C100000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100000>	C99521	Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction-Stable-Over 12 Hours From Symptom Onset|PERCUTANEOUS CORONARY INTERVENTION (PCI) FOR ST ELEVATION MYOCARDIAL INFARCTION (STEMI) (STABLE, >12 HRS FROM SYMPTOM ONSET)	A percutaneous coronary intervention is necessary for a myocardial infarction that presents with ST segment elevation and the subject does not have recurrent or persistent symptoms, symptoms of heart failure or ventricular arrhythmia. The presentation is past twelve hours since onset of symptoms. (ACC)			Therapeutic or Preventive Procedure	CDISC SDTM Cardiac Procedure Indication Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100001>	C99521	Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction-Stable After Successful Full-Dose Thrombolytic Therapy|PERCUTANEOUS CORONARY INTERVENTION (PCI) FOR ST ELEVATION MYOCARDIAL INFARCTION (STEMI) (STABLE AFTER SUCCESSFUL FULL-DOSE THROMBOLYTICS)	A percutaneous coronary intervention is necessary for a myocardial infarction that presents with ST segment elevation and the subject does not have recurrent or persistent symptoms, symptoms of heart failure or ventricular arrhythmia after a successful dose of thrombolytic therapy. (ACC)			Therapeutic or Preventive Procedure	CDISC SDTM Cardiac Procedure Indication Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100002>	C99521	Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction-Unstable-Over 12 Hours From Symptom Onset|PERCUTANEOUS CORONARY INTERVENTION (PCI) FOR ST ELEVATION MYOCARDIAL INFARCTION (STEMI) (UNSTABLE, >12 HRS FROM SYMPTOM ONSET)	A percutaneous coronary intervention is necessary for a myocardial infarction that presents with ST segment elevation and the subject has recurrent or persistent symptoms, symptoms of heart failure or ventricular arrhythmia. The presentation is past twelve hours since onset of symptoms. (ACC)			Therapeutic or Preventive Procedure	CDISC SDTM Cardiac Procedure Indication Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100003>	C80449	Percutaneous Mitral Valve Repair|PERCUTANEOUS MITRAL REPAIR	Invasive procedure through a puncture in the skin, performed for the purpose of reducing regurgitation of the mitral valve. (ACC)			Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100004>	C80430	Pericardial Stripping|PERICARDIAL STRIPPING	Removal or resection of the pericardium. (ACC)			Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100005>	C15839	Post-Cardiac Transplant Evaluation|POST-CARDIAC TRANSPLANT	A procedure to evaluate the health of the an individual after receiving a heart transplant. (ACC)			Health Care Activity	CDISC SDTM Cardiac Procedure Indication Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100006>	C139982	Pre-Operative Evaluation for Non-Cardiovascular Surgery|PRE-OPERATIVE EVALUATION FOR NON-CARDIOVASCULAR SURGERY	A procedure to evaluate the health of the cardiac system to determine feasibility of a non-cardiac related surgical procedure. (ACC)			Health Care Activity	CDISC SDTM Cardiac Procedure Indication Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100007>	C99896	Previously Implanted Cardiac Lead|PREVIOUSLY IMPLANTED	The coronary sinus / left ventricular lead was not implanted because a lead had been previously implanted. (ACC)			Finding	CDISC SDTM Reason Coronary Sinus Access or Left Ventricular Lead Not Implanted Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100008>	C99521	Rescue Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction After Failed Full-Dose Thrombolytic Therapy|RESCUE PERCUTANEOUS CORONARY INTERVENTION (PCI) FOR ST ELEVATION MYOCARDIAL INFARCTION (STEMI) (AFTER FAILED FULL-DOSE THROMBOLYTICS)	A percutaneous coronary intervention is imperative for a myocardial infarction that presents with ST segment elevation after an unsatisfactory response to a full dose of thrombolytic therapy. (ACC)			Therapeutic or Preventive Procedure	CDISC SDTM Cardiac Procedure Indication Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100009>	C99896	Reused Cardiac Lead	The cardiac lead has been left in situ and reused. (ACC)			Finding	
C10000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10000>	C61007	Cyclophosphamide/Fluoxymesterone/Mitolactol/Prednisone/Tamoxifen|CD(P)TH|CTX/DBD/FXM/PRED/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100010>	C99540	Right Cardiac Ventricle Assist Device Procedure	A procedure involving a mechanical pump which receives blood from the right ventricle and delivers it to the pulmonary artery. (ACC)			Therapeutic or Preventive Procedure	
C100011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100011>	C63169	Right Cardiac Ventricle Pacing Malfunction|RIGHT VENTRICULAR PACING MALFUNCTION	The cardiac rhythm device malfunction affected the right ventricular (RV) pacing. (ACC)			Event	CDISC SDTM Cardiac Rhythm Device Failure Manifestation Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100012>	C50797	Severe Cardiac Valve Regurgitation	Evidence of severe retrograde blood flow through the valve(s) of the heart. (ACC)			Disease or Syndrome	
C100013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100013>	C62433	Severe Cardiac Valve Stenosis	The cardiac valve orifice is abnormally narrow, to a severe degree. (ACC)			Finding	
C100014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100014>	C111103	Spontaneous Sustained Ventricular Tachycardia by ECG Finding|SPONTANEOUS SUSTAINED VENTRICULAR TACHYCARDIA|Spontaneous Sustained Ventricular Tachycardia|Spontaneous Sustained Ventricular Tachycardia by EKG Finding	An electrocardiographic finding of ventricular tachycardia that occurs without provocation and does not resolve without intervention.			Finding	CDISC SDTM Cardiac Procedure Indication Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100015>	C99521	Staged Percutaneous Coronary Intervention|STAGED PERCUTANEOUS CORONARY INTERVENTION (PCI)	A subsequent Percutaneous Coronary Intervention in a planned series of procedures, where the first PCI could have been during a prior admission, or during this admission. (ACC)			Therapeutic or Preventive Procedure	CDISC SDTM Cardiac Procedure Indication Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100016>	C25476	Subject Delay in Providing Consent|Patient Delay in Providing Consent|SUBJECT DELAY IN PROVIDING CONSENT	The subject has not provided consent in a timely manner for the procedure to take place. (ACC)			Temporal Concept	CDISC SDTM Non-system Reason for PCI Delay Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100017>	C80430	Surgical Maze Procedure|Cox Maze|SURGICAL MAZE	A cardiac procedure intended to inhibit atrial fibrillation, in which a series of incisions are made in the atria to block abnormal electrical circuits that contribute to atrial fibrillation. (ACC)			Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100018>	C35053	Syncope with High Risk Cardiac Characteristics|SYNCOPE WITH HIGH RISK CHARACTERISTICS	A sudden loss of consciousness with loss of postural tone not related to anesthesia with high risk characteristics. High risk characteristics include non-ischemic dilated cardiomyopathy, or ischemic heart disease with significant ventricular dysfunction, hypertrophic cardiomyopathy, Brugada Syndrome, or Long QT Syndrome. (ACC)			Finding	CDISC SDTM Cardiac Procedure Indication Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100019>	C111103	Syncope with Inducible Ventricular Tachycardia by ECG Finding|SYNCOPE WITH INDUCIBLE VENTRICULAR TACHYCARDIA|Syncope with Inducible Ventricular Tachycardia|Syncope with Inducible Ventricular Tachycardia by EKG Finding	An electrocardiographic finding of ventricular tachycardia accompanied by syncope in the individual.			Finding	CDISC SDTM Cardiac Procedure Indication Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10001>	C63510	CONPADRI-I Regimen|CONPADRI-I|COPADRI-I|CTX/DOX/L-PAM/VCR|Cyclophosphamide-Vincristine-Melphalan-Doxorubicin|Cyclophosphamide/Doxorubicin/Melphalan/Vincristine|Cyclophosphamide/Oncovin/Phenylalanine Nitrogen Mustard/Adriamycin|Cyclophosphamide/Vincristine/Melphalan/Doxorubicin|Cyclophosphamide/Vincristine/Melphalan/Doxorubicin Regimen	A regimen consisting of cyclophosphamide, vincristine, melphalan, and doxorubicin for the treatment of osteosarcoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C100020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100020>	C35317	Three Vessel Coronary Disease|THREE VESSEL DISEASE	There was greater than or equal to 50% stenosis (reduction in cross-sectional area) in three coronary arteries (or greater than or equal to 50% stenosis in the left main coronary artery and greater than or equal to 50% stenosis in the right coronary artery). (ACC)			Disease or Syndrome	CDISC SDTM Coronary Vessel Disease Extent Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100021>	C35552	Thrombolysis in Myocardial Infarction Flow	A grading system for coronary blood flow based on the classification developed by the Thrombolysis in Myocardial Infarction Group. It classifies coronary blood flow into four classes based upon the angiographic appearance of the blood vessels. (ACC)			Finding	
C100022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100022>	C157788	Transcatheter Aortic Valve Implantation|TRANSCATHETER AORTIC VALVE IMPLANT	Use of a thin tube to deliver an artificial valve apparatus between the left ventricle of the heart and the aorta. (ACC)			Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C100023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100023>	C35317	Two Vessel Coronary Disease|TWO VESSEL DISEASE	There was greater than or equal to 50% stenosis (reduction in cross-sectional area) in two coronary arteries (or greater than or equal to 50% stenosis in the left main coronary artery). (ACC)			Disease or Syndrome	CDISC SDTM Coronary Vessel Disease Extent Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100024>	C37254	Typical Coronary Artery Disease Symptom|TYPICAL CORONARY ARTERY DISEASE SYMPTOMS	Deep, poorly localized chest or arm discomfort that is reproducibly associated with physical exertion or emotional stress and is relieved promptly (i.e., in less than 5 minutes) with rest and/or the use of sublingual nitroglycerin. Some patients may have no chest discomfort but present solely with jaw, neck, ear, arm, shoulder, back, or epigastric discomfort or with unexplained dyspnea without discomfort. If these symptoms have a clear relationship to exertion or stress or are relieved promptly with nitrates, they should be considered equivalent to angina. J Am Coll Cardiol, 2007; 50:1-157, doi:10.1016/j.jacc.2007.02.013 (Published online 6 August 2007). (ACC)			Sign or Symptom	CDISC SDTM Coronary Artery Disease Symptoms Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100025>	C99896	Unable to Obtain Acceptable Pacing Thresholds|COULD NOT OBTAIN ACCEPTABLE PACING THRESHOLDS	The coronary sinus / left ventricular lead was not implanted because the operator was unable to obtain acceptable pacing thresholds. (ACC)			Finding	CDISC SDTM Reason Coronary Sinus Access or Left Ventricular Lead Not Implanted Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100026>	C99896	Unable to Obtain Satisfactory Coronary Sinus Access|UNABLE TO OBTAIN SATISFACTORY CORONARY SINUS ACCESS	The coronary sinus / left ventricular lead was not implanted because the operator was unable to obtain satisfactory coronary sinus access. (ACC)			Finding	CDISC SDTM Reason Coronary Sinus Access or Left Ventricular Lead Not Implanted Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100027>	C99896	Unable to Obtain Satisfactory Vascular Access|UNABLE TO OBTAIN SATISFACTORY VASCULAR ACCESS	The coronary sinus / left ventricular lead was not implanted because the operator was unable to obtain satisfactory vascular access. (ACC)			Finding	CDISC SDTM Reason Coronary Sinus Access or Left Ventricular Lead Not Implanted Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100028>	C99896	Unable to Position Lead Due to Coronary Sinus Dissection|UNABLE TO POSITION LEAD DUE TO CORONARY SINUS DISSECTION	The coronary sinus / left ventricular lead was not implanted because the coronary sinus was dissected. (ACC)			Finding	CDISC SDTM Reason Coronary Sinus Access or Left Ventricular Lead Not Implanted Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100029>	C99896	Unable to Position Lead In tributary Vein of Coronary Sinus|UNABLE TO POSITION LEAD IN TRIBUTARY VEIN OF CORONARY SINUS	The coronary sinus / left ventricular lead was not implanted because the operator was unable to position the lead in the tributary vein of the coronary sinus. (ACC)			Finding	CDISC SDTM Reason Coronary Sinus Access or Left Ventricular Lead Not Implanted Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10002>	C61063	Cyclophosphamide/Doxorubicin/Fluorouracil/Methotrexate/Prednisone/Vincristine|CMFP-VA|CTX/DOX/5-FU/MTX/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100030>	C80430	Upgrade to Cardiac Device with Additional Pacing Capabilities|UPGRADE TO A DEVICE WITH ADDITIONAL PACING CAPABILITIES	A device with additional pacing capabilities is replacing the current device. (ACC)			Therapeutic or Preventive Procedure	CDISC SDTM Cardiac Procedure Indication Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100031>	C49236	Urgent Procedure|URGENT	Deferring an urgent procedure increases risk of adverse outcome or clinical deterioration.  Clinical situation warrants performing urgent procedures during the current episode of care to avoid compromising patient safety. (ACC)			Therapeutic or Preventive Procedure	CDISC SDTM Procedure Urgency Status Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100032>	C35552	American College of Cardiology/American Heart Association Lesion Complexity Class|ACC/AHA Lesion Complexity Class	A classification system for coronary stenosis based upon characteristics that influence the difficulty of percutaneous coronary revascularization. (ACC)			Classification	
C100033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100033>	C50479	Cardiac Arrest/Arrhythmia Etiology Unknown|CARDIAC ARREST/ARRHYTHMIA ETIOLOGY UNKNOWN	An episode of cardiac arrest or arrhythmia where the etiology was unknown. (ACC)			Finding	CDISC SDTM Cardiac Procedure Indication Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100034>	C99896	Cardiac Lead Dislodgement Requiring Reposition/Reoperation|LEAD DISLODGEMENT REQUIRING REPOSITION/REOPERATION	The movement (macroscopic or microscopic) of an existing lead within the heart or vascular tree away from the original implantation site. (ACC)			Finding	CDISC SDTM Lead Abnormality Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100035>	C62961	Faulty Device Connector/Header|FAULTY CONNECTOR/HEADER	There is a faulty connector/header in the device. (ACC)			Event	CDISC SDTM Cardiac Procedure Indication Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100036>	C111103	Idiopathic Primary Ventricular Tachycardia/Ventricular Flutter by ECG Finding|IDIOPATHIC PRIMARY VENTRICULAR TACHYCARDIA/VENTRICULAR FLUTTER|Idiopathic Primary Ventricular Tachycardia/Ventricular Flutter|Idiopathic Primary Ventricular Tachycardia/Ventricular Flutter by EKG Finding	An electrocardiographic finding of ventricular tachycardia or ventricular fibrillation of unknown cause. (ACC)			Finding	CDISC SDTM Sudden Death Syndrome Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100037>	C100032	American College of Cardiology/American Heart Association Lesion Complexity Score A|ACC/AHA LESION COMPLEXITY SCORE A|ACC/AHA Lesion Complexity Score A|Low Risk	Discrete (less than 10 mm length) and concentric and readily accessible and non-angulated segment less than 45 degrees and smooth contour and little or no calcification and less than totally occlusive and not ostial in location and no major branch involvement and absence of thrombus. (ACC)			Finding	CDISC SDTM Lesion Complexity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100038>	C100032	American College of Cardiology/American Heart Association Lesion Complexity Score B|ACC/AHA LESION COMPLEXITY SCORE B|ACC/AHA Lesion Complexity Score B|Medium Risk	Tubular (10-20 mm length) or eccentric or moderate tortuosity of proximal segment or moderately angulated segment, 45-90 degrees or irregular contour or moderate to heavy calcification or ostial in location or bifurcation lesions requiring double guidewires or some thrombus present or total occlusion less than 3 months old. (ACC)			Finding	CDISC SDTM Lesion Complexity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100039>	C100032	American College of Cardiology/American Heart Association Lesion Complexity Score C|ACC/AHA LESION COMPLEXITY SCORE C|ACC/AHA Lesion Complexity Score C|High Risk	Diffuse (length greater than 2cm) or excessive tortuosity of proximal segment or extremely angulated segments greater than 90 degrees or total occlusions greater than 3 months old and/or bridging collaterals or inability to protect major side branches or degenerated vein grafts with friable lesions. (ACC)			Finding	CDISC SDTM Lesion Complexity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10003>	C61063	Methotrexate/Teniposide|MTX/VM-26			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100040>	C100021	Thrombolysis in Myocardial Infarction Flow-0|TIMI 0|TIMI Flow-0|TIMI GRADE 0|Thrombolysis in Myocardial Infarction Flow - 0	No perfusion: No antegrade flow beyond the point of occlusion. (www.TIMI.org accessed 21SEP2011) (ACC)			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 9: Therapeutic and Supportive Procedures for COVID-19 Terminology|CDISC SDTM Terminology|CDISC SDTM Thrombolysis in Myocardial Infarction Flow Responses Terminology|Clinical Data Interchange Standards Consortium Terminology|Invasive Coronary/Vascular/Neurovascular Revascularization Treatment Terminology
C100041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100041>	C100021	Thrombolysis in Myocardial Infarction Flow-1|TIMI 1|TIMI Flow-1|TIMI GRADE 1|Thrombolysis in Myocardial Infarction Flow - 1	Penetration without perfusion: The contrast material passes beyond the area of obstruction, but fails to opacify the entire coronary bed distal to the obstruction for the duration of the cine run.  (www.TIMI.org accessed 21SEP2011) (ACC)			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 9: Therapeutic and Supportive Procedures for COVID-19 Terminology|CDISC SDTM Terminology|CDISC SDTM Thrombolysis in Myocardial Infarction Flow Responses Terminology|Clinical Data Interchange Standards Consortium Terminology|Invasive Coronary/Vascular/Neurovascular Revascularization Treatment Terminology
C100042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100042>	C100021	Thrombolysis in Myocardial Infarction Flow-2|TIMI 2|TIMI Flow-2|TIMI GRADE 2|Thrombolysis in Myocardial Infarction Flow - 2	Partial reperfusion: The contrast material passes across the obstruction and opacifies the entire coronary bed distal to the obstruction. However, the rate of entry of contrast into the vessel distal to the obstruction and/or its rate of clearance from the distal bed are perceptibly slower than its entry into and/or clearance from comparable areas not perfused by the culprit vessel (e.g., the opposite coronary artery or coronary bed proximal to the obstruction).(www.TIMI.org accessed 21SEP2011) (ACC)			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 9: Therapeutic and Supportive Procedures for COVID-19 Terminology|CDISC SDTM Terminology|CDISC SDTM Thrombolysis in Myocardial Infarction Flow Responses Terminology|Clinical Data Interchange Standards Consortium Terminology|Invasive Coronary/Vascular/Neurovascular Revascularization Treatment Terminology
C100043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100043>	C100021	Thrombolysis in Myocardial Infarction Flow-3|TIMI 3|TIMI Flow-3|TIMI GRADE 3|Thrombolysis in Myocardial Infarction Flow - 3	Complete perfusion: Antegrade flow into the bed distal to the obstruction occurs as promptly as into the bed proximal to the obstruction and clearance of contrast material from the involved bed is as rapid as from an uninvolved bed in the same vessel or the opposite artery. (www.TIMI.org accessed 21SEP2011) (ACC)			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 9: Therapeutic and Supportive Procedures for COVID-19 Terminology|CDISC SDTM Terminology|CDISC SDTM Thrombolysis in Myocardial Infarction Flow Responses Terminology|Clinical Data Interchange Standards Consortium Terminology|Invasive Coronary/Vascular/Neurovascular Revascularization Treatment Terminology
C100044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100044>	C157795	Pulmonic Valvuloplasty|PULMONIC VALVULOPLASTY	Dilation of the valve between the right ventricle and the pulmonary artery of the heart by inflating a balloon. (ACC)			Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100045>	C49235	Manufacturer Recall|MANUFACTURER RECALL	An imperative issued by the manufacturer of a device that the device needs to be returned to a designated source for repair or replacement. (ACC)			Functional Concept	CDISC SDTM Cardiac Procedure Indication Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100046>	C226473	Evaux Spring Water-based Topical Spray|Evozac|Spring Water/Polysorbate 20/Phenoxyethanol/Zinc Gluconate/Caprylyl Glycol/Chlorphenesin Topical Spray	A skin spray composed of Evaux thermal spring water, the emulsifier polysorbate 20, the preservatives phenoxyethanol and chlorphenesin, zinc gluconate, and the moisturizer caprylyl glycol with prophylactic and calming activity. Evaux thermal spring water is rich in mineral elements particularly of lithium, strontium and manganese.  When sprayed directly onto the skin or scalp, this topical spray may have a calming, moisturizing, healing and nurturing effect. This agent may prevent or decrease skin rashes associated with the administration of EGFR inhibitors or with radiochemotherapy-induced skin reactions.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C100047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100047>	C16275	File Transfer Protocol|FTP|File Transfer Protocol (FTP)	A network protocol designed to move files between a computer and a host over a TCP network, such as the Internet.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C100048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100048>	C100047	Secure File Transfer Protocol|sFTP	A network protocol designed to move files securely between a computer and a host over a TCP network, such as the Internet.			Intellectual Product	
C100049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100049>	C16275	Transfer Of Images And Data|TRIAD	Application software written to allow the submission and download of images and data.			Intellectual Product	
C10004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10004>	C61063	Cyclophosphamide/Fluorouracil/Methotrexate/Prednisone/Tamoxifen/Vincristine|CMFVP(T)|CTX/5-FU/MTX/PRED/TMX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100050>	C17423	Needle Free Injection	A drug delivery system that permits injection of a liquid medication subcutaneously without the use of a needle.			Drug Delivery Device	
C100051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100051>	C9385	Renal Cell Carcinoma Associated with Neuroblastoma|Renal Cell Cancer Associated with Neuroblastoma	Renal cell carcinoma that develops in patients who are long-term survivors of childhood neuroblastoma.	Renal Cell Carcinoma Associated with Neuroblastoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C100052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100052>	C48470	Needle Free Injection Dosing Unit	A dosing unit equal to the amount of active ingredient(s) contained in a single needle free injection unit.			Quantitative Concept	
C100053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100053>	C222260	Sinus Node Functional Assessment	Description of electrical activity and conduction involving the sinoatrial node. (ACC)			Intellectual Product	
C100054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100054>	C204977	Conjunctival Melanocytic Intraepithelial Lesion|C-MIL|C-MIN|Conjunctival Melanocytic Intraepithelial Neoplasia|Conjunctival Primary Acquired Melanosis with Atypia|PAM with Atypia|Primary Acquired Melanosis with Atypia	A spectrum of neoplastic changes that occur in the conjunctiva and range from melanocytic hyperplasia through degrees of atypia to melanoma in situ. The lesions are generally unilateral but often multifocal and appear as flat, irregular brown discolorations of the conjunctiva. They usually affect middle-aged and elderly Caucasians. (WHO 2018)			Neoplastic Process	
C100055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100055>	C198998	Immigrant	An individual who changes his place of residency from one country to another.			Human	
C100056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100056>	C13717	Arterial Access Site|Percutaneous arterial access	Anatomical location where an artery was accessed for a diagnostic or therapeutic procedure.			Body Location or Region	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|Appendix 9: Therapeutic and Supportive Procedures for COVID-19 Terminology|Invasive Coronary/Vascular/Neurovascular Revascularization Treatment Terminology
C100057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100057>	C63340	Arterial Access Closure	A procedure to stop bleeding and close the location of arterial entry following a diagnostic or therapeutic procedure.			Therapeutic or Preventive Procedure	
C100058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100058>	C21514	Pre-Procedure	The time period prior to a diagnostic or therapeutic procedure.			Qualitative Concept	
C100059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100059>	C21514	Post-Procedure	The time period after a diagnostic or therapeutic procedure.			Temporal Concept	
C10005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10005>	C61063	Altretamine/Cyclophosphamide/Doxorubicin/Prednisone/Vincristine|CHHOP|CTX/DOX/HMM/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100060>	C62085	Intrinsic QRS Duration	The duration of the QRS complex that is generated by the subject's own heart. (ACC)			Quantitative Concept	
C100061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100061>	C92234	Paced Ventricular Rhythm without Intrinsic Ventricular Complexes	An electrocardiographic finding that the cardiac rhythm is initiated by a cardiac pacemaker generated electrical impulse in the ventricle. Intrinsic ventricular complexes are absent.			Finding	
C100062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100062>	C99938	Chronic Total Coronary Artery Occlusion	Prolonged complete obstruction of the coronary artery. (ACC)			Disease or Syndrome	
C100063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100063>	C3824|C35552	Coronary Vessel Lesion	Pathologic material in a vessel that obstructs myocardial perfusion. (ACC)			Finding	
C100064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100064>	C12981	Coronary Artery Graft	A vessel segment attached to a coronary artery to facilitate myocardial perfusion. (ACC)			Body Part, Organ, or Organ Component	
C100065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100065>	C83486	Glyceryl Dibehenate|Compritol 888 ATO|Docosanoic Acid, Diester with 1,2,3-propanetriol|GLYCERYL DIBEHENATE|Glyceryl Behenate				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C100066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100066>	C35552	Coronary Lesion Complexity	Characteristics of coronary lesions that contribute to procedural risk during coronary intervention.			Finding	
C100068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100068>	C20985|C191466	Cardiac Ablation|ABLATION, CARDIAC|Catheter ablation	A procedure intended to eliminate or modify a focus or re-entry circuit that causes an arrhythmia in the heart. (ACC)			Therapeutic or Preventive Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C100069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100069>	C35484	Cardiac Valve Injury	An event causes abnormal valve function; this is usually a tear in leaflet or chordae tendinae and manifests as a new regurgitant. (ACC)			Finding	
C10006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10006>	C61063	Altretamine/Cisplatin/Cyclophosphamide/Misonidazole|CDDP/CTX/HMM/MNI|CHIPS			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100070>	C35279	Coronary Venous Dissection	A tear within the wall of a coronary vein. (ACC)			Disease or Syndrome	
C100071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100071>	C222294|C168175	Cardiac Computerized Tomographic Angiography	An imaging technique of the heart and neighboring structures involving helical computed tomography and computer software to generate high-resolution 2-dimensional and 3-dimensional images. (ACC)	Cardiac Computerized Tomographic Angiography		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C100072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100072>	C35552	Coronary Culprit Lesion	The lesion considered to be responsible for the acute coronary syndrome. (ACC)			Finding	
C100073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100073>	C16094	Cardiac Stress Test	The use of physical activity to elicit signs and symptoms of myocardial ischemia. (ACC)			Diagnostic Procedure	
C100074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100074>	C19015	Cardiac Ischemic Risk Score	The relative risk of developing ischemia determined by a cardiac stress test. (ACC)			Quantitative Concept	
C100075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100075>	C100073	Non-Invasive Cardiac Stress Test	Procedures intended to evaluate cardiac function without insertion of intravascular equipment into the central circulation. (ACC)			Diagnostic Procedure	
C100076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100076>	C41328	Sinus Rhythm|SINUS RHYTHM	An electrocardiographic finding of an atrial rhythm which originates from the sinoatrial node that is considered normal for the population. (CDISC)			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 7: Diagnostic Procedures Terminology|CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100077>	C27083	Luminal Carotid Thrombus	A blood clot (thrombus) in the lumen of the carotid artery. (ACC)			Finding	
C100078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100078>	C43432	Transplant Waiting List	A registry of patients awaiting an organ transplant. (ACC)			Intellectual Product	
C100079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100079>	C891	Smoking Tobacco	The cured leaves of Nicotiana tabacum that are processed for use in smoking products such as cigars, cigarettes, and pipes.			Plant	
C10007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10007>	C63442	CytaBOM Regimen|ARA-C/BLEO/MTX/VCR|Bleomycin/Cytarabine/Methotrexate/Vincristine|CytaBOM|Cytarabine-Bleomycin-Vincristine-Methotrexate|Cytarabine-Bleomycin-Vincristine-Methotrexate Regimen|Cytarabine/Bleomycin/Oncovin/Methotrexate|Cytarabine/Bleomycin/Vincristine/Methotrexate	A regimen consisting of cytarabine, bleomycin, methotrexate, and vincristine for the treatment of non-Hodgkin lymphoma (NHL).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens
C100080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100080>	C71316	Cardiac Stent Placement|CARDIAC STENT PLACEMENT	A procedure performed during a percutaneous coronary intervention in which a device is deployed into the lumen of a coronary artery to expand and support the vessel wall such that the vessel remains patent and blood flow is uninhibited.			Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100081>	C50754	In Stent Restenosis	Fifty percent or greater stenosis within an existing stent. (ACC)			Finding	
C100082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100082>	C35552	Guidewire Across Lesion	A measure of procedural success during a percutaneous coronary intervention when a guidewire can be deployed across a coronary artery lesion. (ACC)			Finding	
C100083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100083>	C73502	Coronary Artery Perforation	A dissection that extends through the full thickness of the coronary arterial wall. (ACC)			Finding	
C100084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100084>	C215116	Cardiac Diagnostic Procedure	Procedure to evaluate the structure and/or function of the heart. (ACC)			Diagnostic Procedure	
C100085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100085>	C20080	Coronary Angiography|CORONARY ANGIOGRAPHY|Coronary angiography	The passage of a catheter into the aortic root or other great vessel for the purpose of angiography of the native coronary arteries or bypass grafts supplying native coronary arteries. (ACC)	Coronary Angiography		Diagnostic Procedure	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|Appendix 7: Diagnostic Procedures Terminology|CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C100086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100086>	C35552	Coronary Artery Dominance|COARTDOM	The contribution of blood supply from the right or left vessel system to the posterior descending artery. (ACC)			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100087>	C16830	Intra-Aortic Balloon Pump|IABP|IABP	A medical device that increases myocardial oxygen perfusion while at the same time increasing cardiac output. (ACC)			Medical Device	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 9: Therapeutic and Supportive Procedures for COVID-19 Terminology|Mechanical Support Terminology
C100088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100088>	C583	Interferon Gamma-1a|INTERFERON GAMMA-1A|Imunomax|Imunomax-gamma|Interferon gamma-1a|Recombinant interferon gamma-1a	A recombinant form of the endogenous cytokine human interferon (IFN) gamma-1a, with immunomodulating activity. Upon administration, IFN gamma-1a targets, binds to, and activates the cell-surface IFN-gamma receptor, thereby stimulating innate and adaptive immune responses.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology
C100089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100089>	C583	Interferon Gamma-1b|Actimmune|IFN-g-1b|IFN-gamma 1b|IFNg-1b|INTERFERON GAMMA-1B|Interferon gamma-1b|Interferon gamma-1b, Recombinant|N(Sup 2)-L-Methionyl-1-139-Interferon G|N(sup 2)-L-Methionyl-1-139-interferon gamma (Human Lymphocyte Protein Moiety Reduced)|Recombinant Interferon Gamma-1b|gamma Interferon 1B	A recombinant form of the endogenous cytokine human interferon (IFN) gamma-1b, with immunomodulating activity. Upon administration, IFN gamma-1b targets, binds to, and activates the cell-surface IFN-gamma receptor, stimulating antibody dependent cellular cytotoxicity (ADCC), activating natural killer (NK) cells, and enhancing the oxidative metabolism of macrophages. IFN-gamma plays important roles in the innate and adaptive immune responses.	Interferon Gamma-1b		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C10008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10008>	C61063	Asparaginase/Methotrexate/Vincristine|ASP/MTX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100090>	C62405	Bifocal	Arising from, pertaining to, or having two locations.			Qualitative Concept	
C100091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100091>	C16980	Eosinophil Lysophospholipase|CLC|Charcot-Leyden Crystal Protein|EC 3.1.1.5|Gal-10|Galectin-10|Lysolecithin Acylhydrolase	Eosinophil lysophospholipase (142 aa, ~16 kDa) is encoded by the human CLC gene. This protein is involved in phospholipid metabolism.			Amino Acid, Peptide, or Protein|Enzyme	
C100092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100092>	C20080	Fistulagram|AV Fistulagram|AV Fistulogram|Fistulogram	A diagnostic X-ray procedure on an arteriovenous (AV) fistula following the infusion of a radiopaque contrast material.			Diagnostic Procedure	
C100093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100093>	C5461|C121619	Central Nervous System Nongerminomatous Germ Cell Tumor|Nongerminomatous GCT - CNS|Nongerminomatous germ cell tumor of the CNS	Germ cell tumors of the central nervous system other than germinoma.  This category includes teratoma, choriocarcinoma, embryonal carcinoma, and yolk sac tumor.			Neoplastic Process	NCI CTEP SDC Germ Cell Tumors of the CNS Sub-Category Terminology|NCI CTEP Simplified Disease Classification Terminology
C100094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100094>	C43644	HGNC_ID|HUGO_ID	Indicates that a concept in the 'Gene' branch of the NCI thesaurus maps to a HUGO Gene Nomenclature Committee certified gene.			Conceptual Entity	
C100095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100095>	C27992	Lichenoid	Having the characteristics of a chronic, recurrent, pruritic inflammatory disorder of unknown etiology that affects the skin and mucus membranes. It presents with rashes and papules that tend to resolve spontaneously. It may be associated with hepatitis C. Certain drugs that contain arsenic or bismuth are associated with reactions mimicking lichen planus.			Qualitative Concept	
C100096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100096>	C217121	Oral Mucositis Rating Scale|OMRS|OMRS	A research tool used to assess inflammation in the mouth and classification of oral changes after bone marrow transplant and chronic graft versus host disease.			Intellectual Product	
C100097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100097>	C73338	Ginger Flavor|GINGER	A characteristic of a medicinal product, specifying that its most predominant agreeable savor detected by the unified sensation of taste and olfactory receptors resembles ginger, the rhizome of the perennial plant Zingiber officinale.			Qualitative Concept	FDA Structured Product Labeling Terminology|SPL Flavor Terminology
C100098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100098>	C275	Ademetionine|(+-)-5'-((R*)-((R*)-3-Amino-3-carboxypropyl)methylsulfonio)-5'-deoxyadenosine Hydroxide, Inner Salt|ADEMETIONINE|Methionine, S-adenosyl-, DL-|S-Adenosyl-DL-methionine				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C100099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100099>	C1663	Synthetic Breast Cancer Peptides-Tetanus Toxoid-Poly ICLC Vaccine	A cancer vaccine comprised of nine class I major histocompatibility complex (MHC)-restricted breast cancer associated peptides, the tetanus toxoid helper peptide and the Toll-like receptor 3 (TLR3) agonist poly ICLC, with potential immunostimulatory and antineoplastic activities. The nine peptides derived from six cancer associated proteins are epidermal growth factor receptor 2 (HER2/neu), carcinoembryonic antigen (CEA) and four cancer/testis antigens (CTAs: MAGE-A1, -A3, -A10, and NY-ESO-1). Vaccination with this vaccine may elicit a specific cytotoxic T-lymphocyte (CTL) response against cells overexpressing these tumor associated antigens (TAAs). As a nonspecific T-helper epitope, tetanus toxoid helper peptide binds to class II MHC and results in long-term immunopotentiation by increasing the helper T-cell response. Poly ICLC, the double-stranded RNA molecules of polyinosinic-polycytidylic acid stabilized with poly L-lysine in carboxymethylcellulose, binds to TLR3 and induces the release of cytokines which may help boost the immune response against the TAAs.	Synthetic Breast Cancer Peptides-Tetanus Toxoid-Poly ICLC Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C10009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10009>	C61063	Prednisolone/Tamoxifen|PRDL/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1000>	C1504	Recombinant Amphiregulin|AMPHIREGULIN|AR|CRDGF|KAF	A recombinant form of amphiregulin, a member of the heparin-binding epidermal growth factor (EGF) family. Endogenous amphiregulin is an autocrine growth factor, and binds to the EGF receptor. Overexpressed in several cancer cell types, endogenous amphiregulin may contribute to tumor cell proliferation and metastasis. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C100100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100100>	C281	HPV E1/E2 Interaction Inhibitor Gel AP611074|AP611074|PPI inhibitor AP611074|Protein/Protein Interaction Inhibitor AP611074	A topical gel composed of a human papillomavirus (HPV) E1/E2 protein:protein interaction (PPI) inhibitor with potential antiviral activity. Upon topical application of AP611074, this agent prevents binding of the HPV viral proteins E1 to E2, thereby preventing viral DNA replication and growth of HPV. This inhibits viral proliferation and may prevent the formation of anogenital warts caused by HPV. The HPV proteins E1 and E2 are essential for HPV viral replication.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C100101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100101>	C214992|C206201	Naratuximab Emtansine|IMGN529|MP 529|MP-529|MP529|NARATUXIMAB EMTANSINE	An immunoconjugate that consists of a humanized IgG1 antibody K7153A against the cell-surface antigen CD37 and covalently linked via the uncleavable, maleimide-derived thioether-based linker SMCC to the maytansinoid DM1, with potential pro-apoptotic and cytotoxic activities. Upon administration of naratuximab emtansine, the antibody moiety of IMGN529 binds to CD37 on tumor B-cells and induces an antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), thereby showing pro-apoptotic activity. In addition, after the internalization of this agent and lysosomal degradation, the DM1 moiety binds to tubulin and inhibits tubulin polymerization and microtubule assembly, resulting in a disruption of microtubule activity and cell division, and eventually causing cell death in CD37-positive B-cells. CD37, a transmembrane glycoprotein, is overexpressed in B-cell malignancies. Compared to reducible, cleavable linkers, the non-reducible SMCC linker shows increased stability in plasma.	Naratuximab Emtansine		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C100102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100102>	C28676	Adenovirus/Cytomegalovirus/Epstein-Barr Virus-specific Allogeneic Cytotoxic T Lymphocytes	Allogeneic tri-viral specific, adenovirus, cytomegalovirus and Epstein-Barr virus (Adv, CMV and EBV or ACE), cytotoxic T-lymphocytes (CTLs) with potential antiviral activity. Donor-derived T-cells were exposed to dendritic cells nucelofected with DNA plasmids encoding Hexon and Penton (Adv), pp65 and IE1 (CMV), and LMP2, EBNA1 and BZLF1 (EBV), all are critical proteins for the proliferation of these viruses, and subsequently maintained in the presence of interleukins 4 and 7 with a novel culture device to expand and sustain the repertoire of CTLs. After an allogeneic hematopoietic stem cell transplant (HSCT), infusion of these CTLs primed towards Adv, CMV and EBV may prevent viral infection by these pathogens.	Adenovirus/Cytomegalovirus/Epstein-Barr Virus-specific Allogeneic Cytotoxic T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C100103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100103>	C45416	Cellular Sheet Dosage Form|CELLULAR SHEET	A skin graft sheet composed of viable cells layered on a supporting substrate.			Biomedical or Dental Material	FDA Structured Product Labeling Terminology|SPL Pharmaceutical Dosage Form Terminology
C100104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100104>	C3367	Sign or Symptom|CLINICAL FINDING|CLINICAL SIGNS|Clinical Finding|Clinical Signs|Clinical Signs or Symptoms|Clinical Signs or Symptoms|DESC|Signs or Symptoms	Objective evidence of disease perceptible to the examining practitioner (sign) and subjective evidence of disease perceived by the patient (symptom).			Finding	AML Authorized Value Terminology|AML Disease Characteristics Table|CDISC Root Variable Terminology|CDISC SDTM Supporting Evidence for Re-Treatment Terminology|CDISC SDTM Terminology|CDISC SEND Category for Clinical Observation Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL Authorized Value Terminology|HL Disease Characteristics Table|Newborn Screening Terminology|NICHD Terminology
C100106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100106>	C211913	ADAS-Cog CDISC Version Functional Test Question	A question associated with the ADAS-Cog CDISC version functional test.			Intellectual Product	
C100107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100107>	C211913	BPI Questionnaire Question	A question associated with the BPI questionnaire.			Intellectual Product	
C100108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100108>	C211913	BPI Short Form Questionnaire Question	A question associated with the BPI Short Form questionnaire.			Intellectual Product	
C100109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100109>	C211913	BPRS-Anchored Clinical Classification Question	A question associated with the BPRS-Anchored clinical classification.			Intellectual Product	
C10010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10010>	C61063	Asparaginase/Cyclophosphamide/Methotrexate/Prednisone/Vincristine/Zorubicin|ASP/CTX/MTX/PRED/RBZ/VCR|CROPAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100110>	C120166	CDISC Questionnaire Terminology	The terminology subset that includes terms pertaining to the CDISC questionnaire terminology.			Intellectual Product	CDISC QRS Terminology|Clinical Data Interchange Standards Consortium Terminology
C100111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100111>	C211913	CGI Questionnaire Question	A question associated with the CGI questionnaire.			Intellectual Product	
C100112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100112>	C211913	COMM Questionnaire Question	A question associated with the COMM questionnaire.			Intellectual Product	
C100113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100113>	C211913	C-SSRS Baseline Questionnaire Question	A question associated with the C-SSRS Baseline questionnaire.			Intellectual Product	
C100114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100114>	C211913	EQ-5D-3L Questionnaire Question	A question associated with the EQ-5D-3L questionnaire.			Intellectual Product	
C100115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100115>	C211913	FPSR Questionnaire Question	A question associated with the FPSR questionnaire.			Intellectual Product	
C100116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100116>	C211913	KPS Scale Questionnaire Question	A question associated with the KPS Scale questionnaire.			Intellectual Product	
C100117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100117>	C211913	MDS-UPDRS Questionnaire Question	A question associated with the MDS-UPDRS questionnaire.			Intellectual Product	
C100118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100118>	C211913	MMSE Functional Test Question	A question associated with the MMSE functional test.			Intellectual Product	
C100119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100119>	C211913	MNSI Questionnaire Question	A question associated with the MNSI questionnaire.			Intellectual Product	
C10011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10011>	C61063	Cyclophosphamide/Melphalan/Methylprednisolone|CTX/L-PAM/MePRDL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100120>	C211913	NPI Questionnaire Question	A question associated with the NPI questionnaire.			Intellectual Product	
C100121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100121>	C211913	PDQUALIF Questionnaire Question	A question associated with the PDQUALIF questionnaire.			Intellectual Product	
C100122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100122>	C64430	Pepsinogen Measurement|PEPSNG|Pepsinogen|Pepsinogen	The determination of the amount of pepsinogen present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100123>	C211913	RDQ Questionnaire Question	A question associated with the RDQ questionnaire.			Intellectual Product	
C100124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100124>	C211913	Short-Form MPQ-2 Questionnaire Question	A question associated with the Short-Form MPQ-2 questionnaire.			Intellectual Product	
C100125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100125>	C211913	SOAPP-R Questionnaire Question	A question associated with the SOAPP-R questionnaire.			Intellectual Product	
C100126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100126>	C211913	UPDRS Clinical Classification Question	A question associated with the UPDRS clinical classification.			Intellectual Product	
C100127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100127>	C211913	HAMD-17 Questionnaire Question	A question associated with the HAMD-17 questionnaire.			Intellectual Product	
C100128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100128>	C198996	Partner	A person that is associated with another person in some manner or action.			Human	
C100129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100129>	C100110	CDISC Questionnaire Category Terminology|Category of Questionnaire|QS-QSCAT|QSCAT	Terminology associated with the questionnaire domain categories of the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10012>	C61063	Cyclophosphamide/Prednisone/Vincristine/Zorubicin|CROP|CTX/PRED/VCR/RBZ			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100130>	C66830	CDISC SDTM Relationship to Subject Terminology|RELSUB|Relationship to Subject|SDTM-RELSUB	Terminology associated with the relationship to subject codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100131>	C115302	CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|ADCTN|Alzheimer's Disease Assessment Scale - Cognitive CDISC Version Functional Test Test Name|QS-ADAS-Cog CDISC Version TEST	Test names of functional test questions associated with the CDISC version of the alzheimer's disease assessment scale-cognitive (ADAS-Cog) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100132>	C115302	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|ADCTC|Alzheimer's Disease Assessment Scale - Cognitive CDISC Version Functional Test Test Code|QS-ADAS-Cog CDISC Version TESTCD	Test codes of functional test questions associated with the CDISC version of the alzheimer's disease assessment scale-cognitive (ADAS-Cog) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100133>	C118970	CDISC Clinical Classification BPRS-Anchored Test Name Terminology|BPRSA1TN|Brief Psychiatric Rating Scale-Anchored Clinical Classification Test Name|QS-BPRS-A TEST	Test names of clinical classification questions associated with the Brief Psychiatric Rating Scale-Anchored (BPRS-A) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100134>	C118970	CDISC Clinical Classification BPRS-Anchored Test Code Terminology|BPRSA1TC|Brief Psychiatric Rating Scale-Anchored Clinical Classification Test Code|QS-BPRS-A TESTCD	Test codes of clinical classification questions associated with the Brief Psychiatric Rating Scale-Anchored (BPRS-A) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100135>	C100110	CDISC Questionnaire EQ-5D-3L Test Name Terminology|EQ5D01TN|European Quality of Life Five Dimension Three Level Scale Questionnaire Test Name|QS-EQ-5D-3L TEST	Test names of questionnaire questions associated with the EuroQOL (European Quality of Life) Five Dimension three level scale (EQ-5D-3L) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100136>	C100110	CDISC Questionnaire EQ-5D-3L Test Code Terminology|EQ5D01TC|European Quality of Life Five Dimension Three Level Scale Questionnaire Test Code|QS-EQ-5D-3L TESTCD	Test codes of questionnaire questions associated with the EuroQOL (European Quality of Life) Five Dimension three level scale (EQ-5D-3L) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100137>	C118970	CDISC Clinical Classification HAMD 17 Test Name Terminology|HAMD1TN|Hamilton Depression Rating Scale - 17 Item Clinical Classification Test Name|QS-HAMD 17 TEST	Test names of clinical classification questions associated with the 17 item Hamilton depression rating scale (HAMD-17) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100138>	C118970	CDISC Clinical Classification HAMD 17 Test Code Terminology|HAMD1TC|Hamilton Depression Rating Scale - 17 Item Clinical Classification Test Code|QS-HAMD 17 TESTCD	Test codes of clinical classification questions associated with the 17 item Hamilton depression rating scale (HAMD-17) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100139>	C100110	CDISC Questionnaire MDS-UPDRS Test Name Terminology|Movement Disorder Society Unified Parkinson's Disease Rating Scale Questionnaire Test Name|QS-MDS-UPDRS TEST|UPD2TN	Test names of questionnaire questions associated with the the movement disorder society version of the unified parkinson's disease rating scale (MDS-UPDRS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10013>	C61063	Doxorubicin/Fluoxymesterone/Mitolactol/Tamoxifen|DATH|DBD/DOX/FXM/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100140>	C100110	CDISC Questionnaire MDS-UPDRS Test Code Terminology|Movement Disorder Society Unified Parkinson's Disease Rating Scale Questionnaire Test Code|QS-MDS-UPDRS TESTCD|UPD2TC	Test codes of questionnaire questions associated with the the movement disorder society version of the unified parkinson's disease rating scale (MDS-UPDRS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100141>	C115302	CDISC Functional Test MMSE Test Name Terminology|MMS1TN|Mini-Mental State Examination Functional Test Test Name|QS-MMSE TEST	Test names of functional test questions associated with the mini-mental state examination (MMSE) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100142>	C115302	CDISC Functional Test MMSE Test Code Terminology|MMS1TC|Mini-Mental State Examination Functional Test Test Code|QS-MMSE TESTCD	Test codes of functional test questions associated with the mini-mental state examination (MMSE) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100143>	C100110	CDISC Questionnaire NPI Test Name Terminology|NPI1TN|Neuropsychiatric Inventory Questionnaire Test Name|QS-NPI TEST	Test names of questionnaire questions associated with the neuropsychiatric inventory (NPI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100144>	C100110	CDISC Questionnaire NPI Test Code Terminology|NPI1TC|Neuropsychiatric Inventory Questionnaire Test Code|QS-NPI TESTCD	Test codes of questionnaire questions associated with the neuropsychiatric inventory (NPI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100145>	C103175	CDISC Questionnaire PDQUALIF Test Name Terminology|QS-PDQUALIF TEST	Test names of questionnaire questions associated with the Parkinson's disease quality of life scale (PDQUALIF) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	
C100146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100146>	C103175	CDISC Questionnaire PDQUALIF Test Code Terminology|QS-PDQUALIF TESTCD	Test codes of questionnaire questions associated with the Parkinson's disease quality of life scale (PDQUALIF) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	
C100147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100147>	C118970	CDISC Clinical Classification UPDRS Test Name Terminology|QS-UPDRS TEST|UPD1TN|Unified Parkinson's Disease Rating Scale Clinical Classification Test Name	Test names of clinical classification questions associated with the unified parkinson's disease rating scale (UPDRS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100148>	C118970	CDISC Clinical Classification UPDRS Test Code Terminology|QS-UPDRS TESTCD|UPD1TC|Unified Parkinson's Disease Rating Scale Clinical Classification Test Code	Test codes of clinical classification questions associated with the unified parkinson's disease rating scale (UPDRS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100149>	C103175	CDISC Questionnaire CGI Test Name Terminology	Test names of questionnaire questions associated with the clinical global impression (CGI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	
C10014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10014>	C61063	Fluoxymesterone/Mitolactol/Mitoxantrone/Tamoxifen|D(DHAD)TH|DBD/DHAD/FXM/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100150>	C103175	CDISC Questionnaire CGI Test Code Terminology	Test codes of questionnaire questions associated with the clinical global impression (CGI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	
C100151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100151>	C100110	CDISC Questionnaire MNSI Test Name Terminology|MNSI1TN|Michigan Neuropathy Screening Instrument Questionnaire Test Name|QS-MNSI TEST	Test names of questionnaire questions associated with the Michigan neuropathy screening instrument (MNSI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100152>	C100110	CDISC Questionnaire MNSI Test Code Terminology|MNSI1TC|Michigan Neuropathy Screening Instrument Questionnaire Test Code|QS-MNSI TESTCD	Test codes of questionnaire questions associated with the Michigan neuropathy screening instrument (MNSI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100153>	C100110	CDISC Questionnaire FPSR Test Name Terminology|FPSR1TN|Faces Pain Scale - Revised Questionnaire Test Name|QS-FPSR TEST	Test names of questionnaire questions associated with the revised faces pain scale (FPSR) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100154>	C100110	CDISC Questionnaire FPSR Test Code Terminology|FPSR1TC|Faces Pain Scale - Revised Questionnaire Test Code|QS-FPSR TESTCD	Test codes of questionnaire questions associated with the revised faces pain scale (FPSR) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100155>	C100110	CDISC Questionnaire Short-Form MPQ-2 Test Name Terminology|QS-Short-Form MPQ-2 TEST|SFMP2TN|Short-Form McGill Pain Questionnaire-2 Questionnaire Test Name	Test names of questionnaire questions associated with the short-form McGill pain questionnaire-2 for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100156>	C100110	CDISC Questionnaire Short-Form MPQ-2 Test Code Terminology|QS-Short-Form MPQ-2 TESTCD|SFMP2TC|Short-Form McGill Pain Questionnaire-2 Questionnaire Test Code	Test codes of questionnaire questions associated with the short-form McGill pain questionnaire-2 for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100157>	C100110	CDISC Questionnaire COMM Test Name Terminology|COMM1TN|Current Opioid Misuse Measure Questionnaire Test Name|QS-COMM TEST	Test names of questionnaire questions associated with the current opioid misuse measure (COMM) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100158>	C100110	CDISC Questionnaire COMM Test Code Terminology|COMM1TC|Current Opioid Misuse Measure Questionnaire Test Code|QS-COMM TESTCD	Test codes of questionnaire questions associated with the current opioid misuse measure (COMM) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100159>	C100110	CDISC Questionnaire SOAPP-R Test Name Terminology|QS-SOAPP-R TEST|SOAPR1TN|Screener and Opioid Assessment for Patients with Pain - Revised Questionnaire Test Name	Test names of questionnaire questions associated with the revised screener and opiod assessment for patients with pain for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10015>	C61063	Cisplatin/Dianhydrogalactitol/Doxorubicin|CDDP/DAG/DOX|DAP-II			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100160>	C100110	CDISC Questionnaire SOAPP-R Test Code Terminology|QS-SOAPP-R TESTCD|SOAPR1TC|Screener and Opioid Assessment for Patients with Pain - Revised Questionnaire Test Code	Test codes of questionnaire questions associated with the revised screener and opiod assessment for patients with pain for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100161>	C100110	CDISC Questionnaire BPI Test Name Terminology|BPI1TN|Brief Pain Inventory Questionnaire Test Name|QS-BPI TEST	Test names of questionnaire questions associated with the brief pain inventory (BPI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100162>	C100110	CDISC Questionnaire BPI Test Code Terminology|BPI1TC|Brief Pain Inventory Questionnaire Test Code|QS-BPI TESTCD	Test codes of questionnaire questions associated with the brief pain inventory (BPI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100163>	C100110	CDISC Questionnaire BPI Short Form Test Name Terminology|BPI2TN|Brief Pain Inventory Short Form Questionnaire Test Name|QS-BPI Short Form TEST	Test names of questionnaire questions associated with the short-form brief pain inventory for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100164>	C100110	CDISC Questionnaire BPI Short Form Test Code Terminology|BPI2TC|Brief Pain Inventory Short Form Questionnaire Test Code|QS-BPI Short Form TESTCD	Test codes of questionnaire questions associated with the short-form brief pain inventory for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100165>	C100110	CDISC Questionnaire RDQ Test Name Terminology|QS-RDQ TEST|RDQ01TN|Roland Morris Disability Questionnaire Questionnaire Test Name	Test names of questionnaire questions associated with the Roland Morris disability questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100166>	C100110	CDISC Questionnaire RDQ Test Code Terminology|QS-RDQ TESTCD|RDQ01TC|Roland Morris Disability Questionnaire Questionnaire Test Code	Test codes of questionnaire questions associated with the Roland Morris disability questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100167>	C100110	CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CSS01TN|Columbia-Suicide Severity Rating Scale Baseline Questionnaire Test Name|QS-C-SSRS Baseline TEST	Test names of questionnaire questions associated with the Columbia-Suicide severity rating scale baseline questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100168>	C100110	CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CSS01TC|Columbia-Suicide Severity Rating Scale Baseline Questionnaire Test Code|QS-C-SSRS Baseline TESTCD	Test codes of questionnaire questions associated with the Columbia-Suicide severity rating scale baseline questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100169>	C118970	CDISC Clinical Classification KPS Scale Test Name Terminology|KPSS01TN|Karnofsky Performance Status Scale Clinical Classification Test Name|QS-KPS Scale TEST	Test names of clinical classification questions associated with the Karnofsky performance status scale questionnaire (KPS Scale) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10016>	C61063	Ancitabine Hydrochloride/Daunorubicin/Mercaptopurine/Prednisolone|CYC/DNR/MP/PRDL|DCCMP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100170>	C118970	CDISC Clinical Classification KPS Scale Test Code Terminology|KPSS01TC|Karnofsky Performance Status Scale Clinical Classification Test Code|QS-KPS Scale TESTCD	Test codes of clinical classification questions associated with the Karnofsky performance status scale questionnaire (KPS Scale) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100171>	C211913	SF36 v1.0 Standard Questionnaire Question	A question associated with the SF36 v1.0 questionnaire.			Intellectual Product	
C100172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100172>	C211913	WPAI:SHP v2.0 Questionnaire Question	A question associated with version 2.0 of the WPAI:SHP questionnaire.			Intellectual Product	
C100173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100173>	C100110	CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|QS-SF36 v1.0 Standard TEST|SF361TN|The Short Form 36 Health Survey Standard, US Version 1.0 Questionnaire Test Name	Test names of questionnaire questions associated with the Short Form 36 Health Survey Standard, US Version 1.0 (QS-SF36 v1.0 Standard) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100174>	C100110	CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|QS-SF36 v1.0 Standard TESTCD|SF361TC|The Short Form 36 Health Survey Standard, US Version 1.0 Questionnaire Test Code	Test codes of questionnaire questions associated with the Short Form 36 Health Survey Standard, US Version 1.0 (QS-SF36 v1.0 Standard) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100175>	C100110	CDISC Questionnaire WPAI:SHP v2.0 Test Name Terminology|QS-WPAI-SHP TEST|WPAI01TN|Work Productivity and Activity Impairment Questionnaire - Specific Health Problem V2.0 Questionnaire Test Name	Test names of questionnaire questions associated with the the version 2.0 of the work productivity and activity impairment specific health problem questionnaire (WPAI:SHP) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100176>	C100110	CDISC Questionnaire WPAI:SHP v2.0 Test Code Terminology|QS-WPAI-SHP TESTCD|WPAI01TC|Work Productivity and Activity Impairment Questionnaire - Specific Health Problem V2.0 Questionnaire Test Code	Test codes of questionnaire questions associated with the the version 2.0 of the work productivity and activity impairment specific health problem questionnaire (WPAI:SHP) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100177>	C100106	CDISC ADAS-Cog - Word Recall Average Score|ADCRL|Word Recall|Word Recall	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recall task word average score of trials 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100178>	C100106	CDISC ADAS-Cog - Word Recall Trial 1 Subscore|ADCRLT01|Word Recall Trial 1|Word Recall Trial 1	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Sub-score for word recall task trial 1.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100179>	C100106	CDISC ADAS-Cog - Word Recall Trial 2 Subscore|ADCRLT02|Word Recall Trial 2|Word Recall Trial 2	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Sub-score for word recall task trial 2.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10017>	C61063	Doxorubicin/Fluoxymesterone/Methotrexate/Mitolactol/Tamoxifen/Vincristine|DAVTHML|DBD/DOX/FXM/MTX/TMX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100180>	C100106	CDISC ADAS-Cog - Word Recall Trial 3 Subscore|ADCRLT03|Word Recall Trial 3|Word Recall Trial 3	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Sub-score for word recall task trial 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100181>	C100106	CDISC ADAS-Cog - Word Recall: Word 1|ADCRLW01|Word Recall: Word [1]|Word Recall: Word [1]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recall task word 1 for trial 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100182>	C100106	CDISC ADAS-Cog - Word Recall: Word 2|ADCRLW02|Word Recall: Word [2]|Word Recall: Word [2]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recall task word 2 for trial 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100183>	C100106	CDISC ADAS-Cog - Word Recall: Word 3|ADCRLW03|Word Recall: Word [3]|Word Recall: Word [3]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recall task word 3 for trial 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100184>	C100106	CDISC ADAS-Cog - Word Recall: Word 4|ADCRLW04|Word Recall: Word [4]|Word Recall: Word [4]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recall task word 4 for trial 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100185>	C100106	CDISC ADAS-Cog - Word Recall: Word 5|ADCRLW05|Word Recall: Word [5]|Word Recall: Word [5]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recall task word 5 for trial 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100186>	C100106	CDISC ADAS-Cog - Word Recall: Word 6|ADCRLW06|Word Recall: Word [6]|Word Recall: Word [6]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recall task word 6 for trial 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100187>	C100106	CDISC ADAS-Cog - Word Recall: Word 7|ADCRLW07|Word Recall: Word [7]|Word Recall: Word [7]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recall task word 7 for trial 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100188>	C100106	CDISC ADAS-Cog - Word Recall: Word 8|ADCRLW08|Word Recall: Word [8]|Word Recall: Word [8]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recall task word 8 for trial 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100189>	C100106	CDISC ADAS-Cog - Word Recall: Word 9|ADCRLW09|Word Recall: Word [9]|Word Recall: Word [9]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recall task word 9 for trial 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10018>	C61063	Dianhydrogalactitol/Etoposide|DAG/VP-16|DV			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100190>	C100106	CDISC ADAS-Cog - Word Recall: Word 10|ADCRLW10|Word Recall: Word [10]|Word Recall: Word [10]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recall task word 10 for trial 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100191>	C100106	CDISC ADAS-Cog - Naming Objects and Fingers Summary Score|ADCOF|Naming Objects and Fingers|Naming Objects and Fingers	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task summary score for object and fingers.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100192>	C100106	CDISC ADAS-Cog - Naming Objects and Fingers: 1|ADCOFO01|Naming Objects and Fingers: 1|Naming Objects and Fingers: 1	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for object 1.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100193>	C100106	CDISC ADAS-Cog - Naming Objects and Fingers: 2|ADCOFO02|Naming Objects and Fingers: 2|Naming Objects and Fingers: 2	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for object 2.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100194>	C100106	CDISC ADAS-Cog - Naming Objects and Fingers: 3|ADCOFO03|Naming Objects and Fingers: 3|Naming Objects and Fingers: 3	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for object 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100195>	C100106	CDISC ADAS-Cog - Naming Objects and Fingers: 4|ADCOFO04|Naming Objects and Fingers: 4|Naming Objects and Fingers: 4	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for object 4.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100196>	C100106	CDISC ADAS-Cog - Naming Objects and Fingers: 5|ADCOFO05|Naming Objects and Fingers: 5|Naming Objects and Fingers: 5	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for object 5.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100197>	C100106	CDISC ADAS-Cog - Naming Objects and Fingers: 6|ADCOFO06|Naming Objects and Fingers: 6|Naming Objects and Fingers: 6	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for object 6.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100198>	C100106	CDISC ADAS-Cog - Naming Objects and Fingers: 7|ADCOFO07|Naming Objects and Fingers: 7|Naming Objects and Fingers: 7	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for object 7.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100199>	C100106	CDISC ADAS-Cog - Naming Objects and Fingers: 8|ADCOFO08|Naming Objects and Fingers: 8|Naming Objects and Fingers: 8	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for object 8.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10019>	C63589	DZAPO Regimen|ARA-C/AZA/DNR/PRED/VCR|Azacitidine/Cytarabine/Daunorubicin/Prednisone/Vincristine|Azacytidine/Cytarabine/Daunorubicin/Prednisone/Vincristine|DZAPO|DZAPO|Daunorubicin-Azacitidine-Cytarabine-Prednisone-Vincristine|Daunorubicin/Azacitidine/Ara-C/Prednisone/Oncovin|Daunorubicin/Azacitidine/Cytarabine/Prednisone/Vincristine|Daunorubicin/Azacitidine/Cytarabine/Prednisone/Vincristine Regimen	A regimen consisting of daunorubicin, azacitidine, cytarabine, prednisone and vincristine that may be used in the treatment of childhood acute myeloid leukemia (AML).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C1001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1001>	C2139	Rintatolimod|Ampligen|Ampligen|Atvogen|Poly(I).Poly(c12,U)|Poly(Inosinic Acid) Poly(Cytidylic(12), Uridylic)Acid|RINTATOLIMOD	A synthetic derivative of inosinic acid with antiretroviral and immunomodulatory properties. Atvogen acts through a number of pathways to stimulate intracellular antiviral activity of the immune system: it stimulates interferon production; activates the oligoadenylate synthase-RNase L pathway; stimulates natural killer cell activity; and acts as a non-mitogenic stimulator of the immune system. This agent also inhibits replication of human immunodeficiency virus (HIV) in vitro. (NCI04)	Rintatolimod		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C100200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100200>	C100106	CDISC ADAS-Cog - Naming Objects and Fingers: 9|ADCOFO09|Naming Objects and Fingers: 9|Naming Objects and Fingers: 9	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for object 9.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100201>	C100106	CDISC ADAS-Cog - Naming Objects and Fingers: 10|ADCOFO10|Naming Objects and Fingers: 10|Naming Objects and Fingers: 10	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for object 10.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100202>	C100106	CDISC ADAS-Cog - Naming Objects and Fingers: 11|ADCOFO11|Naming Objects and Fingers: 11|Naming Objects and Fingers: 11	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for object 11.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100203>	C100106	CDISC ADAS-Cog - Naming Objects and Fingers: 12|ADCOFO12|Naming Objects and Fingers: 12|Naming Objects and Fingers: 12	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for object 12.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100204>	C100106	CDISC ADAS-Cog - Naming Objects and Fingers: Thumb|ADCOFF01|Naming Objects and Fingers: Thumb|Naming Objects and Fingers: Thumb	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for fingers of the dominant hand, thumb.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100205>	C100106	CDISC ADAS-Cog - Naming Objects and Fingers: Pointer|ADCOFF02|Naming Objects and Fingers: Pointer|Naming Objects and Fingers: Pointer	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for fingers of the dominant hand, index, or pointer finger.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100206>	C100106	CDISC ADAS-Cog - Naming Objects and Fingers: Middle|ADCOFF03|Naming Objects and Fingers: Middle|Naming Objects and Fingers: Middle	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for fingers of the dominant hand, middle finger.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100207>	C100106	CDISC ADAS-Cog - Naming Objects and Fingers: Ring|ADCOFF04|Naming Objects and Fingers: Ring|Naming Objects and Fingers: Ring	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for fingers of the dominant hand, ring finger.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100208>	C100106	CDISC ADAS-Cog - Naming Objects and Fingers: Pinky|ADCOFF05|Naming Objects and Fingers: Pinky|Naming Objects and Fingers: Pinky	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Naming task for fingers of the dominant hand, little finger or pinky.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100209>	C100106	CDISC ADAS-Cog - Commands Summary Score|ADCCMD|Commands|Commands	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Summary score for commands.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10020>	C61063	Fluorouracil/Methotrexate/Mitolactol/Prednisone|DBD/5-FU/MTX/PRED|DMFP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100210>	C100106	CDISC ADAS-Cog - Commands: Fist|ADCCMD01|Commands: Fist|Commands: Fist	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Commands task for making a fist.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100211>	C100106	CDISC ADAS-Cog - Commands: Ceiling|ADCCMD02|Commands: Ceiling|Commands: Ceiling	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Commands task for pointing to the ceiling then to the floor.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100212>	C100106	CDISC ADAS-Cog - Commands: Pencil|ADCCMD03|Commands: Pencil|Commands: Pencil	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Commands task for put the pencil on top of the card and then put it back.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100213>	C100106	CDISC ADAS-Cog - Commands: Watch|ADCCMD04|Commands: Watch|Commands: Watch	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Commands task for put the watch on the other side of the pencil and then turn over the card.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100214>	C100106	CDISC ADAS-Cog - Commands: Shoulder|ADCCMD05|Commands: Shoulder|Commands: Shoulder	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Commands task for tap each shoulder twice with two fingers keeping your eyes shut.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100215>	C100106	CDISC ADAS-Cog - Delayed Word Recall Summary Score|ADCDRL|Delayed Word Recall|Delayed Word Recall	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Summary score for delayed word recall.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100216>	C100106	CDISC ADAS-Cog - Delayed Word Recall: Word 1|ADCDRL01|Delayed Word Recall: Word [1]|Delayed Word Recall: Word [1]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Delayed word recall task for word 1.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100217>	C100106	CDISC ADAS-Cog - Delayed Word Recall: Word 2|ADCDRL02|Delayed Word Recall: Word [2]|Delayed Word Recall: Word [2]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Delayed word recall task for word 2.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100218>	C100106	CDISC ADAS-Cog - Delayed Word Recall: Word 3|ADCDRL03|Delayed Word Recall: Word [3]|Delayed Word Recall: Word [3]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Delayed word recall task for word 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100219>	C100106	CDISC ADAS-Cog - Delayed Word Recall: Word 4|ADCDRL04|Delayed Word Recall: Word [4]|Delayed Word Recall: Word [4]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Delayed word recall task for word 4.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10021>	C61007	BCG/Cyclophosphamide/Doxorubicin/Tegafur|BCG/CTX/DOX/FT|FAC-BCG			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100220>	C100106	CDISC ADAS-Cog - Delayed Word Recall: Word 5|ADCDRL05|Delayed Word Recall: Word [5]|Delayed Word Recall: Word [5]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Delayed word recall task for word 5.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100221>	C100106	CDISC ADAS-Cog - Delayed Word Recall: Word 6|ADCDRL06|Delayed Word Recall: Word [6]|Delayed Word Recall: Word [6]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Delayed word recall task for word 6.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100222>	C100106	CDISC ADAS-Cog - Delayed Word Recall: Word 7|ADCDRL07|Delayed Word Recall: Word [7]|Delayed Word Recall: Word [7]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Delayed word recall task for word 7.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100223>	C100106	CDISC ADAS-Cog - Delayed Word Recall: Word 8|ADCDRL08|Delayed Word Recall: Word [8]|Delayed Word Recall: Word [8]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Delayed word recall task for word 8.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100224>	C100106	CDISC ADAS-Cog - Delayed Word Recall: Word 9|ADCDRL09|Delayed Word Recall: Word [9]|Delayed Word Recall: Word [9]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Delayed word recall task for word 9.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100225>	C100106	CDISC ADAS-Cog - Delayed Word Recall: Word 10|ADCDRL10|Delayed Word Recall: Word [10]|Delayed Word Recall: Word [10]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Delayed word recall task for word 10.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100226>	C100106	CDISC ADAS-Cog - Constructional Praxis Summary Score|ADCCP|Constructional Praxis|Constructional Praxis	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Summary score for constructional praxis.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100227>	C100106	CDISC ADAS-Cog - Constructional Praxis: Circle|ADCCP01|Constructional Praxis: Circle|Constructional Praxis: Circle	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Constructional praxis task for copying a circle.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100228>	C100106	CDISC ADAS-Cog - Constructional Praxis: 2 Rectangles|ADCCP02|Constructional Praxis: 2 Rectangles|Constructional Praxis: 2 Rectangles	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Constructional praxis task for copying two overlapping rectangles.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100229>	C100106	CDISC ADAS-Cog - Constructional Praxis: Diamond|ADCCP03|Constructional Praxis: Diamond|Constructional Praxis: Diamond	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Constructional praxis task for copying a diamond.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10022>	C61063	Fluorouracil/Razoxane/Semustine|5-FU/ICRF-159/MeCCNU|FIME			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100230>	C100106	CDISC ADAS-Cog - Constructional Praxis: Cube|ADCCP04|Constructional Praxis: Cube|Constructional Praxis: Cube	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Constructional praxis task for copying a cube.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100231>	C100106	CDISC ADAS-Cog - Attempt to Draw|ADCCPS|Attempt to Draw|Attempt to Draw	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Constructional praxis attempted to draw, but drew no forms correctly.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100232>	C100106	CDISC ADAS-Cog - Ideational Praxis Summary Score|ADCIP|Ideational Praxis|Ideational Praxis	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Summary score for ideational praxis.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100233>	C100106	CDISC ADAS-Cog - Ideational Praxis: Fold|ADCIP01|Ideational Praxis: Fold|Ideational Praxis: Fold	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Ideational praxis task for folding the paper.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100234>	C100106	CDISC ADAS-Cog - Ideational Praxis: Insert|ADCIP02|Ideational Praxis: Insert|Ideational Praxis: Insert	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Ideational praxis task for put the paper in the envelop.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100235>	C100106	CDISC ADAS-Cog - Ideational Praxis: Seal|ADCIP03|Ideational Praxis: Seal|Ideational Praxis: Seal	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Ideational praxis task for seal the envelop.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100236>	C100106	CDISC ADAS-Cog - Ideational Praxis: Address|ADCIP04|Ideational Praxis: Address|Ideational Praxis: Address	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Ideational praxis task for address the envelop to yourself.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100237>	C100106	CDISC ADAS-Cog - Ideational Praxis: Stamp|ADCIP05|Ideational Praxis: Stamp|Ideational Praxis: Stamp	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Ideational praxis task for showing where the stamp goes.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100238>	C100106	CDISC ADAS-Cog - Orientation Summary Score|ADCOR|Orientation|Orientation	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Summary score for orientation.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100239>	C100106	CDISC ADAS-Cog - Orientation: Full Name|ADCOR01|Orientation: Full Name|Orientation: Full Name	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Orientation task for knowing one's own full name.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10023>	C63360	Doxorubicin/Mitomycin/Tegafur Regimen|DOX/FT/MITO|Doxorubicin/Mitomycin/Tegafur|FURAM|FURAM|FURAM Regimen|Ftorafur/Adriamycin/Mitomycin|Tegafur-Doxorubicin-Mitomycin|Tegafur/Doxorubicin/Mitomycin	A regimen consisting of doxorubicin, mitomycin, and tegafur that may be used in the treatment of non-small cell lung cancers (NSCLC).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C100240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100240>	C100106	CDISC ADAS-Cog - Orientation: Month|ADCOR02|Orientation: Month|Orientation: Month	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Orientation task for knowing the current month.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100241>	C100106	CDISC ADAS-Cog - Orientation: Date|ADCOR03|Orientation: Date|Orientation: Date	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Orientation task for knowing the current day.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100242>	C100106	CDISC ADAS-Cog - Orientation: Year|ADCOR04|Orientation: Year|Orientation: Year	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Orientation task for knowing the current year.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100243>	C100106	CDISC ADAS-Cog - Orientation: Day of Week|ADCOR05|Orientation: Day of Week|Orientation: Day of Week	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Orientation task for knowing the current day of the week.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100244>	C100106	CDISC ADAS-Cog - Orientation: Season|ADCOR06|Orientation: Season|Orientation: Season	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Orientation task for knowing the current season.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100245>	C100106	CDISC ADAS-Cog - Orientation: Place|ADCOR07|Orientation: Place|Orientation: Place	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Orientation task for knowing the current place.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100246>	C100106	CDISC ADAS-Cog - Orientation: Time|ADCOR08|Orientation: Time|Orientation: Time	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Orientation task for knowing the approximate current clock time.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100247>	C100106	CDISC ADAS-Cog - Word Recognition Summary Score|ADCRG|Word Recognition|Word Recognition	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Summary score for word recognition across trials 1-3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100248>	C100106	CDISC ADAS-Cog - Word Recognition Trial 1 Summary Score|ADCRGT01|Word Recognition Trial 1|Word Recognition Trial 1	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Sub-score for word recognition trial 1.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100249>	C100106	CDISC ADAS-Cog - Word Recognition Trial 2 Summary Score|ADCRGT02|Word Recognition Trial 2|Word Recognition Trial 2	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Sub-score for word recognition trial 2.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10024>	C63589	Asparaginase/Methotrexate Regimen|ASP/MTX|Asparaginase-Methotrexate|Asparaginase/Methotrexate|LAM|Methotrexate-Asparaginase|Methotrexate/Asparaginase	A regimen consisting of asparaginase and methotrexate that may be used in the treatment of pediatric acute myeloid leukemia (AML).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C100250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100250>	C100106	CDISC ADAS-Cog - Word Recognition Trial 3 Summary Score|ADCRGT03|Word Recognition Trial 3|Word Recognition Trial 3	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Sub-score for word recognition trial 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100251>	C100106	CDISC ADAS-Cog - Word Recognition: Word 1|ADCRGW01|Word Recognition: Word [1]|Word Recognition: Word [1]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 1 Trials 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100252>	C100106	CDISC ADAS-Cog - Word Recognition: Word 2|ADCRGW02|Word Recognition: Word [2]|Word Recognition: Word [2]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 2 Trials 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100253>	C100106	CDISC ADAS-Cog - Word Recognition: Word 3|ADCRGW03|Word Recognition: Word [3]|Word Recognition: Word [3]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 3 Trials 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100254>	C100106	CDISC ADAS-Cog - Word Recognition: Word 4|ADCRGW04|Word Recognition: Word [4]|Word Recognition: Word [4]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 4 Trials 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100255>	C100106	CDISC ADAS-Cog - Word Recognition: Word 5|ADCRGW05|Word Recognition: Word [5]|Word Recognition: Word [5]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 5 Trials 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100256>	C100106	CDISC ADAS-Cog - Word Recognition: Word 6|ADCRGW06|Word Recognition: Word [6]|Word Recognition: Word [6]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 6 Trials 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100257>	C100106	CDISC ADAS-Cog - Word Recognition: Word 7|ADCRGW07|Word Recognition: Word [7]|Word Recognition: Word [7]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 7 Trials 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100258>	C100106	CDISC ADAS-Cog - Word Recognition: Word 8|ADCRGW08|Word Recognition: Word [8]|Word Recognition: Word [8]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 8 Trials 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100259>	C100106	CDISC ADAS-Cog - Word Recognition: Word 9|ADCRGW09|Word Recognition: Word [9]|Word Recognition: Word [9]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 9 Trials 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10025>	C61063	Asparaginase/Cytarabine/Doxorubicin/Prednisone/Vincristine|ARA-C/ASP/DOX/PRED/VCR|LAPOCA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100260>	C100106	CDISC ADAS-Cog - Word Recognition: Word 10|ADCRGW10|Word Recognition: Word [10]|Word Recognition: Word [10]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 10 Trials 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100261>	C100106	CDISC ADAS-Cog - Word Recognition: Word 11|ADCRGW11|Word Recognition: Word [11]|Word Recognition: Word [11]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 11 Trials 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100262>	C100106	CDISC ADAS-Cog - Word Recognition: Word 12|ADCRGW12|Word Recognition: Word [12]|Word Recognition: Word [12]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 12 Trials 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100263>	C100106	CDISC ADAS-Cog - Word Recognition: Word 13|ADCRGW13|Word Recognition: Word [13]|Word Recognition: Word [13]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 13 Trials 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100264>	C100106	CDISC ADAS-Cog - Word Recognition: Word 14|ADCRGW14|Word Recognition: Word [14]|Word Recognition: Word [14]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 14 Trials 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100265>	C100106	CDISC ADAS-Cog - Word Recognition: Word 15|ADCRGW15|Word Recognition: Word [15]|Word Recognition: Word [15]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 15 Trials 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100266>	C100106	CDISC ADAS-Cog - Word Recognition: Word 16|ADCRGW16|Word Recognition: Word [16]|Word Recognition: Word [16]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 16 Trials 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100267>	C100106	CDISC ADAS-Cog - Word Recognition: Word 17|ADCRGW17|Word Recognition: Word [17]|Word Recognition: Word [17]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 17 Trials 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100268>	C100106	CDISC ADAS-Cog - Word Recognition: Word 18|ADCRGW18|Word Recognition: Word [18]|Word Recognition: Word [18]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 18 Trials 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100269>	C100106	CDISC ADAS-Cog - Word Recognition: Word 19|ADCRGW19|Word Recognition: Word [19]|Word Recognition: Word [19]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 19 Trials 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10026>	C61063	Chlorambucil/Prednisone/Vinblastine/Vincristine|CLB/PRED/VBL/VCR|LVVP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100270>	C100106	CDISC ADAS-Cog - Word Recognition: Word 20|ADCRGW20|Word Recognition: Word [20]|Word Recognition: Word [20]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 20 Trials 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100271>	C100106	CDISC ADAS-Cog - Word Recognition: Word 21|ADCRGW21|Word Recognition: Word [21]|Word Recognition: Word [21]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 21 Trials 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100272>	C100106	CDISC ADAS-Cog - Word Recognition: Word 22|ADCRGW22|Word Recognition: Word [22]|Word Recognition: Word [22]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 22 Trials 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100273>	C100106	CDISC ADAS-Cog - Word Recognition: Word 23|ADCRGW23|Word Recognition: Word [23]|Word Recognition: Word [23]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 23 Trials 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100274>	C100106	CDISC ADAS-Cog - Word Recognition: Word 24|ADCRGW24|Word Recognition: Word [24]|Word Recognition: Word [24]	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Word recognition task for word 24 Trials 1, 2, 3.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100275>	C100106	CDISC ADAS-Cog - Remembering Test Instructions|ADCRI|Remembering Test Instructions|Remembering Test Instructions	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Remembering test instructions.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100276>	C100106	CDISC ADAS-Cog - Spoken Language Ability|ADCSL|Spoken Language Ability|Spoken Language Ability	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Global rating of the quality of speech, or difficulty in making oneself understood.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100277>	C100106	CDISC ADAS-Cog - Word Difficulty in Spontaneous Speech|ADCDIF|Word Finding Difficulty in Spont Speech|Word Finding Difficulty in Spont Speech	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Difficulty finding the desired word in spontaneous speech.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100278>	C100106	CDISC ADAS-Cog - Comprehension|ADCCMP|Comprehension|Comprehension	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Ability to comprehend speech.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100279>	C100106	CDISC ADAS-Cog - Concentration/Distractibility|ADCCON|Concentration/Distractibility|Concentration/Distractibility	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Ability to concentrate or easily be distracted.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10027>	C61007	Fluorouracil/Mitomycin|5-FU/MITO|MF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100280>	C100106	CDISC ADAS-Cog - Number Cancellation Summary Score|ADCNC|Number Cancellation|Number Cancellation	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Summary score for the number cancellation tasks.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100281>	C100106	CDISC ADAS-Cog - Number Cancellation: Correct|ADCNC01|Number Cancellation: Correct|Number Cancellation: Correct	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Number of targets hit during the number cancellation task.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100282>	C100106	CDISC ADAS-Cog - Number Cancellation: Errors|ADCNC02|Number Cancellation: Errors|Number Cancellation: Errors	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Number of errors during the number cancellation task.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100283>	C100106	CDISC ADAS-Cog - Number Cancellation: Remind|ADCNC03|Number Cancellation: Remind|Number Cancellation: Remind	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Number of times reminded for the number cancellation task.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100284>	C100106	CDISC ADAS-Cog - Executive Function Maze Summary Score|ADCMZ|Executive Function Maze|Executive Function Maze	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Summary score for the executive function maze tasks.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100285>	C100106	CDISC ADAS-Cog - Executive Function Maze: Errors|ADCMZ01|Executive Function Maze: Errors|Executive Function Maze: Errors	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) Number of errors during the executive function maze task.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100286>	C100106	CDISC ADAS-Cog - Executive Function Maze: Time|ADCMZ02|Executive Function Maze: Time|Executive Function Maze: Time	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version (ADAS-Cog CDISC Version) The time taken to complete the executive function maze task.			Intellectual Product	CDISC Functional Test ADAS-Cog CDISC Version Test Code Terminology|CDISC Functional Test ADAS-Cog CDISC Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100287>	C100107	BPI - Marital Status|BPI1-Marital Status|BPI1-Marital Status|BPI101	Brief Pain Inventory (BPI) Marital status.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100288>	C100107	BPI - Education|BPI1-Education|BPI1-Education|BPI102	Brief Pain Inventory (BPI) Education.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100289>	C100107	BPI - Professional Degree|BPI1-Professional Degree|BPI1-Professional Degree|BPI102A	Brief Pain Inventory (BPI) Education. Professional degree.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10028>	C63496	MCBP Regimen|BCNU/CTX/L-PAM/PRED|Carmustine/Cyclophosphamide/Melphalan/Prednisone|MCBP|MCBP|Melphalan-Cyclophosphamide-Carmustine-Prednisone|Melphalan/Cyclophosphamide/BCNU/Prednisone|Melphalan/Cyclophosphamide/Carmustine/Prednisone|Melphalan/Cyclophosphamide/Carmustine/Prednisone Regimen	A regimen consisting of melphalan, cyclophosphamide, carmustine, and prednisone that may be used in the treatment of plasma cell myeloma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C100290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100290>	C100107	BPI - Current Occupation|BPI1-Current Occupation|BPI1-Current Occupation|BPI103	Brief Pain Inventory (BPI) Current occupation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100291>	C100107	BPI - Spouse's Occupation|BPI1-Spouse's Occupation|BPI1-Spouse's Occupation|BPI104	Brief Pain Inventory (BPI) Spouse's occupation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100292>	C100107	BPI - Current Job Status|BPI1-Current Job Status|BPI1-Current Job Status|BPI105	Brief Pain Inventory (BPI) Which of the following best describes your current job status?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100293>	C100107	BPI - How Long Since Diagnosis|BPI1-How Long Since Diagnosis|BPI1-How Long Since Diagnosis|BPI106	Brief Pain Inventory (BPI) How long has it been since you first learned your diagnosis?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100294>	C100107	BPI - Pain Due to Present Disease|BPI1-Pain Due to Present Disease|BPI1-Pain Due to Present Disease|BPI107	Brief Pain Inventory (BPI) Have you ever had pain due to your present disease?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100295>	C100107	BPI - Pain as a Symptom|BPI1-Pain One of Your Symptoms|BPI1-Pain One of Your Symptoms|BPI108	Brief Pain Inventory (BPI) When you first received your diagnosis, was pain one of your symptoms?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100296>	C100107	BPI - Surgery in Past Month|BPI1-Surgery in Past Month|BPI1-Surgery in Past Month|BPI109	Brief Pain Inventory (BPI) Have you had surgery in the past month?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100297>	C100107	BPI - Kind of Surgery in Past Month|BPI1-Kind of Surgery in Past Month|BPI1-Kind of Surgery in Past Month|BPI109A	Brief Pain Inventory (BPI) What kind of surgery have you had in the past month?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100298>	C100107	BPI - Pain Other than Everyday Kinds|BPI1-Pain Other than Everyday Kinds|BPI1-Pain Other than Everyday Kinds|BPI110	Brief Pain Inventory (BPI) Have you had pain other than these everyday kinds of pain during the last week?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100299>	C100107	BPI - Pain Medications in the Last 7 Days|BPI1-Pain Medications in the Last 7 Days|BPI1-Pain Medications in the Last 7 Days|BPI110A	Brief Pain Inventory (BPI) Did you take pain medications in the last 7 days?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10029>	C61063	Doxorubicin/Lomustine/Mechlorethamine|CCNU/DOX/NM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1002>	C530	Therapeutic Angiogenin|ANGIOGENIN	A 14kD non-glycosylated human derived angiogenesis factor, which has the ability to induce neovascularisation with a unique ribonucleolytic activity. (NCI)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C100300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100300>	C100107	BPI - Pain Requires Medication Daily|BPI1-Pain Requires Medication Daily|BPI1-Pain Requires Medication Daily|BPI110B	Brief Pain Inventory (BPI) I feel I have some form of pain that requires medication each and every day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100301>	C100107	BPI - Areas of Pain|BPI1-Areas of Pain|BPI1-Areas of Pain|BPI111A	Brief Pain Inventory (BPI) On the diagram, shade in the areas where you feel pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100302>	C100107	BPI - Area Hurts Most|BPI1-Area Hurts Most|BPI1-Area Hurts Most|BPI111B	Brief Pain Inventory (BPI) On the diagram, put an X on the area that hurts the most.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100303>	C100107	BPI - Pain at its Worst in Last Week|BPI1-Pain at its Worst in Last Week|BPI1-Pain at its Worst in Last Week|BPI112	Brief Pain Inventory (BPI) Please rate your pain by circling the one number that best describes your pain at its worst in the last week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100304>	C100107	BPI - Pain at its Least in Last Week|BPI1-Pain at its Least in Last Week|BPI1-Pain at its Least in Last Week|BPI113	Brief Pain Inventory (BPI) Please rate your pain by circling the one number that best describes your pain at its least in the last week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100305>	C100107	BPI - Pain on the Average|BPI1-Pain on the Average|BPI1-Pain on the Average|BPI114	Brief Pain Inventory (BPI) Please rate your pain by circling the one number that best describes your pain on the average.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100306>	C100107	BPI - Pain Right Now|BPI1-Pain Right Now|BPI1-Pain Right Now|BPI115	Brief Pain Inventory (BPI) Please rate your pain by circling the one number that tells how much pain you have right now.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100307>	C100107	BPI - Things that Make Pain Feel Better|BPI1-Things that Make Pain Feel Better|BPI1-Things that Make Pain Feel Better|BPI116	Brief Pain Inventory (BPI) What kinds of things make your pain feel better?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100308>	C100107	BPI - Things that Make your Pain Worse|BPI1-Things that Make your Pain Worse|BPI1-Things that Make your Pain Worse|BPI117	Brief Pain Inventory (BPI) What kinds of things make your pain feel worse?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100309>	C100107	BPI - Treatments Receiving for Pain|BPI1-Treatments Receiving for Pain|BPI1-Treatments Receiving for Pain|BPI118	Brief Pain Inventory (BPI) What treatments or medications are you receiving for your pain?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10030>	C63510	Doxorubicin/Semustine Regimen|DOX/MeCCNU|Doxorubicin-Semustine|Doxorubicin/Semustine|MAD|MAD|MeCCNU/Adriamycin|MeCCNU/Doxorubicin|Semustine-Doxorubicin|Semustine/Doxorubicin	A regimen consisting of doxorubicin and semustine (methyl CCNU) that may be used in the treatment of metastatic sarcomas.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C100310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100310>	C100107	BPI - Relief Pain Treatments Provided|BPI1-Relief Pain Treatments Provided|BPI1-Relief Pain Treatments Provided|BPI119	Brief Pain Inventory (BPI) In the last week, how much relief have pain treatments or medications provided? Please circle the one percentage that most shows how much relief you have received.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100311>	C100107	BPI - Hours before Pain Returns|BPI1-Hours before Pain Returns|BPI1-Hours before Pain Returns|BPI120	Brief Pain Inventory (BPI) If you take pain medication, how many hours does it take before the pain returns?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100312>	C100107	BPI - Pain Due to Effects of Treatment|BPI1-Pain Due to Effects of Treatment|BPI1-Pain Due to Effects of Treatment|BPI1211	Brief Pain Inventory (BPI) I believe my pain is due to the effects of treatment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100313>	C100107	BPI - Pain Due to Primary Disease|BPI1-Pain Due to Primary Disease|BPI1-Pain Due to Primary Disease|BPI1212	Brief Pain Inventory (BPI) I believe my pain is due to my primary disease.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100314>	C100107	BPI - Pain Due to Unrelated Medical Condition|BPI1-Pain Due to Unrelated Med Condition|BPI1-Pain Due to Unrelated Med Condition|BPI1213	Brief Pain Inventory (BPI) I believe my pain is due to a medical condition unrelated to my primary disease.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100315>	C100107	BPI - Describe Unrelated Medical Condition|BPI1-Describe Unrelated Med Condition|BPI1-Describe Unrelated Med Condition|BPI1213A	Brief Pain Inventory (BPI) I believe my pain is due to a medical condition unrelated to my primary disease. Please describe condition.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100316>	C100107	BPI - Aching|BPI1-Aching|BPI1-Aching|BPI122A	Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; aching.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100317>	C100107	BPI - Throbbing|BPI1-Throbbing|BPI1-Throbbing|BPI122B	Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; throbbing.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100318>	C100107	BPI - Shooting|BPI1-Shooting|BPI1-Shooting|BPI122C	Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; shooting.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100319>	C100107	BPI - Stabbing|BPI1-Stabbing|BPI1-Stabbing|BPI122D	Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; stabbing.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10031>	C63510	Dactinomycin/Doxorubicin/Methotrexate/Vincristine Regimen|DACT/DOX/MTX/VCR|Dactinomycin-Doxorubicin-Methotrexate-Vincristine|Dactinomycin/Doxorubicin/Methotrexate/Vincristine|OMAD|VMAD|VMAD	A regimen consisting of dactinomycin, doxorubicin, methotrexate and vincristine that can be used for the treatment of advanced soft tissue sarcoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C100320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100320>	C100107	BPI - Gnawing|BPI1-Gnawing|BPI1-Gnawing|BPI122E	Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; gnawing.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100321>	C100107	BPI - Sharp|BPI1-Sharp|BPI1-Sharp|BPI122F	Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; sharp.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100322>	C100107	BPI - Tender|BPI1-Tender|BPI1-Tender|BPI122G	Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; tender.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100323>	C100107	BPI - Burning|BPI1-Burning|BPI1-Burning|BPI122H	Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; burning.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100324>	C100107	BPI - Exhausting|BPI1-Exhausting|BPI1-Exhausting|BPI122I	Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; exhausting.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100325>	C100107	BPI - Tiring|BPI1-Tiring|BPI1-Tiring|BPI122J	Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; tiring.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100326>	C100107	BPI - Penetrating|BPI1-Penetrating|BPI1-Penetrating|BPI122K	Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; penetrating.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100327>	C100107	BPI - Nagging|BPI1-Nagging|BPI1-Nagging|BPI122L	Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; nagging.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100328>	C100107	BPI - Numb|BPI1-Numb|BPI1-Numb|BPI122M	Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; numb.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100329>	C100107	BPI - Miserable|BPI1-Miserable|BPI1-Miserable|BPI122N	Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; miserable.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10032>	C61063	Cyclophosphamide/Prednisolone/Teniposide|CTX/PRDL/VM-26			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100330>	C100107	BPI - Unbearable|BPI1-Unbearable|BPI1-Unbearable|BPI122O	Brief Pain Inventory (BPI) Check Yes or No if the adjective applies to your pain; unbearable.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100331>	C100107	BPI - Pain Interfered with General Activity|BPI1-Pain Interfered General Activity|BPI1-Pain Interfered General Activity|BPI123A	Brief Pain Inventory (BPI) Circle the one number that describes how, during the past week, pain has interfered with your general activity.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100332>	C100107	BPI - Pain Interfered with Mood|BPI1-Pain Interfered with Mood|BPI1-Pain Interfered with Mood|BPI123B	Brief Pain Inventory (BPI) Circle the one number that describes how, during the past week, pain has interfered with your mood.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100333>	C100107	BPI - Pain Interfered with Walking Ability|BPI1-Pain Interfered Walking Ability|BPI1-Pain Interfered Walking Ability|BPI123C	Brief Pain Inventory (BPI) Circle the one number that describes how, during the past week, pain has interfered with your walking ability.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100334>	C100107	BPI - Pain Interfered with Normal Work|BPI1-Pain Interfered with Normal Work|BPI1-Pain Interfered with Normal Work|BPI123D	Brief Pain Inventory (BPI) Circle the one number that describes how, during the past week, pain has interfered with your normal work.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100335>	C100107	BPI - Pain Interfered with Relations|BPI1-Pain Interfered with Relations|BPI1-Pain Interfered with Relations|BPI123E	Brief Pain Inventory (BPI) Circle the one number that describes how, during the past week, pain has interfered with your relations with other people.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100336>	C100107	BPI - Pain Interfered with Sleep|BPI1-Pain Interfered with Sleep|BPI1-Pain Interfered with Sleep|BPI123F	Brief Pain Inventory (BPI) Circle the one number that describes how, during the past week, pain has interfered with your sleep.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100337>	C100107	BPI - Pain Interfered with Enjoyment of Life|BPI1-Pain Interfered Enjoyment of Life|BPI1-Pain Interfered Enjoyment of Life|BPI123G	Brief Pain Inventory (BPI) Circle the one number that describes how, during the past week, pain has interfered with your enjoyment of life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100338>	C100107	BPI - Prefer to Take Pain Medicine|BPI1-Prefer to Take Pain Medicine|BPI1-Prefer to Take Pain Medicine|BPI124	Brief Pain Inventory (BPI) I prefer to take my pain medicine.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100339>	C100107	BPI - Take my Pain Medicine|BPI1-Take my Pain Medicine|BPI1-Take my Pain Medicine|BPI125	Brief Pain Inventory (BPI) I take my pain medicine (in a 24 hour period).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10033>	C61063	Fluorouracil/Melphalan|5-FU/L-PAM|PF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100340>	C100107	BPI - Need Stronger Type of Pain Medication|BPI1-Need Stronger Type of Pain Med|BPI1-Need Stronger Type of Pain Med|BPI126	Brief Pain Inventory (BPI) Do you feel you need a stronger type of pain medication?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100341>	C100107	BPI - Need more Pain Medication than Prescribed|BPI1-Need more Pain Med than Prescribed|BPI1-Need more Pain Med than Prescribed|BPI127	Brief Pain Inventory (BPI) Do you feel you need to take more of the pain medication than your doctor has prescribed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100342>	C100107	BPI - Concerned with Too Much Pain Medication Use|BPI1-Concerned Use Too Much Pain Med|BPI1-Concerned Use Too Much Pain Med|BPI128	Brief Pain Inventory (BPI) Are you concerned that you use too much pain medication?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100343>	C100107	BPI - Why Concerned with Too Much Pain Medication Use|BPI1-Why Concerned Use Too Much Pain Med|BPI1-Why Concerned Use Too Much Pain Med|BPI128A	Brief Pain Inventory (BPI) Are you concerned that you use too much pain medication? If Yes, why?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100344>	C100107	BPI - Problems with Side Effects Pain Medication|BPI1-Problems with Side Effects Pain Med|BPI1-Problems with Side Effects Pain Med|BPI129	Brief Pain Inventory (BPI) Are you having problems with side effects from your pain medication?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100345>	C100107	BPI - What Side Effects from Pain Medication|BPI1-Which Side Effects from Pain Med|BPI1-Which Side Effects from Pain Med|BPI129A	Brief Pain Inventory (BPI) Are you having problems with side effects from your pain medication? Which side effects?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100346>	C100107	BPI - Need Further Information about Pain Medication|BPI1-Need Further Info about Pain Med|BPI1-Need Further Info about Pain Med|BPI130	Brief Pain Inventory (BPI) Do you feel you need to receive further information about your pain medication?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100347>	C100107	BPI - Warm Compresses to Relieve Pain|BPI1-Warm Compresses to Relieve Pain|BPI1-Warm Compresses to Relieve Pain|BPI131A	Brief Pain Inventory (BPI) Other methods I use to relieve pain include; warm compresses.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100348>	C100107	BPI - Cold Compresses to Relieve Pain|BPI1-Cold Compresses to Relieve Pain|BPI1-Cold Compresses to Relieve Pain|BPI131B	Brief Pain Inventory (BPI) Other methods I use to relieve pain include; cold compresses.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100349>	C100107	BPI - Relaxation Techniques Relieve Pain|BPI1-Relaxation Techniques Relieve Pain|BPI1-Relaxation Techniques Relieve Pain|BPI131C	Brief Pain Inventory (BPI) Other methods I use to relieve pain include; relaxation techniques.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10034>	C61063	Doxorubicin/Fluorouracil/Melphalan|DOX/5-FU/L-PAM|PAF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100350>	C100107	BPI - Distraction to Relieve Pain|BPI1-Distraction to Relieve Pain|BPI1-Distraction to Relieve Pain|BPI131D	Brief Pain Inventory (BPI) Other methods I use to relieve pain include; distraction.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100351>	C100107	BPI - Biofeedback to Relieve Pain|BPI1-Biofeedback to Relieve Pain|BPI1-Biofeedback to Relieve Pain|BPI131E	Brief Pain Inventory (BPI) Other methods I use to relieve pain include; biofeedback.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100352>	C100107	BPI - Hypnosis to Relieve Pain|BPI1-Hypnosis to Relieve Pain|BPI1-Hypnosis to Relieve Pain|BPI131F	Brief Pain Inventory (BPI) Other methods I use to relieve pain include; hypnosis.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100353>	C100107	BPI - Other Methods to Relieve Pain|BPI1-Other to Relieve Pain|BPI1-Other to Relieve Pain|BPI131G	Brief Pain Inventory (BPI) Other methods I use to relieve pain include; other.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100354>	C100107	BPI - Specified Other Method to Relieve Pain|BPI1-Other specify to Relieve Pain|BPI1-Other specify to Relieve Pain|BPI131H	Brief Pain Inventory (BPI) Other methods I use to relieve pain include; other. Please specify.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100355>	C100107	BPI - Medications not Prescribed Taken for Pain|BPI1-Meds not Prescribed Taken for Pain|BPI1-Meds not Prescribed Taken for Pain|BPI132	Brief Pain Inventory (BPI) Medications not prescribed by my doctor that I take for pain are.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Test Code Terminology|CDISC Questionnaire BPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100356>	C100108	BPI Short Form - Pain Other Than Everyday Kinds|BPI2-Pain Other Than Everyday Kinds|BPI2-Pain Other Than Everyday Kinds|BPI201	Brief Pain Inventory Short Form (BPI Short Form) Have you had pain other than these everyday kinds of pain today?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Short Form Test Code Terminology|CDISC Questionnaire BPI Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100357>	C100108	BPI Short Form - Areas of Pain|BPI2-Areas of Pain|BPI2-Areas of Pain|BPI202A	Brief Pain Inventory Short Form (BPI Short Form) On the diagram, shade in the areas where you feel pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Short Form Test Code Terminology|CDISC Questionnaire BPI Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100358>	C100108	BPI Short Form - Area that Hurts Most|BPI2-Area Hurts Most|BPI2-Area Hurts Most|BPI202B	Brief Pain Inventory Short Form (BPI Short Form) On the diagram, put an X on the area that hurts the most.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Short Form Test Code Terminology|CDISC Questionnaire BPI Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100359>	C100108	BPI Short Form - Pain at its Worst in Last 24 Hours|BPI2-Pain at its Worst in Last 24 Hours|BPI2-Pain at its Worst in Last 24 Hours|BPI203	Brief Pain Inventory Short Form (BPI Short Form) Please rate your pain by circling the one number that best describes your pain at its worst in the last 24 hours.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Short Form Test Code Terminology|CDISC Questionnaire BPI Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10035>	C61007	Mercaptopurine/Methotrexate/Vincristine|MP/MTX/VCR|PIP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100360>	C100108	BPI Short Form - Pain at its Least in Last 24 Hours|BPI2-Pain at its Least in Last 24 Hours|BPI2-Pain at its Least in Last 24 Hours|BPI204	Brief Pain Inventory Short Form (BPI Short Form) Please rate your pain by circling the one number that best describes your pain at its least in the last 24 hours.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Short Form Test Code Terminology|CDISC Questionnaire BPI Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100361>	C100108	BPI Short Form - Pain on the Average|BPI2-Pain on the Average|BPI2-Pain on the Average|BPI205	Brief Pain Inventory Short Form (BPI Short Form) Please rate your pain by circling the one number that best describes your pain on the average.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Short Form Test Code Terminology|CDISC Questionnaire BPI Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100362>	C100108	BPI Short Form - Pain Right Now|BPI2-Pain Right Now|BPI2-Pain Right Now|BPI206	Brief Pain Inventory Short Form (BPI Short Form) Please rate your pain by circling the one number that tells how much pain you have right now.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Short Form Test Code Terminology|CDISC Questionnaire BPI Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100363>	C100108	BPI Short Form - Treatments or Medications Receiving for Pain|BPI2-Treatments Receiving for Pain|BPI2-Treatments Receiving for Pain|BPI207	Brief Pain Inventory Short Form (BPI Short Form) What treatments or medications are you receiving for your pain?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Short Form Test Code Terminology|CDISC Questionnaire BPI Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100364>	C100108	BPI Short Form - Relief from Pain Treatments Provided|BPI2-Relief Pain Treatments Provided|BPI2-Relief Pain Treatments Provided|BPI208	Brief Pain Inventory Short Form (BPI Short Form) In the last 24 hours, how much relief have pain treatments or medications provided? Please circle the one percentage that most shows how much relief you have received.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Short Form Test Code Terminology|CDISC Questionnaire BPI Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100365>	C100108	BPI Short Form - Pain Interfered with General Activity|BPI2-Pain Interfered General Activity|BPI2-Pain Interfered General Activity|BPI209A	Brief Pain Inventory Short Form (BPI Short Form) Circle the one number that describes how, during the past 24 hours, pain has interfered with your general activity.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Short Form Test Code Terminology|CDISC Questionnaire BPI Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100366>	C100108	BPI Short Form - Pain Interfered with Mood|BPI2-Pain Interfered with Mood|BPI2-Pain Interfered with Mood|BPI209B	Brief Pain Inventory Short Form (BPI Short Form) Circle the one number that describes how, during the past 24 hours, pain has interfered with your mood.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Short Form Test Code Terminology|CDISC Questionnaire BPI Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100367>	C100108	BPI Short Form - Pain Interfered with Walking Ability|BPI2-Pain Interfered Walking Ability|BPI2-Pain Interfered Walking Ability|BPI209C	Brief Pain Inventory Short Form (BPI Short Form) Circle the one number that describes how, during the past 24 hours, pain has interfered with your walking ability.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Short Form Test Code Terminology|CDISC Questionnaire BPI Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100368>	C100108	BPI Short Form - Pain Interfered with Normal Work|BPI2-Pain Interfered with Normal Work|BPI2-Pain Interfered with Normal Work|BPI209D	Brief Pain Inventory Short Form (BPI Short Form) Circle the one number that describes how, during the past 24 hours, pain has interfered with your normal work.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Short Form Test Code Terminology|CDISC Questionnaire BPI Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100369>	C100108	BPI Short Form - Pain Interfered with Relations|BPI2-Pain Interfered with Relations|BPI2-Pain Interfered with Relations|BPI209E	Brief Pain Inventory Short Form (BPI Short Form) Circle the one number that describes how, during the past 24 hours, pain has interfered with your relations with other people.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Short Form Test Code Terminology|CDISC Questionnaire BPI Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10036>	C63589	ROAP Regimen|ARA-C/PRED/VCR/RBZ|Cytarabine/Prednisone/Rubidazone/Vincristine|ROAP|ROAP|Rubidazone-Vincristine-Cytarabine-Prednisone|Rubidazone/Oncovin/Ara-C/Prednisone|Rubidazone/Vincristine/Cytarabine/Prednisone|Rubidazone/Vincristine/Cytarabine/Prednisone Regimen	A regimen consisting of zorubicin, vincristine, cytarabine, and prednisone, that may be used in the treatment of acute myeloid leukemia (AML).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C100370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100370>	C100108	BPI Short Form - Pain Interfered with Sleep|BPI2-Pain Interfered with Sleep|BPI2-Pain Interfered with Sleep|BPI209F	Brief Pain Inventory Short Form (BPI Short Form) Circle the one number that describes how, during the past 24 hours, pain has interfered with your sleep.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Short Form Test Code Terminology|CDISC Questionnaire BPI Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100371>	C100108	BPI Short Form - Pain Interfered with Enjoyment of Life|BPI2-Pain Interfered Enjoyment of Life|BPI2-Pain Interfered Enjoyment of Life|BPI209G	Brief Pain Inventory Short Form (BPI Short Form) Circle the one number that describes how, during the past 24 hours, pain has interfered with your enjoyment of life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BPI Short Form Test Code Terminology|CDISC Questionnaire BPI Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100372>	C100109	BPRS-Anchored - Somatic Concern|BPRSA1-Somatic Concern|BPRSA1-Somatic Concern|BPRSA101	Brief Psychiatric Rating Scale-Anchored (BPRS-A) Somatic concern.			Intellectual Product	CDISC Clinical Classification BPRS-Anchored Test Code Terminology|CDISC Clinical Classification BPRS-Anchored Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100373>	C100109	BPRS-Anchored - Anxiety|BPRSA1-Anxiety|BPRSA1-Anxiety|BPRSA102	Brief Psychiatric Rating Scale-Anchored (BPRS-A) Anxiety.			Intellectual Product	CDISC Clinical Classification BPRS-Anchored Test Code Terminology|CDISC Clinical Classification BPRS-Anchored Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100374>	C100109	BPRS-Anchored - Emotional Withdrawal|BPRSA1-Emotional Withdrawal|BPRSA1-Emotional Withdrawal|BPRSA103	Brief Psychiatric Rating Scale-Anchored (BPRS-A) Emotional withdrawal.			Intellectual Product	CDISC Clinical Classification BPRS-Anchored Test Code Terminology|CDISC Clinical Classification BPRS-Anchored Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100375>	C100109	BPRS-Anchored - Conceptual Disorganization|BPRSA1-Conceptual Disorganization|BPRSA1-Conceptual Disorganization|BPRSA104	Brief Psychiatric Rating Scale-Anchored (BPRS-A) Conceptual disorganization.			Intellectual Product	CDISC Clinical Classification BPRS-Anchored Test Code Terminology|CDISC Clinical Classification BPRS-Anchored Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100376>	C100109	BPRS-Anchored - Guilt Feelings|BPRSA1-Guilt Feelings|BPRSA1-Guilt Feelings|BPRSA105	Brief Psychiatric Rating Scale-Anchored (BPRS-A) Guilt feelings.			Intellectual Product	CDISC Clinical Classification BPRS-Anchored Test Code Terminology|CDISC Clinical Classification BPRS-Anchored Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100377>	C100109	BPRS-Anchored - Tension|BPRSA1-Tension|BPRSA1-Tension|BPRSA106	Brief Psychiatric Rating Scale-Anchored (BPRS-A) Tension.			Intellectual Product	CDISC Clinical Classification BPRS-Anchored Test Code Terminology|CDISC Clinical Classification BPRS-Anchored Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100378>	C100109	BPRS-Anchored - Mannerisms and Posturing|BPRSA1-Mannerisms and Posturing|BPRSA1-Mannerisms and Posturing|BPRSA107	Brief Psychiatric Rating Scale-Anchored (BPRS-A) Mannerisms and posturing.			Intellectual Product	CDISC Clinical Classification BPRS-Anchored Test Code Terminology|CDISC Clinical Classification BPRS-Anchored Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100379>	C100109	BPRS-Anchored - Grandiosity|BPRSA1-Grandiosity|BPRSA1-Grandiosity|BPRSA108	Brief Psychiatric Rating Scale-Anchored (BPRS-A) Grandiosity.			Intellectual Product	CDISC Clinical Classification BPRS-Anchored Test Code Terminology|CDISC Clinical Classification BPRS-Anchored Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10037>	C61063	Dacarbazine/Zorubicin|DTIC/RBZ|RUBIDIC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100380>	C100109	BPRS-Anchored - Depressive Mood|BPRSA1-Depressive Mood|BPRSA1-Depressive Mood|BPRSA109	Brief Psychiatric Rating Scale-Anchored (BPRS-A) Depressive mood.			Intellectual Product	CDISC Clinical Classification BPRS-Anchored Test Code Terminology|CDISC Clinical Classification BPRS-Anchored Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100381>	C100109	BPRS-Anchored - Hostility|BPRSA1-Hostility|BPRSA1-Hostility|BPRSA110	Brief Psychiatric Rating Scale-Anchored (BPRS-A) Hostility.			Intellectual Product	CDISC Clinical Classification BPRS-Anchored Test Code Terminology|CDISC Clinical Classification BPRS-Anchored Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100382>	C100109	BPRS-Anchored - Suspiciousness|BPRSA1-Suspiciousness|BPRSA1-Suspiciousness|BPRSA111	Brief Psychiatric Rating Scale-Anchored (BPRS-A) Suspiciousness.			Intellectual Product	CDISC Clinical Classification BPRS-Anchored Test Code Terminology|CDISC Clinical Classification BPRS-Anchored Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100383>	C100109	BPRS-Anchored - Hallucinatory Behavior|BPRSA1-Hallucinatory Behavior|BPRSA1-Hallucinatory Behavior|BPRSA112	Brief Psychiatric Rating Scale-Anchored (BPRS-A) Hallucinatory behavior.			Intellectual Product	CDISC Clinical Classification BPRS-Anchored Test Code Terminology|CDISC Clinical Classification BPRS-Anchored Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100384>	C100109	BPRS-Anchored - Motor Retardation|BPRSA1-Motor Retardation|BPRSA1-Motor Retardation|BPRSA113	Brief Psychiatric Rating Scale-Anchored (BPRS-A) Motor retardation.			Intellectual Product	CDISC Clinical Classification BPRS-Anchored Test Code Terminology|CDISC Clinical Classification BPRS-Anchored Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100385>	C100109	BPRS-Anchored - Uncooperativeness|BPRSA1-Uncooperativeness|BPRSA1-Uncooperativeness|BPRSA114	Brief Psychiatric Rating Scale-Anchored (BPRS-A) Uncooperativeness.			Intellectual Product	CDISC Clinical Classification BPRS-Anchored Test Code Terminology|CDISC Clinical Classification BPRS-Anchored Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100386>	C100109	BPRS-Anchored - Unusual Thought Content|BPRSA1-Unusual Thought Content|BPRSA1-Unusual Thought Content|BPRSA115	Brief Psychiatric Rating Scale-Anchored (BPRS-A) Unusual thought content.			Intellectual Product	CDISC Clinical Classification BPRS-Anchored Test Code Terminology|CDISC Clinical Classification BPRS-Anchored Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100387>	C100109	BPRS-Anchored - Blunted Affect|BPRSA1-Blunted Affect|BPRSA1-Blunted Affect|BPRSA116	Brief Psychiatric Rating Scale-Anchored (BPRS-A) Blunted affect.			Intellectual Product	CDISC Clinical Classification BPRS-Anchored Test Code Terminology|CDISC Clinical Classification BPRS-Anchored Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100388>	C100109	BPRS-Anchored - Excitement|BPRSA1-Excitement|BPRSA1-Excitement|BPRSA117	Brief Psychiatric Rating Scale-Anchored (BPRS-A) Excitement.			Intellectual Product	CDISC Clinical Classification BPRS-Anchored Test Code Terminology|CDISC Clinical Classification BPRS-Anchored Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100389>	C100109	BPRS-Anchored - Disorientation|BPRSA1-Disorientation|BPRSA1-Disorientation|BPRSA118	Brief Psychiatric Rating Scale-Anchored (BPRS-A) Disorientation.			Intellectual Product	CDISC Clinical Classification BPRS-Anchored Test Code Terminology|CDISC Clinical Classification BPRS-Anchored Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10038>	C61063	Methotrexate/Prednisone/Thioguanine/Vincristine|MTX/PRED/TG/VCR|T-MOP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100390>	C62087	Mean QRS Duration Ventricular Paced	The average (mean) duration (time) of the QRS interval, obtained from a set of measurements of the QRS interval while the ventricle rhythm is controlled by an electrical impulse from a mechanical cardiac pacemaker. The QRS interval is defined as the time from the beginning of the QRS complex to the end of the QRS complex, representing the time it takes for the ventricles to depolarize.			Quantitative Concept	
C100391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100391>	C83501	Corrected QT Interval|QTCUNS|QTc|QTc Correction Method Unspecified|QTc Correction Method Unspecified|QTc Interval|QTc Interval|QTc interval	The time interval between the start of the Q wave and the end of the T wave in the cardiac cycle as corrected with a non-specified correction formula.			Quantitative Concept	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 7: Diagnostic Procedures Terminology|CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL Authorized Value Terminology|HL Function Test Table
C100392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100392>	C100114	EQ-5D-3L - Mobility|EQ5D01-Mobility|EQ5D01-Mobility|EQ5D0101	The EuroQol (European Quality of Life) Five Dimension Three Level Scale (EQ-5D-3L) Indicate which statements best describe your own health state today: Mobility.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EQ-5D-3L Test Code Terminology|CDISC Questionnaire EQ-5D-3L Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100393>	C100114	EQ-5D-3L - Self-Care|EQ5D01-Self-Care|EQ5D01-Self-Care|EQ5D0102	The EuroQol (European Quality of Life) Five Dimension Three Level Scale (EQ-5D-3L) Indicate which statements best describe your own health state today: Self-care.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EQ-5D-3L Test Code Terminology|CDISC Questionnaire EQ-5D-3L Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100394>	C100114	EQ-5D-3L - Usual Activities|EQ5D01-Usual Activities|EQ5D01-Usual Activities|EQ5D0103	The EuroQol (European Quality of Life) Five Dimension Three Level Scale (EQ-5D-3L) Indicate which statements best describe your own health state today: Usual activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EQ-5D-3L Test Code Terminology|CDISC Questionnaire EQ-5D-3L Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100395>	C100114	EQ-5D-3L - Pain or Discomfort|EQ5D01-Pain/Discomfort|EQ5D01-Pain/Discomfort|EQ5D0104	The EuroQol (European Quality of Life) Five Dimension Three Level Scale (EQ-5D-3L) Indicate which statements best describe your own health state today: Pain or discomfort.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EQ-5D-3L Test Code Terminology|CDISC Questionnaire EQ-5D-3L Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100396>	C100114	EQ-5D-3L - Anxiety or Depression|EQ5D01-Anxiety/Depression|EQ5D01-Anxiety/Depression|EQ5D0105	The EuroQol (European Quality of Life) Five Dimension Three Level Scale (EQ-5D-3L) Indicate which statements best describe your own health state today: Anxiety or depression.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EQ-5D-3L Test Code Terminology|CDISC Questionnaire EQ-5D-3L Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100397>	C100114	EQ-5D-3L - EQ VAS Score|EQ5D01-EQ VAS Score|EQ5D01-EQ VAS Score|EQ5D0106	The EuroQol (European Quality of Life) Five Dimension Three Level Scale (EQ-5D-3L) Indicate on this scale how good or bad your own health is today, in your opinion.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EQ-5D-3L Test Code Terminology|CDISC Questionnaire EQ-5D-3L Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100398>	C100127	HAMD-17 - Depressed Mood|HAMD1-Depressed Mood|HAMD1-Depressed Mood|HAMD101	Hamilton Depression Rating Scale 17 Item (HAMD-17) Depressed mood: sadness, hopeless, helpless, worthless.			Intellectual Product	CDISC Clinical Classification HAMD 17 Test Code Terminology|CDISC Clinical Classification HAMD 17 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100399>	C100127	HAMD-17 - Feelings of Guilt|HAMD1-Feelings of Guilt|HAMD1-Feelings of Guilt|HAMD102	Hamilton Depression Rating Scale 17 Item (HAMD-17) Feelings of guilt.			Intellectual Product	CDISC Clinical Classification HAMD 17 Test Code Terminology|CDISC Clinical Classification HAMD 17 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10039>	C61063	Amifostine/Cisplatin/Monoclonal Antibody R24|CDDP/MOAB R24/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1003>	C74526|C259	Ansamycin Antineoplastic Antibiotic|Ansamycin Antibiotics|Ansamycins|ansamycin	An antineoplastic antibiotic of macrocyclic benzoquinone isolated from the bacterial genus Streptomyces. Ansamycin antibiotics bind to and inhibit the cytosolic chaperone functions of heat shock protein 90 (HSP90). HSP90 maintains the stability and functional shape of many oncogenic signaling proteins and the inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins that may be over-expressed or overactive in tumor cells.			Chemical Viewed Functionally	
C100400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100400>	C100127	HAMD-17 - Suicide|HAMD1-Suicide|HAMD1-Suicide|HAMD103	Hamilton Depression Rating Scale 17 Item (HAMD-17) Suicide.			Intellectual Product	CDISC Clinical Classification HAMD 17 Test Code Terminology|CDISC Clinical Classification HAMD 17 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100401>	C100127	HAMD-17 - Insomnia - Early Night|HAMD1-Insomnia Early - Early Night|HAMD1-Insomnia Early - Early Night|HAMD104	Hamilton Depression Rating Scale 17 Item (HAMD-17) Insomnia; early in the night.			Intellectual Product	CDISC Clinical Classification HAMD 17 Test Code Terminology|CDISC Clinical Classification HAMD 17 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100402>	C100127	HAMD-17 - Insomnia - Middle Night|HAMD1-Insomnia Middle - Middle Night|HAMD1-Insomnia Middle - Middle Night|HAMD105	Hamilton Depression Rating Scale 17 Item (HAMD-17) Insomnia; middle of the night.			Intellectual Product	CDISC Clinical Classification HAMD 17 Test Code Terminology|CDISC Clinical Classification HAMD 17 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100403>	C100127	HAMD-17 - Insomnia - Early Morning|HAMD1-Insomnia Early Hours - Morning|HAMD1-Insomnia Early Hours - Morning|HAMD106	Hamilton Depression Rating Scale 17 Item (HAMD-17) Insomnia; early hours of the morning.			Intellectual Product	CDISC Clinical Classification HAMD 17 Test Code Terminology|CDISC Clinical Classification HAMD 17 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100404>	C100127	HAMD-17 - Work and Activities|HAMD1-Work and Activities|HAMD1-Work and Activities|HAMD107	Hamilton Depression Rating Scale 17 Item (HAMD-17) Work and activities.			Intellectual Product	CDISC Clinical Classification HAMD 17 Test Code Terminology|CDISC Clinical Classification HAMD 17 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100405>	C100127	HAMD-17 - Retardation|HAMD1-Retardation|HAMD1-Retardation|HAMD108	Hamilton Depression Rating Scale 17 Item (HAMD-17) Retardation.			Intellectual Product	CDISC Clinical Classification HAMD 17 Test Code Terminology|CDISC Clinical Classification HAMD 17 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100406>	C100127	HAMD-17 - Agitation|HAMD1-Agitation|HAMD1-Agitation|HAMD109	Hamilton Depression Rating Scale 17 Item (HAMD-17) Agitation.			Intellectual Product	CDISC Clinical Classification HAMD 17 Test Code Terminology|CDISC Clinical Classification HAMD 17 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100407>	C100127	HAMD-17 - Psychic Anxiety|HAMD1-Anxiety Psychic|HAMD1-Anxiety Psychic|HAMD110	Hamilton Depression Rating Scale 17 Item (HAMD-17) Anxiety psychic.			Intellectual Product	CDISC Clinical Classification HAMD 17 Test Code Terminology|CDISC Clinical Classification HAMD 17 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100408>	C100127	HAMD-17 - Somatic Anxiety|HAMD1-Anxiety Somatic|HAMD1-Anxiety Somatic|HAMD111	Hamilton Depression Rating Scale 17 Item (HAMD-17) Anxiety somatic: physiological concomitants of anxiety such as gastro-intestinal (dry mouth, wind, indigestion, diarrhea, cramps, belching), cardiovascular (palpitations, headaches), respiratory (hyperventilation, sighing), urinary frequency, sweating.			Intellectual Product	CDISC Clinical Classification HAMD 17 Test Code Terminology|CDISC Clinical Classification HAMD 17 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100409>	C100127	HAMD-17 - Somatic Symptoms Gastrointestinal|HAMD1-Somatic Symptoms Gastrointestinal|HAMD1-Somatic Symptoms Gastrointestinal|HAMD112	Hamilton Depression Rating Scale 17 Item (HAMD-17) Somatic symptoms gastro-intestinal.			Intellectual Product	CDISC Clinical Classification HAMD 17 Test Code Terminology|CDISC Clinical Classification HAMD 17 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10040>	C61063	Fluorouracil/Leucovorin Calcium/Sargramostim|CF/5-FU/GM-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100410>	C100127	HAMD-17 - General Somatic Symptoms|HAMD1-General Somatic Symptoms|HAMD1-General Somatic Symptoms|HAMD113	Hamilton Depression Rating Scale 17 Item (HAMD-17) General somatic symptoms.			Intellectual Product	CDISC Clinical Classification HAMD 17 Test Code Terminology|CDISC Clinical Classification HAMD 17 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100411>	C100127	HAMD-17 - Genital Symptoms|HAMD1-Genital Symptoms|HAMD1-Genital Symptoms|HAMD114	Hamilton Depression Rating Scale 17 Item (HAMD-17) Genital symptoms: symptoms such as loss of libido, menstrual disturbances.			Intellectual Product	CDISC Clinical Classification HAMD 17 Test Code Terminology|CDISC Clinical Classification HAMD 17 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100412>	C100127	HAMD-17 - Hypochondriasis|HAMD1-Hypochondriasis|HAMD1-Hypochondriasis|HAMD115	Hamilton Depression Rating Scale 17 Item (HAMD-17) Hypochondriasis.			Intellectual Product	CDISC Clinical Classification HAMD 17 Test Code Terminology|CDISC Clinical Classification HAMD 17 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100413>	C100127	HAMD-17 - Loss of Weight According to Patient|HAMD1-Loss of WT According to Patient|HAMD1-Loss of WT According to Patient|HAMD116A	Hamilton Depression Rating Scale 17 Item (HAMD-17) Loss of weight according to the patient.			Intellectual Product	CDISC Clinical Classification HAMD 17 Test Code Terminology|CDISC Clinical Classification HAMD 17 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100414>	C100127	HAMD-17 - Loss of Weight According to Weekly Measurements|HAMD1-Loss of WT According to WK Meas|HAMD1-Loss of WT According to WK Meas|HAMD116B	Hamilton Depression Rating Scale 17 Item (HAMD-17) Loss of weight according to weekly measurements.			Intellectual Product	CDISC Clinical Classification HAMD 17 Test Code Terminology|CDISC Clinical Classification HAMD 17 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100415>	C100127	HAMD-17 - Insight|HAMD1-Insight|HAMD1-Insight|HAMD117	Hamilton Depression Rating Scale 17 Item (HAMD-17) Insight.			Intellectual Product	CDISC Clinical Classification HAMD 17 Test Code Terminology|CDISC Clinical Classification HAMD 17 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100416>	C100127	HAMD-17 - Total Score|HAMD1-Total Score|HAMD1-Total Score|HAMD118	Hamilton Depression Rating Scale 17 Item (HAMD-17) Total Score.			Intellectual Product	CDISC Clinical Classification HAMD 17 Test Code Terminology|CDISC Clinical Classification HAMD 17 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100417>	C100116	KPS Scale - Karnofsky Performance Status|KPSS01-Karnofsky Performance Status|KPSS01-Karnofsky Performance Status|KPSS0101	Karnofsky Performance Status Scale (KPS Scale) Karnofsky Performance Status.			Intellectual Product	CDISC Clinical Classification KPS Scale Test Code Terminology|CDISC Clinical Classification KPS Scale Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100418>	C48938	Sideroblast Measurement|BLSTSID|Sideroblast|Sideroblast	The determination of the amount of sideroblasts present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100419>	C48938	Ring Sideroblast Measurement|BLSTRSID|Ringed Sideroblasts|Ringed Sideroblasts	The determination of the amount of ringed sideroblasts present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10041>	C61063	Bleomycin/Cisplatin/Cyclophosphamide/Doxorubicin/Fluorouracil/Vincristine|BLEO/CDDP/CTX/DOX/5-FU/VCR|COAd/COB-5P			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100420>	C75340	Tricyclic Antidepressant Measurement|TRCYANDP|Tricyclic Antidepressants|Tricyclic Antidepressants	The determination of the amount of tricyclic antidepressants present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100422>	C62662	Ecarin Clotting Time Measurement|ECT|Ecarin Clotting Time|Ecarin Clotting Time	The determination of the activity of thrombin inhibitors in a biological specimen based on the generation of meizothrombin.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100423>	C80160	CH50 Measurement|CH50|CH50|CH50|CH50 Assay|Complement CH50|Complement CH50|Total Hemolytic Complement CH50	A measurement of the complement required to lyse 50 percent of red blood cells in a biological specimen.	CH50 Measurement		Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C100424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100424>	C49286	Platelet Hematocrit Measurement|PLATHCT|Platelet Hematocrit|Platelet Hematocrit|Thrombocytocrit	The determination of the amount of platelet hematocrit present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100425>	C74949	HDL Cholesterol to LDL Cholesterol Ratio Measurement|HDL Cholesterol/LDL Cholesterol|HDL Cholesterol/LDL Cholesterol|HDLCLDLC	The determination of the ratio of HDL cholesterol compared to LDL cholesterol present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100427>	C64430	Apolipoprotein C2 Measurement|APOC2|APOC2 Measurement|Apolipoprotein C-II Measurement|Apolipoprotein C2|Apolipoprotein C2|Apolipoprotein CII|Apolipoprotein CII Measurement	The determination of the amount of apolipoprotein C2 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100428>	C64430	Apolipoprotein J Measurement|APOJ|APOJ Measurement|Apolipoprotein J|Apolipoprotein J|Clusterin|Clusterin Measurement	The determination of the amount of apolipoprotein J present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100429>	C64430	Alpha-1 Acid Glycoprotein Measurement|A1AGLP|Alpha-1 Acid Glycoprotein|Alpha-1 Acid Glycoprotein	The determination of the amount of alpha-1 acid glycoprotein present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10042>	C61063	Bleomycin/Cyclophosphamide/Cytarabine/Doxorubicin/Etoposide/Methotrexate/Prednisone/Sargramostim/Vincristine|ARA-C/BLEO/CTX/DOX/GM-CSF/MTX/PRED/VCR/VP-16|ProMACE/CytaBOM/GM-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100430>	C64430	Alanine Aminopeptidase Measurement|AAP|Alanine Aminopeptidase|Alanine Aminopeptidase	The determination of the amount of alanine aminopeptidase present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100431>	C64430	Chemokine Receptor CXCR3 Measurement|CXCR3|CXCR3|Chemokine (C-X-C Motif) Receptor 3|Chemokine (C-X-C Motif) Receptor 3|GPR9|Soluble CD183	The determination of the amount of chemokine receptor CXCR3 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100432>	C64430	Ceruloplasmin Measurement|CRLPLSMN|Caeruloplasmin|Ceruloplasmin|Ceruloplasmin	The determination of the amount of ceruloplasmin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100433>	C64430	Kidney Injury Molecule-1 Measurement|HAVCR1 Measurement|HAVcr-1 Measurement|Hepatitis A Virus Cellular Receptor 1|Hepatitis A Virus Cellular Receptor 1 Measurement|KIM-1|KIM-1 Measurement|KIM1|KIM1 Measurement|Kidney Injury Molecule 1 Measurement|Kidney Injury Molecule-1|Kidney Injury Molecule-1	The determination of the amount of kidney injury molecule-1 present in a sample.	Kidney Injury Molecule-1 Measurement		Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C100434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100434>	C80163	Non-Prostatic Acid Phosphatase Measurement|NPAP|Non-Prostatic Acid Phosphatase|Non-Prostatic Acid Phosphatase	The determination of the amount of non-prostatic acid phosphatase present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100435>	C64430	Prealbumin Measurement|PREALB|Prealbumin|Prealbumin|TTR Measurement|Thyroxine-binding Prealbumin|Thyroxine-binding Prealbumin Measurement|Transthyretin|Transthyretin Measurement	The determination of the amount of prealbumin present in a sample.	Prealbumin Measurement		Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C100436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100436>	C64430	Protein S Measurement|PROTS|Protein S|Protein S	The determination of the amount of protein S present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100437>	C64430	Retinol Binding Protein Measurement|RBP|Retinol Binding Protein|Retinol Binding Protein	The determination of the amount of retinol binding protein present in a sample.	Retinol Binding Protein Measurement		Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C100438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100438>	C64430	Soluble Transferrin Receptor Measurement|SLTFRNRC|Soluble Transferrin Receptor|Soluble Transferrin Receptor	The determination of the amount of soluble transferrin receptor present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100439>	C75913	Iohexol Clearance|IOHEXCLR	A measurement of the volume of serum or plasma that would be cleared of Iohexol through excretion for a specified unit of time.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10043>	C61063	Cisplatin/Cyclophosphamide/Fluorouracil/Vincristine|CDDP/CTX/5-FU/VCR|CO-5P			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100440>	C75913	EDTA Clearance|EDTACLR	A measurement of the volume of serum or plasma that would be cleared of Ethylenediamine tetraacetic acid (EDTA) through its excretion for a specified unit of time.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100441>	C75913	Diethylene Triamine Pentaacetic Acid Clearance|DTPA Clearance|DTPA Clearance|DTPACLR	A measurement of the volume of serum or plasma that would be cleared of Diethylenetriamine pentaacetate (DTPA) through its excretion for a specified unit of time.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100442>	C67208	Immature Neutrophils to Leukocytes Ratio Measurement|Immature Neutrophils/Leukocytes|Immature Neutrophils/Leukocytes|NEUTIMLE	The determination of the ratio of immature neutrophils compared to total leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100443>	C67208	Immature Lymphocytes to Leukocytes Ratio Measurement|Immature Lymphocytes/Leukocytes|Immature Lymphocytes/Leukocytes|LYMIMLE	The determination of the ratio of immature lymphocytes compared to total leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100444>	C67208	Immature Lymphocytes Measurement|Immature Lymphocytes|Immature Lymphocytes|LYMIM	The determination of the amount of immature lymphocytes present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100445>	C67208	Immature Granulocytes to Leukocytes Ratio Measurement|GRANIMLE|Immature Granulocytes/Leukocytes|Immature Granulocytes/Leukocytes	The determination of the ratio of immature granulocytes compared to total leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100446>	C28133	Proerythroblast Measurement|BLASTRUB|Proerythroblast|Pronormoblast|Rubriblast|Rubriblast	The determination of the amount of proerythroblasts present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100447>	C74971	Homeostatic Model Assessment of Insulin Resistance	An assessment of beta-cell function and insulin resistance based on fasting blood glucose and insulin concentrations.	Homeostatic Model Assessment of Insulin Resistance		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Terminology
C100448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100448>	C49237	Free Glycerol Measurement|Free Glycerin|Free Glycerol|Free Glycerol|GLYCRLFR	The determination of the amount of free glycerol present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100449>	C98734	Direct Glomerular Filtration Rate from Beta-Trace Protein Adjusted for Standard BSA Measurement|GFR from Beta-Trace Protein Adj for BSA|GFR from Beta-Trace Protein Adj for BSA|GFRBSBTP	A measurement of the glomerular filtration rate (GFR) based on the clearance of beta-trace protein after adjusting it for the the standard body surface area (1.73m2).			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10044>	C61063	Altretamine/Cyclophosphamide/Methotrexate|CMH|CTX/HMM/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100450>	C98734	Direct Glomerular Filtration Rate from Beta-2 Microglobulin Adjusted for Standard BSA Measurement|GFR from B-2 Microglobulin Adj for BSA|GFR from B-2 Microglobulin Adj for BSA|GFRBSB2M	A measurement of the glomerular filtration rate (GFR) based on the clearance of beta-2 microglobulin after adjusting it for the body surface area.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100452>	C49188	Ova and Parasite Measurement|OVAPARS|OVAPARS|Ova and Parasite|Ova and Parasite|Ova and Parasite	The determination of the amount of ova and parasites present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Microbiology Test Code Terminology|CDISC SEND Microbiology Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100453>	C49188	Plasmodium Measurement|Malaria|PLSMDM|Plasmodium|Plasmodium	The determination of the amount of Plasmodium present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100454>	C96683|C81971	Liver Kidney Microsomal Type 1 IgG Antibody Measurement	The determination of the amount of liver kidney microsomal type 1 IgG antibody present in a sample.			Laboratory Procedure	
C100455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100455>	C96683|C81972	Liver Kidney Microsomal Type 1 IgM Antibody Measurement	The determination of the amount of liver kidney microsomal type 1 IgM antibody present in a sample.			Laboratory Procedure	
C100456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100456>	C96683|C81969	Liver Kidney Microsomal Type 1 IgA Antibody Measurement	The determination of the amount of liver kidney microsomal type 1 IgA antibody present in a sample.			Laboratory Procedure	
C100457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100457>	C210010	Ribonucleoprotein Antibody Measurement	The determination of the amount of ribonucleoprotein antibody present in a sample.			Laboratory Procedure	
C100458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100458>	C210010	Scl-70 Antibody Measurement	The determination of the amount of Scl-70 antibody present in a sample.			Laboratory Procedure	
C100459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100459>	C210010	Jo-1 Antibody Measurement	The determination of the amount of Jo-1 antibody present in a sample.			Laboratory Procedure	
C10045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10045>	C61063	Cisplatin/Mitoguazone/Vinblastine|CDDP/MGBG/VBL|CVeM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100460>	C154747	HLA-B27 Antigen Measurement|HLA-B27 Antigen|HLA-B27 Antigen|HLAB27AG|Human Leukocyte Antigen B27	The determination of the amount of HLA-B27 antigen present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100461>	C64430|C49286	Alpha-1 Microglobulin Measurement|A1MICG|Alpha 1 Microglobulin Measurement|Alpha-1 Microglobulin|Alpha-1 Microglobulin|Protein HC	The determination of the amount of alpha-1 microglobulin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100462>	C100461	Alpha-1 Microglobulin to Creatinine Ratio Measurement|A1MCREAT|Alpha-1 Microglobulin/Creatinine|Alpha-1 Microglobulin/Creatinine	The determination of the ratio of alpha-1 microglobulin compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100463>	C210010	DNase-B Antibody Measurement	The determination of the amount of Dnase-B antibody present in a sample.			Laboratory Procedure	
C100464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100464>	C81969	Chlamydia trachomatis IgA Antibody Measurement	The determination of the amount of Chlamydia trachomatis IgA antibody present in a sample.			Laboratory Procedure	
C100465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100465>	C81972	Chlamydia trachomatis IgM Antibody Measurement	The determination of the amount of Chlamydia trachomatis IgM antibody present in a sample.			Laboratory Procedure	
C100466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100466>	C81971	Chlamydia trachomatis IgG Antibody Measurement	The determination of the amount of Chlamydia trachomatis IgG antibody present in a sample.			Laboratory Procedure	
C100467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100467>	C100122	Pepsinogen I Measurement|PEPSNGI|PGA|PGA Measurement|PGI|Pepsinogen A|Pepsinogen A Measurement|Pepsinogen I|Pepsinogen I	The determination of the amount of pepsinogen I present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100468>	C100122	Pepsinogen II Measurement|PEPSNGII|PGC|PGC Measurement|PGII|Pepsinogen C|Pepsinogen C Measurement|Pepsinogen II|Pepsinogen II	The determination of the amount of pepsinogen II present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10046>	C61063	Ampligen/Interleukin-2|ampligen/IL-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100471>	C64548|C62662	Activated Protein C Resistance Measurement|APROTCRS|Activated Protein C Resistance|Activated Protein C Resistance|Factor V Leiden Screen	A measurement of the resistance in the anticoagulation response to activated protein C in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100472>	C74803	Beta Carotene Measurement|BETACRTN|Beta Carotene|Beta Carotene|Beta Carotin|b-Carotene	The determination of the amount of beta-carotene present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100473>	C100117	MDS-UPDRS - Cognitive Impairment|UPD2-Cognitive Impairment|UPD2-Cognitive Impairment|UPD2101	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week have you had problems remembering things, following conversations, paying attention, thinking clearly, or finding your way around the house or in town?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100474>	C100117	MDS-UPDRS - Hallucinations and Psychosis|UPD2-Hallucinations and Psychosis|UPD2-Hallucinations and Psychosis|UPD2102	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week have you seen, heard, smelled or felt things that were not really there?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100475>	C100117	MDS-UPDRS - Depressed Mood|UPD2-Depressed Mood|UPD2-Depressed Mood|UPD2103	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week have you felt low, sad, hopeless or unable to enjoy things? If yes, was this feeling for longer than one day at a time? Did it make it difficult for you carry out your usual activities or to be with people?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100476>	C100117	MDS-UPDRS - Anxious Mood|UPD2-Anxious Mood|UPD2-Anxious Mood|UPD2104	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week have you felt nervous, worried or tense? If yes, was this feeling for longer than one day at a time? Did it make it difficult for you to follow your usual activities or to be with other people?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100477>	C100117	MDS-UPDRS - Apathy|UPD2-Apathy|UPD2-Apathy|UPD2105	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you felt indifferent to doing activities or being with people?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100478>	C100117	MDS-UPDRS - Features of Dopamine Dysregulation Syndrome|UPD2-Ftrs Dopa Dysregulation Synd|UPD2-Ftrs Dopa Dysregulation Synd|UPD2106	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you had unusually strong urges that are hard to control? Do you feel driven to do or think about something and find it hard to stop?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100479>	C100117	MDS-UPDRS - Sleep Problems|UPD2-Sleep Problems|UPD2-Sleep Problems|UPD2107	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you had trouble going to sleep at night or staying asleep through the night?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10047>	C61063	Cisplatin/Cytarabine/Etoposide/Sargramostim|ARA-C/CDDP/GM-CSF/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100480>	C100117	MDS-UPDRS - Daytime Sleepiness|UPD2-Daytime Sleepiness|UPD2-Daytime Sleepiness|UPD2108	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you had trouble staying awake during the daytime?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100481>	C100117	MDS-UPDRS - Pain and Other Sensations|UPD2-Pain and other Sensations|UPD2-Pain and other Sensations|UPD2109	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you had uncomfortable feelings in your body like pain, aches tingling or cramps?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100482>	C100117	MDS-UPDRS - Urinary Problems|UPD2-Urinary Problems|UPD2-Urinary Problems|UPD2110	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you had trouble with urine control?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100483>	C100117	MDS-UPDRS - Constipation Problems|UPD2-Constipation Problems|UPD2-Constipation Problems|UPD2111	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week have you had constipation troubles that cause you difficulty moving your bowels?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100484>	C100117	MDS-UPDRS - Lightheadedness on Standing|UPD2-Lightheadedness on Standing|UPD2-Lightheadedness on Standing|UPD2112	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you felt faint, dizzy or foggy when you stand up after sitting or lying down?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100485>	C100117	MDS-UPDRS - Fatigue|UPD2-Fatigue|UPD2-Fatigue|UPD2113	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you usually felt fatigued?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100486>	C100117	MDS-UPDRS - Speech|UPD2-Speech|UPD2-Speech|UPD2201	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you had problems with your speech?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100487>	C100117	MDS-UPDRS - Saliva and Drooling|UPD2-Saliva and Drooling|UPD2-Saliva and Drooling|UPD2202	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you usually had too much saliva during when you are awake or when you sleep?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100488>	C100117	MDS-UPDRS - Chewing and Swallowing|UPD2-Chewing and Swallowing|UPD2-Chewing and Swallowing|UPD2203	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you usually had problems swallowing pills or eating meals?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100489>	C100117	MDS-UPDRS - Eating Tasks|UPD2-Eating Tasks|UPD2-Eating Tasks|UPD2204	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you usually had troubles handling your food and using eating utensils?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10048>	C61007	Cyclophosphamide/Dexrazoxane/Doxorubicin/Vincristine|ADR-529/CTX/DOX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100490>	C100117	MDS-UPDRS - Dressing|UPD2-Dressing|UPD2-Dressing|UPD2205	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you usually had problems dressing?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100491>	C100117	MDS-UPDRS - Hygiene|UPD2-Hygiene|UPD2-Hygiene|UPD2206	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you usually been slow or do you need help with washing, bathing, shaving, brushing teeth, combing your hair or with other personal hygiene?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100492>	C100117	MDS-UPDRS - Handwriting|UPD2-Handwriting|UPD2-Handwriting|UPD2207	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have people usually had trouble reading your handwriting?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100493>	C100117	MDS-UPDRS - Doing Hobbies and Other Activities|UPD2-Doing Hobbies/Other Activities|UPD2-Doing Hobbies/Other Activities|UPD2208	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you usually had trouble doing your hobbies or other things that you like to do?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100494>	C100117	MDS-UPDRS - Turning in Bed|UPD2-Turning in Bed|UPD2-Turning in Bed|UPD2209	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, do you usually have trouble turning over in bed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100495>	C100117	MDS-UPDRS - Tremor|UPD2-Tremor|UPD2-Tremor|UPD2210	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you usually had shaking or tremor?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100496>	C100117	MDS-UPDRS - Walking and Balance|UPD2-Walking and Balance|UPD2-Walking and Balance|UPD2212	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you usually had problems with balance and walking?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100497>	C100117	MDS-UPDRS - Freezing|UPD2-Freezing|UPD2-Freezing|UPD2213	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, on your usual day when walking, do you suddenly stop or freeze as if your feet are stuck to the floor?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100498>	C100117	MDS-UPDRS - Medication for Parkinson's Disease|UPD2-Medication for PD|UPD2-Medication for PD|UPD23A	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Is the patient on medication for treating the symptoms of Parkinson's Disease?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100499>	C100117	MDS-UPDRS - Clinical State on Medication|UPD2-Clinical State on Meds|UPD2-Clinical State on Meds|UPD23B	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) If the patient is receiving medication for treating the symptoms of Parkinson's Disease, mark the patient's clinical state.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10049>	C61063	Carmustine/Cyclophosphamide/Thiotepa/Vincristine|BCNU/CTX/TSPA/VCR|BTOC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1004>	C2500	Antineoplaston A10|3-Phenylacetylamino-2, 6-piperidinedione|3-Phenylacetylamino-2,6-piperidinedione|A10|ANTINEOPLASTON A10|Atengenal|Benzeneacetamide, N-(2,6-dioxo-3-piperidinyl)-, (S)-	A piperidinedione antineoplaston with potential antineoplastic activity.  Antineoplaston A10 was originally isolated from human urine but is now synthetically derived.  This agent intercalates into DNA, resulting in cell cycle arrest in G1 phase, reduction of mitosis, and decreased protein synthesis.  Antineoplaston A10 may also inhibit ras-oncogene expression and activate tumor suppressor gene p53, leading to cell differentiation and apoptosis. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C100500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100500>	C100117	MDS-UPDRS - Taking Levodopa|UPD2-Taking Levodopa|UPD2-Taking Levodopa|UPD23C	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Is the patient on Levodopa?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100501>	C100117	MDS-UPDRS - Minutes Since Levodopa Dose|UPD2-Minutes Since Levodopa Dose|UPD2-Minutes Since Levodopa Dose|UPD23C1	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Minutes since last Levodopa dose.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100502>	C100117	MDS-UPDRS - Speech Problems|UPD2-Speech Problems|UPD2-Speech Problems|UPD2301	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Speech problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100503>	C100117	MDS-UPDRS - Facial Expression|UPD2-Facial Expression|UPD2-Facial Expression|UPD2302	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Facial expression.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100504>	C100117	MDS-UPDRS - Rigidity Neck|UPD2-Rigidity Neck|UPD2-Rigidity Neck|UPD2303A	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Rigidity neck.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100505>	C100117	MDS-UPDRS - Rigidity Right Upper Extremity|UPD2-Rigidity RT Upper Extremity|UPD2-Rigidity RT Upper Extremity|UPD2303B	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Rigidity right upper extremity.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100506>	C100117	MDS-UPDRS - Rigidity Left Upper Extremity|UPD2-Rigidity Left Upper Extremity|UPD2-Rigidity Left Upper Extremity|UPD2303C	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Rigidity left upper extremity.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100507>	C100117	MDS-UPDRS - Rigidity Right Lower Extremity|UPD2-Rigidity RT Lower Extremity|UPD2-Rigidity RT Lower Extremity|UPD2303D	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Rigidity right lower extremity.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100508>	C100117	MDS-UPDRS - Rigidity Left Lower Extremity|UPD2-Rigidity Left Lower Extremity|UPD2-Rigidity Left Lower Extremity|UPD2303E	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Rigidity left lower extremity.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100509>	C100117	MDS-UPDRS - Right Finger Tapping|UPD2-Right Finger Tapping|UPD2-Right Finger Tapping|UPD2304A	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Right finger tapping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10050>	C61063	Asparaginase/Idarubicin/Prednisone/Vincristine|ASP/IDA/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100510>	C100117	MDS-UPDRS - Left Finger Tapping|UPD2-Left Finger Tapping|UPD2-Left Finger Tapping|UPD2304B	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Left finger tapping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100511>	C100117	MDS-UPDRS - Right Hand Movements|UPD2-Right Hand Movements|UPD2-Right Hand Movements|UPD2305A	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Right hand movements.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100512>	C100117	MDS-UPDRS - Left Hand Movements|UPD2-Left Hand Movements|UPD2-Left Hand Movements|UPD2305B	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Left hand movements.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100513>	C100117	MDS-UPDRS - Pronanation-Supination Movement of Right Hand|UPD2-Pron/Sup Movement of RT Hand|UPD2-Pron/Sup Movement of RT Hand|UPD2306A	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Pronation-supination movements of right hand.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100514>	C100117	MDS-UPDRS - Pronanation-Supination Movement of Left Hand|UPD2-Pron/Sup Movement of Left Hand|UPD2-Pron/Sup Movement of Left Hand|UPD2306B	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Pronation-supination movements of left hand.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100515>	C100117	MDS-UPDRS - Right Toe Tapping|UPD2-Right Toe Tapping|UPD2-Right Toe Tapping|UPD2307A	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Right toe tapping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100516>	C100117	MDS-UPDRS - Left Toe Tapping|UPD2-Left Toe Tapping|UPD2-Left Toe Tapping|UPD2307B	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Left toe tapping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100517>	C100117	MDS-UPDRS - Right Leg Agility|UPD2-Right Leg Agility|UPD2-Right Leg Agility|UPD2308A	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Right leg agility.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100518>	C100117	MDS-UPDRS - Left Leg Agility|UPD2-Left Leg Agility|UPD2-Left Leg Agility|UPD2308B	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Left leg agility.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100519>	C100117	MDS-UPDRS - Arising from Chair|UPD2-Arising from Chair|UPD2-Arising from Chair|UPD2309	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Arising from chair.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10051>	C61063	Carmustine/Triazinate|BCNU/TZT|BT			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100520>	C100117	MDS-UPDRS - Gait|UPD2-Gait|UPD2-Gait|UPD2310	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Gait.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100521>	C100117	MDS-UPDRS - Freezing of Gait|UPD2-Freezing of Gait|UPD2-Freezing of Gait|UPD2311	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Freezing of gait.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100522>	C100117	MDS-UPDRS - Postural Stability|UPD2-Postural Stability|UPD2-Postural Stability|UPD2312	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Postural stability.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100523>	C100117	MDS-UPDRS - Posture|UPD2-Posture|UPD2-Posture|UPD2313	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Posture.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100524>	C100117	MDS-UPDRS - Body Bradykinesia|UPD2-Body Bradykinesia|UPD2-Body Bradykinesia|UPD2314	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Global spontaneity of movement (body bradykinesia).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100525>	C100117	MDS-UPDRS - Postural Tremor of Right Hand|UPD2-Postural Tremor of Right Hand|UPD2-Postural Tremor of Right Hand|UPD2315A	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Postural tremor of the right hand.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100526>	C100117	MDS-UPDRS - Kinetic Tremor of Left Hand|UPD2-Kinetic Tremor of Left Hand|UPD2-Kinetic Tremor of Left Hand|UPD2316B	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Kinetic tremor of the left hand.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100527>	C100117	MDS-UPDRS - Rest Tremor Amplitude Right Upper Extremity|UPD2-Rest Tremor Amplitude RUE|UPD2-Rest Tremor Amplitude RUE|UPD2317A	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Rest tremor amplitude right upper extremity.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100528>	C100117	MDS-UPDRS - Rest Tremor Amplitude Left Upper Extremity|UPD2-Rest Tremor Amplitude LUE|UPD2-Rest Tremor Amplitude LUE|UPD2317B	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Rest tremor amplitude left upper extremity.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100529>	C100117	MDS-UPDRS - Rest Tremor Amplitude Right Lower Extremity|UPD2-Rest Tremor Amplitude RLE|UPD2-Rest Tremor Amplitude RLE|UPD2317C	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Rest tremor amplitude right lower extremity.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10052>	C61063	Asparaginase/Cytarabine/Idarubicin|ARA-C/ASP/IDA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100530>	C100117	MDS-UPDRS - Rest Tremor Amplitude Left Lower Extremity|UPD2-Rest Tremor Amplitude LLE|UPD2-Rest Tremor Amplitude LLE|UPD2317D	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Rest tremor amplitude left lower extremity.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100531>	C100117	MDS-UPDRS - Rest Tremor Amplitude Lip or Jaw|UPD2-Rest Tremor Amplitude Lip/Jaw|UPD2-Rest Tremor Amplitude Lip/Jaw|UPD2317E	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Rest tremor amplitude lip/jaw.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100532>	C100117	MDS-UPDRS - Consistency of Rest Tremor|UPD2-Consistency of Rest Tremor|UPD2-Consistency of Rest Tremor|UPD2318	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Consistency of rest tremor.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100533>	C100117	MDS-UPDRS - Dyskinesias During Exam|UPD2-Dyskinesias During Exam|UPD2-Dyskinesias During Exam|UPD2DA	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Were dyskinesias (chorea or dystonia) present during examination?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100534>	C100117	MDS-UPDRS - Movements Interfere with Ratings|UPD2-Movements Interfere Ratings|UPD2-Movements Interfere Ratings|UPD2DB	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) If yes, did these movements interfere with your ratings?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100535>	C100117	MDS-UPDRS - Hoehn and Yahr Stage|UPD2-Hoehn and Yahr Stage|UPD2-Hoehn and Yahr Stage|UPD2HY	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Hoehn and Yahr Stage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100536>	C100117	MDS-UPDRS - Time Spent with Dyskinesias|UPD2-Time Spent with Dyskinesias|UPD2-Time Spent with Dyskinesias|UPD2401	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Time spent with dyskinesias.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100537>	C100117	MDS-UPDRS - Functional Impact of Dyskinesias|UPD2-Functional Impact Dyskinesias|UPD2-Functional Impact Dyskinesias|UPD2402	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Functional impact of dyskinesias.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100538>	C100117	MDS-UPDRS - Time Spent in the Off State|UPD2-Time Spent in the Off State|UPD2-Time Spent in the Off State|UPD2403	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Time spent in the off state.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100539>	C100117	MDS-UPDRS - Functional Impact of Fluctuations|UPD2-Functional Impact Fluctuations|UPD2-Functional Impact Fluctuations|UPD2404	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Functional impact of fluctuations.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10053>	C63358	CAFP Regimen|CAFP|CAFP|CTX/DOX/5-FU/PRED|Cyclophosphamide-Doxorubicin-Fluorouracil-Prednisone|Cyclophosphamide/Adriamycin/Fluorouracil/Prednisone|Cyclophosphamide/Doxorubicin/Fluorouracil/Prednisone|Cyclophosphamide/Doxorubicin/Fluorouracil/Prednisone Regimen	A regimen consisting of cyclophosphamide, doxorubicin, fluorouracil, and prednisone for the treatment of breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C100540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100540>	C100117	MDS-UPDRS - Complexity of Motor Fluctuations|UPD2-Complexity Motor Fluctuations|UPD2-Complexity Motor Fluctuations|UPD2405	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Complexity of motor fluctuations.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100541>	C100117	MDS-UPDRS - Painful Off-state Dystonia|UPD2-Painful Off-state Dystonia|UPD2-Painful Off-state Dystonia|UPD2406	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Painful off-state dystonia.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100542>	C100118	MMSE - Question 1	The Mini-Mental State Examination (MMSE) Question 1.			Intellectual Product	
C100543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100543>	C100118	MMSE - What Is the Year|MMS1-What Is the Year|MMS1-What Is the Year|MMS101A	Mini-Mental State Examination (MMSE) What is the year?			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100544>	C100118	MMSE - What Is the Season|MMS1-What Is the Season|MMS1-What Is the Season|MMS101B	Mini-Mental State Examination (MMSE) What is the season?			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100545>	C100118	MMSE - What Is the Date|MMS1-What Is the Date|MMS1-What Is the Date|MMS101E	Mini-Mental State Examination (MMSE) What is the date?			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100546>	C100118	MMSE - What Is the Day of Week|MMS1-What Is the Day of Week|MMS1-What Is the Day of Week|MMS101D	Mini-Mental State Examination (MMSE) What is the day of the week?			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100547>	C100118	MMSE - What Is the Month of Year|MMS1-What Is the Month of Year|MMS1-What Is the Month of Year|MMS101C	Mini-Mental State Examination (MMSE) What is the month of the year?			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100548>	C100118	MMSE - Question 2	The Mini-Mental State Examination (MMSE) Question 2.			Intellectual Product	
C100549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100549>	C100118	MMSE - What Is the State|MMS1-What Is the State|MMS1-What Is the State|MMS102A	Mini-Mental State Examination (MMSE) Where are we now? What is the state (province)?			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10054>	C61063	Asparaginase/Cytarabine/Daunorubicin|ARA-C/ASP/DNR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100550>	C100118	MMSE - What Is the County|MMS1-What Is the County|MMS1-What Is the County|MMS102B	Mini-Mental State Examination (MMSE) Where are we now? What is the county (or city/town)?			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100551>	C100118	MMSE - What Is the City or Town|MMS1-What Is the City/Town|MMS1-What Is the City/Town|MMS102C	Mini-Mental State Examination (MMSE) Where are we now? What is the city/town (or part of city/neighborhood)?			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100552>	C100118	MMSE - What Is the Building|MMS1-What Is the Building|MMS1-What Is the Building|MMS102D	Mini-Mental State Examination (MMSE) Where are we now? What is the building (name or type)?			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100553>	C100118	MMSE - What Is the Floor|MMS1-What Is the Floor|MMS1-What Is the Floor|MMS102E	Mini-Mental State Examination (MMSE) Where are we now? What is the floor of the building (room number or address)?			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100554>	C100118	MMSE - Question 3	The Mini-Mental State Examination (MMSE) Question 3.			Intellectual Product	
C100555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100555>	C100118	MMSE - Repeat Word 1|MMS1-Repeat Word 1|MMS1-Repeat Word 1|MMS103A	Mini-Mental State Examination (MMSE) Now repeat those words back to me: Word 1.			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100556>	C100118	MMSE - Repeat Word 2|MMS1-Repeat Word 2|MMS1-Repeat Word 2|MMS103B	Mini-Mental State Examination (MMSE) Now repeat those words back to me: Word 2.			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100557>	C100118	MMSE - Repeat Word 3|MMS1-Repeat Word 3|MMS1-Repeat Word 3|MMS103C	Mini-Mental State Examination (MMSE) Now repeat those words back to me: Word 3.			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100558>	C100118	MMSE - Question 4	The Mini-Mental State Examination (MMSE) Question 4.			Intellectual Product	
C100559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100559>	C100118	MMSE - What is 100 Take Away 7|MMS1-What is 100 Take Away 7|MMS1-What is 100 Take Away 7|MMS104AA	Mini-Mental State Examination (MMSE) What is 100 take away 7 [93]?			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10055>	C61063	Cyclophosphamide/Doxorubicin/Folic Acid/Methotrexate|CAMF|CTX/DOX/FA/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100560>	C100118	MMSE - Keep Subtracting 7 Step 2|MMS1-Keep Subtracting 7 Step 2|MMS1-Keep Subtracting 7 Step 2|MMS104AB	Mini-Mental State Examination (MMSE) Keep going [86].			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100561>	C100118	MMSE - Keep Subtracting 7 Step 3|MMS1-Keep Subtracting 7 Step 3|MMS1-Keep Subtracting 7 Step 3|MMS104AC	Mini-Mental State Examination (MMSE) Keep going [79].			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100562>	C100118	MMSE - Keep Subtracting 7 Step 4|MMS1-Keep Subtracting 7 Step 4|MMS1-Keep Subtracting 7 Step 4|MMS104AD	Mini-Mental State Examination (MMSE) Keep going [72].			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100563>	C100118	MMSE - Keep Subtracting 7 Step 5|MMS1-Keep Subtracting 7 Step 5|MMS1-Keep Subtracting 7 Step 5|MMS104AE	Mini-Mental State Examination (MMSE) Keep going [65].			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100564>	C100118	MMSE - Question 4C	The Mini-Mental State Examination (MMSE) Question 4C.			Intellectual Product	
C100565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100565>	C100118	MMSE - Spell Backward Letter 1|MMS1-Spell Backward Letter 1|MMS1-Spell Backward Letter 1|MMS104BA	Mini-Mental State Examination (MMSE) Spell backward, letter 1.			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100566>	C100118	MMSE - Spell Backward Letter 2|MMS1-Spell Backward Letter 2|MMS1-Spell Backward Letter 2|MMS104BB	Mini-Mental State Examination (MMSE) Spell backward, letter 2.			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100567>	C100118	MMSE - Spell Backward Letter 3|MMS1-Spell Backward Letter 3|MMS1-Spell Backward Letter 3|MMS104BC	Mini-Mental State Examination (MMSE) Spell backward, letter 3.			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100568>	C100118	MMSE - Spell Backward Letter 4|MMS1-Spell Backward Letter 4|MMS1-Spell Backward Letter 4|MMS104BD	Mini-Mental State Examination (MMSE) Spell backward, letter 4.			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100569>	C100118	MMSE - Spell Backward Letter 5|MMS1-Spell Backward Letter 5|MMS1-Spell Backward Letter 5|MMS104BE	Mini-Mental State Examination (MMSE) Spell backward, letter 5.			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10056>	C61063	Cyclophosphamide/Cytarabine/Daunorubicin/Dexamethasone/Thioguanine/Vincristine|ARA-C/CTX/DM/DNR/TG/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100570>	C100118	MMSE - Attention and Calculation Subtotal|MMS1-Attention and Calculation Subtotal|MMS1-Attention and Calculation Subtotal|MMS104	Mini-Mental State Examination (MMSE) Attention and calculation subtotal.			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100571>	C100118	MMSE - Question 5	The Mini-Mental State Examination (MMSE) Question 5.			Intellectual Product	
C100572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100572>	C100118	MMSE - Recall Word 1|MMS1-Recall Word 1|MMS1-Recall Word 1|MMS105A	Mini-Mental State Examination (MMSE) What were those three words I asked you to remember: Word 1?			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100573>	C100118	MMSE - Recall Word 2|MMS1-Recall Word 2|MMS1-Recall Word 2|MMS105B	Mini-Mental State Examination (MMSE) What were those three words I asked you to remember: Word 2?			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100574>	C100118	MMSE - Recall Word 3|MMS1-Recall Word 3|MMS1-Recall Word 3|MMS105C	Mini-Mental State Examination (MMSE) What were those three words I asked you to remember: Word 3?			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100575>	C100118	MMSE - Question 6	The Mini-Mental State Examination (MMSE) Question 6.			Intellectual Product	
C100576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100576>	C100118	MMSE - Naming Object 1|MMS1-Naming Object 1|MMS1-Naming Object 1|MMS106A	Mini-Mental State Examination (MMSE) What is this: Object 1?			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100577>	C100118	MMSE - Naming Object 2|MMS1-Naming Object 2|MMS1-Naming Object 2|MMS106B	Mini-Mental State Examination (MMSE) What is this: Object 2?			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100578>	C100118	MMSE - Repeat What I Say|MMS1-Repeat What I Say|MMS1-Repeat What I Say|MMS107	Mini-Mental State Examination (MMSE) Now I am going to ask you to repeat what I say. Ready? "No ifs, ands, or buts." Now you say that.			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100579>	C100118	MMSE - Question 8	The Mini-Mental State Examination (MMSE) Question 8.			Intellectual Product	
C10057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10057>	C61063	Fenretinide/Tamoxifen|Fenretinide + Tamoxifen|HPR/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100580>	C100118	MMSE - Take in Right Hand|MMS1-Take in Right Hand|MMS1-Take in Right Hand|MMS108A	Mini-Mental State Examination (MMSE) Listen carefully because I am going to ask you to do something. Take this paper in your right hand.			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100581>	C100118	MMSE - Fold in Half|MMS1-Fold in Half|MMS1-Fold in Half|MMS108B	Mini-Mental State Examination (MMSE) Fold it in half.			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100582>	C100118	MMSE - Put on Floor or Table|MMS1-Put on Floor (or Table)|MMS1-Put on Floor (or Table)|MMS108C	Mini-Mental State Examination (MMSE) And put it on the floor (or table).			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100583>	C100118	MMSE - Read This and Do What It Says|MMS1-Read This and Do What It Says|MMS1-Read This and Do What It Says|MMS109	Mini-Mental State Examination (MMSE) Please read this and do what it says.			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100584>	C100118	MMSE - Write a Sentence|MMS1-Write a Sentence|MMS1-Write a Sentence|MMS110	Mini-Mental State Examination (MMSE) Please write a sentence.			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100585>	C100118	MMSE - Copy This Design|MMS1-Copy This Design|MMS1-Copy This Design|MMS111	Mini-Mental State Examination (MMSE) Please copy this design.			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100586>	C100118	MMSE - Total Score|MMS1-Total Score|MMS1-Total Score|MMS112	Mini-Mental State Examination (MMSE) Total score.			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100587>	C100119	MNSI - Legs and/or Feet Numb|MNSI1-Are Your Legs and/or Feet Numb|MNSI1-Are Your Legs and/or Feet Numb|MNSI101	Michigan Neuropathy Screening Instrument (MNSI) History; are your legs and/or feet numb?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100588>	C100119	MNSI - Burning Pain Legs/Feet|MNSI1-Ever Have Burning Pain Legs/Feet|MNSI1-Ever Have Burning Pain Legs/Feet|MNSI102	Michigan Neuropathy Screening Instrument (MNSI) History; do you ever have any burning pain in your legs and/or feet?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100589>	C100119	MNSI - Feet Too Sensitive to Touch|MNSI1-Are Feet Too Sensitive to Touch|MNSI1-Are Feet Too Sensitive to Touch|MNSI103	Michigan Neuropathy Screening Instrument (MNSI) History; are your feet too sensitive to touch?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10058>	C63522	Altretamine/Cisplatin/Cyclophosphamide/Fluorouracil Regimen|Altretamine-Cisplatin-Cyclophosphamide-Fluorouracil|Altretamine/Cisplatin/Cyclophosphamide/Fluorouracil|CDDP/CTX/5-FU/HMM|CHEX-UP|CHEX-UP	A regimen consisting of altretamine, cisplatin, cyclophosphamide and fluorouracil that can be used for the treatment of ovarian cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C100590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100590>	C100119	MNSI - Muscle Cramps Legs/Feet|MNSI1-Get Muscle Cramps Legs/Feet|MNSI1-Get Muscle Cramps Legs/Feet|MNSI104	Michigan Neuropathy Screening Instrument (MNSI) History; do you get muscle cramps in your legs and/or feet?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100591>	C100119	MNSI - Prickling Feelings Legs/Feet|MNSI1-Ever Prickling Feelings Legs/Feet|MNSI1-Ever Prickling Feelings Legs/Feet|MNSI105	Michigan Neuropathy Screening Instrument (MNSI) History; do you ever have any prickling feelings in your legs or feet?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100592>	C100119	MNSI - Hurt When Bed Covers Touch Skin|MNSI1-Hurt When Bed Covers Touch Skin|MNSI1-Hurt When Bed Covers Touch Skin|MNSI106	Michigan Neuropathy Screening Instrument (MNSI) History; does it hurt when the bed covers touch your skin?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100593>	C100119	MNSI - Able to Tell Hot from Cold Water|MNSI1-Able to Tell Hot from Cold Water|MNSI1-Able to Tell Hot from Cold Water|MNSI107	Michigan Neuropathy Screening Instrument (MNSI) History; when you get into the tub or shower, are you able to tell the hot water from the cold water?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100594>	C100119	MNSI - Open Sore on Foot|MNSI1-Ever Had Open Sore on Foot|MNSI1-Ever Had Open Sore on Foot|MNSI108	Michigan Neuropathy Screening Instrument (MNSI) History; have you ever had an open sore on your foot?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100595>	C100119	MNSI - Doctor Says Diabetic Neuropathy|MNSI1-Doctor Says Diabetic Neuropathy|MNSI1-Doctor Says Diabetic Neuropathy|MNSI109	Michigan Neuropathy Screening Instrument (MNSI) History; has your doctor ever told you that you have diabetic neuropathy?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100596>	C100119	MNSI - Feel Weak All Over Most Times|MNSI1-Feel Weak All Over Most Times|MNSI1-Feel Weak All Over Most Times|MNSI110	Michigan Neuropathy Screening Instrument (MNSI) History; do you feel weak all over most of the time?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100597>	C100119	MNSI - Symptoms Worse at Night|MNSI1-Symptoms Worse at Night|MNSI1-Symptoms Worse at Night|MNSI111	Michigan Neuropathy Screening Instrument (MNSI) History; are your symptoms worse at night?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100598>	C100119	MNSI - Legs Hurt When Walking|MNSI1-Legs Hurt When Walking|MNSI1-Legs Hurt When Walking|MNSI112	Michigan Neuropathy Screening Instrument (MNSI) History; do your legs hurt when you walk?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100599>	C100119	MNSI - Able to Sense Feet When Walking|MNSI1-Able to Sense Feet When Walking|MNSI1-Able to Sense Feet When Walking|MNSI113	Michigan Neuropathy Screening Instrument (MNSI) History; are you able to sense your feet when you walk?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10059>	C61063	Dactinomycin/Tumor Necrosis Factor|DACT/TNF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1005>	C1934	Arsenic Trioxide|ARSENIC TRIOXIDE|ATO|Arsenic (III) Oxide|Arsenic Sesquioxide|Arsenic trioxide|Arsenous Acid|Arsenous Acid Anhydride|Arsenous Oxide|Trisenox|Trisenox|White Arsenic|arsenic trioxide	A small-molecule arsenic compound with antineoplastic activity.  The mechanism of action of arsenic trioxide is not completely understood. This agent causes damage to or degradation of the promyelocytic leukemia protein/retinoic acid receptor-alpha (PML/RARa) fusion protein; induces apoptosis in acute promyelocytic leukemia (APL) cells and in many other tumor cell types; promotes cell differentiation and suppresses cell proliferation in many different tumor cell types; and is pro-angiogenic. (NCI04)	Arsenic Trioxide		Inorganic Chemical|Pharmacologic Substance	AML Authorized Value Terminology|AML Total Dose Table|CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C100600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100600>	C100119	MNSI - Skin So Dry That Feet Crack Open|MNSI1-Skin So Dry That Feet Crack Open|MNSI1-Skin So Dry That Feet Crack Open|MNSI114	Michigan Neuropathy Screening Instrument (MNSI) History; is the skin on your feet so dry that it cracks open?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100601>	C100119	MNSI - Ever Had Amputation|MNSI1-Ever Had Amputation|MNSI1-Ever Had Amputation|MNSI115	Michigan Neuropathy Screening Instrument (MNSI) History; have you ever had an amputation?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100602>	C100119	MNSI - History Total|MNSI1-Total|MNSI1-Total|MNSI116	Michigan Neuropathy Screening Instrument (MNSI) History; total.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100603>	C100119	MNSI - Right Foot Appears Normal|MNSI1-Right Foot Appears Normal|MNSI1-Right Foot Appears Normal|MNSI117	Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; appearance of right foot - normal.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100604>	C100119	MNSI - Right Foot Deformities|MNSI1-Right Foot Deformities|MNSI1-Right Foot Deformities|MNSI118	Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; appearance of right foot - deformities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100605>	C100119	MNSI - Right Foot Infection|MNSI1-Right Foot Infection|MNSI1-Right Foot Infection|MNSI120	Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; appearance of right foot - infection.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100606>	C100119	MNSI - Right Foot Fissure|MNSI1-Right Foot Fissure|MNSI1-Right Foot Fissure|MNSI121	Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; appearance of right foot - fissure.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100607>	C100119	MNSI - Right Foot Other Abnormal Specify|MNSI1-Right Foot Other Abnormal Specify|MNSI1-Right Foot Other Abnormal Specify|MNSI122	Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; appearance of right foot - other, specify.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100608>	C100119	MNSI - Left Foot Appears Normal|MNSI1-Left Foot Appears Normal|MNSI1-Left Foot Appears Normal|MNSI123	Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; appearance of left foot - normal.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100609>	C100119	MNSI - Left Foot Deformities|MNSI1-Left Foot Deformities|MNSI1-Left Foot Deformities|MNSI124	Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; appearance of left foot - deformities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10060>	C61063	Cisplatin/Doxorubicin/Fluorouracil/Leucovorin Calcium|CDDP/CF/DOX/5-FU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100610>	C100119	MNSI - Left Foot Infection|MNSI1-Left Foot Infection|MNSI1-Left Foot Infection|MNSI126	Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; appearance of left foot - infection.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100611>	C100119	MNSI - Left Foot Fissure|MNSI1-Left Foot Fissure|MNSI1-Left Foot Fissure|MNSI127	Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; appearance of left foot - fissure.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100612>	C100119	MNSI - Left Foot Other Abnormal Specify|MNSI1-Left Foot Other Abnormal Specify|MNSI1-Left Foot Other Abnormal Specify|MNSI128	Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; appearance of left foot - other, specify.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100613>	C100119	MNSI - Right Foot Ulceration|MNSI1-Right Foot Ulceration|MNSI1-Right Foot Ulceration|MNSI129	Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; right foot - ulceration.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100614>	C100119	MNSI - Left Foot Ulceration|MNSI1-Left Foot Ulceration|MNSI1-Left Foot Ulceration|MNSI130	Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; left foot - ulceration.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100615>	C100119	MNSI - Right Ankle Reflexes|MNSI1-Right Ankle Reflexes|MNSI1-Right Ankle Reflexes|MNSI131	Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; right ankle reflexes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100616>	C100119	MNSI - Left Ankle Reflexes|MNSI1-Left Ankle Reflexes|MNSI1-Left Ankle Reflexes|MNSI132	Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; left ankle reflexes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100617>	C100119	MNSI - Right Foot Vibration Great Toe|MNSI1-Right Foot Vibration Great Toe|MNSI1-Right Foot Vibration Great Toe|MNSI133	Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; right foot - vibration perception at great toe.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100618>	C100119	MNSI - Left Foot Vibration Great Toe|MNSI1-Left Foot Vibration Great Toe|MNSI1-Left Foot Vibration Great Toe|MNSI134	Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; left foot - vibration perception at great toe.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100619>	C100119	MNSI - Right Foot Monofilament|MNSI1-Right Foot Monofilament|MNSI1-Right Foot Monofilament|MNSI135	Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; right foot - monofilament.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10061>	C61063	Altretamine/Lomustine/Methotrexate|CCNU/HMM/MTX|CHEXM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100620>	C100119	MNSI - Left Foot Monofilament|MNSI1-Left Foot Monofilament|MNSI1-Left Foot Monofilament|MNSI136	Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; left foot - monofilament.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100621>	C100119	MNSI - Physical Assessment Total Score|MNSI1-Total Score|MNSI1-Total Score|MNSI137	Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; total score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100622>	C100120	NPI - Have Beliefs That You Know are Not True|NPI1-Beliefs Untrue|NPI1-Beliefs Untrue|NPI1A	Neuropsychiatric Inventory (NPI) Does the patient have beliefs that you know are not true? (for example, insisting that people are trying to harm him/her or steal from him/her)? Has he/she said that family members are not who they say they are or that the house is not their home? I'm not asking about mere suspiciousness; I am interested if the patient is convinced that these things are happening to him/her.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100623>	C100120	NPI - He/She is in Danger|NPI1-In Danger|NPI1-In Danger|NPI1A01	Neuropsychiatric Inventory (NPI) Does the patient believe that he/she is in danger (NPI) that others are planning to hurt him/her?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100624>	C100120	NPI - Others are Stealing From Him/Her|NPI1-Others Are Stealing|NPI1-Others Are Stealing|NPI1A02	Neuropsychiatric Inventory (NPI) Does the patient believe that others are stealing from him/her?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100625>	C100120	NPI - His/Her Spouse is Having an Affair|NPI1-Spouse Having Affair|NPI1-Spouse Having Affair|NPI1A03	Neuropsychiatric Inventory (NPI) Does the patient believe that his/her spouse is having an affair?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100626>	C100120	NPI - Unwelcome Guests are Living in His/Her House|NPI1-Unwelcome Guests in House|NPI1-Unwelcome Guests in House|NPI1A04	Neuropsychiatric Inventory (NPI) Does the patient believe that unwelcome guests are living in his/her house?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100627>	C100120	NPI - His/Her Spouse or Others Are Not Who They Claim To Be|NPI1-People Not Who They Claim|NPI1-People Not Who They Claim|NPI1A05	Neuropsychiatric Inventory (NPI) Does the patient believe that his/her spouse or others are not who they claim to be?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100628>	C100120	NPI - His/Her House Is Not His/Her Home|NPI1-House Not Their Home|NPI1-House Not Their Home|NPI1A06	Neuropsychiatric Inventory (NPI) Does the patient believe that his/her house is not his/her home?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100629>	C100120	NPI - Family Members Plan to Abandon Him/Her|NPI1-Family Plans to Abandon|NPI1-Family Plans to Abandon|NPI1A07	Neuropsychiatric Inventory (NPI) Does the patient believe that family members plan to abandon him/her?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10062>	C61063	Cyclophosphamide/Doxorubicin/Melphalan/Methotrexate/Vincristine|COMPADRI-V|CTX/DOX/L-PAM/MTX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100630>	C100120	NPI - Television or Magazine Figures Are Actually Present In the Home|NPI1-TV/Magazine Figures Present|NPI1-TV/Magazine Figures Present|NPI1A08	Neuropsychiatric Inventory (NPI) Does the patient believe that television or magazine figures are actually present in the home? (Does he/she try to talk or interact with them?)			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100631>	C100120	NPI - Any Other Unusual Things That I Haven't Asked About|NPI1-Other Unusual Beliefs|NPI1-Other Unusual Beliefs|NPI1A09	Neuropsychiatric Inventory (NPI) Does the patient believe any other unusual things that I haven't asked about?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100632>	C100120	NPI - Hallucinations Such as Seeing False Visions or Hearing False Voices|NPI1-False Visions or Voices|NPI1-False Visions or Voices|NPI1B	Neuropsychiatric Inventory (NPI) Does the patient have hallucinations such as seeing false visions or hearing false voices? Does he/she seem to see, hear or experience things that are not present? By this question we do not mean just mistaken beliefs such as stating that someone who has died is still alive; rather we are asking if the patient actually has abnormal experiences of sounds or visions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100633>	C100120	NPI - Describe Hearing Voices or Act as if He/She Hears Voices|NPI1-Hearing Voices|NPI1-Hearing Voices|NPI1B01	Neuropsychiatric Inventory (NPI) Does the patient describe hearing voices or act as if he/she hears voices?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100634>	C100120	NPI - Talk to People Who Are Not There|NPI1-Talk to People Not There|NPI1-Talk to People Not There|NPI1B02	Neuropsychiatric Inventory (NPI) Does the patient talk to people who are not there?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100635>	C100120	NPI - Describe Seeing Things Not Seen by Others|NPI1-See Things Not Seen by Others|NPI1-See Things Not Seen by Others|NPI1B03	Neuropsychiatric Inventory (NPI) Does the patient describe seeing things not seen by others or behave as if he/she is seeing things not seen by others (people, animals, lights, etc.)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100636>	C100120	NPI - Report Smelling Odors Not Smelled by Others|NPI1-Smell Odors Others Do Not Smell|NPI1-Smell Odors Others Do Not Smell|NPI1B04	Neuropsychiatric Inventory (NPI) Does the patient report smelling odors not smelled by others?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100637>	C100120	NPI - Describe Feeling Things on His/Her Skin|NPI1-Feel Things on Skin|NPI1-Feel Things on Skin|NPI1B05	Neuropsychiatric Inventory (NPI) Does the patient describe feeling things on his/her skin or otherwise appear to be feeling things crawling or touching him/her?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100638>	C100120	NPI - Describe Tastes That Are Without Any Known Cause|NPI1-Taste without Known Cause|NPI1-Taste without Known Cause|NPI1B06	Neuropsychiatric Inventory (NPI) Does the patient describe tastes that are without any known cause?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100639>	C100120	NPI - Describe Any Other Unusual Sensory Experiences|NPI1-Other Unusual Sensory Experience|NPI1-Other Unusual Sensory Experience|NPI1B07	Neuropsychiatric Inventory (NPI) Does the patient describe any other unusual sensory experiences?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10063>	C61063	Cyclophosphamide/Doxorubicin/Ethinyl Estradiol/Fluorouracil/Leucovorin Calcium|CALF-E|CF/CTX/DOX/ethinyl estradiol/5-FU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100640>	C100120	NPI - Periods When He/She Refuses to Cooperate|NPI1-Refuse to Cooperate|NPI1-Refuse to Cooperate|NPI1C	Neuropsychiatric Inventory (NPI) Does the patient have periods when he/she refuses to cooperate or won't let people help him/her? Is he/she hard to handle?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100641>	C100120	NPI - Get Upset with Those Trying to Care for Him/Her|NPI1-Get Upset with Caregiver|NPI1-Get Upset with Caregiver|NPI1C01	Neuropsychiatric Inventory (NPI) Does the patient get upset with those trying to care for him/her or resist activities such as bathing or changing clothes?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100642>	C100120	NPI - Stubborn|NPI1-Stubborn|NPI1-Stubborn|NPI1C02	Neuropsychiatric Inventory (NPI) Is the patient stubborn, having to have things his/her way?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100643>	C100120	NPI - Uncooperative|NPI1-Uncooperative|NPI1-Uncooperative|NPI1C03	Neuropsychiatric Inventory (NPI) Is the patient uncooperative, resistive to help from others?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100644>	C100120	NPI - Any Other Behaviors That Make Him/Her Hard to Handle|NPI1-Other Behaviors Hard to Handle|NPI1-Other Behaviors Hard to Handle|NPI1C04	Neuropsychiatric Inventory (NPI) Does the patient have any other behaviors that make him/her hard to handle?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100645>	C100120	NPI - Shout or Curse Angrily|NPI1-Shout or Curse Angrily|NPI1-Shout or Curse Angrily|NPI1C05	Neuropsychiatric Inventory (NPI) Does the patient shout or curse angrily?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100646>	C100120	NPI - Slam doors, Kick Furniture, Throw Things|NPI1-Slam, Kick or Throw Things|NPI1-Slam, Kick or Throw Things|NPI1C06	Neuropsychiatric Inventory (NPI) Does the patient slam doors, kick furniture, throw things?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100647>	C100120	NPI - Attempt to Hurt or Hit Others|NPI1-Hurt or Hit Others|NPI1-Hurt or Hit Others|NPI1C07	Neuropsychiatric Inventory (NPI) Does the patient attempt to hurt or hit others?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100648>	C100120	NPI - Any Other Aggressive or Agitated Behaviors|NPI1-Other Aggressive Behavior|NPI1-Other Aggressive Behavior|NPI1C08	Neuropsychiatric Inventory (NPI) Does the patient have any other aggressive or agitated behaviors?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100649>	C100120	NPI - Seem Sad or Depressed|NPI1-Sad or Depressed|NPI1-Sad or Depressed|NPI1D	Neuropsychiatric Inventory (NPI) Does the patient seem sad or depressed? Does he/she say that he/she feels sad or depressed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10064>	C61063	Cyclophosphamide/Fluorouracil/Leucovorin Calcium/Mitoxantrone|CF/CTX/DHAD/5-FU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100650>	C100120	NPI - Periods of Tearfulness or Sobbing|NPI1-Tearfulness or Sobbing|NPI1-Tearfulness or Sobbing|NPI1D01	Neuropsychiatric Inventory (NPI) Does the patient have periods of tearfulness or sobbing that seem to indicate sadness?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100651>	C100120	NPI - Say, or Act as if He/She is Sad or in Low Spirits|NPI1-Say or Act in Low Spirits|NPI1-Say or Act in Low Spirits|NPI1D02	Neuropsychiatric Inventory (NPI) Does the patient say, or act as if he/she is sad or in low spirits?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100652>	C100120	NPI - Put Him/Herself Down or Say That He/She Feels Like a Failure|NPI1-Feel Like a Failure|NPI1-Feel Like a Failure|NPI1D03	Neuropsychiatric Inventory (NPI) Does the patient put him/herself down or say that he/she feels like a failure?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100653>	C100120	NPI - Say That He/She is a Bad Person|NPI1-Bad Person|NPI1-Bad Person|NPI1D04	Neuropsychiatric Inventory (NPI) Does the patient say that he/she is a bad person or deserves to be punished?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100654>	C100120	NPI - Seem Very Discouraged|NPI1-Discouraged|NPI1-Discouraged|NPI1D05	Neuropsychiatric Inventory (NPI) Does the patient seem very discouraged or say that he/she has no future?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100655>	C100120	NPI - Say He/She is a Burden to the Family|NPI1-Burden to Family|NPI1-Burden to Family|NPI1D06	Neuropsychiatric Inventory (NPI) Does the patient say he/she is a burden to the family or that the family would be better off without him/her?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100656>	C100120	NPI - Express a Wish for Death|NPI1-Wish for Death|NPI1-Wish for Death|NPI1D07	Neuropsychiatric Inventory (NPI) Does the patient express a wish for death or talk about killing himself/herself?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100657>	C100120	NPI - Show Any Other Signs of Depression or Sadness|NPI1-Other Signs of Depression|NPI1-Other Signs of Depression|NPI1D08	Neuropsychiatric Inventory (NPI) Does the patient show any other signs of depression or sadness?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100658>	C100120	NPI - Very Nervous, Worried, or Frightened for No Apparent Reason|NPI1-Nervous or Worried|NPI1-Nervous or Worried|NPI1E	Neuropsychiatric Inventory (NPI) Is the patient very nervous, worried, or frightened for no apparent reason? Does he/she seem very tense or fidgety? Is the patient afraid to be apart from you?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100659>	C100120	NPI - Say That He/She is Worried About Planned Events|NPI1-Worried about Planned Event|NPI1-Worried about Planned Event|NPI1E01	Neuropsychiatric Inventory (NPI) Does the patient say that he/she is worried about planned events?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10065>	C61007	Floxuridine/Leucovorin Calcium|CF/FUDR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100660>	C100120	NPI - Periods of Feeling Shaky, Unable to Relax, or Feeling Excessively Tense|NPI1-Shaky or Unable to Relax|NPI1-Shaky or Unable to Relax|NPI1E02	Neuropsychiatric Inventory (NPI) Does the patient have periods of feeling shaky, unable to relax, or feeling excessively tense?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100661>	C100120	NPI - Periods of Shortness of Breath, Gasping, or Sighing for No Apparent Reason|NPI1-Short of Breath, Gasp, Sigh|NPI1-Short of Breath, Gasp, Sigh|NPI1E03	Neuropsychiatric Inventory (NPI) Does the patient have periods of (or complain of) shortness of breath, gasping, or sighing for no apparent reason other than nervousness?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100662>	C100120	NPI - Complain of Butterflies, Racing or Pounding Heart|NPI1-Butterflies or Racing Heart|NPI1-Butterflies or Racing Heart|NPI1E04	Neuropsychiatric Inventory (NPI) Does the patient complain of butterflies in his/her stomach, or of racing or pounding of the heart in association with nervousness? (Symptoms not explained by ill health).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100663>	C100120	NPI - Avoid Certain Places or Situations That Make Him/Her More Nervous|NPI1-Avoid Places or Situations|NPI1-Avoid Places or Situations|NPI1E05	Neuropsychiatric Inventory (NPI) Does the patient avoid certain places or situations that make him/her more nervous such as riding in the car, meeting with friends, or being in crowds?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100664>	C100120	NPI - Become Nervous and Upset When Separated From You|NPI1-Nervous when Separated|NPI1-Nervous when Separated|NPI1E06	Neuropsychiatric Inventory (NPI) Does the patient become nervous and upset when separated from you (or his/her caregiver)? (Does he/she cling to you to keep from being separated?).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100665>	C100120	NPI - Show Any Other Signs of Anxiety|NPI1-Other Signs of Anxiety|NPI1-Other Signs of Anxiety|NPI1E07	Neuropsychiatric Inventory (NPI) Does the patient show any other signs of anxiety?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100666>	C100120	NPI - Seem Too Cheerful or Too Happy for No Reason|NPI1-Too Cheerful or Happy|NPI1-Too Cheerful or Happy|NPI1F	Neuropsychiatric Inventory (NPI) Does the patient seem too cheerful or too happy for no reason? I don't mean the normal happiness that comes from seeing friends, receiving presents, or spending time with family members. I am asking if the patient has a persistent and abnormally good mood or finds humor where others do not.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100667>	C100120	NPI - Appear to Feel Good or to Be Too Happy|NPI1-Feel Good or Too Happy|NPI1-Feel Good or Too Happy|NPI1F01	Neuropsychiatric Inventory (NPI) Does the patient appear to feel good or to be too happy, different from his/her usual self?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100668>	C100120	NPI - Fine Humor and Laugh at Things That Others Do Not Find Funny|NPI1-Humor Others Do Not Find Funny|NPI1-Humor Others Do Not Find Funny|NPI1F02	Neuropsychiatric Inventory (NPI) Does the patient find humor and laugh at things that others do not find funny?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100669>	C100120	NPI - Seem to Have a Childish Sense of Humor|NPI1-Childish Sense of Humor|NPI1-Childish Sense of Humor|NPI1F03	Neuropsychiatric Inventory (NPI) Does the patient seem to have a childish sense of humor with a tendency to giggle or laugh inappropriately (such as when something unfortunate happens to others)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10066>	C61063	Fluorouracil/Interferon Beta|5-FU/IFN-B			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100670>	C100120	NPI - Tell Jokes or Make Remarks That are Not Funny to Others|NPI1-Jokes Others Do Not Find Funny|NPI1-Jokes Others Do Not Find Funny|NPI1F04	Neuropsychiatric Inventory (NPI) Does the patient tell jokes or make remarks that are not funny to others but seem funny to him/her?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100671>	C100120	NPI - Play Childish Pranks|NPI1-Childish Pranks|NPI1-Childish Pranks|NPI1F05	Neuropsychiatric Inventory (NPI) Does he/she play childish pranks such as pinching or playing "keep away" for the fun of it?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100672>	C100120	NPI - Talk Big or Claim to Have More Abilities or Wealth Than is True|NPI1-Talk Big|NPI1-Talk Big|NPI1F06	Neuropsychiatric Inventory (NPI) Does the patient "talk big" or claim to have more abilities or wealth than is true?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100673>	C100120	NPI - Show Any Other Signs of Feeling Too Good or Being Too Happy|NPI1-Other Signs of Feeling Too Happy|NPI1-Other Signs of Feeling Too Happy|NPI1F07	Neuropsychiatric Inventory (NPI) Does the patient show any other signs of feeling too good or being too happy?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100674>	C100120	NPI - Lost Interest in the World Around Him/Her|NPI1-Lost Interest in World|NPI1-Lost Interest in World|NPI1G	Neuropsychiatric Inventory (NPI) Has the patient lost interest in the world around him/her? Has he/she lost interest in doing things or does he/she lack motivation for starting new activities? Is he/she more difficult to engage in conversation or in doing chores? Is the patient apathetic or indifferent?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100675>	C100120	NPI - Seem Less Spontaneous and Less Active Than Usual|NPI1-Less Spontaneous or Active|NPI1-Less Spontaneous or Active|NPI1G01	Neuropsychiatric Inventory (NPI) Does the patient seem less spontaneous and less active than usual?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100676>	C100120	NPI - Less Likely Initiate to Initiate a Conversation|NPI1-Less Likely Initiate Conversation|NPI1-Less Likely Initiate Conversation|NPI1G02	Neuropsychiatric Inventory (NPI) Is the patient less likely to initiate a conversation?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100677>	C100120	NPI - Less Affectionate or Lacking in Emotions|NPI1-Less Affectionate|NPI1-Less Affectionate|NPI1G03	Neuropsychiatric Inventory (NPI) Is the patient less affectionate or lacking in emotions when compared to his/her usual self?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100678>	C100120	NPI - Contribute Less to Household Chores|NPI1-Contribute Less to Chores|NPI1-Contribute Less to Chores|NPI1G04	Neuropsychiatric Inventory (NPI) Does the patient contribute less to household chores?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100679>	C100120	NPI - Less Interested in the Activities and Plans of Others|NPI1-Less Interest in Activities|NPI1-Less Interest in Activities|NPI1G05	Neuropsychiatric Inventory (NPI) Does the patient seem less interested in the activities and plans of others?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10067>	C61063	Cyclophosphamide/Doxorubicin/Fluorouracil/Streptozocin|CTX/DOX/5-FU/SZC|FAC-S			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100680>	C100120	NPI - Lost Interest in Friends and Family Members|NPI1-Lost Interest in Friends|NPI1-Lost Interest in Friends|NPI1G06	Neuropsychiatric Inventory (NPI) Has the patient lost interest in friends and family members?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100681>	C100120	NPI - Less Enthusiastic About His/Her Usual Interests|NPI1-Less Enthusiastic|NPI1-Less Enthusiastic|NPI1G07	Neuropsychiatric Inventory (NPI) Is the patient less enthusiastic about his/her usual interests?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100682>	C100120	NPI - Show Any Other Signs That He/She Doesn't Care About Doing New Things|NPI1-Other Signs of Not Caring|NPI1-Other Signs of Not Caring|NPI1G08	Neuropsychiatric Inventory (NPI) Does the patient show any other signs that he/she doesn't care about doing new things?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100683>	C100120	NPI - Seem to Act Impulsively Without Thinking|NPI1-Act Impulsively|NPI1-Act Impulsively|NPI1H	Neuropsychiatric Inventory (NPI) Does the patient seem to act impulsively without thinking? Does he/she do or say things that are not usually done or said in public? Does he/she do things that are embarrassing to you or others?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100684>	C100120	NPI - Act Impulsively without Appearing to Consider the Consequences|NPI1-Act Impulsively without Care|NPI1-Act Impulsively without Care|NPI1H01	Neuropsychiatric Inventory (NPI) Does the patient act impulsively without appearing to consider the consequences?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100685>	C100120	NPI - Talk to Total Strangers as if He/She Knew Them|NPI1-Talk to Strangers|NPI1-Talk to Strangers|NPI1H02	Neuropsychiatric Inventory (NPI) Does the patient talk to total strangers as if he/she knew them?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100686>	C100120	NPI - Say Things to People that are Insensitive|NPI1-Say Insensitive Things|NPI1-Say Insensitive Things|NPI1H03	Neuropsychiatric Inventory (NPI) Does the patient say things to people that are insensitive or hurt their feelings?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100687>	C100120	NPI - Say Crude Things or Make Sexual Remarks|NPI1-Make Crude Remarks|NPI1-Make Crude Remarks|NPI1H04	Neuropsychiatric Inventory (NPI) Does the patient say crude things or make sexual remarks that he/she would not usually have said?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100688>	C100120	NPI - Talk Openly About Very Personal or Private Matters|NPI1-Talk Openly about Private Matters|NPI1-Talk Openly about Private Matters|NPI1H05	Neuropsychiatric Inventory (NPI) Does the patient talk openly about very personal or private matters not usually discussed in public?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100689>	C100120	NPI - Take Liberties or Touch or Hug Others|NPI1-Take Liberties or Touch Others|NPI1-Take Liberties or Touch Others|NPI1H06	Neuropsychiatric Inventory (NPI) Does the patient take liberties or touch or hug others in a way that is out of character for him/her?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10068>	C61063	Octreotide/Tamoxifen|SSTN/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100690>	C100120	NPI - Show Any Other Signs of Loss of Control of His/Her Impulses|NPI1-Other Signs of Impulses|NPI1-Other Signs of Impulses|NPI1H07	Neuropsychiatric Inventory (NPI) Does the patient show any other signs of loss of control of his/her impulses?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100691>	C100120	NPI - Get Irritated and Easily Disturbed|NPI1-Irritated and Easily Disturbed|NPI1-Irritated and Easily Disturbed|NPI1I	Neuropsychiatric Inventory (NPI) Does the patient get irritated and easily disturbed? Are his/her moods very changeable? Is he/she abnormally impatient? We do not mean frustration over memory loss or inability to perform usual tasks; we are interested to know if the patient has abnormal irritability, impatience, or rapid emotional changes different from his/her usual self.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100692>	C100120	NPI - Bad Temper, Flying 'Off the Handle' Easily Over Little Things|NPI1-Bad Temper|NPI1-Bad Temper|NPI1I01	Neuropsychiatric Inventory (NPI) Does the patient have a bad temper, flying "off the handle" easily over little things?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100693>	C100120	NPI - Rapidly Change Moods From One to Another|NPI1-Rapidly Change Moods|NPI1-Rapidly Change Moods|NPI1I02	Neuropsychiatric Inventory (NPI) Does the patient rapidly change moods from one to another, being fine one minute and angry the next?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100694>	C100120	NPI - Sudden Flares of Anger|NPI1-Sudden Anger|NPI1-Sudden Anger|NPI1I03	Neuropsychiatric Inventory (NPI) Does the patient have sudden flashes of anger?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100695>	C100120	NPI - Impatient, Having Trouble Coping with Delays|NPI1-Impatient|NPI1-Impatient|NPI1I04	Neuropsychiatric Inventory (NPI) Is the patient impatient, having trouble coping with delays or waiting for planned activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100696>	C100120	NPI - Cranky and Irritable|NPI1-Cranky and Irritable|NPI1-Cranky and Irritable|NPI1I05	Neuropsychiatric Inventory (NPI) Is the patient cranky and irritable?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100697>	C100120	NPI - Argumentative and Difficult to Get Along With|NPI1-Argumentative|NPI1-Argumentative|NPI1I06	Neuropsychiatric Inventory (NPI) Is the patient argumentative and difficult to get along with?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100698>	C100120	NPI - Show Any Other Signs of Irritability|NPI1-Other Signs of Irritability|NPI1-Other Signs of Irritability|NPI1I07	Neuropsychiatric Inventory (NPI) Does the patient show any other signs of irritability?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100699>	C100120	NPI - Pace, Do Things Over and Over, Repeatedly Pick at Things|NPI1-Do Things Repeatedly|NPI1-Do Things Repeatedly|NPI1J	Neuropsychiatric Inventory (NPI) Does the patient pace, do things over and over such as opening closets or drawers, or repeatedly pick at things or wind string or threads?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10069>	C61063	Melphalan/Methylprednisolone/Vincristine|L-PAM/MePRDL/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1006>	C2139	Ammonium Trichlorotellurate|AMMONIUM TRICHLOROTELLURATE|AS-101|IVX-Q-101|Ossirene|Tellurate(1-), trichloro[1,2-ethanediolato(2-)-kappa-O,kappa-O']-,ammonium, (SP-5-22)-	A synthetic non-toxic tellurium derivative, structurally similar to cisplatin, with immunostimulatory and anti-hair loss properties. Ammonium trichlorotellurate induces production of colony stimulating factor (CSF), interleukin-2 (IL-2), and IL-2 receptors by increasing the calcium ion influx through the cell membrane and subsequently exerts its immunostimulatory effects through the CSF-mediated increase in macrophage/granulocytes. This agent is also a potent inducer of interferon and a spectrum of cytokines such as IL-1, IL-6, and tumor necrosis factor (TNF). In animal studies, ammonium trichlorotellurate exerts its anti-hair loss effect by inducing anagen and obstructing spontaneous catagen via promoting follicular keratinocyte proliferation and interfering with terminal differentiation, respectively.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C100700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100700>	C100120	NPI - Pace Around the House Without Apparent Purpose|NPI1-Pace|NPI1-Pace|NPI1J01	Neuropsychiatric Inventory (NPI) Does the patient pace around the house without apparent purpose?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100701>	C100120	NPI - Rummage Around Opening and Unpacking Drawers or Closets|NPI1-Rummage Around and Unpack|NPI1-Rummage Around and Unpack|NPI1J02	Neuropsychiatric Inventory (NPI) Does the patient rummage around opening and unpacking drawers or closets?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100702>	C100120	NPI - Repeatedly Put On and Take Off Clothing|NPI1-Repeatedly Change Clothing|NPI1-Repeatedly Change Clothing|NPI1J03	Neuropsychiatric Inventory (NPI) Does the patient repeatedly put on and take off clothing?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100703>	C100120	NPI - Repetitive Activities or 'Habits'|NPI1-Repetitive Activities or Habits|NPI1-Repetitive Activities or Habits|NPI1J04	Neuropsychiatric Inventory (NPI) Does the patient have repetitive activities or "habits" that he/she performs over and over?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100704>	C100120	NPI - Engage in Repetitive Activities|NPI1-Repetitive Activities|NPI1-Repetitive Activities|NPI1J05	Neuropsychiatric Inventory (NPI) Does the patient engage in repetitive activities such as handling buttons, picking, wrapping string, etc.?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100705>	C100120	NPI - Fidget Excessively, Seem Unable to Sit Still|NPI1-Fidget Excessively|NPI1-Fidget Excessively|NPI1J06	Neuropsychiatric Inventory (NPI) Does the patient fidget excessively, seem unable to sit still, or bounce his/her feet or tap his/her fingers a lot?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100706>	C100120	NPI - Do Any Other Activities Over and Over|NPI1-Other Repetitive Activities|NPI1-Other Repetitive Activities|NPI1J07	Neuropsychiatric Inventory (NPI) Does the patient do any other activities over and over?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100707>	C100120	NPI - Difficulty Sleeping|NPI1-Difficulty Sleeping|NPI1-Difficulty Sleeping|NPI1K	Neuropsychiatric Inventory (NPI) Does the patient have difficulty sleeping (do not count as present if the patient simply gets up once or twice per night to go the bathroom and falls back asleep immediately)? Is he/she up at night? Does he/she wander at night, get dressed, or disturb your sleep?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100708>	C100120	NPI - Difficulty Falling Asleep|NPI1-Difficulty Falling Asleep|NPI1-Difficulty Falling Asleep|NPI1K01	Neuropsychiatric Inventory (NPI) Does the patient have difficulty falling asleep?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100709>	C100120	NPI - Get Up During the Night|NPI1-Get Up during Night|NPI1-Get Up during Night|NPI1K02	Neuropsychiatric Inventory (NPI) Does the patient get up during the night (do not count if the patient gets up once or twice per night only to go to the bathroom and falls back asleep immediately)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10070>	C63358	FACVP Regimen|CTX/DOX/5-FU/VP-16|Cyclophosphamide/Doxorubicin/Etoposide/Fluorouracil|FACVP|FACVP|Fluorouracil-Doxorubicin-Cyclophosphamide-Etoposide|Fluorouracil/Adriamycin/Cyclophosphamide/VP-16|Fluorouracil/Doxorubicin/Cyclophosphamide/Etoposide|Fluorouracil/Doxorubicin/Cyclophosphamide/Etoposide Regimen	A regimen consisting of fluorouracil, doxorubicin, cyclophosphamide, vincristine, and prednisone that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C100710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100710>	C100120	NPI - Wander, Pace or Get Involved in Inappropriate Activities at Night|NPI1-Wander or Pace at Night|NPI1-Wander or Pace at Night|NPI1K03	Neuropsychiatric Inventory (NPI) Does the patient wander, pace or get involved in inappropriate activities at night?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100711>	C100120	NPI - Awaken You During the Night|NPI1-Awaken Caregiver during Night|NPI1-Awaken Caregiver during Night|NPI1K04	Neuropsychiatric Inventory (NPI) Does the patient awaken you during the night?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100712>	C100120	NPI - Wake Up at Night, Dress, and Plan to Go Out|NPI1-Wake at Night and Think Morning|NPI1-Wake at Night and Think Morning|NPI1K05	Neuropsychiatric Inventory (NPI) Does the patient wake up at night, dress, and plan to go out thinking that it is morning and time to start the day?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100713>	C100120	NPI - Awaken Too Early in Morning|NPI1-Awaken Too Early in Morning|NPI1-Awaken Too Early in Morning|NPI1K06	Neuropsychiatric Inventory (NPI) Does the patient awaken too early in the morning (earlier than was his/her habit)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100714>	C100120	NPI - Sleep Excessively During the Day|NPI1-Excessive Sleep during Day|NPI1-Excessive Sleep during Day|NPI1K07	Neuropsychiatric Inventory (NPI) Does the patient sleep excessively during the day?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100715>	C100120	NPI - Any Other Nighttime Behaviors That Bother You|NPI1-Other Nighttime Behaviors|NPI1-Other Nighttime Behaviors|NPI1K08	Neuropsychiatric Inventory (NPI) Does the patient have any other nighttime behaviors that bother you that we haven't talked about?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100716>	C100120	NPI - Change in Appetite, Weight, or Eating Habits|NPI1-Change in Appetite or Weight|NPI1-Change in Appetite or Weight|NPI1L	Neuropsychiatric Inventory (NPI) Has he/she had any change in appetite, weight, or eating habits (count as NA if the patient is incapacitated and has to be fed)? Has there been any change in the type of food he/she prefers?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100717>	C100120	NPI - Loss of Appetite|NPI1-Loss of Appetite|NPI1-Loss of Appetite|NPI1L01	Neuropsychiatric Inventory (NPI) Has he/she had a loss of appetite?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100718>	C100120	NPI - Increase in Appetite|NPI1-Increase in Appetite|NPI1-Increase in Appetite|NPI1L02	Neuropsychiatric Inventory (NPI) Has he/she had an increase in appetite?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100719>	C100120	NPI - Loss of Weight|NPI1-Weight Loss|NPI1-Weight Loss|NPI1L03	Neuropsychiatric Inventory (NPI) Has he/she had a loss of weight?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10071>	C63442|C63356	Cyclophosphamide/Mercaptopurine/Prednisone/Vincristine Regimen|CTX/MP/PRED/VCR|Cyclophosphamide-Mercaptopurine-Prednisone-Vincristine|Cyclophosphamide/Mercaptopurine/Prednisone/Vincristine|VEMP|VEMP	A regimen consisting of vincristine, cyclophosphamide, mercaptopurine, and prednisone that may be used in the treatment of central nervous system (CNS) lymphoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C100720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100720>	C100120	NPI - Gained Weight|NPI1-Weight Gain|NPI1-Weight Gain|NPI1L04	Neuropsychiatric Inventory (NPI) Has he/she gained weight?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100721>	C100120	NPI - Change in Eating Behavior|NPI1-Change in Eating Behavior|NPI1-Change in Eating Behavior|NPI1L05	Neuropsychiatric Inventory (NPI) Has he/she had a change in eating behavior such as putting too much food in his/her mouth at once?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100722>	C100120	NPI - Change in Kind of Food He/She Likes|NPI1-Change in Kind of Food|NPI1-Change in Kind of Food|NPI1L06	Neuropsychiatric Inventory (NPI) Has he/she had a change in the kind of food he/she likes such as eating too many sweets or other specific types of food?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100723>	C100120	NPI - Developed Eating Behaviors Such as Eating Exactly the Same Types of Food|NPI1-Develop Eating Behaviors|NPI1-Develop Eating Behaviors|NPI1L07	Neuropsychiatric Inventory (NPI) Has he/she developed eating behaviors such as eating exactly the same types of food each day or eating the food in exactly the same order?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100724>	C100120	NPI - Any Other Changes in Appetite or Eating|NPI1-Other Changes in Eating|NPI1-Other Changes in Eating|NPI1L08	Neuropsychiatric Inventory (NPI) Have there been any other changes in appetite or eating that I haven't asked about?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100725>	C100121	PDQUALIF - Lightheadedness	Parkinson's Disease Quality of Life Scale (PDQUALIF) Changing position causes me to become lightheaded (lying to standing, or sitting to standing).			Intellectual Product	
C100726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100726>	C100121	PDQUALIF - Imbalance	Parkinson's Disease Quality of Life Scale (PDQUALIF) When walking, I have trouble keeping my balance.			Intellectual Product	
C100727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100727>	C100121	PDQUALIF - Swallowing Difficulty	Parkinson's Disease Quality of Life Scale (PDQUALIF) When eating or drinking fluids, I have difficulty swallowing.			Intellectual Product	
C100728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100728>	C100121	PDQUALIF - Communication	Parkinson's Disease Quality of Life Scale (PDQUALIF) My Parkinson's symptoms affect my ability to communicate with people.			Intellectual Product	
C100729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100729>	C100121	PDQUALIF - Nocturia	Parkinson's Disease Quality of Life Scale (PDQUALIF) The need to go to the bathroom keeps me up at night.			Intellectual Product	
C10072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10072>	C61063	Cyclophosphamide/Dexrazoxane/Doxorubicin/Fluorouracil|ADR-529/CTX/DOX/5-FU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100730>	C100121	PDQUALIF - Sexual Ability	Parkinson's Disease Quality of Life Scale (PDQUALIF) My Parkinson's symptoms affect my ability to show affection in intimate or sexual ways.			Intellectual Product	
C100731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100731>	C100121	PDQUALIF - Neuropathy in Hands or Feet	Parkinson's Disease Quality of Life Scale (PDQUALIF) I have aching/burning/coldness/numbness in my hand/feet.			Intellectual Product	
C100732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100732>	C100121	PDQUALIF - Bladder Control Difficulty	Parkinson's Disease Quality of Life Scale (PDQUALIF) I have difficulty with bladder control (frequency, urgency, inability).			Intellectual Product	
C100733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100733>	C100121	PDQUALIF - Constipation	Parkinson's Disease Quality of Life Scale (PDQUALIF) Constipation is a problem.			Intellectual Product	
C100734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100734>	C100121	PDQUALIF - Trouble with Sleep Initiation or Waking Early	Parkinson's Disease Quality of Life Scale (PDQUALIF) My Parkinson's symptoms cause me to have trouble falling asleep, or waking early.			Intellectual Product	
C100735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100735>	C100121	PDQUALIF - Trouble with Sleep Maintenance	Parkinson's Disease Quality of Life Scale (PDQUALIF) I have trouble staying asleep.			Intellectual Product	
C100736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100736>	C100121	PDQUALIF - Positive Outlook Difficult	Parkinson's Disease Quality of Life Scale (PDQUALIF) My Parkinson's symptoms make it hard to maintain a positive outlook.			Intellectual Product	
C100737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100737>	C100121	PDQUALIF - Burden to Others	Parkinson's Disease Quality of Life Scale (PDQUALIF) My Parkinson's symptoms cause me to feel like a burden to other people.			Intellectual Product	
C100738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100738>	C100121	PDQUALIF - Social Life Affected	Parkinson's Disease Quality of Life Scale (PDQUALIF) My Parkinson's symptoms have affected my social life.			Intellectual Product	
C100739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100739>	C100121	PDQUALIF - Worry about Future	Parkinson's Disease Quality of Life Scale (PDQUALIF) I worry about what the future has in store.			Intellectual Product	
C10073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10073>	C61007	Doxorubicin/Fluorouracil/Mitomycin/Triazinate|DOX/5-FU/MITO/TZT|FAM-T			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100740>	C100121	PDQUALIF - Difficulty in Asking for Help	Parkinson's Disease Quality of Life Scale (PDQUALIF) Asking others for help is difficult for me.			Intellectual Product	
C100741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100741>	C100121	PDQUALIF - Important to Maintain Independence	Parkinson's Disease Quality of Life Scale (PDQUALIF) Maintaining my independence is important to me.			Intellectual Product	
C100742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100742>	C100121	PDQUALIF - Difficulty in Adjusting to Change	Parkinson's Disease Quality of Life Scale (PDQUALIF) It has been difficult to adjust to the changes which have taken place in my body.			Intellectual Product	
C100743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100743>	C100121	PDQUALIF - Social Life Not Affected	Parkinson's Disease Quality of Life Scale (PDQUALIF) My Parkinson's symptoms have not affected my social life.			Intellectual Product	
C100744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100744>	C100121	PDQUALIF - Travel Important	Parkinson's Disease Quality of Life Scale (PDQUALIF) Travel remains an important part of my leisure activities.			Intellectual Product	
C100745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100745>	C100121	PDQUALIF - Family Relationship Affected	Parkinson's Disease Quality of Life Scale (PDQUALIF) My Parkinson's symptoms have affected my family role and responsibility.			Intellectual Product	
C100746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100746>	C100121	PDQUALIF - Social Isolation	Parkinson's Disease Quality of Life Scale (PDQUALIF) My Parkinson's symptoms cause me to stay away from social gatherings.			Intellectual Product	
C100747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100747>	C100121	PDQUALIF - Self Concept Change	Parkinson's Disease Quality of Life Scale (PDQUALIF) My spouse/children/friends' view of me has changed because of my illness.			Intellectual Product	
C100748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100748>	C100121	PDQUALIF - Sexual Desirability	Parkinson's Disease Quality of Life Scale (PDQUALIF) I feel I am less sexually desirable because of my illness.			Intellectual Product	
C100749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100749>	C100121	PDQUALIF - Independent Hygiene in Past 7 Days	Parkinson's Disease Quality of Life Scale (PDQUALIF) In the past 7 days, in my personal hygiene (bathing, hair care, make up, shaving or toileting), I have been independent.			Intellectual Product	
C10074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10074>	C61007	Asparaginase/Cytarabine/Sargramostim|ARA-C/ASP/GM-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100750>	C100121	PDQUALIF - Independent Food Preparation in Past 7 Days	Parkinson's Disease Quality of Life Scale (PDQUALIF) In the past 7 days, in food preparation or eating I am independent.			Intellectual Product	
C100751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100751>	C100121	PDQUALIF - Problem with Communication in the Past 7 Days	Parkinson's Disease Quality of Life Scale (PDQUALIF) In the past 7 days, written or spoken communication is a problem for me.			Intellectual Product	
C100752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100752>	C100121	PDQUALIF - Fatigue in Past 7 Days	Parkinson's Disease Quality of Life Scale (PDQUALIF) In the past 7 days, fatigue makes participation in activities, household chores, shopping or yard work a problem for me.			Intellectual Product	
C100753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100753>	C100121	PDQUALIF - House Work in Past 7 Days	Parkinson's Disease Quality of Life Scale (PDQUALIF) In the past 7 days, my Parkinson's symptoms interfere with my ability to do my usual share in the home.			Intellectual Product	
C100754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100754>	C100121	PDQUALIF - Sleep with Partner in Past 7 Days	Parkinson's Disease Quality of Life Scale (PDQUALIF) In the past 7 days, my nighttime symptoms keep me from sleeping with my spouse/partner.			Intellectual Product	
C100755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100755>	C100121	PDQUALIF - Driving in Past 7 Days	Parkinson's Disease Quality of Life Scale (PDQUALIF) In the past 7 days, my Parkinson's symptoms have interfered with my driving ability.			Intellectual Product	
C100756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100756>	C100121	PDQUALIF - Financial Strain in Past 7 Days	Parkinson's Disease Quality of Life Scale (PDQUALIF) In the past 7 days, my illness has caused a financial strain for me and my family.			Intellectual Product	
C100757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100757>	C100121	PDQUALIF - Parkinson's Symptoms	Parkinson's Disease Quality of Life Scale (PDQUALIF) Compared to 6 months ago, my Parkinson's symptoms are.			Intellectual Product	
C100758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100758>	C62164	Lateral Decubitus Position|Decubitus|LATERAL DECUBITUS|Lateral Decubitus	Lying down or reclining with one side of the body in a downward direction.			Spatial Concept	CDISC SDTM Body Position Terminology|CDISC SDTM Terminology|CDISC SEND Body Position Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C100759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100759>	C91105	Brief Pain Inventory Questionnaire|BPI|BPI1|Brief Pain Inventory	A standardized survey originally developed and copyrighted by Charles S. Cleeland in 1991 which is used to evaluate the severity of a patient's pain and the impact that their pain has on their daily activities. This longer version is more clinically useful, can be completed by the patient or in an interview format and consists of 32 multi-level questions covering areas such as location, type, and severity of pain as well as the use of pain medications.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10075>	C61063	Etoposide/Methotrexate|MTX/VP-16|VMC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100760>	C91105	Brief Pain Inventory Short Form Questionnaire|BPI SHORT FORM|BPI2|Brief Pain Inventory Short Form	A standardized survey originally developed and copyrighted by Charles S. Cleeland in 1991 which is used to evaluate the severity of a patient's pain and the impact that their pain has on their daily activities. This shorter version of the Brief Pain Inventory (BPI) is more useful for clinical trials, can be completed by the patient or in an interview format, and consists of only 9 questions most of which can be answered on a 0-10 rating scale.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100761>	C118969	Brief Psychiatric Rating Scale A Clinical Classification|BPRS-A|BPRSA1|Brief Psychiatric Rating Scale - Anchored	A standardized rating scale originally developed by Margaret G. Woerner, Salvatore Mannuzza and John M. Kane in 1988 which is used to evaluate the severity of an individual's psychiatric symptoms. This version consists of 18 questions or types of psychiatric symptoms such as depression, anxiety, hallucinations, motor skills, or other unusual behaviors and is completed during a semi-structured interview. Each symptom is rated on a scale of 1-7 or 1-9 with 1 being non-existent and 7 being very severe; 9 represents 'can not be assessed'.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100762>	C222259	Alzheimer's Disease Assessment Scale-Cognitive CDISC Version Functional Test|ADAS-COG|ADC	The CDISC version of the Alzheimer's Disease Assessment Scale-Cognitive (CDISC ADAS-Cog) containing 15 summary-level tests. This version is based on combining the total pool of ADAS-Cog tests that were observed during a review of multiple case report forms administered in clinical trials of Alzheimer's disease, as well as the CRF administered in the Alzheimer's Disease Neuroimaging Initiative (ADNI) observational study.  (Modified from Mohs RC, Rosen WG, Davis KL. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull 1983;19(3):448-450. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141(11):1356-1364. Mohs RC, Knopman D, Petersen RC et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11 Suppl 2:S13-S21. Wouters H, van Gool WA, Schmand B, Lindeboom R. Revising the ADAS-cog for a more accurate assessment of cognitive impairment. Alzheimer Dis Assoc Disord 2008;22(3):236-244.).			Intellectual Product	CDISC Functional Test Category Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100763>	C91105	Clinical Global Impression Original Version Questionnaire|CGI Original Version|Clinical Global Impressions Scale|Clinical Global Impressions Scale - CGI	A standardized survey developed by W. Guy in 1976 which is used to evaluate the efficacy of a therapeutic intervention. This instrument consists of 3 sections pertaining to the severity of the patient's illness, their level of improvement and a comparison of the therapeutic effect versus the side effects. The questionnaire is completed by a clinician familiar with the patient's medical history.			Intellectual Product	
C100764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100764>	C91105	Current Opioid Misuse Measure Questionnaire|COMM|COMM1	A standardized rating scale developed and copyrighted by Inflexxicon, Inc. which is used to aid clinicians in determining if a patient may be improperly using opioids for the treatment of pain. This instrument consists of 17 questions which can be completed by the patient. Each question is rated on a scale of 0-4 with 0 being 'never' and 4 being 'very often'. A score equal to or greater than 9 indicates possible misuse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100765>	C91105	Columbia-Suicide Severity Rating Scale Baseline Questionnaire|C-SSRS BASELINE|C-SSRS Baseline|CSS01	A standardized survey developed and copyrighted by Kelly Posner and colleagues with The Research Foundation for Mental Hygiene in 2008 which is used to evaluate a patient's suicidal tendencies. The baseline version questionnaire contains four sections with approximately 40 questions and is administered in an interview format. The first three sections pertain to the patient's suicidal ideations and behaviors while the fourth section assess any actual suicide attempts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100766>	C91105	Faces Pain Scale Revised Questionnaire|FPSR|FPSR1	A standardized rating scale developed and copyrighted by the International Association for the Study of Pain (IASP) in 2001 but is available for non-commercial clinical, educational and research use in the journal Pain (Hicks CL, von Baeyer CL, Spafford P, van Korlaar I, Goodenough B. The Faces Pain Scale - Revised: Toward a common metric in pediatric pain measurement. Pain 2001;93:173-183). This instrument is used to evaluate the severity of pain in an individual who is unable to use a numerical scale alone such as a child. The scale consists of six facial expression representing varying levels of pain which correspond to a number between 0 and 10 where the 0 face represents 'no pain' and the 10 face represents 'very much pain'.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100767>	C118969	Hamilton Depression Rating Scale 17 Item Clinical Classification|HAMD 17|HAMD1	A standardized rating scale developed by M. Hamilton in 1960 which is used to evaluate the severity of an individual's depression. This instrument contains 17 questions or types of symptoms associated with depression such as anxiety, mood, insomnia, and somatic symptoms experienced within the past week and is completed during a semi-structured interview. Each symptom is rated on a scale of 0-2, 0-3, or 0-4 with 0 being absent and 2, 3, or 4 being the most severe. A score of 0-7 is considered normal while a score equal to or greater than 20 qualifies an individual for a clinical trial.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100768>	C118969	Karnofsky Performance Status Scale Clinical Classification|KPS SCALE|KPSS01	A standardized rating scale originally developed by David A. Karnofsky and Joseph H. Burchenal in 1949 which is used to evaluate the degree to which a patient is functionally impaired. This instrument consists of 3 sections, no special care needed, unable to work, and unable to care for one's self and is completed by a clinician based on their observations. There are a total of eleven levels ranging from 0-100 where 0 indicates that the patient is dead and 100 indicates that the patient is normal.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100769>	C91105	Movement Disorder Society Unified Parkinson's Disease Rating Scale Questionnaire|MDS-UPDRS|UPD2	A standardized rating scale developed and copyrighted by the Movement Disorders Society in 2008 and published in the journal Movement Disorders (C.G. Goetz et al. Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale Presentation and Clinimetric Testing Results. Movement Disorders, 23(15):2129-2170.) which is used to evaluate the severity of an individual's Parkinson's disease symptoms. This instrument contains four parts consisting of non-motor and motor experiences in daily living, a motor examination and an assessment of motor complications which is completed during an interview and physical examination. Each symptom is rated on a scale of 0-4 with 0 being normal and 4 being severe.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10076>	C61063	Doxorubicin/Fluorouracil/Triazinate|DOX/5-FU/TZT|FAT			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100771>	C91105	Michigan Neuropathy Screening Instrument Questionnaire|MNSI|MNSI1	A standardized survey developed and copyrighted by the University of Michigan's Diabetes Research and Training Center and is based on Peter Dyck's Neuropathy Screening Profile (Dyck PJ, Karnes J, O'Brien PC, Swanson CJ, Neuropathy Symptom Profile in health, motor neuron disease, diabetic neuropathy, and amyloidosis. Neurology, 1986, 36:1300-1308) which is used to screen for neuropathy particularly in individuals with diabetes. This instrument consists of two parts, the first part is a patient history and can be completed by the patient while the second part is physical exam completed by a health professional.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100772>	C91105	Neuropsychiatric Inventory - 12 Item Version Questionnaire|NPI|NPI-12|NPI-Q|NPI1|Neuropsychiatric Inventory-Questionnaire	A standardized rating scale originally developed and copyrighted by Jeffrey L. Cummings in 1994 as well as published in the journal Neurology (Cummings J.L., The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients. Neurology May 1997 48:10S-16S) which is used to assess the severity of an individual's neuropathic behaviors based on a observations made by the patient's caregiver. This instrument contains 12 neuropsychiatric areas associated with dementia such as delusions, anxiety, motor disturbances, and appetite. Each behavior is evaluated only if the individual displays the behavior. For these behaviors, the frequency is assessed on a scale of 0-4 with 0 being occasionally and 4 being very frequently, the severity is assessed on a scale of 1-3 with 1 being mild and 3 being marked, and the level of distress each behavior inflicts on the caregiver is assessed on a scale of 0-5 with 0 being not distressing and 5 being extremely distressing.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100773>	C91105	Parkinson's Disease Quality of Life Scale Questionnaire|PDQ01|PDQUALIF	A standardized rating scale originally developed and copyrighted by Mickie Welsh and The Parkinson Study Group in 1996 then released for publication in the journal Movement Disorders in 2003 which is used to assist the clinician in evaluating the degree to which the patient's Parkinson's disease symptoms interfere with their quality of life. This instrument contains 33 questions covering 7 areas including social/role function, self-image/sexuality, sleep, outlook on life, physical function, independence, and urinary function and can be completed by the patient. For each question, the patient must choose from five different responses.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100774>	C91105	Roland Morris Disability Questionnaire|RDQ|RDQ01	A standardized survey developed by M.O. Roland and R.W. Morris in 1983 used to assess the level of disability experienced by a patient with back pain. This original version consists of 24 statements and can be completed by the patient. Each statement receives either a 0 if it is not applicable to patient on the day the questionnaire is administered or a 1 if it is applicable.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100775>	C20078	Short Form 36 Health Survey Standard, US Version 1.0 Questionnaire|SF36 V1.0 STANDARD|SF36 v1.0 Standard|SF361	A standardized, multipurpose, general health survey developed by John E. Ware and copyrighted by Medical Outcomes Trust and Quality Metric Inc. in 1988 and 2002 which is used to assess the patient's functional health and overall well-being. This instrument contains 36 questions to be completed by the patient. For each question the patient must choose from five different responses.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100776>	C91105	Short-Form McGill Pain Questionnaire-2|SFMP2|SHORT-FORM MPQ-2	A standardized rating scale developed to evaluate the type and severity of a patients neuropathic or non-neuropathic pain. This revised version contains 22 symptoms associated with neuropathic and non-neuropathic pain which can be completed by the patient. Each symptom is rated on a scale of 0-10 with 0 being no pain and 10 being the worst possible pain. This questionnaire was copyrighted by Ronald Melzack and the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) in 2009 as well as published in the journal pain (Dworkin R.H., Development and initial validation of an expanded and revised version of the Short-form McGill Pain Questionnaire-2 (SF-MPQ-2). Pain, 2009 Jul;144(1-2):35-42).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100777>	C91105	Screener and Opioid Assessment for Patients with Pain Revised Questionnaire|SOAPP-R|SOAPR1	A standardized rating scale developed and copyrighted by Inflexxicon, Inc. which is used to aid clinicians in screening a patient's potential for long-term opioid use in the treatment of pain. This revised version consists of 24 questions which can be completed by the patient. Each question is rated on a scale of 0-4 with 0 being 'never' and 4 being 'very often'. A score equal to or greater than 18 indicates that the patient has a high risk of misusing opioids.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100778>	C118969	Unified Parkinson's Disease Rating Scale Clinical Classification|UPD1|UPDRS	A standardized rating scale originally developed by S. Fahn, R. Elton, and other members of the UPDRS Development Committee in 1987 which is used to evaluate the status of a patient's Parkinson's disease. This instrument is made up of 6 parts consisting of a mental, behavior and mood section, an activities of daily living section, a motor examination, and questions concerning any complications with the patient's current therapy as well as modified versions of the Hoehn and Yahr Staging assessment and the Schwab and England Activities of Daily Living Scale. Each question is either scored with a 0 for a 'no' response and 1 for a 'yes' response or with a 0-4 point scale.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100779>	C91105	Work Productivity and Activity Impairment Specific Health Problems Version 2.0 Questionnaire|WPAI-SHP V2.0|WPAI01	The second version of a standardized survey originally developed by Margaret C. Reilly in 1993 which is used to evaluate the extent to which a patient's specific health problems effect their ability to work and perform daily activities. This instrument consist of 6 questions which can be completed by the patient or in an interview format.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10077>	C61063	Interferon Gamma/Levamisole|IFN-G/LEV			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100780>	C100123	RDQ - Stay at Home|RDQ01-Stay at Home|RDQ01-Stay at Home|RDQ0101	Roland Morris Disability Questionnaire (RDQ) I stay at home most of the time because of my back.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RDQ Test Code Terminology|CDISC Questionnaire RDQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100781>	C100123	RDQ - Change Position Frequently|RDQ01-Change Position Frequently|RDQ01-Change Position Frequently|RDQ0102	Roland Morris Disability Questionnaire (RDQ) I change position frequently to try and get my back comfortable.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RDQ Test Code Terminology|CDISC Questionnaire RDQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100782>	C100123	RDQ - Walk More Slowly|RDQ01-Walk More Slowly|RDQ01-Walk More Slowly|RDQ0103	Roland Morris Disability Questionnaire (RDQ) I walk more slowly than usual because of my back.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RDQ Test Code Terminology|CDISC Questionnaire RDQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100783>	C100123	RDQ - Not Do Any Usual House Jobs|RDQ01-Not Do Any Usual Jobs|RDQ01-Not Do Any Usual Jobs|RDQ0104	Roland Morris Disability Questionnaire (RDQ) Because of my back, I am not doing any of the jobs that I usually do around the house.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RDQ Test Code Terminology|CDISC Questionnaire RDQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100784>	C100123	RDQ - Use Handrail to Get Upstairs|RDQ01-Use Handrail to Get Upstairs|RDQ01-Use Handrail to Get Upstairs|RDQ0105	Roland Morris Disability Questionnaire (RDQ) Because of my back, I use a handrail to get upstairs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RDQ Test Code Terminology|CDISC Questionnaire RDQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100785>	C100123	RDQ - Lie Down to Rest More Often|RDQ01-Lie Down to Rest More Often|RDQ01-Lie Down to Rest More Often|RDQ0106	Roland Morris Disability Questionnaire (RDQ) Because of my back, I lie down to rest more often.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RDQ Test Code Terminology|CDISC Questionnaire RDQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100786>	C100123	RDQ - Hold on to Get Out of a Chair|RDQ01-Hold on to Get Out of a Chair|RDQ01-Hold on to Get Out of a Chair|RDQ0107	Roland Morris Disability Questionnaire (RDQ) Because of my back, I have to hold on to something to get out of an easy chair.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RDQ Test Code Terminology|CDISC Questionnaire RDQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100787>	C100123	RDQ - Get Other People to Do Things|RDQ01-Get Other People to Do Things|RDQ01-Get Other People to Do Things|RDQ0108	Roland Morris Disability Questionnaire (RDQ) Because of my back, I try to get other people to do things for me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RDQ Test Code Terminology|CDISC Questionnaire RDQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100788>	C100123	RDQ - Get Dressed More Slowly|RDQ01-Get Dressed More Slowly|RDQ01-Get Dressed More Slowly|RDQ0109	Roland Morris Disability Questionnaire (RDQ) I get dressed more slowly then usual because of my back.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RDQ Test Code Terminology|CDISC Questionnaire RDQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100789>	C100123	RDQ - Only Stand for Short Periods|RDQ01-Only Stand for Short Periods|RDQ01-Only Stand for Short Periods|RDQ0110	Roland Morris Disability Questionnaire (RDQ) I only stand for short periods of time because of my back.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RDQ Test Code Terminology|CDISC Questionnaire RDQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10078>	C61063	Cyclophosphamide/Doxorubicin/Fluorouracil/Sargramostim|CTX/DOX/5-FU/GM-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100790>	C100123	RDQ - Try Not to Bend or Kneel|RDQ01-Try Not to Bend or Kneel|RDQ01-Try Not to Bend or Kneel|RDQ0111	Roland Morris Disability Questionnaire (RDQ) Because of my back, I try not to bend or kneel down.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RDQ Test Code Terminology|CDISC Questionnaire RDQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100791>	C100123	RDQ - Difficult to Get Out of a Chair|RDQ01-Difficult to Get Out of a Chair|RDQ01-Difficult to Get Out of a Chair|RDQ0112	Roland Morris Disability Questionnaire (RDQ) I find it difficult to get out of a chair because of my back.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RDQ Test Code Terminology|CDISC Questionnaire RDQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100792>	C100123	RDQ - Painful Almost All the Time|RDQ01-Painful Almost All the Time|RDQ01-Painful Almost All the Time|RDQ0113	Roland Morris Disability Questionnaire (RDQ) My back is painful almost all the time.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RDQ Test Code Terminology|CDISC Questionnaire RDQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100793>	C100123	RDQ - Difficult to Turn Over in Bed|RDQ01-Difficult to Turn Over in Bed|RDQ01-Difficult to Turn Over in Bed|RDQ0114	Roland Morris Disability Questionnaire (RDQ) I find it difficult to turn over in bed because of my back.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RDQ Test Code Terminology|CDISC Questionnaire RDQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100794>	C100123	RDQ - Appetite is Not Very Good|RDQ01-Appetite is Not Very Good|RDQ01-Appetite is Not Very Good|RDQ0115	Roland Morris Disability Questionnaire (RDQ) My appetite is not very good because of my back pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RDQ Test Code Terminology|CDISC Questionnaire RDQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100795>	C100123	RDQ - Trouble Putting on Socks or Stockings|RDQ01-Trouble Putting on Socks/Stockings|RDQ01-Trouble Putting on Socks/Stockings|RDQ0116	Roland Morris Disability Questionnaire (RDQ) I have trouble putting on my socks (or stockings) because of the pain in my back.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RDQ Test Code Terminology|CDISC Questionnaire RDQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100796>	C100123	RDQ - Only Walk Short Distances|RDQ01-Only Walk Short Distances|RDQ01-Only Walk Short Distances|RDQ0117	Roland Morris Disability Questionnaire (RDQ) I only walk short distances because of my back.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RDQ Test Code Terminology|CDISC Questionnaire RDQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100797>	C100123	RDQ - Sleep Less Well|RDQ01-Sleep Less Well|RDQ01-Sleep Less Well|RDQ0118	Roland Morris Disability Questionnaire (RDQ) I sleep less well because of my back.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RDQ Test Code Terminology|CDISC Questionnaire RDQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100798>	C100123	RDQ - Get Dressed With Help|RDQ01-Get Dressed With Help|RDQ01-Get Dressed With Help|RDQ0119	Roland Morris Disability Questionnaire (RDQ) Because of my back pain, I get dressed with help from someone else.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RDQ Test Code Terminology|CDISC Questionnaire RDQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100799>	C100123	RDQ - Sit Down Most of the Day|RDQ01-Sit Down Most of the Day|RDQ01-Sit Down Most of the Day|RDQ0120	Roland Morris Disability Questionnaire (RDQ) I sit down for most of the day because of my back.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RDQ Test Code Terminology|CDISC Questionnaire RDQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10079>	C61063	Bleomycin/Procarbazine/Vinblastine|BLEO/PCB/VBL|VPB			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1007>	C1935	Azapicyl|1-ACETYL-2-PICOLINOYLHYDRAZINE|1-Acetyl-2-picolinoylhydrazine|1-acetyl-2-picolinoylhydrazine|2-acetylhydrazide-2-pyridinecarboxylic acid|P-2292	A hydrazine compound that has been investigated for antineoplastic activity. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C100800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100800>	C100123	RDQ - Avoid Heavy Jobs|RDQ01-Avoid Heavy Jobs|RDQ01-Avoid Heavy Jobs|RDQ0121	Roland Morris Disability Questionnaire (RDQ) I avoid heavy jobs around the house because of my back.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RDQ Test Code Terminology|CDISC Questionnaire RDQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100801>	C100123	RDQ - More Irritable With People|RDQ01-More Irritable With People|RDQ01-More Irritable With People|RDQ0122	Roland Morris Disability Questionnaire (RDQ) Because of my back pain, I am more irritable and bad tempered with people than usual.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RDQ Test Code Terminology|CDISC Questionnaire RDQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100802>	C100123	RDQ - Go Upstairs More Slowly|RDQ01-Go Upstairs More Slowly|RDQ01-Go Upstairs More Slowly|RDQ0123	Roland Morris Disability Questionnaire (RDQ) Because of my back, I go upstairs more slowly than usual.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RDQ Test Code Terminology|CDISC Questionnaire RDQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100803>	C100123	RDQ - Stay in Bed|RDQ01-Stay in Bed|RDQ01-Stay in Bed|RDQ0124	Roland Morris Disability Questionnaire (RDQ) I stay in bed most of the time because of my back.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RDQ Test Code Terminology|CDISC Questionnaire RDQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100804>	C100123	RDQ - Total Derived Score|RDQ01-RDQ Total Score|RDQ01-RDQ Total Score|RDQ0125	Roland Morris Disability Questionnaire (RDQ) RDQ total derived score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RDQ Test Code Terminology|CDISC Questionnaire RDQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100805>	C71397|C161421	Biological Grandchild|GRANDCHILD, BIOLOGICAL|Natural Grandchild	A biological child of an individual's biological child.			Human	CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C100806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100806>	C71385|C161421	Biological Grandparent|GRANDPARENT, BIOLOGICAL|Natural Grandparent	A biological parent of the biological father or biological mother.			Human	CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C100808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100808>	C21480	Third Degree Relative|RELATIVE, THIRD DEGREE	Any individual related biologically or legally to another individual and considered two degrees removed from the immediate family as in the case of cousins.			Human	CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100809>	C25204	Biological Sibling|Natural Sibling|SIBLING, BIOLOGICAL	A person's brother or sister with whom they share a genetic makeup inherited from one or both of their shared biological parents.			Human	ALL Authorized Value Terminology|ALL Stem Cell Transplant Table|AML Authorized Value Terminology|AML Stem Cell Transplant Table|CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Stem Cell Transplant Table
C10080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10080>	C61063	Cytarabine/Doxorubicin/Mercaptopurine/Prednisone/Vincristine|ARA-C/DOX/MP/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100810>	C25168	Organ Donor|DONOR, ORGAN	Someone from whom an organ is removed for transplantation or other purpose.			Human	CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100811>	C100128	Pregnancy Partner|PREGNANCY PARTNER	An individual who provides support to a pregnant individual.			Human	CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100812>	C100128	Sexual Partner|SEXUAL PARTNER	A person with whom one has had sexual relations.			Human	CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100813>	C100171	SF36 v1.0 Standard - In General You Say Your Health Is|SF361-In General You Say Your Health Is|SF361-In General You Say Your Health Is|SF36101	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) In general, would you say your health is.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100814>	C100171	SF36 v1.0 Standard - Comp Year Ago Rate Gen Health Now|SF361-Comp Year Ago Rate Gen Health Now|SF361-Comp Year Ago Rate Gen Health Now|SF36102	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) Compared to one year ago, how would you rate your health in general now?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100815>	C100171	SF36 v1.0 Standard - Limit Vigorous Activities|SF361-Limit Vigorous Activities|SF361-Limit Vigorous Activities|SF36103A	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) How much does your health now limit you in - vigorous activities, such as running, lifting heavy objects, participating in strenuous sports.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100816>	C100171	SF36 v1.0 Standard - Limit Moderate Activities|SF361-Limit Moderate Activities|SF361-Limit Moderate Activities|SF36103B	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) How much does your health now limit you in - moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or playing golf.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100817>	C100171	SF36 v1.0 Standard - Limit Lifting or Carrying|SF361-Limit Lifting or Carrying|SF361-Limit Lifting or Carrying|SF36103C	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) How much does your health now limit you in - lifting or carrying groceries.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100818>	C100171	SF36 v1.0 Standard - Limit Climbing Several Flights|SF361-Limit Climbing Several Flights|SF361-Limit Climbing Several Flights|SF36103D	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) How much does your health now limit you in - climbing several flights of stairs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100819>	C100171	SF36 v1.0 Standard - Limit Climbing One Flight Stairs|SF361-Limit Climbing One Flight Stairs|SF361-Limit Climbing One Flight Stairs|SF36103E	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) How much does your health now limit you in - climbing one flight of stairs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10081>	C61063	Altretamine/Etoposide/Procarbazine|HMM/PCB/VP-16|VPH			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100820>	C100171	SF36 v1.0 Standard - Limit Bending/Kneeling/Stooping|SF361-Limit Bending/Kneeling/Stooping|SF361-Limit Bending/Kneeling/Stooping|SF36103F	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) How much does your health now limit you in - bending, kneeling, or stooping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100821>	C100171	SF36 v1.0 Standard - Limit Walking More Than a Mile|SF361-Limit Walking More Than a Mile|SF361-Limit Walking More Than a Mile|SF36103G	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) How much does your health now limit you in - walking more than a mile.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100822>	C100171	SF36 v1.0 Standard - Limit Walking Several Blocks|SF361-Limit Walking Several Blocks|SF361-Limit Walking Several Blocks|SF36103H	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) How much does your health now limit you in - walking several blocks.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100823>	C100171	SF36 v1.0 Standard - Limit Walking One Block|SF361-Limit Walking One Block|SF361-Limit Walking One Block|SF36103I	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) How much does your health now limit you in - walking one block.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100824>	C100171	SF36 v1.0 Standard - Limit Bathing or Dressing Yourself|SF361-Limit Bathing or Dressing Yourself|SF361-Limit Bathing or Dressing Yourself|SF36103J	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) How much does your health now limit you in - bathing or dressing yourself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100825>	C100171	SF36 v1.0 Standard - Physical: Cut Down Time on Work|SF361-Physical: Cut Down Time on Work|SF361-Physical: Cut Down Time on Work|SF36104A	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) During the past 4 weeks, how much of the time have you had any problems with your work or other regular daily activities as a result of your physical health - cut down on the amount of time you spent on work or other activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100826>	C100171	SF36 v1.0 Standard - Physical: Accomplished Less|SF361-Physical: Accomplished Less|SF361-Physical: Accomplished Less|SF36104B	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) During the past 4 weeks, how much of the time have you had any problems with your work or other regular daily activities as a result of your physical health - accomplished less than you would like.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100827>	C100171	SF36 v1.0 Standard - Physical: Limited Kind of Work|SF361-Physical: Limited Kind of Work|SF361-Physical: Limited Kind of Work|SF36104C	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) During the past 4 weeks, how much of the time have you had any problems with your work or other regular daily activities as a result of your physical health - were limited in the kind of work or other activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100828>	C100171	SF36 v1.0 Standard - Physical: Difficulty Perform Work|SF361-Physical: Difficulty Perform Work|SF361-Physical: Difficulty Perform Work|SF36104D	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) During the past 4 weeks, how much of the time have you had any problems with your work or other regular daily activities as a result of your physical health - had difficulty performing the work or other activities (for example, it took extra effort).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100829>	C100171	SF36 v1.0 Standard - Emotional: Cut Down Time on Work|SF361-Emotional: Cut Down Time on Work|SF361-Emotional: Cut Down Time on Work|SF36105A	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) During the past 4 weeks, how much of the time have you had problems with your work or other regular daily activities as a result of any emotional problems (such as feeling depressed or anxious) - cut down on the amount of time you spent on work or other activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10082>	C61063	Bleomycin/Cisplatin/Doxorubicin|ABCX|BLEO/CDDP/DOX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100830>	C100171	SF36 v1.0 Standard - Emotional: Accomplished Less|SF361-Emotional: Accomplished Less|SF361-Emotional: Accomplished Less|SF36105B	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) During the past 4 weeks, how much of the time have you had problems with your work or other regular daily activities as a result of any emotional problems (such as feeling depressed or anxious) - accomplished less than you would like.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100831>	C100171	SF36 v1.0 Standard - Emotional: Did Work Less Carefully|SF361-Emotional: Did Work Less Carefully|SF361-Emotional: Did Work Less Carefully|SF36105C	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) During the past 4 weeks, how much of the time have you had problems with your work or other regular daily activities as a result of any emotional problems (such as feeling depressed or anxious) - did work or other activities less carefully than usual.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100832>	C100171	SF36 v1.0 Standard - Extent Phys/Emotional Interfered|SF361-Extent Phys/Emotional Interfered|SF361-Extent Phys/Emotional Interfered|SF36106	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) During the past 4 weeks, to what extent has your physical health or emotional problems interfered with your normal social activities with family, friends, neighbors, or groups?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100833>	C100171	SF36 v1.0 Standard - How Much Bodily Pain Have You Had|SF361-How Much Bodily Pain Have You Had|SF361-How Much Bodily Pain Have You Had|SF36107	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) How much bodily pain have you had during the past 4 weeks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100834>	C100171	SF36 v1.0 Standard - Pain Interfere With Normal Work|SF361-Pain Interfere With Normal Work|SF361-Pain Interfere With Normal Work|SF36108	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) During the past 4 weeks, how much did pain interfere with your normal work (including both work outside the home and housework)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100835>	C100171	SF36 v1.0 Standard - Did You Feel Full of Pep|SF361-Did You Feel Full of Pep|SF361-Did You Feel Full of Pep|SF36109A	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - did you feel full of pep.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100836>	C100171	SF36 v1.0 Standard - Have You Been Very Nervous Person|SF361-Have You Been Very Nervous Person|SF361-Have You Been Very Nervous Person|SF36109B	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - have you been a very nervous person.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100837>	C100171	SF36 v1.0 Standard - Felt Down Nothing Cheer You Up|SF361-Felt Down Nothing Cheer You Up|SF361-Felt Down Nothing Cheer You Up|SF36109C	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - have you felt so down in the dumps that nothing could cheer you up.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100838>	C100171	SF36 v1.0 Standard - Have You Felt Calm and Peaceful|SF361-Have You Felt Calm and Peaceful|SF361-Have You Felt Calm and Peaceful|SF36109D	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - have you felt calm and peaceful.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100839>	C100171	SF36 v1.0 Standard - Did You Have a Lot of Energy|SF361-Did You Have a Lot of Energy|SF361-Did You Have a Lot of Energy|SF36109E	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - did you have a lot of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10083>	C63358	FUVAC Regimen|CDDP/DOX/5-FU/VBL|FUVAC|FUVAC|Fluorouracil-Vinblastine-Doxorubicin-Cyclophosphamide|Fluorouracil/Vinblastine/Adriamycin/Cyclophosphamide|Fluorouracil/Vinblastine/Doxorubicin/Cyclophosphamide|Fluorouracil/Vinblastine/Doxorubicin/Cyclophosphamide Regimen	A regimen consisting of fluorouracil, vinblastine, doxorubicin, and cyclophosphamide that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C100840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100840>	C100171	SF36 v1.0 Standard - You Felt Downhearted and Blue|SF361-You Felt Downhearted and Blue|SF361-You Felt Downhearted and Blue|SF36109F	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - have you felt downhearted and blue.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100841>	C100171	SF36 v1.0 Standard - Did You Feel Worn Out|SF361-Did You Feel Worn Out|SF361-Did You Feel Worn Out|SF36109G	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - did you feel worn out.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100842>	C100171	SF36 v1.0 Standard - Have You Been Happy Person|SF361-Have You Been Happy Person|SF361-Have You Been Happy Person|SF36109H	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - have you been a happy person.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100843>	C100171	SF36 v1.0 Standard - Did You Feel Tired|SF361-Did You Feel Tired|SF361-Did You Feel Tired|SF36109I	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - did you feel tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100844>	C100171	SF36 v1.0 Standard - Time Phys/Emotional Interfered|SF361-Time Phys/Emotional Interfered|SF361-Time Phys/Emotional Interfered|SF36110	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your social activities (like visiting friends, relatives, etc.)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100845>	C100171	SF36 v1.0 Standard - Get Sick Little Easier Than Other|SF361-Get Sick Little Easier Than Other|SF361-Get Sick Little Easier Than Other|SF36111A	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) How TRUE or FALSE is the following statement for you - I seem to get sick a little easier than other people.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100846>	C100171	SF36 v1.0 Standard - I Am as Healthy as Anybody I Know|SF361-I Am as Healthy as Anybody I Know|SF361-I Am as Healthy as Anybody I Know|SF36111B	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) How TRUE or FALSE is the following statement for you - I am as healthy as anybody I know.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100847>	C100171	SF36 v1.0 Standard - I Expect My Health to Get Worse|SF361-I Expect My Health to Get Worse|SF361-I Expect My Health to Get Worse|SF36111C	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) How TRUE or FALSE is the following statement for you - I expect my health to get worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100848>	C100171	SF36 v1.0 Standard - My Health is Excellent|SF361-My Health is Excellent|SF361-My Health is Excellent|SF36111D	The Short Form 36 (SF-36) Health Survey Standard, US Version 1.0 (SF36 v1.0 Standard) How TRUE or FALSE is the following statement for you - my health is excellent			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v1.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100849>	C100124	SF-MPQ-2 - Throbbing Pain|SFMP2-Throbbing Pain|SFMP2-Throbbing Pain|SFMP201	Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Throbbing pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Code Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10084>	C61063	Cytarabine/Doxorubicin/Mercaptopurine|ARA-C/DOX/MP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100850>	C100124	SF-MPQ-2 - Shooting Pain|SFMP2-Shooting Pain|SFMP2-Shooting Pain|SFMP202	Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Shooting pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Code Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100851>	C100124	SF-MPQ-2 - Stabbing Pain|SFMP2-Stabbing Pain|SFMP2-Stabbing Pain|SFMP203	Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Stabbing pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Code Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100852>	C100124	SF-MPQ-2 - Sharp Pain|SFMP2-Sharp Pain|SFMP2-Sharp Pain|SFMP204	Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Sharp pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Code Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100853>	C100124	SF-MPQ-2 - Cramping Pain|SFMP2-Cramping Pain|SFMP2-Cramping Pain|SFMP205	Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Cramping pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Code Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100854>	C100124	SF-MPQ-2 - Gnawing Pain|SFMP2-Gnawing Pain|SFMP2-Gnawing Pain|SFMP206	Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Gnawing pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Code Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100855>	C100124	SF-MPQ-2 - Hot-burning Pain|SFMP2-Hot-burning Pain|SFMP2-Hot-burning Pain|SFMP207	Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Hot-burning pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Code Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100856>	C100124	SF-MPQ-2 - Aching Pain|SFMP2-Aching Pain|SFMP2-Aching Pain|SFMP208	Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Aching pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Code Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100857>	C100124	SF-MPQ-2 - Heavy Pain|SFMP2-Heavy Pain|SFMP2-Heavy Pain|SFMP209	Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Heavy pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Code Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100858>	C100124	SF-MPQ-2 - Tender|SFMP2-Tender|SFMP2-Tender|SFMP210	Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Tender.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Code Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100859>	C100124	SF-MPQ-2 - Splitting Pain|SFMP2-Splitting Pain|SFMP2-Splitting Pain|SFMP211	Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Splitting pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Code Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10085>	C61063	Altretamine/Cyclophosphamide/Doxorubicin|CTX/DOX/HMM|HAC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100860>	C100124	SF-MPQ-2 - Tiring-Exhausting|SFMP2-Tiring-Exhausting|SFMP2-Tiring-Exhausting|SFMP212	Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Tiring-exhausting.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Code Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100861>	C100124	SF-MPQ-2 - Sickening|SFMP2-Sickening|SFMP2-Sickening|SFMP213	Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Sickening.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Code Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100862>	C100124	SF-MPQ-2 - Fearful|SFMP2-Fearful|SFMP2-Fearful|SFMP214	Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Fearful.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Code Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100863>	C100124	SF-MPQ-2 - Punishing-Cruel|SFMP2-Punishing-Cruel|SFMP2-Punishing-Cruel|SFMP215	Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Punishing-cruel.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Code Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100864>	C100124	SF-MPQ-2 - Electric-Shock Pain|SFMP2-Electric-Shock Pain|SFMP2-Electric-Shock Pain|SFMP216	Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Electric-shock pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Code Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100865>	C100124	SF-MPQ-2 - Cold-Freezing Pain|SFMP2-Cold-Freezing Pain|SFMP2-Cold-Freezing Pain|SFMP217	Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Cold-freezing pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Code Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100866>	C100124	SF-MPQ-2 - Piercing|SFMP2-Piercing|SFMP2-Piercing|SFMP218	Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Piercing.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Code Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100867>	C100124	SF-MPQ-2 - Pain Caused by Light Touch|SFMP2-Pain Caused by Light Touch|SFMP2-Pain Caused by Light Touch|SFMP219	Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Pain caused by light touch.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Code Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100868>	C100124	SF-MPQ-2 - Itching|SFMP2-Itching|SFMP2-Itching|SFMP220	Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Itching.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Code Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100869>	C100124	SF-MPQ-2 - Numbness|SFMP2-Numbness|SFMP2-Numbness|SFMP222	Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Numbness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Code Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10086>	C61063	Cytarabine/Prednisone/Thioguanine/Vincristine|ARA-C/PRED/TG/VCR|ATOP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100870>	C100125	SOAPP-R - How Often Mood Swings|SOAPR1-How Often Mood Swings|SOAPR1-How Often Mood Swings|SOAPR101	Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often do you have mood swings?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOAPP-R Test Code Terminology|CDISC Questionnaire SOAPP-R Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100871>	C100125	SOAPP-R - Need Higher Doses of Medication|SOAPR1-Need Higher Doses of Medication|SOAPR1-Need Higher Doses of Medication|SOAPR102	Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have you felt a need for higher doses of medication to treat your pain?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOAPP-R Test Code Terminology|CDISC Questionnaire SOAPP-R Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100872>	C100125	SOAPP-R - Felt Impatient With Doctors|SOAPR1-Felt Impatient With Doctors|SOAPR1-Felt Impatient With Doctors|SOAPR103	Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have you felt impatient with your doctors?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOAPP-R Test Code Terminology|CDISC Questionnaire SOAPP-R Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100873>	C100125	SOAPP-R - Felt That Things Are Overwhelming|SOAPR1-Felt That Things Are Overwhelming|SOAPR1-Felt That Things Are Overwhelming|SOAPR104	Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have you felt that things are just too overwhelming that you can't handle them?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOAPP-R Test Code Terminology|CDISC Questionnaire SOAPP-R Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100874>	C100125	SOAPP-R - How Often Tension at Home|SOAPR1-How Often Tension at Home|SOAPR1-How Often Tension at Home|SOAPR105	Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often is there tension in the home?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOAPP-R Test Code Terminology|CDISC Questionnaire SOAPP-R Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100875>	C100125	SOAPP-R - How Often Counted Pain Pills|SOAPR1-How Often Counted Pain Pills|SOAPR1-How Often Counted Pain Pills|SOAPR106	Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have you counted pain pills to see how many are remaining?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOAPP-R Test Code Terminology|CDISC Questionnaire SOAPP-R Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100876>	C100125	SOAPP-R - Concerned People Will Judge You|SOAPR1-Concerned People Will Judge You|SOAPR1-Concerned People Will Judge You|SOAPR107	Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have you been concerned that people will judge you for taking pain medication?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOAPP-R Test Code Terminology|CDISC Questionnaire SOAPP-R Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100877>	C100125	SOAPP-R - How Often Feel Bored|SOAPR1-How Often Feel Bored|SOAPR1-How Often Feel Bored|SOAPR108	Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often do you feel bored?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOAPP-R Test Code Terminology|CDISC Questionnaire SOAPP-R Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100878>	C100125	SOAPP-R - How Often Taken More Pain Medication|SOAPR1-How Often Taken More Pain Med|SOAPR1-How Often Taken More Pain Med|SOAPR109	Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have you taken more pain medication than you were supposed to?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOAPP-R Test Code Terminology|CDISC Questionnaire SOAPP-R Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100879>	C100125	SOAPP-R - Worried About Being Left Alone|SOAPR1-Worried About Being Left Alone|SOAPR1-Worried About Being Left Alone|SOAPR110	Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have you worried about being left alone?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOAPP-R Test Code Terminology|CDISC Questionnaire SOAPP-R Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10087>	C61063	Dacarbazine/Dactinomycin/Vincristine|AVD|DACT/DTIC/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100880>	C100125	SOAPP-R - Felt Craving for Medication|SOAPR1-Felt Craving for Medication|SOAPR1-Felt Craving for Medication|SOAPR111	Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have you felt a craving for medication?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOAPP-R Test Code Terminology|CDISC Questionnaire SOAPP-R Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100881>	C100125	SOAPP-R - Others Expressed Concern Over Medication Use|SOAPR1-Expressed Concern Over Med Use|SOAPR1-Expressed Concern Over Med Use|SOAPR112	Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have others expressed concern over your use of medication?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOAPP-R Test Code Terminology|CDISC Questionnaire SOAPP-R Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100882>	C100125	SOAPP-R - How Often Friends Had Problem|SOAPR1-How Often Friends Had Problem|SOAPR1-How Often Friends Had Problem|SOAPR113	Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have any of your close friends had a problem with alcohol or drugs?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOAPP-R Test Code Terminology|CDISC Questionnaire SOAPP-R Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100883>	C100125	SOAPP-R - Others Told You Bad Temper|SOAPR1-Others Told You Bad Temper|SOAPR1-Others Told You Bad Temper|SOAPR114	Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have others told you that you had a bad temper?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOAPP-R Test Code Terminology|CDISC Questionnaire SOAPP-R Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100884>	C100125	SOAPP-R - Felt Consumed to Get Pain Medication|SOAPR1-Felt Consumed to Get Pain Med|SOAPR1-Felt Consumed to Get Pain Med|SOAPR115	Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have you felt consumed by the need to get pain medication?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOAPP-R Test Code Terminology|CDISC Questionnaire SOAPP-R Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100885>	C100125	SOAPP-R - Run Out of Pain Medication Early|SOAPR1-Run Out of Pain Med Early|SOAPR1-Run Out of Pain Med Early|SOAPR116	Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have you run out of pain medication early?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOAPP-R Test Code Terminology|CDISC Questionnaire SOAPP-R Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100886>	C100125	SOAPP-R - Others Kept You From what You Deserve|SOAPR1-Kept From What You Deserve|SOAPR1-Kept From What You Deserve|SOAPR117	Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have others kept you from getting what you deserve?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOAPP-R Test Code Terminology|CDISC Questionnaire SOAPP-R Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100887>	C100125	SOAPP-R - Legal Problems or Arrested|SOAPR1-Legal Problems or Arrested|SOAPR1-Legal Problems or Arrested|SOAPR118	Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often, in your lifetime, have you had legal problems or been arrested?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOAPP-R Test Code Terminology|CDISC Questionnaire SOAPP-R Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100888>	C100125	SOAPP-R - Attended AA or NA Meeting|SOAPR1-Attended AA or NA Meeting|SOAPR1-Attended AA or NA Meeting|SOAPR119	Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have you attended an AA or NA meeting?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOAPP-R Test Code Terminology|CDISC Questionnaire SOAPP-R Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100889>	C100125	SOAPP-R - Argument Where Someone Got Hurt|SOAPR1-Argument Someone Got Hurt|SOAPR1-Argument Someone Got Hurt|SOAPR120	Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have you been in an argument that was so out of control that someone got hurt?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOAPP-R Test Code Terminology|CDISC Questionnaire SOAPP-R Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10088>	C61063	Cytarabine/Zorubicin|ARA-C/RBZ			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100890>	C100125	SOAPP-R - How Often Sexually Abused|SOAPR1-How Often Sexually Abused|SOAPR1-How Often Sexually Abused|SOAPR121	Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have you been sexually abused?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOAPP-R Test Code Terminology|CDISC Questionnaire SOAPP-R Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100891>	C100125	SOAPP-R - Others Suggested Drug or Alcohol Problem|SOAPR1-Suggested Drug or Alcohol Problem|SOAPR1-Suggested Drug or Alcohol Problem|SOAPR122	Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have others suggested that you have a drug or alcohol problem?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOAPP-R Test Code Terminology|CDISC Questionnaire SOAPP-R Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100892>	C100125	SOAPP-R - How Often Borrowed Pain Medication|SOAPR1-How Often Borrowed Pain Meds|SOAPR1-How Often Borrowed Pain Meds|SOAPR123	Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have you had to borrow pain medications from your family or friends?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOAPP-R Test Code Terminology|CDISC Questionnaire SOAPP-R Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100893>	C100125	SOAPP-R - Treated for Alcohol or Drug Problem|SOAPR1-Treated for Alcohol or Drug Prob|SOAPR1-Treated for Alcohol or Drug Prob|SOAPR124	Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) How often have you been treated for an alcohol or drug problem?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOAPP-R Test Code Terminology|CDISC Questionnaire SOAPP-R Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100894>	C100125	SOAPP-R - Any Additional Information|SOAPR1-Any Additional Information|SOAPR1-Any Additional Information|SOAPR125	Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) Please include any additional information you wish about the above answers.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOAPP-R Test Code Terminology|CDISC Questionnaire SOAPP-R Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100895>	C100125	SOAPP-R - Score|SOAPR1-Score|SOAPR1-Score|SOAPR126	Screener and Opioid Assessment for Patients with Pain - Revised (SOAPP-R) Score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOAPP-R Test Code Terminology|CDISC Questionnaire SOAPP-R Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100896>	C13236	Prostatic Fluid|PROSTATIC FLUID	A slightly alkaline fluid produced by the prostate gland. It contributes 20-30% of the total volume of seminal fluid.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100897>	C100900	Thousand Copies per Milliliter|10*3.{copies}/mL|10*3.{copies}/mL|10*3.{copies}/ml|10*3.{copies}/ml|10^3 copies/mL|10^3.{copies}/mL|10^3.{copies}/mL|10^3.{copies}/ml|10^3.{copies}/ml	The unit of concentration expressed as the number of 10 to the third power copies in unit volume equal to one milliliter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100898>	C100900	Million Copies per Milliliter|10*6.{copies}/mL|10*6.{copies}/mL|10*6.{copies}/ml|10*6.{copies}/ml|10^6 copies/mL|10^6.{copies}/mL|10^6.{copies}/mL|10^6.{copies}/ml|10^6.{copies}/ml	The unit of concentration expressed as the number of 10 to the sixth power copies in unit volume equal to one milliliter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100899>	C48572	Diopter|DIOPTER|[diop]|[diop]|[diop]|[diop]|diopter|diopter	A unit of measurement of the optical power of a curved mirror or lens represented by the inverse of the focal length in meters.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology|UCUM Terminology
C10089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10089>	C61063	Cisplatin/Cyclophosphamide/Cytarabine/Hydroxyurea/Lomustine/Methylprednisolone/Procarbazine/Vincristine|ARA-C/CCNU/CDDP/CTX/HU/MePRDL/PCB/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1008>	C2170|C1557	Azaribine|1,2,4-Triazine-3,5(2H,4H)-dione, 2-Beta-D-ribofuranosyl-|2',3',4'-azauridine triacetate|2-(2,3,5-Tri-O-acetyl-beta-D-ribofuranosyl)-as-triazine-3,5(2H,4H)-dione|6-Azauridine Triacetate|6-Azauridine triacetate|AZARIBINE|Azauridine Triacetate|Azauridine triacetate|CB 304|SKI 28426|Triacetyl 6-azauridine|Triacetyl 6-azuridine|Triacetyl-6-azuridine|Triazure|Triazure	The triacetate salt of azauridine, a synthetic triazine nucleoside derivative possessing antineoplastic and anti-psoriatic activity. After metabolism to 6-azauridine-5-prime monophosphate, 6-Azauridine inhibits de novo pyrimidine biosynthesis and its 5-prime triphosphate metabolite gets incorporated into RNA, thereby preventing RNA synthesis.			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C100900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100900>	C67442	Copies per Milliliter|copies/mL|{copies}/mL|{copies}/mL|{copies}/ml|{copies}/ml	A unit of concentration expressed as a number of copies per unit volume equal to one milliliter.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100901>	C100126	UPDRS - Mentation, Behavior and Mood: Intellectual Impairment|UPD1-Mentation:Intellectual Impairment|UPD1-Mentation:Intellectual Impairment|UPD101	Unified Parkinson's Disease Rating Scale (UPDRS) Mentation, behavior and mood; intellectual impairment.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100902>	C100126	UPDRS - Mentation, Behavior and Mood: Thought Disorder|UPD1-Mentation:Thought Disorder|UPD1-Mentation:Thought Disorder|UPD102	Unified Parkinson's Disease Rating Scale (UPDRS) Mentation, behavior and mood; thought disorder.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100903>	C100126	UPDRS - Mentation, Behavior and Mood: Depression|UPD1-Mentation:Depression|UPD1-Mentation:Depression|UPD103	Unified Parkinson's Disease Rating Scale (UPDRS) Mentation, behavior and mood; depression.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100904>	C100126	UPDRS - Mentation, Behavior and Mood: Motivation/Initiative|UPD1-Mentation:Motivation/Initiative|UPD1-Mentation:Motivation/Initiative|UPD104	Unified Parkinson's Disease Rating Scale (UPDRS) Mentation, behavior and mood; motivation/initiative.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100905>	C100126	UPDRS - Activities of Daily Living: Speech|UPD1-Activities:Speech|UPD1-Activities:Speech|UPD105	Unified Parkinson's Disease Rating Scale (UPDRS) Activities of daily living (for both 'on' and 'off'); speech.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100906>	C100126	UPDRS - Activities of Daily Living: Salivation|UPD1-Activities:Salivation|UPD1-Activities:Salivation|UPD106	Unified Parkinson's Disease Rating Scale (UPDRS) Activities of daily living (for both 'on' and 'off'); salivation.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100907>	C100126	UPDRS - Activities of Daily Living: Swallowing|UPD1-Activities:Swallowing|UPD1-Activities:Swallowing|UPD107	Unified Parkinson's Disease Rating Scale (UPDRS) Activities of daily living (for both 'on' and 'off'); swallowing.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100908>	C100126	UPDRS - Activities of Daily Living: Handwriting|UPD1-Activities:Handwriting|UPD1-Activities:Handwriting|UPD108	Unified Parkinson's Disease Rating Scale (UPDRS) Activities of daily living (for both 'on' and 'off'); handwriting.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100909>	C100126	UPDRS - Activities of Daily Living: Cutting Food and Handling Utensils|UPD1-Activities:Cut Food/Handle Utensil|UPD1-Activities:Cut Food/Handle Utensil|UPD109	Unified Parkinson's Disease Rating Scale (UPDRS) Activities of daily living (for both 'on' and 'off'); cutting food and handling utensils.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10090>	C61063	Doxorubicin/Methotrexate/Vinblastine|AVM|DOX/MTX/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100910>	C100126	UPDRS - Activities of Daily Living: Dressing|UPD1-Activities:Dressing|UPD1-Activities:Dressing|UPD110	Unified Parkinson's Disease Rating Scale (UPDRS) Activities of daily living (for both 'on' and 'off'); dressing.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100911>	C100126	UPDRS - Activities of Daily Living: Hygiene|UPD1-Activities:Hygiene|UPD1-Activities:Hygiene|UPD111	Unified Parkinson's Disease Rating Scale (UPDRS) Activities of daily living (for both 'on' and 'off'); hygiene.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100912>	C100126	UPDRS - Activities of Daily Living: Turning in Bed and Adjusting Bed Clothes|UPD1-Activities:Turn Bed/Adj Clothes|UPD1-Activities:Turn Bed/Adj Clothes|UPD112	Unified Parkinson's Disease Rating Scale (UPDRS) Activities of daily living (for both 'on' and 'off'); turning in bed and adjusting bed clothes.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100913>	C100126	UPDRS - Activities of Daily Living: Falling|UPD1-Activities:Falling|UPD1-Activities:Falling|UPD113	Unified Parkinson's Disease Rating Scale (UPDRS) Activities of daily living (for both 'on' and 'off'); falling (unrelated to freezing).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100914>	C100126	UPDRS - Activities of Daily Living: Freezing When Walking|UPD1-Activities:Freezing When Walking|UPD1-Activities:Freezing When Walking|UPD114	Unified Parkinson's Disease Rating Scale (UPDRS) Activities of daily living (for both 'on' and 'off'); freezing when walking.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100915>	C100126	UPDRS - Activities of Daily Living: Walking|UPD1-Activities:Walking|UPD1-Activities:Walking|UPD115	Unified Parkinson's Disease Rating Scale (UPDRS) Activities of daily living (for both 'on' and 'off'); walking.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100916>	C100126	UPDRS - Activities of Daily Living: Tremor|UPD1-Activities:Tremor|UPD1-Activities:Tremor|UPD116	Unified Parkinson's Disease Rating Scale (UPDRS) Activities of daily living (for both 'on' and 'off'); tremor (Symptomatic complaint of tremor in any part of body.).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100917>	C100126	UPDRS - Activities of Daily Living: Sensory Complaints Related to Parkinsonism|UPD1-Activities:Sensory Complaints|UPD1-Activities:Sensory Complaints|UPD117	Unified Parkinson's Disease Rating Scale (UPDRS) Activities of daily living (for both 'on' and 'off'); sensory complaints related to Parkinsonism.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100918>	C100126	UPDRS - Motor Examination: Speech|UPD1-Motor:Speech|UPD1-Motor:Speech|UPD118	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination; speech.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100919>	C100126	UPDRS - Motor Examination: Facial Expression|UPD1-Motor:Facial Expression|UPD1-Motor:Facial Expression|UPD119	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination; facial expression.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10091>	C61063	Altretamine/Doxorubicin/Melphalan|DOX/HMM/L-PAM|HAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100920>	C100126	UPDRS - Motor Examination: Tremor at Rest	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination; tremor at rest (head, upper and lower extremities).			Intellectual Product	
C100921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100921>	C100126	UPDRS - Motor Examination: Action or Postural Tremor of Hand	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination; action or postural tremor of hands.			Intellectual Product	
C100922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100922>	C100126	UPDRS - Motor Examination: Rigidity	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination; rigidity (Judged on passive movement of major joints with patient relaxed in sitting position. Cogwheeling to be ignored.).			Intellectual Product	
C100923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100923>	C100126	UPDRS - Motor Examination: Finger Taps	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination; finger taps (Patient taps thumb with index finger in rapid succession.).			Intellectual Product	
C100924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100924>	C100126	UPDRS - Motor Examination: Hand Movements	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination; hand movements (Patient opens and closes hands in rapid succession.).			Intellectual Product	
C100925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100925>	C100126	UPDRS - Motor Examination: Rapid Alternating Movements of Hands	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination; rapid alternating movements of hands (Pronation-supination movements of hands, vertically and horizontally, with as large an amplitude as possible, both hands simultaneously.).			Intellectual Product	
C100926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100926>	C100126	UPDRS - Motor Examination: Leg Agility	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination; leg agility (Patient taps heel on the ground in rapid succession picking up entire leg. Amplitude should be at least 3 inches.).			Intellectual Product	
C100927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100927>	C100126	UPDRS - Motor Examination: Arising from Chair|UPD1-Motor:Arising from Chair|UPD1-Motor:Arising from Chair|UPD127	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination; arising from chair (Patient attempts to rise from a straightbacked chair, with arms folded across chest.).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100928>	C100126	UPDRS - Motor Examination: Posture|UPD1-Motor:Posture|UPD1-Motor:Posture|UPD128	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination; posture.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100929>	C100126	UPDRS - Motor Examination: Gait|UPD1-Motor:Gait|UPD1-Motor:Gait|UPD129	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination; gait.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10092>	C61063	Altretamine/Doxorubicin/Methotrexate|DOX/HMM/MTX|HAM-II			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100930>	C100126	UPDRS - Motor Examination: Postural Stability|UPD1-Motor:Postural Stability|UPD1-Motor:Postural Stability|UPD130	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination; postural stability (Response to sudden, strong posterior displacement produced by pull on shoulders while patient erect with eyes open and feet slightly apart. Patient is prepared.).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100931>	C100126	UPDRS - Motor Examination: Body Bradykinesia and Hypokinesia|UPD1-Motor:Bradykinesia and Hypokinesia|UPD1-Motor:Bradykinesia and Hypokinesia|UPD131	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination; body bradykinesia and hypokinesia (Combining slowness, hesitancy, decreased arm swing, small amplitude, and poverty of movement in general.).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100932>	C100126	UPDRS - Complications of Therapy: Dyskinesias - Duration|UPD1-Complications:Dyskinesias Duration|UPD1-Complications:Dyskinesias Duration|UPD132	Unified Parkinson's Disease Rating Scale (UPDRS) Complications of therapy (in the past week); dyskinesias, duration; what proportion of the waking day are dyskinesias present? (Historical information.).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100933>	C100126	UPDRS - Complications of Therapy: Dyskinesias - Disability|UPD1-Complications:Dyskinesias Disable|UPD1-Complications:Dyskinesias Disable|UPD133	Unified Parkinson's Disease Rating Scale (UPDRS) Complications of therapy (in the past week); dyskinesias, disability; how disabling are the dyskinesias? (Historical information; may be modified by office examination.).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100934>	C100126	UPDRS - Complications of Therapy: Dyskinesias - Painful Dyskinesias|UPD1-Complications:Dyskinesias Painful|UPD1-Complications:Dyskinesias Painful|UPD134	Unified Parkinson's Disease Rating Scale (UPDRS) Complications of therapy (in the past week); dyskinesias, painful dyskinesias; How painful are the dyskinesias?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100935>	C100126	UPDRS - Complications of Therapy: Dyskinesias - Presence of Early Morning Dystonia|UPD1-Complications:Dyskinesias Dystonia|UPD1-Complications:Dyskinesias Dystonia|UPD135	Unified Parkinson's Disease Rating Scale (UPDRS) Complications of therapy (in the past week); dyskinesias, presence of early morning dystonia (Historical information.).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100936>	C100126	UPDRS - Complications of Therapy: Clinical Fluctuations - Off Periods Predictable|UPD1-Complications:Fluct Predictable|UPD1-Complications:Fluct Predictable|UPD136	Unified Parkinson's Disease Rating Scale (UPDRS) Complications of therapy (in the past week); clinical fluctuations, are 'off' periods predictable?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100937>	C100126	UPDRS - Complications of Therapy: Clinical Fluctuations - Off Periods Unpredictable|UPD1-Complications:Fluct Unpredictable|UPD1-Complications:Fluct Unpredictable|UPD137	Unified Parkinson's Disease Rating Scale (UPDRS) Complications of therapy (in the past week); clinical fluctuations, are 'off' periods unpredictable?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100938>	C100126	UPDRS - Complications of Therapy: Clinical Fluctuations - Off Periods Sudden|UPD1-Complications:Fluct Suddenly|UPD1-Complications:Fluct Suddenly|UPD138	Unified Parkinson's Disease Rating Scale (UPDRS) Complications of therapy (in the past week); clinical fluctuations, do 'off' periods come on suddenly, within a few seconds?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100939>	C100126	UPDRS - Complications of Therapy: Clinical Fluctuations - Average Off Periods Per Day|UPD1-Complications:Fluct Average|UPD1-Complications:Fluct Average|UPD139	Unified Parkinson's Disease Rating Scale (UPDRS) Complications of therapy (in the past week); clinical fluctuations, what proportion of the waking day is the patient 'off' on average?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10093>	C61063	Bleomycin/Cisplatin/Dacarbazine/Vinblastine|BLEO/CDDP/DTIC/VBL|BVDD			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100940>	C100126	UPDRS - Complications of Therapy: Other Complications - Anorexia, Nausea, or Vomiting|UPD1-Complications:Anorex Nausea Vomit|UPD1-Complications:Anorex Nausea Vomit|UPD140	Unified Parkinson's Disease Rating Scale (UPDRS) Complications of therapy (in the past week); other complications, does the patient have anorexia, nausea, or vomiting?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100941>	C100126	UPDRS - Complications of Therapy: Other Complications - Sleep Disturbances|UPD1-Complications:Insomnia Hypersomnol|UPD1-Complications:Insomnia Hypersomnol|UPD141	Unified Parkinson's Disease Rating Scale (UPDRS) Complications of therapy (in the past week); other complications, any sleep disturbances, such as insomnia or hypersomnolence?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100942>	C100126	UPDRS - Complications of Therapy: Other Complications - Symptomatic Orthostasis|UPD1-Complications:Symptom Orthostasis|UPD1-Complications:Symptom Orthostasis|UPD142	Unified Parkinson's Disease Rating Scale (UPDRS) Complications of therapy (in the past week); other complications, does the patient have symptomatic orthostasis? (Record the patient's blood pressure, height and weight on the scoring form).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100943>	C100126	UPDRS - Modified Hoehn and Yahr Staging|UPD1-Modified Hoehn and Yahr Staging|UPD1-Modified Hoehn and Yahr Staging|UPD143	Unified Parkinson's Disease Rating Scale (UPDRS) Modified Hoehn and Yahr Staging.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100944>	C100126	UPDRS - Schwab and England Activities of Daily Living Scale	Unified Parkinson's Disease Rating Scale (UPDRS) Schwab and England Activities of Daily Living Scale.			Intellectual Product	
C100945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100945>	C19332	Pulse Pressure|PULSEPR|PULSEPR|Pulse pressure	The force of a heart contraction measured by the difference between the diastolic and systolic blood pressure measurements.			Clinical Attribute	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|Appendix 6: Symptoms and Signs Terminology|CDISC SDTM Terminology|CDISC SDTM Vital Sign Test Code Terminology|CDISC SDTM Vital Sign Test Name Terminology|CDISC SEND Cardiovascular Test Code Terminology|CDISC SEND Cardiovascular Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Physical Examination Terminology
C100946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100946>	C172255	Forearm Circumference|FARMCIR	A circumferential measurement of the largest part of the forearm.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Vital Sign Test Code Terminology|CDISC SDTM Vital Sign Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100947>	C172255	Hip Circumference|HIPCIR	A circumferential measurement of the largest part of the hip.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Vital Sign Test Code Terminology|CDISC SDTM Vital Sign Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100948>	C172255	Waist Circumference|WSTCIR	A circumferential measurement of the waist, which may be classified as the area immediately below the lowest rib, at the narrowest part of the torso, midpoint between the lowest rib and the iliac crest, or immediately above the iliac crest.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Vital Sign Test Code Terminology|CDISC SDTM Vital Sign Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C100949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100949>	C100172	WPAI:SHP v2.0 - Currently Employed|WPAI01-Currently Employed|WPAI01-Currently Employed|WPAI0101	Work Productivity and Activity Impairment Questionnaire-Specific Health Problem v2.0 (WPAI:SHP) Are you currently employed (working for pay)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WPAI:SHP v2.0 Test Code Terminology|CDISC Questionnaire WPAI:SHP v2.0 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10094>	C61063	Bleomycin/Prednisone/Vincristine|BLEO/PRED/VCR|BOP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100950>	C100172	WPAI:SHP v2.0 - Missed Work Hours Due to Problem|WPAI01-Missed Work Hours Due to Problem|WPAI01-Missed Work Hours Due to Problem|WPAI0102	Work Productivity and Activity Impairment Questionnaire-Specific Health Problem v2.0 (WPAI:SHP) During the past seven days, how many hours did you miss from work because of problems associated with your problem?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WPAI:SHP v2.0 Test Code Terminology|CDISC Questionnaire WPAI:SHP v2.0 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100951>	C100172	WPAI:SHP v2.0 - Missed Work Hours Due to Other Reasons|WPAI01-Missed Work Hours Due to Other|WPAI01-Missed Work Hours Due to Other|WPAI0103	Work Productivity and Activity Impairment Questionnaire-Specific Health Problem v2.0 (WPAI:SHP) During the past seven days, how many hours did you miss from work because of any other reason, such as vacation, holidays, time off to participate in this study?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WPAI:SHP v2.0 Test Code Terminology|CDISC Questionnaire WPAI:SHP v2.0 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100952>	C100172	WPAI:SHP v2.0 - Hours Actually Worked|WPAI01-Hours Actually Worked|WPAI01-Hours Actually Worked|WPAI0104	Work Productivity and Activity Impairment Questionnaire-Specific Health Problem v2.0 (WPAI:SHP) During the past seven days, how many hours did you actually work?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WPAI:SHP v2.0 Test Code Terminology|CDISC Questionnaire WPAI:SHP v2.0 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100953>	C100172	WPAI:SHP v2.0 - Problem Affects Productivity|WPAI01-Problem Affect Productivity|WPAI01-Problem Affect Productivity|WPAI0105	Work Productivity and Activity Impairment Questionnaire-Specific Health Problem v2.0 (WPAI:SHP) During the past seven days, how much did your problem affect your productivity while you were working?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WPAI:SHP v2.0 Test Code Terminology|CDISC Questionnaire WPAI:SHP v2.0 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100954>	C100172	WPAI:SHP v2.0 - Problem Affects Regular Daily Activity|WPAI01-Problem Affect Reg Daily Activity|WPAI01-Problem Affect Reg Daily Activity|WPAI0106	Work Productivity and Activity Impairment Questionnaire-Specific Health Problem v2.0 (WPAI:SHP) During the past seven days, how much did your problem affect your ability to do your regular daily activities, other than work at a job?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WPAI:SHP v2.0 Test Code Terminology|CDISC Questionnaire WPAI:SHP v2.0 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100955>	C100111	CGI - Severity of Illness	Clinical Global Impression (CGI) Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?			Intellectual Product	
C100956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100956>	C100111	CGI - Global Improvement	Clinical Global Impression (CGI) Rate total improvement whether or not, in your judgment, it is due entirely to drug treatment. Compared to his condition at admission to the project, how much has he changed?			Intellectual Product	
C100957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100957>	C100111	CGI - Efficacy Index	Clinical Global Impression (CGI) Rate this item on the basis of drug effect only. Select the terms which best describe the degrees of therapeutic effect and side effects and record the number in the box where the two items intersect.			Intellectual Product	
C100958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100958>	C100112	COMM - Trouble Thinking Clearly or Memory Problems|COMM1-Trouble Thinking Clearly/Memory|COMM1-Trouble Thinking Clearly/Memory|COMM101	Current Opioid Misuse Measure (COMM) In the past 30 days, how often have you had trouble with thinking clearly or had memory problems?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COMM Test Code Terminology|CDISC Questionnaire COMM Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100959>	C100112	COMM - Complaints Not Completing Tasks|COMM1-Complaints Not Completing Tasks|COMM1-Complaints Not Completing Tasks|COMM102	Current Opioid Misuse Measure (COMM) In the past 30 days, how often do people complain that you are not completing necessary tasks? (i.e., doing things that need to be done, such as going to class, work or appointments)			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COMM Test Code Terminology|CDISC Questionnaire COMM Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10095>	C61063	Altretamine/Cisplatin|CDDP/HMM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100960>	C100112	COMM - Other Sources for Pain Medication|COMM1-Other Sources For Pain Medication|COMM1-Other Sources For Pain Medication|COMM103	Current Opioid Misuse Measure (COMM) In the past 30 days, how often have you had to go to someone other than your prescribing physician to get sufficient pain relief from medications? (i.e., another doctor, the Emergency Room, friends, street source)			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COMM Test Code Terminology|CDISC Questionnaire COMM Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100961>	C100112	COMM - Taken Medications Other Than Prescribed|COMM1-Taken Meds Other Than Prescribed|COMM1-Taken Meds Other Than Prescribed|COMM104	Current Opioid Misuse Measure (COMM) In the past 30 days, how often have you taken your medications differently from how they are prescribed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COMM Test Code Terminology|CDISC Questionnaire COMM Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100962>	C100112	COMM - Seriously Thought of Hurting Self|COMM1-Seriously Thought of Hurting Self|COMM1-Seriously Thought of Hurting Self|COMM105	Current Opioid Misuse Measure (COMM) In the past 30 days, how often have you seriously thought about hurting yourself?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COMM Test Code Terminology|CDISC Questionnaire COMM Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100963>	C100112	COMM - Time Spent Thinking About Opioids|COMM1-Time Spent Thinking About Opioids|COMM1-Time Spent Thinking About Opioids|COMM106	Current Opioid Misuse Measure (COMM) In the past 30 days, how much of your time was spent thinking about opioid medications (having enough, taking them, dosing schedule, etc.)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COMM Test Code Terminology|CDISC Questionnaire COMM Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100964>	C100112	COMM - Been in an Argument|COMM1-Been in an Argument|COMM1-Been in an Argument|COMM107	Current Opioid Misuse Measure (COMM) In the past 30 days, how often have you been in an argument?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COMM Test Code Terminology|CDISC Questionnaire COMM Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100965>	C100112	COMM - Trouble Controlling Anger|COMM1-Trouble Controlling Anger|COMM1-Trouble Controlling Anger|COMM108	Current Opioid Misuse Measure (COMM) In the past 30 days, how often have you had trouble controlling your anger (e.g., road rage, screaming, etc.)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COMM Test Code Terminology|CDISC Questionnaire COMM Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100966>	C100112	COMM - Take Medications Belonging to Others|COMM1-Take Meds Belonging to Others|COMM1-Take Meds Belonging to Others|COMM109	Current Opioid Misuse Measure (COMM) In the past 30 days, how often have you needed to take pain medications belonging to someone else?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COMM Test Code Terminology|CDISC Questionnaire COMM Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100967>	C100112	COMM - Worry About Handling Medications|COMM1-Worry About Handling Meds|COMM1-Worry About Handling Meds|COMM110	Current Opioid Misuse Measure (COMM) In the past 30 days, how often have you been worried about how you're handling your medications?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COMM Test Code Terminology|CDISC Questionnaire COMM Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100968>	C100112	COMM - Others Worry About Your Medications|COMM1-Others Worry About Your Meds|COMM1-Others Worry About Your Meds|COMM111	Current Opioid Misuse Measure (COMM) In the past 30 days, how often have others been worried about how you're handling your medications?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COMM Test Code Terminology|CDISC Questionnaire COMM Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100969>	C100112	COMM - Emergency Phone Call or Clinic Visit|COMM1-Emergency Phone Call/Clinic Visit|COMM1-Emergency Phone Call/Clinic Visit|COMM112	Current Opioid Misuse Measure (COMM) In the past 30 days, how often have you had to make an emergency phone call or show up at the clinic without an appointment?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COMM Test Code Terminology|CDISC Questionnaire COMM Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10096>	C61063	Altretamine/Doxorubicin/Fluorouracil/Mitomycin|DOX/5-FU/HMM/MITO|HEXA-FAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100970>	C100112	COMM - Gotten Angry With People|COMM1-Gotten Angry With People|COMM1-Gotten Angry With People|COMM113	Current Opioid Misuse Measure (COMM) In the past 30 days, how often have you gotten angry with people?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COMM Test Code Terminology|CDISC Questionnaire COMM Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100971>	C100112	COMM - Take More Medication Than Prescribed|COMM1-Take More Meds Than Prescribed|COMM1-Take More Meds Than Prescribed|COMM114	Current Opioid Misuse Measure (COMM) In the past 30 days, how often have you had to take more of your medication than prescribed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COMM Test Code Terminology|CDISC Questionnaire COMM Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100972>	C100112	COMM - Borrowed Medication From Others|COMM1-Borrowed Meds From Others|COMM1-Borrowed Meds From Others|COMM115	Current Opioid Misuse Measure (COMM) In the past 30 days, how often have you borrowed pain medication from someone else?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COMM Test Code Terminology|CDISC Questionnaire COMM Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100973>	C100112	COMM - Used Pain Medicine For Other Symptoms|COMM1-Used Pain Meds For Other Symptoms|COMM1-Used Pain Meds For Other Symptoms|COMM116	Current Opioid Misuse Measure (COMM) In the past 30 days, how often have you used your pain medicine for symptoms other than for pain (e.g., to help you sleep, improve your mood, or relieve stress)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COMM Test Code Terminology|CDISC Questionnaire COMM Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100974>	C100112	COMM - Visit Emergency Room|COMM1-Visit Emergency Room|COMM1-Visit Emergency Room|COMM117	Current Opioid Misuse Measure (COMM) In the past 30 days, how often have you had to visit the Emergency Room?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COMM Test Code Terminology|CDISC Questionnaire COMM Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100975>	C100112	COMM - Score|COMM1-Score|COMM1-Score|COMM118	Current Opioid Misuse Measure (COMM) Score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COMM Test Code Terminology|CDISC Questionnaire COMM Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100976>	C100113	C-SSRS Baseline - Wish to be Dead or go to Sleep and not Wake Up|CSS01-Wish to be Dead|CSS01-Wish to be Dead|CSS0101	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Have you wished you were dead or wished you could go to sleep and not wake up?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100977>	C100113	C-SSRS Baseline - Description of Wish to be Dead|CSS01-Wish to be Dead, Describe|CSS01-Wish to be Dead, Describe|CSS0101A	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Description of wishing to be dead.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100978>	C100113	C-SSRS Baseline - Non-Specific Suicidal Thought|CSS01-Non-Specific Suicidal Thought|CSS01-Non-Specific Suicidal Thought|CSS0102	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Have you actually had any thoughts of killing yourself?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100979>	C100113	C-SSRS Baseline - Description of Non-Specific Suicide Thought|CSS01-Non-Specific Suicid Thought, Descr|CSS01-Non-Specific Suicid Thought, Descr|CSS0102A	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Description of non-specific active suicidal thoughts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10097>	C61063	Carmustine/Cisplatin/Cyclophosphamide/Cytarabine/Hydroxyurea/Methylprednisolone/Procarbazine/Vincristine|ARA-C/BCNU/CDDP/CTX/HU/MePRDL/PCB/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100980>	C100113	C-SSRS Baseline - Suicidal Ideation-No Intent|CSS01-Suicidal Ideation-No Intent|CSS01-Suicidal Ideation-No Intent|CSS0103	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Have you been thinking about how you might do this?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100981>	C100113	C-SSRS Baseline - Description of Suicidal Ideation-No Intent|CSS01-Suicidal Ideation-No Intent, Descr|CSS01-Suicidal Ideation-No Intent, Descr|CSS0103A	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Description of active suicidal ideation with any methods (not plan) without intent to act.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100982>	C100113	C-SSRS Baseline - Ideation With Plan/Intent|CSS01-Ideation With Plan/Intent|CSS01-Ideation With Plan/Intent|CSS0105	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100983>	C100113	C-SSRS Baseline - Description of Ideation With Plan and Intent|CSS01-Ideation With Plan/Intent, Descr|CSS01-Ideation With Plan/Intent, Descr|CSS0105A	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Description of active suicidal ideation with specific plan and intent.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100984>	C100113	C-SSRS Baseline - Most Severe Ideation|CSS01-Most Severe Ideation|CSS01-Most Severe Ideation|CSS0106	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Most severe ideation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100985>	C100113	C-SSRS Baseline - Describe Most Severe Ideation|CSS01-Most Severe Ideation, Description|CSS01-Most Severe Ideation, Description|CSS0106A	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Description of most severe ideation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100986>	C100113	C-SSRS Baseline - Frequency of Most Severe Ideation|CSS01-Most Severe Ideation, Frequency|CSS01-Most Severe Ideation, Frequency|CSS0107	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) How many times have you had these thoughts?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100987>	C100113	C-SSRS Baseline - Duration of Most Severe Ideation|CSS01-Most Severe Ideation, Duration|CSS01-Most Severe Ideation, Duration|CSS0108	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) When you have these thoughts, how long do they last?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100988>	C100113	C-SSRS Baseline - Control over Most Severe Ideation|CSS01-Most Severe Ideation, Control|CSS01-Most Severe Ideation, Control|CSS0109	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Could/can you stop thinking about killing yourself or wanting to die if you want to?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100989>	C100113	C-SSRS Baseline - Deterrents to Most Severe Ideation|CSS01-Most Severe Ideation, Deterrents|CSS01-Most Severe Ideation, Deterrents|CSS0110	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Are there things - anyone or anything (e.g., family, religion, pain of death) - that stopped you from wanting to die or acting on thoughts of committing suicide?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10098>	C61063	Amsacrine/Decitabine|AMSA/5-AZA-dCyd|AMSA/DAC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C100990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100990>	C100113	C-SSRS Baseline - Reasons for Most Severe Ideation|CSS01-Most Severe Ideation, Reasons|CSS01-Most Severe Ideation, Reasons|CSS0111	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) What sort of reasons did you have for thinking about wanting to die or killing yourself? Was it to end the pain or stop the way you were feeling (in other words you couldn't go on living with this pain or how you were feeling) or was it to get attention, revenge or a reaction from others? Or both?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100991>	C100113	C-SSRS Baseline - Actual Suicide Attempt|CSS01-Actual Attempt|CSS01-Actual Attempt|CSS0112	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Have you made a suicide attempt? Have you done anything to harm yourself? Have you done anything dangerous where you could have died?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100992>	C100113	C-SSRS Baseline - Number of Actual Suicide Attempts|CSS01-Number of Actual Attempts|CSS01-Number of Actual Attempts|CSS0113	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Total number of actual attempts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100993>	C100113	C-SSRS Baseline - Description of Actual Suicide Attempts|CSS01-Actual Attempt, Describe|CSS01-Actual Attempt, Describe|CSS0113A	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Description of actual attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100994>	C100113	C-SSRS Baseline - Non-suicidal Self-injurious Behavior|CSS01-Non-suicidal Self-injurious Behav|CSS01-Non-suicidal Self-injurious Behav|CSS0114	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Has the subject engaged in non-suicidal self-injurious behavior.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100995>	C100113	C-SSRS Baseline - Interrupted Suicide Attempt|CSS01-Interrupted Attempt|CSS01-Interrupted Attempt|CSS0115	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Has there been a time when you started to do something to try to end your life but someone or something stopped you before you actually did anything?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100996>	C100113	C-SSRS Baseline - Number of Interrupted Suicide Attempts|CSS01-Number of Interrupted Attempts|CSS01-Number of Interrupted Attempts|CSS0116	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Total number of interrupted attempts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100997>	C100113	C-SSRS Baseline - Description of Interrupted Suicide Attempt|CSS01-Interrupted Attempt, Describe|CSS01-Interrupted Attempt, Describe|CSS0116A	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Description of interrupted attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100998>	C100113	C-SSRS Baseline - Aborted Suicide Attempt|CSS01-Aborted Attempt|CSS01-Aborted Attempt|CSS0117	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Has there been a time when you started to do something to try to end your life but you stopped yourself before you actually did anything?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C100999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C100999>	C100113	C-SSRS Baseline - Number of Aborted Suicide Attempts|CSS01-Number of Aborted Attempts|CSS01-Number of Aborted Attempts|CSS0118	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Total number of aborted attempts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10099>	C61063	Decitabine/Idarubicin|5-AZA-dCyd/IDA|DAC/IDA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1009>	C292	Ethyleneimine|AZIRIDINE|Aminoethylene|Azacyclopropane|Azirane|Aziridine|Dimethyleneimine|Dimethylenimine|Ethylenimine|Ethylimine	A monofunctional alkylating agent with potential antineoplastic activity.  Reacting with DNA mainly at guanine and adenine residues, ethylenimine alkylates DNA, thereby producing DNA interstrand crosslinks and DNA breaks, and interfering with DNA replication and cell division. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C101000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101000>	C100113	C-SSRS Baseline - Description of Aborted Suicide Attempt|CSS01-Aborted Attempt, Describe|CSS01-Aborted Attempt, Describe|CSS0118A	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Description of aborted attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101001>	C100113	C-SSRS Baseline - Preparatory Acts or Behaviors Toward Suicide Attempt|CSS01-Preparatory Acts/Behavior|CSS01-Preparatory Acts/Behavior|CSS0119	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Have you taken any steps toward making a suicide attempt or preparing to kill yourself (such as collecting pills, getting a gun, giving valuables away or writing a suicide note)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101002>	C100113	C-SSRS Baseline - Description of Preparatory Acts or Behaviors Toward Suicide Attempt|CSS01-Preparatory Acts/Behavior, Descr|CSS01-Preparatory Acts/Behavior, Descr|CSS0119A	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Description of preparatory acts or behaviors.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101003>	C100113	C-SSRS Baseline - Suicidal Behavior|CSS01-Suicidal Behavior|CSS01-Suicidal Behavior|CSS0120	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Suicidal behavior was present during the assessment period?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101004>	C100113	C-SSRS Baseline - Most Recent Suicide Attempt Date|CSS01-Most Recent Attempt Date|CSS01-Most Recent Attempt Date|CSS0121A	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Most recent actual attempt date.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101005>	C100113	C-SSRS Baseline - Most Recent Suicide Attempt Damage|CSS01-Most Recent Attempt Damage|CSS01-Most Recent Attempt Damage|CSS0121B	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Most recent actual attempt lethality/medical damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101006>	C100113	C-SSRS Baseline - Most Recent Suicide Attempt Potential|CSS01-Most Recent Attempt Potential|CSS01-Most Recent Attempt Potential|CSS0121C	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Most recent actual attempt potential lethality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101007>	C100113	C-SSRS Baseline - Most Lethal Suicide Attempt Date|CSS01-Most Lethal Attempt Date|CSS01-Most Lethal Attempt Date|CSS0122A	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Most lethal actual attempt date.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101008>	C100113	C-SSRS Baseline - Most Lethal Suicide Attempt Damage|CSS01-Most Lethal Attempt Damage|CSS01-Most Lethal Attempt Damage|CSS0122B	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Most lethal actual attempt lethality/medical damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101009>	C100113	C-SSRS Baseline - Most Lethal Suicide Attempt Potential|CSS01-Most Lethal Attempt Potential|CSS01-Most Lethal Attempt Potential|CSS0122C	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Most lethal actual attempt potential lethality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10100>	C63358	CMFT Regimen|CMFT|CMFT|CMFT|CTX/5-FU/MTX/TMX|Cyclophosphamide-Methotrexate-Fluorouracil-Tamoxifen|Cyclophosphamide/Fluorouracil/Methotrexate/Tamoxifen|Cyclophosphamide/Methotrexate/Fluorouracil/Tamoxifen	A regimen consisting of cyclophosphamide, methotrexate, fluorouracil, and tamoxifen that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C101010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101010>	C100113	C-SSRS Baseline - First Suicide Attempt Date|CSS01-First Attempt Date|CSS01-First Attempt Date|CSS0123A	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Initial/first actual attempt date.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101011>	C100113	C-SSRS Baseline - First Suicide Attempt Damage|CSS01-First Attempt Damage|CSS01-First Attempt Damage|CSS0123B	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Initial/first actual attempt lethality/medical damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101012>	C100113	C-SSRS Baseline - First Suicide Attempt Potential|CSS01-First Attempt Potential|CSS01-First Attempt Potential|CSS0123C	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Initial/first actual attempt potential lethality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101013>	C100115	FPSR - How Much Do You Hurt|FPSR1-How Much Do You Hurt|FPSR1-How Much Do You Hurt|FPSR101	Faces Pain Scale Revised (FPSR) Point to the face that shows how much you hurt (right now).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FPSR Test Code Terminology|CDISC Questionnaire FPSR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101014>	C100113	C-SSRS Baseline - Ideation With Intent, No Plan|CSS01-Ideation With Intent, No Plan|CSS01-Ideation With Intent, No Plan|CSS0104	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Have you have these thoughts and had some intention of acting on them?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101015>	C100113	C-SSRS Baseline - Description of Ideation With Intent, No Plan|CSS01-Ideation With Intent No Plan Descr|CSS01-Ideation With Intent No Plan Descr|CSS0104A	Columbia-Suicidality Severity Rating Scale Baseline (C-SSRS Baseline) Description of active suicidal ideation with some intent to act, without specific plan.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101016>	C82037	Carbohydrate-Deficient Transferrin Measurement|CDT|Carbohydrate-Deficient Transferrin|Carbohydrate-Deficient Transferrin	The determination of the amount of transferrin with a reduced number of carbohydrate moieties present in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C101017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101017>	C49237	3,4-Dihydroxyphenylglycol Measurement|3,4-Dihydroxyphenylglycol|3,4-Dihydroxyphenylglycol|3.4 Dihydroxyphenylglycol|DHPG	The determination of the amount of 3,4-Dihydroxyphenylglycol present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C101018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101018>	C100117	MDS-UPDRS - Get Out of Bed, Car, or Deep Chair|UPD2-Get Out of Bed/Car/Deep Chair|UPD2-Get Out of Bed/Car/Deep Chair|UPD2211	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Over the past week, have you usually had trouble getting out of bed, a car seat, or a deep chair?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101019>	C100119	MNSI - Right Foot Dry Skin, Callus|MNSI1-Right Foot Dry Skin, Callus|MNSI1-Right Foot Dry Skin, Callus|MNSI119	Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; appearance of right foot - dry skin, callus.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10101>	C61063	Lomustine/Methotrexate/Vincristine|CCNU/MTX/VCR|CcOM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101020>	C100119	MNSI - Left Foot Dry Skin, Callus|MNSI1-Left Foot Dry Skin, Callus|MNSI1-Left Foot Dry Skin, Callus|MNSI125	Michigan Neuropathy Screening Instrument (MNSI) Physical assessment; appearance of left foot - dry skin, callus.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MNSI Test Code Terminology|CDISC Questionnaire MNSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101021>	C100124	SF-MPQ-2 - Tingling or 'Pins and Needles'|SFMP2-Tingling or 'Pins and Needles'|SFMP2-Tingling or 'Pins and Needles'|SFMP221	Short-Form McGill Pain Questionnaire-2 (Short Form MPQ) Tingling or 'pins and needles'.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Code Terminology|CDISC Questionnaire Short-Form MPQ-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101022>	C27222	Cerebral Arterial Aneurysm|Aneurysm of Cerebral Artery|Cerebral Artery Aneurysm	A balloon type pouch or bulge in the wall of a cerebral artery.			Finding	Neonatal Research Network Terminology|NICHD Terminology
C101023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101023>	C27222	Cerebral Venous Aneurysm|Aneurysm of Cerebral Vein|Cerebral Vein Aneurysm	A balloon type pouch or bulge in the wall of a cerebral vein.			Finding	Neonatal Research Network Terminology|NICHD Terminology
C101024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101024>	C98827	Colon Atresia|Atresia of Colon|Congenital Atresia of Colon|Congenital Atresia of Colon	A congenital malformation characterized by the absence of a normal opening in a part of the colon.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101025>	C98828	Duodenal Atresia|Atresia of Duodenum|Congenital Atresia of Duodenum|Congenital Duodenal Atresia	A congenital malformation characterized by the absence of a normal opening in a part of the duodenum.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101026>	C98828	Ileal Atresia|Atresia of Ileum|Congenital Atresia of Ileum|Congenital Ileal Atresia	A congenital malformation characterized by the absence of a normal opening in a part of the ileum.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101027>	C98828	Jejunal Atresia|Atresia of Jejunum|Congenital Atresia of Jejunum|Congenital Jejunal Atresia	A congenital malformation characterized by the absence of a normal opening in a part of the jejunum.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101028>	C99232	Neonatal Aspiration of Amniotic Fluid	Inhalation of fluid from the amniotic sac into the lungs by the neonate.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology|Perinatal Terminology
C101029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101029>	C84482	Atrioventricular Septal Defect|AV Septal Defect|Common AV Canal|Common Atrioventricular Canal|Common Atrioventricular Canal|Endocardial Cushion Defect	A congenital heart malformation characterized by abnormalities in the anatomic structures that relate to the endocardial cushions. These abnormalities can include defects in the lower part of the atrial septum and the ventricular septum and lack of separation of the mitral and tricuspid valves.			Disease or Syndrome	Cellosaurus Disease Terminology|Neonatal Research Network Terminology|NICHD Terminology
C10102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10102>	C61063	Asparaginase/Cyclophosphamide/Daunorubicin/Methotrexate/Prednisone/Vincristine|ADCOMP|ASP/CTX/DNR/MTX/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101030>	C101029	Complete Atrioventricular Canal Defect Balanced|CAVD, Balanced|Complete AV Canal Defect Balanced|Complete Atrioventricular Canal Defect (Balanced)	Atrioventricular septal defect in which the atrioventricular junction is shared evenly between the left ventricle and right ventricle.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101031>	C101029	Complete Atrioventricular Canal Defect Unbalanced|CAVD, Unbalanced|Complete AV Canal Defect Unbalanced|Complete Atrioventricular Canal Defect (Unbalanced)	Atrioventricular septal defect in which there is usually a single dominant ventricle and a hypoplastic ventricle.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101032>	C99061	Dextrocardia Situs Solitus|Dextrocardia Normal Situs|Dextrocardia, Normal Situs	A congenital heart defect in which the heart is located in the right side and the other organs are in their normal position.			Congenital Abnormality	Neonatal Research Network Terminology|NICHD Terminology
C101033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101033>	C9175	Functional Bowel Obstruction|Functional Intestinal Obstruction|Intestinal Obstruction, Functional	The blockage of bowel contents from evacuation; the causes are attributable to non-structural impediments, such as chemical imbalances or the side effects of medications, narcotics in particular.			Finding	Neonatal Research Network Terminology|NICHD Terminology
C101034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101034>	C3671	Intentional Trauma|Non-accidental Trauma|Nonaccidental Trauma	An injury that is not the result of an accident or natural causes.			Finding	Neonatal Research Network Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C101035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101035>	C3671	Neonatal Injury Related to Birth|Birth Injury|Birth Trauma|Neonatal Birth Injury	An injury sustained to a neonate during the birthing process.			Finding	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology|Neonatal Research Network Terminology|NICHD Terminology|Perinatal Terminology
C101036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101036>	C34982	Retinopathy of Prematurity with Plus Disease	A stage of retinopathy of prematurity characterized by the presence of the following in at least two quadrants around the optic nerve: dilation and tortuosity of major retinal vasculature as a result of increased blood flow.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology|Perinatal Terminology
C101037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101037>	C99232	Transient Tachypnea of the Newborn|Retained Fetal Lung Fluid|TTN|Transitory Tachypnea of Newborn|Type II Respiratory Distress Syndrome|Wet Lung Syndrome	A respiratory disorder characterized by higher than normal respiratory rates among premature and cesarean section delivered neonates whose lungs have not fully matured. The cause is often excess fluid in the lungs, and resolution is aided by supplemental oxygen and sometimes, antibiotics.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology|Perinatal Terminology
C101038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101038>	C97151|C28193	Lethal Multiple Pterygium Syndrome|LMPS	A rare variant of multiple pterygium syndrome, characterized by severe athrogryposis, pterygium, akinesia and often hydrops fetalis and cystic hygroma. This variant is fatal, usually during the second or third trimester of pregnancy.			Congenital Abnormality	
C101039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101039>	C97151|C28193	Escobar Syndrome|Multiple Pterygium Syndrome, Escobar Variant|Non-Lethal Multiple Pterygium Syndrome	A rare congenital disorder, this is the non-lethal variant of multiple pterygium syndrome, characterized by orthopedic and craniofacial abnormalities, pterygium and akinethesia. The majority of cases are autosomal dominant.			Congenital Abnormality	Neonatal Research Network Terminology|NICHD Terminology
C10103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10103>	C61063	Bleomycin/Cisplatin/Mitoguazone/Vindesine|BLEO/CDDP/DAVA/MGBG|DVMB			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101040>	C215178|C101074	Total Colonic Aganglionosis|TCA	Hirschsprung disease characterized by the absence of ganglion cells in the entire colon.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101041>	C34700|C215179	Short Segment Hirschsprung Disease|Short Segment Hirschsprung's Disease	The most common form of Hirschsprung disease characterized by absence of ganglion cells only in the rectum and/or sigmoid colon.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101042>	C3492	Steroid 21-Monooxygenase Deficiency	Less than necessary amount of the enzyme steroid 21-monooxygenase; which is necessary to synthesize cortisol.			Laboratory or Test Result	Neonatal Research Network Terminology|NICHD Terminology
C101043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101043>	C120206	Methemoglobin Reductase Deficiency|Cytochrome B5 Reductase Deficiency|Cytochrome B5 Reductase Deficiency|NADH-CYB5R Deficiency|NADH-Cytochrome B5 Reductase Deficiency|NADH-Dependent Methemoglobin Reductase Deficiency	Less than the necessary amount of the enzyme that converts methemoglobin into hemoglobin.	Cytochrome B5 Reductase Deficiency		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology|Neonatal Research Network Terminology|NICHD Terminology
C101044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101044>	C101214	Spina Bifida Occulta	The mildest form of spina bifida, characterized by any of several neural tube defects which may go undetected until an x-ray is performed. Treatment is symptomatic.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101045>	C98805	Drug Induced Methemoglobinemia|Drug-Induced Methemoglobinemia	Methemoglobinemia that is caused by exposure to certain drugs (xylocaine and benzene).			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101046>	C212844	ATIC/ALK Fusion Gene|ATIC-ALK Fusion Gene|ATIC::ALK Fusion Gene	A fusion gene that results from a chromosomal inversion inv(2)(p23q35) which fuses the first 7 exons of the ATIC gene with exon 20 of the ALK gene. This rearrangement is associated with rare cases of anaplastic large cell lymphoma.			Gene or Genome	
C101047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101047>	C213233	ATIC/ALK Fusion Protein|ATIC-ALK Fusion Protein|ATIC::ALK Fusion Protein|Bifunctional Purine Biosynthesis Protein PURH/ALK Tyrosine Kinase Receptor Fusion Protein|Bifunctional Purine Biosynthesis Protein PURH::ALK Tyrosine Kinase Receptor Fusion Protein	A fusion protein encoded by the ATIC/ALK fusion gene. This protein is comprised of the IMPCH and the dimerization domains of the bifunctional purine biosynthesis protein PURH fused to the cytoplasmic domain of the ALK tyrosine kinase receptor protein, including the tyrosine kinase domain.			Amino Acid, Peptide, or Protein	
C101048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101048>	C28510	BCR/JAK2 Fusion Gene|BCR-JAK2 Fusion Gene|BCR::JAK2 Fusion Gene	A fusion gene that results from a chromosomal translocation t(9;22)(p24;q11.2) which fuses the 5' portion of the BCR gene with the 3' part of the JAK2 gene. This rearrangement is associated with myeloproliferative disorder.	BCR/JAK2 Fusion Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101049>	C17561	BCR/JAK2 Fusion Protein|BCR-JAK2 Fusion Protein|BCR::JAK2 Fusion Protein|Breakpoint Cluster Region Protein/Tyrosine-Protein Kinase JAK2 Fusion Protein|Breakpoint Cluster Region Protein::Tyrosine-Protein Kinase JAK2 Fusion Protein	A fusion protein encoded by the BCR/JAK2 fusion gene. This protein is comprised of the N-terminal coiled-coil domain of breakpoint cluster region protein fused to the C-terminal JH1 tyrosine kinase domain of tyrosine-protein kinase JAK2.	BCR/JAK2 Fusion Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10104>	C61007	Cisplatin/Cyclophosphamide/Vincristine|CDDP/CTX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101050>	C99538	Aortopulmonary Window|AP Window|APSD|APW|Aortopulmonary Septal Defect	A rare, congenital anomaly in the aorta in which a communication exists between the ascending aorta and the pulmonary artery.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101051>	C28510	CBFB/MYH11 Fusion Gene|CBFB::MYH11 Fusion Gene|CBFb-MYH11 Fusion Gene|CBFbeta-MYH11 Fusion Gene|CBFbeta-SMMHC Fusion Gene|CBFbeta/SMMHC Fusion Gene	A fusion gene that results from a chromosomal inversion inv(16)(p13q22) which fuses the 5' portion of the CBFB gene with the 3' part of the MYH11 gene. This rearrangement is associated with acute myeloid leukemia and myelodysplastic syndrome.	CBFB/MYH11 Fusion Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101052>	C17561	CBFB/MYH11 Fusion Protein|CBFB::MYH11 Fusion Protein|CBFb-MYH11 Fusion Protein|CBFbeta-MYH11 Fusion Protein|CBFbeta-SMMHC Fusion Protein|CBFbeta/SMMHC Fusion Protein|Core-Binding Factor Subunit Beta/Myosin-11 Fusion Protein|Core-Binding Factor Subunit Beta::Myosin-11 Fusion Protein	A fusion protein encoded by the CBFB/MYH11 fusion gene. This protein is comprised of most of the core-binding factor subunit beta fused to the C-terminal dimerization domain of myosin-11.			Amino Acid, Peptide, or Protein	
C101053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101053>	C28510	COL1A2/PLAG1 Fusion Gene|COL1A2-PLAG1 Fusion Gene|COL1A2::PLAG1 Fusion Gene	A fusion gene that results from a chromosomal translocation t(7;8)(p22;q13) which fuses the 5' promoter region of the COL1A2 gene upstream of the entire coding region of the PLAG1 gene. This rearrangement is associated with both aberrant expression of the transcription factor zinc finger protein PLAG1 and lipoblastoma.			Gene or Genome	
C101054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101054>	C28510	HAS2/PLAG1 Fusion Gene|HAS2-PLAG1 Fusion Gene|HAS2::PLAG1 Fusion Gene	A fusion gene that results from an intrachromosomal rearrangement of the q arm of chromosome 8 which fuses the 5' promoter region of the HAS2 gene upstream of the entire coding region of the PLAG1 gene. This rearrangement is associated with both aberrant expression of the transcription factor zinc finger protein PLAG1 and lipoblastoma.			Gene or Genome	
C101055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101055>	C201195	FUS/CREB3L1 Fusion Gene|FUS-CREB3L1 Fusion Gene|FUS::CREB3L1 Fusion Gene	A fusion gene that results from a chromosomal rearrangement involving chromosomes 11 and 16 which fuses the first 6 or 9 exons of the FUS gene with exon 5 of the CREB3L1 gene. This rearrangement is associated with fibrosarcoma.			Gene or Genome	
C101056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101056>	C17561	FUS/CREB3L1 Fusion Protein|FUS-CREB3L1 Fusion Protein|FUS::CREB3L1 Fusion Protein|RNA-Binding Protein FUS/Cyclic AMP-Responsive Element-Binding Protein 3-Like Protein 1 Fusion Protein	A predicted fusion protein encoded by the FUS/CREB3L1 fusion gene. This protein is comprised of approximately half the RNA-binding protein FUS fused to the DNA-binding basic domain and leucine zipper dimerization domain of the cyclic AMP-responsive element-binding protein 3-like protein 1.			Amino Acid, Peptide, or Protein	
C101057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101057>	C212853	MLL/ELL Fusion Gene|KMT2A-ELL Fusion Gene|KMT2A/ELL Fusion Gene|KMT2A::ELL Fusion Gene|MLL-ELL Fusion Gene|MLL::ELL Fusion Gene	A fusion gene that results from a chromosomal translocation t(11;19)(q23;p13.1) which fuses the first 7 exons of the MLL gene to most of the coding sequence of the ELL gene. This rearrangement is associated with treatment-related acute myeloid leukemia.	MLL/ELL Fusion Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C101058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101058>	C213256	MLL/ELL Fusion Protein|Histone-Lysine N-Methyltransferase 2A/RNA Polymerase II Elongation Factor ELL Fusion Protein|Histone-Lysine N-Methyltransferase MLL/RNA Polymerase II Elongation Factor ELL Fusion Protein|KMT2A::ELL Fusion Protein|MLL-ELL Fusion Protein|MLL::ELL Fusion Protein|Myeloid/Lymphoid or Mixed-Lineage Leukemia Protein 1/RNA Polymerase II Elongation Factor ELL Fusion Protein	A fusion protein encoded by the MLL/ELL gene. This protein is comprised of the N-terminal AT hook and DNA methyltransferase domains of histone-lysine N-methyltransferase MLL fused to all but the first 46 amino acids of the RNA polymerase II elongation factor ELL.			Amino Acid, Peptide, or Protein	Pediatric Oncology Target Molecular Abnormalities Terminology
C101059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101059>	C212844	MSN/ALK Fusion Gene|MSN-ALK Fusion Gene|MSN::ALK Fusion Gene	A fusion gene that results from a chromosomal translocation t(X;2)(q11;p23) which fuses most of the coding sequence of the MSN gene with the 3' portion of the ALK gene. This rearrangement is associated with rare cases of anaplastic large cell lymphoma.			Gene or Genome	
C10105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10105>	C61063	Cisplatin/Dacarbazine/Etoposide|CDDP/DTIC/VP-16|DVD			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101060>	C213233	MSN/ALK Fusion Protein|MSN-ALK Fusion Protein|MSN::ALK Fusion Protein|Moesin/ALK Tyrosine Kinase Receptor Fusion Protein	A fusion protein encoded by the MSN/ALK fusion gene. This protein is comprised of most of the moesin protein, including the band 4.1 region, fused to the cytoplasmic domain of the ALK tyrosine kinase receptor protein, including the tyrosine kinase domain.			Amino Acid, Peptide, or Protein	
C101061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101061>	C28510	NONO/TFE3 Fusion Gene|NONO-TFE3 Fusion Gene|NONO::TFE3 Fusion Gene|p54nrb/NONO-TFE3 Fusion Gene	A fusion gene that results from a chromosomal inversion inv(X)(p11.2;q12) which fuses exon 9 of the NONO gene with exon 6 of the TFE3 gene. This rearrangement is associated with one case of renal cell carcinoma.			Gene or Genome	
C101062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101062>	C17561	NONO/TFE3 Fusion Protein|NONO-TFE3 Fusion Protein|NONO::TFE3 Fusion Protein|Non-POU Domain-Containing Octamer-Binding Protein/Transcription Factor E3 Fusion Protein|p54nrb/NONO-TFE3 Fusion Protein	A fusion protein encoded by the NONO/TFE3 fusion gene. This protein is comprised of most of the non-POU domain-containing octamer-binding protein fused to the C-terminal basic helix-loop-helix DNA binding and leucine zipper dimerization domains of the transcription factor E3 protein.			Amino Acid, Peptide, or Protein	
C101063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101063>	C28510	NPM1/RARA Short Fusion Gene|NPM-RAR Short Form|NPM1-RARA Short Fusion Gene|NPM1::RARA Short Fusion Gene	A fusion gene (~1.9 kb) that results from a chromosomal translocation t(5;17)(q35;q21) which fuses the first 442 nucleotides of the NPM1 gene to exon 3 of the RARA gene. This rearrangement is rare and is associated with acute myeloid leukemia.			Gene or Genome	
C101064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101064>	C28510	NPM1/RARA Long Fusion Gene|NPM-RAR Long Form|NPM1-RARA Long Fusion Gene|NPM1::RARA Long Fusion Gene	A fusion gene (~2.1 kb) that results from a chromosomal translocation t(5;17)(q35;q21) which fuses the first 484 nucleotides of the NPM1 gene to exon 3 of the RARA gene. This rearrangement is rare and is associated with acute myeloid leukemia.			Gene or Genome	
C101065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101065>	C17561	NPM1/RARA Short Fusion Protein|NPM1-RARA Short Fusion Protein|NPM1::RARA Short Fusion Protein|Nucleophosmin/Retinoic Acid Receptor Alpha Short Fusion Protein	A fusion protein (520 aa, ~57 kDa) encoded by the NPM1/RARA short fusion gene. This protein is comprised of the N-terminus of the nucleophosmin protein fused to the DNA-binding domain, ligand binding domain and coactivator recognition site from the retinoic acid receptor alpha protein.			Amino Acid, Peptide, or Protein	
C101066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101066>	C17561	NPM1/RARA Long Fusion Protein|NPM1-RARA Long Fusion Protein|NPM1::RARA Long Fusion Protein|Nucleophosmin/Retinoic Acid Receptor Alpha Long Fusion Protein	A fusion protein (563 aa, ~63 kDa) encoded by the NPM1/RARA long fusion gene. This protein is comprised of the N-terminus of the nucleophosmin protein fused to the DNA-binding domain, ligand binding domain and coactivator recognition site from the retinoic acid receptor alpha protein.			Amino Acid, Peptide, or Protein	
C101067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101067>	C28510	PAX3/FOXO4 Fusion Gene|PAX3-AFX Fusion Gene|PAX3-FOXO4 Fusion Gene|PAX3/AFX Fusion Gene|PAX3::FOXO4 Fusion Gene	A fusion gene that results from a rearrangement involving chromosome 2 and the X chromosome which fuses the 5' portion of the PAX3 gene to the 3' portion of the FOXO4 gene. This rearrangement is associated with rare variants of alveolar rhabdomyosarcoma.			Gene or Genome	
C101068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101068>	C17561	PAX3/FOXO4 Fusion Protein|PAX3-FOXO4 Fusion Protein|PAX3::FOXO4 Fusion Protein|Paired Box Protein Pax-3/Forkhead Box Protein O4 Fusion Protein	A fusion protein encoded by the PAX3/FOXO4 fusion gene. This protein is comprised of the N-terminal DNA binding domain of paired box protein Pax-3 and the C-terminal transactivation domain of forkhead box protein O4.			Amino Acid, Peptide, or Protein	
C101069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101069>	C28510	PAX3/NCOA1 Fusion Gene|PAX3-NCOA1 Fusion Gene|PAX3::NCOA1 Fusion Gene	A fusion gene that results from a rearrangement of chromosome 2 which fuses exon 6 of the PAX3 gene to either exon 12 of the NCOA1 gene. This rearrangement is associated with rare variants of alveolar rhabdomyosarcoma.			Gene or Genome	
C10106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10106>	C61063	Cytarabine/Etoposide/Prednisone/Teniposide|ARA-C/PRED/VM-26/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101070>	C17561	PAX3/NCOA1 Fusion Protein|PAX3-NCOA1 Fusion Protein|PAX3::NCOA1 Fusion Protein|Paired Box Protein Pax-3/ Nuclear Receptor Coactivator 1 Fusion Protein	A fusion protein encoded by the PAX3/NCOA1 fusion gene. This protein is comprised of the N-terminal DNA binding domain of paired box protein Pax-3 and the C-terminal transactivation domain of nuclear receptor coactivator 1.			Amino Acid, Peptide, or Protein	
C101072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101072>	C28510	SS18L1/SSX1 Fusion Gene|SS18L1-SSX1 Fusion Gene|SS18L1::SSX1 Fusion Gene	A fusion gene that results from a chromosomal translocation t(X;20)(p11;q13.3) which fuses exon 10 of the SS18L1 gene to exon 6 of the SSX1 gene. This rearrangement is associated with synovial sarcoma.			Gene or Genome	
C101073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101073>	C17561	SS18L1/SSX1 Fusion Protein|Calcium-Responsive Transactivator/Protein SSX1 Fusion Protein|SS18L1-SSX1 Fusion Protein|SS18L1::SSX1 Fusion Protein	A fusion protein encoded by the SS18L1/SSX1 fusion gene. This protein is comprised of all but the last 8 amino acids of the calcium-responsive transactivator protein fused to 78 amino acids from the C-terminus of protein SSX1.			Amino Acid, Peptide, or Protein	
C101074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101074>	C34700	Total Intestinal Aganglionosis	A complete lack of ganglia in the intestine. This is an extremely severe form of Hirschsprung disease.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101075>	C212844	TFG/ALK Fusion Gene|TFG-ALK|TFG::ALK Fusion Gene	A fusion gene that results from a chromosomal translocation t(2;3)(p23;q21) which fuses a portion of the 5' part of the TFG gene to the last 10 exons of the ALK gene. This rearrangement is associated with anaplastic large cell lymphoma.			Gene or Genome	
C101076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101076>	C213233	TFG/ALK Fusion Protein|Protein TFG/ALK Tyrosine Kinase Receptor Fusion Protein|TFG-ALK|TFG::ALK Fusion Protein|TRK-Fused Gene/Anaplastic Lymphoma Kinase (Ki-1) Fusion Protein	A fusion protein encoded by the TFG/ALK fusion gene. This protein is comprised of the N-terminus of protein TFG, including the coiled-coil oligomerization domain, fused to the cytoplasmic domain of the ALK tyrosine kinase receptor protein.			Amino Acid, Peptide, or Protein	
C101077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101077>	C101075	TFG/ALK Short Form Fusion Gene|TFG-ALK(S)|TFG::ALK Short Form Fusion Gene	A fusion gene (~2.4 kb) that results from a chromosomal translocation t(2;3)(p23;q21) which fuses a third of the 5' portion of the TFG gene to the last 10 exons of the ALK gene. This rearrangement is associated with anaplastic large cell lymphoma.			Gene or Genome	
C101078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101078>	C101075	TFG/ALK Long Form Fusion Gene|TFG-ALK(L)|TFG::ALK Long Form Fusion Gene	A fusion gene (~2.8 kb) that results from a chromosomal translocation t(2;3)(p23;q21) which fuses the 5' half of the TFG gene to the last 10 exons of the ALK gene. This rearrangement is associated with anaplastic large cell lymphoma.			Gene or Genome	
C101079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101079>	C101075	TFG/ALK Extra Long Form Fusion Gene|TFG-ALK XL|TFG-ALK(XL)|TFG::ALK Extra Long Form Fusion Gene|TRK-Fused Gene/Anaplastic Large Cell Lymphoma Kinase Extra Long Form	A fusion gene (~2.6 kb) that results from a chromosomal translocation t(2;3)(p23;q21) which fuses the 5' half of the TFG gene to the last 10 exons of the ALK gene. This rearrangement is associated with anaplastic large cell lymphoma.			Gene or Genome	
C10107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10107>	C61063	Asparaginase/Cyclophosphamide/Doxorubicin/Methotrexate/Prednisone/Vincristine|ASP/CTX/DOX/MTX/PRED/VCR|MACHO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101080>	C101076	TFG/ALK Short Form Fusion Protein|Protein TFG/ALK Tyrosine Kinase Receptor Short Form Fusion Protein|TFG-ALK(S)|TFG::ALK Short Form Fusion Protein|TRK-Fused Gene/Anaplastic Lymphoma Kinase (Ki-1) Short Form Fusion Protein	A fusion protein (701 aa, ~78 kDa) encoded by the TFG/ALK short form fusion gene. This protein is comprised of about one third of the N-terminal sequence of protein TFG, including the coiled-coil oligomerization domain, fused to the cytoplasmic domain of the ALK tyrosine kinase receptor protein.			Amino Acid, Peptide, or Protein	
C101081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101081>	C101076	TFG/ALK Long Form Fusion Protein|Protein TFG/ALK Tyrosine Kinase Receptor Fusion Protein Long Form|TFG-ALK(L)|TFG::ALK Long Form Fusion Protein|TRK-Fused Gene/Anaplastic Lymphoma Kinase (Ki-1) Fusion Protein Long Form	A fusion protein (756 aa, ~84 kDa) encoded by the TFG/ALK long form fusion gene. This protein is comprised of the N-terminal third of protein TFG, including the coiled-coil oligomerization domain, fused to the cytoplasmic domain of the ALK tyrosine kinase receptor protein.			Amino Acid, Peptide, or Protein	
C101082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101082>	C101076	TFG/ALK Extra Long Form Fusion Protein|Protein TFG/ALK Tyrosine Kinase Receptor Extra Long Form Fusion Protein|TFG-ALK XL|TFG-ALK(XL)|TFG::ALK Extra Long Form Fusion Protein|TRK-Fused Gene/Anaplastic Large Cell Lymphoma Kinase Extra Long Form Fusion Protein	A fusion protein (803 aa, ~89 kDa) encoded by the TFG/ALK extra long form fusion gene. This protein is comprised of the N-terminal half of protein TFG, including the coiled-coil oligomerization domain, fused to the cytoplasmic domain of the ALK tyrosine kinase receptor protein.			Amino Acid, Peptide, or Protein	
C101083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101083>	C212844	TPM3/ALK Fusion Gene|TPM3-ALK Fusion Gene|TPM3::ALK Fusion Gene	A fusion gene that results from a chromosomal translocation t(1;2)(q25;p23) which fuses most of the coding sequence of the TPM3 gene to the last 10 exons of the ALK gene. This rearrangement is associated with anaplastic large cell lymphoma and inflammatory myofibroblastic tumor.			Gene or Genome	
C101084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101084>	C213233	TPM3/ALK Fusion Protein|TPM3-ALK Fusion Protein|TPM3::ALK Fusion Protein|Tropomyosin Alpha-3 Chain/ALK Tyrosine Kinase Receptor Fusion Protein	A fusion protein encoded by the TPM3/ALK fusion gene. This protein is comprised of most of the tropomyosin alpha-3 chain protein fused to the cytoplasmic domain of the ALK tyrosine kinase receptor protein.			Amino Acid, Peptide, or Protein	
C101085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101085>	C212844	TPM4/ALK Fusion Gene|TPM4-ALK Fusion Gene|TPM4::ALK Fusion Gene	A fusion gene that results from a chromosomal translocation t(1;2)(q25;p23) which fuses most of the coding sequence of the TPM4 gene to the last 10 exons of the ALK gene. This rearrangement is associated with inflammatory myofibroblastic tumor.			Gene or Genome	
C101086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101086>	C213233	TPM4/ALK Fusion Protein|TPM4-ALK Fusion Protein|TPM4::ALK Fusion Protein|Tropomyosin Alpha-4 Chain/ALK Tyrosine Kinase Receptor Fusion Protein	A fusion protein encoded by the TPM4/ALK fusion gene. This protein is comprised of most of the tropomyosin alpha-4 chain protein fused to the cytoplasmic domain of the ALK tyrosine kinase receptor protein.			Amino Acid, Peptide, or Protein	
C101087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101087>	C72067	Kukui Nut|Candleberry Seed|Candlenut Seed|Indian Walnut Seed|KUKUI NUT|Kemiri Seed|Kukui Nut Tree Seed				Food	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C101088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101088>	C54362	ARID2 Gene|ARID2|ARID2|ARID2|AT-Rich Interactive Domain 2 Gene	This gene is involved in both transcriptional regulation and chromatin remodeling.	ARID2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C101089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101089>	C101088	ARID2 wt Allele|AT Rich Interactive Domain 2 (ARID, RFX-Like) Gene|AT-Rich Interactive Domain 2 wt Allele|BAF200|BRG1-Associated Factor, 200-kD Gene|CSS6|DKFZp686G052|FLJ30619|KIAA1557|p200	Human ARID2 wild-type allele is located in the vicinity of 12q12 and is approximately 178 kb in length. This allele, which encodes AT-rich interactive domain-containing protein 2, plays a role in both the modulation of chromatin remodeling and transcriptional regulation.	ARID2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10108>	C61063	Methotrexate/Prednisone/Procarbazine/Vincristine|MTX/PCB/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101090>	C26199	AT-Rich Interactive Domain-Containing Protein 2|ARID Domain-Containing Protein 2|ARID2|BAF200|BRG1-Associated Factor 200|Zinc Finger Protein with Activation Potential|Zipzap/p200	AT-rich interactive domain-containing protein 2 (1835 aa, ~197 kDa) is encoded by the human ARID2 gene. This protein is involved in the mediation of chromatin remodeling.	AT-Rich Interactive Domain-Containing Protein 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101091>	C20703	BCOR Gene|BCL6 Corepressor Gene|BCOR|BCOR|BCOR	This gene plays a role in the repression of gene transcription.	BCOR Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|Pediatric Oncology Target Cell Lineage Determinant Terminology
C101092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101092>	C101091	BCOR wt Allele|ANOP2|BCL6 Co-Repressor Gene|BCL6 Corepressor wt Allele|FLJ20285|KIAA1575|MAA2|MCOPS2	Human BCOR wild-type allele is located in the vicinity of Xp11.4 and is approximately 128 kb in length. This allele, which encodes BCL-6 corepressor protein, is involved in transcriptional regulation. Mutation of the gene is associated with microphthalmia syndromic type 2.	BCOR wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101093>	C26199	BCL-6 Corepressor|BCL-6 Interacting Corepressor|BCL6 Co-Repressor|BCoR	BCL-6 corepressor (1755 aa, ~192 kDa) is encoded by the human BCOR gene. This protein plays a role in the negative regulation of transcription.	BCL-6 Corepressor		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Cell Lineage Determinant Terminology
C101094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101094>	C1920|C178427	Trivalent Live-Attenuated Influenza Vaccine|FluMist|Fluenz|Trivalent Intranasal Influenza Vaccine, Live	A weakened live virus vaccine containing three seasonal influenza reassortants with prophylactic activity against influenza subtypes A and B. The trivalent live-attenuated influenza vaccine (LAIV) contains 2 strains of the influenza subtype A, one for H1N1 and one for H3N2, and one strain of subtype B. Upon intranasal administration by sprayer of the trivalent LAIV, the live viruses replicate in the upper respiratory tract and induce an immune response leading to active immunization against influenza subtypes A and B.			Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology
C101095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101095>	C25839	CDK12 Gene|CDK12|CDK12|CDK12|Cyclin Dependent Kinase 12 Gene	This gene is involved in protein phosphorylation, RNA splicing and transcription elongation.	CDK12 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|Pediatric Oncology Target Genes/Proteins Terminology
C101096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101096>	C101095	CDK12 wt Allele|CDC2 Related Protein Kinase 7 Gene|CRK7|CRKR|CRKRS|Cdc2-Related Kinase, Arginine/Serine-Rich Gene|Cyclin Dependent Kinase 12 wt Allele|Cyclin-Dependent Kinase 12 Gene|KIAA0904|hCDK12	Human CDK12 wild-type allele is located in the vicinity of 17q12 and is approximately 73 kb in length. This allele, which encodes cyclin-dependent kinase 12 protein, plays a role in the modulation of protein phosphorylation. Chromosomal deletions within the 17q12 region can lead to out of frame fusions of this gene and the ERBB2 gene and may be associated with gastric cancer.	CDK12 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101097>	C17767	Cyclin-Dependent Kinase 12|CDC2-Related Protein Kinase 7|Cdc2-Related Kinase with an Arginine/Serine-Rich Domain|Cdc2-Related Kinase, Arginine/Serine-Rich|Cell Division Cycle 2-Related Protein Kinase 7|Cell Division Protein Kinase 12|CrkRS|EC 2.7.11.22|EC 2.7.11.23|hCDK12	Cyclin-dependent kinase 12 (1490 aa, ~164 kDa) is encoded by the human CDK12 gene. This protein is involved in the regulation of both RNA splicing and transcription elongation through the mediation of serine/threonine phosphorylation.	Cyclin-Dependent Kinase 12		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Genes/Proteins Terminology
C101098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101098>	C20194	NUTM2A Gene|FAM22A|NUT Family Member 2A Gene|NUTM2A|NUTM2A|NUTM2A	This gene has an unknown function.	NUTM2A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C101099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101099>	C101098	NUTM2A wt Allele|FAM22A|Family with Sequence Similarity 22, Member A Gene|KIAA2020|NUT Family Member 2A wt Allele|RP11-322M19.3	Human NUTM2A wild-type allele is located in the vicinity of 10q23.2 and is approximately 14 kb in length. This allele, which encodes NUT family member 2A protein, has an unknown function. A translocation t(10;17)(q22-23;p13) that fuses this gene with the YWHAE gene is associated with high-grade uterine endometrial stromal sarcoma.	NUTM2A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10109>	C61063	Doxorubicin/Prednisone/Teniposide|DOX/PRED/VM-26|PATen			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1010>	C29750	Nafazatrom|1-(2-(beta-naphthyloxy)ethyl)-3-methyl-2-pyrazolin-5-one|3H-pyrazol-3-one,2,4-dihydro-5-methyl-2-(2-(2-naphthalenyloxy)ethyl)|Bay g 6575|Bay-g 6575|NAFAZATROM	A pyrazolinone derivative with potential antimetastatic activities. Nafazatrom, originally developed as an antithrombotic agent, inhibits the key prostaglandin catabolic enzyme, 15-hydroxyprostaglandin dehydrogenase, which prolongs the biological half-life of prostacyclin (prostaglandin I2; PGI2) and prevents intravascular coagulation. This agent also serves as a reducing cofactor with the hydroperoxidase moiety of cyclooxygenase and accelerates the conversion of arachidonic acid into precursors of PGI2. An elevated level of PGI2 prevents aggregation of platelets; subsequently it decreases the formation of tumor cell-platelet aggregates as well as their sequestration in blood vessels, which is an important initiating step in the development of metastasis.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C101100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101100>	C18466	NUT Family Member 2A|Hypothetical Protein LOC728118|NUTM2A|Protein FAM22A|Protein KIAA2020	NUT family member 2A (878 aa, ~94 kDa) is encoded by the human NUTM2A gene. This protein has an unknown function.	NUT Family Member 2A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101101>	C20194	NUTM2B Gene|FAM22B|NUT Family Member 2B Gene|NUTM2B|NUTM2B|NUTM2B	The function of this gene is unknown.	NUTM2B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C101102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101102>	C101101	NUTM2B wt Allele|FAM22B|Family with Sequence Similarity 22, Member B Gene|NUT Family Member 2B wt Allele|bA119F19.1	Human NUTM2B wild-type allele is located in the vicinity of 10q22.3 and is approximately 16 kb in length. This allele, which encodes NUT family member 2B protein, has no known function. A translocation t(10;17)(q22-23;p13) that fuses this gene with the YWHAE gene is associated with high-grade uterine endometrial stromal sarcoma.	NUTM2B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101103>	C18466	NUT Family Member 2B|NUTM2B|Protein FAM22B	NUT family member 2B (878 aa, ~94 kDa) is encoded by the human NUTM2B gene. This protein has a function that is unknown.	NUT Family Member 2B		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101104>	C20194	FBXO11 Gene|F-Box Protein 11 Gene|FBXO11|FBXO11|FBXO11	This gene plays a role in the recognition of proteins to be ubiquitinylated.	FBXO11 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C101105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101105>	C101104	FBXO11 wt Allele|F-Box Protein 11 wt Allele|FBX11|MGC44383|PRMT9|UBR6|UG063H01|Ubiquitin Protein Ligase E3 Component N-Recognin 6 Gene|VIT1	Human FBXO11 wild-type allele is located in the vicinity of 2p16.3 and is approximately 116 kb in length. This allele, which encodes F-box only protein 11, is involved in the regulation of protein ubiquitination. Polymorphism of the gene is associated with otitis media.	FBXO11 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101106>	C95242	F-Box Only Protein 11|FBXO11|Protein Arginine N-Methyltransferase 9|Ubiquitin Protein Ligase E3 Component N-Recognin 6|VIT-1|Vitiligo-Associated Protein 1	F-box only protein 11 (927 aa, ~104 kDa) is encoded by the human FBXO11 gene. This protein plays a role in substrate recognition for the ubiquitin ligase complex.	F-Box Only Protein 11		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101107>	C20703	HEY1 Gene|HEY1|HEY1|HEY1|Hes Related Family BHLH Transcription Factor With YRPW Motif 1 Gene	This gene is involved in both transcription factor binding and transcriptional repression.	HEY1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C101108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101108>	C101107	HEY1 wt Allele|BHLHb31|CHF-2|CHF2|HERP2|HESR-1|HESR1|HRT-1|HRT1|Hairy/Enhancer-of-Split Related with YRPW Motif 1 Gene|Hes Related Family BHLH Transcription Factor With YRPW Motif 1 wt Allele|MGC1274|OAF1	Human HEY1 wild-type allele is located in the vicinity of 8q21 and is approximately 4 kb in length. This allele, which encodes hairy/enhancer-of-split related with YRPW motif protein 1, plays a role in protein dimerization and the negative regulation of transcription.	HEY1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101109>	C26199	Hairy/Enhancer-of-Split Related with YRPW Motif Protein 1|Basic Helix-Loop-Helix Protein OAF1|CHF-2|Cardiovascular Helix-Loop-Helix Factor 2|Class B Basic Helix-Loop-Helix Protein 31|HES-Related Repressor Protein 1|HESR-1|HEY1|HRT-1|Hairy and Enhancer of Split-Related Protein 1|Hairy-Related Transcription Factor 1|bHLHb31|hHRT1	Hairy/enhancer-of-split related with YRPW motif protein 1 (304 aa, ~33 kDa) is encoded by the human HEY1 gene. This protein is involved in dimerization with transcription factors to suppress transcription.	Hairy/Enhancer-of-Split Related with YRPW Motif Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10110>	C63589	Cytarabine/Daunorubicin/Prednisone/Thioguanine Regimen|ARA-C/DNR/PRED/TG|TRAP	A regimen consisting of cytarabine, daunorubicin, prednisone, and thioguanine that may be used in the treatment of acute myeloid leukemia (AML).			Therapeutic or Preventive Procedure	SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C101110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101110>	C54550	SRSF2 Gene|SRSF2|SRSF2|SRSF2|Serine and Arginine Rich Splicing Factor 2 Gene	This gene plays a role in RNA splicing.	SRSF2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C101111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101111>	C101110	SRSF2 wt Allele|PR264|SC-35|SC35|SFRS2|SFRS2A|SRp30b|Serine and Arginine Rich Splicing Factor 2 wt Allele|Serine/Arginine-Rich Splicing Factor 2 Gene|Splicing Factor, Arginine/Serine-Rich 2 Gene	Human SRSF2 wild-type allele is located in the vicinity of 17q25.1 and is approximately 4 kb in length. This allele, which encodes serine/arginine-rich splicing factor 2 protein, is involved in the regulation of RNA splicing.	SRSF2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101112>	C21298	Serine/Arginine-Rich Splicing Factor 2|Protein PR264|SC-35|SR Splicing Factor 2|SRSF2|Splicing Component, 35 kDa|Splicing Factor SC35|Splicing Factor, Arginine/Serine-Rich 2	Serine/arginine-rich splicing factor 2 (221 aa, ~25 kDa) is encoded by the human SRSF2 gene. This protein plays a role in the modulation of mRNA processing.	Serine/Arginine-Rich Splicing Factor 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101113>	C54550	U2AF1 Gene|U2 Small Nuclear RNA Auxiliary Factor 1 Gene|U2AF1|U2AF1|U2AF1	This gene is involved in the splicing of mRNA.	U2AF1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C101114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101114>	C101113	U2AF1 wt Allele|DKFZp313J1712|FP793|RN|RNU2AF1|U2 Small Nuclear RNA Auxiliary Factor 1 wt Allele|U2AF35|U2AFBP	Human U2AF1 wild-type allele is located in the vicinity of 21q22.3 and is approximately 15 kb in length. This allele, which encodes splicing factor U2AF 35 kDa subunit protein, plays a role in the mediation of messenger RNA processing. A missense mutation may be associated with myelodysplastic syndrome.	U2AF1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101115>	C21298	Splicing Factor U2AF 35 kDa Subunit|U2 Auxiliary Factor 35 kDa Subunit|U2 snRNP Auxiliary Factor Small Subunit|U2(RNU2) Small Nuclear RNA Auxiliary Factor Binding Protein|U2AF1	Splicing factor U2AF 35 kDa subunit (240 aa, ~28 kDa) is encoded by the human U2AF1 gene. This protein is involved in the regulation of mRNA splicing.	Splicing Factor U2AF 35 kDa Subunit		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101116>	C25997	YWHAE Gene|Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein, Epsilon Polypeptide Gene|YWHAE|YWHAE|YWHAE	This gene plays a role in signaling.	YWHAE Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C101117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101117>	C101116	YWHAE wt Allele|14-3-3 Epsilon Gene|14-3-3E|FLJ45465|KCIP-1|MDCR|MDS|Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein, Epsilon Polypeptide wt Allele	Human YWHAE wild-type allele is located in the vicinity of 17p13.3 and is approximately 56 kb in length. This allele, which encodes 14-3-3 protein epsilon, is involved in the modulation of signal transduction.	YWHAE wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101118>	C26231	14-3-3 Protein Epsilon|14-3-3E|Mitochondrial Import Stimulation Factor L Subunit|Protein Kinase C Inhibitor Protein-1|YWHAE	14-3-3 protein epsilon (255 aa, ~29 kDa) is encoded by the human YWHAE gene. This protein plays a role in signal transduction.	14-3-3 Protein Epsilon		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101119>	C25677	Geometric Shape	The spatial outline of an object as described by the configuration of straight or curved lines.			Spatial Concept	
C10111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10111>	C61063	Melphalan/Prednisone/Vincristine|L-PAM/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101120>	C21295	ZRSR2 Gene|ZRSR2|ZRSR2|ZRSR2|Zinc Finger CCCH-type, RNA Binding Motif and Serine/Arginine Rich 2 Gene	This gene is involved in mRNA processing.	ZRSR2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C101121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101121>	C101120	ZRSR2 wt Allele|MGC142014|MGC142040|U2AF1-RS2|U2AF1L2|U2AF1RS2|URP|ZC3H22|Zinc Finger (CCCH type), RNA-Binding Motif And Serine/Arginine Rich 2 Gene|Zinc Finger CCCH-type, RNA Binding Motif and Serine/Arginine Rich 2 wt Allele	Human ZRSR2 wild-type allele is located in the vicinity of Xp22.1 and is approximately 33 kb in length. This allele, which encodes U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2, plays a role in the regulation of RNA splicing.	ZRSR2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101122>	C21298	U2 Small Nuclear Ribonucleoprotein Auxiliary Factor 35 kDa Subunit-Related Protein 2|CCCH Type Zinc Finger, RNA-Binding Motif And Serine/Arginine Rich Protein 2|Renal Carcinoma Antigen NY-REN-20|U2 Small Nuclear Ribonucleoprotein Auxiliary Factor, Small Subunit 2|U2(RNU2) Small Nuclear RNA Auxiliary Factor 1-Like 2|U2AF35-Related Protein|URP|ZRSR2|Zinc Finger-, CCCH Domain-, and RNA-Binding Motif-Containing Serine/Arginine-Rich Protein 2	U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2 (482 aa, ~58 kDa) is encoded by the human ZRSR2 gene. This protein is involved in the modulation of messenger RNA maturation.	U2 Small Nuclear Ribonucleoprotein Auxiliary Factor 35 kDa Subunit-Related Protein 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101123>	C45261	Annotation Collection	A set of annotations, or comments about an idea, subject or item.			Conceptual Entity	
C101124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101124>	C43432	Worklist	A collection of activities or pieces of work that are generally assigned to an individual or machine to perform.			Intellectual Product	
C101125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101125>	C20189	Discordance|Discordant	A lack of agreement of findings.			Conceptual Entity	
C101126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101126>	C20921	STIL Gene|STIL|STIL|STIL|STIL Centriolar Assembly Protein Gene	This gene plays a role in both cellular proliferation and embryonic development.	STIL Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C101127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101127>	C101126	STIL wt Allele|MCPH7|RP1-18D14.8|SCL-Interrupting Locus Gene|SCL/TAL1 Interrupting Locus Gene|SCL/TAL1-Interrupting Locus Gene|SIL|STIL Centriolar Assembly Protein wt Allele|TAL1 (SCL) Interrupting Locus Gene	Human STIL wild-type allele is located in the vicinity of 1p32 and is approximately 64 kb in length. This allele, which encodes SCL-interrupting locus protein, is involved in signaling that promotes cellular proliferation and modulates embryonic development. A chromosomal deletion at 1p32 between this gene and the TAL1 gene is associated with T-cell acute lymphoblastic leukemia. Mutation of the gene is associated with microcephaly primary type 7.	STIL wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101128>	C18515	SCL-Interrupting Locus Protein|STIL|STIL Centriolar Assembly Protein|TAL-1-Interrupting Locus Protein	SCL-interrupting locus protein (1287 aa, ~143 kDa) is encoded by the human STIL gene. This protein plays a role in both the progression of embryonic development and the modulation of cell proliferation.	SCL-Interrupting Locus Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101129>	C74299	Task	An assigned piece of work, usually with a time allotment.			Activity	CareLex eTMF Terminology
C10112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10112>	C61063	Biostim/Melphalan/Prednisone/Vincristine|biostim/L-PAM/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101130>	C93221	Guarana Supplement|Paullinia cupana Supplement	An herbal supplement containing an extract from guarana (Paullinia cupana), a climbing plant of the Sapindaceae family which is native to the Amazon basin, with stimulant, antioxidant and potential chemoprotective activities. Guarana supplement contains various phytochemicals, including caffeine, theobromine, theophylline, tannins, saponins, catechins, epicatechins, proanthocyanidols and other compounds in minor concentrations. Caffeine is a central nervous system stimulant and may reduce chemotherapy-related fatigue. Tannins and other polyphenols may have chemopreventive activity. Intake of the guarana supplement may prevent cancer-related anorexia. In addition, animal studies have demonstrated that the ingestion of guarana resulted in decreased proliferation and increased apoptosis of tumor cells.	Guarana Supplement		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101131>	C266|C227058	Elsiglutide|ELSIGLUTIDE|ZP1846	A synthetic glucagon-like peptide-2 (GLP-2) analogue with potential antidiarrheal and intestinotrophic activities. Upon subcutaneous administration, elsiglutide, a 39 amino acid polypeptide, binds to GLP-2 receptors and thereby promotes proliferation of epithelial cells. Regeneration of endothelial cells damaged during chemotherapy may prevent or decrease chemotherapy-induced diarrhea. In addition, elsiglutide may prevent chemotherapy-induced intestinal injury. GLP-2, a peptide hormone primarily produced in the small intestines in response to food, plays a key role in intestinal epithelial growth, metabolism and regeneration of epithelial cells.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C101132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101132>	C2201|C1742|C129825	mTOR1/2 Kinase Inhibitor ME-344|ME-344|ME-344	An active metabolite of NV-128, a novel flavonoid small molecule inhibitor of the mammalian Target of Rapamycin (mTOR), with potential antineoplastic activity. Upon administration, mTOR1/2 Kinase inhibitor ME-344 downregulates the PIK3/AKT/mTOR pathway and results in chromatin condensation in the absence of caspase activation. Consequently, this agent induces caspase-independent cell death in tumor cells with a de-regulated PIK3/AKT/mTOR pathway or chemotherapeutic resistant cells.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101133>	C1511	Zirconium Zr 89 Desferrioxamine B Monoclonal Antibody huJ591|89Zr-DFO-huJ591	A radioimmunoconjugate comprised of the recombinant humanized monoclonal antibody J591 against prostate-specific membrane antigen (PSMA) conjugated to chelator desferrioxamine B (DFO-B) and labeled with the radioisotope zirconium Zr 89 with potential imaging property used in positron emission tomography (PET) imaging. Upon administration of zirconium Zr 89 desferrioxamine B monoclonal antibody huJ591, the antibody moiety binds to the extracellular domain of PSMA, and the radioisotope moiety may be detected using PET, thereby allowing the imaging and quantification of PSMA-expressing tumor cells. PSMA, or folate hydrolase, is a cell surface peptidase highly expressed by malignant prostate epithelial cells and vascular endothelial cells of numerous solid tumor malignancies. In addition, upon PET imaging this agent provides high tumor:background tissue ratios.	Zirconium Zr 89 Desferrioxamine B Monoclonal Antibody huJ591		Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C101134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101134>	C49154	Entity Statement	A declaration of a relationship between entities, consisting of a subject, predicate and object.			Idea or Concept	
C101135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101135>	C101134	Image Annotation Statement	A statement used to describe something found and to be addressed on an image or series of images. It describes a thing found, measured and graphically annotated on an image or images from the same series. It consists of a subject, predicate and object.			Idea or Concept	
C101136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101136>	C68747	Milliampere Second|mAs	A measure of the electric charge and the time in which the charge is dispersed. This is used as a setting on a radiography machine to determine the density of the radiographic image.			Quantitative Concept	
C101137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101137>	C42534	Dose Length Product|DLP	The product of the number of computed tomography (CT) scans multiplied by the scan width (i.e., total scan length). This value is an indicator of the integrated radiation dose of a specific CT scan. This is expressed in the SI units milligray x centimeters (mGy x cm). DLP is CTDIvol x slice thickness x # of slices.			Quantitative Concept	
C101138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101138>	C42534	Computed Tomography Dose Index Volume|COMPUTED_VOLUME|COMPUTED_VOLUME|CTDIvol|ctdiVol	The International Electrotechnical Commission preferred expression of radiation dose in computed tomography (CT) dosimetry. It is calculated by averaging the radiation dose delivered over x,y and z directions and expressed in the SI unit of Gray (Gy).			Quantitative Concept	BRIDG Attribute Terminology|BRIDG Terminology|EWS Tumor Assessment Table|EWS Variable Terminology|OS Tumor Assessment Table|OS Variable Terminology
C101139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101139>	C92172	EGFR NM_005228.3:c.334_1137del804|EGFR Variant III|EGFR c.334_1137del804|EGFRvIII|EGFRvIII Extracellular Domain Mutation|EGFRvIII Extracellular Domain Variant|EGFRvIII Gene Mutation|Epidermal Growth Factor Receptor Gene c.334_1137del804	A deletion of exons 2-7 of the EGFR gene corresponding to 804 nucleotides starting at position 334 through position 1137.	EGFR NM_005228.3:c.334_1137del804		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Cell Lineage Determinant Terminology
C10113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10113>	C61063	Conjugated Estrogens/Cyclophosphamide/Doxorubicin/Fluorouracil/Methotrexate/Tamoxifen|CAMFTP|CTX/DOX/EST/5-FU/MTX/TMX	A combination of agents containing conjugated estrogens, cyclophosphamide, doxorubicin, fluorouracil, methotrexate and tamoxifen.		Obsolete_Concept	Therapeutic or Preventive Procedure	
C101140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101140>	C98356	EGFR NP_005219.2:p.K29_N298insG|Activating EGFRvIII Mutation|EGFR NP_005219.2:p.Lys29_Asn298insGly|EGFR NP_005219.2:p.V30_R297delK29_N298insG|EGFR NP_005219.2:p.Val30_Arg297delLys29_Asn298insGly|EGFR Variant III|EGFR p. K29_N298insG|EGFR p. Lys29_Asn298insGly|EGFRvIII|EGFRvIII Ectodomain Insertion/Deletion Mutation|EGFRvIII Extracellular Domain Insertion/Deletion Mutation|EGFRvIII Protein Variant|Epidermal Growth Factor Receptor Variant III|Epidermal Growth Factor Receptor vIII|NP_005219.2:p.K29_N298insG|NP_005219.2:p.Lys29_Asn298insGly|NP_005219.2:p.V30_R297delK29_N298insG|NP_005219.2:p.Val30_Arg297delLys29_Asn298insGly|Type III EGF Deletion-Mutant Receptor	A deletion of 268 amino acids of the epidermal growth factor receptor protein from the valine at position 30 through the arginine at position 297 followed by the insertion of a glycine between the lysine at position 29 and the asparagine at position 298.	EGFR NP_005219.2:p.K29_N298insG		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Cell Lineage Determinant Terminology
C101141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101141>	C51944	Lysozyme Immunohistochemistry|Muramidase Immunohistochemistry	An immunohistochemical diagnostic test utilizing an antibody to detect lysozyme in tissues.			Laboratory Procedure	
C101142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101142>	C27993	Research Use Only|For Research Use Only|RUO	An indication that a substance, device or technique is to be used solely for research purposes and cannot be used for prognostic, diagnostic or therapeutic purposes.			Qualitative Concept	SeroNet Authorized Values|SeroNet Study Descriptors
C101143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101143>	C26549	Viral Small RNA|Viral-Derived Short RNA|vsRNA	Small non-coding RNA that is encoded by viral DNA and transcribed by virally-infected cells.			Nucleic Acid, Nucleoside, or Nucleotide	
C101144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101144>	C28533	SYP Gene|SYP|SYP|SYP|Synaptophysin Gene	This gene is involved in vesicle targeting and synaptic plasticity.	SYP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C101145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101145>	C101144	SYP wt Allele|MRX96|MRXSYP|Synaptophysin wt Allele	Human SYP wild-type allele is located within Xp11.23-p11.22 and is approximately 12 kb in length. This allele, which encodes synaptophysin protein, plays a role in synaptic functions. Mutation of the gene is associated with SYP-related mental retardation X-linked.	SYP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101146>	C16386	Synaptophysin|Major Synaptic Vesicle Protein p38|SYP	Synaptophysin (313 aa, ~34 kDa) is encoded by the human SYP gene. This protein is involved in the targeting of synaptic vesicles.	Synaptophysin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101147>	C912	CD57 Antigen|CD57|HNK-1|HNK1|Human Natural Killer-1 Antigen|L2/HNK-1|Leu7	A carbohydrate molecule that contains a sulfoglucuronyl residue and found predominantly on the surface of natural killer cells. It is involved in the modulation of cell-cell and cell-matrix interactions.			Immunologic Factor|Organic Chemical	
C101148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101148>	C20744	DSG3 Gene|DSG3|DSG3|Desmoglein 3 Gene	This gene plays a role in cell-cell adhesion.	DSG3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101149>	C101148	DSG3 wt Allele|ABOLM|CDHF6|Desmoglein 3 (Pemphigus Vulgaris Antigen) Gene|Desmoglein 3 wt Allele|PVA|Pemphigus Vulgaris Antigen Gene	Human DSG3 wild-type allele is located in the vicinity of 18q12.1 and is approximately 31 kb in length. This allele, which encodes desmoglein-3 protein, is involved in the modulation of cell-cell adhesion.	DSG3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10114>	C61063	Biostim/Doxorubicin/Etoposide/Prednisone|biostim/DOX/PRED/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101150>	C18073	Desmoglein-3|130 kDa Pemphigus Vulgaris Antigen|Cadherin Family Member 6|DESMOGLEIN 3|DSG3|Desmoglein 3|PVA	Desmoglein-3 (999 aa, ~108 kDa) is encoded by the human DSG3 gene. This protein plays a role in desmosome-mediated cell-cell adhesion.	Desmoglein-3		Amino Acid, Peptide, or Protein	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101151>	C21295	SPN Gene|CD43|SPN|SPN|Sialophorin Gene	This gene is involved in leukocyte migration.	SPN Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101152>	C101151	SPN wt Allele|CD43|GPL115|LSN|Leukosialin Gene|Sialophorin wt Allele|gpL115	Human SPN wild-type allele is located in the vicinity of 16p11.2 and is approximately 8 kb in length. This allele, which encodes leukosialin protein, plays a role in both chemotaxis and leukocyte migration.	SPN wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101153>	C17728	Leukosialin|Antigen CD43|CD43|CD43|CD43 Antigen|GALGP|Galactoglycoprotein|Leukocyte Large Sialoglycoprotein|Leukocyte Sialoglycoprotein|Sialophorin	Leukosialin (400 aa, ~40 kDa) is encoded by the human SPN gene. This protein is involved in immune cell function.	Leukosialin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C101154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101154>	C25869|C20988	CD9 Gene|CD9|CD9|CD9 Molecule Gene	This gene is involved in both cell adhesion and platelet function.	CD9 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101155>	C101154	CD9 wt Allele|BA2|BTCC-1|CD9 Molecule wt Allele|DRAP-27|MIC3|MRP-1|Motility Related Protein-1 Gene|P24|TSPAN-29|TSPAN29	Human CD9 wild-type allele is located in the vicinity of 12p13.3 and is approximately 39 kb in length. This allele, which encodes CD9 antigen protein, plays a role in platelet degranulation, sperm-egg fusion and cell adhesion.	CD9 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101156>	C16393	CD9 Antigen|5H9 Antigen|Antigen CD9|CD9|Cell Growth-Inhibiting Gene 2 Protein|Leukocyte Antigen MIC3|MRP-1|Motility-Related Protein|Motility-Related Protein -1|Tetraspanin-29|Tspan-29|p24	CD9 antigen (228 aa, ~25 kDa) is encoded by the human CD9 gene. This protein is involved in both sperm-egg fusion and platelet degranulation.	CD9 Antigen		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101157>	C16616	HLA-DRA Gene|HLA-DRA|HLA-DRA|Major Histocompatibility Complex, Class II, DR Alpha Gene	This gene plays a role in antigen presentation.			Gene or Genome	
C101158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101158>	C101157	HLA-DRA wt Allele|DASS-397D15.1|HLA-DRA1|MLRW|Major Histocompatibility Complex, Class II, DR Alpha wt Allele	Human HLA-DRA wild-type allele is located in the vicinity of 6p21.3 and is approximately 5 kb in length. This allele, which encodes HLA class II histocompatibility antigen, DR alpha chain protein, is involved in the mediation of antigen presentation.			Gene or Genome	
C101159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101159>	C16692	HLA Class II Histocompatibility Antigen, DR Alpha Chain|HLA-DRA|Histocompatibility Antigen HLA-DR Alpha|MHC Class II Antigen DRA	HLA class II histocompatibility antigen, DR alpha chain (254 aa, ~29 kDa) is encoded by the human HLA-DRA gene. This protein plays a role in the presentation of antigen for recognition by CD4 T-cells.	HLA Class II Histocompatibility Antigen, DR Alpha Chain		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10115>	C61063	Doxorubicin/Fluorouracil/Methotrexate/Mitomycin|DOX/5-FU/MITO/MTX|M-FAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101161>	C3303	Agonizing Pain	A sensation of great anguish and suffering.			Sign or Symptom	
C101162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101162>	C3303	Annoying Pain	A sensation of discomfort or distress that is bothersome and irritating.			Sign or Symptom	
C101163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101163>	C3303	Killing Pain	A sensation of extreme discomfort and anguish that is perceived as severe enough to cause one's death.			Sign or Symptom	
C101164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101164>	C3303	Miserable Pain	A sensation of discomfort or distress that renders an individual unable to find any happiness.			Sign or Symptom	
C101165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101165>	C3303	Nagging Pain	A sensation of discomfort or distress that is persistent and continuous.			Sign or Symptom	
C101166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101166>	C3303	Sickening Pain	A sensation of discomfort or distress that makes the individual queasy or nauseated.			Sign or Symptom	
C101167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101167>	C3303	Terrifying Pain	A sensation of discomfort or distress that is frightening or scary.			Sign or Symptom	
C101168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101168>	C3303	Tiring Pain	A sensation of discomfort or distress that renders an individual weary and without energy.			Sign or Symptom	
C101169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101169>	C3303	Torturing Pain	A sensation of having discomfort or distress inflicted upon an individual.			Sign or Symptom	
C10116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10116>	C61063	Daunorubicin/Mercaptopurine/Methotrexate/Prednisone/Vincristine|DNR/MP/MTX/PRED/VCR|MTX-DOMP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101170>	C3303	Troublesome Pain	A sensation of discomfort or distress that worries an individual or interrupts their ability to complete desired activities.			Sign or Symptom	
C101171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101171>	C3303	Unbearable Pain	A sensation of extreme discomfort and anguish that is overwhelming and unendurable.			Sign or Symptom	
C101172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101172>	C3303	Burning Pain	A sensation of intensely hot or searing discomfort.			Sign or Symptom	
C101173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101173>	C3303	Cramping Pain	A sense of discomfort or distress that is spasmodic or clenching.			Sign or Symptom	
C101174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101174>	C3303	Crushing Pain	A sense of discomfort or distress that is squeezing or excessively compressing.			Sign or Symptom	
C101175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101175>	C3303	Dull Pain	A sensation of discomfort or distress that is non-specific or without clear boundaries.			Sign or Symptom	
C101176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101176>	C3303	Hurting Pain	A sensation of discomfort or distress that is very unpleasant.			Sign or Symptom	
C101177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101177>	C3303	Pressing Pain	A sensation of discomfort or distress from excess weight or pressure on a specific anatomical location.			Sign or Symptom	
C101178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101178>	C3303	Radiating Pain	A sensation of discomfort or distress that spreads from one anatomic location to another.			Sign or Symptom	
C101179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101179>	C3303	Sharp Pain	A sensation of discomfort or distress that is distinct and intensely focused.			Sign or Symptom	
C10117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10117>	C61063	Mitolactol/Mitoxantrone/Vincristine|D(DHAD)V|DBD/DHAD/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101180>	C3303	Shooting Pain	An intense sensation of discomfort or distress that radiates from one location to another sharply.			Sign or Symptom	
C101181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101181>	C3303	Splitting Pain	An intense sensation of discomfort or distress that feels like being cut apart.			Sign or Symptom	
C101182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101182>	C3303	Stabbing Pain	An intense sensation of discomfort or distress that is sharp and feels as though a knife has penetrated an anatomical location.			Sign or Symptom	
C101183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101183>	C3303	Tearing Pain	An intense sensation of discomfort or distress that feels like being torn or ripped apart.			Sign or Symptom	
C101184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101184>	C20995	Painometer	A self-administered pain assessment tool the Pain-O-Meter (POM) was developed in 1996 by F. Gaston-Johansson to improve the assessment and management of acute and chronic pain.			Intellectual Product	
C101185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101185>	C84742	Dextro-Transposition of the Great Vessels with Intact Ventricular Septum|D-Transposition of the Great Vessels with Intact Ventricular Septum	A congenital heart defect in which there is an abnormal arrangement of any of the primary blood vessels of the heart in conjunction with the notable absence of any pathologic opening between the cardiac ventricles.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101186>	C84742	Dextro-Transposition of the Great Vessels with Ventricular Septal Defect|D-Transposition of the Great Vessels with Ventricular Septal Defect|D-Transposition of the Great Vessels with Ventricular Septal Defect	A congenital heart defect in which there is an abnormal arrangement of any of the primary blood vessels of the heart in conjunction with a pathologic opening between the cardiac ventricles.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101187>	C98814	Bilateral Anophthalmos|Anophthalmos, Bilateral	A rare congenital abnormality characterized by the complete absence of ocular tissue in both orbits.			Congenital Abnormality	Neonatal Research Network Terminology|NICHD Terminology
C101188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101188>	C98814	Unilateral Anophthalmos|Anophthalmos, Unilateral	A rare congenital abnormality characterized by the complete absence of ocular tissue in one orbit.			Congenital Abnormality	Neonatal Research Network Terminology|NICHD Terminology
C101189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101189>	C98989	Bilateral Microphthalmos|Microphthalmos, Bilateral	A congenital abnormality characterized by the presence of two abnormally small eye globes.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C10118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10118>	C61063	Doxorubicin/Thiotepa/Vinblastine|DOX/TSPA/VBL|TAV			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101190>	C98989	Unilateral Microphthalmos|Microphthalmos, Unilateral	A congenital abnormality characterized by the presence of one abnormally small eye globe and one normally sized eye globe.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101191>	C98802|C101193	Acquired Bilateral Cataracts	Cataracts in both eyes that result from the aging process, an injury, or as a manifestation of a systemic disorder.			Disease or Syndrome	NICHD Terminology
C101192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101192>	C98802	Acquired Unilateral Cataract|Cataract, Acquired, Unilateral	A cataract in one eye that results from the aging process, an injury, or as a manifestation of a systemic disorder.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101193>	C26713	Bilateral Cataracts	Partial or complete opacity of the crystalline lens of both eyes that decreases visual acuity and eventually results in blindness. Some cataracts appear in infancy or in childhood, but most develop in older individuals. (Sternberg Diagnostic Surgical Pathology, 3rd ed.)			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101194>	C98888|C101193	Congenital Bilateral Cataracts|Cataract, Congenital, Bilateral	Cataract in both eyes that are present at birth.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101195>	C98888	Congenital Unilateral Cataract|Cataract, Congenital, Unilateral	Cataract in one eye that is present at birth.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101196>	C50802	Congenital Ventricular Tachycardia|Congenital VT|Congenital VTach	An electrocardiographic finding of a tachycardia that originates in the ventricles that is present at birth.			Finding	Neonatal Research Network Terminology|NICHD Terminology
C101197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101197>	C35061	Congenital Supraventricular Tachycardia|Congenital SVT|Congenital SVT|Supraventricular Tachycardia (SVT), Congenital|Supraventricular Tachycardia (SVT), Congential	A disorder present at birth characterized by an electrocardiographic finding of a tachycardia that originates above the ventricles.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101198>	C97172|C26769	Congenital Facial Nerve Palsy	Partial or complete paralysis of the facial muscles of one side of an individual's face that is present at birth. It is caused by damage to the seventh cranial nerve.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology|Perinatal Terminology
C101199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101199>	C99017	Congenital Phrenic Nerve Palsy|Phrenic Nerve Palsy, Congenital	Damage to the phrenic nerve that results in paralysis of the hemidiaphragm at birth.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology|Perinatal Terminology
C10119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10119>	C61063	Cytarabine/Melphalan|AMA|ARA-C/L-PAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1011>	C1976	Beauvericin|BEAUVERICIN	A cyclic hexadepsipeptide antibiotic and mycotoxin isolated from the fungus Beauveria bassiana and various Fusarium fungal species.  As a potassium-specific ionophore, beauvericin A increases intracellular calcium concentrations and triggers DNA fragmentation and apoptosis through a calcium dependent caspase 3-sensitive pathway.  This agent has been studied as a potential antineoplastic agent. (NCI04)			Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C101200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101200>	C98995|C3991	Neonatal Alloimmune Thrombocytopenia|NAIT|Neonatal Thrombocytopenia due to Platelet Alloimmunization	Thrombocytopenia that occurs in neonates as a consequence of transplacental passage of maternal alloantibodies directed against fetal platelet antigens.			Disease or Syndrome	Cellosaurus Disease Terminology|Neonatal Research Network Terminology|NICHD Terminology|Perinatal Terminology
C101201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101201>	C101214	Myelomeningocele|Meningomyelocele|Spina Bifida Cystica|Spina Bifida Cystica	A congenital abnormality in which the spinal cord and meninges protrude through a defect in the spinal column. The protrusion is above the skin surface.			Disease or Syndrome	Cellosaurus Disease Terminology|Neonatal Research Network Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C101202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101202>	C101201	Cervical Myelomeningocele|Cervical Meningomyelocele|Cervical Meningomyelocele	A congenital abnormality in the cervical region of the spine in which the spinal cord and meninges protrude through a defect in the spinal column. The protrusion is above the skin surface.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101203>	C101201	Lumbar Myelomeningocele|Lumbar Meningomyelocele|Lumbar Meningomyelocele	A congenital abnormality in the lumbar region of the spine, in which the spinal cord and meninges protrude through a defect in the spinal column. The protrusion is above the skin surface.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101204>	C27993	Indefinite	Without end.			Qualitative Concept	
C101205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101205>	C64248	Debond Procedure|Debond	A procedure in orthodontics in which brackets are removed from the teeth.			Therapeutic or Preventive Procedure	
C101206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101206>	C38052	Circumferential Supracrestal Fiberotomy|CSF	A surgical procedure to prevent rotational relapse of teeth after an orthodontic treatment; the epithelial attachment surrounding the involved teeth is severed.			Health Care Activity	
C101207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101207>	C101201	Sacral Myelomeningocele|Congenital Sacral Meningocele|Sacral Meningomyelocele	A congenital abnormality in the sacral region of the spine, in which the spinal cord and meninges protrude through a defect in the spinal column. The protrusion is above the skin surface.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101208>	C101201	Thoracic Myelomeningocele|Thoracic Meningomyelocele|Thoracic Meningomyelocele	A congenital abnormality in the thoracic region of the spine, in which the spinal cord and meninges protrude through a defect in the spinal column. The protrusion is above the skin surface.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101209>	C105595	Spinal Meningocele|Meningocele	A congenital abnormality in which the meninges protrude through a defect in the spinal column.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C10120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10120>	C61007	Buthionine Sulfoximine/Melphalan|BSO/L-PAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101210>	C101209	Cervical Meningocele	A congenital abnormality in the cervical region of the spine in which the meninges protrude through a defect in the spinal column.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101211>	C101209	Lumbar Meningocele	A congenital abnormality in the lumbar region of the spine in which the meninges protrude through a defect in the spinal column.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101212>	C101209	Sacral Meningocele	A congenital abnormality in the sacral region of the spine in which the meninges protrude through a defect in the spinal column.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101213>	C101209	Thoracic Meningocele	A congenital abnormality in the thoracic region of the spine in which the meninges protrude through a defect in the spinal column.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101214>	C97172|C27586	Spina Bifida|Rachischisis|SPINA BIFIDA|Spinal Meningocele|Spinal Myelocele|Spinal Myelomeningocele	A congenital neural tube defect in which vertebrae are not fully formed. It results in the protrusion of the spinal cord through the opening of the vertebrae.			Disease or Syndrome	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Cellosaurus Disease Terminology|Clinical Data Interchange Standards Consortium Terminology|Neonatal Research Network Terminology|NICHD Terminology
C101215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101215>	C53543	Mullerian Inhibiting Factor Deficiency|MIS Deficiency|Mullerian Inhibiting Substance Deficiency|Mullerian Inhibiting Substance Deficiency|Müllerian Inhibiting Factor Deficiency|Müllerian Inhibiting Substance Deficiency	A deficiency of the Mullerian inhibiting substance, which is secreted by the Sertoli cells during embryogenesis. It can result in unilateral or bilateral cryptorchidism, testicular regression syndrome and sterility.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101216>	C118317	Myopathy	A non-neoplastic disorder that affects the muscles. Representative examples include muscular dystrophy, metabolic myopathies, muscular atrophies, and dermatomyositis.			Disease or Syndrome	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|Neonatal Research Network Terminology|NICHD Terminology
C101217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101217>	C38060	Retinal Examination	An examination of the retina of the eye using an ophthalmoscope.			Diagnostic Procedure	Neonatal Research Network Terminology|NICHD Terminology
C101218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101218>	C34379	Hemolytic Anemia due to Membrane Defect|Anemia due to Membrane Defect|Hemolytic Anemia due to Erythrocyte Membrane Defect	A group of inherited hemolytic anemias caused by erythrocyte membrane defects. This includes hereditary pyropoikilocytosis, hereditary spherocytosis and hereditary elliptocytosis.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C101219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101219>	C99041	Bilateral Renal Agenesis	A congenital abnormality characterized by the absence of both kidneys.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C10121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10121>	C61063	Cyclophosphamide/Cytarabine/Etoposide/Methotrexate/Prednisone/Vincristine|ARA-C/CTX/MTX/PRED/VCR/VP-16|MOPLACE			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101220>	C99041	Unilateral Renal Agenesis|Congenital Single Kidney|Congenital Solitary Kidney|Congenital Solitary Kidney	A congenital abnormality characterized by the presence of only one kidney.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology|Pediatric Nephrology Terminology
C101221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101221>	C81255	Birth Head Circumference|Head Circumference at Birth|Head Circumference at Initial Disposition	The measurement around a neonate's head at birth.			Quantitative Concept	INC Demographic and Maternal Terminology|INC Terminology|Neonatal Research Network Terminology|NICHD Terminology
C101222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101222>	C2993	Complete Trisomy 21 Syndrome|Down Syndrome	A syndrome characterized by the presence of three complete copies of genetic material for chromosome 21, instead of the normal two. It leads to a variety of abnormalities that include mental retardation, macroglossia, microgenia, epicanthic eyelids, and a single transverse palmar crease.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C101223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101223>	C28193	Complete Trisomy 13 Syndrome|Patau Syndrome	A syndrome characterized by the presence of three complete copies of genetic material for chromosome 13, instead of the normal two. It leads to a variety of abnormalities that include mental retardation, microcephaly, low-set ears, eye structural defects, polydactyly, and limb abnormalities.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101224>	C25464	Bonaire, Sint Eustatius and Saba|535|535|BES|BES|BONAIRE, SINT EUSTATIUS AND SABA|BONAIRE, SINT EUSTATIUS, AND SABA|BQ	Three islands comprising the Caribbean portion of the Netherlands, north of Venezuela and east of Curacao.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Geopolitical Entities, Names, and Codes Terminology
C101225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101225>	C25464	Curacao|531|CURACAO|CURAÇAO|CUW|CUW|CW|Curaçao	An island in the Caribbean Sea, north of Venezuela and east of Aruba, a constituent country of the Kingdom of the Netherlands.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C101226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101226>	C25464	Sint Maarten (Dutch Part)|534|SINT MAARTEN|SINT MAARTEN (DUTCH PART)|SINT MAARTEN (DUTCH)|SX|SXM|SXM|Saint Martin, Dutch|Saint Martin, Netherlands	A country comprising the southern portion of an island in the Caribbean sea, between Anguilla and Saint Barthelemy, a constituent country of the Kingdom of the Netherlands.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Geopolitical Entities, Names, and Codes Terminology
C101227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101227>	C156880	Zelavespib|9H-Purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)-|Hsp90 Inhibitor PU-H71|PU-H-71|PU-H71|PUH71|ZELAVESPIB	A purine-based heat shock protein 90 (Hsp90) inhibitor with potential antineoplastic activity. Zelavespib specifically inhibits active Hsp90, thereby inhibiting its chaperone function and promoting the proteasomal degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. This may result in the inhibition of cellular proliferation in susceptible tumor cell populations. Hsp90, a molecular chaperone protein, is upregulated in a variety of tumor cell types.	Zelavespib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101228>	C26782	Bilateral Glaucoma	Increased pressure in both eyeballs due to obstruction of the outflow of aqueous humor.			Disease or Syndrome	
C101229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101229>	C26740	Hypernatremic Dehydration	Dehydration resulting from abnormally high levels of sodium in the blood. Infants and individuals that are intubated are at highest risk.			Finding	Neonatal Research Network Terminology|NICHD Terminology
C10122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10122>	C63470	TPDCV Regimen|CCNU/DBD/PCB/TG/VCR|TPDCV|TPDCV|TPDCV|Thioguanine-Procarbazine-Mitolactol-Lomustine-Vincristine|Thioguanine/Procarbazine/Mitolactol /CCNU/Vincristine|Thioguanine/Procarbazine/Mitolactol /Lomustine/Vincristine Thioguanine/Procarbazine/Mitolactol l/Lomustine/Vincristine Regimen	A regimen consisting of thioguanine, procarbazine, mitolactol (dibromodulcitol), lomustine, and vincristine that may be used in the treatment of malignant glioma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C101230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101230>	C171082	Triage Status|PRUSTAT|PRUSTAT|Procedure Urgency Status Type|Procedure Urgency Status Type|Procedure Urgency Status Type	The degree of urgency in which a medical procedure must be performed. (ACC)			Qualitative Concept	CDISC SDTM Cardiovascular Findings About Test Code Terminology|CDISC SDTM Cardiovascular Findings About Test Name Terminology|CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101231>	C81906	Medical Device Deployment	The act of instantiating, positioning or activating a medical device inside of the body. (ACC)			Activity	
C101232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101232>	C16830	Intracoronary Device	A device for use within the coronary anatomy. (ACC)			Medical Device	
C101233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101233>	C100063	Coronary Vessel Bifurcation Lesion	A lesion found in the division of a vessel into at least two branches, each of which is 1.5 mm or greater in diameter. (ACC)			Finding	
C101234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101234>	C15315	Cardiac Rehabilitation	A medically supervised program to improve the health and well-being of people who have heart problems. This may include exercise training, education on heart healthy living, and/or counseling to reduce stress. (ACC)	Cardiac Rehabilitation		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology
C101235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101235>	C61547	Exercise Counseling	A process by which a health professional creates a regimen of physical activity intended to maintain or improve the health of a subject. (ACC)	Exercise Counseling		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C101236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101236>	C48228	Defibrillation Threshold	The lowest energy where a defibrillator device terminates an arrhythmia in a particular subject. (ACC)			Quantitative Concept	
C101237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101237>	C48228	Upper Limit of Vulnerability for Induction of Ventricular Fibrillation	Stimulus strength above which electrical stimulation from a cardiac device cannot induce ventricular fibrillation even when the stimulus occurs during the vulnerable period of the cardiac cycle. (ACC)			Quantitative Concept	
C101238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101238>	C25180	Cardiac Lead Function Indicator	An indicator to describe whether the electrical lead device is performing as intended. (ACC)			Conceptual Entity	
C101239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101239>	C16830	In Situ Existing Lead	An insulated electrical conductor designed to connect to an electrical device for which the lead is in situ. (ACC)			Medical Device	
C10123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10123>	C61063	Cisplatin/Cyclophosphamide/Doxorubicin/Misonidazole|CDDP/CTX/DOX/MNI|M-CAP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101240>	C160943	In Situ Lead Status	The state of an insulated wire designed to conduct energy from an electrical device to an anatomic site. (ACC)			Qualitative Concept	
C101241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101241>	C62950	Lead Dislodgement	Movement of a lead away from the original implantation site. (ACC)			Event	
C101242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101242>	C64982	Reimplantation	A surgical procedure that places something in the body that was previously lost or removed.			Therapeutic or Preventive Procedure	
C101243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101243>	C52681	Substance Adverse Event	An unexpected or dangerous reaction to a substance (e.g., food, environmental agent). (ACC)			Finding	
C101244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101244>	C61547|C15372	Tobacco Cessation Counseling	A process by which a health professional provides education, recommendations, or interventions to help clients stop using tobacco products. (ACC)	Tobacco Cessation Counseling		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C101245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101245>	C191466	Antitachycardia Pacing	Delivery of electrical impulses to the heart at a faster rate than the intrinsic rate during an episode of tachycardia, in an attempt to terminate the abnormal tachycardia. (ACC)			Therapeutic or Preventive Procedure	
C101246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101246>	C4080	Perforation due to Lead	Penetration of a lead through a systemic vein, coronary vein, or the myocardium. (ACC)			Finding	
C101247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101247>	C45501	Appropriate Treatment	Correct activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects. (ACC)			Clinical Attribute	
C101248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101248>	C49165	Explantation|EXPLANTED	A surgical procedure that removes something that was implanted in the body.	Explantation		Health Care Activity	CDISC SDTM Device Tracking and Disposition Event Dictionary Derived Term Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C101249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101249>	C50547	Peripheral Embolus	Acute occlusion of a peripheral blood vessel resulting from intravascular migration of material. Examples of embolic material include thrombus, fat, bone marrow, air, and amniotic fluid. (ACC)			Finding	
C10124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10124>	C61063	Bleomycin/Cyclophosphamide/Cytarabine/Doxorubicin/Methotrexate/Prednisone/Vincristine|ARA-C/BLEO/CTX/DOX/MTX/PRED/VCR|COMLA-Plus			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101250>	C50669	Peripheral Nerve Injury|Peripheral Nervous Injury	Sensory or motor loss of peripheral nerve function due to a traumatic event. (ACC)			Finding	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|SeroNet Authorized Values|SeroNet Study Descriptors
C101251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101251>	C99948	Cardioverter Defibrillator Shock Therapy|Cardiac Defibrillator Procedure	Delivery of strong electrical impulses by a cardioverter defibrillator to return the electrical activity of the heart to normal. (ACC)			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Procedures Codelist|CPTAC Terminology
C101252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101252>	C3284	Venous Obstruction	Partial or total occlusion of a vein. (ACC)			Finding	
C101253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101253>	C35317	Aorta Disease	Pathology involving the thoracic, thoracoabdominal, or abdominal aorta (including aneurysms). (ACC)			Disease or Syndrome	
C101254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101254>	C35317	Renal Artery Disease	Pathology involving the main renal arteries or extrarenal arterial branches. (ACC)			Disease or Syndrome	
C101255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101255>	C2355	Aldosterone Receptor Antagonist|Aldosterone inhibitor (mineralocorticoid receptor antagonist)|Antimineralocorticoid	A class of agents that act by selectively inhibiting aldosterone receptor activation with diuretic activity. Aldosterone receptor antagonists bind to and block the activation of aldosterone (mineralocorticoid) receptors on the epithelial cells in the late distal tubule and collecting duct of the kidney, thus preventing the synthesis of aldosterone-induced proteins which enhance Na+ retention and K+ and H+ secretion. The enhanced excretion of Na+ produces diuresis ultimately resulting in a reduction in blood pressure without the loss of K+.			Chemical Viewed Functionally	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|Appendix 8: Pharmacological Therapy Terminology|Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission) Terminology
C101256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101256>	C1327	Glycoprotein IIb/IIIa Antagonist	A class of agents that act by selectively inhibiting glycoprotein IIb/IIIa with anticoagulant activity. Glycoprotein IIb/IIIa antagonists bind to and block the activation of the platelet-surface integrin glycoprotein IIb/IIIa, thus preventing the binding of fibrinogen and von Willebrand factor leading to the inhibition of platelet activation and aggregation.			Chemical Viewed Functionally	
C101257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101257>	C129826	IGF-1R Antisense Oligodeoxynucleotide-treated Autologous Glioma Cells IGV-001|IGF-1R/AS ODN-treated Autologous Glioma Cells IGV-001|IGV 001|IGV-001|IGV001	A preparation of irradiated autologous glioma cells treated ex vivo with IMV-001, an antisense oligodeoxynucleotide of insulin-like growth factor receptor 1 (IGF-1R/AS ODN), and encapsulated within bio-diffusion chambers, with potential antineoplastic activity. The IGF-1R/AS ODN IMV-001-treated autologous glioma cells IGV-001 are encapsulated within implantable and removable bio-diffusion chambers with additional IMV-001, irradiated, and implanted into the patient. The IGF-1R/AS ODN binds to IGF-1R mRNA in glioma cells, and shuts down the translation of IGF-1R in the glioma cells. Downregulation of IGF-1R, in addition to irradiation, induces apoptosis and causes the release of exosomes, which contain tumor-associated antigens (TAAs). The diffusion of exosomes together with the additional IMV-001 from the bio-diffusion chambers may activate the patient's immune system and mount a cytotoxic T-lymphocyte (CTL) response against cells expressing these TAAs. IGF-1R, a receptor tyrosine kinase, is overexpressed in a variety of tumor cell types and is essential for tumor cell growth, transformation and survival.	IGF-1R Antisense Oligodeoxynucleotide-treated Autologous Glioma Cells IGV-001		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101258>	C200765|C176018	CD19CAR-CD3zeta-4-1BB-expressing Allogeneic T-lymphocyte Cells|CART-19 Cells	Allogeneic T-lymphocytes transduced with a modified lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. Upon transfusion, CD19CAR-CD3zeta-4-1BB-expressing allogeneic T-lymphocyte cells direct the T-lymphocytes to CD19-expressing tumor cells, thereby inducing a selective toxicity in CD19-expressing tumor cells. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19 and the inclusion of this signaling domain may increase the antitumor activity compared to the inclusion of the CD3-zeta chain alone. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.	CD19CAR-CD3zeta-4-1BB-expressing Allogeneic T-lymphocyte Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C10125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10125>	C61063	Cytarabine/Dexamethasone/Methotrexate|ARA-C/DM/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101260>	C129820	Multifunctional/Multitargeted Anticancer Agent OMN54|Aneustat|MFMT OMN54|OMN54	An orally available, multivalent herbal formulation containing a novel mixture of whole extracts from three commonly used Chinese medicinal herbs Ganoderma lucidum (lingzhi mushroom), Salvia miltiorrhiza (Chinese sage, or danshen) and Scutellaria barbata (ban zhi lian), with potential immunomodulating, antiangiogenic, anti-inflammatory, antiproliferative and antiviral activities. Although the exact mechanism of action remains to be fully elucidated due to the complexity of the multiple phytochemicals, multifunctional/multitargeted anticancer agent OMN54 appears to work in an additive and synergistic manner by acting on a variety of signaling pathways and on multiple targets, such as vascular endothelial growth factor, nuclear factor kappa B, interleukin-1beta, fibroblast growth factor, and epidermal growth factor.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101261>	C1512	Bevacizumab-IRDye 800CW	An immunoconjugate and a fluorescent tracer consisting of the recombinant humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab conjugated to the N-hydroxysuccinamide (NHS) ester form of the near-infrared (NIR) fluorescent dye IRDye 800CW, that may be used for VEGF-specific tumor imaging. Upon administration, the bevacizumab moiety of bevacizumab-IRDye 800CW binds to VEGF and the fluorescent signal can be visualized using NIR fluorescence imaging (700-1,000 nm).			Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101262>	C53290	Liposomal MUC1/PET-lipid A Vaccine ONT-10|ONT-10	A cancer vaccine comprised of a 43 amino acid epitope from glycoprotein MUC1 (mucin 1) and the synthetic Toll-like receptor 4 (TLR-4) agonist PET lipid A encapsulated in cholesterol/dipalmitoylphosphatidylcholine (DPPC)/dimyristoylphosphatidylglycerol (DMPG) liposomes, with potential immunostimulatory and antineoplastic activities. The MUC1 epitope is composed of two 20 amino glycosylated VNTR (various number tandem repeats) from human MUC1A and including 6 glycosylated sites modified by Tn (alfa-N-acetyl-D-galactosamine). Immunization of liposomal MUC1/PET-lipid A vaccine ONT-10 results in an antibody as well as a cytotoxic T-lymphocyte (CTL) response against hypoglycosylated MUC1 expressing tumor cells. The tumor associated antigen MUC1, a type I transmembrane protein, is overexpressed and aberrantly glycosylated in a variety of tumor cells. As a vaccine adjuvant, PET lipid A, also known as penta erythritol lipid A, stimulates both cellular and humoral responses to the vaccine antigen.			Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101263>	C217652	Sofosbuvir|GS-7977|L-Alanine, N-[[P(S),2'R]-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-, 1-methylethyl Ester|PSI-7977|SOFOSBUVIR	An orally available nucleotide prodrug and a hepatitis C virus (HCV) NS5B polymerase inhibitor with potential HCV inhibiting activity. Upon oral administration, sofosbuvir is metabolized to 2'-deoxy-2'-alpha-fluoro-beta-C-methyluridine-5'-monophosphate, which is then converted into the active triphosphate nucleotide that inhibits the NS5B polymerase, thereby preventing viral replication. The HCV NS5B protein, an RNA-dependent RNA polymerase, is essential for the replication of the viral HCV RNA genome.	Sofosbuvir		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C101264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101264>	C25974	Valecobulin|(S)-N-(4-(3-(1H-1,2,4-Triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide Hydrochloride|CKD-516|Tubulin Polymerization Inhibitor CKD-516|VALECOBULIN	A benzophenone derivative and water soluble valine prodrug of the tubulin binding agent S516, with potential tubulin-inhibiting, vascular-disrupting and antineoplastic activity. Upon administration, valecobulin is converted into its active metabolite S-516 that binds to tubulin and prevents its polymerization in tumor blood vessel endothelial cells and tumor cells. This blocks the formation of the mitotic spindle and leads to cell cycle arrest at the G2/M phase. As a result, this agent disrupts the tumor vasculature and tumor blood flow, deprives tumor cells of nutrients and induces tumor cell apoptosis. In addition, this agent has a direct cytotoxic effect on tumor cells by inhibiting tubulin polymerization.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101265>	C2139	Bovine Lactoferrin Supplement|bLF Supplement	A supplement containing lactoferrin derived from bovine milk with potential chemopreventive, immunostimulating, and antimicrobial activity. Upon administration, lactoferrin binds to metal in the oral cavity and may prevent metal-induced oxidation of lipids. This may reduce the metallic taste and taste disturbances induced by certain metal-containing chemotherapeutics; metal-induced lipid oxidation, and the subsequent production of aldehydes and ketones attribute to the metallic smell. Lactoferrin, a glycoprotein belonging to the transferrin family of metal-binding proteins, can be found in milk and other secretory fluids as well as in polymorphonuclear cells and leukocytes; lactoferrin plays a role in the innate defense of mucosal surfaces and its iron-binding activity is associated with the antibacterial activity.	Bovine Lactoferrin Supplement		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C101266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101266>	C51698|C15361	Random Periareolar Fine-Needle Aspiration|RPFNA|Random Periareolar Fine Needle Aspiration	A procedure in which a fine needle is inserted around the area of the areola to aspirate cells from the breast parenchyma and is used to evaluate the short-term risk of developing breast cancer in women with a family history of breast cancer.	Random Periareolar Fine-Needle Aspiration		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C101267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101267>	C188928|C177692	Hormone Receptor Positive	A finding indicating that the neoplastic cells in a tissue sample test positive for hormone receptors.	Hormone Receptor Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101268>	C98999	Bilateral Optic Nerve Hypoplasia|Bilateral Hypoplasia of the Optic Nerve|Hypoplasia of the Optic Nerve, Bilateral	A congenital abnormality characterized by the underdevelopment of both optic nerves.			Disease or Syndrome	Cellosaurus Disease Terminology|Neonatal Research Network Terminology|NICHD Terminology
C101269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101269>	C98999	Unilateral Optic Nerve Hypoplasia|Hypoplasia of the Optic Nerve, Unilateral|Unilateral Hypoplasia of the Optic Nerve	A congenital abnormality characterized by the underdevelopment of one optic nerve.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C10126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10126>	C61063	Fluorouracil/Prednisone/Vincristine|5-FU/PRED/VCR|VPF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101270>	C84799	Kernicterus Related to Isoimmunization|Kernicterus due to Isoimmunization|Kernicterus due to Isoimmunization|Kernicterus related to Isoimmunization	Encephalopathy in infants due to high levels of unconjugated bilirubin that are a result of Rh incompatibility between the mother and the fetus.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology|Perinatal Terminology
C101271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101271>	C36280	Perinatal Central Nervous System Depression|Difficult Transition to Extrauterine Life	Generalized depression of the central nervous system of an infant during the perinatal period.			Finding	Neonatal Research Network Terminology|NICHD Terminology
C101272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101272>	C99063	Spinal Cord Infarct During Birth|Spinal Cord Infarct Related to Birth|Spinal Cord Infarct during Birth	Ischemic necrosis of the spinal cord due to spinal artery occlusion during the birthing process.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology|Perinatal Terminology
C101273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101273>	C84915	Suspected Necrotizing Enterocolitis	The diagnosis assigned when a health care practitioner feels strongly the patient has necrotizing enterocolitis, but lacks definitive proof.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101274>	C98804	Traumatic Chylothorax	Accumulation of lymph fluid in the pleural cavity as a result of thoracic trauma.			Finding	Neonatal Research Network Terminology|NICHD Terminology
C101275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101275>	C36279	Duodenal Band	A pathologic fibrous band that impedes passage of intestinal contents through the duodenum.			Finding	Neonatal Research Network Terminology|NICHD Terminology
C101276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101276>	C36279	Ileal Band	A pathologic fibrous band that impedes passage of intestinal contents through the ileum.			Finding	Neonatal Research Network Terminology|NICHD Terminology
C101277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101277>	C36279	Jejunal Band	A pathologic fibrous band that impedes passage of intestinal contents through the jejunum.			Finding	Neonatal Research Network Terminology|NICHD Terminology
C101278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101278>	C101035	Spinal Injury Related to Birth|Spinal Cord Injury Related to Birth|Spinal Injury Related to Birth Trauma|Spinal Injury Related to Birth Trauma	An injury to the spine sustained during the birthing process.			Finding	Neonatal Research Network Terminology|NICHD Terminology|Perinatal Terminology
C101279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101279>	C27659	Laryngeal Agenesis|Agenesis of Larynx	A congenital deformity in which there is no laryngeal structure.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C10127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10127>	C61063	Cisplatin/Fluorouracil/Mitomycin/Vincristine|CDDP/5-FU/MITO/VCR|MVPF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101281>	C43646	Has_Data_Element	An association created to relate a data element concept to the codelist term that is used to bundle its subset of valid value concepts.			Conceptual Entity	
C101282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101282>	C20181	Have|Had|Has	Used to describe the possession, relationships, or the state of something or someone.			Classification	
C101283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101283>	C20194	PIK3R2 Gene|PIK3R2|PIK3R2|Phosphoinositide-3-Kinase Regulatory Subunit 2 Gene	This gene is involved in the regulation of receptor tyrosine kinase activity.	PIK3R2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101284>	C101283	PIK3R2 wt Allele|MPPH|MPPH1|P85B|Phosphatidylinositol 3-Kinase, Regulatory Subunit 2 Gene|Phosphatidylinositol 3-Kinase, Regulatory Subunit, 85-kD, Beta Gene|Phosphoinositide-3-Kinase Regulatory Subunit 2 wt Allele|Phosphoinositide-3-Kinase, Regulatory Subunit 2 (Beta) Gene|p85|p85-BETA	Human PIK3R2 wild-type allele is located within 19q13.2-q13.4 and is approximately 17 kb in length. This allele, which encodes phosphatidylinositol 3-kinase regulatory subunit beta protein, plays a role in the modulation of tyrosine phosphorylation.	PIK3R2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101285>	C18466	Phosphatidylinositol 3-Kinase Regulatory Subunit Beta|PI3-Kinase Regulatory Subunit Beta|PI3-Kinase Subunit p85-Beta|PI3K Regulatory Subunit Beta|PIK3R2|Phosphatidylinositol 3-Kinase 85 kDa Regulatory Subunit Beta|Phosphatidylinositol 3-Kinase, Regulatory Subunit, Polypeptide 2|PtdIns-3-Kinase Regulatory Subunit Beta|PtdIns-3-Kinase Regulatory Subunit p85-Beta|p85-Beta	Phosphatidylinositol 3-kinase regulatory subunit beta (728 aa, ~82 kDa) is encoded by the human PIK3R2 gene. This protein is involved in the modulation of both tyrosine phosphorylation and signal transduction.	Phosphatidylinositol 3-Kinase Regulatory Subunit Beta		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101286>	C20921|C158414	RALBP1 Gene|RALBP1|RALBP1|ralA Binding Protein 1 Gene	This gene is involved in the regulation of small GTPase activity.			Gene or Genome	
C101287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101287>	C101286	RALBP1 wt Allele|RIP|RIP1|RLIP1|RLIP76|ralA Binding Protein 1 wt Allele	Human RALBP1 wild-type allele is located in the vicinity of 18p11.3 and is approximately 63 kb in length. This allele, which encodes ralA-binding protein 1, plays a role in the modulation of signaling and small molecule transport.			Gene or Genome	
C101288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101288>	C17298|C158419	RalA-Binding Protein 1|76 kDa Ral-Interacting Protein|DNP-SG ATPase|Dinitrophenyl S-Glutathione ATPase|EC 7.6.2.2|EC 7.6.2.3|Ral-Interacting Protein 1|RalBP1	RalA-binding protein 1 (655 aa, ~76 kDa) is encoded by the human RALBP1 gene. This protein is involved in the regulation of small molecule transport and signaling.			Amino Acid, Peptide, or Protein|Enzyme	
C101289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101289>	C16748	Integrin AlphaM/Beta2|CD11b/CD18|CR3|Complement Receptor 3|Integrin Alpha-M/Beta-2|Mac-1|Macrophage-1 Antigen	Integrin alpha-M/beta2 is a protein complex comprised of a heterodimer of integrin alpha M and integrin beta 2. This complex is involved in anti-bacterial defense and complement internalization.	Integrin AlphaM/Beta2		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10128>	C61063	Doxorubicin/Fluorouracil/Melphalan/Tamoxifen|DOX/5-FU/L-PAM/TMX|PAFT			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101290>	C20194	ATMIN Gene|ATM Interactor Gene|ATMIN|ATMIN	This gene plays a role in the response to DNA damage.			Gene or Genome	
C101291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101291>	C101290	ATMIN wt Allele|ASCIZ|ATM Interactor wt Allele|KIAA0431|ZNF822	Human ATMIN wild-type allele is located in the vicinity of 16q23.2 and is approximately 11 kb in length. This allele, which encodes ATM interactor protein, is involved in both DNA damage response and cell survival.			Gene or Genome	
C101292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101292>	C18466	ATM Interactor|ASCIZ|ATM INteracting Protein|ATM Substrate CHK2-Interacting Zinc Finger Protein|ATM/ATR-Substrate CHEK2-Interacting Zinc Finger Protein|ATM/ATR-Substrate CHK2-Interacting Zinc Finger Protein|ATM/ATR-Substrate Chk2-Interacting Zn++-Finger Protein|Zinc Finger Protein 822	ATM interactor (823 aa, ~88 kDa) is encoded by the human ATMIN gene. This protein plays a role in the modulation of both cell survival and the response to DNA damage.			Amino Acid, Peptide, or Protein	
C101293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101293>	C19645	Next Generation Sequencing|Massively Parallel DNA Sequencing|Massively Parallel Sequencing|Massively Parallel Sequencing|NEXT GENERATION SEQUENCING|NGS|Next Generational Sequencing|Next-Generation Sequencing|Next-Generation Sequencing	Technologies that facilitate the rapid determination of the nucleotide sequence of large numbers of strands or segments of DNA or RNA.	Next Generation Sequencing		Molecular Biology Research Technique	ALL Authorized Value Terminology|ALL Minimal Residual Disease Table|ALL Molecular Analysis Table|AML Authorized Value Terminology|AML Minimal Residual Disease Table|AML Molecular Analysis Table|CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|EWS Authorized Value Terminology|EWS Molecular Analysis Table|OS Authorized Value Terminology|OS Molecular Analysis Table|pFDA Bioinformatics/Genomics Terminology|precisionFDA Terminology
C101294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101294>	C153598|C101293	Whole Genome Sequencing|WGS|WGS|WGS|WGS|WGS (whole genome sequencing)|WHOLE GENOME SEQUENCING|Whole-Genome Sequencing	A procedure that can determine the DNA sequence for nearly the entire genome of an individual.	Whole Genome Sequencing		Molecular Biology Research Technique	Canine Glioma Project Property Terminology|CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTDC Value Terminology|CTRP Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|ICDC Terminology|pFDA Bioinformatics/Genomics Terminology|precisionFDA Terminology|SeroNet Authorized Values|SeroNet Study Descriptors
C101295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101295>	C153598|C101293	Whole Exome Sequencing|Exome|Exome Sequencing|Exome Sequencing|WES|WES|WHOLE EXOME SEQUENCING|WXS|WXS|WXS (whole exome sequencing)|Whole-Exome Sequencing|Whole-exome sequencing	A procedure that can determine the DNA sequence for all of the exons in an individual.	Whole Exome Sequencing		Molecular Biology Research Technique	Canine Glioma Project Property Terminology|CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTDC Value Terminology|CTRP Biomarker Terminology|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|ICDC Terminology|pFDA Bioinformatics/Genomics Terminology|precisionFDA Terminology|SeroNet Authorized Values|SeroNet Study Descriptors
C101296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101296>	C19896	Exome	The portion of the genome that is characterized by exon sequences, which represent the genetic template for the synthesis of proteins and other functional gene products.			Conceptual Entity	
C101297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101297>	C26049	TSPYL2 Gene|TSPY-Like 2 Gene|TSPYL2|TSPYL2	This gene is involved in chromatin remodeling.			Gene or Genome	
C101298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101298>	C101297	TSPYL2 wt Allele|CDA1|CINAP|CTCL|DENTT|HRIHFB2216|NP79|SE204|TSPX|TSPY-Like 2 wt Allele	Human TSPYL2 wild-type allele is located in the vicinity of Xp11.2 and is approximately 6 kb in length. This allele, which encodes testis-specific Y-encoded-like protein 2, plays a role in the remodeling of chromatin.			Gene or Genome	
C101299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101299>	C18466	Testis-Specific Y-Encoded-Like Protein 2|CASK-Interacting Nucleosome Assembly Protein|CTCL-Associated Antigen se20-4|Cell Division Autoantigen 1|Cutaneous T-Cell Lymphoma-Associated Antigen se20-4|Differentially-Expressed Nucleolar TGF-Beta1 Target Protein|NP79|Nuclear Protein of 79 kDa|TSPY-Like Protein 2	Testis-specific Y-encoded-like protein 2 (693 aa, ~79 kDa) is encoded by the human TSPYL2 gene. This protein is involved in the assembly of nucleosomes.			Amino Acid, Peptide, or Protein	
C10129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10129>	C61063	Fluorouracil/Methotrexate/Vinblastine|5-FU/MTX/VBL|MFV			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1012>	C29756|C28197	Benzodiazepine	Drugs from this chemical class are used for their central nervous system depressant properties including sedation, facilitation of sleep, seizure control, general anesthesia, anxiolytic, amnestic, and for detoxification from similar (cross tolerant) drugs			Chemical Viewed Functionally	
C101300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101300>	C133708	CDC34 Gene|CDC34|CDC34|Cell Division Cycle 34 Homolog (S. cerevisiae) Gene	This gene plays a role in protein ubiquitination.			Gene or Genome	
C101301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101301>	C101300	CDC34 wt Allele|Cell Division Cycle 34 Gene|Cell Division Cycle 34 Homolog (S. cerevisiae) wt Allele|E2-CDC34|UBC3|UBCH3|UBE2R1	Human CDC34 wild-type allele is located in the vicinity of 19p13.3 and is approximately 10 kb in length. This allele, which encodes ubiquitin-conjugating enzyme E2 R1 protein, is involved in the modification of ubiquitin.			Gene or Genome	
C101302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101302>	C70772	Therapeutic Area|THERAREA|Therapeutic Areas|therapeutic area	A knowledge field that focuses on research and development of treatments for diseases and pathologic findings, as well as prevention of conditions that negatively impact the health of an individual.			Conceptual Entity	CDISC DDF Study Design Attribute Terminology|CDISC DDF Terminology|CDISC Glossary Terminology|CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C101303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101303>	C133711	Ubiquitin-Conjugating Enzyme E2 R1|(E3-Independent) E2 Ubiquitin-Conjugating Enzyme R1|CDC34|Cell Division Cycle 34|E2 Ubiquitin-Conjugating Enzyme R1|EC 2.3.2.23|EC 2.3.2.24|EC 6.3.2.19, Formerly|Ubiquitin-Conjugating Enzyme E2-32 kDa Complementing|Ubiquitin-Conjugating Enzyme E2-CDC34|Ubiquitin-Protein Ligase R1	Ubiquitin-conjugating enzyme E2 R1 (236 aa, ~27 kDa) is encoded by the human CDC34 gene. This protein plays a role in the processing of ubiquitin for protein modification.			Amino Acid, Peptide, or Protein|Enzyme	
C101304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101304>	C98996	Hemolytic Disease of the Newborn|Erythroblastosis Fetalis|Erythroblastosis Fetalis|HDFN|Hemolytic Disease of the Fetus or Newborn|Isoimmune Hemolytic Disease of the Newborn	A disorder of the fetus or newborn that occurs when fetal cells that are coated with IgG alloantibodies from the mother attack antigens inherited from the father. Severity can range from absence of symptoms to death.			Disease or Syndrome	Newborn Screening Terminology|NICHD Terminology|Perinatal Terminology
C101305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101305>	C36279	Colonic Band	A pathologic fibrous band that impedes passage of intestinal contents through the colon.			Finding	Neonatal Research Network Terminology|NICHD Terminology
C101306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101306>	C20194	NLRP6 Gene|NLR Family, Pyrin Domain Containing 6 Gene|NLRP6|NLRP6	This gene may be involved in inflammation.			Gene or Genome	
C101307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101307>	C101306	NLRP6 wt Allele|CLR11.4|NACHT, Leucine Rich Repeat and PYD Containing 6 Gene|NALP6|NLR Family, Pyrin Domain Containing 6 wt Allele|Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat and Pyrin Domain Containing 6 Gene|PAN3|PYPAF5	Human NLRP6 wild-type allele is located in the vicinity of 11p15 and is approximately 7 kb in length. This allele, which encodes NACHT, LRR and PYD domains-containing protein 6, may play a role in the inflammatory response.			Gene or Genome	
C101308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101308>	C18466	NACHT, LRR and PYD Domains-Containing Protein 6|Angiotensin II/Vasopressin Receptor|NLRP6|PYRIN-Containing APAF1-Like Protein 5	NACHT, LRR and PYD domains-containing protein 6 (892 aa, ~99 kDa) is encoded by the human NLRP6 gene. This protein may be involved in the activation of the inflammatory response.			Amino Acid, Peptide, or Protein	
C101309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101309>	C26003	HTRA1 Gene|HTRA1|HTRA1|HtrA Serine Peptidase 1 Gene	This gene plays a role in proteolysis.			Gene or Genome	
C10130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10130>	C61063	Cisplatin/Hydrazine Sulfate/Vinblastine|CDDP/HDZ/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101310>	C101309	HTRA1 wt Allele|ARMD7|HtrA|HtrA Serine Peptidase 1 wt Allele|L56|ORF480|PRSS11	Human HTRA1 wild-type allele is located in the vicinity of 10q26.3 and is approximately 53 kb in length. This allele, which encodes serine protease HTRA1 protein, is involved in the mediation of proteolysis. Variations in the promoter of the gene are associated with age-related macular degeneration type 7. Mutation of the gene is associated with cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy.			Gene or Genome	
C101311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101311>	C17123	Serine Protease HTRA1|EC 3.4.21.-|HTRA1|High-Temperature Requirement A Serine Peptidase 1|IGFBP5-Protease|L56|Serine Protease 11	Serine protease HTRA1 (480 aa, ~51 kDa) is encoded by the human HTRA1 gene. This protein plays a role in the proteolysis of IGF-binding proteins.			Amino Acid, Peptide, or Protein|Enzyme	
C101312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101312>	C99208	Immature Retinopathy of Prematurity|ROP|ROP|Retinopathy of Prematurity, Immature	An immature state in which retinopathy of prematurity cannot be established.			Finding	Neonatal Research Network Terminology|NICHD Terminology|Perinatal Terminology
C101313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101313>	C3847	Bilateral Renal Dysplasia	A finding of congenital malformations in both kidneys characterized by the presence of cysts of various sizes, primitive ducts, islands of metaplastic cartilage and undifferentiated mesenchyme, and the absence of cortico-medullary demarcation.			Finding	Neonatal Research Network Terminology|NICHD Terminology
C101314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101314>	C35552	Coronary Anomaly|Coronary Anomalies (includes aneurysm, anomalous)	Any deviation from normal in the coronary vasculature.			Finding	Neonatal Research Network Terminology|NICHD Terminology
C101315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101315>	C36279	Colonic Web	A pathologic fibrous net that impedes passage of intestinal contents through the colon.			Finding	Neonatal Research Network Terminology|NICHD Terminology
C101316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101316>	C26769	Facial Nerve Palsy Related to Trauma|Facial Nerve Palsy due to Trauma|Facial Nerve Palsy due to Trauma	Partial or complete paralysis of the facial muscles of one side of an individual's face that is caused by trauma.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101317>	C116822	Fracture of Long Bone Related to Birth|Fracture of Long Bone Related to Birth Trauma|Fracture of Long Bone Related to Birth Trauma	An injury sustained during the birthing process in which the continuity is broken in any bone that is longer in length than width.			Finding	Neonatal Research Network Terminology|NICHD Terminology|Perinatal Terminology
C101318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101318>	C50745|C116822	Fracture of Skull Related to Birth|Fracture of Skull Related to Birth Trauma|Fracture of Skull Related to Birth Trauma	An injury sustained during the birthing process in which the continuity is broken in the skull.			Finding	Neonatal Research Network Terminology|NICHD Terminology|Perinatal Terminology
C101319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101319>	C3185|C118807	Transient Leukemoid Reaction of the Newborn|Leukemoid Reaction of the Newborn|Transient Leukemoid Reaction of Newborn	Increased white blood cell count and increased neutrophil precursors resembling leukemia in a neonate or fetus. Often, this is a response to medications received, infection or Down syndrome.			Laboratory or Test Result	Neonatal Research Network Terminology|NICHD Terminology
C10131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10131>	C61063	Cyclophosphamide/Dexamethasone/Doxorubicin/Verapamil/Vincristine|CTX/DM/DOX/VCR/VPAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101320>	C35095|C28193	Perinatal Blood Aspiration Syndrome|Perinatal Aspiration of Blood	Respiratory distress in the newborn due to inhalation of blood; this is an unusual event and is sometimes linked to the non passage of meconium before delivery or mothers with antepartum hemorrhage.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101321>	C35046	Neonatal Drug Withdrawal|DWN|Drug Withdrawal Syndrome in Newborn	A constellation of neurobehavioral features observed following cessation or reduction of antenatal or postnatal drug exposure.			Mental or Behavioral Dysfunction	Neonatal Research Network Terminology|NICHD Terminology|Perinatal Terminology
C101322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101322>	C84505	Complete Atrioventricular Septal Defect with Tetralogy of Fallot|Tetralogy of Fallot - Complete AV Canal Defect	A rare congenital heart anomaly in which there is coexistence of tetralogy of Fallot and complete atrioventricular septal defect. The latter is characterized by defects in the atrial and ventricular septa and a common atrioventricular valve.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101324>	C50896	Perinatal Intraventricular Hemorrhage	Bleeding within the cerebral ventricles occurring around the time of birth.			Finding	Neonatal Research Network Terminology|NICHD Terminology|Perinatal Terminology
C101325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101325>	C28193	Heterotaxy Syndrome with Polysplenia|Heterotaxy, Polysplenia	A congenital defect in which there is an abnormal spatial arrangement of the internal thoraco-abdominal organs; this manifestation of the disorder presents with many accessory spleens instead of one.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101326>	C28193	Heterotaxy Syndrome with Asplenia|Heterotaxy, Asplenia	A congenital defect in which there is an abnormal spatial arrangement of the internal thoraco-abdominal organs; in this manifestation of the disorder, the spleen is absent.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101327>	C35552	Pericardial Anomaly	Any abnormality involving the pericardium.			Finding	Neonatal Research Network Terminology|NICHD Terminology
C101328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101328>	C84648	Mitochondrial Myopathy	Myopathy caused by mitochondrial abnormalities.			Disease or Syndrome	Cellosaurus Disease Terminology|Neonatal Research Network Terminology|NICHD Terminology
C101329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101329>	C2849	Congenital Malformation Syndrome Related to Known Exogenous Cause|Congenital Malformation Syndrome due to Known Exogenous Cause|Congenital Malformation Syndrome due to Known Exogenous Cause	A syndrome characterized by the presence of structural malformations that are present at birth and can be attributed to an exogenous cause.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C10132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10132>	C61063	Cisplatin/Cyclophosphamide/Doxorubicin/Etoposide/Fluorouracil/Methotrexate/Vincristine|CDDP/CTX/DOX/5-FU/MTX/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101330>	C50822	Neonatal Resuscitation	Measures applied for the restoration of life to a newborn.			Therapeutic or Preventive Procedure	
C101331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101331>	C26872	Respiratory Failure Related to Neuromuscular Disorder|Respiratory Failure due to Neuromuscular Disorder|Respiratory Failure due to Neuromuscular Disorder	Impaired gas exchange by the respiratory system resulting in hypoxemia and decreased oxygenation of the tissues that may be associated with increased arterial levels of carbon dioxide; the respiratory failure is due to a neuromuscular disorder.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101332>	C26872	Respiratory Failure Related to Central Nervous System Disorder|Respiratory Failure due to CNS Disorder|Respiratory Failure due to Central Nervous System Disorder	Impaired gas exchange by the respiratory system resulting in hypoxemia and decreased oxygenation of the tissues that may be associated with increased arterial levels of carbon dioxide; the respiratory failure is due to a central nervous system disorder.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101333>	C2902	Coagulation Disorder Related to Liver Dysfunction|Blood Coagulation Disorder due to Liver Disease|Coagulation Defects due to Liver Disease	A disorder of blood clotting that is attributable to a deficiency in liver function.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101334>	C34816	Organic Acid Metabolism Disorder|Disorder of Organic Acid Metabolism	An inherited disorder that affects the metabolism of any acidic compound containing carbon in a covalent linkage.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101335>	C25954	RNASEL Gene|RNASEL|RNASEL|Ribonuclease L (2',5'-Oligoisoadenylate Synthetase-Dependent) Gene	This gene plays a role in RNA processing.	RNASEL Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101336>	C101335	RNASEL wt Allele|PRCA1|Prostate Cancer Hereditary Type 1 Gene|RNS4|Ribonuclease L (2',5'-Oligoisoadenylate Synthetase-Dependent) wt Allele	Human RNASEL wild-type allele is located in the vicinity of 1q25 and is approximately 16 kb in length. This allele, which encodes 2-5A-dependent ribonuclease protein, is involved in the antiviral response. Mutation of the gene is associated with prostate cancer hereditary type 1.	RNASEL wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101337>	C25959	2-5A-Dependent Ribonuclease|2-5A-Dependent RNase|EC 3.1.26.-|Interferon-Induced 2-5A-Dependent RNase|RNASEL|RNase L|Ribonuclease 4|Ribonuclease L	2-5A-dependent ribonuclease (741 aa, ~84 kDa) is encoded by the human RNASEL gene. This protein plays a role in both RNA processing and the antiviral response.	2-5A-Dependent Ribonuclease		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101338>	C98826	Arterial Thrombosis Related to Vascular Access Complication|Acquired Secondary Arterial Thrombosis due to Catheter Complication	The formation of a thrombus in the artery as a direct result of an activity associated with vascular access.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C101339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101339>	C99107	Venous Thrombosis Related to Vascular Access Complication|Acquired Secondary Venous Thrombosis due to Catheter Complication|Venous Thrombosis due to Vascular Access Complication|Venous Thrombosis due to Vascular Access Complication	The formation of a thrombus in the vein as a direct result of an activity associated with vascular access.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C10133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10133>	C61007	Busulfan/Melphalan|BU/L-PAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101340>	C20988	ARVCF Gene|ARVCF|ARVCF|ARVCF Delta Catenin Family Member Gene	This gene is involved in cell adhesion and mRNA splicing.			Gene or Genome	
C101341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101341>	C101340	ARVCF wt Allele|ARVCF Delta Catenin Family Member wt Allele|Armadillo Repeat Gene Deleted in VCFS|Armadillo Repeat Gene Deleted in Velocardiofacial Syndrome Gene|FLJ35345	Human ARVCF wild-type allele is located in the vicinity of 22q11.21 and is approximately 47 kb in length. This allele, which encodes splicing regulator ARVCF protein, plays a role in mRNA splicing and cell-cell adhesion. Mutation of the gene is associated with velo-cardio-facial syndrome.			Gene or Genome	
C101342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101342>	C16393	Splicing Regulator ARVCF|ARVCF|Armadillo Repeat Protein Deleted In Velo-Cardio-Facial Syndrome	Splicing regulator ARVCF (962 aa, ~105 kDa) is encoded by the human ARVCF gene. This protein is involved in cell adhesion and mRNA splicing.			Amino Acid, Peptide, or Protein	
C101343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101343>	C20194	CRY1 Gene|CRY1|CRY1|Cryptochrome 1 (Photolyase-Like) Gene	This gene plays a role in circadian rhythm.			Gene or Genome	
C101344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101344>	C101343	CRY1 wt Allele|Cryptochrome 1 (Photolyase-Like) wt Allele|PHLL1	Human CRY1 wild-type allele is located within 12q23-q24.1 and is approximately 103 kb in length. This allele, which encodes cryptochrome-1 protein, is involved in the regulation of circadian rhythm.			Gene or Genome	
C101345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101345>	C18466	Cryptochrome-1	Cryptochrome-1 (586 aa, ~66 kDa) is encoded by the human CRY1 gene. This protein plays a role in the circadian rhythm process.			Amino Acid, Peptide, or Protein	
C101346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101346>	C20917	STAG2 Gene|STAG2|STAG2|STAG2|STAG2 Cohesin Complex Component Gene	This gene is involved in cell division.	STAG2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C101347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101347>	C101346	STAG2 wt Allele|HPE13|MKMS|NEDXCF|SA-2|SA2|SA2 Stromalin Gene|SCC3B|STAG2 Cohesin Complex Component wt Allele|Sister Chromatid Cohesion 3 Homolog (S. cerevisiae) B Gene|Sister Chromatid Cohesion 3 Homolog B Gene|Stromal Antigen 2 Gene|bA517O1.1	Human STAG2 wild-type allele is located in the vicinity of Xq25 and is approximately 462 kb in length. This allele, which encodes cohesin subunit SA-2, plays a role in sister chromatid adhesion.	STAG2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101348>	C17761	Cohesin Subunit SA-2|Cohesin Subunit SA2|SCC3 Homolog 2|STAG2|Stromal Antigen 2	Cohesin subunit SA-2 (1231 aa, ~141 kDa) is encoded by the human STAG2 gene. This protein is involved in chromosomal localization.	Cohesin Subunit SA-2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101349>	C20194	UBQLN2 Gene|UBQLN2|UBQLN2|Ubiquilin 2 Gene	This gene may play a role in protein turnover.			Gene or Genome	
C10134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10134>	C61063	Mechlorethamine/Methotrexate/Prednisone/Procarbazine/Vincristine|MTX/NM/PCB/PRED/VCR|echlorethamine/methotrexate/prednisone/procarbazine/vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101350>	C101349	UBQLN2 wt Allele|ALS15|CHAP1|CHAP1/DSK2|DSK2|Dsk2|HRIHFB2157|LIC-2|N4BP4|NEDD4 Binding Protein 4 Gene|PLIC-2|PLIC2|RIHFB2157|Ubiquilin 2 wt Allele|Ubiquilin 2 wt Allele Chap1	Human UBQLN2 wild-type allele is located in the vicinity of Xp11.21 and is approximately 3 kb in length. This allele, which encodes ubiquilin-2 protein, may be involved in the regulation of proteasome activity. Mutation of the gene is associated with amyotrophic lateral sclerosis type 15.			Gene or Genome	
C101351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101351>	C18466	Ubiquilin-2|Chap1|DSK2 Homolog|NEDD4 Binding Protein 4|PLIC-2|Protein Linking IAP with Cytoskeleton 2|Ubiquitin-Like Product Chap1/Dsk2|hPLIC-2	Ubiquilin-2 (624 aa, ~66 kDa) is encoded by the human UBQLN2 gene. This protein may play a role in the modulation of proteasome-mediated protein degradation.			Amino Acid, Peptide, or Protein	
C101352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101352>	C20923	GPR183 Gene|G Protein-Coupled Receptor 183 Gene|GPR183|GPR183	This gene is involved in humoral immunity.			Gene or Genome	
C101353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101353>	C101352	GPR183 wt Allele|EBI2|Epstein-Barr Virus Induced Gene 2 (Lymphocyte-Specific G Protein-Coupled Receptor) Gene|Epstein-Barr Virus-Induced Gene 2|G Protein-Coupled Receptor 183 wt Allele|RP11-461N23.2	Human GPR183 wild-type allele is located in the vicinity of 13q32.3 and is approximately 13 kb in length. This allele, which encodes G-protein coupled receptor 183 protein, plays a role in the modulation of humoral immunity. Aberrant expression of this gene is induced by Epstein-Barr virus and may be associated with virally-induced neoplasms.			Gene or Genome	
C101354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101354>	C18239	G-Protein Coupled Receptor 183|EBI2|EBV-Induced G-Protein Coupled Receptor 2|Epstein-Barr Virus-Induced G-Protein Coupled Receptor 2	G-protein coupled receptor 183 (361 aa, ~41 kDa) is encoded by the human GPR183 gene. This protein is involved in both B-cell maturation and localization.			Amino Acid, Peptide, or Protein|Receptor	
C101355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101355>	C26064	PHLPP1 Gene|PH Domain and Leucine Rich Repeat Protein Phosphatase 1 Gene|PHLPP1|PHLPP1	This gene plays a role in the dephosphorylation of proteins.	PHLPP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101356>	C101355	PHLPP1 wt Allele|KIAA0606|PH Domain and Leucine Rich Repeat Protein Phosphatase 1 wt Allele|PHLPP|PLEKHE1|SCOP	Human PHLPP1 wild-type allele is located in the vicinity of 18q21.32 and is approximately 265 kb in length. This allele, which encodes PH domain leucine-rich repeat-containing protein phosphatase 1 protein, is involved in both signaling and protein dephosphorylation.	PHLPP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101357>	C73913	Oat|Avena Grain|Avena sativa Kernel|Common Oat Grain|OAT				Food	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C101358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101358>	C34078	PH Domain Leucine-Rich Repeat-Containing Protein Phosphatase 1|EC 3.1.3.16|PH Domain-Containing Family E Member 1|PHLPP1|Pleckstrin Homology Domain-Containing Family E Member 1|SCN Circadian Oscillatory Protein|Suprachiasmatic Nucleus Circadian Oscillatory Protein|hSCOP	PH domain leucine-rich repeat-containing protein phosphatase 1 (1717 aa, ~185 kDa) is encoded by the human PHLPP1 gene. This protein plays a role in both protein dephosphorylation and growth factor-mediated signaling.	PH Domain Leucine-Rich Repeat-Containing Protein Phosphatase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101359>	C20921	ARHGAP29 Gene|ARHGAP29|ARHGAP29|Rho GTPase Activating Protein 29 Gene	This gene is involved in Rho-mediated signal transduction.			Gene or Genome	
C10135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10135>	C61063	Cytarabine/Filgrastim|ARA-C/G-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101360>	C101359	ARHGAP29 wt Allele|PARG1|RP11-255E17.1|Rho GTPase Activating Protein 29 wt Allele	Human ARHGAP29 wild-type allele is located in the vicinity of 1p22.1 and is approximately 126 kb in length. This allele, which encodes Rho GTPase-activating protein 29, plays a role in the modulation of signaling.			Gene or Genome	
C101361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101361>	C17298	Rho GTPase-Activating Protein 29|PTPL1-Associated RhoGAP 1|PTPL1-Associated RhoGAP Protein 1|Rho-Type GTPase-Activating Protein 29	Rho GTPase-activating protein 29 (1261 aa, ~142 kDa) is encoded by the human ARHGAP29 gene. This protein is involved in the regulation of Rho protein-mediated signaling.			Amino Acid, Peptide, or Protein	
C101362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101362>	C28193	Complete Trisomy 18 Syndrome|Edwards Syndrome|Trisomy 18	A constellation of symptoms that occur as a result of the presence of a complete third copy of the 18th chromosome. Characteristics include profound mental retardation and severe malformations. Individuals with this syndrome rarely live past one year.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C101363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101363>	C25993	KCNMA1 Gene|KCNMA1|KCNMA1|Potassium Large Conductance Calcium-Activated Channel, Subfamily M, Alpha Member 1 Gene	This gene plays a role in potassium transport.			Gene or Genome	
C101364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101364>	C101363	KCNMA1 wt Allele|BKTM|KCa1.1|MaxiK|Potassium Large Conductance Calcium-Activated Channel, Subfamily M, Alpha Member 1 wt Allele|RP11-443A13.1|SAKCA|SLO|SLO-ALPHA|SLO1|bA205K10.1|mSLO1	Human KCNMA1 wild-type allele is located in the vicinity of 10q22.3 and is approximately 769 kb in length. This allele, which encodes calcium-activated potassium channel subunit alpha-1 protein, is involved in the regulation of potassium transport. Aberrant expression of the gene may play a role in melanoma.			Gene or Genome	
C101365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101365>	C28505	Calcium-Activated Potassium Channel Subunit Alpha-1|BK Channel|BKCA Alpha|Calcium-Activated Potassium Channel, Subfamily M Subunit Alpha-1|K(VCA)Alpha|KCNMA1|KCa1.1|Maxi K Channel|MaxiK|Slo Homolog|Slo-Alpha|Slo1|Slowpoke Homolog|Stretch-Activated Kca Channel|hSlo	Calcium-activated potassium channel subunit alpha-1 (1236 aa, ~138 kDa) is encoded by the human KCNMA1 gene. This protein plays a role in calcium-dependent potassium transport.			Amino Acid, Peptide, or Protein	
C101366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101366>	C133877	Anti-CD40 Monoclonal Antibody Chi Lob 7/4|Chi Lob 7/4	An IgG1 chimeric monoclonal antibody agonist of the cell surface receptor CD40 with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, anti-CD40 monoclonal antibody Chi Lob 7/4 binds to CD40 on a variety of immune cell types, triggering the cellular proliferation and activation of antigen-presenting cells (APCs), activating B cells and T cells, and enhancing the immune response; in addition, this agent binds to the CD40 antigen present on the surfaces of some solid tumor cells, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cytotoxicity (ADCC) eventually resulting in decreased tumor growth. CD40, a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells, many B-cell malignancies, and many solid tumors, mediating both indirect tumor cell death through the activation of the immune system and direct tumor cell apoptosis.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101367>	C2140	CD-expressing Bifidobacterium APS001F|APS001F	A recombinant anaerobic bacterium, Bifidobacterium longum, encoding the cytosine deaminase (CD) gene with potential antineoplastic adjuvant activity. Upon injection, the CD-expressing bifidobacterium preferentially localizes and grows in the hypoxic environment of the tumor and expresses CD, an enzyme that catalyzes the intracellular conversion of the prodrug flucytosine (5-FC) into the antineoplastic agent 5-fluorouracil (5-FU). Upon administration of 5-FC, and subsequent localized conversion into 5-FU and its cytotoxic active metabolites, the tumor is specifically exposed to cytotoxic agents while the exposure to normal tissues is minimal.	CD-expressing Bifidobacterium APS001F		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C101368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101368>	C1291	Danvatirsen|AZD9150|DANVATIRSEN|ISIS 481464|ISIS-STAT3rx	An antisense oligonucleotide targeting signal transducer and activator of transcription 3 (STAT3) with potential antitumor activity. Danvatirsen binds to STAT3 mRNA, thereby inhibiting translation of the transcript. Suppression of STAT3 expression induces tumor cell apoptosis and decreases tumor cell growth. STAT3, a protein overexpressed in a variety of human cancers, plays a critical role in tumor cell growth and survival.	Danvatirsen		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101369>	C2124	Gallium Ga 68-Edotreotide|68Ga-DOTA-TOC|68Ga-DOTA-d-Phe1-Tyr3-octreotide|EDOTREOTIDE GALLIUM GA-68|Ga-68 DOTA0-Tyr3-octreotide|Ga-68 DOTATOC|Ga-68-DOTA-TOC|Ga-68-DOTA-Tyr(3)-octreotide|Gallium Ga 68-DOTATOC	A radioconjugate consisting of the octreotide derivative edotreotide labeled with gallium 68 (Ga-68) with potential application in somatostatin receptor (SSTR) imaging in conjunction with positron emission tomography (PET). Similar to octreotide, gallium Ga 68-edotreotide binds to SSTRs, especially type 2 receptors, present on the cell membranes of many types of neuroendocrine tumor cells and their metastases, thereby allowing for imaging of SSTR-expressing cells upon PET. Gallium Ga 68-edotreotide is produced by substituting tyrosine for phenylalanine at the 3 position of the somatostatin analogue octreotide (Tyr3-octreotide or TOC) and chelating the substituted octreotide to Ga-68 via the macrocyclic chelating agent dodecanetetraacetic acid (DOTA).	Gallium Ga 68-Edotreotide		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C10136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10136>	C63358	TEMP Regimen|CDDP/DHAD/TMX/VP-16|Cisplatin/Etoposide/Mitoxantrone/Tamoxifen|TEMP|TEMP|Tamoxifen/Etoposide/Mitoxantrone/Cisplatin|Tamoxifen/Etoposide/Mitoxantrone/Cisplatin Regimen|Tamoxifen/Etoposide/Mitoxantrone/Platinol	A regimen consisting of tamoxifen, etoposide, mitoxantrone, and cisplatin that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C101370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101370>	C574	Immunomodulatory Agent CC-11006|CC-11006|CC-11006|CC-11006-MDS-001	A proprietary, orally available, small molecule and thalidomide analog, with potential immunomodulating and antineoplastic activity. CC-11006 appears to have a similar mechanism to thalidomide and may modulate the expression of proinflammatory and regulatory cytokines.	Immunomodulatory Agent CC-11006		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101371>	C129826	Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Progenitor Cells	Autologous, CD34-positive hematopoietic progenitor cells (HPCs) transduced with rHIV7-shI-TAR-CCR5RZ, a lentiviral vector encoding three anti-human immunodeficiency virus (HIV) RNA genes, with potential antineoplastic activity. The 3 RNA products produced by the lentilvirus are: a short hairpin RNA (shRNA) targeted to an exon of the HIV-1 genes tat/rev, designated as shI; a decoy for the HIV TAT reactive element, designated as TAR; a ribozyme targeting the host cells CCR5 chemokine receptor, designated as CCR5RZ. Upon administration, lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells expressing the 3 species of RNAs display 3 seperate mechanims of action: the shRNA blocks the transcription of tat/rev, the TAR decoy binds to the TAT protein that is essential for HIV replication, and CCR5RZ catalyzes CCR5 which is needed for viral attachment and entry into the host cells. Altogether, infusion of these HPCs may ultimately inhibit HIV replication and suppress HIV infection.	Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Progenitor Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101374>	C19928|C190731	Putative TGFB1-Induced Anti-Apoptotic Factor 1|12 kDa TGF-Beta-1-Induced Antiapoptotic Factor|TGF-Beta-1-Induced Antiapoptotic Factor 1|TGFB1-Induced Anti-Apoptotic Factor 1|TIAF1	Putative TGFB1-induced anti-apoptotic factor 1 (115 aa, ~12 kDa) is encoded by the human MYO18A gene. This protein plays a role in the modulation of apoptosis.			Amino Acid, Peptide, or Protein	
C101375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101375>	C20921	SH3BP5 Gene|SH3-Domain Binding Protein 5 (BTK-Associated) Gene|SH3BP5|SH3BP5	This gene is involved in the regulation of signaling.			Gene or Genome	
C101376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101376>	C101375	SH3BP5 wt Allele|SAB|SH3-Domain Binding Protein 5 (BTK-Associated) wt Allele|Sab	Human SH3BP5 wild-type allele is located in the vicinity of 3p24.3 and is approximately 87 kb in length. This allele, which encodes SH3 domain-binding protein 5, plays a role in the modulation of intracellular communication.			Gene or Genome	
C101377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101377>	C18515	SH3 Domain-Binding Protein 5|SH3 Domain-Binding Protein That Preferentially Associates with BTK|SH3BP-5	SH3 domain-binding protein 5 (455 aa, ~50 kDa) is encoded by the human SH3BP5 gene. This protein is involved in the inhibition of protein kinases.			Amino Acid, Peptide, or Protein	
C101378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101378>	C20103	THBD Gene|THBD|THBD|Thrombomodulin Gene	This gene plays a role in the modulation of blood coagulation.	THBD Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101379>	C101378	THBD wt Allele|AHUS6|BDCA3|CD141|THPH12|THRM|TM|Thrombomodulin wt Allele	Human THBD wild-type allele is located in the vicinity of 20p11.2 and is approximately 4 kb in length. This allele, which encodes thrombomodulin protein, is involved in the regulation of both blood coagulation and thrombolysis. Mutation of the gene is associated with both thrombophilia and hemolytic uremic syndrome atypical type 6.	THBD wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10137>	C61063	Etanidazole/Melphalan/Prednisone|L-PAM/PRED/SR-2508			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101380>	C18106	Thrombomodulin|Antigen CD141|BDCA-3|CD141|CD141 Antigen|Fetomodulin|TM	Thrombomodulin (575 aa, ~60 kDa) is encoded by the human THBD gene. This protein plays a role in thrombin binding, fibrinolysis and coagulation.	Thrombomodulin		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101381>	C20103	NISCH Gene|NISCH|NISCH|Nischarin Gene	This gene is involved in imidazoline binding and signaling.			Gene or Genome	
C101382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101382>	C101381	NISCH wt Allele|I-1|IR1|IRAS|KIAA0975|Nischarin wt Allele	Human NISCH wild-type allele is located in the vicinity of 3p21.1 and is approximately 38 kb in length. This allele, which encodes nischarin protein, plays a role in imidazoline-mediated signaling.			Gene or Genome	
C101383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101383>	C18106	Nischarin|I-1|I-1 Receptor Candidate Protein|I1R|I1R Candidate Protein|IR1|Imidazoline Receptor 1|Imidazoline Receptor Antisera-Selected Protein|Imidazoline-1 Receptor|Imidazoline-1 Receptor Candidate Protein|hIRAS	Nischarin (1504 aa, ~167 kDa) is encoded by the human NISCH gene. This protein is involved in the regulation of signal transduction.			Amino Acid, Peptide, or Protein|Receptor	
C101384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101384>	C2089	Delcasertib|BMS-875944|DELCASERTIB|KAI-9803				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C101385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101385>	C25802	UNC45A Gene|UNC45A|UNC45A|Unc-45 Homolog A (C. elegans) Gene	This gene plays a role in the modulation of protein folding.			Gene or Genome	
C101386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101386>	C101385	UNC45A wt Allele|FLJ10043|GC-UNC45|GCUNC-45|GCUNC45|IRO039700|SMAP-1|SMAP1|Unc-45 Homolog A (C. elegans) wt Allele	Human UNC45A wild-type allele is located in the vicinity of 15q26.1 and is approximately 24 kb in length. This allele, which encodes protein unc-45 homolog A, is involved in both cell differentiation and muscle development.			Gene or Genome	
C101387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101387>	C17764	Protein Unc-45 Homolog A|GCUNC-45|SMAP-1|Smooth Muscle Cell-Associated Protein 1|UNC45A|Unc-45A	Protein unc-45 homolog A (944 aa, ~103 kDa) is encoded by the human UNC45A gene. This protein plays a role as a chaperone for both progesterone receptor and myosin.			Amino Acid, Peptide, or Protein	
C101388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101388>	C19591	Pulsatility Index|PI	A diagnostic indicator of vascular resistance that is calculated by dividing the difference between the peak systolic and minimum diastolic blood velocities by the mean velocity.			Clinical Attribute	
C101389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101389>	C20744	TPT1 Gene|TPT1|TPT1|Tumor Protein, Translationally-Controlled 1 Gene	This gene is involved in both microtubule stabilization and calcium binding.	TPT1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10138>	C61063	Bleomycin/Cyclophosphamide/Doxorubicin/Methotrexate/Prednisone/Vincristine|BLEO/CTX/DOX/MTX/PRED/VCR|MACOP-B			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101390>	C101389	TPT1 wt Allele|FLJ27337|HRF|Histamine-Releasing Factor, Immunoglobulin E-Dependent Gene|RP11-290D2.1|TCTP|Tumor Protein, Translationally-Controlled 1 wt Allele|p02|p23	Human TPT1 wild-type allele is located in the vicinity of 13q14 and is approximately 4 kb in length. This allele, which encodes translationally-controlled tumor protein, plays a role in the regulation of microtubule dynamics.	TPT1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101391>	C18073	Translationally-Controlled Tumor Protein|Fortilin|HRF|Histamine-Releasing Factor|TCTP|Translationally Controlled Tumor Protein|p23	Translationally-controlled tumor protein (172 aa, ~20 kDa) is encoded by the human TPT1 gene. This protein is involved in both calcium binding and microtubule polymerization.	Translationally-Controlled Tumor Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101392>	C20709	ESRRA Gene|ESRRA|ESRRA|Estrogen-Related Receptor Alpha Gene	This gene plays a role in transcriptional regulation and DNA binding.			Gene or Genome	
C101393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101393>	C101392	ESRRA wt Allele|ERR1|ERRa|ESRL1|Estrogen-Related Receptor Alpha wt Allele|NR3B1	Human ESRRA wild-type allele is located in the vicinity of 11q12 and is approximately 11 kb in length. This allele, which encodes steroid hormone receptor ERR1 protein, is involved in DNA binding and transcriptional activation.			Gene or Genome	
C101394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101394>	C18108	Steroid Hormone Receptor ERR1|ERR-Alpha|ESRRA|Estrogen Receptor-Like 1|Estrogen-Related Receptor Alpha|NR3B1|Nuclear Receptor Subfamily 3 Group B Member 1	Steroid hormone receptor ERR1 (423 aa, ~46 kDa) is encoded by the human ESRRA gene. This protein plays a role in steroid-dependent transcriptional regulation.			Amino Acid, Peptide, or Protein|Receptor	
C101395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101395>	C20194	CATSPERZ Gene|CATSPERZ|CATSPERZ|Catsper Channel Auxiliary Subunit Zeta Gene	This gene is involved in sperm motility.			Gene or Genome	
C101396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101396>	C101395	CATSPERZ wt Allele|C11orf20|Cation Channel, Sperm-Associated, Auxiliary Subunit Zeta Gene|Catsper Channel Auxiliary Subunit Zeta wt Allele|Chromosome 11 Open Reading Frame 20 Gene|DKFZP566E164|TEX40|Testis Expressed 40 Gene|Testis-Expressed Gene 40	Human CATSPERZ wild-type allele is located in the vicinity of 11q13.1 and is approximately 4 kb in length. This allele, which encodes cation channel sperm-associated protein subunit zeta, plays a role in sperm maturation.			Gene or Genome	
C101397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101397>	C18466	Cation Channel Sperm-Associated Protein Subunit Zeta|CATSPERZ|CatSper-Zeta|CatSperzeta|Hypothetical Protein LOC25858|Testis-Expressed Protein 40|Testis-Expressed Sequence 40 Protein|Uncharacterized Protein C11orf20	Cation channel sperm-associated protein subunit zeta (200 aa, ~23 kDa) is encoded by the human CATSPERZ gene. This protein is involved in sperm capacitation.			Amino Acid, Peptide, or Protein	
C101398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101398>	C20921	C9orf72 Gene|C9orf72|C9orf72|C9orf72-SMCR8 Complex Subunit Gene	This gene plays a role in the regulation of both cellular stress responses and autophagy.			Gene or Genome	
C101399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101399>	C101398	C9orf72 wt Allele|ALSFTD|C9orf72-SMCR8 Complex Subunit wt Allele|Chromosome 9 Open Reading Frame 72 Gene|DENND9|DENNL72|FTDALS|Guanine Nucleotide Exchange C9orf72 Gene|MGC23980|RP11-27J8.2	Human C9orf72 wild-type allele is located in the vicinity of 9p21.2 and is approximately 27 kb in length. This allele, which encodes guanine nucleotide exchange factor C9orf72 protein, is involved in guanyl-nucleotide exchange activity that mediates cellular stress responses and regulates autophagy. An expanded GGGGCC hexanucleotide repeat in the non-coding region of the C9orf72 gene is associated with amyotrophic lateral sclerosis and frontotemporal dementia.			Gene or Genome	
C10139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10139>	C61063	Cisplatin/Doxorubicin/Melphalan/Teniposide|CDDP/DOX/L-PAM/VM-26			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1013>	C277	Benznidazole|2-Nitro-N-(phenylmethyl)-1H-imidazole-1-acetamide|BENZNIDAZOLE|N-Benzyl-2-nitroimidazole-1-acetamide|N-benzyl-2-nitroimidazole-1-acetamide|Radanil|Ro-7-1051|Rochagan	A nitroimidazole derivative having an antiprotozoal activity by interfering with parasite protein biosynthesis, influencing cytokines production and stimulating host phagocytosis. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C101400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101400>	C17494	Guanine Nucleotide Exchange Factor C9orf72|C9orf72|Hypothetical Protein LOC203228|Protein C9orf72|Uncharacterized Protein C9orf72	Guanine nucleotide exchange factor C9orf72 (481 aa, ~54 kDa) is encoded by the human C9orf72 gene. This protein plays a role in cellular stress responses, autophagy and guanyl-nucleotide exchange activity.			Amino Acid, Peptide, or Protein	
C101401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101401>	C21550	GRN Gene|GRN|GRN|Granulin Precursor Gene	This gene is involved in inflammation, wound healing and cell proliferation and in the regulation of lysosomal function.	GRN Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101402>	C101401	GRN wt Allele|CLN11|GEP|GP88|Glycoprotein, 88-kD Gene|Granulin Gene|Granulin Precursor wt Allele|Granulin-Epithelin Gene|PCDGF|PEPI|PGRN	Human GRN wild-type allele is located in the vicinity of 17q21.32 and is approximately 8 kb in length. This allele, which encodes progranulin protein, plays a role in wound healing, lysosome acidification and the modulation of inflammation. Mutation of the gene is associated with primary progressive aphasia, neuronal ceroid lipofuscinosis type 11 and ubiquitin-positive frontotemporal dementia.	GRN wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101403>	C20464	Progranulin|Epithelin Precursor|GP88|GRN|Glycoprotein 88|Glycoprotein of 88 kDa|Granulin Precursor|Granulins|Granulins|PC Cell-Derived Growth Factor|PCDGF|PEPI|PGRN|Proepithelin	Progranulin (593 aa, ~64 kDa) is encoded by the human GRN gene. This protein is involved in lysosome acidification, inflammation and wound healing.	Granulins		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101404>	C21295	GPC6 Gene|GPC6|GPC6|Glypican 6 Gene	This gene plays a role in protein binding.			Gene or Genome	
C101405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101405>	C101404	GPC6 wt Allele|Glypican 6 wt Allele|MGC126288|OMIMD1|UNQ369/PRO705	Human GPC6 wild-type allele is located in the vicinity of 13q32 and is approximately 1181 kb in length. This allele, which encodes glypican-6 protein, is involved in cell-protein interactions. Mutation of the gene is associated with omodysplasia type 1.			Gene or Genome	
C101406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101406>	C17728	Glypican-6|GPC6|Glypican Proteoglycan 6	Glypican-6 (555 aa, ~63 kDa) is encoded by the human GPC6 gene. This protein plays a role in the mediation of cell-protein interactions.			Amino Acid, Peptide, or Protein	
C101407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101407>	C21275	TLL1 Gene|TLL1|TLL1|Tolloid-Like 1 Gene	This gene plays a role in both collagen processing and skeletal development.			Gene or Genome	
C101408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101408>	C101407	TLL1 wt Allele|ASD6|TLL|Tolloid-Like 1 wt Allele	Human TLL1 wild-type allele is located within 4q32-q33 and is approximately 231 kb in length. This allele, which encodes tolloid-like protein 1, is involved in both skeletal development and the modification of collagen.			Gene or Genome	
C101409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101409>	C16843	Tolloid-Like Protein 1|EC 3.4.24.-|TLL1	Tolloid-like protein 1 (1013 aa, ~115 kDa) is encoded by the human TLL1 gene. This protein plays a role in both collagen maturation and skeletal development.			Amino Acid, Peptide, or Protein|Enzyme	
C10140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10140>	C61063	Cytarabine/Daunorubicin/Etoposide/Thioguanine|ARA-C/DNR/TG/VP-16|V-TAD			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101410>	C20420	FOXO6 Gene|FOXO6|FOXO6|Forkhead Box O6 Gene	This gene may play a role in transcriptional activation.			Gene or Genome	
C101411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101411>	C101410	FOXO6 wt Allele|Forkhead Box O6 wt Allele	Human FOXO6 wild-type allele is located in the vicinity of 1p34.2 and is approximately 22 kb in length. This allele, which encodes forkhead box protein O6, may be involved in the activation of transcription.			Gene or Genome	
C101412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101412>	C17207	Forkhead Box Protein O6|FOXO6	Forkhead box protein O6 (492 aa, ~51 kDa) is encoded by the human FOXO6 gene. This protein may play a role in the positive regulation of transcription.			Amino Acid, Peptide, or Protein	
C101413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101413>	C25804	AICDA Gene|AICDA|AICDA|Activation Induced Cytidine Deaminase Gene	This gene plays a role in both class-switch recombination in B-lymphocytes and cytidine deamination.	AICDA Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101414>	C101413	AICDA wt Allele|AID|ARP2|Activation Induced Cytidine Deaminase wt Allele|CDA2|HEL-S-284|HIGM2	Human AICDA wild-type allele is located in the vicinity of 12p13 and is approximately 11 kb in length. This allele, which encodes single-stranded DNA cytidine deaminase protein, is involved in both DNA methylation and B-cell differentiation. Mutation of the gene is associated with immunodeficiency with hyper-IgM type 2.	AICDA wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101415>	C16701	Single-Stranded DNA Cytosine Deaminase|AICDA|AID|Activation-Induced Cytidine Deaminase|Cytidine Aminohydrolase|EC 3.5.4.5	Single-stranded DNA cytosine deaminase (198 aa, ~24 kDa) is encoded by the human AICDA gene. This protein plays a role in both B-cell functioning and DNA modification.	Activation-Induced Cytidine Deaminase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101416>	C20194	LIN28B Gene|LIN28B|LIN28B|Lin-28 Homolog B Gene	This gene plays a role in the suppression of miRNA processing.			Gene or Genome	Pediatric Oncology Target Genes/Proteins Terminology
C101417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101417>	C101416	LIN28B wt Allele|CSDD2|FLJ16517|LIN28, C. elegans, Homolog of, B Gene|Lin-28 Homolog B (C. elegans) Gene|Lin-28 Homolog B wt Allele|Lin-28.2|RP3-522O2.2	Human LIN28B wild-type allele is located in the vicinity of 6q21 and is approximately 126 kb in length. This allele, which encodes protein lin-28 homolog B, is involved in the regulation of pre-miRNA degradation.			Gene or Genome	
C101418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101418>	C18466	Protein Lin-28 Homolog B|LIN28B|Lin-28B	Protein lin-28 homolog B (250 aa, ~27 kDa) is encoded by the human LIN28B gene. This protein plays a role in the degradation of pre-miRNA.			Amino Acid, Peptide, or Protein	Pediatric Oncology Target Genes/Proteins Terminology
C101419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101419>	C26057|C20103	RIGI Gene|DDX58|DDX58 Gene|RIG-I|RIGI|RIGI|RNA Sensor RIG-I Gene	This gene plays a role in the antiviral response.	DDX58 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|Pediatric Oncology Immunotherapeutic Target Terminology
C10141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10141>	C61063	Cisplatin/Etoposide/Interleukin-2|CDDP/IL-2/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101420>	C101419	RIGI wt Allele|DDX58|DDX58 wt Allele|DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 58 Gene|DEAD-Box Polypeptide 58 Gene|DEAD/H (Asp-Glu-Ala-Asp/His) Box Polypeptide 58 Gene|DEAD/H-Box 58 Gene|DExD/H-Box Helicase 58 Gene|DKFZp434J1111|FLJ13599|RIG-I|RIG1|RLR-1|RNA Helicase RIG-I Gene|RNA Sensor RIG-I wt Allele|Retinoic Acid Inducible Gene I|Retinoic Acid-Inducible Gene I|SGMRT2	Human RIGI wild-type allele is located in the vicinity of 9p21.1 and is approximately 71 kb in length. This allele, which encodes antiviral innate immune response receptor RIG-I protein, is involved in the recognition of viral RNA and the activation of antiviral signaling pathways. Mutations in the gene are associated with Singleton-Merten syndrome 2.	DDX58 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101421>	C18106|C17417	Antiviral Innate Immune Response Receptor RIG-I|ATP-Dependent RNA Helicase DDX58|DDX58|DEAD Box Protein 58|EC 3.6.4.13|Probable ATP-Dependent RNA Helicase DDX58|RIG-1|RIG-I|RIG-I-Like Receptor 1|RIGI|RLR-1|RNA Helicase RIG-I|RNA Sensor RIG-I|Retinoic Acid-Inducible Gene 1 Protein|Retinoic Acid-Inducible Gene I Protein	Antiviral innate immune response receptor RIG-I (925 aa, ~107 kDa) is encoded by the human RIGI gene. This protein is involved in the activation of antiviral responses.	Antiviral Innate Immune Response Receptor RIG-I		Amino Acid, Peptide, or Protein|Enzyme|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology|Pediatric Oncology Immunotherapeutic Target Terminology
C101422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101422>	C20988	POSTN Gene|POSTN|POSTN|Periostin, Osteoblast Specific Factor Gene	This gene plays a role in both heparin binding and cell adhesion.	POSTN Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101423>	C101422	POSTN wt Allele|OSF-2|OSF2|Osteoblast Specific Factor 2 (Fasciclin I-Like) Gene|PDLPOSTN|PN|Periostin Gene|Periostin, Osteoblast Specific Factor wt Allele|RP11-412K4.1	Human POSTN wild-type allele is located in the vicinity of 13q13.3 and is approximately 47 kb in length. This allele, which encodes periostin protein, is involved in the regulation of cell adhesion.	POSTN wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101424>	C16393	Periostin|OSF-2|Osteoblast-Specific Factor 2|PN|Periodontal Ligament-Specific Periostin	Periostin (836 aa, ~93 kDa) is encoded by the human POSTN gene. This protein plays a role in cell adhesion.	Periostin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101425>	C28533	KIF5B Gene|KIF5B|KIF5B|KIF5B|Kinesin Family Member 5B Gene	This gene is involved in the transport of vesicles along microtubules.	KIF5B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C101426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101426>	C101425	KIF5B wt Allele|HEL-S-61|KINH|KNS|KNS1|Kinesin 1 Heavy Chain Gene|Kinesin Family Member 5B wt Allele|Kinesin, Heavy Chain, Ubiquitous Gene|UKHC	Human KIF5B wild-type allele is located in the vicinity of 10p11.22 and is approximately 47 kb in length. This allele, which encodes kinesin-1 heavy chain protein, plays a role in vesicle transport. A chromosomal inversion involving this gene and the RET gene may be associated with lung adenocarcinoma.	KIF5B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101427>	C16386	Kinesin-1 Heavy Chain|Conventional Kinesin Heavy Chain|KIF5B|Kinesin 1 Heavy Chain|Kinesin Heavy Chain|UKHC|Ubiquitous Kinesin Heavy Chain	Kinesin-1 heavy chain (963 aa, ~110 kDa) is encoded by the human KIF5B gene. This protein is involved in organelle and vesicle transport.	Kinesin-1 Heavy Chain		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101428>	C25997	WDCP Gene|C2orf44|WD Repeat and Coiled Coil Containing Gene|WDCP|WDCP|WDCP	This gene plays a role in binding to tyrosine-protein kinase HCK.	WDCP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C101429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101429>	C101428	WDCP wt Allele|C2orf44|Chromosome 2 Open Reading Frame 44 Gene|FLJ21945|PP384|WD Repeat and Coiled Coil Containing wt Allele	Human WDCP wild-type allele is located in the vicinity of 2p23.3 and is approximately 20 kb in length. This allele, which encodes WD repeat and coiled-coil-containing protein, is involved in binding to tyrosine-protein kinase HCK. A tandem duplication that fuses this gene and the ALK gene may be associated with colorectal cancer.	WDCP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10142>	C61063	Asparaginase/Cyclophosphamide/Cytarabine/Mercaptopurine/Methotrexate/Vincristine|ARA-C/ASP/CTX/MP/MTX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101430>	C26231	WD Repeat and Coiled-Coil-Containing Protein|Chromosome 2 Open Reading Frame 44 Protein|WD Repeat and Coiled-Coil-Containing Protein C2orf44|WD Repeat- and Coiled-Coil-Containing Protein|WD Repeat-Containing Protein C2orf44	WD repeat and coiled-coil-containing protein (721 aa, ~79 kDa) is encoded by the human WDCP gene. This protein plays a role in tyrosine-protein kinase HCK binding.	WD Repeat and Coiled-Coil-Containing Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101431>	C20988	SDC4 Gene|SDC4|SDC4|SDC4|Syndecan 4 Gene	This gene is involved in cell-matrix interactions.	SDC4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C101432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101432>	C101431	SDC4 wt Allele|MGC22217|SYND4|Syndecan 4 wt Allele	Human SDC4 wild-type allele is located in the vicinity of 20q12 and is approximately 23 kb in length. This allele, which encodes syndecan-4 protein, plays a role in heparan sulfate binding.	SDC4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101433>	C16393	Syndecan-4|Amphiglycan|Ryudocan|Ryudocan Core Protein|SYND4	Syndecan-4 (198 aa, ~22 kDa) is encoded by the human SDC4 gene. This protein is involved in cell surface localization of heparan sulfate.	Syndecan-4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101434>	C28533	SLC34A2 Gene|SLC34A2|SLC34A2|SLC34A2|Solute Carrier Family 34 Member 2 Gene	This gene plays a role in phosphate transport.	SLC34A2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C101435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101435>	C101434	SLC34A2 wt Allele|FLJ90534|NAPI-3B|NAPI-IIb|NPTIIb|NaPi-2b|NaPi2b|PULAM|Solute Carrier Family 34 (Sodium Phosphate), Member 2 Gene|Solute Carrier Family 34 (Type II Sodium/Phosphate Cotransporter), Member 2 Gene|Solute Carrier Family 34 Member 2 wt Allele	Human SLC34A2 wild-type allele is located in the vicinity of 4p15.2 and is approximately 23 kb in length. This allele, which encodes sodium-dependent phosphate transport protein 2B, is involved in sodium/phosphate co-transport. Mutation of the gene is associated with pulmonary alveolar microlithiasis. A chromosomal aberration involving this gene and the ROS1 gene may be associated with non-small cell lung cancer.	SLC34A2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101436>	C16386	Sodium-Dependent Phosphate Transport Protein 2B|Na(+)-Dependent Phosphate Cotransporter 2B|Na(+)/Pi Cotransporter 2B|NaPi-2b|NaPi2b|NaPi3b|SLC34A2|Sodium-Phosphate Transport Protein 2B|Sodium/Phosphate Cotransporter 2B|Solute Carrier Family 34 Member 2	Sodium-dependent phosphate transport protein 2B (690 aa, ~76 kDa) is encoded by the human SLC34A2 gene. This protein plays a role in pH-sensitive sodium-dependent phosphate transport.	Sodium-Dependent Phosphate Transport Protein 2B		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101437>	C25997	SH3BP2 Gene|SH3 Domain Binding Protein 2 Gene|SH3BP2|SH3BP2	This gene plays a role in signal transduction.			Gene or Genome	
C101438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101438>	C101437	SH3BP2 wt Allele|3BP-2|3BP2|CRBM|CRPM|Cherubism Gene|FLJ42079|FLJ54978|RES4-23|SH3 Domain Binding Protein 2 wt Allele|SH3-Domain Binding Protein 2 Gene	Human SH3BP2 wild-type allele is located 4p16.3 and is approximately 48 kb in length. This allele, which encodes SH3 domain-binding protein 2, is involved in the modulation of signaling. Mutation of the gene is associated with cherubism.			Gene or Genome	
C101439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101439>	C26231	SH3 Domain-Binding Protein 2|3BP-2|Abl-SH3 Binding Protein 2|TNFAIP3 Interacting Protein 2	SH3 domain-binding protein 2 (561 aa, ~62 kDa) is encoded by the human SH3BP2 gene. This protein plays a role in intracellular signaling.			Amino Acid, Peptide, or Protein	
C10143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10143>	C61063	Doxorubicin/Etoposide/Prednisone|DOX/PRED/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101440>	C20673	CAMTA1 Gene|CAMTA1|CAMTA1|CAMTA1|Calmodulin Binding Transcription Activator 1 Gene	This gene is involved in both DNA binding and transcription.	CAMTA1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C101441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101441>	C101440	CAMTA1 wt Allele|CANPMR|Calmodulin Binding Transcription Activator 1 wt Allele|KIAA0833|MSTP023|RP3-467L1.1	Human CAMTA1 wild-type allele is located within 1p36.31-p36.23 and is approximately 984 kb in length. This allele, which encodes calmodulin-binding transcription activator 1 protein, plays a role in transcriptional regulation. A chromosomal translocation involving this gene and the WWTR gene may be associated with epithelioid hemangioendothelioma.	CAMTA1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101442>	C26199	Calmodulin-Binding Transcription Activator 1|CAMTA1|Calmodulin Binding Transcription Activator 1	Calmodulin-binding transcription activator 1 (1673 aa, ~184 kDa) is encoded by the human CAMTA1 gene. This protein is involved in the modulation of gene transcription.	Calmodulin-Binding Transcription Activator 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101443>	C154302	H3-3A Gene|H3-3A|H3-3A|H3.3 Histone A Gene|H3F3A|H3F3A|H3F3A Gene	This gene is involved in chromatin structure.	H3F3A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C101444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101444>	C101443	H3-3A wt Allele|H3 Histone Family Member 3A Gene|H3.3 Histone A wt Allele|H3.3A|H3F3|H3F3A|H3F3A wt Allele|LOC347376|MGC87782|MGC87783|PP781|RP11-396C23.1	Human H3-3A wild-type allele is located in the vicinity of 1q42.12 and is approximately 10 kb in length. This allele, which encodes histone H3.3 protein, plays a role in both nucleosome assembly and transcriptional regulation.	H3F3A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101445>	C16685	Histone H3.3|H3.3	Histone H3.3 (136 aa, ~15 kDa) is encoded by both the human H3-3A and H3-3B genes. This protein plays a role in chromosomal structure.	Histone H3.3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C101446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101446>	C20194	LRIG3 Gene|LRIG3|LRIG3|LRIG3|Leucine-Rich Repeats and Immunoglobulin-Like Domains 3 Gene	This gene may be involved in signaling.	LRIG3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C101447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101447>	C101446	LRIG3 wt Allele|FLJ90440|KIAA3016|LIG3|Leucine-Rich Repeats and Immunoglobulin-Like Domains 3 wt Allele|UNQ287/PRO326/PRO335	Human LRIG3 wild-type allele is located in the vicinity of 12q14.1 and is approximately 48 kb in length. This allele, which encodes leucine-rich repeats and immunoglobulin-like domains protein 3, may play a role in signaling.	LRIG3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101448>	C18466	Leucine-Rich Repeats and Immunoglobulin-Like Domains Protein 3|LIG-3|LRIG3	Leucine-rich repeats and immunoglobulin-like domains protein 3 (1119 aa, ~123 kDa) is encoded by the human LRIG3 gene. This protein may be involved in signal transduction.	Leucine-Rich Repeats and Immunoglobulin-Like Domains Protein 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101449>	C54362	PHF6 Gene|PHD Finger Protein 6 Gene|PHF6|PHF6|PHF6	This gene plays a role in transcriptional regulation.	PHF6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C10144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10144>	C61063	Trifluoperazine/Vinblastine|TFPZ/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101450>	C101449	PHF6 wt Allele|BFLS|BORJ|Borjeson-Forssman-Lehmann Syndrome Gene|CENP-31|Centromere Protein 31 Gene|KIAA1823|MGC14797|PHD Finger Protein 6 wt Allele	Human PHF6 wild-type allele is located in the vicinity of Xq26.2 and is approximately 56 kb in length. This allele, which encodes PHD finger protein 6, is involved in the regulation of transcription. Mutation of the gene is associated with Borjeson-Forssman-Lehmann syndrome.	PHF6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101451>	C26199	PHD Finger Protein 6|Centromere Protein 31|PHD-Like Zinc Finger Protein|PHF6	PHD finger protein 6 (365 aa, ~41 kDa) is encoded by the human PHF6 gene. This protein plays a role in transcriptional regulation.	PHD Finger Protein 6		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101452>	C20921	ECT2L Gene|ECT2L|ECT2L|ECT2L|Epithelial Cell Transforming Sequence 2 Oncogene-Like Gene	This gene may be involved in guanine nucleotide exchange.	ECT2L Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C101453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101453>	C101452	ECT2L wt Allele|ARHGEF32|C6orf91|Chromosome 6 Open Reading Frame 91 Gene|Epithelial Cell Transforming Sequence 2 Oncogene-Like wt Allele|F-Box Protein 49 Gene|FBXO49|LFDH|RP3-509I19.3|dJ509I19.2|dJ509I19.3|dJ509I19.5	Human ECT2L wild-type allele is located in the vicinity of 6q24.1 and is approximately 108 kb in length. This allele, which encodes epithelial cell-transforming sequence 2 oncogene-like protein, may play a role in the regulation of small GTPase-mediated signaling.	ECT2L wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101454>	C18515	Epithelial Cell-Transforming Sequence 2 Oncogene-Like|F-Box Protein 49|Lung-Specific F-Box and DH Domain-Containing Protein|Putative Guanine Nucleotide Exchange Factor LFDH	Epithelial cell-transforming sequence 2 oncogene-like (904 aa, ~105 kDa) is encoded by the human ECT2L gene. This protein may be involved in signal transduction.	Epithelial Cell-Transforming Sequence 2 Oncogene-Like		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101455>	C25873	MAST1 Gene|MAST1|MAST1|Microtubule Associated Serine/Threonine Kinase 1 Gene	This gene plays a role in cytoskeletal organization.	MAST1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101456>	C101455	MAST1 wt Allele|KIAA0973|Microtubule Associated Serine/Threonine Kinase 1 wt Allele|SAST|SAST170	Human MAST1 wild-type allele is located in the vicinity of 19p13.2 and is approximately 37 kb in length. This allele, which encodes microtubule-associated serine/threonine-protein kinase 1 protein, is involved in both protein phosphorylation and cytoskeletal structure.	MAST1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101457>	C17325	Microtubule-Associated Serine/Threonine-Protein Kinase 1|EC 2.7.11.1|MAST1|Syntrophin-Associated Serine/Threonine-Protein Kinase	Microtubule-associated serine/threonine-protein kinase 1 (1570 aa, ~180 kDa) is encoded by the human MAST1 gene. This protein plays a role in serine/threonine phosphorylation of cytoskeletal proteins.	Microtubule-Associated Serine/Threonine-Protein Kinase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101458>	C25873	MAST2 Gene|MAST2|MAST2|Microtubule Associated Serine/Threonine Kinase 2 Gene	This gene is involved in serine/threonine phosphorylation.	MAST2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101459>	C101458	MAST2 wt Allele|FLJ39200|KIAA0807|MAST205|MTSSK|Microtubule Associated Serine/Threonine Kinase 2 wt Allele|RP4-533D7.1	Human MAST2 wild-type allele is located in the vicinity of 1p34.1 and is approximately 249 kb in length. This allele, which encodes microtubule-associated serine/threonine-protein kinase 2 protein, plays a role in the modulation of serine/threonine phosphorylation of cytoskeleton-associated proteins.	MAST2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10145>	C61063	BCG/Cyclophosphamide/Interleukin-2|BCG/CTX/IL-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101460>	C17325	Microtubule-Associated Serine/Threonine-Protein Kinase 2|EC 2.7.11.1|MAST2	Microtubule-associated serine/threonine-protein kinase 2 (1798 aa, ~196 kDa) is encoded by the human MAST2 gene. This protein is involved in both cytoskeletal organization and protein phosphorylation.	Microtubule-Associated Serine/Threonine-Protein Kinase 2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101461>	C43643	Procedure_Has_Target_Disease	A role used to assert that a procedure or technical method detects, diagnoses, or treats a specified disease state. The domain and range for this role are 'Activity' and 'Disease, Disorder or Finding', respectively.			Conceptual Entity	
C101462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101462>	C43643	Procedure_Uses_Manufactured_Object	A role used to assert that a procedure or technical method requires use of specific artifacts or pieces of equipment. The domain and range for this role are 'Activity' and 'Manufactured Object', respectively.			Conceptual Entity	
C101463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101463>	C54362	ZNF700 Gene|ZNF700|ZNF700|Zinc Finger Protein 700 Gene	This gene plays a role in the regulation of transcription.	ZNF700 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101464>	C101463	ZNF700 wt Allele|DKFZp434I1610|Zinc Finger Protein 700 wt Allele	Human ZNF700 wild-type allele is located in the vicinity of 19p13.2 and is approximately 26 kb in length. This allele, which encodes zinc finger protein 700, is involved in transcriptional regulation.	ZNF700 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101465>	C26199	Zinc Finger Protein 700|ZNF700	Zinc finger protein 700 (742 aa, ~86 kDa) is encoded by the human ZNF700 gene. This protein plays a role in transcriptional regulation.	Zinc Finger Protein 700		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101466>	C54362	GPBP1L1 Gene|GC-Rich Promoter Binding Protein 1-Like 1 Gene|GPBP1L1|GPBP1L1	This gene may be involved in transcriptional regulation.	GPBP1L1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101467>	C101466	GPBP1L1 wt Allele|GC-Rich Promoter Binding Protein 1-Like 1 wt Allele|RP11-767N6.1|SP192	Human GPBP1L1 wild-type allele is located in the vicinity of 1p34.1 and is approximately 61 kb in length. This allele, which encodes vasculin-like protein 1, may play a role in the regulation of transcription.	GPBP1L1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101468>	C26199	Vasculin-Like Protein 1|GC-Rich Promoter-Binding Protein 1-Like 1|GPBP1L1	Vasculin-like protein 1 (474 aa, ~52 kDa) is encoded by the human GPBP1L1 gene. This protein may be involved in the modulation of transcription.	Vasculin-Like Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101469>	C54362	TADA2A Gene|TADA2A|TADA2A|Transcriptional Adaptor 2A Gene	This gene plays a role in both histone acetylation and transcriptional regulation.	TADA2A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10146>	C61063	Cisplatin/Cyclophosphamide/Doxorubicin/Etoposide/Methotrexate/Vincristine/Vindesine|CDDP/CTX/DAVA/DOX/MTX/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101470>	C101469	TADA2A wt Allele|ADA2|ADA2A|KL04P|TADA2L|Transcriptional Adaptor 2A wt Allele|hADA2	Human TADA2A wild-type allele is located within 17q12-q21 and is approximately 71 kb in length. This allele, which encodes transcriptional adapter 2-alpha protein, is involved in the modulation of both histone modification and transcription.	TADA2A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101471>	C26199	Transcriptional Adapter 2-Alpha|ADA2-Like Protein|TADA2A|Transcriptional Adapter 2-Like	Transcriptional adapter 2-alpha (443 aa, ~52 kDa) is encoded by the human TADA2A gene. This protein plays a role in the modulation of transcription by histone acetylation.	Transcriptional Adapter 2-Alpha		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101472>	C26006	SEC16A Gene|SEC16 Homolog A (S. cerevisiae) Gene|SEC16A|SEC16A	This gene is involved in intracellular protein transport.	SEC16A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101473>	C101472	SEC16A wt Allele|KIAA0310|RP11-413M3.10|RP11-413M3.10-002|SEC16 Homolog A (S. cerevisiae) wt Allele|SEC16L|p250	Human SEC16A wild-type allele is located in the vicinity of 9q34.3 and is approximately 43 kb in length. This allele, which encodes protein transport protein Sec16A, plays a role in protein trafficking.	SEC16A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101474>	C16386	Protein Transport Protein Sec16A|SEC16 Homolog A|SEC16A	Protein transport protein Sec16A (2179 aa, ~234 kDa) is encoded by the human SEC16A gene. This protein is involved in the regulation of intracellular protein transport.	Protein Transport Protein Sec16A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101475>	C26006	SEC31A Gene|SEC31 Homolog A, COPII Coat Complex Component Gene|SEC31A|SEC31A	This gene plays a role in anterograde transport.	SEC31A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101476>	C101475	SEC31A wt Allele|ABP125|ABP130|HPBKS|HSPC275|HSPC334|KIAA0905|NEDSOSB|SEC31 Homolog A (S. cerevisiae) wt Allele|SEC31 Homolog A, COPII Coat Complex Component wt Allele|SEC31 Homolog A, COPII Coating Complex Component Gene|SEC31-Like 1 (S. cerevisiae) Gene|SEC31L1|Yeast Sec31p Homolog Gene	Human SEC31A wild-type allele is located in the vicinity of 4q21.3 and is approximately 83 kb in length. This allele, which encodes protein transport protein Sec31A, is involved in protein trafficking.	SEC31A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101477>	C16386	Protein Transport Protein Sec31A|ABP125|ABP130|SEC31-Like Protein 1|SEC31-Related Protein A|SEC31A|Web1-Like Protein	Protein transport protein Sec31A (1220 aa, ~133 kDa) is encoded by the human SEC31A gene. This protein plays a role in the mediation of protein transport between the endoplasmic reticulum and the Golgi apparatus.	Protein Transport Protein Sec31A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101478>	C26006	SEC22B Gene|SEC22 Vesicle Trafficking Protein Homolog B (S. cerevisiae) (gene/pseudogene) Gene|SEC22B|SEC22B	This gene is involved in protein transport.	SEC22B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101479>	C101478	SEC22B wt Allele|ERS-24|SEC22 Vesicle Trafficking Protein Homolog B (S. cerevisiae) (gene/pseudogene) wt Allele|SEC22L1|sec22b	Human SEC22B wild-type allele is located in the vicinity of 1q21.1 and is approximately 21 kb in length. This allele, which encodes vesicle-trafficking protein SEC22b, plays a role in protein trafficking.	SEC22B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10147>	C61063	Dipyridamole/Vinblastine|DP/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101480>	C16386	Vesicle-Trafficking Protein SEC22b|ER-Golgi SNARE of 24 kDa|ERS-24|ERS24|SEC22|SEC22 Vesicle-Trafficking Protein-Like 1|Vesicle-Trafficking Protein Homolog B	Vesicle-trafficking protein SEC22b (215 aa, ~25 kDa) is encoded by the human SEC22B gene. This protein is involved in anterograde transport.	Vesicle-Trafficking Protein SEC22b		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101481>	C20923	GABBR2 Gene|GABBR2|GABBR2|Gamma-Aminobutyric Acid (GABA) B Receptor, 2 Gene	This gene plays a role in signaling.	GABBR2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101482>	C101481	GABBR2 wt Allele|GABABR2|GPR51|GPRC3B|Gamma-Aminobutyric Acid (GABA) B Receptor, 2 wt Allele|HG20|HRIHFB2099	Human GABBR2 wild-type allele is located within 9q22.1-q22.3 and is approximately 421 kb in length. This allele, which encodes gamma-aminobutyric acid type B receptor subunit 2 protein, is involved in gamma-aminobutyric acid-mediated signaling.	GABBR2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101483>	C18239	Gamma-Aminobutyric Acid Type B Receptor Subunit 2|G-Protein Coupled Receptor 51|GABA-B Receptor 2|GABA-B-R2|GABA-BR2|GABABR2|Gb2|HG20	Gamma-aminobutyric acid type B receptor subunit 2 (941 aa, ~106 kDa) is encoded by the human GABBR2 gene. This protein plays a role in the mediation of GABA-dependent signaling.	Gamma-Aminobutyric Acid Type B Receptor Subunit 2		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101484>	C20923	LGR5 Gene|LGR5|LGR5|Leucine-Rich Repeat Containing G Protein-Coupled Receptor 5 Gene	This gene plays a role in receptor-mediated signaling.	LGR5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101485>	C101484	LGR5 wt Allele|FEX|GPR49|GPR67|GRP49|HG38|Leucine-Rich Repeat Containing G Protein-Coupled Receptor 5 wt Allele	Human LGR5 wild-type allele is located within 12q22-q23 and is approximately 147 kb in length. This allele, which encodes leucine-rich repeat-containing G-protein coupled receptor 5 protein, is involved in signaling.	LGR5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101486>	C18239	Leucine-Rich Repeat-Containing G-Protein Coupled Receptor 5|G Protein-Coupled Receptor 49|G-Protein Coupled Receptor 49|G-Protein Coupled Receptor 67|G-Protein Coupled Receptor HG38|LGR5|Leucine-Rich Repeat-Containing G Protein-Coupled Receptor 5|Orphan G Protein-Coupled Receptor HG38	Leucine-rich repeat-containing G-protein coupled receptor 5 (907 aa, ~100 kDa) is encoded by the human LGR5 gene. This protein plays a role in signal transduction.	Leucine-Rich Repeat-Containing G-Protein Coupled Receptor 5		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101487>	C20819	NUP107 Gene|NUP107|NUP107|Nucleoporin 107kDa Gene	This gene is involved in the assembly of the nuclear pore complex.	NUP107 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101488>	C101487	NUP107 wt Allele|NUP84|Nucleoporin 107kDa wt Allele	Human NUP107 wild-type allele is located in the vicinity of 12q15 and is approximately 56 kb in length. This allele, which encodes nuclear pore complex protein Nup107, plays a role in nuclear transport.	NUP107 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101489>	C21183	Nuclear Pore Complex Protein Nup107|107 kDa Nucleoporin|Nucleoporin Nup107	Nuclear pore complex protein Nup107 (925 aa, ~106 kDa) is encoded by the human NUP107 gene. This protein is involved in nuclear pore assembly.	Nuclear Pore Complex Protein Nup107		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10148>	C61063	Bleomycin/Cyclophosphamide/Dexamethasone/Doxorubicin/Procarbazine/Vincristine|BLEO/CTX/DM/DOX/PCB/VCR|COD-BLAM IV			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101491>	C25997	SQSTM1 Gene|SQSTM1|SQSTM1|Sequestosome 1 Gene	This gene is involved in signal transduction.	SQSTM1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101492>	C101491	SQSTM1 wt Allele|A170|OSIL|PDB3|Sequestosome 1 wt Allele|ZIP3|p60|p62|p62B	Human SQSTM1 wild-type allele is located 5q35 and is approximately 32 kb in length. This allele, which encodes sequestosome-1 protein, plays a role in signal transduction. Mutation of the gene is associated with Paget disease of bone.	SQSTM1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101493>	C26231	Sequestosome-1|EBI3-Associated Protein Of 60 kDa|EBIAP|Phosphotyrosine-Independent Ligand for the Lck SH2 Domain Of 62 kDa|SQSTM1|Ubiquitin-Binding Protein p62|p60	Sequestosome-1 (440 aa, ~48 kDa) is encoded by the human SQSTM1 gene. This protein is involved in signaling.	Sequestosome-1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101494>	C21295	PPFIBP1 Gene|PPFIBP1|PPFIBP1|PPFIBP1|PTPRF Interacting Protein, Binding Protein 1 (Liprin Beta 1) Gene	This gene plays a role in protein-protein interactions and cell-matrix adhesion.	PPFIBP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C101495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101495>	C101494	PPFIBP1 wt Allele|KIAA1230|L2|PTPRF Interacting Protein, Binding Protein 1 (Liprin Beta 1) wt Allele|SGT2|hSGT2|hSgt2p	Human PPFIBP1 wild-type allele is located in the vicinity of 12p12.1 and is approximately 172 kb in length. This allele, which encodes liprin-beta-1 protein, is involved in the modulation of protein-protein interactions.	PPFIBP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101496>	C17728	Liprin-Beta-1|PPFIBP1|PTPRF-Interacting Protein-Binding Protein 1|Protein Tyrosine Phosphatase Receptor Type f Polypeptide-Interacting Protein-Binding Protein 1|hSGT2	Liprin-beta-1 (1011 aa, ~114 kDa) is encoded by the human PPFIBP1 gene. This protein plays a role in the mediation of protein-protein interactions.	Liprin-Beta-1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101497>	C21295	ESRP1 Gene|ESRP1|ESRP1|Epithelial Splicing Regulatory Protein 1 Gene	This gene is involved in mRNA processing.	ESRP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101498>	C101497	ESRP1 wt Allele|Epithelial Splicing Regulatory Protein 1 wt Allele|FLJ20171|RBM35A|RMB35A	Human ESRP1 wild-type allele is located in the vicinity of 8q22.1 and is approximately 66 kb in length. This allele, which encodes epithelial splicing regulatory protein 1, plays a role in the regulation of RNA splicing.	ESRP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101499>	C21298	Epithelial Splicing Regulatory Protein 1|ESRP1|RNA-Binding Motif Protein 35A|RNA-Binding Protein 35A	Epithelial splicing regulatory protein 1 (681 aa, ~76 kDa) is encoded by the human ESRP1 gene. This protein is involved in the mediation of mRNA splicing.	Epithelial Splicing Regulatory Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10149>	C65070	BEMP Regimen|BEMP|BEMP|BLEO/CDDP/DAVA/MITO|Bleomycin-Vindesine-Mitomycin-Platinol|Bleomycin/Eldisine/Mitomycin/Platinol|Bleomycin/Eldisine/Mitomycin/Platinol Regimen|Bleomycin/Vindesine/Mitomycin/Cisplatin|Bleomycin/Vindesine/Mitomycin/Cisplatin Regimen|Bleomycin/Vindesine/Mitomycin/Platinol	A regimen consisting of bleomycin, vindesine, mitomycin and cisplatin that may be used in the treatment of disseminated squamous-cell carcinoma of the cervix.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C1014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1014>	C764|C1420	Verteporfin|BPD-MA|Benzoporphyrin Derivative Monoacid Ring A|VERTEPORFIN|Visudyne	A synthetic light-activated agent with photodynamic activity. Upon systemic administration, verteporfin accumulates in neovessels in the eye and, once stimulated by nonthermal red light in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to neovascular endothelium and blood vessel occlusion. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C101500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101500>	C25997	AGTRAP Gene|AGTRAP|AGTRAP|Angiotensin II Receptor-Associated Protein Gene	This gene plays a role in angiotensin signaling.	AGTRAP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101501>	C101500	AGTRAP wt Allele|ATRAP|Angiotensin II Receptor-Associated Protein wt Allele|RP11-56N19.3	Human AGTRAP wild-type allele is located in the vicinity of 1p36.22 and is approximately 19 kb in length. This allele, which encodes type-1 angiotensin II receptor-associated protein, is involved in the modulation of angiotensin signaling.	AGTRAP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101502>	C26231	Type-1 Angiotensin II Receptor-Associated Protein|AT1 Receptor-Associated Protein|ATI Receptor-Associated Protein|Angiotensin II, Type I Receptor-Associated Protein	Type-1 angiotensin II receptor-associated protein (159 aa, ~17 kDa) is encoded by the human AGTRAP gene. This protein plays a role in the negative regulation of angiotensin receptor signaling.	Type-1 Angiotensin II Receptor-Associated Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101503>	C20194	SSBP2 Gene|SSBP2|SSBP2|Single-Stranded DNA Binding Protein 2 Gene	This gene may be involved in DNA stability.	SSBP2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101504>	C101503	SSBP2 wt Allele|HSPC116|SOSS-B2|SSDP2|Single-Stranded DNA Binding Protein 2 wt Allele	Human SSBP2 wild-type allele is located in the vicinity of 5q14.1 and is approximately 339 kb in length. This allele, which encodes single-stranded DNA-binding protein 2, may play a role in the stabilization of genomic DNA.	SSBP2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101505>	C18466	Single-Stranded DNA-Binding Protein 2|SSBP2|Sequence-Specific Single-Stranded-DNA-Binding Protein 2	Single-stranded DNA-binding protein 2 (361 aa, ~38 kDa) is encoded by the human SSBP2 gene. This protein may be involved in genome stability.	Single-Stranded DNA-Binding Protein 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101506>	C21295	FCHSD1 Gene|FCH and Double SH3 Domains 1 Gene|FCHSD1|FCHSD1	This gene may be involved in signal transduction.	FCHSD1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101507>	C101506	FCHSD1 wt Allele|FCH and Double SH3 Domains 1 wt Allele|FLJ00007|NWK2|Nervous Wreck Homolog 2 Gene|Nervous Wreck, Drosophila, Homolog of, 2 Gene|UNQ737/PRO1431	Human FCHSD1 wild-type allele is located in the vicinity of 5q31.3 and is approximately 12 kb in length. This allele, which encodes F-BAR and double SH3 domains protein 1, may play a role in signaling.	FCHSD1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101508>	C17728	F-BAR and Double SH3 Domains Protein 1|FCH and Double SH3 Domains Protein 1|FCHSD1|NWK2|Protein Nervous Wreck 2	F-BAR and double SH3 domains protein 1 (690 aa, ~77 kDa) is encoded by the human FCHSD1 gene. This protein may be involved in signaling.	F-BAR and Double SH3 Domains Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101509>	C37901	API/FDF Analytical Testing Site|API/FDF ANALYTICAL TESTING|API/FDF Analytical Testing|Active Pharmaceutical Ingredient / Finished Dosage Form Analytical Testing Site|Analytical Testing|Testing	Sites that perform testing of the characteristics and attributes of active pharmaceutical ingredients or finished dosage forms.			Spatial Concept	FDA Establishment Activity Terminology|FDA Quality Metrics Terminology|FDA Structured Product Labeling Terminology|PQ/CMC Manufacturing Site Responsibility Category Terminology|SPL Business Operation Terminology
C10150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10150>	C61063	Chlorambucil/Etoposide/Lomustine|CCNU/CLB/VP-16|CEC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101510>	C217464	FDF Manufacture|FDF MANUFACTURE|Finished Dosage Form Manufacture	The act of making a drug product as ready to be utilized or consumed by the end user.			Activity	FDA Structured Product Labeling Terminology|SPL Business Operation Terminology
C101511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101511>	C39421	Clinical Bioequivalence or Bioavailability Study|CLINICAL BIOEQUIVALENCE OR BIOAVALABILITY STUDY	All the activities included in the process of conducting clinical bioequivalence or bioavailability studies.			Research Activity	FDA Structured Product Labeling Terminology|SPL Business Operation Terminology
C101512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101512>	C204844	In Vitro Bioequivalence or Bioanalytical Testing|IN VITRO BIOEQUIVALENCE OR BIOANALYTICAL TESTING	Bioequivalence or bioanalytical testing performed in vitro.			Laboratory Procedure	FDA Structured Product Labeling Terminology|SPL Business Operation Terminology
C101513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101513>	C66902	Transarterial Chemoembolization|TACE	A hepatic artery embolization technique involving the injection of a blocking agent and a chemotherapy agent to treat liver cancers.	Transarterial Chemoembolization		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C101514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101514>	C225418	Transarterial	Through an artery.			Qualitative Concept	
C101515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101515>	C606|C344	Glucurolactone|GLUCUROLACTONE|Gamma-lactone of D-Glucofuranuronic Acid|Guronsan				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C101516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101516>	C27993	Palliative|PALLIATIVE|PB-Palliative Benefit|Palliative - procedure intent	Any action or response, without curative intent, that mitigates some or all of the unpleasant effects of a disease or condition.			Qualitative Concept	CDISC SDTM Terminology|CDISC SDTM Treatment Intent Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|mCode Procedure Intent Value Set|mCode Terminology
C101517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101517>	C210732	Gamma-delta Tocotrienol|GDT|gdT3	An orally available nutritional supplement containing the gamma and delta forms of the vitamin E family member tocotrienol, with hypocholesterolemic, antithrombotic, antioxidant, and potential antineoplastic activity. Upon oral administration, gamma-delta tocotrienol accumulates in cancer cells and may exert their anti-cancer activity in part through 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase downregulation and/or degradation, cell cycle arrest, and induction of caspase-mediated apoptosis. In addition, this agent may inhibit angiogenesis partially through the blockage of vascular endothelial growth factor receptor (VEGFR) and the inhibition of tumor cell-induced vessel formation. Altogether, this may result in the inhibition of tumor cell growth. Further, this agent prevents free radical formation and inhibits lipid peroxidation. Tocotrienols contain 3 double bonds, absent in tocopherols, on its farnesyl isoprenoid side chain that likely contribute to its anti-cancer activities.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101518>	C1505	Tocotrienol-rich Fraction|TRF	An orally available nutritional supplement containing high amounts of the vitamin E family member tocotrienol with antioxidant, hypolipidemic and potential immunomodulating and antiproliferative activity. Upon oral administration, tocotrienol-rich fraction (TRF) accumulates in tumor cells and induces cell cycle arrest, programmed cell death, and inhibits tumor cell proliferation. In addition, this agent suppresses 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase activity and inhibits angiogenesis. Rice bran oil, palm oil and annatto seed oil are common sources of TRF.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101519>	C198646	Edicotinib|1H-Imidazole-2-carboxamide, 5-Cyano-N-(2-(4,4-dimethyl-1-cyclohexen-1-yl)-6-(tetrahydro-2,2,6,6-tetramethyl-2H-pyran-4-yl)-3-pyridinyl)-|4-Cyano-1H-imidazole-2-carboxylic acid N-(2-(4,4-dimethylcyclohex-1-enyl)-6-(2,2,6,6-tetramethyltetrahydropyran-4-yl)pyridin-3-yl)amide|4-Cyano-N-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyl-tetrahydro-2H-pyran-4-yl)pyridin-3-yl)-1H-imidazole-2-carboxamide|EDICOTINIB|JNJ-40346527	A small molecule and orally available inhibitor of colony-stimulating factor-1 receptor (CSF1R; FMS) with potential antineoplastic activity. Edicotinib blocks the receptor-ligand interaction between FMS and its ligand CSF1, thereby preventing autophosphorylation of FMS. As a result, unphosphorylated FMS can not activate FMS-mediated signaling pathways, thus potentially inhibiting cell proliferation in FMS-overexpressed tumor cells. FMS, a tyrosine kinase receptor, is overexpressed in certain tumor cell types and plays an essential role in macrophage differentiation, recruitment, and activation as well as the regulation of cell proliferation.	Edicotinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C10151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10151>	C61063	Doxorubicin/Melphalan/Teniposide|DOX/L-PAM/VM-26|MAV			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101520>	C213472|C159198|C124800	FLT3/KIT Kinase Inhibitor AKN-028|AKN-028|AKN-028|BVT-II	An orally bioavailable protein tyrosine kinase inhibitor for FMS-related tyrosine kinase 3 (FLT3; STK1) and stem cell factor receptor (SCFR; KIT), with potential antineoplastic activity. FLT3/KIT kinase inhibitor AKN-028 binds to and inhibits both the wild-type and mutated forms of FLT3 and SCFR. This may result in an inhibition of tumor cell proliferation in cancer cell types that overexpress these receptor tyrosine kinases.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101521>	C201598|C129822	Anti-DLL4 Monoclonal Antibody MEDI0639|MEDI-0639|MEDI0639	An immunoglobulin G1 lambda monoclonal antibody directed against the Notch ligand delta-like 4 (DLL4) with potential antineoplastic activity. Anti-DLL4 monoclonal antibody MEDI0639 specifically binds to DLL4 and prevents its interaction with Notch receptors, thereby inhibiting Notch-mediated signaling and gene transcription, which may block tumor angiogenesis and eventually the inhibition of tumor cell growth. Activation of Notch receptors by DLL4 stimulates proteolytic cleavage of the Notch intracellular domain (NICD); after cleavage, NICD is translocated to the nucleus and mediates the transcriptional regulation of a variety of genes involved in vascular development. The expression of DLL4 is highly restricted to the vascular endothelium; DLL4/Notch signaling is required for the development of functional tumor blood vessels.	Anti-DLL4 Monoclonal Antibody MEDI0639		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101522>	C1511	Indium In 111 Anti-CD45 Monoclonal Antibody BC8|In 111 MOAB BC8|In 111 Monoclonal Antibody BC8|Indium In 111 Monoclonal Antibody BC8|monoclonal antibody BC8, indium In 111	A radioimmunoconjugate containing the murine IgG1 anti-CD45 monoclonal antibody (MoAb) BC8 labeled with the gamma-emitting isotope indium 111 (In 111), with potential radioimaging application. Upon administration, indium In 111 anti-CD45 monoclonal antibody BC8 binds to CD45 antigen, a receptor protein tyrosine phosphatase expressed on the surface of most of the normal and malignant hematopoietic cells. After binding and internalization by CD45-expressing tumor cells, radioactive In 111 allows for the detection of BC8 distribution and tumor localization using gamma scintigraphy.	Indium In 111 Anti-CD45 Monoclonal Antibody BC8		Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C101523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101523>	C1967|C129825	Tarloxotinib|Hypoxia-activated Prodrug TH-4000|Hypoxin|PR610|TARLOXOTINIB|TH-4000	A proprietary, hypoxia-activated prodrug with potential antineoplastic activity. Upon administration, tarloxotinib is activated in the hypoxic cells within tumors into an irreversible pan-HER inhibitor via a mechanism of action not yet fully elucidated. As a result, this agent inhibits cellular proliferation and differentiation of tumor cells overexpressing HER kinases, which belong to the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. Healthy, normal tissues may be spared due to the hypoxia-specific activity of this agent, potentially reducing systemic toxicity.	Tarloxotinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101524>	C211912	Indusatumab Vedotin|INDUSATUMAB VEDOTIN|MLN0264	An antibody-drug conjugate (ADC) containing a monoclonal antibody directed against guanylyl cyclase C (GCC or GUCY2C) conjugated to monomethylauristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity. The monoclonal antibody moiety of indusatumab vedotin selectively binds to GCC, a transmembrane receptor normally found on intestinal cells and dopamine neurons in the brain, but is also overexpressed on the surface of gastrointestinal cancers. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis in GCC-expressing tumor cells.	Indusatumab Vedotin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101525>	C129824	TRPV6 Calcium Channel Inhibitor SOR-C13|SOR-C13|SOR-C13	An inhibitor of transient receptor potential cation channel vanilloid family member 6 (TRPV6, CaT1 or CATL) with potential antineoplastic activity. TRPV6 calcium channel inhibitor SOR-C13 binds to TRPV6 and prevents the influx of calcium ions into TRPV6-expressing tumor cells. This inhibits the activation of nuclear factor of activated T-cell (NFAT) transcription complex which may result in an inhibition of calcium-dependent cancer cell proliferation and an induction of apoptosis in tumor cells overexpressing TRPV6. The TRPV6 ion channel plays a key role in calcium homeostasis and is highly selective for calcium compared to other cations; it is overexpressed in a variety of tumors and initiates tumor cell growth, proliferation and metastases.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101526>	C71738	Treatment Epoch|TREATMENT	A period in a clinical study during which subjects receive therapeutic treatment.			Research Activity	CDISC SDTM Epoch Terminology|CDISC SDTM Terminology|CDISC SEND Epoch Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C101527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101527>	C32889	Interphalangeal Joint	Hinge joints between the phalanges of the hand or foot.			Anatomical Structure	
C101528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101528>	C101527	Proximal Interphalangeal Joint	Interphalangeal joint located between the first and second phalanges.			Anatomical Structure	
C101529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101529>	C101527	Distal Interphalangeal Joint	Interphalangeal joint located between the second and third phalanges.			Anatomical Structure	
C10152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10152>	C61063	Etoposide/Ifosfamide/Vindesine|DAVA/IFF/VP-16|VPIV			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101530>	C1663	Folate Binding Protein E39 Peptide Vaccine|E39 Peptide Vaccine|FBP E39 Peptide Vaccine	A cancer vaccine comprised of human leukocyte antigen (HLA) A2 restricted folate binding protein (FBP) epitope E39 (amino acids 191 to 199), with potential immunostimulatory and antineoplastic activity. Upon intradermal injection, FBP E39 peptide vaccine may induce a specific cytotoxic T-lymphocyte (CTL) response against FBP-expressing tumor cell types. FBP is a membrane-bound, tumor-associated antigen highly overexpressed in various tumor cell types, such as in breast, ovarian and endometrial cancers; E 39 is a strong immunogenic peptide.	Folate Binding Protein E39 Peptide Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101532>	C69145|C129825	MEK Inhibitor WX-554|WX-554|WX-554	An orally available small molecule mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK) inhibitor, with potential antineoplastic activity. MEK inhibitor WX-554 selectively binds to and inhibits the activity of MEK, thereby preventing the activation of MEK-dependent effector proteins including some transcription factors, which may result in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a dual-specificity threonine/tyrosine kinase that plays a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway, is frequently upregulated in a variety of tumor cell types.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101533>	C73581	Unapproved Drug for Use in Drug Shortage|UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE	A category of drug products that are not officially approved by the responsible agency. Drugs in this category have been processed according to standards set forth by the approving agency, and can be considered potential substitutes when the approved medication is unavailable.			Qualitative Concept	FDA Structured Product Labeling Terminology|SPL Marketing Category Terminology
C101534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101534>	C448	Cicletanine Hydrochloride|CICLETANINE HYDROCHLORIDE|Furo(3,4-c)pyridin-7-ol, 3-(4-chlorophenyl)-1,3-dihydro-6-methyl-, Hydrochloride|WIN-90000 HCl	The hydrochloride salt of a dihydropyridine derivative with diuretic and antihypertensive activity. Cicletanine exerts thiazide-like diuretic activity. In addition, this agent inhibits protein kinase C (PKC) and is able to reverse vasoconstriction through the inhibition of PKC-mediated inhibition of Na/K-ATPase phosphorylation.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C101535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101535>	C67413	Ketobemidone Hydrochloride|1-(4-(3-hydroxyphenyl)-1-methyl-4-piperidinyl)-1-propanone Hydrochloride|Cymidon|Hoechst 10720|KETOBEMIDONE HYDROCHLORIDE|Ketodur|WIN-1539				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C101536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101536>	C521	Flumedroxone Acetate|6alpha-trifluoromethyl-17alpha-acetoxyprogesterone|FLUMEDROXONE ACETATE|WG-537				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C101537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101537>	C737	Spinosad Factor A|SPINOSAD FACTOR A|Spinosyns				Hazardous or Poisonous Substance|Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C101538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101538>	C128462	Molibresib|GSK-525762A|GSK525762|I-BET 762|MOLIBRESIB	A small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins with potential antineoplastic activity. Upon administration, molibresib binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histone peptides. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomain at the N-terminus, BET proteins, comprising of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.	Molibresib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101539>	C87543	Stage I Differentiated Thyroid Gland Carcinoma Under 45 Years AJCC v7|Stage I Differentiated Thyroid Gland Cancer Under 45 Years|Stage I Differentiated Thyroid Gland Carcinoma Under 45 Years|Stage I Thyroid Gland Papillary or Follicular Carcinoma Under 45 Years	Stage I includes: Any T, Any N, M0.  M0: No evidence of distant metastasis.  (from AJCC 7th Ed.)	Stage I Differentiated Thyroid Gland Carcinoma Under 45 Years AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C10153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10153>	C61063	Cyclophosphamide/Doxorubicin/Methotrexate/Vinblastine|CTX/DOX/MTX/VBL|M-CAVE			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101540>	C87543	Stage I Differentiated Thyroid Gland Carcinoma 45 Years and Older AJCC v7|Stage I Differentiated Thyroid Gland Cancer 45 Years and Older|Stage I Differentiated Thyroid Gland Carcinoma 45 Years and Older|Stage I Thyroid Gland Papillary or Follicular Carcinoma 45 Years and Older	Stage I includes: T1, N0, M0.  T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland.  N0: No regional lymph node metastasis.  M0: No evidence of distant metastasis. (from AJCC 7th Ed.)	Stage I Differentiated Thyroid Gland Carcinoma 45 Years and Older AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C101541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101541>	C87544	Stage II Differentiated Thyroid Gland Carcinoma Under 45 Years AJCC v7|Stage II Differentiated Thyroid Gland Cancer Under 45 Years|Stage II Differentiated Thyroid Gland Carcinoma Under 45 Years|Stage II Thyroid Gland Papillary or Follicular Carcinoma Under 45 Years	Stage II includes: Any T, Any N, M1.  M1: Distant metastasis.  (from AJCC 7th Ed.)	Stage II Differentiated Thyroid Gland Carcinoma Under 45 Years AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C101542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101542>	C87544	Stage II Differentiated Thyroid Gland Carcinoma 45 Years and Older AJCC v7|Stage II Differentiated Thyroid Gland Cancer 45 Years and Older|Stage II Differentiated Thyroid Gland Carcinoma 45 Years and Older|Stage II Thyroid Gland Papillary or Follicular Carcinoma 45 Years and Older	Stage II includes: T2, N0, M0.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland.  N0: No regional lymph node metastasis.  M0: No evidence of distant metastasis.  (from AJCC 7th Ed.)	Stage II Differentiated Thyroid Gland Carcinoma 45 Years and Older AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C101543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101543>	C25939	EGLN1 Gene|EGLN1|EGLN1|Egl Nine Homolog 1 (C. elegans) Gene	This gene plays a role in both protein modification and oxygen homeostasis.			Gene or Genome	
C101544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101544>	C101543	EGLN1 wt Allele|C1orf12|DKFZp761F179|ECYT3|Egl Nine Homolog 1 (C. elegans) wt Allele|HIF Prolyl Hydroxylase 2 Gene|HIF-PH2|HIFPH2|HPH-2|HPH2|PHD2|PNAS-118|PNAS-137|SM-20|SM20	Human EGLN1 wild-type allele is located in the vicinity of 1q42.1 and is approximately 61 kb in length. This allele, which encodes egl nine homolog 1 protein, is involved in the response to hypoxia. Mutation of the gene is associated with familial erythrocytosis type 3.			Gene or Genome	
C101545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101545>	C16946	Egl Nine Homolog 1|EC 1.14.11.29|EGLN1|HIF-PH2|HIF-Prolyl Hydroxylase 2|HPH-2|Hypoxia-Inducible Factor Prolyl Hydroxylase 2|PHD2|Prolyl Hydroxylase Domain-Containing Protein 2|SM-20	Egl nine homolog 1 (426 aa, ~46 kDa) is encoded by the human EGLN1 gene. This protein plays a role in the modification of hypoxia-inducible factor alpha proteins in response to hypoxic conditions.			Amino Acid, Peptide, or Protein|Enzyme	
C101546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101546>	C25971	TYK2 Gene|TYK2|TYK2|Tyrosine Kinase 2 Gene	This gene is involved in both protein phosphorylation and interferon-mediated signaling.	TYK2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|Pediatric Oncology Target Genes/Proteins Terminology
C101547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101547>	C101546	TYK2 wt Allele|IMD35|JTK1|Tyrosine Kinase 2 wt Allele	Human TYK2 wild-type allele is located in the vicinity of 19p13.2 and is approximately 30 kb in length. This allele, which encodes non-receptor tyrosine-protein kinase TYK2 protein, plays a role in the mediation of both type I interferon signaling and tyrosine phosphorylation.	TYK2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101548>	C17020	Non-Receptor Tyrosine-Protein Kinase TYK2|EC 2.7.10.2	Non-receptor tyrosine-protein kinase TYK2 (1187 aa, ~134 kDa) is encoded by the human TYK2 gene. This protein is involved in both tyrosine phosphorylation and signal transduction.	Non-Receptor Tyrosine-Protein Kinase TYK2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology|Pediatric Oncology Target Genes/Proteins Terminology
C101549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101549>	C25939	P4HA2 Gene|P4HA2|P4HA2|Prolyl 4-Hydroxylase, Alpha Polypeptide II Gene	This gene is involved in collagen metabolism.			Gene or Genome	
C10154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10154>	C61063	Hydrocortisone/Suramin|HC/SUR|Suramin/HC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101550>	C101549	P4HA2 wt Allele|4-PH Alpha 2 Gene|C-P4Halpha(II) Gene|Collagen Prolyl 4-Hydroxylase Alpha(II)Gene|Prolyl 4-Hydroxylase, Alpha Polypeptide II wt Allele|UNQ290/PRO330	Human P4HA2 wild-type allele is located in the vicinity of 5q31 and is approximately 103 kb in length. This allele, which encodes prolyl 4-hydroxylase subunit alpha-2 protein, plays a role in procollagen processing.			Gene or Genome	
C101551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101551>	C16946	Prolyl 4-Hydroxylase Subunit Alpha-2|4-PH Alpha-2|C-P4H Alpha(II)|Collagen Prolyl 4-Hydroxylase Alpha(II)|EC 1.14.11.2|P4HA2|Procollagen-Proline, 2-Oxoglutarate 4-Dioxygenase, Alpha Polypeptide II|Procollagen-Proline,2-Oxoglutarate-4-Dioxygenase Subunit Alpha-2	Prolyl 4-hydroxylase subunit alpha-2 (535 aa, ~62 kDa) is encoded by the human P4HA2 gene. This protein is involved in collagen maturation.			Amino Acid, Peptide, or Protein|Enzyme	
C101552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101552>	C25804|C25790	MX2 Gene|MX2|MX2|Myxovirus (Influenza Virus) Resistance 2 (Mouse) Gene	This gene plays a role in GTP hydrolysis.			Gene or Genome	
C101553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101553>	C101552	MX2 wt Allele|MXB|Myxovirus (Influenza Virus) Resistance 2 (Mouse) wt Allele	Human MX2 wild-type allele is located in the vicinity of 21q22.3 and is approximately 46 kb in length. This allele, which encodes interferon-induced GTP-binding protein Mx2, is involved in both binding and hydrolysis of GTP.			Gene or Genome	
C101554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101554>	C16725|C16701	Interferon-Induced GTP-Binding Protein Mx2|Interferon-Regulated Resistance GTP-Binding Protein MxB|MX2|Myxovirus Resistance Protein 2|Second Interferon-Induced Protein p78|p78-Related Protein	Interferon-induced GTP-binding protein Mx2 (715 aa, ~82 kDa) is encoded by the human MX2 gene. This protein plays a role in both GTP binding and hydrolysis.			Amino Acid, Peptide, or Protein|Enzyme	
C101555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101555>	C25952	LGALS13 Gene|LGALS13|LGALS13|Lectin, Galactoside-Binding, Soluble, 13 Gene	This gene is involved in lipid metabolism.			Gene or Genome	
C101556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101556>	C101555	LGALS13 wt Allele|GAL13|Galectin 13 Gene|Lectin, Galactoside-Binding, Soluble, 13 wt Allele|PLAC8|PP13	Human LGALS13 wild-type allele is located in the vicinity of 19q13.1 and is approximately 5 kb in length. This allele, which encodes galactoside-binding soluble lectin 13 protein, plays a role in phospholipid metabolism.			Gene or Genome	
C101557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101557>	C16980	Galactoside-Binding Soluble Lectin 13|Beta-Galactoside-Binding Lectin|EC 3.1.1.5|Gal-13|Galectin-13|LGALS13|PP13|Placental Protein 13|Placental Tissue Protein 13	Galactoside-binding soluble lectin 13 (139 aa, ~16 kDa) is encoded by the human LGALS13 gene. This protein is involved in lysophospholipase activity.			Amino Acid, Peptide, or Protein|Enzyme	
C101558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101558>	C20181	Tumor Bed|Tumor bed (morphologic abnormality)	The tissue that envelopes a tumor site, following the surgical removal of the tumor.			Qualitative Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C101559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101559>	C25873	SGK1 Gene|SGK1|SGK1|SGK1|Serum/Glucocorticoid Regulated Kinase 1 Gene	This gene plays a role in both protein phosphorylation and cellular stress response.			Gene or Genome	GDC Terminology|GDC Value Terminology
C10155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10155>	C61063	Cyclophosphamide/Dactinomycin/Doxorubicin/Hydroxyurea/Methotrexate/Vincristine|CHAMOCA|CTX/DACT/DOX/HU/MTX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101560>	C101559	SGK1 wt Allele|RP1-188K17.1|SGK|Serum/Glucocorticoid Regulated Kinase 1 wt Allele|Serum/Glucocorticoid Regulated Kinase Gene	Human SGK1 wild-type allele is located in the vicinity of 6q23 and is approximately 149 kb in length. This allele, which encodes serine/threonine-protein kinase Sgk1 protein, is involved in the modulation of both protein phosphorylation and signaling. Aberrant expression of the gene may be associated with hypertension and diabetic nephropathy.			Gene or Genome	
C101561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101561>	C17325	Serine/Threonine-Protein Kinase Sgk1|EC 2.7.11.1|Serine/Threonine-Protein Kinase Sgk|Serum/Glucocorticoid-Regulated Kinase 1	Serine/threonine-protein kinase Sgk1 (431 aa, ~49 kDa) is encoded by the human SGK1 gene. This protein plays a role in both signaling in response to cellular stress and serine/threonine phosphorylation.			Amino Acid, Peptide, or Protein|Enzyme	
C101562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101562>	C25804	SIRT2 Gene|SIRT2|SIRT2|Sirtuin 2 Gene	This gene plays a role in protein acetylation.	SIRT2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101563>	C101562	SIRT2 wt Allele|FLJ35621|FLJ37491|SIR2|SIR2L|SIR2L2|Sirtuin (Silent Mating Type Information Regulation 2 Homolog) 2 (S. cerevisiae) Gene|Sirtuin 2 wt Allele|Sirtuin Type 2 Gene	Human SIRT2 wild-type allele is located in the vicinity of 19q13 and is approximately 21 kb in length. This allele, which encodes NAD-dependent deacetylase sirtuin-2 protein, is involved in the regulation of protein acetylation.	SIRT2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101564>	C26503	NAD-Dependent Deacetylase Sirtuin-2|EC 3.5.1.-|SIR2-Like Protein 2|SIRT2|Silent Information Regulator 2|Sir2-Related Protein Type 2	NAD-dependent deacetylase sirtuin-2 (389 aa, ~43 kDa) is encoded by the human SIRT2 gene. This protein plays a role in the deacetylation of tubulin.	NAD-Dependent Deacetylase Sirtuin-2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101565>	C26057	DDX3X Gene|DDX3X|DDX3X|DDX3X|DEAD-Box Helicase 3 X-Linked Gene	This gene is involved in RNA binding.	DDX3X Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|Pediatric Oncology Target Genes/Proteins Terminology
C101566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101566>	C101565	DDX3X wt Allele|CAP-Rf|DBX|DDX14|DDX3|DEAD (Asp-Glu-Ala-Asp) Box Helicase 3, X-Linked Gene|DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 3, X-Linked Gene|DEAD-Box Helicase 3 X-Linked wt Allele|DEAD-Box Helicase 3, X-Linked Gene|DEAD/H (Asp-Glu-Ala-Asp/His) Box Polypeptide 3 Gene|DEAD/H Box-3, X-Linked Gene|HLP2|MRX102|MRXSSB	Human DDX3X wild-type allele is located within Xp11.3-p11.23 and is approximately 31 kb in length. This allele, which encodes ATP-dependent RNA helicase DDX3X protein, plays a role in the modulation of RNA structure.	DDX3X wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101567>	C17417	ATP-Dependent RNA Helicase DDX3X|CAP-Rf|DBX|DDX3X|DEAD Box Protein 3, X-Chromosomal|DEAD Box, X Isoform|EC 3.6.4.13|HLP2|Helicase-Like Protein 2	ATP-dependent RNA helicase DDX3X (662 aa, ~73 kDa) is encoded by the human DDX3X gene. This protein is involved in the regulation of RNA structure, localization and metabolism.	ATP-Dependent RNA Helicase DDX3X		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Genes/Proteins Terminology
C101568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101568>	C25943	UBA2 Gene|UBA2|UBA2|Ubiquitin-Like Modifier Activating Enzyme 2 Gene	This gene plays a role in protein modification.			Gene or Genome	
C101569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101569>	C101568	UBA2 wt Allele|ARX|FLJ13058|HRIHFB2115|SAE2|UBLE1B|Ubiquitin-Like Modifier Activating Enzyme 2 wt Allele	Human UBA2 wild-type allele is located in the vicinity of 19q12 and is approximately 42 kb in length. This allele, which encodes SUMO-activating enzyme subunit 2 protein, is involved in the regulation of sumoylation.			Gene or Genome	
C10156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10156>	C61063	Cyclophosphamide/Cytarabine/Doxorubicin/Etoposide/Methotrexate/Prednisone/Vincristine|AMOPLACE|ARA-C/CTX/DOX/MTX/PRED/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101570>	C16796	SUMO-Activating Enzyme Subunit 2|Anthracycline-Associated Resistance ARX|EC 6.3.2.-|SAE2|SUMO-1 Activating Enzyme Subunit 2|SUMO-ACTIVATING ENZYME SUBUNIT 2|UBA2|UBA2|Ubiquitin-Like Activating Enzyme E1B|Ubiquitin-Like-Activating Enzyme E1B|Ubiquitin-like 1-activating enzyme E1B	SUMO-activating enzyme subunit 2 (640 aa, ~71 kDa) is encoded by the human UBA2 gene. This protein plays a role in post-translational protein modification.			Amino Acid, Peptide, or Protein|Enzyme	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C101571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101571>	C25943	SAE1 Gene|SAE1|SAE1|SUMO1 Activating Enzyme Subunit 1 Gene	This gene is involved in post-translational protein modification.			Gene or Genome	
C101572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101572>	C101571	SAE1 wt Allele|AOS1|Activator of SUMO1 Gene|FLJ3091|HSPC140|SUA1|SUMO1 Activating Enzyme Subunit 1 wt Allele|UBLE1A	Human SAE1 wild-type allele is located in the vicinity of 19q13.32 and is approximately 80 kb in length. This allele, which encodes SUMO-activating enzyme subunit 1 protein, plays a role in the promotion of sumoylation.			Gene or Genome	
C101573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101573>	C16796	SUMO-Activating Enzyme Subunit 1|SAE1|SAE1|SUA1|SUMO-1 Activating Enzyme E1 N Subunit|SUMO-1 Activating Enzyme Subunit 1|SUMO-ACTIVATING ENZYME SUBUNIT 1|Sentrin/SUMO-Activating Protein AOS1|Ubiquitin-Like -Activating Enzyme E1A|Ubiquitin-like 1-activating enzyme E1A	SUMO-activating enzyme subunit 1 (346 aa, ~38 kDa) is encoded by the human SAE1 gene. This protein is involved in the regulation of sumoylation.			Amino Acid, Peptide, or Protein|Enzyme	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C101574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101574>	C28404	USP9X Gene|USP9X|USP9X|Ubiquitin Specific Peptidase 9 X-Linked Gene	This gene plays a role in deubiquitination.	USP9X Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101575>	C101574	USP9X wt Allele|DFFRX|Drosophila Fat Facets Related, X-Linked Gene|FAF|FAM|Fat Facets Protein Related, X-Linked Gene|MRX99|MRXS99F|Ubiquitin Specific Peptidase 9 X-Linked wt Allele|Ubiquitin Specific Peptidase 9, X-Linked (Fat Facets-Like, Drosophila) Gene|Ubiquitin Specific Protease 9, X Chromosome (Fat Facets-Like Drosophila) Gene|Ubiquitin Specific Protease 9, X-Linked (Fat Facets-Like, Drosophila) Gene|XLID99|hFAM	Human USP9X wild-type allele is located in the vicinity of Xp11.4 and is approximately 151 kb in length. This allele, which encodes probable ubiquitin carboxyl-terminal hydrolase FAF-X protein, is involved in the modulation of protein ubiquitination.	USP9X wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101576>	C16481	Probable Ubiquitin Carboxyl-Terminal Hydrolase FAF-X|Deubiquitinating Enzyme FAF-X|EC 3.4.19.12|Fat Facets In Mammals|Fat Facets Protein Related, X-Linked|Fat Facets Protein-Related, X-Linked|USP9X|Ubiquitin Thioesterase FAF-X|Ubiquitin Thiolesterase FAF-X|Ubiquitin-Specific Processing Protease FAF-X|Ubiquitin-Specific Protease 9, X Chromosome|Ubiquitin-Specific-Processing Protease FAF-X|hFAM	Probable ubiquitin carboxyl-terminal hydrolase FAF-X (2570 aa, ~292 kDa) is encoded by the human USP9X gene. This protein plays a role in the modulation of post-translational protein modification.	Probable Ubiquitin Carboxyl-Terminal Hydrolase FAF-X		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101577>	C25775	CCR2 Gene|CCR2|CCR2|Chemokine (C-C Motif) Receptor 2 Gene	This gene plays a role in chemokine signaling.	CCR2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101578>	C101577	CCR2 wt Allele|CC-CKR-2|CCR-2|CCR2A|CCR2B|CD192|CKR2|CKR2A|CKR2B|CMKBR2|Chemokine (C-C Motif) Receptor 2 wt Allele|FLJ78302|MCP-1-R|MGC103828|MGC111760|MGC168006|hCG_14621	Human CCR2 wild-type allele is located in the vicinity of 3p21.31 and is approximately 7 kb in length. This allele, which encodes C-C chemokine receptor type 2 protein, is involved in both chemokine binding and signaling.	CCR2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101579>	C18018	C-C Chemokine Receptor Type 2|Antigen CD192|C-C CKR-2|CC-CKR-2|CCR-2|CCR2|CD192|CD192 Antigen|MCP-1 Receptor|MCP-1-R|Monocyte Chemoattractant Protein 1 Receptor|Monocyte Chemotactic Protein 1 Receptor	C-C chemokine receptor type 2 (374 aa, ~42 kDa) is encoded by the human CCR2 gene. This protein plays a role in both cytokine binding and receptor signaling.	C-C Chemokine Receptor Type 2		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10157>	C61063	Altretamine/Carboplatin/Cyclophosphamide/Doxorubicin|CBDCA/CTX/DOX/HMM|CHAC-1			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101580>	C20420	FOXM1 Gene|FOXM1|FOXM1|Forkhead Box M1 Gene	This gene is involved in both transcriptional regulation and cell division.	FOXM1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101581>	C101580	FOXM1 wt Allele|FKHL16|FOXM1B|Forkhead Box M1 wt Allele|HFH-11|HFH11|HNF-3|INS-1|MPHOSPH2|MPP-2|MPP2|PIG29|TGT3|TRIDENT|Trident Gene|WIN	Human FOXM1 wild-type allele is located in the vicinity of 12p13 and is approximately 19 kb in length. This allele, which encodes forkhead box protein M1, plays a role in the modulation of the expression of genes involved in DNA replication. Aberrant expression of the gene is associated with a large number of neoplastic diseases.	FOXM1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101582>	C17207	Forkhead Box Protein M1|FOXM1|Forkhead Box M1B Transcription Factor|Forkhead, Drosophila, Homolog-Like 16|Forkhead-Related Protein FKHL16|HFH-11|HNF-3/Fork-Head Homolog 11|Hepatocyte Nuclear Factor 3 Forkhead Homolog 11|M-Phase Phosphoprotein 2|MPM-2 Reactive Phosphoprotein 2|Transcription Factor Trident|Trident|Winged-Helix Factor From INS-1 Cells	Forkhead box protein M1 (763 aa, ~84 kDa) is encoded by the human FOXM1 gene. This protein is involved in the regulation of both mitosis and transcription.	Forkhead Box Protein M1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101583>	C25804|C19676	TDG Gene|TDG|TDG|Thymine-DNA Glycosylase Gene	This gene is involved in catalyzing DNA repair.	TDG Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101584>	C101583	TDG wt Allele|CD3G|Thymine-DNA Glycosylase wt Allele|hTDG	Human TDG wild-type allele is located in the vicinity of 12q24.1 and is approximately 23 kb in length. This allele, which encodes G/T mismatch-specific thymine DNA glycosylase protein, plays a role in DNA repair.	TDG wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101585>	C21170|C16701	G/T Mismatch-Specific Thymine DNA Glycosylase|CD3G|EC 3.2.2.29|TDG|Thymine-DNA Glycosylase|hTDG	G/T mismatch-specific thymine DNA glycosylase (410 aa, ~46 kDa) is encoded by the human TDG gene. This protein is involved in DNA repair.	G/T Mismatch-Specific Thymine DNA Glycosylase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101586>	C25869|C20921	STING1 Gene|STING|STING1|STING1|Stimulator of Interferon Response cGAMP Interactor 1 Gene|TMEM173	This gene plays a role in the immune response.	STING1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|Pediatric Oncology Immunotherapeutic Target Terminology
C101587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101587>	C101586	STING1 wt Allele|ERIS|FLJ38577|MITA|MPYS|NET23|SAVI|STING|Stimulator of Interferon Response cGAMP Interactor 1 wt Allele|TMEM173|Transmembrane Protein 173 Gene|hMITA|hSTING	Human STING1 wild-type allele is located in the vicinity of 5q31.2 and is approximately 7 kb in length. This allele, which encodes stimulator of interferon genes protein, is involved in both signaling and immunity. Mutation of the gene is associated with infantile-onset STING-associated vasculopathy.	STING1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101588>	C18515	Stimulator of Interferon Genes Protein|ERIS|Endoplasmic Reticulum IFN Stimulator|Endoplasmic Reticulum Interferon Stimulator|Mediator of IRF3 Activation|Mitochondrial Mediator of IRF3 Activation|N-Terminal Methionine-Proline-Tyrosine-Serine Plasma Membrane Tetraspanner|STING|STING1|Stimulator of Interferon Genes|Stimulator of Interferon Protein|TMEM173|Transmembrane Protein 173|hMITA|hSTING	Stimulator of interferon genes protein (379 aa, ~42 kDa) is encoded by the human STING1 gene. This protein plays a role in the modulation of both innate immune responses and signal transduction.	Stimulator of Interferon Genes Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology|Pediatric Oncology Immunotherapeutic Target Terminology
C101589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101589>	C41328	Myocardial Infarction by ECG Finding|MYOCARDIAL INFARCTION|Myocardial Infarction|Myocardial Infarction by EKG Finding	An electrocardiographic finding of pathologic Q waves, which is suggestive of myocardial infarction of one or more regions of the heart. No specification is provided for localization. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10158>	C61063	Cisplatin/Fluorouracil/Vinblastine|CDDP/5-FU/VBL|FVP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101590>	C105822	HOXB9 Gene|HOXB9|HOXB9|Homeobox B9 Gene	This gene is involved in both embryonic development and transcriptional regulation.			Gene or Genome	
C101591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101591>	C101590	HOXB9 wt Allele|HOX-2.5|HOX2|HOX2E|Homeo Box B9 Gene|Homeobox B9 wt Allele	Human HOXB9 wild-type allele is located in the vicinity of 17q21.3 and is approximately 5 kb in length. This allele, which encodes homeobox protein Hox-B9, plays a role in pattern formation.			Gene or Genome	
C101592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101592>	C17207	Homeobox Protein Hox-B9|Homeobox Protein Hox-2.5|Homeobox Protein Hox-2E	Homeobox protein Hox-B9 (250 aa, ~28 kDa) is encoded by the human HOXB9 gene. This protein is involved in transcriptional regulation during embryonic development.			Amino Acid, Peptide, or Protein	
C101593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101593>	C20921	DEPTOR Gene|DEP Domain Containing MTOR-Interacting Protein Gene|DEPTOR|DEPTOR	This gene plays a role in mTOR-mediated signaling.			Gene or Genome	
C101594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101594>	C101593	DEPTOR wt Allele|DEP Domain Containing 6 Gene|DEP Domain Containing MTOR-Interacting Protein wt Allele|DEP.6|DEPDC6|DKFZp564B1778|FLJ12341|FLJ12428|FLJ13854	Human DEPTOR wild-type allele is located in the vicinity of 8q24.12 and is approximately 177 kb in length. This allele, which encodes DEP domain-containing mTOR-interacting protein, is involved in the modulation of the mTOR signaling pathway.			Gene or Genome	
C101595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101595>	C18515	DEP Domain-Containing mTOR-Interacting Protein|DEP Domain-Containing Protein 6|DEPTOR	DEP domain-containing mTOR-interacting protein (409 aa, ~46 kDa) is encoded by the human DEPTOR gene. This protein plays a role in the regulation of mTOR signaling.			Amino Acid, Peptide, or Protein	
C101596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101596>	C101589	Acute Myocardial Infarction by ECG Finding|ACUTE MYOCARDIAL INFARCTION|Acute Myocardial Infarction|Acute Myocardial Infarction by EKG Finding	An electrocardiographic finding showing a current injury of the myocardium.			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C101597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101597>	C101589	Old Myocardial Infarction by ECG Finding|OLD OR AGE INDETERMINATE WALL MYOCARDIAL INFARCTION|Old Myocardial Infarction by EKG Finding|Old Or Age Indeterminate Wall Myocardial Infarction	An electrocardiographic finding of pathologic Q waves, which is suggestive of myocardial infarction of one or more regions of the heart, without evidence of current or ongoing acute infarction. No specification is provided for localization. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C101598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101598>	C101589	Silent Myocardial Infarction by ECG Finding|Silent Myocardial Infarction by EKG Finding	An electrocardiographic finding that a myocardial infarction has occurred concurrently with the absence of clinical symptoms.			Finding	
C101599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101599>	C38534	ATF5 Gene|ATF5|ATF5|Activating Transcription Factor 5 Gene	This gene is involved in the regulation of gene expression.	ATF5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10159>	C63510	VACAD Regimen|Actinomycin-D/Cyclophosphamide/Dacarbazine/Doxorubicin/Vincristine|CTX/DACT/DOX/DTIC/VCR|VACAD|VACAD|Vincristine-Actinomycin-D-Cyclophosphamide-Doxorubicin-Dacarbazine|Vincristine/Actinomycin-D/Cyclophosphamide/Adriamycin/Dacarbazine|Vincristine/Actinomycin-D/Cyclophosphamide/Doxorubicin/Dacarbazine	A regimen consisting of vincristine, actinomycin, cyclophosphamide, doxorubicin, and dacarbazine that may be used in the treatment of metastatic or unresectable pediatric soft tissue sarcomas.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C1015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1015>	C2139	Ubenimex|Bestatin|Bestatin|Bestatin|L-Leucine, N-(3-amino-2-hydroxy-1-oxo-4-phenylbutyl)-, [S-(R*,S*)]-|N-[(2S,3R)-4-phenyl-3-amino-2-hydroxybutyryl]-L-leucine|NK 421|UBENIMEX|[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]-L-leucine|[S-(R*,S*)]-N-(3-amino-2-hydroxy-1-oxo-4-phenylbutyl)-L-leucine	A microbial metabolite and dipeptide with potential immunomodulatory and antitumor activities. Ubenimex competitively inhibits many aminopeptidases, including B, N and leucine aminopeptidases. Aminopeptidases has been implicated in the process of cell adhesion and invasion of tumor cells. Therefore, inhibiting aminopeptidases may partially attribute to the antitumor effect of ubenimex. This agent also activates T lymphocyte, macrophage and bone marrow stem cell as well as stimulates release of interleukin-1 and -2, thus further enhances its antitumor activity.			Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101600>	C101599	ATF5 wt Allele|ATFX|Activating Transcription Factor 5 wt Allele|FLJ34666|HMFN0395	Human ATF5 wild-type allele is located in the vicinity of 19q13.3 and is approximately 5 kb in length. This allele, which encodes cyclic AMP-dependent transcription factor ATF-5 protein, plays a role in the modulation of transcription.	ATF5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101601>	C17286	Cyclic AMP-Dependent Transcription Factor ATF-5|ATF5|Activating Transcription Factor 5|Transcription Factor ATFx|cAMP-Dependent Transcription Factor ATF-5	Cyclic AMP-dependent transcription factor ATF-5 (282 aa, ~30 kDa) is encoded by the human ATF5 gene. This protein is involved in the positive regulation of gene transcription.	Cyclic AMP-Dependent Transcription Factor ATF-5		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101602>	C29938	RNH1 Gene|RNH1|RNH1|Ribonuclease/Angiogenin Inhibitor 1 Gene	This gene plays a role in enzyme inhibition.			Gene or Genome	
C101603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101603>	C101602	RNH1 wt Allele|MGC18200|MGC4569|MGC54054|PRI|RAI|RNH|Ribonuclease/Angiogenin Inhibitor 1 wt Allele	Human RNH1 wild-type allele is located in the vicinity of 11p15.5 and is approximately 13 kb in length. This allele, which encodes ribonuclease inhibitor protein, is involved in the negative regulation of ribonuclease activity.			Gene or Genome	
C101604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101604>	C18072	Ribonuclease Inhibitor|PRI|Placental RNase Inhibitor|Placental Ribonuclease Inhibitor|RAI|Ribonuclease/Angiogenin Inhibitor 1	Ribonuclease inhibitor (461 aa, ~50 kDa) is encoded by the human RNH1 gene. This protein plays a role in the inhibition of ribonucleases.			Amino Acid, Peptide, or Protein	
C101605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101605>	C20745	FSCN1 Gene|FSCN1|FSCN1|Fascin Homolog 1, Actin-Bundling Protein (Strongylocentrotus purpuratus) Gene	This gene is involved in actin filament assembly.	FSCN1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101606>	C101605	FSCN1 wt Allele|FAN1|FLJ38511|FLJ43305|Fascin Homolog 1, Actin-Bundling Protein (Strongylocentrotus purpuratus) wt Allele|HSN|SNL|Singed (Drosophila)-Like (Sea Urchin Fascin Homolog Like) Gene|Singed, Drosophila, Homolog-Like Gene|p55	Human FSCN1 wild-type allele is located in the vicinity of 7p22 and is approximately 14 kb in length. This allele, which encodes fascin protein, plays a role in both actin binding and microfilament remodeling. Aberrant expression of the gene is associated with various types of carcinoma.	FSCN1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101607>	C16492	Fascin|55 kDa Actin-Bundling Protein|FSCN1|Singed-Like Protein|p55	Fascin (493 aa, ~55 kDa) is encoded by the human FSCN1 gene. This protein is involved in the formation of actin filaments.	Fascin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101608>	C20194	DTL Gene|DTL|DTL|Denticleless E3 Ubiquitin Protein Ligase Homolog (Drosophila) Gene	This gene plays a role in protein ubiquitination.			Gene or Genome	
C101609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101609>	C101608	DTL wt Allele|CDT2|CDW1|DCAF2|Denticleless E3 Ubiquitin Protein Ligase Homolog (Drosophila) wt Allele|L2DTL|RAMP	Human DTL wild-type allele is located in the vicinity of 1q32 and is approximately 72 kb in length. This allele, which encodes denticleless protein homolog, is involved in the modulation of ubiquitination.			Gene or Genome	
C10160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10160>	C61063	Doxorubicin/Fluorouracil/Vinblastine|DOX/5-FU/VBL|FUVA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101610>	C95242	Denticleless Protein Homolog|DDB1- and CUL4-Associated Factor 2|Lethal(2) Denticleless Protein Homolog|Retinoic Acid-Regulated Nuclear Matrix-Associated Protein	Denticleless protein homolog (730 aa, ~79 kDa) is encoded by the human DTL gene. This protein plays a role in the regulation of E3 ubiquitin ligase activity.			Amino Acid, Peptide, or Protein	
C101611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101611>	C20194	SHARPIN Gene|SHANK-Associated RH Domain Interactor Gene|SHARPIN|SHARPIN	This gene is involved in polyubiquitination.			Gene or Genome	
C101612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101612>	C101611	SHARPIN wt Allele|DKFZp434N1923|PSEC0216|SHANK-Associated RH Domain Interactor wt Allele|SIPL1	Human SHARPIN wild-type allele is located in the vicinity of 8q24.3 and is approximately 9 kb in length. This allele, which encodes sharpin protein, plays a role in ubiquitin polymerization.			Gene or Genome	
C101613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101613>	C95242	Sharpin|Shank-Associated RH Domain-Interacting Protein|Shank-Interacting Protein-Like 1|hSIPL1	Sharpin (387 aa, ~40 kDa) is encoded by the human SHARPIN gene. This protein is involved in the formation of linear polyubiquitin chains.			Amino Acid, Peptide, or Protein	
C101614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101614>	C20921	AKT1S1 Gene|AKT1 Substrate 1 Gene|AKT1S1|AKT1S1	This gene plays a role in the regulation of mTOR signaling.	AKT1S1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101615>	C101614	AKT1S1 wt Allele|AKT1 Substrate 1 (Proline-Rich) Gene|AKT1 Substrate 1 wt Allele|AKT1 Substrate 1, Proline-Rich Gene|Lobe|MGC2865|PRAS40|Proline-Rich Akt Substrate, 40-kD Gene	Human AKT1S1 wild-type allele is located in the vicinity of 19q13.33 and is approximately 9 kb in length. This allele, which encodes proline-rich AKT1 substrate 1 protein, is involved in the mTOR signaling pathway.	AKT1S1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101616>	C18515	Proline-Rich AKT1 Substrate 1|40 kDa Proline-Rich AKT Substrate|AKT1S1|PRAS40	Proline-rich AKT1 substrate 1 (256 aa, ~27 kDa) is encoded by the human AKT1S1 gene. This protein plays a role in mTOR-dependent signaling.	Proline-Rich AKT1 Substrate 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101617>	C20194	ZMYM3 Gene|ZMYM3|ZMYM3|ZMYM3|Zinc Finger, MYM-Type 3 Gene	This gene is involved in chromatin modification.	ZMYM3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C101618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101618>	C101617	ZMYM3 wt Allele|DXS6673E|KIAA0385|MYM|XFIM|ZNF198L2|ZNF261|Zinc Finger, MYM-Type 3 wt Allele	Human ZMYM3 wild-type allele is located in the vicinity of Xq13.1 and is approximately 16 kb in length. This allele, which encodes zinc finger MYM-type protein 3, plays a role in the regulation of chromatin remodeling, cell morphology and cytoskeletal organization. A chromosomal translocation (X;13) involving this gene is associated with X-linked mental retardation.	ZMYM3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101619>	C18466	Zinc Finger MYM-Type Protein 3|Zinc Finger Protein 261	Zinc finger MYM-type protein 3 (1370 aa, ~152 kDa) is encoded by the human ZMYM3 gene. This protein is involved in histone acetylation.	Zinc Finger MYM-Type Protein 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10161>	C61063	Cyclophosphamide/Cytarabine/Prednisolone/Vincristine|ARA-C/CTX/PRDL/VCR|COAP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101620>	C20194	PRRT2 Gene|PRRT2|PRRT2|Proline-Rich Transmembrane Protein 2 Gene	This gene may play a role in brain and spine development.			Gene or Genome	
C101621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101621>	C101620	PRRT2 wt Allele|DKFZp547J199|DYT10|EKD1|FLJ25513|IFITMD1|Interferon Induced Transmembrane Protein Domain Containing 1 Gene|PKC|Proline-Rich Transmembrane Protein 2 wt Allele	Human PRRT2 wild-type allele is located in the vicinity of 16p11.2 and is approximately 4 kb in length. This allele, which encodes proline-rich transmembrane protein 2, may be involved in the development of the brain and spinal cord. Mutation of the gene is associated with both episodic kinesigenic dyskinesia-1 and infantile convulsion and choreoathetosis syndrome.			Gene or Genome	
C101622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101622>	C18466	Proline-Rich Transmembrane Protein 2|DSPB3|Dispanin Subfamily B Member 3|Interferon Induced Transmembrane Protein Domain Containing 1	Proline-rich transmembrane protein 2 (340 aa, ~35 kDa) is encoded by the human PRRT2 gene. This protein may play a role in central nervous system development.			Amino Acid, Peptide, or Protein	
C101623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101623>	C25790	MS4A2 Gene|MS4A2|MS4A2|Membrane-Spanning 4-Domains, Subfamily A, Member 2 Gene	This gene is involved in immunoglobulin binding.			Gene or Genome	
C101624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101624>	C101623	MS4A2 wt Allele|APY|ATOPY|FCER1B|FCERI|IGEL|IGER|IGHER|IgE Responsiveness (Atopic) Gene|MS4A1|Membrane-Spanning 4-Domains, Subfamily A, Member 2 wt Allele	Human MS4A2 wild-type allele is located within 11q12-q13 and is approximately 10 kb in length. This allele, which encodes high affinity immunoglobulin epsilon receptor subunit beta protein, plays a role in both immunoglobulin binding and mast cell responses.			Gene or Genome	
C101625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101625>	C21160|C18106	High Affinity Immunoglobulin Epsilon Receptor Subunit Beta|Fc Epsilon Receptor I Beta-Chain|FcERI|IgE Fc Receptor Subunit Beta|MS4A2|Membrane-Spanning 4-Domains Subfamily A Member 2	High affinity immunoglobulin epsilon receptor subunit beta (244 aa, ~27 kDa) is encoded by the human MS4A2 gene. This protein is involved in the response to allergens.			Amino Acid, Peptide, or Protein|Receptor	
C101626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101626>	C28533	PITPNC1 Gene|PITPNC1|PITPNC1|Phosphatidylinositol Transfer Protein, Cytoplasmic 1 Gene	This gene plays a role in both signaling and lipid transport.			Gene or Genome	
C101627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101627>	C101626	PITPNC1 wt Allele|Phosphatidylinositol Transfer Protein, Cytoplasmic 1 wt Allele|RDGB-BETA|RDGBB|RDGBB1	Human PITPNC1 wild-type allele is located in the vicinity of 17q24.2 and is approximately 316 kb in length. This allele, which encodes cytoplasmic phosphatidylinositol transfer protein 1, is involved in phospholipid transport.			Gene or Genome	
C101628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101628>	C16386	Cytoplasmic Phosphatidylinositol Transfer Protein 1|M-rdgB beta|Mammalian rdgB Homolog Beta|MrdgBbeta|PITPNC1|RdgBbeta|Retinal Degeneration B Beta 1|Retinal Degeneration B Homolog Beta	Cytoplasmic phosphatidylinositol transfer protein 1 (332 aa, ~38 kDa) is encoded by the human PITPNC1 gene. This protein plays a role in the modulation of both phospholipid-mediated signaling and lipid transport.			Amino Acid, Peptide, or Protein	
C101629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101629>	C20917	GAS6 Gene|GAS6|GAS6|Growth Arrest-Specific 6 Gene	This gene is involved in both receptor binding and signal transduction.	GAS6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10162>	C61063	Cisplatin/Dexamethasone/Etoposide|CDDP/DM/VP-16|CED			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101630>	C101629	GAS6 wt Allele|AXL Stimulatory Factor Gene|AXLLG|AXSF|DKFZp666G247|FLJ34709|Growth Arrest-Specific 6 wt Allele	Human GAS6 wild-type allele is located in the vicinity of 13q34 and is approximately 44 kb in length. This allele, which encodes growth arrest-specific protein 6, plays a role in both ligand-mediated signaling and receptor tyrosine kinase binding.	GAS6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101631>	C17761	Growth Arrest-Specific Protein 6|AXL Receptor Tyrosine Kinase Ligand|AXL Stimulatory Factor|GAS-6|GAS6	Growth arrest-specific protein 6 (721 aa, ~80 kDa) is encoded by the human GAS6 gene. This protein is involved in the modulation of receptor tyrosine kinase-dependent signaling.	Growth Arrest-Specific Protein 6		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101632>	C19676	SWI5 Gene|SWI5|SWI5|SWI5 Homologous Recombination Repair Protein Gene	This gene is involved in double-strand break repair by homologous recombination.			Gene or Genome	
C101633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101633>	C101632	SWI5 wt Allele|C9orf119|Chromosome 9 Open Reading Frame 119 Gene|RP11-395P17.9|SAE3|SAE3, S. cerevisiae, Homolog of Gene|SWI5 Homologous Recombination Repair Protein wt Allele|SWI5 Recombination Repair Homolog (Yeast) Gene|SWI5, S. pombe, Homolog of Gene|bA395P17.9	Human SWI5 wild-type allele is located in the vicinity of 9q34.11 and is approximately 14 kb in length. This allele, which encodes DNA repair protein SWI5 homolog protein, plays a role in the modulation of DNA repair.			Gene or Genome	
C101634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101634>	C21170	DNA Repair Protein SWI5 Homolog|HBV DNAPTP1-Transactivated Protein A|Protein SAE3 Homolog|SWI5|SWI5 Homologous Recombination Repair Protein	DNA repair protein SWI5 homolog (235 aa, ~27 kDa) is encoded by the human SWI5 gene. This protein is involved in DNA repair through homologous recombination.			Amino Acid, Peptide, or Protein|Enzyme	
C101635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101635>	C20921	NUMB Gene|NUMB|NUMB|Numb Homolog (Drosophila) Gene	This gene plays a role in neurogenesis.			Gene or Genome	
C101636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101636>	C101635	NUMB wt Allele|C14orf41|Chromosome 14 Open Reading Frame 41 Gene|FLJ31314|Numb Homolog (Drosophila) wt Allele|S171|c14_5527	Human NUMB wild-type allele is located in the vicinity of 14q24.3 and is approximately 183 kb in length. This allele, which encodes protein numb homolog, is involved in neuronal development.			Gene or Genome	
C101637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101637>	C18515	Protein Numb Homolog|Protein S171|h-Numb	Protein numb homolog (651 aa, ~71 kDa) is encoded by the human NUMB gene. This protein plays a role in the development of neurons.			Amino Acid, Peptide, or Protein	
C101638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101638>	C20420	TBX3 Gene|T-Box 3 Gene|TBX3|TBX3|TBX3	This gene is involved in both transcriptional repression and limb development.	TBX3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C101639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101639>	C101638	TBX3 wt Allele|T-Box 3 wt Allele|TBX3-ISO|UMS|Ulnar Mammary Syndrome Gene|XHL	Human TBX3 wild-type allele is located in the vicinity of 12q24.1 and is approximately 14 kb in length. This allele, which encodes T-box transcription factor TBX3 protein, plays a role in both transcriptional regulation and anterior/posterior axis development. Mutation of the gene is associated with ulnar-mammary syndrome.	TBX3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10163>	C61007	Cyclophosphamide/Prednisone|CP|CTX/PRED			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101640>	C17207	T-Box Transcription Factor TBX3|T-Box Protein 3	T-box transcription factor TBX3 (743 aa, ~79 kDa) is encoded by the human TBX3 gene. This protein is involved in both the negative regulation of transcription and embryogenesis.	T-Box Transcription Factor TBX3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101641>	C97927|C159204	PALB2 Gene Mutation|FANCN Gene Mutation|Fanconi Anemia, Complementation Group N Gene Mutation|PNCA3 Gene Mutation|Partner and Localizer of BRCA2 Gene Mutation	A molecular genetic abnormality that refers to a change in the nucleotide sequence of the PALB2 gene.	PALB2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C101642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101642>	C15675	Adjuvant Radiotherapy	Radiation therapy that is administered to augment or stimulate other treatment modalities or to minimize or prevent disease recurrence.			Therapeutic or Preventive Procedure	
C101643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101643>	C20194	SERPINF1 Gene|SERPINF1|SERPINF1|Serpin Peptidase Inhibitor, Clade F (Alpha-2 Antiplasmin, Pigment Epithelium Derived Factor), Member 1 Gene	This gene is involved in the regulation of cell proliferation.	SERPINF1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101644>	C101643	SERPINF1 wt Allele|EPC-1|OI12|OI6|PEDF|PIG35|Pigment Epithelium-Derived Factor Gene|Proliferation-Inducing Protein 35 Gene|Serpin Peptidase Inhibitor, Clade F (Alpha-2 Antiplasmin, Pigment Epithelium Derived Factor), Member 1 wt Allele	Human SERPINF1 wild-type allele is located in the vicinity of 17p13.3 and is approximately 16 kb in length. This allele, which encodes pigment epithelium-derived factor protein, plays a role in both angiogenesis and cell proliferation. Mutation of the gene is associated with osteogenesis imperfecta type 12.	SERPINF1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101645>	C18582	Pigment Epithelium-Derived Factor|Cell Proliferation-Inducing Gene 35 Protein|EPC-1|PEDF|Proliferation-Inducing Protein 35|SERPINF1|Serpin F1	Pigment epithelium-derived factor (418 aa, ~46 kDa) is encoded by the human SERPINF1 gene. This protein is involved in the regulation of both cell proliferation and angiogenesis.	Pigment Epithelium-Derived Factor		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101646>	C20420	FOXA1 Gene|FOXA1|FOXA1|FOXA1|Forkhead Box A1 Gene	This gene plays a role in the modulation of gene expression.			Gene or Genome	GDC Terminology|GDC Value Terminology
C101647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101647>	C101646	FOXA1 wt Allele|Forkhead Box A1 wt Allele|HNF3A|Hepatocyte Nuclear Factor 3, Alpha Gene|MGC33105|TCF3A	Human FOXA1 wild-type allele is located within 14q12-q13 and is approximately 10 kb in length. This allele, which encodes hepatocyte nuclear factor 3-alpha protein, is involved in transcriptional regulation. Aberrant expression of the gene is associated with several cancers.			Gene or Genome	
C101648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101648>	C17207	Hepatocyte Nuclear Factor 3-Alpha|Forkhead Box Protein A1|FoxA1|HNF-3-Alpha|HNF-3A|TCF-3A|Transcription Factor 3A	Hepatocyte nuclear factor 3-alpha (472 aa, ~49 kDa) is encoded by the human FOXA1 gene. This protein plays a role in the modulation of transcription.			Amino Acid, Peptide, or Protein	
C101649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101649>	C21345	GDF3 Gene|GDF3|GDF3|Growth Differentiation Factor 3 Gene	This gene is involved in the regulation of cell differentiation.			Gene or Genome	
C10164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10164>	C61063	Bleomycin/Cisplatin/Doxorubicin/Etoposide|BLEO/CDDP/DOX/VP-16|EBAP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101650>	C101649	GDF3 wt Allele|Growth Differentiation Factor 3 wt Allele|KFS3|MCOP7|MCOPCB6|UNQ222/PRO248	Human GDF3 wild-type allele is located in the vicinity of 12p13.1 and is approximately 6 kb in length. This allele, which encodes growth/differentiation factor 3 protein, plays a role in cellular differentiation in embryogenesis and during maturation. Mutation of the gene is associated with Klippel-Feil syndrome type 3, microphthalmia isolated with coloboma type 6 and microphthalmia isolated type 7.			Gene or Genome	
C101651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101651>	C20455	Growth/Differentiation Factor 3|GDF-3|Growth Differentiation Factor 3	Growth/differentiation factor 3 (364 aa, ~41 kDa) is encoded by the human GDF3 gene. This protein is involved in the modulation of both cell growth and differentiation.			Amino Acid, Peptide, or Protein	
C101652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101652>	C26006	GOLIM4 Gene|GOLIM4|GOLIM4|Golgi Integral Membrane Protein 4 Gene	This gene plays a role in protein targeting.			Gene or Genome	
C101653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101653>	C101652	GOLIM4 wt Allele|GIMPC|GOLPH4|GPP130|Golgi Integral Membrane Protein 4 wt Allele|P138	Human GOLIM4 wild-type allele is located in the vicinity of 3q26.2 and is approximately 87 kb in length. This allele, which encodes Golgi integral membrane protein 4, is involved in protein trafficking.			Gene or Genome	
C101654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101654>	C16386	Golgi Integral Membrane Protein 4|GIMPc|Golgi Integral Membrane Protein, cis|Golgi Phosphoprotein 4|Golgi Phosphoprotein of 130 kDa|Golgi-Localized Phosphoprotein of 130 kDa|Type II Golgi Membrane Protein|cis Golgi-Localized Calcium-Binding Protein	Golgi integral membrane protein 4 (696 aa, ~82 kDa) is encoded by the human GOLIM4 gene. This protein plays a role in subcellular protein transport.			Amino Acid, Peptide, or Protein	
C101655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101655>	C26048	RGS4 Gene|RGS4|RGS4|Regulator of G-Protein Signaling 4 Gene	This gene is involved in GTPase activation.			Gene or Genome	
C101656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101656>	C101655	RGS4 wt Allele|DKFZp761F1924|MGC2124|MGC60244|RGP4|RP11-430G6.1|Regulator of G-Protein Signaling 4 wt Allele|SCZD9|Schizophrenia Disorder 9 Gene	Human RGS4 wild-type allele is located in the vicinity of 1q23.3 and is approximately 8 kb in length. This allele, which encodes regulator of G-protein signaling 4 protein, plays a role in the modulation of G-protein signaling. Mutation of the gene may be associated with both schizophrenia and Parkinson disease.			Gene or Genome	
C101657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101657>	C18166	Regulator of G-Protein Signaling 4|RGP4|RGS4	Regulator of G-protein signaling 4 (205 aa, ~23 kDa) is encoded by the human RGS4 gene. This protein is involved in the promotion of GTPase activity.			Amino Acid, Peptide, or Protein	
C101658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101658>	C25869|C20194	TMEM138 Gene|TMEM138|TMEM138|Transmembrane Protein 138 Gene	This gene plays a role in cilium formation.			Gene or Genome	
C101659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101659>	C101658	TMEM138 wt Allele|HSPC196|HSPC198|JBTS16|Transmembrane Protein 138 wt Allele	Human TMEM138 wild-type allele is located in the vicinity of 11q12.2 and is approximately 8 kb in length. This allele, which encodes transmembrane protein 138, is involved in ciliogenesis.			Gene or Genome	
C10165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10165>	C61063	Doxorubicin/Floxuridine/Mitomycin|DOX/FUDR/MITO|FAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101660>	C18466	Transmembrane Protein 138	Transmembrane protein 138 (162 aa, ~19 kDa) is encoded by the human TMEM138 gene. This protein plays a role in the formation of cilium.			Amino Acid, Peptide, or Protein	
C101661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101661>	C25869|C20194	TMEM216 Gene|TMEM216|TMEM216|Transmembrane Protein 216 Gene	This gene is involved in ciliogenesis.			Gene or Genome	
C101662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101662>	C101661	TMEM216 wt Allele|Cerebello-Oculo-Renal Syndrome 2 Gene|HSPC244|JBTS2|MGC13379|MKS2|Meckel Syndrome, Type 2 Gene|Transmembrane Protein 216 wt Allele	Human TMEM216 wild-type allele is located in the vicinity of 11q13.1 and is approximately 7 kb in length. This allele, which encodes transmembrane protein 216, plays a role in the formation of cilium. Mutation of the gene is associated with Joubert syndrome type 2 and Meckel syndrome type 2.			Gene or Genome	
C101663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101663>	C18466	Transmembrane Protein 216|TMEM216	Transmembrane protein 216 (138 aa, ~16 kDa) is encoded by the human TMEM216 gene. This protein is involved in cilium formation.			Amino Acid, Peptide, or Protein	
C101664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101664>	C80699	MIR375 Gene|MIR375|MIR375|MicroRNA 375 Gene	This gene plays a role in gene silencing.			Gene or Genome	
C101665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101665>	C101664	MIR375 wt Allele|MIRN375|MicroRNA 375 wt Allele|hsa-mir-375|miRNA375	Human MIR375 wild-type allele is located in the vicinity of 2q35 and is approximately 70 bases in length. This allele, which encodes MIR375 pre-miRNA, is involved in the modulation of gene expression.			Gene or Genome	
C101666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101666>	C25968	MIR375 Pre-miRNA|Pre-MicroRNA 375|Pre-miRNA 375	MIR375 pre-miRNA (70 nucleotides) is encoded by the human MIR375 gene. This oligoribonucleotide plays a role in the regulation of gene silencing.			Nucleic Acid, Nucleoside, or Nucleotide	
C101667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101667>	C73580	Actively Marketed	Indicates that a product is currently being promoted for use.			Functional Concept	
C101668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101668>	C79273	Medical Device Brand Name Family	A grouping of medical devices items based upon brand name.			Intellectual Product	
C101669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101669>	C95381	Manufacturing Date Production Identifier	The production identifier is the date of manufacture.			Intellectual Product	FDA CDRH GUDID Terminology
C10166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10166>	C61063	Medroxyprogesterone/Mitomycin/Vinblastine|MITO/MPA/VBL|MVP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101670>	C95381	Expiration Date Production Identifier	The production identifier is the expiration date.			Intellectual Product	FDA CDRH GUDID Terminology
C101671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101671>	C95381	Serial Number Production Identifier	The production identifier is the serial number.			Intellectual Product	FDA CDRH GUDID Terminology
C101672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101672>	C95381	Lot or Batch Number Production Identifier	The production identifier is the lot or batch number.			Intellectual Product	FDA CDRH GUDID Terminology
C101673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101673>	C44476	Labeled as Containing Natural Rubber Latex	The device label indicates natural rubber latex as a component.			Qualitative Concept	FDA CDRH GUDID Terminology
C101674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101674>	C44476	Human Cells or Tissue Product|HCT/P|HCT/P|Human Cell, Tissue, or Cellular or Tissue-based Product	A product that contains human cells or tissue.			Qualitative Concept	FDA CDRH GUDID Terminology
C101675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101675>	C73616	No Longer Marketed	Indicates that a product was previously promoted for use, but currently is not being promoted.			Qualitative Concept	
C101676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101676>	C79887	Packaged as Sterile|Device is Packaged as Sterile	A device is packaged as being free of any living organisms.			Functional Concept	FDA CDRH GUDID Terminology
C101677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101677>	C25337	FDA Device Listing Number|FDA Listing Number	A number assigned by the FDA to a device during Registration and Listing.			Qualitative Concept	FDA CDRH GUDID Terminology
C101678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101678>	C25364	Direct Marking Device Identifier|DM DI Number	An identifier that is marked directly on a device.			Intellectual Product	FDA CDRH GUDID Terminology
C101679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101679>	C160943	Excepted from Direct Marking|Excepted from Direct Marking (DM)	An indication that a device is excepted from direct marking requirements.			Qualitative Concept	FDA CDRH GUDID Terminology
C10167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10167>	C61063	Procarbazine/Semustine/Vincristine|MeCCNU/PCB/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101680>	C42578|C25681|C150183	French Catheter Gauge|Catheter Gauge|Ch|Charriere (french)|Charrière|Fr|French|French (catheter gauge)|French Catheter Scale|French Gauge|French Scale|[Ch]|[Ch]	The gauge of a catheter with a circumference of approximately 1 millimeter such that it is by convention, exactly one third of a millimeter.			Quantitative Concept	FDA CDRH GUDID Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology|UCUM Terminology
C101681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101681>	C96145	Recommended Handling Atmospheric Pressure|Handling Environment Atmospheric Pressure	The recommended atmospheric pressure for handling or operating a device.			Qualitative Concept	FDA CDRH GUDID Terminology
C101682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101682>	C96145	Recommended Handling Humidity|Handling Environment Humidity	The recommended humidity level for handling or operating a device.			Qualitative Concept	FDA CDRH GUDID Terminology
C101683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101683>	C96145	Recommended Handling Temperature|Handling Environment Temperature	The recommended temperature of the environment when handling or operating a device.			Qualitative Concept	FDA CDRH GUDID Terminology
C101684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101684>	C19711	Device Labeler|Labeler	An individual that labels a device.			Professional or Occupational Group	FDA CDRH GUDID Terminology
C101685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101685>	C25285	Inner Diameter|Inner/Lumen Diameter|Lumen Diameter	The length of a straight line passing through the center of the inner open space of a circular or spheroid object that connects two points on the circumference.			Quantitative Concept	FDA CDRH GUDID Terminology
C101686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101686>	C79273	Medical Device Model Family	A grouping of medical devices based upon model name or number.			Intellectual Product	
C101687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101687>	C25681	Needle Gauge|NDLGAUGE|NDLGAUGE|{NEEDLE GAUGE}|{NEEDLE GAUGE}|{Needle Gauge}|{Needle Gauge}	A number representing the outer diameter of a hypodermic needle.			Quantitative Concept	CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|CDISC SDTM Vaccines Findings About Test Code Terminology|CDISC SDTM Vaccines Findings About Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA CDRH GUDID Terminology
C101688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101688>	C73616	Never Marketed	Indicates that a product was never promoted for use.			Qualitative Concept	
C101689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101689>	C84382	Hydrogen Peroxide Sterilization|Hydrogen Peroxide	A sterilization process that uses hydrogen peroxide to kill microorganisms.			Activity	FDA CDRH GUDID Terminology
C10168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10168>	C61063	Doxorubicin/Mitomycin/Vindesine|DAVA/DOX/MITO|VAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101690>	C84382	Ozone Sterilization|Ozone	A sterilization process that uses ozone gas to kill microorganisms. This process may be used on objects that cannot withstand high temperatures.			Activity	FDA CDRH GUDID Terminology
C101691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101691>	C84382	Chlorine Dioxide Sterilization|Chlorine Dioxide	A sterilization process that uses chlorine dioxide at ambient temperatures to kill microorganisms. This process can be used in large spaces.	Chlorine Dioxide Sterilization		Activity	CTRP Intervention Terminology|CTRP Terminology|FDA CDRH GUDID Terminology
C101692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101692>	C84382	Ethylene Oxide-in-a-Bag Sterilization	A sterilization process that uses ethylene oxide gas enclosed within a sealed bag to kill microorganisms. This process is typically carried out between 30 and 60 degrees C and is applicable for use on small objects that cannot withstand high temperatures.			Activity	
C101693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101693>	C84382	High Intensity Light or Pulse Light Sterilization|High Intensity Light or Pulse Light	A sterilization process that involves the pulsing of a high-power xenon lamp. This process kills microorganisms through the high ultraviolet content of the light and the brief heating effects.			Activity	FDA CDRH GUDID Terminology
C101694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101694>	C84382	Microwave Radiation Sterilization|Microwave Radiation	A sterilization process that uses microwave radiation to kill microorganisms. This process is restricted to materials that contain water and is typically used for food.			Activity	FDA CDRH GUDID Terminology
C101695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101695>	C84382	Sound Wave Sterilization|Sound Waves	A sterilization process that uses high-frequency sound waves to kill microorganisms.			Activity	FDA CDRH GUDID Terminology
C101696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101696>	C84382	Ultraviolet Light Sterilization|Ultraviolet Light	A sterilization process that uses short wavelength radiation to kill microorganisms. This process is used primarily in medical sanitation and sterile work facilities but also has applications for the sterilization of drinking water and waste water.			Activity	FDA CDRH GUDID Terminology
C101697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101697>	C84382	Vaporized Peracetic Acid Sterilization|Peracetic Acid	A sterilization process that uses the vaporized form of peracetic acid to kill microorganisms.			Activity	FDA CDRH GUDID Terminology
C101698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101698>	C25364	Primary Identifier				Intellectual Product	
C101699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101699>	C93402|C101698	Primary Package Identifier|Package DI Number	The main identifier of a package type.			Intellectual Product	FDA CDRH GUDID Terminology
C10169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10169>	C61063	Cisplatin/Cyclophosphamide/Doxorubicin/Vindesine|CDDP/CTX/DAVA/DOX|PACE			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1016>	C68303	Beta-Carotene|.beta.-Carotene|3,7,12,16-tetramethyl-1,18-bis(2,6,6-trimethyl-1-cyclohexenyl)-octadeca-1,3,5,7,9,11,13,15,17-nonaene|BETA CAROTENE|Beta Carotene|Beta-carotene|Beta-carotene|CAROTENE, BETA|Lumitene|Solatene|Solatene|beta carotene|beta-Carotene	A naturally-occurring retinol (vitamin A) precursor obtained from certain fruits and vegetables with potential antineoplastic and chemopreventive activities.  As an anti-oxidant, beta carotene inhibits free-radical damage to DNA.  This agent also induces cell differentiation and apoptosis of some tumor cell types, particularly in early stages of tumorigenesis, and enhances immune system activity by stimulating the release of natural killer cells, lymphocytes, and monocytes. (NCI04)			Pharmacologic Substance|Vitamin	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101700>	C25638	Reason for Direct Part Exempt Marking	An explanation why a medical device product is exempt from direct part marking.			Qualitative Concept	
C101701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101701>	C51968	Labeler Regulatory Contact for FDA	The representative of a labeler company who is the authorized channel for communication between the company and the FDA.			Professional or Occupational Group	
C101702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101702>	C25285	Second Longest Diameter|LONGEST_DIAM_DIM2|LONGEST_DIAM_DIM2	The second longest possible length of a straight line passing through the center of a nearly circular or spheroid object that connects two points on the circumference.			Quantitative Concept	EWS Tumor Assessment Table|EWS Variable Terminology|OS Tumor Assessment Table|OS Variable Terminology
C101703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101703>	C25364	Secondary Identifier				Intellectual Product	
C101704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101704>	C96145	Special Storage Condition|Special Storage Conditions	Specific conditions under which a device should be stored.			Qualitative Concept	FDA CDRH GUDID Terminology
C101705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101705>	C96145	Recommended Storage Atmospheric Pressure|Storage Environment Atmospheric Pressure	The recommended storage atmospheric pressure for a device.			Qualitative Concept	FDA CDRH GUDID Terminology
C101706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101706>	C96145	Recommended Storage Humidity|Storage Environment Humidity	The recommended storage humidity level for a device.			Qualitative Concept	FDA CDRH GUDID Terminology
C101707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101707>	C96145	Recommended Storage Temperature|Storage Environment Temperature	The recommended storage temperature for a device.			Qualitative Concept	FDA CDRH GUDID Terminology
C101708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101708>	C51968	Device Labeler Customer Contact|Customer Contact	Customer contact information for a device labeler.			Professional or Occupational Group	FDA CDRH GUDID Terminology
C101709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101709>	C25285	Third Longest Diameter|LONGEST_DIAM_DIM3|LONGEST_DIAM_DIM3	The third longest possible length of a straight line passing through the center of a nearly circular or spheroid object that connects two points on the circumference.			Quantitative Concept	EWS Tumor Assessment Table|EWS Variable Terminology|OS Tumor Assessment Table|OS Variable Terminology
C10170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10170>	C61007	Mercaptopurine/Methotrexate/Prednisolone/Vincristine|MP/MTX/PRDL/VCR|POMP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101710>	C51968	Third Party Regulatory Information Submitter|Third Party	An outside party delegated to submit regulatory information.			Professional or Occupational Group	FDA CDRH GUDID Terminology
C101711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101711>	C73616	To Be Marketed	Indicates that a product is intended to be promoted for use at a future time.			Qualitative Concept	
C101712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101712>	C84382	Dry Heat Sterilization	A sterilization process that uses high temperature and dry air to kill microorganisms on the surface of objects. This process is restricted to objects that can withstand high temperatures.			Activity	FDA CDRH GUDID Terminology
C101713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101713>	C84382	Ethylene Oxide Sterilization|Ethylene Oxide	A sterilization process that uses ethylene oxide gas to kill microorganisms.			Activity	FDA CDRH GUDID Terminology
C101714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101714>	C84382	Moist Heat or Steam Sterilization	A sterilization process that uses high temperature and moist air to kill microorganisms. The moist air is typically applied at increased atmospheric pressure and the process is restricted to objects that can withstand high temperature and pressure.			Activity	FDA CDRH GUDID Terminology
C101715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101715>	C84382	Radiation Sterilization	A sterilization process that uses radiation such as electron beams, X-rays, gamma rays, or subatomic particles to kill microorganisms.			Activity	FDA CDRH GUDID Terminology
C101716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101716>	C25694	Global Unique Device Identification Database Submission|GUDID|GUDID Submission	The submission of a global unique device identification record.			Intellectual Product	FDA CDRH GUDID Terminology
C101717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101717>	C25364	Unit of Use Device Identifier	An identifier to associate the use of device on a patient when the Universal Device Identifier is applied to a package of multiple devices.			Intellectual Product	FDA CDRH GUDID Terminology
C101718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101718>	C26003	HPN Gene|HPN|HPN|Hepsin Gene	This gene is involved in protein metabolism.			Gene or Genome	
C101719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101719>	C101718	HPN wt Allele|Hepsin wt Allele|TMPRSS1|Transmembrane Protease, Serine 1 Gene	Human HPN wild-type allele is located within 19q11-q13.2 and is approximately 26 kb in length. This allele, which encodes serine protease hepsin protein, plays a role in proteolysis.			Gene or Genome	
C10171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10171>	C61063	Bleomycin/Cyclophosphamide/Methotrexate/Vincristine|BLEO/CTX/MTX/VCR|COMB			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101720>	C17123	Serine Protease Hepsin|EC 3.4.21.106|HPN|TMPRSS1|Transmembrane Protease Serine 1	Serine protease hepsin (417 aa, ~45 kDa) is encoded by the human HPN gene. This protein is involved in proteolysis.			Amino Acid, Peptide, or Protein|Enzyme	NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C101721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101721>	C20703	EED Gene|EED|EED|EED|Embryonic Ectoderm Development Gene	This gene plays a role in the negative regulation of transcription.	EED Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|Pediatric Oncology Target Genes/Proteins Terminology
C101722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101722>	C101698	Primary Device Identifier|Primary DI Number	The main identifier for a device.			Intellectual Product	FDA CDRH GUDID Terminology
C101723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101723>	C101721	EED wt Allele|COGIS|EED, Mouse, Homolog of Gene|Embryonic Ectoderm Development Protein, Mouse, Homolog of Gene|Embryonic Ectoderm Development wt Allele|HEED|WAIT-1|WAIT1	Human EED wild-type allele is located within 11q14.2-q22.3 and is approximately 34 kb in length. This allele, which encodes polycomb protein EED, is involved in both histone methylation and transcriptional regulation.	EED wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101724>	C101703	Secondary Device Identifier|Secondary DI Number	An alternate identification number for a device.			Intellectual Product	FDA CDRH GUDID Terminology
C101725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101725>	C26199	Polycomb Protein EED|EED|Embryonic Ectoderm Development Protein|WAIT-1|WD Protein Associating With Integrin Cytoplasmic Tails 1|hEED	Polycomb protein EED (441 aa, ~50 kDa) is encoded by the human EED gene. This protein plays a role in transcriptional repression mediated by histone methylation.	Polycomb Protein EED		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Genes/Proteins Terminology
C101726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101726>	C54362	RBBP4 Gene|RBBP4|RBBP4|Retinoblastoma Binding Protein 4 Gene	This gene is involved in the regulation of both transcription and cell proliferation.	RBBP4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101727>	C101726	RBBP4 wt Allele|NURF55|RBAP48|RbAp48|Retinoblastoma Binding Protein 4 wt Allele	Human RBBP4 wild-type allele is located 1p35.1 and is approximately 35 kb in length. This allele, which encodes histone-binding protein RBBP4, plays a role in histone binding, transcriptional regulation and cell cycle progression.	RBBP4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101728>	C26199	Histone-Binding Protein RBBP4|CAF-1 Subunit C|CAF-I 48 kDa Subunit|CAF-I p48|Chromatin Assembly Factor 1 Subunit C|Chromatin Assembly Factor I p48 Subunit|Nucleosome-Remodeling Factor Subunit RBAP48|RBBP-4|RBBP4|Retinoblastoma Binding Protein 4|Retinoblastoma-Binding Protein 4|Retinoblastoma-Binding Protein p48	Histone-binding protein RBBP4 (425 aa, ~48 kDa) is encoded by the human RBBP4 gene. This protein is involved in transcriptional regulation, cell proliferation and histone binding.	Histone-Binding Protein RBBP4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101729>	C20921	ERRFI1 Gene|ERBB Receptor Feedback Inhibitor 1 Gene|ERRFI1|ERRFI1	This gene plays a role in the modulation of receptor signaling.	ERRFI1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10172>	C61007	Cisplatin/Fluorouracil|CDDP/5-FU|P-FU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101730>	C101729	ERRFI1 wt Allele|ERBB Receptor Feedback Inhibitor 1 wt Allele|GENE-33|MIG-6|MIG6|Mitogen-Inducible Gene 6|RALT|Receptor-Associated Late Transducer Gene	Human ERRFI1 wild-type allele is located in the vicinity of 1p36 and is approximately 22 kb in length. This allele, which encodes ERBB receptor feedback inhibitor 1 protein, is involved in the regulation of EGF receptor signaling.	ERRFI1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101731>	C17298	ERBB Receptor Feedback Inhibitor 1|MIG-6|Mitogen-Inducible Gene 6 Protein|Receptor-Associated Late Transducer	ERBB receptor feedback inhibitor 1 (462 aa, ~51 kDa) is encoded by the human ERRFI1 gene. This protein plays a role in the regulation of ligand-dependent dimerization.	ERBB Receptor Feedback Inhibitor 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101732>	C154302	H3C2 Gene|H3 Clustered Histone 2 Gene|H3C2|H3C2|HIST1H3B|HIST1H3B|HIST1H3B Gene	This gene is involved in chromatin structure.	HIST1H3B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C101733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101733>	C101732	H3C2 wt Allele|H3 Clustered Histone 2 wt Allele|H3 Histone Family, Member L Gene|H3/l|H3FL|H3b|HIST1 Cluster, H3b Gene|HIST1H3B|HIST1H3B wt Allele|Histone 1, H3b Gene|Histone Cluster 1 H3 Family Member B Gene|Histone Cluster 1, H3b Gene|Histone Gene Cluster 1, H3 Histone Family, Member B Gene|Histone Gene Cluster 1, H3b Gene	Human H3C2 wild-type allele is located in the vicinity of 6p22.1 and is approximately 1 kb in length. This allele, which encodes histone H3.1 protein, plays a role in the modulation of chromatin structure.	HIST1H3B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101734>	C16685	Histone H3.1|H3.1|Histone H3/a|Histone H3/b|Histone H3/c|Histone H3/d|Histone H3/f|Histone H3/h|Histone H3/i|Histone H3/j|Histone H3/k|Histone H3/l	Histone H3.1 (136 aa, ~15 kDa) is encoded by the human H3C1, H3C2, H3C3, H3C4, H3C6, H3C7, H3C8, H3C10, H3C11 and H3C12 genes. This protein plays a role in the formation of chromatin structures.	Histone H3.1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C101735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101735>	C21345	AMH Gene|AMH|AMH|Anti-Mullerian Hormone Gene	This gene plays a role in gonad development.	AMH Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101736>	C101735	AMH wt Allele|Anti-Mullerian Hormone wt Allele|MIF|MIS	Human AMH wild-type allele is located in the vicinity of 19p13.3 and is approximately 3 kb in length. This allele, which encodes Muellerian-inhibiting factor protein, is involved in the morphogenesis of the reproductive system. Mutation of the gene is associated with persistent Muellerian duct syndrome.	AMH wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101737>	C20455	Muellerian-Inhibiting Factor|AMH|Anti-Muellerian Hormone|Anti-Müllerian Hormone|MIS|Muellerian-Inhibiting Substance|Mullerian Inhibiting Factor|Mullerian Inhibiting Substance|Mullerian-Inhibiting Factor|Mullerian-Inhibiting Substance|Müllerian Inhibiting Factor|Müllerian Inhibiting Substance	Muellerian-inhibiting factor (560 aa, ~59 kDa) is encoded by the human AMH gene. This protein plays a role in the development of the male reproductive system.	Muellerian-Inhibiting Factor		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101738>	C20709	NR1D1 Gene|NR1D1|NR1D1|Nuclear Receptor Subfamily 1, Group D, Member 1 Gene	This gene plays a role in both transcriptional regulation and circadian rhythms.			Gene or Genome	
C101739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101739>	C101738	NR1D1 wt Allele|EAR1|Nuclear Receptor Subfamily 1, Group D, Member 1 wt Allele|REV-ERB-Alpha|Rev-ErbA-Alpha|Rev-ErbAalpha|THRA1|THRAL|ear-1|hRev	Human NR1D1 wild-type allele is located in the vicinity of 17q11.2 and is approximately 8 kb in length. This allele, which encodes nuclear receptor subfamily 1 group D member 1 protein, is involved in the regulation of metabolism.			Gene or Genome	
C10173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10173>	C61063	Bleomycin/Cyclophosphamide/Cytarabine/Prednisone/Vincristine|ARA-C/BLEO/CTX/PRED/VCR|COAP-BLEO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101740>	C17671	Nuclear Receptor Subfamily 1 Group D Member 1|EAR-1|NR1D1|Rev-erbA-Alpha|v-erbA-Related Protein 1	Nuclear receptor subfamily 1 group D member 1 (614 aa, ~67 kDa) is encoded by the human NR1D1 gene. This protein plays a role in transcriptional regulation of genes involved in metabolic processes and circadian rhythm.			Amino Acid, Peptide, or Protein|Receptor	
C101741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101741>	C20709	NR1D2 Gene|NR1D2|NR1D2|Nuclear Receptor Subfamily 1, Group D, Member 2 Gene	This gene is involved in transcriptional regulation and metabolic processes.			Gene or Genome	
C101742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101742>	C101741	NR1D2 wt Allele|BD73|EAR-1R|EAR-1r|HZF2|Hs.37288|Nuclear Receptor Subfamily 1, Group D, Member 2 wt Allele|REV-ERB-Beta|RVR	Human NR1D2 wild-type allele is located in the vicinity of 3p24.2 and is approximately 35 kb in length. This allele, which encodes nuclear receptor subfamily 1 group D member 2 protein, plays a role in the regulation of gene expression.			Gene or Genome	
C101743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101743>	C17671	Nuclear Receptor Subfamily 1 Group D Member 2|EAR-1R|NR1D2|Orphan Nuclear Hormone Receptor BD73|Rev-erb-Beta|v-erbA-Related Protein 1-Related	Nuclear receptor subfamily 1 group D member 2 (579 aa, ~65 kDa) is encoded by the human NR1D2 gene. This protein plays a role in circadian rhythms and transcriptional repression.			Amino Acid, Peptide, or Protein|Receptor	
C101744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101744>	C26006	SNX18 Gene|SNX18|SNX18|Sorting Nexin 18 Gene	This gene is involved in both endocytosis and protein trafficking.			Gene or Genome	
C101745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101745>	C101744	SNX18 wt Allele|FLJ11997|FLJ32560|FLJ61062|MGC150827|MGC150829|SH3PX2|SH3PXD3B|SNAG1|Sorting Nexin 18 wt Allele|Sorting Nexin Associated Golgi Protein 1 Gene	Human SNX18 wild-type allele is located in the vicinity of 5q11.2 and is approximately 29 kb in length. This allele, which encodes sorting nexin-18 protein, plays a role in both subcellular protein transport and endocytosis.			Gene or Genome	
C101746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101746>	C16386	Sorting Nexin-18|SH3 and PX Domain-Containing Protein 3B|SNX18|Sorting Nexin 18|Sorting Nexin-Associated Golgi Protein 1	Sorting nexin-18 (628 aa, ~96 kDa) is encoded by the human SNX18 gene. This protein is involved in both protein transport and endocytosis.			Amino Acid, Peptide, or Protein	
C101747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101747>	C20923	FFAR1 Gene|FFAR1|FFAR1|Free Fatty Acid Receptor 1 Gene	This gene plays a role in G protein signaling.			Gene or Genome	
C101748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101748>	C101747	FFAR1 wt Allele|FFA1R|Free Fatty Acid Receptor 1 wt Allele|G Protein-Coupled Receptor 40 Gene|GPCR40|GPR40	Human FFAR1 wild-type allele is located in the vicinity of 19q13.1 and is approximately 1 kb in length. This allele, which encodes free fatty acid receptor 1 protein, is involved in lipid binding, receptor signaling and the regulation of insulin secretion.			Gene or Genome	
C101749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101749>	C18239	Free Fatty Acid Receptor 1|G-Protein Coupled Receptor 40	Free fatty acid receptor 1 (300 aa, ~31 kDa) is encoded by the human FFAR1 gene. This protein plays a role in fatty acid-dependent receptor signaling.			Amino Acid, Peptide, or Protein|Receptor	
C10174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10174>	C61063	Amsacrine/Cyclophosphamide/Hydroxyurea|AMSA/CTX/HU|CMH			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101750>	C20103	KLRK1 Gene|KLRK1|KLRK1|Killer Cell Lectin-Like Receptor Subfamily K, Member 1 Gene|NKG2D Gene	This gene plays a role in the activation of natural killer cells.	KLRK1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101751>	C101750	KLRK1 wt Allele|CD314|D12S2489E|DNA Segment on Chromosome 12 (Unique) 2489 Expressed Sequence Gene|FLJ17759|FLJ75772|KLR|Killer Cell Lectin-Like Receptor Subfamily K, Member 1 wt Allele|NKG2-D|NKG2D	Human KLRK1 wild-type allele is located within 12p13.2-p12.3 and is approximately 19 kb in length. This allele, which encodes NKG2-D type II integral membrane protein, is involved in both ligand binding and lymphocyte activation.	KLRK1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101752>	C18106	NKG2-D Type II Integral Membrane Protein|Antigen CD314|CD Antigen CD314|CD314|CD314 Antigen|KLRK1|Killer Cell Lectin-Like Receptor Subfamily K Member 1|NK Cell Receptor D|NKG2-D-Activating NK Receptor	NKG2-D type II integral membrane protein (216 aa, ~25 kDa) is encoded by the human KLRK1 gene. This protein plays a role in ligand-mediated NK cell activation.	NKG2-D Type II Integral Membrane Protein		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101753>	C20988	CDH23 Gene|CDH23|CDH23|Cadherin-Related 23 Gene	This gene is involved in cell adhesion.			Gene or Genome	
C101754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101754>	C101753	CDH23 wt Allele|CDHR23|Cadherin-Related 23 wt Allele|DFNB12|DKFZp434P2350|FLJ00233|FLJ36499|KIAA1774|KIAA1812|MGC102761|RP11-472K8.4|UNQ1894/PRO4340|USH1D	Human CDH23 wild-type allele is located in the vicinity of 10q22.1 and is approximately 419 kb in length. This allele, which encodes cadherin-23 protein, plays a role in both cell adhesion and stereocilia organization. Mutation of the gene is associated with deafness autosomal recessive type 12 and Usher syndrome types 1D, digenic 1D/F and 3.			Gene or Genome	
C101755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101755>	C16373	Cadherin-23|Otocadherin	Cadherin-23 (3354 aa, ~370 kDa) is encoded by the human CDH23 gene. This protein is involved in the organization of stereocilia and cell-cell adhesion.			Amino Acid, Peptide, or Protein	
C101756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101756>	C25873|C20745	TTN Gene|TTN|TTN|Titin Gene	This gene plays a role in sarcomere structure.			Gene or Genome	
C101757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101757>	C101756	TTN wt Allele|CMD1G|CMH9|CMPD4|Cardiomyopathy, Dilated 1G (Autosomal Dominant) Gene|DKFZp451N061|EOMFC|FLJ26020|FLJ26409|FLJ32040|FLJ34413|FLJ39564|FLJ43066|HMERF|LGMD2J|MYLK5|TMD|Titin wt Allele	Human TTN wild-type allele is located in the vicinity of 2q31 and is approximately 305 kb in length. This allele, which encodes titin protein, is involved in both muscle filament structure and protein phosphorylation. Mutation of the gene is associated with hereditary myopathy with early respiratory failure, familial hypertrophic cardiomyopathy type 9, cardiomyopathy dilated type 1G, tardive tibial muscular dystrophy, limb-girdle muscular dystrophy type 2J and early-onset myopathy with fatal cardiomyopathy.			Gene or Genome	
C101758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101758>	C17325|C16492	Titin|Connectin|EC 2.7.11.1|Rhabdomyosarcoma antigen MU-RMS-40.14|TITIN|TTN	Titin (34350 aa, ~3816 kDa) is encoded by the human TTN gene. This protein plays a role in muscle filament structure and contraction.			Amino Acid, Peptide, or Protein|Enzyme	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C101759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101759>	C21275	MMP10 Gene|MMP10|MMP10|Matrix Metallopeptidase 10 (Stromelysin 2) Gene	This gene plays a role in degradation of proteoglycans and fibronectin.	MMP10 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10175>	C61063	Carmustine/Cyclophosphamide/Dexamethasone|BCNU/CTX/DM|CCD			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101760>	C101759	MMP10 wt Allele|Matrix Metallopeptidase 10 (Stromelysin 2) wt Allele|SL-2|SL2|ST2|STMY2	Human MMP10 wild-type allele is located in the vicinity of 11q22.3 and is approximately 10 kb in length. This allele, which encodes stromelysin-2 protein, is involved in proteolysis of components of the extracellular matrix.	MMP10 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101761>	C18164	Stromelysin-2|EC 3.4.24.22|MMP-10|MMP10|Matrix Metalloprotease 10|Matrix Metalloprotease-10|Matrix Metalloproteinase 10|Matrix Metalloproteinase-10|SL-2|Stromelysin-II|Transin-2	Stromelysin-2 (476 aa, ~54 kDa) is encoded by the human MMP10 gene. This protein plays a role in the metabolism of the extracellular matrix.	Stromelysin-2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101762>	C26147	B3GAT1 Gene|B3GAT1|B3GAT1|Beta-1,3-Glucuronyltransferase 1 (Glucuronosyltransferase P) Gene	This gene plays a role in glycoprotein modification.	B3GAT1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101763>	C14336	Lavandula angustifolia|Common Lavender|English Lavender|English lavender|LAVANDULA ANGUSTIFOLIA WHOLE|lavender|true lavender	A plant with aromatic leaves and flowers that is a member of the mint family. Oil from the flowers has been used in some cultures to treat certain medical problems, to keep insects away, and to wash in. It is also used in aromatherapy. Perillyl alcohol, a substance found in lavender, is being studied in cancer prevention and treatment.			Plant	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C101764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101764>	C101762	B3GAT1 wt Allele|Beta-1,3-Glucuronyltransferase 1 (Glucuronosyltransferase P) wt Allele|CD57|GLCATP|GLCUATP|HNK1|LEU7|NK-1|NK1	Human B3GAT1 wild-type allele is located in the vicinity of 11q25 and is approximately 33 kb in length. This allele, which encodes galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 protein, is involved in the addition of carbohydrate to proteins.	B3GAT1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101765>	C17434	Galactosylgalactosylxylosylprotein 3-Beta-Glucuronosyltransferase 1|B3GAT1|Beta-1,3-Glucuronyltransferase 1|EC 2.4.1.135|GlcAT-P|GlcUAT-P|Glucuronosyltransferase P|UDP-GlcUA:Glycoprotein Beta-1,3-Glucuronyltransferase	Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 (334 aa, ~38 kDa) is encoded by the human B3GAT1 gene. This protein plays a role in protein glycosylation.	Galactosylgalactosylxylosylprotein 3-Beta-Glucuronosyltransferase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101766>	C20673	PPARGC1B Gene|PPARGC1B|PPARGC1B|Peroxisome Proliferator-Activated Receptor Gamma, Coactivator 1 Beta Gene	This gene is involved in the positive regulation of transcription.	PPARGC1B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101767>	C101766	PPARGC1B wt Allele|DKFZp686C1790|ERRL1|FLJ14284|PERC|PGC-1(beta)|PGC1B|Peroxisome Proliferative Activated Receptor, Gamma, Coactivator 1, Beta Gene|Peroxisome Proliferator-Activated Receptor Gamma, Coactivator 1 Beta wt Allele|Peroxisome Proliferator-Activated Receptor-Gamma, Coactivator 1 Beta Gene	Human PPARGC1B wild-type allele is located in the vicinity of 5q32 and is approximately 125 kb in length. This allele, which encodes peroxisome proliferator-activated receptor gamma coactivator 1-beta protein, plays a role in both transcriptional regulation and estrogen receptor signaling.	PPARGC1B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101768>	C26199	Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-Beta|Estrogen Receptor-Related Receptor Ligand 1|PGC-1-Beta|PGC-1-Related Estrogen Receptor Alpha Coactivator|PGC1-Beta|PGC1-Related Estrogen Receptor Coactivator|PPAR-Gamma Coactivator 1-Beta|PPARGC-1-Beta|PPARGC1B	Peroxisome proliferator-activated receptor gamma coactivator 1-beta (1023 aa, ~113 kDa) is encoded by the human PPARGC1B gene. This protein is involved in both estrogen receptor signaling and transcriptional activation.			Amino Acid, Peptide, or Protein	
C101769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101769>	C20194	TFF3 Gene|TFF3|TFF3|Trefoil Factor 3 (Intestinal) Gene	This gene is involved in maintenance of the intestinal mucosa.	TFF3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10176>	C63587	VBMF Regimen|BLEO/5-FU/MTX/VCR|Bleomycin/Fluorouracil/Methotrexate/Vincristine|VBMF|VBMF|Vincristine-Bleomycin-Methotrexate-Fluorouracil|Vincristine/Bleomycin/Methotrexate/Fluorouracil|Vincristine/Bleomycin/Methotrexate/Fluorouracil Regimen	A regimen consisting of vincristine, bleomycin, methotrexate, and fluorouracil that may be used in the treatment of head and neck cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C101770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101770>	C101769	TFF3 wt Allele|HITF|ITF|P1B|TFI|Trefoil Factor 3 (Intestinal) wt Allele	Human TFF3 wild-type allele is located in the vicinity of 21q22.3 and is approximately 4 kb in length. This allele, which encodes trefoil factor 3 protein, plays a role in cell motility and both repair and maintenance of the intestinal mucosa.	TFF3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101771>	C18466	Trefoil Factor 3|Human Intestinal Trefoil Factor|Intestinal Trefoil Factor|Polypeptide P1.B|TFF3|hITF|hP1.B	Trefoil factor 3 (80 aa, ~9 kDa) is encoded by the human TFF3 gene. This protein is involved in both digestion and gastrointestinal mucosa maintenance.	Trefoil Factor 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101772>	C50483|C45233	Respiratory Arrest|Pulmonary Arrest|Pulmonary Arrest	Cessation of breathing function.			Finding	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C101773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101773>	C201275	Mesothelin-specific Chimeric Antigen Receptor-engineered Peripheral Blood Lymphocytes|Anti-mesothelin CAR PBL	A preparation of peripheral blood lymphocytes (PBLs) transduced with a retroviral vector encoding a T cell chimeric antigen receptor (CAR) specific for mesothelin with potential immunostimulatory and antineoplastic activities. After transduction, expansion in culture, and reintroduction into the patient, the mesothelin-specific chimeric antigen receptor-engineered PBLs bind to tumor cells expressing mesothelin. This may stimulate the secretion of cytokines and result in cell lysis of mesothelin-expressing cancer cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in many epithelial-derived cancers.	Mesothelin-specific Chimeric Antigen Receptor-engineered Peripheral Blood Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101774>	C25982	IL33 Gene|IL33|IL33|Interleukin 33 Gene	This gene plays a role in cytokine signaling.	IL33 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101775>	C101774	IL33 wt Allele|C9orf26|Chromosome 9 Open Reading Frame 26 Gene|DKFZp586H0523|DVS27|IL1F11|Interleukin 33 wt Allele|NF-HEV|NFEHEV|RP11-575C20.2	Human IL33 wild-type allele is located in the vicinity of 9p24.1 and is approximately 42 kb in length. This allele, which encodes interleukin-33 protein, is involved in cytokine-mediated activation of inflammation.	IL33 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101776>	C2124	Iobenguane I-124|124I-MIBG|124I-metaiodobenzylguanidine|IOBENGUANE I-124|Iodine I 124 Iobenguane|Iodine I 124 Metaiodobenzylguanidine	A radioconjugate composed of the positron-emitting radioisotope iodine I 124 labeled to iobenguane, the synthetic aralkylguanidine analogue of the neurotransmitter norepinephrine (NE), with potential diagnostic imaging applications upon positron emitting tomography (PET) or computed tomography (CT). Upon administration, iobenguane I-124 is taken up and accumulates in the granules of adrenal medullary chromaffin cells and in the pre-synaptic granules of adrenergic neurons in a manner almost identical with that of NE. In turn, tumor cells can be imaged upon PET or CT.	Iobenguane I-124		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C101777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101777>	C1752|C1663	Multi-epitope Folate Receptor Alpha Peptide Vaccine|FR Alpha Peptide Vaccine	A peptide vaccine containing five immunogenic peptide epitopes of the human folate receptor alpha (FR alpha or FOLR1), including FR30, FR56, FR76, FR113, and FR238, with potential immunomodulating and antineoplastic activity. Upon administration, the multi-epitope FR alpha peptide vaccine may induce a cytotoxic T-lymphocyte (CTL) response against FR alpha-overexpressing tumor cells. FR alpha is a high-affinity folate-binding protein and a member of the folate receptor family; this receptor is overexpressed in a majority of ovarian cancers and in about 50% of breast cancers.	Multi-epitope Folate Receptor Alpha Peptide Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101778>	C1287	Lipegfilgrastim|LIPEGFILGRASTIM|Lonquest|Lonquex|Pegylated granulocyte colony stimulating factor (human short isoform) O(sup 3.137)-((3,5-dideoxy-5-((N-((omega-methoxypoly(oxyethylene))carbonyl)glycyl)amino)-D- glycero-alpha-D-galacto-non-2-ulopyranosylonic acid)-(2->6)-2-(acetylamino)-2-deoxy-alpha-D- galactopyranosyl)-des-(37-39)-(1-methionine)human granulocyte colony-stimulating factor (G-CSF, pluripoietin)|Poly(oxy-1,2-ethanediyl), alpha-hydro-omega-methoxy-, 133-ester with granulocyte colony-stimulating factor (methionyl,133-(O-(2-(acetylamino)-6-O-(N-((N- carboxyglycyl)amino)-alpha-neuraminosyl)-2-deoxy-alpha-D-galactopyranosyl)-L-threonine)) (human)|XM22	A long acting glyco-pegylated recombinant form of human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Similar to G-CSF, lipegfilgrastim binds to and activates specific cell surface receptors, and stimulates neutrophil progenitor proliferation and differentiation. Therefore, this agent may prevent the duration and incidence of chemotherapy-induced neutropenia. Compared to filgrastim, lipegfilgrastim has a prolonged plasma half-life.	Lipegfilgrastim		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C101779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101779>	C20497	Interleukin-33|IL-1F11|IL-33|IL33|Interleukin-1 Family Member 11|NF-HEV|Nuclear Factor from High Endothelial Venules	Interleukin-33 (270 aa, ~31 kDa) is encoded by the human IL33 gene. This protein plays a role in the positive regulation of inflammation.	Interleukin-33		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10177>	C61063	Doxorubicin/Methotrexate/Vincristine|DOX/MTX/VCR|VAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101780>	C20921	ARHGEF2 Gene|ARHGEF2|ARHGEF2|Rho/Rac Guanine Nucleotide Exchange Factor (GEF) 2 Gene	This gene is involved in the modulation of GTPase signaling.	ARHGEF2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101781>	C101780	ARHGEF2 wt Allele|DKFZp547L106|DKFZp547P1516|FLJ45440|GEF|GEF-H1|GEFH1|KIAA0651|LFP40|P40|Rho/Rac Guanine Nucleotide Exchange Factor (GEF) 2 wt Allele	Human ARHGEF2 wild-type allele is located within 1q21-q22 and is approximately 50 kb in length. This allele, which encodes Rho guanine nucleotide exchange factor 2 protein, plays a role in signaling, apoptosis, and cell proliferation.	ARHGEF2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101782>	C17494	Rho Guanine Nucleotide Exchange Factor 2|ARHGEF2|GEF-H1|Guanine Nucleotide Exchange Factor H1|Microtubule-Regulated Rho-GEF|Proliferating Cell Nucleolar Antigen p40	Rho guanine nucleotide exchange factor 2 (986 aa, ~112 kDa) is encoded by the human ARHGEF2 gene. This protein is involved in the regulation of both guanine nucleotide exchange and signal transduction.	Rho Guanine Nucleotide Exchange Factor 2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101783>	C20921	ECT2 Gene|ECT2|ECT2|Epithelial Cell Transforming Sequence 2 Oncogene Gene	This gene plays a role in both GTPase-mediated signaling and cellular stress responses.	ECT2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101784>	C101783	ECT2 wt Allele|ARHGEF31|Epithelial Cell Transforming Sequence 2 Oncogene wt Allele|FLJ10461|MGC138291	Human ECT2 wild-type allele is located within 3q26.1-q26.2 and is approximately 71 kb in length. This allele, which encodes protein ECT2, is involved in the modulation of apoptosis, cytokinesis and signal transduction.	ECT2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101785>	C17494	Protein ECT2|Epithelial Cell-Transforming Sequence 2 Oncogene	Protein ECT2 (914 aa, ~104 kDa) is encoded by the human ECT2 gene. This protein plays a role in the regulation of GTPase-dependent signaling.	Protein ECT2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101786>	C61074|C129825	Multi-AGC Kinase Inhibitor AT13148|AT-13148|AT13148	An orally available, small molecule inhibitor of AGC group kinases, with potential antineoplastic activity. AT13148 inhibits, in an ATP-competitive manner, the enzymatic activity of two AGC kinases, protein kinase B (PKB or AKT) and p70S6K which play key roles in the PI3K/PKB/mTOR signaling pathway. Blockade of this pathway leads to an inhibition of cell growth and the induction of apoptosis in susceptible tumor cells. PI3K/PKB/mTOR pathway is dysregulated in greater than 50% of tumors, and is often correlated with resistance and increased tumor survival. AGC group kinases are serine/threonine kinases that are regulated by secondary messengers such as cyclic AMP and lipids.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101787>	C28681|C138180|C129826	TIL 1383I T Cell Receptor-Transduced Autologous T Cells|TIL 1383I TCR Transduced Autologous T Cells	Autologous peripheral blood lymphocytes-derived T cells transduced with a retroviral encoding TIL 1383I, a T cell receptor (TCR) specific for melanoma antigen tyrosinase, with potential immunostimulating and antineoplastic activity. After transduction, expansion in culture, and reintroduction into the patient, TIL 1383I TCR-transduced autologous T cells bind to tumor cells expressing tyrosinase, which may induce cytokine expression, activation and proliferation of T-cells, and a specific cytotoxic T-lymphocyte (CTL) response against tyrosinase-expressing tumor cells. TIL 1383I TCR originated from a melanoma patient's CD4+ tumor-infiltrating lymphocytes and is reactive against a class I MHC (HLA-A2)-restricted epitope (368-376) of tyrosinase.	TIL 1383I T Cell Receptor-Transduced Autologous T Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101788>	C2139	Lipopolysaccharide|LPS	An endotoxin and biologically active component of the Gram-negative bacterial cell wall that is a Toll-like receptor 4 (TLR4) agonist with potential immunostimulatory activity. Upon internalization, lipopolysaccharide (LPS) activates TLR4 which in turn activates the NFkappaB pathway, in addition to mitogen-activated protein kinases signaling pathways.  This leads to the release of proinflammatory cytokines and stimulates an innate immune response against vaccine antigens.	Lipopolysaccharide		Organic Chemical|Pharmacologic Substance	CTRP Biomarker Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C101789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101789>	C213431|C154231|C129826	Adenoviral Transduced hIL-12-expressing Autologous Dendritic Cells INXN-3001 Plus Activator Ligand INXN-1001|DC-RTS-IL-12|INXN-3001/1001	Autologous dendritic cells tranduced with a replication incompetent adenovirus encoding human pro-inflammatory cytokine interleukin-12 (IL-12) (INXN-3001) in combination with the proprietary orally bioavailable, small molecule activator ligand INXN-1001, with potential immunomodulating and antineoplastic activities. Production of IL-12 is controlled by an inducible DNA element that allows transcription initiation only in the presence of the ligand inducer INXN-1001. Upon intratumoral injection of INXN-3001 and subsequent oral administration of activator ligand, INXN-1001 is able to induce expression of IL-12 in INXN-3001. IL-12 expressed by the adenovirus may activate the immune system by promoting the activation of natural killer cells, inducing the secretion of interferon-gamma and inducing a cytotoxic T lymphocyte response against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation. As INXN-1001 regulates both the timing and the levels of IL-12 expression, IL-12 toxicity can be reduced.	Adenoviral Transduced hIL-12-expressing Autologous Dendritic Cells INXN-3001 Plus Activator Ligand INXN-1001		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C10178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10178>	C61063	Cyclophosphamide/Doxorubicin/Vinblastine|CTX/DOX/VBL|VAC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101790>	C141136|C129825	Alectinib|5H-benzo(b)carbazole-3-carbonitrile, 9-Ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-|AF 802|AF-802|AF802|ALECTINIB|ALK Inhibitor RO5424802|Alecensa|Alecensa|CH 5424802|CH-5424802|CH5424802|RG 7853|RG-7853|RG7853|RO 5424802|RO-5424802|RO5424802	An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, alectinib binds to and inhibits ALK kinase, ALK fusion proteins as well as the gatekeeper mutation ALKL1196M known as one of the mechanisms of acquired resistance to small-molecule kinase inhibitors. The inhibition leads to disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.	Alectinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101791>	C2167|C129825	Olmutinib|2-Propenamide, N-(3-((2-((4-(4-methyl-1-piperazinyl)phenyl)amino)thieno(3,2-d)pyrimidin-4-yl)oxy)phenyl)-|BI 1482694|HM61713|OLMUTINIB	An orally available small molecule, mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Olmutinib binds to and inhibits mutant forms of EGFR, thereby leading to cell death of EGFR-expressing tumor cells. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors which also inhibit the EGFR wild type form.	Olmutinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101792>	C67437	Linoleyl Carbonate-Paclitaxel|2-Linoleyl Carbonate-paclitaxel|LOC-paclitaxel|Linoleyl Carbonate-paclitaxel|PACLITAXEL 2'-LINOLEYL CARBONATE	A formulation of the 6-omega fatty acid derivative 2'-linoleyl carbonate (LOC) conjugated to paclitaxel, a taxane compound extracted from the Pacific yew tree Taxus brevifolia, with potential antineoplastic activity. Paclitaxel binds to and stabilizes tubulin, thereby interfering with the dynamics of microtubule assembly/disassembly and resulting in the inhibition of cell division. LOC enhances the uptake of paclitaxel by tumor cells, thereby concentrating this agent in tumor cells compared to normal cells, and may decrease its toxicity profile; fatty acids serve as energy sources and biochemical precursors for the fast growing tumor cells.	Linoleyl Carbonate-paclitaxel		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101793>	C78284|C2459	Topical Calcitriol|Topical Compound 31543	A topical formulation containing the hormonally active form of vitamin D3, with potential protective activity against chemotherapy-induced alopecia (CIA).  Upon topical application to the scalp, calcitriol may prevent keratinocyte apoptosis in anagen hair follicles. Therefore, this agent may protect against the damaging effects of certain chemotherapeutics to the hair follicles.	Topical Calcitriol		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C101794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101794>	C587	Aerosolized Aldesleukin|Aerosolized Recombinant IL-2	An aerosol formulation of aldesleukin, a recombinant form of interleukin-2 (IL-2), with potential immunostimulating activity. Upon IL-2 inhalation, this cytokine activates lymphokine-activated killer cells and natural killer cells, and induces expression of cytotoxic cytokines, such as interferon-gamma and transforming growth factor-beta. This may eventually halt tumor cell growth. Localized administration of IL-2 may decrease toxicity and increase efficacy.	Aerosolized Aldesleukin		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101795>	C2201|C129825	TORC1/2 Kinase Inhibitor DS-3078a|DS-3078a	An orally bioavailable inhibitor of raptor-mTOR protein complex (TORC1) and rictor-mTOR protein complex (TORC2) with potential antineoplastic activity. TORC1/2 inhibitor DS-3078a binds to and inhibits both TORC1 and TORC2, which may result in tumor cell apoptosis and a decrease in tumor cell proliferation. TORC1 and 2 are upregulated in some tumors and play an important role in the PI3K/Akt/mTOR signaling pathway, which is frequently dysregulated in human cancers.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101796>	C28676	Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes|Allogeneic Adenovirus-specific CTLs	A population of allogeneic cytotoxic T-lymphocytes (CTLs) specifically reactive to human adenovirus (Ad) with potential immunomodulating and anti-adenoviral activities. Upon immunoprophylactic adoptive cell therapy, infusion of allogeneic Ad-specific CTLs may help reconstitute Ad-specific CTL responses in patients at risk of developing Ad infections after allogeneic stem cell transplant or in Ad-infected immunocompromised hosts. These allogeneic Ad-specific CTLs are prepared by multiple rounds of stimulation with donor peripheral blood mononuclear cells and lymphoblastoid cell lines that have been transduced with Ad5f35, a recombinant adenoviral vector carrying no transgene.	Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C101797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101797>	C19676	ABRAXAS1 Gene|ABRAXAS1|ABRAXAS1|Abraxas 1, BRCA1 A Complex Subunit Gene	This gene is involved in the repair of DNA double-strand breaks.	ABRAXAS1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C101798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101798>	C101797	ABRAXAS1 wt Allele|ABRA1|ABRAXAS|Abraxas 1, BRCA1 A Complex Subunit wt Allele|Abraxas Gene|CCDC98|Coiled-Coil Domain Containing 98 Gene|FAM175A|FLJ11520|FLJ12642|FLJ13614|Family with Sequence Similarity 175 Member A Gene|Family with Sequence Similarity 175, Member A Gene|UNQ496/PRO1013	Human ABRAXAS1 wild-type allele is located in the vicinity of 4q21.23 and is approximately 64 kb in length. This allele, which encodes BRCA1-A complex subunit Abraxas 1 protein, plays a role in the mediation of DNA repair and the progression of the cell cycle.	ABRAXAS1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101799>	C21170	BRCA1-A Complex Subunit Abraxas 1|ABRAXAS|ABRAXAS1|Abraxas Protein|BRCA1-A Complex Subunit Abraxas|Coiled-Coil Domain-Containing Protein 98|Protein FAM175A	BRCA1-A complex subunit Abraxas 1 (409 aa, ~47 kDa) is encoded by the human ABRAXAS1 gene. This protein is involved in both DNA repair and cell cycle regulation.	BRCA1-A Complex Subunit Abraxas 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10179>	C61063	Cyclophosphamide/Dactinomycin/Vinblastine|CTX/DACT/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1017>	C471	Glucuronidase Inhibitor|beta-D-Glucuronidase Inhibitors|beta-Glucuronidase Inhibitors	Any substance that inhibits glucuronidase, an enzyme involved in the hydrolysis of glucuronic acid from glucuronides. One of the key processes by which the human body eliminates toxic chemicals and hormones is by glucuronidation. When beta-glucuronidase deconjugates these glucuronides, it prolongs the stay of the hormone or toxic chemical in the body. Inhibition of glucuronidase can produce chemoprotective effects.			Chemical Viewed Functionally	
C101800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101800>	C20420	TFCP2 Gene|TFCP2|TFCP2|Transcription Factor CP2 Gene	This gene plays a role in the positive regulation of transcription.			Gene or Genome	
C101801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101801>	C101800	TFCP2 wt Allele|LBP-1C|LBP1C|LSF|LSF1D|SEF|TFCP2C|Transcription Factor CP2 wt Allele	Human TFCP2 wild-type allele is located in the vicinity of 12q13 and is approximately 79 kb in length. This allele, which encodes alpha-globin transcription factor CP2 protein, is involved in the modulation of gene expression.			Gene or Genome	
C101802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101802>	C17207	Alpha-Globin Transcription Factor CP2|Late SV40 Factor|SAA3 Enhancer Factor|TFCP2|Transcription Factor CP2|Transcription Factor LSF	Alpha-globin transcription factor CP2 (502 aa, ~57 kDa) is encoded by the human TFCP2 gene. This protein plays a role in transcriptional activation.			Amino Acid, Peptide, or Protein	
C101803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101803>	C17123|C16354	F2 Gene Product	A protein encoded by the F2 gene.	F2 Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101804>	C101803	Des-Gamma Carboxyprothrombin|DCP|Des-Gamma-Carboxy Prothrombin|PIVKA-II|Protein Induced by Vitamin K Absence or Antagonist II|Protein Induced by Vitamin K Absence-II|Protein Induced by Vitamin K Absence/Antagonist-II	Des-gamma carboxyprothrombin (622 aa, ~70 kDa) is encoded by the human F2 gene. This protein is involved in blood coagulation. This form of prothrombin is not efficiently converted to the active enzyme thrombin because it lacks gamma-carboxyglutamyl residues. These modified glutamyl residues are absent because of either vitamin K deficiency or inhibition of vitamin K activity that, in turn, inhibits the enzyme that carboxylates these residues, vitamin K-dependent gamma-carboxylase.	Des-Gamma Carboxyprothrombin		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C101805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101805>	C118970	CDISC Clinical Classification AIMS Test Code Terminology|AIMS01TC|Abnormal Involuntary Movement Scale Clinical Classification Test Code|QS-AIMS TESTCD	Test codes of clinical classification questions associated with the Abnormal Involuntary Movement Scale (AIMS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101806>	C118970	CDISC Clinical Classification AIMS Test Name Terminology|AIMS01TN|Abnormal Involuntary Movement Scale Clinical Classification Test Name|QS-AIMS TEST	Test names of clinical classification questions associated with the Abnormal Involuntary Movement Scale (AIMS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101807>	C115302	CDISC Functional Test ADNI AVLT Test Code Terminology|ADNI Auditory Verbal Learning Functional Test Test Code|AVL01TC|QS-ADNI AVLT TESTCD	Test codes of functional test questions associated with the Alzheimer's Disease Neuroimaging Initiative's (ADNI) version of the Auditory Verbal Learning Test (AVLT) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101808>	C115302	CDISC Functional Test ADNI AVLT Test Name Terminology|ADNI Auditory Verbal Learning Functional Test Test Name|AVL01TN|QS-ADNI AVLT TEST	Test names of functional test questions associated with the Alzheimer's Disease Neuroimaging Initiative's (ADNI) version of the Auditory Verbal Learning Test (AVLT) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101809>	C118970	CDISC Clinical Classification BARS Test Code Terminology|BARS01TC|Barnes Akathisia Rating Scale Clinical Classification Test Code|QS-BARS TESTCD	Test codes of clinical classification questions associated with the Barnes Akathisia Rating Scale (BARS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10180>	C61063	Carmustine/Mercaptopurine|BCNU/MP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101810>	C118970	CDISC Clinical Classification BARS Test Name Terminology|BARS01TN|Barnes Akathisia Rating Scale Clinical Classification Test Name|QS-BARS TEST	Test names of clinical classification questions associated with the Barnes Akathisia Rating Scale (BARS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101811>	C118970	CDISC Clinical Classification CDR Test Code Terminology|CDR01TC|Clinical Dementia Rating Clinical Classification Test Code|QS-CDR TESTCD	Test codes of clinical classification questions associated with the Clinical Dementia Rating (CDR) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101812>	C118970	CDISC Clinical Classification CDR Test Name Terminology|CDR01TN|Clinical Dementia Rating Clinical Classification Test Name|QS-CDR TEST	Test names of clinical classification questions associated with the Clinical Dementia Rating (CDR) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101813>	C100110	CDISC Questionnaire COWS Test Code Terminology|COWS1TC|Clinical Opiate Withdrawal Scale Questionnaire Test Code|QS-COWS TESTCD	Test codes of questionnaire questions associated with the Clinical Opiate Withdrawal Scale (COWS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101814>	C100110	CDISC Questionnaire COWS Test Name Terminology|COWS1TN|Clinical Opiate Withdrawal Scale Questionnaire Test Name|QS-COWS TEST	Test names of questionnaire questions associated with the Clinical Opiate Withdrawal Scale (COWS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101815>	C118970	CDISC Clinical Classification ECOG Test Code Terminology|ECOG1TC|Eastern Cooperative Oncology Group Performance Status Clinical Classification Test Code|QS-ECOG TESTCD	Test codes of clinical classification questions associated with the Eastern Cooperative Oncology Group (ECOG) Performance Status for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101816>	C118970	CDISC Clinical Classification ECOG Test Name Terminology|ECOG1TN|Eastern Cooperative Oncology Group Performance Status Clinical Classification Test Name|QS-ECOG TEST	Test names of clinical classification questions associated with the Eastern Cooperative Oncology Group (ECOG) Performance Status for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101817>	C100110	CDISC Questionnaire EQ-5D-5L Test Code Terminology|EQ5D02TC|European Quality of Life Five Dimension Five Level Scale Questionnaire Test Code|QS-EQ-5D-5L TESTCD	Test cods of questionnaire questions associated with the European Quality of Life Five Dimension Five Level Scale (EQ-5D-5L) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101818>	C100110	CDISC Questionnaire EQ-5D-5L Test Name Terminology|EQ5D02TN|European Quality of Life Five Dimension Five Level Scale Questionnaire Test Name|QS-EQ-5D-5L TEST	Test names of questionnaire questions associated with the European Quality of Life Five Dimension Five Level Scale (EQ-5D-5L) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101819>	C118970	CDISC Clinical Classification HAMA Test Code Terminology|HAMA1TC|Hamilton Anxiety Rating Scale Clinical Classification Test Code|QS-HAMA TESTCD	Test codes of clinical classification questions associated with the Hamilton Anxiety Rating Scale (HAMA) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10181>	C61063	Doxorubicin/Etoposide/Mitomycin|DOX/MITO/VP-16|VAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101820>	C118970	CDISC Clinical Classification HAMA Test Name Terminology|HAMA1TN|Hamilton Anxiety Rating Scale Clinical Classification Test Name|QS-HAMA TEST	Test names of clinical classification questions associated with the Hamilton Anxiety Rating Scale (HAMA) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101821>	C118970	CDISC Clinical Classification HAMD 21 Test Code Terminology|HAMD2TC|Hamilton Depression Rating Scale 21-Item Clinical Classification Test Code|QS-HAMD 21 TESTCD	Test codes of clinical classification questions associated with the Hamilton Depression Rating Scale 21-Item (HAMD-21) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101822>	C118970	CDISC Clinical Classification HAMD 21 Test Name Terminology|HAMD2TN|Hamilton Depression Rating Scale 21-Item Clinical Classification Test Name|QS-HAMD 21 TEST	Test names of clinical classification questions associated with the Hamilton Depression Rating Scale 21-Item (HAMD-21) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101823>	C100110	CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|QS-SF36 v1.0 Acute TESTCD|SF362TC|The Short Form 36 Health Survey Acute, US Version 1.0 Questionnaire Test Code	Test codes of questionnaire questions associated with the Short Form 36 Health Survey Acute, US Version 1.0 (SF36 v1.0 Acute) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101824>	C100110	CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|QS-SF36 v1.0 Acute TEST|SF362TN|The Short Form 36 Health Survey Acute, US Version 1.0 Questionnaire Test Name	Test names of questionnaire questions associated with the Short Form 36 Health Survey Acute, US Version 1.0 (SF36 v1.0 Acute) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101825>	C100110	CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|QS-SF36 v2.0 Acute TEST|SF364TN|The Short Form 36 Health Survey Acute, US Version 2.0 Questionnaire Test Name	Test names of questionnaire questions associated with the Short Form 36 Health Survey Acute, US Version 2.0 (SF36 v2.0 Acute) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101826>	C100110	CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|QS-SF36 v2.0 Standard TESTCD|SF363TC|The Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire Test Code	Test codes of questionnaire questions associated with the Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101827>	C100110	CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|QS-SF36 v2.0 Standard TEST|SF363TN|The Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire Test Name	Test names of questionnaire questions associated with the Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101828>	C100110	CDISC Questionnaire SOWS Subjective Test Code Terminology|QS-SOWS Subjective TESTCD|SOWSA1TC|Subjective Opiate Withdrawal Scale Questionnaire Test Code	Test codes of questionnaire questions associated with the Subjective Opiate Withdrawal Scale (SOWS Subjective) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101829>	C100110	CDISC Questionnaire SOWS Subjective Test Name Terminology|QS-SOWS Subjective TEST|SOWSA1TN|Subjective Opiate Withdrawal Scale Questionnaire Test Name	Test names of questionnaire questions associated with the Subjective Opiate Withdrawal Scale (SOWS Subjective) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10182>	C61007	Etoposide/Ifosfamide|EIM|IFF/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101830>	C103175	CDISC Questionnaire YMRS Test Code Terminology|QS-YMRS TESTCD	Test codes of questionnaire questions associated with the Young Mania Rating Scale (YMRS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	
C101831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101831>	C103175	CDISC Questionnaire YMRS Test Name Terminology|QS-YMRS TEST	Test names of questionnaire questions associated with the Young Mania Rating Scale (YMRS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	
C101832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101832>	C66830	CDISC SDTM Findings About Test Code Terminology|FATESTCD|Findings About Test Code|SDTM-FATESTCD	Terminology associated with the findings about test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101833>	C66830	CDISC SDTM Findings About Test Name Terminology|FATEST|Findings About Test Name|SDTM-FATEST	Terminology associated with the findings about test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101834>	C66830	CDISC SDTM Normal Abnormal Response Terminology|NORMABNM|Normal Abnormal Response|SDTM-NORMABNM	Terminology associated with the normal abnormal response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101835>	C103175	CDISC SDTM Findings About Object Terminology|SDTM-FAOBJ	Terminology associated with the findings about the object of the observation codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	
C101836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101836>	C61410	CDISC Clinical Data Element Glossary Terminology|CDISC-CLINDE|CLINDE|Clinical Data Element Glossary	The terminology subset that includes the Clinical Data Element Glossary of terms for the Clinical Data Interchange Standards Consortium (CDISC).			Intellectual Product	Clinical Data Interchange Standards Consortium Terminology
C101837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101837>	C103175	CDISC SDTM Consensus Cardiac Classification Systems Test Name Terminology|SDTM-CCRCLS	Terminology associated with the consensus cardiac classification systems codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	
C101838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101838>	C103175	CDISC SDTM Consensus Cardiac Classification Systems Test Code Terminology|SDTM-CCRCLSCD	Terminology associated with the consensus cardiac classification systems codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	
C101839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101839>	C66830	CDISC SDTM New York Heart Association Class Responses Terminology|NYHAC|New York Heart Association Classification|SDTM-NYHAC	Terminology associated with the New York Heart Association class responses codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10183>	C61063	Chlorambucil/Prednisone/Procarbazine/Vinblastine|CLB/PCB/PRED/VBL|ChlVPP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101840>	C66830	CDISC SDTM Killip Class Responses Terminology|KILLIPC|Killip Class Responses|SDTM-KILLIPC	Terminology associated with the Killip class responses codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101841>	C66830	CDISC SDTM Thrombolysis in Myocardial Infarction Flow Responses Terminology|SDTM-TIMIFLRS|TIMI Flow Responses|TIMIFLRS	Terminology associated with the time flow responses codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101842>	C103175	CDISC SDTM Canadian Cardiovascular Society Classification Terminology|SDTM-CACRDSC	Terminology associated with the Canadian Cardiovascular Society classification codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	
C101843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101843>	C66830	CDISC SDTM Coronary Artery Disease Presentation Terminology|CADPRSN|Coronary Artery Disease Presentation|SDTM-CADPRSN	Terminology associated with the coronary artery disease presentation codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101844>	C66830	CDISC SDTM Coronary Artery Disease Symptoms Terminology|CADSYMP|Coronary Artery Disease Symptoms|SDTM-CADSYMP	Terminology associated with the coronary artery disease symptoms codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101845>	C66830	CDISC SDTM Mechanical Circulatory Support Placement Timing Terminology|MCRCSPTM|Mechanical Circulatory Support Placement Timing|SDTM-MCRCSPTM	Terminology associated with the mechanical circulatory support placement timing codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101846>	C66830	CDISC SDTM Cardiovascular Test Name Terminology|CVTEST|Cardiovascular Test Name|SDTM-CVTEST	Terminology associated with the cardiovascular test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101847>	C66830	CDISC SDTM Cardiovascular Test Code Terminology|CVTESTCD|Cardiovascular Test Code|SDTM-CVTESTCD	Terminology associated with the cardiovascular test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101848>	C66830	CDISC SDTM Protocol Risk Assessment Response Codelist|Protocol Risk Assessment Response|RSKASMT|SDTM-RSKASMT	Terminology associated with the protocol risk assessment response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101849>	C66830	CDISC SDTM Coronary Artery Disease Risk Terminology|CADRISK|Coronary Artery Disease Risk|SDTM-CADRISK	Terminology associated with the coronary artery disease risk codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10184>	C61063	Cyclophosphamide/Lomustine/Prednisone/Procarbazine/Vincristine|CCNU/CTX/PCB/PRED/VCR|COPP-CCNU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101850>	C66830	CDISC SDTM Coronary Vessel Disease Extent Terminology|CVSLDEXT|Coronary Vessel Disease Extent|SDTM-CVSLDEXT	Terminology associated with the coronary vessel disease extent codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101851>	C66830	CDISC SDTM Location of Most Severe Stenosis Within a Graft Terminology|GRSTNLOC|Location of Most Severe Stenosis Within a Graft|SDTM-GRSTNLOC	Terminology associated with the location of the most severe stenosis within a graft codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101852>	C66830	CDISC SDTM Sudden Death Syndrome Type Terminology|SDTHSDTP|SDTM-SDTHSDTP|Sudden Death Syndrome Type	Terminology associated with the sudden death syndrome type codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101853>	C103175	CDISC SDTM Cardiac Valvular Regurgitation Severity Terminology|SDTM-CVLVRSEV	Terminology associated with the cardiac valvular regurgitation severity codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	
C101854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101854>	C103175	CDISC SDTM Cardiac Valvular Stenosis Severity Terminology|SDTM-CVLSTSEV	Terminology associated with the cardiac valvular stenosis severity codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	
C101855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101855>	C66830	CDISC SDTM Non-system Reason for PCI Delay Terminology|NSYSPCID|Non-system Reason for PCI Delay|SDTM-NSYSPCID	Terminology associated with the non-system reason for PCI delay codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101856>	C66830	CDISC SDTM Procedure Urgency Status Terminology|PRURGNCY|Procedure Urgency Status|SDTM-PRURGNCY	Terminology associated with the procedure urgency status codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101857>	C66830	CDISC SDTM Diabetes Therapy Terminology|DIABTHPY|Diabetes Therapy|SDTM-DIABTHPY	Terminology associated with the diabetes therapy codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101858>	C66830	CDISC SDTM Procedure Terminology|PROCEDUR|Procedure|SDTM-PROCEDUR	Terminology associated with the procedure codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101859>	C66830	CDISC SDTM Cardiac Procedure Indication Terminology|CVPRCIND|Cardiac Procedure Indication|SDTM-CVPRCIND	Terminology associated with the cardiac procedure indication codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10185>	C61063	Mercaptopurine/Methotrexate/Methylprednisolone/Vincristine|MePRDL/MP/MTX/VCR|POMP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101860>	C66830	CDISC SDTM Coronary Artery Dominance Terminology|CARTDOM|Coronary Artery Dominance|SDTM-CARTDOM	Terminology associated with the coronary artery dominance codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101861>	C66830	CDISC SDTM Lesion Complexity Terminology|LSNCMPX|Lesion Complexity|SDTM-LSNCMPX	Terminology associated with the lesion complexity codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101862>	C66830	CDISC SDTM Lead Abnormality Terminology|LEADABN|Lead Abnormality|SDTM-LEADABN	Terminology associated with the lead abnormality codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101863>	C66830	CDISC SDTM Discharge Disposition Terminology|DISCHDX|Discharge Disposition|SDTM-DISCHDX	Terminology associated with the discharge disposition codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101864>	C66830	CDISC SDTM Reason Coronary Sinus Access or Left Ventricular Lead Not Implanted Terminology|CSLVLNIM|Reason CS/LV Lead Not Implanted|SDTM-CSLVLNIM	Terminology associated with the reason coronary sinus access or left ventricular lead not implanted codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101865>	C66830	CDISC SDTM Acute Coronary Syndrome Presentation Category Terminology|ACSPCAT|Acute Coronary Syndrome Presentation Category|SDTM-ACSPCAT	Terminology associated with the acute coronary syndrome presentation category codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101866>	C66830	CDISC SDTM Cardiac Rhythm Device Failure Manifestation Terminology|CRYDFMAN|Cardiac Rhythm Device Failure Manifestation|SDTM-CRYDFMAN	Terminology associated with the cardiac rhythm device failure manifestation codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101867>	C66830	CDISC SDTM Lead Status Terminology|LEADSTAT|Lead Status|SDTM-LEADSTAT	Terminology associated with the lead status codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101868>	C66830	CDISC SDTM Left Ventricular Ejection Fraction Measurement Result Terminology|LVEFMRE|Left Ventricular Ejection Fraction Measurement Result|SDTM-LVEFMRE	Terminology associated with the left ventricular ejection fraction measurement result codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101869>	C211913	AIMS Clinical Classification Question	A question associated with the AIMS questionnaire.			Intellectual Product	
C10186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10186>	C61063	Aminoglutethimide/Danazol/Hydrocortisone/Tamoxifen|AGT/DAN/HC/TMX|TAD			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101870>	C211913	ADNI-AVLT Questionnaire Question	A question associated with the ADNI version of the AVLT questionnaire.			Intellectual Product	
C101871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101871>	C211913	BARS Clinical Classification Question	A question associated with the BARS questionnaire.			Intellectual Product	
C101872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101872>	C211913	CDR Clinical Classification Question	A question associated with the CDR clinical classification.			Intellectual Product	
C101873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101873>	C211913	COWS Questionnaire Question	A question associated with the COWS questionnaire.			Intellectual Product	
C101874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101874>	C211913	ECOG Clinical Classification Question	A question associated with the ECOG performance status questionnaire.			Intellectual Product	
C101875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101875>	C211913	EQ-5D-5L Questionnaire Question	A question associated with the EQ-5D-5L questionnaire.			Intellectual Product	
C101876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101876>	C211913	HAMA Questionnaire Question	A question associated with the HAMA questionnaire.			Intellectual Product	
C101877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101877>	C211913	HAMD 21 Questionnaire Question	A question associated with the HAMD 21 questionnaire.			Intellectual Product	
C101878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101878>	C211913	SF36 v1 0 Acute Questionnaire Question	A question associated with the SF36 v1.0 Acute questionnaire.			Intellectual Product	
C101879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101879>	C211913	SF36 v2 0 Standard Questionnaire Question	A question associated with the SF36 v2.0 Standard questionnaire.			Intellectual Product	
C10187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10187>	C61063	Aminoglutethimide/Danazol/Medroxyprogesterone/Tamoxifen|AGT/DAN/MPA/TMX|POND			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101880>	C211913	SF36 v2 0 Acute Questionnaire Question	A question associated with the SF36 v2.0 Acute questionnaire.			Intellectual Product	
C101881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101881>	C211913	SOWS Subjective Questionnaire Question	A question associated with the SOWS questionnaire.			Intellectual Product	
C101882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101882>	C211913	YMRS Questionnaire Question	A question associated with the YMRS questionnaire.			Intellectual Product	
C101883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101883>	C36291	Lead Event Finding	A finding related to a lead event.			Finding	
C101884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101884>	C100110	CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|QS-SF36 v2.0 Acute TESTCD|SF364TC|The Short Form 36 Health Survey Acute, US Version 2.0 Questionnaire Test Code	Test codes of questionnaire questions associated with the Short Form 36 Health Survey Acute, US Version 2.0 (SF36 v2.0 Acute) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101885>	C54452	SPL Business Operation Qualifier Terminology|Business Operation Qualifier|Structured Product Labeling Business Operation Qualifier Terminology	Terminology used to qualify the information on business operations concerned with medical product development, manufacturing, and marketing in the framework of the Structured Product Labeling documents.	SPL Business Operation Qualifier Terminology		Intellectual Product	FDA Structured Product Labeling Terminology
C101886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101886>	C54597	Manufactures Non-Generics	A business that makes brand name products.			Functional Concept	FDA Structured Product Labeling Terminology|SPL Business Operation Qualifier Terminology
C101887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101887>	C49484	Not Tested	Indicates that a test was not performed.			Qualitative Concept	
C101888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101888>	C101589	ST Elevation Myocardial Infarction by ECG Finding|ST ELEVATION MYOCARDIAL INFARCTION|ST Elevation Myocardial Infarction by EKG Finding|STEMI|STEMI	A myocardial infarction that produces elevation in the ST segments of the ECG.			Finding	CDISC SDTM Acute Coronary Syndrome Presentation Category Terminology|CDISC SDTM Coronary Artery Disease Presentation Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101889>	C129821	EphA2-targeting DOPC-encapsulated siRNA|siRNA-EphA2-DOPC	A liposomal formulation consisting of short-interfering RNAs (siRNAs) directed against ephrin type-A receptor 2 (EphA2) and encapsulated into 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) neutral liposomes, with potential antineoplastic activity. Upon internalization, EphA2-targeting DOPC-encapsulated siRNA can hybridize to EphA2 DNA and mRNA, thereby interfering with both the transcription and translation of EphA2, and thus inhibiting tumor cell growth. The cell-surface receptor EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) involved in mammalian development, is overexpressed by a variety of different cancer cell types and plays an important role in tumor growth.	EphA2-targeting DOPC-encapsulated siRNA		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C10188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10188>	C61063	Bleomycin/Doxorubicin/Vincristine|ABV|BLEO/DOX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101890>	C26170	Epidermal Growth Factor Ointment|EGF Ointment|Sesal Yeongo	A topical ointment containing a recombinant form of human epidermal growth factor (EGF) with potential protective activity against EGF receptor (EGFR/HER1) inhibitor-induced cutaneous toxicities. Upon topical application of the EGF ointment, EGF locally activates EGFR, thereby abrogating EGFR inhibition in the skin caused by systemic EGFR inhibiting agents. This may help inhibit the skin rash induced by EGFR antagonists. EGFR, a tyrosine kinase, plays a key role in maintaining epidermal integrity.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C101891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101891>	C1983|C154231	Allogeneic GM-CSF-secreting Tumor Vaccine PANC 6.03 pcDNA-1/GM-Neo|PANC 6.03 pcDNA-1/GM-Neo	An allogeneic cancer vaccine composed of lethally irradiated, whole pancreatic cancer cells transfected with a plasmid carrying the gene for cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Allogeneic GM-CSF-secreting tumor vaccine PANC 6.03 pcDNA-1/GM-Neo secretes GM-CSF thereby activating dendritic cells, promoting antigen presentation to B- and T-cells, and promoting a cytotoxic T-lymphocyte (CTL) response. This may eventually kill tumor cells. The pancreatic tumor cells are derived from the PANC 6.03 tumor cell line.			Cell|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101892>	C1983|C154231	Allogeneic GM-CSF-secreting Tumor Vaccine PANC 10.05 pcDNA-1/GM-Neo|PANC 10.05 pcDNA-1/GM-Neo	An allogeneic cancer vaccine composed of lethally irradiated, whole pancreatic cancer cells transfected with a plasmid carrying the gene for cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Allogeneic GM-CSF-secreting tumor vaccine PANC 10.05 pcDNA-1/GM-Neo secretes GM-CSF thereby activating dendritic cells, promoting antigen presentation to B- and T-cells, and promoting a cytotoxic T-lymphocyte (CTL) response. This may eventually kill tumor cells. The pancreatic tumor cells are derived from the PANC 10.05 tumor cell line.			Cell|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101893>	C1752	HLA-A*2402-Restricted Multipeptide Vaccine S-488410|S-488410	A cancer vaccine composed of HLA-*2402-restricted epitopic peptides derived from three cancer/testis (CT) antigens, with potential antineoplastic activity. Upon subcutaneous administration, HLA-A*2402-restricted multipeptide vaccine S-488410 may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing these CT antigens. CT antigens, normally expressed only in germ cells of the testis, are overexpressed in a wide variety of human cancers.			Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101894>	C67439|C443	Poly-alendronate Dextran-Guanidine Conjugate|Dextran/Alendronate/Guanidine-containing Polybisphosphonate|ODX|Osteodex	A polybisphosphonate dextran-guanidine conjugate with potential anti-resorptive and antineoplastic activities. Alendronic acid and aminoguanidine were conjugated sequentially to oxidized dextran resulting in an average of 8 alendronate and 50 guanidine groups coupled to the dextran backbone. Upon administration, the poly-alendronate dextran-guanidine conjugate inhibits the mevalonate pathway by inhibiting farnesyl diphosphate synthase (FDPS) which leads to a reduction in protein prenylation and to the loss of downstream metabolites essential for osteoclast function. This eventually leads to the induction of apoptosis in osteoclasts. Also, by preventing osteoclast-mediated bone resorption, this agent decreases bone turnover and stabilizes the bone matrix. The guanidine moiety increases the nitrogen content and possibly the activity of the bisphosphonate and its ability to inhibit FDPS. In addition, the guanidine moiety facilitates cell internalization and may contribute to this agent's cytotoxicity.			Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101895>	C199386	Elgemtumab|ELGEMTUMAB|LJM-716|LJM716	A human monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3) with potential antineoplastic activity. Elgemtumab binds to and locks HER3 in the inactive conformation and does not interfere with its interaction with neuregulin (NRG). The inactivated form of HER3 blocks the PI3K/Akt signaling pathway, thereby inhibiting cellular proliferation in HER2 or NRG expressing tumor cells. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors; it has no active kinase domain but is activated through heterodimerization with other members of the EGFR receptor family, such as HER2.	Elgemtumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C101896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101896>	C101870	ADNI AVLT - List A Recall 1 Word 1|AVL01-List A Recall 1 Word 1|AVL01-List A Recall 1 Word 1|AVL01001	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 1, Word 1.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101897>	C101870	ADNI AVLT - List A Recall 1 Word 2|AVL01-List A Recall 1 Word 2|AVL01-List A Recall 1 Word 2|AVL01002	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 1, Word 2.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101898>	C101870	ADNI AVLT - List A Recall 1 Word 3|AVL01-List A Recall 1 Word 3|AVL01-List A Recall 1 Word 3|AVL01003	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 1, Word 3.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101899>	C101870	ADNI AVLT - List A Recall 1 Word 4|AVL01-List A Recall 1 Word 4|AVL01-List A Recall 1 Word 4|AVL01004	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 1, Word 4.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10189>	C61007	Methotrexate/Vinblastine|MTX/VBL|MV			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1018>	C2139	Klebsiella pneumoniae Glycoprotein|Biostim|RU 41.740|RU- 41740	A glycoprotein complex extracted from Klebsiella pneumoniae K2O1 strain with immunostimulating property. This glycoprotein complex consists of 2 repetitive glycoprotein subunits; P1 comes from the bacterial capsule about 95 kD in molecular mass and F1, having an lipopolysaccharide-related structure (350 kDa), is derived from bacterial external membrane. Although the mechanism of action is not fully elucidated, Klebsiella pneumoniae F1 fraction appears to suppress monocyte apoptosis, hence inducing the differentiation of monocytes into macrophages. Furthermore, this agent also enhances humoral and cell-mediated immune responses, and increases natural killer cell cytotoxicity functions. This glycoprotein has been shown to reduce the incidence of infection.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	NCI Drug Dictionary Terminology
C101900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101900>	C101870	ADNI AVLT - List A Recall 1 Word 5|AVL01-List A Recall 1 Word 5|AVL01-List A Recall 1 Word 5|AVL01005	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 1, Word 5.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101901>	C101870	ADNI AVLT - List A Recall 1 Word 6|AVL01-List A Recall 1 Word 6|AVL01-List A Recall 1 Word 6|AVL01006	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 1, Word 6.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101902>	C101870	ADNI AVLT - List A Recall 1 Word 7|AVL01-List A Recall 1 Word 7|AVL01-List A Recall 1 Word 7|AVL01007	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 1, Word 7.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101903>	C101870	ADNI AVLT - List A Recall 1 Word 8|AVL01-List A Recall 1 Word 8|AVL01-List A Recall 1 Word 8|AVL01008	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 1, Word 8.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101904>	C101870	ADNI AVLT - List A Recall 1 Word 9|AVL01-List A Recall 1 Word 9|AVL01-List A Recall 1 Word 9|AVL01009	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 1, Word 9.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101905>	C101870	ADNI AVLT - List A Recall 1 Word 10|AVL01-List A Recall 1 Word 10|AVL01-List A Recall 1 Word 10|AVL01010	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 1, Word 10.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101906>	C101870	ADNI AVLT - List A Recall 1 Word 11|AVL01-List A Recall 1 Word 11|AVL01-List A Recall 1 Word 11|AVL01011	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 1, Word 11.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101907>	C101870	ADNI AVLT - List A Recall 1 Word 12|AVL01-List A Recall 1 Word 12|AVL01-List A Recall 1 Word 12|AVL01012	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 1, Word 12.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101908>	C101870	ADNI AVLT - List A Recall 1 Word 13|AVL01-List A Recall 1 Word 13|AVL01-List A Recall 1 Word 13|AVL01013	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 1, Word 13.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101909>	C101870	ADNI AVLT - List A Recall 1 Word 14|AVL01-List A Recall 1 Word 14|AVL01-List A Recall 1 Word 14|AVL01014	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 1, Word 14.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10190>	C61063	Cyclophosphamide/Lomustine/Melphalan/Prednisolone/Vincristine|CCNU/CTX/L-PAM/PRDL/VCR|CCVMP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101910>	C101870	ADNI AVLT - List A Recall 1 Word 15|AVL01-List A Recall 1 Word 15|AVL01-List A Recall 1 Word 15|AVL01015	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 1, Word 15.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101911>	C101870	ADNI AVLT - List A Recall 1 Total|AVL01-List A Recall 1 Total|AVL01-List A Recall 1 Total|AVL01016	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of words recalled from List A, first attempt.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101912>	C101870	ADNI AVLT - List A Intrusions 1|AVL01-List A Intrusions 1|AVL01-List A Intrusions 1|AVL01017	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of intrusions while recalling List A, first attempt.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101913>	C101870	ADNI AVLT - List A Recall 2 Word 1|AVL01-List A Recall 2 Word 1|AVL01-List A Recall 2 Word 1|AVL01018	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 2, Word 1.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101914>	C101870	ADNI AVLT - List A Recall 2 Word 2|AVL01-List A Recall 2 Word 2|AVL01-List A Recall 2 Word 2|AVL01019	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 2, Word 2.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101915>	C101870	ADNI AVLT - List A Recall 2 Word 3|AVL01-List A Recall 2 Word 3|AVL01-List A Recall 2 Word 3|AVL01020	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 2, Word 3.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101916>	C101870	ADNI AVLT - List A Recall 2 Word 4|AVL01-List A Recall 2 Word 4|AVL01-List A Recall 2 Word 4|AVL01021	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 2, Word 4.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101917>	C101870	ADNI AVLT - List A Recall 2 Word 5|AVL01-List A Recall 2 Word 5|AVL01-List A Recall 2 Word 5|AVL01022	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 2, Word 5.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101918>	C101870	ADNI AVLT - List A Recall 2 Word 6|AVL01-List A Recall 2 Word 6|AVL01-List A Recall 2 Word 6|AVL01023	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 2, Word 6.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101919>	C101870	ADNI AVLT - List A Recall 2 Word 7|AVL01-List A Recall 2 Word 7|AVL01-List A Recall 2 Word 7|AVL01024	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 2, Word 7.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10191>	C61007	Carboplatin/Vincristine|CBDCA/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101920>	C101870	ADNI AVLT - List A Recall 2 Word 8|AVL01-List A Recall 2 Word 8|AVL01-List A Recall 2 Word 8|AVL01025	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 2, Word 8.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101921>	C101870	ADNI AVLT - List A Recall 2 Word 9|AVL01-List A Recall 2 Word 9|AVL01-List A Recall 2 Word 9|AVL01026	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 2, Word 9.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101922>	C101870	ADNI AVLT - List A Recall 2 Word 10|AVL01-List A Recall 2 Word 10|AVL01-List A Recall 2 Word 10|AVL01027	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 2, Word 10.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101923>	C101870	ADNI AVLT - List A Recall 2 Word 11|AVL01-List A Recall 2 Word 11|AVL01-List A Recall 2 Word 11|AVL01028	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 2, Word 11.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101924>	C101870	ADNI AVLT - List A Recall 2 Word 12|AVL01-List A Recall 2 Word 12|AVL01-List A Recall 2 Word 12|AVL01029	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 2, Word 12.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101925>	C101870	ADNI AVLT - List A Recall 2 Word 13|AVL01-List A Recall 2 Word 13|AVL01-List A Recall 2 Word 13|AVL01030	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 2, Word 13.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101926>	C101870	ADNI AVLT - List A Recall 2 Word 14|AVL01-List A Recall 2 Word 14|AVL01-List A Recall 2 Word 14|AVL01031	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 2, Word 14.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101927>	C101870	ADNI AVLT - List A Recall 2 Word 15|AVL01-List A Recall 2 Word 15|AVL01-List A Recall 2 Word 15|AVL01032	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 2, Word 15.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101928>	C101870	ADNI AVLT - List A Recall 2 Total|AVL01-List A Recall 2 Total|AVL01-List A Recall 2 Total|AVL01033	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of words recalled from List A, second attempt.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101929>	C101870	ADNI AVLT - List A Intrusions 2|AVL01-List A Intrusions 2|AVL01-List A Intrusions 2|AVL01034	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of intrusions while recalling List A, second attempt.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10192>	C61007	Carboplatin/Ifosfamide|CBDCA/IFF|IMP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101930>	C101870	ADNI AVLT - List A Recall 3 Word 1|AVL01-List A Recall 3 Word 1|AVL01-List A Recall 3 Word 1|AVL01035	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 3, Word 1.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101931>	C101870	ADNI AVLT - List A Recall 3 Word 2|AVL01-List A Recall 3 Word 2|AVL01-List A Recall 3 Word 2|AVL01036	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 3, Word 2.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101932>	C101870	ADNI AVLT - List A Recall 3 Word 3|AVL01-List A Recall 3 Word 3|AVL01-List A Recall 3 Word 3|AVL01037	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 3, Word 3.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101933>	C101870	ADNI AVLT - List A Recall 3 Word 4|AVL01-List A Recall 3 Word 4|AVL01-List A Recall 3 Word 4|AVL01038	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 3, Word 4.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101934>	C101870	ADNI AVLT - List A Recall 3 Word 5|AVL01-List A Recall 3 Word 5|AVL01-List A Recall 3 Word 5|AVL01039	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 3, Word 5.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101935>	C101870	ADNI AVLT - List A Recall 3 Word 6|AVL01-List A Recall 3 Word 6|AVL01-List A Recall 3 Word 6|AVL01040	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 3, Word 6.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101936>	C101870	ADNI AVLT - List A Recall 3 Word 7|AVL01-List A Recall 3 Word 7|AVL01-List A Recall 3 Word 7|AVL01041	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 3, Word 7.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101937>	C101870	ADNI AVLT - List A Recall 3 Word 8|AVL01-List A Recall 3 Word 8|AVL01-List A Recall 3 Word 8|AVL01042	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 3, Word 8.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101938>	C101870	ADNI AVLT - List A Recall 3 Word 9|AVL01-List A Recall 3 Word 9|AVL01-List A Recall 3 Word 9|AVL01043	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 3, Word 9.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101939>	C101870	ADNI AVLT - List A Recall 3 Word 10|AVL01-List A Recall 3 Word 10|AVL01-List A Recall 3 Word 10|AVL01044	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 3, Word 10.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10193>	C61063	Cyclophosphamide/Etoposide/Methotrexate/Prednisone/Vincristine|CTX/MTX/PRED/VCR/VP-16|MOPLEC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101940>	C101870	ADNI AVLT - List A Recall 3 Word 11|AVL01-List A Recall 3 Word 11|AVL01-List A Recall 3 Word 11|AVL01045	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 3, Word 11.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101941>	C101870	ADNI AVLT - List A Recall 3 Word 12|AVL01-List A Recall 3 Word 12|AVL01-List A Recall 3 Word 12|AVL01046	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 3, Word 12.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101942>	C101870	ADNI AVLT - List A Recall 3 Word 13|AVL01-List A Recall 3 Word 13|AVL01-List A Recall 3 Word 13|AVL01047	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 3, Word 13.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101943>	C101870	ADNI AVLT - List A Recall 3 Word 14|AVL01-List A Recall 3 Word 14|AVL01-List A Recall 3 Word 14|AVL01048	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 3, Word 14.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101944>	C101870	ADNI AVLT - List A Recall 3 Word 15|AVL01-List A Recall 3 Word 15|AVL01-List A Recall 3 Word 15|AVL01049	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 3, Word 15.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101945>	C101870	ADNI AVLT - List A Recall 3 Total|AVL01-List A Recall 3 Total|AVL01-List A Recall 3 Total|AVL01050	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of words recalled from List A, third attempt.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101946>	C101870	ADNI AVLT - List A Intrusions 3|AVL01-List A Intrusions 3|AVL01-List A Intrusions 3|AVL01051	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of intrusions while recalling List A, third attempt.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101947>	C101870	ADNI AVLT - List A Recall 4 Word 1|AVL01-List A Recall 4 Word 1|AVL01-List A Recall 4 Word 1|AVL01052	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 4, Word 1.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101948>	C101870	ADNI AVLT - List A Recall 4 Word 2|AVL01-List A Recall 4 Word 2|AVL01-List A Recall 4 Word 2|AVL01053	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 4, Word 2.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101949>	C101870	ADNI AVLT - List A Recall 4 Word 3|AVL01-List A Recall 4 Word 3|AVL01-List A Recall 4 Word 3|AVL01054	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 4, Word 3.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10194>	C61063	Bleomycin/Mitomycin/Vindesine|BEM|BLEO/DAVA/MITO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101950>	C101870	ADNI AVLT - List A Recall 4 Word 4|AVL01-List A Recall 4 Word 4|AVL01-List A Recall 4 Word 4|AVL01055	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 4, Word 4.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101951>	C101870	ADNI AVLT - List A Recall 4 Word 5|AVL01-List A Recall 4 Word 5|AVL01-List A Recall 4 Word 5|AVL01056	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 4, Word 5.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101952>	C101870	ADNI AVLT - List A Recall 4 Word 6|AVL01-List A Recall 4 Word 6|AVL01-List A Recall 4 Word 6|AVL01057	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 4, Word 6.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101953>	C101870	ADNI AVLT - List A Recall 4 Word 7|AVL01-List A Recall 4 Word 7|AVL01-List A Recall 4 Word 7|AVL01058	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 4, Word 7.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101954>	C101870	ADNI AVLT - List A Recall 4 Word 8|AVL01-List A Recall 4 Word 8|AVL01-List A Recall 4 Word 8|AVL01059	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 4, Word 8.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101955>	C101870	ADNI AVLT - List A Recall 4 Word 9|AVL01-List A Recall 4 Word 9|AVL01-List A Recall 4 Word 9|AVL01060	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 4, Word 9.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101956>	C101870	ADNI AVLT - List A Recall 4 Word 10|AVL01-List A Recall 4 Word 10|AVL01-List A Recall 4 Word 10|AVL01061	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 4, Word 10.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101957>	C101870	ADNI AVLT - List A Recall 4 Word 11|AVL01-List A Recall 4 Word 11|AVL01-List A Recall 4 Word 11|AVL01062	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 4, Word 11.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101958>	C101870	ADNI AVLT - List A Recall 4 Word 12|AVL01-List A Recall 4 Word 12|AVL01-List A Recall 4 Word 12|AVL01063	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 4, Word 12.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101959>	C101870	ADNI AVLT - List A Recall 4 Word 13|AVL01-List A Recall 4 Word 13|AVL01-List A Recall 4 Word 13|AVL01064	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 4, Word 13.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10195>	C61007	Dacarbazine/Doxorubicin/Ifosfamide|DOX/DTIC/IFF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101960>	C101870	ADNI AVLT - List A Recall 4 Word 14|AVL01-List A Recall 4 Word 14|AVL01-List A Recall 4 Word 14|AVL01065	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 4, Word 14.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101961>	C101870	ADNI AVLT - List A Recall 4 Word 15|AVL01-List A Recall 4 Word 15|AVL01-List A Recall 4 Word 15|AVL01066	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 4, Word 15.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101962>	C101870	ADNI AVLT - List A Recall 4 Total|AVL01-List A Recall 4 Total|AVL01-List A Recall 4 Total|AVL01067	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of words recalled from List A, fourth attempt.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101963>	C101870	ADNI AVLT - List A Intrusions 4|AVL01-List A Intrusions 4|AVL01-List A Intrusions 4|AVL01068	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of intrusions while recalling List A, fourth attempt.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101964>	C101870	ADNI AVLT - List A Recall 5 Word 1|AVL01-List A Recall 5 Word 1|AVL01-List A Recall 5 Word 1|AVL01069	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 5, Word 1.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101965>	C101870	ADNI AVLT - List A Recall 5 Word 2|AVL01-List A Recall 5 Word 2|AVL01-List A Recall 5 Word 2|AVL01070	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 5, Word 2.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101966>	C101870	ADNI AVLT - List A Recall 5 Word 3|AVL01-List A Recall 5 Word 3|AVL01-List A Recall 5 Word 3|AVL01071	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 5, Word 3.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101967>	C101870	ADNI AVLT - List A Recall 5 Word 4|AVL01-List A Recall 5 Word 4|AVL01-List A Recall 5 Word 4|AVL01072	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 5, Word 4.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101968>	C101870	ADNI AVLT - List A Recall 5 Word 5|AVL01-List A Recall 5 Word 5|AVL01-List A Recall 5 Word 5|AVL01073	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 5, Word 5.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101969>	C101870	ADNI AVLT - List A Recall 5 Word 6|AVL01-List A Recall 5 Word 6|AVL01-List A Recall 5 Word 6|AVL01074	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 5, Word 6.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10196>	C61063	Cyclophosphamide/Doxorubicin/Etoposide/Interleukin-2|CTX/DOX/IL-2/VP-16|LACE			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101970>	C101870	ADNI AVLT - List A Recall 5 Word 7|AVL01-List A Recall 5 Word 7|AVL01-List A Recall 5 Word 7|AVL01075	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 5, Word 7.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101971>	C101870	ADNI AVLT - List A Recall 5 Word 8|AVL01-List A Recall 5 Word 8|AVL01-List A Recall 5 Word 8|AVL01076	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 5, Word 8.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101972>	C101870	ADNI AVLT - List A Recall 5 Word 9|AVL01-List A Recall 5 Word 9|AVL01-List A Recall 5 Word 9|AVL01077	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 5, Word 9.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101973>	C101870	ADNI AVLT - List A Recall 5 Word 10|AVL01-List A Recall 5 Word 10|AVL01-List A Recall 5 Word 10|AVL01078	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 5, Word 10.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101974>	C101870	ADNI AVLT - List A Recall 5 Word 11|AVL01-List A Recall 5 Word 11|AVL01-List A Recall 5 Word 11|AVL01079	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 5, Word 11.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101975>	C101870	ADNI AVLT - List A Recall 5 Word 12|AVL01-List A Recall 5 Word 12|AVL01-List A Recall 5 Word 12|AVL01080	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 5, Word 12.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101976>	C101870	ADNI AVLT - List A Recall 5 Word 13|AVL01-List A Recall 5 Word 13|AVL01-List A Recall 5 Word 13|AVL01081	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 5, Word 13.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101977>	C101870	ADNI AVLT - List A Recall 5 Word 14|AVL01-List A Recall 5 Word 14|AVL01-List A Recall 5 Word 14|AVL01082	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 5, Word 14.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101978>	C101870	ADNI AVLT - List A Recall 5 Word 15|AVL01-List A Recall 5 Word 15|AVL01-List A Recall 5 Word 15|AVL01083	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 5, Word 15.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101979>	C101870	ADNI AVLT - List A Recall 5 Total|AVL01-List A Recall 5 Total|AVL01-List A Recall 5 Total|AVL01084	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of words recalled from List A, fifth attempt.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10197>	C61063	Floxuridine/Fluorouracil/Leucovorin Calcium|CF/5-FU/FUDR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101980>	C101870	ADNI AVLT - List A Intrusions 5|AVL01-List A Intrusions 5|AVL01-List A Intrusions 5|AVL01085	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of intrusions while recalling List A, fifth attempt.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101981>	C101870	ADNI AVLT - List A Recall 6 (After B) Word 1|AVL01-List A Recall 6 (After B) Word 1|AVL01-List A Recall 6 (After B) Word 1|AVL01086	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 6 (after B Recall), Word 1.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101982>	C101870	ADNI AVLT - List A Recall 6 (After B) Word 2|AVL01-List A Recall 6 (After B) Word 2|AVL01-List A Recall 6 (After B) Word 2|AVL01087	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 6 (after B Recall), Word 2.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101983>	C101870	ADNI AVLT - List A Recall 6 (After B) Word 3|AVL01-List A Recall 6 (After B) Word 3|AVL01-List A Recall 6 (After B) Word 3|AVL01088	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 6 (after B Recall), Word 3.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101984>	C101870	ADNI AVLT - List A Recall 6 (After B) Word 4|AVL01-List A Recall 6 (After B) Word 4|AVL01-List A Recall 6 (After B) Word 4|AVL01089	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 6 (after B Recall), Word 4.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101985>	C101870	ADNI AVLT - List A Recall 6 (After B) Word 5|AVL01-List A Recall 6 (After B) Word 5|AVL01-List A Recall 6 (After B) Word 5|AVL01090	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 6 (after B Recall), Word 5.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101986>	C101870	ADNI AVLT - List A Recall 6 (After B) Word 6|AVL01-List A Recall 6 (After B) Word 6|AVL01-List A Recall 6 (After B) Word 6|AVL01091	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 6 (after B Recall), Word 6.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101987>	C101870	ADNI AVLT - List A Recall 6 (After B) Word 7|AVL01-List A Recall 6 (After B) Word 7|AVL01-List A Recall 6 (After B) Word 7|AVL01092	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 6 (after B Recall), Word 7.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101988>	C101870	ADNI AVLT - List A Recall 6 (After B) Word 8|AVL01-List A Recall 6 (After B) Word 8|AVL01-List A Recall 6 (After B) Word 8|AVL01093	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 6 (after B Recall), Word 8.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101989>	C101870	ADNI AVLT - List A Recall 6 (After B) Word 9|AVL01-List A Recall 6 (After B) Word 9|AVL01-List A Recall 6 (After B) Word 9|AVL01094	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 6 (after B Recall), Word 9.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10198>	C61063	Epirubicin/Prednisone/Vincristine|EOP|EPI/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C101990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101990>	C101870	ADNI AVLT - List A Recall 6 (After B) Word 10|AVL01-List A Recall 6 (After B) Word 10|AVL01-List A Recall 6 (After B) Word 10|AVL01095	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 6 (after B Recall), Word 10.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101991>	C101870	ADNI AVLT - List A Recall 6 (After B) Word 11|AVL01-List A Recall 6 (After B) Word 11|AVL01-List A Recall 6 (After B) Word 11|AVL01096	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 6 (after B Recall), Word 11.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101992>	C101870	ADNI AVLT - List A Recall 6 (After B) Word 12|AVL01-List A Recall 6 (After B) Word 12|AVL01-List A Recall 6 (After B) Word 12|AVL01097	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 6 (after B Recall), Word 12.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101993>	C101870	ADNI AVLT - List A Recall 6 (After B) Word 13|AVL01-List A Recall 6 (After B) Word 13|AVL01-List A Recall 6 (After B) Word 13|AVL01098	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 6 (after B Recall), Word 13.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101994>	C101870	ADNI AVLT - List A Recall 6 (After B) Word 14|AVL01-List A Recall 6 (After B) Word 14|AVL01-List A Recall 6 (After B) Word 14|AVL01099	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 6 (after B Recall), Word 14.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101995>	C101870	ADNI AVLT - List A Recall 6 (After B) Word 15|AVL01-List A Recall 6 (After B) Word 15|AVL01-List A Recall 6 (After B) Word 15|AVL01100	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, Recall 6 (after B Recall), Word 15.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101996>	C101870	ADNI AVLT - List A Recall 6 (After B) Total|AVL01-List A Recall 6 (After B) Total|AVL01-List A Recall 6 (After B) Total|AVL01101	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of words recalled from List A, sixth attempt (after List B recall).			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101997>	C101870	ADNI AVLT - List A Intrusions 6|AVL01-List A Intrusions 6|AVL01-List A Intrusions 6|AVL01102	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of intrusions while recalling List A, sixth attempt (after List B recall).			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101998>	C101870	ADNI AVLT - List B Recall Word 1|AVL01-List B Recall Word 1|AVL01-List B Recall Word 1|AVL01103	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List B, Word 1.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C101999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C101999>	C101870	ADNI AVLT - List B Recall Word 2|AVL01-List B Recall Word 2|AVL01-List B Recall Word 2|AVL01104	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List B, Word 2.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10199>	C61063	Carmustine/Cyclophosphamide/Doxorubicin/Melphalan/Prednisone/Vincristine|BCNU/CTX/DOX/L-PAM/PRED/VCR|VBAPP/VMCPP|VMCPP alternating with VBAPP|VMCPP/VBAPP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1019>	C253	Bisantrene|9,10-Anthracenedicarboxakdehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone]|9,10-Anthracenedicarboxaldehyde Bis(2-imidazolin-2-yl)hydrazone|BISANTRENE	An anthracenyl bishydrazone with antineoplastic activity. Bisantrene intercalates with and disrupts the configuration of DNA, resulting in DNA single-strand breaks, DNA-protein crosslinking, and inhibition of DNA replication.  This agent is similar to doxorubicin in activity, but unlike doxorubicin, does not exhibit cardiotoxicity. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C102000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102000>	C101870	ADNI AVLT - List B Recall Word 3|AVL01-List B Recall Word 3|AVL01-List B Recall Word 3|AVL01105	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List B, Word 3.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102001>	C101870	ADNI AVLT - List B Recall Word 4|AVL01-List B Recall Word 4|AVL01-List B Recall Word 4|AVL01106	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List B, Word 4.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102002>	C101870	ADNI AVLT - List B Recall Word 5|AVL01-List B Recall Word 5|AVL01-List B Recall Word 5|AVL01107	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List B, Word 5.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102003>	C101870	ADNI AVLT - List B Recall Word 6|AVL01-List B Recall Word 6|AVL01-List B Recall Word 6|AVL01108	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List B, Word 6.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102004>	C101870	ADNI AVLT - List B Recall Word 7|AVL01-List B Recall Word 7|AVL01-List B Recall Word 7|AVL01109	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List B, Word 7.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102005>	C101870	ADNI AVLT - List B Recall Word 8|AVL01-List B Recall Word 8|AVL01-List B Recall Word 8|AVL01110	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List B, Word 8.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102006>	C101870	ADNI AVLT - List B Recall Word 9|AVL01-List B Recall Word 9|AVL01-List B Recall Word 9|AVL01111	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List B, Word 9.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102007>	C101870	ADNI AVLT - List B Recall Word 10|AVL01-List B Recall Word 10|AVL01-List B Recall Word 10|AVL01112	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List B, Word 10.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102008>	C101870	ADNI AVLT - List B Recall Word 11|AVL01-List B Recall Word 11|AVL01-List B Recall Word 11|AVL01113	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List B, Word 11.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102009>	C101870	ADNI AVLT - List B Recall Word 12|AVL01-List B Recall Word 12|AVL01-List B Recall Word 12|AVL01114	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List B, Word 12.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10200>	C61007	Bleomycin/Idoxuridine|BLEO/IUDR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102010>	C101870	ADNI AVLT - List B Recall Word 13|AVL01-List B Recall Word 13|AVL01-List B Recall Word 13|AVL01115	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List B, Word 13.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102011>	C101870	ADNI AVLT - List B Recall Word 14|AVL01-List B Recall Word 14|AVL01-List B Recall Word 14|AVL01116	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List B, Word 14.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102012>	C101870	ADNI AVLT - List B Recall Word 15|AVL01-List B Recall Word 15|AVL01-List B Recall Word 15|AVL01117	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List B, Word 15.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102013>	C101870	ADNI AVLT - List B Recall Total|AVL01-List B Recall Total|AVL01-List B Recall Total|AVL01118	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of words recalled from List B.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102014>	C101870	ADNI AVLT - List B Intrusions|AVL01-List B Intrusions|AVL01-List B Intrusions|AVL01119	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of intrusions while recalling List B.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102015>	C101870	ADNI AVLT - List A 30 Min Delay Recall Word 1|AVL01-List A 30 Min Delay Recall Word 1|AVL01-List A 30 Min Delay Recall Word 1|AVL01120	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, 30 Minute Delay Recall, Word 1.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102016>	C101870	ADNI AVLT - List A 30 Min Delay Recall Word 2|AVL01-List A 30 Min Delay Recall Word 2|AVL01-List A 30 Min Delay Recall Word 2|AVL01121	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, 30 Minute Delay Recall, Word 2.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102017>	C101870	ADNI AVLT - List A 30 Min Delay Recall Word 3|AVL01-List A 30 Min Delay Recall Word 3|AVL01-List A 30 Min Delay Recall Word 3|AVL01122	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, 30 Minute Delay Recall, Word 3.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102018>	C101870	ADNI AVLT - List A 30 Min Delay Recall Word 4|AVL01-List A 30 Min Delay Recall Word 4|AVL01-List A 30 Min Delay Recall Word 4|AVL01123	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, 30 Minute Delay Recall, Word 4.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102019>	C101870	ADNI AVLT - List A 30 Min Delay Recall Word 5|AVL01-List A 30 Min Delay Recall Word 5|AVL01-List A 30 Min Delay Recall Word 5|AVL01124	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, 30 Minute Delay Recall, Word 5.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10201>	C63589|C63588|C63442|C63356	Cytarabine/Hydrocortisone/Methotrexate Regimen|ARA-C/HC/MTX|Cytarabine-Hydrocortisone-Methotrexate|Cytarabine/Hydrocortisone/Methotrexate|MHA|TIT	A regimen consisting of cytarabine, hydrocortisone, and methotrexate that may be used in the treatment and prevention of central nervous system (CNS) involvement in leukemias and lymphomas, including acute promyelocytic leukemia (APL), diffuse large B-cell lymphoma (DLBCL), and acute lymphoblastic leukemia (ALL).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C102020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102020>	C101870	ADNI AVLT - List A 30 Min Delay Recall Word 6|AVL01-List A 30 Min Delay Recall Word 6|AVL01-List A 30 Min Delay Recall Word 6|AVL01125	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, 30 Minute Delay Recall, Word 6.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102021>	C101870	ADNI AVLT - List A 30 Min Delay Recall Word 7|AVL01-List A 30 Min Delay Recall Word 7|AVL01-List A 30 Min Delay Recall Word 7|AVL01126	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, 30 Minute Delay Recall, Word 7.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102022>	C101870	ADNI AVLT - List A 30 Min Delay Recall Word 8|AVL01-List A 30 Min Delay Recall Word 8|AVL01-List A 30 Min Delay Recall Word 8|AVL01127	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, 30 Minute Delay Recall, Word 8.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102023>	C101870	ADNI AVLT - List A 30 Min Delay Recall Word 9|AVL01-List A 30 Min Delay Recall Word 9|AVL01-List A 30 Min Delay Recall Word 9|AVL01128	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, 30 Minute Delay Recall, Word 9.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102024>	C101870	ADNI AVLT - List A 30 Min Delay Recall Word 10|AVL01-List A 30 Min Delay Recall Word 10|AVL01-List A 30 Min Delay Recall Word 10|AVL01129	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, 30 Minute Delay Recall, Word 10.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102025>	C101870	ADNI AVLT - List A 30 Min Delay Recall Word 11|AVL01-List A 30 Min Delay Recall Word 11|AVL01-List A 30 Min Delay Recall Word 11|AVL01130	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, 30 Minute Delay Recall, Word 11.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102026>	C101870	ADNI AVLT - List A 30 Min Delay Recall Word 12|AVL01-List A 30 Min Delay Recall Word 12|AVL01-List A 30 Min Delay Recall Word 12|AVL01131	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, 30 Minute Delay Recall, Word 12.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102027>	C101870	ADNI AVLT - List A 30 Min Delay Recall Word 13|AVL01-List A 30 Min Delay Recall Word 13|AVL01-List A 30 Min Delay Recall Word 13|AVL01132	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, 30 Minute Delay Recall, Word 13.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102028>	C101870	ADNI AVLT - List A 30 Min Delay Recall Word 14|AVL01-List A 30 Min Delay Recall Word 14|AVL01-List A 30 Min Delay Recall Word 14|AVL01133	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, 30 Minute Delay Recall, Word 14.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102029>	C101870	ADNI AVLT - List A 30 Min Delay Recall Word 15|AVL01-List A 30 Min Delay Recall Word 15|AVL01-List A 30 Min Delay Recall Word 15|AVL01134	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) List A, 30 Minute Delay Recall, Word 15.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10202>	C61063	Etoposide/Tumor Necrosis Factor|TNF/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102030>	C101870	ADNI AVLT - List A 30 Min Delay Recall Total|AVL01-List A 30 Min Delay Recall Total|AVL01-List A 30 Min Delay Recall Total|AVL01135	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of words recalled from List A, 30 Minute Delay recall.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102031>	C101870	ADNI AVLT - List A 30 Min Delay Intrusions|AVL01-List A 30 Min Delay Intrusions|AVL01-List A 30 Min Delay Intrusions|AVL01136	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of intrusions while recalling List A, 30 Minute Delay.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102032>	C101870	ADNI AVLT - List A Recognition Total|AVL01-List A Recognition Total|AVL01-List A Recognition Total|AVL01137	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of words correct on recognition test.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102033>	C101870	ADNI AVLT - List A Recognition Intrusions|AVL01-List A Recognition Intrusions|AVL01-List A Recognition Intrusions|AVL01138	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Version A (ADNI-AVLT Version A) The number of intrusions on recognition test.			Intellectual Product	CDISC Functional Test ADNI AVLT Test Code Terminology|CDISC Functional Test ADNI AVLT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102034>	C101869	AIMS - Muscles of Facial Expression|AIMS01-Muscles of Facial Expression|AIMS01-Muscles of Facial Expression|AIMS0101	Abnormal Involuntary Movement Scale (AIMS) Facial and Oral Movements, Muscles of facial expression, e.g., movements of forehead, eyebrows, periorbital area, cheeks. Include frowning, blinking, grimacing of upper face.			Intellectual Product	CDISC Clinical Classification AIMS Test Code Terminology|CDISC Clinical Classification AIMS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102035>	C101869	AIMS - Lips and Perioral Area|AIMS01-Lips and Perioral Area|AIMS01-Lips and Perioral Area|AIMS0102	Abnormal Involuntary Movement Scale (AIMS) Facial and Oral Movements, Lips and perioral area, e.g., puckering, pouting, smacking.			Intellectual Product	CDISC Clinical Classification AIMS Test Code Terminology|CDISC Clinical Classification AIMS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102036>	C101869	AIMS - Jaw|AIMS01-Jaw|AIMS01-Jaw|AIMS0103	Abnormal Involuntary Movement Scale (AIMS) Facial and Oral Movements, Jaw, e.g., biting, clenching, chewing, mouth opening, lateral movement.			Intellectual Product	CDISC Clinical Classification AIMS Test Code Terminology|CDISC Clinical Classification AIMS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102037>	C101869	AIMS - Tongue|AIMS01-Tongue|AIMS01-Tongue|AIMS0104	Abnormal Involuntary Movement Scale (AIMS) Facial and Oral Movements, Tongue. Rate only increase in movement both in and out of mouth, not inability to sustain movement.			Intellectual Product	CDISC Clinical Classification AIMS Test Code Terminology|CDISC Clinical Classification AIMS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102038>	C101869	AIMS - Upper Extremities|AIMS01-Upper Extremities|AIMS01-Upper Extremities|AIMS0105	Abnormal Involuntary Movement Scale (AIMS) Extremity Movements, Upper (arms, wrists, hands, fingers). Include movements that are choreic (rapid, objectively purposeless, irregular, spontaneous) or athetoid (slow, irregular, complex, serpentine). Do not include tremor (repetitive, regular, rhythmic movements).			Intellectual Product	CDISC Clinical Classification AIMS Test Code Terminology|CDISC Clinical Classification AIMS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102039>	C101869	AIMS - Lower Extremities|AIMS01-Lower Extremities|AIMS01-Lower Extremities|AIMS0106	Abnormal Involuntary Movement Scale (AIMS) Extremity Movements, Lower (legs, knees, ankles, toes), e.g., lateral knee movement, foot tapping, heel dropping, foot squirming, inversion and eversion of foot.			Intellectual Product	CDISC Clinical Classification AIMS Test Code Terminology|CDISC Clinical Classification AIMS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10203>	C61063	Doxorubicin/Fluorouracil/Leucovorin Calcium/Mitomycin|CF/DOX/5-FU/MITO|FAM-CF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102040>	C101869	AIMS - Neck, Shoulders, Hips|AIMS01-Neck, Shoulders, Hips|AIMS01-Neck, Shoulders, Hips|AIMS0107	Abnormal Involuntary Movement Scale (AIMS) Trunk Movements, Neck, shoulders, hips, e.g., rocking, twisting, squirming, pelvic gyrations. Include diaphragmatic movements.			Intellectual Product	CDISC Clinical Classification AIMS Test Code Terminology|CDISC Clinical Classification AIMS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102041>	C101869	AIMS - Severity of Abnormal Movements|AIMS01-Severity of Abnormal Movements|AIMS01-Severity of Abnormal Movements|AIMS0108	Abnormal Involuntary Movement Scale (AIMS) Global Judgments, Severity of abnormal movements, based on the highest single score on the above items.			Intellectual Product	CDISC Clinical Classification AIMS Test Code Terminology|CDISC Clinical Classification AIMS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102042>	C101869	AIMS - Incapacitation Due to Abnormal Movements|AIMS01-Incapacitation due Abn Movements|AIMS01-Incapacitation due Abn Movements|AIMS0109	Abnormal Involuntary Movement Scale (AIMS) Global Judgments, Incapacitation due to abnormal movements.			Intellectual Product	CDISC Clinical Classification AIMS Test Code Terminology|CDISC Clinical Classification AIMS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102043>	C101869	AIMS - Patient's Awareness of Abnormal Movements|AIMS01-Patient Awareness Abn Movements|AIMS01-Patient Awareness Abn Movements|AIMS0110	Abnormal Involuntary Movement Scale (AIMS) Global Judgments, Patient's awareness of abnormal movements.			Intellectual Product	CDISC Clinical Classification AIMS Test Code Terminology|CDISC Clinical Classification AIMS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102044>	C101869	AIMS - Current Teeth/Dentures Problems|AIMS01-Current Problems Teeth/Dentures|AIMS01-Current Problems Teeth/Dentures|AIMS0111	Abnormal Involuntary Movement Scale (AIMS) Dental Status, Current problems with teeth and/or dentures.			Intellectual Product	CDISC Clinical Classification AIMS Test Code Terminology|CDISC Clinical Classification AIMS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102045>	C101869	AIMS - Patient Usually Wears Dentures|AIMS01-Patient Usually Wear Dentures|AIMS01-Patient Usually Wear Dentures|AIMS0112	Abnormal Involuntary Movement Scale (AIMS) Dental Status, Does patient usually wear dentures?			Intellectual Product	CDISC Clinical Classification AIMS Test Code Terminology|CDISC Clinical Classification AIMS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102046>	C101871	BARS - Objective|BARS01-Objective|BARS01-Objective|BARS0101	Barnes Akathisia Rating Scale (BARS) Objective.			Intellectual Product	CDISC Clinical Classification BARS Test Code Terminology|CDISC Clinical Classification BARS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102047>	C101871	BARS - Subjective, Awareness|BARS01-Subjective, Awareness|BARS01-Subjective, Awareness|BARS0102	Barnes Akathisia Rating Scale (BARS) Subjective, awareness of restlessness.			Intellectual Product	CDISC Clinical Classification BARS Test Code Terminology|CDISC Clinical Classification BARS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102048>	C101871	BARS - Subjective, Distress|BARS01-Subjective, Distress|BARS01-Subjective, Distress|BARS0103	Barnes Akathisia Rating Scale (BARS) Subjective, distress related to restlessness.			Intellectual Product	CDISC Clinical Classification BARS Test Code Terminology|CDISC Clinical Classification BARS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102049>	C101871	BARS - Global Clinical Assessment|BARS01-Global Clinical Assessment|BARS01-Global Clinical Assessment|BARS0104	Barnes Akathisia Rating Scale (BARS) Global clinical assessment of akathisia.			Intellectual Product	CDISC Clinical Classification BARS Test Code Terminology|CDISC Clinical Classification BARS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10204>	C61063	Asparaginase/Doxorubicin/Methotrexate/Prednisone/Vincristine|ASP/DOX/MTX/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102050>	C101872	CDR - Memory|CDR01-Memory|CDR01-Memory|CDR0101	Clinical Dementia Rating (CDR) Memory.			Intellectual Product	CDISC Clinical Classification CDR Test Code Terminology|CDISC Clinical Classification CDR Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102051>	C101872	CDR - Orientation|CDR01-Orientation|CDR01-Orientation|CDR0102	Clinical Dementia Rating (CDR) Orientation.			Intellectual Product	CDISC Clinical Classification CDR Test Code Terminology|CDISC Clinical Classification CDR Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102052>	C101872	CDR - Judgment and Problem Solving|CDR01-Judgment and Problem Solving|CDR01-Judgment and Problem Solving|CDR0103	Clinical Dementia Rating (CDR) Judgment and problem solving.			Intellectual Product	CDISC Clinical Classification CDR Test Code Terminology|CDISC Clinical Classification CDR Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102053>	C101872	CDR - Community Affairs|CDR01-Community Affairs|CDR01-Community Affairs|CDR0104	Clinical Dementia Rating (CDR) Community affairs.			Intellectual Product	CDISC Clinical Classification CDR Test Code Terminology|CDISC Clinical Classification CDR Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102054>	C101872	CDR - Home and Hobbies|CDR01-Home and Hobbies|CDR01-Home and Hobbies|CDR0105	Clinical Dementia Rating (CDR) Home and hobbies.			Intellectual Product	CDISC Clinical Classification CDR Test Code Terminology|CDISC Clinical Classification CDR Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102055>	C101872	CDR - Personal Care|CDR01-Personal Care|CDR01-Personal Care|CDR0106	Clinical Dementia Rating (CDR) Personal care.			Intellectual Product	CDISC Clinical Classification CDR Test Code Terminology|CDISC Clinical Classification CDR Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102056>	C101873	COWS - Resting Pulse Rate|COWS1-Resting Pulse Rate|COWS1-Resting Pulse Rate|COWS101	Clinical Opiate Withdrawal Scale (COWS) Resting pulse rate.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COWS Test Code Terminology|CDISC Questionnaire COWS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102057>	C101873	COWS - Sweating|COWS1-Sweating|COWS1-Sweating|COWS102	Clinical Opiate Withdrawal Scale (COWS) Sweating.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COWS Test Code Terminology|CDISC Questionnaire COWS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102058>	C101873	COWS - Restlessness|COWS1-Restlessness|COWS1-Restlessness|COWS103	Clinical Opiate Withdrawal Scale (COWS) Restlessness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COWS Test Code Terminology|CDISC Questionnaire COWS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102059>	C101873	COWS - Pupil Size|COWS1-Pupil Size|COWS1-Pupil Size|COWS104	Clinical Opiate Withdrawal Scale (COWS) Pupil size.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COWS Test Code Terminology|CDISC Questionnaire COWS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10205>	C61063	Doxorubicin/Fluorouracil/Methotrexate/Sargramostim|DOX/5-FU/GM-CSF/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102060>	C101873	COWS - Bone or Joint Aches|COWS1-Bone or Joint Aches|COWS1-Bone or Joint Aches|COWS105	Clinical Opiate Withdrawal Scale (COWS) Bone or joint aches.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COWS Test Code Terminology|CDISC Questionnaire COWS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102061>	C101873	COWS - Runny Nose or Tearing|COWS1-Runny Nose or Tearing|COWS1-Runny Nose or Tearing|COWS106	Clinical Opiate Withdrawal Scale (COWS) Runny nose or tearing.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COWS Test Code Terminology|CDISC Questionnaire COWS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102062>	C101873	COWS - GI Upset|COWS1-GI Upset|COWS1-GI Upset|COWS107	Clinical Opiate Withdrawal Scale (COWS) GI upset.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COWS Test Code Terminology|CDISC Questionnaire COWS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102063>	C101873	COWS - Tremor|COWS1-Tremor|COWS1-Tremor|COWS108	Clinical Opiate Withdrawal Scale (COWS) Tremor.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COWS Test Code Terminology|CDISC Questionnaire COWS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102064>	C101873	COWS - Yawning|COWS1-Yawning|COWS1-Yawning|COWS109	Clinical Opiate Withdrawal Scale (COWS) Yawning.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COWS Test Code Terminology|CDISC Questionnaire COWS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102065>	C101873	COWS - Anxiety or Irritability|COWS1-Anxiety or Irritability|COWS1-Anxiety or Irritability|COWS110	Clinical Opiate Withdrawal Scale (COWS) Anxiety or irritability.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COWS Test Code Terminology|CDISC Questionnaire COWS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102066>	C101873	COWS - Gooseflesh Skin|COWS1-Gooseflesh Skin|COWS1-Gooseflesh Skin|COWS111	Clinical Opiate Withdrawal Scale (COWS) Gooseflesh skin.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COWS Test Code Terminology|CDISC Questionnaire COWS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102067>	C101875	EQ-5D-5L - Mobility|EQ5D02-Mobility|EQ5D02-Mobility|EQ5D0201	The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Mobility.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EQ-5D-5L Test Code Terminology|CDISC Questionnaire EQ-5D-5L Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102068>	C101875	EQ-5D-5L - Self-Care|EQ5D02-Self-Care|EQ5D02-Self-Care|EQ5D0202	The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Self-care.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EQ-5D-5L Test Code Terminology|CDISC Questionnaire EQ-5D-5L Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102069>	C101875	EQ-5D-5L - Usual Activities|EQ5D02-Usual Activities|EQ5D02-Usual Activities|EQ5D0203	The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Usual activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EQ-5D-5L Test Code Terminology|CDISC Questionnaire EQ-5D-5L Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10206>	C61007	Carboplatin/Cyclophosphamide/Sargramostim/Thiotepa|CBDCA/CTX/GM-CSF/TSPA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102070>	C101875	EQ-5D-5L - Pain or Discomfort|EQ5D02-Pain/Discomfort|EQ5D02-Pain/Discomfort|EQ5D0204	The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Pain or discomfort.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EQ-5D-5L Test Code Terminology|CDISC Questionnaire EQ-5D-5L Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102071>	C101875	EQ-5D-5L - Anxiety or Depression|EQ5D02-Anxiety/Depression|EQ5D02-Anxiety/Depression|EQ5D0205	The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Check the one box that best describes your health today: Anxiety or depression.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EQ-5D-5L Test Code Terminology|CDISC Questionnaire EQ-5D-5L Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102072>	C101875	EQ-5D-5L - EQ VAS Score|EQ5D02-EQ VAS Score|EQ5D02-EQ VAS Score|EQ5D0206	The EuroQol (European Quality of Life) Five Dimension Five Level Scale (EQ-5D-5L) Mark an X on the scale to indicate how your health is today and write the number you marked on the scale in the box below.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EQ-5D-5L Test Code Terminology|CDISC Questionnaire EQ-5D-5L Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102073>	C101876	HAMA - Anxious Mood|HAMA1-Anxious Mood|HAMA1-Anxious Mood|HAMA101	Hamilton Anxiety Rating Scale (HAMA) Anxious mood; worries, anticipation of the worst, fearful anticipation, irritability.			Intellectual Product	CDISC Clinical Classification HAMA Test Code Terminology|CDISC Clinical Classification HAMA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102074>	C101876	HAMA - Tension|HAMA1-Tension|HAMA1-Tension|HAMA102	Hamilton Anxiety Rating Scale (HAMA) Tension; feelings of tension, fatigability, startle response, moved to tears easily, trembling, feelings of restlessness, inability to relax.			Intellectual Product	CDISC Clinical Classification HAMA Test Code Terminology|CDISC Clinical Classification HAMA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102075>	C101876	HAMA - Fears|HAMA1-Fears|HAMA1-Fears|HAMA103	Hamilton Anxiety Rating Scale (HAMA) Fears; of dark, of strangers, of being left alone, of animals, of traffic, of crowds.			Intellectual Product	CDISC Clinical Classification HAMA Test Code Terminology|CDISC Clinical Classification HAMA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102076>	C101876	HAMA - Insomnia|HAMA1-Insomnia|HAMA1-Insomnia|HAMA104	Hamilton Anxiety Rating Scale (HAMA) Insomnia; difficulty falling asleep, broken sleep, unsatisfying sleep and fatigue on waking, dreams, nightmares, night terrors.			Intellectual Product	CDISC Clinical Classification HAMA Test Code Terminology|CDISC Clinical Classification HAMA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102077>	C101876	HAMA - Intellectual|HAMA1-Intellectual|HAMA1-Intellectual|HAMA105	Hamilton Anxiety Rating Scale (HAMA) Intellectual; difficulty in concentration, poor memory.			Intellectual Product	CDISC Clinical Classification HAMA Test Code Terminology|CDISC Clinical Classification HAMA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102078>	C101876	HAMA - Depressed Mood|HAMA1-Depressed Mood|HAMA1-Depressed Mood|HAMA106	Hamilton Anxiety Rating Scale (HAMA) Depressed mood; loss of interest, lack of pleasure in hobbies, depression, early waking, diurnal swing.			Intellectual Product	CDISC Clinical Classification HAMA Test Code Terminology|CDISC Clinical Classification HAMA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102079>	C101876	HAMA - Somatic (Muscular)|HAMA1-Somatic (Muscular)|HAMA1-Somatic (Muscular)|HAMA107	Hamilton Anxiety Rating Scale (HAMA) Somatic (muscular); pains and aches, twitching, stiffness, myoclonic jerks, grinding of teeth, unsteady voice, increased muscular tone.			Intellectual Product	CDISC Clinical Classification HAMA Test Code Terminology|CDISC Clinical Classification HAMA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10207>	C61063	Asparaginase/Cytarabine/Methotrexate/Vincristine|ARA-C/ASP/MTX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102080>	C101876	HAMA - Somatic (Sensory)|HAMA1-Somatic (Sensory)|HAMA1-Somatic (Sensory)|HAMA108	Hamilton Anxiety Rating Scale (HAMA) Somatic (sensory); tinnitus, blurring of vision, hot and cold flushes, feelings of weakness, pricking sensation.			Intellectual Product	CDISC Clinical Classification HAMA Test Code Terminology|CDISC Clinical Classification HAMA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102081>	C101876	HAMA - Cardiovascular Symptoms|HAMA1-Cardiovascular Symptoms|HAMA1-Cardiovascular Symptoms|HAMA109	Hamilton Anxiety Rating Scale (HAMA) Cardiovascular symptoms; tachycardia, palpitations, pain in chest, throbbing of vessels, fainting feelings, missing beat.			Intellectual Product	CDISC Clinical Classification HAMA Test Code Terminology|CDISC Clinical Classification HAMA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102082>	C101876	HAMA - Respiratory Symptoms|HAMA1-Respiratory Symptoms|HAMA1-Respiratory Symptoms|HAMA110	Hamilton Anxiety Rating Scale (HAMA) Respiratory symptoms; pressure or constriction in chest, choking feelings, sighing, dyspnea.			Intellectual Product	CDISC Clinical Classification HAMA Test Code Terminology|CDISC Clinical Classification HAMA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102083>	C101876	HAMA - Gastrointestinal Symptoms|HAMA1-Gastrointestinal Symptoms|HAMA1-Gastrointestinal Symptoms|HAMA111	Hamilton Anxiety Rating Scale (HAMA) Gastrointestinal symptoms; difficulty swallowing, wind abdominal pain, burning sensations, abdominal fullness, nausea, vomiting, borborygmi, looseness of bowels, loss of weight, constipation.			Intellectual Product	CDISC Clinical Classification HAMA Test Code Terminology|CDISC Clinical Classification HAMA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102084>	C101876	HAMA - Genitourinary Symptoms|HAMA1-Genitourinary Symptoms|HAMA1-Genitourinary Symptoms|HAMA112	Hamilton Anxiety Rating Scale (HAMA) Genitourinary symptoms; frequency of micturition, urgency of micturition, amenorrhea, menorrhagia, development of frigidity, premature ejaculation, loss of libido, impotence.			Intellectual Product	CDISC Clinical Classification HAMA Test Code Terminology|CDISC Clinical Classification HAMA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102085>	C101876	HAMA - Autonomic Symptoms|HAMA1-Autonomic Symptoms|HAMA1-Autonomic Symptoms|HAMA113	Hamilton Anxiety Rating Scale (HAMA) Autonomic symptoms; dry mouth, flushing, pallor, tendency to sweat, giddiness, tension, headache, raising of hair.			Intellectual Product	CDISC Clinical Classification HAMA Test Code Terminology|CDISC Clinical Classification HAMA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102086>	C101876	HAMA - Behavior at Interview|HAMA1-Behavior at Interview|HAMA1-Behavior at Interview|HAMA114	Hamilton Anxiety Rating Scale (HAMA) Behavior at interview; fidgeting, restlessness or pacing, tremor of hands, furrowed brow, strained face, sighing or rapid respiration, facial pallor, swallowing, etc.			Intellectual Product	CDISC Clinical Classification HAMA Test Code Terminology|CDISC Clinical Classification HAMA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102087>	C101877	HAMD-21 - Depressed Mood|HAMD2-Depressed Mood|HAMD2-Depressed Mood|HAMD201	Hamilton Depression Rating Scale 21 Item (HAMD-21) Depressed mood; sadness, hopeless, helpless, worthless.			Intellectual Product	CDISC Clinical Classification HAMD 21 Test Code Terminology|CDISC Clinical Classification HAMD 21 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102088>	C101877	HAMD-21 - Feelings of Guilt|HAMD2-Feelings of Guilt|HAMD2-Feelings of Guilt|HAMD202	Hamilton Depression Rating Scale 21 Item (HAMD-21) Feelings of guilt.			Intellectual Product	CDISC Clinical Classification HAMD 21 Test Code Terminology|CDISC Clinical Classification HAMD 21 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102089>	C101877	HAMD-21 - Suicide|HAMD2-Suicide|HAMD2-Suicide|HAMD203	Hamilton Depression Rating Scale 21 Item (HAMD-21) Suicide.			Intellectual Product	CDISC Clinical Classification HAMD 21 Test Code Terminology|CDISC Clinical Classification HAMD 21 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10208>	C61063	Thiotepa/Vinblastine|TSPA/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102090>	C101877	HAMD-21 - Insomnia Early|HAMD2-Insomnia Early|HAMD2-Insomnia Early|HAMD204	Hamilton Depression Rating Scale 21 Item (HAMD-21) Insomnia early.			Intellectual Product	CDISC Clinical Classification HAMD 21 Test Code Terminology|CDISC Clinical Classification HAMD 21 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102091>	C101877	HAMD-21 - Insomnia Middle|HAMD2-Insomnia Middle|HAMD2-Insomnia Middle|HAMD205	Hamilton Depression Rating Scale 21 Item (HAMD-21) Insomnia middle.			Intellectual Product	CDISC Clinical Classification HAMD 21 Test Code Terminology|CDISC Clinical Classification HAMD 21 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102092>	C101877	HAMD-21 - Insomnia Late|HAMD2-Insomnia Late|HAMD2-Insomnia Late|HAMD206	Hamilton Depression Rating Scale 21 Item (HAMD-21) Insomnia late.			Intellectual Product	CDISC Clinical Classification HAMD 21 Test Code Terminology|CDISC Clinical Classification HAMD 21 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102093>	C101877	HAMD-21 - Work and Activities|HAMD2-Work and Activities|HAMD2-Work and Activities|HAMD207	Hamilton Depression Rating Scale 21 Item (HAMD-21) Work and activities.			Intellectual Product	CDISC Clinical Classification HAMD 21 Test Code Terminology|CDISC Clinical Classification HAMD 21 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102094>	C101877	HAMD-21 - Retardation|HAMD2-Retardation|HAMD2-Retardation|HAMD208	Hamilton Depression Rating Scale 21 Item (HAMD-21) Retardation; psychomotor (slowness of thought and speech, impaired ability to concentrate, decreased motor activity).			Intellectual Product	CDISC Clinical Classification HAMD 21 Test Code Terminology|CDISC Clinical Classification HAMD 21 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102095>	C101877	HAMD-21 - Agitation|HAMD2-Agitation|HAMD2-Agitation|HAMD209	Hamilton Depression Rating Scale 21 Item (HAMD-21) Agitation.			Intellectual Product	CDISC Clinical Classification HAMD 21 Test Code Terminology|CDISC Clinical Classification HAMD 21 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102096>	C101877	HAMD-21 - Anxiety Psychological|HAMD2-Anxiety Psychological|HAMD2-Anxiety Psychological|HAMD210	Hamilton Depression Rating Scale 21 Item (HAMD-21) Anxiety psychological.			Intellectual Product	CDISC Clinical Classification HAMD 21 Test Code Terminology|CDISC Clinical Classification HAMD 21 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102097>	C101877	HAMD-21 - Anxiety Somatic|HAMD2-Anxiety Somatic|HAMD2-Anxiety Somatic|HAMD211	Hamilton Depression Rating Scale 21 Item (HAMD-21) Anxiety somatic; physiological concomitants of anxiety, (i.e., effects of autonomic overactivity, 'butterflies,' indigestion, stomach cramps, belching, diarrhea, palpitations, hyperventilation, paresthesia, sweating, flushing, tremor, headache, urinary frequency).			Intellectual Product	CDISC Clinical Classification HAMD 21 Test Code Terminology|CDISC Clinical Classification HAMD 21 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102098>	C101877	HAMD-21 - Somatic Symptoms Gastro-intestinal|HAMD2-Somatic Symptoms Gastro-intestinal|HAMD2-Somatic Symptoms Gastro-intestinal|HAMD212	Hamilton Depression Rating Scale 21 Item (HAMD-21) Somatic symptoms gastro-intestinal.			Intellectual Product	CDISC Clinical Classification HAMD 21 Test Code Terminology|CDISC Clinical Classification HAMD 21 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102099>	C101877	HAMD-21 - Somatic Symptoms General|HAMD2-Somatic Symptoms General|HAMD2-Somatic Symptoms General|HAMD213	Hamilton Depression Rating Scale 21 Item (HAMD-21) Somatic symptoms general.			Intellectual Product	CDISC Clinical Classification HAMD 21 Test Code Terminology|CDISC Clinical Classification HAMD 21 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10209>	C61063	Amifostine/Cisplatin/Interleukin-2|CDDP/IL-2/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1020>	C266|C2080	Bismuth Subsalicylate|BISMUTH SUBSALICYLATE|Bismuth subsalicylate|Pepto Bismol|Pepto-Bismol	A bismuth salt of salicylic acid.  Little absorbed from the gastrointestinal tract, bismuth subsalicylate exerts a local effect on the gastric mucosa, coating it and protecting it from the corrosive effects of acid and pepsin.  This agent also has local antimicrobial properties. (NCI04)			Inorganic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C102100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102100>	C101877	HAMD-21 - Genital Symptoms|HAMD2-Genital Symptoms|HAMD2-Genital Symptoms|HAMD214	Hamilton Depression Rating Scale 21 Item (HAMD-21) Genital symptoms; symptoms such as loss of libido, impaired sexual performance, menstrual disturbances.			Intellectual Product	CDISC Clinical Classification HAMD 21 Test Code Terminology|CDISC Clinical Classification HAMD 21 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102101>	C101877	HAMD-21 - Hypochondriasis|HAMD2-Hypochondriasis|HAMD2-Hypochondriasis|HAMD215	Hamilton Depression Rating Scale 21 Item (HAMD-21) Hypochondriasis.			Intellectual Product	CDISC Clinical Classification HAMD 21 Test Code Terminology|CDISC Clinical Classification HAMD 21 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102102>	C101877	HAMD-21 - Loss of Weight by History|HAMD2-Loss of Weight by History|HAMD2-Loss of Weight by History|HAMD216A	Hamilton Depression Rating Scale 21 Item (HAMD-21) Loss of weight when rating by history.			Intellectual Product	CDISC Clinical Classification HAMD 21 Test Code Terminology|CDISC Clinical Classification HAMD 21 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102103>	C101877	HAMD-21 - Loss of Weight Measured|HAMD2-Loss of Weight Measured|HAMD2-Loss of Weight Measured|HAMD216B	Hamilton Depression Rating Scale 21 Item (HAMD-21) Loss of weight on weekly ratings by war psychiatrist, when actual weight changes are measured.			Intellectual Product	CDISC Clinical Classification HAMD 21 Test Code Terminology|CDISC Clinical Classification HAMD 21 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102104>	C101877	HAMD-21 - Insight|HAMD2-Insight|HAMD2-Insight|HAMD217	Hamilton Depression Rating Scale 21 Item (HAMD-21) Insight.			Intellectual Product	CDISC Clinical Classification HAMD 21 Test Code Terminology|CDISC Clinical Classification HAMD 21 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102105>	C101877	HAMD-21 - Diurnal Variation|HAMD2-Diurnal Variation|HAMD2-Diurnal Variation|HAMD218A	Hamilton Depression Rating Scale 21 Item (HAMD-21) Diurnal variation.			Intellectual Product	CDISC Clinical Classification HAMD 21 Test Code Terminology|CDISC Clinical Classification HAMD 21 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102106>	C101877	HAMD-21 - Diurnal Variation Severity|HAMD2-Diurnal Variation Severity|HAMD2-Diurnal Variation Severity|HAMD218B	Hamilton Depression Rating Scale 21 Item (HAMD-21) Diurnal variation severity.			Intellectual Product	CDISC Clinical Classification HAMD 21 Test Code Terminology|CDISC Clinical Classification HAMD 21 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102107>	C101877	HAMD-21 - Depersonalization and Derealization|HAMD2-Depersonalization/Derealization|HAMD2-Depersonalization/Derealization|HAMD219	Hamilton Depression Rating Scale 21 Item (HAMD-21) Depersonalization and derealization; such as feelings of unreality, nihilistic ideas.			Intellectual Product	CDISC Clinical Classification HAMD 21 Test Code Terminology|CDISC Clinical Classification HAMD 21 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102108>	C101877	HAMD-21 - Paranoid Symptoms|HAMD2-Paranoid Symptoms|HAMD2-Paranoid Symptoms|HAMD220	Hamilton Depression Rating Scale 21 Item (HAMD-21) Paranoid symptoms.			Intellectual Product	CDISC Clinical Classification HAMD 21 Test Code Terminology|CDISC Clinical Classification HAMD 21 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102109>	C101877	HAMD-21 - Obsessional and Compulsive Symptoms|HAMD2-Obsessional/Compulsive Symptoms|HAMD2-Obsessional/Compulsive Symptoms|HAMD221	Hamilton Depression Rating Scale 21 Item (HAMD-21) Obsessional and compulsive symptoms.			Intellectual Product	CDISC Clinical Classification HAMD 21 Test Code Terminology|CDISC Clinical Classification HAMD 21 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10210>	C61063	Amifostine/Thiotepa|TSPA/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102110>	C101877	HAMD-21 - Total Score|HAMD2-Total Score|HAMD2-Total Score|HAMD222	Hamilton Depression Rating Scale 21 Item (HAMD-21) Total score.			Intellectual Product	CDISC Clinical Classification HAMD 21 Test Code Terminology|CDISC Clinical Classification HAMD 21 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102111>	C118969	Abnormal Involuntary Movement Scale Clinical Classification|AIMS|AIMS|AIMS01	A standardized rating scale developed by William Guy in 1976 which is used to evaluate the severity of tardive dyskinesia in individuals taking neuroleptic agents. This instrument contains 5 sections with a total of 12 items pertaining to facial and oral movements, global judgments, trunk movements, dental status, and extremity movements. Each item is rated on either a 0 to 4 scale with 0 being none and 4 being severe, or as 'yes' or 'no.'			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102112>	C222260	Alzheimer's Disease Neuroimaging Initiative Auditory Verbal Learning Test Functional Test|ADNI-AVLT|AVL01|AVLT	The Alzheimer's Disease Neuroimaging Initiative's (ADNI) version of the Auditory Verbal Learning Test (AVLT Version A). This version is modified from A. Rey in 1964 and is used to evaluate verbal learning and memory abilities in both children and adults. The test format consists of a list of 15 words that the patient recalls during 5 separate trials. A second list with 15 new words is read and the patient must recall the words in one trial. Immediately following this task, the patient must recall the words from the first list; then recall them again 30 minutes later. The total number of words and intrusions is tallied for each trial.			Intellectual Product	CDISC Functional Test Category Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102113>	C118969	Barnes Akathisia Rating Scale Clinical Classification|BARS|BARS|BARS01	A standardized rating scale developed by Thomas R. E. Barnes in 1989 to diagnose akathisia associated with use of antipsychotic agents. This instrument contains objective and subjective sections, as well as a global clinical assessment of akathisia. The first two sections contain a total of 3 items which are rated on a scale of 0 to 3 with 0 being none or normal and 3 being severe. The third section is rated on a 0 to 5 scale with 0 being none and 5 being severe.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102114>	C118969	Clinical Dementia Rating Clinical Classification|CDR|CDR|CDR01	A standardized rating scale developed by John C. Morris in 1997 to evaluate the severity of an individual's cognitive impairment. This instrument contains 6 areas which include memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Each item is rated on a scale from 0 to 3 with 0 being none and 3 being severe.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102115>	C91105	Clinical Opiate Withdrawal Scale Questionnaire|COWS|COWS|COWS1	A standardized rating scale developed by Wesson and Ling in 2003 to evaluate the severity of an individual's opiate withdrawal symptoms. This instrument consists of 11 signs or symptoms which are assessed and rated by a clinician. The severity of each sign or symptom correlates with a numerical value. A total score of 5-12 is 'mild'; 13-24 is 'moderate'; 25-36 is 'moderately severe'; and greater than 36 is 'severe withdrawal.'			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102116>	C118969	Eastern Cooperative Oncology Group Performance Status Clinical Classification|ECOG|ECOG|ECOG1	A standardized classification scale, published by Oken et al. in 1982 for the Eastern Cooperative Oncology Group (ECOG), that utilizes a six point rating scale to assess a patient's functional status.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102117>	C91105	European Quality of Life Five Dimension Five Level Scale Questionnaire|EQ-5D-5L|EQ-5D-5L|EQ-5D-5L|EQ5D02	A standardized rating scale which is used as a measure of health outcome. This instrument is a descriptive system consisting of 5 dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. Each dimension has 5 levels ranging from no problem to extreme problem or incapable, which are assessed by the patient.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102118>	C118969	Hamilton Anxiety Rating Scale Clinical Classification|HAM-A|HAMA|HAMA1	A standardized rating scale developed by M. Hamilton in 1959 which is used to evaluate the severity of an individual's state of neurotic anxiety. This instrument contains 14 questions or types of symptoms associated with anxiety such as fear, mood, insomnia, and somatic symptoms, which is completed during a semi-structured interview. Each symptom is rated on a scale of 0-4 with 0 being none and 4 being the most severe. A score of 0-17 is considered 'mild', while a score of 18-24 is 'mild to moderate' and a score greater than 24 is 'moderate to severe.'			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102119>	C118969	Hamilton Depression Rating Scale 21-Item Clinical Classification|HAMD 21|HAMD-21|HAMD2	A standardized rating scale developed by M. Hamilton in 1960 which is used to evaluate the severity of an individual's depression. This version of the instrument contains all 21 questions or types of symptoms associated with depression such as anxiety, mood, insomnia, and somatic symptoms experienced within the past week and is completed during a semi-structured interview. Each symptom is rated on a scale of 0-2, 0-3, or 0-4 with 0 being absent and 2, 3, or 4 being the most severe.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10211>	C61063	Cyclophosphamide/Mitoxantrone/Prednisone/Vincristine|CNOP|CTX/DHAD/PRED/VCR	A combination of agents containing cyclophosphamide, mitoxantrone, prednisone and vincristine.		Obsolete_Concept	Therapeutic or Preventive Procedure	
C102120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102120>	C20078	Short Form 36 Health Survey Acute, US Version 1.0 Questionnaire|SF36 V1.0 ACUTE|SF36 v1.0 Acute|SF362	A standardized, multipurpose, general health survey developed by John E. Ware and copyrighted by the Medical Outcomes Trust and Quality Metric Inc. in 1988 and 2002, which is used to assess the patient's functional health and overall well-being. This first version contains 36 questions that refer to the patient's symptoms or status within the past week and can be completed by the patient. For each question the patient must choose from five different responses.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102121>	C20078	Short Form 36 Health Survey Acute, US Version 2.0 Questionnaire|SF36 V2.0 ACUTE|SF36 v2.0 Acute|SF364	A standardized, multipurpose, general health survey developed by John E. Ware and copyrighted by Quality Metric Inc. and the Medical Outcomes Trust in 1996 and 2000, which is used to assess the patient's functional health and overall well-being. This second version contains 36 questions that refer to the patient's symptoms or status within the past week and can be completed by the patient. For each question the patient must choose from five different responses.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102122>	C20078	Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire|Medical Outcomes Survey 36-Item Short-Form Health Survey|SF36 V2.0 STANDARD|SF36 v2.0 Standard|SF363|Short Form 36 Health Survey	A standardized, multipurpose, general health survey developed by John E. Ware and copyrighted by Quality Metric Inc. and the Medical Outcomes Trust in 1996 and 2000 which is used to assess the patient's functional health and overall well-being. This second version contains 36 questions that refer to the patient's symptoms or status within the past four weeks and can be completed by the patient. For each question the patient must choose from five different responses.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102123>	C91105	Subjective Opiate Withdrawal Scale Questionnaire|SOWS SUBJECTIVE|SOWS Subjective|SOWSA1	A standardized rating scale developed by Leonard Handelsman and colleagues in 1987 to evaluate the severity of an individual's opiate withdrawal signs and symptoms. This instrument contains 16 items or symptoms that pertain to opiate withdrawal, which are completed by the individual. Each item is rated on a scale of 0 to 4 with 0 being not at all and 4 being extremely.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102124>	C118969	Young Mania Rating Scale Clinical Classification|YMRS|YMRS|YMRS01	A standardized rating scale developed by R. C. Young and colleagues in 1978 to assess the severity of an individual's mania. This instrument contains 11 items or symptoms associated with mania which is administered by a clinician. Each item has 5 response options but the weight of each response differs with each item.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102125>	C101878	SF-36 v1.0 Acute - In General You Say Your Health Is|SF362-In General You Say Your Health Is|SF362-In General You Say Your Health Is|SF36201	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) In general, would you say your health is.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102126>	C101878	SF-36 v1.0 Acute - Comp Week Ago Rate Gen Health Now|SF362-Comp Week Ago Rate Gen Health Now|SF362-Comp Week Ago Rate Gen Health Now|SF36202	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) Compared to one week ago, how would you rate your health in general now?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102127>	C101878	SF-36 v1.0 Acute - Limit Vigorous Activities|SF362-Limit Vigorous Activities|SF362-Limit Vigorous Activities|SF36203A	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) How much does your health now limit you in - vigorous activities, such as running, lifting heavy objects, participating in strenuous sports.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102128>	C101878	SF-36 v1.0 Acute - Limit Moderate Activities|SF362-Limit Moderate Activities|SF362-Limit Moderate Activities|SF36203B	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) How much does your health now limit you in - moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or playing golf.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102129>	C101878	SF-36 v1.0 Acute - Limit Lifting or Carrying|SF362-Limit Lifting or Carrying|SF362-Limit Lifting or Carrying|SF36203C	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) How much does your health now limit you in - lifting or carrying groceries.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10212>	C61063	Cyclophosphamide/Doxorubicin/Fluorouracil/Fluoxymesterone/Thiotepa/Vinblastine|CAF/TsAVbH|CTX/DOX/5-FU/FXM/TSPA/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102130>	C101878	SF-36 v1.0 Acute - Limit Climbing Several Flights|SF362-Limit Climbing Several Flights|SF362-Limit Climbing Several Flights|SF36203D	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) How much does your health now limit you in - climbing several flights of stairs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102131>	C101878	SF-36 v1.0 Acute - Limit Climbing One Flight Stairs|SF362-Limit Climbing One Flight Stairs|SF362-Limit Climbing One Flight Stairs|SF36203E	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) How much does your health now limit you in - climbing one flight of stairs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102132>	C101878	SF-36 v1.0 Acute - Limit Bending/Kneeling/Stooping|SF362-Limit Bending/Kneeling/Stooping|SF362-Limit Bending/Kneeling/Stooping|SF36203F	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) How much does your health now limit you in - bending, kneeling, or stooping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102133>	C101878	SF-36 v1.0 Acute - Limit Walking More Than a Mile|SF362-Limit Walking More Than a Mile|SF362-Limit Walking More Than a Mile|SF36203G	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) How much does your health now limit you in - walking more than a mile.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102134>	C101878	SF-36 v1.0 Acute - Limit Walking Several Blocks|SF362-Limit Walking Several Blocks|SF362-Limit Walking Several Blocks|SF36203H	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) How much does your health now limit you in - walking several blocks.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102135>	C101878	SF-36 v1.0 Acute - Limit Walking One Block|SF362-Limit Walking One Block|SF362-Limit Walking One Block|SF36203I	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) How much does your health now limit you in - walking one block.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102136>	C101878	SF-36 v1.0 Acute - Limit Bathing or Dressing Yourself|SF362-Limit Bathing or Dressing Yourself|SF362-Limit Bathing or Dressing Yourself|SF36203J	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) How much does your health now limit you in - bathing or dressing yourself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102137>	C101878	SF-36 v1.0 Acute - Physical: Cut Down Time on Work|SF362-Physical: Cut Down Time on Work|SF362-Physical: Cut Down Time on Work|SF36204A	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) The Short Form 36 Health Survey Acute, US Version 1.0 (SF36 V1.0 ACUTE) -During the past week, have you had any of the following problems with your work or other regular daily activities as a result of your physical health - cut down on the amount of time you spent on work or other activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102138>	C101878	SF-36 v1.0 Acute - Physical: Accomplished Less|SF362-Physical: Accomplished Less|SF362-Physical: Accomplished Less|SF36204B	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) During the past week, have you had any of the following problems with your work or other regular daily activities as a result of your physical health - accomplished less than you would like.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102139>	C101878	SF-36 v1.0 Acute - Physical: Limited Kind of Work|SF362-Physical: Limited Kind of Work|SF362-Physical: Limited Kind of Work|SF36204C	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) During the past week, have you had any of the following problems with your work or other regular daily activities as a result of your physical health - were limited in the kind of work or other activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10213>	C61007	Asparaginase/Cyclophosphamide/Cytarabine/Methotrexate/Vincristine|ARA-C/ASP/CTX/MTX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102140>	C101878	SF-36 v1.0 Acute - Physical: Difficulty Perform Work|SF362-Physical: Difficulty Perform Work|SF362-Physical: Difficulty Perform Work|SF36204D	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) During the past week, have you had any of the following problems with your work or other regular daily activities as a result of your physical health - had difficulty performing the work or other activities (for example, it took extra effort).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102141>	C101878	SF-36 v1.0 Acute - Emotional: Cut Down Time on Work|SF362-Emotional: Cut Down Time on Work|SF362-Emotional: Cut Down Time on Work|SF36205A	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) During the past week, have you had any of the following problems with your work or other regular daily activities as a result of any emotional problems (such as feeling depressed or anxious) - cut down on the amount of time you spent on work or other activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102142>	C101878	SF-36 v1.0 Acute - Emotional: Accomplished Less|SF362-Emotional: Accomplished Less|SF362-Emotional: Accomplished Less|SF36205B	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) During the past week, have you had any of the following problems with your work or other regular daily activities as a result of any emotional problems (such as feeling depressed or anxious) - accomplished less than you would like.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102143>	C101878	SF-36 v1.0 Acute - Emotional: Did Work Less Carefully|SF362-Emotional: Did Work Less Carefully|SF362-Emotional: Did Work Less Carefully|SF36205C	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) During the past week, have you had any of the following problems with your work or other regular daily activities as a result of any emotional problems (such as feeling depressed or anxious) - did work or other activities less carefully than usual.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102144>	C101878	SF-36 v1.0 Acute - Extent Phys/Emotional Interfered|SF362-Extent Phys/Emotional Interfered|SF362-Extent Phys/Emotional Interfered|SF36206	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) During the past week, to what extent has your physical health or emotional problems interfered with your normal social activities with family, friends, neighbors, or groups?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102145>	C101878	SF-36 v1.0 Acute - How Much Bodily Pain Have You Had|SF362-How Much Bodily Pain Have You Had|SF362-How Much Bodily Pain Have You Had|SF36207	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) How much bodily pain have you had during the past week?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102146>	C101878	SF-36 v1.0 Acute - Pain Interfere With Normal Work|SF362-Pain Interfere With Normal Work|SF362-Pain Interfere With Normal Work|SF36208	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) During the past week, how much did pain interfere with your normal work (including both work outside the home and housework)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102147>	C101878	SF-36 v1.0 Acute - Did You Feel Full of Pep|SF362-Did You Feel Full of Pep|SF362-Did You Feel Full of Pep|SF36209A	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - did you feel full of pep.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102148>	C101878	SF-36 v1.0 Acute - Have You Been Very Nervous Person|SF362-Have You Been Very Nervous Person|SF362-Have You Been Very Nervous Person|SF36209B	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - have you been a very nervous person.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102149>	C101878	SF-36 v1.0 Acute - Felt Down Nothing Cheer You Up|SF362-Felt Down Nothing Cheer You Up|SF362-Felt Down Nothing Cheer You Up|SF36209C	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - have you felt so down in the dumps that nothing could cheer you up.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10214>	C63358	Cyclophosphamide/Fluorouracil/Fluoxymesterone/Methotrexate Regimen|CMF-FLU|CMFH|CTX/5-FU/FXM/MTX|Cyclophosphamide-Fluorouracil-Fluoxymesterone-Methotrexate Regimen|Cyclophosphamide/Fluorouracil/Fluoxymesterone/Methotrexate Cyclophosphamide-Fluorouracil-Fluoxymesterone-Methotrexate	A regimen consisting of cyclophosphamide, methotrexate, fluorouracil, and fluoxymesterone that may be used as maintenance therapy for breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C102150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102150>	C101878	SF-36 v1.0 Acute - Have You Felt Calm and Peaceful|SF362-Have You Felt Calm and Peaceful|SF362-Have You Felt Calm and Peaceful|SF36209D	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - have you felt calm and peaceful.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102151>	C101878	SF-36 v1.0 Acute - Did You Have a Lot of Energy|SF362-Did You Have a Lot of Energy|SF362-Did You Have a Lot of Energy|SF36209E	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - did you have a lot of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102152>	C101878	SF-36 v1.0 Acute - You Felt Downhearted and Blue|SF362-You Felt Downhearted and Blue|SF362-You Felt Downhearted and Blue|SF36209F	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - have you felt downhearted and blue.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102153>	C101878	SF-36 v1.0 Acute - Did You Feel Worn Out|SF362-Did You Feel Worn Out|SF362-Did You Feel Worn Out|SF36209G	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - did you feel worn out.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102154>	C101878	SF-36 v1.0 Acute - Have You Been a Happy Person|SF362-Have You Been a Happy Person|SF362-Have You Been a Happy Person|SF36209H	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - have you been a happy person.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102155>	C101878	SF-36 v1.0 Acute - Did You Feel Tired|SF362-Did You Feel Tired|SF362-Did You Feel Tired|SF36209I	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - did you feel tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102156>	C101878	SF-36 v1.0 Acute - Time Phys/Emotional Interfered|SF362-Time Phys/Emotional Interfered|SF362-Time Phys/Emotional Interfered|SF36210	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) During the past week, how much of the time has your physical health or emotional problems interfered with your social activities (like visiting friends, relatives, etc.)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102157>	C101878	SF-36 v1.0 Acute - Get Sick Little Easier Than Other|SF362-Get Sick Little Easier Than Other|SF362-Get Sick Little Easier Than Other|SF36211A	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) How TRUE or FALSE is the following statement for you - I seem to get sick a little easier than other people.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102158>	C101878	SF-36 v1.0 Acute - I Am as Healthy as Anybody I Know|SF362-I Am as Healthy as Anybody I Know|SF362-I Am as Healthy as Anybody I Know|SF36211B	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) How TRUE or FALSE is the following statement for you - I am as healthy as anybody I know.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102159>	C101878	SF-36 v1.0 Acute - I Expect My Health to Get Worse|SF362-I Expect My Health to Get Worse|SF362-I Expect My Health to Get Worse|SF36211C	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) How TRUE or FALSE is the following statement for you - I expect my health to get worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10215>	C61063	Cyclophosphamide/Doxorubicin/Prednisone/Teniposide/Vincristine|CAVPE|CTX/DOX/PRED/VCR/VM-26			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102160>	C101878	SF-36 v1.0 Acute - My Health is Excellent|SF362-My Health is Excellent|SF362-My Health is Excellent|SF36211D	The Short Form 36 Health Survey Acute, Version 1.0 (SF36 v1.0 Acute) How TRUE or FALSE is the following statement for you - my health is excellent			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v1.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102161>	C101880	SF-36 v2.0 Acute - In General You Say Your Health Is|SF364-In General You Say Your Health Is|SF364-In General You Say Your Health Is|SF36401	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) In general, would you say your health is.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102162>	C101880	SF-36 v2.0 Acute - Comp Week Ago Rate Gen Health Now|SF364-Comp Week Ago Rate Gen Health Now|SF364-Comp Week Ago Rate Gen Health Now|SF36402	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) Compared to one week ago, how would you rate your health in general now?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102163>	C101880	SF-36 v2.0 Acute - Limit Vigorous Activities|SF364-Limit Vigorous Activities|SF364-Limit Vigorous Activities|SF36403A	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) How much does your health now limit you in - vigorous activities, such as running, lifting heavy objects, participating in strenuous sports.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102164>	C101880	SF-36 v2.0 Acute - Limit Moderate Activities|SF364-Limit Moderate Activities|SF364-Limit Moderate Activities|SF36403B	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) How much does your health now limit you in - moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or playing golf.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102165>	C101880	SF-36 v2.0 Acute - Limit Lifting or Carrying|SF364-Limit Lifting or Carrying|SF364-Limit Lifting or Carrying|SF36403C	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) How much does your health now limit you in - lifting or carrying groceries.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102166>	C101880	SF-36 v2.0 Acute - Limit Climbing Several Flights|SF364-Limit Climbing Several Flights|SF364-Limit Climbing Several Flights|SF36403D	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) How much does your health now limit you in - climbing several flights of stairs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102167>	C101880	SF-36 v2.0 Acute - Limit Climbing One Flight Stairs|SF364-Limit Climbing One Flight Stairs|SF364-Limit Climbing One Flight Stairs|SF36403E	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) How much does your health now limit you in - climbing one flight of stairs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102168>	C101880	SF-36 v2.0 Acute - Limit Bending/Kneeling/Stooping|SF364-Limit Bending/Kneeling/Stooping|SF364-Limit Bending/Kneeling/Stooping|SF36403F	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) How much does your health now limit you in - bending, kneeling, or stooping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102169>	C101880	SF-36 v2.0 Acute - Limit Walking More Than a Mile|SF364-Limit Walking More Than a Mile|SF364-Limit Walking More Than a Mile|SF36403G	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) How much does your health now limit you in - walking more than a mile.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10216>	C61063	Doxorubicin/Etoposide/Prednisone/Vincristine|AOPE|DOX/PRED/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102170>	C101880	SF-36 v2.0 Acute - Limit Walking Several Hundred Yds|SF364-Limit Walking Several Hundred Yds|SF364-Limit Walking Several Hundred Yds|SF36403H	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) How much does your health now limit you in - walking several hundred yards.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102171>	C101880	SF-36 v2.0 Acute - Limit Walking One Hundred Yards|SF364-Limit Walking One Hundred Yards|SF364-Limit Walking One Hundred Yards|SF36403I	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) How much does your health now limit you in - walking one hundred yards.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102172>	C101880	SF-36 v2.0 Acute - Limit Bathing or Dressing Yourself|SF364-Limit Bathing or Dressing Yourself|SF364-Limit Bathing or Dressing Yourself|SF36403J	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) How much does your health now limit you in - bathing or dressing yourself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102173>	C101880	SF-36 v2.0 Acute - Physical: Cut Down Time on Work|SF364-Physical: Cut Down Time on Work|SF364-Physical: Cut Down Time on Work|SF36404A	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) During the past week, how much of the time have you had any problems with your work or other regular daily activities as a result of your physical health - cut down on the amount of time you spent on work or other activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102174>	C101880	SF-36 v2.0 Acute - Physical: Accomplished Less|SF364-Physical: Accomplished Less|SF364-Physical: Accomplished Less|SF36404B	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) During the past week, how much of the time have you had any problems with your work or other regular daily activities as a result of your physical health - accomplished less than you would like.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102175>	C101880	SF-36 v2.0 Acute - Physical: Limited Kind of Work|SF364-Physical: Limited Kind of Work|SF364-Physical: Limited Kind of Work|SF36404C	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) During the past week, how much of the time have you had any problems with your work or other regular daily activities as a result of your physical health - were limited in the kind of work or other activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102176>	C101880	SF-36 v2.0 Acute - Physical: Difficulty Perform Work|SF364-Physical: Difficulty Perform Work|SF364-Physical: Difficulty Perform Work|SF36404D	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) During the past week, how much of the time have you had any problems with your work or other regular daily activities as a result of your physical health - had difficulty performing the work or other activities (for example, it took extra effort).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102177>	C101880	SF-36 v2.0 Acute - Emotional: Cut Down Time on Work|SF364-Emotional: Cut Down Time on Work|SF364-Emotional: Cut Down Time on Work|SF36405A	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) During the past week, how much of the time have you had problems with your work or other regular daily activities as a result of any emotional problems (such as feeling depressed or anxious) - cut down on the amount of time you spent on work or other activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102178>	C101880	SF-36 v2.0 Acute - Emotional: Accomplished Less|SF364-Emotional: Accomplished Less|SF364-Emotional: Accomplished Less|SF36405B	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) During the past week, how much of the time have you had problems with your work or other regular daily activities as a result of any emotional problems (such as feeling depressed or anxious) - accomplished less than you would like.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102179>	C101880	SF-36 v2.0 Acute - Emotional: Did Work Less Carefully|SF364-Emotional: Did Work Less Carefully|SF364-Emotional: Did Work Less Carefully|SF36405C	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) During the past week, how much of the time have you had problems with your work or other regular daily activities as a result of any emotional problems (such as feeling depressed or anxious) - did work or other activities less carefully than usual.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10217>	C61063	Bleomycin/Carmustine/Etoposide/Methotrexate/Prednisone|BCNU/BLEO/MTX/PRED/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102180>	C101880	SF-36 v2.0 Acute - Extent Phys/Emotional Interfered|SF364-Extent Phys/Emotional Interfered|SF364-Extent Phys/Emotional Interfered|SF36406	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) During the past week, to what extent has your physical health or emotional problems interfered with your normal social activities with family, friends, neighbors, or groups?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102181>	C101880	SF-36 v2.0 Acute - How Much Bodily Pain Have You Had|SF364-How Much Bodily Pain Have You Had|SF364-How Much Bodily Pain Have You Had|SF36407	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) How much bodily pain have you had during the past week?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102182>	C101880	SF-36 v2.0 Acute - Pain Interfere With Normal Work|SF364-Pain Interfere With Normal Work|SF364-Pain Interfere With Normal Work|SF36408	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) During the past week, how much did pain interfere with your normal work (including both work outside the home and housework)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102183>	C101880	SF-36 v2.0 Acute - Did You Feel Full of Life|SF364-Did You Feel Full of Life|SF364-Did You Feel Full of Life|SF36409A	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - did you feel full of life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102184>	C101880	SF-36 v2.0 Acute - Have You Been Very Nervous|SF364-Have You Been Very Nervous|SF364-Have You Been Very Nervous|SF36409B	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - have you been very nervous.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102185>	C101880	SF-36 v2.0 Acute - Felt Down Nothing Cheer You Up|SF364-Felt Down Nothing Cheer You Up|SF364-Felt Down Nothing Cheer You Up|SF36409C	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - have you felt so down in the dumps that nothing could cheer you up.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102186>	C101880	SF-36 v2.0 Acute - Have You Felt Calm and Peaceful|SF364-Have You Felt Calm and Peaceful|SF364-Have You Felt Calm and Peaceful|SF36409D	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - have you felt calm and peaceful.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102187>	C101880	SF-36 v2.0 Acute - Did You Have a Lot of Energy|SF364-Did You Have a Lot of Energy|SF364-Did You Have a Lot of Energy|SF36409E	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - did you have a lot of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102188>	C101880	SF-36 v2.0 Acute - You Felt Downhearted and Depressed|SF364-You Felt Downhearted and Depressed|SF364-You Felt Downhearted and Depressed|SF36409F	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - have you felt downhearted and depressed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102189>	C101880	SF-36 v2.0 Acute - Did You Feel Worn Out|SF364-Did You Feel Worn Out|SF364-Did You Feel Worn Out|SF36409G	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - did you feel worn out.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10218>	C61063	Carmustine/Cyclophosphamide/Thiotepa|BCNU/CTX/TSPA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102190>	C101880	SF-36 v2.0 Acute - Have You Been Happy|SF364-Have You Been Happy|SF364-Have You Been Happy|SF36409H	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - have you been happy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102191>	C101880	SF-36 v2.0 Acute - Did You Feel Tired|SF364-Did You Feel Tired|SF364-Did You Feel Tired|SF36409I	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past week - did you feel tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102192>	C101880	SF-36 v2.0 Acute - Time Phys/Emotional Interfered|SF364-Time Phys/Emotional Interfered|SF364-Time Phys/Emotional Interfered|SF36410	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) During the past week, how much of the time has your physical health or emotional problems interfered with your social activities (like visiting friends, relatives, etc.)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102193>	C101880	SF-36 v2.0 Acute - Get Sick Little Easier Than Other|SF364-Get Sick Little Easier Than Other|SF364-Get Sick Little Easier Than Other|SF36411A	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) How TRUE or FALSE is the following statement for you - I seem to get sick a little easier than other people.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102194>	C101880	SF-36 v2.0 Acute - I Am as Healthy as Anybody I Know|SF364-I Am as Healthy as Anybody I Know|SF364-I Am as Healthy as Anybody I Know|SF36411B	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) How TRUE or FALSE is the following statement for you - I am as healthy as anybody I know.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102195>	C101880	SF-36 v2.0 Acute - I Expect My Health to Get Worse|SF364-I Expect My Health to Get Worse|SF364-I Expect My Health to Get Worse|SF36411C	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) How TRUE or FALSE is the following statement for you - I expect my health to get worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102196>	C101880	SF-36 v2.0 Acute - My Health is Excellent|SF364-My Health is Excellent|SF364-My Health is Excellent|SF36411D	The Short Form 36 Health Survey Acute, Version 2.0 (SF36 v2.0 Acute) How TRUE or FALSE is the following statement for you - my health is excellent			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Code Terminology|CDISC Questionnaire SF36 v2.0 Acute Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102197>	C101879	SF-36 v2.0 Standard - In General You Say Your Health Is|SF363-In General You Say Your Health Is|SF363-In General You Say Your Health Is|SF36301	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) In general, would you say your health is.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102198>	C101879	SF-36 v2.0 Standard - Comp Year Ago Rate Gen Health Now|SF363-Comp Year Ago Rate Gen Health Now|SF363-Comp Year Ago Rate Gen Health Now|SF36302	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) Compared to one year ago, how would you rate your health in general now?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102199>	C101879	SF-36 v2.0 Standard - Limit Vigorous Activities|SF363-Limit Vigorous Activities|SF363-Limit Vigorous Activities|SF36303A	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) How much does your health now limit you in - vigorous activities, such as running, lifting heavy objects, participating in strenuous sports.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10219>	C61063	Bleomycin/Vincristine|BLEO/VCR|BO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1021>	C267	Batanopride|BATANOPRIDE|BMY-25801	A serotonin antagonist having antiemetic properties.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C102200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102200>	C101879	SF-36 v2.0 Standard - Limit Moderate Activities|SF363-Limit Moderate Activities|SF363-Limit Moderate Activities|SF36303B	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) How much does your health now limit you in - moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or playing golf.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102201>	C101879	SF-36 v2.0 Standard - Limit Lifting or Carrying|SF363-Limit Lifting or Carrying|SF363-Limit Lifting or Carrying|SF36303C	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) How much does your health now limit you in - lifting or carrying groceries.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102202>	C101879	SF-36 v2.0 Standard - Limit Climbing Several Flights|SF363-Limit Climbing Several Flights|SF363-Limit Climbing Several Flights|SF36303D	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) How much does your health now limit you in - climbing several flights of stairs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102203>	C101879	SF-36 v2.0 Standard - Limit Climbing One Flight Stairs|SF363-Limit Climbing One Flight Stairs|SF363-Limit Climbing One Flight Stairs|SF36303E	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) How much does your health now limit you in - climbing one flight of stairs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102204>	C101879	SF-36 v2.0 Standard - Limit Bending/Kneeling/Stooping|SF363-Limit Bending/Kneeling/Stooping|SF363-Limit Bending/Kneeling/Stooping|SF36303F	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) How much does your health now limit you in - bending, kneeling, or stooping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102205>	C101879	SF-36 v2.0 Standard - Limit Walking More Than a Mile|SF363-Limit Walking More Than a Mile|SF363-Limit Walking More Than a Mile|SF36303G	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) How much does your health now limit you in - walking more than a mile.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102206>	C101879	SF-36 v2.0 Standard - Limit Walking Several Hundred Yds|SF363-Limit Walking Several Hundred Yds|SF363-Limit Walking Several Hundred Yds|SF36303H	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) How much does your health now limit you in - walking several hundred yards.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102207>	C101879	SF-36 v2.0 Standard - Limit Walking One Hundred Yards|SF363-Limit Walking One Hundred Yards|SF363-Limit Walking One Hundred Yards|SF36303I	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) How much does your health now limit you in - walking one hundred yards.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102208>	C101879	SF-36 v2.0 Standard - Limit Bathing or Dressing Yourself|SF363-Limit Bathing or Dressing Yourself|SF363-Limit Bathing or Dressing Yourself|SF36303J	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) How much does your health now limit you in - bathing or dressing yourself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102209>	C101879	SF-36 v2.0 Standard - Physical: Cut Down Time on Work|SF363-Physical: Cut Down Time on Work|SF363-Physical: Cut Down Time on Work|SF36304A	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) During the past 4 weeks, how much of the time have you had any problems with your work or other regular daily activities as a result of your physical health - cut down on the amount of time you spent on work or other activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10220>	C63487	Bleomycin/Vinblastine Regimen|BLEO/VBL|Bleomycin and Vinblastine|Bleomycin-Vinblastine|Bleomycin/Vinblastine|VB|VB	A regimen consisting of bleomycin and vinblastine that can be used for the treatment of testicular cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C102210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102210>	C101879	SF-36 v2.0 Standard - Physical: Accomplished Less|SF363-Physical: Accomplished Less|SF363-Physical: Accomplished Less|SF36304B	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) During the past 4 weeks, how much of the time have you had any problems with your work or other regular daily activities as a result of your physical health - accomplished less than you would like.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102211>	C101879	SF-36 v2.0 Standard - Physical: Limited Kind of Work|SF363-Physical: Limited Kind of Work|SF363-Physical: Limited Kind of Work|SF36304C	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) During the past 4 weeks, how much of the time have you had any problems with your work or other regular daily activities as a result of your physical health - were limited in the kind of work or other activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102212>	C101879	SF-36 v2.0 Standard - Physical: Difficulty Perform Work|SF363-Physical: Difficulty Perform Work|SF363-Physical: Difficulty Perform Work|SF36304D	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) During the past 4 weeks, how much of the time have you had any problems with your work or other regular daily activities as a result of your physical health - had difficulty performing the work or other activities (for example, it took extra effort).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102213>	C101879	SF-36 v2.0 Standard - Emotional: Cut Down Time on Work|SF363-Emotional: Cut Down Time on Work|SF363-Emotional: Cut Down Time on Work|SF36305A	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) During the past 4 weeks, how much of the time have you had problems with your work or other regular daily activities as a result of any emotional problems (such as feeling depressed or anxious) - cut down on the amount of time you spent on work or other activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102214>	C101879	SF-36 v2.0 Standard - Emotional: Accomplished Less|SF363-Emotional: Accomplished Less|SF363-Emotional: Accomplished Less|SF36305B	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) During the past 4 weeks, how much of the time have you had problems with your work or other regular daily activities as a result of any emotional problems (such as feeling depressed or anxious) - accomplished less than you would like.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102215>	C101879	SF-36 v2.0 Standard - Emotional: Did Work Less Carefully|SF363-Emotional: Did Work Less Carefully|SF363-Emotional: Did Work Less Carefully|SF36305C	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) During the past 4 weeks, how much of the time have you had problems with your work or other regular daily activities as a result of any emotional problems (such as feeling depressed or anxious) - did work or other activities less carefully than usual.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102216>	C101879	SF-36 v2.0 Standard - Extent Phys/Emotional Interfered|SF363-Extent Phys/Emotional Interfered|SF363-Extent Phys/Emotional Interfered|SF36306	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) During the past 4 weeks, to what extent has your physical health or emotional problems interfered with your normal social activities with family, friends, neighbors, or groups?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102217>	C101879	SF-36 v2.0 Standard - How Much Bodily Pain Have You Had|SF363-How Much Bodily Pain Have You Had|SF363-How Much Bodily Pain Have You Had|SF36307	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) How much bodily pain have you had during the past 4 weeks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102218>	C101879	SF-36 v2.0 Standard - Pain Interfere With Normal Work|SF363-Pain Interfere With Normal Work|SF363-Pain Interfere With Normal Work|SF36308	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) During the past 4 weeks, how much did pain interfere with your normal work (including both work outside the home and housework)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102219>	C101879	SF-36 v2.0 Standard - Did You Feel Full of Life|SF363-Did You Feel Full of Life|SF363-Did You Feel Full of Life|SF36309A	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - did you feel full of life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10221>	C61063	Dactinomycin/Etoposide/Ifosfamide/Vincristine|DACT/IFF/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102220>	C101879	SF-36 v2.0 Standard - Have You Been Very Nervous|SF363-Have You Been Very Nervous|SF363-Have You Been Very Nervous|SF36309B	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - have you been very nervous.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102221>	C101879	SF-36 v2.0 Standard - Felt Down Nothing Cheer You Up|SF363-Felt Down Nothing Cheer You Up|SF363-Felt Down Nothing Cheer You Up|SF36309C	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - have you felt so down in the dumps that nothing could cheer you up.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102222>	C101879	SF-36 v2.0 Standard - Have You Felt Calm and Peaceful|SF363-Have You Felt Calm and Peaceful|SF363-Have You Felt Calm and Peaceful|SF36309D	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - have you felt calm and peaceful.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102223>	C101879	SF-36 v2.0 Standard - Did You Have a Lot of Energy|SF363-Did You Have a Lot of Energy|SF363-Did You Have a Lot of Energy|SF36309E	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - did you have a lot of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102224>	C101879	SF-36 v2.0 Standard - You Felt Downhearted and Depressed|SF363-You Felt Downhearted and Depressed|SF363-You Felt Downhearted and Depressed|SF36309F	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - have you felt downhearted and depressed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102225>	C101879	SF-36 v2.0 Standard - Did You Feel Worn Out|SF363-Did You Feel Worn Out|SF363-Did You Feel Worn Out|SF36309G	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - did you feel worn out.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102226>	C101879	SF-36 v2.0 Standard - Have You Been Happy|SF363-Have You Been Happy|SF363-Have You Been Happy|SF36309H	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - have you been happy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102227>	C101879	SF-36 v2.0 Standard - Did You Feel Tired|SF363-Did You Feel Tired|SF363-Did You Feel Tired|SF36309I	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) Please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks - did you feel tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102228>	C101879	SF-36 v2.0 Standard - Time Phys/Emotional Interfered|SF363-Time Phys/Emotional Interfered|SF363-Time Phys/Emotional Interfered|SF36310	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your social activities (like visiting friends, relatives, etc.)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102229>	C101879	SF-36 v2.0 Standard - Get Sick Little Easier Than Other|SF363-Get Sick Little Easier Than Other|SF363-Get Sick Little Easier Than Other|SF36311A	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) How TRUE or FALSE is the following statement for you - I seem to get sick a little easier than other people.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10222>	C61063	Cyclophosphamide/Fluorouracil/Fluoxymesterone/Methotrexate/Tamoxifen|CTX/5-FU/FXM/MTX/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102230>	C101879	SF-36 v2.0 Standard - I Am as Healthy as Anybody I Know|SF363-I Am as Healthy as Anybody I Know|SF363-I Am as Healthy as Anybody I Know|SF36311B	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) How TRUE or FALSE is the following statement for you - I am as healthy as anybody I know.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102231>	C101879	SF-36 v2.0 Standard - I Expect My Health to Get Worse|SF363-I Expect My Health to Get Worse|SF363-I Expect My Health to Get Worse|SF36311C	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) How TRUE or FALSE is the following statement for you - I expect my health to get worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102232>	C101879	SF-36 v2.0 Standard - My Health is Excellent|SF363-My Health is Excellent|SF363-My Health is Excellent|SF36311D	The Short Form 36 Health Survey Standard, US Version 2.0 (SF36 v2.0 Standard) How TRUE or FALSE is the following statement for you - my health is excellent			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Code Terminology|CDISC Questionnaire SF36 v2.0 Standard Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102233>	C101882	YMRS - Elevated Mood	Young Mania Rating Scale (YMRS) Elevated mood.			Intellectual Product	
C102234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102234>	C101882	YMRS - Increased Motor Activity-Energy	Young Mania Rating Scale (YMRS) Increased motor activity-energy.			Intellectual Product	
C102235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102235>	C101882	YMRS - Sexual Interest	Young Mania Rating Scale (YMRS) Sexual interest.			Intellectual Product	
C102236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102236>	C101882	YMRS - Sleep	Young Mania Rating Scale (YMRS) Sleep.			Intellectual Product	
C102237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102237>	C101882	YMRS - Irritability	Young Mania Rating Scale (YMRS) Irritability.			Intellectual Product	
C102238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102238>	C101882	YMRS - Speech (Rate and Amount)	Young Mania Rating Scale (YMRS) Speech (Rate and Amount).			Intellectual Product	
C102239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102239>	C101882	YMRS - Language-Thought Disorder	Young Mania Rating Scale (YMRS) Language-thought disorder.			Intellectual Product	
C10223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10223>	C63358	FLAC Regimen|CALF|CF/CTX/DOX/5-FU|Cyclophosphamide/Doxorubicin/Fluorouracil/Leucovorin|FLAC|Fluorouracil-Leucovorin-Doxorubicin-Cyclophosphamide|Fluorouracil/Leucovorin/Adriamycin/Cyclophosphamide|Fluorouracil/Leucovorin/Doxorubicin/Cyclophosphamide|Fluorouracil/Leucovorin/Doxorubicin/Cyclophosphamide Regimen	A regimen consisting of fluorouracil, leucovorin, doxorubicin, and cyclophosphamide for the treatment of breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C102240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102240>	C101882	YMRS - Content	Young Mania Rating Scale (YMRS) Content.			Intellectual Product	
C102241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102241>	C101882	YMRS - Disruptive-Aggressive Behaviour	Young Mania Rating Scale (YMRS) Disruptive-aggressive behaviour.			Intellectual Product	
C102242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102242>	C101882	YMRS - Appearance	Young Mania Rating Scale (YMRS) Appearance.			Intellectual Product	
C102243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102243>	C101882	YMRS - Insight	Young Mania Rating Scale (YMRS) Insight.			Intellectual Product	
C102244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102244>	C25676	Cardiac Valvular Regurgitation Severity|CVLREGTS	The qualitative measurement of the severity of cardiac valvular regurgitation.			Qualitative Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102245>	C25676	Cardiac Valvular Stenosis Severity|CVLSTNS	The qualitative measurement of the severity of cardiac valvular stenosis.			Qualitative Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102246>	C459	Oral Medication|ORAL MEDICATION	A pharmacological medication intended for administration through the mouth.			Pharmacologic Substance	CDISC SDTM Diabetes Therapy Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102247>	C41206	Institution Not Defined|INSTITUTION NOT DEFINED	The patient will be admitted into an alternative facility not listed.			Health Care Related Organization	CDISC SDTM Discharge Disposition Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102248>	C25179	Short Term General Hospitalization|SHORT TERM GENERAL HOSPITAL|Short Term Hospital	The patient will remain in a basic hospital environment for a brief time.			Event	CDISC SDTM Discharge Disposition Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102249>	C49677	Median Heart Rate	A measurement of the median number of cycles of contraction and subsequent relaxation of the heart, usually expressed as beats per minute, obtained from a set of measurements of the heart rate.			Quantitative Concept	
C10224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10224>	C61063	Cisplatin/Melphalan/Teniposide|CDDP/L-PAM/VM-26			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102250>	C62085	Median PR Duration	A measurement of the median duration (time) of the PR interval, obtained from a set of measurements of the PR interval. The PR interval is defined as the time from the beginning of the P wave (representing the onset of atrial depolarization) to the beginning of the R wave (representing the onset of ventricular depolarization). In some cases, a Q wave will precede the R wave, in which case the PR interval is measured from the beginning of the P wave to the beginning of the Q wave.			Quantitative Concept	
C102251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102251>	C62085	Median QRS Duration	A measurement of the median duration (time) of the QRS interval, obtained from a set of measurements of the QRS interval. The QRS interval is defined as the time from the beginning of the QRS complex to the end of the QRS complex, representing the time it takes for the ventricles to depolarize.			Quantitative Concept	
C102252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102252>	C62085	Median QT Duration	A measurement of the median duration (time) of the QT interval, obtained from a set of measurements of the QT interval. The QT interval is defined as the time from the beginning of the QRS complex to the end of the T wave, representing the time it takes for the ventricles to depolarize and subsequently repolarize. In some cases, the Q wave will be absent, in which case the QT interval is measured from the beginning of the R wave to the end of the T wave.			Quantitative Concept	
C102253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102253>	C62085	Median QTcF	A measurement of the median duration (time) of the QTc interval, obtained from a set of measurements of the QT interval and corrected using the Fridericia's correction formula.			Quantitative Concept	
C102254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102254>	C62085	Median RR Duration	A measurement of the median duration (time) of the RR interval, obtained from a set of measurements of the RR interval. The RR interval is defined as the time between successive peaks of the R wave and can be used to measure the ventricular rate.			Quantitative Concept	
C102255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102255>	C101526	Blinded Treatment Epoch|BLINDED TREATMENT	A period in a clinical study during which subjects receive blinded therapeutic treatment.			Research Activity	CDISC SDTM Epoch Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102256>	C101526	Open Label Treatment Epoch|OPEN LABEL TREATMENT	A period in a clinical study during which subjects receive open label therapeutic treatment.			Research Activity	CDISC SDTM Epoch Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102257>	C49237	Adenosine Diphosphate Measurement|ADP|Adenosine Diphosphate|Adenosine Diphosphate	The determination of the amount of adenosine diphosphate present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102258>	C210010	Antiphospholipid Antibody Measurement|Anti-Phospholipid Antibody Measurement	The determination of the amount of antiphospholipid antibodies present in a sample.			Laboratory Procedure	
C102259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102259>	C49237	Arachidonic Acid Measurement|ARA|Arachidonic Acid|Arachidonic Acid	The determination of the amount of arachidonic acid present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10225>	C61063	Asparaginase/Doxorubicin/Vincristine|ASP/DOX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102260>	C199654	CD34 Measurement|CD34|CD34|CD34 Molecule|CD34 Protein|CD34 Sialomucin|CD34 Sialomucin|CD34SM|Hematopoietic Progenitor Cell Antigen CD34	The determination of the amount of CD34 expressing cells present in a sample.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|HL Authorized Value Terminology|HL Lab Table
C102261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102261>	C48938	Clue Cell Count|CLUECE|Clue Cells|Clue Cells	The determination of the amount of clue cells present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102262>	C74687	Dextroamphetamine Measurement|AMPHETD|Dextroamphetamine|Dextroamphetamine|d-amphetamine	The determination of the amount of dextroamphetamine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102263>	C62662	Endogenous Thrombin Potential Area Under Curve Measurement|ETP Area Under Curve|ETP Area Under Curve|ETPAUC|Endogenous Thrombin Potential Area Under Curve	The measurement of the area under the thrombin generation curve.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102264>	C62662	Endogenous Thrombin Potential Lag Time Measurement|ETP Lag Time|ETP Lag Time|ETPLT|Endogenous Thrombin Potential Lag Time	A measurement of time from the start of the thrombin generation test to the point where a predetermined amount of thrombin is generated.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102265>	C62662	Endogenous Thrombin Potential Lag Time Relative Measurement|ETP Lag Time Relative|ETP Lag Time Relative|ETPLTR|Endogenous Thrombin Potential Lag Time Relative	A relative measurement (ratio or percentage) of time from the start of the thrombin generation test to the point where a predetermined amount of thrombin is generated.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102266>	C62662	Endogenous Thrombin Potential Measurement|ETP|Endogenous Thrombin Potential|Endogenous Thrombin Potential	The determination of the total concentration of thrombin generated in the presence of a substrate in a plasma or blood sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102267>	C62662	Endogenous Thrombin Potential Peak Height Measurement|ETP Peak Height|ETP Peak Height|ETPPH|Endogenous Thrombin Potential Peak Height	The determination of the amount of maximum concentration of thrombin generated during a thrombin generation test.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102268>	C62662	Endogenous Thrombin Potential Peak Height Relative Measurement|ETP Peak Height Relative|ETP Peak Height Relative|ETPPHR|Endogenous Thrombin Potential Peak Height Relative	A relative (ratio or percentage) of the maximum concentration of thrombin generated during a thrombin generation test.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102269>	C62662	Endogenous Thrombin Potential Time to Peak Measurement|ETP Time to Peak|ETP Time to Peak|ETPTP|Endogenous Thrombin Potential Time to Peak	The determination of the amount of time it takes to generate the maximum concentration of thrombin.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10226>	C61063	Caffeine/Cisplatin/Cytarabine|ARA-C/CAF/CDDP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102270>	C62662	Endogenous Thrombin Potential Time to Peak Relative Measurement|ETP Time to Peak Relative|ETP Time to Peak Relative|ETPTPR|Endogenous Thrombin Potential Time to Peak Relative	A relative (ratio or percentage) measurement of the time it takes to generate the maximum concentration of thrombin.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102271>	C98726	Factor V Leiden Measurement|FACTVL|Factor V Leiden|Factor V Leiden	The determination of the amount of Factor V Leiden present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102272>	C62662	Factor XIV Measurement|Autoprothrombin IIA|FACTXIV|Factor XIV|Factor XIV|Protein C|Protein C Antigen|Protein C Measurement|Protein C, Inactivator of Coagulation Factors Va and VIIIa	The determination of the amount of factor XIV present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102273>	C51947	Hematocrit Corrected Reticulocyte Count|Hematocrit Corrected Reticulocytes|Hematocrit Corrected Reticulocytes|RETIHCR	The determination of the amount of hematocrit corrected reticulocytes present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102274>	C67208	Hematocrit Corrected Reticulocytes to Erythrocytes Ratio Measurement|HCT Corrected Reticulocytes/Erythrocytes|HCT Corrected Reticulocytes/Erythrocytes|RETCRRBC	A relative measurement (ratio or percentage) of the hematocrit corrected reticulocytes to erythrocytes present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102275>	C49237	Hydrogen Measurement|HYDROGEN|Hydrogen|Hydrogen	The determination of the amount of hydrogen present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102276>	C67208	Immature Reticulocyte Fraction Measurement|IRF|Immature Reticulocyte Fraction|Immature Reticulocyte Fraction	The determination of the ratio of immature reticulocytes to total reticulocytes present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102277>	C62662	Lupus Anticoagulant Sensitive APTT Measurement|APTT-LA|APTTLA|APTTLAS|Lupus Anticoagulant Sensitive APTT|Lupus Anticoagulant Sensitive APTT	The determination of the amount of time that it takes for clotting to occur when a lupus sensitive reagent is added to a plasma specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102278>	C48938	Lymphoblast Count|BLSTLY|Lymphoblasts|Lymphoblasts|Lymphoblasts|Lymphoid Blasts	The determination of the amount of lymphoblasts (immature cells that differentiate to form lymphocytes) present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C102279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102279>	C71252	P50 Oxygen Measurement|P50 Oxygen|P50 Oxygen|P50OXYGN	The determination of the amount of partial pressure of oxygen when hemoglobin is half saturated that is present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10227>	C61007	Cyclophosphamide/Doxorubicin/Fluorouracil/Leucovorin Calcium/Sargramostim|CF/CTX/DOX/5-FU/GM-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102280>	C158220	Soluble Interleukin 2 Receptor Activity Measurement	The determination of the amount of soluble interleukin 2 receptor activity present in a sample.			Laboratory Procedure	
C102281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102281>	C74957	Sperm Motility Measurement|SPERMMTL|Sperm Motility|Sperm Motility	The determination of the amount of sperm capable of forward, progressive movement present in a semen sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102282>	C17241	Urine Conductivity|CONDUCTU	The determination of the ability of urine to conduct an electrical current. This test is a non-linear function of the electrolyte concentration in the urine.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102283>	C101883	Extracted Lead|EXTRACTED	The lead has been removed from the body.			Finding	CDISC SDTM Lead Status Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102284>	C101883	Reused Lead|REUSED	The lead has been left in situ and reused.			Finding	CDISC SDTM Lead Status Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102285>	C12843	Acute Marginal Artery|ACUTE MARGINAL ARTERY|ACUTE MARGINAL ARTERY SEGMENT(S)|AMARG	The arteries that arise at the junction of the proximal and mid-right coronary artery conduit segments.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102286>	C32958	Circumflex Artery and its Branches|CIRCUMFLEX, OBTUSE MARGINALS, LEFT POSTEROLATERAL AND LEFT POSTERIOR DESCENDING ARTERY BRANCHES	The left circumflex coronary artery and all of its branches, including the obtuse marginals, left posterolateral and left posterior descending artery branches.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102287>	C32958	Circumflex Artery AV Groove Continuation Artery|CIRC AV|CIRCUMFLEX ARTERY AV GROOVE CONTINUATION ARTERY|CIRCUMFLEX ARTERY AV GROOVE CONTINUATION ARTERY SEGMENT	The segment of the left circumflex artery that is distal to the third marginal branch, located in the atrioventricular groove.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102288>	C32392	Costochondral Joint 1|COSTOCHONDRAL JOINT 1	The first hyaline cartilaginous joint between the ribs and costal cartilage.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102289>	C32392	Costochondral Joint 7|COSTOCHONDRAL JOINT 7	The seventh hyaline cartilaginous joint between the ribs and costal cartilage.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10228>	C61007	Cisplatin/Paclitaxel|CDDP/TAX|Cisplatin-Paclitaxel|Cisplatin-Paclitaxel Regimen	A combination of agents containing cisplatin and paclitaxel.		Obsolete_Concept	Therapeutic or Preventive Procedure	
C102290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102290>	C32958	Distal Circumflex Artery|DCIRC|DISTAL CIRCUMFLEX ARTERY|DISTAL CIRCUMFLEX ARTERY SEGMENT	The segment of the left circumflex artery that is between the second and third obtuse marginal branches.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102291>	C101529	Distal Interphalangeal Joint 2|DIP2|DISTAL INTERPHALANGEAL JOINT 2	A ginglymoid (hinge) synovial joint within the second digit of the hand or foot connecting the middle and distal phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102292>	C101529	Distal Interphalangeal Joint 3|DIP3|DISTAL INTERPHALANGEAL JOINT 3	A ginglymoid (hinge) synovial joint within the third digit of the hand or foot connecting the middle and distal phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102293>	C101529	Distal Interphalangeal Joint 4|DIP4|DISTAL INTERPHALANGEAL JOINT 4	A ginglymoid (hinge) synovial joint within the fourth digit of the hand or foot connecting the middle and distal phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102294>	C101529	Distal Interphalangeal Joint 5|DIP5|DISTAL INTERPHALANGEAL JOINT 5	A ginglymoid (hinge) synovial joint within the fifth digit of the hand or foot connecting the middle and distal phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102295>	C32958	Distal Left Anterior Descending Artery|DISTAL LAD ARTERY|DISTAL LAD ARTERY SEGMENT|DLAD	The segment of the left anterior descending (LAD) artery that is distal to the third diagonal branch.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102296>	C12843	Distal Right Coronary Artery Conduit|DISTAL RIGHT CORONARY ARTERY CONDUIT|DISTAL RIGHT CORONARY ARTERY CONDUIT SEGMENT|DRCA	The section of the right coronary artery distal to the origin of the acute marginal artery.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102297>	C32958	First Diagonal Branch Artery|1ST DIAG|FIRST DIAGONAL BRANCH ARTERY|FIRST DIAGONAL BRANCH ARTERY SEGMENT	The first artery arising from the left anterior descending (LAD) artery that supplies the anterolateral wall, when counted from proximal to distal.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102298>	C32958	First Left Posterolateral Branch Artery|1ST LPL|FIRST LEFT POSTEROLATERAL BRANCH ARTERY|FIRST LEFT POSTEROLATERAL BRANCH ARTERY SEGMENT	In an individual with a left-dominant heart, this is the first branch that arises from the circumflex artery atrioventricular groove continuation when counted from proximal to distal. It supplies the posterolateral wall.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102299>	C32958	First Obtuse Marginal Branch Artery|1ST OM|FIRST OBTUSE MARGINAL BRANCH ARTERY|FIRST OBTUSE MARGINAL BRANCH ARTERY SEGMENT|First Left Marginal Artery	The first artery arising from the left circumflex artery that supplies the lateral wall, when counted from proximal to distal.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10229>	C61063	Cyclophosphamide/Fluorouracil/Tamoxifen|CTX/5-FU/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1022>	C1557	Emitefur|(2) m-[[3-(Ethoxymethyl)-5-fluoro-3,6-dihydro-2,6-dioxo-1(2H)-pyrimidinyl]carbonyl]benzoic Acid, 2-Ester with 2,6-Dihydroxynicotinonitrile Benzoate (Ester)|3-((3-(Ethoxymethyl)-5-fluoro-3,6-dihydro-2,6-dioxo-1(2H)-pyrimidinyl)carbonyl)benzoic acid, 6-(benzoyloxy)-3-cyano-2-pyridinyl ester|3-[3-(6-Benzoyloxy-3-cyrano-2-pyridyloxycarbonyl)benzoyl]-1-(ethoxymethyl)-5-fluorouracil|BOF-A2|EMITEFUR|Last-F|[[Ethoxymethyl-5-fluoro-3,6-dihydro-2,6-dioxo-1(2H)-pyrimidinyl]carbonyl]benzoic Acid, 6-(Benzoyloxy)-3-cyano-2-pyridinyl Ester|emitefur	An orally available antimetabolite composed of the 1-ethoxymethyl derivative of 5-fluorouracil (5-FU) and the dihydropyrimidine dehydrogenase (DPYD) inhibitor 3-cyano-2,6-dihydroxypyridine (CNDP) in a 1:1 molar ratio, with antineoplastic activity.  Upon administration, the prodrug emitefur is converted into 5-FU, while CNDP prevents the degradation of 5-FU by inhibiting DPYD and thereby prolonging the half-life of 5-FU. This increases 5-FU's concentration and thus its antitumor activity through inhibition of DNA and RNA synthesis, as well as inhibition of thymidylate synthase activity. In addition, by inhibiting the formation of 5-FU metabolites, some toxic effects associated with these metabolites may be reduced. DPYD is the rate-limiting enzyme in the catabolism of 5-FU.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C102300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102300>	C12843	First Right Posterolateral Artery|1ST RPL|FIRST RIGHT POSTEROLATERAL ARTERY|FIRST RIGHT POSTEROLATERAL ARTERY SEGMENT	In an individual with a right-dominant heart, this is the first branch that arises from the right coronary artery distal to the right posterior descending artery, when counted from proximal to distal.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102301>	C101527	Interphalangeal Joint 1|INTERPHALANGEAL JOINT 1|IP1	A ginglymoid (hinge) synovial joint within the first digit of the hand or foot connecting the proximal and distal phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102302>	C101527	Interphalangeal Joint 2|INTERPHALANGEAL JOINT 2|IP2	A ginglymoid (hinge) synovial joint between the phalanges of the second digit of the hand or foot.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102303>	C101527	Interphalangeal Joint 3|INTERPHALANGEAL JOINT 3|IP3	A ginglymoid (hinge) synovial joint between the phalanges of the third digit of the hand or foot.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102304>	C101527	Interphalangeal Joint 4|INTERPHALANGEAL JOINT 4|IP4	A ginglymoid (hinge) synovial joint between the phalanges of the fourth digit of the hand or foot.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102305>	C101527	Interphalangeal Joint 5|INTERPHALANGEAL JOINT 5|IP5	A ginglymoid (hinge) synovial joint between the phalanges of the fifth digit of the hand or foot.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102306>	C32868|C102301	Interphalangeal Thumb Joint|INTERPHALANGEAL THUMB JOINT|IP THUMB|IP1 of the Hand|Interphalangeal Joint 1 of the Hand	A ginglymoid (hinge) synovial joint within the thumb connecting the proximal and distal phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102307>	C32958	Lateral First Diagonal Branch Artery|LAT 1ST DIAG|LATERAL FIRST DIAGONAL BRANCH ARTERY|LATERAL FIRST DIAGONAL BRANCH ARTERY SEGMENT	The lateral branch distal to a bifurcation of the first diagonal artery.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102308>	C32958	Lateral First Obtuse Marginal Branch Artery|First Obtuse Marginal Lateral Branch|LAT 1ST OM|LATERAL FIRST OBTUSE MARGINAL BRANCH ARTERY|LATERAL FIRST OBTUSE MARGINAL BRANCH ARTERY SEGMENT	The lateral branch distal to a bifurcation of the first obtuse marginal artery.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102309>	C32958	Lateral Ramus Intermedius Artery|LAT RAMUS|LATERAL RAMUS INTERMEDIUS ARTERY|LATERAL RAMUS INTERMEDIUS ARTERY SEGMENT	The lateral branch distal to a bifurcation of the ramus intermedius artery.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10230>	C61063	Cytarabine/Etoposide/Methylprednisolone|ARA-C/MePRDL/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102310>	C32958	Lateral Second Diagonal Branch Artery|LAT 2ND DIAG|LATERAL SECOND DIAGONAL BRANCH ARTERY|LATERAL SECOND DIAGONAL BRANCH ARTERY SEGMENT	The lateral branch distal to a bifurcation of the second diagonal artery.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102311>	C32958	Lateral Second Obtuse Marginal Branch Artery|LAT 2ND OM|LATERAL SECOND OBTUSE MARGINAL BRANCH ARTERY|LATERAL SECOND OBTUSE MARGINAL BRANCH ARTERY SEGMENT|Second Obtuse Marginal Lateral Branch	The lateral branch distal to a bifurcation of the second obtuse marginal artery.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102312>	C32958	Lateral Third Diagonal Branch Artery|LAT 3RD DIAG|LATERAL THIRD DIAGONAL BRANCH ARTERY|LATERAL THIRD DIAGONAL BRANCH ARTERY SEGMENT	The lateral branch distal to a bifurcation of the third diagonal artery.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102313>	C32958	Left Anterior Descending Septal Perforator Artery|LAD SEPTAL PERFORATOR ARTERY|LAD SEPTAL PERFORATOR ARTERY SEGMENTS|LAD SP	The arteries that arise from the left anterior descending (LAD) artery that supply the interventricular septum.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102314>	C32958	Left Posterolateral Descending Artery|LEFT POSTEROLATERAL DESCENDING ARTERY|LEFT POSTEROLATERAL DESCENDING ARTERY SEGMENT|LPDA	In an individual with a left-dominant heart, this branch arises from the circumflex artery atrioventricular groove continuation and supplies the inferior apex of the heart.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102315>	C13164	Left Ventricular Epicardium|LEFT VENTRICULAR EPICARDIUM	The outermost layer of cardiac tissue lining of the left ventricle.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102316>	C33106	Metacarpophalangeal Joint 1|MCP1|METACARPOPHALANGEAL JOINT 1	A condyloid synovial joint within the first digit of the hand connecting the metacarpal to the proximal phalanx.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102317>	C33106	Metacarpophalangeal Joint 2|MCP2|METACARPOPHALANGEAL JOINT 2	A condyloid synovial joint within the second digit of the hand connecting the metacarpal to the proximal phalanx.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102318>	C33106	Metacarpophalangeal Joint 3|MCP3|METACARPOPHALANGEAL JOINT 3	A condyloid synovial joint within the third digit of the hand connecting the metacarpal to the proximal phalanx.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102319>	C33106	Metacarpophalangeal Joint 4|MCP4|METACARPOPHALANGEAL JOINT 4	A condyloid synovial joint within the fourth digit of the hand connecting the metacarpal to the proximal phalanx.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10231>	C61063	Etoposide/Mitoguazone/Mitoxantrone/Vinblastine|DHAD/MGBG/VBL/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102320>	C33106	Metacarpophalangeal Joint 5|MCP5|METACARPOPHALANGEAL JOINT 5	A condyloid synovial joint within the fifth digit of the hand connecting the metacarpal to the proximal phalanx.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102321>	C33108	Metatarsophalangeal Joint 1|METATARSOPHALANGEAL JOINT 1|MTP1	A condyloid synovial joint within the first digit of the foot connecting metatarsal with the proximal phalanx.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102322>	C33108	Metatarsophalangeal Joint 2|METATARSOPHALANGEAL JOINT 2|MTP2	A condyloid synovial joint within the second digit of the foot connecting metatarsal with the proximal phalanx.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102323>	C33108	Metatarsophalangeal Joint 3|METATARSOPHALANGEAL JOINT 3|MTP3	A condyloid synovial joint within the third digit of the foot connecting metatarsal with the proximal phalanx.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102324>	C33108	Metatarsophalangeal Joint 4|METATARSOPHALANGEAL JOINT 4|MTP4	A condyloid synovial joint within the fourth digit of the foot connecting metatarsal with the proximal phalanx.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102325>	C33108	Metatarsophalangeal Joint 5|METATARSOPHALANGEAL JOINT 5|MTP5	A condyloid synovial joint within the fifth digit of the foot connecting metatarsal with the proximal phalanx.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102326>	C32958	Mid-Circumflex Artery|MCIRC|MID-CIRCUMFLEX ARTERY|MID-CIRCUMFLEX ARTERY SEGMENT	The segment of the left circumflex artery between the first and second marginal branches.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102327>	C32958	Mid-Distal Left Anterior Descending Coronary Artery and All Diagonal Coronary Branches|MID/DISTAL LEFT ANTERIOR DESCENDING CORONARY ARTERY AND ALL DIAGONAL CORONARY BRANCHES	All of the arterial branches distal to the proximal left anterior descending coronary artery.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102328>	C32958	Mid-Left Anterior Descending Artery|MID-LAD ARTERY|MID-LAD ARTERY SEGMENT|MLAD	The segment of the left anterior descending (LAD) artery between the first and third diagonal branches.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102329>	C12843	Mid-Right Coronary Artery Conduit|MID-RIGHT CORONARY ARTERY CONDUIT|MID-RIGHT CORONARY ARTERY CONDUIT SEGMENT|MRCA|Mid-right Coronary Artery	The section of the right coronary artery between the right ventricular artery and the acute marginal artery.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10232>	C61063	Fluorouracil/Interleukin-1-Beta|5-FU/IL-1B			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102330>	C33027	Perihilar Lymph Node|Hilar Nodes|Lymph Node(s) Hilar|PERIHILAR LYMPH NODE	A lymph node located in the area around the hilum of an organ.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Biopsy/Surgical Procedures Table|HL Lesion Characteristics Table
C102331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102331>	C32958	Proximal Circumflex Artery|PCIRC|PROXIMAL CIRCUMFLEX ARTERY|PROXIMAL CIRCUMFLEX ARTERY SEGMENT	The section of the left circumflex coronary artery that arises from the left main coronary artery and extends to the first marginal branch.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102332>	C101528	Proximal Interphalangeal Joint 2|PIP2|PROXIMAL INTERPHALANGEAL JOINT 2	A ginglymoid (hinge) synovial joint within the second digit of the hand or foot connecting the proximal and middle phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102333>	C101528	Proximal Interphalangeal Joint 3|PIP3|PROXIMAL INTERPHALANGEAL JOINT 3	A ginglymoid (hinge) synovial joint within the third digit of the hand or foot connecting the proximal and middle phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102334>	C101528	Proximal Interphalangeal Joint 4|PIP4|PROXIMAL INTERPHALANGEAL JOINT 4	A ginglymoid (hinge) synovial joint within the fourth digit of the hand or foot connecting the proximal and middle phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102335>	C101528	Proximal Interphalangeal Joint 5|PIP5|PROXIMAL INTERPHALANGEAL JOINT 5	A ginglymoid (hinge) synovial joint within the fifth digit of the hand or foot connecting the proximal and middle phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102336>	C32958	Proximal Left Anterior Descending Artery|PLAD|PROXIMAL LAD ARTERY|PROXIMAL LAD ARTERY SEGMENT	The section of the left anterior descending coronary artery that arises from the left main coronary artery and extends to the first diagonal branch.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102337>	C12843	Proximal Right Coronary Artery Conduit|PRCA|PROXIMAL RIGHT CORONARY ARTERY CONDUIT|PROXIMAL RIGHT CORONARY ARTERY CONDUIT SEGMENT	The section of the right coronary artery proximal to the origin of the right ventricular artery.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102338>	C32958	Ramus Intermedius Artery|RAMUS|RAMUS ARTERY|RAMUS INTERMEDIUS ARTERY|RAMUS INTERMEDIUS ARTERY SEGMENT	An artery that arises from the left main coronary artery and is positioned between the left anterior descending coronary artery and the circumflex artery.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102339>	C13004	Right Atrial Endocardium|RIGHT ATRIAL ENDOCARDIUM	The innermost layer of endothelial cells and connective tissue that lines the right atrium.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10233>	C61063	Amifostine/Carboplatin|CBDCA/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102340>	C12843	Right Coronary Artery and its Branches|RIGHT CORONARY ARTERY, RIGHT POSTERIOR DESCENDING, RIGHT POSTERIOLATERAL AND ACUTE MARGINAL BRANCHES	The right coronary artery and all of its branches, including the right posterior descending, right posterolateral and acute marginal branches.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102341>	C12843	Right Posterior Atrioventricular Artery|RIGHT POSTERIOR ATRIOVENTRICULAR ARTERY|RIGHT POSTERIOR ATRIOVENTRICULAR ARTERY SEGMENT|RPAV	The arterial branch between the right posterior descending artery segment and the first right posterolateral segment.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102342>	C12843	Right Posterior Descending Artery|RIGHT POSTERIOR DESCENDING ARTERY|RIGHT POSTERIOR DESCENDING ARTERY SEGMENT|RPDA	In an individual with a right-dominant heart, the arterial branch that arises from the distal right coronary artery between the acute marginal artery and the first right posterolateral segment. It supplies the inferior apex of the heart.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102343>	C13004	Right Ventricular Endocardium|RIGHT VENTRICULAR ENDOCARDIUM	The innermost layer of endothelial cells and connective tissue that lines the right ventricle.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102344>	C12843	Second Diagonal Branch Artery|2ND DIAG|SECOND DIAGONAL BRANCH ARTERY|SECOND DIAGONAL BRANCH ARTERY SEGMENT	The second artery arising from the left anterior descending (LAD) artery that supplies the anterolateral wall, when counted from proximal to distal.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102345>	C12843	Second Left Posterolateral Branch Artery|2ND LPL|SECOND LEFT POSTEROLATERAL BRANCH ARTERY|SECOND LEFT POSTEROLATERAL BRANCH ARTERY SEGMENT	In an individual with a left-dominant heart, this is the second branch that arises from the circumflex artery atrioventricular groove continuation when counted from proximal to distal. It supplies the posterolateral wall.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102346>	C12843	Second Obtuse Marginal Branch Artery|2ND OM|SECOND OBTUSE MARGINAL BRANCH ARTERY|SECOND OBTUSE MARGINAL BRANCH ARTERY SEGMENT|Second Left Marginal Artery	The second artery arising from the left circumflex artery that supplies the lateral wall, when counted from proximal to distal.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102347>	C12843	Second Right Posterolateral Artery|2ND RPL|SECOND RIGHT POSTEROLATERAL ARTERY|SECOND RIGHT POSTEROLATERAL ARTERY SEGMENT	In an individual with a right-dominant heart, this is the second branch that arises from the right coronary artery distal to the right posterior descending artery, when counted from proximal to distal.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102348>	C32958	Septal Perforator Artery|PDSP|POSTERIOR DESCENDING SEPTAL PERFORATORS ARTERY|POSTERIOR DESCENDING SEPTAL PERFORATORS ARTERY SEGMENT	The arteries arising from the right posterior descending artery that supply the interventricular septum.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102349>	C12680	Sublingual Region|SUBLINGUAL REGION	The area directly beneath the tongue.			Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10234>	C63487	VAB-6 Regimen|BLEO/CDDP/CTX/DACT/VBL|Bleomycin-Cisplatin-Cyclophosphamide-Dactinomycin-Vinblastine|Bleomycin/Cisplatin/Cyclophosphamide/Dactinomycin/Vinblastine|Bleomycin/Cisplatin/Cyclophosphamide/Dactinomycin/Vinblastine Regimen|VAB-6|VAB-6|VAB-V|VAB-V	A regimen consisting of vinblastine, dactinomycin, bleomycin, cyclophosphamide and cisplatin that may be used in the treatment of testicular cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C102350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102350>	C32958	Third Diagonal Branch Artery|3RD DIAG|THIRD DIAGONAL BRANCH ARTERY|THIRD DIAGONAL BRANCH ARTERY SEGMENT	The third artery arising from the left anterior descending (LAD) artery that supplies the anterolateral wall, when counted from proximal to distal.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102351>	C12843	Third Obtuse Marginal Branch Artery|3RD OM|THIRD OBTUSE MARGINAL BRANCH ARTERY|THIRD OBTUSE MARGINAL BRANCH ARTERY SEGMENT|Third Left Marginal Artery	The third artery arising from the left circumflex artery that supplies the lateral wall, when counted from proximal to distal.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102352>	C12843	Third Posterolateral Descending Artery|3RD LPL|THIRD POSTEROLATERAL DESCENDING ARTERY|THIRD POSTEROLATERAL DESCENDING ARTERY SEGMENT	In an individual with a left-dominant heart, this is the third branch that arises from the circumflex artery atrioventricular groove continuation when counted from proximal to distal. It supplies the posterolateral wall.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102353>	C12843	Third Right Posterolateral Artery|3RD RPL|THIRD RIGHT POSTEROLATERAL ARTERY|THIRD RIGHT POSTEROLATERAL ARTERY SEGMENT	In an individual with a right-dominant heart, this is the third branch that arises from the right coronary artery distal to the right posterior descending artery, when counted from proximal to distal.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102354>	C33735	Transverse Tarsal Joint|Mid-Tarsal Joint|TRANSVERSE TARSAL JOINT	A combination of syndesmosis and synovial joints formed by the articulation of the talus with the navicular and the calcaneus with the cuboid.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102355>	C38061	Study Subject Withdrawal by Parent or Guardian|WITHDRAWAL BY PARENT/GUARDIAN	An indication that a study participant has been removed from the study by the parent or legal guardian.			Finding	CDISC SDTM Reason for Non-Completion Terminology|CDISC SDTM Terminology|CDISC SDTM Tobacco Study Completion/Reason for Non-Completion Terminology|Clinical Data Interchange Standards Consortium Terminology
C102356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102356>	C64774	Accumulation Ratio Area Under the Curve|ARAUC|Accumulation Ratio AUCTAU|Accumulation Ratio AUCTAU	The area under the curve (AUCTAU) at steady state divided by the area under the curve over the initial dosing interval.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102357>	C70918	Accumulation Ratio Cmax|ARCMAX	The maximum concentration at steady state divided by the maximum concentration during the initial dosing interval.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102358>	C85579	Accumulation Ratio Cmin|ARCMIN	The minimum concentration at steady state divided by the minimum concentration during the initial dosing interval.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102359>	C85832	Amount Recovered from T1 to T2|Amt Rec from T1 to T2|Amt Rec from T1 to T2|RCAMINT	The cumulative amount recovered from the specimen type over the interval from T1 to T2.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10235>	C61063	Cisplatin/Fluorouracil/Interleukin-2|CDDP/5-FU/IL-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102360>	C102359	Amount Recovered from T1 to T2 Normalized by Body Mass Index|Amt Rec from T1 to T2 Norm by BMI|Amt Rec from T1 to T2 Norm by BMI|RCAMINTB	The cumulative amount recovered from the specimen type specified in PPSPEC over the interval from T1 to T2 divided by body mass index.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102361>	C102359	Amount Recovered from T1 to T2 Normalized by Surface Area|Amt Rec from T1 to T2 Norm by SA|Amt Rec from T1 to T2 Norm by SA|RCAMINTS	The cumulative amount recovered from the specimen type specified in PPSPEC over the interval from T1 to T2 divided by surface area.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102362>	C102359	Amount Recovered from T1 to T2 Normalized by Weight|Amt Rec from T1 to T2 Norm by WT|Amt Rec from T1 to T2 Norm by WT|RCAMINTW	The cumulative amount recovered from the specimen type specified in PPSPEC over the interval from T1 to T2 divided by weight.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102363>	C85832	Amount Recovered Over Dosing Interval|Amt Rec Over Dosing Interval|Amt Rec Over Dosing Interval|RCAMTAU	The cumulative amount recovered from the specimen type between doses (TAU).			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102364>	C102363	Amount Recovered Over Dosing Interval Normalized by Body Mass Index|Amt Rec Over Dosing Interval Norm by BMI|Amt Rec Over Dosing Interval Norm by BMI|RCAMTAUB	The cumulative amount recovered from the specimen type specified in PPSPEC between doses (TAU) divided by body mass index.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102365>	C102363	Amount Recovered Over Dosing Interval Normalized by Surface Area|Amt Rec Over Dosing Interval Norm by SA|Amt Rec Over Dosing Interval Norm by SA|RCAMTAUS	The cumulative amount recovered from the specimen type specified in PPSPEC between doses (TAU) divided by surface area.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102366>	C102363	Amount Recovered Over Dosing Interval Normalized by Weight|Amt Rec Over Dosing Interval Norm by WT|Amt Rec Over Dosing Interval Norm by WT|RCAMTAUW	The cumulative amount recovered from the specimen type specified in PPSPEC between doses (TAU) divided by weight.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102367>	C41185	Concentration Divided by Body Mass Index|CONCB|Conc by BMI|Conc by BMI	The concentration divided by body mass index.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102368>	C41185	Concentration Divided by Dose|CONCD|Conc by Dose|Conc by Dose	The concentration divided by dose.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102369>	C41185	Concentration Divided by Surface Area|CONCS|Conc by SA|Conc by SA	The concentration divided by surface area.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10236>	C61063	Cisplatin/Mitoxantrone|CDDP/DHAD			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102370>	C41185	Concentration Divided by Weight|CONCW|Conc by WT|Conc by WT	The concentration divided by weight.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102371>	C70917	Initial Volume of Distribution|V0|Vol Dist Initial|Vol Dist Initial	The initial volume of distribution for a substance administered by bolus intravascular dosing.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102372>	C102371	Initial Volume of Distribution Normalized by Body Mass Index|V0B|Vol Dist Initial Norm by BMI|Vol Dist Initial Norm by BMI	The initial volume of distribution for a substance administered by bolus intravascular dosing divided by the body mass index.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102373>	C102371	Initial Volume of Distribution Normalized by Dose|V0D|Vol Dist Initial Norm by Dose|Vol Dist Initial Norm by Dose	The initial volume of distribution for a substance administered by bolus intravascular dosing divided by the dose.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102374>	C102371	Initial Volume of Distribution Normalized by Surface Area|V0S|Vol Dist Initial Norm by SA|Vol Dist Initial Norm by SA	The initial volume of distribution for a substance administered by bolus intravascular dosing divided by the surface area.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102375>	C102371	Initial Volume of Distribution Normalized by Weight|V0W|Vol Dist Initial Norm by WT|Vol Dist Initial Norm by WT	The initial volume of distribution for a substance administered by bolus intravascular dosing divided by the weight.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102376>	C70914	Nonrenal Clearance|NRENALCL|Nonrenal CL|Nonrenal CL	A measurement of the total clearance rate of a substance from the blood minus the renal clearance rate of that substance.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102377>	C85770	Observed Steady State Volume of Distribution Normalized by Body Mass Index|VSSOB|Vol Dist Steady State Obs Norm by BMI|Vol Dist Steady State Obs Norm by BMI	The volume of distribution at steady state based on the observed CLST for a substance administered by intravascular dosing divided by the body mass index.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102378>	C85770	Observed Steady State Volume of Distribution Normalized by Dose|VSSOD|Vol Dist Steady State Obs Norm by Dose|Vol Dist Steady State Obs Norm by Dose	The volume of distribution at steady state based on the observed CLST for a substance administered by intravascular dosing divided by the dose.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102379>	C85770	Observed Steady State Volume of Distribution Normalized by Surface Area|VSSOS|Vol Dist Steady State Obs Norm by SA|Vol Dist Steady State Obs Norm by SA	The volume of distribution at steady state based on the observed CLST for a substance administered by intravascular dosing divided by the surface area.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10237>	C61063	Cyclophosphamide/Interleukin-2|CTX/IL-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102380>	C85770	Observed Steady State Volume of Distribution Normalized by Weight|VSSOW|Vol Dist Steady State Obs Norm by WT|Vol Dist Steady State Obs Norm by WT	The volume of distribution at steady state based on the observed CLST for a substance administered by intravascular dosing divided by the weight.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102381>	C44256	Peak Trough Ratio|PTROUGHR	The ratio of Cmax to Ctrough during a dosing interval.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102382>	C85777	Percent Recovered from T1 to T2|Pct Rec from T1 to T2|Pct Rec from T1 to T2|RCPCINT	The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, over the interval between T1 and T2.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102383>	C102382	Percent Recovered from T1 to T2 Normalized by Body Mass Index|Pct Rec from T1 to T2 Norm by BMI|Pct Rec from T1 to T2 Norm by BMI|RCPCINTB	The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, over the interval between T1 and T2 divided by body mass index.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102384>	C102382	Percent Recovered from T1 to T2 Normalized by Surface Area|Pct Rec from T1 to T2 Norm by SA|Pct Rec from T1 to T2 Norm by SA|RCPCINTS	The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, over the interval between T1 and T2 divided by surface area.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102385>	C102382	Percent Recovered from T1 to T2 Normalized by Weight|Pct Rec from T1 to T2 Norm by WT|Pct Rec from T1 to T2 Norm by WT|RCPCINTW	The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, over the interval between T1 and T2 divided by weight.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102386>	C85777	Percent Recovered Over Dosing Interval|Pct Rec Over Dosing Interval|Pct Rec Over Dosing Interval|RCPCTAU	The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, between doses (TAU).			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102387>	C102386	Percent Recovered Over Dosing Interval Normalized by Body Mass Index|Pct Rec Over Dosing Interval Norm by BMI|Pct Rec Over Dosing Interval Norm by BMI|RCPCTAUB	The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, between doses (TAU) divided by the body mass index.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102388>	C102386	Percent Recovered Over Dosing Interval Normalized by Surface Area|Pct Rec Over Dosing Interval Norm by SA|Pct Rec Over Dosing Interval Norm by SA|RCPCTAUS	The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, between doses (TAU) divided by surface area.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102389>	C102386	Percent Recovered Over Dosing Interval Normalized by Weight|Pct Rec Over Dosing Interval Norm by WT|Pct Rec Over Dosing Interval Norm by WT|RCPCTAUW	The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, between doses (TAU) divided by weight.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10238>	C61063	Cytarabine/Daunorubicin/Dexamethasone/Etoposide/Thioguanine|ARA-C/DM/DNR/TG/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102390>	C85794	Predicted Steady State Volume of Distribution Normalized by Body Mass Index|VSSPB|Vol Dist Steady State Pred Norm by BMI|Vol Dist Steady State Pred Norm by BMI	The volume of distribution at steady state based on the predicted CLST for a substance administered by intravascular dosing divided by the body mass index.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102391>	C85794	Predicted Steady State Volume of Distribution Normalized by Dose|VSSPD|Vol Dist Steady State Pred Norm by Dose|Vol Dist Steady State Pred Norm by Dose	The volume of distribution at steady state based on the predicted CLST for a substance administered by intravascular dosing divided by the dose.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102392>	C85794	Predicted Steady State Volume of Distribution Normalized by Surface Area|VSSPS|Vol Dist Steady State Pred Norm by SA|Vol Dist Steady State Pred Norm by SA	The volume of distribution at steady state based on the predicted CLST for a substance administered by intravascular dosing divided by the surface area.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102393>	C85794	Predicted Steady State Volume of Distribution Normalized by Weight|VSSPW|Vol Dist Steady State Pred Norm by WT|Vol Dist Steady State Pred Norm by WT	The volume of distribution at steady state based on the predicted CLST for a substance administered by intravascular dosing divided by the weight.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102394>	C41185	Trough Concentration|CTROUGH|Conc Trough|Conc Trough|Concentration Trough|Ctrough|Ctrough|Trough Level	Concentration at end of dosing interval.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102395>	C102394	Trough Concentration Divided by Body Mass Index|CTROUGHB|Conc Trough by BMI|Conc Trough by BMI	The trough concentration divided by body mass index.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102396>	C102394	Trough Concentration Divided by Dose|CTROUGHD|Conc Trough by Dose|Conc Trough by Dose	The trough concentration divided by dose.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102397>	C102394	Trough Concentration Divided by Surface Area|CTROUGHS|Conc Trough by SA|Conc Trough by SA	The trough concentration divided by surface area.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102398>	C102394	Trough Concentration Divided by Weight|CTROUGHW|Conc Trough by WT|Conc Trough by WT	The trough concentration divided by weight.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102399>	C38114	Intrajejunal Route of Administration|INTRAJEJUNAL	Administration into the jejunum.			Functional Concept	CDISC SDTM Route of Administration Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10239>	C63588|C63442	CYVE Regimen|ARA-C/VP-16|Ara-C/Etoposide|CYVE|CYVE|Cyclophosphamide and Etoposide (CYVE)|Cytarabine and Etoposide (CYVE)|Cytarabine-Etoposide|Cytarabine/Etoposide|Cytarabine/Etoposide Regimen|Cytarabine/VP-16|Cytarabine/VePesid|Etoposide/Cytarabine	A regimen consisting of cytarabine and etoposide that may be used in the treatment of central nervous system (CNS) lymphomas, Burkitt lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia (ALL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C1023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1023>	C2166	Amoxicillin-Clavulanate Potassium|Augmentin|Augmentin|amoxicillin-clavulanate potassium	A combination of the semisynthetic broad-spectrum antibiotic amoxicillin and the beta-lactamase enzyme inhibitor clavulanate potassium. Clavulanate potassium increases the serum half-life of amoxicillin by inhibiting beta-lactamase-mediated metabolism of amoxicillin.  Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin binding proteins and inhibiting peptidoglycan synthesis, a critical component of bacterial cell walls.			Antibiotic|Organic Chemical|Pharmacologic Substance	NCI Drug Dictionary Terminology
C102400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102400>	C38114	Intrapalatal Route of Administration|INTRAPALATAL	Administration into the palate.			Functional Concept	CDISC SDTM Route of Administration Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102401>	C17102	High Risk|HIGH RISK	The potential future harm that may arise from some present action or attribute or condition is almost certain.			Conceptual Entity	CDISC SDTM Protocol Risk Assessment Response Codelist|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C102402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102402>	C17102	Intermediate Risk|INTERMEDIATE RISK|Moderate Risk	The potential future harm that may arise from some present action or attribute or condition is moderate.			Conceptual Entity	CDISC SDTM Protocol Risk Assessment Response Codelist|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C102403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102403>	C17102	Low Risk|LOW RISK	The potential future harm that may arise from some present action or attribute or condition is small.			Conceptual Entity	CDISC SDTM Protocol Risk Assessment Response Codelist|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C102405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102405>	C48470	Capful Dosing Unit|CAPFUL|Capful|{CAPFUL}|{CAPFUL}|{Capful}|{Capful}	A dosing measurement based on the capful unit.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|NCPDP Dose Unit of Measure Terminology
C102406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102406>	C48564	Centimeter per Second|cm/s|cm/s|cm/s|cm/sec	A unit of both speed (scalar) and velocity (vector), defined as the distance of one centimeter travelled per unit time equal to one second.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102407>	C71330	Decibel|dB|dB|dB|dB|dB|decibel	A unit of measure representing the intensity of an electrical signal or sound which is equal to ten times the logarithm of the ratio of two signals.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C102408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102408>	C101874	ECOG - Performance Status|ECOG1-Performance Status|ECOG1-Performance Status|ECOG101	Eastern Cooperative Oncology Group (ECOG) Performance status.			Intellectual Product	CDISC Clinical Classification ECOG Test Code Terminology|CDISC Clinical Classification ECOG Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102409>	C101881	SOWS Subjective (Handelsman) - I Feel Anxious|SOWSA1-I Feel Anxious|SOWSA1-I Feel Anxious|SOWSA101	Subjective Opiate Withdrawal Scale (SOWS Subjective) I feel anxious.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOWS Subjective Test Code Terminology|CDISC Questionnaire SOWS Subjective Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10240>	C61063	Cytarabine/Mitoxantrone/Thioguanine|ARA-C/DHAD/TG			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102410>	C101881	SOWS Subjective (Handelsman) - I Feel Like Yawning|SOWSA1-I Feel Like Yawning|SOWSA1-I Feel Like Yawning|SOWSA102	Subjective Opiate Withdrawal Scale (SOWS Subjective) I feel like yawning.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOWS Subjective Test Code Terminology|CDISC Questionnaire SOWS Subjective Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102411>	C101881	SOWS Subjective (Handelsman) - I'm Perspiring|SOWSA1-I'm Perspiring|SOWSA1-I'm Perspiring|SOWSA103	Subjective Opiate Withdrawal Scale (SOWS Subjective) I'm perspiring.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOWS Subjective Test Code Terminology|CDISC Questionnaire SOWS Subjective Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102412>	C101881	SOWS Subjective (Handelsman) - My Eyes Are Tearing|SOWSA1-My Eyes Are Tearing|SOWSA1-My Eyes Are Tearing|SOWSA104	Subjective Opiate Withdrawal Scale (SOWS Subjective) My eyes are tearing.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOWS Subjective Test Code Terminology|CDISC Questionnaire SOWS Subjective Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102413>	C101881	SOWS Subjective (Handelsman) - My Nose is Running|SOWSA1-My Nose is Running|SOWSA1-My Nose is Running|SOWSA105	Subjective Opiate Withdrawal Scale (SOWS Subjective) My nose is running.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOWS Subjective Test Code Terminology|CDISC Questionnaire SOWS Subjective Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102414>	C101881	SOWS Subjective (Handelsman) - I Have Goose Flesh|SOWSA1-I Have Goose Flesh|SOWSA1-I Have Goose Flesh|SOWSA106	Subjective Opiate Withdrawal Scale (SOWS Subjective) I have goose flesh.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOWS Subjective Test Code Terminology|CDISC Questionnaire SOWS Subjective Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102415>	C101881	SOWS Subjective (Handelsman) - I Am Shaking|SOWSA1-I Am Shaking|SOWSA1-I Am Shaking|SOWSA107	Subjective Opiate Withdrawal Scale (SOWS Subjective) I am shaking.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOWS Subjective Test Code Terminology|CDISC Questionnaire SOWS Subjective Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102416>	C101881	SOWS Subjective (Handelsman) - I Have Hot Flashes|SOWSA1-I Have Hot Flashes|SOWSA1-I Have Hot Flashes|SOWSA108	Subjective Opiate Withdrawal Scale (SOWS Subjective) I have hot flashes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOWS Subjective Test Code Terminology|CDISC Questionnaire SOWS Subjective Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102417>	C101881	SOWS Subjective (Handelsman) - I Have Cold Flashes|SOWSA1-I Have Cold Flashes|SOWSA1-I Have Cold Flashes|SOWSA109	Subjective Opiate Withdrawal Scale (SOWS Subjective) I have cold flashes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOWS Subjective Test Code Terminology|CDISC Questionnaire SOWS Subjective Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102418>	C101881	SOWS Subjective (Handelsman) - My Bones and Muscles Ache|SOWSA1-My Bones and Muscles Ache|SOWSA1-My Bones and Muscles Ache|SOWSA110	Subjective Opiate Withdrawal Scale (SOWS Subjective) My bones and muscles ache.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOWS Subjective Test Code Terminology|CDISC Questionnaire SOWS Subjective Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102419>	C101881	SOWS Subjective (Handelsman) - I Feel Restless|SOWSA1-I Feel Restless|SOWSA1-I Feel Restless|SOWSA111	Subjective Opiate Withdrawal Scale (SOWS Subjective) I feel restless.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOWS Subjective Test Code Terminology|CDISC Questionnaire SOWS Subjective Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10241>	C61063	Cytarabine/Mitoxantrone/Thioguanine/Vincristine|ARA-C/DHAD/TG/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102420>	C101881	SOWS Subjective (Handelsman) - I Feel Nauseous|SOWSA1-I Feel Nauseous|SOWSA1-I Feel Nauseous|SOWSA112	Subjective Opiate Withdrawal Scale (SOWS Subjective) I feel nauseous.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOWS Subjective Test Code Terminology|CDISC Questionnaire SOWS Subjective Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102421>	C101881	SOWS Subjective (Handelsman) - I Feel Like Vomiting|SOWSA1-I Feel Like Vomiting|SOWSA1-I Feel Like Vomiting|SOWSA113	Subjective Opiate Withdrawal Scale (SOWS Subjective) I feel like vomiting.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOWS Subjective Test Code Terminology|CDISC Questionnaire SOWS Subjective Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102422>	C101881	SOWS Subjective (Handelsman) - My Muscles Twitch|SOWSA1-My Muscles Twitch|SOWSA1-My Muscles Twitch|SOWSA114	Subjective Opiate Withdrawal Scale (SOWS Subjective) My muscles twitch.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOWS Subjective Test Code Terminology|CDISC Questionnaire SOWS Subjective Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102423>	C101881	SOWS Subjective (Handelsman) - I Have Cramps in My Stomach|SOWSA1-I Have Cramps in My Stomach|SOWSA1-I Have Cramps in My Stomach|SOWSA115	Subjective Opiate Withdrawal Scale (SOWS Subjective) I have cramps in my stomach.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOWS Subjective Test Code Terminology|CDISC Questionnaire SOWS Subjective Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102424>	C101881	SOWS Subjective (Handelsman) - I Feel Like Shooting Up Now|SOWSA1-I Feel Like Shooting Up Now|SOWSA1-I Feel Like Shooting Up Now|SOWSA116	Subjective Opiate Withdrawal Scale (SOWS Subjective) I feel like shooting up now.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SOWS Subjective Test Code Terminology|CDISC Questionnaire SOWS Subjective Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102425>	C32958	Lateral Third Obtuse Marginal Branch Artery|LAT 3RD OM|LATERAL THIRD OBTUSE MARGINAL BRANCH ARTERY|LATERAL THIRD OBTUSE MARGINAL BRANCH ARTERY SEGMENT|Third Obtuse Marginal Lateral Branch	The lateral branch distal to a bifurcation of the third obtuse marginal artery.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102426>	C102394	Accumulation Ratio Ctrough|ARCTROUG	The trough concentration at steady state divided by the trough concentration during the initial dosing interval.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102427>	C20917	KHDRBS1 Gene|KH Domain Containing, RNA Binding, Signal Transduction Associated 1 Gene|KHDRBS1|KHDRBS1	This gene is involved in cell cycle progression, RNA splicing and signal transduction regulation.	KHDRBS1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C102428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102428>	C102427	KHDRBS1 wt Allele|FLJ34027|KH Domain Containing, RNA Binding, Signal Transduction Associated 1 wt Allele|SAM68|Sam68|p62|p68	Human KHDRBS1 wild-type allele is located in the vicinity of 1p32 and is approximately 47 kb in length. This allele, which encodes KH domain-containing, RNA-binding, signal transduction-associated protein 1, plays a role in the modulation of Wnt-dependent signaling, cell cycle progression, RNA processing and apoptosis regulation.	KHDRBS1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102429>	C17761	KH Domain-Containing, RNA-Binding, Signal Transduction-Associated Protein 1|GAP-Associated Tyrosine Phosphoprotein p62|KHDRBS1|Sam68|Src-Associated in Mitosis 68 kDa Protein|p21 Ras GTPase-Activating Protein-Associated p62|p68	KH domain-containing, RNA-binding, signal transduction-associated protein 1 (443 aa, ~48 kDa) is encoded by the human KHDRBS1 gene. This protein is involved in signaling pathway modulation and the mediation of alternative RNA splicing that regulates apoptosis.	KH Domain-Containing, RNA-Binding, Signal Transduction-Associated Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10242>	C61063	Etoposide/Mitomycin|MITO/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102430>	C37900	Vaccine Provider	A person or organization that is licensed, certified or otherwise authorized or permitted by law to administer vaccinations in the ordinary course of business or practice of a profession.	Vaccine Provider		Professional or Occupational Group	CTRP Intervention Terminology|CTRP Terminology|FDA Individual Case Safety Report Terminology|Type of Reporter ICSR Terminology
C102431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102431>	C39409	Funding Source for Product	Source of money used to acquire the product.			Functional Concept	FDA Individual Case Safety Report Terminology|Observation ICSR Terminology
C102432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102432>	C102431	Private Funding|Private Funds|Private Funds	Money available for projects or products in the private sector that does not include government contribution, grants or contracts.			Functional Concept	FDA Individual Case Safety Report Terminology|Observation ICSR Terminology
C102433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102433>	C102431	Military Funding|Military Funds|Military Funds	Government funds available to support military operations.			Functional Concept	FDA Individual Case Safety Report Terminology|Observation ICSR Terminology
C102434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102434>	C102431	Public Funding|Public Funds|Public Funds	Money available in the public sector, including the local, city, county, state and federal government.			Functional Concept	FDA Individual Case Safety Report Terminology|Observation ICSR Terminology
C102436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102436>	C25716	Required Emergency Room or Doctor Visit	An event in which a visit to the emergency room or to the doctor is considered essential to prevent permanent impairment or damage.			Event	
C102437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102437>	C20849	S100A4 Gene|S100 Calcium Binding Protein A4 Gene|S100A4|S100A4	This gene is involved in both signaling and calcium binding.	S100A4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C102438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102438>	C102437	S100A4 wt Allele|18A2|42A|CAPL|FSP1|MTS1|Malignant Transformation Suppression 1 Gene|P9KA|PEL98|S100 Calcium Binding Protein A4 wt Allele|S100 Calcium-Binding Protein A4 (Calcium Protein, Calvasculin, Metastasin, Murine Placental Homolog) Gene	Human S100A4 wild-type allele is located in the vicinity of 1q21 and is approximately 7 kb in length. This allele, which encodes protein S100-A4, plays a role in calcium binding, cell differentiation and signaling.	S100A4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102439>	C29924	Protein S100-A4|Calcium Placental Protein|Calvasculin|Fibroblast-Specific Protein-1|Leukemia Multidrug Resistance Associated Protein|Malignant Transformation Suppression 1|Metastasin|Placental Calcium-Binding Protein|Protein Mts1|S100 Calcium-Binding Protein A4|S100A4	Protein S100-A4 (101 aa, ~12 kDa) is encoded by the human S100A4 gene. This protein is involved in both the positive regulation of signaling and calcium binding.	Protein S100-A4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10243>	C61063	Fluorouracil/PALA|5-FU/PALA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102440>	C26057	CHD8 Gene|CHD8|CHD8|Chromodomain Helicase DNA Binding Protein 8 Gene	This gene plays a role in both chromatin remodeling and transcriptional regulation.			Gene or Genome	
C102441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102441>	C102440	CHD8 wt Allele|Axis Duplication Inhibitor Gene|Chromodomain Helicase DNA Binding Protein 8 wt Allele|DKFZp686N17164|DUPLIN|HELSNF1|KIAA1564	Human CHD8 wild-type allele is located in the vicinity of 14q11.2 and is approximately 71 kb in length. This allele, which encodes chromodomain-helicase-DNA-binding protein 8, is involved in both transcriptional regulation and chromatin modification.			Gene or Genome	
C102442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102442>	C16517	Chromodomain-Helicase-DNA-Binding Protein 8|ATP-Dependent Helicase CHD8|CHD-8|CHD8|Chromodomain Helicase DNA-Binding Protein 8|Duplin|EC 3.6.4.12|Helicase with SNF2 Domain 1	Chromodomain-helicase-DNA-binding protein 8 (2581 aa, ~291 kDa) is encoded by the human CHD8 gene. This protein plays a role in chromatin remodeling that regulates transcription.			Amino Acid, Peptide, or Protein|Enzyme	
C102443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102443>	C25337	Number of Hospitalization Days	The number of inpatient hospital days.			Quantitative Concept	Adverse Event Outcome ICSR Terminology|FDA Individual Case Safety Report Terminology
C102444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102444>	C25993	SCN2A Gene|SCN2A|SCN2A|Sodium Voltage-Gated Channel Alpha Subunit 2 Gene	This gene is involved in neuronal excitation.			Gene or Genome	
C102445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102445>	C102444	SCN2A wt Allele|BFIC3|BFIS3|BFNIS|EIEE11|HBA|HBSCI|HBSCII|NAC2|Na(v)1.2|Nav1.2|SCN2A1|SCN2A2|Sodium Channel, Brain Type II, Alpha Subunit Gene|Sodium Channel, Neuronal Type II, Alpha Subunit Gene|Sodium Channel, Neuronal Type II, Alpha Subunit-1 Gene|Sodium Channel, Voltage Gated, Type II, Alpha Subunit Gene|Sodium Channel, Voltage-Gated, Type II, Alpha 1 Polypeptide Gene|Sodium Channel, Voltage-Gated, Type II, Alpha 2 Polypeptide Gene|Sodium Channel, Voltage-Gated, Type II, Alpha Polypeptide Gene|Sodium Channel, Voltage-Gated, Type II, Alpha Subunit Gene|Sodium Voltage-Gated Channel Alpha Subunit 2 wt Allele	Human SCN2A wild-type allele is located in the vicinity of 2q24.3 and is approximately 153 kb in length. This allele, which encodes sodium channel protein type 2 subunit alpha protein, plays a role in both sodium transport and membrane potential. Mutation of the gene is associated with both benign familial infantile type 3 seizures and epileptic encephalopathy early infantile type 11.			Gene or Genome	
C102446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102446>	C28505	Sodium Channel Protein Type 2 Subunit Alpha|HBSC II|SCN2A|Sodium Channel Protein Brain II Subunit Alpha|Sodium Channel Protein Type II Subunit Alpha|Voltage-Gated Sodium Channel Subunit Alpha Nav1.2	Sodium channel protein type 2 subunit alpha (2005 aa, ~228 kDa) is encoded by the human SCN2A gene. This protein is involved in membrane polarization.			Amino Acid, Peptide, or Protein	
C102447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102447>	C25993	SCN1A Gene|SCN1A|SCN1A|Sodium Voltage-Gated Channel Alpha Subunit 1 Gene	This gene is involved in sodium transport.	SCN1A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C102448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102448>	C102447	SCN1A wt Allele|EIEE6|FEB3|FEB3A|FHM3|Febrile Convulsions 3 Gene|GEFSP2|HBSCI|NAC1|NAV1.1|Nav1.1|SCN1|SMEI|Sodium Channel, Brain Type I, Alpha Subunit Gene|Sodium Channel, Neuronal Type I, Alpha Subunit Gene|Sodium Channel, Voltage Gated, Type I, Alpha Subunit Gene|Sodium Channel, Voltage-Gated, Type I, Alpha Subunit Gene|Sodium Voltage-Gated Channel Alpha Subunit 1 wt Allele	Human SCN1A wild-type allele is located in the vicinity of 2q24.3 and is approximately 84 kb in length. This allele, which encodes sodium channel protein type 1 subunit alpha, plays a role in voltage-gated sodium transport. Mutation of the gene is associated with generalized epilepsy with febrile seizures plus type 2, Dravet syndrome, intractable childhood epilepsy with generalized tonic-clonic seizures, familial hemiplegic migraine type 3 and familial febrile convulsions type 3A.	SCN1A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102449>	C28505	Sodium Channel Protein Type 1 Subunit Alpha|Nav1.1|SCN1A|Sodium Channel Protein Brain I Subunit Alpha|Sodium Channel Protein Type I Subunit Alpha|Voltage-Gated Sodium Channel Subunit Alpha Nav1.1	Sodium channel protein type 1 subunit alpha (2009 aa, ~229 kDa) is encoded by the human SCN1A gene. This protein is involved in the modulation of sodium transport.	Sodium Channel Protein Type 1 Subunit Alpha		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10244>	C61063	Ifosfamide/Mitoxantrone|DHAD/IFF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102450>	C50414	Resulted in Prolongation of Hospitalization|Resulted in prolongation of hospitalization	An indication or description that an extended period of hospitalization is necessary.			Finding	Adverse Event Outcome ICSR Terminology|FDA Individual Case Safety Report Terminology
C102451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102451>	C21055	Disability or Permanent Damage|Resulted in permanent disability|Resulted in permanent disability	A sustained and substantial impairment or disruption of a person's ability to conduct normal life functions for the remainder of his/her life.			Finding	Adverse Event Outcome ICSR Terminology|FDA Individual Case Safety Report Terminology
C102452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102452>	C25804	KATNAL2 Gene|KATNAL2|KATNAL2|Katanin Catalytic Subunit A1 Like 2 Gene	This gene plays a role in ATP hydrolysis.			Gene or Genome	
C102453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102453>	C102452	KATNAL2 wt Allele|DKFZp667C165|Katanin Catalytic Subunit A Like 2 Gene|Katanin Catalytic Subunit A1 Like 2 wt Allele|Katanin p60 Subunit A Like 2 Gene|Katanin p60 Subunit A-Like 2 Gene|MGC33211	Human KATNAL2 wild-type allele is located in the vicinity of 18q21.1 and is approximately 102 kb in length. This allele, which encodes katanin p60 ATPase-containing subunit A-like 2 protein, is involved in both ATP hydrolysis and microtubule depolymerization.			Gene or Genome	
C102454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102454>	C16701	Katanin p60 ATPase-Containing Subunit A-Like 2|EC 3.6.4.3|KATNA-Like 2|KATNAL2|Katanin p60 Subunit A-Like 2|p60 Katanin-Like 2	Katanin p60 ATPase-containing subunit A-like 2 (538 aa, ~61 kDa) is encoded by the human KATNAL2 gene. This protein plays a role in both hydrolysis of ATP and microtubule dynamics.			Amino Acid, Peptide, or Protein|Enzyme	
C102455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102455>	C38187	NTNG1 Gene|NTNG1|NTNG1|Netrin G1 Gene	This gene is involved in axon formation.			Gene or Genome	
C102456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102456>	C102455	NTNG1 wt Allele|Axon Guidance Molecule Gene|KIAA0976|LMNT1|Lmnt1|Netrin G1 wt Allele|UNQ571/PRO1133|YLSR571	Human NTNG1 wild-type allele is located in the vicinity of 1p13.3 and is approximately 343 kb in length. This allele, which encodes netrin-G1 protein, plays a role in neurite outgrowth.			Gene or Genome	
C102457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102457>	C686	Netrin-G1|Laminet 1|Laminet-1|Netrin G1	Netrin-G1 (539 aa, ~61 kDa) is encoded by the human NTNG1 gene. This protein is involved in axonogenesis.			Amino Acid, Peptide, or Protein	
C102458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102458>	C25993|C20103	GRIN2B Gene|GRIN2B|GRIN2B|Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 2B Gene	This gene plays a role in both neurotransmitter binding and ion transport.	GRIN2B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C102459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102459>	C102458	GRIN2B wt Allele|EIEE27|GluN2B|Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 2B wt Allele|Glutamate Receptor, Ionotropic, N-Methyl-D-Aspartate 2B Gene|MGC142178|MGC142180|MRD6|NMDAR2B|NR2B|hNR3	Human GRIN2B wild-type allele is located in the vicinity of 12p12 and is approximately 419 kb in length. This allele, which encodes glutamate receptor ionotropic, NMDA 2B protein, is involved in both glutamate binding and calcium transport. Mutation of the gene and chromosomal translocations involving the gene, t(9;12)(p23;p13.1) and t(10;12)(q21.1;p13.1), are associated with mental retardation.	GRIN2B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10245>	C61063	Interferon Gamma/Tumor Necrosis Factor|IFN-G/TNF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102460>	C28505|C18106	Glutamate Receptor Ionotropic, NMDA 2B|GRIN2B|GluN2B|Glutamate Receptor Subunit Epsilon-2|Glutamate [NMDA] Receptor Subunit Epsilon-2|N-Methyl D-Aspartate Receptor Subtype 2B|N-Methyl-D-Aspartate Receptor Channel, Subunit Epsilon-2|N-Methyl-D-Aspartate Receptor Subunit 2B|N-Methyl-D-Aspartate Receptor Subunit 3|NMDAR2B|NR2B|NR3|hNR3	Glutamate receptor ionotropic, NMDA 2B (1484 aa, ~166 kDa) is encoded by the human GRIN2B gene. This protein plays a role in both calcium transport and glutamate binding.	Glutamate Receptor Ionotropic, NMDA 2B		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102461>	C20103	SCARB1 Gene|SCARB1|SCARB1|Scavenger Receptor Class B, Member 1 Gene	This gene is involved in lipid and lipoprotein binding.	SCARB1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C102462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102462>	C102461	SCARB1 wt Allele|CD36 Antigen (Collagen Type I Receptor, Thrombospondin Receptor)-Like 1 Gene|CD36 Antigen-Like 1 Gene|CD36L1|CLA-1|CLA1|HDLQTL6|MGC138242|SR-B1|SR-BI|SRB1|Scavenger Receptor Class B, Member 1 wt Allele|Scavenger Receptor, Class B, Member 1 Gene	Human SCARB1 wild-type allele is located in the vicinity of 12q24.31 and is approximately 106 kb in length. This allele, which encodes scavenger receptor class B member 1 protein, plays a role in both binding and import of lipids and lipoproteins.	SCARB1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102463>	C18106	Scavenger Receptor Class B Member 1|CD36 Antigen-Like 1|CD36 and LIMPII Analogous 1|CD36L1|CLA-1|Collagen Type I Receptor, Thrombospondin Receptor-Like 1|SCARB1|SR-BI	Scavenger receptor class B member 1 (552 aa, ~61 kDa) is encoded by the human SCARB1 gene. This protein is involved in the import of lipoproteins.	Scavenger Receptor Class B Member 1		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C102464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102464>	C25869|C20988	CD151 Gene|CD151|CD151|CD151 Molecule (Raph Blood Group) Gene	This gene plays a role in cell-matrix adhesion.			Gene or Genome	
C102465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102465>	C102464	CD151 wt Allele|CD151 Antigen Gene|CD151 Molecule (Raph Blood Group) wt Allele|GP27|MER2|PETA-3|PETA3|RAPH|SFA-1|SFA1|TSPAN24	Human CD151 wild-type allele is located in the vicinity of 11p15.5 and is approximately 7 kb in length. This allele, which encodes CD151 antigen protein, is involved in both signaling and epithelial cell adhesion to the basal lamina. Mutation of the gene is associated with nephropathy with pretibial epidermolysis bullosa and deafness.			Gene or Genome	
C102466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102466>	C16393	CD151 Antigen|Antigen CD151|CD151|GP27|Membrane Glycoprotein SFA-1|PETA-3|Platelet-Endothelial Tetraspan Antigen 3|Tetraspanin-24|Tspan-24	CD151 antigen (253 aa, ~28 kDa) is encoded by the human CD151 gene. This protein plays a role in both cell adhesion and signal transduction.			Amino Acid, Peptide, or Protein	
C102467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102467>	C15346	Other Vaccinations Given within Four Weeks|Other Vaccinations Given within 4 Weeks|Other vaccinations given within 4 weeks	Vaccines that the patient received within four weeks prior to the current vaccine administration date being reported.			Finding	FDA Individual Case Safety Report Terminology|Observation ICSR Terminology
C102468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102468>	C156809	Illness at Time of Vaccination|Illness at time of vaccination	Illnesses that exist and/or were observed in a patient at the time the patient received vaccination.			Finding	FDA Individual Case Safety Report Terminology|Observation ICSR Terminology
C102469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102469>	C17468	Number of Siblings	An individual's total number of brothers and sisters.			Qualitative Concept	FDA Individual Case Safety Report Terminology|Observation ICSR Terminology
C10246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10246>	C61007	Interleukin-2/Lymphokine-Activated Killer Cells|IL-2/LAK|IL2/LAK			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102470>	C52681	Adverse Event Following Immunization|AEFI|Adverse event following prior vaccination	Any unfavorable or unintended symptom, sign, or disease including an abnormal laboratory finding) temporally associated with the previous administration of vaccine(s) that may or may not be considered related to the vaccine administration. Such events can be intervention related, dose related, route related, patient related, or caused by an interaction with other product(s) or procedure(s).			Finding	FDA Individual Case Safety Report Terminology|Observation ICSR Terminology
C102471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102471>	C20420	YY1 Gene|YY1|YY1|YY1 Transcription Factor Gene	This gene is involved in the negative regulation of transcription.			Gene or Genome	
C102472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102472>	C102471	YY1 wt Allele|DELTA|INO80S|NF-E1|UCRBP|YIN-YANG-1|YY1 Transcription Factor wt Allele	Human YY1 wild-type allele is located within 14q and is approximately 44 kb in length. This allele, which encodes transcriptional repressor protein YY1, plays a role in both transcriptional repression and DNA repair.			Gene or Genome	
C102473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102473>	C17207	Transcriptional Repressor Protein YY1|Delta Transcription Factor|INO80 Complex Subunit S|NF-E1|YY-1|Yin and Yang 1	Transcriptional repressor protein YY1 (414 aa, ~45 kDa) is encoded by the human YY1 gene. This protein is involved in both DNA repair and the repression of transcription.			Amino Acid, Peptide, or Protein	
C102474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102474>	C20420	MLXIPL Gene|MLX Interacting Protein-Like Gene|MLXIPL|MLXIPL	This gene plays a role in both DNA binding and transcriptional regulation.			Gene or Genome	
C102475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102475>	C102474	MLXIPL wt Allele|BHLHD14|CHREBP|MIO|MLX Interacting Protein-Like wt Allele|MONDOB|WBSCR14|WS-bHLH|Williams Beuren Syndrome Chromosome Region 14 Gene|bHLHd14	Human MLXIPL wild-type allele is located in the vicinity of 7q11.23 and is approximately 31 kb in length. This allele, which encodes carbohydrate-responsive element-binding protein, is involved in the regulation of transcription. Deletion of the gene is associated with Williams-Beuren syndrome.			Gene or Genome	
C102476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102476>	C17207	Carbohydrate-Responsive Element-Binding Protein|ChREBP|Class D Basic Helix-Loop-Helix Protein 14|MLX Interactor|MLX-Interacting Protein-Like|MLXIPL|WS Basic-Helix-Loop-Helix Leucine Zipper Protein|WS-bHLH|Williams-Beuren Syndrome Chromosomal Region 14 Protein|bHLHd14	Carbohydrate-responsive element-binding protein (852 aa, ~93 kDa) is encoded by the human MLXIPL gene. This protein plays a role in transcriptional regulation.			Amino Acid, Peptide, or Protein	
C102477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102477>	C26147	MGAT4C Gene|MGAT4C|MGAT4C|Mannosyl (Alpha-1,3-)-Glycoprotein Beta-1,4-N-Acetylglucosaminyltransferase, Isozyme C (Putative) Gene	This gene is involved in protein glycosylation.			Gene or Genome	
C102478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102478>	C102477	MGAT4C wt Allele|GNT-IV-H|GNTIVH|HGNT-IV-H|Mannosyl (Alpha-1,3-)-Glycoprotein Beta-1,4-N-Acetylglucosaminyltransferase, Isozyme C (Putative) wt Allele	Human MGAT4C wild-type allele is located in the vicinity of 12q21 and is approximately 860 kb in length. This allele, which encodes alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase C protein, plays a role in post-translational protein modification.			Gene or Genome	
C102479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102479>	C17434	Alpha-1,3-Mannosyl-Glycoprotein 4-Beta-N-Acetylglucosaminyltransferase C|EC 2.4.1.145|GlcNAc-T IVc|GnT-IVc|MGAT4C|N-Acetylglucosaminyltransferase IV Homolog|N-Acetylglucosaminyltransferase IVc|N-Glycosyl-Oligosaccharide-Glycoprotein N-Acetylglucosaminyltransferase IVc|UDP-N-Acetylglucosamine: Alpha-1,3-D-Mannoside Beta-1,4-N-Acetylglucosaminyltransferase IVc|hGnT-IV-H	Alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase C (478 aa, ~56 kDa) is encoded by the human MGAT4C gene. This protein is involved in protein glycosylation.			Amino Acid, Peptide, or Protein|Enzyme	
C10247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10247>	C61063	Asparaginase/Cytarabine/Prednisone/Vincristine|AOPA|ARA-C/ASP/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102480>	C26006	UNC119 Gene|UNC119|UNC119|Unc-119 Homolog (C. elegans) Gene	This gene plays a role in protein trafficking.			Gene or Genome	
C102481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102481>	C102480	UNC119 wt Allele|HRG4|POC7|POC7A|RG4|Unc-119 Homolog (C. elegans) wt Allele	Human UNC119 wild-type allele is located in the vicinity of 17q11.2 and is approximately 6 kb in length. This allele, which encodes protein unc-119 homolog A, is involved in the modulation of subcellular protein localization. Mutation of the gene is associated with cone-rod dystrophy.			Gene or Genome	
C102482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102482>	C16386	Protein Unc-119 Homolog A|Retinal Protein 4|UNC119|hRG4	Protein unc-119 homolog A (240 aa, ~27 kDa) is encoded by the human UNC119 gene. This protein plays a role in subcellular protein localization.			Amino Acid, Peptide, or Protein	
C102483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102483>	C25941	FKBP1A Gene|FKBP Prolyl Isomerase 1A Gene|FKBP1A|FKBP1A	This gene is involved in both signaling and protein folding.	FKBP1A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C102484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102484>	C102483	FKBP1A wt Allele|FK506 Binding Protein 1A, 12kDa Gene|FK506 Binding Protein, 12-kD Gene|FK506 Binding Protein, T-Cell Gene|FK506-Binding Protein 1 Gene|FK506-Binding Protein 1A (12kD) Gene|FK506-Binding Protein, T-Cell, 12-kD Gene|FKBP Prolyl Isomerase 1A wt Allele|FKBP-12|FKBP-1A|FKBP1|FKBP12|PKC12|PKCI2|PPIASE|RP11-314N13.2	Human FKBP1A wild-type allele is located in the vicinity of 20p13 and is approximately 24 kb in length. This allele, which encodes peptidyl-prolyl cis-trans isomerase FKBP1A protein, plays a role in the regulation of both signal transduction and protein folding.	FKBP1A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102485>	C16759	Peptidyl-Prolyl Cis-Trans Isomerase FKBP1A|12 kDa FK506-Binding Protein|12 kDa FKBP|Calstabin 1|Calstabin-1|Calstabin1|EC 5.2.1.8|FK506-Binding Protein 1A|FKBP Prolyl Isomerase 1A|FKBP-12|FKBP-1A|FKBP1A|Immunophilin FKBP12|PPIase FKBP1A|Protein Kinase C Inhibitor 2|Rotamase	Peptidyl-prolyl cis-trans isomerase FKBP1A (108 aa, ~12 kDa) is encoded by the human FKBP1A gene. This protein is involved in both protein folding and the modulation of TGF-beta signaling.	Peptidyl-Prolyl Cis-Trans Isomerase FKBP1A		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102486>	C25993	TRPC4 Gene|TRPC4|TRPC4|Transient Receptor Potential Cation Channel, Subfamily C, Member 4 Gene	This gene plays a role in calcium ion transport.			Gene or Genome	
C102487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102487>	C102486	TRPC4 wt Allele|HTRP-4|HTRP4|MGC119570|MGC119571|MGC119572|MGC119573|TRP4|Transient Receptor Potential Cation Channel, Subfamily C, Member 4 wt Allele	Human TRPC4 wild-type allele is located in the vicinity of 13q13.3 and is approximately 234 kb in length. This allele, which encodes short transient receptor potential channel 4 protein, is involved in the modulation of cellular calcium.			Gene or Genome	
C102488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102488>	C28505	Short Transient Receptor Potential Channel 4|Trp-Related Protein 4|TrpC4|hTrp-4|hTrp4	Short transient receptor potential channel 4 (977 aa, ~112 kDa) is encoded by the human TRPC4 gene. This protein plays a role in the transport of calcium.			Amino Acid, Peptide, or Protein	
C102489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102489>	C25804	HDAC7 Gene|HDAC7|HDAC7|Histone Deacetylase 7 Gene	This gene is involved in both histone modification and chromatin modeling.	HDAC7 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10248>	C61063	Asparaginase/Cyclophosphamide/Cytarabine|ARA-C/ASP/CTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102490>	C102489	HDAC7 wt Allele|DKFZP586J0917|DKFZp586J0917|FLJ99588|HD7A|HDAC7A|Histone Deacetylase 7 wt Allele	Human HDAC7 wild-type allele is located in the vicinity of 12q13.1 and is approximately 50 kb in length. This allele, which encodes histone deacetylase 7 protein, plays a role in histone modification.	HDAC7 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102491>	C16682	Histone Deacetylase 7|EC 3.5.1.98|HD7|HD7a|HDAC7|Histone Deacetylase 7A	Histone deacetylase 7 (952 aa, ~103 kDa) is encoded by the human HDAC7 gene. This protein is involved in chromatin remodeling.	Histone Deacetylase 7		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102492>	C25804	HDAC9 Gene|HDAC9|HDAC9|Histone Deacetylase 9 Gene	This gene plays a role in chromatin modification.	HDAC9 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C102493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102493>	C102492	HDAC9 wt Allele|DKFZp779K1053|HD7|HD7b|HD9|HDAC|HDAC7|HDAC7B|HDAC9B|HDAC9FL|HDRP|Histone Deacetylase 9 wt Allele|KIAA0744|MITR	Human HDAC9 wild-type allele is located in the vicinity of 7p21.1 and is approximately 910 kb in length. This allele, which encodes histone deacetylase 9 protein, is involved in the modification of histones.	HDAC9 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102494>	C16682	Histone Deacetylase 9|EC 3.5.1.98|HD7|HD7b|HD9|HDAC9|Histone Deacetylase 7B|Histone Deacetylase-Related Protein|MEF2-Interacting Transcription Repressor MITR|MITR	Histone deacetylase 9 (1011 aa, ~111 kDa) is encoded by the human HDAC9 gene. This protein plays a role in the modification of chromatin structure.	Histone Deacetylase 9		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102495>	C20194	CDK5R1 Gene|CDK5R1|CDK5R1|Cyclin-Dependent Kinase 5, Regulatory Subunit 1 (p35) Gene	This gene is involved in neuronal differentiation.			Gene or Genome	
C102496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102496>	C102495	CDK5R1 wt Allele|CDK5P35|CDK5R|Cyclin-Dependent Kinase 5, Regulatory Subunit 1 (p35) wt Allele|MGC33831|NCK5A|p23|p25|p35|p35nck5a	Human CDK5R1 wild-type allele is located in the vicinity of 17q11.2 and is approximately 5 kb in length. This allele, which encodes cyclin-dependent kinase 5 activator 1 protein, plays a role in the regulation of neurite outgrowth.			Gene or Genome	
C102497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102497>	C18466	Cyclin-Dependent Kinase 5 Activator 1|CDK5 Activator 1|Cyclin-Dependent Kinase 5 Regulatory Subunit 1|TPKII Regulatory Subunit	Cyclin-dependent kinase 5 activator 1 (307 aa, ~34 kDa) is encoded by the human CDK5R1 gene. This protein is involved in the modulation of both kinase activity and neuronal development.			Amino Acid, Peptide, or Protein	
C102498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102498>	C20923	S1PR1 Gene|S1PR1|S1PR1|Sphingosine-1-Phosphate Receptor 1 Gene	This gene plays a role in lipid binding.	S1PR1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C102499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102499>	C102498	S1PR1 wt Allele|CD363|CHEDG1|D1S3362|ECGF1|EDG-1|EDG1|Endothelial Differentiation, Sphingolipid G-Protein-Coupled Receptor, 1 Gene|FLJ58121|S1P1|Sphingosine-1-Phosphate Receptor 1 wt Allele	Human S1PR1 wild-type allele is located in the vicinity of 1p21 and is approximately 5 kb in length. This allele, which encodes sphingosine 1-phosphate receptor 1 protein, is involved in sphingolipid binding.	S1PR1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10249>	C61063	Fluorouracil/Methotrexate/PALA|5-FU/MTX/PALA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1024>	C2139	Bropirimine|2-Amino-5-bromo-6-phenyl-4(3H)-pyrimidone|2-amino-5-bromo-6-phenyl-4-(3H)-pyrimidinone|4(3H)-Pyrimidinone, 2-amino-5-bromo-6-phenyl-|4-Pyrimidinol, 2-amino-5-bromo-6-phenyl-|4-Pyrimidinol, 2-amino-5-bromo-6-phenyl-|ABPP|ABPP|BROPIRIMINE|Remisar|U-54,461	An oral immunostimulant that causes the body to produce interferon and other substances.			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C102500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102500>	C18239	Sphingosine 1-Phosphate Receptor 1|Antigen CD363|CD363|CD363 Antigen|Endothelial Differentiation G-Protein Coupled Receptor 1|S1P Receptor 1|S1P Receptor Edg-1|S1P1|Sphingosine 1-Phosphate Receptor Edg-1	Sphingosine 1-phosphate receptor 1 (382 aa, ~43 kDa) is encoded by the human S1PR1 gene. This protein plays a role in phospholipid binding.	Sphingosine 1-Phosphate Receptor 1		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102501>	C20420	KLF5 Gene|KLF5|KLF5|Kruppel-Like Factor 5 (Intestinal) Gene	This gene plays a role in the positive regulation of transcription.			Gene or Genome	
C102502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102502>	C102501	KLF5 wt Allele|BTEB2|CKLF|IKLF|Kruppel-Like Factor 5 (Intestinal) wt Allele	Human KLF5 wild-type allele is located in the vicinity of 13q22.1 and is approximately 23 kb in length. This allele, which encodes Krueppel-like factor 5 protein, is involved in the regulation of transcription.			Gene or Genome	
C102503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102503>	C17207	Krueppel-Like Factor 5|BTE-Binding Protein 2|Basic Transcription Element-Binding Protein 2|Colon Krueppel-Like Factor|GC-Box-Binding Protein 2|Intestinal-Enriched Krueppel-Like Factor|KLF5|Transcription Factor BTEB2	Krueppel-like factor 5 (457 aa, ~51 kDa) is encoded by the human KLF5 gene. This protein plays a role in transcriptional activation.			Amino Acid, Peptide, or Protein	
C102504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102504>	C25870	QPCT Gene|Glutaminyl-Peptide Cyclotransferase Gene|QPCT|QPCT	This gene is involved in protein modification.			Gene or Genome	
C102505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102505>	C102504	QPCT wt Allele|GCT|Glutaminyl-Peptide Cyclotransferase wt Allele|QC|sQC	Human QPCT wild-type allele is located in the vicinity of 2p22.2 and is approximately 29 kb in length. This allele, which encodes glutaminyl-peptide cyclotransferase protein, plays a role in the post-translational protein modification.			Gene or Genome	
C102506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102506>	C16259	Glutaminyl-Peptide Cyclotransferase|EC 2.3.2.5|Glutaminyl Cyclase|Glutaminyl-tRNA Cyclotransferase|Glutamyl Cyclase|QC|sQC	Glutaminyl-peptide cyclotransferase (361 aa, ~41 kDa) is encoded by the human QPCT gene. This protein is involved in the synthesis of cyclic glutamyl peptides.			Amino Acid, Peptide, or Protein|Enzyme	
C102507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102507>	C20420	FOXA3 Gene|FOXA3|FOXA3|Forkhead Box A3 Gene	This gene plays a role in the activation of transcription.			Gene or Genome	
C102508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102508>	C102507	FOXA3 wt Allele|FKHH3|Forkhead Box A3 wt Allele|HNF3G|Hepatocyte Nuclear Factor 3, Gamma Gene|MGC10179|TCF3G	Human FOXA3 wild-type allele is located within 19q13.2-q13.4 and is approximately 10 kb in length. This allele, which encodes hepatocyte nuclear factor 3-gamma protein, is involved in transcriptional activation.			Gene or Genome	
C102509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102509>	C17207	Hepatocyte Nuclear Factor 3-Gamma|Fork head-Related Protein FKH H3|Forkhead Box Protein A3|HNF-3-Gamma|HNF-3G|TCF-3G|Transcription Factor 3G	Hepatocyte nuclear factor 3-gamma (350 aa, ~37 kDa) is encoded by the human FOXA3 gene. This protein plays a role in the positive regulation of transcription.			Amino Acid, Peptide, or Protein	
C10250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10250>	C61063	Carboplatin/Vinblastine|CBDCA/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102510>	C16615	NKX2-5 Gene|NK2 Homeobox 5 Gene|NKX2-5|NKX2-5	This gene plays a role in both transcriptional regulation and heart development.			Gene or Genome	
C102511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102511>	C102510	NKX2-5 wt Allele|CHNG5|CSX|CSX1|FLJ52202|FLJ97166|FLJ97195|FLJ97197|FLJ99536|HLHS2|NK2 Homeobox 5 wt Allele|NKX2.5|NKX2E|NKX4-1|Tinman Paralog (Drosophila) Gene|VSD3	Human NKX2-5 wild-type allele is located in the vicinity of 5q34 and is approximately 3 kb in length. This allele, which encodes homeobox protein Nkx-2.5, is involved in both heart development and the modulation of transcription. Mutation of the gene is associated with atrial septal defect type 7, tetralogy of Fallot, and congenital hypothyroidism non-goitrous type 5.			Gene or Genome	
C102512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102512>	C17207	Homeobox Protein Nkx-2.5|Cardiac-Specific Homeobox|Homeobox Protein CSX|Homeobox Protein NK-2 Homolog E	Homeobox protein Nkx-2.5 (324 aa, ~35 kDa) is encoded by the human NKX2-5 gene. This protein plays a role in myocardial differentiation.			Amino Acid, Peptide, or Protein	
C102513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102513>	C28533	SLC12A2 Gene|SLC12A2|SLC12A2|Solute Carrier Family 12 (Sodium/Potassium/Chloride Transporters), Member 2 Gene	This gene is involved in ion transport.			Gene or Genome	
C102514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102514>	C102513	SLC12A2 wt Allele|BSC|BSC2|MGC104233|NKCC1|Solute Carrier Family 12 (Sodium/Potassium/Chloride Transporters), Member 2 wt Allele	Human SLC12A2 wild-type allele is located in the vicinity of 5q23.3 and is approximately 106 kb in length. This allele, which encodes solute carrier family 12 member 2 protein, plays a role in cellular homeostasis.			Gene or Genome	
C102515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102515>	C16386	Solute Carrier Family 12 Member 2|Basolateral Na-K-Cl Symporter|Bumetanide-Sensitive Sodium-(Potassium)-Chloride Cotransporter 1|SLC12A2	Solute carrier family 12 member 2 (1212 aa, ~131 kDa) is encoded by the human SLC12A2 gene. This protein is involved in ion reabsorption.			Amino Acid, Peptide, or Protein	
C102516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102516>	C63534	Image Plane|ANTPLANE|Anatomical Plane|Anatomical Plane	The position and orientation of the image slice relative to the patient-based coordinate system.			Spatial Concept	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102517>	C20921	PREX2 Gene|PREX2|PREX2|PREX2|Phosphatidylinositol-3,4,5-Trisphosphate-Dependent Rac Exchange Factor 2 Gene	This gene is involved in guanine nucleotide exchange activity that regulates the GTPase activity of Rac family proteins.			Gene or Genome	GDC Terminology|GDC Value Terminology
C102518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102518>	C102517	PREX2 wt Allele|6230420N16Rik|DEP.2|DEPDC2|FLJ12987|P-REX2|Phosphatidylinositol-3,4,5-Trisphosphate-Dependent Rac Exchange Factor 2 wt Allele	Human PREX2 wild-type allele is located in the vicinity of 8q13.2 and is approximately 285 kb in length. This allele, which encodes phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 2 protein, plays a role in the regulation of small GTPase-dependent signaling.			Gene or Genome	
C102519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102519>	C17494	Phosphatidylinositol 3,4,5-Trisphosphate-Dependent Rac Exchanger 2 Protein|DEP Domain-Containing Protein 2|P-Rex2|PREX2|PtdIns(3,4,5)-Dependent Rac Exchanger 2	Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 2 protein (1606 aa, ~183 kDa) is encoded by the human PREX2 gene. This protein is involved in the activation of Rac family GTPases.			Amino Acid, Peptide, or Protein	
C10251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10251>	C61063	Cisplatin/Mitomycin/Triazinate|CDDP/MITO/TZT			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102520>	C54362	ARID1B Gene|ARID1B|ARID1B|ARID1B|AT-Rich Interactive Domain 1B Gene	This gene plays a role in both chromatin remodeling and transcriptional regulation.	ARID1B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C102521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102521>	C102520	ARID1B wt Allele|6A3-5|AT Rich Interactive Domain 1B (SWI1-Like) Gene|AT-Rich Interactive Domain 1B wt Allele|BAF-Associated Factor, 250-kD, B Gene|BAF250B|BAF250b|BRIGHT|CSS1|DAN15|ELD/OSA1|KIAA1235|MRD12|OSA2|P250R|RP11-419L10.1|p250R	Human ARID1B wild-type allele is located in the vicinity of 6q25.1 and is approximately 433 kb in length. This allele, which encodes AT-rich interactive domain-containing protein 1B, is involved in both cell type-specific transcriptional regulation and chromatin remodeling.	ARID1B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102522>	C26199	AT-Rich Interactive Domain-Containing Protein 1B|ARID Domain-Containing Protein 1B|ARID1B|BAF250B|BRG1-Associated Factor 250b|BRG1-Binding Protein hELD/OSA1|ELD (Eyelid)/OSA Protein|Osa Homolog 2|hOsa2|p250R	AT-rich interactive domain-containing protein 1B (2236 aa, ~236 kDa) is encoded by the human ARID1B gene. This protein plays a role in transcriptional regulation mediated by chromatin remodeling.	AT-Rich Interactive Domain-Containing Protein 1B		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102523>	C25873	MAP3K13 Gene|MAP3K13|MAP3K13|MAP3K13|Mitogen-Activated Protein Kinase Kinase Kinase 13 Gene	This gene is involved in both protein phosphorylation and signaling.			Gene or Genome	GDC Terminology|GDC Value Terminology
C102524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102524>	C102523	MAP3K13 wt Allele|LZK|MEKK13|MGC133196|MLK|Mitogen-Activated Protein Kinase Kinase Kinase 13 wt Allele	Human MAP3K13 wild-type allele is located in the vicinity of 3q27 and is approximately 206 kb in length. This allele, which encodes mitogen-activated protein kinase kinase kinase 13 protein, plays a role in the modulation of both JNK-dependent signaling and serine/threonine phosphorylation.			Gene or Genome	
C102525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102525>	C17325	Mitogen-Activated Protein Kinase Kinase Kinase 13|EC 2.7.11.25|Leucine Zipper-Bearing Kinase|MAP3K13|MLK|Mixed Lineage Kinase	Mitogen-activated protein kinase kinase kinase 13 (966 aa, ~108 kDa) is encoded by the human MAP3K13 gene. This protein is involved in the mediation of serine/threonine phosphorylation.			Amino Acid, Peptide, or Protein|Enzyme	
C102526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102526>	C1595	Doxycycline Phosphate|2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S-(4alpha,4aalpha,5alpha,5aalpha,6alpha,12aalpha))-, Phosphate (1:1) (Salt)|DOXYCYCLINE PHOSPHATE				Antibiotic|Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C102527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102527>	C21275	ACE2 Gene|ACE2|ACE2|Angiotensin I Converting Enzyme 2 Gene	This gene plays a role in both proteolysis and vasodilation.	ACE2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C102528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102528>	C102527	ACE2 wt Allele|ACEH|Angiotensin I Converting Enzyme (Peptidyl-Dipeptidase A) 2 Gene|Angiotensin I Converting Enzyme 2 wt Allele|DKFZp434A014|UNQ868/PRO1885	Human ACE2 wild-type allele is located in the vicinity of Xp22 and is approximately 41 kb in length. This allele, which encodes angiotensin-converting enzyme 2 protein, is involved in both peptide hormone-processing and vasodilation.	ACE2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102529>	C34331	Stomach Cramp|Stomach Cramps	An involuntary muscular contraction in the stomach. Often, this cramp is spasmodic and can be uncomfortable.			Sign or Symptom	
C10252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10252>	C61007	Cyclophosphamide/Cytarabine|ARA-C/CTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102530>	C16843	Angiotensin-Converting Enzyme 2|ACE-Related Carboxypeptidase|ACE2|ACEH|Angiotensin I Converting Enzyme 2|Angiotensin I-Converting Enzyme 2|Angiotensin-Converting Enzyme Homolog|EC 3.4.17.23|Metalloprotease MPROT15	Angiotensin-converting enzyme 2 (805 aa, ~92 kDa) is encoded by the human ACE2 gene. This protein plays a role in both vasodilation and protein cleavage.	Angiotensin-Converting Enzyme 2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C102531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102531>	C42077	Pulmonary Infiltrate|Lung Infiltrate|Pulmonary infiltrates	A finding indicating the presence of an inflammatory or neoplastic cellular infiltrate in the lung parenchyma.			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 7: Diagnostic Procedures Terminology
C102532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102532>	C3113	Lymphoid Hyperplasia	A benign or malignant, diffuse and/or follicular lymphocytic proliferation.			Disease or Syndrome	GDC Terminology|GDC Value Terminology
C102533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102533>	C50602	Myopia|Myopic|Nearsighted|Nearsightedness	The condition in which the individual does not see far distances clearly.			Finding	
C102534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102534>	C20194	SPOP Gene|SPOP|SPOP|SPOP|Speckle Type BTB/POZ Protein Gene	This gene is involved in protein ubiquitination, which often leads to proteasomal degradation.	SPOP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C102535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102535>	C199386	Anti-ErbB3 Monoclonal Antibody AV-203|AV 203|AV-203|AV-203|AV203|Anti-ErbB3 MoAb AV-203|CAN-017	A humanized monoclonal antibody (MoAb) directed against the human receptor tyrosine-protein kinase ErbB-3 (HER3) with potential antineoplastic activity. Anti-ErbB3 MoAb AV-203 binds to and inhibits both ligand neuregulin-1 (NRG-1)-dependent and ligand-independent ErbB3 activation, which may result in inhibition of ErbB3-dependent PI3K/Akt signaling and may lead to inhibition of cellular proliferation and differentiation. ErbB3, a member of the epidermal growth factor receptor (EGFR) family, is frequently overexpressed in solid tumors and its overexpression generally correlates with poor prognosis and tumor resistance; it has no active kinase domain itself but is activated through heterodimerization with other members of the EGFR receptor family that do.	Anti-ErbB3 Monoclonal Antibody AV-203		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102536>	C184953	Hyaluronic Acid-based Hydrating Vaginal Gel|Hyalo GYN	A clear, colorless water-based vaginal gel containing the partial benzyl ester of hyaluronic acid (HA) with potential hydrating activity. Upon vaginal application, HA adheres to the vaginal mucosa where it retains water, provides moisture to the vagina and protects the vaginal mucosa. This gel may provide relief in vaginal dryness and may prevent sexual discomfort, itching and irritation. This HA derivative is less susceptible to enzymatic breakdown and provides longer lasting activity compared to HA. HA is naturally present in the vaginal epithelium.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C102537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102537>	C102534	SPOP wt Allele|BTBD32|NEDMACE|NEDMIDF|NSDVS1|NSDVS2|Speckle Type BTB/POZ Protein wt Allele|Speckle-Type BTB/POZ Protein Gene|Speckle-Type POZ Protein Gene|TEF2	Human SPOP wild-type allele is located in the vicinity of 17q21.33 and is approximately 79 kb in length. This allele, which encodes speckle-type POZ protein, plays a role in the regulation of protein ubiquitination. Mutation of the gene is associated with Nabais Sa-de Vries syndrome, types 1 and 2.	SPOP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102538>	C95242	Speckle-Type POZ Protein|HIB Homolog 1|Roadkill Homolog 1|SPOP|Speckle-Type BTB/POZ Protein	Speckle-type POZ protein (374 aa, ~42 kDa) is encoded by the human SPOP gene. This protein is involved the ubiquitination of proteins.	Speckle-Type POZ Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102539>	C29639	Water-based Vaginal Lubricant	A water-based vaginal lubricant with hydration activity. Upon application to the vagina, the water-based vaginal lubricant provides moisture and may relieve dryness and sexual discomfort.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C10253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10253>	C61063	Cytarabine/Teniposide|ARA-C/VM-26			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102540>	C184953	Lactoperoxidase/Lysozyme/Lactoferrin-based Prebiotic Vaginal Lubricant|Luvena	A preservative-free, prebiotic vaginal lubricant with potential moisturizing and protective activities. Upon vaginal application, the lactoperoxidase/lysozyme/lactoferrin-based prebiotic vaginal lubricant moisturizes the vagina and may relieve and/or prevent dryness, itching, irritation, odor and infection. The vaginal lubricant contains anti-yeast proteins and enzymes, including lactoperoxidase, lysozyme and lactoferrin which are naturally found in vaginal fluid and help maintain the natural microflora in the vagina. The prebiotic glycogen helps restore and maintain the beneficial microorganisms in the vagina and maintains a healthy acidic pH. Altogether, this protects the vagina against the actions of harmful bacteria.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C102541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102541>	C1663	Adenovirus-PSA Prostate Cancer Vaccine|Ad/PSA Vaccine|Adenovirus/PSA Vaccine	A cancer vaccine composed of a genetically engineered, replication-deficient type 5 adenovirus carrying the human prostate-specific antigen (PSA), with potential immunostimulating and antineoplastic activities. Upon subcutaneous vaccination with the adenovirus-PSA prostate cancer vaccine, the adenovirus infects cells and expresses PSA. In turn, PSA may activate the immune system and may induce a cytotoxic T-lymphocyte response against PSA-expressing tumor cells. PSA, a tumor associated antigen, is expressed by prostate epithelial cells and is overexpressed in prostate cancer.	Adenovirus-PSA Prostate Cancer Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102542>	C20923	F2RL3 Gene|Coagulation Factor II (Thrombin) Receptor-Like 3 Gene|F2RL3|F2RL3	This gene plays a role in both receptor signaling and platelet activation.			Gene or Genome	
C102543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102543>	C102542	F2RL3 wt Allele|Coagulation Factor II (Thrombin) Receptor-Like 3 wt Allele|PAR4	Human F2RL3 wild-type allele is located in the vicinity of 19p12 and is approximately 3 kb in length. This allele, which encodes proteinase-activated receptor 4 protein, is involved in the modulation of both platelet activation and receptor signaling.			Gene or Genome	
C102544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102544>	C18239	Proteinase-Activated Receptor 4|Coagulation Factor II Receptor-Like 3|PAR-4|Protease-Activated Receptor-4|Proteinase-Activated Receptor-4|Thrombin Receptor-Like 3	Proteinase-activated receptor 4 (385 aa, ~41 kDa) is encoded by the human F2RL3 gene. This protein plays a role in both the mediation of receptor signaling and the promotion of platelet activation.			Amino Acid, Peptide, or Protein|Receptor	
C102545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102545>	C717|C204441	Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta|Recombinant VSV-IFN-beta|VSV-hIFN-b	A recombinant, replicating oncolytic vesicular stomatitis virus (VSV) carrying the human interferon-beta (IFN-b) gene, with potential immunomodulating and antineoplastic activities. Upon intratumoral administration, recombinant VSV expressing IFN-b replicates in the tumor environment specifically, partially due to defective innate antiviral host defense mechanisms in tumor cells, involving type I IFNs, and exerts its cytolytic activity towards the tumor cells. By expressing human IFN-b, an INF-b-mediated antiviral immune response in surrounding normal cells is activated which protects normal cells against virus replication and VSV-mediated cell lysis. However, tumor cells have a defective IFN-b-mediated innate antiviral immune response allowing for VSV to replicate in these cells without interference. In addition, the IFN-b produced by VSV may activate an immune response in surrounding normal cells and may activate T-lymphocytes, dendritic cells and natural killer cells; thus, inducing an anti-tumor immune response against the tumor cells. VSV, a single-stranded RNA virus belonging to the genus Vesiculovirus of the family Rhabdoviridae, is relatively nonpathogenic to healthy humans.	Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta		Pharmacologic Substance|Virus	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102546>	C198515	Selinexor|2-Propenoic Acid, 3-(3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-, 2-(2-Pyrazinyl)hydrazide, (2Z)-|ATG-010|CRM1 Nuclear Export Inhibitor KPT-330|KPT 330|KPT-330|KPT330|Nexpovio|SELINEXOR|SINE KPT-330|Selective Inhibitor of Nuclear Export KPT-330|Xpovio	An orally available, small molecule inhibitor of CRM1 (chromosome region maintenance 1 protein, exportin 1 or XPO1), with potential antineoplastic activity. Selinexor modifies the essential CRM1-cargo binding residue cysteine-528, thereby irreversibly inactivates CRM1-mediated nuclear export of cargo proteins such as tumor suppressor proteins (TSPs), including p53, p21, BRCA1/2, pRB, FOXO, and other growth regulatory proteins. As a result, this agent, via the approach of selective inhibition of nuclear export (SINE), restores endogenous tumor suppressing processes to selectively eliminate tumor cells while sparing normal cells. CRM1, the major export factor for proteins from the nucleus to the cytoplasm, is overexpressed in a variety of cancer cell types.	Selinexor		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C102547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102547>	C210691	Beta-hydroxy-beta-methylbutyrate Supplement|HMB Supplement	A nutritional supplement containing the active metabolite of the essential amino acid leucine, with potential anti-catabolic and anabolic activities. Upon oral administration of beta-hydroxy-beta-methylbutyrate (HMB), this leucine metabolite may decrease protein breakdown and increase protein synthesis thereby increasing muscle strength and mass. Although the exact mechanisms remain to be fully elucidated, multiple mechanisms have been proposed: 1) HMB is a precursor of cholesterol synthesis in skeletal muscle cells thereby increasing sarcolemmal integrity; 2) HMB may inhibit the ubiquitin-proteasome proteolytic pathway responsible for the specific degradation of intracellular proteins, thereby preventing muscular proteolysis; and/or 3) HMB may stimulate protein synthesis through a mammalian target of rapamycin (mTOR)-mediated mechanism.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C102548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102548>	C25804	PADI4 Gene|PADI4|PADI4|Peptidyl Arginine Deiminase, Type IV Gene	This gene is involved in arginine modification.			Gene or Genome	
C102549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102549>	C102548	PADI4 wt Allele|PAD|PAD4|PADI5|PDI4|PDI5|Peptidyl Arginine Deiminase, Type IV wt Allele|Peptidyl Arginine Deiminase, Type V Gene	Human PADI4 wild-type allele is located in the vicinity of 1p36.13 and is approximately 56 kb in length. This allele, which encodes protein-arginine deiminase type-4 protein, plays a role in the post-translational protein modification. Mutation of the gene is associated with susceptibility to rheumatoid arthritis.			Gene or Genome	
C10254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10254>	C63358	MVT Regimen|DHAD/TSPA/VP-16|Etoposide/Mitoxantrone/Thiotepa|MVT|MVT|Mitoxantrone-Etoposide-Thiotepa|Mitoxantrone/Etoposide/Thiotepa|Mitoxantrone/Etoposide/Thiotepa Regimen|Mitoxantrone/VePesid/Thiotepa	A regimen consisting of mitoxantrone, etoposide, and thiotepa that may be used in the treatment of relapsed breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C102550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102550>	C16701	Protein-Arginine Deiminase Type-4|EC 3.5.3.15|HL-60 PAD|PADI-H Protein|PADI4|Peptidyl Arginine Deiminase, Type V|Peptidylarginine Deiminase IV|Protein-Arginine Deiminase Type IV	Protein-arginine deiminase type-4 (663 aa, ~74 kDa) is encoded by the human PADI4 gene. This protein is involved in the deimination of arginine residues in histones.			Amino Acid, Peptide, or Protein|Enzyme	
C102551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102551>	C25870	HS6ST2 Gene|HS6ST2|HS6ST2|Heparan Sulfate 6-O-Sulfotransferase 2 Gene	This gene plays a role in the modification of heparan sulfate.			Gene or Genome	
C102552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102552>	C102551	HS6ST2 wt Allele|Heparan Sulfate 6-O-Sulfotransferase 2 wt Allele|MGC130022|MGC130023|PSEC0092|RP3-435D1.3	Human HS6ST2 wild-type allele is located in the vicinity of Xq26.2 and is approximately 335 kb in length. This allele, which encodes heparan-sulfate 6-O-sulfotransferase 2 protein, is involved in proteoglycan modification.			Gene or Genome	
C102553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102553>	C17210	Heparan-Sulfate 6-O-Sulfotransferase 2|EC 2.8.2.-|HS6ST-2|HS6ST2	Heparan-sulfate 6-O-sulfotransferase 2 (605 aa, ~69 kDa) is encoded by the human HS6ST2 gene. This protein plays a role in the sulfation of proteoglycans.			Amino Acid, Peptide, or Protein|Enzyme	
C102554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102554>	C1742|C1557	Trifluridine and Tipiracil Hydrochloride|FTD-TPI|Lonsurf|TAS 102|TAS-102|TAS102|Thymidine, Alpha,alpha,alpha-trifluoro-, Mixt. with 5-Chloro-6-((2-imino-1-pyrrolidinyl)methyl)-2,4(1H,3H)-pyrimidinedione Monohydrochloride|Tipiracil Hydrochloride Mixture with Trifluridine|Trifluridine and Tipiracil|Trifluridine and tipiracil|Trifluridine/Tipiracil|Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102	An orally bioavailable combination agent composed of the cytotoxic pyrimidine analog trifluridine (5-trifluoro-2'-deoxythymidine or TFT) and a thymidine phosphorylase inhibitor (TPI) tipiracil hydrochloride, in a molar ratio of 1.0:0.5 (TFT:TPI), with potential antineoplastic activity. After oral administration of TAS-102, TFT is phosphorylated to the active monophosphate form TF-TMP, which binds covalently to the active site of thymidylate synthase, thereby reducing the nucleotide pool levels required for DNA replication. Furthermore, the triphosphate form TF-TTP can be incorporated into DNA, which induces DNA fragmentation and leads to the inhibition of tumor growth. TPI exhibits a dual effect: 1) an anti-angiogenic effect mediated through the inhibition of thymidine phosphorylase, which plays important role in nucleotide metabolism and a variety of development processes, including angiogenesis, 2) increased bioavailability of the normally short-lived antimetabolite TFT by preventing its degradation into the inactive form trifluorothymine (TF-Thy). The synergistic effect of the components in TAS-10 may demonstrate antitumor activity in 5-FU-resistant cancer cells.	Trifluridine and Tipiracil Hydrochloride		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102555>	C797|C29639	R1 Cooling Gel Plus R2 Moisturizing/Sun Protecting Lotion|R1/R2 Waterjel	A skin care treatment system consisting of a cytokine-containing milk-based cooling gel and a cytokine-containing milk-based soothing lotion with hydrating and potential protective activity against radiation-induced dermatitis. Application of the R1 cooling gel immediately upon radiation treatment may hydrate the skin, provide cooling relief, and may protect the skin against radiation-induced dermatitis. The subsequent application of the R2 lotion moisturizes the skin while also protecting the skin against inflammation. In addition, R2 contains avobenzone, homosalate, octinoxate and octocrylene, which exert UVA and UVB skin protective activity.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C102556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102556>	C42645	Low Interval Point in Time Date Data Type|IVL.LOW<TS.DATE>|IVL.LOW<TS.DATE>	A data type comprised of a set of consecutive low values of an ordered point in time date datatype.			Qualitative Concept	BRIDG Data Type Terminology|BRIDG Terminology
C102557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102557>	C25275	Planned Occurrence|POCCUR	An instance of an event or incident that is intended to take place.			Event	CDISC Root Variable Terminology
C102558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102558>	C82573	Visit End Time|VISENTIM	The stop time of the visit.			Temporal Concept	CDISC Variable Terminology
C102559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102559>	C91106	Performed Medical Condition Result|PerformedMedicalConditionResult|PerformedMedicalConditionResult	The result of an actual line of questioning about a sign, symptom, disease, or other medical occurrence.			Finding	BRIDG Class Terminology|BRIDG Terminology
C10255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10255>	C61063	Fluorouracil/Semustine|5-FU/MeCCNU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102560>	C27993	Favorable	Expressing something as positive, advantageous or desired.			Qualitative Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C102561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102561>	C27993	Unfavorable	Expressing something as negative, undesired or adverse.			Qualitative Concept	GDC Terminology|GDC Value Terminology
C102562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102562>	C85413	International Neuroblastoma Pathology Classification|INPC|inpc grade|inpc_grade	A classification system established by adopting the original system proposed by Shimada with subsequent revisions. The INPC distinguishes favorable and unfavorable histology groups.			Classification	GDC Property Terminology|GDC Terminology
C102563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102563>	C174459	International Neuroblastoma Risk Group Classification System|INRG Classification System|Neuroblastoma Risk Group	A classification system developed to establish a consensus approach for pretreatment risk stratification of neuroblastomas.			Classification	
C102564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102564>	C155764	Capivasertib|AZD 5363|AZD-5363|AZD5363|CAPIVASERTIB|Truqap	A novel pyrrolopyrimidine derivative, and an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. Capivasertib binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism. A wide range of solid and hematological malignancies show dysregulated PI3K/AKT/mTOR signaling due to mutations in multiple signaling components. By targeting AKT, the key node in the PIK3/AKT signaling network, this agent may be used as monotherapy or combination therapy for a variety of human cancers.	Capivasertib		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102565>	C208255|C1512	Ipafricept|Fusion Protein For Immune Applications (fpia) Comprising Homo Sapiens FZD8 (Frizzled Family Receptor 8, Frizzled-8) Extracellular Domain, Fused With Homo Sapiens Immunoglobulin G1 Fc Fragment|Fzd8-Fc|IPAFRICEPT|OMP 54F28|OMP-54F28	A proprietary fusion protein comprised of the cysteine-rich domain of frizzled family receptor 8 (Fzd8) fused to the human immunoglobulin Fc domain with potential antineoplastic activity. Upon intravenous administration, ipafricept competes with the membrane-bound Fzd8 receptor for its ligand, Wnt proteins, thereby antagonizing Wnt signaling. This may result in the inhibition of Wnt-driven tumor growth. Fzd8, a member of the Frizzled family of G protein-coupled receptors, is one of the components in the Wnt/beta-catenin signaling pathway that plays key roles in embryogenesis and cancer growth.	Ipafricept		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102566>	C214993|C200086	Mirvetuximab Soravtansine|Elahere|IMGN 853|IMGN-853|IMGN853|M9346A-sulfo-SPDB-DM4|MIRVETUXIMAB SORAVTANSINE|Mirvetuximab Soravtansine-gynx|Mirvetuximab soravtansine|Soriatuximab Gedotinib|TAK 853|TAK-853|TAK853	An immunoconjugate consisting of the humanized monoclonal antibody M9346A against folate receptor 1 (FOLR1) conjugated, via the disulfide-containing cleavable linker sulfo-SPDB, to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. The anti-FOLR1 monoclonal antibody moiety of mirvetuximab soravtansine targets and binds to the cell surface antigen FOLR1. After antibody-antigen interaction and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, thereby inhibiting cell division and cell growth of FOLR1-expressing tumor cells. FOLR1, a member of the folate receptor family is overexpressed on a variety of epithelial-derived cancer cells. The sulfo-SPDB linker prevents cleavage in the bloodstream and may improve this agent's efficacy in multidrug resistant tumor cells.	Mirvetuximab Soravtansine		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102567>	C93144	Saccharomyces boulardii Probiotic Supplement|Floratil|S. boulardii Probiotic	A probiotic containing the non-pathogenic yeast Saccharomyces boulardii with antidiarrheal and potential anti-inflammatory, antimicrobial and immunomodulating activities. As a dietary supplement, S. boulardii may improve digestion and help maintain adequate colonization of the gastrointestinal (GI) tract by modulating the composition of the normal intestinal microflora. During colonization of the GI tract, S. boulardii forms a protective barrier that helps maintain the integrity of the epithelial barrier. This prevents attachment of pathogens to the intestinal mucosa. In addition, this probiotic secretes a protease that binds to and degrades toxins A and B produced by Clostridium difficile, thereby preventing their harmful effects. Dietary supplementation with this bacterium may reduce the secretion of proinflammatory cytokines and may potentiate natural and acquired immunity.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C102568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102568>	C67437	Docetaxel Lipid Microspheres|DLE|DT-LM|Docetaxel Lipid Emulsion	A lipid microsphere (LM)-based formulation containing the poorly water soluble taxane docetaxel, a semi-synthetic analogue of paclitaxel, with antineoplastic activity. Docetaxel binds specifically to the beta-tubulin subunit of the microtubule, stabilizing tubulin and inhibiting microtubule disassembly, which causes cell cycle arrest at the G2/M phase and leads to cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response. Compared to docetaxel alone, the LM formulation may enhance stability, improve efficacy and may reduce toxicity; this formulation does not contain toxic detergents needed to solubilize docetaxel which further improves its side effect profile.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102569>	C1742	Recombinant EphB4-HSA Fusion Protein|SEPHB4-HSA|sEphB4-HSA	A recombinant fusion protein composed of the full-length extracellular domain (soluble) of human receptor tyrosine kinase ephrin type-B receptor 4 (sEphB4) and fused, at its C-terminus, to full-length human serum albumin (HSA), with potential antineoplastic and anti-angiogenic activities. sEphB4-HSA functions as a decoy receptor for the membrane-bound ligand Ephrin-B2 (Efnb2) and interferes with the binding of Efnb2 to its native receptors, including EphB4 and EphA3. This may result in a reduction of angiogenesis and a reduction in cell growth of Efnb2 and/or EphB4 over-expressing tumor cells. In addition, this agent also prevents the angiogenic effects of numerous growth factors due to interactions between Efnb2 and EphB4. Efnb2 and EphB4 are overexpressed in a variety of tumor cell types; the bi-directional signaling of Efnb2-EphB4 plays an important role in angiogenesis and tumor cell migration, invasion, and proliferation. Albumin reduces this agent's degradation, improves circulation time and may thus improve efficacy.	Recombinant EphB4-HSA Fusion Protein		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C10256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10256>	C63588	Mercaptopurine/Methotrexate Regimen|Linker Regimen maintenance|MP/MTX|Mercaptopurine and Methotrexate	A regimen consisting of mercaptopurine and methotrexate that may be used in the treatment of acute lymphoblastic leukemia (ALL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C102570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102570>	C9474|C179934	Broad Ligament Adenosarcoma	An extremely rare adenosarcoma that arises from the broad ligament.			Neoplastic Process	
C102571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102571>	C477	Epoetin Zeta|SB309|Silapo	A recombinant form of the endogenous human cytokine erythropoietin (EPO) with erythropoiesis-stimulating activity. Similar to EPO, epoetin zeta binds to and activates erythropoietin receptors on the surface of committed erythroid progenitors in the bone marrow resulting in their proliferation and differentiation into functional erythrocytes. This may enhance red blood cell counts and hemoglobin levels. Epoetin zeta differs from other epoetins in its glycosylation profile. EPO is a glycosylated polypeptide primarily produced by renal peritubular cells and its synthesis is regulated by a serum oxygenation feedback mechanism.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	NCI Drug Dictionary Terminology
C102573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102573>	C88117	Tuberculosis Contact	Any exposure to a suspected or confirmed tuberculosis causing agent.			Qualitative Concept	
C102574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102574>	C41328	Ventricular Repolarization Abnormality|REPOLARIZATION ABNORMALITY|Repolarization Abnormality	An electrocardiographic finding of an abnormality of T wave duration or morphology or of early repolarization. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102575>	C66830	CDISC SDTM Contact Case Investigation Contact Type Terminology|CCINVTYP|Contact Case Investigation Contact Type|SDTM-CCINVTYP	Terminology associated with the contact case investigation contact type codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102576>	C103175	CDISC SDTM Directly Observed Therapy Location Terminology|SDTM-DOBSTLOC	Terminology associated with the directly observed therapy location codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	
C102577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102577>	C66830	CDISC SDTM Drug Resistance Status Terminology|DRSTAT|Drug Resistance Status|SDTM-DRSTAT	Terminology associated with the drug resistance status codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102578>	C66830	CDISC SDTM Disease Outcome Terminology|DSSOUT|Disease Outcome|SDTM-DSSOUT	Terminology associated with the disease outcome codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102579>	C66830	CDISC SDTM Supporting Evidence for Re-Treatment Terminology|EVDRETRT|SDTM-EVDRETRT|Supporting Evidence for Re-Treatment	Terminology associated with the supporting evidence for re-treatment codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10257>	C61063	Mercaptopurine/Prednisone/Vincristine|MP/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102580>	C103175	CDISC SDTM Laboratory Test Standard Character Result Terminology|SDTM-LBSTRESC	Terminology associated with the laboratory test standard character result codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	
C102581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102581>	C66830	CDISC SDTM Microbial Identification Certainty Terminology|MCIDCERT|Microbial Identification Certainty|SDTM-MCIDCERT	Terminology associated with the microbial identification certainty codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102582>	C66830	CDISC SDTM Priority of Tuberculosis Contact Terminology|PRITBCON|Priority of Tuberculosis Contact|SDTM-PRITBCON	Terminology associated with the priority of tuberculosis contact codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102583>	C66830	CDISC SDTM Reason for Treatment Interruption Terminology|REASTINT|Reason for Treatment Interruption|SDTM-REASTINT	Terminology associated with the reason for treatment interruption codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102584>	C66830	CDISC SDTM Reason For Treatment Terminology|REASTRT|Reason For Treatment|SDTM-REASTRT	Terminology associated with the reason for treatment codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102585>	C103175	CDISC SDTM Treatment Failure Reason Terminology|SDTM-REASTRTF	Terminology associated with the treatment failure reason codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	
C102586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102586>	C103175	CDISC SDTM Reason Treatment Not Administered Terminology|SDTM-RSTRTNA	Terminology associated with the reason treatment not administered codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	
C102587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102587>	C66830	CDISC SDTM Social Risk Factor Terminology|RISKSOC|SDTM-RISKSOC|Social Risk Factor	Terminology associated with the social risk factor codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102588>	C103175	CDISC SDTM Contact Setting Terminology|SDTM-SETCON	Terminology associated with the contact setting codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	
C102589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102589>	C103175	CDISC SDTM Treatment Episode Terminology|SDTM-TRTEPSD	Terminology associated with the treatment episode codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	
C10258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10258>	C61063	Fludarabine/Prednisone|FAMP/PRED			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102590>	C66830	CDISC SDTM Vaccination Evidence Source Terminology|SDTM-VCNEVD|VCNEVD|Vaccination Evidence Source	Terminology associated with the vaccination evidence source codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102591>	C101596	Acute Anterolateral Myocardial Infarction by ECG Finding|ACUTE ANTEROLATERAL WALL MYOCARDIAL INFARCTION|Acute Anterolateral Myocardial Infarction by EKG Finding|Acute Anterolateral Wall Myocardial Infarction	An electrocardiographic finding of pathologic Q waves with accompanying ST elevation in leads V3 through V6, which is suggestive of acute myocardial infarction of the anterolateral wall of the left ventricle. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102592>	C101596	Acute Anteroseptal Myocardial Infarction by ECG Finding|ACUTE ANTEROSEPTAL WALL MYOCARDIAL INFARCTION|Acute Anteroseptal Myocardial Infarction by EKG Finding|Acute Anteroseptal Wall Myocardial Infarction|Acute anteroseptal MI	An electrocardiographic finding of pathologic Q waves with accompanying ST elevation in leads V1 through V4, which is suggestive of acute myocardial infarction of the anteroseptal wall of the left ventricle. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102593>	C101596	Acute High Lateral Myocardial Infarction by ECG Finding|ACUTE HIGH LATERAL WALL MYOCARDIAL INFARCTION|Acute High Lateral Myocardial Infarction by EKG Finding|Acute High Lateral Wall Myocardial Infarction	An electrocardiographic finding of pathologic Q waves with accompanying ST elevation in leads I and aVL, which is suggestive of acute myocardial infarction of the high lateral wall of the left ventricle. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102594>	C101596	Acute Right Ventricular Myocardial Infarction by ECG Finding|ACUTE RIGHT VENTRICULAR WALL MYOCARDIAL INFARCTION|Acute Right Ventricular Myocardial Infarction by EKG Finding|Acute Right Ventricular Wall Myocardial Infarction|Acute Right ventricular MI	An electrocardiographic finding in leads V1 or V2 of an initial R wave duration greater than or equal to 40 ms, R wave greater than S wave, upright T wave, with accompanying ST elevation, which is suggestive of acute myocardial infarction of the ventricular wall of the left ventricle. Evidence of inferior or lateral myocardial infarction is usually also present. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102595>	C101596	Acute Septal Myocardial Infarction by ECG Finding|ACUTE SEPTAL WALL MYOCARDIAL INFARCTION|Acute Septal Myocardial Infarction by EKG Finding|Acute Septal Wall Myocardial Infarction	An electrocardiographic finding of pathologic Q waves with accompanying ST elevation in leads V1, V2 and often V3, which is suggestive of acute myocardial infarction of the intraventricular septum. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102596>	C80503	Atrial Bigeminy by ECG Finding|ATRIAL BIGEMINY|Atrial Bigeminy|Atrial Bigeminy by EKG Finding	An electrocardiographic finding of a sinus beat followed by a premature atrial complexes for three or more consecutive cycles; a regularly irregular rhythm of normal and abnormal P waves in a 1-1 ratio. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102597>	C80503	Atrial Couplet by ECG Finding|ATRIAL COUPLETS|Atrial Couplet|Atrial Couplet by EKG Finding|Atrial Couplets	An electrocardiographic finding in which two premature atrial complexes occur sequentially. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102598>	C80503	Atrial Trigeminy by ECG Finding|ATRIAL TRIGEMINY|Atrial Trigeminy|Atrial Trigeminy|Atrial Trigeminy by EKG Finding	An electrocardiographic finding of two sinus beats followed by a premature atrial complex for 3 or more consecutive cycles; a regularly irregular rhythm of normal and abnormal P waves in a 2-1 ratio. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102599>	C23044	Auramine Staining Method|AURAMINE STAIN|Auramine O	A microscopy acid fast staining method that utilizes auramine O, a bright yellow ketonimine dye, which binds to the mycolic acid in the cell walls of acid fast microorganisms.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10259>	C61063	Cyclophosphamide/Diethylstilbestrol/Fluorouracil/Methotrexate|CTX/DES/5-FU/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1025>	C784|C1974	Bruceantin|2H-3, 11c-(Epoxymethano)phenanthro[10,1-bc]pyran, Picras-3-en-21-oic Acid Derivative|BRUCEANTIN|BRUCEANTIN|Picras-3-en-21-oic Acid, 15-[(3,4-dimethyl-1-oxo-2-pentenyl)oxy]-13,20-epoxy-3,11, 12-trihydroxy-2,16-dioxo-, Methyl Ester, (11beta,12alpha,15beta(E))|Picras-3-en-21-oic acid, 15-[(3, 4-dimethyl-1-oxo-2-pentenyl)oxy]-13,20-epoxy-3,11,12-trihydroxy-2, 16-dioxo-, methyl ester [11.beta.,12.alpha.,15.beta.(E)]-|Picras-3-en-21-oic acid, 15-[(3, 4-dimethyl-1-oxo-2-pentenyl)oxy]-13,20-epoxy-3,11,12-trihydroxy-2, 16-dioxo-, methyl ester, [11.beta.,12.alpha.,15.beta.(E)]-|[11Beta,12alpha,15beta(E)]-15-[(3,4-dimethyl-1-oxo-2-pentenyl)oxy]-13,20-epoxy-3,11,12-trihydroxy-2,16-dioxopicras-3-en-21-oic Acid Methyl Ester	A triterpene quassinoid antineoplastic antibiotic isolated from the plant Brucea antidysenterica.  Bruceantin inhibits the peptidyl transferase elongation reaction, resulting in decreased protein and DNA synthesis.  Bruceantin also has antiamoebic and antimalarial activity. (NCI04)			Antibiotic|Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102600>	C102602	Bacteriological Cure|BACTERIOLOGICAL CURE	There are no indicators of bacterial infection in an individual who previously had an infection.			Finding	CDISC SDTM Disease Outcome Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102601>	C102602	Bacteriological Failure|BACTERIOLOGICAL FAILURE	There are indicators of bacterial infection in the individual who previously had an infection.			Finding	CDISC SDTM Disease Outcome Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102602>	C205055	Bacteriological Finding|BACTERIOLOGICAL FINDING	Objective evidence of bacterial infection perceptible to the examiner by laboratory procedure.			Finding	CDISC SDTM Supporting Evidence for Re-Treatment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102603>	C62257	Blocked Atrial Premature Complex by ECG Finding|Atrial premature complexes, nonconducted|Blocked Atrial Premature Complex|Blocked Atrial Premature Complex by EKG Finding|Non-conducted SVE|PREMATURE ATRIAL COMPLEXES BLOCKED|Premature Atrial Complex Blocked|Premature Atrial Complexes Non-conducted	An electrocardiographic finding of premature atrial complexes which are not conducted to the ventricle, and which are not followed by a QRS complex. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102604>	C62256	Blocked Ventricular Premature Complex by ECG Finding|Blocked Ventricular Premature Complex|Blocked Ventricular Premature Complex by EKG Finding	An electrocardiographic finding of a premature ventricular complex which occurs between two normal QRS complexes which have normal timing. (CDISC)			Finding	
C102605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102605>	C49556	Cardiovascular System Findings Domain|CV|Cardiovascular System Findings	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to cardiovascular system findings.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|CDISC SEND Domain Abbreviation Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102606>	C88117	Casual Contact|CASUAL CONTACT	A way of contracting a disease through everyday interactions (nonsexual) with an infected person.			Qualitative Concept	CDISC SDTM Contact Case Investigation Contact Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102607>	C50995	Clinical Cure|CLINICAL CURE	The absence of signs or symptoms of disease in an individual who previously had a disease.			Finding	CDISC SDTM Disease Outcome Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102608>	C50995	Clinical Failure|CLINICAL FAILURE	The occurrence or recurrence of disease signs or symptoms after treatment.			Finding	CDISC SDTM Disease Outcome Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102609>	C88117	Contact With Exposure During Medical Procedure|CONTACT WITH EXPOSURE DURING MEDICAL PROCEDURE	A way of contracting a disease by interacting with an individual that has been exposed to the disease while undergoing a medical procedure.			Qualitative Concept	CDISC SDTM Contact Case Investigation Contact Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10260>	C61063	Cisplatin/Etoposide/Mitoguazone|CDDP/MGBG/VP-16|CVM|CVpMG			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102610>	C88117	Contact With Exposure In Crowd Setting|CONTACT WITH EXPOSURE IN CROWD SETTING	A way of contracting a disease by physically associating with an infected group of individuals.			Qualitative Concept	CDISC SDTM Contact Case Investigation Contact Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102611>	C88117	Contact With Medical Risk Factor|CONTACT WITH MEDICAL RISK FACTOR	A way of contracting a disease by interacting with an individual that is considered at high risk for having the disease.			Qualitative Concept	CDISC SDTM Contact Case Investigation Contact Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102612>	C16632	Country of Potential Disease Exposure|CTRYDEXP	System of classification based on the nation in which an individual was exposed to a disease, regardless of the nation in which he/she currently resides.			Geographic Area	CDISC SDTM Subject Characteristic Test Code Terminology|CDISC SDTM Subject Characteristic Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102613>	C19332	Current or Recent Employee or Volunteer in Homeless Shelter|CURRENT OR RECENT EMPLOYEE OR VOLUNTEER IN HOMELESS SHELTER	An individual who is presently or not long ago worked or offered to assist without pay at a temporary housing facility for persons without a stable or permanent residence.			Organism Attribute	CDISC SDTM Social Risk Factor Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102614>	C19332	Current or Recent Employee or Volunteer in Jail or Prison|CURRENT OR RECENT EMPLOYEE OR VOLUNTEER IN JAIL OR PRISON	An individual who is presently or not long ago worked or offered to assist without pay at an institution where persons are confined for punishment and to protect the public.			Organism Attribute	CDISC SDTM Social Risk Factor Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102615>	C19332	Current or Recent Employee or Volunteer in Nursing Home|CURRENT OR RECENT EMPLOYEE OR VOLUNTEER IN NURSING HOME	An individual who is presently or not long ago worked or offered to assist without pay at a residential health care facility for persons with chronic illness or disability.			Organism Attribute	CDISC SDTM Social Risk Factor Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102616>	C49556	Device Events Domain|DE|Device Events	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to device events.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102617>	C49556	Device Exposure Domain|DX|Device Exposure	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to device exposure.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102618>	C49556	Device Identifiers Domain|DI|Device Identifiers	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to device identifiers.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102619>	C49556	Device Properties Domain|DO|Device Properties	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to device properties.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10261>	C61063	Cisplatin/Mitomycin/Vinblastine|CDDP/MITO/VBL|CVeMi|MiPV|PVeMi			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102620>	C49556	Device to Subject Relationship Domain|DR|Device-Subject Relationships	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to device to subject relationship.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102621>	C49556	Device Tracking and Disposition Domain|DT|Device Tracking and Disposition	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to device tracking and disposition.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102622>	C49556	Device-In-Use Domain|DU|Device In-Use	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to device-in-use.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102623>	C41328	Dextrocardia by ECG Finding|DEXTROCARDIA|Dextrocardia|Dextrocardia by EKG Finding	An electrocardiographic finding suggestive of dextrocardia with situs inversus, characterized by reversal of normal anterior R wave progression and the appearance of reversal of the right and left arm electrodes. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102624>	C459	Directly Observed Therapy	Medication is dispensed and consumed under the direct supervision of personnel at a clinical site.			Pharmacologic Substance	
C102625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102625>	C41198	Disease Contact Investigation	A public health activity whereby individuals who have been exposed to a person with a suspected or confirmed contagious illness are identified, usually for the purpose of identifying additional cases of the illness, or to offer some form of prophylactic intervention to either prevent or ameliorate disease in the exposed individual.			Activity	
C102626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102626>	C45501	Drug Resistance Status|DRSTAT|DRSTAT	The determination of whether the microbe or lesion is resistant to drugs normally used in treatment.			Finding	CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|CDISC SDTM Tuberculosis Findings About Test Code Terminology|CDISC SDTM Tuberculosis Findings About Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C102627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102627>	C12877	Dural Venous Sinus|Cerebral Sinus|Cranial Sinus|DURAL VENOUS SINUS	Venous channels within the dura mater of the brain which receives both blood from blood vessels within the brain as well as cerebrospinal fluid then drains into the internal jugular vein. Unlike other blood vessels, dural venous sinuses lack valves and other vessel associated layers.			Body Space or Junction	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102628>	C90443	Early R Wave Transition by ECG Finding|EARLY R WAVE TRANSITION|Early R Wave Progression|Early R Wave Progression|Early R Wave Transition|Early R Wave Transition|Early R Wave Transition by EKG Finding	An electrocardiographic finding where the amplitude of the R wave becomes greater than the amplitude of the S wave in the QRS complex at an unusually early point in the precordial leads, usually in leads V1 or V2. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102629>	C41328	Early Repolarization|EARLY REPOLARIZATION|ERP|Early Repolarization Pattern|Early Ventricular Repolarization	An electrocardiographic finding of J point and ST segment elevation in the absence of other signs of acute ischemia or pericarditis. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10262>	C61063	Cisplatin/Mitomycin/Vindesine|CDDP/DAVA/MITO|MVP|MiPE|MiViP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102630>	C49556	Endocrine System Findings Domain|ED|Endocrine System Findings	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to endocrine system findings.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102631>	C25164	Entry Date from Country of Potential Disease Exposure|CTRYDDTC|Entry Date from Ptntl Cntry Disease Exp|Entry Date from Ptntl Cntry Disease Exp	The date on which the subject arrived in the reporting country from the country of potential disease exposure.			Temporal Concept	CDISC SDTM Subject Characteristic Test Code Terminology|CDISC SDTM Subject Characteristic Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102632>	C17455	Enzyme-linked Immunosorbent Spot Assay|ELISPOT|ELISPOT|ELISpot	A highly sensitive immunoassay capable of detecting secreted materials from individual cells upon activation. If the material of interest is secreted in response to a particular stimulus, then the material will bind to a specific immobilized antibody. Binding is then verified and visualized by applying other antibodies that have been tagged in some way.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|SeroNet Authorized Values|SeroNet Study Descriptors
C102633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102633>	C16523	Extensively Drug Resistance Process|EXTENSIVE DRUG RESISTANCE|XDR	Resistance to nearly all known drugs, particularly the most efficacious or non-first line drugs, used in the treatment of a particular disease.			Pathologic Function	CDISC SDTM Drug Resistance Status Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102634>	C41328	Extreme Right Axis Deviation|NORTHWEST AXIS|Northwest Axis|Northwest Axis|Right superior axis	An electrocardiographic finding of a frontal plane QRS axis from -90 to +180 degrees. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102635>	C200647	Failure After First Treatment|FAILURE AFTER FIRST TREATMENT	A lack of response to the first cycle of therapy.			Finding	CDISC SDTM Reason For Treatment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102636>	C200647	Failure After Multiple Treatments|FAILURE AFTER MULTIPLE TREATMENTS	A lack of response to more than one cycle of therapy.			Finding	CDISC SDTM Reason For Treatment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102637>	C49556	Fetal Findings Domain	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to fetal findings.			Idea or Concept	
C102638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102638>	C45501	Forgot to Take Medication Dose|FORGOT TO TAKE MEDICATION DOSE	A patient's failure to remember to take a dose of medication.			Finding	CDISC SDTM Reason for Treatment Interruption Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102639>	C41328	Fusion Complex|FUSION COMPLEX|Fusion Beat|Fusion Complexes	An electrocardiographic finding that occurs when electrical activation of the atria or ventricles occurs from two separate sites. This results in a P wave or QRS complex that displays merged characteristics of beats originating from the two different sites. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10263>	C61063	Cisplatin/Vinblastine|CDDP/VBL|PVe|V-DDP|VP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102640>	C49556	Digestive System Findings Domain|GI|Gastrointestinal System Findings|Gastrointestinal System Findings Domain	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to digestive system findings.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102641>	C49556	Hematopoietic System Findings Domain|HM|Hematopoietic System Findings	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to hematopoietic system findings.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102642>	C62016	High Grade Atrioventricular Block by ECG Finding|ADVANCED/HIGH GRADE AV BLOCK|Advanced Atrioventricular Block|Advanced/High Grade AV Block|High Grade Atrioventricular Block|High Grade Atrioventricular Block by EKG Finding	An electrocardiographic finding of intermittent failure of atrial electrical impulse conduction to the ventricles, characterized by two or more consecutive non-conducted P waves. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102643>	C101589	High Lateral Myocardial Infarction by ECG Finding|HIGH LATERAL WALL MYOCARDIAL INFARCTION|High Lateral Myocardial Infarction by EKG Finding|High Lateral Wall Myocardial Infarction	An electrocardiographic finding of pathologic Q waves in leads I and aVL, which is suggestive of myocardial infarction of the high lateral wall of the left ventricle. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102644>	C102573	High-priority Tuberculosis Subject|HIGH-PRIORITY TUBERCULOSIS CONTACT	An individual that has tested positive for pulmonary, laryngeal, or pleural tuberculosis and may or may not present with cavitary disease.			Organism Attribute	CDISC SDTM Priority of Tuberculosis Contact Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102645>	C19332	Homeless During Past Year|HOMELESS DURING PAST YEAR	An individual without a stable or permanent residence within the last 365 days.			Organism Attribute	CDISC SDTM Social Risk Factor Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102646>	C88117	Household Contact|HOUSEHOLD CONTACT	A way of contracting a disease through interactions with an infected person in the same residence.			Qualitative Concept	CDISC SDTM Contact Case Investigation Contact Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102647>	C25341	Household Environment|HOUSEHOLD ENVIRONMENT	The area in which an individual lives.			Geographic Area	CDISC SDTM Environmental Setting Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102648>	C100055	Immigrant From High Tuberculosis Prevalent Area	An individual that has migrated from a country with a high occurrence of tuberculosis.			Human	
C102649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102649>	C49556	Immune System Findings Domain	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to immune system findings.			Idea or Concept	
C10264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10264>	C61063	Cisplatin/Vindesine|CDDP/DAVA|Vind-Plat			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102650>	C25341	In the Field|FIELD|FLD	A setting outside the clinic or a comparable health care facility, e.g., a doctor's office, the subject's home or workplace, a school, a public park, or a restaurant.			Conceptual Entity	CDISC SDTM Environmental Setting Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102651>	C49556	Integumentary System Findings Domain|IG|Integumentary System Findings	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to integumentary system findings.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102652>	C71051	Junctional Premature Complex by ECG Finding|JUNCTIONAL PREMATURE COMPLEX|Junctional Extra Beat|Junctional Premature Complex|Junctional Premature Complex by EKG Finding|Junctional Premature Complexes	An electrocardiographic finding of an ectopic impulse originating in the AV junction presenting as a QRS complex of supraventricular origin which is not preceded by a P wave. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102653>	C90443	Late R Wave Transition by ECG Finding|LATE R WAVE TRANSITION|Late R Wave Transition|Late R Wave Transition|Late R Wave Transition by EKG Finding	An electrocardiographic finding where the amplitude of the R wave does not become greater than the amplitude of the S wave until an unusually late point in the precordial leads, usually in leads V4 to V6. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102654>	C27140	Left Ventricular Aneurysm	A bulge or ballooning in the wall of the left ventricle of the heart.			Finding	
C102655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102655>	C71076|C162788	Left Ventricular Hypertrophy with Strain by ECG Finding|LEFT VENTRICULAR HYPERTROPHY WITH STRAIN|Left Ventricular Hypertrophy With Strain|Left Ventricular Hypertrophy with Strain by EKG Finding	An electrocardiographic finding suggestive of a hypertrophied left ventricle, characterized by large QRS amplitudes, ST depression and T wave inversion. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102656>	C17632	Line Probe Assay|LINE PROBE ASSAY|LPA|LPA|LiPA|LiPA	A technique in which polymerase chain reaction is used to amplify specific nucleic acid sequences in a biospecimen. The product of this reaction is then applied to a nitrocellulose test strip containing complementary DNA probes.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102657>	C19332	Lived in Refugee Camp|LIVED IN REFUGEE CAMP	An individual that resided in a camp for those displaced from their homeland.			Organism Attribute	CDISC SDTM Social Risk Factor Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102658>	C68898	Log10 Colony Forming Units per Gram|log10 CFU/g|{log10}.[CFU]/g|{log10}.[CFU]/g	A logarithmic-scale (base 10) unit for measuring colony forming units per unit of mass equal to one gram.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102659>	C68902	Log10 Colony Forming Units per Milliliter|log10 CFU/mL|{log10}.[CFU]/mL|{log10}.[CFU]/mL|{log10}.[CFU]/ml|{log10}.[CFU]/ml	A logarithmic-scale (base 10) unit for measuring colony forming units per unit of volume equal to one milliliter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10265>	C61063	Cisplatin/Cyclophosphamide/Doxorubicin|CAP-I|CAP-II|CDDP/CTX/DOX|CISCA-II|PAC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102660>	C199000	Long-term Facility Resident|LONG-TERM FACILITY RESIDENT	An individual that lives at a healthcare facility that provides rehabilitative, restorative, and/or ongoing skilled nursing care to patients or residents in need of assistance with activities of daily living.			Human	CDISC SDTM Social Risk Factor Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102661>	C20055	Loop-mediated Isothermal Amplification|LAMP|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION	A type of nucleic acid amplification test in which sample DNA is exposed to a single temperature in the presence of multiple sets of primers and a polymerase with replication and high strand displacement activity. This test negates the need for thermal cyclers and may be a low cost alternative to PCR.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102662>	C102573	Low-priority Tuberculosis Subject|LOW-PRIORITY TUBERCULOSIS CONTACT	An individual that has had limited exposure to an individual with tuberculosis and has a low probability of having had a recent infection.			Organism Attribute	CDISC SDTM Priority of Tuberculosis Contact Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102663>	C176720	Medication Lost	The medication is no longer held or possessed by the subject and is incapable of being recovered or regained.			Finding	
C102664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102664>	C176720	Medication Misplaced|MEDICATION MISPLACED	Medications that were lost because they were put in the wrong place.			Finding	CDISC SDTM Reason for Treatment Interruption Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102665>	C102573	Medium-priority Tuberculosis Subject|MEDIUM-PRIORITY TUBERCULOSIS CONTACT	An individual that has tested negative for pulmonary, laryngeal, or pleural tuberculosis but has had a non-cavitary chest x-ray that is consistent with tuberculosis.			Organism Attribute	CDISC SDTM Priority of Tuberculosis Contact Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102666>	C19332	Member of High Risk Population|RISKPOP	An indication that a person is part of a population group that has a greater chance of contracting a disease or disorder.			Organism Attribute	CDISC SDTM Subject Characteristic Test Code Terminology|CDISC SDTM Subject Characteristic Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102667>	C205055	Microbial Identification Certainty	A qualification that describes the degree of certainty of the correctness of a microbial identification test result.			Functional Concept	
C102668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102668>	C19347	Microbial Liquid Culture|MICROBIAL CULTURE, LIQUID	A method for growing microorganisms in liquid culture media.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102669>	C19347	Microbial Solid Culture|MICROBIAL CULTURE, SOLID	A method for growing microorganisms in solid culture media.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10266>	C61063	Cyclophosphamide/Doxorubicin/Lomustine/Prednisone/Vincristine|CCNU/CTX/DOX/PRED/VCR|COPAC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102670>	C198995	Migratory Worker|MIGRATORY WORKER	An individual who moves from one location to another location within or outside of their homeland for work.			Human	CDISC SDTM Social Risk Factor Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102671>	C103175	Morphology Findings Domain	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to morphology findings.			Idea or Concept	
C102672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102672>	C62257	Multifocal Atrial Premature Complex by ECG Finding|Multifocal Atrial Premature Complex|Multifocal Atrial Premature Complex by EKG Finding|Multifocal SVE|Multifocal Supraventricular Extra Beats|PREMATURE ATRIAL COMPLEXES MULTIFOCAL|Premature Atrial Complex Multifocal|Premature Atrial Complexes Multiform	An electrocardiographic finding of premature atrial complexes which have 2 or more distinct morphologies, suggesting origin at more than one atrial site. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102673>	C62256	Multifocal Ventricular Premature Complex by ECG Finding|Multifocal VES|Multifocal VPCS|Multifocal Ventricular Extra Beats|Multifocal Ventricular Premature Complex|Multifocal Ventricular Premature Complex by EKG Finding|PREMATURE VENTRICULAR COMPLEXES MULTIFOCAL|Premature Ventricular Complex Multifocal	An electrocardiographic finding of premature ventricular complexes which have two or more distinct morphologies, suggesting origin at more than one ventricular site. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102674>	C49556	Musculoskeletal Findings, Connective and Soft Tissue Findings Domain|MK|Musculoskeletal System Findings	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to musculoskeletal findings, connective and soft tissue findings.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102675>	C41328	Myocardial Ischemia by ECG Finding|Myocardial Ischemia by EKG Finding	An electrocardiographic finding of ST and T wave changes consistent with impaired myocardial perfusion.			Finding	
C102676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102676>	C62667	Myocardial Perfusion Imaging|Myocardial perfusion imaging|Myocardial perfusion imaging	A procedure that captures pictures of blood flow throughout the heart muscle.			Diagnostic Procedure	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|ACC/AHA COVID-19 Appendix Variables|Appendix 7: Diagnostic Procedures Terminology
C102677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102677>	C49556	Nervous System Findings Domain|NV|Nervous System Findings	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to nervous system findings.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|CDISC SEND Domain Abbreviation Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102678>	C49556	Nonclinical Pregnancy Results Domain|Nonclinical Pregnancy Results|PY	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to nonclinical pregnancy results.			Idea or Concept	CDISC SDTM Terminology|CDISC SEND Domain Abbreviation Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102679>	C25341	Non-household Environment|NON-HOUSEHOLD ENVIRONMENT	An area outside of that in which an individual lives.			Geographic Area	CDISC SDTM Environmental Setting Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10267>	C61063	Bleomycin/Dacarbazine/Doxorubicin/Mechlorethamine/Prednisone/Procarbazine/Vinblastine/Vincristine|ABVD/MOPP|BLEO/DOX/DTIC/NM/PCB/PRED/VBL/VCR|MA/MA|MOPP alternating with ABVD|MOPP/ABVD			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102680>	C111105	Non-Sustained Atrial Tachycardia by ECG Finding|NON-SUSTAINED ATRIAL TACHYCARDIA|Non-Sustained Atrial Tachycardia|Non-Sustained Atrial Tachycardia|Non-Sustained Atrial Tachycardia by EKG Finding	An electrocardiographic finding of an atrial tachycardia which terminates in less than 30 seconds. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102681>	C100076	Normal Sinus Rhythm|NORMAL SINUS RHYTHM	An electrocardiographic finding of an atrial rhythm which originates from the sinoatrial node that is considered normal for the population. There are no extra beats or conduction abnormalities. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102682>	C48655	Not Offered|Not offered	Is not an option.			Qualitative Concept	
C102683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102683>	C85774	Observed Volume of Distribution Normalized by Dose|VZOD|Vz Obs Norm by Dose|Vz Obs Norm by Dose	The volume of distribution associated with the terminal slope following intravascular administration, calculated using the observed value of the last non-zero concentration, divided by the dose.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102684>	C101597	Old or Age Indeterminate Anterior Myocardial Infarction by ECG Finding|OLD OR AGE INDETERMINATE ANTERIOR WALL MYOCARDIAL INFARCTION|Old Or Age Indeterminate Anterior Wall Myocardial Infarction|Old or Age Indeterminate Anterior Myocardial Infarction by EKG Finding	An electrocardiographic finding of pathologic Q waves in leads V3 and V4, which is suggestive of myocardial infarction of the anterior wall of the left ventricle, without evidence of current or ongoing acute infarction. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102685>	C101597	Old or Age Indeterminate Anterolateral Myocardial Infarction by ECG Finding|OLD OR AGE INDETERMINATE ANTEROLATERAL WALL MYOCARDIAL INFARCTION|Old Or Age Indeterminate Anterolateral Wall Myocardial Infarction|Old or Age Indeterminate Anterolateral Myocardial Infarction by EKG Finding	An electrocardiographic finding of pathologic Q waves in leads V3 through V6, which is suggestive of myocardial infarction of the anterolateral wall of the left ventricle, without evidence of current or ongoing acute infarction. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102686>	C101597	Old or Age Indeterminate Anteroseptal Myocardial Infarction by ECG Finding|OLD OR AGE INDETERMINATE ANTEROSEPTAL WALL MYOCARDIAL INFARCTION|Old Or Age Indeterminate Anteroseptal Wall Myocardial Infarction|Old or Age Indeterminate Anteroseptal Myocardial Infarction by EKG Finding	An electrocardiographic finding of pathologic Q waves in leads V1 through V4, which is suggestive of myocardial infarction of the anteroseptal wall of the left ventricle, without evidence of current or ongoing acute infarction. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102687>	C101597	Old or Age Indeterminate Extensive Anterior Myocardial Infarction by ECG Finding|OLD OR AGE INDETERMINATE EXTENSIVE ANTERIOR WALL MYOCARDIAL INFARCTION|Old Or Age Indeterminate Extensive Anterior Wall Myocardial Infarction|Old or Age Indeterminate Extensive Anterior Myocardial Infarction by EKG Finding	An electrocardiographic finding of pathologic Q waves in leads V1 to V6, I and aVL, which is suggestive of myocardial infarction involving the anterior and anterolateral walls of the left ventricle, without evidence of current or ongoing acute infarction. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102688>	C101597	Old or Age Indeterminate High Lateral Myocardial Infarction by ECG Finding|OLD OR AGE INDETERMINATE HIGH LATERAL WALL MYOCARDIAL INFARCTION|Old Or Age Indeterminate High Lateral Wall Myocardial Infarction|Old or Age Indeterminate High Lateral Myocardial Infarction by EKG Finding	An electrocardiographic finding of pathologic Q waves in leads I and aVL, which is suggestive of myocardial infarction of the high lateral wall of the left ventricle, without evidence of current or ongoing acute infarction. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102689>	C101597	Old or Age Indeterminate Inferior Myocardial Infarction by ECG Finding|OLD OR AGE INDETERMINATE INFERIOR WALL MYOCARDIAL INFARCTION|Old Or Age Indeterminate Inferior Wall Myocardial Infarction|Old or Age Indeterminate Inferior Myocardial Infarction by EKG Finding	An electrocardiographic finding of pathologic Q waves in leads III, aVF and often II, which is suggestive of myocardial infarction of the inferior wall of the left ventricle, without evidence of current or ongoing acute infarction. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10268>	C61007	Cisplatin/Cyclophosphamide/Etoposide|CDDP/CTX/VP-16|CVP|PCE|PVC|VCP-1			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102690>	C101597	Old or Age Indeterminate Lateral Myocardial Infarction by ECG Finding|OLD OR AGE INDETERMINATE LATERAL WALL MYOCARDIAL INFARCTION|Old Or Age Indeterminate Lateral Wall Myocardial Infarction|Old or Age Indeterminate Lateral Myocardial Infarction by EKG Finding	An electrocardiographic finding of pathologic Q waves in leads V5, V6, I and aVL, which is suggestive of myocardial infarction of the lateral wall of the left ventricle, without evidence of current or ongoing acute infarction. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102691>	C101597	Old or Age Indeterminate Posterior Myocardial Infarction by ECG Finding|OLD OR AGE INDETERMINATE POSTERIOR WALL MYOCARDIAL INFARCTION|Old Or Age Indeterminate Posterior Wall Myocardial Infarction|Old or Age Indeterminate Posterior Myocardial Infarction by EKG Finding	An electrocardiographic finding in leads V1 or V2 of an initial R wave duration greater than or equal to 40 ms, R wave greater than S wave, and upright T wave, which is suggestive of myocardial infarction of the posterior wall of the left ventricle, without evidence of current or ongoing acute infarction. Evidence of inferior or lateral myocardial infarction is usually also present. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102692>	C101597	Old or Age Indeterminate Right Ventricular Myocardial Infarction by ECG Finding|OLD OR AGE UNDETERMINED RIGHT VENTRICULAR MYOCARDIAL INFARCTION|Old or Age Indeterminate Right Ventricular Myocardial Infarction by EKG Finding	An electrocardiographic finding, in the presence of an old or age indeterminate inferior wall myocardial infarction, of Q waves greater than or equal to 40 ms in duration in the right ventricular leads V4R through V6R. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102693>	C101597	Old or Age Indeterminate Septal Myocardial Infarction by ECG Finding|OLD OR AGE INDETERMINATE SEPTAL WALL MYOCARDIAL INFARCTION|Old Or Age Indeterminate Septal Wall Myocardial Infarction|Old or Age Indeterminate Septal Myocardial Infarction by EKG Finding	An electrocardiographic finding of pathologic Q waves in leads V1, V2 and often V3, which is suggestive of myocardial infarction of the intraventricular septum, without evidence of current or ongoing acute infarction. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102694>	C49556	Pairing Events Domain|PA|Pairing Events	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to pairing events.			Idea or Concept	CDISC SDTM Terminology|CDISC SEND Domain Abbreviation Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102695>	C96619	Per 100 High Powered Fields|/10*2.[HPF]|/10*2.[HPF]|/100 HPFs|/10^2.[HPF]|/10^2.[HPF]|Per 100HPF	A unit of measurement of the number of entities per unit of area equal to one hundred high powered fields.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102696>	C85798	Predicted Volume of Distribution Normalized by Dose|VZPD|Vz Pred Norm by Dose|Vz Pred Norm by Dose	The volume of distribution associated with the terminal slope following intravascular administration, calculated using the predicted value of the last non-zero concentration, divided by the dose.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102697>	C27993	Presumptive|PRESUMPTIVE	Supplying or being a probable or reasonable settlement or result.			Qualitative Concept	CDISC SDTM Microbial Identification Certainty Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102698>	C91752	Previous Patient Noncompliance	A previous episode of failure by a patient to follow medical advice, take medication as directed, or adhere to a prescribed course of treatment.			Finding	
C102699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102699>	C41085	Priority of Disease Contact|PRICON	The categorization of individuals with or without the potential for having tuberculosis.			Intellectual Product	CDISC SDTM Subject Characteristic Test Code Terminology|CDISC SDTM Subject Characteristic Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10269>	C61007	Cisplatin/Cyclophosphamide/Etoposide/Lomustine/Vincristine|CCNU/CDDP/CTX/VCR/VP-16|CCVVP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1026>	C2089	Bryostatin 1|B705008K112|B705008K112|BRYOSTATIN 1|Bryostatin I|bryostatin 1	A macrocyclic lactone isolated from the bryozoan Bugula neritina with antineoplastic activity.  Bryostatin 1 binds to and inhibits the cell-signaling enzyme protein kinase C, resulting in the inhibition of tumor cell proliferation, the promotion of tumor cell differentiation, and the induction of tumor cell apoptosis. This agent may act synergistically with other chemotherapeutic agents. (NCI04)	Bryostatin 1		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102700>	C49556	Procedure Domain|PR|Procedures	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to procedure.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|CDISC SEND Domain Abbreviation Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102701>	C41328	QRS Axis Indeterminate|INDETERMINATE QRS AXIS|Indeterminate Axis|Indeterminate QRS Axis	An electrocardiographic finding in which the frontal plane QRS axis cannot be calculated.			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102702>	C25638	Reason for Treatment	The reason the treatment was administered.			Idea or Concept	
C102703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102703>	C25638	Reason for Treatment Interruption	The reason the drug or therapy was temporarily ceased.			Idea or Concept	
C102704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102704>	C25638	Reason Treatment Not Administered|reason treatment not given|reason_treatment_not_given	The reason the treatment was not administered.			Idea or Concept	GDC Property Terminology|GDC Terminology
C102705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102705>	C85878	Refugee From High Tuberculosis Prevalent Area	An individual that has fled a country for their own safety which has a high occurrence of tuberculosis.			Human	
C102706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102706>	C102574	Repolarization Abnormality Secondary To Ventricular Hypertrophy|REPOLARIZATION ABNORMALITY SECONDARY TO VENTRICULAR HYPERTROPHY|ST-T change due to ventricular hypertrophy	An electrocardiographic finding of ST depression and T wave inversion in the presence of increased QRS amplitude which are thought to be due to left ventricular hypertrophy.			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102707>	C49556	Reproductive System Findings Domain|RP|Reproductive System Findings	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to reproductive system findings.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102708>	C16551	Setting of Disease Contact|SETCON|Setting of Contact|Setting of Contact	The environment within which the person may have come into contact with a disease carrier, or played the role of a disease carrier.			Functional Concept	CDISC SDTM Subject Characteristic Test Code Terminology|CDISC SDTM Subject Characteristic Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102709>	C41328	Short QTc Interval|SHORT QTC INTERVAL	An electrocardiographic finding of a QT interval corrected for heart rate that is shorter than the lower limit of normal. Thresholds for different age, sex, and patient populations exist.			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10270>	C63589	PATCO Regimen|ARA-C/CTX/PRED/TG/VCR|Cyclophosphamide/Cytarabine/Prednisone/Thioguanine/Vincristine|PATCO|PATCO|PATCO|Prednisone-Cytarabine-Thioguanine-Cyclophosphamide-Vincristine|Prednisone/Ara-C/Thioguanine/Cyclophosphamide/Oncovin|Prednisone/Cytarabine/Thioguanine/Cyclophosphamide/Vincristine|Prednisone/Cytarabine/Thioguanine/Cyclophosphamide/Vincristine Regimen|T-COAP	A regimen consisting of prednisone, cytarabine, 6-thioguanine, cyclophosphamide, and vincristine that may be used in the treatment of childhood acute myeloid leukemia (AML).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C102710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102710>	C37901	Site of Directly Observed Therapy	The physical location at which the medication or therapy was observed, by the healthcare provider, as being taken by the subject.			Geographic Area	
C102711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102711>	C17103	Social Risk Factor|RISKSOC	Social factors such as personal behavior, lifestyle, or environment belonging to the subject which are known to increase the likelihood of infection and disease.			Clinical Attribute	CDISC SDTM Subject Characteristic Test Code Terminology|CDISC SDTM Subject Characteristic Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102712>	C16551	Social Setting|SOCIAL SETTING	The surroundings or environment in which social activities occur.			Geographic Area	CDISC SDTM Environmental Setting Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102713>	C41198	Source Case Investigation	A public health activity for the determination of who transmitted a disease to another subject and whether this person: is still infectious; was reported to the health department as a disease case or suspect; or has infected others.			Activity	
C102714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102714>	C214011	Subject in Contact With Tuberculosis Source	An individual that came into contact with a source of tuberculosis.			Organism Attribute	
C102715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102715>	C54359	Sub-therapeutic Drug Level	A drug serum concentration below therapeutic levels.			Finding	
C102716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102716>	C12745	Superficial Lymph Node|SUPERFICIAL LYMPH NODE	A lymph node located in a superficial part of the body.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102717>	C43583	Supporting Evidence for Retreatment	Clinical evidence to support reason for re-treatment of disease.			Idea or Concept	
C102718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102718>	C71035	T Wave Alternans by ECG Finding|T WAVE ALTERNANS|T Wave Alternans|T Wave Alternans|T Wave Alternans by EKG Finding	An electrocardiographic finding in which there are variations in the shape, amplitude, or direction of the T wave from one beat to the next.			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102719>	C214012	Travel To High Burden Tuberculosis Country	Entry into one or more of the 22 countries that have a relatively high prevalence of tuberculosis cases.			Organism Attribute	
C10271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10271>	C61007	Cytarabine/Daunorubicin|ARA-C/DNR|CAD|DA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102720>	C168631	Treatment Episode Indicator	An indication of whether this is the individual's first time being treated for a disease or that they are receiving a subsequent treatment.			Conceptual Entity	
C102721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102721>	C25638	Treatment Failure Reason	The reason the drug or therapy was unsuccessful in treating the condition.			Idea or Concept	
C102722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102722>	C49556	Tumor Response Domain	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to tumor response.			Idea or Concept	
C102723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102723>	C25284	Type of Contagion Contact|TYPCON|Type of Contact|Type of Contact	Identification and clinical investigation of disease contacts.			Functional Concept	CDISC SDTM Subject Characteristic Test Code Terminology|CDISC SDTM Subject Characteristic Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102724>	C62257	Unifocal Atrial Premature Complex by ECG Finding|PREMATURE ATRIAL COMPLEXES UNIFOCAL|Premature Atrial Complex Unifocal|Unifocal Atrial Premature Complex|Unifocal Atrial Premature Complex by EKG Finding	An electrocardiographic finding of premature atrial complexes which have a single distinct morphology, suggesting origin at one atrial site.			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102725>	C62256	Unifocal Ventricular Premature Complex by ECG Finding|PREMATURE VENTRICULAR COMPLEXES UNIFOCAL|Premature Ventricular Complex Unifocal|Unifocal VES|Unifocal VPCS|Unifocal Ventricular Extra Beats|Unifocal Ventricular Premature Complex|Unifocal Ventricular Premature Complex by EKG Finding	An electrocardiographic finding of premature ventricular complexes which have a single distinct morphology, suggesting origin at one ventricular site.			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102726>	C49556	Urinary System Findings Domain|UR|Urinary System Findings	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to urinary system findings.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102727>	C25683	Vaccination Evidence Source	Source of information regarding the subject's vaccination status.			Qualitative Concept	
C102728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102728>	C111101	Ventricular Parasystole by ECG Finding|Parasystole|VENTRICULAR PARASYSTOLE|Ventricular Parasystole|Ventricular Parasystole|Ventricular Parasystole by EKG Finding	An electrocardiographic finding of normal sinus rhythm coexisting with a regular ectopic ventricular rhythm.			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102729>	C85775	Volume of Distribution of Fraction Dose Observed Normalized by Dose|VZFOD|Vz Obs by F Norm by Dose|Vz Obs by F Norm by Dose	The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using the observed value of the last non-zero concentration, divided by the dose.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10272>	C61063	Cytarabine/Doxorubicin/Etoposide/Thioguanine|ARA-C/DOX/TG/VP-16|VATA-II			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102730>	C85799	Volume of Distribution of Fraction Dose Predicted Normalized by Dose|VZFPD|Vz Pred by F Norm by Dose|Vz Pred by F Norm by Dose	The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using the predicted value of the last non-zero concentration, divided by the dose.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102731>	C101589	New Myocardial Infarction by ECG Finding|NEW MYOCARDIAL INFARCTION|New Myocardial Infarction|New Myocardial Infarction by EKG Finding	An electrocardiographic finding of pathologic Q waves, which is suggestive of myocardial infarction of one or more regions of the heart and which is new compared to prior ECGs. No specification is provided for localization. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102732>	C102731	New Anterior Myocardial Infarction by ECG Finding|NEW ANTERIOR WALL MYOCARDIAL INFARCTION|New Anterior MI|New Anterior Myocardial Infarction by EKG Finding|New Anterior Wall Myocardial Infarction	An electrocardiographic finding of pathologic Q waves in leads V3 and V4, which is suggestive of myocardial infarction of the anterior wall of the left ventricle and which is new compared to prior ECGs. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102733>	C102731	New Anterolateral Myocardial Infarction by ECG Finding|NEW ANTEROLATERAL WALL MYOCARDIAL INFARCTION|New Anterolateral Myocardial Infarction by EKG Finding|New Anterolateral Wall Myocardial Infarction	An electrocardiographic finding of pathologic Q waves in leads V3 through V6, which is suggestive of myocardial infarction of the anterolateral wall of the left ventricle and which is new compared to prior ECGs. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102734>	C102731	New Anteroseptal Myocardial Infarction by ECG Finding|NEW ANTEROSEPTAL WALL MYOCARDIAL INFARCTION|New Anteroseptal Myocardial Infarction by EKG Finding|New Anteroseptal Wall Myocardial Infarction	An electrocardiographic finding of pathologic Q waves in leads V1 through V4, which is suggestive of myocardial infarction of the anteroseptal wall of the left ventricle and which is new compared to prior ECGs. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102735>	C102731	New Extensive Anterior Myocardial Infarction by ECG Finding|NEW EXTENSIVE ANTERIOR WALL MYOCARDIAL INFARCTION|New Extensive Anterior Myocardial Infarction by EKG Finding|New Extensive Anterior Wall Myocardial Infarction	An electrocardiographic finding of pathologic Q waves in leads V1 to V6, I and aVL, which is suggestive of myocardial infarction involving the anterior and anterolateral walls of the left ventricle and which is new compared to prior ECGs. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102736>	C102731	New High Lateral Myocardial Infarction by ECG Finding|NEW HIGH LATERAL WALL MYOCARDIAL INFARCTION|New High Lateral Myocardial Infarction by EKG Finding|New High Lateral Wall Myocardial Infarction	An electrocardiographic finding of pathologic Q waves in leads I and aVL, which is suggestive of myocardial infarction of the high lateral wall of the left ventricle and which is new compared to prior ECGs. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102737>	C102731	New Inferior Myocardial Infarction by ECG Finding|NEW INFERIOR WALL MYOCARDIAL INFARCTION|New Inferior Myocardial Infarction by EKG Finding|New Inferior Wall Myocardial Infarction	An electrocardiographic finding of pathologic Q waves in leads III, aVF and often II, which is suggestive of myocardial infarction of the inferior wall of the left ventricle and which is new compared to prior ECGs. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102738>	C102731	New Lateral Myocardial Infarction by ECG Finding|NEW LATERAL WALL MYOCARDIAL INFARCTION|New Lateral Myocardial Infarction by EKG Finding|New Lateral Wall Myocardial Infarction	An electrocardiographic finding of pathologic Q waves in leads V5, V6, I and aVL, which is suggestive of myocardial infarction of the lateral wall of the left ventricle and which is new compared to prior ECGs. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C102739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102739>	C102731	New Septal Myocardial Infarction by ECG Finding|NEW SEPTAL WALL MYOCARDIAL INFARCTION|New Septal Myocardial Infarction by EKG Finding|New Septal Wall Myocardial Infarction	An electrocardiographic finding of pathologic Q waves in leads V1, V2 and often V3, which is suggestive of myocardial infarction of the intraventricular septum and which is new compared to prior ECGs. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10273>	C61063	Cytarabine/Etoposide/Methotrexate|ARA-C/MTX/VP-16|EMCC (EMC2)|MACE			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102740>	C25692	Clinical Observation Subcategory|CLSCAT	A subdivision of clinical observational data.			Classification	CDISC Variable Terminology
C102741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102741>	C82498	Clinical Observation Result Category|CLRESCAT	A classification of a clinical observation result.			Classification	CDISC Variable Terminology
C102742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102742>	C82498	Death Diagnosis Result Category|DDRESCAT	A classification of a death diagnosis result.			Classification	CDISC Variable Terminology
C102743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102743>	C15300	Interstitial Photodynamic Therapy|I-PDT|Interstitial Illumination Photodynamic Therapy	Photodynamic therapy that uses light-emitting fibers to treat deep-seated solid tumors.	Interstitial Photodynamic Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C102745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102745>	C245	Extended Release Bupivacaine Hydrochloride Resorbable Matrix Formulation|ER Bupivacaine HCl|SABER-Bupivacaine Hydrochloride|Sustained Release Bupivacaine Hydrochloride	An extended release (ER) injectable formulation composed of the hydrochloride salt form of bupivacaine, an amide-type, long-acting local anesthetic, in a resorbable sucrose acetate isobutyrate-based matrix, with analgesic activity. Following administration in or around a specific site, ER bupivacaine is released from the matrix over an extended period of time. Upon release, bupivacaine reversibly binds to specific voltage-gated sodium ion channels in the neuronal membrane, resulting in a decrease in the voltage-dependent membrane permeability to sodium ions, membrane destabilization, and depolarization inhibition thus disrupting nerve impulse conduction. This eventually leads to a reversible loss of sensation. This formulation may provide pain relief up to 72 hours.	Extended Release Bupivacaine Hydrochloride Resorbable Matrix Formulation		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C102746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102746>	C62554	PARP/Tankyrase Inhibitor 2X-121 |2X-121|2X-121|E-7449|E7449|PARP/TNKS Inhibitor 2X-121|PARP/Tankyrase Inhibitor 2X-121	An orally available small molecule inhibitor of the nuclear enzymes poly (ADP-ribose) polymerase (PARP) 1 and 2, with potential antineoplastic activity. Upon administration, E7449 selectively binds to PARP 1 and 2, thereby preventing the repair of damaged DNA via the base excision repair (BER) pathway. This agent enhances the accumulation of single and double strand DNA breaks and promotes genomic instability eventually leading to apoptosis. PARP 1/2 inhibitor E7449 may enhance the cytotoxicity of DNA-damaging agents and of radiotherapy. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA.	PARP/Tankyrase Inhibitor 2X-121		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102747>	C275	PLED-based MnSOD Mimetic|CALMANGAFODIPIR|Calmangafodipir|PLEDOx|PP-095	A derivative of pyridoxyl ethyldiamine (PLED) and mimetic of the human mitochondrial manganese superoxide dismutase (MnSOD), with antioxidant, metal chelating and potential chemoprotective activities. Upon administration, PLED-based MnSOD mimetic mimics MnSOD and scavenges oxygen free radicals such as superoxide anion, hydrogen peroxide, and hydroxyl radical, thereby preventing oxygen free radical damage to macromolecules such as DNA and minimizing oxygen free radical-related chemotoxicity in normal tissues. In addition, this agent is able to strongly bind to iron.	PLED-based MnSOD Mimetic		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C102748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102748>	C2080	Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia Extract Granules|Samital Granules|V. myrtillus/M. cordata/E. angustfolia Extract Granules	A proprietary suspension formulation prepared from granules of standardized extracts from the fruits of Vaccinium myrtillus, the aerial parts of Macleaya cordata and the roots of Echinacea angustifolia, with potential anti-mucositis, anti-inflammatory, and analgesic activities. The main active ingredients of this formulation include anthocyanosides and procyanidins, benzophenanthridinic alkaloids, and alkylamides from V. myrtillus, M. cordata and E. angustifolia extracts, respectively. Upon administration in the mucosal cavity, the anthocyanosides scavenge free radicals, form a protective barrier on the mucosa, and protect the integrity of the capillary vessels; the benzophenanthridine alkaloids prevent the production of pro-inflammatory cytokines by inhibiting NF-kB and may halt the growth of microorganisms; the alkylamides inhibit cyclooxygenase and 5-lipoxygenase thereby blocking productions of prostaglandin and leukotriene. Furthermore, alkylamides modulate the expression of tumor necrosis factor alpha and other cytokines involved in inflammation processes through cannabinoid type 2 receptors and as cannabinomimetics they may also exert analgesic activity.	Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia Extract Granules		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C10274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10274>	C61007	Doxorubicin/Fluorouracil|AFA|DOX/5-FU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102750>	C1511	Zirconium Zr 89-labeled Anti-PlGF Monoclonal Antibody RO5323441|89Zr-RO5323441	A radioimmunoconjugate comprised of the humanized IgG1 monoclonal antibody directed against placental growth factor (PlGF) and labeled with zirconium Zr 89 (Zr 89), with potential radiotracer activity upon positron emission tomography (PET) imaging. The monoclonal antibody moiety of RO5323441 binds to both PlGF-1 and -2, thereby preventing the binding of PlGF-1 and -2 to the vascular endothelial growth factor receptor-1 (VEGFR-1) and the subsequent activation of VEGFR-1. The radioisotope moiety of RO5323441 may be detected using PET, thereby allowing for visualization of the antibody's distribution and PlGF expression. PlGF, a member of the VEGF sub-family and a key molecule in angiogenesis and vasculogenesis, is upregulated in many cancers.			Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	NCI Drug Dictionary Terminology
C102751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102751>	C1752|C1663	WT1 Peptide Vaccine WT2725|WT2725	A peptide cancer vaccine comprised of a peptide derived from Wilms tumor gene 1 (WT1) protein, with potential immunomodulating and antineoplastic activities. Upon administration, WT2725 may induce a specific cytotoxic T-lymphocyte (CTL) response against WT1-overexpressing tumor cells. WT1 protein, a zinc finger DNA-binding protein, is overexpressed in leukemic cells and in a vast number of non-hematological solid tumors.	WT1 Peptide Vaccine WT2725		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102752>	C2150|C1557	Fosgemcitabine Palabenamide|Acelarin|FOSGEMCITABINE PALABENAMIDE|Gemictabine ProTide|NUC 1031|NUC-1031	A pyrimidine analogue and a proprietary prodrug based on an aryloxy phosphoramidate derivative of gemcitabine with potential antineoplastic activity. Upon intravenous administration and cellular uptake, fosgemcitabine palabenamide is converted into the active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP). dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA replication; dFdCTP is incorporated into DNA, resulting in premature termination of DNA replication and eventually induction of apoptosis. With the phosphoramidate moiety on the gemcitabine monophosphate group, NUC-1031 has improved properties over its parent molecule: 1) is more lipophilic and accumulates in cancer cells by passive diffusion and does not require a nucleoside transporter, 2) as the agent is delivered in the monophosphate form, the first phosphorylation step by deoxycytidine kinase is not required, 3) this agent is not susceptible to deactivation by cytidine deaminase cleavage of the monophosphorylated form. Altogether, this may help overcome resistance to gemcitabine.	Fosgemcitabine Palabenamide		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102753>	C28310	Adenovirus Encoding Tyrosinase/MART-1/MAGEA6-transduced Autologous Dendritic Cell Vaccine|AdVTMM2-transduced Dendritic Cell Vaccine	A cell-based cancer vaccine composed of autologous dendritic cells (DCs) transduced with a recombinant adenoviral vector encoding three full length human melanoma associated antigens (MAAs), tyrosinase, melan-A (MART-1) and the melanoma antigen A6 (MAGEA6), with potential antineoplastic activity. Upon intradermal administration, adenovirus encoding tyrosinase/MART-1/MAGEA6-transduced autologous DC vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tyrosinase/MART-1/MAGEA6-positive tumor cells, which may result in tumor cell death and decreased tumor growth. Tyrosinase, a melanoma-specific differentiation antigen, catalyzes the first step of melanin synthesis in melanocytes. Vaccination with multi-antigen modified DC may improve the efficacy of the DC immunotherapy.	Adenovirus Encoding Tyrosinase/MART-1/MAGEA6-transduced Autologous Dendritic Cell Vaccine		Cell|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102754>	C141136|C129825	Ensartinib|6-Amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]- N-{4-[(3R,5S)-3,5-dimethylpiperazine- 1-carbonyl]phenyl}pyridazine-3-carboxamide|ENSARTINIB|X 396|X-396|X396	An orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon oral administration, ensartinib binds to and inhibits ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to the disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-expressing tumor cells. In addition, ensartinib inhibits various other kinases, including the receptor tyrosine kinase c-Met (hepatocyte growth factor receptor; HGFR; MET) and the receptor tyrosine kinase C-ros oncogene 1 (ROS1). ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors; ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCIt Antineoplastic Agent Terminology
C102755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102755>	C84868	Ulimorelin Hydrochloride|(2R,5S,8R,11R)-5-Cyclopropyl-11-((4-fluorophenyl)methyl)-2,7,8-trimethyl-2,3,4,5,7,8,10,11,13,14,15,16-dodecahydro-6H-1,4,7,10,13- benzoxatetraazacyclooctadecine-6,9,12-trione Hydrochloride Monohydrate|TZP-101|ULIMORELIN HYDROCHLORIDE	The hydrochloride salt form of ulimorelin, a macrocyclic ghrelin peptidomimetic, with potential gastrointestinal (GI) prokinetic activity. Upon intravenous administration, ulimorelin binds to the ghrelin receptor in the GI tract and may stimulate GI motility. Ghrelin is a natural ligand for growth hormone secretagogue receptors and is normally localized in the proximal GI tract. The ghrelin receptor signaling pathway mediates multiple GI functions, including motility and gastric emptying.	Ulimorelin Hydrochloride		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C102756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102756>	C129986	Sheng-Mai San|Panax ginseng/Ophiopogon japonicus/Schisandra chinensis Herbal Supplement|Shengmai San	A Chinese herbal medicine composed of extracts from the roots of Panax Ginseng (ren shen) and Ophiopogon japonicas (mai men dong), and the berries of Schisandra chinensis (wu wei zi) with potential protective activity. Ginseng contains a complex mixture of saponins, ginsenosides and panaxosides; homoisoflavonoids isolated from Ophiopogon show anti-inflammatory properties; Schisandra contains abundant amounts of phytoestrogen lignans with antioxidant activity. Although the mechanism of action maybe inexplicit or complex, these phytochemicals work synergistically and may improve symptoms such as shortness of breath, sweating, cough, thirst, dry mouth, and palpitations as well as have an effect on chemotherapy or radiotherapy-induced fatigue, weakness, and neutropenia.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C102757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102757>	C213868	Allodepleted Haploidentical T Cells-expressing Inducible Caspase 9|iCasp9 Allogeneic T Cells	Allodepleted haploidentical T-lymphocytes transduced with the Gal-V pseudotyped retrovirus vector encoding SFG.iCasp9-2A-deltaCD19, with potential immune reconstitution property. SFG.iCasp9-2A-deltaCD19 contains the suicide gene inducible caspase 9 (iCasp9) linked with a 2A-like cleavable peptide to the selectable marker, truncated human CD19 (deltaCD19). iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9 using a short linker (SGGGS). Donor T cell therapy may help control transplant-related viral infections following allogeneic hematopoietic stem cell transplantation. However, even the addition of allodepleted donor T cells can lead to graft-versus-host disease (GVHD). In the event that GVHD begins to develop, the chemical homodimerizer AP1903 can be administered, which binds to the FKBP12-F36V domain activating caspase 9. This results in the death of T cells causing GVHD while sparing the virus reactive T-cells.	Allodepleted Haploidentical T Cells-expressing Inducible Caspase 9		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C102758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102758>	C200766|C176018	Tisagenlecleucel|CART-19|CART19|CTL 019|CTL-019|CTL019|CTL019 T-cells|Kymriah|TISAGENLECLEUCEL|Tisa-cel|Tisagenlecleucel-T	Autologous T-lymphocytes transduced with a modified lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. Upon transfusion, tisagenlecleucel directs the T-lymphocytes to CD19-expressing tumor cells, thereby inducing a selective toxicity in CD19-expressing tumor cells. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19 and the inclusion of this signaling domain may increase the antitumor activity compared to the inclusion of the CD3-zeta chain alone. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. CD3-zeta (or CD247) is a transmembrane signaling adaptor polypeptide that regulates the assembly of complete TCR complexes and their expression on the cell surface.	Tisagenlecleucel		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102759>	C93144	Lactobacillus plantarum 299v/Lactobacillus acidophilus/Bifidobacterium lactis Probiotic Supplement|Goodbelly Probiotic	A powder-based, probiotic supplement drink containing the non-pathogenic microorganisms Lactobacillus plantarum 299v, Lactobacillus acidophilus, and Bifidobacterium lactis, with potential immunomodulating and protective activities. Upon oral ingestion, the naturally-occurring bacterial components in this dietary supplement may improve digestion and help maintain adequate colonization of the gastrointestinal (GI) tract by modulating the composition of the normal microflora. During colonization in the GI tract, the bacteria may form a protective intestinal barrier which may prevent damage to the mucosal epithelia caused by toxins and attachment of potential pathogens, thereby protecting against infections. In addition, this agent may reduce the secretion of proinflammatory cytokines and may potentiate natural and acquired immunity.	Lactobacillus plantarum 299v/Lactobacillus acidophilus/Bifidobacterium lactis Probiotic Supplement		Bacterium|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C10275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10275>	C61063	Cyclophosphamide/Doxorubicin/Etoposide/Lomustine/Vincristine|CCNU/CTX/DOX/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102760>	C25873	SRPK1 Gene|SRPK1|SRPK1|SRSF Protein Kinase 1 Gene	This gene is involved in both protein phosphorylation and RNA splicing.			Gene or Genome	
C102761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102761>	C102760	SRPK1 wt Allele|RP3-422H11.1|SFRSK1|SRSF Protein Kinase 1 wt Allele	Human SRPK1 wild-type allele is located in the vicinity of 6p21.31 and is approximately 88 kb in length. This allele, which encodes SRSF protein kinase 1 protein, plays a role in phosphorylation of proteins involved in RNA splicing.			Gene or Genome	
C102762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102762>	C17325	SRSF Protein Kinase 1|EC 2.7.11.1|SFRS Protein Kinase 1|SR-Protein-Specific Kinase 1|Serine/Arginine-Rich Protein-Specific Kinase 1|Serine/Arginine-Rich Splicing Factor Kinase 1|Serine/Threonine-Protein Kinase SRPK1	SRSF protein kinase 1 (655 aa, ~74 kDa) is encoded by the human SRPK1 gene. This protein is involved in the phosphorylation of splicing factors.			Amino Acid, Peptide, or Protein|Enzyme	
C102763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102763>	C89340|C15332	Cervical Cerclage|Cervical Stitch|Tracheloplasty	A surgical procedure performed to prevent a miscarriage by stitching the opening of the cervix closed.			Therapeutic or Preventive Procedure	
C102764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102764>	C20420	ZFPM2 Gene|ZFPM2|ZFPM2|Zinc Finger Protein, Multitype 2 Gene	This gene plays a role in both cardiac development and transcriptional regulation.	ZFPM2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C102765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102765>	C102764	ZFPM2 wt Allele|DIH3|FOG2|Modulator of Transcription Factor GATA4 Gene|ZNF89B|Zinc Finger Protein, Multitype 2 wt Allele|hFOG-2	Human ZFPM2 wild-type allele is located in the vicinity of 8q23 and is approximately 486 kb in length. This allele, which encodes zinc finger protein ZFPM2, is involved in transcriptional regulation during heart development. Mutation of the gene is associated with both diaphragmatic hernia 3 and tetralogy of Fallot. A complex chromosomal rearrangement fuses this gene and the RUNX1 gene and is associated with myelodysplasia.	ZFPM2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102766>	C17207	Zinc Finger Protein ZFPM2|FOG-2|Friend of GATA 2|Friend of GATA Protein 2|Zinc Finger Protein 89B|Zinc Finger Protein Multitype 2|hFOG-2	Zinc finger protein ZFPM2 (1151 aa, ~128 kDa) is encoded by the human ZFPM2 gene. This protein plays a role in DNA binding, transcriptional regulation and cardiac development.	Zinc Finger Protein ZFPM2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102767>	C25869|C25790	CD37 Gene|CD37|CD37|CD37 Molecule Gene	This gene is involved in the regulation of immunoglobulin production.	CD37 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|Pediatric Oncology Target Cell Lineage Determinant Terminology
C102768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102768>	C102767	CD37 wt Allele|CD37 Antigen Gene|CD37 Molecule wt Allele|GP52-40|TSPAN26	Human CD37 wild-type allele is located in the vicinity of 19q13.3 and is approximately 5 kb in length. This allele, which encodes leukocyte antigen CD37 protein, plays a role in the modulation of immunoglobulin production.	CD37 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102769>	C16725	Leukocyte Antigen CD37|Antigen CD37|CD37|CD37 Antigen|Cell Differentiation Antigen 37|Leukocyte Surface Antigen CD37|Tetraspanin-26|Tspan-26	Leukocyte antigen CD37 (281 aa, ~32 kDa) is encoded by the human CD37 gene. This protein is involved in the regulation of humoral immunity.	Leukocyte Antigen CD37		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Cell Lineage Determinant Terminology
C10276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10276>	C61007	Cytarabine/Methotrexate|ARA-C/MTX|CCM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102770>	C25804	SIRT7 Gene|SIRT7|SIRT7|Sirtuin 7 Gene	This gene plays a role in post-translational protein modification.			Gene or Genome	
C102771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102771>	C102770	SIRT7 wt Allele|SIR2L7|Sirtuin (Silent Mating Type Information Regulation 2 Homolog) 7 (S. cerevisiae) Gene|Sirtuin 7 wt Allele	Human SIRT7 wild-type allele is located in the vicinity of 17q25 and is approximately 6 kb in length. This allele, which encodes NAD-dependent protein deacetylase sirtuin-7 protein, is involved in the modulation of protein acetylation.			Gene or Genome	
C102772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102772>	C26503	NAD-Dependent Protein Deacetylase Sirtuin-7|EC 3.5.1.-|Regulatory Protein SIR2 Homolog 7|SIR2-Like Protein 7|SIRT7	NAD-dependent protein deacetylase sirtuin-7 (400 aa, ~45 kDa) is encoded by the human SIRT7 gene. This protein plays a role in protein deacetylation.			Amino Acid, Peptide, or Protein|Enzyme	
C102773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102773>	C21282	AMD1 Gene|AMD1|AMD1|Adenosylmethionine Decarboxylase 1 Gene	This gene is involved in polyamine biosynthesis.			Gene or Genome	
C102774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102774>	C102773	AMD1 wt Allele|ADOMETDC|AMD|Adenosylmethionine Decarboxylase 1 wt Allele|RP11-397G5.3|SAMDC	Human AMD1 wild-type allele is located in the vicinity of 6q21 and is approximately 21 kb in length. This allele, which encodes S-adenosylmethionine decarboxylase proenzyme protein, plays a role in the synthesis of both spermine and spermidine.			Gene or Genome	
C102775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102775>	C16804	S-Adenosylmethionine Decarboxylase Proenzyme|AMD1|AdoMetDC|EC 4.1.1.50|S-Adenosyl-L-Methionine Carboxy-Lyase|S-Adenosyl-L-Methionine Decarboxylase|S-Adenosyl-Methionine Decarboxylase|S-Adenosylmethionine Decarboxylase 1|SAMDC	S-adenosylmethionine decarboxylase proenzyme (334 aa, ~38 kDa) is encoded by the human AMD1 gene. This protein is involved in polyamine metabolism.			Amino Acid, Peptide, or Protein|Enzyme	
C102776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102776>	C25939	SCD Gene|SCD|SCD|Stearoyl-CoA Desaturase Gene	This gene plays a role in fatty acid metabolism.	SCD Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C102777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102777>	C102776	SCD wt Allele|FADS5|MSTP008|SCD1|SCDOS|Stearoyl-CoA Desaturase (Delta-9-Desaturase) Gene|Stearoyl-CoA Desaturase wt Allele	Human SCD wild-type allele is located in the vicinity of 10q24.31 and is approximately 18 kb in length. This allele, which encodes stearoyl-CoA desaturase protein, is involved in fatty acid biosynthesis.	SCD wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102778>	C16946	Stearoyl-CoA Desaturase|Acyl-CoA Desaturase|Acyl-CoA Desaturase|Delta(9)-Desaturase|Delta-9 Desaturase|Delta-9-Desaturase|EC 1.14.19.1|Fatty Acid Desaturase|SCD|SCD1|hSCD1	Stearoyl-CoA desaturase (359 aa, ~42 kDa) is encoded by the human SCD gene. This protein plays a role in the synthesis of fatty acids.	Acyl-CoA Desaturase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102779>	C20921	SARM1 Gene|SARM1|SARM1|Sterile Alpha and TIR Motif Containing 1 Gene	This gene is involved in both signaling and immunity.			Gene or Genome	
C10277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10277>	C61063	Cytarabine/Thioguanine|ARA-C/TG|TA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102780>	C102779	SARM1 wt Allele|KIAA0524|SAMD2|SARM|Sterile Alpha and TIR Motif Containing 1 wt Allele	Human SARM1 wild-type allele is located in the vicinity of 17q11 and is approximately 37 kb in length. This allele, which encodes sterile alpha and TIR motif-containing protein 1, plays a role in both immunity and signal transduction.			Gene or Genome	
C102781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102781>	C18515	Sterile Alpha and TIR Motif-Containing Protein 1|SAM Domain-Containing Protein 2|SARM1|Sterile Alpha Motif Domain-Containing Protein 2|Sterile Alpha and Armadillo Repeat Protein|Sterile Alpha and HEAT/Armadillo Motif Protein|Tir-1 Homolog	Sterile alpha and TIR motif-containing protein 1 (724 aa, ~79 kDa) is encoded by the human SARM1 gene. This protein is involved in immune responsive signaling.			Amino Acid, Peptide, or Protein	
C102782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102782>	C28310	Recombinant Human MUC1-Oxidized Polymannose-pulsed Autologous Dendritic Cell Vaccine	A cancer vaccine containing autologous dendritic cells pulsed with a fusion product of an epitope of human tumor-associated epithelial mucin 1 (MUC1) antigen and the vaccine adjuvant mannan (oxidized mannose), with potential antineoplastic activity. When the modified dendritic cells are returned to the patient, they may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the MUC1 antigen, resulting in tumor cell lysis. Addition of manna in this vaccine, enhances immune recognition. MUC1 antigen, a high-molecular-weight transmembrane glycoprotein, is overexpressed on many tumor cells.	Recombinant Human MUC1-Oxidized Polymannose-pulsed Autologous Dendritic Cell Vaccine		Cell|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102783>	C204999|C200106	Sacituzumab Govitecan|IMMU 132|IMMU-132|IMMU132|RS7 SN38|RS7-SN38|RS7SN38|SACITUZUMAB GOVITECAN|Sacituzumab Govitecan-hziy|Sacituzumab govitecan|Trodelvy|hRS7-SN38 Antibody Drug Conjugate	An antibody drug conjugate containing the humanized monoclonal antibody, hRS7, against tumor-associated calcium signal transducer 2 (TACSTD2 or TROP2) and linked to the active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), with potential antineoplastic activity. The antibody moiety of sacituzumab govitecan selectively binds to TROP2. After internalization and proteolytic cleavage, SN-38 selectively stabilizes topoisomerase I-DNA covalent complexes, resulting in DNA breaks that inhibit DNA replication and trigger apoptosis. TROP2, also known as epithelial glycoprotein-1 (EGP-1), is a transmembrane calcium signal transducer that is overexpressed by a variety of human epithelial carcinomas; this antigen is involved in the regulation of cell-cell adhesion and its expression is associated with increased cancer growth, aggressiveness and metastasis.	Sacituzumab Govitecan		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102784>	C201511|C129822	Talacotuzumab|Anti-IL-3 Receptor Alpha Monoclonal Antibody CSL362|CSL 362|CSL362|JNJ-56022473|JNJ56022473|TALACOTUZUMAB	A humanized IgG1 monoclonal antibody against CD123 (Interleukin-3 receptor alpha chain or IL3RA) with potential antineoplastic activity. Upon intravenous administration, talacotuzumab binds to and neutralizes CD123. This may inhibit IL-3-dependent signaling and may inhibit proliferation and differentiation in CD123-positive tumor cells. CSL362 contains an engineered Fc region which increases its binding affinity to Fc-gamma receptors on the surface of natural killer (NK) cells thereby initiating antibody-dependent cellular cytotoxicity (ADCC). CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with increased leukemic cell proliferation and aggressiveness.	Talacotuzumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102785>	C1511	Iodine I 124 Anti-phosphatidylserine Monoclonal Antibody PGN650|I-124 Anti-PS MoAb PNG650|I-124 PGN650	A radioimmunoconjugate composed of the F(ab')2 fragment of human monoclonal antibody PGN650 against phosphatidylserine (PS) labeled with the radioisotope iodine I 124, with potential imaging activity upon positron-emission tomography (PET). Upon administration, the MoAb moiety of PGN650 binds to exposed PS on tumor cells, thereby allowing for the visualization of tumors upon PET. This may facilitate the assessment of the effectiveness of antitumor agents. The phospholipid PS is normally located on the inner leaflet of the plasma membrane of healthy cells but is flipped to the outer leaflet in the endothelial lining of the tumor vasculature and other tumor cells in response to chemo- or radio- treatments in addition to oxidative stress.			Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	NCI Drug Dictionary Terminology
C102786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102786>	C78275	Rivipansel|GMI-1070|PF-06460031|RIVIPANSEL	A synthetic, glycomimetic molecule and pan-selectin antagonist, with potential use in a vaso-occlusive crisis. Upon administration, rivipansel prevents the interaction between leukocytes and the endothelium and may prevent cell activation and adhesion. By preventing selectin-mediated cell adhesion in sickle cell anemia, this agent may inhibit red blood cell-white blood cell interactions, normalize blood flow and reduce inflammation and vascular occlusive pain. GMI-1070 has the strongest antagonistic activity towards E-selectin but a sulfate-binding domain allows for interactions with P- and L-selectins. Selectins, containing lectin- and EGF-like domains, are a family of cell adhesion molecules implicated in inflammatory processes and cancer.	Rivipansel		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C102787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102787>	C39619|C1951|C1663	HPV E6/E7 DNA Vaccine GX-188E|GX-188E	A therapeutic DNA vaccine encoding the E6/E7 fusion protein of human papillomavirus (HPV) subtypes 16 and 18, plus the immune-enhancer, Fms-like tyrosine kinase-3 ligand (FLT3L), with potential immunostimulating and antineoplastic activities. DNA vaccine GX-188E is administered using a proprietary delivery system that electroporates the vaccine into cervical cells. Expression of the E6/E7 fusion product may elicit a cytotoxic T-lymphocyte (CTL) response against cervical cancer cells expressing E6 and E7 oncoproteins, resulting in tumor cell lysis. FLT3L is a ligand for the FLT3 tyrosine kinase receptor, which upon activation stimulates the proliferation of hematopoietic progenitor cells. HPV type 16 and 18 are the most common HPV types involved in cervical carcinogenesis.			Immunologic Factor|Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102788>	C1966	Deuterated Phenanthrene|Phenanthrene-D10|[D10] phenanthrene|[D10]Phe	A noncarcinogenic and structural analogue of polycyclic aromatic hydrocarbon (PAH), phenanthrene labeled with deuterium ([D10]Phe) with potential use in assessing an individual's capacity for PAH metabolism by the diol epoxide pathway. Upon oral or inhalation administration, [D10]Phe is metabolized into the tetraol end product ([D10]PheT) via the diol epoxide pathway, and can be quantified in urine. [D10]PheT can be used as a biomarker to assess PAHs metabolic activation and may therefore determine an individual's susceptibility to carcinogenicity upon PAH exposure.	Deuterated Phenanthrene		Indicator, Reagent, or Diagnostic Aid|Organic Chemical	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C102789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102789>	C142078	Inducible CD4+CD25+ Regulatory T Cells|iTregs	Inducible regulatory T-lymphocytes that express CD4, CD25 (the alpha chain of the interleukin 2 receptor) and forkhead box P3 (FOXP3), with potential immunomodulating activity. Inducible CD4+CD25+ T regulatory cells (iTregs) are a subset of CD4+ T lymphocytes that are induced from CD25- precursors in peripheral lymphoid organs with interleukin-2 and transforming growth factor-beta. These regulatory T cells are essential in maintaining immunologic homeostasis. They may also prevent autoimmunity by suppressing self-reactive T cells, and may induce tolerance to allogeneic organ transplants such as in hematopoietic stem cell transplants.	Inducible CD4+CD25+ Regulatory T Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C10278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10278>	C63359	Doxorubicin/Etoposide/Methotrexate Regimen|AMV|DOX/MTX/VP-16|Doxorubicin-Etoposide-Methotrexate|Doxorubicin/Etoposide/Methotrexate|VAM|VAM	A regimen consisting of doxorubicin, etoposide and methotrexate that can be used for the treatment of small cell lung cancer (SCLC).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C102790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102790>	C20420	HAND2 Gene|HAND2|HAND2|Heart and Neural Crest Derivatives Expressed 2 Gene	This gene plays a role in both transcriptional regulation and cardiac development.			Gene or Genome	
C102791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102791>	C102790	HAND2 wt Allele|BHLHA26|DHAND|DHAND2|Heart and Neural Crest Derivatives Expressed 2 wt Allele|Hed|Thing2|bHLHa26|dHand	Human HAND2 wild-type allele is located in the vicinity of 4q33 and is approximately 5 kb in length. This allele, which encodes heart- and neural crest derivatives-expressed protein 2, is involved in cardiac morphogenesis, DNA binding and transcriptional modulation.			Gene or Genome	
C102792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102792>	C17207	Heart- and Neural Crest Derivatives-Expressed Protein 2|Basic Helix-Loop-Helix Transcription Factor HAND2|Class A Basic Helix-Loop-Helix Protein 26|Deciduum, Heart, Autonomic Nervous System and Neural Crest Derivatives-Expressed Protein 2|HAND2|bHLHa26|dHAND	Heart- and neural crest derivatives-expressed protein 2 (217 aa, ~24 kDa) is encoded by the human HAND2 gene. This protein plays a role in the regulation of gene expression during heart development.			Amino Acid, Peptide, or Protein	
C102793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102793>	C20103	LILRB2 Gene|LILRB2|LILRB2|Leukocyte Immunoglobulin-Like Receptor, Subfamily B (With TM and ITIM Domains), Member 2 Gene	This gene is involved in immunity.	LILRB2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C102794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102794>	C102793	LILRB2 wt Allele|CD85D|ILT4|LILRA6|LIR-2|LIR2|Leukocyte Immunoglobulin-Like Receptor, Subfamily B (With TM and ITIM Domains), Member 2 wt Allele|MIR-10|MIR10	Human LILRB2 wild-type allele is located in the vicinity of 19q13.4 and is approximately 7 kb in length. This allele, which encodes leukocyte immunoglobulin-like receptor subfamily B member 2 protein, plays a role in binding to class I MHC antigens and the regulation of T-cell responses.	LILRB2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102795>	C18106	Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 2|Antigen CD85d|CD85 Antigen-Like Family Member D|CD85d|CD85d Antigen|ILT-4|Immunoglobulin-Like Transcript 4|LILRB2|LIR-2|Leukocyte Immunoglobulin-Like Receptor 2|MIR-10|Monocyte/Macrophage Immunoglobulin-Like Receptor 10	Leukocyte immunoglobulin-like receptor subfamily B member 2 (598 aa, ~65 kDa) is encoded by the human LILRB2 gene. This protein is involved in the regulation of class I MHC antigen responses.	Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 2		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102796>	C28533|C25804	DNM2 Gene|DNM2|DNM2|DNM2|Dynamin 2 Gene	This gene plays a role in both GTP hydrolysis and microtubule organization.			Gene or Genome	GDC Terminology|GDC Value Terminology
C102797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102797>	C102796	DNM2 wt Allele|CMT2M|CMTDI1|CMTDIB|DI-CMTB|DYN2|DYNII|Dynamin 2 wt Allele	Human DNM2 wild-type allele is located in the vicinity of 19p13.2 and is approximately 118 kb in length. This allele, which encodes dynamin-2 protein, is involved in both microtubule polymerization and GTPase activity. Mutation of the gene is associated with centronuclear myopathy type 1 and Charcot-Marie-Tooth disease types dominant intermediate B and 2M axonal.			Gene or Genome	
C102798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102798>	C16701|C16386	Dynamin-2|DNM2|EC 3.6.5.5	Dynamin-2 (870 aa, ~98 kDa) is encoded by the human DNM2 gene. This protein plays a role in both microtubule polymerization and GTP hydrolysis.			Amino Acid, Peptide, or Protein|Enzyme	
C102799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102799>	C26003	RELN Gene|RELN|RELN|Reelin Gene	This gene is involved in both proteolysis and signaling.			Gene or Genome	
C10279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10279>	C63358	FOAM Regimen|DOX/5-FU/MITO/VCR|Doxorubicin/Fluorouracil/Mitomycin/Vincristine|FOAM|FOAM|Fluorouracil-Vincristine-Doxorubicin-Mitomycin|Fluorouracil-Vincristine-Doxorubicin-Mitomycin Regimen|Fluorouracil/Oncovin/Adriamycin/Mitomycin|Fluorouracil/Vincristine/Doxorubicin/Mitomycin|VFAM	A regimen consisting of fluorouracil, vincristine, doxorubicin, and mitomycin that may be used for the treatment of breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C1027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1027>	C521	Budesonide|(RS)-11beta,16alpha,17,21,-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal w/ Butyraldehyde|BUDESONIDE|Budecort|Butacort|Eltair|Nasocort|Preferid|Pregna-1,4-diene-3,20-dione,16,17-(butylidenebis(oxy))-11,21-dihydroxy-, (11beta,16alpha)-|Pulmicort|Pulmicort Turbuhaler|Rhinocort|budesonide	A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. Upon administration, budesonide binds to intracellular glucocorticoid receptors (GRs) and induces the expression of glucocorticoid-responsive genes that encode for anti-inflammatory mediators, such as certain anti-inflammatory cytokines, including interleukin 10 (IL-10), and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both mediators of inflammation. In addition, budesonide prevents the release of pro-inflammatory cytokines from epithelial cells and macrophages, including interleukin 6 (IL-6), IL-8, interferon-beta (IFNb), and inhibits nuclear factor kappa-B (NF-kB) activation thereby decreasing NF-kB-mediated inflammation.	Budesonide		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C102800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102800>	C102799	RELN wt Allele|LIS2|PRO1598|RL|Reelin wt Allele	Human RELN wild-type allele is located in the vicinity of 7q22 and is approximately 518 kb in length. This allele, which encodes reelin protein, plays a role in extracellular matrix proteolysis, signal transduction and neuronal development. Mutation of the gene is associated with lissencephaly type 2.			Gene or Genome	
C102801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102801>	C17123	Reelin|EC 3.4.21.-|RELN	Reelin (3460 aa, ~388 kDa) is encoded by the human RELN gene. This protein is involved in both neuronal development and proteolysis.			Amino Acid, Peptide, or Protein|Enzyme	
C102802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102802>	C25997	SH2B3 Gene|SH2B Adaptor Protein 3 Gene|SH2B3|SH2B3|SH2B3	This gene plays a role in T-cell activation.	SH2B3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|Pediatric Oncology Target Genes/Proteins Terminology
C102803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102803>	C102802	SH2B3 wt Allele|IDDM20|LNK|SH2B Adaptor Protein 3 wt Allele	Human SH2B3 wild-type allele is located in the vicinity of 12q24 and is approximately 46 kb in length. This allele, which encodes SH2B adapter protein 3, is involved in signal transduction. Mutation of the gene is associated with susceptibility to both celiac disease type 13 and insulin-dependent diabetes mellitus.	SH2B3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102804>	C26231	SH2B Adapter Protein 3|Lymphocyte Adapter Protein|Lymphocyte Adaptor Protein|Lymphocyte-Specific Adapter Protein Lnk|SH2B3|Signal Transduction Protein Lnk	SH2B adapter protein 3 (575 aa, ~63 kDa) is encoded by the human SH2B3 gene. This protein plays a role in T-cell receptor signaling.	SH2B Adapter Protein 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Genes/Proteins Terminology
C102805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102805>	C20194	KANSL1 Gene|KANSL1|KANSL1|KAT8 Regulatory NSL Complex Subunit 1 Gene	This gene is involved in histone acetylation.			Gene or Genome	
C102806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102806>	C102805	KANSL1 wt Allele|CENP-36|KAT8 Regulatory NSL Complex Subunit 1 wt Allele|KIAA1267|MSL1V1|MSL1v1|NSL1|hMSL1v1	Human KANSL1 wild-type allele is located in the vicinity of 17q21.31 and is approximately 195 kb in length. This allele, which encodes KAT8 regulatory NSL complex subunit 1 protein, plays a role in the modulation of histone acetylation. Mutation of the gene is associated with 17q21.31 microdeletion syndrome.			Gene or Genome	
C102807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102807>	C18466	KAT8 Regulatory NSL Complex Subunit 1|Centromere Protein 36|KANSL1|MLL1/MLL Complex Subunit KANSL1|MSL1 Homolog 1|NSL Complex Protein NSL1|Non-Specific Lethal 1 Homolog|hMSL1v1	KAT8 regulatory NSL complex subunit 1 (1105 aa, ~121 kDa) is encoded by the human KANSL1 gene. This protein is involved in the regulation of histone acetylation.			Amino Acid, Peptide, or Protein	
C102808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102808>	C25952|C25871	PFKFB3 Gene|6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 Gene|PFKFB3|PFKFB3	This gene plays a role in carbohydrate metabolism.			Gene or Genome	
C102809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102809>	C102808	PFKFB3 wt Allele|6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 wt Allele|IPFK2|PFK2|RP11-298K24.3|iPFK-2	Human PFKFB3 wild-type allele is located in the vicinity of 10p15.1 and is approximately 91 kb in length. This allele, which encodes 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3, is involved in both the synthesis and degradation of fructose 2,6-bisphosphate.			Gene or Genome	
C10280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10280>	C67292	Doxorubicin/Fluorouracil/Semustine Regimen|DOX/5-FU/MeCCNU|Doxorubicin-Fluorouracil-Semustine|Doxorubicin/Fluorouracil/Semustine|MEFA|MeCCNU/Fluorouracil/Adriamycin|MeFA|MeFA	A regimen consisting of doxorubicin, fluorouracil, and semustine that may be used in the treatment of certain hepatic cancers.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C102810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102810>	C16984|C16981	6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3|6PF-2-K/Fru-2,6-P2ase 3|6PF-2-K/Fru-2,6-P2ase Brain/Placenta-Type Isozyme|PFK/FBPase 3|PFKFB3|Renal Carcinoma Antigen NY-REN-56|iPFK-2	6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (520 aa, ~60 kDa) is encoded by the human PFKFB3 gene. This protein plays a role in the metabolism of fructose.			Amino Acid, Peptide, or Protein|Enzyme	
C102811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102811>	C20194	PTGFRN Gene|PTGFRN|PTGFRN|Prostaglandin F2 Receptor Negative Regulator Gene	This gene is involved in the inhibition of prostaglandin binding.			Gene or Genome	
C102812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102812>	C102811	PTGFRN wt Allele|CD315|CD9P-1|CD9P1|EWI-F|EWIF|FPRP|KIAA1436|Prostaglandin F2 Receptor Negative Regulator wt Allele|SMAP-6	Human PTGFRN wild-type allele is located in the vicinity of 1p13.1 and is approximately 80 kb in length. This allele, which encodes prostaglandin F2 receptor negative regulator protein, plays a role in inhibition of ligand-receptor interactions.			Gene or Genome	
C102813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102813>	C18466	Prostaglandin F2 Receptor Negative Regulator|Antigen CD315|CD315|CD315 Antigen|CD9 Partner 1|CD9P-1|EWI Motif-Containing Protein F|EWI-F|Glu-Trp-Ile EWI Motif-Containing Protein F|Prostaglandin F2-Alpha Receptor Regulatory Protein|Prostaglandin F2-Alpha Receptor-Associated Protein	Prostaglandin F2 receptor negative regulator (879 aa, ~99 kDa) is encoded by the human PTGFRN gene. This protein is involved in the inhibition of both prostaglandin F2-alpha binding to its receptor and any downstream signaling pathways.			Amino Acid, Peptide, or Protein	
C102814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102814>	C20194	ZNF678 Gene|ZNF678|ZNF678|Zinc Finger Protein 678 Gene	This gene may play a role in transcriptional regulation.			Gene or Genome	
C102815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102815>	C102814	ZNF678 wt Allele|MGC42493|Zinc Finger Protein 678 wt Allele	Human ZNF678 wild-type allele is located in the vicinity of 1q42.13 and is approximately 99 kb in length. This allele, which encodes zinc finger protein 678, may be involved in transcriptional regulation.			Gene or Genome	
C102816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102816>	C18466	Zinc Finger Protein 678|Hypothetical Protein MGC42493	Zinc finger protein 678 (525 aa, ~61 kDa) is encoded by the human ZNF678 gene. This protein may play a role in transcriptional regulation.			Amino Acid, Peptide, or Protein	
C102817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102817>	C133710	TRIM36 Gene|TRIM36|TRIM36|Tripartite Motif Containing 36 Gene	This gene is involved in protein modification.			Gene or Genome	
C102818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102818>	C102817	TRIM36 wt Allele|HAPRIN|RBCC728|RNF98|Tripartite Motif Containing 36 wt Allele	Human TRIM36 wild-type allele is located in the vicinity of 5q22.3 and is approximately 56 kb in length. This allele, which encodes E3 ubiquitin-protein ligase TRIM36 protein, plays a role in both protein modification and the regulation of protein degradation.			Gene or Genome	
C102819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102819>	C21254	E3 Ubiquitin-Protein Ligase TRIM36|EC 2.3.2.27|EC 6.3.2.-, Formerly|RING Finger Protein 98|Tripartite Motif-Containing Protein 36|Zinc-Binding Protein Rbcc728	E3 ubiquitin-protein ligase TRIM36 (728 aa, ~83 kDa) is encoded by the human TRIM36 gene. This protein is involved in the regulation of protein degradation.			Amino Acid, Peptide, or Protein|Enzyme	
C10281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10281>	C61063	Doxorubicin/Vincristine|AO|DOX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102820>	C26764	Chronic Endometritis	A non-granulomatous or granulomatous chronic inflammation of the endometrium. Causes include sexually transmitted pathogens and gynecological procedures. Patients may present with irregular bleeding.			Disease or Syndrome	
C102821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102821>	C20921	SPRED1 Gene|SPRED1|SPRED1|SPRED1|Sprouty Related EVH1 Domain Containing 1 Gene	This gene plays a role in the modulation of signaling.	SPRED1 Gene		Gene or Genome	CCPS Genetics Terminology|Childhood Cancer Predisposition Study Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C102822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102822>	C102821	SPRED1 wt Allele|FLJ33903|LGSS|NFLS|PPP1R147|Protein Phosphatase 1, Regulatory Subunit 147 Gene|Sprouty Related EVH1 Domain Containing 1 wt Allele|Sprouty-Related, EVH1 Domain Containing 1 Gene|hSpred1|spred-1	Human SPRED1 wild-type allele is located in the vicinity of 15q14 and is approximately 105 kb in length. This allele, which encodes sprouty-related, EVH1 domain-containing protein 1, is involved in the regulation of signal transduction.	SPRED1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102823>	C18515	Sprouty-Related, EVH1 Domain-Containing Protein 1|Spred-1|Sprouty-Related EVH1 Domain-Containing Protein 1|Suppressor of Ras/MAPK Activation|hSpred1	Sprouty-related, EVH1 domain-containing protein 1 (444 aa, ~50 kDa) is encoded by the human SPRED1 gene. This protein plays a role in signal transduction regulation.	Sprouty-Related, EVH1 Domain-Containing Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102824>	C28480|C26003	PROC Gene|PROC|PROC|Protein C (Inactivator Of Coagulation Factors Va and VIIIa) Gene	This gene is involved in the modulation of blood coagulation.			Gene or Genome	
C102825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102825>	C102824	PROC wt Allele|APC|PC|PROC1|Protein C (Inactivator Of Coagulation Factors Va and VIIIa) wt Allele|THPH3|THPH4	Human PROC wild-type allele is located within 2q13-q14 and is approximately 11 kb in length. This allele, which encodes vitamin K-dependent protein C, plays a role in the negative regulation of blood coagulation. Mutation of the gene is associated with thrombophilia due to protein C deficiency.			Gene or Genome	
C102826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102826>	C17123|C16354	Vitamin K-Dependent Protein C|Anticoagulant Protein C|Autoprothrombin IIA|Blood Coagulation Factor XIV|EC 3.4.21.69|PROC|Protein C	Vitamin K-dependent protein C (461 aa, ~52 kDa) is encoded by the human PROC gene. This protein is involved in the degradation of factors Va and VIIIa.			Amino Acid, Peptide, or Protein|Enzyme	
C102827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102827>	C25873	EIF2AK3 Gene|EIF2AK3|EIF2AK3|Eukaryotic Translation Initiation Factor 2 Alpha Kinase 3 Gene	This gene plays a role in the regulation of translation.	EIF2AK3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C102828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102828>	C102827	EIF2AK3 wt Allele|Eukaryotic Translation Initiation Factor 2 Alpha Kinase 3 wt Allele|Eukaryotic Translation Initiation Factor 2-Alpha Kinase 3 Gene|PEK|PERK|WRS	Human EIF2AK3 wild-type allele is located in the vicinity of 2p12 and is approximately 71 kb in length. This allele, which encodes eukaryotic translation initiation factor 2-alpha kinase 3 protein, is involved in both protein phosphorylation and the negative regulation of translation. Mutation of the gene is associated with Wolcott-Rallison syndrome.	EIF2AK3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102829>	C17325	Eukaryotic Translation Initiation Factor 2-Alpha Kinase 3|EC 2.7.11.1|EIF2AK3|Eukaryotic Translation Initiation Factor 2 Alpha Kinase 3|HsPEK|PERK|PKR-Like ER Kinase|PRKR-Like Endoplasmic Reticulum Kinase|Pancreatic eIF2-Alpha Kinase	Eukaryotic translation initiation factor 2-alpha kinase 3 (1116 aa, ~125 kDa) is encoded by the human EIF2AK3 gene. This protein plays a role in the inhibition of protein synthesis.	Eukaryotic Translation Initiation Factor 2-Alpha Kinase 3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10282>	C61063	Altretamine/Etoposide/Methotrexate|HMM/MTX/VP-16|MVH|VHM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102830>	C21295	HNRNPD Gene|HNRNPD|HNRNPD|Heterogeneous Nuclear Ribonucleoprotein D (AU-Rich Element RNA Binding Protein 1, 37kDa) Gene	This gene is involved in RNA catabolism.			Gene or Genome	
C102831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102831>	C102830	HNRNPD wt Allele|AUF1|AUF1A|HNRPD|Heterogeneous Nuclear Ribonucleoprotein D (AU-Rich Element RNA Binding Protein 1, 37kDa) wt Allele|P37|hnRNPD0	Human HNRNPD wild-type allele is located in the vicinity of 4q21 and is approximately 22 kb in length. This allele, which encodes heterogeneous nuclear ribonucleoprotein D0, plays a role in the catabolism of RNA.			Gene or Genome	
C102832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102832>	C21298	Heterogeneous Nuclear Ribonucleoprotein D0|AU-Rich Element RNA-Binding Protein 1|HNRNPD|hnRNP D0	Heterogeneous nuclear ribonucleoprotein D0 (355 aa, ~38 kDa) is encoded by the human HNRNPD gene. This protein is involved in both RNA transport and splicing.			Amino Acid, Peptide, or Protein	
C102833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102833>	C54452	SPL Combination Product Type Terminology|Combination Product Types|Structured Product Labeling Combination Product Type Terminology	Terminology used for representation of the type of part 3 combination in the framework of the Structured Product Labeling documents.	SPL Combination Product Type Terminology		Intellectual Product	FDA Structured Product Labeling Terminology
C102834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102834>	C54696	Type 1: Convenience Kit or Co-Package	Products meeting the definition at 21 CFR 3.2(e)(2), such as surgical kits, first aid kits, or drugs co-packaged with delivery devices.			Manufactured Object	FDA Structured Product Labeling Terminology|SPL Combination Product Type Terminology
C102835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102835>	C54696	Type 2: Prefilled Drug Delivery Device/System|Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)|Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)	Products meeting the definition at 21 CFR 3.2(e)(1) comprised of a delivery device containing a drug, such as a prefilled syringe.			Manufactured Object	FDA Structured Product Labeling Terminology|SPL Combination Product Type Terminology
C102836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102836>	C54696	Type 3: Prefilled Biologic Delivery Device/System|Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)|Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)	Products meeting the definition at 21 CFR 3.2(e)(1) comprised of a delivery device containing a biological product, such as a prefilled syringe.			Manufactured Object	FDA Structured Product Labeling Terminology|SPL Combination Product Type Terminology
C102837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102837>	C54696	Type 4: Device Coated/Impregnated/Otherwise Combined with Drug	Products meeting the definition at 21 CFR 3.2(e)(1) comprised of a device coated or impregnated with a drug, such as a drug-eluting stent.			Manufactured Object	FDA Structured Product Labeling Terminology|SPL Combination Product Type Terminology
C102838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102838>	C54696	Type 5: Device Coated or Otherwise Combined with Biologic	Products meeting the definition at 21 CFR 3.2(e)(1) comprised of a device coated or otherwise combined with a biological product, such as a surgical implant.			Manufactured Object	FDA Structured Product Labeling Terminology|SPL Combination Product Type Terminology
C102839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102839>	C54696	Type 6: Drug/Biologic Combination	Products meeting the definition at 21 CFR 3.2(e)(1), comprised of a drug and a biological product that are chemically, physically, or otherwise combined to form a single entity, such as an antibody and a drug.			Manufactured Object	FDA Structured Product Labeling Terminology|SPL Combination Product Type Terminology
C10283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10283>	C61063	Fluorouracil/Methotrexate|5-FU/MTX|MF|MeF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102840>	C54696	Type 7: Separate Products Requiring Cross Labeling	Products meeting the definition at 21 CFR 3.2(e)(3) or (4) comprised of a separately marketed drug, device, and/ or biological product, such as certain light-activated drugs and associated light sources.			Manufactured Object	FDA Structured Product Labeling Terminology|SPL Combination Product Type Terminology
C102841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102841>	C54696	Type 8: Possible Combination Based on Cross Labeling of Separate Products|Type 8: Possible Combination Based on Cross Labeling of Separate Products (Temporary Type)|Type 8: Possible Combination Based on Cross Labeling of Separate Products (Temporary Type)	Investigational products that may meet the definition at 21 CFR 3.2(e)(3) or (4) but for which combination product status remains uncertain based on the information available at the stage of product development or evaluation, comprised of a separately marketed drug, device, and/or biological product.			Manufactured Object	FDA Structured Product Labeling Terminology|SPL Combination Product Type Terminology
C102842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102842>	C54696	Type 9: Other Type of Part 3 Combination Product|Type 9: Other Type of Part 3 Combination Product (e.g., Drug/Device/Biological Product)|Type 9: Other Type of Part 3 Combination Product (e.g., Drug/Device/Biological Product)	Any products not falling within types 1 through 8 that satisfy the definition for combination product at 21 CFR 3.2(e), such as a single-entity product comprised of a drug, device, and a biological product.			Manufactured Object	FDA Structured Product Labeling Terminology|SPL Combination Product Type Terminology
C102843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102843>	C27993	Usual|Customary|Typical|Usually	That which is considered customary.			Qualitative Concept	
C102844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102844>	C27993	Extreme|Extremely	The highest degree of severity.			Qualitative Concept	Generalized Anxiety Disorder - 7 Questionnaire|NCCN Guidelines Distress Management Distress Thermometer Screening Tool Version 1.2011|Patient Health Questionnaire - 9 Item
C102845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102845>	C6639	Stage 2A Neuroblastoma|Stage IIA Neuroblastoma	Localized tumor with incomplete gross excision; representative ipsilateral nonadherent lymph nodes negative for tumor microscopically. (cancer.gov)	Stage 2A Neuroblastoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C102846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102846>	C6639	Stage 2B Neuroblastoma|Stage IIB Neuroblastoma	Localized tumor with or without complete gross excision, with ipsilateral nonadherent lymph nodes positive for tumor. Enlarged contralateral lymph nodes must be negative microscopically. (cancer.gov)	Stage 2B Neuroblastoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C102847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102847>	C2163	Carmustine Sustained-Release Implant Wafer|CASANT Wafer	A sustained release (SR) implant wafer containing the lipophilic nitrosourea carmustine (BCNU) with antineoplastic activity. Upon intracranial administration of the implant wafer and subsequent release of BCNU from the wafer, this agent alkylates and cross-links DNA during all phases of the cell cycle, resulting in the disruption of DNA function, cell cycle arrest, and apoptosis. This wafer contains the biodegradable copolymer PLGA (poly(lactide-co-glycolide) as the major drug delivery vehicle which is slowly degraded into water and carbon dioxide thereby continously releasing BCNU over approximately 3-4 weeks. Compared to systemic administration of BCNU alone, this local SR formulation is able to maintain higher drug concentrations locally over a longer period of time while minimizing exposure to other tissues.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102848>	C29639|C26170	Absorbable Adhesion Barrier Gel|Oxiplex/AP Gel	An isotonic, sterile, absorbable adhesion barrier gel composed of polyethylene oxide and sodium carboxymethylcellulose, with protective activity. Upon application of a single layer into the uterine cavity at the end of any hysteroscopic surgery, the absorbable adhesion barrier gel may provide a protective barrier which protects the traumatized tissue and allows for healing. This gel may therefore prevent the formation of post-surgical intrauterine adhesions.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C102849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102849>	C129824	CK2-targeting Synthetic Peptide CIGB-300|CIBG-300|CIGB-300|CIGB-325|P15-tat	A synthetic peptide targeting the substrates of casein kinase 2 (CK2), with potential antineoplastic activity. Upon administration and nucleolar localization, CK2-targeting synthetic peptide CIGB-300 binds to phosphoacceptor sites on the CK2 substrates, in particular the oncoprotein nucleophosmin (B23 or NPM1). This blocks the activation of B23 and induces apoptosis, thereby inhibiting tumor cell growth in susceptible tumor cells. CK2, a protein kinase often overexpressed in a variety of cancer cell types, appears to be correlated with malignant transformation, tumor growth and survival. Overexpression of B23 has been correlated with increased cellular growth and proliferation as well as inhibition of differentiation and apoptosis.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C10284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10284>	C61063	Altretamine/Cisplatin/Cyclophosphamide|CDDP/CTX/HMM|CHD			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102850>	C1742	Naphthalimide Analogue UNBS5162|1-(2-(2-(Dimethylamino)ethyl)-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-5-yl)urea|UNBS-5162|UNBS5162	An amonafide (naphthalimide) derivative and pan-antagonist of chemokine ligand (CXCL) expression, with potential anti-angiogenic activity. Although UNBS5162 is a derivative of amonafide, this agent appears to have a different profile to that of amonafide and its exact mechanism of action remains to be fully elucidated. This agent seems to decrease the expression of various proangiogenic CXCL chemokines in vitro and may have synergistic effects with radiotherapy or chemotherapy. CXCLs are small cytokines in the CXC chemokine family that are overexpressed in certain cancers; CXCL-mediated signaling plays a key role in angiogenesis and tumor progression.	Naphthalimide Analogue UNBS5162		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102851>	C783	Ulinastatin|Bikunin|Trypsin Inhibitor, Bikunin|ULINASTATIN|UTI|Urinary Trypsin Inhibitor	A multivalent Kunitz-type serine protease inhibitor derived from human urine, with potential protective, anti-fibrinolytic and anticoagulant activities. Upon administration, ulinastatin (or urinary trypsinogen inhibitor) inhibits the activities of a variety of enzymes, including trypsin, chymotrypsin, thrombin, kallikrein, plasmin, elastase, cathepsin, lipase, hyaluronidase, factors IXa, Xa, XIa, and XlIa, and polymorphonuclear leukocyte elastase. In addition, ulinastatin inhibits the excessive release of proinflammatory mediators, such as tumor necrosis factor-alpha, interleukin-6 and -8, and chemokines. Altogether, this agent may improve the microcirculation, perfusion and function of tissues and may protect organ injury.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C102852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102852>	C93259|C129825	Fruquintinib|6-(6,7-Dimethoxyquinazolin-4-yl)oxy-N,2-dimethyl-1-benzofuran-3-carboxamide|Elunate|FRUQUINTINIB|Fruzaqla|HMPL 013|HMPL-013|HMPL013|VEGFR-1/2/3 Inhibitor HMPL-013	An orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and antineoplastic activities. Upon oral administration, fruquintinib inhibits VEGF-induced phosphorylation of VEGFRs 1, 2, and 3 which may result in the inhibition of migration, proliferation and survival of endothelial cells, microvessel formation, the inhibition of tumor cell proliferation, and tumor cell death. Expression of VEGFRs may be upregulated in a variety of tumor cell types.	Fruquintinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102853>	C20401|C129822	Anti-TGF-beta RII Monoclonal Antibody IMC-TR1|IMC-TR1|LY3022859	A monoclonal antibody directed against transforming growth factor-beta receptor type II (TGF-beta RII) with potential antineoplastic activity. Anti-TGF-beta RII monoclonal antibody IMC-TR1 specifically targets and binds to TGF-beta R11, thereby preventing the activation of TGF-beta RII-mediated signaling pathways. TGF-beta RII is mutated in a number of cancer cell types and is involved in cancer cell proliferation and tumor progression.	Anti-TGF-beta RII Monoclonal Antibody IMC-TR1		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102854>	C208255|C1287	Efbemalenograstim alfa|EFBEMALENOGRASTIM ALFA|F-627|F627|Recombinant Dimeric G-CSF Fusion Protein F627|Rh G-CSF Fc Fusion Protein F-627	A recombinant dimeric fusion peptide of the human granulocyte colony-stimulating factor (G-CSF; filgrastim), with immunomodulating and hematopoietic activities. Efbemalenograstim alfa binds to the cell surface G-CSF receptors (G-CSFRs) inducing receptor dimerization and activation of signaling cascades such as the Jak-STAT and mitogen-activated protein kinase pathways. This stimulates neutrophil progenitor proliferation and differentiation. Compared to other preparations of monomer recombinant G-CSF, dimeric filgrastim may allow for stronger activation of G-CSFRs and a faster myeloid precursor response thus enhancing neutrophil recovery upon myelosuppressive therapy.	Efbemalenograstim alfa		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C102855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102855>	C147923|C129818	Lapiteronel|CFG 920|CFG-920|CFG920|CYP17/CYP11B2 Inhibitor LAE001|LAE 001|LAE-001|LAE001|LAPITERONEL	An orally bioavailable, non-steroidal, potent, reversible, dual inhibitor of cytochrome P450 17 (CYP17 or CYP17A1) and CYP11B2, with potential antiandrogen and antineoplastic activities. Upon oral administration, lapiteronel inhibits the enzymatic activity of CYP17A1 in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells. Lapiteronel also inhibits the enzymatic activity of CYP11B2, thereby inhibiting aldosterone production. This may reduce the elevated aldosterone levels resulting from CYP17 inhibition and androgen deprivation, leading to a reduction in mineralocorticoid side effects including cardiovascular complications. The cytochrome P450 enzyme CYP17A1, localized to the endoplasmic reticulum, exhibits both 17alpha-hydroxylase and 17,20-lyase activities, and plays a key role in the steroidogenic pathway that produces steroidal hormones. The cytochrome P450 enzyme CYP11B2, aldosterone synthase, is an enzyme that plays a key role in aldosterone biosynthesis.	Lapiteronel		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102856>	C2150|C1557	Gemcitabine Prodrug LY2334737|LY-2334737|LY-2334737|LY2334737	An orally available valproic acid prodrug of gemcitabine, a broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine prodrug LY2334737 is hydrolyzed by carboxylesterase 2 (CES2) and releases gemcitabine systemically over a period of time consistent with formation rate-limited kinetics. In turn, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate and triphosphate (dFdCDP and dFdCTP) by deoxycytidine kinase. dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA replication; dFdCTP is incorporated into DNA, resulting in premature termination of DNA replication and eventually the induction of apoptosis. Compared to gemcitabine, this prodrug is able to avoid hydrolysis in enterocytes and the portal circulation thus avoiding first pass metabolism and increasing systemic gemcitabine availability. In addition, the slow release of gemcitabine may enhance efficacy while lowering toxicity. CES2, a serine ester hydrolase, is expressed in certain tumors which may allow for increased conversion of gemcitabine at the tumor site thus increases cytotoxicity.	Gemcitabine Prodrug LY2334737		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102857>	C20047	Recursive Partitioning Assessment|RPA	A set of pretreatment prognostic factors used to predict potential outcomes for neurooncology patients.			Health Care Activity	
C102858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102858>	C42645	Low Interval Integer Data Type|IVL.LOW<INT>	A data type comprised of a set of consecutive low valued integers of an ordered base data type.			Qualitative Concept	
C102859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102859>	C42645	Low Interval Point in Time Date and Time Data Type|IVL.LOW<TS.DATETIME>	A data type comprised of a set of consecutive low values, comprised of a date and time value that corresponds with a specific point in the time continuum, of an ordered base data type.			Qualitative Concept	
C10285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10285>	C61063	Cisplatin/Methotrexate|CDDP/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102860>	C42645	Interval Quantity Data Type|IVL<QTY>	A data type comprised of a set of consecutive values of an ordered base, which is an abstract generalization for all value data types that have an order relationship.			Qualitative Concept	
C102861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102861>	C25180	Negation Indicator|negationIndicator|negationIndicator	Specifies whether an activity did not occur.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C102862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102862>	C2395	Long Acting Myeloid Growth Factor|Long-Acting Myeloid Growth Factor	Any of the synthetic, long-acting hematopoietic growth factors that stimulate the growth of myeloid cells.			Pharmacologic Substance	
C102863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102863>	C2395	Short Acting Myeloid Growth Factor|Short-Acting Myeloid Growth Factor	Any of the synthetic, short-acting hematopoietic growth factors that stimulate the growth of myeloid cells.			Pharmacologic Substance	
C102864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102864>	C36291	Significant Intercurrent Illness	Any disease or disorder of relevance that occurs before, during or after another illness.			Finding	
C102865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102865>	C1907	Diammonium Glycyrrhizinate|18beta-Glycyrrhizic Acid Diammoniumsalt|DIAMMONIUM GLYCYRRHIZINATE|alpha-D-Glucopyranosiduronic acid, (3beta,20beta)-20-carboxy-11-oxo-30-norolean-12-en-3-yl 2-O-beta-D-Glucopyranuronosyl-, Diammonium Salt (9CI)	The diammonium salt of glycyrrhizin and the active constituent in the traditional Chinese medicinal herb Glycyrrhiza uralensis (Chinese liquorice or Gan-Cao) with anti-inflammatory, antioxidant and hepatoprotective properties. Diammonium glycyrrhizinate (DG) is slowly metabolized within the cells into glycyrrhetic acid, which inhibits enzymes that control cortisol metabolism and contributes to this agent's anti-inflammatory effect. Although the exact mechanism of action remains to be fully elucidated, DG may prevent or reduce hepatotoxicity via the scavenging of free radicals. This agent also upregulates the expression of transcription coactivator PGC-1alpha and modulates hepatic enzymes such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), superoxide dismutase and glutathion peroxidase.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C102866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102866>	C20993	Hopkins Verbal Learning Test Revised|HVLT-R	An assessment tool to ascertain verbal learning and memory skills that is well tolerated by those with moderate to severe dementia.			Intellectual Product	
C102867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102867>	C25198	Analysis of Data Log	A record of data captured about device logging functions, error logs, keystroke logs and device alarm history.			Intellectual Product	
C102868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102868>	C78274	Aspirin/Simvastatin/Atenolol/Ramipril/Thiazide Capsule|Polycap|Quintapill	An orally bioavailable combination pill containing aspirin, simvastatin, atenolol, ramipril and thiazide with preventive activity against cardiovascular disease (CVD). Aspirin is a cyclooxygenase inhibitor with antiplatelet, analgesic, antipyretic and anti-inflammatory activities; simvastatin is a statin with a cholesterol lowering effect; and the beta-blocker atenolol as well as the ACE inhibitor ramipril and the thiazide diuretic all have blood pressure lowering activity. Upon oral administration of aspirin/simvastatin/atenolol/ramipril/thiazide capsule, the combined effects of the active ingredients in this formulation lower the risk of CVD.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C102869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102869>	C125932	International Neuroblastoma Response Criteria|INRC|INRC	A standard approach to aid in the stratification of neuroblastoma risk and disease evaluation.			Intellectual Product	
C10286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10286>	C61063	Cisplatin/Ifosfamide|CDDP/IFF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102870>	C39986|C121619	Ovarian Non-Dysgerminomatous Germ Cell Tumor|Ovarian Nondysgerminomatous Germ Cell Tumor|Ovarian nondysgerm. GCT, NOS|Ovarian nondysgerminomatous germ cell tumor, NOS	A malignant germ cell tumor other than dysgerminoma that arises from the ovary.			Neoplastic Process	NCI CTEP SDC Ovarian Germ Cell Cancer Sub-Category Terminology|NCI CTEP Simplified Disease Classification Terminology
C102871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102871>	C9293	Primary Central Nervous System Neoplasm|CNS primary tumor, NOS	A benign or malignant neoplasm that arises from the brain or the spinal cord.			Neoplastic Process	NCI CTEP SDC CNS Neoplasm (Primary Tumor), Miscellaneous Sub-Category Terminology|NCI CTEP Simplified Disease Classification Terminology
C102872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102872>	C9466|C214954	Pharyngeal Squamous Cell Carcinoma|Pharyngeal (including Hypopharyngeal and Oropharyngeal) squamous cell carcinoma|Pharyngeal Throat Squamous Cell Cancer|Pharyngeal squam. cell carcinoma	A squamous cell carcinoma that arises from the pharynx.	Pharyngeal Squamous Cell Carcinoma		Neoplastic Process	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology|NCI CTEP SDC Head and Neck Squamous Cell Carcinoma Sub-Category Terminology|NCI CTEP Simplified Disease Classification Terminology|NCIt Neoplasm Core Terminology
C102873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102873>	C25193	Teacher|EDUCATOR|Educator|Instructor	One who instructs or educates others.			Occupation or Discipline	CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C102874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102874>	C2139	HPV-16 E6 Peptides Vaccine/Candida albicans Extract|HPV-16 E6 Peptides Vaccine/Candin|PepCan	A human papillomavirus (HPV) type 16 vaccine containing four E6 peptides in combination with an extract of Candida albicans, with potential immunomodulating and antineoplastic activities. Upon administration of HPV-16 E6 peptides vaccine/Candida albicans extract, the four HPV-16 E6 peptides and the Candida albicans may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against cells expressing the E6 oncoprotein, resulting in tumor cell lysis. The HPV 16 transforming protein E6 is expressed in precancerous and malignant cervical lesions, and HPV may be a cause of some head and neck squamous cell carcinomas (HNSCCs). Candida albicans allergenic extract may be used as a recall antigen to stimulate the immune system against HPV.	HPV-16 E6 Peptides Vaccine/Candida albicans Extract		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102875>	C67502	Nanoparticle-encapsulated Doxorubicin Hydrochloride|BA-003|Doxorubicin Transdrug|Livatag	A formulation of nanoparticles encapsulating the hydrochloride salt form of the anthracycline antibiotic doxorubicin, with potential antitumor activity. Upon intravenous administration, doxorubicin intercalates DNA, interferes with the activity of topoisomerase II, and causes DNA adducts and other DNA damage, resulting in tumor cell growth inhibition and apoptosis. This agent also interacts with cell membrane lipids causing lipid peroxidation. Delivery of doxorubicin in nanoparticles may improve drug penetration into tumors and may circumvent the tumor cells multidrug resistance mechanisms and may therefore be effective in chemoresistant tumor cells.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102876>	C213665|C129825	Tirabrutinib|6-Amino-9-((3R)-1-(2-butynoyl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one|8H-Purin-8-one,6-amino-7,9-dihydro-9-((3R)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl)|GS 4059|GS-4059|GS4059|ONO-4059|ONO4059|TIRABRUTINIB	An orally available formulation containing an inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity. Upon administration, tirabrutinib covalently binds to BTK within B cells, thereby preventing B cell receptor signaling and impeding B cell development. As a result, this agent may inhibit the proliferation of B cell malignancies. BTK, a cytoplasmic tyrosine kinase and member of the Tec family of kinases, plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.	Tirabrutinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102877>	C93170	Olinvacimab|OLINVACIMAB|TTAC-0001	A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, olinvacimab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102878>	C2311	Boanmycin Hydrochloride|BAM HCl|BLEOMYCIN A6 HYDROCHLORIDE|Bleomycin A6 Hydrochloride	The hydrochloride salt form of boanmycin (aka bleomycin A6), a component of the antibiotic bleomycin produced by Streptomyces species, with potential antineoplastic activity. Upon administration, boanmycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals. This causes single- and double-stranded DNA breaks which eventually leads to cell death. Compared to bleomycin, boanmycin appears to have a more favorable toxicity profile.			Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102879>	C1752	hTERT/Survivin/CMV Multipeptide Vaccine	A vaccine containing multiple peptides derived from the human telomerase reverse transcriptase (hTERT), survivin and cytomegalovirus (CMV), with potential immunostimulating and antineoplastic activities. Upon administration, hTERT/survivin/CMV multipeptide vaccine may elicit a cytotoxic T cell (CTL) response against tumor cells espressing hTERT, survivin and CMV. hTERT, the catalytic subunit of telomerase, and the inhibitor of apoptosis (IAP) family member survivin, both often upregulated in tumor cells, play key roles in tumor cell growth and survival. Further, CMV expression is correlated with certain types of cancer.	hTERT/Survivin/CMV Multipeptide Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C10287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10287>	C61063	Altretamine/Doxorubicin/Fluoxymesterone/Methotrexate/Mitolactol/Prednisone/Tamoxifen/Vincristine|DBD/DOX/FXM/HMM/MTX/PRED/TMX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102880>	C2201|C1742	Everolimus Tablets for Oral Suspension|Afinitor Disperz	Tablets for oral suspension containing everolimus, a derivative of the natural macrocyclic lactone sirolimus, with immunosuppressive and antineoplastic activities. After suspension of the everolimus tablets in water and oral administration, this agent inhibits the activation of the serine/threonine kinase mammalian target of rapamycin (mTOR) by binding to mTOR's cytosolic receptor immunophilin FK Binding Protein-12 (FKBP-12). Inhibition of the mTOR complex may result in the inhibition of the phosphatidylinositol 3 kinase/Akt/mTOR pathway and an inhibition in the expression of vascular endothelial cell growth factor (VEGF) and hypoxia-inducible factor. Ultimately, this may result in decreased tumor cell proliferation and tumor angiogenesis. This pediatric formulation can dissolve easily in a small volume of water making it easier to swallow and is available in smaller dose increments thereby allowing for greater dosing flexibility.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102881>	C213716|C129839	Thioureidobutyronitrile|4-ISOTHIOUREIDOBUTYRONITRILE|4-Isothioureidobutyronitrile|Carbamimidothioic Acid, 3-Cyanopropyl Ester|Kevetrin	A water-soluble, small molecule and activator of the tumor suppressor protein p53, with potential antineoplastic activity. Upon intravenous administration, thioureidobutyronitrile activates p53 which in turn induces the expressions of p21 and PUMA (p53 up-regulated modulator of apoptosis), thereby inhibiting cancer cell growth and causing tumor cell apoptosis. Thioureidobutyronitrile may be effective in drug-resistant cancers with mutated p53. p53 tumor suppressor, a transcription factor regulating the expression of many stress response genes and mediating various anti-proliferative processes, is often mutated in cancer cells.	Thioureidobutyronitrile		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102882>	C2124	Uniformly-labeled [13C]glucose|U-13C-Glucose|[U-13C] Glucose	A non-radioactive, naturally occurring carbon 13 (13C) glucose isotopomer in which all six carbons are 13C, with potential imaging application. Upon administration of uniformly-labeled [U-13C] glucose, the glucose is taken up and metabolized by tumors and the 13C-containing metabolites can be imaged by 13C nuclear magnetic resonance (NMR) spectroscopy. Since tumor cells take up and metabolize glucose in higher amounts and through different pathways than normal cells, this agent may help assess the metabolic phenotype of the tumor.	Uniformly-labeled [13C]glucose		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C102883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102883>	C7062	Miscellaneous Neoplasm|Miscellaneous Tumors|Miscellaneous neoplasm, NOS	A benign or malignant neoplasm which is not further characterized.			Neoplastic Process	GDC Terminology|GDC Value Terminology|NCI CTEP SDC Miscellaneous Neoplasm Sub-Category Terminology|NCI CTEP Simplified Disease Classification Terminology
C102884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102884>	C27718	Human Papillomavirus-Related Malignant Neoplasm in AIDS Patient|AIDS-related HPV-related cancer|AIDS-related HPV-related cancer, NOS	A malignant neoplasm caused by human papillomavirus in an a patient with a history of AIDS.			Neoplastic Process	NCI CTEP SDC AIDS-related Human Papillomavirus Sub-Category Terminology|NCI CTEP Simplified Disease Classification Terminology
C102885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102885>	C54362	LDB1 Gene|LDB1|LDB1|LIM Domain Binding 1 Gene	This gene is involved in the modulation of transcription.			Gene or Genome	
C102886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102886>	C102885	LDB1 wt Allele|CLIM2|LIM Domain Binding 1 wt Allele|NLI	Human LDB1 wild-type allele is located within 10q24-q25 and is approximately 13 kb in length. This allele, which encodes LIM domain-binding protein 1, plays a role in the regulation of gene transcription.			Gene or Genome	
C102887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102887>	C26199	LIM Domain-Binding Protein 1|CLIM-2|Carboxyl Terminal LIM Domain-Binding Protein 2|Carboxyl-Terminal LIM Domain-Binding Protein 2|LDB-1|LDB1|LIM Domain-Binding Factor CLIM2|LIM Domain-Binding Factor-1|Nuclear LIM Interactor|hLdb1	LIM domain-binding protein 1 (411 aa, ~47 kDa) is encoded by the human LDB1 gene. This protein is involved in transcription factor regulation.			Amino Acid, Peptide, or Protein	
C102888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102888>	C26064	CTDNEP1 Gene|CTD Nuclear Envelope Phosphatase 1 Gene|CTDNEP1|CTDNEP1	This gene plays a role in protein dephosphorylation.	CTDNEP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C102889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102889>	C102888	CTDNEP1 wt Allele|CTD Nuclear Envelope Phosphatase 1 wt Allele|DULLARD|HSA011916|NET56	Human CTDNEP1 wild-type allele is located in the vicinity of 17p13 and is approximately 8 kb in length. This allele, which encodes CTD nuclear envelope phosphatase 1 protein, is involved in the modulation of fatty acid phosphatases.	CTDNEP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10288>	C61063	Altretamine/Cyclophosphamide/Doxorubicin/Fluorouracil/Fluoxymesterone/Methotrexate/Prednisone/Tamoxifen/Vinblastine|CTX/DOX/5-FU/FXM/HMM/MTX/PRED/TMX/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102890>	C34078	CTD Nuclear Envelope Phosphatase 1|C-Terminal Domain Nuclear Envelope Phosphatase 1|CTDNEP1|EC 3.1.3.16|Serine/Threonine-Protein Phosphatase Dullard	CTD nuclear envelope phosphatase 1 (244 aa, ~28 kDa) is encoded by the human CTDNEP1 gene. This protein plays a role in the dephosphorylation and regulation of fatty acid phosphatase proteins.	CTD Nuclear Envelope Phosphatase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102891>	C20420	SOX10 Gene|SOX10|SOX10|SRY (Sex Determining Region Y)-Box 10 Gene	This gene is involved in both transcriptional regulation and anatomic structure morphogenesis.	SOX10 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C102892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102892>	C102891	SOX10 wt Allele|DOM|Dominant Megacolon, Mouse, Human Homolog of Gene|PCWH|RP5-1039K5.9|SRY (Sex Determining Region Y)-Box 10 wt Allele|SRY-Related HMG-Box Gene 10|WS2E|WS4|WS4C	Human SOX10 wild-type allele is located in the vicinity of 22q13.1 and is approximately 17 kb in length. This allele, which encodes transcription factor SOX-10 protein, plays a role in transcriptional activation. Mutation of the gene is associated with Waardenburg syndrome types 2E and 4C and with peripheral demyelinating neuropathy, central dysmyelinating leukodystrophy, Waardenburg syndrome, and Hirschsprung disease.	SOX10 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102893>	C17207	Transcription Factor SOX-10|SOX10|SRY-Related HMG-Box Gene 10 Protein	Transcription factor SOX-10 (466 aa, ~50 kDa) is encoded by the human SOX10 gene. This protein is involved in the regulation of gene expression.	Transcription Factor SOX-10		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102894>	C26003	TASP1 Gene|TASP1|TASP1|Taspase, Threonine Aspartase, 1 Gene	This gene plays a role in both proteolysis and transcriptional regulation.			Gene or Genome	
C102895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102895>	C102894	TASP1 wt Allele|C20orf13|Chromosome 20 Open Reading Frame 13 Gene|FLJ20212|Taspase, Threonine Aspartase, 1 wt Allele|dJ585I14.2	Human TASP1 wild-type allele is located in the vicinity of 20p12.1 and is approximately 373 kb in length. This allele, which encodes threonine aspartase 1 protein, is involved in proteolysis.			Gene or Genome	
C102896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102896>	C16965	Threonine Aspartase 1|EC 3.4.25.-|TASP1|Taspase 1|Taspase-1	Threonine aspartase 1 (420 aa, ~44 kDa) is encoded by the human TASP1 gene. This protein plays a role in the proteolysis of histone-lysine N-methyltransferase MLL protein.			Amino Acid, Peptide, or Protein|Enzyme	
C102897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102897>	C6958|C4822	High Grade Astrocytic Tumor|High Grade Astrocytic Neoplasm|High-Grade Astrocytic Neoplasm|High-Grade Astrocytic Tumor	An astrocytic tumor exhibiting high-grade morphological characteristics. This category includes anaplastic astrocytoma, glioblastoma, and astrocytoma, IDH-mutant, grade 4.			Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|NCIt Neoplasm Core Terminology
C102898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102898>	C28533	MTCH2 Gene|MTCH2|MTCH2|Mitochondrial Carrier 2 Gene	This gene is involved in transport through the inner mitochondrial membrane.			Gene or Genome	
C102899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102899>	C102898	MTCH2 wt Allele|2310034D24Rik|HSPC032|MIMP|Mitochondrial Carrier 2 wt Allele|Mitochondrial Carrier Homolog 2 (C. elegans) Gene|SLC25A50|Solute Carrier Family 25, Member 50 Gene	Human MTCH2 wild-type allele is located in the vicinity of 11p11.2 and is approximately 25 kb in length. This allele, which encodes mitochondrial carrier homolog 2 protein, plays a role in mitochondrial polarization.			Gene or Genome	
C10289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10289>	C61007	Carboplatin/Etoposide|CBDCA/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1028>	C1967	Butein|2',3,4,4'-Tetrahydroxy-chalcone|BUTEIN	A flavonoid obtained from the seed of Cyclopia subternata. It is a specific protein tyrosine kinase inhibitor that induces apoptosis. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C102900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102900>	C16386	Mitochondrial Carrier Homolog 2|MTCH2|Met-Induced Mitochondrial Protein|Solute Carrier Family 25 Member 50	Mitochondrial carrier homolog 2 (303 aa, ~33 kDa) is encoded by the human MTCH2 gene. This protein is involved in the modulation of mitochondrial polarization.			Amino Acid, Peptide, or Protein	
C102901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102901>	C26064	PPP6C Gene|PPP6C|PPP6C|PPP6C|Protein Phosphatase 6, Catalytic Subunit Gene	This gene plays a role in both protein dephosphorylation and signaling.			Gene or Genome	GDC Terminology|GDC Value Terminology
C102902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102902>	C102901	PPP6C wt Allele|PP6|PP6C|Protein Phosphatase 6, Catalytic Subunit wt Allele|RP11-366O20.1	Human PPP6C wild-type allele is located in the vicinity of 9q33.3 and is approximately 43 kb in length. This allele, which encodes serine/threonine-protein phosphatase 6 catalytic subunit protein, is involved in protein dephosphorylation, signal transduction and cell cycle regulation.			Gene or Genome	
C102903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102903>	C34078	Serine/Threonine-Protein Phosphatase 6 Catalytic Subunit|EC 3.1.3.16|PP6C|PPP6C	Serine/threonine-protein phosphatase 6 catalytic subunit (305 aa, ~35 kDa) is encoded by the human PPP6C gene. This protein plays a role in protein dephosphorylation, cell cycle progression and receptor signaling.			Amino Acid, Peptide, or Protein|Enzyme	
C102904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102904>	C44391|C14226	Human Papillomavirus-31|31|HPV 31|HPV-31|HPV31|HPV31|HUMAN PAPILLOMAVIRUS TYPE 31|Human Papillomavirus 31|Human Papillomavirus Type 31|Human papillomavirus 31	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-31 is associated with a high risk for cervical intraepithelial neoplasia.	Human Papillomavirus-31		Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C102905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102905>	C54443	NCI CTEP Simplified Disease Classification Terminology|NCI CTEP SDC Terminology	The NCI Cancer Therapy Evaluation Program (CTEP) Simplified Disease Classification (SDC), a three level hierarchy of Category, Sub-Category, and coding Term intended to provide an intuitive classification of neoplastic diseases to meet the needs of CTEP while still allowing reporting based on the Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.  All CTEP SDC Terms are matched to NCIt concepts, which are linked to SDC Categories and Sub-Categories through Concept_In_Subset association relationships.			Intellectual Product	
C102906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102906>	C26006	SNX31 Gene|SNX31|SNX31|Sorting Nexin 31 Gene	This gene is involved in intracellular transport.			Gene or Genome	
C102907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102907>	C102906	SNX31 wt Allele|MGC39715|Sorting Nexin 31 wt Allele	Human SNX31 wild-type allele is located in the vicinity of 8q22.3 and is approximately 91 kb in length. This allele, which encodes sorting nexin-31 protein, plays a role in intracellular transport.			Gene or Genome	
C102908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102908>	C16386	Sorting Nexin-31|SNX31|Sorting Nexin 31	Sorting nexin-31 (440 aa, ~51 kDa) is encoded by the human SNX31 gene. This protein is involved in the mediation of intracellular transport.			Amino Acid, Peptide, or Protein	
C102909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102909>	C19676	WHR1 Gene|STK19|WHR1|WHR1|Winged Helix Repair Factor 1 Gene	This gene plays a role in transcription-coupled nucleotide excision repair (TC-NER).			Gene or Genome	
C10290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10290>	C61063	Carboplatin/Fluorouracil/Methotrexate|CBDCA/5-FU/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102910>	C102909	WHR1 wt Allele|D6S60|D6S60E|DADB-112B14.2|G11|HLA-RP1|MHC Class III HLA-RP1 Gene|Nuclear Serine/Threonine Protein Kinase Gene|RP1|STK19|Serine/Threonine Kinase 19 Gene|Serine/Threonine-Protein Kinase 19 Gene|TWH19|Tandem Winged Helix Protein Previously Known as STK19 Gene|Winged Helix Repair Factor 1 wt Allele	Human WHR1 wild-type allele is located in the vicinity of 6p21.33 and is approximately 12 kb in length. This allele, which encodes winged helix repair factor 1 protein, is involved in the assembly and repair activity of the transcription-coupled nucleotide excision repair (TC-NER) complex.			Gene or Genome	
C102911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102911>	C21170	Winged Helix Repair Factor 1|Inactive Serine/Threonine-Protein Kinase 19|Protein G11|Protein RP1|STK19|Tandem Winged Helix Protein Formerly Known as STK19|Tandem Winged Helix Protein Previously Known as STK19|WHR1	Winged helix repair factor 1 (254 aa, ~28 kDa) is encoded by the human WHR1 gene. This protein plays a role in the assembly and activity of the transcription-coupled nucleotide excision repair (TC-NER) complex that is recruited to DNA lesions where transcription via the RNA polymerase II complex has stalled.			Amino Acid, Peptide, or Protein|Enzyme	
C102912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102912>	C28404	USP44 Gene|USP44|USP44|Ubiquitin Specific Peptidase 44 Gene	This gene is involved in both cell cycle and protein deubiquitination.			Gene or Genome	
C102913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102913>	C102912	USP44 wt Allele|FLJ14528|Ubiquitin Specific Peptidase 44 wt Allele	Human USP44 wild-type allele is located in the vicinity of 12q22 and is approximately 35 kb in length. This allele, which encodes ubiquitin carboxyl-terminal hydrolase 44 protein, plays a role in both anaphase and the removal of ubiquitin from protein substrates.			Gene or Genome	
C102914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102914>	C16481	Ubiquitin Carboxyl-Terminal Hydrolase 44|Deubiquitinating Enzyme 44|EC 3.4.19.12|USP44|Ubiquitin Specific Peptidase 44|Ubiquitin Specific Protease 44|Ubiquitin Thioesterase 44|Ubiquitin-Specific-Processing Protease 44	Ubiquitin carboxyl-terminal hydrolase 44 (712 aa, ~81 kDa) is encoded by the human USP44 gene. This protein is involved in the proteolytic removal of ubiquitin.			Amino Acid, Peptide, or Protein|Enzyme	
C102915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102915>	C133710	RNF20 Gene|RNF20|RNF20|Ring Finger Protein 20, E3 Ubiquitin Protein Ligase Gene	This gene plays a role in polyubiquitination, histone modification and transcriptional regulation.			Gene or Genome	
C102916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102916>	C102915	RNF20 wt Allele|BRE1|BRE1 E3 Ubiquitin Ligase Homolog (S. cerevisiae) Gene|BRE1A|FLJ11189|FLJ20382|KAIA2779|Ring Finger Protein 20, E3 Ubiquitin Protein Ligase wt Allele|hBRE1	Human RNF20 wild-type allele is located in the vicinity of 9q22 and is approximately 29 kb in length. This allele, which encodes E3 ubiquitin-protein ligase BRE1A protein, is involved in the modulation of transcription, polyubiquitination and histone modification.			Gene or Genome	
C102917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102917>	C21254	E3 Ubiquitin-Protein Ligase BRE1A|BRE1-A|EC 2.3.2.27|EC 6.3.2.-, Formerly|RING Finger Protein 20|hBRE1	E3 ubiquitin-protein ligase BRE1A (975 aa, ~114 kDa) is encoded by the human RNF20 gene. This protein plays a role in the ubiquitination of histones.			Amino Acid, Peptide, or Protein|Enzyme	
C102918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102918>	C18326	SPDEF Gene|SAM Pointed Domain Containing ets Transcription Factor Gene|SPDEF|SPDEF	This gene may be involved in prostate development and prostate cancer.	SPDEF Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C102919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102919>	C102918	SPDEF wt Allele|PDEF|PSE|RP11-375E1 A.3|RP11-375E1__A.3|SAM Pointed Domain Containing ets Transcription Factor wt Allele|bA375E1.3	Human SPDEF wild-type allele is located in the vicinity of 6p21.3 and is approximately 19 kb in length. This allele, which encodes SAM pointed domain-containing Ets transcription factor, plays a role in transcriptional regulation.	SPDEF wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10291>	C61063	Asparaginase/Cytarabine/Daunorubicin/Prednisone/Teniposide/Vincristine|ARA-C/ASP/DNR/PRED/VCR/VM-26			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102920>	C17207	SAM Pointed Domain-Containing Ets Transcription Factor|Prostate Epithelium-Specific Ets Transcription Factor|Prostate-Derived Ets Factor|Prostate-Specific Ets|SPDEF	SAM pointed domain-containing Ets transcription factor (335 aa, ~38 kDa) is encoded by the human SPDEF gene. This protein is involved in transcriptional regulation and may modulate both prostate development and prostate cancer progression.	SAM Pointed Domain-Containing Ets Transcription Factor		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102921>	C21275	MMP13 Gene|MMP13|MMP13|Matrix Metallopeptidase 13 (Collagenase 3) Gene	This gene plays a role in proteolysis of collagen.			Gene or Genome	
C102922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102922>	C102921	MMP13 wt Allele|CLG3|MANDP1|Matrix Metallopeptidase 13 (Collagenase 3) wt Allele	Human MMP13 wild-type allele is located in the vicinity of 11q22.3 and is approximately 13 kb in length. This allele, which encodes collagenase 3 protein, is involved in collagen catabolism. Mutation of the gene is associated with both spondyloepimetaphyseal dysplasia Missouri type and metaphyseal anadysplasia type 1.			Gene or Genome	
C102923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102923>	C18164	Collagenase 3|Collagenase-3|EC 3.4.24.-|MMP-13|MMP13|Matrix Metalloprotease 13|Matrix Metalloprotease-13|Matrix Metalloproteinase 13|Matrix Metalloproteinase-13	Collagenase 3 (471 aa, ~54 kDa) is encoded by the human MMP13 gene. This protein plays a role in the proteolysis of the extracellular matrix.			Amino Acid, Peptide, or Protein|Enzyme	
C102924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102924>	C20420	TBR1 Gene|T-Box, Brain, 1 Gene|TBR1|TBR1	This gene is involved in both brain development and transcriptional regulation.			Gene or Genome	
C102925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102925>	C102924	TBR1 wt Allele|T-Box, Brain, 1 wt Allele|TBR-1|TES-56	Human TBR1 wild-type allele is located in the vicinity of 2q24 and is approximately 10 kb in length. This allele, which encodes T-box brain protein 1, plays a role in DNA binding, gene transcription and brain development.			Gene or Genome	
C102926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102926>	C17207	T-Box Brain Protein 1|T-Brain-1|TBR-1|TES-56	T-box brain protein 1 (682 aa, ~74 kDa) is encoded by the human TBR1 gene. This protein is involved in both transcriptional regulation and brain development.			Amino Acid, Peptide, or Protein	
C102927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102927>	C20420	EOMES Gene|EOMES|EOMES|Eomesodermin Gene	This gene plays a role in both transcriptional activation and embryonic development.	EOMES Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C102928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102928>	C102927	EOMES wt Allele|Eomesodermin (Xenopus laevis) Homolog Gene|Eomesodermin wt Allele|Eomesodermin, Xenopus, Homolog of Gene|T-Box, Brain, 2 Gene|TBR2	Human EOMES wild-type allele is located 3p24.1 and is approximately 7 kb in length. This allele, which encodes eomesodermin homolog protein, is involved in both embryonic development and the regulation of gene transcription.	EOMES wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102929>	C17207	Eomesodermin Homolog|T-Box Brain Protein 2|T-Box Brain2|T-Brain-2|TBR-2	Eomesodermin homolog (686 aa, ~73 kDa) is encoded by the human EOMES gene. This protein plays a role in transcriptional activation of genes involved in trophoblast differentiation, gastrulation, and brain development.	Eomesodermin Homolog		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10292>	C61063	Cisplatin/Ifosfamide/Vinblastine|CDDP/IFF/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102930>	C25802	DNAJB6 Gene|DNAJB6|DNAJB6|DnaJ (Hsp40) Homolog, Subfamily B, Member 6 Gene	This gene is involved in protein chaperone activity.			Gene or Genome	
C102931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102931>	C102930	DNAJB6 wt Allele|DJ4|DnaJ|DnaJ (Hsp40) Homolog, Subfamily B, Member 6 wt Allele|HHDJ1|HSJ-2|HSJ2|LGMD1E|MRJ|MSJ-1|tcag7.555	Human DNAJB6 wild-type allele is located in the vicinity of 7q36.3 and is approximately 82 kb in length. This allele, which encodes DnaJ homolog subfamily B member 6 protein, plays a role in the regulation of protein folding and aggregation. Mutation of the gene is associated with limb-girdle muscular dystrophy type 1E.			Gene or Genome	
C102932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102932>	C17764	DnaJ Homolog Subfamily B Member 6|DNAJB6|HHDJ1|HSJ-2|Heat Shock Protein J2|MRJ|MSJ-1	DnaJ homolog subfamily B member 6 (326 aa, ~36 kDa) is encoded by the human DNAJB6 gene. This protein is involved in the mediation of protein folding and the inhibition of protein aggregation.			Amino Acid, Peptide, or Protein	
C102933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102933>	C25870	LCLAT1 Gene|LCLAT1|LCLAT1|Lysocardiolipin Acyltransferase 1 Gene	This gene plays a role in phospholipid metabolism.			Gene or Genome	
C102934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102934>	C102933	LCLAT1 wt Allele|1AGPAT8|AGPAT8|ALCAT1|HSRG1849|LYCAT|Lysocardiolipin Acyltransferase 1 wt Allele|UNQ1849|UNQ1849/PRO3579	Human LCLAT1 wild-type allele is located in the vicinity of 2p23.1 and is approximately 197 kb in length. This allele, which encodes lysocardiolipin acyltransferase 1 protein, is involved in the modification of phospholipids.			Gene or Genome	
C102935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102935>	C16259	Lysocardiolipin Acyltransferase 1|1-AGP Acyltransferase 8|1-AGPAT 8|1-Acylglycerol-3-Phosphate O-Acyltransferase 8|Acyl-CoA:Lysocardiolipin Acyltransferase 1|EC 2.3.1.-|EC 2.3.1.51	Lysocardiolipin acyltransferase 1 (414 aa, ~49 kDa) is encoded by the human LCLAT1 gene. This protein plays a role in lipid acylation.			Amino Acid, Peptide, or Protein|Enzyme	
C102936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102936>	C20194	SNCAIP Gene|SNCAIP|SNCAIP|Synuclein, Alpha Interacting Protein Gene	This gene is involved in the modulation of ubiquitination.	SNCAIP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C102937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102937>	C102936	SNCAIP wt Allele|SYPH1|Sph1|Synuclein, Alpha Interacting Protein wt Allele	Human SNCAIP wild-type allele is located in the vicinity of 5q23.2 and is approximately 153 kb in length. This allele, which encodes synphilin-1 protein, plays a role in the regulation of protein ubiquitination. Mutation of the gene may be associated with Parkinson disease.	SNCAIP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102938>	C95242	Synphilin-1|Alpha-Synuclein-Interacting Protein|Sph1	Synphilin-1 (919 aa, ~100 kDa) is encoded by the human SNCAIP gene. This protein is involved in the modulation of ubiquitin ligase activity.	Synphilin-1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102939>	C20988	CD99 Gene|CD99|CD99|CD99|CD99 Molecule Gene	This gene plays a role in the cell adhesion process.	CD99 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C10293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10293>	C61007	Etoposide/Thiotepa|TSPA/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102940>	C102939	CD99 wt Allele|Antigen Identified By Monoclonal Antibodies 12E7, F21 and O13 Gene|CD99 Molecule wt Allele|HBA71|MIC2|MIC2X|MIC2Y|MSK5X	Human CD99 wild-type allele is located in the vicinity of both Xp22.32 and Yp11.3 and is approximately 50 kb in length. This allele, which encodes CD99 antigen protein, is involved in cell adhesion.	CD99 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102941>	C16393	CD99 Antigen|12E7|CD99|CD99|Cell Surface Antigen 12E7|Cell Surface Antigen HBA-71|Cell Surface Antigen O13|E2 Antigen|MIC2 Surface Antigen|Protein MIC2|Surface Antigen MIC2|T-Cell Surface Glycoprotein E2	CD99 antigen (185 aa, ~19 kDa) is encoded by the human CD99 gene. This protein plays a role in cell adhesion.	CD99 Antigen		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|EWS Authorized Value Terminology|EWS Immunohistochemistry Table
C102942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102942>	C26072	PIK3C2B Gene|PIK3C2B|PIK3C2B|Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Beta Gene	This gene is involved in the metabolism of phosphoinositol.	PIK3C2B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C102943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102943>	C102942	PIK3C2B wt Allele|C2-PI3K|PI3K-C2beta|PI3KC2B|Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Beta wt Allele|Phosphatidylinositol-4-Phosphate 3-Kinase, Catalytic Subunit Type 2 Beta Gene|RP11-739N20.5	Human PIK3C2B wild-type allele is located in the vicinity of 1q32 and is approximately 72 kb in length. This allele, which encodes phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta protein, plays a role in the regulation of phosphoinositol signaling.	PIK3C2B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102944>	C16984	Phosphatidylinositol 4-Phosphate 3-Kinase C2 Domain-Containing Subunit Beta|C2-PI3K|EC 2.7.1.154|PI3K-C2-Beta|PIK3C2B|Phosphatidylinositol 3-Kinase C2 Domain-Containing Beta Polypeptide|Phosphoinositide 3-Kinase-C2-Beta|PtdIns-3-Kinase C2 Subunit Beta	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta (1634 aa, ~185 kDa) is encoded by the human PIK3C2B gene. This protein is involved in both second messenger signaling and the phosphorylation of phosphoinositol.	Phosphatidylinositol 4-Phosphate 3-Kinase C2 Domain-Containing Subunit Beta		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102945>	C26072	PIK3C2G Gene|PIK3C2G|PIK3C2G|Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Gamma Gene	This gene is involved in the phosphorylation of phosphoinositol.	PIK3C2G Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C102946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102946>	C102945	PIK3C2G wt Allele|PI3K-C2-Gamma|PI3K-C2GAMMA|Phosphatidylinositol 3-Kinase, Class 2, Gamma Gene|Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Gamma wt Allele|Phosphatidylinositol-4-Phosphate 3-Kinase, Catalytic Subunit Type 2 Gamma Gene|Phosphoinositide-3-Kinase, Class 2, Gamma Polypeptide Gene	Human PIK3C2G wild-type allele is located in the vicinity of 12p12 and is approximately 401 kb in length. This allele, which encodes phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma protein, plays a role in both the phosphorylation of phospholipids and the modulation of second messenger signaling.	PIK3C2G wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102947>	C16984	Phosphatidylinositol 4-Phosphate 3-Kinase C2 Domain-Containing Subunit Gamma|EC 2.7.1.154|PI3K-C2-Gamma|PIK3C2G|PTDINS-3-Kinase C2 Gamma|Phosphatidylinositol 3-Kinase C2 Domain-Containing Gamma|Phosphatidylinositol 3-Kinase C2 Domain-Containing Gamma Polypeptide|Phosphatidylinositol-4-Phosphate 3-Kinase C2 Domain-Containing Gamma Polypeptide|Phosphatidylinositol-4-Phosphate 3-Kinase C2 Domain-Containing Subunit Gamma|Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Gamma|Phosphoinositide 3-Kinase-C2-Gamma|PtdIns-3-Kinase C2 Subunit Gamma	Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma (1445 aa, ~166 kDa) is encoded by the human PIK3C2G gene. This protein is involved in the modulation of phosphoinositol signaling.	Phosphatidylinositol 4-Phosphate 3-Kinase C2 Domain-Containing Subunit Gamma		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102948>	C20194	CD109 Gene|CD109|CD109|CD109 Molecule Gene	This gene may be involved in both signal regulation and inhibition of proteolysis.	CD109 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C102949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102949>	C102948	CD109 wt Allele|CD109 Antigen (Gov Platelet Alloantigens) Gene|CD109 Molecule wt Allele|CPAMD7|DKFZp762L1111|FLJ38569|Gov Platelet Alloantigens Gene|RP11-525G3.1	Human CD109 wild-type allele is located in the vicinity of 6q13 and is approximately 133 kb in length. This allele, which encodes CD109 antigen protein, may play a role in the modulation of both proteolysis and signaling.	CD109 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10294>	C61063	Amphotericin B/Flucytosine|Amphotericin B/5-FC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102950>	C18466	CD109 Antigen|150 kDa TGF-Beta-1-Binding Protein|Activated T-Cell Marker CD109|C3 and PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 7|CD109|Platelet-Specific Gov Antigen|p180|r150	CD109 antigen (1445 aa, ~162 kDa) is encoded by the human CD109 gene. This protein may be involved in both proteolysis and signaling.	CD109 Antigen		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102951>	C16615	OTX2 Gene|OTX2|OTX2|Orthodenticle Homeobox 2 Gene	This gene is involved in both embryonic development and transcriptional regulation.	OTX2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C102952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102952>	C102951	OTX2 wt Allele|CPHD6|MCOPS5|Orthodenticle Homeobox 2 wt Allele	Human OTX2 wild-type allele is located in the vicinity of 14q22.3 and is approximately 10 kb in length. This allele, which encodes homeobox protein OTX2, plays a role in the positive regulation of gene expression during embryonic pattern formation. Mutation of the gene is associated with both microphthalmia syndromic type 5 and pituitary hormone deficiency combined type 6.	OTX2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102953>	C17207	Homeobox Protein OTX2|Orthodenticle Homolog 2	Homeobox protein OTX2 (289 aa, ~32 kDa) is encoded by the human OTX2 gene. This protein is involved in both transcriptional regulation and embryonic development.	Homeobox Protein OTX2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102954>	C35317	Systemic Arterial Hypertensive Disorder|Hypertensive Disorder, Systemic Arterial	Any condition resulting in systemically elevated blood pressure that is attributed to an arterial source.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C102955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102955>	C12679	Great Blood Vessel|GREAT VESSELS|Structure of great blood vessel (organ) (body structure)	Any of the major arteries or veins attached to the cardiac atria or ventricles. This includes the aorta, superior and inferior vena cava and the pulmonary arteries and veins.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|Neonatal Research Network Terminology|NICHD Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table
C102956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102956>	C25873	HIPK2 Gene|HIPK2|HIPK2|Homeodomain Interacting Protein Kinase 2 Gene	This gene plays a role in the phosphorylation of transcription factors.			Gene or Genome	
C102957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102957>	C102956	HIPK2 wt Allele|Homeodomain Interacting Protein Kinase 2 wt Allele|PRO0593	Human HIPK2 wild-type allele is located within 7q32-q34 and is approximately 231 kb in length. This allele, which encodes homeodomain-interacting protein kinase 2 protein, is involved in serine/threonine phosphorylation, cell cycle regulation and apoptosis.			Gene or Genome	
C102958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102958>	C17325	Homeodomain-Interacting Protein Kinase 2|EC 2.7.11.1|Homeodomain Interacting Protein Kinase 2|hHIPk2	Homeodomain-interacting protein kinase 2 (1198 aa, ~131 kDa) is encoded by the human HIPK2 gene. This protein plays a role in protein phosphorylation, transcriptional regulation and cell cycle progression.			Amino Acid, Peptide, or Protein|Enzyme	
C102959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102959>	C20338	WRAP53 Gene|WD Repeat Containing Antisense to TP53 Gene|WRAP53|WRAP53|WRAP53	This gene is involved in telomerase activity.	WRAP53 Gene		Gene or Genome	CCPS Genetics Terminology|Childhood Cancer Predisposition Study Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10295>	C61063	Doxorubicin/Ethiodized Oil|DOX/Ethiodized Oil			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102960>	C102959	WRAP53 wt Allele|DKCB3|FLJ10385|TCAB1|WD Repeat Containing Antisense to TP53 wt Allele|WD Repeat Containing, Antisense to TP53 Gene|WD Repeat Domain 79 Gene|WD-Encoding RNA Antisense to P53 Gene|WDR79	Human WRAP53 wild-type allele is located in the vicinity of 17p13.1 and is approximately 17 kb in length. This allele, which encodes telomerase Cajal body protein 1, plays a role in telomere maintenance. Mutation of the gene is associated with dyskeratosis congenita autosomal recessive type 3.	WRAP53 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102961>	C18466	Telomerase Cajal Body Protein 1|WD Repeat-Containing Protein 79|WD Repeat-Containing Protein WRAP53|WD40 Protein Wrap53|WD40 Repeat-Containing Protein Encoding RNA Antisense to p53|WRAP53	Telomerase Cajal body protein 1 (548 aa, ~59 kDa) is encoded by the human WRAP53 gene. This protein is involved in the positive regulation of telomere synthesis.	Telomerase Cajal Body Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102962>	C21295	ZFP36 Gene|ZFP36|ZFP36|Zinc Finger Protein 36, C3H Type, Homolog (Mouse) Gene	This gene plays a role in RNA turnover.			Gene or Genome	
C102963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102963>	C102962	ZFP36 wt Allele|G0S24|GOS24|NUP475|RNF162A|TIS11|TTP|Zinc Finger Protein 36, C3H Type, Homolog (Mouse) wt Allele|zfp-36	Human ZFP36 wild-type allele is located in the vicinity of 19q13.1 and is approximately 3 kb in length. This allele, which encodes tristetraprolin protein, is involved in the regulation of RNA degradation.			Gene or Genome	
C102964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102964>	C21298	Tristetraprolin|G0/G1 Switch Regulatory Protein 24|Growth Factor-Inducible Nuclear Protein NUP475|Protein TIS11A|TIS11|TTP|Zfp-36|Zinc Finger Protein 36 Homolog	Tristetraprolin (326 aa, ~34 kDa) is encoded by the human ZFP36 gene. This protein plays a role in both RNA binding and metabolism.			Amino Acid, Peptide, or Protein	
C102965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102965>	C20100	WNT16 Gene|WNT16|WNT16|Wingless-Type MMTV Integration Site Family, Member 16 Gene	This gene is involved in receptor signaling.	WNT16 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C102966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102966>	C102965	WNT16 wt Allele|Wingless-Type MMTV Integration Site Family, Member 16 wt Allele|Wingless-Type MMTV Integration Site Family, Member 16b Gene	Human WNT16 wild-type allele is located in the vicinity of 7q31 and is approximately 16 kb in length. This allele, which encodes protein Wnt-16, plays a role in both receptor binding and ligand-mediated signaling.	WNT16 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102967>	C20394	Protein Wnt-16|Wingless-Type MMTV Integration Site Family, Member 16|Wingless-Type MMTV Integration Site Family, Member 16b	Protein Wnt-16 (365 aa, ~41 kDa) is encoded by the human WNT16 gene. This protein is involved in ligand-dependent signaling.	Protein Wnt-16		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C102968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102968>	C20703	ID3 Gene|ID3|ID3|ID3|Inhibitor of DNA Binding 3, Dominant Negative Helix-Loop-Helix Protein Gene	This gene plays a role in transcriptional repression.			Gene or Genome	GDC Terminology|GDC Value Terminology
C102969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102969>	C102968	ID3 wt Allele|1R21|BHLHB25|HEIR-1|Inhibitor of DNA Binding 3, Dominant Negative Helix-Loop-Helix Protein wt Allele|bHLHb25	Human ID3 wild-type allele is located within 1p36.13-p36.12 and is approximately 2 kb in length. This allele, which encodes DNA-binding protein inhibitor ID-3 protein, is involved in the negative regulation of gene expression.			Gene or Genome	
C10296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10296>	C61007	Cisplatin/Doxorubicin/Etoposide/Fluorouracil/Mitomycin|CDDP/DOX/5-FU/MITO/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102970>	C26199	DNA-Binding Protein Inhibitor ID-3|Class B Basic Helix-Loop-Helix Protein 25|Helix-Loop-Helix Protein HEIR-1|ID-Like Protein Inhibitor HLH 1R21|ID3|Inhibitor of DNA Binding 3|bHLHb25	DNA-binding protein inhibitor ID-3 (119 aa, ~12 kDa) is encoded by the human ID3 gene. This protein plays a role in the inhibition of transcription factor activity.			Amino Acid, Peptide, or Protein	
C102971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102971>	C50822	Cardiac Resuscitation	Measures performed to restore cardiac function.			Therapeutic or Preventive Procedure	Neonatal Research Network Terminology|NICHD Terminology
C102972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102972>	C20845	MRPL45 Gene|MRPL45|MRPL45|Mitochondrial Ribosomal Protein L45 Gene	This gene is involved in mitochondrial RNA translation.			Gene or Genome	
C102973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102973>	C102972	MRPL45 wt Allele|L45mt|MRP-L45|Mitochondrial Ribosomal Protein L45 wt Allele	Human MRPL45 wild-type allele is located in the vicinity of 17q21.2 and is approximately 26 kb in length. This allele, which encodes 39S ribosomal protein L45, mitochondrial, plays a role in the translation of mitochondrial RNA.			Gene or Genome	
C102974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102974>	C21210	39S Ribosomal Protein L45, Mitochondrial|L45mt|MRP-L45|Mitochondrial Ribosomal Protein L45	39S ribosomal protein L45, mitochondrial (306 aa, ~35 kDa) is encoded by the human MRPL45 gene. This protein is involved in mitochondrial gene product expression.			Amino Acid, Peptide, or Protein	
C102975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102975>	C26987|C116822	Fracture of Clavicle Related to Birth|Fracture of Clavicle Related to Birth Trauma|Fracture of Clavicle Related to Birth Trauma	An injury sustained during the birthing process in which the continuity is broken in the clavicle.			Finding	Neonatal Research Network Terminology|NICHD Terminology|Perinatal Terminology
C102976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102976>	C213472|C212990	Src/Abl Kinase Inhibitor AZD0424|AZD-0424|AZD0424	An orally bioavailable small molecule tyrosine kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Upon oral administration, AZD0424 selectively inhibits both Src and Abl kinase activity which may result in the inhibition of tumor growth in susceptible tumor cells. Src and Abl kinases are upregulated in certain tumor cells and play important roles in tumor cell proliferation and metastasis.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102977>	C26849	Meconium Peritonitis	Inflammation of the peritoneum caused by an intrauterine intestinal perforation leading to presence of meconium within the fetal peritoneal cavity. This is frequently seen as intra-abdominal calcifications on imaging.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C102978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102978>	C28310|C129826	Apoptotic Autologous Tumor Cells-pulsed Alpha-type-1 Polarized Dendritic Cells	A cell based cancer vaccine composed of mature polarized dendritic cells (DCs) and pulsed with apoptotic autologous tumor cells that has potential immunostimulating and antineoplatic activities. Dendritic cells (DCs) were treated with interleukin-1beta, tumor necrosis factor alpha, interferon-alpha (IFN-a), IFN-gamma and polyinosinic:polycytidylic acid (p-I:C) to produce mature alpha type-1 polarized DCs (alphaDC1) that are capable of producing high levels of interleukin-12p70 (IL-12p70). The alphaDC1 are subsequently pulsed with apoptotic autologous tumor cells. Upon administration, these DCs are able to induce a potent cytotoxic T lymphocyte (CTL) response against tumor associated antigens (TAAs), resulting in tumor cell lysis and inhibition of tumor cell growth. Apoptotic tumor cells contain an array of TAAs.			Cell|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102979>	C26796	Congenital Hydronephrosis	Collection of urine in the renal pelvis that results in dilatation of the renal pelvis and calyces that is present at birth.			Disease or Syndrome	Cellosaurus Disease Terminology|Neonatal Research Network Terminology|NICHD Terminology
C10297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10297>	C61063	Mechlorethamine/Prednisone/Procarbazine/Sargramostim/Vincristine|GM-CSF/NM/PCB/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102980>	C215102|C213143	Anti-ENPP3 Antibody-drug Conjugate AGS-16C3F|ADC AGS-16C3F|AGS-16C3F|AGS-16C3F	An antibody-drug conjugate (ADC) containing a fully human monoclonal antibody (AGS-16C) directed to the ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3), conjugated via a non-cleavable linker to monomethyl auristatin F (MMAF), an auristatin derivative and a potent microtubule inhibitor, that has potential antineoplastic activity. Upon intravenous administration of ADC AGS-16C3F, the monoclonal antibody moiety of this conjugate selectively binds to ENPP3 then is internalized and undergoes proteolytic cleavage to release MMAF. MMAF binds to and inhibits tubulin polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. While normally expressed at low levels in the proximal tubules of the kidney, the type II transmembrane glycoprotein ENPP3 has been found to be overexpressed in renal neoplasms.	Anti-ENPP3 Antibody-drug Conjugate AGS-16C3F		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102981>	C2124|C129819	Iodine I 131 Rituximab|(131)I-Rituximab|131I-Rituxan|RITUXIMAB I-131	A radioimmunoconjugate comprised of rituximab, a recombinant chimeric monoclonal antibody directed against the CD20 antigen, and labeled with iodine I 131 with potential antineoplastic activity. The antibody moiety of iodine I 131 rituximab binds to the CD20 antigen thereby delivering cytotoxic iodine I 131 specifically to cancer cells expressing CD20. The CD20 antigen, a hydrophobic transmembrane protein, is expressed on normal pre-B and mature B lymphocytes.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102982>	C1752	Gag:267-274 Peptide Vaccine	A peptide vaccine containing the amino acids 267 through 274 of the human immunodeficiency virus type 1 (HIV-1) gag core protein (gag:267-274), with potential immunostimulating activity. Upon vaccination, the immune system may exert a potent cytotoxic T-lymphocyte (CTL) response against the xenoantigen gag:267-274 and produces pro-inflammatory cytokines. The concomitant administration of a cancer peptide vaccine may benefit from an already activated immune system and may augment an immune response against the administered tumor associated antigen(s). Gag:267-274 peptide is highly immunogenic and may potentially be used as a cancer immunoadjuvant.	Gag:267-274 Peptide Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C102984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102984>	C78356	Congenital Ileal Stenosis	Narrowing of the lumen of the ileum that is present at birth.			Finding	Neonatal Research Network Terminology|NICHD Terminology
C102985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102985>	C78400	Congenital Jejunal Stenosis	Narrowing of the lumen of the jejunum that is present at birth.			Finding	Neonatal Research Network Terminology|NICHD Terminology
C102986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102986>	C62800	Somatotropin Deficiency	Abnormally low levels of circulating somatotropin.			Finding	Neonatal Research Network Terminology|NICHD Terminology
C102987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102987>	C27297	Testosterone Biosynthesis Deficiency	Inadequate production of circulating testosterone.			Finding	Neonatal Research Network Terminology|NICHD Terminology
C102988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102988>	C20993	Patient Reported Outcomes Measurement Information System|PROMIS|PROMIS	A project to develop standards for the collection and analysis of patient-reported health status data using a system of highly reliable, precise measures for physical, mental, and social well-being. Patients are asked a series of rigorously reviewed questions covering common domains and metrics across differing conditions and treatments. The questions can be administered in short forms or adaptively through computerized adaptive testing and reports can be generated to allow clinicians to better understand how treatments might affect the quality of life of their patients.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C102989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102989>	C91105	PROMIS Adult Sleep-Related Impairment Item Bank|Patient Reported Outcomes Measurement Information System Adult Sleep-Related Impairment Item Bank	A set of questions designed to evaluate patient-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours, and assess functional impairments during wakefulness associated with sleep problems or impaired alertness.			Intellectual Product	
C10298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10298>	C61063	Asparaginase/Daunorubicin/Prednisolone/Vincristine|ASP/DNR/PRDL/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C102990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102990>	C98845	Brachial Plexus Palsy Related to Birth|Brachial Plexus Palsy due to Birth Trauma|Brachial Plexus Palsy due to Birth Trauma	Birth injury to the brachial plexus. It results in paralysis of the muscles of the shoulder, arm, and hand. It manifests as lack of mobility in the arm, usually in the first week of life. In the majority of cases there is spontaneous recovery.			Finding	Neonatal Research Network Terminology|NICHD Terminology|Perinatal Terminology
C102991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102991>	C91105	List of Threatening Experiences Questionnaire|Brief Life Event Questionnaire|LTE Questionnaire|LTE-Q|List of Threatening Experiences	A 12 category life events questionnaire designed to assess the quality of life of a patient before, during and following stressful life events.			Intellectual Product	
C102992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102992>	C35553|C205055	Fungemia	A laboratory test result indicating the presence of fungi or yeasts in the blood.			Laboratory or Test Result	
C102993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102993>	C35553|C102602	Bacteremia	A laboratory test result that indicates the presence of bacteria in the blood.			Laboratory or Test Result	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Infectious Disease Terminology
C102994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102994>	C27992	Immunohematological|Immunohematologic	Pertaining to antigen and antibody reactions that involve hematopoietic cells.			Qualitative Concept	
C102995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102995>	C14226	Human Papillomavirus-26|Alphapapillomavirus 5|HPV-26|HPV26|Human Papillomavirus Type 26	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-26 may be associated with a high risk for cervical intraepithelial neoplasia.			Virus	GDC Deprecated Terminology|GDC Terminology
C102996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102996>	C44391|C14226	Human Papillomavirus-33|33|HPV 33|HPV-33|HPV33|HPV33|HUMAN PAPILLOMAVIRUS TYPE 33|Human Papillomavirus 33|Human Papillomavirus Type 33|Human papillomavirus 33	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-33 is associated with a high risk for cervical intraepithelial neoplasia.	Human Papillomavirus-33		Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C102997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102997>	C44391|C14226	Human Papillomavirus-35|35|HPV 35|HPV-35|HPV35|HPV35|HUMAN PAPILLOMAVIRUS TYPE 35|Human Papillomavirus Type 35|Human papillomavirus 35	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-35 is associated with a high risk for cervical intraepithelial neoplasia.	Human Papillomavirus-35		Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C102998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102998>	C44391|C14226	Human Papillomavirus-39|39|HPV 39|HPV-39|HPV39|HPV39|HUMAN PAPILLOMAVIRUS TYPE 39|Human Papillomavirus Type 39|Human papillomavirus 39	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-39 is associated with a high risk for cervical intraepithelial neoplasia.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C102999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C102999>	C44391|C14226	Human Papillomavirus-45|45|HPV 45|HPV-45|HPV45|HPV45|HUMAN PAPILLOMAVIRUS TYPE 45|Human Papillomavirus Type 45|Human papillomavirus 45	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-45 is associated with a high risk for cervical intraepithelial neoplasia.	Human Papillomavirus-45		Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C10299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10299>	C61063	Asparaginase/Cyclophosphamide/Cytarabine/Dexamethasone/Doxorubicin/Vincristine|ARA-C/ASP/CTX/DM/DOX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1029>	C2130	Buthionine Sulfoximine|2-Amino-4-(S-butylsulfonimidoyl) Butanoic Acid|BSO|BUTHIONINE SULFOXIMINE, L-|Butanoic Acid, 2-Amino-4-(S-butylsulfonimidoyl)-|Butanoic acid, 2-amino-4-(S-butylsulfonimidoyl)-|Buthionine Sulphoximine|L-Buthionine Sulfoximine|L-Buthionine sulfoximine|S-(3-Amino-3-carboxypropyl)-S-butylsulfoximine|S-(n-Butyl)homocysteine Sulfoximine|buthionine sulfoximine	A synthetic amino acid. Buthionine sulfoximine irreversibly inhibits gamma-glutamylcysteine synthase, thereby depleting cells of glutathione, a metabolite that plays a critical role in protecting cells against oxidative stress, and resulting in free radical-induced apoptosis. Elevated glutathione levels are associated with tumor cell resistance to alkylating agents and platinum compounds. By depleting cells of glutathione, this agent may enhance the in vitro and in vivo cytotoxicities of various chemotherapeutic agents in drug-resistant tumors. Buthionine sulfoximine may also exhibit antiangiogenesis activity. (NCI04)	Buthionine Sulfoximine		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103000>	C44391|C14226	Human Papillomavirus-51|51|HPV 51|HPV-51|HPV51|HPV51|HUMAN PAPILLOMAVIRUS TYPE 51|Human Papillomavirus Type 51|Human papillomavirus 51	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-51 is associated with a high risk for cervical intraepithelial neoplasia.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C103001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103001>	C44391|C14226	Human Papillomavirus-52|52|HPV 52|HPV-52|HPV52|HPV52|HUMAN PAPILLOMAVIRUS TYPE 52|Human Papillomavirus Type 52|Human papillomavirus 52	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-52 is associated with a high risk for cervical intraepithelial neoplasia.	Human Papillomavirus-52		Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C103002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103002>	C14226	Human Papillomavirus-53|Alphapapillomavirus 6|HPV 53|HPV-53|HPV53|HUMAN PAPILLOMAVIRUS TYPE 53|Human Papillomavirus Type 53	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-53 may be associated with a high risk for cervical intraepithelial neoplasia.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Deprecated Terminology|GDC Terminology
C103003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103003>	C44391|C14226	Human Papillomavirus-56|56|HPV 56|HPV-56|HPV56|HPV56|HUMAN PAPILLOMAVIRUS TYPE 56|Human Papillomavirus Type 56|Human papillomavirus 56	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-56 is associated with a high risk for cervical intraepithelial neoplasia.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C103004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103004>	C44391|C14226	Human Papillomavirus-58|58|HPV 58|HPV-58|HPV58|HPV58|HUMAN PAPILLOMAVIRUS TYPE 58|Human Papillomavirus Type 58|Human papillomavirus 58	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-58 is associated with a high risk for cervical intraepithelial neoplasia.	Human Papillomavirus-58		Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C103005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103005>	C44391|C14226	Human Papillomavirus-59|59|HPV 59|HPV-59|HPV59|HPV59|HUMAN PAPILLOMAVIRUS TYPE 59|Human Papillomavirus Type 59|Human papillomavirus 59	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-59 is associated with a high risk for cervical intraepithelial neoplasia.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C103006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103006>	C14226	Human Papillomavirus-66|66|HPV 66|HPV-66|HPV66|HPV66|HUMAN PAPILLOMAVIRUS TYPE 66|Human Papillomavirus Type 66|Human papillomavirus 66	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-66 is associated with a high risk for cervical intraepithelial neoplasia.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C103007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103007>	C44391|C14226	Human Papillomavirus-68|68|HPV 68|HPV-68|HPV68|HPV68|HUMAN PAPILLOMAVIRUS TYPE 68|Human Papillomavirus Type 68|Human papillomavirus 68	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-68 may be associated with a high risk for cervical intraepithelial neoplasia.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C103008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103008>	C14226	Human Papillomavirus-73|73|HPV-73|HPV73|HPV73|Human Papillomavirus Type 73	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-73 may be associated with a high risk for cervical intraepithelial neoplasia.			Virus	GDC Terminology|GDC Value Terminology
C103009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103009>	C44391|C14226	Human Papillomavirus-82|HPV-82|HPV82|Human Papillomavirus Type 82	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-82 may be associated with a high risk for cervical intraepithelial neoplasia.			Virus	GDC Deprecated Terminology|GDC Terminology
C10300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10300>	C61063	Asparaginase/Cyclophosphamide/Cytarabine/Mercaptopurine/Methotrexate|ARA-C/ASP/CTX/MP/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103010>	C102905	NCI CTEP SDC CNS Neoplasm (Primary Tumor) Category Terminology|CNS Neoplasm (Primary Tumor)|NCI CTEP Simple Disease Classification CNS Neoplasm (Primary Tumor) Category Terminology	CNS Neoplasm (Primary Tumor) is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103011>	C102905	NCI CTEP SDC AIDS-related Malignancy and Condition Category Terminology|AIDS-related Malignancy and Condition|NCI CTEP Simple Disease Classification AIDS-related Malignancy and Condition Category Terminology	AIDS-related Malignancy and Condition is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103012>	C102905	NCI CTEP SDC Bone Neoplasm Category Terminology|Bone Neoplasm|NCI CTEP Simple Disease Classification Bone Neoplasm Category Terminology	Bone Neoplasm is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103013>	C102905	NCI CTEP SDC Breast Neoplasm Category Terminology|Breast Neoplasm|NCI CTEP Simple Disease Classification Breast Neoplasm Category Terminology	Breast Neoplasm is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103014>	C102905	NCI CTEP SDC CNS-excluded Nervous System Neoplasm and Disorder Category Terminology|CNS-excluded Nervous System Neoplasm and Disorder|NCI CTEP Simple Disease Classification CNS-excluded Nervous System Neoplasm and Disorder Category Terminology	CNS-excluded Nervous System Neoplasm and Disorder is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103015>	C102905	NCI CTEP SDC Endocrine Neoplasm Category Terminology|Endocrine Neoplasm|NCI CTEP Simple Disease Classification Endocrine Neoplasm Category Terminology	Endocrine Neoplasm is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103016>	C102905	NCI CTEP SDC Eye Neoplasm Category Terminology|Eye Neoplasm|NCI CTEP Simple Disease Classification Eye Neoplasm Category Terminology	Eye Neoplasm is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103017>	C102905	NCI CTEP SDC Gastrointestinal Neoplasm Category Terminology|Gastrointestinal Neoplasm|NCI CTEP Simple Disease Classification Gastrointestinal Neoplasm Category Terminology	Gastrointestinal Neoplasm is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103018>	C102905	NCI CTEP SDC Germ Cell Neoplasm Category Terminology|Germ Cell Neoplasm|NCI CTEP Simple Disease Classification Germ Cell Neoplasm Category Terminology	Germ Cell Neoplasm is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103019>	C102905	NCI CTEP SDC Head and Neck Neoplasm Category Terminology|Head and Neck Neoplasm|NCI CTEP Simple Disease Classification Head and Neck Neoplasm Category Terminology	Head and Neck Neoplasm is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C10301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10301>	C61063	Asparaginase/Cytarabine/Mercaptopurine/Methotrexate/Prednisolone/Teniposide/Vincristine|ARA-C/ASP/MP/MTX/PRDL/VCR/VM-26			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103020>	C102905	NCI CTEP SDC Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma) Category Terminology|Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma)|NCI CTEP Simple Disease Classification Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma) Category Terminology	Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma) is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103021>	C102905	NCI CTEP SDC Immune Disorder (excluding AIDS and malignancy) Category Terminology|Immune Disorder (excluding AIDS and malignancy)|NCI CTEP Simple Disease Classification Immune Disorder (excluding AIDS and malignancy) Category Terminology	Immune Disorder (excluding AIDS and malignancy) is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103022>	C102905	NCI CTEP SDC Kidney Neoplasm Category Terminology|Kidney Neoplasm|NCI CTEP Simple Disease Classification Kidney Neoplasm Category Terminology	Kidney Neoplasm is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103023>	C102905	NCI CTEP SDC Lung, Mediastinal and Pleural Neoplasm Category Terminology|Lung, Mediastinal and Pleural Neoplasm|NCI CTEP Simple Disease Classification Lung, Mediastinal and Pleural Neoplasm Category Terminology	Lung, Mediastinal and Pleural Neoplasm is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103024>	C102905	NCI CTEP SDC Miscellaneous Neoplasm Category Terminology|Miscellaneous Neoplasm|NCI CTEP Simple Disease Classification Miscellaneous Neoplasm Category Terminology	Miscellaneous Neoplasm is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103025>	C102905	NCI CTEP SDC Non-neoplastic Disorder Category Terminology|NCI CTEP Simple Disease Classification Non-neoplastic Disorder Category Terminology|Non-neoplastic Disorder	Non-neoplastic Disorder is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103026>	C102905	NCI CTEP SDC Reproductive System Neoplasm, Female Category Terminology|NCI CTEP Simple Disease Classification Reproductive System Neoplasm, Female Category Terminology|Reproductive System Neoplasm, Female	Reproductive System Neoplasm, Female is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103027>	C102905	NCI CTEP SDC Reproductive System Neoplasm, Male Category Terminology|NCI CTEP Simple Disease Classification Reproductive System Neoplasm, Male Category Terminology|Reproductive System Neoplasm, Male	Reproductive System Neoplasm, Male is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103028>	C102905	NCI CTEP SDC Skin Neoplasm Category Terminology|NCI CTEP Simple Disease Classification Skin Neoplasm Category Terminology|Skin Neoplasm	Skin Neoplasm is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103029>	C102905	NCI CTEP SDC Soft Tissue Neoplasm Category Terminology|NCI CTEP Simple Disease Classification Soft Tissue Neoplasm Category Terminology|Soft Tissue Neoplasm	Soft Tissue Neoplasm is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C10302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10302>	C61063	Daunorubicin/Dexamethasone/Ifosfamide/Methotrexate/Thioguanine/Vindesine|DAVA/DM/DNR/IFF/MTX/TG			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103030>	C102905	NCI CTEP SDC Urothelial Tract Neoplasm Category Terminology|NCI CTEP Simple Disease Classification Urothelial Tract Neoplasm Category Terminology|Urothelial Tract Neoplasm	Urothelial Tract Neoplasm is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103031>	C103010	NCI CTEP SDC Astrocytoma, High Grade Sub-Category Terminology|Astrocytoma, High Grade|NCI CTEP Simple Disease Classification Astrocytoma, High Grade Sub-Category Terminology	Astrocytoma, High Grade is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103032>	C103011	NCI CTEP SDC AIDS-related Human Papillomavirus Sub-Category Terminology|AIDS-related Human Papillomavirus|NCI CTEP Simple Disease Classification AIDS-related Human Papillomavirus Sub-Category Terminology	AIDS-related Human Papillomavirus is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103033>	C103011	NCI CTEP SDC AIDS-related Kaposi Sarcoma Sub-Category Terminology|AIDS-related Kaposi Sarcoma|NCI CTEP Simple Disease Classification AIDS-related Kaposi Sarcoma Sub-Category Terminology	AIDS-related Kaposi Sarcoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103034>	C103011	NCI CTEP SDC AIDS-related Lymphoma Sub-Category Terminology|AIDS-related Lymphoma|NCI CTEP Simple Disease Classification AIDS-related Lymphoma Sub-Category Terminology	AIDS-related Lymphoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103035>	C103011	NCI CTEP SDC AIDS-related Malignancy and Condition, Miscellaneous Sub-Category Terminology|AIDS-related Malignancy and Condition, Miscellaneous|NCI CTEP Simple Disease Classification AIDS-related Malignancy and Condition, Miscellaneous Sub-Category Terminology	AIDS-related Malignancy and Condition, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103036>	C103012	NCI CTEP SDC Bone Neoplasm, Miscellaneous Sub-Category Terminology|Bone Neoplasm, Miscellaneous|NCI CTEP Simple Disease Classification Bone Neoplasm, Miscellaneous Sub-Category Terminology	Bone Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103037>	C103012	NCI CTEP SDC Chondrosarcoma Sub-Category Terminology|Chondrosarcoma|NCI CTEP Simple Disease Classification Chondrosarcoma Sub-Category Terminology	Chondrosarcoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103038>	C103012	NCI CTEP SDC Ewing Sarcoma Sub-Category Terminology|Ewing Sarcoma|NCI CTEP Simple Disease Classification Ewing Sarcoma Sub-Category Terminology	Ewing Sarcoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103039>	C103012	NCI CTEP SDC Osteosarcoma Sub-Category Terminology|NCI CTEP Simple Disease Classification Osteosarcoma Sub-Category Terminology|Osteosarcoma	Osteosarcoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C10303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10303>	C63524	CDB Regimen|BCNU/CDDP/DTIC|CDB|CDB|Carmustine-Cisplatin-Dacarbazine|Carmustine/Cisplatin/Dacarbazine|Carmustine/Cisplatin/Dacarbazine Regimen|DTIC+BCNU+Cisplatin|DTIC-BCNU-Cisplatin Regimen|Dacarbazine-Carmustine-Cisplatin Regimen	A regimen consisting of carmustine, cisplatin, and dacarbazine that may be used in the treatment of metastatic melanoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C103040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103040>	C103013	NCI CTEP SDC Breast Cancer - In Situ Sub-Category Terminology|Breast Cancer - In situ|NCI CTEP Simple Disease Classification Breast Cancer - In situ Sub-Category Terminology	Breast Cancer - In Situ is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103041>	C103013	NCI CTEP SDC Breast Cancer - Invasive Sub-Category Terminology|Breast Cancer - Invasive|NCI CTEP Simple Disease Classification Breast Cancer - Invasive Sub-Category Terminology	Breast Cancer - Invasive is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103042>	C103013	NCI CTEP SDC Breast Neoplasm, Miscellaneous Sub-Category Terminology|Breast Neoplasm, Miscellaneous|NCI CTEP Simple Disease Classification Breast Neoplasm, Miscellaneous Sub-Category Terminology	Breast Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103043>	C103010	NCI CTEP SDC Astrocytoma, Low Grade Sub-Category Terminology|Astrocytoma, Low Grade|NCI CTEP Simple Disease Classification Astrocytoma, Low Grade Sub-Category Terminology	Astrocytoma, Low Grade is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103044>	C103010	NCI CTEP SDC Choroid Plexus Tumors Sub-Category Terminology|Choroid Plexus Tumors|NCI CTEP Simple Disease Classification Choroid Plexus Tumors Sub-Category Terminology	Choroid Plexus Tumors is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103045>	C103010	NCI CTEP SDC CNS Neoplasm (Primary Tumor), Miscellaneous Sub-Category Terminology|CNS Neoplasm (Primary Tumor), Miscellaneous|NCI CTEP Simple Disease Classification CNS Neoplasm (Primary Tumor), Miscellaneous Sub-Category Terminology	CNS Neoplasm (Primary Tumor), Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103046>	C103010	NCI CTEP SDC Embryonal Tumors of the CNS Sub-Category Terminology|Embryonal Tumors of the CNS|NCI CTEP Simple Disease Classification Embryonal Tumors of the CNS Sub-Category Terminology	Embryonal Tumors of the CNS is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103047>	C103010	NCI CTEP SDC Ependymal Tumors Sub-Category Terminology|Ependymal Tumors|NCI CTEP Simple Disease Classification Ependymal Tumors Sub-Category Terminology	Ependymal Tumors is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103048>	C103010	NCI CTEP SDC Germ Cell Tumors of the CNS Sub-Category Terminology|Germ Cell Tumors of the CNS|NCI CTEP Simple Disease Classification Germ Cell Tumors of the CNS Sub-Category Terminology	Germ Cell Tumors of the CNS is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103049>	C103010	NCI CTEP SDC Meningeal Tumors Sub-Category Terminology|Meningeal Tumors|NCI CTEP Simple Disease Classification Meningeal Tumors Sub-Category Terminology	Meningeal Tumors is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C10304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10304>	C61063	Cisplatin/Tamoxifen|CDDP/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103050>	C103010	NCI CTEP SDC Oligodendroglial Tumors Sub-Category Terminology|NCI CTEP Simple Disease Classification Oligodendroglial Tumors Sub-Category Terminology|Oligodendroglial Tumors	Oligodendroglial Tumors is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103051>	C103010	NCI CTEP SDC Tumors of the Sellar Region Sub-Category Terminology|NCI CTEP Simple Disease Classification Tumors of the Sellar Region Sub-Category Terminology|Tumors of the Sellar Region	Tumors of the Sellar Region is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103052>	C103014	NCI CTEP SDC CNS-excluded Nervous System Neoplasm, Miscellaneous Sub-Category Terminology|CNS-excluded Nervous System Neoplasm, Miscellaneous|NCI CTEP Simple Disease Classification CNS-excluded Nervous System Neoplasm, Miscellaneous Sub-Category Terminology	CNS-excluded Nervous System Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103053>	C103014	NCI CTEP SDC Neuroblastoma Sub-Category Terminology|NCI CTEP Simple Disease Classification Neuroblastoma Sub-Category Terminology|Neuroblastoma	Neuroblastoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103054>	C103014	NCI CTEP SDC Neurofibromatosis Sub-Category Terminology|NCI CTEP Simple Disease Classification Neurofibromatosis Sub-Category Terminology|Neurofibromatosis	Neurofibromatosis is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103055>	C103015	NCI CTEP SDC Adrenal Cancer Sub-Category Terminology|Adrenal Cancer|NCI CTEP Simple Disease Classification Adrenal Cancer Sub-Category Terminology	Adrenal Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103056>	C103015	NCI CTEP SDC Endocrine Neoplasm, Miscellaneous Sub-Category Terminology|Endocrine Neoplasm, Miscellaneous|NCI CTEP Simple Disease Classification Endocrine Neoplasm, Miscellaneous Sub-Category Terminology	Endocrine Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103057>	C103015	NCI CTEP SDC Neuroendocrine Cancer Sub-Category Terminology|NCI CTEP Simple Disease Classification Neuroendocrine Cancer Sub-Category Terminology|Neuroendocrine Cancer	Neuroendocrine Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103058>	C103015	NCI CTEP SDC Parathyroid Cancer Sub-Category Terminology|NCI CTEP Simple Disease Classification Parathyroid Cancer Sub-Category Terminology|Parathyroid Cancer	Parathyroid Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103059>	C103015	NCI CTEP SDC Thyroid Cancer Sub-Category Terminology|NCI CTEP Simple Disease Classification Thyroid Cancer Sub-Category Terminology|Thyroid Cancer	Thyroid Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C10305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10305>	C61063	Eflornithine/Mitoguazone|DFMO/MGBG			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103060>	C103016	NCI CTEP SDC Malignant Eye Neoplasm, Miscellaneous Sub-Category Terminology|Malignant Eye Neoplasm, Miscellaneous|NCI CTEP Simple Disease Classification Malignant Eye Neoplasm, Miscellaneous Sub-Category Terminology	Malignant Eye Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103061>	C103016	NCI CTEP SDC Retinoblastoma Sub-Category Terminology|NCI CTEP Simple Disease Classification Retinoblastoma Sub-Category Terminology|Retinoblastoma	Retinoblastoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103062>	C103017	NCI CTEP SDC Anal Cancer Sub-Category Terminology|Anal Cancer|NCI CTEP Simple Disease Classification Anal Cancer Sub-Category Terminology	Anal Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103063>	C103017	NCI CTEP SDC Colorectal Cancer Sub-Category Terminology|Colorectal Cancer|NCI CTEP Simple Disease Classification Colorectal Cancer Sub-Category Terminology	Colorectal Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103064>	C103017	NCI CTEP SDC Gastroesophageal Cancer Sub-Category Terminology|Gastroesophageal Cancer|NCI CTEP Simple Disease Classification Gastroesophageal Cancer Sub-Category Terminology	Gastroesophageal Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103065>	C103017	NCI CTEP SDC Gastrointestinal Neoplasm, Miscellaneous Sub-Category Terminology|Gastrointestinal Neoplasm, Miscellaneous|NCI CTEP Simple Disease Classification Gastrointestinal Neoplasm, Miscellaneous Sub-Category Terminology	Gastrointestinal Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103066>	C103017	NCI CTEP SDC Liver and Hepatobiliary Cancer Sub-Category Terminology|Liver and Hepatobiliary Cancer|NCI CTEP Simple Disease Classification Liver and Hepatobiliary Cancer Sub-Category Terminology	Liver and Hepatobiliary Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103067>	C103017	NCI CTEP SDC Pancreatic Cancer (excluding Islets) Sub-Category Terminology|NCI CTEP Simple Disease Classification Pancreatic Cancer (excluding Islets) Sub-Category Terminology|Pancreatic Cancer (excluding Islets)	Pancreatic Cancer (excluding Islets) is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103068>	C103017	NCI CTEP SDC Small Intestine Cancer Sub-Category Terminology|NCI CTEP Simple Disease Classification Small Intestine Cancer Sub-Category Terminology|Small Intestine Cancer	Small Intestine Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103069>	C103018	NCI CTEP SDC Extragonadal Germ Cell Cancer (excluding Gestational Trophoblastic Disease and Germ Cell Tumors of the CNS) Sub-Category Terminology|Extragonadal Germ Cell Cancer (excluding Gestational Trophoblastic Disease and Germ Cell Tumors of the CNS)|NCI CTEP Simple Disease Classification Extragonadal Germ Cell Cancer (excluding Gestational Trophoblastic Disease and Germ Cell Tumors of the CNS) Sub-Category Terminology	Extragonadal Germ Cell Cancer (excluding Gestational Trophoblastic Disease and Germ Cell Tumors of the CNS) is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C10306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10306>	C61063	Asparaginase/Cytarabine/Mercaptopurine/Methotrexate/Prednisone/Teniposide|ARA-C/ASP/MP/MTX/PRED/VM-26			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103070>	C103018	NCI CTEP SDC Germ Cell Neoplasm, Miscellaneous Sub-Category Terminology|Germ Cell Neoplasm, Miscellaneous|NCI CTEP Simple Disease Classification Germ Cell Neoplasm, Miscellaneous Sub-Category Terminology	Germ Cell Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103071>	C103018	NCI CTEP SDC Ovarian Germ Cell Cancer Sub-Category Terminology|NCI CTEP Simple Disease Classification Ovarian Germ Cell Cancer Sub-Category Terminology|Ovarian Germ Cell Cancer	Ovarian Germ Cell Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103072>	C103018	NCI CTEP SDC Testicular Germ Cell Cancer Sub-Category Terminology|NCI CTEP Simple Disease Classification Testicular Germ Cell Cancer Sub-Category Terminology|Testicular Germ Cell Cancer	Testicular Germ Cell Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103073>	C103019	NCI CTEP SDC Head and Neck Neoplasm, Miscellaneous Sub-Category Terminology|Head and Neck Neoplasm, Miscellaneous|NCI CTEP Simple Disease Classification Head and Neck Neoplasm, Miscellaneous Sub-Category Terminology	Head and Neck Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103074>	C103019	NCI CTEP SDC Head and Neck Precancerous Condition Sub-Category Terminology|Head and Neck Precancerous Condition|NCI CTEP Simple Disease Classification Head and Neck Precancerous Condition Sub-Category Terminology	Head and Neck Precancerous Condition is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103075>	C103019	NCI CTEP SDC Head and Neck Squamous Cell Carcinoma Sub-Category Terminology|Head and Neck Squamous Cell Carcinoma|NCI CTEP Simple Disease Classification Head and Neck Squamous Cell Carcinoma Sub-Category Terminology	Head and Neck Squamous Cell Carcinoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103076>	C103019	NCI CTEP SDC Nasopharyngeal Cancer Sub-Category Terminology|NCI CTEP Simple Disease Classification Nasopharyngeal Cancer Sub-Category Terminology|Nasopharyngeal Cancer	Nasopharyngeal Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103077>	C103019	NCI CTEP SDC Salivary Gland Cancer Sub-Category Terminology|NCI CTEP Simple Disease Classification Salivary Gland Cancer Sub-Category Terminology|Salivary Gland Cancer	Salivary Gland Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103078>	C103020	NCI CTEP SDC Hematopoietic Neoplasm, Miscellaneous Sub-Category Terminology|Hematopoietic Neoplasm, Miscellaneous|NCI CTEP Simple Disease Classification Hematopoietic Neoplasm, Miscellaneous Sub-Category Terminology	Hematopoietic Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103079>	C103020	NCI CTEP SDC Mastocytosis Sub-Category Terminology|Mastocytosis|NCI CTEP Simple Disease Classification Mastocytosis Sub-Category Terminology	Mastocytosis is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C10307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10307>	C61063	Amiodarone/Vinblastine|Amiodarone/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103080>	C103021	NCI CTEP SDC Immune Disorder (excluding AIDS and malignancy), Miscellaneous Sub-Category Terminology|Immune Disorder (excluding AIDS and malignancy), Miscellaneous|NCI CTEP Simple Disease Classification Immune Disorder (excluding AIDS and malignancy), Miscellaneous Sub-Category Terminology	Immune Disorder (excluding AIDS and malignancy), Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103081>	C103021	NCI CTEP SDC Immunodeficiency and Immunosuppression Disorder Sub-Category Terminology|Immunodeficiency and Immunosuppression Disorder|NCI CTEP Simple Disease Classification Immunodeficiency and Immunosuppression Disorder Sub-Category Terminology	Immunodeficiency and Immunosuppression Disorder is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103082>	C103022	NCI CTEP SDC Clear Cell Sarcoma of the Kidney Sub-Category Terminology|Clear Cell Sarcoma of the Kidney|NCI CTEP Simple Disease Classification Clear Cell Sarcoma of the Kidney Sub-Category Terminology	Clear Cell Sarcoma of the Kidney is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103083>	C103022	NCI CTEP SDC Kidney Neoplasm, Miscellaneous Sub-Category Terminology|Kidney Neoplasm, Miscellaneous|NCI CTEP Simple Disease Classification Kidney Neoplasm, Miscellaneous Sub-Category Terminology	Kidney Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103084>	C103022	NCI CTEP SDC Renal Cell Carcinoma Sub-Category Terminology|NCI CTEP Simple Disease Classification Renal Cell Carcinoma Sub-Category Terminology|Renal Cell Carcinoma	Renal Cell Carcinoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103085>	C103022	NCI CTEP SDC Rhabdoid Tumor of the Kidney Sub-Category Terminology|NCI CTEP Simple Disease Classification Rhabdoid Tumor of the Kidney Sub-Category Terminology|Rhabdoid Tumor of the Kidney	Rhabdoid Tumor of the Kidney is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103086>	C103022	NCI CTEP SDC Wilms Tumor Sub-Category Terminology|NCI CTEP Simple Disease Classification Wilms Tumor Sub-Category Terminology|Wilms Tumor	Wilms Tumor is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103087>	C103023	NCI CTEP SDC Lung, Mediastinal and Pleural Neoplasm, Miscellaneous Sub-Category Terminology|Lung, Mediastinal and Pleural Neoplasm, Miscellaneous|NCI CTEP Simple Disease Classification Lung, Mediastinal and Pleural Neoplasm, Miscellaneous Sub-Category Terminology	Lung, Mediastinal and Pleural Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103088>	C103023	NCI CTEP SDC Mediastinal Cancer Sub-Category Terminology|Mediastinal Cancer|NCI CTEP Simple Disease Classification Mediastinal Cancer Sub-Category Terminology	Mediastinal Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103089>	C103023	NCI CTEP SDC Mesothelioma Sub-Category Terminology|Mesothelioma|NCI CTEP Simple Disease Classification Mesothelioma Sub-Category Terminology	Mesothelioma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C10308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10308>	C61063	Doxorubicin/Quinidine|DOX/QND			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103090>	C103023	NCI CTEP SDC Non-Small Cell Lung Cancer Sub-Category Terminology|NCI CTEP Simple Disease Classification Non-Small Cell Lung Cancer Sub-Category Terminology|Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103091>	C103023	NCI CTEP SDC Small Cell Lung Cancer Sub-Category Terminology|NCI CTEP Simple Disease Classification Small Cell Lung Cancer Sub-Category Terminology|Small Cell Lung Cancer	Small Cell Lung Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103092>	C103024	NCI CTEP SDC Carcinoma, Miscellaneous Sub-Category Terminology|Carcinoma, Miscellaneous|NCI CTEP Simple Disease Classification Carcinoma, Miscellaneous Sub-Category Terminology	Carcinoma, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103093>	C103024	NCI CTEP SDC Metastases, Distant (excluding specified site of origin) Sub-Category Terminology|Metastases, Distant (excluding specified site of origin)|NCI CTEP Simple Disease Classification Metastases, Distant (excluding specified site of origin) Sub-Category Terminology	Metastases, Distant (excluding specified site of origin) is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103094>	C103024	NCI CTEP SDC Miscellaneous Neoplasm Sub-Category Terminology|Miscellaneous Neoplasm|NCI CTEP Simple Disease Classification Miscellaneous Neoplasm Sub-Category Terminology	Miscellaneous Neoplasm is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103095>	C103024	NCI CTEP SDC Solid Tumor, Miscellaneous Sub-Category Terminology|NCI CTEP Simple Disease Classification Solid Tumor, Miscellaneous Sub-Category Terminology|Solid Tumor, Miscellaneous	Solid Tumor, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103096>	C103024	NCI CTEP SDC Vascular Tumor, Miscellaneous Sub-Category Terminology|NCI CTEP Simple Disease Classification Vascular Tumor, Miscellaneous Sub-Category Terminology|Vascular Tumor, Miscellaneous	Vascular Tumor, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103097>	C103025	NCI CTEP SDC Non-neoplastic Disorder, Miscellaneous Sub-Category Terminology|NCI CTEP Simple Disease Classification Non-neoplastic Disorder, Miscellaneous Sub-Category Terminology|Non-neoplastic Disorder, Miscellaneous	Non-neoplastic Disorder, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103098>	C103026	NCI CTEP SDC Cervical Cancer Sub-Category Terminology|Cervical Cancer|NCI CTEP Simple Disease Classification Cervical Cancer Sub-Category Terminology	Cervical Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103099>	C103026	NCI CTEP SDC Cervical Intraepithelial Neoplasia (CIN) Sub-Category Terminology|Cervical Intraepithelial Neoplasia (CIN)|NCI CTEP Simple Disease Classification Cervical Intraepithelial Neoplasia (CIN) Sub-Category Terminology	Cervical Intraepithelial Neoplasia (CIN) is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C10309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10309>	C61063	Quinidine/Vinblastine|QND/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1030>	C1556	Butocin|BUTOCIN|Benin|Butocine|N-(5-(6-purinylthio)valeryl)glycine ethyl ester|benin|benin spofa|butocine	A S-substituted analog of mercaptopurine and purine antagonist with cytostatic activity. Butocin inhibits purine nucleotide synthesis and DNA replication.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C103100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103100>	C103026	NCI CTEP SDC Female Reproductive System Neoplasm, Miscellaneous Sub-Category Terminology|Female Reproductive System Neoplasm, Miscellaneous|NCI CTEP Simple Disease Classification Female Reproductive System Neoplasm, Miscellaneous Sub-Category Terminology	Female Reproductive System Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103101>	C103026	NCI CTEP SDC Gestational Trophoblastic Disease Sub-Category Terminology|Gestational Trophoblastic Disease|NCI CTEP Simple Disease Classification Gestational Trophoblastic Disease Sub-Category Terminology	Gestational Trophoblastic Disease is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103102>	C103026	NCI CTEP SDC Ovarian Cancer (excluding Ovarian Germ Cell Cancer) Sub-Category Terminology|NCI CTEP Simple Disease Classification Ovarian Cancer (excluding Ovarian Germ Cell Cancer) Sub-Category Terminology|Ovarian Cancer (excluding Ovarian Germ Cell Cancer)	Ovarian Cancer (excluding Ovarian Germ Cell Cancer) is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103103>	C103026	NCI CTEP SDC Uterine Cancer Sub-Category Terminology|NCI CTEP Simple Disease Classification Uterine Cancer Sub-Category Terminology|Uterine Cancer	Uterine Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103104>	C103026	NCI CTEP SDC Vaginal Cancer Sub-Category Terminology|NCI CTEP Simple Disease Classification Vaginal Cancer Sub-Category Terminology|Vaginal Cancer	Vaginal Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103105>	C103026	NCI CTEP SDC Vaginal Intraepithelial Neoplasia (VIN) Sub-Category Terminology|NCI CTEP Simple Disease Classification Vaginal Intraepithelial Neoplasia (VIN) Sub-Category Terminology|Vaginal Intraepithelial Neoplasia (VIN)	Vaginal Intraepithelial Neoplasia (VIN) is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103106>	C103026	NCI CTEP SDC Vulvar Cancer Sub-Category Terminology|NCI CTEP Simple Disease Classification Vulvar Cancer Sub-Category Terminology|Vulvar Cancer	Vulvar Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103107>	C103027	NCI CTEP SDC Male Reproductive System Neoplasm, Miscellaneous Sub-Category Terminology|Male Reproductive System Neoplasm, Miscellaneous|NCI CTEP Simple Disease Classification Male Reproductive System Neoplasm, Miscellaneous Sub-Category Terminology	Male Reproductive System Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103108>	C103027	NCI CTEP SDC Penile Cancer Sub-Category Terminology|NCI CTEP Simple Disease Classification Penile Cancer Sub-Category Terminology|Penile Cancer	Penile Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103109>	C103027	NCI CTEP SDC Prostate Cancer Sub-Category Terminology|NCI CTEP Simple Disease Classification Prostate Cancer Sub-Category Terminology|Prostate Cancer	Prostate Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C10310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10310>	C61063	BCG/Fluorouracil|BCG/5-FU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103110>	C103027	NCI CTEP SDC Prostatic Intraepithelial Neoplasia (PIN) Sub-Category Terminology|NCI CTEP Simple Disease Classification Prostatic Intraepithelial Neoplasia (PIN) Sub-Category Terminology|Prostatic Intraepithelial Neoplasia (PIN)	Prostatic Intraepithelial Neoplasia (PIN) is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103111>	C103027	NCI CTEP SDC Testicular Cancer (excluding Testicular Germ Cell Cancer) Sub-Category Terminology|NCI CTEP Simple Disease Classification Testicular Cancer (excluding Testicular Germ Cell Cancer) Sub-Category Terminology|Testicular Cancer (excluding Testicular Germ Cell Cancer)	Testicular Cancer (excluding Testicular Germ Cell Cancer) is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103112>	C103028	NCI CTEP SDC Basal Cell Carcinoma Sub-Category Terminology|Basal Cell Carcinoma|NCI CTEP Simple Disease Classification Basal Cell Carcinoma Sub-Category Terminology	Basal Cell Carcinoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103113>	C103028	NCI CTEP SDC Melanoma Sub-Category Terminology|Melanoma|NCI CTEP Simple Disease Classification Melanoma Sub-Category Terminology	Melanoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103114>	C103028	NCI CTEP SDC Merkel Cell Tumor Sub-Category Terminology|Merkel Cell Tumor|NCI CTEP Simple Disease Classification Merkel Cell Tumor Sub-Category Terminology	Merkel Cell Tumor is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103115>	C103028	NCI CTEP SDC Skin Neoplasm, Miscellaneous Sub-Category Terminology|NCI CTEP Simple Disease Classification Skin Neoplasm, Miscellaneous Sub-Category Terminology|Skin Neoplasm, Miscellaneous	Skin Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103116>	C103028	NCI CTEP SDC Squamous Cell Carcinoma of the Skin Sub-Category Terminology|NCI CTEP Simple Disease Classification Squamous Cell Carcinoma of the Skin Sub-Category Terminology|Squamous Cell Carcinoma of the Skin	Squamous Cell Carcinoma of the Skin is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103117>	C103029	NCI CTEP SDC Non-Rhabdomyosarcoma Soft Tissue Sarcoma Sub-Category Terminology|NCI CTEP Simple Disease Classification Non-Rhabdomyosarcoma Soft Tissue Sarcoma Sub-Category Terminology|Non-Rhabdomyosarcoma Soft Tissue Sarcoma	Non-Rhabdomyosarcoma Soft Tissue Sarcoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103118>	C103029	NCI CTEP SDC Rhabdomyosarcoma Sub-Category Terminology|NCI CTEP Simple Disease Classification Rhabdomyosarcoma Sub-Category Terminology|Rhabdomyosarcoma	Rhabdomyosarcoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103119>	C103029	NCI CTEP SDC Soft Tissue Neoplasm, Miscellaneous Sub-Category Terminology|NCI CTEP Simple Disease Classification Soft Tissue Neoplasm, Miscellaneous Sub-Category Terminology|Soft Tissue Neoplasm, Miscellaneous	Soft Tissue Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C10311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10311>	C61063	Bropirimine/Tamoxifen|ABPP/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103120>	C102905	NCI CTEP SDC Hematopoietic Neoplasm/Lymphoma Category Terminology|Hematopoietic Neoplasm/Lymphoma|NCI CTEP Simplified Disease Classification Hematopoietic Neoplasm/Lymphoma Category Terminology	Hematopoietic Neoplasm/Lymphoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	
C103121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103121>	C102905	NCI CTEP SDC Hematopoietic Neoplasm/Leukemia Category Terminology|Hematopoietic Neoplasm/Leukemia|NCI CTEP Simple Disease Classification Hematopoietic Neoplasm/Leukemia Category Terminology	Hematopoietic Neoplasm/Leukemia is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103122>	C102905	NCI CTEP SDC Hematopoietic Neoplasm/Myeloma Category Terminology|Hematopoietic Neoplasm/Myeloma|NCI CTEP Simple Disease Classification Hematopoietic Neoplasm/Myeloma Category Terminology	Hematopoietic Neoplasm/Myeloma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103123>	C103121	NCI CTEP SDC Acute Lymphoblastic Leukemia Sub-Category Terminology|Acute Lymphoblastic Leukemia|NCI CTEP Simple Disease Classification Acute Lymphoblastic Leukemia Sub-Category Terminology	Acute Lymphoblastic Leukemia is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103124>	C103121	NCI CTEP SDC Acute Myeloid Leukemia Sub-Category Terminology|Acute Myeloid Leukemia|NCI CTEP Simple Disease Classification Acute Myeloid Leukemia Sub-Category Terminology	Acute Myeloid Leukemia is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103125>	C103121	NCI CTEP SDC Chronic Lymphoid Leukemia Sub-Category Terminology|Chronic Lymphoid Leukemia|NCI CTEP Simple Disease Classification Chronic Lymphoid Leukemia Sub-Category Terminology	Chronic Lymphoid Leukemia is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103126>	C103121	NCI CTEP SDC Chronic Myeloproliferative Disease Sub-Category Terminology|Chronic Myeloproliferative Disease|NCI CTEP Simple Disease Classification Chronic Myeloproliferative Disease Sub-Category Terminology	Chronic Myeloproliferative Disease is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103127>	C103121	NCI CTEP SDC Leukemia, Miscellaneous Sub-Category Terminology|Leukemia, Miscellaneous|NCI CTEP Simple Disease Classification Leukemia, Miscellaneous Sub-Category Terminology	Leukemia, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103128>	C103121	NCI CTEP SDC Myelodysplastic Syndrome Sub-Category Terminology|Myelodysplastic Syndrome|NCI CTEP Simple Disease Classification Myelodysplastic Syndrome Sub-Category Terminology	Myelodysplastic Syndrome is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103129>	C103121	NCI CTEP SDC Myelodysplastic/Myeloproliferative Disease Sub-Category Terminology|Myelodysplastic/Myeloproliferative Disease|NCI CTEP Simple Disease Classification Myelodysplastic/Myeloproliferative Disease Sub-Category Terminology	Myelodysplastic/Myeloproliferative Disease is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C10312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10312>	C61063	Acyclovir/Zidovudine|ACV/ZDV			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103130>	C103122	NCI CTEP SDC Myeloma Sub-Category Terminology|Myeloma|NCI CTEP Simple Disease Classification Myeloma Sub-Category Terminology	Myeloma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103131>	C103030	NCI CTEP SDC Urothelial Tract/Bladder Cancer Sub-Category Terminology|NCI CTEP Simple Disease Classification Urothelial Tract/Bladder Cancer Sub-Category Terminology|Urothelial Tract/Bladder Cancer	Urothelial Tract/Bladder Cancer is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103132>	C103030	NCI CTEP SDC Urothelial Tract/Bladder Neoplasm, Miscellaneous Sub-Category Terminology|NCI CTEP Simple Disease Classification Urothelial Tract/Bladder Neoplasm, Miscellaneous Sub-Category Terminology|Urothelial Tract/Bladder Neoplasm, Miscellaneous	Urothelial Tract/Bladder Neoplasm, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103133>	C103120	NCI CTEP SDC Non-Hodgkin Lymphoma Sub-Category Terminology|NCI CTEP Simple Disease Classification Non-Hodgkin Lymphoma Sub-Category Terminology|Non-Hodgkin Lymphoma	Non-Hodgkin Lymphoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103134>	C103120	NCI CTEP SDC B-Cell Proliferations of Uncertain Malignant Potential Sub-Category Terminology|B-Cell Proliferations of Uncertain Malignant Potential|NCI CTEP Simple Disease Classification B-Cell Proliferations of Uncertain Malignant Potential Sub-Category Terminology	B-Cell Proliferations of Uncertain Malignant Potential is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103135>	C103120	NCI CTEP SDC Hodgkin Lymphoma Sub-Category Terminology|Hodgkin Lymphoma|NCI CTEP Simple Disease Classification Hodgkin Lymphoma Sub-Category Terminology	Hodgkin Lymphoma is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103136>	C103120	NCI CTEP SDC Lymphoma, Miscellaneous Sub-Category Terminology|Lymphoma, Miscellaneous|NCI CTEP Simple Disease Classification Lymphoma, Miscellaneous Sub-Category Terminology	Lymphoma, Miscellaneous is an NCI Cancer Therapeutic Evaluation Program (CTEP) Simplified Disease Classification (SDC) category used to organize cancer-related disease coding that harmonizes with and supports reporting based on the global standard Medical Dictionary for Drug Regulatory Reporting (MedDRA) terminology.			Intellectual Product	NCI CTEP Simplified Disease Classification Terminology
C103137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103137>	C27993	Anaerobic	A chemical process that does not require oxygen or occurs in the absence of oxygen.			Qualitative Concept	
C103138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103138>	C20047	NIH Consensus Response Criteria for Chronic GVHD|NIH Chronic GVHD Consensus Project Response Criteria|NIH Consensus Response Criteria for cGVHD|NIH cGVHD Consensus Project Response Criteria	A tool used to assess response to therapy for chronic Graft versus Host Disease (cGVHD) based on clinical trial findings and recommended by the NIH Chronic Graft-versus-Host Disease Consensus Response Criteria Working Group. The criteria were established in 2005 (Biol Blood Marrow Transplant, 12 (2006), pp. 252-266) and revised in 2014 (Biol Blood Marrow Transplant, 21 (2015), pp. 984-999).			Clinical Attribute	
C103139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103139>	C126699	Complete Response in cGVHD|Complete Response in chronic Graft vs Host Disease	Complete resolution of all signs and symptoms in all affected organs or tissues in chronic Graft versus Host Disease (cGVHD).			Finding	
C10313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10313>	C61007	Cyclophosphamide/Vincristine|CTX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103140>	C126713	Partial Response in cGVHD|Partial Response in chronic Graft vs Host Disease	Improvement in one or more organ or tissue without progression in other affected organs or tissue in chronic Graft versus Host Disease (cGVHD).			Finding	
C103141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103141>	C151961	Less Than Partial Response in cGVHD|Less Than Partial Response in chronic Graft vs Host Disease	Change towards improvement from the pretreatment baseline, but not meeting the criteria for Complete Response or Partial Response in chronic Graft versus Host Disease (cGVHD).			Finding	
C103142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103142>	C18213	Stable cGVHD|Stable Disease|Stable chronic Graft vs Host Disease	No change in chronic Graft versus Host Disease (cGVHD) progression during the preceding 3 months.			Finding	
C103143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103143>	C54095	Exacerbation of cGVHD|Exacerbation of chronic Graft vs Host Disease|Flare	A worsening of chronic Graft versus Host Disease (cGVHD) manifestations during withdrawal of immunosuppressive therapy which does not exceed those at the beginning of the trial and improves after reinstatement of previous treatment.			Finding	
C103144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103144>	C28193	Perlman Syndrome|Renal Hamartomas, Nephroblastomatosis and Fetal Gigantism	A rare, autosomal recessive syndrome characterized by the presence of polyhydramnios, neonatal macrosomia, craniofacial abnormalities, nephroblastomatosis, and predisposition to Wilms tumor.  The prognosis is poor.			Disease or Syndrome	CCPS Disease Terminology|Cellosaurus Disease Terminology|Childhood Cancer Predisposition Study Terminology
C103145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103145>	C35571	Progressive cGVHD|Progressive Disease|Progressive chronic Graft vs Host Disease	Failure of therapy to control chronic Graft versus Host Disease (cGVHD).			Finding	
C103146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103146>	C165202	Mixed Response in cGVHD|Mixed Response in chronic Graft vs Host Disease	Improvement in some organs, but worsening in others in chronic Graft versus Host Disease (cGVHD); this is categorized as progressive disease.			Finding	
C103147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103147>	C159200	Venetoclax|4-(4-((2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide|ABT 199|ABT-0199|ABT-199|ABT199|GDC 0199|GDC-0199|GDC0199|RG7601|VENETOCLAX|Venclexta|Venclyxto	An orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. Venetoclax mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of Bcl-2 proteins thereby repressing Bcl-2 activity and restoring apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in some cancers and plays an important role in the regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival. Compared to the Bcl-2 inhibitor navitoclax, this agent does not inhibit bcl-XL and does not cause bcl-XL-mediated thrombocytopenia.	Venetoclax		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103149>	C73539	S-Adenosylhomocysteine|(S)-5'-(S)-(3-Amino-3-carboxypropyl)-5'-thioadenosine|AdoHCy|S-ADENOSYL-L-HOMOCYSTEINE|S-Adenosyl-L-homocysteine|SAH	An amino acid derivative and an intermediate in the synthesis of cysteine and adenosine. S-adenosylhomocysteine (SAH) is formed upon S-adenosylmethionine (SAM)-dependent methylation (homocysteine methionine cycle) of biological molecules, such as DNA, RNA, and proteins. It is then hydrolyzed by S-adenosylhomocysteine hydrolase to form adenosine and homocysteine. As SAH modulates methylation dependent reactions, SAH levels and the ratio of SAH:SAM may be used to assess methylation status of macrocolecules.			Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C10314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10314>	C61007	Dactinomycin/Vincristine|DACT/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103150>	C73539	3-Chlorotyrosine|3-CHLOROTYROSINE|3-Chloro-L-Tyrosine|Chlorotyrosine|Cl-Tyr|L-(8CI)-3-Chloro-Tyrosine|Monochlorotyrosine	A specific biomarker of hypochlorous acid (HClO), the oxidation product of myeloperoxidase (MPO). Under oxidative stress, 3-chlorotyrosine is produced in proteins with tyrosine residues by the strong oxidant HClO. HClO which is formed at sites of inflammation is also the anti-bacterial molecule produced by neutrophils through MPO-catalyzed oxidation. MPO is a heme-containing enzyme secreted by activated neutrophils and monocytes; it is the only enzyme that produces HClO. Therefore, 3-chlorotyrosine can potentially be used to help determine the extent of neutrophilic inflammation.			Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C103152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103152>	C38155	Hematopoietic Cell Transplant Relapse	Recurrence of malignancy following hematopoietic cell transplantation, based on one or more of the following parameters: marrow morphology, flow cytometry, cytogenetic studies, including fluorescence in situ hybridization, electrophoresis, immunofixation assays, and polymerase chain reaction-based assays for disease markers, or imaging results.			Finding	
C103153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103153>	C25636	Hematopoietic Cell Transplant Relapse Low Risk Rate	Risk of hematopoietic cell transplant relapse rates per patient year with p value between 0.00 and 0.24.			Conceptual Entity	
C103154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103154>	C25636	Hematopoietic Cell Transplant Relapse Standard Risk Rate	Risk of hematopoietic cell transplant relapse rates per patient year with p value between 0.26 and 0.37.			Conceptual Entity	
C103155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103155>	C25636	Hematopoietic Cell Transplant Relapse High Risk Rate	Risk of hematopoietic cell transplant relapse rates per patient year with p value higher than 0.52.			Conceptual Entity	
C103156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103156>	C99016	Congenital Phrenic Nerve Injury|Phrenic Nerve Injury, Congenital	Damage to the phrenic nerve that is present at birth.			Finding	Neonatal Research Network Terminology|NICHD Terminology|Perinatal Terminology
C103157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103157>	C101330	Cardiac Compression during Initial Resuscitation	An emergency measure on newborns, which requires assistance to begin breathing at birth. Initial resuscitation includes administration of positive-pressure ventilation and chest compressions to empty the ventricles of the heart in an effort to circulate the blood, and also to stimulate the heart so that it will resume its pumping action.			Therapeutic or Preventive Procedure	Neonatal Research Network Terminology|NICHD Terminology
C103158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103158>	C25209	Bioassay Measurement	The act of measuring or estimating a quantity resulting from a laboratory test or analysis of the biological activity of a substance performed by studying its effect on an organism or in a test tube under controlled conditions.			Quantitative Concept	
C103159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103159>	C45261	Data Collection|data collection	The act or process of gathering data for testing or research purposes.	Data Collection		Idea or Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C10315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10315>	C61007	Dactinomycin/Doxorubicin/Vincristine|DACT/DOX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103160>	C25638	Subject Exclusion Reason	The explanation given as to why a subject was prevented from being allowed to participate in a study.			Idea or Concept	
C103161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103161>	C15697	Planned Treatment Regimen	The intended treatment plan that specifies the dosage, the schedule, and the duration of treatment.			Functional Concept	
C103162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103162>	C25198	Related Record	A piece of data that is related to another piece of data.			Intellectual Product	
C103163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103163>	C82552	Study Treatment Causality	The principle that a relationship exists between a study treatment (cause) and the occurrence of an event (effect).			Idea or Concept	
C103164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103164>	C199140	Subject Pool	The total group of study subjects that may participate in a study.			Group	
C103165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103165>	C25284	Subject Visit Type	The kind of visit undertaken by the subject within a study, such as inpatient, outpatient, telephone, etc.			Qualitative Concept	
C103166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103166>	C13442	Anatomical Portion or Totality|PORTOT	An anatomical qualifier that describes the arrangement or apportioning of an entity within a body part, region or organ.			Organism Attribute	CDISC Root Variable Terminology
C103167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103167>	C42703	Data Origin	The primary point where the data was generated or collected.			Idea or Concept	
C103168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103168>	C103175	FDA Toxicity Measure Type Terminology	Terminology codelist used to describe the kind of scale used to measure the toxicity of a substance.			Intellectual Product	
C103169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103169>	C103175	FDA Act Type Terminology	Terminology codelist used to describe the principal observations for human clinical and non-human non-clinical studies for the FDA CDA guide.			Intellectual Product	
C10316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10316>	C61007	Amifostine/Cisplatin|CDDP/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103170>	C35046	Postnatal Drug Withdrawal	Withdrawal signs and symptoms that present during the postnatal period and are caused by drug use by the pregnant mother.			Mental or Behavioral Dysfunction	Neonatal Research Network Terminology|NICHD Terminology
C103171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103171>	C27073	Recurrent Laryngeal Nerve Injury	Damage to the recurrent laryngeal nerve.			Finding	Neonatal Research Network Terminology|NICHD Terminology
C103172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103172>	C2902|C104003	Congenital Bleeding Disorder|Congenital Bleeding Defect|Congenital Coagulation Defect	A bleeding disorder that is diagnosed during childhood, with the presenting symptom of excessive bleeding.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C103173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103173>	C201615	Age at Time of Vaccination|Age at Vaccination|Age at the Time of Vaccination	The age of the subject at the time of the vaccination.			Organism Attribute	FDA Individual Case Safety Report Terminology|Observation ICSR Terminology
C103174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103174>	C45513	Equipment Qualification	The process by which a piece of equipment is verified that it performs according to its specifications.			Activity	
C103175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103175>	C54443	Unused Subset Concept	A terminology codelist concept that is not currently in use.			Intellectual Product	
C103176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103176>	C25404	Requalification	The action of repeating the qualification or reconfirming that a person, process, product or piece of equipment is suitable for a particular postition or task.			Activity	
C103177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103177>	C1931|C129839	Beta-elemene|(1S,2S,4R)-2,4-diisopropenyl-1-methyl-1-vinylcyclohexane|(1alpha,2beta,4beta)-1-Methyl-2,4-bis(methylvinyl)-1- vinylcyclohexane	One of the isomers of elemene, a lipid soluble sesquiterpene and the active component isolated from the Chinese medicinal herb Rhizoma zedoariae with potential antineoplastic and chemopreventive activities. Although the exact mechanism of action through which beta-elemene exerts its effect has yet to be fully elucidated, this agent appears to induce apoptosis through different mechanisms of action and induces cell cycle arrest at different stages based on the tumor cell type involved. Beta-elemene may sensitize cancer cells to other chemotherapeutic agents.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103178>	C1505	Modified Citrus Pectin Supplement|PectaSol-C	A dietary supplement containing the modified citrus pectin (MCP) derived from the soluble fiber of citrus fruit peels and a galectin-3 inhibitor with potential antioxidant, hypocholesterolemic, immunostimulatory, metal chelating, and anti-metastatic activities. MCP is a low molecular weight version of pectin composed of short, slightly-branched carbohydrate chains and is modified for enhanced absorbability. The bioactive fragments, most likely the galactan-containing portion, of pectin binds to galectin-3, a carbohydrate-binding protein involved in imflammation, heart disease and is upregulated on the surface of certain types of tumor cells. Binding of MCP may result in the suppression of cancer cell aggregation, adhesion, proliferation and metastasis. In addition, MCP decreases prostate specific antigen (PSA) levels and may remove heavy metals. Also, unsaturated oligogalacturonic acids in MCP may stimulate the immune system through the activation of natural killer cells, cytotoxic T-cells, and B-cells.			Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103179>	C471	Pinometostat|DOT1L Inhibitor EPZ-5676|EPZ-5676|PINOMETOSTAT	A small molecule inhibitor of histone methyltransferase with potential antineoplastic activity. Upon intravenous administration, pinometostat specifically blocks the activity of the histone lysine-methyltransferase DOT1L, thereby inhibiting the methylation of nucleosomal histone H3 on lysine 79 (H3K79) that is bound to the mixed lineage leukemia (MLL) fusion protein which targets genes and blocks the expression of leukemogenic genes. This eventually leads to an induction of apoptosis in the leukemic cells bearing the MLL gene translocations. DOT1L, a non-SET domain-containing histone methyltransferase, specifically methylates H3K79 and plays a key role in normal cell differentiation and in the development of leukemia with MLL gene rearrangement on chromosome 11 and promotes the expression of leukemia-causing genes.	Pinometostat		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C10317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10317>	C61063	Lomustine/Mitoxantrone/Vinblastine|CCNU/DHAD/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103180>	C81893	Data Standard|data standards	A statement that defines conventions, guidelines, characteristics or methods for consistent data handling to facilitate exchange or processing of the data. This set of criteria are reviewed by and agreed upon by the user community or a governing body before they are released and adopted for use.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA-NIH Modernizing Research and Evidence Glossary Terminology
C103181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103181>	C226455	Soy Lecithin/Glycerol Dioleate-based Oral Spray|Episil	An oral spray containing soy phospholipid and glycerol dioleate, with protective, analgesic and anti-mucositic activities. Upon spraying onto the oral mucosal surface and contact with saliva, the soy lecithin/glycerol dioleate-based oral spray forms a gel and adheres to the mucosal surfaces thereby forming a lipid film. This provides a protective barrier and an analgesic effect within the oral cavity. In addition, the lipid barrier prevents bacterial growth at affected areas thereby decreasing infection risk.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C103182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103182>	C62289	CDISC Domain|Clinical Data Interchange Standards Consortium Domain	A collection of data variables or metadata for use with a Clinical Data Interchange Standards Consortium (CDISC) data submission. Representative examples include Laboratory (LB), Subject Characteristics (SC), and Trial Summary (TS).			Functional Concept	
C103183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103183>	C35046	In Utero Drug Withdrawal|In-utero Drug Withdrawal	Drug withdrawal symptoms in a fetus following maternal discontinuation or reduction of use of one or more addictive substance(s) that have caused fetal physiological dependence.			Mental or Behavioral Dysfunction	Neonatal Research Network Terminology|NICHD Terminology
C103184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103184>	C78488	Genu Recurvatum|Hyperextension Deformity of Knee|Hyperextension of Knee Deformity	An abnormal alignment of the knee backwards that is due to a deformity in the knee joint.			Congenital Abnormality|Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C103185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103185>	C35107|C27613	Congenital Reproductive System Abnormality|Congenital Abnormality of the Reproductive System	A disorder that affects the female or male reproductive system and is present at birth. Representative examples include ovarian agenesis, vaginal agenesis, and penile agenesis.			Congenital Abnormality	Neonatal Research Network Terminology|NICHD Terminology
C103186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103186>	C103185	Sexual Differentiation Disorder|CARD|Conditions Affecting Reproductive Development|DSD|Differences of Sex Development|Disorder of Sexual Differentiation|Disorders of Sex Development|Intersex|Intersex Conditions	A congenital disorder characterized by abnormalities in the development of the sexual characteristics.			Congenital Abnormality	Cellosaurus Disease Terminology|Neonatal Research Network Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C103187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103187>	C99065|C101324	Perinatal Subependymal Hemorrhage with Intraventricular and Intracerebral Extension	A hemorrhage that involves the subependymal region, the lateral cerebral ventricles and the brain tissue occurring around the time of birth.			Finding	Neonatal Research Network Terminology|NICHD Terminology|Perinatal Terminology
C103188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103188>	C99016	Acquired Phrenic Nerve Injury|Phrenic Nerve Injury, Acquired	Damage to the phrenic nerve that was not present at birth.			Finding	Neonatal Research Network Terminology|NICHD Terminology|Perinatal Terminology
C103189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103189>	C99017	Acquired Phrenic Nerve Palsy	Damage to the phrenic nerve that results in paralysis of the hemidiaphragm and was not present at birth.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology|Perinatal Terminology
C10318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10318>	C61063	Dexamethasone/Metoclopramide/Midazolam|DM/MCP/Midazolam			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103190>	C27165	Perinatal Respiratory Distress	A pathological increase in the effort and frequency or breathing movements during the perinatal period.			Sign or Symptom	Neonatal Research Network Terminology|NICHD Terminology
C103191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103191>	C98909	Perinatal Cyanotic Attack	Episodes of cyanosis during the perinatal period.			Finding	Neonatal Research Network Terminology|NICHD Terminology
C103192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103192>	C28310	Plasmacytoid Dendritic Cell Vaccine|pDC Vaccine	A whole cell vaccine derived from a distinct subset of dendritic cells (DCs) with a plasma cell-like morphology that exhibits immunomodulating activity. Plasmacytoid dendritic cells (pDCs) express a characteristic set of surface markers, such as CD123 (interleukin-3 receptor alpha chain), BDCA-2 (blood dendritic cell antigen 2; CD303) and BDCA-4 (CD304), as well as intracellular toll-like receptors 7 and 9. Upon stimulation, the activated pDCs produce substantial amounts of interferon (IFN) alpha, and to a lesser degree IFN-beta, as well as other cytokines and chemokines, such as tumor necrosis factor alpha and interleukins 1, 6 and 8. In addition, these pDCs, directly or indirectly stimulate T-cells, B-cells and natural killer cells. This may potentially lead to increased immunity against tumor cells.			Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103193>	C1742|C129821	Tumor-Cells Apoptosis Factor Hormone-Peptide|NEROFE|Nerofe	A synthetic 14-amino acid peptide derived from a novel human peptide hormone, Tumor-Cells Apoptosis Factor (TCApF), with potential antineoplastic activity. Upon intravenous administration, tumor-cells apoptosis factor hormone-peptide binds to the T1/ST2 receptor (IL1RL1) and activates both caspase 8 and Bcl-2 mediated apoptosis, in addition to the activation of p38 MAPK and JNK signaling cascades in tumor cells. Furthermore, this agent inhibits angiogenesis by suppressing the expressions of vascular endothelial growth factor A (VEGFA) and fms-related tyrosine kinase 1 (VEGFR1).  Tumor-cells apoptosis factor hormone-peptide also modulates immune system responses via increasing the expressions of interleukin-10 and anti-angiogenic interleukin. T1/ST2 receptor, a member of the toll/interleukin-1 receptor superfamily, is overexpressed in certain cancer cells.	Tumor-Cells Apoptosis Factor Hormone-Peptide		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103194>	C128057	Durvalumab|DURVALUMAB|Imfinzi|Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer|MEDI 4736|MEDI-4736|MEDI4736	A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types.	Durvalumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103195>	C547	Lexaptepid Pegol|LEXAPTEPID PEGOL|NOX-H94	A proprietary 44-nucleotide L-stereoisomer RNA oligonucleotide conjugated to a 40 kDa polyethylene glycol (PEG) that targets hepcidin with potential anti-anemic activity. Upon intravenous or subcutaneous administration, lexaptepid pegol binds to hepcidin and prevents it from binding to the iron channel ferroportin, located on the basolateral surface of gastrointestinal enterocytes and the plasma membrane of macrophages. This prevents hepcidin-induced internalization and degradation of ferroportin, thus decreasing macrophage iron retention. In turn, binding of NOX-H94 to hepcidin normalizes plasma iron levels and increases erythropoiesis. This may inhibit anemia caused by inflammation. Hepcidin, a peptide hormone that plays a key role in the homeostasis of systemic iron, is upregulated during acute and chronic inflammation in response to cytokines. The unique mirror-image configuration of this agent renders it resistant to hydrolysis and shows a low antigenicity profile. Pegylation increases the half-life of this agent.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C103196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103196>	C2124	Fluorine F 18 4-L-fluoroglutamine (2S,4R)|18F Fluoroglutamine|[18F] 4-L-fluoroglutamine (2S,4R)	A radioconjugate and glutamine analog consisting of the fluorine F 18 labeled 2S, 4R stereoisomer of 4-fluoroglutamine with potential use as a metabolic tracer for tumor imaging. Upon intravenous administration, fluorine F 18 4-L-fluoroglutamine (2S,4R) is preferentially taken up by cancer cells, possibly driven by c-Myc upregulation. Upon positron emission tomography (PET), cancer cells can be imaged. Tumor cells use the amino acid glutamine for nutritional purposes necessary for energy production and growth; as tumor cells proliferate more rapidly than normal healthy cells, glutamine uptake is higher in certain cancer cells.	Fluorine F 18 4-L-fluoroglutamine (2S,4R)		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C103198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103198>	C45305	Racemate|RACEMIC|Racemic	An equimolar mixture of two enantiomers. A racemate is optically inactive.			Substance	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C103199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103199>	C158425|C13442	Organism Part|ORGANISM PART	A portion of an organism.			Qualitative Concept	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C10319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10319>	C61063	Cisplatin/Cyclophosphamide/10-EdAM|CDDP/CTX/EDAM|Cisplatin/Cyclophosphamide/Edatrexate			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1031>	C511|C2153	Piritrexim|2,4-Diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine|6-((2,5-Dimethoxyphenyl)methyl)-5-methylpyrido(2,3-d)pyrimidine-2,4-diamine|6-[(2,5-Dimethoxyphenyl)methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine|BW 301U|BW-301U|PIRITREXIM|piritrexim	A synthetic antifolate agent with antiparasitic, antipsoriatic and antitumor properties. Piritrexim inhibits the enzyme dihydrofolate reductase enzyme, thereby disrupting folate metabolism and DNA synthesis and cell division. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103200>	C225418|C171083	Organism Part Location|ORGANISM PART LOCATION	Anatomical placement of a particular portion of an organism.			Qualitative Concept	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C103201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103201>	C176811	Optical Rotation|OPTICAL ACTIVITY|Optical Activity	The ability of a chiral substance to rotate the plane of polarization of a beam of transmitted plane-polarized light, either clockwise (to the right) or counterclockwise (to the left).			Phenomenon or Process	FDA Structured Product Labeling Terminology|PQ/CMC Test Category Terminology|SPL Substance Indexing Terminology
C103202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103202>	C103201	Dextrorotatory|(+)|DEXTROROTATORY	The ability of an optically active substance to rotate the plane of polarized light clockwise (to the right).			Phenomenon or Process	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C103203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103203>	C103201	Levorotatory|(-)|LEVOROTATORY	The ability of an optically active substance to rotate the plane of polarized light counterclockwise (to the left).			Phenomenon or Process	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C103204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103204>	C103201	Nonrotatory|(+/-)|NONROTATORY	The inability of a substance to rotate the plane of polarized light.			Phenomenon or Process	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C103205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103205>	C45306	Chemical Substance Excluding Protein or Nucleic Acid|CHEMICAL SUBSTANCE	A type of substance that may be described as a stoichiometric or non-stoichiometric single molecular entity and is not a protein or nucleic acid substance.			Substance	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C103206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103206>	C45306	Structurally Diverse Substance|STRUCTURALLY DIVERSE SUBSTANCE	A type of polydisperse substance isolated from a single source that is a complex mixture which cannot be described as a limited set of single substance.			Substance	FDA Structured Product Labeling Terminology|PQ/CMC Substance Classification Terminology|SPL Substance Indexing Terminology
C103207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103207>	C41186|C17771	Chiral|CHIRAL|Chirality|enantiomer	An object or molecule that is not superimposable on its mirror image. The classic description of chirality is the comparison of the hand in a mirror, because the mirror image is the opposite. A chiral molecule has one or more chiral centers.			Phenomenon or Process	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C103208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103208>	C41186|C17771	Achiral|ACHIRAL|Achirality	An object or molecule that is superimposable on its mirror image. The classic description of achirality is the comparison of the glass of water in a mirror, because the mirror image is identical. An achiral molecule has no chiral centers.			Conceptual Entity	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C103209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103209>	C176811	Epimeric|EPIMERIC|Epimer	A particular kind of diastereoisomers that differ in their stereochemistry at only one chiral center; the stereochemistry at all other chiral centers is identical.			Conceptual Entity	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C10320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10320>	C61063	Bleomycin/Cyclophosphamide/Dexamethasone/Doxorubicin/Methotrexate/Sargramostim/Vincristine|BLEO/CTX/DM/DOX/GM-CSF/MTX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103210>	C41186|C17771	Meso Compound|MESO	An achiral member of a set of diastereoisomers that is not optically active while the other isomers within the set are optically active.			Conceptual Entity	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C103211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103211>	C45788	Square Planar 1 Molecular Geometry|SP-4-1|SQUARE PLANAR 1|Square Planar 1	Square planar molecular geometry where the Cahn-Ingold-Prelog (CIP) priority of the donor atom directly across from the priority 1 donor atom is also 1.			Spatial Concept	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C103212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103212>	C45788	Square Planar 2 Molecular Geometry|SP-4-2|SQUARE PLANAR 2|Square Planar 2	Square planar molecular geometry where the Cahn-Ingold-Prelog (CIP) priority of the donor atom directly across from the priority 1 donor atom is 2.			Spatial Concept	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C103213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103213>	C45788	Square Planar 3 Molecular Geometry|SP-4-3|SQUARE PLANAR 3|Square Planar 3	Square planar molecular geometry where the Cahn-Ingold-Prelog (CIP) priority of the donor atom directly across from the priority 1 donor atom is 3.			Spatial Concept	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C103214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103214>	C45788	Square Planar 4 Molecular Geometry|SP-4-4|SQUARE PLANAR 4|Square Planar 4	Square planar molecular geometry where the Cahn-Ingold-Prelog (CIP) priority of the donor atom directly across from the priority 1 donor atom is 4.			Spatial Concept	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C103215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103215>	C45788	Tetrahedral Molecular Geometry|T-4|TETRAHEDRAL	A molecule in which the central atom is bound to four atoms that form the vertices of a tetrahedron.			Spatial Concept	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C103216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103216>	C45788	Octahedral 12 Molecular Geometry|OC-6-12|OCTAHEDRAL 12|trans-octahedral	Octahedral molecular geometry where the Cahn-Ingold-Prelog (CIP) priority of the lowest priority donor atom directly across from (trans to) a priority 1 donor atom is also 1 and the priority of the donor atom across from (trans to) the highest priority atom in the plane perpendicular to this reference axis is 2.			Spatial Concept	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C103217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103217>	C45788	Octahedral 22 Molecular Geometry|OC-6-22|OCTAHEDRAL 22|mer-octahedral	Octahedral molecular geometry where the Cahn-Ingold-Prelog (CIP) priority of the lowest priority donor atom directly across from (trans to) a priority 1 donor atom is 2 and the priority of the donor atom across from (trans to) the highest priority atom in the plane perpendicular to this reference axis is 2.			Spatial Concept	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C103218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103218>	C45788	Octahedral 21 Molecular Geometry|OC-6-21|OCTAHEDRAL 21|cis-octahedral|fac-octahedral	Octahedral molecular geometry where the Cahn-Ingold-Prelog (CIP) priority of the lowest priority donor atom directly across from (trans to) a priority 1 donor atom is 2 and the priority of the donor atom across from (trans to) the highest priority atom in the plane perpendicular to this reference axis is 1.			Spatial Concept	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C103219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103219>	C25161	Cahn-Ingold-Prelog Priority System|CAHN-INGOLD-PRELOG PRIORITY SYSTEM|CIP System|CIP System|Cahn-Ingold-Prelog Priority Rules	Rules created by Robert Sidney Cahn, Christopher Kelk Ingold and Vladimir Prelog to name stereoisomers in organic chemistry.			Classification	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C10321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10321>	C61063	Cyclophosphamide/Doxorubicin/Sargramostim|CTX/DOX/GM-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103220>	C45788	Axial R|AXIAL R|DELTA|P|Ra	Chirality axis based stereochemistry where, using the Cahn-Ingold-Prelog (CIP) priority rules, the priorities (from highest to lowest) of the substituent atoms exist in a clockwise direction.			Spatial Concept	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C103221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103221>	C45788	Axial S|AXIAL S|LAMBDA|M|Sa	Chirality axis based stereochemistry where, using the Cahn-Ingold-Prelog (CIP) priority rules, the priorities (from highest to lowest) of the substituent atoms exist in a counterclockwise direction.			Spatial Concept	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C103222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103222>	C34007	Popliteal Fossa|POPLITEAL FOSSA|Popliteal Fossa Structure|popliteal area|popliteal fossa	A diamond-shaped depression located in the back of the knee joint.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|UBERON Terminology
C103223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103223>	C36292	Genetic Finding	A laboratory test result that indicates the status of a molecular genetic or cytogenetic event in a pathologic process.			Laboratory or Test Result	
C103224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103224>	C29578	Bamipine Dihydrochloride|BAMIPINE DIHYDROCHLORIDE|Piperidine, 4-(N-benzyl-N-phenylamino)-1-methyl-, Dihydrochloride				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C103225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103225>	C36184	Ischemic Necrosis|Geographic (ischemic)	Loss of vascularization and tissue death caused by the disruption in the arterial access. Common causes include trauma due to accidents, insect or reptile bites, severe cold exposure or pathological conditions such as infarctions or blood dyscrasias.			Finding	CRF7 Pathology Review Table|Neonatal Research Network Terminology|NICHD Terminology
C103226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103226>	C98882	Pulmonary Trunk Hypoplasia	Underdeveloped pulmonary arteries.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C103227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103227>	C45306	Protein/Peptide Substance|PROTEIN/PEPTIDE SUBSTANCE	A substance that may be described as a discrete sequence of alpha-amino-acids connected through peptide bonds.			Substance	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C103228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103228>	C3143	Perinatal Jaundice Related to Inspissated Bile Syndrome|Perinatal Jaundice due to Inspissated Bile Syndrome|Perinatal Jaundice due to Inspissated Bile Syndrome	Yellow pigmentation of the skin, mucous membranes and eyes due to hyperbilirubinemia caused by inspissated bile plugs in the bile ducts during the perinatal period.			Finding	Neonatal Research Network Terminology|NICHD Terminology|Perinatal Terminology
C103229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103229>	C17155	Photoacoustic Spectroscopy|Photoacoustic	The technique of measuring the effect of absorbed electromagnetic energy on solids, liquids and gases through detection of the acoustic waves released from the absorbing material.			Laboratory Procedure	
C10322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10322>	C61063	Carmustine/Cyclophosphamide/Etoposide/Filgrastim|BCNU/CTX/G-CSF/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103230>	C1931	Phellodendron amurense Bark Extract|Nexrutine|PHELLODENDRON AMURENSE BARK	A proprietary formulation consisting of a Phellodendron amurense (Amur cork tree) bark extract, often used in traditional Chinese medicine, with anti-inflammatory, anti-oxidant and potential chemopreventive and antineoplastic activities. Phellodendron amurense bark extract contains certain isoquinoline alkaloids, flavone glycosides and phenolic compounds. Upon administration of Phellodendron amurense bark extract, the various phytochemicals in this formulation modulate multiple signal transduction pathways. This agent appears to block the activation of the transcription factor cAMP response binding protein (CREB) and inhibits Akt signaling, thereby inhibiting tumor cell growth and inducing apoptosis in Akt- and CREB-overexpressing cancer cells. In addition, this agent inhibits cyclooxygenase type 2 (COX-2), nuclear factor kappa b (NF-kB) and tumor necrosis factor alpha (TNF-a)-mediated signaling; COX-2, NF-kB and TNF-a are upregulated in certain types of cancer and during inflammation.	Phellodendron amurense Bark Extract		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103231>	C101250	Brachial Plexus Injury	Damage to the nerves in the brachial plexus network. These nerves originate in the spinal column and innervate the shoulder, arm and hand. Often, damage is sustained from overstretching or motor vehicle accidents.			Finding	Neonatal Research Network Terminology|NICHD Terminology
C103232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103232>	C16481|C16389	Cathepsin S|CTSS|Cathepsin S Precursor|EC 3.4.22.27	Cathepsin S (331 aa, ~37 kDa) is encoded by the human CTSS gene. This protein is involved in both proteolysis and immunity.			Amino Acid, Peptide, or Protein|Enzyme	
C103233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103233>	C2975	Cystic Fibrosis with Meconium Ileus	A congenital metabolic detected in the neonatal period that is characterized by the presence of a meconium ileus. The disease affects the exocrine glands andis inherited as an autosomal trait. The secretions of exocrine glands are abnormal, resulting in excessively viscid mucus production which causes obstruction of passageways (including pancreatic and bile ducts, intestines, and bronchi). The sweat sodium and chloride content are increased. Symptoms usually appear in childhood and include meconium ileus, poor growth despite good appetite, malabsorption and foul bulky stools, chronic bronchitis with cough, recurrent pneumonia, bronchiectasis, emphysema, clubbing of the fingers, and salt depletion in hot weather.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C103234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103234>	C28404	CTSS Gene|CTSS|CTSS|Cathepsin S Gene	This gene is involved in the proteolysis of antigenic proteins.			Gene or Genome	
C103235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103235>	C103234	CTSS wt Allele|Cathepsin S wt Allele	Human CTSS wild-type allele is located in the vicinity of 1q21 and is approximately 36 kb in length. This allele, which encodes cathepsin S protein, plays a role in antigen processing.			Gene or Genome	
C103236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103236>	C92719|C89338	Fetal Neurodevelopmental Disorder	A fetal affliction that has a neurological basis and manifests as a developmental disability.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C103237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103237>	C25404	Decant|Decanted	To transfer liquid from one container to another.			Activity	
C103238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103238>	C34007	Antecubital Fossa|ANTECUBITAL FOSSA|Antecubital Region|Cubital Fossa|Elbow Pit	A triangular space on the anterior side of the elbow joint. Three main veins of the arm, the brachial artery, the medial nerve and the tendon of the biceps pass through this space.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C103239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103239>	C51635	Total Proctocolectomy|Pan-Procto Colectomy|Pan-Procto Colectomy|Pan-Proctocolectomy|Panproctocolectomy	Surgical removal of the entire colon, anus, and rectum.			Therapeutic or Preventive Procedure	GDC Terminology|GDC Value Terminology
C10323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10323>	C61007	Cyclophosphamide/Doxorubicin/Etoposide/Filgrastim|CTX/DOX/G-CSF/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103240>	C17771	Chemical Structure|CHEMICAL STRUCTURE	A representation of the arrangement of atoms and bonds.			Conceptual Entity	FDA Structured Product Labeling Terminology|PQ/CMC Representation Types Terminology|SPL Substance Indexing Terminology
C103241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103241>	C176811	Substance Dispersity|DISPERSITY	A measure of the heterogeneity of sizes, shapes or masses of molecules or particles.			Conceptual Entity	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C103242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103242>	C78162|C64958|C159453	Endoscopic Mucosal Resection|EMR|Endoscopic Mucosal Resection (EMR)	An endoscopic procedure that visualizes a part of the gastrointestinal tract to first identify and demarcate superficial mucosal lesions, then to guide a submucosal injection to the site to lift the lesion and finally to aid in the removal of the lesion.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|GDC Terminology|GDC Value Terminology
C103243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103243>	C45305	Mixture Component|MIXTURE COMPONENT	A substance that occurs as part of a mixture substance.			Substance	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C103244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103244>	C157603	Cryomold	A small shaped container used to create blocks of frozen specimens in a cryopreservative solution for future sectioning and microscopic analysis.			Manufactured Object	
C103245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103245>	C41275	Cryovial	A vial used to store specimens in a cryopreservative at very low temperatures.			Manufactured Object	
C103246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103246>	C186578	Chemical Moiety|CHEMICAL MOIETY|moiety	A single entity that can be represented as a set of atoms usually connected through a continuous set of covalent bonds.			Substance	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C103247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103247>	C91105	Assessment of Survivor Concerns|ASC|ASC	A brief questionnaire designed to measure fears about recurrence and health in cancer survivors.			Intellectual Product	
C103248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103248>	C173934	Worry About Future Diagnostic Tests Question|I Worry About Future Diagnostic Tests|Worry About Future Diagnostic Tests	A question about how much an individual worries or worried about the need to have future diagnostic tests.			Intellectual Product	Assessment of Survivor Concerns
C103249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103249>	C173934	Worry About Another Type of Cancer Question|I Worry About Another Type Of Cancer|Worry About Another Type of Cancer	A question about how much an individual worries or worried about having another type of cancer.			Intellectual Product	Assessment of Survivor Concerns
C10324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10324>	C61063	Methotrexate/Vincristine|MTX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103250>	C173934	Worry About My Cancer Coming Back Question|I Worry About My Cancer Coming Back|Worry About My Cancer Coming Back	A question about how much an individual worries or worried about their cancer coming back.			Intellectual Product	Assessment of Survivor Concerns
C103251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103251>	C173934	Worry About My Health Question|I Worry About My Health|Worried About Health|Worry About My Health	A question about how much an individual worries or worried about their health.			Intellectual Product	Assessment of Survivor Concerns|Impact of Weight on Quality of Life-Lite
C103252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103252>	C173934|C173890	Worry About My Children's Health Question|I Worry About My Children's Health|Worry About My Children's Health	A question about how much an individual worries or worried about the health of their children.			Intellectual Product	Assessment of Survivor Concerns
C103253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103253>	C91105	PROMIS Global Health Questionnaire|10 PROMIS Global Health|PROMIS Global|PROMIS Global-10|Ten PROMIS Global Health Questionnaire	A 10 question instrument designed to provide an efficient way of gathering general perceptions of health.			Intellectual Product	HL Authorized Value Terminology|HL Patient Reported Outcomes Metadata Table
C103254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103254>	C91103	In General Would You Say Your Health Is Question|In General Would You Say Your Health Is|In General Would You Say Your Health Is|In general, how would you describe your health|In general, would you say your health is	A question about an individual's assessment of their general health.			Intellectual Product	Edmonton Frail Scale|PROMIS Adult Global Health Domain|PROMIS Global Health Questionnaire
C103255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103255>	C173504	In General Would You Say Your Quality Of Life Is Question|In General Would You Say Your Quality Of Life Is|In General Would You Say Your Quality Of Life Is|In general, would you say your quality of life is	A question about an individual's assessment of their quality of life.			Intellectual Product	PROMIS Adult Global Health Domain|PROMIS Global Health Questionnaire
C103256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103256>	C91103	In General How Would You Rate Your Physical Health Question|In General How Would You Rate Your Physical Health|In General How Would You Rate Your Physical Health|In general, how would you rate your physical health	A question about an individual's rating of their physical health.			Intellectual Product	PROMIS Adult Global Health Domain|PROMIS Global Health Questionnaire
C103257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103257>	C173597	In General How Would You Rate Your Mental Health Including Your Mood And Ability To Think Question|In General How Would You Rate Your Mental Health|In General How Would You Rate Your Mental Health Including Your Mood And Ability To Think|In General How Would You Rate Your Mental Health Including Your Mood And Ability To Think|In general, how would you rate your mental health, including your mood and your ability to think	A question about an individual's rating of their mental health, including emotions and ability to think.			Intellectual Product	PROMIS Adult Global Health Domain|PROMIS Global Health Questionnaire
C103258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103258>	C173792	In General How Would You Rate Your Satisfaction with Your Social Activities and Relationships Question|In General How Would You Rate Your Satisfaction With Your Social Activities And Relationships|In General How Would You Rate Your Satisfaction with Your Social Activities and Relationships|In general, how would you rate your satisfaction with your social activities and relationships	A question about an individual's rating of their satisfaction with social activities and relationships.			Intellectual Product	PROMIS Adult Global Health Domain|PROMIS Global Health Questionnaire
C103259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103259>	C91103	In General Please Rate How Well You Carry Out Your Usual Social Activities And Roles Question|In General Please Rate How Well You Carry Out Your Usual Social Activities And Roles|In General Please Rate How Well You Carry Out Your Usual Social Activities And Roles|In general, please rate how well you carry out your usual social activities and roles. (This includes activities at home, at work and in your community, and responsibilities as a parent, child, spouse, employee, friend, etc)	A question about an individual's rating of how well they carry out their usual social activities and roles.			Intellectual Product	PROMIS Adult Global Health Domain|PROMIS Global Health Questionnaire
C10325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10325>	C61007	Cisplatin/Vincristine|CDDP/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103260>	C91102	To What Extent Are You Able to Carry Out Your Everyday Physical Activities Such as Walking Climbing Stairs Carrying Groceries or Moving a Chair Question|To What Extent Are You Able To Carry Out Everyday Physical Activities|To What Extent Are You Able to Carry Out Your Everyday Physical Activities Such as Walking Climbing Stairs Carrying Groceries or Moving a Chair|To what extent are you able to carry out your everyday physical activities such as walking, climbing stairs, carrying groceries, or moving a chair	A person's assessment of the extent to which they can carry out everyday physical activities.			Intellectual Product	PROMIS Adult Global Health Domain
C103261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103261>	C173386|C172982|C118873	In The Past 7 Days How Often Have You Been Bothered By Emotional Problems Such As Feeling Anxious Depressed Or Irritable Question|In The Past 7 Days How Often Have You Been Bothered By Emotional Problems|In The Past 7 Days How Often Have You Been Bothered By Emotional Problems Such As Feeling Anxious Depressed Or Irritable|In The Past 7 Days How Often Have You Been Bothered By Emotional Problems Such As Feeling Anxious Depressed Or Irritable|In the past 7 days, how often have you been bothered by emotional problems such as feeling anxious, depressed or irritable	A question about an individual's assessment of how often they have been bothered by emotional problems in the past seven days.			Intellectual Product	PROMIS Adult Global Health Domain|PROMIS Global Health Questionnaire
C103262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103262>	C173347	In The Past 7 Days How Would You Rate Your Fatigue On Average Question|In The Past 7 Days How Would You Rate Your Fatigue On Average|In The Past 7 Days How Would You Rate Your Fatigue On Average|In the past 7 days, how would you rate your fatigue on average	A question about an individual's rating of the average amount of fatigue they have felt in the past seven days.			Intellectual Product	PROMIS Adult Global Health Domain|PROMIS Global Health Questionnaire
C103263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103263>	C173346	In The Past 7 Days How Would You Rate Your Pain On Average Question|In The Past 7 Days How Would You Rate Your Pain On Average|In The Past 7 Days How Would You Rate Your Pain On Average|In the past 7 days how bad was your pain on average|In the past 7 days, how would you rate your pain on average	A question about an individual's rating of the average amount of pain they have felt in the past seven days.			Intellectual Product	PROMIS Adult Global Health Domain|PROMIS Global Health Questionnaire
C103264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103264>	C37901	Tissue Source Site|TSS|TSS|TSS|Tissue Source|Tissue Source Site (TSS)	A clinical site that collects and provides patient samples and clinical metadata for research use.			Spatial Concept	Canine Glioma Project Property Terminology|CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Medical History Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Normal Endometrial Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form|CRF8 Pathology Review Table|ICDC Terminology
C103265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103265>	C15227	Macrodissection	A laboratory procedure where manual dissection of a frozen or fixed biospecimen block is performed to isolate a specific tissue type or cell population of interest.			Health Care Activity	
C103266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103266>	C101253	Congenital Aortic Arch Hypoplasia|Congenital Hypoplasia Aortic Arch|Congenital Hypoplasia of Aortic Arch	An underdeveloped aortic arch that is present at birth. This symptom is usually found in association with other cardiac defects that characterize left heart syndrome.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C103267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103267>	C41227	Narrow Surgical Margin|Close Surgical Margin	An indication that a surgical margin is in close proximity to the excised tumor.			Clinical Attribute	
C103268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103268>	C15725	Hand Assisted Laparoscopy|Hand Assisted Laparoscopic Surgery|Hand-Assisted Laparoscopy	A type of laparoscopic surgery where the surgeon uses both a laparoscope and his or her hand to help with dissection, retraction, and removal of tissue through a hand port incision.			Health Care Activity	
C103269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103269>	C225418	Endorectal|Transrectal	Pertaining to the lumen or inner part of the rectum.			Qualitative Concept	
C10326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10326>	C61063	Cisplatin/Cyclophosphamide/Doxorubicin/Etoposide/Methotrexate/Vincristine|CDDP/CTX/DOX/MTX/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103270>	C41192|C113777	Consent Waiver|Waiver Of Informed Consent	The release from the requirement to obtain informed consent during a study that is granted by Human Subject Protection committee for a research institution for a protocol that is being reviewed by the Institutional Review Board.			Governmental or Regulatory Activity	GDC Terminology|GDC Value Terminology
C103271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103271>	C93221	Largetrifoliolious Bugbane Rhizome Supplement|Ximingting	A proprietary tablet formulation containing an extract from Largetrifoliolious Bugbane rhizome (Shengma), the dried root of Cimicifuga sp., with potential use for relieving menopausal symptoms. The Largetrifoliolious bugbane rhizome supplement contains total saponins, including phytoestrogens that can modulate estrogen receptor signaling. This supplement is used to reduce disease symptoms, such as sweating, toothache, headache, ulcers, and insomnia. In women, this supplement may be used to reduce symptoms related to menopause.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C103272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103272>	C308|C29707	Nitroglycerin Transdermal Patch|GTN Transdermal Patch|Glyceryl Trinitrate Transdermal Patch|Minitran	A sustained release transdermal patch containing the organic nitrate nitroglycerin, with vasodilator and potential immunomodulating activities. Upon application to the skin, nitroglycerin is continuously released from the patch and absorbed. In turn, nitroglycerin is converted into nitric oxide (NO), which activates guanylyl cyclase, increasing cyclic guanosine monophosphate concentration thus resulting in smooth muscle relaxation. In addition, activation of NO-mediated signaling pathways may inhibit hypoxia-induced tumor cell invasiveness, chemoresistance, evasion of immune cell recognition and cancer cell progression. Particularly, reactivation of NO-mediated signaling appears to inhibit the increased tumor cell shedding of the major histocompatibility complex class I chain-related (MIC) molecules MICA and MICB as is seen in hypoxic tumor environments; MIC molecules play key roles in tumor cell immune surveillance through their interaction with the C-type lectin-like NKG2D receptor on natural killer, lymphokine-activated killer and effector T cells.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103273>	C155727	Erdafitinib|1,2-Ethanediamine, N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-(3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl)-|Balversa|ERDAFITINIB|JNJ 42756493|JNJ-42756493|JNJ42756493	An orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity. Upon oral administration, erdafitinib binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways and thus the inhibition of tumor cell proliferation and tumor cell death in FGFR-overexpressing tumor cells. FGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival.	Erdafitinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103274>	C200527|C129822	Brontictuzumab|BRONTICTUZUMAB|Immunoglobulin G2-lambda, Anti-(homo Sapiens Notch1 (Notch 1, Translocation-associated Notch-1, TAN-1,Tan1)), Humanized Monoclonal Antibody|OMP-52M51	A humanized monoclonal antibody directed against the Notch-1 receptor with potential antineoplastic activity. Upon administration, brontictuzumab binds to Notch-1 on the cell surface, thereby inhibiting Notch-mediated signaling and tumor cell proliferation. Notch 1, a type 1 transmembrane protein belonging to the Notch family, functions as a receptor for membrane bound ligands and has various roles during development; dysregulated Notch signaling is associated with increased cell growth and chemoresistance in cancers.	Brontictuzumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103275>	C93144	Lactobacillus acidophilus/Streptococcus thermophilus/Bifidobacterium lactis/L. rhamnosus/B. longum/B. bifidum-based Probiotic Supplement	A nutritional supplement containing probiotic cultures of Lactobacillus acidophilus (L. acidophilus), L. rhamnosus Streptococcus thermophilus, Bifidobacterium lactis, (B. lactis), B. longum and B. bifidum, with gastrointestinal (GI) protective and immunomodulating activities. Upon oral administration, the bacteria in this probiotic supplement help maintain adequate colonization of the GI tract and modulate the composition of the normal microflora. Upon colonization of the GI tract, the probiotic bacteria form a protective barrier that helps maintain the integrity of the epithelial barrier. This will interfere with the attachment of pathogenic bacteria and other harmful substances, prevent inflammation and improve GI function.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C103276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103276>	C663	Pegylated Liposomal Mitomycin C Lipid-based Prodrug|JNJ-27548547|JNJ-27548547|PL-MLP|Promitil	A pegylated liposomal formulation comprised of a lipophilic prodrug of the antineoplastic antibiotic mitomycin C containing a cleavable disulfide bond (PL-MLP), with potential antineoplastic activity. Upon administration of the pegylated liposomal mitomycin C lipid-based prodrug, the MLP moiety becomes activated upon thiolysis at the tumor site, thereby releasing mitomycin C. Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.  The thiolytic environment and upregulated expression of thioredoxins at the tumor site allow for the activation and release of mitomycin C. This prodrug formulation allows for greater circulation time, less systemic toxicity and increased accumulation of mitomycin C at the tumor site.			Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103277>	C2152|C129825	Acalisib|6-Fluoro-3-phenyl-2-((1S)-1-(7H-purin-6-ylamino)ethyl)quinazolin-4(3H)-one|ACALISIB|CAL-120|GS-9820	An inhibitor of the beta and delta isoforms of the 110 kDa catalytic subunit of class IA phosphoinositide-3 kinases (PI3K) with potential immunomodulating and antineoplastic activities. Acalisib inhibits the activity of PI3K, thereby preventing the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), which decreases tumor cell proliferation and induces cell death. PI3K-mediated signaling is often dysregulated in cancer cells; the targeted inhibition of PI3K is designed to preserve PI3K signaling in normal, non-neoplastic cells.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103278>	C2124	Fluorine F 18 d-FMAU|1-(2'-Deoxy-2'-[18F]fluoro-beta-D-arabinofuranosyl)thymine|18F-FMAU|2'-Deoxy-2'-[18F]fluoro-5-methyl-1-beta-D-arabinofuranosyluracil|5-METHYL-2'-FLUOROARAURACIL F-18	A radioconjugate comprised of the synthetic pyrimidine analogue 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)thymine (d-FMAU) labeled with the radioisotope fluorine F 18 (18F-d-FMAU), that can potentially be used as an imaging agent upon positron emission tomography (PET). Upon administration, fluorine F 18 FMAU is distributed and taken up by cells based on the rate of the cell's DNA synthesis. Upon PET imaging, cell proliferation in tumors can be assessed as tumor cells have a higher rate of DNA synthesis than normal, healthy cells. This agent is not catabolized and has a long half-life compared to the radioconjugate carbon C 11 thymidine.	Fluorine F 18 d-FMAU		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C103279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103279>	C29697	PEG-3350/Sodium Sulfate/Sodium Chloride/Potassium Chloride/Sodium Ascorbate/Ascorbic Acid-based Laxative|Moviprep|PEG-Asc	A preparation containing the nonabsorbable polymer polyethylene glycol (PEG or macrogol) 3350 and sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid with laxative activity. Upon oral administration, the PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid-based laxative promotes the retention of water in the bowel. This increases the water content of stool, which results in increased gastrointestinal motility and evacuation of colonic contents. This results in a complete cleansing of the colon. Compared to the 4 liter PEG-3350-based preparations, this PEG-based laxative is a low volume (2 liter) preparation, which improves patients' tolerance.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C10327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10327>	C61063	Carmustine/Cyclophosphamide/Melphalan/Misonidazole/Prednisone|BCNU/CTX/L-PAM/MNI/PRED			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103280>	C217121	Body Image Scale|BIS	A brief questionnaire for assessing body image changes in patients with cancer.			Intellectual Product	
C103282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103282>	C161324	Religious Group	A group of people characterized by the practice of a common religion.			Population Group	
C103283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103283>	C211623|C103282	Sephardic Jew|SEPHARDIC JEW|Sephardi	A member of the Jewish faith whose ancestors lived in North Africa, the Middle East, Portugal or Spain.			Population Group	CDISC CDASH Terminology|CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103284>	C103282	Buddhist	A religious group that follows the teachings of Siddhartha Gautama, who taught that the end of suffering can be achieved by eliminating the desire for material comforts.			Population Group	
C103285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103285>	C103282	Muslim|Islamic	A religious group that follows the words and belief system founded by the prophet Muhammad and are written in the Koran.			Population Group	
C103286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103286>	C103282	Roman Catholic|Catholic	A religious group that has beliefs derived from the first practicing Christians and is led by the pope, or bishop of Rome.			Population Group	
C103287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103287>	C103282	Protestant Christian|Protestant	A religious group encompassing numerous Christian denominations and a wide theological spectrum that have a common origin stemming from the Reformation which resulted in separation from the Catholic Church and its practices.			Population Group	
C103288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103288>	C103282	Eastern Orthodox Christian|Byzantine|Eastern Orthodox|Greek Orthodox	A religious group whose beliefs are based on the practices defined by the first seven ecumenical councils and whose members are located in or descended from the people of Eastern or Southeastern Europe.			Population Group	
C103289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103289>	C103287	Seventh Day Adventist	A religious group of Protestant Christians whose beliefs are distinguished by the observance of Saturday as the Sabbath and by its emphasis on the imminent end of the world and second coming of Jesus Christ.			Population Group	
C10328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10328>	C63589	Cytarabine/Hydroxyurea Regimen|ARA-C/HU|Cytarabine-Hydroxyurea|Cytarabine/Hydroxyurea|Hydroxyurea-Cytarabine|Hydroxyurea/Cytarabine|ara-C-HU	A regimen consisting of cytarabine and hydroxyurea that may be used in the treatment of acute myeloid leukemia (AML).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C103290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103290>	C103282	Mormon|LDS	A religious group that identifies with the beliefs and culture of the Latter-Day Saint movement.			Population Group	
C103291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103291>	C103282	Hindu	A religious group that encompasses a diverse set of beliefs and traditions that originated in the Indian subcontinent.			Population Group	
C103292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103292>	C173160	Feel Self-Conscious About Appearance Question|Feel Self-Conscious About Appearance|Feeling Self-Conscious About Appearance|Have you been feeling self-conscious about your appearance	A question about whether an individual feels or felt self conscious about their appearance.			Intellectual Product	Body Image Scale
C103293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103293>	C173812|C173219	Feel Physically Less Attractive as Result of Disease or Treatment Question|Feel Less Physically Attractive Due to Disease or Treatment|Feel Physically Less Attractive as Result of Disease or Treatment|Feel Physically Less Attractive as a Result of Illness or Treatment|Have you felt less physically attractive as a result of your disease or treatment|Have you felt physically less attractive as a result of your disease and treatment|Have you felt physically less attractive as a result of your illness or treatment	A question about whether an individual feels or has felt less physically attractive as a result of their disease or treatment.			Intellectual Product	Bladder Cancer Muscle-Invasive 30 Questionnaire|Body Image Scale|Quality of Life Questionnaire - Pancreatic Cancer 26
C103294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103294>	C53053	Serious Clinical Event Type	A category of clinical events regarded as having similar characteristics considered crucial and consequential.			Classification	
C103295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103295>	C25284	Clinical Event Pattern Type	A category of clinical events which have a recurrent characteristic feature.			Functional Concept	
C103296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103296>	C4991|C27851	AIDS-Related Human Papillomavirus Infection|AIDS-Related HPV Infection|AIDS-Related Human Papilloma Virus Infection|AIDS-related HPV infections	An opportunistic infection caused by the human papillomavirus in a patient with AIDS.			Disease or Syndrome	NCI CTEP SDC AIDS-related Human Papillomavirus Sub-Category Terminology|NCI CTEP Simplified Disease Classification Terminology
C103297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103297>	C129824	Nucleolin Antagonist IPP-204106N|IPP-204106|N6L	A synthetic, multivalent, lysine-rich, pseudopeptide and nucleolin antagonist with potential anti-angiogenic, antineoplastic and pro-apoptotic activities. Upon administration, IPP-204106N antagonizes nucleolin leading to a downregulation of cell-surface nucleolin; preventing the binding of certain growth promoting ligands to nucleolin may suppress tumor cell proliferation and angiogenesis. In addition, IPP-204106N is able to translocate to the nucleolus and bind to nucleolar nucleolin. This prevents nucleolin from binding to and stabilizing mRNA of the anti-apoptotic Bcl2; destabilizing Bcl2 mRNA leads to a reduction in Bcl2 protein synthesis and induces apoptosis. Further, this agent can antagonize nucleophosmin. Nucleolin, a nucleolar phosphoprotein, is overexpressed on the cell surface of certain cancer cells and binds ligands involved in cell proliferation, adhesion and angiogenesis.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103298>	C128462	Birabresib|6H-Thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-6-acetamide, 4-(4-Chlorophenyl)-N-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6S)-|BIRABRESIB|BRD 2/3/4 Inhibitor OTX015|MK-8628|OTX015	A synthetic, small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins 2, 3 and 4 with potential antineoplastic activity. Upon administration, birabresib binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histone peptides. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes, including c-Myc-dependent target genes, may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomain at the N-terminus, the BET proteins BRD2, BRD3, BRD4 are transcriptional regulators that play an important role in cellular growth.	Birabresib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103299>	C29697	PEG-based Laxative NER1006|NER1006	A preparation containing the nonabsorbable polymer polyethylene glycol (PEG or macrogol) 3350 with laxative activity. Upon oral administration, the PEG-3350-based laxative NER1006 promotes the retention of water in the bowel. This increases both the water content and volume of stool, which results in increased gastrointestinal motility and the evacuation of colonic contents leading to a complete cleansing of the colon. Compared to the 4 liter PEG-3350-based preparations, this PEG-based laxative is a low volume (2 liter) preparation, which may improve tolerance.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C10329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10329>	C63587	Fluorouracil/Hydroxyurea Regimen|5-FU/HU|Fluorouracil-Hydroxyurea|Fluorouracil-Hydroxyurea Regimen	A regimen consisting of fluorouracil and hydroxyurea that may be used in the treatment of head and neck cancers.			Therapeutic or Preventive Procedure	
C1032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1032>	C204	Cactinomycin|ACTINOMYCIN C|Actinomycin C|CACTINOMYCIN	A chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces chrysomallus.  Cactinomycin binds to DNA by intercalating between guanine and cytosine, forming stable antibiotic-DNA complexes that inhibit RNA and protein synthesis. (NCI04)			Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C103300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103300>	C1892|C1742	Ginsenoside Rg3 Capsule|Shen Yi Capsule	A capsule containing the steroidal saponin ginsenoside Rg3 isolated from the root of Panax ginseng, with potential cancer preventive and anti-angiogenic activities. Upon oral administration, ginsenoside Rg3 appears to inhibit endothelial cell proliferation, migration and tubular formation, and promotes cancer cell apoptosis. This agent also modulates the activities of certain growth factors, such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and matrix metalloproteinases (MMPs), on tumor angiogenesis. In addition, ginsenoside Rg3 may be able to sensitize cancer cells to some chemotherapeutic agents.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103303>	C173792	Dissatisfaction with Appearance When Dressed Question|Dissatisfaction with Appearance When Dressed|Dissatisfaction with Appearance When Dressed|Have you been dissatisfied with your appearance when dressed	A question about whether an individual is or was diissatisfied with their appearance when dressed.			Intellectual Product	Body Image Scale
C103304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103304>	C173812|C173160	Feel Less Feminine Due to Disease or Treatment Question|Feel Less Feminine Due to Disease or Treatment|Feeling Less Feminine Due to Disease or Treatment|Have you been feeling less feminine as a result of your disease or treatment	A question about whether an individual feels or felt less feminine as a result of their disease or treatment.			Intellectual Product	Body Image Scale
C103305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103305>	C176022	Difficult to Look at Self Naked Question|Did you find it difficult to look at yourself naked|Difficult to Look at Self Naked|Difficult to Look at Self Naked	A question about whether an individual finds or found it difficult looking at themselves naked.			Intellectual Product	Body Image Scale
C103306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103306>	C173812|C173704|C173160	Feel Less Sexually Attractive Due to Disease or Treatment Question|Feel Less Sexually Attractive Due to Disease or Treatment|Feel Less Sexually Attractive Due to Disease or Treatment|Feeling less sexually attractive|Have you been feeling less sexually attractive as a result of your disease or treatment	A question about whether an individual feels or felt less sexually attractive as a result of their disease or treatment.			Intellectual Product	Body Image Scale|Lymphedema Symptom Intensity and Distress Survey - Arm
C103307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103307>	C176022|C175989|C173160	Avoid People Due to Physical Appearance Question|Avoid People Due to Physical Appearance|Avoid People Due to Physical Appearance|Did you avoid people because of the way you felt about your physical appearance	A question about whether an individual avoids or has avoided people because of the way they feel about their physical appearance.			Intellectual Product	Body Image Scale
C103308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103308>	C173812|C173160	Feel that Treatment has Left Body Less Whole Question|Feel that Treatment has Left Body Less Whole|Feel that Treatment has Left Body Less Whole|Have you been feeling that your treatment has left your body less whole	A question about whether an individual feels or felt that treatment has left their body less whole.			Intellectual Product	Body Image Scale
C103309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103309>	C173792	Feel Dissatisfied with Body Question|Dissatisfied with Body|Feel Dissatisfied with Body|Feel Dissatisfied with Body|Have Been Dissatisfied with Body|Have you been dissatisfied with your body|Have you been feeling dissatisfied with your body	A question about whether an individual is or was dissatisfied with their body.			Intellectual Product	Bladder Cancer Muscle-Invasive 30 Questionnaire|Body Image Scale|Quality of Life Questionnaire - Pancreatic Cancer 26
C10330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10330>	C61063	Melphalan/Misonidazole|L-PAM/MNI			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103310>	C173792	Dissatisfied with Appearance of Scar Question|Dissatisfied with Appearance of Scar|Dissatisfied with Appearance of Scar|Have you been dissatisfied with the appearance of your scar	A question about whether an individual is or was dissatisfied with the appearance of their scar.			Intellectual Product	Body Image Scale
C103311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103311>	C123618	Very Good Partial Response in Neuroblastoma	Greater than 90% reduction of primary tumor; no metastatic tumor (as above except bone); no new bone lesions, all pre-existing lesions improved on bone scan; HVA/VMA normal.			Finding	
C103312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103312>	C178717	Complete Response in Neuroblastoma	No evidence of primary tumor, no evidence of metastases (chest, abdomen, liver, bone, bone marrow, nodes, etc.), and HVA/VMA normal.			Finding	
C103313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103313>	C18058	Partial Response in Neuroblastoma	Fifty to 90% reduction of primary tumor; 50% or greater reduction in measurable sites of metastases; 0-1 bone marrow samples with tumor; number of positive bone sites decreased by greater than 50%.			Finding	
C103314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103314>	C123600	No Response in Neuroblastoma	No new lesions; less than 50% reduction but less than 25% increase in any existing lesion (exclude bone marrow evaluation).			Finding	
C103315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103315>	C165202	Mixed Response in Neuroblastoma	Greater than 50% reduction of any measurable lesion (primary or metastases) with, less than 50% reduction in any other site; no new lesions; less than 25% increase in any existing lesion (exclude bone marrow evaluation).			Finding	
C103316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103316>	C91105	Multidimensional Body-Self Relations Questionnaire Appearance Orientation|MBSRQ|MBSRQ|Multidimensional Body-Self Relations Questionnaire (MBSRQ) - Appearance Orientation	A well-validated, self-report inventory for the assessment of body image.			Intellectual Product	
C103317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103317>	C91103	Before Going Out in Public I Notice My Looks Question|Before Going Out in Public I Notice My Looks|Before Going Out in Public I Notice My Looks|Before going out in public, I always notice how I look	A question about whether an individual notices or has noticed how they look before going out in public.			Intellectual Product	Multidimensional Body-Self Relations Questionnaire Appearance Orientation
C103318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103318>	C176022	Careful to Buy Clothes that Make Me Look Good Question|Careful to Buy Clothes that Make Me Look Good|Careful to Buy Clothes that Make Me Look Good|I am careful to buy clothes that will make me look my best	A question about whether an individual is or was careful to buy clothes that make them look good.			Intellectual Product	Multidimensional Body-Self Relations Questionnaire Appearance Orientation
C103319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103319>	C91103	Check My Appearance in Mirror Whenever Can Question|Check My Appearance in Mirror Whenever|Check My Appearance in Mirror Whenever|Check My Appearance in Mirror Whenever Can|I check my appearance in a mirror whenever I can	A question about whether an individual checks or has checked their appearance using a mirror whenever they can.			Intellectual Product	Multidimensional Body-Self Relations Questionnaire Appearance Orientation
C10331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10331>	C61063	Cyclophosphamide/Interleukin-2/Tumor Infiltrating Lymphocytes|CTX/IL-2/TIL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103320>	C91103	Before Going Out I Spend Time Preparing Question|Before Going Out I Spend Time Preparing|Before Going Out I Spend Time Preparing|Before going out I usually spend a lot of time getting ready	A question about whether an individual spends or has spent much time getting ready before going out.			Intellectual Product	Multidimensional Body-Self Relations Questionnaire Appearance Orientation
C103321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103321>	C176022	Important that I Look Good Question|Important that I Look Good|Important that I Look Good|It is important that I always look good	A question about whether an individual feels or felt it is important they look good.			Intellectual Product	Multidimensional Body-Self Relations Questionnaire Appearance Orientation
C103322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103322>	C91103	Use Very Few Grooming Products Question|I use very few grooming products|Use Very Few Grooming Products|Use Very Few Grooming Products	A question about an individual's use of very few grooming products.			Intellectual Product	Multidimensional Body-Self Relations Questionnaire Appearance Orientation
C103323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103323>	C91103	Self-Conscious if Grooming is Wrong Question|I am self-conscious if my grooming isn't right|Self-Conscious if Grooming is Wrong|Self-Conscious if Grooming is Wrong	A question about whether an individual is or was self-conscious if their grooming is wrong.			Intellectual Product	Multidimensional Body-Self Relations Questionnaire Appearance Orientation
C103324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103324>	C91103	Wear Whatever is Handy Without Care Question|I usually wear whatever is handy without caring how it looks|Wear Whatever is Handy Without Care|Wear Whatever is Handy Without Care	A question about whether an individual wears or wore whatever is handy without caring how it looked.			Intellectual Product	Multidimensional Body-Self Relations Questionnaire Appearance Orientation
C103325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103325>	C173597	Do Not Care What Others Think of My Appearance Question|Do Not Care What Others Think of My Appearance|Do Not Care What Others Think of My Appearance|I don't care what people think about my appearance	A question about whether an individual cares or has cared about what people think about their appearance.			Intellectual Product	Multidimensional Body-Self Relations Questionnaire Appearance Orientation
C103326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103326>	C91103	Special Care with Hair Grooming Question|I take special care with my hair grooming|Special Care with Hair Grooming|Special Care with Hair Grooming	A question about whether an individual takes or took special care with their hair grooming.			Intellectual Product	Multidimensional Body-Self Relations Questionnaire Appearance Orientation
C103327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103327>	C173597	Never Think About Appearance Question|I never think about my appearance|Never Think About Appearance|Never Think About Appearance	A question about whether an individual never thinks or has never thought about their appearance.			Intellectual Product	Multidimensional Body-Self Relations Questionnaire Appearance Orientation
C103328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103328>	C91103	Always Trying to Improve Physical Appearance Question|Always Trying to Improve Physical Appearance|Always Trying to Improve Physical Appearance|I am always trying to improve my physical appearance	A question about whether an individual is or was always trying to improve their physical appearance.			Intellectual Product	Multidimensional Body-Self Relations Questionnaire Appearance Orientation
C103329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103329>	C165634	CDISC Define-XML General Observation Class Terminology|DEFINE-GNRLOBSC|GNRLOBSC|General Observation Class	The terminology that includes concepts relevant to the Clinical Data Interchange Standards Consortium (CDISC) Define-XML standard general observation classes.			Intellectual Product	CDISC Define-XML Terminology|Clinical Data Interchange Standards Consortium Terminology
C10332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10332>	C61063	Doxorubicin/Fluorouracil/Thiotepa|DOX/5-FU/TSPA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103330>	C66830	CDISC SDTM Subject Characteristic Test Name Terminology|SCTEST|SDTM-SCTEST|Subject Characteristic Test Name	The terminology that includes concepts relevant to the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM) subject characteristics test names.			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103331>	C91105	Breast Cancer Treatment Outcomes Scale-Cosmetic Status|BCTOS|BCTOS|Breast Cancer Treatment Outcomes Scale (BCTOS) - Cosmetic Status	A measure of perceived aesthetics after breast-conserving surgical treatment and radiotherapy.			Intellectual Product	
C103332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103332>	C173806|C173791	Breast Size Different Since Cancer Treatment Question|Breast Size Difference Since Cancer Treatment|Breast Size Difference Since Cancer Treatment|Breast size	A question about the difference in an individual's breast size between the treated and untreated breast since treatment for breast cancer.			Intellectual Product	Breast Cancer Treatment Outcomes Scale-Cosmetic Status
C103333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103333>	C173806|C173791	Breast Texture Different Since Cancer Treatment Question|Breast Texture Difference Since Cancer Treatment|Breast Texture Difference Since Cancer Treatment|Breast texture (hardening)	A question about the difference in an individual's breast texture or hardening between the treated and untreated breast since treatment for breast cancer.			Intellectual Product	Breast Cancer Treatment Outcomes Scale-Cosmetic Status
C103334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103334>	C173806	Nipple Appearance Difference Since Breast Cancer Treatment Question|Nipple Appearance Difference Since Breast Cancer Treatment|Nipple Appearance Difference Since Cancer Treatment|Nipple appearance	A question about whether an individual feels or felt there is a difference in nipple appearance between the treated and untreated breast since treatment for breast cancer.			Intellectual Product	
C103335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103335>	C173806|C173791	Breast Shape Different Since Cancer Treatment Question|Breast Shape Difference Since Cancer Treatment|Breast Shape Difference Since Cancer Treatment|Breast Shape Different Since Cancer Treatment|Breast shape	A question about the difference in an individual's breast shape between the treated and untreated breast since treatment for breast cancer.			Intellectual Product	Breast Cancer Treatment Outcomes Scale-Cosmetic Status
C103336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103336>	C173806|C173791	Breast Elevation Difference Since Cancer Treatment Question|Breast Elevation Difference Since Cancer Treatment|Breast Elevation Difference Since Cancer Treatment|Breast Elevation Different Since Cancer Treatment|Breast elevation (how high the breast is)	A question about the difference in an individual's breast elevation between the treated and untreated breast since treatment for breast cancer.			Intellectual Product	Breast Cancer Treatment Outcomes Scale-Cosmetic Status
C103337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103337>	C173806|C173791	Fit of Bra Different Since Breast Cancer Treatment Question|Fit of Bra|Fit of Bra Difference Since Breast Cancer Treatment	A question about whether an individual's bra fits differently between the treated and untreated breast since treatment for breast cancer.			Intellectual Product	Breast Cancer Treatment Outcomes Scale-Cosmetic Status
C103338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103338>	C173806|C173791	Fit of Clothing Different Since Breast Cancer Treatment Question|Fit of Clothing Difference Since Breast Cancer Treatment|Fit of clothing	A question about whether an individual's clothing fits differently between the treated and untreated breast since treatment for breast cancer.			Intellectual Product	Breast Cancer Treatment Outcomes Scale-Cosmetic Status
C103339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103339>	C25404	Pretreatment|pretreatment	Any relevant actions that were performed or occurred prior to a specific treatment.			Activity	GDC Property Terminology
C10333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10333>	C61063	Cyclophosphamide/Doxorubicin/Fluorouracil/Tamoxifen|CTX/DOX/5-FU/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103341>	C25616	Pretreatment Period|Pretreatment	The time prior to the treatment of interest.			Qualitative Concept	
C103342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103342>	C226673	Very Good|Very good	An indication that something has a high degree of quality, value or worth.			Intellectual Product	Pittsburgh Sleep Quality Index
C103343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103343>	C74742	Prostaglandin Measurement|PG|Prostaglandin|Prostaglandin	The determination of the amount of the total prostaglandin in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103344>	C80157	11-Dehydro-Thromboxane B2 Measurement|11-Dehydro-Thromboxane B2|11-Dehydro-Thromboxane B2|TXB2_D11	The determination of the amount of the 11-dehydro-thromboxane B2 in a sample.	11-Dehydro-Thromboxane B2 Measurement		Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C103345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103345>	C49237	3,4-Dihydroxyphenylacetic Acid Measurement|3,4-Dihydroxyphenylacetic Acid|3,4-Dihydroxyphenylacetic Acid|DOPAC	The determination of the amount of the 3,4-dihydroxyphenylacetic acid in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103346>	C77537	Abdominal Skinfold Thickness|ABSKNF	A measurement for determining the subcutaneous fat layer thickness whereby a pinch of skin approximately five centimeters to the right of the umbilicus is measured using calipers.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Vital Sign Test Code Terminology|CDISC SDTM Vital Sign Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103347>	C25446	Absolute Change From Nadir|ACHNAD	The value of the current measurement minus the lowest value previously recorded.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C103348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103348>	C62662	Activated Coagulation Time|ACT|Activated Clotting Time	The determination of the amount of the inhibition of blood coagulation in response to anticoagulant therapies.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103349>	C74906	Alpha Tocopherol Measurement|ALTCPHRL|Alpha Tocopherol|Alpha Tocopherol	The determination of the amount of the alpha tocopherol in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10334>	C61063	Mitoxantrone/Thiotepa|DHAD/TSPA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103350>	C103349	Alpha Tocopherol to Vitamin E Ratio Measurement|ATPVITE|Alpha Tocopherol to Total Vitamin E Ratio Measurement|Alpha Tocopherol/Vitamin E|Alpha Tocopherol/Vitamin E	The determination of the ratio of alpha-tocopherol compared with the total vitamin E in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103351>	C64430	Alpha-2 Antiplasmin Measurement|APLSMA2|Alpha-2 Antiplasmin|Alpha-2 Antiplasmin|Alpha-2 Plasmin Inhibitor|Serpin F2 Measurement	The determination of the amount of the alpha-2 antiplasmin in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103352>	C81999	Amyloid Beta 1-38 Measurement|AMYLB38|Amyloid Beta 1-38|Amyloid Beta 1-38|Amyloid Beta 38|Amyloid Beta 38 Protein	The determination of the amount of amyloid beta protein which is composed of peptides 1 to 38 in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103353>	C81999	Amyloid Beta 1-40 Measurement|AMYLB40|Amyloid Beta 1-40|Amyloid Beta 1-40|Amyloid Beta 40|Amyloid Beta 40 Protein	The determination of the amount of amyloid beta protein which is composed of peptides 1 to 40 in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103354>	C124337	Apolipoprotein A4 Measurement|APOA4|APOA4 Measurement|Apolipoprotein A4|Apolipoprotein A4	The determination of the amount of the apolipoprotein A4 in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103355>	C124337	Apolipoprotein A5 Measurement|APOA5|APOA5 Measurement|Apolipoprotein A5|Apolipoprotein A5	The determination of the amount of the apolipoprotein A5 in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103356>	C64430	Apolipoprotein B to Apolipoprotein A1 Ratio Measurement|APOBAPA1|Apolipoprotein B/Apolipoprotein A1|Apolipoprotein B/Apolipoprotein A1	The determination of the ratio of the Apolipoprotein B compared with Apolipoprotein A1 in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103357>	C64430	Beta Catenin Measurement|Beta Catenin|Beta Catenin|CATNINB	The determination of the amount of the beta catenin in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103358>	C81979|C81971	Beta-2 Glycoprotein 1 IgG Antibody Measurement|APOH IgG Antibody Measurement|Apolipoprotein H IgG Antibody Measurement	The determination of the amount of the Beta-2 glycoprotein 1 IgG antibodies in a sample.			Laboratory Procedure	
C103359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103359>	C81979|C81972	Beta-2 Glycoprotein 1 IgM Antibody Measurement|APOH IgM Antibody Measurement|Apolipoprotein H IgM Antibody Measurement	The determination of the amount of the Beta-2 glycoprotein 1 IgM antibodies in a sample.			Laboratory Procedure	
C10335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10335>	C61007	Cyclophosphamide/Daunorubicin/Methotrexate/Prednisone/Vincristine|CTX/DNR/MTX/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103360>	C49237	Calcium and Phosphorus Product Measurement|CAPHOSPD|Calcium - Phosphorus Product|Calcium - Phosphorus Product	The determination of the amount of the product of the calcium and phosphate measurements in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103361>	C209976	Cancer Antigen 1 Measurement|CA1AG|Cancer Antigen 1|Cancer Antigen 1	The determination of the amount of the cancer antigen 1 in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103362>	C209976	Cancer Antigen 15-3 Measurement|CA15_3AG|Cancer Antigen 15-3|Cancer Antigen 15-3|Carbohydrate Antigen 15-3	The determination of the amount of the cancer antigen 15-3 in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103363>	C81972	Cardiolipin IgM Antibody Measurement	The determination of the amount of the cardiolipin IgM antibodies in a sample.			Laboratory Procedure	
C103364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103364>	C48938	CD1 Expressing Cell Measurement	A count of the CD1 expressing cells per unit of a biological specimen.			Laboratory Procedure	
C103365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103365>	C48938	CD14 Expressing Cell Measurement	A count of the CD14 expressing cells per unit of a biological specimen.			Laboratory Procedure	
C103366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103366>	C48938	CD2 Expressing Cell Measurement	A count of the CD2 expressing cells per unit of a biological specimen.			Laboratory Procedure	
C103367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103367>	C67208	CD2 Expressing Cell to Lymphocyte Ratio Measurement	The determination of the ratio of CD2 expressing cells compared with the total number of lymphocytes in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	
C103368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103368>	C48938	CD20 Expressing Cell Measurement	A count of the CD20 expressing cells per unit of a biological specimen.			Laboratory Procedure	
C103369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103369>	C48938	CD5 Expressing Cell Measurement	A count of the CD5 expressing cells per unit of a biological specimen.			Laboratory Procedure	
C10336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10336>	C61007	Cyclophosphamide/Thioguanine|CTX/TG			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103370>	C48938	CD56 Expressing Cell Measurement|NCAM1 Expressing Cell Measurement	A count of the CD56 expressing cells per unit of a biological specimen.			Laboratory Procedure	
C103371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103371>	C47824	CDISC Basic Data Structure Dataset|BASIC DATA STRUCTURE|BDS|Basic Data Structure	An ADaM BDS dataset contains one or more records per subject, per analysis parameter, per analysis time point. Variables include the value being analyzed (e.g., AVAL) and the description of the value being analyzed (e.g., PARAM). Other variables in the dataset provide more information about the value being analyzed (e.g., the subject identification) or describe and trace the derivation of it (e.g., DTYPE) or support the analysis of it (e.g., treatment variables, covariates).			Idea or Concept	CDISC Define-XML General Observation Class Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103372>	C41079	CDISC Events Class|EVENTS|Events	This SDTM class captures planned protocol milestones such as randomization and study completion, and occurrences, conditions, or incidents independent of planned study evaluations occurring during the trial (e.g., adverse events) or prior to the trial (e.g., medical history).			Intellectual Product	CDISC Define-XML General Observation Class Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103373>	C41079	CDISC Findings Class|FINDINGS|Findings	This SDTM class captures the observations resulting from planned evaluations to address specific tests or questions such as laboratory tests, ECG testing, and questions listed on questionnaires.			Intellectual Product	CDISC Define-XML General Observation Class Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103374>	C41079	CDISC Interventions Class|INTERVENTIONS|Interventions	This SDTM class captures investigational, therapeutic and other treatments that are administered to the subject (with some actual or expected physiological effect) either as specified by the study protocol (e.g., exposure to study drug), coincident with the study assessment period (e.g., concomitant medications), or self-administered by the subject (such as use of alcohol, tobacco, or caffeine).			Intellectual Product	CDISC Define-XML General Observation Class Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103375>	C47824	CDISC Other ADaM Dataset|ADAM OTHER|ADaM Other	An ADaM analysis dataset that doesn't conform to the ADSL or BDS structure.			Idea or Concept	CDISC Define-XML General Observation Class Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103376>	C41079	CDISC Relationship Class|RELATIONSHIP|Relationships	This SDTM class provides a means to link related records between datasets. It includes the RELREC and SUPPQUAL datasets.			Intellectual Product	CDISC Define-XML General Observation Class Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103377>	C41079	CDISC Special Purpose Class|SPECIAL PURPOSE|SPECIAL-PURPOSE|Special Purpose	This SDTM class contains a set of domains which do not conform to the Findings, Events or Interventions observation classes. The domains included are DM, CO, SE and SV.			Intellectual Product	CDISC Define-XML General Observation Class Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103378>	C47824	CDISC Subject Level Analysis Dataset|ADSL|SUBJECT LEVEL ANALYSIS DATASET|Subject Level Analysis Dataset	The Subject-Level Analysis Dataset (ADSL) is a one-record-per-subject dataset which contains variables that describe subject demographic characteristics and group the subjects for analysis. ADSL is the primary source for subject-level variables included in other analysis datasets such as population flags and treatment variables.			Idea or Concept	CDISC Define-XML General Observation Class Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103379>	C41079	CDISC Trial Design Class|TRIAL DESIGN|Trial Design	This SDTM class describes the plan for the procedures to be followed in a clinical trial, including planned and actual timing of events, control group, method of allocating treatments, blinding methods, assignment of epochs that subjects pass through in the course of a trial.			Intellectual Product	CDISC Define-XML General Observation Class Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10337>	C61063	Daunorubicin/Hydroxyurea|DNR/HU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103380>	C120632	Cholesteryl Ester Transfer Protein Activity Measurement|CETP Activity Measurement|CETPA|Cholesteryl Ester Transfer Protein Act|Cholesteryl Ester Transfer Protein Act	The determination of the amount of the biological activity of cholesteryl ester transfer protein in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103381>	C150637	Clostridium difficile Toxin Measurement|CDFTXN|Clostridium difficile Toxin|Clostridium difficile Toxin	The determination of the amount of the Clostridium difficile toxin in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103382>	C81971	Clostridium tetani IgG Antibody Measurement	The determination of the amount of the Clostridium tetani IgG antibody in a sample.			Laboratory Procedure	
C103383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103383>	C64430	Collagen Type IV Measurement|COL4|Collagen Type IV|Collagen Type IV	The determination of the amount of the collagen type IV in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103384>	C32761	Common Iliac Lymph Node|COMMON ILIAC LYMPH NODE|Common iliac lymph node group (body structure)|Lymph Node(s) Iliac-Common|common iliac lymph node|common iliac node	A lymph node located adjacent to the common iliac artery. (NCI)			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C103385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103385>	C50995	Complete Response with Incomplete Bone Marrow Recovery|CRi|Complete Remission with Incomplete Blood Count Recovery	The disappearance of all signs of cancer in response to treatment accompanied by incomplete bone marrow recovery, as evidenced by persistent anemia, thrombocytopenia or neutropenia.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C103386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103386>	C62662	Dilute Russell's Viper Venom Time to Control Ratio Measurement|DRVVTRT|Dilute Russell's Viper Venom Time Ratio|Dilute Russell's Viper Venom Time Ratio|Lupus Anticoagulant Ratio	The determination of the ratio of the dilute Russell's viper venom time in a subject sample to a control sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103387>	C177992	Dipeptidyl Peptidase-4 Activity Measurement|DPP4 Activity Measurement	The determination of the amount of the biological activity of dipeptidyl peptidase-4 in a sample.			Laboratory Procedure	
C103388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103388>	C81971	Diphtheria IgG Antibody Measurement	The determination of the amount of the Diphtheria IgG antibodies in a sample.			Laboratory Procedure	
C103389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103389>	C64493	Every Eight Weeks|EVERY 8 WEEKS|Every 8 weeks|Q8S	Every eight weeks.			Temporal Concept	CDISC SDTM Frequency Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10338>	C61063	Carmustine/Methotrexate|BCNU/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103390>	C64493	Every Five Weeks|EVERY 5 WEEKS|Every 5 weeks|Q5S	Every five weeks.			Temporal Concept	CDISC SDTM Frequency Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103391>	C134576	Experimental Organism Benign Basalioma|BASALIOMA, BENIGN|Basalioma	A benign epithelial neoplasm arising from primary epithelial germ cells of the piliary complex.			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C103392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103392>	C134576	Experimental Organism Benign Bone Osteofibroma	A benign neoplasm, morphologically a fibroma with osseous components.			Neoplastic Process	
C103393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103393>	C134576	Experimental Organism Malignant Hepatocholangiocellular Carcinoma|CARCINOMA, HEPATOCHOLANGIOCELLULAR, MALIGNANT|Hepatocholangiocellular Carcinoma	A malignant mixed neoplasm of the liver comprising neoplastic hepatocytes and bile duct epithelial cells; both elements displaying evidence of malignancy.			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C103394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103394>	C134576	Experimental Organism Malignant Hibernoma|HIBERNOMA, MALIGNANT|Malignant Hibernoma	A malignant neoplasm arising from the brown adipose tissue in animals, usually in the subcutis and the thoracic cavity.			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C103395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103395>	C98725	Factor IX Activity Measurement|Christmas Factor Activity|Christmas Factor Activity Measurement|FACTIXA|Factor IX Activity|Factor IX Activity	The determination of the amount of the biological activity of factor IX in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103396>	C98726	Factor V Activity Measurement|FACTVA|Factor V Activity|Factor V Activity|Labile Factor Activity	The determination of the amount of the biological activity of factor V in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103397>	C81960	Factor VII Activity Measurement|FACTVIIA|Factor VII Activity|Factor VII Activity|Proconvertin Activity|Stable Factor Activity	The determination of the amount of the biological activity of factor VII in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103398>	C103397	Factor VIIa Activity Measurement|FCTVIIAA|Factor VIIa Activity|Factor VIIa Activity	The determination of the amount of the biological activity of factor VIIa in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103399>	C81961	Factor VIII Activity Measurement|Anti-hemophilic Factor Activity|FCTVIIIA|Factor VIII Activity|Factor VIII Activity|Factor VIII:C	The determination of the amount of the biological activity of factor VIII in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10339>	C61063	Cytarabine/Vincristine|ARA-C/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1033>	C47795	Caffeine Citrate|CAFFEINE CITRATE|Caffeina Citrata|Citrated Caffeine	Commercial citrate of caffeine, though not a definite salt.  It is the alkaloid caffeine, with a portion of adherent citric acid, as indicated by its pharmacopoeial name (citrated caffeine). Its general action and uses are the same as those given under caffeine. Caffeine citrate is used chiefly as a remedy for the idiopathic headache (migraine). This salt is very soluble in water, and is assimilated much more readily than pure caffeine when taken into the stomach. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C103400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103400>	C17007	FDG-Positron Emission Tomography|FDG|FDG-PET|FDG-PET|FDG-PET Imaging	An imaging technique that utilizes positron emission tomography to produce a three-dimensional image of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced into the body on the biologically active molecule (fludeoxyglucose) FDG. FDG is an analogue of glucose which when imaged will give tissue metabolic activity, in terms of regional glucose uptake.	FDG-Positron Emission Tomography		Diagnostic Procedure	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|Appendix 7: Diagnostic Procedures Terminology|CRF5 Response Evaluation Image Evaluation Table|CTRP Intervention Terminology|CTRP Terminology
C103401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103401>	C17007	FLT-Positron Emission Tomography|FLT-PET|Fluoro-L-Thymidine-Positron Emission Tomography	An imaging technique that utilizes positron emission tomography to produce a three-dimensional image of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced into the body on the biologically active molecule fluoro-L-thymidine (FLT). FLT when imaged will give tissue metabolic activity, in terms of cell proliferation.	FLT-Positron Emission Tomography		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C103402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103402>	C61041	HDL Particle Size Measurement|HDL Particle Size|HDL Particle Size|HDLPSZ	The determination of the amount of the average particle size of high-density lipoprotein in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103403>	C81971	Helicobacter pylori IgG Antibody Measurement	The determination of the amount of the Helicobacter pylori IgG antibody in a sample.			Laboratory Procedure	
C103404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103404>	C166040|C135409	Hepatitis B DNA Measurement|HBDNA|HBV DNA|HBV DNA|HBV DNA Measurement|Hepatitis B Virus DNA|Hepatitis B Virus DNA|Hepatitis B Virus DNA Measurement	The determination of the amount of hepatitis B virus DNA in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C103405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103405>	C210010	Human Albumin Antibody Measurement	The determination of the amount of the human albumin antibody in a sample.			Laboratory Procedure	
C103406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103406>	C210010	Human Anti-Mouse Antibody Measurement|HAMA|HAMAB|Human Anti-Mouse Antibody|Human Anti-Mouse Antibody	The determination of the amount of the human anti-mouse antibody in a sample.			Laboratory Procedure	CDISC SDTM Immunogenicity Specimen Assessments Test Code Terminology|CDISC SDTM Immunogenicity Specimen Assessments Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103407>	C48938	Immunoblast Count|BLASTIMM|Immunoblastic Lymphocytes|Immunoblasts|Immunoblasts	The determination of the amount of the immunoblasts in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103408>	C81971	Influenza A IgG Antibody Measurement	The determination of the amount of the Influenza A IgG antibody in a sample.			Laboratory Procedure	
C103409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103409>	C81971	Influenza B IgG Antibody Measurement	The determination of the amount of the Influenza B IgG antibody in a sample.			Laboratory Procedure	
C10340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10340>	C61063	Etoposide/Ifosfamide/Mitoxantrone|DHAD/IFF/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103410>	C81183	Isoleucine Measurement|ILE|Isoleucine|Isoleucine	The determination of the amount of the isoleucine in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103411>	C70699	Lavage Fluid|LAVAGE FLUID|Wash Fluid	Fluid introduced into, and collected from, a body cavity by lavage procedure.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103412>	C61042	LDL Particle Size Measurement|LDL Particle Size|LDL Particle Size|LDLPSZ	The determination of the amount of the average particle size of low-density lipoprotein in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103413>	C80157	Leukotriene B4 Measurement|LTB4|Leukotriene B4|Leukotriene B4	The determination of the amount of the leukotriene B4 in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103414>	C80157	Leukotriene D4 Measurement|LTD4|Leukotriene D4|Leukotriene D4	The determination of the amount of the leukotriene D4 in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103415>	C80157	Leukotriene E4 Measurement|LTE4|Leukotriene E4|Leukotriene E4	The determination of the amount of the leukotriene E4 in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103416>	C94189	Measured Tumor Identification|MEASURED	The identification of a tumor that is present at baseline and will be quantifiably measured over the course of the study.			Diagnostic Procedure	CDISC SDTM Terminology|CDISC SDTM Tumor and Lesion Identification Test Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C103417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103417>	C32298	Median Or Lower Cervical Lymph Node|MEDIAN OR LOWER CERVICAL LYMPH NODE	A lymph node located in the median or lower region of the neck. (NCI)			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103418>	C210010	Myelin Antibody Measurement	The determination of the amount of the myelin antibodies in a sample.			Laboratory Procedure	
C103419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103419>	C64430	N-acetyl-beta-D-glucosaminidase Measurement|Beta-N-acetyl-D-glucosaminidase|N-acetyl-beta-D-glucosaminidase|N-acetyl-beta-D-glucosaminidase|NAGASE	The determination of the amount of the N-acetyl-beta-D-glucosaminidase in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10341>	C61063	Thiotepa/Vincristine|TSPA/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103420>	C35571	New Lesion Progression|NEWLPROG	An assessment of the equivocality of disease progression based on a newly identified lesion.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Assessment Test Code Terminology|CDISC SDTM Tumor Response Assessment Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C103421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103421>	C25458	New Tumor Confirmation|NEWCONF|New Tumor Confirmed|New Tumor Confirmed	The confirmation (by other methods or modalities) that a tumor, which has not been previously seen or characterized, is present in the subject.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C103423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103423>	C94189	Non-Measurable Tumor Identification|NON-MEASURABLE	The identification of a tumor that is incapable of being measured at baseline.			Diagnostic Procedure	CDISC SDTM Terminology|CDISC SDTM Tumor and Lesion Identification Test Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C103424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103424>	C49484	Not All Lesions Evaluated|NOT ALL EVALUATED|Not All Evaluated|Not Evaluated	Not all target lesions were assessed. Or not all non-target lesions were assessed.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Terminology
C103425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103425>	C94189	Not Measured Tumor Identification|NOT MEASURED	The identification of a tumor that is present at baseline and will not be quantifiably measured over the course of the study.			Diagnostic Procedure	CDISC SDTM Terminology|CDISC SDTM Tumor and Lesion Identification Test Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C103426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103426>	C33027	Paratracheal Lymph Node|PARATRACHEAL LYMPH NODE	A lymph node located adjacent to the trachea within the mediastinum. (NCI)			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103427>	C62662	Platelet Aggregation Measurement|PLATAGGR|Platelet Aggregation|Platelet Aggregation|Platelet Function	The determination of the amount of the association of platelets to one another via adhesion molecules in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103428>	C32298	Posterior Cervical Lymph Node|POSTERIOR CERVICAL LYMPH NODE	A lymph node located in the posterior region of the neck. (NCI)			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103429>	C33027	Preauricular Lymph Node|PREAURICULAR LYMPH NODE|Pre-auricular Nodes|Preauricular Nodes	A lymph node located anterior to the auricle of the ear.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL Authorized Value Terminology|HL Biopsy/Surgical Procedures Table|HL Lesion Characteristics Table|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C10342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10342>	C61063	Cisplatin/Cyclophosphamide/Etoposide/Thiotepa/Vincristine|CDDP/CTX/TSPA/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103430>	C64430	Procalcitonin Measurement|PCT|Procalcitonin|Procalcitonin	The determination of the amount of the procalcitonin in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103431>	C103343	Prostaglandin D2 Measurement|PGD2|Prostaglandin D2|Prostaglandin D2	The determination of the amount of the prostaglandin D2 in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103432>	C64430	Prostaglandin D2 Synthase Measurement|Beta-Trace Protein|Beta-Trace Protein Measurement|PGD2S|Prostaglandin D2 Synthase|Prostaglandin D2 Synthase	The determination of the amount of the prostaglandin D2 synthase in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103433>	C64430	Prostaglandin E Synthase Measurement|PGES|Prostaglandin E Synthase|Prostaglandin E Synthase	The determination of the amount of the prostaglandin E synthase in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103434>	C103343	Prostaglandin E1 Measurement|PGE1|Prostaglandin E1|Prostaglandin E1	The determination of the amount of the prostaglandin E1 in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103435>	C103343	Prostaglandin E2 Measurement|PGE2|Prostaglandin E2|Prostaglandin E2	The determination of the amount of the prostaglandin E2 in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103436>	C103343	Prostaglandin F1 Alpha Measurement|PGF1A|Prostaglandin F1 Alpha|Prostaglandin F1 Alpha	The determination of the amount of the prostaglandin F1 alpha in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103437>	C103343	Prostaglandin F2 Alpha Measurement|PGF2A|Prostaglandin F2 Alpha|Prostaglandin F2 Alpha	The determination of the amount of the prostaglandin F2 alpha in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103438>	C25763	Rectosigmoid Colon|COLON, RECTOSIGMOID	A portion of the large intestine that includes the sigmoid colon and rectum.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C103439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103439>	C33027	Retrocrural Lymph Node|RETROCRURAL LYMPH NODE	A lymph node located within the most inferior portion of the posterior mediastinum. (NCI)			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10343>	C61063	Fluorouracil/Leucovorin Calcium/PALA|CF/5-FU/PALA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103440>	C81971|C163751	Rubella IgG Antibody Measurement	The determination of the amount of the Rubella IgG antibody in a sample.			Laboratory Procedure	
C103441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103441>	C96631	Sum of Diameters of Non Lymph Node Tumors|SUMNLNLD|Sum Diameters of Non Lymph Node Tumors|Sum Diameters of Non Lymph Node Tumors	A calculation of the aggregated diameter values for tumors other than the lymph nodes.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C103442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103442>	C94189	Target Extra Nodal Tumor Identification|TARGET EXTRA NODAL	The identification of a target tumor located outside of or independent of the lymph node.			Diagnostic Procedure	CDISC SDTM Terminology|CDISC SDTM Tumor and Lesion Identification Test Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C103443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103443>	C94189	Target Nodal Tumor Identification|TARGET NODAL	The identification of a target tumor located at or near the lymph node.			Diagnostic Procedure	CDISC SDTM Terminology|CDISC SDTM Tumor and Lesion Identification Test Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C103444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103444>	C94189	Target Nodule Tumor Identification|TARGET NODULE	The identification of a target tumor located within the liver or spleen, as defined by the International Working Group (IWG) guidelines for lymphoma.			Diagnostic Procedure	CDISC SDTM Terminology|CDISC SDTM Tumor and Lesion Identification Test Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C103445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103445>	C80157	Thromboxane B2 Measurement|TXB2|Thromboxane B2|Thromboxane B2	The determination of the amount of the thromboxane B2 in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103446>	C64430	Thyroglobulin Measurement|TG|TGLOB|Thyroglobulin|Thyroglobulin	The determination of the amount of the thyroglobulin in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103447>	C32298	Upper Cervical Lymph Node|UPPER CERVICAL LYMPH NODE	A lymph node located in the upper region of the neck. (NCI)			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103448>	C74949|C74906	Vitamin E to Cholesterol Ratio Measurement|VITECHOL|Vitamin E/Cholesterol|Vitamin E/Cholesterol	The determination of the ratio of vitamin E compared with the total cholesterol in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103449>	C74803	Vitamin K1 Measurement|Phylloquinone|Phytomenadione|VITK1|Vitamin K1|Vitamin K1	The determination of the amount of the Vitamin K1 in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10344>	C61063	Lomustine/Mitolactol/Procarbazine/Thioguanine|CCNU/DBD/PCB/TG			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103450>	C64806	VLDL Particle Size Measurement|VLDL Particle Size|VLDL Particle Size|VLDLPSZ	The determination of the amount of the average particle size of very-low-density lipoprotein in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103451>	C75385	Whole Parathyroid Hormone Measurement|PTHW|Parathyrin Hormone, Whole|Parathyroid Hormone, Whole|Parathyroid Hormone, Whole	The determination of the amount of the whole parathyroid hormone (consisting of amino acids 1-84) in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103452>	C66973	Per Milliliter|/mL|/mL|/mL|/mL|/ml|/ml|Per mL|per milliliter	A volume unit equal to one milliliter used as a denominator to build a derived unit expressed as a ratio. (NCI)			Quantitative Concept	HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C103453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103453>	C64431	Albumin to Total Protein Ratio Measurement|ALBPROT|Albumin/Total Protein|Albumin/Total Protein	The determination of the ratio of the albumin compared with total protein in a biological sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103454>	C34007	Iliac Fossa|ILIAC FOSSA	The large smooth and concave surface of the ilium.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103455>	C34007	Ischiorectal Fossa|ISCHIORECTAL FOSSA|Ischioanal Fossa	A tetrahedral region of adipose tissue located in the ischiorectal region with its base between the tuberosity of the ischium and the lower end of the rectum and its apex at the point where the obturator fascia and the Levator ani membrane divide.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C103456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103456>	C89807	Occipital Scalp|OCCIPITAL SCALP	The occipital region of the skin that covers the top of the head.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103457>	C27993	Very Severe|Very severe|Very severe	Exceedingly intense or unpleasant in degree, quality or extent.			Qualitative Concept	Patient Reported Outcomes Version of CTCAE|PRO-CTCAE Attribute Value Terminology|PRO-CTCAE Version 1.0 Questionnaire Terminology
C103458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103458>	C100110	CDISC Questionnaire ADCS-CGIC Test Name Terminology|ACGC01TN|Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change Questionnaire Test Name|QS-ADCS-CGIC TEST	Test names of questionnaire questions associated with the Alzheimer's disease cooperative study-clinical global impression of change questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103459>	C100110	CDISC Questionnaire ADCS-CGIC Test Code Terminology|ACGC01TC|Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change Questionnaire Test Code|QS-ADCS-CGIC TESTCD	Test codes of questionnaire questions associated with the Alzheimer's disease cooperative study-clinical global impression of change questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10345>	C67509|C63442|C63356	ICE Regimen|CBDCA/IFF/VP-16|Carboplatin/Etoposide/Ifosfamide|ICE|ICE|ICE|ICE|ICE regimen|Ifosfamide-Carboplatin-Etoposide Regimen|Ifosfamide/Carboplatin/Etoposide	A regimen consisting of carboplatin, etoposide and ifosfamide that can be used in the treatment of non-Hodgkin and Hodgkin lymphomas, including diffuse large B-cell lymphoma and T-cell lymphoma, mycosis fungoides/Sezary syndrome, and gestational trophoblastic neoplasia (GTN).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|NCI Drug Dictionary Terminology|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C103460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103460>	C100110	CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CSS02TN|Columbia-Suicide Severity Rating Scale Since Last Visit Questionnaire Test Name|QS-C-SSRS SINCE LAST VISIT TEST	Test names of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Since Last Visit (C-SSRS Since Last Vist) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103461>	C100110	CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CSS02TC|Columbia-Suicide Severity Rating Scale Since Last Visit Questionnaire Test Code|QS-C-SSRS SINCE LAST VISIT TESTCD	Test codes of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Since Last Visit (C-SSRS Since Last Vist) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103462>	C100110	CDISC Questionnaire ESS Test Name Terminology|ESS01TN|Epworth Sleepiness Scale Questionnaire Test Name|QS-ESS TEST	Test names of questionnaire questions associated with the Epworth sleepiness scale questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103463>	C100110	CDISC Questionnaire ESS Test Code Terminology|ESS01TC|Epworth Sleepiness Scale Questionnaire Test Code|QS-ESS TESTCD	Test codes of questionnaire questions associated with the Epworth sleepiness scale questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103464>	C100110	CDISC Questionnaire FIQR Test Name Terminology|FIQR01TN|QS-FIQR TEST|Revised Fibromyalgia Impact Questionnaire Questionnaire Test Name	Test names of questionnaire questions associated with the revised fibromyalgia impact questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103465>	C100110	CDISC Questionnaire FIQR Test Code Terminology|FIQR01TC|QS-FIQR TESTCD|Revised Fibromyalgia Impact Questionnaire Questionnaire Test Code	Test codes of questionnaire questions associated with the revised fibromyalgia impact questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103466>	C100110	CDISC Questionnaire GAD-7 Test Name Terminology|GAD01TN|Generalized Anxiety Disorder - 7 Questionnaire Test Name|QS-GAD-7 TEST	Test names of questionnaire questions associated with the generalized anxiety disorder 7 item questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103467>	C100110	CDISC Questionnaire GAD-7 Test Code Terminology|GAD01TC|Generalized Anxiety Disorder - 7 Questionnaire Test Code|QS-GAD-7 TESTCD	Test codes of questionnaire questions associated with the generalized anxiety disorder 7 item questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103468>	C100110	CDISC Questionnaire HADS Test Name Terminology|HADS01TN|Hospital Anxiety and Depression Scale Questionnaire Test Name|QS-HADS TEST	Test names of questionnaire questions associated with the hospital anxiety and depression scale questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103469>	C100110	CDISC Questionnaire HADS Test Code Terminology|HADS01TC|Hospital Anxiety and Depression Scale Questionnaire Test Code|QS-HADS TESTCD	Test codes of questionnaire questions associated with the hospital anxiety and depression scale questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10346>	C61063	Dexamethasone/Doxorubicin/Verapamil/Vincristine|DM/DOX/VCR/VPAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103470>	C100110	CDISC Questionnaire IIEF Test Name Terminology|IIEF01TN|International Index of Erectile Function Questionnaire Test Name|QS-IIEF TEST	Test names of questionnaire questions associated with the international index of erectile function questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103471>	C100110	CDISC Questionnaire IIEF Test Code Terminology|IIEF01TC|International Index of Erectile Function Questionnaire Test Code|QS-IIEF TESTCD	Test codes of questionnaire questions associated with the international index of erectile function questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103472>	C100110	CDISC Questionnaire NPS Test Name Terminology|NPS01TN|Neuropathic Pain Scale Questionnaire Test Name|QS-NPS TEST	Test names of questionnaire questions associated with the neuropathic pain scale questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103473>	C100110	CDISC Questionnaire NPS Test Code Terminology|NPS01TC|Neuropathic Pain Scale Questionnaire Test Code|QS-NPS TESTCD	Test codes of questionnaire questions associated with the neuropathic pain scale questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103474>	C100110	CDISC Questionnaire OAB-q Test Name Terminology|OABQ01TN|QS-OAB-q TEST|The Overactive Bladder Questionnaire Questionnaire Test Name	Test names of questionnaire questions associated with the overactive bladder questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103475>	C100110	CDISC Questionnaire OAB-q Test Code Terminology|OABQ01TC|QS-OAB-q TESTCD|The Overactive Bladder Questionnaire Questionnaire Test Code	Test codes of questionnaire questions associated with the overactive bladder questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103476>	C100110	CDISC Questionnaire OAB-q Short Form Test Name Terminology|OABQ02TN|QS-OAB-q Short Form TEST|The Overactive Bladder Questionnaire Short Form Questionnaire Test Name	Test names of questionnaire questions associated with the overactive bladder questionnaire short form for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103477>	C100110	CDISC Questionnaire OAB-q Short Form Test Code Terminology|OABQ02TC|QS-OAB-q Short Form TESTCD|The Overactive Bladder Questionnaire Short Form Questionnaire Test Code	Test codes of questionnaire questions associated with the overactive bladder questionnaire short form for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103478>	C100110	CDISC Questionnaire ODI v2.1a Test Name Terminology|ODI01TN|QS-ODI v2.1a TEST|The Oswestry Disability Index Version 2.1a Questionnaire Test Name	Test names of questionnaire questions associated with the Oswestry disability index version 2.1a questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103479>	C100110	CDISC Questionnaire ODI v2.1a Test Code Terminology|ODI01TC|QS-ODI v2.1a TESTCD|The Oswestry Disability Index Version 2.1a Questionnaire Test Code	Test codes of questionnaire questions associated with the Oswestry disability index version 2.1a questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10347>	C61063	Doxorubicin/Fluorouracil/Tamoxifen/Thiotepa|DOX/5-FU/TMX/TSPA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103480>	C100110	CDISC Questionnaire PHQ-9 Test Name Terminology|PHQ01TN|Patient Health Questionnaire - 9 Item Questionnaire Test Name|QS-PHQ-9 TEST	Test names of questionnaire questions associated with the 9 item patient health questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103481>	C100110	CDISC Questionnaire PHQ-9 Test Code Terminology|PHQ01TC|Patient Health Questionnaire - 9 Item Questionnaire Test Code|QS-PHQ-9 TESTCD	Test codes of questionnaire questions associated with the 9 item patient health questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103482>	C100110	CDISC Questionnaire PHQ-15 Test Name Terminology|PHQ02TN|Patient Health Questionnaire - 15 Item Questionnaire Test Name|QS-PHQ-15 TEST	Test names of questionnaire questions associated with the 15 item patient health questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103483>	C100110	CDISC Questionnaire PHQ-15 Test Code Terminology|PHQ02TC|Patient Health Questionnaire - 15 Item Questionnaire Test Code|QS-PHQ-15 TESTCD	Test codes of questionnaire questions associated with the 15 item patient health questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103484>	C100110	CDISC Questionnaire SIQR Test Name Terminology|QS-SIQR TEST|SIQR01TN|Symptom Impact Questionnaire Questionnaire Test Name	Test names of questionnaire questions associated with the symptom impact questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103485>	C100110	CDISC Questionnaire SIQR Test Code Terminology|QS-SIQR TESTCD|SIQR01TC|Symptom Impact Questionnaire Questionnaire Test Code	Test codes of questionnaire questions associated with the symptom impact questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103486>	C103175	CDISC Questionnaire SOWS Short Test Name Terminology|QS-SOWS Short TEST	Test names of questionnaire questions associated with the short opiate withdrawal scale questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	
C103487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103487>	C103175	CDISC Questionnaire SOWS Short Test Code Terminology|QS-SOWS Short TESTCD	Test codes of questionnaire questions associated with the short opiate withdrawal scale questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	
C103488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103488>	C100110	CDISC Questionnaire UPS Test Name Terminology|QS-UPS TEST|UPS01TN|Urgency Perception Scale Questionnaire Test Name	Test names of questionnaire questions associated with the urgency perception scale questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103489>	C100110	CDISC Questionnaire UPS Test Code Terminology|QS-UPS TESTCD|UPS01TC|Urgency Perception Scale Questionnaire Test Code	Test codes of questionnaire questions associated with the urgency perception scale questionnaire for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10348>	C61063	Fluorouracil/Methotrexate/Tamoxifen/Thiotepa|5-FU/MTX/TMX/TSPA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103490>	C211913	ADCS-CGIC Questionnaire Question	A question associated with the ADCS-CGIC questionnaire.			Intellectual Product	
C103491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103491>	C211913	C-SSRS Since Last Visit Questionnaire Question	A question associated with the C-SSRS Since Last Visit questionnaire.			Intellectual Product	
C103492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103492>	C211913	ESS Questionnaire Question	A question associated with the ESS questionnaire.			Intellectual Product	
C103493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103493>	C211913	FIQR Questionnaire Question	A question associated with the FIQR questionnaire.			Intellectual Product	
C103494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103494>	C211913	GAD-7 Questionnaire Question	A question associated with the GAD-7 questionnaire.			Intellectual Product	
C103495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103495>	C211913	HADS Questionnaire Question	A question associated with the HADS questionnaire.			Intellectual Product	
C103496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103496>	C211913	IIEF Questionnaire Question	A question associated with the IIEF questionnaire.			Intellectual Product	
C103497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103497>	C211913	NPS Questionnaire Question	A question associated with the NPS questionnaire.			Intellectual Product	
C103498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103498>	C211913	OAB-q Questionnaire Question	A question associated with the OAB-q questionnaire.			Intellectual Product	
C103499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103499>	C211913	OAB-q Short Form Questionnaire Question	A question associated with the OAB-q Short Form questionnaire.			Intellectual Product	
C10349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10349>	C61063	Cisplatin/Etoposide/Sargramostim|CDDP/GM-CSF/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1034>	C263	Heparin Calcium|Calciparine|HEPARIN CALCIUM	The calcium salt form of heparin.  As a glycosaminoglycan anticoagulant, heparin calcium binds to antithrombin III to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C103500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103500>	C211913	ODI v2.1a Questionnaire Question	A question associated with the ODI v2.1a questionnaire.			Intellectual Product	
C103501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103501>	C211913	PHQ-9 Questionnaire Question	A question associated with the PHQ-9 questionnaire.			Intellectual Product	
C103502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103502>	C211913	PHQ-15 Questionnaire Question	A question associated with the PHQ-15 questionnaire.			Intellectual Product	
C103503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103503>	C211913	SIQR Questionnaire Question	A question associated with the SIQR questionnaire.			Intellectual Product	
C103504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103504>	C211913	SOWS Short Questionnaire Question	A question associated with the SOWS Short questionnaire.			Intellectual Product	
C103505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103505>	C211913	UPS Questionnaire Question	A question associated with the UPS questionnaire.			Intellectual Product	
C103506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103506>	C175261	Likert Score 1	A subjective score of 1 on a Likert scale.			Intellectual Product	
C103507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103507>	C175261	Likert Score 6	A subjective score of 6 on a Likert scale.			Intellectual Product	
C103508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103508>	C175261	Likert Score 7	A subjective score of 7 on a Likert scale.			Intellectual Product	
C103509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103509>	C175261	Likert Score 8	A subjective score of 8 on a Likert scale.			Intellectual Product	
C10350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10350>	C61063	Cisplatin/Doxorubicin/Etoposide/Ifosfamide|CDDP/DOX/IFF/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103510>	C175261	Likert Score 9	A subjective score of 9 on a Likert scale.			Intellectual Product	
C103511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103511>	C3303	Worst Imaginable Pain|Pain as bad as you can imagine	The most severe pain an individual can conceive of experiencing.			Sign or Symptom	Linear Analogue Self-Assessment
C103512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103512>	C17204|C17007	Positron Emission Tomography and Computed Tomography Scan|PET-CT Scan|PET-CT Scan|PET/CT SCAN|Positron Emission Tomography/Computed Tomography	An imaging technique that utilizes positron emission tomography and computed tomography in a single machine.	Positron Emission Tomography and Computed Tomography Scan		Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|HL Authorized Value Terminology|HL Imaging Table|HL Lesion Characteristics Table|HL Subject Response Table
C103513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103513>	C18475|C16434	High Performance Liquid Chromatography Mass Spectrometry|HPLC/MS|High Performance Liquid Chromatography/Mass Spectrometry	An analytical technique wherein high performance liquid chromatography is coupled to mass spectrometry in order to separate, identify, and quantify substances in a sample.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103514>	C17007|C16809	Positron Emission Tomography and Magnetic Resonance Imaging|PET-MRI Scan|PET/MRI|PET/MRI SCAN|Positron Emission Tomography/Magnetic Resonance Imaging Hybrid Imaging	An imaging technique that utilizes positron emission tomography and magnetic resonance imaging in a single machine.	Positron Emission Tomography and Magnetic Resonance Imaging		Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|HL Authorized Value Terminology|HL Imaging Table|HL Lesion Characteristics Table|HL Subject Response Table
C103515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103515>	C91105	Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change Questionnaire|ACGC01|ADCS-CGIC|ADCS-CGIC	A standardized rating scale developed by Lon S. Schneider in 1997 to evaluate a clinically relevant change in an individual's Alzheimer's Disease symptoms. This instrument consists of an interview that is given to both the patient and their caregiver by a clinician at a baseline visit and then is repeated at the 2, 6, and 12 month visits. Based on the information gather at the 2, 6, and 12 month visits, the clinician rates the patients change from baseline on a 7 increment scale ranging from 'Marked Improvement' to 'Marked Worsening.'			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103516>	C91105	Columbia-Suicide Severity Rating Scale Since Last Visit Questionnaire|C-SSRS SINCE LAST VISIT|C-SSRS Since Last Visit|CSS02	A standardized survey developed and copyrighted by Kelly Posner and colleagues with The Research Foundation for Mental Hygiene in 2008 which is used to evaluate a patient's suicidal tendencies at a subsequent visit. The since last visit version questionnaire contains four sections with approximately 40 questions and is administered in an interview format. The first three sections pertain to the patient's suicidal ideations and behaviors while the fourth section assess any actual suicide attempts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103517>	C91105	Epworth Sleepiness Scale Questionnaire|ESS|ESS|ESS01|Epworth Sleepiness Scale	A standardized rating scale used to assess an individual's general level of daytime sleepiness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103518>	C91105	Revised Fibromyalgia Impact Questionnaire|FIQR|FIQR|FIQR01	A standardized survey originally developed in the late 1980s and subsequently copyrighted by Robert M Bennett and Ronald Friend and published in the Arthritis Research and Therapy journal (Bennett RM, Friend R, Jones KD, Ward R, Han BK, and Ross RL. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Research and Therapy 2009, 11:R120) which is used to evaluate an individual's fibromyalgia symptoms and the extent they interfere with daily living. This instrument is a self-administered questionnaire with 3 sections with a total of 21 items pertaining to the difficulty of performing an activity, the overall impact of fibromyalgia, and the intensity of common fibromyalgia symptoms all within the past 7 days. Each item is ranked on a scale from 0-10.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103519>	C91105	Generalized Anxiety Disorder - 7 Questionnaire|GAD-7|GAD-7|GAD01|General Anxiety Disorder-7|General Anxiety Disorder-7 Questionnaire|Generalized Anxiety Disorder 7-item Scale (GAD-7)	A seven item validated, self-reported questionnaire for screening, and assessing the severity of generalized anxiety disorder in clinical practice and research settings.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10351>	C61063	Cyclophosphamide/Interleukin-2/Lymphokine-Activated Killer Cells|CTX/IL-2/LAK			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103520>	C91105	Hospital Anxiety and Depression Scale Questionnaire|HADS|HADS|HADS Questionnaire|HADS01|Hospital Anxiety and Depression Scale Questionnaire (HADS)	A standardized survey developed and copyrighted by A. S. Zigmond and R. P. Snaith in 1983, 1992, 1994 and published in the Acta Psychiatrica Scandinavica journal (A.S. Zigmond and R.P. Snaith. The Hospital Anxiety and Depression Scale. Acta psychiart. scand. 1983, 67:361-370) which is used to detect depression and anxiety in individuals in a hospital or medical outpatient clinic. This instrument is a self-administered questionnaire consisting of 14 items that assess how the individual has felt over the past week. Each item as 4 response options that are associated with a score of 0 to 3.	Hospital Anxiety and Depression Scale Questionnaire		Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C103521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103521>	C91105	International Index of Erectile Function Questionnaire|IIEF|IIEF|IIEF01	A standardized survey developed and published by Raymond C. Rosen and colleagues in 1997 which is used to assess erectile function. This instrument is a self-administered questionnaire with 15 items each with as set of 5 or 6 response options associated with a score of 1-5 or 1-6.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103522>	C91105|C20995	Neuropathic Pain Scale Questionnaire|NPS|NPS|NPS01	A standardized survey developed and copyrighted by Brad Galer and Mark Jensen in 1997 and published in the journal Neurology (BS Galer and MP Jensen. Development and preliminary validation of a pain measure specific to neuropathic pain: The Neuropathic Pain Scale. Neurology. 1997, 48:332-338.) which is used to assess specific pain qualities associated with neuropathic pain. This instrument consists of 10 items that can be completed by the patient. Each item is rated on a scale of 0-10 with 0 representing none and 10 representing the worst. However, one item is multi-level with open ended responses.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103523>	C91105	The Overactive Bladder Questionnaire|OAB-Q|OAB-q|OABQ01	A standardized survey developed and published by K. Coyne and colleagues in 2002 in the journal Quality of Life Research which is used to evaluate the all symptoms associated with overactive bladder. This instrument contains 33 items pertaining to bladder symptoms occurring during the past week that can be self-administered. Each item is rated on a scale of 1-6 with 1 representing none or not at all and 6 representing a great deal or all the time.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103524>	C91105	The Overactive Bladder Questionnaire Short Form|OAB-Q SHORT FORM|OAB-q Short Form|OABQ02	A standardized survey developed by K. Coyne and colleagues in 2004 and presented at the Joint Meeting of the International Continence Society and the International Urogynecological Association which is used to evaluate the symptoms associated with overactive bladder. This self-administered, shorter version of the Overactive Bladder Questionnaire (OAB-q) contains 19 items pertaining to bladder symptoms occurring during the past four weeks. Each item is rated on a scale of 1-6 with 1 representing none or not at all and 6 representing a great deal or all the time.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103525>	C91105	The Oswestry Disability Index Version 2.1a Questionnaire|ODI V2.1A|ODI v2.1a|ODI01	A standardized survey initially developed by John O'Brien in 1976 then published in 1980 by Jeremy Fairbank. This version (2.1a) is copyrighted by Jeremy Fairbank and is used in the assessment and management of spinal disorders. There are 10 items pertaining to a variety of topics including personal care, walking, standing, sleeping and traveling. Each item has six responses.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103526>	C91105	Patient Health Questionnaire - 9 Item|PHQ-9|PHQ-9|PHQ01|Patient Health Questionnaire (PHQ-9)|Patient Health Questionnaire-9	A 9-item scale using each of the 9 DSM-IV criteria with self-reported frequency of "0" (not at all) to "3" (nearly every day). One of the most widely used instruments to assess depression, PHQ-9 scores of 5, 10, 15, and 20 represent mild, moderate, moderately severe, and severe depression, respectively.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103527>	C91105	Patient Health Questionnaire - 15 Item|PHQ-15|PHQ-15|PHQ02	A standardized survey developed and published by Kurt Kroenke, Robert Spitzer and Janet Williams in 2002 in the journal Psychosomatic Medicine which is used to assess the severity of an individual's somatic symptoms. This self-administered instrument contains 15 items pertaining to topics such as stomach pain, headaches, dizziness, and trouble sleeping. Each item is rated on a scale of 0-2 with 0 being 'not bothered at all' and 2 being 'bothered a lot.'			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103528>	C91105	Symptom Impact Questionnaire|SIQR|SIQR|SIQR01	A standardized survey developed and copyrighted by Ronald Friend and Robert Bennett that is published in the journal Arthritis Research and Therapy. This instrument was developed along with the Revised Fibromyalgia Questionnaire (FIQR) and was intended for use in assessing symptoms associated with rheumatoid arthritis and systemic lupus erythematous. There are three sections including function, overall impact and symptoms with a total of 21 items. Each item is rated on a 0-10 scale with 0 being none and 10 being the most severe.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103529>	C91105	Short Opiate Withdrawal Scale Questionnaire|SOWS SHORT|SOWS Short|SOWSB1	A standardized survey developed and published by Michael Gossop in the journal Addictive Behaviors which is used to assess the signs and symptoms associated with opiate withdrawal. This instrument is a shorter version of the Opiate Withdrawal Scale (OWS) containing 10 items related to symptoms such as stomach cramps, heart pounding and runny eyes. Each item is rated as none, mild, moderate or severe.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10352>	C61063	Edatrexate/Mitomycin/Vinblastine|EDAM/MITO/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103530>	C91105	Urgency Perception Scale Questionnaire|UPS|UPS01|USP	A standardized rating scale developed and published by Linda Cardozo, Karin Coyne and Eboo Versi in 2004 and copyrighted by Pfizer which is used to assess an individual's sense of urinary urgency. This instrument consists of one item in which the individual rates their experience when they have the desire to urinate. The item has three responses that receive a score of 0, 1, or 2.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103531>	C103490	ADCS-CGIC - Clinical Impression of Change from Baseline|ACGC01-Clinical Impression of Change|ACGC01-Clinical Impression of Change|ACGC0101	Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Clinical impression of change from baseline.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-CGIC Test Code Terminology|CDISC Questionnaire ADCS-CGIC Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103532>	C103491	C-SSRS Since Last Visit - Suicide|CSS02-Suicide|CSS02-Suicide|CSS0221	C-SSRS Since Last Visit (C-SSRS Since Last Visit) Suicide.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103533>	C103491	C-SSRS Since Last Visit - Most Lethal Attempt Date|CSS02-Most Lethal Attempt Date|CSS02-Most Lethal Attempt Date|CSS0222A	C-SSRS Since Last Visit (C-SSRS Since Last Visit) Most lethal actual attempt date.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103534>	C103491	C-SSRS Since Last Visit - Most Lethal Actual Attempt Lethality/Medical Damage|CSS02-Most Lethal Attempt Damage|CSS02-Most Lethal Attempt Damage|CSS0222B	C-SSRS Since Last Visit (C-SSRS Since Last Visit) Most lethal actual attempt lethality/medical damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103535>	C103491	C-SSRS Since Last Visit - Most Lethal Actual Attempt Potential Lethality|CSS02-Most Lethal Attempt Potential|CSS02-Most Lethal Attempt Potential|CSS0222C	C-SSRS Since Last Visit (C-SSRS Since Last Visit) Most lethal actual attempt potential lethality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103536>	C103492	ESS - Sitting and Reading|ESS01-Sitting and Reading|ESS01-Sitting and Reading|ESS0101	Epworth Sleepiness Scale (ESS) Sitting and reading.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ESS Test Code Terminology|CDISC Questionnaire ESS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103537>	C103492	ESS - Watching TV|ESS01-Watching TV|ESS01-Watching TV|ESS0102	Epworth Sleepiness Scale (ESS) Watching TV.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ESS Test Code Terminology|CDISC Questionnaire ESS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103538>	C103492	ESS - Sitting, Inactive in a Public Place|ESS01-Sitting Inactive in a Public Place|ESS01-Sitting Inactive in a Public Place|ESS0103	Epworth Sleepiness Scale (ESS) Sitting, inactive in a public place (e.g. a theatre or a meeting).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ESS Test Code Terminology|CDISC Questionnaire ESS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103539>	C103492	ESS - As a Passenger in a Car for an Hour Without a Break|ESS01-Passenger for Hour Without Break|ESS01-Passenger for Hour Without Break|ESS0104	Epworth Sleepiness Scale (ESS) As a passenger in a car for an hour without a break.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ESS Test Code Terminology|CDISC Questionnaire ESS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10353>	C61063	Cyclophosphamide/Doxorubicin/Fluorouracil/Goserelin/Tamoxifen|CTX/DOX/5-FU/TMX/ZDX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103540>	C103492	ESS - Lying Down to Rest in the Afternoon When Circumstances Permit|ESS01-Lying Down to Rest In Afternoon|ESS01-Lying Down to Rest In Afternoon|ESS0105	Epworth Sleepiness Scale (ESS) Lying down to rest in the afternoon when circumstances permit.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ESS Test Code Terminology|CDISC Questionnaire ESS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103541>	C103492	ESS - Sitting and Talking to Someone|ESS01-Sitting and Talking to Someone|ESS01-Sitting and Talking to Someone|ESS0106	Epworth Sleepiness Scale (ESS) Sitting and talking to someone.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ESS Test Code Terminology|CDISC Questionnaire ESS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103542>	C103492	ESS - Sitting Quietly After a Lunch without Alcohol|ESS01-Sitting Quietly After Lunch|ESS01-Sitting Quietly After Lunch|ESS0107	Epworth Sleepiness Scale (ESS) Sitting quietly after a lunch without alcohol.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ESS Test Code Terminology|CDISC Questionnaire ESS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103543>	C103492	ESS - In a car, While Stopped for a Few Minutes in the Traffic|ESS01-In Car Stopped Few Minutes Traffic|ESS01-In Car Stopped Few Minutes Traffic|ESS0108	Epworth Sleepiness Scale (ESS) In a car, while stopped for a few minutes in the traffic.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ESS Test Code Terminology|CDISC Questionnaire ESS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103544>	C103493	FIQR - Brush or Comb Your Hair|FIQR01-Brush or Comb Your Hair|FIQR01-Brush or Comb Your Hair|FIQR0101	Revised Fibromyalgia Impact Questionnaire (FIQR) Brush or comb your hair.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FIQR Test Code Terminology|CDISC Questionnaire FIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103545>	C103493	FIQR - Walk Continuously for 20 Minutes|FIQR01-Walk Continuously for 20 Minutes|FIQR01-Walk Continuously for 20 Minutes|FIQR0102	Revised Fibromyalgia Impact Questionnaire (FIQR) Walk continuously for 20 minutes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FIQR Test Code Terminology|CDISC Questionnaire FIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103546>	C103493	FIQR - Prepare a Homemade Meal|FIQR01-Prepare a Homemade Meal|FIQR01-Prepare a Homemade Meal|FIQR0103	Revised Fibromyalgia Impact Questionnaire (FIQR) Prepare a homemade meal.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FIQR Test Code Terminology|CDISC Questionnaire FIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103547>	C103493	FIQR - Vacuum Scrub or Sweep Floors|FIQR01-Vacuum Scrub or Sweep Floors|FIQR01-Vacuum Scrub or Sweep Floors|FIQR0104	Revised Fibromyalgia Impact Questionnaire (FIQR) Vacuum, scrub or sweep floors.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FIQR Test Code Terminology|CDISC Questionnaire FIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103548>	C103493	FIQR - Lift and Carry a Bag Full of Groceries|FIQR01-Lift/Carry Bag Full of Groceries|FIQR01-Lift/Carry Bag Full of Groceries|FIQR0105	Revised Fibromyalgia Impact Questionnaire (FIQR) Lift and carry a bag full of groceries.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FIQR Test Code Terminology|CDISC Questionnaire FIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103549>	C103493	FIQR - Climb One Flight of Stairs|FIQR01-Climb One Flight of Stairs|FIQR01-Climb One Flight of Stairs|FIQR0106	Revised Fibromyalgia Impact Questionnaire (FIQR) Climb one flight of stairs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FIQR Test Code Terminology|CDISC Questionnaire FIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10354>	C61063	Cyclophosphamide/Doxorubicin/Fluorouracil/Goserelin|CTX/DOX/5-FU/ZDX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103550>	C103493	FIQR - Change Bed Sheets|FIQR01-Change Bed Sheets|FIQR01-Change Bed Sheets|FIQR0107	Revised Fibromyalgia Impact Questionnaire (FIQR) Change bed sheets.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FIQR Test Code Terminology|CDISC Questionnaire FIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103551>	C103493	FIQR - Sit in a Chair for 45 Minutes|FIQR01-Sit in a Chair for 45 Minutes|FIQR01-Sit in a Chair for 45 Minutes|FIQR0108	Revised Fibromyalgia Impact Questionnaire (FIQR) Sit in a chair for 45 minutes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FIQR Test Code Terminology|CDISC Questionnaire FIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103552>	C103493	FIQR - Go Shopping for Groceries|FIQR01-Go Shopping for Groceries|FIQR01-Go Shopping for Groceries|FIQR0109	Revised Fibromyalgia Impact Questionnaire (FIQR) Go shopping for groceries.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FIQR Test Code Terminology|CDISC Questionnaire FIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103553>	C103493	FIQR - Fibromyalgia Prevented Me from Accomplishing Goals for the Week|FIQR01-Fibromyalgia Prevented Goals|FIQR01-Fibromyalgia Prevented Goals|FIQR0110	Revised Fibromyalgia Impact Questionnaire (FIQR) Fibromyalgia prevented me from accomplishing goals for the week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FIQR Test Code Terminology|CDISC Questionnaire FIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103554>	C103493	FIQR - I was Completely Overwhelmed by My Fibromyalgia Symptoms|FIQR01-Overwhelmed by Fibromyalgia|FIQR01-Overwhelmed by Fibromyalgia|FIQR0111	Revised Fibromyalgia Impact Questionnaire (FIQR) I was completely overwhelmed by my fibromyalgia symptoms.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FIQR Test Code Terminology|CDISC Questionnaire FIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103555>	C103493	FIQR - Pain|FIQR01-Pain|FIQR01-Pain|FIQR0112	Revised Fibromyalgia Impact Questionnaire (FIQR) Please rate your level of pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FIQR Test Code Terminology|CDISC Questionnaire FIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103556>	C103493	FIQR - Energy|FIQR01-Energy|FIQR01-Energy|FIQR0113	Revised Fibromyalgia Impact Questionnaire (FIQR) Please rate your level of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FIQR Test Code Terminology|CDISC Questionnaire FIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103557>	C103493	FIQR - Stiffness|FIQR01-Stiffness|FIQR01-Stiffness|FIQR0114	Revised Fibromyalgia Impact Questionnaire (FIQR) Please rate your level of stiffness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FIQR Test Code Terminology|CDISC Questionnaire FIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103558>	C103493	FIQR - Your Sleep|FIQR01-Your Sleep|FIQR01-Your Sleep|FIQR0115	Revised Fibromyalgia Impact Questionnaire (FIQR) Please rate the quality of your sleep.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FIQR Test Code Terminology|CDISC Questionnaire FIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103559>	C103493	FIQR - Depression|FIQR01-Depression|FIQR01-Depression|FIQR0116	Revised Fibromyalgia Impact Questionnaire (FIQR) Please rate your level of depression.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FIQR Test Code Terminology|CDISC Questionnaire FIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10355>	C61063	Carmustine/Tiazofurin|BCNU/TCAR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103560>	C103493	FIQR - Memory Problems|FIQR01-Memory Problems|FIQR01-Memory Problems|FIQR0117	Revised Fibromyalgia Impact Questionnaire (FIQR) Please rate your level of memory problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FIQR Test Code Terminology|CDISC Questionnaire FIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103561>	C103493	FIQR - Anxiety|FIQR01-Anxiety|FIQR01-Anxiety|FIQR0118	Revised Fibromyalgia Impact Questionnaire (FIQR) Please rate your level of anxiety.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FIQR Test Code Terminology|CDISC Questionnaire FIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103562>	C103493	FIQR - Tenderness to Touch|FIQR01-Tenderness to Touch|FIQR01-Tenderness to Touch|FIQR0119	Revised Fibromyalgia Impact Questionnaire (FIQR) Please rate your level of tenderness to touch.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FIQR Test Code Terminology|CDISC Questionnaire FIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103563>	C103493	FIQR - Balance Problems|FIQR01-Balance Problems|FIQR01-Balance Problems|FIQR0120	Revised Fibromyalgia Impact Questionnaire (FIQR) Please rate your level of balance problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FIQR Test Code Terminology|CDISC Questionnaire FIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103564>	C103493	FIQR - Sensitivity to Loud Noises, Bright Lights, Odors and Cold|FIQR01-Sensitivity Noise/Light/Odor/Cold|FIQR01-Sensitivity Noise/Light/Odor/Cold|FIQR0121	Revised Fibromyalgia Impact Questionnaire (FIQR) Please rate your level of sensitivity to loud noises, bright lights, odors and cold.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FIQR Test Code Terminology|CDISC Questionnaire FIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103565>	C103494	GAD-7 - Feeling Nervous Anxious or On Edge|GAD01-Feeling Nervous Anxious or On Edge|GAD01-Feeling Nervous Anxious or On Edge|GAD0101	Generalized Anxiety Disorder - 7 (GAD-7) Feeling nervous, anxious or on edge.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GAD-7 Test Code Terminology|CDISC Questionnaire GAD-7 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103566>	C103494	GAD-7 - Not Being Able to Stop or Control Worrying|GAD01-Not Able to Stop/Control Worrying|GAD01-Not Able to Stop/Control Worrying|GAD0102	Generalized Anxiety Disorder - 7 (GAD-7) Not being able to stop or control worrying.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GAD-7 Test Code Terminology|CDISC Questionnaire GAD-7 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103567>	C103494	GAD-7 - Worrying Too Much About Different Things|GAD01-Worrying Too Much About Things|GAD01-Worrying Too Much About Things|GAD0103	Generalized Anxiety Disorder - 7 (GAD-7) Worrying too much about different things.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GAD-7 Test Code Terminology|CDISC Questionnaire GAD-7 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103568>	C103494	GAD-7 - Trouble Relaxing|GAD01-Trouble Relaxing|GAD01-Trouble Relaxing|GAD0104	Generalized Anxiety Disorder - 7 (GAD-7) Trouble relaxing.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GAD-7 Test Code Terminology|CDISC Questionnaire GAD-7 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103569>	C103494	GAD-7 - Being so Restless That it is Hard to Sit Still|GAD01-Being Restless Hard to Sit Still|GAD01-Being Restless Hard to Sit Still|GAD0105	Generalized Anxiety Disorder - 7 (GAD-7) Being so restless that it is hard to sit still.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GAD-7 Test Code Terminology|CDISC Questionnaire GAD-7 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10356>	C61063	Cisplatin/Fluorouracil/Leucovorin Calcium/Mitomycin|CDDP/CF/5-FU/MITO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103570>	C103494	GAD-7 - Becoming Easily Annoyed or Irritable|GAD01-Becoming Easily Annoyed/Irritable|GAD01-Becoming Easily Annoyed/Irritable|GAD0106	Generalized Anxiety Disorder - 7 (GAD-7) Becoming easily annoyed or irritable.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GAD-7 Test Code Terminology|CDISC Questionnaire GAD-7 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103571>	C103494	GAD-7 - Feel Afraid as if Something Awful Might Happen|GAD01-Feel Afraid/Something Awful Happen|GAD01-Feel Afraid/Something Awful Happen|GAD0107	Generalized Anxiety Disorder - 7 (GAD-7) Feeling afraid as if something awful might happen.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GAD-7 Test Code Terminology|CDISC Questionnaire GAD-7 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103572>	C103494	GAD-7 - Problems Made it Difficult to Work, Take Care of Things, or Get Along with Other People|GAD01-Difficult to Work/Take Care Things|GAD01-Difficult to Work/Take Care Things|GAD0108	Generalized Anxiety Disorder - 7 (GAD-7) If you checked off any problems, how difficult have these problems made it for you to do your work, take care of things at home, or get along with other people?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GAD-7 Test Code Terminology|CDISC Questionnaire GAD-7 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103573>	C103495	HADS - I Feel Tense or Wound Up|HADS01-I Feel Tense or Wound Up|HADS01-I Feel Tense or Wound Up|HADS0101	Hospital Anxiety and Depression Scale (HADS) I feel tense or 'wound up.'			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HADS Test Code Terminology|CDISC Questionnaire HADS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103574>	C103495	HADS - I Still Enjoy the Things I Used to Enjoy|HADS01-Enjoy the Things I Used to Enjoy|HADS01-Enjoy the Things I Used to Enjoy|HADS0102	Hospital Anxiety and Depression Scale (HADS) I still enjoy the things I used to enjoy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HADS Test Code Terminology|CDISC Questionnaire HADS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103575>	C103495	HADS - I Get a Frightened Feeling Something Awful is About to Happen|HADS01-Something Awful About to Happen|HADS01-Something Awful About to Happen|HADS0103	Hospital Anxiety and Depression Scale (HADS) I get a sort of frightened feeling as if something awful is about to happen.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HADS Test Code Terminology|CDISC Questionnaire HADS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103576>	C103495	HADS - I Can Laugh and See Funny Side of Things|HADS01-I Can Laugh and See Funny Side|HADS01-I Can Laugh and See Funny Side|HADS0104	Hospital Anxiety and Depression Scale (HADS) I can laugh and see the funny side of things.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HADS Test Code Terminology|CDISC Questionnaire HADS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103577>	C103495	HADS - Worrying Thoughts Go Through My Mind|HADS01-Worrying Thoughts Go Through Mind|HADS01-Worrying Thoughts Go Through Mind|HADS0105	Hospital Anxiety and Depression Scale (HADS) Worrying thoughts go through my mind.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HADS Test Code Terminology|CDISC Questionnaire HADS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103578>	C103495	HADS - I Feel Cheerful|HADS01-I Feel Cheerful|HADS01-I Feel Cheerful|HADS0106	Hospital Anxiety and Depression Scale (HADS) I feel cheerful.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HADS Test Code Terminology|CDISC Questionnaire HADS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103579>	C103495	HADS - I Can Sit at Ease and Feel Relaxed|HADS01-Sit at Ease and Feel Relaxed|HADS01-Sit at Ease and Feel Relaxed|HADS0107	Hospital Anxiety and Depression Scale (HADS) I can sit at ease and feel relaxed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HADS Test Code Terminology|CDISC Questionnaire HADS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10357>	C61063	Asparaginase/Cyclophosphamide/Cytarabine/Thioguanine/Vincristine|ARA-C/ASP/CTX/TG/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103580>	C103495	HADS - I Feel as if I am Slowed Down|HADS01-I Feel as if I am Slowed Down|HADS01-I Feel as if I am Slowed Down|HADS0108	Hospital Anxiety and Depression Scale (HADS) I feel as if I am slowed down.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HADS Test Code Terminology|CDISC Questionnaire HADS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103581>	C103495	HADS - I Get Frightened Feeling Like Butterflies in the Stomach|HADS01-Butterflies in the Stomach|HADS01-Butterflies in the Stomach|HADS0109	Hospital Anxiety and Depression Scale (HADS) I get a sort of frightened feeling like 'butterflies' in the stomach.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HADS Test Code Terminology|CDISC Questionnaire HADS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103582>	C103495	HADS - I Have Lost Interest in My Appearance|HADS01-Lost Interest in My Appearance|HADS01-Lost Interest in My Appearance|HADS0110	Hospital Anxiety and Depression Scale (HADS) I have lost interest in my appearance.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HADS Test Code Terminology|CDISC Questionnaire HADS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103583>	C103495	HADS - I Feel Restless as if I Have to be on the Move|HADS01-Feel Restless be on the Move|HADS01-Feel Restless be on the Move|HADS0111	Hospital Anxiety and Depression Scale (HADS) I feel restless as if I have to be on the move.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HADS Test Code Terminology|CDISC Questionnaire HADS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103584>	C103495	HADS - I Look Forward with Enjoyment to Things|HADS01-Look Forward with Enjoyment|HADS01-Look Forward with Enjoyment|HADS0112	Hospital Anxiety and Depression Scale (HADS) I look forward with enjoyment to things.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HADS Test Code Terminology|CDISC Questionnaire HADS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103585>	C103495	HADS - I Get Sudden Feelings of Panic|HADS01-I Get Sudden Feelings of Panic|HADS01-I Get Sudden Feelings of Panic|HADS0113	Hospital Anxiety and Depression Scale (HADS) I get sudden feelings of panic.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HADS Test Code Terminology|CDISC Questionnaire HADS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103586>	C103495	HADS - I Can Enjoy a Good Book or Radio or Television Programme|HADS01-Enjoy Good Book/Radio/Television|HADS01-Enjoy Good Book/Radio/Television|HADS0114	Hospital Anxiety and Depression Scale (HADS) I can enjoy a good book or radio or television programme.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HADS Test Code Terminology|CDISC Questionnaire HADS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103587>	C103496	IIEF - Able to Get an Erection During Sexual Activity|IIEF01-Erection During Sexual Activity|IIEF01-Erection During Sexual Activity|IIEF01-Erection Frequency|IIEF0101	International Index of Erectile Function (IIEF) Over the past four weeks how often were you able to get an erection during sexual activity?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IIEF Test Code Terminology|CDISC Questionnaire IIEF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103588>	C103496	IIEF - Erections Hard Enough for Penetration|IIEF01-Erection Firmness|IIEF01-Erection Hard Enough to Penetrate|IIEF01-Erection Hard Enough to Penetrate|IIEF0102	International Index of Erectile Function (IIEF) Over the past four weeks when you had erections with sexual stimulation, how often were your erections hard enough for penetration?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IIEF Test Code Terminology|CDISC Questionnaire IIEF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103589>	C103496	IIEF - Able to Penetrate Your Partner|IIEF01-Able to Penetrate Your Partner|IIEF01-Able to Penetrate Your Partner|IIEF01-Penetration Ability|IIEF0103	International Index of Erectile Function (IIEF) Over the past four weeks when you attempted sexual intercourse, how often were you able to penetrate (enter) your partner?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IIEF Test Code Terminology|CDISC Questionnaire IIEF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10358>	C61063	Interferon Gamma/Sargramostim|GM-CSF/IFN-G			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103590>	C103496	IIEF - Able to Maintain Your Erection After You Had Penetrated Your Partner|IIEF01-Maintain Erection After Penetrate|IIEF01-Maintain Erection After Penetrate|IIEF01-Maintenance Frequency|IIEF0104	International Index of Erectile Function (IIEF) Over the past four weeks during sexual intercourse, how often were you able to maintain your erection after you had penetrated (entered) your partner?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IIEF Test Code Terminology|CDISC Questionnaire IIEF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103591>	C103496	IIEF - Maintain Your Erection to Completion of Intercourse|IIEF01-Maintain Erection to Completion|IIEF01-Maintain Erection to Completion|IIEF01-Maintenance Ability|IIEF0105	International Index of Erectile Function (IIEF) Over the past four weeks during sexual intercourse, how difficult was it to maintain your erection to completion of intercourse?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IIEF Test Code Terminology|CDISC Questionnaire IIEF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103592>	C103496	IIEF - How Many Times Have You Attempted Sexual Intercourse|IIEF01-Intercourse Frequency|IIEF01-Times Attempted Sexual Intercours|IIEF01-Times Attempted Sexual Intercours|IIEF0106	International Index of Erectile Function (IIEF) Over the past four weeks how many times have you attempted sexual intercourse?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IIEF Test Code Terminology|CDISC Questionnaire IIEF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103593>	C103496	IIEF - How Often was it Satisfactory for You|IIEF01-How Often was it Satisfactory|IIEF01-How Often was it Satisfactory|IIEF01-Intercourse Satisfaction|IIEF0107	International Index of Erectile Function (IIEF) Over the past four weeks when you attempted sexual intercourse, how often was it satisfactory for you?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IIEF Test Code Terminology|CDISC Questionnaire IIEF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103594>	C103496	IIEF - How Much Have You Enjoyed Sexual Intercourse|IIEF01-Enjoyed Sexual Intercourse|IIEF01-Enjoyed Sexual Intercourse|IIEF01-Intercourse Enjoyment|IIEF0108	International Index of Erectile Function (IIEF) Over the past four weeks how much have you enjoyed sexual intercourse?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IIEF Test Code Terminology|CDISC Questionnaire IIEF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103595>	C103496	IIEF - How Often Did You Ejaculate|IIEF01-Ejaculation Frequency|IIEF01-How Often Did You Ejaculate|IIEF01-How Often Did You Ejaculate|IIEF0109	International Index of Erectile Function (IIEF) Over the past four weeks when you had sexual stimulation or intercourse, how often did you ejaculate?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IIEF Test Code Terminology|CDISC Questionnaire IIEF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103596>	C103496	IIEF - Did You Have Feeling of Orgasm With or Without Ejaculation|IIEF01-Did You Have Feeling of Orgasm|IIEF01-Did You Have Feeling of Orgasm|IIEF01-Orgasm Frequency|IIEF0110	International Index of Erectile Function (IIEF) Over the past four weeks when you had sexual stimulation or intercourse, how often did you have the feeling of orgasm with our without ejaculation?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IIEF Test Code Terminology|CDISC Questionnaire IIEF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103597>	C103496	IIEF - How Often Have You Felt Sexual Desire|IIEF01-Desire Frequency|IIEF01-Have You Felt Sexual Desire|IIEF01-Have You Felt Sexual Desire|IIEF0111	International Index of Erectile Function (IIEF) Over the past four weeks how often have you felt sexual desire?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IIEF Test Code Terminology|CDISC Questionnaire IIEF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103598>	C103496	IIEF - Rate Your Level of Sexual Desire|IIEF01-Desire Level|IIEF01-Rate Your Level of Sexual Desire|IIEF01-Rate Your Level of Sexual Desire|IIEF0112	International Index of Erectile Function (IIEF) Over the past four weeks how would you rate your level of sexual desire?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IIEF Test Code Terminology|CDISC Questionnaire IIEF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103599>	C103496	IIEF - Satisfied with Overall Sex Life|IIEF01-Overall Satisfaction|IIEF01-Satisfied with Overall Sex Life|IIEF01-Satisfied with Overall Sex Life|IIEF0113	International Index of Erectile Function (IIEF) Over the past four weeks how satisfied have you been with your overall sex life?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IIEF Test Code Terminology|CDISC Questionnaire IIEF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10359>	C61063	Cytarabine/Daunorubicin/Etoposide/Prednisolone/Thioguanine/Vincristine|ARA-C/DNR/PRDL/TG/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1035>	C1927	Calicheamicin Gamma 1I	An oligosaccharide enediyne antitumor antibiotic isolated from Micromonospora echinospora ssp. Calichensis.  Calicheamicin Gamma 1I binds to the minor groove of DNA, resulting in site-specific double-strand breaks and apoptosis. (NCI04)			Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C103600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103600>	C103496	IIEF - Satisfied with Your Sexual Relationship with Your Partner|IIEF01-Relationship Satisfaction|IIEF01-Satisfy with Sexual Relationship|IIEF01-Satisfy with Sexual Relationship|IIEF0114	International Index of Erectile Function (IIEF) Over the past four weeks how satisfied have you been with your sexual relationship with your partner?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IIEF Test Code Terminology|CDISC Questionnaire IIEF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103601>	C103496	IIEF - Your Confidence to Get and Keep an Erection|IIEF01-Confidence to Get/Keep Erection|IIEF01-Confidence to Get/Keep Erection|IIEF01-Erection Confidence|IIEF0115	International Index of Erectile Function (IIEF) Over the past four weeks how do you rate your confidence that you could get and keep an erection?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IIEF Test Code Terminology|CDISC Questionnaire IIEF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103602>	C100120	NPI - Delusions Frequency|NPI1-Delusions Frequency|NPI1-Delusions Frequency|NPI1A10	Neuropsychiatric Inventory (NPI) Frequency of the delusions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103603>	C100120	NPI - Delusions Severity|NPI1-Delusions Severity|NPI1-Delusions Severity|NPI1A11	Neuropsychiatric Inventory (NPI) Severity of the delusions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103604>	C100120	NPI - Delusions Distress|NPI1-Delusions Distress|NPI1-Delusions Distress|NPI1A12	Neuropsychiatric Inventory (NPI) Delusion: How emotionally distressing do you find this behavior?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103605>	C100120	NPI - Hallucinations Frequency|NPI1-Hallucinations Frequency|NPI1-Hallucinations Frequency|NPI1B08	Neuropsychiatric Inventory (NPI) Frequency of the hallucinations.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103606>	C100120	NPI - Hallucinations Severity|NPI1-Hallucinations Severity|NPI1-Hallucinations Severity|NPI1B09	Neuropsychiatric Inventory (NPI) Severity of the hallucinations.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103607>	C100120	NPI - Hallucinations Distress|NPI1-Hallucinations Distress|NPI1-Hallucinations Distress|NPI1B10	Neuropsychiatric Inventory (NPI) Hallucinations: How emotionally distressing do you find this behavior?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103608>	C100120	NPI - Agitation/Aggression Frequency|NPI1-Agitation/Aggression Frequency|NPI1-Agitation/Aggression Frequency|NPI1C09	Neuropsychiatric Inventory (NPI) Frequency of the agitation/aggression.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103609>	C100120	NPI - Agitation/Aggression Severity|NPI1-Agitation/Aggression Severity|NPI1-Agitation/Aggression Severity|NPI1C10	Neuropsychiatric Inventory (NPI) Severity of the agitation/aggression.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10360>	C61063	Cyclophosphamide/Doxorubicin/Etoposide/Filgrastim/Prednisone/Vincristine|CTX/DOX/G-CSF/PRED/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103610>	C100120	NPI - Agitation/Aggression Distress|NPI1-Agitation/Aggression Distress|NPI1-Agitation/Aggression Distress|NPI1C11	Neuropsychiatric Inventory (NPI) Agitation/Aggression: How emotionally distressing do you find this behavior?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103611>	C100120	NPI - Depression/Dysphoria Frequency|NPI1-Depression/Dysphoria Frequency|NPI1-Depression/Dysphoria Frequency|NPI1D09	Neuropsychiatric Inventory (NPI) Frequency of the depression/dysphoria.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103612>	C100120	NPI - Depression/Dysphoria Severity|NPI1-Depression/Dysphoria Severity|NPI1-Depression/Dysphoria Severity|NPI1D10	Neuropsychiatric Inventory (NPI) Severity of the depression/dysphoria.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103613>	C100120	NPI - Depression/Dysphoria Distress|NPI1-Depression/Dysphoria Distress|NPI1-Depression/Dysphoria Distress|NPI1D11	Neuropsychiatric Inventory (NPI) Depression/Dysphoria: How emotionally distressing do you find this behavior?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103614>	C100120	NPI - Anxiety Frequency|NPI1-Anxiety Frequency|NPI1-Anxiety Frequency|NPI1E08	Neuropsychiatric Inventory (NPI) Frequency of the anxiety.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103615>	C100120	NPI - Anxiety Severity|NPI1-Anxiety Severity|NPI1-Anxiety Severity|NPI1E09	Neuropsychiatric Inventory (NPI) Severity of the anxiety.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103616>	C100120	NPI - Anxiety Distress|NPI1-Anxiety Distress|NPI1-Anxiety Distress|NPI1E10	Neuropsychiatric Inventory (NPI) Anxiety: How emotionally distressing do you find this behavior?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103617>	C100120	NPI - Elation/Euphoria Frequency|NPI1-Elation/Euphoria Frequency|NPI1-Elation/Euphoria Frequency|NPI1F08	Neuropsychiatric Inventory (NPI) Frequency of the elation/euphoria.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103618>	C100120	NPI - Elation/Euphoria Severity|NPI1-Elation/Euphoria Severity|NPI1-Elation/Euphoria Severity|NPI1F09	Neuropsychiatric Inventory (NPI) Severity of the elation/euphoria.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103619>	C100120	NPI - Elation/Euphoria Distress|NPI1-Elation/Euphoria Distress|NPI1-Elation/Euphoria Distress|NPI1F10	Neuropsychiatric Inventory (NPI) Elation/Euphoria: How emotionally distressing do you find this behavior?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10361>	C61063	Carboplatin/Cisplatin/Etoposide|CBDCA/CDDP/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103620>	C100120	NPI - Apathy/Indifference Frequency|NPI1-Apathy/Indifference Frequency|NPI1-Apathy/Indifference Frequency|NPI1G09	Neuropsychiatric Inventory (NPI) Frequency of the apathy/indifference.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103621>	C100120	NPI - Apathy/Indifference Severity|NPI1-Apathy/Indifference Severity|NPI1-Apathy/Indifference Severity|NPI1G10	Neuropsychiatric Inventory (NPI) Severity of the apathy/indifference.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103622>	C100120	NPI - Apathy/Indifference Distress|NPI1-Apathy/Indifference Distress|NPI1-Apathy/Indifference Distress|NPI1G11	Neuropsychiatric Inventory (NPI) Apathy/Indifference: How emotionally distressing do you find this behavior?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103623>	C100120	NPI - Disinhibition Frequency|NPI1-Disinhibition Frequency|NPI1-Disinhibition Frequency|NPI1H08	Neuropsychiatric Inventory (NPI) Frequency of the disinhibition.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103624>	C100120	NPI - Disinhibition Severity|NPI1-Disinhibition Severity|NPI1-Disinhibition Severity|NPI1H09	Neuropsychiatric Inventory (NPI) Severity of the disinhibition.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103625>	C100120	NPI - Disinhibition Distress|NPI1-Disinhibition Distress|NPI1-Disinhibition Distress|NPI1H10	Neuropsychiatric Inventory (NPI) Disinhibition: How emotionally distressing do you find this behavior?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103626>	C100120	NPI - Irritability/Lability Frequency|NPI1-Irritability/Lability Frequency|NPI1-Irritability/Lability Frequency|NPI1I08	Neuropsychiatric Inventory (NPI) Frequency of the irritability/lability.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103627>	C100120	NPI - Irritability/Lability Severity|NPI1-Irritability/Lability Severity|NPI1-Irritability/Lability Severity|NPI1I09	Neuropsychiatric Inventory (NPI) Severity of the irritability/lability.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103628>	C100120	NPI - Irritability/Lability Distress|NPI1-Irritability/Lability Distress|NPI1-Irritability/Lability Distress|NPI1I10	Neuropsychiatric Inventory (NPI) Irritability/Lability: How emotionally distressing do you find this behavior?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103629>	C100120	NPI - Aberrant Motor Behavior Frequency|NPI1-Aberrant Motor Behavior Frequency|NPI1-Aberrant Motor Behavior Frequency|NPI1J08	Neuropsychiatric Inventory (NPI) Frequency of the aberrant motor behavior.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10362>	C61063	Asparaginase/Cyclophosphamide/Cytarabine/Idarubicin/Methotrexate/Prednisone/Vincristine|ARA-C/ASP/CTX/IDA/MTX/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103630>	C100120	NPI - Aberrant Motor Behavior Severity|NPI1-Aberrant Motor Behavior Severity|NPI1-Aberrant Motor Behavior Severity|NPI1J09	Neuropsychiatric Inventory (NPI) Severity of the aberrant motor behavior.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103631>	C100120	NPI - Aberrant Motor Behavior Distress|NPI1-Aberrant Motor Behavior Distress|NPI1-Aberrant Motor Behavior Distress|NPI1J10	Neuropsychiatric Inventory (NPI) Aberrant Motor Behavior: How emotionally distressing do you find this behavior?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103632>	C100120	NPI - Sleep and Nighttime Behavior Disorders Frequency|NPI1-Sleep/Nighttime Behavior Frequency|NPI1-Sleep/Nighttime Behavior Frequency|NPI1K09	Neuropsychiatric Inventory (NPI) Frequency of the nighttime behavior.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103633>	C100120	NPI - Sleep and Nighttime Behavior Disorders Severity|NPI1-Sleep/Nighttime Behavior Severity|NPI1-Sleep/Nighttime Behavior Severity|NPI1K10	Neuropsychiatric Inventory (NPI) Severity of the nighttime behavior.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103634>	C100120	NPI - Sleep and Nighttime Behavior Disorders Distress|NPI1-Sleep/Nighttime Behavior Distress|NPI1-Sleep/Nighttime Behavior Distress|NPI1K11	Neuropsychiatric Inventory (NPI) Sleep and Nighttime Behavior Disorders: How emotionally distressing do you find this behavior?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103635>	C100120	NPI - Appetite and Eating Disorders Frequency|NPI1-Appetite/Eating Disorder Frequency|NPI1-Appetite/Eating Disorder Frequency|NPI1L09	Neuropsychiatric Inventory (NPI) Frequency of the changes in eating habits or appetite.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103636>	C100120	NPI - Appetite and Eating Disorders Severity|NPI1-Appetite/Eating Disorder Severity|NPI1-Appetite/Eating Disorder Severity|NPI1L10	Neuropsychiatric Inventory (NPI) Severity of the changes in eating habits or appetite.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103637>	C100120	NPI - Appetite and Eating Disorders Distress|NPI1-Appetite/Eating Disorder Distress|NPI1-Appetite/Eating Disorder Distress|NPI1L11	Neuropsychiatric Inventory (NPI) Appetite and Eating Disorders: How emotionally distressing do you find this behavior?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103638>	C103497	NPS - Tell Us How Intense Your Pain Is|NPS01-Tell Us How Intense Your Pain Is|NPS01-Tell Us How Intense Your Pain Is|NPS0101	Neuropathic Pain Scale (NPS) Please use the scale below to tell us how intense your pain is.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPS Test Code Terminology|CDISC Questionnaire NPS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103639>	C103497	NPS - Tell Us How Sharp Your Pain Feels|NPS01-Tell Us How Sharp Your Pain Feels|NPS01-Tell Us How Sharp Your Pain Feels|NPS0102	Neuropathic Pain Scale (NPS) Please use the scale below to tell us how sharp your pain feels. Words used to describe 'sharp' feelings include 'like a knife,' 'like a spike,' 'jabbing,' or 'like jolts.'			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPS Test Code Terminology|CDISC Questionnaire NPS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10363>	C61063	Dactinomycin/Idarubicin/Mercaptopurine/Methotrexate/Prednisone/Vincristine|DACT/IDA/MP/MTX/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103640>	C103497	NPS - Tell Us How Hot Your Pain Feels|NPS01-Tell Us How Hot Your Pain Feels|NPS01-Tell Us How Hot Your Pain Feels|NPS0103	Neuropathic Pain Scale (NPS) Please use the scale below to tell us how hot your pain feels. Words used to describe very hot pain include 'burning' and 'on fire.'			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPS Test Code Terminology|CDISC Questionnaire NPS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103641>	C103497	NPS - Tell Us How Dull Your Pain Feels|NPS01-Tell Us How Dull Your Pain Feels|NPS01-Tell Us How Dull Your Pain Feels|NPS0104	Neuropathic Pain Scale (NPS) Please use the scale below to tell us how dull your pain feels. Words used to describe very dull pain include 'like a dull toothache,' 'dull pain,' and 'like a bruise.'			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPS Test Code Terminology|CDISC Questionnaire NPS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103642>	C103497	NPS - Tell Us How Cold Your Pain Feels|NPS01-Tell Us How Cold Your Pain Feels|NPS01-Tell Us How Cold Your Pain Feels|NPS0105	Neuropathic Pain Scale (NPS) Please use the scale below to tell us how cold your pain feels. Words used to describe very cold pain included 'like ice' and 'freezing.'			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPS Test Code Terminology|CDISC Questionnaire NPS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103643>	C103497	NPS - Tell Us How Sensitive Your Skin is to Light Touch or Clothing|NPS01-Sensitiv Skin to Light Touch/Cloth|NPS01-Sensitiv Skin to Light Touch/Cloth|NPS0106	Neuropathic Pain Scale (NPS) Please use the scale below to tell us how sensitive your skin is to light touch or clothing. Words used to describe sensitive skin include 'like sunburned skin,' and 'raw skin.'			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPS Test Code Terminology|CDISC Questionnaire NPS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103644>	C103497	NPS - Tell Us How Itchy Your Pain Feels|NPS01-Tell Us How Itchy Your Pain Feels|NPS01-Tell Us How Itchy Your Pain Feels|NPS0107	Neuropathic Pain Scale (NPS) Please use the scale below to tell us how itchy your pain feels. Words used to describe itchy pain include 'like poison oak' and 'like a mosquito bite.'			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPS Test Code Terminology|CDISC Questionnaire NPS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103645>	C103497	NPS - Describe the Time Quality Of Your Pain|NPS01-Describe Time Quality Of Your Pain|NPS01-Describe Time Quality Of Your Pain|NPS0108	Neuropathic Pain Scale (NPS) Which of the following best describes the time quality of your pain? Please check only one answer.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPS Test Code Terminology|CDISC Questionnaire NPS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103646>	C103497	NPS - Describe the Background Pain|NPS01-Describe the Background Pain|NPS01-Describe the Background Pain|NPS0108A	Neuropathic Pain Scale (NPS) I feel a background pain all of the time and occasional flare-ups (break-through pain) some of the time. Describe the background pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPS Test Code Terminology|CDISC Questionnaire NPS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103647>	C103497	NPS - Describe the Flare-up Pain|NPS01-Describe the Flare-up Pain|NPS01-Describe the Flare-up Pain|NPS0108B	Neuropathic Pain Scale (NPS) I feel a background pain all of the time and occasional flare-ups (break-through pain) some of the time. Describe the flare-up (break-through) pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPS Test Code Terminology|CDISC Questionnaire NPS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103648>	C103497	NPS - Describe the Single Type of Pain All Time|NPS01-Describe Single Type Pain All Time|NPS01-Describe Single Type Pain All Time|NPS0108C	Neuropathic Pain Scale (NPS) I feel a single type of pain all the time. Describe this pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPS Test Code Terminology|CDISC Questionnaire NPS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103649>	C103497	NPS - Describe the Occasional Pain|NPS01-Describe the Occasional Pain|NPS01-Describe the Occasional Pain|NPS0108D	Neuropathic Pain Scale (NPS) I fee a single type of pain only sometimes. Other times, I am pain free. Describe the occasional pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPS Test Code Terminology|CDISC Questionnaire NPS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10364>	C61063	Carmustine/Cyclophosphamide/Dactinomycin/Mercaptopurine/Methotrexate/Prednisone/Vincristine|BCNU/CTX/DACT/MP/MTX/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103650>	C103497	NPS - Tell Us Overall How Unpleasant Your Pain is to You|NPS01-Tell How Unpleasant Your Pain Feel|NPS01-Tell How Unpleasant Your Pain Feel|NPS0109	Neuropathic Pain Scale (NPS) Now that you have told us the different physical aspects of your pain, the different types of sensations, we want you to tell us overall how unpleasant your pain is to you. Words used to describe very unpleasant pain include 'miserable' and intolerable.' Remember, pain can have a low intensity, buy still feel extremely unpleasant, and some kinds of pain can have a high intensity but be very tolerable. With this scale, please tell us how unpleasant your pain feels.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPS Test Code Terminology|CDISC Questionnaire NPS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103651>	C103497	NPS - How Intense is Your Deep Pain|NPS01-How Intense is Your Deep Pain|NPS01-How Intense is Your Deep Pain|NPS0110A	Neuropathic Pain Scale (NPS) Lastly, we want you to give us an estimate of the severity of your deep versus surface pain. We want your to rate each location of pain separately. We realize that it can be difficult to make these estimates, and most likely it will be a 'best guess,' but please give us your best estimate. How intense is your deep pain?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPS Test Code Terminology|CDISC Questionnaire NPS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103652>	C103497	NPS - How Intense is Your Surface Pain|NPS01-How Intense is Your Surface Pain|NPS01-How Intense is Your Surface Pain|NPS0110B	Neuropathic Pain Scale (NPS) Lastly, we want you to give us an estimate of the severity of your deep versus surface pain. We want your to rate each location of pain separately. We realize that it can be difficult to make these estimates, and most likely it will be a 'best guess,' but please give us your best estimate. How intense is your surface pain?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPS Test Code Terminology|CDISC Questionnaire NPS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103653>	C103498	OAB-q - Frequent Urination During the Daytime|OABQ01-Frequent Urination During Daytime|OABQ01-Frequent Urination During Daytime|OABQ0101	The Overactive Bladder Questionnaire (OAB-q) Frequent urination during the daytime hours?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103654>	C103498	OAB-q - Uncomfortable Urge to Urinate|OABQ01-Uncomfortable Urge to Urinate|OABQ01-Uncomfortable Urge to Urinate|OABQ0102	The Overactive Bladder Questionnaire (OAB-q) An uncomfortable urge to urinate?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103655>	C103498	OAB-q - Sudden Urge to Urinate with Little or No Warning|OABQ01-Sudden Urge to Urinate No Warning|OABQ01-Sudden Urge to Urinate No Warning|OABQ0103	The Overactive Bladder Questionnaire (OAB-q) A sudden urge to urinate with little or no warning?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103656>	C103498	OAB-q - Accidental Loss of Urine|OABQ01-Accidental Loss of Urine|OABQ01-Accidental Loss of Urine|OABQ0104	The Overactive Bladder Questionnaire (OAB-q) Accidental loss of small amounts of urine?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103657>	C103498	OAB-q - Nighttime Urination|OABQ01-Nighttime Urination|OABQ01-Nighttime Urination|OABQ0105	The Overactive Bladder Questionnaire (OAB-q) Nighttime urination?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103658>	C103498	OAB-q - Waking Up at Night Because You had to Urinate|OABQ01-Waking Up at Night had to Urinate|OABQ01-Waking Up at Night had to Urinate|OABQ0106	The Overactive Bladder Questionnaire (OAB-q) Waking up at night because you had to urinate?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103659>	C103498	OAB-q - Uncontrollable Urge to Urinate|OABQ01-Uncontrollable Urge to Urinate|OABQ01-Uncontrollable Urge to Urinate|OABQ0107	The Overactive Bladder Questionnaire (OAB-q) An uncontrollable urge to urinate?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10365>	C61063	Carboplatin/Cyclophosphamide/Mitoxantrone|CBDCA/CTX/DHAD			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103660>	C103498	OAB-q - Urine Loss Associated with a Strong Desire to Urinate|OABQ01-Urine Loss Strong Desire Urinate|OABQ01-Urine Loss Strong Desire Urinate|OABQ0108	The Overactive Bladder Questionnaire (OAB-q) Urine loss associated with a strong desire to urinate?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103661>	C103498	OAB-q - Carefully Plan Your Commute|OABQ01-Carefully Plan Your Commute|OABQ01-Carefully Plan Your Commute|OABQ0109	The Overactive Bladder Questionnaire (OAB-q) Made you carefully plan your commute?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103662>	C103498	OAB-q - Feel Drowsy or Sleepy During the Day|OABQ01-Feel Drowsy or Sleepy During Day|OABQ01-Feel Drowsy or Sleepy During Day|OABQ0110	The Overactive Bladder Questionnaire (OAB-q) Caused you to feel drowsy or sleepy during the day?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103663>	C103498	OAB-q - Plan 'Escape Routes' to Restrooms|OABQ01-Plan 'Escape Routes' to Restrooms|OABQ01-Plan 'Escape Routes' to Restrooms|OABQ0111	The Overactive Bladder Questionnaire (OAB-q) Caused you to plan "escape routes" to restrooms in public places?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103664>	C103498	OAB-q - Caused You Distress|OABQ01-Caused You Distress|OABQ01-Caused You Distress|OABQ0112	The Overactive Bladder Questionnaire (OAB-q) Caused you distress?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103665>	C103498	OAB-q - Frustrated You|OABQ01-Frustrated You|OABQ01-Frustrated You|OABQ0113	The Overactive Bladder Questionnaire (OAB-q) Frustrated you?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103666>	C103498	OAB-q - Feel Like There is Something Wrong with You|OABQ01-Feel Something Wrong with You|OABQ01-Feel Something Wrong with You|OABQ0114	The Overactive Bladder Questionnaire (OAB-q) Made you feel like there is something wrong with you?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103667>	C103498	OAB-q - Interfered with a Good Night's Rest|OABQ01-Interfered with Good Night's Rest|OABQ01-Interfered with Good Night's Rest|OABQ0115	The Overactive Bladder Questionnaire (OAB-q) Interfered with your ability to get a good night's rest?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103668>	C103498	OAB-q - Decrease Your Physical Activities|OABQ01-Decrease Your Physical Activities|OABQ01-Decrease Your Physical Activities|OABQ0116	The Overactive Bladder Questionnaire (OAB-q) Caused you to decrease your physical activities (exercising, sports, etc.)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103669>	C103498	OAB-q - Prevented You From Feeling Rested Upon Waking|OABQ01-Prevented From Feeling Rested|OABQ01-Prevented From Feeling Rested|OABQ0117	The Overactive Bladder Questionnaire (OAB-q) Prevented you from feeling rested upon waking in the morning?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10366>	C61063	Fluorouracil/Leucovorin Calcium/Thiotepa|CF/5-FU/TSPA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103670>	C103498	OAB-q - Frustrated Your Family and Friends|OABQ01-Frustrated Family and Friends|OABQ01-Frustrated Family and Friends|OABQ0118	The Overactive Bladder Questionnaire (OAB-q) Frustrated your family and friends?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103671>	C103498	OAB-q - Caused You Anxiety or Worry|OABQ01-Caused You Anxiety or Worry|OABQ01-Caused You Anxiety or Worry|OABQ0119	The Overactive Bladder Questionnaire (OAB-q) Caused you anxiety or worry?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103672>	C103498	OAB-q - Stay Home More Often Than You Would Prefer|OABQ01-Stay Home More Often Than Prefer|OABQ01-Stay Home More Often Than Prefer|OABQ0120	The Overactive Bladder Questionnaire (OAB-q) Caused you to stay home more often than you would prefer?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103673>	C103498	OAB-q - Adjust Your Travel Plans so That You are Always Near a Restroom|OABQ01-Adjust Travel Plans Near Restroom|OABQ01-Adjust Travel Plans Near Restroom|OABQ0121	The Overactive Bladder Questionnaire (OAB-q) Caused you to adjust your travel plans so that you are always near a restroom?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103674>	C103498	OAB-q - Avoid Activities Away From Restrooms|OABQ01-Avoid Act Away From Restroom|OABQ01-Avoid Act Away From Restroom|OABQ0122	The Overactive Bladder Questionnaire (OAB-q) Made you avoid activities away from restrooms (i.e., walks, running, hiking)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103675>	C103498	OAB-q - Frustrated or Annoyed About the Amount of Time You Spend in the Restroom|OABQ01-Amount of Time Spend in Restroom|OABQ01-Amount of Time Spend in Restroom|OABQ0123	The Overactive Bladder Questionnaire (OAB-q) Made you frustrated or annoyed about the amount of time you spend in the restroom?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103676>	C103498	OAB-q - Awakened You During Sleep|OABQ01-Awakened You During Sleep|OABQ01-Awakened You During Sleep|OABQ0124	The Overactive Bladder Questionnaire (OAB-q) Awakened you during sleep?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103677>	C103498	OAB-q - Made You Worry About Odor or Hygiene|OABQ01-Worry About Odor or Hygiene|OABQ01-Worry About Odor or Hygiene|OABQ0125	The Overactive Bladder Questionnaire (OAB-q) Made you worry about odor or hygiene?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103678>	C103498	OAB-q - Uncomfortable While Traveling With Others|OABQ01-Uncomfortable Travel with Others|OABQ01-Uncomfortable Travel with Others|OABQ0126	The Overactive Bladder Questionnaire (OAB-q) Made you uncomfortable while traveling with others because of needing to stop for a restroom?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103679>	C103498	OAB-q - Affected Your Relationships with Family and Friends|OABQ01-Affected Relationships|OABQ01-Affected Relationships|OABQ0127	The Overactive Bladder Questionnaire (OAB-q) Affected your relationships with family and friends?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10367>	C61063	Interleukin-2/Lymphokine-Activated Killer Cells/Monoclonal Antibody R24|IL-2/LAK/MOAB R24			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103680>	C103498	OAB-q - Decrease Participating in Social Gatherings|OABQ01-Decrease Participating Gatherings|OABQ01-Decrease Participating Gatherings|OABQ0128	The Overactive Bladder Questionnaire (OAB-q) Caused you to decrease participating in social gatherings, such as parties or visits with family or friends?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103681>	C103498	OAB-q - Caused You Embarrassment|OABQ01-Caused You Embarrassment|OABQ01-Caused You Embarrassment|OABQ0129	The Overactive Bladder Questionnaire (OAB-q) Caused you embarrassment?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103682>	C103498	OAB-q - Interfered with Getting Sleep|OABQ01-Interfered with Getting Sleep|OABQ01-Interfered with Getting Sleep|OABQ0130	The Overactive Bladder Questionnaire (OAB-q) Interfered with getting the amount of sleep you needed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103683>	C103498	OAB-q - Caused Problems with Your Partner or Spouse|OABQ01-Caused Problems Partner/Spouse|OABQ01-Caused Problems Partner/Spouse|OABQ0131	The Overactive Bladder Questionnaire (OAB-q) Caused you to have problems with your partner or spouse?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103684>	C103498	OAB-q - Plan Activities More Carefully|OABQ01-Plan Activities More Carefully|OABQ01-Plan Activities More Carefully|OABQ0132	The Overactive Bladder Questionnaire (OAB-q) Caused you to plan activities more carefully?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103685>	C103498	OAB-q - Locate Closest Restroom as Soon as You Arrive|OABQ01-Locate Closest Restroom|OABQ01-Locate Closest Restroom|OABQ0133	The Overactive Bladder Questionnaire (OAB-q) Caused you to locate the closest restroom as soon as you arrive at a place you have never been?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Test Code Terminology|CDISC Questionnaire OAB-q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103686>	C103499	OAB-q Short Form - Uncomfortable Urge to Urinate|OABQ02-Uncomfortable Urge to Urinate|OABQ02-Uncomfortable Urge to Urinate|OABQ0201	The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) An uncomfortable urge to urinate?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Short Form Test Code Terminology|CDISC Questionnaire OAB-q Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103687>	C103499	OAB-q Short Form - Sudden Urge to Urinate with Little or No Warning|OABQ02-Sudden Urge to Urinate No Warning|OABQ02-Sudden Urge to Urinate No Warning|OABQ0202	The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) A sudden urge to urinate with little or no warning?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Short Form Test Code Terminology|CDISC Questionnaire OAB-q Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103688>	C103499	OAB-q Short Form - Accidental Loss of Urine|OABQ02-Accidental Loss of Urine|OABQ02-Accidental Loss of Urine|OABQ0203	The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Accidental loss of small amounts of urine?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Short Form Test Code Terminology|CDISC Questionnaire OAB-q Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103689>	C103499	OAB-q Short Form - Nighttime Urination|OABQ02-Nighttime Urination|OABQ02-Nighttime Urination|OABQ0204	The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Nighttime urination?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Short Form Test Code Terminology|CDISC Questionnaire OAB-q Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10368>	C61063	Cyclophosphamide/Etoposide/Thiotepa|CTX/TSPA/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103690>	C103499	OAB-q Short Form - Waking Up at Night Because You had to Urinate|OABQ02-Waking Up at Night had to Urinate|OABQ02-Waking Up at Night had to Urinate|OABQ0205	The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Waking up at night because you had to urinate?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Short Form Test Code Terminology|CDISC Questionnaire OAB-q Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103691>	C103499	OAB-q Short Form - Urine Loss Associated with a Strong Desire to Urinate|OABQ02-Urine Loss Strong Desire Urinate|OABQ02-Urine Loss Strong Desire Urinate|OABQ0206	The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Urine loss associated with strong desire to urinate?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Short Form Test Code Terminology|CDISC Questionnaire OAB-q Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103692>	C103499	OAB-q Short Form - Plan 'Escape Routes' to Restrooms|OABQ02-Plan 'Escape Routes' to Restrooms|OABQ02-Plan 'Escape Routes' to Restrooms|OABQ0207	The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Caused you to plan "escape routes" to restrooms in public places?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Short Form Test Code Terminology|CDISC Questionnaire OAB-q Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103693>	C103499	OAB-q Short Form - Feel Like There is Something Wrong with You|OABQ02-Feel Something is Wrong with You|OABQ02-Feel Something is Wrong with You|OABQ0208	The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Made you feel like there is something wrong with you?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Short Form Test Code Terminology|CDISC Questionnaire OAB-q Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103694>	C103499	OAB-q Short Form - Interfered with a Good Night's Rest|OABQ02-Interfered with Good Night's Rest|OABQ02-Interfered with Good Night's Rest|OABQ0209	The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Interfered with your ability to get a good night's rest?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Short Form Test Code Terminology|CDISC Questionnaire OAB-q Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103695>	C103499	OAB-q Short Form - Frustrated or Annoyed About the Amount of Time You Spend in the Restroom|OABQ02-Frustrated about Time in Restroom|OABQ02-Frustrated about Time in Restroom|OABQ0210	The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Made you frustrated or annoyed about the amount of time you spend in the restroom?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Short Form Test Code Terminology|CDISC Questionnaire OAB-q Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103696>	C103499	OAB-q Short Form - Avoid Activities Away From Restrooms|OABQ02-Avoid Activ Away From Restroom|OABQ02-Avoid Activ Away From Restroom|OABQ0211	The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Made you avoid activities away from restrooms (i.e., walks, running, hiking)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Short Form Test Code Terminology|CDISC Questionnaire OAB-q Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103697>	C103499	OAB-q Short Form - Awakened You During Sleep|OABQ02-Awakened You During Sleep|OABQ02-Awakened You During Sleep|OABQ0212	The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Awakened you during sleep?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Short Form Test Code Terminology|CDISC Questionnaire OAB-q Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103698>	C103499	OAB-q Short Form - Decrease Your Physical Activities|OABQ02-Decrease Physical Activities|OABQ02-Decrease Physical Activities|OABQ0213	The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Caused you to decrease your physical activities (exercising, sports, etc.)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Short Form Test Code Terminology|CDISC Questionnaire OAB-q Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103699>	C103499	OAB-q Short Form - Caused Problems with Your Partner or Spouse|OABQ02-Caused Problems Partner/Spouse|OABQ02-Caused Problems Partner/Spouse|OABQ0214	The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Caused you to have problems with your partner or spouse?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Short Form Test Code Terminology|CDISC Questionnaire OAB-q Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10369>	C61063	Dacarbazine/Interleukin-2|DTIC/IL-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1036>	C2562	Canola Oil|CANOLA OIL	Vegetable oil developed from rapeseed plant.			Food	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C103700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103700>	C103499	OAB-q Short Form - Uncomfortable While Traveling With Others|OABQ02-Uncomfortable Travel with Others|OABQ02-Uncomfortable Travel with Others|OABQ0215	The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Made you uncomfortable while travelling with others because of needing to stop for a restroom?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Short Form Test Code Terminology|CDISC Questionnaire OAB-q Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103701>	C103499	OAB-q Short Form - Affected Your Relationships with Family and Friends|OABQ02-Affected Relationships|OABQ02-Affected Relationships|OABQ0216	The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Affected your relationships with family and friends?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Short Form Test Code Terminology|CDISC Questionnaire OAB-q Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103702>	C103499	OAB-q Short Form - Interfered with Getting Sleep|OABQ02-Interfered with Getting Sleep|OABQ02-Interfered with Getting Sleep|OABQ0217	The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Interfered with getting the amount of sleep you needed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Short Form Test Code Terminology|CDISC Questionnaire OAB-q Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103703>	C103499	OAB-q Short Form - Caused You Embarrassment|OABQ02-Caused You Embarrassment|OABQ02-Caused You Embarrassment|OABQ0218	The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Caused you embarrassment?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Short Form Test Code Terminology|CDISC Questionnaire OAB-q Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103704>	C103499	OAB-q Short Form - Locate Closest Restroom as Soon as You Arrive|OABQ02-Locate Closest Restroom|OABQ02-Locate Closest Restroom|OABQ0219	The Overactive Bladder Questionnaire Short Form (OAB-q Short Form) Caused you to locate the closest restroom as soon as you arrive at a place you have never been?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire OAB-q Short Form Test Code Terminology|CDISC Questionnaire OAB-q Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103705>	C103501	PHQ-9 - Little Interest or Pleasure in Doing Things|PHQ01-Little Interest/Pleasure in Things|PHQ01-Little Interest/Pleasure in Things|PHQ0101	Patient Health Questionnaire - 9 (PHQ-9) Over the last 2 weeks, how often have you been bothered by: Little interest or pleasure in doing things.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ-9 Test Code Terminology|CDISC Questionnaire PHQ-9 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103706>	C103501	PHQ-9 - Feeling Down, Depressed, or Hopeless|PHQ01-Feeling Down Depressed or Hopeless|PHQ01-Feeling Down Depressed or Hopeless|PHQ0102	Patient Health Questionnaire - 9 (PHQ-9) Over the last 2 weeks, how often have you been bothered by: Feeling down, depressed, or hopeless.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ-9 Test Code Terminology|CDISC Questionnaire PHQ-9 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103707>	C103501	PHQ-9 - Trouble Falling or Staying Asleep, or Sleeping Too Much|PHQ01-Trouble Falling or Staying Asleep|PHQ01-Trouble Falling or Staying Asleep|PHQ0103	Patient Health Questionnaire - 9 (PHQ-9) Over the last 2 weeks, how often have you been bothered by: Trouble falling or staying asleep, or sleeping too much.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ-9 Test Code Terminology|CDISC Questionnaire PHQ-9 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103708>	C103501	PHQ-9 - Feeling Tired or Having Little Energy|PHQ01-Feeling Tired or Little Energy|PHQ01-Feeling Tired or Little Energy|PHQ0104	Patient Health Questionnaire - 9 (PHQ-9) Over the last 2 weeks, how often have you been bothered by: Feeling tired or having little energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ-9 Test Code Terminology|CDISC Questionnaire PHQ-9 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103709>	C103501	PHQ-9 - Poor Appetite or Overeating|PHQ01-Poor Appetite or Overeating|PHQ01-Poor Appetite or Overeating|PHQ0105	Patient Health Questionnaire - 9 (PHQ-9) Over the last 2 weeks, how often have you been bothered by: Poor appetite or overeating.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ-9 Test Code Terminology|CDISC Questionnaire PHQ-9 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10370>	C61063	Cisplatin/Dacarbazine/Tamoxifen|CDDP/DTIC/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103710>	C103501	PHQ-9 - Feeling Bad About Yourself|PHQ01-Feeling Bad About Yourself|PHQ01-Feeling Bad About Yourself|PHQ0106	Patient Health Questionnaire - 9 (PHQ-9) Over the last 2 weeks, how often have you been bothered by: Feeling bad about yourself - or that you are a failure or have let yourself or your family down.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ-9 Test Code Terminology|CDISC Questionnaire PHQ-9 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103711>	C103501	PHQ-9 - Trouble Concentrating on Things|PHQ01-Trouble Concentrating on Things|PHQ01-Trouble Concentrating on Things|PHQ0107	Patient Health Questionnaire - 9 (PHQ-9) Over the last 2 weeks, how often have you been bothered by: Trouble concentrating on things, such as reading the newspaper or watching television.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ-9 Test Code Terminology|CDISC Questionnaire PHQ-9 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103712>	C103501	PHQ-9 - Moving or Speaking Slowly or the Opposite being Fidgety or Restless|PHQ01-Moving Slowly or Fidgety/Restless|PHQ01-Moving Slowly or Fidgety/Restless|PHQ0108	Patient Health Questionnaire - 9 (PHQ-9) Over the last 2 weeks, how often have you been bothered by: Moving or speaking so slowly that other people could have noticed? Or the opposite - being so fidgety or restless that you have been moving around a lot more than usual.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ-9 Test Code Terminology|CDISC Questionnaire PHQ-9 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103713>	C103501	PHQ-9 - Thoughts That You Would be Better Off Dead|PHQ01-Thoughts You Be Better Off Dead|PHQ01-Thoughts You Be Better Off Dead|PHQ0109	Patient Health Questionnaire - 9 (PHQ-9) Over the last 2 weeks, how often have you been bothered by: Thoughts that you would be better off dead or of hurting yourself in some way.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ-9 Test Code Terminology|CDISC Questionnaire PHQ-9 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103714>	C103501	PHQ-9 - How Difficult have Problems Made it for You to Work, Take Care of Things, or Get Along with Other People|PHQ01-Difficult to Work/Take Care Things|PHQ01-Difficult to Work/Take Care Things|PHQ0110	Patient Health Questionnaire - 9 (PHQ-9) If you checked off any problems, how difficult have these problems made it for you to do your work, take care of things at home, or get along with other people?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ-9 Test Code Terminology|CDISC Questionnaire PHQ-9 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103715>	C103502	PHQ-15 - Stomach Pain|PHQ02-Stomach Pain|PHQ02-Stomach Pain|PHQ0201	Patient Health Questionnaire - 15 (PHQ-15) Stomach pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ-15 Test Code Terminology|CDISC Questionnaire PHQ-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103716>	C103502	PHQ-15 - Back Pain|PHQ02-Back Pain|PHQ02-Back Pain|PHQ0202	Patient Health Questionnaire - 15 (PHQ-15) Back pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ-15 Test Code Terminology|CDISC Questionnaire PHQ-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103717>	C103502	PHQ-15 - Pain In Your Arms, Legs, or Joints|PHQ02-Pain In Your Arms, Legs, or Joints|PHQ02-Pain In Your Arms, Legs, or Joints|PHQ0203	Patient Health Questionnaire - 15 (PHQ-15) Pain in your arms, legs, or joints (knees, hips, etc.).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ-15 Test Code Terminology|CDISC Questionnaire PHQ-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103718>	C103502	PHQ-15 - Menstrual Cramp or Other Problems with Your Periods|PHQ02-Menstrual Cramp/Problem Periods|PHQ02-Menstrual Cramp/Problem Periods|PHQ0204	Patient Health Questionnaire - 15 (PHQ-15) Menstrual cramps or other problems with your periods [Women only].			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ-15 Test Code Terminology|CDISC Questionnaire PHQ-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103719>	C103502	PHQ-15 - Headaches|PHQ02-Headaches|PHQ02-Headaches|PHQ0205	Patient Health Questionnaire - 15 (PHQ-15) Headaches.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ-15 Test Code Terminology|CDISC Questionnaire PHQ-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10371>	C61063	Busulfan/Mitoxantrone|BU/DHAD			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103720>	C103502	PHQ-15 - Chest Pain|PHQ02-Chest Pain|PHQ02-Chest Pain|PHQ0206	Patient Health Questionnaire - 15 (PHQ-15) Chest pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ-15 Test Code Terminology|CDISC Questionnaire PHQ-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103721>	C103502	PHQ-15 - Dizziness|PHQ02-Dizziness|PHQ02-Dizziness|PHQ0207	Patient Health Questionnaire - 15 (PHQ-15) Dizziness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ-15 Test Code Terminology|CDISC Questionnaire PHQ-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103722>	C103502	PHQ-15 - Fainting Spells|PHQ02-Fainting Spells|PHQ02-Fainting Spells|PHQ0208	Patient Health Questionnaire - 15 (PHQ-15) Fainting spells.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ-15 Test Code Terminology|CDISC Questionnaire PHQ-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103723>	C103502	PHQ-15 - Feeling Your Heart Pound or Race|PHQ02-Feeling Your Heart Pound or Race|PHQ02-Feeling Your Heart Pound or Race|PHQ0209	Patient Health Questionnaire - 15 (PHQ-15) Feeling your heart pound or race.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ-15 Test Code Terminology|CDISC Questionnaire PHQ-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103724>	C103502	PHQ-15 - Shortness of Breath|PHQ02-Shortness of Breath|PHQ02-Shortness of Breath|PHQ0210	Patient Health Questionnaire - 15 (PHQ-15) Shortness of breath.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ-15 Test Code Terminology|CDISC Questionnaire PHQ-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103725>	C103502	PHQ-15 - Pain or Problems During Sexual Intercourse|PHQ02-Pain/Problems During Intercourse|PHQ02-Pain/Problems During Intercourse|PHQ0211	Patient Health Questionnaire - 15 (PHQ-15) Pain or problems during sexual intercourse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ-15 Test Code Terminology|CDISC Questionnaire PHQ-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103726>	C103502	PHQ-15 - Constipation, Loose Bowels, or Diarrhea|PHQ02-Constipation/Loose Bowels/Diarrhea|PHQ02-Constipation/Loose Bowels/Diarrhea|PHQ0212	Patient Health Questionnaire - 15 (PHQ-15) Constipation, loose bowels, or diarrhea.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ-15 Test Code Terminology|CDISC Questionnaire PHQ-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103727>	C103502	PHQ-15 - Nausea, Gas, or Indigestion|PHQ02-Nausea, Gas, or Indigestion|PHQ02-Nausea, Gas, or Indigestion|PHQ0213	Patient Health Questionnaire - 15 (PHQ-15) Nausea, gas, or indigestion.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ-15 Test Code Terminology|CDISC Questionnaire PHQ-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103728>	C103502	PHQ-15 - Feeling Tired or Having Low Energy|PHQ02-Feeling Tired or Having Low Energy|PHQ02-Feeling Tired or Having Low Energy|PHQ0214	Patient Health Questionnaire - 15 (PHQ-15) Feeling tired or having low energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ-15 Test Code Terminology|CDISC Questionnaire PHQ-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103729>	C103502	PHQ-15 - Trouble Sleeping|PHQ02-Trouble Sleeping|PHQ02-Trouble Sleeping|PHQ0215	Patient Health Questionnaire - 15 (PHQ-15) Trouble sleeping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ-15 Test Code Terminology|CDISC Questionnaire PHQ-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10372>	C61063	Cyclophosphamide/Interleukin-2/Monoclonal Antibody R24|CTX/IL-2/MOAB R24			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103730>	C103503	SIQR - Brush or Comb Your Hair|SIQR01-Brush or Comb Your Hair|SIQR01-Brush or Comb Your Hair|SIQR0101	Symptom Impact Questionnaire (SIQR) Brush or comb your hair.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQR Test Code Terminology|CDISC Questionnaire SIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103731>	C103503	SIQR - Walk Continuously for 20 Minutes|SIQR01-Walk Continuously for 20 Minutes|SIQR01-Walk Continuously for 20 Minutes|SIQR0102	Symptom Impact Questionnaire (SIQR) Walk continuously for 20 minutes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQR Test Code Terminology|CDISC Questionnaire SIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103732>	C103503	SIQR - Prepare a Homemade Meal|SIQR01-Prepare a Homemade Meal|SIQR01-Prepare a Homemade Meal|SIQR0103	Symptom Impact Questionnaire (SIQR) Prepare a homemade meal.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQR Test Code Terminology|CDISC Questionnaire SIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103733>	C103503	SIQR - Vacuum Scrub or Sweep Floors|SIQR01-Vacuum Scrub or Sweep Floors|SIQR01-Vacuum Scrub or Sweep Floors|SIQR0104	Symptom Impact Questionnaire (SIQR) Vacuum, scrub or sweep floors.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQR Test Code Terminology|CDISC Questionnaire SIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103734>	C103503	SIQR - Lift and Carry a Bag Full of Groceries|SIQR01-Lift/Carry Bag Full of Groceries|SIQR01-Lift/Carry Bag Full of Groceries|SIQR0105	Symptom Impact Questionnaire (SIQR) Lift and carry a bag full of groceries.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQR Test Code Terminology|CDISC Questionnaire SIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103735>	C103503	SIQR - Climb One Flight of Stairs|SIQR01-Climb One Flight of Stairs|SIQR01-Climb One Flight of Stairs|SIQR0106	Symptom Impact Questionnaire (SIQR) Climb one flight of stairs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQR Test Code Terminology|CDISC Questionnaire SIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103736>	C103503	SIQR - Change Bed Sheets|SIQR01-Change Bed Sheets|SIQR01-Change Bed Sheets|SIQR0107	Symptom Impact Questionnaire (SIQR) Change bed sheets.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQR Test Code Terminology|CDISC Questionnaire SIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103737>	C103503	SIQR - Sit in a Chair for 45 Minutes|SIQR01-Sit in a Chair for 45 Minutes|SIQR01-Sit in a Chair for 45 Minutes|SIQR0108	Symptom Impact Questionnaire (SIQR) Sit in a chair for 45 minutes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQR Test Code Terminology|CDISC Questionnaire SIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103738>	C103503	SIQR - Go Shopping for Groceries|SIQR01-Go Shopping for Groceries|SIQR01-Go Shopping for Groceries|SIQR0109	Symptom Impact Questionnaire (SIQR) Go shopping for groceries.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQR Test Code Terminology|CDISC Questionnaire SIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103739>	C103503	SIQR - My Medical Problem Prevented Me from Accomplishing Goals for the Week|SIQR01-Prevent from Accomplishing Goals|SIQR01-Prevent from Accomplishing Goals|SIQR0110	Symptom Impact Questionnaire (SIQR) My medical problems prevented me from accomplishing goals for week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQR Test Code Terminology|CDISC Questionnaire SIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10373>	C61063	Chlorambucil/Etoposide/Prednisone/Vincristine|CLB/PRED/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103740>	C103503	SIQR - I was Completely Overwhelmed by My Medical Problem|SIQR01-Overwhelmed by Medical Problems|SIQR01-Overwhelmed by Medical Problems|SIQR0111	Symptom Impact Questionnaire (SIQR) I was completely overwhelmed by my medical problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQR Test Code Terminology|CDISC Questionnaire SIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103741>	C103503	SIQR - Pain|SIQR01-Pain|SIQR01-Pain|SIQR0112	Symptom Impact Questionnaire (SIQR) Please rate your level of pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQR Test Code Terminology|CDISC Questionnaire SIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103742>	C103503	SIQR - Energy|SIQR01-Energy|SIQR01-Energy|SIQR0113	Symptom Impact Questionnaire (SIQR) Please rate your level of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQR Test Code Terminology|CDISC Questionnaire SIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103743>	C103503	SIQR - Stiffness|SIQR01-Stiffness|SIQR01-Stiffness|SIQR0114	Symptom Impact Questionnaire (SIQR) Please rate your level of stiffness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQR Test Code Terminology|CDISC Questionnaire SIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103744>	C103503	SIQR - Your Sleep|SIQR01-Your Sleep|SIQR01-Your Sleep|SIQR0115	Symptom Impact Questionnaire (SIQR) Please rate the quality of your sleep.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQR Test Code Terminology|CDISC Questionnaire SIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103745>	C103503	SIQR - Depression|SIQR01-Depression|SIQR01-Depression|SIQR0116	Symptom Impact Questionnaire (SIQR) Please rate your level of depression.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQR Test Code Terminology|CDISC Questionnaire SIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103746>	C103503	SIQR - Memory Problems|SIQR01-Memory Problems|SIQR01-Memory Problems|SIQR0117	Symptom Impact Questionnaire (SIQR) Please rate your level of memory problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQR Test Code Terminology|CDISC Questionnaire SIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103747>	C103503	SIQR - Anxiety|SIQR01-Anxiety|SIQR01-Anxiety|SIQR0118	Symptom Impact Questionnaire (SIQR) Please rate your level of anxiety.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQR Test Code Terminology|CDISC Questionnaire SIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103748>	C103503	SIQR - Tenderness to Touch|SIQR01-Tenderness to Touch|SIQR01-Tenderness to Touch|SIQR0119	Symptom Impact Questionnaire (SIQR) Please rate your level of tenderness to touch.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQR Test Code Terminology|CDISC Questionnaire SIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103749>	C103503	SIQR - Balance Problems|SIQR01-Balance Problems|SIQR01-Balance Problems|SIQR0120	Symptom Impact Questionnaire (SIQR) Please rate your level of balance problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQR Test Code Terminology|CDISC Questionnaire SIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10374>	C61063	Cytarabine/Etoposide/Prednisone|ARA-C/PRED/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103750>	C103503	SIQR - Sensitivity to Loud Noises, Bright Lights, Odors and Cold|SIQR01-Sensitivity Noise/Light/Odor/Cold|SIQR01-Sensitivity Noise/Light/Odor/Cold|SIQR0121	Symptom Impact Questionnaire (SIQR) Please rate your level of sensitivity to loud noises, bright lights, odors and cold.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQR Test Code Terminology|CDISC Questionnaire SIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103751>	C103504	SOWS Short - Feeling Sick	Short Opiate Withdrawal Scale (SOWS Short) Feeling sick.			Intellectual Product	
C103752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103752>	C103504	SOWS Short - Stomach Cramps	Short Opiate Withdrawal Scale (SOWS Short) Stomach cramps.			Intellectual Product	
C103753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103753>	C103504	SOWS Short - Muscle Spasms/Twitching	Short Opiate Withdrawal Scale (SOWS Short) Muscle spasms/twitching.			Intellectual Product	
C103754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103754>	C103504	SOWS Short - Feelings of Coldness	Short Opiate Withdrawal Scale (SOWS Short) Feelings of coldness.			Intellectual Product	
C103755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103755>	C103504	SOWS Short - Heart Pounding	Short Opiate Withdrawal Scale (SOWS Short) Heart pounding.			Intellectual Product	
C103756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103756>	C103504	SOWS Short - Muscular Tension	Short Opiate Withdrawal Scale (SOWS Short) Muscular tension.			Intellectual Product	
C103757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103757>	C103504	SOWS Short - Aches and Pains	Short Opiate Withdrawal Scale (SOWS Short) Aches and pains.			Intellectual Product	
C103758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103758>	C103504	SOWS Short - Yawning	Short Opiate Withdrawal Scale (SOWS Short) Yawning.			Intellectual Product	
C103759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103759>	C103504	SOWS Short - Runny Eyes	Short Opiate Withdrawal Scale (SOWS Short) Runny eyes.			Intellectual Product	
C10375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10375>	C61063	Busulfan/Cytarabine/Etoposide|ARA-C/BU/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103760>	C103504	SOWS Short - Insomnia/Problems Sleeping	Short Opiate Withdrawal Scale (SOWS Short) Insomnia/problems sleeping.			Intellectual Product	
C103761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103761>	C103505	UPS - Describe Your Experience When You Desire to Urinate|UPS01-Describe Your Desire to Urinate|UPS01-Describe Your Desire to Urinate|UPS0101	Urgency Perception Scale (UPS) Which of the following would typically describe your experience when you have a desire to urinate.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire UPS Test Code Terminology|CDISC Questionnaire UPS Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103762>	C103500	ODI v2.1a - Pain Intensity|ODI01-Pain Intensity|ODI01-Pain Intensity|ODI0101	The Oswestry Disability Index Version 2.1a (ODI v2.1a) Section 1: Pain intensity.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ODI v2.1a Test Code Terminology|CDISC Questionnaire ODI v2.1a Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103763>	C103500	ODI v2.1a - Personal Care|ODI01-Personal Care|ODI01-Personal Care|ODI0102	The Oswestry Disability Index Version 2.1a (ODI v2.1a) Section 2: Personal care (washing, dressing, etc.).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ODI v2.1a Test Code Terminology|CDISC Questionnaire ODI v2.1a Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103764>	C103500	ODI v2.1a - Lifting|ODI01-Lifting|ODI01-Lifting|ODI0103	The Oswestry Disability Index Version 2.1a (ODI v2.1a) Section 3: Lifting.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ODI v2.1a Test Code Terminology|CDISC Questionnaire ODI v2.1a Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103765>	C103500	ODI v2.1a - Walking|ODI01-Walking|ODI01-Walking|ODI0104	The Oswestry Disability Index Version 2.1a (ODI v2.1a) Section 4: Walking.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ODI v2.1a Test Code Terminology|CDISC Questionnaire ODI v2.1a Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103766>	C103500	ODI v2.1a - Sitting|ODI01-Sitting|ODI01-Sitting|ODI0105	The Oswestry Disability Index Version 2.1a (ODI v2.1a) Section 5: Sitting.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ODI v2.1a Test Code Terminology|CDISC Questionnaire ODI v2.1a Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103767>	C103500	ODI v2.1a - Standing|ODI01-Standing|ODI01-Standing|ODI0106	The Oswestry Disability Index Version 2.1a (ODI v2.1a) Section 6: Standing.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ODI v2.1a Test Code Terminology|CDISC Questionnaire ODI v2.1a Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103768>	C103500	ODI v2.1a - Sleeping|ODI01-Sleeping|ODI01-Sleeping|ODI0107	The Oswestry Disability Index Version 2.1a (ODI v2.1a) Section 7: Sleeping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ODI v2.1a Test Code Terminology|CDISC Questionnaire ODI v2.1a Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103769>	C103500	ODI v2.1a - Sex Life|ODI01-Sex Life|ODI01-Sex Life|ODI0108	The Oswestry Disability Index Version 2.1a (ODI v2.1a) Section 8: Sex life (if applicable).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ODI v2.1a Test Code Terminology|CDISC Questionnaire ODI v2.1a Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10376>	C61063	Doxorubicin/Prochlorperazine|DOX/PCPZ			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103770>	C103500	ODI v2.1a - Social Life|ODI01-Social Life|ODI01-Social Life|ODI0109	The Oswestry Disability Index Version 2.1a (ODI v2.1a) Section 9: Social life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ODI v2.1a Test Code Terminology|CDISC Questionnaire ODI v2.1a Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103771>	C103500	ODI v2.1a - Travelling|ODI01-Travelling|ODI01-Travelling|ODI0110	The Oswestry Disability Index Version 2.1a (ODI v2.1a) Section 10: Travelling.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ODI v2.1a Test Code Terminology|CDISC Questionnaire ODI v2.1a Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103772>	C103491	C-SSRS Since Last Visit - Wish to be Dead or go to Sleep and not Wake Up|CSS02-Wish to be Dead|CSS02-Wish to be Dead|CSS0201	Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Have you wished you were dead or wished you could go to sleep and not wake up?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103773>	C103491	C-SSRS Since Last Visit - Description of Wish to be Dead|CSS02-Wish to be Dead, Describe|CSS02-Wish to be Dead, Describe|CSS0201A	Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Description of wishing to be dead.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103774>	C103491	C-SSRS Since Last Visit - Non-Specific Suicidal Thought|CSS02-Non-Specific Suicidal Thought|CSS02-Non-Specific Suicidal Thought|CSS0202	Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Have you actually had any thoughts of killing yourself?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103775>	C103491	C-SSRS Since Last Visit - Description of Non-Specific Suicide Thought|CSS02-Non-Specific Suicid Thought, Descr|CSS02-Non-Specific Suicid Thought, Descr|CSS0202A	Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Description of non-specific active suicidal thoughts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103776>	C103491	C-SSRS Since Last Visit - Suicidal Ideation-No Intent|CSS02-Suicidal Ideation-No Intent|CSS02-Suicidal Ideation-No Intent|CSS0203	Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Have you been thinking about how you might do this?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103777>	C103491	C-SSRS Since Last Visit - Description of Suicidal Ideation-No Intent|CSS02-Suicidal Ideation-No Intent, Descr|CSS02-Suicidal Ideation-No Intent, Descr|CSS0203A	Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Description of active suicidal ideation with any methods (not plan) without intent to act.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103778>	C103491	C-SSRS Since Last Visit - Description of Ideation With Plan and Intent|CSS02-Ideation With Plan/Intent, Descr|CSS02-Ideation With Plan/Intent, Descr|CSS0205A	Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Description of active suicidal ideation with specific plan and intent.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103779>	C103491	C-SSRS Since Last Visit - Most Severe Ideation|CSS02-Most Severe Ideation|CSS02-Most Severe Ideation|CSS0206	Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Most severe ideation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10377>	C61007	Cytarabine/Fludarabine|ARA-C/FAMP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103780>	C103491	C-SSRS Since Last Visit - Describe Most Severe Ideation|CSS02-Most Severe Ideation, Description|CSS02-Most Severe Ideation, Description|CSS0206A	Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Description of most severe ideation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103781>	C103491	C-SSRS Since Last Visit - Frequency of Most Severe Ideation|CSS02-Most Severe Ideation, Frequency|CSS02-Most Severe Ideation, Frequency|CSS0207	Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) How many times have you had these thoughts?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103782>	C103491	C-SSRS Since Last Visit - Duration of Most Severe Ideation|CSS02-Most Severe Ideation, Duration|CSS02-Most Severe Ideation, Duration|CSS0208	Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) When you have these thoughts, how long do they last?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103783>	C103491	C-SSRS Since Last Visit - Control over Most Severe Ideation|CSS02-Most Severe Ideation, Control|CSS02-Most Severe Ideation, Control|CSS0209	Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Could/can you stop thinking about killing yourself or wanting to die if you want to?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103784>	C103491	C-SSRS Since Last Visit - Deterrents to Most Severe Ideation|CSS02-Most Severe Ideation, Deterrents|CSS02-Most Severe Ideation, Deterrents|CSS0210	Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Are there things - anyone or anything (e.g., family, religion, pain of death) - that stopped you from wanting to die or acting on thoughts of committing suicide?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103785>	C103491	C-SSRS Since Last Visit - Reasons for Most Severe Ideation|CSS02-Most Severe Ideation, Reasons|CSS02-Most Severe Ideation, Reasons|CSS0211	Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) What sort of reasons did you have for thinking about wanting to die or killing yourself? Was it to end the pain or stop the way you were feeling (in other words you couldn't go on living with this pain or how you were feeling) or was it to get attention, revenge or a reaction from others? Or both?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103786>	C103491	C-SSRS Since Last Visit - Actual Suicide Attempt|CSS02-Actual Attempt|CSS02-Actual Attempt|CSS0212	Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Have you made a suicide attempt? Have you done anything to harm yourself? Have you done anything dangerous where you could have died?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103787>	C103491	C-SSRS Since Last Visit - Number of Actual Suicide Attempts|CSS02-Number of Actual Attempts|CSS02-Number of Actual Attempts|CSS0213	Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Total number of actual attempts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103788>	C103491	C-SSRS Since Last Visit - Description of Actual Suicide Attempts|CSS02-Actual Attempt, Describe|CSS02-Actual Attempt, Describe|CSS0213A	Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Description of suicidal or self-injurious behaviors.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103789>	C103491	C-SSRS Since Last Visit - Non-suicidal Self-injurious Behavior|CSS02-Non-suicidal Self-injurious Behav|CSS02-Non-suicidal Self-injurious Behav|CSS0214	Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Has the subject engaged in non-suicidal self-injurious behavior.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10378>	C61063	Doxorubicin/Sargramostim|DOX/GM-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103790>	C103491	C-SSRS Since Last Visit - Interrupted Suicide Attempt|CSS02-Interrupted Attempt|CSS02-Interrupted Attempt|CSS0215	Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Has there been a time when you started to do something to try to end your life but someone or something stopped you before you actually did anything?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103791>	C103491	C-SSRS Since Last Visit - Number of Interrupted Suicide Attempts|CSS02-Number of Interrupted Attempts|CSS02-Number of Interrupted Attempts|CSS0216	Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Total number of interrupted attempts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103792>	C103491	C-SSRS Since Last Visit - Description of Interrupted Suicide Attempt|CSS02-Interrupted Attempt, Describe|CSS02-Interrupted Attempt, Describe|CSS0216A	Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Description of interrupted attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103793>	C103491	C-SSRS Since Last Visit - Aborted Suicide Attempt|CSS02-Aborted Attempt|CSS02-Aborted Attempt|CSS0217	Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Has there been a time when you started to do something to try to end your life but you stopped yourself before you actually did anything?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103794>	C103491	C-SSRS Since Last Visit - Number of Aborted Suicide Attempts|CSS02-Number of Aborted Attempts|CSS02-Number of Aborted Attempts|CSS0218	Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Total number of aborted attempts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103795>	C103491	C-SSRS Since Last Visit - Description of Aborted Suicide Attempt|CSS02-Aborted Attempt, Describe|CSS02-Aborted Attempt, Describe|CSS0218A	Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Description of interrupted attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103796>	C103491	C-SSRS Since Last Visit - Preparatory Acts or Behaviors Toward Suicide Attempt|CSS02-Preparatory Acts/Behavior|CSS02-Preparatory Acts/Behavior|CSS0219	Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Have you taken any steps toward making a suicide attempt or preparing to kill yourself (such as collecting pills, getting a gun, giving valuables away or writing a suicide note)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103797>	C103491	C-SSRS Since Last Visit - Description of Preparatory Acts or Behaviors Toward Suicide Attempt|CSS02-Preparatory Acts/Behavior, Descr|CSS02-Preparatory Acts/Behavior, Descr|CSS0219A	Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Description of preparatory acts or behaviors.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103798>	C103491	C-SSRS Since Last Visit - Suicidal Behavior|CSS02-Suicidal Behavior|CSS02-Suicidal Behavior|CSS0220	Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Suicidal behavior was present during the assessment period?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103799>	C103491	C-SSRS Since Last Visit - Ideation With Intent, No Plan|CSS02-Ideation With Intent, No Plan|CSS02-Ideation With Intent, No Plan|CSS0204	Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Have you have these thoughts and had some intention of acting on them?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10379>	C61063	Carboplatin/Cisplatin/Ifosfamide|CBDCA/CDDP/IFF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1037>	C2150	Caracemide|Acetamide, N-[(Methylamino)carbonyl]-N-[[(methylamino)carbonyl]oxy]-(9CI)|Acetamide, N-[(methylamino)carbonyl]-N-[[(methylamino)carbonyl]oxy]- (9CI)|CARACEMIDE|N-Acetyl-N-(methylcarbamoyloxy)-N'-methylurea	An agent derived from acetohydroxamic acid with potential antineoplastic activity.  Caracemide inhibits ribonuclease reductase, resulting in decreased DNA synthesis and tumor growth; it also inhibits acetylcholinesterase.  In vivo, caracemide contributes to the formation of the neurotoxin methyl isocyanate; this effect, along with the agent's acetylcholinesterase activity, may be responsible for the severe central nervous system toxicity observed in clinical trials. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103800>	C103491	C-SSRS Since Last Visit - Description of Ideation With Intent, No Plan|CSS02-Ideation With Intent No Plan Descr|CSS02-Ideation With Intent No Plan Descr|CSS0204A	Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Description of active suicidal ideation with some intent to act, without specific plan.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103801>	C103491	C-SSRS Since Last Visit - Ideation With Plan/Intent|CSS02-Ideation With Plan/Intent|CSS02-Ideation With Plan/Intent|CSS0205	Columbia-Suicidality Severity Rating Scale Since Last Visit (C-SSRS Since Last Visit) Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103802>	C226653	Definitely Disagree	An unequivocal feeling of opposition.			Intellectual Product	
C103803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103803>	C226653	Mostly Disagree	A predominant feeling of opposition.			Intellectual Product	
C103804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103804>	C226653|C176244	Neither Agree or Disagree|Neutral|No Opinion	Without concurrence or opposition.			Intellectual Product	Canine Quality of Life Survey|ICDC Terminology|MD Anderson Dysphagia Inventory|PRECINCT Property Terminology
C103805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103805>	C176244	Mostly Agree	A predominant feeling of concurrence.			Intellectual Product	
C103806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103806>	C176244	Definitely Agree|Definitely|Definitely Agree Answer	A subjective answer of very strong agreement.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C103807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103807>	C27993	Slight|Slightly	Small or little in size, quantity, or degree.			Qualitative Concept	
C103808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103808>	C48938	CD19 Expressing Cell Count	The determination of the amount of the CD19 expressing cells in a sample.			Laboratory Procedure	
C103809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103809>	C48938	CD3 Expressing Cell Count	The determination of the amount of the CD3 expressing cells in a sample.			Laboratory Procedure	
C10380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10380>	C61063	Carboplatin/Doxorubicin/Etoposide/Vincristine|CBDCA/DOX/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103810>	C48938	CD4 Expressing Cell Count|CD4 Count|cd4 count|cd4_count	The determination of the amount of the CD4 expressing cells in a sample.	CD4 Expressing Cell Count		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Property Terminology|GDC Terminology
C103811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103811>	C48938	CD8 Expressing Cell Count	The determination of the amount of the CD8 expressing cells in a sample.			Laboratory Procedure	
C103812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103812>	C67208	CD19 Cell to Lymphocyte Ratio Measurement	The determination of the ratio of CD19 cells compared to lymphocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	
C103813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103813>	C67208	CD3 Cell to Lymphocyte Ratio Measurement	The determination of the ratio of CD3 cells compared to lymphocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	
C103814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103814>	C48938	CD4 Cell to CD8 Cell Ratio Measurement	The determination of the ratio of CD4 cells compared to CD8 cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	
C103815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103815>	C67208	CD4 Cell to Lymphocyte Ratio Measurement	The determination of the ratio of CD4 cells compared to lymphocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	
C103816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103816>	C67208	CD8 Cell to Lymphocyte Ratio Measurement	The determination of the ratio of CD8 cells compared to lymphocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	
C103817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103817>	C9479|C4863	Hereditary Prostate Carcinoma|Hereditary Prostate Cancer|Hereditary Prostate Cancer	Prostate carcinoma that has developed in relatives of patients with a history of prostate carcinoma.	Hereditary Prostate Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|NCIt Neoplasm Core Terminology
C103818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103818>	C61550	Iliac Crest|ILIAC CREST	The thick curved ridge in the upper area of the ilium.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103819>	C2124	Carbon C 11 Erlotinib Hydrochloride|C11-Erlotinib Hydrochloride	The hydrochloride salt form of the quinazoline derivative erlotinib labeled with the positron-emitting isotope carbon C 11, with potential use in imaging.  Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic tyrosine kinase domain of the epidermal growth factor receptor (EGFR). Following exposure to this agent, EGFR expression status can be determined and EGFR overexpressing tumor cells can be visualized using positron emission tomography (PET) imaging. This may be useful in determining the tumor cell response to a particular EGFR kinase inhibitor in individual patients. EGFR, a receptor tyrosine kinase, is overexpressed in numerous cancer cell types, and plays a significant role in tumor cell progression.	Carbon C 11 Erlotinib Hydrochloride		Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C10381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10381>	C61063	Mechlorethamine/Vincristine|NM/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103820>	C20401|C141144|C129822	Lirilumab|BMS-986015|IPH2102|LIRILUMAB	A fully human monoclonal antibody against killer-cell immunoglobulin-like receptors (KIR), with potential antineoplastic activity. Upon administration, lirilumab binds to KIR, thereby preventing the binding of KIR ligands to KIR on natural killer (NK) cells. By blocking these inhibitory receptors, NK cells become activated and attack cancer cells leading to tumor cell death. KIR, a member of the immunoglobulin superfamily, is expressed on the surface of NK cells.	Lirilumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103821>	C308	Amnion-derived Cellular Cytokine Solution|ACSS	A topical cellular cytokine solution containing a distinct combination of growth factors and cytokines secreted by and released from amnion-derived multipotent progenitor (AMP) cells, with potential immunomodulating and skin healing activities. The amnion-derived cellular cytokine solution (ACCS) contains near physiological levels of transforming growth factor beta, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2, as well as the angiogenesis factors platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF) and angiogenin that are normally found in healing wounds. Upon spraying the solution onto affected areas, the cytokines and growth factors in ACCS appear to increase the migration, proliferation and differentiation of both keratinocytes and fibroblasts; enhance the migration and phagocytosis of macrophages in wounds; and increase epithelialization. Together these processes may accelerate skin healing and tissue repair. Also, ACCS may be beneficial in the treatment of radiation burns of the skin.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C103822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103822>	C308	Injectable Astragalus membranaceus Polysaccharide|ASTRAGALUS MONGHOLICUS ROOT POLYSACCHARIDES|Injectable APS|Injectable PG2	An injectable form of a polysaccharide isolated from the radix of Astragalus membranaceus (PG2), used in traditional Chinese medicine, with potential hematopoiesis inducing and immunomodulating activities. Upon injection, APS may be able to relieve certain chemotherapy-induced side effects, including myelosuppression, fatigue, mucositis, pain, nausea and vomiting, as well as loss of appetite and body weight. Also, APS may exert immunostimulatory activities by stimulating B-lymphocytes, activating T-lymphocytes, inducing cytokine production, and activating macrophages and natural killer cells through as of yet unidentified mechanism(s). APS may improve compliance of radiotherapy and/or chemotherapy.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C103823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103823>	C1752|C1663	XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410|PVX-410	A cancer vaccine containing immunogenic, HLA-A2-specific epitopes derived from X-box-binding protein 1-unspliced (XBP1-US), XBP1-spliced (SP), syndecan-1 (CD138), and CS1 (CD2 subset 1, CRACC, SLAMF7, CD319) with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, XBP1-US/XBP1-SP/CD138/CS1 multipeptide vaccine PVX-410 may stimulate the immune system to induce a cytotoxic T-lymphocyte response against the four myeloma-specific antigens.  The tumor associated antigens (TAAs) XBP1-US, XBP1-SP, CD138 and CS1, are overexpressed on the surface of multiple myeloma (MM) cells.	XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103824>	C681|C67413	Oxycodone Hydrochloride/Naloxone Hydrochloride Prolonged-release Tablet|Targin|Targinact	A prolonged-release tablet formulation composed of the hydrochloride salt form of the opioid receptor agonist oxycodone and the hydrochloride salt form of the opioid receptor antagonist naloxone which may produce analgesia while relieving opioid-mediated gastrointestinal (GI) side effects. Upon oral administration, oxycodone binds to opioid receptors, thereby mimicking the effects of endogenous opiates to provide analgesia. As naloxone is very poorly absorbed, this agent binds locally to opiate receptors in the GI tract, thereby preventing oxycodone from binding to these receptors. This relieves the opioid-related side effects on the GI tract, including opioid-induced constipation.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C103825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103825>	C129839	Smac Mimetic GDC-0917|CUDC 427|CUDC-427|CUDC427|GDC-0917|GDC-0917|IAP Antagonist GDC-0917|L-Prolinamide, N-methyl-L-alanyl-(2S)-2-cyclohexylglycyl-N-(2-(2-oxazolyl)-4-phenyl-5-thiazolyl)-|RG 7459|RG-7459|RG7459|SMAC/DIABLO Mimetic GDC-0917	An orally available, monovalent mimetic of second mitochondrial-derived activator of caspases (Smac/DIABLO) and inhibitor of IAPs (Inhibitor of Apoptosis Proteins) with potential antineoplastic activity. Smac mimetic GDC-0917 binds to the Smac binding groove on IAPs, including the direct caspase inhibitor X chromosome-linked IAP (XIAP) and the cellular IAPs 1 and 2. This inhibits the activities of these IAPs and promotes the induction of apoptosis through apoptotic signaling pathways.  IAPs are overexpressed by many cancer cell types and suppress apoptosis by binding to and inhibiting active caspases-3, -7 and -9 via their baculoviral lAP repeat (BIR) domains.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103826>	C155725	Taladegib|4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide|Benzamide, 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)-|LY-2940680|LY2940680|TALADEGIB	An orally bioavailable small molecule antagonist of the Hedgehog (Hh)-ligand cell surface receptor smoothened (Smo) with potential antineoplastic activity. Taladegib inhibits signaling that is mediated by the Hh pathway protein Smo, which may result in a suppression of the Hh signaling pathway and may lead to the inhibition of the proliferation of tumor cells in which this pathway is abnormally activated. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair; constitutive activation of this pathway is associated with uncontrolled cellular proliferation and has been observed in a variety of cancers.	Taladegib		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103827>	C226341|C201282|C129822	Pasotuxizumab|AMG-212|BAY2010112|MT112|PASOTUXIZUMAB	A recombinant T-cell engaging bispecific monoclonal antibody (BiTE) directed against human prostate specific membrane antigen (PSMA) and the CD3 epsilon subunit of the T cell receptor complex, with potential immunostimulating and antineoplastic activities.  Pasotuxizumab possesses two antigen-recognition sites, one for PSMA, and one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR). This bispecific monoclonal antibody brings PSMA-expressing tumor cells and cytotoxic T lymphocytes (CTLs) together, which may result in the CTL-mediated cell death of PSMA-expressing cells. PSMA, a tumor associated antigen, is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103828>	C1742|C129824	Galectin-1 Inhibitor OTX008|Gal-1 Inhibitor OTX008|KM-0118|OTX-008|OTX008	A calixarene-based compound and galectin-1 (Gal-1) inhibitor with potential anti-angiogenic and antineoplastic activities. Upon subcutaneous administration, galectin-1 inhibitor OTX008 binds Gal-1 which leads to Gal-1 oxidation and proteasomal degradation, through an as of yet not fully elucidated mechanism, and eventually downregulation of Gal-1. This decreases tumor cell growth and inhibits angiogenesis. Gal-1, a multifunctional carbohydrate-binding protein, is often overexpressed on tumor cells and plays a key role in cancer cell proliferation, apoptosis, tumor angiogenesis and evasion of immune responses.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103829>	C137999|C129826	FAP-specific CD8-positive T Cells	A preparation of CD8-positive T cells specific for human fibroblast activating protein (FAP) with potential immunopotentiating activity. T cells have been genetically modified to express a chimeric antigen receptor specific for FAP. Upon infusion, the FAP-specific CD8-positive T cells bind to FAP-expressing tumor cells and exhibit a selective toxicity to tumor cells. This may result in both tumor cell lysis and inhibition of tumor cell growth. FAP, a cell surface glycoprotein, is overexpressed on tumor-associated fibroblasts but minimally expressed on normal, healthy cells.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C10382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10382>	C61063	Carboplatin/Etoposide/Mechlorethamine/Vincristine|CBDCA/NM/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103830>	C1663	Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine	A recombinant chaperone-peptide complex-based vaccine composed of a complex between heat shock protein hsp110 and the human melanoma-associated antigen gp100, with potential antineoplastic activity. Upon vaccination, recombinant hsp110-gp100 chaperone complex activates the immune system to exert a cytotoxic T cell immune response and antigen-specific interferon-gamma production against gp100-overexpressing cancer cells. Gp100, is overexpressed in a variety of cancer cell types. Hsp110, binds to and chaperones full-length proteins during heat shock; as an immunoadjuvant it is able to enhance an immune response against antigen(s) and stimulate T-lymphocyte activation.	Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103831>	C2124	Fluorine F 18 FMDHT|18F FMDHT|[7Alpha-18F]fluoro-17alpha-methyl-5alpha-dihydrotestosterone|[F-18] FMDHT	A radioconjugate containing a derivative of the androgen testosterone (FMDHT) and labeled with the radioisotope fluorine F 18, with potential use as an imaging agent for positron emission tomography (PET). Upon administration, fluorine F 18 FMDHT binds to the androgen receptor (AR). Upon PET imaging, AR-expressing prostate tumor cells can be imaged and assessed.			Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	NCI Drug Dictionary Terminology
C103832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103832>	C91105	FACT-P Questionnaire|FACT-P|FACT-P|Functional Assessment of Cancer Therapy- Prostate|Functional Assessment of Cancer Therapy- Prostate (FACT-P version 4)	The FACT-P is a multidimensional, self-report quality of life instrument specifically designed for use with prostate cancer patients. It consists of 27 core items which assess patient function in four domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by 12 site specific items to assess for prostate related symptoms (from GEM website https://www.gem-beta.org/public/MeasureDetail.aspx?mid=1074&cat=2)			Intellectual Product	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C103833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103833>	C173981	Losing Weight Question|Have Lost Weight|Have Weight Loss|Have you lost weight|I am losing weight|Losing Weight|Losing Weight|Lost Weight|Weight Loss|Weight loss	A question about whether an individual is losing or has lost weight.			Intellectual Product	Dexamethasone Symptom Questionnaire-Chronic|Dexamethasone Symptom Questionnaire|FACT-Hep Questionnaire|FACT-L Questionnaire|FACT-P Questionnaire|Memorial Symptom Assessment Scale - Short Form|Quality of Life Questionnaire - Head & Neck 35
C103834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103834>	C173346|C172982	Aches and Pains Bother Me Question|Aches and Pains Bother Me|Aches and Pains Bother Me|I have aches and pains that bother me	A question about whether an individual is or was bothered by aches and pains.			Intellectual Product	FACT-P Questionnaire
C103835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103835>	C91126	Have Painful Body Parts Question|Have Painful Body Parts|Have Painful Body Parts|I have certain parts of my body where I experience pain	A question about whether an individual has or had pain in certain parts of their body.			Intellectual Product	FACT-P Questionnaire
C103836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103836>	C173792	Satisfied with Present Comfort Level Question|I am satisfied with my present comfort level|Satisfied with Physical Appearance|Satisfied with Present Comfort Level	A question about an individual's satisfaction with their present comfort level.			Intellectual Product	FACT-P Questionnaire
C103837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103837>	C173160	Feel Like a Man Question|Feel Like a Man|Feel Like a Man|I am able to feel like a man	A question about whether an individual feels or felt like a man.			Intellectual Product	FACT-P Questionnaire
C103838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103838>	C173938|C173398	Trouble Moving Bowels Question|I have trouble moving my bowels|Trouble Moving Bowels|Trouble Moving Bowels	A question about a whether an individual has or had trouble moving their bowels.			Intellectual Product	FACT-P Questionnaire
C103839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103839>	C173803|C173398	Difficulty Urinating Question|Difficulty Urinating|Difficulty Urinating|I have difficulty urinating	A question about whether an individual has or had difficulty urinating.			Intellectual Product	FACT-P Questionnaire
C10383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10383>	C61063	Cisplatin/Ifosfamide/Sargramostim/Vinblastine|CDDP/GM-CSF/IFF/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103840>	C173803	Unusual Frequent Urination Question|I urinate more frequently than usual|Unusual Frequent Urination|Unusual Frequent Urination	A question about whether an individual urinates or was urinating more frequently than usual.			Intellectual Product	FACT-P Questionnaire
C103841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103841>	C173803|C173695	Activities Limited by Urination Problems Question|Activities Limited by Urination Problems|Activities Limited by Urination Problems|My problems with urinating limit my activities	A question about whether an individual is or has limited their activities due to urination problems.			Intellectual Product	FACT-P Questionnaire
C103842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103842>	C173704|C173045	Have and Maintain an Erection Question|Achieve and Maintain an Erection|Have and Maintain an Erection|I am able to have and maintain an erection|Sexual Function (problems with achieving / maintaining an erection)	A question about an individual's ability to have and maintain an erection.			Intellectual Product	FACT-P Questionnaire|Patient Oriented Prostate Utility Scale
C103843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103843>	C91105	Patient Reported Outcomes Version of CTCAE|PRO-CTCAE|PRO-CTCAE|PRO-CTCAE|Patient-Reported Outcomes version of the CTCAE (PRO-CTCAE)	A library of items for patient self-reporting of symptoms and side effects associated with cancer treatment trials.			Intellectual Product	HL Authorized Value Terminology|HL Patient Reported Outcomes Metadata Table|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C103844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103844>	C173791|C173603	Worst Severity Past Seven Days Breast Enlargement or Tenderness Question|In the last 7 days, what was the SEVERITY of your BREAST AREA ENLARGEMENT OR TENDERNESS at its WORST|Worst Severity Last Seven Days Breast Enlargement or Tenderness|Worst Severity Last Seven Days Breast Enlargement or Tenderness|Worst Severity Past Seven Days Breast Enlargement or Tenderness	A question about an individual's observation of the worst severity they have experienced related to breast area enlargement or tenderness in the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C103845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103845>	C64848	Hemoglobin Variant Measurement|HGBVAR|Hemoglobin Variants|Hemoglobin Variants	A test to measure the variants of hemoglobin.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Neonatal Research Network Terminology|NICHD Terminology
C103846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103846>	C225418	Retrocrural	Of or pertaining to the most inferior portion of the posterior mediastinum.			Spatial Concept	
C103847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103847>	C13442	Portacaval	Of or pertaining to the portal vein and inferior vena cava.			Spatial Concept	
C103848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103848>	C225418	Preauricular	Of or pertaining to the area in front of the auricle of the ear.			Spatial Concept	
C103849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103849>	C91105	Pittsburgh Sleep Quality Index|PSQI|PSQI|PSQI1|Pittsburgh Sleep Quality Index (PSQI) SF-10	A self-rated questionnaire which assesses sleep quality and disturbances over a one month time interval.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10384>	C61063	Cisplatin/Etoposide/Ifosfamide/Sargramostim|CDDP/GM-CSF/IFF/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103850>	C91105	FACT-Cognitive Function|FAC075|FACT-COG|FACT-COG V3|FACT-COG Version 3|FACT-Cognitive Function v3|Functional Assessment of Cancer Therapy-Cognitive Function Version 3	The FACT-Cognitive Function questionnaire is a 37 item measure developed by Dr. David Cella to evaluate knowledge and information processing.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C103851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103851>	C27993	Regardless	Lacking consideration or without thoughtful attention.			Qualitative Concept	
C103852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103852>	C225418	Extra-Adrenal	Pertaining to tissues outside the adrenal gland.			Spatial Concept	
C103853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103853>	C62674	Cycled Drug Stability Study-Complex	Studies designed to determine the effects of multiple rounds of changing conditions on a drug's stability and efficacy. A complex cycled drug stability study will test a multiple factor during the same study.			Intellectual Product	
C103854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103854>	C48800	Biopathology Center|BPC	A College of American Pathologists (CAP) accredited biorepository with the primary objective of long-term acquisition and storage of a large number of cancer, normal and diseased biospecimens obtained from patients with Informed Consent, and related data for the purpose of supporting cutting edge research.			Professional or Occupational Group	
C103855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103855>	C21541	Seattle Cancer Care Alliance|SCCA	A world-class cancer treatment center that unites doctors from Fred Hutchinson Cancer Research Center, UW Medicine and Seattle Children's.			Health Care Related Organization	
C103856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103856>	C1287	Eflapegrastim|EFLAPEGRASTIM|HM10460A|HNK460|LAPS-GCSF|SPI-2012|SPI2012	A long-acting, recombinant analog of the endogenous human granulocyte colony-stimulating factor (G-CSF) with hematopoietic activity. Similar to G-CSF, eflapegrastim binds to and activates specific cell surface receptors and stimulates neutrophil progenitor proliferation and differentiation, as well as selected neutrophil functions. Therefore, this agent may decrease the duration and incidence of chemotherapy-induced neutropenia. The long-acting G-CSF analog SPI-2012 extends the half-life of G-CSF, allowing for administration once every 3 weeks.	Eflapegrastim		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C103857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103857>	C20401|C129822	Anti-GRP78 Monoclonal Antibody PAT-SM6|PAT-SM6	A IgM monoclonal antibody (MoAb) against 78-kDa glucose-regulated protein (GRP78; also called BiP or HSPA5), with potential proapoptotic and antineoplastic activities. Upon intravenous administration of the anti-GRP78 monoclonal antibody PAT-SM6, the MoAb strongly binds to GRP78, thereby preventing the activation of multiple GRP78-mediated pathways and blocking the GRP78-induced suppression of apoptotic pathways. This eventually leads to the induction of tumor cell apoptosis and a reduction in tumor cell proliferation. GRP78, the endoplasmic reticulum (ER) chaperone and unfolded protein response (UPR) regulator, is overexpressed on the surface of a variety of cancer cell types; its expression is associated with increased tumor cell survival and proliferation, as well as angiogenesis and resistance to chemotherapy.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103858>	C2140	Internalized-arginylglycylaspartic Acid Cyclic Peptide|CEND 1|CEND-1|IRGD|L-Cysteine, L-Cysteinyl-L-Arginylglycyl-L-.Alpha.-Aspartyl-L-Lysylglycyl-L-Prolyl-L-.Alpha.-Aspartyl-, Cyclic (1->9)-Disulfide|LSTA 1|LSTA-1|LSTA1|iRGD	A 9 amino acid-based cyclic, tumor specific homing, arginine-glycine-aspartic acid (RGD)-based peptide (CRGDKRGPDC), with tumor penetrating activity. The iRGD contains the RGD motif as well as the C-terminal end binding (CendR) motif that increases internalization. Upon administration, the RGD motif of the iRGD peptide is able to specifically target tumors by binding to alphavbeta3/alphavbeta5 integrins on tumor endothelium. In turn, iRGD is cleaved by specific tumor proteases, which exposes the positively charged CendR motif. This motif binds to neuropilin-1 (NRP-1), a receptor overexpressed on certain tumor cells. This increases vascular permeability of tumor blood vessels and promotes tumor penetration. Compared to other RGD peptides, this agent is able to both improve delivery and increase the accumulation of co-administered or conjugated chemotherapeutic agents in the tumor.	Internalized-arginylglycylaspartic Acid Cyclic Peptide		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C103859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103859>	C199386	Anti-ErbB3 Monoclonal Antibody REGN1400|REGN 1400|REGN-1400|REGN-1400|REGN1400	A human monoclonal antibody directed against the human epidermal growth factor receptor ErbB3 (Her3) with potential antineoplastic activity. Upon administration, anti-ErbB3 monoclonal antibody REGN1400 binds to ErbB3 and prevents neuregulin 1 ligand binding to ErbB3, which may result in an inhibition of ErbB3-dependent phosphatidylinositol-3 kinase (PI3K)/Akt signaling. This eventually leads to the inhibition of cellular proliferation and differentiation. ErbB3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in a variety of solid tumors and its overexpression generally correlates with poor prognosis and tumor resistance.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C10385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10385>	C61063	Cytarabine/Daunorubicin/Sargramostim|ARA-C/DNR/GM-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103860>	C20401|C129822	Anti-HLA-DR Monoclonal Antibody IMMU-114|Anti-HLA-DR MoAb L243|IMMU-114|hL243gamma4P	A humanized IgG4 monoclonal antibody that targets the human leukocyte antigen HLA-DR, with potential antineoplastic activity. Upon administration, anti-HLA-DR monoclonal antibody IMMU-114 binds to HLA-DR on HLA-DR-expressing tumor cells and, although the exact mechanism has yet to be fully elucidated, appears to induce hyperactivation of ERK- and JNK-dependent mitogen activated protein kinase signaling pathways. This may lead to mitochondrial membrane depolarization and reactive oxygen species (ROS) generation. This eventually leads to an induction of tumor cell apoptosis and a reduction in tumor cell proliferation. IMMU-14 may be beneficial in the treatment of graft versus host disease (GVHD) as it appears to suppress T-lymphocyte proliferation and natural killer (NK) cell activation. As the Fc region of the orgnial IgG1 MoAb was replaced with the IgG4 isotype, IMMU-114 does not induce a complement cytotoxicity (CDC) or an antibody-dependent cell-mediated cytotoxicity (ADCC). HLA-DR, a MHC class II molecule, is found on various b-cell hematologic malignancies and in autoimmune diseases as well as on normal cells.	Anti-HLA-DR Monoclonal Antibody IMMU-114		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103861>	C2152|C202468|C129825	PI3K Alpha/Beta Inhibitor BAY1082439|BAY-1082439|BAY1082439	An orally bioavailable inhibitor of the class I phosphoinositide 3-kinase (PI3K) alpha and beta isoforms with potential antineoplastic activity. PI3K alpha/beta inhibitor BAY1082439 selectively inhibits both PI3K alpha, including mutated forms of PIK3CA, and PI3K beta in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K-expressing and/or PTEN-driven tumor cells. By specifically targeting class I PI3K alpha and beta, this agent may be more efficacious and less toxic than pan PI3K inhibitors. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and results in increased tumor cell growth, survival, and resistance to chemotherapy and radiotherapy. PIK3CA, one of the most highly mutated oncogenes, encodes the p110-alpha catalytic subunit of the class I PI3K. PTEN, a tumor suppressor protein and negative regulator of PI3K activity, is often mutated in a variety of cancer cells.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103862>	C2517	Allogeneic Irradiated Melanoma Cell Vaccine CSF470|CSF 470 Vaccine|CSF470 Vaccine	An allogeneic cancer vaccine composed of a mixture of lethally irradiated whole melanoma cancer cells obtained from four different melanoma cell lines, with potential immunostimulating and antineoplastic activities. Upon intradermal injections, allogeneic irradiated melanoma cell vaccine may stimulate the body's immune system to exert a cytotoxic T-lymphocyte response and antibody-dependent cellular cytotoxicity (ADCC) against the melanoma cancer cells.			Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103863>	C28227|C199386|C182012	Istiratumab|ISTIRATUMAB|MM-005|MM-141	A bispecific monoclonal antibody directed against the human epidermal growth factor receptor ErbB3 (Her3) and the human insulin-like growth factor-1 receptor (IGF-1R), with potential antineoplastic activity. The anti-IGF-1R targeting arm of Istiratumab binds to IGF-1R on tumor cells thereby preventing the binding of the natural ligands IGF-1, 2 and heregulin (HRG) to IGF-1R; the anti-ErbB3 therapeutic arm prevents the binding of neuregulin (NRG) to ErbB3. This prevents the activation of the PI3K/AKT signal transduction pathway and may result in both the induction of apoptosis and a decrease in cellular proliferation in IGF-1R and ErbB3-overexpressing tumor cells. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily, and ErB3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, are frequently overexpressed in solid tumors.	Istiratumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103864>	C2124	Gallium Ga 68-labeled DOTA Di-HSG Peptide IMP-288|Ga-68-IMP-288	A radiolabeled divalent histamine-succinyl-glycine (HSG) hapten-peptide linked with the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to the radionuclide gallium (Ga) 68 with potential use in diagnostic imaging. After pretargeting with a bispecific monoclonal antibody (BiMoAB) directed against both a tumor associated antigen (TAA) and the HSG hapten-peptide, the HSG portion of administered gallium Ga 68-labeled di-HSG-DOTA peptide IMP-288 binds the anti-HSG portion of the BiMoAB; Ga-68 radioisotopic activity localized to tumor cells bearing the TAA can then be visualized upon positron emission tomography (PET).			Pharmacologic Substance	NCI Drug Dictionary Terminology
C103865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103865>	C28681|C129826	Autologous Bone Marrow-derived CD34/CXCR4-positive Stem Cells AMR-001|AMR-001	A cell-based product containing autologous bone marrow derived CD34 positive and C-X-C chemokine receptor type 4 (CXCR4) positive stem cells with potential antiapoptotic and proangiogenic activities. Upon intracoronary infusion after a myocardial infarction (MI), autologous bone marrow-derived CD34/CXCR4-positive stem cells may preserve cardiac muscle cells and prevent apoptosis; thus improving myocardial perfusion. CD34/CXCR4-positive stem cells are naturally mobilized upon cell injury through signaling by hypoxia inducing factor (HIF), which is secreted in response to hypoxia. In turn, HIF induces the synthesis of stromal-derived factor 1 (SDF-1) and vascular endothelial growth factor (VEGF) which mobilize CD34/CXCR4 positive stem cells; CXCR4 is the receptor for stromal-derived factor 1 (SDF-1).	Autologous Bone Marrow-derived CD34/CXCR4-positive Stem Cells AMR-001		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103866>	C2701	High-titer RSV Immune Globulin RI-001|RI-001	A plasma-derived, polyclonal, intravenous immunoglobulin formulation (IVIG) containing standardized high levels of antibodies against respiratory syncytial virus (RSV), a single-stranded, enveloped paramyxovirus, with potential immunomodulating activity. The high-titer RSV immune globulin RI-001 is derived from healthy donors with high amounts of RSV antibodies. Upon intravenous administration, the antibodies against RSV may provide passive immunization against RSV. This may prevent lower respiratory tract infections by RSV in immunocompromised patients. The polyclonal antibodies in RI-001 are able to target various viral epitopes.	High-titer RSV Immune Globulin RI-001		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C103867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103867>	C27297	Norepinephrine-Secreting|Norepinephrine Secreting	A finding indicating that an excess amount of norepinephrine is secreted by a tumor.			Finding	GDC Terminology|GDC Value Terminology
C103868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103868>	C27297	Normetanephrine-Secreting|Normetanephrine Secreting	A finding indicating that an excess amount of normetanephrine is secreted by a tumor.			Finding	GDC Terminology|GDC Value Terminology
C103869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103869>	C27297	Epinephrine-Secreting|Epinephrine Secreting	A finding indicating that an excess amount of epinephrine is secreted by a tumor.			Finding	GDC Terminology|GDC Value Terminology
C10386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10386>	C61063	Ethacrynic Acid/Melphalan|EA/L-PAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103870>	C27297	Metanephrine-Secreting|Metanephrine Secreting	A finding indicating that an excess amount of metanephrine is secreted by a tumor.			Finding	GDC Terminology|GDC Value Terminology
C103871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103871>	C27297	Dopamine-Secreting|Dopamine Secreting	A finding indicating that an excess amount of dopamine is secreted by a tumor.			Finding	GDC Terminology|GDC Value Terminology
C103872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103872>	C27297	Methoxytyramine-Secreting|Methoxytyramine Secreting	A finding indicating that an excess amount of methoxytyramine is secreted by a tumor.			Finding	GDC Terminology|GDC Value Terminology
C103873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103873>	C25939	SDHA Gene|SDHA|SDHA|SDHA|SDHA|Succinate Dehydrogenase Complex, Subunit A, Flavoprotein (Fp) Gene	This gene is involved in the mitochondrial respiratory chain.	SDHA Gene		Gene or Genome	CCPS Genetics Terminology|Childhood Cancer Predisposition Study Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C103874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103874>	C103873	SDHA wt Allele|CMD1GG|FP|PGL5|SDH1|SDH2|SDHF|Succinate Dehydrogenase Complex, Subunit A, Flavoprotein (Fp) wt Allele	Human SDHA wild-type allele is located in the vicinity of 5p15 and is approximately 38 kb in length. This allele, which encodes succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial protein, plays a role in cellular respiration. Mutation of the gene is associated with both mitochondrial complex II deficiency and cardiomyopathy dilated type 1GG.	SDHA wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103875>	C16946	Succinate Dehydrogenase [Ubiquinone] Flavoprotein Subunit, Mitochondrial|EC 1.3.5.1|Flavoprotein Subunit of Complex II|Fp|SDHA|SDHA	Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial (664 aa, ~73 kDa) is encoded by the human SDHA gene. This protein is involved in the mitochondrial electron transport chain.	Succinate Dehydrogenase [Ubiquinone] Flavoprotein Subunit, Mitochondrial		Amino Acid, Peptide, or Protein|Enzyme	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103876>	C28533|C158414	ABCA5 Gene|ABCA5|ABCA5|ATP Binding Cassette Subfamily A Member 5 Gene	This gene is involved in both ATP binding and catabolism.	ABCA5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C103877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103877>	C103876	ABCA5 wt Allele|ABC13|ATP Binding Cassette Subfamily A, Member 5 wt Allele|ATP-Binding Cassette, Sub-Family A (ABC1), Member 5 Gene|ATP-Binding Cassette, Subfamily A, Member 5 Gene|EST90625|HTC3|KIAA1888	Human ABCA5 wild-type allele is located in the vicinity of 17q24.3 and is approximately 83 kb in length. This allele, which encodes cholesterol transporter ABCA5 protein, plays a role in both the binding and metabolism of ATP.	ABCA5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103878>	C17750|C158419	Cholesterol Transporter ABCA5|ABCA5|ATP-Binding Cassette A5|ATP-Binding Cassette Sub-Family A Member 5|ATP-Binding Cassette Sub-Family A Member 5	Cholesterol transporter ABCA5 (1642 aa, ~187 kDa) is encoded by the human ABCA5 gene. This protein is involved in ATP hydrolysis.	ATP-Binding Cassette Sub-Family A Member 5		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103879>	C28533|C158414	ABCC4 Gene|ABCC4|ABCC4|ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 4 Gene	This gene plays a role in both cellular detoxification and platelet degranulation.	ABCC4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10387>	C61007	Cyclophosphamide/Diethylstilbestrol/Fluorouracil|CTX/DES/5-FU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103880>	C103879	ABCC4 wt Allele|ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 4 wt Allele|Canalicular Multispecific Organic Anion Transporter (ABC Superfamily) Gene|EST170205|MOAT-B|MOATB|MRP4|bA464I2.1	Human ABCC4 wild-type allele is located in the vicinity of 13q32 and is approximately 282 kb in length. This allele, which encodes multidrug resistance-associated protein 4, is involved in ATP hydrolysis, anion transport and platelet activation.	ABCC4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103881>	C17750|C158419	Multidrug Resistance-Associated Protein 4|ABCC4|ATP-Binding Cassette Sub-Family C Member 4|Canalicular Multispecific Organic Anion Transporter|MOAT-B|MRP/cMOAT-Related ABC Transporter|Multi-Specific Organic Anion Transporter B	Multidrug resistance-associated protein 4 (1325 aa, ~150 kDa) is encoded by the human ABCC4 gene. This protein plays a role in platelet degranulation, ATP hydrolysis and organic anion transport.	Multidrug Resistance-Associated Protein 4		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103882>	C28533|C158414	ABCC2 Gene|ABCC2|ABCC2|ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 2 Gene	This gene is involved in drug efflux.	ABCC2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C103883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103883>	C103882	ABCC2 wt Allele|ABC30|ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 2 wt Allele|CMOAT|CMOAT1|CMRP|Canalicular Multispecific Organic Anion Transporter 1 Gene|DJS|MRP2|cMRP	Human ABCC2 wild-type allele is located in the vicinity of 10q24 and is approximately 69 kb in length. This allele, which encodes canalicular multispecific organic anion transporter 1 protein, plays a role in both multidrug resistance and organic anion transport. Mutation of the gene is associated with Dubin-Johnson syndrome.	ABCC2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103884>	C17750|C158419	Canalicular Multispecific Organic Anion Transporter 1|ABCC2|ATP-Binding Cassette Sub-Family C Member 2|Canalicular Multidrug Resistance Protein|Multidrug Resistance-Associated Protein 2	Canalicular multispecific organic anion transporter 1 (1545 aa, ~174 kDa) is encoded by the human ABCC2 gene. This protein is involved in both anion transport and multidrug resistance.	Canalicular Multispecific Organic Anion Transporter 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103885>	C25943	ACACA Gene|ACACA|ACACA|ACACA|Acetyl-CoA Carboxylase Alpha Gene	This gene plays a role in the synthesis of long-chain fatty acids.	ACACA Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C103886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103886>	C103885	ACACA wt Allele|ACAC|ACACAD|ACACalpha|ACC|ACC1|ACCA|ACCalpha|Acac1|Acetyl-CoA Carboxylase Alpha wt Allele	Human ACACA wild-type allele is located in the vicinity of 17q21 and is approximately 325 kb in length. This allele, which encodes acetyl-CoA carboxylase 1 protein, is involved in long-chain fatty acid biosynthesis. Mutation of the gene is associated with acetyl-CoA carboxylase 1 deficiency.	ACACA wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103887>	C16796	Acetyl-CoA Carboxylase 1|ACACA|ACC|ACC-Alpha|ACC1|Acetyl-Coenzyme A Carboxylase Alpha|EC 6.4.1.2	Acetyl-CoA carboxylase 1 (2346 aa, ~266 kDa) is encoded by the human ACACA gene. This protein plays a role in the modulation of long-chain fatty acid biosynthesis.	Acetyl-CoA Carboxylase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103888>	C25804	ACER1 Gene|ACER1|ACER1|Alkaline Ceramidase 1 Gene	This gene is involved in ceramide metabolism.	ACER1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C103889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103889>	C19285	TNFRSF8 Gene Product	A protein encoded by the TNFRSF8 gene.			Amino Acid, Peptide, or Protein	
C10388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10388>	C61063	BCG/Mitomycin|BCG/MITO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103890>	C103889	Soluble Tumor Necrosis Factor Receptor Superfamily Member 8|Soluble Ber-H2|Soluble CD30|Soluble CD30L Receptor|Soluble Ki-1|Soluble Ki-1 Antigen|sCD30	Soluble tumor necrosis factor receptor superfamily member 8 (~85 kDa) is encoded by the human TNFRSF8 gene. This enzymatically processed protein may be involved in the inhibition of tumor necrosis factor ligand superfamily member 8 (CD30 ligand) binding to its cell surface-localized receptor.	Soluble Tumor Necrosis Factor Receptor Superfamily Member 8		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103891>	C103888	ACER1 wt Allele|ALKCDase1|ASAH3|Alkaline Ceramidase 1 wt Allele|N-Acylsphingosine Amidohydrolase (Alkaline Ceramidase) 3 Gene	Human ACER1 wild-type allele is located in the vicinity of 19p13.3 and is approximately 27 kb in length. This allele, which encodes alkaline ceramidase 1 protein, plays a role in the conversion of ceramides to sphingosine.	ACER1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103892>	C16701	Alkaline Ceramidase 1|ACER1|Acylsphingosine Deacylase 3|AlkCDase 1|Alkaline CDase 1|EC 3.5.1.23|N-Acylsphingosine Amidohydrolase 3	Alkaline ceramidase 1 (264 aa, ~31 kDa) is encoded by the human ACER1 gene. This protein is involved in the catabolism of sphingolipid ceramides.	Alkaline Ceramidase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103893>	C25804	ACER2 Gene|ACER2|ACER2|Alkaline Ceramidase 2 Gene	This gene plays a role in sphingosine biosynthesis.	ACER2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C103894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103894>	C103893	ACER2 wt Allele|ALKCDase2|ASAH3L|Alkaline Ceramidase 2 wt Allele|N-Acylsphingosine Amidohydrolase 3-Like Gene|PP11646|RP11-363E7.1	Human ACER2 wild-type allele is located 9p22.1 and is approximately 44 kb in length. This allele, which encodes alkaline ceramidase 2 protein, is involved in the catabolism of sphingolipid ceramides.	ACER2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103895>	C16701	Alkaline Ceramidase 2|ACER2|Acylsphingosine Deacylase 3-Like|AlkCDase 2|Alkaline CDase 2|EC 3.5.1.23|N-Acylsphingosine Amidohydrolase 3-Like|haCER2	Alkaline ceramidase 2 (275 aa, ~31 kDa) is encoded by the human ACER2 gene. This protein plays a role in ceramide metabolism and sphingosine synthesis.	Alkaline Ceramidase 2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103896>	C25804	ACER3 Gene|ACER3|ACER3|Alkaline Ceramidase 3 Gene	This gene is involved in the catabolism of phytoceramides.	ACER3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C103897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103897>	C103896	ACER3 wt Allele|APHC|Alkaline Ceramidase 3 wt Allele|FLJ11238|PHCA|Phytoceramidase, Alkaline Gene	Human ACER3 wild-type allele is located in the vicinity of 11q13.5 and is approximately 166 kb in length. This allele, which encodes alkaline ceramidase 3 protein, plays a role in phytoceramide metabolism.	ACER3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103898>	C16701	Alkaline Ceramidase 3|ACER3|AlkCDase 3|Alkaline CDase 3|Alkaline Dihydroceramidase SB89|Alkaline Phytoceramidase|EC 3.5.1.-|aPHC	Alkaline ceramidase 3 (267 aa, ~32 kDa) is encoded by the human ACER3 gene. This protein is involved in the synthesis of phytosphingosine.	Alkaline Ceramidase 3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103899>	C25804	ASAH1 Gene|ASAH1|ASAH1|N-Acylsphingosine Amidohydrolase (Acid Ceramidase) 1 Gene	This gene plays a role in sphingolipid metabolism.	ASAH1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10389>	C61063	Carboplatin/Etoposide/Interleukin-1-Beta|CBDCA/IL-1B/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1038>	C798|C2077	Carbogen|CARBOGEN|carbogen	An inhalant consisting of hyperoxic gas (95%-98% oxygen and 2%-5% carbon dioxide) with radiosensitizing properties.  Inhaled carbogen reduces diffusion-limited tumor hypoxia, increasing tumor radiosensitivity due to the increased availability of molecular oxygen for cytotoxic radiation-induced oxygen free radical production. (NCI04)			Inorganic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C103900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103900>	C103899	ASAH1 wt Allele|AC|ACDase|ASAH|FLJ21558|N-Acylsphingosine Amidohydrolase (Acid Ceramidase) 1 wt Allele|PHP|PHP32|SMAPME	Human ASAH1 wild-type allele is located in the vicinity 8p22 of and is approximately 29 kb in length. This allele, which encodes acid ceramidase protein, is involved in ceramide metabolism. Mutation of the gene is associated with both Farber lipogranulomatosis and spinal muscular atrophy with progressive myoclonic epilepsy.	ASAH1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103901>	C16701	Acid Ceramidase|AC|ACDase|ASAH1|Acid CDase|Acylsphingosine Deacylase|EC 3.5.1.23|N-Acylsphingosine Amidohydrolase|PHP32|Putative 32 kDa Heart Protein	Acid ceramidase (395 aa, ~45 kDa) is encoded by the human ASAH1 gene. This protein plays a role in sphingosine biosynthesis.	Acid Ceramidase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103902>	C25804	ASAH2 Gene|ASAH2|ASAH2|N-Acylsphingosine Amidohydrolase (Non-Lysosomal Ceramidase) 2 Gene	This gene is involved in sphingolipid-ceramide hydrolysis.	ASAH2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C103903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103903>	C103902	ASAH2 wt Allele|BCDase|HNAC1|LCDase|N-Acylsphingosine Amidohydrolase (Non-Lysosomal Ceramidase) 2 wt Allele|N-Cdase|NCDase	Human ASAH2 wild-type allele is located in the vicinity of 10q11.21 and is approximately 155 kb in length. This allele, which encodes neutral ceramidase protein, plays a role in sphingolipid metabolism.	ASAH2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103904>	C16701	Neutral Ceramidase|ASAH2|Acylsphingosine Deacylase 2|BCDase|EC 3.5.1.23|LCDase|Mitochondrial Ceramidase|N-Acylsphingosine Amidohydrolase 2|N-CDase|NCDase|Non-Lysosomal Ceramidase|hCD	Neutral ceramidase (780 aa, ~86 kDa) is encoded by the human ASAH2 gene. This protein is involved in ceramide hydrolysis.	Neutral Ceramidase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103905>	C20194	ASAH2B Gene|ASAH2B|ASAH2B|ASAH2C|N-Acylsphingosine Amidohydrolase 2B Gene	This gene may play a role in sphingolipid metabolism.	ASAH2B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C103906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103906>	C103905	ASAH2B wt Allele|ASAH2-Like Gene|ASAH2C|ASAH2L|Ceramidase, Nonlysosomal, C Gene|N-Acylsphingosine Amidohydrolase (Non-Lysosomal Ceramidase) 2B Gene|N-Acylsphingosine Amidohydrolase (Non-Lysosomal Ceramidase) 2C Gene|N-Acylsphingosine Amidohydrolase 2B wt Allele|bA449O16.3|bA98I6.3	Human ASAH2B wild-type allele is located in the vicinity of 10q11.23 and is approximately 77 kb in length. This allele, which encodes putative inactive neutral ceramidase B protein, may be involved in ceramide metabolism.	ASAH2B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103907>	C18466	Putative Inactive Neutral Ceramidase B|ASAH2-Like Protein|ASAH2B|ASAH2C|Putative Inactive N-Acylsphingosine Amidohydrolase 2B|Putative Inactive Non-Lysosomal Ceramidase B	Putative inactive neutral ceramidase B (165 aa, ~19 kDa) is encoded by the human ASAH2B gene. This protein may play a role in ceramide hydrolysis.	Putative Inactive Neutral Ceramidase B		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10390>	C61063	Dipyridamole/Fluorouracil/Leucovorin Calcium/Zidovudine|CF/DP/5-FU/ZDV			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103911>	C38186	Imaging Quality Assurance Review Center|QARC|Quality Assurance Review Center	A research program that provides specialized radiotherapy quality assurance and diagnostic imaging data management services.			Health Care Related Organization	
C103912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103912>	C32265	Carpometacarpal Joint 1|CARPOMETACARPAL JOINT 1|CMC1|Carpometacarpal Joint of the Thumb	A saddle-shaped synovial joint between the metacarpal of the thumb and the trapezium.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103913>	C32265	Carpometacarpal Joint 2|CARPOMETACARPAL JOINT 2|CMC2	A plane joint primarily between the second metacarpal and the trapezoid, which also connects with the trapezium and capitate.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103914>	C32265	Carpometacarpal Joint 3|CARPOMETACARPAL JOINT 3|CMC3	A plane joint between the third metacarpal and the capitate.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103915>	C32265	Carpometacarpal Joint 4|CARPOMETACARPAL JOINT 4|CMC4	A plane joint between the fourth metacarpal and the hamate.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103916>	C32265	Carpometacarpal Joint 5|CARPOMETACARPAL JOINT 5|CMC5	A plane joint between the fifth metacarpal and the pisiform.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C103917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103917>	C99137	Right Aortic Arch	An anatomic abnormality that occurs during embryonic development, in which the aortic arch is right-sided.			Congenital Abnormality	Neonatal Research Network Terminology|NICHD Terminology
C103918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103918>	C75464	Microcystic Renal Disease	A congenital renal disorder characterized by the presence of small cysts in the renal cortex and/or renal medulla.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C103919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103919>	C3970	Solitary Multilocular Kidney Cyst|Solitary Multilocular Renal Cyst|Solitary Multilocular Renal Cyst	A single cyst in the kidney with several compartments.			Finding	Neonatal Research Network Terminology|NICHD Terminology
C10391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10391>	C61063	Cyclophosphamide/Doxorubicin/Etoposide/Methotrexate/Sargramostim/Vincristine|CTX/DOX/GM-CSF/MTX/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103920>	C84767|C34368	Hemoglobin Barts|Bart's Hemoglobinopathy|Hemoglobin Bart's Hydrops	A severe and rare form of alpha thalassemia characterized by the absence of alpha globin chains. It results in hydrops fetalis, severe anemia, hepatosplenomegaly, heart defects, and genitourinary abnormalities. It leads to death in utero or shortly thereafter.			Disease or Syndrome	Cellosaurus Disease Terminology|Neonatal Research Network Terminology|NICHD Terminology
C103921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103921>	C53543	Lissencephaly	A rare genetic brain malformation characterized by smooth folds and grooves in the brain. There are approximately 20 different types of lissencephaly that are identified by various symptoms.			Disease or Syndrome	Cellosaurus Disease Terminology|Neonatal Research Network Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C103922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103922>	C26927	Congenital Hydroureter	Dilatation of the ureter caused by obstruction of urine flow that is present at birth.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C103923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103923>	C98899	Congenital Postural Scoliosis	Abnormal sideways curvature of the spine that is present at birth.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C103924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103924>	C25939	ALOX12 Gene|ALOX12|ALOX12|Arachidonate 12-Lipoxygenase Gene	This gene plays a role in oxidation of fatty acids.	ALOX12 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C103925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103925>	C103924	ALOX12 wt Allele|12-LOX|12S-LOX|Arachidonate 12-Lipoxygenase wt Allele|LOG12	Human ALOX12 wild-type allele is located in the vicinity of 17p13.1 and is approximately 15 kb in length. This allele, which encodes arachidonate 12-lipoxygenase, 12S-type protein, is involved in leukotriene synthesis.	ALOX12 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103926>	C28459	Arachidonate 12-Lipoxygenase, 12S-Type|12S-LOX|12S-Lipoxygenase|ALOX12|EC 1.13.11.31|Platelet-Type Lipoxygenase 12	Arachidonate 12-lipoxygenase, 12S-type (663 aa, ~76 kDa) is encoded by the human ALOX12 gene. This protein plays a role in both fatty acid oxidation and leukotriene biosynthesis.	Arachidonate 12-Lipoxygenase, 12S-Type		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103927>	C25804	ARG1 Gene|ARG1|ARG1|Arginase, Liver Gene	This gene plays a role in the urea cycle.	ARG1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C103928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103928>	C103927	ARG1 wt Allele|Arginase, Liver wt Allele	Human ARG1 wild-type allele is located 6q23 and is approximately 11 kb in length. This allele, which encodes arginase-1 protein, is involved in the metabolism of both amino acids and urea. Mutation of the gene is associated with argininemia.	ARG1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103929>	C16701	Arginase-1|ARG1|Arginase A1|EC 3.5.3.1|L-Arginine Amidinohydrolase|L-Arginine Ureahydrolase|Liver-Type Arginase|Type I Arginase	Arginase-1 (322 aa, ~35 kDa) is encoded by the human ARG1 gene. This protein plays a role in the cleavage of L-arginine to L-ornithine and urea.	Arginase-1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10392>	C61063	Cyclophosphamide/Doxorubicin/Etoposide/Methotrexate/Pentamidine/Sargramostim/Vincristine/Zidovudine|CTX/DOX/GM-CSF/MTX/PAD/VCR/VP-16/ZDV			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103930>	C25952	ARSA Gene|ARSA|ARSA|Arylsulfatase A Gene	This gene is involved in the metabolism of cerebroside sulfate.	ARSA Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C103931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103931>	C103930	ARSA wt Allele|Arylsulfatase A wt Allele|MLD|Metachromatic Leucodystrophy Gene|Metachromatic Leukodystrophy Gene	Human ARSA wild-type allele is located in the vicinity of 22q13.33 and is approximately 3 kb in length. This allele, which encodes arylsulfatase A protein, plays a role in the catabolism of cerebroside sulfate. Mutation of the gene is associated with leukodystrophy metachromatic.	ARSA wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103932>	C16561	Arylsulfatase A|ARSA|ASA|Cerebroside 3-Sulfatase|Cerebroside-Sulfatase|EC 3.1.6.8	Arylsulfatase A (507 aa, ~54 kDa) is encoded by the human ARSA gene. This protein is involved in the hydrolysis of cerebroside sulfate.	Arylsulfatase A		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103933>	C25193	Automotive Occupations|Automotive	A class of professional or vocational positions of employment that involve work with automobiles.			Occupation or Discipline	
C103934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103934>	C148248	Welding Occupations|Welding	A class of professional or vocational positions of employment that involve work with welding.			Occupation or Discipline	
C103935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103935>	C62436	Congenital Pulmonary Valve Insufficiency|Congenital Insufficiency of Pulmonary Valve|Congenital Pulmonary Insufficiency|Congenital pulmonary valve insufficiency	Dysfunction of the pulmonary valve characterized by incomplete valve closure that is present at birth.			Disease or Syndrome	mCode Elixhauser Valvular Disease Value Set|mCode Terminology|Neonatal Research Network Terminology|NICHD Terminology
C103936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103936>	C51223	Congenital Aortic Valve Insufficiency|Congenital Aortic Insufficiency|Congenital Insufficiency of Aortic Valve|Congenital insufficiency of aortic valve|Congential Aortic Valve Insufficiency	Dysfunction of the aortic valve characterized by incomplete valve closure that is present at birth.			Disease or Syndrome	mCode Elixhauser Valvular Disease Value Set|mCode Terminology|Neonatal Research Network Terminology|NICHD Terminology
C103937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103937>	C26147	B4GALT6 Gene|B4GALT6|B4GALT6|UDP-Gal:BetaGlcNAc Beta 1,4- Galactosyltransferase, Polypeptide 6 Gene	This gene plays a role in glycosphingolipid synthesis.	B4GALT6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C103938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103938>	C103937	B4GALT6 wt Allele|B4Gal-T6|UDP-Gal:BetaGlcNAc Beta 1,4- Galactosyltransferase, Polypeptide 6 wt Allele|beta4Gal-T6|beta4GalT-VI	Human B4GALT6 wild-type allele is located in the vicinity of 18q11 and is approximately 62 kb in length. This allele, which encodes beta-1,4-galactosyltransferase 6 protein, is involved in ceramide metabolism.	B4GALT6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103939>	C17434	Beta-1,4-Galactosyltransferase 6|B4GALT6|Beta-1,4-GalTase 6|Beta4Gal-T6|EC 2.4.1.-|EC 2.4.1.274|Glucosylceramide Beta-1,4-Galactosyltransferase|LacCer Synthase|Lactosylceramide Synthase|UDP-Gal:Beta-GlcNAc Beta-1,4-Galactosyltransferase 6|UDP-Gal:Glucosylceramide Beta-1,4-Galactosyltransferase|UDP-Galactose:Beta-N-Acetylglucosamine Beta-1,4-Galactosyltransferase 6|b4Gal-T6	Beta-1,4-galactosyltransferase 6 (382 aa, ~45 kDa) is encoded by the human B4GALT6 gene. This protein plays a role in the glycosylation of ceramides.	Beta-1,4-Galactosyltransferase 6		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10393>	C61063	Eflornithine/Lomustine/Procarbazine/Vincristine|CCNU/DFMO/PCB/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103940>	C25943	FPGS Gene|FPGS|FPGS|Folylpolyglutamate Synthase Gene	This gene plays a role in the metabolism of both folate and polyglutamate.	FPGS Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C103941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103941>	C103940	FPGS wt Allele|Folylpolyglutamate Synthase wt Allele|RP11-228B15.1	Human FPGS wild-type allele is located in the vicinity of 9q34.1 and is approximately 20 kb in length. This allele, which encodes folylpolyglutamate synthase, mitochondrial protein, is involved in the metabolism of folates.	FPGS wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103942>	C16796	Folylpolyglutamate Synthase, Mitochondrial|EC 6.3.2.17|FPGS|Folylpoly-Gamma-Glutamate Synthetase|Tetrahydrofolate Synthase|Tetrahydrofolylpolyglutamate Synthase	Folylpolyglutamate synthase, mitochondrial (587 aa, ~65 kDa) is encoded by the human FPGS gene. This protein plays a role in the conversion of folates to polyglutamate derivatives.	Folylpolyglutamate Synthase, Mitochondrial		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103943>	C28404	GGH Gene|GGH|GGH|Gamma-Glutamyl Hydrolase (Conjugase, Folylpolygammaglutamyl Hydrolase) Gene	This gene is involved in polyglutamate hydrolysis.	GGH Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C103944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103944>	C103943	GGH wt Allele|GH|Gamma-Glutamyl Hydrolase (Conjugase, Folylpolygammaglutamyl Hydrolase) wt Allele	Human GGH wild-type allele is located in the vicinity of 8q12.3 and is approximately 24 kb in length. This allele, which encodes gamma-glutamyl hydrolase protein, plays a role in glutamine metabolism.	GGH wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103945>	C16481	Gamma-Glutamyl Hydrolase|Conjugase|EC 3.4.19.9|GGH|GH|Gamma-Glu-X Carboxypeptidase	Gamma-glutamyl hydrolase (318 aa, ~36 kDa) is encoded by the human GGH gene. This protein is involved in the hydrolysis of gamma-linked glutamate bonds.	Gamma-Glutamyl Hydrolase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103946>	C28533	SLC19A1 Gene|SLC19A1|SLC19A1|Solute Carrier Family 19 Member 1 Gene	This gene plays a role in folate transport.	SLC19A1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C103947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103947>	C103946	SLC19A1 wt Allele|CHMD|FOLT|IFC-1|IFC1|MEGAF|REFC|RFC|RFC1|RFT-1|Solute Carrier Family 19 (Folate Transporter), Member 1 Gene|Solute Carrier Family 19 Member 1 wt Allele|hRFC|hSLC19A1	Human SLC19A1 wild-type allele is located in the vicinity of 21q22.3 and is approximately 51 kb in length. This allele, which encodes folate transporter 1 protein, is involved in folic acid metabolism.	SLC19A1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103948>	C16386	Folate Transporter 1|FOLT|IFC-1|Intestinal Folate Carrier 1|Placental Folate Transporter|RFC|RFT-1|Reduced Folate Carrier 1|Reduced Folate Carrier Protein|Reduced Folate Transporter 1|SLC19A1|Solute Carrier Family 19 Member 1|hRFC1|hSLC19A1	Folate transporter 1 (591 aa, ~65 kDa) is encoded by the human SLC19A1 gene. This protein plays a role in the transmembrane transport of folate.	Folate Transporter 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103949>	C28533|C158414	ABCC5 Gene|ABCC5|ABCC5|ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 5 Gene	This gene plays a role in the transport of organic anions and nucleotides.	ABCC5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10394>	C61007	Carboplatin/Doxorubicin|CBDCA/DOX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103950>	C103949	ABCC5 wt Allele|ABC33|ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 5 wt Allele|EST277145|MOAT-C|MOATC|MRP5|SMRP|pABC11	Human ABCC5 wild-type allele is located in the vicinity of 3q27 and is approximately 98 kb in length. This allele, which encodes multidrug resistance-associated protein 5, is involved in the transport of cyclic nucleotides.	ABCC5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103951>	C17750|C158419	Multidrug Resistance-Associated Protein 5|ABCC5|ATP-Binding Cassette Sub-Family C Member 5|MOAT-C|Multi-Specific Organic Anion Transporter C|SMRP|pABC11	Multidrug resistance-associated protein 5 (1437 aa, ~161 kDa) is encoded by the human ABCC5 gene. This protein plays a role in the export of cyclic nucleotides.	Multidrug Resistance-Associated Protein 5		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103952>	C21295	PLVAP Gene|PLVAP|PLVAP|Plasmalemma Vesicle Associated Protein Gene	This gene may be involved in caveolae structure.	PLVAP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C103953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103953>	C103952	PLVAP wt Allele|FELS|PV-1|PV1|Plasmalemma Vesicle Associated Protein wt Allele|gp68	Human PLVAP wild-type allele is located in the vicinity of 19p13.2 and is approximately 26 kb in length. This allele, which encodes plasmalemma vesicle-associated protein, may play a role in the formation of caveolae.	PLVAP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103954>	C17728	Plasmalemma Vesicle-Associated Protein|Fenestrated Endothelial-Linked Structure Protein|Fenestrated-Endothelial Linked Structure Protein|PLVAP|PV-1|PV-1 Protein|Plasmalemma Vesicle Protein 1	Plasmalemma vesicle-associated protein (442 aa, ~51 kDa) is encoded by the human PLVAP gene. This protein is involved in the structure of caveolae in endothelial cells.	Plasmalemma Vesicle-Associated Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103955>	C20194	BCCIP Gene|BCCIP|BCCIP|BRCA2 and CDKN1A Interacting Protein Gene	This gene may be involved in both cell cycle progression and DNA damage repair.	BCCIP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C103956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103956>	C98877	Coloboma of the Retina|Coloboma of Retina	A congenital or acquired defect characterized by the presence of a hole in the retina.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C103957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103957>	C103955	BCCIP wt Allele|BRCA2 and CDKN1A Interacting Protein wt Allele|TOK-1|TOK1	Human BCCIP wild-type allele is located in the vicinity of 10q26.1 and is approximately 30 kb in length. This allele, which encodes BRCA2 and CDKN1A-interacting protein, may play a role in both DNA damage repair and the cell cycle.	BCCIP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103958>	C18466	BRCA2 and CDKN1A-Interacting Protein|BCCIP|BRCA2 and Cip1/p21 Interacting Protein|Cdk Inhibitor P21 Binding Protein|P21- and CDK-Associated Protein 1|Protein TOK-1	BRCA2 and CDKN1A-interacting protein (314 aa, ~36 kDa) is encoded by the human BCCIP gene. This protein may be involved in the regulation of both cell cycle progression and DNA repair.	BRCA2 and CDKN1A-Interacting Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103959>	C38534	ATF3 Gene|ATF3|ATF3|Activating Transcription Factor 3 Gene	This gene plays a role in the negative regulation of transcription.	ATF3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10395>	C61063	Carboplatin/Doxorubicin/Sargramostim|CBDCA/DOX/GM-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103960>	C103959	ATF3 wt Allele|Activating Transcription Factor 3 wt Allele|RP11-338C15.1	Human ATF3 wild-type allele is located in the vicinity of 1q32.3 and is approximately 55 kb in length. This allele, which encodes cyclic AMP-dependent transcription factor ATF-3 protein, is involved in both transcriptional repression and DNA binding.	ATF3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103961>	C17286	Cyclic AMP-Dependent Transcription Factor ATF-3|ATF-3|ATF3|Activating Transcription Factor 3|cAMP-Dependent Transcription Factor ATF-3	Cyclic AMP-dependent transcription factor ATF-3 (181 aa, ~21 kDa) is encoded by the human ATF3 gene. This protein plays a role in both DNA binding and the repression of gene expression.	Cyclic AMP-Dependent Transcription Factor ATF-3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103962>	C20745	ANLN Gene|ANLN|ANLN|Anillin Actin Binding Protein Gene	This gene is involved in cytokinesis.	ANLN Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C103963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103963>	C103962	ANLN wt Allele|ANILLIN|Anillin (Drosophila Scraps Homolog), Actin Binding Protein Gene|Anillin Actin Binding Protein wt Allele|Anillin, Actin Binding Protein (Scraps Homolog, Drosophila) Gene|Anillin, Actin Binding Protein Gene|FSGS8|Scraps|scra	Human ANLN wild-type allele is located within 7p15-p14 and is approximately 64 kb in length. This allele, which encodes anillin, plays a role in cleavage furrow dynamics.	ANLN wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103964>	C16492	Anillin|ANLN|Actin-Binding Protein Anillin	Anillin (1124 aa, ~124 kDa) is encoded by the human ANLN gene. This protein plays a role in in maintaining the structural integrity of the cleavage furrow and in the completion of cell cleavage.	Anillin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103965>	C20746	ACTB Gene|ACTB|ACTB|Actin Beta Gene	This gene is involved in both cytoskeletal arrangement and cell motility.	ACTB Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C103966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103966>	C103965	ACTB wt Allele|Actin Beta wt Allele|Actin, Beta Gene|BRWS1|PS1TP5BP1	Human ACTB wild-type allele is located in the vicinity of 7p22 and is approximately 37 kb in length. This allele, which encodes actin, cytoplasmic 1 protein, plays a role in the modulation of both cell motility and cell shape. Mutation of the gene is associated with dystonia juvenile-onset and Baraitser-Winter syndrome type 1.	ACTB wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103967>	C173346	Pain Keeps Me From Doing Things I Want to Do Question|My pain keeps me from doing things I want to do|Pain Keeps Me From Doing Things I Want to Do|Pain Keeps Me From Doing Things I Want to Do	A question about whether an individual has or had pain that kept them from doing things they wanted to do.			Intellectual Product	FACT-P Questionnaire
C103968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103968>	C53543|C34816	Pyruvate Dehydrogenase Deficiency|PDH	A genetic disorder caused by mutations in the genes that are responsible for production of protein components of the pyruvate dehydrogenase complex. It may present with lactic acidosis. Signs and symptoms include developmental delays, seizures and hypotonia.			Disease or Syndrome	Cellosaurus Disease Terminology|Neonatal Research Network Terminology|NICHD Terminology
C103969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103969>	C16258	Actin, Cytoplasmic 1|ACTB|Beta-Actin|PS1TP5-Binding Protein 1	Actin, cytoplasmic 1 (375 aa, ~42 kDa) is encoded by the human ACTB gene. This protein is involved in both cell motility and morphology.	Actin, Cytoplasmic 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10396>	C61007	Cisplatin/Lomustine/Vincristine|CCNU/CDDP/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103970>	C20746	ACTA2 Gene|ACTA2|ACTA2|Actin Alpha 2, Smooth Muscle Gene	This gene plays a role in both cell morphology and cell motility.	ACTA2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C103971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103971>	C103970	ACTA2 wt Allele|AAT6|ACTSA|ACTVS|Actin Alpha 2, Smooth Muscle wt Allele|Actin, Alpha 2, Smooth Muscle, Aorta Gene|Actin, Alpha, Smooth Muscle, Aortic Gene|Actin, Alpha-2, Smooth Muscle, Aorta Gene|Actin, Vascular Smooth Muscle|GIG46|MYMY5	Human ACTA2 wild-type allele is located in the vicinity of 10q23.3 and is approximately 56 kb in length. This allele, which encodes actin, aortic smooth muscle protein, is involved in smooth muscle cell contraction. Mutations of this gene predispose patients to a variety of diffuse and diverse vascular diseases, including premature onset coronary artery disease, premature ischemic strokes, familial aortic aneurysm thoracic type 6, Moyamoya disease type 5 and multisystemic smooth muscle dysfunction syndrome.	ACTA2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103972>	C16258	Actin, Aortic Smooth Muscle|ACTA2|Alpha-Actin-2|Alpha-Cardiac Actin|Alpha-SMA|Alpha-Smooth Muscle Actin|Cell Growth-Inhibiting Gene 46 Protein	Actin, aortic smooth muscle (377 aa, ~42 kDa) is encoded by the human ACTA2 gene. This protein plays a role in the contraction of smooth muscle.	Actin, Aortic Smooth Muscle		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103973>	C20103	ADIPOR1 Gene|ADIPOR1|ADIPOR1|Adiponectin Receptor 1 Gene	This gene is involved in hormone binding and signal transduction.	ADIPOR1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C103974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103974>	C103973	ADIPOR1 wt Allele|ACDCR1|Adiponectin Receptor 1 wt Allele|CGI-45|CGI45|PAQR1|TESBP1A	Human ADIPOR1 wild-type allele is located in the vicinity of 1q32.1 and is approximately 18 kb in length. This allele, which encodes adiponectin receptor protein 1, plays a role in adiponectin-mediated signaling.	ADIPOR1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103975>	C18106	Adiponectin Receptor Protein 1|ADIPOR1|Adiponectin Receptor 1|Progestin and AdipoQ Receptor Family Member I	Adiponectin receptor protein 1 (375 aa, ~43 kDa) is encoded by the human ADIPOR1 gene. This protein is involved in adiponectin binding and signal transduction.	Adiponectin Receptor Protein 1		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103976>	C20103	ADIPOR2 Gene|ADIPOR2|ADIPOR2|Adiponectin Receptor 2 Gene	This gene plays a role in adiponectin binding and ligand-mediated signaling.	ADIPOR2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C103977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103977>	C103976	ADIPOR2 wt Allele|ACDCR2|Adiponectin Receptor 2 wt Allele|PAQR2	Human ADIPOR2 wild-type allele is located in the vicinity of 12p13.31 and is approximately 100 kb in length. This allele, which encodes adiponectin receptor protein 2, is involved in hormone-mediated signaling.	ADIPOR2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103978>	C18106	Adiponectin Receptor Protein 2|ADIPOR2|Adiponectin Receptor 2|Progestin and AdipoQ Receptor Family Member II	Adiponectin receptor protein 2 (386 aa, ~44 kDa) is encoded by the human ADIPOR2 gene. This protein plays a role in adiponectin-mediated signal transduction.	Adiponectin Receptor Protein 2		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103979>	C20703	ZGLP1 Gene|ZGLP1|ZGLP1|Zinc Finger, GATA-Like Protein 1 Gene	This gene is involved in transcriptional repression.	ZGLP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10397>	C61007	Daunorubicin/Dexamethasone/Vincristine|DM/DNR/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103980>	C103979	ZGLP1 wt Allele|GLP-1|GLP1|Zinc Finger, GATA-Like Protein 1 wt Allele	Human ZGLP1 wild-type allele is located in the vicinity of 19p13.2 and is approximately 5 kb in length. This allele, which encodes GATA-type zinc finger protein 1, plays a role in the negative regulation of transcription.	ZGLP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103981>	C26199	GATA-Type Zinc Finger Protein 1|GATA Like Protein 1|GATA Like Protein-1|GATA-Like Protein 1|GLP-1|ZGLP1	GATA-type zinc finger protein 1 (271 aa, ~30 kDa) is encoded by the human ZGLP1 gene. This protein is involved in the inhibition of transcription by GATA family transcription factors.	GATA-Type Zinc Finger Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103982>	C25375	Voluntary Report|Voluntary	A type of report that is voluntary.			Intellectual Product	Adverse Event Outcome ICSR Terminology|FDA Individual Case Safety Report Terminology
C103983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103983>	C28020	Product Use Error				Phenomenon or Process	FDA Individual Case Safety Report Terminology|Type of Event ICSR Terminology
C103984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103984>	C25939	NQO2 Gene|NAD(P)H Dehydrogenase, Quinone 2 Gene|NQO2|NQO2	This gene is involved in the reduction of quinones.	NQO2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C103985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103985>	C103984	NQO2 wt Allele|DHQV|DIA6|NAD(P)H Dehydrogenase, Quinone 2 wt Allele|NAD(P)H Menadione Oxidoreductase 2, Dioxin-Inducible Gene|NMOR2|QR2|RP1-90J20.3	Human NQO2 wild-type allele is located in the vicinity of 6p25.2 and is approximately 32 kb in length. This allele, which encodes ribosyldihydronicotinamide dehydrogenase [quinone] protein, plays a role in both vitamin metabolism and detoxification.	NQO2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103986>	C16946	Ribosyldihydronicotinamide Dehydrogenase [Quinone]|EC 1.10.99.2|NQO2|NRH Dehydrogenase [Quinone] 2|NRH:Quinone Oxidoreductase 2|QR2|Quinone Reductase 2|Ribosyldihydronicotinamide Dehydrogenase	Ribosyldihydronicotinamide dehydrogenase [quinone] (231 aa, ~26 kDa) is encoded by the human NQO2 gene. This protein is involved in the metabolism of quinone-containing compounds.	Ribosyldihydronicotinamide Dehydrogenase [Quinone]		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103987>	C25939	CBR3 Gene|CBR3|CBR3|Carbonyl Reductase 3 Gene	This gene plays a role in the reduction of carbonyl-containing compounds.	CBR3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C103988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103988>	C103987	CBR3 wt Allele|Carbonyl Reductase 3 wt Allele|SDR21C2|Short Chain Dehydrogenase/Reductase Family 21C, Member 2 Gene|hCBR3	Human CBR3 wild-type allele is located in the vicinity of 21q22.2 and is approximately 12 kb in length. This allele, which encodes carbonyl reductase [NADPH] 3 protein, is involved in the metabolism of carbonyl-containing compounds.	CBR3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103989>	C16946	Carbonyl Reductase [NADPH] 3|CBR3|Carbonyl Reductase 3|EC 1.1.1.184|NADPH-Dependent Carbonyl Reductase 3	Carbonyl reductase [NADPH] 3 (277 aa, ~31 kDa) is encoded by the human CBR3 gene. This protein plays a role in the reduction of metabolically active carbonyl compounds.	Carbonyl Reductase [NADPH] 3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10398>	C61063	Cyclophosphamide/Etoposide/Mercaptopurine/Methotrexate|CTX/MP/MTX/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C103990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103990>	C16295	Human Anti-Human Antibody|HAHA|Human Anti-Human Antibodies	Human antibodies which recognize other human antibodies. These can develop in certain disease states or in response to treatment with therapeutic antibodies which can limit the effectiveness of the treatment.	Human Anti-Human Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C103991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103991>	C20194	BAALC Gene|BAALC|BAALC|Brain and Acute Leukemia, Cytoplasmic Gene	This gene may be involved in neural and hematopoietic cell functions.	BAALC Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C103992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103992>	C103991	BAALC wt Allele|Brain and Acute Leukemia, Cytoplasmic wt Allele	Human BAALC wild-type allele is located in the vicinity of 8q22.3 and is approximately 90 kb in length. This allele, which encodes brain and acute leukemia cytoplasmic protein, may play a role in the functioning of neurons and hematopoietic cells. Aberrant expression may be associated with acute myeloid leukemia.	BAALC wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103993>	C18466	Brain and Acute Leukemia Cytoplasmic Protein|BAALC	Brain and acute leukemia cytoplasmic protein (180 aa, ~19 kDa) is encoded by the human BAALC gene. This protein may be involved in synapse function or hematopoiesis.	Brain and Acute Leukemia Cytoplasmic Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103994>	C26147	MTAP Gene|MTAP|MTAP|Methylthioadenosine Phosphorylase Gene	This gene plays a role in purine salvage.	MTAP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C103995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103995>	C103994	MTAP wt Allele|BDMF|DMSFH|DMSMFH|LGMBF|MSAP|Methylthioadenosine Phosphorylase wt Allele|c86fus	Human MTAP wild-type allele is located in the vicinity of 9p21 and is approximately 230 kb in length. This allele, which encodes S-methyl-5'-thioadenosine phosphorylase protein, is involved in the metabolism of both polyamines and purines. Mutation of the gene is associated with diaphyseal medullary stenosis with malignant fibrous histiocytoma.	MTAP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103996>	C17434	S-Methyl-5'-Thioadenosine Phosphorylase|5'-Methylthioadenosine Phosphorylase|EC 2.4.2.28|MTA Phosphorylase|MTAP|MTAPase|MeSAdo Phosphorylase|S-Methyl-5-Thioadenosine Phosphorylase	S-methyl-5'-thioadenosine phosphorylase (283 aa, ~31 kDa) is encoded by the human MTAP gene. This protein plays a role in amino acid, nucleotide and polyamine metabolism.	S-Methyl-5-Thioadenosine Phosphorylase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C103997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103997>	C25802	HSPA1A Gene|HSPA1A|HSPA1A|Heat Shock 70 kDa Protein 1A Gene	This gene is involved in protein folding.	HSPA1A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C103998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103998>	C25802	HSPA1B Gene|HSPA1B|HSPA1B|Heat Shock 70 kDa Protein 1B Gene	This gene plays a role in protein chaperone activity.	HSPA1B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C103999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C103999>	C103997	HSPA1A wt Allele|DAQB-147D11.1|HSP70-1|HSP70-1A|HSP70I|HSP72|HSPA1|Heat Shock 70 kDa Protein 1A wt Allele	Human HSPA1A wild-type allele is located in the vicinity of 6p21.3 and is approximately 2 kb in length. This allele, which encodes heat shock 70 kDa protein 1A/1B, plays a role in protein chaperone activity.	HSPA1A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10399>	C61063	Asparaginase/Dexamethasone/Vincristine|ASP/DM/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1039>	C97452	Carbovir|(+ -)-Carbovir|2',3'-didehydro-2',3'-dideoxyguanosine|CARBOVIR	A nucleoside reverse transcriptase inhibitor analog of guanosine. Carbovir decreases HIV viral loads, retards or prevents the damage to the immune system, and reduces the risk of developing AIDS.			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C104000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104000>	C103998	HSPA1B wt Allele|HSP70-1B|HSP70-2|Heat Shock 70 kDa Protein 1B wt Allele	Human HSPA1B wild-type allele is located in the vicinity of 6p21.3 and is approximately 3 kb in length. This allele, which encodes heat shock 70 kDa protein 1A/1B, is involved in protein folding.	HSPA1B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104001>	C17764	Heat Shock 70 kDa Protein 1A/1B|DnaK-Type Molecular Chaperone HSP70-1|HSP70-1/HSP70-2|HSP70.1/HSP70.2|HSP72|HSPA1|HSPA1A/HSPA1B|Heat Shock 70 kDa Protein 1|Heat Shock 70 kDa Protein 1/2	Heat shock 70 kDa protein 1A/1B (641 aa, ~70 kDa) is encoded by the human HSPA1A and HSPA1B genes. This protein is involved in the mediation of protein folding.	Heat Shock 70 kDa Protein 1A/1B		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104002>	C709	Deoxyuridine Triphosphate|2'-Deoxyuridine 5'-(Tetrahydrogen Triphosphate)|2'-Deoxyuridine 5'-Triphosphate|dUTP	A uracil nucleotide comprised of three phosphate groups esterified to the deoxyribose sugar moiety.	Deoxyuridine Triphosphate		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology
C104003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104003>	C26324	Congenital Hematological Disorder	A disorder of the blood that is present at birth.			Disease or Syndrome	NICHD Terminology
C104004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104004>	C245	Topical Cocaine Hydrochloride	A topical formulation of the hydrochloride salt of the tropane alkaloid cocaine, with local anesthetic activity. Upon topical application of the cocaine hydrochloride solution to nasal mucous membranes, cocaine reversibly binds to and blocks the voltage-gated sodium channels in the neuronal cell membranes. By stabilizing neuronal membranes, cocaine inhibits the initiation and conduction of nerve impulses and produces a reversible loss of sensation.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C104005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104005>	C1287	Pegfilgrastim Biosimilar LA-EP2006|LA-EP2006	A biosimilar of pegfilgrastim, a long-acting pegylated form of recombinant human granulocyte colony-stimulating factor (G-CSF) filgrastim, with hematopoietic activity. In a similar manner to G-CSF, pegfilgrastim biosimilar LA-EP2006 binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. Therefore, this agent may prevent the incidence and shorten the duration of chemotherapy-induced neutropenia. Conjugation of the cytokine with a branched polyethylene glycol molecule significantly increases this agent's therapeutic half-life compared to filgrastim.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	NCI Drug Dictionary Terminology
C104006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104006>	C201174|C200766	Anti-CD20-CAR-CD3zeta-4-1BB-expressing Autologous T-lymphocyte Cells	A preparation of autologous blood T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) consisting of an anti-CD20 scFv (single chain variable fragment); the cytoplasmic portion of the human TCR-[zeta] molecule; and the co-stimulatory molecule 4-1BB (CD137), with potential immunostimulating and antineoplastic activities. Upon transfusion, anti-CD20-CAR-CD3zeta-4-1BB-expressing autologous T-lymphocyte cells direct T-cells to CD20-expressing tumor cells. This results in cytotoxic T lymphocyte (CTL) and antibody responses against CD20-expressing tumor cells, causing tumor cell lysis. The CD20 antigen, a non-glycosylated cell surface phosphoprotein, is a B-cell specific cell surface antigen expressed in B-cell lineage malignancies. CD3 zeta is one of several membrane-bound polypeptides found in the T-cell receptor (TCR)/CD3 complex and regulates the assembly of complete TCR complexes and their expression on the cell surface. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD20; the inclusion of this signaling domain may increase the antitumor activity compared to the inclusion of the CD3-zeta chain alone.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C104007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104007>	C2124	Technetium Tc 99m-3PRGD2|(99m)Tc-PEG(4)-E[PEG(4)-c(RGDfK)](2) ((99m)Tc-3PRGD2)|99mTc-3PRGD2	A radiopharmaceutical agent comprised of a pegylated arginine-glycine-aspartic acid (RGD) dimer (PRGD2) labeled with technetium Tc 99m, with potential alphaVbeta3 integrin imaging activity when used with single photon emission computed tomography (SPECT). After intravenous administration of technetium Tc 99m-3PRGD2, the RGD moiety binds to alphaVbeta3 integrin on the cell membrane via the cyclic RGD motif. Upon PET imaging, alphaVbeta3 integrin-expressing tumor cells can be visualized and expression levels can be quantified. Compared to other radiolabeled RGD-containing peptides, this agent shows an increased affinity for alphaVbeta3 integrin, enhanced tumor uptake as well as improved pharmacokinetics. AlphaVbeta3 integrin, a member of the integrin receptor family, is overexpressed on certain tumor cells and tumor endothelial cells while minimally or not expressed on healthy, normal cells; this receptor plays a key role in angiogenesis, tumor proliferation and survival.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C104008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104008>	C2152|C1946|C129825	Fimepinostat|CUDC-907|FIMEPINOSTAT	An orally bioavailable inhibitor of both phosphoinositide 3-kinase (PI3K) class I and pan histone deacetylase (HDAC) enzymes, with potential antineoplastic activity. Upon oral administration, fimepinostat inhibits the activity of both PI3K class I isoforms and HDAC, thereby preventing the activation of the PI3K-AKT-mTOR signal transduction pathway that is often overactivated in many cancer cell types. This may prevent growth of PI3K and/or HDAC-expressing tumor cells. CUDC-907 shows an increased inhibition of tumor cell growth and induction of apoptosis when compared to inhibitors that target either PI3K or HDAC.	Fimepinostat		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C104009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104009>	C28681|C129826	MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells	A preparation of polyclonal autologous CD8 positive T-lymphocytes specific for the Merkel cell polyomavirus (MCPyV) T antigen (TAg) with potential antineoplastic activity. Peripheral blood lymphocytes from a Merkel cell carcinoma (MCC) patient were obtained and antigen-specific CD8+ T cells targeting a specific MCPyV TAg epitope were derived and expanded ex vivo. Upon infusion of the MCPyV TAg-specific polyclonal autologous CD8-positive T cell vaccine, the T cells recognize the MCPyV antigen and exert a cytotoxic T-lymphocyte response against the MCPyV TAg-expressing MCC cells. MCPyV is expressed in about 80% of MCC and is not expressed in normal, human tissue; the MCPyVTag oncoprotein plays a key role in MCC survival and tumor cell proliferation.	MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C10400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10400>	C61063	Cyclophosphamide/Mercaptopurine/Methotrexate/Vincristine|CTX/MP/MTX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104010>	C1511	Zirconium Zr 89-labeled RO5479599|89Zr-RO5479599|89Zr-labeled RO5479599	A radioimmunoconjugate containing a glycoengineered, humanized monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3) and labeled with the radioisotope zirconium Zr 89, with radioisotopic activity and potential use as an imaging agent as well as potential antineoplastic activity. Upon administration, the RO5479599 moiety of zirconium Zn 89-labeled RO5479599 binds to the extracellular domain of HER3 and inhibits HER3 dimerization, thereby preventing EGFR-dependent signaling. In addition, RO5479599 elicits enhanced antibody-dependent cellular cytotoxicity (ADCC). Upon binding, the radioisotope moiety may be detected using positron emission tomography (PET), thereby allowing the imaging and quantification of HER3-expressing tumor cells. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors; it has no active kinase domain but is activated through heterodimerization with other members of the EGFR receptor family, such as HER2.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	NCI Drug Dictionary Terminology
C104011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104011>	C18513	Nuclear Grade III or IV	Nuclear pleomorphism in tumor cells defined either as grade III or IV.			Classification	GDC Terminology|GDC Value Terminology
C104012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104012>	C208255	Luspatercept|(79-L-aspartic Acid(L>D))Human Activin Receptor Type-2B (ACTR-IIB, EC=2.7.11.30) Precursor-(25-131)-peptide (Extracellular Domain Fragment) Fusion Protein with Triglycyl-human Immunoglobulin Heavy Constant Gamma 1 Fc Fragment-(8-232)-peptide Dimer (114-114':117-117')-bisdisulfide|ACE 536|ACE-536|ACE536|LUSPATERCEPT|Luspatercept-aamt|Reblozyl	A soluble, recombinant fusion protein composed of a modified form of the extracellular domain of human activin receptor type IIb (ActRIIb) and linked to the human IgG1 Fc domain, with red blood cell stimulating activity. Upon subcutaneous administration, luspatercept inhibits several ligands in the transforming growth factor (TGF)-beta superfamily. This prevents activation of a variety of TGF-beta superfamily members involved in late stage erythropoiesis and results in an increased differentiation and proliferation of erythroid progenitors. luspatercept acts at a different, later stage than erythropoietin. This agent ultimately enhances red blood cell production and prevents anemia.	Luspatercept		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C104013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104013>	C35867	Zona Fasciculata-Resembling Cells are Less Than or Equal to Twenty Five Percent|Cytoplasm Presence of Less than or Equal to Twenty Five Percent	A morphologic finding indicating the presence of less than or equal to twenty five percent of clear or vacuolated cells that resemble the normal zona fasciculata in adrenocortical tumors.			Finding	
C104014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104014>	C20047	WEISS System|WEISS Assessment|weiss assessment score|weiss_assessment_score	An evaluation system that uses histologic criteria to assess and differentiate malignancy in adrenocortical tumors.			Clinical Attribute	GDC Property Terminology|GDC Terminology
C104015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104015>	C104014	WEISS Criteria|WEISS Category|weiss assessment findings|weiss_assessment_findings	Histopathologic criteria to evaluate adrenocortical tumors.  These criteria include nuclear grade III or IV, mitotic rate greater than five per fifty high power fields, presence of atypical mitotic figures, presence of less than or equal to twenty five percent of clear or vacuolated cells that resemble normal zona fasciculata, diffuse architecture, necrosis, venous invasion, sinusoid invasion, and invasion of tumor capsule.			Clinical Attribute	GDC Property Terminology|GDC Terminology
C104016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104016>	C36285	ENSAT Staging Finding v7|European Network for the Study of Adrenal Tumors Staging Finding v7	A finding about one or more characteristics of adrenal cancer, following the rules of the ENSAT staging v7 classification system.			Finding	
C104017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104017>	C104016	Pathologic ENSAT Staging Finding v7|ensat pathologic stage|ensat_pathologic_stage	A pathologic finding about one or more characteristics of adrenal cancer, following the rules of the ENSAT staging v7 classification system.			Finding	GDC Property Terminology|GDC Terminology
C104018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104018>	C104017	Pathologic Primary Tumor ENSAT Staging Finding v7|ensat pathologic t|ensat_pathologic_t	A pathologic finding about one or more characteristics of adrenal cancer, following the rules of the ENSAT staging v7 classification system as they pertain to staging of the primary tumor.			Finding	GDC Property Terminology|GDC Terminology
C104019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104019>	C104018	pT1 ENSAT Staging Finding v7	Adrenal cancer with tumor size equal or less than 5.0 cm.  There is no invasion of tissues outside the adrenal gland. (7th Ed, 2009)			Finding	GDC Terminology|GDC Value Terminology
C10401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10401>	C61007	Flutamide/Leuprolide|FLUT/LEUP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104020>	C104018	pT2 ENSAT Staging Finding v7	Adrenal cancer with tumor size more than 5.0 cm. There is no invasion of tissues outside the adrenal gland. (7th Ed, 2009)			Finding	GDC Terminology|GDC Value Terminology
C104021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104021>	C104018	pT3 ENSAT Staging Finding v7	Adrenal cancer with tumor of any size.  There is invasion of the fat that surrounds the adrenal gland. (7th Ed, 2009)			Finding	GDC Terminology|GDC Value Terminology
C104022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104022>	C104018	pT4 ENSAT Staging Finding v7	Adrenal cancer with tumor of any size.  There is invasion of nearby organs such as the kidney, pancreas, spleen or liver. (7th Ed, 2009)			Finding	GDC Terminology|GDC Value Terminology
C104023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104023>	C104017	Pathologic Lymph Nodes ENSAT Staging Finding v7|ensat pathologic n|ensat_pathologic_n	A pathologic finding about one or more characteristics of adrenal cancer, following the rules of the ENSAT staging v7 classification system as they pertain to staging of the lymph nodes.			Finding	GDC Property Terminology|GDC Terminology
C104024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104024>	C104023	pN0 ENSAT Staging Finding v7	Adrenal cancer with no involvement of regional lymph nodes. (7th Ed, 2009)			Finding	GDC Terminology|GDC Value Terminology
C104025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104025>	C104023	pN1 ENSAT Staging Finding v7	Adrenal cancer with involvement of regional lymph nodes. (7th Ed, 2009)			Finding	GDC Terminology|GDC Value Terminology
C104026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104026>	C104016	Clinical ENSAT Staging Finding v7	A clinical finding about one or more characteristics of adrenal cancer, following the rules of the ENSAT staging v7 classification system.			Finding	
C104027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104027>	C104026	Clinical Distant Metastasis ENSAT Staging Finding v7|ensat clinical m|ensat_clinical_m	A clinical finding about one or more characteristics of adrenal cancer, following the rules of the ENSAT staging v7 classification system as they pertain to distant metastases.			Finding	GDC Property Terminology|GDC Terminology
C104028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104028>	C104027	cM0 ENSAT Staging Finding v7	Adrenal cancer with no involvement of distant organs or tissues. (7th Ed, 2009)			Finding	GDC Terminology|GDC Value Terminology
C104029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104029>	C104027	cM1 ENSAT Staging Finding v7	Adrenal cancer with involvement of distant organs or tissues such as liver, bone or brain. (7th Ed, 2009)			Finding	GDC Terminology|GDC Value Terminology
C10402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10402>	C61063	Cisplatin/Etoposide/Hydrazine Sulfate|CDDP/HDZ/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104030>	C9325	Adrenal Cortical Carcinoma by ENSAT Stage|Adrenal Cortex Carcinoma by ENSAT Stage	A term that refers to the staging of adrenal cortical carcinoma according to the European Network for the Study of Adrenal Tumors (ENSAT).			Neoplastic Process	
C104031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104031>	C104030	ENSAT Stage I Adrenal Cortical Carcinoma|ENSAT Stage I Adrenal Cortex Cancer|ENSAT Stage I Adrenal Cortex Carcinoma	Stage I includes: T1, N0, M0.  Tumor 5 cm or less in greatest dimension. The tumor has not invaded the surrounding tissues or organs and has not spread to lymph nodes or distant organs or tissues.  (ENSAT 7th Ed, 2009)	ENSAT Stage I Adrenal Cortex Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C104032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104032>	C104030	ENSAT Stage II Adrenal Cortical Carcinoma|ENSAT Stage II Adrenal Cortex Cancer|ENSAT Stage II Adrenal Cortex Carcinoma	Stage II includes: T2, N0, M0. Tumor greater than 5 cm. The tumor has not invaded surrounding tissues or organs and has not spread to lymph nodes or distant organs or tissues. (ENSAT 7th Ed, 2009)	ENSAT Stage II Adrenal Cortex Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C104033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104033>	C104030	ENSAT Stage III Adrenal Cortical Carcinoma|ENSAT Stage III Adrenal Cortex Cancer|ENSAT Stage III Adrenal Cortex Carcinoma	Stage III includes: T3/T4, N0/N1, M0.  Tumor of any size that has spread to the fat outside the adrenal gland or into nearby organs or tissues and/or has spread to the regional lymph nodes. (ENSAT 7th Ed, 2009)	ENSAT Stage III Adrenal Cortex Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C104034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104034>	C104030	ENSAT Stage IV Adrenal Cortical Carcinoma|ENSAT Stage IV Adrenal Cortex Cancer|ENSAT Stage IV Adrenal Cortex Carcinoma	Stage IV includes: Any T, Any N, M1. Tumor of any size that involves distant organs such as liver, bone or brain. The tumor may or may not involve nearby organs, tissues or lymph nodes. (ENSAT 7th Ed, 2009)	ENSAT Stage IV Adrenal Cortex Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C104035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104035>	C25939	HSD17B1 Gene|HSD17B1|HSD17B1|Hydroxysteroid 17-Beta Dehydrogenase 1 Gene	This gene is involved in estrogen biosynthesis.	HSD17B1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104036>	C104035	HSD17B1 wt Allele|E17KSR|EDH17B2|EDHB17|HSD17|Hydroxysteroid (17-Beta) Dehydrogenase 1 Gene|Hydroxysteroid 17-Beta Dehydrogenase 1 wt Allele|MGC138140|SDR28C1	Human HSD17B1 wild-type allele is located in the vicinity of 17q21.2 and is approximately 4 kb in length. This allele, which encodes estradiol 17-beta-dehydrogenase 1 protein, plays a role in converting both estrogens and androgens to their active forms.	HSD17B1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104037>	C16946	Estradiol 17-Beta-Dehydrogenase 1|17-Beta-HSD 1|17-Beta-HSD I|17-Beta-Hydroxysteroid Dehydrogenase I|17-Beta-Hydroxysteroid Dehydrogenase Type 1|20 Alpha-Hydroxysteroid Dehydrogenase|20-alpha-HSD|E2DH|Estradiol 17-Beta-Dehydrogenase-1|HSD17B1|Hydroxysteroid (17-Beta) Dehydrogenase 1 Isoform|Placental 17-Beta-Hydroxysteroid Dehydrogenase|Short Chain Dehydrogenase/Reductase Family 28CE, Member 1	Estradiol 17-beta-dehydrogenase 1 (328 aa, ~35 kDa) is encoded by the human HSD17B1 gene. This protein is involved in the conversion of both estrogens and androgens to their active intracellular forms.	Estradiol 17-Beta-Dehydrogenase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104038>	C20409	BCL2A1 Gene|BCL2-Related Protein A1 Gene|BCL2A1|BCL2A1|BFL1	This gene plays a role in the inflammatory process.	BCL2A1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|Pediatric Oncology Biomarkers/Targets Associated with Other Relevant Evidence
C104039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104039>	C104038	BCL2A1 wt Allele|A1/BFL|ACC-1|ACC-2|BCL2-Related Protein A1 wt Allele|BCL2L5|BFL1|GRS|HBPA1	Human BCL2A1 wild-type allele is located in the vicinity of 15q24.3 and is approximately 14 kb in length. This allele, which encodes Bcl-2-related protein A1, is involved in the down-regulation of apoptosis and mediation of the inflammatory response.	BCL2A1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10403>	C61007	Fluorouracil/L-Leucovorin|5-FU/L-CF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104040>	C19928	BCL-2-Related Protein A1|A1/BFL|BCL-2-Like Protein 5|BCL2-L-5|BCL2-Related Protein A1|BCL2-Related Protein A1|BCL2A1|BFL1 Protein|Hematopoietic BCL2-Related Protein A1|Hemopoietic-Specific Early Response Protein|Potein BFL-1|Protein GRS	Bcl-2-related protein A1 (175 aa, ~20 kDa) is encoded by the human BCL2A1 gene. This protein plays a role in the regulation of inflammation.	BCL2-Related Protein A1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Biomarkers/Targets Associated with Other Relevant Evidence
C104041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104041>	C20921	CAMK2N1 Gene|CAMK2N1|CAMK2N1|Calcium/Calmodulin-Dependent Protein Kinase II Inhibitor 1 Gene	This gene is involved in intracellular signaling.	CAMK2N1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104042>	C104041	CAMK2N1 wt Allele|Calcium/Calmodulin-Dependent Protein Kinase II Inhibitor 1 wt Allele|PRO1489|RP11-401M16.1	Human CAMK2N1 wild-type allele is located in the vicinity of 1p36.12 and is approximately 4 kb in length. This allele, which encodes calcium/calmodulin-dependent protein kinase II inhibitor 1 protein, plays a role in inhibition of calcium-dependent cell signaling.	CAMK2N1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104043>	C18515	Calcium/Calmodulin-Dependent Protein Kinase II Inhibitor 1|CAMK2N1	Calcium/calmodulin-dependent protein kinase II inhibitor 1 (78 aa, ~9 kDa) is encoded by the human CAMK2N1 gene. This protein is involved in inhibition of calcium-dependent cell signaling.	Calcium/Calmodulin-Dependent Protein Kinase II Inhibitor 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104044>	C217121	Hot Flash Related Daily Inference Scale|HFRDIS|Hot Flash Related Daily Inference Scale (HFRDIS)	A tool designed to measure the impact of hot flashes on overall quality of life as well as nine specific activities using a 10 point Likert scale.			Intellectual Product	
C104045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104045>	C174048	ERK Inhibitor MK-8353|MK-8353|MK-8353-001|SCH 900353	An orally available inhibitor of extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon oral administration, MK-8353 inhibits both ERK phosphorylation and activation of ERK-mediated signal transduction pathways; thereby, preventing ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is often upregulated in a variety of tumor cell types and plays a role in tumor cell proliferation, differentiation and survival.	ERK Inhibitor MK-8353		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C104046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104046>	C54306	CTAG2 Gene|CTAG2|CTAG2|Cancer/Testis Antigen 2 Gene	This gene may play a role in tumorigenesis.	CTAG2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104047>	C104046	CTAG2 wt Allele|CAMEL|CTAG2|Cancer/Testis Antigen 2 wt Allele|ESO2|LAGE1	Human CTAG2 wild-type allele is located in the vicinity of Xq28 and is approximately 2 kb in length. This allele, which encodes cancer/testis antigen 2 protein, may be involved in tumorigenesis of melanomas, sarcomas, and other tumor types.	CTAG2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104048>	C514|C1742	Itraconazole Dispersion In Polymer Matrix|SUBA-Itraconazole	A proprietary oral formulation composed of the poorly soluble, synthetic triazole agent, itraconazole, dispersed in a polymer matrix, with antifungal and potential anti-angiogenic activities. Upon oral administration, itraconazole inhibits the enzyme cytochrome P450 lanosterol 14 alpha-demethylase, resulting in a decrease in fungal ergosterol synthesis. Although the exact mechanism through which itraconazole inhibits angiogenesis has yet to be fully elucidated, this agent appears to inhibit the Hedgehog (Hh) signaling pathway, cholesterol synthesis and mammalian target of rapamycin (mTOR) signaling in endothelial cells. This agent may also prevent the activation of and signaling by various angiogenic growth factors. By decreasing the tumor vasculature and nutrient supply, itraconazole ultimately inhibits tumor cell growth. The solid dispersion of itraconazole in the polymer matrix enhances dissolution of itraconazole in the gastrointestinal tract and increases its bioavailability; this allows for the administration of a much lower dose compared to itraconazole alone.	Itraconazole Dispersion In Polymer Matrix		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C104049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104049>	C153123	Cancer/Testis Antigen 2|Autoimmunogenic Cancer/Testis Antigen NY-ESO-2|CT6.2|CT6.2b|CTAG2|Cancer/Testis Antigen 2 Isoform LAGE-1B|Cancer/Testis Antigen 6.2|Cancer/Testis Antigen 6.2b|Isoform LAGE-1B|L Antigen Family Member 1|L Antigen Family Member 1 Isoform B|LAGE-1|LAGE-1L	Cancer/testis antigen 2 (210 aa, ~21 kDa) is encoded by the human CTAG2 gene. This protein may play a role in tumorigenesis of several tissues.	Cancer/Testis Antigen 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10404>	C61063	Carboplatin/Cytarabine/Etoposide/Methylprednisolone|ARA-C/CBDCA/MePRDL/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104050>	C21282	CA9 Gene|CA9|CA9|Carbonic Anhydrase IX Gene	This gene may be involved in cell proliferation and transformation.	CA9 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104051>	C104050	CA9 wt Allele|CA9|CAIX|Carbonic Anhydrase IX wt Allele|G250	Human CA9 wild-type allele is located in the vicinity of 9p13.3 and is approximately 7 kb in length. This allele, which encodes carbonic anhydrase 9 protein, plays a role in intracellular pH balance.	CA9 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104052>	C16804	Carbonic Anhydrase 9|CA-IX|CA9|Carbonic Anhydrase IX|Carbonic Dehydratase IX|Membrane Antigen MN|P54/58N|RCC-Associated Protein G250|Renal Cell Carcinoma-Associated Protein G250|pMW1	Carbonic anhydrase 9 (459 aa, ~50 kDa) is encoded by the human CA9 gene. This protein is involved in intracellular pH balance and may be involved in cell proliferation and transformation.	Carbonic Anhydrase 9		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104053>	C26003	CTSG Gene|CTSG|CTSG|Cathepsin G Gene	This gene plays a role in protein degradation.	CTSG Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104054>	C104053	CTSG wt Allele|CATG|CG|CTSG|Cathepsin G wt Allele	Human CTSG wild-type allele is located in the vicinity of 14q12 and is approximately 3 kb in length. This allele, which encodes cathepsin G protein, is involved in protein processing and degradation.	CTSG wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104055>	C1891	Telapristone Acetate|(8S,11R,13S,14S,17R)-11-(4-(Dimethylamino)phenyl)-17-(2-methoxyacetyl)-13-methyl-3-oxo-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl Acetate|CDB-4124|Proellex|Progenta|TELAPRISTONE ACETATE	The acetate form of the 21-substituted-19-nor-progestin telapristone, an orally available selective progesterone receptor modulator (SPRM), with potential anti-progesterone and antineoplastic activities. Upon oral administration, CDB-4124 competitively binds to the progesterone receptor (PR) in progesterone-responsive tissue and inhibits PR-mediated gene expression. This interferes with progesterone activity in the reproductive system. As a result, this agent may suppress ovulation and inhibit proliferation of endometrial tissue. Also, this agent may prevent cell growth and induce apoptosis in estrogen receptor (ER) and PR-positive breast cancer cells through a reduction in progesterone levels, ER downregulation and a suppression of the expression of cyclin-dependent kinases (CDK) 2 and 4, ultimately leading to G1/S cell cycle arrest. Unlike some other SPRMs, this agent does not exert any estrogenic, androgenic, anti-estrogenic, and anti-androgenic activities.	Telapristone Acetate		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C104056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104056>	C17123|C16389	Cathepsin G|CG|CTSG|EC 3.4.21	Cathepsin G (255 aa, ~29 kDa) is encoded by the human CTSG gene. This protein plays a role in protein processing and may be involved in connective tissue remodeling at sites of infection.	Cathepsin G		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104057>	C1891	Telapristone|11Beta-(4-(dimethylamino)phenyl)-17-hydroxy-21-methoxy-19- norpregna-4,9-diene-3,20-dione|TELAPRISTONE	An orally available 21-substituted-19-nor-progestin and selective progesterone receptor modulator (SPRM), with potential anti-progesterone and antineoplastic activities. Upon oral administration, telapristone competitively binds to the progesterone receptor (PR) in progesterone-responsive tissue and inhibits PR-mediated gene expression. This interferes with progesterone activity in the reproductive system. As a result, this agent may suppress ovulation and inhibit proliferation of endometrial tissue. Also, this agent may prevent cell growth and induce apoptosis in estrogen receptor (ER) and PR-positive breast cancer cells through a reduction in progesterone levels, ER downregulation and a suppression of the expression of cyclin-dependent kinases (CDK) 2 and 4, ultimately leading to G1/S cell cycle arrest. Unlike some other SPRMs, this agent does not exert any estrogenic, androgenic, anti-estrogenic, and anti-androgenic activities.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C104058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104058>	C199386	Lumretuzumab|LUMRETUZUMAB|RO5479599	An immunoconjugate containing a glycoengineered, humanized monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3), with potential antineoplastic activity. Upon administration,  lumretuzumab binds to the extracellular domain of HER3 and inhibits HER3 dimerization; thereby, preventing EGFR-dependent signaling. In addition, RO5479599 stimulates the immune system to exert antibody-dependent cellular cytotoxicity (ADCC). This may decrease proliferation of HER3-overexpressing tumor cells. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors; it has no active kinase domain but is activated through heterodimerization with other members of the EGFR receptor family, such as HER2.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C104059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104059>	C20921	SLAMF1 Gene|SLAMF1|SLAMF1|Signaling Lymphocytic Activation Molecule Family Member 1 Gene	This gene is involved in immune cell function.	SLAMF1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10405>	C61063	Carboplatin/Mitoxantrone|CBDCA/DHAD			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104060>	C104059	SLAMF1 wt Allele|CD150|CDw150|SLAMF1|Signaling Lymphocytic Activation Molecule Family Member 1 wt Allele	Human SLAMF1 wild-type allele is located in the vicinity of 1q23.3 and is approximately 39 kb in length. This allele, which encodes signaling lymphocytic activation molecule protein, plays a role in initiating signal transduction networks in immune cells.	SLAMF1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104061>	C18515	Signaling Lymphocytic Activation Molecule|CD150|CDw150|IPO-3|SLAMF1|Signaling Lymphocytic Activation Molecule Family Member 1	Signaling lymphocytic activation molecule (335 aa, ~37 kDa) is encoded by the human SLAMF1 gene. This protein is involved in immune cell regulation and acts as a microbial sensor.	Signaling Lymphocytic Activation Molecule		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104062>	C20103	CD163 Gene|CD163|CD163|CD163 Molecule Gene	This gene plays a role in endocytosis by macrophages.	CD163 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104063>	C104062	CD163 wt Allele|CD163|CD163 Molecule wt Allele|M130|MM130	Human CD163 wild-type allele is located in the vicinity of 12p13.3 and is approximately 33 kb in length. This allele, which encodes scavenger receptor cysteine-rich type 1 protein M130, is involved in the clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages.	CD163 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104064>	C18106	Scavenger Receptor Cysteine-Rich Type 1 Protein M130|Antigen CD163|CD163|CD163 Antigen|CD163 Molecule|Cluster of Differentiation 163|Hemoglobin Scavenger Receptor|Macrophage-Associated Antigen	Scavenger receptor cysteine-rich type 1 protein M130 (1156 aa, ~125 kDa) is encoded by the human CD163 gene. This protein plays a role in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages.	Scavenger Receptor Cysteine-Rich Type 1 Protein M130		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104065>	C20988	CD226 Gene|CD226|CD226|CD226 Molecule Gene	This gene is involved in megakaryocytic cell maturation.	CD226 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104066>	C104065	CD226 wt Allele|CD226 Antigen Gene|CD226 Molecule wt Allele|DNAM-1|DNAM1|PTA1|TLiSA1	Human CD226 wild-type allele is located in the vicinity of 18q22.3 and is approximately 96 kb in length. This allele, which encodes CD226 antigen protein, plays a role in cellular adhesion of platelets and megakaryocytic cells.	CD226 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104067>	C16393	CD226 Antigen|CD226 Molecule|DNAM-1|DNAX Accessory Molecule 1|Platelet and T-Cell Activation Antigen 1|T Lineage-Specific Activation Antigen 1 Antigen	CD226 antigen (336 aa, ~38 kDa) is encoded by the human CD226 gene. This protein is involved in cellular adhesion of platelets and megakaryocytic cells and megakaryocytic cell maturation.	CD226 Antigen		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104068>	C20103	CD244 Gene|CD244|CD244|CD244 Molecule, Natural Killer Cell Receptor 2B4 Gene	This gene plays a role in leukocyte activation and immune function.	CD244 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104069>	C104068	CD244 wt Allele|2B4|CD244 Molecule, Natural Killer Cell Receptor 2B4 wt Allele|NAIL|NKR2B4|Nmrk|SLAMF4	Human CD244 wild-type allele is located in the vicinity of 1q23.1 and is approximately 32 kb in length. This allele, which encodes natural killer cell receptor 2B4 protein, is involved in non-MHC-restricted NK cell killing.	CD244 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10406>	C61007	Carboplatin/Etoposide/Melphalan|CBDCA/L-PAM/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104070>	C18106	Natural Killer Cell Receptor 2B4|CD244 Antigen|CD244 Molecule|NAIL|NK Cell Activation-inducing Ligand|NK Cell Type I Receptor Protein 2B4|NKR2B4|Natural Killer Cell Activation-Inducing Ligand|SLAM Family Member 4|SLAMF4|Signaling Lymphocytic Activation Molecule 4|h2B4	Natural killer cell receptor 2B4 (370 aa, ~42 kDa) is encoded by the human CD244 gene. This protein plays a role in natural killer cell immune function.	Natural Killer Cell Receptor 2B4		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104071>	C21165	CD27 Gene|CD27|CD27|CD27 Molecule Gene|TNFRSF7	This gene is involved in maintenance of T cell immunity.	CD27 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104072>	C104071	CD27 wt Allele|CD27|CD27 Molecule wt Allele|LPFS2|S152|T14|TNFRSF7|Tp55|Tumor Necrosis Factor Receptor Superfamily, Member 7 Gene	Human CD27 wild-type allele is located in the vicinity of 12p13 and is approximately 7 kb in length. This allele, which encodes CD27 antigen protein, plays a role in regulating B-cell activation and immunoglobulin synthesis.	CD27 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104073>	C19285	CD27 Antigen|CD27 Molecule|CD27L Receptor|T-Cell Activation Antigen CD27|T-Cell Activation Antigen S152|TNFRSF7|Tumor Necrosis Factor Receptor Superfamily Member 7|Tumor Necrosis Factor Receptor Superfamily, Member 7	CD27 antigen (260 aa, ~29 kDa) is encoded by the human CD27 gene. This protein is involved in regulating B-cell activation, immunoglobulin synthesis, and apoptosis.	CD27 Antigen		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104074>	C20103	CD69 Gene|CD69|CD69|CD69 Molecule Gene	This gene plays a role in signal transduction.	CD69 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104075>	C104074	CD69 wt Allele|AIM|AIM/CD69|BL-AC/P26|C-type Lectin Domain Family 2, Member C Gene|CD69|CD69 Antigen (p60, Early T-Cell Activation Antigen) Gene|CD69 Molecule wt Allele|CLEC2C|EA1|GP32/28|MLR-3	Human CD69 wild-type allele is located in the vicinity of 12p13 and is approximately 8 kb in length. This allele, which encodes early activation antigen CD69 protein, is involved in T-cell proliferation and signal transduction in natural killer cells and platelets.	CD69 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104076>	C18106	Early Activation Antigen CD69|AIM|Activation Inducer Molecule|C-type Lectin Domain Family 2 Member C|CD69 Antigen|CD69 Molecule|EA1|Early Lymphocyte Activation Antigen|Early T-Cell Activation Antigen p60|GP32/28|Leukocyte Surface Antigen Leu-23|MLR-3	Early activation antigen CD69 (199 aa, ~23 kDa) is encoded by the human CD69 gene. This protein plays a role in signal transduction in natural killer cells and platelets.	Early Activation Antigen CD69		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104077>	C21114	CD70 Gene|CD70|CD70|CD70 Molecule Gene	This gene is involved in immune function.	CD70 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|Pediatric Oncology Target Cell Lineage Determinant Terminology
C104078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104078>	C104077	CD70 wt Allele|CD27L|CD27LG|CD70|CD70 Molecule wt Allele|TNFSF7	Human CD70 wild-type allele is located in the vicinity of 19p13 and is approximately 8 kb in length. This allele, which encodes CD70 antigen protein, plays a role in T-cell activation and proliferation.	CD70 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104079>	C20500	CD70 Antigen|CD27 Ligand|CD27L|CD70|CD70 Molecule|Ki-24 Antigen|Surface Antigen CD70|TNFSF7|Tumor Necrosis Factor (Ligand) Superfamily, Member 7|Tumor Necrosis Factor Ligand Superfamily Member 7	CD70 antigen (193 aa, ~21 kDa) is encoded by the human CD70 gene. This protein is involved in T-cell activation and proliferation and may also play a role in B-cell activation.	CD70 Antigen		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Cell Lineage Determinant Terminology
C10407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10407>	C61063	Carmustine/Vincristine|BCNU/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104080>	C54266	Enjoyment of Life	The level of happiness or contentment that an individual professes, or is observed to display with regards to their life situation.			Mental Process	Hot Flash Related Daily Inference Scale|MD Anderson Symptom Inventory - Head and Neck
C104081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104081>	C33061	Naive T-Lymphocyte|Naive T Cell|Naive T Cells|Naive T Lymphocyte|Naive T-Cell|Th0	A mature T-lymphocyte that has differentiated in the bone marrow and undergone central tolerance selection in the thymus but has not interacted with its cognate antigen. These cells are characterized by the presence of the T-cell receptor, L-selectin and the IL-7 receptor and the absence of CD25, CD44, CD69 and CD45R0.	Naive T-Lymphocyte		Cell	CTRP Biomarker Terminology|CTRP Terminology
C104082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104082>	C33061	Memory T-Lymphocyte|Memory T Cell|Memory T Cells|Memory T Lymphocyte|Memory T-Cell	A mature T-lymphocyte that has encountered its cognate antigen and is primed to reproduce and elicit a stronger immune response upon a second encounter with the antigen. These cells are characterized by the presence CD45R0.	Memory T-Lymphocyte		Cell	CTRP Biomarker Terminology|CTRP Terminology
C104083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104083>	C33061	Effector T-Lymphocyte|Effector T Cell|Effector T Cells|Effector T Lymphocyte|Effector T-Cell	A mature T-lymphocyte that has differentiated into a form that can mount an antigen-specific immune response.	Effector T-Lymphocyte		Cell	CTRP Biomarker Terminology|CTRP Terminology
C104084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104084>	C20921	NDRG2 Gene|NDRG Family Member 2 Gene|NDRG2|NDRG2	This gene is involved in the regulation of cellular differentiation.	NDRG2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104085>	C104084	NDRG2 wt Allele|KIAA1248|NDRG Family Member 2 wt Allele|SYLD	Human NDRG2 wild-type allele is located in the vicinity of 14q11.2 and is approximately 54 kb in length. This allele, which encodes protein NDRG2, plays a role in the modulation of both Wnt signaling pathways and cell differentiation.	NDRG2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104086>	C18515	Protein NDRG2|N-myc Downstream-Regulated Gene 2 Protein|NDRG2|Protein Syld709613	Protein NDRG2 (371 aa, ~41 kDa) is encoded by the human NDRG2 gene. This protein is involved in both dendritic cell differentiation and Wnt signaling.	Protein NDRG2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104087>	C20194	ESM1 Gene|ESM1|ESM1|Endothelial Cell-Specific Molecule 1 Gene	This gene may play a role in endothelial cell-leukocyte interactions.	ESM1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104088>	C104087	ESM1 wt Allele|Endothelial Cell-Specific Molecule 1 wt Allele|endocan	Human ESM1 wild-type allele is located in the vicinity of 5q11.2 and is approximately 8 kb in length. This allele, which encodes endothelial cell-specific molecule 1 protein, may be involved in the interactions between leukocytes and endothelial cells.	ESM1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104089>	C18466	Endothelial Cell-Specific Molecule 1|ESM-1|ESM1	Endothelial cell-specific molecule 1 (184 aa, ~20 kDa) is encoded by the human ESM1 gene. This protein may play a role in the modulation of leukocyte-endothelial cell interactions.	Endothelial Cell-Specific Molecule 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10408>	C61063	Carmustine/Nimodipine/Vincristine|BCNU/NIMO/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104090>	C20194	PLXDC1 Gene|PLXDC1|PLXDC1|Plexin Domain Containing 1 Gene	This gene is involved in capillary formation.	PLXDC1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104091>	C104090	PLXDC1 wt Allele|Plexin Domain Containing 1 wt Allele|TEM3|TEM7	Human PLXDC1 wild-type allele is located in the vicinity of 17q21.1 and is approximately 90 kb in length. This allele, which encodes plexin domain-containing protein 1, plays a role in the capillary tube formation.	PLXDC1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104092>	C18574	Plexin Domain-Containing Protein 1|PLXDC1|Tumor Endothelial Marker 3|Tumor Endothelial Marker 7	Plexin domain-containing protein 1 (500 aa, ~56 kDa) is encoded by the human PLXDC1 gene. This protein is involved in endothelial tube formation.	Plexin Domain-Containing Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104093>	C20988	ANTXR1 Gene|ANTXR1|ANTXR1|Anthrax Toxin Receptor 1 Gene	This gene plays a role in cell-matrix adhesion.	ANTXR1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104094>	C104093	ANTXR1 wt Allele|ATR|Anthrax Toxin Receptor 1 wt Allele|FLJ10601|FLJ21776|TEM8	Human ANTXR1 wild-type allele is located in the vicinity of 2p13.1 and is approximately 236 kb in length. This allele, which encodes anthrax toxin receptor 1 protein, is involved in the modulation of cytoskeletal rearrangement, cellular adhesion and cell migration. Mutation of the gene is associated with hemangioma capillary infantile.	ANTXR1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104095>	C16393	Anthrax Toxin Receptor 1|ANTXR1|Tumor Endothelial Marker 8	Anthrax toxin receptor 1 (564 aa, ~63 kDa) is encoded by the human ANTXR1 gene. This protein plays a role in the regulation of both cell adhesion and cellular motility.	Anthrax Toxin Receptor 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104096>	C25994	APLN Gene|APLN|APLN|Apelin Gene	This gene is involved in the regulation of both immune responses and HIV-1 infection.	APLN Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104097>	C104096	APLN wt Allele|AGTRL1 Ligand Gene|APEL|Apelin wt Allele|UNQ471|XNPEP2	Human APLN wild-type allele is located in the vicinity of Xq25 and is approximately 10 kb in length. This allele, which encodes apelin protein, plays a role in immunity and the negative regulation of HIV-1 infection.	APLN wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104098>	C1746	Apelin|AGTRL1 Ligand|APJ Endogenous Ligand|APLN	Apelin (77 aa, ~9 kDa) is encoded by the human APLN gene. This protein is involved in both the inhibition of HIV-1 entry into cells and in immune responses.	Apelin		Amino Acid, Peptide, or Protein|Hormone	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104099>	C28597	Glycogen Synthase Kinase 3|GSK-3|GSK3|Glycogen Synthase Kinase- 3	A family of serine/threonine protein kinases that is involved in intracellular signaling, cellular proliferation, cell migration, inflammation and immune responses, glucose regulation, and apoptosis.	Glycogen Synthase Kinase 3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Biomarkers/Targets Associated with Other Relevant Evidence
C10409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10409>	C61007	Floxuridine/Fluorouracil|5-FU/FUDR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1040>	C292	Carzinophilin|CARZINOPHILIN|CARZINOPHILIN A|CZP|Cardinophillin|Cardinophyllin|Carzinophyllin	An ethylenimine antineoplastic antibiotic isolated from the bacterium Streptomyces sahachiroi.  Carzinophilin forms interstrand DNA cross-links, thereby inhibiting DNA synthesis. (NCI04)			Antibiotic|Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C104100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104100>	C136791	Pancreastatin|Chromogranin-A 272-319 Peptide	Pancreastatin (48 aa, ~5 kDa) is encoded by the human CHGA gene. This protein is released from the full length chromogranin-A protein by caspase cleavage and plays a role in the inhibition of the release of chromogranin-A, parathyroid hormone and somatostatin.	Pancreastatin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104101>	C21170|C17434	PARP1 Gene Product|PARP Gene Product	A protein encoded by the PARP1 gene.	PARP1 Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104102>	C104101	Poly [ADP-Ribose] Polymerase 1 p85|ADP-Ribosyltransferase Diphtheria Toxin-Like 1 p85|ADPRT 1 p85|ARTD1 p85|Cleaved Poly [ADP-Ribose] Polymerase 1|NAD(+) ADP-Ribosyltransferase 1 p85|PARP p85|PARP1 p85|Poly [ADP-Ribose] Polymerase p85|Poly(ADP Ribose) Polymerase 1 p85|Poly(ADP Ribose) Polymerase p85|Poly[ADP-Ribose] Synthase 1 p85	Poly [ADP-ribose] polymerase 1 p85 (800 aa, ~89 kDa) is encoded by the human PARP1 gene. This protein is released from the full length poly [ADP-ribose] polymerase 1 protein by caspase-3- or caspase-7-dependent cleavage and is involved in DNA repair.	Poly [ADP-Ribose] Polymerase 1 p85		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104103>	C17708	Leisure Activity|Leisure Activities	Activities done for the purpose of relaxation or diversion from routine work.			Daily or Recreational Activity	Hot Flash Related Daily Inference Scale
C104104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104104>	C26147	UGT1A7 Gene|UDP Glucuronosyltransferase 1 Family, Polypeptide A7 Gene|UGT1A7|UGT1A7	This gene plays a role in detoxification.	UGT1A7 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104105>	C104104	UGT1A7 wt Allele|1-7|UDP Glucuronosyltransferase 1 Family, Polypeptide A7 wt Allele|UDP Glycosyltransferase 1 Family, Polypeptide A6 Gene|UDPGT|UGT-1G|UGT1-07|UGT1.7|UGT1G	Human UGT1A7 wild-type allele is located in the vicinity of 2q37 and is approximately 91 kb in length. This allele, which encodes UDP-glucuronosyltransferase 1-7 protein, is involved in the metabolism of drugs and xenobiotics. Variation of the gene is associated with decreased metabolic activity.	UGT1A7 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104106>	C17434	UDP-Glucuronosyltransferase 1-7|EC 2.4.1.17|UDP-Glucuronosyltransferase 1-G|UDP-Glucuronosyltransferase 1A7|UDPGT 1-7|UGT-1G|UGT1*7|UGT1-07|UGT1.7|UGT1A7|UGT1G	UDP-glucuronosyltransferase 1-7 (530 aa, ~60 kDa) is encoded by the human UGT1A7 gene. This protein is involved in the conjugation and elimination of toxins.	UDP-Glucuronosyltransferase 1-7		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104107>	C25790	CD8A Gene|CD8A|CD8A|CD8a Molecule Gene	This gene is involved in immune function.	CD8A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104108>	C104107	CD8A wt Allele|CD8|CD8a Molecule wt Allele|Leu2|MAL|p32	Human CD8A wild-type allele is located in the vicinity of 2p11.2 and is approximately 24 kb in length. This allele, which encodes T-cell surface glycoprotein CD8 alpha chain protein, plays a role in antigen recognition by T-cells.	CD8A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104109>	C16725	T-Cell Surface Glycoprotein CD8 Alpha Chain|CD8a Molecule|Leu2 T-Lymphocyte Antigen|OKT8 T-Cell Antigen|T-Cell Antigen Leu2|T-Lymphocyte Differentiation Antigen T8/Leu-2|p32	T-cell surface glycoprotein CD8 alpha chain (235 aa, ~26 kDa) is encoded by the human CD8A gene. This protein is involved in cell-cell interactions during antigen recognition by T-cells.	T-Cell Surface Glycoprotein CD8 Alpha Chain		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10410>	C61063	Cisplatin/Cyclophosphamide/Interleukin-2|CDDP/CTX/IL-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104110>	C20917	CDC20 Gene|CDC20|CDC20|Cell Division Cycle 20 Homolog (S. cerevisiae) Gene	This gene plays a role in cell cycle progression.	CDC20 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104111>	C104110	CDC20 wt Allele|CDC20A|Cell Division Cycle 20 Homolog (S. cerevisiae) wt Allele|bA276H19.3|p55CDC	Human CDC20 wild-type allele is located in the vicinity of 1p34.1 and is approximately 4 kb in length. This allele, which encodes cell division cycle protein 20 homolog protein, is involved in spindle assembly checkpoint and metaphase arrest.	CDC20 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104112>	C17761	Cell Division Cycle Protein 20 Homolog|CDC20|p55CDC	Cell division cycle protein 20 homolog (499 aa, ~55 kDa) is encoded by the human CDC20 gene. This protein plays a role in metaphase arrest.	Cell Division Cycle Protein 20 Homolog		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104113>	C25900|C20988	CEACAM1 Gene|CEACAM1|CEACAM1|Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (Biliary Glycoprotein) Gene	This gene is involved in cell-cell interactions.	CEACAM1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104114>	C104113	CEACAM1 wt Allele|BGP|BGP1|BGPI|CD66a|Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (Biliary Glycoprotein) wt Allele	Human CEACAM1 wild-type allele is located in the vicinity of 19q13.2 and is approximately 21 kb in length. This allele, which encodes carcinoembryonic antigen-related cell adhesion molecule 1 protein, plays a role in cell-cell interactions in differentiation, angiogenesis, apoptosis, immune response, and tumorigenesis.	CEACAM1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104115>	C18466	Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1|BGP-1|Biliary Glycoprotein 1|CD66a Antigen|CEACAM1	Carcinoembryonic antigen-related cell adhesion molecule 1 (526 aa, ~58 kDa) is encoded by the human CEACAM1 gene. This protein is involved in differentiation, angiogenesis, apoptosis, immune response, and tumorigenesis.	Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104116>	C20420	CEBPB Gene|CCAAT/Enhancer Binding Protein (C/EBP), Beta Gene|CEBPB|CEBPB	This gene plays a role in immune and inflammatory responses.	CEBPB Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104117>	C104116	CEBPB wt Allele|C/EBP-beta|CCAAT/Enhancer Binding Protein (C/EBP), Beta wt Allele|CRP2|IL6DBP|LAP|NF-IL6|NFIL6|TCF5	Human CEBPB wild-type allele is located in the vicinity of 20q13.1 and is approximately 2 kb in length. This allele, which encodes CCAAT/enhancer-binding protein beta protein, is involved in both the acute-phase reaction and inflammation.	CEBPB wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104118>	C17207	CCAAT/Enhancer Binding Protein Beta|CEBPB|Interleukin 6-Dependent DNA-Binding Protein|Liver Activator Protein|Nuclear Factor of Interleukin 6|TCF-5|Transcription Factor 5	CCAAT/enhancer-binding protein beta (345 aa, ~36 kDa) is encoded by the human CEBPB gene. This protein plays a role in the regulation of acute-phase reaction, inflammation and hemopoiesis.	CCAAT/Enhancer Binding Protein Beta		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104119>	C20917|C20745	CEP55 Gene|CEP55|CEP55|Centrosomal Protein 55kDa Gene	This gene is involved in mitotic exit and cytokinesis.	CEP55 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10411>	C61063	Cisplatin/Cytarabine/Fluorouracil|ARA-C/CDDP/5-FU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104120>	C104119	CEP55 wt Allele|C10orf3|CT111|Centrosomal Protein 55kDa wt Allele|Chromosome 10 Open Reading Frame 3 Gene|FLJ10540|RP11-30E16.2|URCC6	Human CEP55 wild-type allele is located in the vicinity of 10q24.1 and is approximately 32 kb in length. This allele, which encodes centrosomal protein of 55 kDa, plays a role in mitotic exit and cytokinesis.	CEP55 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104121>	C17761|C16492	Centrosomal Protein of 55 kDa|Cancer/Testis Antigen 111|Cep55|Up-Regulated in Colon Cancer 6	Centrosomal protein of 55 kDa (464 aa, ~54 kDa) is encoded by the human CEP55 gene. This protein is involved in mitotic exit and cytokinesis.	Centrosomal Protein of 55 kDa		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104122>	C20347	CERKL Gene|CERKL|CERKL|Ceramide Kinase Like Gene	This gene plays a role in apoptosis.	CERKL Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104123>	C104122	CERKL wt Allele|Ceramide Kinase Like wt Allele|Ceramide Kinase-like Gene|RP26|Retinitis Pigmentosa 26 (Autosomal Recessive) Gene|Retinitis Pigmentosa 26 Gene	Human CERKL wild-type allele is located in the vicinity of 2q31.3 and is approximately 144 kb in length. This allele, which encodes ceramide kinase-like protein, is involved in protecting cells from apoptosis in oxidative stress conditions.	CERKL wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104124>	C19928	Ceramide Kinase-like Protein|CERKL	Ceramide kinase-like protein (558 aa, ~63 kDa) is encoded by the human CERKL gene. This protein plays a role in protecting cells from apoptosis in oxidative stress conditions.	Ceramide Kinase-like Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104125>	C25870|C20348	CERS5 Gene|CERS5|CERS5|Ceramide Synthase 5 Gene	This gene is involved in ceramide synthesis and cell signaling.	CERS5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104126>	C104125	CERS5 wt Allele|Ceramide Synthase 5 wt Allele|FLJ25304|LAG1 Homolog, Ceramide Synthase 5 Gene|LAG1 Longevity Assurance Homolog 5 (S. cerevisiae) Gene|LAG1, S. cerevisiae, Homolog of 5 Gene|LASS5|MGC45411|TRAM Homolog 4 Gene|Trh4	Human CERS5 wild-type allele is located in the vicinity of 12q13.12 and is approximately 38 kb in length. This allele, which encodes ceramide synthase 5 protein, plays a role in cell signaling and apoptosis.	CERS5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104127>	C19928|C16259	Ceramide Synthase 5|CerS5|EC 2.3.1.24|LAG1 Longevity Assurance Homolog 5|Sphingosine N-Acyltransferase CERS5	Ceramide synthase 5 (392 aa, ~46 kDa) is encoded by the human CERS5 gene. This protein is involved in apoptosis via the mitochondrial death pathway.	Ceramide Synthase 5		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104128>	C25775	CCR7 Gene|CCR7|CCR7|CCR7|Chemokine (C-C motif) Receptor 7 Gene	This gene plays a role in immune function.	CCR7 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C104129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104129>	C104128	CCR7 wt Allele|BLR2|CD197|CDw197|CMKBR7|Chemokine (C-C motif) Receptor 7 wt Allele|EBI1	Human CCR7 wild-type allele is located within 17q12-q21.2 and is approximately 12 kb in length. This allele, which encodes C-C chemokine receptor type 7 protein, is involved in lymphocyte activation.	CCR7 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10412>	C61063	Cisplatin/Cytarabine/Fluorouracil/Sargramostim|ARA-C/CDDP/5-FU/GM-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104130>	C18018	C-C Chemokine Receptor Type 7|CD197 Antigen|Epstein-Barr Virus-Induced G-Protein Coupled Receptor 1|Lymphocyte-Specific G Protein-Coupled Peptide Receptor|MIP-3 Beta Receptor	C-C chemokine receptor type 7 (378 aa, ~43 kDa) is encoded by the human CCR7 gene. This protein plays a role in memory T-cell migration and dendritic cell maturation.	C-C Chemokine Receptor Type 7		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104131>	C25790	CLEC4C Gene|C-type Lectin Domain Family 4, Member C Gene|CLEC4C|CLEC4C	This gene is involved in immune function.	CLEC4C Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104132>	C104131	CLEC4C wt Allele|BDCA2|C-type Lectin Domain Family 4, Member C wt Allele|CD303|CLECSF11|CLECSF7|DLEC|HECL	Human CLEC4C wild-type allele is located within 12p13.2-p12.3 and is approximately 22 kb in length. This allele, which encodes c-type lectin domain family 4 member C protein, plays a role in antigen processing and presentation.	CLEC4C wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104133>	C16725	C-Type Lectin Domain Family 4 Member C|Blood Dendritic Cell Antigen 2 Protein|C-Type (Calcium Dependent, Carbohydrate-Recognition Domain) 11|C-Type (Calcium Dependent, Carbohydrate-Recognition Domain) Lectin, Superfamily Member 7|CD303 Antigen|CLEC4C	C-type lectin domain family 4 member C (213 aa, ~25 kDa) is encoded by the human CLEC4C gene. This protein is involved in antigen processing and presentation to T-cells.	C-Type Lectin Domain Family 4 Member C		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104134>	C20917|C20731	CDC25C Gene|CDC25C|CDC25C|Cell Division Cycle 25 Homolog C Gene	This gene plays a role in regulation of cell division.	CDC25C Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104135>	C104134	CDC25C wt Allele|CDC25|Cell Division Cycle 25 Homolog C wt Allele|PPP1R60	Human CDC25C wild-type allele is located in the vicinity of 5q31 and is approximately 53 kb in length. This allele, which encodes m-phase inducer phosphatase 3 protein, is involved in mitotic control and cell cycle progression.	CDC25C wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104136>	C25880|C17761	M-Phase Inducer Phosphatase 3|CDC25C|Cell Division Cycle 25 Homolog C|Dual Specificity Phosphatase Cdc25C|EC 3.1.3.48|Protein Phosphatase 1, Regulatory Subunit 60	M-phase inducer phosphatase 3 (473 aa, ~53 kDa) is encoded by the human CDC25C gene. This protein plays a role in cell cycle progression through the G1/S checkpoint.	M-Phase Inducer Phosphatase 3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104137>	C25939	CP Gene|CP|CP|Ceruloplasmin (Ferroxidase) Gene	This gene is a metalloprotein involved in copper binding in plasma.	CP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104138>	C104137	CP wt Allele|CP-2|Ceruloplasmin (Ferroxidase) wt Allele	Human CP wild-type allele is located within 3q23-q25 and is approximately 60 kb in length. This allele, which encodes ceruloplasmin protein, plays a role in iron homeostasis and neuronal survival. Mutations cause aceruloplasminemia, which results in iron accumulation and tissue damage, and is associated with diabetes and neurologic abnormalities.	CP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104139>	C16946	Ceruloplasmin|CP|Ferroxidase	Ceruloplasmin (1065 aa, ~122 kDa) is encoded by the human CP gene. This protein is involved in iron homeostasis.	Ceruloplasmin		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10413>	C61063	Asparaginase/Cyclophosphamide/Cytarabine/Methotrexate|ARA-C/ASP/CTX/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104140>	C26016	CRBN Gene|CRBN|CRBN|Cereblon Gene	This gene plays a role in limb outgrowth and may play a role in brain development.	CRBN Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|Pediatric Oncology Target Cell Lineage Determinant Terminology
C104141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104141>	C104140	CRBN wt Allele|Cereblon wt Allele|MRT2A|Mental Retardation, Non-Syndromic, Autosomal Recessive, 2A	Human CRBN wild-type allele is located in the vicinity of 3p26.3 and is approximately 31 kb in length. This allele, which encodes protein cereblon protein, is involved in ubiquitin-mediated protein degradation. Mutations are associated with autosomal recessive nonsyndromic mental retardation.	CRBN wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104142>	C95242	Protein Cereblon|CRBN	Protein cereblon (442 aa, ~51 kDa) is encoded by the human CRBN gene. This protein plays a role in assembly and regulation of calcium-activated potassium channels in brain.	Protein Cereblon		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Cell Lineage Determinant Terminology
C104143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104143>	C26010	CXCL16 Gene|CXCL16|CXCL16|Chemokine (C-X-C motif) Ligand 16 Gene	This gene may be involved in immune-cell chemotaxis.	CXCL16 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104144>	C104143	CXCL16 wt Allele|CXCLG16|Chemokine (C-X-C motif) Ligand 16 wt Allele|SR-PSOX|SRPSOX	Human CXCL16 wild-type allele is located in the vicinity of 17p13 and is approximately 6 kb in length. This allele, which encodes C-X-C motif chemokine 16 protein, may play a role in lymphocyte chemotaxis and scavenger receptor for oxidized low density lipoprotein.	CXCL16 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104145>	C20467	C-X-C Motif Chemokine 16|CXC Chemokine Ligand 16|CXCL16|Scavenger Receptor for Phosphatidylserine and Oxidized Low Density Lipoprotein	C-X-C motif chemokine 16 (254 aa, ~28 kDa) is encoded by the human CXCL16 gene. This protein may be involved in lymphocyte chemotaxis.	C-X-C Motif Chemokine 16		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104146>	C26511	CYP24A1 Gene|CYP24A1|CYP24A1|Cytochrome P450 Family 24 Subfamily A Member 1 Gene	This gene plays a role in vitamin D3 metabolism and calcium homeostasis.	CYP24A1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104147>	C104146	CYP24A1 wt Allele|CP24|CYP24|Cytochrome P450 Family 24 Subfamily A Member 1 wt Allele|Cytochrome P450, Family 24, Subfamily A, Polypeptide 1 Gene|Cytochrome P450, Subfamily XXIV (Vitamin D 24-Hydroxylase) Gene|Cytochrome P450, Subfamily XXIV Gene|Exo-Mitochondrial Protein Gene|HCAI|HCINF1|LncBCAS1-4_1|P450-CC24|Vitamin D 24-Hydroxylase Gene	Human CYP24A1 wild-type allele is located in the vicinity of 20q13.2 and is approximately 21 kb in length. This allele, which encodes 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial protein, is involved in vitamin D3 metabolism and calcium homeostasis. Mutations in CYP24A1 are associated with infantile hypercalcemia.	CYP24A1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104148>	C16484	1,25-Dihydroxyvitamin D(3) 24-Hydroxylase, Mitochondrial|1,25-Dihydroxyvitamin D3 24-Hydroxylase|24-OHase|CYP24A1|Cytochrome P450 24A1|Cytochrome P450 Family 24 Subfamily A Member 1|Cytochrome P450-CC24|EC 1.14.13.16|Exo-Mitochondrial Protein|Vitamin D 24-Hydroxylase|Vitamin D(3) 24-Hydroxylase	1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (514 aa, ~59 kDa) is encoded by the human CYP24A1 gene. This protein plays a role in calcium homeostasis.	1,25-Dihydroxyvitamin D(3) 24-Hydroxylase, Mitochondrial		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104149>	C26511	CYP27A1 Gene|CYP27A1|CYP27A1|Cytochrome P450, Family 27, Subfamily A, Polypeptide 1 Gene	This gene is involved in cholesterol homeostasis and bile synthesis.	CYP27A1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10414>	C61063	Dactinomycin/Doxorubicin/Mercaptopurine/Methotrexate/Prednisone/Vincristine|DACT/DOX/MP/MTX/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104150>	C104149	CYP27A1 wt Allele|CP27|CTX|CYP27|Cytochrome P450, Family 27, Subfamily A, Polypeptide 1 wt Allele	Human CYP27A1 wild-type allele is located within 2q35 and is approximately 34 kb in length. This allele, which encodes sterol 26-hydroxylase, mitochondrial protein, plays a role in bile synthesis and cholesterol homeostasis. Mutations in CYP27A1 are associated with cerebrotendinous xanthomatosis.	CYP27A1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104151>	C16484	Sterol 26-Hydroxylase, Mitochondrial|5-beta-cholestane-3-alpha, 7-alpha, 12-alpha-triol 26-Hydroxylase|CYP27A1|Cholestanetriol 26-Monooxygenase|Cytochrome P-450C27/25|Cytochrome P450 27|Cytochrome P450 27A1|EC 1.14.13.15|Sterol 27-hydroxylase|Vitamin D(3) 25-Hydroxylase	Sterol 26-hydroxylase, mitochondrial (531 aa, ~60 kDa) is encoded by the human CYP27A1 gene. This protein is involved in cholesterol homeostasis and bile synthesis.	Sterol 26-Hydroxylase, Mitochondrial		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104152>	C63586	FOLFIRI-Cetuximab Regimen|FOLFIRI and Cetuximab|FOLFIRI and Cetuximab (L-Leucovorin)|FOLFIRI-Erbitux Regimen|FOLFIRI/Cetuximab Regimen|Leucovorin-Fluorouracil-Irinotecan-Cetuximab Regimen	A regimen consisting of leucovorin (folinic acid), 5-fluorouracil, and irinotecan plus cetuximab that can be used for the treatment of colorectal cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|NCI Drug Dictionary Terminology|Pharmacotherapy Regimens
C104153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104153>	C211912	Polatuzumab Vedotin|ADC DCDS4501A|Antibody-Drug Conjugate DCDS4501A|DCDS4501A|FCU 2711|FCU-2711|FCU2711|POLATUZUMAB VEDOTIN|Polatuzumab vedotin|Polivy|RG 7596|RG-7596|RG7596|Ro 5541077-000|polatuzumab vedotin-piiq	An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against B-cell antigen receptor complex-associated protein beta chain (CD79B) conjugated, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity.  Upon administration, the monoclonal antibody moiety of polatuzumab vedotin selectively binds to CD79B, a protein which is abundantly expressed on the surface of B-cells. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. CD79B, a component of the B-cell receptor (BCR), plays a key role in B-cell receptor signaling and is expressed on the surface of almost all types of malignant B-cells.	Polatuzumab Vedotin		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C104154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104154>	C812	Circulating Cell-Free RNA|Circulating RNA|cfRNA	RNA found in blood plasma and other bodily fluids that is not associated with cells.	Circulating Cell-Free RNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology
C104155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104155>	C19540	CLLU1 Gene|CLLU1|CLLU1|Chronic Lymphocytic Leukemia Up-Regulated 1 Gene	This gene may be involved in leukemia.	CLLU1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104156>	C104155	CLLU1 wt Allele|Chronic Lymphocytic Leukemia Up-Regulated 1 wt Allele|Chronic Lymphocytic Leukemia Upregulated Gene 1	Human CLLU1 wild-type allele is located in the vicinity of 12q22 and is approximately 70 kb in length. This allele, which encodes chronic lymphocytic leukemia up-regulated protein 1, may play a role in chronic lymphocytic leukemia.	CLLU1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104157>	C54672	Chronic Lymphocytic Leukemia Up-Regulated Protein 1|CLLU1	Chronic lymphocytic leukemia up-regulated protein 1 (121 aa, ~14 kDa) is encoded by the human CLLU1 gene. This protein may be involved in chronic lymphocytic leukemia.	Chronic Lymphocytic Leukemia Up-Regulated Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104158>	C20462	BMF Gene|BMF|BMF|Bcl2 Modifying Factor Gene	This gene plays a role in apoptosis.	BMF Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104159>	C104158	BMF wt Allele|Bcl2 Modifying Factor wt Allele|FLJ00065	Human BMF wild-type allele is located in the vicinity of 15q14 and is approximately 21 kb in length. This allele, which encodes bcl-2-modifying factor protein, is involved in the regulation of apoptosis.	BMF wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10415>	C61063	Nimodipine/Vincristine|NIMO/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104160>	C19928	Bcl-2-Modifying Factor|BMF	Bcl-2-modifying factor (184 aa, ~21 kDa) is encoded by the human BMF gene. This protein plays a role in the positive regulation of pro-apoptotic gene products.	Bcl-2-Modifying Factor		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104161>	C28533|C20917	KIF23 Gene|KIF23|KIF23|Kinesin Family Member 23 Gene	This gene is involved in cytokinesis and microtubule movement.	KIF23 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104162>	C104161	KIF23 wt Allele|CHO1|KNSL5|Kinesin Family Member 23 wt Allele|Kinesin-Like 5 (Mitotic Kinesin-Like Protein 1) Gene|MKLP-1|MKLP1	Human KIF23 wild-type allele is located in the vicinity of 15q23 and is approximately 34 kb in length. This allele, which encodes kinesin-like protein KIF23, plays a role in microtubule motor activity, mitotic spindle formation and cytokinesis.	KIF23 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104163>	C17761|C16386	Kinesin-Like Protein KIF23|KIF23|Kinesin-Like Protein 5|Mitotic Kinesin-Like Protein 1	Kinesin-like protein KIF23 (960 aa, ~110 kDa) is encoded by the human KIF23 gene. This protein is involved in mitotic spindle assembly, cytokinesis and microtubule-dependent motor activity.	Kinesin-Like Protein KIF23		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104164>	C20745	TUBB Gene|TUBB|TUBB|Tubulin, Beta Class I Gene	This gene plays a role in microtubule structure and function.	TUBB Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104165>	C104164	TUBB wt Allele|DAAP-285E11.4|M40|MGC16435|OK/SW-cl.56|TUBB1|TUBB5|Tubb5|Tubulin, Beta Class I wt Allele	Human TUBB wild-type allele is located in the vicinity of 6p21.33 and is approximately 5 kb in length. This allele, which encodes tubulin beta chain protein, is involved in microtubule dynamics.	TUBB wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104166>	C129655	Tubulin Beta Chain|Beta 5-Tubulin|Beta Ib Tubulin|Beta1-Tubulin|Class I Beta-Tubulin|TUBB|Tubulin Beta Polypeptide|Tubulin Beta-5 Chain|Tubulin, Beta|Tubulin, Beta Polypeptide	Tubulin beta chain (444 aa, ~50 kDa) is encoded by the human TUBB gene. This protein plays a role in both the structure and functioning of microtubules.	Tubulin Beta Chain		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104167>	C211912|C155713	Pinatuzumab Vedotin|ADC DCDT2980S|Antibody-Drug Conjugate DCDT2980S|DCDT2980S|PINATUZUMAB VEDOTIN	An antibody-drug conjugate (ADC) composed of MCDT2219A, a humanized IgG1 anti-CD22 monoclonal antibody covalently linked, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of pinatuzumab vedotin binds to B cell-specific CD22 receptors and is rapidly internalized, thereby delivering MMAE intracellularly. Upon proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. CD22, a cell surface glycoprotein, is expressed on mature B-cells and on most malignant B-cells.	Pinatuzumab Vedotin		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C104168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104168>	C20745	TUBA3C Gene|TUBA3C|TUBA3C|Tubulin, Alpha 3c Gene	This gene is involved in both the structure and functioning of microtubules.	TUBA3C Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104169>	C104168	TUBA3C wt Allele|TUBA2|Tubulin, Alpha 2 Gene|Tubulin, Alpha 3c wt Allele|bA408E5.3	Human TUBA3C wild-type allele is located in the vicinity of 13q12.11 and is approximately 8 kb in length. This allele, which encodes tubulin alpha-3C/D chain protein, plays a role in microtubule structure and function.	TUBA3C wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10416>	C61063	Cytarabine/Methylprednisolone/Mitoxantrone/Vincristine|ARA-C/DHAD/MePRDL/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104170>	C129386	Tubulin Alpha-3C/D Chain|Alpha-Tubulin 2|Alpha-Tubulin 3C/D|TUBA3C|Tubulin Alpha-2 Chain	Tubulin alpha-3C/D chain (450 aa, ~50 kDa) is encoded by the human TUBA3C gene. This protein is involved in microtubule structural dynamics.	Tubulin Alpha-3C/D Chain		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104172>	C25790	CRTAM Gene|CRTAM|CRTAM|Cytotoxic and Regulatory T-Cell Molecule Gene	This gene is involved in immune function.	CRTAM Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104173>	C104172	CRTAM wt Allele|CD355|Cytotoxic and Regulatory T-Cell Molecule wt Allele	Human CRTAM wild-type allele is located in the vicinity of 11q24.1 and is approximately 34 kb in length. This allele, which encodes cytotoxic and regulatory T-cell molecule protein, plays a role in promoting natural killer (NK) cell cytotoxicity.	CRTAM wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104174>	C16725	Cytotoxic and Regulatory T-Cell Molecule|CD355 Antigen|CRTAM|Class I MHC Restricted T Cell Associated Molecule|Class-I MHC-Restricted T-Cell-Associated Molecule|Cytotoxic and Regulatory T Cell Molecule	Cytotoxic and regulatory T-cell molecule (393 aa, ~47 kDa) is encoded by the human CRTAM gene. This protein is involved in promoting natural killer (NK) cell cytotoxicity and may promote interferon-gamma (IFN-gamma) secretion by CD8+ cells.	Cytotoxic and Regulatory T-Cell Molecule		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104175>	C25939	DEGS1 Gene|DEGS1|DEGS1|Delta 4-Desaturase, Sphingolipid 1 Gene	This gene plays a role in fatty acid biosynthesis.	DEGS1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104176>	C104175	DEGS1 wt Allele|DEGS|DEGS-1|DES1|Degenerative Spermatocyte Homolog 1, Lipid Desaturase (Drosophila) Gene|Delta 4-Desaturase, Sphingolipid 1 wt Allele|Delta(4)-Desaturase, Sphingolipid 1 Gene|Des-1|FADS7|MLD	Human DEGS1 wild-type allele is located within 1q41-q42.12 and is approximately 18 kb in length. This allele, which encodes sphingolipid delta(4)-desaturase DES1 protein, is involved in fatty acid biosynthesis.	DEGS1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104177>	C16946	Sphingolipid Delta(4)-Desaturase DES1|Cell Migration-Inducing Gene 15 Protein|DEGS1|DES1|Degenerative Spermatocyte Homolog 1|Delta(4)-Desaturase, Sphingolipid 1|Dihydroceramide Desaturase|Dihydroceramide Desaturase 1|Membrane Fatty Acid (Lipid) Desaturase|Membrane Lipid Desaturase|Sphingolipid Delta(4)-Desaturase 1	Sphingolipid delta(4)-desaturase DES1 (323 aa, ~38 kDa) is encoded by the human DEGS1 gene. This protein plays a role in fatty acid biosynthesis.	Sphingolipid Delta(4)-Desaturase DES1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104178>	C25939	DEGS2 Gene|DEGS2|DEGS2|Delta(4)-Desaturase, Sphingolipid 2 Gene	This gene is involved in sphingolipid biosynthesis.	DEGS2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104179>	C104178	DEGS2 wt Allele|C14orf66|Chromosome 14 Open Reading Frame 66|DES2|Delta(4)-Desaturase, Sphingolipid 2 wt Allele|FADS8	Human DEGS2 wild-type allele is located in the vicinity of 14q32.2 and is approximately 14 kb in length. This allele, which encodes sphingolipid delta(4)-desaturase/C4-hydroxylase DES2 protein, plays a role in sphingolipid biosynthesis.	DEGS2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10417>	C61063	Carboplatin/Cytarabine/Etoposide|ARA-C/CBDCA/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104180>	C16946	Sphingolipid Delta(4)-Desaturase/C4-Hydroxylase DES2|DEGS2|DES2|Degenerative Spermatocyte Homolog 2|Degenerative Spermatocyte Homolog 2, Lipid Desaturase|Degenerative Spermatocyte Homolog 2, Lipid Desaturase (Drosophila)|Sphingolipid C4-Hydroxylase/Delta 4-Desaturase	Sphingolipid delta(4)-desaturase/C4-hydroxylase DES2 (323 aa, ~37 kDa) is encoded by the human DEGS2 gene. This protein is involved in sphingolipid biosynthesis.	Sphingolipid Delta(4)-Desaturase/C4-Hydroxylase DES2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104181>	C20921	DCAF7 Gene|DCAF7|DCAF7|DDB1 and CUL4 Associated Factor 7 Gene	This gene may play a role in regulation of transcription.	DCAF7 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104182>	C104181	DCAF7 wt Allele|AN11|AN11, Petunia, Homolog of Gene|DDB1 and CUL4 Associated Factor 7 wt Allele|HAN11|SWAN-1|WDR68	Human DCAF7 wild-type allele is located in the vicinity of 17q23.3 and is approximately 44 kb in length. This allele, which encodes DDB1- and CUL4-associated factor 7 protein, may be involved in regulation of transcription.	DCAF7 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104183>	C95242|C18515	DDB1- and CUL4-Associated Factor 7|DCAF7|Human Anthocyanin|Seven-WD-Repeat Protein of the AN11 Family-1|WD Repeat Domain 68|WD Repeat-Containing Protein 68|WD Repeat-Containing Protein An11 Homolog	DDB1- and CUL4-associated factor 7 (342 aa, ~39 kDa) is encoded by the human DCAF7 gene. This protein may play a role in regulation of transcription.	DDB1- and CUL4-Associated Factor 7		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104184>	C20462	DDIT4 Gene|DDIT4|DDIT4|DNA-Damage-Inducible Transcript 4 Gene	This gene is involved in responses to cellular energy levels and cellular stress.	DDIT4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104185>	C104184	DDIT4 wt Allele|DNA-Damage-Inducible Transcript 4 wt Allele|Dig2|FLJ20500|REDD-1|REDD1|RTP801	Human DDIT4 wild-type allele is located in the vicinity of 10q22.1 and is approximately 2 kb in length. This allele, which encodes DNA damage-inducible transcript 4 protein, plays a role in responses to cellular stress and regulates apoptosis in response to DNA damage.	DDIT4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104186>	C19928	DNA Damage-Inducible Transcript 4 Protein|HIF-1 Responsive Protein|Protein Regulated in Development and DNA Damage Response 1|RTP801	DNA damage-inducible transcript 4 protein (232 aa, ~25 kDa) is encoded by the human DDIT4 gene. This protein is involved in responses to cellular stress and regulates apoptosis in response to DNA damage.	DNA Damage-Inducible Transcript 4 Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104187>	C21240	EIF2S1 Gene|EIF2S1|EIF2S1|Eukaryotic Translation Initiation Factor 2, Subunit 1 Alpha, 35kDa Gene	This gene plays a role in translation initiation.	EIF2S1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104188>	C104187	EIF2S1 wt Allele|EIF-2-alpha|EIF2|EIF2A|Eukaryotic Translation Initiation Factor 2, Subunit 1 Alpha, 35kDa wt Allele	Human EIF2S1 wild-type allele is located in the vicinity of 14q21.3 and is approximately 27 kb in length. This allele, which encodes eukaryotic translation initiation factor 2 subunit 1 protein, is involved in the initiation of protein translation.	EIF2S1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104189>	C17461	Eukaryotic Translation Initiation Factor 2 Subunit 1|EIF2S1|Eukaryotic Translation Initiation Factor 2 Subunit Alpha|eIF-2-alpha|eIF-2A|eIF-2alpha	Eukaryotic translation initiation factor 2 subunit 1 (315 aa, ~36 kDa) is encoded by the human EIF2S1 gene. This protein plays a role in the initiation of protein translation.	Eukaryotic Translation Initiation Factor 2 Subunit 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10418>	C61063	Fluorouracil/Hydroxyurea/Idoxuridine|5-FU/HU/IUDR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104190>	C26057|C21240	EIF4A1 Gene|EIF4A1|EIF4A1|Eukaryotic Translation Initiation Factor 4A1 Gene	This gene is involved in translation initiation.	EIF4A1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104191>	C104190	EIF4A1 wt Allele|DDX2A|EIF-4A|EIF4A|Eukaryotic Translation Initiation Factor 4A1 wt Allele|eIF-4A-I|eIF4A-I	Human EIF4A1 wild-type allele is located in the vicinity of 17p13 and is approximately 6 kb in length. This allele, which encodes eukaryotic initiation factor 4A-I, plays a role in translation initiation.	EIF4A1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104192>	C17461|C17417	Eukaryotic Initiation Factor 4A-I|ATP-Dependent RNA Helicase eIF4A-1|EC 3.6.4.13|Eukaryotic Translation Initiation Factor 4A, Isoform 1|eIF-4A-I|eIF4A-I	Eukaryotic initiation factor 4A-I (406 aa, ~46 kDa) is encoded by the human EIF4A1 gene. This protein is involved in translation initiation.	Eukaryotic Initiation Factor 4A-I		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104193>	C25184	Lactate Dehydrogenase Isoenzyme 5|HLDH5|LD-5|LDH Isoenzyme 5|LDH-5|Lactate Dehydrogenase Isoenzyme-5|Lactic Dehydrogenase Isoenzyme 5	A protein complex that is comprised of a homotetramer of the L-lactate dehydrogenase A chain which is encoded by the human LDHA gene. This enzyme complex is involved in the last step of anaerobic glycolysis and is expressed in the liver and in skeletal muscle.	Lactate Dehydrogenase Isoenzyme 5		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104194>	C20130	Cyclin D|CCND|Cyclin-D|G1/S-Specific Cyclin-D	A protein family that is synthesized during the G1 phase of the cell cycle and drives the G1/S phase transition through the positive regulation of cyclin-dependent kinase activity. There are 3 CCND genes in humans.	Cyclin D		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104195>	C26003	ELANE Gene|ELANE|ELANE|Elastase, Neutrophil Expressed Gene	This gene plays a role in innate host defense.	ELANE Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104196>	C104195	ELANE wt Allele|ELA2|Elastase 2, Neutrophil Gene|Elastase, Leukocyte Gene|Elastase, Neutrophil Expressed wt Allele|Elastase, Neutrophil Gene|Elastase, Neutrophil-Expressed Gene|GE|HLE|HNE|NE|PMN-E|Protease, Serine, Bone Marrow Gene|SCN1	Human ELANE wild-type allele is located in the vicinity of 19p13.3 and is approximately 4 kb in length. This allele, which encodes neutrophil elastase protein, is involved in innate host defense and tissue remodeling.	ELANE wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104197>	C20130	Cyclin E|CCNE|Cyclin-E|G1/S-Specific Cyclin-E	A protein family that is synthesized during the G1 phase of the cell cycle and drives the G1/S phase transition through the positive regulation of cyclin-dependent kinase 2 activity. There are 2 CCNE genes in humans.	Cyclin E		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104198>	C17123	Neutrophil Elastase|Bone Marrow Serine Protease|EC 3.4.21.37|ELANE|Elastase 2|Elastase 2, Neutrophil|Elastase, Neutrophil Expressed|Granulocyte-Derived Elastase|Human Leukocyte Elastase|Leukocyte Elastate|Medullasin|PMN Elastase|Polymorphonuclear Elastase	Neutrophil elastase (267 aa, ~29 kDa) is encoded by the human ELANE gene. This protein plays a role in innate host defense and tissue remodeling.	Neutrophil Elastase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104199>	C21176	I-Kappa-B Kinase|IKK|IKappaB Kinase|IkappaB Kinase Complex|Inhibitor of Nuclear Factor Kappa-B Kinase|Nuclear Factor NF-Kappa-B Inhibitor Kinase|Nuclear Factor NFKappaB Inhibitor Kinase	An enzyme complex that is involved in serine/threonine phosphorylation, inflammation and the regulation of the nuclear factor kappa-light-chain-enhancer of activated B cells protein complex. I-kappa-B kinase is comprised of three proteins, inhibitor of nuclear factor kappa-B kinase subunit alpha, beta and gamma.	I-Kappa-B Kinase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10419>	C61063	Carboplatin/Cisplatin/Doxorubicin/Methotrexate/Vinblastine|CBDCA/CDDP/DOX/MTX/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1041>	C357	Cefepime Hydrochloride|CEFEPIME HYDROCHLORIDE|Maxipime|Pyrrolidinium, 1-((7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methyl-, hydroxide, inner salt, (6R-(6alpha,7beta(Z)))-	The hydrochloride salt of a semi-synthetic, beta-lactamase-resistant, fourth-generation cephalosporin antibiotic derived from an Acremonium fungal species with broad-spectrum bactericidal activity. Administered parenterally, cefepime inhibits bacterial cell wall synthesis by binding to and inactivating penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity, resulting in a reduction of bacterial cell wall stability and cell lysis. This agent is more active against a variety of Gram-positive pathogens compared to third-generation cephalosporins.	Cefepime Hydrochloride		Antibiotic|Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C104200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104200>	C143054	Type III Procollagen N-Terminal Peptide|P3NP|Procollagen-3 N-Terminal Peptide|Procollagen-III N-Terminal Peptide	Type III procollagen N-terminal peptide (P3NP) is encoded by the human COL3A1 gene. This peptide is produced by N-terminal cleavage of the N-terminal pro-peptide of type III collagen (Pro-C3). P3NP is a marker of collagen fibril synthesis, Pro-C3 and type III collagen turnover, muscle growth and repair, sarcopenia and fibrosis in hepatic tissue and muscle tissue.	Type III Procollagen N-Terminal Peptide		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104201>	C518|C268	Ganglioside GQ|A2B5|A2B5 Antigen|GQ Ganglioside	A sialoglycosphingolipid that is a branched nonasaccharide containing five sialyl residues, two galactose residues, one N-acetylgalactosamine residue and a glucose residue. This ceramide is found associated with the surface of the plasma membrane in developing thymic epithelial cells, oligodendrocyte progenitors, neuroendocrine cells, neurons and neuroblastoma cells.	Ganglioside GQ		Immunologic Factor|Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C104202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104202>	C268	Oligodendrocyte Marker O4|O4	A sulfated galactosylceramide that is a differentiation marker on the surface of oligodendrocyte precursors in the central nervous system.	Oligodendrocyte Marker O4		Immunologic Factor|Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C104203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104203>	C21282	ENO1 Gene|ENO1|ENO1|Enolase 1, (Alpha) Gene	This gene is involved in glycolysis.	ENO1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104204>	C104203	ENO1 wt Allele|ENO1L1|Enolase 1, (Alpha) wt Allele|MBP-1|MPB1|NNE|PPH	Human ENO1 wild-type allele is located in the vicinity of 1p36.2 and is approximately 18 kb in length. This allele, which encodes alpha-enolase protein, plays a role in glycolysis and tumor suppression, and acts as a structural lens protein.	ENO1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104205>	C16804	Alpha-Enolase|2-phospho-D-glycerate Hydro-lyase|Alpha Enolase Like 1|EC 4.2.1.1|Enolase 1|Enolase-Alpha|MYC Promoter-Binding Protein 1|Non-Neural Enolase|Phosphopyruvate Hydratase|Plasminogen-Binding Protein|Tau-Crystallin	Alpha-enolase (434 aa, ~47 kDa) is encoded by the human ENO1 gene. This protein is involved in glycolysis and tumor suppression, and acts as a structural lens protein.	Alpha-Enolase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104206>	C25997	PXN Gene|PXN|PXN|Paxillin Gene	This gene plays a role in cytoskeleton remodeling.	PXN Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104207>	C104206	PXN wt Allele|PAX|Paxillin wt Allele|hCG_1778014	Human PXN wild-type allele is located in the vicinity of 12q24.31 and is approximately 55 kb in length. This allele, which encodes paxillin protein, is involved in focal adhesions, cytoskeletal structure and integrin-mediated signaling.	PXN wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104208>	C26231	Paxillin|PXN	Paxillin (591 aa, ~65 kDa) is encoded by the human PXN gene. This protein plays a role in cell adhesion, integrin-mediated signal transduction and actin remodeling.	Paxillin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104209>	C25952	ENPP2 Gene|ENPP2|ENPP2|Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 Gene	This gene plays a role in the hydrolysis of lysophospholipids.	ENPP2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10420>	C61063	Cisplatin/Cyclosporine|CDDP/CYSP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104210>	C104209	ENPP2 wt Allele|ATX|ATX-X|E-NPP2|Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 wt Allele|NPP2|PD-IALPHA|PDNP2	Human ENPP2 wild-type allele is located in the vicinity of 8q24.1 and is approximately 116 kb in length. This allele, which encodes ectonucleotide pyrophosphatase/phosphodiesterase family member 2 protein, is involved in cell growth, survival, migration and angiogenesis. Expression is upregulated in several kinds of carcinomas.	ENPP2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104211>	C16561	Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2|Autotaxin|Autotaxin-T|EC 3.1.4.39|ENPP2|Extracellular Lysophospholipase D|Phosphodiesterase I/Nucleotide Pyrophosphatase 2|Plasma Lysophospholipase D	Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (863 aa, ~99 kDa) is encoded by the human ENPP2 gene. This protein plays a role in cell growth, survival, migration and angiogenesis.	Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104212>	C25972	PTPN13 Gene|PTPN13|PTPN13|PTPN13|Protein Tyrosine Phosphatase, Non-Receptor Type 13 (APO-1/CD95 (Fas)-Associated Phosphatase) Gene	This gene is involved in both protein dephosphorylation and signal transduction.	PTPN13 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C104213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104213>	C104212	PTPN13 wt Allele|FAP-1|PNP1|PTP-BAS|PTP-BL|PTP1E|PTPL1|PTPLE|Protein Tyrosine Phosphatase, Non-Receptor Type 13 (APO-1/CD95 (Fas)-Associated Phosphatase) wt Allele|hPTP1E	Human PTPN13 wild-type allele is located in the vicinity of 4q21.3 and is approximately 221 kb in length. This allele, which encodes tyrosine-protein phosphatase non-receptor type 13 protein, plays a role in both signaling and dephosphorylation of phosphotyrosine.	PTPN13 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104214>	C106408	Tyrosine-Protein Phosphatase Non-Receptor Type 13	Tyrosine-protein phosphatase non-receptor type 13 (2485 aa, ~277 kDa) is encoded by the human PTPN13 gene. This protein is involved in both the regulation of signaling and the mediation of protein phosphatase activity.	Tyrosine-Protein Phosphatase Non-Receptor Type 13		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104215>	C28480|C26003	F12 Gene|Coagulation Factor XII (Hageman Factor) Gene|F12|F12	This gene is involved in blood coagulation and fibrinolysis.	F12 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104216>	C20745	TNNT2 Gene|TNNT2|TNNT2|Troponin T2, Cardiac Type Gene	This gene plays a role in muscle filament movement.	TNNT2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104217>	C104215	F12 wt Allele|Coagulation Factor XII (Hageman Factor) wt Allele|HAE3|HAEX|HAF	Human F12 wild-type allele is located within 5q33-qter and is approximately 8 kb in length. This allele, which encodes coagulation factor XII protein, plays a role in coagulation, fibrinolysis, and the generation of bradykinin and angiotensin. Mutations in the F12 gene are associated with angioedema, hereditary, type III.	F12 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104218>	C104216	TNNT2 wt Allele|CMD1D|CMH2|CMPD2|Cardiomyopathy, Dilated 1D (Autosomal Dominant) Gene|Cardiomyopathy, Hypertrophic 2 Gene|LVNC6|RCM3|TnTC|Troponin T Type 2 (Cardiac) Gene|Troponin T2, Cardiac Type wt Allele|cTnT	Human TNNT2 wild-type allele is located in the vicinity of 1q32.1 and is approximately 19 kb in length. This allele, which encodes troponin T, cardiac muscle, is involved in muscle contraction.	TNNT2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104219>	C17123|C16354	Coagulation Factor XII|Beta-Factor XIIa Part 1|Beta-Factor XIIa Part 2|Coagulation Factor XIIa Heavy Chain|Coagulation Factor XIIa Light Chain|EC 3.4.21.38|F12|Hageman Factor	Coagulation factor XII (615 aa, ~68 kDa) is encoded by the human F12 gene. This protein is involved in blood coagulation and fibrinolysis.	Coagulation Factor XII		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10421>	C61063	Acivicin/Aminosyn|Aminosyn/AT-125			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104220>	C38041	Troponin T, Cardiac Muscle|Cardiac Muscle Troponin T|Cardiac Troponin T|TNNT2|TnTc|cTnT	Troponin T, cardiac muscle (298 aa, ~36 kDa) is encoded by the human TNNT2 gene. This protein plays a role in cardiac muscle contraction.	Troponin T, Cardiac Muscle		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104221>	C20194	FBXO32 Gene|F-Box Protein 32 Gene|FBXO32|FBXO32	This gene plays a role in protein ubiquitination and degradation.	FBXO32 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104222>	C104221	FBXO32 wt Allele|ATROGIN1|F-Box Protein 32 wt Allele|FLJ3242|Fbx32|MAFbx	Human FBXO32 wild-type allele is located in the vicinity of 8q24.13 and is approximately 43 kb in length. This allele, which encodes f-box only protein 32, is involved in protein ubiquitination and degradation.	FBXO32 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104223>	C20745	TNNI3 Gene|TNNI3|TNNI3|Troponin I3, Cardiac Type Gene	This gene is involved in cardiac muscle contraction.	TNNI3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104224>	C104223	TNNI3 wt Allele|CMD1FF|CMD2A|CMH7|RCM1|TNNC1|Troponin I Type 3 (Cardiac) wt Allele|cTnI	Human TNNI3 wild-type allele is located in the vicinity of 19q13.4 and is approximately 6 kb in length. This allele, which encodes troponin I, cardiac muscle, plays a role in muscle filament sliding.	TNNI3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104225>	C95242	F-Box Only Protein 32|Atrogin 1|Atrogin-1|F-Box Protein 32|FBXO32|Muscle Atrophy F-Box Protein	F-box only protein 32 (355 aa, ~42 kDa) is encoded by the human FBXO32 gene. This protein plays a role in protein ubiquitination and degradation.	F-Box Only Protein 32		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104226>	C17343	Troponin I, Cardiac Muscle|Cardiac Troponin I|TNNI3|cTnI	Troponin I, cardiac muscle (210 aa, ~24 kDa) is encoded by the human TNNI3 gene. This protein is involved in muscle filament movement in cardiac cells.	Troponin I, Cardiac Muscle		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104227>	C25840	CCNA1 Gene|CCNA1|CCNA1|Cyclin A1 Gene	This gene is involved in cell cycle regulation.	CCNA1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104228>	C104227	CCNA1 wt Allele|CT146|Cyclin A1 wt Allele	Human CCNA1 wild-type allele is located within 13q13.3 and is approximately 11 kb in length. This allele, which encodes cyclin-A1 protein, plays a role in the control of the cell cycle at the G1/S and G2/M transitions.	CCNA1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104229>	C17349	Cyclin-A1|CCNA1|Cyclin A1	Cyclin-A1 (465 aa, ~52 kDa) is encoded by the human CCNA1 gene. This protein is involved in the G1/S and G2/M cell cycle transitions.	Cyclin-A1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10422>	C61063	Carboplatin/Doxorubicin/Methotrexate/Vinblastine|CBDCA/DOX/MTX/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104230>	C26070	ALPL Gene|ALPL|ALPL|Alkaline Phosphatase, Biomineralization Associated Gene	This gene may play a role in matrix mineralization.	ALPL Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104231>	C104230	ALPL wt Allele|AP-TNAP|APTNAP|Alkaline Phosphatase, Biomineralization Associated wt Allele|Alkaline Phosphatase, Liver/Bone/Kidney Gene|HOPS|HPPA|HPPC|HPPI|HPPO|TNAP|TNS-ALP|TNSALP	Human ALPL wild-type allele is located in the vicinity of 1p36.12 and is approximately 69 kb in length. This allele, which encodes alkaline phosphatase, tissue-nonspecific isozyme protein, may be involved in matrix mineralization. Mutations in this gene are associated with infantile, childhood and adult hypophosphatasias and odontohypophosphatasia.	ALPL wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104232>	C16276	Alkaline Phosphatase, Tissue-Nonspecific Isozyme|ALPL|AP-TNAP|Alkaline Phosphatase Liver/Bone/Kidney Isozyme|Alkaline Phosphomonoesterase|EC 3.1.3.1|EC 3.9.1.1|Liver/Bone/Kidney-Type Alkaline Phosphatase|Phosphoamidase|Phosphocreatine Phosphatase|TNAP|TNS-ALP|TNSALP|Tissue Non-Specific Alkaline Phosphatase|Tissue-Nonspecific ALP	Alkaline phosphatase, tissue-nonspecific isozyme (524 aa, ~57 kDa) is encoded by the human ALPL gene. This protein may play a role in matrix mineralization.	Alkaline Phosphatase, Tissue-Nonspecific Isozyme		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104233>	C26511	CYP1B1 Gene|CYP1B1|CYP1B1|Cytochrome P450, Family 1, Subfamily B, Polypeptide 1 Gene	This gene plays a role in eye development, steroid catabolism and xenobiotic metabolism.	CYP1B1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104234>	C25790|C20103	FCGR1A Gene|CD64|FCGR1A|FCGR1A|Fc Fragment of IgG, High Affinity Ia, Receptor (CD64) Gene	This gene is involved in the immune response.	FCGR1A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104235>	C104233	CYP1B1 wt Allele|CP1B|CYPIB1|Cytochrome P450, Family 1, Subfamily B, Polypeptide 1 wt Allele|Cytochrome P450, Subfamily I (Dioxin-Inducible), Polypeptide 1 (Glaucoma 3, Primary Infantile) Gene|GLC3A|P4501B1	Human CYP1B1 wild-type allele is located in the vicinity of 2p22.2 and is approximately 43 kb in length. This allele, which encodes cytochrome P450 1B1 protein, is involved in both the development of the eye and the metabolism of xenobiotics and steroids. Mutation of the gene is associated with primary congenital glaucoma type 3A, primary open angle glaucoma and Peters anomaly.	CYP1B1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104236>	C104234	FCGR1A wt Allele|CD64A|FCG1|FCGR1|FCRI|Fc Fragment of IgG, High Affinity Ia, Receptor (CD64) wt Allele|IGFR1	Human FCGR1A wild-type allele is located within 1q21.2-q21.3 and is approximately 10 kb in length. This allele, which encodes high affinity immunoglobulin gamma Fc receptor I protein, plays a role in both innate and adaptive immune responses.	FCGR1A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104237>	C16484	Cytochrome P450 1B1|CYP1B1|CYPIB1|EC 1.14.14.1	Cytochrome P450 1B1 (543 aa, ~61 kDa) is encoded by the human CYP1B1 gene. This protein plays a role in the metabolism of steroids and xenobiotics.	Cytochrome P450 1B1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104238>	C21160|C18106	High Affinity Immunoglobulin Gamma Fc Receptor I|CD64|CD64 Antigen|FCGR1A|Fc Gamma Receptor|Fc Gamma Receptor I A1|Fc-Gamma RI|Fc-Gamma RIA|IgG Fc Receptor I	High affinity immunoglobulin gamma Fc receptor I (374 aa, ~43 kDa) is encoded by the human FCGR1A gene. This protein is involved in the immune response and signal transduction.	High Affinity Immunoglobulin Gamma Fc Receptor I		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104239>	C19676	RAD23B Gene|RAD23 Homolog B (S. cerevisiae) Gene|RAD23B|RAD23B	This gene is involved in DNA excision repair.	RAD23B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10423>	C61007	Carmustine/Etoposide/Thiotepa|BCNU/TSPA/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104240>	C104239	RAD23B wt Allele|HHR23B|HR23B|P58|RAD23 Homolog B (S. cerevisiae) wt Allele|RP11-131A5.1	Human RAD23B wild-type allele is located in the vicinity of 9q31.2 and is approximately 49 kb in length. This allele, which encodes UV excision repair protein RAD23 homolog B protein, plays a role in the repair of DNA damage.	RAD23B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104241>	C21170	UV Excision Repair Protein RAD23 Homolog B|HR23B|RAD23B|XP-C Repair Complementing Complex 58 kDa|XP-C Repair Complementing Protein|XP-C Repair-Complementing Complex 58 kDa Protein|hHR23B	UV excision repair protein RAD23 homolog B (409 aa, ~43 kDa) is encoded by the human RAD23B gene. This protein is involved in nucleotide-excision repair of DNA damage.	UV Excision Repair Protein RAD23 Homolog B		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104242>	C20745	TUBB3 Gene|TUBB3|TUBB3|Tubulin Beta 3 Class III Gene	This gene is involved in microtubule function and structure.	TUBB3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104243>	C104242	TUBB3 wt Allele|CDCBM|CFEOM3|CFEOM3A|FEOM3|Fibrosis of Extraocular Muscles, Congenital, 3 Gene|TUBB4|Tubulin Beta 3 Class III wt Allele|Tubulin, Beta 3 Class III Gene|Tubulin, Beta, Class III Gene|Tubulin, Beta-3 Gene|beta-4	Human TUBB3 wild-type allele is located in the vicinity of 16q24.3 and is approximately 17 kb in length. This allele, which encodes tubulin beta-3 chain protein, plays a role in maintaining microtubule structure.	TUBB3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104244>	C129655	Tubulin Beta-3 Chain|Class III Beta-Tubulin|TUBB3|Tubulin Beta-4 Chain|Tubulin Beta-III|Tuj-1 Antigen	Tubulin beta-3 chain (450 aa, ~50 kDa) is encoded by the human TUBB3 gene. This protein is involved in both axonal guidance and microtubule structure.	Tubulin Beta-3 Chain		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104245>	C20708	RORC Gene|RAR Related Orphan Receptor C Gene|RORC|RORC	This gene plays a role in steroid hormone receptor activity.	RORC Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104246>	C104245	RORC wt Allele|IMD42|NR1F3|RAR Related Orphan Receptor C wt Allele|RAR-Related Orphan Receptor C Gene|RAR-Related Orphan Receptor Gamma Gene|RORG|RZR-GAMMA|RZRG|TOR	Human RORC wild-type allele is located in the vicinity of 1q21 and is approximately 26 kb in length. This allele, which encodes nuclear receptor ROR-gamma protein, is involved in transcriptional activation.	RORC wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104247>	C106313	Nuclear Receptor ROR-Gamma|NR1F3|Nuclear Receptor RZR-Gamma|Nuclear Receptor Subfamily 1 Group F Member 3|RAR-Related Orphan Receptor C|RAR-Related Orphan Receptor Gamma|RORC|RZR-Gamma|Retinoic Acid-Binding Receptor Gamma|Retinoid-Related Orphan Receptor Gamma|Retinoid-Related Orphan Receptor-Gamma	Nuclear receptor ROR-gamma (518 aa, ~58 kDa) is encoded by the human RORC gene. This protein plays a role in ligand-mediated transcriptional regulation.	Nuclear Receptor ROR-Gamma		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104248>	C20420	TBX21 Gene|T-Box 21 Gene|TBX21|TBX21	This gene is involved in the regulation of cytokine gene expression.	TBX21 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104249>	C104248	TBX21 wt Allele|T-Box 21 wt Allele|T-PET|T-bet|TBET|TBLYM	Human TBX21 wild-type allele is located in the vicinity of 17q21.32 and is approximately 13 kb in length. This allele, which encodes T-box transcription factor TBX21 protein, plays a role in the transcriptional regulation of interferon-gamma. Genetic variation is associated with susceptibility to asthma with nasal polyps and aspirin intolerance.	TBX21 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10424>	C61007	Etoposide/Idarubicin/Methotrexate|IDA/MTX/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104250>	C17207	T-Box Transcription Factor TBX21|T-Box Expressed In T Cells|T-Box Protein 21|T-Cell-Specific T-Box Transcription Factor T-Bet|TBX21|Transcription Factor TBLYM	T-box transcription factor TBX21 (535 aa, ~58 kDa) is encoded by the human TBX21 gene. This protein is involved in the regulation of interferon-gamma gene expression.	T-Box Transcription Factor TBX21		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104251>	C20988	ITGB7 Gene|ITGB7|ITGB7|Integrin, Beta 7 Gene	This gene plays a role in both cell-matrix adhesion and integrin-mediated signaling.	ITGB7 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104252>	C104251	ITGB7 wt Allele|Integrin, Beta 7 wt Allele|Integrin, Beta-7 Gene	Human ITGB7 wild-type allele is located in the vicinity of 12q13.13 and is approximately 16 kb in length. This allele, which encodes integrin beta-7 protein, is involved in the regulation of both integrin-mediated signaling and cell-matrix adhesion.	ITGB7 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104253>	C16393	Integrin Beta-7|Gut Homing Receptor Beta Subunit|ITGB7|Integrin Beta 7 Subunit	Integrin beta-7 (798 aa, ~87 kDa) is encoded by the human ITGB7 gene. This protein plays a role in both cell adhesion and the mediation of integrin signaling.	Integrin Beta-7		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104254>	C20921	DLL3 Gene|DLL3|DLL3|Delta Like Canonical Notch Ligand 3 Gene	This gene is involved in both notch-mediated signaling and neurogenesis.	DLL3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104255>	C104254	DLL3 wt Allele|Delta (Drosophila)-Like 3 Gene|Delta Like Canonical Notch Ligand 3 wt Allele|Delta, Drosophila, Homolog of, 3 Gene|Delta-Like 3 (Drosophila) Gene|SCDO1	Human DLL3 wild-type allele is located in the vicinity of 19q13 and is approximately 10 kb in length. This allele, which encodes delta-like protein 3, plays a role in both neural cell differentiation and somitogenesis. Mutation of the gene is associated with spondylocostal dysostosis type 1.	DLL3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104256>	C18515	Delta-Like Protein 3|DLL3|Delta 3|Delta-Like 3|Delta3|Drosophila Delta Homolog 3	Delta-like protein 3 (618 aa, ~65 kDa) is encoded by the human DLL3 gene. This protein is involved in binding to notch proteins, mesoderm development and neurogenesis.	Delta-Like Protein 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104257>	C20420	HES4 Gene|HES4|HES4|Hairy and Enhancer of Split 4 (Drosophila) Gene	This gene plays a role in the repression of transcription.	HES4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104258>	C104257	HES4 wt Allele|BHLHB42|Hairy and Enhancer of Split 4 (Drosophila) wt Allele|bHLHb42	Human HES4 wild-type allele is located in the vicinity of 1p36.33 and is approximately 1 kb in length. This allele, which encodes transcription factor HES-4 protein, is involved in the negative regulation of transcription.	HES4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104259>	C17207	Transcription Factor HES-4|Class B Basic Helix-Loop-Helix Protein 42|HES4|Hairy and Enhancer of Split 4|bHLH Factor Hes4|bHLHb42|hHES4	Transcription factor HES-4 (221 aa, ~24 kDa) is encoded by the human HES4 gene. This protein plays a role in transcriptional repression.	Transcription Factor HES-4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10425>	C61063	Cisplatin/Etoposide/Thiotepa|CDDP/TSPA/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104260>	C20401|C129822	Imalumab|BAX-69|BAX069|BAX69|IMALUMAB|Immunoglobulin G1-kappa, Anti-(Homo sapiens MIF (Macrophage Migration Inhibitory Factor, Glycosylation-inhibiting Factor, GlIF, GIF)), Homo sapiens Monoclonal Antibody	A human, recombinant monoclonal antibody (MoAb) against macrophage migration inhibitory factor (MIF), with potential immunomodulating, anti-inflammatory and antineoplastic activities. Upon intravenous administration, imalumab binds to MIF, blocking its activity and preventing the MIF-mediated secretion of certain cytokines, including interleukin-1 beta and tumor necrosis factor-alpha. This may lead to an inhibition of cancer cell proliferation in MIF-overexpressing tumor cells. MIF, a pro-inflammatory cytokine overexpressed in some cancers, plays a key role in inflammation, immune responses and cancer cell proliferation.	Imalumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C104262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104262>	C12680	Eloquent Brain Areas|Eloquent Brain	Areas of the brain that control speech, motor functions, and sensory processing which are required for an individual to understand and interact with others and the environment.			Body Location or Region	
C104263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104263>	C26003	GZMB Gene|GZMB|GZMB|Granzyme B (Granzyme 2, Cytotoxic T-Lymphocyte-Associated Serine Esterase 1) Gene	This gene plays a role in cell-mediated cytolysis.	GZMB Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104266>	C226473	AK 3012	A proprietary topical formulation. Upon subcutaneous administration, the active ingredient in AK 3012 may inhibit actinic keratosis.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C104267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104267>	C155727	Derazantinib|ARQ 087|ARQ-087|DERAZANTINIB	An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. Derazantinib binds to and potently inhibits the activity of FGFR subtypes 1, 2 and 3. This may result in the inhibition of FGFR-mediated signal transduction pathways, tumor cell proliferation, tumor angiogenesis and tumor cell death in FGFR-overexpressing tumor cells. FGFR, a receptor tyrosine kinase, is upregulated in many tumor cell types and plays a key role in tumor cellular proliferation, differentiation, angiogenesis and survival.	Derazantinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C104268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104268>	C17123	Granzyme B|C11|CTLA-1|CTSGL1|Cathepsin G-Like 1|Cytotoxic Serine Protease B|Cytotoxic T-Lymphocyte Proteinase 2|Cytotoxic T-Lymphocyte-Associated Serine Esterase 1|EC 3.4.21.79|Fragmentin|Fragmentin-2|GZMB|Granzyme 2|Granzyme-2|HLP|Human Lymphocyte Protein|Lymphocyte Protease|SECT|T-Cell Serine Protease 1-3E	Granzyme B (247 aa, ~28 kDa) is encoded by the human GZMB gene. This protein plays a role in the mediation of cell-dependent cytotoxicity.	Granzyme B		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104269>	C2124	Fluorine F 18-labeled S-(3-Fluoropropyl)homocysteine Hydrochloride|(18F)-D-FPHCYS|18F-FPM|[(18)F]FPHCys	The hydrochloride salt form of a radioconjugate composed of a synthetic derivative of the amino acid methionine radiolabeled with fluoride F 18, with potential use as a tumor imaging agent during positron emission tomography (PET). Upon administration, fluorine F 18-labeled S-(3-fluoropropyl) homocysteine is preferentially taken up by tumor cells through an amino acid transporter, which is overexpressed by cancer cells. As tumor cells have a higher rate of proliferation than normal cells, these cancer cells have increased rates of protein synthesis and thus an increased demand for amino acids. This allows for visualization of tumors cells upon PET.			Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C10426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10426>	C61063	Cisplatin/Doxorubicin/Etoposide/Sargramostim|CDDP/DOX/GM-CSF/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104270>	C799	Iridium Ir 192|IRIDIUM IR-192|Ir-192|Iridium-192	A radioactive isotope of iridium. Iridium-192 emits gamma rays and has a half-life of 74 days. A high dose rate of this radioisotope can be used in brachytherapy to treat tumors by selectively delivering a cytotoxic dose of radiation to the tumor site.			Element, Ion, or Isotope|Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C104271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104271>	C25790	HAMP Gene|HAMP|HAMP|Hepcidin Antimicrobial Peptide Gene	This gene is involved in both iron metabolism and antimicrobial activity.	HAMP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104272>	C104271	HAMP wt Allele|HEPC|HFE2B|Hepcidin Antimicrobial Peptide wt Allele|LEAP-1|LEAP1|PLTR	Human HAMP wild-type allele is located in the vicinity of 19q13.1 and is approximately 3 kb in length. This allele, which encodes hepcidin protein, plays a role in both antimicrobial activity and iron homeostasis. Mutation of the gene is associated with hemochromatosis type 2B.	HAMP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104273>	C210746	Fish Oil/Glycerol/Egg Lecithin-based Emulsion|FISH OIL TRIGLYCERIDES|Omegaven	An injectable, nutritional lipid emulsion composed of 10% fish oil and high amounts of the fish oil-derived polyunsaturated omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Additionally, the fish oil/glycerol/egg lecithin-based emulsion contains, myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, octadecatetraenoic acid, eicosaenoic acid, arachidonic acid, docosaenoic acid, and docosapentaenoic acid. This agent supplies essential fatty acids that can be incorporated into cell membranes. The fatty acids may decrease the production of certain pro-inflammatory cytokines, including interleukin 1 (IL-1), IL-6 and tumor necrosis factor (TNF). In addition to fish oil, this lipid emulsion contains egg phospholipids to maintain membrane integrity; glycerol to provide energy through glycolysis; and the antioxidant alpha-tocopherol (vitamin E).			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C104274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104274>	C218849|C16725	Hepcidin|HAMP|LEAP-1|Liver-Expressed Antimicrobial Peptide 1|PLTR|Putative Liver Tumor Regressor	Hepcidin (84 aa, ~9 kDa) is encoded by the human HAMP gene. This protein is involved in antimicrobial activity and iron absorption and storage.	Hepcidin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104275>	C1511	Licartin|(131)I-labeled HAb18 F(ab')(2)|Iodine I 131 Metuximab|Iodine[131I] Metuximab|[131I] mAb HAb18G/CD147	An immunoradioconjugate containing metuximab, an antibody fragment targeting the hepatocellular cancer (HCC)-associated antigen HAb18G/CD147, that is conjugated to the radioisotope iodine I 131, with potential antineoplastic activity. Upon administration, the metuximab moiety of licartin targets and binds to HAb18G/CD147 on HCC cells; upon internalization, the radioisotope I 131 delivers a cytotoxic dose of gamma radiation, thereby causing selective destruction of HAb18G/CD147-expressing cells. HAb18G/CD147, a member of CD147 family, is overexpressed in HCC and fibroblasts and its expression is associated with cancer cell progression and increased adhesion, invasion and metastasis.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C104276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104276>	C25790|C20103	HAVCR2 Gene|HAVCR2|HAVCR2|Hepatitis A Virus Cellular Receptor 2 Gene|TIM3	This gene plays a role in macrophage and T helper cell activation.	HAVCR2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|Pediatric Oncology Immunotherapeutic Target Terminology
C104277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104277>	C104276	HAVCR2 wt Allele|CD366|FLJ14428|HAVcr-2|Hepatitis A Virus Cellular Receptor 2 wt Allele|KIM-3|TIM3|TIMD-3|TIMD3|Tim-3	Human HAVCR2 wild-type allele is located in the vicinity of 5q33.3 and is approximately 57 kb in length. This allele, which encodes hepatitis A virus cellular receptor 2 protein, is involved in the activation of macrophages and helper T cells.	HAVCR2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104278>	C18106|C16725	Hepatitis A Virus Cellular Receptor 2|CD366|CD366 Antigen|HAVCR2|HAVcr-2|Kidney Injury Molecule-3|T Cell Immunoglobulin Mucin 3|T Cell Immunoglobulin Mucin-3|T-Cell Immunoglobulin and Mucin Domain-Containing Protein 3|T-Cell Membrane Protein 3|TIM-3|TIM3|TIMD-3	Hepatitis A virus cellular receptor 2 (301 aa, ~33 kDa) is encoded by the human HAVCR2 gene. This protein plays a role in the regulation of T helper cell and macrophage activation.	Hepatitis A Virus Cellular Receptor 2		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Immunotherapeutic Target Terminology
C104279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104279>	C173398	Trouble Doing Strenuous Activities Like Carrying a Heavy Shopping Bag or Suitcase Question|Do you have trouble doing strenuous activities, like carrying a heavy shopping bag or a suitcase|Trouble Doing Strenuous Activities Like Carrying a Heavy Shopping Bag or Suitcase	A question about whether an individual has or had trouble performing strenuous activities, such as carrying a heavy shopping bag or a suitcase.			Intellectual Product	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30
C10427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10427>	C61063	Cisplatin/Etoposide/Megestrol|CDDP/MEG/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104280>	C162996	p53/HDM2 Interaction Inhibitor CGM097|CGM-097|CGM097|HDM2/p53 Inhibitor CGM097	An orally bioavailable HDM2 (human homolog of double minute 2) antagonist with potential antineoplastic activity. Upon oral administration, p53/HDM2 interaction inhibitor CGM097 inhibits the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited, which may result in the restoration of p53 signaling and, thus, the p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger nuclear phosphoprotein, is a negative regulator of the p53 pathway, often overexpressed in cancer cells and has been implicated in cancer cell proliferation and survival.	p53/HDM2 Interaction Inhibitor CGM097		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C104281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104281>	C173398|C173135	Trouble Taking Long Walk Question|Do you have any trouble taking a long walk|Trouble Taking Long Walk	A question about whether an individual has or had trouble taking a long walk.			Intellectual Product	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30
C104282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104282>	C173398|C173135	Trouble Taking Short Walk Outside House Question|Do you have any trouble taking a short walk outside of the house|Trouble Taking Short Walk Outside House	A question about whether an individual has or had trouble taking a short walk outside the house.			Intellectual Product	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30
C104283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104283>	C173458	Stay in Bed or Chair During Day Question|Do you need to stay in bed or a chair during the day|Stay in Bed or Chair During Day	A question about whether an individual needs or needed to stay in either a bed or a chair during the day.			Intellectual Product	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30
C104284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104284>	C178350	Need Help with Eating, Dressing, Washing, or Toilet Question|Do you need help with eating, dressing, washing yourself or using the toilet|Need Help with Eating, Dressing, Washing, or Toilet	A question about whether an individual requires or required assistance with eating, dressing, washing themselves or using the toilet.			Intellectual Product	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30
C104285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104285>	C173924|C173787|C173695	Limited in Doing Work or Daily Activities Question|Limited in Doing Work or Daily Activities|Were you limited in doing either your work or other daily activities	A question about whether an individual limits or was limited in performing work or daily activities.			Intellectual Product	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30
C104286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104286>	C173695	Limited in Pursuing Hobbies or Leisure Activities Question|Limited in Pursuing Hobbies or Leisure Activities|Were you limited in pursuing your hobbies or other leisure time activities	A question about whether an individual limits or was limited in pursuing their hobbies or leisure time activities.			Intellectual Product	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30
C104287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104287>	C25804	HDAC11 Gene|HDAC11|HDAC11|Histone Deacetylase 11 Gene	This gene is involved in deacetylation of histones.	HDAC11 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104288>	C104287	HDAC11 wt Allele|HD11|Histone Deacetylase 11 wt Allele	Human HDAC11 wild-type allele is located in the vicinity of 3p25.1 and is approximately 27 kb in length. This allele, which encodes histone deacetylase 11 protein, plays a role in the epigenetic regulation of transcription.	HDAC11 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104289>	C16682	Histone Deacetylase 11|EC 3.5.1.98|HD11|HDAC11	Histone deacetylase 11 (347 aa, ~39 kDa) is encoded by the human HDAC11 gene. This protein is involved in both histone deacetylation and transcriptional regulation.	Histone Deacetylase 11		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10428>	C61063	BCG/Interleukin-2|BCG/IL-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104291>	C217659|C20401|C1742|C129822	Anti-Tissue Factor Monoclonal Antibody MORAb-066|Anti-TF Monoclonal Antibody MORAb-066|MORAb-066	A humanized monoclonal antibody against human tissue factor (TF), with potential antiangiogenic, anticoagulant and anti-inflammatory activities. Upon administration, anti-TF monoclonal antibody MORAb-066 binds to TF and prevents Factor VIIa (FVIIa) from binding, thereby interfering with the activation of Factor X (FX) into FXa. This may prevent thrombin formation and cancer-associated venous thromboembolism, and may inhibit angiogenesis and tumor cell proliferation. TF, a transmembrane protein and initiator of the coagulation cascade, is overexpressed in many tumor cells and tumor endothelial cells; its expression is correlated with metastasis, angiogenesis, tumor cell growth and tumor-associated thrombosis.	Anti-Tissue Factor Monoclonal Antibody MORAb-066		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C104292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104292>	C2201|C2152|C192218	Panulisib|AK15176|P7170|PANULISIB|PI3K/mTOR/ALK-1/DNA-PK Inhibitor P7170	An orally bioavailable inhibitor of phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR), activin receptor-like kinase 1 (ALK-1) and DNA-dependent protein kinase (DNA-PK), with potential anti-angiogenic and antineoplastic activities. Upon oral administration, panulisib inhibits the activity of all four kinases. This prevents PI3K/mTOR and ALK-1-mediated signaling pathways and may lead to the inhibition of cancer cell growth in PI3K/mTOR-overexpressing tumor cells and angiogenesis in ALK-1-overexpressing endothelial cells. Also, by inhibiting DNA-PK, this agent inhibits the ability of tumor cells to repair damaged DNA. The PI3K/mTOR pathway is upregulated in a variety of tumors and plays an important role in regulating cancer cell proliferation, growth, and survival. ALK-1, a member of the transforming growth factor beta (TGF-b) type I receptor family, is overexpressed on endothelial cells in a variety of tumor types and increases endothelial cell proliferation and migration. DNA-PK is activated upon DNA damage and plays a key role in repairing double-stranded DNA breaks.	Panulisib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C104293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104293>	C91103	Need Rest Question|Did you need to rest|Need Rest	A question about whether an individual needs or needed rest.			Intellectual Product	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30
C104294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104294>	C173925|C173398	Trouble Sleeping Question|Did you have trouble with sleep|Difficulty Sleeping|Do you have trouble sleeping|Have Trouble Sleeping|Have you had trouble sleeping|I had trouble sleeping|I have trouble sleeping|Trouble Sleeping|Trouble falling/staying asleep or sleeping too much|Trouble sleeping	A question about whether an individual has or had trouble sleeping.			Intellectual Product	Dexamethasone Symptom Questionnaire-Chronic|Dexamethasone Symptom Questionnaire|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30|Memorial Symptom Assessment Scale - Short Form|Patient Health Questionnaire - 9 Item
C104295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104295>	C173219	Feel Weak Question|Do you feel physically weak (not strong)|Feel Weak|Feeling physically weak (not strong)|Have you felt weak|I feel physically weak (not strong)|I felt weak|Weak	A question about whether an individual feels or felt weak.			Intellectual Product	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30|Pediatric Quality of Life Inventory|PROMIS Pediatric and Parent Proxy Physical Health Domain
C104296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104296>	C173981	Lacks Appetite Question|Have you lacked appetite|Lack of appetite|Lacks Appetite	A question about whether an individual lacks or lacked an appetite.			Intellectual Product	Dexamethasone Symptom Questionnaire-Chronic|Dexamethasone Symptom Questionnaire|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30|Memorial Symptom Assessment Scale - Short Form
C104298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104298>	C173604	Have Emesis Question|Have Emesis|Have you vomited	A question about whether an individual has vomited.			Intellectual Product	Dexamethasone Symptom Questionnaire-Chronic|Dexamethasone Symptom Questionnaire|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30
C104299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104299>	C173981	Have Constipation Question|Constipation|Have Been Constipated|Have Constipation|Have you been constipated	A question about whether an individual is or has been constipated.			Intellectual Product	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30|Memorial Symptom Assessment Scale - Short Form
C10429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10429>	C159435	Cisplatin/Cyclophosphamide/Doxorubicin/Prednisone Regimen|CAPPr|CAPPr|CDDP/CTX/DOX/PRED|Cisplatin-Cyclophosphamide-Doxorubicin-Prednisone|Cisplatin/Cyclophosphamide/Doxorubicin/Prednisone	A regimen consisting of cisplatin, cyclophosphamide, doxorubicin and prednisone that can be used for the treatment of thymomas and thymic carcinomas.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C1042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1042>	C29578	Cetirizine|CETIRIZINE	Cetirizine is a metabolite of hydroxyzine and a selective peripheral histamine H1-receptor antagonist. It is used for symptomatic treatment of seasonal and perennial allergic rhinitis and for chronic urticaria. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C104300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104300>	C173981|C173936	Have Diarrhea Question|Diarrhea|Have Diarrhea|Have you had diarrhea|I have diarrhea	A question about whether an individual has or had diarrhea.			Intellectual Product	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30|FACT-Hep Questionnaire|Memorial Symptom Assessment Scale - Short Form
C104301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104301>	C173935	Feel Tired Question|Do you feel tired|Feel Tired|Feel Tired|Feeling tired|Feeling tired or having little energy|I feel tired|Tired|Were you tired	A question about whether an individual feels or felt tired.			Intellectual Product	Edmonton Symptom Assessment System|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30|Patient Health Questionnaire - 9 Item|Pediatric Quality of Life Inventory|Symptom Screening in Pediatrics
C104302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104302>	C173160	Feel Tense Question|Am Tense|Did you feel tense|Feel Tense|Felt Tense|Have you felt tense or high-strung|I feel tense|I feel tense or wound up	A question about whether an individual feels or has felt tense.			Intellectual Product	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30|Hospital Anxiety and Depression Scale Questionnaire|Medical Outcomes Study Your Feelings Questionnaire|Multidimensional Fatigue Symptom Inventory-Short Form
C104303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104303>	C20420	EPAS1 Gene|EPAS1|EPAS1|EPAS1|Endothelial PAS Domain Protein 1 Gene	This gene plays a role in the cellular response to hypoxia.	EPAS1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C104304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104304>	C173934	Feel Worried Question|Did you worry|Feel Worried|Feel Worry|Felt Worried|Had Worrying|Have Worried|I felt worried|Worrying	A question about whether an individual feels or felt worried.			Intellectual Product	Emotional Distress - Anxiety Subordinate Domain|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30|Memorial Symptom Assessment Scale - Short Form
C104305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104305>	C104303	EPAS1 wt Allele|BHLHE73|ECYT4|Endothelial PAS Domain Protein 1 wt Allele|HIF-2-Alpha Gene|HIF2A|HLF|Hypoxia-Inducible Factor 2, Alpha Subunit Gene|Hypoxia-Inducible Factor-2 Alpha Subunit Gene|MOP2|Member of PAS Superfamily 2 Gene|PASD2|bHLHe73	Human EPAS1 wild-type allele is located within 2p21-p16 and is approximately 93 kb in length. This allele, which encodes endothelial PAS domain-containing protein 1, is involved in the regulation of transcription in response to oxygen. Mutation of the gene is associated with familial erythrocytosis type 4.	EPAS1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104306>	C17207	Endothelial PAS Domain-Containing Protein 1|Basic-Helix-Loop-Helix-PAS Protein MOP2|Class E Basic Helix-Loop-Helix Protein 73|EPAS-1|EPAS1|HIF-1 Alpha-Like Factor|HIF-1-Alpha-Like Factor|HIF-1alpha-Like Factor|HIF-2-Alpha|HIF2-Alpha|HLF|Hypoxia-Inducible Factor 2 Alpha|Hypoxia-Inducible Factor 2-Alpha|Member of PAS Protein 2|PAS Domain-Containing Protein 2|bHLHe73	Endothelial PAS domain-containing protein 1 (870 aa, ~96 kDa) is encoded by the human EPAS1 gene. This protein plays a role in both the response to hypoxia and transcriptional regulation.	Endothelial PAS Domain-Containing Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104307>	C176426|C173398	Difficulty Concentrating Reading Newspaper or Watching Television Question|Difficulty Concentrating Reading Newspaper or Watching Television|Have you had difficulty in concentrating on things, like reading a newspaper or watching television|Trouble concentrating on things, such as reading the newspaper or watching television	A question about whether an individual has or had difficulty concentrating while reading a newspaper or watching the television.			Intellectual Product	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30|Patient Health Questionnaire - 9 Item
C104308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104308>	C173160	Feel Irritable Question|Do you feel irritable|Feel Irritable|Feeling irritable	A question about whether an individual feels or felt irritable.			Intellectual Product	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30|Memorial Symptom Assessment Scale - Short Form
C104309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104309>	C173160	Feel Depressed Question|Did you feel depressed|Do you feel depressed|Feel Depressed|Feel Depressed|Feeling down, depressed, or hopeless|Felt Depressed|I felt depressed	A question about whether an individual feels or felt depressed.			Intellectual Product	Center for Epidemiologic Studies Depression Scale|Edmonton Symptom Assessment System|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30|Medical Outcomes Study Your Feelings Questionnaire|Patient Health Questionnaire - 9 Item|PROMIS-43 Adult Profile v2.0
C10430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10430>	C61063	Cisplatin/Dihydro-5-Azacytidine|CDDP/DHAC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104310>	C173812|C173584|C173151	Interference with Family Life due to Physical Condition or Medical Treatment Question|Has your physical condition or medical treatment interfered with your family life|Interference with Family Life due to Physical Condition or Medical Treatment	A question about whether an individual's physical condition or medical treatment interferes or has interfered with their family life.			Intellectual Product	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30
C104311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104311>	C173812|C173584	Interference with Social Activities due to Physical Condition or Medical Treatment Question|Has your physical condition or medical treatment interfered with your social activities|Interference with Social Activities due to Physical Condition or Medical Treatment	A question about whether an individual's physical condition or medical treatment interferes or has interfered with their social activities.			Intellectual Product	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30
C104312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104312>	C173812	Financial Difficulties due to Physical Condition or Medical Treatment Question|Financial Difficulties due to Physical Condition or Medical Treatment|Has your physical condition or medical treatment caused you financial difficulties	A question about whether an individual has or had financial difficulties due to their physical condition or medical treatment.			Intellectual Product	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30
C104313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104313>	C91103	Overall Health Rating During Past Week Question|How would you rate your overall health during the past week|Overall Health Rating During Past Week	A question about an individual's rating of their overall health during the past week.			Intellectual Product	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30
C104314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104314>	C173504	Overall Quality of Life Rating During Past Week Question|How would you rate your overall quality of life during the past week|Overall Quality of Life Rating During Past Week	A question about an individual's rating of the overall quality of life during the past week.			Intellectual Product	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30
C104315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104315>	C226694	Very Poor|Very poor	Of especially low value or worth.			Intellectual Product	Canine Quality of Life Survey|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30|ICDC Terminology|PRECINCT Property Terminology
C104316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104316>	C16617	HLA-G Gene|HLA-G|HLA-G|Major Histocompatibility Complex, Class I, G Gene	This gene is involved in antigen processing and presentation.	HLA-G Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104317>	C104316	HLA-G wt Allele|DADB-15K14.8|HLA-6.0|HLA-G Histocompatibility Antigen, Class I, G Gene|HLAG|MHC-G|Major Histocompatibility Complex, Class I, G wt Allele	Human HLA-G wild-type allele is located in the vicinity 6p21.3 and is approximately 4 kb in length. This allele, which encodes HLA class I histocompatibility antigen, alpha chain G protein, plays a role in MHC class I-mediated immune responses.	HLA-G wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104318>	C173981	Have Hot Flashes Question|Did you have hot flushes|Have Hot Flashes|Have Hot Flushes|I have hot flashes	A question about whether an individual has or had hot flashes.			Intellectual Product	FACT-ES Questionnaire|Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors 21
C104319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104319>	C91105	Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors 21|EORTC QLQ-GINET21|QLQ-G.I.NET21|QLQ-G.I.NET21	A questionnaire intended for use among patients with gastrointestinal-related neuroendocrine tumors, who vary in disease stage and treatments.			Intellectual Product	
C10431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10431>	C61063	Interleukin-2/Monoclonal Antibody 14G2A|IL-2/MOAB 14G2A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104320>	C176022|C173981	Look Flushed or Red Question|Have you noticed or been told by others that you looked flushed/red|Look Flushed or Red	A question about whether an individual appears or has appeared flushed or red.			Intellectual Product	Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors 21
C104321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104321>	C173981	Have Night Sweats Question|Do you have night sweats|Have Night Sweats|I have night sweats	A question about whether an individual has or had night sweats.			Intellectual Product	FACT-ES Questionnaire|Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors 21
C104322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104322>	C173518	Have Abdominal Discomfort Question|Do you have abdominal discomfort|Have Abdominal Discomfort|Have you had abdominal discomfort	A question about whether an individual has or had abdominal discomfort.			Intellectual Product	Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors 21|Quality of Life Questionnaire - Pancreatic Cancer 26
C104323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104323>	C111630	Feel Abdomen is Bloated Question|Did you have a bloated feeling in your abdomen|Feel Abdomen is Bloated|Feel Bloated in Abdomen|Have Bloated Feeling|Have Bloated Feeling in Abdomen|Have you had a bloated feeling in your abdomen	A question about whether an individual feels or felt their abdomen is bloated.			Intellectual Product	Bladder Cancer Muscle-Invasive 30 Questionnaire|Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors 21|Quality of Life Questionnaire - Pancreatic Cancer 26
C104324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104324>	C173981	Have Problem with Flatulence Question|Have Problem with Flatulence|Have you had a problem with passing wind / gas / flatulence	A question about whether an individual has or had a problem with flatulence.			Intellectual Product	Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors 21
C104325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104325>	C173981	Have Heartburn Question|Have Heartburn	A question about whether an individual has or had heartburn.			Intellectual Product	
C104326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104326>	C188083|C173398	Have Difficulty Eating Question|Have Difficulty Eating|Have you had difficulties with eating	A question about whether an individual has or had difficulty eating.			Intellectual Product	Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors 21
C104327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104327>	C20706	HLA Class I Histocompatibility Antigen, Alpha Chain G|HLA G Antigen|HLA-G|MHC Class I Antigen G|b2 Microglobulin	HLA class I histocompatibility antigen, alpha chain G (338 aa, ~38 kDa) is encoded by the human HLA-G gene. This protein is involved in the mediation of antigen presentation and processing.	HLA Class I Histocompatibility Antigen, Alpha Chain G		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104328>	C173933|C173812	Have Side Effects From Treatment Question|Have Side Effects From Treatment|Have you had side effects from your treatment	A question about whether an individual has or had side effects from their treatment.			Intellectual Product	Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors 21
C104329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104329>	C173981	Have Problem with Repeated Injections Question|Have Problem with Repeated Injections|Have you had a problem with repeated injections?	A question about whether an individual has or had a problem with repeated injections.			Intellectual Product	Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors 21
C10432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10432>	C61063	Carboplatin/Cyclophosphamide/Etanidazole|CBDCA/CTX/SR-2508			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104330>	C173934	Worry About Tumor Recurrence in Other Body Areas Question|Were you worried about the tumour recurring in other areas of the body|Worry About Tumor Recurrence in Other Body Areas	A question about whether an individual worries or worried about tumor recurrence in other areas of the body.			Intellectual Product	Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors 21
C104331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104331>	C105821	HOXA3 Gene|HOXA3|HOXA3|Homeobox A3 Gene	This gene plays a role in both transcription and anterior/posterior axis formation.	HOXA3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104332>	C104331	HOXA3 wt Allele|HOX1|HOX1E|Homeobox A3 wt Allele	Human HOXA3 wild-type allele is located in the vicinity of 7p15.2 and is approximately 46 kb in length. This allele, which encodes homeobox protein Hox-A3, is involved in both pattern formation and the regulation of gene expression.	HOXA3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104333>	C42095	Divergent Differentiation	A microscopic finding indicating that a tumor exhibits more than one line of histologic differentiation.			Finding	
C104334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104334>	C17207	Homeobox Protein Hox-A3|HOXA3|Homeo Box 1E|Homeo Box A3|Homeobox Protein Hox-1E	Homeobox protein Hox-A3 (443 aa, ~46 kDa) is encoded by the human HOXA3 gene. This protein plays a role in both the modulation of gene expression and anterior/posterior embryonic patterning.	Homeobox Protein Hox-A3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104335>	C105822	HOXB6 Gene|HOXB6|HOXB6|Homeobox B6 Gene	This gene is involved in the modulation of embryonic gene expression.	HOXB6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104336>	C104335	HOXB6 wt Allele|HOX2|HOX2B|HU-2|Homeobox B6 wt Allele|Hox-2.2	Human HOXB6 wild-type allele is located in the vicinity of 17q21.32 and is approximately 11 kb in length. This allele, which encodes homeobox protein Hox-B6, plays a role in transcription of patterning genes.	HOXB6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104337>	C17207	Homeobox Protein Hox-B6|HOXB6|Homeo Box 2B|Homeo Box B6|Homeobox Protein Hox-2.2|Homeobox Protein Hox-2B|Homeobox Protein Hu-2	Homeobox protein Hox-B6 (224 aa, ~25 kDa) is encoded by the human HOXB6 gene. This protein is involved in embryonic pattern formation.	Homeobox Protein Hox-B6		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104338>	C25802	HSPD1 Gene|HSPD1|HSPD1|Heat Shock 60kDa Protein 1 (Chaperonin) Gene	This gene plays a role in protein folding.	HSPD1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104339>	C104338	HSPD1 wt Allele|CPN60|GROEL|GroEL|HLD4|HSP-60|HSP60|HSP65|Heat Shock 60kDa Protein 1 (Chaperonin) wt Allele|HuCHA60|SPG13|Spastic Paraplegia 13 (Autosomal Dominant) Gene	Human HSPD1 wild-type allele is located in the vicinity of 2q33.1 and is approximately 30 kb in length. This allele, which encodes 60 kDa heat shock protein, mitochondrial, is involved in both import and folding of mitochondrial proteins. Mutation of the gene is associated with spastic paraplegia 13 and leukodystrophy hypomyelinating type 4.	HSPD1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10433>	C61063	Cyclosporine/Interferon Gamma|CYSP/IFN-G			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104340>	C17764	60 kDa Heat Shock Protein, Mitochondrial|60 kDa Chaperonin|CPN60|Chaperonin 60|HSP-60|HSPD1|Heat Shock Protein 60|Heat Shock Protein 65|Hsp60|HuCHA60|Mitochondrial Matrix Protein P1|P60 Lymphocyte Protein|Short Heat Shock Protein 60 Hsp60s1	60 kDa heat shock protein, mitochondrial (573 aa, ~61 kDa) is encoded by the human HSPD1 gene. This protein plays a role in mitochondrial protein folding.	60 kDa Heat Shock Protein, Mitochondrial		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104341>	C25982	IL20 Gene|IL20|IL20|Interleukin 20 Gene	This gene is involved in cytokine signaling.	IL20 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104342>	C104341	IL20 wt Allele|IL-20|IL10D|Interleukin 20 wt Allele|UNQ852/PRO1801|ZCYTO10	Human IL20 wild-type allele is located in the vicinity of 1q32 and is approximately 4 kb in length. This allele, which encodes interleukin-20 protein, plays a role in cytokine signaling through activation of signal transducer and activator of transcription 3.	IL20 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104343>	C20497	Interleukin-20|Cytokine Zcyto10|Four Alpha Helix Cytokine|IL-20|IL20|Interleukin 20	Interleukin-20 (176 aa, ~20 kDa) is encoded by the human IL20 gene. This protein is involved in the regulation of signal transducer and activator of transcription 3-mediated signaling.	Interleukin-20		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104344>	C25982	IL21 Gene|IL21|IL21|Interleukin 21 Gene	This gene plays a role in both cytokine signaling and immune responses.	IL21 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104345>	C104344	IL21 wt Allele|IL-21|Interleukin 21 wt Allele|Za11	Human IL21 wild-type allele is located within 4q26-q27 and is approximately 8 kb in length. This allele, which encodes interleukin-21 protein, is involved in both immunity and signaling.	IL21 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104346>	C20497	Interleukin-21|IL-21|IL21|Za11	Interleukin-21 (155 aa, ~18 kDa) is encoded by the human IL21 gene. This protein plays a role in both receptor-mediated signaling and the inflammatory response.	Interleukin-21		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104347>	C21550	IFNL2 Gene|IFNL2|IFNL2|Interferon, Lambda 2 Gene	This gene is involved in both immunomodulation and antiviral responses.	IFNL2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104348>	C104347	IFNL2 wt Allele|IL-28A|IL28A|Interferon, Lambda 2 wt Allele|Interleukin 28A Gene|ZCYTO20	Human IFNL2 wild-type allele is located in the vicinity of 19q13.13 and is approximately 2 kb in length. This allele, which encodes interferon lambda-2 protein, plays a role in both the response to viral infection and cytokine signaling.	IFNL2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104349>	C20464	Interferon Lambda-2|Cytokine Zcyto20|IFN-Lambda-2|IFNL2|IL-28A|Interferon Lambda 2|Interferon-Lambda 2|Interferon-Lambda-2|Interleukin-28A	Interferon lambda-2 (200 aa, ~22 kDa) is encoded by the human IFNL2 gene. This protein is involved in both cytokine-mediated signaling and antiviral activity.	Interferon Lambda-2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10434>	C61063	Floxuridine/Fluorouracil/Leucovorin Calcium/Levamisole|CF/5-FU/FUDR/LEV			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104350>	C21550	IFNL1 Gene|IFNL1|IFNL1|Interferon, Lambda 1 Gene	This gene plays a role in both the antiviral response and signaling.	IFNL1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104351>	C104350	IFNL1 wt Allele|IL-29|IL29|Interferon, Lambda 1 wt Allele|Interleukin 29 Gene|ZCYTO21	Human IFNL1 wild-type allele is located in the vicinity of 19q13.13 and is approximately 2 kb in length. This allele, which encodes interferon lambda-1 protein, is involved in both cytokine-dependent signaling and host defense.	IFNL1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104352>	C20464	Interferon Lambda-1|Cytokine Zcyto21|IFN-Lambda-1|IFNL1|IL-29|Interferon Lambda 1|Interferon-Lambda 1|Interferon-Lambda-1|Interleukin-29	Interferon lambda-1 (200 aa, ~22 kDa) is encoded by the human IFNL1 gene. This protein plays a role in both cytokine signaling and the response to viral infection.	Interferon Lambda-1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104354>	C104263	GZMB wt Allele|CCPI|CGL-1|CGL1|CSP-B|CSPB|CTLA1|CTSGL1|GRB|GranzB|Granzyme B (Granzyme 2, Cytotoxic T-Lymphocyte-Associated Serine Esterase 1) wt Allele|HLP|Protease, Serine, B Gene|SECT	Human GZMB wild-type allele is located in the vicinity of 14q11.2 and is approximately 3 kb in length. This allele, which encodes granzyme B protein, is involved in both proteolysis and cellular immune responses.	GZMB wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104355>	C91105	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30|EORTC QLC-C30|EORTC QLC-C30|The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)	A 30-item questionnaire about patient ability to function, symptoms related to the cancer and its treatment, overall health and quality of life, and perceived financial impact of cancer and its treatment.			Intellectual Product	
C104356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104356>	C28533|C20917	KIF2C Gene|KIF2C|KIF2C|Kinesin Family Member 2C Gene	This gene is involved in microtubule dynamics.	KIF2C Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104357>	C104356	KIF2C wt Allele|KNSL6|Kinesin Family Member 2C wt Allele|Kinesin-Like 6 (Mitotic Centromere-Associated Kinesin) Gene|MCAK|RP11-269F19.1	Human KIF2C wild-type allele is located in the vicinity of 1p34.1 and is approximately 28 kb in length. This allele, which encodes kinesin-like protein KIF2C, plays a role in the regulation of microtubule depolymerization.	KIF2C wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104358>	C17761|C16386	Kinesin-Like Protein KIF2C|KIF2C|Kinesin-Like 6|Kinesin-Like Protein 6|MCAK|Mitotic Centromere-Associated Kinesin	Kinesin-like protein KIF2C (725 aa, ~81 kDa) is encoded by the human KIF2C gene. This protein is involved in tubulin depolymerization.	Kinesin-Like Protein KIF2C		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104359>	C20103	KIR3DL1 Gene|KIR3DL1|KIR3DL1|Killer Cell Immunoglobulin Like Receptor, Three Ig Domains and Long Cytoplasmic Tail 1 Gene	This gene plays a role in natural killer cell activity.	KIR3DL1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10435>	C61063	Cimetidine/Cyclophosphamide/Indomethacin/Interleukin-2|cimetidine/CTX/IL-2/Indomethacin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104360>	C104359	KIR3DL1 wt Allele|AMB11|CD158E|CD158E1|CD158e1|CD158e1/2|CD158e2|KIR|KIR3DL1/S1|Killer Cell Immunoglobulin Like Receptor, Three Ig Domains and Long Cytoplasmic Tail 1 wt Allele|Killer Cell Immunoglobulin-Like Receptor, Three Domains, Long Cytoplasmic Tail, 1 Gene|NKAT3|NKB1|NKB1B|cl-11|cl-2|nkat3	Human KIR3DL1 wild-type allele is located in the vicinity of 19q13.4 and is approximately 142 kb in length. This allele, which encodes killer cell immunoglobulin-like receptor 3DL1 protein, is involved in the regulation of natural killer cell activity.	KIR3DL1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104361>	C18106	Killer Cell Immunoglobulin-Like Receptor 3DL1|CD158 Antigen-Like Family Member E|CD158e|CD158e Antigen|HLA-BW4-Specific Inhibitory NK Cell Receptor|KIR Antigen 3DL1|KIR3DL1|MHC Class I NK Cell Receptor|NK-receptor|NKAT-3|Natural Killer-Associated Transcript 3|p70 Killer Cell Inhibitory Receptor|p70 NK Receptor CL-2/CL-11|p70 Natural Killer Cell Receptor Clones CL-2/CL-11	Killer cell immunoglobulin-like receptor 3DL1 (444 aa, ~49 kDa) is encoded by the human KIR3DL1 gene. This protein plays a role in the modulation of cell-mediated cytotoxicity.	Killer Cell Immunoglobulin-Like Receptor 3DL1		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104362>	C20103	KLRC1 Gene|KLRC1|KLRC1|Killer Cell Lectin-Like Receptor Subfamily C, Member 1 Gene	This gene is involved in the regulation of immune responses.	KLRC1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104363>	C104362	KLRC1 wt Allele|CD159A|Killer Cell Lectin-Like Receptor Subfamily C, Member 1 wt Allele|Killer Cell Lectin-Like Receptor, Subfamily C, Member 1 Gene|NKG2|NKG2-A|NKG2-B|NKG2A	Human KLRC1 wild-type allele is located in the vicinity of 12p13 and is approximately 12 kb in length. This allele, which encodes NKG2-A/NKG2-B type II integral membrane protein, plays a role in the regulation of immune signaling pathways.	KLRC1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104364>	C18106	NKG2-A/NKG2-B Type II Integral Membrane Protein|C-Lectin Type II Protein|CD159 Antigen-Like Family Member A|CD159a|CD159a Antigen|KLRC1|NK Cell Receptor A|NKG2-1/B Activating NK Receptor|NKG2-A/B Type II Integral Membrane Protein|NKG2-A/B-Activating NK Receptor|Natural Killer Cell Lectin|Natural Killer Group Protein 2	NKG2-A/NKG2-B type II integral membrane protein (233 aa, ~26 kDa) is encoded by the human KLRC1 gene. This protein is involved in the modulation of cell-mediated immunity.	NKG2-A/NKG2-B Type II Integral Membrane Protein		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C104365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104365>	C173084	Concern About Home Life Disruption Question|Concern About Home Life Disruption|Were you concerned about disruption of home life	A question about whether an individual has or had concerns about disruption of their home life.			Intellectual Product	Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors 21
C104366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104366>	C173934	Worry About Future Health Question|Have you worried about your health in the future|Were you worried about your health in the future|Worried About Health in Future|Worried About Health in the Future|Worry About Future Health	A question about whether an individual worries or worried about their health in the future.			Intellectual Product	Bladder Cancer Muscle-Invasive 30 Questionnaire|Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors 21|Quality of Life Questionnaire - Pancreatic Cancer 26
C104367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104367>	C173812|C173348	Distress About Illness or Treatment to Those Close to You Question|Distress About Illness or Treatment to Those Close to You|How distressing has your illness or treatment been to those close to you	A question about whether an individual feels those close to them are distressed by their disease or treatment.			Intellectual Product	Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors 21
C104368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104368>	C173981	Have Weight Loss Problem Question|Has weight loss been a problem for you|Have Weight Loss Problem	A question about whether an individual has or had a weight loss problem.			Intellectual Product	Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors 21
C104369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104369>	C173981	Have Weight Gain Problem Question|Has weight gain been a problem for you|Have Weight Gain Problem	A question about whether an individual has or had a weight gain problem.			Intellectual Product	Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors 21
C10436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10436>	C61063	Amifostine/Carboplatin/Cisplatin|CBDCA/CDDP/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104370>	C173934	Worry About Test Results Question|Did you worry about the results of examinations and tests|Did you worry about the results of your tests|Worry About Results of Examinations and Tests|Worry About Test Results	A question about whether an individual worries or worried about test results.			Intellectual Product	Bladder Cancer Muscle-Invasive 30 Questionnaire|Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors 21
C104371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104371>	C173981|C173346	Have Aches or Pains in Muscles or Bones Question|Have Aches or Pains in Muscles or Bones|Have you had aches or pains in your muscles or bones	A question about whether an individual has or had aches or pains in their muscles or bones.			Intellectual Product	Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors 21
C104372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104372>	C173695	Have Limited Ability to Travel Question|Did you have any limitations in your ability to travel|Have Limited Ability to Travel	A question about whether an individual has or had limited ability to travel.			Intellectual Product	Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors 21
C104373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104373>	C3113|C2909	Pseudoangiomatous Stromal Hyperplasia|Breast Pseudoangiomatous Stromal Hyperplasia|PASH	A benign proliferation of the stromal cells in the breast.  It is classified as simple, when associated with the presence of slit-like spaces without erythrocytes and as fascicular/proliferative, when spindle cell proliferation without atypia is present.  It is often seen in breast tissue specimens as small foci associated with benign epithelial lesions.  Pseudoangiomatous stromal hyperplasia presenting as a well-circumscribed palpable mass is rare.			Disease or Syndrome	
C104374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104374>	C176537|C173812	Have Problem Receiving Adequate Disease and Treatment Information Question|Have Problem Receiving Adequate Disease and Treatment Information|Have you had problems receiving adequate information about your disease and treatment	A question about whether an individual has or had a problem receiving adequate disease and treatment information.			Intellectual Product	Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors 21
C104375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104375>	C173812|C173704|C173160	Feel Disease or Treatment Adversely Affects Sex Life Question|Feel Disease or Treatment Adversely Affects Sex Life|Has the disease or treatment affected your sex life (for the worse)	A question about whether an individual feels or felt that their disease or treatment adversely affected their sex life.			Intellectual Product	Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors 21
C104376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104376>	C54306	GAGE2A Gene|G Antigen 2A Gene|GAGE2A|GAGE2A	This gene may play a role in tumorigenesis.	GAGE2A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104377>	C104376	GAGE2A wt Allele|CT4.2|G Antigen 2A wt Allele|GAGE-2|GAGE-2A|GAGE2	Human GAGE2A wild-type allele is located in the vicinity of Xp11.23 and is approximately 7 kb in length. This allele, which encodes G antigen 2A protein, may play a role in tumorigenesis.	GAGE2A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104378>	C54672	G Antigen 2A|Cancer/Testis Antigen 4.2|Cancer/Testis Antigen Family 4, Member 2|G Antigen 2|G Antigen 2A/2B	G antigen 2A (116 aa, ~13 kDa) is encoded by the human GAGE2A gene. This protein may be involved in tumorigenesis.	G Antigen 2A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104379>	C20921	FGD4 Gene|FGD4|FGD4|FYVE, RhoGEF and PH Domain Containing 4 Gene	This gene plays a role in regulation of the actin cytoskeleton and cell shape.	FGD4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10437>	C61007	Dipyridamole/Fluorouracil/PALA|DP/5-FU/PALA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104380>	C104379	FGD4 wt Allele|CMT4H|FGD1 Family, Member 4 Gene|FRABP|FYVE, RhoGEF and PH Domain Containing 4 wt Allele|Frabin Gene|ZFYVE6	Human FGD4 wild-type allele is located in the vicinity of 12p11.21 and is approximately 246 kb in length. This allele, which encodes FYVE, RhoGEF and PH domain-containing protein 4, is involved in regulation of the actin cytoskeleton and cell shape. Mutations in this gene are associated with Charcot-Marie-Tooth disease type 4H (CMT4H).	FGD4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104381>	C17494	FYVE, RhoGEF and PH Domain-Containing Protein 4|Actin Filament-Binding Protein Frabin|Actin-Filament Binding Protein Frabin|FGD1 Family, Member 4|FGD1-Related F-Actin-Binding Protein|FGD4|Frabin|Zinc Finger FYVE Domain-Containing Protein 6	FYVE, RhoGEF and PH domain-containing protein 4 (766 aa, ~87 kDa) is encoded by the human FGD4 gene. This protein plays a role in regulation of the actin cytoskeleton and cell shape.	FYVE, RhoGEF and PH Domain-Containing Protein 4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104382>	C18568	FGF23 Gene|FGF23|FGF23|Fibroblast Growth Factor 23 Gene	This gene is involved in phosphate homeostasis.	FGF23 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104383>	C104382	FGF23 wt Allele|ADHR|FGF-23|FGFN|Fibroblast Growth Factor 23 wt Allele|HPDR2|HYPF|PHPTC	Human FGF23 wild-type allele is located in the vicinity of 12p13.3 and is approximately 12 kb in length. This allele, which encodes fibroblast growth factor 23 protein, plays a role in regulation of phosphate homeostasis. Mutations in this gene are associated with autosomal dominant hypophosphatemic rickets (ADHR) and familial tumoral calcinosis with hyperphosphatemia. It is overexpressed in oncogenic hypophosphatemic osteomalacia (OHO).	FGF23 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104384>	C20426	Fibroblast Growth Factor 23|FGF-23|Phosphatonin|Tumor-Derived Hypophosphatemia Inducing Factor|Tumor-Derived Hypophosphatemia-Inducing Factor	Fibroblast growth factor 23 (251 aa, ~28 kDa) is encoded by the human FGF23 gene. This protein is involved in inhibition of renal tubular phosphate transport.	Fibroblast Growth Factor 23		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104385>	C21344	VEGFD Gene|FIGF|VEGFD|Vascular Endothelial Growth Factor D Gene	This gene plays a role in angiogenesis, lymphangiogenesis, and endothelial cell growth.	VEGFD Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104386>	C104385	VEGFD wt Allele|FIGF|VEGF-D|VEGFD|Vascular Endothelial Growth Factor D wt Allele|c-Fos Induced Growth Factor (Vascular Endothelial Growth Factor D) Gene	Human VEGFD wild-type allele is located in the vicinity of Xp22.2 and is approximately 39 kb in length. This allele, which encodes vascular endothelial growth factor D, is involved in endothelial cell growth, angiogenesis, and lymphangiogenesis.	VEGFD wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104387>	C20424	Vascular Endothelial Growth Factor D|FIGF|Fos-Induced Growth Factor|VEGF-D|VEGFD|c-Fos-Induced Growth Factor	Vascular endothelial growth factor D (354 aa, ~40 kDa) is encoded by the human VEGFD gene. This protein plays a role in angiogenesis, lymphangiogenesis, and endothelial cell growth, and also has effects on the permeability of blood vessels.	Vascular Endothelial Growth Factor D		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104388>	C25941	FKBP8 Gene|FK506 Binding Protein 8, 38kDa Gene|FKBP8|FKBP8	This gene is involved in immunoregulation.	FKBP8 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104389>	C104388	FKBP8 wt Allele|FK506 Binding Protein 8, 38kDa wt Allele|FKBP-38|FKBP-8|FKBP38|FKBPr38|PPIase FKBP8|hFKBP38	Human FKBP8 wild-type allele is located in the vicinity of 19p12 and is approximately 12 kb in length. This allele, which encodes peptidyl-prolyl cis-trans isomerase FKBP8 protein, plays a role in immunoregulation, protein folding, and protein trafficking.	FKBP8 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10438>	C61063	Daunorubicin/Tamoxifen|DNR/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104390>	C16759	Peptidyl-Prolyl Cis-Trans Isomerase FKBP8|38 kDa FK506-Binding Protein|EC 5.2.1.8|FK506-Binding Protein 8|FKBP8|Rotamase	Peptidyl-prolyl cis-trans isomerase FKBP8 (412 aa, ~45 kDa) is encoded by the human FKBP8 gene. This protein is involved in immunoregulation, protein folding, and protein trafficking and may play a role in neurons associated with memory.	Peptidyl-Prolyl Cis-Trans Isomerase FKBP8		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104391>	C26000	FMOD Gene|FMOD|FMOD|Fibromodulin Gene	This gene may play a role in the assembly of the extracellular matrix.	FMOD Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104392>	C104391	FMOD wt Allele|FM|Fibromodulin wt Allele|SLRR2E	Human FMOD wild-type allele is located in the vicinity of 1q32 and is approximately 11 kb in length. This allele, which encodes fibromodulin protein, may be involved in the assembly of the extracellular matrix.	FMOD wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104393>	C17351	Fibromodulin|Collagen-Binding 59 kDa Protein|FMOD|Fibromodulin Proteoglycan|KSPG Fibromodulin|Keratan Sulfate Proteoglycan Fibromodulin	Fibromodulin (376 aa, ~43 kDa) is encoded by the human FMOD gene. This protein may play a role in the assembly of the extracellular matrix.	Fibromodulin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104394>	C20420	FOXP3 Gene|FOXP3|FOXP3|Forkhead Box P3 Gene	This gene is involved in transcription regulation and the immune response.	FOXP3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104395>	C104394	FOXP3 wt Allele|AIID|DIETER|Forkhead Box P3 wt Allele|IPEX|JM2|PIDX|SCURFIN|XPID	Human FOXP3 wild-type allele is located in the vicinity of Xp11.23 and is approximately 14 kb in length. This allele, which encodes forkhead box protein P3, plays a role in transcription regulation and the immune response. Mutations in this gene are associated with immunodeficiency polyendocrinopathy, enteropathy, X-linked syndrome (IPEX).	FOXP3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104396>	C17207	Forkhead Box Protein P3|FOXP3|FOXP3delta7|Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked|Scurfin	Forkhead box protein P3 (431 aa, ~47 kDa) is encoded by the human FOXP3 gene. This protein is involved in transcription regulation and the immune response.	Forkhead Box Protein P3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104397>	C25994	FSHB Gene|FSHB|FSHB|Follicle Stimulating Hormone, Beta Polypeptide Gene	This gene plays a role in induction of egg and sperm production.	FSHB Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104398>	C104397	FSHB wt Allele|FSH-B|Follicle Stimulating Hormone, Beta Polypeptide wt Allele	Human FSHB wild-type allele is located in the vicinity of 11p13 and is approximately 4 kb in length. This allele, which encodes follitropin subunit beta protein, is involved in induction of sperm and egg production. Mutations in this gene are associated with follicle-stimulating hormone deficiency, isolated.	FSHB wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104399>	C1746	Follitropin Subunit Beta|FSH-beta|Follicle Stimulating Hormone Beta Subunit|Follicle Stimulating Hormone, Beta Polypeptide|Follitropin Beta Chain	Follitropin subunit beta (129 aa, ~15 kDa) is encoded by the human FSHB gene. This protein plays a role in induction of egg and sperm production.	Follitropin Subunit Beta		Amino Acid, Peptide, or Protein|Hormone	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10439>	C61063	Cisplatin/Cytarabine/Dexamethasone/Etoposide/Sargramostim|ARA-C/CDDP/DM/GM-CSF/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1043>	C699	CGP-6809|EDMN|ethyl-6-deoxy-3,5-di-O-methyl-6-(3-methyl-3-nitrosoureido)-alpha-D-glucofuranoside	A water-soluble nitrosourea that cross-links with DNA, causing inhibition of DNA synthesis.			Organic Chemical|Pharmacologic Substance	NCI Drug Dictionary Terminology
C104400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104400>	C26147	FUT4 Gene|FUT4|FUT4|Fucosyltransferase 4 Gene	This gene is involved in the generation of fucosylated carbohydrate structures.	FUT4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104401>	C104400	FUT4 wt Allele|Alpha (1,3) Fucosyltransferase, Myeloid-Specific Gene|CD15 Fucosyltransferase Gene|ELFT|FCT3A|FUC-TIV|FUTIV|Fucosyltransferase 4 (Alpha (1,3) Fucosyltransferase, Myeloid-Specific) Gene|Fucosyltransferase 4 wt Allele|LeX Fucosyltransferase Gene|SSEA-1 Fucosyltransferase Gene	Human FUT4 wild-type allele is located in the vicinity of 11q21 and is approximately 6 kb in length. This allele, which encodes alpha-(1,3)-fucosyltransferase 4 protein, plays a role in the generation of fucosylated carbohydrate structures.	FUT4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104402>	C17434	Alpha-(1,3)-Fucosyltransferase 4|4-Galactosyl-N-Acetylglucosaminide 3-Alpha-L-Fucosyltransferase|Alpha-(1,3)-Fucosyltransferase|Alpha-3-Fucosyltransferase|CD15 Fucosyltransferase|EC 2.4.1.152|EC 2.4.1.65, Formerly|ELAM Ligand Fucosyltransferase|ELAM-1 Ligand Fucosyltransferase|FUT4|Fuc-TIV|FucT-IV|Fucosyltransferase 4|Fucosyltransferase IV|Galactoside 3-L-Fucosyltransferase|LeX Fucosyltransferase|Lewis X Fucosyltransferase|SSEA-1 Fucosyltransferase|Stage-Specific Embryonic Antigen 1 Fucosyltransferase	Alpha-(1,3)-fucosyltransferase 4 (530 aa, ~60 kDa) is encoded by the human FUT4 gene. This protein is involved in the generation of fucosylated carbohydrate structures.	Alpha-(1,3)-Fucosyltransferase 4		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104403>	C20923	FZD8 Gene|FZD8|FZD8|Frizzled Class Receptor 8 Gene	This gene plays a role in cell signaling.	FZD8 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104404>	C104403	FZD8 wt Allele|FZ-8|Frizzled (Drosophila) Homolog 8 Gene|Frizzled 8, Seven Transmembrane Spanning Receptor Gene|Frizzled Class Receptor 8 wt Allele|Frizzled Family Receptor 8 Gene|Frizzled Homolog 8 (Drosophila) Gene|Frizzled, Drosophila, Homolog of, 8 Gene|hFZ8	Human FZD8 wild-type allele is located in the vicinity of 10p11.2 and is approximately 3 kb in length. This allele, which encodes frizzled-8 protein, is involved in beta-catenin signaling.	FZD8 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104405>	C18239	Frizzled-8|FZ-8|Frizzled 8|Frizzled Family Receptor 8|Frizzled Homolog 8|hFZ8	Frizzled-8 (694 aa, ~73 kDa) is encoded by the human FZD8 gene. This protein plays a role in beta-catenin signaling.	Frizzled-8		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104406>	C21295	LGALS1 Gene|LGALS1|LGALS1|Lectin, Galactoside-Binding, Soluble, 1 Gene	This gene may play a role in modulating cell-cell and cell-matrix interactions.	LGALS1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104407>	C104406	LGALS1 wt Allele|GAL1|GBP|HBL|HLBP14|HPL|Lectin, Galactoside-Binding, Soluble, 1 wt Allele	Human LGALS1 wild-type allele is located in the vicinity of 22q13.1 and is approximately 4 kb in length. This allele, which encodes galectin-1 protein, may be involved in modulating cell-cell and cell-matrix interactions and in regulating apoptosis.	LGALS1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104408>	C17728	Galectin-1|14 kDa Laminin-Binding Protein|14 kDa Lectin|Beta-Galactoside-Binding Lectin L-14-I|Beta-Galactoside-Binding Protein 14kDa|Galaptin|Galectin 1|LGALS1|Lactose-Binding Lectin 1|Putative MAPK-Activating Protein PM12|S-Lac Lectin 1	Galectin-1 (135 aa, ~15 kDa) is encoded by the human LGALS1 gene. This protein may play a role in modulating cell-cell and cell-matrix interactions and may regulate apoptosis, cell proliferation and cell differentiation.	Galectin-1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104409>	C25939	GAPDH Gene|GAPDH|GAPDH|Glyceraldehyde-3-Phosphate Dehydrogenase Gene	This gene is involved in carbohydrate metabolism.	GAPDH Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10440>	C61007	Dexamethasone/Doxorubicin/Quinine/Verapamil/Vincristine|DM/DOX/QUIN/VCR/VPAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104410>	C104409	GAPDH wt Allele|G3PD|GAPD|Glyceraldehyde-3-Phosphate Dehydrogenase wt Allele	Human GAPDH wild-type allele is located in the vicinity of 12p13.31 and is approximately 4 kb in length. This allele, which encodes glyceraldehyde-3-phosphate dehydrogenase protein, plays a role in carbohydrate metabolism.	GAPDH wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104411>	C16946	Glyceraldehyde-3-Phosphate Dehydrogenase|Aging-Associated Gene 9 Protein|EC 1.2.1.12|GAPDH|Peptidyl-Cysteine S-Nitrosylase GAPDH	Glyceraldehyde-3-phosphate dehydrogenase (335 aa, ~36 kDa) is encoded by the human GAPDH gene. This protein is involved in carbohydrate metabolism.	Glyceraldehyde-3-Phosphate Dehydrogenase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104412>	C471|C1742	Roneparstat|100NA,RO-H|RONEPARSTAT|SST0001	An N-acetylated, glycol-split form of heparin that is devoid of anticoagulant activity and is an inhibitor of heparanase with antineoplastic and antiangiogenic activities. Upon subcutaneous administration, roneparstat inhibits the activity of heparanase. This prevents the heparanase-mediated cleavage of heparan sulfate (HS) proteoglycans on cell surfaces and within the extracellular matrix. In addition, this agent prevents the heparanase-induced production of a number of angiogenic growth factors, including matrix metalloproteinase-9, hepatocyte growth factor and vascular endothelial growth factor. Altogether, this leads to an inhibition of both tumor cell growth and angiogenesis. Heparanase, an enzyme that is responsible for the proteolytic cleavage of proteoglycans, is upregulated in a variety of tumor cell types and promotes tumor cell growth; it plays a key role in tumor cell invasion, metastasis and angiogenesis.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C104413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104413>	C2152|C129825	Umbralisib|2-((1S)-1-(4-Amino-3-(3-fluoro-4-(1-methylethoxy)phenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-1-benzopyran-4-one|RP-5264|RP5264|TGR 1202|TGR-1202|TGR1202|UMBRALISIB	An orally bioavailable, selective inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinases (PI3K) with potential antineoplastic activity.  PI3K-delta inhibitor TGR-1202 inhibits PI3K and prevents the activation of the PI3K/AKT kinase signaling pathway. This decreases proliferation and induces cell death in susceptible tumor cells.  Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in tumor cells and cells of the hematopoietic lineage. The targeted inhibition of PI3K-delta allows for PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.	Umbralisib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C104414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104414>	C471	Geranylgeranyltransferase I Inhibitor|GGTI-I|GGTase-I Inhibitor	A substance that inhibits protein geranylgeranyltransferase type 1 (GGTase-I), with potential antineoplastic activity. GGTase-I is involved in the posttranslational modification of a number of oncogenic GTPases, including K-Ras, N-Ras, RhoA, RhoC, Cdc42, RalA, RalB and Rac1. Inhibition of the prenylation of these oncogenic proteins inhibits both their oncogenic activity and membrane localization. This may result in cell cycle arrest and apoptosis. Protein geranylgeranylation, catayzed by GGTase-I, plays a critical role in malignant transformation and cancer cell proliferation, migration and invasion.	Geranylgeranyltransferase I Inhibitor		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C104415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104415>	C203001|C119988	Gene-Modified HIV-Protected Hematopoietic Stem Cells	Autologous hematopoietic stem cells (HSCs) genetically modified to be resistant to infection by human immunodeficiency virus (HIV). Allogeneic human autologous HSCs are isolated and transduced ex vivo with three different anti-HIV genes. Upon infusion into the HIV-infected lymphoma patient, the gene-modified HIV-protected HSCs are resistant to HIV entry and replication thereby preventing HIV infection in these proliferating stem cells and any differentiated cells that they give rise to. This results in the formation of immune cells resistant to HIV which also may be able to destroy HIV-infected cells.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology
C104416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104416>	C20420	GATA6 Gene|GATA Binding Protein 6 Gene|GATA6|GATA6	This gene plays a role in regulation of cellular differentiation and organogenesis during development.	GATA6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104417>	C104416	GATA6 wt Allele	Human GATA6 wild-type allele is located within 18q11-q12 and is approximately 33 kb in length. This allele, which encodes transcription factor GATA-6 protein, is involved in regulation of cellular differentiation and organogenesis during development. Mutations in this gene are associated with several congenital defects.	GATA6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104418>	C17207	Transcription Factor GATA-6|GATA-Binding Factor 6|GATA-Binding Protein 6	Transcription factor GATA-6 (595 aa, ~60 kDa) is encoded by the human GATA6 gene. This protein plays a role in regulation of cellular differentiation and organogenesis during development.	Transcription Factor GATA-6		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104419>	C1978	Autologous GM-CSF-secreting Lethally Irradiated Leukemia Cell Vaccine|Autologous GVAX Leukemia Vaccine	An autologous cancer vaccine composed of lethally irradiated leukemia cells that are genetically modified to secrete the immunostimulatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Upon intradermal injection, the autologous GM-CSF-secreting lethally irradiated leukemia cell vaccine secretes GM-CSF. In turn, GM-CSF may stimulate the immune system to attack tumor cells by enhancing the activation of dendritic cells (DCs) and promoting antigen presentation to both B- and T-lymphocytes. In addition, GM-CSF promotes antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function.	Autologous GM-CSF-secreting Lethally Irradiated Leukemia Cell Vaccine		Cell|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C10441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10441>	C61063	Carboplatin/Etoposide/Monoclonal Antibody 3F8|CBDCA/MOAB 3F8/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104420>	C1511	Zirconium Zr 89 DFO-MSTP2109A|89Zr-DFO-MSTP2109A	A radioimmunoconjugate composed of the radioisotope zirconium Zr 89 conjugated to an antibody that targets six transmembrane epithelial antigen of the prostate 1 (STEAP1) that can potentially be used as a prostate cancer tracer during positron emission tomography (PET). Upon administration of zirconium Zr 89 DFO-MSTP2109A, the antibody moiety DFO-MSTP2109A binds to STEAP1 on prostate cancer cells. In turn, Zr 89 allows for the visualization of those cells using PET. STEAP1, a six-transmembrane domain protein, is overexpressed on the surface of prostate cancer cells.	Zirconium Zr 89 DFO-MSTP2109A		Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C104421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104421>	C25804	GBA1 Gene|GBA|GBA Gene|GBA1|GBA1|Glucosylceramidase Beta 1 Gene	This gene plays a role in the turnover of cellular membranes through the hydrolysis of glucosylceramides and other complex lipids.	GBA Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104422>	C104421	GBA1 wt Allele|Beta-Glucosidase, Acid Gene|GBA|GBA wt Allele|GC|GCB|GLUC|Glucosidase, Beta, Acid Gene|Glucosidase, Beta; Acid (includes Glucosylceramidase) Gene|Glucosylceramidase Beta 1 wt Allele	Human GBA1 wild-type allele is located in the vicinity of 1q22 and is approximately 10 kb in length. This allele, which encodes lysosomal acid glucosylceramidase protein, is involved in the production of ceramides from glucosylceramides. Mutations in this gene are associated with Gaucher disease and with increased susceptibility to Lewy body dementia or late-onset Parkinson disease.	GBA wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104423>	C16701	Lysosomal Acid Glucosylceramidase|Acid Beta-Glucosidase|Alglucerase|Beta-GC|Beta-Glucocerebrosidase|Beta-Glucosylceramidase 1|Cholesterol Glucosyltransferase|Cholesteryl-Beta-Glucosidase|D-Glucosyl-N-Acylsphingosine Glucohydrolase|EC 3.2.1.45|GBA|GBA1|Glucocerebrosidase|Glucosylceramidase|Glucosylceramidase|Glucosylceramidase Beta|Glucosylceramidase Beta 1|Imiglucerase|Lysosomal Acid GCase|Lysosomal Cholesterol Glycosyltransferase|Lysosomal Galactosylceramidase|Lysosomal Glucocerebrosidase|Lysosomal Glycosylceramidase|SGTase	Lysosomal acid glucosylceramidase (536 aa, ~60 kDa) is encoded by the human GBA1 gene. This protein plays a role in the hydrolysis of glucosylceramides yielding free ceramide.	Glucosylceramidase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104424>	C25804	GBA2 Gene|GBA2|GBA2|Glucosylceramidase Beta 2 Gene	This gene plays a role in bile acid hydrolysis.	GBA2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104425>	C104424	GBA2 wt Allele|AD035|DKFZp762K054|Glucosidase, Beta (Bile Acid) 2 Gene|Glucosylceramidase Beta 2 wt Allele|KIAA1605	Human GBA2 wild-type allele is located in the vicinity of 9p13.3 and is approximately 13 kb in length. This allele, which encodes non-lysosomal glucosylceramidase protein, is involved in the generation and prevention of glycolipid accumulation and bile acid hydrolysis.	GBA2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104426>	C16701	Non-Lysosomal Glucosylceramidase|Beta-Glucocerebrosidase 2|Beta-Glucosidase 2|Bile Acid Beta-Glucosidase|EC 3.2.1.45|GBA2|Glucosylceramidase 2|NLGase	Non-lysosomal glucosylceramidase (927, ~105 kDa) is encoded by the human GBA2 gene. This protein plays a role in the generation and prevention of glycolipid accumulation.	Non-Lysosomal Glucosylceramidase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104427>	C25994	GHRL Gene|GHRL|GHRL|Ghrelin/Obestatin Prepropeptide Gene	This gene is involved in regulating growth hormone release and satiety, thirst and anxiety.	GHRL Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104428>	C104427	GHRL wt Allele|Ghrelin/Obestatin Prepropeptide wt Allele|MTLRP	Human GHRL wild-type allele is located within 3p26-p25 and is approximately 7 kb in length. This allele, which encodes appetite-regulating hormone protein, plays a role in satiety, thirst and anxiety and regulating growth hormone release.	GHRL wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104429>	C1746	Appetite-Regulating Hormone|Ghrelin|Ghrelin, Growth Hormone Secretagogue Receptor Ligand|Growth Hormone Secretagogue|Growth Hormone-Releasing Peptide|Motilin-Related Peptide|Obestatin|Protein M46	Appetite-regulating hormone (117 aa, ~13 kDa) is encoded by the human GHRL gene. This protein is involved in satiety, thirst and anxiety and regulating growth hormone release.	Appetite-Regulating Hormone		Amino Acid, Peptide, or Protein|Hormone	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10442>	C61063	Cyclophosphamide/Doxorubicin/Etoposide/Prednisolone/Vincristine|CTX/DOX/PRDL/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104430>	C25994	GIP Gene|GIP|GIP|Gastric Inhibitory Polypeptide Gene	This gene plays a role in glucose homeostasis.	GIP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104431>	C104430	GIP wt Allele|Gastric Inhibitory Polypeptide wt Allele	Human GIP wild-type allele is located within 17q21.3-q22 and is approximately 10 kb in length. This allele, which encodes gastric inhibitory polypeptide, is involved in insulin secretion and glucose homeostasis.	GIP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104432>	C1746	Gastric Inhibitory Polypeptide|GIP|Glucose-Dependent Insulinotropic Polypeptide|Incretin Hormone	Gastric inhibitory polypeptide (153 aa, ~17 kDa) is encoded by the human GIP gene. This protein plays a role in insulin secretion and glucose homeostasis.	Gastric Inhibitory Polypeptide		Amino Acid, Peptide, or Protein|Hormone	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104433>	C16946	Glutathione Peroxidase 2|EC 1.11.1.9|GPX2|Gastrointestinal Glutathione Peroxidase|Glutathione Peroxidase-Gastrointestinal|Glutathione Peroxidase-Related Protein 2	Glutathione peroxidase 2 (190 aa, ~22 kDa) is encoded by the human GPX2 gene. This protein is involved in detoxification and digestion.	Glutathione Peroxidase 2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104434>	C25939	GPX2 Gene|GPX2|GPX2|Glutathione Peroxidase 2 (Gastrointestinal) Gene	This gene is involved in digestion.	GPX2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104435>	C104434	GPX2 wt Allele|GI-GPx|GPRP|GPRP-2|GPx-2|GPx-GI|GSHPX-GI|GSHPx-2|Glutathione Peroxidase 2 (Gastrointestinal) wt Allele	Human GPX2 wild-type allele is located in the vicinity of 14q23.3 and is approximately 4 kb in length. This allele, which encodes glutathione peroxidase 2 protein, plays a role in digestion and detoxification.	GPX2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104437>	C43578	Treatment Emergent Flag|treatmentEmergentFlag|treatmentEmergentIndicator	An indication as to whether an event began or was made worse by the treatment.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Class and Attribute Terminology|BRIDG Terminology
C104438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104438>	C45561	CE Mark	A label which indicates that a product conforms with the essential requirements of the applicable European Community directives.			Conceptual Entity	
C104439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104439>	C25499	First in Human|firstInHuman	The first time an active substance or agent is administered to a human during a study.			Event	BRIDG Class and Attribute Terminology|BRIDG Terminology
C10443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10443>	C61063	Cyclophosphamide/Dexverapamil/Doxorubicin/Etoposide/Prednisone/Vincristine|CTX/DOX/PRED/R-VPAM/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104440>	C25207	Standard Time|standardTime	Geographic local time without an offset for daylight saving time.			Temporal Concept	BRIDG Attribute Terminology|BRIDG Terminology
C104441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104441>	C25162	Non-Reason Code|nonReasonCode|nonReasonCode	A coded value specifying that an expected reason for something occurring was not the motivation, cause or rationale in this particular case.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Class and Attribute Terminology|BRIDG Terminology
C104442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104442>	C25463	Distinct Product Count|distinctProductCount	The determination of the number of distinct products.			Quantitative Concept	BRIDG Attribute Terminology|BRIDG Terminology
C104443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104443>	C91105	MD Anderson Dysphagia Inventory|M.D. Anderson Dysphagia Inventory|MDADI|MDADI|MDDI01	A standardized 20-item self-administered questionnaire, developed by Chen AY et al. in 2001 that utilizes a five-point rating scale to assess the impact of dysphagia on the quality of life of patients with head and neck cancer.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C104444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104444>	C173787|C173695|C173454	Ability to Swallow Limits Daily Activities Question|Ability to Swallow Limits Daily Activities|My swallowing ability limits my day-to-day activities	A question about whether an individual's ability to swallow limits or has limited their daily activities.			Intellectual Product	MD Anderson Dysphagia Inventory
C104445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104445>	C173601	Embarrassed by My Eating Habits Question|Embarrassed by My Eating Habits|I am embarrassed by my eating habits	A question about whether an individual is or has been embarrassed by their eating habits.			Intellectual Product	MD Anderson Dysphagia Inventory
C104446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104446>	C173398|C173160	Feel Like People Have Difficulty Cooking for Me Question|Feel Like People Have Difficulty Cooking for Me|People have difficulty cooking for me	A question about whether an individual feels or felt that people had difficulty cooking for them.			Intellectual Product	MD Anderson Dysphagia Inventory
C104447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104447>	C173454	Swallowing More Difficult at End of Day Question|Swallowing More Difficult at End of Day|Swallowing is more difficult at the end of the day	A question about whether an individual's swallowing is or was more difficult at the end of the day.			Intellectual Product	MD Anderson Dysphagia Inventory
C104448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104448>	C173160	Do Not Feel Self-Conscious When Eating Question|Do Not Feel Self-Conscious When Eating|Does Not Feel Self-Conscious When Eating|I do not feel self-conscious when I eat	A question about whether an individual does not feel or didn't feel self conscious when eating.			Intellectual Product	MD Anderson Dysphagia Inventory
C104449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104449>	C125410	Upset by Swallowing Problem Question|I am upset by my swallowing problem|Upset by Swallowing Problem	A question about whether an individual is or was upset by their swallowing problem.			Intellectual Product	MD Anderson Dysphagia Inventory
C10444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10444>	C61063	Cyclophosphamide/Dexverapamil/Doxorubicin/Etoposide/Prednisolone/Vincristine|CTX/DOX/PRDL/R-VPAM/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104450>	C173454	Swallowing Takes Great Effort Question|Swallowing Takes Great Effort|Swallowing takes great effort	A question about whether an individual feels or felt that swallowing takes great effort.			Intellectual Product	MD Anderson Dysphagia Inventory
C104451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104451>	C173454	Does Not Go Out due to Swallowing Problem Question|Do Not Go Out Due to Swallowing Problem|Does Not Go Out due to Swallowing Problem|I do not go out because of my swallowing problem	A question about whether an individual does or does not go out due to their swallowing problem.			Intellectual Product	MD Anderson Dysphagia Inventory
C104452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104452>	C125410	Swallowing Difficulty Causes Lost Income Question|My swallowing difficulty has caused me to lose income|Swallowing Difficulty Causes Lost Income	A question about whether an individual's swallowing difficulties result in or have resulted in lost income.			Intellectual Product	MD Anderson Dysphagia Inventory
C104453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104453>	C173454	Takes Longer to Eat due to Swallowing Problem Question|It takes me longer to eat because of my swallowing problem|Takes Longer to Eat due to Swallowing Problem	A question about whether an individual feels or felt it takes longer to eat because of their swallowing problem.			Intellectual Product	MD Anderson Dysphagia Inventory
C104454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104454>	C173045	Asked Why Unable to Eat Something Question|Asked Why Unable to Eat Something|People ask me, Why can't you eat that	A question about whether an individual is or was questioned about their ability to eat something.			Intellectual Product	MD Anderson Dysphagia Inventory
C104455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104455>	C91103	Others Irritated by My Eating Problem Question|'Others Irritated by My Eating Problem'|Other people are irritated by my eating problem	A question about whether others are irritated by an individual's eating problem.			Intellectual Product	MD Anderson Dysphagia Inventory
C104456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104456>	C173134	Cough When Drinking Liquids Question|Cough When Drinking Liquids|I cough when I try to drink liquids	A question about whether an individual coughs or coughed when they drink liquids.			Intellectual Product	MD Anderson Dysphagia Inventory
C104457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104457>	C26063	Exosome	A secretory vesicle between 30 and 90 nm in diameter that can play a role in receptor recycling, plasma membrane protein shedding, and the secretion of proteins and RNA.	Exosome		Cell Component	CTRP Biomarker Terminology|CTRP Terminology
C104458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104458>	C173695|C173454	Swallowing Problems Limit Social and Personal Life Question|My swallowing problems limit my social and personal life	A question about whether an individual's swallowing problems limit or have limited their social and personal life.			Intellectual Product	MD Anderson Dysphagia Inventory
C104459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104459>	C19928	BID Gene Product	A protein encoded by the human BID gene.			Amino Acid, Peptide, or Protein	
C10445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10445>	C61063	Fluorouracil/Idoxuridine/Leucovorin Calcium|CF/5-FU/IUDR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104460>	C104459	Truncated BID|Truncated BH3-Interacting Domain Death Agonist|tBID	Truncated BID is encoded by the human BID gene and is a C-terminal peptide that results from caspase-8 cleavage of the BH3-interacting domain death agonist protein. This protein fragment localizes with the mitochondrial membrane and can stimulate the release of cytochrome c and promote the progression of apoptosis.	Truncated BID		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104461>	C54306	GAGE8 Gene|G Antigen 8 Gene|GAGE8|GAGE8	This gene may be involved in transformation.	GAGE8 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104462>	C173160	Feel Free to Go Out to Eat with Friends, Neighbors and Relatives Question|Feel Free to Go Out to Eat with Friends, Neighbors and Relatives|I feel free to go out to eat with my friends, neighbors, and relatives	A question about whether an individual feels or felt free to go out to eat with friends, neighbors and relatives.			Intellectual Product	MD Anderson Dysphagia Inventory
C104463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104463>	C104461	GAGE8 wt Allele|CT4.8|Cancer/Testis Antigen Family 4, Member 8 Gene|G Antigen 8 wt Allele|GAGE-8	Human GAGE8 wild-type allele is located in the vicinity of Xp11 and is approximately 7 kb in length. This allele, which encodes G antigen 2D protein, may play a role in tumor progression.	GAGE8 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104464>	C173695|C173454	Limit Food Intake due to Swallowing Difficulty Question|I limit my food intake because of my swallowing difficulty|Limit Food Intake due to Swallowing Difficulty	A question about whether an individual limits or has limited food intake due to swallowing difficulty.			Intellectual Product	MD Anderson Dysphagia Inventory
C104465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104465>	C173454|C173045	Unable to Maintain Weight due to Swallowing Problem Question|I cannot maintain my weight because of my swallowing problem|Unable to Maintain Weight due to Swallowing Problem	A question about whether an individual is or was unable to maintain weight due to their swallowing problem.			Intellectual Product	MD Anderson Dysphagia Inventory
C104466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104466>	C173454	Have Low Self-Esteem due to Swallowing Problem Question|Have Low Self-Esteem due to Swallowing Problem|I have low self-esteem because of my swallowing problem	A question about whether an individual has or had low self-esteem because of their swallowing problem.			Intellectual Product	MD Anderson Dysphagia Inventory
C104467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104467>	C173454|C173219	Feel Like Swallowing Huge Amount of Food Question|Feel Like Swallowing Huge Amount of Food|I feel that I am swallowing a huge amount of food	A question about whether an individual feels or felt as though they are swallowing a huge amount of food.			Intellectual Product	MD Anderson Dysphagia Inventory
C104468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104468>	C173160	Feel Excluded due to Eating Habits Question|Feel Excluded due to Eating Habits|I feel excluded because of my eating habits	A question about whether an individual feels or felt excluded due to their eating habits.			Intellectual Product	MD Anderson Dysphagia Inventory
C104469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104469>	C54672	G Antigen 2D|CT4.8|Cancer/Testis Antigen 4.8|G Antigen 8|GAGE-2D|GAGE-8|GAGE2D|GAGE8	G antigen 2D (116 aa, ~13 kDa) is encoded by both the human GAGE2D and GAGE8 genes. This protein may be involved in tumor antigenicity.	G Antigen 2D		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10446>	C61063	Filgrastim/Paclitaxel|G-CSF/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104470>	C54306	GAGE7 Gene|G Antigen 7 Gene|GAGE7|GAGE7	This gene may play a role in tumor progression.	GAGE7 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104471>	C104470	GAGE7 wt Allele|AL4|CT4.7|Cancer/Testis Antigen Family 4, Member 7 Gene|G Antigen 7 wt Allele|GAGE-7	Human GAGE7 wild-type allele is located within Xp11.4-p11.2 and is approximately 7 kb in length. This allele, which encodes G antigen 7 protein, may be involved in tumor antigenicity.	GAGE7 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104472>	C54672	G Antigen 7|CT4.7|Cancer/Testis Antigen 4.7|GAGE-12I|GAGE-7|GAGE-7B|GAGE-8|GAGE7	G antigen 7 (117 aa, ~13 kDa) is encoded by the human GAGE7 gene. This protein may play a role in tumor recognition.	G Antigen 7		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104473>	C54306	GAGE6 Gene|G Antigen 6 Gene|GAGE6|GAGE6	This gene may be involved in tumor recognition.	GAGE6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104474>	C104473	GAGE6 wt Allele|CT4.6|Cancer/Testis Antigen Family 4, Member 6 Gene|G Antigen 6 wt Allele|GAGE-6	Human GAGE6 wild-type allele is located within Xp11.4-p11.2 and is approximately 7 kb in length. This allele, which encodes G antigen 6 protein, may play a role in tumor transformation.	GAGE6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104475>	C176244	Strongly Agree	Intense concurrence.			Intellectual Product	Canine Quality of Life Survey|ICDC Terminology|MD Anderson Dysphagia Inventory|PRECINCT Property Terminology
C104476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104476>	C226653	Strongly Disagree	Intensely at odds.			Intellectual Product	Canine Quality of Life Survey|ICDC Terminology|MD Anderson Dysphagia Inventory|PRECINCT Property Terminology
C104477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104477>	C54672	G Antigen 6|CT4.6|Cancer/Testis Antigen 4.6|GAGE-6|GAGE6	G antigen 6 (117 aa, ~13 kDa) is encoded by the human GAGE6 gene. This protein may be involved in tumor malignancy.	G Antigen 6		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104478>	C176244	Agree	To concur.			Intellectual Product	Canine Quality of Life Survey|ICDC Terminology|MD Anderson Dysphagia Inventory|PRECINCT Property Terminology
C104479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104479>	C226653	Disagree	To be at odds.			Intellectual Product	Canine Quality of Life Survey|ICDC Terminology|MD Anderson Dysphagia Inventory|PRECINCT Property Terminology
C10447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10447>	C61063	Amifostine/Mitomycin|MITO/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104480>	C54306	GAGE5 Gene|G Antigen 5 Gene|GAGE5|GAGE5	This gene may play a role in tumor antigenicity.	GAGE5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104481>	C104480	GAGE5 wt Allele|CT4.5|Cancer/Testis Antigen Family 4, Member 5 Gene|G Antigen 5 wt Allele|GAGE-5	Human GAGE5 wild-type allele is located within Xp11.4-p11.2 and is approximately 7 kb in length. This allele, which encodes G antigen 5 protein, may be involved in tumor recognition.	GAGE5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104482>	C54672	G Antigen 5|CT4.5|Cancer/Testis Antigen 4.5|GAGE-5|GAGE5	G antigen 5 (117 aa, ~13 kDa) is encoded by the human GAGE5 gene. This protein may play a role in tumor formation.	G Antigen 5		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104483>	C54306	GAGE4 Gene|G Antigen 4 Gene|GAGE4|GAGE4	This gene may be involved in tumor malignancy.	GAGE4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104484>	C54672	G Antigen 4|CT4.4|Cancer/Testis Antigen 4.4|GAGE-4|GAGE4	G antigen 4 (117 aa, ~13 kDa) is encoded by the human GAGE4 gene. This protein may be involved in tumor transformation.	G Antigen 4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104485>	C104483	GAGE4 wt Allele|CT4.4|Cancer/Testis Antigen Family 4, Member 4 Gene|G Antigen 4 wt Allele|GAGE-4	Human GAGE4 wild-type allele is located within Xp11.4-p11.2 and is approximately 6 kb in length. This allele, which encodes G antigen 4 protein, may play a role in tumor formation.	GAGE4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104489>	C54306	GAGE1 Gene|G Antigen 1 Gene|GAGE1|GAGE1	This gene may be involved in tumorigenesis.	GAGE1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10448>	C61063	Cytarabine/Interleukin-3|ARA-C/IL-3			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104490>	C104489	GAGE1 wt Allele|CT4.1|Cancer/Testis Antigen Family 4, Member 1 Gene|G Antigen 1 wt Allele|GAGE-1	Human GAGE1 wild-type allele is located in the vicinity of Xp11.23 and is approximately 10 kb in length. This allele, which encodes G antigen 1 protein, may play a role in both T-cell binding and tumor formation.	GAGE1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104491>	C54672	G Antigen 1|Antigen MZ2-F|CT4.1|Cancer/Testis Antigen 4.1|GAGE-1|GAGE1	G antigen 1 (139 aa, ~16 kDa) is encoded by the human GAGE1 gene. This protein may be involved in tumor formation.	G Antigen 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104492>	C54306	BAGE Gene|B Melanoma Antigen Gene|BAGE|BAGE	This gene may play a role in melanoma.	BAGE Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104493>	C104492	BAGE wt Allele|B Melanoma Antigen wt Allele|BAGE1|CT2.1|Cancer/Testis Antigen Family 2, Member 1 Gene	Human BAGE wild-type allele is located in the vicinity of 21p11.1 and is approximately 2 kb in length. This allele, which encodes B melanoma antigen 1 protein, may be involved in melanoma progression.	BAGE wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104494>	C54672	B Melanoma Antigen 1|Antigen MZ2-BA|B Melanoma Antigen|BAGE|CT2.1|Cancer/Testis Antigen 2.1	B melanoma antigen 1 (43 aa, ~5 kDa) is encoded by the human BAGE gene. This protein may play a role in melanoma tumorigenesis.	B Melanoma Antigen 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104495>	C17049	Other Race|OTHER RACE|RACEOTH	Individuals who do not necessarily identify with any particular race or others who do not wish to self select into a racial category(ies).			Population Group	CDISC Variable Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology|SeroNet Authorized Values|SeroNet Research Participant Metadata|SeroNet Study Descriptors
C104496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104496>	C54306	MAGEA10 Gene|MAGEA10|MAGEA10|Melanoma Antigen Family A, 10 Gene	This gene may be involved in tumor transformation.	MAGEA10 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104497>	C104496	MAGEA10 wt Allele|CT1.10|Cancer/Testis Antigen Family 1, Member 10 Gene|MAGE10|MGC10599|Melanoma Antigen Family A, 10 wt Allele	Human MAGEA10 wild-type allele is located in the vicinity of Xq28 and is approximately 5 kb in length. This allele, which encodes melanoma-associated antigen 10 protein, may plays a role in tumorigenesis.	MAGEA10 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104498>	C54672	Melanoma-Associated Antigen 10|CT1.10|Cancer/Testis Antigen 1.10|MAGE-10 Antigen|MAGE-A10|MAGEA10|Melanoma Antigen 10	Melanoma-associated antigen 10 (369 aa, ~41 kDa) is encoded by the human MAGEA10 gene. This protein may be involved in tumor progression.	Melanoma-Associated Antigen 10		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104499>	C54306	MAGEA2 Gene|MAGEA2|MAGEA2|Melanoma Antigen Family A, 2 Gene	This gene plays a role in p53-mediated signaling.	MAGEA2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10449>	C61063	Carboplatin/Cisplatin/Etoposide/Sargramostim|CBDCA/CDDP/GM-CSF/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1044>	C2018	Fadrozole Hydrochloride|(+/-)-p-(5,6,7,8-Tetrahydroimidazo(1,5-a)pyridin-5-yl)benzonitrile Monohydrochloride|4-(5,6,7,8-Tetrahydroimidazo(1,5-a)pyridin-5-yl)benzonitrile Hydrochloride|4-(5,6,7,8-Tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Monohydrochloride|Afema|Arensin|CGS 16949A|CGS-16949A|CGS16949A|FADROZOLE HYDROCHLORIDE	The hydrochloride salt of the nonsteroidal aromatase inhibitor fadrozole with potential antineoplastic activity. Fadrozole specifically inhibits aromatase, blocking the aromatization of androstenedione and testosterone into estrone and estradiol, respectively, the final step in estrogen biosynthesis; the reduction in estrogen levels may inhibit growth in estrogen-dependent cancers. Aromatase, a member of the cytochrome P-450 superfamily, is found in many tissues; overexpression has been linked to the development of preneoplastic and neoplastic changes in breast tissue.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C104500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104500>	C104499	MAGEA2 wt Allele	Human MAGEA2 wild-type allele is located in the vicinity of Xq28 and is approximately 4 kb in length. This allele, which encodes melanoma-associated antigen 2 protein, is involved in the regulation of p53-dependent signal transduction.	MAGEA2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104501>	C54672	Melanoma-Associated Antigen 2|CT1.2|Cancer/Testis Antigen 1.2|MAGE-2 Antigen|MAGE-A2|MAGEA2|Melanoma Antigen 2	Melanoma-associated antigen 2 (314 aa, ~35 kDa) is encoded by the human MAGEA2 and MAGEA2B genes. This protein plays a role in the modulation of p53-dependent signaling pathways.	Melanoma-Associated Antigen 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104502>	C20744	SEPTIN4 Gene|SEPT4|SEPT4 Gene|SEPTIN4|SEPTIN4|Septin 4 Gene	This gene is involved in both cytoskeletal maintenance and GTPase activity.	SEPT4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104503>	C104502	SEPTIN4 wt Allele|ARTS|BRADEION|C17orf47|CE5B3|Chromosome 17 Open Reading Frame 47 Gene|FLJ40121|H5|MART|PNUTL2|Peanut-Like 2 Gene|SEP4|SEPT4|SEPT4 wt Allele|Septin 4 wt Allele|hCDCREL-2|hucep-7	Human SEPTIN4 wild-type allele is located in the vicinity of 17q22 and is approximately 20 kb in length. This allele, which encodes septin-4 protein, plays a role in both GTP hydrolysis and the structure of the cytoskeleton.	SEPT4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104504>	C25364	Batch Number|BATCH|Batch Code|Batch Identifier|Batch Identifier	A distinctive alpha-numeric identification code assigned by the manufacturer or distributor to a specific quantity of manufactured material or product that is produced in a manner that is expected to render it homogeneous.			Intellectual Product	CDISC DDF Medical Device Identifier Type Value Set Terminology|CDISC DDF Terminology|CDISC SDTM Device Identifier Parameter Long Name Terminology|CDISC SDTM Device Identifier Parameter Short Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C104505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104505>	C18073	Septin-4|ARTS|Apoptosis-Related Protein In The TGF-Beta Signaling Pathway|Bradeion Beta|Brain Protein H5|CE5B3 Beta|Cell Division Control-Related Protein 2|Cerebral Protein 7|Peanut-Like Protein 2|SEPT4|SEPTIN4|Septin-M|hCDCREL-2	Septin-4 (478 aa, ~55 kDa) is encoded by the human SEPTIN4 gene. This protein is involved in both cytoskeletal structure and GTP hydrolysis.	Septin-4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104506>	C25804	HDAC10 Gene|HDAC10|HDAC10|Histone Deacetylase 10 Gene	This gene plays a role in the regulation of histone acetylation.	HDAC10 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104507>	C104506	HDAC10 wt Allele|HD10|Histone Deacetylase 10 wt Allele|RP3-402G11.7	Human HDAC10 wild-type allele is located in the vicinity of 22q13.31 and is approximately 6 kb in length. This allele, which encodes histone deacetylase 10 protein, is involved in both transcriptional regulation and histone deacetylation.	HDAC10 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104508>	C16682	Histone Deacetylase 10|EC 3.5.1.98|HD10|HDAC10	Histone deacetylase 10 (669 aa, ~71 kDa) is encoded by the human HDAC10 gene. This protein plays a role in both the deacetylation of histones and transcriptional regulation.	Histone Deacetylase 10		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104509>	C54306	MAGEA1 Gene|MAGEA1|MAGEA1|Melanoma Antigen Family A, 1 (Directs Expression of Antigen MZ2-E) Gene	This gene may play a role in embryonal development, tumor transformation, or tumor progression.	MAGEA1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10450>	C61063	Chlorambucil/Epirubicin|CLB/EPI			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104510>	C104509	MAGEA1 wt Allele|CT1.1|MAGE1|MGC9326|Melanoma Antigen Family A, 1 (Directs Expression of Antigen MZ2-E) wt Allele	Human MAGEA1 wild-type allele is located in the vicinity of Xq28 and is approximately 6 kb in length. This allele, which encodes melanoma-associated antigen 1 protein, may be involved in embryonal development, tumor transformation, or tumor progression.	MAGEA1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104511>	C54672	Melanoma-Associated Antigen 1|Cancer/Testis Antigen 1.1|Cancer/Testis Antigen Family 1, Member 1|MAGE-1 Antigen|MAGE-A1|MAGEA1|Melanoma Antigen Family A 1|Melanoma Antigen MAGE-1|Melanoma-Associated Antigen MZ2-E	Melanoma-associated antigen 1 (309 aa, ~34 kDa) is encoded by the human MAGEA1 gene. This protein may play a role in embryonal development, tumor transformation, or tumor progression.	Melanoma-Associated Antigen 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104512>	C54306	MAGEA4 Gene|MAGEA4|MAGEA4|Melanoma Antigen Family A, 4 Gene	This gene may be involved in embryonal development, tumor transformation, or tumor progression.	MAGEA4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104513>	C104512	MAGEA4 wt Allele|CT1.4|MAGE-41|MAGE-X2|MAGE4|MAGE4A|MAGE4B|MGC21336|Melanoma Antigen Family A, 4 wt Allele	Human MAGEA4 wild-type allele is located in the vicinity of Xq28 and is approximately 13 kb in length. This allele, which encodes melanoma-associated antigen 4 protein, may play a role in embryonal development, tumor transformation, or tumor progression.	MAGEA4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104514>	C21165	TNFRSF10C Gene|TNFRSF10C|TNFRSF10C|Tumor Necrosis Factor Receptor Superfamily, Member 10c, Decoy without an Intracellular Domain Gene C	This gene is involved in both ligand binding and the negative regulation of apoptotic signaling.	TNFRSF10C Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104515>	C54672	Melanoma-Associated Antigen 4|Cancer/Testis Antigen 1.4|Cancer/Testis Antigen Family 1, Member 4|MAGE-4 Antigen|MAGE-41 Antigen|MAGE-A4|MAGE-X2 Antigen|MAGEA4	Melanoma-associated antigen 4 (317 aa, ~35 kDa) is encoded by the human MAGEA4 gene. This protein may be involved in embryonal development, tumor transformation, or tumor progression.	Melanoma-Associated Antigen 4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104516>	C104514	TNFRSF10C wt Allele|CD263|DCR1|DCR1-TNFR|LIT|TRAIL-R3|TRAILR3|TRID|Tumor Necrosis Factor Receptor Superfamily, Member 10c, Decoy without an Intracellular Domain wt Allele|UNQ321/PRO366	Human TNFRSF10C wild-type allele is located within 8p22-p21 and is approximately 48 kb in length. This allele, which encodes tumor necrosis factor receptor superfamily member 10C protein, plays a role in both apoptosis inhibition and ligand binding.	TNFRSF10C wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104517>	C54306	MAGEA6 Gene|MAGEA6|MAGEA6|Melanoma Antigen Family A, 6 Gene	This gene may enhance ubiquitin ligase activity.	MAGEA6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104518>	C104517	MAGEA6 wt Allele|MAGE-3b|MAGE3B|Melanoma Antigen Family A, 6 wt Allele	Human MAGEA6 wild-type allele is located in the vicinity of Xq28 and is approximately 4 kb in length. This allele, which encodes melanoma-associated antigen 6 protein, may enhance ubiquitin ligase activity.	MAGEA6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104519>	C54672	Melanoma-Associated Antigen 6|Cancer/Testis Antigen 1.6|Cancer/Testis Antigen Family 1, Member 6|MAGE-6 Antigen|MAGE-A6|MAGE3B Antigen|MAGEA6|Melanoma Antigen Family A, 6	Melanoma-associated antigen 6 (314 aa, ~35 kDa) is encoded by the human MAGEA6 gene. This protein may enhance ubiquitin ligase activity.	Melanoma-Associated Antigen 6		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10451>	C61063	Altretamine/Carboplatin/Cyclophosphamide|CBDCA/CTX/HMM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104520>	C19285	Tumor Necrosis Factor Receptor Superfamily Member 10C|Antagonist Decoy Receptor For TRAIL/Apo-2L|CD263|CD263 Antigen|DcR1|Decoy Receptor 1|Decoy TRAIL Receptor Without Death Domain|Lymphocyte Inhibitor of TRAIL|TNF-Related Apoptosis-Inducing Ligand Receptor 3|TNFRSF10C|TRAIL Receptor 3|TRAIL Receptor without an Intracellular Domain|TRAIL-R3	Tumor necrosis factor receptor superfamily member 10C (259 aa, ~27 kDa) is encoded by the human TNFRSF10C gene. This protein is involved in both binding to tumor necrosis factor ligand superfamily member 10 and the inhibition of apoptosis.	Tumor Necrosis Factor Receptor Superfamily Member 10C		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104521>	C54306	MAGEB18 Gene|MAGE Family Member B18 Gene|MAGEB18|MAGEB18	This gene may enhance ubiquitin ligase activity.	MAGEB18 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104522>	C104521	MAGEB18 wt Allele|MAGE Family Member B18 wt Allele|MGC33889|Melanoma Antigen Family B, 18 Gene	Human MAGEB18 wild-type allele is located in the vicinity of Xp21.3 and is approximately 2 kb in length. This allele, which encodes melanoma-associated antigen B18 protein, may enhance ubiquitin ligase activity.	MAGEB18 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104523>	C54672	Melanoma-Associated Antigen B18|MAGE-B18|MAGE-B18 Antigen|MAGEB18|Melanoma Antigen Family B, 18	Melanoma-associated antigen B18 (343 aa, ~39 kDa) is encoded by the human MAGEB18 gene. This protein may enhance ubiquitin ligase activity.	Melanoma-Associated Antigen B18		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104524>	C54306	MAGEC1 Gene|MAGE Family Member C1 Gene|MAGEC1|MAGEC1	This gene may play a role in embryonal development, tumor transformation, or tumor progression.	MAGEC1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104525>	C104524	MAGEC1 wt Allele|CT7|CT7.1|MAGE Family Member C1 wt Allele|MAGE-C1|MGC39366|Melanoma Antigen Family C, 1 Gene|Melanoma Antigen, Family C, 1 Gene	Human MAGEC1 wild-type allele is located in the vicinity of Xq26 and is approximately 6 kb in length. This allele, which encodes melanoma-associated antigen C1 protein, may be involved in embryonal development, tumor transformation, or tumor progression.	MAGEC1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104526>	C54672	Melanoma-Associated Antigen C1|CT7|CT7.1|Cancer/Testis Antigen 7.1|Cancer/Testis Antigen Family 7, Member 1|MAGE-C1 Antigen|MAGEC1|Melanoma Antigen Family C, 1	Melanoma-associated antigen C1 (1142 aa, ~124 kDa) is encoded by the human MAGEC1 gene. This protein may play a role in embryonal development, tumor transformation, or tumor progression.	Melanoma-Associated Antigen C1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104527>	C54306	MAGEC2 Gene|MAGEC2|MAGEC2|Melanoma Antigen Family C, 2 Gene	This gene may enhance ubiquitin ligase activity.	MAGEC2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104528>	C104527	MAGEC2 wt Allele|CT10|HCA587|MAGE-C2|MAGEE1|Melanoma Antigen Family C, 2 wt Allele	Human MAGEC2 wild-type allele is located in the vicinity of Xq27 and is approximately 3 kb in length. This allele, which encodes melanoma-associated antigen C2 protein, may enhance ubiquitin ligase activity. The gene is frequently expressed in head and neck carcinomas, breast carcinomas, non-small-cell lung carcinomas, and sarcomas.	MAGEC2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104529>	C54672	Melanoma-Associated Antigen C2|CT10|Cancer/Testis Antigen 10|Hepatocellular Cancer Antigen 587|Hepatocellular Carcinoma-Associated Antigen 587|MAGE-C2 Antigen|MAGE-E1 Antigen|MAGEC2|Melanoma Antigen Family C, 2|Melanoma Antigen, Family E, 1, Cancer/Testis Specific, Cancer/Testis Antigen 10	Melanoma-associated antigen C2 (373 aa, ~41 kDa) is encoded by the human MAGEC2 gene. This protein may enhance ubiquitin ligase activity.	Melanoma-Associated Antigen C2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10452>	C63358	PMFAC Regimen|CTX/DOX/5-FU/MTX/PRED|Cyclophosphamide/Doxorubicin/Fluorouracil/Methotrexate/Prednisone|PMFAC|PMFAC|Prednisone-Methotrexate-Fluorouracil-Doxorubicin-Cyclophosphamide|Prednisone/Methotrexate/Fluorouracil/Adriamycin/Cyclophosphamide|Prednisone/Methotrexate/Fluorouracil/Doxorubicin/Cyclophosphamide	A regimen consisting of prednisone, methotrexate, fluorouracil, doxorubicin, and cyclophosphamide that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C104530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104530>	C20420	HES3 Gene|HES3|HES3|Hairy and Enhancer of Split 3 (Drosophila) Gene	This gene plays a role in transcriptional repression.	HES3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104531>	C104530	HES3 wt Allele|BHLHB43|Hairy and Enhancer of Split 3 (Drosophila) wt Allele|RP1-120G22.7|bHLHb43	Human HES3 wild-type allele is located in the vicinity of 1p36.31 and is approximately 1 kb in length. This allele, which encodes transcription factor HES-3 protein, is involved in the negative regulation of transcription.	HES3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104532>	C17207	Transcription Factor HES-3|Class B Basic Helix-Loop-Helix Protein 43|HES3|Hairy and Enhancer of Split 3|bHLHb43	Transcription factor HES-3 (186 aa, ~20 kDa) is encoded by the human HES3 gene. This protein plays a role in the repression of transcription.	Transcription Factor HES-3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104533>	C20710	HES6 Gene|HES6|HES6|Hairy and Enhancer of Split 6 (Drosophila) Gene	This gene plays a role in the modulation of transcription.	HES6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104534>	C104533	HES6 wt Allele|HES-6|Hairy and Enhancer of Split 6 (Drosophila) wt Allele|bHLHb41|bHLHc23	Human HES6 wild-type allele is located in the vicinity of 2q37.3 and is approximately 2 kb in length. This allele, which encodes transcription cofactor HES-6 protein, is involved in the regulation of gene expression.	HES6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104535>	C26199	Transcription Cofactor HES-6|C-HAIRY1|Class B Basic Helix-Loop-Helix Protein 41|HES6|Hairy and Enhancer of Split 6|bHLHb41	Transcription cofactor HES-6 (224 aa, ~24 kDa) is encoded by the human HES6 gene. This protein plays a role in the modulation of transcription factor activity.	Transcription Cofactor HES-6		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104536>	C20703	HEY2 Gene|HEY2|HEY2|Hairy/Enhancer-Of-Split Related With YRPW Motif 2 Gene	This gene is involved in both transcriptional regulation and Notch signaling pathways.	HEY2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104537>	C104536	HEY2 wt Allele|CHF1|GRIDLOCK|GRL|HERP|HERP1|HESR2|HRT2|Hairy/Enhancer-Of-Split Related With YRPW Motif 2 wt Allele|RP1-293L8.3|bHLHb32	Human HEY2 wild-type allele is located in the vicinity of 6q21 and is approximately 14 kb in length. This allele, which encodes hairy/enhancer-of-split related with YRPW motif protein 2, plays a role in both Notch signal transduction and transcriptional repression.	HEY2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104538>	C20348	NLRP1 Gene|NALP1|NLR Family Pyrin Domain Containing 1 Gene|NLRP1|NLRP1	This gene plays a role in the induction of apoptosis.	NLRP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104539>	C104538	NLRP1 wt Allele|AIADK|CARD7|CIDED|CLR17.1|DEFCAP|DEFCAP-L/S|DKFZp586O1822|KIAA0926|MSPC|NAC|NALP1|NLR Family Pyrin Domain Containing 1 wt Allele|NLR Family, Pyrin Domain Containing 1 Gene|NLRP1A|NLRP1A, Mouse, Homolog of Gene|PP1044|SLEV1|Systemic Lupus Erythematosus, Vitiligo-Related 1 Gene|VAMAS1	Human NLRP1 wild-type allele is located in the vicinity of 17p13.2 and is approximately 120 kb in length. This allele, which encodes NACHT, LRR and PYD domains-containing protein 1, is involved in apoptosis induction. Mutations in the gene are associated with vitiligo-associated multiple autoimmune disease susceptibility 1.	NLRP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10453>	C61063	Cisplatin/Cyclophosphamide/Fluorouracil/Methotrexate/Prednisone|CDDP/CTX/5-FU/MTX/PRED			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104540>	C26199	Hairy/Enhancer-of-Split Related With YRPW Motif Protein 2|Cardiovascular Helix-Loop-Helix Factor 1|Class B Basic Helix-Loop-Helix Protein 32|HES-Related Repressor Protein 2|HEY2|HRT-2|Hairy and Enhancer of Split-Related Protein 2|Hairy-Related Transcription Factor 2|Hairy/Enhancer-Of-Split Related With YRPW Motif Protein 2|Protein Gridlock Homolog|bHLHb32|hCHF1|hHRT2	Hairy/enhancer-of-split related with YRPW motif protein 2 (337 aa, ~36 kDa) is encoded by the human HEY2 gene. This protein is involved in both the negative regulation of gene expression and Notch-dependent signaling.	Hairy/Enhancer-Of-Split Related With YRPW Motif Protein 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104541>	C19928	NACHT, LRR and PYD Domains-Containing Protein 1|Caspase Recruitment Domain Protein 7|Caspase Recruitment Domain-Containing Protein 7|Death Effector Filament-Forming CED4-Like Apoptosis Protein|Death Effector Filament-Forming ced-4-Like Apoptosis Protein|NACHT Domain-, Leucine-Rich Repeat-, and PYD-Containing Protein 1|NACHT, LRR and PYD Containing Protein 1|NACHT, Leucine Rich Repeat and PYD (Pyrin Domain) Containing 1|NACHT, Leucine Rich Repeat and PYD Containing 1|NLR Family, Pyrin Domain Containing 1|NLRP1|Nucleotide-Binding Domain and Caspase Recruitment Domain|Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat and Pyrin Domain Containing 1	NACHT, LRR and PYD domains-containing protein 1 (1473 aa, ~166 kDa) is encoded by the human NLRP1 gene. This protein plays a role in the induction of apoptosis.	NACHT, LRR and PYD Domains-Containing Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C104542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104542>	C28533	SLC29A2 Gene|SLC29A2|SLC29A2|Solute Carrier Family 29 (Nucleoside Transporters), Member 2 Gene	This gene plays a role in nucleoside transport.	SLC29A2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104543>	C20103	NCR2 Gene|NCR2|NCR2|Natural Cytotoxicity Triggering Receptor 2 Gene	This gene is involved in natural killer cell function.	NCR2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104544>	C104543	NCR2 wt Allele|CD336|LY95|Lymphocyte Antigen 95, Mouse, Homolog of Gene|NK-p44|NKp44|Natural Cytotoxicity Triggering Receptor 2 wt Allele|dJ149M18.1	Human NCR2 wild-type allele is located in the vicinity of 6p21.1 and is approximately 15 kb in length. This allele, which encodes natural cytotoxicity triggering receptor 2 protein plays a role in natural killer cell function.	NCR2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104545>	C104542	SLC29A2 wt Allele|DER12|ENT2|HNP36|Solute Carrier Family 29 (Nucleoside Transporters), Member 2 wt Allele	Human SLC29A2 wild-type allele is located in the vicinity of 11q13 and is approximately 10 kb in length. This allele, which encodes equilibrative nucleoside transporter 2, is involved in nucleoside equilibration.	SLC29A2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104546>	C18106	Natural Cytotoxicity Triggering Receptor 2|Activating NK Receptor NKp44|CD336 Antigen|Lymphocyte Antigen 95 Homolog|NK Cell-Activating Receptor|NK-p44|NKp44|Natural Killer Cell p44-Related Protein	Natural cytotoxicity triggering receptor 2 (276 aa, ~30 kDa) is encoded by the human NCR2 gene. This protein is involved in natural killer cell function.	Natural Cytotoxicity Triggering Receptor 2		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104547>	C16386	Equilibrative Nucleoside Transporter 2|36 kDa Nucleolar Protein HNP36|Delayed-Early Response Protein 12|Equilibrative NBMPR-Insensitive Nucleoside Transporter|Equilibrative Nitrobenzylmercaptopurine Riboside-Insensitive Nucleoside Transporter|Hydrophobic Nucleolar Protein, 36 kDa|Nucleoside Transporter, Ei-Type|SLC29A2|Solute Carrier Family 29 Member 2|hENT2	Equilibrative nucleoside transporter 2 (456 aa, ~50 kDa) is encoded by the human SLC29A2 gene. This protein plays a role in nucleoside transport for nucleotide salvage.	Equilibrative Nucleoside Transporter 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104548>	C20103	NCR3 Gene|NCR3|NCR3|Natural Cytotoxicity Triggering Receptor 3 Gene	This gene plays a role in natural killer cell function.	NCR3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104549>	C104548	NCR3 wt Allele|1C7|CD337|LY117|MALS|NK-p30|NKp30|Natural Cytotoxicity Triggering Receptor 3 wt Allele	Human NCR3 wild-type allele is located in the vicinity of 6p21.3 and is approximately 4 kb in length. This allele, which encodes natural cytotoxicity triggering receptor 3 protein, is involved in natural killer cell function.	NCR3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10454>	C61063	Cyclophosphamide/Melphalan|CTX/L-PAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104550>	C18106	Natural Cytotoxicity Triggering Receptor 3|Activating NK-A1 Receptor|Activating Natural Killer Receptor p30|CD337 Antigen|Lymphocyte Antigen 117|NCR3|Natural Killer Cell p30-Related Protein	Natural cytotoxicity triggering receptor 3 (201 aa, ~22 kDa) is encoded by the human NCR3 gene. This protein plays a role in natural killer cell function.	Natural Cytotoxicity Triggering Receptor 3		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104551>	C20194	TBL2 Gene|TBL2|TBL2|Transducin (Beta)-Like 2 Gene	This gene may be involved in signaling.	TBL2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104552>	C104551	TBL2 wt Allele|Transducin (Beta)-Like 2 wt Allele|UNQ563/PRO1125|WBSCR13|WS-betaTRP|Williams-Beuren Syndrome Chromosome Region 13 Gene	Human TBL2 wild-type allele is located in the vicinity of 7q11.23 and is approximately 10 kb in length. This allele, which encodes transducin beta-like protein 2, may play a role in signal transduction. In Williams-Beuren syndrome, the chromosomal region this gene is located in is deleted.	TBL2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104553>	C18466	Transducin Beta-Like Protein 2|TBL2|WS Beta-Transducin Repeats Protein|WS-betaTRP|Williams-Beuren Syndrome Chromosomal Region 13 Protein	Transducin beta-like protein 2 (447 aa, ~50 kDa) is encoded by the human TBL2 gene. This protein may be involved in signal transduction.	Transducin Beta-Like Protein 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104554>	C20673	IRF8 Gene|IRF8|IRF8|Interferon Regulatory Factor 8 Gene	This gene plays a role in the regulation of cytokine gene expression.	IRF8 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104555>	C104554	IRF8 wt Allele|H-ICSBP|ICSBP|ICSBP1|IRF-8|Interferon Regulatory Factor 8 wt Allele	Human IRF8 wild-type allele is located in the vicinity of 16q24.1 and is approximately 24 kb in length. This allele, which encodes interferon regulatory factor 8 protein, is involved in the modulation of interferon and interferon-inducible gene expression.	IRF8 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104556>	C17207	Interferon Regulatory Factor 8|H-ICSBP|ICSBP|IRF-8|IRF8|Interferon Consensus Sequence-Binding Protein	Interferon regulatory factor 8 (426 aa, ~48 kDa) is encoded by the human IRF8 gene. This protein plays a role in the regulation of gene transcription.	Interferon Regulatory Factor 8		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104557>	C30073	NES Gene|NES|NES|Nestin Gene	This gene is involved in mitosis.	NES Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104558>	C20194	RAB40B Gene|RAB40B|RAB40B|RAB40B, Member RAS Oncogene Family Gene	This gene may be involved in protein ubiquitination and secretory vesicle transport.	RAB40B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104559>	C104558	RAB40B wt Allele|RAB40B, Member RAS Oncogene Family wt Allele|RAR|SEC4L	Human RAB40B wild-type allele is located in the vicinity of 17q25.3 and is approximately 44 kb in length. This allele, which encodes ras-related protein Rab-40B protein, may play a role in secretory vesicle transport and protein ubiquitination.	RAB40B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10455>	C159909	VIP-B Regimen|BLEO/CDDP/IFF/VP-16|Bleomycin/Cisplatin/Etoposide/Ifosfamide|Etoposide-Ifosfamide-Cisplatin-Bleomycin|Etoposide-Ifosfamide-Cisplatin-Bleomycin Regimen|Etoposide/Ifosfamide/Cisplatin/Bleomycin|VIP-B|VIP-B|VePesid/Ifosfamide/Platinol/Bleomycin	A regimen consisting of etoposide, ifosfamide, cisplatin, and bleomycin that may be used in the treatment of certain germ cell tumors.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C104560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104560>	C18466	Ras-Related Protein Rab-40B|GTP-Binding Protein Homologous To Saccharomyces Cerevisiae SEC4|Protein Rar|RAB40B|SOCS Box-Containing Protein RAR	Ras-related protein Rab-40B (278 aa, ~31 kDa) is encoded by the human RAB40B gene. This protein may be involved in the regulation of ubiquitination and vesicle transport.	Ras-Related Protein Rab-40B		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104561>	C104557	NES wt Allele|FLJ21841|Nestin wt Allele	Human NES wild-type allele is located in the vicinity of 1q23.1 and is approximately 7 kb in length. This allele, which encodes nestin protein, plays a role in mitosis.	NES wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104562>	C20694	Nestin|NES	Nestin (1621 aa, ~177 kDa) is encoded by the human NES gene. This protein is involved in mitosis.	Nestin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104563>	C26016|C25790	NCF2 Gene|NCF2|NCF2|Neutrophil Cytosolic Factor 2 Gene	This gene plays a role in the generation of superoxide in neutrophils.	NCF2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104564>	C104563	NCF2 wt Allele|Chronic Granulomatous Disease, Autosomal 2 Gene|NCF-2|NOXA2|Neutrophil Cytosolic Factor 2 (65kD, Chronic Granulomatous Disease, Autosomal 2) Gene|Neutrophil Cytosolic Factor 2 wt Allele|P67-PHOX|P67PHOX|p67 PHOX	Human NCF2 wild-type allele is located in the vicinity of 1q25 and is approximately 35 kb in length. This allele, which encodes neutrophil cytosol factor 2 protein, is involved in the generation of superoxide in neutrophils. Mutations in this gene are associated with chronic granulomatous disease.	NCF2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104565>	C16725	Neutrophil Cytosol Factor 2|67 kDa Neutrophil Oxidase Factor|NADPH Oxidase Activator 2|NCF-2|NCF2|Neutrophil Cytosolic Factor 2|Neutrophil Cytosolic Factor 2|Neutrophil NADPH Oxidase Factor 2|p67phox	Neutrophil cytosol factor 2 (526 aa, ~60 kDa) is encoded by the human NCF2 gene. This protein plays a role in the generation of superoxide in neutrophils.	Neutrophil Cytosolic Factor 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104566>	C26110	NNMT Gene|NNMT|NNMT|Nicotinamide N-Methyltransferase Gene	This gene is involved in the detoxification of xenobiotic compounds.	NNMT Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104567>	C104566	NNMT wt Allele|Nicotinamide N-Methyltransferase wt Allele	Human NNMT wild-type allele is located in the vicinity of 11q23.1 and is approximately 55 kb in length. This allele, which encodes nicotinamide N-methyltransferase protein, plays a role in the detoxification of metabolism of xenobiotic compounds.	NNMT wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104568>	C16849	Nicotinamide N-Methyltransferase|EC 2.1.1.1|NNMT	Nicotinamide N-methyltransferase (264 aa, ~30 kDa) is encoded by the human NNMT gene. This protein is involved in the detoxification of xenobiotic compounds.	Nicotinamide N-Methyltransferase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104569>	C20744	HOMER3 Gene|HOMER3|HOMER3|Homer Homolog 3 (Drosophila) Gene	This gene plays a role in the structure of the postsynaptic density.	HOMER3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10456>	C61063	Cisplatin/Doxorubicin/Filgrastim/Methotrexate/Vinblastine|CDDP/DOX/G-CSF/MTX/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104570>	C25939	NOX4 Gene|NADPH Oxidase 4 Gene|NOX4|NOX4	This gene plays a role as an oxygen sensor in signal transduction.	NOX4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104571>	C104570	NOX4 wt Allele|KOX|KOX-1|NADPH Oxidase 4 wt Allele|RENOX	Human NOX4 wild-type allele is located in the vicinity of 11q14.3 and is approximately 265 kb in length. This allele, which encodes NADPH oxidase 4 protein, is involved as an oxygen sensor in signal transduction, cell differentiation, and tumor cell growth.	NOX4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104572>	C16946	NADPH Oxidase 4|EC 1.6.3.-|Kidney Oxidase-1|Kidney Superoxide-Producing NADPH Oxidase|NOX4|Renal NAD(P)H-Oxidase	NADPH oxidase 4 (578 aa, ~67 kDa) is encoded by the human NOX4 gene. This protein plays a role as an oxygen sensor in cell differentiation and signal transduction.	NADPH Oxidase 4		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104573>	C104569	HOMER3 wt Allele|HOMER-3|Homer Homolog 3 (Drosophila) wt Allele|Homer, Neuronal Immediate Early Gene, 3|VESL3	Human HOMER3 wild-type allele is located in the vicinity of 19p13.11 and is approximately 12 kb in length. This allele, which encodes homer protein homolog 3 protein, is involved in protein localization at the postsynaptic density.	HOMER3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104574>	C18073	Homer Protein Homolog 3|HOMER3|Homer-3	Homer protein homolog 3 (361 aa, ~40 kDa) is encoded by the human HOMER3 gene. This protein plays a role in protein-protein interactions.	Homer Protein Homolog 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104575>	C20921	TRIB2 Gene|TRIB2|TRIB2|Tribbles Pseudokinase 2 Gene	This gene is involved in the regulation of mitogen activated protein kinase activity.	TRIB2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104576>	C104575	TRIB2 wt Allele|C5FW|GS3955|TRB2|Tribbles Homolog 2 (Drosophila) Gene|Tribbles Pseudokinase 2 wt Allele|Tribbles, Drosophila, Homolog of, 2 Gene	Human TRIB2 wild-type allele is located in the vicinity of 2p24.3 and is approximately 26 kb in length. This allele, which encodes tribbles homolog 2 protein, plays a role in the modulation of MAP kinase-dependent signaling.	TRIB2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104577>	C18515	Tribbles Homolog 2|TRB-2|TRIB2	Tribbles homolog 2 (343 aa, ~39 kDa) is encoded by the human TRIB2 gene. This protein is involved in the modulation of MAP kinase activation.	Tribbles Homolog 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104578>	C29936	SERPINB9 Gene|SERPINB9|SERPINB9|Serpin Peptidase Inhibitor, Clade B (Ovalbumin), Member 9 Gene	This gene plays a role in the regulation of granzyme B-mediated proteolysis.	SERPINB9 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104579>	C104578	SERPINB9 wt Allele|CAP-3|CAP3|PI-9|PI9|Serpin Peptidase Inhibitor, Clade B (Ovalbumin), Member 9 wt Allele	Human SERPINB9 wild-type allele is located in the vicinity of 6p25 and is approximately 16 kb in length. This allele, which encodes serpin B9 protein, is involved in the negative regulation of serine protease activity.	SERPINB9 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10457>	C61063	Cisplatin/Filgrastim/Paclitaxel|CDDP/G-CSF/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104580>	C17122	Serpin B9|CAP-3|CAP3|Cytoplasmic Antiproteinase 3|PI-9|Peptidase Inhibitor 9|SERPINB9	Serpin B9 (376 aa, ~42 kDa) is encoded by the human SERPINB9 gene. This protein plays a role in the inhibition of granzyme B.	Serpin B9		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104581>	C20194	PELO Gene|PELO|PELO|Pelota mRNA Surveillance and Ribosome Rescue Factor Gene	This gene may be involved in cell division and RNA degradation.	PELO Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104582>	C104581	PELO wt Allele|CGI-17|PRO1770|Pelota (Drosophila) Homolog Gene|Pelota Homolog (Drosophila) Gene|Pelota Homolog Gene|Pelota mRNA Surveillance and Ribosome Rescue Factor wt Allele|Pelota, Drosophila, Homolog of Gene	Human PELO wild-type allele is located in the vicinity of 5q11.2 and is approximately 16 kb in length. This allele, which encodes protein pelota homolog, may play a role in RNA degradation and cell division.	PELO wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104583>	C18466	Protein Pelota Homolog|PELO|Protein Dom34 homolog|hPelota	Protein pelota homolog (385 aa, ~43 kDa) is encoded by the human PELO gene. This protein may be involved in endoribonuclease activity and chromosomal segregation during mitosis.	Protein Pelota Homolog		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104584>	C21295	NSMAF Gene|NSMAF|NSMAF|Neutral Sphingomyelinase (N-SMase) Activation Associated Factor Gene	This gene is involved in TNF-mediated cell signaling.	NSMAF Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104585>	C104584	NSMAF wt Allele|FAN|Neutral Sphingomyelinase (N-SMase) Activation Associated Factor wt Allele	Human NSMAF wild-type allele is located within 8q12-q13 and is approximately 76 kb in length. This allele, which encodes protein FAN, plays a role in regulating TNF-induced cellular responses.	NSMAF wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104586>	C17728	Protein FAN|Factor Associated with N-SMase Activation|Factor Associated with Neutral Sphingomyelinase Activation|NSMAF	Protein FAN (917 aa, ~104 kDa) is encoded by the human NSMAF gene. This protein is involved in cell signaling via the TNF pathway.	Protein FAN		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104587>	C25952	NT5C2 Gene|5'-Nucleotidase, Cytosolic II Gene|NT5C2|NT5C2|NT5C2	This gene plays a role in purine metabolism.	NT5C2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|Pediatric Oncology Target Genes/Proteins Terminology
C104588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104588>	C104587	NT5C2 wt Allele|5'-Nucleotidase (Purine), Cytosolic Type B Gene|5'-Nucleotidase, Cytosolic II wt Allele|5-Prime-Nucleotidase, Cytosolic II Gene|GMP|NT5B|NT5CP|Nucleotidase, 5-Prime, Cytosolic II Gene|Nucleotidase, 5-Prime, Type B Gene|PNT5|Purine 5-Prime-Nucleotidase Gene|Spastic Paraplegia 45 (Autosomal Recessive) Gene|cN-II	Human NT5C2 wild-type allele is located in the vicinity of 10q24.32 and is approximately 107 kb in length. This allele, which encodes cytosolic purine 5'-nucleotidase protein, is involved in the cellular metabolism of purines.	NT5C2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104589>	C16561	Cytosolic Purine 5'-Nucleotidase|5'-Nucleotidase (Purine), Cytosolic Type B|Cytosolic 5'-Nucleotidase II|Cytosolic Purine 5-Nucleotidase|EC 3.1.3.5|IMP-Specific 5'-NT|NT5C2|Purine 5' Nucleotidase	Cytosolic purine 5'-nucleotidase (561 aa, ~65 kDa) is encoded by the human NT5C2 gene. This protein plays a role in the maintenance of intracellular purine pools.	Cytosolic Purine 5-Nucleotidase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Genes/Proteins Terminology
C10458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10458>	C61063	Flutamide/Leuprolide/Suramin|FLUT/LEUP/SUR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104590>	C26000	BGLAP Gene|BGLAP|BGLAP|Bone Gamma-Carboxyglutamate Protein Gene	This gene is involved in bone structure and the regulation of bone formation.	BGLAP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104591>	C104590	BGLAP wt Allele|BGP|Bone Gamma-Carboxyglutamate (Gla) Protein (Osteocalcin) Gene|Bone Gamma-Carboxyglutamate (Gla) Protein Gene|Bone Gamma-Carboxyglutamate Protein wt Allele|OC|OCN	Human BGLAP wild-type allele is located within 1q25-q31 and is approximately 1 kb in length. This allele, which encodes osteocalcin protein, plays a role in the regulation of bone formation.	BGLAP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104592>	C17351	Osteocalcin|BGLAP|BGP|Bone Gamma-Carboxyglutamate Acid Protein|Bone Gamma-Carboxyglutamate Protein|Bone Gla Protein|Gamma-Carboxyglutamic Acid Protein|Gamma-Carboxyglutamic Acid-Containing Protein	Osteocalcin (100 aa, ~11 kDa) is encoded by the human BGLAP gene. This protein is involved in bone development.	Osteocalcin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104593>	C91105	Linear Analogue Self-Assessment|LASA|LASA	A self-reported questionnaire used to measure general well-being and the major domains of quality of life (mental, physical, emotional, social, and spiritual well-being) in patients receiving cancer therapy.			Intellectual Product	
C104594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104594>	C173504	Overall Quality of Life Question|Overall Quality of Life|your overall Quality of Life	A question about an individual's overall quality of life.			Intellectual Product	Linear Analogue Self-Assessment
C104595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104595>	C107400	Overall Intellectual Well-Being Question|Overall Intellectual Well-Being|your overall mental (intellectual) well being	A question about an individual's overall intellectual well-being.			Intellectual Product	Linear Analogue Self-Assessment
C104596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104596>	C107400	Overall Physical Well-Being Question|Overall Physical Well-Being|your overall physical well being	A question about an individual's overall physical well-being.			Intellectual Product	Linear Analogue Self-Assessment
C104597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104597>	C107400	Overall Emotional Well-Being Question|Emotional Well-Being|Overall Emotional Well-Being|your overall emotional well being	A question about an individual's overall emotional well-being.			Intellectual Product	Linear Analogue Self-Assessment|Patient Oriented Prostate Utility Scale
C104598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104598>	C176021	Level of Social Activity Question|Level of Social Activity|your level of social activity	A question about an individual's level of social activity.			Intellectual Product	Linear Analogue Self-Assessment
C104599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104599>	C107400	Overall Spiritual Well-Being Question|Overall Spiritual Well-Being|your overall spiritual well being	A question about an individual's overall spiritual well-being.			Intellectual Product	Linear Analogue Self-Assessment
C10459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10459>	C61063	Fluorouracil/Leucovorin Calcium/Mitoxantrone/Vincristine|CF/DHAD/5-FU/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1045>	C79611	Chamomile|chamomile	The flower-heads of either the plant Anthemis nobilis or the plant Matricaria chamomilla.  Chamomile has a warm aromatic odour and a very bitter taste and contains volatile oils which are a mixture of butyl and amyl angelates and valerates.  Due to its coumarin constituents, large doses may interfere with coagulation. (NCI04)			Plant	NCI Drug Dictionary Terminology
C104600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104600>	C173358|C173346	Frequency of Pain Question|Frequency of Pain|How Often Have Pain|How Often Pain|How often did you have pain|Pain|Pain Frequency|the frequency of your pain	A question about an individual's frequency of pain.			Intellectual Product	Linear Analogue Self-Assessment|Memorial Symptom Assessment Scale|Ped-PRO-CTCAE|Symptom Distress Scale
C104601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104601>	C173346	Average Severity of Pain Question|Average Severity of Pain|Pain on the Average|the severity of your pain, on the average	A question about an individual's average severity of pain.			Intellectual Product	Brief Pain Inventory Short Form Questionnaire|Linear Analogue Self-Assessment
C104602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104602>	C173347	Average Level of Fatigue Question|Average Level of Fatigue|Fatigue on Average|How fatigued were you on average|your level of fatigue, on the average	A question about an individual's average level of fatigue.			Intellectual Product	Linear Analogue Self-Assessment|PROMIS Adult Physical Health Domain|PROMIS-43 Adult Profile v2.0
C104603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104603>	C173151	Level of Support from Friends and Family Question|Level of Support from Family and Friends|Level of Support from Friends and Family|Support From Family and Friends|your level of support from friends and family	A question about an individual's level of support from their friends and family.			Intellectual Product	Linear Analogue Self-Assessment|Patient Oriented Prostate Utility Scale
C104604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104604>	C187306|C173084	Concern About Finances Question|Concern About Finances|your financial concerns	A question about whether an individual has or had concerns about finances.			Intellectual Product	Linear Analogue Self-Assessment
C104605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104605>	C173084	Concern About Legal Matters - Will and Advanced Directives Question|Concern About Legal Matters - Will and Advanced Directives|your legal concerns (will, advanced directives, etc.)	A question about whether an individual has or had concerns about personal legal matters, such as a will and advanced directives.			Intellectual Product	Linear Analogue Self-Assessment
C104606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104606>	C175302	Constant Concern|Constant concerns	A response that indicates a state of continual concern.			Intellectual Product	Linear Analogue Self-Assessment
C104607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104607>	C175302	No Concerns|No concerns	An answer indicative of no worries.			Intellectual Product	Linear Analogue Self-Assessment
C104608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104608>	C226725	Highest Level of Support	An answer confirming the highest level of support.			Intellectual Product	
C104609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104609>	C226673	As Good As It Can Be|As good as it can be	A response indicating the something is as good as can be expected or imagined.			Intellectual Product	Linear Analogue Self-Assessment
C10460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10460>	C61063	Cytarabine/Daunorubicin/Pegaspargase/Prednisone/Vincristine|ARA-C/DNR/PEG-ASP/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104610>	C226633	As Bad As It Can Be|As Bad As You Can Imagine|As Bad as You Can Imagine|As bad as it can be	A response indicating the something is as bad as can be expected or imagined.			Intellectual Product	Linear Analogue Self-Assessment|MD Anderson Symptom Inventory - Head and Neck
C104611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104611>	C20194	MAP1LC3A Gene|MAP1LC3A|MAP1LC3A|Microtubule-Associated Protein 1 Light Chain 3 Alpha Gene	This gene plays a role in autophagocytosis.	MAP1LC3A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104612>	C104611	MAP1LC3A wt Allele|ATG8|LC3|LC3A|MAP1ALC3|MAP1BLC3|Microtubule-Associated Protein 1 Light Chain 3 Alpha wt Allele	Human MAP1LC3A wild-type allele is located in the vicinity of 20q11.22 and is approximately 13 kb in length. This allele, which encodes microtubule-associated proteins 1A/1B light chain 3A protein, is involved in microtubule function and autophagocytosis.	MAP1LC3A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104613>	C18466	Microtubule-Associated Proteins 1A/1B Light Chain 3A|Autophagy-Related Protein LC3 A|Autophagy-Related Ubiquitin-Like Modifier LC3 A|MAP1 Light Chain 3-Like Protein 1|MAP1A/1B Light Chain 3 A|MAP1A/MAP1B LC3 A|MAP1A/MAP1B Light Chain 3 A|MAP1LC3A|Microtubule-Associated Protein 1 Light Chain 3 Alpha|Microtubule-Associated Proteins 1A/1B Light Chain 3	Microtubule-associated proteins 1A/1B light chain 3A (121 aa, ~14 kDa) is encoded by the human MAP1LC3A gene. This protein plays a role in autophagocytosis and microtubule function.	Microtubule-Associated Proteins 1A/1B Light Chain 3A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104614>	C25952	LPL Gene|LPL|LPL|Lipoprotein Lipase Gene	This gene is involved in both lipoprotein uptake and triglyceride metabolism.	LPL Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104615>	C104614	LPL wt Allele|HDLCQ11|LIPD|Lipoprotein Lipase wt Allele	Human LPL wild-type allele is located in the vicinity of 8p21.3 and is approximately 66 kb in length. This allele, which encodes lipoprotein lipase, plays a role in both triglyceride metabolism and lipoprotein uptake. Mutations in this gene are associated with several disorders of lipoprotein metabolism.	LPL wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104616>	C16561	Lipoprotein Lipase|3.1.1.34|LPL	Lipoprotein lipase (475 aa, ~53 kDa) is encoded by the human LPL gene. This protein is involved in the metabolism of triglycerides.	Lipoprotein Lipase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104617>	C25790	LRRC19 Gene|LRRC19|LRRC19|Leucine Rich Repeat Containing 19 Gene	This gene may play a role in inducing innate immune responses in kidney and other tissues.	LRRC19 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104618>	C104617	LRRC19 wt Allele|FLJ21302|Leucine Rich Repeat Containing 19 wt Allele	Human LRRC19 wild-type allele is located in the vicinity of 9p21.2 and is approximately 13 kb in length. This allele, which encodes leucine-rich repeat-containing protein 19, may be involved in inducing innate immune responses in kidney and other tissues.	LRRC19 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104619>	C16725	Leucine-Rich Repeat-Containing Protein 19|LRRC19|Leucine Rich Repeat Containing 19	Leucine-rich repeat-containing protein 19 (370 aa, ~42 kDa) is encoded by the human LRRC19 gene. This protein may play a role in inducing innate immune responses in kidney and other tissues.	Leucine-Rich Repeat-Containing Protein 19		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10461>	C61063	Fluorouracil/Interleukin-2/Leucovorin Calcium/Lymphokine-Activated Killer Cells|CF/5-FU/IL-2/LAK			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104620>	C25791|C25790	LAG3 Gene|LAG3|LAG3|Lymphocyte Activation 3 Gene	This gene is involved in the activation of T-cells and natural killer cells.	LAG3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|Pediatric Oncology Immunotherapeutic Target Terminology
C104621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104621>	C104620	LAG3 wt Allele|CD223|FDC|LAG-3|Lymphocyte Activating 3 wt Allele|Lymphocyte-Activation Gene 3 Gene	Human LAG3 wild-type allele is located in the vicinity of 12p13.32 and is approximately 6 kb in length. This allele, which encodes lymphocyte activation gene 3 protein, plays a role in the activation of natural killer cells and T-cells.	LAG3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104622>	C20989	Total Body Water Measurement|TBW|Total Body Water|Total Body Water	A measurement of the quantity of water within the body, including both the intracellular and extracellular compartments.			Diagnostic Procedure	CDISC SDTM Terminology|CDISC SDTM Vital Sign Test Code Terminology|CDISC SDTM Vital Sign Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C104623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104623>	C16725	Lymphocyte Activation Gene 3 Protein|CD223|CD223 Antigen|LAG-3|LAG3|Protein FDC	Lymphocyte activation gene 3 protein (525 aa, ~57 kDa) is encoded by the human LAG3 gene. This protein is involved in the activation of T-cells and natural killer cells.	Lymphocyte Activation Gene 3 Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Immunotherapeutic Target Terminology
C104624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104624>	C25952	LYPLA1 Gene|LYPLA1|LYPLA1|Lysophospholipase I Gene	This gene plays a role in regulating membrane lysophospholipids.	LYPLA1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104625>	C104624	LYPLA1 wt Allele|APT-1|APT1|LPL-I|LPL1|Lysophospholipase I wt Allele|hAPT1	Human LYPLA1 wild-type allele is located in the vicinity of 8q11.23 and is approximately 56 kb in length. This allele, which encodes acyl-protein thioesterase 1 protein, is involved in regulating the level of lysophospholipids in membranes.	LYPLA1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104626>	C16561	Acyl-Protein Thioesterase 1|Acyl-protein Thioesterase-1|EC 3.1.2.-|LYPLA1|LysoPLA I|Lysophospholipase I|Lysophospholipid-Specific Lysophospholipase	Acyl-protein thioesterase 1 (230 aa, ~25 kDa) is encoded by the human LYPLA1 gene. This protein plays a role in regulating membrane lysophospholipid levels.	Acyl-Protein Thioesterase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104627>	C26039	LAMP1 Gene|LAMP1|LAMP1|Lysosomal-Associated Membrane Protein 1 Gene	This gene is involved in cell adhesion and may be involved in tumor cell metastasis.	LAMP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104628>	C104627	LAMP1 wt Allele|CD107a|LAMP-1|LAMPA|LGP120|Lysosomal-Associated Membrane Protein 1 wt Allele	Human LAMP1 wild-type allele is located in the vicinity of 13q34 and is approximately 27 kb in length. This allele, which encodes lysosome-associated membrane glycoprotein 1 protein, plays a role in selectin-mediated cell adhesion and may play a role in tumor cell metastasis.	LAMP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104629>	C18466	Lysosome-Associated Membrane Glycoprotein 1|CD107 Antigen-Like Family Member A|CD107a Antigen|LAMP-1|LAMP1|Lysosomal-Associated Membrane Protein 1|Lysosome-Associated Membrane Protein 1	Lysosome-associated membrane glycoprotein 1 (417 aa, ~45 kDa) is encoded by the human LAMP1 gene. This membrane glycoprotein is involved in selectin-mediated cell adhesion and may be involved in tumor cell metastasis.	Lysosome-Associated Membrane Glycoprotein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10462>	C61063	Carboplatin/Interleukin-1-Alpha|CBDCA/IL-1A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104630>	C25790	MR1 Gene|MR1|MR1|Major Histocompatibility Complex, Class I-Related Gene	This gene plays a role in antigen presentation.	MR1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104631>	C104630	MR1 wt Allele|HLALS|Major Histocompatibility Complex, Class I-Related wt Allele	Human MR1 wild-type allele is located in the vicinity of 1q25.3 and is approximately 29 kb in length. This allele, which encodes major histocompatibility complex class I-related gene protein, is involved in antigen presentation in the gut.	MR1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104632>	C16725	Major Histocompatibility Complex Class I-Related Gene Protein|Class I Histocompatibility Antigen-Like Protein|MHC Class I-Like Antigen MR-1|MHC Class I-Related Gene Protein|MHC Class-I Related-Gene Protein|Major Histocompatibility Complex, Class I-Like Sequence	Major histocompatibility complex class I-related gene protein (341 aa, ~39 kDa) is encoded by the human MR1 gene. This protein plays a role in gut antigen presentation.	Major Histocompatibility Complex Class I-Related Gene Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104633>	C20103	MRC1 Gene|MRC1|MRC1|Mannose Receptor, C Type 1 Gene	This gene is involved in endocytosis of glycoproteins by macrophages.	MRC1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104634>	C104633	MRC1 wt Allele|CD206|CLEC13D|CLEC13DL|MMR|MRC1L1|Mannose Receptor, C Type 1 wt Allele|bA541I19.1	Human MRC1 wild-type allele is located in the vicinity of 10p12.33 and is approximately 102 kb in length. This allele, which encodes macrophage mannose receptor 1 protein, plays a role in mediating endocytosis of glycoproteins by macrophages.	MRC1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104635>	C18106	Macrophage Mannose Receptor 1|C-Type Lectin Domain Family 13 Member D|C-Type Lectin Domain Family 13 Member D-Like|CD206 Antigen|Macrophage Mannose Receptor 1-Like Protein 1|Mannose Receptor, C Type 1|Mannose Receptor, C Type 1-Like 1	Macrophage mannose receptor 1 (1456 aa, ~166 kDa) is encoded by the human MRC1 gene. This protein is involved in mediating macrophage endocytosis of glycoproteins.	Macrophage Mannose Receptor 1		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104636>	C20745	MAP4 Gene|MAP4|MAP4|Microtubule-Associated Protein 4 Gene	This gene plays a role in promoting microtubule assembly.	MAP4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104637>	C104636	MAP4 wt Allele|MAP-4|Microtubule-Associated Protein 4 wt Allele	Human MAP4 wild-type allele is located in the vicinity of 3p21 and is approximately 239 kb in length. This allele, which encodes microtubule-associated protein 4, is involved in both microtubule assembly and cell cycle progression.	MAP4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104638>	C16861	Microtubule-Associated Protein 4|MAP-4|MAP4|Microtubule Associated Protein 4	Microtubule-associated protein 4 (1152 aa, ~121 kDa) is encoded by the human MAP4 gene. This protein plays a role in both microtubule assembly and cell cycle progression.	Microtubule-Associated Protein 4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104639>	C20194	CAPG Gene|CAPG|CAPG|Capping Protein (Actin Filament), Gelsolin-Like Gene	This gene is involved in actin-based motility in non-muscle cells.	CAPG Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10463>	C61063	Carboplatin/Etoposide/Ifosfamide/Sargramostim|CBDCA/GM-CSF/IFF/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104640>	C104639	CAPG wt Allele|AFCP|Capping Protein (Actin Filament), Gelsolin-Like wt Allele|MCP	Human CAPG wild-type allele is located in the vicinity of 2p11.2 and is approximately 24 kb in length. This allele, which encodes macrophage-capping protein, plays a role in actin-based motility in non-muscle cells.	CAPG wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104641>	C18466	Macrophage-Capping Protein|Actin Regulatory Protein CAP-G|Actin-Regulatory Protein CAP-G|Gelsolin-Like Capping Protein|Macrophage Capping Protein	Macrophage-capping protein (348 aa, ~39 kDa) is encoded by the human CAPG gene. This protein is involved in actin-based motility in non-muscle cells.	Macrophage-Capping Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104642>	C20917	MDC1 Gene|MDC1|MDC1|Mediator of DNA Damage Checkpoint 1 Gene	This gene plays a role in cell cycle progression.	MDC1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104643>	C104642	MDC1 wt Allele|Em:AB023051.5|KIAA0170|Mediator of DNA Damage Checkpoint 1 wt Allele|Mediator of DNA-Damage Checkpoint 1 Gene|NFBD1	Human MDC1 wild-type allele is located in the vicinity of 6p21.3 and is approximately 18 kb in length. This allele, which encodes mediator of DNA damage checkpoint protein 1, is involved in checkpoint mediated cell cycle arrest.	MDC1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104644>	C17761	Mediator of DNA Damage Checkpoint Protein 1|Homolog to Drosophila Photoreceptor Protein Calphotin|MDC1|Mediator of DNA Damage Checkpoint 1|Nuclear Factor with BRCT Domains 1	Mediator of DNA damage checkpoint protein 1 (2089 aa, ~227 kDa) is encoded by the human MDC1 gene. This protein plays a role in checkpoint mediated cell cycle arrest.	Mediator of DNA Damage Checkpoint Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104645>	C20103	MRC2 Gene|MRC2|MRC2|Mannose Receptor, C type 2 Gene	This gene is involved in extracellular matrix remodeling.	MRC2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104646>	C104645	MRC2 wt Allele|CD280|CLEC13E|ENDO180|Endocytic Receptor (Macrophage Mannose Receptor Family) Gene|KIAA0709|Mannose Receptor, C type 2 wt Allele|UPARAP	Human MRC2 wild-type allele is located in the vicinity of 17q23.2 and is approximately 66 kb in length. This allele, which encodes C-type mannose receptor 2, plays a role in extracellular matrix remodeling and may play a role in tumorigenesis and metastasis.	MRC2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104647>	C18106	C-Type Mannose Receptor 2|C-Type Lectin Domain Family 13 Member E|CD280 Antigen|Endo180|Endocytic Receptor 180|Macrophage Mannose Receptor 2|UPAR-Associated Protein|Urokinase Plasminogen Activator Receptor-Associated Protein|Urokinase Receptor-Associated Protein|Urokinase-Type Plasminogen Activator Receptor-Associated Protein|uPARAP	C-type mannose receptor 2 (1479 aa, ~167 kDa) is encoded by the human MRC2 gene. This protein is involved in remodeling of the extracellular matrix and may play a role in the tumorigenesis and metastasis.	C-Type Mannose Receptor 2		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104648>	C25790	MICB Gene|MHC Class I Polypeptide-Related Sequence B Gene|MICB|MICB	This gene plays a role in activation of the immune cytolytic response.	MICB Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104649>	C104648	MICB wt Allele|MHC Class I Polypeptide-Related Sequence B wt Allele|MIC-B|PERB11.2	Human MICB wild-type allele is located in the vicinity of 6p21.3 and is approximately 16 kb in length. This allele, which encodes MHC class I polypeptide-related sequence B protein, is involved in cytolytic activation of natural killer cells, CD8 alpha-beta T cells, and gamma-delta T cells.	MICB wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10464>	C61063	Cisplatin/Cyclophosphamide/Leuprolide|CDDP/CTX/LEUP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104650>	C16725	MHC Class I Polypeptide-Related Sequence B|MIC-B	MHC class I polypeptide-related sequence B (383 aa, ~43 kDa) is encoded by the human MICB gene. This protein plays a role in activation of cytolysis by natural killer cells, CD8 alpha-beta T cells, and gamma-delta T cells.	MHC Class I Polypeptide-Related Sequence B		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104651>	C133710	MIB1 Gene|MIB1|MIB1|MIB1|Mindbomb E3 Ubiquitin Protein Ligase 1 Gene	This gene is involved in both ubiquitination and cell signaling.	MIB1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C104652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104652>	C104651	MIB1 wt Allele|DIP-1|DIP1|KIAA1323|MIB|Mindbomb E3 Ubiquitin Protein Ligase 1 wt Allele|Mindbomb Homolog 1 (Drosophila) Gene|ZZANK2|ZZZ6	Human MIB1 wild-type allele is located in the vicinity of 18q11.2 and is approximately 130 kb in length. This allele, which encodes E3 ubiquitin-protein ligase MIB1 protein, plays a role in both ubiquitination and the regulation of Delta-mediated Notch signaling.	MIB1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104653>	C21254	E3 Ubiquitin-Protein Ligase MIB1|DAPK-Interacting Protein 1|EC 2.3.2.27|EC 6.3.2.-, Formerly|MIB1|Mind Bomb Homolog 1|Ubiquitin Ligase Mind Bomb|Ubiquitin Ligase Protein MIB1|Zinc Finger ZZ Type with Ankyrin Repeat Domain Protein 2	E3 ubiquitin-protein ligase MIB1 (1006 aa, ~110 kDa) is encoded by the human MIB1 gene. This protein is involved in both ubiquitination and the regulation of Delta-mediated Notch signaling.	E3 Ubiquitin-Protein Ligase MIB1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104654>	C20673	IRF9 Gene|IRF9|IRF9|Interferon Regulatory Factor 9 Gene	This gene plays a role in both transcription regulation and cell signaling.	IRF9 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104655>	C104654	IRF9 wt Allele|IRF-9|ISGF3|ISGF3G|Interferon Regulatory Factor 9 wt Allele	Human IRF9 wild-type allele is located in the vicinity of 14q11.2 and is approximately 6 kb in length. This allele, which encodes interferon regulatory factor 9 protein, is involved in both transcription regulation and signaling by type I interferons.	IRF9 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104656>	C17207	Interferon Regulatory Factor 9|IFN-Alpha-Responsive Transcription Factor Subunit|IRF9|ISGF-3 Gamma|ISGF3 p48 Subunit|Interferon-Stimulated Gene Factor 3 Gamma|Interferon-Stimulated Transcription Factor 3, Gamma (48kD)|Interferon-Stimulated Transcription Factor 3, Gamma 48kDa|Transcriptional Regulator ISGF3 Subunit Gamma|p48	Interferon regulatory factor 9 (393 aa, ~44 kDa) is encoded by the human IRF9 gene. This protein plays a role in activating transcription via type I interferon signaling.	Interferon Regulatory Factor 9		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104657>	C20921	ISG15 Gene|ISG15|ISG15|ISG15 Ubiquitin-Like Modifier Gene	This gene is involved in both protein tagging and cell signaling.	ISG15 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104658>	C104657	ISG15 wt Allele|G1P2|IFI15|IP17|ISG15 Ubiquitin-Like Modifier wt Allele|UCRP|hUCRP	Human ISG15 wild-type allele is located in the vicinity of 1p36.33 and is approximately 1 kb in length. This allele, which encodes ubiquitin-like protein ISG15, plays a role in type I interferon signaling.	ISG15 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104659>	C18515	Ubiquitin-Like Protein ISG15|Interferon, Alpha-Inducible Protein (Clone IFI-15K)|Interferon-Induced 15 kDa Protein|Interferon-Induced 17 kDa Protein|Interferon-Induced 17-kDa/15-kDa Protein|Interferon-Stimulated Protein, 15 kDa|Ubiquitin Cross-Reactive Protein	Ubiquitin-like protein ISG15 (165 aa, ~18 kDa) is encoded by the human ISG15 gene. This protein is involved in type I interferon-mediated signaling.	Ubiquitin-Like Protein ISG15		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C10465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10465>	C61063	Interferon Gamma/Interleukin-2/Tumor Infiltrating Lymphocytes|IFN-G/IL-2/TIL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104660>	C21240	EIF5 Gene|EIF5|EIF5|Eukaryotic Translation Initiation Factor 5 Gene	This gene plays a role in the initiation of translation.	EIF5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104661>	C104660	EIF5 wt Allele|EIF-5|EIF-5A|Eukaryotic Translation Initiation Factor 5 wt Allele	Human EIF5 wild-type allele is located in the vicinity of 14q32.32 and is approximately 11 kb in length. This allele, which encodes eukaryotic translation initiation factor 5 protein, is involved in both GTP hydrolysis and the association of the 40S and 60S ribosomal subunits.	EIF5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104662>	C17461	Eukaryotic Translation Initiation Factor 5|EIF5|eIF-5	Eukaryotic translation initiation factor 5 (431 aa, ~49 kDa) is encoded by the human EIF5 gene. This protein plays a role in the interaction between the 40S and 60S ribosomal subunits.	Eukaryotic Translation Initiation Factor 5		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104663>	C16672	DNAJ Protein|Chaperone DnaJ|DNA-J|DnaJ Co-Chaperone|DnaJ Family|Heat Shock Protein 40|Hsp40	A family of proteins that is involved in protein folding. DNAJ proteins are co-chaperones that modulate the ATPase activity of DNAK (Hsp70) proteins.	DNAJ Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104664>	C187760	Epstein-Barr Nuclear Antigen 2|BYRF1|EBNA-2|EBNA2|EBV Nuclear Antigen 2|Epstein-Barr Virus Nuclear Antigen 2	Epstein-Barr nuclear antigen 2 (487 aa, ~55 kDa) is encoded by the Epstein-Barr virus EBNA2 gene. This protein is involved in the activation of host B-cells.	Epstein-Barr Nuclear Antigen 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104665>	C80699	MIR382 Gene|MIR382|MIR382|MicroRNA 382 Gene	This gene plays a role in the regulation of transcription.	MIR382 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104666>	C104665	MIR382 wt Allele|MIRN382|MicroRNA 382 wt Allele|hsa-mir-382|mir-382	Human MIR382 wild-type allele is located in the vicinity of 14q32.31 and is approximately 76 bp in length. This allele, which encodes MIR382 pre-microRNA, is involved in the regulation of transcription.	MIR382 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104667>	C25968	MIR382 Pre-miRNA|Pre-miRNA MIR382|Pre-microRNA MIR382	MIR382 pre-microRNA (76 bases) is encoded by the human MIR382 gene. This oligoribonucleotide plays a role in the regulation of transcription.	MIR382 Pre-miRNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104668>	C202673	KIT Exon 11 Mutation|CD117 Exon 11 Mutation|Exon 11|KIT Proto-Oncogene Tyrosine Protein Kinase Gene Exon 11 Mutation|c-KIT Exon 11 Mutation|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Gene Exon 11 Mutation	A molecular genetic abnormality indicating the presence of a mutation in exon 11 of the KIT gene located within 4q11-q12.	KIT Exon 11 Mutation		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104669>	C20194	MST1L Gene|MST1L|MST1L|MST1P9|Macrophage Stimulating 1 Like (Pseudogene) Gene	This gene encodes a non-functional member of the peptidase S1 family.	MST1L Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10466>	C61063	Asparaginase/Cytarabine/Methotrexate/Prednisone/Thioguanine|ARA-C/ASP/MTX/PRED/TG			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104670>	C104669	MST1L wt Allele|BRF-1|D1F15S1A|MSPL-7|MSPL7|MST1P9|MSTP7|MSTP9|Macrophage Stimulating 1 (Hepatocyte Growth Factor-Like) Pseudogene 9 Gene|Macrophage Stimulating 1 Like (Pseudogene) wt Allele|Macrophage Stimulating 1 Like Gene|Macrophage Stimulating 1-Like Gene|Macrophage Stimulating, Pseudogene 7 Gene|Macrophage Stimulating, Pseudogene 9 Gene	Human MST1L wild-type allele is located 1p36.13 and is approximately 15 kb in length. This allele encodes putative macrophage stimulating 1-like protein, a non-functional member of the peptidase S1 family.	MST1L wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104671>	C18466	Putative Macrophage-Stimulating 1-Like Protein|BRF-1|Brain Rescue Factor 1|Brain-Rescue-Factor-1|Hepatocyte Growth Factor-Like Protein Homolog|MST1L|Putative Macrophage-Stimulating Protein MSTP9|Putative Macrophage-Stimulating Protein MSTP9	Putative macrophage stimulating 1-like protein (715 aa, ~80 kDa) is encoded by the human MST1L gene. This protein is a non-functional member of the peptidase S1 family.	Putative Macrophage-Stimulating Protein MSTP9		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104672>	C39712	KIT Exon 9 Mutation|CD117 Exon 9 Mutation|Exon 9|KIT Proto-Oncogene Tyrosine Protein Kinase Gene Exon 9 Mutation|c-KIT Exon 9 Mutation|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Gene Exon 9 Mutation	A molecular genetic abnormality indicating the presence of a mutation in exon 9 of the KIT gene located within 4q11-q12.	KIT Exon 9 Mutation		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104673>	C202673	KIT Exon 13 Mutation|CD117 Exon 13 Mutation|Exon 13|KIT Proto-Oncogene Tyrosine Protein Kinase Gene Exon 13 Mutation|c-KIT Exon 13 Mutation|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Gene Exon 13 Mutation	A molecular genetic abnormality indicating the presence of a mutation in exon 13 of the KIT gene located within 4q11-q12.	KIT Exon 13 Mutation		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104674>	C49142	Genome-Wide DNA Copy Number|copy number|copy_number	The number of DNA sequence copies found over the entire genome of an individual.	Genome-Wide DNA Copy Number		Quantitative Concept	CTRP Biomarker Terminology|CTRP Terminology|GDC Property Terminology|GDC Terminology
C104675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104675>	C17070	Fc-Gamma Receptor|FCGR|Fc Gamma R|Fc Gamma Receptor|Fc GammaR|Fc-Gamma R|Fc-GammaR	Receptors belonging to the immunoglobulin superfamily that bind to the Fc portion of IgG molecules and play a role in the phagocytosis of opsonized bacteria.	Fc-Gamma Receptor		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104676>	C20130	Tenascin Family|Tenascin	A protein family comprised of extracellular matrix-resident glycoproteins that play a role in embryonic development and wound healing.	Tenascin Family		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104677>	C20130	Microtubule-Associated Proteins 1A/1B Light Chain 3|Autophagy-Related Protein Lc3|Autophagy-Related Ubiquitin-Like Modifier LC3|LC3|MAP1 Light Chain 3-Like Protein|MAP1A/MAP1B Light Chain 3|MAP1LC3|Microtubule-Associated Protein 1 Light Chain 3	A protein family whose members bind to microtubule-associated protein 1A and 1B and are involved in the formation of autophagosomes.	Microtubule-Associated Proteins 1A/1B Light Chain 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104678>	C28624	Killer-Cell Immunoglobulin-Like Receptor|CD158|CD158 Family|KIR|Killer Cell Immunoglobulin-Like Receptor|Killer Ig Receptor|Killer Ig-Like Receptor|Killer-Cell Immunoglobulin-Like Receptor Family	A family of cell surface proteins found on natural killer cells that both interact with MHC class I molecules and modulate natural killer cell-mediated cytotoxicity.	Killer-Cell Immunoglobulin-Like Receptor		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104679>	C21176	Interleukin-2 Receptor|High Affinity Interleukin-2 Receptor|IL-2 Receptor|IL-2R|IL2 Receptor|IL2R|Interleukin 2 Receptor	A heterotrimeric protein found on the cell surface of immune cells that binds to interleukin-2. This receptor is comprised of alpha, beta and gamma subunits; the alpha and beta subunits bind interleukin-2 while the downstream ligand-dependent signaling is mediated by the gamma subunit.	Interleukin-2 Receptor		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10467>	C61063	Asparaginase/Cytarabine/Methotrexate/Prednisone/Vincristine|ARA-C/ASP/MTX/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104680>	C16342	Ancestry-Informative Marker|AIM|Ancestry Informative Marker	A set of genetic polymorphisms that are found in different frequencies between populations from different geographical regions.	Ancestry-Informative Marker		Functional Concept	CTRP Biomarker Terminology|CTRP Terminology
C104681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104681>	C29936	SERPINC1 Gene|SERPINC1|SERPINC1|Serpin Peptidase Inhibitor, Clade C (Antithrombin), Member 1 Gene	This gene is involved in the regulation of the coagulation cascade.	SERPINC1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104682>	C104681	SERPINC1 wt Allele|AT3|AT3D|ATIII|MGC22579|PRO0309|Serpin Peptidase Inhibitor, Clade C (Antithrombin), Member 1 wt Allele|THPH7	Human SERPINC1 wild-type allele is located in the vicinity of 1q25.1 and is approximately 14 kb in length. This allele, which encodes antithrombin-III protein, plays a role in both protease inhibition and blood coagulation. Mutation of the gene is associated with antithrombin III deficiency.	SERPINC1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104683>	C17122	Antithrombin-III|ATIII|Antithrombin III|SERPINC1|Serine-Cysteine Proteinase Inhibitor Clade C Member 1|Serpin C1	Antithrombin-III (464 aa, ~53 kDa) is encoded by the human SERPINC1 gene. This protein is involved in the negative regulation of serine proteinase activity during blood coagulation.	Antithrombin-III		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104684>	C21295	CELF2 Gene|CELF2|CELF2|CUGBP, Elav-Like Family Member 2 Gene	This gene plays a role in RNA processing.	CELF2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104685>	C104684	CELF2 wt Allele|BRUNOL3|CUGBP, Elav-Like Family Member 2 wt Allele|CUGBP2|ETR-3|ETR3|NAPOR|NAPOR-2	Human CELF2 wild-type allele is located in the vicinity of 10p13 and is approximately 331 kb in length. This allele, which encodes CUGBP Elav-like family member 2 protein, is involved in both RNA metabolism and heart contraction.	CELF2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104686>	C21298	CUGBP Elav-Like Family Member 2|Bruno-Like Protein 3|CELF-2|CELF2|CUG Triplet Repeat RNA-Binding Protein 2|CUG Triplet Repeat, RNA Binding Protein 2|CUG Triplet Repeat, RNA-Binding Protein 2|CUG-BP- and ETR-3-Like Factor 2|CUG-BP2|ELAV-Type Rna-Binding Protein 3|ETR-3|Neuroblastoma Apoptosis-Related RNA-Binding Protein|RNA-Binding Protein BRUNOL-3|hNAPOR	CUGBP Elav-like family member 2 (508 aa, ~54 kDa) is encoded by the human CELF2 gene. This protein plays a role in both heart contraction and RNA processing.	CUGBP Elav-Like Family Member 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104687>	C16615	MEIS2 Gene|MEIS2|MEIS2|Meis Homeobox 2 Gene	This gene is involved in the regulation gene expression.	MEIS2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104688>	C104687	MEIS2 wt Allele|HsT18361|MRG1|Meis (Mouse) Homolog 2 Gene|Meis Homeobox 2 wt Allele|Meis Homolog 2 Gene|Meis1, Myeloid Ecotropic Viral Integration Site 1 Homolog 2 Gene|Meis1-Related Gene 1	Human MEIS2 wild-type allele is located in the vicinity of 15q14 and is approximately 212 kb in length. This allele, which encodes homeobox protein Meis2, plays a role in transcriptional regulation.	MEIS2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104689>	C17207	Homeobox Protein Meis2|MEIS2|Meis1-Related Protein 1|TALE Homeobox Protein Meis2	Homeobox protein Meis2 (477 aa, ~52 kDa) is encoded by the human MEIS2 gene. This protein is involved in the modulation of gene transcription.	Homeobox Protein Meis2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10468>	C61063	Asparaginase/Prednisone|ASP/PRED			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104690>	C20420	NFYA Gene|NFYA|NFYA|Nuclear Transcription Factor Y, Alpha Gene	This gene plays a role in both DNA binding and transcriptional regulation.	NFYA Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104691>	C104690	NFYA wt Allele|CBF-A|CBF-B|HAP2|NF-YA|Nuclear Transcription Factor Y, Alpha wt Allele	Human NFYA wild-type allele is located in the vicinity of 6p21.3 and is approximately 29 kb in length. This allele, which encodes nuclear transcription factor Y subunit alpha protein, is involved in binding to the CCAAT motif in gene promoters.	NFYA wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104692>	C17207	Nuclear Transcription Factor Y Subunit Alpha|CAAT Box DNA-Binding Protein Subunit A|CAAT-Box DNA Binding Protein Subunit A|CCAAT-Binding Transcription Factor Subunit B|HAP2 CCAAT-Binding Protein|NF-YA|NFYA|Nuclear Transcription Factor Y Subunit A|Transcription Factor NF-Y, A Subunit	Nuclear transcription factor Y subunit alpha (347 aa, ~37 kDa) is encoded by the human NFYA gene. This protein plays a role in both transcriptional regulation and gene promoter binding.	Nuclear Transcription Factor Y Subunit Alpha		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104693>	C21295	STRA6 Gene|STRA6|STRA6|Stimulated By Retinoic Acid 6 Gene	This gene is involved in organogenesis.	STRA6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104694>	C104693	STRA6 wt Allele|FLJ12541|MCOPCB8|MCOPS9|PP14296|Stimulated By Retinoic Acid 6 wt Allele|Stimulated By Retinoic Acid Gene 6 Homolog (Mouse) Gene|UNQ3126/PRO10282/PRO19578	Human STRA6 wild-type allele is located in the vicinity of 15q24.1 and is approximately 33 kb in length. This allele, which encodes stimulated by retinoic acid gene 6 protein homolog, plays a role in both retinol metabolism and organ development. Mutation of the gene is associated with both syndromic microphthalmia type 9 and isolated colobomatous microphthalmia.	STRA6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104695>	C17728	Stimulated By Retinoic Acid Gene 6 Protein Homolog|STRA6	Stimulated by retinoic acid gene 6 protein homolog (667 aa, ~74 kDa) is encoded by the human STRA6 gene. This protein is involved in retinoid metabolism.	Stimulated By Retinoic Acid Gene 6 Protein Homolog		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104696>	C20917	TOB2 Gene|TOB2|TOB2|Transducer of ERBB2, 2 Gene	This gene plays a role in cell cycle regulation.	TOB2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104697>	C104696	TOB2 wt Allele|CTA-223H9.7|KIAA1663|TOB4|TOBL|TROB2|Transducer of ERBB2, 2 wt Allele|bK223H9	Human TOB2 wild-type allele is located in the vicinity of 22q13.2 and is approximately 14 kb in length. This allele, which encodes protein Tob2, is involved in both cell cycle arrest and the negative regulation of cell proliferation.	TOB2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104698>	C17761	Protein Tob2|Protein Tob4|TOB2|Transducer of ErbB-2 2	Protein Tob2 (344 aa, ~37 kDa) is encoded by the human TOB2 gene. This protein plays a role in cell cycle arrest.	Protein Tob2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104699>	C20988	CXADR Gene|CXADR|CXADR|Coxsackie Virus and Adenovirus Receptor Gene	This gene is involved in both cell-cell adhesion and viral infection.	CXADR Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10469>	C61063	Cyclophosphamide/Cytarabine/Daunorubicin/Methotrexate/Prednisone/Thioguanine/Vincristine|ARA-C/CTX/DNR/MTX/PRED/TG/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1046>	C1974	Chaparrinone|Picras-3-ene-2,16-dione, 11,20-epoxy-1,11,12-trihydroxy-, (1beta,11beta,12alpha)-	A quassinoid phytochemical isolated from Ailanthus integrifolia sp. calycina and other plant species with potential antineoplastic activity.  Chaparrinone inhibits protein synthesis, has antimalarial properties, and is cytotoxic to some tumor cells. (NCI04)			Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C104700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104700>	C104699	CXADR wt Allele|CAR|CAR4/6|Coxsackie Virus and Adenovirus Receptor wt Allele|HCAR	Human CXADR wild-type allele is located in the vicinity of 21q21.1 and is approximately 81 kb in length. This allele, which encodes coxsackievirus and adenovirus receptor protein, plays a role in both viral infection and tight junction formation.	CXADR wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104701>	C16393	Coxsackievirus and Adenovirus Receptor|46 kD Coxsackievirus and Adenovirus Receptor (CAR) Protein|CAR|CVB3-Binding Protein|CXADR|Coxsackievirus B-Adenovirus Receptor|HCVADR|hCAR	Coxsackievirus and adenovirus receptor (365 aa, ~40 kDa) is encoded by the human CXADR gene. This protein is involved in both the formation of the epithelial apical junction complex and viral infection.	Coxsackievirus and Adenovirus Receptor		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104702>	C20744	MVP Gene|MVP|MVP|Major Vault Protein Gene	This gene plays a role in vault ribonucleoprotein complex structure.	MVP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104703>	C104702	MVP wt Allele|LRP|Major Vault Protein wt Allele|VAULT1	Human MVP wild-type allele is located in the vicinity of 16p11.2 and is approximately 28 kb in length. This allele, which encodes major vault protein, is involved in vault ribonucleoprotein complex structure and function.	MVP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104704>	C18073	Major Vault Protein|Lung Resistance-Related Protein|MVP	Major vault protein (893 aa, ~100 kDa) is encoded by the human MVP gene. This protein plays a role in both the structure and function of vault ribonucleoprotein complexes.	Major Vault Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104705>	C25873	CAMK2A Gene|CAMK2A|CAMK2A|Calcium/Calmodulin-Dependent Protein Kinase II Alpha Gene	This gene is involved in both protein phosphorylation and signaling.	CAMK2A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104706>	C104705	CAMK2A wt Allele|CAMKA|Calcium/Calmodulin-Dependent Protein Kinase II Alpha wt Allele|KIAA0968	Human CAMK2A wild-type allele is located in the vicinity of 5q32 and is approximately 71 kb in length. This allele, which encodes calcium/calmodulin-dependent protein kinase type II subunit alpha protein, plays a role in both signal transduction and serine/threonine phosphorylation.	CAMK2A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104707>	C17325	Calcium/Calmodulin-Dependent Protein Kinase Type II Subunit Alpha|CAMK2A|CaM Kinase II Alpha Subunit|CaM Kinase II Subunit Alpha|CaM-Kinase II Alpha Chain|CaMK-II Alpha Subunit|CaMK-II Subunit Alpha|CaMKIINalpha|Calcium/Calmodulin-Dependent Protein Kinase (CaM Kinase) II Alpha|Calcium/Calmodulin-Dependent Protein Kinase II Alpha-B Subunit|Calcium/Calmodulin-Dependent Protein Kinase Type II Alpha Chain|EC 2.7.11.17	Calcium/calmodulin-dependent protein kinase type II subunit alpha (478 aa, ~54 kDa) is encoded by the human CAMK2A gene. This protein is involved in both serine/threonine phosphorylation and neurotransmission.	Calcium/Calmodulin-Dependent Protein Kinase Type II Subunit Alpha		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104708>	C153246	RAD50 Gene|RAD50|RAD50|RAD50 Double Strand Break Repair Protein Gene	This gene plays a role in DNA double-strand break repair.	RAD50 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104709>	C104708	RAD50 wt Allele|NBSLD|RAD50 (S. cerevisiae) Homolog Gene|RAD50 Double Strand Break Repair Protein wt Allele|RAD50 Homolog (S. cerevisiae) Gene|RAD50 Homolog, Double Strand Break Repair Protein Gene|RAD50, S. cerevisiae, Homolog of Gene|RAD50-2|RAD502|hRad50	Human RAD50 wild-type allele is located in the vicinity of 5q31 and is approximately 89 kb in length. This allele, which encodes DNA repair protein RAD50, is involved in DNA double-strand break repair, cell cycle checkpoint activation, telomere maintenance, and meiotic recombination. Mutations in this gene are associated with Nijmegen breakage syndrome-like disorder.	RAD50 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10470>	C61063	Asparaginase/Cyclophosphamide/Cytarabine/Daunorubicin/Methotrexate/Prednisone/Thioguanine/Vincristine|ARA-C/ASP/CTX/DNR/MTX/PRED/TG/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104710>	C21170	DNA Repair Protein RAD50|EC 3.6.1.15|EC 3.6.3.27|RAD50|hRAD50	DNA repair protein RAD50 (1312 aa, ~154 kDa) is encoded by the human RAD50 gene. This protein plays a role in DNA double-strand break repair, cell cycle checkpoint activation, telomere maintenance, and meiotic recombination.	DNA Repair Protein RAD50		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104711>	C20813|C159207	RAD51 Gene|RAD51|RAD51|RAD51 Recombinase Gene	This gene is involved in both homologous recombination and repair of DNA.	RAD51 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104712>	C104711	RAD51 wt Allele|BRCC5|FANCR|HRAD51|HsRad51|HsT16930|MRMV2|RAD51 Homolog (S. cerevisiae) Gene|RAD51 Recombinase wt Allele|RAD51, S. cerevisiae, Homolog of A Gene|RAD51, S. cerevisiae, Homolog of Gene|RAD51A|RECA	Human RAD51 wild-type allele is located in the vicinity of 15q15.1 and is approximately 37 kb in length. This allele, which encodes DNA repair protein RAD51 homolog 1 protein, plays a role in both DNA repair and homologous recombination.	RAD51 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104713>	C21170	DNA Repair Protein RAD51 Homolog 1|BRCA1/BRCA2-Containing Complex, Subunit 5|RAD51|RAD51 (S. cerevisiae) Homolog (E coli RecA Homolog)|RAD51 Homolog (RecA Homolog, E. coli)|RAD51 Homolog (RecA Homolog, E. coli) (S. cerevisiae)|RAD51 Homolog A|RecA, E. coli, Homolog of|RecA-Like Protein|Recombination Protein A	DNA repair protein RAD51 homolog 1 (339 aa, ~37 kDa) is encoded by the human RAD51 gene. This protein is involved in both homologous recombination and DNA repair.	DNA Repair Protein RAD51 Homolog 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104714>	C20347	PARK7 Gene|PARK7|PARK7|Parkinson Protein 7 Gene	This gene plays a role in the modulation of apoptotic signaling.	PARK7 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104715>	C104714	PARK7 wt Allele|CTA-215D11.1|DJ-1|DJ1|Parkinson Disease (Autosomal Recessive, Early Oonset) 7 Gene|Parkinson Protein 7 wt Allele	Human PARK7 wild-type allele is located in the vicinity of 1p36.23 and is approximately 31 kb in length. This allele, which encodes protein DJ-1, is involved in the negative regulation of apoptosis. Mutation of the gene is associated with Parkinson disease type 7.	PARK7 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104716>	C19928	Protein DJ-1|EC 3.4.-.-|Oncogene DJ1|PARK7|Parkinson Disease Protein 7	Protein DJ-1 (189 aa, ~20 kDa) is encoded by the human PARK7 gene. This protein plays a role in the downregulation of apoptosis.	Protein DJ-1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104717>	C212943|C19676	PARP2 Gene|PARP2|PARP2|Poly(ADP-Ribose) Polymerase 2 Gene	This gene is involved in base excision repair of DNA.	PARP2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104718>	C104717	PARP2 wt Allele|ADP-Ribosyltransferase (NAD+; Poly(ADP-Ribose) Polymerase)-Like 2 Gene|ADPRT2|ADPRTL2|ADPRTL3|ARTD2|PARP-2|Poly (ADP-Ribose) Polymerase 2 Gene|Poly (ADP-Ribose) Polymerase Family, Member 2 Gene|Poly(ADP-Ribose) Polymerase 2 wt Allele|pADPRT-2	Human PARP2 wild-type allele is located within 14q11.2-q12 and is approximately 14 kb in length. This allele, which encodes poly [ADP-ribose] polymerase 2 protein, plays a role in DNA repair through base excision.	PARP2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104719>	C17362	RASSF5 Gene|RAS Association (RalGDS/AF-6) Domain Family Member 5 Gene|RASSF5|RASSF5	This gene plays a role in both lymphocyte adhesion and suppression of cell growth.	RASSF5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10471>	C61063	Doxorubicin/Estradiol/Goserelin/Thiotepa/Vinblastine|DOX/ESDL/TSPA/VBL/ZDX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104720>	C21170|C17434	Poly [ADP-Ribose] Polymerase 2|ADP-Ribosyltransferase 2|ADP-Ribosyltransferase Diphtheria Toxin-Like 2|ADP-Ribosyltransferase-Like 2|ADPRT-2|ARTD2|EC 2.4.2.30|NAD(+) ADP-Ribosyltransferase 2|PARP-2|PARP2|Poly (ADP-Ribose) Polymerase 2|Poly (ADP-Ribosyl) Transferase-Like 2|Poly(ADP-Ribose) Synthase 2|Poly[ADP-Ribose] Synthase 2|hPARP-2|pADPRT-2	Poly [ADP-ribose] polymerase 2 (583 aa, ~66 kDa) is encoded by the human PARP2 gene. This protein is involved in the initiation of DNA repair.	Poly [ADP-Ribose] Polymerase 2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104721>	C104719	RASSF5 wt Allele|Maxp1|NORE1|NORE1A|NORE1B|RAPL|RAS Association (RalGDS/AF-6) Domain Family Member 5 Gene wt Allele|RASSF3	Human RASSF5 wild-type allele is located in the vicinity of 1q32.1 and is approximately 82 kb in length. This allele, which encodes RAS association domain-containing protein 5, is involved in both tumor suppression and lymphocyte adhesion.	RASSF5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104722>	C20982	Ras Association Domain-Containing Protein 5|New RAS Effector 1|Novel RAS Effector 1|RAS Association (RalGDS/AF-6) Domain Family 5|RAS Association Domain-Containing Protein 5|RAS Effector-Like Protein|Rap1-Binding Protein|Regulator for Cell Adhesion and Polarization Enriched in Lymphoid Tissue|Tumor Suppressor RASSF3	RAS association domain-containing protein 5 (418 aa, ~47 kDa) is encoded by the human RASSF5 gene. This protein plays a role in both lymphocyte adhesion and tumor suppression.	Ras Association Domain-Containing Protein 5		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104723>	C25953	RPP40 Gene|RPP40|RPP40|Ribonuclease P/MRP 40kDa Subunit Gene	This gene is involved in tRNA metabolism.	RPP40 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104724>	C104723	RPP40 wt Allele|RNASEP1|Ribonuclease P/MRP 40kDa Subunit wt Allele|bA428J1.3	Human RPP40 wild-type allele is located in the vicinity of 6p25.1 and is approximately 9 kb in length. This allele, which encodes ribonuclease P protein subunit p40 protein, plays a role in the generation of tRNA molecules.	RPP40 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104725>	C25959	Ribonuclease P Protein Subunit p40|EC 3.1.26.5|RNase P Subunit 1|RNaseP Protein p40|RPP40|Ribonuclease P 40kDa Subunit|Ribonuclease P, 40kD Subunit|Ribonuclease P1	Ribonuclease P protein subunit p40 (363 aa, ~42 kDa) is encoded by the human RPP40 gene. This protein is involved in cleavage of tRNA molecules.	Ribonuclease P Protein Subunit p40		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104726>	C20845	RPS14 Gene|RPS14|RPS14|Ribosomal Protein S14 Gene	This gene plays a role in translation as a structural protein of the 40S ribosome subunit.	RPS14 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104727>	C104726	RPS14 wt Allele|EMTB|Emetine Resistance Gene|Ribosomal Protein S14 wt Allele|S14	Human RPS14 wild-type allele is located within 5q31-q33 and is approximately 7 kb in length. This allele, which encodes 40S ribosomal protein S14, is involved in translation as a structural protein of the 40S ribosome subunit. Loss of this gene may be the cause of 5q deletion syndrome.	RPS14 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104728>	C21210	40S Ribosomal Protein S14|RPS14|Ribosomal Protein S14|Small Ribosomal Subunit Protein uS11	40S ribosomal protein S14 (151 aa, ~16 kDa) is encoded by the human RPS14 gene. This protein plays a role in translation as a structural protein of the 40S ribosome subunit.	40S Ribosomal Protein S14		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104729>	C20703	PBXIP1 Gene|PBXIP1|PBXIP1|Pre-B-Cell Leukemia Homeobox Interacting Protein 1 Gene	This gene plays a role in the negative regulation of transcription.	PBXIP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10472>	C61063	Fluoxymesterone/Tamoxifen|FXM/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104730>	C104729	PBXIP1 wt Allele|HPIP|Pre-B-Cell Leukemia Homeobox Interacting Protein 1 wt Allele|RP11-307C12.2	Human PBXIP1 wild-type allele is located in the vicinity of 1q21.3 and is approximately 12 kb in length. This allele, which encodes pre-B-cell leukemia transcription factor-interacting protein 1, is involved in the negative regulation of transcription factor activity.	PBXIP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104731>	C2124	Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2|99mTc-HYNIC-IL2	A radioconjugate composed of the cytokine interleukin-2 (IL-2) conjugated to the bifunctional chelating agent succinimidyl-6-hydrazinopyridine-3-carboxylate (HYNIC-NHS) and co-ligand tricine and labeled with the radioisotope technetium Tc 99m (99mTc-HYNIC-IL2), that can potentially be used as a diagnostic agent to detect tumor inflammation. Upon intravenous administration, IL-2 selectively binds to the IL-2 receptor (IL-2R) expressed on tumor infiltrating lymphocytes (TILs); upon internalization, the Tc99m moiety can be visualized using radioimaging, which allows the quantification of TILs expressing IL-2R. This agent detects tumor enlargement due to invasion by TILs and not tumor progression.	Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C104732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104732>	C1742|C143099|C129825	Savolitinib|AZD 6094|AZD6094|HMPL-504|SAVOLITINIB|Volitinib	An orally bioavailable inhibitor of the c-Met receptor tyrosine kinase with potential antineoplastic activity. Savolitinib selectively binds to and inhibits the activation of c-Met in an ATP-competitive manner, and disrupts c-Met signal transduction pathways. This may result in cell growth inhibition in tumors that overexpress the c-Met protein. C-Met encodes the hepatocyte growth factor receptor tyrosine kinase and plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis; this protein is overexpressed or mutated in a variety of cancers.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C104733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104733>	C26199	Pre-B-Cell Leukemia Transcription Factor-Interacting Protein 1|Hematopoietic PBX-Interacting Protein|Hematopoietic PBX1-Interacting Protein1|PBX Homeobox-Interacting Protein 1|PBXIP1|Pre-B-Cell Leukemia Transcription Factor Interacting Protein 1	Pre-B-cell leukemia transcription factor-interacting protein 1 (731 aa, ~81 kDa) is encoded by the human PBXIP1 gene. This protein plays a role in the repression of gene transcription.	Pre-B-Cell Leukemia Transcription Factor-Interacting Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104734>	C1752|C1663	WT1 235-243 Peptide Vaccine	A synthetic peptide vaccine consisting of a HLA-A24-restricted human Wilms' Tumor protein-1 (WT1) peptide comprised of amino acids 235 through 243, a MHC class I-restricted peptide, with potential immunomodulating and antitumor activities. Vaccination with WT1 235-243 peptide may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation. WT1, a zinc finger DNA-binding protein, is overexpressed in most types of leukemia and in a variety of solid cancers.	WT1 235-243 Peptide Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C104735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104735>	C20194	RICTOR Gene|RICTOR|RICTOR|RPTOR Independent Companion of MTOR, Complex 2 Gene	This gene is involved in the regulation of cell growth.	RICTOR Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104736>	C104735	RICTOR wt Allele|AVO3|KIAA1999|MGC39830|PIA|RPTOR Independent Companion of MTOR, Complex 2 wt Allele|hAVO3|mAVO3	Human RICTOR wild-type allele is located in the vicinity of 5p13.1 and is approximately 136 kb in length. This allele, which encodes rapamycin-insensitive companion of mTOR protein, plays a role in nutrient-dependent regulation of cell growth.	RICTOR wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104737>	C1752|C1663	WT1 247-261 Peptide Vaccine	A synthetic peptide vaccine consisting of a HLA-DRw53-restricted human Wilms' Tumor protein-1 (WT1) peptide comprised of amino acids 247 through 261, a HLA class II-restricted WT1 peptide, with potential immunomodulating and antitumor activities. Vaccination with WT1 247-261 peptide may stimulate a CD4-positive helper T-lymphocyte-mediated immune response against WT1 expressing cells. Activated helper T-cells stimulate dendritic cells, and activate the proliferation of other T-lymphoctes and B-lymphocytes. This causes tumor cell lysis and inhibition of cancer cell proliferation in WT1-overexpressing tumor cells. WT1, a zinc finger DNA-binding protein, is overexpressed in most types of leukemia and in a variety of solid cancers.	WT1 247-261 Peptide Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C104738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104738>	C1752|C1663	WT1 124-138 Peptide Vaccine	A synthetic peptide vaccine consisting of a HLA-DR15-restricted human Wilms' Tumor protein-1 (WT1) peptide comprised of amino acids 124 through 138, a HLA class II-restricted WT1 peptide, with potential immunomodulating and antitumor activities. Vaccination with WT1 124-138 peptide may stimulate a CD4-positive helper T-lymphocyte-mediated immune response against WT1 expressing cells. Activated helper T-cells stimulate dendritic cells, and activate the proliferation of other T-lymphoctes and B-lymphocytes. This causes tumor cell lysis and inhibition of cancer cell proliferation in WT1-overexpressing tumor cells. WT1, a zinc finger DNA-binding protein, is overexpressed in most types of leukemia and in a variety of solid cancers.	WT1 124-138 Peptide Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C104739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104739>	C25952	PDE2A Gene|PDE2A|PDE2A|Phosphodiesterase 2A, cGMP-Stimulated Gene	This gene is involved in second messenger molecule metabolism.	PDE2A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10473>	C61063	Carboplatin/Fluorouracil/Procarbazine|CBDCA/5-FU/PCB			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104740>	C18466	Rapamycin-Insensitive Companion of mTOR|AVO3 Homolog|Pianissimo|RICTOR|RPTOR Independent Companion of MTOR, Complex 2|TORC2-Specific Protein AVO3	Rapamycin-insensitive companion of mTOR (1708 aa, ~192 kDa) is encoded by the human RICTOR gene. This protein is involved in regulation of cell growth in response to nutrients and growth factors.	Rapamycin-Insensitive Companion of mTOR		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104741>	C104739	PDE2A wt Allele|CGS-PDE|PDE2A1|PED2A4|Phosphodiesterase 2A, cGMP-Stimulated wt Allele|cGSPDE	Human PDE2A wild-type allele is located in the vicinity of 11q13.4 and is approximately 98 kb in length. This allele, which encodes cGMP-dependent 3',5'-cyclic phosphodiesterase protein, plays a role in the metabolism of both cyclic AMP and cyclic GMP.	PDE2A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104742>	C16561	cGMP-Dependent 3',5'-Cyclic Phosphodiesterase|CGS-PDE|Cyclic GMP-Stimulated Phosphodiesterase|EC 3.1.4.17|PDE2A|cGMP-Dependent 3,5-Cyclic Phosphodiesterase|cGMP-Stimulated Phosphodiesterase 1|cGMP-Stimulated Phosphodiesterase 4|cGSPDE	cGMP-dependent 3',5'-cyclic phosphodiesterase (941 aa, ~106 kDa) is encoded by the human PDE2A gene. This protein is involved in the catabolism of both cyclic GMP and cyclic AMP.	cGMP-Dependent 3,5-Cyclic Phosphodiesterase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104744>	C174048	Ulixertinib|1H-Pyrrole-2-carboxamide, 4-(5-chloro-2-((1-methylethyl)amino)-4-pyridinyl)-N-((1S)-1-(3-chlorophenyl)-2-hydroxyethyl)-|BVD-523|ULIXERTINIB|VRT752271	An orally available inhibitor of extracellular signal-regulated kinase (ERK) 1 and 2, with potential antineoplastic activity. Upon oral administration, ulixertinib inhibits both ERK 1 and 2, thereby preventing the activation of ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.	Ulixertinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C104745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104745>	C1404|C129825	Amcasertib|AMCASERTIB|BBI503	An orally available cancer cell stemness kinase inhibitor with potential antineoplastic activity. Even though the exact target has not been fully elucidated, amcasertib targets and inhibits one or more pathways involved in cancer stem cell survival. As a result, cancer stem cell (CSC) growth as well as heterogeneous cancer cell growth is inhibited. CSCs, self-replicating cells able to differentiate into heterogeneous cancer cells, appear to be responsible for both tumor relapse and metastasis.	Amcasertib		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C104746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104746>	C1967|C129825	IGF-1R Inhibitor PL225B|PL225B	An orally bioavailable inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. IGF-1R inhibitor PL225B selectively binds to and inhibits the activities of IGF-1R, which may result in both the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis in IGF-1R-overexpressing tumor cells. IGF-1R, a receptor tyrosine kinase overexpressed in a variety of human cancers, plays a significant role in the stimulation of cellular proliferation, oncogenic transformation, and suppression of apoptosis.	IGF-1R Inhibitor PL225B		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C104747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104747>	C1752|C1663	UV1 Telomerase Peptide Vaccine|UV1/hTERT Peptide Vaccine	A synthetic, peptide cancer vaccine directed against the human telomerase reverse transcriptase catalytic subunit (hTERT) with potential immunomodulating activity. Vaccination with the UV1 telomerase peptide may stimulate cytotoxic T-cells to recognize and kill telomerase-expressing cells. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation.	UV1 Telomerase Peptide Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C104748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104748>	C209396|C146993	Darolutamide|Antiandrogen ODM-201|BAY 1841788|BAY-1841788|BAY1841788|DAROLUTAMIDE|Nubeqa|ODM 201|ODM-201|ODM201	A formulation containing an androgen receptor (AR) antagonist with potential antineoplastic activity. Darolutamide binds to ARs in target tissues; subsequently, inhibiting androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes that regulate prostate cancer cell proliferation. This ultimately leads to an inhibition of growth in AR-expressing prostate cancer cells.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C104749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104749>	C21344	PDGFC Gene|PDGFC|PDGFC|Platelet Derived Growth Factor C Gene	This gene plays a role in growth factor signaling.	PDGFC Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10474>	C61063	Fluorouracil/Leucovorin Calcium/Zidovudine|CF/5-FU/ZDV			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104750>	C104749	PDGFC wt Allele|FALLOTEIN|Platelet Derived Growth Factor C wt Allele|SCDGF|UNQ174/PRO200	Human PDGFC wild-type allele is located in the vicinity of 4q23 and is approximately 211 kb in length. This allele, which encodes platelet-derived growth factor C protein, is involved in both embryonic development and growth factor signaling.	PDGFC wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104751>	C20424	Platelet-Derived Growth Factor C|Fallotein|PDGF-C|PDGFC|SCDGF|Secretory Growth Factor-Like Protein|Spinal Cord-Derived Growth Factor|VEGF-E	Platelet-derived growth factor C (345 aa, ~39 kDa) is encoded by the human PDGFC gene. This protein plays a role in both growth factor receptor binding and embryonic development.	Platelet-Derived Growth Factor C		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104752>	C20194	RLF Gene|RLF|RLF|Rearranged L-myc Fusion Gene	This gene may play a role in transcriptional regulation.	RLF Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104753>	C104752	RLF wt Allele|Rearranged L-myc Fusion wt Allele|ZNF292L|Zn-15L	Human RLF wild-type allele is located in the vicinity of 1p32 and is approximately 80 kb in length. This allele, which encodes zinc finger protein RLF, may be involved in DNA binding and transcriptional regulation.	RLF wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104754>	C18466	Zinc Finger Protein RLF|Rearranged L-myc Fusion Gene Protein|Rearranged L-myc Fusion Sequence|Zn-15 Related|Zn-15-Related Protein	Zinc finger protein RLF (1914 aa, ~218 kDa) is encoded by the human RLF gene. This protein may play a role in DNA binding and transcriptional regulation.	Zinc Finger Protein RLF		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104755>	C19676	RPA1 Gene|RPA1|RPA1|Replication Protein A1, 70kDa Gene	This gene is involved in DNA metabolism.	RPA1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104756>	C104755	RPA1 wt Allele|HSSB|MST075|MSTP075|REPA1|RF-A|RP-A|RPA70|Replication Protein A1, 70kDa wt Allele	Human RPA1 wild-type allele is located in the vicinity of 17p13.3 and is approximately 70 kb in length. This allele, which encodes replication protein A 70 kDa DNA-binding subunit protein, plays a role in stabilizing single-stranded DNA structures.	RPA1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104757>	C21170	Replication Protein A 70 kDa DNA-Binding Subunit|RF-A Protein 1|RP-A p70|RPA1|Replication Factor A Protein 1|Replication Protein A1 70kDa|Replication Protein A1, 70kDa|Single-Stranded DNA-Binding Protein	Replication protein A 70 kDa DNA-binding subunit (616 aa, ~68 kDa) is encoded by the human RPA1 gene. This protein is involved in stabilizing single-stranded DNA structures.	Replication Protein A 70 kDa DNA-Binding Subunit		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104758>	C25873	PDK1 Gene|PDK1|PDK1|Pyruvate Dehydrogenase Kinase, Isozyme 1 Gene	This gene is involved in glucose metabolism.	PDK1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104759>	C104758	PDK1 wt Allele|PDHK1|Pyruvate Dehydrogenase Kinase, Isozyme 1 wt Allele	Human PDK1 wild-type allele is located in the vicinity of 2q31.1 and is approximately 70 kb in length. This allele, which encodes [pyruvate dehydrogenase [lipoamide]] kinase isozyme 1, mitochondrial protein, plays a role in carbohydrate metabolism.	PDK1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10475>	C61063	Filgrastim/Piroxantrone|G-CSF/PXT			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104760>	C20845	RPL13A Gene|RPL13A|RPL13A|Ribosomal Protein L13a Gene	This gene plays a role in translation as a structural protein of the 60S ribosome subunit.	RPL13A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104761>	C17325	[Pyruvate Dehydrogenase [Lipoamide]] Kinase Isozyme 1, Mitochondrial|EC 2.7.11.2|Mitochondrial Pyruvate Dehydrogenase, Lipoamide, Kinase Isoenzyme 1|PDK-1|PDK1|Pyruvate Dehydrogenase Kinase Isoform 1|Pyruvate Dehydrogenase Kinase, Isoenzyme 1	[Pyruvate dehydrogenase [lipoamide]] kinase isozyme 1, mitochondrial (436 aa, ~49 kDa) is encoded by the human PDK1 gene. This protein is involved in pyruvate and glucose metabolism.	[Pyruvate Dehydrogenase [Lipoamide]] Kinase Isozyme 1, Mitochondrial		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104762>	C104760	RPL13A wt Allele|L13A|Ribosomal Protein L13a wt Allele|TSTA1	Human RPL13A wild-type allele is located in the vicinity of 19q13.3 and is approximately 8 kb in length. This allele, which encodes 60S ribosomal protein L13a, is involved in translation as a structural protein of the 60S ribosome subunit.	RPL13A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104763>	C21210	60S Ribosomal Protein L13a|23 kDa Highly Basic Protein|Large Ribosomal Subunit Protein uL13|RPL13A|Tissue Specific Transplantation Antigen 1	60S ribosomal protein L13a (203 aa, ~24 kDa) is encoded by the human RPL13A gene. This protein plays a role in translation as a structural protein of the 60S ribosome subunit.	60S Ribosomal Protein L13a		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104764>	C25873	RPS6KA1 Gene|RPS6KA1|RPS6KA1|Ribosomal Protein S6 Kinase A1 Gene	This gene is involved in controlling cell growth and differentiation.	RPS6KA1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104765>	C104764	RPS6KA1 wt Allele|HU-1|MAPKAPK-1a|MAPKAPK1A|RSK|RSK-1|RSK1|Ribosomal Protein S6 Kinase A1 wt Allele|Ribosomal Protein S6 Kinase, 90-kD, 1 Gene|Ribosomal Protein S6 Kinase, 90kD, Polypeptide 1 Gene|Ribosomal Protein S6 Kinase, 90kDa, Polypeptide 1 Gene|dJ590P13.1|dJ590P13.1 (Ribosomal Protein S6 Kinase, 90kD, Polypeptide 1) Gene|p90Rsk	Human RPS6KA1 wild-type allele is located in the vicinity of 1p36.11 and is approximately 45 kb in length. This allele, which encodes ribosomal protein S6 kinase alpha-1 protein, plays a role in regulating transcription, cellular proliferation, differentiation, and survival.	RPS6KA1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104766>	C17325	Ribosomal Protein S6 Kinase Alpha-1|90 kDa Ribosomal Protein S6 Kinase 1|EC 2.7.11.1|MAP Kinase-Activated Protein Kinase 1a|MAPK-Activated Protein Kinase 1a|MAPKAP Kinase 1a|MAPKAPK-1a|Mitogen-Activated Protein Kinase-Activated Protein Kinase 1a|RPS6KA1|RSK-1|Ribosomal Protein S6 Kinase 1|Ribosomal Protein S6 Kinase Alpha 1|Ribosomal S6 Kinase 1|S6K-Alpha 1|S6K-Alpha-1|p90-RSK 1|p90RSK1|p90S6K	Ribosomal protein S6 kinase alpha-1 (735 aa, ~83 kDa) is encoded by the human RPS6KA1 gene. This protein is involved in MAPK signaling and regulation of cell growth, proliferation, and differentiation.	Ribosomal Protein S6 Kinase Alpha-1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104767>	C20921	RPTOR Gene|RPTOR|RPTOR|Regulatory Associated Protein of mTOR Complex 1 Gene	This gene is involved in regulating cell growth.	RPTOR Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104768>	C104767	RPTOR wt Allele|KIAA1303|KOG1|Mip1|Raptor Gene|Regulatory Associated Protein of mTOR Complex 1 wt Allele|Regulatory Associated Protein of mTOR, Complex 1 Gene	Human RPTOR wild-type allele is located in the vicinity of 17q25.3 and is approximately 422 kb in length. This allele, which encodes regulatory-associated protein of mTOR protein, plays a role in regulating cell growth in response to nutrient and insulin levels.	RPTOR wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104769>	C18515	Regulatory-Associated Protein of mTOR|RPTOR|Raptor|p150 Target of Rapamycin (TOR)-Scaffold Protein|p150 Target of Rapamycin (TOR)-Scaffold Protein Containing WD-Repeats	Regulatory-associated protein of mTOR (1335 aa, ~149 kDa) is encoded by the human RPTOR gene. This protein is involved in regulating cell growth and survival in response to nutrient and hormonal signals.	Regulatory-Associated Protein of mTOR		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10476>	C61063	Doxorubicin/Paclitaxel|DOX/TAX|Paclitaxel/Doxorubicin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104770>	C20847	RRM2B Gene|RRM2B|RRM2B|Ribonucleotide Reductase M2 B (TP53 Inducible) Gene	This gene plays a role in deoxyribonucleoside diphosphate metabolism.	RRM2B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104771>	C104770	RRM2B wt Allele|MTDPS8A|MTDPS8B|P53R2|PEOA5|Ribonucleotide Reductase M2 B (TP53 Inducible) wt Allele	Human RRM2B wild-type allele is located in the vicinity of 8q23.1 and is approximately 35 kb in length. This allele, which encodes ribonucleoside-diphosphate reductase subunit M2 B protein, is involved in generation of deoxyribonucleoside diphosphates. Mutations in this gene have been associated with autosomal recessive mitochondrial DNA depletion syndrome, autosomal dominant progressive external ophthalmoplegia-5, and mitochondrial neurogastrointestinal encephalopathy.	RRM2B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104772>	C16946	Ribonucleoside-Diphosphate Reductase Subunit M2 B|EC 1.17.4.1|RRM2B|Ribonucleotide Reductase M2 B (TP53 Inducible)|TP53-Inducible Ribonucleotide Reductase M2 B|p53-Inducible Ribonucleotide Reductase Short Form Beta|p53-Inducible Ribonucleotide Reductase Small Subunit 2 Homolog|p53-Inducible Ribonucleotide Reductase Small Subunit 2-Like Protein|p53R2	Ribonucleoside-diphosphate reductase subunit M2 B (351 aa, ~41 kDa) is encoded by the human RRM2B gene. This protein plays a role in the metabolism of deoxyribonucleoside diphosphates.	Ribonucleoside-Diphosphate Reductase Subunit M2 B		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104773>	C20923	S1PR2 Gene|S1PR2|S1PR2|Sphingosine-1-Phosphate Receptor 2 Gene	This gene is involved in both cell proliferation and cell survival.	S1PR2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104774>	C104773	S1PR2 wt Allele|AGR16|EDG-5|EDG5|Gpcr13|H218|LPB2|S1P2|Sphingosine-1-Phosphate Receptor 2 wt Allele	Human S1PR2 wild-type allele is located in the vicinity of 19p13.2 and is approximately 10 kb in length. This allele, which encodes sphingosine 1-phosphate receptor 2 protein, plays a role in cell proliferation, cell survival, and transcriptional activation.	S1PR2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104775>	C18239	Sphingosine 1-Phosphate Receptor 2|Endothelial Differentiation G-Protein Coupled Receptor 5|Endothelial Differentiation, Sphingolipid G-Protein-Coupled Receptor, 5|S1P Receptor 2|S1P Receptor EDG-5|S1P Receptor EDG5|Sphingosine 1-Phosphate Receptor EDG-5|Sphingosine-1-Phosphate Receptor 2	Sphingosine 1-phosphate receptor 2 (353 aa, ~39 kDa) is encoded by the human S1PR2 gene. This protein is involved in transcriptional activation, cell proliferation and cell survival.	Sphingosine 1-Phosphate Receptor 2		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104776>	C20923	S1PR3 Gene|S1PR3|S1PR3|Sphingosine-1-Phosphate Receptor 3 Gene	This gene encodes a G protein-coupled receptor that may play a role in the regulation of angiogenesis and vascular endothelial cell function.	S1PR3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104777>	C104776	S1PR3 wt Allele|EDG-3|EDG3|LPB3|S1P3|Sphingosine-1-Phosphate Receptor 3 wt Allele	Human S1PR3 wild-type allele is located within 9q22.1-q22.2 and is approximately 14 kb in length. This allele, which encodes sphingosine 1-phosphate receptor 3 protein, may be involved in regulating angiogenesis and vascular endothelial cell function.	S1PR3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104778>	C18239	Sphingosine 1-Phosphate Receptor 3|Endothelial Differentiation G-Protein Coupled Receptor 3|Endothelial Differentiation, Sphingolipid G-Protein-Coupled Receptor, 3|G Protein-Coupled Receptor, Endothelial Differentiation Gene-3|S1P Receptor 3|S1P Receptor EDG-3|S1P Receptor EDG3|Sphingosine 1-Phosphate Receptor EDG-3|Sphingosine-1-Phosphate Receptor 3	Sphingosine 1-phosphate receptor 3 (378 aa, ~42 kDa) is encoded by the human S1PR3 gene. This G protein-coupled receptor may play a role in vascular endothelial cell function and regulation of angiogenesis.	Sphingosine 1-Phosphate Receptor 3		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104779>	C20923	S1PR4 Gene|S1PR4|S1PR4|Sphingosine-1-Phosphate Receptor 4 Gene	This gene encodes a G protein-coupled receptor that may be involved in cell migration processes in lymphocytes.	S1PR4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10477>	C61063	Doxorubicin/Filgrastim/Paclitaxel|DOX/G-CSF/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104780>	C104779	S1PR4 wt Allele|EDG6|LPC1|S1P4|SLP4|Sphingosine-1-Phosphate Receptor 4 wt Allele	Human S1PR4 wild-type allele is located in the vicinity of 19p13.3 and is approximately 2 kb in length. This allele, which encodes sphingosine 1-phosphate receptor 4 protein, may play a role in cell migration processes in lymphocytes.	S1PR4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104781>	C18239	Sphingosine 1-Phosphate Receptor 4|Endothelial Differentiation G-Protein Coupled Receptor 6|Endothelial Differentiation, G Protein Coupled Receptor 6|Endothelial Differentiation, G-Protein-Coupled Receptor 6|Endothelial Differentiation, Lysophosphatidic Acid G-Protein-Coupled Receptor, 6|S1P Receptor 4|S1P Receptor EDG-6|Sphingosine 1-Phosphate Receptor EDG6|Sphingosine-1-Phosphate Receptor 4	Sphingosine 1-phosphate receptor 4 (384 aa, ~42 kDa) is encoded by the human S1PR4 gene. This G protein-coupled receptor may be involved in cell migration processes in lymphocytes.	Sphingosine 1-Phosphate Receptor 4		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104782>	C20923	S1PR5 Gene|S1PR5|S1PR5|Sphingosine-1-Phosphate Receptor 5 Gene	This gene plays a role in regulating cell proliferation, apoptosis, motility, and neurite retraction.	S1PR5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104783>	C104782	S1PR5 wt Allele|EDG-8|EDG8|S1P5|SPPR-1|SPPR-2|Sphingosine-1-Phosphate Receptor 5 wt Allele	Human S1PR5 wild-type allele is located in the vicinity of 19p13.2 and is approximately 11 kb in length. This allele, which encodes sphingosine 1-phosphate receptor 5 protein, is involved in the regulation of cell proliferation, apoptosis, motility, and neurite retraction.	S1PR5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104784>	C18239	Sphingosine 1-Phosphate Receptor 5|Endothelial Differentiation G-Protein-Coupled Receptor 8|Endothelial Differentiation, Sphingolipid G-Protein-Coupled Receptor, 8|S1P Receptor 5|S1P Receptor EDG-8|Sphingosine 1-Phosphate Receptor EDG-8|Sphingosine 1-Phosphate Receptor EDG8|Sphingosine-1-Phosphate Receptor 5	Sphingosine 1-phosphate receptor 5 (398 aa, ~42 kDa) is encoded by the human S1PR5 gene. This protein plays a role in the regulation of cell proliferation and motility, apoptosis, and neurite retraction.	Sphingosine 1-Phosphate Receptor 5		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104785>	C20194	PDPN Gene|PDPN|PDPN|PDPN|Podoplanin Gene	This gene plays a role in cell shape.	PDPN Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C104786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104786>	C104785	PDPN wt Allele|AGGRUS|CTA-520D8.1|GP36|GP40|Gp38|HT1A-1|Lung Type-I Cell Membrane-Associated Glycoprotein Gene|OTS8|PA2.26|PSEC0003|PSEC0025|Podoplanin wt Allele|T1A|T1A-2	Human PDPN wild-type allele is located in the vicinity of 1p36.21 and is approximately 34 kb in length. This allele, which encodes podoplanin protein, is involved in the modulation of cell shape.	PDPN wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104787>	C18466	Podoplanin|Aggrus|Glycoprotein 36|Gp36|PA2.26 Antigen|PDPN|T1-Alpha|hT1alpha-1|hT1alpha-2	Podoplanin (162 aa, ~17 kDa) is encoded by the human PDPN gene. This protein plays a role in the determination of cell shape.	Podoplanin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104788>	C73706	Position	A reference to the alignment of an object, a particular situation or view of a situation, or the location of an object.			Conceptual Entity	
C104789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104789>	C25871	PFKM Gene|PFKM|PFKM|Phosphofructokinase, Muscle Gene	This gene is involved in glycolysis in muscle cells.	PFKM Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10478>	C61063	Cyclophosphamide/Daunorubicin/Dexamethasone/Etoposide/Methotrexate/Thiotepa/Vincristine|CTX/DM/DNR/MTX/TSPA/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104790>	C104789	PFKM wt Allele|GSD7|PFK-1|PFK1|PFKA|PFKX|Phosphofructokinase, Muscle wt Allele|Phosphofructokinase, Polypeptide X Gene	Human PFKM wild-type allele is located in the vicinity of 12q13.11 and is approximately 41 kb in length. This allele, which encodes 6-phosphofructokinase, muscle type protein, plays a role in muscle cell metabolism of glucose. Mutation of the gene is associated with glycogen storage disease type 7.	PFKM wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104791>	C16984	6-Phosphofructokinase, Muscle Type|6-Phosphofructo-1-Kinase|EC 2.7.1.11|PFK-A|PFKM|Phosphofructo-1-Kinase Isozyme A|Phosphofructokinase 1|Phosphofructokinase-M|Phosphohexokinase	6-phosphofructokinase, muscle type (780 aa, ~85 kDa) is encoded by the human PFKM gene. This protein is involved in the mediation of muscle cell glycolysis.	6-Phosphofructokinase, Muscle Type		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104792>	C20194	PIGF Gene|PIGF|PIGF|Phosphatidylinositol Glycan Anchor Biosynthesis, Class F Gene	This gene plays a role in the synthesis of glycophosphatidyl inositol anchors.	PIGF Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104793>	C104792	PIGF wt Allele|Phosphatidylinositol Glycan Anchor Biosynthesis, Class F wt Allele|Phosphatidylinositol Glycan, Class F Gene	Human PIGF wild-type allele is located within 2p21-p16 and is approximately 36 kb in length. This allele, which encodes phosphatidylinositol-glycan biosynthesis class F protein, is involved in protein lipidation.	PIGF wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104794>	C18466	Phosphatidylinositol-Glycan Biosynthesis Class F Protein|GPI11 Homolog|PIG-F|PIGF	Phosphatidylinositol-glycan biosynthesis class F protein (219 aa, ~25 kDa) is encoded by the human PIGF gene. This protein plays a role in glycophosphatidyl inositol anchor biosynthesis.	Phosphatidylinositol-Glycan Biosynthesis Class F Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104795>	C25870	PIAS1 Gene|PIAS|PIAS1|PIAS1|Protein Inhibitor of Activated STAT, 1 Gene	This gene is involved in both signal transduction and the sumoylation of proteins.	PIAS1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104796>	C104795	PIAS1 wt Allele|DDXBP1|GBP|GU/RH-II|Protein Inhibitor of Activated STAT, 1 wt Allele|ZMIZ3|Zinc Finger, MIZ-Type Containing 3 Gene	Human PIAS1 wild-type allele is located in the vicinity of 15q23 and is approximately 137 kb in length. This allele, which encodes E3 SUMO-protein ligase PIAS1 protein, plays a role in both protein sumoylation and signaling.	PIAS1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104797>	C16259	E3 SUMO-Protein Ligase PIAS1|AR Interacting Protein|DEAD/H (Asp-Glu-Ala-Asp/His) Box Binding Protein 1|DEAD/H Box-Binding Protein 1|E3 SUMO-Protein Transferase PIAS1|EC 2.3.2.-|GBP|Gu-Binding Protein|PIAS1|Protein Inhibitor of Activated STAT Protein 1|Protein Inhibitor of Activated STAT-1|RNA Helicase II-Binding Protein	E3 SUMO-protein ligase PIAS1 (651 aa, ~72 kDa) is encoded by the human PIAS1 gene. This protein is involved in the mediation of protein sumoylation.	E3 SUMO-Protein Ligase PIAS1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104798>	C25873	PIM2 Gene|PIM2|PIM2|Pim-2 Oncogene Gene	This gene plays a role in protein phosphorylation, cell proliferation and the regulation of apoptosis.	PIM2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104799>	C104798	PIM2 wt Allele|Pim-2 Oncogene wt Allele|Proto-Oncogene Pim-2 (Serine Threonine Kinase) Gene	Human PIM2 wild-type allele is located in the vicinity of Xp11.23 and is approximately 6 kb in length. This allele, which encodes serine/threonine-protein kinase pim-2 protein, is involved in the modulation of cell proliferation, serine/threonine phosphorylation and apoptosis.	PIM2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10479>	C61063	Asparaginase/Cytarabine/Etoposide/Methotrexate/Methylprednisolone/Vincristine|ARA-C/ASP/MePRDL/MTX/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1047>	C697	Chlornaphazine|CHLORNAPHAZINE	An alkylating antineoplastic agent no longer used in the United States, because it induces chromosomal aberration and causes cancer. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C104800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104800>	C17325	Serine/Threonine-Protein Kinase Pim-2|EC 2.7.11.1|PIM2|Pim-2h|Serine/Threonine Protein Kinase Pim-2	Serine/threonine-protein kinase pim-2 (311 aa, ~34 kDa) is encoded by the human PIM2 gene. This protein plays a role in apoptosis regulation, protein phosphorylation and cell proliferation.	Serine/Threonine-Protein Kinase Pim-2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104801>	C25873	PRKCI Gene|PRKCI|PRKCI|Protein Kinase C, Iota Gene	This gene plays a role in the negative regulation of apoptosis.	PRKCI Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104802>	C104801	PRKCI wt Allele|DXS1179E|PKCI|Protein Kinase C, Iota wt Allele|nPKC-iota	Human PRKCI wild-type allele is located in the vicinity of 3q26.3 and is approximately 84 kb in length. This allele, which encodes protein kinase C iota type protein, is involved in both apoptosis and protein phosphorylation.	PRKCI wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104803>	C17325	Protein Kinase C Iota Type|Atypical Protein Kinase C-Lambda/Iota|EC 2.7.11.13|PRKC-Lambda/Iota|PRKCI|aPKC-Lambda/Iota|nPKC-Iota	Protein kinase C iota type (596 aa, ~68 kDa) is encoded by the human PRKCI gene. This protein plays a role in serine/threonine phosphorylation.	Protein Kinase C Iota Type		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104804>	C20194	PRUNE2 Gene|PRUNE2|PRUNE2|Prune Homolog 2 (Drosophila) Gene	This gene may be involved in apoptosis.	PRUNE2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104805>	C104804	PRUNE2 wt Allele|A214N16.3|BMCC1|BNIPXL|C9orf65|Chromosome 9 Open Reading Frame 65 Gene|KIAA0367|Prune Homolog 2 (Drosophila) wt Allele|RP11-214N16.3|RP11-58J3.2|bA214N16.3	Human PRUNE2 wild-type allele is located in the vicinity of 9q21.2 and is approximately 295 kb in length. This allele, which encodes protein prune homolog 2, may play a role in apoptosis regulation.	PRUNE2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104806>	C18466	Protein Prune Homolog 2|BCH Motif-Containing Molecule at the Carboxyl Terminal Region 1|BNIP2 Motif-Containing Molecule at the C-Terminal Region 1|PRUNE2	Protein prune homolog 2 (3088 aa, ~341 kDa) is encoded by the human PRUNE2 gene. This protein may be involved in the regulation of apoptosis.	Protein Prune Homolog 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104807>	C20194	PSENEN Gene|PSENEN|PSENEN|Presenilin Enhancer 2 Homolog (C. elegans) Gene	This gene plays a role in the regulation of both gamma-secretase activity and Notch signaling pathways.	PSENEN Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104808>	C104807	PSENEN wt Allele|MDS033|MSTP064|PEN-2|PEN2|Presenilin Enhancer 2 Homolog (C. elegans) wt Allele	Human PSENEN wild-type allele is located in the vicinity of 19q13.12 and is approximately 1 kb in length. This allele, which encodes gamma-secretase subunit PEN-2 protein, is involved in the regulation of both Notch-dependent signaling and intramembrane proteolysis.	PSENEN wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104809>	C18466	Gamma-Secretase Subunit PEN-2|Hematopoietic Stem/Progenitor Cells Protein MDS033|PSENEN|Presenilin Enhancer Protein 2	Gamma-secretase subunit PEN-2 (101 aa, ~12 kDa) is encoded by the human PSENEN gene. This protein plays a role in Notch protein cleavage and signal transduction.	Gamma-Secretase Subunit PEN-2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10480>	C61063	Asparaginase/Cytarabine/Etoposide|ARA-C/ASP/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104810>	C25994	PYY Gene|PYY|PYY|Peptide YY Gene	This gene is involved in gastrointestinal function.	PYY Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104811>	C104810	PYY wt Allele|PYY-I|PYY1|Peptide YY wt Allele	Human PYY wild-type allele is located in the vicinity of 17q21.1 and is approximately 52 kb in length. This allele, which encodes peptide YY protein, plays a role in signaling that modulates digestion. Genetic variations in this gene may contribute to obesity.	PYY wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104812>	C1746	Peptide YY|PYY|PYY-I|Peptide Tyrosine Tyrosine	Peptide YY (97 aa, ~11 kDa) is encoded by the human PYY gene. This protein is involved in hormone signaling to regulate gastrointestinal processes.	Peptide YY		Amino Acid, Peptide, or Protein|Hormone	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104813>	C2849	Branchial Cleft Remnant|Branchial Cleft|Branchial cleft	A congenital defect in the neck that occurs during early embryonic development.  It is caused by developmental abnormalities of the pharyngeal arches and results in the development of a cyst or a fissure in the side of the neck.			Congenital Abnormality	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C104814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104814>	C25784	RAB5C Gene|RAB5C|RAB5C|RAB5C, Member RAS Oncogene Family Gene	This gene plays a role in GTP hydrolysis.	RAB5C Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104815>	C104814	RAB5C wt Allele|L1880|RAB5C, Member RAS Oncogene Family wt Allele|RAB5CL|RAB5L|RABL	Human RAB5C wild-type allele is located in the vicinity of 17q21.2 and is approximately 30 kb in length. This allele, which encodes Ras-related protein Rab-5C, is involved in GTP metabolism and may be involved in vesicle transport.	RAB5C wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104816>	C18549	Ras-Related Protein Rab-5C|L1880|RAB5C|RAB5L	Ras-related protein Rab-5C (216 aa, ~23 kDa) is encoded by the human RAB5C gene. This protein plays a role in GTPase activity.	Ras-Related Protein Rab-5C		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104817>	C25784	RAC3 Gene|RAC3|RAC3|Ras-Related C3 Botulinum Toxin Substrate 3 (Rho Family, Small GTP Binding Protein Rac3) Gene	This gene is involved in both cytoskeletal remodeling and GTPase activity.	RAC3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104818>	C104817	RAC3 wt Allele|Ras-Related C3 Botulinum Toxin Substrate 3 (Rho Family, Small GTP Binding Protein Rac3) wt Allele|Rho Family, Small GTP Binding Protein Rac3 Gene	Human RAC3 wild-type allele is located in the vicinity of 17q25.3 and is approximately 3 kb in length. This allele, which encodes Ras-related C3 botulinum toxin substrate 3 protein, plays a role in both GTP hydrolysis and the formation of cell protrusions.	RAC3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104819>	C18549	Ras-Related C3 Botulinum Toxin Substrate 3|RAC3|p21-Rac3	Ras-related C3 botulinum toxin substrate 3 (192 aa, ~21 kDa) is encoded by the human RAC3 gene. This protein is involved in the formation of lamellipodia and membrane ruffles.	Ras-Related C3 Botulinum Toxin Substrate 3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10481>	C61063	Interleukin-2/PEG-Interleukin-2|IL-2/PEG-IL-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104820>	C63271	Wireless Communication Problem	Problems with the RF wireless technology characteristics and performance (e.g., frequency, output power, range, reception), wireless quality of service, wireless coexistence, security of wireless signals and data, and electromagnetic compatibility.			Event	CDRH Medical Device Problem Terminology
C104821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104821>	C25952	PLCG1 Gene|PLCG1|PLCG1|PLCG1|Phospholipase C, Gamma 1 Gene	This gene is involved in both intracellular signaling and second messenger production.	PLCG1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C104822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104822>	C104821	PLCG1 wt Allele|NCKAP3|PLC-II|PLC1|PLC148|PLCgamma1|Phospholipase C, Gamma 1 (Formerly Subtype 148) Gene|Phospholipase C, Gamma 1 wt Allele	Human PLCG1 wild-type allele is located within 20q12-q13.1 and is approximately 39 kb in length. This allele, which encodes 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 protein, plays a role in second messenger production.	PLCG1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104824>	C16980	1-Phosphatidylinositol 4,5-Bisphosphate Phosphodiesterase Gamma-1|EC 3.1.4.11|Inositoltrisphosphohydrolase Monophosphatidylinositol Phosphodiesterase|PLC-148|PLC-Gamma-1|PLC-II|PLCG1|Phosphatidylinositol Phospholipase C|Phosphoinositidase C|Phosphoinositide Phospholipase C|Phosphoinositide Phospholipase C-Gamma-1|Phospholipase C-148|Phospholipase C-Gamma-1|Phospholipase C-II|Triphosphoinositide Phosphodiesterase	1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 (1290 aa, ~149 kDa) is encoded by the human PLCG1 gene. This protein is involved in the intracellular propagation of signals from ligand-dependent receptor-type tyrosine kinases.	1-Phosphatidylinositol 4,5-Bisphosphate Phosphodiesterase Gamma-1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104825>	C14336	Primula veris				Plant	
C104826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104826>	C14336	Pulsatilla vulgaris|PULSATILLA VULGARIS WHOLE				Plant	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C104827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104827>	C28533	APBA1 Gene|APBA1|APBA1|Amyloid Beta (A4) Precursor Protein-Binding, Family A, Member 1 Gene	This gene is involved in synaptic vesicle exocytosis.	APBA1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104828>	C104827	APBA1 wt Allele|Amyloid Beta (A4) Precursor Protein-Binding, Family A, Member 1 wt Allele|D9S411E|LIN10|MINT1|X11|X11A|X11ALPHA	Human APBA1 wild-type allele is located within 9q13-q21.1 and is approximately 245 kb in length. This allele, which encodes amyloid beta A4 precursor protein-binding family A member 1 protein, plays a role in both the exocytosis of synaptic vesicles and amyloid beta A4 precursor protein proteolysis.	APBA1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104829>	C16386	Amyloid Beta A4 Precursor Protein-Binding Family A Member 1|APBA1|Adapter Protein X11alpha|Mint-1|Neuron-Specific X11 Protein|Neuronal Munc18-1-Interacting Protein 1	Amyloid beta A4 precursor protein-binding family A member 1 (837 aa, ~93 kDa) is encoded by the human APBA1 gene. This protein is involved in both the proteolytic processing of amyloid beta A4 precursor protein and neuronal vesicle exocytosis.	Amyloid Beta A4 Precursor Protein-Binding Family A Member 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10482>	C61063	Cisplatin/Dacarbazine/Interleukin-2/Tamoxifen|CDDP/DTIC/IL-2/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104830>	C25873	CAMK2B Gene|CAMK2B|CAMK2B|Calcium/Calmodulin-Dependent Protein Kinase II Beta Gene	This gene plays a role in calcium signaling.	CAMK2B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104831>	C104830	CAMK2B wt Allele|CAM2|CAMK2|CAMKB|Calcium/Calmodulin-Dependent Protein Kinase II Beta wt Allele	Human CAMK2B wild-type allele is located within 7p14.3-p14.1 and is approximately 117 kb in length. This allele, which encodes calcium/calmodulin-dependent protein kinase type II subunit beta protein, is involved in calcium signaling and neuron function.	CAMK2B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104832>	C17325	Calcium/Calmodulin-Dependent Protein Kinase Type II Subunit Beta|CaM Kinase II Beta Subunit|CaM Kinase II Subunit Beta|CaM-Kinase II Beta Chain|CaMK-II Subunit Beta|Calcium/Calmodulin-Dependent Protein Kinase (CaM Kinase) II Beta|EC 2.7.11.1|Proline Rich Calmodulin-Dependent Protein Kinase	Calcium/calmodulin-dependent protein kinase type II subunit beta (666 aa, ~73 kDa) is encoded by the human CAMK2B gene. This protein plays a role in calcium signaling in the central nervous system.	Calcium/Calmodulin-Dependent Protein Kinase Type II Subunit Beta		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104833>	C25873	CAMK2G Gene|CAMK2G|CAMK2G|Calcium/Calmodulin-Dependent Protein Kinase II Gamma Gene	This gene is involved in calcium signaling.	CAMK2G Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104834>	C104833	CAMK2G wt Allele|CAMK|CAMK-II|CAMKG|Calcium/Calmodulin-Dependent Protein Kinase II Gamma wt Allele	Human CAMK2G wild-type allele is located in the vicinity of 10q22 and is approximately 62 kb in length. This allele, which encodes calcium/calmodulin-dependent protein kinase type II subunit gamma protein, plays a role in calcium signaling.	CAMK2G wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104835>	C17325	Calcium/Calmodulin-Dependent Protein Kinase Type II Subunit Gamma|CAMK2G|CaM Kinase II Subunit Gamma|CaMK-II Subunit Gamma|Calcium/Calmodulin-Dependent Protein Kinase (CaM Kinase) II Gamma|EC 2.7.11.17	Calcium/calmodulin-dependent protein kinase type II subunit gamma (558 aa, ~63 kDa) is encoded by the human CAMK2G gene. This protein is involved in calcium signaling.	Calcium/Calmodulin-Dependent Protein Kinase Type II Subunit Gamma		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104836>	C20917|C20731	CDC25B Gene|CDC25B|CDC25B|Cell Division Cycle 25B Gene	This gene plays a role in mitotic progression.	CDC25B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104837>	C104836	CDC25B wt Allele|CDC25HU2|Cell Division Cycle 25B wt Allele	Human CDC25B wild-type allele is located in the vicinity of 20p13 and is approximately 19 kb in length. This allele, which encodes M-phase inducer phosphatase 2 protein, is involved in control of progression through the cell cycle.	CDC25B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104838>	C25880|C17761	M-Phase Inducer Phosphatase 2|CDC25B|Cell Division Cycle 25 Homolog B (S. cerevisiae)|Cell Division Cycle 25 Homolog B (S. pombe)|Dual Specificity Phosphatase Cdc25B|EC 3.1.3.48	M-phase inducer phosphatase 2 (580 aa, ~65 kDa) is encoded by the human CDC25B gene. This protein plays a role in progression through the mitotic cell cycle.	M-Phase Inducer Phosphatase 2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104839>	C20194	NANOS3 Gene|NANOS3|NANOS3|Nanos Homolog 3 (Drosophila) Gene	This gene is involved in maintaining germ cell lineages.	NANOS3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10483>	C61063	Idoxuridine/Leucovorin Calcium|CF/IUDR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104840>	C104839	NANOS3 wt Allele|NANOS1L|NOS-3|NOS3|Nanos Homolog 3 (Drosophila) wt Allele	Human NANOS3 wild-type allele is located in the vicinity of 19p13.13 and is approximately 4 kb in length. This allele, which encodes nanos homolog 3 protein, plays a role in maintaining germ cells in an undifferentiated state.	NANOS3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104841>	C18466	Nanos Homolog 3	Nanos homolog 3 (173 aa, ~19 kDa) is encoded by the human NANOS3 gene. This protein is involved in maintaining germ cells in an undifferentiated state.	Nanos Homolog 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104842>	C25873	NEK3 Gene|NEK3|NEK3|NIMA-Related Kinase 3 Gene	This gene plays a role in neuronal morphogenesis.	NEK3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104843>	C28533	APBA2 Gene|APBA2|APBA2|Amyloid Beta (A4) Precursor Protein-Binding, Family A, Member 2 Gene	This gene plays a role in neuronal transport.	APBA2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104844>	C104842	NEK3 wt Allele|HSPK 36|HSPK36|MGC29949|NIMA-Related Kinase 3 wt Allele	Human NEK3 wild-type allele is located in the vicinity of 13q14.13 and is approximately 27 kb in length. This allele, which encodes serine/threonine-protein kinase Nek3 protein, is involved in neuronal morphogenesis and polarity.	NEK3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104845>	C104843	APBA2 wt Allele|Amyloid Beta (A4) Precursor Protein-Binding, Family A, Member 2 wt Allele|D15S1518E|HsT16821|LIN-10|MGC:14091|MINT2|X11-BETA|X11L	Human APBA2 wild-type allele is located within 15q11-q12 and is approximately 281 kb in length. This allele, which encodes amyloid beta A4 precursor protein-binding family A member 2 protein, is involved in both amyloid beta A4 precursor protein processing and vesicle transport.	APBA2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104846>	C17325	Serine/Threonine-Protein Kinase Nek3|EC 2.7.11.1|Glycogen Synthase A Kinase|NIMA (Never in Mitosis Gene A)-Related Kinase 3|Never in Mitosis A-Related Kinase 3|NimA-Related Protein Kinase 3|Phosphorylase B Kinase Kinase	Serine/threonine-protein kinase Nek3 (506 aa, ~58 kDa) is encoded by the human NEK3 gene. This protein plays a role in morphogenesis and polarity of neurons.	Serine/Threonine-Protein Kinase Nek3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104847>	C16386	Amyloid Beta A4 Precursor Protein-Binding Family A Member 2|APBA2|Adapter Protein X11beta|Mint-2|Munc18-1-Interacting Protein 2|Neuron-Specific X11L Protein|Neuronal Munc18-1-Interacting Protein 2|X11-Like Protein	Amyloid beta A4 precursor protein-binding family A member 2 (749 aa, ~83 kDa) is encoded by the human APBA2 gene. This protein plays a role in the modulation of both vesicle transport and proteolytic processing of amyloid beta A4 precursor protein.	Amyloid Beta A4 Precursor Protein-Binding Family A Member 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104848>	C28533	APBA3 Gene|APBA3|APBA3|Amyloid Beta (A4) Precursor Protein-Binding, Family A, Member 3 Gene	This gene is involved in the modulation of amyloid beta A4 precursor protein proteolysis.	APBA3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104849>	C104848	APBA3 wt Allele|Amyloid Beta (A4) Precursor Protein-Binding, Family A, Member 3 wt Allele|MGC:15815|X11L2|mint3	Human APBA3 wild-type allele is located in the vicinity of 19p13.3 and is approximately 11 kb in length. This allele, which encodes amyloid beta A4 precursor protein-binding family A member 3 protein, plays a role in amyloid beta A4 precursor protein binding.	APBA3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10484>	C61063	Cyclophosphamide/Dexamethasone/Vincristine|CTX/DM/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104850>	C16386	Amyloid Beta A4 Precursor Protein-Binding Family A Member 3|APBA3|Adapter Protein X11gamma|Mint-3|Munc18-1-Interacting Protein 3|Neuron-Specific X11L2 Protein|Neuronal Munc18-1-Interacting Protein 3|X11-Like 2 Protein	Amyloid beta A4 precursor protein-binding family A member 3 (575 aa, ~61 kDa) is encoded by the human APBA3 gene. This protein is involved in the regulation of amyloid beta A4 precursor protein proteolysis.	Amyloid Beta A4 Precursor Protein-Binding Family A Member 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104851>	C26147	B4GALT1 Gene|B4GALT1|B4GALT1|UDP-Gal:BetaGlcNAc Beta 1,4- Galactosyltransferase, Polypeptide 1 Gene	This gene plays a role in carbohydrate synthesis.	B4GALT1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104852>	C104851	B4GALT1 wt Allele|B4GAL-T1|CDG2D|GGTB2|GT1|GTB|UDP-Gal:BetaGlcNAc Beta 1,4- Galactosyltransferase, Polypeptide 1 wt Allele|beta4Gal-T1	Human B4GALT1 wild-type allele is located in the vicinity of 9p13 and is approximately 63 kb in length. This allele, which encodes beta-1,4-galactosyltransferase 1 protein, is involved in lactose synthesis. Mutation of the gene is associated with congenital disorder of glycosylation type 2D.	B4GALT1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104853>	C17434	Beta-1,4-Galactosyltransferase 1|B4GALT1|Beta-1,4-GalTase 1|Beta4Gal-T1|EC 2.4.1.-|Glycoprotein-4-Beta-Galactosyltransferase 2|UDP-Gal:Beta-GlcNAc Beta-1,4-Galactosyltransferase 1|UDP-Galactose:Beta-N-Acetylglucosamine Beta-1,4-Galactosyltransferase 1|b4Gal-T1	Beta-1,4-galactosyltransferase 1 (398 aa, ~44 kDa) is encoded by the human B4GALT1 gene. This protein plays a role in the biosynthesis of lactose.	Beta-1,4-Galactosyltransferase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104854>	C54401|C20194	SNURF Gene|SNRPN Upstream Reading Frame Gene|SNURF|SNURF	This gene may be involved in cerebral development.	SNURF Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104855>	C104854	SNURF wt Allele|SNRPN Upstream Reading Frame wt Allele	Human SNURF wild-type allele is located in the vicinity of 15q12 and is approximately 45 kb in length. This allele, which encodes SNRPN upstream reading frame protein, may play a role in brain development. Splice variants or chromosomal translocation causing deletion of either the 5' untranslated region or the coding region of the gene is associated with either Angelman syndrome or Prader-Willi syndrome due to parental imprint switch failure.	SNURF wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104856>	C54674|C18466	SNRPN Upstream Reading Frame Protein|SNURF	SNRPN upstream reading frame protein (71 aa, ~8 kDa) is encoded by the human SNURF gene. This protein may be involved in the development of the brain.	SNRPN Upstream Reading Frame Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104857>	C21295	LGALS3 Gene|LGALS3|LGALS3|Lectin, Galactoside-Binding, Soluble, 3 Gene	This gene plays a role in carbohydrate binding.	LGALS3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104858>	C104857	LGALS3 wt Allele|CBP35|GAL3|GALBP|GALIG|L31|LGALS2|Lectin, Galactoside-Binding, Soluble, 3 wt Allele|MAC-2|MAC2	Human LGALS3 wild-type allele is located in the vicinity of 14q22.3 and is approximately 21 kb in length. This allele, which encodes galectin-3 protein, is involved in both carbohydrate recognition and immunity.	LGALS3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104859>	C17728	Galectin-3|35 kDa Lectin|CBP 35|Carbohydrate-Binding Protein 35|GALBP|Gal-3|Galactose-Specific Lectin 3|Galactoside-Binding Protein|IgE-Binding Protein|L-31|LGALS3|Laminin-Binding Protein|Lectin L-29|Mac-2 Antigen	Galectin-3 (250 aa, ~26 kDa) is encoded by the human LGALS3 gene. This protein plays a role in both antibody-mediated immunity and carbohydrate binding.	Galectin-3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10485>	C61063	Cyclophosphamide/Dexamethasone/Filgrastim/Vincristine|CTX/DM/G-CSF/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104860>	C20710	TLE1 Gene|TLE1|TLE1|Transducin-Like Enhancer of Split 1 (E(Sp1) Homolog, Drosophila) Gene	This gene is involved in the modulation of gene transcription.	TLE1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104861>	C104860	TLE1 wt Allele|ESG|ESG1|Enhancer of Split Groucho 1 Gene|GRG1|RP11-203D19.1|Transducin-Like Enhancer of Split 1 (E(Sp1) Homolog, Drosophila) wt Allele	Human TLE1 wild-type allele is located in the vicinity of 9q21.32 and is approximately 106 kb in length. This allele, which encodes transducin-like enhancer protein 1, plays a role in the regulation of transcription.	TLE1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104862>	C26199	Transducin-Like Enhancer Protein 1|E(Sp1) Homolog|ESG1|Enhancer of Split Groucho-Like Protein 1|TLE1	Transducin-like enhancer protein 1 (770 aa, ~83 kDa) is encoded by the human TLE1 gene. This protein is involved in transcriptional regulation.	Transducin-Like Enhancer Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104863>	C25804	AHCY Gene|AHCY|AHCY|Adenosylhomocysteinase Gene	This gene plays a role in amino acid metabolism.	AHCY Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104864>	C104863	AHCY wt Allele|Adenosylhomocysteinase wt Allele|SAHH|adoHcyase	Human AHCY wild-type allele is located in the vicinity of 20q11.22 and is approximately 32 kb in length. This allele, which encodes adenosylhomocysteinase protein, is involved in the metabolism of amino acids. Mutation of the gene is associated with hypermethioninemia with S-adenosylhomocysteine hydrolase deficiency.	AHCY wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104865>	C25939	SESN3 Gene|SESN3|SESN3|Sestrin 3 Gene	This gene is involved in regulating levels of intracellular reactive oxygen species.	SESN3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104866>	C16701	Adenosylhomocysteinase|AHCY|AdoHcyase|EC 3.3.1.1|S-Adenosyl-L-Homocysteine Hydrolase|S-Adenosylhomocysteine Hydrolase	Adenosylhomocysteinase (432 aa, ~48 kDa) is encoded by the human AHCY gene. This protein plays a role in amino acid modification.	Adenosylhomocysteinase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104867>	C104865	SESN3 wt Allele|MGC29667|SEST3|Sestrin 3 wt Allele	Human SESN3 wild-type allele is located in the vicinity of 11q21 and is approximately 67 kb in length. This allele, which encodes sestrin-3 protein, plays a role in regulating levels of intracellular reactive oxygen species.	SESN3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104868>	C16946	Sestrin-3|EC 1.11.1.-|SESN3|Sestrin 3	Sestrin-3 (492 aa, ~57 kDa) is encoded by the human SESN3 gene. This protein is involved in regulating levels of intracellular reactive oxygen species.	Sestrin-3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104869>	C26110	BHMT Gene|BHMT|BHMT|Betaine--Homocysteine S-Methyltransferase Gene|Betaine-Homocysteine S-Methyltransferase Gene	This gene is involved in homocysteine metabolism.	BHMT Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10486>	C61063	Carmustine/Cisplatin/Cyclophosphamide/Filgrastim|BCNU/CDDP/CTX/G-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104870>	C104869	BHMT wt Allele|BHMT1|Betaine--Homocysteine S-Methyltransferase wt Allele|Betaine-Homocysteine S-Methyltransferase Gene|HEL-S-61p	Human BHMT wild-type allele is located in the vicinity of 5q14.1 and is approximately 21 kb in length. This allele, which encodes betaine-homocysteine S-methyltransferase 1 protein, plays a role in amino acid metabolism.	BHMT wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104871>	C94954	Megavoltage Planar Imaging|MV - radiography|MV Planar Imaging	Planar imaging that includes megavoltage images.			Diagnostic Procedure	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C104872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104872>	C16849	Betaine-Homocysteine S-Methyltransferase 1|BHMT|BHMT1|Betaine--Homocysteine Methyltransferase|Betaine--Homocysteine S-Methyltransferase 1|Betaine—Homocysteine S-Methyltransferase|EC 2.1.1.5|Epididymis Secretory Sperm Binding Protein Li 61p	Betaine-homocysteine S-methyltransferase 1 (406 aa, ~45 kDa) is encoded by the human BHMT gene. This protein is involved in the metabolism of homocysteine.	Betaine-Homocysteine S-Methyltransferase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104873>	C94954	Kilovoltage Planar Imaging|KV Planar Imaging|kV - radiography|kV Planar Imaging	Planar imaging that includes kilovoltage images.			Diagnostic Procedure	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C104874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104874>	C26511	CYP26B1 Gene|CYP26B1|CYP26B1|Cytochrome P450, Family 26, Subfamily B, Polypeptide 1 Gene	This gene plays a role in the metabolism of retinoic acid.	CYP26B1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104875>	C104874	CYP26B1 wt Allele|CYP26A2|Cytochrome P450, Family 26, Subfamily B, Polypeptide 1 wt Allele|Cytochrome P450, Subfamily XXVIA, Polypeptide 2 Gene|Cytochrome P450, Subfamily XXVIB, Polypeptide 1 Gene|P450, Retinoic Acid-Inactivating, 2 Gene|P450RAI-2|P450RAI2|RHFCA	Human CYP26B1 wild-type allele is located in the vicinity of 2p13.2 and is approximately 19 kb in length. This allele, which encodes cytochrome P450 26B1 protein, is involved in the specific inactivation of all-trans-retinoic acid. Mutations in this gene are associated with craniofacial and other skeletal anomalies.	CYP26B1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104876>	C16484	Cytochrome P450 26B1|CYP26B1|Cytochrome P450 26A2|Cytochrome P450 Retinoic Acid-Inactivating 2|Cytochrome P450 Retinoid Metabolizing Protein|Cytochrome P450RAI-2|EC 1.14.-.-|Retinoic Acid-Metabolizing Cytochrome	Cytochrome P450 26B1 (512 aa, ~58 kDa) is encoded by the human CYP26B1 gene. This protein plays a role in the metabolism of all-trans-retinoic acid.	Cytochrome P450 26B1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104877>	C71695	Megavoltage Cone Beam Computed Tomography|Cone Beam Megavoltage CT|Cone Beam Megavoltage CT Imaging|Cone Beam Megavoltage Computed Tomography|Cone Beam Megavoltage Computed Tomography Imaging|Cone Beam Megavoltage Imaging|Conebeam CT - MV|MV Cone Beam CT|Megavoltage Computed Tomography	Cone beam computed tomography that includes megavoltage images.	Megavoltage Cone Beam Computed Tomography		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C104878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104878>	C21295	DND1 Gene|DND1|DND1|Dead End Homolog 1 (Zebrafish) Gene	This gene is involved in regulation of gene expression.	DND1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104879>	C104878	DND1 wt Allele|Dead End Homolog 1 (Zebrafish) wt Allele|MGC34750|RBMS4	Human DND1 wild-type allele is located in the vicinity of 5q31.3 and is approximately 3 kb in length. This allele, which encodes dead end protein homolog 1 protein, plays a role in regulating gene expression by prohibiting miRNA-mediated gene suppression. Reduced expression of this gene has been implicated in tongue squamous cell carcinoma.	DND1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10487>	C61007	Cyclophosphamide/Doxorubicin/Filgrastim/Prednisone/Vincristine|CTX/DOX/G-CSF/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104880>	C71695	Kilovoltage Cone Beam Computed Tomography|Cone Beam Kilovoltage CT Imaging|Cone Beam Kilovoltage Computed Tomography|Cone Beam Kilovoltage Computed Tomography Imaging|Cone Beam Kilovoltage Imaging|Conebeam CT - kV|KV Cone Beam CT|kV Cone Beam CT	Cone beam computed tomography that includes kilovoltage images.			Diagnostic Procedure	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C104881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104881>	C26110	BHMT2 Gene|BHMT2|BHMT2|Betaine--Homocysteine S-Methyltransferase 2 Gene|Betaine-Homocysteine S-Methyltransferase 2 Gene	This gene plays a role in the metabolism of homocysteine.	BHMT2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104882>	C21298	Dead End Protein Homolog 1|RNA-Binding Motif, Single-Stranded-Interacting Protein 4	Dead end protein homolog 1 (353 aa, ~39 kDa) is encoded by the human DND1 gene. This protein is involved in miRNA-mediated gene suppression.	Dead End Protein Homolog 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104883>	C104881	BHMT2 wt Allele|Betaine--Homocysteine S-Methyltransferase 2 wt Allele|Betaine-Homocysteine S-Methyltransferase 2 Gene	Human BHMT2 wild-type allele is located in the vicinity of 5q13 and is approximately 20 kb in length. This allele, which encodes S-methylmethionine-homocysteine S-methyltransferase BHMT2 protein, is involved in methionine synthesis.	BHMT2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104884>	C16849	S-Methylmethionine-Homocysteine S-Methyltransferase BHMT2|BHMT2|Betaine--Homocysteine S-Methyltransferase 2|Betaine-Homocysteine Methyltransferase 2|Betaine-Homocysteine S-Methyltransferase 2|Betaine—Homocysteine S-Methyltransferase 2|EC 2.1.1.5|S-Methylmethionine--Homocysteine S-Methyltransferase BHMT2|S-Methylmethionine—Homocysteine S-Methyltransferase BHMT2|SMM-Hcy Methyltransferase	S-methylmethionine-homocysteine S-methyltransferase BHMT2 (363 aa, ~40 kDa) is encoded by the human BHMT2 gene. This protein plays a role in the conversion of homocysteine to methionine.	S-Methylmethionine-Homocysteine S-Methyltransferase BHMT2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104885>	C25870	CHAT Gene|CHAT|CHAT|Choline O-Acetyltransferase Gene	This gene is involved in neurotransmitter biosynthesis.	CHAT Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104886>	C104885	CHAT wt Allele|CHOACTASE|CMS1A|CMS1A2|Choline O-Acetyltransferase wt Allele	Human CHAT wild-type allele is located in the vicinity of 10q11.2 and is approximately 85 kb in length. This allele, which encodes choline O-acetyltransferase protein, plays a role in the synthesis of acetylcholine. Mutation of the gene is associated with congenital myasthenic syndrome with episodic apnea (familial infantile myasthenia gravis 2).	CHAT wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104887>	C16259	Choline O-Acetyltransferase|Acetyl CoA:Choline O-Acetyltransferase|CHAT|CHOACTase|ChAT|Choline Acetylase|Choline Acetyltransferase|EC 2.3.1.6	Choline O-acetyltransferase (748 aa, ~83 kDa) is encoded by the human CHAT gene. This protein is involved in acetylcholine biosynthesis.	Choline O-Acetyltransferase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104888>	C17204	CT on Rails|CT On Rails	A system that improves the accuracy of radiation treatment by precisely identifying the location of the tumor.  It involves the pairing of the machine used to deliver external beam radiotherapy with a CT scanner.			Diagnostic Procedure	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C104889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104889>	C20744	DST Gene|DST|DST|Dystonin Gene	This gene plays a structural role in cytoskeleton networks.	DST Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10488>	C61063	Diaziquone/Sargramostim|AZQ/GM-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104890>	C104889	DST wt Allele|BP230|BP240|BPA|BPAG1|CATX-15|CATX15|D6S1101|DMH|DT|Dystonin wt Allele|FLJ13425|FLJ21489|FLJ30627|FLJ32235|HSAN6|KIAA0728|MACF2	Human DST wild-type allele is located in the vicinity of 6p12.1 and is approximately 497 kb in length. This allele, which encodes dystonin protein, is involved in the structure of cytoskeleton networks. Mutations in this gene are associated with Hereditary Sensory and Autonomic Neuropathy Type VI.	DST wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104891>	C18073	Dystonin|230 kDa Bullous Pemphigoid Antigen|230/240 kDa Bullous Pemphigoid Antigen|BASEMENT MEMBRANE ZONE BP230|BMZ BP230|BP230|BPAG1|Bullous Pemphigoid Antigen|Bullous Pemphigoid Antigen 1|Bullous Pemphigoid Antigen 1|Bullous Pemphigoid Antigen 1, 230/240kDa|DST|Dystonia Musculorum Protein|Hemidesmosomal Plaque Protein|Trabeculin-Beta	Dystonin (7570 aa, ~860 kDa) is encoded by the human DST gene. This protein plays a structural role in cytoskeleton networks.	Dystonin		Amino Acid, Peptide, or Protein	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104892>	C91105	FACT-Hep Questionnaire|FACT-Hep|Functional Assessment of Cancer Therapy-Hepatobilliary Cancer	A subscale complement to the FACT-G questionnaire developed specifically for evaluating quality of life of patients with hepatobiliary cancer (liver, bile duct and pancreas).			Intellectual Product	
C104893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104893>	C20420	E2F6 Gene|E2F Transcription Factor 6 Gene|E2F6|E2F6	This gene is involved in cell cycle entry.	E2F6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104894>	C104893	E2F6 wt Allele|E2F Transcription Factor 6 wt Allele|E2F-6	Human E2F6 wild-type allele is located in the vicinity of 2p25.1 and is approximately 22 kb in length. This allele, which encodes transcription factor E2F6 protein, plays a role in entry into the cell cycle.	E2F6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104895>	C25939	CHDH Gene|CHDH|CHDH|Choline Dehydrogenase Gene	This gene is involved in choline metabolism.	CHDH Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104896>	C17207	Transcription Factor E2F6|E2F Transcription Factor 6	Transcription factor E2F6 (281 aa, ~32 kDa) is encoded by the human E2F6 gene. This protein is involved in entry into the cell cycle, but not cell cycle progression.	Transcription Factor E2F6		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104897>	C104895	CHDH wt Allele|Choline Dehydrogenase wt Allele	Human CHDH wild-type allele is located in the vicinity of 3p21.1 and is approximately 30 kb in length. This allele, which encodes choline dehydrogenase, mitochondrial protein, plays a role in the metabolism of choline.	CHDH wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104898>	C16946	Choline Dehydrogenase, Mitochondrial|CDH|CHD|CHDH|EC 1.1.99.1	Choline dehydrogenase, mitochondrial (594 aa, ~65 kDa) is encoded by the human CHDH gene. This protein is involved in the conversion of choline to betaine.	Choline Dehydrogenase, Mitochondrial		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104899>	C25802	PSMG2 Gene|PSMG2|PSMG2|Proteasome (Prosome, Macropain) Assembly Chaperone 2 Gene	This gene plays a role in assembly of the 20S proteasome.	PSMG2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10489>	C61007	Cyclophosphamide/Fludarabine|CTX/FAMP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1048>	C1420	Chloroaluminum Phthalocyanine|AlSPc|Aluminum Sulfonated Phthalocyanine|Non-Sulfonated Chloroaluminum Phthalocyanine|Sulfonated Aluminum Phthalocyanine	A rhodamine-based dye used as a photosensitizing agent in cytotoxic photodynamic therapy. (NCI)			Organic Chemical|Pharmacologic Substance	
C104900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104900>	C104899	PSMG2 wt Allele|CLAST3|HCCA3|HDCMC29P|HSPC260|HsT1707|MDS003|MGC15092|PAC-2|PAC2|Proteasome (Prosome, Macropain) Assembly Chaperone 2 wt Allele|TNFSF5IP1	Human PSMG2 wild-type allele is located in the vicinity of 18p11.21 and is approximately 23 kb in length. This allele, which encodes proteasome assembly chaperone 2 protein, plays a role in promoting assembly of the 20S proteasome.	PSMG2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104901>	C17764	Proteasome Assembly Chaperone 2|CD40 Ligand-Activated Specific Transcript 3|Hepatocellular Carcinoma Susceptibility Protein|Hepatocellular Carcinoma-Susceptibility Protein|Likely Ortholog of Mouse CD40 Ligand-Activated Specific Transcript 3 (Clast3)|PSMG2|Proteasome (Prosome, Macropain) Assembly Chaperone 2|Proteasome Assembling Chaperone 2|Tumor Necrosis Factor Superfamily, Member 5-Induced Protein 1|X 003 Protein	Proteasome assembly chaperone 2 (264 aa, ~29 kDa) is encoded by the human PSMG2 gene. This protein plays a role in promoting assembly of the 20S proteasome.	Proteasome Assembly Chaperone 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104902>	C105770	Have Swelling or Cramps in Stomach Question|Have Swelling or Cramps in Stomach|I have swelling or cramps in my stomach area	A question about whether an individual has or had swelling or cramps in the area of the stomach.			Intellectual Product	FACT-Hep Questionnaire
C104903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104903>	C20194	STRA8 Gene|STRA8|STRA8|Stimulated by Retinoic Acid 8 Gene	This gene may be involved in spermatogenesis.	STRA8 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104904>	C104903	STRA8 wt Allele|Stimulated by Retinoic Acid 8 wt Allele	Human STRA8 wild-type allele is located in the vicinity of 7q33 and is approximately 27 kb in length. This allele, which encodes stimulated by retinoic acid gene 8 protein, may play a role in spermatogenesis.	STRA8 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104905>	C18466	Stimulated by Retinoic Acid Gene 8 Protein|Stimulated by Retinoic Acid Gene 8 Homolog (Mouse)|Stimulated by Retinoic Acid Gene 8 Protein Homolog	Stimulated by retinoic acid gene 8 protein (330 aa, ~37 kDa) is encoded by the human STRA8 gene. This protein may be involved in spermatogenesis.	Stimulated by Retinoic Acid Gene 8 Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104906>	C173938	Have Control of Bowels Question|Have Control of Bowels|I have control of my bowels	A question about whether an individual has or had control of their bowels.			Intellectual Product	FACT-Hep Questionnaire
C104907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104907>	C16742	Radio Beacon Transponder System|RF Beacons	A tracking system that monitors the position of the target organ or tissue in real-time in order to spare surrounding tissues from radiation exposure during treatment.	Radio Beacon Transponder System		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C104908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104908>	C91103	Digests Food Well Question|Digests Food Well|I can digest my food well	A question about whether an individual digests or has digested their food well.			Intellectual Product	FACT-Hep Questionnaire
C104909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104909>	C25871	CHPT1 Gene|CHPT1|CHPT1|Choline Phosphotransferase 1 Gene	This gene plays a role in phospholipid metabolism.	CHPT1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10490>	C61063	Filgrastim/Fluorouracil/Leucovorin Calcium|CF/5-FU/G-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104910>	C173160	Unhappy with Change in Appearance Question|I am unhappy about a change in my appearance|Unhappy with Change in Appearance	A question about whether an individual is or was unhappy with a change in their appearance.			Intellectual Product	FACT-Hep Questionnaire
C104911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104911>	C104909	CHPT1 wt Allele|CPT|CPT1|Choline Phosphotransferase 1 wt Allele|MSTP022	Human CHPT1 wild-type allele is located within 12q and is approximately 47 kb in length. This allele, which encodes cholinephosphotransferase 1 protein, is involved in phosphatidylcholine metabolism.	CHPT1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104912>	C16984	Cholinephosphotransferase 1|AAPT1-Like Protein|CHPT1|Cholinephosphotransferase 1 Alpha|Diacylglycerol Cholinephosphotransferase 1|EC 2.7.8.2|Phosphatidylcholine Synthesizing Enzyme|hCPT1	Cholinephosphotransferase 1 (406 aa, ~45 kDa) is encoded by the human CHPT1 gene. This protein plays a role in phosphatidylcholine biosynthesis.	Cholinephosphotransferase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104913>	C20103	FOLR2 Gene|FOLR2|FOLR2|Folate Receptor 2 (Fetal) Gene	This gene is involved in folic acid uptake.	FOLR2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104914>	C93323	Photon Beam Radiation Therapy|External beam radiation therapy using photons (procedure)|PHOTON Therapy|Photon|Photon EBRT|Photon External Beam Radiotherapy|Radiation, Photon Beam|photon beam radiation therapy	Radiation therapy using photon beam.	Photon Beam Radiation Therapy		Therapeutic or Preventive Procedure	CRF4 Treatment Radiation Table|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|mCode Radiotherapy Modality Value Set|mCode Teleradiotherapy Modality Value Set|mCode Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C104915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104915>	C104913	FOLR2 wt Allele|BETA-HFR|FBP|FBP/PL-1|FR-BETA|FR-P3|Folate Receptor 2 (Fetal) wt Allele	Human FOLR2 wild-type allele is located within 11q13.3-q14.1 and is approximately 5 kb in length. This allele, which encodes folate receptor beta protein, plays a role in the internalization of folic acid.	FOLR2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104916>	C18106	Folate Receptor Beta|FBP|FOLR2|FR-Beta|Folate Receptor 2|Folate Receptor, Fetal/Placental|Folate-Binding Protein, Fetal/Placental|Placental Folate-Binding Protein	Folate receptor beta (255 aa, ~29 kDa) is encoded by the human FOLR2 gene. This protein is involved in folic acid transport.	Folate Receptor Beta		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104917>	C91126	Have Back Pain Question|Have Back Pain|Have Pain in Back|Have you had back pain|Have you had pain in your back|I have pain in my back	A question about whether an individual has or had back pain.			Intellectual Product	FACT-Hep Questionnaire|Quality of Life Questionnaire - Pancreatic Cancer 26|Quality of Life Questionnaire-Multiple Myeloma 20
C104918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104918>	C172982	Bothered by Constipation Question|Bothered by Constipation|I am bothered by constipation	A question about whether an individual is or has been bothered by constipation.			Intellectual Product	FACT-Hep Questionnaire
C104919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104919>	C15470	Cobalt-60 Radiation Therapy	Radiation therapy using gamma radiation generated from cobalt-60.			Therapeutic or Preventive Procedure	
C10491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10491>	C61007	Asparaginase/Cyclophosphamide/Cytarabine/Dexamethasone/Doxorubicin/Thioguanine/Vincristine|ARA-C/ASP/CTX/DM/DOX/TG/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104920>	C25943|C25939|C25804	MTHFD1 Gene|MTHFD1|MTHFD1|Methylenetetrahydrofolate Dehydrogenase (NADP+ Dependent) 1, Methenyltetrahydrofolate Cyclohydrolase, Formyltetrahydrofolate Synthetase Gene	This gene plays a role in folate metabolism.	MTHFD1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104921>	C173045	Able to Do Usual Activities Question|Able to Do Usual Activities|Able to Perform Usual Activities|I am able to do my usual activities	A question about whether an individual is or was able to perform their usual activities.			Intellectual Product	FACT-Hep Questionnaire
C104922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104922>	C104920	MTHFD1 wt Allele|MTHFC|MTHFD|Methylenetetrahydrofolate Dehydrogenase (NADP+ Dependent) 1, Methenyltetrahydrofolate Cyclohydrolase, Formyltetrahydrofolate Synthetase wt Allele	Human MTHFD1 wild-type allele is located in the vicinity of 14q24 and is approximately 72 kb in length. This allele, which encodes C-1-tetrahydrofolate synthase, cytoplasmic protein, is involved in the metabolism of folic acid. Mutation of the gene is associated with susceptibility to folate-sensitive neural tube defects.	MTHFD1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104923>	C16946|C16796|C16701	C-1-Tetrahydrofolate Synthase, Cytoplasmic|5,10-Methylenetetrahydrofolate Dehydrogenase, 5,10-Methylenetetrahydrofolate Cyclohydrolase, 10-Formyltetrahydrofolate Synthetase|C1-THF Synthase|Cytoplasmic C-1-Tetrahydrofolate Synthase|MTHFD1	C-1-tetrahydrofolate synthase, cytoplasmic (935 aa, ~102 kDa) is encoded by the human MTHFD1 gene. This protein plays a role in folic acid metabolism.	C-1-Tetrahydrofolate Synthase, Cytoplasmic		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104924>	C20921	CRABP2 Gene|CRABP2|CRABP2|Cellular Retinoic Acid Binding Protein 2 Gene	This gene plays a role in retinoic acid binding.	CRABP2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104925>	C105895	Bothered by Jaundice or Yellow Skin Color Question|Bothered by Jaundice or Yellow Skin Color|I am bothered by jaundice or yellow color to my skin	A question about whether an individual is or has been bothered by their jaundice or yellow skin color.			Intellectual Product	FACT-Hep Questionnaire
C104926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104926>	C104924	CRABP2 wt Allele|CRABP-II|Cellular Retinoic Acid Binding Protein 2 wt Allele|RBP6	Human CRABP2 wild-type allele is located in the vicinity of 1q21.3 and is approximately 6 kb in length. This allele, which encodes cellular retinoic acid-binding protein 2, is involved in both retinoic acid binding and retinoic acid signaling.	CRABP2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104927>	C18515	Cellular Retinoic Acid-Binding Protein 2|Cellular Retinoic Acid Binding Protein 2|Cellular Retinoic Acid-Binding Protein II	Cellular retinoic acid-binding protein 2 (138 aa, ~16 kDa) is encoded by the human CRABP2 gene. This protein plays a role in retinoic acid signaling.	Cellular Retinoic Acid-Binding Protein 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104928>	C49238	CBFA2T2 Gene|CBFA2T2|CBFA2T2|CBFA2T2|Core-Binding Factor, Runt Domain, Alpha Subunit 2; Translocated to, 2 Gene	This gene may be involved in tumor suppression.	CBFA2T2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C104929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104929>	C173981	Have Fever Question|Have Fever|I have had fevers	A question about whether an individual has or had a fever.			Intellectual Product	FACT-Hep Questionnaire
C10492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10492>	C61063	Carboplatin/Interleukin-3|CBDCA/IL-3			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104930>	C104928	CBFA2T2 wt Allele|Core-Binding Factor, Runt Domain, Alpha Subunit 2; Translocated to, 2 wt Allele|EHT|MTGR1|ZMYND3	Human CBFA2T2 wild-type allele is located in the vicinity of 20q11 and is approximately 160 kb in length. This allele, which encodes protein CBFA2T2, may play a role in tumor suppression. This gene is frequently fused to RUNX1 by the t(8;21)(q22;q22) translocation in acute myeloid leukemia.	CBFA2T2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104931>	C173981|C172828	Have Itch Question|Had Itching|Have Itch|Have Itching|Have you had itching|I have had itching|Itching	A question about whether an individual has or had itching.			Intellectual Product	FACT-Hep Questionnaire|Memorial Symptom Assessment Scale - Short Form|Quality of Life Questionnaire - Pancreatic Cancer 26
C104932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104932>	C54673	Protein CBFA2T2|Core-Binding Factor, Runt Domain, Alpha Subunit 2; Translocated to, 2|ETO Homolog on Chromosome 20|ETO Homologous on Chromosome 20|MTG8-Like Protein|MTG8-Related Protein 1|Myeloid Translocation Gene-Related Protein 1|Myeloid Translocation-Related Protein 1|p85	Protein CBFA2T2 (604 aa, ~67 kDa) is encoded by the human CBFA2T2 gene. This protein may be involved in tumor suppression.	Protein CBFA2T2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104933>	C202123	Volume Modulated Arc Therapy|VMAT|VMAT|Volumetric Modulated Arc Therapy (procedure)	Radiation therapy delivered to the whole volume of target tissue by a single rotation of the linear accelerator gantry.	Volume Modulated Arc Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|mCode Photon Beam Technique Value Set|mCode Radiotherapy Technique Value Set|mCode Teleradiotherapy Technique Value Set|mCode Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C104934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104934>	C173981|C173063	Notice Change in the Way Food Tastes Question|Change in the way food tastes|Changes in taste|Have Change in the Way Food Tastes|I have had a change in the way food tastes|Notice Change in the Way Food Tastes	A question about whether an individual notices or noticed a change in the way food tastes.			Intellectual Product	FACT-Hep Questionnaire|Memorial Symptom Assessment Scale - Short Form|Symptom Screening in Pediatrics
C104935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104935>	C173981	Have Chills Question|Have Chills|I have had chills	A question about whether an individual has or had chills.			Intellectual Product	FACT-Hep Questionnaire
C104936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104936>	C21295	CRIP2 Gene|CRIP2|CRIP2|Cysteine-Rich Protein 2 Gene	This gene encodes a putative transcription factor that may play a role in differentiation of smooth muscle tissue.	CRIP2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104937>	C173981	Have Dry Mouth Question|Did you have a dry mouth|Do you often experience "dry mouth"|Dry mouth|Experience Dry Mouth|Have Dry Mouth|My mouth is dry	A question about whether an individual has or had a dry mouth.			Intellectual Product	FACT-H&N Questionnaire|FACT-Hep Questionnaire|Healthy Volunteer Medical History Questionnaire|Memorial Symptom Assessment Scale - Short Form|Quality of Life Questionnaire - Pancreatic Cancer 26
C104938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104938>	C104936	CRIP2 wt Allele|CRIP|CRP-2|CRP2|Cysteine-Rich Protein 2 wt Allele|ESP1	Human CRIP2 wild-type allele is located in the vicinity of 14q32.3 and is approximately 7 kb in length. This allele encodes cysteine-rich protein 2, a putative transcription factor that may be involved in smooth muscle tissue differentiation.	CRIP2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104939>	C156140	Have Discomfort or Pain in Stomach Question|Have Discomfort or Pain in Stomach|I have discomfort or pain in my stomach area|I have pain in my stomach area	A question about whether an individual has or had discomfort or pain in the stomach.			Intellectual Product	FACT-E Questionnaire|FACT-Hep Questionnaire
C10493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10493>	C61063	Methotrexate/Thioguanine|MTX/TG			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104940>	C17728	Cysteine-Rich Protein 2|CRIP2|Cysteine-Rich Intestinal Protein|LIM Domain Protein ESP1/CRP2|Protein ESP1	Cysteine-rich protein 2 (208 aa, ~22 kDa) is encoded by the human CRIP2 gene. This putative transcription factor may play a role in differentiation of smooth muscle tissue.	Cysteine-Rich Protein 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104941>	C66897	Scanning Proton Beam Therapy|Spot Scanning	Proton beam radiation therapy in which magnets deflect and steer the proton beam.  (Adapted from medicalphysicsweb)			Therapeutic or Preventive Procedure	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C104942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104942>	C66897	Scattering Proton Beam Therapy|Passive Scattering	Proton beam radiation therapy in which the proton beam is spread by placing scattering material in the path of the protons.  (Adapted from medicalphysicsweb)			Therapeutic or Preventive Procedure	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C104943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104943>	C25939|C25804	MTHFD2 Gene|MTHFD2|MTHFD2|Methylenetetrahydrofolate Dehydrogenase (NADP+ Dependent) 2, Methenyltetrahydrofolate Cyclohydrolase Gene	This gene is involved in the metabolism of folic acid.	MTHFD2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104944>	C104943	MTHFD2 wt Allele|Methylenetetrahydrofolate Dehydrogenase (NADP+ Dependent) 2, Methenyltetrahydrofolate Cyclohydrolase wt Allele|NMDMC	Human MTHFD2 wild-type allele is located in the vicinity of 2p13.1 and is approximately 19 kb in length. This allele, which encodes bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial protein, plays a role in folic acid metabolism.	MTHFD2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104945>	C16946|C16701	Bifunctional Methylenetetrahydrofolate Dehydrogenase/Cyclohydrolase, Mitochondrial|MTHFD2|NAD-Dependent Methylene Tetrahydrofolate Dehydrogenase Cyclohydrolase	Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial (350 aa, ~38 kDa) is encoded by the human MTHFD2 gene. This protein is involved in folate metabolism.	Bifunctional Methylenetetrahydrofolate Dehydrogenase/Cyclohydrolase, Mitochondrial		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104946>	C26110	MTR Gene|5-Methyltetrahydrofolate-Homocysteine Methyltransferase Gene|MTR|MTR	This gene plays a role in methionine biosynthesis.	MTR Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104947>	C16830	MR-Based Treatment Machine	An instrument that integrates magnetic resonance imaging with delivery of radiation therapy.			Medical Device	
C104948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104948>	C104946	MTR wt Allele|5-Methyltetrahydrofolate-Homocysteine Methyltransferase wt Allele|MS|cblG	Human MTR wild-type allele is located in the vicinity of 1q43 and is approximately 109 kb in length. This allele, which encodes methionine synthase protein, is involved in the synthesis of methionine. Mutation of the gene is associated with both methylcobalamin deficiency type G and susceptibility to folate-sensitive neural tube defects.	MTR wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104949>	C16849	Methionine Synthase|5-Methyltetrahydrofolate--Homocysteine Methyltransferase|5-Methyltetrahydrofolate-Homocysteine Methyltransferase 1|5-Methyltetrahydrofolate—Homocysteine Methyltransferase|Cobalamin-Dependent Methionine Synthase|EC 2.1.1.13|MS|MTR|Vitamin-B12 Dependent Methionine Synthase	Methionine synthase (1265 aa, ~141 kDa) is encoded by the human MTR gene. This protein plays a role in the methylation of homocysteine.	Methionine Synthase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10494>	C61063	Carboplatin/Fluorouracil/Hydroxyurea/Leucovorin Calcium|CBDCA/CF/5-FU/HU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104950>	C20912	CRLF1 Gene|CRLF1|CRLF1|Cytokine Receptor-Like Factor 1 Gene	This gene may be involved in regulating the immune system.	CRLF1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104951>	C104950	CRLF1 wt Allele|CISS|CISS1|CLF|CLF-1|Cytokine Receptor-Like Factor 1 wt Allele|NR6|ZcytoR5	Human CRLF1 wild-type allele is located in the vicinity of 19p12 and is approximately 14 kb in length. This allele, which encodes cytokine receptor-like factor 1 protein, may play roles in nervous system development and immune function. Mutations in this gene are associated with cold-induced sweating syndrome and Crisponi syndrome.	CRLF1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104952>	C17667	Cytokine Receptor-Like Factor 1|Class I Cytokine Receptor|Cytokine Type 1 Receptor CRLP-1|Cytokine-Like Factor 1	Cytokine receptor-like factor 1 (422 aa, ~46 kDa) is encoded by the human CRLF1 gene. This protein may be involved in both immune function and nervous system development.	Cytokine Receptor-Like Factor 1		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104953>	C25871	PCYT1A Gene|PCYT1A|PCYT1A|Phosphate Cytidylyltransferase 1, Choline, Alpha Gene	This gene is involved in phosphatidylcholine biosynthesis	PCYT1A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104954>	C104953	PCYT1A wt Allele|CCTA|CT|CTA|CTPCT|Cytidylyltransferase, CTP-Phosphocholine Gene|PCYT1|Phosphate Cytidylyltransferase 1, Choline Gene|Phosphate Cytidylyltransferase 1, Choline, Alpha Isoform Gene|Phosphate Cytidylyltransferase 1, Choline, Alpha wt Allele	Human PCYT1A wild-type allele is located in the vicinity of 3q29 and is approximately 74 kb in length. This allele, which encodes choline-phosphate cytidylyltransferase A protein, plays a role in phospholipid biosynthesis.	PCYT1A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104955>	C16615	LHX3 Gene|LHX3|LHX3|LIM Homeobox 3 Gene	This gene encodes a transcription factor that plays a role in both pituitary development and motor neuron specification.	LHX3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104956>	C104955	LHX3 wt Allele|CPHD3|LIM Homeobox 3 wt Allele|LIM3|M2-LHX3	Human LHX3 wild-type allele is located in the vicinity of 9q34.3 and is approximately 9 kb in length. This allele, which encodes LIM/homeobox protein LHX3, is a transcription factor involved in motor neuron specification and pituitary development. Mutations in this gene are associated with combined pituitary hormone deficiency 3.	LHX3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104957>	C16925	Choline-Phosphate Cytidylyltransferase A|CCT A|CCT-alpha|CT A|CTP:Phosphocholine Cytidylyltransferase A|EC 2.7.7.15|PCYT1A|Phosphorylcholine Transferase A	Choline-phosphate cytidylyltransferase A (367 aa, ~42 kDa) is encoded by the human PCYT1A gene. This protein is involved in the biosynthesis of phosphatidylcholine.	Choline-Phosphate Cytidylyltransferase A		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104958>	C17207	LIM/Homeobox Protein LHX3|LIM Homeobox 3|LIM Homeobox Protein 3|LIM/Homeodomain Protein LHX3	LIM/homeobox protein LHX3 (397 aa, ~43 kDa) is encoded by the human LHX3 gene. This transcription factor plays a role in pituitary development.	LIM/Homeobox Protein LHX3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104959>	C20420	ZNF423 Gene|ZNF423|ZNF423|Zinc Finger Protein 423 Gene	This gene is involved in olfactory neurogenesis.	ZNF423 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10495>	C61063	Cisplatin/Fluorouracil/Hydroxyurea/Leucovorin Calcium|CDDP/CF/5-FU/HU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104960>	C104959	ZNF423 wt Allele|Ebfaz|KIAA0760|NPHP14|OAZ|Roaz|ZFP104|ZFP423|Zinc Finger Protein 423 wt Allele|hOAZ	Human ZNF423 wild-type allele is located in the vicinity of 16q12 and is approximately 370 kb in length. This allele, which encodes zinc finger protein 423, plays a role in differentiation and maturation of olfactory receptor neurons. Mutations in this gene are associated with Joubert syndrome 19 and nephronophthisis 14.	ZNF423 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104961>	C17207	Zinc Finger Protein 423|Early B-cell Factor Associated Zinc Finger Protein|Olf1/EBF-Associated Zinc Finger Protein|Smad- and Olf-Interacting Zinc Finger Protein|ZNF423	Zinc finger protein 423 (1284 aa, ~145 kDa) is encoded by the human ZNF423 gene. This protein is involved in differentiation of olfactory receptor neurons.	Zinc Finger Protein 423		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104962>	C20194	ATG5 Gene|ATG5|ATG5|Autophagy Related 5 Gene	This gene plays a role in autophagy and may play a role in apoptosis.	ATG5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104963>	C104962	ATG5 wt Allele|APG5|APG5 (Autophagy 5, S. cerevisiae)-Like Gene|APG5 Autophagy 5-Like (S. cerevisiae) Gene|APG5 Autophagy 5-Like Gene|APG5, S. cerevisiae, Homolog of Gene|APG5-Like Gene|APG5L|ASP|ATG5 Autophagy Related 5 Homolog (S. cerevisiae) Gene|ATG5 Autophagy Related 5 Homolog Gene|Autophagy 5, S. cerevisiae, Homolog of Gene|Autophagy Related 5 wt Allele|SCAR25|hAPG5	Human ATG5 wild-type allele is located in the vicinity of 6q21 and is approximately 141 kb in length. This allele, which encodes autophagy protein 5, is involved in autophagy and may be involved in apoptosis.	ATG5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104964>	C18466	Autophagy Protein 5|APG5-Like|ATG5|ATG5 Autophagy Related 5 Homolog|Apoptosis Specific Protein|Apoptosis-Specific Protein|Autophagy Related 5	Autophagy protein 5 (275 aa, ~32 kDa) is encoded by the human ATG5 gene. This protein plays a role in autophagy and may play a role in apoptosis.	Autophagy Protein 5		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104965>	C26110	PEMT Gene|PEMT|PEMT|Phosphatidylethanolamine N-Methyltransferase Gene	This gene plays a role in phosphatidylethanolamine metabolism.	PEMT Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104966>	C104965	PEMT wt Allele|PEAMT|PEMPT|PEMT2|PNMT|Phosphatidylethanolamine N-Methyltransferase wt Allele	Human PEMT wild-type allele is located in the vicinity of 17p11.2 and is approximately 86 kb in length. This allele, which encodes phosphatidylethanolamine N-methyltransferase protein, is involved in phosphatidylcholine biosynthesis.	PEMT wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104967>	C16849	Phosphatidylethanolamine N-Methyltransferase|EC 2.1.1.17|EC 2.1.1.71|PEAMT|PEMT|PEMT2	Phosphatidylethanolamine N-methyltransferase (199 aa, ~22 kDa) is encoded by the human PEMT gene. This protein plays a role in the methylation of phosphatidylethanolamine to synthesize phosphatidylcholine.	Phosphatidylethanolamine N-Methyltransferase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104968>	C26110	SHMT1 Gene|SHMT1|SHMT1|Serine Hydroxymethyltransferase 1 (Soluble) Gene	This gene is involved in amino acid metabolism.	SHMT1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104969>	C104968	SHMT1 wt Allele|CSHMT|MGC15229|MGC24556|SHMT|Serine Hydroxymethyltransferase 1 (Soluble) wt Allele	Human SHMT1 wild-type allele is located in the vicinity of 17p11.2 and is approximately 36 kb in length. This allele, which encodes serine hydroxymethyltransferase, cytosolic protein, plays a role in the metabolism of both amino acids and folate.	SHMT1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10496>	C61063	Carboplatin/Doxorubicin/Ifosfamide|CBDCA/DOX/IFF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104970>	C16849	Serine Hydroxymethyltransferase, Cytosolic|EC 2.1.2.1|Glycine Hydroxymethyltransferase|SHMT|SHMT1|Serine Methylase	Serine hydroxymethyltransferase, cytosolic (483 aa, ~53 kDa) is encoded by the human SHMT1 gene. This protein is involved in the conversion of glycine to serine.	Serine Hydroxymethyltransferase, Cytosolic		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104971>	C25952	PLA2G1B Gene|PLA2G1B|PLA2G1B|Phospholipase A2, Group IB (Pancreas) Gene	This gene plays a role in phospholipid metabolism.	PLA2G1B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104972>	C104971	PLA2G1B wt Allele|PLA2|PLA2A|PPLA2|Phospholipase A2, Group IB (Pancreas) wt Allele	Human PLA2G1B wild-type allele is located within 12q23-q24.1 and is approximately 6 kb in length. This allele, which encodes phospholipase A2 protein, is involved in phosphoglyceride metabolism.	PLA2G1B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104973>	C16980	Phospholipase A2|EC 3.1.1.4|Group IB Phospholipase A2|PLA2G1B|Phosphatidylcholine 2-Acylhydrolase 1B|Phospholipase A2 Group IB	Phospholipase A2 (148 aa, ~16 kDa) is encoded by the human PLA2G1B gene. This protein plays a role in fatty acid metabolism.	Phospholipase A2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104974>	C25870	GSTA1 Gene|GSTA1|GSTA1|Glutathione S-Transferase Alpha 1 Gene	This gene is involved in glutathione metabolism.	GSTA1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104975>	C104974	GSTA1 wt Allele|GST2|GSTA1-1|GTH1|Glutathione S-Transferase Alpha 1 wt Allele|RP11-392A23.1	Human GSTA1 wild-type allele is located in the vicinity of 6p12.2 and is approximately 13 kb in length. This allele, which encodes glutathione S-transferase A1, plays a role in the metabolism of glutathione.	GSTA1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104976>	C20075	Glutathione S-Transferase A1|EC 2.5.1.18|GST Class-Alpha Member 1|GST HA Subunit 1|GST-Epsilon|GSTA1|GSTA1-1|GTH1|Glutathione S-Alkyltransferase A1|Glutathione S-Aryltransferase A1|S-(Hydroxyalkyl)Glutathione Lyase A1	Glutathione S-transferase A1 (222 aa, ~26 kDa) is encoded by the human GSTA1 gene. This protein is involved in glutathione metabolism.	Glutathione S-Transferase A1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104977>	C21518|C20103	CR2 Gene|CD21|CR2|CR2|Complement Component (3d/Epstein Barr Virus) Receptor 2 Gene	This gene plays a role in the innate immune response.	CR2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104978>	C104977	CR2 wt Allele|C3DR|CD21|CR|CVID7|Complement Component (3d/Epstein Barr Virus) Receptor 2 wt Allele|RP11-78B10.1|SLEB9	Human CR2 wild-type allele is located in the vicinity of 1q32 and is approximately 36 kb in length. This allele, which encodes complement receptor type 2 protein, is involved in the activation of both B-cells and complement-mediated immunity. Mutation of the gene is associated with systemic lupus erythematosus type 9.	CR2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104979>	C21523|C18106	Complement Receptor Type 2|CD21|CD21 Antigen|CR2|Complement C3d Receptor|Cr2|EBV Receptor|Epstein-Barr Virus Receptor	Complement receptor type 2 (1033 aa, ~113 kDa) is encoded by the human CR2 gene. This protein plays a role in the activation of complement-mediated immunity.	Complement Receptor Type 2		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10497>	C61007	Cyclophosphamide/Doxorubicin/Filgrastim|CTX/DOX/G-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104980>	C20917	CKS1B Gene|CDC28 Protein Kinase Regulatory Subunit 1B Gene|CKS1B|CKS1B	This gene plays a role in the regulation of cyclin dependent kinase activity.	CKS1B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104981>	C104980	CKS1B wt Allele|CDC28 Protein Kinase Regulatory Subunit 1B wt Allele|CKS1|PNAS-16|PNAS-18|ckshs1	Human CKS1B wild-type allele is located in the vicinity of 1q21.3 and is approximately 5 kb in length. This allele, which encodes cyclin-dependent kinases regulatory subunit 1 protein, is involved in cell cycle progression.	CKS1B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104982>	C17761	Cyclin-Dependent Kinases Regulatory Subunit 1|CDC2-Associated Protein CKS1|CDC28 Protein Kinase 1|CDC28 Protein Kinase 1B|CKS-1|CKS1B|Cell Division Control Protein CKS1|NB4 Apoptosis/Differentiation Related Protein	Cyclin-dependent kinases regulatory subunit 1 (79 aa, ~10 kDa) is encoded by the human CKS1B gene. This protein plays a role in the regulation of cell cycle progression as an essential cofactor for cyclin dependent kinases.	Cyclin-Dependent Kinases Regulatory Subunit 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104983>	C73539	Pyridinoline|Hydroxylysylpyridinoline	A non-reducible crosslinker for collagen. This compound is fluorescent and is found in mature bone and cartilage collagens. Pyridinoline found in the blood can be an indicator of bone degradation.	Pyridinoline		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C104984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104984>	C20130	Protein Tyrosine Phosphatase Type IVA|PTPN4A	A family of prenylated protein tyrosine phosphatases that plays a role in both phosphotyrosine catabolism and signal transduction pathways, which in turn modulate many different cellular processes.	Protein Tyrosine Phosphatase Type IVA		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104985>	C16981	INPP5D Gene Product	A protein encoded by the INPP5D gene.	INPP5D Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104986>	C104985	Phosphatidylinositol 3,4,5-Trisphosphate 5-Phosphatase 1 Isoform 3|Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatase 1 Isoform 3|SIP-110|Short-SHIP|Truncated INPP5D|s-SHIP	Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 isoform 3 (976 aa, ~109 kDa) is encoded by the human INPP5D gene. This protein plays a role in the removal of phosphate from phosphatidylinositol trisphosphate and may play a role in stem cell maintenance.	Phosphatidylinositol 3,4,5-Trisphosphate 5-Phosphatase 1 Isoform 3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104987>	C62792	HLA Class II Histocompatibility Antigen, DQ Alpha 1 Chain|DC-1 Alpha Chain|DC-alpha|HLA-DCA|HLA-DQA1|MHC Class II DQA1	HLA class II histocompatibility antigen, DQ alpha 1 chain (254 aa, ~28 kDa) is encoded by the human HLA-DQA1 gene. This protein is involved in modulation of peptide antigen binding and endocytosis.	HLA Class II Histocompatibility Antigen, DQ Alpha 1 Chain		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104988>	C116433	Palliative Radiation Therapy for Metastatic Cancer	Radiation therapy given as palliative treatment to a patient with metastatic cancer.			Therapeutic or Preventive Procedure	
C104989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104989>	C15751	Retreatment of Progressive Local Disease with External Beam Radiation	External beam radiation therapy given as retreatment of locally progressive cancer.			Therapeutic or Preventive Procedure	
C10498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10498>	C61063	Doxorubicin/Vinblastine|DOX/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C104990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104990>	C15195	Retreatment of Progressive Local Disease with Brachytherapy	Brachytherapy given as retreatment of locally progressive cancer.			Therapeutic or Preventive Procedure	
C104991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104991>	C49236	Retreatment of Progressive Local Disease with Cryotherapy and HIFU	Cryotherapy and high intensity focused ultrasound given as retreatment of locally progressive cancer.			Therapeutic or Preventive Procedure	
C104992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104992>	C16830	Rectal Balloon	An air filled rectal balloon that is used for prostate immobilization in patients receiving radiation therapy for prostate cancer.			Medical Device	
C104993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104993>	C19747	Film Portal Imaging	The acquisition of images of an anatomic area that is being irradiated using radiotherapy beams and films as imaging media.			Medical Device	
C104994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104994>	C19747	Electronic Portal Imaging	The acquisition of images of an anatomic area that is being irradiated using radiotherapy beams and an electronic detector.	Electronic Portal Imaging		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C104995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104995>	C20194	SCGB3A1 Gene|SCGB3A1|SCGB3A1|Secretoglobin, Family 3A, Member 1 Gene	This gene encodes a secreted protein of unknown function.	SCGB3A1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104996>	C104995	SCGB3A1 wt Allele|HIN-1|HIN1|LU105|PnSP-2|Secretoglobin, Family 3A, Member 1 wt Allele|UGRP2	Human SCGB3A1 wild-type allele is located within 5q35-qter and is approximately 1 kb in length. This allele encodes secretoglobin family 3A member 1 protein, a secreted protein of unknown function.	SCGB3A1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104997>	C18466	Secretoglobin Family 3A Member 1|Cytokine HIN-1|Cytokine High in Normal-1|High in Normal 1|Pneumo Secretory Protein 2|Uteroglobin-Related Protein 2	Secretoglobin family 3A member 1 (104 aa, ~10 kDa) is encoded by the human SCGB3A1 gene. This is a secreted protein of unknown function.	Secretoglobin Family 3A Member 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C104998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104998>	C20988	SDC2 Gene|SDC2|SDC2|Syndecan 2 Gene	This gene is involved in cell proliferation, cell migration and cell-matrix interactions.	SDC2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C104999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C104999>	C104998	SDC2 wt Allele|CD362|HSPG|HSPG1|SYND2|Syndecan 2 wt Allele	Human SDC2 wild-type allele is located within 8q22-q23 and is approximately 118 kb in length. This allele, which encodes syndecan-2 protein, plays a role in cell-matrix interactions, cell migration, and cell proliferation.	SDC2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10499>	C61063	Dimethylbusulfan/Etoposide|DMB/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1049>	C699	Chlorozotocin|1-(2-chloroethyl)-1-nitroso-3-(D-glucos-2-yl)urea|2-[3-(2-chloroethyl)-3-nitrosoureido]-2-deoxy-D-glucopyranose|2-[[[(2-chloroethyl)nitrosamino]carbonyl]amino]-2-deoxy-D-glucose|CHLOROZOTOCIN|CHLZ|CZT|Chlorozotocyna|D-Glucopyranose, 2-[[[(2-chloroethyl)nitrosoamino]carbonyl]amino]-2-deoxy-|D-Glucose, 2-[[[(2-chloroethyl)nitrosoamino]carbonyl]amino]-2-deoxy- (9CI)|D-glucopyranose, 2-[[[(2-chloroethyl)nitrosoamino]carbonyl]amino]-2-deoxy|D-glucose, 2-[[[(2-chloroethyl)nitrosoamino]carbonyl]amino]-2-deoxy- (9CI)|DCNU|DCNU|Dome	A glucose-linked chloroethylnitrosourea with potential antineoplastic activity.  Chlorozotocin alkylates DNA and proteins, induces the formation of interstrand DNA and DNA-protein crosslinks, and causes DNA strand breakage, thereby damaging DNA and resulting in cell death.  This agent has been shown to exhibit antitumor and immunomodulatory effects in cell lines and animal models.  Chlorozotocin is a mutagen and is less myelotoxic than other nitrosoureas. (NCI04)			Antibiotic|Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C105000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105000>	C16393	Syndecan-2|CD362 Antigen|Cell Surface-Associated Heparan Sulfate Proteoglycan 1|Fibroglycan|Heparan Sulfate Proteoglycan 1, Cell Surface-Associated|Heparan Sulfate Proteoglycan Core Protein|SDC2|Syndecan Proteoglycan 2	Syndecan-2 (201 aa, ~22 kDa) is encoded by the human SDC2 gene. This protein is involved in cell migration, cell proliferation, and cell-matrix interactions. In addition, this protein acts as a receptor for HIV-1.	Syndecan-2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105001>	C20921	SFRP2 Gene|SFRP2|SFRP2|Secreted Frizzled-Related Protein 2 Gene	This gene is involved in regulating cell growth and differentiation as a modulator of Wnt signaling.	SFRP2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105002>	C105001	SFRP2 wt Allele|FRP-2|FRP2|SARP-1|SARP1|SDF-5|Secreted Frizzled-Related Protein 2 wt Allele|sFRP-2	Human SFRP2 wild-type allele is located in the vicinity of 4q31.3 and is approximately 9 kb in length. This allele, which encodes secreted frizzled-related protein 2, plays a role in modulating Wnt signaling of cell growth and differentiation.	SFRP2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105003>	C18515	Secreted Frizzled-Related Protein 2|FRP-2|SARP-1|Secreted Apoptosis Related Protein|Secreted Apoptosis-Related Protein 1|sFRP-2	Secreted frizzled-related protein 2 (295 aa, ~33 kDa) is encoded by the human SFRP2 gene. This protein is involved in regulating cell growth and differentiation as a modulator of Wnt signaling.	Secreted Frizzled-Related Protein 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105004>	C20921	SFRP5 Gene|SFRP5|SFRP5|Secreted Frizzled-Related Protein 5 Gene	This gene may play a role in determining the polarity of photoreceptor cells in the retina.	SFRP5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105005>	C105004	SFRP5 wt Allele|FRP-1b|FRP1B|SARP-3|SARP3|Secreted Frizzled-Related Protein 5 wt Allele|sFRP-5	Human SFRP5 wild-type allele is located in the vicinity of 10q24.1 and is approximately 5 kb in length. This allele, which encodes secreted frizzled-related protein 5, a signaling protein that may be involved in determining the polarity of photoreceptor cells in the retina.	SFRP5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105006>	C18515	Secreted Frizzled-Related Protein 5|FRP-1b|Frizzled-Related Protein 1b|SARP-3|Secreted Apoptosis Related Protein 3|Secreted Apoptosis-Related Protein 3|sFRP-5	Secreted frizzled-related protein 5 (317 aa, ~36 kDa) is encoded by the human SFRP5 gene. This protein may play a role in determining the polarity of photoreceptor cells in the retina.	Secreted Frizzled-Related Protein 5		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105007>	C20194	SEL1L Gene|SEL1L|SEL1L|Sel-1 Suppressor of Lin-12-Like (C. elegans) Gene	This gene is involved in protein degradation.	SEL1L Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105008>	C105007	SEL1L wt Allele|IBD2|PRO1063|SEL1-Like|SEL1L1|Sel-1 Suppressor of Lin-12-Like (C. elegans) wt Allele|Sel-1L|TSA305	Human SEL1L wild-type allele is located in the vicinity of 14q31 and is approximately 62 kb in length. This allele, which encodes protein Sel-1 homolog 1 protein, plays a role in degradation of misfolded proteins.	SEL1L wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105009>	C18466	Protein Sel-1 Homolog 1|SEL1-Like|Sel-1 (Suppressor of Lin-12, C.elegans)-Like|Sel-1 Suppressor of Lin-12-Like 1|Suppressor of Lin 12 (Sel-1), C. elegans, Homolog of|Suppressor of Lin-12-Like Protein 1	Protein Sel-1 homolog 1 (794 aa, ~89 kDa) is encoded by the human SEL1L gene. This protein is involved in degradation of misfolded endoplasmic reticulum proteins.	Protein Sel-1 Homolog 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10500>	C61063	Dacarbazine/Tamoxifen|DTIC/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105010>	C29936	SERPINA1 Gene|SERPINA1|SERPINA1|Serpin Family A Member 1 Gene	This gene plays a role in both coagulation and the regulation of proteolysis.	SERPINA1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105011>	C105010	SERPINA1 wt Allele|A1A|A1AT|AAT|Alpha1AT|PI|PI1|PRO2275|Protease Inhibitor 1 (Anti-Elastase), Alpha-1-Antitrypsin Gene|Serine (Or Cysteine) Proteinase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 1 Gene|Serine (Or Cysteine) Proteinase Inhibitor, Clade A, Member 1 Gene|Serine (or Cysteine) Proteinase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 1 Gene|Serpin Family A Member 1 wt Allele|Serpin Peptidase Inhibitor Clade A (Alpha-1antiproteinase, Antitrypsin) Member 1 Gene|Serpin Peptidase Inhibitor Clade A Member 1 Gene|Serpin Peptidase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 1 Gene|nNIF	Human SERPINA1 wild-type allele is located in the vicinity of 14q32.1 and is approximately 14 kb in length. This allele, which encodes alpha-1-antitrypsin protein, is involved in both the regulation of proteolysis and coagulation. Mutations in this gene are associated with pulmonary disease, emphysema, and bleeding disorders.	SERPINA1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105012>	C17122	Alpha-1-Antitrypsin|AAT|Alpha-1 Antitrypsin|Alpha-1 Protease Inhibitor|Alpha-1-Antiproteinase|Alpha1AT|Anti-Elastase|PI|Protease Inhibitor 1|SERPINA1|Serine (or Cysteine) Proteinase Inhibitor, Clade A, Member 1|Serpin A1|Serpin Family A Member 1|Serpin Peptidase Inhibitor Clade A Member 1	Alpha-1-antitrypsin (418 aa, ~47 kDa) is encoded by the human SERPINA1 gene. This protein plays a role in regulation of proteolysis.	Alpha-1-Antitrypsin		Amino Acid, Peptide, or Protein	CTRP Agent Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105013>	C26110	SETMAR Gene|SET Domain and Mariner Transposase Fusion Gene|SETMAR|SETMAR	This gene is involved in epigenetic transcriptional activation.	SETMAR Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105014>	C105013	SETMAR wt Allele|SET Domain and Mariner Transposase Fusion Gene wt Allele|hsMar1	Human SETMAR wild-type allele is located in the vicinity of 3p26.1 and is approximately 14 kb in length. This allele, which encodes histone-lysine N-methyltransferase SETMAR protein, plays a role in epigenetic transcriptional activation and may be involved in mediating genomic integration of foreign DNA.	SETMAR wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105015>	C16849	Histone-Lysine N-Methyltransferase SETMAR|EC 2.1.1.43|Metnase|SET Domain and Mariner Transposase Fusion Gene-Containing Protein	Histone-lysine N-methyltransferase SETMAR (671 aa, ~77 kDa) is encoded by the human SETMAR gene. This protein is involved in epigenetic transcriptional activation.	Histone-Lysine N-Methyltransferase SETMAR		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105016>	C25871	SGMS1 Gene|SGMS1|SGMS1|Sphingomyelin Synthase 1 Gene	This gene plays a role in phosphatidylcholine and ceramide metabolism.	SGMS1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105017>	C105016	SGMS1 wt Allele|MGC17342|MOB|MOB1|SMS1|Sphingomyelin Synthase 1 wt Allele|TMEM23|hmob33	Human SGMS1 wild-type allele is located in the vicinity of 10q11.2 and is approximately 319 kb in length. This allele, which encodes phosphatidylcholine:ceramide cholinephosphotransferase 1 protein, is involved in the mediation of apoptosis.	SGMS1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105018>	C16984	Phosphatidylcholine:Ceramide Cholinephosphotransferase 1|EC 2.7.8.27|Medulla Oblongata-Derived Protein|Protein MOB|SGMS1|Sphingomyelin Synthase 1|Transmembrane Protein 23	Phosphatidylcholine:ceramide cholinephosphotransferase 1 (419 aa, ~49 kDa) is encoded by the human SGMS1 gene. This protein plays a role in apoptosis.	Phosphatidylcholine:Ceramide Cholinephosphotransferase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105019>	C25952	SMPD1 Gene|SMPD1|SMPD1|Sphingomyelin Phosphodiesterase 1, Acid Lysosomal Gene	This gene plays a role in ceramide metabolism.	SMPD1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10501>	C61063	Amifostine/Cisplatin/Etoposide|CDDP/VP-16/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105020>	C105019	SMPD1 wt Allele|ASM|ASMASE|NPD|Sphingomyelin Phosphodiesterase 1, Acid Lysosomal wt Allele|Sphingomyelinase, Acid Gene	Human SMPD1 wild-type allele is located within 11p15.4-p15.1 and is approximately 5 kb in length. This allele, which encodes sphingomyelin phosphodiesterase protein, is involved in ceramide biosynthesis. Mutation of the gene is associated with Niemann-Pick disease type A and type B.	SMPD1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105021>	C16561	Sphingomyelin Phosphodiesterase|Acid Sphingomyelinase|EC 3.1.4.12|SMPD1|Sphingomyelinase, Acid|aSMase	Sphingomyelin phosphodiesterase (629 aa, ~70 kDa) is encoded by the human SMPD1 gene. This protein plays a role in sphingomyelin catabolism.	Sphingomyelin Phosphodiesterase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C105022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105022>	C25952	SMPD2 Gene|SMPD2|SMPD2|Sphingomyelin Phosphodiesterase 2, Neutral Membrane (Neutral Sphingomyelinase) Gene	This gene is involved in sphingomyelin catabolism.	SMPD2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105023>	C105022	SMPD2 wt Allele|ISC1|NSMASE|NSMASE1|RP5-919F19.2|Sphingomyelin Phosphodiesterase 2, Neutral Membrane (Neutral Sphingomyelinase) wt Allele	Human SMPD2 wild-type allele is located in the vicinity of 6q21 and is approximately 3 kb in length. This allele, which encodes sphingomyelin phosphodiesterase 2 protein, plays a role in ceramide metabolism.	SMPD2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105024>	C25871	SGMS2 Gene|SGMS2|SGMS2|Sphingomyelin Synthase 2 Gene	This gene is involved in cell growth.	SGMS2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105025>	C105024	SGMS2 wt Allele|MGC26963|SMS2|Sphingomyelin Synthase 2 wt Allele	Human SGMS2 wild-type allele is located in the vicinity of 4q25 and is approximately 90 kb in length. This allele, which encodes phosphatidylcholine:ceramide cholinephosphotransferase 2 protein, plays a role in cell growth.	SGMS2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105026>	C16561	Sphingomyelin Phosphodiesterase 2|EC 3.1.4.12|Lyso-PAF-PLC|Lyso-Platelet-Activating Factor-Phospholipase C|N-SMase|Neutral Sphingomyelinase|SMPD2|nSMase	Sphingomyelin phosphodiesterase 2 (423 aa, ~48 kDa) is encoded by the human SMPD2 gene. This protein is involved in phospholipid metabolism.	Sphingomyelin Phosphodiesterase 2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105027>	C16984	Phosphatidylcholine:Ceramide Cholinephosphotransferase 2|EC 2.7.8.27|SGMS2|Sphingomyelin Synthase 2	Phosphatidylcholine:ceramide cholinephosphotransferase 2 (365 aa, ~42 kDa) is encoded by the human SGMS2 gene. This protein is involved in cell growth.	Phosphatidylcholine:Ceramide Cholinephosphotransferase 2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105028>	C21282	SGPL1 Gene|SGPL1|SGPL1|Sphingosine-1-Phosphate Lyase 1 Gene	This gene plays a role in the metabolism of phosphorylated sphingoid bases.	SGPL1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105029>	C25952	SMPD3 Gene|SMPD3|SMPD3|Sphingomyelin Phosphodiesterase 3, Neutral Membrane (Neutral Sphingomyelinase II) Gene	This gene plays a role in phospholipid metabolism.	SMPD3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10502>	C61063	Cyclophosphamide/Etoposide/Sargramostim|CTX/GM-CSF/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105030>	C105028	SGPL1 wt Allele|KIAA1252|S1PL|SPL|SPL 1|Sphingosine-1-Phosphate Lyase 1 wt Allele|hSPL	Human SGPL1 wild-type allele is located in the vicinity of 10q21 and is approximately 65 kb in length. This allele, which encodes sphingosine-1-phosphate lyase 1 protein, is involved in both the metabolism of phosphorylated sphingoid bases and apoptosis.	SGPL1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105031>	C105029	SMPD3 wt Allele|NSMASE2|Sphingomyelin Phosphodiesterase 3, Neutral Membrane (Neutral Sphingomyelinase II) wt Allele	Human SMPD3 wild-type allele is located in the vicinity of 16q22.1 and is approximately 90 kb in length. This allele, which encodes sphingomyelin phosphodiesterase 3 protein, is involved in sphingomyelin metabolism.	SMPD3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105032>	C16561	Sphingomyelin Phosphodiesterase 3|EC 3.1.4.12|Neutral Sphingomyelinase II|SMPD3|nSMase-2|nSMase2	Sphingomyelin phosphodiesterase 3 (655 aa, ~71 kDa) is encoded by the human SMPD3 gene. This protein plays a role in ceramide biosynthesis.	Sphingomyelin Phosphodiesterase 3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105033>	C16804	Sphingosine-1-Phosphate Lyase 1|EC 4.1.2.27|SGPL1|SP-Lyase 1|Sphingosine-1-Phosphate Aldolase	Sphingosine-1-phosphate lyase 1 (568 aa, ~64 kDa) is encoded by the human SGPL1 gene. This protein plays a role in apoptosis, the elevation of stress-induced ceramide production, and the metabolism of phosphorylated sphingoid bases.	Sphingosine-1-Phosphate Lyase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105034>	C91105	FACT-H&N Questionnaire|FACT Head and Neck Questionnaire	A subscale complement to the FACT-G questionnaire developed specifically for evaluating quality of life of patients with head and neck cancer.	FACT-H&N Questionnaire		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C105035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105035>	C25952	SMPD4 Gene|SMPD4|SMPD4|Sphingomyelin Phosphodiesterase 4, Neutral Membrane (Neutral Sphingomyelinase-3) Gene	This gene is involved in ceramide biosynthesis.	SMPD4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105036>	C105035	SMPD4 wt Allele|FLJ20297|FLJ20756|KIAA1418|NET13|NSMASE-3|NSMASE3|Sphingomyelin Phosphodiesterase 4, Neutral Membrane (Neutral Sphingomyelinase-3) wt Allele	Human SMPD4 wild-type allele is located in the vicinity of 2q21.1 and is approximately 31 kb in length. This allele, which encodes sphingomyelin phosphodiesterase 4 protein, plays a role in phospholipid metabolism.	SMPD4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105037>	C26070	SGPP1 Gene|SGPP1|SGPP1|Sphingosine-1-Phosphate Phosphatase 1 Gene	This gene is involved in sphingosine-1-phosphate degradation.	SGPP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105038>	C105037	SGPP1 wt Allele|Sphingosine-1-Phosphate Phosphatase 1 wt Allele|Spp1|hSPP1	Human SGPP1 wild-type allele is located in the vicinity of 14q23.2 and is approximately 44 kb in length. This allele, which encodes sphingosine-1-phosphate phosphatase 1 protein, plays a role in intracellular and extracellular sphingosine-1-phosphate levels.	SGPP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105039>	C16561	Sphingomyelin Phosphodiesterase 4|EC 3.1.4.12|Neutral Sphingomyelinase III|SMPD4|nSMase-3|nSMase3	Sphingomyelin phosphodiesterase 4 (827 aa, ~93 kDa) is encoded by the human SMPD4 gene. This protein is involved in sphingomyelin catabolism.	Sphingomyelin Phosphodiesterase 4		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10503>	C61063	Piroxantrone/Sargramostim|GM-CSF/PXT			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105040>	C16981	Sphingosine-1-Phosphate Phosphatase 1|EC 3.1.3.-|SGPP1|SPPase1|Sphingosine-1-Phosphatase 1|hSPPase1	Sphingosine-1-phosphate phosphatase 1 (441 aa, ~49 kDa) is encoded by the human SGPP1 gene. This protein is involved in regulating intracellular and extracellular sphingosine-1-phosphate levels.	Sphingosine-1-Phosphate Phosphatase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105041>	C188083|C173045	Able to Eat Liked Food Question|Able to Eat Liked Food|I am able to eat the foods that I like	A question about whether an individual is or was able to eat the foods they like.			Intellectual Product	FACT-H&N Questionnaire
C105042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105042>	C173398	Have Trouble Breathing Question|Have Trouble Breathing|I have trouble breathing	A question about whether an individual has or had trouble breathing.			Intellectual Product	FACT-H&N Questionnaire
C105043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105043>	C26070	SGPP2 Gene|SGPP2|SGPP2|Sphingosine-1-Phosphate Phosphatase 2 Gene	This gene plays a role in sphingosine-1-phosphate catabolism.	SGPP2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105044>	C173937	Voice Has Usual Quality and Strength Question|My voice has its usual quality and strength|Voice Has Usual Quality and Strength	A question about whether an individual's voice has or had the usual quality and strength.			Intellectual Product	FACT-H&N Questionnaire
C105045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105045>	C105043	SGPP2 wt Allele|FLJ39004|SPP2|Sphingosine-1-Phosphate Phosphatase 2 wt Allele|hSPP2	Human SGPP2 wild-type allele is located in the vicinity of 2q36.1 and is approximately 136 kb in length. This allele, which encodes sphingosine-1-phosphate phosphatase 2 protein, is involved in intracellular and extracellular sphingosine-1-phosphate levels.	SGPP2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105046>	C188083|C173045	Able to Eat as Much Food as Desired Question|Able to Eat as Much Food as Desired|I am able to eat as much food as I want	A question about whether an individual is or was able to eat as much food as they want.			Intellectual Product	FACT-H&N Questionnaire
C105047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105047>	C16981	Sphingosine-1-Phosphate Phosphatase 2|EC 3.1.3.-|SGPP2|SPPase2|Sphingosine 1-Phosphate Phosphohydrolase 2|Sphingosine-1-Phosphatase 2	Sphingosine-1-phosphate phosphatase 2 (399 aa, ~48 kDa) is encoded by the human SGPP2 gene. This protein plays a role in regulating intracellular and extracellular sphingosine-1-phosphate levels.	Sphingosine-1-Phosphate Phosphatase 2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105048>	C176022|C173160	Unhappy with Face and Neck Appearance Question|I am unhappy with how my face and neck look|Unhappy with Face and Neck Appearance	A question about whether an individual is or was unhappy with the appearance of their face and neck.			Intellectual Product	FACT-H&N Questionnaire
C105049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105049>	C173454	Swallowing Naturally and Easily Question|I can swallow naturally and easily|Swallowing Naturally and Easily	A question about whether an individual is or was able to swallow naturally and easily.			Intellectual Product	FACT-H&N Questionnaire
C10504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10504>	C61063	Carboplatin/Epoetin Alfa/Etoposide|CBDCA/EPO/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105050>	C173060	Smoke Cigarettes or Other Tobacco Products Question|I smoke cigarettes or other tobacco products|Smoke Cigarettes or Other Tobacco Products	A question about whether an individual smokes cigarettes or other tobacco products.			Intellectual Product	FACT-H&N Questionnaire
C105051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105051>	C173703	Drinks Alcohol Such as Beer or Wine Question|Drinks Alcohol Such as Beer or Wine|I drink alcohol (e.g. beer, wine, etc.)	A question about whether an individual drinks alcohol, such as beer or wine.			Intellectual Product	FACT-H&N Questionnaire
C105052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105052>	C173045	Able to Communicate with Others Question|Able to Communicate with Others|I am able to communicate with others	A question about whether an individual is or was able to communicate with others.			Intellectual Product	FACT-H&N Questionnaire
C105053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105053>	C188083|C173045	Able to Eat Solid Food Question|Able to Eat Solid Food|I can eat solid foods	A question about whether an individual is or was able to eat solid food.			Intellectual Product	FACT-H&N Questionnaire
C105054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105054>	C91126	Have Pain in Mouth, Throat or Neck Question|Have Pain in Mouth, Throat or Neck|I have pain in my mouth, throat or neck	A question about whether an individual has or had pain in the mouth, throat or neck.			Intellectual Product	FACT-H&N Questionnaire
C105055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105055>	C25791|C20921	SLAMF6 Gene|SLAM Family Member 6 Gene|SLAMF6|SLAMF6	This gene acts as a coreceptor in the process of natural killer cell activation.	SLAMF6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105056>	C105055	SLAMF6 wt Allele|CD352|KALI|KALIb|Ly108|NTB-A|NTBA|SF2000|SLAM Family Member 6 wt Allele	Human SLAMF6 wild-type allele is located in the vicinity of 1q23.2 and is approximately 38 kb in length. This allele, which encodes SLAM family member 6 protein, plays a role as a coreceptor in natural killer cell activation.	SLAMF6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105057>	C18515|C16725	SLAM Family Member 6|Activating NK Receptor|CD352 Antigen|NK-T-B-Antigen|NTBA Receptor|Natural Killer-, T- and B-Cell Antigen|SLAMF6	SLAM family member 6 (332 aa, ~37 kDa) is encoded by the human SLAMF6 gene. This protein acts as a coreceptor in the process of natural killer cell activation.	SLAM Family Member 6		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105058>	C28533	SLC1A4 Gene|SLC1A4|SLC1A4|Solute Carrier Family 1 (Glutamate/Neutral Amino Acid Transporter), Member 4 Gene	This gene plays a role in amino acid transport.	SLC1A4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105059>	C105058	SLC1A4 wt Allele|ASCT-1|ASCT1|SATT|Solute Carrier Family 1 (Glutamate/Neutral Amino Acid Transporter), Member 4 wt Allele	Human SLC1A4 wild-type allele is located within 2p15-p13 and is approximately 35 kb in length. This allele, which encodes neutral amino acid transporter A protein, is involved in sodium-dependent transport of alanine, serine, cysteine, and threonine.	SLC1A4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10505>	C61007	Carboplatin/Cytarabine/Dexamethasone|ARA-C/CBDCA/DM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105060>	C16386	Neutral Amino Acid Transporter A|Alanine/Serine/Cysteine/Threonine Transporter 1|Glutamate/Neutral Amino Acid Transporter|Solute Carrier Family 1 Member 4	Neutral amino acid transporter A (532 aa, ~56 kDa) is encoded by the human SLC1A4 gene. This protein plays a role in transporting alanine, serine, cysteine, and threonine.	Neutral Amino Acid Transporter A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105061>	C28533	SLC29A1 Gene|SLC29A1|SLC29A1|Solute Carrier Family 29 Member 1 (Augustine Blood Group) Gene	This gene is involved in mediating the cellular uptake of nucleosides.	SLC29A1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105062>	C105061	SLC29A1 wt Allele|ENT1|Solute Carrier Family 29 (Equilibrative Nucleoside Transporter), Member 1 Gene|Solute Carrier Family 29 (Nucleoside Transporter), Member 1 Gene|Solute Carrier Family 29 (Nucleoside Transporters), Member 1 Gene|Solute Carrier Family 29 Member 1 (Augustine Blood Group) wt Allele|hENT1	Human SLC29A1 wild-type allele is located in the vicinity of 6p21.1 and is approximately 15 kb in length. This allele, which encodes equilibrative nucleoside transporter 1 protein, plays a role in mediating both influx and efflux of nucleosides across the plasma membrane.	SLC29A1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105063>	C16386	Equilibrative Nucleoside Transporter 1|Equilibrative NBMPR-Sensitive Nucleoside Transporter|Equilibrative Nitrobenzylmercaptopurine Riboside (NBMPR)-Sensitive Nucleoside Transporter|Equilibrative Nitrobenzylmercaptopurine Riboside-Sensitive Nucleoside Transporter|Nucleoside Transporter, ES-Type|SLC29A1|Solute Carrier Family 29 Member 1|hENT1	Equilibrative nucleoside transporter 1 (456 aa, ~50 kDa) is encoded by the human SLC29A1 gene. This protein is involved in mediating nucleoside influx and efflux.	Equilibrative Nucleoside Transporter 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105064>	C28533	SLC4A1 Gene|SLC4A1|SLC4A1|Solute Carrier Family 4, Anion Exchanger, Member 1 (Erythrocyte Membrane Protein Band 3, Diego Blood Group) Gene	This gene plays a role in carbon dioxide transport from tissues to lungs.	SLC4A1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105065>	C105064	SLC4A1 wt Allele|AE 1|AE1|BND3|CD233|DI|EMPB3|EPB|FR|RTA1A|SW|Solute Carrier Family 4, Anion Exchanger, Member 1 (Erythrocyte Membrane Protein Band 3, Diego Blood Group) wt Allele|WD|WD1|WR	Human SLC4A1 wild-type allele is located in the vicinity of 17q21.31 and is approximately 20 kb in length. This allele, which encodes band 3 anion transport protein, is involved in elimination of carbon dioxide from tissues. Mutations in this gene are associated with both hereditary spherocytosis and distal renal tubular acidosis. Other mutations result in novel blood group antigens.	SLC4A1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105066>	C16386	Band 3 Anion Transport Protein|Anion Exchange Protein 1|Anion Exchanger 1|Anion Exchanger-1|CD233 Antigen|Erythrocyte Membrane Protein Band 3|Erythroid Anion Exchange Protein|Froese Blood Group|SLC4A1|Solute Carrier Family 4 Member 1|Solute Carrier Family 4, Anion Exchanger, Number 1|Swann Blood Group|Waldner Blood Group|Wright Blood Group	Band 3 anion transport protein (911 aa, ~102 kDa) is encoded by the human SLC4A1 gene. This protein plays a role in chloride/bicarbonate exchange.	Band 3 Anion Transport Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105067>	C28533	SLC4A3 Gene|SLC4A3|SLC4A3|Solute Carrier Family 4, Anion Exchanger, Member 3 Gene	This gene is involved in mediating chloride/bicarbonate exchange in cardiac myocytes.	SLC4A3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105068>	C105067	SLC4A3 wt Allele|AE 3|AE3|CAE3/BAE3|SLC2C|Solute Carrier Family 4, Anion Exchanger, Member 3 wt Allele	Human SLC4A3 wild-type allele is located in the vicinity of 2q36 and is approximately 15 kb in length. This allele, which encodes anion exchange protein 3, plays a role in chloride/bicarbonate exchange in cardiac myocytes.	SLC4A3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105069>	C16386	Anion Exchange Protein 3|Anion Exchanger 3|Anion Exchanger 3, Neuronal|Cardiac/Brain Band 3-Like Protein|Neuronal Band 3-Like Protein|Solute Carrier Family 4 Member 3	Anion exchange protein 3 (1232 aa, ~136 kDa) is encoded by the human SLC4A3 gene. This protein is involved in chloride/bicarbonate exchange in cardiac myocytes.	Anion Exchange Protein 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10506>	C61063	Carboplatin/Cytarabine/Dexamethasone/Sargramostim|ARA-C/CBDCA/DM/GM-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105070>	C28533	SLC18A2 Gene|SLC18A2|SLC18A2|Solute Carrier Family 18 (Vesicular Monoamine), Member 2 Gene	This gene plays a role in neurotransmitter transport.	SLC18A2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105071>	C105070	SLC18A2 wt Allele|SVAT|SVMT|Solute Carrier Family 18 (Vesicular Monoamine), Member 2 wt Allele|VAT2|VMAT2	Human SLC18A2 wild-type allele is located in the vicinity of 10q25 and is approximately 38 kb in length. This allele, which encodes synaptic vesicular amine transporter protein, is involved in the subcellular localization of neurotransmitters.	SLC18A2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105072>	C16386	Synaptic Vesicular Amine Transporter|Monoamine Transporter|SLC18A2|Solute Carrier Family 18 Member 2|VAT2|Vesicle Monoamine Transporter Type 2|Vesicle Monoamine/H+ Antiporter|Vesicular Amine Transporter 2	Synaptic vesicular amine transporter (514 aa, ~56 kDa) is encoded by the human SLC18A2 gene. This protein plays a role in pumping monoamine neurotransmitters into synaptic vesicles.	Synaptic Vesicular Amine Transporter		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105073>	C28533	SLC22A1 Gene|SLC22A1|SLC22A1|Solute Carrier Family 22 (Organic Cation Transporter), Member 1 Gene	This gene is involved in cation transport.	SLC22A1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105074>	C105073	SLC22A1 wt Allele|HOCT1|OCT1|Solute Carrier Family 22 (Organic Cation Transporter), Member 1 wt Allele|oct1_cds	Human SLC22A1 wild-type allele is located in the vicinity of 6q25.3 and is approximately 37 kb in length. This allele, which encodes solute carrier family 22 member 1 protein, plays a role in the transport of organic cations.	SLC22A1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105075>	C16386	Solute Carrier Family 22 Member 1|Organic Cation Transporter 1|SLC22A1|hOCT1	Solute carrier family 22 member 1 (554 aa, ~61 kDa) is encoded by the human SLC22A1 gene. This protein is involved in bidirectional cation transport.	Solute Carrier Family 22 Member 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105076>	C20921	SOST Gene|SOST|SOST|Sclerostin Gene	This gene plays a role in bone growth.	SOST Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105077>	C105076	SOST wt Allele|CDD|Sclerosteosis Gene|Sclerostin wt Allele|UNQ2976/PRO7455/PRO7476|VBCH	Human SOST wild-type allele is located in the vicinity of 17q11.2 and is approximately 5 kb in length. This allele, which encodes sclerostin protein, is involved in the negative regulation of ossification. Mutation of the gene is associated with bone dysplasias including sclerosteosis type 1, van Buchem disease and craniodiaphyseal dysplasia autosomal dominant.	SOST wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105078>	C18515	Sclerostin|SOST	Sclerostin (213 aa, ~24 kDa) is encoded by the human SOST gene. This protein plays a role in the regulation of bone growth and Wnt signaling pathways.	Sclerostin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105079>	C20420	SOX11 Gene|SOX11|SOX11|SRY-Box 11 Gene	This gene is involved in the negative regulation of transcription.	SOX11 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10507>	C61063	Carboplatin/Dacarbazine|CBDCA/DTIC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105080>	C105079	SOX11 wt Allele|MRD27|SRY (Sex Determining Region Y)-Box 11 Gene|SRY (Sex-Determining Region Y)-Box 11 Gene|SRY Box 11 Gene|SRY-Box 11 wt Allele|SRY-Related HMG-Box Gene 11	Human SOX11 wild-type allele is located in the vicinity of 2p25 and is approximately 9 kb in length. This allele, which encodes transcription factor SOX-11 protein, plays a role in the negative regulation of transcription.	SOX11 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105081>	C17207	Transcription Factor SOX-11|SOX11	Transcription factor SOX-11 (441 aa, ~47 kDa) is encoded by the human SOX11 gene. This protein is involved in transcriptional repression.	Transcription Factor SOX-11		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105082>	C20921	SPRY4 Gene|SPRY4|SPRY4|Sprouty RTK Signaling Antagonist 4 Gene	This gene plays a role in the inhibition of receptor signaling.	SPRY4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105083>	C105082	SPRY4 wt Allele|HH17|Sprouty Homolog 4 (Drosophila) Gene|Sprouty Homolog 4 Gene|Sprouty RTK Signaling Antagonist 4 wt Allele|Sprouty, Drosophila, Homolog of, 4 Gene	Human SPRY4 wild-type allele is located in the vicinity of 5q31.3 and is approximately 16 kb in length. This allele, which encodes protein sprouty homolog 4, is involved in the negative regulation of signaling.	SPRY4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105084>	C18515	Protein Sprouty Homolog 4|SPRY4|Spry-4	Protein sprouty homolog 4 (299 aa, ~33 kDa) is encoded by the human SPRY4 gene. This protein plays a role in the inhibition of receptor-mediated signaling pathways.	Protein Sprouty Homolog 4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105085>	C20420	SREBF1 Gene|SREBF1|SREBF1|Sterol Regulatory Element Binding Transcription Factor 1 Gene	This gene is involved in both transcriptional regulation and lipid homeostasis.	SREBF1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105086>	C105085	SREBF1 wt Allele|BHLHD1|SREBP-1c|SREBP1|Sterol Regulatory Element Binding Transcription Factor 1 wt Allele|bHLHd1	Human SREBF1 wild-type allele is located in the vicinity of 17p11.2 and is approximately 26 kb in length. This allele, which encodes sterol regulatory element-binding protein 1, plays a role in both lipid homeostasis and the positive regulation of transcription.	SREBF1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105087>	C26199	Sterol Regulatory Element-Binding Protein 1|Class D Basic Helix-Loop-Helix Protein 1|SREBF1|SREBP-1|Sterol Regulatory Element-Binding Transcription Factor 1|bHLHd1	Sterol regulatory element-binding protein 1 (1147 aa, ~122 kDa) is encoded by the human SREBF1 gene. This protein is involved in both transcriptional activation and cholesterol homeostasis.	Sterol Regulatory Element-Binding Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105088>	C25952	SULF2 Gene|SULF2|SULF2|Sulfatase 2 Gene	This gene plays a role in heparan sulfate metabolism.	SULF2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105089>	C105088	SULF2 wt Allele|HSULF-2|KIAA1247|RP5-1049G16.1|SULF-2|Sulfatase 2 wt Allele|UNQ559/PRO1120	Human SULF2 wild-type allele is located within 20q13.12-q13.13 and is approximately 130 kb in length. This allele, which encodes extracellular sulfatase Sulf-2 protein, is involved in the modulation of proteoglycan binding specificity.	SULF2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10508>	C61063	Carboplatin/Dacarbazine/Tamoxifen|CBDCA/DTIC/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105090>	C16561	Extracellular Sulfatase Sulf-2|EC 3.1.6.-|SULF2|hSulf-2	Extracellular sulfatase Sulf-2 (870 aa, ~100 kDa) is encoded by the human SULF2 gene. This protein plays a role in the removal of O-sulfate groups from heparan sulfate proteoglycans.	Extracellular Sulfatase Sulf-2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105091>	C20923	TBXA2R Gene|TBXA2R|TBXA2R|Thromboxane A2 Receptor Gene	This gene is involved in platelet aggregation.	TBXA2R Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105092>	C105091	TBXA2R wt Allele|BDPLT13|TXA2-R|Thromboxane A2 Receptor wt Allele	Human TBXA2R wild-type allele is located in the vicinity of 19p13.3 and is approximately 12 kb in length. This allele, which encodes thromboxane A2 receptor protein, plays a role in both receptor signaling and platelet aggregation. Mutation of the gene is associated with bleeding disorder platelet-type 13.	TBXA2R wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105093>	C18239	Thromboxane A2 Receptor|Prostanoid TP Receptor|TBXA2R|TXA2-R	Thromboxane A2 receptor (343 aa, ~37 kDa) is encoded by the human TBXA2R gene. This protein is involved in both the stimulation of platelet activation and ligand-mediated signaling.	Thromboxane A2 Receptor		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105094>	C25952|C19676	TDP1 Gene|TDP1|TDP1|Tyrosyl-DNA Phosphodiesterase 1 Gene	This gene plays a role in the repair of both single and double strand breaks in DNA.	TDP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105095>	C105094	TDP1 wt Allele|FLJ11090|SCAN1|Tyrosyl-DNA Phosphodiesterase 1 wt Allele	Human TDP1 wild-type allele is located in the vicinity of 14q32.11 and is approximately 90 kb in length. This allele, which encodes tyrosyl-DNA phosphodiesterase 1 protein, is involved in DNA repair. Mutation of the gene is associated with spinocerebellar ataxia autosomal recessive with axonal neuropathy.	TDP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105096>	C21170|C16561	Tyrosyl-DNA Phosphodiesterase 1|EC 3.1.4.-|TDP1|Tyr-DNA Phosphodiesterase 1	Tyrosyl-DNA phosphodiesterase 1 (608 aa, ~68 kDa) is encoded by the human TDP1 gene. This protein plays a role in single and double strand break repair of DNA.	Tyrosyl-DNA Phosphodiesterase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105097>	C54362	NELFCD Gene|NELFCD|NELFCD|Negative Elongation Factor Complex Member C/D Gene	This gene is involved in the negative regulation of transcript elongation.	NELFCD Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105098>	C105097	NELFCD wt Allele|HSPC130|NELF-C|NELF-D|NELFD|Negative Elongation Factor Complex Member C/D wt Allele|TH1|TH1-Like (Drosophila) Gene|TH1L	Human NELFCD wild-type allele is located in the vicinity of 20q13 and is approximately 14 kb in length. This allele, which encodes negative elongation factor C/D protein, plays a role in the inhibition of transcriptional elongation.	NELFCD wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105099>	C26199	Negative Elongation Factor C/D|NELF-C/D|NELFCD|Negative Elongation Factor Proteins C and D|TH1-Like Protein|Trihydrophobin 1	Negative elongation factor C/D (590 aa, ~66 kDa) is encoded by the human NELFCD gene. This protein is involved in transcriptional pausing.	Negative Elongation Factor C/D		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10509>	C61063	Cyclophosphamide/Dexamethasone/Doxorubicin/Methotrexate/Vincristine|CTX/DM/DOX/MTX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1050>	C582|C1968	Asulacrine Isethionate|9-(2-Methoxy-4-(methylsulfonylamino)phenylamino)-N,5-dimethyl-4-acridinecarboxamide 2-hydroxyethanesulfonate|ASULACRINE ISETHIONATE|CI-921|CI-921	The isethionate salt of an amsacrine analogue with antineoplastic properties. Asulacrine inhibits the enzyme topoisomerase ll, thereby blocking DNA replication and RNA and protein synthesis.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C105100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105100>	C20744	TMPO Gene|TMPO|TMPO|Thymopoietin Gene	This gene plays a role in nuclear structure.	TMPO Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105101>	C105100	TMPO wt Allele|CMD1T|LAP2|LEMD4|PRO0868|TP|Thymopoietin wt Allele	Human TMPO wild-type allele is located in the vicinity of 12q22 and is approximately 34 kb in length. This allele, which encodes both lamina-associated polypeptide 2, isoform alpha and lamina-associated polypeptide 2, isoforms beta/gamma proteins, is involved in the maintenance of nuclear structure. Mutation of the gene is associated with cardiomyopathy dilated type 1T.	TMPO wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105102>	C882	Lamina-Associated Polypeptide 2, Isoform Alpha|LEM Domain Containing 4|Lamina-Associated Polypeptide 2|TMPO|TP Alpha|TPRP Isoform Alpha|Thymopoietin|Thymopoietin Isoform Alpha|Thymopoietin-Related Peptide Isoform Alpha	Lamina-associated polypeptide 2, isoform alpha (694 aa, ~75 kDa) is encoded by the human TMPO gene. This protein plays a role in the structure of the nucleus.	Lamina-Associated Polypeptide 2, Isoform Alpha		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105103>	C882	Lamina-Associated Polypeptide 2, Isoforms Beta/Gamma|LEM Domain Containing 4|Lamina-Associated Polypeptide 2|TMPO|TP Beta/Gamma|TPRP Isoforms Beta/Gamma|Thymopoietin|Thymopoietin, Isoforms Beta/Gamma|Thymopoietin-Related Peptide Isoforms Beta/Gamma	Lamina-associated polypeptide 2, isoforms beta/gamma (694 aa, ~75 kDa) is encoded by the human TMPO gene. This protein is involved in the mediation of nuclear structure.	Lamina-Associated Polypeptide 2, Isoforms Beta/Gamma		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105105>	C25869|C20988	TMEM204 Gene|TMEM204|TMEM204|Transmembrane Protein 204 Gene	This gene is involved in cell-cell adhesion.	TMEM204 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105106>	C105105	TMEM204 wt Allele|C16orf30|CLP24|Chromosome 16 Open Reading Frame 30 Gene|Transmembrane Protein 204 wt Allele|UNQ6509/PRO21434	Human TMEM204 wild-type allele is located in the vicinity of 16p13.3 and is approximately 27 kb in length. This allele, which encodes transmembrane protein 204, plays a role in the regulation of cell-cell adhesion.	TMEM204 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105107>	C16393	Transmembrane Protein 204|Claudin-Like Protein 24|TMEM204	Transmembrane protein 204 (226 aa, ~25 kDa) is encoded by the human TMEM204 gene. This protein is involved in cellular permeability.	Transmembrane Protein 204		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105108>	C20921	TRAF1 Gene|TNF Receptor-Associated Factor 1 Gene|TRAF1|TRAF1	This gene plays a role in TNF receptor family-mediated signaling.	TRAF1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105109>	C105108	TRAF1 wt Allele|EBI6|MGC:10353|TNF Receptor-Associated Factor 1 wt Allele	Human TRAF1 wild-type allele is located within 9q33-q34 and is approximately 27 kb in length. This allele, which encodes TNF receptor-associated factor 1 protein, is involved in both the modulation of TNF receptor family-mediated signal transduction and the regulation of protein ubiquitination.	TRAF1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10510>	C61007	Cyclophosphamide/Filgrastim|CTX/G-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105110>	C26231	TNF Receptor-Associated Factor 1|Epstein-Barr Virus-Induced Protein 6|TRAF1	TNF receptor-associated factor 1 (416 aa, ~46 kDa) is encoded by the human TRAF1 gene. This protein plays a role in the regulation of both protein ubiquitination and TNF receptor family-mediated signaling pathways.	TNF Receptor-Associated Factor 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105111>	C21165	TNFRSF9 Gene|TNF Receptor Superfamily Member 9 Gene|TNFRSF9|TNFRSF9	This gene plays a role in receptor signaling in T-cells.	TNFRSF9 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105112>	C105111	TNFRSF9 wt Allele|4-1BB|4-1BB, Mouse, Homolog of Gene|CD137|CDw137|Homolog of Mouse 4-1BB Gene|ILA|Induced By Lymphocyte Activation (ILA) Gene|Induced By Lymphocyte Activation Gene|Interleukin-Activated Receptor, Homolog of Mouse Ly63 Gene|Ly63, Mouse, Homolog of Gene|TNF Receptor Superfamily Member 9 wt Allele|Tumor Necrosis Factor Receptor Superfamily, Member 9 Gene	Human TNFRSF9 wild-type allele is located in the vicinity of 1p36 and is approximately 21 kb in length. This allele, which encodes tumor necrosis factor receptor superfamily member 9, is involved in T-cell development.	TNFRSF9 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105113>	C153500	Tumor Necrosis Factor Receptor Superfamily Member 9|4-1BB Ligand Receptor|CD137|CD137 Antigen|CDw137|Receptor Protein 4-1BB|T Cell Antigen ILA|T-Cell Antigen 4-1BB Homolog|T-Cell Antigen ILA|TNFRSF9	Tumor necrosis factor receptor superfamily member 9 (255 aa, ~28 kDa) is encoded by the human TNFRSF9 gene. This protein plays a role in receptor signal transduction in activated T-lymphocytes.	Tumor Necrosis Factor Receptor Superfamily Member 9		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105114>	C25941	PTGES2 Gene|PTGES2|PTGES2|Prostaglandin E Synthase 2 Gene	This gene plays a role in prostaglandin biosynthesis.	PTGES2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105115>	C105114	PTGES2 wt Allele|C9orf15|Chromosome 9 Open Reading Frame 15 Gene|FLJ14038|GBF-1|GBF1|PGES2|Prostaglandin E Synthase 2 wt Allele|Prostaglandin E Synthase, Microsomal Gene|RP11-395P17.2|mPGES-2|p53-Induced Gene 12	Human PTGES2 wild-type allele is located in the vicinity of 9q34.11 and is approximately 8 kb in length. This allele, which encodes prostaglandin E synthase 2 protein, is involved in both transcriptional activation and the production of prostaglandin E2.	PTGES2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105116>	C16759	Prostaglandin E Synthase 2|EC 5.3.99.3|GATE-Binding Factor 1|Gamma-Interferon-Activated Transcriptional Element-Binding Factor 1|Membrane-Associated Prostaglandin E Synthase 2|Membrane-Associated Prostaglandin E Synthase-2|Microsomal Prostaglandin E Synthase 2|PTGES2|Prostaglandin-H(2) E-Isomerase|mPGE Synthase-2|mPGES-2	Prostaglandin E synthase 2 (377 aa, ~42 kDa) is encoded by the human PTGES2 gene. This protein plays a role in both the synthesis of prostaglandin E2 and transcriptional activation.	Prostaglandin E Synthase 2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105117>	C20921	MAPKAP1 Gene|MAPKAP1|MAPKAP1|Mitogen-Activated Protein Kinase Associated Protein 1 Gene	This gene is involved in growth factor-mediated signaling.	MAPKAP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105118>	C105117	MAPKAP1 wt Allele|JC310|MGC2745|MIP1|Mitogen-Activated Protein Kinase Associated Protein 1 wt Allele|RP11-269P11.1|SIN1|SIN1b|SIN1g	Human MAPKAP1 wild-type allele is located in the vicinity of 9q34.3 and is approximately 270 kb in length. This allele, which encodes target of rapamycin complex 2 subunit MAPKAP1 protein, plays a role in the regulation of cell growth and survival.	MAPKAP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105119>	C18515	Target of Rapamycin Complex 2 Subunit MAPKAP1|MAPKAP1|MEKK2-Interacting Protein 1|Mitogen-Activated Protein Kinase 2-Associated Protein 1|Mitogen-Activated Protein Kinase Associated Protein 1|SAPK-Interacting Protein 1|Stress-Activated Map Kinase-Interacting Protein 1|TORC2 Subunit MAPKAP1|mSIN1	Target of rapamycin complex 2 subunit MAPKAP1 (522 aa, ~59 kDa) is encoded by the human MAPKAP1 gene. This protein is involved in the modulation of growth factor-dependent signaling.	Target of Rapamycin Complex 2 Subunit MAPKAP1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10511>	C61063	Filgrastim/Interleukin-1-Beta|G-CSF/IL-1B			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105120>	C20194	TNFAIP1 Gene|TNFAIP1|TNFAIP1|Tumor Necrosis Factor, Alpha-Induced Protein 1 (Endothelial) Gene	This gene plays a role in the regulation of protein ubiquitination.	TNFAIP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105121>	C105120	TNFAIP1 wt Allele|B12|B61|BACURD2|BTBD34|EDP1|MGC2317|Tumor Necrosis Factor, Alpha-Induced Protein 1 (Endothelial) wt Allele|hBACURD2	Human TNFAIP1 wild-type allele is located within 17q22-q23 and is approximately 11 kb in length. This allele, which encodes BTB/POZ domain-containing adapter for CUL3-mediated RhoA degradation protein 2, is involved in the modulation of the ubiquitination of transforming protein RhoA.	TNFAIP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105122>	C95242	BTB/POZ Domain-Containing Adapter for CUL3-Mediated RhoA Degradation Protein 2|BTB/POZ Domain-Containing Adapter For CUL3-Mediated RhoA Degradation Protein 2|BTB/POZ Domain-Containing Protein TNFAIP1|Protein B12|TNFAIP1|Tumor Necrosis Factor, Alpha-Induced Protein 1, Endothelial|hBACURD2	BTB/POZ domain-containing adapter for CUL3-mediated RhoA degradation protein 2 (316 aa, ~36 kDa) is encoded by the human TNFAIP1 gene. This protein plays a role in substrate recognition for an E3 ubiquitin ligase complex.	BTB/POZ Domain-Containing Adapter For CUL3-Mediated RhoA Degradation Protein 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105123>	C21240	EIF4E Gene|EIF4E|EIF4E|Eukaryotic Translation Initiation Factor 4E Gene	This gene is involved in translation initiation.	EIF4E Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105124>	C105123	EIF4E wt Allele|CBP|EIF4E1|EIF4EL1|EIF4F|Eukaryotic Translation Initiation Factor 4E wt Allele	Human EIF4E wild-type allele is located within 4q21-q25 and is approximately 59 kb in length. This allele, which encodes eukaryotic translation initiation factor 4E protein, plays a role in both mRNA cap recognition and ribosome recruitment.	EIF4E wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105125>	C17461	Eukaryotic Translation Initiation Factor 4E|Eukaryotic Translation Initiation Factor 4E-Like 1|eIF-4E|eIF-4F 25 kDa Subunit|eIF4E|mRNA Cap-Binding Protein	Eukaryotic translation initiation factor 4E (217 aa, ~25 kDa) is encoded by the human EIF4E gene. This protein is involved in the initiation of mRNA translation.	Eukaryotic Translation Initiation Factor 4E		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105126>	C25939	MTRR Gene|5-Methyltetrahydrofolate-Homocysteine Methyltransferase Reductase Gene|MTRR|MTRR	This gene plays a role in the metabolism of vitamins and amino acids.	MTRR Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105127>	C105126	MTRR wt Allele|5-Methyltetrahydrofolate-Homocysteine Methyltransferase Reductase wt Allele|MSR|cblE	Human MTRR wild-type allele is located in the vicinity of 5p15.31 and is approximately 55 kb in length. This allele, which encodes methionine synthase reductase protein, is involved in both B vitamin metabolism and methionine synthesis. Mutation of the gene is associated with both folate-sensitive neural tube defects and methylcobalamin deficiency type E.	MTRR wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105128>	C16946	Methionine Synthase Reductase|5-Methyltetrahydrofolate-Homocysteine Methyltransferase Reductase|EC 1.16.1.8|MSR|MTRR	Methionine synthase reductase (725 aa, ~80 kDa) is encoded by the human MTRR gene. This protein plays a role in both methionine biosynthesis and B vitamin metabolism.	Methionine Synthase Reductase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105129>	C100110	CDISC Questionnaire DAD Test Name Terminology|DAD01TN|Disability Assessment for Dementia Questionnaire Test Name|QS-DAD TEST	Test names of questionnaire questions associated with the Disability Assessment for Dementia (DAD)for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10512>	C61063	Cisplatin/Fluorouracil/Hydroxyurea|CDDP/5-FU/HU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105130>	C100110	CDISC Questionnaire DAD Test Code Terminology|DAD01TC|Disability Assessment for Dementia Questionnaire Test Code|QS-DAD TESTCD	Test codes of questionnaire questions associated with the Disability Assessment for Dementia (DAD)for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105131>	C100110	CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CSS03TN|Columbia-Suicide Severity Rating Scale Baseline/Screening Version Phase 1 Study Questionnaire Test Name|QS-C-SSRS BASELINE/SCREENING VERSION PHASE 1 STUDY TEST	Test names of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale (C-SSRS) Baseline/Screening Version Phase 1 Study Version 1/14/09for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105132>	C100110	CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CSS03TC|Columbia-Suicide Severity Rating Scale Baseline/Screening Version Phase 1 Study Questionnaire Test Code|QS-C-SSRS BASELINE/SCREENING VERSION PHASE 1 STUDY TESTCD	Test codes of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale (C-SSRS) Baseline/Screening Version Phase 1 Study Version 1/14/09 for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105133>	C100110	CDISC Questionnaire PI v1 Test Name Terminology|PI01TN|Pain Intensity Questionnaire Test Name|QS-PI TEST	Test names of questionnaire questions associated with the Pain Intensity (PI) version 1 for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105134>	C100110	CDISC Questionnaire PI v1 Test Code Terminology|PI01TC|Pain Intensity Questionnaire Test Code|QS-PI TESTCD	Test codes of questionnaire questions associated with the Pain Intensity (PI) version 1 for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105135>	C100110	CDISC Questionnaire PR v1 Test Name Terminology|PR01TN|Pain Relief Questionnaire Test Name|QS-PR TEST	Test names of questionnaire questions associated with the Pain Relief (PR) version 1 for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105136>	C100110	CDISC Questionnaire PR v1 Test Code Terminology|PR01TC|Pain Relief Questionnaire Test Code|QS-PR TESTCD	Test codes of questionnaire questions associated with the Pain Relief (PR) version 1 for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105137>	C100110	CDISC Questionnaire GCGI v1 Test Name Terminology|GCGI01TN|General Clinical Global Impressions Questionnaire Test Name|QS-GCGI TEST	Test names of questionnaire questions associated with the General Clinical Global Impressions (GCGI) version 1 for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105138>	C100110	CDISC Questionnaire GCGI v1 Test Code Terminology|GCGI01TC|General Clinical Global Impressions Questionnaire Test Code|QS-GCGI TESTCD	Test codes of questionnaire questions associated with the General Clinical Global Impressions (GCGI) version 1 for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105139>	C100110	CDISC Questionnaire ADCS-ADL Test Name Terminology|ADL01TN|Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory Questionnaire Test Name|QS-ADCS-ADL TEST	Test names of questionnaire questions associated with the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10513>	C61063	Cisplatin/Filgrastim/Fluorouracil/Hydroxyurea|CDDP/5-FU/G-CSF/HU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105140>	C100110	CDISC Questionnaire ADCS-ADL Test Code Terminology|ADL01TC|Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory Questionnaire Test Code|QS-ADCS-ADL TESTCD	Test codes of questionnaire questions associated with the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105141>	C211913	C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Questionnaire Question	A question associated with the C-SSRS Baseline/Screening Version Phase 1 Study version 1/14/09 questionnaire.			Intellectual Product	
C105142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105142>	C211913	DAD Questionnaire Question	A question associated with the DAD questionnaire.			Intellectual Product	
C105143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105143>	C211913	PI Questionnaire Question	A question associated with the PI version 1 questionnaire.			Intellectual Product	
C105144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105144>	C211913	PR Questionnaire Question	A question associated with the PR version 1 questionnaire.			Intellectual Product	
C105145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105145>	C211913	GCGI Questionnaire Question	A question associated with the GCGI version 1 questionnaire.			Intellectual Product	
C105146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105146>	C211913	ADCS-ADL Questionnaire Question	A question associated with the ADCS-ADL questionnaire.			Intellectual Product	
C105148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105148>	C25939	HSD17B3 Gene|HSD17B3|HSD17B3|Hydroxysteroid (17-Beta) Dehydrogenase 3 Gene	This gene plays a role in the metabolism of testosterone.	HSD17B3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105149>	C105148	HSD17B3 wt Allele|EDH17B3|Hydroxysteroid (17-Beta) Dehydrogenase 3 wt Allele|SDR12C2	Human HSD17B3 wild-type allele is located in the vicinity of 9q22 and is approximately 67 kb in length. This allele, which encodes testosterone 17-beta-dehydrogenase 3 protein, is involved in the conversion of androstenedione to testosterone. Deficiency can result in male pseudohermaphroditism with gynecomastia.	HSD17B3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10514>	C61063	Etoposide/Fluorouracil/Leucovorin Calcium|CF/5-FU/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105150>	C213143|C198859	Denintuzumab Mafodotin|ADC SGN-19A|DENINTUZUMAB MAFODOTIN|Denintuzumab mafodotin|Immunoglobulin G1-kappa Auristatin F Conjugate, Anti-(homosapiens CD19 (B Lymphocyte Surface Antigen B4, leu-12)), Humanized Monoclonal Antibody|SGN CD19A|SGN-19A|SGN-CD19A|SGNCD19A	An immunoconjugate consisting of an anti-CD19 monoclonal antibody conjugated to the auristatin derivative monomethyl auristatin F (MMAF), with potential antineoplastic activity. Upon administration of denintuzumab mafodotin, the antibody moiety targets the cell surface antigen CD19, found on a number of B-cell-derived cancers. Upon antibody/antigen binding and internalization, the immunoconjugate releases MMAF, which binds to tubulin and inhibits its polymerization. Inhibition of tubulin polymerization may result in G2/M phase arrest and tumor cell apoptosis. This causes inhibition of cell growth of CD19-expressing tumor cells. CD19, a B-cell antigen, is overexpressed by a variety of different cancer cell types.	Denintuzumab Mafodotin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C105151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105151>	C16946	Testosterone 17-Beta-Dehydrogenase 3|17-Beta-HSD 3|17-Beta-HSD3|17-Beta-Hydroxysteroid Dehydrogenase Type 3|EC 1.1.1.64|HSD17B3|Short Chain Dehydrogenase/Reductase Family 12C, Member 2|Testicular 17-Beta-Hydroxysteroid Dehydrogenase	Testosterone 17-beta-dehydrogenase 3 (310 aa, ~35 kDa) is encoded by the human HSD17B3 gene. This protein plays a role in the reduction of androstenedione to testosterone.	Testosterone 17-Beta-Dehydrogenase 3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105152>	C25939	HSD17B6 Gene|HSD17B6|HSD17B6|Hydroxysteroid (17-Beta) Dehydrogenase 6 Gene	This gene is involved in androgen catabolism.	HSD17B6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105153>	C105152	HSD17B6 wt Allele|HSE|Hydroxysteroid (17-Beta) Dehydrogenase 6 wt Allele|RODH|SDR9C6	Human HSD17B6 wild-type allele is located in the vicinity of 12q13 and is approximately 36 kb in length. This allele, which encodes 17-beta-hydroxysteroid dehydrogenase type 6 protein, plays a role in androgen catabolism.	HSD17B6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105154>	C16946	17-Beta-Hydroxysteroid Dehydrogenase Type 6|17-Beta-HSD 6|17-Beta-HSD6|3(Alpha->Beta)-Hydroxysteroid Epimerase|3(Alpha->Beta)-Hydroxysteroid Epimerase I|3-Alpha->Beta-HSE|3-Alpha->Beta-Hydroxysteroid Epimerase|3-Hydroxysteroid Epimerase|EC 1.1.1.105|EC 1.1.1.62|EC 1.1.1.63|HSD17B6|Hydroxysteroid (17-Beta) Dehydrogenase 6|Hydroxysteroid (17-Beta) Dehydrogenase 6 Homolog (Mouse)|NAD+ -Dependent 3 Alpha-Hydroxysteroid Dehydrogenase 3-Hydroxysteroid Epimerase|Oxidative 3-Alpha Hydroxysteroid Dehydrogenase|Oxidative 3-Alpha-Hydroxysteroid-Dehydrogenase|Retinol Dehydrogenase|Short Chain Dehydrogenase/Reductase Family 9C, Member 6	17-beta-hydroxysteroid dehydrogenase type 6 (317 aa, ~36 kDa) is encoded by the human HSD17B6 gene. This protein is involved in androgen catabolism.	17-Beta-Hydroxysteroid Dehydrogenase Type 6		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105155>	C25941|C25939	HSD3B2 Gene|HSD3B2|HSD3B2|Hydroxy-Delta-5-Steroid Dehydrogenase, 3 Beta- and Steroid Delta-Isomerase 2 Gene	This gene plays a role in the biosynthesis of hormonal steroids.	HSD3B2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105156>	C105155	HSD3B2 wt Allele|HSD3B|HSDB|HSDB3B|Hydroxy-Delta-5-Steroid Dehydrogenase, 3 Beta- and Steroid Delta-Isomerase wt Allele|SDR11E2	Human HSD3B2 wild-type allele is located in the vicinity of 1p13.1 and is approximately 8 kb in length. This allele, which encodes 3 beta-hydroxysteroid dehydrogenase/delta 5->4-isomerase type 2 protein, is involved in the oxidative conversion of ketosteroids during the biosynthesis of hormonal steroids. Mutations in this gene are associated with 3-beta-hydroxysteroid dehydrogenase, type II, deficiency.	HSD3B2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105157>	C16946|C16759	3 Beta-Hydroxysteroid Dehydrogenase/Delta 5->4-Isomerase Type 2|3 Beta-Hydroxysteroid Dehydrogenase Type II|3 Beta-Hydroxysteroid Dehydrogenase Type II, Delta 5-Delta 4-Isomerase Type II, 3 Beta-HSD Type II|3 Beta-Hydroxysteroid Dehydrogenase/Delta 5-->4-Isomerase Type 2|3 Beta-Hydroxysteroid Dehydrogenase/Delta 5-->4-Isomerase Type II|3 Beta-Hydroxysteroid Dehydrogenase/Delta 5->4-Isomerase Type II|3 Beta-Hydroxysteroid Dehydrogenase/Delta 5—>4-Isomerase Type 2|3 Beta-Hydroxysteroid Dehydrogenase/Delta 5—>4-Isomerase Type II|3-Beta-HSD Adrenal and Gonadal Type|3-Beta-HSD II|3-Beta-HSD Type II|3-Beta-Hydroxy-5-Ene Steroid Dehydrogenase|3-Beta-Hydroxy-Delta(5)-Steroid Dehydrogenase|Delta 5-Delta 4-Isomerase Type II|EC 1.1.1.145|EC 5.3.3.1|HSD3B2|Progesterone Reductase|Short Chain Dehydrogenase/Reductase Family 11E, Member 2	3 beta-hydroxysteroid dehydrogenase/Delta 5->4-isomerase type 2 (372 aa, ~42 kDa) is encoded by the human HSD3B2 gene. This protein plays an oxidative role in the biosynthesis of hormonal steroids.	3 Beta-Hydroxysteroid Dehydrogenase/Delta 5->4-Isomerase Type 2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105158>	C25939	SRD5A1 Gene|SRD5A1|SRD5A1|Steroid-5-Alpha-Reductase, Alpha Polypeptide 1 (3-Oxo-5 Alpha-Steroid Delta 4-Dehydrogenase Alpha 1) Gene	This gene is involved in the metabolism of androgens.	SRD5A1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105159>	C105158	SRD5A1 wt Allele|S5AR 1|Steroid-5-Alpha-Reductase, Alpha Polypeptide 1 (3-Oxo-5 Alpha-Steroid Delta 4-Dehydrogenase Alpha 1) wt Allele	Human SRD5A1 wild-type allele is located 5p15 and is approximately 36 kb in length. This allele, which encodes 3-oxo-5-alpha-steroid 4-dehydrogenase 1 protein, plays a role in the conversion of testosterone into dihydrotestosterone.	SRD5A1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10515>	C61063	Brequinar/Fluorouracil|BREQ/5-FU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105160>	C16946	3-Oxo-5-Alpha-Steroid 4-Dehydrogenase 1|3-Oxo-5 Alpha-Steroid Delta 4-Dehydrogenase Alpha 1|5-Alpha Reductase|EC 1.3.1.30|EC 1.3.99.5|SR Type 1|SRD5A1|Steroid 5-Alpha-Reductase 1|Steroid 5-Alpha-Reductase Type I	3-oxo-5-alpha-steroid 4-dehydrogenase 1 (259 aa, ~29 kDa) is encoded by the human SRD5A1 gene. This protein is involved in sexual differentiation and androgen physiology.	3-Oxo-5-Alpha-Steroid 4-Dehydrogenase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105161>	C25939	SRD5A3 Gene|SRD5A3|SRD5A3|Steroid 5 Alpha-Reductase 3 Gene	This gene plays a role in the metabolism of testosterone.	SRD5A3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105162>	C105161	SRD5A3 wt Allele|CDG1P|CDG1Q|FLJ13352|KRIZI|S5AR 3|SRD5A2L|SRD5A2L1|Steroid 5 Alpha-Reductase 3 wt Allele	Human SRD5A3 wild-type allele is located 4q12 and is approximately 27 kb in length. This allele, which encodes probable polyprenol reductase protein, is involved in both the metabolism of testosterone and the early steps of protein N-linked glycosylation.  Mutations in this gene are associated with congenital disorder of glycosylation type Iq.	SRD5A3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105163>	C16946	Probable Polyprenol Reductase|3-Oxo-5-Alpha-Steroid 4-Dehydrogenase 3|EC 1.3.1.30|SR Type 3|SRD5A3|Steroid 5-Alpha-Reductase 2-Like|Steroid 5-Alpha-Reductase 3	Probable polyprenol reductase (318 aa, ~37 kDa) is encoded by the human SRD5A3 gene. This protein plays a role in the metabolism of testosterone and maintenance of the androgen-androgen receptor activation pathway.	Probable Polyprenol Reductase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105164>	C91105	Columbia-Suicide Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 Questionnaire|C-SSRS BASELINE/SCREENING VERSION PHASE 1 STUDY|C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09|CSS03	A standardized rating scale developed by Posner et al (version 1/14/09), which is used to determine the presence of suicidal ideation or behavior. The baseline/screening version phase 1 study questionnaire contains 23 items across 4 domains; suicidal ideation, intensity of ideation, suicidal behavior and actual attempts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105165>	C91105	Disability Assessment for Dementia Questionnaire|DAD|DAD|DAD01	A standardized questionnaire developed by Gelinas et al in 1998, which is used to measure the changes in functional activities in patients with Alzheimer's disease. The questionnaire contains 40 items across 3 domains; basic activities of daily living, instrumental activities of daily living and leisure activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105166>	C91105	Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory Questionnaire|ADCS-ADL|ADCS-ADL|ADL01	A standardized questionnaire developed by Galasko et al in 1997 as part of the Alzheimer's disease cooperative study, which is used to measure the performance of activities of daily living by patients diagnosed with Alzheimer's disease. The questionnaire contains 23 items (and a number of sub-items within the 23 main items) with a range of preset answers that are assigned points based on performance.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105167>	C91105	STANDARDS Pain Intensity Questionnaire|PI|PI|PI01	Version 1 (2012-08-07) of the pain intensity questionnaire created by the STANDARDS (Standardized Analgesic Database for Research, Discovery, and Submissions) committee and sponsored by ACTTION (Analgesic Clinical Trial Translations, Innovations, Opportunities, and Networks).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105168>	C91105	STANDARDS Pain Relief Questionnaire|PR|PR|PR01	Version 1 (2012-08-07) of the pain relief questionnaire created by the STANDARDS (Standardized Analgesic Database for Research, Discovery, and Submissions) committee and sponsored by ACTTION (Analgesic Clinical Trial Translations, Innovations, Opportunities, and Networks).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105169>	C91105	STANDARDS General Clinical Global Impressions Questionnaire|GCGI|GCGI|GCGI01	Version 1 (2012-08-07) of the general clinical global impression of pain questionnaire created by the STANDARDS (Standardized Analgesic Database for Research, Discovery, and Submissions) committee and sponsored by ACTTION (Analgesic Clinical Trial Translations, Innovations, Opportunities, and Networks).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10516>	C61063	Cyclophosphamide/Interleukin-3/Sargramostim|CTX/GM-CSF/IL-3			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105170>	C105142	DAD - Decide to Wash or Take a Bath or Shower|DAD01-Decide to Wash|DAD01-Decide to Wash|DAD0101	Disability Assessment for Dementia (DAD) Decide to wash himself/herself or to take a bath or shower?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105171>	C105142	DAD - Decide to Brush Teeth or Care for Dentures|DAD01-Decide to Brush Teeth Dentures|DAD01-Decide to Brush Teeth Dentures|DAD0102	Disability Assessment for Dementia (DAD) Decide to brush his/her teeth or care for his/her dentures?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105172>	C105142	DAD - Decide to Care for His/Her Hair|DAD01-Decide to Care For Hair|DAD01-Decide to Care For Hair|DAD0103	Disability Assessment for Dementia (DAD) Decide to care for his/her hair (wash and comb)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105173>	C105142	DAD - Prepare the Water, Towels, and Soap for Washing, Taking a Bath or Shower|DAD01-Prepare For Washing Bath Shower|DAD01-Prepare For Washing Bath Shower|DAD0104	Disability Assessment for Dementia (DAD) Prepare the water, towels, and soap for washing, taking a bath or a shower?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105174>	C105142	DAD - Wash and Dry All Parts of Body Safely and Completely|DAD01-Wash and Dry Body Safely|DAD01-Wash and Dry Body Safely|DAD0105	Disability Assessment for Dementia (DAD) Wash and dry all parts of his/her body safely and completely?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105175>	C105142	DAD - Brush Teeth or Take Care of Dentures Appropriately|DAD01-Brush Teeth Take Care of Dentures|DAD01-Brush Teeth Take Care of Dentures|DAD0106	Disability Assessment for Dementia (DAD) Brush his/her teeth or take care of his/her dentures appropriately?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105176>	C105142	DAD - Take Care of His/Her Hair|DAD01-Take Care of Hair|DAD01-Take Care of Hair|DAD0107	Disability Assessment for Dementia (DAD) Take care of his/her hair (wash and comb)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105177>	C105142	DAD - Decide to Dress Himself/Herself|DAD01-Decide to Dress|DAD01-Decide to Dress|DAD0108	Disability Assessment for Dementia (DAD) Decide to dress himself/herself?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105178>	C105142	DAD - Choose Appropriate Clothing|DAD01-Choose Appropriate Clothing|DAD01-Choose Appropriate Clothing|DAD0109	Disability Assessment for Dementia (DAD) Choose appropriate clothing (with regard to the occasion, neatness, the weather and color combination)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105179>	C105142	DAD - Dress in the Appropriate Order|DAD01-Dress in Appropriate Order|DAD01-Dress in Appropriate Order|DAD0110	Disability Assessment for Dementia (DAD) Dress himself/herself in the appropriate order (undergarments, pant/dress, shoes)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10517>	C61063	Cyclophosphamide/Detox/Interleukin-2|CTX/DETOX/IL-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105180>	C105142	DAD - Dress Himself/Herself Completely|DAD01-Dress Completely|DAD01-Dress Completely|DAD0111	Disability Assessment for Dementia (DAD) Dress himself/herself completely?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105181>	C105142	DAD - Undress Himself/Herself Completely|DAD01-Undress Completely|DAD01-Undress Completely|DAD0112	Disability Assessment for Dementia (DAD) Undress himself/herself completely?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105182>	C105142	DAD - Decide to Use the Toilet at Appropriate Times|DAD01-Use Toilet at Appropriate Times|DAD01-Use Toilet at Appropriate Times|DAD0113	Disability Assessment for Dementia (DAD) Decide to use the toilet at appropriate times?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105183>	C105142	DAD - Use the Toilet Without Accidents|DAD01-Use Toilet Without Accidents|DAD01-Use Toilet Without Accidents|DAD0114	Disability Assessment for Dementia (DAD) Use the toilet without 'accidents'?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105184>	C105142	DAD - Decide That He/She Needs to Eat|DAD01-Decide That He/She Needs to Eat|DAD01-Decide That He/She Needs to Eat|DAD0115	Disability Assessment for Dementia (DAD) Decide that he/she needs to eat?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105185>	C105142	DAD - Choose Appropriate Utensils and Seasonings When Eating|DAD01-Choose Appropriate Utensils|DAD01-Choose Appropriate Utensils|DAD0116	Disability Assessment for Dementia (DAD) Choose appropriate utensils and seasonings when eating?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105186>	C105142	DAD - Eat Meals at a Normal Pace and with Appropriate Manners|DAD01-Eat at Normal Pace With Manners|DAD01-Eat at Normal Pace With Manners|DAD0117	Disability Assessment for Dementia (DAD) Eat his/her meals at a normal pace and with appropriate manners?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105187>	C105142	DAD - Decide to Prepare a Light Meal or Snack for Himself/Herself|DAD01-Decide to Prepare Meal Snack|DAD01-Decide to Prepare Meal Snack|DAD0118	Disability Assessment for Dementia (DAD) Decide to prepare a light meal or snack for himself/herself?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105188>	C105142	DAD - Adequately Plan a Light Meal or Snack|DAD01-Adequately Plan Light Meal Snack|DAD01-Adequately Plan Light Meal Snack|DAD0119	Disability Assessment for Dementia (DAD) Adequately plan a light meal or snack (ingredients, cookware)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105189>	C105142	DAD - Safely Prepare or Cook a Light Meal or Snack|DAD01-Prepare or Cook Light Meal Snack|DAD01-Prepare or Cook Light Meal Snack|DAD0120	Disability Assessment for Dementia (DAD) Prepare or cook a light meal or a snack safely?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10518>	C61063	Bleomycin/Cisplatin/Etoposide/Filgrastim|BLEO/CDDP/G-CSF/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105190>	C105142	DAD - Attempt to Telephone Someone at a Suitable Time|DAD01-Telephone Someone at Suitable Time|DAD01-Telephone Someone at Suitable Time|DAD0121	Disability Assessment for Dementia (DAD) Attempt to telephone someone at a suitable time?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105191>	C105142	DAD - Find and Dial a Telephone Number Correctly|DAD01-Find and Dial Telephone Number|DAD01-Find and Dial Telephone Number|DAD0122	Disability Assessment for Dementia (DAD) Find and dial a telephone number correctly?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105192>	C105142	DAD - Carry Out an Appropriate Telephone Conversation|DAD01-Carry Out Telephone Conversation|DAD01-Carry Out Telephone Conversation|DAD0123	Disability Assessment for Dementia (DAD) Carry out an appropriate telephone conversation?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105193>	C105142	DAD - Write and Convey a Telephone Message Adequately|DAD01-Write Convey Telephone Message|DAD01-Write Convey Telephone Message|DAD0124	Disability Assessment for Dementia (DAD) Write and convey a telephone message adequately?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105194>	C105142	DAD - Decide to Go Out at an Appropriate Time|DAD01-Decide to Go Out|DAD01-Decide to Go Out|DAD0125	Disability Assessment for Dementia (DAD) Decide to go out (walk, visit, shop) at an appropriate time?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105195>	C105142	DAD - Adequately Organize an Outing with Respect to Transportation, Keys, Destination, Weather, Money, Shopping List|DAD01-Adequately Organize an Outing|DAD01-Adequately Organize an Outing|DAD0126	Disability Assessment for Dementia (DAD) Adequately organize an outing with respect to transportation, keys, destination, weather, necessary money, shopping list?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105196>	C105142	DAD - Go Out and Reach a Familiar Destination Without Getting Lost|DAD01-Go Out Without Getting Lost|DAD01-Go Out Without Getting Lost|DAD0127	Disability Assessment for Dementia (DAD) Go out and reach a familiar destination without getting lost?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105197>	C105142	DAD - Safely Take the Adequate Mode of Transportation|DAD01-Safely Take Transportation|DAD01-Safely Take Transportation|DAD0128	Disability Assessment for Dementia (DAD) Safely take the adequate mode of transportation (car, bus, taxi)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105198>	C105142	DAD - Return From the Store with Appropriate Items|DAD01-Return From Store With Items|DAD01-Return From Store With Items|DAD0129	Disability Assessment for Dementia (DAD) Return from the store with the appropriate items?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105199>	C105142	DAD - Show an Interest in Personal Affairs such as Finances and Written Correspondence|DAD01-Show Interest in Personal Affairs|DAD01-Show Interest in Personal Affairs|DAD0130	Disability Assessment for Dementia (DAD) Show an interest in his/her personal affairs such as his/her finances and written correspondence?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10519>	C61063	Bleomycin/Cisplatin/Filgrastim/Vincristine|BLEO/CDDP/G-CSF/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1051>	C744|C1327	Cilostazol|6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone|CILOSTAZOL|Pletal	A quinolinone derivative and cellular phosphodiesterase inhibitor, more specific for phosphodiesterase III (PDE III). Although the exact mechanism of action of is unknown, cilostazol and its metabolites appears to inhibit PDE III activity, thereby suppressing cyclic adenosine monophosphate (cAMP) degradation. This results in an increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation.	Cilostazol		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C105200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105200>	C105142	DAD - Organize Finances to Pay Bills|DAD01-Organize Finances to Pay Bills|DAD01-Organize Finances to Pay Bills|DAD0131	Disability Assessment for Dementia (DAD) Organize his/her finances to pay his/her bills (checks, bank statement, bills)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105201>	C105142	DAD - Adequately Organize Correspondence|DAD01-Adequately Organize Correspondence|DAD01-Adequately Organize Correspondence|DAD0132	Disability Assessment for Dementia (DAD) Adequately organize his/her correspondence with respect to stationery, address, stamps?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105202>	C105142	DAD - Handle Money Adequately|DAD01-Handle Money Adequately|DAD01-Handle Money Adequately|DAD0133	Disability Assessment for Dementia (DAD) Handle his/her money adequately (deal with cash)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105203>	C105142	DAD - Decide to Take Medications at the Correct Time|DAD01-Take Medications at Correct Time|DAD01-Take Medications at Correct Time|DAD0134	Disability Assessment for Dementia (DAD) Decide to take his/her medications at the correct time?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105204>	C105142	DAD - Take Medications as Prescribed|DAD01-Take Medications as Prescribed|DAD01-Take Medications as Prescribed|DAD0135	Disability Assessment for Dementia (DAD) Take his/her medications as prescribed (according to the right dosage)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105205>	C105142	DAD - Show an Interest in Leisure Activities|DAD01-Show Interest in Leisure Activity|DAD01-Show Interest in Leisure Activity|DAD0136	Disability Assessment for Dementia (DAD) Show an interest in leisure activity(ies)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105206>	C105142	DAD - Take an Interest in Household Chores as in the Past|DAD01-Take Interest in Household Chores|DAD01-Take Interest in Household Chores|DAD0137	Disability Assessment for Dementia (DAD) Take an interest in household chores that he/she used to perform in the past?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105207>	C105142	DAD - Plan and Organize Adequately Household Chores as in the Past|DAD01-Plan Organize Household Chores|DAD01-Plan Organize Household Chores|DAD0138	Disability Assessment for Dementia (DAD) Plan and organize adequately household chores that he/she used to perform in the past?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105208>	C105142	DAD - Complete Household Chores Adequately as in the Past|DAD01-Complete Household Chores|DAD01-Complete Household Chores|DAD0139	Disability Assessment for Dementia (DAD) Complete household chores adequately as he/she used to perform in the past?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105209>	C105142	DAD - Stay Safely at Home When Needed|DAD01-Stay Safely at Home When Needed|DAD01-Stay Safely at Home When Needed|DAD0140	Disability Assessment for Dementia (DAD) Stay safely at home by himself/herself when needed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10520>	C61063	Bleomycin/Cisplatin/Etoposide/Filgrastim/Ifosfamide|BLEO/CDDP/G-CSF/IFF/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105210>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Wish to be Dead (Lifetime)|CSS03-Wish to be Dead-Life|CSS03-Wish to be Dead-Life|CSS0301A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study (C-SSRS Baseline/Screening Version Phase 1) Have you wished you were dead or wished you could go to sleep and not wake up? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105211>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Wish to be Dead (Past 6 Months)|CSS03-Wish to be Dead-P6M|CSS03-Wish to be Dead-P6M|CSS0301B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study (C-SSRS Baseline/Screening Version Phase 1) Have you wished you were dead or wished you could go to sleep and not wake up? (Past 6 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105212>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Description of Wish to be Dead (Lifetime)|CSS03-Wish to be Dead, Describe|CSS03-Wish to be Dead, Describe|CSS0301C	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study (C-SSRS Baseline/Screening Version Phase 1) Description of wishing to be dead.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105213>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Non-Specific Active Suicidal Thoughts (Lifetime)|CSS03-Non-Spec Suicid Thought-Life|CSS03-Non-Spec Suicid Thought-Life|CSS0302A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Have you actually had any thoughts of killing yourself? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105214>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Non-Specific Active Suicidal Thoughts (Past 6 Months)|CSS03-Non-Spec Suicid Thought-P6M|CSS03-Non-Spec Suicid Thought-P6M|CSS0302B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Have you actually had any thoughts of killing yourself? (Past 6 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105215>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Description of Non-Specific Active Suicidal Thoughts (Lifetime)|CSS03-Non-Spec Suicid Thought, Describe|CSS03-Non-Spec Suicid Thought, Describe|CSS0302C	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Description of non-specific active suicidal thoughts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105216>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act (Lifetime)|CSS03-Idea, No Intent, No Plan-Life|CSS03-Idea, No Intent, No Plan-Life|CSS0303A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Have you been thinking about how you might do this? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105217>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act (Past 6 Months)|CSS03-Idea, No Intent, No Plan-P6M|CSS03-Idea, No Intent, No Plan-P6M|CSS0303B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Have you been thinking about how you might do this? (Past 6 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105218>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Description of Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act (Lifetime)|CSS03-Idea, No Intent, No Plan, Describe|CSS03-Idea, No Intent, No Plan, Describe|CSS0303C	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Description of active suicidal ideation with any methods (not plan) without intent to act.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105219>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Active Suicidal Ideation with Some Intent to Act, without Specific Plan (Lifetime)|CSS03-Idea, Intent, No Plan-Life|CSS03-Idea, Intent, No Plan-Life|CSS0304A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Have you had these thoughts and had some intention of acting on them? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10521>	C61063	Chlorambucil/Ethacrynic Acid|CLB/EA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105220>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Active Suicidal Ideation with Some Intent to Act, without Specific Plan (Past 6 Months)|CSS03-Idea, Intent, No Plan-P6M|CSS03-Idea, Intent, No Plan-P6M|CSS0304B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Have you had these thoughts and had some intention of acting on them? (Past 6 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105221>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Description of Active Suicidal Ideation with Some Intent to Act, without Specific Plan (Lifetime)|CSS03-Idea, Intent, No Plan, Describe|CSS03-Idea, Intent, No Plan, Describe|CSS0304C	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Description of active suicidal ideation with some intent to act, without specific plan.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105222>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Active Suicidal Ideation with Specific Plan and Intent (Lifetime)|CSS03-Idea, Plan, Intent-Life|CSS03-Idea, Plan, Intent-Life|CSS0305A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105223>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Active Suicidal Ideation with Specific Plan and Intent (Past 6 Months)|CSS03-Idea, Plan, Intent-P6M|CSS03-Idea, Plan, Intent-P6M|CSS0305B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan? (Past 6 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105224>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Description of Active Suicidal Ideation with Specific Plan and Intent (Lifetime)|CSS03-Idea, Plan, Intent, Describe|CSS03-Idea, Plan, Intent, Describe|CSS0305C	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Description of active suicidal ideation with specific plan and intent.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105225>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Most Severe Ideation (Lifetime)|CSS03-Most Severe Idea-Life|CSS03-Most Severe Idea-Life|CSS0306A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Most severe ideation. (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105226>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Describe Most Severe Ideation (Lifetime)|CSS03-Most Severe Idea, Desc-Life|CSS03-Most Severe Idea, Desc-Life|CSS0306B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Description of ideation. (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105227>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Most Severe Ideation (Past 6 Months)|CSS03-Most Severe Idea-P6M|CSS03-Most Severe Idea-P6M|CSS0306C	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Most severe ideation. (Past 6 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105228>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Describe Most Severe Ideation (Past 6 Months)|CSS03-Most Severe Idea, Desc-P6M|CSS03-Most Severe Idea, Desc-P6M|CSS0306D	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Description of ideation. (Past 6 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105229>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Frequency of Most Severe Ideation (Lifetime)|CSS03-Most Severe Idea, Frequency-Life|CSS03-Most Severe Idea, Frequency-Life|CSS0307A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) How many times have you had these thoughts? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10522>	C61063	Cyclosporine/Dexamethasone/Doxorubicin/Vincristine|CYSP/DM/DOX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105230>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Frequency of Most Severe Ideation (Past 6 Months)|CSS03-Most Severe Idea, Frequency-P6M|CSS03-Most Severe Idea, Frequency-P6M|CSS0307B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) How many times have you had these thoughts? (Past 6 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105231>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Duration of Most Severe Ideation (Lifetime)|CSS03-Most Severe Idea, Duration-Life|CSS03-Most Severe Idea, Duration-Life|CSS0308A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) When you have these thoughts, how long do they last? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105232>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Duration of Most Severe Ideation (Past 6 Months)|CSS03-Most Severe Idea, Duration-P6M|CSS03-Most Severe Idea, Duration-P6M|CSS0308B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) When you have these thoughts, how long do they last? (Past 6 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105233>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Controllability of Most Severe Ideation (Lifetime)|CSS03-Most Severe Idea, Control-Life|CSS03-Most Severe Idea, Control-Life|CSS0309A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Could/can you stop thinking about killing yourself or wanting to die if you want to? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105234>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Controllability of Most Severe Ideation (Past 6 Months)|CSS03-Most Severe Idea, Control-P6M|CSS03-Most Severe Idea, Control-P6M|CSS0309B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Could/can you stop thinking about killing yourself or wanting to die if you want to? (Past 6 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105235>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Deterrents to Most Severe Ideation (Lifetime)|CSS03-Most Severe Idea, Deterrents-Life|CSS03-Most Severe Idea, Deterrents-Life|CSS0310A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Are there things-anyone or anything (e.g., family, religion, pain of death) that stopped you from wanting to die or acting on thoughts of committing suicide? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105236>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Deterrents to Most Severe Ideation (Past 6 Months)|CSS03-Most Severe Idea, Deterrents-P6M|CSS03-Most Severe Idea, Deterrents-P6M|CSS0310B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Are there things-anyone or anything (e.g., family, religion, pain of death) that stopped you from wanting to die or acting on thoughts of committing suicide? (Past 6 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105237>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Reasons for Most Severe Ideation (Lifetime)|CSS03-Most Severe Idea, Reasons-Life|CSS03-Most Severe Idea, Reasons-Life|CSS0311A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) What sort of reasons did you have for thinking about wanting to die or killing yourself? Was it to end the pain or stop the way you were feeling (in other words you couldn't go on living with this pain or how you were feeling) or was it to get attention, revenge or a reaction from others? Or both? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105238>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Reasons for Most Severe Ideation (Past 6 Months)|CSS03-Most Severe Idea, Reasons-P6M|CSS03-Most Severe Idea, Reasons-P6M|CSS0311B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) What sort of reasons did you have for thinking about wanting to die or killing yourself? Was it to end the pain or stop the way you were feeling (in other words you couldn't go on living with this pain or how you were feeling) or was it to get attention, revenge or a reaction from others? Or both? (Past 6 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105239>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Actual Suicide Attempt|CSS03-Actual Attempt|CSS03-Actual Attempt|CSS0312	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Have you made a suicide attempt? Have you done anything to harm yourself? Have you done anything dangerous where you could have died?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10523>	C61063	Interferon Gamma/Macrophage Colony-Stimulating Factor|IFN-G/M-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105240>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Number of Actual Suicide Attempts|CSS03-Number of Actual Attempts|CSS03-Number of Actual Attempts|CSS0313	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Total number of actual attempts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105241>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Description of Actual Suicide Attempt|CSS03-Actual Attempt, Describe|CSS03-Actual Attempt, Describe|CSS0313A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Description of actual attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105242>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Non-suicidal Self-injurious Behavior|CSS03-Non-suicidal Self-injurious Behav|CSS03-Non-suicidal Self-injurious Behav|CSS0314	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Has the subject engaged in non-suicidal self-injurious behavior.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105243>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Interrupted Suicide Attempt|CSS03-Interrupted Attempt|CSS03-Interrupted Attempt|CSS0315	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Has there been a time when you started to do something to try to end your life but someone or something stopped you before you actually did anything?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105244>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Number of Interrupted Suicide Attempts|CSS03-Number of Interrupted Attempts|CSS03-Number of Interrupted Attempts|CSS0316	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Total number of interrupted.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105245>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Description of Interrupted Suicide Attempt|CSS03-Interrupted Attempt, Describe|CSS03-Interrupted Attempt, Describe|CSS0316A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Description of interrupted attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105246>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Aborted Suicide Attempt|CSS03-Aborted Attempt|CSS03-Aborted Attempt|CSS0317	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Has there been a time when you started to do something to try to end your life but you stopped yourself before you actually did anything?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105247>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Number of Aborted Suicide Attempts|CSS03-Number of Aborted Attempts|CSS03-Number of Aborted Attempts|CSS0318	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Total number of aborted.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105248>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Description of Aborted Suicide Attempt|CSS03-Aborted Attempt, Describe|CSS03-Aborted Attempt, Describe|CSS0318A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Description of aborted attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105249>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Preparatory Acts or Behaviors Toward Suicide Attempt|CSS03-Preparatory Acts/Behavior|CSS03-Preparatory Acts/Behavior|CSS0319	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Have you taken any steps toward making a suicide attempt or preparing to kill yourself (such as collecting pills, getting a gun, giving valuables away or writing a suicide note)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10524>	C61063	Cyclophosphamide/Doxorubicin/Fluorouracil/Interleukin-3/Leucovorin Calcium|CF/CTX/DOX/5-FU/IL-3			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105250>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Description of Preparatory Acts or Behaviors Toward Suicide Attempt|CSS03-Preparatory Acts/Behavior, Descr|CSS03-Preparatory Acts/Behavior, Descr|CSS0319A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Description of preparatory acts or behaviors.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105251>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Suicidal Behavior|CSS03-Suicidal Behavior|CSS03-Suicidal Behavior|CSS0320	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Suicidal behavior was present during the assessment period?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105252>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Most Recent Suicide Attempt Date|CSS03-Most Recent Attempt Date|CSS03-Most Recent Attempt Date|CSS0321A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Most recent attempt date.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105253>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Most Recent Suicide Attempt Actual Lethality/Medical Damage|CSS03-Most Recent Attempt Damage|CSS03-Most Recent Attempt Damage|CSS0321B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Most recent attempt actual lethality/medical damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105254>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Most Recent Suicide Attempt Potential Lethality|CSS03-Most Recent Attempt Potential|CSS03-Most Recent Attempt Potential|CSS0321C	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Most recent attempt potential lethality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105255>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Most Lethal Suicide Attempt Date|CSS03-Most Lethal Attempt Date|CSS03-Most Lethal Attempt Date|CSS0322A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Most lethal attempt date.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105256>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Most Lethal Suicide Attempt Actual Lethality/Medical Damage|CSS03-Most Lethal Attempt Damage|CSS03-Most Lethal Attempt Damage|CSS0322B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Most lethal attempt actual lethality/medical damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105257>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - Most Lethal Suicide Attempt Potential Lethality|CSS03-Most Lethal Attempt Potential|CSS03-Most Lethal Attempt Potential|CSS0322C	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Most lethal attempt potential lethality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105258>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - First Suicide Attempt Date|CSS03-First Attempt Date|CSS03-First Attempt Date|CSS0323A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Initial/first attempt date.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105259>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - First Suicide Attempt Actual Lethality/Medical Damage|CSS03-First Attempt Damage|CSS03-First Attempt Damage|CSS0323B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Initial/first attempt actual lethality/medical damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10525>	C61063	Cyclophosphamide/Doxorubicin/Fluorouracil/Interleukin-3/Leucovorin Calcium/Sargramostim|CF/CTX/DOX/5-FU/GM-CSF/IL-3|Cyclophosphamide/Doxorubicin/Fluorouracil/Interleukin-3/Leucovorincalcium/Sargramostim			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105260>	C105141	C-SSRS Baseline/Screening Version Phase 1 Study - First Suicide Attempt Potential Lethality|CSS03-First Attempt Potential|CSS03-First Attempt Potential|CSS0323C	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version Phase 1 Study 1/14/09 (C-SSRS Baseline/Screening Version Phase 1 Study 1/14/09) Initial/first attempt potential lethality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Phase 1 Study Version 1/14/09 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105261>	C105143	PI - Pain Intensity For Various Time Periods of Evaluation|PI01-Pain Intensity|PI01-Pain Intensity|PI0101	Pain Intensity (PI v1) Pain intensity for various time periods of evaluation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PI v1 Test Code Terminology|CDISC Questionnaire PI v1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105262>	C105143	PI - Average Pain Intensity For Various Time Periods of Evaluation|PI01-Average Pain Intensity|PI01-Average Pain Intensity|PI0102	Pain Intensity (PI v1) Average pain intensity for various time periods of evaluation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PI v1 Test Code Terminology|CDISC Questionnaire PI v1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105263>	C105143	PI - Minimum Pain Intensity For Various Time Periods of Evaluation|PI01-Minimum Pain Intensity|PI01-Minimum Pain Intensity|PI0103	Pain Intensity (PI v1) Minimum pain intensity for various time periods of evaluation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PI v1 Test Code Terminology|CDISC Questionnaire PI v1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105264>	C105143	PI - Maximum Pain Intensity For Various Time Periods of Evaluation|PI01-Maximum Pain Intensity|PI01-Maximum Pain Intensity|PI0104	Pain Intensity (PI v1) Maximum pain intensity for various time periods of evaluation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PI v1 Test Code Terminology|CDISC Questionnaire PI v1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105265>	C105143	PI - Least Pain Intensity For Various Time Periods of Evaluation|PI01-Least Pain Intensity|PI01-Least Pain Intensity|PI0105	Pain Intensity (PI v1) Least pain intensity for various time periods of evaluation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PI v1 Test Code Terminology|CDISC Questionnaire PI v1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105266>	C105143	PI - Worst Pain Intensity For Various Time Periods of Evaluation|PI01-Worst Pain Intensity|PI01-Worst Pain Intensity|PI0106	Pain Intensity (PI v1) Worst pain intensity for various time periods of evaluation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PI v1 Test Code Terminology|CDISC Questionnaire PI v1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105267>	C105144	PR - Pain Relief For Various Time Periods of Evaluation|PR01-Pain Relief|PR01-Pain Relief|PR0101	Pain Intensity (PR v1) Pain relief for various time periods of evaluation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PR v1 Test Code Terminology|CDISC Questionnaire PR v1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105268>	C105144	PR - Average Pain Relief For Various Time Periods of Evaluation|PR01-Average Pain Relief|PR01-Average Pain Relief|PR0102	Pain Intensity (PR v1) Average pain relief for various time periods of evaluation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PR v1 Test Code Terminology|CDISC Questionnaire PR v1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105269>	C105144	PR - Minimum Pain Relief For Various Time Periods of Evaluation|PR01-Minimum Pain Relief|PR01-Minimum Pain Relief|PR0103	Pain Intensity (PR v1) Minimum pain relief for various time periods of evaluation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PR v1 Test Code Terminology|CDISC Questionnaire PR v1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10526>	C61063	Doxorubicin/Suramin|DOX/SUR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105270>	C105144	PR - Maximum Pain Relief For Various Time Periods of Evaluation|PR01-Maximum Pain Relief|PR01-Maximum Pain Relief|PR0104	Pain Intensity (PR v1) Maximum pain relief for various time periods of evaluation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PR v1 Test Code Terminology|CDISC Questionnaire PR v1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105271>	C105144	PR - Least Pain Relief For Various Time Periods of Evaluation|PR01-Least Pain Relief|PR01-Least Pain Relief|PR0105	Pain Intensity (PR v1) Least pain relief for various time periods of evaluation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PR v1 Test Code Terminology|CDISC Questionnaire PR v1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105272>	C105144	PR - Worst Pain Relief For Various Time Periods of Evaluation|PR01-Worst Pain Relief|PR01-Worst Pain Relief|PR0106	Pain Intensity (PR v1) Worst pain relief for various time periods of evaluation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PR v1 Test Code Terminology|CDISC Questionnaire PR v1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105273>	C105144	PR - Starting Pain Half Gone|PR01-Starting Pain at Least 1/2 Gone|PR01-Starting Pain at Least 1/2 Gone|PR0107	Pain Intensity (PR v1) Starting pain at least 1/2 gone?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PR v1 Test Code Terminology|CDISC Questionnaire PR v1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105274>	C105144	PR - Was There Perceptible Pain Relief|PR01-Was there Perceptible Pain Relief|PR01-Was there Perceptible Pain Relief|PR0108	Pain Intensity (PR v1) Was there perceptible pain relief?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PR v1 Test Code Terminology|CDISC Questionnaire PR v1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105275>	C105144	PR - Time to Perceptible Pain Relief|PR01-Time to Perceptible Pain Relief|PR01-Time to Perceptible Pain Relief|PR0109	Pain Intensity (PR v1) Time to perceptible pain relief.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PR v1 Test Code Terminology|CDISC Questionnaire PR v1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105276>	C105144	PR - Was There Meaningful Pain Relief|PR01-Was there Meaningful Pain Relief|PR01-Was there Meaningful Pain Relief|PR0110	Pain Intensity (PR v1) Was there meaningful pain relief?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PR v1 Test Code Terminology|CDISC Questionnaire PR v1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105277>	C105144	PR - Time to Meaningful Pain Relief|PR01-Time to Meaningful Pain Relief|PR01-Time to Meaningful Pain Relief|PR0111	Pain Intensity (PR v1) Time to meaningful pain relief.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PR v1 Test Code Terminology|CDISC Questionnaire PR v1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105278>	C105145	GCGI - Global Severity of Pain|GCGI01-Global Severity of Pain|GCGI01-Global Severity of Pain|GCGI0101	General Clinical Global Impressions (GCGI v1) Global severity of pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GCGI v1 Test Code Terminology|CDISC Questionnaire GCGI v1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105279>	C105145	GCGI - Global Improvement of Pain|GCGI01-Global Improvement of Pain|GCGI01-Global Improvement of Pain|GCGI0102	General Clinical Global Impressions (GCGI v1) Global improvement of pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GCGI v1 Test Code Terminology|CDISC Questionnaire GCGI v1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10527>	C61063	Pentoxifylline/Suramin/Thiotepa|PTX/SUR/TSPA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105280>	C105145	GCGI - Global Disease Status of Pain|GCGI01-Global Disease Status of Pain|GCGI01-Global Disease Status of Pain|GCGI0103	General Clinical Global Impressions (GCGI v1) Global disease status of pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GCGI v1 Test Code Terminology|CDISC Questionnaire GCGI v1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105281>	C105145	GCGI - Pain Treatment Preference|GCGI01-Pain Treatment Preference|GCGI01-Pain Treatment Preference|GCGI0104	General Clinical Global Impressions (GCGI v1) Pain treatment preference.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GCGI v1 Test Code Terminology|CDISC Questionnaire GCGI v1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105282>	C105145	GCGI - Global Rating of Pain Medication|GCGI01-Global Rating of Pain Medication|GCGI01-Global Rating of Pain Medication|GCGI0105	General Clinical Global Impressions (GCGI v1) Global rating of pain medication.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GCGI v1 Test Code Terminology|CDISC Questionnaire GCGI v1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105283>	C105146	ADCS-ADL - Description of Usual Performance of Eating|ADL01-Usual Eating Performance|ADL01-Usual Eating Performance|ADL0101	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Regarding eating: which best describes the subject's usual performance during the past 4 weeks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105284>	C105146	ADCS-ADL - Description of Optimal Performance of Walking|ADL01-Optimal Walking Performance|ADL01-Optimal Walking Performance|ADL0102	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Regarding walking (or getting around in a wheelchair), in the past 4 weeks, which best describes his/her optimal performance.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105285>	C105146	ADCS-ADL - Usual Bowel and Bladder Function at Toilet|ADL01-Usual Bowel/Bladder Function|ADL01-Usual Bowel/Bladder Function|ADL0103	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Regarding bowel and bladder function at the toilet, which best describes his/her usual performance in the past 4 weeks.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105286>	C105146	ADCS-ADL - Description of Usual Performance of Bathing|ADL01-Usual Bathing Performance|ADL01-Usual Bathing Performance|ADL0104	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Regarding bathing, in the past 4 weeks, which best describes his/her usual performance.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105287>	C105146	ADCS-ADL - Description of Optimal Performance of Grooming|ADL01-Optimal Grooming Performance|ADL01-Optimal Grooming Performance|ADL0105	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Regarding grooming, in the past 4 weeks, which best describes his/her optimal performance.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105288>	C105146	ADCS-ADL - Select First Clothes for the Day|ADL01-Select First Clothes for the Day|ADL01-Select First Clothes for the Day|ADL0106	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Regarding dressing in the past 4 weeks: Did the subject select his/her first set of clothes for the day?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105289>	C105146	ADCS-ADL - Description of Usual Performance of Dressing|ADL01-Usual Dressing Performance|ADL01-Usual Dressing Performance|ADL0106A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) If yes, which best describes usual performance.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10528>	C61063	Cisplatin/Filgrastim/Methotrexate/Vinblastine|CDDP/G-CSF/MTX/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105290>	C105146	ADCS-ADL - Description of Usual Performance of Physically Getting Dressed|ADL01-Usual Physically Dressing Perform|ADL01-Usual Physically Dressing Perform|ADL0106B	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Regarding physically getting dressed, which best describes his/her usual performance in the past 4 weeks.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105291>	C105146	ADCS-ADL - Use a Telephone|ADL01-Use a Telephone|ADL01-Use a Telephone|ADL0107	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, did the subject use a telephone?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105292>	C105146	ADCS-ADL - Description of Highest Performance of Telephone Use|ADL01-Highest Telephone Use Performance|ADL01-Highest Telephone Use Performance|ADL0107A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) If yes, which best describes his/her highest level of performance.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105293>	C105146	ADCS-ADL - Watch Television|ADL01-Watch Television|ADL01-Watch Television|ADL0108	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, did the subject watch television?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105294>	C105146	ADCS-ADL - Select or Ask for Television Program|ADL01-Select Television Program|ADL01-Select Television Program|ADL0108A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Did the subject usually select or ask for different programs or his/her favorite show?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105295>	C105146	ADCS-ADL - Talk About TV Content While Watching|ADL01-Talk About TV Content While Watch|ADL01-Talk About TV Content While Watch|ADL0108B	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Did the subject usually talk about the content of a program while watching it?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105296>	C105146	ADCS-ADL - Talk About TV Content Within a Day After Watching|ADL01-Talk About TV Content Within a Day|ADL01-Talk About TV Content Within a Day|ADL0108C	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Did the subject talk about the content of a program within a day (24 hours) after watching it?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105297>	C105146	ADCS-ADL - Pay Attention to Conversation|ADL01-Pay Attention to Conversation|ADL01-Pay Attention to Conversation|ADL0109	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, did the subject ever appear to pay attention to conversation or small talk for at least 5 minutes?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105298>	C105146	ADCS-ADL - Usual Conversation Participation|ADL01-Usual Conversation Participation|ADL01-Usual Conversation Participation|ADL0109A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) If yes, which best describes his/her usual degree of participation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105299>	C105146	ADCS-ADL - Clear Dishes After Meal or Snack|ADL01-Clear Dishes|ADL01-Clear Dishes|ADL0110	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Standard Version (ADCS-ADL Standard) Did the subject clear the dishes from the table after a meal or snack?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10529>	C61063	Doxorubicin/Filgrastim/Thiotepa|DOX/G-CSF/TSPA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1052>	C2139	CL 246738|3,6-bis-(2-piperidinoethoxyl)acridine trihydrochloride|CL 246,738	An immunomodulator, 3,6-bis(2-piperidinoethoxy) acridine trihydrochloride, used in a phase I study for possible immunostimulatory effects in colorectal cancer. (NCI)			Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C105300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105300>	C105146	ADCS-ADL - Description of Usual Performance of Clearing Dishes|ADL01-Clear Dishes Usual Performance|ADL01-Clear Dishes Usual Performance|ADL0110A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) If yes, which best describes how he/she usually performed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105301>	C105146	ADCS-ADL - Find Personal Belongings at Home|ADL01-Find Belongings|ADL01-Find Belongings|ADL0111	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, did the subject usually manage to find his/her personal belongings at home?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105302>	C105146	ADCS-ADL - Description of Usual Performance of Finding Personal Belonging at Home|ADL01-Find Belongings Usual Performance|ADL01-Find Belongings Usual Performance|ADL0111A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) If yes, which best describes how he/she usually performed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105303>	C105146	ADCS-ADL - Obtain Beverage for Self|ADL01-Obtain Beverage|ADL01-Obtain Beverage|ADL0112	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, did the subject obtain a hot or cold beverage for him/herself?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105304>	C105146	ADCS-ADL - Description of Highest Performance of Obtaining Beverage|ADL01-Obtain Beverage Highest Perform|ADL01-Obtain Beverage Highest Perform|ADL0112A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) If yes, which best describes his/her highest level of performance.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105305>	C105146	ADCS-ADL - Make a Meal or Snack at Home|ADL01-Make a Meal|ADL01-Make a Meal|ADL0113	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, did the subject make him/herself a meal or snack at home?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105306>	C105146	ADCS-ADL - Highest Level of Food Preparation|ADL01-Highest Level of Food Preparation|ADL01-Highest Level of Food Preparation|ADL0113A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) If yes, which best describes his/her highest level of food preparation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105307>	C105146	ADCS-ADL - Dispose of Garbage in Appropriate Place at Home|ADL01-Dispose of Garbage|ADL01-Dispose of Garbage|ADL0114	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, did the subject dispose of garbage or litter in an appropriate place or container at home?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105308>	C105146	ADCS-ADL - Description of Usual Performance of Garbage Disposal|ADL01-Dispose Garbage Usual Performance|ADL01-Dispose Garbage Usual Performance|ADL0114A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) If yes, which best describes how he/she usually performed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105309>	C105146	ADCS-ADL - Get Around Outside Home|ADL01-Get Around Outside Home|ADL01-Get Around Outside Home|ADL0115	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, did the subject get around (or travel) outside of his/her home?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10530>	C61063	Doxorubicin/Thiotepa|DOX/TSPA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105310>	C105146	ADCS-ADL - Description of Optimal Performance of Getting Around Outside of Home|ADL01-Get Around Optimal Performance|ADL01-Get Around Optimal Performance|ADL0115A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) If yes, which best describes his/her optimal performance.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105311>	C105146	ADCS-ADL - Go Shopping|ADL01-Go Shopping|ADL01-Go Shopping|ADL0116	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, did the subject ever go shopping?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105312>	C105146	ADCS-ADL - How Subject Usually Selects Items|ADL01-How Usually Selects Items|ADL01-How Usually Selects Items|ADL0116A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Which one best describes how the subject usually selects items.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105313>	C105146	ADCS-ADL - Pay for Items Without Supervision or Physical Help|ADL01-Pay Without Supervision|ADL01-Pay Without Supervision|ADL0116B	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Did the subject usually pay for items without supervision or physical help?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105314>	C105146	ADCS-ADL - Keep Appointments or Meetings with Others|ADL01-Keep Appointments|ADL01-Keep Appointments|ADL0117	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, did the subject keep appointments or meetings with other people, such as relatives, a doctor, the hairdresser, etc.?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105315>	C105146	ADCS-ADL - Description of Awareness of Appointment Ahead of Time|ADL01-Aware of Appointment Ahead of Time|ADL01-Aware of Appointment Ahead of Time|ADL0117A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) If yes, which best describes his/her awareness of the meeting ahead of time.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105316>	C105146	ADCS-ADL - Subject Left on Their Own|ADL01-Left On His/Her Own|ADL01-Left On His/Her Own|ADL0118	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, was the subject ever left on his/her own?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105317>	C105146	ADCS-ADL - Left Away From Home for Fifteen Minutes or Longer|ADL01-Left Away From Home|ADL01-Left Away From Home|ADL0118A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Was the subject left away from home, for 15 minutes or longer, during the day?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105318>	C105146	ADCS-ADL - Left at Home for One Hour or Longer|ADL01-Left at Home for 1 Hour or Longer|ADL01-Left at Home for 1 Hour or Longer|ADL0118B	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Was the subject left: at home, for an hour or longer, during the day?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105319>	C105146	ADCS-ADL - Left at Home for Less Than One Hour|ADL01-Left at Home for Less Than 1 Hour|ADL01-Left at Home for Less Than 1 Hour|ADL0118C	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Was the subject left at home, for less than 1 hour, during the day?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10531>	C61063	Cisplatin/Fluorouracil/Mitomycin/Vindesine|CDDP/DAVA/5-FU/MITO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105320>	C105146	ADCS-ADL - Talk About Current Events|ADL01-Talk About Current Events|ADL01-Talk About Current Events|ADL0119	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, did the subject talk about current events?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105321>	C105146	ADCS-ADL - Talk About Events on TV that Subject Did not Take Part In|ADL01-Talk About Events Heard/Read About|ADL01-Talk About Events Heard/Read About|ADL0119A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Did the subject talk about events that he/she heard or read about or saw on TV but did not take part in?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105322>	C105146	ADCS-ADL - Talk About Events Outside of Home that Subject Took Part In|ADL01-Talk About Outside Events|ADL01-Talk About Outside Events|ADL0119B	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Did the subject talk about events that he/she took part in outside home involving family, friends, or neighbors?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105323>	C105146	ADCS-ADL - Talk About Events at Home that Subject Took Part in or Watched|ADL01-Talk About at Home Events|ADL01-Talk About at Home Events|ADL0119C	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Did the subject talk about events that occurred at home that he/she took part in or watched?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105324>	C105146	ADCS-ADL - Read for More Than Five Minutes|ADL01-Read More Than 5 Minutes|ADL01-Read More Than 5 Minutes|ADL0120	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, did the subject read a magazine, newspaper or book for more than 5 minutes at a time?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105325>	C105146	ADCS-ADL - Talk About What Subject Read Less Than One Hour After Reading|ADL01-Talk Within 1 Hour After Reading|ADL01-Talk Within 1 Hour After Reading|ADL0120A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Did the subject usually talk about details of what he/she read while or shortly (less than 1 hour) after reading?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105326>	C105146	ADCS-ADL - Talk About What Subject Read More Than One Hour After Reading|ADL01-Talk 1 Hour or More After Reading|ADL01-Talk 1 Hour or More After Reading|ADL0120B	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Did the subject usually talk about what he/she read 1 hour or longer after reading?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105327>	C105146	ADCS-ADL - Write Things Down|ADL01-Write Things Down|ADL01-Write Things Down|ADL0121	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, did the subject ever write things down?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105328>	C105146	ADCS-ADL - Description of Most Complicated Writings|ADL01-Most Complicated Writings|ADL01-Most Complicated Writings|ADL0121A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) If yes, which best describes the most complicated things that he/she wrote.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105329>	C105146	ADCS-ADL - Perform Pastime, Hobby or Game|ADL01-Perform Pastime|ADL01-Perform Pastime|ADL0122	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, did the subject perform a pastime, hobby or game?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10532>	C61063	Cisplatin/Doxorubicin/Methotrexate/Sargramostim/Vinblastine|CDDP/DOX/GM-CSF/MTX/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105330>	C105146	ADCS-ADL - Pastime: Card or Board Games|ADL01-Pastime: Card or Board Games|ADL01-Pastime: Card or Board Games|ADL0122A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Which pastimes did he/she perform: Card or board games.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105331>	C105146	ADCS-ADL - Pastime: Bingo|ADL01-Pastime: Bingo|ADL01-Pastime: Bingo|ADL0122B	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Which pastimes did he/she perform: bingo.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105332>	C105146	ADCS-ADL - Pastime: Crosswords|ADL01-Pastime: Crosswords|ADL01-Pastime: Crosswords|ADL0122C	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Which pastimes did he/she perform: crosswords.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105333>	C105146	ADCS-ADL - Pastime: Art|ADL01-Pastime: Art|ADL01-Pastime: Art|ADL0122D	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Which pastimes did he/she perform: art.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105334>	C105146	ADCS-ADL - Pastime: Musical Instrument|ADL01-Pastime: Musical Instrument|ADL01-Pastime: Musical Instrument|ADL0122E	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Which pastimes did he/she perform: musical instrument.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105335>	C105146	ADCS-ADL - Pastime: Knitting|ADL01-Pastime: Knitting|ADL01-Pastime: Knitting|ADL0122F	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Which pastimes did he/she perform: knitting.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105336>	C105146	ADCS-ADL - Pastime: Sewing|ADL01-Pastime: Sewing|ADL01-Pastime: Sewing|ADL0122G	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Which pastimes did he/she perform: sewing.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105337>	C105146	ADCS-ADL - Pastime: Reading|ADL01-Pastime: Reading|ADL01-Pastime: Reading|ADL0122H	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Which pastimes did he/she perform: reading.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105338>	C105146	ADCS-ADL - Pastime: Gardening|ADL01-Pastime: Gardening|ADL01-Pastime: Gardening|ADL0122I	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Which pastimes did he/she perform: gardening.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105339>	C105146	ADCS-ADL - Pastime: Golf|ADL01-Pastime: Golf|ADL01-Pastime: Golf|ADL0122J	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Which pastimes did he/she perform: golf.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10533>	C67297	VM Regimen|L-PAM/VCR|Melphalan-Vincristine|Melphalan/Vincristine|VM|VM|Vincristine-Melphalan|Vincristine/Melphalan|Vincristine/Melphalan Regimen	A regimen consisting of vincristine and melphalan that may be used in combination with irradiation and combination in the treatment of pediatric metastatic rhabdomyosarcoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C105340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105340>	C105146	ADCS-ADL - Pastime: Tennis|ADL01-Pastime: Tennis|ADL01-Pastime: Tennis|ADL0122K	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Which pastimes did he/she perform: tennis.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105341>	C105146	ADCS-ADL - Pastime: Workshop|ADL01-Pastime: Workshop|ADL01-Pastime: Workshop|ADL0122L	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Which pastimes did he/she perform: workshop.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105342>	C105146	ADCS-ADL - Pastime: Fishing|ADL01-Pastime: Fishing|ADL01-Pastime: Fishing|ADL0122M	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Which pastimes did he/she perform: fishing.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105343>	C105146	ADCS-ADL - Pastime: Other|ADL01-Pastime: Other|ADL01-Pastime: Other|ADL0122N	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Which pastimes did he/she perform: other.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105344>	C105146	ADCS-ADL - Pastime: Other Specify|ADL01-Pastime: Other Specify|ADL01-Pastime: Other Specify|ADL0122O	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Which pastimes did he/she perform: other specify.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105345>	C105146	ADCS-ADL - Performed Hobbies Only at Day Care|ADL01-Hobbies Only at Day Care|ADL01-Hobbies Only at Day Care|ADL0122P	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) If the subject performs hobbies/pastimes only at day care, check here.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105346>	C105146	ADCS-ADL - Description of Usual Performance of Common Pastimes|ADL01-Usual Common Pastimes Performance|ADL01-Usual Common Pastimes Performance|ADL0122Q	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) If yes, how did the subject usually perform his/her most common pastimes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105347>	C105146	ADCS-ADL - Use Household Appliance to do Chores|ADL01-Use Household Appliance|ADL01-Use Household Appliance|ADL0123	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) In the past 4 weeks, did the subject use a household appliance to do chores?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105348>	C105146	ADCS-ADL - Appliance: Washer|ADL01-Appliance: Washer|ADL01-Appliance: Washer|ADL0123A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Check all that were used: washer.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105349>	C105146	ADCS-ADL - Appliance: Dryer|ADL01-Appliance: Dryer|ADL01-Appliance: Dryer|ADL0123B	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Check all that were used: dryer.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10534>	C61063	Carboplatin/Cisplatin/Cyclophosphamide/Filgrastim|CBDCA/CDDP/CTX/G-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105350>	C105146	ADCS-ADL - Appliance: Vacuum|ADL01-Appliance: Vacuum|ADL01-Appliance: Vacuum|ADL0123C	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Check all that were used: vacuum.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105351>	C105146	ADCS-ADL - Appliance: Dishwasher|ADL01-Appliance: Dishwasher|ADL01-Appliance: Dishwasher|ADL0123D	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Check all that were used: dishwasher.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105352>	C105146	ADCS-ADL - Appliance: Toaster|ADL01-Appliance: Toaster|ADL01-Appliance: Toaster|ADL0123E	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Check all that were used: toaster.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105353>	C105146	ADCS-ADL - Appliance: Toaster Oven|ADL01-Appliance: Toaster Oven|ADL01-Appliance: Toaster Oven|ADL0123F	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Check all that were used: toaster oven.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105354>	C105146	ADCS-ADL - Appliance: Range|ADL01-Appliance: Range|ADL01-Appliance: Range|ADL0123G	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Check all that were used: range.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105355>	C105146	ADCS-ADL - Appliance: Microwave|ADL01-Appliance: Microwave|ADL01-Appliance: Microwave|ADL0123H	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Check all that were used: microwave.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105356>	C105146	ADCS-ADL - Appliance: Food Processor|ADL01-Appliance: Food Processor|ADL01-Appliance: Food Processor|ADL0123I	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Check all that were used: food processor.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105357>	C105146	ADCS-ADL - Appliance: Other|ADL01-Appliance: Other|ADL01-Appliance: Other|ADL0123J	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Check all that were used: other.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105358>	C105146	ADCS-ADL - Appliance: Other Specify|ADL01-Appliance: Other Specify|ADL01-Appliance: Other Specify|ADL0123K	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Check all that were used: other specify.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105359>	C105146	ADCS-ADL - Description of Usual Use of Commonly Used Appliances|ADL01-Use Common Used Appliances|ADL01-Use Common Used Appliances|ADL0123L	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) If yes, for the most commonly used appliances, which best describes how the subject usually used them.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10535>	C61007	Filgrastim/Topotecan|G-CSF/TOPO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105360>	C105146	ADCS-ADL - Total Score|ADL01-Total ADCS-ADL Score|ADL01-Total ADCS-ADL Score|ADL0124	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Total score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105361>	C105146	ADCS-ADL - Number of 'Don't Know' Responses|ADL01-Number Don't Know Responses|ADL01-Number Don't Know Responses|ADL0125	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Number of 'Don't Know' responses.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Test Code Terminology|CDISC Questionnaire ADCS-ADL Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105362>	C84468	APOE*4 Allele|APOE*E4|APOE-epsilon4 Allele|APOE4 Allele|ApoE4|Apolipoprotein E*4 Allele|Apolipoprotein E4 Allele|NM_000041.2:c.388T>C	Human APOE*4 allele is located in the vicinity of 19q13.2 and is approximately 4 kb in length. This allele, which encodes apolipoprotein E4 protein, plays a role in triglyceride metabolism. The allele is associated with increased occurrence of both Alzheimer disease and coronary artery disease.	APOE*4 Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C105363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105363>	C16386	APOE Gene Product	A protein encoded by the APOE gene.	APOE Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105364>	C105363	Apolipoprotein E4|Apo-E4|ApoE4|NP_000032.1:p.C130R|NP_000032.1:p.C130R,R176R|NP_000032.1:p.Cys130Arg|NP_000032.1:p.Cys130Arg,Arg176Arg	Apolipoprotein E4 (317 aa, ~36 kDa) is encoded by the human APOE gene. This protein is involved in triglyceride metabolism.	Apolipoprotein E4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C105365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105365>	C25966	MicroRNA 29b|MIR29B|MIRN29b|has-mir-29b|hsa-miR-29b-3p|miR29b	A 23 ribonucleotide sequence that is a final product of the processing of either MIR29B1 pre-miRNA or MIR29B2 pre-miRNA. This oligonucleotide may be involved in the negative regulation of gene expression.	MicroRNA 29b		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105366>	C121977	KIR Ligand|Killer-Cell Immunoglobulin-Like Receptor Ligand	The major histocompatibility proteins that are ligands for the killer-cell immunoglobulin-like receptors found on natural killer cells. Binding of these ligands to their cognate receptors plays a role in the activation of natural killer cells.	KIR Ligand		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105367>	C17660	NTRK1 Gene Product	A protein encoded by the NTRK1 gene.	NTRK1 Gene Product		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105368>	C105367	High Affinity Nerve Growth Factor Receptor Isoform TrkA-III|EC 2.7.10.1|NTRK1 Isoform TrkA-III|Nerve Growth Factor Receptor Type 1 Isoform TrkA-III|Neurotrophic Tyrosine Kinase Receptor Type 1 Isoform TrkA-III|TrkA-III|TrkAIII|Tropomyosin-Related Kinase A Isoform TrkA-III|Tyrosine Kinase Receptor A Isoform TrkA-III|Tyrosine Kinase Receptor Isoform TrkA-III	High affinity nerve growth factor receptor isoform TrkA-III (698 aa, ~77 kDa) is encoded by the human NTRK1 gene. This protein is involved in constitutive signaling and tyrosine phosphorylation.	High Affinity Nerve Growth Factor Receptor Isoform TrkA-III		Amino Acid, Peptide, or Protein|Enzyme|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105369>	C13432	6q11-q27|6q11-27	A chromosome band present on 6q.	6q11-q27		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10536>	C61063	Cyclophosphamide/Dexamethasone/Doxorubicin/Quinine/Verapamil/Vincristine|CTX/DM/DOX/QUIN/VCR/VPAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105370>	C814	Bacterial 16S RNA|16S Ribosomal RNA|16S rRNA|Bacterial 16S Ribosomal RNA|Bacterial 16S rRNA	The RNA component of the small (30S) subunit of prokaryotic ribosomes.	Bacterial 16S RNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology
C105371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105371>	C80699	MIR518E Gene|MIR518E|MIR518E|MicroRNA 518e Gene	This gene may be involved in the repression of gene expression.	MIR518E Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105372>	C105371	MIR518E wt Allele|MIRN518E|MicroRNA 518e wt Allele|hsa-mir-518e|mir-518e	Human MIR518E wild-type allele is located in the vicinity of 19q13.42 and is approximately 88 bases in length. This allele, which encodes MIR518E pre-miRNA, may play a role in the silencing of gene expression.	MIR518E wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105373>	C25968	MIR518E Pre-miRNA|Pre-MicroRNA 518e|Pre-miRNA 518e	MIR518E pre-miRNA (88 nucleotides) is encoded by the human MIR518E gene. This oligoribonucleotide may be involved in gene silencing.	MIR518E Pre-miRNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105374>	C21344	NGF Gene|NGF|NGF|Nerve Growth Factor (Beta Polypeptide) Gene	This gene plays a role in the maintenance of sympathetic and sensory neurons.	NGF Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105375>	C105374	NGF wt Allele|Beta-NGF|HSAN5|NGFB|Nerve Growth Factor (Beta Polypeptide) wt Allele	Human NGF wild-type allele is located in the vicinity of 1p13.1 and is approximately 52 kb in length. This allele, which encodes beta-nerve growth factor protein, is involved in the modulation of both the growth and the differentiation of neurons. Mutation of the gene is associated with hereditary sensory and autonomic neuropathy type 5.	NGF wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105376>	C21295	ANXA2 Gene|ANXA2|ANXA2|Annexin A2 Gene	This gene is involved in skeletal system development.	ANXA2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105377>	C105376	ANXA2 wt Allele|ANX2|ANX2L4|Annexin A2 wt Allele|CAL1H|LIP2|LPC2|LPC2D|P36|PAP-IV	Human ANXA2 wild-type allele is located in the vicinity of 15q22.2 and is approximately 56 kb in length. This allele, which encodes annexin A2 protein, plays a role in both bone development and signaling.	ANXA2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105378>	C17728	Annexin A2|ANXA2|Annexin II|Annexin-2|Calpactin I Heavy Chain|Calpactin I Heavy Polypeptide|Calpactin-1 Heavy Chain|Chromobindin 8|Chromobindin-8|Lipocortin II|PAP-IV|Placental Anticoagulant Protein IV|Protein I|p36	Annexin A2 (339 aa, ~39 kDa) is encoded by the human ANXA2 gene. This protein is involved in ligand binding, signal transduction and bone development.	Annexin A2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105379>	C21518	C1QA Gene|C1QA|C1QA|Complement C1q A Chain Gene	This gene plays a role in the classical complement pathway.	C1QA Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10537>	C61063	Carboplatin/Ifosfamide/Sargramostim|CBDCA/GM-CSF/IFF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105380>	C105379	C1QA wt Allele|C1qA|Complement C1q A Chain wt Allele|Complement Component 1, Q Subcomponent, Alpha Polypeptide Gene|Complement Component 1, q Subcomponent, A Chain Gene|Complement Component C1q, A Chain Gene	Human C1QA wild-type allele is located in the vicinity of 1p36.12 and is approximately 3 kb in length. This allele, which encodes complement C1q subcomponent subunit A protein, is involved in the initiation of complement-mediated immunity. Mutation of the gene is associated with complement component C1q deficiency.	C1QA wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105381>	C21523	Complement C1q Subcomponent Subunit A|C1QA|Complement Component 1, q Subcomponent, A Chain|Complement Component 1, q Subcomponent, Alpha Polypeptide|Complement Component C1q A Chain|Complement Subcomponent C1q Chain A	Complement C1q subcomponent subunit A (245 aa, ~26 kDa) is encoded by the human C1QA gene. This protein plays a role in the activation of the classical complement pathway.	Complement C1q Subcomponent Subunit A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105382>	C21295	REG3A Gene|REG3A|REG3A|Regenerating Islet-Derived 3 Alpha Gene	This gene may be involved in pancreatic cell proliferation and differentiation.	REG3A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105383>	C105382	REG3A wt Allele|HIP|HIP/PAP|Hepatocarcinoma-Intestine-Pancreas Gene|INGAP|PAP|PAP-H|PAP1|PBCGF|REG-III|REG3|Regenerating Islet-Derived 3 Alpha wt Allele	Human REG3A wild-type allele is located in the vicinity of 2p12 and is approximately 3 kb in length. This allele, which encodes regenerating islet-derived protein 3-alpha, may play a role in both the proliferation and differentiation of islet cells.	REG3A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105384>	C17728	Regenerating Islet-Derived Protein 3-Alpha|HIP/PAP|Hepatointestinal Pancreatic Protein|Human Proislet Peptide|INGAP|INGAP|ISLET NEOGENESIS ASSOCIATED PROTEIN|Islet Neogenesis Associated Protein|Islet Neogenesis-Associated Protein|PAP Homologous Protein|Pancreatic Beta Cell Growth Factor|Pancreatitis-Associated Protein|Pancreatitis-Associated Protein 1|Proliferation-Inducing Protein 34|Proliferation-Inducing Protein 42|REG-3-Alpha|REG3A|Reg III-Alpha|Regenerating Islet-Derived Protein III-Alpha	Regenerating islet-derived protein 3-alpha (175 aa, ~19 kDa) is encoded by the human REG3A gene. This protein may be involved in pancreatic inflammation.	Regenerating Islet-Derived Protein 3-Alpha		Amino Acid, Peptide, or Protein	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105385>	C49238	ST2 Gene|ST2|ST2|Suppression of Tumorigenicity 2 Gene	Human ST2 gene is located within 11p14.3-p12 and has no known gene product. This locus may play a role in tumor suppression.	ST2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105386>	C28404	UCHL1 Gene|UCHL1|UCHL1|Ubiquitin Carboxyl-Terminal Esterase L1 (Ubiquitin Thiolesterase) Gene	This gene plays a role in the metabolism of ubiquitinated proteins.	UCHL1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105387>	C105386	UCHL1 wt Allele|PARK5|PGP 9.5|PGP9.5|PGP95|Ubiquitin Carboxyl-Terminal Esterase L1 (Ubiquitin Thiolesterase) wt Allele|Uch-L1	Human UCHL1 wild-type allele is located in the vicinity of 4p13 and is approximately 12 kb in length. This allele, which encodes ubiquitin carboxyl-terminal hydrolase isozyme L1 protein, is involved in the deubiquitination of proteins. Mutation of the gene is associated with Parkinson disease type 5.	UCHL1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105388>	C16481	Ubiquitin Carboxyl-Terminal Hydrolase Isozyme L1|EC 3.4.19.12|Neuron Cytoplasmic Protein 9.5|PGP 9.5|PGP9.5|UCH-L1|UCHL1|Ubiquitin Thioesterase L1	Ubiquitin carboxyl-terminal hydrolase isozyme L1 (223 aa, ~25 kDa) is encoded by the human UCHL1 gene. This protein plays a role in ubiquitin metabolism.	Ubiquitin Carboxyl-Terminal Hydrolase Isozyme L1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105389>	C29936	PI3 Gene|PI3|PI3|Peptidase Inhibitor 3, Skin-Derived Gene	This gene plays a role in the inhibition of elastase activity.	PI3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10538>	C61063	Epoetin Alfa/Filgrastim|EPO/G-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105390>	C105389	PI3 wt Allele|Cementoin|ESI|Peptidase Inhibitor 3, Skin-Derived wt Allele|SKALP|WAP3|WFDC14	Human PI3 wild-type allele is located in the vicinity of 20q13.12 and is approximately 2 kb in length. This allele, which encodes elafin protein, is involved in the regulation of connective tissue proteolysis.	PI3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105391>	C17122	Elafin|ESI|Elastase-Specific Inhibitor|PI-3|PI3|Peptidase Inhibitor 3|Protease Inhibitor WAP3|SKALP|Skin-Derived Antileukoproteinase|Trappin-2|WAP Four-Disulfide Core Domain Protein 14	Elafin (117 aa, ~12 kDa) is encoded by the human PI3 gene. This protein plays a role in the inhibition of neutrophil and pancreatic elastase proteinase activity.	Elafin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105392>	C1892	Phenethyl Isothiocyanate-containing Watercress Juice|PEITC-containing Watercress Juice	A juice extracted from watercress containing high amounts of phenethyl isothiocyanate (PEITC), with potential chemopreventive and antitumor activities. Although the mechanism(s) of action through which PEITC exerts its effect(s) has yet to be fully elucidated, PEITC is able to induce apoptosis in tumor cells through the induction of reactive oxygen species (ROS). Additionally, PEITC is able to modulate extracellular signal-regulated kinases (ERK), c-Jun N-terminal kinase (JNK) and mitogen-activated protein kinase (MAPK) signal transduction pathways, activating the expression of stress-responsive genes and eventually inducing apoptosis. PEITC also inhibits the expression of genes involved in tumor progression such as HIF, STAT-3, HER2, BCL-XL, and XIAP and induces the expression of genes involved in tumor suppression such as p53, ATF-2, and p57. Furthermore, this agent has been shown to reactivate the gene expression of certain detoxification enzymes.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C105393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105393>	C20658	CCNC Gene|CCNC|CCNC|CCNC|Cyclin C Gene	This gene plays a role in the modulation of gene transcription.	CCNC Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C105394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105394>	C105393	CCNC wt Allele|CycC|Cyclin C wt Allele	Human CCNC wild-type allele is located in the vicinity of 6q21 and is approximately 27 kb in length. This allele, which encodes cyclin-C protein, is involved in the regulation of transcription.	CCNC wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105395>	C28676|C213868	Rivogenlecleucel|BPX-501|RIVOGENLECLEUCEL	Allogeneic, T-lymphocytes with potential immune reconstitution activity. Donor T-lymphocytes are transduced with a retroviral vector (BPZ-1001) encoding the inducible suicide gene caspase 9 (iCasp9) and linked to a drug binding domain. Donor T-cell therapy may help control transplant-related infections following allogeneic hematopoietic stem cell transplantation. However, the addition of donor T-cells can lead to graft-versus-host disease (GVHD). In the event that GVHD begins to develop, the chemical homodimerizer AP1903 can be administered, which binds to the drug binding domain and induces caspase 9 expression. This activates apoptosis in the T-cells causing GVHD.	Rivogenlecleucel		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C105396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105396>	C26199|C17349	Cyclin-C|CCNC|SRB11 Homolog|hSRB11	Cyclin-C (283 aa, ~33 kDa) is encoded by the human CCNC gene. This protein plays a role in the regulation of the Mediator transcriptional coactivator complex.	Cyclin-C		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105397>	C21295	MT1G Gene|MT1G|MT1G|Metallothionein 1G Gene	This gene is involved in chelation.	MT1G Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105398>	C105397	MT1G wt Allele|MT1|MT1K|Metallothionein 1G wt Allele	Human MT1G wild-type allele is located in the vicinity of 16q13 and is approximately 1 kb in length. This allele, which encodes metallothionein-1G protein, plays a role in both binding and transport of trace metals.	MT1G wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105399>	C129824	Monocarboxylate Transporter 1 Inhibitor AZD3965|AZD-3965|AZD3965|MCT1 Inhibitor AZD3965	An orally available inhibitor of monocarboxylate transporter 1 (MCT1), with potential antineoplastic activity. Upon oral administration, MCT1 inhibitor AZD3965 binds to MCT1 and prevents the transport of lactate into and out of the cell. This leads to an accumulation of lactate, intracellular acidification, and eventually cancer cell death. MCT1, a protein overexpressed on tumor cells, is responsible for the transport of monocarboxylates across the cell membrane and plays a key role in cell metabolism.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C10539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10539>	C61063	Interleukin-2/Levamisole|IL-2/LEV			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1053>	C1450	Zeniplatin|CL 286,558|ZENIPLATIN|cis-(2,2-Bis(aminomethyl)-1,3-propanediol)(1,1-cyclobutanedicarboxylato)platinum	A third-generation, water-soluble platinum compound. (NCI)			Inorganic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C105400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105400>	C16845	Metallothionein-1G|MT-1G|MT-1K|MT-IG|MT1G|Metallothionein-1K|Metallothionein-IG	Metallothionein-1G (62 aa, ~6 kDa) is encoded by the human MT1G gene. This protein is involved in trace metal binding.	Metallothionein-1G		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105401>	C2189	Idroxioleic Acid|2-Hydroxyoleic Acid|2-OHOA|2OHOA|IDROXIOLEIC ACID|Minerval|NFX88|SML-0256	An orally bioavailable, synthetic analog of the fatty acid oleic acid, with potential antitumor activity. Upon administration,idroxioleic acid activates sphingomyelin synthase (SMS), thereby increasing the concentration of sphingomyelin (SM) and diacylglycerol (DAG) in the tumor cell membrane and decreasing membrane levels of phosphatidylethanolamine (PE) and phosphatidylcholine (PC). This restores the normal, healthy levels and ratios of membrane lipids. By restoring normal membrane lipid structure and composition, this agent inhibits membrane-protein associated signaling and the aberrant activity of signaling pathways in certain tumor cells, including the Ras/MAPK and PI3K/AKt pathways. This inhibits tumor cell proliferation, induces tumor cell differentiation, and eventually can cause cell death.	Idroxioleic Acid		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C105402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105402>	C211609|C129825	Entospletinib|6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine|ENTO|ENTOSPLETINIB|GS 9973|GS-9973|GS9973|Imidazo(1,2-a)pyrazin-8-amine, 6-(1H-indazol-6-yl)-N-(4-(4-morpholinyl)phenyl)-	An orally available inhibitor of spleen tyrosine kinase (Syk), with potential antineoplastic activity. Upon oral administration of entospletinib, this agent may inhibit the activity of Syk, which inhibits B-cell receptor (BCR) signaling and leads to an inhibition of tumor cell activation, migration, adhesion and proliferation. Syk, a non-receptor cytoplasmic, BCR-associated tyrosine kinase, is expressed in hematopoietic tissues and is often overexpressed in hematopoeitic malignancies.	Entospletinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C105403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105403>	C2124|C129819	Lutetium Lu 177 DOTA-Tetulomab|177Lu-DOTA-HH1|177Lu-Dota-Tetulomab|177Lu-HH1|TETULOMAB TETRAXETAN LU-177	A radioimmunoconjugate, which consists of a monoclonal antibody against the cell-surface antigen CD37 covalently linked, via the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. The antibody moiety of lutetium Lu 177 DOTA-tetulomab binds to CD37 on tumor B-cells. Upon internalization, the radioisotope moiety delivers a cytotoxic dose of beta radiation to CD37-expressing tumor cells. CD37, a transmembrane glycoprotein, is overexpressed in B-cell malignancies.	Lutetium Lu 177 DOTA-Tetulomab		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C105404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105404>	C20923	NPY1R Gene|NPY1R|NPY1R|Neuropeptide Y Receptor Y1 Gene	This gene is involved in diverse physiological functions as a receptor for neuropeptide Y.	NPY1R Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105405>	C105404	NPY1R wt Allele|NPY1-R|NPYR|NPYY1|Neuropeptide Y Receptor Y1 wt Allele	Human NPY1R wild-type allele is located within 4q31.3-q32 and is approximately 21 kb in length. This allele, which encodes neuropeptide Y receptor type 1 protein, plays a role in diverse physiological functions as a receptor for neuropeptide Y.	NPY1R wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105406>	C18968|C18239	Neuropeptide Y Receptor Type 1|NPY1-R	Neuropeptide Y receptor type 1 (384 aa, ~44 kDa) is encoded by the human NPY1R gene. This protein is involved in diverse physiological functions as a receptor for neuropeptide Y.	Neuropeptide Y Receptor Type 1		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105407>	C38617	Glossopharyngeal Sulcus	A groove between the base of the tongue and the palatine tonsil.			Body Part, Organ, or Organ Component	
C105408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105408>	C20923	NPY2R Gene|NPY2R|NPY2R|Neuropeptide Y Receptor Y2 Gene	This gene plays a role in diverse physiological functions as a peptide hormone receptor.	NPY2R Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105409>	C105408	NPY2R wt Allele|NPY2-R|Neuropeptide Y Receptor Y2 wt Allele	Human NPY2R wild-type allele is located in the vicinity of 4q31 and is approximately 8 kb in length. This allele, which encodes neuropeptide Y receptor type 2 protein, is involved in diverse physiological functions as a receptor for neuropeptide Y.	NPY2R wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10540>	C61063	Carboplatin/Etoposide/Ifosfamide/Interleukin-1-Alpha|CBDCA/IFF/IL-1A/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105410>	C18968|C18239	Neuropeptide Y Receptor Type 2|NPY-Y2 Receptor|Y2 Receptor	Neuropeptide Y receptor type 2 (381 aa, ~43 kDa) is encoded by the human NPY2R gene. This protein plays a role in diverse physiological functions as a receptor for neuropeptide Y.	Neuropeptide Y Receptor Type 2		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105411>	C20923	NPY5R Gene|NPY5R|NPY5R|Neuropeptide Y Receptor Y5 Gene	This gene is involved in binding to neuropeptide Y.	NPY5R Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105412>	C105411	NPY5R wt Allele|NPY5-R|NPYR5|NPYY5-R|Neuropeptide Y Receptor Y5 wt Allele	Human NPY5R wild-type allele is located within 4q31-q32 and is approximately 8 kb in length. This allele, which encodes neuropeptide Y receptor type 5 protein, plays a role in diverse physiological functions as a receptor for neuropeptide Y.	NPY5R wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105413>	C18968|C18239	Neuropeptide Y Receptor Type 5|NPY-Y5 Receptor|Y5 Receptor	Neuropeptide Y receptor type 5 (445 aa, ~51 kDa) is encoded by the human NPY5R gene. This protein is involved in diverse physiological functions as a receptor for neuropeptide Y.	Neuropeptide Y Receptor Type 5		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105414>	C20849	S100A10 Gene|S100 Calcium Binding Protein A10 Gene|S100A10|S100A10	This gene plays a role in cell cycle progression and cell differentiation.	S100A10 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105415>	C105414	S100A10 wt Allele|42C|ANX2L|ANX2LG|CAL1L|CLP11|GP11|P11|S100 Calcium Binding Protein A10 wt Allele	Human S100A10 wild-type allele is located in the vicinity of 1q21 and is approximately 11 kb in length. This allele, which encodes protein S100-A10, is involved in cell cycle progression and cell differentiation and may be involved in exocytosis and endocytosis.	S100A10 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105416>	C29924	Protein S100-A10|Annexin II Ligand, Calpactin I, Light Polypeptide|Annexin II Tetramer (AIIt) p11 Subunit|Calpactin I Light Chain|Calpactin-I Light Chain|Cellular Ligand of Annexin II|S100 Calcium Binding Protein A10 (Annexin II Ligand, Calpactin I, Light Polypeptide (p11))|S100 Calcium-Binding Protein A10|S100 Calcium-Binding Protein A10 (Annexin II Ligand, Calpactin I, Light Polypeptide (p11))|S100A10|p10|p10 Protein|p11	Protein S100-A10 (97 aa, ~11 kDa) is encoded by the human S100A10 gene. This protein plays a role in cell cycle progression and cell differentiation and may be involved in exocytosis and endocytosis.	Protein S100-A10		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105417>	C25939	AKR1C1 Gene|AKR1C1|AKR1C1|Aldo-Keto Reductase Family 1, Member C1 Gene	This gene is involved in the metabolism of aldehydes and ketones.	AKR1C1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105418>	C105417	AKR1C1 wt Allele|Aldo-Keto Reductase Family 1, Member C1 (Dihydrodiol Dehydrogenase 1; 20-Alpha (3-Alpha)-Hydroxysteroid Dehydrogenase) Gene|Aldo-Keto Reductase Family 1, Member C1 wt Allele|C9|DD1|DD1/DD2|DDH|DDH1|H-37|HAKRC|HBAB|MBAB	Human AKR1C1 wild-type allele is located within 10p15-p14 and is approximately 91 kb in length. This allele, which encodes aldo-keto reductase family 1 member C1 protein, plays a role in the conversion of progesterone to its inactive form, 20-alpha-dihydroxyprogesterone, and may have a role in the transport of bile.	AKR1C1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105419>	C16946	Aldo-Keto Reductase Family 1 Member C1|2-Alpha-HSD|20 Alpha-Hydroxysteroid Dehydrogenase|20-Alpha-HSD|20-Alpha-Hydroxysteroid Dehydrogenase|AKR1C1|Aldo-Keto Reductase C|Chlordecone Reductase Homolog HAKRC|Dihydrodiol Dehydrogenase 1|Dihydrodiol Dehydrogenase 1/2|Dihydrodiol Dehydrogenase Isoform DD1|EC 1.1.1.112|EC 1.1.1.149|EC 1.3.1.20|Hepatic Dihydrodiol Dehydrogenase|High-Affinity Hepatic Bile Acid-Binding Protein|Indanol Dehydrogenase|Trans-1,2-Dihydrobenzene-1,2-Diol Dehydrogenase|Type II 3-Alpha-Hydroxysteroid Dehydrogenase	Aldo-keto reductase family 1 member C1 (323 aa, ~37 kDa) is encoded by the human AKR1C1 gene. This protein is involved in the conversion of progesterone to its inactive form and may have a role in the transport of bile.	Aldo-Keto Reductase Family 1 Member C1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10541>	C61063	Cisplatin/Cyclophosphamide/Etoposide/Interleukin-2/Sargramostim|CDDP/CTX/GM-CSF/IL-2/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105420>	C26147	UGT2B15 Gene|UDP Glucuronosyltransferase 2 Family, Polypeptide B15 Gene|UGT2B15|UGT2B15	This gene is involved in the metabolism of steroids and xenobiotics.	UGT2B15 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105421>	C105420	UGT2B15 wt Allele|HLUG4|UDP Glucuronosyltransferase 2 Family, Polypeptide B15 wt Allele|UDPGT 2B8|UDPGT2B15|UDPGTH3|UGT2B8	Human UGT2B15 wild-type allele is located in the vicinity of 4q13 and is approximately 24 kb in length. This allele, which encodes UDP-glucuronosyltransferase 2B15 protein, plays a role in the detoxification of xenobiotics and steroids.	UGT2B15 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105422>	C17434	UDP-Glucuronosyltransferase 2B15|EC 2.4.1.17|HLUG4|UDP Glycosyltransferase 2 Family, Member B15|UDP Glycosyltransferase 2 Family, Polypeptide B15|UDP Glycosyltransferase 2B15|UDP-Glucuronosyltransferase 2B8|UDP-Glucuronosyltransferase UGT2B15|UDP-Glucuronyltransferase, Family 2, Beta-15|UDPGT 2B15|UDPGT 2B8|UDPGTh-3|UGT2B15	UDP-glucuronosyltransferase 2B15 (530 aa, ~61 kDa) is encoded by the human UGT2B15 gene. This protein is involved in the catabolism of xenobiotics and steroids.	UDP-Glucuronosyltransferase 2B15		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105423>	C26147	UGT2B17 Gene|UDP Glucuronosyltransferase 2 Family, Polypeptide B17 Gene|UGT2B17|UGT2B17	This gene plays a role in detoxification of steroids and xenobiotics.	UGT2B17 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105424>	C105423	UGT2B17 wt Allele|UDP Glucuronosyltransferase 2 Family, Polypeptide B17 wt Allele|UDPGT2B17	Human UGT2B17 wild-type allele is located in the vicinity of 4q13 and is approximately 31 kb in length. This allele, which encodes UDP-glucuronosyltransferase 2B17 protein, is involved in the catabolism of xenobiotics and steroids. Copy number variation of the gene is associated with aberrant bone mineral density quantitative trait which can lead to osteoporosis.	UGT2B17 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105425>	C17434	UDP-Glucuronosyltransferase 2B17|C19-Steroid-Specific UDP-Glucuronosyltransferase|C19-Steroid-Specific UDPGT|EC 2.4.1.17|UDP Glycosyltransferase 2 Family, Member B17|UDP Glycosyltransferase 2 Family, Polypeptide B17|UDP-Glucuronyltransferase, Family 2, Beta-17|UDPGT 2B17|UGT2B17	UDP-glucuronosyltransferase 2B17 (530 aa, ~61 kDa) is encoded by the human UGT2B17 gene. This protein plays a role in the metabolism of steroids and xenobiotics.	UDP-Glucuronosyltransferase 2B17		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105426>	C25939	AKR1C2 Gene|AKR1C2|AKR1C2|Aldo-Keto Reductase Family 1, Member C2 Gene	This gene plays a role in the metabolism of steroid hormones.	AKR1C2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105427>	C105426	AKR1C2 wt Allele|Aldo-Keto Reductase Family 1, Member C2 (Dihydrodiol Dehydrogenase 2; Bile Acid Binding Protein; 3-Alpha Hydroxysteroid Dehydrogenase, Type III) Gene|Aldo-Keto Reductase Family 1, Member C2 wt Allele|BABP|DD|DD-2|DD/BABP|DD2|DDH2|HAKRD|HBAB|MCDR2|SRXY8	Human AKR1C2 wild-type allele is located within 10p15-p14 and is approximately 30 kb in length. This allele, which encodes aldo-keto reductase family 1 member C2 protein, is involved in the metabolism of steroid hormones and the inactivation of androgens. Mutations in this gene are associated with 46XY sex reversal 8.	AKR1C2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105428>	C16946	Aldo-Keto Reductase Family 1 Member C2|3-Alpha-HSD3|AKR1C-Pseudo|AKR1C2|Chlordecone Reductase Homolog HAKRD|Dihydrodiol Dehydrogenase 2|Dihydrodiol Dehydrogenase/Bile Acid-Binding Protein|EC 1.1.1.213|EC 1.3.1.20|Pseudo-Chlordecone Reductase|Trans-1,2-Dihydrobenzene-1,2-Diol Dehydrogenase|Type II Dihydrodiol Dehydrogenase|Type III 3-Alpha-Hydroxysteroid Dehydrogenase	Aldo-keto reductase family 1 member C2 (323 aa, ~37 kDa) is encoded by the human AKR1C2 gene. This protein plays a role in the metabolism of steroid hormones and the inactivation of androgens.	Aldo-Keto Reductase Family 1 Member C2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105429>	C28533	SLCO2B1 Gene|SLCO2B1|SLCO2B1|Solute Carrier Organic Anion Transporter Family, Member 2B1 Gene	This gene is involved in transport of organic anions.	SLCO2B1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10542>	C61063	Etoposide/Metronidazole|METRO/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105430>	C105429	SLCO2B1 wt Allele|KIAA0880|OATP-B|OATP-RP2|OATP2B1|OATPB|OATPRP2|SLC21A9|Solute Carrier Organic Anion Transporter Family, Member 2B1 wt Allele	Human SLCO2B1 wild-type allele is located in the vicinity of 11q13 and is approximately 106 kb in length. This allele, which encodes solute carrier organic anion transporter family member 2B1, plays a role in transport of organic anions and may function in regulation of placental uptake of sulfated steroids.	SLCO2B1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105431>	C16386	Solute Carrier Organic Anion Transporter Family Member 2B1|Organic Anion Transporter B|Organic Anion Transporter Polypeptide-Related Protein 2|SLCO2B1|Solute Carrier Family 21 (Organic Anion Transporter), Member 9|Solute Carrier Family 21 Member 9	Solute carrier organic anion transporter family member 2B1 (709 aa, ~77 kDa) is encoded by the human SLCO2B1 gene. This protein is involved in transport of organic anions and may function in regulation of placental uptake of sulfated steroids.	Solute Carrier Organic Anion Transporter Family Member 2B1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105432>	C105821	HOXA7 Gene|HOXA7|HOXA7|Homeobox A7 Gene	This gene is involved in spatial and temporal regulation of gene expression during embryonic development.	HOXA7 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105433>	C105432	HOXA7 wt Allele|ANTP|HOX1|HOX1.1|HOX1A|Homeobox A7 wt Allele	Human HOXA7 wild-type allele is located in the vicinity of 7p15.2 and is approximately 4 kb in length. This allele, which encodes homeobox protein Hox-A7, plays a role in anterior-posterior regulation of gene expression during embryonic development.	HOXA7 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105434>	C17207	Homeobox Protein Hox-A7|Homeo Box A7|Homeobox Protein Hox 1.1|Homeobox Protein Hox-1A	Homeobox protein Hox-A7 (230 aa, ~25 kDa) is encoded by the human HOXA7 gene. This protein is involved in anterior-posterior patterning during embryonic development.	Homeobox Protein Hox-A7		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105435>	C105822	HOXB4 Gene|HOXB4|HOXB4|Homeobox B4 Gene	This gene plays a role in spatial regulation of gene expression during embryonic development.	HOXB4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105436>	C105435	HOXB4 wt Allele|HOX-2.6|HOX2|HOX2F|Homeobox B4 wt Allele	Human HOXB4 wild-type allele is located in the vicinity of 17q21.32 and is approximately 5 kb in length. This allele, which encodes homeobox protein Hox-B4, is involved in anterior-posterior regulation of gene expression during embryonic development.	HOXB4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105437>	C17207	Homeobox Protein Hox-B4|Homeo Box 2F|Homeo Box B4|Homeobox Protein Hox-2.6|Homeobox Protein Hox-2F	Homeobox protein Hox-B4 (251 aa, ~28 kDa) is encoded by the human HOXB4 gene. This protein plays a role in anterior-posterior patterning during embryonic development.	Homeobox Protein Hox-B4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105438>	C64430	Amyloid Beta Precursor Protein Measurement|APPB|Amyloid Beta Precursor|Amyloid Beta Precursor Protein|Amyloid Beta Precursor Protein|Amyloid Precursor Beta|Amyloid Precursor Protein	The determination of the amount of amyloid beta precursor protein present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105439>	C48938	CD11A Expressing Cell Count	The determination of the amount of the CD11a expressing cells in a sample.			Laboratory Procedure	
C10543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10543>	C61063	Etoposide/Ketoconazole/Metronidazole|KCZ/METRO/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105440>	C48938	CD11B Expressing Cell Count	The determination of the amount of the CD11b expressing cells in a sample.			Laboratory Procedure	
C105441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105441>	C81183	Cystine Measurement|CYSTINE|Cystine|Cystine	The determination of the amount of cystine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105442>	C102272	Factor XIV Activity Measurement|FACTXIVA|Factor XIV Activity|Factor XIV Activity|Protein C Activity|Protein C Function	The determination of the amount of Factor XIV activity present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105443>	C47868	FibroTest Score Measurement|FBRTST|FibroSURE Score|FibroSure Score Measurement|FibroTest Score|FibroTest Score	A patented biomarker test (APHP, 2001) that measures liver pathology through the assessment of a six-parameter blood test (for alpha-2-macroglobulin, haptoglobin, apolipoprotein A1, gamma-glutamyl transpeptidase, total bilirubin, and alanine aminotransferase), taking into account the age and sex of the patient.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105444>	C67208	Lymphoblast to Leukocyte Ratio Measurement|BLSTLYLE|Lymphoblasts/Leukocytes|Lymphoblasts/Leukocytes	The determination of the ratio of lymphoblasts compared to total leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105445>	C75342	Theophylline Measurement|THEOPHYL|Theophylline|Theophylline	The determination of the amount of theophylline present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105446>	C34076	Ischial Tuberosity|ISCHIAL TUBEROSITY	The bony prominence of the lower part of the ischium.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105447>	C34076	Sacral Tuberosity|SACRAL TUBEROSITY	The prominence on the lateral surface of the sacrum, posterior to the auricular surface of the sacrum.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105448>	C74590	Failure to Meet Randomization Criteria|FAILURE TO MEET RANDOMIZATION CRITERIA	An indication that the subject has been unable to fulfill the criteria required for assignment into a randomized group.			Idea or Concept	CDISC SDTM Reason for Non-Completion Terminology|CDISC SDTM Terminology|CDISC SDTM Tobacco Study Completion/Reason for Non-Completion Terminology|Clinical Data Interchange Standards Consortium Terminology
C105449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105449>	C85534	Excretion Rate From T1 to T2|ERINT|Excret Rate from T1 to T2|Excret Rate from T1 to T2	The excretion rate over the interval from T1 to T2.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10544>	C61063	Dipyridamole/Etoposide/Ketoconazole/Metronidazole|DP/KCZ/METRO/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105450>	C85534	Excretion Rate From T1 to T2 Normalized by BMI|ERINTB|Excret Rate from T1 to T2 Norm by BMI|Excret Rate from T1 to T2 Norm by BMI	The excretion rate over the interval from T1 to T2 divided by the body mass index.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105451>	C85534	Excretion Rate From T1 to T2 Normalized by Dose|ERINTD|Excret Rate from T1 to T2 Norm by Dose|Excret Rate from T1 to T2 Norm by Dose	The excretion rate over the interval from T1 to T2 divided by the dose.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105452>	C85534	Excretion Rate From T1 to T2 Normalized by SA|ERINTS|Excret Rate from T1 to T2 Norm by SA|Excret Rate from T1 to T2 Norm by SA	The excretion rate over the interval from T1 to T2 divided by the surface area.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105453>	C85534	Excretion Rate From T1 to T2 Normalized by WT|ERINTW|Excret Rate from T1 to T2 Norm by WT|Excret Rate from T1 to T2 Norm by WT	The excretion rate over the interval from T1 to T2 divided by the weight.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105454>	C102376	Nonrenal Clearance Normalized by BMI|NRENLCLB|Nonrenal CL Norm by BMI|Nonrenal CL Norm by BMI	The total clearance of a substance from the blood minus the renal clearance divided by the body mass index.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105455>	C102376	Nonrenal Clearance Normalized by Dose|NRENLCLD|Nonrenal CL Norm by Dose|Nonrenal CL Norm by Dose	The total clearance of a substance from the blood minus the renal clearance divided by the dose.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105456>	C102376	Nonrenal Clearance Normalized by SA|NRENLCLS|Nonrenal CL Norm by SA|Nonrenal CL Norm by SA	The total clearance of a substance from the blood minus the renal clearance divided by the surface area.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105457>	C102376	Nonrenal Clearance Normalized by WT|NRENLCLW|Nonrenal CL Norm by WT|Nonrenal CL Norm by WT	The total clearance of a substance from the blood minus the renal clearance divided by the weight.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105458>	C75913	Renal Clearance Normalized by BMI|RENALCLB|Renal CL Norm by BMI|Renal CL Norm by BMI	The rate at which a substance is removed from the blood via the kidneys, divided by the body mass index.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105459>	C75913	Renal Clearance Normalized by Dose|RENALCLD|Renal CL Norm by Dose|Renal CL Norm by Dose	The rate at which a substance is removed from the blood via the kidneys, divided by the dose.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10545>	C61063	Dipyridamole/Etoposide/Ketoconazole/Metronidazole/Tamoxifen|DP/KCZ/METRO/TMX/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105460>	C75913	Renal Clearance Normalized by SA|RENALCLS|Renal CL Norm by SA|Renal CL Norm by SA	The rate at which a substance is removed from the blood via the kidneys, divided by the surface area.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105461>	C75913	Renal Clearance Normalized by WT|RENALCLW|Renal CL Norm by WT|Renal CL Norm by WT	The rate at which a substance is removed from the blood via the kidneys, divided by the weight.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105462>	C48207	Gram Per Milliliter Per Milligram Per Kilogram|Milligram per Milliliter per Microgram per Kilogram|g/mL/(mg/kg)|g/mL/(mg/kg)|g/mL/(mg/kg)|g/mL/(mg/kg)|g/mL/(mg/kg)|g/ml/(mg/kg)|g/ml/(mg/kg)|mg/mL/(ug/kg)|mg/mL/(ug/kg)|mg/mL/(ug/kg)|mg/mL/(ug/kg)|mg/ml/(ug/kg)|mg/ml/(ug/kg)	A dose calculation unit expressed in grams per milliliter, divided by milligram per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105463>	C92571	Gram Per Milliliter Per Milligram Per Kilogram Per Day|Milligram per Milliliter per Microgram per Kilogram per Day|g/mL/(mg/kg/d)|g/mL/(mg/kg/d)|g/mL/(mg/kg/day)|g/mL/(mg/kg/day)|g/mL/(mg/kg/day)|g/mL/(mg/kg/day)|g/ml/(mg/kg/d)|g/ml/(mg/kg/d)|mg/mL/(ug/kg/d)|mg/mL/(ug/kg/d)|mg/mL/(ug/kg/day)|mg/mL/(ug/kg/day)|mg/mL/(ug/kg/day)|mg/ml/(ug/kg/d)|mg/ml/(ug/kg/d)	A dose calculation unit expressed in grams per milliliter, divided by milligram per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105464>	C92571	Hour Times Gram Per Milliliter Per Milligram Per Kilogram|g*h/mL/(mg/kg)|h*g/mL/(mg/kg)|h*g/mL/(mg/kg)|h*g/mL/(mg/kg)|h.g/mL/(mg/kg)|h.g/mL/(mg/kg)|h.g/ml/(mg/kg)|h.g/ml/(mg/kg)	A dose calculation unit expressed in hours times grams per milliliter, divided by milligram per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105465>	C92571	Hour Times Gram Per Milliliter Per Milligram Per Kilogram Per Day|g*h/mL/(mg/kg/day)|h*g/mL/(mg/kg/day)|h*g/mL/(mg/kg/day)|h*g/mL/(mg/kg/day)|h.g/mL/(mg/kg/d)|h.g/mL/(mg/kg/d)|h.g/ml/(mg/kg/d)|h.g/ml/(mg/kg/d)	A dose calculation unit expressed in hours times grams per milliliter, divided by milligram per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105466>	C92571	Hour Times Microgram Per Milliliter Per Milligram Per Kilogram|h*ug/mL/(mg/kg)|h*ug/mL/(mg/kg)|h*ug/mL/(mg/kg)|h.ug/mL/(mg/kg)|h.ug/mL/(mg/kg)|h.ug/ml/(mg/kg)|h.ug/ml/(mg/kg)|ug*h/mL/(mg/kg)	A dose calculation unit expressed in hours times micrograms per milliliter, divided by milligram per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105467>	C92571	Hour Times Microgram Per Milliliter Per Milligram Per Kilogram Per Day|h*ng/mL/(ug/kg/day)|h*ng/mL/(ug/kg/day)|h*ug/mL/(mg/kg/day)|h*ug/mL/(mg/kg/day)|h*ug/mL/(mg/kg/day)|h*ug/mL/(mg/kg/day)|h.ug/mL/(mg/kg/d)|h.ug/mL/(mg/kg/d)|h.ug/ml/(mg/kg/d)|h.ug/ml/(mg/kg/d)|ug*h/mL/(mg/kg/day)	A dose calculation unit expressed in hours times micrograms per milliliter, divided by milligram per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105468>	C92571	Hour Times Milligram Per Milliliter Per Milligram Per Kilogram|h*mg/mL/(mg/kg)|h*mg/mL/(mg/kg)|h*mg/mL/(mg/kg)|h.mg/mL/(mg/kg)|h.mg/mL/(mg/kg)|h.mg/ml/(mg/kg)|h.mg/ml/(mg/kg)|mg*h/mL/(mg/kg)	A dose calculation unit expressed in hours times milligrams per milliliter, divided by milligram per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105469>	C92571	Hour Times Milligram Per Milliliter Per Milligram Per Kilogram Per Day|h*mg/mL/(mg/kg/day)|h*mg/mL/(mg/kg/day)|h*mg/mL/(mg/kg/day)|h.mg/mL/(mg/kg/d)|h.mg/mL/(mg/kg/d)|h.mg/ml/(mg/kg/d)|h.mg/ml/(mg/kg/d)|mg*h/mL/(mg/kg/day)	A dose calculation unit expressed in hours times milligrams per milliliter, divided by milligram per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10546>	C61063	Dipyridamole/Etoposide/Ketoconazole/Metronidazole/Quinidine/Tamoxifen|DP/KCZ/METRO/QND/TMX/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105470>	C92571	Hour Times Nanogram Per Milliliter Per Milligram Per Kilogram Per Day|h*ng/mL/(mg/kg/day)|h*ng/mL/(mg/kg/day)|h*ng/mL/(mg/kg/day)|h.ng/mL/(mg/kg/d)|h.ng/mL/(mg/kg/d)|h.ng/ml/(mg/kg/d)|h.ng/ml/(mg/kg/d)|ng*h/mL/(mg/kg/day)	A dose calculation unit expressed in hours times nanograms per milliliter, divided by milligram per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105471>	C92571	Hour Times Picogram Per Milliliter Per Milligram Per Kilogram|h*pg/mL/(mg/kg)|h*pg/mL/(mg/kg)|h*pg/mL/(mg/kg)|h.pg/mL/(mg/kg)|h.pg/mL/(mg/kg)|h.pg/ml/(mg/kg)|h.pg/ml/(mg/kg)|pg*h/mL/(mg/kg)	A dose calculation unit expressed in hours times picograms per milliliter, divided by milligram per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105472>	C92571	Hour Times Picogram Per Milliliter Per Milligram Per Kilogram Per Day|h*pg/mL/(mg/kg/day)|h*pg/mL/(mg/kg/day)|h*pg/mL/(mg/kg/day)|h.pg/mL/(mg/kg/d)|h.pg/mL/(mg/kg/d)|h.pg/ml/(mg/kg/d)|h.pg/ml/(mg/kg/d)|pg*h/mL/(mg/kg/day)	A dose calculation unit expressed in hours times picograms per milliliter, divided by milligram per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105473>	C48207	Microgram Per Milliliter Per Milligram Per Kilogram|Nanogram per Milliliter per Microgram per Kilogram|mg/L/mg/kg|ng/mL/(ug/kg)|ng/mL/(ug/kg)|ng/mL/(ug/kg)|ng/mL/(ug/kg)|ng/ml/(ug/kg)|ng/ml/(ug/kg)|ug/mL/(mg/kg)|ug/mL/(mg/kg)|ug/mL/(mg/kg)|ug/mL/(mg/kg)|ug/mL/(mg/kg)|ug/ml/(mg/kg)|ug/ml/(mg/kg)	A dose calculation unit expressed in micrograms per milliliter, divided by milligram per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105474>	C92571	Microgram Per Milliliter Per Milligram Per Kilogram Per Day|Nanogram per Milliliter per Microgram per Kilogram per Day|mg/L/mg/kg/day|ng/mL/(ug/kg/d)|ng/mL/(ug/kg/d)|ng/mL/(ug/kg/day)|ng/mL/(ug/kg/day)|ng/mL/(ug/kg/day)|ng/ml/(ug/kg/d)|ng/ml/(ug/kg/d)|ug/mL/(mg/kg/d)|ug/mL/(mg/kg/d)|ug/mL/(mg/kg/day)|ug/mL/(mg/kg/day)|ug/mL/(mg/kg/day)|ug/mL/(mg/kg/day)|ug/ml/(mg/kg/d)|ug/ml/(mg/kg/d)	A dose calculation unit expressed in micrograms per milliliter, divided by milligram per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105475>	C48207	Milligram Per Milliliter Per Milligram Per Kilogram|Microgram per Milliliter per Microgram per Kilogram|g/L/mg/kg|mg/mL/(mg/kg)|mg/mL/(mg/kg)|mg/mL/(mg/kg)|mg/mL/(mg/kg)|mg/mL/(mg/kg)|mg/ml/(mg/kg)|mg/ml/(mg/kg)|ug/mL/(ug/kg)|ug/mL/(ug/kg)|ug/mL/(ug/kg)|ug/mL/(ug/kg)|ug/ml/(ug/kg)|ug/ml/(ug/kg)	A dose calculation unit expressed in milligrams per milliliter, divided by milligram per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105476>	C92571	Milligram Per Milliliter Per Milligram Per Kilogram Per Day|Microgram per Milliliter per Microgram per Kilogram per Day|g/L/mg/kg/day|mg/mL/(mg/kg/d)|mg/mL/(mg/kg/d)|mg/mL/(mg/kg/day)|mg/mL/(mg/kg/day)|mg/mL/(mg/kg/day)|mg/mL/(mg/kg/day)|mg/ml/(mg/kg/d)|mg/ml/(mg/kg/d)|ug/mL/(ug/kg/d)|ug/mL/(ug/kg/d)|ug/mL/(ug/kg/day)|ug/mL/(ug/kg/day)|ug/mL/(ug/kg/day)|ug/ml/(ug/kg/d)|ug/ml/(ug/kg/d)	A dose calculation unit expressed in milligrams per milliliter, divided by milligram per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105477>	C48207	Nanogram Per Milliliter Per Milligram Per Kilogram|Picogram per Milliliter per Microgram per Kilogram|ng/mL/(mg/kg)|ng/mL/(mg/kg)|ng/mL/(mg/kg)|ng/mL/(mg/kg)|ng/mL/(mg/kg)|ng/ml/(mg/kg)|ng/ml/(mg/kg)|pg/mL/(ug/kg)|pg/mL/(ug/kg)|pg/mL/(ug/kg)|pg/mL/(ug/kg)|pg/ml/(ug/kg)|pg/ml/(ug/kg)|ug/L/mg/kg	A dose calculation unit expressed in manograms per milliliter, divided by milligram per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105478>	C92571	Nanogram Per Milliliter Per Milligram Per Kilogram Per Day|Picogram per Milliliter per Microgram per Kilogram per Day|ng/mL/(mg/kg/d)|ng/mL/(mg/kg/d)|ng/mL/(mg/kg/day)|ng/mL/(mg/kg/day)|ng/mL/(mg/kg/day)|ng/mL/(mg/kg/day)|ng/ml/(mg/kg/d)|ng/ml/(mg/kg/d)|pg/mL/(ug/kg/d)|pg/mL/(ug/kg/d)|pg/mL/(ug/kg/day)|pg/mL/(ug/kg/day)|pg/mL/(ug/kg/day)|pg/ml/(ug/kg/d)|pg/ml/(ug/kg/d)|ug/L/mg/kg/day	A dose calculation unit expressed in nanograms per milliliter, divided by milligram per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105479>	C48207	Picogram Per Milliliter Per Milligram Per Kilogram|Femtogram per Milliliter per Microgram per Kilogram|fg/mL/(ug/kg)|fg/mL/(ug/kg)|fg/mL/(ug/kg)|fg/mL/(ug/kg)|fg/ml/(ug/kg)|fg/ml/(ug/kg)|ng/L/mg/kg|pg/mL/(mg/kg)|pg/mL/(mg/kg)|pg/mL/(mg/kg)|pg/mL/(mg/kg)|pg/mL/(mg/kg)|pg/ml/(mg/kg)|pg/ml/(mg/kg)	A dose calculation unit expressed in picograms per milliliter, divided by milligram per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10547>	C61063	Cyclosporine/Dipyridamole/Etoposide/Ketoconazole/Metronidazole/Quinidine/Tamoxifen|CYSP/DP/KCZ/METRO/QND/TMX/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105480>	C92571	Picogram Per Milliliter Per Milligram Per Kilogram Per Day|Femtogram per Milliliter per Microgram per Kilogram per Day|fg/mL/(ug/kg/d)|fg/mL/(ug/kg/d)|fg/mL/(ug/kg/day)|fg/mL/(ug/kg/day)|fg/mL/(ug/kg/day)|fg/ml/(ug/kg/d)|fg/ml/(ug/kg/d)|ng/L/mg/kg/day|pg/mL/(mg/kg/d)|pg/mL/(mg/kg/d)|pg/mL/(mg/kg/day)|pg/mL/(mg/kg/day)|pg/mL/(mg/kg/day)|pg/mL/(mg/kg/day)|pg/ml/(mg/kg/d)|pg/ml/(mg/kg/d)	A dose calculation unit expressed in picograms per milliliter, divided by milligram per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105481>	C48564	Centimeter Per Minute|Centimeters per Minute|cm/min|cm/min|cm/min|cm/minute	A unit of both speed (scalar) and velocity (vector), defined as the distance of one centimeter traveled per unit time equal to one minute.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105482>	C42574	Centisecond|10^-2 sec|10^-2 sec|cs|cs|cs|csec|csec	A unit of time equal to one hundredth of a second (10E-2 seconds).			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105483>	C64567	Decamole Per Liter|Decamole per Liter|Moles per Deciliter|Moles per Deciliter|damol/L|damol/L|damol/L|damol/l|damol/l|mol/dL|mol/dL	A unit of concentration (molarity unit) equal to one decamole of solute in one liter of solution.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105484>	C67218	Fraction of 1|Proportion of 1|fraction of 1|{fraction of 1}|{fraction of 1}	A unit for expressing a percentage as a decimal whereby the total value is measured as a fraction of the numeric 1.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105485>	C67442	Gram Per Gram of Creatinine|g/g Creatinine|g/g{Creatinine}|g/g{Creatinine}|mg/mg Creatinine	A unit of substance concentration defined as the number of grams per gram of creatinine.			Quantitative Concept	
C105486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105486>	C67442	Gram Per Mole of Creatinine|g/mol Creatinine|g/mol{creatinine}|g/mol{creatinine}|mg/mmol Creatinine	A unit of substance concentration defined as the number of grams per mole quantity of creatinine.			Quantitative Concept	
C105487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105487>	C67333	Hectopascal|hPa|hPa|hPa	A SI derived unit of pressure equivalent to one hundred pascals, 1 millibar or 0.0145 pounds per square inch.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105488>	C67391	Hundred Billion Per Liter|10*11/L|10*11/L|10*11/l|10*11/l|10^11/L|10^11/L|10^11/L|10^11/l|10^11/l|10^5/mm3|10^5/mm3|10^5/uL|10^5/uL|10^8/mL|10^8/mL	A concentration unit expressed as a number or quantity of objects in hundred billions per unit of volume equal to one liter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105489>	C67391	Hundred Million Per Liter|10*8/L|10*8/L|10*8/l|10*8/l|10^2/mm3|10^2/mm3|10^2/uL|10^2/uL|10^5/mL|10^5/mL|10^8/L|10^8/L|10^8/L|10^8/l|10^8/l	A concentration unit expressed as a number or quantity of objects in hundred millions per unit of volume equal to one liter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10548>	C61063	Doxorubicin/Verapamil|DOX/VPAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105490>	C67391	Hundred Thousand Per Liter|10*5/L|10*5/L|10*5/l|10*5/l|10^2/mL|10^2/mL|10^5/L|10^5/L|10^5/L|10^5/l|10^5/l	A concentration unit expressed as a number or quantity of objects in hundred thousands per unit of volume equal to one liter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105491>	C64559	Kilodalton|Kilounified Atomic Mass Unit|Kilounified Atomic Mass Unit|kDa|kDa|kiloDalton|ku|ku|ku|{kDa}|{kDa}	A unit of atomic mass equal to one thousand daltons.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|PQ/CMC Units of Measure Terminology
C105492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105492>	C67333	Kilopascal Per Liter Per Second|Pa/mL/sec|Pa/mL/sec|kPa/L/s|kPa/L/s|kPa/L/s|kPa/L/sec|kPa/L/sec|kPa/l/s|kPa/l/s	A unit of resistance equal to the number of kilopascals per unit of volume equal to one liter per unit of time equal to one second.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105493>	C42574	Kilosecond|10^3 sec|10^3 sec|kilosecond|ks|ks|ks|ks|ks|ksec|ksec	A unit of time equal to one thousand seconds (10E3 seconds).			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C105494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105494>	C48568	Liter Per Hour Per Square Meter|(L/h)/m2|(L/h)/m2|(L/h)/m2|(L/h)/m2|(l/h)/m2|(l/h)/m2|L/h/m2|L/h/m2|L/h/m2|L/h/m2|Liters per Hour per Square Meter|l/h/m2|l/h/m2	A unit expressed as one liter of volume per unit of time equal to one hour per square meter of area.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105495>	C69174	Liter Per Liter|Deciliter per Deciliter|L/L|L/L|L/L|L/L|L/L|Liter per Liter|Liter per Liter|Microliter per Microliter|Milliliter per Milliliter|Nanoliter per Nanoliter|dL/dL|dL/dL|dL/dL|l/l|l/l|liter per liter|mL/mL|mL/mL|mL/mL|nL/nL|uL/uL|uL/uL|uL/uL	A measure of volume concentration expressed as the number of liters of a dissolved substance per liter of solution.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C105496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105496>	C48568	Liter Per Minute Per Square Meter|(L/min)/m2|(L/min)/m2|(L/min)/m2|(L/min)/m2|(l/min)/m2|(l/min)/m2|L/(min.m2)|L/m/m2|L/min/m2|L/min/m2|L/min/m2|L/min/m2|Liters per Minute per Square Meter|l/min/m2|l/min/m2|liter per minute per square meter|liters/min/m^2	A unit expressed as one liter of volume per unit of time equal to one minute per square meter of area. (NCI)			Quantitative Concept	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 7: Diagnostic Procedures Terminology|CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C105497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105497>	C67375	Microgram Equivalent|ug.eq|ug.eq|ugEq|ugEq	A unit of relative amount of substance concentration equal to one millionth of a gram of an equivalent weight.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105498>	C66973	Micromole Per Liter Per Second|Micromoles per Liter per Second|umol/(L*s)|umol/(s*L)|umol/L/s|umol/L/s|umol/L/s|umol/L/sec|umol/L/sec|umol/l/s|umol/l/s|umol/s/L	A concentration unit equal to one micromole of solute in one liter of solution per unit of time equal to one second.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105499>	C67319	Microvolt Second|Microvolt * Seconds|Microvolt Seconds|uV*s|uV*sec|uV*sec|uV.s|uV.s	A SI derived unit of magnetic flux, equal to the flux that produces in a circuit of one turn an electromotive force of one microvolt, when the flux is uniformly reduced to zero within one second.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10549>	C61063	Cisplatin/Etoposide/Filgrastim/Melphalan|CDDP/G-CSF/L-PAM/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1054>	C261	Clarithromycin|6-O-Methylerythromycin|Abbott-56268|Biaxin|CLARITHROMYCIN|clarithromycin	A semisynthetic 14-membered ring macrolide antibiotic.  Clarithromycin binds to the 50S ribosomal subunit and inhibits RNA-dependent protein synthesis in susceptible organisms.  Clarithromycin has been shown to eradicate gastric MALT (mucosa-associated lymphoid tissue) lymphomas, presumably due to the eradication of tumorigenic Helicobacter pylori infection. This agent also acts as a biological response modulator, possibly inhibiting angiogenesis and tumor growth through alterations in growth factor expression. (NCI04)	Clarithromycin		Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C105500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105500>	C48034	Mile Per Hour|Miles Per Hour|Miles per Hour|[mi_i]/h|[mi_i]/h|mph|mph	A unit of both speed (scalar) and velocity (vector), defined as the distance of one mile traveled per unit time equal to one hour.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105501>	C67442	Milliequivalent Per Gram of Creatinine|mEq/g Creatinine|meq/g{Creatinine}|meq/g{Creatinine}	A unit of relative amount of substance concentration defined as the concentration of milliequivalents per gram of creatinine.			Quantitative Concept	
C105502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105502>	C67442	Milligram Per Gram of Creatinine|mg/g Creatinine|mg/g{Creatinine}|mg/g{Creatinine}|ug/mg Creatinine	A unit of substance concentration defined as the number of milligrams per gram of creatinine.			Quantitative Concept	
C105503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105503>	C48572	Milliliter per Centimeter|dL/m|dL/m|mL/cm|mL/cm|mL/cm|ml/cm|ml/cm	A unit of measure equal to the number of milliliters per unit of length equal to one centimeter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105504>	C69174	Milliliter per Deciliter|Milliliters per Deciliter|mL/dL|mL/dL|mL/dL|mL/dL|mL/dL|milliliter per deciliter|ml/dl|ml/dl	A measure of volume concentration expressed as the number of milliters of a dissolved substance per deciliter of solution.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C105505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105505>	C48568	Milliliter Per Second Per 1.73 Meter Squared|mL/s/1.73 m2|mL/s/173/100.m2|mL/s/173/100.m2|mL/sec/1.73m2|mL/sec/1.73m2|ml/s/173/100.m2|ml/s/173/100.m2	A metric unit of volumetric flow rate defined as the rate at which one milliliter of matter travels during the period of time equal to one second per 1.73 meters squared of body surface area.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105506>	C67415	Millimeter Mercury Per Liter Per Minute|mmHg/L/min|mmHg/L/min|mm[Hg]/L/min|mm[Hg]/L/min|mm[Hg]/l/min|mm[Hg]/l/min	A unit of resistance equal to the number of millimeters of mercury per unit of volume equal to one liter per unit of time equal to one minute.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105507>	C48564	Millimeter Per Minute|Millimeters per Minute|mL/m|millimeter per minute|mm/min|mm/min|mm/min|mm/min	A unit of both speed (scalar) and velocity (vector), defined as the distance of one millimeter traveled per unit time equal to one minute.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C105508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105508>	C48564	Millimeter Per Second|Millimeters per Second|mm/s|mm/s|mm/s|mm/sec|mm/sec	A unit of both speed (scalar) and velocity (vector), defined as the distance of one millimeter traveled per unit time equal to one second.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105509>	C48564	Millimeter per Two Hours|Millimeters per Two Hours|mm/2.h|mm/2.h|mm/2h|mm/2h	A unit of both speed (scalar) and velocity (vector), defined as the distance of one centimeter traveled per unit time equal to two hours.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10550>	C61063	Asparaginase/Cyclophosphamide/Daunorubicin/Filgrastim/Prednisone/Vincristine|ASP/CTX/DNR/G-CSF/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105510>	C67442	Millimole Per Gram of Creatinine|mmol/g Creatinine|mmol/g{Creatinine}|mmol/g{Creatinine}	A unit of substance concentration defined as the concentration of millimoles of solute per gram of creatinine.			Quantitative Concept	
C105511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105511>	C67442	Millimole Per Mole of Creatinine|mmol/mol CREAT|mmol/mol CREATININE|mmol/mol Creatinine|mmol/mol.{CREATININE}|mmol/mol{Creatinine}|mmol/mol{Creatinine}|umol/mmol CREATININE	A unit of substance concentration defined as the concentration of millimoles of solute per mole of creatinine.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105512>	C67319	Millivolt Minute|Millivolt * Minutes|mV*min|mV*min|mV.min|mV.min	A SI derived unit of magnetic flux, equal to the flux that produces in a circuit of one turn an electromotive force of one millivolt, when the flux is uniformly reduced to zero within one minute.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105513>	C67375	Nanounit Per Centiliter|Nanounit per Centiliter|nU/cL|nU/cL|{nUnit}/cL|{nUnit}/cL|{nUnit}/cl|{nUnit}/cl|{nU}/cL|{nU}/cL|{nU}/cl|{nU}/cl	An arbitrary unit of substance content expressed in nanounit(s) per centiliter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105514>	C66973	Per Deciliter|/dL|/dL|/dL|/dL|/dl|/dl|per deciliter	A volume unit equal to one deciliter used as a denominator to build a derived unit expressed as a ratio.			Quantitative Concept	HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C105515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105515>	C66973	Per Liter|/L|/L|/L|/L|/l|/l|per liter	A volume unit equal to one liter used as a denominator to build a derived unit expressed as a ratio.			Quantitative Concept	HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C105516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105516>	C48572	Per Visual Field|/VF|/VF|/{VF}|/{VF}	A unit of measure equal to the instances of an entity per visual field of a microscope.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105517>	C67391	Ten Billion Per Liter|10*10/L|10*10/L|10*10/l|10*10/l|10^10/L|10^10/L|10^10/L|10^10/l|10^10/l|10^4/mm3|10^4/mm3|10^4/uL|10^4/uL|10^7/mL|10^7/mL	A concentration unit expressed as a number or quantity of objects in ten billions per unit of volume equal to one liter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105518>	C67456	Tera International Unit Per Liter|10*12.[IU]/L|10*12.[IU]/L|10*12.[IU]/l|10*12.[IU]/l|10*12.[iU]/L|10*12.[iU]/L|10*12.[iU]/l|10*12.[iU]/l|10^12 IU/L|10^12 IU/L|10^12.[IU]/L|10^12.[IU]/L|10^12.[IU]/l|10^12.[IU]/l|10^12.[iU]/L|10^12.[iU]/L|10^12.[iU]/l|10^12.[iU]/l|TIU/L|TIU/L|Tera International Unit per Liter	Unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of 10^12 international unit per one liter of system volume.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105519>	C67391	Thousand Per Liter|/mL|1/mL|10*3/L|10*3/L|10*3/L|10*3/l|10*3/l|10^3/L|10^3/L|10^3/L|10^3/L|10^3/l|10^3/l	A concentration unit expressed as a number or quantity of objects in thousands per unit of volume equal to one liter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C10551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10551>	C61063	Asparaginase/Cyclophosphamide/Cytarabine/Filgrastim/Mercaptopurine/Vincristine|ARA-C/ASP/CTX/G-CSF/MP/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105520>	C67375	Unit Per Centiliter|U/cL|U/cL|Unit per Centiliter|{Unit}/cL|{Unit}/cL|{Unit}/cl|{Unit}/cl|{U}/cL|{U}/cL|{U}/cl|{U}/cl	An arbitrary unit of substance concentration expressed in unit(s) per centiliter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105521>	C67375	Unit Per Deciliter|U/dL|U/dL|Unit per Deciliter|{Unit}/dL|{Unit}/dL|{Unit}/dl|{Unit}/dl|{U}/dL|{U}/dL|{U}/dl|{U}/dl	An arbitrary unit of substance concentration expressed in unit(s) per deciliter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105522>	C67375	Unit Per Gram Hemoglobin|U/g HGB|U/g Hb|U/g Hb|U/g Hemoglobin|U/g{HGB}|U/g{HGB}	Unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one unit per gram of hemoglobin.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C105523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105523>	C67375	Unit Per Gram of Creatinine|U/g Creatinine|U/g{creatinine}|U/g{creatinine}	A unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one unit per gram of creatinine.			Quantitative Concept	
C105524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105524>	C67319	Volt Per Second|V/s|V/s|V/s|V/s|V/sec|V/sec|Volt per Second	A SI derived rate unit equal to one volt per unit of time equal to one second.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105525>	C17660	RET Gene Product	A protein encoded by the RET gene.			Amino Acid, Peptide, or Protein|Enzyme	
C105526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105526>	C17728	EGFR Gene Product	A protein encoded by the EGFR gene.			Amino Acid, Peptide, or Protein	
C105527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105527>	C173346|C107401	Pain at its Worst Question|Pain at its Worst|Pain at its Worst|Your pain at its WORST	A question about an individual's pain at its worst.			Intellectual Product	Brief Pain Inventory Short Form Questionnaire|MD Anderson Symptom Inventory - Head and Neck|PROMIS Short Form - Pain Intensity
C105528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105528>	C173347|C107401	Fatigue at its Worst Question|Fatigue at its Worst|Your fatigue (tiredness) at its WORST	A question about an individual's fatigue at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Head and Neck
C105529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105529>	C173130|C107401	Nausea at its Worst Question|Nausea at its Worst|Your nausea at its WORST	A question about an individual's nausea at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Head and Neck
C10552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10552>	C61063	Altretamine/Cisplatin/Etoposide|CDDP/HMM/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105530>	C173925|C107401	Disturbed Sleep at its Worst Question|Disturbed Sleep at its Worst|Your disturbed sleep at its WORST	A question about an individual's disturbed sleep at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Head and Neck
C105531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105531>	C173348|C107401	Being Distressed at its Worst Question|Being Distressed at its Worst|Your feeling of being distressed (upset) at its WORST	A question about an individual's distress at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Head and Neck
C105532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105532>	C107401	Shortness of Breath at its Worst Question|Shortness of Breath at its Worst|Worst Possible Shortness of Breath|Your shortness of breath at its WORST	A question about an individual's shortness of breath at its worst.			Intellectual Product	Edmonton Symptom Assessment System|MD Anderson Symptom Inventory - Head and Neck
C105533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105533>	C107401	Problem with Remembering Things at its Worst Question|Problem with Remembering Things at its Worst|Your problem with remembering things at its WORST	A question about an individual's memory at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Head and Neck
C105534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105534>	C107401	Problem with Lack of Appetite at its Worst Question|Problem with Lack of Appetite at its Worst|Your problem with lack of appetite at its WORST	A question about an individual's lack of appetite at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Head and Neck
C105535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105535>	C173925|C107401|C107397	Feeling Drowsy at its Worst Question|Feeling Drowsy at its Worst|Worst Possible Drowsiness|Your feeling drowsy (sleepy) at its WORST	A question about an individual's feeling drowsy at its worst.			Intellectual Product	Edmonton Symptom Assessment System|MD Anderson Symptom Inventory - Head and Neck
C105536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105536>	C107401	Dry Mouth at its Worst Question|Dry Mouth at its Worst|Your having a dry mouth at its WORST	A question about an individual's dry mouth at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Head and Neck
C105537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105537>	C173160|C107401	Feeling Sad at its Worst Question|Feeling Sad at its Worst|Your feeling sad at its WORST	A question about an individual's feeling sad at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Head and Neck
C105538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105538>	C173604|C107401	Vomiting at its Worst Question|Vomiting at its Worst|Your vomiting at its WORST	A question about an individual's vomiting at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Head and Neck
C105539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105539>	C173734|C107401	Numbness or Tingling at its Worst Question|Numbness or Tingling at its Worst|Your numbness or tingling at its WORST	A question about an individual's numbness and tingling at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Head and Neck
C10553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10553>	C61063	Amifostine/Melphalan|L-PAM/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105540>	C107401	Mucus in Mouth and Throat at its Worst Question|Mucus in Mouth and Throat at its Worst|Your problem with mucus in your mouth and throat at its WORST	A question about an individual's mucus in mouth or throat at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Head and Neck
C105541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105541>	C173454|C173398|C107401	Swallowing or Chewing Difficulties at its Worst Question|Swallowing or Chewing Difficulties at its Worst|Your difficulty swallowing/chewing at its WORST	A question about an individual's swallowing or chewing difficulties at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Head and Neck
C105542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105542>	C173937|C173398|C107401	Voice or Speech Difficulties at its Worst Question|Voice or Speech Difficulties at its Worst|Your difficulty with voice/speech at its WORST	A question about an individual's voice or speech difficulties at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Head and Neck
C105543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105543>	C107401	Choking or Coughing - Food or Liquids Going Down the Wrong Pipe at its Worst Question|Choking or Coughing - Food or Liquids Going Down the Wrong Pipe at its Worst|Your choking/coughing (food/liquids going down the wrong pipe) at its WORST	A question about an individual's choking or coughing - such as food or liquids going down the wrong pipe at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Head and Neck
C105544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105544>	C107401	Constipation at its Worst Question|Constipation at its Worst|Your constipation at its WORST	A question about an individual's constipation at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Head and Neck
C105545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105545>	C107401	Problem Tasting Food at its Worst Question|Your problem with tasting food at its WORST	A question about an individual's problem tasting food at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Head and Neck
C105546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105546>	C173584|C173457	Symptoms Interfere with Life Question|How have your symptoms interfered with your life|How much does it interfere with your activities|Symptoms Interfere with Life	A question about an individual feeling that symptoms are or were interfering with their life.			Intellectual Product	MD Anderson Symptom Inventory - Head and Neck|Older Americans Resource Scale Multidimensional Functional Assessment Questionnaire
C105547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105547>	C107401	Problem with Teeth or Gums at its Worst Question|Problem with Teeth or Gums at its Worst|Your problem with your teeth or gums at its WORST	A question about an individual's teeth or gums at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Head and Neck
C105548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105548>	C173346|C107401	Skin Pain or Burning or Rash at its Worst Question|Skin Pain or Burning or Rash at its Worst|Your skin pain/burning/rash at its WORST	A question about an individual's skin pain or burning or rash at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Head and Neck
C105549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105549>	C173924	Work Including Work Around the House Question|Normal work (includes work both outside the home and daily chores)|Work (including work around the house)|Work Including Work Around the House	A question about an individual's work, including work around the house.			Intellectual Product	MD Anderson Symptom Inventory - Head and Neck
C10554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10554>	C61007	Cytarabine/Pegaspargase|ARA-C/PEG-ASP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105550>	C107401	Mouth or Throat Sores at its Worst Question|Mouth or Throat Sores at its Worst|Your mouth/throat sores at their WORST	A question about an individual's mouth or throat sores at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Head and Neck
C105551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105551>	C91105	MD Anderson Symptom Inventory - Head and Neck|MDASI-HN	A self-administered questionnaire designed specifically for evaluating the severity of symptoms related to head and neck cancer.			Intellectual Product	
C105552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105552>	C81265	Timeline Followback Method	A calendar-based measure for assessing self-reported retrospective daily estimates of alcohol, tobacco and/or illicit substance use.			Conceptual Entity	
C105553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105553>	C1816	Crack Cocaine|Crack	An illegal drug composed of the smokable, baseform of cocaine that is produced by dissolving cocaine hydrochloride in an alkali solution, usually sodium bicarbonate and water, and subsequent boiling. Cocaine causes euphoria, loss of appetite, insomnia, and is highly addictive.			Substance	
C105554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105554>	C1816	Hallucinogen	Any naturally-derived or synthetic substance that can induce hallucinations.			Chemical Viewed Functionally	
C105555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105555>	C7550|C213446	Ovarian High Grade Serous Adenocarcinoma|High Grade Ovarian Serous Adenocarcinoma|High Grade Ovarian Serous Adenocarcinoma|High Grade Ovarian Serous Adenocarcinoma|High Grade Ovarian Serous Adenocarcinoma|High-Grade Ovarian Serous Adenocarcinoma|Ovarian High-Grade Serous Adenocarcinoma	A rapidly growing serous adenocarcinoma that arises from the ovary. It is characterized by the presence of high-grade cytologic features and frequent mitotic figures.	High Grade Ovarian Serous Adenocarcinoma		Neoplastic Process	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology|NCIt Neoplasm Core Terminology
C105556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105556>	C7550|C213448	Ovarian Low Grade Serous Adenocarcinoma|Invasive Ovarian Micropapillary Serous Carcinoma|Invasive Ovarian Micropapillary Serous Carcinoma|Low Grade Ovarian Serous Adenocarcinoma|Low Grade Ovarian Serous Adenocarcinoma|Low-Grade Ovarian Serous Adenocarcinoma|Ovarian Low-Grade Serous Adenocarcinoma	A slow-growing serous adenocarcinoma that arises from the ovary. It usually originates from borderline neoplastic processes or adenofibromas. It is characterized by the presence of low-grade cytologic features and infrequent mitotic figures.	Invasive Ovarian Micropapillary Serous Carcinoma		Neoplastic Process	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology|NCIt Neoplasm Core Terminology
C105557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105557>	C25941	TPI1 Gene|TPI1|TPI1|Triosephosphate Isomerase 1 Gene	This gene plays a role in glycolysis and gluconeogenesis.	TPI1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105558>	C105557	TPI1 wt Allele|TIM|TPI|Triosephosphate Isomerase 1 wt Allele	Human TPI1 wild-type allele is located in the vicinity of 12p13.31 and is approximately 4 kb in length. This allele, which encodes triosephosphate isomerase protein, is involved in the isomerization of both glyceraldehyde 3-phosphate (G3P) and dihydroxy-acetone phosphate (DHAP) in both glycolysis and gluconeogenesis. Mutations in this gene are associated with triosephosphate isomerase deficiency.	TPI1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105559>	C16759	Triosephosphate Isomerase|EC 5.3.1.1|TPI1|Triose-Phosphate Isomerase	Triosephosphate isomerase (286 aa, ~31 kDa) is encoded by the human TPI1 gene. This protein plays a role in the isomerization of glyceraldehydes in both glycolysis and gluconeogenesis.	Triosephosphate Isomerase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10555>	C61063	Idarubicin/Tretinoin|ATRA/IDA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105560>	C26110|C21240	TRDMT1 Gene|TRDMT1|TRDMT1|tRNA Aspartic Acid Methyltransferase 1 Gene	This gene is involved in methylation of aspartic acid transfer RNA.	TRDMT1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105561>	C105560	TRDMT1 wt Allele|DMNT2|DNMT2|M.HsaIIP|MHSAIIP|PUMET|RNMT1|tRNA Aspartic Acid Methyltransferase 1 wt Allele	Human TRDMT1 wild-type allele is located in the vicinity of 10p15.1 and is approximately 60 kb in length. This allele, which encodes tRNA (cytosine(38)-C(5))-methyltransferase protein, plays a role in methylation of aspartic acid transfer RNA but also has DNA-(cytosine-C5) methyltransferase activity.	TRDMT1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105562>	C17107	tRNA (Cytosine(38)-C(5))-Methyltransferase|DNA (Cytosine-5)-Methyltransferase-Like Protein 2|DNA (Cytosine-5-)-Methyltransferase 2|DNA MTase Homolog HsaIIP|DNA Methyltransferase Homolog HsaIIP|DNA Methyltransferase-2|EC 2.1.1.204|PuMet|TRDMT1|tRNA (Cytosine-5-)-Methyltransferase	tRNA (Cytosine(38)-C(5))-Methyltransferase (391 aa, ~46 kDa) is encoded by the human TRDMT1 gene. This protein is involved in the specific methylation of cytosine 38 in the anticodon loop of tRNA(Asp).	tRNA (Cytosine(38)-C(5))-Methyltransferase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105563>	C54362	TSC22D3 Gene|TSC22 Domain Family, Member 3 Gene|TSC22D3|TSC22D3	This gene plays a role in the function of both T-cells and macrophages.	TSC22D3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105564>	C105563	TSC22D3 wt Allele|DIP|DSIPI|GILZ|TSC-22R|TSC22 Domain Family, Member 3 wt Allele|hDIP	Human TSC22D3 wild-type allele is located in the vicinity of Xq22.3 and is approximately 64 kb in length. This allele, which encodes TSC22 domain family protein 3, is involved in both the transcriptional regulation of apoptotic genes and immunosuppression.	TSC22D3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105565>	C26199	TSC22 Domain Family Protein 3|DSIP-Immunoreactive Leucine Zipper Protein|DSIP-Immunoreactive Peptide|Delta Sleep Inducing Peptide, Immunoreactor|Delta Sleep-Inducing Peptide Immunoreactor|Glucocorticoid-Induced Leucine Zipper Protein|Protein DIP|TSC-22 Related Protein|TSC-22-Like Protein|TSC-22-Related Protein|TSC22D3	TSC22 domain family protein 3 (134 aa, ~15 kDa) is encoded by the human TSC22D3 gene. This protein plays a role in both apoptosis in T-cells and immunosuppression in macrophages.	TSC22 Domain Family Protein 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105566>	C21165	TNFRSF18 Gene|TNFRSF18|TNFRSF18|Tumor Necrosis Factor Receptor Superfamily Member 18 Gene	This gene is involved in T-cell function.	TNFRSF18 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105567>	C105566	TNFRSF18 wt Allele|AITR|CD357|ENERGEN|GITR|GITR-D|Glucocorticoid-Induced TNFR-Related Gene|Tumor Necrosis Factor Receptor Superfamily Member 18 wt Allele|Tumor Necrosis Factor Receptor Superfamily, Member 18 Gene	Human TNFRSF18 wild-type allele is located in the vicinity of 1p36.3 and is approximately 3 kb in length. This allele, which encodes tumor necrosis factor receptor superfamily member 18 protein, plays a role in dominant immunological self-tolerance and may play a role in both T-cell activation and T-cell programmed cell death.	TNFRSF18 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105568>	C19285	Tumor Necrosis Factor Receptor Superfamily Member 18|Activation-Inducible TNFR Family Member|Activation-Inducible TNFR Family Receptor|CD357 Antigen|GITR|Glucocorticoid-Induced TNFR-Related Protein|TNF Receptor Superfamily Activation-Inducible Protein|TNFRSF18	Tumor necrosis factor receptor superfamily member 18 (241 aa, ~26 kDa) is encoded by the human TNFRSF18 gene. This protein is involved in T-cell-mediated immune function.	Tumor Necrosis Factor Receptor Superfamily Member 18		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105569>	C21165	TNFRSF21 Gene|TNFRSF21|TNFRSF21|Tumor Necrosis Factor Receptor Superfamily, Member 21 Gene	This gene plays a role in the induction of apoptosis.	TNFRSF21 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10556>	C61063	Idarubicin/Mercaptopurine/Methotrexate/Prednisone/Vincristine|IDA/MP/MTX/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105570>	C105569	TNFRSF21 wt Allele|BM-018|CD358|DR6|Tumor Necrosis Factor Receptor Superfamily, Member 21 wt Allele	Human TNFRSF21 wild-type allele is located in the vicinity of 6p21.1 and is approximately 78 kb in length. This allele, which encodes tumor necrosis factor receptor superfamily member 21 protein, is involved in the induction of apoptosis and may be involved in both inflammation and immune regulation.	TNFRSF21 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105571>	C19285	Tumor Necrosis Factor Receptor Superfamily Member 21|CD358 Antigen|Death Receptor 6|TNFR-Related Death Receptor 6	Tumor necrosis factor receptor superfamily member 21 (655 aa, ~72 kDa) is encoded by the human TNFRSF21 gene. This protein plays a role in the induction of apoptosis and may play a role in T-helper cell activation.	Tumor Necrosis Factor Receptor Superfamily Member 21		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105572>	C26147	UGT1A6 Gene|UDP Glucuronosyltransferase 1 Family, Polypeptide A6 Gene|UGT1A6|UGT1A6	This gene is involved in the excretion of phenolic metabolites.	UGT1A6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105573>	C105572	UGT1A6 wt Allele|GNT1|HLUGP|HLUGP1|UDP Glucuronosyltransferase 1 Family, Polypeptide A6 wt Allele|UDPGT|UDPGT 1-6|UGT-1F|UGT1|UGT1*6|UGT1-06|UGT1.6|UGT1A6S|UGT1F	Human UGT1A6 wild-type allele is located in the vicinity of 2q37 and is approximately 82 kb in length. This allele, which encodes UDP-glucuronosyltransferase 1-6 protein, plays a role in both the conjugation and excretion of phenols.	UGT1A6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105574>	C17434	UDP-Glucuronosyltransferase 1-6|EC 2.4.1.17|Phenol-Metabolizing UDP-Glucuronosyltransferase|UDP Glycosyltransferase 1 Family, Polypeptide A6|UDP-Glucuronosyltransferase 1 Family Polypeptide A6s|UDP-Glucuronosyltransferase 1-F|UDP-Glucuronosyltransferase 1A6|UGT1A6	UDP-glucuronosyltransferase 1-6 (532 aa, ~61 kDa) is encoded by the human UGT1A6 gene. This protein is involved in the elimination of phenolic metabolites.	UDP-Glucuronosyltransferase 1-6		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105575>	C26147	UGT2B7 Gene|UDP Glucuronosyltransferase 2 Family, Polypeptide B7 Gene|UGT2B7|UGT2B7	This gene plays a role in estrogen metabolism.	UGT2B7 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105576>	C105575	UGT2B7 wt Allele|UDP Glucuronosyltransferase 2 Family, Polypeptide B7 wt Allele|UDPGT 2B7|UDPGT 2B9|UDPGT2B7|UDPGTH2|UDPGTh-2|UGT2B9|UGTB2B9	Human UGT2B7 wild-type allele is located in the vicinity of 4q13 and is approximately 62 kb in length. This allele, which encodes UDP-glucuronosyltransferase 2B7 protein, is involved in regulating levels of estrogens and estradiols.	UGT2B7 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105577>	C17434	UDP-Glucuronosyltransferase 2B7|3,4-Catechol Estrogen Specific|3,4-Catechol Estrogen-Specific UDPGT|EC 2.4.1.17|UDP Glucuronosyltransferase 2B7|UDP Glycosyltransferase 2 Family, Polypeptide B7|UDP-Glucuronosyltransferase 2B9|UDP-Glucuronyltransferase, Family 2, Beta-7|UGT2B7	UDP-glucuronosyltransferase 2B7 (529 aa, ~61 kDa) is encoded by the human UGT2B7 gene. This protein plays a role in regulating the metabolism of estrogen metabolites.	UDP-Glucuronosyltransferase 2B7		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105578>	C1933	Cannabinoid|Cannabinoids	Any compound capable of activating the cannabinoid receptor CB1 and/or CB2. Cannabinoids include phytocannabinoids, endocannabinoids and (semi-)synthetic cannabinoids. They exert a wide variety of biological activities including anti-inflammatory, anti-emetic, anticonvulsant, antiglaucoma, analgesic and neuroprotective effects; while some exert psychoactive effects, including euphoria.			Chemical Viewed Structurally	
C105579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105579>	C225418	Intrathoracic|Internal Thorax	Within the thoracic cavity.			Spatial Concept	
C10557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10557>	C61063	Cyclophosphamide/Doxorubicin/Etoposide/Medroxyprogesterone/Quinine|CTX/DOX/MPA/QUIN/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105580>	C25790	ULBP1 Gene|UL16 Binding Protein 1 Gene|ULBP1|ULBP1	This gene is involved in the function of natural killer cells.	ULBP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105581>	C105580	ULBP1 wt Allele|Alcan-Beta Gene|MULT1|N2DL-1|N2DL1|NKG2DL1|RAET1I|Retinoic Acid Early Transcript 1I Gene|UL16 Binding Protein 1 wt Allele	Human ULBP1 wild-type allele is located in the vicinity of 6q25.1 and is approximately 10 kb in length. This allele, which encodes UL16-binding protein 1, plays a role in the production of both cytokines and chemokines by natural killer cells.	ULBP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105582>	C16725	UL16-Binding Protein 1|ALCAN-Beta|N2DL-1|NKG2D Ligand 1|NKG2D Ligand 1|NKG2DL1|Retinoic Acid Early Transcript 1I|ULBP1	UL16-binding protein 1 (244 aa, ~28 kDa) is encoded by the human ULBP1 gene. This protein is involved in activation of multiple signaling pathways in primary NK cells.	NKG2D Ligand 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105583>	C25790	ULBP2 Gene|UL16 Binding Protein 2 Gene|ULBP2|ULBP2	This gene plays a role in the function of natural killer cells.	ULBP2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105584>	C105583	ULBP2 wt Allele|ALCAN-Alpha Gene|N2DL-2|N2DL2|NKG2DL2|RAET1H|Retinoic Acid Early Transcript 1H Gene|UL16 Binding Protein 2 wt Allele	Human ULBP2 wild-type allele is located in the vicinity of 6q25.1 and is approximately 7 kb in length. This allele, which encodes UL16-binding protein 2, is involved in the activation of multiple signaling pathways in primary NK cells.	ULBP2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105585>	C47868	Glucose Measurement|GLUC|Glucose|Glucose|Glucose|Glucose	The determination of the amount of glucose present in a sample.	Glucose Measurement		Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|OS Authorized Value Terminology|OS Lab Table
C105586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105586>	C74949	Cholesterol Measurement|CHOL|Cholesterol|Cholesterol|Total Cholesterol	The determination of the amount of total cholesterol present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105587>	C74949	High Density Lipoprotein Cholesterol Measurement|HDL|HDL Cholesterol|HDL Cholesterol|HDL Cholesterol Measurement|High-Density Lipoprotein Cholesterol Measurement	The determination of the amount of high-density lipoprotein cholesterol present in a sample.	High Density Lipoprotein Cholesterol Measurement		Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C105588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105588>	C74949	Low Density Lipoprotein Cholesterol Measurement|LDL|LDL Cholesterol|LDL Cholesterol|LDL Cholesterol Measurement|LDL-C Measurement|LDL-Cholesterol Measurement|Low Density Lipoprotein-Cholesterol Measurement|Low-Density Lipoprotein Cholesterol Measurement|Low-Density Lipoprotein-Cholesterol Measurement	The determination of the amount of low-density lipoprotein cholesterol present in a sample.	Low Density Lipoprotein Cholesterol Measurement		Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C105589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105589>	C74949	Very Low Density Lipoprotein Cholesterol Measurement|VLDL|VLDL Cholesterol|VLDL Cholesterol|VLDL Cholesterol Measurement	The determination of the amount of very low-density lipoprotein cholesterol present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10558>	C61063	Pentostatin/Sargramostim|DCF/GM-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105590>	C74948	Ammonium Biurate Crystals Measurement|Acid Ammonium Urate Crystals|Ammonium Biurate Crystals|Ammonium Biurate Crystals|Ammonium Urate Crystals|CYAMMBIU	The determination of the amount of ammonium biurate crystals present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105591>	C16725	UL16-Binding Protein 2|Alcan-Alpha|N2DL-2|NKG2D Ligand 2|NKG2D Ligand 2|NKG2DL2|Retinoic Acid Early Transcript 1H|UL16 Binding Protein 2|ULBP2	UL16-binding protein 2 (246 aa, ~27 kDa) is encoded by the human ULBP2 gene. This protein plays a role in the production of both cytokines and chemokines by natural killer cells.	NKG2D Ligand 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105592>	C25790	ULBP3 Gene|UL16 Binding Protein 3 Gene|ULBP3|ULBP3	This gene is involved in the function of natural killer cells.	ULBP3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105593>	C105592	ULBP3 wt Allele|ALCAN-Gamma Gene|N2DL-3|N2DL3|NKG2DL3|RAET1N|Retinoic Acid Early Transcript 1N Gene|UL16 Binding Protein 3 wt Allele	Human ULBP3 wild-type allele is located in the vicinity of 6q25.1 and is approximately 8 kb in length. This allele, which encodes UL16-binding protein 3, plays a role in the production of both cytokines and chemokines by natural killer cells.	ULBP3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105594>	C16725	UL16-Binding Protein 3|Alcan-Gamma|N2DL-3|NKG2D Ligand 3|NKG2D Ligand 3|NKG2DL3|Retinoic Acid Early Transcript 1N|UL16 Binding Protein 3|ULBP3	UL16-binding protein 3 (244 aa, ~28 kDa) is encoded by the human ULBP3 gene. This protein is involved in activation of multiple signaling pathways in primary NK cells.	NKG2D Ligand 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105595>	C97172|C89338	Meningocele|Central Nervous System Meningocele	A congenital abnormality in which the meninges protrude through a defect in the spinal column or the cranium.			Disease or Syndrome	
C105596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105596>	C21344	VEGFB Gene|VEGFB|VEGFB|Vascular Endothelial Growth Factor B Gene	This gene plays a role in regulation of blood vessel physiology.	VEGFB Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105597>	C105596	VEGFB wt Allele|VEGF-B|VEGFL|VRF|Vascular Endothelial Growth Factor B wt Allele	Human VEGFB wild-type allele is located in the vicinity of 11q13 and is approximately 4 kb in length. This allele, which encodes vascular endothelial growth factor B protein, is involved in both endothelial cell proliferation and angiogenesis.	VEGFB wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105598>	C20424	Vascular Endothelial Growth Factor B|VEGF-Related Factor	Vascular endothelial growth factor B (207 aa, ~22 kDa) is encoded by the human VEGFB gene. This protein plays a role in both the formation of blood vessels and endothelial cell physiology.	Vascular Endothelial Growth Factor B		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105599>	C26006	VPS18 Gene|VPS18|VPS18|Vacuolar Protein Sorting 18 Homolog (S. cerevisiae) Gene	This gene is involved in intracellular trafficking.	VPS18 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10559>	C61063	Carboplatin/Diethyldithiocarbamate|CBDCA/DTC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1055>	C1291	Custirsen Sodium|(3'-5')d(P-thio)([2'-O-(2-methoxyethyl)]m5rC-[2'-O-(2-methoxyethyl)]rA-[2'-O-(2- methoxyethyl)]rG-[2'-O-(2-methoxyethyl)]m5rC-A-G-C-A-G-A-G-T-C-T-T-C-A-[2'-O-(2- methoxyethyl)]m5rU-[2'-O-(2-methoxyethyl)]m5rC-[2'-O-(2-methoxyethyl)]rA-[2'-O-(2- methoxyethyl)]m5rU), Eicosasodium Salt|Antisense TRPM-2|Antisense Testosterone-Repressed Prostate Message 2|CUSTIRSEN SODIUM|Clusterin Antisense Oligonucleotide|ISIS 112989|OGX 011|OGX-011|OGX011|TRPM-2 Antisense|custirsen sodium	The eicosasodium salt of a mixed-backbone antisense oligodeoxynucleotide with chemosensitizing properties. Custirsen inhibits testosterone-repressed prostate message-2 (TRPM-2). Administration of custirsen abrogates the anti-apoptotic effect of TRPM-2, thereby sensitizing cells to chemotherapy and resulting in tumor cell death. TRPM-2 is an anti-apoptotic clusterin that is overexpressed by prostate cancer cells and is associated with chemoresistance.	Custirsen Sodium		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C105600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105600>	C105599	VPS18 wt Allele|KIAA1475|PEP3|VPS18, CORVET/HOPS Core Subunit Gene|Vacuolar Protein Sorting 18 Homolog (S. cerevisiae) wt Allele|Vacuolar Protein Sorting 18, Yeast, Homolog of Gene|hVPS18	Human VPS18 wild-type allele is located within 15q14-q15 and is approximately 10 kb in length. This allele, which encodes vacuolar protein sorting-associated protein 18, plays a role in the segregation of intracellular molecules into distinct organelles.	VPS18 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105601>	C16386	Vacuolar Protein Sorting-Associated Protein 18|Vacuolar Protein Sorting Protein 18|Vacuolar Protein Sorting-Associated Protein 18 Homolog|hVPS18	Vacuolar protein sorting-associated protein 18 (973 aa, ~110 kDa) is encoded by the human VPS18 gene. This protein is involved in vesicle-mediated protein trafficking.	Vacuolar Protein Sorting-Associated Protein 18		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105602>	C25873	WNK1 Gene|WNK Lysine Deficient Protein Kinase 1 Gene|WNK1|WNK1	This gene plays a role in regulation of electrolyte homeostasis.	WNK1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105603>	C105602	WNK1 wt Allele|HSAN2|HSN2|Hereditary Sensory Neuropathy, Type II Gene|KDP|KIAA0344|PHA2C|PPP1R167|PRKWNK1|PSK|Protein Kinase, Lysine Deficient 1 Gene|Protein Kinase, Lysine-Deficient 1|Protein Phosphatase 1, Regulatory Subunit 167 Gene|WNK Lysine Deficient Protein Kinase 1 wt Allele|hWNK1|p65	Human WNK1 wild-type allele is located in the vicinity of 12p13.3 and is approximately 159 kb in length. This allele, which encodes serine/threonine-protein kinase WNK1 protein, is involved in regulation of blood pressure by controlling the transport of both sodium and chloride ions. Mutations in this gene are associated with both pseudohypoaldosteronism type II and hereditary sensory neuropathy type II.	WNK1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105604>	C17325	Serine/Threonine-Protein Kinase WNK1|EC 2.7.11.1|Erythrocyte 65 kDa Protein|Kinase Deficient Protein|Prostate-Derived Sterile 20-Like Kinase|Protein Kinase Lysine-Deficient 1|Protein Kinase with No Lysine 1|WNK Lysine Deficient Protein Kinase 1 Isoform|WNK1|hWNK1|p65	Serine/threonine-protein kinase WNK1 (2382 aa, ~251 kDa) is encoded by the human WNK1 gene. This protein plays a role in controling sodium and chloride ion transport.	Serine/Threonine-Protein Kinase WNK1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105605>	C16615	ZEB1 Gene|ZEB1|ZEB1|ZEB1|Zinc Finger E-Box Binding Homeobox 1 Gene	This gene is involved in the transcriptional repression of interleukin 2.	ZEB1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C105606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105606>	C105605	ZEB1 wt Allele|AREB6|BZP|DELTAEF1|FECD6|NIL-2-A|NIL2A|PPCD3|Posterior Polymorphous Corneal Dystrophy 3 Gene|T-Lymphocyte-Specific Interleukin 2 Inhibitor Gene|TCF-8|TCF8|Transcription Factor 8 (Represses Interleukin 2 Expression) Gene|ZEB|ZFHEP|ZFHX1A|Zinc Finger E-Box Binding Homeobox 1 wt Allele	Human ZEB1 wild-type allele is located in the vicinity of 10p11.2 and is approximately 214 kb in length. This allele, which encodes zinc finger E-box-binding homeobox 1 protein, plays a role in the transcriptional repression of interleukin-2 gene expression. Mutations in this gene are associated with both posterior polymorphous corneal dystrophy-3 and late-onset Fuchs endothelial corneal dystrophy.	ZEB1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105607>	C17207	Zinc Finger E-Box-Binding Homeobox 1|Delta-Crystallin Enhancer Binding Factor 1|NIL-2-A Zinc Finger Protein|Negative Regulator of IL2|TCF-8|Transcription Factor 8|ZEB1|Zinc Finger Homeodomain Enhancer-Binding Protein	Zinc finger E-box-binding homeobox 1 (1124 aa, ~124 kDa) is encoded by the human ZEB1 gene. This protein is involved in both the transcriptional repression of interleukin 2 and the positive regulation of neuronal differentiation.	Zinc Finger E-Box-Binding Homeobox 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105608>	C20703	ZMYND8 Gene|ZMYND8|ZMYND8|Zinc Finger, MYND-Type Containing 8 Gene	This gene plays a role in protein kinase C function.	ZMYND8 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105609>	C105608	ZMYND8 wt Allele|KIAA1125|PRKCBP1|PRO2893|RACK7|Zinc Finger, MYND-Type Containing 8 wt Allele	Human ZMYND8 wild-type allele is located in the vicinity of 20q13.12 and is approximately 148 kb in length. This allele, which encodes protein kinase C-binding protein 1, is involved in the function of protein kinase C. The encoded protein is also a cutaneous T-cell lymphoma-associated antigen.	ZMYND8 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10560>	C61063	Levamisole/Tamoxifen|LEV/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105610>	C26199	Protein Kinase C-Binding Protein 1|CTCL Tumor Antigen se14-3|CTCL-Associated Antigen se14-3|Cutaneous T-Cell Lymphoma Associated Antigen se14-3|Cutaneous T-Cell Lymphoma-Associated Antigen se14-3|Predicted Protein of HQ2893|Protein Kinase C Binding Protein 1|ZMYND8|Zinc Finger MYND Domain Containing Protein 8|Zinc Finger MYND Domain-Containing Protein 8	Protein kinase C-binding protein 1 (1186 aa, ~132 kDa) is encoded by the human ZMYND8 gene. This protein plays a role in protein kinase C function and may be a transcriptional regulator.	Protein Kinase C-Binding Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105611>	C2124	Copper Cu 62 Ethylglyoxal Bis(thiosemicarbazone)|62Cu-ETS|62Cu-Ethylglyoxal Bis|62Cu-Ethylglyoxal Bis(thiosemicarbazone)	A radiopharmaceutical composed of the nonspecific perfusion agent ethylglyoxal bis(thiosemicarbazone) (ETS) linked to the beta-emitting, radioisotope copper Cu 62, with potential tumor imaging activity upon positron emitting tomography (PET). Upon injection, copper Cu 62-ETS distributes to various organs, especially the kidneys and the myocardium. Upon PET imaging, tumor blood flow can be visualized and the efficacy of antineoplastic and anti-angiogenic chemotherapeutics can be assessed. Cu62-ETS has a short half life of 9.74 minutes. ETS has an enhanced hyperemic response compared to other perfusion agents.	Copper Cu 62 Ethylglyoxal Bis(thiosemicarbazone)		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C105612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105612>	C201551	Depatuxizumab Mafodotin|ABT-414|DEPATUXIZUMAB MAFODOTIN	An antibody-drug conjugate (ADC) consisting of depatuxizumab, a humanized monoclonal antibody directed against human epidermal growth factor receptor (EGFR), conjugated to the auristatin derivative monomethyl auristatin F (MMAF), with potential antineoplastic activity. Upon administration of depatuxizumab mafodotin, depatuxizumab targets and binds to EGFR expressed on tumor cell surfaces. Upon internalization, the MMAF moiety is released, binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest, tumor cell apoptosis and inhibition of cellular proliferation in tumor cells that overexpress EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.	Depatuxizumab Mafodotin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C105613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105613>	C2150|C1557	Gemcitabine Hydrochloride Emulsion|D07001-F4	An orally available nanoparticle-based formulation containing the hydrochloride salt form of gemcitabine, a broad-spectrum antimetabolite and deoxycytidine analogue, with antineoplastic activity. The formulation consists of an oil-in-water emulsion in which gemicitabine is solubilized in the excipient matrix containing a mixture of oil and (co)surfactants. Upon oral administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA, resulting in premature termination of DNA replication and the induction of apoptosis. Further, dFdCDP inhibits ribonucleotide reductase and reduces the deoxynucleotide pool available for DNA synthesis. Compared to gemcitabine alone, the emulsion allows for increased oral bioavailability and decreases its susceptibility to deamination and deactivation by cytidine deaminase.			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C105614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105614>	C200766|C176018	Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T Cells|Autologous CD19R:CD28:lentiviral/EGFRt+ T Cells	A preparation of genetically modified autologous central memory (Tcm) enriched T-cells transduced with a replication incompetent lentiviral vector expressing a chimeric antigen receptor (CAR), containing a CD28 signaling domain fused to both CD3 zeta, which targets the CD19 antigen, and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells are directed to CD19-expressing tumor cells, thereby inducing a selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.  Devoid of both ligand binding domains and tyrosine kinase activity, EGFRt both facilitates in vivo detection of the administered T-cells and can promote elimination of those cells upon a cetuximab-induced antibody dependent cellular cytotoxicity response. The costimulatory signaling domain enhances proliferation of T cells and antitumor activity.	Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C105616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105616>	C1935	Astragalus-based Formulation Qing Shu Yi Qi Tang|QSYQT|Qing-Shu-Yi-Qi-Tang	An herbal remedy containing Astragalus membranaceus, Panax ginseng, Atractylodes chinensis Koidz, Cimicifuga foetida, A. macrocephala Koidz, Alisma orientale Juzep, and Citrus reticulata Blanco, with potential immunomodulating, anti-oxidant and anticachexia activities. Upon oral consumption, the ingredients in this herbal supplement may modulate the activity of the immune system through a decrease in both the expression of nuclear factor-kappa B (NF-kappa B) and the production of pro-inflammatory cytokines such as interleukin-1beta (Il-1b), IL-6, and tumor necrosis factor-alpha (TNF-alpha). Increased levels of pro-inflammatory cytokines are correlated with decreased appetite and weight loss; thus, this herbal remedy may improve immune function, appetite and weight gain, which could prevent cachexia.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C105617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105617>	C275|C2081	Magnesium Isoglycyrrhizinate|MAGNESIUM ISOGLYCYRRHIZINATE|Tianqingganmei	The magnesium salt form of the saponin, isoglycyrrhizinate, a derivative of glycyrrhizic acid extracted from the roots of the plant Glycyrrhiza glabra, with potential anti-inflammatory, antioxidant and hepatoprotective activities. Although the exact mechanism of action remains to be fully elucidated, magnesium isoglycyrrhizinate may prevent or reduce hepatotoxicity through the scavenging of free radicals. This agent also modulates the activity of hepatic enzymes such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), superoxide dismutase (SOD) and glutathione peroxidase.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C105618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105618>	C2701	Therapeutic Hepatitis C Immune Globulin|Anti-HCV Immunoglobulin|Biotest-HCIG|Civacir|HCIG|HEPATITIS C IMMUNE GLOBULIN (HUMAN)	A human plasma-derived, polyclonal, intravenous immunoglobulin G (IgG) formulation containing high levels of antibodies against hepatitis C virus (HCV), a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family, with potential immunomodulating and antiviral activities. The hepatitis C IgG is isolated from donors expressing high amounts of HCV antibodies. Upon intravenous administration, the anti-HCV antibodies bind to the virus and provide passive immunization against HCV. This may prevent both infection by HCV in immunocompromised patients and hepatitis C-related liver disease. The polyclonal anti-HCV antibodies are able to target various viral epitopes.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C10561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10561>	C61063	Fluorouracil/Idoxuridine/Leucovorin Calcium/PALA|CF/5-FU/IUDR/PALA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105620>	C19729	Alvin J Siteman Cancer Center|Siteman|Siteman Cancer Center	The Alvin J Siteman Cancer Center is dedicated to advancing new approaches to cancer prevention, diagnosis, and treatment through research. It became an NCI-designated cancer center in 2001 and achieved Comprehensive Cancer Center status in 2004. Parent institutions include Barnes-Jewish Hospital and Washington University School of Medicine. Partner institutions include St. Louis Children's Hospital and BJC Healthcare.			Health Care Related Organization	
C105622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105622>	C19980	Dan L Duncan Cancer Center|DLDCC|Dan L Duncan Cancer Center at the Baylor College of Medicine|Duncan Cancer Center at BCM	The Dan L Duncan Cancer Center focuses on cancer research, patient care, training, and education. It became an NCI-designated cancer center in 2007. It is a consortium made up of Baylor College of Medicine and its three primary teaching hospital affiliates: Ben Taub Hospital, Michael E DeBakey Veterans Affairs Medical Center, and Texas Children's Hospital.			Professional or Occupational Group	
C105623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105623>	C19980	Harold C Simmons Cancer Center|Harold C Simmons Cancer Center at the University of Texas Southwestern Medical Center|Harold C Simmons Comprehensive Cancer Center|Simmons Cancer Center	The Harold C Simmons Cancer Center is focused on translational cancer research. It became an NCI-designated cancer center in 2010. It is part of University of Texas Southwestern Medical Center.			Professional or Occupational Group	
C105624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105624>	C19980	Hollings Cancer Center|HCC	The mission of the Hollings Cancer Center is to reduce the cancer burden in South Carolina through high-quality patient care, research, professional education, and cancer prevention programs with a focus on reaching underserved populations. It became an NCI-designated cancer center in 2009. It is a Medical University of South Carolina center.			Professional or Occupational Group	
C105626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105626>	C19980	Stanford Cancer Institute|SCI|Stanford Cancer Institute at Stanford University	The Stanford Cancer Institute is focused on improving the diagnosis, treatment, and outcomes for cancer patients, understanding cancer etiologies among diverse populations, and reducing the incidence of cancer. It became an NCI-designated cancer center in 2007. It is a Stanford School of Medicine center.			Professional or Occupational Group	
C105627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105627>	C19980	The University of Kansas Cancer Center|KUCC	The University of Kansas Cancer Center is focused on using drug discovery, delivery, and development to transform the delivery of clinical care in Kansas and Missouri. It became an NCI-designated cancer center in 2012. Its partners include University of Kansas, University of Kansas Medical Center, University of Kansas Hospital, KU School of Pharmacy, University of Kansas School of Medicine, Wichita, and Stowers Institute for Medical Research.			Professional or Occupational Group	
C105628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105628>	C19980	University of Maryland Marlene and Stewart Greenebaum Cancer Center|UMGCC|University of Maryland Greenebaum Cancer Center	The mission of the University of Maryland Marlene and Stewart Greenebaum Cancer Center is to conduct innovative basic and clinical research that will impact the understanding and treatment of cancer around the world and to provide state-of-the-art clinical care to cancer patients in Maryland and beyond. It became an NCI-designated cancer center in 2008. Its parent institutions include University of Maryland School of Medicine and University of Maryland Medical System.			Professional or Occupational Group	
C105629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105629>	C19980	University of New Mexico Cancer Center|UNM Cancer Center|UNMCC	The mission of the University of New Mexico Cancer Center is to reduce the burden of cancer incidence and mortality by discovering the genetic, environmental, social, and behavioral factors that contribute to the distinct cancer patterns and disparities in the American Southwest; translate its scientific discoveries to novel diagnostic, screening, prevention, and therapeutic tools and clinical trials; and assure that all New Mexicans have access to outstanding cancer treatment and clinical trials. It became an NCI-designated cancer center in 2005. It is a University of New Mexico center.			Professional or Occupational Group	
C10562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10562>	C61063	Fluorouracil/Leucovorin Calcium/PALA/Zidovudine|CF/5-FU/PALA/ZDV			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105630>	C19980	Winship Cancer Institute|Winship|Winship Cancer Institute of Emory University	Winship Cancer Institute is dedicated to the integration of innovative clinical and basic science research with patient care for the prevention, treatment, and control of cancer. It became an NCI-designated cancer center in 2009. It is a component of the Robert W. Woodruff Health Sciences Center of Emory University.			Professional or Occupational Group	
C105631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105631>	C54452	SPL Substance Indexing Terminology|Structured Product Labeling Substance Indexing Terminology	Terminology used for representation of the information with substance indexing in the framework of the Structured Product Labeling documents.	SPL Substance Indexing Terminology		Intellectual Product	FDA Structured Product Labeling Terminology
C105632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105632>	C33763	Left Thigh|LT|LT	A part of the lower limb, located between the hip and the knee and located on the left side of the body.			Body Part, Organ, or Organ Component	FDA Individual Case Safety Report Terminology|Vaccination Site on Body ICSR Terminology
C105633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105633>	C32141	Left Arm|LA|LA	The portion of the upper extremity between the shoulder and the wrist and located on the left side of the body.			Body Part, Organ, or Organ Component	CRF2 History and Physical Exam at Diagnosis Table|FDA Individual Case Safety Report Terminology|Vaccination Site on Body ICSR Terminology
C105634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105634>	C32446	Left Deltoid|LD|LD	The muscle that creates the rounded contour of the shoulder which originates from the lateral third of the clavicle, the superior surface of the acromion process, and the posterior border of the spine of the scapula and inserts on the lateral side of the shaft of the humerus. The deltoid muscle is innervated by the brachial plexus arising from the fifth and sixth cervical nerves and controls abduction, extension, flexion, and rotation of the arm. This is the deltoid on the left side of the body.			Body Part, Organ, or Organ Component	FDA Individual Case Safety Report Terminology|Vaccination Site on Body ICSR Terminology
C105635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105635>	C32446	Right Deltoid|RD|RD	The muscle that creates the rounded contour of the shoulder which originates from the lateral third of the clavicle, the superior surface of the acromion process, and the posterior border of the spine of the scapula and inserts on the lateral side of the shaft of the humerus. The deltoid muscle is innervated by the brachial plexus arising from the fifth and sixth cervical nerves and controls abduction, extension, flexion, and rotation of the arm. This is the deltoid on the right side of the body.			Body Part, Organ, or Organ Component	FDA Individual Case Safety Report Terminology|Vaccination Site on Body ICSR Terminology
C105636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105636>	C32141	Right Arm|RA|RA	The portion of the upper extremity between the shoulder and the wrist and located on the right side of the body.			Body Part, Organ, or Organ Component	CRF2 History and Physical Exam at Diagnosis Table|FDA Individual Case Safety Report Terminology|Vaccination Site on Body ICSR Terminology
C105637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105637>	C33763	Right Thigh|RT|RT	A part of the lower limb, located between the hip and the knee and located on the right side of the body.			Body Part, Organ, or Organ Component	FDA Individual Case Safety Report Terminology|Vaccination Site on Body ICSR Terminology
C105638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105638>	C52933	Left Gluteus Medius|LG|LG	One of the three gluteal muscles on the lateral surface of the pelvic bone that abducts and rotates the thigh located on the left side of the body.			Body Part, Organ, or Organ Component	FDA Individual Case Safety Report Terminology|Vaccination Site on Body ICSR Terminology
C105639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105639>	C52933	Right Gluteus Medius|RG|RG	One of the three gluteal muscles on the lateral surface of the pelvic bone that abducts and rotates the thigh located on the right side of the body.			Body Part, Organ, or Organ Component	FDA Individual Case Safety Report Terminology|Vaccination Site on Body ICSR Terminology
C10563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10563>	C61063	Somatuline/Suramin|Somatuline/SUR|Suramin/Somatuline			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105640>	C53073	Left Vastus Lateralis|LVL|LVL	The largest muscle in the quadriceps femoris that is responsible for extending and stabilizing the knee located on the left side of the body.			Body Part, Organ, or Organ Component	FDA Individual Case Safety Report Terminology|Vaccination Site on Body ICSR Terminology
C105641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105641>	C53073	Right Vastus Lateralis|RVL|RVL	The largest muscle in the quadriceps femoris that is responsible for extending and stabilizing the knee located on the right side of the body.			Body Part, Organ, or Organ Component	FDA Individual Case Safety Report Terminology|Vaccination Site on Body ICSR Terminology
C105642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105642>	C32628	Left Lower Forearm|LLFA|LLFA	The distal half of the left upper limb between the elbow and the wrist.			Body Part, Organ, or Organ Component	FDA Individual Case Safety Report Terminology|Vaccination Site on Body ICSR Terminology
C105643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105643>	C32628	Right Lower Forearm|RLFA|RLFA	The distal half of the right upper limb between the elbow and the wrist.			Body Part, Organ, or Organ Component	FDA Individual Case Safety Report Terminology|Vaccination Site on Body ICSR Terminology
C105644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105644>	C28566	Microtubule-Associated Proteins 1A/1B Light Chain 3-II|LC3 II|LC3-II|MAP1LC3-II	Microtubule-associated proteins 1A/1B light chain 3-II proteins (LC3-II) are products of the autophagy-dependent processing of microtubule-associated proteins 1A/1B light chain 3 family proteins (LC3). During autophagy, LC3 proteins are cleaved by cysteine protease ATG4B to form LC3-I intermediates which are located in the cytoplasm. As autophagy progresses, LC3-I proteins interact with both ubiquitin-like modifier-activating enzyme ATG7 and ubiquitin-like-conjugating enzyme ATG3. These interactions result in further proteolysis and the conjugation of a phospholipid anchor to form the membrane localized LC3-II.	Microtubule-Associated Proteins 1A/1B Light Chain 3-II		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105645>	C21080	DNA Replication Timing|Replication Timing|Replication Timing Program	The process that establishes the temporal order of the replication of segments of DNA along a chromosome or in an entire genome.	DNA Replication Timing		Genetic Function	CTRP Biomarker Terminology|CTRP Terminology
C105646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105646>	C212853	MLL/MLLT11 Fusion Gene|KMT2A::MLLT11 Fusion Gene|MLL-AF1q Fusion Gene|MLL-MLLT11 Fusion Gene|MLL/AF1q Fusion Gene|MLL::MLLT11 Fusion Gene	A fusion gene that results from a chromosomal translocation t(1;11)(q21;q23) which fuses the first 6 exons of the MLL gene to the 5' untranslated region of the MLLT11 gene. This rearrangement is associated with acute myelomonocytic leukemia.	MLL/MLLT11 Fusion Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105647>	C213256	MLL/MLLT11 Fusion Protein|Histone-Lysine N-Methyltransferase MLL/Protein AF1q Fusion Protein|KMT2A::MLLT11 Fusion Protein|MLL-AF1q Fusion Protein|MLL-MLLT11 Fusion Protein|MLL/AF1q Fusion Protein|MLL::MLLT11 Fusion Protein	A fusion protein encoded by the MLL/MLLT11 fusion gene. This protein is comprised of the N-terminal half of the histone-lysine N-methyltransferase MLL protein, including the AT hook DNA binding domain and the DNA methyltransferase domain, fused to the N-terminus of the entire protein AF1q.	MLL/MLLT11 Fusion Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105648>	C54306	XAGE1 Family Gene|CT12.1|Cancer-Testis Antigen 12.1 Gene|Cancer/Testis Antigen Family 12, Member 1 Gene|G Antigen Family D Member 2 Gene|GAGED2|X Antigen Family, Member 1|X Antigen Family, Member 1 Gene|XAGE-1|XAGE1	A subfamily of the GAGE gene family that is comprised of at least 5 nearly identical loci clustered in the vicinity of Xp11.22.	XAGE1 Family Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105649>	C54306	Cancer/Testis Antigen Family 47 Gene|CT47|CT47A|Cancer/Testis Antigen 47|Cancer/Testis Antigen Family 47	A family of genes that is comprised of 13 nearly identical loci that are clustered in the vicinity of Xq24.	Cancer/Testis Antigen Family 47 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10564>	C61063	Flutamide/Leuprolide/Somatuline/Suramin|FLUT/LEUP/somatuline/SUR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105650>	C13377	C-Circle|C-Circles|CC|Extrachromosomal Telomeric C-Rich DNA Circles|Partially Double-Stranded Circles of Telomeric C-Strand DNA	A stretch of telomeric DNA where the normally guanine-rich (TTAGGG)n overhanging sequence has gaps while the cytosine-rich (AATCCC)n opposite strand remains intact. The resulting partially single-stranded telomere can adopt a circular confirmation.	C-Circle		Cell Component	CTRP Biomarker Terminology|CTRP Terminology
C105651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105651>	C20348	DIABLO Gene|DIABLO|DIABLO|Diablo IAP-Binding Mitochondrial Protein Gene|Diablo, IAP-Binding Mitochondrial Protein Gene	This gene plays a role in the positive regulation of apoptosis.	DIABLO Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105652>	C105651	DIABLO wt Allele|DFNA64|DIABLO-S|Diablo IAP-Binding Mitochondrial Protein wt Allele|Diablo, IAP-Binding Mitochondrial Protein Gene|FLJ10537|FLJ25049|SMAC|SMAC3|hCG_1782202	Human DIABLO wild-type allele is located in the vicinity of 12q24.31 and is approximately 20 kb in length. This allele, which encodes diablo IAP-binding mitochondrial protein, is involved in the promotion of caspase-mediated apoptosis. Mutation of the gene is associated with deafness autosomal dominant type 64.	DIABLO wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105653>	C19928	Diablo IAP-Binding Mitochondrial Protein|DIABLO|Diablo Homolog, Mitochondrial|Diablo Homolog, Mitochondrial|Direct IAP-Binding Protein with Low pI|Second Mitochondria-Derived Activator of Caspase|Smac	Diablo IAP-binding mitochondrial protein (239 aa, ~27 kDa) is encoded by the human DIABLO gene. This protein plays a role in the activation of caspase-dependent apoptosis.	Diablo Homolog, Mitochondrial		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105654>	C20194	LAGE3 Gene|L Antigen Family, Member 3 Gene|LAGE3|LAGE3	This gene has no known function.	LAGE3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105655>	C105654	LAGE3 wt Allele|CVG5|DNA Segment on Chromosome X (Unique) 9879 Expressed Sequence Gene|DXS9879E|DXS9951E|ESO3|ITBA2|L Antigen Family, Member 3 wt Allele|XX-FW81657B9.4	Human LAGE3 wild-type allele is located in the vicinity of Xq28 and is approximately 2 kb in length. This allele, which encodes L antigen family member 3 protein, has no known function.	LAGE3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105656>	C18466	L Antigen Family Member 3|LAGE3|Protein ESO-3|Protein ITBA2	L antigen family member 3 (143 aa, ~15 kDa) is encoded by the human LAGE3 gene. This protein has no known function.	L Antigen Family Member 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105657>	C25997	ITSN1 Gene|ITSN1|ITSN1|Intersectin 1 (SH3 Domain Protein) Gene	This gene plays a role in both signal transduction and endocytosis.	ITSN1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105658>	C105657	ITSN1 wt Allele|Human Intersectin-SH3 Domain-Containing Protein SH3P17 Gene|ITSN|Intersectin 1 (SH3 Domain Protein) wt Allele|SH3D1A|SH3P17	Human ITSN1 wild-type allele is located within 21q22.1-q22.2 and is approximately 257 kb in length. This allele, which encodes intersectin-1 protein, is involved in both vesicle endocytosis and small GTPase-mediated signaling.	ITSN1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105659>	C26231	Intersectin-1|ITSN1|SH3 Domain-Containing Protein 1A|SH3P17	Intersectin-1 (1721 aa, ~195 kDa) is encoded by the human ITSN1 gene. This protein plays a role in the regulation of both small GTPase activity and clathrin-dependent endocytosis.	Intersectin-1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10565>	C61063	Interleukin-2/Interleukin-6|IL-2/IL-6			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105660>	C19896	Allelic Imbalance|Allele Imbalance	Any variance from the expected 1:1 ratio for the expression of the two inherited parental alleles for the same gene.	Allelic Imbalance		Qualitative Concept	CTRP Biomarker Terminology|CTRP Terminology
C105661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105661>	C21240	NCL Gene|NCL|NCL|Nucleolin Gene	This gene is involved in ribosome assembly.	NCL Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105662>	C105661	NCL wt Allele|C23|Nucleolin wt Allele	Human NCL wild-type allele is located in the vicinity of 2q37.1 and is approximately 30 kb in length. This allele, which encodes nucleolin protein, plays a role in both ribosomal assembly and chromosome decondensation.	NCL wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105663>	C38576	Nucleolin|NCL|Protein C23	Nucleolin (710 aa, ~77 kDa) is encoded by the human NCL gene. This protein is involved in both chromatin decondensation and ribosome assembly.	Nucleolin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105664>	C25870	GSTM4 Gene|GSTM4|GSTM4|Glutathione S-Transferase Mu 4 Gene	This gene plays a role in the metabolism of both glutathione and xenobiotics.	GSTM4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105665>	C105664	GSTM4 wt Allele|GSTM4-4|GTM4|Glutathione S-Transferase Mu 4 wt Allele	Human GSTM4 wild-type allele is located in the vicinity of 1p13.3 and is approximately 9 kb in length. This allele, which encodes glutathione S-transferase Mu 4 protein, is involved in xenobiotic metabolism.	GSTM4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105666>	C20075	Glutathione S-Transferase Mu 4|EC 2.5.1.18|GST Class-Mu 4|GST-Mu2|GSTM4|GSTM4-4|Glutathione S-Alkyltransferase M4|Glutathione S-Aralkyltransferase M4|Glutathione S-Aryltransferase M4|Glutathione S-Transferase M4|S-(Hydroxyalkyl)Glutathione Lyase M4	Glutathione S-transferase Mu 4 (218 aa, ~26 kDa) is encoded by the human GSTM4 gene. This protein plays a role in the metabolism of glutathione, 1-chloro-2,4-dinitrobenzene and other xenobiotics.	Glutathione S-Transferase Mu 4		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105667>	C52657	ARIA Oncology Information System|ARIA	A proprietary information and image management system designed to oversee oncology care.			Intellectual Product	
C105668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105668>	C52657	MOSAIQ Oncology Information Management System|MOSAIQ	A proprietary information management system designed as a vendor-neutral platform that collects radiation oncology and medical oncology patient data into a single user interface.			Intellectual Product	
C105669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105669>	C52657	ONCOCHART Management Tool|ONCOCHART	A proprietary charge capture, documentation and electronic medical record system for radiation oncology.			Intellectual Product	
C10566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10566>	C61007	Fluorouracil/Leucovorin Calcium/Trimetrexate Glucuronate|CF/5-FU/TMTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105670>	C52657	MEDITECH Health Record System|MEDITECH	Any of the electronic health record systems and solutions developed by the MEDITECH corporation.			Intellectual Product	
C105671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105671>	C52657	McKesson Health Record System|McKesson	Any of the electronic health record systems and solutions developed by the McKesson corporation.			Intellectual Product	
C105672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105672>	C52657	Epic Health Record System|Epic	Any of the electronic health record systems and solutions developed by the Epic corporation.			Intellectual Product	
C105673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105673>	C52657	NextGen Healthcare Record System|NextGen	Any of the electronic health record systems and solutions developed by the NextGen corporation.			Intellectual Product	
C105674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105674>	C17146	BrainLab iPlan	A proprietary treatment planning system that uses template-based workflow to facilitate the planning for Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiotherapy (SBRT).			Manufactured Object	
C105675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105675>	C17146	Varian Eclipse	A proprietary treatment planning system for radiation therapy planning.			Manufactured Object	
C105676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105676>	C17146	Nucletron Oncentra	A proprietary DICOM-compliant treatment planning software system.			Manufactured Object	
C105677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105677>	C17146	Philips Pinnacle	A proprietary radiation therapy planning system developed by the Philips corporation.			Manufactured Object	
C105678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105678>	C17146	Elekta Xio	A proprietary 3D intensity-modulated radiation therapy treatment planning platform developed by the Elekta corporation.			Manufactured Object	
C105679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105679>	C30073	KRT5 Gene|KRT5|KRT5|Keratin 5 Gene	This gene is involved in epidermal integrity.	KRT5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10567>	C61063	Asparaginase/Cytarabine/Mercaptopurine/Methotrexate/Vincristine|ARA-C/ASP/MP/MTX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105680>	C105679	KRT5 wt Allele|CK5|DDD|DDD1|EBS2|Epidermolysis Bullosa Simplex 2 Dowling-Meara/Kobner/Weber-Cockayne Types Gene|K5|KRT5A|Keratin 5 (Epidermolysis Bullosa Simplex, Dowling-Meara/Kobner/Weber-Cockayne Types) Gene|Keratin 5 wt Allele|Keratin 5, Type II Gene	Human KRT5 wild-type allele is located in the vicinity of 12q13.13 and is approximately 6 kb in length. This allele, which encodes keratin, type II cytoskeletal 5 protein, plays a role in the formation of the epidermis. Mutation of the gene is associated with Dowling-Degos disease and several subtypes of epidermolysis bullosa simplex.	KRT5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105681>	C20694	Keratin, Type II Cytoskeletal 5|58 kDa Cytokeratin|CK-5|Cytokeratin-5|K5|KRT5|Keratin-5|Type-II Keratin Kb5	Keratin, type II cytoskeletal 5 (590 aa, ~62 kDa) is encoded by the human KRT5 gene. This protein is involved in the structure of the epidermis.	Keratin, Type II Cytoskeletal 5		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105682>	C30073	KRT72 Gene|KRT72|KRT72|Keratin 72 Gene	This gene plays a role in hair formation.	KRT72 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105683>	C105682	KRT72 wt Allele|CK6|Cytokeratin 72 Gene|K6IRS2|K6irs|KB35|KRT6|KRT6IRS2|Keratin 6, Inner Root Sheath, 2 Gene|Keratin 72 wt Allele|Keratin 72, Type II Gene|Keratin, Type II Cytoskeletal 72 Gene	Human KRT72 wild-type allele is located in the vicinity of 12q13.13 and is approximately 16 kb in length. This allele, which encodes keratin, type II cytoskeletal 72 protein, is involved in the formation of hair.	KRT72 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105684>	C20694	Keratin, Type II Cytoskeletal 72|CK-6|CK-72|Cytokeratin 72|Cytokeratin-72|K72|KRT72|Keratin 72|Keratin Protein K6irs|Keratin-72|Type II Inner Root Sheath-Specific Keratin-K6irs2|Type-II Keratin Kb35	Keratin, type II cytoskeletal 72 (511 aa, ~56 kDa) is encoded by the human KRT72 gene. This protein plays a role in hair formation.	Keratin, Type II Cytoskeletal 72		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105685>	C17153	Emergency Medicine	The medical specialty concerned with the prompt diagnosis and treatment of injuries, trauma, or sudden illness.			Biomedical Occupation or Discipline	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C105686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105686>	C16962	Neonatology	A branch of pediatric medicine focused on the diagnosis and treatment of newborns.			Biomedical Occupation or Discipline	
C105687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105687>	C17173	Neurosurgery|Neurological Surgery	A surgical specialty concerned with surgical treatment of the nervous system.			Biomedical Occupation or Discipline	
C105688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105688>	C17153	Obstetrics and Gynecology|OBG/GYN|OBGYN	A medical specialty concerned with the female reproductive organs in their pregnant and non-pregnant states.			Biomedical Occupation or Discipline	
C105689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105689>	C17153	Physical Medicine and Rehabilitation|Physiatry|Rehabilitation Medicine	A medical specialty focused on restoring functional ability and quality of life to people with physical impairments or disabilities.			Biomedical Occupation or Discipline	
C10568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10568>	C61063	Asparaginase/Mercaptopurine/Methotrexate/Pegaspargase/Vincristine|ARA-C/MP/MTX/PEG-ASP/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105690>	C17153	Podiatry	A medical specialty concerned with care and treatment of human feet in health and disease.			Biomedical Occupation or Discipline	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C105691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105691>	C54447	Vaccination Site on Body ICSR Terminology	Terminology used in Individual Case Safety Reports to specify an anatomic site where a vaccination was administered.			Intellectual Product	FDA Individual Case Safety Report Terminology
C105692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105692>	C16749	Pulmonary Medicine|Pulmonary|Pulmonology	A medical specialty concerned with diagnosis and treatment of lung disorders and other breathing problems.			Biomedical Occupation or Discipline	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C105693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105693>	C17153	Sports Medicine	A medical specialty concerned with the diagnosis and treatment or injuries or illness resulting from athletic activities.			Biomedical Occupation or Discipline	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C105694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105694>	C17173	General Surgery	A surgical specialty that focuses on surgical management of diseases of the abdominal organs.			Biomedical Occupation or Discipline	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C105695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105695>	C20745	PDLIM2 Gene|PDLIM2|PDLIM2|PDZ and LIM Domain 2 (Mystique) Gene	This gene is involved in the regulation of both cell migration and cell adhesion.	PDLIM2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105696>	C105695	PDLIM2 wt Allele|MYSTIQUE|PDZ and LIM Domain 2 (Mystique) wt Allele|PP6345|SLIM	Human PDLIM2 wild-type allele is located in the vicinity of 8p21.3 and is approximately 20 kb in length. This allele, which encodes PDZ and LIM domain protein 2, plays a role in cytoskeletal processes involved in cell adhesion.	PDLIM2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105697>	C16492	PDZ and LIM Domain Protein 2|PDLIM2|PDZ-LIM Protein Mystique|STAT-Interacting LIM Protein	PDZ and LIM domain protein 2 (352 aa, ~37 kDa) is encoded by the human PDLIM2 gene. This protein is involved in actin binding, cell migration and cell adhesion.	PDZ and LIM Domain Protein 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105698>	C17173	Hand Surgery	A surgical specialty concerned with the surgical management of disease, disability, or injury of the upper extremity.			Biomedical Occupation or Discipline	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C105699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105699>	C17173	Vascular Surgery	A surgical specialty that focuses on diagnosis and management of disorders of the arterial, venous and lymphatic systems, other than the intracranial vessels and the heart.			Biomedical Occupation or Discipline	
C10569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10569>	C61063	Dexamethasone/Doxorubicin/Methotrexate/Pegaspargase/Vincristine|DM/DOX/MTX/PEG-ASP/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1056>	C2139	Copovithane|BAY I 7433|COPOVITHANE|CPV	A synthetic polymer (copolymer of 1,3-bis(methylaminocarboxyl)-2-methylenepropanecarbamate and N-vinyl pyrrolidone) of low molecular weight which acts as a nonspecific immune modulator and has been shown to have significant antitumor activity in vitro and in vivo in preclinical and some early clinical studies. The mechanism of action is unknown. Immunologic evaluation revealed some improvement in helper and suppressor T cell ratio, in vitro cytotoxicity tests, and lymphocyte blastogenic response. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C105700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105700>	C17173	Urological Surgery	A surgical specialty concerned with surgical treatment of the diseases of the urinary tract and urogenital system.			Biomedical Occupation or Discipline	
C105701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105701>	C25712	Detection Limit|LLOD|LOD|Limit of Detection|Lower Limit of Detection|Lower Limit of Detection	The smallest concentration of an analyte that can be determined with a stated precision or confidence.			Conceptual Entity	CDISC ADaM Derivation Type Terminology|Clinical Data Interchange Standards Consortium Terminology
C105702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105702>	C20194	PGBD5 Gene|PGBD5|PGBD5|PiggyBac Transposable Element Derived 5 Gene	This gene may play a role in gene transposition.	PGBD5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105703>	C105702	PGBD5 wt Allele|DKFZp761A0620|FLJ11413|PiggyBac Transposable Element Derived 5 wt Allele|PiggyBac Transposable Element-Derived Gene 5	Human PGBD5 wild-type allele is located in the vicinity of 1q42.13 and is approximately 104 kb in length. This allele, which encodes piggyBac transposable element-derived protein 5, may involved in transposition.	PGBD5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105704>	C45781	Molecular Density	The number of molecules contained in a specific volume.			Conceptual Entity	
C105705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105705>	C45781	Unit Density	The number of arbitrary units of something contained in a specific volume.			Conceptual Entity	
C105706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105706>	C204466	Serum or Plasma|SERUM OR PLASMA|Ser/Plas	The non-cellular portion of the circulating blood, with or without the clotting proteins present.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C105707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105707>	C28013	Karnofsky Performance Status 100|100|100|100|100|100: Normal, no complaints; no evidence of disease|Australia-Modified Karnofsky Performance Status 100	Normal; no complaints; no evidence of disease.			Clinical Attribute	Australia-Modified Karnofsky Performance Status|CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Normal Endometrial Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form|CRF1 Registration Table|EWS Authorized Value Terminology|EWS Disease Characteristics Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Disease Characteristics Table|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C105708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105708>	C18466	PiggyBac Transposable Element-Derived Protein 5|PGBD5|PiggyBac Domain-Related Protein 5|PiggyBac Transposase 5	PiggyBac transposable element-derived protein 5 (455 aa, ~52 kDa) is encoded by the human PGBD5 gene. This protein may play a role in transposable DNA element movement.	PiggyBac Transposable Element-Derived Protein 5		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105709>	C28013	Karnofsky Performance Status 90|90|90|90|90|90: Able to carry on normal activity; minor signs or symptoms of disease|Australia-Modified Karnofsky Performance Status 90	Able to carry on normal activity; minor signs or symptoms of disease.			Clinical Attribute	Australia-Modified Karnofsky Performance Status|CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Normal Endometrial Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form|CRF1 Registration Table|EWS Authorized Value Terminology|EWS Disease Characteristics Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Disease Characteristics Table|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C10570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10570>	C61063	Asparaginase/Dexamethasone/Doxorubicin/Mercaptopurine/Methotrexate/Vincristine|ASP/DM/DOX/MP/MTX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105710>	C28013	Karnofsky Performance Status 80|80|80|80|80|80: Normal activity with effort; some signs or symptoms of disease|Australia-Modified Karnofsky Performance Status 80	Normal activity with effort; some sign or symptoms of disease.			Clinical Attribute	Australia-Modified Karnofsky Performance Status|CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Normal Endometrial Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form|CRF1 Registration Table|EWS Authorized Value Terminology|EWS Disease Characteristics Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Disease Characteristics Table|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C105711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105711>	C28013	Karnofsky Performance Status 70|70|70|70|70|70: Cares for self; unable to carry on normal activity or to do active work|Australia-Modified Karnofsky Performance Status 70	Cares for self; unable to carry on normal activity or do active work.			Clinical Attribute	Australia-Modified Karnofsky Performance Status|CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Normal Endometrial Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form|CRF1 Registration Table|EWS Authorized Value Terminology|EWS Disease Characteristics Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Disease Characteristics Table|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C105712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105712>	C28013	Karnofsky Performance Status 60|60|60|60|60|60: Requires occasional assistance; but is able to care for most of his/her needs|Australia-Modified Karnofsky Performance Status 60	Requires occasional assistance, but is able to care for most personal needs.			Clinical Attribute	Australia-Modified Karnofsky Performance Status|CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Normal Endometrial Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form|CRF1 Registration Table|EWS Authorized Value Terminology|EWS Disease Characteristics Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Disease Characteristics Table|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C105713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105713>	C28013	Karnofsky Performance Status 50|50|50|50|50|50: Requires considerable assistance and frequent medical care|Australia-Modified Karnofsky Performance Status 50	Requires considerable assistance and frequent medical care.			Clinical Attribute	Australia-Modified Karnofsky Performance Status|CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Normal Endometrial Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form|CRF1 Registration Table|EWS Authorized Value Terminology|EWS Disease Characteristics Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Disease Characteristics Table|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C105714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105714>	C28013	Karnofsky Performance Status 40|40|40|40|40|40: Disabled; requires special care	Disabled; requires special care and assistance.			Clinical Attribute	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Normal Endometrial Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form|CRF1 Registration Table|EWS Authorized Value Terminology|EWS Disease Characteristics Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Disease Characteristics Table|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C105715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105715>	C28013	Karnofsky Performance Status 30|30|30|30|30|30: Severely disabled	Severely disabled; hospitalization is indicated, although death not imminent.			Clinical Attribute	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Normal Endometrial Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form|CRF1 Registration Table|EWS Authorized Value Terminology|EWS Disease Characteristics Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Disease Characteristics Table|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C105716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105716>	C28013	Karnofsky Performance Status 20|20|20|20|20|20: Very sick; requiring hospitalization	Very sick; hospitalization necessary; active support treatment is necessary.			Clinical Attribute	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Normal Endometrial Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form|CRF1 Registration Table|EWS Authorized Value Terminology|EWS Disease Characteristics Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Disease Characteristics Table|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C105717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105717>	C20921	DACT2 Gene|DACT2|DACT2|Dapper, Antagonist of Beta-Catenin, Homolog 2 (Xenopus laevis) Gene	This gene is involved in the regulation of signaling pathways.	DACT2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105718>	C28013	Karnofsky Performance Status 10|10|10|10|10|10: Moribund; fatal processes progressing rapidly	Moribund; fatal processes progressing rapidly.	Roughly equivalent to ECOG 4		Clinical Attribute	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Normal Endometrial Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form|CRF1 Registration Table|EWS Authorized Value Terminology|EWS Disease Characteristics Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Disease Characteristics Table|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C105719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105719>	C105717	DACT2 wt Allele|C6orf116|Chromosome 6 Open Reading Frame 116 Gene|DAPPER2|DPR2|Dapper, Antagonist of Beta-Catenin, Homolog 2 (Xenopus laevis) wt Allele|PP13671|RP11-503C24.7|bA503C24.7	Human DACT2 wild-type allele is located in the vicinity of 6q27 and is approximately 27 kb in length. This allele, which encodes dapper homolog 2 protein, plays a role in the negative regulation of signal transduction.	DACT2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10571>	C61063	Asparaginase/Dexamethasone/Doxorubicin/Methotrexate/Vincristine|ASP/DM/DOX/MTX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105720>	C28013	Karnofsky Performance Status 0|0|0|0|0|0: Dead|Australia-Modified Karnofsky Performance Status 0	Dead.			Clinical Attribute	Australia-Modified Karnofsky Performance Status|CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Normal Endometrial Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form|CRF1 Registration Table|EWS Authorized Value Terminology|EWS Disease Characteristics Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Disease Characteristics Table|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C105721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105721>	C20641	ECOG Performance Status|ECOG|ECOG Score|Eastern Cooperative Oncology Group Performance Status|ecog performance status|ecog performance status|ecog_performance_status|ecog_performance_status	A performance status scale designed to assess disease progression and its affect on the daily living abilities of the patient.			Clinical Attribute	CTDC Property Terminology|GDC Property Terminology|GDC Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C105722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105722>	C105721	ECOG Performance Status 0|0|0: Asymptomatic|ECOG 0	Fully active, able to carry on all pre-disease performance without restriction.	ECOG Performance Status 0		Clinical Attribute	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form|CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C105723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105723>	C105721	ECOG Performance Status 1|1|1: Symptomatic, but fully ambulatory|ECOG 1	Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.	ECOG Performance Status 1		Clinical Attribute	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form|CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C105724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105724>	C18515	Dapper Homolog 2|DACT2|Dapper Antagonist of Catenin 2	Dapper homolog 2 (774 aa, ~83 kDa) is encoded by the human DACT2 gene. This protein is involved in the inhibition of signal transduction.	Dapper Homolog 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105725>	C105721	ECOG Performance Status 2|2|2: Symptomatic, in bed less than 50% of day|ECOG 2	Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours.	ECOG Performance Status 2		Clinical Attribute	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form|CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C105726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105726>	C105721	ECOG Performance Status 3|3|3: Symptomatic, in bed more than 50% of day, but not bed-ridden|ECOG 3	Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours.			Clinical Attribute	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C105727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105727>	C105721	ECOG Performance Status 4|4|4: Bed-ridden|ECOG 4	Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair.			Clinical Attribute	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C105728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105728>	C105721	ECOG Performance Status 5|5|ECOG 5	Dead.			Clinical Attribute	GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C105729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105729>	C26147	DAD1 Gene|DAD1|DAD1|Defender Against Cell Death 1 Gene	This gene plays a role in peptide glycosylation.	DAD1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10572>	C61063	Asparaginase/Dexamethasone/Mercaptopurine/Methotrexate/Vincristine|ASP/DM/MP/MTX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105730>	C105729	DAD1 wt Allele|Defender Against Cell Death 1 wt Allele|OST2|Oligosaccharyltransferase 2 Homolog (S. cerevisiae) Gene	Human DAD1 wild-type allele is located 14q11.2 and is approximately 24 kb in length. This allele, which encodes dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit DAD1 protein, is involved in the glycosylation of proteins.	DAD1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105731>	C41075|C192572	Stranded Seed Implant|Stranded Seed	An implant consisting of multiple radioactive pellets linked together.			Medical Device	
C105732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105732>	C41075|C192572	Loose Seed Implant|Loose Seed	A radioactive implant consisting of individual pellets.			Medical Device	
C105733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105733>	C33904	Whole-Pelvis	All of the tissues and organs within the pelvic cavity considered together. This is generally taken to mean the prostate gland, seminal vesicles, and pelvic lymph nodes.			Conceptual Entity	
C105734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105734>	C17434	Dolichyl-Diphosphooligosaccharide-Protein Glycosyltransferase Subunit DAD1|DAD-1|DAD1|Defender Against Cell Death 1|Dolichyl-Diphosphooligosaccharide--Protein Glycosyltransferase Subunit DAD1|Dolichyl-Diphosphooligosaccharide—Protein Glycosyltransferase Subunit DAD1|EC 2.4.99.18|Oligosaccharyl Transferase Subunit DAD1	Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit DAD1 (113 aa, ~12 kDa) is encoded by the human DAD1 gene. This protein plays a role in the addition of high-mannose oligosaccharides to asparagine residues.	Dolichyl-Diphosphooligosaccharide-Protein Glycosyltransferase Subunit DAD1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105735>	C81239	Homicide and Legal Intervention	Causes of death attributable to homicide or resulting from legal police intervention.			Finding	
C105736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105736>	C36291	Accidents and Adverse Effects	Causes of death attributable to accidents or their adverse events.			Finding	
C105737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105737>	C21295	SELENOP Gene|SELENOP|SELENOP|SEPP1|Selenoprotein P Gene	This gene is involved in selenium metabolism.	SELENOP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105738>	C105737	SELENOP wt Allele|SELP|SEPP|SEPP1|SeP|Selenoprotein P wt Allele|Selenoprotein P, Plasma, 1 Gene|Selenoprotein P, Plasma,1 Gene	Human SELENOP wild-type allele is located in the vicinity of 5q12 and is approximately 88 kb in length. This allele, which encodes selenoprotein P, plays a role in selenium distribution.	SELENOP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105739>	C20315	Selenoprotein P|SELENOP|SEPP1|SeP	Selenoprotein P (381 aa, ~43 kDa) is encoded by the human SELENOP gene. This protein is involved in the modulation of selenium metabolism.	Selenoprotein P		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10573>	C61063	Dexamethasone/Doxorubicin/Mercaptopurine/Methotrexate/Pegaspargase/Vincristine Regimen|DM/DOX/MP/MTX/PEG-ASP/VCR|Dexamethasone-Doxorubicin-Mercaptopurine-Methotrexate-Pegaspargase-Vincristine|Dexamethasone/Doxorubicin/Mercaptopurine/Methotrexate/Pegaspargase/Vincristine|Doxorubicin/Mercaptopurine/Methotrexate/Pegaspargase/Vincristine/Dexamethasone	A regimen consisting of dexamethasone, doxorubicin, mercaptopurine, methotrexate, pegaspargase, and vincristine that may be used in the treatment of acute lymphoblastic leukemia (ALL).			Therapeutic or Preventive Procedure	
C105740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105740>	C45501	Treatment Completed as Prescribed|Treatment Completed|Treatment completed (situation)	Indicates that the patient was fully compliant with the full course of treatment.			Clinical Attribute	mCode Terminology|mCode Treatment Termination Reason Value Set|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C105741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105741>	C45501	Treatment Terminated Due to Toxicity|Treatment Stopped Due to Toxicity	Indicates that the patient terminated the treatment due to toxicity related to the treatment.			Clinical Attribute	GDC Terminology|GDC Value Terminology
C105742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105742>	C16696	Non-Academic Hospital	A hospital that is not affiliated with a university.			Health Care Related Organization	
C105743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105743>	C211570	Free-Standing Clinic	A facility that provides medical care that can be safely performed without requiring inpatient hospital care.			Health Care Related Organization	
C105744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105744>	C49237	Sediment Analysis|Microscopic Sediment Analysis|SEDEXAM|Sediment Examination|Sediment Examination	An observation, assessment or examination of the sediment in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C105745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105745>	C91105	Breast Lymphedema Symptom Survey|BLSS	A self-administered questionnaire designed to measure the degree of distress associated with the signs and symptoms of lymphedema in an operated breast.			Intellectual Product	
C105746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105746>	C173791|C173593|C173219	Breast Appears or Feels Swollen Question|Breast Appears or Feels Swollen|Does your breast appear or feel swollen	A question about whether an individual feels their breast is or was swollen.			Intellectual Product	Breast Lymphedema Symptom Survey
C105747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105747>	C173561	How Much Does It Bother You Question|How Much Bothered|How Much Does It Bother You|How much does it bother you	A question about how much something bothers an individual.			Intellectual Product	Breast Lymphedema Symptom Survey|Symptom Screening in Pediatrics
C105748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105748>	C173791|C173219	Breast Feels Heavy Question|Breast Feels Heavy|Does your breast feel heavy	A question about whether an individual feels their breast is or was heavy.			Intellectual Product	Breast Lymphedema Symptom Survey
C105749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105749>	C173791	Breast Appears Redder Question|Breast Appears Redder|Is your breast redder in color	A question about whether an individual thinks the color of their breast is or was redder.			Intellectual Product	Breast Lymphedema Symptom Survey
C10574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10574>	C61007	Dexamethasone/Mercaptopurine/Methotrexate/Pegaspargase/Vincristine|DM/MP/MTX/PEG-ASP/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105750>	C173791|C156140	Have Pain, Tenderness, or Discomfort in Breast Question|Do you have pain, tenderness, or discomfort in your breast|Have Pain, Tenderness, or Discomfort in Breast	A question about whether an individual has or had pain, tenderness or discomfort in their breast.			Intellectual Product	Breast Lymphedema Symptom Survey
C105751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105751>	C173981	Have Axillary Fullness or Numbness Question|Do you have axillary fullness or numbness|Have Axillary Fullness or Numbness	A question about whether an individual has axillary fullness or numbness.			Intellectual Product	Breast Lymphedema Symptom Survey
C105752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105752>	C48792	Study Element|ELEMENT	An artifact that is one of the individual components of the study.			Conceptual Entity	CDISC Variable Terminology
C105753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105753>	C54443	Toxicity Grade Scale Type Terminology	Terminology codelist containing values associated with identifiable classes of grading scales used to classify toxicity.			Intellectual Product	
C105754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105754>	C54091|C19498	Human Clinical Subject Data Section	A section within the study document pertaining to data collected from human clinical study subjects.			Intellectual Product	
C105755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105755>	C54091|C19498	Non-human Clinical Subject Data Section	A section within the study document pertaining to data collected from non-human clinical study subjects.			Intellectual Product	
C105756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105756>	C25638	Serious Adverse Event Reason	The rationale for why the adverse event was reported as being serious.			Idea or Concept	
C105757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105757>	C54443	Serious Adverse Event Reason Type Terminology	Terminology codelist containing values associated with the rationale for why the adverse event was reported as being serious.			Intellectual Product	
C105758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105758>	C25457	Biospecimen Usability	A qualitative or quantitative measure that describes a biospecimen's suitability for testing purposes.			Qualitative Concept	
C105759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105759>	C199140	Subject Trial Set|TRIAL SET	The collection of subjects that have a common set of parameters defined in the protocol (could be experimental parameters, treatment parameters, or sponsor-defined attributes).			Population Group	CDISC SEND Reference ID Level Description Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10575>	C61007	Dexamethasone/Mercaptopurine/Methotrexate/Vincristine|DM/MP/MTX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105760>	C82550	Clinical Event Pattern	The pattern of a clinical event.			Idea or Concept	
C105761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105761>	C54443	True False Response Terminology	Terminology codelist used for any True False responses.			Intellectual Product	
C105762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105762>	C12236	Anterior Tonsillar Pillar	The anterior border of the tonsillar fossa.  It is composed of the palatoglossus muscle.			Body Space or Junction	
C105763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105763>	C91105	Lymphedema and Breast Cancer Questionnaire|LBCQ	A condensed version of a self-administered or structured interview questionnaire designed specifically for evaluating lymphedema symptoms after surgery for breast cancer.			Intellectual Product	
C105764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105764>	C173695	Have Limited Movement of Shoulder Question|Do you have limited movement of your shoulder|Have Limited Movement of Shoulder	A question about whether an individual has or had limited movement of their shoulder.			Intellectual Product	Lymphedema and Breast Cancer Questionnaire
C105765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105765>	C173695	Have Limited Movement of Elbow Question|Do you have limited movement of your elbow|Have Limited Movement of Elbow	A question about whether an individual has or had limited movement of their wrist.			Intellectual Product	Lymphedema and Breast Cancer Questionnaire
C105766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105766>	C173695	Have Limited Movement of Wrist Question|Do you have limited movement of your wrist|Have Limited Movement of Wrist	A question about whether an individual has or had limited movement of their wrist.			Intellectual Product	Lymphedema and Breast Cancer Questionnaire
C105767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105767>	C173695	Have Limited Movement of Fingers Question|Do you have limited movement of your fingers|Have Limited Movement of Fingers	A question about whether an individual has or had limited movement of their fingers.			Intellectual Product	Lymphedema and Breast Cancer Questionnaire
C105768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105768>	C104295	Feel Weakness in Arm or Hand Question|Does your arm or hand feel weak|Feel Weakness in Arm or Hand	A question about whether an individual has or had weakness in their arm or hand.			Intellectual Product	Lymphedema and Breast Cancer Questionnaire
C105769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105769>	C173981	Have Tenderness Question|Have Tenderness|Have you experienced tenderness	A question about whether an individual has or had tenderness.			Intellectual Product	Lymphedema and Breast Cancer Questionnaire
C10576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10576>	C61063	Asparaginase/Cyclophosphamide/Cytarabine/Filgrastim|ARA-C/ASP/CTX/G-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105770>	C173981|C173593	Have Swelling Question|Have Swelling|Have you experienced swelling	A question about whether an individual has or had swelling.			Intellectual Product	Lymphedema and Breast Cancer Questionnaire
C105771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105771>	C105770	Have Swelling with Pitting Question|Have Swelling with Pitting|Have you experienced swelling with pitting	A question about whether an individual has or had swelling or pitting; which occurs when you press firmly on your skin and the dent stays long enough to feel it when you slide the pad of your finger across it.			Intellectual Product	Lymphedema and Breast Cancer Questionnaire
C105772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105772>	C173981	Have Redness Question|Have Redness|Have you experienced redness	A question about whether an individual has or had redness.			Intellectual Product	Lymphedema and Breast Cancer Questionnaire
C105773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105773>	C173981	Have Blistering Question|Have Blistering|Have you experienced blistering	A question about whether an individual has or had blistering.			Intellectual Product	Lymphedema and Breast Cancer Questionnaire
C105774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105774>	C173981	Have Firmness or Tightness Question|Have Firmness or Tightness|Have you experienced firmness / tightness	A question about whether an individual has or had firmness or tightness.			Intellectual Product	Lymphedema and Breast Cancer Questionnaire
C105775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105775>	C173981	Have Increased Temperature in Arm Question|Have Increased Temperature in Arm|Have you experienced increased temperature in your arm	A question about whether an individual has or had increased temperature in arm.			Intellectual Product	Lymphedema and Breast Cancer Questionnaire
C105776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105776>	C173981	Have Heaviness Question|Have Heaviness|Have you experienced heaviness	A question about whether an individual has or had heaviness.			Intellectual Product	Lymphedema and Breast Cancer Questionnaire
C105777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105777>	C173734	Have Numbness Question|Have Numbness|Have you experienced numbness	A question about whether an individual has or had numbness.			Intellectual Product	Lymphedema and Breast Cancer Questionnaire
C105778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105778>	C173981	Have Stiffness Question|Have Stiffness|Have you experienced stiffness	A question about whether an individual has or had stiffness.			Intellectual Product	Lymphedema and Breast Cancer Questionnaire
C105779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105779>	C173981	Have Aching Question|Have Aching|Have you experienced aching	A question about whether an individual has or had aching.			Intellectual Product	Lymphedema and Breast Cancer Questionnaire
C10577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10577>	C61063	Asparaginase/Cyclophosphamide/Filgrastim|ARA-C/CTX/G-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105780>	C105770	Have Chest Wall Swelling Question|Have Chest Wall Swelling|Have you experienced chest wall swelling	A question about whether an individual has or had chest wall swelling.			Intellectual Product	Lymphedema and Breast Cancer Questionnaire
C105781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105781>	C173791|C105770	Have Breast Swelling Question|Have Breast Swelling|Have you experienced breast swelling	A question about whether an individual has or had breast swelling.			Intellectual Product	Lymphedema and Breast Cancer Questionnaire
C105782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105782>	C173981	Have Pockets of Fluid Develop Question|Have Pockets of Fluid Develop|Have you experienced pockets of fluid developing	A question about whether an individual has or had pockets of fluid develop.			Intellectual Product	Lymphedema and Breast Cancer Questionnaire
C105783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105783>	C173457	Have Other Symptoms Question|Have Other Symptoms|Have you experienced other symptoms|Other Symptoms	A question about whether an individual has or had other symptoms.			Intellectual Product	Lymphedema and Breast Cancer Questionnaire
C105784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105784>	C15677	Axillary Lymph Node Dissection without Prior Sentinel Lymph Node Biopsy	A surgical procedure in which the axillary lymph node group is dissected and removed without prior removal and examination of the sentinel lymph node.			Health Care Activity	
C105785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105785>	C62439	Fifty|50	A natural number greater than forty-nine and less than fifty-one and the quantity that it denotes.			Quantitative Concept	
C105786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105786>	C62439	Ninety|90	A natural number greater than eighty-nine and less than ninety-one and the quantity that it denotes.			Quantitative Concept	
C105787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105787>	C62439	Ninety Nine|99|Ninety-Nine	A natural number greater than ninety-eight and less than one hundred and the quantity that it denotes.			Quantitative Concept	
C105788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105788>	C62439	Eighty|80	A natural number greater than seventy-nine and less than eighty-one and the quantity that it denotes.			Quantitative Concept	
C105789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105789>	C62439	Eighty Nine|89|Eighty-Nine	A natural number greater than eighty-eight and less than ninety and the quantity that it denotes.			Quantitative Concept	
C10578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10578>	C61063	Asparaginase/Filgrastim/Teniposide|ARA-C/G-CSF/VM-26			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105790>	C62439	Seventy|70	A natural number greater than sixty-nine and less than seventy-one and the quantity that it denotes.			Qualitative Concept	
C105791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105791>	C62439	Seventy Nine|79|Seventy-Nine	A natural number greater than seventy-eight and less than eighty and the quantity that it denotes.			Quantitative Concept	
C105792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105792>	C62439	Sixty|60	A natural number greater than fifty-nine and less than sixty-one and the quantity that it denotes.			Quantitative Concept	
C105793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105793>	C62439	Sixty Nine|69|Sixty-Nine	A natural number greater than sixty-eight and less than seventy and the quantity that it denotes.			Quantitative Concept	
C105794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105794>	C62439	Fifty Nine|59|Fifty-Nine	A natural number greater than fifty-eight and less than sixty and the quantity that it denotes.			Quantitative Concept	
C105795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105795>	C62439	Forty|40	A natural number greater than thirty-nine and less than forty-one and the quantity that it denotes.			Quantitative Concept	
C105796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105796>	C62439	Forty Nine|49|Forty-Nine	A natural number greater than forty-eight and less than fifty and the quantity that it denotes.			Quantitative Concept	
C105797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105797>	C62439	Thirty|30	A natural number greater than twenty-nine and less than thirty-one and the quantity that it denotes.			Quantitative Concept	
C105798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105798>	C62439	Thirty Nine|39|Thirty-Nine	A natural number greater than thirty-eight and less than forty and the quantity that it denotes.			Quantitative Concept	
C105799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105799>	C62439	Twenty|20	A natural number greater than nineteen and less than twenty-one and the quantity that it denotes.	Twenty		Quantitative Concept	CTRP Biomarker Terminology|CTRP Terminology
C10579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10579>	C61063	Doxorubicin/Filgrastim/Mercaptopurine/Prednisone/Vincristine|DOX/G-CSF/MP/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1057>	C1556	Cordycepin|3'-Deoxyadenosine|3'-dA-CE Phosphoramidite|3-dAdenosine|9-Cordyceposidoadenine|COR|CORDYCEPIN|CORDYCEPIN|Cordycepine|Kordicepin|cordycepin	A purine nucleoside antimetabolite and antibiotic isolated from the fungus Cordyceps militaris with potential antineoplastic, antioxidant, and anti-inflammatory activities. Cordycepin is an inhibitor of polyadenylation, activates AMP-activated protein kinase (AMPK) and reduces mammalian target of rapamycin (mTOR) signaling, which may result in both the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase belonging to the phosphatidylinositol 3-kinase (PI3K)-related kinase (PIKK) family, plays an important role in the PI3K/AKT/mTOR signaling pathway that regulates cell growth and proliferation, and its expression or activity is frequently dysregulated in human cancers.	Cordycepin		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C105800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105800>	C62439	Twenty Nine|29|Twenty-Nine	A natural number greater than twenty-eight and less than thirty and the quantity that it denotes.			Quantitative Concept	
C105801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105801>	C62439	Nineteen|19	A natural number greater than eighteen and less than twenty and the quantity that it denotes.	Nineteen		Quantitative Concept	CTRP Biomarker Terminology|CTRP Terminology
C105802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105802>	C129821	Liposome-encapsulated miR-34 Mimic MRX34|MRX34	A liposomal formulation containing a nucleotide that mimics the human tumor suppressor microRNA (miRNA) miR-34, with potential antineoplastic activity. Upon administration, liposome-encapsulated MRX34 mimics miR-34 by inhibiting the expression of a variety of oncogenes including MYC, MET, BCL2, and beta-catenin. This induces cell cycle arrest, senescence and apoptosis in susceptible tumor cells. miR-34 is downregulated in most solid and hematologic malignancies and regulates the expression of a variety of genes. This miRNA plays an important role in the inhibition of cancer cell stemness, metastasis and cancer cell survival.	Liposome-encapsulated miR-34 Mimic MRX34		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C105803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105803>	C20401|C129822	Andecaliximab|ANDECALIXIMAB|GS-5745	A humanized monoclonal antibody against matrix metalloproteinase 9 (MMP-9), with potential antineoplastic activity. Upon administration, andecaliximab binds to MMP-9 and inhibits its enzymatic activity. This results in an inhibition of extracellular matrix protein degradation and, potentially, the inhibition of angiogenesis, tumor growth, invasion, and metastasis. MMP-9, a protein belonging to the MMP family, plays a key role in the degradation of collagens and proteoglycans; increased activity of MMP-9 has been associated with increased invasion and metastasis of cancer.	Andecaliximab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C105804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105804>	C213472|C129825	Fms/Trk Tyrosine Kinase Inhibitor PLX7486 Tosylate|PLX7486-TsOH	The tosylate salt form of PLX7486, a selective inhibitor of the receptor tyrosine kinases colony-stimulating factor-1 receptor (CSF1R; fms) and neurotrophic tyrosine kinase receptor types 1, 2 and 3 (TrkA, TrkB, and TrkC, respectively) with potential antineoplastic activity. Upon administration, PLX7486 binds to and inhibits the activity of these tyrosine kinases. This inhibits Fms and Trk-mediated signaling transduction pathways that are upregulated in certain cancer cell types. This may eventually halt tumor cell proliferation in Fms and TrkA, TrkB, and/or TrkC-overexpressing tumor cells. Fms and TrkA, TrkB, and TrkC are receptor tyrosine kinases that are upregulated or mutated in a variety of tumors and promote tumor cell proliferation and survival.	Fms/Trk Tyrosine Kinase Inhibitor PLX7486 Tosylate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C105805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105805>	C112889	Anti-CD19 Monoclonal Antibody DI-B4|DI-B4|anti-CD19 MoAb DI-B4	A low-fucosylated, humanized, IgG1 isotype, monoclonal antibody directed against the B-cell-specific membrane protein CD19 with potential immunostimulating and antineoplastic activities. Anti-CD19 monoclonal antibody DI-B4 binds to CD19, which may result in a strong antibody-dependent cellular cytotoxicity (ADCC) directed at CD19-expressing B-cells but with minimal complement dependent cytotoxicity. DI-B4 contains low levels of fucose, which contributes to its enhanced ADCC activity. CD19 is a B-cell specific membrane antigen that is widely expressed during B-cell development and in all B-cell lineage malignancies.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C105806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105806>	C28310	Autologous Sarcoma Lysate-pulsed Dendritic Cell Vaccine	A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from sarcoma cells with potential immunostimulatory and antineoplastic activities. Upon administration, the autologous sarcoma lysate-pulsed dendritic cell vaccine exposes the immune system to an undefined amount of sarcoma-type tumor associated antigens (TAA), which may result in the induction of both specific anti-tumoral cytotoxic T lymphocytes (CTL) and antibody-dependent responses against the sarcoma TAA-expressing cells, resulting in sarcoma cell lysis.			Cell|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C105807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105807>	C129820	Autologous Sarcoma Cell Lysate	A cell lysate derived from sarcoma cells with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, the autologous sarcoma cell lysate exposes the immune system to an undefined amount of sarcoma-type tumor associated antigens (TAA), which may result in the induction of both specific anti-tumoral cytotoxic T lymphocytes (CTL) and antibody-dependent responses against the sarcoma TAA-expressing cells, resulting in sarcoma cell lysis.	Autologous Sarcoma Cell Lysate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C105808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105808>	C1511	Indium In 111 Pertuzumab|111In-pertuzumab	A radioimmunoconjugate composed of a humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the tyrosine kinase receptor human epidermal growth factor-2 (HER-2) and linked to the gamma-emitting radioisotope indium In 111, with potential use in radioimaging. Upon administration, indium In 111 pertuzumab binds to HER-2. After binding and internalization into HER-2-expressing tumor cells, radioactive In 111 facilitates the detection of HER-2-expressing tumor cells using single photon emission computed tomography (SPECT). This may predict or evaluate the tumor's response to certain HER-2-targeting chemotherapeutics.			Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	NCI Drug Dictionary Terminology
C105809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105809>	C129826	AdGMCAIX-transduced Autologous Dendritic Cells|DC-AdGMCAIX|DCs expressing CMCA9 Gene	Autologous dendritic cells (DCs) transduced with a recombinant, replication-defective adenoviral vector expressing the fusion gene granulocyte-macrophage colony-stimulating factor (GM-CSF) and carbonic anhydrase IX (CA-IX or CA9) (GMCA-9), with potential immunomodulating activity. The autologous DCs are transduced ex vivo and express the GMCA-9 fusion protein on the cell surface. Upon intradermal administration of the AdGMCAIX-transduced autologous DCs back into the patient, the DCs activate the immune system to both mount a cytotoxic T lymphocyte-mediated response against tumor cells positive for the CA9 antigen, and generate memory T cells. This may result in decreased tumor growth. CA9, also known as G250, is a renal cell carcinoma (RCC)-associated antigen and a member of the carbonic anhydrase family that contains a human leukocyte antigen (HLA)-A2.1-restricted epitope; it is found in a majority of renal cell carcinomas while absent in most normal tissues. The cytokine GM-CSF enhances the immunogenicity of CA9-based DC vaccines.	AdGMCAIX-transduced Autologous Dendritic Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C10580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10580>	C61063	Doxorubicin/Filgrastim/Prednisone/Vincristine|DOX/G-CSF/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105810>	C129820	Autologous Glioma Cell Lysate	A cell lysate derived from glioma cells with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, the autologous glioma cell lysate exposes the immune system to an undefined amount of glioma-type tumor associated antigens (TAA), which may result in the induction of both specific anti-tumoral cytotoxic T lymphocytes (CTL) and antibody-dependent responses against the glioma TAA-expressing cells, resulting in glioma cell lysis.			Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C105811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105811>	C213309|C204256	Ad-hCMV-TK	A human serotype 5, replication-defective, first generation adenoviral vector, with the viral E1a and E3 protein encoding regions deleted, which is engineered to express the herpes simplex virus thymidine kinase (HSV-tk) gene under the transcriptional control of the CMV promoter. This agent, when administered in conjunction with a synthetic acyclic guanosine analogue, possesses potential antineoplastic activity. Upon administration into the peritumoral region after tumor resection, adenoviral vector encoding HSV thymidine kinase is transduced into tumor cells, and HSV-tk is expressed. Tumor cells expressing HSV-tk are sensitive to synthetic acyclic guanosine analogues. Subsequent administration of a synthetic acyclic guanosine analogue, such as valacyclovir (VCV) or ganciclovir (GCV), kills the tumor cells expressing HSV-tk. The release of tumor-associated antigens (TAA) by dying tumor cells may then stimulate an antitumor cytotoxic T lymphocyte (CTL) response, directed aganst any remaining tumor cells.	Ad-hCMV-TK		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C105813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105813>	C213309|C204256|C129820	Ad-hCMV-Flt3L	A human serotype 5, replication-defective, first generation adenoviral vector, with the viral E1a and E3 protein encoding regions deleted, which is engineered to express the soluble, immune-mediated stimulatory gene human fms-like tyrosine kinase 3 ligand (Flt3L), under the transcriptional control of the CMV promoter, with potential immunostimulating activity. Upon administration, Ad-hCMV-Flt3L is transduced into tumor cells and Flt3L is expressed. Flt3L stimulates both the proliferation of dendritic cells (DCs) and their migration to the tumor site. Upon exposure to the tumor-associated antigens (TAA) released from dying glioma cells, which were killed by thymidine kinase-mediated valacyclovir-induced tumor cell death, the DCs initiate a specific immune response against any remaining TAA-expressing tumor cells. Flt3L is a hematopoietic growth factor and ligand for the Flt3 tyrosine kinase receptor.	Ad-hCMV-Flt3L		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C105814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105814>	C62439	One Hundred|100	A natural number greater than ninety-nine and less than one hundred-one and the quantity that it denotes.			Quantitative Concept	
C105815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105815>	C215677	NUP98/KDM5A Fusion Gene|NUP98-KDM5A Fusion Gene|NUP98-RBBP2 Fusion Gene|NUP98/RBBP2 Fusion Gene|NUP98::KDM5A Fusion Gene	A fusion gene that results from a chromosomal translocation t(11;12)(p15;p13) which fuses the first 13 exons of the NUP98 gene with exons 28-31 of the KDM5A gene. This fusion is associated with acute megakaryoblastic leukemia.	NUP98/KDM5A Fusion Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105816>	C17561	NUP98/KDM5A Fusion Protein|NUP98-JARID1A Fusion Protein|NUP98-KDM5A Fusion Protein|NUP98-RBBP2 Fusion Protein|NUP98/JARID1A Fusion Protein|NUP98/RBBP2 Fusion Protein|NUP98::KDM5A Fusion Protein|Nuclear Pore Complex Protein Nup98-Nup96/Jumonji/ARID Domain-Containing Protein 1A Fusion Protein|Nuclear Pore Complex Protein Nup98-Nup96/Lysine-Specific Demethylase 5A Fusion Protein|Nuclear Pore Complex Protein Nup98-Nup96/Retinoblastoma-Binding Protein 2 Fusion Protein	A fusion protein encoded by the NUP98/KDM5A fusion gene. This protein is comprised of the N-terminal nucleoporin GLFG repeat domains of the nuclear pore complex protein Nup98-Nup96 protein fused to the C-terminal PHD domain of the lysine-specific demethylase 5A protein.	NUP98/KDM5A Fusion Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105817>	C212851	MNX1/ETV6 Fusion Gene|HLXB9-ETV6 Fusion Gene|HLXB9/ETV6 Fusion Gene|MNX1-ETV6 Fusion Gene|MNX1::ETV6 Fusion Gene	A fusion gene that results from a chromosomal translocation t(7;12)(q36;p13) which fuses the first exon of the MNX1 gene with exon 3 of the ETV6 gene. This aberration is associated with infant acute myeloid leukemia.	MNX1/ETV6 Fusion Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105818>	C213236	MNX1/ETV6 Fusion Protein|HLXB9-ETV6 Fusion Protein|HLXB9/ETV6 Fusion Protein|Homeobox Protein HB9/Transcription Factor ETV6 Fusion Protein|MNX1-ETV6 Fusion Protein|MNX1::ETV6 Fusion Protein|Motor Neuron and Pancreas Homeobox Protein 1/Transcription Factor ETV6 Fusion Protein	A fusion protein encoded by the MNX1/ETV6 fusion gene. This protein is comprised of the N-terminal portion of the motor neuron and pancreas homeobox protein 1 protein, including the polyalanine repeat domain, fused to most of the transcription factor ETV6 protein, including the helix-loop-helix and ETS domains.	MNX1/ETV6 Fusion Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105819>	C28510	CBFA2T3/GLIS2 Fusion Gene|CBFA2T3-GLIS2 Fusion Gene|CBFA2T3::GLIS2 Fusion Gene	A fusion gene that results from a chromosomal translocation inv(16)(p13q24) which fuses either the first 10 or 11 exons of the CBFA2T3 gene with either exon 1 or exon 3 of the GLIS2 gene. This fusion is associated with acute megakaryoblastic leukemia.	CBFA2T3/GLIS2 Fusion Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10581>	C61007	Cyclophosphamide/Dactinomycin/Doxorubicin/Filgrastim/Vincristine|CTX/DACT/DOX/G-CSF/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105820>	C17561	CBFA2T3/GLIS2 Fusion Protein|CBFA2T3-GLIS2 Fusion Protein|CBFA2T3::GLIS2 Fusion Protein|Protein CBFA2T3/Zinc Finger Protein GLIS2 Fusion Protein|Protein CBFA2T3::Zinc Finger Protein GLIS2 Fusion Protein	A fusion protein encoded by the CBFA2T3/GLIS2 fusion gene. This protein is comprised of the N-terminal TAFH domain of the protein CBFA2T3 protein fused to the zinc finger protein GLIS2 protein.	CBFA2T3/GLIS2 Fusion Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105821>	C16615	HOXA Gene Family|HOX1|HOXA|HOXA|HOXA Family|HOXA Gene|Homeo Box 1|Homeo Box A|Homeo Box A Cluster|Homeobox A|Homeobox A Cluster|Hox-1|Hox-A	A family of genes found in a cluster on the p arm of chromosome 7. These genes encode transcription factors that play a role in gene expression, morphogenesis, and cell differentiation.	HOXA Gene Family		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105822>	C16615	HOXB Gene Family|HOX2|HOXB|HOXB|HOXB Family|HOXB Gene|Homeo Box 2|Homeo Box B|Homeo Box B Cluster|Homeobox B|Homeobox B Cluster|Hox-2	A family of genes found in a cluster on the q arm of chromosome 17. These genes encode transcription factors that play a role in gene expression, cell proliferation and cell differentiation.	HOXB Gene Family		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105823>	C98307	BRAF NP_004324.2:p.V600X|BRAF Codon 600 Mutation|BRAF NP_004324.2:p.Val600 Mutation|BRAF NP_004324.2:p.Val600Xxx|BRAF V600 Mutation|BRAF V600 Protein Variation|BRAF V600X|BRAF p.V600 Mutation|BRAF p.V600X|BRAF p.Val600 Mutation|BRAF p.Val600Xxx|BRAFV600|NP_004324.2:p.V600 Mutation|NP_004324.2:p.V600X|NP_004324.2:p.Val600 Mutation|NP_004324.2:p.Val600Xxx|Other BRAF V600 mutation|Serine/Threonine-Protein Kinase B-raf Protein V600 Mutation|Serine/Threonine-Protein Kinase B-raf Protein V600 Protein Variation|Serine/Threonine-Protein Kinase B-raf Protein V600X|Serine/Threonine-Protein Kinase B-raf Protein Val600 Mutation|Serine/Threonine-Protein Kinase B-raf Protein Val600Xxx	A change in the valine at position 600 of the serine/threonine-protein kinase B-raf protein to another amino acid.	BRAF NP_004324.2:p.V600X		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105824>	C20130	Adrenergic Receptor|Adrenoceptor|Catecholamine Receptor|Norepinephrine Receptor	A family of G protein-coupled receptors that bind catecholamines and play a role in the stimulation of the sympathetic nervous system.	Adrenergic Receptor		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105825>	C18520	Protein Carbonyl Content|Protein Carbonyl Group|Protein Carbonyl Level	The presence of carbonyl derivatives of certain amino acids in a biological sample is indicative of protein oxidation. Oxidized proteins can be markers for oxidative stress.	Protein Carbonyl Content		Functional Concept	CTRP Biomarker Terminology|CTRP Terminology
C105826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105826>	C707	8-Oxoguanine|1H-Purine-6,8-Dione, 2-Amino-|1H-Purine-6,8-Dione, 2-Amino-7,9-Dihydro-|2-Amino-6,8-Dihydroxypurine|2-Amino-7,9-Dihydro-1H-Purine-6,8-Dione|2-Aminopurine-6,8-Diol|7,8-Dihydro-8-Oxoguanine|8-Hydroxyguanine|8-Oxo-7,8-Dihydroguanine|8-Oxo-Gua|8OG|Purine-6,8(1H,9H)-Dione, 2-Amino-|Purine-6,8-Diol, 2-Amino-	A derivative of the purine nucleoside guanine that is found in DNA that has been damaged due to exposure to reactive oxygen species or ionizing radiation.	8-Oxoguanine		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology
C105827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105827>	C492	12-Methyltetradecanoic Acid|12-MTA|12-Methyl-Tetradecanoic Acid|Anteiso-Pentadecanoic Acid|Anteisopentadecanoic Acid|Aseanostatin P5|Sarcinic Acid|Tetradecanoic Acid, 12-Methyl-	A branched-chain saturated fatty acid that is comprised of tetradecanoic acid with a methyl group on the carbon in the twelfth position.	12-Methyltetradecanoic Acid		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C105828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105828>	C492	13-Methyltetradecanoic Acid|13-METHYLTETRADECANOIC ACID|13-MTA|13-Methyl-Tetradecanoic Acid|Tetradecanoic Acid, 13-Methyl-	A branched-chain saturated fatty acid that is comprised of tetradecanoic acid with a methyl group on the carbon in the thirteenth position.	13-Methyltetradecanoic Acid		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C105829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105829>	C25941	FKBP5 Gene|FK506 Binding Protein 5 Gene|FKBP5|FKBP5	This gene plays a role in protein folding.	FKBP5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10582>	C61063	Etoposide/Filgrastim/Melphalan|G-CSF/L-PAM/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105830>	C105829	FKBP5 wt Allele|AIG6|FK506 Binding Protein 5 wt Allele|FKBP51|FKBP54|P54|PPIase|Ptg-10|RP3-340B19.6	Human FKBP5 wild-type allele is located in the vicinity of 6p21.31 and is approximately 155 kb in length. This allele, which encodes peptidyl-prolyl cis-trans isomerase FKBP5 protein, is involved in the modulation of protein folding.	FKBP5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105831>	C16759	Peptidyl-Prolyl Cis-Trans Isomerase FKBP5|51 kDa FK506-Binding Protein|51 kDa FK506-Binding Protein 5|51 kDa FKBP|54 kDa Progesterone Receptor-Associated Immunophilin|Androgen-Regulated Protein 6|EC 5.2.1.8|FF1 Antigen|FK506-Binding Protein 5|FKBP-5|FKBP-51|FKBP5|FKBP54|HSP90-Binding Immunophilin|PPIase FKBP5|Rotamase|T-Cell FK506-Binding Protein|p54	Peptidyl-prolyl cis-trans isomerase FKBP5 (457 aa, ~51 kDa) is encoded by the human FKBP5 gene. This protein plays a role in the mediation of protein folding.	Peptidyl-Prolyl Cis-Trans Isomerase FKBP5		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105832>	C21282|C19676	NEIL3 Gene|NEIL3|NEIL3|Nei Endonuclease VIII-Like 3 (E. coli) Gene	This gene plays a role in DNA repair.	NEIL3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105833>	C105832	NEIL3 wt Allele|FGP2|FLJ10858|FPG2|NEI3|Nei Endonuclease VIII-Like 3 (E. coli) wt Allele|hFPG2|hNEI3	Human NEIL3 wild-type allele is located in the vicinity of 4q34.3 and is approximately 53 kb in length. This allele, which encodes endonuclease 8-like 3 protein, is involved in DNA binding and repair.	NEIL3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105834>	C21170|C16804	Endonuclease 8-Like 3|DNA Glycosylase FPG2|DNA Glycosylase hFPG2|DNA Glycosylase/AP Lyase Neil3|EC 3.2.2.-|EC 4.2.99.18|Endonuclease VIII-Like 3|NEIL3|Nei-Like Protein 3	Endonuclease 8-like 3 (605 aa, ~68 kDa) is encoded by the human NEIL3 gene. This protein plays a role in binding and repair of single-stranded DNA.	Endonuclease 8-Like 3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105835>	C20194	ATP5F1E Gene|ATP Synthase F1 Subunit Epsilon Gene|ATP5E|ATP5E Gene|ATP5F1E|ATP5F1E	This gene is involved in ATP synthesis.	ATP5E Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105836>	C105835	ATP5F1E wt Allele|ATP Synthase F1 Subunit Epsilon wt Allele|ATP Synthase, H+ Transporting, Mitochondrial F1 Complex, Epsilon Subunit Gene|ATP5E|ATP5E wt Allele|ATPE|MC5DN3	Human ATP5F1E wild-type allele is located in the vicinity of 20q13.32 and is approximately 7 kb in length. This allele, which encodes ATP synthase subunit epsilon, mitochondrial protein, plays a role in ATP biosynthesis. Mutation of the gene is associated with mitochondrial complex V (ATP synthase) deficiency nuclear type 3.	ATP5E wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105837>	C18466	ATP Synthase Subunit Epsilon, Mitochondrial|ATP Synthase F1 Subunit Epsilon|ATP5E|ATP5F1E|ATPase Subunit Epsilon|Mitochondrial ATP Synthase Epsilon Chain	ATP synthase subunit epsilon, mitochondrial (51 aa, ~6 kDa) is encoded by the human ATP5F1E gene. This protein is involved in the biosynthesis of ATP.	ATP Synthase Subunit Epsilon, Mitochondrial		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105838>	C26000	BGN Gene|BGN|BGN|Biglycan Gene	This gene plays a role in extracellular matrix structure.	BGN Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105839>	C105838	BGN wt Allele|Biglycan wt Allele|DSPG1|PG-S1|PGI|SLRR1A	Human BGN wild-type allele is located in the vicinity of Xq28 and is approximately 15 kb in length. This allele, which encodes biglycan protein, is involved in the composition of the extracellular matrix.	BGN wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10583>	C61063	Cisplatin/Doxorubicin/Etoposide/Filgrastim/Ifosfamide|CDDP/DOX/G-CSF/IFF/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105840>	C17351	Biglycan|BGN|Biglycan Proteoglycan|Bone/Cartilage Proteoglycan I|Bone/Cartilage Proteoglycan-I|Dermatan Sulphate Proteoglycan I|PG-S1|Proteoglycan-I|Small Leucine-Rich Protein 1A	Biglycan (368 aa, ~42 kDa) is encoded by the human BGN gene. This protein plays a role in connective tissue structure.	Biglycan		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105841>	C21295	EFNB2 Gene|EFNB2|EFNB2|Ephrin-B2 Gene	This gene is involved in cell-cell signaling.	EFNB2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105842>	C105841	EFNB2 wt Allele|EPLG5|Ephrin-B2 wt Allele|HTKL|Htk-L|LERK5|MGC126226|MGC126227|MGC126228|RP11-272L14.1	Human EFNB2 wild-type allele is located in the vicinity of 13q33 and is approximately 45 kb in length. This allele, which encodes ephrin-B2 protein, plays a role in intercellular signal transduction.	EFNB2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105843>	C17728	Ephrin-B2|EFNB2|EPH-Related Receptor Tyrosine Kinase Ligand 5|HTK Ligand|HTK-L|LERK-5|Ligand of Eph-Related Kinase 5	Ephrin-B2 (333 aa, ~37 kDa) is encoded by the human EFNB2 gene. This protein is involved in cell-cell communication.	Ephrin-B2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105844>	C20921	GADD45B Gene|GADD45B|GADD45B|Growth Arrest and DNA-Damage-Inducible, Beta Gene	This gene plays a role in signaling, apoptosis and cell growth.	GADD45B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105845>	C105844	GADD45B wt Allele|DKFZP566B133|GADD45BETA|Growth Arrest and DNA-Damage-Inducible, Beta wt Allele|MYD118	Human GADD45B wild-type allele is located in the vicinity of 19p13.3 and is approximately 2 kb in length. This allele, which encodes growth arrest and DNA damage-inducible protein GADD45 beta, is involved in the modulation of apoptosis, signaling and cell growth.	GADD45B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105846>	C18515	Growth Arrest and DNA Damage-Inducible Protein GADD45 Beta|GADD45B|Growth Arrest and DNA-Damage-Inducible Beta|Myeloid Differentiation Primary Response Protein MyD118|Negative Growth Regulatory Protein MyD118	Growth arrest and DNA damage-inducible protein GADD45 beta (160 aa, ~18 kDa) is encoded by the human GADD45B gene. This protein plays a role in the regulation of cell growth, apoptosis and signaling.	Growth Arrest and DNA Damage-Inducible Protein GADD45 Beta		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105847>	C20917	MAD2L1 Gene|MAD2 Mitotic Arrest Deficient-Like 1 (Yeast) Gene|MAD2L1|MAD2L1	This gene is involved in mitosis.	MAD2L1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105848>	C105847	MAD2L1 wt Allele|HSMAD2|MAD2|MAD2 Mitotic Arrest Deficient-Like 1 (Yeast) wt Allele	Human MAD2L1 wild-type allele is located in the vicinity of 4q27 and is approximately 8 kb in length. This allele, which encodes mitotic spindle assembly checkpoint protein MAD2A, plays a role in the regulation of mitotic progression.	MAD2L1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105849>	C17761	Mitotic Spindle Assembly Checkpoint Protein MAD2A|HsMAD2|MAD2-Like Protein 1|MAD2L1|Mitotic Arrest Deficient 2-Like Protein 1|Mitotic Arrest Deficient, Yeast, Homolog-Like 1	Mitotic spindle assembly checkpoint protein MAD2A (205 aa, ~24 kDa) is encoded by the human MAD2L1 gene. This protein is involved in the mitotic spindle-assembly checkpoint.	Mitotic Spindle Assembly Checkpoint Protein MAD2A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10584>	C61063	Bleomycin/Doxorubicin/Etoposide/Mechlorethamine/Vinblastine/Vincristine|BLEO/DOX/NM/VBL/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105850>	C2124	[18F]L-FMAC|2'-Deoxy-2'-18F-fluoro-5-methyl-beta-L-arabinofuranosylcytosine|L-FMAC F-18|L-fluorine F 18-FMAC	A radioconjugate composed of 2'-deoxy-2'-18F-fluoro-5-methyl-beta-L-arabinofuranosylcytosine ([18F]L-FMAC), a L-deoxycytidine analog and high-affinity substrate for deoxycytidine kinase (DCK), labeled with fluorine F 18, with potential diagnostic activity during positron emission tomography (PET) imaging. Upon administration, [18F]L-FMAC is preferentially taken up by and accumulated in cells with high DCK levels, including tumor cells with dysregulated nucleoside metabolism. After phosphorylation by DCK, the 18F moiety can be visualized by PET imaging. As many nucleoside analog prodrugs are chemotherapeutic agents that require DCK for their phosphorylation and activation, [18F]L-FMAC can potentially be used as a marker to measure DCK activity and to predict the chemotherapeutic efficacy of DCK-dependent prodrugs. DCK, a rate-limiting enzyme in the deoxyribonucleoside salvage pathway for DNA synthesis, is overexpressed in certain solid tumors, lymphoid and myeloid malignancies and certain immune cells, such as proliferating T-lymphocytes. The L-enantiomer is less susceptible to deamination by cytidine deaminase (CDA) than the D-enantiomer and increases the stability of this radioconjugate.	[18F]L-FMAC		Indicator, Reagent, or Diagnostic Aid|Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C105851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105851>	C200258	Zotiraciclib Citrate|20-Oxa-5,7,14,27-tetraazatetracyclo(19.3.1.12,6.18,12)heptacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene, 14-Methyl-, 2-Hydroxy-1,2,3-propanetricarboxylate (1:1)|SB1317 Citrate|TG02 Citrate|ZOTIRACICLIB CITRATE	An orally bioavailable citrate salt form of zotiraciclib a multi-kinase inhibitor for cyclin dependent kinase (CDK) subtypes 1, 2, 7 and 9, Janus-associated kinase 2 (JAK2), FMS-related tyrosine kinase 3 (FLT3, FLK2, STK1), with potential antineoplastic activity. Upon oral administration, CDK/JAK2/FLT3 Inhibitor TG02 binds to and inhibits the CDK subtypes, JAK2, and FLT3. TG02 also inhibits, to a lesser extent, TYK2, TYRO3, STAT5 and P38delta. This may result in both an induction of apoptosis and an inhibition of tumor cell proliferation in cancer cells that overexpress these kinases. JAK2, often upregulated or mutated in a variety of cancer cells, mediates STAT3 activation and plays a key role in tumor cell proliferation and survival. CDKs are serine/threonine kinases that play key roles in the regulation of the cell cycle and cellular proliferation. FLT3, a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias.	Zotiraciclib Citrate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C105852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105852>	C25871	PGK1 Gene|PGK1|PGK1|Phosphoglycerate Kinase 1 Gene	This gene plays a role in glycolysis.	PGK1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105853>	C2149|C129825	Ralimetinib Mesylate|3H-Imidazo(4,5-b)pyridin-2-amine, 5-(2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-(2,2-dimethylpropyl)-, Methanesulfonate (1:2)|LY-2228820|LY2228820|LY2228820 Dimesylate|RALIMETINIB MESYLATE|Ralimetinib Dimesylate	The dimesylate salt form of LY2228820, a tri-substituted imidazole derivative and orally available, p38 mitogen-activated protein kinase (MAPK) inhibitor with potential anti-inflammatory and antineoplastic activities. Upon administration, ralimetinib inhibits the activity of p38, particularly the alpha and beta isoforms, thereby inhibiting MAPKAPK2 phosphorylation and preventing p38 MAPK-mediated signaling. This may inhibit the production of a variety of cytokines involved in inflammation, cellular proliferation and angiogenesis such as tumor necrosis factor alpha (TNFa), interleukin (IL)-1, -6 and -8, vascular endothelial growth factor, and macrophage inflammatory protein-1 alpha. Ultimately this induces apoptosis and reduces tumor cell proliferation. In addition, inhibition of the p38 MAPK pathway by LY2228820 increases the antineoplastic activity of certain chemotherapeutic agents. p38 MAPK, a serine/threonine protein kinase that is often upregulated in cancer cells, plays a crucial role in tumor cell proliferation, angiogenesis and metastasis.	Ralimetinib Mesylate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C105854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105854>	C105852	PGK1 wt Allele|MIG10|OK/SW-cl.110|PGKA|Phosphoglycerate Kinase 1 wt Allele|RP4-570L12.1	Human PGK1 wild-type allele is located in the vicinity of Xq13.3 and is approximately 64 kb in length. This allele, which encodes phosphoglycerate kinase 1 protein, is involved in both glycolysis and gluconeogenesis. Mutation of the gene is associated with phosphoglycerate kinase 1 deficiency.	PGK1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105855>	C16984	Phosphoglycerate Kinase 1|Cell Migration-Inducing Gene 10 Protein|EC 2.7.2.3|PGK1|PRP 2|Primer Recognition Protein 2	Phosphoglycerate kinase 1 (417 aa, ~45 kDa) is encoded by the human PGK1 gene. This protein plays a role in glycolysis.	Phosphoglycerate Kinase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105856>	C25993	CACNA1G Gene|CACNA1G|CACNA1G|Calcium Channel, Voltage-Dependent, T Type, Alpha 1G Subunit Gene	This gene is involved in calcium transport.	CACNA1G Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105857>	C105856	CACNA1G wt Allele|Ca(V)T.1|Calcium Channel, Voltage-Dependent, T Type, Alpha 1G Subunit wt Allele|Cav3.1|KIAA1123|NBR13	Human CACNA1G wild-type allele is located in the vicinity of 17q22 and is approximately 66 kb in length. This allele, which encodes voltage-dependent T-type calcium channel subunit alpha-1G protein, plays a role in both calcium transport and membrane depolarization.	CACNA1G wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105858>	C28505	Voltage-Dependent T-Type Calcium Channel Subunit Alpha-1G|CACNA1G|Cav3.1c|NBR13|Voltage-Dependent Calcium Channel Alpha 1G Subunit|Voltage-Gated Calcium Channel Subunit Alpha Cav3.1	Voltage-dependent T-type calcium channel subunit alpha-1G (2377 aa, ~262 kDa) is encoded by the human CACNA1G gene. This protein is involved in both membrane depolarization and calcium import.	Voltage-Dependent T-Type Calcium Channel Subunit Alpha-1G		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105859>	C20420	NEUROG1 Gene|NEUROG1|NEUROG1|Neurogenin 1 Gene	This gene plays a role in both neuronal differentiation and transcriptional regulation.	NEUROG1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10585>	C61063	Interleukin-1-Alpha/Interleukin-2|IL-1A/IL-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105860>	C105859	NEUROG1 wt Allele|AKA|BHLHA6|Math4C|NEUROD3|NGN|NGN1|Neurogenic Differentiation 3 Gene|Neurogenin 1 wt Allele|bHLHa6|ngn1	Human NEUROG1 wild-type allele is located within 5q23-q31 and is approximately 2 kb in length. This allele, which encodes neurogenin-1 protein, is involved in both transcriptional regulation and neuronal differentiation.	NEUROG1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105861>	C17207	Neurogenin-1|Class A Basic Helix-Loop-Helix Protein 6|NEUROG1|NGN-1|NeuroD3|Neurogenic Basic-Helix-Loop-Helix Protein|Neurogenic Differentiation Factor 3|bHLHa6	Neurogenin-1 (237 aa, ~26 kDa) is encoded by the human NEUROG1 gene. This protein plays a role in both neuron differentiation and the regulation of gene expression.	Neurogenin-1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105862>	C26147	UGT1A9 Gene|UDP Glucuronosyltransferase 1 Family, Polypeptide A9 Gene|UGT1A9|UGT1A9	This gene is involved in phenol detoxification.	UGT1A9 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105863>	C105862	UGT1A9 wt Allele|GNT1|HLUGP4|LUGP4|UDP Glucuronosyltransferase 1 Family, Polypeptide A9 wt Allele|UDPGT|UDPGT 1-9|UGT-1I|UGT1-09|UGT1-9|UGT1.9|UGT1AI|UGT1I	Human UGT1A9 wild-type allele is located in the vicinity of 2q37 and is approximately 101 kb in length. This allele, which encodes UDP-glucuronosyltransferase 1-9 protein, plays a role in the detoxification of phenolic compounds.	UGT1A9 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105864>	C17434	UDP-Glucuronosyltransferase 1-9|EC 2.4.1.17|UDP Glycosyltransferase 1 Family, Polypeptide A9|UDP-Glucuronosyltransferase 1-I|UDP-Glucuronosyltransferase 1A9|UDPGT 1-9|UGT-1I|UGT1*9|UGT1-09|UGT1.9|UGT1A9|UGT1I|lugP4	UDP-glucuronosyltransferase 1-9 (530 aa, ~60 kDa) is encoded by the human UGT1A9 gene. This protein is involved in the metabolism of phenolic compounds.	UDP-Glucuronosyltransferase 1-9		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105865>	C21295	LBP Gene|LBP|LBP|Lipopolysaccharide Binding Protein Gene	This gene plays a role in anti-bacterial response.	LBP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105866>	C105865	LBP wt Allele|BPI Fold Containing Family D, Member 2 Gene|BPIFD2|Lipopolysaccharide Binding Protein wt Allele	Human LBP wild-type allele is located in the vicinity of 20q11.23 and is approximately 31 kb in length. This allele, which encodes lipopolysaccharide-binding protein, is involved in binding to lipopolysaccharide.	LBP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105867>	C17728	Lipopolysaccharide-Binding Protein|LBP|LPS-BP	Lipopolysaccharide-binding protein (481 aa, ~53 kDa) is encoded by the human LBP gene. This protein plays a role in lipopolysaccharide binding.	Lipopolysaccharide-Binding Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105868>	C20923	HTR1A Gene|5-Hydroxytryptamine (Serotonin) Receptor 1A, G Protein-Coupled Gene|HTR1A|HTR1A	This gene is involved in serotonin-dependent signaling.	HTR1A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105869>	C105868	HTR1A wt Allele|5-HT-1A|5-HT1A|5-Hydroxytryptamine (Serotonin) Receptor 1A Gene|5-Hydroxytryptamine (Serotonin) Receptor 1A, G Protein-Coupled wt Allele|5HT1a|ADRB2RL1|ADRBRL1|G-21|PFMCD	Human HTR1A wild-type allele is located within 5q11.2-q13 and is approximately 2 kb in length. This allele, which encodes 5-hydroxytryptamine receptor 1A protein, plays a role in both neurotransmitter binding and G protein-coupled receptor signaling. Mutation of the gene is associated with menstrual cycle-dependent periodic fevers.	HTR1A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10586>	C61063	Trifluoperazine/Verapamil|TFPZ/VPAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105870>	C18239	5-Hydroxytryptamine Receptor 1A|5-HT-1A|5-HT1A|5-HT1a Receptor|Beta-2-Adrenergic Receptor-Like Protein G-21|G-21|HTR1A|Serotonin 5-HT-1A Receptor|Serotonin Receptor 1A	5-hydroxytryptamine receptor 1A (422 aa, ~46 kDa) is encoded by the human HTR1A gene. This protein is involved in both serotonin binding and neurotransmitter-mediated signal transduction.	5-Hydroxytryptamine Receptor 1A		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105871>	C25939	TPH1 Gene|TPH1|TPH1|Tryptophan Hydroxylase 1 Gene	This gene plays a role in amino acid metabolism.	TPH1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105872>	C105871	TPH1 wt Allele|TPH|TPRH|TRPH|Tryptophan Hydroxylase (Tryptophan 5-Monooxygenase) Gene|Tryptophan Hydroxylase 1 wt Allele	Human TPH1 wild-type allele is located within 11p15.3-p14 and is approximately 25 kb in length. This allele, which encodes tryptophan 5-hydroxylase 1 protein, is involved in tryptophan metabolism.	TPH1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105873>	C16865	Tryptophan 5-Hydroxylase 1|EC 1.14.16.4|TPH1|Tryptophan 5-Monooxygenase|Tryptophan 5-Monooxygenase 1	Tryptophan 5-hydroxylase 1 (444 aa, ~51 kDa) is encoded by the human TPH1 gene. This protein plays a role in the metabolism of tryptophan.	Tryptophan 5-Hydroxylase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105874>	C28533	SLC6A4 Gene|SLC6A4|SLC6A4|Solute Carrier Family 6 (Neurotransmitter Transporter, Serotonin), Member 4 Gene	This gene is involved in serotonin transport.	SLC6A4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105875>	C105874	SLC6A4 wt Allele|5-HTT|5-HTTLPR|5HTT|HTT|OCD1|SERT|SERT1|Solute Carrier Family 6 (Neurotransmitter Transporter, Serotonin), Member 4 wt Allele|hSERT	Human SLC6A4 wild-type allele is located in the vicinity of 17q11.2 and is approximately 42 kb in length. This allele, which encodes sodium-dependent serotonin transporter protein, plays a role in serotonin uptake. Polymorphism in the promoter region affects gene expression and lower gene expression is associated with depression. Coding region variations are associated with genetic susceptibility to both obsessive-compulsive disorder and alcoholism.	SLC6A4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105876>	C16386	Sodium-Dependent Serotonin Transporter|5-Hydroxytryptamine Transporter|5HT Transporter|5HTT|Na+/Cl- Dependent Serotonin Transporter|SLC6A4|Solute Carrier Family 6 Member 4	Sodium-dependent serotonin transporter (630 aa, ~70 kDa) is encoded by the human SLC6A4 gene. This protein is involved in serotonin internalization.	Sodium-Dependent Serotonin Transporter		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105877>	C25993	CLCN7 Gene|CLCN7|CLCN7|Chloride Channel, Voltage-Sensitive 7 Gene	This gene plays a role in ion transport.	CLCN7 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105878>	C105877	CLCN7 wt Allele|CLC-7|CLC7|Chloride Channel 7 Gene|Chloride Channel, Voltage-Sensitive 7 wt Allele|OPTA2|OPTB4|PPP1R63|Protein Phosphatase 1, Regulatory Subunit 63 Gene	Human CLCN7 wild-type allele is located in the vicinity of 16p13 and is approximately 31 kb in length. This allele, which encodes H(+)/Cl(-) exchange transporter 7 protein, is involved in chloride ion transport. Mutation of the gene is associated with both osteopetrosis autosomal dominant type 2 and osteopetrosis autosomal recessive type 4.	CLCN7 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105879>	C28505	H(+)/Cl(-) Exchange Transporter 7|CLCN7|Chloride Channel 7 Alpha Subunit|Chloride Channel Protein 7|ClC-7	H(+)/Cl(-) exchange transporter 7 (805 aa, ~89 kDa) is encoded by the human CLCN7 gene. This protein plays a role in proton-coupled, chloride anion transport.	H(+)/Cl(-) Exchange Transporter 7		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10587>	C61007	Doxorubicin/Filgrastim|DOX/G-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105880>	C173924|C173084	Concerned About Keeping My Job, Including Work at Home Question|Concerned About Keeping My Job, Including Work at Home|I am concerned about keeping my job (include work at home)	A question about whether an individual is or was concerned about keeping their job including their work at home.			Intellectual Product	FACT-BMT Questionnaire
C105881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105881>	C173160	Feel Distant from People Question|Feel Distant from People|I feel distant from other people	A question about whether an individual feels or felt distant from other people.			Intellectual Product	FACT-BMT Questionnaire
C105882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105882>	C173934	Worry the Transplant Will Not Work Question|I worry that the transplant will not work|Worry the Transplant Will Not Work	A question about whether an individual worries or worried that the transplant will not work.			Intellectual Product	FACT-BMT Questionnaire
C105883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105883>	C173812	Treatment Effects are Worse than Imagined Question|The effects of treatment are worse than I had imagined|Treatment Effects are Worse than Imagined	A question about whether an individual feels or felt the treatment effects are worse than imagined.			Intellectual Product	FACT-BMT Questionnaire
C105884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105884>	C176022	Like My Body Appearance Question|I like the appearance of my body|Like My Body Appearance	A question about whether an individual likes or liked the appearance of their body.			Intellectual Product	FACT-BMT Questionnaire
C105885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105885>	C173045	Able to Get Around by Myself Question|Able to Get Around by Myself|I am able to get around by myself	A question about whether an individual is or was able to get around by themselves.			Intellectual Product	FACT-BMT Questionnaire
C105886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105886>	C173981|C173704	Interested in Sex Question|Have you had any interest in sexual relations|I am interested in sex|Interest in Sexual Relations|Interested in Sex	A question about whether an individual is or was interested in sex.			Intellectual Product	FACT-BMT Questionnaire|Rectal Cancer Female Sexuality Score
C105887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105887>	C173978|C173084	Concern about Ability to Have Children Question|Concern about Ability to Have Children|Concerned about Ability to Have Children|Have Concerns About Ability to Have Children|I have concerns about my ability to have children|Were you concerned about your ability to have children	A question about whether an individual has or had concerns about their ability to have children.			Intellectual Product	FACT-BMT Questionnaire|Quality of Life Questionnaire - Testicular Cancer 26
C105888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105888>	C173086	Have Confidence in Nurse Question|Have Confidence in Nurse|I have confidence in my nurse(s)	A question about whether an individual has or had confidence in their nurse(s).			Intellectual Product	FACT-BMT Questionnaire
C105889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105889>	C91103	Regret Having Bone Marrow Transplant Question|I regret having the bone marrow transplant|Regret Having Bone Marrow Transplant	A question about whether an individual regrets or regretted having a bone marrow transplant.			Intellectual Product	FACT-BMT Questionnaire
C10588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10588>	C61063	Doxorubicin/Trifluoperazine/Vinblastine/Verapamil|DOX/Trifluoperazine/VBL/VPAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105890>	C173045	Able to Remember Question|Able to Remember|I can remember things|I have been able to remember things, like where I left my keys or wallet	A question about whether an individual is or was able to remember things.			Intellectual Product	FACT-BMT Questionnaire|FACT-Cognitive Function
C105891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105891>	C173045	Able to Concentrate Question|Able to Concentrate|Concentration|Concentration Distress|I am able to concentrate|I can concentrate well|I have been able to concentrate	A question about whether an individual is or was able to concentrate.			Intellectual Product	FACT-BMT Questionnaire|FACT-Cognitive Function|Multidimensional Fatigue Inventory|Symptom Distress Scale
C105892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105892>	C173981|C173790	Have Blurry Eyesight Question|Did you have blurred vision|Have Blurred Vision|Have Blurry Eyesight|My eyesight is blurry|Was your vision blurred	A question about whether an individual has or had blurry eyesight.			Intellectual Product	FACT-BMT Questionnaire|Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20 Items|Quality of Life Questionnaire-Brain Neoplasm 20 Items
C105893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105893>	C173063|C172982	Bothered by Food Taste Change Question|Bothered by Change in Food Taste|Bothered by Food Taste Change|I am bothered by a change in the way food tastes	A question about whether an individual is or was bothered by changes in the taste of food.			Intellectual Product	FACT-BMT Questionnaire
C105894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105894>	C173981	Have Tremor Question|Have Tremor|I have tremors	A question about whether an individual has or had tremors.			Intellectual Product	FACT-BMT Questionnaire
C105895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105895>	C172982	Bothered By Skin Problems Question|Bothered By Skin Problems|I am bothered by skin problems	A question about whether an individual is or was bothered by skin problems.			Intellectual Product	FACT-BMT Questionnaire
C105896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105896>	C173981|C173938	Have Bowel Trouble Question|Have Bowel Trouble|I have trouble with my bowels	A question about whether an individual has or had bowel troubles.			Intellectual Product	FACT-BMT Questionnaire
C105897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105897>	C173151	Illness is Personal Hardship for Close Family Members Question|Illness is Personal Hardship for Close Family Members|My illness is a personal hardship for my close family members	A question about whether an individual feels their illness is or was a personal hardship for close family members.			Intellectual Product	FACT-BMT Questionnaire
C105898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105898>	C173812|C173151	Treatment Cost is a Burden to Me or My Family Question|The cost of my treatment is a burden on me or my family|Treatment Cost is a Burden to Me or My Family	A question about whether an individual feels the cost of treatment is or was a burden to them or their family.			Intellectual Product	FACT-BMT Questionnaire
C105899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105899>	C173981	Have Frequent Colds or Infections Question|Have Frequent Colds or Infections|I have frequent colds/infections	A question about whether an individual has or had frequent colds or infections.			Intellectual Product	FACT-BMT Questionnaire
C10589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10589>	C61063	Carboplatin/Edatrexate|CBDCA/EDAM|Carboplatin/10-EdAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1058>	C521	Cortisone Acetate|21-(Acetyloxy)-17-hydroxypregn-4-ene-3,11,20-trione|21-(Acetyloxy)-17-hydroxypregn-4-ene-3,11,20-trione|6alpha,9Difluoro-11beta,17,21-trihydroxypregna-1,4- diene-3,20-dione 21-acetate 17- Butyrate|CORTISONE ACETATE|Cortisone acetate|Cortogen|Cortogen|Cortone|Cortone|Cortone acetate	The acetate salt form of cortisone, a synthetic or semisynthetic analog of the naturally occurring cortisone hormone produced by the adrenal glands with anti-inflammatory and immunomodulating properties. Cortisone acetate diffuses through the cell membrane and binds to nuclear glucocorticoid receptors. The receptor-ligand complex binds to promotor regions of certain genes and initiates RNA transcription. This results in an induction of synthesis of certain anti-inflammatory proteins while inhibiting the synthesis of certain inflammatory mediators.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C105900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105900>	C20420	GLIS2 Gene|GLIS Family Zinc Finger 2 Gene|GLIS2|GLIS2|GLIS2	This gene is involved in transcriptional regulation and signaling pathway modulation.	GLIS2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C105901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105901>	C105900	GLIS2 wt Allele|GLI-Similar 2 Gene|GLIS Family Zinc Finger 2 wt Allele|NKL|NPHP7|Nephrocystin-7 Gene	Human GLIS2 wild-type allele is located in the vicinity of 16p13.3 and is approximately 25 kb in length. This allele, which encodes zinc finger protein GLIS2, plays a role in the modulation of both signaling and transcription. Mutation of the gene is associated with type 7 nephronophthisis.	GLIS2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105902>	C17207	Zinc Finger Protein GLIS2|GLI-Similar 2|GLI-Similar Protein 2|GLIS2|Kruppel-Like Zinc Finger Protein GLIS2|Neuronal Krueppel-Like Protein	Zinc finger protein GLIS2 (524 aa, ~56 kDa) is encoded by the human GLIS2 gene. This protein is involved in the regulation of transcription and the repression of signaling pathways.	Zinc Finger Protein GLIS2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105903>	C20467	PPBP Gene Product	A protein encoded by the PPBP gene.	PPBP Gene Product		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105904>	C174459	Lauren Classification|Histologic Type (Lauren Classification)|LAUREN CLASSIFICATION	A classification scheme in which gastric adenocarcinomas are separated into diffuse adenocarcinoma, intestinal type adenocarcinoma, mixed adenocarcinoma, or indeterminate type adenocarcinoma.			Classification	CDISC SDTM Microscopic Findings Test Detail Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C105905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105905>	C16484	Cytochrome P450 2A6|1,4-Cineole 2-Exo-Monooxygenase|CYP2A6|CYPIIA6|Coumarin 7-Hydroxylase|Cytochrome P450 IIA3|Cytochrome P450(I)|EC 1.14.13.-	Cytochrome P450 2A6 (494 aa, ~57 kDa) is encoded by the human CYP2A6 gene. This protein is involved in the metabolism of xenobiotics.	Cytochrome P450 2A6		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105906>	C97928	JAK2 Protein Variant|JAK-2 Protein Variant|Janus Kinase 2 Protein Variant|Tyrosine-Protein Kinase JAK2 Protein Variant	A variation in the amino acid sequence for the tyrosine-protein kinase JAK2 protein.	JAK2 Protein Variant		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C105907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105907>	C177694|C103223	Claudin-Low|Claudin-Low Profile|Claudin-Low Transcriptional Profile	A genetic profile indicating low expression of cellular tight junction proteins, including E-cadherin, which is often associated with triple-negative breast cancer and tumor-infiltrating lymphocytes.	Claudin-Low		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C105908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105908>	C117283	JAK2 NP_004963.1:p.V617F|JAK2 NP_004963.1:p.Val617Phe|JAK2 V617F|JAK2 Val617Phe|JAK2 p.V617F|JAK2 p.Val617Phe|Janus Kinase 2 V617F|Janus Kinase 2 Val617Phe|Janus Kinase-2 V617F|Janus Kinase-2 Val617Phe|NP_004963.1:p.V617F|NP_004963.1:p.Val617Phe|Tyrosine-Protein Kinase JAK2 V617F|Tyrosine-Protein Kinase JAK2 Val617Phe	A change in the amino acid residue at position 617 in the tyrosine-protein kinase JAK2 protein where valine has been replaced by phenylalanine.	JAK2 NP_004963.1:p.V617F		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105909>	C174178|C136641	JAK2 NM_004972.3:c.1848_1849delinsCT|JAK-2 c.1848_1849TG>CT|JAK-2 c.1848_1849delTGinsCT|JAK2 NM_004972.3:c.1848_1849TG>CT|JAK2 NM_004972.3:c.1848_1849TG>CT|JAK2 NM_004972.3:c.1848_1849delTGinsCT|JAK2 c.1848_1849TG>CT|JAK2 c.1848_1849delTGinsCT|JTK10 c.1848_1849TG>CT|JTK10 c.1848_1849delTGinsCT|Janus Kinase 2 c.1848_1849TG>CT|Janus Kinase 2 c.1848_1849delTGinsCT|NM_004972.3:c.1848_1849TG>CT|NM_004972.3:c.1848_1849delTGinsCT|NM_004972.3:c.1848_1849delinsCT	A complex substitution where the nucleotide sequence at positions 1848 and 1849 of the coding sequence of the JAK2 gene has changed from thymine-guanine to cytosine-thymine.	JAK2 NM_004972.3:c.1848_1849TG>CT		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10590>	C61063	BCG/Isoniazid|BCG/INH			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105910>	C174178|C136641	JAK2 NM_004972.3:c.1849G>T|JAK-2 c.1849G>T|JAK2 c.1849G>T|JTK10 c.1849G>T|Janus Kinase 2 c.1849G>T|NM_004972.3:c.1849G>T	A nucleotide substitution at position 1849 of the coding sequence of the JAK2 gene where guanine has been mutated to thymine.	JAK2 NM_004972.3:c.1849G>T		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105911>	C84255|C136641	JAK2 NM_004972.3:c.2792A>G|JAK-2 c.2792A>G|JAK2 c.2792A>G|JTK10 c.2792A>G|Janus Kinase 2 c.2792A>G|NM_004972.3:c.2792A>G	A nucleotide substitution at position 2792 of the coding sequence of the JAK2 gene where adenine has been mutated to guanine.	JAK2 NM_004972.3:c.2792A>G		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105912>	C105906	JAK2 NP_004963.1:p.Y931C|JAK2 NP_004963.1:p.Tyr931Cys|JAK2 Tyr931Cys|JAK2 Y931C|JAK2 p.Tyr931Cys|JAK2 p.Y931C|Janus Kinase 2 Tyr931Cys|Janus Kinase 2 Y931C|NP_004963.1:p.Tyr931Cys|NP_004963.1:p.Y931C|Tyrosine-Protein Kinase JAK2 Tyr931Cys|Tyrosine-Protein Kinase JAK2 Y931C	A change in the amino acid residue at position 931 in the tyrosine-protein kinase JAK2 protein where tyrosine has been replaced by cysteine.	JAK2 NP_004963.1:p.Y931C		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105913>	C105906	JAK2 NP_004963.1:p.E985K|JAK2 E985K|JAK2 Glu985Lys|JAK2 NP_004963.1:p.Glu985Lys|JAK2 p.E985K|JAK2 p.Glu985Lys|Janus Kinase 2 E985K|Janus Kinase 2 Glu985Lys|NP_004963.1:p.E985K|NP_004963.1:p.Glu985Lys|Tyrosine-Protein Kinase JAK2 E985K|Tyrosine-Protein Kinase JAK2 Glu985Lys	A change in the amino acid residue at position 985 in the tyrosine-protein kinase JAK2 protein where glutamic acid has been replaced by lysine.	JAK2 NP_004963.1:p.E985K		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105914>	C105906	JAK2 NP_004963.1:p.G935R|JAK2 G935R|JAK2 Gly935Arg|JAK2 NP_004963.1:p.Gly935Arg|JAK2 p.G935R|JAK2 p.Gly935Arg|Janus Kinase 2 G935R|Janus Kinase 2 Gly935Arg|NP_004963.1:p.G935R|NP_004963.1:p.Gly935Arg|Tyrosine-Protein Kinase JAK2 G935R|Tyrosine-Protein Kinase JAK2 Gly935Arg	A change in the amino acid residue at position 935 in the tyrosine-protein kinase JAK2 protein where glycine has been replaced by arginine.	JAK2 NP_004963.1:p.G935R		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105915>	C105906	JAK2 NP_004963.1:p.I960V|JAK2 I960V|JAK2 Ile960Val|JAK2 NP_004963.1:p.Ile690Val|JAK2 p.I960V|JAK2 p.Ile960Val|Janus Kinase 2 I960V|Janus Kinase 2 Ile960Val|NP_004963.1:p.I960V|NP_004963.1:p.Ile960Val|Tyrosine-Protein Kinase JAK2 I960V|Tyrosine-Protein Kinase JAK2 Ile960Val	A change in the amino acid residue at position 960 in the tyrosine-protein kinase JAK2 protein where isoleucine has been replaced by valine.	JAK2 NP_004963.1:p.I960V		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105916>	C105906	JAK2 NP_004963.1:p.M929I|JAK2 M929I|JAK2 Met929Ile|JAK2 NP_004963.1:p.Met929Ile|JAK2 p.M929I|JAK2 p.Met929Ile|Janus Kinase 2 M929I|Janus Kinase 2 Met929Ile|NP_004963.12:p.Met929Ile|NP_004963.1:p.M929I|Tyrosine-Protein Kinase JAK2 M929I|Tyrosine-Protein Kinase JAK2 Met929Ile	A change in the amino acid residue at position 929 in the tyrosine-protein kinase JAK2 protein where methionine has been replaced by isoleucine.	JAK2 NP_004963.1:p.M929I		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105917>	C105906	JAK2 NP_004963.1:p.R938L|JAK2 Arg938Leu|JAK2 NP_004963.1:p.Arg938Leu|JAK2 R938L|JAK2 p.Arg938Leu|JAK2 p.R938L|Janus Kinase 2 Arg938Leu|Janus Kinase 2 R938L|NP_004963.1:p.Arg938Leu|NP_004963.1:p.R938L|Tyrosine-Protein Kinase JAK2 Arg938Leu|Tyrosine-Protein Kinase JAK2 R938L	A change in the amino acid residue at position 938 in the tyrosine-protein kinase JAK2 protein where arginine has been replaced by leucine.	JAK2 NP_004963.1:p.R938L		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105918>	C21344	EPGN Gene|EPGN|EPGN|Epithelial Mitogen Gene	This gene plays a role in epithelial cell growth.	EPGN Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105919>	C105918	EPGN wt Allele|ALGV3072|EPG|Epithelial Mitogen Homolog (Mouse) Gene|Epithelial Mitogen wt Allele|PRO9904	Human EPGN wild-type allele is located in the vicinity of 4q13.3 and is approximately 7 kb in length. This allele, which encodes epigen protein, is involved in epidermal cell survival, proliferation, and migration.	EPGN wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10591>	C61063	Cisplatin/Edatrexate|CDDP/EDAM|Cisplatin/10-EdAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105920>	C20970	Epigen|EPG|Epithelial Mitogen|Epithelial Mitogen Homolog	Epigen (154 aa, ~17 kDa) is encoded by the human EPGN gene. This protein plays a role in survival, proliferation, and migration of epidermal cells.	Epigen		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105921>	C13432	5p15	A chromosome band present on 5p.	5p15		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105922>	C29936	A2M Gene|A2M|A2M|Alpha-2-Macroglobulin Gene	This gene has activity as a protease inhibitor.	A2M Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105923>	C105922	A2M wt Allele|A2MD|Alpha-2-Macroglobulin wt Allele|CPAMD5|FWP007|S863-7	Human A2M wild-type allele is located in the vicinity of 12p13.31 and is approximately 49 kb in length. This allele, which encodes alpha-2-macroglobulin protein, plays a role in various processes as a protease inhibitor. Mutations in this gene are associated with alpha-2-macroglobulin deficiency and susceptibility to Alzheimer disease.	A2M wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105924>	C18072	Alpha-2-Macroglobulin|A2M|Alpha-2-M|C3 and PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 5	Alpha-2-macroglobulin (1474 aa, ~163 kDa) is encoded by the human A2M gene. This protein has activity as a protease inhibitor.	Alpha-2-Macroglobulin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105925>	C26147	TMTC1 Gene|TMTC1|TMTC1|Transmembrane O-Mannosyltransferase Targeting Cadherins 1 Gene	This gene is involved in serine/threonine mannosylation.	TMTC1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105926>	C105925	TMTC1 wt Allele|ARG99|FLJ31400|FLJ41625|OLF|TMTC1A|Transmembrane O-Mannosyltransferase Targeting Cadherins 1 wt Allele|Transmembrane and Tetratricopeptide Repeat Containing 1 Gene	Human TMTC1 wild-type allele is located in the vicinity of 12p11.22 and is approximately 284 kb in length. This allele, which encodes transmembrane and TPR repeat-containing protein 1, a mitochondrial integral membrane protein of unknown function.	TMTC1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105927>	C17434	Protein O-Mannosyl-Transferase TMTC1|EC 2.4.1.109|Transmembrane and TPR Repeat-Containing Protein 1|Transmembrane and TPR Repeat-Containing Protein 1|Transmembrane and Tetratricopeptide Repeat Containing 1A	Protein O-mannosyl-transferase TMTC1 (882 aa, ~99 kDa) is encoded by the human TMTC1 gene. This protein is involved in protein mannosylation.	Transmembrane and TPR Repeat-Containing Protein 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105928>	C20923	EDNRB Gene|EDNRB|EDNRB|Endothelin Receptor Type B Gene	This gene is involved in cell signaling.	EDNRB Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105929>	C105928	EDNRB wt Allele|ABCDS|ET-B|ET-BR|ETB|ETB1|ETBR|ETRB|Endothelin Receptor Type B wt Allele|HSCR|HSCR2|WS4A	Human EDNRB wild-type allele is located in the vicinity of 13q22 and is approximately 24 kb in length. This allele, which encodes endothelin receptor type B protein, plays a role in vasoconstriction, vasodilation, bronchoconstriction and cell proliferation. Mutations in this gene are associated with ABCD syndrome, Waardenburg syndrome, type 4A, and susceptibility to Hirschsprung disease 2.	EDNRB wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10592>	C61063	Hexamethylene Bisacetamide/Tretinoin|ATRA/HMBA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105930>	C18239	Endothelin Receptor Type B|EDNRB|ET-B|ET-BR|Endothelin B Receptor|Endothelin B Receptor|Endothelin Receptor Non-Selective Type	Endothelin receptor type B (442 aa, ~50 kDa) is encoded by the human EDNRB gene. This protein is involved in vasoconstriction and vasodilation.	Endothelin B Receptor		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105931>	C20921	FGD5 Gene|FGD5|FGD5|FYVE, RhoGEF and PH Domain Containing 5 Gene	This gene plays a role in the reorganization of the actin cytoskeleton.	FGD5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105932>	C105931	FGD5 wt Allele|FLJ00274|FLJ39957|FYVE, RhoGEF and PH Domain Containing 5 wt Allele|ZFYVE23	Human FGD5 wild-type allele is located in the vicinity of 3p25.1 and is approximately 116 kb in length. This allele, which encodes FYVE, RhoGEF and PH domain-containing protein 5, is involved in both signal transduction and the reorganization of the actin cytoskeleton.	FGD5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105933>	C17494	FYVE, RhoGEF and PH Domain-Containing Protein 5|FGD5|Zinc Finger FYVE Domain-Containing Protein 23	FYVE, RhoGEF and PH domain-containing protein 5 (1462 aa, ~160 kDa) is encoded by the human FGD5 gene. This protein plays a role in both signal transduction and the reorganization of the actin cytoskeleton.	FYVE, RhoGEF and PH Domain-Containing Protein 5		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105934>	C54362	LDB2 Gene|LDB2|LDB2|LIM Domain Binding 2 Gene	This gene is involved in the regulation of transcription.	LDB2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105935>	C105934	LDB2 wt Allele|CLIM-1|CLIM1|LDB-2|LDB1|LIM Domain Binding 2 wt Allele	Human LDB2 wild-type allele is located in the vicinity of 4p16 and is approximately 397 kb in length. This allele, which encodes LIM domain-binding protein 2, plays a role in the modulation of gene transcription.	LDB2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105936>	C26199	LIM Domain-Binding Protein 2|Carboxyl-Terminal LIM Domain-Binding Protein 1|LDB2|LIM Binding Domain 2|LIM Domain-Binding Factor CLIM1|LIM Domain-Binding Factor-2	LIM domain-binding protein 2 (373 aa, ~43 kDa) is encoded by the human LDB2 gene. This protein is involved in transcription factor regulation.	LIM Domain-Binding Protein 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105937>	C20194	PALMD Gene|PALMD|PALMD|Palmdelphin Gene	This gene may play a role in plasma membrane dynamics.	PALMD Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105938>	C105937	PALMD wt Allele|C1orf11|FLJ20271|PALML|Palmdelphin wt Allele	Human PALMD wild-type allele is located in the vicinity of 1p22-p21 and is approximately 49 kb in length. This allele, which encodes palmdelphin protein, may be involved in plasma membrane dynamics.	PALMD wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105939>	C18466	Palmdelphin|Paralemnin-Like Protein	Palmdelphin (551 aa, ~63 kDa) is encoded by the human PALMD gene. This protein may play a role in plasma membrane dynamics.	Palmdelphin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10593>	C61007	Bromocriptine/Flutamide|BRCR/FLUT			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105940>	C20130	Serum Amyloid A|SAA	A family of apolipoproteins that are associated with high-density lipoprotein particles in the serum. These proteins may play a role in both the acute-phase of inflammation and in cholesterol transport.	Serum Amyloid A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105941>	C26070	PLPP3 Gene|PLPP3|PLPP3|PPAP2B|Phospholipid Phosphatase 3 Gene	This gene is involved in the metabolism of diacylglycerol.	PLPP3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105942>	C105941	PLPP3 wt Allele|Dri42|LPP3|PAP-2b|PAP2B|PPAP2B|Phosphatidic Acid Phosphatase Type 2B Gene|Phospholipid Phosphatase 3 wt Allele|VCIP	Human PLPP3 wild-type allele is located in the vicinity of 1p32.2 and is approximately 151 kb in length. This allele, which encodes phospholipid phosphatase 3 protein, plays a role in both diacylglycerol metabolism and phospholipase D cell signaling.	PLPP3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105943>	C16981	Phospholipid Phosphatase 3|EC 3.1.3.4|Lipid Phosphate Phosphohydrolase 3|PAP2 Beta|PAP2-Beta|PLPP3|Phosphatidate Phosphohydrolase Type 2b|Phosphatidic Acid Phosphatase 2b|Phosphatidic Acid Phosphatase Type 2B|Type-2 Phosphatidic Acid Phosphatase-Beta|VCIP|Vascular Endothelial Growth Factor and Type I Collagen Inducible|Vascular Endothelial Growth Factor and Type I Collagen-Inducible Protein	Phospholipid phosphatase 3 (311 aa, ~35 kDa) is encoded by the human PLPP3 gene. This protein is involved in both cell signaling and diacylglycerol metabolism.	Phospholipid Phosphatase 3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105944>	C20921	SPRY1 Gene|SPRY1|SPRY1|Sprouty Homolog 1, Antagonist of FGF Signaling (Drosophila) Gene	This gene may play a role in both signaling and organogenesis.	SPRY1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105945>	C105944	SPRY1 wt Allele|Sprouty Homolog 1, Antagonist of FGF Signaling (Drosophila) Gene wt Allele|Spry-1|hSPRY1	Human SPRY1 wild-type allele is located in the vicinity of 4q28.1 and is approximately 7 kb in length. This allele, which encodes protein sprouty homolog 1, may act as an antagonist of fibroblast growth factor signaling in organogenesis.	SPRY1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105946>	C18515	Protein Sprouty Homolog 1|Sprouty (Drosophila) Homolog 1 (Antagonist of FGF Signaling)|Sprouty, Drosophila, Homolog of, 1 (Antagonist of FGF Signaling)	Protein sprouty homolog 1 (319 aa, ~35 kDa) is encoded by the human SPRY1 gene. This protein may play a role in fibroblast growth factor signaling in organogenesis.	Protein Sprouty Homolog 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105947>	C28597	Mitogen-Activated Protein Kinase Kinase|MAP Kinase Kinase|MAP2K|MAPKK|MAPKK1|MEK|MEK1|MEK2|MKK	A family of dual-specific protein kinases that are activated through phosphorylation by mitogen-activated protein kinase kinase kinase (MAP3K, MAPKKK) proteins and can subsequently phosphorylate and activate mitogen-activated protein kinases (MAPK).	Mitogen-Activated Protein Kinase Kinase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105948>	C45564	3-Hydroxycotinine|1-Methyl-3-Hydroxy-5-(3-Pyridyl)-2-Pyrrolidinone|3'-Hydroxycotinine|3-HC|3-Hydroxy-1-Methyl-5-(3-Pyridinyl)-2-Pyrrolidinone|3-OH-Cotinine|3HC	A metabolite of nicotine that is detectable in the urine of smokers.	3-Hydroxycotinine		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C105949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105949>	C73539	Homocysteine|2-Amino-4-Mercapto-Butanoic Acid|2-Amino-4-Mercapto-Butyric acid|2-Amino-4-Mercaptobutyric Acid|2-Amino-4-Sulfanylbutanoic Acid|Butanoic Acid, 2-Amino-4-Mercapto-|Butyric Acid, 2-Amino-4-Mercapto-|HOMOCYSTEINE|Hcy|Homo-Cys	An amino acid derivative and homolog of cysteine containing an additional methylene bridge. Homocysteine is a product of methionine metabolism and elevated plasma levels are associated with cardiovascular disease, Alzheimer disease and several metabolic diseases.	Homocysteine		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C10594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10594>	C61063	Bromocriptine/Flutamide/Leuprolide|BRCR/FLUT/LEUP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105950>	C709	Arabinofuranosylcytosine Triphosphate|Ara-CTP|AraCTP|Arabinosylcytosine 5'-Triphosphate|Arabinosylcytosine Triphosphate|CYTARABINE TRIPHOSPHATE|Cytarabine Triphosphate|Cytosine Arabinoside Triphosphate|Triphosphate, Arabinofuranosylcytosine|Triphosphate, Arabinosylcytosine|Triphosphate, Cytarabine	A triphosphate nucleotide analog that is the metabolized, biologically active form of cytarabine. This metabolite is a competitive inhibitor of DNA synthesis.	Arabinofuranosylcytosine Triphosphate		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C105951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105951>	C709	Deoxyribonucleotide Triphosphate|dNTP	A nucleotide comprised of either a purine or pyrimidine nitrogenous base bound to a deoxyribose sugar esterified with three phosphate groups. These molecules are essential for DNA synthesis.	Deoxyribonucleotide Triphosphate		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology
C105952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105952>	C20130	Apolipoprotein A|APOA|Apo A	A family of apolipoproteins that bind to and transport lipids. These proteins are involved in the structural integrity of high-density lipoprotein particles.	Apolipoprotein A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105953>	C20745	SYNPO Gene|SYNPO|SYNPO|Synaptopodin Gene	This gene is involved in both cell morphology and cell motility.	SYNPO Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105954>	C105953	SYNPO wt Allele|KIAA1029|SYNPO1|Synaptopodin wt Allele	Human SYNPO wild-type allele is located in the vicinity of 5q33.1 and is approximately 58 kb in length. This allele, which encodes synaptopodin protein, plays a role in actin-mediated cell motility and cell morphology.	SYNPO wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105955>	C16492	Synaptopodin|SYNPO	Synaptopodin (929 aa, ~94 kDa) is encoded by the human SYNPO gene. This protein is involved in actin-mediated cell morphology and cell motility.	Synaptopodin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105956>	C20420	TCF4 Gene|TCF4|TCF4|Transcription Factor 4 Gene	This gene plays a role in transcriptional regulation.	TCF4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105957>	C105956	TCF4 wt Allele|E2-2|ITF-2|ITF2|PTHS|SEF-2|SEF2|SEF2-1|SEF2-1A|SEF2-1B|TCF-4|Transcription Factor 4 wt Allele|bHLHb19	Human TCF4 wild-type allele is located 18q21.1 and is approximately 442 kb in length. This allele, which encodes transcription factor 4 protein, is involved in transcriptional regulation of immunoglobulin genes. Mutations in this gene are associated with Pitt-Hopkins syndrome.	TCF4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105958>	C17207	Transcription Factor 4|Class B Basic Helix-Loop-Helix Protein 19|Immunoglobulin Transcription Factor 2|SL3-3 Enhancer Factor 2|TCF4	Transcription factor 4 (667 aa, ~71 kDa) is encoded by the human TCF4 gene. This protein plays a role in the regulation of immunoglobulin transcription.	Transcription Factor 4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105959>	C20130	Excision Repair Cross-Complementing Family|ERCC|Excision Repair Cross Complementing-Group|Excision Repair Cross-Complementing Protein Family|Excision Repair Cross-Complementing Rodent Repair Deficiency, Complementation Group Protein	A family of DNA repair proteins.	Excision Repair Cross-Complementing Family		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10595>	C61063	Flutamide/Ketoconazole/Leuprolide|FLUT/KCZ/LEUP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105960>	C20130	DNA Ligase|EC 6.5.1.1|Polydeoxyribonucleotide Synthase|Polynucleotide Ligase	A family of enzymes that catalyze the formation of phosphodiester bonds to repair broken strands of DNA.	DNA Ligase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105961>	C25982	IL22 Gene|IL22|IL22|Interleukin 22 Gene	This gene is involved in the immune response.	IL22 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105962>	C105961	IL22 wt Allele|IL-21|IL-D110|IL-TIF|IL21|ILTIF|Interleukin 22 wt Allele|MGC79382|MGC79384|TIFIL-23|TIFa	Human IL22 wild-type allele is located in the vicinity of 12q15 and is approximately 5 kb in length. This allele, which encodes interleukin-22, plays a role in both cell signaling and regulation of the immune response.	IL22 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105963>	C20497	Interleukin-22|Cytokine Zcyto18|IL-10-Related T-Cell-Derived Inducible Factor|IL-10-Related T-Cell-Derived-Inducible Factor|IL-22|IL22|Zcyto18	Interleukin-22 (179 aa, ~20 kDa) is encoded by the human IL22 gene. This protein is involved in both cell signaling and the immune response.	Interleukin-22		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105964>	C20194	RWDD3 Gene|RWD Domain Containing 3 Gene|RWDD3|RWDD3	This gene plays a role in sumoylation.	RWDD3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105965>	C105964	RWDD3 wt Allele|DKFZP566K023|RSUME|RWD Domain Containing 3 wt Allele	Human RWDD3 wild-type allele is located in the vicinity of 1p21.3 and is approximately 13 kb in length. This allele, which encodes RWD domain-containing protein 3, is involved in the regulation of protein sumoylation.	RWDD3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105966>	C18466	RWD Domain-Containing Protein 3|RSUME1|RWD Domain-Containing Sumoylation Enhancer|RWD-Containing Sumoylation Enhancer|RWDD3	RWD domain-containing protein 3 (267 aa, ~31 kDa) is encoded by the human RWDD3 gene. This protein plays a role in the sumoylation of proteins.	RWD Domain-Containing Protein 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105967>	C21114	TNFSF13 Gene|TNFSF13|TNFSF13|Tumor Necrosis Factor (Ligand) Superfamily, Member 13 Gene	This gene is involved in B cell development.	TNFSF13 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105968>	C105967	TNFSF13 wt Allele|APRIL|CD256|TALL-2|TALL2|TRDL-1|Tumor Necrosis Factor (Ligand) Family, Member 13A Gene|Tumor Necrosis Factor (Ligand) Superfamily, Member 13 wt Allele|Tumor Necrosis Factor Ligand Superfamily, Member 13 Gene|Tumor Necrosis Factor Ligand Superfamily, Member 13A Gene|ZTNF2	Human TNFSF13 wild-type allele is located in the vicinity of 17p13.1 and is approximately 3 kb in length. This allele, which encodes tumor necrosis factor ligand superfamily member 13 protein, plays a role in the regulation of both B cell development and apoptosis.	TNFSF13 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105969>	C20500	Tumor Necrosis Factor Ligand Superfamily Member 13|A Proliferation-Inducing Ligand|APRIL|CD256 Antigen|TNF- and APOL-Related Leukocyte Expressed Ligand 2|TNF-Related Death Ligand 1|TNFSF13|Tumor Necrosis Factor-Like Protein ZTNF2|Tumor Necrosis Factor-Related Death Ligand-1	Tumor necrosis factor ligand superfamily member 13 (250 aa, ~27 kDa) is encoded by the human TNFSF13 gene. This protein is involved in the regulation of both apoptosis and B cell development.	Tumor Necrosis Factor Ligand Superfamily Member 13		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10596>	C61063	Flutamide/Ketoconazole|FLUT/KCZ			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105971>	C21176	Calprotectin|Leukocyte L1 Complex|MRP-8/MRP-14 Complex|S100A8/A9 Complex|S100A8/S100A9 Complex	A heterodimeric or heterotetrameric protein complex comprised of protein S100A8 and protein S100A9. This complex is expressed in the cytosol of neutrophils and macrophages and plays a role in multiple host defense related processes including immunomodulation, neutrophil chemotaxis and both antibacterial and antifungal responses.	Calprotectin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105972>	C20912	IL13RA2 Gene|IL13RA2|IL13RA2|Interleukin 13 Receptor Subunit Alpha 2 Gene	This gene plays a role in both B-cell maturation and differentiation.	IL13RA2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|Pediatric Oncology Target Cell Lineage Determinant Terminology
C105973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105973>	C105972	IL13RA2 wt Allele|CD213a2|CT19|IL-13R|IL-13RA2|IL13BP|IL13R|Interleukin 13 Receptor Subunit Alpha 2 wt Allele|Interleukin 13 Receptor, Alpha 2 Gene	Human IL13RA2 wild-type allele is located within Xq13.1-q28 and is approximately 16 kb in length. This allele, which encodes interleukin-13 receptor subunit alpha-2 protein, is involved in both the maturation and differentiation of B-cells.	IL13RA2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105974>	C16692	HLA-DR15 Antigen|HLA Class II Histocompatibility Antigen Complex, DR15|HLA-DR15|Major Histocompatibility Complex, Class II, DR15	HLA-DR15 antigen is a set of polymorphic glycoprotein complexes encoded by the human HLA-DRA and HLA-DRB1 genes. This protein complex is involved in the presentation of antigens to CD4+ T lymphocytes.	HLA-DR15 Antigen		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105975>	C17667	Interleukin-13 Receptor Subunit Alpha-2|CD213a2 Antigen|Cancer/Testis Antigen 19|IL-13 Receptor Subunit Alpha-2|IL-13R Subunit Alpha-2|IL-13R-Alpha-2|IL13RA2|Interleukin 13 Binding Protein|Interleukin 13 Receptor Alpha 2 Chain|Interleukin-13-Binding Protein	Interleukin-13 receptor subunit alpha-2 (380 aa, ~44 kDa) is encoded by the human IL13RA2 gene. This protein plays a role in both B-cell differentiation and maturation.	Interleukin-13 Receptor Subunit Alpha-2		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Cell Lineage Determinant Terminology
C105976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105976>	C113513	HLA Class I Histocompatibility Antigen, A-24 Alpha Chain|Aw-24|HLA Class I Histocompatibility Antigen, A*24 Alpha Chain|HLA Class I Histocompatibility Antigen, A-9 Alpha Chain|HLA-A*24|HLA-A24|HLA-A24 Antigen|Leukocyte Antigen Class I-A24|MHC Class I Antigen A*24|MHC Class I Antigen HLA-A24 Heavy Chain|Major Histocompatibility Complex, Class I, A*24|Major Histocompatibility Complex, Class I, A24	HLA class I histocompatibility antigen, A-24 alpha chain protein (365 aa, ~41 kDa) is encoded by the human HLA-A gene. This protein plays a role in the presentation of foreign antigens to the immune system.	HLA Class I Histocompatibility Antigen, A-24 Alpha Chain		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105977>	C30073	KRT17 Gene|KRT17|KRT17|Keratin 17 Gene	This gene plays a role in the development of epidermal appendages.	KRT17 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105978>	C105977	KRT17 wt Allele|39.1|CK-17|K17|Keratin 17 wt Allele|PC|PC2|PCHC1	Human KRT17 wild-type allele is located in the vicinity of 17q21.2 and is approximately 5 kb in length. This allele, which encodes keratin, type I cytoskeletal 17 protein, is involved in the formation of hair follicles and sebaceous glands. Mutations in this gene are associated with Jackson-Lawler type pachyonychia congenita and steatocystoma multiplex.	KRT17 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105979>	C21176	5-HT3 Receptor|5-HT-3 Receptor|5-HT-3R|5-HT3R|5-Hydroxytryptamine 3 Receptor|5HT3 Receptor|5HT3R|Serotonin 5-HT-3 Receptor|Serotonin Receptor Type 3|Type 3 Serotonin Receptor	A protein complex that plays a role in neurotransmitter-gated ion transport. It is a pentamer that binds serotonin and is comprised of either five 5-hydroxytryptamine receptor 3A subunits or a combination of four 5-hydroxytryptamine receptor 3A molecules with one of the alternative subunits, 5-hydroxytryptamine receptor 3B, 3C, 3D or 3E.	5-HT3 Receptor		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10597>	C61063	Trifluoperazine/Verapamil/Vinblastine|TFPZ/VBL/VPAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105980>	C20694	Keratin, Type I Cytoskeletal 17|Cytokeratin-17|KRT17|Keratin 17|Keratin 17 Epitope S1|Keratin 17 Epitope S2|Keratin 17 Epitope S4|Keratin-17	Keratin, type I cytoskeletal 17 (432 aa, ~48 kDa) is encoded by the human KRT17 gene. This protein plays a role in the development of hair follicles and other skin appendages.	Keratin, Type I Cytoskeletal 17		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105981>	C30073	KRT14 Gene|KRT14|KRT14|Keratin 14 Gene	This gene is involved in the regulation of cell shape.	KRT14 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105982>	C105981	KRT14 wt Allele|CK-14|CK14|EBS3|EBS4|K14|Keratin 14 wt Allele|NFJ	Human KRT14 wild-type allele is located within 17q12-q21 and is approximately 5 kb in length. This allele, which encodes keratin, type I cytoskeletal 14 protein, plays a role in the regulation of cell morphology. Mutations in this gene are associated with dermatopathia pigmentosa reticularis, Naegeli-Franceschetti-Jadassohn syndrome, and several types of epidermolysis bullosa simplex.	KRT14 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105983>	C20694	Keratin, Type I Cytoskeletal 14|CK-14|Cytokeratin 14|Cytokeratin-14|K14|KRT14|Keratin 14|Keratin-14	Keratin, type I cytoskeletal 14 (472 aa, ~52 kDa) is encoded by the human KRT14 gene. This protein is involved in cell morphology regulation.	Keratin, Type I Cytoskeletal 14		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105984>	C101803	F1.2|F1+2|F1-2|Pro-Thrombin Activation Fragment|Prothrombin Activation Fragment|Prothrombin Activation Fragment F1-2|Prothrombin Activation Fragment F1.2	The two peptides that can be released by proteolytic activation of prothrombin to thrombin. The level of these fragments is directly proportional to the amount of active thrombin in a blood sample.	F1.2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105985>	C80699	MIR150 Gene|MIR150|MIR150|MicroRNA 150 Gene	This gene may be involved in the regulation of protein expression.	MIR150 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105986>	C105985	MIR150 wt Allele|MIRN150|MicroRNA 150 wt Allele|hsa-mir-150|miR-150|miRNA 150|miRNA150|mir-150	Human MIR150 wild-type allele is located in the vicinity of 19q13.33 and is 84 bases in length. This allele, which encodes MIR150 pre-miRNA, may play a role in the regulation of gene transcription.	MIR150 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105987>	C25968	MIR150 Pre-miRNA|MIR150 pre-miRNA|Pre-MicroRNA 150|Pre-miRNA 150|Pre-miRNA MIR150	MIR150 pre-miRNA (84 bases) is encoded by the human MIR150 gene. This ribonucleotide may be involved in the regulation of transcription.	MIR150 Pre-miRNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105988>	C80699	MIR191 Gene|MIR191|MIR191|MicroRNA 191 Gene	This gene is involved in the regulation of gene expression.	MIR191 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105989>	C105988	MIR191 wt Allele|MIRN191|MicroRNA 191 wt Allele|hsa-mir-191|miR-191|miRNA 191|miRNA191|mir-191	Human MIR191 wild-type allele is located in the vicinity of 3p21.31 and is 92 bases in length. This allele, which encodes MIR191 pre-miRNA, may play a role in the regulation of transcription.	MIR191 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10598>	C61063	Cisplatin/Cyclophosphamide/Doxorubicin/Etoposide/Fluorouracil/Vincristine|CDDP/CTX/DOX/5-FU/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C105990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105990>	C25968	MIR191 Pre-miRNA|MIR191 pre-miRNA|Pre-MicroRNA 191|Pre-miRNA 191|Pre-miRNA MIR191	MIR191 pre-miRNA (92 bases) is encoded by the human MIR191 gene. This ribonucleotide may be involved in the regulation of gene transcription.	MIR191 Pre-miRNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105991>	C25870	SULT1E1 Gene|SULT1E1|SULT1E1|Sulfotransferase Family 1E, Estrogen-Preferring, Member 1 Gene	This gene plays a role in estrogen metabolism.	SULT1E1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105992>	C105991	SULT1E1 wt Allele|EST|EST-1|ST1E1|STE|Sulfotransferase Family 1E, Estrogen-Preferring, Member 1 wt Allele	Human SULT1E1 wild-type allele is located in the vicinity of 4q13.1 and is approximately 49 kb in length. This allele, which encodes estrogen sulfotransferase protein, is involved in the metabolism of estrogen.	SULT1E1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105993>	C17210	Estrogen Sulfotransferase|EC 2.8.2.4|EST-1|Estrone Sulfotransferase|ST1E1|SULT1E1|Sulfotransferase 1E1|Sulfotransferase, Estrogen-Preferring	Estrogen sulfotransferase (294 aa, ~35 kDa) is encoded by the human SULT1E1 gene. This protein plays a role in the conjugation of sulfate to estrogens.	Estrogen Sulfotransferase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105994>	C20194	BAG3 Gene|BAG3|BAG3|BCL2-Associated Athanogene 3 Gene	This gene is involved in the regulation of both protein folding and apoptosis.	BAG3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105995>	C105994	BAG3 wt Allele|BAG-3|BCL2-Associated Athanogene 3 wt Allele|BIS	Human BAG3 wild-type allele is located within 10q25.2-q26.2 and is approximately 26 kb in length. This allele, which encodes BAG family molecular chaperone regulator 3 protein, plays a role in the modulation of both apoptosis and protein folding. Mutation of the gene is associated with both myopathy myofibrillar type 6 and cardiomyopathy dilated type 1HH.	BAG3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105996>	C18466	BAG Family Molecular Chaperone Regulator 3|BAG-3|BAG-Family Molecular Chaperone Regulator-3|BAG3|Bcl-2-Associated Athanogene 3|Bcl-2-Binding Protein Bis|Docking Protein CAIR-1	BAG family molecular chaperone regulator 3 (575 aa, ~62 kDa) is encoded by the human BAG3 gene. This protein is involved in both protein chaperone activity modulation and the negative regulation of apoptosis.	BAG Family Molecular Chaperone Regulator 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105997>	C20420	RELB Gene|RELB|RELB|v-rel Reticuloendotheliosis Viral Oncogene Homolog B Gene	This gene is involved in transcriptional regulation of immune processes.	RELB Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C105998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105998>	C105997	RELB wt Allele|I-REL|IREL|REL-B|v-rel Reticuloendotheliosis Viral Oncogene Homolog B wt Allele	Human RELB wild-type allele is located in the vicinity of 19q13.32 and is approximately 37 kb in length. This allele, which encodes transcription factor RelB protein, plays a role in transcriptional regulation of immune processes.	RELB wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C105999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C105999>	C17207	Transcription Factor RelB|v-rel Avian Reticuloendotheliosis Viral Oncogene Homolog B (Nuclear Factor of Kappa Light Polypeptide Gene Enhancer in B-cells 3)|v-rel Avian Reticuloendotheliosis Viral Oncogene Homolog B, Nuclear Factor of Kappa Light Polypeptide Gene Enhancer in B-cells 3	Transcription factor RelB (579 aa, ~62 kDa) is encoded by the human RELB gene. This protein is involved in transcriptional regulation of immune processes.	Transcription Factor RelB		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10599>	C61007	Busulfan/Etoposide|BU/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1059>	C146993	Cyproterone Acetate|3'H-Cyclopropa(1,2)pregna-1,4,6-triene-3,20-dione, 17-(Acetyloxy)-6-chloro-1,2-dihydro-, (1beta,2beta)-|6-Chloro-1b,2b-dihydro-17a-hydroxy-3'H-cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione Acetate|Andro-Diane|Androcur|Androcur|CYPROTERONE ACETATE|Chloro-6-hydroxy-17 Alpha Methylene-1 Alpha, 2 Alpha Pregnadiene-4,6 Dione-3, 20 Acetate|CyPat|Cyprone|Cyprostat|Cyproteronazetat|Cyproterone acetate|Cyproteroni Acetas|Diane|Dianette|SH 714|SH-714|SH-714|cyproterone acetate	The acetate salt of a synthetic steroidal antiandrogen with weak progestational and antineoplastic activities. Cyproterone binds the androgen receptor (AR), thereby preventing androgen-induced receptor activation in target tissues and inhibiting the growth of testosterone-sensitive tumor cells. This agent also exerts progestational agonist properties at the level of the pituitary that reduce luteinizing hormone (LH), resulting in reductions in testicular androgen secretion and serum testosterone levels. Treatment with cyproterone alone results in incomplete suppression of serum testosterone levels.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106000>	C28533	SERPINA7 Gene|SERPINA7|SERPINA7|Serpin Peptidase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 7 Gene	This gene plays a role in thyroid hormone binding.	SERPINA7 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106001>	C25939	STEAP1 Gene|STEAP1|STEAP1|Six Transmembrane Epithelial Antigen of the Prostate 1 Gene	This gene plays a role at cell-cell junctions.	STEAP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|Pediatric Oncology Immunotherapeutic Target Terminology
C106002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106002>	C106001	STEAP1 wt Allele|PRSS24|STEAP|Six Transmembrane Epithelial Antigen of the Prostate 1 wt Allele	Human STEAP1 wild-type allele is located in the vicinity of 7q21 and is approximately 10 kb in length. This allele, which encodes metalloreductase STEAP1 protein, plays a role at cell-cell junctions.	STEAP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106003>	C16946	Metalloreductase STEAP1|EC 1.16.1.-|STEAP1|Six-Transmembrane Epithelial Antigen of the Prostate 1	Metalloreductase STEAP1 (339 aa, ~40 kDa) is encoded by the human STEAP1 gene. This protein plays a role at cell-cell junctions.	Metalloreductase STEAP1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Immunotherapeutic Target Terminology
C106004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106004>	C106000	SERPINA7 wt Allele|Serine (Or Cysteine) Proteinase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 7 Gene|Serpin Peptidase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 7 wt Allele|TBG|TBG, Serum Gene|Thyroxine-Binding Globulin of Serum Gene	Human SERPINA7 wild-type allele is located in the vicinity of Xq22.2 and is approximately 6 kb in length. This allele, which encodes thyroxine-binding globulin protein, is involved in thyroid hormone transport. Mutation of the gene is associated with thyroxine-binding globulin deficiency.	SERPINA7 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106005>	C16386	Thyroxine-Binding Globulin|SERPINA7|Serpin A7|Serpin Family A Member 7|T4-Binding Globulin|Thyroxin-Binding Globulin	Thyroxine-binding globulin (415 aa, ~46 kDa) is encoded by the human SERPINA7 gene. This protein plays a role in both binding to and transport of both thyroxine and triiodothyroxine.	Thyroxine-Binding Globulin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106006>	C20912	IL1RL1 Gene|IL1RL1|IL1RL1|Interleukin 1 Receptor Like 1 Gene	This gene plays a role in interleukin binding and receptor signaling.	IL1RL1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106007>	C20921	SEMA3F Gene|SEMA3F|SEMA3F|Sema Domain, Immunoglobulin Domain (Ig), Short Basic Domain, Secreted, (Semaphorin) 3F Gene	This gene is involved in both cell signaling and axon guidance.	SEMA3F Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106008>	C106007	SEMA3F wt Allele|SEMA4|SEMAK|Sema Domain, Immunoglobulin Domain (Ig), Short Basic Domain, Secreted, (Semaphorin) 3F wt Allele	Human SEMA3F wild-type allele is located in the vicinity of 3p21.3 and is approximately 34 kb in length. This allele, which encodes semaphorin-3F protein, plays a role in both axon guidance and cell signaling.	SEMA3F wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106009>	C106006	IL1RL1 wt Allele|DER4|FIT-1|Growth Stimulation-Expressed Gene|Growth Stimulation-Expressed Gene Mouse, Homolog of Gene|Homolog of Mouse Growth Stimulation-Expressed Gene|IL33R|Interleukin 1 Receptor Like 1 wt Allele|Interleukin 1 Receptor-Like 1 Gene|Interleukin 1 Receptor-Related Protein Gene|Interleukin 33 Receptor Gene|ST2|ST2, Mouse, Homolog of Gene|ST2L|ST2V|T1	Human IL1RL1 wild-type allele is located in the vicinity of 2q12 and is approximately 41 kb in length. This allele, which encodes interleukin-1 receptor-like 1, is involved in immune response signal transduction.	IL1RL1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10600>	C61063	Cytarabine/Etoposide/Methotrexate/Prednisone|ARA-C/MTX/PRED/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106010>	C18515	Semaphorin-3F|SEMA3F|Sema III/F|Sema IV|Semaphorin III/F|Semaphorin IV	Semaphorin-3F (785 aa, ~88 kDa) is encoded by the human SEMA3F gene. This protein is involved in both cell signaling and axon guidance.	Semaphorin-3F		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106011>	C17667	Interleukin-1 Receptor-Like 1|IL1RL1|Interleukin 1 Receptor-Related Protein|Protein ST2	Interleukin-1 receptor-like 1 (556 aa, ~63 kDa) is encoded by the human IL1RL1 gene. This protein plays a role in binding interleukin-33 and immune response signaling.	Interleukin-1 Receptor-Like 1		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106012>	C20194	LRRC32 Gene|LRRC32|LRRC32|Leucine Rich Repeat Containing 32 Gene	This gene plays a role in the regulation of immune cell function.	LRRC32 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106013>	C106012	LRRC32 wt Allele|D11S833E|GARP|Leucine Rich Repeat Containing 32 wt Allele	Human LRRC32 wild-type allele is located within 11q13.5-q14 and is approximately 13 kb in length. This allele, which encodes leucine-rich repeat-containing protein 32, is involved in the regulation of immune cell function.	LRRC32 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106014>	C18466	Leucine-Rich Repeat-Containing Protein 32|GARP|Garpin|Glycoprotein A Repetitions Predominant|LRRC32	Leucine-rich repeat-containing protein 32 (662 aa, ~72 kDa) is encoded by the human LRRC32 gene. This protein plays a role in the regulation of immune cell function.	Leucine-Rich Repeat-Containing Protein 32		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106015>	C29936	SERPINA9 Gene|GCET1|SERPINA9|SERPINA9|Serpin Family A Member 9	This gene is involved in trypsin activity regulation.	SERPINA9 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C106016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106016>	C106015	SERPINA9 wt Allele|CENTERIN|GCET1|Germinal Center B Cell-Expressed Transcript 1 Gene|Germinal Center B-Cell-Expressed Transcript 1 Gene|SERPINA11|SERPINA11b|Serine (or Cysteine) Proteinase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 9 Gene|Serpin Family A Member 9 wt Allele|Serpin Peptidase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 9 Gene|Serpin Peptidase Inhibitor, Clade A, Member 9 Gene|UNQ692/PRO1337	Human SERPINA9 wild-type allele is located in the vicinity of 14q32.13 and is approximately 17 kb in length. This allele, which encodes Serpin A9 protein, plays a role in the regulation of trypsin activity.	SERPINA9 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106017>	C17122	Serpin A9|Centerin|Germinal Center B-Cell-Expressed Transcript 1 Protein|Serine Proteinase Inhibitor A11	Serpin A9 (417 aa, ~47 kDa) is encoded by the human SERPINA9 gene. This protein is involved in trypsin activity regulation.	Serpin A9		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106018>	C20745	SPTBN2 Gene|SPTBN2|SPTBN2|Spectrin, Beta, Non-Erythrocytic 2 Gene	This gene plays a role in actin filament function.	SPTBN2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106019>	C106018	SPTBN2 wt Allele|GTRAP41|KIAA0302|SCA5|Spectrin, Beta, Non-Erythrocytic 2 wt Allele	Human SPTBN2 wild-type allele is located in the vicinity of 11q13.2 and is approximately 44 kb in length. This allele, which encodes spectrin beta chain, non-erythrocytic 2 protein, is involved in the regulation of actin filament function. Mutations in this gene are associated with spinocerebellar ataxia 5.	SPTBN2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10601>	C61063	Cisplatin/Ifosfamide/Mitomycin|CDDP/IFF/MITO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106020>	C16492	Spectrin Beta Chain, Non-Erythrocytic 2|Beta-III Spectrin|Glutamate Transporter EAAT4-Associated Protein 41|Spectrin Beta Chain, Brain 2|Spectrin, Non-Erythroid Beta Chain 2|Spinocerebellar Ataxia 5|Spinocerebellar Ataxia 5 Protein	Spectrin beta chain, non-erythrocytic 2 (2390 aa, ~271 kDa) is encoded by the human SPTBN2 gene. This protein plays a role in the regulation of actin filament function.	Spectrin Beta Chain, Non-Erythrocytic 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106021>	C28533|C17967|C158414	ABCC3 Gene|ABCC3|ABCC3|ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 3 Gene	This gene is involved in bile metabolism.	ABCC3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106022>	C106021	ABCC3 wt Allele|ABC31|ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 3 wt Allele|EST90757|MLP2|MOAT-D|MRP3|cMOAT2	Human ABCC3 wild-type allele is located in the vicinity of 17q22 and is approximately 57 kb in length. This allele, which encodes canalicular multispecific organic anion transporter 2 protein, plays a role in bile metabolism and transport.	ABCC3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106023>	C17750|C158419	Canalicular Multispecific Organic Anion Transporter 2|ABCC3|ATP-Binding Cassette Sub-Family C Member 3|MOAT-D|Multi-Specific Organic Anion Transporter D|Multidrug Resistance-Associated Protein 3	Canalicular multispecific organic anion transporter 2 (1527 aa, ~169 kDa) is encoded by the human ABCC3 gene. This protein is involved in both the transport and metabolism of bile.	Canalicular Multispecific Organic Anion Transporter 2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106024>	C20731	DUSP6 Gene|DUSP6|DUSP6|Dual Specificity Phosphatase 6 Gene	This gene plays a role in MAP kinase dephosphorylation.	DUSP6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106025>	C106024	DUSP6 wt Allele|Dual Specificity Phosphatase 6 wt Allele|HH19|MKP3|PYST1	Human DUSP6 wild-type allele is located within 12q22-q23 and is approximately 6 kb in length. This allele, which encodes dual specificity protein phosphatase 6 protein, is involved in protein dephosphorylation and the negative regulation of mitogen-activated protein kinase-dependent signaling.	DUSP6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106026>	C25880	Dual Specificity Protein Phosphatase 6|DUSP6|Dual Specificity Protein Phosphatase PYST1|Dual-Specificity Protein Phosphatase 6|EC 3.1.3.16|EC 3.1.3.48|MAP Kinase Phosphatase 3|MKP-3|Mitogen-Activated Protein Kinase Phosphatase 3	Dual specificity protein phosphatase 6 (381 aa, ~42 kDa) is encoded by the human DUSP6 gene. This protein plays a role in both dephosphorylation and inactivation of mitogen-activated protein kinases.	Dual Specificity Protein Phosphatase 6		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106027>	C20921	SPRY2 Gene|SPRY2|SPRY2|Sprouty Homolog 2 (Drosophila) Gene	This gene is involved in the negative regulation of growth factor signaling.	SPRY2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106028>	C106027	SPRY2 wt Allele|Sprouty Homolog 2 (Drosophila) wt Allele|hSPRY2	Human SPRY2 wild-type allele is located in the vicinity of 13q31.1 and is approximately 5 kb in length. This allele, which encodes protein sprouty homolog 2, plays a role in modulation of growth factor signaling pathways.	SPRY2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106029>	C18515	Protein Sprouty Homolog 2|SPRY2|Sprouty 2|Spry-2	Protein sprouty homolog 2 (315 aa, ~35 kDa) is encoded by the human SPRY2 gene. This protein is involved in antagonism of growth factor signaling pathways.	Protein Sprouty Homolog 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10602>	C61063	Carboplatin/Etoposide/Interleukin-3|CBDCA/IL-3/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106030>	C28533	APOB Gene|APOB|APOB|Apolipoprotein B Gene	This gene plays a role in lipid transport.	APOB Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106031>	C106030	APOB wt Allele|Apolipoprotein B (Including Ag(x) Antigen) Gene|Apolipoprotein B wt Allele|FLDB|LDLCQ4	Human APOB wild-type allele is located within 2p24-p23 and is approximately 43 kb in length. This allele, which encodes apolipoprotein B-100 protein, is involved in both transport and cellular binding of lipoprotein particles. Mutation of the gene is associated with both familial ligand-defective apolipoprotein B-100 and familial hypobetalipoproteinemia type 1.	APOB wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106032>	C16386	Apolipoprotein B-100|APOB|Apo B-100|ApoB-100	Apolipoprotein B-100 (4563 aa, ~516 kDa) is encoded by the human APOB gene. This protein plays a role in both transport and cellular uptake of LDL particles.	Apolipoprotein B-100		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106033>	C20194	TRIM16 Gene|TRIM16|TRIM16|Tripartite Motif Containing 16 Gene	This gene is involved in both keratinocyte differentiation and histone acetylation.	TRIM16 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106034>	C106033	TRIM16 wt Allele|EBBP|Tripartite Motif Containing 16 wt Allele|Tripartite Motif-Containing 16 Gene	Human TRIM16 wild-type allele is located in the vicinity of 17p11.2 and is approximately 56 kb in length. This allele, which encodes tripartite motif-containing protein 16, plays a role in retinoic acid signaling, histone acetylation and keratinocyte differentiation.	TRIM16 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106035>	C21254	Tripartite Motif-Containing Protein 16|E3 Ubiquitin-Protein Ligase TRIM16|EC 2.3.2.27|Estrogen-Responsive B Box Protein|TRIM16	Tripartite motif-containing protein 16 (564 aa, ~64 kDa) is encoded by the human TRIM16 gene. This protein is involved in histone acetylation, keratinocyte differentiation and retinoic acid signaling.	Tripartite Motif-Containing Protein 16		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106036>	C52006	Percutaneous Fluoroscopic Gastrostomy|PFG|Percutaneous fluoroscopic gastrostomy (PFG)	The placement of a feeding tube through the abdominal wall into the stomach with the assistance of fluoroscopic guidance.			Therapeutic or Preventive Procedure	
C106037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106037>	C21514	Pre-dose Measure|Pre-dose	A measure that relates specifically to the last value collected prior to the time of the first dose of a treatment.			Qualitative Concept	
C106038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106038>	C44476	Not Made with Natural Rubber Latex	The composition of the materials of an item do not contain natural rubber latex.			Functional Concept	FDA CDRH GUDID Terminology
C106039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106039>	C131123	FDA CDRH GUDID Terminology|FDA Center for Devices and Radiological Health Global Unique Device Identification Database Terminology	A set of terminology created to support the efforts of the FDA CDRH Global Unique Device Identification Database project.			Intellectual Product	FDA Terminology
C10603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10603>	C61063	Interleukin-1-Beta/Interleukin-2|IL-1B/IL-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106040>	C52006	Percutaneous Endoscopic Gastrostomy|PEG|Percutaneous endoscopic gastrostomy (PEG)	The placement of a feeding tube through the abdominal wall into the stomach using an endoscope.			Therapeutic or Preventive Procedure	
C106041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106041>	C53264	Device Size Text	Information about the size of the device that is not represented elsewhere.			Qualitative Concept	FDA CDRH GUDID Terminology
C106042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106042>	C12745	Distant Lymph Node|DISTANT LYMPH NODE|Lymph Node(s) Distant	A lymph node located distant to the anatomic site of interest.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C106043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106043>	C106105	Natural Rubber|NATURAL LATEX RUBBER|Natural Rubber Latex	The natural extract of tropical rubber plants.			Classification	FDA CDRH GUDID Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C106044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106044>	C25180	Magnetic Resonance Imaging Safety Labeling Information|MRI Safety Labeling Information	Safety information about the MRI device that is included on the device label.			Functional Concept	FDA CDRH GUDID Terminology
C106045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106045>	C106044	Magnetic Resonance Safe|MR Safe	The device poses no known hazards resulting from exposure to any MR environment. MR Safe items are composed of materials that are electrically nonconductive, nonmetallic, and nonmagnetic. See ASTM F2503.			Functional Concept	FDA CDRH GUDID Terminology
C106046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106046>	C106044	Magnetic Resonance Conditional|MR Conditional	A device with demonstrated safety in the MR environment within defined conditions. At a minimum, address the conditions of the static magnetic field, the switched gradient magnetic field and the radiofrequency fields.  Additional conditions, including specific configurations of the item, may be required. See ASTM F2503.			Functional Concept	FDA CDRH GUDID Terminology
C106047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106047>	C106044	Magnetic Resonance Unsafe|MR Unsafe	The device which poses unacceptable risks to the patient, medical staff or other persons within the MR environment. See ASTM F2503			Functional Concept	FDA CDRH GUDID Terminology
C106048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106048>	C19830|C19770	Chromatin Immunoprecipitation|ChIP	A technique that utilizes immunoprecipitation to find protein-DNA interactions in a biological sample. First, the sample is treated causing the formation of protein-chromatin crosslinks. Then, the sample is sheared to separate individual protein-DNA complexes. Finally, an antibody directed against a protein of interest is applied and the protein-DNA complexes are immunoprecipitated.			Molecular Biology Research Technique	
C106049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106049>	C17350|C153598|C106048	ChIP-Seq|ChIP-Seq (chromatin ImmunoPrecipitation)|ChIP-Sequencing|Chromatin Immunoprecipitation Sequencing	A molecular genetic technique that combines chromatin immunoprecipitation (ChIP) with massively parallel DNA sequencing to map the binding sites of DNA-associated proteins in a sample of cells. First, crosslinked protein-DNA complexes are isolated using ChIP. Next, the crosslinks are broken, the proteins are removed and the purified DNA is modified with adaptor oligonucleotides to facilitate massively parallel DNA sequencing. Following sequencing, the DNA sequences that are obtained can be mapped to their genomic locations.			Molecular Biology Research Technique	CTDC Value Terminology|GDC Terminology|GDC Value Terminology
C10604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10604>	C61063	Cisplatin/Cyclophosphamide/Paclitaxel|CDDP/CTX/TAX|Cisplatin/Paclitaxel/Cyclophosphamide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106050>	C17350|C106048	ChIP-On-Chip|ChIP-Chip|Chromatin Immunoprecipitation-On-Chip	A molecular genetic technique that combines chromatin immunoprecipitation (ChIP) with DNA microarray technology to find candidate binding sites of DNA-associated proteins in a biological specimen. First, crosslinked protein-DNA complexes are isolated using ChIP. Next, the crosslinks are broken, the proteins are removed and the purified DNA is amplified, denatured and labeled with a fluorescent tag. The labeled, denatured DNA fragments are applied to a DNA microarray where they can hybridize to their complementary DNA sequence. After hybridization occurs, the microarray chip is imaged and the captured fluorescence signals from the array are normalized and subjected to statistical analysis. Finally, validated positive spots on the microarray can predict which DNA sequences interact with the protein of interest.			Molecular Biology Research Technique	
C106051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106051>	C153598	FAIRE-Seq|Formaldehyde-Assisted Isolation of Regulatory Elements Sequencing	A molecular genetic technique that depletes a biological sample of nucleosomal DNA and then subjects the non-nucleosome-associated DNA to next-generation sequencing. Since nucleosome disruption of chromatin is indicative of active sites of DNA transcription, this technique can isolate DNA sequences that are involved in transcriptional regulation. First, a sample is treated with formaldehyde to form DNA-protein crosslinks, followed by sample lysis and sonication. The processed sample is subjected to phenol/chloroform extraction and the DNA in the aqueous phase is analyzed using next-generation sequencing techniques.			Molecular Biology Research Technique	
C106052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106052>	C153598	DNase-Seq|DNase I Hypersensitive Sites Sequencing|DNase-Hypersensitivity (sequencing of hypersensitive sites or segments of open chromatin that are more readily cleaved by DNaseI)	A molecular genetic technique where genome-wide sequencing is performed on DNA regions that are super sensitive to cleavage by DNase I to identify putative DNA regulatory sequences.			Molecular Biology Research Technique	CTDC Value Terminology
C106053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106053>	C153598	NOMe-Seq|NOME-Seq|Nucleosome Occupancy and Methylome Sequencing	A DNA sequencing technique that can both determine DNA methylation status and distinguish non-nucleosomal DNA from nucleosome-associated DNA. This technique subjects samples to both bisulfite treatment to modify unmethylated cytosines and GpC methyltransferase treatment to identify non-nucleosomal DNA regions. The treated samples are then analyzed using next-generation sequencing techniques.			Molecular Biology Research Technique	
C106054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106054>	C153598	Bisulfite Sequencing|BS-Seq|Bisulfite-Seq|Bisulfite-Seq|Bisulfite-Seq (sequencing following treatment of DNA with bisulfite to convert cytosine residues to uracil)|Bisulphite Conversion Followed by Sequencing|DNA Methylation Sequencing|Methyl-C-Seq|MethylC-Seq|Methylation Sequencing|Methylation Sequencing	A DNA sequencing technique that can differentiate cytosine from 5-methylcytosine in a DNA sample. First, a denatured DNA sample is treated with bisulfite which converts non-methylated cytosine to uracil. Next, the sample is amplified using a PCR method that does not discriminate between non-methylated and methylated sequences. The amplified DNA is subjected to nucleotide sequencing. The resulting sequence is compared to an identical control sample of DNA that was not treated with bisulfite. Unmethylated cytosines will be displayed as cytosines in the control sample and as thymines in the bisulfite-treated sample.			Molecular Biology Research Technique	CTDC Value Terminology|GDC Terminology|GDC Value Terminology|SeroNet Authorized Values|SeroNet Study Descriptors
C106056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106056>	C153598	MNase Sequencing|MNase|MNase	A molecular genetic technique where genome-wide sequencing is performed on chromosomal DNA that is resistant to treatment with micrococcal nuclease. This technique identifies nucleosomal DNA sequences.			Molecular Biology Research Technique	
C106057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106057>	C19896	Methylome	The characterization of all of the nucleic acid methylation modifications in a particular cell or in the genome of an organism.			Conceptual Entity	
C106058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106058>	C54362	PHF20 Gene|PHD Finger Protein 20 Gene|PHF20|PHF20	This gene plays a role in both histone acetylation and transcriptional regulation.			Gene or Genome	
C106059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106059>	C106058	PHF20 wt Allele|C20orf104|Chromosome 20 Open Reading Frame 104 Gene|GLEA2|HCA58|NZF|PHD Finger Protein 20 wt Allele|RP5-1121G12.1|TZP|dJ1121G12.1	Human PHF20 wild-type allele is located within 20q11.22-q11.23 and is approximately 178 kb in length. This allele, which encodes PHD finger protein 20, is involved in transcriptional regulation and histone acetylation.			Gene or Genome	
C10605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10605>	C61063	Indomethacin/Interleukin-1-Alpha/Etoposide|IL-1A/Indomethacin/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106060>	C26199	PHD Finger Protein 20|Glioma-Expressed Antigen 2|Hepatocellular Carcinoma-Associated Antigen 58|Novel Zinc Finger Protein|PHF20|Transcription Factor TZP	PHD finger protein 20 (1012 aa, ~115 kDa) is encoded by the human PHF20 gene. This protein plays a role in the acetylation of histones and transcriptional regulation.			Amino Acid, Peptide, or Protein	
C106061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106061>	C25873	NEK9 Gene|NEK9|NEK9|NIMA (Never In Mitosis Gene A)-Related Kinase 9 Gene	This gene is involved in protein phosphorylation and cell division.			Gene or Genome	
C106062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106062>	C106061	NEK9 wt Allele|DKFZp434D0935|MGC16714|NERCC|NERCC1|NIMA (Never In Mitosis Gene A)-Related Kinase 9 wt Allele|Nek8	Human NEK9 wild-type allele is located in the vicinity of 14q24.3 and is approximately 45 kb in length. This allele, which encodes serine/threonine-protein kinase Nek9 protein, plays a role in the modulation of protein phosphorylation, mitosis and cell division.			Gene or Genome	
C106063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106063>	C17325	Serine/Threonine-Protein Kinase Nek9|EC 2.7.11.1|NIMA-Related Kinase Nek8|Nek8|Nercc1 Kinase|NimA-Related Kinase 8|NimA-Related Protein Kinase 9	Serine/threonine-protein kinase Nek9 (979 aa, ~107 kDa) is encoded by the human NEK9 gene. This protein is involved in the progression of mitosis and the mediation of protein phosphorylation.			Amino Acid, Peptide, or Protein|Enzyme	
C106064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106064>	C20194	SPARCL1 Gene|SPARC-Like 1 (Hevin) Gene|SPARCL1|SPARCL1	This gene may be involved in leukocyte transendothelial migration.	SPARCL1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106065>	C106064	SPARCL1 wt Allele|MAST 9|MAST9|PIG33|SC1|SPARC-Like 1 (Hevin) wt Allele	Human SPARCL1 wild-type allele is located in the vicinity of 4q22.1 and is approximately 58 kb in length. This allele, which encodes SPARC-like protein 1, may play a role in both endothelium structure and leukocyte migration.	SPARCL1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106066>	C18466	SPARC-Like Protein 1|Hevin|High Endothelial Venule Protein|MAST 9|Mast9|Proliferation-Inducing Protein 33	SPARC-like protein 1 (664 aa, ~75 kDa) is encoded by the human SPARCL1 gene. This protein may be involved in both leukocyte extravasation and endothelial cell-cell adhesion.	SPARC-Like Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106067>	C20921	RSPO2 Gene|R-Spondin 2 Gene|RSPO2|RSPO2|RSPO2	This gene plays a role in both Wnt signaling and embryonic morphogenesis.	RSPO2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C106068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106068>	C106067	RSPO2 wt Allele|CRISTIN2|HHRRD|MGC35555|R-Spondin 2 wt Allele|R-Spondin Family, Member 2 Gene|TETAMS2|UNQ9384/PRO34209	Human RSPO2 wild-type allele is located in the vicinity of 8q23.1 and is approximately 184 kb in length. This allele, which encodes R-spondin-2 protein, is involved in both signal transduction and embryonic limb formation.	RSPO2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106069>	C18515	R-Spondin-2|Roof Plate-Specific Spondin-2|hRspo2	R-spondin-2 (243 aa, ~28 kDa) is encoded by the human RSPO2 gene. This protein plays a role in beta-catenin-mediated signaling and bone, limb and lung development.	R-Spondin-2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10606>	C61063	Amphotericin B/Colistin Sulfate/Tobramycin|amphotericin B/colistin sulfate/TBM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106070>	C25784	RRAS Gene|RAS Related Gene|RRAS|RRAS|RRAS	This gene is involved in both axon guidance and the promotion of angiogenesis.	RRAS Gene		Gene or Genome	CCPS Genetics Terminology|Childhood Cancer Predisposition Study Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106071>	C106070	RRAS wt Allele|Oncogene RRAS|R-Ras|RAS Related wt Allele|Related RAS Viral (R-Ras) Oncogene Homolog Gene|Related RAS Viral Oncogene Homolog Gene	Human RRAS wild-type allele is located within 19q13.3-qter and is approximately 5 kb in length. This allele, which encodes Ras-related protein R-Ras, plays a role in both cytoskeletal rearrangement and angiogenesis.	RRAS wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106072>	C18549	Ras-Related Protein R-Ras|EC 3.6.5.-|RRAS|Ras Family Small GTP Binding Protein R-Ras|p23	Ras-related protein R-Ras (218 aa, ~23 kDa) is encoded by the human RRAS gene. This protein is involved in both the positive regulation of angiogenesis and cytoskeletal modeling in axons.	Ras-Related Protein R-Ras		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106073>	C85254	Double Strand Brachytherapy	An internal radiation treatment technique in which radioactive seeds are embedded in suture material and directly affixed to target cancerous tissue.			Therapeutic or Preventive Procedure	
C106074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106074>	C85254	Fletcher-suit Brachytherapy	An internal radiation treatment technique in which a curved, hollow applicator with a rounded reservoir at the tip is inserted into the uterus or cervix and then injected with radioactive sources for the treatment of gynecological cancers.			Therapeutic or Preventive Procedure	
C106075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106075>	C150011|C138129	Manchester Ovoid	One of a pair of pre-loaded, ovoid-shaped applicators containing radium that is inserted into the vagina as part of the Manchester system for gynecologic intracavity brachytherapy delivery.			Drug Delivery Device	
C106076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106076>	C85254	Tandem Brachytherapy|Tandem	An internal radiation treatment technique in which a small metal tube filled with a radioactive source is placed inside the uterus for the treatment of gynecological cancers.			Therapeutic or Preventive Procedure	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C106077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106077>	C85254	Mini Ovoid Brachytherapy|Ovoid	An internal radiation treatment technique in which a small diameter hollow metal sphere filled with a radioactive source is placed inside the uterus for the treatment of gynecological cancers.			Therapeutic or Preventive Procedure	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C106078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106078>	C85254	Mesh Brachytherapy	An internal radiation treatment technique in which a piece of thin, flexible mesh made of vicryl and implanted with radioactive seeds is surgically attached to target tissue where it emits a low dose of radiation over a prolonged period of time.			Therapeutic or Preventive Procedure	
C106079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106079>	C16830	Vaginal Cylinder|Cylinder	A metallic tube that is inserted into the vagina in order to facilitate delivery of vaginal intracavitary radiation therapy.			Medical Device	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C10607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10607>	C61063	Cytarabine/Idarubicin/Interleukin-3|ARA-C/IDA/IL-3			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106080>	C25784	RHOJ Gene|RHOJ|RHOJ|Ras Homolog Family Member J Gene	This gene plays a role in both GTP hydrolysis and cytoskeletal remodeling.			Gene or Genome	
C106081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106081>	C106080	RHOJ wt Allele|ARHJ|FLJ14445|RAS-Like, Family 7, Member B Gene|RASL7B|RHOI|Ras Homolog Family Member J wt Allele|Ras Homolog Gene Family, Member J Gene|TC10B|TCL	Human RHOJ wild-type allele is located in the vicinity of 14q23.2 and is approximately 89 kb in length. This allele, which encodes Rho-related GTP-binding protein RhoJ, is involved in both cellular morphology and GTP metabolism.			Gene or Genome	
C106082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106082>	C18277	Rho-Related GTP-Binding Protein RhoJ|RAS-Like, Family 7, Member B|RHOJ|Ras Homolog Gene Family, Member J|Ras-Like Protein Family Member 7B|TC10-Like Rho GTPase|Tc10-Like GTP-Binding Protein	Rho-related GTP-binding protein RhoJ (214 aa, ~24 kDa) is encoded by the human RHOJ gene. This protein plays a role in the regulation of both GTP hydrolysis and cellular morphology.			Amino Acid, Peptide, or Protein|Enzyme	
C106083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106083>	C25993	PIEZO1 Gene|PIEZO1|PIEZO1|Piezo-Type Mechanosensitive Ion Channel Component 1 Gene	This gene plays a role in ion transport.			Gene or Genome	
C106084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106084>	C106083	PIEZO1 wt Allele|FAM38A|Family with Sequence Similarity 38, Member A Gene|KIAA0233|Mib|Piezo-Type Mechanosensitive Ion Channel Component 1 wt Allele	Human PIEZO1 wild-type allele is located in the vicinity of 16q24.3 and is approximately 70 kb in length. This allele, which encodes piezo-type mechanosensitive ion channel component 1 protein, is involved in mechanically regulated ion transport.			Gene or Genome	
C106085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106085>	C28505	Piezo-Type Mechanosensitive Ion Channel Component 1|Membrane Protein Induced By Beta-Amyloid Treatment|Mib|Protein FAM38A|Protein PIEZO1	Piezo-type mechanosensitive ion channel component 1 (2521 aa, ~287 kDa) is encoded by the human PIEZO1 gene. This protein plays a role in detection of mechanical stimuli.			Amino Acid, Peptide, or Protein	
C106086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106086>	C25993	PIEZO2 Gene|PIEZO2|PIEZO2|Piezo-Type Mechanosensitive Ion Channel Component 2 Gene	This gene is involved in the response to mechanical stimuli.			Gene or Genome	
C106087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106087>	C106086	PIEZO2 wt Allele|C18orf30|C18orf58|Chromosome 18 Open Reading Frame 30 Gene|Chromosome 18 Open Reading Frame 58 Gene|FAM38B|FAM38B2|FLJ23144|FLJ23403|FLJ34907|Family with Sequence Similarity 38, Member B Gene|HsT748|HsT771|Piezo-Type Mechanosensitive Ion Channel Component 2 wt Allele	Human PIEZO2 wild-type allele is located in the vicinity of 18p11.21 and is approximately 479 kb in length. This allele, which encodes piezo-type mechanosensitive ion channel component 2 protein, plays a role in the conduction of mechanical impulses.			Gene or Genome	
C106088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106088>	C28505	Piezo-Type Mechanosensitive Ion Channel Component 2|Protein FAM38B|Protein PIEZO2	Piezo-type mechanosensitive ion channel component 2 (2752 aa, ~318 kDa) is encoded by the human PIEZO2 gene. This protein is involved in ion transport.			Amino Acid, Peptide, or Protein	
C106089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106089>	C25804	PSMC2 Gene|PSMC2|PSMC2|Proteasome 26S Subunit, ATPase 2 Gene	This gene is involved in the regulation of proteasomal activity.			Gene or Genome	
C10608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10608>	C61063	Carboplatin/Cytarabine/Idarubicin|ARA-C/CBDCA/IDA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106090>	C106089	PSMC2 wt Allele|MSS1|Mammalian Suppressor of sgv-1 of Yeast Gene|Nbla10058|Protease 26S, Subunit 7 Gene|Proteasome (Prosome, Macropain) 26S Subunit, ATPase, 2 Gene|Proteasome 26S Subunit, ATPase 2 wt Allele|Proteasome 26S Subunit, ATPase, 2 Gene|RPT1|S7	Human PSMC2 wild-type allele is located within 7q22.1-q22.3 and is approximately 25 kb in length. This allele, which encodes 26S proteasome regulatory subunit 7 protein, plays a role in both ATP hydrolysis and the modulation of proteasomal activity.			Gene or Genome	
C106091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106091>	C16701	26S Proteasome Regulatory Subunit 7|26S Protease Regulatory Subunit 7|26S Proteasome AAA-ATPase Subunit RPT1|PSMC2|Protease 26S Subunit 7|Proteasome 26S Subunit ATPase 2|Protein MSS1|Putative Protein Product of Nbla10058|Testis Secretory Sperm-Binding Protein Li 197a	26S proteasome regulatory subunit 7 (433 aa, ~49 kDa) is encoded by the human PSMC2 gene. This protein is involved in both the regulation of proteasome-mediated degradation of ubiquitinated proteins and ATP hydrolysis.			Amino Acid, Peptide, or Protein|Enzyme	
C106092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106092>	C20103	KIR2DS1 Gene|KIR2DS1|KIR2DS1|Killer Cell Immunoglobulin-Like Receptor, Two Domains, Short Cytoplasmic Tail, 1 Gene	This gene plays a role in the regulation of immune responses.			Gene or Genome	
C106093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106093>	C106092	KIR2DS1 wt Allele|CD158H|CD158a|EB6ActI|EB6ActII|Killer Cell Immunoglobulin-Like Receptor, Two Domains, Short Cytoplasmic Tail, 1 wt Allele|XXbac-BCX195L8.7|p50.1	Human KIR2DS1 wild-type allele is located in the vicinity of 19q13.4 and is approximately 14 kb in length. This allele, which encodes killer cell immunoglobulin-like receptor 2DS1 protein, is involved in the modulation of NK cell function.			Gene or Genome	
C106094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106094>	C18106	Killer Cell Immunoglobulin-Like Receptor 2DS1|CD158 Antigen-Like Family Member H|CD158h|CD158h Antigen|KIR2DS1|Killer Cell Immunoglobulin-Like Receptor KIRDS1|MHC Class I NK Cell Receptor Eb6 ActI	Killer cell immunoglobulin-like receptor 2DS1 (304 aa, ~34 kDa) is encoded by the human KIR2DS1 gene. This protein plays a role in natural killer cell-mediated immunity.			Amino Acid, Peptide, or Protein|Receptor	
C106095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106095>	C28533	VAMP1 Gene|VAMP1|VAMP1|Vesicle-Associated Membrane Protein 1 (Synaptobrevin 1) Gene	This gene is involved in neurotransmitter secretion.			Gene or Genome	
C106096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106096>	C106095	VAMP1 wt Allele|SYB1|VAMP-1|Vesicle-Associated Membrane Protein 1 (Synaptobrevin 1) wt Allele	Human VAMP1 wild-type allele is located within 12p and is approximately 9 kb in length. This allele, which encodes vesicle-associated membrane protein 1, plays a role in the secretion of neurotransmitters.			Gene or Genome	
C106097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106097>	C16386	Vesicle-Associated Membrane Protein 1|Synaptobrevin 1|Synaptobrevin-1|VAMP-1|VAMP1	Vesicle-associated membrane protein 1 (118 aa, ~13 kDa) is encoded by the human VAMP1 gene. This protein is involved in neurotransmitter secretion.			Amino Acid, Peptide, or Protein	
C106098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106098>	C19540	FAM83A Gene|FAM83A|FAM83A|Family with Sequence Similarity 83 Member A Gene	This gene may be involved in tumor resistance.			Gene or Genome	
C106099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106099>	C106098	FAM83A wt Allele|BJ-TSA-9|Family with Sequence Similarity 83 Member A wt Allele|Family with Sequence Similarity 83, Member A Gene|MGC14128|TSGP	Human FAM83A wild-type allele is located in the vicinity of 8q24.13 and is approximately 31 kb in length. This allele, which encodes protein FAM83A, may play a role in chemotherapy-resistant tumors.			Gene or Genome	
C10609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10609>	C61063	Fluorouracil/Leucovorin Calcium/Methylmercaptopurine Riboside/PALA|CF/5-FU/MMPR/PALA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1060>	C599|C1967	Daidzein|4',7-Dihydroxyisoflavone|7-Hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one|DAIDZEIN|daidzein	An isoflavone extract from soy, which is an inactive analog of the tyrosine kinase inhibitor genistein. It has antioxidant and phytoestrogenic properties. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C106100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106100>	C54672	Protein FAM83A|Tumor Antigen BJ-TSA-9|Tumor-Specific Gene Expressed In Prostate Protein	Protein FAM83A (434 aa, ~47 kDa) is encoded by the human FAM83A gene. This protein may be involved in tumor drug resistance.			Amino Acid, Peptide, or Protein	
C106101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106101>	C100104	Absence of Signs or Symptoms|No Clinical Signs, Symptoms or Conditions|Silent	Absence of detectable signs or symptoms.			Finding	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology
C106102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106102>	C20181	Sensate	Related to the perception of sensory stimuli.			Qualitative Concept	
C106103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106103>	C36282	Pharyngeal Residue	Substance remaining in the pharynx after swallowing.			Finding	
C106104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106104>	C66892	Plant-based Natural Product	Any mixture of substances or products derived from a plant or from part of a plant.			Classification	
C106105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106105>	C106104	Plant or Plant Part Extract	Any extract from a plant or from part of a plant.			Classification	
C106107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106107>	C21295	CIB1 Gene|CIB1|CIB1|Calcium and Integrin Binding 1 (Calmyrin) Gene	This gene plays a role in cell adhesion, megakaryocyte differentiation, apoptosis regulation and calcium binding.			Gene or Genome	
C106108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106108>	C106107	CIB1 wt Allele|CALMYRIN|CIB|CIBP|Calcium and Integrin Binding 1 (Calmyrin) wt Allele|KIP|KIP1|PRKDCIP|SIP2-28	Human CIB1 wild-type allele is located within 15q25.3-q26 and is approximately 4 kb in length. This allele, which encodes calcium and integrin-binding protein 1, is involved in megakaryocyte differentiation, integrin regulation, calcium binding and apoptosis.			Gene or Genome	
C106109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106109>	C21214	Calcium and Integrin-Binding Protein 1|CIB|CIB1|CIBP|Calcium- and Integrin-Binding Protein|Calmyrin|DNA-Dependent Protein Kinase Interacting Protein|DNA-PKcs-Interacting Protein|KIP|Kinase-Interacting Protein|SIP2-28|SNK-Interacting Protein 2-28	Calcium and integrin-binding protein 1 (191 aa, ~22 kDa) is encoded by the human CIB1 gene. This protein plays a role in calcium binding, integrin activity regulation, apoptosis modulation and megakaryocyte differentiation.			Amino Acid, Peptide, or Protein	
C10610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10610>	C61063	Cisplatin/Muramyl Tripeptide Phosphatidylethanolamine Liposome|CDDP/MTP-PE Liposome			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106110>	C106409	PTPRD Gene|PTPRD|PTPRD|Protein Tyrosine Phosphatase, Receptor Type, D Gene	This gene is involved in both dendrite morphology and protein dephosphorylation.	PTPRD Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106111>	C106110	PTPRD wt Allele|HPTP|HPTPD|HPTPDELTA|PTPD|Protein Tyrosine Phosphatase, Receptor Type, D wt Allele|Protein-Tyrosine Phosphatase, Receptor-Type, D Gene|Protein-Tyrosine Phosphatase, Receptor-Type, Delta Gene|RPTPDELTA	Human PTPRD wild-type allele is located within 9p23-p24.3 and is approximately 2298 kb in length. This allele, which encodes receptor-type tyrosine-protein phosphatase delta protein, plays a role in both phosphotyrosine dephosphorylation and dendrite morphogenesis.	PTPRD wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106112>	C17444	Receptor-Type Tyrosine-Protein Phosphatase Delta|EC 3.1.3.48|PTPRD|Protein Tyrosine Phosphatase, Receptor Type, Delta Polypeptide|Protein-Tyrosine Phosphatase Delta|Protein-Tyrosine Phosphatase-Delta|R-PTP-Delta	Receptor-type tyrosine-protein phosphatase delta (1912 aa, ~215 kDa) is encoded by the human PTPRD gene. This protein is involved in both dendrite morphogenesis and phosphotyrosine dephosphorylation.	Receptor-Type Tyrosine-Protein Phosphatase Delta		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106113>	C106409	PTPRK Gene|PTPRK|PTPRK|PTPRK|Protein Tyrosine Phosphatase, Receptor Type, K Gene	This gene is involved in receptor signaling, cell-cell contact and cell migration.			Gene or Genome	GDC Terminology|GDC Value Terminology
C106114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106114>	C106113	PTPRK wt Allele|PTPK|Protein Tyrosine Phosphatase, Receptor Type, K wt Allele|R-PTP-Kappa|RP3-480J14.1	Human PTPRK wild-type allele is located within 6q22.2-q22.3 and is approximately 552 kb in length. This allele, which encodes receptor-type tyrosine-protein phosphatase kappa protein, plays a role in cell-cell adhesion, cell migration and receptor signaling.			Gene or Genome	
C106115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106115>	C17444	Receptor-Type Tyrosine-Protein Phosphatase Kappa|EC 3.1.3.48|PTPRK|Protein Tyrosine Phosphatase Kappa|Protein Tyrosine Phosphatase, Receptor Type, K|Protein-Tyrosine Phosphatase Kappa|Protein-Tyrosine Phosphatase, Receptor Type, Kappa|R-PTP-Kappa	Receptor-type tyrosine-protein phosphatase kappa (1439 aa, ~162 kDa) is encoded by the human PTPRK gene. This protein is involved in protein dephosphorylation, cell migration, receptor signaling and cell-cell contact.			Amino Acid, Peptide, or Protein|Enzyme	
C106116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106116>	C192643	Cusatuzumab|ARGX-110|Anti-CD70 Monoclonal Antibody ARGX-110|CUSATUZUMAB	A defucosylated, humanized IgG1 monoclonal antibody directed against the extracellular domain of the human CD70 molecule with potential antineoplastic activity. Upon administration, cusatuzumab selectively binds to, and neutralizes the activity of CD70, which may also induce an antibody-dependent cellular cytotoxicity (ADCC) response against CD70-expressing tumor cells. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on a number of solid and hematological tumors. Its overexpression may play an important role in evasion of immune surveillance.	Cusatuzumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106117>	C200766	T1E28z CAR-expressing Autologous CD4-positive T Lymphocytes|4ab T1E28z Positive T-cells	Autologous CD4 positive T-lymphocytes engineered to express the chimeric antigen receptor (CAR) T1E28z containing the ErbB ligand, T1E, fused to the hinge region, transmembrane domain and endodomain of CD28 and the CD3zeta endodomain, with potential immunomodulating and antineoplastic activities. T1E, a chimeric polypeptide containing the N-terminus of human transforming growth factor (TGF)-alpha fused to the C-terminus of epidermal growth factor (EGF), binds to ErbB1 homodimers and heterodimers as well as ErbB2/3 heterodimers, but not to ErbB2 or erbB3 alone. Upon intratumoral administration, the promiscuous ErbB ligand T1E of the T1E28z CAR-expressing autologous CD4-positive T lymphocytes binds to the specific ErbB homo- and heterodimers on tumor cells. This induces selective toxicity in ErbB-expressing tumor cells resulting in tumor cell lysis. ErbB1, ErbB2 and ErbB3, members of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, are frequently overexpressed in solid tumors and play key roles in tumor cell proliferation and tumor angiogenesis.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106118>	C20401|C129822	Xentuzumab|BI 836845|Immunoglobulin G1, Anti-(Human Insulin-like Growth Factor I) (Human Monoclonal PS05388 Heavy Chain), Disulfide with Human Monoclonal PS05388 Light Chain, Dimer|XENTUZUMAB	A humanized IgG1 insulin-like growth factor (IGF) monoclonal antibody targeting the IGF ligands 1 (IGF-1) and 2 (IGF-2), with potential antineoplastic activity. Upon administration, xentuzumab binds to both IGF-1 and IGF-2 and inhibits the binding of these ligands to their receptor, IGF-1R. This blocks the insulin growth factor (IGF) signaling pathway, which is upregulated in a number of cancer cell types and plays a key role in cancer cell proliferation and chemoresistance. In addition, BI 836845 prevents the binding of IGF-2 to insulin receptor variant A (IR-A), preventing its activation.	Xentuzumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106119>	C214964|C211912	Sofituzumab Vedotin|DMUC5754A|SOFITUZUMAB VEDOTIN	An antibody drug conjugate (ADC) consisting of a humanized IgG1 monoclonal antibody targeting the MUC16 protein (CA-125) conjugated to, via a cleavable linker, the antimicrotubulin agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. The monoclonal antibody moiety of sofituzumab vedotin selectively binds to MUC16. After internalization of the drug conjugate and proteolytic cleavage of the linker, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M-phase growth arrest and tumor cell apoptosis. MUC16, a transmembrane protein, is overexpressed on the cell surface of more than 80 percent of ovarian cancer cells but not on healthy cells.	Sofituzumab Vedotin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C10611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10611>	C61063	Ifosfamide/Muramyl Tripeptide Phosphatidylethanolamine Liposome|IFF/MTP-PE Liposome			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106120>	C162996	p53-HDM2 Interaction Inhibitor MI-773|MI-773|SAR-405838|SAR405838|p53-MDM2 Interaction Inhibitor MI-773	An orally available spiro-oxindole HDM2 (human double minute 2) antagonist with potential antineoplastic activity. Upon oral administration, the p53-HDM2 protein-protein interaction inhibitor MI-773 binds to HDM2, preventing the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored, which may result in the restoration of p53 signaling and lead to the p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger protein and a negative regulator of the p53 pathway, is often overexpressed in cancer cells. It has been implicated in cancer cell proliferation and survival.	p53-HDM2 Interaction Inhibitor MI-773		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106121>	C67502	Glutathione Pegylated Liposomal Doxorubicin Hydrochloride Formulation 2B3-101|2B3-101	A glutathione (GSH) pegylated, liposome-encapsulated preparation of the hydrochloride salt form of the anthracycline antineoplastic antibiotic doxorubicin, with potential anetineoplastic activity. Upon administration, the glutathione pegylated liposomal formulation 2B3-101 specifically delivers doxorubicin into the brain. Doxorubicin intercalates between DNA base pairs and interferes with topoisomerase II activity, which inhibits both DNA replication and RNA synthesis, resulting in cancer cell death and tumor regression. Doxorubicin also generates reactive oxygen species, which causes cell membrane lipid peroxidation leading to cytotoxicity. The pegylated liposomal delivery of doxorubicin improves drug penetration into tumors and prolongs circulation time, thereby increasing doxorubicin's efficacy and decreasing its toxicity. Conjugation of GSH to the PEG molecules directs the liposomes to the GSH transporters on the blood brain barrier (BBB) and improves the delivery of doxorubicin into the brain.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106122>	C19177	Clinical Fellow - Speech Language Pathologist|CF-SLP	A speech language pathologist who is providing services in a mentored, professional training setting prior to receiving a certificate of clinical competence.			Professional or Occupational Group	
C106123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106123>	C201491	iC9-GD2-CD28-OX40-expressing T Lymphocytes|iC9-GD2 T Lymphocytes	Modified T-lymphocytes expressing a 3rd generation chimeric antigen receptor (CAR) specific for the disialoganglioside GD2, which contains the CD3zeta chain, the signaling domains of the co-stimulatory molecules CD28 and CD134 (OX-40) and the suicide gene inducible caspase 9 (iCasp9), with potential immunomodulating and antineoplastic activities. Upon administration, iC9-GD2-CD28-OX40-expressing T lymphocytes target the GD2 antigen on tumor cells, thereby providing selective toxicity towards GD2-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered, which binds to the drug binding FKBP12-F36V domain and activates caspase 9, resulting in the apoptosis of the administered T-cells. The tumor associated antigen GD2 is overexpressed on the surface of almost all tumors of neuroectodermal origin. OX40 and CD28, both T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation.	iC9-GD2-CD28-OX40-expressing T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106124>	C308	Poly-gamma Glutamic Acid|Gamma-polyglutamic Acid|Poly-gamma-glutamate|gamma-PGA	A water-soluble and biodegradable polymer naturally synthesized by various strains of Bacillus and composed of D- and L-glutamic acid polymerized via gamma-amide linkages, with potential antineoplastic activity. Upon administration, poly-gamma glutamic acid may augment the immune response by increasing the production of interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) and inducing the activation of macrophage and natural killer (NK) cells. IFN-gamma is a major mediator of innate and adaptive immunity against viral and intracellular bacterial infections as well as for tumor control. TNF-alpha is a cytokine involved in systemic inflammation, which is capable of inducing apoptotic cell death and exhibits anti-tumoral effects.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106125>	C19177	Certificate of Clinical Competence - Speech Language Pathologist|CCC-SLP	A speech language pathologist who has received a certificate of clinical competence.			Professional or Occupational Group	
C106126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106126>	C69145|C62556|C129825	MEK/Aurora Kinase Inhibitor BI 847325|BI 847325	An orally available dual inhibitor of mitogen-activated protein kinase kinase (MEK) and Aurora kinases, with potential antineoplastic activity. Upon oral administration, MEK/Aurora kinase inhibitor BI 847325 selectively binds to and inhibits the activity of MEK, which both prevents the activation of MEK-dependent effector proteins and inhibits growth factor-mediated cell signaling. BI 847325 also binds to and inhibits the activity of the Aurora kinases A, B and C which may disrupt the assembly of the mitotic spindle apparatus, prevent chromosome segregation, and inhibit both cellular division and proliferation in Aurora kinase-overexpressing tumor cells.  Altogether, this leads to the inhibition of cell proliferation and tumor growth as well as the induction of tumor regression. MEK, a dual-specificity threonine/tyrosine kinase that plays a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway, is frequently upregulated in a variety of tumor cell types. Aurora kinases are serine-threonine kinases that play essential roles in mitotic checkpoint control and are overexpressed by a wide variety of cancer cell types.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106127>	C19177	Board Recognized Specialist - Swallowing|BCS-S|BRS-S|Board Certified Specialist - Swallowing|Board Certified Specialist in Swallowing and Swallowing Disorders	A certified speech language pathologist who is board recognized as an expert in swallowing disorders.			Professional or Occupational Group	
C106128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106128>	C66892	Animal-based Natural Product	Any substance or product derived from an animal.			Classification	
C106129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106129>	C66892	Marine-based Natural Product	Any substance or product derived from any organism that lives in bodies of fresh or salt water.			Classification	
C10612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10612>	C61063	Asparaginase/Daunorubicin/Mercaptopurine/Methotrexate/Prednisone/Vincristine|ASP/DNR/MP/MTX/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106130>	C106128	Venom	A concentrated fluid of poisonous and biologically active substances secreted by a variety of animals that can be injected or in some other way introduced into another animal or human, usually by a bite or a sting.			Classification	
C106131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106131>	C66892	Fungus-based Natural Product	Any mixture of substances or products derived from fungi.			Classification	
C106132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106132>	C106128	Venom Protein	Protein isolated from venom.			Classification	
C106133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106133>	C84382	FDA Classified Non-traditional Sterilization Method	Sterilization methods that do not have a long history of safe and effective use and for which there are no FDA-recognized standards, but for which published information on validation of these methods exists and for which FDA has previously evaluated data as part of a QS evaluation and determined the methods to be adequate.			Classification	
C106134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106134>	C28102	Clinical Variant	A form of a disease with clinical features that differ from other forms of the same disease.			Classification	
C106135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106135>	C25474	Statistical Data Grouping|Analysis Project|Analysis Project	A grouping of data of statistical interest generated from a specific research study.			Idea or Concept	
C106136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106136>	C54362	CHAF1A Gene|CHAF1A|CHAF1A|Chromatin Assembly Factor 1, Subunit A (p150) Gene	This gene plays a role in both transcriptional regulation and nucleosome assembly.	CHAF1A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106137>	C106136	CHAF1A wt Allele|CAF|CAF-1|CAF1|CAF1B|CAF1P150|Chromatin Assembly Factor 1, Subunit A (p150) wt Allele|MGC71229|P150	Human CHAF1A wild-type allele is located in the vicinity of 19p13.3 and is approximately 42 kb in length. This allele, which encodes chromatin assembly factor 1 subunit A protein, is involved in both histone complex assembly and transcriptional regulation.	CHAF1A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106138>	C26199	Chromatin Assembly Factor 1 Subunit A|CAF-1 Subunit A|CAF-I 150 kDa Subunit|CAF-I p150|CHAF1A|Chromatin Assembly Factor I (150 kDa)|Chromatin Assembly Factor I p150 Subunit|hp150	Chromatin assembly factor 1 subunit A (956 aa, ~107 kDa) is encoded by the human CHAF1A gene. This protein plays a role in replication-dependent nucleosome assembly.	Chromatin Assembly Factor 1 Subunit A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106139>	C20194	CRY2 Gene|CRY2|CRY2|Cryptochrome 2 (Photolyase-Like) Gene	This gene is involved in circadian rhythm.	CRY2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10613>	C61063	Cyclophosphamide/Cytarabine/Mercaptopurine/Vincristine|ARA-C/CTX/MP/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106140>	C106139	CRY2 wt Allele|Cryptochrome 2 (Photolyase-Like) wt Allele|HCRY2|KIAA0658|PHLL2	Human CRY2 wild-type allele is located in the vicinity of 11p11.2 and is approximately 36 kb in length. This allele, which encodes cryptochrome-2 protein, plays a role in the regulation of circadian rhythms.	CRY2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106141>	C18466	Cryptochrome-2|CRY2|Growth-Inhibiting Protein 37	Cryptochrome-2 (593 aa, ~67 kDa) is encoded by the human CRY2 gene. This protein is involved in blue light-dependent regulation of the circadian feedback loop.	Cryptochrome-2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106142>	C19676	DCLRE1A Gene|DCLRE1A|DCLRE1A|DNA Cross-Link Repair 1A Gene	This gene plays a role in both DNA repair and the cell cycle.	DCLRE1A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106143>	C106142	DCLRE1A wt Allele|DNA Cross-Link Repair 1A (PSO2 Homolog, S. cerevisiae) Gene|DNA Cross-Link Repair 1A wt Allele|DNA-Crosslink Repair Gene SNM1|KIAA0086|PSO2|PSO2 Homolog (S. cerevisiae) Gene|SNM1|SNM1A|hSNM1	Human DCLRE1A wild-type allele is located in the vicinity of 10q25.1 and is approximately 20 kb in length. This allele, which encodes DNA cross-link repair 1A protein, is involved in both interstrand DNA repair and cell cycle progression.	DCLRE1A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106144>	C21170	DNA Cross-Link Repair 1A Protein|DCLRE1A|SNM1 Homolog A|hSNM1|hSNM1A	DNA cross-link repair 1A protein (1040 aa, ~116 kDa) is encoded by the human DCLRE1A gene. This protein plays a role in both the mitotic spindle cell cycle checkpoint and DNA repair.	DNA Cross-Link Repair 1A Protein		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106145>	C87194	Mexican State	Any of the 31 states that comprise the United Mexican States.			Geographic Area	
C106146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106146>	C106145	Veracruz|Free and Sovereign State of Veracruz|Veracruz-Llave	A state in east-central Mexico on the Gulf of Mexico east of Puebla. Its capital is Xalapa.			Geographic Area	
C106147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106147>	C106145	Zacatecas|Free and Sovereign State of Zacatecas	A state in north-central Mexico. Its capital is Zacatecas.			Geographic Area	
C106148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106148>	C106145	Michoacan|Free and Sovereign State of Michoacan|Free and Sovereign State of Michoacán|Michoacan de Ocampo|Michoacán|Michoacán de Ocampo	A state in south western Mexico on the Pacific Ocean. Its capital is Morelia.			Geographic Area	
C106149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106149>	C106145	Morelos|Free and Sovereign State of Morelos	A state in south central Mexico. Its capital is Cuernavaca.			Geographic Area	
C10614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10614>	C61063	Cyclophosphamide/Cytarabine/Doxorubicin/Vincristine|ARA-C/CTX/DOX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106150>	C106145	Nayarit|Free and Sovereign State of Nayarit	A state on the central Pacific coast of Mexico that includes the islands of Marias, Isabel, Tres Marietas and Farallon La Pena. Its capital is Tepic.			Geographic Area	
C106151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106151>	C106145	Nuevo Leon|Free and Sovereign State of Nuevo Leon	A state in the north eastern of Mexico. Its capital is Monterrey.			Geographic Area	
C106152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106152>	C106145	Oaxaca|Free and Sovereign State of Oaxaca	A state in the south of Mexico on the Pacific Ocean. Its capital is Oaxaca de Juarez.			Geographic Area	
C106153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106153>	C106145	Puebla|Free and Sovereign State of Puebla	A state in south central Mexico. Its capital is Puebla de Zaragoza.			Geographic Area	
C106154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106154>	C106145	Queretaro|Free and Sovereign State of Queretaro|Free and Sovereign State of Querétaro|Queretaro de Arteaga|Querétaro|Querétaro de Arteaga	A state in central Mexico. Its capital is Santiago de Queretaro.			Geographic Area	
C106155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106155>	C106145	Quintana Roo|Free and Sovereign State of Quintana Roo	A state in south eastern Mexico, on the Yucatan peninsula. Its capital is Chetumal.			Geographic Area	
C106156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106156>	C106145	Sinaloa|Free and Sovereign State of Sinaloa	A state in western Mexico on the Gulf of California. Its capital is Culiacan.			Geographic Area	
C106157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106157>	C106145	San Luis Potosi|Free and Sovereign State of San Luis Potosi|Free and Sovereign State of San Luis Potosí|San Luis Potosí	A state in central Mexico. Its capital is San Luis Potosi.			Geographic Area	
C106158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106158>	C106145	Sonora|Free and Sovereign State of Sonora	A state in north western Mexico on the Gulf of California. Its capital is Hermosillo.			Geographic Area	
C106159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106159>	C106145	Tabasco|Free and Sovereign State of Tabasco	A state in south eastern Mexico on the Gulf of Mexico. Its capital is Villahermosa.			Geographic Area	
C10615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10615>	C61063	Etoposide/Ifosfamide/Methotrexate/Vincristine|IFF/MTX/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106160>	C106145	Tamaulipas|Free and Sovereign State of Tamaulipas	A state in north eastern Mexico on the Gulf of Mexico. Its capital is Ciudad Victoria.			Geographic Area	
C106161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106161>	C106145	Tlaxcala|Free and Sovereign State of Tlaxcala	A state in southeastern central Mexico. Its capital is Tlaxcala.			Geographic Area	
C106162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106162>	C25804|C19676	MBD4 Gene|MBD4|MBD4|Methyl-CpG Binding Domain 4, DNA Glycosylase Gene	This gene is involved in DNA mismatch repair.	MBD4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106163>	C106145	Baja California|Free and Sovereign State of Baja California	A state in Mexico comprising the northern half of the Baja California peninsula. Its capital is Mexicali.			Geographic Area	
C106164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106164>	C106162	MBD4 wt Allele|G/5-Fluorouracil Mismatch Glycosylase With Biphasic Kinetics Gene|MED1|Methyl-CpG Binding Domain 4, DNA Glycosylase wt Allele|Methyl-CpG Binding Domain Protein 4 Gene|TPDS2|UVM1	Human MBD4 wild-type allele is located in the vicinity of 3q21.3 and is approximately 9 kb in length. This allele, which encodes methyl-CpG-binding domain protein 4, plays a role in DNA mismatch repair.	MBD4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106165>	C106145	Baja California Sur|Free and Sovereign State of Baja California Sur	A state in Mexico comprising the southern half of the Baja California peninsula. Its capital is La Paz.			Geographic Area	
C106166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106166>	C106145	Chiapas|Free and Sovereign State of Chiapas	The southernmost state of Mexico, bordering on the Pacific Ocean. Its capital is Tuxtla Gutierrez.			Geographic Area	
C106167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106167>	C106145	Coahuila|Coahuila de Zaragoza|Free and Sovereign State of Coahuila	A state in northern Mexico bordering with Texas. Its capital is Saltillo.			Geographic Area	
C106168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106168>	C21170|C16701	Methyl-CpG-Binding Domain Protein 4|3,N(4)-Ethenocytosine Glycosylase|EC 3.2.2.-|G/5-Fluorouracil Mismatch Glycosylase with Biphasic Kinetics|G/T Mismatch Glycosylase|G/U Mismatch Glycosylase|MBD4|Methyl-CpG-Binding Endonuclease 1|Methyl-CpG-Binding Protein MBD4|Mismatch-Specific DNA N-Glycosylase|Putative Methyl-CpG Binding Protein	Methyl-CpG-binding domain protein 4 (580 aa, ~66 kDa) is encoded by the human MBD4 gene. This protein is involved in the DNA mismatch-specific glycosylase activity.	Methyl-CpG-Binding Domain Protein 4		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106169>	C106145	Colima|Free and Sovereign State of Colima	A state in south western Mexico bordering on the Pacific Ocean. Its capital is Colima.			Geographic Area	
C10616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10616>	C61007	Cyclophosphamide/Daunorubicin/Dexamethasone/Methotrexate/Pegaspargase/Vincristine|CTX/DM/DNR/MTX/PEG-ASP/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106170>	C106145	Guerrero|Free and Sovereign State of Guerrero	A state in southern Mexico bordering on the Pacific Ocean. Its capital is Chilpancingo de los Bravo.			Geographic Area	
C106171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106171>	C106145	Guanajuato|Free and Sovereign State of Guanajuato	A state in central Mexico. Its capital is Guanajuato.			Geographic Area	
C106172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106172>	C106145	Hidalgo|Free and Sovereign State of Hidalgo	A state in east central Mexico. Its capital is Pachuca.			Geographic Area	
C106173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106173>	C106145	Jalisco|Free and Sovereign State of Jalisco	A state in south western Mexico bordering on the Pacific Ocean. Its capital is Guadalajara.			Geographic Area	
C106174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106174>	C25160	Mexican City	A named municipality within a Mexican state.			Geographic Area	
C106175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106175>	C106145	Durango|Free and Sovereign State of Durango	A state in northwestern central Mexico. Its capital is Durango.			Geographic Area	
C106176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106176>	C106174	Distrito Federal of Mexico	The capital of Mexico and seat of the federal powers of the Mexican Union. It is a federal entity separate from the 31 Mexican states.			Geographic Area	
C106177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106177>	C84386	Micronization|Fluid Energy Milling|Micronize|Particle Sizing, Micronization	A process to reduce a solid material to particles with an average size described in microns.			Laboratory Procedure	FDA eManufacturing Terminology|PQ/CMC Unit Operations Subcategory Terminology
C106178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106178>	C42713	Extended Release Depot Dosage Form|DEPOT|Depot|Depot Dosage Form|Depot Extended Release Dosage Form|Depot Extended Release Dosage Form	Parenteral sustained-release systems of microparticles, implants, or biodegradable polymer-excipients designed to release their active pharmaceutical ingredient over a prolonged period of time.			Biomedical or Dental Material	CDISC SDTM Dosage Form Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106179>	C21514	Month of the Year	Any of the 12 major divisions of the year, each lasting approximately 30 days.			Qualitative Concept	
C10617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10617>	C61063	Dexamethasone/Mercaptopurine/Vincristine|DM/MP/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106180>	C106179	January	The first month of the year in the Gregorian calendar.			Qualitative Concept	
C106181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106181>	C106179	February	The second month of the year in the Gregorian calendar.			Qualitative Concept	
C106182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106182>	C106179	March	The third month of the year in the Gregorian calendar.			Qualitative Concept	
C106183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106183>	C106179	April	The fourth month of the year in the Gregorian calendar.			Qualitative Concept	
C106184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106184>	C106179	May	The fifth month of the year in the Gregorian calendar.			Qualitative Concept	
C106185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106185>	C106179	June	The sixth month of the year in the Gregorian calendar.			Qualitative Concept	
C106186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106186>	C106179	July	The seventh month of the year in the Gregorian calendar.			Qualitative Concept	
C106187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106187>	C106179	August	The eighth month of the year in the Gregorian calendar.			Qualitative Concept	
C106188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106188>	C106179	September	The ninth month of the year in the Gregorian calendar.			Qualitative Concept	
C106189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106189>	C106179	October	The tenth month of the year in the Gregorian calendar.			Qualitative Concept	
C10618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10618>	C61063	Cyclophosphamide/Cytarabine/Pegaspargase|ARA-C/CTX/PEG-ASP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106190>	C21282|C19676	NTHL1 Gene|NTHL1|NTHL1|NTHL1|Nth Like DNA Glycosylase 1 Gene	This gene plays a role in nucleotide-excision DNA repair.	NTHL1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C106191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106191>	C106179	November	The eleventh month of the year in the Gregorian calendar.			Qualitative Concept	
C106192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106192>	C106179	December	The twelfth month of the year in the Gregorian calendar.			Qualitative Concept	
C106193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106193>	C106190	NTHL1 wt Allele|Endonuclease III, E. coli, Homolog of Gene|NTH1|Nth (E.Coli Endonuclease III)-Like 1 Gene|Nth Endonuclease III-Like 1 (E. coli) Gene|Nth Like DNA Glycosylase 1 wt Allele|OCTS3	Human NTHL1 wild-type allele is located in the vicinity of 16p13.3 and is approximately 8 kb in length. This allele, which encodes endonuclease III-like protein 1, is involved in DNA repair by nucleotide-excision.	NTHL1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106194>	C21170|C16804	Endonuclease III-Like Protein 1|Bifunctional DNA N-Glycosylase/DNA-(Apurinic or Apyrimidinic Site) Lyase|DNA Glycosylase/AP Lyase|EC 4.2.99.18|Endonuclease III-Like Protein|NTHL1|Nth (E.coli Endonuclease III)-Like 1|Nth Endonuclease III-Like 1|Nth-Like 1	Endonuclease III-like protein 1 (312 aa, ~34 kDa) is encoded by the human NTHL1 gene. This protein plays a role in nucleotide-excision repair.	Endonuclease III-Like Protein 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106195>	C106145	Aguascalientes|Free and Sovereign State of Aguascalientes	A state in central Mexico. Its capital is Aguascalientes.			Geographic Area	
C106196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106196>	C106145	Campeche|Free and Sovereign State of Campeche	A state in south eastern Mexico on the Yucatan Peninsula. Its capital is San Francisco de Campeche.			Geographic Area	
C106197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106197>	C106145	Chihuahua|Free and Sovereign State of Chihuahua	A state in northern Mexico on the US border. Its capital is Chihuahua.			Geographic Area	
C106198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106198>	C20923	GPER1 Gene|G Protein-Coupled Estrogen Receptor 1 Gene|GPER|GPER1|GPER1	This gene plays a role in both estrogen binding and G protein-coupled receptor signaling.	GPER1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106199>	C106198	GPER1 wt Allele|CEPR|CMKRL2|DRY12|FEG-1|G Protein-Coupled Estrogen Receptor 1 wt Allele|G Protein-Coupled Receptor 30 Gene|GPCR-Br|GPER|GPR30|LERGU|LERGU2|LyGPR|mER	Human GPER1 wild-type allele is located in the vicinity of 7p22.3 and is approximately 12 kb in length. This allele, which encodes G-protein coupled estrogen receptor 1 protein, is involved in both G protein-coupled receptor signaling and estrogen binding.	GPER1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10619>	C61063	Cisplatin/Doxorubicin/Edatrexate/Vinblastine|CDDP/DOX/EDAM/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1061>	C1510	Daunorubicin-DNA Complex|DNR-DNA complex|Daunomycin-DNA Complex	A complex comprised of Daunorubicin linked to DNA to enhance the topoisomerase II-mediated interaction with the DNA base pairs and reduce cardiotoxicity associated with anthracyclines. (NCI)			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	NCI Drug Dictionary Terminology
C106200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106200>	C18239	G-Protein Coupled Estrogen Receptor 1|Chemoattractant Receptor-Like 2|Chemokine Receptor-Like 2|Constitutively Expressed Peptide-Like Receptor|FEG-1|Flow-Induced Endothelial G-Protein Coupled Receptor 1|G Protein-Coupled Estrogen Receptor 1|G Protein-Coupled Receptor 30|G-Protein Coupled Receptor 30|GPCR-BR|GPER|Heptahelix Receptor|IL8-Related Receptor DRY12|LYGPR|Lymphocyte-Derived G-Protein Coupled Receptor|Membrane Estrogen Receptor|mER	G-protein coupled estrogen receptor 1 (375 aa, ~42 kDa) is encoded by the human GPER1 gene. This protein plays a role in estrogen-dependent G protein-coupled receptor signaling.	G-Protein Coupled Estrogen Receptor 1		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106201>	C12680	Interdigital Region	The space between the digits of the hand or foot.			Body Location or Region	
C106202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106202>	C13035	Ureterovesical Junction|UVJ|UVJ|VESICOURETERIC JUNCTION|VUJ	The area where the ureter joins the urinary bladder.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106203>	C13035	Ureteropelvic Junction|UPJ	The area where the ureter joins the renal pelvis.			Body Part, Organ, or Organ Component	
C106204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106204>	C213472|C159199|C124800	Crenolanib Besylate|4-Piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1Hbenzimidazol-1-yl]-8-quinolinyl]-, Benzenesulfonate (1:1)|CP-868,596-26|CP-86859626|CRENOLANIB BESYLATE|[1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine Monobenzenesulfonate	The besylate salt form of crenolanib, an orally bioavailable benzimidazole targeting the platelet-derived growth factor receptor (PDGFR) subtypes alpha and beta and FMS-related tyrosine kinase 3 (Flt3), with potential antineoplastic activity. Upon oral administration, crenolanib binds to and inhibits both wild-type and mutated forms of PDGFR and Flt3, which may result in the inhibition of PDGFR- and Flt3-related signal transduction pathways. This results in inhibition of tumor angiogenesis and tumor cell proliferation in PDGFR and/or Flt3 overexpressing tumor cells. PDGFR and Flt3, class III receptor tyrosine kinases, are upregulated or mutated in many tumor cell types.	Crenolanib Besylate		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106205>	C29640	Drospirenone/Ethinyl Estradiol|Yasmin|Yaz	A combination of two steroid sex hormones, the estrogen ethinyl estradiol and a progestin drospirenone, used for contraceptive purposes.  The combination of ethinyl estradiol with drospirenone suppresses the hypothalamic-pituitary system, leading to an inhibition of the release of gonadotropin hormones follicle stimulating hormone (FSH) and luteinizing hormone (LH). The inhibition of FSH release suppresses the development of ovarian follicle. The decreased release of LH inhibits ovulation. In addition, thickening of the cervical mucus and the endometrium is promoted, thereby altering the endometrium in such a way as to discourage implantation.			Organic Chemical|Pharmacologic Substance	
C106206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106206>	C25939	LDHA Gene|LDHA|LDHA|Lactate Dehydrogenase A Gene	This gene is involved in carbohydrate metabolism.	LDHA Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106207>	C106206	LDHA wt Allele|GSD11|LDH, Subunit M Gene|LDH1|LDHM|Lactate Dehydrogenase A wt Allele|PIG19|Proliferation-Inducing Gene 19	Human LDHA wild-type allele is located in the vicinity of 11p15.4 and is approximately 14 kb in length. This allele, which encodes L-lactate dehydrogenase A chain protein, plays a role in fermentation. Mutation of the gene is associated with glycogen storage disease 11.	LDHA wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106208>	C16946	L-Lactate Dehydrogenase A Chain|Cell Proliferation-Inducing Gene 19 Protein|EC 1.1.1.27|LDH Muscle Subunit|LDH-A|LDH-M|LDHA|Lactate Dehydrogenase A|Lactate Dehydrogenase M|Renal Carcinoma Antigen NY-REN-59	L-lactate dehydrogenase A chain (332 aa, ~37 kDa) is encoded by the human LDHA gene. This protein is involved in the metabolism of lactate and pyruvate.	L-Lactate Dehydrogenase A Chain		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106209>	C25993	ATP6AP1 Gene|ATP6AP1|ATP6AP1|ATPase H+ Transporting Accessory Protein 1 Gene	This gene plays a role in organelle acidification.	ATP6AP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10620>	C61063	Cytarabine/Etoposide/Ifosfamide/Mercaptopurine/Methotrexate|ARA-C/IFF/MP/MTX/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106210>	C106209	ATP6AP1 wt Allele|16A|ATP6IP1|ATP6S1|ATPase H+ Transporting Accessory Protein 1 wt Allele|ATPase, H+ Transporting, Lysosomal (Vacuolar Proton Pump), Subunit 1 wt Allele|ATPase, H+ Transporting, Lysosomal Accessory Protein 1 Gene|ATPase, H+ Transporting, Lysosomal Interacting Protein 1 Gene|Ac45|CF2|H-ATPase Subunit Gene|MGC129781|VATPS1|XAP-3|XAP3|XX-FW83563B9.4	Human ATP6AP1 wild-type allele is located in the vicinity of Xq28 and is approximately 8 kb in length. This allele, which encodes V-type proton ATPase subunit S1 protein, is involved in vacuolar acidification.	ATP6AP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106211>	C28505	V-Type Proton ATPase Subunit S1|ATP6AP1|ATPase H+ Transporting Accessory Protein 1|Protein XAP-3|V-ATPase Ac45 Subunit|V-ATPase S1 Accessory Protein|V-ATPase Subunit S1|Vacuolar ATPase Subunit 1|Vacuolar Proton Pump Subunit S1	V-type proton ATPase subunit S1 (470 aa, ~52 kDa) is encoded by the human ATP6AP1 gene. This protein plays a role in the acidification of vacuoles.	V-Type Proton ATPase Subunit S1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106212>	C20103	AGER Gene|AGER|AGER|Advanced Glycosylation End Product-Specific Receptor Gene	This gene is involved in binding to advanced glycation end products.	AGER Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106213>	C106212	AGER wt Allele|Advanced Glycosylation End Product-Specific Receptor wt Allele|DAMA-358M23.4|RAGE	Human AGER wild-type allele is located in the vicinity of 6p21.3 and is approximately 3 kb in length. This allele, which encodes advanced glycosylation end product-specific receptor protein, plays a role in both advanced glycation end product recognition and inflammatory signaling.	AGER wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106214>	C18106	Advanced Glycosylation End Product-Specific Receptor|AGER|RAGE|Receptor For Advanced Glycosylation End Products	Advanced glycosylation end product-specific receptor (404 aa, ~43 kDa) is encoded by the human AGER gene. This protein is involved in advanced glycation end product binding, inflammatory responses and receptor-mediated signaling.	Advanced Glycosylation End Product-Specific Receptor		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106215>	C20194	WT1-AS Gene|WT1 Antisense RNA Gene|WT1-AS|WT1-AS	This gene may play a role in the regulation of gene expression.	WT1-AS Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106216>	C106215	WT1-AS wt Allele|WIT-1|WIT1|WT1 Antisense RNA (Non-Protein Coding) Gene|WT1 Antisense RNA wt Allele|WT1-AS1|WT1AS|Wilms Tumor Upstream Neighbor 1 Gene|Wilms Tumor-Associated Antisense RNA Gene|dJ74J1.1	Human WT1-AS wild-type allele is located in the vicinity of 11p13 and is approximately 23 kb in length. This allele, which encodes Wilms tumor-associated antisense RNA, may be involved in the regulation of WT1 gene expression. This gene is imprinted in the kidney, displays preferential expression from the paternal allele, and imprinting defects at chromosome 11p13 may be associated with Wilms tumor.	WT1-AS wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106217>	C88924	Wilms Tumor-Associated Antisense RNA|WIT-1|WT1-AS	Wilms tumor-associated antisense RNA (~23 kb) is encoded by the human WT1-AS gene. This large non-coding RNA may play a role in the expression of the WT1 gene.	Wilms Tumor-Associated Antisense RNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106218>	C25873	TAOK3 Gene|TAO Kinase 3 Gene|TAOK3|TAOK3	This gene is involved in both protein phosphorylation and signal transduction.	TAOK3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106219>	C106218	TAOK3 wt Allele|DPK|JIK|KDS|MAP3K18|TAO Kinase 3 wt Allele	Human TAOK3 wild-type allele is located within 12q and is approximately 223 kb in length. This allele, which encodes serine/threonine-protein kinase TAO3 protein, plays a role in both signal transduction and serine/threonine phosphorylation.	TAOK3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10621>	C61063	Carboplatin/Cyclophosphamide/Etoposide/Vincristine|CBDCA/CTX/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106220>	C17325	Serine/Threonine-Protein Kinase TAO3|CTCL-Associated Antigen HD-CL-09|Cutaneous T-Cell Lymphoma-Associated Antigen HD-CL-09|Dendritic Cell-Derived Protein Kinase|EC 2.7.11.1|JNK/SAPK-Inhibitory Kinase|Jun Kinase-Inhibitory Kinase|Kinase from Chicken Homolog A|TAOK3|Thousand and One Amino Acid Protein 3|hKFC-A	Serine/threonine-protein kinase TAO3 (898 aa, ~105 kDa) is encoded by the human TAOK3 gene. This protein is involved in both serine/threonine phosphorylation and mitogen-activated kinase signaling pathway regulation.	Serine/Threonine-Protein Kinase TAO3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106221>	C25790	VTCN1 Gene|V-Set Domain Containing T Cell Activation Inhibitor 1 Gene|VTCN1|VTCN1	This gene plays a role in the regulation of cell-mediated immunity.	VTCN1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106222>	C106221	VTCN1 wt Allele|B7 Family Member, H4 Gene|B7 Superfamily Member 1 Gene|B7-H4|B7H4|B7S1|B7X|B7h.5|FLJ22418|PRO1291|RP11-229A19.4|UNQ659/PRO1291|V-Set Domain Containing T Cell Activation Inhibitor 1 wt Allele|VCTN1	Human VTCN1 wild-type allele is located in the vicinity of 1p13.1 and is approximately 67 kb in length. This allele, which encodes V-set domain-containing T-cell activation inhibitor 1 protein, is involved in the negative regulation of T-cell-mediated immunity.	VTCN1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106223>	C16725	V-Set Domain-Containing T-Cell Activation Inhibitor 1|B7 Homolog 4|B7h.5|Immune Costimulatory Protein B7-H4|Protein B7S1|T-Cell Costimulatory Molecule B7x|VTCN1	V-set domain-containing T-cell activation inhibitor 1 (282 aa, ~31 kDa) is encoded by the human VTCN1 gene. This protein plays a role in the inhibition of T-cell functions.	V-Set Domain-Containing T-Cell Activation Inhibitor 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106224>	C25942	POLD1 Gene|DNA Polymerase Delta 1, Catalytic Subunit Gene|POLD1|POLD1|POLD1	This gene is involved in DNA replication and proofreading.	POLD1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C106225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106225>	C106224	POLD1 wt Allele|CDC2|CDC2 Homolog (S. cerevisiae) Gene|CRCS10|DNA Polymerase Delta 1, Catalytic Subunit wt Allele|MDPL|POLD|Polymerase (DNA Directed), Delta 1, Catalytic Subunit (125kD) Gene|Polymerase (DNA Directed), Delta 1, Catalytic Subunit Gene|Polymerase (DNA) Delta 1, Catalytic Subunit Gene|Polymerase (DNA-Directed), Delta 1, Catalytic Subunit Gene|Polymerase, DNA, Delta Gene	Human POLD1 wild-type allele is located in the vicinity of 19q13.3 and is approximately 34 kb in length. This allele, which encodes DNA polymerase delta catalytic subunit protein, plays a role in DNA replication. Mutation of the gene may be associated with increased susceptibility to colorectal malignancies.	POLD1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106226>	C16512	DNA Polymerase Delta Catalytic Subunit|CDC2 Homolog|DNA Polymerase Subunit Delta p125|EC 2.7.7.7|POLD1	DNA polymerase delta catalytic subunit (1107 aa, ~124 kDa) is encoded by the human POLD1 gene. This protein is involved in both DNA leading strand synthesis and Okazaki fragment completion.	DNA Polymerase Delta Catalytic Subunit		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106227>	C20194	POLD3 Gene|POLD3|POLD3|Polymerase (DNA Directed), Delta 3, Accessory Subunit Gene	This gene plays a role in the optimization of DNA replication.	POLD3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106228>	C106227	POLD3 wt Allele|KIAA0039|P66|P68|Pol Delta C Subunit (p66) Gene|Polymerase (DNA Directed), Delta 3, Accessory Subunit wt Allele	Human POLD3 wild-type allele is located in the vicinity of 11q14 and is approximately 175 kb in length. This allele, which encodes DNA polymerase delta subunit 3 protein, is involved in the positive regulation of DNA replication. Somatic mutation of the gene may be associated with renal cell carcinoma.	POLD3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106229>	C18466	DNA Polymerase Delta Subunit 3|DNA Polymerase Subunit Delta p66|POLD3	DNA polymerase delta subunit 3 (466 aa, ~51 kDa) is encoded by the human POLD3 gene. This protein plays a role in DNA replication.	DNA Polymerase Delta Subunit 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10622>	C61063	Carboplatin/Carmustine/Tamoxifen|BCNU/CBDCA/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106230>	C200766	cMet CAR-mRNA Electroporated Autologous T Lymphocytes|cMet RNA CAR T Cells	A preparation of autologous T-lymphocytes that have been electroporated with an mRNA encoding a chimeric antigen receptor (CAR) consisting of an anti-human hepatocyte growth factor receptor (HGFR or cMet) scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta) coupled to the co-stimulatory molecule 4-1BB (CD137), with potential antineoplastic activities. Upon intratumoral administration, cMet CAR-mRNA electroporated autologous T lymphocytes direct T-cells to cMet-expressing tumor cells, which induces a selective toxicity in cMet-expressing tumor cells and causes tumor cell lysis. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of cMet. The inclusion of the 4-1BB signaling domain may increase the antitumor activity as compared to the inclusion of the CD3-zeta chain alone. The mRNA CAR is expressed for a limited amount of time, which can prevent serious, unforeseen side effects. cMet, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.	cMet CAR-mRNA Electroporated Autologous T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106231>	C181141	mRNA-derived Prostate Cancer Vaccine CV9104|CV9104|RNActive-derived Prostate Cancer Vaccine CV9104	A prostate cancer vaccine containing six messenger RNAs (mRNAs) encoding for antigens upregulated in prostate cancer, including mRNAs for prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), prostatic acid phosphatase (PAP), and mucin 1 (MUC1), with potential antineoplastic and immunomodulating activities. Upon intradermal administration of mRNA-derived prostate cancer vaccine CV9104, this agent enters cells, the mRNAs are translated into the respective prostate specific antigens and may cause the immune system to mount a cytotoxic T lymphocyte response (CTL) against PSA-, PSMA-, PAP- and MUC1-expressing prostate tumor cells. The mRNAs used in this vaccine are modified to have enhanced translational potency and adjuvant activities. PSA, PSMA, PAP and MUC1 are frequently upregulated in prostate cancer cells; their expression in prostate cancer has been correlated with disease progression.			Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106232>	C25942	POLE Gene|DNA Polymerase Epsilon, Catalytic Subunit Gene|POLE|POLE|POLE	This gene is involved in both DNA replication and DNA base-excision repair.	POLE Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C106233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106233>	C106232	POLE wt Allele|CRCS12|DNA Polymerase Epsilon, Catalytic Subunit wt Allele|FILS|IMAGEI|POLE1|Polymerase (DNA Directed), Epsilon Gene|Polymerase (DNA Directed), Epsilon, Catalytic Subunit Gene|Polymerase (DNA Directed), Epsilon-1 Gene|Polymerase, DNA, Epsilon Gene|Polymerase, DNA, Epsilon-1 Gene	Human POLE wild-type allele is located in the vicinity of 12q24.3 and is approximately 213 kb in length. This allele, which encodes DNA polymerase epsilon catalytic subunit A protein, plays a role in both DNA base-excision repair and DNA replication. Mutation of the gene may be associated with both increased susceptibility to colorectal malignancies and facial dysmorphism, immunodeficiency, livedo, and short stature (FILS) syndrome.	POLE wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106234>	C1892	Olive Oil Extract/Curcumin-based Capsule|PhytoMed Medical Food Suppement	A capsule containing an extract of olive oil, rich in polyphenols, and curcumin, the polyphenol derived from the plant Curcuma longa, also known as turmeric, with potential anti-neoplastic, -angiogenic, -inflammatory, -oxidant and chemopreventive activities. The olive oil extract/curcumin-based capsule is rich in phytonutrients, especially polyphenols. Upon oral administration, the polyphenols, and other active ingredients in this supplement may exert anti-inflammatory activity by decreasing the production of inflammation mediators, such as TNF-alpha, interleukin (IL) 1-beta, IL-6, IL-10, interferon gamma, thromboxane B2, and leukotriene B4. They also inhibit a variety of pro-inflammatory enzymes, such as cyclooxygenase 1 (COX-1) and COX-2, block the formation of reactive-oxygen species and neutralize free radicals. In addition, curcumin and some other polyphenols disrupt cell signal transduction pathways involved in carcinogenesis. Specifically, curcumin inhibits cell invasion by inhibiting matrix metalloproteinase-9 (MMP-9) expression by suppressing NF-kB and AP-1 activation.			Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106235>	C2116	Brilanestrant|ARN-810|BRILANESTRANT|GDC-0810|RO7056118|SERD ARN-810	An orally available, nonsteroidal selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, brilanestrant binds to the estrogen receptor and induces a conformational change that results in the degradation of the receptor. This may inhibit the growth and survival of ER-expressing cancer cells.	Brilanestrant		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106236>	C16512	DNA Polymerase Epsilon Catalytic Subunit A|DNA Polymerase II Subunit A|EC 2.7.7.7|POLE	DNA polymerase epsilon catalytic subunit A (2286 aa, ~262 kDa) is encoded by the human POLE gene. This protein is involved in both DNA repair and DNA replication.	DNA Polymerase Epsilon Catalytic Subunit A		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106237>	C25942|C19676	POLI Gene|POLI|POLI|Polymerase (DNA Directed) Iota Gene	This gene plays a role in DNA damage repair.	POLI Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106238>	C106237	POLI wt Allele|Polymerase (DNA Directed) Iota wt Allele|Polymerase, DNA, Iota Gene|RAD30, S. cerevisiae, Homolog of, B Gene|RAD30B|RAD3OB	Human POLI wild-type allele is located in the vicinity of 18q21.1 and is approximately 52 kb in length. This allele, which encodes DNA polymerase iota protein, is involved in DNA repair.	POLI wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106239>	C21170|C16512	DNA Polymerase Iota|EC 2.7.7.7|Eta2|POLI|RAD30 Homolog B	DNA polymerase iota (740 aa, ~83 kDa) is encoded by the human POLI gene. This protein plays a role in the repair of DNA damage during DNA replication.	DNA Polymerase Iota		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10623>	C61063	Cyclophosphamide/Interleukin-1-Alpha|CTX/IL-1A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106240>	C25942|C19676	POLK Gene|POLK|POLK|Polymerase (DNA Directed) Kappa Gene	This gene is involved in translesion DNA synthesis.	POLK Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106241>	C106240	POLK wt Allele|DINB1|DINP|POLQ|Polymerase (DNA Directed) Kappa wt Allele|Polymerase (DNA-Directed) Kappa Gene|Polymerase, DNA, Kappa Gene	Human POLK wild-type allele is located in the vicinity of 5q13 and is approximately 89 kb in length. This allele, which encodes DNA polymerase kappa protein, plays a role in the repair of DNA damage during DNA replication.	POLK wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106242>	C28310|C154231	Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201|Adenovector-transduced AP1903-inducible iMC-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201|BPX-201	A genetically-modified, dendritic cell-based (DCs) vaccine in which the autologous cells are transduced with an adenoviral vector expressing the tumor antigen prostate-specific membrane antigen (PSMA) and a fusion protein composed of synthetic ligand inducible adjuvant iMC composed of a drug-inducible costimulatory CD40 receptor (iCD40) and the adaptor protein MyD88, with potential immunomodulating and antineoplastic activities. The iCD40 contains a membrane-localized cytoplasmic CD40 domain fused to the FK506 modified drug-binding protein 12 (FKBP12). Upon intradermal administration of BPX-201, these DCs accumulate in local draining lymph nodes. Twenty-four hours after vaccination, the dimerizing agent AP1903 is administered. AP1903 binds to the drug binding domain, leading to iMC oligomerization and activation of iCD40 and MyD88-mediated signaling in iMC-expressing DCs. This signaling pathway activates the DCs and stimulates a cytotoxic T-lymphocyte (CTL) response against host tumor cells that express PSMA. PSMA, a glycoprotein secreted by prostatic epithelial and ductal cells, is overexpressed in prostate cancer cells and is used as a tumor marker for both diagnosis and treatment evaluation. MyD88 is involved in interleukin 1 receptor (IL1R) and toll-like receptor (TLR) signaling.	Adenovector-transduced AP1903-inducible MyD88/CD40-expressing Autologous PSMA-specific Prostate Cancer Vaccine BPX-201		Cell|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106243>	C21170|C16512	DNA Polymerase Kappa|DINB Protein|DINP|EC 2.7.7.7|POLK	DNA polymerase kappa (870 aa, ~99 kDa) is encoded by the human POLK gene. This protein is involved in DNA damage repair.	DNA Polymerase Kappa		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106244>	C19676|C133710	RAD18 Gene|RAD18|RAD18|RAD18 Homolog (S. cerevisiae) Gene	This gene plays a role in both protein ubiquitination and DNA repair.	RAD18 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106245>	C106244	RAD18 wt Allele|RAD18 Homolog (S. cerevisiae) wt Allele|RAD18, S. cerevisiae, Homolog Gene|RNF73	Human RAD18 wild-type allele is located within 3p25-p24 and is approximately 188 kb in length. This allele, which encodes E3 ubiquitin-protein ligase RAD18 protein, is involved in both repair of UV-damaged DNA and protein ubiquitination.	RAD18 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106246>	C21254|C21170	E3 Ubiquitin-Protein Ligase RAD18|EC 2.3.2.27|EC 6.3.2.-, Formerly|Postreplication Repair Protein RAD18|RAD18|RING Finger Protein 73|hHR18|hRAD18	E3 ubiquitin-protein ligase RAD18 (495 aa, ~56 kDa) is encoded by the human RAD18 gene. This protein plays a role in both ubiquitination and postreplication repair of UV-damaged DNA.	E3 Ubiquitin-Protein Ligase RAD18		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106247>	C200766|C176018	Autologous CD19-28z Chimeric Antigen Receptor-expressing T-lymphocytes|CAR 19-28z T Cells	Genetically modified autologous T-lymphocytes transduced with a replication incompetent retroviral vector expressing a chimeric T cell antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment), fused to the extracellular, transmembrane and intracellular signaling domains of the T cell co-stimulatory receptor CD28 and the cytoplasmic signaling domain of the zeta chain of the TCR/CD3 complex (CD3-zeta) (CAR19-28z), with potential antineoplastic activities. Upon intravenous administration, autologous CD19-28z CAR-expressing T-lymphocytes are directed to CD19-expressing tumor cells, which induces selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. The CD28 co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19. The inclusion of the CD28 signaling domain may increase proliferation of T-cells and antitumor activity compared to the inclusion of the CD3-zeta chain alone.	Autologous CD19-28z Chimeric Antigen Receptor-expressing T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106249>	C19676	RAD23A Gene|RAD23 Homolog A (S. cerevisiae) Gene|RAD23A|RAD23A	This gene is involved in both nucleotide excision repair and the regulation of protein degradation.	RAD23A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10624>	C61063	Carboplatin/Milodistim|CBDCA/PIXY321			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106250>	C128057	Atezolizumab|ATEZOLIZUMAB|Immunoglobulin G1, Anti-(human CD Antigen cd274) (Human Monoclonal MPDL3280A Heavy Chain), Disulfide with Human Monoclonal MPDL3280A Kappa-chain, Dimer|MPDL 3280A|MPDL 328OA|MPDL-3280A|MPDL3280A|MPDL328OA|RG 7446|RG-7446|RG7446|RO 5541267|RO-5541267|RO5541267|Tecentriq	A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1; PDCD1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 (CD80) expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).	Atezolizumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106251>	C106249	RAD23A wt Allele|HHR23A|HR23A|MGC111083|RAD23 (S. cerevisiae) Homolog A Gene|RAD23 Homolog A (S. cerevisiae) wt Allele|RAD23, Yeast Homolog, A Gene	Human RAD23A wild-type allele is located in the vicinity of 19p13.2 and is approximately 8 kb in length. This allele, which encodes UV excision repair protein RAD23 homolog A, plays a role in both proteasome-dependent protein degradation and nucleotide excision repair.	RAD23A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106252>	C21170	UV Excision Repair Protein RAD23 Homolog A|HR23A|RAD23A|hHR23A	UV excision repair protein RAD23 homolog A (363 aa, ~40 kDa) is encoded by the human RAD23A gene. This protein is involved in both DNA repair and the targeting of ubiquitinated proteins to the proteasome.	UV Excision Repair Protein RAD23 Homolog A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106253>	C107589	CXCR4 Peptide Antagonist LY2510924|LY2510924	An inhibitor of CXC chemokine receptor 4 (CXCR4), with potential antineoplastic activity. Upon subcutaneous administration, CXCR4 inhibitor LY2510924 binds to the chemokine receptor CXCR4, thereby preventing CXCR4 binding to its ligand, stromal derived factor-1 (SDF-1), and subsequent receptor activation. This may result in decreased tumor cell proliferation and migration. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types.	CXCR4 Peptide Antagonist LY2510924		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106254>	C2336	Tovorafenib|(R)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-N-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide|BIIB 024|BIIB-024|BIIB024|DAY 101|DAY-101|DAY101|MLN 2480|MLN-2480|MLN2480|Ojemda|TAK 580|TAK-580|TAK580|TOVORAFENIB|pan-RAF Kinase Inhibitor DAY101	An orally available inhibitor of wild-type and certain mutant forms of A-Raf, B-Raf and C-Raf protein kinases, with potential antineoplastic activity. Upon administration, tovorafenib inhibits Raf-mediated signal transduction pathways, which may lead to an inhibition of tumor cell growth. Raf protein kinases play a key role in the RAF/MEK/ERK signaling pathway, which is often deregulated in human cancers and plays a key role in tumor cell proliferation and survival.	Tovorafenib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106255>	C21240	RBM4 Gene|RBM4|RBM4|RNA Binding Motif Protein 4 Gene	This gene plays a role in both alternative splicing and mRNA translation.	RBM4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106256>	C211912	Anti-FcRH5 Antibody-drug Conjugate DFRF4539A|Anti-FcRH5 ADC DFRF4539A|DFRF4539A|RG 7598|RG-7598|RG7598	An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) Fc receptor-like protein 5 (FcRH5; CD307; FCRL5; IRTA2; BXMAS1) and conjugated to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, via the protease-labile linker maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (MC-VC-PABC), with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of anti-FcRH5 ADC DFRF4539A selectively binds to FcRH5 expressed on the surface of myeloma cells. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and tumor cell apoptosis. FcRH5, an immune receptor translocation-associated protein/Fc receptor homolog (IRTA/FCRH) family member and a B-cell lineage marker, is overexpressed on myeloma cells.	Anti-FcRH5 Antibody-drug Conjugate DFRF4539A		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106257>	C1752|C1663	WT1 Peptide Vaccine OCV-501|OCV-501	A peptide cancer vaccine comprised of a peptide derived from Wilms tumor gene 1 (WT1) protein, with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, WT1 peptide vaccine OCV-501 may stimulate a CD4-positive helper T-lymphocyte-mediated immune response against WT1 expressing cells. WT1 protein, a zinc finger DNA-binding protein, is overexpressed in leukemic cells and in some solid tumors.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106258>	C106255	RBM4 wt Allele|LARK|RBM4A|RNA Binding Motif Protein 4 wt Allele|ZCCHC21|ZCRB3A	Human RBM4 wild-type allele is located in the vicinity of 11q13 and is approximately 28 kb in length. This allele, which encodes RNA-binding protein 4, is involved in muscle cell differentiation, translation of mRNA and alternative splicing.	RBM4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106259>	C210987	PIM Kinase Inhibitor LGH447|LGH-447|LGH-447|LGH447|PIM 447|PIM-447|PIM447	An orally available pan-PIM protein kinase inhibitor with potential antineoplastic activity. PIM kinase inhibitor LGH447 binds to and inhibits the activities of PIM-1, -2 and -3 serine/threonine kinases, which may result in the interruption of the G1/S phase cell cycle transition, the expression of the pro-apoptotic Bcl2 protein and tumor cell apoptosis in cells that overexpress PIMs. PIM kinases, downstream effectors of many cytokine and growth factor signaling pathways, play key roles in cell cycle progression and apoptosis inhibition and may be overexpressed in various malignancies.	PIM Kinase Inhibitor LGH447		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C10625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10625>	C61063	Busulfan/Cyclophosphamide/Cytarabine|ARA-C/BU/CTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106260>	C38576	RNA-Binding Protein 4|Lark Homolog|RBM4|RNA-Binding Motif Protein 4|RNA-Binding Motif Protein 4a|Zinc Finger CCHC-Type and RNA Binding Motif 3A|hLark	RNA-binding protein 4 (364 aa, ~40 kDa) is encoded by the human RBM4 gene. This protein plays a role in alternative splicing, muscle cell differentiation and translation.	RNA-Binding Protein 4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106261>	C2152|C129825	PI3K-beta Inhibitor GSK2636771|GSK-2636771|GSK2636771	An orally bioavailable, substituted benzimidazole inhibitor of the class I phosphoinositide 3-kinase (PI3K) beta isoform with potential antineoplastic activity. PI3K beta inhibitor GSK2636771 selectively inhibits PI3K beta kinase activity in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K beta-expressing and/or PTEN-driven tumor cells. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and results in the promotion of tumor cell growth, survival, and resistance to both chemotherapy and radiotherapy. PI3K beta is the p110-beta catalytic subunit of the class I PI3K. PTEN, a tumor suppressor protein and negative regulator of PI3K activity, is often mutated in a variety of cancer cells.	PI3K-beta Inhibitor GSK2636771		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106262>	C164001|C129822	Telisotuzumab|ABT-700|Anti-c-Met Monoclonal Antibody ABT-700|TELISOTUZUMAB	An immunoglobulin G1 (IgG1) humanized monoclonal antibody directed against human hepatocyte growth factor receptor (HGFR or c-Met), with potential antineoplastic activity. Telisotuzumab binds to c-Met, thereby preventing both c-Met binding to its ligand, HGF and the subsequent activation of the HGF/c-Met signaling pathway. This may cause cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.	Telisotuzumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106263>	C153246	RAD52 Gene|RAD52|RAD52|RAD52 Homolog, DNA Repair Protein Gene	This gene is involved in both double-strand break repair and homologous recombination.	RAD52 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106264>	C106263	RAD52 wt Allele|RAD52 (S. cerevisiae) Homolog Gene|RAD52 Homolog (S. cerevisiae) Gene|RAD52 Homolog, DNA Repair Protein wt Allele|RAD52, Yeast Homolog of Gene	Human RAD52 wild-type allele is located within 12p13-p12.2 and is approximately 79 kb in length. This allele, which encodes DNA repair protein RAD52 homolog, plays a role in both homologous recombination and DNA repair.	RAD52 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106265>	C21170	DNA Repair Protein RAD52 Homolog|RAD52|Recombination Protein RAD52|Rhabdomyosarcoma Antigen MU-RMS-40.23	DNA repair protein RAD52 homolog (418 aa, ~46 kDa) is encoded by the human RAD52 gene. This protein is involved in both homologous recombination and double-strand break repair.	DNA Repair Protein RAD52 Homolog		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106266>	C214992|C129823	Anti-CD27L Antibody-drug Conjugate AMG 172|AMG 172|AMG-172|AMG-172	An immunoconjugate consisting of a human IgG1 monoclonal antibody directed against CD27L conjugated, via a non-cleavable linker, to the cytotoxic agent maytansinoid DM1, with potential antineoplastic activity. The monoclonal antibody moiety of this immunoconjugate binds to CD27L on tumor cell surfaces. After internalization, the DM1 moiety binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting both cell division and proliferation of cancer cells that express CD27L. CD27L, a type II transmembrane protein and member of the tumor necrosis factor family, is a co-stimulatory molecule constitutively expressed on a subset of activated T-cells, B-cells, and dendritic cells, which is overexpressed in certain tumor cell types.	Anti-CD27L Antibody-drug Conjugate AMG 172		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106267>	C1663	Brachyury-expressing Yeast Vaccine GI-6301|GI-6301|GI-6301	A cancer vaccine composed of a heat-killed, recombinant form of the yeast Saccharomyces cerevisiae that is genetically modified to express the transcription factor brachyury protein, with potential antineoplastic activity. Upon subcutaneous administration, the brachyury-expressing yeast vaccine GI-6301 is recognized by dendritic cells, processed, and presented by Class I and II MHC molecules on the dendritic cell surface. This elicits a targeted CD4+ and CD8+ T-lymphocyte-mediated immune response. This process kills brachyury-expressing tumor cells. Brachyury is overexpressed in a variety of tumor types and plays an important role in cancer progression and metastasis.	Brachyury-expressing Yeast Vaccine GI-6301		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106269>	C20988	CADM1 Gene|CADM1|CADM1|Cell Adhesion Molecule 1 Gene	This gene plays a role in cell-cell adhesion.	CADM1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10626>	C61063	Cyclosporine/Tamoxifen/Vinblastine|CYSP/TMX/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106270>	C106269	CADM1 wt Allele|BL2|Cell Adhesion Molecule 1 wt Allele|IGSF4|IGSF4A|NECL2|Necl-2|RA175|ST17|SYNCAM|TSLC1|sTSLC-1|sgIGSF|synCAM1	Human CADM1 wild-type allele is located in the vicinity of 11q23.2 and is approximately 336 kb in length. This allele, which encodes cell adhesion molecule 1 protein, is involved in the modulation of cell-cell adhesion.	CADM1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106271>	C213366|C129821	Liposome-encapsulated RB94 Plasmid DNA Gene Therapy Agent SGT-94|SGT-94|TfRscFv/Lip/RB94	A systemic gene therapy anti-cancer agent composed of cationic liposomes, which encapsulates plasmid DNA encoding for the tumor suppressor gene RB94 and is complexed with anti-transferrin receptor single chain antibody fragment (TfRscFv), with potential antineoplastic activity. Upon systemic administration of liposome-encapsulated RB94 plasmid DNA gene therapy agent SGT-94, the TfRscFv portion of this agent selectively targets the tumor cells expressing transferrin receptors. TfRscFv binding to the transferrin receptor allows receptor-mediated endocytosis and transfection, followed by the expression of RB94 gene. This induces tumor cell apoptosis through an as of yet unknown pathway. RB94 is a modified, N-terminal truncated form of the full-length protein retinoblastoma gene RB110, and exerts enhanced antitumor activity. The transferrin receptor (TfR) functions in cellular iron uptake through its interaction with transferrin, and is overexpressed in a variety of tumor types.	Liposome-encapsulated RB94 Plasmid DNA Gene Therapy Agent SGT-94		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106272>	C16393	Cell Adhesion Molecule 1|CADM1|IgSF4|Immunoglobulin Superfamily Member 4|NECL-2|Nectin-Like 2|Nectin-Like Protein 2|SgIgSF|Spermatogenic Immunoglobulin Superfamily|SynCAM|Synaptic Cell Adhesion Molecule|TSLC-1|Tumor Suppressor in Lung Cancer 1	Cell adhesion molecule 1 (442 aa, ~49 kDa) is encoded by the human CADM1 gene. This protein plays a role in calcium-dependent cell-cell adhesion.	Cell Adhesion Molecule 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106273>	C101304	ABO Hemolytic Disease of the Newborn|ABO Hemolytic Disease of Newborn|ABO Isoimmunization|Hemolytic Disease due to ABO Isoimmunization	A condition of the newborn characterized by the destruction of red blood cells initiated by the transmission of anti-A or anti-B antibodies from a mother to the child via the placenta against A or B antigens of the newborn's blood.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology|Perinatal Terminology
C106274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106274>	C20420	PAX1 Gene|PAX1|PAX1|Paired Box 1 Gene	This gene is involved in both skeletal development and T-cell differentiation.	PAX1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106275>	C106274	PAX1 wt Allele|HUP48|Paired Box 1 wt Allele|Paired Box Gene 1|Paired Domain Gene HuP48|RP5-1065O2.3	Human PAX1 wild-type allele is located in the vicinity of 20p11.2 and is approximately 10 kb in length. This allele, which encodes paired box protein Pax-1, plays a role in transcriptional regulation.	PAX1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106276>	C17207	Paired Box Protein Pax-1|HuP48|PAX1	Paired box protein Pax-1 (534 aa, ~55 kDa) is encoded by the human PAX1 gene. This protein is involved in the regulation of transcription during both skeletal development and T-cell differentiation.	Paired Box Protein Pax-1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106277>	C25952|C20917|C19676	RAD9A Gene|RAD9 Homolog A (S. pombe) Gene|RAD9A|RAD9A	This gene plays a role in both cell cycle checkpoint control and DNA repair.	RAD9A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106278>	C106277	RAD9A wt Allele|RAD9|RAD9 (S. pombe) Homolog Gene|RAD9 Homolog A (S. pombe) wt Allele|RAD9, S. pombe, Homolog of Gene|RAD9, S. pombe, Homolog of, A Gene	Human RAD9A wild-type allele is located within 11q13.1-q13.2 and is approximately 7 kb in length. This allele, which encodes cell cycle checkpoint control protein RAD9A, is involved in the regulation of both DNA repair and cell cycle progression.	RAD9A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106279>	C21170|C17761|C16499	Cell Cycle Checkpoint Control Protein RAD9A|DNA Repair Exonuclease rad9 Homolog A|EC 3.1.11.2|RAD9A|hRAD9	Cell cycle checkpoint control protein RAD9A (391 aa, ~43 kDa) is encoded by the human RAD9A gene. This protein plays a role in DNA repair-dependent cell cycle checkpoint control.	Cell Cycle Checkpoint Control Protein RAD9A		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10627>	C61063	Interleukin-2/Interleukin-4/Tumor Infiltrating Lymphocytes|IL-2/IL-4/TIL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106280>	C20917|C19676	RAD9B Gene|RAD9 Homolog B (S. pombe) Gene|RAD9B|RAD9B	This gene is involved in both DNA repair and cell cycle progression.	RAD9B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106281>	C106280	RAD9B wt Allele|FLJ40346|RAD9 Homolog B (S. pombe) wt Allele|RAD9, S. pombe, Homolog of, B Gene	Human RAD9B wild-type allele is located in the vicinity of 12q24.11 and is approximately 30 kb in length. This allele, which encodes cell cycle checkpoint control protein RAD9B, plays a role in DNA repair-dependent cell cycle checkpoint control.	RAD9B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106282>	C21170|C17761	Cell Cycle Checkpoint Control Protein RAD9B|Cell Cycle Checkpoint Control Protein RAD9B Homolog|DNA Repair Exonuclease rad9 Homolog B|RAD9B|hRAD9B	Cell cycle checkpoint control protein RAD9B (426 aa, ~48 kDa) is encoded by the human RAD9B gene. This protein is involved in the modulation of both cell cycle progression and DNA repair.	Cell Cycle Checkpoint Control Protein RAD9B		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106283>	C25942|C19676	REV1 Gene|REV1|REV1|REV1, Polymerase (DNA Directed) Gene	This gene plays a role in repair of DNA during replication.	REV1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106284>	C106283	REV1 wt Allele|REV1 (Yeast Homolog)- Like Gene|REV1 (Yeast Homolog)-Like Gene|REV1 Homolog (S. cerevisiae) Gene|REV1, Polymerase (DNA Directed) wt Allele|REV1, S. cerevisiae, Homolog of Gene|REV1-Like (Yeast) Gene|REV1L	Human REV1 wild-type allele is located within 2q11.1-q11.2 and is approximately 90 kb in length. This allele, which encodes DNA repair protein REV1, is involved in the repair of replicating DNA.	REV1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106285>	C21170|C16512	DNA Repair Protein REV1|AIBP80|Alpha Integrin-Binding Protein 80|Alpha-Integrin-Binding Protein 80|EC 2.7.7.-|REV1|REV1 Homolog|REV1- Like|REV1-Like|Rev1-Like Terminal Deoxycytidyl Transferase	DNA repair protein REV1 (1251 aa, ~138 kDa) is encoded by the human REV1 gene. This protein plays a role in translesion DNA synthesis.	DNA Repair Protein REV1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106286>	C20921	NPRL3 Gene|NPRL3|NPRL3|Nitrogen Permease Regulator-Like 3 (S. cerevisiae) Gene	This gene has no known function.	NPRL3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106287>	C106286	NPRL3 wt Allele|C16orf35|CGTHBA|Chromosome 16 Open Reading Frame 35 Gene|Conserved Gene Telomeric to Alpha Globin Cluster Gene|HS-40|MARE|NPR3|Nitrogen Permease Regulator-Like 3 (S. cerevisiae) wt Allele|RMD11|Z69666.1-003	Human NPRL3 wild-type allele is located in the vicinity of 16p13.3 and is approximately 55 kb in length. This allele, which encodes nitrogen permease regulator 3-like protein, has no known function.	NPRL3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106288>	C17298	GATOR Complex Protein NPRL3|-14 Gene Protein|Alpha-Globin Regulatory Element-Containing Gene Protein|NPRL3|Nitrogen Permease Regulator 3-Like Protein|Protein CGTHBA	GATOR complex protein NPRL3 (569 aa, ~64 kDa) is encoded by the human NPRL3 gene. This protein has no known function.	GATOR Complex Protein NPRL3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106289>	C20194	SUMO1 Gene|SMT3 Suppressor of Mif Two 3 Homolog 1 (S. cerevisiae) Gene|SUMO1|SUMO1	This gene plays a role in post-translational protein modification.	SUMO1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10628>	C61007	Cytarabine/Tretinoin|ARA-C/ATRA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106290>	C106289	SUMO1 wt Allele|DAP1|GMP1|OFC10|OK/SW-cl.43|PIC1|SENP2|SMT3|SMT3 Suppressor of Mif Two 3 Homolog 1 (S. cerevisiae) wt Allele|SMT3 Suppressor of Mif Two 3 Homolog 1 (Yeast) Gene|SMT3C|SMT3H3|UBL1|Ubiquitin-Like 1 (Sentrin) Gene	Human SUMO1 wild-type allele is located in the vicinity of 2q33 and is approximately 32 kb in length. This allele, which encodes small ubiquitin-related modifier 1 protein, is involved in the post-translational modification of proteins.	SUMO1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106291>	C18466	Small Ubiquitin-Related Modifier 1|GAP Modifying Protein 1|GAP-Modifying Protein 1|GMP1|SMT3 Homolog 3|SUMO-1|SUMO1|Sentrin|Smt3C|Ubiquitin-Homology Domain Protein PIC1|Ubiquitin-Like Protein SMT3C|Ubiquitin-Like Protein UBL1	Small ubiquitin-related modifier 1 (101 aa, ~12 kDa) is encoded by the human SUMO1 gene. This protein plays a role in post-translational protein modification.	Small Ubiquitin-Related Modifier 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106292>	C20194	TNP1 Gene|TNP1|TNP1|Transition Protein 1 (During Histone to Protamine Replacement) Gene	This gene is involved in spermatid maturation.	TNP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106293>	C106292	TNP1 wt Allele|TP1|Transition Protein 1 (During Histone to Protamine Replacement) wt Allele	Human TNP1 wild-type allele is located within 2q35-q36 and is approximately 1 kb in length. This allele, which encodes spermatid nuclear transition protein 1, plays a role in sperm morphology.	TNP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106294>	C18466	Spermatid Nuclear Transition Protein 1|STP-1|TNP1|TP-1|Transition Protein 1	Spermatid nuclear transition protein 1 (55 aa, ~6 kDa) is encoded by the human TNP1 gene. This protein is involved in the maturation of sperm.	Spermatid Nuclear Transition Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106295>	C20194	TRPC2 Gene|TRPC2|TRPC2|Transient Receptor Potential Cation Channel, Subfamily C, Member 2 Gene|Transient Receptor Potential Cation Channel, Subfamily C, Member 2, Pseudogene Gene	Human TRPC2 gene is located within 11p15.4-p15.3 and is approximately 28 kb in length. This gene is a pseudogene that has no known functional product.	TRPC2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106296>	C40557	Macrometastasis	Metastasis that is clinically obvious.			Finding	
C106297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106297>	C174459	Clinical Classification for Oncology	Tumor classification based on pre-treatment information obtained from the physical examination, radiology tests, and biopsies.			Classification	
C106298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106298>	C133708	UBE2A Gene|UBE2A|UBE2A|Ubiquitin-Conjugating Enzyme E2A Gene	This gene is involved in histone ubiquitination.	UBE2A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106299>	C48885	Any T	No specification on the details of the primary tumor growth.			Finding	
C10629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10629>	C61063	Edatrexate/Ifosfamide|EDAM/IFF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1062>	C1594	Daunorubicinol|13-Dihydrodaunomycin|13-Dihydrodaunorubicin|13-Hydroxydaunomycin|5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(1-hydroxyethyl)-1-methoxy-, (8S-cis)-|DAUNORUBICINOL|Daunomycinol|Daunorubicineal|Duborimycin|Leukaemomycin D	An anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Daunorubicinol exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis. (NCI04)			Antibiotic|Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106300>	C106298	UBE2A wt Allele|HHR6A|MRXS30|MRXSN|RAD6, Yeast, Homolog of, Type A Gene|RAD6A|UBC2|Ubiquitin-Conjugating Enzyme E2A wt Allele	Human UBE2A wild-type allele is located in the vicinity of Xq24 and is approximately 10 kb in length. This allele, which encodes ubiquitin-conjugating enzyme E2 A protein, plays a role in histone modification.	UBE2A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106301>	C35867	Isolated Tumor Cells	The presence of single tumor cells or tiny clusters of tumor cells in a pathologic specimen.			Finding	
C106302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106302>	C133711	Ubiquitin-Conjugating Enzyme E2 A|E2 Ubiquitin-Conjugating Enzyme A|EC 2.3.2.23|EC 6.3.2.19, Formerly|HR6A|RAD6 Homolog A|UBE2A|Ubiquitin Carrier Protein A|Ubiquitin-Protein Ligase A|hHR6A	Ubiquitin-conjugating enzyme E2 A (152 aa, ~17 kDa) is encoded by the human UBE2A gene. This protein is involved in the monoubiquitination of histone H2B.	Ubiquitin-Conjugating Enzyme E2 A		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106303>	C79428	Tumor Size Measurement	The measurement of the size of a tumor mass either clinically or in a surgically resected specimen.			Health Care Activity	NAACCR Terminology
C106304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106304>	C25161	Tumor Regression Grade|tumor regression grade|tumor_regression_grade	A pathologic grading system used to evaluate the tumor response to preoperative chemotherapy and radiation.			Classification	GDC Property Terminology|GDC Terminology
C106305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106305>	C207050	Visceral and Parietal Pleural Invasion|Pleural/Elastic Layer Invasion	A finding indicating that a malignant tumor has invaded the elastic layer and surface of visceral pleura and has extended to the parietal pleura and/or chest wall.			Finding	
C106306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106306>	C25804|C19676	UNG Gene|UNG|UNG|Uracil DNA Glycosylase Gene	This gene plays a role in DNA repair.	UNG Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106307>	C106306	UNG wt Allele|DGU|DNA Glycosylase, Uracil Gene|HIGM4|HIGM5|UDG|UNG1|UNG15|UNG2|Uracil DNA Glycosylase wt Allele|Uracil-DNA Glycosylase Gene	Human UNG wild-type allele is located within 12q23-q24.1 and is approximately 13 kb in length. This allele, which encodes uracil-DNA glycosylase protein, is involved in the removal of uracil from DNA.	UNG wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106308>	C185330	Uracil-DNA Glycosylase|EC 3.2.2.27|UDG|UDG1A|UDG1N|UNG|UNG2|Uracil-DNA Glycosylase 2|Uracil-DNA Glycosylase Isoform 2|Uracil-DNA Glycosylase, Nuclear Isoform	Uracil-DNA glycosylase (313 aa, ~35 kDa) is encoded by the human UNG gene. This protein plays a role in DNA metabolism.	Uracil-DNA Glycosylase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106309>	C25804	WRNIP1 Gene|WRNIP1|WRNIP1|Werner Helicase Interacting Protein 1 Gene	This gene is involved in both ATP hydrolysis and DNA replication.	WRNIP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10630>	C61063	Cisplatin/Etoposide/Tretinoin|ATRA/CDDP/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106310>	C106309	WRNIP1 wt Allele|FLJ22526|RP11-420G6.2|WHIP|Werner Helicase Interacting Protein 1 wt Allele|bA420G6.2	Human WRNIP1 wild-type allele is located in the vicinity of 6p25.2 and is approximately 21 kb in length. This allele, which encodes ATPase WRNIP1 protein, plays a role in both DNA replication and ATP hydrolysis.	WRNIP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106311>	C16701	ATPase WRNIP1|Putative Helicase RUVBL|WRNIP1|Werner Helicase-Interacting Protein 1	ATPase WRNIP1 (665 aa, ~72 kDa) is encoded by the human WRNIP1 gene. This protein is involved in both ATP hydrolysis and DNA replication.	ATPase WRNIP1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106312>	C18520	Advanced Glycation End Product|AGE|AGEs|Advanced Glycation End-Product|Advanced Glycation Endproduct|Advanced Glycation Endproducts|Advanced Glycosylation End Product|Advanced Glycosylation End Products	Nonenzymatically glycosylated proteins or lipids which accumulate in vascular tissue during aging and at an accelerated rate in diabetes.	Advanced Glycation End Product		Functional Concept	CTRP Biomarker Terminology|CTRP Terminology
C106313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106313>	C20036	RORC Gene Product	A protein encoded by the RORC gene.	RORC Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106314>	C106313	Nuclear Receptor ROR-Gamma T|Nuclear Receptor ROR Gamma T|Nuclear Receptor ROR-Gamma Isoform 2|Nuclear Receptor RORgamma(t)|Nuclear Receptor RZR-Gamma Isoform 2|Nuclear Receptor Subfamily 1 Group F Member 3 Isoform 2|RORgT|RORgammaT|Retinoic Acid-Binding Receptor Gamma Isoform 2|Retinoic Acid-Related Orphan Receptor Gamma T|Retinoid-Related Orphan Receptor Gamma Isoform 2|Retinoid-Related Orphan Receptor-Gamma Isoform 2	Nuclear receptor ROR-gamma T (497 aa, ~56 kDa) is encoded by the human RORC gene. This protein is involved in both ligand-dependent transcriptional regulation and the differentiation of helper T-cells.	Nuclear Receptor ROR-Gamma T		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106315>	C2873	Hyperploidy	A chromosomal abnormality in that is characterized by an addition of chromosomes that results in a chromosome number that is not an exact multiple of the haploid number.	Hyperploidy		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Terminology
C106316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106316>	C19449	DNA Hydroxymethylation	A DNA modification process where a hydrogen at the C5-position of a cytosine residue is replaced with a hydroxmethyl group.	DNA Hydroxymethylation		Genetic Function	CTRP Biomarker Terminology|CTRP Terminology
C106317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106317>	C28042	Mitosis-Karyorrhexis Index|MKI|mitosis karyorrhexis index|mitosis_karyorrhexis_index	A tumor cell proliferation measurement represented by the number of cells in mitosis plus the number of cells in karyorrhexis per 5000 cells.	Mitosis-Karyorrhexis Index		Quantitative Concept	CTRP Biomarker Terminology|CTRP Terminology|GDC Property Terminology|GDC Terminology
C106318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106318>	C13432	3p14	A chromosome band present on 3p.	3p14		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106319>	C20130	Peripheral Lymph Node Addressin|L-Selectin Ligand|MECA-79 Antigen|PNAd|SELL Ligand	A group of sulfated sialomucins that share a carbohydrate epitope synthesized by N-acetylglucosamine 6-O-sulfotransferase. The glycoproteins with this modification include sulfated ligands for L-selectin and are involved in tethering and rolling of lymphocytes along high endothelial venules (HEV) of lymphoid tissues.	Peripheral Lymph Node Addressin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10631>	C61063	Asparaginase/Cisplatin/Cytarabine/Dexamethasone/Etoposide|ARA-C/ASP/CDDP/DM/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106320>	C15277	Total Skin-Sparing Mastectomy|TSSM	Mastectomy with preservation of the breast skin and the skin of the nipple and areola.			Therapeutic or Preventive Procedure	
C106321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106321>	C20420	TBX4 Gene|T-Box 4 Gene|TBX4|TBX4	This gene plays a role in skeletal development.			Gene or Genome	
C106322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106322>	C106321	TBX4 wt Allele|SPS|T-Box 4 wt Allele	Human TBX4 wild-type allele is located within 17q21-q22 and is approximately 33 kb in length. This allele, which encodes T-box transcription factor TBX4 protein, is involved in both transcriptional regulation and limb formation. Mutation of the gene is associated with small patella syndrome.			Gene or Genome	
C106323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106323>	C17207	T-Box Transcription Factor TBX4|T-Box Protein 4|TBX4	T-box transcription factor TBX4 (545 aa, ~60 kDa) is encoded by the human TBX4 gene. This protein plays a role in both limb formation and transcriptional regulation.			Amino Acid, Peptide, or Protein	
C106324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106324>	C54452	SPL Lot Distribution Data - Distribution Codes Terminology|SPL Lot Distribution Data - Distribution Codes|Structured Product Labeling Lot Distribution Data - Distribution Codes	Terminology to support Structured Product Labeling with lot distribution data and distribution codes.	SPL Lot Distribution Data - Distribution Codes		Intellectual Product	FDA Structured Product Labeling Terminology
C106325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106325>	C25256	Quantity Distributed per Reporting Interval|Distributed per reporting interval	Quantity of items distributed in a reporting period.			Quantitative Concept	FDA Structured Product Labeling Terminology|SPL Lot Distribution Data - Distribution Codes Terminology
C106326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106326>	C25256	Quantity Distributed Anticipated Total|Distributed - anticipated total	Anticipated quantity of items distributed.			Quantitative Concept	FDA Structured Product Labeling Terminology|SPL Lot Distribution Data - Distribution Codes Terminology
C106327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106327>	C26070	INPP4B Gene|INPP4B|INPP4B|Inositol Polyphosphate-4-Phosphatase Type II B Gene	This gene is involved in phosphatidylinositol metabolism.	INPP4B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106328>	C25256	Quantity Final Containers Returned|Returned	Quantity of final containers returned.			Quantitative Concept	FDA Structured Product Labeling Terminology|SPL Lot Distribution Data - Distribution Codes Terminology
C106329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106329>	C106327	INPP4B wt Allele|Inositol Polyphosphate-4-Phosphatase Type II B wt Allele|Inositol Polyphosphate-4-Phosphatase, Type II, 105-kD Gene|Inositol Polyphosphate-4-Phosphatase, Type II, 105kD Gene|Inositol Polyphosphate-4-Phosphatase, Type II, 105kDa Gene	Human INPP4B wild-type allele is located in the vicinity of 4q31.21 and is approximately 824 kb in length. This allele, which encodes inositol polyphosphate 4-phosphatase type II protein, plays a role in the regulation of phosphatidylinositol signaling and metabolism.	INPP4B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10632>	C61063	Cytarabine/Filgrastim/Tretinoin|ARA-C/ATRA/G-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106330>	C16981	Inositol Polyphosphate 4-Phosphatase Type II|4-Phosphatase II|EC 3.1.3.66|INPP4B|Inositol Polyphosphate 4-Phosphatase II|Inositol Polyphosphate-4-Phosphatase Type II|Type II Inositol 3,4-Bisphosphate 4-Phosphatase|Type II Inositol-3,4-Bisphosphate 4-Phosphatase	Inositol polyphosphate 4-phosphatase type II (924 aa, ~105 kDa) is encoded by the human INPP4B gene. This protein is involved in the modulation of phosphatidylinositol metabolism and signaling.	Inositol Polyphosphate 4-Phosphatase Type II		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106331>	C25943	SLC27A3 Gene|SLC27A3|SLC27A3|Solute Carrier Family 27 (Fatty Acid Transporter), Member 3 Gene	This gene plays a role in fatty acid metabolism.			Gene or Genome	
C106332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106332>	C106331	SLC27A3 wt Allele|ACSVL3|FATP3|PSEC0067|Solute Carrier Family 27 (Fatty Acid Transporter), Member 3 wt Allele|UNQ367/PRO703|VLCS-3	Human SLC27A3 wild-type allele is located in the vicinity of 1q21.3 and is approximately 6 kb in length. This allele, which encodes long-chain fatty acid transport protein 3, is involved in fatty acid-acyl-CoA synthesis.			Gene or Genome	
C106333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106333>	C16796	Long-Chain Fatty Acid Transport Protein 3|EC 6.2.1.-|FATP-3|Fatty Acid Transport Protein 3|SLC27A3|Solute Carrier Family 27 Member 3|VLCS-3|Very Long-Chain Acyl-CoA Synthetase Homolog 3	Long-chain fatty acid transport protein 3 (730 aa, ~79 kDa) is encoded by the human SLC27A3 gene. This protein plays a role in the metabolism of fatty acids.			Amino Acid, Peptide, or Protein|Enzyme	
C106334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106334>	C28533|C25943	SLC27A4 Gene|SLC27A4|SLC27A4|Solute Carrier Family 27 (Fatty Acid Transporter), Member 4 Gene	This gene is involved in both fatty acid transport and metabolism.			Gene or Genome	
C106335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106335>	C106334	SLC27A4 wt Allele|ACSVL4|FATP4|IPS|Solute Carrier Family 27 (Fatty Acid Transporter), Member 4 wt Allele	Human SLC27A4 wild-type allele is located in the vicinity of 9q34.11 and is approximately 21 kb in length. This allele, which encodes long-chain fatty acid transport protein 4, plays a role in both the transport and metabolism of fatty acids.			Gene or Genome	
C106336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106336>	C16796|C16386	Long-Chain Fatty Acid Transport Protein 4|EC 6.2.1.-|FATP-4|Fatty Acid Transport Protein 4|SLC27A4|Solute Carrier Family 27 Member 4	Long-chain fatty acid transport protein 4 (643 aa, ~72 kDa) is encoded by the human SLC27A4 gene. This protein is involved in the mediation of both fatty acid transport and acyl-CoA conjugation of long-chain and very-long-chain fatty acids.			Amino Acid, Peptide, or Protein|Enzyme	
C106337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106337>	C133708	UBE2L3 Gene|UBE2L3|UBE2L3|Ubiquitin-Conjugating Enzyme E2L 3 Gene	This gene plays a role in protein ubiquitination.			Gene or Genome	
C106338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106338>	C106337	UBE2L3 wt Allele|E2-F1|L-UBC|UBCH7|UbcM4|Ubiquitin-Conjugating Enzyme E2L 3 wt Allele	Human UBE2L3 wild-type allele is located in the vicinity of 22q11.2 and is approximately 75 kb in length. This allele, which encodes ubiquitin-conjugating enzyme E2 L3 protein, is involved in the ubiquitination of proteins.			Gene or Genome	
C106339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106339>	C133711	Ubiquitin-Conjugating Enzyme E2 L3|E2 Ubiquitin-Conjugating Enzyme L3|EC 2.3.2.23|EC 6.3.2.19, Formerly|L-UBC|UBE2L3|UbcH7|Ubiquitin Carrier Protein L3|Ubiquitin-Conjugating Enzyme E2-F1|Ubiquitin-Conjugating Enzyme UBCH7|Ubiquitin-Protein Ligase L3	Ubiquitin-conjugating enzyme E2 L3 (154 aa, ~18 kDa) is encoded by the human UBE2L3 gene. This protein plays a role in E2 ubiquitin ligase activity.			Amino Acid, Peptide, or Protein|Enzyme	
C10633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10633>	C61063	Carboplatin/Cyclophosphamide/Etoposide/Melphalan|CBDCA/CTX/L-PAM/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106340>	C20194	FAM131B Gene|FAM131B|FAM131B|FAM131B|Family with Sequence Similarity 131 Member B Gene	This gene has not been characterized.			Gene or Genome	GDC Terminology|GDC Value Terminology
C106341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106341>	C106340	FAM131B wt Allele|Family with Sequence Similarity 131 Member B wt Allele|Family with Sequence Similarity 131, Member B Gene|KIAA0773	Human FAM131B wild-type allele is located in the vicinity of 7q34 and is approximately 9 kb in length. This allele, which encodes protein FAM131B, has not been characterized.			Gene or Genome	
C106342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106342>	C18466	Protein FAM131B	Protein FAM131B (332 aa, ~36 kDa) is encoded by the human FAM131B gene. This protein has no known function.			Amino Acid, Peptide, or Protein	
C106343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106343>	C26006	KLC1 Gene|KLC1|KLC1|Kinesin Light Chain 1 Gene	This gene plays a role in microtubule-based movement.			Gene or Genome	
C106344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106344>	C106343	KLC1 wt Allele|KLC|KNS2|KNS2A|Kinesin 2 Gene|Kinesin Light Chain 1 wt Allele|hKLC1B|hKLC1G|hKLC1J|hKLC1N|hKLC1P|hKLC1R|hKLC1S	Human KLC1 wild-type allele is located in the vicinity of 14q32.3 and is approximately 140 kb in length. This allele, which encodes kinesin light chain 1 protein, is involved in organelle transport.			Gene or Genome	
C106345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106345>	C16386	Kinesin Light Chain 1|KLC 1|KLC1|Kinesin 2 60/70kDa|Medulloblastoma Antigen MU-MB-2.50	Kinesin light chain 1 (573 aa, ~65 kDa) is encoded by the human KLC1 gene. This protein plays a role in microtubule motor activity.			Amino Acid, Peptide, or Protein	
C106346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106346>	C21295	EFEMP1 Gene|EFEMP1|EFEMP1|EGF Containing Fibulin Like Extracellular Matrix Protein 1 Gene	This gene is involved in receptor binding.	EFEMP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106347>	C106346	EFEMP1 wt Allele|DHRD|DRAD|EGF Containing Fibulin Like Extracellular Matrix Protein 1 wt Allele|EGF Containing Fibulin-Like Extracellular Matrix Protein 1 Gene|FBLN3|FBNL|FIBL-3|Fibrillin-Like Gene|Fibulin 3 Gene|MLVT|MTLV|S1-5	Human EFEMP1 wild-type allele is located in the vicinity of 2p16 and is approximately 58 kb in length. This allele, which encodes EGF-containing fibulin-like extracellular matrix protein 1, plays a role in cell surface receptor binding. Aberrant expression of the gene is associated with glioma. Mutation of the gene is associated with Doyne honeycomb retinal dystrophy.	EFEMP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106348>	C17728	EGF-Containing Fibulin-Like Extracellular Matrix Protein 1|EFEMP1|EGF Containing Fibulin-Like Extracellular Matrix Protein 1|Extracellular Protein S1-5|FIBL-3|Fibrillin-Like Protein|Fibulin 3|Fibulin-3	EGF-containing fibulin-like extracellular matrix protein 1 (493 aa, ~55 kDa) is encoded by the human EFEMP1 gene. This protein is involved in receptor binding.	EGF-Containing Fibulin-Like Extracellular Matrix Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106349>	C20917	CIZ1 Gene|CDKN1A Interacting Zinc Finger Protein 1 Gene|CIZ1|CIZ1	This gene plays a role in the regulation of DNA replication.			Gene or Genome	
C10634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10634>	C61063	Cyclophosphamide/Doxorubicin/Interleukin-3/Prednisone/Vincristine/Zidovudine|CTX/DOX/IL-3/PRED/VCR/ZDV			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106350>	C106349	CIZ1 wt Allele|CDKN1A Interacting Zinc Finger Protein 1 wt Allele|LSFR1|NP94|ZNF356	Human CIZ1 wild-type allele is located in the vicinity of 9q34.1 and is approximately 38 kb in length. This allele, which encodes Cip1-interacting zinc finger protein, is involved in the positive regulation of DNA replication.			Gene or Genome	
C106351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106351>	C17761	Cip1-Interacting Zinc Finger Protein|CDKN1A-Interacting Zinc Finger Protein 1|CIZ1|Nuclear Protein NP94|Zinc Finger Protein 356	Cip1-interacting zinc finger protein (898 aa, ~100 kDa) is encoded by the human CIZ1 gene. This protein plays a role in the modulation of both cyclin-dependent kinase inhibitor 1 protein localization and DNA replication.			Amino Acid, Peptide, or Protein	
C106352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106352>	C20744	SDCBP Gene|SDCBP|SDCBP|Syndecan Binding Protein (Syntenin) Gene	This gene is involved in protein-protein interactions.			Gene or Genome	
C106353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106353>	C106352	SDCBP wt Allele|MDA-9|ST1|SYCL|Syndecan Binding Protein (Syntenin) wt Allele|TACIP18	Human SDCBP wild-type allele is located in the vicinity of 8q12 and is approximately 30 kb in length. This allele, which encodes syntenin-1 protein, plays a role in the mediation of syndecan coupling to the cytoskeleton.			Gene or Genome	
C106354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106354>	C18073	Syntenin-1|MDA-9|Melanoma Differentiation Associated Protein 9|Melanoma Differentiation-Associated Protein 9|Pro-TGF-Alpha Cytoplasmic Domain-Interacting Protein 18|SDCBP|Scaffold Protein Pbp1|Syndecan-Binding Protein 1|TACIP18	Syntenin-1 (298 aa, ~32 kDa) is encoded by the human SDCBP gene. This protein is involved in mediating intracellular protein-protein interactions.			Amino Acid, Peptide, or Protein	
C106355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106355>	C21550	IFNL3 Gene|IFNL3|IFNL3|Interferon, Lambda 3 Gene	This gene plays a role in cytokine signaling.			Gene or Genome	
C106356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106356>	C106355	IFNL3 wt Allele|IL-28B|IL28B|IL28C|Interferon, Lambda 3 wt Allele|Interleukin 28B (Interferon, Lambda 3) Gene|Interleukin 28B Gene|ZCYTO22	Human IFNL3 wild-type allele is located in the vicinity of 19q13.13 and is approximately 1 kb in length. This allele, which encodes interferon lambda-3 protein, is involved in both cytokine receptor binding and immunomodulation.			Gene or Genome	
C106357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106357>	C20464	Interferon Lambda-3|Cytokine Zcyto22|IFN-Lambda-3|IFN-Lambda-4|IFNL3|IL-28B|IL-28C|Interferon Lambda 3|Interferon Lambda-4|Interferon-Lambda 3|Interferon-Lambda-3|Interleukin-28B|Interleukin-28C	Interferon lambda-3 (196 aa, ~22 kDa) is encoded by the human IFNL3 gene. This protein plays a role in cytokine signaling.			Amino Acid, Peptide, or Protein	
C106358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106358>	C20420	ZNF444 Gene|ZNF444|ZNF444|ZNF444|Zinc Finger Protein 444 Gene	This gene is involved in LDL metabolism, transcriptional regulation and DNA binding.			Gene or Genome	GDC Terminology|GDC Value Terminology
C106359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106359>	C106358	ZNF444 wt Allele|EZF-2|EZF2|FLJ11137|ZSCAN17|Zinc Finger Protein 444 wt Allele	Human ZNF444 wild-type allele is located in the vicinity of 19q13.43 and is approximately 28 kb in length. This allele, which encodes zinc finger protein 444, plays a role in transcriptional activation, DNA binding and LDL metabolism.			Gene or Genome	
C10635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10635>	C61007	Dexrazoxane/Doxorubicin|ADR-529/DOX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106360>	C17207	Zinc Finger Protein 444|EZF-2|Endothelial Zinc Finger Protein 2|ZNF444|Zinc Finger and SCAN domain-Containing Protein 17	Zinc finger protein 444 (327 aa, ~35 kDa) is encoded by the human ZNF444 gene. This protein is involved in both LDL metabolism and the positive regulation of transcription.			Amino Acid, Peptide, or Protein	
C106361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106361>	C20103	SCARF1 Gene|SCARF1|SCARF1|Scavenger Receptor Class F, Member 1 Gene	This gene plays a role in cholesterol metabolism.			Gene or Genome	
C106362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106362>	C106361	SCARF1 wt Allele|KIAA0149|SREC|SREC-I|SREC1|Scavenger Receptor Class F, Member 1 wt Allele	Human SCARF1 wild-type allele is located in the vicinity of 17p13.3 and is approximately 12 kb in length. This allele, which encodes scavenger receptor class F member 1 protein, is involved in the metabolism of acetylated LDL.			Gene or Genome	
C106363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106363>	C18106	Scavenger Receptor Class F Member 1|Acetyl LDL Receptor|Endothelial Cells Scavenger Receptor|SCARF1|SREC-I|Scavenger Receptor Expressed By Endothelial Cells 1	Scavenger receptor class F member 1 (830 aa, ~87 kDa) is encoded by the human SCARF1 gene. This protein plays a role in both the internalization and degradation of acetylated LDL.			Amino Acid, Peptide, or Protein|Receptor	
C106364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106364>	C20921	BAIAP2L1 Gene|BAI1-Associated Protein 2-Like 1 Gene|BAIAP2L1|BAIAP2L1	This gene plays a role in both signaling and cytoskeletal modeling.	BAIAP2L1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106365>	C106364	BAIAP2L1 wt Allele|BAI1-Associated Protein 2-Like 1 wt Allele|IRTKS	Human BAIAP2L1 wild-type allele is located in the vicinity of 7q22.1 and is approximately 109 kb in length. This allele, which encodes brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 1, is involved in both cytoskeletal modeling and signal transduction.	BAIAP2L1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106366>	C18515	Brain-Specific Angiogenesis Inhibitor 1-Associated Protein 2-Like Protein 1|BAI1-Associated Protein 2-Like Protein 1|BAIAP2L1|Insulin Receptor Tyrosine Kinase Substrate	Brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 1 (511 aa, ~57 kDa) is encoded by the human BAIAP2L1 gene. This protein plays a role in cytoskeletal remodeling.	Brain-Specific Angiogenesis Inhibitor 1-Associated Protein 2-Like Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106367>	C1511	Zirconium Zr 89-labeled Monoclonal Antibody MMOT0530A|89Zr-MMOT|89Zr-MMOT0530A	A radioimmunoconjugate composed of a monoclonal antibody that targets an antigen overexpressed in pancreatic and ovarian cancer and labeled with the radioisotope zirconium Zr 89, with potential use for assessing tumor antigen expression using positron emission tomography (PET). Upon administration of zirconium Zr 89-labeled monoclonal antibody MMOT0530A, this agent targets an antigen expressed on certain tumor cells and is internalized.  Following tumor cell uptake, the radioisotope moiety can be visualized using PET imaging. This may result in both the quantification of tumor antigen expression and an assessment of the response to treatment with therapeutics targeting the antigen.			Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	NCI Drug Dictionary Terminology
C106368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106368>	C208296	Mocravimod Hydrochloride|2-Amino-2-propanediol Hydrochloride|KRP-203|KRP203|MOCRAVIMOD HYDROCHLORIDE	The hydrochloride salt form of mocravimod, a sphingosine 1-phosphate (S1P) receptor agonist, with potential immunosuppressive activity. Upon administration of mocravimod, this agent binds to S1P receptors on lymphocytes, which prevents binding of serum S1P to S1P receptors and leads to S1P receptor internalization. This reduces the number of circulating blood leukocytes and accelerates lymphocyte homing into peripheral lymph nodes, thereby preventing their infiltration into peripheral inflammatory sites. This agent also decreases the production of inflammatory cytokines by lymphocytes, such as interferon gamma (IFN-g), interleukin-12 (IL-12), and tumor necrosis factor (TNF).			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106369>	C2843	Simmitecan Hydrochloride|SIMMITECAN	The hydrochloride salt form of simmitecan, an ester prodrug of chimmitecan, a 9-alkyl substituted camptothecin derivative with potential antineoplastc activity. Upon intravenous administration, simmitecan is hydrolyzed by carboxylesterase and the activated form, chimmitecan, is produced. Chimmitecan inhibits topoisomerase I, stabilizes covalent topoisomerase I-DNA complexes, and inhibits the religation of topoisomerase I-mediated single-strand DNA breaks. Futhermore, the covalent topoisomerase I-DNA complexes interfere and block the DNA replication machinery, resulting in the production of potentially lethal double-strand DNA breaks. This leads to an inhibition of DNA replication and the induction of apoptosis. The modification at position 9 yields improved cytotoxicity compared to some other camptothecin analogues.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C10636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10636>	C63358	Doxorubicin/Vinorelbine Regimen|DOX/VNB|Doxorubicin and Vinorelbine|Doxorubicin-Vinorelbine|Doxorubicin/Vinorelbine|NA|NA|NA Regimen|Navelbine/Adriamycin|Vinorelbine-Doxorubicin|Vinorelbine/Doxorubicin	A regimen consisting of doxorubicin and vinorelbine that may be used in the treatment of advanced breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C106371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106371>	C210732	Alpha-lipoic Acid-Palladium/Vitamin/Mineral Supplement|LAPd|Palladium Lipoic Complex|PolyMVA	A proprietary water- and lipid-soluble polymer-based nutritional supplement composed of a complex mixture of alpha-lipoic acid bound to palladium (Palladium Lipoic Acid Complex (PdLA)) and other minerals, vitamins and amino acids, including vitamins B1, B2 and B12, formylmethionine, acetyl cysteine, and trace amounts of molybdinum, rhodium, and ruthenium, with potential anti-oxidant and cytoprotective activities. Upon oral administration, the alpha-lipoic acid-palladium/vitamin/mineral supplement acts as a free radical scavenger, crosses the cell membrane and is able to transfer electrons from fatty acids to DNA via the electron transport chain in mitochondria, which protects against DNA damage. This could protect non-cancerous cells from the oxidative damage caused by radiation and chemotherapy. In addition, in the hypoxic conditions found within tumors, the excess electrons can generate free radicals within mitochondria and could induce both cytochrome c release and apoptosis.			Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106372>	C16108	International Bone Marrow Transplant Registry|IBMTR|IBMTR	An international research organization based in Milwaukee, Wisconsin that collects and analyzes data of recipients of allogeneic and autologous hematopoietic stem cell transplants.			Intellectual Product	
C106373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106373>	C50334	Chest Tube Flutter Valve|Heimlich Valve	A type of valve that connects to a chest tube and facilitates the drainage of fluid, air, and other materials out of the pleural cavity, while not permitting the flow back into the pleural cavity. The valve "flutters" to open in one direction only.			Medical Device	
C106374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106374>	C176422	Charlson Comorbidity Index Derived from Chart Review|CCI-CR|Charlson Comorbidity Index|Charlson Comorbidity Index Chart Review Version|Charlson Comorbidity Index Chart Review Version	A method of predicting mortality by weighting comorbid conditions calculated by reviewing an individual's chart.			Intellectual Product	
C106375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106375>	C173981	Had a Myocardial Infarction Question|Had a Myocardial Infarction|Has the patient had a myocardial infarction	A question about whether an individual had a myocardial infarction.			Intellectual Product	Charlson Comorbidity Index Derived from Chart Review
C106376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106376>	C91103	Hospitalized or Treated for Heart Failure Question|Has the patient been hospitalized or treated for heart failure|Hospitalized or Treated for Heart Failure	A question about whether an individual has been hospitalized or treated for heart failure.			Intellectual Product	Charlson Comorbidity Index Derived from Chart Review
C106377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106377>	C173981	Has Peripheral Vascular Disease Question|Does the patient have peripheral vascular disease|Has Peripheral Vascular Disease	A question about whether an individual has or had peripheral vascular disease.			Intellectual Product	Charlson Comorbidity Index Derived from Chart Review
C106378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106378>	C173981	Has a Cerebrovascular Accident or Transient Ischemic Disease Question|Has a Cerebrovascular Accident or Transient Ischemic Disease|Has the patient had a CVA or transient ischemic disease	A question about whether an individual has or had a cerebrovascular accident or transient ischemic disease.			Intellectual Product	Charlson Comorbidity Index Derived from Chart Review
C106379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106379>	C173981	Has Hemiplegia Question|Does the patient have hemiplegia|Has Hemiplegia	A question about whether an individual has or had hemiplegia.			Intellectual Product	Charlson Comorbidity Index Derived from Chart Review
C10637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10637>	C61063	Fluorouracil/Vinorelbine|5-FU/VNB			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106380>	C173981	Has Asthma, Chronic Lung Disease, Chronic Bronchitis or Emphysema Question|Does the patient have asthma, chronic lung disease, chronic bronchitis or emphysema|Has Asthma, Chronic Lung Disease, Chronic Bronchitis or Emphysema	A question about whether an individual has or had asthma, chronic lung disease, chronic bronchitis or emphysema.			Intellectual Product	Charlson Comorbidity Index Derived from Chart Review
C106381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106381>	C173812	Has Diabetes that Requires Treatment Question|Does the patient have diabetes that requires treatment|Has Diabetes that Requires Treatment	A question about whether an individual has or had diabetes requiring treatment.			Intellectual Product	Charlson Comorbidity Index Derived from Chart Review
C106382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106382>	C173981	Has End Organ Damage from Diabetes Question|Does the patient have end organ damage from diabetes|Has End Organ Damage from Diabetes|Have End Organ Damage from Diabetes	A question about whether an individual has or had end organ damage as a result of diabetes.			Intellectual Product	Charlson Comorbidity Index Derived from Chart Review
C106383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106383>	C173981	Has Moderate or Severe Renal Disease Question|Does the patient have moderate or severe renal disease|Has Moderate or Severe Renal Disease|Moderate to Severe Chronic Kidney Disease	A question about whether an individual has or had moderate or severe renal disease.			Intellectual Product	Charlson Comorbidity Index Derived from Chart Review
C106384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106384>	C173981	Has Chronic Liver Disease Question|Does the patient have a chronic liver disease|Has Chronic Liver Disease	A question about whether an individual has or had a chronic liver disease.			Intellectual Product	Charlson Comorbidity Index Derived from Chart Review
C106385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106385>	C173981	Has Moderate or Severe Liver Disease Question|Does the patient have moderate to severe liver disease|Has Moderate or Severe Liver Disease	A question about whether an individual has or had moderate or severe liver disease.			Intellectual Product	Charlson Comorbidity Index Derived from Chart Review
C106386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106386>	C173981	Has Gastric or Peptic Ulcer Question|Has Gastric or Peptic Ulcer|Has the patient had gastric or peptic ulcers	A question about whether an individual has or had gastric or peptic ulcers.			Intellectual Product	Charlson Comorbidity Index Derived from Chart Review
C106387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106387>	C173981	Has Cancer Other than Basal Cell Skin Cancer Question|Has Cancer Other than Basal Cell Skin Cancer|Has the patient had cancer (other than basal cell skin cancer)	A question about whether an individual has or had cancer other than basal cell skin cancer.			Intellectual Product	Charlson Comorbidity Index Derived from Chart Review
C106388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106388>	C173981	Has Metastatic Solid Tumor Question|Has Metastatic Solid Tumor|Has the patient had a metastatic solid tumor	A question about whether an individual has or had a metastatic solid tumor.			Intellectual Product	Charlson Comorbidity Index Derived from Chart Review
C106389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106389>	C173981	Has Alzheimer's, Dementia from any Etiology or any Serious Cognitive Impairment Question|Does the patient have Alzheimer's, dementia from any etiology or any serious cognitive impairment|Has Alzheimer's, Dementia from any Etiology or any Serious Cognitive Impairment	A question about whether an individual has Alzheimer's, dementia from any etiology or any serious cognitive impairment.			Intellectual Product	Charlson Comorbidity Index Derived from Chart Review
C10638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10638>	C61063	Carboplatin/Etoposide/Ifosfamide/Etanidazole|CBDCA/IFF/SR-2508/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106390>	C173981	Has any Rheumatic or Connective Tissue Disease Question|Does the patient have any rheumatic or connective tissue disease|Has any Rheumatic or Connective Tissue Disease	A question about whether an individual has or had any rheumatic or connective tissue disease.			Intellectual Product	Charlson Comorbidity Index Derived from Chart Review
C106391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106391>	C173981	Has HIV or AIDS Question|Does the patient have HIV or AIDS|Has HIV or AIDS|Have HIV or AIDS	A question about whether an individual has HIV or AIDS.			Intellectual Product	Charlson Comorbidity Index Derived from Chart Review
C106392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106392>	C173981	Has Hypertension Question|Does the patient have hypertension|Has Hypertension	A question about whether an individual has or had hypertension.			Intellectual Product	Charlson Comorbidity Index Derived from Chart Review
C106393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106393>	C173981	Has Decubitus Ulcer, Peripheral Skin Ulcer or Repeated Episodes of Cellulitis Question|Has Decubitus Ulcer, Peripheral Skin Ulcer or Repeated Episodes of Cellulitis|Has the patient had decubitus ulcers, peripheral skin ulcers or repeated episodes of cellulitis	A question about whether an individual has or had decubitus ulcers, peripheral skin ulcers or repeated episodes of cellulitis.			Intellectual Product	Charlson Comorbidity Index Derived from Chart Review
C106394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106394>	C173981	Has Depression Question|Does the patient have depression|Has Depression|Have Depression	A question about whether an individual has or had depression.			Intellectual Product	Charlson Comorbidity Index Derived from Chart Review
C106395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106395>	C91103	Using Warfarin or Coumadin Question|Is the patient on warfarin or coumadin|Using Warfarin or Coumadin	A question about whether an individual is or was using warfarin or coumadin.			Intellectual Product	Charlson Comorbidity Index Derived from Chart Review
C106396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106396>	C199143	Center for International Blood and Marrow Transplant Research|CIBMTR|CIBMTR	A combined research program of NMDP (formerly the National Marrow Donor Program) and the Medical College of Wisconsin that collaborates with the global scientific community to advance hematopoietic cell transplantation and cellular therapy research worldwide.			Professional or Occupational Group	
C106397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106397>	C54073	European Group for Blood and Marrow Transplantation|EMBT|EMBT	A non-profit organization that allows scientists and physicians participating in clinical bone marrow transplantation to share their experience and develop co-operative studies.			Professional or Occupational Group	
C106398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106398>	C15322	Pulmonary Hygiene|Bronchial Hygiene Therapy|Bronchopulmonary Hygiene|Pulmonary Toilet|Respiratory Hygiene|Respiratory Toilet	Non-invasive therapeutic modalities intended to assist in mobilizing and clearing excess bronchopulmonary secretions that are obstructive to airflow. Techniques include postural drainage, external percussive or vibratory therapy and facilitated expectoration.			Therapeutic or Preventive Procedure	
C106399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106399>	C91833	Nasoduodenal Tube|Dobhoff Tube|ND Tube|Nasoduodenal Feeding Tube	A hollow tube that is directed into the duodenum from the nose.			Medical Device	NICHD Terminology|Pediatric Medical Device Terminology
C10639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10639>	C61063	Bleomycin/Doxorubicin/Etoposide/Vincristine|BLEO/DOX/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1063>	C2139	Defensins	Highly conserved cysteine-rich peptides that play a role in host defense, and may be produced in response to microbial products or proinflammatory cytokines. Defensins bind to microbial cell membranes and can become aggregate either to form pore-like structures or to encapsulate the microbe. These peptide aggregates lead to destabilization of the cell membrane and, subsequently, to lysis of the microbe.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	
C106400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106400>	C91105	FACT-L Questionnaire|FACT-L|Functional Assessment of Cancer Therapy Lung Questionnaire	A subscale complement to the FACT-G developed specifically for evaluating quality of life of lung cancer patients. It may also be useful to assess quality of life in patients with other lung diseases.			Intellectual Product	
C106401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106401>	C172982	Bothered by Hair Loss Question|Bothered by Hair Loss|Did hair loss bother you|I am bothered by hair loss|Upset by Hair Loss|Were you upset by the loss of your hair	A question about whether an individual is or was bothered by hair loss.			Intellectual Product	FACT-L Questionnaire|Quality of Life Questionnaire-Brain Neoplasm 20 Items|Quality of Life Questionnaire-Multiple Myeloma 20
C106402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106402>	C173219	Feels Tightness in the Chest Question|Feels Tightness in the Chest|I feel tightness in my chest	A question about whether an individual feels or has felt tightness in the chest.			Intellectual Product	FACT-L Questionnaire
C106403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106403>	C91103	Breathing is Easy Question|Breathing is Easy|Breathing is easy for me	A question about whether an individual's breathing is or was easy.			Intellectual Product	FACT-L Questionnaire
C106404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106404>	C173060	Has Ever Smoked Question|Ever Worked in Place Where Other People Smoked Cigarettes Indoors|Have you ever smoked	A question about whether an individual has ever smoked.			Intellectual Product	FACT-L Questionnaire
C106405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106405>	C173060	Regrets Smoking Question|I regret my smoking|Regret Smoking|Regrets Smoking	A question about whether an individual regrets or regretted smoking.			Intellectual Product	FACT-L Questionnaire
C106406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106406>	C759	Spermine|1,4-Bis(Aminopropyl) Butanediamine|1,4-Bis(Aminopropyl)Butanediamine|1,4-Butanediamine, N,N'-Bis(3-Aminopropyl)-|1,4-Butanediamine, N1,N4-Bis(3-Aminopropyl)-|1,4-Diaminobutane, N,N'-Bis(3-Aminopropyl)-|4,9-Diaza-1,12-Dodecanediamine|4,9-Diazadodecamethylenediamine|Diaminopropyltetramethylenediamine|N,N'-Bis(3-Aminopropyl)-1,4-Butanediamine|SPERMINE	A polyamine that has a similar structure to tetradecane but the carbons at positions 1, 5, 10 and 14 are replaced by nitrogens. Spermine plays a broad role in cellular metabolic processes.	Spermine		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C106407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106407>	C25966	MicroRNA 124|MIR124|MIRN124|hsa-miR-124|hsa-miR-124-3p|hsa-miR-124a|miR-124	A 20 ribonucleotide sequence that is a final product of the processing of either MIR124-1 pre-miRNA, MIR124-2 pre-miRNA or MIR124-3 pre-miRNA. This oligonucleotide may be involved in the negative regulation of gene expression.	MicroRNA 124		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106408>	C17444	Non-Receptor Type Protein Tyrosine Phosphatase|Cytosolic Protein Tyrosine Phosphatase|Non-Receptor PTPase|Non-Receptor Protein Tyrosine Phosphatase|PTPN|Protein Tyrosine Phosphatase Non-Receptor Type|Tyrosine-Protein Phosphatase Non-Receptor Type	A group of cytosolic enzymes that specifically remove tyrosine-bound phosphate groups from many phosphoproteins, including many enzymes phosphorylated by a tyrosine kinase. These proteins play a role in the modulation of tyrosine phosphorylation and dephosphorylation in cellular signaling pathways.			Amino Acid, Peptide, or Protein|Enzyme	Pediatric Oncology Biomarkers/Targets Associated with Other Relevant Evidence
C106409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106409>	C26059	Receptor-Type Protein Tyrosine Phosphatase Gene|Receptor Type PTP Gene|Receptor Tyrosine Phosphatase Gene	A family of genes that encode transmembrane receptors, which also have protein tyrosine phosphatase activity. These genes are involved in both the removal of phosphate groups from tyrosine residues and the modulation of signaling pathways.			Gene or Genome	
C10640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10640>	C61063	Etoposide/Procarbazine/Vincristine|PCB/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106410>	C29639|C29302	Carboxymethylcellulose Sodium-containing Eye Drop|Celluvisc|Celluvisc|Refresh Celluvisc	An eye drop solution containing the sodium salt form of carboxymethylcellulose (CMC) used as artificial tears. Upon application of the drops into the eye, carboxymethylcellulose sodium lubricates the eye and prevents or relieves dryness and irritation.			Pharmacologic Substance	
C106411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106411>	C17444	PTPRE Gene Product	A protein encoded by the PTPRE gene.			Amino Acid, Peptide, or Protein	
C106412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106412>	C16843	CPE Gene Product	A protein encoded by the CPE gene.			Amino Acid, Peptide, or Protein	
C106413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106413>	C20917	ATRIP Gene|ATR Interacting Protein Gene|ATRIP|ATRIP	This gene is involved in the DNA damage checkpoint.			Gene or Genome	
C106414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106414>	C106413	ATRIP wt Allele|ATR Interacting Protein wt Allele|ATR-Interacting Protein Gene|FLJ12343|MGC20625|MGC21482|MGC26740|hCG_1997849	Human ATRIP wild-type allele is located in the vicinity of 3p21.31 and is approximately 19 kb in length. This allele, which encodes ATR-interacting protein, plays a role in cell cycle checkpoint signaling.			Gene or Genome	
C106415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106415>	C17761	ATR-Interacting Protein|ATM and Rad3-Related-Interacting Protein|ATR Interacting Protein|ATRIP	ATR-interacting protein (791 aa, ~86 kDa) is encoded by the human ATRIP gene. This protein is involved in signaling during the DNA damage checkpoint of the cell cycle.			Amino Acid, Peptide, or Protein	
C106416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106416>	C28533|C158414	ATP2A2 Gene|ATP2A2|ATP2A2|ATPase, Ca++ Transporting, Cardiac Muscle, Slow Twitch 2 Gene	This gene plays a role in cardiac muscle contraction.			Gene or Genome	
C106417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106417>	C106416	ATP2A2 wt Allele|ATP2B|ATPase, Ca++ Dependent, Slow-Twitch, Cardiac Muscle-2 Gene|ATPase, Ca++ Transporting, Cardiac Muscle, Slow Twitch 2 wt Allele|DAR|DD|SERCA2|Sarcoplasmic Reticulum Ca(2+)-ATPase 2 Gene	Human ATP2A2 wild-type allele is located in the vicinity of 12q24.11 and is approximately 70 kb in length. This allele, which encodes sarcoplasmic/endoplasmic reticulum calcium ATPase 2 protein, is involved in the modulation of cardiac muscle contractility. Mutation of the gene is associated with both Darier disease and acrokeratosis verruciformis.			Gene or Genome	
C106418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106418>	C16386|C158419	Sarcoplasmic/Endoplasmic Reticulum Calcium ATPase 2|ATP2A2|Calcium Pump 2|Calcium-Transporting ATPase Sarcoplasmic Reticulum Type, Slow Twitch Skeletal Muscle Isoform|Cardiac Ca2+ ATPase|EC 3.6.3.8, Formerly|EC 7.2.2.10|Endoplasmic Reticulum Class 1/2 Ca(2+) ATPase|SERCA2|SR Ca(2+)-ATPase 2	Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (1042 aa, ~115 kDa) is encoded by the human ATP2A2 gene. This protein plays a role in both heart contraction and ATP hydrolysis.			Amino Acid, Peptide, or Protein|Enzyme	
C106419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106419>	C38187	HCRT Gene|HCRT|HCRT|Hypocretin (Orexin) Neuropeptide Precursor Gene	This gene is involved in neuropeptide signaling.			Gene or Genome	
C10641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10641>	C61063	Doxorubicin/Streptozocin|DOX/SZC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106420>	C106419	HCRT wt Allele|Hypocretin (Orexin) Neuropeptide Precursor wt Allele|NRCLP1|OX|PPOX	Human HCRT wild-type allele is located in the vicinity of 17q21 and is approximately 1 kb in length. This allele, which encodes orexin protein, plays a role in both G-protein coupled receptor signaling and feeding behavior. Mutation of the gene is associated with narcolepsy 1.			Gene or Genome	
C106421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106421>	C686	Orexin|Hcrt|Hypocretin|Prepro-Orexin|Preproorexin	Orexin (131 aa, ~13 kDa) is encoded by the human HCRT gene. This protein is involved in neuropeptide-dependent signaling and feeding behavior.			Amino Acid, Peptide, or Protein	
C106422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106422>	C20744	GAN Gene|GAN|GAN|Gigaxonin Gene	This gene plays a role in both neurofilament structure and ubiquitination.			Gene or Genome	
C106423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106423>	C106422	GAN wt Allele|GAN1|Giant Axonal Neuropathy (Gigaxonin) Gene|Gigaxonin wt Allele|KLHL16	Human GAN wild-type allele is located in the vicinity of 16q24.1 and is approximately 65 kb in length. This allele, which encodes gigaxonin protein, is involved in both ubiquitination and neurofilament structure. Mutation of the gene is associated with giant axonal neuropathy.			Gene or Genome	
C106424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106424>	C18073	Gigaxonin|GAN|Kelch-Like Family Member 16|Kelch-Like Protein 16	Gigaxonin (597 aa, ~68 kDa) is encoded by the human GAN gene. This protein plays a role in the modulation of both protein ubiquitination and neurofilament structure.			Amino Acid, Peptide, or Protein	
C106425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106425>	C21240	PDCD11 Gene|PDCD11|PDCD11|Programmed Cell Death 11 Gene	This gene is involved in RNA processing.			Gene or Genome	
C106426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106426>	C106425	PDCD11 wt Allele|ALG-4|ALG4|Apoptosis-Linked Gene 4|KIAA0185|NFBP|Programmed Cell Death 11 wt Allele|RRP5	Human PDCD11 wild-type allele is located in the vicinity of 10q24.33 and is approximately 50 kb in length. This allele, which encodes protein RRP5 homolog, plays a role in ribosomal RNA processing.			Gene or Genome	
C106427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106427>	C38576	Protein RRP5 Homolog|NF-Kappa-B-Binding Protein|NFBP|PDCD11|Programmed Cell Death Protein 11	Protein RRP5 homolog (1871 aa, ~209 kDa) is encoded by the human PDCD11 gene. This protein is involved in rRNA biosynthesis.			Amino Acid, Peptide, or Protein	
C106428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106428>	C213472|C1742|C129825	Catequentinib Hydrochloride|1-((4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolyl)oxymethyl)cyclopropanamine, Dihydrochloride|ALTN HCl|Anlotinib Hydrochloride|CATEQUENTINIB HYDROCHLORIDE|Cyclopropanamine, 1-(((4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-, Hydrochloride (1:2)|Fukewei	The hydrochloride salt form of catequentinib, a receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities. Upon administration, catequentinib targets multiple RTKs, including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt tumor cell growth.	Catequentinib Hydrochloride		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106429>	C176018	PBTL CD19CAR-28/CD137/zeta|CD19CAR/28137-bearing ATLs	Peripheral blood T-lymphocytes (PBTLs) transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) coupled to the costimulatory signaling domain CD28, the signaling domain of 4-1BB (CD137), and the zeta chain of the T-cell receptor (TCR), with potential immunomodulating and antineoplastic activities. Upon transfusion, PBTL CD19CAR-28/CD137zeta directs the T-lymphocytes to CD19-expressing tumor cells and induces selective toxicity in CD19-expressing tumor cells. CD28, a T-cell surface-associated co-stimulatory molecule, is required for full T-cell activation, proliferation, and survival. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19. Furthermore, inclusion of the 4-1BB signaling domain may increase the antitumor activity compared to the inclusion of the CD28 costimulatory domain and TCR zeta chain alone. CD19 antigen is a B-cell specific cell surface antigen, which is expressed in all B-cell lineage malignancies.	PBTL CD19CAR-28/CD137/zeta		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C10642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10642>	C61007	Leucovorin Calcium/Mercaptopurine/Methotrexate|CF/MP/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106430>	C2159	Protein Phosphatase 2A Inhibitor LB-100|LB-100|LB-100|PP2A Inhibitor LB-100	A water soluble inhibitor of the protein phosphatase 2A (PP2A), with potential chemo- and radiotherapy enhancing activity. Upon injection, PP2A inhibitor LB-100 inhibits the removal of phosphate groups from proteins essential for cell cycle progression. When used with radio- or chemotherapy treatment, this agent prevents the activation of PP2A-mediated repair mechanisms and allows for malignant cells to progress through the cell cycle without having their damaged DNA repaired. This enhances the cytotoxic effect of the chemotherapeutic or radiotherapeutic agent and results in tumor cell apoptosis. PP2A, a serine/threonine phosphatase that plays a key role in the control of cell growth and DNA damage repair.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106431>	C241	Topical Menthol Cream	A topical cream containing menthol that both causes a localized cooling sensation and has analgesic activities. Upon topical application, menthol acts on the cold-sensitive transient receptor potential cation channel subfamily M member 8 (TMPR8), which provides a cooling sensation. This treatment also provides an analgesic effect through the activation of the inhibitory Group II/III metabotropic glutamate receptors (mGluRs). This may decrease neuropathic pain from chemotherapy. In addition, the topical application of menthol causes vasodilation.	Topical Menthol Cream		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C106432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106432>	C128037	Pembrolizumab|BCD-201|GME 751|GME751|Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide with Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide|Keytruda|Lambrolizumab|MK 3475|MK-3475|MK3475|PEMBROLIZUMAB|Pembrolizumab Biosimilar BCD-201|Pembrolizumab Biosimilar GME751|Pembrolizumab Biosimilar QL2107|Pembrolizumab Biosimilar RPH-075|Pembrolizumab Biosimilar SB27|QL2107|RPH 075|RPH-075|RPH075|SB 27|SB-27|SB27|SCH 900475|SCH-900475|SCH900475|pembrolizumab	A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.	Pembrolizumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|HL Authorized Value Terminology|HL Protocol Treatment Modifications Table|HL Total Dose Table|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C106433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106433>	C26057	DDX52 Gene|DDX52|DDX52|DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 52 Gene	This gene plays a role in both RNA binding and ATP hydrolysis.			Gene or Genome	
C106434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106434>	C106433	DDX52 wt Allele|DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 52 wt Allele|HUSSY-19|HUSSY19|Human Sequence Similar to Yeast 19 Gene|ROK1|ROK1, S. cerevisiae, Homolog of, Gene	Human DDX52 wild-type allele is located in the vicinity of 17q21.1 and is approximately 34 kb in length. This allele, which encodes probable ATP-dependent RNA helicase DDX52 protein, is involved in both ATP hydrolysis and RNA binding.			Gene or Genome	
C106435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106435>	C17417	Probable ATP-Dependent RNA Helicase DDX52|ATP-Dependent RNA Helicase ROK1-Like|DDX52|DEAD Box Protein 52|EC 3.6.4.13	Probable ATP-dependent RNA helicase DDX52 (599 aa, ~67 kDa) is encoded by the human DDX52 gene. This protein plays a role in both RNA binding and ATPase activity.			Amino Acid, Peptide, or Protein|Enzyme	
C106436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106436>	C20103	NOTCH3 Gene|NOTCH3|NOTCH3|NOTCH3|Notch 3 Gene	This gene plays a role in both intercellular signaling and cell fate determination.	NOTCH3 Gene		Gene or Genome	CCPS Genetics Terminology|Childhood Cancer Predisposition Study Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106437>	C106436	NOTCH3 wt Allele|CADASIL|CASIL|IMF2|Notch (Drosophila) Homolog 3 Gene|Notch 3 wt Allele|Notch Homolog 3 (Drosophila) Gene|Notch Homolog 3 Gene|Notch, Drosophila, Homolog of, 3 Gene	Human NOTCH3 wild-type allele is located within 19p13.2-p13.1 and is approximately 41 kb in length. This allele, which encodes neurogenic locus notch homolog protein 3, is involved in both cell-cell signaling and cell differentiation. Mutation of the gene is associated with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).	NOTCH3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106438>	C18106	Neurogenic Locus Notch Homolog Protein 3|NOTCH3|Notch 3|Notch Homolog 3	Neurogenic locus notch homolog protein 3 (2321 aa, ~244 kDa) is encoded by the human NOTCH3 gene. This protein plays a role in both cell fate commitment and cell-cell signaling.	Neurogenic Locus Notch Homolog Protein 3		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106439>	C20194	PSAP Gene|PSAP|PSAP|Prosaposin Gene	This gene is involved in the promotion of lipid degradation.	PSAP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10643>	C61063	Asparaginase/Mercaptopurine/Methotrexate|ASP/MP/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106440>	C106439	PSAP wt Allele|GLBA|PARK24|PSAPD|Prosaposin wt Allele|SAP1|SAP2|Variant Gaucher Disease and Variant Metachromatic Leukodystrophy Gene	Human PSAP wild-type allele is located within 10q21-q22 and is approximately 35 kb in length. This allele, which encodes prosaposin protein, plays a role in the positive regulation of lipid hydrolysis. Mutation of the gene is associated with combined saposin deficiency, leukodystrophy metachromatic due to saposin-B deficiency, Gaucher disease, atypical, due to saposin C deficiency, Krabbe disease, atypical, due to saposin A deficiency and Tay-Sachs disease.	PSAP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106441>	C186550	Prosaposin|PSAP|Proactivator Polypeptide	Prosaposin (524 aa, ~58 kDa) is encoded by the human PSAP gene. This protein is involved in sphingolipid catabolism.	Prosaposin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106442>	C20921	DHH Gene|DHH|DHH|Desert Hedgehog Gene	This gene plays a role in regulating morphogenesis.	DHH Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106443>	C106442	DHH wt Allele|Desert Hedgehog wt Allele|GDXYM|HHG-3|MGC35145|SRXY7	Human DHH wild-type allele is located in the vicinity of 12q13.12 and is approximately 5 kb in length. This allele, which encodes desert hedgehog protein, is involved in the regulation of both male gonadal differentiation and perineurial development. Mutations in this gene are associated with both 46XY partial gonadal dysgenesis, with minifascicular neuropathy, and 46XY sex reversal 7.	DHH wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106444>	C18515	Desert Hedgehog Protein|Desert Hedgehog (Drosophila) Homolog|Desert Hedgehog Homolog|Mutant Desert Hedgehog	Desert hedgehog protein (396 aa, ~344 kDa) is encoded by the human DHH gene. This protein plays a role in the regulation of male gonadal morphogenesis.	Desert Hedgehog Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106445>	C20921	IHH Gene|IHH|IHH|Indian Hedgehog Gene	This gene is involved in growth, patterning and morphogenesis.	IHH Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106446>	C106445	IHH wt Allele|BDA1|HHG-2|HHG2|Indian Hedgehog wt Allele	Human IHH wild-type allele is located within 2q33-q35 and is approximately 6 kb in length. This allele, which encodes indian hedgehog protein, plays a role in both bone growth and differentiation. Mutations in this gene are associated with acrocapitofemoral dysplasia and brachydactyly, type A1.	IHH wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106447>	C20988	PODXL Gene|PODXL|PODXL|Podocalyxin-Like Gene	This gene plays a role in the modulation of cell migration.	PODXL Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106448>	C18515	Indian Hedgehog Protein|Indian Hedgehog (Drosophila) Homolog|Indian Hedgehog Homolog|Indian Hedgehog Homolog (Drosophila)	Indian hedgehog protein (411 aa, ~45 kDa) is encoded by the human IHH gene. This protein is involved in both bone growth patterning and morphogenesis.	Indian Hedgehog Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106449>	C106447	PODXL wt Allele|Gp200|PC|PCLP|PCLP-1|PCLP1|Podocalyxin-Like wt Allele	Human PODXL wild-type allele is located within 7q32-q33 and is approximately 58 kb in length. This allele, which encodes podocalyxin protein, is involved in both cell-cell adhesion and cell migration. Aberrant expression of the gene in tumors is associated with a poor prognosis.	PODXL wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10644>	C61007	Fluorouracil/Leucovorin Calcium/Mitomycin|CF/5-FU/MITO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106450>	C16393	Podocalyxin|GCTM-2 Antigen|Gp200|PC|PCLP-1|PODXL|Podocalyxin-Like Protein 1	Podocalyxin (558 aa, ~59 kDa) is encoded by the human PODXL gene. This protein plays a role in both cell migration and cell-cell adhesion.	Podocalyxin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106451>	C20917	GAS1 Gene|GAS1|GAS1|Growth Arrest-Specific 1 Gene	This gene plays a role in cell growth suppression.	GAS1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106452>	C106451	GAS1 wt Allele|GAS-1|Growth Arrest-Specific 1 wt Allele	Human GAS1 wild-type allele is located within 9q21.3-q22 and is approximately 3 kb in length. This allele, which encodes growth arrest-specific protein 1, is involved in cell growth suppression through cell cycle arrest. Mutations in this gene play a role in holoprosencephaly.	GAS1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106453>	C20347	TRIAP1 Gene|TP53 Regulated Inhibitor of Apoptosis 1 Gene|TRIAP1|TRIAP1	This gene is involved in the inhibition of apoptosis.			Gene or Genome	
C106454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106454>	C17761	Growth Arrest-Specific Protein 1|GAS-1|GAS1	Growth arrest-specific protein 1 (345 aa, ~36 kDa) is encoded by the human GAS1 gene. This protein plays a role in both cell cycle arrest and cell growth suppression.	Growth Arrest-Specific Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106455>	C106453	TRIAP1 wt Allele|15E1.1|HSPC132|MDM35|Mitochondrial Distribution and Morphology 35 Homolog (S. cerevisiae) Gene|P53CSV|TP53 Regulated Inhibitor of Apoptosis 1 wt Allele|WF-1|p53CSV	Human TRIAP1 wild-type allele is located in the vicinity of 12q24.31 and is approximately 2 kb in length. This allele, which encodes TP53-regulated inhibitor of apoptosis 1, plays a role in the negative regulation of apoptosis.			Gene or Genome	
C106456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106456>	C19928	TP53-Regulated Inhibitor of Apoptosis 1|Protein 15E1.1|TRIAP1|WF-1|p53-Inducible Cell-Survival Factor|p53CSV	TP53-regulated inhibitor of apoptosis 1 (76 aa, ~9 kDa) is encoded by the human TRIAP1 gene. This protein is involved in cell survival.			Amino Acid, Peptide, or Protein	
C106457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106457>	C25784	RAB23 Gene|RAB23|RAB23|RAB23, Member RAS Oncogene Family Gene	This gene is involved in intracellular membrane trafficking.	RAB23 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106458>	C106457	RAB23 wt Allele|HSPC137|RAB23, Member RAS Oncogene Family wt Allele	Human RAB23 wild-type allele is located in the vicinity of 6p11 and is approximately 33 kb in length. This allele, which encodes ras-related protein Rab-23, plays a role in both intracellular signaling and intracellular membrane trafficking. Mutations in this gene are associated with Carpenter syndrome.	RAB23 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106459>	C18549	Ras-Related Protein Rab-23|RAB Family Small GTP Binding Protein RAB 23|RAB23	Ras-related protein Rab-23 (237 aa, ~27 kDa) is encoded by the human RAB23 gene. This protein is involved in both intracellular signaling and intracellular membrane trafficking.	Ras-Related Protein Rab-23		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10645>	C61063	Carboplatin/Thymidine|CBDCA/TDR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106460>	C212942	BRDT Gene|BRDT|BRDT|Bromodomain Testis-Specific Gene	This gene plays a role in both chromatin remodeling and spermatogenesis.	BRDT Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106461>	C89271	Unable to Accommodate Disability or Language|Unable to accommodate disability or language	Unable to meet the requirements of an individual's disability or language.			Finding	
C106462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106462>	C106460	BRDT wt Allele|BRD6|Bromodomain Testis-Specific wt Allele|CT9	Human BRDT wild-type allele is located in the vicinity of 1p22.1 and is approximately 65 kb in length. This allele, which encodes bromodomain testis-specific protein, is involved in both spermatogenesis and chromatin remodeling.	BRDT wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106463>	C26199	Bromodomain Testis-Specific Protein|BRDT|CT9|Cancer/Testis Antigen 9|RING3-Like Protein	Bromodomain testis-specific protein (947 aa, ~108 kDa) is encoded by the human BRDT gene. This protein plays a role in chromatin remodeling during spermatogenesis.	Bromodomain Testis-Specific Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106464>	C25688	Not Returned	An indication that an item was not returned.			Qualitative Concept	
C106465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106465>	C133710	DTX2 Gene|DTX2|DTX2|Deltex Homolog 2 (Drosophila) Gene	This gene plays a role in regulation of cell-cell communication.	DTX2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106466>	C106465	DTX2 wt Allele|Deltex Homolog 2 (Drosophila) wt Allele|HDTX2|KIAA1528|RNF58	Human DTX2 wild-type allele is located in the vicinity of 7q11.23 and is approximately 44 kb in length. This allele, which encodes probable E3 ubiquitin-protein ligase DTX2 protein, is involved in regulation of Notch signaling.	DTX2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106467>	C70703	Patient did not Complete Study|Patient Did Not Complete Study	The status of a patient who did not complete a study.			Functional Concept	
C106468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106468>	C21254	Probable E3 Ubiquitin-Protein Ligase DTX2|DTX2|Deltex (Drosophila) Homolog 2|Deltex2|EC 2.3.2.27|EC 6.3.2.-, Formerly|Protein Deltex-2|RING Finger Protein 58|RING-Type E3 Ubiquitin Transferase DTX2|Zinc Ion Binding Protein	Probable E3 ubiquitin-protein ligase DTX2 (622 aa, ~67 kDa) is encoded by the human DTX2 gene. This protein plays a role in regulation of cell-cell communication during cell fate determination.	Probable E3 Ubiquitin-Protein Ligase DTX2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106469>	C91103	Booklet Return Not Requested Question|Booklet Return Not Requested|Booklet Return Not Requested	The return of a booklet is or was not requested.			Finding	
C10646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10646>	C61063	Etoposide/Topotecan|TOPO/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106470>	C45501	Treatment on Hold|Delayed|Treatment On Hold	A treatment is suspended.			Clinical Attribute	HL Authorized Value Terminology|HL Protocol Treatment Modifications Table
C106471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106471>	C25638	Scheduled by Mistake	The erroneous scheduling of an event.			Finding	
C106472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106472>	C20921	ANGPTL1 Gene|ANGPTL1|ANGPTL1|Angiopoietin-Like 1 Gene	This gene is involved in the regulation of hematopoietic stem cells.	ANGPTL1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106473>	C25638	Incorrect Booklet Given	The wrong booklet was provided to an individual.			Finding	
C106474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106474>	C106472	ANGPTL1 wt Allele|ANG-3|ANG3|ANGPT3|ARP1|AngY|Angiopoietin-Like 1 wt Allele|DJ595C2.2|UNQ162	Human ANGPTL1 wild-type allele is located in the vicinity of 1q25.2 and is approximately 22 kb in length. This allele, which encodes angiopoietin-related protein 1, plays a role in the regulation of hematopoietic stem cells.	ANGPTL1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106475>	C18515	Angiopoietin-Related Protein 1|ANGPTL1|Angioarrestin|Angiopoietin 3|Angiopoietin Y1|Angiopoietin-3|Angiopoietin-Like Protein 1|DJ595C2.2 (Angiopoietin Y1)	Angiopoietin-related protein 1 (491 aa, ~57 kDa) is encoded by the human ANGPTL1 gene. This protein is involved in the regulation of hematopoietic stem cells.	Angiopoietin-Related Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106476>	C25638	Protocol Misinterpreted|Misinterpreted Protocol	A protocol was misinterpreted.			Finding	
C106477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106477>	C43369	Staff Error	An error made by a staff member.			Conceptual Entity	
C106478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106478>	C66830	CDISC SDTM Reproductive System Findings Test Name Terminology|RPTEST|Reproductive System Findings Test Name|SDTM-RPTEST	Terminology associated with the reproductive system findings test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106479>	C66830	CDISC SDTM Reproductive System Findings Test Code Terminology|RPTESTCD|Reproductive System Findings Test Code|SDTM-RPTESTCD	Terminology associated with the reproductive system findings test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10647>	C61007	Dexamethasone/Floxuridine/Leucovorin Calcium|CF/DM/FUDR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106480>	C66830	CDISC SDTM Device Identifier Parameter Long Name Terminology|DIPARM|Device Identifier Long Name|SDTM-DIPARM	Terminology associated with the device identifier long name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106481>	C66830	CDISC SDTM Device Identifier Parameter Short Name Terminology|DIPARMCD|Device Identifier Short Name|SDTM-DIPARMCD	Terminology associated with the device identifier short name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106482>	C77526|C66830	CDISC SDTM Device-In-Use Test Name Terminology|DUTEST|Device-In-Use Test Name|SDTM-DUTEST	Terminology associated with the device-in-use test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106483>	C77526|C66830	CDISC SDTM Device-In-Use Test Code Terminology|DUTESTCD|Device-In-Use Test Code|SDTM-DUTESTCD	Terminology associated with the device-in-use test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106484>	C70699	Infranatant	The liquid, solid or semi-solid lying below a liquid residue, which is separated by crystallization, precipitation or centrifugation of a biological sample.			Body Substance	
C106485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106485>	C70699	Supernatant	The liquid lying above a liquid, solid or semi-solid residue, which is separated by crystallization, precipitation or centrifugation of a biological sample.			Body Substance	
C106486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106486>	C171086	Staff Not Available	A staff member is or was not available.			Finding	
C106487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106487>	C48655	No Reason Given|Not Given	There was no excuse provided.			Qualitative Concept	HL Authorized Value Terminology|HL Protocol Treatment Modifications Table
C106488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106488>	C25994	ANGPT4 Gene|ANGPT4|ANGPT4|Angiopoietin 4 Gene	This gene plays a role in both vascular development and angiogenesis.	ANGPT4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106489>	C106488	ANGPT4 wt Allele|AGP4|ANG-3|ANG-4|ANG3|ANG4|Angiopoietin 4 wt Allele	Human ANGPT4 wild-type allele is located in the vicinity of 20p13 and is approximately 44 kb in length. This allele, which encodes angiopoietin-4 protein, is involved in both vascular development and angiogenesis.	ANGPT4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10648>	C61063	Amifostine/Cyclophosphamide|CTX/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106490>	C91103	Patient Did Not Like Question Content Question|Patient Did Not Like Question Content|Patient Did Not Like Question Content	Patient did not like the question content.			Finding	
C106491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106491>	C18574	Angiopoietin-4|ANGPT4|Angiopoietin-3|DJ824F16.2 (Angiopoietin 4)	Angiopoietin-4 (503 aa, ~57 kDa) is encoded by the human ANGPT4 gene. This protein plays a role in both vascular development and angiogenesis.	Angiopoietin-4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106492>	C16669	Individual Physical Condition|Physical Condition	The physical condition of an individual.			Organism Attribute	
C106493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106493>	C25790	CD1D Gene|CD1D|CD1D|CD1d Molecule Gene	This gene is involved in antigen presentation.	CD1D Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106494>	C106493	CD1D wt Allele|CD1A|CD1d Molecule wt Allele|R3	Human CD1D wild-type allele is located within 1q22-q23 and is approximately 6 kb in length. This allele, which encodes antigen-presenting glycoprotein CD1d, plays a role in glycolipid antigen presentation.	CD1D wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106495>	C16725	Antigen-Presenting Glycoprotein CD1d|Antigen CD1d|CD1D|CD1d|CD1d Antigen|Differentiation Antigen CD1-Alpha-3|HMC Class I Antigen-Like Glycoprotein CD1D|R3G1|T-Cell Surface Glycoprotein CD1d|Thymocyte Antigen CD1D	Antigen-presenting glycoprotein CD1d (335 aa, ~38 kDa) is encoded by the human CD1D gene. This protein is involved in lipid antigen presentation.	Antigen-Presenting Glycoprotein CD1d		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106496>	C101589	Acute Extensive Anterior Wall Myocardial Infarction by ECG Finding|ACUTE EXTENSIVE ANTERIOR WALL MYOCARDIAL INFARCTION|Acute Extensive Anterior Wall Myocardial Infarction by EKG Finding	An electrocardiographic finding of pathologic Q waves with accompanying ST elevation in leads V1 to V6, I and aVL, which is suggestive of acute myocardial infarction involving the anterior and anterolateral walls of the left ventricle. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106497>	C69260	Age at Menopause|MENOAGE|Menopause Age|Menopause Age	The age at which permanent cessation of menses occurs.			Clinical Attribute	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106498>	C64467|C64433	Alanine Aminotransferase to Aspartate Aminotransferase Ratio Measurement|ALT/AST|ALT/AST|ALTAST	The determination of the ratio of alanine aminotransferase (ALT) compared to aspartate aminotransferase (AST) present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106499>	C74732	Alpha Fetoprotein Activity Measurement	The determination of the amount of the alpha fetoprotein activity present in a sample.			Laboratory Procedure	
C10649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10649>	C61063	Cyclosporine/Etoposide/Mitoxantrone|CYSP/DHAD/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1064>	C263	Defibrotide Sodium|DEFIBROTIDE SODIUM|Defibrinotide|Defibrotide|Defitelio|Fraction P|Noravid|Prociclide|defibrotide	A polydeoxyribonucleotide with antithrombotic, thrombolytic, and fibrinolytic properties.  Defibrotide induces the release of prostaglandin 12 and reduces the expression of adhesion molecules on endothelial cells, thereby interfering with platelet and leukocyte adhesion to the endothelium. (NCI04)	Defibrotide Sodium		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C106500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106500>	C90336	Anesthetized Exsanguination and Perfusion Euthanasia|ANESTHETIZED EXSANGUINATION AND PERFUSION|Anesthetized Perfusion	A method of euthanasia whereby a subject is anesthetized and the blood of the body is replaced by a perfusate.			Research Activity	CDISC SEND Method of Termination Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106501>	C71460	Birth Control Method|BCMETHOD	The method by which conception or impregnation is prevented. This may be achieved through the use of devices, drugs or surgery.			Activity	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106502>	C41328	Biventricular Hypertrophy by ECG Finding|BIVENTRICULAR HYPERTROPHY|Biventricular Hypertrophy by EKG Finding	An electrocardiographic finding suggestive of enlargement or thickening of both ventricles, with a combination of findings which are related to LVH and RVH, such as voltage criteria for LVH in the presence of marked right axis deviation. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106503>	C41328	Brugada Syndrome Pattern by ECG Finding|BRUGADA SYNDROME PATTERN|Brugada Syndrome Pattern by EKG Finding	An electrocardiographic finding of complete or incomplete right bundle branch block accompanied by ST elevation in leads V1-V3. This may be noted at rest or can be provoked by medication challenge. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106504>	C154813	Budding Yeast Measurement|Budding Yeast|YEASTBUD|YEASTBUD|Yeast Budding|Yeast Budding|Yeast Budding	Examination of a biological specimen to detect the presence of any yeast cells that are in the budding phase of asexual reproduction.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106505>	C209976	Cancer Antigen 72-4 Measurement|CA 72-4|CA72_4AG|Cancer Antigen 72-4|Cancer Antigen 72-4|Carbohydrate Antigen 72-4|TAG-72|TAG-72|Tumor Associated Antigen 72 Measurement|Tumor-Associated Antigen TAG-72 Measurement|Tumor-Associated Glycoprotein 72 Measurement	The determination of the amount of the cancer antigen 72-4 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C106506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106506>	C90336	Captive Bolt and Exsanguination Euthanasia|CAPTIVE BOLT EXSANGUINATION	A method of euthanasia whereby a subject is shot in the brain with a captive bolt pistol causing immediate and permanent unconsciousness or death, followed by draining the body of blood.			Research Activity	CDISC SEND Method of Termination Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106507>	C90336	Carbon Dioxide and Exsanguination Euthanasia|Asphyxia Exsanguination|CARBON DIOXIDE EXSANGUINATION	A method of euthanasia whereby a subject inhales carbon dioxide until asphyxiation occurs and then the body is immediately drained of blood.			Research Activity	CDISC SEND Method of Termination Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106508>	C19332	Childbearing Potential|CHILDPOT	An indicator as to whether the female subject has the potential to become pregnant.			Clinical Attribute	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106509>	C49237	Chloride Clearance Measurement|CLCLR|Chloride Clearance|Chloride Clearance	The determination of the amount of the chloride clearance in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10650>	C61063	Cyclophosphamide/Didanosine/Doxorubicin/Etoposide/Vincristine|CTX/ddI/DOX/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106510>	C215448	Coil Strength|COILSTR	The maximum voltage allowable to pass through an electromagnetic coil.			Quantitative Concept	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106511>	C74760	Corticosterone to Creatinine Ratio Measurement|CRTCREAT|Corticosterone/Creatinine|Corticosterone/Creatinine	The determination of the ratio of corticosterone compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106512>	C74760	Cortisol to Creatinine Ratio Measurement|CORCREAT|Cortisol/Creatinine|Cortisol/Creatinine	The determination of the ratio of cortisol compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106513>	C74760	Cystatin C to Creatinine Ratio Measurement|CYSCREAT|Cystatin C/Creatinine|Cystatin C/Creatinine	The determination of the ratio of cystatin C compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106514>	C64430	Cytokeratin 19 Fragment 21-1 Measurement|CYFRA21-1|CYFRA211|Cytokeratin 19 Fragment 21-1|Cytokeratin 19 Fragment 21-1	The determination of the amount of the cytokeratin 19 fragment 21-1 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106515>	C70699	Dialysis Fluid|DIALYSIS FLUID|Dialysate|Dialysate	The fluid which runs through a dialysis machine and captures, for discard or analysis, the excess water and waste from the blood stream through diffusion and ultrafiltration.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106516>	C19238	Dipstick	A strip of paper or other composite material that is coated or impregnated with reagents designed to detect the presence of an analyte in a liquid by producing a color change on the strip or is read using an instrument.			Manufactured Object	
C106517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106517>	C17230	Elastography|ELASTOGRAPHY	An ultrasound-based imaging technique used to examine the stiffness or elasticity of a tissue by applying mechanical compression or vibration to the tissue being imaged.	Elastography		Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C106518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106518>	C81971|C171143	Epstein-Barr Nuclear Antigen 1 IgG Ab Measurement	The determination of the amount of the Epstein-Barr nuclear antigen 1 IgG antibody present in a sample.			Laboratory Procedure	
C106519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106519>	C210012|C171143	Epstein-Barr Virus Infection Status|EBV Profile Interpretation|EBVINTP|Epstein-Barr Virus Antibody Profile|Epstein-Barr Virus Panel	An assessment of Epstein-Barr virus infection based on a panel of EBV antigen antibody tests.			Laboratory Procedure	CDISC SDTM Immunogenicity Specimen Assessments Test Code Terminology|CDISC SDTM Immunogenicity Specimen Assessments Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10651>	C61007	Cyclosporine/Cytarabine/Daunorubicin|ARA-C/CYSP/DNR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106520>	C101589	Extensive Anterior Wall Myocardial Infarction by ECG Finding|EXTENSIVE ANTERIOR WALL MYOCARDIAL INFARCTION|Extensive Anterior Wall Myocardial Infarction by EKG Finding	An electrocardiographic finding of pathologic Q waves in leads V1 to V6, I and aVL, which is suggestive of myocardial infarction involving the anterior and anterolateral walls of the left ventricle. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106521>	C64430	Fatty Acid Binding Protein 3 Measurement|FABP-11|FABP3|FABP3 Measurement|Fatty Acid Binding Protein 3|Fatty Acid Binding Protein 3|Fatty Acid Binding Protein 3, Muscle And Heart|Fatty Acid Binding Protein, Heart|Fatty Acid-Binding Protein 3 Measurement|H-FABP|Heart-Type Fatty Acid-Binding Protein|Heart-type Fatty Acid Binding Protein Measurement|M-FABP	The determination of the amount of the fatty acid binding protein 3 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106522>	C49556	Fetal Measurements Domain|FM|Fetal Measurements	A findings domain that captures individual fetal body and tissue weights, as well as growth measurements.			Idea or Concept	CDISC SDTM Terminology|CDISC SEND Domain Abbreviation Terminology|Clinical Data Interchange Standards Consortium Terminology
C106523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106523>	C65109	Flame Photometry|FLAME PHOTOMETRY	A type of atomic spectroscopy capable of qualitatively or quantitatively determining certain cations (particularly Na, K, Rb, Cs, Ca, Ba, Cu) by utilizing a low temperature flame capable of exciting a valence electron to an upper energy state which emits light at a wavelength unique to each cation as the electron returns to its ground state.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106524>	C48572	Frames Per Second|F/s|FPS|Frames per Second|Frames/s|Frames/s|Frames/sec|Frames/sec|{Frames}/s|{Frames}/s	A unit of measure equal to the number of visual frames per unit of time equal to one second.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106525>	C64848	Hemoglobin Distribution Width Measurement|HDW|Hemoglobin Concentration Distribution Width|Hemoglobin Distribution Width|Hemoglobin Distribution Width	A quantitative measurement of the distribution of the hemoglobin concentration in red blood cells.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106526>	C81971|C119283	Hepatitis E Virus IgG Antibody Measurement	The determination of the amount of IgG antibody to the hepatitis E virus in a biological specimen			Laboratory Procedure	
C106527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106527>	C210012|C210010|C161395	HIV Antibody Measurement	A quantitative measurement of the antibody reaction of a biological specimen to the HIV virus.			Laboratory Procedure	
C106528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106528>	C92571	Hour Squared Times Micromole Per Liter|h2*umol/L|h2.umol/L|h2.umol/L|h2.umol/l|h2.umol/l	Hours squared times micromoles per liter.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106529>	C92571	Hour Squared Times Picomole Per Liter|h2*pmol/L|h2.pmol/L|h2.pmol/L|h2.pmol/l|h2.pmol/l	Hours squared times picomoles per liter.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10652>	C61063	Cisplatin/Cytarabine/Hydroxyurea|ARA-C/CDDP/HU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106530>	C92571	Hour times Millimole Per Liter Per Gram|Hour Times Mole Per Liter Per Kilogram|h*mmol/L/g|h*mmol/L/g|h*mmol/L/g|h*mol/L/kg|h*mol/L/kg|h.mmol/L/g|h.mmol/L/g|h.mmol/l/g|h.mmol/l/g|h.mol/L/kg|h.mol/L/kg|h.mol/l/kg|h.mol/l/kg	Hours times millimoles per liter divided by grams.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106531>	C92571	Hour times Mole Per Liter Per Gram|h*mmol/L/mg|h*mmol/L/mg|h*mol/L/g|h*mol/L/g|h*mol/L/g|h*umol/L/ug|h*umol/L/ug|h.mmol/L/mg|h.mmol/L/mg|h.mmol/l/mg|h.mmol/l/mg|h.mol/L/g|h.mol/L/g|h.mol/l/g|h.mol/l/g|h.umol/L/ug|h.umol/L/ug|h.umol/l/ug|h.umol/l/ug	Hours times moles per liter divided by grams.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106532>	C92571	Hour times Picomole Per Liter Per Gram|Hour Times Nanomole Per Liter Per Kilogram|h*nmol/L/kg|h*nmol/L/kg|h*pmol/L/g|h*pmol/L/g|h*pmol/L/g|h.nmol/L/kg|h.nmol/L/kg|h.nmol/l/kg|h.nmol/l/kg|h.pmol/L/g|h.pmol/L/g|h.pmol/l/g|h.pmol/l/g	Hours times picomoles per liter divided by grams.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106533>	C94929	Image Acquisition Matrix Size|AQMTRXSZ	A measurement of the number of data fields, pixels or data points assigned to each linear dimension in a digital image.			Quantitative Concept	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106534>	C41145	Image Slice Thickness|STHICK|Slice Thickness|Slice Thickness|sliceThickness	The dimension between two surfaces of an imaging plane.			Quantitative Concept	BRIDG Attribute Terminology|BRIDG Terminology|CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106535>	C67208	Immunoblasts to Lymphocytes Ratio Measurement|BLSTIMLY|Immunoblasts/Lymphocytes|Immunoblasts/Lymphocytes|Lymphocytes, Immunoblastic/Lymphocytes	The determination of the ratio of immunoblasts compared to all lymphocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106536>	C111328	Immunoturbidimetry|IMMUNOTURBIDIMETRY|Immunoturbidimetric Assay|Turbidimetric Immunoassay	A method that measures the absorbance of light from a sample which is used for quantifying an amount of analyte based on the level of turbidity produced by the formation and precipitation of an immune complex containing the analyte.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106537>	C64430	Intact Glucose-dependent Insulinotropic Peptide Measurement|GIPI|Glucose-dep Insulinotropic Pep, Intact|Glucose-dep Insulinotropic Pep, Intact|Intact GIP|Intact Gastric Inhibitory Polypeptide|Intact Glucose-dependent Insulinotropic Peptide	The determination of the amount of the intact (containing amino acids 1-42) glucose-dependent insulinotropic peptide present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106538>	C15172	Lewis, Rat Strain|LEW|LEWIS	Derived from Wistar stock by the laboratory of Dr. Lewis at the Wistar Institute in the 1940s and 1950s, the Lewis is a white albino rat with genotype a, TyrC. The Lewis rat has a MHC haplotype of RT1A'.			Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106539>	C64430	Lipocalin-2 Measurement|LCN2|LCN2|Lipocalin-2|Lipocalin-2|Lipocalin-2|NGAL|NGAL Measurement|Neutrophil Gelatinase-Associated Lipocalin|Neutrophil Gelatinase-Associated Lipocalin Measurement|Oncogene 24p3	The determination of the amount of lipocalin-2 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10653>	C61007	Cisplatin/Topotecan|CDDP/TOPO	A combination of agents containing cisplatin and topotecan.		Obsolete_Concept	Therapeutic or Preventive Procedure	
C106540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106540>	C74760|C106539	Lipocalin-2 to Creatinine Ratio Measurement|LCN2CREA|Lipocalin-2/Creatinine|Lipocalin-2/Creatinine|NGAL/Creatinine|Neutrophil Gelatinase-Associated Lipocalin/Creatinine	The determination of the ratio of lipocalin-2 compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106541>	C117720	Menopause Status|MENOSTAT|Menopausal Status|menopause status|menopause_status	An indicator as to whether the female subject is in menopause.			Clinical Attribute	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|GDC Property Terminology|GDC Terminology
C106542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106542>	C49669	Milliliters Per Millimeter of Mercury|Milliliters per Millimeter of Mercury|mL/mmHg|mL/mmHg|mL/mm[Hg]|mL/mm[Hg]|ml/mm[Hg]|ml/mm[Hg]	A unit equal to the volume in milliliters per one millimeter rise of mercury in a barometer at the Earth's surface.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106543>	C92571	Minute Times Picomole Per Liter|min*pmol/L|min.pmol/L|min.pmol/L|min.pmol/l|min.pmol/l	Minutes times picomoles per liter.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106544>	C67208	Monocytes to Macrocytes Ratio Measurement|MONOMA|Monocytes/Macrocytes|Monocytes/Macrocytes	The determination of the ratio of monocytes compared to macrocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106545>	C20645	Multi-slice Spiral Computed Tomography|MULTI-SLICE SPIRAL CT|Multi-Slice Spiral Computed Tomography|Multi-slice Spiral CT	A type of spiral computed tomography that employs multiple rows of detectors, each capable of producing a simultaneous image (slice).			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106546>	C74760	Myoglobin to Creatinine Ratio Measurement|MGBCREAT|Myoglobin/Creatinine|Myoglobin/Creatinine	The determination of the ratio of myoglobin compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106547>	C64430	Myosin Light Chain 3 Measurement|Cardiac myosin light chain 1|MYL3|Myosin Light Chain 3|Myosin Light Chain 3|Myosin light chain 1, slow-twitch muscle B/ventricular isoform	The determination of the amount of myosin light chain 3 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106548>	C101589	New Posterior Wall Myocardial Infarction by ECG Finding|NEW POSTERIOR WALL MYOCARDIAL INFARCTION|New Posterior Wall Myocardial Infarction by EKG Finding	An electrocardiographic finding in leads V1 or V2 of an initial R wave duration greater than or equal to 40 ms, R wave greater than S wave, and upright T wave, which is suggestive of myocardial infarction of the posterior wall of the left ventricle, and which is new compared to prior ECGs. Evidence of inferior or lateral myocardial infarction is usually also present. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106549>	C77107	NIH Minipig|NIH SLA MINIATURE SWINE	An inbred strain of miniature swine developed by Sachs et al at the NIH in 1976 from a cross between a Hormel pig and a Vita Vet miniature pig.			Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10654>	C61063	Cyclophosphamide/Doxorubicin/Etoposide/Vincristine/Zidovudine|CTX/DOX/VCR/VP-16/ZDV			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106550>	C25337	Number of Abortions|ABORTN	A measurement of the total number of instances in which there has been a termination of pregnancy happening before the fetus is able to sustain independent life.			Quantitative Concept	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106551>	C25337	Number of Pregnancies|Maternal Gravity|PREGNN|Total Number of Pregnancies|number of pregnancies|number_of_pregnancies|pregnancy count|pregnancy_count	A measurement of the total number of pregnancy events experienced by the female subject.			Quantitative Concept	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Property Terminology|GDC Terminology|INC Demographic and Maternal Terminology|INC Terminology
C106552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106552>	C103175	Pharmacogenomics Biomarker Domain	A special purpose domain and reference dataset that associates observed genetic mutations with medical conclusions (e.g. disease diagnosis, drug resistance).			Idea or Concept	
C106553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106553>	C49237	Phosphate Clearance Measurement|PHOSCLR|Phosphate Clearance|Phosphate Clearance	The determination of the amount of the phosphate clearance in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106554>	C106484	Plasma Infranatant|INFRANATANT, PLASMA	The liquid, solid or semi-solid lying below a liquid residue, which is separated by crystallization, precipitation or centrifugation of a plasma sample.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106555>	C106485	Plasma Supernatant|SUPERNATANT, PLASMA	The liquid lying above a liquid, solid or semi-solid residue, which is separated by crystallization, precipitation or centrifugation of a plasma sample.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106556>	C17610	Platelet-poor Plasma|PLATELET POOR PLASMA|PPP	A plasma sample that is prepared from whole blood, which has undergone a number of centrifugation steps to decrease the amount of platelets.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106557>	C17610	Platelet-rich Plasma|PLATELET RICH PLASMA|PRP|Platelet Rich Plasma|Platelet Rich Plasma	A plasma sample that is prepared from whole blood, which has undergone a number of centrifugation steps to concentrate the amount of platelets.	Platelet Rich Plasma		Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Agent Terminology|CTRP Terminology
C106558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106558>	C106484	Pleural Fluid Infranatant|INFRANATANT, PLEURAL FLUID	The liquid, solid or semi-solid lying below a liquid residue, which is separated by crystallization, precipitation or centrifugation of a pleural fluid sample.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106559>	C106485	Pleural Fluid Supernatant|SUPERNATANT, PLEURAL FLUID	The liquid lying above a liquid, solid or semi-solid residue, which is separated by crystallization, precipitation or centrifugation of a pleural fluid sample.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10655>	C61007	Cyclophosphamide/Paclitaxel|CTX/TAX|Paclitaxel/Cyclophosphamide	A combination of agents containing cyclophosphamide and paclitaxel.		Obsolete_Concept	Therapeutic or Preventive Procedure	
C106560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106560>	C64853	Potassium Clearance Measurement|KCLR|Potassium Clearance|Potassium Clearance	The determination of the amount of the potassium clearance in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106561>	C19332	Pregnant During the Study|PREGST	An indicator as to whether the female subject is pregnant during the study period.			Clinical Attribute	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106562>	C25673|C163747	Pulse Sequence|PULSSEQ	A serially recurrent arrangement of radiofrequency pulses that are applied to the sample.			Spatial Concept	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106563>	C215448	Receiver Bandwidth|RCBDWDTH	The range between the minimum and maximum cut-off frequencies for a particular receiver, commonly measured in Hertz.			Quantitative Concept	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106564>	C53265	Reconstruction Filter Type|RCFLTRTP	A classification of the reconstruction filter used to suppress noise, enhance edges, perform resolution recovery and smooth an image.			Qualitative Concept	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106565>	C106484	Serum Infranatant|INFRANATANT, SERUM	The liquid, solid or semi-solid lying below a liquid residue, which is separated by crystallization, precipitation or centrifugation of a serum sample.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106566>	C106485	Serum Supernatant|SUPERNATANT, SERUM	The liquid lying above a liquid, solid or semi-solid residue, which is separated by crystallization, precipitation or centrifugation of a serum sample.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106567>	C20645	Single-slice Spiral Computed Tomography|SINGLE-SLICE SPIRAL CT|Single-Slice Spiral Computed Tomography|Single-slice Spiral CT	A type of spiral computed tomography that employs only one detector that produces one image (slice).			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106568>	C49237	Sodium Clearance Measurement|NACLR|Sodium Clearance|Sodium Clearance	The determination of the amount of the sodium clearance in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106569>	C74957	Specimen Weight Measurement|SPWEIGHT|SPWEIGHT|Specimen Weight|Specimen Weight|Specimen Weight	A quantitative measurement of the weight of a biological specimen.			Laboratory Procedure	CDISC SDTM Biospecimen Characteristics Test Code Terminology|CDISC SDTM Biospecimen Characteristics Test Name Terminology|CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10656>	C61063	Estramustine/Vinblastine|EM/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106570>	C53265	Stereotactic Surgery Frame Type|SFMTYP	The type or classification of the cage structure used to immobilize the head or other body part in preparation for stereotactic surgery.			Qualitative Concept	CDISC SDTM Device Identifier Parameter Long Name Terminology|CDISC SDTM Device Identifier Parameter Short Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106571>	C103175	Subject Biomarker Domain	A special purpose domain that associates the subject with the medical conclusions contained in the PB domain based on the observations reported in PF.			Idea or Concept	
C106572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106572>	C161043	Suffolk Sheep|SUFFOLK	A strain of sheep originally derived in England in the 1880s from a cross between a Southdown ram and a Norfolk Horned ewe. The Suffolk sheep has a white-colored body, black face and legs, and has a wool type of medium.			Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106573>	C14421	Swiss Webster Mouse|SW|SWISS WEBSTER|SWR	Derived from inbreeding of Swiss mice at the Rockefeller Institute in 1926 by Dr. Leslie Webster, the Swiss Webster is a white albino mouse with genotype TyrC. The superior nurturing ability of the Swiss Webster makes it ideal for embryo transfers.			Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106574>	C92745|C62662	Thrombin to Antithrombin Ratio Measurement|TAT|Thrombin/Antithrombin|Thrombin/Antithrombin|Thrombin/Antithrombin III	The determination of the ratio of thrombin compared to antithrombin present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106575>	C74760	Tissue Inhibitor of Metalloproteinase 1 to Creatinine Ratio Measurement|TIMP1/Creatinine|TIMP1/Creatinine|TIMP1CRE|Tissue Inhibitor of Metalloproteinase 1/Creatinine	The determination of the ratio of tissue inhibitor of metalloproteinase 1 compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C106576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106576>	C71473	Trial Site Terminated by Sponsor|SITE TERMINATED BY SPONSOR	An indication that a clinical study was stopped at a particular site by its sponsor.			Research Activity	CDISC SDTM Reason for Non-Completion Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106577>	C49556	Tumor Identifier Domain|TU|Tumor/Lesion Identification	A domain that represents the data that uniquely identifies tumors.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106578>	C49556	Tumor Results Domain|TR|Tumor/Lesion Results	A findings domain that represents quantitative measurements and/or qualitative assessments of the tumors identified in the TU domain.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106579>	C80503	U Wave Abnormality by ECG Finding|Abnormal U Wave|U WAVE ABNORMALITY|U Wave Abnormality|U Wave Abnormality by EKG Finding	An electrocardiographic finding of U waves which have increased amplitude, are inverted, or merged with the preceding T wave.			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C10657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10657>	C61063	Cytarabine/Dexamethasone/Etoposide/Ifosfamide/Methotrexate/Vincristine|ARA-C/DM/IFF/MTX/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106580>	C68781	Unplanned Terminal Sacrifice	An indication that the subject was sacrificed prior to the end of the planned treatment period, and the subject was not otherwise moribund.			Research Activity	
C106581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106581>	C49556	Viral Resistance Domain|Viral Resistance Findings Domain	A findings domain that captures information regarding the genetics of viral drug resistance. It contains the reference sequence used to validate the observed genetic mutation of interest.			Idea or Concept	
C106582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106582>	C20921	DLL1 Gene|DLL1|DLL1|Delta-Like 1 (Drosophila) Gene	This gene is involved in notch signaling.	DLL1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106583>	C106582	DLL1 wt Allele|DELTA1|DL1|Delta-Like 1 (Drosophila) wt Allele	Human DLL1 wild-type allele is located in the vicinity of 6q27 and is approximately 8 kb in length. This allele, which encodes delta-like protein 1, plays a role in notch signaling during hematopoietic cell fate determination.	DLL1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106584>	C25939	ALKBH7 Gene|ALKBH7|ALKBH7|AlkB, Alkylation Repair Homolog 7 (E. Coli) Gene	This gene plays a role in oxidation.			Gene or Genome	
C106585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106585>	C106584	ALKBH7 wt Allele|ABH7|AlkB, Alkylation Repair Homolog 7 (E. Coli) wt Allele|MGC10974|SPATA11|UNQ6002|UNQ6002/PRO34564	Human ALKBH7 wild-type allele is located in the vicinity of 19p13.3 and is approximately 3 kb in length. This allele, which encodes alpha-ketoglutarate-dependent dioxygenase alkB homolog 7 protein, is involved in the regulation of redox activity.			Gene or Genome	
C106586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106586>	C18515	Delta-Like Protein 1|DLK1|Delta|Delta (Drosophila)-Like 1|Delta1|Drosophila Delta Homolog 1|H-Delta-1	Delta-like protein 1 (723 aa, ~78 kDa) is encoded by the human DLL1 gene. This protein is involved in cell fate decisions during hematopoiesis.	Delta-Like Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Cell Lineage Determinant Terminology
C106587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106587>	C28459	Alpha-Ketoglutarate-Dependent Dioxygenase AlkB Homolog 7|ALKBH7|Alkylated DNA Repair Protein AlkB Homolog 7|EC 1.14.11.-|Spermatogenesis Cell Proliferation-Related Protein|Spermatogenesis-Associated Protein 11	Alpha-ketoglutarate-dependent dioxygenase alkB homolog 7 (221 aa, ~25 kDa) is encoded by the human ALKBH7 gene. This protein plays a role in oxidoreductase activity.			Amino Acid, Peptide, or Protein|Enzyme	
C106588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106588>	C28533	SLC7A5 Gene|SLC7A5|SLC7A5|Solute Carrier Family 7 Member 5 Gene	This gene plays a role in high-affinity transport of large neutral amino acids.	SLC7A5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106589>	C106588	SLC7A5 wt Allele|4F2 LC|4F2LC|Antigen Defined By Monoclonal Antibody 4F2, Light Chain Gene|CD98|CD98LC|D16S469E|E16|HLAT1|LAT1|MPE16|Solute Carrier Family 7 (Amino Acid Transporter Light Chain, L System), Member 5 Gene|Solute Carrier Family 7 (Cationic Amino Acid Transporter, Y+ System), Member 5|Solute Carrier Family 7 Member 5 wt Allele	Human SLC7A5 wild-type allele is located in the vicinity of 16q24.3 and is approximately 39 kb in length. This allele, which encodes large neutral amino acids transporter small subunit 1 protein, is involved in cellular uptake of large neutral amino acids.	SLC7A5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10658>	C61063	Bleomycin/Didanosine/Doxorubicin/Vincristine|BLEO/ddI/DOX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106590>	C16386	Large Neutral Amino Acids Transporter Small Subunit 1|4F2 LC|4F2 Light Chain|4F2LC|CD98 Light Chain|E16|Integral Membrane Protein E16|L-Type Amino Acid Transporter 1|Large Neutral Amino Acids Transporter 1|Membrane Protein E16|SLC7A5|Sodium-Independent Neutral Amino Acid Transporter LAT1|Solute Carrier Family 7 Member 5|Y+ System Cationic Amino Acid Transporter|hLAT1	Large neutral amino acids transporter small subunit 1 (507 aa, ~55 kDa) is encoded by the human SLC7A5 gene. This protein plays a role in both neutral amino acid transport and neurogenesis in the brain.	Large Neutral Amino Acids Transporter Small Subunit 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106591>	C25869|C20921	CD63 Gene|CD63|CD63|CD63 Molecule Gene	This gene is involved in signal transduction.	CD63 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106592>	C106591	CD63 wt Allele|CD63 Molecule wt Allele|LAMP-3|ME491|MLA1|OMA81H|TSPAN30	Human CD63 wild-type allele is located within 12q12-q13 and is approximately 4 kb in length. This allele, which encodes CD63 antigen protein, plays a role in signal transduction and may play a role in growth regulation. Mutation of this gene is associated with tumor progression and deficiency of the protein is associated with Hermansky-Pudlak syndrome.	CD63 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106593>	C18515	CD63 Antigen|CD63 Antigen (Melanoma 1 Antigen)|Granulophysin|Lysosomal-Associated Membrane Protein 3|Lysosome-Associated Membrane Glycoprotein 3|Melanoma-Associated Antigen ME491|Melanoma-Associated Antigen MLA1|Ocular Melanoma-Associated Antigen|Tetraspanin-30|Tspan-30	CD63 antigen (238 aa, ~256 kDa) is encoded by the human CD63 gene. This protein is involved in signal transduction and may play a role in growth regulation.	CD63 Antigen		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106594>	C25939	CYBB Gene|CYBB|CYBB|Cytochrome B-245 Beta Chain Gene	This gene plays a role in the generation of superoxide in phagocytes.	CYBB Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106595>	C106594	CYBB wt Allele|AMCBX2|CGD|CGDX|Cytochrome B-245 Beta Chain wt Allele|Cytochrome B-245, Beta Polypeptide Gene|Cytochrome b(-245), Beta Subunit Gene|Cytochrome b(588), Beta Subunit Gene|GP91-1|GP91-PHOX|NOX2|gp91 phox	Human CYBB wild-type allele is located in the vicinity of Xp21.1 and is approximately 33 kb in length. This allele, which encodes cytochrome B-245 heavy chain protein, is involved in the microbicidal oxidase system of phagocytes. Mutations in this gene are associated with both atypical mycobacteriosis, familial, X-linked 2 and chronic granulomatous disease, X-linked.	CYBB wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106596>	C16486	Cytochrome B-245 Heavy Chain|CGD91-Phox|CYBB|Cytochrome B(558) Subunit Beta|Cytochrome B558 Subunit Beta|EC 1.6.3|Heme-Binding Membrane Glycoprotein Gp91phox|NADPH Oxidase 2|Neutrophil Cytochrome B 91 kDa Polypeptide|Superoxide-Generating NADPH Oxidase Heavy Chain Subunit|gp91 phox|gp91-1|gp91-phox|p22 Phagocyte B-Cytochrome	Cytochrome B-245 heavy chain (570 aa, ~65 kDa) is encoded by the human CYBB gene. This protein plays a role in the microbicidal activity of phagocytes.	Cytochrome B-245 Heavy Chain		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106597>	C20709	NR2C2 Gene|NR2C2|NR2C2|Nuclear Receptor Subfamily 2, Group C, Member 2 Gene	This gene is involved in hormone-dependent transcriptional regulation.			Gene or Genome	
C106598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106598>	C106597	NR2C2 wt Allele|Nuclear Receptor Subfamily 2, Group C, Member 2 wt Allele|TAK1|TR2R1|TR4|hTAK1	Human NR2C2 wild-type allele is located in the vicinity of 3p25 and is approximately 106 kb in length. This allele, which encodes nuclear receptor subfamily 2 group C member 2 protein, plays a role in hormone-mediated transcriptional regulation. Aberrant expression of the gene may be associated with corticotrophic malignancies and Cushing disease.			Gene or Genome	
C106599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106599>	C17671	Nuclear Receptor Subfamily 2 Group C Member 2|NR2C2|Nuclear Hormone Receptor TR4|Orphan Nuclear Receptor TAK1|Orphan Nuclear Receptor TR4|TR4 Nuclear Hormone Receptor|Testicular Nuclear Receptor 4|Testicular Receptor 4	Nuclear receptor subfamily 2 group C member 2 (596 aa, ~65 kDa) is encoded by the human NR2C2 gene. This protein is involved in both hormone binding and transcriptional regulation.			Amino Acid, Peptide, or Protein|Receptor	
C10659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10659>	C61063	Cyclosporine/Dactinomycin/Vincristine|CYSP/DACT/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1065>	C798	Desmethylmisonidazole|1,2-propanediol, 3-(2-nitro-1h-imidazol-1-yl)-|DESMETHYLMISONIDAZOLE|Demethylmisonidazole|Demethylmisonidazole|Ro 05-9963|SR-1530	A radiosensitizer that targets hypoxic cells and act as oxygen substitute making tumor cells sensitive to radiation damage.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C106600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106600>	C21295	BPI Gene|BPI|BPI|Bactericidal/Permeability-Increasing Protein Gene	This gene is involved in lipopolysaccharide binding.	BPI Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106601>	C106600	BPI wt Allele|BPIFD1|Bactericidal/Permeability-Increasing Protein wt Allele|CAP 57|RBPI	Human BPI wild-type allele is located in the vicinity of 20q11.23 and is approximately 77 kb in length. This allele, which encodes bactericidal permeability-increasing protein, plays a role in defense against gram-negative bacterial infections.	BPI wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106602>	C17728	Bactericidal Permeability-Increasing Protein|BACTERICIDAL PERMEABILITY-INCREASING PROTEIN|BPI|BPI|BPI Fold Containing Family D, Member 1|Bactericidal/Permeability-Increasing Protein|RBPI	Bactericidal permeability-increasing protein (487 aa, ~54 kDa) is encoded by the human BPI gene. This protein is involved in both defense against gram-negative bacterial infections and lipopolysaccharide binding.	Bactericidal Permeability-Increasing Protein		Amino Acid, Peptide, or Protein	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106603>	C20194	MACC1 Gene|MACC1|MACC1|Metastasis Associated in Colon Cancer 1 Gene	This gene plays a role in regulation of the hepatocyte growth factor receptor pathway.	MACC1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106604>	C106603	MACC1 wt Allele|7A5|Metastasis Associated in Colon Cancer 1 wt Allele|SH3BP4L	Human MACC1 wild-type allele is located in the vicinity of 7p21.1 and is approximately 83 kb in length. This allele, which encodes metastasis-associated in colon cancer protein 1, is involved in promoting both cell motility and cell proliferation. Expression of this gene in colon cancers is a prognostic indicator for metastasis formation.	MACC1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106605>	C18466	Metastasis-Associated in Colon Cancer Protein 1|MACC1|Putative Binding Protein 7a5|SH3 Domain-Containing Protein 7a5	Metastasis-associated in colon cancer protein 1 (852 aa, ~97 kDa) is encoded by the human MACC1 gene. This protein plays a role in both cell proliferation and cell motility.	Metastasis-Associated in Colon Cancer Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106606>	C25872|C20921	MAP2K2 Gene|MAP2K2|MAP2K2|MAP2K2|Mitogen-Activated Protein Kinase Kinase 2 Gene	This gene plays a role in both protein phosphorylation and signal transduction.	MAP2K2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|Pediatric Oncology Target Genes/Proteins Terminology
C106607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106607>	C106606	MAP2K2 wt Allele|MAPKK2|MEK2|MKK2|Mitogen-Activated Protein Kinase Kinase 2 wt Allele|PRKMK2	Human MAP2K2 wild-type allele is located in the vicinity of 19p13.3 and is approximately 34 kb in length. This allele, which encodes dual specificity mitogen-activated protein kinase kinase 2 protein, is involved in both MAPK and toll-like receptor signaling pathways. Mutation of the gene is associated with cardiofaciocutaneous syndrome.	MAP2K2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106608>	C20921	SEMA4D Gene|SEMA4D|SEMA4D|Sema Domain, Immunoglobulin Domain (Ig), Transmembrane Domain (TM) and Short Cytoplasmic Domain, (semaphorin) 4D Gene	This gene is involved in both cell-cell signaling and axonal growth cone guidance.	SEMA4D Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106609>	C106608	SEMA4D wt Allele|A8|BB18|CD100|Coll-4|FLJ39737|GR3|SEMAJ|Sema Domain, Immunoglobulin Domain (Ig), Transmembrane Domain (TM) and Short Cytoplasmic Domain, (semaphorin) 4D wt Allele	Human SEMA4D wild-type allele is located in the vicinity of 9q22.2 and is approximately 137 kb in length. This allele, which encodes semaphorin-4D protein, plays a role in both axonal growth cone guidance and cell-cell signaling.	SEMA4D wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10660>	C61063	Busulfan/Cyclophosphamide/Diaziquone|AZQ/BU/CTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106610>	C18515	Semaphorin-4D|C9orf164|CD100 Antigen|Chromosome 9 Open Reading Frame 164|M-Sema-G|SEMA4D	Semaphorin-4D (862 aa, ~96 kDa) is encoded by the human SEMA4D gene. This protein is involved in both axonal growth cone guidance in the developing central nervous system and cell-cell signaling.	Semaphorin-4D		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106611>	C25997|C20420	SMAD1 Gene|SMAD Family Member 1 Gene|SMAD1|SMAD1	This gene plays a role in the regulation of bone morphogenetic proteins.	SMAD1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106612>	C106611	SMAD1 wt Allele|BSP-1|BSP1|HSMAD1|JV4-1|JV41|MADH1|MADR1|SMAD Family Member 1 wt Allele	Human SMAD1 wild-type allele is located in the vicinity of 4q31.21 and is approximately 78 kb in length. This allele, which encodes mothers against decapentaplegic homolog 1 protein, is involved in the regulation of cell growth, apoptosis, morphogenesis, development and immune responses.	SMAD1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106613>	C26231|C17207	Mothers Against Decapentaplegic Homolog 1|MAD Homolog 1|MAD, Mothers Against Decapentaplegic Homolog 1|MAD, Mothers Against Decapentaplegic Homolog 1 (Drosophila)|Mad-Related Protein 1|Mothers Against DPP Homolog 1|SMAD, Mothers Against DPP Homolog 1 (Drosophila)|TGF-Beta Signaling Protein 1|Transforming Growth Factor-Beta Signaling Protein 1|Transforming Growth Factor-Beta-Signaling Protein 1	Mothers against decapentaplegic homolog 1 (465 aa, ~52 kDa) is encoded by the human SMAD1 gene. This protein plays a role in regulating the action of bone morphogenic proteins in cell growth, apoptosis, morphogenesis, development and immune responses.	Mothers Against Decapentaplegic Homolog 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106614>	C28533	SLCO1B1 Gene|SLCO1B1|SLCO1B1|Solute Carrier Organic Anion Transporter Family, Member 1B1 Gene	This gene is involved in sodium-independent uptake of numerous endogenous compounds in the liver.	SLCO1B1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106615>	C106614	SLCO1B1 wt Allele|HBLRR|LST-1|LST1|OATP-C|OATP1B1|OATP2|OATPC|SLC21A6|Solute Carrier Organic Anion Transporter Family, Member 1B1 wt Allele	Human SLCO1B1 wild-type allele is located in the vicinity of 12p12 and is approximately 109 kb in length. This allele, which encodes solute carrier organic anion transporter family member 1B1 protein, plays a role in both endogenous factor uptake in the liver and the removal of drug compounds. Mutations in this gene are associated with hyperbilirubinemia, Rotor type, digenic.	SLCO1B1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106616>	C16386	Solute Carrier Organic Anion Transporter Family Member 1B1|Liver-Specific Organic Anion Transporter 1|SLCO1B1|Sodium-Independent Organic Anion-Transporting Polypeptide 2|Solute Carrier Family 21 (Organic Anion Transporter), Member 6|Solute Carrier Family 21 Member 6	Solute carrier organic anion transporter family member 1B1 (691 aa, ~76 kDa) is encoded by the human SLCO1B1 gene. This protein is involved in the sodium-independent uptake of endogenous compounds in the liver.	Solute Carrier Organic Anion Transporter Family Member 1B1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106617>	C28533	SLCO1B3 Gene|SLCO1B3|SLCO1B3|Solute Carrier Organic Anion Transporter Family, Member 1B3 Gene	This gene plays a role in both the sodium-independent uptake of endogenous and xenobiotic compounds and the transport of bile acid and bilirubin.	SLCO1B3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106618>	C106617	SLCO1B3 wt Allele|HBLRR|LST-2|LST-3TM13|LST2|LST3|OATP-8|OATP1B3|OATP8|SLC21A8|Solute Carrier Organic Anion Transporter Family, Member 1B3 wt Allele	Human SLCO1B3 wild-type allele is located in the vicinity of 12p12 and is approximately 279 kb in length. This allele, which encodes solute carrier organic anion transporter family member 1B3 protein, is involved in both bile acid and bilirubin transport and sodium-independent uptake of endogenous and xenobiotic compounds. Mutations in this gene are associated with hyperbilirubinemia, Rotor type, digenic.	SLCO1B3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106619>	C16386	Solute Carrier Organic Anion Transporter Family Member 1B3|Liver-Specific Organic Anion Transporter 2|Liver-Specific Organic Anion Transporter 3TM13|Organic Anion Transporter 8|Organic Anion Transporter LST-3c|Organic Anion-Transporting Polypeptide 8|SLCO1B3|Solute Carrier Family 21 Member 8	Solute carrier organic anion transporter family member 1B3 (702 aa, ~74 kDa) is encoded by the human SLCO1B3 gene. This protein plays a role in both the uptake of endogenous and xenobiotic compounds in the liver and bile acid and bilirubin transport.	Solute Carrier Organic Anion Transporter Family Member 1B3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10661>	C61063	Carboplatin/Cyclophosphamide/Interleukin-1-Beta|CBDCA/CTX/IL-1B			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106620>	C25873	MAP3K5 Gene|MAP3K5|MAP3K5|Mitogen-Activated Protein Kinase Kinase Kinase 5 Gene	This gene is involved in the MAP kinase signal transduction pathway.	MAP3K5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106621>	C217121|C21154	Fatigue Severity Scale|FSS|FSS|FSS01	A numeric scale to assess the severity of an individual's fatigue over the past week while performing a variety of usual tasks.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106622>	C106620	MAP3K5 wt Allele|ASK-1|ASK1|MAPKKK5|MEKK 5|MEKK5|Mitogen-Activated Protein Kinase Kinase Kinase 5 wt Allele	Human MAP3K5 wild-type allele is located in the vicinity of 6q22.33 and is approximately 235 kb in length. This allele, which encodes mitogen-activated protein kinase kinase kinase 5 protein, plays a role in mediating cell signaling during cell fate determination.	MAP3K5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106623>	C17325	Mitogen-Activated Protein Kinase Kinase Kinase 5|ASK1|Apoptosis Signal Regulating Kinase 1|Apoptosis Signal-Regulating Kinase 1|EC 2.7.11.25|MAP/ERK Kinase Kinase 5|MAP3K5|MAPK/ERK Kinase Kinase 5|MEK Kinase 5	Mitogen-activated protein kinase kinase kinase 5 (1374 aa, ~155 kDa) is encoded by the human MAP3K5 gene. This protein is involved in the apoptosis signal transduction pathway through mitochondria-dependent caspase activation.	Mitogen-Activated Protein Kinase Kinase Kinase 5		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106624>	C21154|C121547	Visual Analogue Fatigue Scale|VAFS	A numeric scale used to describe an individual's global fatigue.			Intellectual Product	
C106625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106625>	C173347	Motivation Lower When Fatigued Question|Motivation Lower When Fatigued|My motivation is lower when I am fatigued	A question about whether an individual's motivation is or was lower when fatigued.			Intellectual Product	Fatigue Severity Scale
C106626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106626>	C173347	Exercise Brings on Fatigue Question|Exercise Brings on Fatigue|Exercise brings on my fatigue	A question about whether exercise brings or brought on an individual's fatigue.			Intellectual Product	Fatigue Severity Scale
C106627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106627>	C173347	Easily Fatigued Question|Easily Fatigued|I am easily fatigued	A question about whether an individual is or was easily fatigued.			Intellectual Product	Fatigue Severity Scale
C106628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106628>	C173584|C173347	Fatigue Interferes with Physical Functioning Question|Fatigue Interferes with Physical Functioning|Fatigue interferes with my physical functioning	A question about whether an individual's fatigue interferes or interfered with physical functioning.			Intellectual Product	Fatigue Severity Scale
C106629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106629>	C173347	Fatigue Causes Frequent Problems Question|Fatigue Causes Frequent Problems|Fatigue causes frequent problems for me	A question about whether an individual's fatigue causes or caused frequent problems.			Intellectual Product	Fatigue Severity Scale
C10662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10662>	C61007	Carboplatin/Paclitaxel|CBDCA/Paclitaxel|CBDCA/TAX|Carboplatin-Paclitaxel|Carboplatin-Paclitaxel Regimen			Obsolete_Concept	Therapeutic or Preventive Procedure	GDC Regimen Terminology|GDC Terminology
C106630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106630>	C173347	Fatigue Prevents Sustained Physical Functioning Question|Fatigue Prevents Sustained Physical Functioning|My fatigue prevents sustained physical functioning	A question about whether an individual's fatigue prevents or prevented sustained physical functioning.			Intellectual Product	Fatigue Severity Scale
C106631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106631>	C173584|C173347	Fatigue Interferes with Certain Duties and Responsibilities Question|Fatigue Interferes with Certain Duties and Responsibilities|Fatigue interferes with carrying out certain duties and responsibilities	A question about whether an individual's fatigue interferes or interfered with certain duties or responsibilities.			Intellectual Product	Fatigue Severity Scale
C106632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106632>	C173457|C173347	Fatigue among Most Disabling Symptoms Question|Fatigue among Most Disabling Symptoms|Fatigue is among my most disabling symptoms	A question about whether an individual's fatigue is or was among their most disabling symptoms.			Intellectual Product	Fatigue Severity Scale
C106633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106633>	C18152	Dual Specificity Mitogen-Activated Protein Kinase Kinase 2|EC 2.7.12.2|ERK Activator Kinase 2|MAP Kinase Kinase 2|MAP2K2|MAPK/ERK Kinase 2|MAPKK 2|MEK 2|MKK2|Mitogen-Activated Protein Kinase Kinase 2	Dual specificity mitogen-activated protein kinase kinase 2 (400 aa, ~44 kDa) is encoded by the human MAP2K2 gene. This protein plays a role in protein phosphorylation.	Dual Specificity Mitogen-Activated Protein Kinase Kinase 2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Genes/Proteins Terminology
C106634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106634>	C173924|C173584|C173347|C173151	Fatigue Interferes with Work, Family, or Social Life Question|Fatigue Interferes with Work, Family, or Social Life|Fatigue interferes with my work, family, or social life	A question about whether an individual's fatigue interferes or interfered with work, family, or social life.			Intellectual Product	Fatigue Severity Scale
C106635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106635>	C20194	SETBP1 Gene|SET Binding Protein 1 Gene|SETBP1|SETBP1|SETBP1|SETBP1	This gene may be involved in the modulation of protein SET activity.	SETBP1 Gene		Gene or Genome	CCPS Genetics Terminology|Childhood Cancer Predisposition Study Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C106636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106636>	C106635	SETBP1 wt Allele|KIAA0437|MRD29|SEB|SET Binding Protein 1 wt Allele	Human SETBP1 wild-type allele is located in the vicinity of 18q21.1 and is approximately 388 kb in length. This allele, which encodes SET-binding protein, may play a role in the regulation of protein SET activity. Mutation of the gene is associated with Schinzel-Giedion midface retraction syndrome. A chromosomal translocation, t(11;18)(p15;q12), involving this gene and the NUP98 gene is involved in T-cell acute lymphoblastic leukemia.	SETBP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106637>	C18466	SET-Binding Protein|SEB|SET-Binding Protein 1|SETBP1	SET-binding protein (1596 aa, ~175 kDa) is encoded by the human SETBP1 gene. This protein is involved in binding to protein SET.	SET-Binding Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C106638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106638>	C25871	CGAS Gene|CGAS|CGAS|Cyclic GMP-AMP Synthase Gene|MB21D1	This gene plays a role in the biosynthesis of cyclic dinucleotides.	CGAS Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C106639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106639>	C106638	CGAS wt Allele|C6orf150|Chromosome 6 Open Reading Frame 150 Gene|Cyclic GMP-AMP Synthase wt Allele|D4|MB21D1|Mab-21 Domain Containing 1 Gene|cGAS|h-cGAS	Human CGAS wild-type allele is located in the vicinity of 6q13 and is approximately 39 kb in length. This allele, which encodes cyclic GMP-AMP synthase protein, is involved in both immunity and cyclic nucleotide synthesis.	CGAS wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10663>	C61063	Doxorubicin/Fluorouracil/Vinorelbine|DOX/5-FU/VNB			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106640>	C16925	Cyclic GMP-AMP Synthase|2'3'-cGAMP Synthase|CGAS|EC 2.7.7.86|MB21D1|Mab-21 Domain-Containing Protein 1|Mab21 Domain-Containing Protein 1|Protein MB21D1|cGAMP synthase|cGAS|h-cGAS	Cyclic GMP-AMP synthase (522 aa, ~59 kDa) is encoded by the human CGAS gene. This protein plays a role both cyclic dinucleotide synthesis and immune response activation.	Cyclic GMP-AMP Synthase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C106641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106641>	C25941	NAXE Gene|APOA1BP|NAD(P)HX Epimerase Gene|NAXE|NAXE	This gene is involved in both apolipoprotein A-I binding and nicotinamide-adenine dinucleotide metabolism.			Gene or Genome	
C106642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106642>	C106641	NAXE wt Allele|AIBP|APOA1BP|Apolipoprotein A-I Binding Protein Gene|MGC119143|MGC119144|MGC119145|NAD(P)HX Epimerase wt Allele|PEBEL|RP11-284F21.3|YJEFN1	Human NAXE wild-type allele is located in the vicinity of 1q22 and is approximately 3 kb in length. This allele, which encodes NAD(P)H-hydrate epimerase protein, is involved in both NAD metabolism and apolipoprotein A-I binding.			Gene or Genome	
C106643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106643>	C217464	Human Prescription Drug Manufacturing|Manufactures human prescription drug products	The process of manufacturing prescription medications for humans by a pharmaceutical company.			Activity	FDA Structured Product Labeling Terminology|SPL Business Operation Qualifier Terminology
C106644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106644>	C16759	NAD(P)H-Hydrate Epimerase|AI-BP|APOA1BP|ApoA-I Binding Protein|ApoA-I-Binding Protein|ApoA1-Binding Protein|Apolipoprotein A-I-Binding Protein|EC 5.1.99.6|NAD(P)HX Epimerase|NAXE|YjeF N-Terminal Domain-Containing Protein 1|YjeF_N1	NAD(P)H-hydrate epimerase (288 aa, ~32 kDa) is encoded by the human NAXE gene. This protein is involved in both lipoprotein binding and nucleotide metabolism.			Amino Acid, Peptide, or Protein|Enzyme	
C106645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106645>	C217464	Human Over-the-Counter Drug Manufacturing	The process of manufacturing non-prescription medications for humans by a pharmaceutical company.			Activity	
C106646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106646>	C173981	Would Never Doze Question|Would Never Doze|would never doze	A question about the likelihood an individual would never doze.			Intellectual Product	Epworth Sleepiness Scale Questionnaire
C106647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106647>	C173981	Slight Chance of Dozing Question|Slight Chance of Dozing|slight chance of dozing	A question about whether an individual has or had a slight likelihood of dozing.			Intellectual Product	Epworth Sleepiness Scale Questionnaire
C106648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106648>	C173981	Moderate Chance of Dozing Question|Moderate Chance of Dozing|moderate chance of dozing	A question about whether an individual has or had a moderate likelihood of dozing.			Intellectual Product	Epworth Sleepiness Scale Questionnaire
C106649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106649>	C173981	High Chance of Dozing Question|High Chance of Dozing|high chance of dozing	A question about whether an individual has or had a high likelihood of dozing.			Intellectual Product	Epworth Sleepiness Scale Questionnaire
C10664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10664>	C61063	Etoposide/Paclitaxel|TAX/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106650>	C100110	CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|ADL03TN|Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory MCI Version Questionnaire Test Name|QS-ADCS-ADL MCI TEST	Test names of questionnaire questions associated with the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory MCI (ADCS-ADL MCI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106651>	C100110	CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|ADL03TC|Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory MCI Version Questionnaire Test Code|QS-ADCS-ADL MCI TESTCD	Test codes of questionnaire questions associated with the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory MCI (ADCS-ADL MCI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106652>	C100110	CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|ADL02TN|Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory Severe Dementia Version Questionnaire Test Name|QS-ADCS-ADL Severe Dementia TEST	Test names of questionnaire questions associated with the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory Severe Dementia (ADCS-ADL Severe Dementia) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106653>	C100110	CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|ADL02TC|Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory Severe Dementia Version Questionnaire Test Code|QS-ADCS-ADL Severe Dementia TESTCD	Test codes of questionnaire questions associated with the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory Severe Dementia (ADCS-ADL Severe Dementia) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106654>	C118970	CDISC Clinical Classification BDI Test Name Terminology|BDI01TN|Baseline Dyspnea Index Clinical Classification Test Name|QS-BDI TEST	Test names of clinical classification questions associated with the Baseline Dyspnea Index (BDI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106655>	C118970	CDISC Clinical Classification BDI Test Code Terminology|BDI01TC|Baseline Dyspnea Index Clinical Classification Test Code|QS-BDI TESTCD	Test codes of clinical classification questions associated with the Baseline Dyspnea Index (BDI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106656>	C118970	CDISC Clinical Classification TDI Test Name Terminology|QS-TDI TEST|TDI01TN|Transition Dyspnea Index Clinical Classification Test Name	Test names of clinical classification questions associated with the Transition Dyspnea Index (TDI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106657>	C118970	CDISC Clinical Classification TDI Test Code Terminology|QS-TDI TESTCD|TDI01TC|Transition Dyspnea Index Clinical Classification Test Code	Test codes of clinical classification questions associated with the Transition Dyspnea Index (TDI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106658>	C100110	CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CSS05TN|Columbia-Suicide Severity Rating Scale Already Enrolled Subjects Questionnaire Test Name|QS-C-SSRS Already Enrolled Subjects TEST	Test names of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106659>	C100110	CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CSS05TC|Columbia-Suicide Severity Rating Scale Already Enrolled Subjects Questionnaire Test Code|QS-C-SSRS Already Enrolled Subjects TESTCD	Test codes of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10665>	C61063	Doxorubicin/Fluorouracil/Leucovorin Calcium/Vinorelbine|CF/DOX/5-FU/VNB			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106660>	C100110	CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CSS04TN|Columbia-Suicide Severity Rating Scale Baseline/Screening Version Questionnaire Test Name|QS-C-SSRS Baseline/Screening Version TEST	Test names of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106661>	C100110	CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CSS04TC|Columbia-Suicide Severity Rating Scale Baseline/Screening Version Questionnaire Test Code|QS-C-SSRS Baseline/Screening Version TESTCD	Test codes of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106662>	C100110	CDISC Questionnaire GDS Test Name Terminology|GDS01TN|Geriatric Depression Scale Questionnaire Test Name|QS-GDS TEST	Test names of questionnaire questions associated with the Geriatric Depression Scale (GDS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106663>	C100110	CDISC Questionnaire GDS Test Code Terminology|GDS01TC|Geriatric Depression Scale Questionnaire Test Code|QS-GDS TESTCD	Test codes of questionnaire questions associated with the Geriatric Depression Scale (GDS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106664>	C100110	CDISC Questionnaire GDS-SF Test Name Terminology|GDS02TN|Geriatric Depression Scale Short Form Questionnaire Test Name|QS-GDS-SF TEST	Test names of questionnaire questions associated with the Geriatric Depression Scale Short Form (GDS-SF) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106665>	C100110	CDISC Questionnaire GDS-SF Test Code Terminology|GDS02TC|Geriatric Depression Scale Short Form Questionnaire Test Code|QS-GDS-SF TESTCD	Test codes of questionnaire questions associated with the Geriatric Depression Scale Short Form (GDS-SF) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106666>	C100110	CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|HAQ01TN|Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale Questionnaire Test Name|QS-HAQ-DI TEST	Test names of questionnaire questions associated with the Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106667>	C100110	CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|HAQ01TC|Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale Questionnaire Test Code|QS-HAQ-DI TESTCD	Test codes of questionnaire questions associated with the Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106668>	C100110	CDISC Questionnaire MMRC Test Name Terminology|MMRC01TN|Modified Medical Research Council Dyspnea Scale Questionnaire Test Name|QS-MMRC TEST	Test names of questionnaire questions associated with the Modified Medical Research Council Dyspnea Scale (MMRC) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106669>	C100110	CDISC Questionnaire MMRC Test Code Terminology|MMRC01TC|Modified Medical Research Council Dyspnea Scale Questionnaire Test Code|QS-MMRC TESTCD	Test codes of questionnaire questions associated with the Modified Medical Research Council Dyspnea Scale (MMRC) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10666>	C61063	Interferon Gamma/Melphalan/Tumor Necrosis Factor|IFN-G/L-PAM/TNF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106670>	C100110	CDISC Questionnaire SGRQ-C Test Name Terminology|QS-SGRQ-C TEST|SGRQC1TN|St. George's Respiratory Questionnaire for COPD Patients Questionnaire Test Name	Test names of questionnaire questions associated with the St.George's Respiratory Questionnaire for COPD Patients (SGRQ-C) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106671>	C100110	CDISC Questionnaire SGRQ-C Test Code Terminology|QS-SGRQ-C TESTCD|SGRQC1TC|St. George's Respiratory Questionnaire for COPD Patients Questionnaire Test Code	Test codes of questionnaire questions associated with the St.George's Respiratory Questionnaire for COPD Patients (SGRQ-C) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106672>	C211913	ADCS-ADL MCI Questionnaire Question	A question associated with the ADCS-ADL MCI questionnaire.			Intellectual Product	
C106673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106673>	C211913	ADCS-ADL Severe Dementia Questionnaire Question	A question associated with the ADCS-ADL Severe Dementia questionnaire.			Intellectual Product	
C106674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106674>	C211913	BDI Clinical Classification Question	A question associated with the BDI questionnaire.			Intellectual Product	
C106675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106675>	C211913	TDI Clinical Classification Question	A question associated with the TDI questionnaire.			Intellectual Product	
C106676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106676>	C211913	C-SSRS Already Enrolled Subjects Questionnaire Question	A question associated with the C-SSRS Already Enrolled Subjects questionnaire.			Intellectual Product	
C106677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106677>	C211913	C-SSRS Baseline/Screening Version Questionnaire Question	A question associated with the C-SSRS Baseline/Screening Version questionnaire.			Intellectual Product	
C106678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106678>	C211913	GDS Questionnaire Question	A question associated with the GDS questionnaire.			Intellectual Product	
C106679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106679>	C211913	Geriatric Depression Scale Short Form Questionnaire Question|GDS-SF Questionnaire Question	A question associated with the Geriatric Depression Scale Short Form questionnaire.			Intellectual Product	
C10667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10667>	C61063	Altretamine/Paclitaxel|HMM/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106680>	C211913	HAQ-DI Questionnaire Question	A question associated with the HAQ-DI questionnaire.			Intellectual Product	
C106681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106681>	C211913	MMRC Questionnaire Question	A question associated with the MMRC questionnaire.			Intellectual Product	
C106682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106682>	C211913	SGRQ-C Questionnaire Question	A question associated with the SGRQ-C questionnaire.			Intellectual Product	
C106683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106683>	C27993	Time-Consuming|Time-consuming	Requiring a great amount of time.			Qualitative Concept	
C106684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106684>	C176426|C173458	Sitting and Reading Question|Sitting and Reading|Sitting and reading	A question about an individual's likelihood of dozing while sitting and reading.			Intellectual Product	Epworth Sleepiness Scale Questionnaire
C106685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106685>	C173458	Watching TV Question|Watching TV|Watching TV	A question about an individual's activity of watching television.			Intellectual Product	Epworth Sleepiness Scale Questionnaire
C106686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106686>	C173458	Sitting Inactive in Public Place Question|Sitting Inactive in Public Place|Sitting inactive in a public place	A question about an individual's likelihood of dozing while sitting inactive in a public place.			Intellectual Product	Epworth Sleepiness Scale Questionnaire
C106687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106687>	C91103	Passenger in Car for Hour without Break Question|As a passenger in a car for an hour without a break|Passenger in Car for Hour without Break	A question about an individual's likelihood of dozing while being a passenger in a car for an hour without a break.			Intellectual Product	Epworth Sleepiness Scale Questionnaire
C106688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106688>	C91103	Lying Down for Afternoon Rest when Circumstances Permit Question|Lying Down for Afternoon Rest when Circumstances Permit|Lying down to rest in the afternoon when circumstances permit	A question about an individual's likelihood of dozing when lying down to rest in the afternoon when circumstances permit.			Intellectual Product	Epworth Sleepiness Scale Questionnaire
C106689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106689>	C173458	Sitting and Talking to Someone Question|Sitting and Talking to Someone|Sitting and talking to someone	A question about an individual's likelihood of dozing while sitting and talking to someone.			Intellectual Product	Epworth Sleepiness Scale Questionnaire
C10668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10668>	C61063	Carboplatin/Cisplatin/Paclitaxel|CBDCA/CDDP/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106690>	C173458	Sitting Quietly after Lunch without Alcohol Question|Sitting Quietly after Lunch without Alcohol|Sitting quietly after a lunch without alcohol	A question about an individual's likelihood of dozing while sitting quietly after a lunch without alcohol.			Intellectual Product	Epworth Sleepiness Scale Questionnaire
C106691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106691>	C91103	Stopped in Car for Few Minutes in Traffic Question|In a car, while stopped for a few minutes in traffic|Stopped in Car for Few Minutes in Traffic	A question about an individual's likelihood of dosing off while being in a car stopped for a few minutes in traffic.			Intellectual Product	Epworth Sleepiness Scale Questionnaire
C106692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106692>	C173925	Doze or Fall Asleep Question|Doze Off or Fall Asleep	A question about an individual's likelihood to doze or fall asleep.			Intellectual Product	Epworth Sleepiness Scale Questionnaire
C106693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106693>	C118969	Baseline Dyspnea Index Clinical Classification|BDI|BDI|BDI01	A standardized rating scale developed by Mahler et al in 1984, which is a general scale used to measure the rating of severity of dyspnea at a single state (as baseline). The questionnaire contains 3 categories of 24 items; functional impairment, magnitude of task and magnitude of effort. The instrument is scored on a five-grade scale for each category, where grade 0 represents very severe impairment and grade 4 represents no impairment.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106694>	C118969	Transition Dyspnea Index Clinical Classification|TDI|TDI|TDI01	A standardized rating scale developed by Mahler et al in 1984, which is a general scale used to measure the changes in dyspnea severity from the baseline as established by the Baseline Dyspnea Index (BDI). The questionnaire contains 3 categories of 24 items change in functional impairment, change in magnitude of task, change in magnitude of effort. The instrument is scored on a seven-grade scale for each category, where grade -3 represents major deterioration and grade +3 represents major improvement.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106695>	C91105	Columbia-Suicide Severity Rating Scale Already Enrolled Subjects Questionnaire|C-SSRS ALREADY ENROLLED SUBJECTS|C-SSRS Already Enrolled Subjects|CSS05	A standardized rating scale developed by Posner et al (version 1/14/09), which is used to determine the presence of suicidal ideation or behavior. The already enrolled subjects version questionnaire contains 24 items across 4 domains; suicidal ideation, intensity of ideation, suicidal behavior and actual attempts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106696>	C91105	Columbia-Suicide Severity Rating Scale Baseline/Screening Version Questionnaire|C-SSRS BASELINE/SCREENING VERSION|C-SSRS Baseline/Screening Version|CSS04	A standardized rating scale developed by Posner et al (version 1/14/09), which is used to determine the presence of suicidal ideation or behavior. The baseline/screening version questionnaire contains 23 items across 4 domains; suicidal ideation, intensity of ideation, suicidal behavior and actual attempts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106697>	C91105	Geriatric Depression Scale Questionnaire|GDS|GDS|GDS01	A standardized rating scale developed by Yesavage et al in 1983, which is a self-report assessment used to identify depression in older adults. The questionnaire contains 30 items. All questions are answered 'yes' or 'no'.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106698>	C91105	Geriatric Depression Scale Short Form Questionnaire|GDS SHORT FORM|GDS-SF|GDS02	A standardized rating scale developed by Sheikh et al in 1986, which is a shorter version derived from the original GDS and used to identify depression in older adults. The questionnaire contains 15 items. All questions are answered 'yes' or 'no'.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106699>	C91105	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale Questionnaire|HAQ-DI WITH VAS|HAQ-DI With VAS|HAQ01	A standardized questionnaire developed by James F. Fries in 1983, which is originally used to measure outcome in patients with Rheumatoid Arthritis. It has also been applied to patients with HIV/AIDS and in studies of normal aging. The HAQ-DI With VAS is a generic instrument which focuses on self-reported, patient-oriented outcome measures. The questionnaire contains 8 categories of 46 items; dressing and grooming, arising, eating, walking, hygiene, reaching, grip, and activities. A 0-3 grade scale is used, where grade 0 represents category performed without any difficulty and grade 3 represents category performed with the greatest difficulty (unable to do).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10669>	C61063	Paclitaxel/Topotecan|TAX/TOPO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1066>	C1594	Detorubicin|14-Diethoxyacetoxydaunorubicin|DETORUBICIN|Diethoxy-,2-(4-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl)-2-oxoethyl ester,(2S-cis) Acetic Acid	A semi-synthetic derivative of the anthracycline antineoplastic antibiotic daunorubicin. Detorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. Detorubicin is less toxic than daunorubicin.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C106700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106700>	C91105	Modified Medical Research Council Dyspnea Scale Questionnaire|MMRC|MMRC|MMRC01	A standardized rating scale developed by Mahler and Wells in 1988, which is a general scale used to measure the rating of dyspnea or breathlessness. The questionnaire contains 1 question and a 0-4 grade answer scale, where grade 0 represents the lowest level of dyspnea impairment perceived, and level 4 represents the greatest dyspnea impairment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106701>	C106674	BDI - Functional Impairment|BDI01-Functional Impairment|BDI01-Functional Impairment|BDI0101	Baseline Dyspnea Index (BDI) Functional impairment.			Intellectual Product	CDISC Clinical Classification BDI Test Code Terminology|CDISC Clinical Classification BDI Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106702>	C106674	BDI - Magnitude of Task|BDI01-Magnitude of Task|BDI01-Magnitude of Task|BDI0102	Baseline Dyspnea Index (BDI) Magnitude of task.			Intellectual Product	CDISC Clinical Classification BDI Test Code Terminology|CDISC Clinical Classification BDI Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106703>	C106674	BDI - Magnitude of Effort|BDI01-Magnitude of Effort|BDI01-Magnitude of Effort|BDI0103	Baseline Dyspnea Index (BDI) Magnitude of effort.			Intellectual Product	CDISC Clinical Classification BDI Test Code Terminology|CDISC Clinical Classification BDI Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106704>	C106675	TDI - Change in Functional Impairment|TDI01-Change in Functional Impairment|TDI01-Change in Functional Impairment|TDI0101	Transition Dyspnea Index (TDI) Change in functional impairment.			Intellectual Product	CDISC Clinical Classification TDI Test Code Terminology|CDISC Clinical Classification TDI Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106705>	C106675	TDI - Change in Magnitude of Task|TDI01-Change in Magnitude of Task|TDI01-Change in Magnitude of Task|TDI0102	Transition Dyspnea Index (TDI) Change in magnitude of task.			Intellectual Product	CDISC Clinical Classification TDI Test Code Terminology|CDISC Clinical Classification TDI Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106706>	C106675	TDI - Change in Magnitude of Effort|TDI01-Change in Magnitude of Effort|TDI01-Change in Magnitude of Effort|TDI0103	Transition Dyspnea Index (TDI) Change in magnitude of effort.			Intellectual Product	CDISC Clinical Classification TDI Test Code Terminology|CDISC Clinical Classification TDI Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106707>	C106677	C-SSRS Baseline/Screening Version - Wish to be Dead (Lifetime)|CSS04-Wish to be Dead-Life|CSS04-Wish to be Dead-Life|CSS0401A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Have you wished you were dead or wished you could go to sleep and not wake up? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106708>	C106677	C-SSRS Baseline/Screening Version - Wish to be Dead (Past X Months)|CSS04-Wish to be Dead-P_M|CSS04-Wish to be Dead-P_M|CSS0401B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Have you wished you were dead or wished you could go to sleep and not wake up? (Past X Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106709>	C106677	C-SSRS Baseline/Screening Version - Description of Wish to be Dead|CSS04-Wish to be Dead, Describe|CSS04-Wish to be Dead, Describe|CSS0401C	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Description of wishing to be dead.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10670>	C61063	Eflornithine/Piroxicam|DFMO/PXM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106710>	C106677	C-SSRS Baseline/Screening Version - Non-Specific Active Suicidal Thoughts (Lifetime)|CSS04-Non-Spec Suicid Thought-Life|CSS04-Non-Spec Suicid Thought-Life|CSS0402A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Have you actually had any thoughts of killing yourself? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106711>	C106677	C-SSRS Baseline/Screening Version - Non-Specific Active Suicidal Thoughts (Past X Months)|CSS04-Non-Spec Suicid Thought-P_M|CSS04-Non-Spec Suicid Thought-P_M|CSS0402B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Have you actually had any thoughts of killing yourself? (Past X Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106712>	C106677	C-SSRS Baseline/Screening Version - Description of Non-Specific Active Suicidal Thoughts|CSS04-Non-Spec Suicid Thought, Describe|CSS04-Non-Spec Suicid Thought, Describe|CSS0402C	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Description of non-specific active suicidal thoughts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106713>	C106677	C-SSRS Baseline/Screening Version - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act (Lifetime)|CSS04-Idea, No Intent, No Plan-Life|CSS04-Idea, No Intent, No Plan-Life|CSS0403A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Have you been thinking about how you might do this? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106714>	C106677	C-SSRS Baseline/Screening Version - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act (Past X Months)|CSS04-Idea, No Intent, No Plan-P_M|CSS04-Idea, No Intent, No Plan-P_M|CSS0403B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Have you been thinking about how you might do this? (Past X Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106715>	C106677	C-SSRS Baseline/Screening Version - Description of Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act|CSS04-Idea, No Intent, No Plan, Describe|CSS04-Idea, No Intent, No Plan, Describe|CSS0403C	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Description of active suicidal ideation with any methods (not plan) without intent to act.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106716>	C106677	C-SSRS Baseline/Screening Version - Active Suicidal Ideation with Specific Plan and Intent (Lifetime)|CSS04-Idea, Plan, Intent-Life|CSS04-Idea, Plan, Intent-Life|CSS0405A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Have you started to work out or worked out the details of how to kill yourself? Do you intent to carry out this plan? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106717>	C106677	C-SSRS Baseline/Screening Version - Active Suicidal Ideation with Specific Plan and Intent (Past X Months)|CSS04-Idea, Plan, Intent-P_M|CSS04-Idea, Plan, Intent-P_M|CSS0405B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Have you started to work out or worked out the details of how to kill yourself? Do you intent to carry out this plan? (Past X Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106718>	C106677	C-SSRS Baseline/Screening Version - Description of Active Suicidal Ideation with Specific Plan and Intent|CSS04-Idea, Plan, Intent, Describe|CSS04-Idea, Plan, Intent, Describe|CSS0405C	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Description of active suicidal ideation with specific plan and intent.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106719>	C106677	C-SSRS Baseline/Screening Version - Most Severe Ideation (Lifetime)|CSS04-Most Severe Idea-Life|CSS04-Most Severe Idea-Life|CSS0406A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Most severe ideation. (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10671>	C61063	Chlorambucil/Cladribine|2-CdA/CLB			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106720>	C106677	C-SSRS Baseline/Screening Version - Describe Most Severe Ideation (Lifetime)|CSS04-Most Severe Idea, Desc-Life|CSS04-Most Severe Idea, Desc-Life|CSS0406B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Description of most severe Ideation. (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106721>	C106677	C-SSRS Baseline/Screening Version - Most Severe Ideation (Past X Months)|CSS04-Most Severe Idea-P_M|CSS04-Most Severe Idea-P_M|CSS0406C	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Most severe ideation. (Past X Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106722>	C106677	C-SSRS Baseline/Screening Version - Describe Most Severe Ideation (Past X Months)|CSS04-Most Severe Idea, Desc-P_M|CSS04-Most Severe Idea, Desc-P_M|CSS0406D	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Description of most severe ideation. (Past X Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106723>	C106677	C-SSRS Baseline/Screening Version - Frequency of Most Severe Ideation (Lifetime)|CSS04-Most Severe Idea, Frequency-Life|CSS04-Most Severe Idea, Frequency-Life|CSS0407A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) How many times have you had these thoughts? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106724>	C106677	C-SSRS Baseline/Screening Version - Frequency of Most Severe Ideation (Past X Months)|CSS04-Most Severe Idea, Frequency-P_M|CSS04-Most Severe Idea, Frequency-P_M|CSS0407B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) How many times have you had these thoughts? (Past X Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106725>	C106677	C-SSRS Baseline/Screening Version - Duration of Most Severe Ideation (Lifetime)|CSS04-Most Severe Idea, Duration-Life|CSS04-Most Severe Idea, Duration-Life|CSS0408A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) When you have the thoughts, how long do they last? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106726>	C106677	C-SSRS Baseline/Screening Version - Duration of Most Severe Ideation (Past X Months)|CSS04-Most Severe Idea, Duration-P_M|CSS04-Most Severe Idea, Duration-P_M|CSS0408B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) When you have the thoughts, how long do they last? (Past X Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106727>	C106677	C-SSRS Baseline/Screening Version - Controllability of Most Severe Ideation (Lifetime)|CSS04-Most Severe Idea, Control-Life|CSS04-Most Severe Idea, Control-Life|CSS0409A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Could/can you stop thinking about killing yourself or wanting to die if you want to? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106728>	C106677	C-SSRS Baseline/Screening Version - Controllability of Most Severe Ideation (Past X Months)|CSS04-Most Severe Idea, Control-P_M|CSS04-Most Severe Idea, Control-P_M|CSS0409B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Could/can you stop thinking about killing yourself or wanting to die if you want to? (Past X Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106729>	C106677	C-SSRS Baseline/Screening Version - Deterrents to Most Severe Ideation (Lifetime)|CSS04-Most Severe Idea, Deterrents-Life|CSS04-Most Severe Idea, Deterrents-Life|CSS0410A				Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10672>	C61063	Hydrocortisone/Mitoxantrone|DHAD/HC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106730>	C106677	C-SSRS Baseline/Screening Version - Deterrents to Most Severe Ideation (Past X Months)|CSS04-Most Severe Idea, Deterrents-P_M|CSS04-Most Severe Idea, Deterrents-P_M|CSS0410B				Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106731>	C106677	C-SSRS Baseline/Screening Version - Reasons for Most Severe Ideation (Lifetime)|CSS04-Most Severe Idea, Reasons-Life|CSS04-Most Severe Idea, Reasons-Life|CSS0411A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) What sort of reasons did you have for thinking about wanting to die or killing yourself? Was it to end the pain or stop the way you were feeling (in other words you couldn't go on living with this pain or how you were feeling) or was it to get attention, revenge or a reaction from others? Or both? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106732>	C106677	C-SSRS Baseline/Screening Version - Reasons for Most Severe Ideation (Past X Months)|CSS04-Most Severe Idea, Reasons-P_M|CSS04-Most Severe Idea, Reasons-P_M|CSS0411B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) What sort of reasons did you have for thinking about wanting to die or killing yourself? Was it to end the pain or stop the way you were feeling (in other words you couldn't go on living with this pain or how you were feeling) or was it to get attention, revenge or a reaction from others? Or both? (Past X Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106733>	C106677	C-SSRS Baseline/Screening Version - Actual Suicide Attempt (Lifetime)|CSS04-Actual Attempt-Life|CSS04-Actual Attempt-Life|CSS0412A				Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106734>	C106677	C-SSRS Baseline/Screening Version - Actual Suicide Attempt (Past X Years)|CSS04-Actual Attempt-P_Y|CSS04-Actual Attempt-P_Y|CSS0412B				Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106735>	C106677	C-SSRS Baseline/Screening Version - Number of Actual Suicide Attempts (Lifetime)|CSS04-Number of Actual Attempts-Life|CSS04-Number of Actual Attempts-Life|CSS0413A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Total number of attempts. (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106736>	C106677	C-SSRS Baseline/Screening Version - Number of Actual Suicide Attempts (Past X Years)|CSS04-Number of Actual Attempts-P_Y|CSS04-Number of Actual Attempts-P_Y|CSS0413B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Total number of attempts. (Past X Years).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106737>	C106677	C-SSRS Baseline/Screening Version - Description of Actual Suicide Attempt|CSS04-Actual Attempt, Describe|CSS04-Actual Attempt, Describe|CSS0413C	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Description of actual attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106738>	C106677	C-SSRS Baseline/Screening Version - Non-suicidal Self-injurious Behavior (Lifetime)|CSS04-Non-suicidal Self-injur Behav-Life|CSS04-Non-suicidal Self-injur Behav-Life|CSS0414A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Has subject engage in non-suicidal self-injurious behavior? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106739>	C106677	C-SSRS Baseline/Screening Version - Non-suicidal Self-injurious Behavior (Past X Years)|CSS04-Non-suicidal Self-injur Behav-P_Y|CSS04-Non-suicidal Self-injur Behav-P_Y|CSS0414B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Has subject engage in non-suicidal self-injurious behavior? (Past X Years).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10673>	C61063	Cytarabine/Daunorubicin/Etoposide/Interleukin-3|ARA-C/DNR/IL-3/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106740>	C106677	C-SSRS Baseline/Screening Version - Interrupted Suicide Attempt (Lifetime)|CSS04-Interrupted Attempt-Life|CSS04-Interrupted Attempt-Life|CSS0415A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Has there been a time when you started to do something to end your life but someone or something stopped you before you actually did anything? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106741>	C106677	C-SSRS Baseline/Screening Version - Interrupted Suicide Attempt (Past X Years)|CSS04-Interrupted Attempt-P_Y|CSS04-Interrupted Attempt-P_Y|CSS0415B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Has there been a time when you started to do something to end your life but someone or something stopped you before you actually did anything? (Past X Years)			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106742>	C106677	C-SSRS Baseline/Screening Version - Number of Interrupted Suicide Attempts (Lifetime)|CSS04-Number of Interrupt Attempts-Life|CSS04-Number of Interrupt Attempts-Life|CSS0416A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Total number of interrupted. (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106743>	C106677	C-SSRS Baseline/Screening Version - Number of Interrupted Suicide Attempts (Past X Years)|CSS04-Number of Interrupt Attempts-P_Y|CSS04-Number of Interrupt Attempts-P_Y|CSS0416B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Total number of interrupted. (Past X Years).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106744>	C106677	C-SSRS Baseline/Screening Version - Description of Interrupted Suicide Attempt|CSS04-Interrupted Attempt, Describe|CSS04-Interrupted Attempt, Describe|CSS0416C	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Description of interrupted attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106745>	C106677	C-SSRS Baseline/Screening Version - Aborted Suicide Attempt (Lifetime)|CSS04-Aborted Attempt-Life|CSS04-Aborted Attempt-Life|CSS0417A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Has there been a time when you started to do something to try to end your life but you stopped yourself before you actually did anything? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106746>	C106677	C-SSRS Baseline/Screening Version - Aborted Suicide Attempt (Past X Years)|CSS04-Aborted Attempt-P_Y|CSS04-Aborted Attempt-P_Y|CSS0417B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Has there been a time when you started to do something to try to end your life but you stopped yourself before you actually did anything? (Past X Years).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106747>	C106677	C-SSRS Baseline/Screening Version - Number of Aborted Suicide Attempts (Lifetime)|CSS04-Number of Aborted Attempts-Life|CSS04-Number of Aborted Attempts-Life|CSS0418A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Total number of aborted. (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106748>	C106677	C-SSRS Baseline/Screening Version - Number of Aborted Suicide Attempts (Past X Years)|CSS04-Number of Aborted Attempts-P_Y|CSS04-Number of Aborted Attempts-P_Y|CSS0418B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Total number of aborted. (Past X Years).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106749>	C106677	C-SSRS Baseline/Screening Version - Description of Aborted Suicide Attempt|CSS04-Aborted Attempt, Describe|CSS04-Aborted Attempt, Describe|CSS0418C	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Description of aborted attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10674>	C61063	Cytarabine/Dexverapamil/Etoposide/Idarubicin|ARA-C/IDA/R-VPAM/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106750>	C106677	C-SSRS Baseline/Screening Version - Preparatory Acts or Behaviors Toward Suicide Attempt (Lifetime)|CSS04-Preparatory Acts/Behavior-Life|CSS04-Preparatory Acts/Behavior-Life|CSS0419A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Have you taken any steps towards making a suicide attempt or preparing to kill yourself (such as collecting pills, getting a gun, giving valuables away or writing a suicide note)? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106751>	C106677	C-SSRS Baseline/Screening Version - Preparatory Acts or Behaviors Toward Suicide Attempt (Past X Years)|CSS04-Preparatory Acts/Behavior-P_Y|CSS04-Preparatory Acts/Behavior-P_Y|CSS0419B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Have you taken any steps towards making a suicide attempt or preparing to kill yourself (such as collecting pills, getting a gun, giving valuables away or writing a suicide note)? (Past X Years).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106752>	C106677	C-SSRS Baseline/Screening Version - Description of Preparatory Acts or Behaviors Toward Suicide Attempt|CSS04-Preparatory Acts/Behav, Descr|CSS04-Preparatory Acts/Behav, Descr|CSS0419C	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Description of preparatory acts or behavior.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106753>	C106677	C-SSRS Baseline/Screening Version - Suicidal Behavior (Lifetime)|CSS04-Suicidal Behavior-Life|CSS04-Suicidal Behavior-Life|CSS0420A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Suicidal behavior was present during the assessment period? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106754>	C106677	C-SSRS Baseline/Screening Version - Suicidal Behavior (Past X Years)|CSS04-Suicidal Behavior-P_Y|CSS04-Suicidal Behavior-P_Y|CSS0420B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Suicidal behavior was present during the assessment period? (Past X Years).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106755>	C106677	C-SSRS Baseline/Screening Version - Most Recent Suicide Attempt Date|CSS04-Most Recent Attempt Date|CSS04-Most Recent Attempt Date|CSS0421A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Most recent attempt date.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106756>	C106677	C-SSRS Baseline/Screening Version - Most Recent Suicide Attempt Actual Lethality/Medical Damage|CSS04-Most Recent Attempt Damage|CSS04-Most Recent Attempt Damage|CSS0421B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Most recent attempt actual lethality/medical damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106757>	C106677	C-SSRS Baseline/Screening Version - Most Recent Suicide Attempt Potential Lethality|CSS04-Most Recent Attempt Potential|CSS04-Most Recent Attempt Potential|CSS0421C	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Most recent attempt potential lethality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106758>	C106677	C-SSRS Baseline/Screening Version - Most Lethal Suicide Attempt Date|CSS04-Most Lethal Attempt Date|CSS04-Most Lethal Attempt Date|CSS0422A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Most lethal attempt date.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106759>	C106677	C-SSRS Baseline/Screening Version - Most Lethal Suicide Attempt Actual Lethality/Medical Damage|CSS04-Most Lethal Attempt Damage|CSS04-Most Lethal Attempt Damage|CSS0422B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Most lethal attempt actual lethality/medical damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10675>	C61063	Doxorubicin/Melphalan/Methylprednisolone|DOX/L-PAM/MePRDL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106760>	C106677	C-SSRS Baseline/Screening Version - Most Lethal Suicide Attempt Potential Lethality|CSS04-Most Lethal Attempt Potential|CSS04-Most Lethal Attempt Potential|CSS0422C	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Most lethal attempt potential lethality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106761>	C106677	C-SSRS Baseline/Screening Version - First Suicide Attempt Date|CSS04-First Attempt Date|CSS04-First Attempt Date|CSS0423A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Initial/first attempt date.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106762>	C106677	C-SSRS Baseline/Screening Version - First Suicide Attempt Actual Lethality/Medical Damage|CSS04-First Attempt Damage|CSS04-First Attempt Damage|CSS0423B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Initial/first attempt actual lethality/medical damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106763>	C106677	C-SSRS Baseline/Screening Version - First Suicide Attempt Potential Lethality|CSS04-First Attempt Potential|CSS04-First Attempt Potential|CSS0423C	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Initial/first attempt potential lethality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106764>	C106678	GDS - Basically Satisfied With Life|GDS01-Satisfied With Life|GDS01-Satisfied With Life|GDS0101	Geriatric Depression Scale (GDS) Are you basically satisfied with your life?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106765>	C106678	GDS - Dropped Activities and Interests|GDS01-Dropped Activities and Interests|GDS01-Dropped Activities and Interests|GDS0102	Geriatric Depression Scale (GDS) Have you dropped many of your activities and interests?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106766>	C106678	GDS - Feel Life Is Empty|GDS01-Life Is Empty|GDS01-Life Is Empty|GDS0103	Geriatric Depression Scale (GDS) Do you feel that your life is empty?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106767>	C106678	GDS - Often Get Bored|GDS01-Bored Often|GDS01-Bored Often|GDS0104	Geriatric Depression Scale (GDS) Do you often get bored?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106768>	C106678	GDS - Hopeful About Future|GDS01-Hopeful About Future|GDS01-Hopeful About Future|GDS0105	Geriatric Depression Scale (GDS) Are you hopeful about the future?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106769>	C106678	GDS - Bothered by Thoughts|GDS01-Bothered by Thoughts|GDS01-Bothered by Thoughts|GDS0106	Geriatric Depression Scale (GDS) Are you bothered by thoughts you can't get out of your head?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10676>	C61007	Melphalan/Methylprednisolone|L-PAM/MePRDL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106770>	C106678	GDS - Good Spirits Most of Time|GDS01-Good Spirits Most of Time|GDS01-Good Spirits Most of Time|GDS0107	Geriatric Depression Scale (GDS) Are you in good spirits most of the time?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106771>	C106678	GDS - Afraid of Something Bad Happening|GDS01-Afraid of Something Bad Happening|GDS01-Afraid of Something Bad Happening|GDS0108	Geriatric Depression Scale (GDS) Are you afraid that something bad is going to happen to you?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106772>	C106678	GDS - Feel Happy Most of Time|GDS01-Feel Happy Most of Time|GDS01-Feel Happy Most of Time|GDS0109	Geriatric Depression Scale (GDS) Do you feel happy most of the time?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106773>	C106678	GDS - Often Feel Helpless|GDS01-Often Feel Helpless|GDS01-Often Feel Helpless|GDS0110	Geriatric Depression Scale (GDS) Do you often feel helpless?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106774>	C106678	GDS - Get Restless and Fidgety|GDS01-Get Restless and Fidgety|GDS01-Get Restless and Fidgety|GDS0111	Geriatric Depression Scale (GDS) Do you often get restless and fidgety?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106775>	C106678	GDS - Prefer to Stay Home|GDS01-Prefer to Stay Home|GDS01-Prefer to Stay Home|GDS0112	Geriatric Depression Scale (GDS) Do you prefer to stay at home, rather than going out and doing new things?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106776>	C106678	GDS - Frequently Worry About Future|GDS01-Worry About Future|GDS01-Worry About Future|GDS0113	Geriatric Depression Scale (GDS) Do you frequently worry about the future?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106777>	C106678	GDS - More Memory Problems Than Most|GDS01-Memory Problems|GDS01-Memory Problems|GDS0114	Geriatric Depression Scale (GDS) Do you feel you have more problems with memory than most?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106778>	C106678	GDS - Think Wonderful to Be Alive|GDS01-Wonderful to Be Alive|GDS01-Wonderful to Be Alive|GDS0115	Geriatric Depression Scale (GDS) Do you think it is wonderful to be alive now?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106779>	C106678	GDS - Feel Downhearted and Blue|GDS01-Feel Downhearted and Blue|GDS01-Feel Downhearted and Blue|GDS0116	Geriatric Depression Scale (GDS) Do you often feel downhearted and blue?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10677>	C61007	Cytarabine/Mercaptopurine|ARA-C/MP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106780>	C106678	GDS - Feel Worthless|GDS01-Feel Worthless|GDS01-Feel Worthless|GDS0117	Geriatric Depression Scale (GDS) Do you feel pretty worthless the way you are now?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106781>	C106678	GDS - Worry About the Past|GDS01-Worry About the Past|GDS01-Worry About the Past|GDS0118	Geriatric Depression Scale (GDS) Do you worry a lot about the past?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106782>	C106678	GDS - Find Life Exciting|GDS01-Find Life Exciting|GDS01-Find Life Exciting|GDS0119	Geriatric Depression Scale (GDS) Do you find life very exciting?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106783>	C106678	GDS - Hard to Start New Projects|GDS01-Hard to Start New Projects|GDS01-Hard to Start New Projects|GDS0120	Geriatric Depression Scale (GDS) Is it hard for you to get started on new projects?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106784>	C106678	GDS - Feel Full of Energy|GDS01-Feel Full of Energy|GDS01-Feel Full of Energy|GDS0121	Geriatric Depression Scale (GDS) Do you feel full of energy?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106785>	C106678	GDS - Feel Situation Is Hopeless|GDS01-Feel Hopeless|GDS01-Feel Hopeless|GDS0122	Geriatric Depression Scale (GDS) Do you feel that your situation is hopeless?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106786>	C106678	GDS - Think Most People Better Off Than You|GDS01-Most People Better Off Than You|GDS01-Most People Better Off Than You|GDS0123	Geriatric Depression Scale (GDS) Do you think that most people are better off than you are?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106787>	C106678	GDS - Often Upset Over Little Things|GDS01-Often Upset Over Little Things|GDS01-Often Upset Over Little Things|GDS0124	Geriatric Depression Scale (GDS) Do you frequently get upset over little things?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106788>	C106678	GDS - Frequently Feel Like Crying|GDS01-Frequently Feel Like Crying|GDS01-Frequently Feel Like Crying|GDS0125	Geriatric Depression Scale (GDS) Do you frequently feel like crying?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106789>	C106678	GDS - Have Trouble Concentrating|GDS01-Trouble Concentrating|GDS01-Trouble Concentrating|GDS0126	Geriatric Depression Scale (GDS) Do you have trouble concentrating?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10678>	C61063	Cyclosporine/Vinblastine|CYSP/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106790>	C106678	GDS - Enjoy Getting Up in the Morning|GDS01-Enjoy Getting Up in the Morning|GDS01-Enjoy Getting Up in the Morning|GDS0127	Geriatric Depression Scale (GDS) Do you enjoy getting up in the morning?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106791>	C106678	GDS - Prefer to Avoid Social Gatherings|GDS01-Avoid Social Gatherings|GDS01-Avoid Social Gatherings|GDS0128	Geriatric Depression Scale (GDS) Do you prefer to avoid social gatherings?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106792>	C106678	GDS - Easy to Make Decisions|GDS01-Easy to Make Decisions|GDS01-Easy to Make Decisions|GDS0129	Geriatric Depression Scale (GDS) Is it easy for you to make decisions?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106793>	C106678	GDS - Mind as Clear as It Used to Be|GDS01-Mind as Clear as It Used to Be|GDS01-Mind as Clear as It Used to Be|GDS0130	Geriatric Depression Scale (GDS) Is your mind as clear as it used to be?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106794>	C106679	GDS-SF - Basically Satisfied With Life|GDS02-Satisfied With Life|GDS02-Satisfied With Life|GDS0201	Geriatric Depression Scale, Short Form (GDS-SF) Are you basically satisfied with your life?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS-SF Test Code Terminology|CDISC Questionnaire GDS-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106795>	C106679	GDS-SF - Dropped Activities and Interests|GDS02-Dropped Activities and Interests|GDS02-Dropped Activities and Interests|GDS0202	Geriatric Depression Scale, Short Form (GDS-SF) Have you dropped many of your activities and interests?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS-SF Test Code Terminology|CDISC Questionnaire GDS-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106796>	C106679	GDS-SF - Feel Life Is Empty|GDS02-Life Is Empty|GDS02-Life Is Empty|GDS0203	Geriatric Depression Scale, Short Form (GDS-SF) Do you feel that your life is empty?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS-SF Test Code Terminology|CDISC Questionnaire GDS-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106797>	C106679	GDS-SF - Often Get Bored|GDS02-Bored Often|GDS02-Bored Often|GDS0204	Geriatric Depression Scale, Short Form (GDS-SF) Do you often get bored?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS-SF Test Code Terminology|CDISC Questionnaire GDS-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106798>	C106679	GDS-SF - Good Spirits Most of Time|GDS02-Good Spirits Most of Time|GDS02-Good Spirits Most of Time|GDS0205	Geriatric Depression Scale, Short Form (GDS-SF) Are you in good spirits most of the time?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS-SF Test Code Terminology|CDISC Questionnaire GDS-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106799>	C106679	GDS-SF - Afraid of Something Bad Happening|GDS02-Afraid of Something Bad Happening|GDS02-Afraid of Something Bad Happening|GDS0206	Geriatric Depression Scale, Short Form (GDS-SF) Are you afraid that something bad is going to happen to you?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS-SF Test Code Terminology|CDISC Questionnaire GDS-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10679>	C61063	Tamoxifen/Vinblastine|TMX/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1067>	C521	Dexamethasone Acetate, Unspecified|DEXAMETHASONE ACETATE, UNSPECIFIED FORM|Dalalone DP|Dalalone LA|Decadron LA|Dexamethasone Acetate|Dexamethasone acetate|Dexasone LA|Solurex LA	The acetate salt form of Dexamethasone, a synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)	Dexamethasone Acetate		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C106800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106800>	C106679	GDS-SF - Feel Happy Most of Time|GDS02-Feel Happy Most of Time|GDS02-Feel Happy Most of Time|GDS0207	Geriatric Depression Scale, Short Form (GDS-SF) Do you feel happy most of the time?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS-SF Test Code Terminology|CDISC Questionnaire GDS-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106801>	C106679	GDS-SF - Often Feel Helpless|GDS02-Often Feel Helpless|GDS02-Often Feel Helpless|GDS0208	Geriatric Depression Scale, Short Form (GDS-SF) Do you often feel helpless?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS-SF Test Code Terminology|CDISC Questionnaire GDS-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106802>	C106679	GDS-SF - Prefer to Stay Home|GDS02-Prefer to Stay Home|GDS02-Prefer to Stay Home|GDS0209	Geriatric Depression Scale, Short Form (GDS-SF) Do you prefer to stay at home, rather than going out and doing new things?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS-SF Test Code Terminology|CDISC Questionnaire GDS-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106803>	C106679	GDS-SF - More Memory Problems Than Most|GDS02-Memory Problems|GDS02-Memory Problems|GDS0210	Geriatric Depression Scale, Short Form (GDS-SF) Do you feel you have more problems with memory than most?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS-SF Test Code Terminology|CDISC Questionnaire GDS-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106804>	C106679	GDS-SF - Think Wonderful to Be Alive|GDS02-Wonderful to Be Alive|GDS02-Wonderful to Be Alive|GDS0211	Geriatric Depression Scale, Short Form (GDS-SF) Do you think it is wonderful to be alive now?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS-SF Test Code Terminology|CDISC Questionnaire GDS-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106805>	C106679	GDS-SF - Feel Worthless|GDS02-Feel Worthless|GDS02-Feel Worthless|GDS0212	Geriatric Depression Scale, Short Form (GDS-SF) Do you feel pretty worthless the way you are now?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS-SF Test Code Terminology|CDISC Questionnaire GDS-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106806>	C106679	GDS-SF - Feel Full of Energy|GDS02-Feel Full of Energy|GDS02-Feel Full of Energy|GDS0213	Geriatric Depression Scale, Short Form (GDS-SF) Do you feel full of energy?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS-SF Test Code Terminology|CDISC Questionnaire GDS-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106807>	C106679	GDS-SF - Feel Situation is Hopeless|GDS02-Feel Hopeless|GDS02-Feel Hopeless|GDS0214	Geriatric Depression Scale, Short Form (GDS-SF) Do you feel that your situation is hopeless?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS-SF Test Code Terminology|CDISC Questionnaire GDS-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106808>	C106679	GDS-SF - Think Most People Better Off Than You|GDS02-Most People Better Off Than You|GDS02-Most People Better Off Than You|GDS0215	Geriatric Depression Scale, Short Form (GDS-SF) Do you think that most people are better off than you are?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS-SF Test Code Terminology|CDISC Questionnaire GDS-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106809>	C106680	HAQ-DI With VAS - Able to Dress Yourself|HAQ01-Dress Yourself|HAQ01-Dress Yourself|HAQ0101	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Dressing and grooming: are you able to dress yourself, including tying shoelaces and doing buttons?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10680>	C61063	Asparaginase/Cyclophosphamide/Cytarabine/Daunorubicin/Doxorubicin/Mercaptopurine/Vincristine|ARA-C/ASP/CTX/DNR/DOX/MP/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106810>	C106680	HAQ-DI With VAS - Able to Shampoo Hair|HAQ01-Shampoo Your Hair|HAQ01-Shampoo Your Hair|HAQ0102	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Dressing and grooming: are you able to shampoo your hair?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106811>	C106680	HAQ-DI With VAS - Able to Stand Up From Chair|HAQ01-Stand Up From a Straight Chair|HAQ01-Stand Up From a Straight Chair|HAQ0103	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Arising: are you able to stand up from a straight chair?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106812>	C106680	HAQ-DI With VAS - Able to Get In and Out of Bed|HAQ01-Get In and Out of Bed|HAQ01-Get In and Out of Bed|HAQ0104	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Arising: are you able to get in and out of bed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106813>	C106680	HAQ-DI With VAS - Able to Cut Meat|HAQ01-Cut Your Meat|HAQ01-Cut Your Meat|HAQ0105	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Eating: are you able to cut your meat?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106814>	C106680	HAQ-DI With VAS - Able to Lift Cup or Glass to Mouth|HAQ01-Lift a Full Cup or Glass to Mouth|HAQ01-Lift a Full Cup or Glass to Mouth|HAQ0106	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Eating: are you able to lift a full cup or glass to your mouth?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106815>	C106680	HAQ-DI With VAS - Able to Open Milk Carton|HAQ01-Open a New Milk Carton|HAQ01-Open a New Milk Carton|HAQ0107	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Eating: are you able to open a new milk carton?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106816>	C106680	HAQ-DI With VAS - Able to Walk Outdoors On Flat Ground|HAQ01-Walk Outdoors on Flat Ground|HAQ01-Walk Outdoors on Flat Ground|HAQ0108	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Walking: are you able to walk outdoors on flat ground?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106817>	C106680	HAQ-DI With VAS - Able to Climb Up Steps|HAQ01-Climb Up Five Steps|HAQ01-Climb Up Five Steps|HAQ0109	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Walking: are you able to climb up five steps?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106818>	C106680	HAQ-DI With VAS - Aids or Devices - Cane|HAQ01-Aid: Cane|HAQ01-Aid: Cane|HAQ0110	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Cane.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106819>	C106680	HAQ-DI With VAS - Aids or Devices - Walker|HAQ01-Aid: Walker|HAQ01-Aid: Walker|HAQ0111	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Walker.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10681>	C61063	Asparaginase/Cyclophosphamide/Cytarabine/Daunorubicin/Mercaptopurine/Methotrexate/Vincristine|ARA-C/ASP/CTX/DNR/MP/MTX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106820>	C106680	HAQ-DI With VAS - Aids or Devices - Crutches|HAQ01-Aid: Crutches|HAQ01-Aid: Crutches|HAQ0112	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Crutches.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106821>	C106680	HAQ-DI With VAS - Aids or Devices - Wheelchair|HAQ01-Aid: Wheelchair|HAQ01-Aid: Wheelchair|HAQ0113	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Wheelchair.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106822>	C106680	HAQ-DI With VAS - Aids or Devices - Used For Dressing|HAQ01-Aid: Devices Used for Dressing|HAQ01-Aid: Devices Used for Dressing|HAQ0114	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Devices used for dressing (button hook, zipper pull, long-handled shoe horn, etc.).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106823>	C106680	HAQ-DI With VAS - Aids or Devices - Built Up or Special Utensils|HAQ01-Aid: Built Up or Special Utensils|HAQ01-Aid: Built Up or Special Utensils|HAQ0115	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Built up or special utensils.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106824>	C106680	HAQ-DI With VAS - Aids or Devices - Special or Built Up Chair|HAQ01-Aid: Special or Built Up Chair|HAQ01-Aid: Special or Built Up Chair|HAQ0116	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Special or built up chair.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106825>	C106680	HAQ-DI With VAS - Aids or Devices For Dress/Arising/Eat/Walk-Other|HAQ01-Othr Aid (Dress/Arising/Eat/Walk)|HAQ01-Othr Aid (Dress/Arising/Eat/Walk)|HAQ0117	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Other (for dressing and grooming, arising, eating and walking).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106826>	C106680	HAQ-DI With VAS - Aids or Devices For Dress/Arising/Eat/Walk-Specify|HAQ01-Spec Aid (Dress/Arising/Eat/Walk)|HAQ01-Spec Aid (Dress/Arising/Eat/Walk)|HAQ0118	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Specify (for dressing and grooming, arising, eating and walking).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106827>	C106680	HAQ-DI With VAS - Help From Another Person - Dressing and Grooming|HAQ01-Help: Dressing and Grooming|HAQ01-Help: Dressing and Grooming|HAQ0119	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Categories usually need help from another person - Dressing and grooming.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106828>	C106680	HAQ-DI With VAS - Help From Another Person - Arising|HAQ01-Help: Arising|HAQ01-Help: Arising|HAQ0120	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Categories usually need help from another person - Arising.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106829>	C106680	HAQ-DI With VAS - Help From Another Person - Eating|HAQ01-Help: Eating|HAQ01-Help: Eating|HAQ0121	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Categories usually need help from another person - Eating.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10682>	C61063	Asparaginase/Daunorubicin/Dexamethasone/Ifosfamide/Mercaptopurine/Methotrexate/Vindesine|ASP/DAVA/DM/DNR/IFF/MP/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106830>	C106680	HAQ-DI With VAS - Help From Another Person - Walking|HAQ01-Help: Walking|HAQ01-Help: Walking|HAQ0122	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Categories usually need help from another person - Walking.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106831>	C106680	HAQ-DI With VAS - Able to Wash and Dry Body|HAQ01-Wash and Dry Your Body|HAQ01-Wash and Dry Your Body|HAQ0123	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Hygiene: are you able to wash and dry your body?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106832>	C106680	HAQ-DI With VAS - Able to Take Tub Bath|HAQ01-Take a Tub Bath|HAQ01-Take a Tub Bath|HAQ0124	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Hygiene: are you able to take a tub bath?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106833>	C106680	HAQ-DI With VAS - Able to Get On and Off Toilet|HAQ01-Get On and Off The Toilet|HAQ01-Get On and Off The Toilet|HAQ0125	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Hygiene: are you able to get on and off the toilet?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106834>	C106680	HAQ-DI With VAS - Able to Reach and Get Down Object From Above Head|HAQ01-Reach-Get Down 5 Lb Obj Above Head|HAQ01-Reach-Get Down 5 Lb Obj Above Head|HAQ0126	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Reach: are you able to reach and get down a 5 pound object (such as a bag of sugar) from just above your head?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106835>	C106680	HAQ-DI With VAS - Able to Bend Down and Pick Up Clothing From Floor|HAQ01-Bend Down Pick Up Clothing - Floor|HAQ01-Bend Down Pick Up Clothing - Floor|HAQ0127	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Reach: are you able to bend down and pick up clothing from the floor?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106836>	C106680	HAQ-DI With VAS - Able to Open Car Doors|HAQ01-Open Car Doors|HAQ01-Open Car Doors|HAQ0128	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Grip: are you able to open car doors?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106837>	C106680	HAQ-DI With VAS - Able to Open Previously Opened Jars|HAQ01-Open Jars Previously Opened|HAQ01-Open Jars Previously Opened|HAQ0129	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Grip: are you able to open jars which have been previously opened?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106838>	C106680	HAQ-DI With VAS - Able to Turn Faucets On and Off|HAQ01-Turn Faucets On And Off|HAQ01-Turn Faucets On And Off|HAQ0130	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Grip: are you able to turn faucets on and off?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106839>	C106680	HAQ-DI With VAS - Able to Run Errands and Shop|HAQ01-Run Errands and Shop|HAQ01-Run Errands and Shop|HAQ0131	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Activities: are you able to run errands and shop?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10683>	C61007	Asparaginase/Cytarabine/Dexamethasone/Etoposide|ARA-C/ASP/DM/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106840>	C106680	HAQ-DI With VAS - Able to Get In and Out of Car|HAQ01-Get In and Out of a Car|HAQ01-Get In and Out of a Car|HAQ0132	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Activities: are you able to get in and out of a car?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106841>	C106680	HAQ-DI With VAS - Able to Do Chores - Vacuuming or Yardwork|HAQ01-Able to Do Chores|HAQ01-Able to Do Chores|HAQ0133	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Activities: are you able to do chores such as vacuuming or yardwork?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106842>	C106680	HAQ-DI With VAS - Aids or Devices - Raised Toilet Seat|HAQ01-Aid: Raised Toilet Seat|HAQ01-Aid: Raised Toilet Seat|HAQ0134	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Raised toilet seat.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106843>	C106680	HAQ-DI With VAS - Aids or Devices - Bathtub Seat|HAQ01-Aid: Bathtub Seat|HAQ01-Aid: Bathtub Seat|HAQ0135	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Bathtub seat.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106844>	C106680	HAQ-DI With VAS - Aids or Devices - Bathtub Bar|HAQ01-Aid: Bathtub Bar|HAQ01-Aid: Bathtub Bar|HAQ0137	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Bathtub bar.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106845>	C106680	HAQ-DI With VAS - Aids or Devices - Long-Handled Appliances for Reach|HAQ01-Aid: Long-Handled Appl Reach|HAQ01-Aid: Long-Handled Appl Reach|HAQ0138	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Long-handled appliances for reach.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106846>	C106680	HAQ-DI With VAS - Aids or Devices - Long-Handled Appliances in Bathroom|HAQ01-Aid: Long-Handled Appl Bathroom|HAQ01-Aid: Long-Handled Appl Bathroom|HAQ0139	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Long-handled appliances in bathroom.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106847>	C106680	HAQ-DI With VAS - Help From Another Person - Hygiene|HAQ01-Help: Hygiene|HAQ01-Help: Hygiene|HAQ0142	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Categories usually need help from another person - Hygiene.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106848>	C106680	HAQ-DI With VAS - Help From Another Person - Reach|HAQ01-Help: Reach|HAQ01-Help: Reach|HAQ0143	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Categories usually need help from another person - Reach.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106849>	C106680	HAQ-DI With VAS - Help From Another Person - Gripping and Opening Things|HAQ01-Help: Gripping and Opening Things|HAQ01-Help: Gripping and Opening Things|HAQ0144	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Categories usually need help from another person - Gripping and opening things.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10684>	C61063	Dactinomycin/Doxorubicin/Etoposide/Ifosfamide/Vincristine|DACT/DOX/IFF/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106850>	C106680	HAQ-DI With VAS - Help From Another Person - Errands and Chores|HAQ01-Help: Errands and Chores|HAQ01-Help: Errands and Chores|HAQ0145	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) Categories usually need help from another person - Errands and chores.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106851>	C106680	HAQ-DI With VAS - Severity of Pain in the Past Week|HAQ01-Severity of Pain|HAQ01-Severity of Pain|HAQ0146	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) How much pain have you had because of your illness in the past week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106852>	C106681	MMRC - Description of Level of Breathlessness|MMRC01-Description of Breathlessness|MMRC01-Description of Breathlessness|MMRC0101				Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MMRC Test Code Terminology|CDISC Questionnaire MMRC Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106853>	C106682	SGRQ-C - Description of Your Current Health|SGRQC1-Describe Your Current Health|SGRQC1-Describe Your Current Health|SGRQC101	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Before completing the rest of the questionnaire: please check one box to show how you describe your current health.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106854>	C106682	SGRQ-C - Cough|SGRQC1-I Cough|SGRQC1-I Cough|SGRQC102	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Please check one box for each question: I cough.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106855>	C106682	SGRQ-C - Bring Up Phlegm|SGRQC1-I Bring Up Phlegm|SGRQC1-I Bring Up Phlegm|SGRQC103	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Please check one box for each question: I bring up phlegm (sputum).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106856>	C106682	SGRQ-C - Have Shortness of Breath|SGRQC1-I Have Shortness of Breath|SGRQC1-I Have Shortness of Breath|SGRQC104	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Please check one box for each question: I have shortness of breath.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106857>	C106682	SGRQ-C - Have Attacks of Wheezing|SGRQC1-I Have Attacks of Wheezing|SGRQC1-I Have Attacks of Wheezing|SGRQC105	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Please check one box for each question: I have attacks of wheezing.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106858>	C106682	SGRQ-C - Number of Respiratory Attacks Last Year|SGRQC1-How Many Respiratory Attacks|SGRQC1-How Many Respiratory Attacks|SGRQC106	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Please check one box for each question: How many respiratory attacks did you have during the last year?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106859>	C106682	SGRQ-C - Good Days with Few Respiratory Problems|SGRQC1-How Often Do You Have Good Days|SGRQC1-How Often Do You Have Good Days|SGRQC107	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Please check one box for each question: How often do you have good days (with few respiratory problems)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10685>	C61063	Cytarabine/Idarubicin/Teniposide|ARA-C/IDA/VM-26			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106860>	C106682	SGRQ-C - Wheezing Worse In the Morning|SGRQC1-Wheeze Worse in the Morning|SGRQC1-Wheeze Worse in the Morning|SGRQC108	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Please check one box for each question: If you wheeze, is it worse when you get up in the morning?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106861>	C106682	SGRQ-C - Description of Your Respiratory Problems|SGRQC1-Describe Your Resp Problems|SGRQC1-Describe Your Resp Problems|SGRQC109	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) How would you describe your respiratory problems?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106862>	C106682	SGRQ-C - Feel Breathless Washing or Dressing Yourself|SGRQC1-Washing or Dressing Yourself|SGRQC1-Washing or Dressing Yourself|SGRQC110	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Questions about what activities usually make you feel breathless: Washing or dressing yourself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106863>	C106682	SGRQ-C - Feel Breathless Walking Around the House|SGRQC1-Walking Around the House|SGRQC1-Walking Around the House|SGRQC111	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Questions about what activities usually make you feel breathless: Walking around the house.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106864>	C106682	SGRQ-C - Feel Breathless Walking Outside on Level Ground|SGRQC1-Walking Outside on Level Ground|SGRQC1-Walking Outside on Level Ground|SGRQC112	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Questions about what activities usually make you feel breathless: Walking outside on level ground.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106865>	C106682	SGRQ-C - Feel Breathless Walking Up a Flight of Stairs|SGRQC1-Walking Up a Flight of Stairs|SGRQC1-Walking Up a Flight of Stairs|SGRQC113	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Questions about what activities usually make you feel breathless: Walking up a flight of stairs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106866>	C106682	SGRQ-C - Feel Breathless Walking Up Hills|SGRQC1-Walking Up Hills|SGRQC1-Walking Up Hills|SGRQC114	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Questions about what activities usually make you feel breathless: Walking up hills.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106867>	C106682	SGRQ-C - Coughing Hurts|SGRQC1-Coughing Hurts|SGRQC1-Coughing Hurts|SGRQC115	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Some more questions about your cough and breathlessness: Coughing hurts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106868>	C106682	SGRQ-C - Coughing Makes Me Tired|SGRQC1-Coughing Makes Me Tired|SGRQC1-Coughing Makes Me Tired|SGRQC116	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Some more questions about your cough and breathlessness: Coughing makes me tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106869>	C106682	SGRQ-C - Short of Breath When Talk|SGRQC1-Short of Breath When Talk|SGRQC1-Short of Breath When Talk|SGRQC117	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Some more questions about your cough and breathlessness: I am short of breath when I talk.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10686>	C61063	Cyclosporine/Paclitaxel|CYSP/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106870>	C106682	SGRQ-C - Short of Breath When Bend Over|SGRQC1-Short of Breath When Bend Over|SGRQC1-Short of Breath When Bend Over|SGRQC118	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Some more questions about your cough and breathlessness: I am short of breath when I bend over.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106871>	C106682	SGRQ-C - Coughing Disturbs My Sleep|SGRQC1-Coughing Disturbs My Sleep|SGRQC1-Coughing Disturbs My Sleep|SGRQC119	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Some more questions about your cough and breathlessness: My coughing or breathing disturbs my sleep.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106872>	C106682	SGRQ-C - Get Exhausted Easily|SGRQC1-Get Exhausted Easily|SGRQC1-Get Exhausted Easily|SGRQC120	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Some more questions about your cough and breathlessness: I get exhausted easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106873>	C106682	SGRQ-C - Cough Is Embarrassing in Public|SGRQC1-Cough Is Embarrassing in Public|SGRQC1-Cough Is Embarrassing in Public|SGRQC121	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Questions about other effects that your respiratory problems may have on you: My cough or breathing is embarrassing in public.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106874>	C106682	SGRQ-C - Afraid or Panic When Cannot Catch Breath|SGRQC1-Afraid When Cannot Catch Breath|SGRQC1-Afraid When Cannot Catch Breath|SGRQC123	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Questions about other effects that your respiratory problems may have on you: I get afraid or panic when I cannot catch my breath.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106875>	C106682	SGRQ-C - Not in Control of Respiratory Problems|SGRQC1-Not in Control of Resp Problems|SGRQC1-Not in Control of Resp Problems|SGRQC124	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Questions about other effects that your respiratory problems may have on you: I feel that I am not in control of my respiratory problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106876>	C106682	SGRQ-C - Become Frail Because of Respiratory Problems|SGRQC1-Frail Because of Resp Problems|SGRQC1-Frail Because of Resp Problems|SGRQC125	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Questions about other effects that your respiratory problems may have on you: I have become frail or an invalid because of my respiratory problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106877>	C106682	SGRQ-C - Exercise Is Not Safe for Me|SGRQC1-Exercise Is Not Safe for Me|SGRQC1-Exercise Is Not Safe for Me|SGRQC126	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Questions about other effects that your respiratory problems may have on you: Exercise is not safe for me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106878>	C106682	SGRQ-C - Everything Seems Too Much Effort|SGRQC1-Everything Too Much Effort|SGRQC1-Everything Too Much Effort|SGRQC127	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Questions about other effects that your respiratory problems may have on you: Everything seems too much of an effort.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106879>	C106682	SGRQ-C - Take a Long Time to Get Washed or Dressed|SGRQC1-Take a Long Time to Get Washed|SGRQC1-Take a Long Time to Get Washed|SGRQC128	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) These are questions about how your activities might be affected by your respiratory problems: I take a long time to get washed or dressed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10687>	C61063	Dexverapamil/Paclitaxel|R-VPAM/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106880>	C106682	SGRQ-C - Cannot Take a Bath or Shower|SGRQC1-Cannot Take a Bath or Shower|SGRQC1-Cannot Take a Bath or Shower|SGRQC129	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) These are questions about how your activities might be affected by your respiratory problems: I cannot take a bath or shower, or I take a long time to do it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106881>	C106682	SGRQ-C - Walk Slower Than Other People My Age|SGRQC1-Walk Slow Than Others My Age|SGRQC1-Walk Slow Than Others My Age|SGRQC130	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) These are questions about how your activities might be affected by your respiratory problems: I walk slower than other people my age, or I stop to rest.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106882>	C106682	SGRQ-C - Jobs Take a Long Time|SGRQC1-Jobs Take a Long Time|SGRQC1-Jobs Take a Long Time|SGRQC131	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) These are questions about how your activities might be affected by your respiratory problems: Jobs such as household chores take a long time, or I have to stop to rest.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106883>	C106682	SGRQ-C - Walk Up Flight of Stairs Slowly|SGRQC1-Walk Up Flight of Stairs Slowly|SGRQC1-Walk Up Flight of Stairs Slowly|SGRQC132	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) These are questions about how your activities might be affected by your respiratory problems: If I walk up one flight of stairs, I have to go slowly or stop.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106884>	C106682	SGRQ-C - If Walk Fast Have to Stop|SGRQC1-If I Hurry, I Have to Stop|SGRQC1-If I Hurry, I Have to Stop|SGRQC133	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) These are questions about how your activities might be affected by your respiratory problems: If I hurry or walk fast, I have to stop or slow down.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106885>	C106682	SGRQ-C - Difficult to Walk Up Hills|SGRQC1-Difficult to Walk Up Hills|SGRQC1-Difficult to Walk Up Hills|SGRQC134	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) These are questions about how your activities might be affected by your respiratory problems: My breathing makes it difficult to do things such as walk up hills, carry things up stairs, light gardening such as weeding, dance, bowl or play golf.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106886>	C106682	SGRQ-C - Difficult to Carry Heavy Loads|SGRQC1-Difficult to Carry Heavy Loads|SGRQC1-Difficult to Carry Heavy Loads|SGRQC135	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) These are questions about how your activities might be affected by your respiratory problems: My breathing makes it difficult to do things such as carry heavy loads, dig in the garden or shovel snow, jog or walk briskly (5 miles per hour), play tennis or swim.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106887>	C106682	SGRQ-C - How Respiratory Problems Affect You|SGRQC1-How Resp Problems Affect You|SGRQC1-How Resp Problems Affect You|SGRQC141	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) How do your respiratory problems affect you?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106888>	C91105	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory Mild Cognitive Impairment Questionnaire|ADCS-ADL MCI|ADCS-ADL MCI|ADL03	A standardized questionnaire developed by Galasko et al in 1997 as part of the Alzheimer's disease cooperative study, which is used to measure the performance of activities of daily living by patients diagnosed with Alzheimer's disease, exhibiting evidence of mild cognitive impairment (MCI). The questionnaire contains 24 items (and a number of sub-items within the 24 main items) with a range of preset answers that are assigned points based on performance.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106889>	C91105	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory Severe Dementia Questionnaire|ADCS-ADL SEVERE DEMENTIA|ADCS-ADL Severe Dementia|ADL02	A standardized questionnaire developed by Galasko et al in 1997 as part of the Alzheimer's disease cooperative study, which is used to measure the performance of activities of daily living by patients diagnosed with advanced stage or severe Alzheimer's disease. The questionnaire contains 19 items (and a number of sub-items within the 19 main items) with a range of preset answers that are assigned points based on performance.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10688>	C61007	Ifosfamide/Paclitaxel|IFF/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106890>	C91105	St. George's Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease Patients|SGRQ-C|SGRQ-C|SGRQC1	A standardized rating scale developed by Jones et al in 1992, which is a shorter version derived from the original SGRQ, and used to measure health impairment and perceived well-being (quality of life) in patients with asthma and chronic obstructive pulmonary disease (COPD). It has also been used in patients with bronchiectasis, post tuberculosis, kyphoscoliosis and sarcoidosis. The questionnaire contains 2 parts of 14 questions. Part 1 comprises questions 1 to 7 and addresses the frequency of a subject's respiratory symptoms. Part 2 has questions 8 to 14 and addresses the patient's current state.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106891>	C106672	ADCS-ADL MCI - Find Personal Belongings|ADL03-Find Personal Belongings|ADL03-Find Personal Belongings|ADL0301	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject usually manage to find his or her personal belongings at home?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106892>	C106672	ADCS-ADL MCI - Description of Usual Performance of Finding Belongings|ADL03-Find Belongings Usual Performance|ADL03-Find Belongings Usual Performance|ADL0301A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, which best describes how he or she usually performed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106893>	C106672	ADCS-ADL MCI - Select First Clothes for the Day|ADL03-Select First Clothes for the Day|ADL03-Select First Clothes for the Day|ADL0302	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject select his or her first set of clothes for the day?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106894>	C106672	ADCS-ADL MCI - Description of Usual Performance of Selecting First Clothes for the Day|ADL03-Usual Dressing Performance|ADL03-Usual Dressing Performance|ADL0302A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, which best describes his or her usual performance.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106895>	C106672	ADCS-ADL MCI - Description of Usual Performance of Physically Getting Dressed|ADL03-Usual Physically Dressing Perform|ADL03-Usual Physically Dressing Perform|ADL0303	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Regarding physically getting dressed, which best describes his or her usual performance in the past 4 weeks.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106896>	C106672	ADCS-ADL MCI - Clean Room|ADL03-Clean Room|ADL03-Clean Room|ADL0304	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject clean a living-, sitting-, or family room?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106897>	C106672	ADCS-ADL MCI - Description of Usual Performance of Cleaning Room|ADL03-Clean Room Performance|ADL03-Clean Room Performance|ADL0304A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, which best describes how he or she usually performed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106898>	C106672	ADCS-ADL MCI - Balance Checkbook|ADL03-Balance Checkbook|ADL03-Balance Checkbook|ADL0305	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject balance his or her checkbook or a credit card statement?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106899>	C106672	ADCS-ADL MCI - Description of Usual Performance of Balancing Checkbook|ADL03-Balance Checkbook Performance|ADL03-Balance Checkbook Performance|ADL0305A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, which best describes how he or she usually performed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10689>	C61063	Etoposide/Tretinoin|ATRA/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1068>	C784|C674	Anguidine|3Alpha,4Beta, 15-triol, 12, 13-epoxy-,4, 15-diacetate (8CI)|4, 15-Diacetoxyscirpen-3-ol|4Beta, 15-diacetoxy-3alpha-hydroxy-12, 13-epoxytrichothec-9-ene|ANGUIDINE|ANGUIDINE|Anguidin|DAS|DIACETOXYSCIRPENOL|Diacetoxyscirpenol|MM 4462|Trichothec-9-ene-3, 4, 15-triol, 12, 13-epoxy-, 4, 15-diacetate (3alpha, 4beta)-(9CI)|Trichothec-9-ene-3, 4,15-triol, 12,13-epoxy-, 4,15-diacetate, (3.alpha.,4.beta.)- (9CI)|Trichothec-9-ene-3,4, 15-triol, 12,13-epoxy-, 4,15-diacetate|Trichothec-9-ene-3,4, 15-triol, 12,13-epoxy-, 4,15-diacetate|Trichothec-9-ene-3,4, 15-triol, 12,13-epoxy-, 4,15-diacetate, (3.alpha.,4.beta.)- (9CI)|Trichothec-9-ene-3,4,15-triol, 12,13-epoxy-, 4, 15-diacetate|Trichothec-9-ene-3,4,15-triol, 12,13-epoxy-, 4,15-diacetate|Trichothec-9-ene-3,4,15-triol, 12,13-epoxy-, 4,15-diacetate, (3.alpha.,4.beta.)- (9CI)	A trichothecene mycotoxin and potent teratogen. Anguidine inhibits initiation of protein synthesis, resulting in the death of rapidly proliferating cells.  Anguidine also has been shown to both potentiate and protect against the cytotoxic effects of other drugs.  (NCI04)			Hazardous or Poisonous Substance|Organic Chemical|Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C106900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106900>	C106672	ADCS-ADL MCI - Write Things Down|ADL03-Write Things Down|ADL03-Write Things Down|ADL0306	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject ever write things down?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106901>	C106672	ADCS-ADL MCI - Description of Usual Performance of Most Complicated Things Written|ADL03-Most Complicated Writings|ADL03-Most Complicated Writings|ADL0306A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, which best describes the most complicated things that he or she wrote.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106902>	C106672	ADCS-ADL MCI - Clean Laundry|ADL03-Clean Laundry|ADL03-Clean Laundry|ADL0307	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject clean a load of laundry?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106903>	C106672	ADCS-ADL MCI - Description of Usual Performance of Clean Laundry|ADL03-Laundry Cleaning Performance|ADL03-Laundry Cleaning Performance|ADL0307A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, which best describes how he or she usually performed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106904>	C106672	ADCS-ADL MCI - Keep Appointments|ADL03-Keep Appointments|ADL03-Keep Appointments|ADL0308	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject keep appointments or meetings with other people, such as relatives, a doctor, the hairdresser, etc.?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106905>	C106672	ADCS-ADL MCI - Description of Awareness of the Meeting Ahead of Time|ADL03-Aware of Appointment Ahead of Time|ADL03-Aware of Appointment Ahead of Time|ADL0308A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, which best describes his or her awareness of the meeting ahead of time.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106906>	C106672	ADCS-ADL MCI - Use a Telephone|ADL03-Use a Telephone|ADL03-Use a Telephone|ADL0309	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject use a telephone?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106907>	C106672	ADCS-ADL MCI - Description of Highest Level of Performance of Telephone Use|ADL03-Highest Telephone Use Performance|ADL03-Highest Telephone Use Performance|ADL0309A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, which best describes his or her highest level of performance.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106908>	C106672	ADCS-ADL MCI - Make a Meal or Snack|ADL03-Make a Meal|ADL03-Make a Meal|ADL0310	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject make him or herself a meal or snack at home?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106909>	C106672	ADCS-ADL MCI - Description of Highest Level of Food Preparation|ADL03-Highest Level of Food Preparation|ADL03-Highest Level of Food Preparation|ADL0310A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, which best describes his or her highest level of food preparation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10690>	C61063	Aminoglutethimide/Suramin|AGT/SUR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106910>	C106672	ADCS-ADL MCI - Travel Outside Home|ADL03-Get Around Outside Home|ADL03-Get Around Outside Home|ADL0311	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject get around (or travel) outside of his or her home?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106911>	C106672	ADCS-ADL MCI - Description of Optimal Performance of Travelling Outside Home|ADL03-Get Around Optimal Performance|ADL03-Get Around Optimal Performance|ADL0311A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, which best describes his or her optimal performance.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106912>	C106672	ADCS-ADL MCI - Talk About Current Events|ADL03-Talk About Current Events|ADL03-Talk About Current Events|ADL0312	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject talk about current events?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106913>	C106672	ADCS-ADL MCI - Talk About Regional, National or International Events|ADL03-Regional, National, International|ADL03-Regional, National, International|ADL0312A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, did subject talk about regional, national, or international events?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106914>	C106672	ADCS-ADL MCI - Talk About Outside Home Events|ADL03-Talk About Outside Events|ADL03-Talk About Outside Events|ADL0312B	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, did subject talk about events outside home involving family, friends, or neighbors?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106915>	C106672	ADCS-ADL MCI - Talk About at Home Events|ADL03-Talk About at Home Events|ADL03-Talk About at Home Events|ADL0312C	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, did subject talk about events that occurred at home that he or she took part in or watched?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106916>	C106672	ADCS-ADL MCI - Converse Without Repeating|ADL03-Talk Without Repeating|ADL03-Talk Without Repeating|ADL0312D	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, did subject converse without repeating him or herself, or asking the same questions repeatedly?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106917>	C106672	ADCS-ADL MCI - Read More Than 5 Minutes|ADL03-Read More Than 5 Minutes|ADL03-Read More Than 5 Minutes|ADL0313	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject read a magazine, newspaper or book for more than 5 minutes at a time?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106918>	C106672	ADCS-ADL MCI - Select or Ask for Something to Read|ADL03-Select/Ask for Something to Read|ADL03-Select/Ask for Something to Read|ADL0313A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, did subject usually select or ask for something to read?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106919>	C106672	ADCS-ADL MCI - Talk Within 1 Hour After Reading|ADL03-Talk Within 1 Hour After Reading|ADL03-Talk Within 1 Hour After Reading|ADL0313B	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, did subject usually talk about what he or she read while or shortly after reading (less than 1 hour)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10691>	C61063	PSC 833/Vinblastine|PSC 833/VBL|PSC/Vinblastine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106920>	C106672	ADCS-ADL MCI - Talk Within 24 Hours After Reading|ADL03-Talk Within 1 Day After Reading|ADL03-Talk Within 1 Day After Reading|ADL0313C	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, did subject usually talk about what he or she read 1-24 hours after reading?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106921>	C106672	ADCS-ADL MCI - Watch Television|ADL03-Watch Television|ADL03-Watch Television|ADL0314	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject watch television?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106922>	C106672	ADCS-ADL MCI - Select or Ask for Programs or Show|ADL03-Select Television Program|ADL03-Select Television Program|ADL0314A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, did subject usually select or ask for different programs or his or her favorite show?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106923>	C106672	ADCS-ADL MCI - Talk About Content of Program While Watching|ADL03-Talk About TV Content While Watch|ADL03-Talk About TV Content While Watch|ADL0314B	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, did subject usually talk about the content of a program while watching it?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106924>	C106672	ADCS-ADL MCI - Talk About Content of Program After Watching Within a Day|ADL03-Talk About TV Content Within a Day|ADL03-Talk About TV Content Within a Day|ADL0314C	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, did subject talk about the content of a program within a day (24 hours) after watching it?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106925>	C106672	ADCS-ADL MCI - Go Shopping At a Store|ADL03-Go Shopping|ADL03-Go Shopping|ADL0315	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject ever go shopping at a store?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106926>	C106672	ADCS-ADL MCI - Select Correct Items Without Help|ADL03-Select Items Without Help|ADL03-Select Items Without Help|ADL0315A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, did subject usually select correct items without supervision or help?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106927>	C106672	ADCS-ADL MCI - Pay for Items on His or Her Own|ADL03-Pay Items On His/Her Own|ADL03-Pay Items On His/Her Own|ADL0315B	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, did subject usually pay for items on his or her own?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106928>	C106672	ADCS-ADL MCI - Left on His or Her Own|ADL03-Left On His/Her Own|ADL03-Left On His/Her Own|ADL0316	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, was subject ever left on his or her own?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106929>	C106672	ADCS-ADL MCI - Left Away From Home Longer Than 15 Minutes|ADL03-Left Away From Home|ADL03-Left Away From Home|ADL0316A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, was subject left away from home, for 15 minutes or longer, during the day?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10692>	C61063	Cytarabine/Fludarabine/Idarubicin|ARA-C/FAMP/IDA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106930>	C106672	ADCS-ADL MCI - Left at Home Longer Than an Hour|ADL03-Left at Home for 1 Hour or Longer|ADL03-Left at Home for 1 Hour or Longer|ADL0316B	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, was subject left at home, for an hour or longer, during the day?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106931>	C106672	ADCS-ADL MCI - Left at Home Less Than an Hour|ADL03-Left at Home for Less Than 1 Hour|ADL03-Left at Home for Less Than 1 Hour|ADL0316C	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, was subject left at home, for less than 1 hour, during the day?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106932>	C106672	ADCS-ADL MCI - Use Household Appliance|ADL03-Use Household Appliance|ADL03-Use Household Appliance|ADL0317	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject use a household appliance to do chores?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106933>	C106672	ADCS-ADL MCI - Use Household Appliance: Dishwasher|ADL03-Appliance: Dishwasher|ADL03-Appliance: Dishwasher|ADL0317D	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check household appliances that apply: dishwasher.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106934>	C106672	ADCS-ADL MCI - Use Household Appliance: Power Tools|ADL03-Appliance: Power Tools|ADL03-Appliance: Power Tools|ADL0317E	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check household appliances that apply: power tool(s).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106935>	C106672	ADCS-ADL MCI - Use Household Appliance: Toaster Oven|ADL03-Appliance: Toaster Oven|ADL03-Appliance: Toaster Oven|ADL0317F	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check household appliances that apply: toaster oven.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106936>	C106672	ADCS-ADL MCI - Use Household Appliance: Range|ADL03-Appliance: Range|ADL03-Appliance: Range|ADL0317G	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check household appliances that apply: range.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106937>	C106672	ADCS-ADL MCI - Use Household Appliance: Microwave|ADL03-Appliance: Microwave|ADL03-Appliance: Microwave|ADL0317H	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check household appliances that apply: microwave.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106938>	C106672	ADCS-ADL MCI - Use Household Appliance: Food Processor|ADL03-Appliance: Food Processor|ADL03-Appliance: Food Processor|ADL0317I	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check household appliances that apply: food processor.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106939>	C106672	ADCS-ADL MCI - Use Household Appliance: Other|ADL03-Appliance: Other|ADL03-Appliance: Other|ADL0317J	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check household appliances that apply: other.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10693>	C63587	Cisplatin/Fluorouracil/Paclitaxel Regimen|CDDP/5-FU/TAX|Cisplatin-Fluorouracil-Paclitaxel|Cisplatin-Fluorouracil-Paclitaxel Regimen|Platinol/Fluorouracil/Taxol	A regimen consisting of cisplatin, fluorouracil and paclitaxel that may be used in the treatment of squamous cell carcinoma of the head and neck.			Therapeutic or Preventive Procedure	
C106940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106940>	C106672	ADCS-ADL MCI - Use Household Appliance: Other Specify|ADL03-Appliance: Other Specify|ADL03-Appliance: Other Specify|ADL0317K	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check household appliances that apply: other specify.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106941>	C106672	ADCS-ADL MCI - Description of Usual Use of Commonly Used Appliances|ADL03-Use Common Used Appliances (q17a)|ADL03-Use Common Used Appliances (q17a)|ADL0317L	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, for the 1 or 2 most commonly used appliances, which best describes how subject usually used them.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106942>	C106672	ADCS-ADL MCI - Perform Pastime, Hobby or Game|ADL03-Perform Pastime|ADL03-Perform Pastime|ADL0318	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject perform a pastime, hobby or game?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106943>	C106672	ADCS-ADL MCI - Perform Pastime, Hobby or Game: Card or Board Games|ADL03-Pastime: Card or Board Games|ADL03-Pastime: Card or Board Games|ADL0318A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check pastimes that apply: card or board games.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106944>	C106672	ADCS-ADL MCI - Perform Pastime, Hobby or Game: Bingo|ADL03-Pastime: Bingo|ADL03-Pastime: Bingo|ADL0318B	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check pastimes that apply: Bingo.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106945>	C106672	ADCS-ADL MCI - Perform Pastime, Hobby or Game: Crosswords|ADL03-Pastime: Crosswords|ADL03-Pastime: Crosswords|ADL0318C	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check pastimes that apply: crosswords.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106946>	C106672	ADCS-ADL MCI - Perform Pastime, Hobby or Game: Art|ADL03-Pastime: Art|ADL03-Pastime: Art|ADL0318D	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check pastimes that apply: art.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106947>	C106672	ADCS-ADL MCI - Perform Pastime, Hobby or Game: Musical Instrument|ADL03-Pastime: Musical Instrument|ADL03-Pastime: Musical Instrument|ADL0318E	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check pastimes that apply: musical instrument.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106948>	C106672	ADCS-ADL MCI - Perform Pastime, Hobby or Game: Knitting|ADL03-Pastime: Knitting|ADL03-Pastime: Knitting|ADL0318F	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check pastimes that apply: knitting.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106949>	C106672	ADCS-ADL MCI - Perform Pastime, Hobby or Game: Sewing|ADL03-Pastime: Sewing|ADL03-Pastime: Sewing|ADL0318G	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check pastimes that apply: sewing.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10694>	C61063	Cisplatin/Estramustine/Etoposide|CDDP/EM/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106950>	C106672	ADCS-ADL MCI - Perform Pastime, Hobby or Game: Reading|ADL03-Pastime: Reading|ADL03-Pastime: Reading|ADL0318H	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check pastimes that apply: reading.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106951>	C106672	ADCS-ADL MCI - Perform Pastime, Hobby or Game: Gardening|ADL03-Pastime: Gardening|ADL03-Pastime: Gardening|ADL0318I	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check pastimes that apply: gardening.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106952>	C106672	ADCS-ADL MCI - Perform Pastime, Hobby or Game: Golf|ADL03-Pastime: Golf|ADL03-Pastime: Golf|ADL0318J	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check pastimes that apply: golf.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106953>	C106672	ADCS-ADL MCI - Perform Pastime, Hobby or Game: Tennis|ADL03-Pastime: Tennis|ADL03-Pastime: Tennis|ADL0318K	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check pastimes that apply: tennis.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106954>	C106672	ADCS-ADL MCI - Perform Pastime, Hobby or Game: Workshop|ADL03-Pastime: Workshop|ADL03-Pastime: Workshop|ADL0318L	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check pastimes that apply: workshop.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106955>	C106672	ADCS-ADL MCI - Perform Pastime, Hobby or Game: Fishing|ADL03-Pastime: Fishing|ADL03-Pastime: Fishing|ADL0318M	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check pastimes that apply: fishing.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106956>	C106672	ADCS-ADL MCI - Perform Pastime, Hobby or Game: Other|ADL03-Pastime: Other|ADL03-Pastime: Other|ADL0318N	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check pastimes that apply: other.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106957>	C106672	ADCS-ADL MCI - Perform Pastime, Hobby or Game: Other Specify|ADL03-Pastime: Other Specify|ADL03-Pastime: Other Specify|ADL0318O	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check pastimes that apply: other specify.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106958>	C106672	ADCS-ADL MCI - Require Help to Perform Hobbies|ADL03-Hobbies Needed Help (Q18a)|ADL03-Hobbies Needed Help (Q18a)|ADL0318P	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Did subject require supervision, or help, to perform any of these hobbies?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106959>	C106672	ADCS-ADL MCI - List Hobbies Lost Ability to Perform|ADL03-Hobbies Unable to Perform (Q18b)|ADL03-Hobbies Unable to Perform (Q18b)|ADL0318Q	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) List any hobby(ies) that the subject has lost the ability to perform.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10695>	C61063	Cisplatin/Decitabine|CDDP/DAC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106960>	C106672	ADCS-ADL MCI - Drive a Car|ADL03-Drive Car|ADL03-Drive Car|ADL0319	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) In the past 4 weeks, did subject drive a car?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106961>	C106672	ADCS-ADL MCI - Description of Optimal Performance of Driving Car|ADL03-Drive Car Optimal Performance|ADL03-Drive Car Optimal Performance|ADL0319A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, which best describes his or her optimal performance.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106962>	C106672	ADCS-ADL MCI - Take Medications Regularly|ADL03-Take Medications Regularly|ADL03-Take Medications Regularly|ADL0320	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) During the past 4 weeks, did subject take his or her medications regularly?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106963>	C106672	ADCS-ADL MCI - Description of Taking Medications Regularly|ADL03-Take Medications Performance|ADL03-Take Medications Performance|ADL0320A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, was this.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106964>	C106672	ADCS-ADL MCI - Carry Through Complex Activities to Completion|ADL03-Complete Complex Activities|ADL03-Complete Complex Activities|ADL0321	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) During the past 4 weeks, did subject usually carry through complex or time-consuming activities to completion?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106965>	C106672	ADCS-ADL MCI - Description of Extent Needing Reminder|ADL03-Extent Needed Reminders|ADL03-Extent Needed Reminders|ADL0321A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, which best describes extent to which he or she needed reminders.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106966>	C106672	ADCS-ADL MCI - Initiate Complex Daily Activities|ADL03-Initiate Complex Activities|ADL03-Initiate Complex Activities|ADL0322	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) During the past 4 weeks, to what extent did subject initiate complex daily activities or projects (e.g., hobbies, travel)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106967>	C106672	ADCS-ADL MCI - Time Taken to Complete Complex Activities|ADL03-Time to Complete Complex Tasks|ADL03-Time to Complete Complex Tasks|ADL0323	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) During the past 4 weeks, how long did it usually take subject to complete complex or time-consuming tasks or activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106968>	C106672	ADCS-ADL MCI - Extenuating Circumstance|ADL03-Extenuating Circumstances|ADL03-Extenuating Circumstances|ADL0324	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Has an extenuating circumstance (such as a physical health problem, change in residence, change in support network, death of a family member, etc.) contributed to a recent alteration in the subject's activities of daily living?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106969>	C106672	ADCS-ADL MCI - Explain Extenuating Circumstance|ADL03-Explain Circumstance|ADL03-Explain Circumstance|ADL0324A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, explain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10696>	C61063	Cisplatin/Doxorubicin/Etoposide/Vincristine|CDDP/DOX/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106970>	C106672	ADCS-ADL MCI - Subscore for Items 1 to 3|ADL03-Subscore for Items 1 to 3|ADL03-Subscore for Items 1 to 3|ADL0326	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Subscore for page 1. (Range = 0-10).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106971>	C106672	ADCS-ADL MCI - Subscore for Items 4 to 7|ADL03-Subscore for Items 4 to 7|ADL03-Subscore for Items 4 to 7|ADL0327	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Subscore for page 2. (Range = 0-8).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106972>	C106672	ADCS-ADL MCI - Subscore for Items 8 to 10|ADL03-Subscore for Items 8 to 10|ADL03-Subscore for Items 8 to 10|ADL0328	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Subscore for page 3. (Range = 0-10).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106973>	C106672	ADCS-ADL MCI - Subscore for Items 11 to 12|ADL03-Subscore for Items 11 to 12d|ADL03-Subscore for Items 11 to 12d|ADL0329	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Subscore for page 4. (Range = 0-7).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106974>	C106672	ADCS-ADL MCI - Subscore for Items 13 to 14|ADL03-Subscore for Items 13 to 14c|ADL03-Subscore for Items 13 to 14c|ADL0330	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Subscore for page 5. (Range = 0-6).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106975>	C106672	ADCS-ADL MCI - Subscore for Items 15 to 16|ADL03-Subscore for Items 15 to 16c|ADL03-Subscore for Items 15 to 16c|ADL0331	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Subscore for page 6. (Range = 0-5).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106976>	C106672	ADCS-ADL MCI - Subscore for Item 17|ADL03-Subscore for Item 17|ADL03-Subscore for Item 17|ADL0332	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Subscore for page 7. (Range = 0-4).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106977>	C106672	ADCS-ADL MCI - Subscore for Item 18|ADL03-Subscore for Item 18|ADL03-Subscore for Item 18|ADL0333	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Subscore for page 8. (Range = 0-3).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106978>	C106672	ADCS-ADL MCI - ADL Total Score|ADL03-Total ADCS-ADL Score|ADL03-Total ADCS-ADL Score|ADL0334	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) ADL total score: sum the page subscores for pages 1-8 of the ADL (items 1-18). (Range = 0-53).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106979>	C106673	ADCS-ADL Severe Dementia - Description of Usual Performance of Eating|ADL02-Usual Eating Performance|ADL02-Usual Eating Performance|ADL0201	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) Regarding eating, which best describes subject's usual performance during the last 4 weeks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10697>	C61063	Carboplatin/Estramustine/Etoposide|CBDCA/EM/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106980>	C106673	ADCS-ADL Severe Dementia - Description of Optimal Performance of Walking|ADL02-Optimal Walking Performance|ADL02-Optimal Walking Performance|ADL0202	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) Regarding walking (or getting around in a wheelchair) in the past 4 weeks, which best describes subject's optimal performance?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106981>	C106673	ADCS-ADL Severe Dementia - Usual Bowel and Bladder Function at Toilet|ADL02-Usual Bowel/Bladder Function|ADL02-Usual Bowel/Bladder Function|ADL0203	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) Regarding bowel and bladder function at the toilet, which best describes subject's usual performance during the past 4 weeks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106982>	C106673	ADCS-ADL Severe Dementia - Description of Usual Performance of Bathing|ADL02-Usual Bathing Performance|ADL02-Usual Bathing Performance|ADL0204	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) Regarding bathing, in the past 4 weeks, which best describes subject's usual performance?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106983>	C106673	ADCS-ADL Severe Dementia - Description of Optimal Performance of Grooming|ADL02-Optimal Grooming Performance|ADL02-Optimal Grooming Performance|ADL0205	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) Regarding grooming, in the past 4 weeks, which best describes subject's optimal performance?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106984>	C106673	ADCS-ADL Severe Dementia - Description of Usual Performance of Physically Getting Dressed|ADL02-Usual Physically Dressing Perform|ADL02-Usual Physically Dressing Perform|ADL0206				Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106985>	C106673	ADCS-ADL Severe Dementia - Use a Telephone|ADL02-Use a Telephone|ADL02-Use a Telephone|ADL0207	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) In the past 4 weeks, did subject use a telephone?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106986>	C106673	ADCS-ADL Severe Dementia - Description of Highest Performance of Telephone Use|ADL02-Highest Telephone Use Performance|ADL02-Highest Telephone Use Performance|ADL0207A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) If yes, which best describes subject's highest level of performance.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106987>	C106673	ADCS-ADL Severe Dementia - Watch Television|ADL02-Watch Television|ADL02-Watch Television|ADL0208	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) In the past 4 weeks, did subject watch television?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106988>	C106673	ADCS-ADL Severe Dementia - Select or Ask for Television Program|ADL02-Select Television Program|ADL02-Select Television Program|ADL0208A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) If yes, did subject usually select or ask for different programs or subject's favorite show?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106989>	C106673	ADCS-ADL Severe Dementia - Talk About TV Content While Watching|ADL02-Talk About TV Content While Watch|ADL02-Talk About TV Content While Watch|ADL0208B	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) If yes, did subject usually talk about the content of a program while watching it?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10698>	C61007	Cyclophosphamide/Epirubicin|CTX/EPI			Obsolete_Concept	Therapeutic or Preventive Procedure	
C106990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106990>	C106673	ADCS-ADL Severe Dementia - Talk About TV Content Within a Day After Watching|ADL02-Talk About TV Content Within a Day|ADL02-Talk About TV Content Within a Day|ADL0208C	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) If yes, did subject talk about the content of a program within a day (24 hours) after watching it?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106991>	C106673	ADCS-ADL Severe Dementia - Pay Attention to Conversation|ADL02-Pay Attention to Conversation|ADL02-Pay Attention to Conversation|ADL0209	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) In the past 4 weeks, did subject ever appear to pay attention to conversation or small talk for at least 5 minutes?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106992>	C106673	ADCS-ADL Severe Dementia - Usual Conversation Participation|ADL02-Usual Conversation Participation|ADL02-Usual Conversation Participation|ADL0209A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) If yes, which best describes subject's usual degree of participation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106993>	C106673	ADCS-ADL Severe Dementia - Clear Dishes After Meal or Snack|ADL02-Clear Dishes|ADL02-Clear Dishes|ADL0210	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) Did subject clear the dishes from the table after a meal or snack?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106994>	C106673	ADCS-ADL Severe Dementia - Description of Usual Performance of Clearing Dishes|ADL02-Clear Dishes Usual Performance|ADL02-Clear Dishes Usual Performance|ADL0210A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) If yes, which best describes how subject usually performed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106995>	C106673	ADCS-ADL Severe Dementia - Find Personal Belongings at Home|ADL02-Find Belongings|ADL02-Find Belongings|ADL0211	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) In the past 4 weeks, did subject usually manage to find his or her personal belongings at home?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106996>	C106673	ADCS-ADL Severe Dementia - Description of Usual Performance of Finding Personal Belonging at Home|ADL02-Find Belongings Usual Performance|ADL02-Find Belongings Usual Performance|ADL0211A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) If yes, which best describes how subject usually performed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106997>	C106673	ADCS-ADL Severe Dementia - Obtain Beverage for Self|ADL02-Obtain Beverage|ADL02-Obtain Beverage|ADL0212	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) In the past 4 weeks, did subject obtain a hot or cold beverage for him or herself?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106998>	C106673	ADCS-ADL Severe Dementia - Description of Highest Performance of Obtaining Beverage|ADL02-Obtain Beverage Highest Perform|ADL02-Obtain Beverage Highest Perform|ADL0212A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) If yes, which best describes subject highest level of performance.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C106999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C106999>	C106673	ADCS-ADL Severe Dementia - Dispose of Garbage in Appropriate Place at Home|ADL02-Dispose of Garbage|ADL02-Dispose of Garbage|ADL0213	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) In the past 4 weeks, did subject dispose of garbage or litter in an appropriate place or container at home?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10699>	C61063	Epoetin Alfa/Interleukin-3|EPO/IL-3			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1069>	C45188	Dibenzo (a,l) pyrene|1,2,3,4-Dibenzopyrene|DB(a,l)P|DIBENZO(A,L)PYRENE|Dibenzo(def,p)chrysene|Dibenzo[a,l]pyrene	A yellowish-reddish, carcinogenic aromatic hydrocarbon consisting of six fused rings and produced by the incomplete combustion of organic matter. Dibenzo[a,e]pyrene is primarily found in coal gasification products, cigarette smoke and fossil fuels. This substance is used only for research purposes to induce tumorigenesis. Dibenzo[a,e]pyrene is a mutagen and is reasonably anticipated to be a human carcinogen.			Hazardous or Poisonous Substance|Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107000>	C106673	ADCS-ADL Severe Dementia - Description of Usual Performance of Garbage Disposal|ADL02-Dispose Garbage Usual Performance|ADL02-Dispose Garbage Usual Performance|ADL0213A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) If yes, which best describes how subject usually performed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107001>	C106673	ADCS-ADL Severe Dementia - Get Around Outside Home|ADL02-Get Around Outside Home|ADL02-Get Around Outside Home|ADL0214	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) In the past 4 weeks, did subject get around (or travel) outside of his or her home?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107002>	C106673	ADCS-ADL Severe Dementia - Description of Optimal Performance of Getting Around Outside of Home|ADL02-Get Around Optimal Performance|ADL02-Get Around Optimal Performance|ADL0214A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) If yes, which best describes subject subject's optimal performance.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107003>	C106673	ADCS-ADL Severe Dementia - Subject Left on Their Own|ADL02-Left On His/Her Own|ADL02-Left On His/Her Own|ADL0215	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) In the past 4 weeks, was subject ever left on his or her own?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107004>	C106673	ADCS-ADL Severe Dementia - Alone Away From Home for Fifteen Minutes or Longer|ADL02-Left Away From Home|ADL02-Left Away From Home|ADL0215A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) If yes, was subject left away from home for 15 minutes or longer during the day?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107005>	C106673	ADCS-ADL Severe Dementia - Alone at Home for One Hour or Longer|ADL02-Left at Home for 1 Hour or Longer|ADL02-Left at Home for 1 Hour or Longer|ADL0215B	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) If yes, was subject left at home for an hour or longer during the day?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107006>	C106673	ADCS-ADL Severe Dementia - Alone at Home for Less Than One Hour|ADL02-Left at Home for Less Than 1 Hour|ADL02-Left at Home for Less Than 1 Hour|ADL0215C	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) If yes, was subject left at home for less than 1 hour during the day?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107007>	C106673	ADCS-ADL Severe Dementia - Turn On Faucet to Wash Without Help|ADL02-Run Water Faucet to Wash|ADL02-Run Water Faucet to Wash|ADL0216	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) In the past 4 weeks, did subject usually run water from a faucet to wash subject's hands or face without help?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107008>	C106673	ADCS-ADL Severe Dementia - Turn Off Faucet After Wash Without Help|ADL02-Turn Off Faucet|ADL02-Turn Off Faucet|ADL0217	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) In the past 4 weeks, did subject usually turn off the faucet after finishing running water without help?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107009>	C106673	ADCS-ADL Severe Dementia - Turn On Light Without Help Entering Room|ADL02-Turn On Light|ADL02-Turn On Light|ADL0218	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) In the past 4 weeks, did subject usually turn on a light without help when entering a dark room or area?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10700>	C61063	Interleukin-2/Macrophage Colony-Stimulating Factor|IL-2/M-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107010>	C106673	ADCS-ADL Severe Dementia - Turn Off Light Without Help Leaving Room|ADL02-Turn Off Light|ADL02-Turn Off Light|ADL0219	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) In the past 4 weeks, did subject usually turn off lights without help when leaving a room or going to sleep?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107011>	C106673	ADCS-ADL Severe Dementia - Sum of Items 1-5|ADL02-Sum 1 to 5|ADL02-Sum 1 to 5|ADL0220	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) Sum of items 1-5. (Range is 0-15).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107012>	C106673	ADCS-ADL Severe Dementia - Sum of Items 6-8|ADL02-Sum 6 to 8|ADL02-Sum 6 to 8|ADL0221	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) Sum of items 6-8. (Range is 0-13).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107013>	C106673	ADCS-ADL Severe Dementia - Sum of Items 9-12|ADL02-Sum 9 to 12|ADL02-Sum 9 to 12|ADL0222	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) Sum of items 9-12. (Range is 0-12).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107014>	C106673	ADCS-ADL Severe Dementia - Sum of Items 13-15|ADL02-Sum 13 to 15|ADL02-Sum 13 to 15|ADL0223	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) Sum of items 13-15. (Range is 0-10).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107015>	C106673	ADCS-ADL Severe Dementia - Sum of Items 16-19|ADL02-Sum 16 to 19|ADL02-Sum 16 to 19|ADL0224	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) Sum of items 16-19. (Range is 0-4).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107016>	C106673	ADCS-ADL Severe Dementia - Total Score|ADL02-Total ADCS-ADL Score|ADL02-Total ADCS-ADL Score|ADL0225	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, Severe Dementia (ADCS-ADL Severe Dementia) Total score. (Range is 0-54).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Code Terminology|CDISC Questionnaire ADCS-ADL Severe Dementia Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107017>	C106677	C-SSRS Baseline/Screening Version - Active Suicidal Ideation with Some Intent to Act, without Specific Plan (Lifetime)|CSS04-Idea, Intent, No Plan-Life|CSS04-Idea, Intent, No Plan-Life|CSS0404A	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Have you had these thoughts and had some intention of acting on them? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107018>	C106677	C-SSRS Baseline/Screening Version - Active Suicidal Ideation with Some Intent to Act, without Specific Plan (Past X Months)|CSS04-Idea, Intent, No Plan-P_M|CSS04-Idea, Intent, No Plan-P_M|CSS0404B	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Have you had these thoughts and had some intention of acting on them? (Past X Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107019>	C106677	C-SSRS Baseline/Screening Version - Description of Active Suicidal Ideation with Some Intent to Act, without Specific Plan|CSS04-Idea, Intent, No Plan, Describe|CSS04-Idea, Intent, No Plan, Describe|CSS0404C	Columbia-Suicidality Severity Rating Scale Baseline/Screening Version (C-SSRS Baseline/Screening Version) Description of active suicidal ideation with some intent to act, without specific plan.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Code Terminology|CDISC Questionnaire C-SSRS Baseline/Screening Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10701>	C63468	Bicalutamide/Leuprolide Regimen|Bicalutamide and Leuprolide|Bicalutamide-Leuprolide|Bicalutamide/Leuprolide|CDX/LEUP|Casidex/Lupron	A regimen consisting of bicalutamide and leuprolide acetate that may be used in the treatment of certain types of prostate cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C107020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107020>	C106680	HAQ-DI With VAS - Aids or Devices - Jar Opener (Jars Previously Opened)|HAQ01-Aid: Jar Opener (Previously Open)|HAQ01-Aid: Jar Opener (Previously Open)|HAQ0136	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Jar opener (for jars previously opened).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107021>	C106682	SGRQ-C - Respiratory Problems a Nuisance to Family, Friends or Neighbours|SGRQC1-Respiratory Problems a Nuisance|SGRQC1-Respiratory Problems a Nuisance|SGRQC122	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Questions about other effects that your respiratory problems may have on you: My respiratory problems are a nuisance to my family, friends or neighbors.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107022>	C106682	SGRQ-C - Respiratory Problems Affect Daily Life: Cannot Play Sports|SGRQC1-Cannot Play Sports|SGRQC1-Cannot Play Sports|SGRQC136	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) We would like to know how your respiratory problems usually affect your daily life: I cannot play sports or do other physical activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107023>	C106682	SGRQ-C - Respiratory Problems Affect Daily Life: Cannot Go Out for Entertainment|SGRQC1-Cannot Go Out for Entertainment|SGRQC1-Cannot Go Out for Entertainment|SGRQC137	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) We would like to know how your respiratory problems usually affect your daily life: I cannot go out for entertainment or recreation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107024>	C106682	SGRQ-C - Respiratory Problems Affect Daily Life: Cannot Go Out to Do Shopping|SGRQC1-Cannot Go Out to Do Shopping|SGRQC1-Cannot Go Out to Do Shopping|SGRQC138	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) We would like to know how your respiratory problems usually affect your daily life: I cannot go out of the house to do the shopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107025>	C106682	SGRQ-C - Respiratory Problems Affect Daily Life: Cannot Do Household Chores|SGRQC1-Cannot Do Household Chores|SGRQC1-Cannot Do Household Chores|SGRQC139	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) We would like to know how your respiratory problems usually affect your daily life: I cannot do household chores.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107026>	C106682	SGRQ-C - Respiratory Problems Affect Daily Life: Cannot Move Far From Bed|SGRQC1-Cannot Move Far From My Bed|SGRQC1-Cannot Move Far From My Bed|SGRQC140	St. George's Respiratory Questionnaire for COPD Patients (SGRQ-C) We would like to know how your respiratory problems usually affect your daily life: I cannot move far from my bed or chair.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ-C Test Code Terminology|CDISC Questionnaire SGRQ-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107027>	C106676	C-SSRS Already Enrolled Subjects - Wish to Be Dead (Prior to Study Entry)|CSS05-Wish to be Dead-Prior|CSS05-Wish to be Dead-Prior|CSS0501A	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects) Have you wished you were dead or wished you could go to sleep and not wake up? (Prior to Study Entry).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107028>	C106676	C-SSRS Already Enrolled Subjects - Wish to Be Dead (Since Study Start)|CSS05-Wish to be Dead-Since|CSS05-Wish to be Dead-Since|CSS0501B	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects) Have you wished you were dead or wished you could go to sleep and not wake up? (Since Study Start).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107029>	C106676	C-SSRS Already Enrolled Subjects - Description of Wish to Be Dead|CSS05-Wish to be Dead, Describe|CSS05-Wish to be Dead, Describe|CSS0501C	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Description of wishing to be dead.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10702>	C63468	Bicalutamide/Goserelin Regimen|Bicalutamide and Goserelin|Bicalutamide-Goserelin|Bicalutamide-Goserelin Regimen|Bicalutamide/Goserelin|CDX/ZDX|Goserelin/Bicalutamide	A regimen consisting of bicalutamide and goserelin that can be used for the treatment of prostate cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C107030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107030>	C106676	C-SSRS Already Enrolled Subjects - Non-Specific Active Suicidal Thoughts (Prior to Study Entry)|CSS05-Non-Spec Suicid Thought-Prior|CSS05-Non-Spec Suicid Thought-Prior|CSS0502A	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Have you actually had any thoughts of killing yourself? (Prior to Study Entry).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107031>	C106676	C-SSRS Already Enrolled Subjects - Non-Specific Active Suicidal Thoughts (Since Study Start)|CSS05-Non-Spec Suicid Thought-Since|CSS05-Non-Spec Suicid Thought-Since|CSS0502B	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Have you actually had any thoughts of killing yourself? (Since Study Start).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107032>	C106676	C-SSRS Already Enrolled Subjects - Description of Non-Specific Active Suicidal Thoughts|CSS05-Non-Spec Suicid Thought, Describe|CSS05-Non-Spec Suicid Thought, Describe|CSS0502C	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Description of non-specific active suicidal Thoughts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107033>	C106676	C-SSRS Already Enrolled Subjects - Active Suicidal Ideation With Any Methods (Not Plan) Without Intent to Act (Prior to Study Entry)|CSS05-Idea, No Intent, No Plan-Prior|CSS05-Idea, No Intent, No Plan-Prior|CSS0503A	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Have you been thinking about how you might do this? (Prior to Study Entry).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107034>	C106676	C-SSRS Already Enrolled Subjects - Active Suicidal Ideation With Any Methods (Not Plan) Without Intent to Act (Since Study Start)|CSS05-Idea, No Intent, No Plan-Since|CSS05-Idea, No Intent, No Plan-Since|CSS0503B	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Have you been thinking about how you might do this? (Since Study Start).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107035>	C106676	C-SSRS Already Enrolled Subjects - Description of Active Suicidal Ideation With Any Methods (Not Plan) Without Intent to Act|CSS05-Idea, No Intent, No Plan, Describe|CSS05-Idea, No Intent, No Plan, Describe|CSS0503C	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Description of active suicidal ideation with any methods (not plan) without intent to act.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107036>	C106676	C-SSRS Already Enrolled Subjects - Active Suicidal Ideation With Some Intent to Act, Without Specific Plan (Prior to Study Entry)|CSS05-Idea, Intent, No Plan-Prior|CSS05-Idea, Intent, No Plan-Prior|CSS0504A	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Have you had these thoughts and had some intention of acting on them? (Prior to Study Entry).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107037>	C106676	C-SSRS Already Enrolled Subjects - Active Suicidal Ideation With Some Intent to Act, Without Specific Plan (Since Study Start)|CSS05-Idea, Intent, No Plan-Since|CSS05-Idea, Intent, No Plan-Since|CSS0504B	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Have you had these thoughts and had some intention of acting on them? (Since Study Start).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107038>	C106676	C-SSRS Already Enrolled Subjects - Description of Active Suicidal Ideation With Some Intent to Act, Without Specific Plan|CSS05-Idea, Intent, No Plan, Describe|CSS05-Idea, Intent, No Plan, Describe|CSS0504C	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Description of active suicidal ideation with some intent to act, without specific plan.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107039>	C106676	C-SSRS Already Enrolled Subjects - Active Suicidal Ideation With Specific Plan and Intent (Prior to Study Entry)|CSS05-Idea, Plan, Intent-Prior|CSS05-Idea, Plan, Intent-Prior|CSS0505A	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan? (Prior to Study Entry).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10703>	C61063	Fluorouracil/Triacetyluridine|5-FU/TAU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107040>	C106676	C-SSRS Already Enrolled Subjects - Active Suicidal Ideation With Specific Plan and Intent (Since Study Start)|CSS05-Idea, Plan, Intent-Since|CSS05-Idea, Plan, Intent-Since|CSS0505B	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan? (Since Study Start).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107041>	C106676	C-SSRS Already Enrolled Subjects - Description of Active Suicidal Ideation With Specific Plan and Intent|CSS05-Idea, Plan, Intent, Describe|CSS05-Idea, Plan, Intent, Describe|CSS0505C	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Description of active suicidal ideation with specific plan and intent.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107042>	C106676	C-SSRS Already Enrolled Subjects - Most Severe Ideation (Prior to Study Entry)|CSS05-Most Severe Idea-Prior|CSS05-Most Severe Idea-Prior|CSS0506A	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Most severe ideation. (Prior to Study Entry).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107043>	C106676	C-SSRS Already Enrolled Subjects - Describe Most Severe Ideation (Prior to Study Entry)|CSS05-Most Severe Idea, Desc-Prior|CSS05-Most Severe Idea, Desc-Prior|CSS0506B	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Description of most severe Ideation. (Prior to Study Entry).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107044>	C106676	C-SSRS Already Enrolled Subjects - Most Severe Ideation (Since Study Start)|CSS05-Most Severe Idea-Since|CSS05-Most Severe Idea-Since|CSS0506C	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Most severe ideation. (Since Study Start).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107045>	C106676	C-SSRS Already Enrolled Subjects - Describe Most Severe Ideation (Since Study Start)|CSS05-Most Severe Idea, Desc-Since|CSS05-Most Severe Idea, Desc-Since|CSS0506D	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Description of most severe Ideation. (Since Study Start).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107046>	C106676	C-SSRS Already Enrolled Subjects - Frequency of Most Severe Ideation (Prior to Study Entry)|CSS05-Most Severe Idea, Frequency-Prior|CSS05-Most Severe Idea, Frequency-Prior|CSS0507A	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) How many times have you had these thoughts? (Prior to Study Entry).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107047>	C106676	C-SSRS Already Enrolled Subjects - Frequency of Most Severe Ideation (Since Study Start)|CSS05-Most Severe Idea, Frequency-Since|CSS05-Most Severe Idea, Frequency-Since|CSS0507B	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) How many times have you had these thoughts? (Since Study Start).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107048>	C106676	C-SSRS Already Enrolled Subjects - Duration of Most Severe Ideation (Prior to Study Entry)|CSS05-Most Severe Idea, Duration-Prior|CSS05-Most Severe Idea, Duration-Prior|CSS0508A	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) When you have the thoughts, how long do they last? (Prior to Study Entry).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107049>	C106676	C-SSRS Already Enrolled Subjects - Duration of Most Severe Ideation (Since Study Start)|CSS05-Most Severe Idea, Duration-Since|CSS05-Most Severe Idea, Duration-Since|CSS0508B	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) When you have the thoughts, how long do they last? (Since Study Start).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10704>	C61063	Cisplatin/Floxuridine/Leucovorin Calcium|CDDP/CF/FUDR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107050>	C106676	C-SSRS Already Enrolled Subjects - Controllability of Most Severe Ideation (Prior to Study Entry)|CSS05-Most Severe Idea, Control-Prior|CSS05-Most Severe Idea, Control-Prior|CSS0509A	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Could/can you stop thinking about killing yourself or wanting to die if you want to? (Prior to Study Entry).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107051>	C106676	C-SSRS Already Enrolled Subjects - Controllability of Most Severe Ideation (Since Study Start)|CSS05-Most Severe Idea, Control-Since|CSS05-Most Severe Idea, Control-Since|CSS0509B	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Could/can you stop thinking about killing yourself or wanting to die if you want to? (Since Study Start).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107052>	C106676	C-SSRS Already Enrolled Subjects - Deterrents to Most Severe Ideation (Prior to Study Entry)|CSS05-Most Severe Idea, Deterrents-Prior|CSS05-Most Severe Idea, Deterrents-Prior|CSS0510A	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Are there things-anyone or anything (e.g., family, religion, pain of death) that stopped you from wanting to die or acting on thoughts of committing suicide? (Prior to Study Entry).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107053>	C106676	C-SSRS Already Enrolled Subjects - Deterrents to Most Severe Ideation (Since Study Start)|CSS05-Most Severe Idea, Deterrents-Since|CSS05-Most Severe Idea, Deterrents-Since|CSS0510B	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Are there things-anyone or anything (e.g., family, religion, pain of death) that stopped you from wanting to die or acting on thoughts of committing suicide? (Since Study Start).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107054>	C106676	C-SSRS Already Enrolled Subjects - Reasons For Most Severe Ideation (Prior to Study Entry)|CSS05-Most Severe Idea, Reasons-Prior|CSS05-Most Severe Idea, Reasons-Prior|CSS0511A	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) What sort of reasons did you have for thinking about wanting to die or killing yourself? Was it to end the pain or stop the way you were feeling (in other words you couldn't go on living with this pain or how you were feeling) or was it to get attention, revenge or a reaction from others? Or both? (Prior to Study Entry).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107055>	C106676	C-SSRS Already Enrolled Subjects - Reasons For Most Severe Ideation (Since Study Start)|CSS05-Most Severe Idea, Reasons-Since|CSS05-Most Severe Idea, Reasons-Since|CSS0511B	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) What sort of reasons did you have for thinking about wanting to die or killing yourself? Was it to end the pain or stop the way you were feeling (in other words you couldn't go on living with this pain or how you were feeling) or was it to get attention, revenge or a reaction from others? Or both? (Since Study Start).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107056>	C106676	C-SSRS Already Enrolled Subjects - Actual Suicide Attempt (Prior to Study Entry)|CSS05-Actual Attempt-Prior|CSS05-Actual Attempt-Prior|CSS0512A	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Have you made a suicide attempt? Have you done anything to harm yourself? Have you done anything dangerous where you could have died? (Prior to Study Entry).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107057>	C106676	C-SSRS Already Enrolled Subjects - Actual Suicide Attempt (Since Study Start)|CSS05-Actual Attempt-Since|CSS05-Actual Attempt-Since|CSS0512B	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Have you made a suicide attempt? Have you done anything to harm yourself? Have you done anything dangerous where you could have died? (Since Study Start).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107058>	C106676	C-SSRS Already Enrolled Subjects - Number of Actual Suicide Attempts (Prior to Study Entry)|CSS05-Number of Actual Attempts-Prior|CSS05-Number of Actual Attempts-Prior|CSS0513A	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Total number of actual attempts. (Prior to Study Entry).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107059>	C106676	C-SSRS Already Enrolled Subjects - Number of Actual Suicide Attempts (Since Study Start)|CSS05-Number of Actual Attempts-Since|CSS05-Number of Actual Attempts-Since|CSS0513B	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Total number of actual attempts. (Since Study Start).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10705>	C61063	Carmustine/Cisplatin/Thiotepa|BCNU/CDDP/TSPA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107060>	C106676	C-SSRS Already Enrolled Subjects - Description of Actual Suicide Attempt|CSS05-Actual Attempt, Describe|CSS05-Actual Attempt, Describe|CSS0513C	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Description of actual attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107061>	C106676	C-SSRS Already Enrolled Subjects - Non-suicidal Self-injurious Behavior (Prior to Study Entry)|CSS05-Non-suicid Self-injur Behav-Prior|CSS05-Non-suicid Self-injur Behav-Prior|CSS0514A	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Has subject engaged in non-suicidal self-injurious behavior? (Prior to Study Entry).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107062>	C106676	C-SSRS Already Enrolled Subjects - Non-suicidal Self-injurious Behavior (Since Study Start)|CSS05-Non-suicid Self-injur Behav-Since|CSS05-Non-suicid Self-injur Behav-Since|CSS0514B	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Has subject engaged in non-suicidal self-injurious behavior? (Since Study Start).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107063>	C106676	C-SSRS Already Enrolled Subjects - Interrupted Suicide Attempt (Prior to Study Entry)|CSS05-Interrupted Attempt-Prior|CSS05-Interrupted Attempt-Prior|CSS0515A	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Has there been a time when you started to do something to end your life but someone or something stopped you before you actually did anything? (Prior to Study Entry).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107064>	C106676	C-SSRS Already Enrolled Subjects - Interrupted Suicide Attempt (Since Study Start)|CSS05-Interrupted Attempt-Since|CSS05-Interrupted Attempt-Since|CSS0515B	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Has there been a time when you started to do something to end your life but someone or something stopped you before you actually did anything? (Since Study Start).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107065>	C106676	C-SSRS Already Enrolled Subjects - Number of Interrupted Suicide Attempts (Prior to Study Entry)|CSS05-Num of Interrupted Attempts-Prior|CSS05-Num of Interrupted Attempts-Prior|CSS0516A	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Total number of interrupted. (Prior to Study Entry).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107066>	C106676	C-SSRS Already Enrolled Subjects - Number of Interrupted Suicide Attempts (Since Study Start)|CSS05-Num of Interrupted Attempts-Since|CSS05-Num of Interrupted Attempts-Since|CSS0516B	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Total number of interrupted. (Since Study Start).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107067>	C106676	C-SSRS Already Enrolled Subjects - Description of Interrupted Suicide Attempt|CSS05-Interrupted Attempt, Describe|CSS05-Interrupted Attempt, Describe|CSS0516C	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Description of interrupted attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107068>	C106676	C-SSRS Already Enrolled Subjects - Aborted Suicide Attempt (Prior to Study Entry)|CSS05-Aborted Attempt-Prior|CSS05-Aborted Attempt-Prior|CSS0517A	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Has there been a time when you started to do something to try to end your life but you stopped yourself before you actually did anything? (Prior to Study Entry).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107069>	C106676	C-SSRS Already Enrolled Subjects - Aborted Suicide Attempt (Since Study Start)|CSS05-Aborted Attempt-Since|CSS05-Aborted Attempt-Since|CSS0517B	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Has there been a time when you started to do something to try to end your life but you stopped yourself before you actually did anything? (Since Study Start).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10706>	C61063	Carboplatin/Cisplatin/Cyclophosphamide/Etoposide|CBDCA/CDDP/CTX/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107070>	C106676	C-SSRS Already Enrolled Subjects - Number of Aborted Suicide Attempts (Prior to Study Entry)|CSS05-Number of Aborted Attempts-Prior|CSS05-Number of Aborted Attempts-Prior|CSS0518A	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Total number of aborted. (Prior to Study Entry).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107071>	C106676	C-SSRS Already Enrolled Subjects - Number of Aborted Suicide Attempts (Since Study Start)|CSS05-Number of Aborted Attempts-Since|CSS05-Number of Aborted Attempts-Since|CSS0518B	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Total number of aborted. (Since Study Start).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107072>	C106676	C-SSRS Already Enrolled Subjects - Description of Aborted Suicide Attempt|CSS05-Aborted Attempt, Describe|CSS05-Aborted Attempt, Describe|CSS0518C	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Description of aborted attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107073>	C106676	C-SSRS Already Enrolled Subjects - Preparatory Acts or Behaviors Toward Suicide Attempt (Prior to Study Entry)|CSS05-Preparatory Acts/Behavior-Prior|CSS05-Preparatory Acts/Behavior-Prior|CSS0519A	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Have you taken any steps towards making a suicide attempt or preparing to kill yourself (such as collecting pills, getting a gun, giving valuables away or writing a suicide note)? (Prior to Study Entry).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107074>	C106676	C-SSRS Already Enrolled Subjects - Preparatory Acts or Behaviors Toward Suicide Attempt (Since Study Start)|CSS05-Preparatory Acts/Behavior-Since|CSS05-Preparatory Acts/Behavior-Since|CSS0519B	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Have you taken any steps towards making a suicide attempt or preparing to kill yourself (such as collecting pills, getting a gun, giving valuables away or writing a suicide note)? (Since Study Start).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107075>	C106676	C-SSRS Already Enrolled Subjects - Description of Preparatory Acts or Behaviors Toward Suicide Attempt|CSS05-Preparatory Acts/Behavior, Descr|CSS05-Preparatory Acts/Behavior, Descr|CSS0519C	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Description of preparatory acts or behavior.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107076>	C106676	C-SSRS Already Enrolled Subjects - Suicidal Behavior (Prior to Study Entry)|CSS05-Suicidal Behavior-Prior|CSS05-Suicidal Behavior-Prior|CSS0520A	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Suicidal behavior was present during the assessment period? (Prior to Study Entry).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107077>	C106676	C-SSRS Already Enrolled Subjects - Suicidal Behavior (Since Study Start)|CSS05-Suicidal Behavior-Since|CSS05-Suicidal Behavior-Since|CSS0520B	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Suicidal behavior was present during the assessment period? (Since Study Start).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107078>	C106676	C-SSRS Already Enrolled Subjects - Completed Suicide (Prior to Study Entry)|CSS05-Completed Suicide-Prior|CSS05-Completed Suicide-Prior|CSS0521A	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Completed suicide? (Prior to Study Entry)			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107079>	C106676	C-SSRS Already Enrolled Subjects - Completed Suicide (Since Study Start)|CSS05-Completed Suicide-Since|CSS05-Completed Suicide-Since|CSS0521B	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Completed suicide? (Since Study Start)			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10707>	C61063	Leuprolide/Suramin|LEUP/SUR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107080>	C106676	C-SSRS Already Enrolled Subjects - Most Recent Suicide Attempt Date|CSS05-Most Recent Attempt Date|CSS05-Most Recent Attempt Date|CSS0522A	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Most recent attempt date.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107081>	C106676	C-SSRS Already Enrolled Subjects - Most Recent Suicide Attempt Actual Lethality/Medical Damage|CSS05-Most Recent Attempt Damage|CSS05-Most Recent Attempt Damage|CSS0522B	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Most recent attempt actual lethality/medical damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107082>	C106676	C-SSRS Already Enrolled Subjects - Most Recent Suicide Attempt Potential Lethality|CSS05-Most Recent Attempt Potential|CSS05-Most Recent Attempt Potential|CSS0522C	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Most recent attempt potential lethality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107083>	C106676	C-SSRS Already Enrolled Subjects - Most Lethal Suicide Attempt Date|CSS05-Most Lethal Attempt Date|CSS05-Most Lethal Attempt Date|CSS0523A	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Most lethal attempt date.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107084>	C106676	C-SSRS Already Enrolled Subjects - Most Lethal Suicide Attempt Actual Lethality/Medical Damage|CSS05-Most Lethal Attempt Damage|CSS05-Most Lethal Attempt Damage|CSS0523B	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Most lethal attempt actual lethality/medical damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107085>	C106676	C-SSRS Already Enrolled Subjects - Most Lethal Suicide Attempt Potential Lethality|CSS05-Most Lethal Attempt Potential|CSS05-Most Lethal Attempt Potential|CSS0523C	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Most lethal attempt potential lethality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107086>	C106676	C-SSRS Already Enrolled Subjects - First Suicide Attempt Date|CSS05-First Attempt Date|CSS05-First Attempt Date|CSS0524A	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Initial/first attempt date.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107087>	C106676	C-SSRS Already Enrolled Subjects - First Suicide Attempt Actual Lethality/Medical Damage|CSS05-First Attempt Damage|CSS05-First Attempt Damage|CSS0524B	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Initial/first attempt actual lethality/medical damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107088>	C106676	C-SSRS Already Enrolled Subjects - First Suicide Attempt Potential Lethality|CSS05-First Attempt Potential|CSS05-First Attempt Potential|CSS0524C	Columbia-Suicidality Severity Rating Scale Already Enrolled Subjects (C-SSRS Already Enrolled Subjects ) Initial/first attempt potential lethality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Code Terminology|CDISC Questionnaire C-SSRS Already Enrolled Subjects Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107089>	C106672	ADCS-ADL MCI - Use Household Appliance: Washer|ADL03-Appliance: Washer|ADL03-Appliance: Washer|ADL0317A	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check household appliances that apply: washer.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C10708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10708>	C61063	Aminoglutethimide/Leuprolide|AGT/LEUP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107090>	C106672	ADCS-ADL MCI - Use Household Appliance: Dryer|ADL03-Appliance: Dryer|ADL03-Appliance: Dryer|ADL0317B	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check household appliances that apply: dryer.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107091>	C106672	ADCS-ADL MCI - Use Household Appliance: Vacuum|ADL03-Appliance: Vacuum|ADL03-Appliance: Vacuum|ADL0317C	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) If yes, check household appliances that apply: vacuum.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107092>	C106672	ADCS-ADL MCI - Points for Questions (1-18) Answered 'Don't Know'|ADL03-Total Points for 'Don't Know'|ADL03-Total Points for 'Don't Know'|ADL0325	Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory, MCI (ADCS-ADL MCI) Were any questions (1-18) answered 'Don't Know'? If yes, calculate total points for 'Don't Know'.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADCS-ADL MCI Test Code Terminology|CDISC Questionnaire ADCS-ADL MCI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107093>	C106680	HAQ-DI With VAS - Aids or Devices For Hygiene/Reach/Grip/Act-Other|HAQ01-Othr Aid (Hygiene/Reach/Grip/Act)|HAQ01-Othr Aid (Hygiene/Reach/Grip/Act)|HAQ0140	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Other (for hygiene, reach, grip and activities).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107094>	C106680	HAQ-DI With VAS - Aids or Devices For Hygiene/Reach/Grip/Act-Specify|HAQ01-Spec Aid (Hygiene/Reach/Grip/Act)|HAQ01-Spec Aid (Hygiene/Reach/Grip/Act)|HAQ0141	Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale (HAQ-DI With VAS) AIDS or DEVICES that you usually use for any of these activities - Specify (for hygiene, reach, grip and activities).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI With VAS Test Code Terminology|CDISC Questionnaire HAQ-DI With VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107095>	C64468	Allogeneic Conditioning|Allo Conditioning|Allogeneic (allo) Conditioning	A preparative treatment regimen given prior to a cell transplantation from a genetically non-identical donor. The regimen consists of chemotherapy with or without radiation and is intended to kill cancerous cells before the transplantation and to provide immunosuppression to prevent the rejection of the donor's stem cells.			Therapeutic or Preventive Procedure	
C107096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107096>	C64468	Autologous Conditioning|Auto Conditioning|Autologous (auto) Conditioning	A preparative treatment regimen given prior to autologous cell transplantation. The regimen consists of chemotherapy with or without radiation and is intended to kill cancerous cells before the transplantation.			Therapeutic or Preventive Procedure	
C107097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107097>	C49556	Disease Response Domain|Disease Response and Clin Classification|RS	A domain for disease response evaluations.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107098>	C41328	QTcB Prolongation|PROLONGED QTcB|QTCB PROLONGATION	An electrocardiographic finding in which the QT interval corrected for heart rate using Bazett's formula is prolonged. Thresholds for different age, sex, and patient populations exist.			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C107099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107099>	C41328	QTcF Prolongation|PROLONGED QTcF|Prolonged QTcF|QTCF PROLONGATION	An electrocardiographic finding in which the QT interval corrected for heart rate using Fridericia's formula is prolonged. Thresholds for different age, sex, and patient populations exist.	QTcF Prolongation		Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C10709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10709>	C61063	Ketoconazole/Paclitaxel|KCZ/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1070>	C1450	Iproplatin|(OC-6-33)-dichlorodihydroxybis(2-propanamine)platinum|CHIP|Diisopropylammine-trans-dihydroxymalonatoplatinum(IV)|IPROPLATIN|JM-9|Platinum, dichlorodihydroxybis(2-propanamine)-, (oc-6-33)-	A synthetic second-generation platinum-containing compound related to cisplatin. Iproplatin binds to and forms DNA crosslinks and platinum-DNA adducts, resulting in DNA replication failure and cell death.  Although less prone to glutathione inactivation compared to cisplatin, resistance to this agent has been observed in vitro due to repair of platination damage by tumor cells. (NCI04)			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C107100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107100>	C62256	Interpolated Premature Ventricular Complex by ECG Finding|Interpolated PVC|Interpolated Premature Ventricular Complex|Interpolated Premature Ventricular Complex by EKG Finding|Interpolated VE|Interpolated VES|Interpolated VPC|Interpolated VPC|Interpolated Ventricular Extra Beat|Interpolated Ventricular Premature Complex|PREMATURE VENTRICULAR COMPLEX INTERPOLATED|Premature Ventricular Complexes Interpolated	An electrocardiographic finding of a premature ventricular complex which occurs between two normal QRS complexes which have normal timing. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C107101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107101>	C3114	Anaphylaxis	An acute hypersensitive immune response that occurs from exposure to an allergen. It results from the release of histamine and histamine-like substances from mast cells, and can present with breathing difficulty due to narrowed airways, dizziness and hypotension, skin rash, weak pulse, nausea and vomiting.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C107102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107102>	C2863	Agranulocytosis	A marked decrease in the number of mature granulocytes (most often neutrophils) in the peripheral blood.			Laboratory or Test Result	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C107103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107103>	C28554	Sudden Death|Sudden Death, NOS	An unexpected death without warning.			Finding	
C107104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107104>	C26000	NID2 Gene|NID2|NID2|Nidogen 2 (Osteonidogen) Gene	This gene plays a structural role in the basement membrane.	NID2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107105>	C107104	NID2 wt Allele|NID-2|Nidogen 2 (Osteonidogen) wt Allele	Human NID2 wild-type allele is located in the vicinity of 14q22.1 and is approximately 64 kb in length. This allele, which encodes nidogen-2 protein, is involved inmaintaining the structure of the basement membrane.	NID2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107106>	C17351	Nidogen-2|NID2|Nidogen 2|Osteonidogen	Nidogen-2 (1375 aa, ~151 kDa) is encoded by the human NID2 gene. This protein plays a role in both basement membrane structure and cell adhesion.	Nidogen-2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107107>	C25870	ACLY Gene|ACLY|ACLY|ATP Citrate Lyase Gene	This gene is involved in acetyl-CoA metabolism.	ACLY Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107108>	C107107	ACLY wt Allele|ACL|ATP Citrate Lyase wt Allele|ATPCL|CLATP	Human ACLY wild-type allele is located in the vicinity of 17q21.2 and is approximately 63 kb in length. This allele, which encodes ATP-citrate synthase protein, plays a role in both acetyl-CoA metabolism and de novo lipid synthesis.	ACLY wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107109>	C16259	ATP-Citrate Synthase|ACLY|ATP Citrate Lyase|ATP-Citrate (Pro-S-)-Lyase|Citrate Cleavage Enzyme|EC 2.3.3.8	ATP-citrate synthase (1101 aa, ~121 kDa) is encoded by the human ACLY gene. This protein is involved in both the synthesis of cytosolic acetyl-CoA and the de novo lipid synthesis.	ATP-Citrate Synthase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10710>	C61063	Carboplatin/Interleukin-1-Alpha/Methylene Blue|CBDCA/IL-1A/MB			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107110>	C25870	MGST2 Gene|MGST2|MGST2|Microsomal Glutathione S-Transferase 2 Gene	This gene plays a role in the metabolism of leukotriene C4.	MGST2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107111>	C107110	MGST2 wt Allele|GST2|Glutathione S-Transferase, Microsomal, 2 Gene|MGST-II|Microsomal Glutathione S-Transferase 2 wt Allele	Human MGST2 wild-type allele is located in the vicinity of 4q28.3 and is approximately 75 kb in length. This allele, which encodes microsomal glutathione S-transferase 2 protein, is involved in both the metabolism of leukotriene C4 and the inflammation process.	MGST2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107112>	C20075	Microsomal Glutathione S-Transferase 2|EC 2.5.1.18|Microsomal GST-2|Microsomal GST-II	Microsomal glutathione S-transferase 2 (147 aa, ~17 kDa) is encoded by the human MGST2 gene. This protein plays a role in both the regulation of inflammation and the synthesis of leukotriene C4.	Microsomal Glutathione S-Transferase 2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107113>	C26001	COL7A1 Gene|COL7A1|COL7A1|Collagen Type VII Alpha 1 Chain Gene	This gene is involved in the organization of the epithelial basement membrane.	COL7A1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107114>	C107113	COL7A1 wt Allele|Collagen Type VII Alpha 1 Chain wt Allele|Collagen, Type VII, Alpha 1 Gene|EBD1|EBDCT|EBR1|NDNC8	Human COL7A1 wild-type allele is located in the vicinity of 3p21.31 and is approximately 31 kb in length. This allele, which encodes collagen alpha-1(VII) chain protein, plays a role in interactions between squamous epithelia and the basement membrane. Mutations in this gene are associated with all forms of dystrophic epidermolysis bullosa.	COL7A1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107115>	C16447	Collagen Alpha-1(VII) Chain|COL7A1|Collagen VII, Alpha-1 Polypeptide|Epidermolysis Bullosa, Dystrophic, Dominant And Recessive|LC Collagen|Long-Chain Collagen	Collagen alpha-1(VII) chain (2944 aa, ~295 kDa) is encoded by the human COL7A1 gene. This protein is involved in interactions between squamous epithelia and the basement membrane.	Collagen Alpha-1(VII) Chain		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107116>	C26006	GABARAPL2 Gene|GABA(A) Receptor-Associated Protein-Like 2 Gene|GABARAPL2|GABARAPL2	This gene plays a role in intra-Golgi trafficking.	GABARAPL2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107117>	C107116	GABARAPL2 wt Allele|ATG8|ATG8C|FLC3A|GABA(A) Receptor-Associated Protein-Like 2 wt Allele|GATE-16|GATE16|GATE16, Bovine, Homolog of Gene|GEF-2|GEF2	Human GABARAPL2 wild-type allele is located in the vicinity of 16q22.1 and is approximately 12 kb in length. This allele, which encodes gamma-aminobutyric acid receptor-associated protein-like 2, is involved in the regulation of intra-Golgi transport.	GABARAPL2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107118>	C16386	Gamma-Aminobutyric Acid Receptor-Associated Protein-Like 2|GABA-A Receptor-Associated Protein-Like Protein 2|GABARAPL2|Ganglioside Expression Factor 2|General Protein Transport Factor P16|Golgi-Associated ATPase Enhancer of 16 Kda|MAP1 Light Chain 3 Related Protein|MAP1 Light Chain 3-Related Protein	Gamma-aminobutyric acid receptor-associated protein-like 2 (117 aa, ~14 kDa) is encoded by the human GABARAPL2 gene. This protein plays a role in the regulation of intra-Golgi transport.	Gamma-Aminobutyric Acid Receptor-Associated Protein-Like 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107119>	C26057	CHD1 Gene|CHD1|CHD1|Chromodomain Helicase DNA Binding Protein 1 Gene	This gene is involved in the modification of chromatin structure.	CHD1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10711>	C61063	Asparaginase/Cytarabine/Dexamethasone/Doxorubicin/Mercaptopurine/Vincristine|ARA-C/ASP/DM/DOX/MP/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107120>	C107119	CHD1 wt Allele|CHD-1|Chromodomain Helicase DNA Binding Protein 1 wt Allele|PILBOS	Human CHD1 wild-type allele is located within 5q15-q21 and is approximately 71 kb in length. This allele, which encodes chromodomain-helicase-DNA-binding protein 1, plays a role in the regulation of transcription by the modification of chromatin structure.	CHD1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107121>	C16517	Chromodomain-Helicase-DNA-Binding Protein 1|ATP-Dependent Helicase CHD1|CHD1|Chromodomain Helicase DNA Binding Protein 1|Chromodomain Helicase DNA-Binding Protein 1|EC 3.6.1|EC 3.6.4.12	Chromodomain-helicase-DNA-binding protein 1 (1710 aa, ~197 kDa) is encoded by the human CHD1 gene. This protein is involved in the regulation of transcription by the modification of chromatin structure.	Chromodomain-Helicase-DNA-Binding Protein 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107122>	C20921	DAB2IP Gene|DAB2 Interacting Protein Gene|DAB2IP|DAB2IP	This gene may play a role in tumor suppression.	DAB2IP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107123>	C107122	DAB2IP wt Allele|AF9Q34|AIP1|DAB2 Interacting Protein wt Allele|DIP1/2|KIAA1743	Human DAB2IP wild-type allele is located within 9q33.1-q33.3 and is approximately 218 kb in length. This allele, which encodes disabled homolog 2-interacting protein, may be involved in tumor suppression.	DAB2IP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107124>	C17298	Disabled Homolog 2-Interacting Protein|ASK-Interacting Protein 1|ASK1-Interacting Protein 1|DAB2 Interaction Protein|DAB2-Interacting Protein|DOC-2/DAB2 Interactive Protein|NGAP-Like Protein	Disabled homolog 2-interacting protein (1189 aa, ~132 kDa) is encoded by the human DAB2IP gene. This protein may play a role in tumor suppression.	Disabled Homolog 2-Interacting Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107125>	C26064	PHLPP2 Gene|PH Domain and Leucine Rich Repeat Protein Phosphatase 2 Gene|PHLPP2|PHLPP2	This gene is involved in the regulation of apoptosis.	PHLPP2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107126>	C107125	PHLPP2 wt Allele|KIAA0931|PH Domain and Leucine Rich Repeat Protein Phosphatase 2 wt Allele|PHLPPL	Human PHLPP2 wild-type allele is located in the vicinity of 16q22.2 and is approximately 87 kb in length. This allele, which encodes PH domain leucine-rich repeat-containing protein phosphatase 2 protein, plays a role in the regulation of apoptosis and may act as a tumor suppressor.	PHLPP2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107127>	C34078	PH Domain Leucine-Rich Repeat-Containing Protein Phosphatase 2|EC 3.1.3.16|PH Domain Leucine-Rich Repeat-Containing Protein Phosphatase-Like|PH Domain and Leucine Rich Repeat Protein Phosphatase-Like|PH Domain and Leucine-Rich Repeat Protein Phosphatase-Like|PHLPP-Like|PHLPP2	PH domain leucine-rich repeat-containing protein phosphatase 2 (1323 aa, ~147 kDa) is encoded by the human PHLPP2 gene. This protein is involved in the regulation of apoptosis and may act as a tumor suppressor.	PH Domain Leucine-Rich Repeat-Containing Protein Phosphatase 2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107128>	C20988	ITGAE Gene|ITGAE|ITGAE|Integrin, Alpha E (Antigen CD103, Human Mucosal Lymphocyte Antigen 1; Alpha Polypeptide) Gene	This gene plays a role in cell adhesion.	ITGAE Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107129>	C107128	ITGAE wt Allele|CD103|HUMINAE|Human Mucosal Lymphocyte Antigen 1, Alpha Subunit Gene|Integrin, Alpha E (Antigen CD103, Human Mucosal Lymphocyte Antigen 1; Alpha Polypeptide) wt Allele|Integrin, Alpha-E Gene	Human ITGAE wild-type allele is located in the vicinity of 17p13 and is approximately 87 kb in length. This allele, which encodes integrin alpha-E protein, is involved in cell adhesion and may play a role in activation of intestinal intraepithelial lymphocytes.	ITGAE wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10712>	C61063	Asparaginase/Cyclophosphamide/Cytarabine/Dexamethasone/Doxorubicin/Mercaptopurine/Vincristine|ARA-C/ASP/CTX/DM/DOX/MP/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107130>	C16393	Integrin Alpha-E|Antigen CD103, Human Mucosal Lymphocyte Antigen 1; Alpha Polypeptide|CD103|CD103 Antigen|HML-1 Antigen|Integrin Alpha-IEL|Mucosal Lymphocyte 1 Antigen	Integrin alpha-E (1179 aa, ~130 kDa) is encoded by the human ITGAE gene. This protein plays a role in cell adhesion and may be involved in activation of intestinal intraepithelial lymphocytes.	Integrin Alpha-E		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107131>	C20194	FST Gene|FST|FST|Follistatin Gene	This gene is involved in the regulation of cell growth.	FST Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107132>	C107131	FST wt Allele|FS|Follistatin wt Allele	Human FST wild-type allele is located in the vicinity of 5q11.2 and is approximately 7 kb in length. This allele, which encodes follistatin protein, plays a role in inhibiting both follicle-stimulating hormone release and activin-mediated cell growth.	FST wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107133>	C18466	Follistatin|Activin-Binding Protein|FS|FST|Follistatin Isoform FST317	Follistatin (344 aa, ~38 kDa) is encoded by the human FST gene. This protein is involved in inhibiting both activin-mediated cell growth and follicle-stimulating hormone release.	Follistatin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107134>	C54401|C20917|C20420	NDN Gene|NDN|NDN|Necdin, MAGE Family Member Gene	This gene plays a role in cell cycle arrest.	NDN Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107135>	C107134	NDN wt Allele|HsT16328|Necdin (Mouse) Homolog Gene|Necdin Homolog (Mouse) Gene|Necdin Homolog Gene|Necdin, MAGE Family Member wt Allele|Necdin, Melanoma Antigen (MAGE) Family Member Gene|PWCR|Prader-Willi Syndrome Chromosome Region Gene	Human NDN wild-type allele is located in the vicinity of 15q11.2 and is approximately 2 kb in length. This allele, which encodes necdin protein, is involved in suppression of cell growth in postmitotic neurons. Mutations in this gene are associated with Prader-Willi syndrome.	NDN wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107136>	C54674|C17761|C17207	Necdin|NDN	Necdin (321 aa, ~36 kDa) is encoded by the human NDN gene. This protein plays a role in suppression of cell growth in postmitotic neurons.	Necdin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107137>	C97139	Kinome Response Profile|Kinome Response Signature	A protein expression profile to define and quantitate the activity and drug responsiveness of the expressed kinome.	Kinome Response Profile		Clinical Attribute	CTRP Biomarker Terminology|CTRP Terminology
C107138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107138>	C1636	17-Alpha-Hydroxypregnenolone|17-HYDROXYPREGNENOLONE|17-Hydroxypregnenolone|17-OH-Pregnenolone|17a-Pregnenolone|3-Beta,17-Alpha-Dihydroxypregn-5-En-20-One|3-Beta,17-Dihydroxypregn-5-En-20-One|5-Pregnen-3Beta,17Alpha-Diol-20-One|Pregn-5-En-20-One, 3-Beta,17-Dihydroxy-	An endogenous steroid hormone synthesized by the hydroxylation of pregnenolone, which can act either as a neuroactive steroid or as a prohormone for progestogens, mineralocorticoids, glucocorticoids, androgens, estrogens, and the neuroactive steroids.	17-Alpha-Hydroxypregnenolone		Organic Chemical|Pharmacologic Substance	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107139>	C18276	Kinome	The set of all kinases expressed in a cell or contained in a genome.	Kinome		Conceptual Entity	CTRP Biomarker Terminology|CTRP Terminology
C10713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10713>	C61063	Asparaginase/Cyclophosphamide/Cytarabine/Dexamethasone/Mercaptopurine/Methotrexate/Vincristine|ARA-C/ASP/CTX/DM/MP/MTX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107140>	C218	Phenanthrene Tetraol|Phe-Tetraol|Phenanthrene Tetraols	A class of chemicals that are products of polycyclic aromatic hydrocarbon metabolism.	Phenanthrene Tetraol		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C107141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107141>	C45678	Crotonaldehyde|1-Formylpropene|2-Butenal|2-Butenaldehyde|3-Methylacrolein|Beta-Methylacrolein|CROTONALDEHYDE|Crotonal|Crotonic Aldehyde|Crotylaldehyde|Methylpropenal|Propylene Aldehyde	An unsaturated aldehyde with commercial applications, including the manufacture of sorbic acid, that is also found in tobacco smoke, gasoline and diesel engine exhausts, and smoke from wood burning. Airborne exposure to this chemical can cause eyes, nose, throat, and lung irritation.	Crotonaldehyde		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107142>	C73539	S-Phenyl-N-Acetylcysteine|2-Acetamido-3-Phenylthiopropanoic Acid|L-Cysteine, N-Acetyl-S-Phenyl-|Phenylmercapturic Acid|S-Benzyl Mercapturic Acid|S-Phenylmercapturic Acid|SPMA	A modified form of acetylcysteine that is a metabolite of benzene and may be found in the urine of smokers.	S-Phenyl-N-Acetylcysteine		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C107143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107143>	C73539	Monohydroxybutylmercapturic Acid|MHBMA	A modified form of acetylcysteine that is a metabolite of 1,3-butadiene and may be found in the urine of smokers.	Monohydroxybutylmercapturic Acid		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C107144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107144>	C73539	3-Hydroxypropylmercapturic Acid|1-(N-Acetylcysteinyl)-Propan-3-Ol|2-Acetamido-3-(3'-Hydroxypropylthio)Propanoic Acid|3-HPMA|3-Hydroxypropyl Mercapturic Acid|N-Acetyl-S-(3-Hydroxypropyl)Cysteine|S-(3-Hydroxypropyl)Cysteine N-Acetate	A modified form of acetylcysteine that is a metabolite of acrolein and may be found in the urine of smokers.	3-Hydroxypropylmercapturic Acid		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C107145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107145>	C73539	4-Hydroxybut-2-Ylmercapturic Acid|2-(N-Acetylcysteinyl)Butan-4-Ol|4-Hydroxybut-2-Yl Mercapturic Acid|HBMA	A modified form of acetylcysteine that is a metabolite of crotonaldehyde and may be found in the urine of smokers.	4-Hydroxybut-2-Ylmercapturic Acid		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C107146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107146>	C73539	N-Acetyl-S-(2-Hydroxyethyl)Cysteine|(N-Acetylcysteinyl)Ethanol|2-Hydroxyethyl Mercapturic Acid|2-Hydroxyethylmercapturic Acid|Alanine, N-Acetyl-3-((2-Hydroxyethyl)Thio)-|HEMA|N-ACETYL-S-(2-HYDROXYETHYL)-L-CYSTEINE|N-Acetyl-S-2-Hydroxyethyl-L-Cysteine|S-(Beta-Hydroxyethyl)Mercapturic Acid	A modified form of acetylcysteine that is a metabolite of ethylene oxide and may be found in the urine of smokers.	N-Acetyl-S-(2-Hydroxyethyl)Cysteine		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107147>	C21176	Glutathione S-Transferase Alpha|GST-Alpha|GSTA|hGSTA	A homo- or heterodimeric form of the glutathione S-transferase enzyme that is comprised of two alpha family subunits.	Glutathione S-Transferase Alpha		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107148>	C21176	Glutathione S-Transferase Mu|GST-Mu|GSTM|hGSTM	A homo- or heterodimeric form of the glutathione S-transferase enzyme that is comprised of two mu family subunits.	Glutathione S-Transferase Mu		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107149>	C20184|C20130	AMP-Activated Protein Kinase Beta|5' AMP-Activated Protein Kinase Beta|5' Adenosine Monophosphate-Activated Protein Kinase Beta|5'-AMP-Activated Protein Kinase Beta|5'-AMP-Activated Protein Kinase Subunit Beta|AMPK Subunit Beta|AMPKb|AMPKbeta	A family of proteins that function as a regulatory beta subunit for the 5'-AMP-activated protein kinase (AMPK) protein complex. AMPK is a heterotrimeric protein kinase complex that plays a key role in regulating cellular energy metabolism and is comprised of a catalytic alpha subunit and non-catalytic beta and gamma subunits. The beta subunit exists as two isoforms, each is encoded by a separate gene.	AMP-Activated Protein Kinase Beta		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10714>	C61063	Cyclosporine/Interleukin-2/Methylprednisolone|CYSP/IL-2/MePRDL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107150>	C117186	Organic Anion Transporter Protein|OATP|Organic Anion Transport Protein|Organic Anion Transporter|Organic Anion Transporting Polypeptide|Organic Anion-Transporting Polypeptide|SLCO|Solute Carrier Organic Anion	A family of transmembrane proteins that play a role in the transport of organic anions including bile acids and bilirubin.	Organic Anion Transporter Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107151>	C18520	Histone H3 Dimethyl Lys28|H3K27me2|H3K27me2 Antigen|H3K28me2|Histone H3 Dimethyl Lys27|Histone H3 Dimethyl Lys27|Histone H3 Dimethyl Lysine 28	A post-translationally modified form of histone H3 where the lysine residue at position 28 is dimethylated. This modification may be a marker for transcriptional repression.	Histone H3 Dimethyl Lys27		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107152>	C18520	Histone H3 Dimethyl Lys4|H3K4me2|H3K4me2 Antigen|Histone H3 Dimethyl Lys5|Histone H3 Dimethyl Lysine 4|Histone H3 Dimethyl Lysine 5	A post-translationally modified form of histone H3 where the lysine residue at position 4 is dimethylated. This modification may be a marker for transcriptionally active genes.	Histone H3 Dimethyl Lys4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107153>	C18520	Histone H3 Trimethyl Lys4|H3K4me3|H3K4me3|H3K4me3 Antigen|Histone H3 Trimethyl Lys5|Histone H3 Trimethyl Lysine 4|Histone H3 Trimethyl Lysine 5	A post-translationally modified form of histone H3 where the lysine residue at position 4 is trimethylated. This modification may be a marker for areas of active gene expression.	Histone H3 Trimethyl Lys4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C107154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107154>	C98356	EGFR NP_005219.2:p.G719X|Activating G719X Mutation|EGFR G719 Mutation|EGFR G719X|EGFR Gly719Xxx|EGFR NP_005219.2:p.Gly719Xxx|EGFR exon 18 G719X|EGFR p.G719X|Epidermal Growth Factor Receptor G719X|Exon 18 Gly719|NP_005219.2:p.G719X|NP_005219.2:p.Gly719Xxx|Proto-Oncogene c-ErbB-1 G719X|Receptor Tyrosine-Protein Kinase erbB-1 G719X	A change in the amino acid residue at position 719 in the epidermal growth factor receptor protein where glycine has been replaced by another amino acid.	EGFR NP_005219.2:p.G719X		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107155>	C2289	Androstanedione|Androstane-3,17-Dione|DIHYDROANDROSTENEDIONE|Dihydroandrostenedione|Etiocholane-3,17-Dione	A steroid hormone that is a mixture of alpha and beta isomers, which have different orientations for the hydrogen group at position 5. 5alpha-androstanedione is a metabolic precursor for both testosterone and estrone.	Androstanedione		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107156>	C20993	NCCN Guidelines Distress Management Distress Thermometer Screening Tool Version 1.2011|NCCN Guidelines Version 1.2011 Distress Management Distress Thermometer Screening Tool	A single-item question screening tool developed by the National Comprehensive Cancer Network (NCCN) Distress Management Panel used to identify patient distress coming from any source.			Intellectual Product	
C107157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107157>	C20993	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011|NCCN Guidelines Version 1.2011 Distress Management Problem List Screening Tool	A screening tool developed by the National Comprehensive Cancer Network (NCCN) Distress Management Panel used to identify patient problems in five categories.			Intellectual Product	
C107158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107158>	C173348	Distressed During the Past Week on a Scale of 0 to 10 Question|Distressed During the Past Week on a Scale of 0 to 10|How distressed have you been during the past week on a scale of 0 to 10	A question about an individual's level of distress during the past week.			Intellectual Product	NCCN Guidelines Distress Management Distress Thermometer Screening Tool Version 1.2011
C107159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107159>	C28310|C129826	MART-1/gp100/Tyrosinase/MAGE-A3 Peptides-loaded Irradiated Allogeneic Plasmacytoid Dendritic Cells|GeniusVac-Mel4	Irradiated allogeneic, HLA-A*0201 positive, plasmacytoid dendritic cells (pDCs) loaded with 4 melanoma peptides derived from the tumor associated antigens (TAAs) MelA/MART-1, gp100/pmel17, tyrosinase, and MAGE-A3, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the irradiated allogeneic pDCs may trigger functional multi-specific T cells from peripheral blood mononuclear cells and tumor-infiltrating lymphocytes, and activate the immune system to mount a cytotoxic T-lymphocyte response against HLA-A*0201 positive melanoma cancer cells expressing the TAAs MelA/MART-1, gp100/pmel17, tyrosinase, and MAGE-A3. These TAAs are upregulated in a variety of tumor cells. The pDCs are derived from a distinct subset of dendritic cells (DCs) with a plasma cell-like morphology and express a characteristic set of surface markers and may increase the anti-tumor immune responses.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C10715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10715>	C61063	Cyclophosphamide/Doxorubicin/Etoposide/Prednisone/Vincristine/Zidovudine|CTX/DOX/PRED/VCR/VP-16/ZDV			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107160>	C201556|C129826	Oncolytic Adenovirus ICOVIR5-infected Autologous Mesenchymal Stem Cells|Celyvir	Bone marrow-derived autologous mesenchymal stem cells (MSCs) infected with the oncolytic, replication-competent adenovirus ICOVIR5, with potential antineoplastic activity. Upon infusion of the oncolytic adenovirus ICOVIR5-infected autologous MSCs, these cells target the adenovirus to tumors. The oncolytic virus then selectively transfects and replicates in the tumor cells causing a direct cytotoxic effect and lysis of the tumor cells. In addition, the viral infection may stimulate an immune response against the virally-infected tumor cells. This may lead to an inhibition of cancer cell proliferation. ICOVIR-5, a virus derived from wild-type human adenovirus serotype 5 (Had5), has been modified to selectively replicate in tumor cells that have a deregulated retinoblastoma/E2F pathway.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C107161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107161>	C226455	Heparan Sulfate Glycosaminoglycan Mimetic Nanopolymer Mouthwash|MUCIPLIQ Mouthwash	A nanopolymer-based mouthwash formulation containing a mimetic of the glycosaminoglycan (GAG) heparan sulfate, with potential anti-mucositic and protective activities. Upon rinsing with the mouthwash, GAGs bind to heparan sulfate binding sites on macromolecules within the extracellular matrix (EMC), which prevents the destruction of the ECM and protects both growth factors and cytokines from being degraded. By replacing the GAGs damaged by chemotherapy and/or radiation, this mouthwash may protect healthy tissue against the cytotoxic effects of chemotherapy and radiation and may prevent against radio-chemotherapy-induced mucositis.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C107162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107162>	C173353	Distress over Practical Problem with Child Care Question|Distress over Practical Problem with Child Care|Practical Problems Child Care	A question about an individual's distress related to their practical problems with child care.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107163>	C1511	Gallium Ga 68-labeled Affibody ABY-025|Gallium Ga 68-[maleimide-DOTA-Cys61]-ZHER2:2891-Cys|[68Ga]ABY-025	A radioconjugate composed of an optimized affibody conjugated, via its C-terminal cysteine, to maleimide-DOTA, and linked to the radioisotope gallium Ga 68, with potential use as a tracer for human epidermal growth factor receptor type 2 (HER2; ErbB2)-expressing tumors using positron emission tomography (PET). Upon intravenous administration of the gallium Ga 68-labeled affibody ABY-025, the affibody targets HER2-expressing tumor cells. This facilitates both detection of HER2-expressing tumor cells and assessment of responses to HER2-targeting chemotherapeutic agents during PET imaging. The affibody is an optimized antibody mimetic based on a 6.5-kDa 3-helical bundle Z domain derived from the staphylococcal protein A (Z her2:342); the nonbinding surface of the Z domain is reengineered (Z her2:2891) to increase binding affinity for HER2 and to improve tumor imaging. HER2 is overexpressed in many cancer cell types.			Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	NCI Drug Dictionary Terminology
C107164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107164>	C1590	Benzaldehyde Dimethane Sulfonate|BEN|DMS-612|DMS612|NSC 281612	A dimethane sulfonate derivative and alkylating agent with a structure similar to other alkylating agents such as chlorambucil, busulfan and melphalan, with potential antineoplastic activity. Although the exact mechanism of action has yet to be fully elucidated, benzaldehyde dimethane sulfonate alkylates DNA, which results in DNA double strand breaks, inhibition of DNA replication, cell cycle arrest and cell death. In addition, this agent is metabolized by the enzyme aldehyde dehydrogenase (ALDH) into the active carboxylic acid metabolite benzoic acid dimethane sulfonate (BA), which further contributes to its alkylating activity. Unlike other alkylating agents, benzaldehyde dimethane sulfonate has demonstrated antitumor activity in renal cell carcinoma.	Benzaldehyde Dimethane Sulfonate		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C107165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107165>	C1505	Carbohydrate Supplement Drink|Carbohydrate Drink	A nutritional supplement drink containing 12.5% carbohydrates, which may enhance recovery following gastrointestinal (GI) surgery. Oral intake of the carbohydrate drink before surgery may prevent insulin resistance and associated hyperglycemia. It may also maintain adequate protein balance and muscle function. Ultimately, giving carbohydrates immediately before surgery may improve overall recovery time and return of GI function. It may also decrease muscle loss.	Carbohydrate Supplement Drink		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C107166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107166>	C1752|C1663	pBCAR3 Phosphopeptide-tetanus Peptide Vaccine|pBCAR3-phosphopeptide Plus Tet Vaccine	A vaccine composed of a phosphorylated peptide from the tumor associated antigen breast cancer anti-estrogen resistance-3 (BCAR3) and a tetanus-derived peptide, with potential immunomodulating and antineoplastic activities. Upon administration of pBCAR3 phosphopeptide-tetanus peptide vaccine, the pBCAR3 phosphopeptide may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against phosphopeptide-containing tumor cells. The tetanus peptide serves as an immunoadjuvant and induces a helper T-cell response, which may help stimulate an immune response against the pBCAR3-expressing melanoma tumor cells. BCAR3 is upregulated in a variety of cancer cells.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C107167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107167>	C1752|C1663	pIRS2 Phosphopeptide-tetanus Peptide Vaccine|pIRS2-phosphopeptide Plus Tet Vaccine	A vaccine composed of a phosphorylated peptide from the tumor associated antigen insulin receptor substrate-2 (IRS2) and a tetanus-derived peptide, with potential immunomodulating and antineoplastic activities. Upon administration of pIRS2 phosphopeptide-tetanus peptide vaccine, the pIRS2 phosphopeptide may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against phosphopeptide-containing tumor cells. The tetanus peptide serves as an immunoadjuvant and induces a helper T-cell response which may help stimulate an immune response against the pIRS2-expressing melanoma tumor cells. IRS2 is upregulated in a variety of cancer cells.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C107168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107168>	C1752|C1663	pBCAR3/pIRS2-Phosphopeptide-tetanus Peptide Vaccine|2-MpP Phosphopeptide-tetanus Peptide Vaccine	A vaccine composed of phosphorylated peptides from the tumor associated antigens breast cancer anti-estrogen resistance-3 (BCAR3) and insulin receptor substrate-2 (IRS2) and a tetanus-derived peptide, with potential immunomodulating and antineoplastic activities. Upon administration of pBCAR3/pIRS2 phosphopeptide-tetanus peptide vaccine, the pBCAR3/pIRS2 phosphopeptide may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing either phosphopeptide. The tetanus peptide serves as an immunoadjuvant and induces a helper T-cell response which may help stimulate an immune response against pBCAR3 and pIRS2-expressing melanoma tumor cells. BCAR3 and IRS2 are upregulated in a variety of cancer cells.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C107169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107169>	C2517	Allogeneic HLA-A2/4-1BB ligand-expressing Melanoma Vaccine	An allogeneic melanoma cell vaccine derived from a cell line with high expression of melanoma associated antigens and genetically modified to express both HLA-A2 and 4-1BB ligand, with potential immunostimulating and antineoplastic activities. Upon administration, the 4-1BB ligand of the allogeneic HLA-A2/4-1BB ligand-expressing melanoma vaccine binds to 4-1BB on activated T-lymphocytes, which induces a strong immune response against HLA-A2 positive melanoma cells.			Cell|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C10716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10716>	C61063	Interleukin-2/Monoclonal Antibody 14G2A/Sargramostim|GM-CSF/IL-2/MOAB 14G2A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107170>	C173353	Distress over Practical Problem with Housing Question|Distress over Practical Problem with Housing|Practical Problems Housing	A question about an individual's distress related to their practical problems with housing.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107171>	C187306|C173353	Distress over Practical Problem with Insurance or Finances Question|Distress over Practical Problem with Insurance or Finances|Practical Problems Insurance/Financial	A question about an individual's distress related to their practical problems with insurance or finances.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107172>	C173353	Distress over Practical Problem with Transportation Question|Distress over Practical Problem with Transportation|Practical Problems Transportation	A question about an individual's distress related to their practical problems with transportation.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107173>	C173924|C173353	Distress over Practical Problem with Work or School Question|Distress over Practical Problem with Work or School|Practical Problems Work/School	A question about an individual's distress related to their practical problems with work or school.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107174>	C174127|C173812|C173353	Distress over Practical Problem with Treatment Decisions Question|Distress over Practical Problem with Treatment Decisions|Practical Problems Treatment decisions	A question about an individual's distress related to their practical problems with treatment decisions.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107175>	C173890|C173351|C173151	Distress over Family Problem of Dealing with Children Question|Distress over Family Problem of Dealing with Children|Family Problems Dealing with children	A question about an individual's distress related to their family problems dealing with children.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107176>	C173351|C173151	Distress over Family Problem of Dealing with Partner Question|Distress over Family Problem of Dealing with Partner|Family Problems Dealing with partner	A question about an individual's distress related to their family problems dealing with partner.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107177>	C173978|C173351|C173151	Distress over Family Problem with Ability to Have Children Question|Distress over Family Problem with Ability to Have Children|Family Problems Ability to have children	A question about an individual's distress related to their family problems with the ability to have children.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107178>	C173351|C173151	Distress over Family Problem with Family Health Issues Question|Distress over Family Problem with Family Health Issues|Family Problems Family health issues	A question about an individual's distress related to their family problems dealing with family health issues.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107179>	C173349	Distress over Emotional Problem with Depression Question|Distress over Emotional Problem with Depression|Emotional Problems Depression	A question about an individual's distress related to their emotional problems with depression.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C10717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10717>	C61063	Cisplatin/Cytarabine/Etoposide/Prednisone|ARA-C/CDDP/PRED/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107180>	C173349	Distress over Emotional Problem with Fear Question|Distress over Emotional Problem with Fear|Emotional Problems Fears	A question about an individual's distress related to their emotional problems with fear.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107181>	C173349	Distress over Emotional Problem with Nervousness Question|Distress over Emotional Problem with Nervousness|Emotional Problems Nervousness	A question about an individual's distress related to their emotional problems with nervousness.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107182>	C173349	Distress over Emotional Problem with Sadness Question|Distress over Emotional Problem with Sadness|Emotional Problems Sadness	A question about an individual's distress related to their emotional problems with sadness.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107183>	C173934|C173349	Distress over Emotional Problem with Worry Question|Distress over Emotional Problem with Worry|Emotional Problems Worry	A question about an individual's distress related to their emotional problems with worry.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107184>	C173349	Distress over Emotional Problem with Loss of Interest in Usual Activities Question|Distress over Emotional Problem with Loss of Interest in Usual Activities|Emotional Problems Loss of interest in usual activities	A question about an individual's distress related to their emotional problems with loss of interest in usual activities.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107185>	C173348	Distress over Spiritual or Religious Concerns Question|Distress over Spiritual or Religious Concerns|Distress over Spiritual or Religious Concerns|Spiritual/religious concerns	A question about an individual's distress related to their spiritual or religious concerns.	Distress over Spiritual or Religious Concerns		Intellectual Product	CTRP Disease Terminology|CTRP Terminology|NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107186>	C173350	Distress over Physical Problem with Appearance Question|Distress over Physical Problem with Appearance|Physical Problems Appearance	A question about an individual's distress related to their physical problems with appearance.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107187>	C173350	Distress over Physical Problem with Bathing or Dressing Question|Distress over Physical Problem with Bathing or Dressing|Physical Problems Bathing/dressing	A question about an individual's distress related to their physical problems with bathing or dressing.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107188>	C61078	Mucoadhesive Paclitaxel Formulation|DHP107	An orally available, mucoadhesive lipid preparation consisting of paclitaxel, a compound extracted from the Pacific yew tree Taxus brevifolia, in a formulation that is comprised of a mixture of monoolein, tricarprylin, and Tween 80, with potential antineoplastic activity. Upon oral administration, DHP107 forms droplets and micelles in the intestine; these adhere to mucoepithelial cells in the gastrointestinal tract and are absorbed through lipid-based uptake mechanisms. Upon absorption, paclitaxel binds to and stabilizes tubulin molecules, which results in the inhibition of both microtubule depolymerization and cell division. This agent also induces apoptosis by both binding to and blocking the function of the apoptosis inhibitor protein B-cell Leukemia 2 (Bcl-2).The mucoadhesive paclitaxel formulation does not contain P-glycoprotein inhibitors, the solvent cremophor or any other toxic solvent.	Mucoadhesive Paclitaxel Formulation		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C107189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107189>	C173350	Distress over Physical Problem with Breathing Question|Distress over Physical Problem with Breathing|Physical Problems Breathing	A question about an individual's distress related to their physical problems with breathing.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C10718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10718>	C61063	Dexamethasone/Methotrexate/Thiotepa/Vincristine|DM/MTX/TSPA/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107190>	C201495|C200766	CD33CAR-CD3zeta-4-1BB-expressing Autologous T-Lymphocytes|Anti-CD33 TCR zeta:CD137 CAR T Cells|CART-33 TCR zeta:CD137 Cells|CART33 TCR zeta:CD137 Cells	Autologous T-lymphocytes transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD33 scFv (single chain variable fragment) coupled to the signaling domain of 4-1BB (CD137) and the zeta chain of the T-cell receptor (TCRzeta), with potential immunomodulating and antineoplastic activities. Upon transfusion, CD33-specific CAR retroviral vector-transduced autologous T lymphocytes target CD33-expressing tumor cells and induce selective toxicity in CD33-expressing tumor cells. Following binding to CD33, the 4-1BB co-stimulatory molecule signaling domain enhances both activation and signaling. Inclusion of the 4-1BB signaling domain may also increase the antitumor activity when compared to the inclusion of the CD3-zeta chain alone. CD33 is expressed on normal non-pluripotent hematopoietic stem cells as well as on myeloid leukemia cells.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C107191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107191>	C200766	EGFR CAR-CD3zeta-4-1BB-expressing Autologous T-Lymphocytes|CART-EGFR TCR zeta:CD137 Cells	Autologous human T-lymphocytes transduced with a retroviral vector encoding an anti-epidermal growth factor receptor (EGFR) chimeric T cell receptor (chimeric antigen receptor or CAR) gene coupled to the signaling domains from both CD3 zeta and CD137 (4-1BB), with potential immunostimulatory and antineoplastic activities. Upon administration, the chimeric EGFR antigen receptor-modified autologous T lymphocytes bind to the EGFR antigen on tumor cell surfaces; subsequently, EGFR-expressing tumor cells may be lysed. Following binding to EGFR, the 4-1BB co-stimulatory molecule signaling domain enhances both activation and signaling. Inclusion of the 4-1BB signaling domain may also increase the antitumor activity when compared to the inclusion of the CD3-zeta chain alone. EGFR, a receptor tyrosine kinase (RTK) overexpressed by a variety of cancer cell types, plays key roles in tumor cell proliferation and tumor angiogenesis.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C107192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107192>	C173803|C173350	Distress over Physical Problem with Changes in Urination Question|Distress over Physical Problem with Changes in Urination|Physical Problems Changes in urination	A question about an individual's distress related to their physical problems with changes in urination.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107193>	C173350	Distress over Physical Problem with Constipation Question|Distress over Physical Problem with Constipation|Physical Problems Constipation	A question about an individual's distress related to their physical problems with constipation.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107194>	C173936|C173350	Distress over Physical Problem with Diarrhea Question|Distress over Physical Problem with Diarrhea|Physical Problems Diarrhea	A question about an individual's distress related to their physical problems with diarrhea.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107195>	C173350	Distress over Physical Problem with Eating Question|Distress over Physical Problem with Eating|Physical Problems Eating	A question about an individual's distress related to their physical problems with eating.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107196>	C173350|C173347	Distress over Physical Problem with Fatigue Question|Distress over Physical Problem with Fatigue|Physical Problems Fatigue	A question about an individual's distress related to their physical problems with fatigue.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107197>	C173593|C173350|C173219	Distress over Physical Problem with Feeling Swollen Question|Distress over Physical Problem with Feeling Swollen|Physical Problems Feeling Swollen	A question about an individual's distress related to their physical problems with feeling swollen.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107198>	C173350	Distress over Physical Problem with Fevers Question|Distress over Physical Problem with Fevers|Physical Problems Fevers	A question about an individual's distress related to their physical problems with fevers.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107199>	C173350	Distress over Physical Problem with Getting Around Question|Distress over Physical Problem with Getting Around|Physical Problems Getting around	A question about an individual's distress related to their physical problems with getting around.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C10719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10719>	C61063	Carboplatin/Etoposide/Ifosfamide/Vincristine|CBDCA/IFF/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1071>	C1420	Porfimer Sodium|CL-184116|DHE|Dihematoporphyrin Ester|Dihematoporphyrin Ether|HPD|Hematoporphyrin Derivative|Hematoporphyrin derivative|PORFIMER SODIUM|Photobarr|Photofrin II|Photofrin II|dihematoporphyrin ether|hematoporphyrin derivative|photofrin|porfimer sodium	The sodium salt of a mixture of oligomers formed by ether and ester linkages of up to eight porphyrin units with photodynamic activity. Absorbed selectively by tumor cells, porfimer produces oxygen radicals after activation by 630 nm wavelength laser light, resulting in tumor cell cytotoxicity. In addition, tumor cell death may occur due to ischemic necrosis secondary to vascular occlusion that appears to be partly mediated by the release of thromboxane A2.	Porfimer Sodium		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C107200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107200>	C173350	Distress over Physical Problem with Indigestion Question|Distress over Physical Problem with Indigestion|Physical Problems Indigestion	A question about an individual's distress related to their physical problems with indigestion.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107201>	C176020|C173350	Distress over Physical Problem with Memory or Concentration Question|Distress over Physical Problem with Memory or Concentration|Physical Problems Memory/concentration	A question about an individual's distress related to their physical problems with memory or concentration.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107202>	C173350	Distress over Physical Problem with Mouth Sores Question|Distress over Physical Problem with Mouth Sores|Physical Problems Mouth sores	A question about an individual's distress related to their physical problems with mouth sores.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107203>	C173350	Distress over Physical Problem with Nausea Question|Distress over Physical Problem with Nausea|Physical Problems Nausea	A question about an individual's distress related to their physical problems with nausea.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107204>	C173350	Distress over Physical Problem with Dry or Congested Nose Question|Distress over Physical Problem with Dry or Congested Nose|Physical Problems Nose dry/congested	A question about an individual's distress related to their physical problems with nose dryness or congestion.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107205>	C173350|C173346	Distress over Physical Problem with Pain Question|Distress over Physical Problem with Pain|Physical Problems Pain	A question about an individual's distress related to their physical problems with pain.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107206>	C173704|C173350	Distress over Physical Problem with Sexual Activity Question|Distress over Physical Problem with Sexual Activity|Physical Problems Sexual	A question about an individual's distress related to their physical problems with sexual activity.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107207>	C173350|C172828	Distress over Physical Problem with Dry or Itchy Skin Question|Distress over Physical Problem with Dry or Itchy Skin|Physical Problems Skin dry/itchy	A question about an individual's distress related to their physical problems with skin dryness or itchiness.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107208>	C173925|C173350	Distress over Physical Problem with Sleep Question|Distress over Physical Problem with Sleep|Physical Problems Sleep	A question about an individual's distress related to their physical problems with sleep.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107209>	C173734|C173350	Distress over Physical Problem with Tingling in Hands or Feet Question|Distress over Physical Problem with Tingling in Hands or Feet|Physical Problems Tingling in hands/feet	A question about an individual's distress related to their physical problems with tingling in hands or feet.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C10720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10720>	C61063	Busulfan/Cyclophosphamide/Cytarabine/Sargramostim|ARA-C/BU/CTX/GM-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107210>	C173348	Distress over Other Problem Question|Distress over Other Problem|Other Problems	A question about an individual's distress related to other problems not included in the list.			Intellectual Product	NCCN Guidelines Distress Management Problem List Screening Tool Version 1.2011
C107211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107211>	C15277	Skin-Sparing Mastectomy	Removal of the breast tissue, nipple, areola, and original biopsy scar, but not the breast skin.			Therapeutic or Preventive Procedure	
C107212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107212>	C15277	Oncoplastic Partial Mastectomy/Lumpectomy with Oncoplastic Closure|Oncoplastic Surgery|Oncoplastic Surgical Procedure	A surgical procedure in which there is full-thickness excision of the malignant breast tumor and surrounding breast parenchyma to allow resection with wide surgical margins, while the remaining fibroglandular breast tissue is transposed to preserve the breast shape and cosmetic appearance in the best possible way.			Therapeutic or Preventive Procedure	
C107213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107213>	C54346	Dose Escalation|Dose-Escalation	A stepwise increase in the amount of a therapeutic or investigational agent given to an individual.			Functional Concept	
C107214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107214>	C173457	Little Interest or Pleasure in Doing Things Question|Little Interest or Pleasure in Doing Things|Little interest or pleasure in doing things	A question about whether an individual has or had little interest or pleasure in doing things.			Intellectual Product	Patient Health Questionnaire - 9 Item
C107215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107215>	C173981	Poor Appetite or Overeating Question|Poor Appetite or Overeating|Poor appetite or overeating	A question about whether an individual has or had a poor appetite or was overeating.			Intellectual Product	Patient Health Questionnaire - 9 Item
C107216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107216>	C173160|C173151	Feeling Bad about Yourself or Feeling Like a Failure or Have Let Yourself or Your Family Down Question|Feeling Bad about Yourself or Feeling Like a Failure or Have Let Yourself or Your Family Down|Feeling bad about yourself or that you are a failure or have let yourself or your family down	A question about whether an individual feels or felt bad about oneself or that one is a failure or has let oneself or their family down.			Intellectual Product	Patient Health Questionnaire - 9 Item
C107217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107217>	C91103	Moving or Speaking So Slowly that Other People Could Have Noticed Question|Moving or Speaking So Slowly that Other People Could Have Noticed|Moving or speaking so slowly that other people could have noticed	A question about whether an individual has or has been moving or speaking so slowly that other people could have noticed.			Intellectual Product	Patient Health Questionnaire - 9 Item
C107218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107218>	C173981	So Fidgety or Restless that You Have Been Moving around More Question|Being so fidgety or restless that you have been moving around more|So Fidgety or Restless that You Have Been Moving around More	A question about whether an individual was being so fidgety or restless that it seemed that one has been moving around more.			Intellectual Product	Patient Health Questionnaire - 9 Item
C107219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107219>	C173597	Thoughts You Would be Better Off Dead or Hurting Yourself Some Way Question|Thoughts You Would be Better Off Dead or Hurting Yourself Some Way|Thoughts that you would be better off dead or of hurting yourself in some way	A question about whether an individual has or had thoughts that one would be better off dead or of hurting oneself in some way.			Intellectual Product	Patient Health Questionnaire - 9 Item
C10721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10721>	C61063	Filgrastim/Fludarabine|FAMP/G-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107220>	C173924	Problems Made It Difficult to Do Work, Take Care of Things at Home, or Get Along with Other People Question|How difficult have these problems made it for you to do your work, take care of things at home, or get along with other people|Problems Made It Difficult to Do Work, Take Care of Things at Home, or Get Along with Other People	A question about how difficult an individual's problems have made it to do their work, take care of things at home, or get along with other people.			Intellectual Product	Patient Health Questionnaire - 9 Item
C107221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107221>	C27993	Several	An indefinite small quantity that is more than two but less than many.			Qualitative Concept	Generalized Anxiety Disorder - 7 Questionnaire|Patient Health Questionnaire - 9 Item
C107222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107222>	C27993	Nearly|Almost|Almost	Not quite or just short of.			Qualitative Concept	Generalized Anxiety Disorder - 7 Questionnaire|Patient Health Questionnaire - 9 Item|Patient Reported Outcomes Version of CTCAE
C107223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107223>	C21514	More than Half the Days|More than one-half the days|Over half the days	A time period that includes one-half of the total number of days plus at least one more.			Temporal Concept	Generalized Anxiety Disorder - 7 Questionnaire|Patient Health Questionnaire - 9 Item
C107225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107225>	C15354	Augmentation Mammoplasty|Breast Augmentation	A surgical procedure for increasing breast size using a prosthetic implant.	Augmentation Mammoplasty		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C107226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107226>	C217122	Neck Dissection Impairment Index|NDII	A health-related instrument to identify the factors that affect quality of life related to shoulder dysfunction following neck dissection for head and neck cancers.			Intellectual Product	
C107227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107227>	C172982|C156140	Bothered by Neck or Shoulder Pain or Discomfort Question|Are you bothered by neck or shoulder pain or discomfort|Bothered by Neck or Shoulder Pain or Discomfort	A question about whether an individual is or was bothered by neck or shoulder pain or discomfort.			Intellectual Product	Neck Dissection Impairment Index
C107228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107228>	C172982	Bothered by Shoulder Stiffness Question|Are you bothered by shoulder stiffness|Bothered by Shoulder Stiffness	A question about whether an individual is or was bothered by shoulder stiffness.			Intellectual Product	Neck Dissection Impairment Index
C107229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107229>	C173398|C172982	Bothered by Difficulty with Self-Care Activities Because of Neck or Shoulder Question|Are you bothered by difficulty with self-care activities because of your neck or shoulder|Bothered by Difficulty with Self-Care Activities Because of Neck or Shoulder	A question about whether an individual is or was bothered by difficulty with self-care activities because of their neck or shoulder.			Intellectual Product	Neck Dissection Impairment Index
C10722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10722>	C61063	Thioguanine/Tiazofurin|TCAR/TG			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107230>	C173695	Limited in Ability to Lift Light Objects Because of Shoulder or Neck Question|Have you been limited in your ability to lift light objects because of your shoulder or neck|Limited in Ability to Lift Light Objects Because of Shoulder or Neck	A question about whether an individual is or was limited by their ability to lift light objects because of their shoulder or neck.			Intellectual Product	Neck Dissection Impairment Index
C107231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107231>	C173695	Limited in Ability to Lift Heavy Objects Because of Shoulder or Neck Question|Have you been limited in your ability to lift heavy objects because of your shoulder or neck|Limited in Ability to Lift Heavy Objects Because of Shoulder or Neck	A question about whether an individual is or was limited by their ability to lift heavy objects because of their shoulder or neck.			Intellectual Product	Neck Dissection Impairment Index
C107232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107232>	C173695	Limited in Ability to Reach above for Objects Because of Shoulder or Neck Question|Have you been limited in your ability to reach above for objects because of your shoulder or neck|Limited in Ability to Reach above for Objects Because of Shoulder or Neck	A question about whether an individual is or was limited by their ability to reach above for objects because of their shoulder or neck.			Intellectual Product	Neck Dissection Impairment Index
C107233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107233>	C176021|C172982	Bothered by Overall Activity Level Because of Shoulder or Neck Question|Are you bothered by your overall activity level because of your shoulder or neck|Bothered by Overall Activity Level Because of Shoulder or Neck	A question about whether an individual is or was bothered by overall activity level because of their shoulder or neck.			Intellectual Product	Neck Dissection Impairment Index
C107234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107234>	C173812	Treatment of Neck Affected Participation in Social Activities Question|Has the treatment of your neck affected your participation in social activities|Treatment of Neck Affected Participation in Social Activities	A question about whether an individual's neck treatment affects or has affected their participation in social activities.			Intellectual Product	Neck Dissection Impairment Index
C107235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107235>	C173695	Limited in Ability to do Leisure or Recreational Activities Because of Neck or Shoulder Question|Have you been limited in your ability to do leisure or recreational activities because of your neck or shoulder|Limited in Ability to do Leisure or Recreational Activities Because of Neck or Shoulder	A question about whether an individual is or was limited in doing leisure or recreational activities because of their neck or shoulder.			Intellectual Product	Neck Dissection Impairment Index
C107236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107236>	C173924|C173695	Limited in Ability to do Work Because of Neck or Shoulder Question|Have you been limited in your ability to do work because of your neck or shoulder|Limited in Ability to do Work Because of Neck or Shoulder	A question about whether an individual is or was limited in doing work because of their neck or shoulder.			Intellectual Product	Neck Dissection Impairment Index
C107238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107238>	C199169	FAK Inhibitor VS-4718|VS-4718|VS-4718	An orally bioavailable focal adhesion kinase (FAK) inhibitor with potential antineoplastic activity. Upon administration, VS-4718 inhibits FAK, blocks fibronectin-stimulated FAK autophosphorylation of Tyr397, and may prevent the integrin-mediated activation of several downstream signal transduction pathways, including ERK, JNK/MAPK and PI3K/Akt. This results in the reduction of the number of cancer stem cells (CSCs) and inhibits tumor cell migration, proliferation and survival. The cytoplasmic tyrosine kinase FAK is a signal transducer for integrins and is constitutively activated in various tumor cell types; it is involved in tumor cell invasion, migration and proliferation and plays a key role in the development, function and survival of CSCs.	FAK Inhibitor VS-4718		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C107239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107239>	C129824	FACT Complex-targeting Curaxin CBL0137|CBL0137	An orally available curaxin-based agent targeting the Facilitates Chromatin Transcription (FACT) complex, with potential antineoplastic activity. Upon administration, CBL0137 binds to FACT and sequesters the FACT complex on chromatin, which inhibits its activity. This prevents transcription of certain genes involved in cancer-associated signaling pathways; it specifically inhibits the transcription of both NF-kappa B and heat shock transcription factor 1 (HSF1) and simultaneously activates p53. This causes an increase in tumor cell apoptosis and a decrease in tumor cell proliferation, in FACT-positive cancers. In addition, this agent is able to sensitize FACT-positive tumor cells to the cytotoxic effects of other chemotherapeutic agents. FACT, a transcription and replication factor composed of the Structure Specific Recognition Protein (SSRP1) and suppressor of Ty 16 (Spt16) proteins, is expressed in a variety of tumor cells while almost absent in normal cells; its expression is associated with increased tumor aggressiveness and poor prognosis.	FACT Complex-targeting Curaxin CBL0137		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C10723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10723>	C61063	Filgrastim/Merbarone|G-CSF/MERB			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107240>	C1505	L-methylfolate|5-MTHF|5-Methyl terahydrofolic Acid|5-Methyltetrahydrofolate|Deplin|L-Glutamic Acid, N-(4-(((2-amino-1,4,5,6,7,8-hexahydro-5- methyl-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-|L-methyltetrahydrofolate	A nutritional supplement containing the biologically active form of the B9 vitamin folate, 5-methyltetrahydrofolate (L-methylfolate), with potential antineoplastic activity. Upon administration, L-methylfolate is able to provide methyl groups allowing an increase in the level of DNA methylation in the promoter regions of certain tumor-promoting genes, thereby reversing the DNA hypomethylation of these genes and inactivating them. This may result in a decrease of both tumor cell proliferation and tumor progression. In addition, administration of L-methylfolate may sensitize tumor cells to the cytotoxic effects of other chemotherapeutic agents. Unlike folic acid, L-methylfolate is able to cross the blood brain barrier and could be beneficial in the treatment of brain tumors. DNA hypomethylation of certain genes leads to chromosome instability and contributes to tumor development.	L-methylfolate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C107242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107242>	C200765|C176018	CD19CAR-CD28zeta-4-1BB-expressing Allogeneic T Lymphocytes|Allogeneic CD19.CAR/28137zeta T-lymphocytes	Allogeneic T-lymphocytes transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) coupled to the costimulatory signaling domain CD28, the signaling domain of 4-1BB (CD137), and the zeta chain of the T-cell receptor (TCR), with potential immunomodulating and antineoplastic activities. Upon transfusion, CD19CAR-CD28 zeta-4-1BB-expressing allogeneic T lymphocytes directs the T-lymphocytes to and induces selective toxicity in CD19-expressing tumor cells. CD28, a T-cell surface-associated co-stimulatory molecule, is required for T-cell activation, proliferation, and survival. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19. Furthermore, inclusion of the 4-1BB signaling domain may increase the antitumor activity compared to the inclusion of the CD28 costimulatory domain and TCR zeta chain alone. CD19 antigen is a B-cell specific cell surface antigen, which is expressed in all B-cell lineage malignancies.	CD19CAR-CD28zeta-4-1BB-expressing Allogeneic T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C107243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107243>	C1752|C1663	PEP-CMV Vaccine	A peptide vaccine derived from cytomegalovirus (CMV) antigens with potential immunostimulating activity. Intradermal administration of the PEP-CMV vaccine may stimulate the immune system to mount a specific helper and cytotoxic T-lymphocyte (CTL) response against CMV-infected tumor cells. Infection with the herpesvirus CMV may play a significant role in tumor cell initiation and progression as well as chemoresistance.	PEP-CMV Vaccine		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C107244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107244>	C574	Topical Sirolimus|NPC-12G|NPC-12G Gel|Rapamune Topical Formulation	A topical formulation containing the macrolide sirolimus (rapamycin), which is produced by the organism Streptomyces hygroscopicus, with potential anti-proliferative activity. Upon application of topical sirolimus, this agent migrates into the skin and is internalized by the affected cells. In turn, sirolimus binds to the immunophilin FK binding protein-12 (FKBP-12) and forms a sirolimus:FKBP-12 complex. This complex binds to and inhibits the activity of the serine/threonine kinase mammalian target of rapamycin (mTOR).  It also decreases the production of vascular endothelial growth factor (VEGF) and results in the suppression of cellular proliferation.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C107245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107245>	C155322	Agerafenib|1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Hydrochloride|AC013773|AGERAFENIB|CEP-32496|RXDX-105	An orally available v-raf murine sarcoma viral oncogene homolog B1 (B-raf) serine/threonine protein kinase inhibitor with potential antineoplastic activity. Agerafenib specifically and selectively inhibits the activity of the mutated form (V600E) of B-raf kinase. This inhibits the activation of the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway and may result in a decrease in the proliferation of tumor cells expressing the mutated B-raf gene. The Raf mutation BRAF V600E, in which valine is substituted for glutamic acid at residue 600, is frequently found in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival.	Agerafenib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C107246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107246>	C172982|C118873	How Often Bothered by Problems Question|How Often Bothered by Problems|How often bothered by problems	A question about how often an individual is or was bothered by problems.			Intellectual Product	Generalized Anxiety Disorder - 7 Questionnaire
C107247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107247>	C173386	Feeling Nervous, Anxious or on Edge Question|Feeling Anxious|Feeling Nervous, Anxious or on Edge|Feeling nervous, anxious or on edge	A question about whether an individual feels or felt nervous, anxious or on edge.			Intellectual Product	Edmonton Symptom Assessment System|Generalized Anxiety Disorder - 7 Questionnaire
C107248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107248>	C173934|C173045	Not Able to Stop or Control Worrying Question|Not Able to Stop or Control Worrying|Not being able to stop or control worrying	A question about whether an individual is not or was not able to stop or control worrying.			Intellectual Product	Generalized Anxiety Disorder - 7 Questionnaire
C107249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107249>	C173934	Worrying too Much about Different Things Question|Worrying too Much about Different Things|Worrying too much about different things	A question about whether an individual worries or worried too much about different things.			Intellectual Product	Generalized Anxiety Disorder - 7 Questionnaire
C10724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10724>	C61063	Edatrexate/Paclitaxel|EDAM/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107250>	C173398	Trouble Relaxing Question|Trouble Relaxing|Trouble relaxing	A question about whether an individual has or had trouble relaxing.			Intellectual Product	Generalized Anxiety Disorder - 7 Questionnaire
C107251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107251>	C173398	Being So Restless it is Hard to Sit Still Question|Being So Restless it is Hard to Sit Still|Being so restless that it is hard to sit still	A question about whether an individual is or was so restless that it was hard to sit still.			Intellectual Product	Generalized Anxiety Disorder - 7 Questionnaire
C107252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107252>	C91103	Becoming Easily Annoyed or Irritable Question|Becoming Easily Annoyed or Irritable|Becoming easily annoyed or irritable	A question about whether an individual becomes or became easily annoyed or irritable.			Intellectual Product	Generalized Anxiety Disorder - 7 Questionnaire
C107253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107253>	C173160	Feeling Afraid as if Something Awful Might Happen Question|Feeling Afraid as if Something Awful Might Happen|Feeling afraid as if something awful might happen	A question about whether an individual feels or felt afraid as if something awful might happen.			Intellectual Product	Generalized Anxiety Disorder - 7 Questionnaire
C107254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107254>	C173924	How Difficult have Problems Made it to do Work, Take Care of Things at Home, or Get Along with other People Question|How Difficult have Problems Made it to do Work, Take Care of Things at Home, or Get Along with other People|How difficult have problems made it for you to do your work, take care of things at home, or get along with other people	A question about how difficult problems have made it for an individual to do work, take care of things at home, or get along with other people.			Intellectual Product	Generalized Anxiety Disorder - 7 Questionnaire
C107255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107255>	C79688	Abies sachalinensis var. sachalinensis oil|ABIES SACHALINENSIS LEAFY TWIG OIL|Japanese Pine Needle Oil|Sakhalin Fir Oil	The essential oil of Abies sachalinensis var. sachalinensis. Sakhalin oil is said to promote relaxation.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107256>	C79688	Abies sibirica Leaf Oil|ABIES SIBIRICA LEAF OIL|Siberian Fir Oil|Siberian Pine Oil	The essential oil of Abies sibirica. Siberian fir oil is used in aromatherapy and perfumes.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107257>	C79688	Achillea millefolium Oil|ACHILLEA MILLEFOLIUM OIL|Yarrow Oil	The essential oil of Achillea millefolium, the yarrow plant. Yarrow oil has activities that can be beneficial to the nervous, genitourinary and digestive systems, and can be used topically for skin care.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107258>	C79688	Aesculus hippocastanum Seed Fluid Extract|AESCULUS HIPPOCASTANUM SEED OIL|Aesculus hippocastanum Seed Oil|Horse Chestnut Seed Oil	The oil extracted from the seeds of Aesculus hippocastanum. Horse chestnut oil is used topically as a treatment for rheumatism and phlebitis.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107259>	C79688	Almond Oil|ALMOND OIL|Sweet Almond Oil	The oil extracted from the seed fruits of Prunus amygdalus. Almond oil is typically used as a skin emollient and for massage.	Almond Oil		Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C10725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10725>	C61063	Fluorouracil/Gallium Nitrate|5-FU/GAN			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107260>	C79688	Ambrette Seed Oil|AMBRETTE SEED OIL	The oil extracted from the seeds of Abelmoschus moschatus. Ambrette seed oil is used for aches and stiffness and for its aromatic properties.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107261>	C79688	Amomum villosum Leaf Oil|Black Cardamom Oil|WURFBAINIA VILLOSA LEAF OIL	The essential oil of Amomum villosum. Black cardamom oil is used for treatment of the digestive tract.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107262>	C79688	Angelica Root Oil|ANGELICA ROOT OIL	The oil extracted from the roots of Angelica archangelica. Angelica root oil is used in aromatherapy and to stimulate the immune system.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107263>	C79688	Angelica Seed Oil|ANGELICA SEED OIL	The oil extracted from the seeds of Angelica archangelica. Angelica seed oil is used primarily in aromatherapy.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107264>	C79688	Apricot Kernel Oil|APRICOT KERNEL OIL	The oil cold-pressed from the dried seeds of the fruit of the apricot tree. Apricot kernel oil is used for frying and cooking, in the cosmetic industry, and for skin care.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107265>	C79688	Argan Oil|ARGAN OIL|Moroccan Oil	The oil extracted from the kernels of Argania spinosa. Moroccan oil is used as a food ingredient and for cosmetic purposes.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107266>	C79688	Asafetida Oil|Asant|Devil's Dung|FERULA ASSA-FOETIDA OIL|Giant Fennel Oil	The oily resin obtained from the rhizomes of Ferula species, especially Ferula asafoetida. Asafetida oil is used as a flavoring and in medicinal preparations.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107267>	C79688	Avocado Oil|AVOCADO OIL	The oil extracted from the fruits of Persea americana. Avocado oil is used is used as a food ingredient, as a cooking oil, and for lubrication and in cosmetics.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107268>	C79688	Backhousia citriodora Leaf Oil|BACKHOUSIA CITRIODORA LEAF OIL|Lemon Myrtle Oil|Sweet Verbena Oil	The essential oil of Backhousia citriodora. One form of lemonmyrtle oil is used as a flavoring or for its aromatic properties. The other form of lemon myrtle oil is used in the production of citronella.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107269>	C79688	Balsam Peru Oil|BALSAM PERU OIL	The essentail oil of Myroxylon balsamum. Balsam peru oil is used primarily in parfumery and skin care preparations.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C10726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10726>	C61063	Paclitaxel/Quinine|QUIN/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107270>	C79688	Bay Fruit Oil|BAY FRUIT OIL	The oil extracted from the fruit of Laurus nobilis. Bay fruit oil can be used for its anti-rheumatism effects.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107271>	C79688	Bay Leaf Oil|BAY LEAF OIL	The essential oil of Laurus nobilis. Bay leaf oil can be used to ease muscular aches and pain.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107272>	C79688	Bitter Almond Oil|BITTER ALMOND OIL	The oil extracted from the seed press-cake of Prunus amygdalus var. amara. Bitter almond oil is used as a flavoring and sweetener.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107273>	C79688	Bitter Fennel Fruit Oil|FOENICULUM VULGARE FRUIT OIL	The oil extracted from the fruit of Foeniculum vulgare. Bitter fennel fruit oil can be used as treatment for digestive complaints.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107274>	C79688	Brassica napus Oil|BRASSICA NAPUS SUBSP. NAPUS OIL|Rapeseed Oil	The oil extracted from the seeds of Brassica napus. Rapeseed oil was traditionally used as an industrial lubricant but newer varieties are used for animal feed, vegetable oil for human consumption, and biodiesel.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107275>	C79688	Camelina sativa Seed Oil|CAMELINA SATIVA SEED OIL	The oil extracted from the seeds of Camelina sativa. Camelina oil is used as vegetable oil and animal feed and was also used as a lamp oil.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107276>	C79688	Canaga Oil|Cananga Oil|YLANG-YLANG OIL	The essential oil of Cananga odorata. Cananga oil is used primarily in aromatherapy preparations.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107277>	C79688	Carapa guianensis Seed Oil|Brazilian Mahogany Oil|CARAPA GUIANENSIS SEED OIL	The oil extracted from the seed kernels of Carapa guianensis. Carapa oil is used as a lamp oil, in the making of soap, and for topical skin application.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107278>	C79688	Caraway Oil|CARAWAY OIL	The oil pressed from the seed fruits of Carum carvi. Caraway oil is used as a fragrance component.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107279>	C79688	Cardamom Oil|CARDAMOM OIL	The essential oil from Elettaria cardomomum. Cardamom oil is used for its aromatic properties, in cooking, and in medicinal preparations.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C10727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10727>	C61063	Floxuridine/Leucovorin Calcium/PALA|CF/FUDR/PALA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107280>	C79688	Carrot Seed Oil|CARROT SEED OIL|Wild Carrot Seed Oil	The oil extracted from the seeds of Daucus carota. Carrot seed oil is primarily used in skin treatment preparations.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107281>	C79688	Cashew Oil|CASHEW OIL	The oil extracted from the nut fruit of Anacardium occidentale. Cashew oil is primarily used as a cooking oil.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107282>	C79688	Cedrus deodara Seed Oil|CEDRUS DEODARA SEED OIL|Himalayan Cedar Oil	The essential oil of Cedrus deodara. Cedar oil is used in cleaning products and for aromatherapy.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107283>	C106128	Cervus elaphus Horn Oil|CERVUS ELAPHUS HORN OIL|Deer Antler Extract	An extract obtained from deer antler velvet. Deer antler extract contains insulin-like growth factor-1, estrone and estradiol. It is used for its growth hormone activities and is considered a performance-enhancing drug.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107284>	C79688	Chamaecyparis obtusa Wood Oil|CHAMAECYPARIS OBTUSA WOOD OIL|Hinoki Wood Oil	The oil extracted from the wood of Chamaecyparis obtusa. Hinoki wood oil has anti-bacterial properties and is used in perfumes, toothpaste, and hair tonic as well as for aromatherapy.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107285>	C79688	Chamaemelum nobile Flower Oil|CHAMAEMELUM NOBILE FLOWER OIL|Chamomile Oil	The oil extracted from the petals of Chamaemelum nobile. Chamomile oil has anti-inflammatory properties.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107286>	C79688	Chilean Hazelnut Oil|CHILEAN HAZELNUT OIL	The oil extracted from the nuts of Gevuina avellana. Hazelnut oil is a good source of vitamin E and is typically used in skincare preparations.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107287>	C79688	Chinese Cinnamon Leaf Oil|CHINESE CINNAMON LEAF OIL	The essential oil of Cinnamomum cassia. Cinnamon leaf oil is used primarily in aromatherapy.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107288>	C79688	Cinnamomum loureirii Bark Extract|Cinnamomum loureiroi Bark Extract|SAIGON CINNAMON BARK OIL|Saigon Cinnamon Bark Oil|Vietnamese Cassia Oil|Vietnamese Cinnamon Oil	The oil extracted from the bark of Cinnamomum loureiroi. Saigon cinnamon bark oil is used primarily in aromatherapy.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107289>	C79688	Cinnamomum zeylanicum Bark Extract|CINNAMON BARK OIL|Cinnamon Bark Oil	The oil extracted from the bark of Cinnamomum zeylanicum. Cinnamon bark oil has antibacterial and antifungal properties but is an irritant to skin. It is used primarily in aromatherapy.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C10728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10728>	C61007	Cytarabine/Dexamethasone/Etoposide/Vincristine|ARA-C/DM/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107290>	C79688	Cinnamon Leaf Oil|CINNAMON LEAF OIL	The oil extracted from the leaves of Cinnamomum zeylanicum. Cinnamon leaf oil is used primarily in aromatherapy.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107291>	C79688	Citrus bergamia Extract|BERGAMOT OIL|Bergamot Oil	The oil extracted from the fruit peel of Citrus bergamia. Bergamot oil is used in the treatment of psoriasis, mycosis fungoides, and vitiligo. Additionally, it is used as a citrus flavoring agent.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107292>	C79688	Citrus sinensis Flower Oil|CITRUS SINENSIS FLOWER OIL|Neroli|Orange Blossom Essential Oil	The essential oil from the flower of Citrus sinensis. Orange blossom oil is used primarily for aromatherapy.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107293>	C79688	Clary Sage Oil|CLARY SAGE OIL	The essential oil of Salvia sclarea. Clary sage oil is used in the treatment of depression, stress, insomnia and deep seated tension.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107294>	C79688	Coix lacryma-jobi Oil|COIX LACRYMA-JOBI SEED OIL|Job's Tears Seed Oil	The oil extracted from the seeds of Coix lacryma-jobi. Coix lacryma-jobi oil is used primarily in skincare preparations.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107295>	C79688	Cucumber Seed Oil|CUCUMBER SEED OIL	The oil extracted from the seeds of Cucumis sativus. Cucumber seed oil is used primarily in skincare preparations.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107296>	C79688	Cumin Oil|CUMIN OIL	The oil extracted from the seeds of Cuminum cyminum. Cumin oil is used in treatments of the digestive system.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107297>	C79688	Curcuma Aromatica Root Oil|CURCUMA AROMATICA ROOT OIL|Curcuma wenyujin Rhizome Oil|Curcuma wenyujin Root Oil|White Turmeric Root Oil	The oil extracted from the root tuber of Curcuma wenyujin.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107298>	C79688	Curcuma xanthorrhiza Oil|CURCUMA ZANTHORRHIZA OIL|Curcuma xanthorrhiza Root Oil|Curcuma zanthorrhiza Oil	The oil extracted from the root tuber of Curcuma xanthorrhiza. Curcuma xanthorrhiza oil is used primarily in skincare preparations.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C107299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107299>	C79688	Cymbopogon schoenanthus Oil|CYMBOPOGON SCHOENANTHUS OIL|Camel Grass Oil|Lemongrass Oil	The essential oil of Cymbopogon schoenanthus. Cymbopogon schoenanthus oil is used for its aromatic properties.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C10729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10729>	C61007	Cyclophosphamide/Cytarabine/Daunorubicin/Thioguanine|ARA-C/CTX/DNR/TG			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1072>	C45176	1,1-Dimethylhydrazine|1,1-DIMETHYLHYDRAZINE|Dimazine|Dimazine|Dimethylhydrazine|UDMH|UDMH	A clear, colorless, flammable, hygroscopic liquid with a fishy smell that emits toxic fumes of nitrogen oxides when heated to decomposition, and turns yellow upon contact with air. 1,1-Dimethylhydrazine is mainly used as a high-energy fuel in jets and rockets, but is also used in chemical synthesis, in photography and to control the growth of vegetation. This substance is also found in tobacco products. Exposure to 1,1-dimethylhydrazine results in irritation of skin, eyes and mucous membranes, and can affect liver and central nervous system. 1,1-Dimethylhydrazine is reasonably anticipated to be a human carcinogen. (NCI05)			Hazardous or Poisonous Substance|Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107300>	C79688	Davana Oil|DAVANA OIL|Dhavanam	The essential oil of Artemisia pallens. Davana oil is used in making perfumes and can be processed to yield the anthelmintic chemical santonin.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107301>	C79688	Dianthus caryophyllus Flower Oil|Carnation Flower Oil|DIANTHUS CARYOPHYLLUS FLOWER OIL	The oil extracted from the flowers of Dianthus caryophyllus. Carnation flower oil is used as a fragrance component.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107302>	C79688	Dill Seed Oil|DILL SEED OIL	The oil extracted from the seeds of Anethum graveolens. Dill seed oil is believed to sooth the nerves and is also used for digestive issues.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107303>	C79688	Dill Weed Oil|DILLWEED OIL	The essential oil of Anethum graveolens. Dill weed oil is used as treatment for digestive complaints.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107304>	C79688	East Indian Lemongrass Oil|EAST INDIAN LEMONGRASS OIL	The essential oil of Cymbopogon flexuosus. East Indian lemongrass oil has antifungal activity.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107305>	C106128	Emu Oil|EMU OIL	An oil rendered from the fat of the emu, Dromaius novaehollandiae. Emu oil is used for its anti-inflammatory and wound healing properties.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107306>	C79688	European Hazelnut Oil|EUROPEAN HAZELNUT OIL	The oil extracted from the nuts of Corylus avellana. Hazelnut oil is used as a food ingredient and flavoring.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107307>	C79688	Fenugreek Seed Oil|FENUGREEK SEED OIL	The oil pressed or distilled from the seeds of trigonella foenum gracecum. Fenugreek seed oil has activity as a phytoestrogen and topical activity as an antimicrobial agent.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107308>	C497	Fish Liver Oil|FISH LIVER OIL	The oil extracted from fish such as cod, salmon, and shark. Fish liver oils typically contain high levels of omega-3 fatty acids, EPA and DHA, and vitamins A and D. It is used as a dietary supplement.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107309>	C79688	Geranium Oil Algerian Type|GERANIUM OIL, ALGERIAN TYPE|Geranium Oil African Type	The essential oil of Pelargonium graveolens. Geranium oil is used primarily for its aromatic properties.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C10730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10730>	C61063	Dexamethasone/Floxuridine/Mitomycin|DM/FUDR/MITO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107310>	C79688	Ginger Oil|GINGER OIL|Ginger Root Oil	The essential oil of Zingiber officinale. Ginger oil has been used for digestive health.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107311>	C79688	Grape Seed Oil|GRAPE SEED OIL|Grape Oil|Grapeseed Oil	The oil extracted from the seeds of grapes. Grape seed oil is used in cooking and cosmetics and for medicinal purposes.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107312>	C79688	Grapefruit Seed Oil|GRAPEFRUIT SEED OIL|Grapefruit Seed Extract	The oil extracted from the seeds, pulp, and white membranes of Citrus paradisi. Grapefruit seed oil is used as a food supplement and in cosmetics.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107313>	C497	Halibut Liver Oil|HALIBUT LIVER OIL	The oil extracted from the liver of Hippoglossus species. Halibut liver oil is taken as a supplement for vitamins A and D.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107314>	C79688	Hippophae rhamnoides Fruit Oil|HIPPOPHAE RHAMNOIDES FRUIT OIL|Sea Buckthorn Fruit Oil	The oil extracted from the fruit of Hippophae rhamnoides. Sea buckhorn fruit oil is used primarily in skincare preparations.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107315>	C79688	Hops Oil|HOPS OIL|Hops Flower Essential Oil	The essential oil of Humulus lupulus. Hops oil has antimicrobial and antiseptic properties and is also reported to have diuretic and sedative effect.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107316>	C79688	Horehound Oil|HOREHOUND OIL	The essential oil of Marrubium vulgare. Horehound oil is used typically in expectorants and cough suppressants.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107317>	C79688	Indian Frankincense Oil|INDIAN FRANKINCENSE OIL	The oil extracted from the resin of various Boswellia species. Frankincense oil is used in perfumes, cosmetics, and pharmaceuticals.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107318>	C79688	Jojoba Oil|JOJOBA OIL	The oil extracted from the seeds of Simmondsia chinensis. Jojoba oil is used primarily in cosmetics.	Jojoba Oil		Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C107319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107319>	C79688	Kanuka Oil|KANUKA OIL	The essential oil of Leptospermum (Kunzea) ericoides. Kanuka oil has anti-fungal and anti-inflammatory properties and is used in skincare preparations.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C10731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10731>	C61063	Cisplatin/Edatrexate/Ifosfamide|CDDP/EDAM/IFF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107320>	C106128	Lanolin Oil|LANOLIN OIL|Wool Oil	The liquid phase oil separated from lanolin. Lanolin oil is used primarily in skin care products.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107321>	C79688	Lemon Oil|LEMON OIL, COLD PRESSED	The oil extracted from the fruit peel of Citrus limon. Lemon oil is used as a flavoring and for its aromatic qualities. It is also said to have many medicinal purposes.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107322>	C79688	Levant Cottonseed Oil|LEVANT COTTONSEED OIL	The oil extracted from the seeds of Gossypium herbaceum. Levant cottonseed oil is a source of gossypol and has antispermacidal activity.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107323>	C79688	Lime Oil|LIME OIL, COLD PRESSED	The oil extracted from the fruit peel of Citrus aurantifolia. Lime oil can be taken as an antioxidant and may help support immune health. Additionally, it is used as a flavoring agent.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107324>	C79688	Linseed Oil|Flaxseed Oil|LINSEED OIL	The oil extracted from the seeds of Linum usitatissimum. Linseed oil is used as a nutritional supplement and as a polymerizing resin.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107325>	C79688	Lovage Oil|LOVAGE OIL	The essential oil of Levisticum officinale or the oil extracted from its roots. The leaf oil is used for the treatment of digestive ailments and in skincare.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107326>	C79688	Mace Oil|MACE OIL|Mace Essential Oil	The essential oil of the nutmeg (Myristica fragrans). Mace oil is used as a flavoring and in pharmaceuticals for its analgesic, antispasmodic, laxative, and stimulant activities.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107327>	C79688	Mango Seed Oil|MANGO SEED OIL|Mango Butter	The oil extracted from the kernel of Mangifera indica. Mango seed oil is typically used in skincare preparations.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107328>	C79688	Manuka Oil|MANUKA OIL	The essential oil of Leptospermum scoparium. Manuka oil has anti-fungal and anti-inflammatory properties and is used in skincare preparations.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107329>	C79688	Melaleuca quinquenervia Leaf Oil|Cajeput Oil|MELALEUCA QUINQUENERVIA LEAF OIL	The essential oil of Melaleuca quinquenervia. Melaleuca quinquenervia oil has antiseptic and antibacterial properties and is used in cosmetic products.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C10732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10732>	C61063	Busulfan/Cyclophosphamide/Mitoxantrone|BU/CTX/DHAD			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107330>	C497	Menhaden Oil|MENHADEN OIL	The oil extracted from various Brevoortia and Ethmidium species. Menhaden oil is used industrially in paint production and the tanning of leather as was as in livestock feeds.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107331>	C79688	Mentha arvensis Flower Oil|MENTHA ARVENSIS FLOWER OIL	The essential oil of Mentha arvensis, the field mint. Mentha arvensis flower oil is used as a flavoring and can also be used for the treatment of skin problems.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107332>	C79688	Mustard Oil|MUSTARD OIL	The vegetable oil pressed from seeds or the essential oil extracted from the seeds of Brassica nigra, Brassica juncea, or Brassica hirta. Mustard oil is used as a cooking oil, a source of omega-3 fatty acids, and in various medicinal preparations.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107333>	C79688	Myrtle Leaf Oil|MYRTLE LEAF OIL	The essential oil of Myrtus communis. Myrtle leaf oil is taken internally for urinary infections, digestive problems, bronchial congestion, and dry coughs.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107334>	C79688	Neatsfoot Oil|NEATSFOOT OIL	The oil rendered from the shin bones and feet of cattle. Neatsfoot oil is used primarily as a conditioning, softening, and preservative agent for leather.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107335>	C79688	Nigella sativa Seed Oil|NIGELLA SATIVA SEED OIL|Nigella sativa Blackseed Oil	The oil extracted from the seeds of Nigella sativa. Blackseed oil is used primarily for its nutritive properties.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C107336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107336>	C79688	Nutmeg Oil|NUTMEG OIL	The essential oil obtained from ground nutmeg. Nutmeg oil is typically used as a food flavoring but also has analgesic properties.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107337>	C79688	Orange Oil Extract|ORANGE OIL, COLD PRESSED|Orange Oil	The oil extracted from the fruit peel of Citrus sinensis. Orange oil is used as a flavoring, a solvent and for its aromatic properties.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107338>	C79688	Oregano Leaf Oil|OREGANO LEAF OIL	The essential oil of Origanum vulgare. Oregano oil has antibacterial and antifungal properties.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107339>	C79688	Origanum majorana Leaf Extract|SWEET MARJORAM OIL|Sweet Marjoram Oil	The essential oil of Origanum marjorana. Marjoram oil is reported to have sedative effects and to be useful in calming asthma and other respiratory symptoms.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C10733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10733>	C61063	Floxuridine/Mitomycin|FUDR/MITO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107340>	C79688	Orris Root Extract|IRIS PALLIDA ROOT OIL|Orris Root Oil	The oil extracted from the roots of Iris germanica, Iris florentina, and Iris pallida. Orris root oil is used as a perfume ingredient and as an ingredient in gin.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107341>	C79688	Palmarosa Oil|PALMAROSA OIL	The essential oil of Cymbopogon martini. Palmarosa oil is used in treatments for the skin, nervous, and digestive systems.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107342>	C79688	Parsley Seed Oil|PARSLEY SEED OIL	The oil extracted from the seeds of Petroselinum sativum. Parsley seed oil is used primarily for the treatment of digestive issues.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107343>	C79688	Pelargonium capitatum Oil|PELARGONIUM CAPITATUM OIL	The essential oil of Pelargonium capitatum. Pelargonium capitatum oil is used for its aromatic properties and as an ingredient in skincare preparations.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107344>	C79688	Pelargonium odoratissimum Oil|PELARGONIUM ODORATISSIMUM OIL	The essential oil of Pelargonium odoratissimum. Pelargonium odoratissimum oil is used for its aromatic properties and as an ingredient in skincare preparations.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107345>	C79688	Pelargonium radens Oil|PELARGONIUM RADENS OIL	The essential oil of Pelargonium radens. Pelargonium radens oil is used for its aromatic properties and as an ingredient in skincare preparations.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107346>	C79688	Pelargonium Roseum Oil|PELARGONIUM ROSEUM OIL	The essential oil of Pelargonium roseum. Pelargonium roseum oil is used for its aromatic properties and as an ingredient in skincare preparations.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107347>	C79688	Perilla frutescens Leaf Oil|PERILLA FRUTESCENS LEAF OIL	The essential oil of Perilla frutescens. (note: the seed oil is the more common, traditionally used as a lamp oil and as drying oil finish)			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107348>	C79688	Pine Needle Oil Pinus mugo|Mugo Pine Oil|PINE NEEDLE OIL (PINUS MUGO)	The essential oil of Pinus mugo. Mugo pine oil is used primarily for its aroma but is also used in massage oils.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107349>	C79688	Pistachio Oil|PISTACHIO OIL	The oil extracted from the fruit of Pistacia vera. Pistachio oil is used as a food oil.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C10734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10734>	C61063	Doxorubicin/Topotecan|DOX/TOPO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107350>	C79688	Pomegranate Seed Oil|POMEGRANATE SEED OIL	The oil extracted from the seeds of Punica granatum. Pomegranite seed oil is a source of antioxidants and is used in skincare preparations.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107351>	C79688	Pumpkin Seed Oil|PUMPKIN SEED OIL	The oil extracted from the seeds of Cucurbita pepo var. styriaca. Pumpkin seed oil is used primarily as a food flavoring.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107352>	C79688	Rhododendron dauricum Leaf Oil|RHODODENDRON DAURICUM LEAF OIL	The essential oil of Rhododendron dauricum.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107353>	C79688	Ribes nigrum Seed|Black Currant Seed Oil|RIBES NIGRUM SEED OIL|Ribes nigrum Seed Oil	The oil extracted from the seeds of Ribes nigrum. Black currant oil is a source of gamma-linoleic acid and may have immune-enhancing effects.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107354>	C79688	Rice Germ Oil|RICE GERM OIL|Rice Bran Extract|Rice Bran Oil	The oil extracted from the germ and inner husk of Oryza sativa grains. Rice bran oil is used as a cooking oil and as a substitute for carnauba wax in cosmetics, confectionery, shoe creams and polishing compounds.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107355>	C79688	Rosa alba Flower Extract|ROSA X ALBA FLOWER OIL|Rosa alba Flower Oil	The oil extracted from the flower petals of Rosa alba. Rosa alba oil is used for its aromatic properties.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107356>	C79688	Rosa centifolia Flower Oil|ROSA CENTIFOLIA FLOWER OIL|Rose Oil	The oil extracted from the flowers of Rosa centifolia. Rose oil is used as a frangrance component.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107357>	C79688	Rosa damascena Flower Oil|ROSA X DAMASCENA FLOWER OIL	The oil extracted from the flowers of Rosa damascena. Rose oil is used as a frangrance component.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107358>	C79688	Rosa gallica Flower Oil|ROSA GALLICA FLOWER OIL	The oil extracted from the flowers of Rosa gallica. Rose oil is used as a frangrance component.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107359>	C79688	Rosa moschata Oil|ROSA MOSCHATA OIL	The oil extracted from the flowers of Rosa moschata. Rose oil is used in skincare preparations.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C10735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10735>	C61007	Methotrexate/Zidovudine|MTX/ZDV			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107360>	C79688	Rosemary Oil|ROSEMARY OIL	The essential oil of Rosmarinus officinalis. Rosemary oil is used primarily for its aromatic properties.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C107361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107361>	C79688	Saffron Oil|SAFFRON OIL	The oil extracted from the stigmas of the Crocus sativus flower. Saffron oil is used for external application in uterine sores.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107362>	C79688	Saigon Cinnamon Leaf Oil|SAIGON CINNAMON LEAF OIL	The essential oil of Cinnamomum loureiroi. Saigon cinnamon leaf oil is used primarily in aromatherapy.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107363>	C79688	Sambucus canadensis Flower Oil|Elder Flower Oil|Elderberry Flower Oil|SAMBUCUS CANADENSIS FLOWER OIL	The oil extracted from the flowers of Sambucus canadensis. Elder flower oil can be taken as a natural laxitive or used externally for skin conditions.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107364>	C79688	Sambucus nigra Flower Oil|European Elder Flower Oil|SAMBUCUS NIGRA FLOWER OIL	The oil extracted from the flowers of Sambucus nigra. European elder flower oil can be taken as a natural laxitive or used externally for skin conditions.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107365>	C79688	Sandalwood Oil|Indian Sandalwood Oil|SANDALWOOD OIL	The oil extracted from the heartwood of Santalum album. Sandalwood oil is used in perfumery, aromatherapy and skin care.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107366>	C79688	Santalum spicatum Oil|Australian Sandalwood Oil|SANTALUM SPICATUM OIL	The oil extracted from the heartwood of Santalum spicatum. Australian sandalwood oil is used as a substitute for Inidan sandalwood oil in perfumery, aromatherapy and skin care.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107367>	C79688	Thyme Oil|THYME OIL	The essential oil of Thymus vulgaris. Thyme oil is used for its antibiotic and antifungal activities.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107368>	C79688	Turmeric Oil|TURMERIC OIL	The oil extracted from the rhizomes of Curcuma longa. Turmerica oil is used for aromatherapy and can be used for its antioxidant and anti-inflammatory properties.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107369>	C79688	Turpentine Oil|Spirit of Turpentine|TURPENTINE OIL|Turpentine|Wood Turpentine	The oily fluid obtained by the distillation of various pine resins. Turpentine is used as a solvent, industrial ingredient, and medicinal ingredient.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C10736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10736>	C61063	Daunorubicin/Methylprednisolone/Vincristine|DNR/MePRDL/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107370>	C79688	Walnut Oil|WALNUT OIL	The oil pressed from English walnut seeds, Juglans regia. Walnut oil is most often used as a flavoring ingredient in cooking.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107371>	C79688	West Indian Lemongrass Oil|Lemongrass Oil|WEST INDIAN LEMONGRASS OIL	The essential oil of Cymbopogon citratus. Lemongrass oils have been used as a pesticide or preservative and may have antifungal properties.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107372>	C79688	Wheat Germ Oil|WHEAT GERM OIL	The oil extracted from the germ of the wheat kernel. Wheat germ oil can be used as a source of vitamin E and for the treatment of skin conditions.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107373>	C79688	White Pine Oil|WHITE PINE OIL	The essential oil of Pinus strobus. White pine oil may be used for skincare preparations and aromatherapy. It is also used commonly in household cleaning products.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107374>	C79688	Wild Thyme Oil|WILD THYME OIL	The essential oil of Thymus serpyllum. Wild thyme oil is primarily used in skincare preparations.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107375>	C79688	Zedoary Oil|CURCUMA ZEDOARIA OIL	The oil extracted from the rhizomes of Curcuma zedoaria. Zedoary oil is typically used in treatments for digestive complaints.			Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107376>	C50802	Pediatric Non-Congenital Ventricular Tachycardia|Pediatric Non-congenital Ventricular Tachycardia	A disorder characterized by an electrocardiographic finding of three or more consecutive complexes of ventricular origin that was not present at birth in an individual under age 21. The QRS complexes are wide and have an abnormal morphology.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C107377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107377>	C27574	Musculoskeletal Disorder|Disorder of Musculoskeletal System|Musculoskeletal System Disorder|Musculoskeletal System Disorder|Musculoskeletal System Disorder	A non-neoplastic or neoplastic disorder that affects muscles and bones.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology|HL Authorized Value Terminology|HL Late Effects Table|Neonatal Research Network Terminology|NICHD Terminology
C107378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107378>	C91105	MD Anderson Symptom Inventory - Core|MD Anderson Symptom Inventory (Core MDASI)|MDASI-Core	A self-administered questionnaire designed to assess multiple symptoms experienced by cancer patients and the interference with daily living caused by these symptoms.			Intellectual Product	
C107379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107379>	C91105	MD Anderson Symptom Inventory - Lung Chemoradiation|MD Anderson Symptom Inventory Lung Chemoradiation (MDASI-LC)|MDASI-LC	A self-administered questionnaire designed specifically for evaluating the severity of symptoms related to lung cancer and chemoradiation treatment.			Intellectual Product	
C10737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10737>	C61063	Cytarabine/Methotrexate/Teniposide/Thioguanine|ARA-C/MTX/TG/VM-26			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107380>	C173134|C107401	Coughing at its Worst Question|Coughing at its Worst|Your coughing at its WORST	A question about an individual's coughing at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Lung Chemoradiation
C107381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107381>	C107401	Sore Throat at its Worst Question|Sore Throat at its Worst|Your sore throat at its WORST	A question about an individual's sore throat at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Lung Chemoradiation
C107382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107382>	C125410|C107401	Difficulty Swallowing at its Worst Question|Difficulty Swallowing at its Worst|Your difficulty swallowing at its WORST	A question about an individual's difficulty swallowing at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Lung Chemoradiation
C107383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107383>	C160624	Pedicle TRAM Flap Procedure|Pedicle TRAM flap|Pedicled Transverse Rectus Abdominis Myocutaneous Flap	A type of breast reconstruction in which a section of skin, muscle, fat, and blood vessels from the abdomen is separated from surrounding tissue while retaining its blood supply, and tunneled under the skin to form a new breast mound.			Therapeutic or Preventive Procedure	
C107384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107384>	C162996	Milademetan Tosylate|DS-3032 Tosylate|DS-3032b|DS-3032b Tosylate|MILADEMETAN TOSYLATE	The tosylate form of milademetan, an orally available MDM2 (murine double minute 2) antagonist with potential antineoplastic activity. Upon oral administration, milademetan binds to, and prevents the binding of MDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This results in the restoration of p53 signaling and leads to the p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein and a negative regulator of the p53 pathway, is overexpressed in cancer cells; it has been implicated in cancer cell proliferation and survival.	Milademetan Tosylate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C107385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107385>	C84327	Ultra Low Temperature Freezer|Ultra Cold Freezer|Ultra Low Freezer|Ultra-cold Freezer|Ultra-low Freezer	A type of freezer that can maintain temperatures between -80 and -86 degrees C.			Manufactured Object	
C107386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107386>	C2152|C129825	PI3K Inhibitor WX-037|WX-037|WX-037	A phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor WX-037 specifically inhibits PI3K, which prevents the activation of the PI3K/protein kinase B-mediated signaling pathway. This may result in the inhibition of both tumor cell growth and survival in PI3K-overexpressing tumor cells. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C107387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107387>	C1450	BP-Cx1-Platinum Complex BP-C1|BP-C1	A combination agent composed of the benzo-poly-carbonic-acid polymer BP-Cx1 chelated to platinum with potential antineoplastic activity. Upon intramuscular injection, the polymer moiety of BP-Cx1-Platinum Complex BP-C1 (BP-C1) alters the permeability of the cell membranes, which allows for increased penetration of platinum into tumor cells. In turn, platinum binds to nucleophilic groups such as GC-rich sites in DNA and induces intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition. In addition, the BP-Cx1 ligand is able to stimulate the innate immune system and upregulates a variety of cytokines including interferon, tumor necrosis factor-alpha (TNF-alpha), granulocyte macrophage-colony stimulating factor (GM-CSF), and various interleukins (ILs) such as IL-6 and IL-25. In comparison to cisplatin and other platinum-based compounds, treatment with BP-C1 allows for less platinum administration, which reduces platinum-associated systemic toxicity and side effects, and enhances the safety profile while maintaining or improving its efficacy.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C107388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107388>	C213143|C207626	Anti-5T4 Antibody-drug Conjugate PF-06263507|PF-06263507|PF-06263507	An antibody-drug conjugate composed of an antibody directed against 5T4 and conjugated, via the stable linker maleimidocaproyl (mc), to the microtubule inhibitor monomethyl auristatin phenylalanine (MMAF), with potential antineoplastic activity. Upon administration, the antibody moiety of PF-06263507 selectively binds to cells expressing the 5T4 oncofetal antigen. After internalization and enzymatic cleavage of the immunoconjugate within the tumor cell cytosol, free MMAF binds to tubulin and inhibits its polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. 5T4, a transmembrane glycoprotein, is overexpressed by a variety of cancer cell types; its expression is correlated with increased invasiveness.	Anti-5T4 Antibody-drug Conjugate PF-06263507		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C107389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107389>	C518|C1509	Monosialotetrahexosylganglioside|GANGLIOSIDE GM1|GM-1|GM1|Ganglioside GM-1|Monosialoanglioside GM1	A glycosphingolipid containing a sialic acid residue found in neuronal cell membranes, with potential neuroprotective and neuroregenerative activities. Upon administration, monosialotetrahexosylganglioside, also called GM-1, is able to both prevent neurologic damage and induce regeneration of damaged neurons through neurotrophic repair mechanisms, enhancement of the production of neutrophins, and augmenting neurite outgrowth. In addition, GM-1 exerts anti-excitotoxic activity, prevents necrosis, and improves neuronal recovery and function.	Monosialotetrahexosylganglioside		Immunologic Factor|Organic Chemical	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C10738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10738>	C61063	Asparaginase/Cyclophosphamide/Mercaptopurine/Methotrexate|ASP/CTX/MP/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107390>	C97630	Asbestos Mining	An occupation that involves the extraction of asbestos from naturally-occurring silicate deposits. Asbestos miners were shown to have an increased risk of developing asbestosis, bronchogenic carcinoma and malignant mesothelioma.			Occupation or Discipline	
C107391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107391>	C21154	Edmonton Symptom Assessment System|ESAS|Edmonton Symptom Assessment System (ESAS)	A self-report assessment tool to screen for the intensity of nine symptoms commonly experienced by cancer patients in palliative care.			Intellectual Product	
C107392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107392>	C173346|C107401	Worst Possible Pain Question|Worst Possible Pain|Worst Possible Pain	A question about an individual's experience of pain at its worst.			Intellectual Product	Edmonton Symptom Assessment System
C107393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107393>	C173935|C107401	Worst Possible Tiredness Question|Worst Possible Tiredness|Worst Possible Tiredness	A question about an individual's experience of tiredness at its worst.			Intellectual Product	Edmonton Symptom Assessment System
C107394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107394>	C173130|C107401	Worst Possible Nausea Question|Worst Possible Nausea|Worst Possible Nausea	A question about an individual's experience of nausea at its worst.			Intellectual Product	Edmonton Symptom Assessment System
C107395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107395>	C107401	Worst Possible Depression Question|Worst Possible Depression|Worst Possible Depression	A question about an individual's experience of depression at its worst.			Intellectual Product	Edmonton Symptom Assessment System
C107396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107396>	C173386|C107401	Worst Possible Anxiety Question|Worst Possible Anxiety|Worst Possible Anxiety	A question about an individual's experience of anxiety at its worst.			Intellectual Product	Edmonton Symptom Assessment System
C107397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107397>	C173219	Feel Drowsy Question|Drowsy|Feel Drowsy|Feel Drowsy	A question about whether an individual feels or felt drowsy.			Intellectual Product	Edmonton Symptom Assessment System|Memorial Symptom Assessment Scale - Short Form
C107398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107398>	C107401	Worst Possible Appetite Question|Worst Possible Appetite|Worst Possible Appetite	A question about an individual's appetite at its worst.			Intellectual Product	Edmonton Symptom Assessment System
C107399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107399>	C173160|C107401	Worst Possible Feeling of Overall Well-Being Question|Worst Possible Feeling of Overall Well-Being|Worst Possible Feeling of Well-Being|Worst Possible Feeling of Wellbeing	A question about an individual's experience of overall well-being at its worst.			Intellectual Product	Edmonton Symptom Assessment System
C10739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10739>	C61007	Cytarabine/Mercaptopurine/Methotrexate/Teniposide/Thioguanine|ARA-C/MP/MTX/TG/VM-26			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1073>	C222	Dimethylmyleran|2,5-Dimethanesulfonoxyhexane|DMB|DMM|Dimethyl-Myleran|Dimethylbusulfan	An aliphatic analogue of busulfan with potential antineoplastic activity.  As an alkylating agent, dimethylbusulfan induces neutropenia and has been shown to exhibit antitumor effects in some animal models.  Alkylating agents exert cytotoxic and chemotherapeutic effects by transferring alkyl groups to DNA, thereby damaging DNA and interfering with DNA synthesis and cell division. (NCI04)			Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C107400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107400>	C91102	Overall Well-Being Question|Overall Well-Being|Well-Being|Wellbeing	A question about an individual's overall well-being.			Intellectual Product	Edmonton Symptom Assessment System
C107401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107401>	C173457	Symptom at Worst Question|Worst Possible Symptom|Worst Possible Symptom|Worst Possible Symptom Question	A question about an individual's symptom at its worst.			Intellectual Product	Edmonton Symptom Assessment System
C107402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107402>	C173935|C173603|C173347	Worst Severity Past Seven Days Fatigue, Tiredness, or Lack of Energy Question|Over the past 7 days, what was the SEVERITY of your FATIGUE, TIREDNESS, OR LACK OF ENERGY at its WORST|Worst Severity Past Seven Days Fatigue, Tiredness, or Lack of Energy	A question about an individual's observation of the worst severity they have experienced related to fatigue, tiredness, or lack of energy over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C107403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107403>	C173787|C173737|C173584|C173347	Past Seven Days How Much Fatigue, Tiredness, or Lack of Energy Interfered with Usual or Daily Activities Question|Over the past 7 days, how much did FATIGUE, TIREDNESS, OR LACK OF ENERGY at its WORST INTERFERE with your usual or daily activities|Past Seven Days How Much Fatigue, Tiredness, or Lack of Energy Interfered with Usual or Daily Activities	A question about how much an individual's fatigue, tiredness, or lack of energy interfered with their usual or daily activities over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C107404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107404>	C173734|C173603	Worst Severity Past Seven Days Numbness or Tingling in Hands or Feet Question|Over the past 7 days, what was the SEVERITY of your NUMBNESS OR TINGLING IN YOUR HANDS OR FEET at its WORST	A question about an individual's observation of the worst severity they have experienced related to numbness or tingling in hands or feet over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C107405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107405>	C173787|C173737|C173734|C173584	Past Seven Days Numbness or Tingling in Hands or Feet Interfering with Usual or Daily Activities Question|Over the past 7 days, how much did NUMBNESS OR TINGLING IN YOUR HANDS OR FEET INTERFERE with your usual or daily activities|Past Seven Days Numbness or Tingling in Hands or Feet Interfering with Usual or Daily Activities	A question about an individual's numbness or tingling in hands or feet interfering with usual or daily activities over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C107406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107406>	C104600	Past Seven Days Frequency of Pain Question|Over the past 7 days, how OFTEN did you have PAIN|Past Seven Days Frequency of Pain	A question about an individual's frequency of pain over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C107407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107407>	C173603|C173346	Worst Severity Past Seven Days Pain Question|Over the past 7 days, what was the SEVERITY of your PAIN at its WORST|Worst Severity Past Seven Days Pain	A question about an individual's observation of the worst severity they have experienced related to pain over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C107408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107408>	C173787|C173737|C173584|C173346	Past Seven Days Pain Interfering with Usual or Daily Activities Question|Over the past 7 days, how much did PAIN INTERFERE with your usual or daily activities|Past Seven Days Pain Interfering with Usual or Daily Activities	A question about an individual's pain interfering with usual or daily activities over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C107409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107409>	C173603	Worst Severity Past Seven Days Constipation Question|Over the past 7 days, what was the SEVERITY of your CONSTIPATION at its WORST|Worst Severity Past Seven Days Constipation	A question about an individual's observation of the worst severity they have experienced related to constipation over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C10740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10740>	C61063	Etoposide/Mitoxantrone/Prednisone/Vincristine|DHAD/PRED/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107410>	C173603	Worst Severity Past Seven Days Problems with Concentration Question|Over the past 7 days, what was the SEVERITY of your PROBLEMS WITH CONCENTRATION at their WORST|Worst Severity Past Seven Days Problems with Concentration	A question about an individual's observation of the worst severity they have experienced related to problems with concentration over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C107411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107411>	C173787|C173737|C173584	Past Seven Days Problems with Concentration Interfering with Usual or Daily Activities Question|Over the past 7 days, how much did PROBLEMS WITH CONCENTRATION INTERFERE with your usual or daily activities|Past Seven Days Problems with Concentration Interfering with Usual or Daily Activities	A question about an individual's problems with concentration interfering with usual or daily activities over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C107412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107412>	C173737|C173358	Past Seven Days Frequency of Tremors Question|Over the past 7 days, how OFTEN did you have TREMORS|Past Seven Days Frequency of Tremors	A question about an individual's frequency of tremors over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C107413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107413>	C173603	Worst Severity Past Seven Days Tremors Question|Over the past 7 days, what was the SEVERITY of your TREMORS at their WORST|Worst Severity Past Seven Days Tremors	A question about an individual's observation of the worst severity they have experienced related to tremors over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C107414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107414>	C173737|C173457	Past Seven Days Other Symptoms to Report Question|Over the past 7 days, do you have any other symptoms that you wish to report|Past Seven Days Other Symptoms to Report	A question about an individual's other symptoms over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C107415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107415>	C173603	Worst Severity Past Seven Days Other Symptom Question|Over the past 7 days, what was the severity of this symptom at its WORST|Worst Severity Past Seven Days Other Symptom	A question about an individual's observation of the worst severity they have experienced related to another symptom over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C107416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107416>	C84382	Nitrogen Dioxide Sterilization|Nitrogen Dioxide	A sterilization process that uses nitrogen dioxide to kill microorganisms.			Activity	FDA CDRH GUDID Terminology
C107417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107417>	C84382	Supercritical Carbon Dioxide Sterilization|Supercritical Carbon Dioxide	A sterilization process that uses supercritical carbon dioxide to kill microorganisms.			Activity	FDA CDRH GUDID Terminology
C107418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107418>	C84382	Liquid Chemical Sterilization|Liquid Chemical Sterilant	A sterilization process to kill microorganisms using a liquid sterilant.			Activity	FDA CDRH GUDID Terminology
C107419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107419>	C84382	High-level Disinfectant Sterilization|High Level Disinfectant	A sterilization method that uses a disinfectant for a period of time to kill all microorganisms except small numbers of bacterial spores.			Activity	FDA CDRH GUDID Terminology
C10741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10741>	C61007	Carboplatin/Thiotepa|CBDCA/TSPA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107420>	C25873|C20194	DCAF1 Gene|DCAF1|DCAF1|DDB1 and CUL4 Associated Factor 1 Gene|VPRBP	This gene plays a role in both the ubiquitination and phosphorylation of proteins.	DCAF1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107421>	C107420	DCAF1 wt Allele|DDB1 and CUL4 Associated Factor 1 wt Allele|KIAA0800|MGC102804|RIP|VPRBP|Vpr (HIV-1) Binding Protein Gene	Human DCAF1 wild-type allele is located in the vicinity of 3p21.2 and is approximately 110 kb in length. This allele, which encodes DDB1- and CUL4-associated factor 1 protein, is involved in both substrate recognition by the E3 ubiquitin-protein ligase complex and serine-threonine phosphorylation.	DCAF1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107422>	C95242|C17325	DDB1- and CUL4-Associated Factor 1|DCAF1|DDB1 and CUL4 Associated Factor 1|EC 2.7.11.1|HIV-1 Vpr-Binding Protein|Protein VPRBP|Serine/Threonine-Protein Kinase VPRBP|Vpr-Binding Protein|Vpr-Interacting Protein	DDB1- and CUL4-associated factor 1 (1507 aa, ~169 kDa) is encoded by the human DCAF1 gene. This protein plays a role in both serine/threonine-protein kinase activity and E3 ubiquitin-protein ligase complex substrate recognition.	DDB1- and CUL4-Associated Factor 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107423>	C54306	MAGEB2 Gene|MAGEB2|MAGEB2|Melanoma Antigen Family B, 2 Gene	This gene is involved in protein ubiquitination.	MAGEB2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107424>	C16126	Social Security Death Index|SSDI	A publically-accessible database derived from the Social Security Administration's (SSA) Death Master File Extract. It includes a listing of the vital statistics of a majority of decedents reported to the SSA since 1962.			Intellectual Product	GDC Terminology|GDC Value Terminology
C107425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107425>	C107423	MAGEB2 wt Allele|CT3.2|DAM6|MAGE-XP-2|MGC26438|Melanoma Antigen Family B, 2 wt Allele	Human MAGEB2 wild-type allele is located in the vicinity of Xp21.3 and is approximately 5 kb in length. This allele, which encodes melanoma-associated antigen B2 protein, plays a role in regulating ubiquitin ligase activity.	MAGEB2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107426>	C19498	Obituary	A published record of a person's death that usually includes a brief biography and details of the funeral arrangements.			Intellectual Product	
C107427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107427>	C18520	Histone H3 Lysine 4|H3K4|Histone H3 Dimethyl Lys5|Histone H3 Lys4|Histone H3 Lysine 5|Lysine 4 of Histone H3	The lysine residue found at amino acid position 4 in the histone H3 protein. Methylation of this residue may be a marker for transcriptionally active genes.	Histone H3 Lysine 4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107428>	C54672	Melanoma-Associated Antigen B2|Cancer/Testis Antigen 3.2|Cancer/Testis Antigen Family 3, Member 2|DSS-AHC Critical Interval MAGE Superfamily 6|DSS/AHC Critical Interval MAGE Superfamily 6|MAGE XP-2 Antigen|MAGE-B2 Antigen|MAGEB2	Melanoma-associated antigen B2 (319 aa, ~35 kDa) is encoded by the human MAGEB2 gene. This protein is involved in enhancing ubiquitin ligase activity.	Melanoma-Associated Antigen B2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107429>	C18520	Histone H3 Lysine 9|H3K9|Histone H3 Lys10|Histone H3 Lys9|Histone H3 Lysine 10|Lysine 9 of Histone H3	The lysine residue found at amino acid position 9 in the histone H3 protein. Methylation of this residue may be a marker for transcriptionally repressed genes.	Histone H3 Lysine 9		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10742>	C61063	Cisplatin/Etoposide/Vincristine|CDDP/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107430>	C16295	Human Anti-Ricin Antibody|HARA	A human antibody which recognizes ricin epitopes. These antibodies often develop in response to treatment with immunotoxins that are comprised of ricin immunoconjugates and limit the effectiveness of the treatment.	Human Anti-Ricin Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C107431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107431>	C13442	Macrovessel Density	The density of vessels with an internal diameter greater than 100 microns. Changes in density can occur in or near tumors.	Macrovessel Density		Qualitative Concept	CTRP Biomarker Terminology|CTRP Terminology
C107432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107432>	C19449	DNA Fragmentation	A process that results in the breaking of macromolecular DNA into small pieces.	DNA Fragmentation		Genetic Function	CTRP Biomarker Terminology|CTRP Terminology
C107433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107433>	C20130	Phosphodiesterase Type 4|3',5'-Cyclic-AMP 5'-Nucleotidohydrolase Type 4|3',5'-Cyclic-AMP Phosphodiesterase Type 4|PDE4|cAMP-Specific 3',5'-Cyclic Phosphodiesterase 4|cAMP-Specific PDE Type 4|cAMP-Specific Phosphodiesterase 4|cAMP-Specific Phosphodiesterase Type 4	A family of phosphodiesterases that hydrolyze cyclic AMP to form AMP. This enzyme family is the primary cyclic nucleotide phosphodiesterase expressed by immune cells.	Phosphodiesterase Type 4		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107434>	C62439	Twenty One|21|Twenty-One	A natural number greater than twenty and less than twenty-two and the quantity that it denotes.	Twenty One		Quantitative Concept	CTRP Biomarker Terminology|CTRP Terminology
C107435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107435>	C64809	Fractional Excretion of Sodium|FENA|FENa|FeNa|Fractional Excretion of Na|Fractional Sodium Excretion|Fractional Sodium Excretion|Fractional Sodium Excretion	The percentage of the total sodium filtered by the kidney that is excreted in the urine. The fractional excretion is calculated by multiplying urinary sodium concentration by the plasma creatinine concentration, then dividing by the urinary creatinine concentration multiplied by the plasma sodium concentration. The resulting ratio is multiplied by 100.	Fractional Excretion of Sodium		Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C107436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107436>	C25804	GLB1 Gene|GLB1|GLB1|Galactosidase, Beta 1 Gene	This gene plays a role in ganglioside metabolism.	GLB1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107437>	C107436	GLB1 wt Allele|BGAL|EBP|ELNR1|Galactosidase, Beta 1 wt Allele|MPS4B	Human GLB1 wild-type allele is located in the vicinity of 3p22.3 and is approximately 101 kb in length. This allele, which encodes beta-galactosidase protein, is involved in the hydrolysis of the terminal beta-galactose from ganglioside substrates.	GLB1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107438>	C16701	Beta-Galactosidase|Acid Beta-Galactosidase|EC 3.2.1.23|Elastin Receptor 1|Elastin Receptor 1 (67kD)|Elastin Receptor 1, 67kDa|GLB1|Lactase	Beta-galactosidase (677 aa, ~76 kDa) is encoded by the human GLB1 gene. This protein plays a role in the hydrolysis of the terminal beta-galactose from ganglioside substrates.	Beta-Galactosidase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107439>	C1916	Tetrahydrobiopterin|(1R,2S)-(2-Amino-3,4,5,6,7,8-Hexahydro-4-Oxo-6-Pteridinyl)-1,2- Propandiol|2-Amino-6-(1,2-Dihydroxypropyl)-5,6,7,8-Tetrahydoro-4(1H)-Pteridinone|2-Amino-6-(1,2-Dihydroxypropyl)-5,6,7,8-Tetrahydropteridin-4(3H)-One|4(1H)-Pteridinone, 5,6,7,8-Tetrahydro-2-Amino-6-(1,2-Dihydroxypropyl)-|5,6,7,8-Tetrahydro-2-Amino-6-(1,2-Dihydroxypropyl)-4(1H)-Pteridinone|5,6,7,8-Tetrahydrobiopterin|BH4|Biopterin, 5,6,7,8-Tetrahydro-|L-Erythro-2-Amino-6-(1,2-Dihydroxypropyl)-5,6,7,8-Tetrahydro-4(3H)- Pteridinon	A cofactor that is essential for the activity of aromatic amino acid hydroxylases. Tetrahydrobiopterin degrades phenylalanine, and facilitates the biosynthesis of several neurotransmitters and the production of nitric oxide.	Tetrahydrobiopterin		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C10743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10743>	C61063	Doxorubicin/Edatrexate|DOX/EDAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107440>	C39713	Calcitroic Acid|(1S,3R,5Z,7E)-1,3-Dihydroxy-24-Nor-9,10-Secochola-5,7,10(19)-Trien-23-Oic Acid|1alpha,3beta-Dihydroxy-24-Nor-9,10-Seco-5,7,10(19)-Cholatrien-23-Oic Acid|1alpha-Hydroxy-23-Carboxytetranorvitamin D|1alpha-Hydroxy-24,25,26,27-Tetranorvitamin D3 23-Carboxylic Acid|24-Nor-9,10-Secochola-5,7,10(19)-Trien-23-Oic Acid, 1,3-Dihydroxy-, (1alpha,3beta,5Z,7E)-|CALCITROIC ACID	A metabolite of calcidiol that is produced by 1,25-dihydroxyvitamin D3 24-hydroxylase (CYP24A1).	Calcitroic Acid		Vitamin	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107441>	C25870	SULT1A1 Gene|SULT1A1|SULT1A1|Sulfotransferase Family, Cytosolic, 1A, Phenol-Preferring, Member 1 Gene	This gene is involved in the metabolism of catecholamines, phenolic drugs and neurotransmitters.	SULT1A1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107442>	C107441	SULT1A1 wt Allele|HAST1/HAST2|P-PST|P-PST 1|PST|ST1A1|ST1A3|STP|STP1|Sulfotransferase Family, Cytosolic, 1A, Phenol-Preferring, Member 1 wt Allele|TSPST1|Ts-PST	Human SULT1A1 wild-type allele is located in the vicinity of 16p12.1 and is approximately 18 kb in length. This allele, which encodes sulfotransferase 1A1 protein, plays a role in the sulfate conjugation of catecholamines, phenolic drugs and neurotransmitters.	SULT1A1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107443>	C17210	Sulfotransferase 1A1|Aryl Sulfotransferase 1|EC 2.8.2.1|HAST1/HAST2|P-PST|Phenol Sulfotransferase 1|Phenol-Sulfating Phenol Sulfotransferase 1|ST1A3|SULT1A1|Thermostable Phenol Sulfotransferase|Thermostable Phenol Sulfotransferase1|Ts-PST	Sulfotransferase 1A1 (295 aa, ~34 kDa) is encoded by the human SULT1A1 gene. This protein is involved in the sulfate conjugation of catecholamines, phenolic drugs and neurotransmitters.	Sulfotransferase 1A1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107444>	C20194	CSNK2B Gene|CSNK2B|CSNK2B|Casein Kinase 2, Beta Polypeptide Gene	This gene plays a role in the regulation of casein kinase II.	CSNK2B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107445>	C107444	CSNK2B wt Allele|CK2B|CK2N|CSK2B|Casein Kinase 2, Beta Polypeptide wt Allele|G5A	Human CSNK2B wild-type allele is located in the vicinity of 6p21.33 and is approximately 5 kb in length. This allele, which encodes casein kinase II subunit beta protein, is involved in the regulation of casein kinase II.	CSNK2B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107446>	C18466	Casein Kinase II Subunit Beta|CK II Beta|Casein Kinase II Beta Subunit|G5a, Phosvitin|Phosvitin|Protein G5a	Casein kinase II subunit beta (215 aa, ~25 kDa) is encoded by the human CSNK2B gene. This protein plays a role in the regulation of casein kinase II.	Casein Kinase II Subunit Beta		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107447>	C25993|C20103	GABRG1 Gene|GABRG1|GABRG1|Gamma-Aminobutyric Acid (GABA) A Receptor, Gamma 1 Gene	This gene is involved in the regulation of neurotransmission.	GABRG1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107448>	C107447	GABRG1 wt Allele|Gamma-Aminobutyric Acid (GABA) A Receptor, Gamma 1 wt Allele	Human GABRG1 wild-type allele is located in the vicinity of 4p12 and is approximately 88 kb in length. This allele, which encodes gamma-aminobutyric acid receptor subunit gamma-1 protein, plays a role in mediating neuronal inhibition.	GABRG1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107449>	C28505|C18106	Gamma-Aminobutyric Acid Receptor Subunit Gamma-1|GABA(A) Receptor Subunit Gamma-1|GABA(A) Receptor, Gamma|GABRG1|Gamma-1 Polypeptide|Gamma-Aminobutyric Acid Receptor Subunit Gamma	Gamma-aminobutyric acid receptor subunit gamma-1 (465 aa, ~54 kDa) is encoded by the human GABRG1 gene. This protein is involved in mediating neuronal inhibition.	Gamma-Aminobutyric Acid Receptor Subunit Gamma-1		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10744>	C61063	Filgrastim/Tretinoin|ATRA/G-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107450>	C21176|C178221|C16393	67 kDa Laminin Receptor|67 kD Laminin Receptor|67LR|67kD Laminin Receptor|67kD, Ribosomal Protein SA|Colon Carcinoma Laminin-Binding Protein|LAMBR|LAMR1|LR|LamR|Laminin Receptor|Laminin Receptor 1|Laminin Receptor, 67-kD|Laminin Receptor-1|Laminin Receptor-1 (67kD)	67 kDa laminin receptor is a homodimer of 40S ribosomal protein SA. This cell surface receptor binds laminin and may interact with major prion protein.	67 kDa Laminin Receptor		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107451>	C26057	DDX31 Gene|DDX31|DDX31|DEAD-Box Helicase 31 Gene	This gene plays a role in the regulation of RNA secondary structure.	DDX31 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107452>	C107451	DDX31 wt Allele|DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 31 Gene|DEAD-Box Helicase 31 wt Allele|FLJ13633|FLJ14578|FLJ23349|PPP1R25	Human DDX31 wild-type allele is located in the vicinity of 9q34.13 and is approximately 77 kb in length. This allele, which encodes probable ATP-dependent RNA helicase DDX31 protein, is involved in the regulation of RNA secondary structure.	DDX31 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107453>	C17417	Probable ATP-Dependent RNA Helicase DDX31|DDX31|DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 31|DEAD Box Protein 31|DEAD/DEXH Helicase DDX31|DEAD/H (Asp-Glu-Ala-Asp/His) Box Polypeptide 31|EC 3.6.4.13|G2 Helicase|Helicain|Protein Phosphatase 1, Regulatory Subunit 25	Probable ATP-dependent RNA helicase DDX31 (851 aa, ~94 kDa) is encoded by the human DDX31 gene. This protein plays a role in the regulation of RNA secondary structure.	Probable ATP-Dependent RNA Helicase DDX31		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107454>	C25997	GAB1 Gene|GAB1|GAB1|GRB2 Associated Binding Protein 1 Gene	This gene is involved in intracellular signaling.	GAB1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107455>	C107454	GAB1 wt Allele|DFNB26|Deafness, Autosomal Recessive 26 Gene|GRB2 Associated Binding Protein 1 wt Allele|GRB2-Associated Binding Protein 1 Gene	Human GAB1 wild-type allele is located in the vicinity of 4q31.21 and is approximately 138 kb in length. This allele, which encodes GRB2-associated-binding protein 1, plays a role in the intracellular signaling pathways of several growth factor receptors.	GAB1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107456>	C26231	GRB2-Associated-Binding Protein 1|GAB1|GRB2-Associated Binder 1|GRB2-Associated Binding Protein 1|Growth Factor Receptor Bound Protein 2-Associated Protein|Growth Factor Receptor Bound Protein 2-Associated Protein 1	GRB2-associated-binding protein 1 (694 aa, ~77 kDa) is encoded by the human GAB1 gene. This protein is involved in intracellular signaling from growth factor receptors.	GRB2-Associated-Binding Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107457>	C38534	ATF4 Gene|ATF4|ATF4|Activating Transcription Factor 4 Gene	This gene plays a role in transcription.	ATF4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107458>	C107457	ATF4 wt Allele|Activating Transcription Factor 4 wt Allele|CREB-2|CREB2|TAXREB67|TXREB	Human ATF4 wild-type allele is located in the vicinity of 22q13.1 and is approximately 3 kb in length. This allele, which encodes cyclic AMP-dependent transcription factor ATF-4 protein, is involved in the regulation of gene transcription.	ATF4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107459>	C17286	Cyclic AMP-Dependent Transcription Factor ATF-4|ATF4|CAMP Response Element-Binding Protein 2|CAMP-Dependent Transcription Factor ATF-4|CAMP-Responsive Element-Binding Protein 2|Cyclic AMP-Responsive Element-Binding Protein 2|DNA-Binding Protein TAXREB67|Tax-Responsive Enhancer Element-Binding Protein 67	Cyclic AMP-dependent transcription factor ATF-4 (351 aa, ~39 kDa) is encoded by the human ATF4 gene. This protein plays a role in the regulation of gene transcription.	Cyclic AMP-Dependent Transcription Factor ATF-4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10745>	C61063	Cyclophosphamide/Procarbazine/Vincristine|CTX/PCB/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107460>	C28533	SLC16A1 Gene|MCT1|SLC16A1|SLC16A1|Solute Carrier Family 16 Member 1 Gene	This gene is involved in monocarboxylate transport.	SLC16A1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|Pediatric Oncology Biomarkers/Targets Associated with Other Relevant Evidence
C107461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107461>	C107460	SLC16A1 wt Allele|HHF7|MCT|MCT 1|MCT1|Solute Carrier Family 16 (Monocarboxylate Transporter), Member 1 Gene|Solute Carrier Family 16 (Monocarboxylic Acid Transporters), Member 1 Gene|Solute Carrier Family 16 Member 1 wt Allele|Solute Carrier Family 16, Member 1 (Monocarboxylic Acid Transporter 1) Gene	Human SLC16A1 wild-type allele is located in the vicinity of 1p12 and is approximately 45 kb in length. This allele, which encodes monocarboxylate transporter 1 protein, plays a role in the transport of monocarboxylates across the plasma membrane. Mutations in this gene are associated with erythrocyte lactate transporter defect and hyperinsulinemic hypoglycemia, familial, 7.	SLC16A1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107462>	C16386	Monocarboxylate Transporter 1|MCT 1|MCT1|SLC16A1|Solute Carrier Family 16 Member 1	Monocarboxylate transporter 1 (500 aa, ~54 kDa) is encoded by the human SLC16A1 gene. This protein is involved in monocarboxylate transport across the plasma membrane.	Monocarboxylate Transporter 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Biomarkers/Targets Associated with Other Relevant Evidence
C107463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107463>	C28533	SLC16A4 Gene|SLC16A4|SLC16A4|Solute Carrier Family 16, Member 4 Gene	This gene plays a role in monocarboxylate transport.	SLC16A4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107464>	C107463	SLC16A4 wt Allele|MCT 4|MCT 5|MCT4|MCT5|Solute Carrier Family 16, Member 4 wt Allele	Human SLC16A4 wild-type allele is located in the vicinity of 1p13.3 and is approximately 28 kb in length. This allele, which encodes monocarboxylate transporter 5 protein, is involved in monocarboxylate transport across the plasma membrane.	SLC16A4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107465>	C16386	Monocarboxylate Transporter 5|Monocarboxylate Transporter 4|SLC16A4|Solute Carrier Family 16 (Monocarboxylic Acid Transporters), Member 4|Solute Carrier Family 16 Member 4|Solute Carrier Family 16, Member 4 (Monocarboxylic Acid Transporter 5)	Monocarboxylate transporter 5 (487 aa, ~54 kDa) is encoded by the human SLC16A4 gene. This protein plays a role in the transport of monocarboxylates across the plasma membrane.	Monocarboxylate Transporter 5		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107466>	C28533	SLC46A1 Gene|SLC46A1|SLC46A1|Solute Carrier Family 46 (Folate Transporter), Member 1 Gene	This gene plays a role in folate and antifolate transport.	SLC46A1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107467>	C107466	SLC46A1 wt Allele|G21|HCP1|HsPCFT|MGC9564|PCFT|PCFT/HCP1|Solute Carrier Family 46 (Folate Transporter), Member 1 wt Allele|hPCFT	Human SLC46A1 wild-type allele is located in the vicinity of 17q11.2 and is approximately 13 kb in length. This allele, which encodes proton-coupled folate transporter protein, is involved in transport of both folate and antifolate across the plasma membrane, and heme transport in duodenal enterocytes. Mutations in this gene are associated with hereditary folate malabsorption.	SLC46A1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107468>	C16386	Proton-Coupled Folate Transporter|Heme Carrier Protein 1|SLC46A1|Solute Carrier Family 46 Member 1|Solute Carrier Family 46, Member 1	Proton-coupled folate transporter (459 aa, ~50 kDa) is encoded by the human SLC46A1 gene. This protein plays a role in folate and antifolate transport across the plasma membrane, and heme transport in duodenal enterocytes.	Proton-Coupled Folate Transporter		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107469>	C25900|C20988	CEACAM6 Gene|CEACAM6|CEACAM6|Carcinoembryonic Antigen Related Cell Adhesion Molecule 6 Gene	This gene plays a probable role in both cell-cell signaling and cell adhesion.	CEACAM6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10746>	C61063	Dexamethasone/Doxorubicin/Prednisone/Quinine/Vincristine|DM/DOX/PRED/QUIN/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107470>	C107469	CEACAM6 wt Allele|CD66c|CEAL|Carcinoembryonic Antigen Related Cell Adhesion Molecule 6 wt Allele|Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6 (Non-Specific Cross Reacting Antigen) Gene|NCA	Human CEACAM6 wild-type allele is located in the vicinity of 19q13.2 and is approximately 17 kb in length. This allele, which encodes carcinoembryonic antigen-related cell adhesion molecule 6 protein, plays a probable role in both cell adhesion and cell-cell signaling.	CEACAM6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107471>	C18466	Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6|CD66c|CD66c Antigen|CEA-Like Protein|CEACAM6|Cluster Of Differentiation 66c|Non-Specific Cross Reacting Antigen|Non-Specific Crossreacting Antigen|Nonspecific Crossreacting Antigen|Normal Cross-Reacting Antigen|Normal Crossreacting Antigen	Carcinoembryonic antigen-related cell adhesion molecule 6 (344 aa, ~37 kDa) is encoded by the human CEACAM6 gene. This plays a probable role in both cell-cell signaling and cell adhesion.	Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107472>	C20709	NR1I3 Gene|NR1I3|NR1I3|Nuclear Receptor Subfamily 1, Group I, Member 3 Gene	This gene is involved in both drug metabolism and bilirubin clearance.	NR1I3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107473>	C107472	NR1I3 wt Allele|CAR|CAR1|MB67|Nuclear Receptor Subfamily 1, Group I, Member 3 wt Allele	Human NR1I3 wild-type allele is located in the vicinity of 1q23.3 and is approximately 9 kb in length. This allele, which encodes nuclear receptor subfamily 1 group I member 3 protein, plays a role in the regulation of xenobiotic and endobiotic metabolism.	NR1I3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107474>	C17671	Nuclear Receptor Subfamily 1 Group I Member 3|Constitutive Activator of Retinoid Response|Constitutive Active Receptor|Constitutive Active Response|Constitutive Androstane Nuclear Receptor Variant 2|Constitutive Androstane Nuclear Receptor Variant 3|Constitutive Androstane Nuclear Receptor Variant 4|Constitutive Androstane Nuclear Receptor Variant 5|Constitutive Androstane Receptor|NR1I3|Orphan Nuclear Hormone Receptor|Orphan Nuclear Receptor MB67	Nuclear receptor subfamily 1 group I member 3 (352 aa, ~40 kDa) is encoded by the human NR1I3 gene. This protein is involved in the regulation of xenobiotic and endobiotic metabolism.	Nuclear Receptor Subfamily 1 Group I Member 3		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107475>	C21295	ELAVL1 Gene|ELAV (Embryonic Lethal, Abnormal Vision, Drosophila)-Like 1 (Hu Antigen R) Gene|ELAVL1|ELAVL1	This gene plays a role in the regulation of gene expression.	ELAVL1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107476>	C107475	ELAVL1 wt Allele|ELAV (Embryonic Lethal, Abnormal Vision, Drosophila)-Like 1 (Hu Antigen R) wt Allele|ELAV1|HUR|Hua|MelG	Human ELAVL1 wild-type allele is located in the vicinity of 19p13.2 and is approximately 47 kb in length. This allele, which encodes ELAV-like protein 1, is involved in the regulation of mRNA stability.	ELAVL1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107477>	C21298	ELAV-Like Protein 1|ELAV Like RNA Binding Protein 1|Embryonic Lethal, Abnormal Vision, Drosophila, Homolog-Like 1|Hu Antigen R|Hu-Antigen R	ELAV-like protein 1 (326 aa, ~36 kDa) is encoded by the human ELAVL1 gene. This protein plays a role in the regulation of gene expression by stabilizing AU-rich element-containing mRNAs.	ELAV-Like Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107478>	C98362	KRAS NP_004976.2:p.Q61X|GTPase KRas Gln61Xxx|GTPase KRas Q61X|K-Ras 2 Q61X|KRAS Codon 61 Mutation|KRAS Gln61Xxx|KRAS NP_004976.2:p.Gln61Xxx|KRAS Q61 Mutation|KRAS Q61X|KRAS p.Gln61Xxx|KRAS p.Q61X|Ki-Ras Q61X|NP_004976.2:p.Gln61Xxx|NP_004976.2:p.Q61X|Specific codon 61 mutation not stated|c-K-ras Q61X	A change in the amino acid residue at position 61 in the GTPase KRas protein where glutamine has been replaced by another amino acid.	KRAS NP_004976.2:p.Q61X		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107479>	C98362	KRAS NP_004976.2:p.A146X|GTPase KRas A146X|GTPase KRas Ala146Xxx|K-Ras 2 A146X|KRAS A146 Mutation|KRAS A146X|KRAS Ala146Xxx|KRAS NP_004976.2:p.Ala146Xxx|KRAS p.A146X|KRAS p.Ala146Xxx|Ki-Ras A146X|NP_004976.2:p.A146X|NP_004976.2:p.Ala146Xxx|c-K-ras A146X	A change in the amino acid residue at position 146 in the GTPase KRas protein where alanine has been replaced by another amino acid.	KRAS NP_004976.2:p.A146X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10747>	C63588	Dexamethasone/Doxorubicin/Prednisone/Vincristine Regimen|DM/DOX/PRED/VCR|Dexamethasone-Doxorubicin-Prednisone-Vincristine|Dexamethasone/Doxorubicin/Prednisone/Vincristine|Doxorubicin/Vincristine/Dexamethasone/Prednisone	A regimen consisting of dexamethasone, doxorubicin, prednisone, and vincristine that may be used in the treatment of acute lymphoblastic leukemia (ALL).			Therapeutic or Preventive Procedure	
C107480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107480>	C98460	PIK3CA NP_006209.2:p.E542X|NP_006209.2:p.Glu542Xxx|PI3Kalpha E542X|PIK3CA E542 Mutation|PIK3CA E542X|PIK3CA Glu542Xxx|PIK3CA NP_006209.2:p.Glu542Xxx|PIK3CA p.E542X|PIK3CA p.Glu542Xxx|Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 110 kDa Catalytic Subunit Alpha E542X|Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Isoform E542X|Phosphoinositide-3-Kinase Catalytic Alpha Polypeptide E542X|p110alpha E542X	A change in the amino acid residue at position 542 in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform protein where glutamic acid has been replaced by another amino acid.	PIK3CA NP_006209.2:p.E542X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107481>	C98460	PIK3CA NP_006209.2:p.E545X|NP_006209.2:p.Glu545Xxx|PI3Kalpha E545X|PIK3CA E545 Mutation|PIK3CA E545X|PIK3CA Glu545Xxx|PIK3CA NP_006209.2:p.Glu545Xxx|PIK3CA p.E545X|PIK3CA p.Glu545Xxx|Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 110 kDa Catalytic Subunit Alpha E545X|Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Isoform E545X|Phosphoinositide-3-Kinase Catalytic Alpha Polypeptide E545X|p110alpha E545X	A change in the amino acid residue at position 545 in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform protein where glutamic acid has been replaced by another amino acid.	PIK3CA NP_006209.2:p.E545X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107482>	C98460	PIK3CA NP_006209.2:p.H1047X|NP_006209.2:p.His1047Xxx|PI3Kalpha H1047X|PIK3CA H1047 Mutation|PIK3CA H1047X|PIK3CA His1047Xxx|PIK3CA NP_006209.2:p.His1047Xxx|PIK3CA p.H1047X|PIK3CA p.His1047Xxx|Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 110 kDa Catalytic Subunit Alpha H1047X|Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Isoform H1047X|Phosphoinositide-3-Kinase Catalytic Alpha Polypeptide H1047X|p110alpha H1047X	A change in the amino acid residue at position 1047 in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform protein where histidine has been replaced by another amino acid.	PIK3CA NP_006209.2:p.H1047X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107483>	C98439	NRAS NP_002515.1:p.G12X|GTPase NRas G12X|NP_002515.1:p.G12X|NP_002515.1:p.Gly12Xxx|NRAS G12 Mutation|NRAS G12X|NRAS Gly12Xxx|NRAS NP_002515.1:p.Gly12Xxx|NRAS p.G12X|NRAS p.Gly12Xxx|Transforming Protein N-Ras G12X	A change in the amino acid residue at position 12 in the GTPase NRas protein where glycine has been replaced by another amino acid.	NRAS NP_002515.1:p.G12X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107484>	C98439	NRAS NP_002515.1:p.G13X|GTPase NRas G13X|NP_002515.1:p.G13X|NP_002515.1:p.Gly13Xxx|NRAS G13 Mutation|NRAS G13X|NRAS Gly13Xxx|NRAS NP_002515.1:p.Gly13Xxx|NRAS p.G13X|NRAS p.Gly13Xxx|Transforming Protein N-Ras G13X	A change in the amino acid residue at position 13 in the GTPase NRas protein where glycine has been replaced by another amino acid.	NRAS NP_002515.1:p.G13X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107485>	C98439	NRAS NP_002515.1:p.Q61X|GTPase NRas Q61X|NP_002515.1:p.Gln61Xxx|NP_002515.1:p.Q61X|NRAS Gln61Xxx|NRAS NP_002515.1:p.Gln61Xxx|NRAS Q61 Mutation|NRAS Q61X|NRAS p.Gln61Xxx|NRAS p.Q61X|Transforming Protein N-Ras Q61X	A change in the amino acid residue at position 61 in the GTPase NRas protein where glutamine has been replaced by another amino acid.	NRAS NP_002515.1:p.Q61X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107486>	C18493	Tumor Microenvironment of Metastasis Density|TMEM Density|TMEM Score|Tumor Microenvironment of Metastasis Score	A marker of potential sites for tumor metastasis, where separate histological stains for perivascular macrophages, blood vessel-resident endothelial cells and tumor cells are co-localized in a tissue section.	Tumor Microenvironment of Metastasis Density		Indicator, Reagent, or Diagnostic Aid	CTRP Biomarker Terminology|CTRP Terminology
C107487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107487>	C26070	ALPP Gene|ALPP|ALPP|Alkaline Phosphatase, Placental Gene	This gene plays a role in phosphatase activity in the placenta.	ALPP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107488>	C27993	Triphasic	Occurring in or characterized by three phases or stages.			Functional Concept	
C107489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107489>	C20641	Australia-Modified Karnofsky Performance Status|AKPS|Australia-Modified Karnofsky Performance Scale (AKPS)|Australia-Modified Karnofsky Performance Status Scale	A measure of an individual's overall performance status or ability to perform their activities of daily living while undergoing care using a single score assigned by a clinician based on observations of a patient's ability to perform common tasks relating to activity, work and self-care.			Clinical Attribute	
C10748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10748>	C61063	Estramustine/Etoposide|EM/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107490>	C107489	Australia-Modified Karnofsky Performance Status 40	In bed more than 50% of the time.			Clinical Attribute	Australia-Modified Karnofsky Performance Status
C107491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107491>	C107489	Australia-Modified Karnofsky Performance Status 30	Almost completely bedfast.			Clinical Attribute	Australia-Modified Karnofsky Performance Status
C107492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107492>	C107489	Australia-Modified Karnofsky Performance Status 20	Totally bedfast and requiring extensive nursing care by professionals and/or family.			Clinical Attribute	Australia-Modified Karnofsky Performance Status
C107493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107493>	C107489	Australia-Modified Karnofsky Performance Status 10	Comatose or barely arousable.			Clinical Attribute	Australia-Modified Karnofsky Performance Status
C107494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107494>	C25404	Auto-triggered	Activation of a system without outside interference.			Activity	
C107495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107495>	C16295	Anti-Drug Antibody|ADA|ATA|Anti-Drug Antibodies|Anti-Drug Antibodies|Anti-Therapeutic Agent Antibody|Anti-Therapeutic Antibody	An antibody that binds to an administered drug or therapeutic agent. Expression of these antibodies is thought to be induced by (repeated) administration.	Anti-Drug Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C107496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107496>	C17898|C107495	Neutralizing Anti-Drug Antibody|NADA|Neutralizing Anti-Drug Antibodies	An antibody that binds to an administered drug and inhibits the biological activity of that drug. Expression of these antibodies is thought to be induced by (repeated) drug administration.	Neutralizing Anti-Drug Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C107497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107497>	C27993	Convenient|Convenience	Suited for the intended purpose.			Qualitative Concept	
C107498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107498>	C20189	Useful|Usefulness	Helpful for doing or achieving something.			Qualitative Concept	
C107499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107499>	C4876	Sickness|Sick|Sick	A state of ill health, bodily malfunction, or discomfort.			Sign or Symptom	
C10749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10749>	C61063	Interferon Beta/Isotretinoin|13-CRA/IFN-B			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1074>	C78568	Dinoprost Tromethamine|DINOPROST TROMETHAMINE|Dinoprost tromethamine	A synthetic analogue of the naturally occurring prostaglandin F2 alpha.  Prostaglandin F2 alpha stimulates myometrial activity, relaxes the cervix, inhibits corpus luteal steroidogenesis, and induces luteolysis by direct action on the corpus luteum. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C107501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107501>	C29637|C226455	Aloe/Anise/Ascorbic Acid/Clove/Peppermint/Spearmint/Thyme-based Mouthwash	A herbal-based mouthrinse containing aloe, anise, ascorbic acid, clove, peppermint, spearmint and thyme, with potential anti-mucositic activity. When aloe/anise/ascorbic acid/clove/peppermint/spearmint/thyme-based mouthwash is used as a rinse, the ingredients in this agent may prevent or decrease inflammation and bacterial infections.This may prevent or inhibit radiotherapy- or chemotherapy-induced mucositis and decreases the pain associated with mucositis.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C107502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107502>	C1663	Glioblastoma Cancer Vaccine ERC1671|ERC-1671|ERC1671|Gliovac	A cancer vaccine composed of a combination of autologous glioblastoma (GBM) tumor cells, allogeneic GBM tumor cells, generated from three different GBM donor cancer patients, and the lysates of all of these cells, with potential antineoplastic activity. Upon intradermal administration of GBM cancer vaccine ERC1671, the mixture of the autologous and allogeneic cells and lysates stimulates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against GBM-associated antigens, which leads to the destruction of glioblastoma cells.	Glioblastoma Cancer Vaccine ERC1671		Cell|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C107503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107503>	C129821|C129820	Nogapendekin Alfa|NOGAPENDEKIN ALFA	A mutated form of the cytokine interleukin (IL)-15 (IL-15N72D), with potential immunomodulating and antineoplastic activities. Upon administration, nogapendekin alfa binds to the IL-15 receptor on natural killer (NK) and CD8+ T lymphocytes, which activates and increases the levels of NK cells and memory T-cells. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation.	Nogapendekin Alfa		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C107504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107504>	C717|C204256	Recombinant Human Adenovirus Type 5 H101|H-101|H101|Oncorine|rAd5 H101	A replication selective, recombinant, E1B and partial E3 gene deleted form of human adenovirus type 5, with potential antineoplastic activity. Upon intratumoral injection of recombinant human adenovirus type 5, the adenovirus selectively replicates in cancer cells while preventing viral replication in normal, healthy cells. This induces a selective adenovirus-mediated cytotoxicity in cancer cells, which leads to cancer cell lysis. In addition, viral spread to adjacent cells, following lysis of infected cells, may activate the immune system to kill the infected tumor cells. The E1B protein causes p53 inactivation, which promotes viral replication; deletion of E1B allows for p53 activation in normal cells, which prevents viral replication in normal, healthy cells. The mutation and subsequent inactivation of p53 in cancer cells enables the E1B-deleted adenovirus to selectively replicate in cancer cells. Partial deletion of E3, encoding the adenovirus death protein, enhances the safety profile of the administered adenovirus.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C107505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107505>	C137999|C129826	CD138CAR-CD137/TCRzeta-expressing T Lymphocytes|CART-138 TCR zeta:CD137	T-lymphocytes transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) specific for syndecan-1 (CD138) (CART-138 T cells) coupled to the signaling domain of 4-1BB (CD137), and the zeta chain of the T-cell receptor (TCRzeta), with potential immunomodulating and antineoplastic activities. Upon transfusion, CD138CAR- CD137/TCRzeta -expressing T lymphocytes directs the T-lymphocytes to syndecan-1-expressing tumor cells and induces selective toxicity in those tumor cells. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of syndecan-1. Syndecan-1, a type 1 transmembrane proteoglycan and tumor associated antigen, is overexpressed in a variety of cancer cells. It plays a key role in the regulation of cell growth, differentiation, and adhesion, and its expression is correlated with poor prognosis.	CD138CAR-CD137/TCRzeta-expressing T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C107506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107506>	C156804	Tazemetostat|E 7438|E-7438|E7438|EPZ 6438|EPZ-6438|EPZ6438|N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(oxan-4-yl)amino)-4-methyl-4'-((morpholin-4-yl)methyl)(1,1'-biphenyl)-3-carboxamide|N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide|TAZEMETOSTAT	An orally available, small molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone methyl transferase EZH2, with potential antineoplastic activity. Upon oral administration, tazemetostat selectively inhibits the activity of both wild-type and mutated forms of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased tumor cell proliferation in EZH2 mutated cancer cells. EZH2, which belongs to the class of histone methyltransferases (HMTs), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation.	Tazemetostat		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCIt Antineoplastic Agent Terminology
C107507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107507>	C91105	Multinational Association of Supportive Care in Cancer Antiemesis Tool|MASCC Antiemesis Tool|MASCC Antiemesis Tool (MAT)|MAT	A self-administered questionnaire designed to assess a patient's level of nausea and vomiting associated with chemotherapy.			Intellectual Product	
C107508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107508>	C25213	Baseline Nausea and Vomiting	A set of parameters established as a reference to gauge levels of nausea and vomiting.			Clinical Attribute	Multinational Association of Supportive Care in Cancer Antiemesis Tool
C107509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107509>	C173604	Vomiting in the Last 24 Hours Question|In the last 24 hours, did you have any vomiting|Vomiting in the Last 24 Hours	A question about whether an individual vomited in the last 24 hours.			Intellectual Product	Multinational Association of Supportive Care in Cancer Antiemesis Tool
C10750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10750>	C61063	Beta Carotene/Vitamin A|beta carotene/VIT-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107510>	C125278	How Often Vomited During This Period Question|How Often Vomited During This Period|If you vomited during this period, how many times did it happen	A question about how often an individual vomited during the specified time period.			Intellectual Product	Multinational Association of Supportive Care in Cancer Antiemesis Tool
C107511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107511>	C173130	Nausea in the Last 24 Hours Question|In the last 24 hours, did you have any nausea|Nausea in the Last 24 Hours	A question about whether an individual had nausea in the last 24 hours.			Intellectual Product	Multinational Association of Supportive Care in Cancer Antiemesis Tool
C107512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107512>	C107511	How Much Nausea in the Last 24 Hours Question|How Much Nausea in the Last 24 Hours|How much nausea did you have in the last 24 hours	A question about how much nausea an individual experienced in the last 24 hours.			Intellectual Product	Multinational Association of Supportive Care in Cancer Antiemesis Tool
C107513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107513>	C3259	Nausea and Vomiting During the First 24 Hours After Chemotherapy|Nausea and Vomiting during the first 24 hours after chemotherapy	Nausea and vomiting occurring during the first 24 hours following chemotherapy.			Finding	Multinational Association of Supportive Care in Cancer Antiemesis Tool
C107514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107514>	C173604	Vomiting in the 24 Hours Since Chemotherapy Question|In the 24 hours since chemotherapy, did you have any vomiting|Vomiting in the 24 Hours Since Chemotherapy	A question about whether an individual vomited in the 24 hours after chemotherapy.			Intellectual Product	Multinational Association of Supportive Care in Cancer Antiemesis Tool
C107515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107515>	C125278	How Often Vomited in the 24 Hours Since Chemotherapy Question|How Often Vomited in the 24 Hours Since Chemotherapy|If you vomited in the 24 hours since chemotherapy, how many times did it happen	A question about how often an individual vomited in the 24 hours after chemotherapy.			Intellectual Product	Multinational Association of Supportive Care in Cancer Antiemesis Tool
C107516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107516>	C107511	Nausea in the 24 Hours Since Chemotherapy Question|In the 24 hours since chemotherapy, did you have any nausea|Nausea in the 24 Hours Since Chemotherapy	A question about whether an individual had nausea in the 24 hours after chemotherapy.			Intellectual Product	Multinational Association of Supportive Care in Cancer Antiemesis Tool
C107517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107517>	C3259	Delayed Nausea and Vomiting	Nausea and vomiting occurring more than 24 hours following chemotherapy.			Finding	Multinational Association of Supportive Care in Cancer Antiemesis Tool
C107518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107518>	C173604	Vomiting During This Period Question|During this period, did you have any vomiting|Vomiting During This Period	A question about whether an individual vomited during the specified time period.			Intellectual Product	Multinational Association of Supportive Care in Cancer Antiemesis Tool
C107519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107519>	C173130	Nausea During This Period Question|During this period, did you have any nausea|Nausea During This Period	A question about whether an individual had nausea during the specified time period.			Intellectual Product	Multinational Association of Supportive Care in Cancer Antiemesis Tool
C10751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10751>	C61063	Dipyridamole/Fluorouracil/Leucovorin Calcium/Mitomycin|CF/DP/5-FU/MITO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107520>	C173130	How Much Nausea During This Period Question|How Much Nausea During This Period|How much nausea did you have during this period|Nausea|Nausea Frequency	A question about how much nausea an individual experienced during the specified time period.			Intellectual Product	Multinational Association of Supportive Care in Cancer Antiemesis Tool|Symptom Distress Scale
C107521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107521>	C226692|C226671	As Much As Possible|As much as possible	A response that indicates the largest amount imagined.			Intellectual Product	Multinational Association of Supportive Care in Cancer Antiemesis Tool
C107522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107522>	C173604	Did You Take Any Medication Except the Study Drug for Vomiting in the Past 24 Hours Question|Did You Take Any Medication Except the Study Drug for Vomiting in the Past 24 Hours|Did you take any medication (except study drug) for VOMITING in the past 24 hours	A question about whether an individual took any medication, except the study drug, for vomiting in the past 24 hours.			Intellectual Product	Multinational Association of Supportive Care in Cancer Antiemesis Tool
C107523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107523>	C173130	Did You Take Any Medication Except the Study Drug for Nausea in the Past 24 Hours Question|Did You Take Any Medication Except the Study Drug for Nausea in the Past 24 Hours|Did you take any medication (except study drug) for NAUSEA in the past 24 hours	A question about whether an individual took any medication, except the study drug, for nausea in the past 24 hours.			Intellectual Product	Multinational Association of Supportive Care in Cancer Antiemesis Tool
C107524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107524>	C25638	Scheduled By Doctor|Scheduled by doctor	Indicates that an event was planned in advance by a doctor.			Idea or Concept	Multinational Association of Supportive Care in Cancer Antiemesis Tool
C107525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107525>	C25638	Needed Help	The individual required assistance.			Idea or Concept	Multinational Association of Supportive Care in Cancer Antiemesis Tool
C107526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107526>	C25638	Concerned I Would Develop Symptoms|Concerned I would develop symptoms	The individual was concerned they would develop symptoms.			Idea or Concept	Multinational Association of Supportive Care in Cancer Antiemesis Tool
C107527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107527>	C34941	Pregnancy-Related Nausea and/or Vomiting|Pregnancy-related nausea and/or vomiting	Nausea and/or vomiting co-occurring with pregnancy.			Finding	Multinational Association of Supportive Care in Cancer Antiemesis Tool
C107528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107528>	C173902|C157609	Chemotherapy-Related Nausea and/or Vomiting|Chemotherapy-Induced Nausea and Vomiting|Chemotherapy-related nausea and/or vomiting	Nausea and/or vomiting co-occurring with a cycle of chemotherapy.	Chemotherapy-Induced Nausea and Vomiting		Finding	CTRP Disease Terminology|CTRP Terminology|Multinational Association of Supportive Care in Cancer Antiemesis Tool
C107529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107529>	C171256	Pillow	A cushion or support for the head or other body part; usually consisting of a cloth case surrounding a filler of feathers, down, plastic fibers, latex, rubber, or other foam material.			Manufactured Object	
C10752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10752>	C61063	Methotrexate/Paclitaxel|MTX/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107530>	C13442	Hepatojugular	Of, or pertaining to, the liver and jugular vein.			Spatial Concept	
C107531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107531>	C12555	Pancreatic Stellate Cell|PSC|PSCs|PaSC|PaSCs|Pancreatic Stellate Cells	A star-shaped, myofibroblast-like cell in the pancreas associated with tissue maintenance. When pancreatic stellate cells are activated in response to an injury, they proliferate and synthesize large amounts of extracellular matrix. Pancreatic cancer cells can increase the activation of pancreatic stellate cells, which leads to fibrosis.	Pancreatic Stellate Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C107532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107532>	C91105	Osoba Nausea and Emesis Module|ONEM	A self-administered questionnaire designed to measure the short-term impact of nausea, emesis, and retching on patients receiving emetogenic chemotherapy.			Intellectual Product	
C107533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107533>	C173584|C107511	Nausea Interfered With Appetite During Past 24 Hours Question|During the past 24 hours did NAUSEA interfere with your appetite|Nausea Interfered With Appetite During Past 24 Hours	A question about whether an individual had nausea that interfered with appetite during the past 24 hours.			Intellectual Product	Osoba Nausea and Emesis Module
C107534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107534>	C173925|C107511	Nausea Affected Sleep During Past 24 Hours Question|During the past 24 hours did NAUSEA affect your sleep|Nausea Affected Sleep During Past 24 Hours	A question about whether an individual had nausea that affected sleep during the past 24 hours.			Intellectual Product	Osoba Nausea and Emesis Module
C107535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107535>	C173584|C173458|C107511	Nausea Interfered with Physical Activities During Past 24 Hours Question|During the past 24 hours did NAUSEA interfere with your physical activities|Nausea Interfered with Physical Activities During Past 24 Hours	A question about whether an individual had nausea that interfered with physical activities during the past 24 hours.			Intellectual Product	Osoba Nausea and Emesis Module
C107536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107536>	C173584|C107511	Nausea Interfered With Social Life During Past 24 Hours Question|During the past 24 hours did NAUSEA interfere with your social life|Nausea Interfered With Social Life During Past 24 Hours	A question about whether an individual had nausea that interfered with social life during the past 24 hours.			Intellectual Product	Osoba Nausea and Emesis Module
C107537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107537>	C173584|C107511	Nausea Interfered With Enjoyment of Life During Past 24 Hours Question|During the past 24 hours did NAUSEA interfere with your enjoyment of life|Nausea Interfered With Enjoyment of Life During Past 24 Hours	A question about whether an individual had nausea that interfered with enjoyment of life during the past 24 hours.			Intellectual Product	Osoba Nausea and Emesis Module
C107538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107538>	C173604|C173584	Vomiting or Dry Heaves Interfered With Appetite During Past 24 Hours Question|During the past 24 hours did VOMITING or DRY HEAVES interfere with your appetite|Vomiting or Dry Heaves Interfered With Appetite During Past 24 Hours	A question about whether an individual had vomiting or dry heaves that interfered with appetite during the past 24 hours.			Intellectual Product	Osoba Nausea and Emesis Module
C107539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107539>	C173925|C173604	Vomiting or Dry Heaves Affected Sleep During Past 24 Hours Question|During the past 24 hours did VOMITING or DRY HEAVES affect your sleep|Vomiting or Dry Heaves Affected Sleep During Past 24 Hours	A question about whether an individual had vomiting or dry heaves that affected sleep during the past 24 hours.			Intellectual Product	Osoba Nausea and Emesis Module
C10753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10753>	C61063	Filgrastim/Methotrexate/Paclitaxel|G-CSF/MTX/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107540>	C173604|C173584|C173458	Vomiting or Dry Heaves Interfered with Physical Activities During Past 24 Hours Question|During the past 24 hours did VOMITING or DRY HEAVES interfere with your physical activities|Vomiting or Dry Heaves Interfered with Physical Activities During Past 24 Hours	A question about whether an individual had vomiting or dry heaves that interfered with physical activities during the past 24 hours.			Intellectual Product	Osoba Nausea and Emesis Module
C107541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107541>	C173604|C173584	Vomiting or Dry Heaves Interfered With Social Life During Past 24 Hours Question|During the past 24 hours did VOMITING or DRY HEAVES interfere with your social life|Vomiting or Dry Heaves Interfered With Social Life During Past 24 Hours	A question about whether an individual had vomiting or dry heaves that interfered with social life during the past 24 hours.			Intellectual Product	Osoba Nausea and Emesis Module
C107542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107542>	C173604|C173584	Vomiting or Dry Heaves Interfered With Enjoyment of Life During Past 24 Hours Question|During the past 24 hours did VOMITING or DRY HEAVES interfere with your enjoyment of life|Vomiting or Dry Heaves Interfered With Enjoyment of Life During Past 24 Hours	A question about whether an individual had vomiting or dry heaves that interfered with enjoyment of life during the past 24 hours.			Intellectual Product	Osoba Nausea and Emesis Module
C107543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107543>	C91105	Treatment Satisfaction Questionnaire for Medication|TSQM-9|Treatment Satisfaction Questionnaire for Medication (TSQM-9)	A 9 question subset of the Treatment Satisfaction Questionnaire for Medication that omits the five items of the side effects domain.			Intellectual Product	
C107544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107544>	C173792	Satisfaction with Ability of Medication to Prevent or Treat Condition Question|How satisfied or dissatisfied are you with the ability of the medication to prevent or treat your condition|Satisfaction with Ability of Medication to Prevent or Treat Condition	A question about how satisfied or dissatisfied an individual is with the ability of a medication to prevent or treat a condition.			Intellectual Product	Treatment Satisfaction Questionnaire for Medication
C107545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107545>	C173792|C173457	Satisfaction with Way Medication Relieves Symptoms Question|How satisfied or dissatisfied are you with the way the medication relieves your symptoms|Satisfaction with Way Medication Relieves Symptoms	A question about how satisfied or dissatisfied an individual is with the way a medication relieves symptoms.			Intellectual Product	Treatment Satisfaction Questionnaire for Medication
C107546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107546>	C173792	Satisfaction with Time it Takes Medication to Start Working Question|How satisfied or dissatisfied are you with the amount of time it takes the medication to start working|Satisfaction with Time it Takes Medication to Start Working	A question about how satisfied or dissatisfied an individual is with the amount of time is takes for a medication to start working.			Intellectual Product	Treatment Satisfaction Questionnaire for Medication
C107547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107547>	C91103	Ease of Using Medication in its Present Form Question|Ease of Using Medication in its Present Form|How easy or difficult is it to use the medication in its current form	A question about how easy or difficult it is to use a medication in its current form.			Intellectual Product	Treatment Satisfaction Questionnaire for Medication
C107548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107548>	C91103	Ease of Planning When to Use Medication Each Time Question|Ease of Planning When to Use Medication Each Time|How easy or difficult is it to plan when you will use the medication each time	A question about how easy or difficult it is to plan when to use a medication each time.			Intellectual Product	Treatment Satisfaction Questionnaire for Medication
C107549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107549>	C91103	Convenience of Taking Medication as Instructed Question|Convenience of Taking Medication as Instructed|How convenient or inconvenient is it to take the medication as instructed	A question about how convenient or inconvenient it is to take a medication as instructed.			Intellectual Product	Treatment Satisfaction Questionnaire for Medication
C10754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10754>	C61007	Cyclophosphamide/Doxorubicin/Paclitaxel|CTX/DOX/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107550>	C173086	Confidence that Taking Medication is a Good Thing Question|Confidence that Taking Medication is a Good Thing|Overall, how confident are you that taking the medication is a good thing for you	A question about how confident an individual is that taking the medication is a good thing.			Intellectual Product	Treatment Satisfaction Questionnaire for Medication
C107551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107551>	C91103	Certainty that Good Outweighs the Bad Things About Medication Question|Certainty that Good Outweighs the Bad Things About Medication|How certain are you that the good things about your medication outweigh the bad things	A question about how certain an individual is that the good things about a medication outweigh the bad things.			Intellectual Product	Treatment Satisfaction Questionnaire for Medication
C107552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107552>	C173792	Satisfaction with Medication Question|Satisfaction with Medication|Taking all things into account, how satisfied or dissatisfied are you with this medication	A question about how satisfied or dissatisfied an individual is with a medication.			Intellectual Product	Treatment Satisfaction Questionnaire for Medication
C107553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107553>	C107487	ALPP wt Allele|ALP|Alkaline Phosphatase, Placental (Regan Isozyme) Gene|Alkaline Phosphatase, Placental wt Allele|PALP|PLAP|PLAP-1	Human ALPP wild-type allele is located in the vicinity of 2q37 and is approximately 4 kb in length. This allele, which encodes alkaline phosphatase, placental type protein, is involved in placental alkaline phosphatase activity.	ALPP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107554>	C16276	Alkaline Phosphatase, Placental Type|ALPP|Alkaline Phosphatase Regan Isozyme|Alkaline Phosphomonoesterase|EC 3.1.3.1|PLAP-1|Placental Alkaline Phosphatase 1|Regan Isozyme	Alkaline phosphatase, placental type (535 aa, ~58 kDa) is encoded by the human ALPP gene. This protein plays a role in phosphate metabolism.	Alkaline Phosphatase, Placental Type		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107555>	C471	Bufalin|3,14-Dihydroxy-Bufa-20,22-Dienolide|3-Beta,14-Dihydroxy-5-Beta-Bufa-20,22-Dienolide|3beta,14beta-Dihydroxy-5beta-Bufa-20,22-Dienolide|5-Beta-Bufa-20,22-Dienolide, 3-Beta,14-Dihydroxy-|5beta-Bufa-20,22-Dienolide, 3beta,14-Dihydroxy- (8CI)|BUFALIN|Bufa-20,22-Dienolide, 3,14-Dihydroxy-, (3-Beta,5-Beta)- (9CI)|Bufa-20,22-Dienolide, 3,14-Dihydroxy-, (3beta,5beta)- (9CI)	An active ingredient and one of the glycosides in the traditional Chinese medicine ChanSu; it is also a bufadienolide toxin originally isolated from the venom of the Chinese toad Bufo gargarizans, with potential cardiotonic and antineoplastic activity. Although the mechanism of action of bufalin is still under investigation, this agent is a specific Na+/K+-ATPase inhibitor and can induce apoptosis in cancer cell lines through the activation of the transcription factor AP-1 via a mitogen activated protein kinase (MAPK) pathway.	Bufalin		Pharmacologic Substance	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C107556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107556>	C88516	Metanephrine|4-Hydroxy-3-Methoxy-Alpha-((Methylamino)Methyl)-Benzenemethanol|Benzenemethanol, 4-Hydroxy-3-Methoxy-Alpha-((Methylamino)Methyl)-|METANEPHRINE, (+/-)|Metadrenaline	A product of the O-methylation of epinephrine by catechol O-methyltransferase, which has no physiologic activity. Increased levels of free metanephrine in patient blood plasma samples may be a diagnostic indicator for pheochromocytoma.	Metanephrine		Hormone	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107557>	C26511	CYP3A Gene Locus|CYP3|CYP3A|CYP3A|Cytochrome P450 Family 3 Subfamily A Gene Locus|Cytochrome P450, Family 3, Subfamily A Gene Locus|Cytochrome P450, Subfamily IIIA (Niphedipine Oxidase) Gene Locus	Human CYP3A gene locus is located within 7q21.3-q22.1 and is approximately 218 kb in length. This locus includes four protein-encoding genes, CYP3A4, CYP3A5, CYP3A7 and CYP3A43, and two pseudogenes, CYP3A5P1 and CYP3A5P2. The protein-encoding genes are involved in drug metabolism and the biosynthesis of cholesterol, steroids and other lipids.	CYP3A Gene Locus		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107558>	C21176	B-Cell Receptor Complex|B Cell Receptor|B Cell Receptor Complex|B-Cell Antigen Receptor Complex|B-Cell Receptor|BCR	A membrane bound protein complex comprised of an immunoglobulin molecule associated with a heterodimer, called CD79, containing one CD79A protein and one CD79B protein. The immunoglobulin determines the ligand specificity of the complex and the CD79 heterodimer promotes signal transduction. This receptor is involved in antigen processing and presentation.	B-Cell Receptor Complex		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107559>	C21176	Casein Kinase 2|CK II|CK2|CKII|Casein Kinase II|EC 2.7.11.1	A serine/threonine kinase that is a tetrameric protein complex comprised of 2 catalytic alpha subunits and 2 regulatory beta subunits. This kinase complex is involved in the modulation of many cellular processes, including cell cycle progression and apoptosis regulation.	Casein Kinase 2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Biomarkers/Targets Associated with Other Relevant Evidence
C10755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10755>	C61063	Cisplatin/Etoposide/Fluorouracil/Leucovorin Calcium|CDDP/CF/5-FU/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107560>	C879	Thromboxane B2|(5Z,13E,15S)-9alpha,11,15-Trihydroxythromboxa-5,13-Dien-1-Oic Acid|5-Heptenoic Acid, 7-(Tetrahydro-4,6-Dihydroxy-2-(3-Hydroxy-1-Octenyl)- 2H-Pyran-3-Yl)-, (2R-(2alpha(1E,3S*),3beta(Z),4beta,6alpha))-|THROMBOXANE B2|TXB2|Thromboxa-5,13-Dien-1-Oic Acid, 9,11,15-Trihydroxy-, (5Z,9alpha,13E,15S)-	An eicosanoid and biologically inactive metabolite of thromboxane A2. Thromboxane B2 is released during anaphylaxis. As thromboxane A2 has a short half-life, the levels of thromboxane B2 can be used to indirectly measure the production of thromboxane A2	Thromboxane B2		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107561>	C27993	Certain|Certainty|Confident|Sure	Having no doubts; definitely true.			Qualitative Concept	
C107562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107562>	C136722	Angiotensin-2|AGT|Ang2|Angiotensin 1-8|Angiotensin II	Angiotensin-2 (8 aa, ~1 kDa) is encoded by the human AGT gene. This protein is involved in vasoconstriction, heart rate and renal absorption of water and sodium.	Angiotensin-2		Amino Acid, Peptide, or Protein|Hormone	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107563>	C18520	Fibrin Monomer|Soluble Fibrin Monomer	Derivatives of thrombin-cleaved fibrinogen that are plasma soluble due to limiting amounts of the clot promoting protein factor XIII. Detection of these proteins may be used to aid in the diagnosis or exclusion of thrombotic events or determine if a patient is at risk for post-operative hemorrhage.	Fibrin Monomer		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107564>	C16676	S-Nitroso-Hemoglobin|S-Nitrosated Hemoglobin|S-Nitrosohemoglobin	Hemoglobin that has a nitric oxide bound to the cysteine at position 93 in the beta-globin chain.	S-Nitroso-Hemoglobin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107565>	C16284	Alpha-Amylase|1,4-Alpha-D-Glucan Glucanohydrolase|4-Alpha-D-Glucan Glucanohydrolase|Alpha Amylase|EC 3.2.1.1|Endoamylase|Glycogenase	A family of hydrolases that cleaves alpha-linkages in polysaccharides, such as starch and glycogen, and yield glucose and maltose. This family includes the amylase forms that are produced by mammals. In humans, alpha-amylase is produced by salivary glands and the pancreas.	Alpha-Amylase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107566>	C20130	Cancer/Testis Antigen|CT|CTA|CTAs|CTs|Cancer Testis Antigen|Cancer Testis Antigens|Cancer/Testis Antigens	A family of immunogenic proteins that are found in a wide variety of tumors but are not expressed in adult somatic cells. Non-pathologic expression of these proteins is restricted to male germ cells.	Cancer/Testis Antigen		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107567>	C16447	C-Telopeptide of Type I Collagen Generated by Matrix Metalloproteinases|1CTP|CTX-MMP|Cross-Linked C-Terminal Telopeptide of Type I Collagen Generated by Matrix Metalloproteinases|ICTP|MMP-Generated C-Terminal Telopeptide Type 1 Collagen	This polypeptide is comprised of the carboxy-terminal portions of fibrillar collagen, which are joined through trivalent crosslinks and released during the degradation of mature type I collagen by matrix metalloproteinases. Increased serum concentrations of these peptides are associated with pathologies that cause bone lysis, such as multiple myeloma, osteolytic metastases, and rheumatoid arthritis. Increased blood levels of these peptides are associated with renal insufficiency.	C-Telopeptide of Type I Collagen Generated by Matrix Metalloproteinases		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107568>	C223204|C116399	PDGFRA NM_006206.4:c.2525A>T|CD140A c.2525A>T|NM_006206.4:c.2525A>T|PDGFR-2 c.2525A>T|PDGFR2 c.2525A>T|PDGFRA c.2525A>T|Platelet-Derived Growth Factor Receptor, Alpha Polypeptide c.2525A>T|RHEPDGFRA c.2525A>T	A nucleotide substitution at position 2525 of the coding sequence of the PDGFRA gene where adenine has been mutated to thymine.	PDGFRA NM_006206.4:c.2525A>T		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107569>	C97928	PDGFRA Protein Variant|CD140a Antigen Protein Variant|PDGFR-Alpha Protein Variant|Platelet-Derived Growth Factor Receptor Alpha Protein Variant	A variation in the amino acid sequence for the platelet-derived growth factor receptor alpha protein.	PDGFRA Protein Variant		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10756>	C61063	Etoposide/Ifosfamide/Melphalan|IFF/L-PAM/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107570>	C107569	PDGFRA NP_006197.1:p.D842V|CD140a Antigen Asp842Val|CD140a Antigen D842V|NP_006197.1:p.Asp842Val|NP_006197.1:p.D842V|PDGFR Alpha Asp842Val|PDGFR Alpha D842V Mutation|PDGFR-Alpha Asp842Val|PDGFR-Alpha D842V|PDGFRA Asp842Val|PDGFRA D842V|PDGFRA D842V Mutation|PDGFRA NP_006197.1:p.Asp842Val|PDGFRA p.Asp842Val|PDGFRA p.D842V|Platelet-Derived Growth Factor Receptor Alpha Asp842Val|Platelet-Derived Growth Factor Receptor Alpha D842V	A change in the amino acid residue at position 842 in the platelet-derived growth factor receptor alpha protein where aspartic acid has been replaced by valine.	PDGFRA NP_006197.1:p.D842V		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107571>	C20194	PROS1 Gene|PROS1|PROS1|Protein S (Alpha) Gene	This gene plays a role in inhibiting blood coagulation.	PROS1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107572>	C107571	PROS1 wt Allele|PROS|PS21|PS22|PS23|PS24|PS25|PSA|Protein S (Alpha) wt Allele|Protein S, Alpha Gene|THPH5|THPH6	Human PROS1 wild-type allele is located in the vicinity of 3q11.2 and is approximately 101 kb in length. This allele, which encodes vitamin K-dependent protein S, is involved in the regulation of coagulation. Mutations in this gene are associated with both autosomal dominant and autosomal recessive thrombophilia due to protein S deficiency.	PROS1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107573>	C18466	Vitamin K-Dependent Protein S|PROS1|Protein Sa|Vitamin K-Dependent Plasma Protein S	Vitamin K-dependent protein S (676 aa, ~75 kDa) is encoded by the human PROS1 gene. This protein plays a role in coagulation regulation.	Vitamin K-Dependent Protein S		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107574>	C28533	SLC22A2 Gene|SLC22A2|SLC22A2|Solute Carrier Family 22 (Organic Cation Transporter), Member 2 Gene	This gene is involved in mediating the uptake of organic compounds.	SLC22A2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107575>	C107574	SLC22A2 wt Allele|HOCT2|OCT2|Solute Carrier Family 22 (Organic Cation Transporter), Member 2 wt Allele	Human SLC22A2 wild-type allele is located in the vicinity of 6q25.3 and is approximately 107 kb in length. This allele, which encodes solute carrier family 22 member 2 protein, plays a role in mediating tubular uptake of organic compounds from the circulation.	SLC22A2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107576>	C16386	Solute Carrier Family 22 Member 2|Organic Cation Transporter 2|SLC22A2	Solute carrier family 22 member 2 (555 aa, ~63 kDa) is encoded by the human SLC22A2 gene. This protein is involved in mediating tubular uptake of organic compounds from the circulation.	Solute Carrier Family 22 Member 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107577>	C28533	SLC18A1 Gene|SLC18A1|SLC18A1|Solute Carrier Family 18 (Vesicular Monoamine Transporter), Member 1 Gene	This gene is involved in the transport of biogenic monoamines.	SLC18A1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107578>	C107577	SLC18A1 wt Allele|CGAT|Solute Carrier Family 18 (Vesicular Monoamine Transporter), Member 1 wt Allele|VAT1|VMAT1	Human SLC18A1 wild-type allele is located in the vicinity of 8p21.3 and is approximately 38 kb in length. This allele, which encodes chromaffin granule amine transporter protein, plays a role in the accumulation of cytosolic monoamines in secretory vesicles.	SLC18A1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107579>	C97927|C146713	FGFR2 Gene Mutation|BEK Gene Mutation|CD332 Gene Mutation|ECT1 Gene Mutation|FGFR-2 Gene Mutation|Fibroblast Growth Factor Receptor 2 Gene Mutation|K-SAM Gene Mutation|KGFR Gene Mutation|Positive	A change in the nucleotide sequence of the FGFR2 gene.	FGFR2 Gene Mutation		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10757>	C61063	Cisplatin/Interleukin-1-Alpha|CDDP/IL-1A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107580>	C16386	Chromaffin Granule Amine Transporter|Solute Carrier Family 18 Member 1|Vesicular Amine Transporter 1	Chromaffin granule amine transporter (525 aa, ~56 kDa) is encoded by the human SLC18A1 gene. This protein is involved in the transport of biogenic monoamines into secretory vesicles.	Chromaffin Granule Amine Transporter		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107581>	C97928	FGFR2 Protein Variant|CD332 Antigen Protein Variant|FGFR-2 Protein Variant|Fibroblast Growth Factor Receptor 2 Protein Variant|KGFR Protein Variant|Keratinocyte Growth Factor Receptor Protein Variant	A variation in the amino acid sequence for the fibroblast growth factor receptor 2 protein.	FGFR2 Protein Variant		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107582>	C20912	IL10RA Gene|IL10RA|IL10RA|Interleukin 10 Receptor, Alpha Gene	This gene plays a role in immunosuppression.	IL10RA Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107583>	C107579	FGFR2 NM_000141.4:c.755C>G|BEK c.755C>G|CD332 c.755C>G|ECT1 c.755C>G|FGFR2 c.755C>G|Fibroblast Growth Factor Receptor 2 c.755C>G|K-SAM c.755C>G|KGFR c.755C>G|NM_000141.4:c.755C>G	A nucleotide substitution at position 755 of the coding sequence of the FGFR2 gene where cytosine has been mutated to guanine.	FGFR2 NM_000141.4:c.755C>G		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107584>	C107582	IL10RA wt Allele|CD210|CD210a|CDW210A|HIL-10R|IBD28|IL-10R1|IL-10RA|IL10R|Interleukin 10 Receptor, Alpha wt Allele	Human IL10RA wild-type allele is located in the vicinity of 11q23.3 and is approximately 15 kb in length. This allele, which encodes interleukin-10 receptor subunit alpha protein, is involved in the regulation of immunosuppression. Mutations in this gene are associated with inflammatory bowel disease 28, early onset, autosomal recessive.	IL10RA wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107585>	C107581	FGFR2 NP_000132.3:p.S252W|CD332 Antigen S252W|CD332 Antigen Ser252Trp|FGFR-2 S252W|FGFR-2 Ser252Trp|FGFR2 NP_000132.3:p.Ser252Trp|FGFR2 S252W|FGFR2 Ser252Trp|FGFR2 p.S252W|FGFR2 p.Ser252Trp|Fibroblast Growth Factor Receptor 2 S252W|Fibroblast Growth Factor Receptor 2 Ser252Trp|KGFR S252W|KGFR Ser252Trp|Keratinocyte Growth Factor Receptor S252W|Keratinocyte Growth Factor Receptor Ser252Trp|NP_000132.3:p.S252W|NP_000132.3:p.Ser252Trp	A change in the amino acid residue at position 252 in the fibroblast growth factor receptor 2 protein where serine has been replaced by tryptophan.	FGFR2 NP_000132.3:p.S252W		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107586>	C17667	Interleukin-10 Receptor Subunit Alpha|CD210 Antigen|IL-10R Subunit 1|IL-10R Subunit Alpha|Interleukin-10 Receptor Alpha Chain|Interleukin-10 Receptor Subunit 1	Interleukin-10 receptor subunit alpha (578 aa, ~63 kDa) is encoded by the human IL10RA gene. This protein plays a role in the regulation of immunosuppression.	Interleukin-10 Receptor Subunit Alpha		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107587>	C36291	Failure to Thrive|Failure to thrive	A clinical finding indicating less than normal growth in an infant or child, or a state of global decline in an adult.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C107588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107588>	C20130	Interleukin-8 Receptor|IL8R|Interleukin 8 Receptor	A family of chemokine receptors that specifically bind to interleukin-8 and play a role in G-protein-coupled receptor-mediated signal transduction.	Interleukin-8 Receptor		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107589>	C63817|C215099	CXCR4 Inhibitor	An antagonist of the C-X-C chemokine receptor type 4 (CXCR4). CXCR4, which belongs to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types.			Chemical Viewed Functionally	
C10758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10758>	C61063	Carboplatin/Etoposide/Interleukin-6/Sargramostim|CBDCA/GM-CSF/IL-6/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107590>	C107579	FGFR2 NM_000141.4:c.758C>G|BEK c.758C>G|CD332 c.758C>G|ECT1 c.758C>G|FGFR2 c.758C>G|Fibroblast Growth Factor Receptor 2 c.758C>G|K-SAM c.758C>G|KGFR c.758C>G|NM_000141.4:c.758C>G	A nucleotide substitution at position 758 of the coding sequence of the FGFR2 gene where cytosine has been mutated to guanine.	FGFR2 NM_000141.4:c.758C>G		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107591>	C107581	FGFR2 NP_000132.3:p.P253R|CD332 Antigen P253R|CD332 Antigen Pro253Arg|FGFR-2 P253R|FGFR-2 Pro253Arg|FGFR2 NP_000132.3:p.Pro253Arg|FGFR2 P253R|FGFR2 Pro253Arg|FGFR2 p.P253R|FGFR2 p.Pro253Arg|Fibroblast Growth Factor Receptor 2 P253R|Fibroblast Growth Factor Receptor 2 Pro253Arg|KGFR P253R|KGFR Pro253Arg|Keratinocyte Growth Factor Receptor P253R|Keratinocyte Growth Factor Receptor Pro253Arg|NP_000132.3:p.P253R|NP_000132.3:p.Pro253Arg	A change in the amino acid residue at position 253 in the fibroblast growth factor receptor 2 protein where proline has been replaced by arginine.	FGFR2 NP_000132.3:p.P253R		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107592>	C107579	FGFR2 NM_000141.4:c.1115C>G|BEK c.1115C>G|CD332 c.1115C>G|ECT1 c.1115C>G|FGFR2 c.1115C>G|Fibroblast Growth Factor Receptor 2 c.1115C>G|K-SAM c.1115C>G|KGFR c.1115C>G|NM_000141.4:c.1115C>G	A nucleotide substitution at position 1115 of the coding sequence of the FGFR2 gene where cytosine has been mutated to guanine.	FGFR2 NM_000141.4:c.1115C>G		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107593>	C107581	FGFR2 NP_000132.3:p.S372C|CD332 Antigen S372C|CD332 Antigen Ser372Cys|FGFR-2 S372C|FGFR-2 Ser372Cys|FGFR2 NP_000132.3:p.Ser372Cys|FGFR2 S372C|FGFR2 Ser372Cys|FGFR2 p.S372C|FGFR2 p.Ser372Cys|Fibroblast Growth Factor Receptor 2 S372C|Fibroblast Growth Factor Receptor 2 Ser372Cys|KGFR S372C|KGFR Ser372Cys|Keratinocyte Growth Factor Receptor S372C|Keratinocyte Growth Factor Receptor Ser372Cys|NP_000132.3:p.S372C|NP_000132.3:p.Ser372Cys|NP_001138385.1:p.S373C|NP_001138385.1:p.Ser373Cys	A change in the amino acid residue at position 372 in the fibroblast growth factor receptor 2 protein where serine has been replaced by cysteine.	FGFR2 NP_000132.3:p.S372C		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107594>	C107579	FGFR2 NM_000141.4:c.1124A>G|BEK c.1124A>G|CD332 c.1124A>G|ECT1 c.1124A>G|FGFR2 c.1124A>G|Fibroblast Growth Factor Receptor 2 c.1124A>G|K-SAM c.1124A>G|KGFR c.1124A>G|NM_000141.4:c.1124A>G	A nucleotide substitution at position 1124 of the coding sequence of the FGFR2 gene where adenine has been mutated to guanine.	FGFR2 NM_000141.4:c.1124A>G		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107595>	C107581	FGFR2 NP_000132.3:p.Y375C|CD332 Antigen Tyr375Cys|CD332 Antigen Y375C|FGFR-2 Tyr375Cys|FGFR-2 Y375C|FGFR2 NP_000132.3:p.Tyr375Cys|FGFR2 Tyr375Cys|FGFR2 p.Tyr375Cys|FGFR2 p.Y375C|Fibroblast Growth Factor Receptor 2 Tyr375Cys|Fibroblast Growth Factor Receptor 2 Y375C|KGFR Y375C|Keratinocyte Growth Factor Receptor Tyr375Cys|Keratinocyte Growth Factor Receptor Y375C|NP_000132.3:p.Tyr375Cys|NP_000132.3:p.Y375C|NP_001138385.1:p.Tyr376Cys|NP_001138385.1:p.Y376C	A change in the amino acid residue at position 375 in the fibroblast growth factor receptor 2 protein where tyrosine has been replaced by cysteine.	FGFR2 NP_000132.3:p.Y375C		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107596>	C107579	FGFR2 NM_000141.4:c.1144T>C|BEK c.1144T>C|CD332 c.1144T>C|ECT1 c.1144T>C|FGFR2 c.1144T>C|Fibroblast Growth Factor Receptor 2 c.1144T>C|K-SAM c.1144T>C|KGFR c.1144T>C|NM_000141.4:c.1144T>C	A nucleotide substitution at position 1144 of the coding sequence of the FGFR2 gene where thymine has been mutated to cytosine.	FGFR2 NM_000141.4:c.1144T>C		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107597>	C107581	FGFR2 NP_000132.3:p.C382R|CD332 Antigen C382R|CD332 Antigen Cys382Arg|FGFR-2 C382R|FGFR-2 Cys382Arg|FGFR2 C382R|FGFR2 Cys382Arg|FGFR2 NP_000132.3:p.Cys382Arg|FGFR2 p.C382R|FGFR2 p.Cys382Arg|Fibroblast Growth Factor Receptor 2 C382R|Fibroblast Growth Factor Receptor 2 Cys382Arg|KGFR C382R|KGFR Cys382Arg|Keratinocyte Growth Factor Receptor C382R|Keratinocyte Growth Factor Receptor Cys382Arg|NP_000132.3:p.C382R|NP_000132.3:p.Cys382Arg|NP_001138385.1:p.C383R|NP_001138385.1:p.Cys383Arg	A change in the amino acid residue at position 382 in the fibroblast growth factor receptor 2 protein where cysteine has been replaced by arginine.	FGFR2 NP_000132.3:p.C382R		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107598>	C107579	FGFR2 NM_000141.4:c.1647T>A|BEK c.1647T>A|CD332 c.1647T>A|ECT1 c.1647T>A|FGFR2 c.1647T>A|Fibroblast Growth Factor Receptor 2 c.1647T>A|K-SAM c.1647T>A|KGFR c.1647T>A|NM_000141.4:c.1647T>A	A nucleotide substitution at position 1647 of the coding sequence of the FGFR2 gene where thymine has been mutated to adenine.	FGFR2 NM_000141.4:c.1647T>A		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107599>	C107579	FGFR2 NM_000141.4:c.1647T>G|BEK c.1647T>G|CD332 c.1647T>G|ECT1 c.1647T>G|FGFR2 c.1647T>G|Fibroblast Growth Factor Receptor 2 c.1647T>G|K-SAM c.1647T>G|KGFR c.1647T>G|NM_000141.4:c.1647T>G	A nucleotide substitution at position 1647 of the coding sequence of the FGFR2 gene where thymine has been mutated to guanine.	FGFR2 NM_000141.4:c.1647T>G		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10759>	C61063	Ciprofloxacin/Cisplatin/Cyclophosphamide/Etoposide/Pentoxifylline|CDDP/CPFX/CTX/PTX/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1075>	C1510	Doxorubicin-DNA Complex|Adriamycin-DNA Complex	A complex comprised of Doxorubicin linked to DNA to enhance the topoisomerase II-mediated interaction with the DNA base pairs and reduce cardiotoxicity associated with anthracyclines. (NCI)			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	NCI Drug Dictionary Terminology
C107600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107600>	C107581	FGFR2 NP_000132.3:p.N549K|CD332 Antigen Asn549Lys|CD332 Antigen N549K|FGFR-2 Asn549Lys|FGFR-2 N549K|FGFR2 Asn549Lys|FGFR2 N549K|FGFR2 NP_000132.3:p.Asn549Lys|FGFR2 p.Asn549Lys|FGFR2 p.N549K|Fibroblast Growth Factor Receptor 2 Asn549Lys|Fibroblast Growth Factor Receptor 2 N549K|KGFR Asn549Lys|KGFR N549K|Keratinocyte Growth Factor Receptor Asn549Lys|Keratinocyte Growth Factor Receptor N549K|NP_000132.3:p.Asn549Lys|NP_000132.3:p.N549K|NP_001138385.1:p.Asn550Lys|NP_001138385.1:p.N550K	A change in the amino acid residue at position 549 in the fibroblast growth factor receptor 2 protein where asparagine has been replaced by lysine.	FGFR2 NP_000132.3:p.N549K		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107601>	C41260	Other Asian	A person having origins in the original peoples of Asia, but not China, India, Korea, the Philippine Islands or Vietnam.			Population Group	
C107602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107602>	C41219	Other Pacific Islander|OTHER PACIFIC ISLANDER	A person having origins in the original peoples of the Pacific Islands, but not Guam, Hawaii, the Mariana Islands or Samoa.			Population Group	CDISC CDASH Terminology|CDISC SDTM Collected Race Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107603>	C107579	FGFR2 NM_000141.4:c.1645A>C|BEK c.1645A>C|CD332 c.1645A>C|ECT1 c.1645A>C|FGFR2 c.1645A>C|Fibroblast Growth Factor Receptor 2 c.1645A>C|K-SAM c.1645A>C|KGFR c.1645A>C|NM_000141.4:c.1645A>C	A nucleotide substitution at position 1645 of the coding sequence of the FGFR2 gene where cytosine has been mutated to guanine.	FGFR2 NM_000141.4:c.1645A>C		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107604>	C107581	FGFR2 NP_000132.3:p.N549H|CD332 Antigen Asn549His|CD332 Antigen N549H|FGFR-2 Asn549His|FGFR-2 N549H|FGFR2 Asn549His|FGFR2 N549H|FGFR2 NP_000132.3:p.Asn549His|FGFR2 p.Asn549His|FGFR2 p.N549H|Fibroblast Growth Factor Receptor 2 Asn549His|Fibroblast Growth Factor Receptor 2 N549H|KGFR Asn549His|KGFR N549H|Keratinocyte Growth Factor Receptor Asn549His|Keratinocyte Growth Factor Receptor N549H|NP_000132.3:p.Asn549His|NP_000132.3:p.N549H|NP_001138385.1:p.Asn550His|NP_001138385.1:p.N550H	A change in the amino acid residue at position 549 in the fibroblast growth factor receptor 2 protein where asparagine has been replaced by histidine.	FGFR2 NP_000132.3:p.N549H		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107605>	C107579	FGFR2 NM_000141.4:c.1975A>G|BEK c.1975A>G|CD332 c.1975A>G|ECT1 c.1975A>G|FGFR2 c.1975A>G|Fibroblast Growth Factor Receptor 2 c.1975A>G|K-SAM c.1975A>G|KGFR c.1975A>G|NM_000141.4:c.1975A>G	A nucleotide substitution at position 1975 of the coding sequence of the FGFR2 gene where adenine has been mutated to guanine.	FGFR2 NM_000141.4:c.1975A>G		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107606>	C107581	FGFR2 NP_000132.3:p.K659E|CD332 Antigen K659E|CD332 Antigen Lys659Glu|FGFR-2 K659E|FGFR-2 Lys659Glu|FGFR2 K659E|FGFR2 Lys659Glu|FGFR2 NP_000132.3:p.Lys659Glu|FGFR2 p.K659E|FGFR2 p.Lys659Glu|Fibroblast Growth Factor Receptor 2 K659E|Fibroblast Growth Factor Receptor 2 Lys659Glu|KGFR K659E|KGFR Lys659Glu|Keratinocyte Growth Factor Receptor K659E|Keratinocyte Growth Factor Receptor Lys659Glu|NP_000132.3:p.K659E|NP_000132.3:p.Lys659Glu|NP_001138385.1:p.K660E|NP_001138385.1:p.Lys660Glu	A change in the amino acid residue at position 659 in the fibroblast growth factor receptor 2 protein where lysine has been replaced by glutamic acid.	FGFR2 NP_000132.3:p.K659E		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107607>	C17459	Mexican or Mexican American	A person of Mexican or Mexican American culture or origin, regardless of race.			Population Group	
C107608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107608>	C17459	Cuban|CUBAN	A person of Cuban culture or origin, regardless of race.			Population Group	CDISC CDASH Terminology|CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C107609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107609>	C17459	Other Hispanic or Latino(a)	A person of Spanish culture or origin, but not Cuban, Mexican, Puerto Rican, South or Central American, regardless of race.			Population Group	
C10760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10760>	C61063	Carmustine/Cyclophosphamide/Etoposide/Melphalan|BCNU/CTX/L-PAM/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107610>	C29936	SPINT1 Gene|SPINT1|SPINT1|Serine Peptidase Inhibitor, Kunitz Type 1 Gene	This gene plays a role in the regulation of hepatocyte growth factor maturation.	SPINT1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107611>	C107610	SPINT1 wt Allele|HAI|HAI1|MANSC2|Serine Peptidase Inhibitor, Kunitz Type 1 wt Allele|UNQ223/PRO256	Human SPINT1 wild-type allele is located in the vicinity of 15q15.1 and is approximately 14 kb in length. This allele, which encodes Kunitz-type protease inhibitor 1 protein, is involved in both the inhibition of proteolysis and the modulation of growth factor signaling.	SPINT1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107612>	C17122	Kunitz-Type Protease Inhibitor 1|Hepatocyte Growth Factor Activator Inhibitor|Hepatocyte Growth Factor Activator Inhibitor Type 1|SPINT1|Serine Protease Inhibitor, Kunitz Type 1|Serine Protease Inhibitor, Kunitz-Type, 1	Kunitz-type protease inhibitor 1 (529 aa, ~58 kDa) is encoded by the human SPINT1 gene. This protein plays a role in both growth factor signaling and the regulation of protease activity.	Kunitz-Type Protease Inhibitor 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107613>	C20933	ADRA2C Gene|ADRA2C|ADRA2C|Adrenoceptor Alpha 2C Gene	This gene is involved in the regulation of neurotransmitter release.	ADRA2C Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107614>	C107613	ADRA2C wt Allele|ADRA2L2|ADRA2RL2|ADRARL2|ALPHA2CAR|Adrenergic, Alpha-2C-, Receptor Gene|Adrenoceptor Alpha 2C wt Allele|Alpha2-AR-C4	Human ADRA2C wild-type allele is located in the vicinity of 4p16 and is approximately 2 kb in length. This allele, which encodes alpha-2C adrenergic receptor protein, plays a role in the inhibition of G protein-coupled receptor-mediated adenylate cyclase activity.	ADRA2C wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107615>	C20932	Alpha-2C Adrenergic Receptor|Alpha-2 Adrenergic Receptor Subtype C4|Alpha-2C Adrenoceptor|Alpha-2C Adrenoreceptor|Alpha-2C-Adrenergic Receptor|Alpha-2CAR	Alpha-2C adrenergic receptor (462 aa, ~50 kDa) is encoded by the human ADRA2C gene. This protein is involved in catecholamine-induced regulation of adenylate cyclase signaling.	Alpha-2C Adrenergic Receptor		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107616>	C25939	TXNRD1 Gene|TXNRD1|TXNRD1|Thioredoxin Reductase 1 Gene	This gene plays a role in the maintenance of cellular redox signaling.	TXNRD1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107617>	C107616	TXNRD1 wt Allele|GRIM-12|GRIM12|KDRF|TR|TR1|TRXR1|TXNR|Thioredoxin Reductase 1 wt Allele|Trxr1	Human TXNRD1 wild-type allele is located within 12q23-q24.1 and is approximately 135 kb in length. This allele, which encodes thioredoxin reductase 1, cytoplasmic protein, is involved in the modulation of oxidative stress.	TXNRD1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107618>	C16946	Thioredoxin Reductase 1, Cytoplasmic|EC 1.8.1.9|GRIM-12|Gene Associated With Retinoic And IFN-Induced Mortality 12 Protein|Gene Associated With Retinoic And Interferon-Induced Mortality 12 Protein|KM-102-Derived Reductase-Like Factor|TR|TXNRD1|Thioredoxin Reductase GRIM-12|Thioredoxin Reductase TR1	Thioredoxin reductase 1, cytoplasmic (649 aa, ~71 kDa) is encoded by the human TXNRD1 gene. This protein plays a role in cellular redox reactions.	Thioredoxin Reductase 1, Cytoplasmic		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107619>	C25939	TXNRD2 Gene|TXNRD2|TXNRD2|Thioredoxin Reductase 2 Gene	This gene is involved in the reduction of thioredoxin.	TXNRD2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C10761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10761>	C61063	Doxorubicin/Hydroxyurea|DOX/HU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107620>	C107619	TXNRD2 wt Allele|SELZ|TR|TR-BETA|TR3|TRXR2|Thioredoxin Reductase 2 wt Allele	Human TXNRD2 wild-type allele is located in the vicinity of 22q11.21 and is approximately 66 kb in length. This allele, which encodes thioredoxin reductase 2, mitochondrial protein, plays a role in thioredoxin redox potential.	TXNRD2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107621>	C16946	Thioredoxin Reductase 2, Mitochondrial|EC 1.8.1.9|SelZ|Selenoprotein Z|TR-Beta|TXNRD2|Thioredoxin Reductase 3|Thioredoxin Reductase Beta|Thioredoxin Reductase TR3	Thioredoxin reductase 2, mitochondrial (524 aa, ~57 kDa) is encoded by the human TXNRD2 gene. This protein is involved in thioredoxin reduction.	Thioredoxin Reductase 2, Mitochondrial		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107622>	C54362	TTF1 Gene|TTF1|TTF1|Transcription Termination Factor, RNA Polymerase I Gene	This gene plays a role in the termination of transcription.	TTF1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107623>	C107622	TTF1 wt Allele|TTF-1|TTF-I|Transcription Termination Factor, RNA Polymerase I wt Allele	Human TTF1 wild-type allele is located in the vicinity of 9q34.13 and is approximately 31 kb in length. This allele, which encodes transcription termination factor 1 protein, is involved in both transcriptional termination and replication fork arrest.	TTF1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107624>	C26199	Transcription Termination Factor 1|RNA Polymerase I Termination Factor|TTF-1|TTF1|Transcription Termination Factor I	Transcription termination factor 1 (905 aa, ~103 kDa) is encoded by the human TTF1 gene. This protein plays a role in transcription arrest.	Transcription Termination Factor 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107625>	C30073	KRT13 Gene|KRT13|KRT13|Keratin 13 Gene	This gene is involved in epithelial cell structure.	KRT13 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107626>	C107625	KRT13 wt Allele|CK13|K13|Keratin 13 wt Allele|MGC161462|MGC3781	Human KRT13 wild-type allele is located in the vicinity of 17q21.2 and is approximately 5 kb in length. This allele, which encodes keratin, type I cytoskeletal 13 protein, plays a role in epidermal development. Mutation of the gene is associated with white sponge nevus.	KRT13 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107627>	C20694	Keratin, Type I Cytoskeletal 13|CK-13|Cytokeratin 13|Cytokeratin-13|K13|KRT13|Keratin-13	Keratin, type I cytoskeletal 13 (458 aa, ~50 kDa) is encoded by the human KRT13 gene. This protein is involved in the development of the epidermal endothelium.	Keratin, Type I Cytoskeletal 13		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107628>	C173604	Did You Take Any Medication Except the Study Drug for Vomiting During This Period Question|Did You Take Any Medication Except the Study Drug for Vomiting During This Period|Did you take any medication (except study drug) for VOMITING during this period	A question about whether an individual took any medication, except the study drug, for vomiting during the specified time period.			Intellectual Product	Multinational Association of Supportive Care in Cancer Antiemesis Tool
C107629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107629>	C173130	Did You Take Any Medication Except the Study Drug for Nausea During This Period Question|Did You Take Any Medication Except the Study Drug for Nausea During This Period|Did you take any medication (except study drug) for NAUSEA during this period	A question about whether an individual took any medication, except the study drug, for nausea during the specified time period.			Intellectual Product	Multinational Association of Supportive Care in Cancer Antiemesis Tool
C10762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10762>	C61063	Lomustine/Methotrexate|CCNU/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107630>	C91105	Expanded Prostate Cancer Index Composite|EPIC|Expanded Prostate Cancer Index Composite (EPIC)	A self-administered questionnaire designed to evaluate patient function and bother after prostate cancer treatment.			Intellectual Product	
C107631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107631>	C91105	Expanded Prostate Cancer Index Composite, Sexual Medications/Devices Supplement|EPIC-SMD|Sexual Medications/Devices Supplement	A component of the EPIC designed to assess the use of erectile aids among patients treated for prostate cancer.			Intellectual Product	
C107632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107632>	C91103	Have Penile Prosthesis Question|Do you have a penile prosthesis|Have Penile Prosthesis	A question about whether an individual has or had a penile prosthesis.			Intellectual Product	Expanded Prostate Cancer Index Composite, Sexual Medications/Devices Supplement
C107633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107633>	C91103	Used Medications or Devices to Aid or Improve Erections Question|Have you used any medications or devices to aid or improve erections|Used Medications or Devices to Aid or Improve Erections	A question about whether an individual uses or used medications or devices to aid or improve erections.			Intellectual Product	Expanded Prostate Cancer Index Composite, Sexual Medications/Devices Supplement
C107634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107634>	C173509	Medicine or Device Tried or Currently Used to Improve Erection Question|Medicine or Device Tried or Currently Used to Improve Erection|Medicine or device tried or currently used to improve erection	A question about which medicine or device an individual uses or has used to improve an erection.			Intellectual Product	Expanded Prostate Cancer Index Composite, Sexual Medications/Devices Supplement
C107635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107635>	C49236	Penile Injection Therapy|Penile injection therapy	Self-administered injections of vasodilators into the corpus cavernosa to promote engorgement and tumescence of the glans with sexual stimulation.			Therapeutic or Preventive Procedure	Expanded Prostate Cancer Index Composite, Sexual Medications/Devices Supplement
C107636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107636>	C16830	Vacuum Erection Device|Vacuum erection device	Device consisting of a plastic cylinder with an elastic retention band at its base attached to an external pump. The pump creates a vacuum that draws blood into the shaft of the penis and then the user slides the elastic ring down to the base to maintain the erection.	Vacuum Erection Device		Medical Device	CTRP Intervention Terminology|CTRP Terminology|Expanded Prostate Cancer Index Composite, Sexual Medications/Devices Supplement
C107637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107637>	C226630	Have Not Tried It|Have NOT tried it	A response that something has not been tried by an individual.			Intellectual Product	Expanded Prostate Cancer Index Composite, Sexual Medications/Devices Supplement
C107638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107638>	C226630	Tried It but Not Helpful|Tried it, but was NOT HELPFUL	A response that something has been tried by an individual but it has not been found to be helpful.			Intellectual Product	Expanded Prostate Cancer Index Composite, Sexual Medications/Devices Supplement
C107639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107639>	C226701|C226678	Helped but Not Using It Now|It HELPED, but I am NOT using it NOW	A response that something has helped an individual but it is not being used now.			Intellectual Product	Expanded Prostate Cancer Index Composite, Sexual Medications/Devices Supplement
C10763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10763>	C61063	Estramustine/Paclitaxel|EM/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107640>	C226701|C226678	Helped and Using It Sometimes|It HELPED, and I use it SOMETIMES	A response that something has helped an individual and it is being used sometimes.			Intellectual Product	Expanded Prostate Cancer Index Composite, Sexual Medications/Devices Supplement
C107641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107641>	C226701|C226678	Helped and Using It Always|It HELPED, and I use it ALWAYS	A response that something has helped an individual and it is being used always.			Intellectual Product	Expanded Prostate Cancer Index Composite, Sexual Medications/Devices Supplement
C107642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107642>	C173704	Describe Usual Quality of Erections Without Assistance of Medicines or Devices During Last 4 Weeks Question|Describe Usual Quality of Erections Without Assistance of Medicines or Devices During Last 4 Weeks|How would you describe the usual quality of your erections WITHOUT THE ASSISTANCE of medicines or devices DURING THE LAST 4 WEEKS	A question about how an individual would describe the usual quality of their erections without the assistance of medications or devices during the last four weeks.			Intellectual Product	Expanded Prostate Cancer Index Composite, Sexual Medications/Devices Supplement
C107643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107643>	C175563	Not Firm Enough for Sexual Activity|Not firm enough for any sexual activity	A response about an individual's erections not being firm enough for any sexual activity.			Intellectual Product	Expanded Prostate Cancer Index Composite, Sexual Medications/Devices Supplement
C107644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107644>	C176252	Firm Enough for Masturbation and Foreplay Only|Firm enough for masturbation and foreplay only	A response about an individual's erections being firm enough for masturbation and foreplay only.			Intellectual Product	Expanded Prostate Cancer Index Composite, Sexual Medications/Devices Supplement
C107645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107645>	C176252	Firm Enough for Intercourse|Firm enough for intercourse	A response about an individual's erections being firm enough for intercourse.			Intellectual Product	Expanded Prostate Cancer Index Composite, Sexual Medications/Devices Supplement
C107646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107646>	C133710	TRAF7 Gene|TNF Receptor-Associated Factor 7, E3 Ubiquitin Protein Ligase Gene|TRAF7|TRAF7|TRAF7	This gene is involved in both MAPK signaling and protein ubiquitination.	TRAF7 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C107647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107647>	C107646	TRAF7 wt Allele|CAFDADD|DKFZp586I021|MGC7807|RFWD1|RNF119|TNF Receptor Associated Factor 7 wt Allele|TNF Receptor-Associated Factor 7, E3 Ubiquitin Protein Ligase wt Allele	Human TRAF7 wild-type allele is located in the vicinity of 16p13.3 and is approximately 22 kb in length. This allele, which encodes E3 ubiquitin-protein ligase TRAF7 protein, plays a role in the positive regulation of both protein ubiquitination and MAPK signaling pathways.	TRAF7 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107648>	C21254	E3 Ubiquitin-Protein Ligase TRAF7|EC 2.3.2.27|EC 6.3.2.-, Formerly|RING Finger Protein 119|RING Finger and WD Repeat Domains-Containing Protein 1|RING Finger and WD Repeat-Containing Protein 1|RING-Type E3 Ubiquitin Transferase TRAF7|Ring Finger and WD Repeat Domain 1|TNF Receptor-Associated Factor 7	E3 ubiquitin-protein ligase TRAF7 (670 aa, ~75 kDa) is encoded by the human TRAF7 gene. This protein is involved in both protein ubiquitination and MAPK signaling.	E3 Ubiquitin-Protein Ligase TRAF7		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107649>	C133710	RNF43 Gene|RNF43|RNF43|RNF43|Ring Finger Protein 43 Gene	This gene is involved in both protein ubiquitination and the Wnt signaling pathway.	RNF43 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C10764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10764>	C61063	Edatrexate/Filgrastim/Paclitaxel|EDAM/G-CSF/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107650>	C107649	RNF43 wt Allele|DKFZp781H0392|FLJ20315|RNF124|Ring Finger Protein 43 wt Allele|SSPCS|URCC	Human RNF43 wild-type allele is located in the vicinity of 17q23.2 and is approximately 65 kb in length. This allele, which encodes E3 ubiquitin-protein ligase RNF43 protein, plays a role in both signaling and protein ubiquitination.	RNF43 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107651>	C21254	E3 Ubiquitin-Protein Ligase RNF43|EC 2.3.2.27|EC 6.3.2.-, Formerly|RING Finger Protein 124|RING-Type E3 Ubiquitin Transferase RNF43|Ring Finger Protein 43	E3 ubiquitin-protein ligase RNF43 (783 aa, ~86 kDa) is encoded by the human RNF43 gene. This protein is involved in the modulation of both Wnt signaling and protein ubiquitination.	E3 Ubiquitin-Protein Ligase RNF43		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107652>	C20845	RPL5 Gene|RPL5|RPL5|RPL5|RPL5|Ribosomal Protein L5 Gene	This gene plays a role in ribosome assembly.	RPL5 Gene		Gene or Genome	CCPS Genetics Terminology|Childhood Cancer Predisposition Study Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C107653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107653>	C107652	RPL5 wt Allele|DBA6|L5|MSTP030|PPP1R135|Protein Phosphatase 1, Regulatory Subunit 135 Gene|Ribosomal Protein L5 wt Allele|uL18	Human RPL5 wild-type allele is located in the vicinity of 1p22.1 and is approximately 10 kb in length. This allele, which encodes 60S ribosomal protein L5, is involved in the formation of the 60S ribosome. Mutation of the gene is associated with Diamond-Blackfan anemia 6.	RPL5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107654>	C21210	60S Ribosomal Protein L5|Large Ribosomal Subunit Protein uL18|RPL5|Ribosomal Protein L5	60S ribosomal protein L5 (297 aa, ~34 kDa) is encoded by the human RPL5 gene. This protein plays a role in both ribosome formation and RNA binding.	60S Ribosomal Protein L5		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107655>	C20338	POT1 Gene|POT1|POT1|POT1|Protection of Telomeres Protein 1 Gene	This gene plays a role in the regulation of telomere length.	POT1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C107656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107656>	C107655	POT1 wt Allele|CMM10|DKFZp586D211|GLM9|HPOT1|Protection of Telomeres 1 Homolog (S. pombe) Gene|Protection of Telomeres 1 wt Allele|hPot1	Human POT1 wild-type allele is located in the vicinity of 7q31.33 and is approximately 108 kb in length. This allele, which encodes protection of telomeres protein 1, is involved in the positive regulation of telomerase.	POT1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107657>	C16518	Protection of Telomeres Protein 1|POT1|POT1-Like Telomere End-Binding Protein|Protection of Telomeres 1 Homolog|hPot1	Protection of telomeres protein 1 (634 aa, ~71 kDa) is encoded by the human POT1 gene. This protein plays a role in telomere maintenance.	Protection of Telomeres Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107658>	C54362	CNOT3 Gene|CCR4-NOT Transcription Complex, Subunit 3 Gene|CNOT3|CNOT3|CNOT3	This gene is involved in mRNA degradation, miRNA-mediated repression, translational regulation and general transcription regulation.	CNOT3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C107659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107659>	C107658	CNOT3 wt Allele|CCR4-NOT Transcription Complex, Subunit 3 wt Allele|KIAA0691|LENG2|NOT3|NOT3 (Negative Regulator of Transcription 3, Yeast) Homolog Gene|NOT3H|Negative Regulator of Transcription 3, S. cerevisiae, Homolog of, Gene|XXbac-BCX105G6.1	Human CNOT3 wild-type allele is located in the vicinity of 19q13.4 and is approximately 18 kb in length. This allele, which encodes CCR4-NOT transcription complex subunit 3 protein, plays a role in RNA processing, translational regulation and transcriptional regulation.	CNOT3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10765>	C61063	Carboplatin/Etoposide/Ifosfamide/Milodistim|CBDCA/IFF/PIXY321/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107660>	C26199	CCR4-NOT Transcription Complex Subunit 3|CCR4-Associated Factor 3|CNOT3|Leukocyte Receptor Cluster Member 2	CCR4-NOT transcription complex subunit 3 (753 aa, ~82 kDa) is encoded by the human CNOT3 gene. This protein is involved in transcriptional regulation, RNA processing and translational regulation.	CCR4-NOT Transcription Complex Subunit 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107661>	C20194	STRN Gene|STRN|STRN|STRN|Striatin, Calmodulin Binding Protein Gene	This gene may play a role in cell scaffolding or calcium signaling.	STRN Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C107662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107662>	C107661	STRN wt Allele|SG2NA|Striatin, Calmodulin Binding Protein wt Allele	Human STRN wild-type allele is located in the vicinity of 2p22.2 and is approximately 123 kb in length. This allele, which encodes striatin protein, maybe involved in calcium signaling or cell junction formation.	STRN wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107663>	C18466	Striatin|STRN|Striatin, Calmodulin Binding Protein|Striatin, Calmodulin-Binding Protein	Striatin (780 aa, ~86 kDa) is encoded by the human STRN gene. This protein may play a role in calcium-mediated signaling.	Striatin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107664>	C20703	IRF2BP2 Gene|IRF2BP2|IRF2BP2|Interferon Regulatory Factor 2 Binding Protein 2 Gene	This gene plays a role in transcriptional repression.	IRF2BP2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107665>	C107664	IRF2BP2 wt Allele|IRF-2BP2|Interferon Regulatory Factor 2 Binding Protein 2 wt Allele	Human IRF2BP2 wild-type allele is located in the vicinity of 1q42.3 and is approximately 5 kb in length. This allele, which encodes interferon regulatory factor 2-binding protein 2, is involved in the repression of interferon gene expression.	IRF2BP2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107666>	C26199	Interferon Regulatory Factor 2-Binding Protein 2|IRF-2-Binding Protein 2|IRF-2BP2|IRF2-Binding Protein 2|IRF2BP2	Interferon regulatory factor 2-binding protein 2 (587 aa, ~61 kDa) is encoded by the human IRF2BP2 gene. This protein plays a role in the negative regulation of interferon expression.	Interferon Regulatory Factor 2-Binding Protein 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107667>	C16615	CDX1 Gene|CDX1|CDX1|Caudal Type Homeobox 1 Gene	This gene is involved in gene expression in the intestine.	CDX1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C107668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107668>	C107667	CDX1 wt Allele|CDX-1|Caudal Type Homeobox 1 wt Allele	Human CDX1 wild-type allele is located in the vicinity of 5q32 and is approximately 19 kb in length. This allele, which encodes homeobox protein CDX-1, plays a role in the regulation of intestinal gene expression.	CDX1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C107669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107669>	C17207	Homeobox Protein CDX-1|CDX1|Caudal Type Homeo Box Transcription Factor 1|Caudal Type Homeobox Transcription Factor 1|Caudal-Type Homeobox Protein 1|Caudal-Type Homeobox Protein CDX1|Caudal-Type Homeobox Transcription Factor 1	Homeobox protein CDX-1 (265 aa, ~28 kDa) is encoded by the human CDX1 gene. This protein is involved in the modulation of gene expression in the intestine.	Homeobox Protein CDX-1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C10766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10766>	C61063	Fluorouracil/Leucovorin Calcium/Methotrexate/PALA/Triacetyluridine|CF/5-FU/MTX/PALA/TAU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107670>	C97716	Adjustable Dose Pre-filled Pen Syringe|Adjustable Dose Pre-Filled Drug Pen	A syringe with a measured dose of medication that has an apparatus that enables the user to specify the amount of the medication to deliver in an injection.			Manufactured Object	NCPDP Strength Form Terminology
C107671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107671>	C22113	Mucin-Depleted Foci of the Mouse Intestinal Tract|MDF of the Mouse Intestinal Tract	Precancerous dysplastic lesions depleted of mucin in the colonic mucosa of the mouse.			Disease or Syndrome	
C107672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107672>	C22152	Intramucosal Carcinoma of the Mouse Intestinal Tract	Infiltration of malignant glandular epithelial cells into the lamina propria of the intestine of the mouse without involvement of the submucosa.			Neoplastic Process	
C107673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107673>	C22117	Serrated Lesion of the Mouse Intestinal Tract	A large intestinal glandular mucosal lesion in the mouse characterized by epithelial infoldings and ectopic crypt formation.			Neoplastic Process	
C107674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107674>	C22151	Metastatic Carcinoma of the Mouse Intestinal Tract	A carcinoma that arises from the intestinal tract of the mouse and has spread to other anatomic sites.			Neoplastic Process	
C107675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107675>	C54452	SPL Race Terminology|Structured Product Labeling Race Terminology	Terminology used for representation of the race designation in the framework of the Structured Product Labeling documents.	SPL Race Terminology		Intellectual Product	FDA Structured Product Labeling Terminology
C107676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107676>	C1450	Dicycloplatin|DCP|DICYCLOPLATIN	A third-generation, supramolecular platinum-based compound composed of carboplatin linked, by a strong hydrogen bond, to 1,1-cyclobutane dicarboxylate (CBDCA), with potential antineoplastic activity. Although the exact mechanism of action has yet to be fully elucidated, dicycloplatin appears to have a mechanism of action similar to that of other platinum-based compounds, which involves both DNA binding and the formation of DNA crosslinks. This mechanism results in the induction of apoptosis and cell growth inhibition. Compared to carboplatin alone, dicycloplatin shows enhanced solubility and stability in aqueous solution and appears to have a more favorable toxicity profile.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C107677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107677>	C15187	AAV-DC-CTL Tumor Cell Targeting Therapy|ACTL Therapy|Antigen-specific Cytotoxic T Lymphocytes Induced by Dendritic Cells Infected by Recombinant Adeno-associated Virus Therapy	A tumor-targeted therapy consisting of cytotoxic T lymphocytes (CTLs) that are exposed ex vivo to dendritic cells (DCs) transfected with a recombinant adeno-associated virus (rAAV) encoding a specific tumor associated antigen (TAA) gene. Autologous peripheral blood mononuclear cells (PBMC) are collected and separated into monocytes and lymphocytes. The monocytes are infected with the rAAV that carries the TAA gene; this is followed by co-culture of the monocyte-derived, mature rAAV-transfected DCs and the isolated lymphocytes to generate CTLs against the specific TAA. These CTLs are transfused back into the patient for cancer therapy. The CTLs specifically kill tumor cells expressing the TAA, which results in a reduction of tumor cell proliferation.			Therapeutic or Preventive Procedure	
C107678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107678>	C216105	Rovalpituzumab Tesirine|ROVALPITUZUMAB TESIRINE|Rova-T|SC16LD6.5	An antibody-drug conjugate (ADC) containing a humanized IgG1 monoclonal antibody (MAb) directed against the delta-like protein 3 (DLL3), conjugated to the cytotoxic pyrrolobenzodiazepine (PBD) dimer D6.5 (SC-DR002) via a maleimide-containing linker with an eight-carbon polyethylene glycol spacer and a cathepsin B-cleavable valine-alanine dipeptide, with potential antineoplastic activity. The MAb moiety of rovalpituzumab tesirine selectively binds to DLL3 on tumor cell surfaces. Upon internalization of the ADC, the dipeptide linker is cleaved and D6.5 is released. Then the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of DLL3-overexpressing tumor cells. DLL3, a membrane protein that binds to Notch receptors and regulates Notch-mediated signaling and gene transcription, is overexpressed by certain cancers but is rarely expressed by normal, healthy cells.	Rovalpituzumab Tesirine		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C10767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10767>	C61063	Fluorouracil/Leucovorin Calcium/Paclitaxel|CF/5-FU/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107680>	C697|C1742	Melphalan Flufenamide|Ethyl (2S)-2-((2S)-2-Amino-3-(4-(bis(2-chloroethyl)amino)phenyl)propanamido)-3-(4-fluorophenyl)propanoate|J-1|J1|L-melphalanyl-p-L-fluorophenylalanine Ethyl Ester|MELPHALAN FLUFENAMIDE|Melflufen|Melphalan flufenamide|Prodrug J1|Ygalo	A peptide-drug conjugate composed of a peptide conjugated, via an aminopeptidase-targeting linkage, to the alkylating agent melphalan, with potential antineoplastic and anti-angiogenic activities. Upon administration, the highly lipophilic melphalan flufenamide penetrates cell membranes and enters cells. In aminopeptidase-positive tumor cells, melphalan flufenamide is hydrolyzed by peptidases to release the hydrophilic alkylating agent melphalan. This results in the specific release and accumulation of melphalan in aminopeptidase-positive tumor cells. Melphalan alkylates DNA at the N7 position of guanine residues and induces DNA intra- and inter-strand cross-linkages. This results in the inhibition of DNA and RNA synthesis and the induction of apoptosis, thereby inhibiting tumor cell proliferation. Peptidases are overexpressed by certain cancer cells. The administration of melphalan flufenamide allows for enhanced efficacy and reduced toxicity compared to melphalan.	Melphalan Flufenamide		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C107681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107681>	C1663	Allogeneic Autophagosome-enriched Vaccine DPV-001|Allogeneic DRibble Vaccine DPV-001|DPV 001|DPV-001|DPV-001 Vaccine|DPV001|DRiPs and SLiPs-containing Blebs Vaccine DPV-001|DRibble Vaccine DPV-001|Dribble Cancer Vaccine DPV-001|Dribbles Vaccine DPV-001|Tumor-derived Autophagosomes Vaccine DPV-001|Vaccine DPV-001	An off-the-shelf (OTS) autophagosome-enriched tumor vaccine composed of dendritic cell (DC)-targeting microvesicles containing short lived proteins (SLiPs) and defective ribosomal products (DRiPs) derived from tumor cells, with potential immunostimulating and antineoplastic activities. The DriPs- and SLiPs-filled autophagosome microvesicles are made by treating two human non-small cell lung cancer (NSCLC) cell lines, UbiLT3 (non-specific histopathology) and UbiLT6 (adenocarcinoma-like) with both a proteasome inhibitor, to prevent protein degradation, and an autophagy inducer. DPV-001 contains a wide variety of NSCLC-derived TAAs, many as immunogenic altered-peptide ligands (APL), and numerous damage-associated molecular pattern molecules (DAMPs) with Toll-like receptor (TLR) 2, 3, 4, 7 and 9 agonist activities. Upon administration of allogeneic autophagosome-enriched vaccine DPV-001, the proteins in the vaccine target DCs and may stimulate the immune system to mount cytotoxic T-lymphocyte (CTL) and helper T-lymphocyte responses against the TAAs. The TAAs are overexpressed in a variety of cancer cell types other than NSCLC. The tumor-associated SLiPS and DRiPs are highly unstable and normally degraded by tumor cell proteasomes. They are typically not processed and cross-presented by antigen-presenting cells (APCs).	Allogeneic Autophagosome-enriched Vaccine DPV-001		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C107682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107682>	C241	Substance P-Saporin|SP-SAP	An agent composed of substance P (SP) conjugated to the ribosome-inactivating protein and neurotoxin saporin (SAP), isolated from the seeds of the plant Saponaria officinalis (SP-SAP), with potential analgesic activity. Upon administration, SP-SAP targets the SP receptor, neurokinin-1 receptor (NK-1R), located on neurons. When SP-SAP binds NK-1R and the receptor/conjugate complex internalizes, the saporin moiety inactivates ribosomes and prevents protein synthesis, which causes cell death, destroys NK-1R-expressing nerves and decreases pain perception.	Substance P-Saporin		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C107683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107683>	C133879	Aprutumab|AGC-2500|APRUTUMAB|BAY-1179470|BAY1179470	An antibody against the fibroblast growth factor receptor type 2 (FGFR2), with potential antineoplastic activity. Upon administration, aprutumab binds to and inhibits FGFR2, which may result in the inhibition of both FGFR2 phosphorylation and FGFR2-mediated signal transduction pathways. This results in the inhibition of cell proliferation and the induction of cell death of FGFR2-expressing tumor cells. FGFR2, upregulated in many tumor cell types, is a receptor tyrosine kinase, which is essential to tumor cellular proliferation, differentiation and survival.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C107684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107684>	C2152|C129825	PI3Kbeta Inhibitor AZD8186|AZD-8186|AZD-8186|AZD8186	An inhibitor of the beta isoform of phosphoinositide-3 kinase (PI3K), with potential antineoplastic activity. Upon administration, PI3Kbeta inhibitor AZD8186 selectively inhibits the activity of PI3Kbeta in the PI3K/Akt/mTOR signaling pathway, which may result in a decrease of tumor cell proliferation and induces cell death in PI3K-expressing cancer cells. By specifically targeting class I PI3K beta, this agent may be more efficacious and less toxic than pan PI3K inhibitors. PI3K-mediated signaling is often dysregulated in cancer cells and contributes to increased tumor cell growth, survival, and tumor resistance to a variety of antineoplastic agents.	PI3Kbeta Inhibitor AZD8186		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C107685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107685>	C129821	BC-819 Plasmid/Polyethylenimine Complex|BC-819/PEI|DTA-H19/PEI	A plasmid DNA encoding for the A fragment of Diphtheria Toxin (DTA) under the control of the H19 gene promoter (BC-819 or DTA-H19) and mixed with the transfectant polyethylenimine (PEI), with potential antineoplastic activity. Upon administration, the PEI moiety enhances the entry of the agent into rapidly dividing cells. Upon cell entry, activation of the H19 gene promoter-containing plasmids and DTA expression are limited to tumor cells, as high levels of H19 expression are only found in tumor cells. DTA disrupts protein synthesis. Tumor-cell selective expression of this toxin leads to the selective destruction of the tumor while sparing healthy, normal cells. H19, an oncofetal, regulatory RNA, is overexpressed in certain cancer cells while its expression in normal cells is minimal or absent; it plays a key role in cancer progression, angiogenesis and metastasis.			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C107686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107686>	C2152|C129825	Dezapelisib|5H-Thiazolo(3,2-a)pyrimidin-5-one, 6-(3-Fluorophenyl)-3-methyl-7-((1S)-1-(9H-purin-6-ylamino)ethyl)-|DEZAPELISIB|INCB040093	An orally bioavailable, selective inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinases (PI3K) with potential antineoplastic activity. Dezapelisib specifically inhibits PI3Kdelta, which prevents both the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and the activation of the PI3K/AKT kinase signaling pathway. This decreases proliferation and induces cell death in PI3K-overexpressing tumor cells. Unlike other isoforms of PI3K, PI3Kdelta is often overexpressed in tumor cells, especially those of hematologic origin, and plays a crucial role in tumor cell regulation and survival. The targeted inhibition of PI3Kdelta allows for PI3K signaling in normal, non-neoplastic cells.	Dezapelisib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C107687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107687>	C49292	US County|United States County	A region in the United States created by territorial division for the purpose of local government.			Geographic Area	
C107688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107688>	C107687	Autauga County, AL|AL001|Autauga County|Autauga County, Alabama				Geographic Area	US Counties Terminology
C107689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107689>	C107687	Baldwin County, AL|AL003|Baldwin County|Baldwin County, Alabama				Geographic Area	US Counties Terminology
C10768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10768>	C61063	Filgrastim/Fluorouracil/Leucovorin Calcium/Paclitaxel|CF/5-FU/G-CSF/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107690>	C107687	Barbour County, AL|AL005|Barbour County|Barbour County, Alabama				Geographic Area	US Counties Terminology
C107691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107691>	C107687	Bibb County, AL|AL007|Bibb County|Bibb County, Alabama				Geographic Area	US Counties Terminology
C107692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107692>	C107687	Blount County, AL|AL009|Blount County|Blount County, Alabama				Geographic Area	US Counties Terminology
C107693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107693>	C107687	Bullock County, AL|AL011|Bullock County|Bullock County, Alabama				Geographic Area	US Counties Terminology
C107694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107694>	C107687	Butler County, AL|AL013|Butler County|Butler County, Alabama				Geographic Area	US Counties Terminology
C107695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107695>	C107687	Calhoun County, AL|AL015|Calhoun County|Calhoun County, Alabama				Geographic Area	US Counties Terminology
C107696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107696>	C107687	Chambers County, AL|AL017|Chambers County|Chambers County, Alabama				Geographic Area	US Counties Terminology
C107697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107697>	C107687	Cherokee County, AL|AL019|Cherokee County|Cherokee County, Alabama				Geographic Area	US Counties Terminology
C107698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107698>	C107687	Chilton County, AL|AL021|Chilton County|Chilton County, Alabama				Geographic Area	US Counties Terminology
C107699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107699>	C107687	Choctaw County, AL|AL023|Choctaw County|Choctaw County, Alabama				Geographic Area	US Counties Terminology
C10769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10769>	C61063	Edatrexate/Leucovorin Calcium|CF/EDAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1076>	C243|C2360	Dromostanolone|17 Beta-hydroxy-2 alpha-methyl-5 alpha-androstan-3-one|2 Alpha-5 alpha-17 beta-17-hydroxy-2-methyl-androstan-3-one|2 Alpha-methylandrostan-17 beta-ol-3-one|2 Alpha-methyldihydrotestosterone|2.alpha.-Methyldihydrotestosterone|5.alpha.-Androstan-3-one, 17.beta.-hydroxy-2.alpha.-methyl-|DROMOSTANOLONE|Drostanolone|Drostanolone	A synthetic anabolic steroid related to dihydrotestosterone that has antiestrogenic effects. Dromostanolone inhibits the growth of estrogen receptor-presenting breast cancers; its virilizing effects limit its clinical usefulness. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C107700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107700>	C107687	Clarke County, AL|AL025|Clarke County|Clarke County, Alabama				Geographic Area	US Counties Terminology
C107701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107701>	C107687	Clay County, AL|AL027|Clay County|Clay County, Alabama				Geographic Area	US Counties Terminology
C107702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107702>	C107687	Cleburne County, AL|AL029|Cleburne County|Cleburne County, Alabama				Geographic Area	US Counties Terminology
C107703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107703>	C107687	Coffee County, AL|AL031|Coffee County|Coffee County, Alabama				Geographic Area	US Counties Terminology
C107704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107704>	C107687	Colbert County, AL|AL033|Colbert County|Colbert County, Alabama				Geographic Area	US Counties Terminology
C107705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107705>	C107687	Conecuh County, AL|AL035|Conecuh County|Conecuh County, Alabama				Geographic Area	US Counties Terminology
C107706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107706>	C107687	Coosa County, AL|AL037|Coosa County|Coosa County, Alabama				Geographic Area	US Counties Terminology
C107707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107707>	C107687	Covington County, AL|AL039|Covington County|Covington County, Alabama				Geographic Area	US Counties Terminology
C107708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107708>	C107687	Crenshaw County, AL|AL041|Crenshaw County|Crenshaw County, Alabama				Geographic Area	US Counties Terminology
C107709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107709>	C107687	Cullman County, AL|AL043|Cullman County|Cullman County, Alabama				Geographic Area	US Counties Terminology
C10770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10770>	C61063	Cyclosporine/Cytarabine/Etoposide/Mitoxantrone|ARA-C/CYSP/DHAD/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107710>	C107687	Dale County, AL|AL045|Dale County|Dale County, Alabama				Geographic Area	US Counties Terminology
C107711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107711>	C107687	Dallas County, AL|AL047|Dallas County|Dallas County, Alabama				Geographic Area	US Counties Terminology
C107712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107712>	C107687	DeKalb County, AL|AL049|DeKalb County|DeKalb County, Alabama				Geographic Area	US Counties Terminology
C107713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107713>	C107687	Elmore County, AL|AL051|Elmore County|Elmore County, Alabama				Geographic Area	US Counties Terminology
C107714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107714>	C107687	Escambia County, AL|AL053|Escambia County|Escambia County, Alabama				Geographic Area	US Counties Terminology
C107715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107715>	C107687	Etowah County, AL|AL055|Etowah County|Etowah County, Alabama				Geographic Area	US Counties Terminology
C107716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107716>	C107687	Fayette County, AL|AL057|Fayette County|Fayette County, Alabama				Geographic Area	US Counties Terminology
C107717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107717>	C107687	Franklin County, AL|AL059|Franklin County|Franklin County, Alabama				Geographic Area	US Counties Terminology
C107718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107718>	C107687	Geneva County, AL|AL061|Geneva County|Geneva County, Alabama				Geographic Area	US Counties Terminology
C107719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107719>	C107687	Greene County, AL|AL063|Greene County|Greene County, Alabama				Geographic Area	US Counties Terminology
C10771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10771>	C61063	Cyclophosphamide/Doxorubicin/Methotrexate/Methylprednisolone/Prednisone/Vincristine|CTX/DOX/MePRDL/MTX/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107720>	C107687	Hale County, AL|AL065|Hale County|Hale County, Alabama				Geographic Area	US Counties Terminology
C107721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107721>	C107687	Henry County, AL|AL067|Henry County|Henry County, Alabama				Geographic Area	US Counties Terminology
C107722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107722>	C107687	Houston County, AL|AL069|Houston County|Houston County, Alabama				Geographic Area	US Counties Terminology
C107723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107723>	C107687	Jackson County, AL|AL071|Jackson County|Jackson County, Alabama				Geographic Area	US Counties Terminology
C107724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107724>	C107687	Jefferson County, AL|AL073|Jefferson County|Jefferson County, Alabama				Geographic Area	US Counties Terminology
C107725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107725>	C107687	Lamar County, AL|AL075|Lamar County|Lamar County, Alabama				Geographic Area	US Counties Terminology
C107726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107726>	C107687	Lauderdale County, AL|AL077|Lauderdale County|Lauderdale County, Alabama				Geographic Area	US Counties Terminology
C107727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107727>	C107687	Lawrence County, AL|AL079|Lawrence County|Lawrence County, Alabama				Geographic Area	US Counties Terminology
C107728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107728>	C107687	Lee County, AL|AL081|Lee County|Lee County, Alabama				Geographic Area	US Counties Terminology
C107729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107729>	C107687	Limestone County, AL|AL083|Limestone County|Limestone County, Alabama				Geographic Area	US Counties Terminology
C10772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10772>	C61063	Cisplatin/Etoposide/Tamoxifen|CDDP/TMX/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107730>	C107687	Lowndes County, AL|AL085|Lowndes County|Lowndes County, Alabama				Geographic Area	US Counties Terminology
C107731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107731>	C107687	Macon County, AL|AL087|Macon County|Macon County, Alabama				Geographic Area	US Counties Terminology
C107732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107732>	C107687	Madison County, AL|AL089|Madison County|Madison County, Alabama				Geographic Area	US Counties Terminology
C107733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107733>	C107687	Marengo County, AL|AL091|Marengo County|Marengo County, Alabama				Geographic Area	US Counties Terminology
C107734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107734>	C107687	Marion County, AL|AL093|Marion County|Marion County, Alabama				Geographic Area	US Counties Terminology
C107735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107735>	C107687	Marshall County, AL|AL095|Marshall County|Marshall County, Alabama				Geographic Area	US Counties Terminology
C107736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107736>	C107687	Mobile County, AL|AL097|Mobile County|Mobile County, Alabama				Geographic Area	US Counties Terminology
C107737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107737>	C107687	Monroe County, AL|AL099|Monroe County|Monroe County, Alabama				Geographic Area	US Counties Terminology
C107738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107738>	C107687	Montgomery County, AL|AL101|Montgomery County|Montgomery County, Alabama				Geographic Area	US Counties Terminology
C107739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107739>	C107687	Morgan County, AL|AL103|Morgan County|Morgan County, Alabama				Geographic Area	US Counties Terminology
C10773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10773>	C61063	BCG/Bropirimine|ABPP/BCG			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107740>	C107687	Perry County, AL|AL105|Perry County|Perry County, Alabama				Geographic Area	US Counties Terminology
C107741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107741>	C107687	Pickens County, AL|AL107|Pickens County|Pickens County, Alabama				Geographic Area	US Counties Terminology
C107742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107742>	C107687	Pike County, AL|AL109|Pike County|Pike County, Alabama				Geographic Area	US Counties Terminology
C107743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107743>	C107687	Randolph County, AL|AL111|Randolph County|Randolph County, Alabama				Geographic Area	US Counties Terminology
C107744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107744>	C107687	Russell County, AL|AL113|Russell County|Russell County, Alabama				Geographic Area	US Counties Terminology
C107745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107745>	C107687	St. Clair County, AL|AL115|St. Clair County|St. Clair County, Alabama				Geographic Area	US Counties Terminology
C107746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107746>	C107687	Shelby County, AL|AL117|Shelby County|Shelby County, Alabama				Geographic Area	US Counties Terminology
C107747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107747>	C107687	Sumter County, AL|AL119|Sumter County|Sumter County, Alabama				Geographic Area	US Counties Terminology
C107748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107748>	C107687	Talladega County, AL|AL121|Talladega County|Talladega County, Alabama				Geographic Area	US Counties Terminology
C107749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107749>	C107687	Tallapoosa County, AL|AL123|Tallapoosa County|Tallapoosa County, Alabama				Geographic Area	US Counties Terminology
C10774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10774>	C61063	Cyclophosphamide/Doxorubicin/Fluorouracil/Leucovorin Calcium/Milodistim|CF/CTX/DOX/5-FU/PIXY321			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107750>	C107687	Tuscaloosa County, AL|AL125|Tuscaloosa County|Tuscaloosa County, Alabama				Geographic Area	US Counties Terminology
C107751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107751>	C107687	Walker County, AL|AL127|Walker County|Walker County, Alabama				Geographic Area	US Counties Terminology
C107752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107752>	C107687	Washington County, AL|AL129|Washington County|Washington County, Alabama				Geographic Area	US Counties Terminology
C107753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107753>	C107687	Wilcox County, AL|AL131|Wilcox County|Wilcox County, Alabama				Geographic Area	US Counties Terminology
C107754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107754>	C107687	Winston County, AL|AL133|Winston County|Winston County, Alabama				Geographic Area	US Counties Terminology
C107755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107755>	C107687	Aleutians East Borough, AK|AK013|Aleutians East Borough|Aleutians East Borough, Alaska				Geographic Area	US Counties Terminology
C107756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107756>	C107687	Aleutians West Census Area, AK|AK016|Aleutians West Census Area|Aleutians West Census Area, Alaska				Geographic Area	US Counties Terminology
C107757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107757>	C107687	Anchorage Municipality, AK|AK020|Anchorage Municipality|Anchorage Municipality, Alaska				Geographic Area	US Counties Terminology
C107758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107758>	C107687	Bethel Census Area, AK|AK050|Bethel Census Area|Bethel Census Area, Alaska				Geographic Area	US Counties Terminology
C107759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107759>	C107687	Bristol Bay Borough, AK|AK060|Bristol Bay Borough|Bristol Bay Borough, Alaska				Geographic Area	US Counties Terminology
C10775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10775>	C61063	Carboplatin/Fluorouracil/Vincristine|CBDCA/5-FU/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107760>	C107687	Denali Borough, AK|AK068|Denali Borough|Denali Borough, Alaska				Geographic Area	US Counties Terminology
C107761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107761>	C107687	Dillingham Census Area, AK|AK070|Dillingham Census Area|Dillingham Census Area, Alaska				Geographic Area	US Counties Terminology
C107762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107762>	C107687	Fairbanks North Star Borough, AK|AK090|Fairbanks North Star Borough|Fairbanks North Star Borough, Alaska				Geographic Area	US Counties Terminology
C107763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107763>	C107687	Haines Borough, AK|AK100|Haines Borough|Haines Borough, Alaska				Geographic Area	US Counties Terminology
C107764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107764>	C107687	Hoonah-Angoon Census Area, AK|AK105|Hoonah-Angoon Census Area|Hoonah-Angoon Census Area, Alaska				Geographic Area	US Counties Terminology
C107765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107765>	C107687	Juneau City and Borough, AK|AK110|Juneau City and Borough|Juneau City and Borough, Alaska				Geographic Area	US Counties Terminology
C107766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107766>	C107687	Kenai Peninsula Borough, AK|AK122|Kenai Peninsula Borough|Kenai Peninsula Borough, Alaska				Geographic Area	US Counties Terminology
C107767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107767>	C107687	Ketchikan Gateway Borough, AK|AK130|Ketchikan Gateway Borough|Ketchikan Gateway Borough, Alaska				Geographic Area	US Counties Terminology
C107768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107768>	C107687	Kodiak Island Borough, AK|AK150|Kodiak Island Borough|Kodiak Island Borough, Alaska				Geographic Area	US Counties Terminology
C107769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107769>	C107687	Lake and Peninsula Borough, AK|AK164|Lake and Peninsula Borough|Lake and Peninsula Borough, Alaska				Geographic Area	US Counties Terminology
C10776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10776>	C61063	Filgrastim/Pyrazoloacridine|G-CSF/PZA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107770>	C107687	Matanuska-Susitna Borough, AK|AK170|Matanuska-Susitna Borough|Matanuska-Susitna Borough, Alaska				Geographic Area	US Counties Terminology
C107771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107771>	C107687	Nome Census Area, AK|AK180|Nome Census Area|Nome Census Area, Alaska				Geographic Area	US Counties Terminology
C107772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107772>	C107687	North Slope Borough, AK|AK185|North Slope Borough|North Slope Borough, Alaska				Geographic Area	US Counties Terminology
C107773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107773>	C107687	Northwest Arctic Borough, AK|AK188|Northwest Arctic Borough|Northwest Arctic Borough, Alaska				Geographic Area	US Counties Terminology
C107774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107774>	C107687	Petersburg Census Area, AK|AK195|Petersburg Census Area|Petersburg Census Area, Alaska				Geographic Area	US Counties Terminology
C107775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107775>	C107687	Prince of Wales-Hyder Census Area, AK|AK198|Prince of Wales-Hyder Census Area|Prince of Wales-Hyder Census Area, Alaska				Geographic Area	US Counties Terminology
C107776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107776>	C107687	Sitka City and Borough, AK|AK220|Sitka City and Borough|Sitka City and Borough, Alaska				Geographic Area	US Counties Terminology
C107777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107777>	C107687	Skagway Municipality, AK|AK230|Skagway Municipality|Skagway Municipality, Alaska				Geographic Area	US Counties Terminology
C107778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107778>	C107687	Southeast Fairbanks Census Area, AK|AK240|Southeast Fairbanks Census Area|Southeast Fairbanks Census Area, Alaska				Geographic Area	US Counties Terminology
C107779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107779>	C107687	Valdez-Cordova Census Area, AK|AK261|Valdez-Cordova Census Area|Valdez-Cordova Census Area, Alaska				Geographic Area	US Counties Terminology
C10777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10777>	C61063	Filgrastim/Paclitaxel/Topotecan|G-CSF/TAX/TOPO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107780>	C107687	Wade Hampton Census Area, AK|AK270|Wade Hampton Census Area|Wade Hampton Census Area, Alaska				Geographic Area	US Counties Terminology
C107781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107781>	C107687	Wrangell City and Borough, AK|AK275|Wrangell City and Borough|Wrangell City and Borough, Alaska				Geographic Area	US Counties Terminology
C107782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107782>	C107687	Yakutat City and Borough, AK|AK282|Yakutat City and Borough|Yakutat City and Borough, Alaska				Geographic Area	US Counties Terminology
C107783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107783>	C107687	Yukon-Koyukuk Census Area, AK|AK290|Yukon-Koyukuk Census Area|Yukon-Koyukuk Census Area, Alaska				Geographic Area	US Counties Terminology
C107784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107784>	C107687	Apache County, AZ|AZ001|Apache County|Apache County, Arizona				Geographic Area	US Counties Terminology
C107785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107785>	C107687	Cochise County, AZ|AZ003|Cochise County|Cochise County, Arizona				Geographic Area	US Counties Terminology
C107786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107786>	C107687	Coconino County, AZ|AZ005|Coconino County|Coconino County, Arizona				Geographic Area	US Counties Terminology
C107787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107787>	C107687	Gila County, AZ|AZ007|Gila County|Gila County, Arizona				Geographic Area	US Counties Terminology
C107788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107788>	C107687	Graham County, AZ|AZ009|Graham County|Graham County, Arizona				Geographic Area	US Counties Terminology
C107789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107789>	C107687	Greenlee County, AZ|AZ011|Greenlee County|Greenlee County, Arizona				Geographic Area	US Counties Terminology
C10778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10778>	C61063	Cisplatin/Cyclosporine/Doxorubicin|CDDP/CYSP/DOX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107790>	C107687	La Paz County, AZ|AZ012|La Paz County|La Paz County, Arizona				Geographic Area	US Counties Terminology
C107791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107791>	C107687	Maricopa County, AZ|AZ013|Maricopa County|Maricopa County, Arizona				Geographic Area	US Counties Terminology
C107792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107792>	C107687	Mohave County, AZ|AZ015|Mohave County|Mohave County, Arizona				Geographic Area	US Counties Terminology
C107793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107793>	C107687	Navajo County, AZ|AZ017|Navajo County|Navajo County, Arizona				Geographic Area	US Counties Terminology
C107794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107794>	C107687	Pima County, AZ|AZ019|Pima County|Pima County, Arizona				Geographic Area	US Counties Terminology
C107795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107795>	C107687	Pinal County, AZ|AZ021|Pinal County|Pinal County, Arizona				Geographic Area	US Counties Terminology
C107796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107796>	C107687	Santa Cruz County, AZ|AZ023|Santa Cruz County|Santa Cruz County, Arizona				Geographic Area	US Counties Terminology
C107797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107797>	C107687	Yavapai County, AZ|AZ025|Yavapai County|Yavapai County, Arizona				Geographic Area	US Counties Terminology
C107798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107798>	C107687	Yuma County, AZ|AZ027|Yuma County|Yuma County, Arizona				Geographic Area	US Counties Terminology
C107799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107799>	C107687	Arkansas County, AR|AR001|Arkansas County|Arkansas County, Arkansas				Geographic Area	US Counties Terminology
C10779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10779>	C61063	Cisplatin/Pentoxifylline|CDDP/PTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1077>	C243	Dromostanolone Propionate|2 Alpha-Methyldihydrotestosterone Propionate|2-Alpha-Methyldihydrotestosterone Propionate|2.alpha.-Methyldihydrotestosterone propionate|Compound 32379|DROMOSTANOLONE PROPIONATE|Drolban|Drostanolone Propionate|Drostanolone propionate|Emdisterone|Emdisterone|Masterid|Masterid|Masteril|Masteril|Masteron|Masterone|Masterone|Permastril|Permastril	The propionate salt form of dromostanolone, a synthetic anabolic steroid related to dihydrotestosterone that has antiestrogenic effects.  Dromostanolone inhibits the growth of estrogen receptor-presenting breast cancers; its virilizing effects limit its clinical usefulness. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C107800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107800>	C107687	Ashley County, AR|AR003|Ashley County|Ashley County, Arkansas				Geographic Area	US Counties Terminology
C107801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107801>	C107687	Baxter County, AR|AR005|Baxter County|Baxter County, Arkansas				Geographic Area	US Counties Terminology
C107802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107802>	C107687	Benton County, AR|AR007|Benton County|Benton County, Arkansas				Geographic Area	US Counties Terminology
C107803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107803>	C107687	Boone County, AR|AR009|Boone County|Boone County, Arkansas				Geographic Area	US Counties Terminology
C107804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107804>	C107687	Bradley County, AR|AR011|Bradley County|Bradley County, Arkansas				Geographic Area	US Counties Terminology
C107805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107805>	C107687	Calhoun County, AR|AR013|Calhoun County|Calhoun County, Arkansas				Geographic Area	US Counties Terminology
C107806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107806>	C107687	Carroll County, AR|AR015|Carroll County|Carroll County, Arkansas				Geographic Area	US Counties Terminology
C107807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107807>	C107687	Chicot County, AR|AR017|Chicot County|Chicot County, Arkansas				Geographic Area	US Counties Terminology
C107808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107808>	C107687	Clark County, AR|AR019|Clark County|Clark County, Arkansas				Geographic Area	US Counties Terminology
C107809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107809>	C107687	Clay County, AR|AR021|Clay County|Clay County, Arkansas				Geographic Area	US Counties Terminology
C10780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10780>	C61063	Methotrexate/Pegaspargase|MTX/PEG-ASP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107810>	C107687	Cleburne County, AR|AR023|Cleburne County|Cleburne County, Arkansas				Geographic Area	US Counties Terminology
C107811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107811>	C107687	Cleveland County, AR|AR025|Cleveland County|Cleveland County, Arkansas				Geographic Area	US Counties Terminology
C107812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107812>	C107687	Columbia County, AR|AR027|Columbia County|Columbia County, Arkansas				Geographic Area	US Counties Terminology
C107813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107813>	C107687	Conway County, AR|AR029|Conway County|Conway County, Arkansas				Geographic Area	US Counties Terminology
C107814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107814>	C107687	Craighead County, AR|AR031|Craighead County|Craighead County, Arkansas				Geographic Area	US Counties Terminology
C107815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107815>	C107687	Crawford County, AR|AR033|Crawford County|Crawford County, Arkansas				Geographic Area	US Counties Terminology
C107816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107816>	C107687	Crittenden County, AR|AR035|Crittenden County|Crittenden County, Arkansas				Geographic Area	US Counties Terminology
C107817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107817>	C107687	Cross County, AR|AR037|Cross County|Cross County, Arkansas				Geographic Area	US Counties Terminology
C107818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107818>	C107687	Dallas County, AR|AR039|Dallas County|Dallas County, Arkansas				Geographic Area	US Counties Terminology
C107819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107819>	C107687	Desha County, AR|AR041|Desha County|Desha County, Arkansas				Geographic Area	US Counties Terminology
C10781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10781>	C61063	Cisplatin/Etoposide/Filgrastim/Ifosfamide/Interleukin-3|CDDP/G-CSF/IFF/IL-3/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107820>	C107687	Drew County, AR|AR043|Drew County|Drew County, Arkansas				Geographic Area	US Counties Terminology
C107821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107821>	C107687	Faulkner County, AR|AR045|Faulkner County|Faulkner County, Arkansas				Geographic Area	US Counties Terminology
C107822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107822>	C107687	Franklin County, AR|AR047|Franklin County|Franklin County, Arkansas				Geographic Area	US Counties Terminology
C107823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107823>	C107687	Fulton County, AR|AR049|Fulton County|Fulton County, Arkansas				Geographic Area	US Counties Terminology
C107824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107824>	C107687	Garland County, AR|AR051|Garland County|Garland County, Arkansas				Geographic Area	US Counties Terminology
C107825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107825>	C107687	Grant County, AR|AR053|Grant County|Grant County, Arkansas				Geographic Area	US Counties Terminology
C107826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107826>	C107687	Greene County, AR|AR055|Greene County|Greene County, Arkansas				Geographic Area	US Counties Terminology
C107827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107827>	C107687	Hempstead County, AR|AR057|Hempstead County|Hempstead County, Arkansas				Geographic Area	US Counties Terminology
C107828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107828>	C107687	Hot Spring County, AR|AR059|Hot Spring County|Hot Spring County, Arkansas				Geographic Area	US Counties Terminology
C107829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107829>	C107687	Howard County, AR|AR061|Howard County|Howard County, Arkansas				Geographic Area	US Counties Terminology
C10782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10782>	C61063	Cisplatin/Filgrastim/Ifosfamide/Interleukin-3/Vinblastine|CDDP/G-CSF/IFF/IL-3/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107830>	C107687	Independence County, AR|AR063|Independence County|Independence County, Arkansas				Geographic Area	US Counties Terminology
C107831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107831>	C107687	Izard County, AR|AR065|Izard County|Izard County, Arkansas				Geographic Area	US Counties Terminology
C107832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107832>	C107687	Jackson County, AR|AR067|Jackson County|Jackson County, Arkansas				Geographic Area	US Counties Terminology
C107833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107833>	C107687	Jefferson County, AR|AR069|Jefferson County|Jefferson County, Arkansas				Geographic Area	US Counties Terminology
C107834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107834>	C107687	Johnson County, AR|AR071|Johnson County|Johnson County, Arkansas				Geographic Area	US Counties Terminology
C107835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107835>	C107687	Lafayette County, AR|AR073|Lafayette County|Lafayette County, Arkansas				Geographic Area	US Counties Terminology
C107836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107836>	C107687	Lawrence County, AR|AR075|Lawrence County|Lawrence County, Arkansas				Geographic Area	US Counties Terminology
C107837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107837>	C107687	Lee County, AR|AR077|Lee County|Lee County, Arkansas				Geographic Area	US Counties Terminology
C107838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107838>	C107687	Lincoln County, AR|AR079|Lincoln County|Lincoln County, Arkansas				Geographic Area	US Counties Terminology
C107839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107839>	C107687	Little River County, AR|AR081|Little River County|Little River County, Arkansas				Geographic Area	US Counties Terminology
C10783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10783>	C63442|C63356	Bleomycin/Cyclophosphamide/Doxorubicin/Prednisolone/Vindesine Regimen|BLEO/CTX/DAVA/DOX/PRDL|Bleomycin/Cyclophosphamide/Doxorubicin/Prednisolone/Vindesine|CHEP Bleo|CHEP-Bleomycin|LNH 84|LNH-84|LNH-84 Regimen	A regimen consisting of bleomycin, cyclophosphamide, doxorubicin, prednisolone, and vindesine that can be used for the treatment of lymphoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C107840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107840>	C107687	Logan County, AR|AR083|Logan County|Logan County, Arkansas				Geographic Area	US Counties Terminology
C107841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107841>	C107687	Lonoke County, AR|AR085|Lonoke County|Lonoke County, Arkansas				Geographic Area	US Counties Terminology
C107842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107842>	C107687	Madison County, AR|AR087|Madison County|Madison County, Arkansas				Geographic Area	US Counties Terminology
C107843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107843>	C107687	Marion County, AR|AR089|Marion County|Marion County, Arkansas				Geographic Area	US Counties Terminology
C107844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107844>	C107687	Miller County, AR|AR091|Miller County|Miller County, Arkansas				Geographic Area	US Counties Terminology
C107845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107845>	C107687	Mississippi County, AR|AR093|Mississippi County|Mississippi County, Arkansas				Geographic Area	US Counties Terminology
C107846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107846>	C107687	Monroe County, AR|AR095|Monroe County|Monroe County, Arkansas				Geographic Area	US Counties Terminology
C107847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107847>	C107687	Montgomery County, AR|AR097|Montgomery County|Montgomery County, Arkansas				Geographic Area	US Counties Terminology
C107848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107848>	C107687	Nevada County, AR|AR099|Nevada County|Nevada County, Arkansas				Geographic Area	US Counties Terminology
C107849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107849>	C107687	Newton County, AR|AR101|Newton County|Newton County, Arkansas				Geographic Area	US Counties Terminology
C10784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10784>	C61063	Fazarabine/Filgrastim|ARA-AC/G-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107850>	C107687	Ouachita County, AR|AR103|Ouachita County|Ouachita County, Arkansas				Geographic Area	US Counties Terminology
C107851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107851>	C107687	Perry County, AR|AR105|Perry County|Perry County, Arkansas				Geographic Area	US Counties Terminology
C107852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107852>	C107687	Phillips County, AR|AR107|Phillips County|Phillips County, Arkansas				Geographic Area	US Counties Terminology
C107853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107853>	C107687	Pike County, AR|AR109|Pike County|Pike County, Arkansas				Geographic Area	US Counties Terminology
C107854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107854>	C107687	Poinsett County, AR|AR111|Poinsett County|Poinsett County, Arkansas				Geographic Area	US Counties Terminology
C107855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107855>	C107687	Polk County, AR|AR113|Polk County|Polk County, Arkansas				Geographic Area	US Counties Terminology
C107856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107856>	C107687	Pope County, AR|AR115|Pope County|Pope County, Arkansas				Geographic Area	US Counties Terminology
C107857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107857>	C107687	Prairie County, AR|AR117|Prairie County|Prairie County, Arkansas				Geographic Area	US Counties Terminology
C107858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107858>	C107687	Pulaski County, AR|AR119|Pulaski County|Pulaski County, Arkansas				Geographic Area	US Counties Terminology
C107859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107859>	C107687	Randolph County, AR|AR121|Randolph County|Randolph County, Arkansas				Geographic Area	US Counties Terminology
C10785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10785>	C61007	Cyclophosphamide/Topotecan|CTX/TOPO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107860>	C107687	St. Francis County, AR|AR123|St. Francis County|St. Francis County, Arkansas				Geographic Area	US Counties Terminology
C107861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107861>	C107687	Saline County, AR|AR125|Saline County|Saline County, Arkansas				Geographic Area	US Counties Terminology
C107862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107862>	C107687	Scott County, AR|AR127|Scott County|Scott County, Arkansas				Geographic Area	US Counties Terminology
C107863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107863>	C107687	Searcy County, AR|AR129|Searcy County|Searcy County, Arkansas				Geographic Area	US Counties Terminology
C107864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107864>	C107687	Sebastian County, AR|AR131|Sebastian County|Sebastian County, Arkansas				Geographic Area	US Counties Terminology
C107865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107865>	C107687	Sevier County, AR|AR133|Sevier County|Sevier County, Arkansas				Geographic Area	US Counties Terminology
C107866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107866>	C107687	Sharp County, AR|AR135|Sharp County|Sharp County, Arkansas				Geographic Area	US Counties Terminology
C107867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107867>	C107687	Stone County, AR|AR137|Stone County|Stone County, Arkansas				Geographic Area	US Counties Terminology
C107868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107868>	C107687	Union County, AR|AR139|Union County|Union County, Arkansas				Geographic Area	US Counties Terminology
C107869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107869>	C107687	Van Buren County, AR|AR141|Van Buren County|Van Buren County, Arkansas				Geographic Area	US Counties Terminology
C10786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10786>	C61063	Cisplatin/Cyclophosphamide/Thiotepa|CDDP/CTX/TSPA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107870>	C107687	Washington County, AR|AR143|Washington County|Washington County, Arkansas				Geographic Area	US Counties Terminology
C107871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107871>	C107687	White County, AR|AR145|White County|White County, Arkansas				Geographic Area	US Counties Terminology
C107872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107872>	C107687	Woodruff County, AR|AR147|Woodruff County|Woodruff County, Arkansas				Geographic Area	US Counties Terminology
C107873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107873>	C107687	Yell County, AR|AR149|Yell County|Yell County, Arkansas				Geographic Area	US Counties Terminology
C107874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107874>	C107687	Alameda County, CA|Alameda County|Alameda County, California|CA001				Geographic Area	US Counties Terminology
C107875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107875>	C107687	Alpine County, CA|Alpine County|Alpine County, California|CA003				Geographic Area	US Counties Terminology
C107876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107876>	C107687	Amador County, CA|Amador County|Amador County, California|CA005				Geographic Area	US Counties Terminology
C107877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107877>	C107687	Butte County, CA|Butte County|Butte County, California|CA007				Geographic Area	US Counties Terminology
C107878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107878>	C107687	Calaveras County, CA|CA009|Calaveras County|Calaveras County, California				Geographic Area	US Counties Terminology
C107879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107879>	C107687	Colusa County, CA|CA011|Colusa County|Colusa County, California				Geographic Area	US Counties Terminology
C10787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10787>	C61063	Gallium Nitrate/Ifosfamide/Vinblastine|GAN/IFF/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107880>	C107687	Contra Costa County, CA|CA013|Contra Costa County|Contra Costa County, California				Geographic Area	US Counties Terminology
C107881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107881>	C107687	Del Norte County, CA|CA015|Del Norte County|Del Norte County, California				Geographic Area	US Counties Terminology
C107882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107882>	C107687	El Dorado County, CA|CA017|El Dorado County|El Dorado County, California				Geographic Area	US Counties Terminology
C107883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107883>	C107687	Fresno County, CA|CA019|Fresno County|Fresno County, California				Geographic Area	US Counties Terminology
C107884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107884>	C107687	Glenn County, CA|CA021|Glenn County|Glenn County, California				Geographic Area	US Counties Terminology
C107885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107885>	C107687	Humboldt County, CA|CA023|Humboldt County|Humboldt County, California				Geographic Area	US Counties Terminology
C107886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107886>	C107687	Imperial County, CA|CA025|Imperial County|Imperial County, California				Geographic Area	US Counties Terminology
C107887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107887>	C107687	Inyo County, CA|CA027|Inyo County|Inyo County, California				Geographic Area	US Counties Terminology
C107888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107888>	C107687	Kern County, CA|CA029|Kern County|Kern County, California				Geographic Area	US Counties Terminology
C107889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107889>	C107687	Kings County, CA|CA031|Kings County|Kings County, California				Geographic Area	US Counties Terminology
C10788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10788>	C61063	Busulfan/Thiotepa|BU/TSPA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107890>	C107687	Lake County, CA|CA033|Lake County|Lake County, California				Geographic Area	US Counties Terminology
C107891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107891>	C107687	Lassen County, CA|CA035|Lassen County|Lassen County, California				Geographic Area	US Counties Terminology
C107892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107892>	C107687	Los Angeles County, CA|CA037|Los Angeles County|Los Angeles County, California				Geographic Area	US Counties Terminology
C107893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107893>	C107687	Madera County, CA|CA039|Madera County|Madera County, California				Geographic Area	US Counties Terminology
C107894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107894>	C107687	Marin County, CA|CA041|Marin County|Marin County, California				Geographic Area	US Counties Terminology
C107895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107895>	C107687	Mariposa County, CA|CA043|Mariposa County|Mariposa County, California				Geographic Area	US Counties Terminology
C107896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107896>	C107687	Mendocino County, CA|CA045|Mendocino County|Mendocino County, California				Geographic Area	US Counties Terminology
C107897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107897>	C107687	Merced County, CA|CA047|Merced County|Merced County, California				Geographic Area	US Counties Terminology
C107898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107898>	C107687	Modoc County, CA|CA049|Modoc County|Modoc County, California				Geographic Area	US Counties Terminology
C107899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107899>	C107687	Mono County, CA|CA051|Mono County|Mono County, California				Geographic Area	US Counties Terminology
C10789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10789>	C61063	Mitoxantrone/Paclitaxel/Thiotepa|DHAD/TAX/TSPA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1078>	C2169|C1557	Brequinar Sodium|BREQUINAR SODIUM|Brequinar sodium|DUP-785|DUP785|Sodium 6-Fluoro-2-(2'-fluoro-4-biphenylyl)-3-methyl-4-quinolinecarboxylate	The sodium salt form of Brequinar.  Brequinar inhibits the enzyme dihydroorotate dehydrogenase, thereby blocking de novo pyrimidine biosynthesis.  This agent may also enhance the in vivo antitumor effect of antineoplastic agents such as 5-FU. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C107900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107900>	C107687	Monterey County, CA|CA053|Monterey County|Monterey County, California				Geographic Area	US Counties Terminology
C107901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107901>	C107687	Napa County, CA|CA055|Napa County|Napa County, California				Geographic Area	US Counties Terminology
C107902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107902>	C107687	Nevada County, CA|CA057|Nevada County|Nevada County, California				Geographic Area	US Counties Terminology
C107903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107903>	C107687	Orange County, CA|CA059|Orange County|Orange County, California				Geographic Area	US Counties Terminology
C107904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107904>	C107687	Placer County, CA|CA061|Placer County|Placer County, California				Geographic Area	US Counties Terminology
C107905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107905>	C107687	Plumas County, CA|CA063|Plumas County|Plumas County, California				Geographic Area	US Counties Terminology
C107906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107906>	C107687	Riverside County, CA|CA065|Riverside County|Riverside County, California				Geographic Area	US Counties Terminology
C107907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107907>	C107687	Sacramento County, CA|CA067|Sacramento County|Sacramento County, California				Geographic Area	US Counties Terminology
C107908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107908>	C107687	San Benito County, CA|CA069|San Benito County|San Benito County, California				Geographic Area	US Counties Terminology
C107909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107909>	C107687	San Bernardino County, CA|CA071|San Bernardino County|San Bernardino County, California				Geographic Area	US Counties Terminology
C10790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10790>	C61063	Busulfan/Ciprofloxacin/Cyclophosphamide/Pentoxifylline|BU/CPFX/CTX/PTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107910>	C107687	San Diego County, CA|CA073|San Diego County|San Diego County, California				Geographic Area	US Counties Terminology
C107911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107911>	C107687	San Francisco County, CA|CA075|San Francisco County|San Francisco County, California				Geographic Area	US Counties Terminology
C107912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107912>	C107687	San Joaquin County, CA|CA077|San Joaquin County|San Joaquin County, California				Geographic Area	US Counties Terminology
C107913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107913>	C107687	San Luis Obispo County, CA|CA079|San Luis Obispo County|San Luis Obispo County, California				Geographic Area	US Counties Terminology
C107914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107914>	C107687	San Mateo County, CA|CA081|San Mateo County|San Mateo County, California				Geographic Area	US Counties Terminology
C107915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107915>	C107687	Santa Barbara County, CA|CA083|Santa Barbara County|Santa Barbara County, California				Geographic Area	US Counties Terminology
C107916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107916>	C107687	Santa Clara County, CA|CA085|Santa Clara County|Santa Clara County, California				Geographic Area	US Counties Terminology
C107917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107917>	C107687	Santa Cruz County, CA|CA087|Santa Cruz County|Santa Cruz County, California				Geographic Area	US Counties Terminology
C107918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107918>	C107687	Shasta County, CA|CA089|Shasta County|Shasta County, California				Geographic Area	US Counties Terminology
C107919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107919>	C107687	Sierra County, CA|CA091|Sierra County|Sierra County, California				Geographic Area	US Counties Terminology
C10791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10791>	C61063	Busulfan/Melphalan/Thiotepa|BU/L-PAM/TSPA|BuMelT			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107920>	C107687	Siskiyou County, CA|CA093|Siskiyou County|Siskiyou County, California				Geographic Area	US Counties Terminology
C107921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107921>	C107687	Solano County, CA|CA095|Solano County|Solano County, California				Geographic Area	US Counties Terminology
C107922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107922>	C107687	Sonoma County, CA|CA097|Sonoma County|Sonoma County, California				Geographic Area	US Counties Terminology
C107923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107923>	C107687	Stanislaus County, CA|CA099|Stanislaus County|Stanislaus County, California				Geographic Area	US Counties Terminology
C107924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107924>	C107687	Sutter County, CA|CA101|Sutter County|Sutter County, California				Geographic Area	US Counties Terminology
C107925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107925>	C107687	Tehama County, CA|CA103|Tehama County|Tehama County, California				Geographic Area	US Counties Terminology
C107926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107926>	C107687	Trinity County, CA|CA105|Trinity County|Trinity County, California				Geographic Area	US Counties Terminology
C107927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107927>	C107687	Tulare County, CA|CA107|Tulare County|Tulare County, California				Geographic Area	US Counties Terminology
C107928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107928>	C107687	Tuolumne County, CA|CA109|Tuolumne County|Tuolumne County, California				Geographic Area	US Counties Terminology
C107929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107929>	C107687	Ventura County, CA|CA111|Ventura County|Ventura County, California				Geographic Area	US Counties Terminology
C10792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10792>	C61063	Busulfan/Ciprofloxacin/Melphalan/Pentoxifylline/Thiotepa|BU/CPFX/L-PAM/PTX/TSPA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107930>	C107687	Yolo County, CA|CA113|Yolo County|Yolo County, California				Geographic Area	US Counties Terminology
C107931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107931>	C107687	Yuba County, CA|CA115|Yuba County|Yuba County, California				Geographic Area	US Counties Terminology
C107932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107932>	C107687	Adams County, CO|Adams County|Adams County, Colorado|CO001				Geographic Area	US Counties Terminology
C107933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107933>	C107687	Alamosa County, CO|Alamosa County|Alamosa County, Colorado|CO003				Geographic Area	US Counties Terminology
C107934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107934>	C107687	Arapahoe County, CO|Arapahoe County|Arapahoe County, Colorado|CO005				Geographic Area	US Counties Terminology
C107935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107935>	C107687	Archuleta County, CO|Archuleta County|Archuleta County, Colorado|CO007				Geographic Area	US Counties Terminology
C107936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107936>	C107687	Baca County, CO|Baca County|Baca County, Colorado|CO009				Geographic Area	US Counties Terminology
C107937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107937>	C107687	Bent County, CO|Bent County|Bent County, Colorado|CO011				Geographic Area	US Counties Terminology
C107938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107938>	C107687	Boulder County, CO|Boulder County|Boulder County, Colorado|CO013				Geographic Area	US Counties Terminology
C107939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107939>	C107687	Broomfield County, CO|Broomfield County|Broomfield County, Colorado|CO014				Geographic Area	US Counties Terminology
C10793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10793>	C61063	Carboxypeptidase-G2/Leucovorin Calcium/Methotrexate|CF/CPG2/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107940>	C107687	Chaffee County, CO|CO015|Chaffee County|Chaffee County, Colorado				Geographic Area	US Counties Terminology
C107941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107941>	C107687	Cheyenne County, CO|CO017|Cheyenne County|Cheyenne County, Colorado				Geographic Area	US Counties Terminology
C107942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107942>	C107687	Clear Creek County, CO|CO019|Clear Creek County|Clear Creek County, Colorado				Geographic Area	US Counties Terminology
C107943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107943>	C107687	Conejos County, CO|CO021|Conejos County|Conejos County, Colorado				Geographic Area	US Counties Terminology
C107944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107944>	C107687	Costilla County, CO|CO023|Costilla County|Costilla County, Colorado				Geographic Area	US Counties Terminology
C107945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107945>	C107687	Crowley County, CO|CO025|Crowley County|Crowley County, Colorado				Geographic Area	US Counties Terminology
C107946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107946>	C107687	Custer County, CO|CO027|Custer County|Custer County, Colorado				Geographic Area	US Counties Terminology
C107947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107947>	C107687	Delta County, CO|CO029|Delta County|Delta County, Colorado				Geographic Area	US Counties Terminology
C107948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107948>	C107687	Denver County, CO|CO031|Denver County|Denver County, Colorado				Geographic Area	US Counties Terminology
C107949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107949>	C107687	Dolores County, CO|CO033|Dolores County|Dolores County, Colorado				Geographic Area	US Counties Terminology
C10794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10794>	C61063	Asparaginase/Daunorubicin/Prednisolone/Vindesine|ASP/DAVA/DNR/PRDL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107950>	C107687	Douglas County, CO|CO035|Douglas County|Douglas County, Colorado				Geographic Area	US Counties Terminology
C107951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107951>	C107687	Eagle County, CO|CO037|Eagle County|Eagle County, Colorado				Geographic Area	US Counties Terminology
C107952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107952>	C107687	Elbert County, CO|CO039|Elbert County|Elbert County, Colorado				Geographic Area	US Counties Terminology
C107953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107953>	C107687	El Paso County, CO|CO041|El Paso County|El Paso County, Colorado				Geographic Area	US Counties Terminology
C107954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107954>	C107687	Fremont County, CO|CO043|Fremont County|Fremont County, Colorado				Geographic Area	US Counties Terminology
C107955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107955>	C107687	Garfield County, CO|CO045|Garfield County|Garfield County, Colorado				Geographic Area	US Counties Terminology
C107956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107956>	C107687	Gilpin County, CO|CO047|Gilpin County|Gilpin County, Colorado				Geographic Area	US Counties Terminology
C107957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107957>	C107687	Grand County, CO|CO049|Grand County|Grand County, Colorado				Geographic Area	US Counties Terminology
C107958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107958>	C107687	Gunnison County, CO|CO051|Gunnison County|Gunnison County, Colorado				Geographic Area	US Counties Terminology
C107959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107959>	C107687	Hinsdale County, CO|CO053|Hinsdale County|Hinsdale County, Colorado				Geographic Area	US Counties Terminology
C10795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10795>	C61063	Cytarabine/Etoposide/Ifosfamide/Methotrexate/Prednisolone|ARA-C/IFF/MTX/PRDL/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107960>	C107687	Huerfano County, CO|CO055|Huerfano County|Huerfano County, Colorado				Geographic Area	US Counties Terminology
C107961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107961>	C107687	Jackson County, CO|CO057|Jackson County|Jackson County, Colorado				Geographic Area	US Counties Terminology
C107962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107962>	C107687	Jefferson County, CO|CO059|Jefferson County|Jefferson County, Colorado				Geographic Area	US Counties Terminology
C107963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107963>	C107687	Kiowa County, CO|CO061|Kiowa County|Kiowa County, Colorado				Geographic Area	US Counties Terminology
C107964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107964>	C107687	Kit Carson County, CO|CO063|Kit Carson County|Kit Carson County, Colorado				Geographic Area	US Counties Terminology
C107965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107965>	C107687	Lake County, CO|CO065|Lake County|Lake County, Colorado				Geographic Area	US Counties Terminology
C107966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107966>	C107687	La Plata County, CO|CO067|La Plata County|La Plata County, Colorado				Geographic Area	US Counties Terminology
C107967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107967>	C107687	Larimer County, CO|CO069|Larimer County|Larimer County, Colorado				Geographic Area	US Counties Terminology
C107968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107968>	C107687	Las Animas County, CO|CO071|Las Animas County|Las Animas County, Colorado				Geographic Area	US Counties Terminology
C107969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107969>	C107687	Lincoln County, CO|CO073|Lincoln County|Lincoln County, Colorado				Geographic Area	US Counties Terminology
C10796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10796>	C61063	Doxorubicin/Prednisolone/Vincristine|DOX/PRDL/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107970>	C107687	Logan County, CO|CO075|Logan County|Logan County, Colorado				Geographic Area	US Counties Terminology
C107971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107971>	C107687	Mesa County, CO|CO077|Mesa County|Mesa County, Colorado				Geographic Area	US Counties Terminology
C107972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107972>	C107687	Mineral County, CO|CO079|Mineral County|Mineral County, Colorado				Geographic Area	US Counties Terminology
C107973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107973>	C107687	Moffat County, CO|CO081|Moffat County|Moffat County, Colorado				Geographic Area	US Counties Terminology
C107974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107974>	C107687	Montezuma County, CO|CO083|Montezuma County|Montezuma County, Colorado				Geographic Area	US Counties Terminology
C107975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107975>	C107687	Montrose County, CO|CO085|Montrose County|Montrose County, Colorado				Geographic Area	US Counties Terminology
C107976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107976>	C107687	Morgan County, CO|CO087|Morgan County|Morgan County, Colorado				Geographic Area	US Counties Terminology
C107977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107977>	C107687	Otero County, CO|CO089|Otero County|Otero County, Colorado				Geographic Area	US Counties Terminology
C107978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107978>	C107687	Ouray County, CO|CO091|Ouray County|Ouray County, Colorado				Geographic Area	US Counties Terminology
C107979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107979>	C107687	Park County, CO|CO093|Park County|Park County, Colorado				Geographic Area	US Counties Terminology
C10797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10797>	C61063	Cyclophosphamide/Prednisolone|CTX/PRDL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107980>	C107687	Phillips County, CO|CO095|Phillips County|Phillips County, Colorado				Geographic Area	US Counties Terminology
C107981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107981>	C107687	Pitkin County, CO|CO097|Pitkin County|Pitkin County, Colorado				Geographic Area	US Counties Terminology
C107982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107982>	C107687	Prowers County, CO|CO099|Prowers County|Prowers County, Colorado				Geographic Area	US Counties Terminology
C107983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107983>	C107687	Pueblo County, CO|CO101|Pueblo County|Pueblo County, Colorado				Geographic Area	US Counties Terminology
C107984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107984>	C107687	Rio Blanco County, CO|CO103|Rio Blanco County|Rio Blanco County, Colorado				Geographic Area	US Counties Terminology
C107985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107985>	C107687	Rio Grande County, CO|CO105|Rio Grande County|Rio Grande County, Colorado				Geographic Area	US Counties Terminology
C107986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107986>	C107687	Routt County, CO|CO107|Routt County|Routt County, Colorado				Geographic Area	US Counties Terminology
C107987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107987>	C107687	Saguache County, CO|CO109|Saguache County|Saguache County, Colorado				Geographic Area	US Counties Terminology
C107988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107988>	C107687	San Juan County, CO|CO111|San Juan County|San Juan County, Colorado				Geographic Area	US Counties Terminology
C107989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107989>	C107687	San Miguel County, CO|CO113|San Miguel County|San Miguel County, Colorado				Geographic Area	US Counties Terminology
C10798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10798>	C61063	Cytarabine/Dexamethasone/Ifosfamide/Methotrexate/Teniposide/Vincristine|ARA-C/DM/IFF/MTX/VCR/VM-26			Obsolete_Concept	Therapeutic or Preventive Procedure	
C107990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107990>	C107687	Sedgwick County, CO|CO115|Sedgwick County|Sedgwick County, Colorado				Geographic Area	US Counties Terminology
C107991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107991>	C107687	Summit County, CO|CO117|Summit County|Summit County, Colorado				Geographic Area	US Counties Terminology
C107992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107992>	C107687	Teller County, CO|CO119|Teller County|Teller County, Colorado				Geographic Area	US Counties Terminology
C107993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107993>	C107687	Washington County, CO|CO121|Washington County|Washington County, Colorado				Geographic Area	US Counties Terminology
C107994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107994>	C107687	Weld County, CO|CO123|Weld County|Weld County, Colorado				Geographic Area	US Counties Terminology
C107995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107995>	C107687	Yuma County, CO|CO125|Yuma County|Yuma County, Colorado				Geographic Area	US Counties Terminology
C107996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107996>	C107687	Fairfield County, CT|CT001|Fairfield County|Fairfield County, Connecticut				Geographic Area	US Counties Terminology
C107997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107997>	C107687	Hartford County, CT|CT003|Hartford County|Hartford County, Connecticut				Geographic Area	US Counties Terminology
C107998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107998>	C107687	Litchfield County, CT|CT005|Litchfield County|Litchfield County, Connecticut				Geographic Area	US Counties Terminology
C107999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C107999>	C107687	Middlesex County, CT|CT007|Middlesex County|Middlesex County, Connecticut				Geographic Area	US Counties Terminology
C10799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10799>	C61063	Cytarabine/Dexamethasone/Etoposide/Vindesine|ARA-C/DAVA/DM/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1079>	C1927	Dynemicin A|DYNEMICIN A	An enediyne antineoplastic antibiotic hybrid containing an anthraquinone moiety isolated from the bacterium Micromonospora chersina.  The anthraquinone moiety intercalates into DNA and the benzene diradical intermediate of the enediyne core binds to the minor groove of DNA, resulting in double-strand breaks in DNA, inhibition of DNA replication and apoptosis. (NCI04)			Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C108000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108000>	C107687	New Haven County, CT|CT009|New Haven County|New Haven County, Connecticut				Geographic Area	US Counties Terminology
C108001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108001>	C107687	New London County, CT|CT011|New London County|New London County, Connecticut				Geographic Area	US Counties Terminology
C108002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108002>	C107687	Tolland County, CT|CT013|Tolland County|Tolland County, Connecticut				Geographic Area	US Counties Terminology
C108003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108003>	C107687	Windham County, CT|CT015|Windham County|Windham County, Connecticut				Geographic Area	US Counties Terminology
C108004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108004>	C107687	Kent County, DE|DE001|Kent County|Kent County, Delaware				Geographic Area	US Counties Terminology
C108005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108005>	C107687	New Castle County, DE|DE003|New Castle County|New Castle County, Delaware				Geographic Area	US Counties Terminology
C108006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108006>	C107687	Sussex County, DE|DE005|Sussex County|Sussex County, Delaware				Geographic Area	US Counties Terminology
C108007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108007>	C87191	District of Columbia|D.C.|DC|DC001|US: District of Columbia|Washington, DC	The area in the United States comprised of a 68 square mile area northeast of the Potomac River donated by the state of Maryland.  The District of Columbia, also known as D.C., is not a state, nor is it part of any state.  It is a "federal district" established by the US Constitution as the seat of government. The district is occupied entirely by the city of Washington.			Geographic Area	SeroNet Authorized Values|SeroNet Study Descriptors|US Counties Terminology
C108008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108008>	C107687	Alachua County, FL|Alachua County|Alachua County, Florida|FL001				Geographic Area	US Counties Terminology
C108009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108009>	C107687	Baker County, FL|Baker County|Baker County, Florida|FL003				Geographic Area	US Counties Terminology
C10800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10800>	C61063	Doxorubicin/Etoposide/Mitotane/Vincristine|DDD/DOX/VCR/VP-16|MAVE			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108010>	C107687	Bay County, FL|Bay County|Bay County, Florida|FL005				Geographic Area	US Counties Terminology
C108011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108011>	C107687	Bradford County, FL|Bradford County|Bradford County, Florida|FL007				Geographic Area	US Counties Terminology
C108012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108012>	C107687	Brevard County, FL|Brevard County|Brevard County, Florida|FL009				Geographic Area	US Counties Terminology
C108013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108013>	C107687	Broward County, FL|Broward County|Broward County, Florida|FL011				Geographic Area	US Counties Terminology
C108014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108014>	C107687	Calhoun County, FL|Calhoun County|Calhoun County, Florida|FL013				Geographic Area	US Counties Terminology
C108015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108015>	C107687	Charlotte County, FL|Charlotte County|Charlotte County, Florida|FL015				Geographic Area	US Counties Terminology
C108016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108016>	C107687	Citrus County, FL|Citrus County|Citrus County, Florida|FL017				Geographic Area	US Counties Terminology
C108017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108017>	C107687	Clay County, FL|Clay County|Clay County, Florida|FL019				Geographic Area	US Counties Terminology
C108018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108018>	C107687	Collier County, FL|Collier County|Collier County, Florida|FL021				Geographic Area	US Counties Terminology
C108019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108019>	C107687	Columbia County, FL|Columbia County|Columbia County, Florida|FL023				Geographic Area	US Counties Terminology
C10801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10801>	C63358	Cyclophosphamide/Methotrexate Regimen|CTX/MTX|Cyclophosphamide and Methotrexate (CM)|Cyclophosphamide-Methotrexate|Cyclophosphamide/MTX|Cyclophosphamide/Methotrexate|Cytoxan/Trexall|MECY|MeCy|Methotrexate-Cyclophosphamide|Methotrexate/Cyclophosphamide	A regimen consisting of oral cyclophosphamide and methotrexate that may be used in the treatment of metastatic breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C108020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108020>	C107687	DeSoto County, FL|DeSoto County|DeSoto County, Florida|FL027				Geographic Area	US Counties Terminology
C108021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108021>	C107687	Dixie County, FL|Dixie County|Dixie County, Florida|FL029				Geographic Area	US Counties Terminology
C108022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108022>	C107687	Duval County, FL|Duval County|Duval County, Florida|FL031				Geographic Area	US Counties Terminology
C108023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108023>	C107687	Escambia County, FL|Escambia County|Escambia County, Florida|FL033				Geographic Area	US Counties Terminology
C108024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108024>	C107687	Flagler County, FL|FL035|Flagler County|Flagler County, Florida				Geographic Area	US Counties Terminology
C108025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108025>	C107687	Franklin County, FL|FL037|Franklin County|Franklin County, Florida				Geographic Area	US Counties Terminology
C108026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108026>	C107687	Gadsden County, FL|FL039|Gadsden County|Gadsden County, Florida				Geographic Area	US Counties Terminology
C108027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108027>	C107687	Gilchrist County, FL|FL041|Gilchrist County|Gilchrist County, Florida				Geographic Area	US Counties Terminology
C108028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108028>	C107687	Glades County, FL|FL043|Glades County|Glades County, Florida				Geographic Area	US Counties Terminology
C108029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108029>	C107687	Gulf County, FL|FL045|Gulf County|Gulf County, Florida				Geographic Area	US Counties Terminology
C10802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10802>	C61063	Carmustine/Dacarbazine/Thymidine|BCNU/DTIC/TDR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108030>	C107687	Hamilton County, FL|FL047|Hamilton County|Hamilton County, Florida				Geographic Area	US Counties Terminology
C108031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108031>	C107687	Hardee County, FL|FL049|Hardee County|Hardee County, Florida				Geographic Area	US Counties Terminology
C108032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108032>	C107687	Hendry County, FL|FL051|Hendry County|Hendry County, Florida				Geographic Area	US Counties Terminology
C108033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108033>	C107687	Hernando County, FL|FL053|Hernando County|Hernando County, Florida				Geographic Area	US Counties Terminology
C108034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108034>	C107687	Highlands County, FL|FL055|Highlands County|Highlands County, Florida				Geographic Area	US Counties Terminology
C108035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108035>	C107687	Hillsborough County, FL|FL057|Hillsborough County|Hillsborough County, Florida				Geographic Area	US Counties Terminology
C108036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108036>	C107687	Holmes County, FL|FL059|Holmes County|Holmes County, Florida				Geographic Area	US Counties Terminology
C108037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108037>	C107687	Indian River County, FL|FL061|Indian River County|Indian River County, Florida				Geographic Area	US Counties Terminology
C108038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108038>	C107687	Jackson County, FL|FL063|Jackson County|Jackson County, Florida				Geographic Area	US Counties Terminology
C108039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108039>	C107687	Jefferson County, FL|FL065|Jefferson County|Jefferson County, Florida				Geographic Area	US Counties Terminology
C10803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10803>	C61063	Cytarabine/Ifosfamide|ARA-C/IFF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108040>	C107687	Lafayette County, FL|FL067|Lafayette County|Lafayette County, Florida				Geographic Area	US Counties Terminology
C108041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108041>	C107687	Lake County, FL|FL069|Lake County|Lake County, Florida				Geographic Area	US Counties Terminology
C108042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108042>	C107687	Lee County, FL|FL071|Lee County|Lee County, Florida				Geographic Area	US Counties Terminology
C108043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108043>	C107687	Leon County, FL|FL073|Leon County|Leon County, Florida				Geographic Area	US Counties Terminology
C108044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108044>	C107687	Levy County, FL|FL075|Levy County|Levy County, Florida				Geographic Area	US Counties Terminology
C108045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108045>	C107687	Liberty County, FL|FL077|Liberty County|Liberty County, Florida				Geographic Area	US Counties Terminology
C108046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108046>	C107687	Madison County, FL|FL079|Madison County|Madison County, Florida				Geographic Area	US Counties Terminology
C108047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108047>	C107687	Manatee County, FL|FL081|Manatee County|Manatee County, Florida				Geographic Area	US Counties Terminology
C108048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108048>	C107687	Marion County, FL|FL083|Marion County|Marion County, Florida				Geographic Area	US Counties Terminology
C108049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108049>	C107687	Martin County, FL|FL085|Martin County|Martin County, Florida				Geographic Area	US Counties Terminology
C10804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10804>	C61063	Cyclophosphamide/Indomethacin/Interleukin-2/Tumor Infiltrating Lymphocytes|CTX/IL-2/Indomethacin/TIL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108050>	C107687	Miami-Dade County, FL|FL086|Miami-Dade County|Miami-Dade County, Florida				Geographic Area	US Counties Terminology
C108051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108051>	C107687	Monroe County, FL|FL087|Monroe County|Monroe County, Florida				Geographic Area	US Counties Terminology
C108052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108052>	C107687	Nassau County, FL|FL089|Nassau County|Nassau County, Florida				Geographic Area	US Counties Terminology
C108053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108053>	C107687	Okaloosa County, FL|FL091|Okaloosa County|Okaloosa County, Florida				Geographic Area	US Counties Terminology
C108054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108054>	C107687	Okeechobee County, FL|FL093|Okeechobee County|Okeechobee County, Florida				Geographic Area	US Counties Terminology
C108055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108055>	C107687	Orange County, FL|FL095|Orange County|Orange County, Florida				Geographic Area	US Counties Terminology
C108056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108056>	C107687	Osceola County, FL|FL097|Osceola County|Osceola County, Florida				Geographic Area	US Counties Terminology
C108057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108057>	C107687	Palm Beach County, FL|FL099|Palm Beach County|Palm Beach County, Florida				Geographic Area	US Counties Terminology
C108058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108058>	C107687	Pasco County, FL|FL101|Pasco County|Pasco County, Florida				Geographic Area	US Counties Terminology
C108059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108059>	C107687	Pinellas County, FL|FL103|Pinellas County|Pinellas County, Florida				Geographic Area	US Counties Terminology
C10805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10805>	C61063	Indomethacin/Interleukin-2/Lymphokine-Activated Killer Cells|IL-2/Indomethacin/LAK			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108060>	C107687	Polk County, FL|FL105|Polk County|Polk County, Florida				Geographic Area	US Counties Terminology
C108061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108061>	C107687	Putnam County, FL|FL107|Putnam County|Putnam County, Florida				Geographic Area	US Counties Terminology
C108062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108062>	C107687	St. Johns County, FL|FL109|St. Johns County|St. Johns County, Florida				Geographic Area	US Counties Terminology
C108063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108063>	C107687	St. Lucie County, FL|FL111|St. Lucie County|St. Lucie County, Florida				Geographic Area	US Counties Terminology
C108064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108064>	C107687	Santa Rosa County, FL|FL113|Santa Rosa County|Santa Rosa County, Florida				Geographic Area	US Counties Terminology
C108065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108065>	C107687	Sarasota County, FL|FL115|Sarasota County|Sarasota County, Florida				Geographic Area	US Counties Terminology
C108066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108066>	C107687	Seminole County, FL|FL117|Seminole County|Seminole County, Florida				Geographic Area	US Counties Terminology
C108067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108067>	C107687	Sumter County, FL|FL119|Sumter County|Sumter County, Florida				Geographic Area	US Counties Terminology
C108068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108068>	C107687	Suwannee County, FL|FL121|Suwannee County|Suwannee County, Florida				Geographic Area	US Counties Terminology
C108069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108069>	C107687	Taylor County, FL|FL123|Taylor County|Taylor County, Florida				Geographic Area	US Counties Terminology
C10806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10806>	C61007	Hydroxyurea/Tretinoin|ATRA/HU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108070>	C107687	Union County, FL|FL125|Union County|Union County, Florida				Geographic Area	US Counties Terminology
C108071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108071>	C107687	Volusia County, FL|FL127|Volusia County|Volusia County, Florida				Geographic Area	US Counties Terminology
C108072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108072>	C107687	Wakulla County, FL|FL129|Wakulla County|Wakulla County, Florida				Geographic Area	US Counties Terminology
C108073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108073>	C107687	Walton County, FL|FL131|Walton County|Walton County, Florida				Geographic Area	US Counties Terminology
C108074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108074>	C107687	Washington County, FL|FL133|Washington County|Washington County, Florida				Geographic Area	US Counties Terminology
C108075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108075>	C107687	Appling County, GA|Appling County|Appling County, Georgia|GA001				Geographic Area	US Counties Terminology
C108076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108076>	C107687	Atkinson County, GA|Atkinson County|Atkinson County, Georgia|GA003				Geographic Area	US Counties Terminology
C108077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108077>	C107687	Bacon County, GA|Bacon County|Bacon County, Georgia|GA005				Geographic Area	US Counties Terminology
C108078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108078>	C107687	Baker County, GA|Baker County|Baker County, Georgia|GA007				Geographic Area	US Counties Terminology
C108079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108079>	C107687	Baldwin County, GA|Baldwin County|Baldwin County, Georgia|GA009				Geographic Area	US Counties Terminology
C10807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10807>	C61007	Cisplatin/Vinorelbine|CDDP/VNB			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108080>	C107687	Banks County, GA|Banks County|Banks County, Georgia|GA011				Geographic Area	US Counties Terminology
C108081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108081>	C107687	Barrow County, GA|Barrow County|Barrow County, Georgia|GA013				Geographic Area	US Counties Terminology
C108082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108082>	C107687	Bartow County, GA|Bartow County|Bartow County, Georgia|GA015				Geographic Area	US Counties Terminology
C108083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108083>	C107687	Ben Hill County, GA|Ben Hill County|Ben Hill County, Georgia|GA017				Geographic Area	US Counties Terminology
C108084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108084>	C107687	Berrien County, GA|Berrien County|Berrien County, Georgia|GA019				Geographic Area	US Counties Terminology
C108085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108085>	C107687	Bibb County, GA|Bibb County|Bibb County, Georgia|GA021				Geographic Area	US Counties Terminology
C108086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108086>	C107687	Bleckley County, GA|Bleckley County|Bleckley County, Georgia|GA023				Geographic Area	US Counties Terminology
C108087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108087>	C107687	Brantley County, GA|Brantley County|Brantley County, Georgia|GA025				Geographic Area	US Counties Terminology
C108088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108088>	C107687	Brooks County, GA|Brooks County|Brooks County, Georgia|GA027				Geographic Area	US Counties Terminology
C108089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108089>	C107687	Bryan County, GA|Bryan County|Bryan County, Georgia|GA029				Geographic Area	US Counties Terminology
C10808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10808>	C61007	Asparaginase/Vincristine|ASP/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108090>	C107687	Bulloch County, GA|Bulloch County|Bulloch County, Georgia|GA031				Geographic Area	US Counties Terminology
C108091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108091>	C107687	Burke County, GA|Burke County|Burke County, Georgia|GA033				Geographic Area	US Counties Terminology
C108092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108092>	C107687	Butts County, GA|Butts County|Butts County, Georgia|GA035				Geographic Area	US Counties Terminology
C108093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108093>	C107687	Calhoun County, GA|Calhoun County|Calhoun County, Georgia|GA037				Geographic Area	US Counties Terminology
C108094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108094>	C107687	Camden County, GA|Camden County|Camden County, Georgia|GA039				Geographic Area	US Counties Terminology
C108095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108095>	C107687	Candler County, GA|Candler County|Candler County, Georgia|GA043				Geographic Area	US Counties Terminology
C108096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108096>	C107687	Carroll County, GA|Carroll County|Carroll County, Georgia|GA045				Geographic Area	US Counties Terminology
C108097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108097>	C107687	Catoosa County, GA|Catoosa County|Catoosa County, Georgia|GA047				Geographic Area	US Counties Terminology
C108098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108098>	C107687	Charlton County, GA|Charlton County|Charlton County, Georgia|GA049				Geographic Area	US Counties Terminology
C108099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108099>	C107687	Chatham County, GA|Chatham County|Chatham County, Georgia|GA051				Geographic Area	US Counties Terminology
C10809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10809>	C61063	Dipyridamole/Methotrexate|DP/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1080>	C259|C1968	Elsamitrucin|10-O-Elsaminosylelsarosylchartarin|BBM 2478A|BMY-28090|BRN 5214813|Benzo(h)(1)benzopyrano(5,4,3-cde)(1)ebnzopyran-5,12-dione,10((2-O-(2-amino-2,6-dideoxy-3-O-methyl-alpha-D-galactopyranosyl)-6-deoxy-3-C-methyl-beta-D-galactopyranosyl)oxy)-6-hydroxy-1-methyl|ELSAMITRUCIN|Elsamicin A|Elsamitrucina|Elsamitrucine|Elsamitrucinum	An heterocyclic antineoplastic antibiotic isolated from the bacterium Actinomycete strain J907-21.  Elsamitrucin intercalates into DNA at guanine-cytosine (G-C)-rich sequences and inhibits topoisomerase I and II, resulting in single-strand breaks and inhibition of DNA replication. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C108100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108100>	C107687	Chattahoochee County, GA|Chattahoochee County|Chattahoochee County, Georgia|GA053				Geographic Area	US Counties Terminology
C108101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108101>	C107687	Chattooga County, GA|Chattooga County|Chattooga County, Georgia|GA055				Geographic Area	US Counties Terminology
C108102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108102>	C107687	Cherokee County, GA|Cherokee County|Cherokee County, Georgia|GA057				Geographic Area	US Counties Terminology
C108103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108103>	C107687	Clarke County, GA|Clarke County|Clarke County, Georgia|GA059				Geographic Area	US Counties Terminology
C108104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108104>	C107687	Clay County, GA|Clay County|Clay County, Georgia|GA061				Geographic Area	US Counties Terminology
C108105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108105>	C107687	Clayton County, GA|Clayton County|Clayton County, Georgia|GA063				Geographic Area	US Counties Terminology
C108106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108106>	C107687	Clinch County, GA|Clinch County|Clinch County, Georgia|GA065				Geographic Area	US Counties Terminology
C108107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108107>	C107687	Cobb County, GA|Cobb County|Cobb County, Georgia|GA067				Geographic Area	US Counties Terminology
C108108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108108>	C107687	Coffee County, GA|Coffee County|Coffee County, Georgia|GA069				Geographic Area	US Counties Terminology
C108109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108109>	C107687	Colquitt County, GA|Colquitt County|Colquitt County, Georgia|GA071				Geographic Area	US Counties Terminology
C10810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10810>	C61063	Cyclophosphamide/Epirubicin/Tamoxifen|CTX/EPI/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108110>	C107687	Columbia County, GA|Columbia County|Columbia County, Georgia|GA073				Geographic Area	US Counties Terminology
C108111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108111>	C107687	Cook County, GA|Cook County|Cook County, Georgia|GA075				Geographic Area	US Counties Terminology
C108112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108112>	C107687	Coweta County, GA|Coweta County|Coweta County, Georgia|GA077				Geographic Area	US Counties Terminology
C108113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108113>	C107687	Crawford County, GA|Crawford County|Crawford County, Georgia|GA079				Geographic Area	US Counties Terminology
C108114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108114>	C107687	Crisp County, GA|Crisp County|Crisp County, Georgia|GA081				Geographic Area	US Counties Terminology
C108115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108115>	C107687	Dade County, GA|Dade County|Dade County, Georgia|GA083				Geographic Area	US Counties Terminology
C108116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108116>	C107687	Dawson County, GA|Dawson County|Dawson County, Georgia|GA085				Geographic Area	US Counties Terminology
C108117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108117>	C107687	Decatur County, GA|Decatur County|Decatur County, Georgia|GA087				Geographic Area	US Counties Terminology
C108118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108118>	C107687	DeKalb County, GA|DeKalb County|DeKalb County, Georgia|GA089				Geographic Area	US Counties Terminology
C108119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108119>	C107687	Dodge County, GA|Dodge County|Dodge County, Georgia|GA091				Geographic Area	US Counties Terminology
C10811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10811>	C61007	Cyclophosphamide/Doxorubicin/Toremifene|CTX/DOX/TOR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108120>	C107687	Dooly County, GA|Dooly County|Dooly County, Georgia|GA093				Geographic Area	US Counties Terminology
C108121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108121>	C107687	Dougherty County, GA|Dougherty County|Dougherty County, Georgia|GA095				Geographic Area	US Counties Terminology
C108122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108122>	C107687	Douglas County, GA|Douglas County|Douglas County, Georgia|GA097				Geographic Area	US Counties Terminology
C108123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108123>	C107687	Early County, GA|Early County|Early County, Georgia|GA099				Geographic Area	US Counties Terminology
C108124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108124>	C107687	Echols County, GA|Echols County|Echols County, Georgia|GA101				Geographic Area	US Counties Terminology
C108125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108125>	C107687	Effingham County, GA|Effingham County|Effingham County, Georgia|GA103				Geographic Area	US Counties Terminology
C108126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108126>	C107687	Elbert County, GA|Elbert County|Elbert County, Georgia|GA105				Geographic Area	US Counties Terminology
C108127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108127>	C107687	Emanuel County, GA|Emanuel County|Emanuel County, Georgia|GA107				Geographic Area	US Counties Terminology
C108128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108128>	C107687	Evans County, GA|Evans County|Evans County, Georgia|GA109				Geographic Area	US Counties Terminology
C108129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108129>	C107687	Fannin County, GA|Fannin County|Fannin County, Georgia|GA111				Geographic Area	US Counties Terminology
C10812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10812>	C61063	Cyclophosphamide/Epirubicin/Toremifene|CTX/EPI/TOR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108130>	C107687	Fayette County, GA|Fayette County|Fayette County, Georgia|GA113				Geographic Area	US Counties Terminology
C108131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108131>	C107687	Floyd County, GA|Floyd County|Floyd County, Georgia|GA115				Geographic Area	US Counties Terminology
C108132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108132>	C107687	Forsyth County, GA|Forsyth County|Forsyth County, Georgia|GA117				Geographic Area	US Counties Terminology
C108133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108133>	C107687	Franklin County, GA|Franklin County|Franklin County, Georgia|GA119				Geographic Area	US Counties Terminology
C108134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108134>	C107687	Fulton County, GA|Fulton County|Fulton County, Georgia|GA121				Geographic Area	US Counties Terminology
C108135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108135>	C107687	Gilmer County, GA|GA123|Gilmer County|Gilmer County, Georgia				Geographic Area	US Counties Terminology
C108136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108136>	C107687	Glascock County, GA|GA125|Glascock County|Glascock County, Georgia				Geographic Area	US Counties Terminology
C108137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108137>	C107687	Glynn County, GA|GA127|Glynn County|Glynn County, Georgia				Geographic Area	US Counties Terminology
C108138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108138>	C107687	Gordon County, GA|GA129|Gordon County|Gordon County, Georgia				Geographic Area	US Counties Terminology
C108139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108139>	C107687	Grady County, GA|GA131|Grady County|Grady County, Georgia				Geographic Area	US Counties Terminology
C10813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10813>	C61007	Cytarabine/Dexamethasone/Etoposide/Ifosfamide/Methotrexate|ARA-C/DM/IFF/MTX/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108140>	C107687	Greene County, GA|GA133|Greene County|Greene County, Georgia				Geographic Area	US Counties Terminology
C108141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108141>	C107687	Gwinnett County, GA|GA135|Gwinnett County|Gwinnett County, Georgia				Geographic Area	US Counties Terminology
C108142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108142>	C107687	Habersham County, GA|GA137|Habersham County|Habersham County, Georgia				Geographic Area	US Counties Terminology
C108143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108143>	C107687	Hall County, GA|GA139|Hall County|Hall County, Georgia				Geographic Area	US Counties Terminology
C108144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108144>	C107687	Hancock County, GA|GA141|Hancock County|Hancock County, Georgia				Geographic Area	US Counties Terminology
C108145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108145>	C107687	Haralson County, GA|GA143|Haralson County|Haralson County, Georgia				Geographic Area	US Counties Terminology
C108146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108146>	C107687	Harris County, GA|GA145|Harris County|Harris County, Georgia				Geographic Area	US Counties Terminology
C108147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108147>	C107687	Hart County, GA|GA147|Hart County|Hart County, Georgia				Geographic Area	US Counties Terminology
C108148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108148>	C107687	Heard County, GA|GA149|Heard County|Heard County, Georgia				Geographic Area	US Counties Terminology
C108149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108149>	C107687	Henry County, GA|GA151|Henry County|Henry County, Georgia				Geographic Area	US Counties Terminology
C10814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10814>	C61007	Cyclophosphamide/Dexamethasone/Doxorubicin/Methotrexate|CTX/DM/DOX/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108150>	C107687	Houston County, GA|GA153|Houston County|Houston County, Georgia				Geographic Area	US Counties Terminology
C108151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108151>	C107687	Irwin County, GA|GA155|Irwin County|Irwin County, Georgia				Geographic Area	US Counties Terminology
C108152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108152>	C107687	Jackson County, GA|GA157|Jackson County|Jackson County, Georgia				Geographic Area	US Counties Terminology
C108153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108153>	C107687	Jasper County, GA|GA159|Jasper County|Jasper County, Georgia				Geographic Area	US Counties Terminology
C108154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108154>	C107687	Jeff Davis County, GA|GA161|Jeff Davis County|Jeff Davis County, Georgia				Geographic Area	US Counties Terminology
C108155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108155>	C107687	Jefferson County, GA|GA163|Jefferson County|Jefferson County, Georgia				Geographic Area	US Counties Terminology
C108156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108156>	C107687	Jenkins County, GA|GA165|Jenkins County|Jenkins County, Georgia				Geographic Area	US Counties Terminology
C108157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108157>	C107687	Johnson County, GA|GA167|Johnson County|Johnson County, Georgia				Geographic Area	US Counties Terminology
C108158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108158>	C107687	Jones County, GA|GA169|Jones County|Jones County, Georgia				Geographic Area	US Counties Terminology
C108159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108159>	C107687	Lamar County, GA|GA171|Lamar County|Lamar County, Georgia				Geographic Area	US Counties Terminology
C10815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10815>	C61007	Cyclophosphamide/Dexamethasone|CTX/DM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108160>	C107687	Lanier County, GA|GA173|Lanier County|Lanier County, Georgia				Geographic Area	US Counties Terminology
C108161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108161>	C107687	Laurens County, GA|GA175|Laurens County|Laurens County, Georgia				Geographic Area	US Counties Terminology
C108162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108162>	C107687	Lee County, GA|GA177|Lee County|Lee County, Georgia				Geographic Area	US Counties Terminology
C108163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108163>	C107687	Liberty County, GA|GA179|Liberty County|Liberty County, Georgia				Geographic Area	US Counties Terminology
C108164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108164>	C107687	Lincoln County, GA|GA181|Lincoln County|Lincoln County, Georgia				Geographic Area	US Counties Terminology
C108165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108165>	C107687	Long County, GA|GA183|Long County|Long County, Georgia				Geographic Area	US Counties Terminology
C108166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108166>	C107687	Lowndes County, GA|GA185|Lowndes County|Lowndes County, Georgia				Geographic Area	US Counties Terminology
C108167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108167>	C107687	Lumpkin County, GA|GA187|Lumpkin County|Lumpkin County, Georgia				Geographic Area	US Counties Terminology
C108168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108168>	C107687	McDuffie County, GA|GA189|McDuffie County|McDuffie County, Georgia				Geographic Area	US Counties Terminology
C108169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108169>	C107687	McIntosh County, GA|GA191|McIntosh County|McIntosh County, Georgia				Geographic Area	US Counties Terminology
C10816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10816>	C61063	Bryostatin 1/Tretinoin|ATRA/BRYO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108170>	C107687	Macon County, GA|GA193|Macon County|Macon County, Georgia				Geographic Area	US Counties Terminology
C108171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108171>	C107687	Madison County, GA|GA195|Madison County|Madison County, Georgia				Geographic Area	US Counties Terminology
C108172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108172>	C107687	Marion County, GA|GA197|Marion County|Marion County, Georgia				Geographic Area	US Counties Terminology
C108173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108173>	C107687	Meriwether County, GA|GA199|Meriwether County|Meriwether County, Georgia				Geographic Area	US Counties Terminology
C108174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108174>	C107687	Miller County, GA|GA201|Miller County|Miller County, Georgia				Geographic Area	US Counties Terminology
C108175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108175>	C107687	Mitchell County, GA|GA205|Mitchell County|Mitchell County, Georgia				Geographic Area	US Counties Terminology
C108176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108176>	C107687	Monroe County, GA|GA207|Monroe County|Monroe County, Georgia				Geographic Area	US Counties Terminology
C108177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108177>	C107687	Montgomery County, GA|GA209|Montgomery County|Montgomery County, Georgia				Geographic Area	US Counties Terminology
C108178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108178>	C107687	Morgan County, GA|GA211|Morgan County|Morgan County, Georgia				Geographic Area	US Counties Terminology
C108179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108179>	C107687	Murray County, GA|GA213|Murray County|Murray County, Georgia				Geographic Area	US Counties Terminology
C10817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10817>	C61063	Floxuridine/Hydroxyurea/Leucovorin Calcium|CF/FUDR/HU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108180>	C107687	Muscogee County, GA|GA215|Muscogee County|Muscogee County, Georgia				Geographic Area	US Counties Terminology
C108181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108181>	C107687	Newton County, GA|GA217|Newton County|Newton County, Georgia				Geographic Area	US Counties Terminology
C108182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108182>	C107687	Oconee County, GA|GA219|Oconee County|Oconee County, Georgia				Geographic Area	US Counties Terminology
C108183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108183>	C107687	Oglethorpe County, GA|GA221|Oglethorpe County|Oglethorpe County, Georgia				Geographic Area	US Counties Terminology
C108184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108184>	C107687	Paulding County, GA|GA223|Paulding County|Paulding County, Georgia				Geographic Area	US Counties Terminology
C108185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108185>	C107687	Peach County, GA|GA225|Peach County|Peach County, Georgia				Geographic Area	US Counties Terminology
C108186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108186>	C107687	Pickens County, GA|GA227|Pickens County|Pickens County, Georgia				Geographic Area	US Counties Terminology
C108187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108187>	C107687	Pierce County, GA|GA229|Pierce County|Pierce County, Georgia				Geographic Area	US Counties Terminology
C108188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108188>	C107687	Pike County, GA|GA231|Pike County|Pike County, Georgia				Geographic Area	US Counties Terminology
C108189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108189>	C107687	Polk County, GA|GA233|Polk County|Polk County, Georgia				Geographic Area	US Counties Terminology
C10818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10818>	C61063	Carboplatin/Cytarabine/Hydroxyurea|ARA-C/CBDCA/HU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108190>	C107687	Pulaski County, GA|GA235|Pulaski County|Pulaski County, Georgia				Geographic Area	US Counties Terminology
C108191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108191>	C107687	Putnam County, GA|GA237|Putnam County|Putnam County, Georgia				Geographic Area	US Counties Terminology
C108192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108192>	C107687	Quitman County, GA|GA239|Quitman County|Quitman County, Georgia				Geographic Area	US Counties Terminology
C108193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108193>	C107687	Rabun County, GA|GA241|Rabun County|Rabun County, Georgia				Geographic Area	US Counties Terminology
C108194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108194>	C107687	Randolph County, GA|GA243|Randolph County|Randolph County, Georgia				Geographic Area	US Counties Terminology
C108195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108195>	C107687	Richmond County, GA|GA245|Richmond County|Richmond County, Georgia				Geographic Area	US Counties Terminology
C108196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108196>	C107687	Rockdale County, GA|GA247|Rockdale County|Rockdale County, Georgia				Geographic Area	US Counties Terminology
C108197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108197>	C107687	Schley County, GA|GA249|Schley County|Schley County, Georgia				Geographic Area	US Counties Terminology
C108198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108198>	C107687	Screven County, GA|GA251|Screven County|Screven County, Georgia				Geographic Area	US Counties Terminology
C108199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108199>	C107687	Seminole County, GA|GA253|Seminole County|Seminole County, Georgia				Geographic Area	US Counties Terminology
C10819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10819>	C61063	Cyclophosphamide/Perflubron|CTX/PFOB			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1081>	C245	Eutectic Mixture of Local Anesthetics|EMLA|Lidocaine-Prilocaine Eutectic Mixture|Lidocaine/Prilocaine|Oraqix	A topical anesthetic cream, containing lidocaine 2.5% and prilocaine 2.5%, that provides neuralgia pain relief by causing loss of cutaneous sensation through reversible blockade of conduction in nerve fibers. (NCI)	Eutectic Mixture of Local Anesthetics		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C108200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108200>	C107687	Spalding County, GA|GA255|Spalding County|Spalding County, Georgia				Geographic Area	US Counties Terminology
C108201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108201>	C107687	Stephens County, GA|GA257|Stephens County|Stephens County, Georgia				Geographic Area	US Counties Terminology
C108202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108202>	C107687	Stewart County, GA|GA259|Stewart County|Stewart County, Georgia				Geographic Area	US Counties Terminology
C108203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108203>	C107687	Sumter County, GA|GA261|Sumter County|Sumter County, Georgia				Geographic Area	US Counties Terminology
C108204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108204>	C107687	Talbot County, GA|GA263|Talbot County|Talbot County, Georgia				Geographic Area	US Counties Terminology
C108205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108205>	C107687	Taliaferro County, GA|GA265|Taliaferro County|Taliaferro County, Georgia				Geographic Area	US Counties Terminology
C108206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108206>	C107687	Tattnall County, GA|GA267|Tattnall County|Tattnall County, Georgia				Geographic Area	US Counties Terminology
C108207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108207>	C107687	Taylor County, GA|GA269|Taylor County|Taylor County, Georgia				Geographic Area	US Counties Terminology
C108208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108208>	C107687	Telfair County, GA|GA271|Telfair County|Telfair County, Georgia				Geographic Area	US Counties Terminology
C108209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108209>	C107687	Terrell County, GA|GA273|Terrell County|Terrell County, Georgia				Geographic Area	US Counties Terminology
C10820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10820>	C61063	Carboplatin/Topotecan|CBDCA/TOPO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108210>	C107687	Thomas County, GA|GA275|Thomas County|Thomas County, Georgia				Geographic Area	US Counties Terminology
C108211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108211>	C107687	Tift County, GA|GA277|Tift County|Tift County, Georgia				Geographic Area	US Counties Terminology
C108212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108212>	C107687	Toombs County, GA|GA279|Toombs County|Toombs County, Georgia				Geographic Area	US Counties Terminology
C108213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108213>	C107687	Towns County, GA|GA281|Towns County|Towns County, Georgia				Geographic Area	US Counties Terminology
C108214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108214>	C107687	Treutlen County, GA|GA283|Treutlen County|Treutlen County, Georgia				Geographic Area	US Counties Terminology
C108215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108215>	C107687	Troup County, GA|GA285|Troup County|Troup County, Georgia				Geographic Area	US Counties Terminology
C108216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108216>	C107687	Turner County, GA|GA287|Turner County|Turner County, Georgia				Geographic Area	US Counties Terminology
C108217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108217>	C107687	Twiggs County, GA|GA289|Twiggs County|Twiggs County, Georgia				Geographic Area	US Counties Terminology
C108218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108218>	C107687	Union County, GA|GA291|Union County|Union County, Georgia				Geographic Area	US Counties Terminology
C108219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108219>	C107687	Upson County, GA|GA293|Upson County|Upson County, Georgia				Geographic Area	US Counties Terminology
C10821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10821>	C63589	Cytarabine/Topotecan Regimen|ARA-C/TOPO|AraC/Topotecan|Cytarabine-Topotecan|Cytarabine/Topotecan|Cytosar-U/Hycamtin	A regimen consisting of cytarabine and topotecan that may be used in certain types of acute myeloid leukemia (AML).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C108220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108220>	C107687	Walker County, GA|GA295|Walker County|Walker County, Georgia				Geographic Area	US Counties Terminology
C108221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108221>	C107687	Walton County, GA|GA297|Walton County|Walton County, Georgia				Geographic Area	US Counties Terminology
C108222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108222>	C107687	Ware County, GA|GA299|Ware County|Ware County, Georgia				Geographic Area	US Counties Terminology
C108223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108223>	C107687	Warren County, GA|GA301|Warren County|Warren County, Georgia				Geographic Area	US Counties Terminology
C108224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108224>	C107687	Washington County, GA|GA303|Washington County|Washington County, Georgia				Geographic Area	US Counties Terminology
C108225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108225>	C107687	Wayne County, GA|GA305|Wayne County|Wayne County, Georgia				Geographic Area	US Counties Terminology
C108226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108226>	C107687	Webster County, GA|GA307|Webster County|Webster County, Georgia				Geographic Area	US Counties Terminology
C108227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108227>	C107687	Wheeler County, GA|GA309|Wheeler County|Wheeler County, Georgia				Geographic Area	US Counties Terminology
C108228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108228>	C107687	White County, GA|GA311|White County|White County, Georgia				Geographic Area	US Counties Terminology
C108229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108229>	C107687	Whitfield County, GA|GA313|Whitfield County|Whitfield County, Georgia				Geographic Area	US Counties Terminology
C10822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10822>	C61063	Cyclophosphamide/Doxorubicin/Filgrastim/Fluorouracil/Leucovorin Calcium|CF/CTX/DOX/5-FU/G-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108230>	C107687	Wilcox County, GA|GA315|Wilcox County|Wilcox County, Georgia				Geographic Area	US Counties Terminology
C108231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108231>	C107687	Wilkes County, GA|GA317|Wilkes County|Wilkes County, Georgia				Geographic Area	US Counties Terminology
C108232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108232>	C107687	Wilkinson County, GA|GA319|Wilkinson County|Wilkinson County, Georgia				Geographic Area	US Counties Terminology
C108233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108233>	C107687	Worth County, GA|GA321|Worth County|Worth County, Georgia				Geographic Area	US Counties Terminology
C108234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108234>	C107687	Hawaii County, HI|HI001|Hawaii County|Hawaii County, Hawaii				Geographic Area	US Counties Terminology
C108235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108235>	C107687	Honolulu County, HI|HI003|Honolulu County|Honolulu County, Hawaii				Geographic Area	US Counties Terminology
C108236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108236>	C107687	Kalawao County, HI|HI005|Kalawao County|Kalawao County, Hawaii				Geographic Area	US Counties Terminology
C108237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108237>	C107687	Kauai County, HI|HI007|Kauai County|Kauai County, Hawaii				Geographic Area	US Counties Terminology
C108238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108238>	C107687	Maui County, HI|HI009|Maui County|Maui County, Hawaii				Geographic Area	US Counties Terminology
C108239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108239>	C107687	Ada County, ID|Ada County|Ada County, Idaho|ID001				Geographic Area	US Counties Terminology
C10823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10823>	C61063	Cisplatin/Etoposide/Paclitaxel|CDDP/TAX/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108240>	C107687	Adams County, ID|Adams County|Adams County, Idaho|ID003				Geographic Area	US Counties Terminology
C108241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108241>	C107687	Bannock County, ID|Bannock County|Bannock County, Idaho|ID005				Geographic Area	US Counties Terminology
C108242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108242>	C107687	Bear Lake County, ID|Bear Lake County|Bear Lake County, Idaho|ID007				Geographic Area	US Counties Terminology
C108243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108243>	C107687	Benewah County, ID|Benewah County|Benewah County, Idaho|ID009				Geographic Area	US Counties Terminology
C108244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108244>	C107687	Bingham County, ID|Bingham County|Bingham County, Idaho|ID011				Geographic Area	US Counties Terminology
C108245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108245>	C107687	Blaine County, ID|Blaine County|Blaine County, Idaho|ID013				Geographic Area	US Counties Terminology
C108246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108246>	C107687	Boise County, ID|Boise County|Boise County, Idaho|ID015				Geographic Area	US Counties Terminology
C108247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108247>	C107687	Bonner County, ID|Bonner County|Bonner County, Idaho|ID017				Geographic Area	US Counties Terminology
C108248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108248>	C107687	Bonneville County, ID|Bonneville County|Bonneville County, Idaho|ID019				Geographic Area	US Counties Terminology
C108249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108249>	C107687	Boundary County, ID|Boundary County|Boundary County, Idaho|ID021				Geographic Area	US Counties Terminology
C10824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10824>	C61063	Cisplatin/Etoposide/Filgrastim/Paclitaxel|CDDP/G-CSF/TAX/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108250>	C107687	Butte County, ID|Butte County|Butte County, Idaho|ID023				Geographic Area	US Counties Terminology
C108251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108251>	C107687	Camas County, ID|Camas County|Camas County, Idaho|ID025				Geographic Area	US Counties Terminology
C108252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108252>	C107687	Canyon County, ID|Canyon County|Canyon County, Idaho|ID027				Geographic Area	US Counties Terminology
C108253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108253>	C107687	Caribou County, ID|Caribou County|Caribou County, Idaho|ID029				Geographic Area	US Counties Terminology
C108254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108254>	C107687	Cassia County, ID|Cassia County|Cassia County, Idaho|ID031				Geographic Area	US Counties Terminology
C108255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108255>	C107687	Clark County, ID|Clark County|Clark County, Idaho|ID033				Geographic Area	US Counties Terminology
C108256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108256>	C107687	Clearwater County, ID|Clearwater County|Clearwater County, Idaho|ID035				Geographic Area	US Counties Terminology
C108257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108257>	C107687	Custer County, ID|Custer County|Custer County, Idaho|ID037				Geographic Area	US Counties Terminology
C108258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108258>	C107687	Elmore County, ID|Elmore County|Elmore County, Idaho|ID039				Geographic Area	US Counties Terminology
C108259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108259>	C107687	Franklin County, ID|Franklin County|Franklin County, Idaho|ID041				Geographic Area	US Counties Terminology
C10825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10825>	C61063	Filgrastim/Penclomedine|G-CSF/PEN			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108260>	C107687	Fremont County, ID|Fremont County|Fremont County, Idaho|ID043				Geographic Area	US Counties Terminology
C108261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108261>	C107687	Gem County, ID|Gem County|Gem County, Idaho|ID045				Geographic Area	US Counties Terminology
C108262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108262>	C107687	Gooding County, ID|Gooding County|Gooding County, Idaho|ID047				Geographic Area	US Counties Terminology
C108263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108263>	C107687	Idaho County, ID|ID049|Idaho County|Idaho County, Idaho				Geographic Area	US Counties Terminology
C108264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108264>	C107687	Jefferson County, ID|ID051|Jefferson County|Jefferson County, Idaho				Geographic Area	US Counties Terminology
C108265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108265>	C107687	Jerome County, ID|ID053|Jerome County|Jerome County, Idaho				Geographic Area	US Counties Terminology
C108266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108266>	C107687	Kootenai County, ID|ID055|Kootenai County|Kootenai County, Idaho				Geographic Area	US Counties Terminology
C108267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108267>	C107687	Latah County, ID|ID057|Latah County|Latah County, Idaho				Geographic Area	US Counties Terminology
C108268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108268>	C107687	Lemhi County, ID|ID059|Lemhi County|Lemhi County, Idaho				Geographic Area	US Counties Terminology
C108269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108269>	C107687	Lewis County, ID|ID061|Lewis County|Lewis County, Idaho				Geographic Area	US Counties Terminology
C10826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10826>	C61063	Doxorubicin/Methotrexate|DOX/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108270>	C107687	Lincoln County, ID|ID063|Lincoln County|Lincoln County, Idaho				Geographic Area	US Counties Terminology
C108271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108271>	C107687	Madison County, ID|ID065|Madison County|Madison County, Idaho				Geographic Area	US Counties Terminology
C108272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108272>	C107687	Minidoka County, ID|ID067|Minidoka County|Minidoka County, Idaho				Geographic Area	US Counties Terminology
C108273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108273>	C107687	Nez Perce County, ID|ID069|Nez Perce County|Nez Perce County, Idaho				Geographic Area	US Counties Terminology
C108274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108274>	C107687	Oneida County, ID|ID071|Oneida County|Oneida County, Idaho				Geographic Area	US Counties Terminology
C108275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108275>	C107687	Owyhee County, ID|ID073|Owyhee County|Owyhee County, Idaho				Geographic Area	US Counties Terminology
C108276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108276>	C107687	Payette County, ID|ID075|Payette County|Payette County, Idaho				Geographic Area	US Counties Terminology
C108277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108277>	C107687	Power County, ID|ID077|Power County|Power County, Idaho				Geographic Area	US Counties Terminology
C108278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108278>	C107687	Shoshone County, ID|ID079|Shoshone County|Shoshone County, Idaho				Geographic Area	US Counties Terminology
C108279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108279>	C107687	Teton County, ID|ID081|Teton County|Teton County, Idaho				Geographic Area	US Counties Terminology
C10827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10827>	C61063	Cisplatin/Doxorubicin/Methotrexate/Muramyl Tripeptide Phosphatidylethanolamine Liposome|CDDP/DOX/MTP-PE Liposome/MTX|Cisplatin/Doxorubicin/Methotrexate/Muramyl Tripeptide Phosphatidylethanolamine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108280>	C107687	Twin Falls County, ID|ID083|Twin Falls County|Twin Falls County, Idaho				Geographic Area	US Counties Terminology
C108281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108281>	C107687	Valley County, ID|ID085|Valley County|Valley County, Idaho				Geographic Area	US Counties Terminology
C108282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108282>	C107687	Washington County, ID|ID087|Washington County|Washington County, Idaho				Geographic Area	US Counties Terminology
C108283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108283>	C107687	Adams County, IL|Adams County|Adams County, Illinois|IL001				Geographic Area	US Counties Terminology
C108284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108284>	C107687	Alexander County, IL|Alexander County|Alexander County, Illinois|IL003				Geographic Area	US Counties Terminology
C108285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108285>	C107687	Bond County, IL|Bond County|Bond County, Illinois|IL005				Geographic Area	US Counties Terminology
C108286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108286>	C107687	Boone County, IL|Boone County|Boone County, Illinois|IL007				Geographic Area	US Counties Terminology
C108287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108287>	C107687	Brown County, IL|Brown County|Brown County, Illinois|IL009				Geographic Area	US Counties Terminology
C108288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108288>	C107687	Bureau County, IL|Bureau County|Bureau County, Illinois|IL011				Geographic Area	US Counties Terminology
C108289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108289>	C107687	Calhoun County, IL|Calhoun County|Calhoun County, Illinois|IL013				Geographic Area	US Counties Terminology
C10828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10828>	C61063	Cisplatin/Ifosfamide/Muramyl Tripeptide Phosphatidylethanolamine Liposome|CDDP/IFF/MTP-PE Liposome|Cisplatin/Ifosfamide/Muramyl Tripeptide Phosphatidylethanolamine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108290>	C107687	Carroll County, IL|Carroll County|Carroll County, Illinois|IL015				Geographic Area	US Counties Terminology
C108291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108291>	C107687	Cass County, IL|Cass County|Cass County, Illinois|IL017				Geographic Area	US Counties Terminology
C108292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108292>	C107687	Champaign County, IL|Champaign County|Champaign County, Illinois|IL019				Geographic Area	US Counties Terminology
C108293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108293>	C107687	Christian County, IL|Christian County|Christian County, Illinois|IL021				Geographic Area	US Counties Terminology
C108294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108294>	C107687	Clark County, IL|Clark County|Clark County, Illinois|IL023				Geographic Area	US Counties Terminology
C108295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108295>	C107687	Clay County, IL|Clay County|Clay County, Illinois|IL025				Geographic Area	US Counties Terminology
C108296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108296>	C107687	Clinton County, IL|Clinton County|Clinton County, Illinois|IL027				Geographic Area	US Counties Terminology
C108297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108297>	C107687	Coles County, IL|Coles County|Coles County, Illinois|IL029				Geographic Area	US Counties Terminology
C108298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108298>	C107687	Cook County, IL|Cook County|Cook County, Illinois|IL031				Geographic Area	US Counties Terminology
C108299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108299>	C107687	Crawford County, IL|Crawford County|Crawford County, Illinois|IL033				Geographic Area	US Counties Terminology
C10829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10829>	C61063	Carboplatin/Interleukin-6/Sargramostim|CBDCA/GM-CSF/IL-6			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1082>	C1557	Enocitabine|BHAC|Behenoyl Cytarabine|Behenoyl cytarabine|ENOCITABINE	A pyrimidine antimetabolite converted to Cytarabine in the body. (NCI)			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology
C108300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108300>	C107687	Cumberland County, IL|Cumberland County|Cumberland County, Illinois|IL035				Geographic Area	US Counties Terminology
C108301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108301>	C107687	DeKalb County, IL|DeKalb County|DeKalb County, Illinois|IL037				Geographic Area	US Counties Terminology
C108302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108302>	C107687	De Witt County, IL|De Witt County|De Witt County, Illinois|IL039				Geographic Area	US Counties Terminology
C108303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108303>	C107687	Douglas County, IL|Douglas County|Douglas County, Illinois|IL041				Geographic Area	US Counties Terminology
C108304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108304>	C107687	DuPage County, IL|DuPage County|DuPage County, Illinois|IL043				Geographic Area	US Counties Terminology
C108305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108305>	C107687	Edgar County, IL|Edgar County|Edgar County, Illinois|IL045				Geographic Area	US Counties Terminology
C108306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108306>	C107687	Edwards County, IL|Edwards County|Edwards County, Illinois|IL047				Geographic Area	US Counties Terminology
C108307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108307>	C107687	Effingham County, IL|Effingham County|Effingham County, Illinois|IL049				Geographic Area	US Counties Terminology
C108308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108308>	C107687	Fayette County, IL|Fayette County|Fayette County, Illinois|IL051				Geographic Area	US Counties Terminology
C108309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108309>	C107687	Ford County, IL|Ford County|Ford County, Illinois|IL053				Geographic Area	US Counties Terminology
C10830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10830>	C61007	Carboplatin/Filgrastim/Topotecan|CBDCA/G-CSF/TOPO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108310>	C107687	Franklin County, IL|Franklin County|Franklin County, Illinois|IL055				Geographic Area	US Counties Terminology
C108311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108311>	C107687	Fulton County, IL|Fulton County|Fulton County, Illinois|IL057				Geographic Area	US Counties Terminology
C108312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108312>	C107687	Gallatin County, IL|Gallatin County|Gallatin County, Illinois|IL059				Geographic Area	US Counties Terminology
C108313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108313>	C107687	Greene County, IL|Greene County|Greene County, Illinois|IL061				Geographic Area	US Counties Terminology
C108314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108314>	C107687	Grundy County, IL|Grundy County|Grundy County, Illinois|IL063				Geographic Area	US Counties Terminology
C108315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108315>	C107687	Hamilton County, IL|Hamilton County|Hamilton County, Illinois|IL065				Geographic Area	US Counties Terminology
C108316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108316>	C107687	Hancock County, IL|Hancock County|Hancock County, Illinois|IL067				Geographic Area	US Counties Terminology
C108317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108317>	C107687	Hardin County, IL|Hardin County|Hardin County, Illinois|IL069				Geographic Area	US Counties Terminology
C108318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108318>	C107687	Henderson County, IL|Henderson County|Henderson County, Illinois|IL071				Geographic Area	US Counties Terminology
C108319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108319>	C107687	Henry County, IL|Henry County|Henry County, Illinois|IL073				Geographic Area	US Counties Terminology
C10831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10831>	C61063	Bleomycin/Cisplatin/Etoposide/Ifosfamide/Vinblastine|BLEO/CDDP/IFF/VBL/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108320>	C107687	Iroquois County, IL|IL075|Iroquois County|Iroquois County, Illinois				Geographic Area	US Counties Terminology
C108321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108321>	C107687	Jackson County, IL|IL077|Jackson County|Jackson County, Illinois				Geographic Area	US Counties Terminology
C108322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108322>	C107687	Jasper County, IL|IL079|Jasper County|Jasper County, Illinois				Geographic Area	US Counties Terminology
C108323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108323>	C107687	Jefferson County, IL|IL081|Jefferson County|Jefferson County, Illinois				Geographic Area	US Counties Terminology
C108324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108324>	C107687	Jersey County, IL|IL083|Jersey County|Jersey County, Illinois				Geographic Area	US Counties Terminology
C108325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108325>	C107687	Jo Daviess County, IL|IL085|Jo Daviess County|Jo Daviess County, Illinois				Geographic Area	US Counties Terminology
C108326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108326>	C107687	Johnson County, IL|IL087|Johnson County|Johnson County, Illinois				Geographic Area	US Counties Terminology
C108327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108327>	C107687	Kane County, IL|IL089|Kane County|Kane County, Illinois				Geographic Area	US Counties Terminology
C108328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108328>	C107687	Kankakee County, IL|IL091|Kankakee County|Kankakee County, Illinois				Geographic Area	US Counties Terminology
C108329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108329>	C107687	Kendall County, IL|IL093|Kendall County|Kendall County, Illinois				Geographic Area	US Counties Terminology
C10832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10832>	C61063	Cisplatin/Doxorubicin/Floxuridine/Leucovorin Calcium|CDDP/CF/DOX/FUDR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108330>	C107687	Knox County, IL|IL095|Knox County|Knox County, Illinois				Geographic Area	US Counties Terminology
C108331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108331>	C107687	Lake County, IL|IL097|Lake County|Lake County, Illinois				Geographic Area	US Counties Terminology
C108332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108332>	C107687	LaSalle County, IL|IL099|LaSalle County|LaSalle County, Illinois				Geographic Area	US Counties Terminology
C108333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108333>	C107687	Lawrence County, IL|IL101|Lawrence County|Lawrence County, Illinois				Geographic Area	US Counties Terminology
C108334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108334>	C107687	Lee County, IL|IL103|Lee County|Lee County, Illinois				Geographic Area	US Counties Terminology
C108335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108335>	C107687	Livingston County, IL|IL105|Livingston County|Livingston County, Illinois				Geographic Area	US Counties Terminology
C108336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108336>	C107687	Logan County, IL|IL107|Logan County|Logan County, Illinois				Geographic Area	US Counties Terminology
C108337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108337>	C107687	McDonough County, IL|IL109|McDonough County|McDonough County, Illinois				Geographic Area	US Counties Terminology
C108338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108338>	C107687	McHenry County, IL|IL111|McHenry County|McHenry County, Illinois				Geographic Area	US Counties Terminology
C108339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108339>	C107687	McLean County, IL|IL113|McLean County|McLean County, Illinois				Geographic Area	US Counties Terminology
C10833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10833>	C61063	Cisplatin/Dexamethasone/Doxorubicin/Floxuridine/Leucovorin Calcium|CDDP/CF/DM/DOX/FUDR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108340>	C107687	Macon County, IL|IL115|Macon County|Macon County, Illinois				Geographic Area	US Counties Terminology
C108341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108341>	C107687	Macoupin County, IL|IL117|Macoupin County|Macoupin County, Illinois				Geographic Area	US Counties Terminology
C108342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108342>	C107687	Madison County, IL|IL119|Madison County|Madison County, Illinois				Geographic Area	US Counties Terminology
C108343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108343>	C107687	Marion County, IL|IL121|Marion County|Marion County, Illinois				Geographic Area	US Counties Terminology
C108344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108344>	C107687	Marshall County, IL|IL123|Marshall County|Marshall County, Illinois				Geographic Area	US Counties Terminology
C108345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108345>	C107687	Mason County, IL|IL125|Mason County|Mason County, Illinois				Geographic Area	US Counties Terminology
C108346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108346>	C107687	Massac County, IL|IL127|Massac County|Massac County, Illinois				Geographic Area	US Counties Terminology
C108347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108347>	C107687	Menard County, IL|IL129|Menard County|Menard County, Illinois				Geographic Area	US Counties Terminology
C108348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108348>	C107687	Mercer County, IL|IL131|Mercer County|Mercer County, Illinois				Geographic Area	US Counties Terminology
C108349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108349>	C107687	Monroe County, IL|IL133|Monroe County|Monroe County, Illinois				Geographic Area	US Counties Terminology
C10834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10834>	C61063	Cyclosporine/Dexamethasone/Vinblastine|CYSP/DM/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108350>	C107687	Montgomery County, IL|IL135|Montgomery County|Montgomery County, Illinois				Geographic Area	US Counties Terminology
C108351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108351>	C107687	Morgan County, IL|IL137|Morgan County|Morgan County, Illinois				Geographic Area	US Counties Terminology
C108352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108352>	C107687	Moultrie County, IL|IL139|Moultrie County|Moultrie County, Illinois				Geographic Area	US Counties Terminology
C108353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108353>	C107687	Ogle County, IL|IL141|Ogle County|Ogle County, Illinois				Geographic Area	US Counties Terminology
C108354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108354>	C107687	Peoria County, IL|IL143|Peoria County|Peoria County, Illinois				Geographic Area	US Counties Terminology
C108355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108355>	C107687	Perry County, IL|IL145|Perry County|Perry County, Illinois				Geographic Area	US Counties Terminology
C108356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108356>	C107687	Piatt County, IL|IL147|Piatt County|Piatt County, Illinois				Geographic Area	US Counties Terminology
C108357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108357>	C107687	Pike County, IL|IL149|Pike County|Pike County, Illinois				Geographic Area	US Counties Terminology
C108358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108358>	C107687	Pope County, IL|IL151|Pope County|Pope County, Illinois				Geographic Area	US Counties Terminology
C108359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108359>	C107687	Pulaski County, IL|IL153|Pulaski County|Pulaski County, Illinois				Geographic Area	US Counties Terminology
C10835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10835>	C61063	Carboplatin/Cisplatin/Cyclophosphamide/Etoposide/Paclitaxel|CBDCA/CDDP/CTX/TAX/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108360>	C107687	Putnam County, IL|IL155|Putnam County|Putnam County, Illinois				Geographic Area	US Counties Terminology
C108361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108361>	C107687	Randolph County, IL|IL157|Randolph County|Randolph County, Illinois				Geographic Area	US Counties Terminology
C108362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108362>	C107687	Richland County, IL|IL159|Richland County|Richland County, Illinois				Geographic Area	US Counties Terminology
C108363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108363>	C107687	Rock Island County, IL|IL161|Rock Island County|Rock Island County, Illinois				Geographic Area	US Counties Terminology
C108364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108364>	C107687	St. Clair County, IL|IL163|St. Clair County|St. Clair County, Illinois				Geographic Area	US Counties Terminology
C108365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108365>	C107687	Saline County, IL|IL165|Saline County|Saline County, Illinois				Geographic Area	US Counties Terminology
C108366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108366>	C107687	Sangamon County, IL|IL167|Sangamon County|Sangamon County, Illinois				Geographic Area	US Counties Terminology
C108367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108367>	C107687	Schuyler County, IL|IL169|Schuyler County|Schuyler County, Illinois				Geographic Area	US Counties Terminology
C108368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108368>	C107687	Scott County, IL|IL171|Scott County|Scott County, Illinois				Geographic Area	US Counties Terminology
C108369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108369>	C107687	Shelby County, IL|IL173|Shelby County|Shelby County, Illinois				Geographic Area	US Counties Terminology
C10836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10836>	C61007	Fluorouracil/Irinotecan/Leucovorin Calcium|5FU/Leucovorin/Irinotecan|CF/CPT-11/5-FU|IFL|Saltz Regimen	A combination of agents containing fluorouracil, irinotecan and leucovorin calcium.		Obsolete_Concept	Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C108370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108370>	C107687	Stark County, IL|IL175|Stark County|Stark County, Illinois				Geographic Area	US Counties Terminology
C108371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108371>	C107687	Stephenson County, IL|IL177|Stephenson County|Stephenson County, Illinois				Geographic Area	US Counties Terminology
C108372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108372>	C107687	Tazewell County, IL|IL179|Tazewell County|Tazewell County, Illinois				Geographic Area	US Counties Terminology
C108373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108373>	C107687	Union County, IL|IL181|Union County|Union County, Illinois				Geographic Area	US Counties Terminology
C108374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108374>	C107687	Vermilion County, IL|IL183|Vermilion County|Vermilion County, Illinois				Geographic Area	US Counties Terminology
C108375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108375>	C107687	Wabash County, IL|IL185|Wabash County|Wabash County, Illinois				Geographic Area	US Counties Terminology
C108376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108376>	C107687	Warren County, IL|IL187|Warren County|Warren County, Illinois				Geographic Area	US Counties Terminology
C108377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108377>	C107687	Washington County, IL|IL189|Washington County|Washington County, Illinois				Geographic Area	US Counties Terminology
C108378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108378>	C107687	Wayne County, IL|IL191|Wayne County|Wayne County, Illinois				Geographic Area	US Counties Terminology
C108379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108379>	C107687	White County, IL|IL193|White County|White County, Illinois				Geographic Area	US Counties Terminology
C10837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10837>	C61063	Gallium Nitrate/Hydroxyurea|GAN/HU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108380>	C107687	Whiteside County, IL|IL195|Whiteside County|Whiteside County, Illinois				Geographic Area	US Counties Terminology
C108381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108381>	C107687	Will County, IL|IL197|Will County|Will County, Illinois				Geographic Area	US Counties Terminology
C108382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108382>	C107687	Williamson County, IL|IL199|Williamson County|Williamson County, Illinois				Geographic Area	US Counties Terminology
C108383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108383>	C107687	Winnebago County, IL|IL201|Winnebago County|Winnebago County, Illinois				Geographic Area	US Counties Terminology
C108384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108384>	C107687	Woodford County, IL|IL203|Woodford County|Woodford County, Illinois				Geographic Area	US Counties Terminology
C108385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108385>	C107687	Adams County, IN|Adams County|Adams County, Indiana|IN001				Geographic Area	US Counties Terminology
C108386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108386>	C107687	Allen County, IN|Allen County|Allen County, Indiana|IN003				Geographic Area	US Counties Terminology
C108387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108387>	C107687	Bartholomew County, IN|Bartholomew County|Bartholomew County, Indiana|IN005				Geographic Area	US Counties Terminology
C108388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108388>	C107687	Benton County, IN|Benton County|Benton County, Indiana|IN007				Geographic Area	US Counties Terminology
C108389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108389>	C107687	Blackford County, IN|Blackford County|Blackford County, Indiana|IN009				Geographic Area	US Counties Terminology
C10838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10838>	C61063	Cyclophosphamide/Milodistim|CTX/PIXY321			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108390>	C107687	Boone County, IN|Boone County|Boone County, Indiana|IN011				Geographic Area	US Counties Terminology
C108391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108391>	C107687	Brown County, IN|Brown County|Brown County, Indiana|IN013				Geographic Area	US Counties Terminology
C108392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108392>	C107687	Carroll County, IN|Carroll County|Carroll County, Indiana|IN015				Geographic Area	US Counties Terminology
C108393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108393>	C107687	Cass County, IN|Cass County|Cass County, Indiana|IN017				Geographic Area	US Counties Terminology
C108394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108394>	C107687	Clark County, IN|Clark County|Clark County, Indiana|IN019				Geographic Area	US Counties Terminology
C108395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108395>	C107687	Clay County, IN|Clay County|Clay County, Indiana|IN021				Geographic Area	US Counties Terminology
C108396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108396>	C107687	Clinton County, IN|Clinton County|Clinton County, Indiana|IN023				Geographic Area	US Counties Terminology
C108397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108397>	C107687	Crawford County, IN|Crawford County|Crawford County, Indiana|IN025				Geographic Area	US Counties Terminology
C108398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108398>	C107687	Daviess County, IN|Daviess County|Daviess County, Indiana|IN027				Geographic Area	US Counties Terminology
C108399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108399>	C107687	Dearborn County, IN|Dearborn County|Dearborn County, Indiana|IN029				Geographic Area	US Counties Terminology
C10839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10839>	C61063	Carboplatin/Cyclophosphamide/Milodistim/Thiotepa|CBDCA/CTX/PIXY321/TSPA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1083>	C470|C1456	Staphylococcal Enterotoxin A|SEA|SEA|STAPHYLOCOCCAL ENTEROTOXIN A	A bacterial enterotoxin with potential immunostimulatory activity. Staphylococcal enterotoxin A (SEA), a gram positive bacterial superantigen (SAg), is a potent stimulator of T-cell activation. SEA superantigen binds directly to class II major histocompatibility complex (MHC) molecules and to the V beta region of the T-cell receptor (TCR), leading to an amplified T-cell response. In response to SEA, both CD4+ and CD8+ cells proliferate, secrete cytokines, and demonstrate enhanced cytotoxic activity against a broad range of antigens. Vaccination with the SEA protein, administered by direct transfection into tumor cells, may elicit a non-specific cytotoxic T-cell (CTL) response and result in decreased tumor cell growth.			Amino Acid, Peptide, or Protein|Immunologic Factor	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C108400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108400>	C107687	Decatur County, IN|Decatur County|Decatur County, Indiana|IN031				Geographic Area	US Counties Terminology
C108401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108401>	C107687	DeKalb County, IN|DeKalb County|DeKalb County, Indiana|IN033				Geographic Area	US Counties Terminology
C108402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108402>	C107687	Delaware County, IN|Delaware County|Delaware County, Indiana|IN035				Geographic Area	US Counties Terminology
C108403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108403>	C107687	Dubois County, IN|Dubois County|Dubois County, Indiana|IN037				Geographic Area	US Counties Terminology
C108404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108404>	C107687	Elkhart County, IN|Elkhart County|Elkhart County, Indiana|IN039				Geographic Area	US Counties Terminology
C108405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108405>	C107687	Fayette County, IN|Fayette County|Fayette County, Indiana|IN041				Geographic Area	US Counties Terminology
C108406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108406>	C107687	Floyd County, IN|Floyd County|Floyd County, Indiana|IN043				Geographic Area	US Counties Terminology
C108407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108407>	C107687	Fountain County, IN|Fountain County|Fountain County, Indiana|IN045				Geographic Area	US Counties Terminology
C108408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108408>	C107687	Franklin County, IN|Franklin County|Franklin County, Indiana|IN047				Geographic Area	US Counties Terminology
C108409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108409>	C107687	Fulton County, IN|Fulton County|Fulton County, Indiana|IN049				Geographic Area	US Counties Terminology
C10840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10840>	C61007	Cytarabine/Doxorubicin/Prednisone/Thioguanine/Vincristine|ARA-C/DOX/PRED/TG/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108410>	C107687	Gibson County, IN|Gibson County|Gibson County, Indiana|IN051				Geographic Area	US Counties Terminology
C108411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108411>	C107687	Grant County, IN|Grant County|Grant County, Indiana|IN053				Geographic Area	US Counties Terminology
C108412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108412>	C107687	Greene County, IN|Greene County|Greene County, Indiana|IN055				Geographic Area	US Counties Terminology
C108413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108413>	C107687	Hamilton County, IN|Hamilton County|Hamilton County, Indiana|IN057				Geographic Area	US Counties Terminology
C108414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108414>	C107687	Hancock County, IN|Hancock County|Hancock County, Indiana|IN059				Geographic Area	US Counties Terminology
C108415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108415>	C107687	Harrison County, IN|Harrison County|Harrison County, Indiana|IN061				Geographic Area	US Counties Terminology
C108416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108416>	C107687	Hendricks County, IN|Hendricks County|Hendricks County, Indiana|IN063				Geographic Area	US Counties Terminology
C108417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108417>	C107687	Henry County, IN|Henry County|Henry County, Indiana|IN065				Geographic Area	US Counties Terminology
C108418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108418>	C107687	Howard County, IN|Howard County|Howard County, Indiana|IN067				Geographic Area	US Counties Terminology
C108419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108419>	C107687	Huntington County, IN|Huntington County|Huntington County, Indiana|IN069				Geographic Area	US Counties Terminology
C10841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10841>	C61063	Interleukin-1-Alpha/Methotrexate|IL-1A/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108420>	C107687	Jackson County, IN|IN071|Jackson County|Jackson County, Indiana				Geographic Area	US Counties Terminology
C108421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108421>	C107687	Jasper County, IN|IN073|Jasper County|Jasper County, Indiana				Geographic Area	US Counties Terminology
C108422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108422>	C107687	Jay County, IN|IN075|Jay County|Jay County, Indiana				Geographic Area	US Counties Terminology
C108423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108423>	C107687	Jefferson County, IN|IN077|Jefferson County|Jefferson County, Indiana				Geographic Area	US Counties Terminology
C108424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108424>	C107687	Jennings County, IN|IN079|Jennings County|Jennings County, Indiana				Geographic Area	US Counties Terminology
C108425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108425>	C107687	Johnson County, IN|IN081|Johnson County|Johnson County, Indiana				Geographic Area	US Counties Terminology
C108426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108426>	C107687	Knox County, IN|IN083|Knox County|Knox County, Indiana				Geographic Area	US Counties Terminology
C108427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108427>	C107687	Kosciusko County, IN|IN085|Kosciusko County|Kosciusko County, Indiana				Geographic Area	US Counties Terminology
C108428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108428>	C107687	LaGrange County, IN|IN087|LaGrange County|LaGrange County, Indiana				Geographic Area	US Counties Terminology
C108429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108429>	C107687	Lake County, IN|IN089|Lake County|Lake County, Indiana				Geographic Area	US Counties Terminology
C10842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10842>	C61063	Lomustine/Vincristine|CCNU/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108430>	C107687	LaPorte County, IN|IN091|LaPorte County|LaPorte County, Indiana				Geographic Area	US Counties Terminology
C108431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108431>	C107687	Lawrence County, IN|IN093|Lawrence County|Lawrence County, Indiana				Geographic Area	US Counties Terminology
C108432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108432>	C107687	Madison County, IN|IN095|Madison County|Madison County, Indiana				Geographic Area	US Counties Terminology
C108433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108433>	C107687	Marion County, IN|IN097|Marion County|Marion County, Indiana				Geographic Area	US Counties Terminology
C108434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108434>	C107687	Marshall County, IN|IN099|Marshall County|Marshall County, Indiana				Geographic Area	US Counties Terminology
C108435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108435>	C107687	Martin County, IN|IN101|Martin County|Martin County, Indiana				Geographic Area	US Counties Terminology
C108436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108436>	C107687	Miami County, IN|IN103|Miami County|Miami County, Indiana				Geographic Area	US Counties Terminology
C108437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108437>	C107687	Monroe County, IN|IN105|Monroe County|Monroe County, Indiana				Geographic Area	US Counties Terminology
C108438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108438>	C107687	Montgomery County, IN|IN107|Montgomery County|Montgomery County, Indiana				Geographic Area	US Counties Terminology
C108439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108439>	C107687	Morgan County, IN|IN109|Morgan County|Morgan County, Indiana				Geographic Area	US Counties Terminology
C10843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10843>	C61063	Interferon Gamma/Interleukin-2/Melphalan/Tumor Necrosis Factor|IFN-G/IL-2/L-PAM/TNF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108440>	C107687	Newton County, IN|IN111|Newton County|Newton County, Indiana				Geographic Area	US Counties Terminology
C108441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108441>	C107687	Noble County, IN|IN113|Noble County|Noble County, Indiana				Geographic Area	US Counties Terminology
C108442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108442>	C107687	Ohio County, IN|IN115|Ohio County|Ohio County, Indiana				Geographic Area	US Counties Terminology
C108443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108443>	C107687	Orange County, IN|IN117|Orange County|Orange County, Indiana				Geographic Area	US Counties Terminology
C108444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108444>	C107687	Owen County, IN|IN119|Owen County|Owen County, Indiana				Geographic Area	US Counties Terminology
C108445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108445>	C107687	Parke County, IN|IN121|Parke County|Parke County, Indiana				Geographic Area	US Counties Terminology
C108446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108446>	C107687	Perry County, IN|IN123|Perry County|Perry County, Indiana				Geographic Area	US Counties Terminology
C108447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108447>	C107687	Pike County, IN|IN125|Pike County|Pike County, Indiana				Geographic Area	US Counties Terminology
C108448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108448>	C107687	Porter County, IN|IN127|Porter County|Porter County, Indiana				Geographic Area	US Counties Terminology
C108449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108449>	C107687	Posey County, IN|IN129|Posey County|Posey County, Indiana				Geographic Area	US Counties Terminology
C10844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10844>	C61063	Cyclophosphamide/Filgrastim/Topotecan|CTX/G-CSF/TOPO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108450>	C107687	Pulaski County, IN|IN131|Pulaski County|Pulaski County, Indiana				Geographic Area	US Counties Terminology
C108451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108451>	C107687	Putnam County, IN|IN133|Putnam County|Putnam County, Indiana				Geographic Area	US Counties Terminology
C108452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108452>	C107687	Randolph County, IN|IN135|Randolph County|Randolph County, Indiana				Geographic Area	US Counties Terminology
C108453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108453>	C107687	Ripley County, IN|IN137|Ripley County|Ripley County, Indiana				Geographic Area	US Counties Terminology
C108454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108454>	C107687	Rush County, IN|IN139|Rush County|Rush County, Indiana				Geographic Area	US Counties Terminology
C108455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108455>	C107687	St. Joseph County, IN|IN141|St. Joseph County|St. Joseph County, Indiana				Geographic Area	US Counties Terminology
C108456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108456>	C107687	Scott County, IN|IN143|Scott County|Scott County, Indiana				Geographic Area	US Counties Terminology
C108457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108457>	C107687	Shelby County, IN|IN145|Shelby County|Shelby County, Indiana				Geographic Area	US Counties Terminology
C108458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108458>	C107687	Spencer County, IN|IN147|Spencer County|Spencer County, Indiana				Geographic Area	US Counties Terminology
C108459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108459>	C107687	Starke County, IN|IN149|Starke County|Starke County, Indiana				Geographic Area	US Counties Terminology
C10845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10845>	C61063	Methotrexate/Procarbazine/Vincristine|MTX/PCB/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108460>	C107687	Steuben County, IN|IN151|Steuben County|Steuben County, Indiana				Geographic Area	US Counties Terminology
C108461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108461>	C107687	Sullivan County, IN|IN153|Sullivan County|Sullivan County, Indiana				Geographic Area	US Counties Terminology
C108462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108462>	C107687	Switzerland County, IN|IN155|Switzerland County|Switzerland County, Indiana				Geographic Area	US Counties Terminology
C108463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108463>	C107687	Tippecanoe County, IN|IN157|Tippecanoe County|Tippecanoe County, Indiana				Geographic Area	US Counties Terminology
C108464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108464>	C107687	Tipton County, IN|IN159|Tipton County|Tipton County, Indiana				Geographic Area	US Counties Terminology
C108465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108465>	C107687	Union County, IN|IN161|Union County|Union County, Indiana				Geographic Area	US Counties Terminology
C108466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108466>	C107687	Vanderburgh County, IN|IN163|Vanderburgh County|Vanderburgh County, Indiana				Geographic Area	US Counties Terminology
C108467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108467>	C107687	Vermillion County, IN|IN165|Vermillion County|Vermillion County, Indiana				Geographic Area	US Counties Terminology
C108468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108468>	C107687	Vigo County, IN|IN167|Vigo County|Vigo County, Indiana				Geographic Area	US Counties Terminology
C108469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108469>	C107687	Wabash County, IN|IN169|Wabash County|Wabash County, Indiana				Geographic Area	US Counties Terminology
C10846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10846>	C61063	Cyclophosphamide/Idarubicin/Prednisone/Vincristine|CTX/IDA/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108470>	C107687	Warren County, IN|IN171|Warren County|Warren County, Indiana				Geographic Area	US Counties Terminology
C108471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108471>	C107687	Warrick County, IN|IN173|Warrick County|Warrick County, Indiana				Geographic Area	US Counties Terminology
C108472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108472>	C107687	Washington County, IN|IN175|Washington County|Washington County, Indiana				Geographic Area	US Counties Terminology
C108473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108473>	C107687	Wayne County, IN|IN177|Wayne County|Wayne County, Indiana				Geographic Area	US Counties Terminology
C108474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108474>	C107687	Wells County, IN|IN179|Wells County|Wells County, Indiana				Geographic Area	US Counties Terminology
C108475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108475>	C107687	White County, IN|IN181|White County|White County, Indiana				Geographic Area	US Counties Terminology
C108476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108476>	C107687	Whitley County, IN|IN183|Whitley County|Whitley County, Indiana				Geographic Area	US Counties Terminology
C108477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108477>	C107687	Adair County, IA|Adair County|Adair County, Iowa|IA001				Geographic Area	US Counties Terminology
C108478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108478>	C107687	Adams County, IA|Adams County|Adams County, Iowa|IA003				Geographic Area	US Counties Terminology
C108479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108479>	C107687	Allamakee County, IA|Allamakee County|Allamakee County, Iowa|IA005				Geographic Area	US Counties Terminology
C10847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10847>	C61063	Carboplatin/Filgrastim/Paclitaxel|CBDCA/G-CSF/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108480>	C107687	Appanoose County, IA|Appanoose County|Appanoose County, Iowa|IA007				Geographic Area	US Counties Terminology
C108481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108481>	C107687	Audubon County, IA|Audubon County|Audubon County, Iowa|IA009				Geographic Area	US Counties Terminology
C108482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108482>	C107687	Benton County, IA|Benton County|Benton County, Iowa|IA011				Geographic Area	US Counties Terminology
C108483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108483>	C107687	Black Hawk County, IA|Black Hawk County|Black Hawk County, Iowa|IA013				Geographic Area	US Counties Terminology
C108484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108484>	C107687	Boone County, IA|Boone County|Boone County, Iowa|IA015				Geographic Area	US Counties Terminology
C108485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108485>	C107687	Bremer County, IA|Bremer County|Bremer County, Iowa|IA017				Geographic Area	US Counties Terminology
C108486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108486>	C107687	Buchanan County, IA|Buchanan County|Buchanan County, Iowa|IA019				Geographic Area	US Counties Terminology
C108487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108487>	C107687	Buena Vista County, IA|Buena Vista County|Buena Vista County, Iowa|IA021				Geographic Area	US Counties Terminology
C108488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108488>	C107687	Butler County, IA|Butler County|Butler County, Iowa|IA023				Geographic Area	US Counties Terminology
C108489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108489>	C107687	Calhoun County, IA|Calhoun County|Calhoun County, Iowa|IA025				Geographic Area	US Counties Terminology
C10848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10848>	C61063	Asparaginase/Cytarabine/Filgrastim|ARA-C/ASP/G-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108490>	C107687	Carroll County, IA|Carroll County|Carroll County, Iowa|IA027				Geographic Area	US Counties Terminology
C108491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108491>	C107687	Cass County, IA|Cass County|Cass County, Iowa|IA029				Geographic Area	US Counties Terminology
C108492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108492>	C107687	Cedar County, IA|Cedar County|Cedar County, Iowa|IA031				Geographic Area	US Counties Terminology
C108493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108493>	C107687	Cerro Gordo County, IA|Cerro Gordo County|Cerro Gordo County, Iowa|IA033				Geographic Area	US Counties Terminology
C108494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108494>	C107687	Cherokee County, IA|Cherokee County|Cherokee County, Iowa|IA035				Geographic Area	US Counties Terminology
C108495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108495>	C107687	Chickasaw County, IA|Chickasaw County|Chickasaw County, Iowa|IA037				Geographic Area	US Counties Terminology
C108496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108496>	C107687	Clarke County, IA|Clarke County|Clarke County, Iowa|IA039				Geographic Area	US Counties Terminology
C108497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108497>	C107687	Clay County, IA|Clay County|Clay County, Iowa|IA041				Geographic Area	US Counties Terminology
C108498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108498>	C107687	Clayton County, IA|Clayton County|Clayton County, Iowa|IA043				Geographic Area	US Counties Terminology
C108499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108499>	C107687	Clinton County, IA|Clinton County|Clinton County, Iowa|IA045				Geographic Area	US Counties Terminology
C10849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10849>	C61063	Cisplatin/Etoposide/Filgrastim|CDDP/G-CSF/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1084>	C470|C1456	Staphylococcal Enterotoxin B|SEB|SEB|STAPHYLOCOCCAL ENTEROTOXIN B	A bacterial enterotoxin with potential immunostimulatory activity. Staphylococcal enterotoxin B (SEB), a gram positive superantigen produced by Staphylococcus aureus, is a potent stimulator of T-cell activation. SEB binds directly to class II major histocompatibility complex (MHC) molecules and the V beta region of the T-cell receptor (TCR), leading to an amplified T-cell response. In response to SEB, both CD4+ and CD8+ cells proliferate, secrete cytokines and demonstrate enhanced cytotoxic activity against a broad range of antigens. Co-administration of SEB with interleukin-2 (IL-2) by direct injection into tumor cells, may induce clonal T-cell expansion and potentiate apoptosis of tumor cells, resulting in decreased tumor growth.			Amino Acid, Peptide, or Protein|Immunologic Factor	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C108500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108500>	C107687	Crawford County, IA|Crawford County|Crawford County, Iowa|IA047				Geographic Area	US Counties Terminology
C108501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108501>	C107687	Dallas County, IA|Dallas County|Dallas County, Iowa|IA049				Geographic Area	US Counties Terminology
C108502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108502>	C107687	Davis County, IA|Davis County|Davis County, Iowa|IA051				Geographic Area	US Counties Terminology
C108503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108503>	C107687	Decatur County, IA|Decatur County|Decatur County, Iowa|IA053				Geographic Area	US Counties Terminology
C108504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108504>	C107687	Delaware County, IA|Delaware County|Delaware County, Iowa|IA055				Geographic Area	US Counties Terminology
C108505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108505>	C107687	Des Moines County, IA|Des Moines County|Des Moines County, Iowa|IA057				Geographic Area	US Counties Terminology
C108506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108506>	C107687	Dickinson County, IA|Dickinson County|Dickinson County, Iowa|IA059				Geographic Area	US Counties Terminology
C108507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108507>	C107687	Dubuque County, IA|Dubuque County|Dubuque County, Iowa|IA061				Geographic Area	US Counties Terminology
C108508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108508>	C107687	Emmet County, IA|Emmet County|Emmet County, Iowa|IA063				Geographic Area	US Counties Terminology
C108509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108509>	C107687	Fayette County, IA|Fayette County|Fayette County, Iowa|IA065				Geographic Area	US Counties Terminology
C10850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10850>	C61007	Ciprofloxacin/Cisplatin/Etoposide|CDDP/CPFX/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108510>	C107687	Floyd County, IA|Floyd County|Floyd County, Iowa|IA067				Geographic Area	US Counties Terminology
C108511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108511>	C107687	Franklin County, IA|Franklin County|Franklin County, Iowa|IA069				Geographic Area	US Counties Terminology
C108512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108512>	C107687	Fremont County, IA|Fremont County|Fremont County, Iowa|IA071				Geographic Area	US Counties Terminology
C108513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108513>	C107687	Greene County, IA|Greene County|Greene County, Iowa|IA073				Geographic Area	US Counties Terminology
C108514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108514>	C107687	Grundy County, IA|Grundy County|Grundy County, Iowa|IA075				Geographic Area	US Counties Terminology
C108515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108515>	C107687	Guthrie County, IA|Guthrie County|Guthrie County, Iowa|IA077				Geographic Area	US Counties Terminology
C108516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108516>	C107687	Hamilton County, IA|Hamilton County|Hamilton County, Iowa|IA079				Geographic Area	US Counties Terminology
C108517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108517>	C107687	Hancock County, IA|Hancock County|Hancock County, Iowa|IA081				Geographic Area	US Counties Terminology
C108518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108518>	C107687	Hardin County, IA|Hardin County|Hardin County, Iowa|IA083				Geographic Area	US Counties Terminology
C108519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108519>	C107687	Harrison County, IA|Harrison County|Harrison County, Iowa|IA085				Geographic Area	US Counties Terminology
C10851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10851>	C61063	Ciprofloxacin/Cisplatin/Etoposide/Filgrastim|CDDP/CPFX/G-CSF/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108520>	C107687	Henry County, IA|Henry County|Henry County, Iowa|IA087				Geographic Area	US Counties Terminology
C108521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108521>	C107687	Howard County, IA|Howard County|Howard County, Iowa|IA089				Geographic Area	US Counties Terminology
C108522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108522>	C107687	Humboldt County, IA|Humboldt County|Humboldt County, Iowa|IA091				Geographic Area	US Counties Terminology
C108523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108523>	C107687	Ida County, IA|IA093|Ida County|Ida County, Iowa				Geographic Area	US Counties Terminology
C108524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108524>	C107687	Iowa County, IA|IA095|Iowa County|Iowa County, Iowa				Geographic Area	US Counties Terminology
C108525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108525>	C107687	Jackson County, IA|IA097|Jackson County|Jackson County, Iowa				Geographic Area	US Counties Terminology
C108526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108526>	C107687	Jasper County, IA|IA099|Jasper County|Jasper County, Iowa				Geographic Area	US Counties Terminology
C108527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108527>	C107687	Jefferson County, IA|IA101|Jefferson County|Jefferson County, Iowa				Geographic Area	US Counties Terminology
C108528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108528>	C107687	Johnson County, IA|IA103|Johnson County|Johnson County, Iowa				Geographic Area	US Counties Terminology
C108529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108529>	C107687	Jones County, IA|IA105|Jones County|Jones County, Iowa				Geographic Area	US Counties Terminology
C10852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10852>	C61063	Dacarbazine/Interleukin-1-Alpha|DTIC/IL-1A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108530>	C107687	Keokuk County, IA|IA107|Keokuk County|Keokuk County, Iowa				Geographic Area	US Counties Terminology
C108531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108531>	C107687	Kossuth County, IA|IA109|Kossuth County|Kossuth County, Iowa				Geographic Area	US Counties Terminology
C108532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108532>	C107687	Lee County, IA|IA111|Lee County|Lee County, Iowa				Geographic Area	US Counties Terminology
C108533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108533>	C107687	Linn County, IA|IA113|Linn County|Linn County, Iowa				Geographic Area	US Counties Terminology
C108534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108534>	C107687	Louisa County, IA|IA115|Louisa County|Louisa County, Iowa				Geographic Area	US Counties Terminology
C108535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108535>	C107687	Lucas County, IA|IA117|Lucas County|Lucas County, Iowa				Geographic Area	US Counties Terminology
C108536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108536>	C107687	Lyon County, IA|IA119|Lyon County|Lyon County, Iowa				Geographic Area	US Counties Terminology
C108537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108537>	C107687	Madison County, IA|IA121|Madison County|Madison County, Iowa				Geographic Area	US Counties Terminology
C108538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108538>	C107687	Mahaska County, IA|IA123|Mahaska County|Mahaska County, Iowa				Geographic Area	US Counties Terminology
C108539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108539>	C107687	Marion County, IA|IA125|Marion County|Marion County, Iowa				Geographic Area	US Counties Terminology
C10853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10853>	C61063	Cyclophosphamide/Etoposide/Filgrastim|CTX/G-CSF/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108540>	C107687	Marshall County, IA|IA127|Marshall County|Marshall County, Iowa				Geographic Area	US Counties Terminology
C108541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108541>	C107687	Mills County, IA|IA129|Mills County|Mills County, Iowa				Geographic Area	US Counties Terminology
C108542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108542>	C107687	Mitchell County, IA|IA131|Mitchell County|Mitchell County, Iowa				Geographic Area	US Counties Terminology
C108543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108543>	C107687	Monona County, IA|IA133|Monona County|Monona County, Iowa				Geographic Area	US Counties Terminology
C108544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108544>	C107687	Monroe County, IA|IA135|Monroe County|Monroe County, Iowa				Geographic Area	US Counties Terminology
C108545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108545>	C107687	Montgomery County, IA|IA137|Montgomery County|Montgomery County, Iowa				Geographic Area	US Counties Terminology
C108546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108546>	C107687	Muscatine County, IA|IA139|Muscatine County|Muscatine County, Iowa				Geographic Area	US Counties Terminology
C108547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108547>	C107687	O'Brien County, IA|IA141|O'Brien County|O'Brien County, Iowa				Geographic Area	US Counties Terminology
C108548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108548>	C107687	Osceola County, IA|IA143|Osceola County|Osceola County, Iowa				Geographic Area	US Counties Terminology
C108549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108549>	C107687	Page County, IA|IA145|Page County|Page County, Iowa				Geographic Area	US Counties Terminology
C10854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10854>	C61007	Cytarabine/Milodistim/Mitoxantrone|ARA-C/DHAD/PIXY321			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108550>	C107687	Palo Alto County, IA|IA147|Palo Alto County|Palo Alto County, Iowa				Geographic Area	US Counties Terminology
C108551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108551>	C107687	Plymouth County, IA|IA149|Plymouth County|Plymouth County, Iowa				Geographic Area	US Counties Terminology
C108552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108552>	C107687	Pocahontas County, IA|IA151|Pocahontas County|Pocahontas County, Iowa				Geographic Area	US Counties Terminology
C108553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108553>	C107687	Polk County, IA|IA153|Polk County|Polk County, Iowa				Geographic Area	US Counties Terminology
C108554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108554>	C107687	Pottawattamie County, IA|IA155|Pottawattamie County|Pottawattamie County, Iowa				Geographic Area	US Counties Terminology
C108555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108555>	C107687	Poweshiek County, IA|IA157|Poweshiek County|Poweshiek County, Iowa				Geographic Area	US Counties Terminology
C108556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108556>	C107687	Ringgold County, IA|IA159|Ringgold County|Ringgold County, Iowa				Geographic Area	US Counties Terminology
C108557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108557>	C107687	Sac County, IA|IA161|Sac County|Sac County, Iowa				Geographic Area	US Counties Terminology
C108558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108558>	C107687	Scott County, IA|IA163|Scott County|Scott County, Iowa				Geographic Area	US Counties Terminology
C108559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108559>	C107687	Shelby County, IA|IA165|Shelby County|Shelby County, Iowa				Geographic Area	US Counties Terminology
C10855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10855>	C61063	Paclitaxel/PSC 833|PSC 833/TAX|PSC/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108560>	C107687	Sioux County, IA|IA167|Sioux County|Sioux County, Iowa				Geographic Area	US Counties Terminology
C108561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108561>	C107687	Story County, IA|IA169|Story County|Story County, Iowa				Geographic Area	US Counties Terminology
C108562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108562>	C107687	Tama County, IA|IA171|Tama County|Tama County, Iowa				Geographic Area	US Counties Terminology
C108563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108563>	C107687	Taylor County, IA|IA173|Taylor County|Taylor County, Iowa				Geographic Area	US Counties Terminology
C108564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108564>	C107687	Union County, IA|IA175|Union County|Union County, Iowa				Geographic Area	US Counties Terminology
C108565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108565>	C107687	Van Buren County, IA|IA177|Van Buren County|Van Buren County, Iowa				Geographic Area	US Counties Terminology
C108566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108566>	C107687	Wapello County, IA|IA179|Wapello County|Wapello County, Iowa				Geographic Area	US Counties Terminology
C108567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108567>	C107687	Warren County, IA|IA181|Warren County|Warren County, Iowa				Geographic Area	US Counties Terminology
C108568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108568>	C107687	Washington County, IA|IA183|Washington County|Washington County, Iowa				Geographic Area	US Counties Terminology
C108569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108569>	C107687	Wayne County, IA|IA185|Wayne County|Wayne County, Iowa				Geographic Area	US Counties Terminology
C10856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10856>	C61007	Cyclosporine/Methotrexate|CYSP/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108570>	C107687	Webster County, IA|IA187|Webster County|Webster County, Iowa				Geographic Area	US Counties Terminology
C108571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108571>	C107687	Winnebago County, IA|IA189|Winnebago County|Winnebago County, Iowa				Geographic Area	US Counties Terminology
C108572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108572>	C107687	Winneshiek County, IA|IA191|Winneshiek County|Winneshiek County, Iowa				Geographic Area	US Counties Terminology
C108573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108573>	C107687	Woodbury County, IA|IA193|Woodbury County|Woodbury County, Iowa				Geographic Area	US Counties Terminology
C108574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108574>	C107687	Worth County, IA|IA195|Worth County|Worth County, Iowa				Geographic Area	US Counties Terminology
C108575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108575>	C107687	Wright County, IA|IA197|Wright County|Wright County, Iowa				Geographic Area	US Counties Terminology
C108576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108576>	C107687	Allen County, KS|Allen County|Allen County, Kansas|KS001				Geographic Area	US Counties Terminology
C108577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108577>	C107687	Anderson County, KS|Anderson County|Anderson County, Kansas|KS003				Geographic Area	US Counties Terminology
C108578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108578>	C107687	Atchison County, KS|Atchison County|Atchison County, Kansas|KS005				Geographic Area	US Counties Terminology
C108579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108579>	C107687	Barber County, KS|Barber County|Barber County, Kansas|KS007				Geographic Area	US Counties Terminology
C10857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10857>	C61063	Dexamethasone/Vincristine|DM/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108580>	C107687	Barton County, KS|Barton County|Barton County, Kansas|KS009				Geographic Area	US Counties Terminology
C108581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108581>	C107687	Bourbon County, KS|Bourbon County|Bourbon County, Kansas|KS011				Geographic Area	US Counties Terminology
C108582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108582>	C107687	Brown County, KS|Brown County|Brown County, Kansas|KS013				Geographic Area	US Counties Terminology
C108583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108583>	C107687	Butler County, KS|Butler County|Butler County, Kansas|KS015				Geographic Area	US Counties Terminology
C108584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108584>	C107687	Chase County, KS|Chase County|Chase County, Kansas|KS017				Geographic Area	US Counties Terminology
C108585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108585>	C107687	Chautauqua County, KS|Chautauqua County|Chautauqua County, Kansas|KS019				Geographic Area	US Counties Terminology
C108586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108586>	C107687	Cherokee County, KS|Cherokee County|Cherokee County, Kansas|KS021				Geographic Area	US Counties Terminology
C108587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108587>	C107687	Cheyenne County, KS|Cheyenne County|Cheyenne County, Kansas|KS023				Geographic Area	US Counties Terminology
C108588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108588>	C107687	Clark County, KS|Clark County|Clark County, Kansas|KS025				Geographic Area	US Counties Terminology
C108589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108589>	C107687	Clay County, KS|Clay County|Clay County, Kansas|KS027				Geographic Area	US Counties Terminology
C10858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10858>	C61063	Etoposide/Interleukin-1-Alpha|IL-1A/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108590>	C107687	Cloud County, KS|Cloud County|Cloud County, Kansas|KS029				Geographic Area	US Counties Terminology
C108591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108591>	C107687	Coffey County, KS|Coffey County|Coffey County, Kansas|KS031				Geographic Area	US Counties Terminology
C108592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108592>	C107687	Comanche County, KS|Comanche County|Comanche County, Kansas|KS033				Geographic Area	US Counties Terminology
C108593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108593>	C107687	Cowley County, KS|Cowley County|Cowley County, Kansas|KS035				Geographic Area	US Counties Terminology
C108594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108594>	C107687	Crawford County, KS|Crawford County|Crawford County, Kansas|KS037				Geographic Area	US Counties Terminology
C108595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108595>	C107687	Decatur County, KS|Decatur County|Decatur County, Kansas|KS039				Geographic Area	US Counties Terminology
C108596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108596>	C107687	Dickinson County, KS|Dickinson County|Dickinson County, Kansas|KS041				Geographic Area	US Counties Terminology
C108597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108597>	C107687	Doniphan County, KS|Doniphan County|Doniphan County, Kansas|KS043				Geographic Area	US Counties Terminology
C108598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108598>	C107687	Douglas County, KS|Douglas County|Douglas County, Kansas|KS045				Geographic Area	US Counties Terminology
C108599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108599>	C107687	Edwards County, KS|Edwards County|Edwards County, Kansas|KS047				Geographic Area	US Counties Terminology
C10859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10859>	C61063	Carboplatin/Etoposide/Tamoxifen|CBDCA/TMX/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1085>	C470|C1456	Staphylococcal Enterotoxin C|SEC|SEC|STAPHYLOCOCCAL ENTEROTOXIN C	Staphylococcal enterotoxin C.  A superantigen and member of a family of genetically related proteins produced by Staphylococcus aureus and Streptococcus pyogenes.  An extremely potent activator of T lymphocytes when presented on MHC class II antigens.			Amino Acid, Peptide, or Protein|Immunologic Factor	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C108600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108600>	C107687	Elk County, KS|Elk County|Elk County, Kansas|KS049				Geographic Area	US Counties Terminology
C108601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108601>	C107687	Ellis County, KS|Ellis County|Ellis County, Kansas|KS051				Geographic Area	US Counties Terminology
C108602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108602>	C107687	Ellsworth County, KS|Ellsworth County|Ellsworth County, Kansas|KS053				Geographic Area	US Counties Terminology
C108603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108603>	C107687	Finney County, KS|Finney County|Finney County, Kansas|KS055				Geographic Area	US Counties Terminology
C108604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108604>	C107687	Ford County, KS|Ford County|Ford County, Kansas|KS057				Geographic Area	US Counties Terminology
C108605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108605>	C107687	Franklin County, KS|Franklin County|Franklin County, Kansas|KS059				Geographic Area	US Counties Terminology
C108606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108606>	C107687	Geary County, KS|Geary County|Geary County, Kansas|KS061				Geographic Area	US Counties Terminology
C108607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108607>	C107687	Gove County, KS|Gove County|Gove County, Kansas|KS063				Geographic Area	US Counties Terminology
C108608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108608>	C107687	Graham County, KS|Graham County|Graham County, Kansas|KS065				Geographic Area	US Counties Terminology
C108609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108609>	C107687	Grant County, KS|Grant County|Grant County, Kansas|KS067				Geographic Area	US Counties Terminology
C10860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10860>	C61063	Cisplatin/Ifosfamide/Paclitaxel|CDDP/IFF/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108610>	C107687	Gray County, KS|Gray County|Gray County, Kansas|KS069				Geographic Area	US Counties Terminology
C108611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108611>	C107687	Greeley County, KS|Greeley County|Greeley County, Kansas|KS071				Geographic Area	US Counties Terminology
C108612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108612>	C107687	Greenwood County, KS|Greenwood County|Greenwood County, Kansas|KS073				Geographic Area	US Counties Terminology
C108613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108613>	C107687	Hamilton County, KS|Hamilton County|Hamilton County, Kansas|KS075				Geographic Area	US Counties Terminology
C108614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108614>	C107687	Harper County, KS|Harper County|Harper County, Kansas|KS077				Geographic Area	US Counties Terminology
C108615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108615>	C107687	Harvey County, KS|Harvey County|Harvey County, Kansas|KS079				Geographic Area	US Counties Terminology
C108616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108616>	C107687	Haskell County, KS|Haskell County|Haskell County, Kansas|KS081				Geographic Area	US Counties Terminology
C108617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108617>	C107687	Hodgeman County, KS|Hodgeman County|Hodgeman County, Kansas|KS083				Geographic Area	US Counties Terminology
C108618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108618>	C107687	Jackson County, KS|Jackson County|Jackson County, Kansas|KS085				Geographic Area	US Counties Terminology
C108619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108619>	C107687	Jefferson County, KS|Jefferson County|Jefferson County, Kansas|KS087				Geographic Area	US Counties Terminology
C10861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10861>	C61007	Cyclophosphamide/Doxorubicin/Etoposide/Prednisone|CTX/DOX/PRED/VP-16|PACE	A combination of agents containing cyclophosphamide, doxorubicin, etoposide and prednisone.		Obsolete_Concept	Therapeutic or Preventive Procedure	
C108620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108620>	C107687	Jewell County, KS|Jewell County|Jewell County, Kansas|KS089				Geographic Area	US Counties Terminology
C108621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108621>	C107687	Johnson County, KS|Johnson County|Johnson County, Kansas|KS091				Geographic Area	US Counties Terminology
C108622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108622>	C107687	Kearny County, KS|KS093|Kearny County|Kearny County, Kansas				Geographic Area	US Counties Terminology
C108623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108623>	C107687	Kingman County, KS|KS095|Kingman County|Kingman County, Kansas				Geographic Area	US Counties Terminology
C108624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108624>	C107687	Kiowa County, KS|KS097|Kiowa County|Kiowa County, Kansas				Geographic Area	US Counties Terminology
C108625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108625>	C107687	Labette County, KS|KS099|Labette County|Labette County, Kansas				Geographic Area	US Counties Terminology
C108626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108626>	C107687	Lane County, KS|KS101|Lane County|Lane County, Kansas				Geographic Area	US Counties Terminology
C108627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108627>	C107687	Leavenworth County, KS|KS103|Leavenworth County|Leavenworth County, Kansas				Geographic Area	US Counties Terminology
C108628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108628>	C107687	Lincoln County, KS|KS105|Lincoln County|Lincoln County, Kansas				Geographic Area	US Counties Terminology
C108629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108629>	C107687	Linn County, KS|KS107|Linn County|Linn County, Kansas				Geographic Area	US Counties Terminology
C10862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10862>	C61063	Cytarabine/Homoharringtonine|ARA-C/HH			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108630>	C107687	Logan County, KS|KS109|Logan County|Logan County, Kansas				Geographic Area	US Counties Terminology
C108631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108631>	C107687	Lyon County, KS|KS111|Lyon County|Lyon County, Kansas				Geographic Area	US Counties Terminology
C108632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108632>	C107687	McPherson County, KS|KS113|McPherson County|McPherson County, Kansas				Geographic Area	US Counties Terminology
C108633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108633>	C107687	Marion County, KS|KS115|Marion County|Marion County, Kansas				Geographic Area	US Counties Terminology
C108634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108634>	C107687	Marshall County, KS|KS117|Marshall County|Marshall County, Kansas				Geographic Area	US Counties Terminology
C108635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108635>	C107687	Meade County, KS|KS119|Meade County|Meade County, Kansas				Geographic Area	US Counties Terminology
C108636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108636>	C107687	Miami County, KS|KS121|Miami County|Miami County, Kansas				Geographic Area	US Counties Terminology
C108637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108637>	C107687	Mitchell County, KS|KS123|Mitchell County|Mitchell County, Kansas				Geographic Area	US Counties Terminology
C108638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108638>	C107687	Montgomery County, KS|KS125|Montgomery County|Montgomery County, Kansas				Geographic Area	US Counties Terminology
C108639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108639>	C107687	Morris County, KS|KS127|Morris County|Morris County, Kansas				Geographic Area	US Counties Terminology
C10863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10863>	C61063	Cytarabine/Mitoxantrone/Sargramostim|ARA-C/DHAD/GM-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108640>	C107687	Morton County, KS|KS129|Morton County|Morton County, Kansas				Geographic Area	US Counties Terminology
C108641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108641>	C107687	Nemaha County, KS|KS131|Nemaha County|Nemaha County, Kansas				Geographic Area	US Counties Terminology
C108642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108642>	C107687	Neosho County, KS|KS133|Neosho County|Neosho County, Kansas				Geographic Area	US Counties Terminology
C108643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108643>	C107687	Ness County, KS|KS135|Ness County|Ness County, Kansas				Geographic Area	US Counties Terminology
C108644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108644>	C107687	Norton County, KS|KS137|Norton County|Norton County, Kansas				Geographic Area	US Counties Terminology
C108645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108645>	C107687	Osage County, KS|KS139|Osage County|Osage County, Kansas				Geographic Area	US Counties Terminology
C108646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108646>	C107687	Osborne County, KS|KS141|Osborne County|Osborne County, Kansas				Geographic Area	US Counties Terminology
C108647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108647>	C107687	Ottawa County, KS|KS143|Ottawa County|Ottawa County, Kansas				Geographic Area	US Counties Terminology
C108648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108648>	C107687	Pawnee County, KS|KS145|Pawnee County|Pawnee County, Kansas				Geographic Area	US Counties Terminology
C108649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108649>	C107687	Phillips County, KS|KS147|Phillips County|Phillips County, Kansas				Geographic Area	US Counties Terminology
C10864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10864>	C61063	Cytarabine/Idarubicin/Sargramostim|ARA-C/GM-CSF/IDA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108650>	C107687	Pottawatomie County, KS|KS149|Pottawatomie County|Pottawatomie County, Kansas				Geographic Area	US Counties Terminology
C108651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108651>	C107687	Pratt County, KS|KS151|Pratt County|Pratt County, Kansas				Geographic Area	US Counties Terminology
C108652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108652>	C107687	Rawlins County, KS|KS153|Rawlins County|Rawlins County, Kansas				Geographic Area	US Counties Terminology
C108653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108653>	C107687	Reno County, KS|KS155|Reno County|Reno County, Kansas				Geographic Area	US Counties Terminology
C108654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108654>	C107687	Republic County, KS|KS157|Republic County|Republic County, Kansas				Geographic Area	US Counties Terminology
C108655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108655>	C107687	Rice County, KS|KS159|Rice County|Rice County, Kansas				Geographic Area	US Counties Terminology
C108656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108656>	C107687	Riley County, KS|KS161|Riley County|Riley County, Kansas				Geographic Area	US Counties Terminology
C108657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108657>	C107687	Rooks County, KS|KS163|Rooks County|Rooks County, Kansas				Geographic Area	US Counties Terminology
C108658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108658>	C107687	Rush County, KS|KS165|Rush County|Rush County, Kansas				Geographic Area	US Counties Terminology
C108659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108659>	C107687	Russell County, KS|KS167|Russell County|Russell County, Kansas				Geographic Area	US Counties Terminology
C10865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10865>	C61063	Aminocamptothecin/Filgrastim|9-AC/G-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108660>	C107687	Saline County, KS|KS169|Saline County|Saline County, Kansas				Geographic Area	US Counties Terminology
C108661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108661>	C107687	Scott County, KS|KS171|Scott County|Scott County, Kansas				Geographic Area	US Counties Terminology
C108662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108662>	C107687	Sedgwick County, KS|KS173|Sedgwick County|Sedgwick County, Kansas				Geographic Area	US Counties Terminology
C108663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108663>	C107687	Seward County, KS|KS175|Seward County|Seward County, Kansas				Geographic Area	US Counties Terminology
C108664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108664>	C107687	Shawnee County, KS|KS177|Shawnee County|Shawnee County, Kansas				Geographic Area	US Counties Terminology
C108665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108665>	C107687	Sheridan County, KS|KS179|Sheridan County|Sheridan County, Kansas				Geographic Area	US Counties Terminology
C108666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108666>	C107687	Sherman County, KS|KS181|Sherman County|Sherman County, Kansas				Geographic Area	US Counties Terminology
C108667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108667>	C107687	Smith County, KS|KS183|Smith County|Smith County, Kansas				Geographic Area	US Counties Terminology
C108668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108668>	C107687	Stafford County, KS|KS185|Stafford County|Stafford County, Kansas				Geographic Area	US Counties Terminology
C108669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108669>	C107687	Stanton County, KS|KS187|Stanton County|Stanton County, Kansas				Geographic Area	US Counties Terminology
C10866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10866>	C61063	Bleomycin/Doxorubicin/Etoposide/Prednisolone/Vincristine|BLEO/DOX/PRDL/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108670>	C107687	Stevens County, KS|KS189|Stevens County|Stevens County, Kansas				Geographic Area	US Counties Terminology
C108671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108671>	C107687	Sumner County, KS|KS191|Sumner County|Sumner County, Kansas				Geographic Area	US Counties Terminology
C108672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108672>	C107687	Thomas County, KS|KS193|Thomas County|Thomas County, Kansas				Geographic Area	US Counties Terminology
C108673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108673>	C107687	Trego County, KS|KS195|Trego County|Trego County, Kansas				Geographic Area	US Counties Terminology
C108674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108674>	C107687	Wabaunsee County, KS|KS197|Wabaunsee County|Wabaunsee County, Kansas				Geographic Area	US Counties Terminology
C108675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108675>	C107687	Wallace County, KS|KS199|Wallace County|Wallace County, Kansas				Geographic Area	US Counties Terminology
C108676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108676>	C107687	Washington County, KS|KS201|Washington County|Washington County, Kansas				Geographic Area	US Counties Terminology
C108677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108677>	C107687	Wichita County, KS|KS203|Wichita County|Wichita County, Kansas				Geographic Area	US Counties Terminology
C108678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108678>	C107687	Wilson County, KS|KS205|Wilson County|Wilson County, Kansas				Geographic Area	US Counties Terminology
C108679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108679>	C107687	Woodson County, KS|KS207|Woodson County|Woodson County, Kansas				Geographic Area	US Counties Terminology
C10867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10867>	C61007	Chlorambucil/Prednisolone/Procarbazine/Vinblastine|CLB/PCB/PRDL/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108680>	C107687	Wyandotte County, KS|KS209|Wyandotte County|Wyandotte County, Kansas				Geographic Area	US Counties Terminology
C108681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108681>	C107687	Adair County, KY|Adair County|Adair County, Kentucky|KY001				Geographic Area	US Counties Terminology
C108682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108682>	C107687	Allen County, KY|Allen County|Allen County, Kentucky|KY003				Geographic Area	US Counties Terminology
C108683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108683>	C107687	Anderson County, KY|Anderson County|Anderson County, Kentucky|KY005				Geographic Area	US Counties Terminology
C108684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108684>	C107687	Ballard County, KY|Ballard County|Ballard County, Kentucky|KY007				Geographic Area	US Counties Terminology
C108685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108685>	C107687	Barren County, KY|Barren County|Barren County, Kentucky|KY009				Geographic Area	US Counties Terminology
C108686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108686>	C107687	Bath County, KY|Bath County|Bath County, Kentucky|KY011				Geographic Area	US Counties Terminology
C108687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108687>	C107687	Bell County, KY|Bell County|Bell County, Kentucky|KY013				Geographic Area	US Counties Terminology
C108688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108688>	C107687	Boone County, KY|Boone County|Boone County, Kentucky|KY015				Geographic Area	US Counties Terminology
C108689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108689>	C107687	Bourbon County, KY|Bourbon County|Bourbon County, Kentucky|KY017				Geographic Area	US Counties Terminology
C10868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10868>	C61007	Cisplatin/Cyclophosphamide/Etoposide/Filgrastim|CDDP/CTX/G-CSF/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108690>	C107687	Boyd County, KY|Boyd County|Boyd County, Kentucky|KY019				Geographic Area	US Counties Terminology
C108691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108691>	C107687	Boyle County, KY|Boyle County|Boyle County, Kentucky|KY021				Geographic Area	US Counties Terminology
C108692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108692>	C107687	Bracken County, KY|Bracken County|Bracken County, Kentucky|KY023				Geographic Area	US Counties Terminology
C108693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108693>	C107687	Breathitt County, KY|Breathitt County|Breathitt County, Kentucky|KY025				Geographic Area	US Counties Terminology
C108694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108694>	C107687	Breckinridge County, KY|Breckinridge County|Breckinridge County, Kentucky|KY027				Geographic Area	US Counties Terminology
C108695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108695>	C107687	Bullitt County, KY|Bullitt County|Bullitt County, Kentucky|KY029				Geographic Area	US Counties Terminology
C108696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108696>	C107687	Butler County, KY|Butler County|Butler County, Kentucky|KY031				Geographic Area	US Counties Terminology
C108697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108697>	C107687	Caldwell County, KY|Caldwell County|Caldwell County, Kentucky|KY033				Geographic Area	US Counties Terminology
C108698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108698>	C107687	Calloway County, KY|Calloway County|Calloway County, Kentucky|KY035				Geographic Area	US Counties Terminology
C108699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108699>	C107687	Campbell County, KY|Campbell County|Campbell County, Kentucky|KY037				Geographic Area	US Counties Terminology
C10869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10869>	C61063	Cisplatin/Cytarabine/Idarubicin/Methylprednisolone|ARA-C/CDDP/IDA/MePRDL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1086>	C1456	Toxic Shock Syndrome Toxin-1|TSST-1	Staphylococcal toxic shock syndrome toxin 1.  A superantigen with the potential to suppress plasma cell differentiation and antibody responsiveness. Potent pyrogen, induces T lymphocyte proliferation, requiring interleukin 1 release from macrophages, suppresses immunoglobulin production, enhances endotoxin shock, and enhances hypersensitivity skin reactions. Causes staphylococcal toxic shock syndrome (TSS).			Amino Acid, Peptide, or Protein|Immunologic Factor	
C108700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108700>	C107687	Carlisle County, KY|Carlisle County|Carlisle County, Kentucky|KY039				Geographic Area	US Counties Terminology
C108701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108701>	C107687	Carroll County, KY|Carroll County|Carroll County, Kentucky|KY041				Geographic Area	US Counties Terminology
C108702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108702>	C107687	Carter County, KY|Carter County|Carter County, Kentucky|KY043				Geographic Area	US Counties Terminology
C108703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108703>	C107687	Casey County, KY|Casey County|Casey County, Kentucky|KY045				Geographic Area	US Counties Terminology
C108704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108704>	C107687	Christian County, KY|Christian County|Christian County, Kentucky|KY047				Geographic Area	US Counties Terminology
C108705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108705>	C107687	Clark County, KY|Clark County|Clark County, Kentucky|KY049				Geographic Area	US Counties Terminology
C108706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108706>	C107687	Clay County, KY|Clay County|Clay County, Kentucky|KY051				Geographic Area	US Counties Terminology
C108707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108707>	C107687	Clinton County, KY|Clinton County|Clinton County, Kentucky|KY053				Geographic Area	US Counties Terminology
C108708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108708>	C107687	Crittenden County, KY|Crittenden County|Crittenden County, Kentucky|KY055				Geographic Area	US Counties Terminology
C108709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108709>	C107687	Cumberland County, KY|Cumberland County|Cumberland County, Kentucky|KY057				Geographic Area	US Counties Terminology
C10870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10870>	C61063	Bleomycin/Idarubicin/Methylprednisolone/Vincristine|BLEO/CTX/IDA/MePRDL/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108710>	C107687	Daviess County, KY|Daviess County|Daviess County, Kentucky|KY059				Geographic Area	US Counties Terminology
C108711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108711>	C107687	Edmonson County, KY|Edmonson County|Edmonson County, Kentucky|KY061				Geographic Area	US Counties Terminology
C108712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108712>	C107687	Elliott County, KY|Elliott County|Elliott County, Kentucky|KY063				Geographic Area	US Counties Terminology
C108713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108713>	C107687	Estill County, KY|Estill County|Estill County, Kentucky|KY065				Geographic Area	US Counties Terminology
C108714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108714>	C107687	Fayette County, KY|Fayette County|Fayette County, Kentucky|KY067				Geographic Area	US Counties Terminology
C108715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108715>	C107687	Fleming County, KY|Fleming County|Fleming County, Kentucky|KY069				Geographic Area	US Counties Terminology
C108716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108716>	C107687	Floyd County, KY|Floyd County|Floyd County, Kentucky|KY071				Geographic Area	US Counties Terminology
C108717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108717>	C107687	Franklin County, KY|Franklin County|Franklin County, Kentucky|KY073				Geographic Area	US Counties Terminology
C108718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108718>	C107687	Fulton County, KY|Fulton County|Fulton County, Kentucky|KY075				Geographic Area	US Counties Terminology
C108719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108719>	C107687	Gallatin County, KY|Gallatin County|Gallatin County, Kentucky|KY077				Geographic Area	US Counties Terminology
C10871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10871>	C61063	Filgrastim/Interleukin-6|G-CSF/IL-6			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108720>	C107687	Garrard County, KY|Garrard County|Garrard County, Kentucky|KY079				Geographic Area	US Counties Terminology
C108721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108721>	C107687	Grant County, KY|Grant County|Grant County, Kentucky|KY081				Geographic Area	US Counties Terminology
C108722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108722>	C107687	Graves County, KY|Graves County|Graves County, Kentucky|KY083				Geographic Area	US Counties Terminology
C108723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108723>	C107687	Grayson County, KY|Grayson County|Grayson County, Kentucky|KY085				Geographic Area	US Counties Terminology
C108724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108724>	C107687	Green County, KY|Green County|Green County, Kentucky|KY087				Geographic Area	US Counties Terminology
C108725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108725>	C107687	Greenup County, KY|Greenup County|Greenup County, Kentucky|KY089				Geographic Area	US Counties Terminology
C108726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108726>	C107687	Hancock County, KY|Hancock County|Hancock County, Kentucky|KY091				Geographic Area	US Counties Terminology
C108727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108727>	C107687	Hardin County, KY|Hardin County|Hardin County, Kentucky|KY093				Geographic Area	US Counties Terminology
C108728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108728>	C107687	Harlan County, KY|Harlan County|Harlan County, Kentucky|KY095				Geographic Area	US Counties Terminology
C108729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108729>	C107687	Harrison County, KY|Harrison County|Harrison County, Kentucky|KY097				Geographic Area	US Counties Terminology
C10872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10872>	C61063	Carboplatin/Etoposide/Filgrastim/Ifosfamide/Interleukin-6|CBDCA/G-CSF/IFF/IL-6/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108730>	C107687	Hart County, KY|Hart County|Hart County, Kentucky|KY099				Geographic Area	US Counties Terminology
C108731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108731>	C107687	Henderson County, KY|Henderson County|Henderson County, Kentucky|KY101				Geographic Area	US Counties Terminology
C108732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108732>	C107687	Henry County, KY|Henry County|Henry County, Kentucky|KY103				Geographic Area	US Counties Terminology
C108733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108733>	C107687	Hickman County, KY|Hickman County|Hickman County, Kentucky|KY105				Geographic Area	US Counties Terminology
C108734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108734>	C107687	Hopkins County, KY|Hopkins County|Hopkins County, Kentucky|KY107				Geographic Area	US Counties Terminology
C108735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108735>	C107687	Jackson County, KY|Jackson County|Jackson County, Kentucky|KY109				Geographic Area	US Counties Terminology
C108736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108736>	C107687	Jefferson County, KY|Jefferson County|Jefferson County, Kentucky|KY111				Geographic Area	US Counties Terminology
C108737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108737>	C107687	Jessamine County, KY|Jessamine County|Jessamine County, Kentucky|KY113				Geographic Area	US Counties Terminology
C108738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108738>	C107687	Johnson County, KY|Johnson County|Johnson County, Kentucky|KY115				Geographic Area	US Counties Terminology
C108739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108739>	C107687	Kenton County, KY|KY117|Kenton County|Kenton County, Kentucky				Geographic Area	US Counties Terminology
C10873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10873>	C61063	Cyclophosphamide/Topotecan/Vincristine|CTX/TOPO/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108740>	C107687	Knott County, KY|KY119|Knott County|Knott County, Kentucky				Geographic Area	US Counties Terminology
C108741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108741>	C107687	Knox County, KY|KY121|Knox County|Knox County, Kentucky				Geographic Area	US Counties Terminology
C108742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108742>	C107687	Larue County, KY|KY123|Larue County|Larue County, Kentucky				Geographic Area	US Counties Terminology
C108743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108743>	C107687	Laurel County, KY|KY125|Laurel County|Laurel County, Kentucky				Geographic Area	US Counties Terminology
C108744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108744>	C107687	Lawrence County, KY|KY127|Lawrence County|Lawrence County, Kentucky				Geographic Area	US Counties Terminology
C108745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108745>	C107687	Lee County, KY|KY129|Lee County|Lee County, Kentucky				Geographic Area	US Counties Terminology
C108746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108746>	C107687	Leslie County, KY|KY131|Leslie County|Leslie County, Kentucky				Geographic Area	US Counties Terminology
C108747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108747>	C107687	Letcher County, KY|KY133|Letcher County|Letcher County, Kentucky				Geographic Area	US Counties Terminology
C108748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108748>	C107687	Lewis County, KY|KY135|Lewis County|Lewis County, Kentucky				Geographic Area	US Counties Terminology
C108749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108749>	C107687	Lincoln County, KY|KY137|Lincoln County|Lincoln County, Kentucky				Geographic Area	US Counties Terminology
C10874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10874>	C61063	Dacarbazine/Doxorubicin/Filgrastim/Ifosfamide|DOX/DTIC/G-CSF/IFF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108750>	C107687	Livingston County, KY|KY139|Livingston County|Livingston County, Kentucky				Geographic Area	US Counties Terminology
C108751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108751>	C107687	Logan County, KY|KY141|Logan County|Logan County, Kentucky				Geographic Area	US Counties Terminology
C108752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108752>	C107687	Lyon County, KY|KY143|Lyon County|Lyon County, Kentucky				Geographic Area	US Counties Terminology
C108753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108753>	C107687	McCracken County, KY|KY145|McCracken County|McCracken County, Kentucky				Geographic Area	US Counties Terminology
C108754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108754>	C107687	McCreary County, KY|KY147|McCreary County|McCreary County, Kentucky				Geographic Area	US Counties Terminology
C108755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108755>	C107687	McLean County, KY|KY149|McLean County|McLean County, Kentucky				Geographic Area	US Counties Terminology
C108756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108756>	C107687	Madison County, KY|KY151|Madison County|Madison County, Kentucky				Geographic Area	US Counties Terminology
C108757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108757>	C107687	Magoffin County, KY|KY153|Magoffin County|Magoffin County, Kentucky				Geographic Area	US Counties Terminology
C108758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108758>	C107687	Marion County, KY|KY155|Marion County|Marion County, Kentucky				Geographic Area	US Counties Terminology
C108759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108759>	C107687	Marshall County, KY|KY157|Marshall County|Marshall County, Kentucky				Geographic Area	US Counties Terminology
C10875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10875>	C61063	Carboplatin/Pentoxifylline|CBDCA/PTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108760>	C107687	Martin County, KY|KY159|Martin County|Martin County, Kentucky				Geographic Area	US Counties Terminology
C108761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108761>	C107687	Mason County, KY|KY161|Mason County|Mason County, Kentucky				Geographic Area	US Counties Terminology
C108762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108762>	C107687	Meade County, KY|KY163|Meade County|Meade County, Kentucky				Geographic Area	US Counties Terminology
C108763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108763>	C107687	Menifee County, KY|KY165|Menifee County|Menifee County, Kentucky				Geographic Area	US Counties Terminology
C108764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108764>	C107687	Mercer County, KY|KY167|Mercer County|Mercer County, Kentucky				Geographic Area	US Counties Terminology
C108765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108765>	C107687	Metcalfe County, KY|KY169|Metcalfe County|Metcalfe County, Kentucky				Geographic Area	US Counties Terminology
C108766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108766>	C107687	Monroe County, KY|KY171|Monroe County|Monroe County, Kentucky				Geographic Area	US Counties Terminology
C108767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108767>	C107687	Montgomery County, KY|KY173|Montgomery County|Montgomery County, Kentucky				Geographic Area	US Counties Terminology
C108768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108768>	C107687	Morgan County, KY|KY175|Morgan County|Morgan County, Kentucky				Geographic Area	US Counties Terminology
C108769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108769>	C107687	Muhlenberg County, KY|KY177|Muhlenberg County|Muhlenberg County, Kentucky				Geographic Area	US Counties Terminology
C10876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10876>	C61063	Bleomycin/Cisplatin/Etoposide/Mitomycin|BLEO/CDDP/MITO/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108770>	C107687	Nelson County, KY|KY179|Nelson County|Nelson County, Kentucky				Geographic Area	US Counties Terminology
C108771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108771>	C107687	Nicholas County, KY|KY181|Nicholas County|Nicholas County, Kentucky				Geographic Area	US Counties Terminology
C108772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108772>	C107687	Ohio County, KY|KY183|Ohio County|Ohio County, Kentucky				Geographic Area	US Counties Terminology
C108773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108773>	C107687	Oldham County, KY|KY185|Oldham County|Oldham County, Kentucky				Geographic Area	US Counties Terminology
C108774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108774>	C107687	Owen County, KY|KY187|Owen County|Owen County, Kentucky				Geographic Area	US Counties Terminology
C108775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108775>	C107687	Owsley County, KY|KY189|Owsley County|Owsley County, Kentucky				Geographic Area	US Counties Terminology
C108776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108776>	C107687	Pendleton County, KY|KY191|Pendleton County|Pendleton County, Kentucky				Geographic Area	US Counties Terminology
C108777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108777>	C107687	Perry County, KY|KY193|Perry County|Perry County, Kentucky				Geographic Area	US Counties Terminology
C108778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108778>	C107687	Pike County, KY|KY195|Pike County|Pike County, Kentucky				Geographic Area	US Counties Terminology
C108779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108779>	C107687	Powell County, KY|KY197|Powell County|Powell County, Kentucky				Geographic Area	US Counties Terminology
C10877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10877>	C61063	Mitoxantrone/Paclitaxel|DHAD/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108780>	C107687	Pulaski County, KY|KY199|Pulaski County|Pulaski County, Kentucky				Geographic Area	US Counties Terminology
C108781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108781>	C107687	Robertson County, KY|KY201|Robertson County|Robertson County, Kentucky				Geographic Area	US Counties Terminology
C108782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108782>	C107687	Rockcastle County, KY|KY203|Rockcastle County|Rockcastle County, Kentucky				Geographic Area	US Counties Terminology
C108783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108783>	C107687	Rowan County, KY|KY205|Rowan County|Rowan County, Kentucky				Geographic Area	US Counties Terminology
C108784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108784>	C107687	Russell County, KY|KY207|Russell County|Russell County, Kentucky				Geographic Area	US Counties Terminology
C108785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108785>	C107687	Scott County, KY|KY209|Scott County|Scott County, Kentucky				Geographic Area	US Counties Terminology
C108786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108786>	C107687	Shelby County, KY|KY211|Shelby County|Shelby County, Kentucky				Geographic Area	US Counties Terminology
C108787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108787>	C107687	Simpson County, KY|KY213|Simpson County|Simpson County, Kentucky				Geographic Area	US Counties Terminology
C108788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108788>	C107687	Spencer County, KY|KY215|Spencer County|Spencer County, Kentucky				Geographic Area	US Counties Terminology
C108789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108789>	C107687	Taylor County, KY|KY217|Taylor County|Taylor County, Kentucky				Geographic Area	US Counties Terminology
C10878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10878>	C61063	Cisplatin/Tumor Necrosis Factor|CDDP/TNF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108790>	C107687	Todd County, KY|KY219|Todd County|Todd County, Kentucky				Geographic Area	US Counties Terminology
C108791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108791>	C107687	Trigg County, KY|KY221|Trigg County|Trigg County, Kentucky				Geographic Area	US Counties Terminology
C108792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108792>	C107687	Trimble County, KY|KY223|Trimble County|Trimble County, Kentucky				Geographic Area	US Counties Terminology
C108793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108793>	C107687	Union County, KY|KY225|Union County|Union County, Kentucky				Geographic Area	US Counties Terminology
C108794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108794>	C107687	Warren County, KY|KY227|Warren County|Warren County, Kentucky				Geographic Area	US Counties Terminology
C108795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108795>	C107687	Washington County, KY|KY229|Washington County|Washington County, Kentucky				Geographic Area	US Counties Terminology
C108796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108796>	C107687	Wayne County, KY|KY231|Wayne County|Wayne County, Kentucky				Geographic Area	US Counties Terminology
C108797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108797>	C107687	Webster County, KY|KY233|Webster County|Webster County, Kentucky				Geographic Area	US Counties Terminology
C108798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108798>	C107687	Whitley County, KY|KY235|Whitley County|Whitley County, Kentucky				Geographic Area	US Counties Terminology
C108799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108799>	C107687	Wolfe County, KY|KY237|Wolfe County|Wolfe County, Kentucky				Geographic Area	US Counties Terminology
C10879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10879>	C140180	Busulfan/Cyclophosphamide/Thiotepa Regimen|BU/CTX/TSPA|Bu/TT/Cy|Busulfan-Cyclophosphamide-Thiotepa Regimen|Busulfan/Cyclophosphamide/Thiotepa|Cyclophosphamide/ Busulfan/Thiotepa|Cyclophosphamide/Thiotepa/Busulfan|TBC|TBC Regimen|Thiotepa/Busulfan/Cyclophosphamide|Thiotepa/Cyclophosphamide/Busulfan	A regimen consisting of busulfan, cyclophosphamide and thiotepa that may be used for the treatment of central nervous system (CNS) cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology
C1087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1087>	C663	Apaziquone|3-hydroxymethyl-5-aziridinyl-1-methyl-2-(1H-indole-4,7-dione) prop-beta-en-alpha-ol|APAZIQUONE|E O9|EO9|Eoquin|Neoquin|Qapzola	An indolequinone bioreductive prodrug and analog of mitomycin C with potential antineoplastic and radiosensitization activities. Apaziquone is converted to active metabolites in hypoxic cells by intracellular reductases, which are present in greater amounts in hypoxic tumor cells. The active metabolites alkylate DNA, resulting in apoptotic cell death. This agent displays selectivity activity towards both hypoxic solid tumors, which exhibits higher expression of cytochrome P450 reductase, and well-oxygenated malignant cells that overexpress the bioreductive enzyme NQO1 (NAD(P)H: quinone oxidoreductase). Apaziquone may selectively sensitize hypoxic tumor cells to radiocytotoxicity.	Apaziquone		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C108800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108800>	C107687	Woodford County, KY|KY239|Woodford County|Woodford County, Kentucky				Geographic Area	US Counties Terminology
C108801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108801>	C107687	Acadia Parish, LA|Acadia Parish|Acadia Parish, Louisiana|LA001				Geographic Area	US Counties Terminology
C108802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108802>	C107687	Allen Parish, LA|Allen Parish|Allen Parish, Louisiana|LA003				Geographic Area	US Counties Terminology
C108803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108803>	C107687	Ascension Parish, LA|Ascension Parish|Ascension Parish, Louisiana|LA005				Geographic Area	US Counties Terminology
C108804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108804>	C107687	Assumption Parish, LA|Assumption Parish|Assumption Parish, Louisiana|LA007				Geographic Area	US Counties Terminology
C108805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108805>	C107687	Avoyelles Parish, LA|Avoyelles Parish|Avoyelles Parish, Louisiana|LA009				Geographic Area	US Counties Terminology
C108806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108806>	C107687	Beauregard Parish, LA|Beauregard Parish|Beauregard Parish, Louisiana|LA011				Geographic Area	US Counties Terminology
C108807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108807>	C107687	Bienville Parish, LA|Bienville Parish|Bienville Parish, Louisiana|LA013				Geographic Area	US Counties Terminology
C108808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108808>	C107687	Bossier Parish, LA|Bossier Parish|Bossier Parish, Louisiana|LA015				Geographic Area	US Counties Terminology
C108809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108809>	C107687	Caddo Parish, LA|Caddo Parish|Caddo Parish, Louisiana|LA017				Geographic Area	US Counties Terminology
C10880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10880>	C61007	Cytarabine/Filgrastim/Idarubicin/Interleukin-6|ARA-C/G-CSF/IDA/IL-6			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108810>	C107687	Calcasieu Parish, LA|Calcasieu Parish|Calcasieu Parish, Louisiana|LA019				Geographic Area	US Counties Terminology
C108811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108811>	C107687	Caldwell Parish, LA|Caldwell Parish|Caldwell Parish, Louisiana|LA021				Geographic Area	US Counties Terminology
C108812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108812>	C107687	Cameron Parish, LA|Cameron Parish|Cameron Parish, Louisiana|LA023				Geographic Area	US Counties Terminology
C108813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108813>	C107687	Catahoula Parish, LA|Catahoula Parish|Catahoula Parish, Louisiana|LA025				Geographic Area	US Counties Terminology
C108814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108814>	C107687	Claiborne Parish, LA|Claiborne Parish|Claiborne Parish, Louisiana|LA027				Geographic Area	US Counties Terminology
C108815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108815>	C107687	Concordia Parish, LA|Concordia Parish|Concordia Parish, Louisiana|LA029				Geographic Area	US Counties Terminology
C108816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108816>	C107687	De Soto Parish, LA|De Soto Parish|De Soto Parish, Louisiana|LA031				Geographic Area	US Counties Terminology
C108817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108817>	C107687	East Baton Rouge Parish, LA|East Baton Rouge Parish|East Baton Rouge Parish, Louisiana|LA033				Geographic Area	US Counties Terminology
C108818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108818>	C107687	East Carroll Parish, LA|East Carroll Parish|East Carroll Parish, Louisiana|LA035				Geographic Area	US Counties Terminology
C108819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108819>	C107687	East Feliciana Parish, LA|East Feliciana Parish|East Feliciana Parish, Louisiana|LA037				Geographic Area	US Counties Terminology
C10881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10881>	C61063	Cytarabine/Etoposide/Filgrastim/Interleukin-6/Mitoxantrone|ARA-C/DHAD/G-CSF/IL-6/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108820>	C107687	Evangeline Parish, LA|Evangeline Parish|Evangeline Parish, Louisiana|LA039				Geographic Area	US Counties Terminology
C108821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108821>	C107687	Franklin Parish, LA|Franklin Parish|Franklin Parish, Louisiana|LA041				Geographic Area	US Counties Terminology
C108822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108822>	C107687	Grant Parish, LA|Grant Parish|Grant Parish, Louisiana|LA043				Geographic Area	US Counties Terminology
C108823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108823>	C107687	Iberia Parish, LA|Iberia Parish|Iberia Parish, Louisiana|LA045				Geographic Area	US Counties Terminology
C108824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108824>	C107687	Iberville Parish, LA|Iberville Parish|Iberville Parish, Louisiana|LA047				Geographic Area	US Counties Terminology
C108825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108825>	C107687	Jackson Parish, LA|Jackson Parish|Jackson Parish, Louisiana|LA049				Geographic Area	US Counties Terminology
C108826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108826>	C107687	Jefferson Parish, LA|Jefferson Parish|Jefferson Parish, Louisiana|LA051				Geographic Area	US Counties Terminology
C108827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108827>	C107687	Jefferson Davis Parish, LA|Jefferson Davis Parish|Jefferson Davis Parish, Louisiana|LA053				Geographic Area	US Counties Terminology
C108828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108828>	C107687	Lafayette Parish, LA|LA055|Lafayette Parish|Lafayette Parish, Louisiana				Geographic Area	US Counties Terminology
C108829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108829>	C107687	Lafourche Parish, LA|LA057|Lafourche Parish|Lafourche Parish, Louisiana				Geographic Area	US Counties Terminology
C10882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10882>	C61063	Cyclophosphamide/Filgrastim/Interleukin-6|CTX/G-CSF/IL-6			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108830>	C107687	La Salle Parish, LA|LA059|La Salle Parish|La Salle Parish, Louisiana				Geographic Area	US Counties Terminology
C108831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108831>	C107687	Lincoln Parish, LA|LA061|Lincoln Parish|Lincoln Parish, Louisiana				Geographic Area	US Counties Terminology
C108832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108832>	C107687	Livingston Parish, LA|LA063|Livingston Parish|Livingston Parish, Louisiana				Geographic Area	US Counties Terminology
C108833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108833>	C107687	Madison Parish, LA|LA065|Madison Parish|Madison Parish, Louisiana				Geographic Area	US Counties Terminology
C108834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108834>	C107687	Morehouse Parish, LA|LA067|Morehouse Parish|Morehouse Parish, Louisiana				Geographic Area	US Counties Terminology
C108835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108835>	C107687	Natchitoches Parish, LA|LA069|Natchitoches Parish|Natchitoches Parish, Louisiana				Geographic Area	US Counties Terminology
C108836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108836>	C107687	Orleans Parish, LA|LA071|Orleans Parish|Orleans Parish, Louisiana				Geographic Area	US Counties Terminology
C108837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108837>	C107687	Ouachita Parish, LA|LA073|Ouachita Parish|Ouachita Parish, Louisiana				Geographic Area	US Counties Terminology
C108838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108838>	C107687	Plaquemines Parish, LA|LA075|Plaquemines Parish|Plaquemines Parish, Louisiana				Geographic Area	US Counties Terminology
C108839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108839>	C107687	Pointe Coupee Parish, LA|LA077|Pointe Coupee Parish|Pointe Coupee Parish, Louisiana				Geographic Area	US Counties Terminology
C10883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10883>	C61007	Carboplatin/Etoposide/Filgrastim/Ifosfamide/Paclitaxel|CBDCA/G-CSF/IFF/TAX/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108840>	C107687	Rapides Parish, LA|LA079|Rapides Parish|Rapides Parish, Louisiana				Geographic Area	US Counties Terminology
C108841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108841>	C107687	Red River Parish, LA|LA081|Red River Parish|Red River Parish, Louisiana				Geographic Area	US Counties Terminology
C108842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108842>	C107687	Richland Parish, LA|LA083|Richland Parish|Richland Parish, Louisiana				Geographic Area	US Counties Terminology
C108843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108843>	C107687	Sabine Parish, LA|LA085|Sabine Parish|Sabine Parish, Louisiana				Geographic Area	US Counties Terminology
C108844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108844>	C107687	St. Bernard Parish, LA|LA087|St. Bernard Parish|St. Bernard Parish, Louisiana				Geographic Area	US Counties Terminology
C108845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108845>	C107687	St. Charles Parish, LA|LA089|St. Charles Parish|St. Charles Parish, Louisiana				Geographic Area	US Counties Terminology
C108846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108846>	C107687	St. Helena Parish, LA|LA091|St. Helena Parish|St. Helena Parish, Louisiana				Geographic Area	US Counties Terminology
C108847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108847>	C107687	St. James Parish, LA|LA093|St. James Parish|St. James Parish, Louisiana				Geographic Area	US Counties Terminology
C108848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108848>	C107687	St. John the Baptist Parish, LA|LA095|St. John the Baptist Parish|St. John the Baptist Parish, Louisiana				Geographic Area	US Counties Terminology
C108849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108849>	C107687	St. Landry Parish, LA|LA097|St. Landry Parish|St. Landry Parish, Louisiana				Geographic Area	US Counties Terminology
C10884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10884>	C61063	Carboplatin/Etoposide/Ifosfamide/Paclitaxel|CBDCA/IFF/TAX/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108850>	C107687	St. Martin Parish, LA|LA099|St. Martin Parish|St. Martin Parish, Louisiana				Geographic Area	US Counties Terminology
C108851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108851>	C107687	St. Mary Parish, LA|LA101|St. Mary Parish|St. Mary Parish, Louisiana				Geographic Area	US Counties Terminology
C108852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108852>	C107687	St. Tammany Parish, LA|LA103|St. Tammany Parish|St. Tammany Parish, Louisiana				Geographic Area	US Counties Terminology
C108853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108853>	C107687	Tangipahoa Parish, LA|LA105|Tangipahoa Parish|Tangipahoa Parish, Louisiana				Geographic Area	US Counties Terminology
C108854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108854>	C107687	Tensas Parish, LA|LA107|Tensas Parish|Tensas Parish, Louisiana				Geographic Area	US Counties Terminology
C108855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108855>	C107687	Terrebonne Parish, LA|LA109|Terrebonne Parish|Terrebonne Parish, Louisiana				Geographic Area	US Counties Terminology
C108856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108856>	C107687	Union Parish, LA|LA111|Union Parish|Union Parish, Louisiana				Geographic Area	US Counties Terminology
C108857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108857>	C107687	Vermilion Parish, LA|LA113|Vermilion Parish|Vermilion Parish, Louisiana				Geographic Area	US Counties Terminology
C108858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108858>	C107687	Vernon Parish, LA|LA115|Vernon Parish|Vernon Parish, Louisiana				Geographic Area	US Counties Terminology
C108859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108859>	C107687	Washington Parish, LA|LA117|Washington Parish|Washington Parish, Louisiana				Geographic Area	US Counties Terminology
C10885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10885>	C61063	Melphalan/Paclitaxel|L-PAM/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108860>	C107687	Webster Parish, LA|LA119|Webster Parish|Webster Parish, Louisiana				Geographic Area	US Counties Terminology
C108861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108861>	C107687	West Baton Rouge Parish, LA|LA121|West Baton Rouge Parish|West Baton Rouge Parish, Louisiana				Geographic Area	US Counties Terminology
C108862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108862>	C107687	West Carroll Parish, LA|LA123|West Carroll Parish|West Carroll Parish, Louisiana				Geographic Area	US Counties Terminology
C108863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108863>	C107687	West Feliciana Parish, LA|LA125|West Feliciana Parish|West Feliciana Parish, Louisiana				Geographic Area	US Counties Terminology
C108864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108864>	C107687	Winn Parish, LA|LA127|Winn Parish|Winn Parish, Louisiana				Geographic Area	US Counties Terminology
C108865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108865>	C107687	Androscoggin County, ME|Androscoggin County|Androscoggin County, Maine|ME001				Geographic Area	US Counties Terminology
C108866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108866>	C107687	Aroostook County, ME|Aroostook County|Aroostook County, Maine|ME003				Geographic Area	US Counties Terminology
C108867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108867>	C107687	Cumberland County, ME|Cumberland County|Cumberland County, Maine|ME005				Geographic Area	US Counties Terminology
C108868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108868>	C107687	Franklin County, ME|Franklin County|Franklin County, Maine|ME007				Geographic Area	US Counties Terminology
C108869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108869>	C107687	Hancock County, ME|Hancock County|Hancock County, Maine|ME009				Geographic Area	US Counties Terminology
C10886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10886>	C61063	Cyclophosphamide/Mitoxantrone/Prednisolone/Vincristine|CTX/DHAD/PRDL/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108870>	C107687	Kennebec County, ME|Kennebec County|Kennebec County, Maine|ME011				Geographic Area	US Counties Terminology
C108871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108871>	C107687	Knox County, ME|Knox County|Knox County, Maine|ME013				Geographic Area	US Counties Terminology
C108872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108872>	C107687	Lincoln County, ME|Lincoln County|Lincoln County, Maine|ME015				Geographic Area	US Counties Terminology
C108873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108873>	C107687	Oxford County, ME|ME017|Oxford County|Oxford County, Maine				Geographic Area	US Counties Terminology
C108874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108874>	C107687	Penobscot County, ME|ME019|Penobscot County|Penobscot County, Maine				Geographic Area	US Counties Terminology
C108875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108875>	C107687	Piscataquis County, ME|ME021|Piscataquis County|Piscataquis County, Maine				Geographic Area	US Counties Terminology
C108876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108876>	C107687	Sagadahoc County, ME|ME023|Sagadahoc County|Sagadahoc County, Maine				Geographic Area	US Counties Terminology
C108877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108877>	C107687	Somerset County, ME|ME025|Somerset County|Somerset County, Maine				Geographic Area	US Counties Terminology
C108878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108878>	C107687	Waldo County, ME|ME027|Waldo County|Waldo County, Maine				Geographic Area	US Counties Terminology
C108879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108879>	C107687	Washington County, ME|ME029|Washington County|Washington County, Maine				Geographic Area	US Counties Terminology
C10887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10887>	C61063	Carboplatin/Cyclosporine/Paclitaxel|CBDCA/CYSP/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108880>	C107687	York County, ME|ME031|York County|York County, Maine				Geographic Area	US Counties Terminology
C108881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108881>	C107687	Allegany County, MD|Allegany County|Allegany County, Maryland|MD001				Geographic Area	US Counties Terminology
C108882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108882>	C107687	Anne Arundel County, MD|Anne Arundel County|Anne Arundel County, Maryland|MD003				Geographic Area	US Counties Terminology
C108883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108883>	C107687	Baltimore County, MD|Baltimore County|Baltimore County, Maryland|MD005				Geographic Area	US Counties Terminology
C108884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108884>	C107687	Calvert County, MD|Calvert County|Calvert County, Maryland|MD009				Geographic Area	US Counties Terminology
C108885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108885>	C107687	Caroline County, MD|Caroline County|Caroline County, Maryland|MD011				Geographic Area	US Counties Terminology
C108886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108886>	C107687	Carroll County, MD|Carroll County|Carroll County, Maryland|MD013				Geographic Area	US Counties Terminology
C108887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108887>	C107687	Cecil County, MD|Cecil County|Cecil County, Maryland|MD015				Geographic Area	US Counties Terminology
C108888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108888>	C107687	Charles County, MD|Charles County|Charles County, Maryland|MD017				Geographic Area	US Counties Terminology
C108889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108889>	C107687	Dorchester County, MD|Dorchester County|Dorchester County, Maryland|MD019				Geographic Area	US Counties Terminology
C10888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10888>	C61063	Cisplatin/Filgrastim/Topotecan|CDDP/G-CSF/TOPO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108890>	C107687	Frederick County, MD|Frederick County|Frederick County, Maryland|MD021				Geographic Area	US Counties Terminology
C108891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108891>	C107687	Garrett County, MD|Garrett County|Garrett County, Maryland|MD023				Geographic Area	US Counties Terminology
C108892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108892>	C107687	Harford County, MD|Harford County|Harford County, Maryland|MD025				Geographic Area	US Counties Terminology
C108893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108893>	C107687	Howard County, MD|Howard County|Howard County, Maryland|MD027				Geographic Area	US Counties Terminology
C108894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108894>	C107687	Kent County, MD|Kent County|Kent County, Maryland|MD029				Geographic Area	US Counties Terminology
C108895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108895>	C107687	Montgomery County, MD|MD031|Montgomery County|Montgomery County, Maryland				Geographic Area	US Counties Terminology
C108896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108896>	C107687	Prince George's County, MD|MD033|Prince George's County|Prince George's County, Maryland				Geographic Area	US Counties Terminology
C108897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108897>	C107687	Queen Anne's County, MD|MD035|Queen Anne's County|Queen Anne's County, Maryland				Geographic Area	US Counties Terminology
C108898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108898>	C107687	St. Mary's County, MD|MD037|St. Mary's County|St. Mary's County, Maryland				Geographic Area	US Counties Terminology
C108899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108899>	C107687	Somerset County, MD|MD039|Somerset County|Somerset County, Maryland				Geographic Area	US Counties Terminology
C10889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10889>	C61063	Bleomycin/Cisplatin/Epoetin Alfa/Etoposide/Filgrastim/Ifosfamide/Vinblastine|BLEO/CDDP/EPO/G-CSF/IFF/VBL/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1088>	C68454	Epigallocatechin Gallate|(-)-Epigallocatechin-3-Gallate|(2R-cis)-3,4-Dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl 3,4,5-Trihydroxybenzoate|EGCG|EGCG|EPIGALLOCATECHIN GALLATE|Epigallocatechin-3-Gallate|Epigallocatechin-3-Gallate|Epigallocatechin-Gallate|Epigallocatechingallate|Tea catechin|[(2R,3R)-2-(3,4,5-trihydroxyphenyl)-5,7-dihydroxy-chroman-3-yl] 3,4,5-trihydroxybenzoate	A phenolic antioxidant found in a number of plants such as green and black tea. It inhibits cellular oxidation and prevents free radical damage to cells. It is under study as a potential cancer chemopreventive agent. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C108900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108900>	C107687	Talbot County, MD|MD041|Talbot County|Talbot County, Maryland				Geographic Area	US Counties Terminology
C108901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108901>	C107687	Washington County, MD|MD043|Washington County|Washington County, Maryland				Geographic Area	US Counties Terminology
C108902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108902>	C107687	Wicomico County, MD|MD045|Wicomico County|Wicomico County, Maryland				Geographic Area	US Counties Terminology
C108903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108903>	C107687	Worcester County, MD|MD047|Worcester County|Worcester County, Maryland				Geographic Area	US Counties Terminology
C108904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108904>	C107687	Baltimore City, MD|Baltimore City|Baltimore City, Maryland|MD510				Geographic Area	US Counties Terminology
C108905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108905>	C107687	Barnstable County, MA|Barnstable County|Barnstable County, Massachusetts|MA001				Geographic Area	US Counties Terminology
C108906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108906>	C107687	Berkshire County, MA|Berkshire County|Berkshire County, Massachusetts|MA003				Geographic Area	US Counties Terminology
C108907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108907>	C107687	Bristol County, MA|Bristol County|Bristol County, Massachusetts|MA005				Geographic Area	US Counties Terminology
C108908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108908>	C107687	Dukes County, MA|Dukes County|Dukes County, Massachusetts|MA007				Geographic Area	US Counties Terminology
C108909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108909>	C107687	Essex County, MA|Essex County|Essex County, Massachusetts|MA009				Geographic Area	US Counties Terminology
C10890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10890>	C61063	Cisplatin/Epoetin Alfa/Etoposide/Filgrastim/Ifosfamide|CDDP/EPO/G-CSF/IFF/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108910>	C107687	Franklin County, MA|Franklin County|Franklin County, Massachusetts|MA011				Geographic Area	US Counties Terminology
C108911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108911>	C107687	Hampden County, MA|Hampden County|Hampden County, Massachusetts|MA013				Geographic Area	US Counties Terminology
C108912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108912>	C107687	Hampshire County, MA|Hampshire County|Hampshire County, Massachusetts|MA015				Geographic Area	US Counties Terminology
C108913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108913>	C107687	Middlesex County, MA|MA017|Middlesex County|Middlesex County, Massachusetts				Geographic Area	US Counties Terminology
C108914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108914>	C107687	Nantucket County, MA|MA019|Nantucket County|Nantucket County, Massachusetts				Geographic Area	US Counties Terminology
C108915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108915>	C107687	Norfolk County, MA|MA021|Norfolk County|Norfolk County, Massachusetts				Geographic Area	US Counties Terminology
C108916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108916>	C107687	Plymouth County, MA|MA023|Plymouth County|Plymouth County, Massachusetts				Geographic Area	US Counties Terminology
C108917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108917>	C107687	Suffolk County, MA|MA025|Suffolk County|Suffolk County, Massachusetts				Geographic Area	US Counties Terminology
C108918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108918>	C107687	Worcester County, MA|MA027|Worcester County|Worcester County, Massachusetts				Geographic Area	US Counties Terminology
C108919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108919>	C107687	Alcona County, MI|Alcona County|Alcona County, Michigan|MI001				Geographic Area	US Counties Terminology
C10891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10891>	C61063	Carboplatin/Filgrastim/Interleukin-6/Paclitaxel|CBDCA/G-CSF/IL-6/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108920>	C107687	Alger County, MI|Alger County|Alger County, Michigan|MI003				Geographic Area	US Counties Terminology
C108921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108921>	C107687	Allegan County, MI|Allegan County|Allegan County, Michigan|MI005				Geographic Area	US Counties Terminology
C108922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108922>	C107687	Alpena County, MI|Alpena County|Alpena County, Michigan|MI007				Geographic Area	US Counties Terminology
C108923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108923>	C107687	Antrim County, MI|Antrim County|Antrim County, Michigan|MI009				Geographic Area	US Counties Terminology
C108924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108924>	C107687	Arenac County, MI|Arenac County|Arenac County, Michigan|MI011				Geographic Area	US Counties Terminology
C108925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108925>	C107687	Baraga County, MI|Baraga County|Baraga County, Michigan|MI013				Geographic Area	US Counties Terminology
C108926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108926>	C107687	Barry County, MI|Barry County|Barry County, Michigan|MI015				Geographic Area	US Counties Terminology
C108927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108927>	C107687	Bay County, MI|Bay County|Bay County, Michigan|MI017				Geographic Area	US Counties Terminology
C108928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108928>	C107687	Benzie County, MI|Benzie County|Benzie County, Michigan|MI019				Geographic Area	US Counties Terminology
C108929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108929>	C107687	Berrien County, MI|Berrien County|Berrien County, Michigan|MI021				Geographic Area	US Counties Terminology
C10892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10892>	C61063	Benznidazole/Lomustine|benznidazole/CCNU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108930>	C107687	Branch County, MI|Branch County|Branch County, Michigan|MI023				Geographic Area	US Counties Terminology
C108931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108931>	C107687	Calhoun County, MI|Calhoun County|Calhoun County, Michigan|MI025				Geographic Area	US Counties Terminology
C108932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108932>	C107687	Cass County, MI|Cass County|Cass County, Michigan|MI027				Geographic Area	US Counties Terminology
C108933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108933>	C107687	Charlevoix County, MI|Charlevoix County|Charlevoix County, Michigan|MI029				Geographic Area	US Counties Terminology
C108934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108934>	C107687	Cheboygan County, MI|Cheboygan County|Cheboygan County, Michigan|MI031				Geographic Area	US Counties Terminology
C108935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108935>	C107687	Chippewa County, MI|Chippewa County|Chippewa County, Michigan|MI033				Geographic Area	US Counties Terminology
C108936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108936>	C107687	Clare County, MI|Clare County|Clare County, Michigan|MI035				Geographic Area	US Counties Terminology
C108937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108937>	C107687	Clinton County, MI|Clinton County|Clinton County, Michigan|MI037				Geographic Area	US Counties Terminology
C108938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108938>	C107687	Crawford County, MI|Crawford County|Crawford County, Michigan|MI039				Geographic Area	US Counties Terminology
C108939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108939>	C107687	Delta County, MI|Delta County|Delta County, Michigan|MI041				Geographic Area	US Counties Terminology
C10893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10893>	C61063	Flutamide/Goserelin/Suramin|FLUT/SUR/ZDX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108940>	C107687	Dickinson County, MI|Dickinson County|Dickinson County, Michigan|MI043				Geographic Area	US Counties Terminology
C108941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108941>	C107687	Eaton County, MI|Eaton County|Eaton County, Michigan|MI045				Geographic Area	US Counties Terminology
C108942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108942>	C107687	Emmet County, MI|Emmet County|Emmet County, Michigan|MI047				Geographic Area	US Counties Terminology
C108943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108943>	C107687	Genesee County, MI|Genesee County|Genesee County, Michigan|MI049				Geographic Area	US Counties Terminology
C108944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108944>	C107687	Gladwin County, MI|Gladwin County|Gladwin County, Michigan|MI051				Geographic Area	US Counties Terminology
C108945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108945>	C107687	Gogebic County, MI|Gogebic County|Gogebic County, Michigan|MI053				Geographic Area	US Counties Terminology
C108946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108946>	C107687	Grand Traverse County, MI|Grand Traverse County|Grand Traverse County, Michigan|MI055				Geographic Area	US Counties Terminology
C108947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108947>	C107687	Gratiot County, MI|Gratiot County|Gratiot County, Michigan|MI057				Geographic Area	US Counties Terminology
C108948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108948>	C107687	Hillsdale County, MI|Hillsdale County|Hillsdale County, Michigan|MI059				Geographic Area	US Counties Terminology
C108949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108949>	C107687	Houghton County, MI|Houghton County|Houghton County, Michigan|MI061				Geographic Area	US Counties Terminology
C10894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10894>	C61007	Carboplatin/Etoposide/Vincristine|CBDCA/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108950>	C107687	Huron County, MI|Huron County|Huron County, Michigan|MI063				Geographic Area	US Counties Terminology
C108951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108951>	C107687	Ingham County, MI|Ingham County|Ingham County, Michigan|MI065				Geographic Area	US Counties Terminology
C108952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108952>	C107687	Ionia County, MI|Ionia County|Ionia County, Michigan|MI067				Geographic Area	US Counties Terminology
C108953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108953>	C107687	Iosco County, MI|Iosco County|Iosco County, Michigan|MI069				Geographic Area	US Counties Terminology
C108954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108954>	C107687	Iron County, MI|Iron County|Iron County, Michigan|MI071				Geographic Area	US Counties Terminology
C108955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108955>	C107687	Isabella County, MI|Isabella County|Isabella County, Michigan|MI073				Geographic Area	US Counties Terminology
C108956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108956>	C107687	Jackson County, MI|Jackson County|Jackson County, Michigan|MI075				Geographic Area	US Counties Terminology
C108957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108957>	C107687	Kalamazoo County, MI|Kalamazoo County|Kalamazoo County, Michigan|MI077				Geographic Area	US Counties Terminology
C108958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108958>	C107687	Kalkaska County, MI|Kalkaska County|Kalkaska County, Michigan|MI079				Geographic Area	US Counties Terminology
C108959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108959>	C107687	Kent County, MI|Kent County|Kent County, Michigan|MI081				Geographic Area	US Counties Terminology
C10895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10895>	C61063	Doxorubicin/Filgrastim/Ifosfamide|DOX/G-CSF/IFF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108960>	C107687	Keweenaw County, MI|Keweenaw County|Keweenaw County, Michigan|MI083				Geographic Area	US Counties Terminology
C108961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108961>	C107687	Lake County, MI|Lake County|Lake County, Michigan|MI085				Geographic Area	US Counties Terminology
C108962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108962>	C107687	Lapeer County, MI|Lapeer County|Lapeer County, Michigan|MI087				Geographic Area	US Counties Terminology
C108963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108963>	C107687	Leelanau County, MI|Leelanau County|Leelanau County, Michigan|MI089				Geographic Area	US Counties Terminology
C108964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108964>	C107687	Lenawee County, MI|Lenawee County|Lenawee County, Michigan|MI091				Geographic Area	US Counties Terminology
C108965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108965>	C107687	Livingston County, MI|Livingston County|Livingston County, Michigan|MI093				Geographic Area	US Counties Terminology
C108966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108966>	C107687	Luce County, MI|Luce County|Luce County, Michigan|MI095				Geographic Area	US Counties Terminology
C108967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108967>	C107687	Mackinac County, MI|MI097|Mackinac County|Mackinac County, Michigan				Geographic Area	US Counties Terminology
C108968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108968>	C107687	Macomb County, MI|MI099|Macomb County|Macomb County, Michigan				Geographic Area	US Counties Terminology
C108969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108969>	C107687	Manistee County, MI|MI101|Manistee County|Manistee County, Michigan				Geographic Area	US Counties Terminology
C10896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10896>	C61007	Goserelin/Tamoxifen|TMX/ZDX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108970>	C107687	Marquette County, MI|MI103|Marquette County|Marquette County, Michigan				Geographic Area	US Counties Terminology
C108971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108971>	C107687	Mason County, MI|MI105|Mason County|Mason County, Michigan				Geographic Area	US Counties Terminology
C108972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108972>	C107687	Mecosta County, MI|MI107|Mecosta County|Mecosta County, Michigan				Geographic Area	US Counties Terminology
C108973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108973>	C107687	Menominee County, MI|MI109|Menominee County|Menominee County, Michigan				Geographic Area	US Counties Terminology
C108974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108974>	C107687	Midland County, MI|MI111|Midland County|Midland County, Michigan				Geographic Area	US Counties Terminology
C108975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108975>	C107687	Missaukee County, MI|MI113|Missaukee County|Missaukee County, Michigan				Geographic Area	US Counties Terminology
C108976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108976>	C107687	Monroe County, MI|MI115|Monroe County|Monroe County, Michigan				Geographic Area	US Counties Terminology
C108977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108977>	C107687	Montcalm County, MI|MI117|Montcalm County|Montcalm County, Michigan				Geographic Area	US Counties Terminology
C108978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108978>	C107687	Montmorency County, MI|MI119|Montmorency County|Montmorency County, Michigan				Geographic Area	US Counties Terminology
C108979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108979>	C107687	Muskegon County, MI|MI121|Muskegon County|Muskegon County, Michigan				Geographic Area	US Counties Terminology
C10897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10897>	C63358	Leuprolide/Tamoxifen Regimen|LEUP/TMX|Leuprolide-Tamoxifen|Leuprolide-Tamoxifen Regimen|Leuprolide/Tamoxifen|Tamoxifen/Leuprolide	A regimen consisting of leuprolide and tamoxifen that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C108980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108980>	C107687	Newaygo County, MI|MI123|Newaygo County|Newaygo County, Michigan				Geographic Area	US Counties Terminology
C108981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108981>	C107687	Oakland County, MI|MI125|Oakland County|Oakland County, Michigan				Geographic Area	US Counties Terminology
C108982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108982>	C107687	Oceana County, MI|MI127|Oceana County|Oceana County, Michigan				Geographic Area	US Counties Terminology
C108983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108983>	C107687	Ogemaw County, MI|MI129|Ogemaw County|Ogemaw County, Michigan				Geographic Area	US Counties Terminology
C108984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108984>	C107687	Ontonagon County, MI|MI131|Ontonagon County|Ontonagon County, Michigan				Geographic Area	US Counties Terminology
C108985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108985>	C107687	Osceola County, MI|MI133|Osceola County|Osceola County, Michigan				Geographic Area	US Counties Terminology
C108986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108986>	C107687	Oscoda County, MI|MI135|Oscoda County|Oscoda County, Michigan				Geographic Area	US Counties Terminology
C108987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108987>	C107687	Otsego County, MI|MI137|Otsego County|Otsego County, Michigan				Geographic Area	US Counties Terminology
C108988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108988>	C107687	Ottawa County, MI|MI139|Ottawa County|Ottawa County, Michigan				Geographic Area	US Counties Terminology
C108989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108989>	C107687	Presque Isle County, MI|MI141|Presque Isle County|Presque Isle County, Michigan				Geographic Area	US Counties Terminology
C10898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10898>	C61063	Cyclophosphamide/Fluorouracil/Leuprolide/Methotrexate/Tamoxifen|CTX/5-FU/LEUP/MTX/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C108990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108990>	C107687	Roscommon County, MI|MI143|Roscommon County|Roscommon County, Michigan				Geographic Area	US Counties Terminology
C108991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108991>	C107687	Saginaw County, MI|MI145|Saginaw County|Saginaw County, Michigan				Geographic Area	US Counties Terminology
C108992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108992>	C107687	St. Clair County, MI|MI147|St. Clair County|St. Clair County, Michigan				Geographic Area	US Counties Terminology
C108993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108993>	C107687	St. Joseph County, MI|MI149|St. Joseph County|St. Joseph County, Michigan				Geographic Area	US Counties Terminology
C108994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108994>	C107687	Sanilac County, MI|MI151|Sanilac County|Sanilac County, Michigan				Geographic Area	US Counties Terminology
C108995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108995>	C107687	Schoolcraft County, MI|MI153|Schoolcraft County|Schoolcraft County, Michigan				Geographic Area	US Counties Terminology
C108996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108996>	C107687	Shiawassee County, MI|MI155|Shiawassee County|Shiawassee County, Michigan				Geographic Area	US Counties Terminology
C108997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108997>	C107687	Tuscola County, MI|MI157|Tuscola County|Tuscola County, Michigan				Geographic Area	US Counties Terminology
C108998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108998>	C107687	Van Buren County, MI|MI159|Van Buren County|Van Buren County, Michigan				Geographic Area	US Counties Terminology
C108999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C108999>	C107687	Washtenaw County, MI|MI161|Washtenaw County|Washtenaw County, Michigan				Geographic Area	US Counties Terminology
C10899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10899>	C61063	Cyclophosphamide/Fluorouracil/Goserelin/Methotrexate/Tamoxifen|CTX/5-FU/MTX/TMX/ZDX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1089>	C243|C2360	Epitiostanol|10275-S|EPITIOSTANOL	An androgenic anabolic steroid having potent anti-estrogenic effect, which inhibits the progression of estrogen-stimulated cancers such as breast cancer. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C109000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109000>	C107687	Wayne County, MI|MI163|Wayne County|Wayne County, Michigan				Geographic Area	US Counties Terminology
C109001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109001>	C107687	Wexford County, MI|MI165|Wexford County|Wexford County, Michigan				Geographic Area	US Counties Terminology
C109002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109002>	C107687	Aitkin County, MN|Aitkin County|Aitkin County, Minnesota|MN001				Geographic Area	US Counties Terminology
C109003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109003>	C107687	Anoka County, MN|Anoka County|Anoka County, Minnesota|MN003				Geographic Area	US Counties Terminology
C109004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109004>	C107687	Becker County, MN|Becker County|Becker County, Minnesota|MN005				Geographic Area	US Counties Terminology
C109005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109005>	C107687	Beltrami County, MN|Beltrami County|Beltrami County, Minnesota|MN007				Geographic Area	US Counties Terminology
C109006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109006>	C107687	Benton County, MN|Benton County|Benton County, Minnesota|MN009				Geographic Area	US Counties Terminology
C109007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109007>	C107687	Big Stone County, MN|Big Stone County|Big Stone County, Minnesota|MN011				Geographic Area	US Counties Terminology
C109008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109008>	C107687	Blue Earth County, MN|Blue Earth County|Blue Earth County, Minnesota|MN013				Geographic Area	US Counties Terminology
C109009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109009>	C107687	Brown County, MN|Brown County|Brown County, Minnesota|MN015				Geographic Area	US Counties Terminology
C10900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10900>	C61063	Cyclophosphamide/Doxorubicin/Leuprolide/Tamoxifen|CTX/DOX/LEUP/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109010>	C107687	Carlton County, MN|Carlton County|Carlton County, Minnesota|MN017				Geographic Area	US Counties Terminology
C109011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109011>	C107687	Carver County, MN|Carver County|Carver County, Minnesota|MN019				Geographic Area	US Counties Terminology
C109012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109012>	C107687	Cass County, MN|Cass County|Cass County, Minnesota|MN021				Geographic Area	US Counties Terminology
C109013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109013>	C107687	Chippewa County, MN|Chippewa County|Chippewa County, Minnesota|MN023				Geographic Area	US Counties Terminology
C109014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109014>	C107687	Chisago County, MN|Chisago County|Chisago County, Minnesota|MN025				Geographic Area	US Counties Terminology
C109015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109015>	C107687	Clay County, MN|Clay County|Clay County, Minnesota|MN027				Geographic Area	US Counties Terminology
C109016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109016>	C107687	Clearwater County, MN|Clearwater County|Clearwater County, Minnesota|MN029				Geographic Area	US Counties Terminology
C109017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109017>	C107687	Cook County, MN|Cook County|Cook County, Minnesota|MN031				Geographic Area	US Counties Terminology
C109018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109018>	C107687	Cottonwood County, MN|Cottonwood County|Cottonwood County, Minnesota|MN033				Geographic Area	US Counties Terminology
C109019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109019>	C107687	Crow Wing County, MN|Crow Wing County|Crow Wing County, Minnesota|MN035				Geographic Area	US Counties Terminology
C10901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10901>	C61063	Cyclophosphamide/Doxorubicin/Goserelin/Tamoxifen|CTX/DOX/TMX/ZDX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109020>	C107687	Dakota County, MN|Dakota County|Dakota County, Minnesota|MN037				Geographic Area	US Counties Terminology
C109021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109021>	C107687	Dodge County, MN|Dodge County|Dodge County, Minnesota|MN039				Geographic Area	US Counties Terminology
C109022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109022>	C107687	Douglas County, MN|Douglas County|Douglas County, Minnesota|MN041				Geographic Area	US Counties Terminology
C109023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109023>	C107687	Faribault County, MN|Faribault County|Faribault County, Minnesota|MN043				Geographic Area	US Counties Terminology
C109024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109024>	C107687	Fillmore County, MN|Fillmore County|Fillmore County, Minnesota|MN045				Geographic Area	US Counties Terminology
C109025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109025>	C107687	Freeborn County, MN|Freeborn County|Freeborn County, Minnesota|MN047				Geographic Area	US Counties Terminology
C109026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109026>	C107687	Goodhue County, MN|Goodhue County|Goodhue County, Minnesota|MN049				Geographic Area	US Counties Terminology
C109027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109027>	C107687	Grant County, MN|Grant County|Grant County, Minnesota|MN051				Geographic Area	US Counties Terminology
C109028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109028>	C107687	Hennepin County, MN|Hennepin County|Hennepin County, Minnesota|MN053				Geographic Area	US Counties Terminology
C109029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109029>	C107687	Houston County, MN|Houston County|Houston County, Minnesota|MN055				Geographic Area	US Counties Terminology
C10902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10902>	C61063	Asparaginase/Cytarabine/Etoposide/Methotrexate/Prednisone/Thioguanine/Vincristine|ARA-C/ASP/MTX/PRED/TG/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109030>	C107687	Hubbard County, MN|Hubbard County|Hubbard County, Minnesota|MN057				Geographic Area	US Counties Terminology
C109031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109031>	C107687	Isanti County, MN|Isanti County|Isanti County, Minnesota|MN059				Geographic Area	US Counties Terminology
C109032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109032>	C107687	Itasca County, MN|Itasca County|Itasca County, Minnesota|MN061				Geographic Area	US Counties Terminology
C109033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109033>	C107687	Jackson County, MN|Jackson County|Jackson County, Minnesota|MN063				Geographic Area	US Counties Terminology
C109034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109034>	C107687	Kanabec County, MN|Kanabec County|Kanabec County, Minnesota|MN065				Geographic Area	US Counties Terminology
C109035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109035>	C107687	Kandiyohi County, MN|Kandiyohi County|Kandiyohi County, Minnesota|MN067				Geographic Area	US Counties Terminology
C109036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109036>	C107687	Kittson County, MN|Kittson County|Kittson County, Minnesota|MN069				Geographic Area	US Counties Terminology
C109037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109037>	C107687	Koochiching County, MN|Koochiching County|Koochiching County, Minnesota|MN071				Geographic Area	US Counties Terminology
C109038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109038>	C107687	Lac qui Parle County, MN|Lac qui Parle County|Lac qui Parle County, Minnesota|MN073				Geographic Area	US Counties Terminology
C109039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109039>	C107687	Lake County, MN|Lake County|Lake County, Minnesota|MN075				Geographic Area	US Counties Terminology
C10903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10903>	C61063	Altretamine/Etoposide|HMM/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109040>	C107687	Lake of the Woods County, MN|Lake of the Woods County|Lake of the Woods County, Minnesota|MN077				Geographic Area	US Counties Terminology
C109041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109041>	C107687	Le Sueur County, MN|Le Sueur County|Le Sueur County, Minnesota|MN079				Geographic Area	US Counties Terminology
C109042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109042>	C107687	Lincoln County, MN|Lincoln County|Lincoln County, Minnesota|MN081				Geographic Area	US Counties Terminology
C109043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109043>	C107687	Lyon County, MN|Lyon County|Lyon County, Minnesota|MN083				Geographic Area	US Counties Terminology
C109044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109044>	C107687	McLeod County, MN|MN085|McLeod County|McLeod County, Minnesota				Geographic Area	US Counties Terminology
C109045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109045>	C107687	Mahnomen County, MN|MN087|Mahnomen County|Mahnomen County, Minnesota				Geographic Area	US Counties Terminology
C109046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109046>	C107687	Marshall County, MN|MN089|Marshall County|Marshall County, Minnesota				Geographic Area	US Counties Terminology
C109047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109047>	C107687	Martin County, MN|MN091|Martin County|Martin County, Minnesota				Geographic Area	US Counties Terminology
C109048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109048>	C107687	Meeker County, MN|MN093|Meeker County|Meeker County, Minnesota				Geographic Area	US Counties Terminology
C109049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109049>	C107687	Mille Lacs County, MN|MN095|Mille Lacs County|Mille Lacs County, Minnesota				Geographic Area	US Counties Terminology
C10904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10904>	C61063	Dexamethasone/Dexniguldipine/Doxorubicin/Prednisone/Vincristine|DM/DNIG/DOX/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109050>	C107687	Morrison County, MN|MN097|Morrison County|Morrison County, Minnesota				Geographic Area	US Counties Terminology
C109051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109051>	C107687	Mower County, MN|MN099|Mower County|Mower County, Minnesota				Geographic Area	US Counties Terminology
C109052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109052>	C107687	Murray County, MN|MN101|Murray County|Murray County, Minnesota				Geographic Area	US Counties Terminology
C109053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109053>	C107687	Nicollet County, MN|MN103|Nicollet County|Nicollet County, Minnesota				Geographic Area	US Counties Terminology
C109054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109054>	C107687	Nobles County, MN|MN105|Nobles County|Nobles County, Minnesota				Geographic Area	US Counties Terminology
C109055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109055>	C107687	Norman County, MN|MN107|Norman County|Norman County, Minnesota				Geographic Area	US Counties Terminology
C109056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109056>	C107687	Olmsted County, MN|MN109|Olmsted County|Olmsted County, Minnesota				Geographic Area	US Counties Terminology
C109057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109057>	C107687	Otter Tail County, MN|MN111|Otter Tail County|Otter Tail County, Minnesota				Geographic Area	US Counties Terminology
C109058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109058>	C107687	Pennington County, MN|MN113|Pennington County|Pennington County, Minnesota				Geographic Area	US Counties Terminology
C109059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109059>	C107687	Pine County, MN|MN115|Pine County|Pine County, Minnesota				Geographic Area	US Counties Terminology
C10905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10905>	C61063	Dexamethasone/Dexniguldipine/Doxorubicin/Vincristine|DM/DNIG/DOX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109060>	C107687	Pipestone County, MN|MN117|Pipestone County|Pipestone County, Minnesota				Geographic Area	US Counties Terminology
C109061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109061>	C107687	Polk County, MN|MN119|Polk County|Polk County, Minnesota				Geographic Area	US Counties Terminology
C109062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109062>	C107687	Pope County, MN|MN121|Pope County|Pope County, Minnesota				Geographic Area	US Counties Terminology
C109063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109063>	C107687	Ramsey County, MN|MN123|Ramsey County|Ramsey County, Minnesota				Geographic Area	US Counties Terminology
C109064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109064>	C107687	Red Lake County, MN|MN125|Red Lake County|Red Lake County, Minnesota				Geographic Area	US Counties Terminology
C109065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109065>	C107687	Redwood County, MN|MN127|Redwood County|Redwood County, Minnesota				Geographic Area	US Counties Terminology
C109066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109066>	C107687	Renville County, MN|MN129|Renville County|Renville County, Minnesota				Geographic Area	US Counties Terminology
C109067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109067>	C107687	Rice County, MN|MN131|Rice County|Rice County, Minnesota				Geographic Area	US Counties Terminology
C109068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109068>	C107687	Rock County, MN|MN133|Rock County|Rock County, Minnesota				Geographic Area	US Counties Terminology
C109069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109069>	C107687	Roseau County, MN|MN135|Roseau County|Roseau County, Minnesota				Geographic Area	US Counties Terminology
C109070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109070>	C107687	St. Louis County, MN|MN137|St. Louis County|St. Louis County, Minnesota				Geographic Area	US Counties Terminology
C109071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109071>	C107687	Scott County, MN|MN139|Scott County|Scott County, Minnesota				Geographic Area	US Counties Terminology
C109072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109072>	C107687	Sherburne County, MN|MN141|Sherburne County|Sherburne County, Minnesota				Geographic Area	US Counties Terminology
C109073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109073>	C107687	Sibley County, MN|MN143|Sibley County|Sibley County, Minnesota				Geographic Area	US Counties Terminology
C109074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109074>	C107687	Stearns County, MN|MN145|Stearns County|Stearns County, Minnesota				Geographic Area	US Counties Terminology
C109075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109075>	C107687	Steele County, MN|MN147|Steele County|Steele County, Minnesota				Geographic Area	US Counties Terminology
C109076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109076>	C107687	Stevens County, MN|MN149|Stevens County|Stevens County, Minnesota				Geographic Area	US Counties Terminology
C109077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109077>	C107687	Swift County, MN|MN151|Swift County|Swift County, Minnesota				Geographic Area	US Counties Terminology
C109078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109078>	C107687	Todd County, MN|MN153|Todd County|Todd County, Minnesota				Geographic Area	US Counties Terminology
C109079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109079>	C107687	Traverse County, MN|MN155|Traverse County|Traverse County, Minnesota				Geographic Area	US Counties Terminology
C10907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10907>	C61063	Gallium Nitrate/Paclitaxel|GAN/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109080>	C107687	Wabasha County, MN|MN157|Wabasha County|Wabasha County, Minnesota				Geographic Area	US Counties Terminology
C109081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109081>	C107687	Wadena County, MN|MN159|Wadena County|Wadena County, Minnesota				Geographic Area	US Counties Terminology
C109082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109082>	C107687	Waseca County, MN|MN161|Waseca County|Waseca County, Minnesota				Geographic Area	US Counties Terminology
C109083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109083>	C107687	Washington County, MN|MN163|Washington County|Washington County, Minnesota				Geographic Area	US Counties Terminology
C109084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109084>	C107687	Watonwan County, MN|MN165|Watonwan County|Watonwan County, Minnesota				Geographic Area	US Counties Terminology
C109085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109085>	C107687	Wilkin County, MN|MN167|Wilkin County|Wilkin County, Minnesota				Geographic Area	US Counties Terminology
C109086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109086>	C107687	Winona County, MN|MN169|Winona County|Winona County, Minnesota				Geographic Area	US Counties Terminology
C109087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109087>	C107687	Wright County, MN|MN171|Wright County|Wright County, Minnesota				Geographic Area	US Counties Terminology
C109088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109088>	C107687	Yellow Medicine County, MN|MN173|Yellow Medicine County|Yellow Medicine County, Minnesota				Geographic Area	US Counties Terminology
C109089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109089>	C107687	Adams County, MS|Adams County|Adams County, Mississippi|MS001				Geographic Area	US Counties Terminology
C10908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10908>	C61063	Filgrastim/Gallium Nitrate/Paclitaxel|GAN/G-CSF/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109090>	C107687	Alcorn County, MS|Alcorn County|Alcorn County, Mississippi|MS003				Geographic Area	US Counties Terminology
C109091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109091>	C107687	Amite County, MS|Amite County|Amite County, Mississippi|MS005				Geographic Area	US Counties Terminology
C109092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109092>	C107687	Attala County, MS|Attala County|Attala County, Mississippi|MS007				Geographic Area	US Counties Terminology
C109093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109093>	C107687	Benton County, MS|Benton County|Benton County, Mississippi|MS009				Geographic Area	US Counties Terminology
C109094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109094>	C107687	Bolivar County, MS|Bolivar County|Bolivar County, Mississippi|MS011				Geographic Area	US Counties Terminology
C109095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109095>	C107687	Calhoun County, MS|Calhoun County|Calhoun County, Mississippi|MS013				Geographic Area	US Counties Terminology
C109096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109096>	C107687	Carroll County, MS|Carroll County|Carroll County, Mississippi|MS015				Geographic Area	US Counties Terminology
C109097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109097>	C107687	Chickasaw County, MS|Chickasaw County|Chickasaw County, Mississippi|MS017				Geographic Area	US Counties Terminology
C109098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109098>	C107687	Choctaw County, MS|Choctaw County|Choctaw County, Mississippi|MS019				Geographic Area	US Counties Terminology
C109099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109099>	C107687	Claiborne County, MS|Claiborne County|Claiborne County, Mississippi|MS021				Geographic Area	US Counties Terminology
C10909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10909>	C61063	Paclitaxel/Thiotepa|TAX/TSPA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1090>	C478	Estradiol Valerate|Delestrogen|ESTRADIOL VALERATE	The parenterally-administered synthetic valerate ester of estradiol, a steroid sex hormone vital to the maintenance of fertility and secondary sexual characteristics in females.  As the primary, most potent estrogen hormone produced by the ovaries, estradiol binds to and activates specific nuclear receptors.  This agent exhibits mild anabolic and metabolic properties, and increases blood coagulability. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C109100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109100>	C107687	Clarke County, MS|Clarke County|Clarke County, Mississippi|MS023				Geographic Area	US Counties Terminology
C109101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109101>	C107687	Clay County, MS|Clay County|Clay County, Mississippi|MS025				Geographic Area	US Counties Terminology
C109102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109102>	C107687	Coahoma County, MS|Coahoma County|Coahoma County, Mississippi|MS027				Geographic Area	US Counties Terminology
C109103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109103>	C107687	Copiah County, MS|Copiah County|Copiah County, Mississippi|MS029				Geographic Area	US Counties Terminology
C109104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109104>	C107687	Covington County, MS|Covington County|Covington County, Mississippi|MS031				Geographic Area	US Counties Terminology
C109105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109105>	C107687	DeSoto County, MS|DeSoto County|DeSoto County, Mississippi|MS033				Geographic Area	US Counties Terminology
C109106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109106>	C107687	Forrest County, MS|Forrest County|Forrest County, Mississippi|MS035				Geographic Area	US Counties Terminology
C109107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109107>	C107687	Franklin County, MS|Franklin County|Franklin County, Mississippi|MS037				Geographic Area	US Counties Terminology
C109108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109108>	C107687	George County, MS|George County|George County, Mississippi|MS039				Geographic Area	US Counties Terminology
C109109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109109>	C107687	Greene County, MS|Greene County|Greene County, Mississippi|MS041				Geographic Area	US Counties Terminology
C10910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10910>	C61007	Carmustine/O6-Benzylguanine|BCNU/BG			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109110>	C107687	Grenada County, MS|Grenada County|Grenada County, Mississippi|MS043				Geographic Area	US Counties Terminology
C109111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109111>	C107687	Hancock County, MS|Hancock County|Hancock County, Mississippi|MS045				Geographic Area	US Counties Terminology
C109112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109112>	C107687	Harrison County, MS|Harrison County|Harrison County, Mississippi|MS047				Geographic Area	US Counties Terminology
C109113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109113>	C107687	Hinds County, MS|Hinds County|Hinds County, Mississippi|MS049				Geographic Area	US Counties Terminology
C109114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109114>	C107687	Holmes County, MS|Holmes County|Holmes County, Mississippi|MS051				Geographic Area	US Counties Terminology
C109115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109115>	C107687	Humphreys County, MS|Humphreys County|Humphreys County, Mississippi|MS053				Geographic Area	US Counties Terminology
C109116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109116>	C107687	Issaquena County, MS|Issaquena County|Issaquena County, Mississippi|MS055				Geographic Area	US Counties Terminology
C109117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109117>	C107687	Itawamba County, MS|Itawamba County|Itawamba County, Mississippi|MS057				Geographic Area	US Counties Terminology
C109118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109118>	C107687	Jackson County, MS|Jackson County|Jackson County, Mississippi|MS059				Geographic Area	US Counties Terminology
C109119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109119>	C107687	Jasper County, MS|Jasper County|Jasper County, Mississippi|MS061				Geographic Area	US Counties Terminology
C10911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10911>	C61007	Cyclophosphamide/Didanosine/Doxorubicin/Etoposide|CTX/ddI/DOX/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109120>	C107687	Jefferson County, MS|Jefferson County|Jefferson County, Mississippi|MS063				Geographic Area	US Counties Terminology
C109121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109121>	C107687	Jefferson Davis County, MS|Jefferson Davis County|Jefferson Davis County, Mississippi|MS065				Geographic Area	US Counties Terminology
C109122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109122>	C107687	Jones County, MS|Jones County|Jones County, Mississippi|MS067				Geographic Area	US Counties Terminology
C109123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109123>	C107687	Kemper County, MS|Kemper County|Kemper County, Mississippi|MS069				Geographic Area	US Counties Terminology
C109124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109124>	C107687	Lafayette County, MS|Lafayette County|Lafayette County, Mississippi|MS071				Geographic Area	US Counties Terminology
C109125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109125>	C107687	Lamar County, MS|Lamar County|Lamar County, Mississippi|MS073				Geographic Area	US Counties Terminology
C109126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109126>	C107687	Lauderdale County, MS|Lauderdale County|Lauderdale County, Mississippi|MS075				Geographic Area	US Counties Terminology
C109127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109127>	C107687	Lawrence County, MS|Lawrence County|Lawrence County, Mississippi|MS077				Geographic Area	US Counties Terminology
C109128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109128>	C107687	Leake County, MS|Leake County|Leake County, Mississippi|MS079				Geographic Area	US Counties Terminology
C109129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109129>	C107687	Lee County, MS|Lee County|Lee County, Mississippi|MS081				Geographic Area	US Counties Terminology
C10912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10912>	C61007	Antineoplaston A10/Antineoplaston AS2-1|A10/AS2-1			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109130>	C107687	Leflore County, MS|Leflore County|Leflore County, Mississippi|MS083				Geographic Area	US Counties Terminology
C109131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109131>	C107687	Lincoln County, MS|Lincoln County|Lincoln County, Mississippi|MS085				Geographic Area	US Counties Terminology
C109132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109132>	C107687	Lowndes County, MS|Lowndes County|Lowndes County, Mississippi|MS087				Geographic Area	US Counties Terminology
C109133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109133>	C107687	Madison County, MS|MS089|Madison County|Madison County, Mississippi				Geographic Area	US Counties Terminology
C109134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109134>	C107687	Marion County, MS|MS091|Marion County|Marion County, Mississippi				Geographic Area	US Counties Terminology
C109135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109135>	C107687	Marshall County, MS|MS093|Marshall County|Marshall County, Mississippi				Geographic Area	US Counties Terminology
C109136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109136>	C107687	Monroe County, MS|MS095|Monroe County|Monroe County, Mississippi				Geographic Area	US Counties Terminology
C109137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109137>	C107687	Montgomery County, MS|MS097|Montgomery County|Montgomery County, Mississippi				Geographic Area	US Counties Terminology
C109138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109138>	C107687	Neshoba County, MS|MS099|Neshoba County|Neshoba County, Mississippi				Geographic Area	US Counties Terminology
C109139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109139>	C107687	Newton County, MS|MS101|Newton County|Newton County, Mississippi				Geographic Area	US Counties Terminology
C10913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10913>	C61063	Cisplatin/Cytarabine/Dexamethasone/Idarubicin|ARA-C/CDDP/DM/IDA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109140>	C107687	Noxubee County, MS|MS103|Noxubee County|Noxubee County, Mississippi				Geographic Area	US Counties Terminology
C109141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109141>	C107687	Oktibbeha County, MS|MS105|Oktibbeha County|Oktibbeha County, Mississippi				Geographic Area	US Counties Terminology
C109142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109142>	C107687	Panola County, MS|MS107|Panola County|Panola County, Mississippi				Geographic Area	US Counties Terminology
C109143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109143>	C107687	Pearl River County, MS|MS109|Pearl River County|Pearl River County, Mississippi				Geographic Area	US Counties Terminology
C109144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109144>	C107687	Perry County, MS|MS111|Perry County|Perry County, Mississippi				Geographic Area	US Counties Terminology
C109145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109145>	C107687	Pike County, MS|MS113|Pike County|Pike County, Mississippi				Geographic Area	US Counties Terminology
C109146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109146>	C107687	Pontotoc County, MS|MS115|Pontotoc County|Pontotoc County, Mississippi				Geographic Area	US Counties Terminology
C109147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109147>	C107687	Prentiss County, MS|MS117|Prentiss County|Prentiss County, Mississippi				Geographic Area	US Counties Terminology
C109148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109148>	C107687	Quitman County, MS|MS119|Quitman County|Quitman County, Mississippi				Geographic Area	US Counties Terminology
C109149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109149>	C107687	Rankin County, MS|MS121|Rankin County|Rankin County, Mississippi				Geographic Area	US Counties Terminology
C10914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10914>	C61063	Cisplatin/Cytarabine/Dexamethasone/Idarubicin/Methotrexate|ARA-C/CDDP/DM/IDA/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109150>	C107687	Scott County, MS|MS123|Scott County|Scott County, Mississippi				Geographic Area	US Counties Terminology
C109151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109151>	C107687	Sharkey County, MS|MS125|Sharkey County|Sharkey County, Mississippi				Geographic Area	US Counties Terminology
C109152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109152>	C107687	Simpson County, MS|MS127|Simpson County|Simpson County, Mississippi				Geographic Area	US Counties Terminology
C109153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109153>	C107687	Smith County, MS|MS129|Smith County|Smith County, Mississippi				Geographic Area	US Counties Terminology
C109154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109154>	C107687	Stone County, MS|MS131|Stone County|Stone County, Mississippi				Geographic Area	US Counties Terminology
C109155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109155>	C107687	Sunflower County, MS|MS133|Sunflower County|Sunflower County, Mississippi				Geographic Area	US Counties Terminology
C109156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109156>	C107687	Tallahatchie County, MS|MS135|Tallahatchie County|Tallahatchie County, Mississippi				Geographic Area	US Counties Terminology
C109157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109157>	C107687	Tate County, MS|MS137|Tate County|Tate County, Mississippi				Geographic Area	US Counties Terminology
C109158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109158>	C107687	Tippah County, MS|MS139|Tippah County|Tippah County, Mississippi				Geographic Area	US Counties Terminology
C109159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109159>	C107687	Tishomingo County, MS|MS141|Tishomingo County|Tishomingo County, Mississippi				Geographic Area	US Counties Terminology
C10915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10915>	C61063	Etoposide/Fluorouracil|5-FU/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109160>	C107687	Tunica County, MS|MS143|Tunica County|Tunica County, Mississippi				Geographic Area	US Counties Terminology
C109161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109161>	C107687	Union County, MS|MS145|Union County|Union County, Mississippi				Geographic Area	US Counties Terminology
C109162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109162>	C107687	Walthall County, MS|MS147|Walthall County|Walthall County, Mississippi				Geographic Area	US Counties Terminology
C109163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109163>	C107687	Warren County, MS|MS149|Warren County|Warren County, Mississippi				Geographic Area	US Counties Terminology
C109164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109164>	C107687	Washington County, MS|MS151|Washington County|Washington County, Mississippi				Geographic Area	US Counties Terminology
C109165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109165>	C107687	Wayne County, MS|MS153|Wayne County|Wayne County, Mississippi				Geographic Area	US Counties Terminology
C109166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109166>	C107687	Webster County, MS|MS155|Webster County|Webster County, Mississippi				Geographic Area	US Counties Terminology
C109167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109167>	C107687	Wilkinson County, MS|MS157|Wilkinson County|Wilkinson County, Mississippi				Geographic Area	US Counties Terminology
C109168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109168>	C107687	Winston County, MS|MS159|Winston County|Winston County, Mississippi				Geographic Area	US Counties Terminology
C109169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109169>	C107687	Yalobusha County, MS|MS161|Yalobusha County|Yalobusha County, Mississippi				Geographic Area	US Counties Terminology
C10916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10916>	C61063	Carboplatin/Milodistim/Paclitaxel|CBDCA/PIXY321/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109170>	C107687	Yazoo County, MS|MS163|Yazoo County|Yazoo County, Mississippi				Geographic Area	US Counties Terminology
C109171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109171>	C107687	Adair County, MO|Adair County|Adair County, Missouri|MO001				Geographic Area	US Counties Terminology
C109172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109172>	C107687	Andrew County, MO|Andrew County|Andrew County, Missouri|MO003				Geographic Area	US Counties Terminology
C109173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109173>	C107687	Atchison County, MO|Atchison County|Atchison County, Missouri|MO005				Geographic Area	US Counties Terminology
C109174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109174>	C107687	Audrain County, MO|Audrain County|Audrain County, Missouri|MO007				Geographic Area	US Counties Terminology
C109175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109175>	C107687	Barry County, MO|Barry County|Barry County, Missouri|MO009				Geographic Area	US Counties Terminology
C109176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109176>	C107687	Barton County, MO|Barton County|Barton County, Missouri|MO011				Geographic Area	US Counties Terminology
C109177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109177>	C107687	Bates County, MO|Bates County|Bates County, Missouri|MO013				Geographic Area	US Counties Terminology
C109178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109178>	C107687	Benton County, MO|Benton County|Benton County, Missouri|MO015				Geographic Area	US Counties Terminology
C109179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109179>	C107687	Bollinger County, MO|Bollinger County|Bollinger County, Missouri|MO017				Geographic Area	US Counties Terminology
C10917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10917>	C61063	Cisplatin/Dacarbazine/Interleukin-2/Vinblastine|CDDP/DTIC/IL-2/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109180>	C107687	Boone County, MO|Boone County|Boone County, Missouri|MO019				Geographic Area	US Counties Terminology
C109181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109181>	C107687	Buchanan County, MO|Buchanan County|Buchanan County, Missouri|MO021				Geographic Area	US Counties Terminology
C109182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109182>	C107687	Butler County, MO|Butler County|Butler County, Missouri|MO023				Geographic Area	US Counties Terminology
C109183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109183>	C107687	Caldwell County, MO|Caldwell County|Caldwell County, Missouri|MO025				Geographic Area	US Counties Terminology
C109184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109184>	C107687	Callaway County, MO|Callaway County|Callaway County, Missouri|MO027				Geographic Area	US Counties Terminology
C109185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109185>	C107687	Camden County, MO|Camden County|Camden County, Missouri|MO029				Geographic Area	US Counties Terminology
C109186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109186>	C107687	Cape Girardeau County, MO|Cape Girardeau County|Cape Girardeau County, Missouri|MO031				Geographic Area	US Counties Terminology
C109187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109187>	C107687	Carroll County, MO|Carroll County|Carroll County, Missouri|MO033				Geographic Area	US Counties Terminology
C109188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109188>	C107687	Carter County, MO|Carter County|Carter County, Missouri|MO035				Geographic Area	US Counties Terminology
C109189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109189>	C107687	Cass County, MO|Cass County|Cass County, Missouri|MO037				Geographic Area	US Counties Terminology
C10918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10918>	C61063	Cytarabine/Filgrastim/Idarubicin|ARA-C/G-CSF/IDA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109190>	C107687	Cedar County, MO|Cedar County|Cedar County, Missouri|MO039				Geographic Area	US Counties Terminology
C109191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109191>	C107687	Chariton County, MO|Chariton County|Chariton County, Missouri|MO041				Geographic Area	US Counties Terminology
C109192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109192>	C107687	Christian County, MO|Christian County|Christian County, Missouri|MO043				Geographic Area	US Counties Terminology
C109193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109193>	C107687	Clark County, MO|Clark County|Clark County, Missouri|MO045				Geographic Area	US Counties Terminology
C109194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109194>	C107687	Clay County, MO|Clay County|Clay County, Missouri|MO047				Geographic Area	US Counties Terminology
C109195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109195>	C107687	Clinton County, MO|Clinton County|Clinton County, Missouri|MO049				Geographic Area	US Counties Terminology
C109196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109196>	C107687	Cole County, MO|Cole County|Cole County, Missouri|MO051				Geographic Area	US Counties Terminology
C109197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109197>	C107687	Cooper County, MO|Cooper County|Cooper County, Missouri|MO053				Geographic Area	US Counties Terminology
C109198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109198>	C107687	Crawford County, MO|Crawford County|Crawford County, Missouri|MO055				Geographic Area	US Counties Terminology
C109199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109199>	C107687	Dade County, MO|Dade County|Dade County, Missouri|MO057				Geographic Area	US Counties Terminology
C10919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10919>	C61063	Cytarabine/Etoposide/Filgrastim/Mitoxantrone|ARA-C/DHAD/G-CSF/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1091>	C2181	Estrone Sulfate|ESTRONE SULFATE	An aqueous substance that is the sulfate salt form of estrone. (NCI)	Estrone Sulfate		Organic Chemical|Pharmacologic Substance	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C109200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109200>	C107687	Dallas County, MO|Dallas County|Dallas County, Missouri|MO059				Geographic Area	US Counties Terminology
C109201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109201>	C107687	Daviess County, MO|Daviess County|Daviess County, Missouri|MO061				Geographic Area	US Counties Terminology
C109202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109202>	C107687	DeKalb County, MO|DeKalb County|DeKalb County, Missouri|MO063				Geographic Area	US Counties Terminology
C109203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109203>	C107687	Dent County, MO|Dent County|Dent County, Missouri|MO065				Geographic Area	US Counties Terminology
C109204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109204>	C107687	Douglas County, MO|Douglas County|Douglas County, Missouri|MO067				Geographic Area	US Counties Terminology
C109205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109205>	C107687	Dunklin County, MO|Dunklin County|Dunklin County, Missouri|MO069				Geographic Area	US Counties Terminology
C109206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109206>	C107687	Franklin County, MO|Franklin County|Franklin County, Missouri|MO071				Geographic Area	US Counties Terminology
C109207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109207>	C107687	Gasconade County, MO|Gasconade County|Gasconade County, Missouri|MO073				Geographic Area	US Counties Terminology
C109208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109208>	C107687	Gentry County, MO|Gentry County|Gentry County, Missouri|MO075				Geographic Area	US Counties Terminology
C109209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109209>	C107687	Greene County, MO|Greene County|Greene County, Missouri|MO077				Geographic Area	US Counties Terminology
C10920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10920>	C61063	Dexamethasone/Methotrexate/Procarbazine/Vincristine|DM/MTX/PCB/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109210>	C107687	Grundy County, MO|Grundy County|Grundy County, Missouri|MO079				Geographic Area	US Counties Terminology
C109211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109211>	C107687	Harrison County, MO|Harrison County|Harrison County, Missouri|MO081				Geographic Area	US Counties Terminology
C109212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109212>	C107687	Henry County, MO|Henry County|Henry County, Missouri|MO083				Geographic Area	US Counties Terminology
C109213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109213>	C107687	Hickory County, MO|Hickory County|Hickory County, Missouri|MO085				Geographic Area	US Counties Terminology
C109214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109214>	C107687	Holt County, MO|Holt County|Holt County, Missouri|MO087				Geographic Area	US Counties Terminology
C109215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109215>	C107687	Howard County, MO|Howard County|Howard County, Missouri|MO089				Geographic Area	US Counties Terminology
C109216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109216>	C107687	Howell County, MO|Howell County|Howell County, Missouri|MO091				Geographic Area	US Counties Terminology
C109217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109217>	C107687	Iron County, MO|Iron County|Iron County, Missouri|MO093				Geographic Area	US Counties Terminology
C109218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109218>	C107687	Jackson County, MO|Jackson County|Jackson County, Missouri|MO095				Geographic Area	US Counties Terminology
C109219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109219>	C107687	Jasper County, MO|Jasper County|Jasper County, Missouri|MO097				Geographic Area	US Counties Terminology
C10921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10921>	C61063	Carboplatin/Cyclophosphamide/Filgrastim|CBDCA/CTX/G-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109220>	C107687	Jefferson County, MO|Jefferson County|Jefferson County, Missouri|MO099				Geographic Area	US Counties Terminology
C109221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109221>	C107687	Johnson County, MO|Johnson County|Johnson County, Missouri|MO101				Geographic Area	US Counties Terminology
C109222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109222>	C107687	Knox County, MO|Knox County|Knox County, Missouri|MO103				Geographic Area	US Counties Terminology
C109223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109223>	C107687	Laclede County, MO|Laclede County|Laclede County, Missouri|MO105				Geographic Area	US Counties Terminology
C109224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109224>	C107687	Lafayette County, MO|Lafayette County|Lafayette County, Missouri|MO107				Geographic Area	US Counties Terminology
C109225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109225>	C107687	Lawrence County, MO|Lawrence County|Lawrence County, Missouri|MO109				Geographic Area	US Counties Terminology
C109226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109226>	C107687	Lewis County, MO|Lewis County|Lewis County, Missouri|MO111				Geographic Area	US Counties Terminology
C109227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109227>	C107687	Lincoln County, MO|Lincoln County|Lincoln County, Missouri|MO113				Geographic Area	US Counties Terminology
C109228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109228>	C107687	Linn County, MO|Linn County|Linn County, Missouri|MO115				Geographic Area	US Counties Terminology
C109229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109229>	C107687	Livingston County, MO|Livingston County|Livingston County, Missouri|MO117				Geographic Area	US Counties Terminology
C10922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10922>	C61063	Cisplatin/Pyrazoloacridine|CDDP/PZA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109230>	C107687	McDonald County, MO|MO119|McDonald County|McDonald County, Missouri				Geographic Area	US Counties Terminology
C109231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109231>	C107687	Macon County, MO|MO121|Macon County|Macon County, Missouri				Geographic Area	US Counties Terminology
C109232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109232>	C107687	Madison County, MO|MO123|Madison County|Madison County, Missouri				Geographic Area	US Counties Terminology
C109233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109233>	C107687	Maries County, MO|MO125|Maries County|Maries County, Missouri				Geographic Area	US Counties Terminology
C109234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109234>	C107687	Marion County, MO|MO127|Marion County|Marion County, Missouri				Geographic Area	US Counties Terminology
C109235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109235>	C107687	Mercer County, MO|MO129|Mercer County|Mercer County, Missouri				Geographic Area	US Counties Terminology
C109236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109236>	C107687	Miller County, MO|MO131|Miller County|Miller County, Missouri				Geographic Area	US Counties Terminology
C109237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109237>	C107687	Mississippi County, MO|MO133|Mississippi County|Mississippi County, Missouri				Geographic Area	US Counties Terminology
C109238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109238>	C107687	Moniteau County, MO|MO135|Moniteau County|Moniteau County, Missouri				Geographic Area	US Counties Terminology
C109239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109239>	C107687	Monroe County, MO|MO137|Monroe County|Monroe County, Missouri				Geographic Area	US Counties Terminology
C10923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10923>	C61063	Cisplatin/Filgrastim/Pyrazoloacridine|CDDP/G-CSF/PZA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109240>	C107687	Montgomery County, MO|MO139|Montgomery County|Montgomery County, Missouri				Geographic Area	US Counties Terminology
C109241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109241>	C107687	Morgan County, MO|MO141|Morgan County|Morgan County, Missouri				Geographic Area	US Counties Terminology
C109242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109242>	C107687	New Madrid County, MO|MO143|New Madrid County|New Madrid County, Missouri				Geographic Area	US Counties Terminology
C109243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109243>	C107687	Newton County, MO|MO145|Newton County|Newton County, Missouri				Geographic Area	US Counties Terminology
C109244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109244>	C107687	Nodaway County, MO|MO147|Nodaway County|Nodaway County, Missouri				Geographic Area	US Counties Terminology
C109245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109245>	C107687	Oregon County, MO|MO149|Oregon County|Oregon County, Missouri				Geographic Area	US Counties Terminology
C109246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109246>	C107687	Osage County, MO|MO151|Osage County|Osage County, Missouri				Geographic Area	US Counties Terminology
C109247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109247>	C107687	Ozark County, MO|MO153|Ozark County|Ozark County, Missouri				Geographic Area	US Counties Terminology
C109248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109248>	C107687	Pemiscot County, MO|MO155|Pemiscot County|Pemiscot County, Missouri				Geographic Area	US Counties Terminology
C109249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109249>	C107687	Perry County, MO|MO157|Perry County|Perry County, Missouri				Geographic Area	US Counties Terminology
C10924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10924>	C61063	Carboxyamidotriazole/Paclitaxel|CAI/Paclitaxel|CAI/TAX	A combination of agents containing carboxyamidotriazole and paclitaxel.		Obsolete_Concept	Therapeutic or Preventive Procedure	
C109250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109250>	C107687	Pettis County, MO|MO159|Pettis County|Pettis County, Missouri				Geographic Area	US Counties Terminology
C109251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109251>	C107687	Phelps County, MO|MO161|Phelps County|Phelps County, Missouri				Geographic Area	US Counties Terminology
C109252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109252>	C107687	Pike County, MO|MO163|Pike County|Pike County, Missouri				Geographic Area	US Counties Terminology
C109253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109253>	C107687	Platte County, MO|MO165|Platte County|Platte County, Missouri				Geographic Area	US Counties Terminology
C109254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109254>	C107687	Polk County, MO|MO167|Polk County|Polk County, Missouri				Geographic Area	US Counties Terminology
C109255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109255>	C107687	Pulaski County, MO|MO169|Pulaski County|Pulaski County, Missouri				Geographic Area	US Counties Terminology
C109256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109256>	C107687	Putnam County, MO|MO171|Putnam County|Putnam County, Missouri				Geographic Area	US Counties Terminology
C109257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109257>	C107687	Ralls County, MO|MO173|Ralls County|Ralls County, Missouri				Geographic Area	US Counties Terminology
C109258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109258>	C107687	Randolph County, MO|MO175|Randolph County|Randolph County, Missouri				Geographic Area	US Counties Terminology
C109259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109259>	C107687	Ray County, MO|MO177|Ray County|Ray County, Missouri				Geographic Area	US Counties Terminology
C10925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10925>	C61007	Cyclophosphamide/Doxorubicin/Methylprednisolone/Vincristine|CTX/DOX/MePRDL/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109260>	C107687	Reynolds County, MO|MO179|Reynolds County|Reynolds County, Missouri				Geographic Area	US Counties Terminology
C109261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109261>	C107687	Ripley County, MO|MO181|Ripley County|Ripley County, Missouri				Geographic Area	US Counties Terminology
C109262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109262>	C107687	St. Charles County, MO|MO183|St. Charles County|St. Charles County, Missouri				Geographic Area	US Counties Terminology
C109263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109263>	C107687	St. Clair County, MO|MO185|St. Clair County|St. Clair County, Missouri				Geographic Area	US Counties Terminology
C109264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109264>	C107687	Ste. Genevieve County, MO|MO186|Ste. Genevieve County|Ste. Genevieve County, Missouri				Geographic Area	US Counties Terminology
C109265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109265>	C107687	St. Francois County, MO|MO187|St. Francois County|St. Francois County, Missouri				Geographic Area	US Counties Terminology
C109266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109266>	C107687	St. Louis County, MO|MO189|St. Louis County|St. Louis County, Missouri				Geographic Area	US Counties Terminology
C109267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109267>	C107687	Saline County, MO|MO195|Saline County|Saline County, Missouri				Geographic Area	US Counties Terminology
C109268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109268>	C107687	Schuyler County, MO|MO197|Schuyler County|Schuyler County, Missouri				Geographic Area	US Counties Terminology
C109269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109269>	C107687	Scotland County, MO|MO199|Scotland County|Scotland County, Missouri				Geographic Area	US Counties Terminology
C10926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10926>	C61063	BMS-182751/Etoposide|BMS-182751/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109270>	C107687	Scott County, MO|MO201|Scott County|Scott County, Missouri				Geographic Area	US Counties Terminology
C109271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109271>	C107687	Shannon County, MO|MO203|Shannon County|Shannon County, Missouri				Geographic Area	US Counties Terminology
C109272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109272>	C107687	Shelby County, MO|MO205|Shelby County|Shelby County, Missouri				Geographic Area	US Counties Terminology
C109273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109273>	C107687	Stoddard County, MO|MO207|Stoddard County|Stoddard County, Missouri				Geographic Area	US Counties Terminology
C109274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109274>	C107687	Stone County, MO|MO209|Stone County|Stone County, Missouri				Geographic Area	US Counties Terminology
C109275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109275>	C107687	Sullivan County, MO|MO211|Sullivan County|Sullivan County, Missouri				Geographic Area	US Counties Terminology
C109276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109276>	C107687	Taney County, MO|MO213|Taney County|Taney County, Missouri				Geographic Area	US Counties Terminology
C109277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109277>	C107687	Texas County, MO|MO215|Texas County|Texas County, Missouri				Geographic Area	US Counties Terminology
C109278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109278>	C107687	Vernon County, MO|MO217|Vernon County|Vernon County, Missouri				Geographic Area	US Counties Terminology
C109279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109279>	C107687	Warren County, MO|MO219|Warren County|Warren County, Missouri				Geographic Area	US Counties Terminology
C10927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10927>	C61063	Cyclophosphamide/Dexamethasone/Doxorubicin/Etoposide|CTX/DM/DOX/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109280>	C107687	Washington County, MO|MO221|Washington County|Washington County, Missouri				Geographic Area	US Counties Terminology
C109281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109281>	C107687	Wayne County, MO|MO223|Wayne County|Wayne County, Missouri				Geographic Area	US Counties Terminology
C109282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109282>	C107687	Webster County, MO|MO225|Webster County|Webster County, Missouri				Geographic Area	US Counties Terminology
C109283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109283>	C107687	Worth County, MO|MO227|Worth County|Worth County, Missouri				Geographic Area	US Counties Terminology
C109284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109284>	C107687	Wright County, MO|MO229|Wright County|Wright County, Missouri				Geographic Area	US Counties Terminology
C109285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109285>	C107687	St. Louis City, MO|MO510|St. Louis City|St. Louis City, Missouri				Geographic Area	US Counties Terminology
C109286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109286>	C107687	Beaverhead County, MT|Beaverhead County|Beaverhead County, Montana|MT001				Geographic Area	US Counties Terminology
C109287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109287>	C107687	Big Horn County, MT|Big Horn County|Big Horn County, Montana|MT003				Geographic Area	US Counties Terminology
C109288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109288>	C107687	Blaine County, MT|Blaine County|Blaine County, Montana|MT005				Geographic Area	US Counties Terminology
C109289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109289>	C107687	Broadwater County, MT|Broadwater County|Broadwater County, Montana|MT007				Geographic Area	US Counties Terminology
C10928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10928>	C61063	Isotretinoin/Vitamin E|13-CRA/VIT-E			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109290>	C107687	Carbon County, MT|Carbon County|Carbon County, Montana|MT009				Geographic Area	US Counties Terminology
C109291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109291>	C107687	Carter County, MT|Carter County|Carter County, Montana|MT011				Geographic Area	US Counties Terminology
C109292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109292>	C107687	Cascade County, MT|Cascade County|Cascade County, Montana|MT013				Geographic Area	US Counties Terminology
C109293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109293>	C107687	Chouteau County, MT|Chouteau County|Chouteau County, Montana|MT015				Geographic Area	US Counties Terminology
C109294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109294>	C107687	Custer County, MT|Custer County|Custer County, Montana|MT017				Geographic Area	US Counties Terminology
C109295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109295>	C107687	Daniels County, MT|Daniels County|Daniels County, Montana|MT019				Geographic Area	US Counties Terminology
C109296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109296>	C107687	Dawson County, MT|Dawson County|Dawson County, Montana|MT021				Geographic Area	US Counties Terminology
C109297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109297>	C107687	Deer Lodge County, MT|Deer Lodge County|Deer Lodge County, Montana|MT023				Geographic Area	US Counties Terminology
C109298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109298>	C107687	Fallon County, MT|Fallon County|Fallon County, Montana|MT025				Geographic Area	US Counties Terminology
C109299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109299>	C107687	Fergus County, MT|Fergus County|Fergus County, Montana|MT027				Geographic Area	US Counties Terminology
C10929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10929>	C61063	Dexverapamil/Vinblastine|R-VPAM/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1092>	C798	Etanidazole|1H-Imidazole-1-acetamide, N-(2-hydroxyethyl)-2-nitro-|2-Nitroimidazole-1-acetamide, N-(2-hydroxyethyl)-|ETANIDAZOLE|SR-2508|etanidazole	A 2-nitroimidazole with radiosensitizing properties. Etanidazole depletes glutathione and inhibits glutathione transferase, thereby enhancing the cytotoxicity of ionizing radiation. This agent may also be useful as an imaging agent for identifying hypoxic, drug-resistant regions of primary tumors or metastases.  (NCI04)	Etanidazole		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C109300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109300>	C107687	Flathead County, MT|Flathead County|Flathead County, Montana|MT029				Geographic Area	US Counties Terminology
C109301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109301>	C107687	Gallatin County, MT|Gallatin County|Gallatin County, Montana|MT031				Geographic Area	US Counties Terminology
C109302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109302>	C107687	Garfield County, MT|Garfield County|Garfield County, Montana|MT033				Geographic Area	US Counties Terminology
C109303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109303>	C107687	Glacier County, MT|Glacier County|Glacier County, Montana|MT035				Geographic Area	US Counties Terminology
C109304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109304>	C107687	Golden Valley County, MT|Golden Valley County|Golden Valley County, Montana|MT037				Geographic Area	US Counties Terminology
C109305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109305>	C107687	Granite County, MT|Granite County|Granite County, Montana|MT039				Geographic Area	US Counties Terminology
C109306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109306>	C107687	Hill County, MT|Hill County|Hill County, Montana|MT041				Geographic Area	US Counties Terminology
C109307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109307>	C107687	Jefferson County, MT|Jefferson County|Jefferson County, Montana|MT043				Geographic Area	US Counties Terminology
C109308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109308>	C107687	Judith Basin County, MT|Judith Basin County|Judith Basin County, Montana|MT045				Geographic Area	US Counties Terminology
C109309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109309>	C107687	Lake County, MT|Lake County|Lake County, Montana|MT047				Geographic Area	US Counties Terminology
C10930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10930>	C61063	Cisplatin/Docetaxel/Fluorouracil/Leucovorin Calcium|CDDP/CF/5-FU/TXT			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109310>	C107687	Lewis and Clark County, MT|Lewis and Clark County|Lewis and Clark County, Montana|MT049				Geographic Area	US Counties Terminology
C109311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109311>	C107687	Liberty County, MT|Liberty County|Liberty County, Montana|MT051				Geographic Area	US Counties Terminology
C109312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109312>	C107687	Lincoln County, MT|Lincoln County|Lincoln County, Montana|MT053				Geographic Area	US Counties Terminology
C109313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109313>	C107687	McCone County, MT|MT055|McCone County|McCone County, Montana				Geographic Area	US Counties Terminology
C109314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109314>	C107687	Madison County, MT|MT057|Madison County|Madison County, Montana				Geographic Area	US Counties Terminology
C109315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109315>	C107687	Meagher County, MT|MT059|Meagher County|Meagher County, Montana				Geographic Area	US Counties Terminology
C109316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109316>	C107687	Mineral County, MT|MT061|Mineral County|Mineral County, Montana				Geographic Area	US Counties Terminology
C109317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109317>	C107687	Missoula County, MT|MT063|Missoula County|Missoula County, Montana				Geographic Area	US Counties Terminology
C109318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109318>	C107687	Musselshell County, MT|MT065|Musselshell County|Musselshell County, Montana				Geographic Area	US Counties Terminology
C109319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109319>	C107687	Park County, MT|MT067|Park County|Park County, Montana				Geographic Area	US Counties Terminology
C10931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10931>	C61007	Cisplatin/Doxorubicin/Paclitaxel|CDDP/DOX/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109320>	C107687	Petroleum County, MT|MT069|Petroleum County|Petroleum County, Montana				Geographic Area	US Counties Terminology
C109321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109321>	C107687	Phillips County, MT|MT071|Phillips County|Phillips County, Montana				Geographic Area	US Counties Terminology
C109322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109322>	C107687	Pondera County, MT|MT073|Pondera County|Pondera County, Montana				Geographic Area	US Counties Terminology
C109323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109323>	C107687	Powder River County, MT|MT075|Powder River County|Powder River County, Montana				Geographic Area	US Counties Terminology
C109324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109324>	C107687	Powell County, MT|MT077|Powell County|Powell County, Montana				Geographic Area	US Counties Terminology
C109325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109325>	C107687	Prairie County, MT|MT079|Prairie County|Prairie County, Montana				Geographic Area	US Counties Terminology
C109326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109326>	C107687	Ravalli County, MT|MT081|Ravalli County|Ravalli County, Montana				Geographic Area	US Counties Terminology
C109327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109327>	C107687	Richland County, MT|MT083|Richland County|Richland County, Montana				Geographic Area	US Counties Terminology
C109328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109328>	C107687	Roosevelt County, MT|MT085|Roosevelt County|Roosevelt County, Montana				Geographic Area	US Counties Terminology
C109329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109329>	C107687	Rosebud County, MT|MT087|Rosebud County|Rosebud County, Montana				Geographic Area	US Counties Terminology
C10932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10932>	C61007	Cisplatin/Doxorubicin/Filgrastim/Paclitaxel|CDDP/DOX/G-CSF/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109330>	C107687	Sanders County, MT|MT089|Sanders County|Sanders County, Montana				Geographic Area	US Counties Terminology
C109331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109331>	C107687	Sheridan County, MT|MT091|Sheridan County|Sheridan County, Montana				Geographic Area	US Counties Terminology
C109332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109332>	C107687	Silver Bow County, MT|MT093|Silver Bow County|Silver Bow County, Montana				Geographic Area	US Counties Terminology
C109333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109333>	C107687	Stillwater County, MT|MT095|Stillwater County|Stillwater County, Montana				Geographic Area	US Counties Terminology
C109334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109334>	C107687	Sweet Grass County, MT|MT097|Sweet Grass County|Sweet Grass County, Montana				Geographic Area	US Counties Terminology
C109335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109335>	C107687	Teton County, MT|MT099|Teton County|Teton County, Montana				Geographic Area	US Counties Terminology
C109336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109336>	C107687	Toole County, MT|MT101|Toole County|Toole County, Montana				Geographic Area	US Counties Terminology
C109337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109337>	C107687	Treasure County, MT|MT103|Treasure County|Treasure County, Montana				Geographic Area	US Counties Terminology
C109338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109338>	C107687	Valley County, MT|MT105|Valley County|Valley County, Montana				Geographic Area	US Counties Terminology
C109339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109339>	C107687	Wheatland County, MT|MT107|Wheatland County|Wheatland County, Montana				Geographic Area	US Counties Terminology
C10933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10933>	C61063	Etoposide/Mitoxantrone/Sargramostim|DHAD/GM-CSF/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109340>	C107687	Wibaux County, MT|MT109|Wibaux County|Wibaux County, Montana				Geographic Area	US Counties Terminology
C109341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109341>	C107687	Yellowstone County, MT|MT111|Yellowstone County|Yellowstone County, Montana				Geographic Area	US Counties Terminology
C109342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109342>	C107687	Adams County, NE|Adams County|Adams County, Nebraska|NE001				Geographic Area	US Counties Terminology
C109343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109343>	C107687	Antelope County, NE|Antelope County|Antelope County, Nebraska|NE003				Geographic Area	US Counties Terminology
C109344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109344>	C107687	Arthur County, NE|Arthur County|Arthur County, Nebraska|NE005				Geographic Area	US Counties Terminology
C109345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109345>	C107687	Banner County, NE|Banner County|Banner County, Nebraska|NE007				Geographic Area	US Counties Terminology
C109346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109346>	C107687	Blaine County, NE|Blaine County|Blaine County, Nebraska|NE009				Geographic Area	US Counties Terminology
C109347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109347>	C107687	Boone County, NE|Boone County|Boone County, Nebraska|NE011				Geographic Area	US Counties Terminology
C109348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109348>	C107687	Box Butte County, NE|Box Butte County|Box Butte County, Nebraska|NE013				Geographic Area	US Counties Terminology
C109349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109349>	C107687	Boyd County, NE|Boyd County|Boyd County, Nebraska|NE015				Geographic Area	US Counties Terminology
C10934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10934>	C61063	Etoposide/Novobiocin|NBC/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109350>	C107687	Brown County, NE|Brown County|Brown County, Nebraska|NE017				Geographic Area	US Counties Terminology
C109351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109351>	C107687	Buffalo County, NE|Buffalo County|Buffalo County, Nebraska|NE019				Geographic Area	US Counties Terminology
C109352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109352>	C107687	Burt County, NE|Burt County|Burt County, Nebraska|NE021				Geographic Area	US Counties Terminology
C109353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109353>	C107687	Butler County, NE|Butler County|Butler County, Nebraska|NE023				Geographic Area	US Counties Terminology
C109354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109354>	C107687	Cass County, NE|Cass County|Cass County, Nebraska|NE025				Geographic Area	US Counties Terminology
C109355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109355>	C107687	Cedar County, NE|Cedar County|Cedar County, Nebraska|NE027				Geographic Area	US Counties Terminology
C109356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109356>	C107687	Chase County, NE|Chase County|Chase County, Nebraska|NE029				Geographic Area	US Counties Terminology
C109357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109357>	C107687	Cherry County, NE|Cherry County|Cherry County, Nebraska|NE031				Geographic Area	US Counties Terminology
C109358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109358>	C107687	Cheyenne County, NE|Cheyenne County|Cheyenne County, Nebraska|NE033				Geographic Area	US Counties Terminology
C109359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109359>	C107687	Clay County, NE|Clay County|Clay County, Nebraska|NE035				Geographic Area	US Counties Terminology
C10935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10935>	C61007	Cisplatin/Tirapazamine|CDDP/SR-4233			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109360>	C107687	Colfax County, NE|Colfax County|Colfax County, Nebraska|NE037				Geographic Area	US Counties Terminology
C109361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109361>	C107687	Cuming County, NE|Cuming County|Cuming County, Nebraska|NE039				Geographic Area	US Counties Terminology
C109362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109362>	C107687	Custer County, NE|Custer County|Custer County, Nebraska|NE041				Geographic Area	US Counties Terminology
C109363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109363>	C107687	Dakota County, NE|Dakota County|Dakota County, Nebraska|NE043				Geographic Area	US Counties Terminology
C109364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109364>	C107687	Dawes County, NE|Dawes County|Dawes County, Nebraska|NE045				Geographic Area	US Counties Terminology
C109365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109365>	C107687	Dawson County, NE|Dawson County|Dawson County, Nebraska|NE047				Geographic Area	US Counties Terminology
C109366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109366>	C107687	Deuel County, NE|Deuel County|Deuel County, Nebraska|NE049				Geographic Area	US Counties Terminology
C109367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109367>	C107687	Dixon County, NE|Dixon County|Dixon County, Nebraska|NE051				Geographic Area	US Counties Terminology
C109368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109368>	C107687	Dodge County, NE|Dodge County|Dodge County, Nebraska|NE053				Geographic Area	US Counties Terminology
C109369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109369>	C107687	Douglas County, NE|Douglas County|Douglas County, Nebraska|NE055				Geographic Area	US Counties Terminology
C10936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10936>	C61063	Bleomycin/Cyclophosphamide/Doxorubicin/Prednisone/Procarbazine/Vinblastine/Vincristine|BLEO/CTX/DOX/PCB/PRED/VBL/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109370>	C107687	Dundy County, NE|Dundy County|Dundy County, Nebraska|NE057				Geographic Area	US Counties Terminology
C109371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109371>	C107687	Fillmore County, NE|Fillmore County|Fillmore County, Nebraska|NE059				Geographic Area	US Counties Terminology
C109372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109372>	C107687	Franklin County, NE|Franklin County|Franklin County, Nebraska|NE061				Geographic Area	US Counties Terminology
C109373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109373>	C107687	Frontier County, NE|Frontier County|Frontier County, Nebraska|NE063				Geographic Area	US Counties Terminology
C109374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109374>	C107687	Furnas County, NE|Furnas County|Furnas County, Nebraska|NE065				Geographic Area	US Counties Terminology
C109375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109375>	C107687	Gage County, NE|Gage County|Gage County, Nebraska|NE067				Geographic Area	US Counties Terminology
C109376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109376>	C107687	Garden County, NE|Garden County|Garden County, Nebraska|NE069				Geographic Area	US Counties Terminology
C109377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109377>	C107687	Garfield County, NE|Garfield County|Garfield County, Nebraska|NE071				Geographic Area	US Counties Terminology
C109378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109378>	C107687	Gosper County, NE|Gosper County|Gosper County, Nebraska|NE073				Geographic Area	US Counties Terminology
C109379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109379>	C107687	Grant County, NE|Grant County|Grant County, Nebraska|NE075				Geographic Area	US Counties Terminology
C10937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10937>	C61007	Cisplatin/Epirubicin/Fluorouracil|CDDP/EPI/5-FU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109380>	C107687	Greeley County, NE|Greeley County|Greeley County, Nebraska|NE077				Geographic Area	US Counties Terminology
C109381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109381>	C107687	Hall County, NE|Hall County|Hall County, Nebraska|NE079				Geographic Area	US Counties Terminology
C109382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109382>	C107687	Hamilton County, NE|Hamilton County|Hamilton County, Nebraska|NE081				Geographic Area	US Counties Terminology
C109383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109383>	C107687	Harlan County, NE|Harlan County|Harlan County, Nebraska|NE083				Geographic Area	US Counties Terminology
C109384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109384>	C107687	Hayes County, NE|Hayes County|Hayes County, Nebraska|NE085				Geographic Area	US Counties Terminology
C109385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109385>	C107687	Hitchcock County, NE|Hitchcock County|Hitchcock County, Nebraska|NE087				Geographic Area	US Counties Terminology
C109386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109386>	C107687	Holt County, NE|Holt County|Holt County, Nebraska|NE089				Geographic Area	US Counties Terminology
C109387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109387>	C107687	Hooker County, NE|Hooker County|Hooker County, Nebraska|NE091				Geographic Area	US Counties Terminology
C109388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109388>	C107687	Howard County, NE|Howard County|Howard County, Nebraska|NE093				Geographic Area	US Counties Terminology
C109389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109389>	C107687	Jefferson County, NE|Jefferson County|Jefferson County, Nebraska|NE095				Geographic Area	US Counties Terminology
C10938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10938>	C61063	Prednisone/Thioguanine/Vincristine|PRED/TG/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109390>	C107687	Johnson County, NE|Johnson County|Johnson County, Nebraska|NE097				Geographic Area	US Counties Terminology
C109391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109391>	C107687	Kearney County, NE|Kearney County|Kearney County, Nebraska|NE099				Geographic Area	US Counties Terminology
C109392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109392>	C107687	Keith County, NE|Keith County|Keith County, Nebraska|NE101				Geographic Area	US Counties Terminology
C109393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109393>	C107687	Keya Paha County, NE|Keya Paha County|Keya Paha County, Nebraska|NE103				Geographic Area	US Counties Terminology
C109394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109394>	C107687	Kimball County, NE|Kimball County|Kimball County, Nebraska|NE105				Geographic Area	US Counties Terminology
C109395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109395>	C107687	Knox County, NE|Knox County|Knox County, Nebraska|NE107				Geographic Area	US Counties Terminology
C109396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109396>	C107687	Lancaster County, NE|Lancaster County|Lancaster County, Nebraska|NE109				Geographic Area	US Counties Terminology
C109397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109397>	C107687	Lincoln County, NE|Lincoln County|Lincoln County, Nebraska|NE111				Geographic Area	US Counties Terminology
C109398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109398>	C107687	Logan County, NE|Logan County|Logan County, Nebraska|NE113				Geographic Area	US Counties Terminology
C109399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109399>	C107687	Loup County, NE|Loup County|Loup County, Nebraska|NE115				Geographic Area	US Counties Terminology
C10939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10939>	C61063	Carboplatin/Etoposide/Mitoxantrone/Thiotepa|CBDCA/DHAD/TSPA/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1093>	C1331	Etoposide Phosphate|ETOPOSIDE PHOSPHATE|Etopophos|Etopophos|etoposide phosphate	A phosphate salt of a semisynthetic derivative of podophyllotoxin. Etoposide binds to the enzyme topoisomerase II, inducing double-strand DNA breaks, inhibiting DNA repair, and resulting in decreased DNA synthesis and tumor cell proliferation. Cells in the S and G2 phases of the cell cycle are most sensitive to this agent. (NCI04)	Etoposide Phosphate		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GCT Authorized Value Terminology|GCT Total Dose Table|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Protocol Treatment Modifications Table|HL Total Dose Table|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C109400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109400>	C107687	McPherson County, NE|McPherson County|McPherson County, Nebraska|NE117				Geographic Area	US Counties Terminology
C109401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109401>	C107687	Madison County, NE|Madison County|Madison County, Nebraska|NE119				Geographic Area	US Counties Terminology
C109402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109402>	C107687	Merrick County, NE|Merrick County|Merrick County, Nebraska|NE121				Geographic Area	US Counties Terminology
C109403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109403>	C107687	Morrill County, NE|Morrill County|Morrill County, Nebraska|NE123				Geographic Area	US Counties Terminology
C109404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109404>	C107687	Nance County, NE|NE125|Nance County|Nance County, Nebraska				Geographic Area	US Counties Terminology
C109405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109405>	C107687	Nemaha County, NE|NE127|Nemaha County|Nemaha County, Nebraska				Geographic Area	US Counties Terminology
C109406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109406>	C107687	Nuckolls County, NE|NE129|Nuckolls County|Nuckolls County, Nebraska				Geographic Area	US Counties Terminology
C109407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109407>	C107687	Otoe County, NE|NE131|Otoe County|Otoe County, Nebraska				Geographic Area	US Counties Terminology
C109408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109408>	C107687	Pawnee County, NE|NE133|Pawnee County|Pawnee County, Nebraska				Geographic Area	US Counties Terminology
C109409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109409>	C107687	Perkins County, NE|NE135|Perkins County|Perkins County, Nebraska				Geographic Area	US Counties Terminology
C10940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10940>	C61063	CI-980/Filgrastim|CI-980/G-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109410>	C107687	Phelps County, NE|NE137|Phelps County|Phelps County, Nebraska				Geographic Area	US Counties Terminology
C109411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109411>	C107687	Pierce County, NE|NE139|Pierce County|Pierce County, Nebraska				Geographic Area	US Counties Terminology
C109412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109412>	C107687	Platte County, NE|NE141|Platte County|Platte County, Nebraska				Geographic Area	US Counties Terminology
C109413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109413>	C107687	Polk County, NE|NE143|Polk County|Polk County, Nebraska				Geographic Area	US Counties Terminology
C109414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109414>	C107687	Red Willow County, NE|NE145|Red Willow County|Red Willow County, Nebraska				Geographic Area	US Counties Terminology
C109415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109415>	C107687	Richardson County, NE|NE147|Richardson County|Richardson County, Nebraska				Geographic Area	US Counties Terminology
C109416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109416>	C107687	Rock County, NE|NE149|Rock County|Rock County, Nebraska				Geographic Area	US Counties Terminology
C109417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109417>	C107687	Saline County, NE|NE151|Saline County|Saline County, Nebraska				Geographic Area	US Counties Terminology
C109418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109418>	C107687	Sarpy County, NE|NE153|Sarpy County|Sarpy County, Nebraska				Geographic Area	US Counties Terminology
C109419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109419>	C107687	Saunders County, NE|NE155|Saunders County|Saunders County, Nebraska				Geographic Area	US Counties Terminology
C10941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10941>	C61063	Dexamethasone/Etoposide/Ifosfamide/Methotrexate/Pegaspargase/Vincristine|DM/IFF/MTX/PEG-ASP/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109420>	C107687	Scotts Bluff County, NE|NE157|Scotts Bluff County|Scotts Bluff County, Nebraska				Geographic Area	US Counties Terminology
C109421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109421>	C107687	Seward County, NE|NE159|Seward County|Seward County, Nebraska				Geographic Area	US Counties Terminology
C109422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109422>	C107687	Sheridan County, NE|NE161|Sheridan County|Sheridan County, Nebraska				Geographic Area	US Counties Terminology
C109423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109423>	C107687	Sherman County, NE|NE163|Sherman County|Sherman County, Nebraska				Geographic Area	US Counties Terminology
C109424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109424>	C107687	Sioux County, NE|NE165|Sioux County|Sioux County, Nebraska				Geographic Area	US Counties Terminology
C109425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109425>	C107687	Stanton County, NE|NE167|Stanton County|Stanton County, Nebraska				Geographic Area	US Counties Terminology
C109426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109426>	C107687	Thayer County, NE|NE169|Thayer County|Thayer County, Nebraska				Geographic Area	US Counties Terminology
C109427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109427>	C107687	Thomas County, NE|NE171|Thomas County|Thomas County, Nebraska				Geographic Area	US Counties Terminology
C109428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109428>	C107687	Thurston County, NE|NE173|Thurston County|Thurston County, Nebraska				Geographic Area	US Counties Terminology
C109429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109429>	C107687	Valley County, NE|NE175|Valley County|Valley County, Nebraska				Geographic Area	US Counties Terminology
C10942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10942>	C61063	Cytarabine/Dexamethasone/Etoposide/Idarubicin/Ifosfamide/Methotrexate/Pegaspargase/Thioguanine/Vincristine|ARA-C/DM/IDA/IFF/MTX/PEG-ASP/TG/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109430>	C107687	Washington County, NE|NE177|Washington County|Washington County, Nebraska				Geographic Area	US Counties Terminology
C109431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109431>	C107687	Wayne County, NE|NE179|Wayne County|Wayne County, Nebraska				Geographic Area	US Counties Terminology
C109432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109432>	C107687	Webster County, NE|NE181|Webster County|Webster County, Nebraska				Geographic Area	US Counties Terminology
C109433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109433>	C107687	Wheeler County, NE|NE183|Wheeler County|Wheeler County, Nebraska				Geographic Area	US Counties Terminology
C109434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109434>	C107687	York County, NE|NE185|York County|York County, Nebraska				Geographic Area	US Counties Terminology
C109435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109435>	C107687	Churchill County, NV|Churchill County|Churchill County, Nevada|NV001				Geographic Area	US Counties Terminology
C109436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109436>	C107687	Clark County, NV|Clark County|Clark County, Nevada|NV003				Geographic Area	US Counties Terminology
C109437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109437>	C107687	Douglas County, NV|Douglas County|Douglas County, Nevada|NV005				Geographic Area	US Counties Terminology
C109438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109438>	C107687	Elko County, NV|Elko County|Elko County, Nevada|NV007				Geographic Area	US Counties Terminology
C109439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109439>	C107687	Esmeralda County, NV|Esmeralda County|Esmeralda County, Nevada|NV009				Geographic Area	US Counties Terminology
C10943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10943>	C61063	Cytarabine/Dexamethasone/Etoposide/Methotrexate/Pegaspargase/Thioguanine/Vincristine|ARA-C/DM/MTX/PEG-ASP/TG/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109440>	C107687	Eureka County, NV|Eureka County|Eureka County, Nevada|NV011				Geographic Area	US Counties Terminology
C109441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109441>	C107687	Humboldt County, NV|Humboldt County|Humboldt County, Nevada|NV013				Geographic Area	US Counties Terminology
C109442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109442>	C107687	Lander County, NV|Lander County|Lander County, Nevada|NV015				Geographic Area	US Counties Terminology
C109443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109443>	C107687	Lincoln County, NV|Lincoln County|Lincoln County, Nevada|NV017				Geographic Area	US Counties Terminology
C109444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109444>	C107687	Lyon County, NV|Lyon County|Lyon County, Nevada|NV019				Geographic Area	US Counties Terminology
C109445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109445>	C107687	Mineral County, NV|Mineral County|Mineral County, Nevada|NV021				Geographic Area	US Counties Terminology
C109446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109446>	C107687	Nye County, NV|NV023|Nye County|Nye County, Nevada				Geographic Area	US Counties Terminology
C109447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109447>	C107687	Pershing County, NV|NV027|Pershing County|Pershing County, Nevada				Geographic Area	US Counties Terminology
C109448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109448>	C107687	Storey County, NV|NV029|Storey County|Storey County, Nevada				Geographic Area	US Counties Terminology
C109449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109449>	C107687	Washoe County, NV|NV031|Washoe County|Washoe County, Nevada				Geographic Area	US Counties Terminology
C10944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10944>	C61063	Dexamethasone/Idarubicin/Ifosfamide/Methotrexate/Thioguanine/Vincristine|DM/IDA/IFF/MTX/TG/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109450>	C107687	White Pine County, NV|NV033|White Pine County|White Pine County, Nevada				Geographic Area	US Counties Terminology
C109451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109451>	C107687	Carson City, NV|Carson City|Carson City, Nevada|NV510				Geographic Area	US Counties Terminology
C109452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109452>	C107687	Belknap County, NH|Belknap County|Belknap County, New Hampshire|NH001				Geographic Area	US Counties Terminology
C109453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109453>	C107687	Carroll County, NH|Carroll County|Carroll County, New Hampshire|NH003				Geographic Area	US Counties Terminology
C109454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109454>	C107687	Cheshire County, NH|Cheshire County|Cheshire County, New Hampshire|NH005				Geographic Area	US Counties Terminology
C109455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109455>	C107687	Coos County, NH|Coos County|Coos County, New Hampshire|NH007				Geographic Area	US Counties Terminology
C109456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109456>	C107687	Grafton County, NH|Grafton County|Grafton County, New Hampshire|NH009				Geographic Area	US Counties Terminology
C109457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109457>	C107687	Hillsborough County, NH|Hillsborough County|Hillsborough County, New Hampshire|NH011				Geographic Area	US Counties Terminology
C109458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109458>	C107687	Merrimack County, NH|Merrimack County|Merrimack County, New Hampshire|NH013				Geographic Area	US Counties Terminology
C109459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109459>	C107687	Rockingham County, NH|NH015|Rockingham County|Rockingham County, New Hampshire				Geographic Area	US Counties Terminology
C10945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10945>	C61063	Methotrexate/Thioguanine/Vincristine|MTX/TG/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109460>	C107687	Strafford County, NH|NH017|Strafford County|Strafford County, New Hampshire				Geographic Area	US Counties Terminology
C109461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109461>	C107687	Sullivan County, NH|NH019|Sullivan County|Sullivan County, New Hampshire				Geographic Area	US Counties Terminology
C109462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109462>	C107687	Atlantic County, NJ|Atlantic County|Atlantic County, New Jersey|NJ001				Geographic Area	US Counties Terminology
C109463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109463>	C107687	Bergen County, NJ|Bergen County|Bergen County, New Jersey|NJ003				Geographic Area	US Counties Terminology
C109464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109464>	C107687	Burlington County, NJ|Burlington County|Burlington County, New Jersey|NJ005				Geographic Area	US Counties Terminology
C109465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109465>	C107687	Camden County, NJ|Camden County|Camden County, New Jersey|NJ007				Geographic Area	US Counties Terminology
C109466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109466>	C107687	Cape May County, NJ|Cape May County|Cape May County, New Jersey|NJ009				Geographic Area	US Counties Terminology
C109467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109467>	C107687	Cumberland County, NJ|Cumberland County|Cumberland County, New Jersey|NJ011				Geographic Area	US Counties Terminology
C109468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109468>	C107687	Essex County, NJ|Essex County|Essex County, New Jersey|NJ013				Geographic Area	US Counties Terminology
C109469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109469>	C107687	Gloucester County, NJ|Gloucester County|Gloucester County, New Jersey|NJ015				Geographic Area	US Counties Terminology
C10946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10946>	C61007	Carmustine/Mitolactol|BCNU/DBD			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109470>	C107687	Hudson County, NJ|Hudson County|Hudson County, New Jersey|NJ017				Geographic Area	US Counties Terminology
C109471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109471>	C107687	Hunterdon County, NJ|Hunterdon County|Hunterdon County, New Jersey|NJ019				Geographic Area	US Counties Terminology
C109472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109472>	C107687	Mercer County, NJ|Mercer County|Mercer County, New Jersey|NJ021				Geographic Area	US Counties Terminology
C109473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109473>	C107687	Middlesex County, NJ|Middlesex County|Middlesex County, New Jersey|NJ023				Geographic Area	US Counties Terminology
C109474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109474>	C107687	Monmouth County, NJ|Monmouth County|Monmouth County, New Jersey|NJ025				Geographic Area	US Counties Terminology
C109475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109475>	C107687	Morris County, NJ|Morris County|Morris County, New Jersey|NJ027				Geographic Area	US Counties Terminology
C109476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109476>	C107687	Ocean County, NJ|NJ029|Ocean County|Ocean County, New Jersey				Geographic Area	US Counties Terminology
C109477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109477>	C107687	Passaic County, NJ|NJ031|Passaic County|Passaic County, New Jersey				Geographic Area	US Counties Terminology
C109478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109478>	C107687	Salem County, NJ|NJ033|Salem County|Salem County, New Jersey				Geographic Area	US Counties Terminology
C109479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109479>	C107687	Somerset County, NJ|NJ035|Somerset County|Somerset County, New Jersey				Geographic Area	US Counties Terminology
C10947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10947>	C61063	Interleukin-2/Monoclonal Antibody Ch14.18/Monoclonal Antibody R24|IL-2/MOAB Ch14.18/MOAB R24			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109480>	C107687	Sussex County, NJ|NJ037|Sussex County|Sussex County, New Jersey				Geographic Area	US Counties Terminology
C109481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109481>	C107687	Union County, NJ|NJ039|Union County|Union County, New Jersey				Geographic Area	US Counties Terminology
C109482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109482>	C107687	Warren County, NJ|NJ041|Warren County|Warren County, New Jersey				Geographic Area	US Counties Terminology
C109483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109483>	C107687	Bernalillo County, NM|Bernalillo County|Bernalillo County, New Mexico|NM001				Geographic Area	US Counties Terminology
C109484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109484>	C107687	Catron County, NM|Catron County|Catron County, New Mexico|NM003				Geographic Area	US Counties Terminology
C109485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109485>	C107687	Chaves County, NM|Chaves County|Chaves County, New Mexico|NM005				Geographic Area	US Counties Terminology
C109486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109486>	C107687	Cibola County, NM|Cibola County|Cibola County, New Mexico|NM006				Geographic Area	US Counties Terminology
C109487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109487>	C107687	Colfax County, NM|Colfax County|Colfax County, New Mexico|NM007				Geographic Area	US Counties Terminology
C109488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109488>	C107687	Curry County, NM|Curry County|Curry County, New Mexico|NM009				Geographic Area	US Counties Terminology
C109489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109489>	C107687	De Baca County, NM|De Baca County|De Baca County, New Mexico|NM011				Geographic Area	US Counties Terminology
C10948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10948>	C61063	Carboplatin/Cyclophosphamide/Paclitaxel|CBDCA/CTX/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109490>	C107687	Dona Ana County, NM|Dona Ana County|Dona Ana County, New Mexico|NM013				Geographic Area	US Counties Terminology
C109491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109491>	C107687	Eddy County, NM|Eddy County|Eddy County, New Mexico|NM015				Geographic Area	US Counties Terminology
C109492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109492>	C107687	Grant County, NM|Grant County|Grant County, New Mexico|NM017				Geographic Area	US Counties Terminology
C109493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109493>	C107687	Guadalupe County, NM|Guadalupe County|Guadalupe County, New Mexico|NM019				Geographic Area	US Counties Terminology
C109494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109494>	C107687	Harding County, NM|Harding County|Harding County, New Mexico|NM021				Geographic Area	US Counties Terminology
C109495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109495>	C107687	Hidalgo County, NM|Hidalgo County|Hidalgo County, New Mexico|NM023				Geographic Area	US Counties Terminology
C109496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109496>	C107687	Lea County, NM|Lea County|Lea County, New Mexico|NM025				Geographic Area	US Counties Terminology
C109497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109497>	C107687	Lincoln County, NM|Lincoln County|Lincoln County, New Mexico|NM027				Geographic Area	US Counties Terminology
C109498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109498>	C107687	Los Alamos County, NM|Los Alamos County|Los Alamos County, New Mexico|NM028				Geographic Area	US Counties Terminology
C109499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109499>	C107687	Luna County, NM|Luna County|Luna County, New Mexico|NM029				Geographic Area	US Counties Terminology
C10949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10949>	C61063	Carboplatin/Cyclophosphamide/Filgrastim/Paclitaxel|CBDCA/CTX/G-CSF/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1094>	C2150|C1556	Fludarabine|2-Fluoro-9-beta-arabinofuranosyladenine|2-Fluorovidarabine|9-Beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine|9-Beta-D-arabinofuranosyl-2-fluoroadenine|FLUDARABINE|Fluradosa|fludarabine	A fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Administered parenterally as a phosphate salt, fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.  (NCI04)			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	AML Authorized Value Terminology|AML Total Dose Table|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|HL Authorized Value Terminology|HL Protocol Treatment Modifications Table|HL Total Dose Table|NCIt Antineoplastic Agent Terminology
C109500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109500>	C107687	McKinley County, NM|McKinley County|McKinley County, New Mexico|NM031				Geographic Area	US Counties Terminology
C109501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109501>	C107687	Mora County, NM|Mora County|Mora County, New Mexico|NM033				Geographic Area	US Counties Terminology
C109502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109502>	C107687	Otero County, NM|NM035|Otero County|Otero County, New Mexico				Geographic Area	US Counties Terminology
C109503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109503>	C107687	Quay County, NM|NM037|Quay County|Quay County, New Mexico				Geographic Area	US Counties Terminology
C109504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109504>	C107687	Rio Arriba County, NM|NM039|Rio Arriba County|Rio Arriba County, New Mexico				Geographic Area	US Counties Terminology
C109505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109505>	C107687	Roosevelt County, NM|NM041|Roosevelt County|Roosevelt County, New Mexico				Geographic Area	US Counties Terminology
C109506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109506>	C107687	Sandoval County, NM|NM043|Sandoval County|Sandoval County, New Mexico				Geographic Area	US Counties Terminology
C109507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109507>	C107687	San Juan County, NM|NM045|San Juan County|San Juan County, New Mexico				Geographic Area	US Counties Terminology
C109508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109508>	C107687	San Miguel County, NM|NM047|San Miguel County|San Miguel County, New Mexico				Geographic Area	US Counties Terminology
C109509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109509>	C107687	Santa Fe County, NM|NM049|Santa Fe County|Santa Fe County, New Mexico				Geographic Area	US Counties Terminology
C10950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10950>	C61063	Cisplatin/Epoetin Alfa/Iron|CDDP/EPO/iron			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109510>	C107687	Sierra County, NM|NM051|Sierra County|Sierra County, New Mexico				Geographic Area	US Counties Terminology
C109511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109511>	C107687	Socorro County, NM|NM053|Socorro County|Socorro County, New Mexico				Geographic Area	US Counties Terminology
C109512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109512>	C107687	Taos County, NM|NM055|Taos County|Taos County, New Mexico				Geographic Area	US Counties Terminology
C109513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109513>	C107687	Torrance County, NM|NM057|Torrance County|Torrance County, New Mexico				Geographic Area	US Counties Terminology
C109514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109514>	C107687	Union County, NM|NM059|Union County|Union County, New Mexico				Geographic Area	US Counties Terminology
C109515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109515>	C107687	Valencia County, NM|NM061|Valencia County|Valencia County, New Mexico				Geographic Area	US Counties Terminology
C109516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109516>	C107687	Albany County, NY|Albany County|Albany County, New York|NY001				Geographic Area	US Counties Terminology
C109517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109517>	C107687	Allegany County, NY|Allegany County|Allegany County, New York|NY003				Geographic Area	US Counties Terminology
C109518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109518>	C107687	Bronx County, NY|Bronx County|Bronx County, New York|NY005				Geographic Area	US Counties Terminology
C109519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109519>	C107687	Broome County, NY|Broome County|Broome County, New York|NY007				Geographic Area	US Counties Terminology
C10951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10951>	C61063	Detox/Keyhole Limpet Hemocyanin/Sialyl Tn Antigen|DETOX/KLH/STn antigen			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109520>	C107687	Cattaraugus County, NY|Cattaraugus County|Cattaraugus County, New York|NY009				Geographic Area	US Counties Terminology
C109521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109521>	C107687	Cayuga County, NY|Cayuga County|Cayuga County, New York|NY011				Geographic Area	US Counties Terminology
C109522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109522>	C107687	Chautauqua County, NY|Chautauqua County|Chautauqua County, New York|NY013				Geographic Area	US Counties Terminology
C109523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109523>	C107687	Chemung County, NY|Chemung County|Chemung County, New York|NY015				Geographic Area	US Counties Terminology
C109524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109524>	C107687	Chenango County, NY|Chenango County|Chenango County, New York|NY017				Geographic Area	US Counties Terminology
C109525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109525>	C107687	Clinton County, NY|Clinton County|Clinton County, New York|NY019				Geographic Area	US Counties Terminology
C109526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109526>	C107687	Columbia County, NY|Columbia County|Columbia County, New York|NY021				Geographic Area	US Counties Terminology
C109527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109527>	C107687	Cortland County, NY|Cortland County|Cortland County, New York|NY023				Geographic Area	US Counties Terminology
C109528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109528>	C107687	Delaware County, NY|Delaware County|Delaware County, New York|NY025				Geographic Area	US Counties Terminology
C109529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109529>	C107687	Dutchess County, NY|Dutchess County|Dutchess County, New York|NY027				Geographic Area	US Counties Terminology
C10952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10952>	C61063	CT-1501R/Interleukin-2|CT-1501R/IL-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109530>	C107687	Erie County, NY|Erie County|Erie County, New York|NY029				Geographic Area	US Counties Terminology
C109531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109531>	C107687	Essex County, NY|Essex County|Essex County, New York|NY031				Geographic Area	US Counties Terminology
C109532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109532>	C107687	Franklin County, NY|Franklin County|Franklin County, New York|NY033				Geographic Area	US Counties Terminology
C109533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109533>	C107687	Fulton County, NY|Fulton County|Fulton County, New York|NY035				Geographic Area	US Counties Terminology
C109534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109534>	C107687	Genesee County, NY|Genesee County|Genesee County, New York|NY037				Geographic Area	US Counties Terminology
C109535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109535>	C107687	Greene County, NY|Greene County|Greene County, New York|NY039				Geographic Area	US Counties Terminology
C109536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109536>	C107687	Hamilton County, NY|Hamilton County|Hamilton County, New York|NY041				Geographic Area	US Counties Terminology
C109537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109537>	C107687	Herkimer County, NY|Herkimer County|Herkimer County, New York|NY043				Geographic Area	US Counties Terminology
C109538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109538>	C107687	Jefferson County, NY|Jefferson County|Jefferson County, New York|NY045				Geographic Area	US Counties Terminology
C109539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109539>	C107687	Kings County, NY|Kings County|Kings County, New York|NY047				Geographic Area	US Counties Terminology
C10953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10953>	C61063	ImmTher/Indomethacin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109540>	C107687	Lewis County, NY|Lewis County|Lewis County, New York|NY049				Geographic Area	US Counties Terminology
C109541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109541>	C107687	Livingston County, NY|Livingston County|Livingston County, New York|NY051				Geographic Area	US Counties Terminology
C109542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109542>	C107687	Madison County, NY|Madison County|Madison County, New York|NY053				Geographic Area	US Counties Terminology
C109543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109543>	C107687	Monroe County, NY|Monroe County|Monroe County, New York|NY055				Geographic Area	US Counties Terminology
C109544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109544>	C107687	Montgomery County, NY|Montgomery County|Montgomery County, New York|NY057				Geographic Area	US Counties Terminology
C109545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109545>	C107687	Nassau County, NY|NY059|Nassau County|Nassau County, New York				Geographic Area	US Counties Terminology
C109546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109546>	C107687	New York County, NY|NY061|New York County|New York County, New York				Geographic Area	US Counties Terminology
C109547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109547>	C107687	Niagara County, NY|NY063|Niagara County|Niagara County, New York				Geographic Area	US Counties Terminology
C109548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109548>	C107687	Oneida County, NY|NY065|Oneida County|Oneida County, New York				Geographic Area	US Counties Terminology
C109549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109549>	C107687	Onondaga County, NY|NY067|Onondaga County|Onondaga County, New York				Geographic Area	US Counties Terminology
C10954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10954>	C61007	Cisplatin/Safingol|CDDP/safingol|Cisplatin/Dihydrosphingosine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109550>	C107687	Ontario County, NY|NY069|Ontario County|Ontario County, New York				Geographic Area	US Counties Terminology
C109551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109551>	C107687	Orange County, NY|NY071|Orange County|Orange County, New York				Geographic Area	US Counties Terminology
C109552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109552>	C107687	Orleans County, NY|NY073|Orleans County|Orleans County, New York				Geographic Area	US Counties Terminology
C109553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109553>	C107687	Oswego County, NY|NY075|Oswego County|Oswego County, New York				Geographic Area	US Counties Terminology
C109554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109554>	C107687	Otsego County, NY|NY077|Otsego County|Otsego County, New York				Geographic Area	US Counties Terminology
C109555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109555>	C107687	Putnam County, NY|NY079|Putnam County|Putnam County, New York				Geographic Area	US Counties Terminology
C109556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109556>	C107687	Queens County, NY|NY081|Queens County|Queens County, New York				Geographic Area	US Counties Terminology
C109557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109557>	C107687	Rensselaer County, NY|NY083|Rensselaer County|Rensselaer County, New York				Geographic Area	US Counties Terminology
C109558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109558>	C107687	Richmond County, NY|NY085|Richmond County|Richmond County, New York				Geographic Area	US Counties Terminology
C109559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109559>	C107687	Rockland County, NY|NY087|Rockland County|Rockland County, New York				Geographic Area	US Counties Terminology
C10955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10955>	C61063	Doxorubicin/Ketoconazole|DOX/KCZ			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109560>	C107687	St. Lawrence County, NY|NY089|St. Lawrence County|St. Lawrence County, New York				Geographic Area	US Counties Terminology
C109561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109561>	C107687	Saratoga County, NY|NY091|Saratoga County|Saratoga County, New York				Geographic Area	US Counties Terminology
C109562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109562>	C107687	Schenectady County, NY|NY093|Schenectady County|Schenectady County, New York				Geographic Area	US Counties Terminology
C109563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109563>	C107687	Schoharie County, NY|NY095|Schoharie County|Schoharie County, New York				Geographic Area	US Counties Terminology
C109564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109564>	C107687	Schuyler County, NY|NY097|Schuyler County|Schuyler County, New York				Geographic Area	US Counties Terminology
C109565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109565>	C107687	Seneca County, NY|NY099|Seneca County|Seneca County, New York				Geographic Area	US Counties Terminology
C109566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109566>	C107687	Steuben County, NY|NY101|Steuben County|Steuben County, New York				Geographic Area	US Counties Terminology
C109567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109567>	C107687	Suffolk County, NY|NY103|Suffolk County|Suffolk County, New York				Geographic Area	US Counties Terminology
C109568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109568>	C107687	Sullivan County, NY|NY105|Sullivan County|Sullivan County, New York				Geographic Area	US Counties Terminology
C109569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109569>	C107687	Tioga County, NY|NY107|Tioga County|Tioga County, New York				Geographic Area	US Counties Terminology
C10956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10956>	C61063	Cytarabine/Dexamethasone/Etoposide/Idarubicin/Thioguanine|ARA-C/DM/IDA/TG/VP-16|IDA DCTER			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109570>	C107687	Tompkins County, NY|NY109|Tompkins County|Tompkins County, New York				Geographic Area	US Counties Terminology
C109571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109571>	C107687	Ulster County, NY|NY111|Ulster County|Ulster County, New York				Geographic Area	US Counties Terminology
C109572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109572>	C107687	Warren County, NY|NY113|Warren County|Warren County, New York				Geographic Area	US Counties Terminology
C109573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109573>	C107687	Washington County, NY|NY115|Washington County|Washington County, New York				Geographic Area	US Counties Terminology
C109574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109574>	C107687	Wayne County, NY|NY117|Wayne County|Wayne County, New York				Geographic Area	US Counties Terminology
C109575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109575>	C107687	Westchester County, NY|NY119|Westchester County|Westchester County, New York				Geographic Area	US Counties Terminology
C109576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109576>	C107687	Wyoming County, NY|NY121|Wyoming County|Wyoming County, New York				Geographic Area	US Counties Terminology
C109577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109577>	C107687	Yates County, NY|NY123|Yates County|Yates County, New York				Geographic Area	US Counties Terminology
C109578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109578>	C107687	Alamance County, NC|Alamance County|Alamance County, North Carolina|NC001				Geographic Area	US Counties Terminology
C109579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109579>	C107687	Alexander County, NC|Alexander County|Alexander County, North Carolina|NC003				Geographic Area	US Counties Terminology
C10957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10957>	C61063	Cisplatin/Cyclophosphamide/Filgrastim/Paclitaxel|CDDP/CTX/G-CSF/TAX|Cisplatin/Pacli/Cyclo/GCSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109580>	C107687	Alleghany County, NC|Alleghany County|Alleghany County, North Carolina|NC005				Geographic Area	US Counties Terminology
C109581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109581>	C107687	Anson County, NC|Anson County|Anson County, North Carolina|NC007				Geographic Area	US Counties Terminology
C109582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109582>	C107687	Ashe County, NC|Ashe County|Ashe County, North Carolina|NC009				Geographic Area	US Counties Terminology
C109583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109583>	C107687	Avery County, NC|Avery County|Avery County, North Carolina|NC011				Geographic Area	US Counties Terminology
C109584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109584>	C107687	Beaufort County, NC|Beaufort County|Beaufort County, North Carolina|NC013				Geographic Area	US Counties Terminology
C109585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109585>	C107687	Bertie County, NC|Bertie County|Bertie County, North Carolina|NC015				Geographic Area	US Counties Terminology
C109586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109586>	C107687	Bladen County, NC|Bladen County|Bladen County, North Carolina|NC017				Geographic Area	US Counties Terminology
C109587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109587>	C107687	Brunswick County, NC|Brunswick County|Brunswick County, North Carolina|NC019				Geographic Area	US Counties Terminology
C109588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109588>	C107687	Buncombe County, NC|Buncombe County|Buncombe County, North Carolina|NC021				Geographic Area	US Counties Terminology
C109589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109589>	C107687	Burke County, NC|Burke County|Burke County, North Carolina|NC023				Geographic Area	US Counties Terminology
C10958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10958>	C61063	Hydroxyurea/Pentoxifylline|HU/PTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109590>	C107687	Cabarrus County, NC|Cabarrus County|Cabarrus County, North Carolina|NC025				Geographic Area	US Counties Terminology
C109591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109591>	C107687	Caldwell County, NC|Caldwell County|Caldwell County, North Carolina|NC027				Geographic Area	US Counties Terminology
C109592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109592>	C107687	Camden County, NC|Camden County|Camden County, North Carolina|NC029				Geographic Area	US Counties Terminology
C109593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109593>	C107687	Carteret County, NC|Carteret County|Carteret County, North Carolina|NC031				Geographic Area	US Counties Terminology
C109594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109594>	C107687	Caswell County, NC|Caswell County|Caswell County, North Carolina|NC033				Geographic Area	US Counties Terminology
C109595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109595>	C107687	Catawba County, NC|Catawba County|Catawba County, North Carolina|NC035				Geographic Area	US Counties Terminology
C109596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109596>	C107687	Chatham County, NC|Chatham County|Chatham County, North Carolina|NC037				Geographic Area	US Counties Terminology
C109597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109597>	C107687	Cherokee County, NC|Cherokee County|Cherokee County, North Carolina|NC039				Geographic Area	US Counties Terminology
C109598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109598>	C107687	Chowan County, NC|Chowan County|Chowan County, North Carolina|NC041				Geographic Area	US Counties Terminology
C109599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109599>	C107687	Clay County, NC|Clay County|Clay County, North Carolina|NC043				Geographic Area	US Counties Terminology
C10959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10959>	C61063	Flutamide/Isotretinoin/Leuprolide|13-CRA/FLUT/LEUP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1095>	C271	Pyrimethamine-Sulfadoxine|Fansidar|Fansidar|Pyrimethamine Sulfadoxine	A combination product containing pyrimethamine and sulfadoxine.  Pyrimethamine is a competitive inhibitor of dihydrofolate reductase (DHFR).  DHFR is a key enzyme in the redox cycle for production of tetrahydrofolate, a cofactor that is required for the synthesis of DNA and proteins.  Sulfadoxine competitively antagonizes paraaminobenzoic acid (PABA), resulting in disruption of folic acid synthesis and ultimately DNA synthesis. Sulfadoxine acts synergistically with pyrimethamine. (NCI04)			Organic Chemical|Pharmacologic Substance	
C109600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109600>	C107687	Cleveland County, NC|Cleveland County|Cleveland County, North Carolina|NC045				Geographic Area	US Counties Terminology
C109601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109601>	C107687	Columbus County, NC|Columbus County|Columbus County, North Carolina|NC047				Geographic Area	US Counties Terminology
C109602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109602>	C107687	Craven County, NC|Craven County|Craven County, North Carolina|NC049				Geographic Area	US Counties Terminology
C109603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109603>	C107687	Cumberland County, NC|Cumberland County|Cumberland County, North Carolina|NC051				Geographic Area	US Counties Terminology
C109604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109604>	C107687	Currituck County, NC|Currituck County|Currituck County, North Carolina|NC053				Geographic Area	US Counties Terminology
C109605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109605>	C107687	Dare County, NC|Dare County|Dare County, North Carolina|NC055				Geographic Area	US Counties Terminology
C109606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109606>	C107687	Davidson County, NC|Davidson County|Davidson County, North Carolina|NC057				Geographic Area	US Counties Terminology
C109607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109607>	C107687	Davie County, NC|Davie County|Davie County, North Carolina|NC059				Geographic Area	US Counties Terminology
C109608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109608>	C107687	Duplin County, NC|Duplin County|Duplin County, North Carolina|NC061				Geographic Area	US Counties Terminology
C109609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109609>	C107687	Durham County, NC|Durham County|Durham County, North Carolina|NC063				Geographic Area	US Counties Terminology
C10960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10960>	C61063	Interleukin-2/MART-1 Antigen|IL-2/MART-1			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109610>	C107687	Edgecombe County, NC|Edgecombe County|Edgecombe County, North Carolina|NC065				Geographic Area	US Counties Terminology
C109611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109611>	C107687	Forsyth County, NC|Forsyth County|Forsyth County, North Carolina|NC067				Geographic Area	US Counties Terminology
C109612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109612>	C107687	Franklin County, NC|Franklin County|Franklin County, North Carolina|NC069				Geographic Area	US Counties Terminology
C109613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109613>	C107687	Gaston County, NC|Gaston County|Gaston County, North Carolina|NC071				Geographic Area	US Counties Terminology
C109614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109614>	C107687	Gates County, NC|Gates County|Gates County, North Carolina|NC073				Geographic Area	US Counties Terminology
C109615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109615>	C107687	Graham County, NC|Graham County|Graham County, North Carolina|NC075				Geographic Area	US Counties Terminology
C109616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109616>	C107687	Granville County, NC|Granville County|Granville County, North Carolina|NC077				Geographic Area	US Counties Terminology
C109617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109617>	C107687	Greene County, NC|Greene County|Greene County, North Carolina|NC079				Geographic Area	US Counties Terminology
C109618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109618>	C107687	Guilford County, NC|Guilford County|Guilford County, North Carolina|NC081				Geographic Area	US Counties Terminology
C109619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109619>	C107687	Halifax County, NC|Halifax County|Halifax County, North Carolina|NC083				Geographic Area	US Counties Terminology
C10961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10961>	C61007	Cisplatin/Irinotecan|CDDP/CPT-11			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109620>	C107687	Harnett County, NC|Harnett County|Harnett County, North Carolina|NC085				Geographic Area	US Counties Terminology
C109621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109621>	C107687	Haywood County, NC|Haywood County|Haywood County, North Carolina|NC087				Geographic Area	US Counties Terminology
C109622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109622>	C107687	Henderson County, NC|Henderson County|Henderson County, North Carolina|NC089				Geographic Area	US Counties Terminology
C109623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109623>	C107687	Hertford County, NC|Hertford County|Hertford County, North Carolina|NC091				Geographic Area	US Counties Terminology
C109624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109624>	C107687	Hoke County, NC|Hoke County|Hoke County, North Carolina|NC093				Geographic Area	US Counties Terminology
C109625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109625>	C107687	Hyde County, NC|Hyde County|Hyde County, North Carolina|NC095				Geographic Area	US Counties Terminology
C109626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109626>	C107687	Iredell County, NC|Iredell County|Iredell County, North Carolina|NC097				Geographic Area	US Counties Terminology
C109627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109627>	C107687	Jackson County, NC|Jackson County|Jackson County, North Carolina|NC099				Geographic Area	US Counties Terminology
C109628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109628>	C107687	Johnston County, NC|Johnston County|Johnston County, North Carolina|NC101				Geographic Area	US Counties Terminology
C109629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109629>	C107687	Jones County, NC|Jones County|Jones County, North Carolina|NC103				Geographic Area	US Counties Terminology
C10962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10962>	C61063	Cisplatin/Doxorubicin/Tamoxifen|CDDP/DOX/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109630>	C107687	Lee County, NC|Lee County|Lee County, North Carolina|NC105				Geographic Area	US Counties Terminology
C109631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109631>	C107687	Lenoir County, NC|Lenoir County|Lenoir County, North Carolina|NC107				Geographic Area	US Counties Terminology
C109632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109632>	C107687	Lincoln County, NC|Lincoln County|Lincoln County, North Carolina|NC109				Geographic Area	US Counties Terminology
C109633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109633>	C107687	McDowell County, NC|McDowell County|McDowell County, North Carolina|NC111				Geographic Area	US Counties Terminology
C109634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109634>	C107687	Macon County, NC|Macon County|Macon County, North Carolina|NC113				Geographic Area	US Counties Terminology
C109635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109635>	C107687	Madison County, NC|Madison County|Madison County, North Carolina|NC115				Geographic Area	US Counties Terminology
C109636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109636>	C107687	Martin County, NC|Martin County|Martin County, North Carolina|NC117				Geographic Area	US Counties Terminology
C109637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109637>	C107687	Mecklenburg County, NC|Mecklenburg County|Mecklenburg County, North Carolina|NC119				Geographic Area	US Counties Terminology
C109638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109638>	C107687	Mitchell County, NC|Mitchell County|Mitchell County, North Carolina|NC121				Geographic Area	US Counties Terminology
C109639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109639>	C107687	Montgomery County, NC|Montgomery County|Montgomery County, North Carolina|NC123				Geographic Area	US Counties Terminology
C10963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10963>	C61063	Etoposide/Mitoxantrone/PSC 833|DHAD/PSC 833/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109640>	C107687	Moore County, NC|Moore County|Moore County, North Carolina|NC125				Geographic Area	US Counties Terminology
C109641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109641>	C107687	Nash County, NC|NC127|Nash County|Nash County, North Carolina				Geographic Area	US Counties Terminology
C109642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109642>	C107687	New Hanover County, NC|NC129|New Hanover County|New Hanover County, North Carolina				Geographic Area	US Counties Terminology
C109643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109643>	C107687	Northampton County, NC|NC131|Northampton County|Northampton County, North Carolina				Geographic Area	US Counties Terminology
C109644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109644>	C107687	Onslow County, NC|NC133|Onslow County|Onslow County, North Carolina				Geographic Area	US Counties Terminology
C109645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109645>	C107687	Orange County, NC|NC135|Orange County|Orange County, North Carolina				Geographic Area	US Counties Terminology
C109646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109646>	C107687	Pamlico County, NC|NC137|Pamlico County|Pamlico County, North Carolina				Geographic Area	US Counties Terminology
C109647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109647>	C107687	Pasquotank County, NC|NC139|Pasquotank County|Pasquotank County, North Carolina				Geographic Area	US Counties Terminology
C109648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109648>	C107687	Pender County, NC|NC141|Pender County|Pender County, North Carolina				Geographic Area	US Counties Terminology
C109649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109649>	C107687	Perquimans County, NC|NC143|Perquimans County|Perquimans County, North Carolina				Geographic Area	US Counties Terminology
C10964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10964>	C61063	Estramustine/Vinorelbine|EM/VNB			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109650>	C107687	Person County, NC|NC145|Person County|Person County, North Carolina				Geographic Area	US Counties Terminology
C109651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109651>	C107687	Pitt County, NC|NC147|Pitt County|Pitt County, North Carolina				Geographic Area	US Counties Terminology
C109652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109652>	C107687	Polk County, NC|NC149|Polk County|Polk County, North Carolina				Geographic Area	US Counties Terminology
C109653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109653>	C107687	Randolph County, NC|NC151|Randolph County|Randolph County, North Carolina				Geographic Area	US Counties Terminology
C109654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109654>	C107687	Richmond County, NC|NC153|Richmond County|Richmond County, North Carolina				Geographic Area	US Counties Terminology
C109655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109655>	C107687	Robeson County, NC|NC155|Robeson County|Robeson County, North Carolina				Geographic Area	US Counties Terminology
C109656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109656>	C107687	Rockingham County, NC|NC157|Rockingham County|Rockingham County, North Carolina				Geographic Area	US Counties Terminology
C109657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109657>	C107687	Rowan County, NC|NC159|Rowan County|Rowan County, North Carolina				Geographic Area	US Counties Terminology
C109658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109658>	C107687	Rutherford County, NC|NC161|Rutherford County|Rutherford County, North Carolina				Geographic Area	US Counties Terminology
C109659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109659>	C107687	Sampson County, NC|NC163|Sampson County|Sampson County, North Carolina				Geographic Area	US Counties Terminology
C10965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10965>	C61063	Folic Acid/Lometrexol|FA/LMTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109660>	C107687	Scotland County, NC|NC165|Scotland County|Scotland County, North Carolina				Geographic Area	US Counties Terminology
C109661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109661>	C107687	Stanly County, NC|NC167|Stanly County|Stanly County, North Carolina				Geographic Area	US Counties Terminology
C109662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109662>	C107687	Stokes County, NC|NC169|Stokes County|Stokes County, North Carolina				Geographic Area	US Counties Terminology
C109663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109663>	C107687	Surry County, NC|NC171|Surry County|Surry County, North Carolina				Geographic Area	US Counties Terminology
C109664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109664>	C107687	Swain County, NC|NC173|Swain County|Swain County, North Carolina				Geographic Area	US Counties Terminology
C109665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109665>	C107687	Transylvania County, NC|NC175|Transylvania County|Transylvania County, North Carolina				Geographic Area	US Counties Terminology
C109666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109666>	C107687	Tyrrell County, NC|NC177|Tyrrell County|Tyrrell County, North Carolina				Geographic Area	US Counties Terminology
C109667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109667>	C107687	Union County, NC|NC179|Union County|Union County, North Carolina				Geographic Area	US Counties Terminology
C109668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109668>	C107687	Vance County, NC|NC181|Vance County|Vance County, North Carolina				Geographic Area	US Counties Terminology
C109669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109669>	C107687	Wake County, NC|NC183|Wake County|Wake County, North Carolina				Geographic Area	US Counties Terminology
C10966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10966>	C61007	Cisplatin/Docetaxel|CDDP/TXT			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109670>	C107687	Warren County, NC|NC185|Warren County|Warren County, North Carolina				Geographic Area	US Counties Terminology
C109671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109671>	C107687	Washington County, NC|NC187|Washington County|Washington County, North Carolina				Geographic Area	US Counties Terminology
C109672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109672>	C107687	Watauga County, NC|NC189|Watauga County|Watauga County, North Carolina				Geographic Area	US Counties Terminology
C109673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109673>	C107687	Wayne County, NC|NC191|Wayne County|Wayne County, North Carolina				Geographic Area	US Counties Terminology
C109674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109674>	C107687	Wilkes County, NC|NC193|Wilkes County|Wilkes County, North Carolina				Geographic Area	US Counties Terminology
C109675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109675>	C107687	Wilson County, NC|NC195|Wilson County|Wilson County, North Carolina				Geographic Area	US Counties Terminology
C109676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109676>	C107687	Yadkin County, NC|NC197|Yadkin County|Yadkin County, North Carolina				Geographic Area	US Counties Terminology
C109677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109677>	C107687	Yancey County, NC|NC199|Yancey County|Yancey County, North Carolina				Geographic Area	US Counties Terminology
C109678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109678>	C107687	Adams County, ND|Adams County|Adams County, North Dakota|ND001				Geographic Area	US Counties Terminology
C109679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109679>	C107687	Barnes County, ND|Barnes County|Barnes County, North Dakota|ND003				Geographic Area	US Counties Terminology
C10967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10967>	C61007	Bleomycin/Cisplatin/Cyclophosphamide/Etoposide|BLEO/CDDP/CTX/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109680>	C107687	Benson County, ND|Benson County|Benson County, North Dakota|ND005				Geographic Area	US Counties Terminology
C109681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109681>	C107687	Billings County, ND|Billings County|Billings County, North Dakota|ND007				Geographic Area	US Counties Terminology
C109682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109682>	C107687	Bottineau County, ND|Bottineau County|Bottineau County, North Dakota|ND009				Geographic Area	US Counties Terminology
C109683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109683>	C107687	Bowman County, ND|Bowman County|Bowman County, North Dakota|ND011				Geographic Area	US Counties Terminology
C109684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109684>	C107687	Burke County, ND|Burke County|Burke County, North Dakota|ND013				Geographic Area	US Counties Terminology
C109685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109685>	C107687	Burleigh County, ND|Burleigh County|Burleigh County, North Dakota|ND015				Geographic Area	US Counties Terminology
C109686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109686>	C107687	Cass County, ND|Cass County|Cass County, North Dakota|ND017				Geographic Area	US Counties Terminology
C109687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109687>	C107687	Cavalier County, ND|Cavalier County|Cavalier County, North Dakota|ND019				Geographic Area	US Counties Terminology
C109688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109688>	C107687	Dickey County, ND|Dickey County|Dickey County, North Dakota|ND021				Geographic Area	US Counties Terminology
C109689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109689>	C107687	Divide County, ND|Divide County|Divide County, North Dakota|ND023				Geographic Area	US Counties Terminology
C10968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10968>	C61007	Carmustine/Temozolomide|BCNU/TMZ			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109690>	C107687	Dunn County, ND|Dunn County|Dunn County, North Dakota|ND025				Geographic Area	US Counties Terminology
C109691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109691>	C107687	Eddy County, ND|Eddy County|Eddy County, North Dakota|ND027				Geographic Area	US Counties Terminology
C109692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109692>	C107687	Emmons County, ND|Emmons County|Emmons County, North Dakota|ND029				Geographic Area	US Counties Terminology
C109693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109693>	C107687	Foster County, ND|Foster County|Foster County, North Dakota|ND031				Geographic Area	US Counties Terminology
C109694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109694>	C107687	Golden Valley County, ND|Golden Valley County|Golden Valley County, North Dakota|ND033				Geographic Area	US Counties Terminology
C109695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109695>	C107687	Grand Forks County, ND|Grand Forks County|Grand Forks County, North Dakota|ND035				Geographic Area	US Counties Terminology
C109696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109696>	C107687	Grant County, ND|Grant County|Grant County, North Dakota|ND037				Geographic Area	US Counties Terminology
C109697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109697>	C107687	Griggs County, ND|Griggs County|Griggs County, North Dakota|ND039				Geographic Area	US Counties Terminology
C109698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109698>	C107687	Hettinger County, ND|Hettinger County|Hettinger County, North Dakota|ND041				Geographic Area	US Counties Terminology
C109699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109699>	C107687	Kidder County, ND|Kidder County|Kidder County, North Dakota|ND043				Geographic Area	US Counties Terminology
C10969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10969>	C61063	Fluorouracil/Levamisole/L-Leucovorin|5-FU/L-CF/LEV			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1096>	C1557	Fazarabine|1,3, 5-Triazin-2(1H)-one, 4-Amino-1-beta-D- arabinofuranosyl- (9CI)|1,3, 5-Triazin-2(1H)-one, 4-amino-1-.beta.-D- arabinofuranosyl- (9CI)|1-.beta.-D-Arabinofuranosyl-5-azacytosine|1-Beta-D-arabinofuranosyl-5-azacytosine|Ara AC|Ara AC|FAZARABINE|Kymarabine|Kymarabine|ara-AC|fazarabine	An orally-active pyrimidine analogue of an aza-substituted cytidine in which the ribose moiety is replaced by an arabinose sugar. Similar in action to cytarabine, fazarabine is phosphorylated by deoxycytidine kinase to a triphosphate form which competes with thymidine for incorporation into DNA; its incorporation into DNA inhibits DNA synthesis, resulting in tumor cell death and tumor necrosis. The presence of deoxycytidine kinase in a tumor is a determinant of tumor sensitivity to this drug. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C109700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109700>	C107687	LaMoure County, ND|LaMoure County|LaMoure County, North Dakota|ND045				Geographic Area	US Counties Terminology
C109701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109701>	C107687	Logan County, ND|Logan County|Logan County, North Dakota|ND047				Geographic Area	US Counties Terminology
C109702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109702>	C107687	McHenry County, ND|McHenry County|McHenry County, North Dakota|ND049				Geographic Area	US Counties Terminology
C109703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109703>	C107687	McIntosh County, ND|McIntosh County|McIntosh County, North Dakota|ND051				Geographic Area	US Counties Terminology
C109704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109704>	C107687	McKenzie County, ND|McKenzie County|McKenzie County, North Dakota|ND053				Geographic Area	US Counties Terminology
C109705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109705>	C107687	McLean County, ND|McLean County|McLean County, North Dakota|ND055				Geographic Area	US Counties Terminology
C109706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109706>	C107687	Mercer County, ND|Mercer County|Mercer County, North Dakota|ND057				Geographic Area	US Counties Terminology
C109707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109707>	C107687	Morton County, ND|Morton County|Morton County, North Dakota|ND059				Geographic Area	US Counties Terminology
C109708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109708>	C107687	Mountrail County, ND|Mountrail County|Mountrail County, North Dakota|ND061				Geographic Area	US Counties Terminology
C109709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109709>	C107687	Nelson County, ND|ND063|Nelson County|Nelson County, North Dakota				Geographic Area	US Counties Terminology
C10970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10970>	C61007	Carbogen/Niacinamide|NICOGEN/UN1014			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109710>	C107687	Oliver County, ND|ND065|Oliver County|Oliver County, North Dakota				Geographic Area	US Counties Terminology
C109711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109711>	C107687	Pembina County, ND|ND067|Pembina County|Pembina County, North Dakota				Geographic Area	US Counties Terminology
C109712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109712>	C107687	Pierce County, ND|ND069|Pierce County|Pierce County, North Dakota				Geographic Area	US Counties Terminology
C109713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109713>	C107687	Ramsey County, ND|ND071|Ramsey County|Ramsey County, North Dakota				Geographic Area	US Counties Terminology
C109714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109714>	C107687	Ransom County, ND|ND073|Ransom County|Ransom County, North Dakota				Geographic Area	US Counties Terminology
C109715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109715>	C107687	Renville County, ND|ND075|Renville County|Renville County, North Dakota				Geographic Area	US Counties Terminology
C109716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109716>	C107687	Richland County, ND|ND077|Richland County|Richland County, North Dakota				Geographic Area	US Counties Terminology
C109717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109717>	C107687	Rolette County, ND|ND079|Rolette County|Rolette County, North Dakota				Geographic Area	US Counties Terminology
C109718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109718>	C107687	Sargent County, ND|ND081|Sargent County|Sargent County, North Dakota				Geographic Area	US Counties Terminology
C109719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109719>	C107687	Sheridan County, ND|ND083|Sheridan County|Sheridan County, North Dakota				Geographic Area	US Counties Terminology
C10971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10971>	C61063	Leucovorin Calcium/Tegafur/Uracil|CF/UFT			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109720>	C107687	Sioux County, ND|ND085|Sioux County|Sioux County, North Dakota				Geographic Area	US Counties Terminology
C109721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109721>	C107687	Slope County, ND|ND087|Slope County|Slope County, North Dakota				Geographic Area	US Counties Terminology
C109722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109722>	C107687	Stark County, ND|ND089|Stark County|Stark County, North Dakota				Geographic Area	US Counties Terminology
C109723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109723>	C107687	Steele County, ND|ND091|Steele County|Steele County, North Dakota				Geographic Area	US Counties Terminology
C109724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109724>	C107687	Stutsman County, ND|ND093|Stutsman County|Stutsman County, North Dakota				Geographic Area	US Counties Terminology
C109725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109725>	C107687	Towner County, ND|ND095|Towner County|Towner County, North Dakota				Geographic Area	US Counties Terminology
C109726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109726>	C107687	Traill County, ND|ND097|Traill County|Traill County, North Dakota				Geographic Area	US Counties Terminology
C109727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109727>	C107687	Walsh County, ND|ND099|Walsh County|Walsh County, North Dakota				Geographic Area	US Counties Terminology
C109728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109728>	C107687	Ward County, ND|ND101|Ward County|Ward County, North Dakota				Geographic Area	US Counties Terminology
C109729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109729>	C107687	Wells County, ND|ND103|Wells County|Wells County, North Dakota				Geographic Area	US Counties Terminology
C10972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10972>	C61063	Fludarabine/Mitoxantrone|DHAD/FAMP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109730>	C107687	Williams County, ND|ND105|Williams County|Williams County, North Dakota				Geographic Area	US Counties Terminology
C109731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109731>	C107687	Adams County, OH|Adams County|Adams County, Ohio|OH001				Geographic Area	US Counties Terminology
C109732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109732>	C107687	Allen County, OH|Allen County|Allen County, Ohio|OH003				Geographic Area	US Counties Terminology
C109733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109733>	C107687	Ashland County, OH|Ashland County|Ashland County, Ohio|OH005				Geographic Area	US Counties Terminology
C109734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109734>	C107687	Ashtabula County, OH|Ashtabula County|Ashtabula County, Ohio|OH007				Geographic Area	US Counties Terminology
C109735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109735>	C107687	Athens County, OH|Athens County|Athens County, Ohio|OH009				Geographic Area	US Counties Terminology
C109736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109736>	C107687	Auglaize County, OH|Auglaize County|Auglaize County, Ohio|OH011				Geographic Area	US Counties Terminology
C109737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109737>	C107687	Belmont County, OH|Belmont County|Belmont County, Ohio|OH013				Geographic Area	US Counties Terminology
C109738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109738>	C107687	Brown County, OH|Brown County|Brown County, Ohio|OH015				Geographic Area	US Counties Terminology
C109739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109739>	C107687	Butler County, OH|Butler County|Butler County, Ohio|OH017				Geographic Area	US Counties Terminology
C10973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10973>	C61063	Ifosfamide/Vinorelbine|IFF/VNB			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109740>	C107687	Carroll County, OH|Carroll County|Carroll County, Ohio|OH019				Geographic Area	US Counties Terminology
C109741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109741>	C107687	Champaign County, OH|Champaign County|Champaign County, Ohio|OH021				Geographic Area	US Counties Terminology
C109742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109742>	C107687	Clark County, OH|Clark County|Clark County, Ohio|OH023				Geographic Area	US Counties Terminology
C109743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109743>	C107687	Clermont County, OH|Clermont County|Clermont County, Ohio|OH025				Geographic Area	US Counties Terminology
C109744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109744>	C107687	Clinton County, OH|Clinton County|Clinton County, Ohio|OH027				Geographic Area	US Counties Terminology
C109745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109745>	C107687	Columbiana County, OH|Columbiana County|Columbiana County, Ohio|OH029				Geographic Area	US Counties Terminology
C109746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109746>	C107687	Coshocton County, OH|Coshocton County|Coshocton County, Ohio|OH031				Geographic Area	US Counties Terminology
C109747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109747>	C107687	Crawford County, OH|Crawford County|Crawford County, Ohio|OH033				Geographic Area	US Counties Terminology
C109748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109748>	C107687	Cuyahoga County, OH|Cuyahoga County|Cuyahoga County, Ohio|OH035				Geographic Area	US Counties Terminology
C109749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109749>	C107687	Darke County, OH|Darke County|Darke County, Ohio|OH037				Geographic Area	US Counties Terminology
C10974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10974>	C61063	Fluorouracil/L-Leucovorin/Methotrexate|5-FU/L-CF/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109750>	C107687	Defiance County, OH|Defiance County|Defiance County, Ohio|OH039				Geographic Area	US Counties Terminology
C109751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109751>	C107687	Delaware County, OH|Delaware County|Delaware County, Ohio|OH041				Geographic Area	US Counties Terminology
C109752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109752>	C107687	Erie County, OH|Erie County|Erie County, Ohio|OH043				Geographic Area	US Counties Terminology
C109753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109753>	C107687	Fairfield County, OH|Fairfield County|Fairfield County, Ohio|OH045				Geographic Area	US Counties Terminology
C109754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109754>	C107687	Fayette County, OH|Fayette County|Fayette County, Ohio|OH047				Geographic Area	US Counties Terminology
C109755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109755>	C107687	Franklin County, OH|Franklin County|Franklin County, Ohio|OH049				Geographic Area	US Counties Terminology
C109756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109756>	C107687	Fulton County, OH|Fulton County|Fulton County, Ohio|OH051				Geographic Area	US Counties Terminology
C109757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109757>	C107687	Gallia County, OH|Gallia County|Gallia County, Ohio|OH053				Geographic Area	US Counties Terminology
C109758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109758>	C107687	Geauga County, OH|Geauga County|Geauga County, Ohio|OH055				Geographic Area	US Counties Terminology
C109759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109759>	C107687	Greene County, OH|Greene County|Greene County, Ohio|OH057				Geographic Area	US Counties Terminology
C10975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10975>	C61063	Cytarabine/Daunorubicin/Etoposide/Filgrastim|ARA-C/DNR/G-CSF/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109760>	C107687	Guernsey County, OH|Guernsey County|Guernsey County, Ohio|OH059				Geographic Area	US Counties Terminology
C109761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109761>	C107687	Hamilton County, OH|Hamilton County|Hamilton County, Ohio|OH061				Geographic Area	US Counties Terminology
C109762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109762>	C107687	Hancock County, OH|Hancock County|Hancock County, Ohio|OH063				Geographic Area	US Counties Terminology
C109763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109763>	C107687	Hardin County, OH|Hardin County|Hardin County, Ohio|OH065				Geographic Area	US Counties Terminology
C109764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109764>	C107687	Harrison County, OH|Harrison County|Harrison County, Ohio|OH067				Geographic Area	US Counties Terminology
C109765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109765>	C107687	Henry County, OH|Henry County|Henry County, Ohio|OH069				Geographic Area	US Counties Terminology
C109766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109766>	C107687	Highland County, OH|Highland County|Highland County, Ohio|OH071				Geographic Area	US Counties Terminology
C109767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109767>	C107687	Hocking County, OH|Hocking County|Hocking County, Ohio|OH073				Geographic Area	US Counties Terminology
C109768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109768>	C107687	Holmes County, OH|Holmes County|Holmes County, Ohio|OH075				Geographic Area	US Counties Terminology
C109769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109769>	C107687	Huron County, OH|Huron County|Huron County, Ohio|OH077				Geographic Area	US Counties Terminology
C10976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10976>	C61063	Busulfan/Cytarabine/Melphalan|ARA-C/BU/L-PAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109770>	C107687	Jackson County, OH|Jackson County|Jackson County, Ohio|OH079				Geographic Area	US Counties Terminology
C109771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109771>	C107687	Jefferson County, OH|Jefferson County|Jefferson County, Ohio|OH081				Geographic Area	US Counties Terminology
C109772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109772>	C107687	Knox County, OH|Knox County|Knox County, Ohio|OH083				Geographic Area	US Counties Terminology
C109773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109773>	C107687	Lake County, OH|Lake County|Lake County, Ohio|OH085				Geographic Area	US Counties Terminology
C109774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109774>	C107687	Lawrence County, OH|Lawrence County|Lawrence County, Ohio|OH087				Geographic Area	US Counties Terminology
C109775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109775>	C107687	Licking County, OH|Licking County|Licking County, Ohio|OH089				Geographic Area	US Counties Terminology
C109776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109776>	C107687	Logan County, OH|Logan County|Logan County, Ohio|OH091				Geographic Area	US Counties Terminology
C109777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109777>	C107687	Lorain County, OH|Lorain County|Lorain County, Ohio|OH093				Geographic Area	US Counties Terminology
C109778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109778>	C107687	Lucas County, OH|Lucas County|Lucas County, Ohio|OH095				Geographic Area	US Counties Terminology
C109779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109779>	C107687	Madison County, OH|Madison County|Madison County, Ohio|OH097				Geographic Area	US Counties Terminology
C10977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10977>	C61063	Dexverapamil/Doxorubicin|DOX/R-VPAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109780>	C107687	Mahoning County, OH|Mahoning County|Mahoning County, Ohio|OH099				Geographic Area	US Counties Terminology
C109781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109781>	C107687	Marion County, OH|Marion County|Marion County, Ohio|OH101				Geographic Area	US Counties Terminology
C109782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109782>	C107687	Medina County, OH|Medina County|Medina County, Ohio|OH103				Geographic Area	US Counties Terminology
C109783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109783>	C107687	Meigs County, OH|Meigs County|Meigs County, Ohio|OH105				Geographic Area	US Counties Terminology
C109784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109784>	C107687	Mercer County, OH|Mercer County|Mercer County, Ohio|OH107				Geographic Area	US Counties Terminology
C109785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109785>	C107687	Miami County, OH|Miami County|Miami County, Ohio|OH109				Geographic Area	US Counties Terminology
C109786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109786>	C107687	Monroe County, OH|Monroe County|Monroe County, Ohio|OH111				Geographic Area	US Counties Terminology
C109787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109787>	C107687	Montgomery County, OH|Montgomery County|Montgomery County, Ohio|OH113				Geographic Area	US Counties Terminology
C109788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109788>	C107687	Morgan County, OH|Morgan County|Morgan County, Ohio|OH115				Geographic Area	US Counties Terminology
C109789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109789>	C107687	Morrow County, OH|Morrow County|Morrow County, Ohio|OH117				Geographic Area	US Counties Terminology
C10978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10978>	C61007	Daunorubicin/Pegaspargase/Prednisone/Vincristine|DNR/PEG-ASP/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109790>	C107687	Muskingum County, OH|Muskingum County|Muskingum County, Ohio|OH119				Geographic Area	US Counties Terminology
C109791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109791>	C107687	Noble County, OH|Noble County|Noble County, Ohio|OH121				Geographic Area	US Counties Terminology
C109792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109792>	C107687	Ottawa County, OH|OH123|Ottawa County|Ottawa County, Ohio				Geographic Area	US Counties Terminology
C109793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109793>	C107687	Paulding County, OH|OH125|Paulding County|Paulding County, Ohio				Geographic Area	US Counties Terminology
C109794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109794>	C107687	Perry County, OH|OH127|Perry County|Perry County, Ohio				Geographic Area	US Counties Terminology
C109795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109795>	C107687	Pickaway County, OH|OH129|Pickaway County|Pickaway County, Ohio				Geographic Area	US Counties Terminology
C109796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109796>	C107687	Pike County, OH|OH131|Pike County|Pike County, Ohio				Geographic Area	US Counties Terminology
C109797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109797>	C107687	Portage County, OH|OH133|Portage County|Portage County, Ohio				Geographic Area	US Counties Terminology
C109798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109798>	C107687	Preble County, OH|OH135|Preble County|Preble County, Ohio				Geographic Area	US Counties Terminology
C109799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109799>	C107687	Putnam County, OH|OH137|Putnam County|Putnam County, Ohio				Geographic Area	US Counties Terminology
C10979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10979>	C61063	Daunorubicin/Milodistim/Pegaspargase/Prednisone/Vincristine|DNR/PEG-ASP/PIXY321/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1097>	C2017	Exemestane|6-Methyleneandrosta-1,4-diene-3,17-dione|Aromasin|Aromasin|EXEMESTANE|FCE-24304|exemestane	An irreversible steroidal aromatase inhibitor, with antiestrogen and antineoplastic activities. Upon oral administration, exemestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the peripheral aromatization of androgens, including androstenedione and testosterone, to estrogens. This lowers estrogen levels in the blood circulation.	Exemestane		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C109800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109800>	C107687	Richland County, OH|OH139|Richland County|Richland County, Ohio				Geographic Area	US Counties Terminology
C109801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109801>	C107687	Ross County, OH|OH141|Ross County|Ross County, Ohio				Geographic Area	US Counties Terminology
C109802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109802>	C107687	Sandusky County, OH|OH143|Sandusky County|Sandusky County, Ohio				Geographic Area	US Counties Terminology
C109803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109803>	C107687	Scioto County, OH|OH145|Scioto County|Scioto County, Ohio				Geographic Area	US Counties Terminology
C109804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109804>	C107687	Seneca County, OH|OH147|Seneca County|Seneca County, Ohio				Geographic Area	US Counties Terminology
C109805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109805>	C107687	Shelby County, OH|OH149|Shelby County|Shelby County, Ohio				Geographic Area	US Counties Terminology
C109806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109806>	C107687	Stark County, OH|OH151|Stark County|Stark County, Ohio				Geographic Area	US Counties Terminology
C109807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109807>	C107687	Summit County, OH|OH153|Summit County|Summit County, Ohio				Geographic Area	US Counties Terminology
C109808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109808>	C107687	Trumbull County, OH|OH155|Trumbull County|Trumbull County, Ohio				Geographic Area	US Counties Terminology
C109809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109809>	C107687	Tuscarawas County, OH|OH157|Tuscarawas County|Tuscarawas County, Ohio				Geographic Area	US Counties Terminology
C10980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10980>	C61063	Interleukin-2/NG-Monomethyl-L-Arginine|IL-2/NMA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109810>	C107687	Union County, OH|OH159|Union County|Union County, Ohio				Geographic Area	US Counties Terminology
C109811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109811>	C107687	Van Wert County, OH|OH161|Van Wert County|Van Wert County, Ohio				Geographic Area	US Counties Terminology
C109812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109812>	C107687	Vinton County, OH|OH163|Vinton County|Vinton County, Ohio				Geographic Area	US Counties Terminology
C109813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109813>	C107687	Warren County, OH|OH165|Warren County|Warren County, Ohio				Geographic Area	US Counties Terminology
C109814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109814>	C107687	Washington County, OH|OH167|Washington County|Washington County, Ohio				Geographic Area	US Counties Terminology
C109815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109815>	C107687	Wayne County, OH|OH169|Wayne County|Wayne County, Ohio				Geographic Area	US Counties Terminology
C109816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109816>	C107687	Williams County, OH|OH171|Williams County|Williams County, Ohio				Geographic Area	US Counties Terminology
C109817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109817>	C107687	Wood County, OH|OH173|Wood County|Wood County, Ohio				Geographic Area	US Counties Terminology
C109818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109818>	C107687	Wyandot County, OH|OH175|Wyandot County|Wyandot County, Ohio				Geographic Area	US Counties Terminology
C109819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109819>	C107687	Adair County, OK|Adair County|Adair County, Oklahoma|OK001				Geographic Area	US Counties Terminology
C10981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10981>	C61063	Leucovorin Calcium/Trimetrexate Glucuronate|CF/TMTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109820>	C107687	Alfalfa County, OK|Alfalfa County|Alfalfa County, Oklahoma|OK003				Geographic Area	US Counties Terminology
C109821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109821>	C107687	Atoka County, OK|Atoka County|Atoka County, Oklahoma|OK005				Geographic Area	US Counties Terminology
C109822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109822>	C107687	Beaver County, OK|Beaver County|Beaver County, Oklahoma|OK007				Geographic Area	US Counties Terminology
C109823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109823>	C107687	Beckham County, OK|Beckham County|Beckham County, Oklahoma|OK009				Geographic Area	US Counties Terminology
C109824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109824>	C107687	Blaine County, OK|Blaine County|Blaine County, Oklahoma|OK011				Geographic Area	US Counties Terminology
C109825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109825>	C107687	Bryan County, OK|Bryan County|Bryan County, Oklahoma|OK013				Geographic Area	US Counties Terminology
C109826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109826>	C107687	Caddo County, OK|Caddo County|Caddo County, Oklahoma|OK015				Geographic Area	US Counties Terminology
C109827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109827>	C107687	Canadian County, OK|Canadian County|Canadian County, Oklahoma|OK017				Geographic Area	US Counties Terminology
C109828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109828>	C107687	Carter County, OK|Carter County|Carter County, Oklahoma|OK019				Geographic Area	US Counties Terminology
C109829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109829>	C107687	Cherokee County, OK|Cherokee County|Cherokee County, Oklahoma|OK021				Geographic Area	US Counties Terminology
C10982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10982>	C61063	Cyclophosphamide/Fluorouracil/Pirarubicin|CTX/5-FU/THP-DOX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109830>	C107687	Choctaw County, OK|Choctaw County|Choctaw County, Oklahoma|OK023				Geographic Area	US Counties Terminology
C109831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109831>	C107687	Cimarron County, OK|Cimarron County|Cimarron County, Oklahoma|OK025				Geographic Area	US Counties Terminology
C109832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109832>	C107687	Cleveland County, OK|Cleveland County|Cleveland County, Oklahoma|OK027				Geographic Area	US Counties Terminology
C109833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109833>	C107687	Coal County, OK|Coal County|Coal County, Oklahoma|OK029				Geographic Area	US Counties Terminology
C109834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109834>	C107687	Comanche County, OK|Comanche County|Comanche County, Oklahoma|OK031				Geographic Area	US Counties Terminology
C109835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109835>	C107687	Cotton County, OK|Cotton County|Cotton County, Oklahoma|OK033				Geographic Area	US Counties Terminology
C109836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109836>	C107687	Craig County, OK|Craig County|Craig County, Oklahoma|OK035				Geographic Area	US Counties Terminology
C109837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109837>	C107687	Creek County, OK|Creek County|Creek County, Oklahoma|OK037				Geographic Area	US Counties Terminology
C109838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109838>	C107687	Custer County, OK|Custer County|Custer County, Oklahoma|OK039				Geographic Area	US Counties Terminology
C109839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109839>	C107687	Delaware County, OK|Delaware County|Delaware County, Oklahoma|OK041				Geographic Area	US Counties Terminology
C10983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10983>	C61063	Dacarbazine/Pirarubicin|DTIC/THP-DOX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109840>	C107687	Dewey County, OK|Dewey County|Dewey County, Oklahoma|OK043				Geographic Area	US Counties Terminology
C109841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109841>	C107687	Ellis County, OK|Ellis County|Ellis County, Oklahoma|OK045				Geographic Area	US Counties Terminology
C109842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109842>	C107687	Garfield County, OK|Garfield County|Garfield County, Oklahoma|OK047				Geographic Area	US Counties Terminology
C109843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109843>	C107687	Garvin County, OK|Garvin County|Garvin County, Oklahoma|OK049				Geographic Area	US Counties Terminology
C109844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109844>	C107687	Grady County, OK|Grady County|Grady County, Oklahoma|OK051				Geographic Area	US Counties Terminology
C109845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109845>	C107687	Grant County, OK|Grant County|Grant County, Oklahoma|OK053				Geographic Area	US Counties Terminology
C109846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109846>	C107687	Greer County, OK|Greer County|Greer County, Oklahoma|OK055				Geographic Area	US Counties Terminology
C109847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109847>	C107687	Harmon County, OK|Harmon County|Harmon County, Oklahoma|OK057				Geographic Area	US Counties Terminology
C109848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109848>	C107687	Harper County, OK|Harper County|Harper County, Oklahoma|OK059				Geographic Area	US Counties Terminology
C109849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109849>	C107687	Haskell County, OK|Haskell County|Haskell County, Oklahoma|OK061				Geographic Area	US Counties Terminology
C10984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10984>	C61063	Zalcitabine/Zidovudine|ddC/ZDV			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109850>	C107687	Hughes County, OK|Hughes County|Hughes County, Oklahoma|OK063				Geographic Area	US Counties Terminology
C109851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109851>	C107687	Jackson County, OK|Jackson County|Jackson County, Oklahoma|OK065				Geographic Area	US Counties Terminology
C109852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109852>	C107687	Jefferson County, OK|Jefferson County|Jefferson County, Oklahoma|OK067				Geographic Area	US Counties Terminology
C109853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109853>	C107687	Johnston County, OK|Johnston County|Johnston County, Oklahoma|OK069				Geographic Area	US Counties Terminology
C109854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109854>	C107687	Kay County, OK|Kay County|Kay County, Oklahoma|OK071				Geographic Area	US Counties Terminology
C109855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109855>	C107687	Kingfisher County, OK|Kingfisher County|Kingfisher County, Oklahoma|OK073				Geographic Area	US Counties Terminology
C109856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109856>	C107687	Kiowa County, OK|Kiowa County|Kiowa County, Oklahoma|OK075				Geographic Area	US Counties Terminology
C109857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109857>	C107687	Latimer County, OK|Latimer County|Latimer County, Oklahoma|OK077				Geographic Area	US Counties Terminology
C109858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109858>	C107687	Le Flore County, OK|Le Flore County|Le Flore County, Oklahoma|OK079				Geographic Area	US Counties Terminology
C109859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109859>	C107687	Lincoln County, OK|Lincoln County|Lincoln County, Oklahoma|OK081				Geographic Area	US Counties Terminology
C10985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10985>	C61063	Cyclophosphamide/Interferon Alfa/Interleukin-2|CTX/IFN-A/IL-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109860>	C107687	Logan County, OK|Logan County|Logan County, Oklahoma|OK083				Geographic Area	US Counties Terminology
C109861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109861>	C107687	Love County, OK|Love County|Love County, Oklahoma|OK085				Geographic Area	US Counties Terminology
C109862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109862>	C107687	McClain County, OK|McClain County|McClain County, Oklahoma|OK087				Geographic Area	US Counties Terminology
C109863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109863>	C107687	McCurtain County, OK|McCurtain County|McCurtain County, Oklahoma|OK089				Geographic Area	US Counties Terminology
C109864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109864>	C107687	McIntosh County, OK|McIntosh County|McIntosh County, Oklahoma|OK091				Geographic Area	US Counties Terminology
C109865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109865>	C107687	Major County, OK|Major County|Major County, Oklahoma|OK093				Geographic Area	US Counties Terminology
C109866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109866>	C107687	Marshall County, OK|Marshall County|Marshall County, Oklahoma|OK095				Geographic Area	US Counties Terminology
C109867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109867>	C107687	Mayes County, OK|Mayes County|Mayes County, Oklahoma|OK097				Geographic Area	US Counties Terminology
C109868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109868>	C107687	Murray County, OK|Murray County|Murray County, Oklahoma|OK099				Geographic Area	US Counties Terminology
C109869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109869>	C107687	Muskogee County, OK|Muskogee County|Muskogee County, Oklahoma|OK101				Geographic Area	US Counties Terminology
C10986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10986>	C61063	Interferon Alfa/Vinblastine|IFN-A/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109870>	C107687	Noble County, OK|Noble County|Noble County, Oklahoma|OK103				Geographic Area	US Counties Terminology
C109871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109871>	C107687	Nowata County, OK|Nowata County|Nowata County, Oklahoma|OK105				Geographic Area	US Counties Terminology
C109872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109872>	C107687	Okfuskee County, OK|OK107|Okfuskee County|Okfuskee County, Oklahoma				Geographic Area	US Counties Terminology
C109873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109873>	C107687	Oklahoma County, OK|OK109|Oklahoma County|Oklahoma County, Oklahoma				Geographic Area	US Counties Terminology
C109874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109874>	C107687	Okmulgee County, OK|OK111|Okmulgee County|Okmulgee County, Oklahoma				Geographic Area	US Counties Terminology
C109875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109875>	C107687	Osage County, OK|OK113|Osage County|Osage County, Oklahoma				Geographic Area	US Counties Terminology
C109876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109876>	C107687	Ottawa County, OK|OK115|Ottawa County|Ottawa County, Oklahoma				Geographic Area	US Counties Terminology
C109877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109877>	C107687	Pawnee County, OK|OK117|Pawnee County|Pawnee County, Oklahoma				Geographic Area	US Counties Terminology
C109878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109878>	C107687	Payne County, OK|OK119|Payne County|Payne County, Oklahoma				Geographic Area	US Counties Terminology
C109879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109879>	C107687	Pittsburg County, OK|OK121|Pittsburg County|Pittsburg County, Oklahoma				Geographic Area	US Counties Terminology
C10987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10987>	C61007	Fluorouracil/Interferon Alfa|5-FU/IFN-A|5FU/Interferon|IFN/5FU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109880>	C107687	Pontotoc County, OK|OK123|Pontotoc County|Pontotoc County, Oklahoma				Geographic Area	US Counties Terminology
C109881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109881>	C107687	Pottawatomie County, OK|OK125|Pottawatomie County|Pottawatomie County, Oklahoma				Geographic Area	US Counties Terminology
C109882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109882>	C107687	Pushmataha County, OK|OK127|Pushmataha County|Pushmataha County, Oklahoma				Geographic Area	US Counties Terminology
C109883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109883>	C107687	Roger Mills County, OK|OK129|Roger Mills County|Roger Mills County, Oklahoma				Geographic Area	US Counties Terminology
C109884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109884>	C107687	Rogers County, OK|OK131|Rogers County|Rogers County, Oklahoma				Geographic Area	US Counties Terminology
C109885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109885>	C107687	Seminole County, OK|OK133|Seminole County|Seminole County, Oklahoma				Geographic Area	US Counties Terminology
C109886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109886>	C107687	Sequoyah County, OK|OK135|Sequoyah County|Sequoyah County, Oklahoma				Geographic Area	US Counties Terminology
C109887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109887>	C107687	Stephens County, OK|OK137|Stephens County|Stephens County, Oklahoma				Geographic Area	US Counties Terminology
C109888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109888>	C107687	Texas County, OK|OK139|Texas County|Texas County, Oklahoma				Geographic Area	US Counties Terminology
C109889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109889>	C107687	Tillman County, OK|OK141|Tillman County|Tillman County, Oklahoma				Geographic Area	US Counties Terminology
C10988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10988>	C61063	Interferon Alfa/Sargramostim/Zidovudine|GM-CSF/IFN-A/ZDV			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109890>	C107687	Tulsa County, OK|OK143|Tulsa County|Tulsa County, Oklahoma				Geographic Area	US Counties Terminology
C109891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109891>	C107687	Wagoner County, OK|OK145|Wagoner County|Wagoner County, Oklahoma				Geographic Area	US Counties Terminology
C109892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109892>	C107687	Washington County, OK|OK147|Washington County|Washington County, Oklahoma				Geographic Area	US Counties Terminology
C109893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109893>	C107687	Washita County, OK|OK149|Washita County|Washita County, Oklahoma				Geographic Area	US Counties Terminology
C109894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109894>	C107687	Woods County, OK|OK151|Woods County|Woods County, Oklahoma				Geographic Area	US Counties Terminology
C109895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109895>	C107687	Woodward County, OK|OK153|Woodward County|Woodward County, Oklahoma				Geographic Area	US Counties Terminology
C109896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109896>	C107687	Baker County, OR|Baker County|Baker County, Oregon|OR001				Geographic Area	US Counties Terminology
C109897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109897>	C107687	Benton County, OR|Benton County|Benton County, Oregon|OR003				Geographic Area	US Counties Terminology
C109898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109898>	C107687	Clackamas County, OR|Clackamas County|Clackamas County, Oregon|OR005				Geographic Area	US Counties Terminology
C109899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109899>	C107687	Clatsop County, OR|Clatsop County|Clatsop County, Oregon|OR007				Geographic Area	US Counties Terminology
C10989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10989>	C61063	Doxorubicin/eflornithine/Interferon Alfa|DFMO/DOX/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1098>	C804	Fenretinide|4-(all-trans-retino-yl)aminophenol|4-HPR|4-Hydroxyphenylretinamide|All-trans-4'-Hydroxyretinanilide|FENRETINIDE|Fenretinimide|HPR-4|McN-R-1967|N-(4-hydroxyphenyl)retinamide|N-(4-hydroxyphenyl)retinamide|all-trans-4'-hydroxyretinanilide|all-trans-N-(4-Hydroxyphenyl)retinamide|all-trans-N-4'-hydroxyretinanilide|fenretinide	An orally-active synthetic phenylretinamide analogue of retinol (vitamin A) with potential antineoplastic and chemopreventive activities.  Fenretinide binds to and activates retinoic acid receptors (RARs), thereby inducing cell differentiation and apoptosis in some tumor cell types.  This agent also inhibits tumor growth by modulating angiogenesis-associated growth factors and their receptors and exhibits retinoid receptor-independent apoptotic properties. (NCI04)	Fenretinide		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C109900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109900>	C107687	Columbia County, OR|Columbia County|Columbia County, Oregon|OR009				Geographic Area	US Counties Terminology
C109901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109901>	C107687	Coos County, OR|Coos County|Coos County, Oregon|OR011				Geographic Area	US Counties Terminology
C109902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109902>	C107687	Crook County, OR|Crook County|Crook County, Oregon|OR013				Geographic Area	US Counties Terminology
C109903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109903>	C107687	Curry County, OR|Curry County|Curry County, Oregon|OR015				Geographic Area	US Counties Terminology
C109904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109904>	C107687	Deschutes County, OR|Deschutes County|Deschutes County, Oregon|OR017				Geographic Area	US Counties Terminology
C109905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109905>	C107687	Douglas County, OR|Douglas County|Douglas County, Oregon|OR019				Geographic Area	US Counties Terminology
C109906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109906>	C107687	Gilliam County, OR|Gilliam County|Gilliam County, Oregon|OR021				Geographic Area	US Counties Terminology
C109907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109907>	C107687	Grant County, OR|Grant County|Grant County, Oregon|OR023				Geographic Area	US Counties Terminology
C109908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109908>	C107687	Harney County, OR|Harney County|Harney County, Oregon|OR025				Geographic Area	US Counties Terminology
C109909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109909>	C107687	Hood River County, OR|Hood River County|Hood River County, Oregon|OR027				Geographic Area	US Counties Terminology
C10990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10990>	C61063	Interferon Alfa/Prednisone|IFN-A/PRED			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109910>	C107687	Jackson County, OR|Jackson County|Jackson County, Oregon|OR029				Geographic Area	US Counties Terminology
C109911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109911>	C107687	Jefferson County, OR|Jefferson County|Jefferson County, Oregon|OR031				Geographic Area	US Counties Terminology
C109912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109912>	C107687	Josephine County, OR|Josephine County|Josephine County, Oregon|OR033				Geographic Area	US Counties Terminology
C109913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109913>	C107687	Klamath County, OR|Klamath County|Klamath County, Oregon|OR035				Geographic Area	US Counties Terminology
C109914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109914>	C107687	Lake County, OR|Lake County|Lake County, Oregon|OR037				Geographic Area	US Counties Terminology
C109915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109915>	C107687	Lane County, OR|Lane County|Lane County, Oregon|OR039				Geographic Area	US Counties Terminology
C109916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109916>	C107687	Lincoln County, OR|Lincoln County|Lincoln County, Oregon|OR041				Geographic Area	US Counties Terminology
C109917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109917>	C107687	Linn County, OR|Linn County|Linn County, Oregon|OR043				Geographic Area	US Counties Terminology
C109918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109918>	C107687	Malheur County, OR|Malheur County|Malheur County, Oregon|OR045				Geographic Area	US Counties Terminology
C109919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109919>	C107687	Marion County, OR|Marion County|Marion County, Oregon|OR047				Geographic Area	US Counties Terminology
C10991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10991>	C61007	Interferon Alfa/Tamoxifen|IFN-A/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109920>	C107687	Morrow County, OR|Morrow County|Morrow County, Oregon|OR049				Geographic Area	US Counties Terminology
C109921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109921>	C107687	Multnomah County, OR|Multnomah County|Multnomah County, Oregon|OR051				Geographic Area	US Counties Terminology
C109922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109922>	C107687	Polk County, OR|OR053|Polk County|Polk County, Oregon				Geographic Area	US Counties Terminology
C109923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109923>	C107687	Sherman County, OR|OR055|Sherman County|Sherman County, Oregon				Geographic Area	US Counties Terminology
C109924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109924>	C107687	Tillamook County, OR|OR057|Tillamook County|Tillamook County, Oregon				Geographic Area	US Counties Terminology
C109925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109925>	C107687	Umatilla County, OR|OR059|Umatilla County|Umatilla County, Oregon				Geographic Area	US Counties Terminology
C109926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109926>	C107687	Union County, OR|OR061|Union County|Union County, Oregon				Geographic Area	US Counties Terminology
C109927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109927>	C107687	Wallowa County, OR|OR063|Wallowa County|Wallowa County, Oregon				Geographic Area	US Counties Terminology
C109928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109928>	C107687	Wasco County, OR|OR065|Wasco County|Wasco County, Oregon				Geographic Area	US Counties Terminology
C109929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109929>	C107687	Washington County, OR|OR067|Washington County|Washington County, Oregon				Geographic Area	US Counties Terminology
C10992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10992>	C61063	Fluorouracil/Interferon Alfa/Mitomycin|5-FU/IFN-A/MITO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109930>	C107687	Wheeler County, OR|OR069|Wheeler County|Wheeler County, Oregon				Geographic Area	US Counties Terminology
C109931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109931>	C107687	Yamhill County, OR|OR071|Yamhill County|Yamhill County, Oregon				Geographic Area	US Counties Terminology
C109932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109932>	C107687	Adams County, PA|Adams County|Adams County, Pennsylvania|PA001				Geographic Area	US Counties Terminology
C109933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109933>	C107687	Allegheny County, PA|Allegheny County|Allegheny County, Pennsylvania|PA003				Geographic Area	US Counties Terminology
C109934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109934>	C107687	Armstrong County, PA|Armstrong County|Armstrong County, Pennsylvania|PA005				Geographic Area	US Counties Terminology
C109935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109935>	C107687	Beaver County, PA|Beaver County|Beaver County, Pennsylvania|PA007				Geographic Area	US Counties Terminology
C109936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109936>	C107687	Bedford County, PA|Bedford County|Bedford County, Pennsylvania|PA009				Geographic Area	US Counties Terminology
C109937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109937>	C107687	Berks County, PA|Berks County|Berks County, Pennsylvania|PA011				Geographic Area	US Counties Terminology
C109938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109938>	C107687	Blair County, PA|Blair County|Blair County, Pennsylvania|PA013				Geographic Area	US Counties Terminology
C109939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109939>	C107687	Bradford County, PA|Bradford County|Bradford County, Pennsylvania|PA015				Geographic Area	US Counties Terminology
C10993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10993>	C61063	Eflornithine/Interferon Alfa|DFMO/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109940>	C107687	Bucks County, PA|Bucks County|Bucks County, Pennsylvania|PA017				Geographic Area	US Counties Terminology
C109941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109941>	C107687	Butler County, PA|Butler County|Butler County, Pennsylvania|PA019				Geographic Area	US Counties Terminology
C109942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109942>	C107687	Cambria County, PA|Cambria County|Cambria County, Pennsylvania|PA021				Geographic Area	US Counties Terminology
C109943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109943>	C107687	Cameron County, PA|Cameron County|Cameron County, Pennsylvania|PA023				Geographic Area	US Counties Terminology
C109944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109944>	C107687	Carbon County, PA|Carbon County|Carbon County, Pennsylvania|PA025				Geographic Area	US Counties Terminology
C109945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109945>	C107687	Centre County, PA|Centre County|Centre County, Pennsylvania|PA027				Geographic Area	US Counties Terminology
C109946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109946>	C107687	Chester County, PA|Chester County|Chester County, Pennsylvania|PA029				Geographic Area	US Counties Terminology
C109947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109947>	C107687	Clarion County, PA|Clarion County|Clarion County, Pennsylvania|PA031				Geographic Area	US Counties Terminology
C109948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109948>	C107687	Clearfield County, PA|Clearfield County|Clearfield County, Pennsylvania|PA033				Geographic Area	US Counties Terminology
C109949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109949>	C107687	Clinton County, PA|Clinton County|Clinton County, Pennsylvania|PA035				Geographic Area	US Counties Terminology
C10994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10994>	C61063	Interferon Alfa/interleukin-2/Tumor Infiltrating Lymphocytes|IFN-A/IL-2/TIL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109950>	C107687	Columbia County, PA|Columbia County|Columbia County, Pennsylvania|PA037				Geographic Area	US Counties Terminology
C109951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109951>	C107687	Crawford County, PA|Crawford County|Crawford County, Pennsylvania|PA039				Geographic Area	US Counties Terminology
C109952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109952>	C107687	Cumberland County, PA|Cumberland County|Cumberland County, Pennsylvania|PA041				Geographic Area	US Counties Terminology
C109953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109953>	C107687	Dauphin County, PA|Dauphin County|Dauphin County, Pennsylvania|PA043				Geographic Area	US Counties Terminology
C109954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109954>	C107687	Delaware County, PA|Delaware County|Delaware County, Pennsylvania|PA045				Geographic Area	US Counties Terminology
C109955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109955>	C107687	Elk County, PA|Elk County|Elk County, Pennsylvania|PA047				Geographic Area	US Counties Terminology
C109956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109956>	C107687	Erie County, PA|Erie County|Erie County, Pennsylvania|PA049				Geographic Area	US Counties Terminology
C109957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109957>	C107687	Fayette County, PA|Fayette County|Fayette County, Pennsylvania|PA051				Geographic Area	US Counties Terminology
C109958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109958>	C107687	Forest County, PA|Forest County|Forest County, Pennsylvania|PA053				Geographic Area	US Counties Terminology
C109959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109959>	C107687	Franklin County, PA|Franklin County|Franklin County, Pennsylvania|PA055				Geographic Area	US Counties Terminology
C10995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10995>	C61063	Dexamethasone/Doxorubicin/Interferon Alfa/Vincristine|DM/DOX/IFN-A/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109960>	C107687	Fulton County, PA|Fulton County|Fulton County, Pennsylvania|PA057				Geographic Area	US Counties Terminology
C109961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109961>	C107687	Greene County, PA|Greene County|Greene County, Pennsylvania|PA059				Geographic Area	US Counties Terminology
C109962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109962>	C107687	Huntingdon County, PA|Huntingdon County|Huntingdon County, Pennsylvania|PA061				Geographic Area	US Counties Terminology
C109963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109963>	C107687	Indiana County, PA|Indiana County|Indiana County, Pennsylvania|PA063				Geographic Area	US Counties Terminology
C109964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109964>	C107687	Jefferson County, PA|Jefferson County|Jefferson County, Pennsylvania|PA065				Geographic Area	US Counties Terminology
C109965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109965>	C107687	Juniata County, PA|Juniata County|Juniata County, Pennsylvania|PA067				Geographic Area	US Counties Terminology
C109966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109966>	C107687	Lackawanna County, PA|Lackawanna County|Lackawanna County, Pennsylvania|PA069				Geographic Area	US Counties Terminology
C109967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109967>	C107687	Lancaster County, PA|Lancaster County|Lancaster County, Pennsylvania|PA071				Geographic Area	US Counties Terminology
C109968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109968>	C107687	Lawrence County, PA|Lawrence County|Lawrence County, Pennsylvania|PA073				Geographic Area	US Counties Terminology
C109969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109969>	C107687	Lebanon County, PA|Lebanon County|Lebanon County, Pennsylvania|PA075				Geographic Area	US Counties Terminology
C10996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10996>	C61063	Cisplatin/Interferon Alfa/interleukin-2|CDDP/IFN-A/IL-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109970>	C107687	Lehigh County, PA|Lehigh County|Lehigh County, Pennsylvania|PA077				Geographic Area	US Counties Terminology
C109971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109971>	C107687	Luzerne County, PA|Luzerne County|Luzerne County, Pennsylvania|PA079				Geographic Area	US Counties Terminology
C109972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109972>	C107687	Lycoming County, PA|Lycoming County|Lycoming County, Pennsylvania|PA081				Geographic Area	US Counties Terminology
C109973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109973>	C107687	McKean County, PA|McKean County|McKean County, Pennsylvania|PA083				Geographic Area	US Counties Terminology
C109974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109974>	C107687	Mercer County, PA|Mercer County|Mercer County, Pennsylvania|PA085				Geographic Area	US Counties Terminology
C109975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109975>	C107687	Mifflin County, PA|Mifflin County|Mifflin County, Pennsylvania|PA087				Geographic Area	US Counties Terminology
C109976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109976>	C107687	Monroe County, PA|Monroe County|Monroe County, Pennsylvania|PA089				Geographic Area	US Counties Terminology
C109977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109977>	C107687	Montgomery County, PA|Montgomery County|Montgomery County, Pennsylvania|PA091				Geographic Area	US Counties Terminology
C109978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109978>	C107687	Montour County, PA|Montour County|Montour County, Pennsylvania|PA093				Geographic Area	US Counties Terminology
C109979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109979>	C107687	Northampton County, PA|Northampton County|Northampton County, Pennsylvania|PA095				Geographic Area	US Counties Terminology
C10997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10997>	C61063	Cyclophosphamide/Doxorubicin/Interferon Alfa/Prednisone/Vincristine|CTX/DOX/IFN-A/PRED/VCR|I-COPA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109980>	C107687	Northumberland County, PA|Northumberland County|Northumberland County, Pennsylvania|PA097				Geographic Area	US Counties Terminology
C109981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109981>	C107687	Perry County, PA|PA099|Perry County|Perry County, Pennsylvania				Geographic Area	US Counties Terminology
C109982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109982>	C107687	Philadelphia County, PA|PA101|Philadelphia County|Philadelphia County, Pennsylvania				Geographic Area	US Counties Terminology
C109983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109983>	C107687	Pike County, PA|PA103|Pike County|Pike County, Pennsylvania				Geographic Area	US Counties Terminology
C109984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109984>	C107687	Potter County, PA|PA105|Potter County|Potter County, Pennsylvania				Geographic Area	US Counties Terminology
C109985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109985>	C107687	Schuylkill County, PA|PA107|Schuylkill County|Schuylkill County, Pennsylvania				Geographic Area	US Counties Terminology
C109986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109986>	C107687	Snyder County, PA|PA109|Snyder County|Snyder County, Pennsylvania				Geographic Area	US Counties Terminology
C109987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109987>	C107687	Somerset County, PA|PA111|Somerset County|Somerset County, Pennsylvania				Geographic Area	US Counties Terminology
C109988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109988>	C107687	Sullivan County, PA|PA113|Sullivan County|Sullivan County, Pennsylvania				Geographic Area	US Counties Terminology
C109989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109989>	C107687	Susquehanna County, PA|PA115|Susquehanna County|Susquehanna County, Pennsylvania				Geographic Area	US Counties Terminology
C10998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10998>	C61063	Fluorouracil/Interferon Alfa/PALA|5-FU/IFN-A/PALA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C109990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109990>	C107687	Tioga County, PA|PA117|Tioga County|Tioga County, Pennsylvania				Geographic Area	US Counties Terminology
C109991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109991>	C107687	Union County, PA|PA119|Union County|Union County, Pennsylvania				Geographic Area	US Counties Terminology
C109992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109992>	C107687	Venango County, PA|PA121|Venango County|Venango County, Pennsylvania				Geographic Area	US Counties Terminology
C109993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109993>	C107687	Warren County, PA|PA123|Warren County|Warren County, Pennsylvania				Geographic Area	US Counties Terminology
C109994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109994>	C107687	Washington County, PA|PA125|Washington County|Washington County, Pennsylvania				Geographic Area	US Counties Terminology
C109995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109995>	C107687	Wayne County, PA|PA127|Wayne County|Wayne County, Pennsylvania				Geographic Area	US Counties Terminology
C109996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109996>	C107687	Westmoreland County, PA|PA129|Westmoreland County|Westmoreland County, Pennsylvania				Geographic Area	US Counties Terminology
C109997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109997>	C107687	Wyoming County, PA|PA131|Wyoming County|Wyoming County, Pennsylvania				Geographic Area	US Counties Terminology
C109998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109998>	C107687	York County, PA|PA133|York County|York County, Pennsylvania				Geographic Area	US Counties Terminology
C109999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C109999>	C107687	Bristol County, RI|Bristol County|Bristol County, Rhode Island|RI001				Geographic Area	US Counties Terminology
C10999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C10999>	C61063	Mitoxantrone/Interferon Alfa|DHAD/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1099>	C2319	Finasteride|(5alpha,17beta)-N-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide|Chibro-Proscar|FINASTERIDE|Finastid|MK 906|Pro-Cure|Propecia|Propeshia|Proscar|Prostide|Urprosan|finasteride	A synthetic 4-azasteroid compound. Finasteride competitively binds to and inhibits steroid type II 5-alpha-reductase in the prostate gland, liver, and skin, thereby interfering with the enzymatic conversion of testosterone to 5-dihydrotestosterone (DHT) and reducing serum DHT levels. The reduction in serum DHT levels results in diminished stimulation of androgen receptors in the nuclei of prostate cells and, so, diminished prostate cell proliferation.	Finasteride		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C110000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110000>	C107687	Kent County, RI|Kent County|Kent County, Rhode Island|RI003				Geographic Area	US Counties Terminology
C110001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110001>	C107687	Newport County, RI|Newport County|Newport County, Rhode Island|RI005				Geographic Area	US Counties Terminology
C110002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110002>	C107687	Providence County, RI|Providence County|Providence County, Rhode Island|RI007				Geographic Area	US Counties Terminology
C110003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110003>	C107687	Washington County, RI|RI009|Washington County|Washington County, Rhode Island				Geographic Area	US Counties Terminology
C110004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110004>	C107687	Abbeville County, SC|Abbeville County|Abbeville County, South Carolina|SC001				Geographic Area	US Counties Terminology
C110005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110005>	C107687	Aiken County, SC|Aiken County|Aiken County, South Carolina|SC003				Geographic Area	US Counties Terminology
C110006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110006>	C107687	Allendale County, SC|Allendale County|Allendale County, South Carolina|SC005				Geographic Area	US Counties Terminology
C110007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110007>	C107687	Anderson County, SC|Anderson County|Anderson County, South Carolina|SC007				Geographic Area	US Counties Terminology
C110008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110008>	C107687	Bamberg County, SC|Bamberg County|Bamberg County, South Carolina|SC009				Geographic Area	US Counties Terminology
C110009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110009>	C107687	Barnwell County, SC|Barnwell County|Barnwell County, South Carolina|SC011				Geographic Area	US Counties Terminology
C11000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11000>	C61063	Interferon Alfa/Zidovudine|IFN-A/ZDV			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110010>	C107687	Beaufort County, SC|Beaufort County|Beaufort County, South Carolina|SC013				Geographic Area	US Counties Terminology
C110011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110011>	C107687	Berkeley County, SC|Berkeley County|Berkeley County, South Carolina|SC015				Geographic Area	US Counties Terminology
C110012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110012>	C107687	Calhoun County, SC|Calhoun County|Calhoun County, South Carolina|SC017				Geographic Area	US Counties Terminology
C110013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110013>	C107687	Charleston County, SC|Charleston County|Charleston County, South Carolina|SC019				Geographic Area	US Counties Terminology
C110014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110014>	C107687	Cherokee County, SC|Cherokee County|Cherokee County, South Carolina|SC021				Geographic Area	US Counties Terminology
C110015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110015>	C107687	Chester County, SC|Chester County|Chester County, South Carolina|SC023				Geographic Area	US Counties Terminology
C110016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110016>	C107687	Chesterfield County, SC|Chesterfield County|Chesterfield County, South Carolina|SC025				Geographic Area	US Counties Terminology
C110017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110017>	C107687	Clarendon County, SC|Clarendon County|Clarendon County, South Carolina|SC027				Geographic Area	US Counties Terminology
C110018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110018>	C107687	Colleton County, SC|Colleton County|Colleton County, South Carolina|SC029				Geographic Area	US Counties Terminology
C110019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110019>	C107687	Darlington County, SC|Darlington County|Darlington County, South Carolina|SC031				Geographic Area	US Counties Terminology
C11001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11001>	C61063	Lomustine/Interferon Alfa|CCNU/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110020>	C107687	Dillon County, SC|Dillon County|Dillon County, South Carolina|SC033				Geographic Area	US Counties Terminology
C110021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110021>	C107687	Dorchester County, SC|Dorchester County|Dorchester County, South Carolina|SC035				Geographic Area	US Counties Terminology
C110022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110022>	C107687	Edgefield County, SC|Edgefield County|Edgefield County, South Carolina|SC037				Geographic Area	US Counties Terminology
C110023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110023>	C107687	Fairfield County, SC|Fairfield County|Fairfield County, South Carolina|SC039				Geographic Area	US Counties Terminology
C110024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110024>	C107687	Florence County, SC|Florence County|Florence County, South Carolina|SC041				Geographic Area	US Counties Terminology
C110025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110025>	C107687	Georgetown County, SC|Georgetown County|Georgetown County, South Carolina|SC043				Geographic Area	US Counties Terminology
C110026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110026>	C107687	Greenville County, SC|Greenville County|Greenville County, South Carolina|SC045				Geographic Area	US Counties Terminology
C110027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110027>	C107687	Greenwood County, SC|Greenwood County|Greenwood County, South Carolina|SC047				Geographic Area	US Counties Terminology
C110028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110028>	C107687	Hampton County, SC|Hampton County|Hampton County, South Carolina|SC049				Geographic Area	US Counties Terminology
C110029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110029>	C107687	Horry County, SC|Horry County|Horry County, South Carolina|SC051				Geographic Area	US Counties Terminology
C11002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11002>	C61063	Cyclophosphamide/Interferon Alfa/interleukin-2/Tumor Infiltrating Lymphocytes|CTX/IFN-A/IL-2/TIL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110030>	C107687	Jasper County, SC|Jasper County|Jasper County, South Carolina|SC053				Geographic Area	US Counties Terminology
C110031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110031>	C107687	Kershaw County, SC|Kershaw County|Kershaw County, South Carolina|SC055				Geographic Area	US Counties Terminology
C110032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110032>	C107687	Lancaster County, SC|Lancaster County|Lancaster County, South Carolina|SC057				Geographic Area	US Counties Terminology
C110033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110033>	C107687	Laurens County, SC|Laurens County|Laurens County, South Carolina|SC059				Geographic Area	US Counties Terminology
C110034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110034>	C107687	Lee County, SC|Lee County|Lee County, South Carolina|SC061				Geographic Area	US Counties Terminology
C110035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110035>	C107687	Lexington County, SC|Lexington County|Lexington County, South Carolina|SC063				Geographic Area	US Counties Terminology
C110036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110036>	C107687	McCormick County, SC|McCormick County|McCormick County, South Carolina|SC065				Geographic Area	US Counties Terminology
C110037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110037>	C107687	Marion County, SC|Marion County|Marion County, South Carolina|SC067				Geographic Area	US Counties Terminology
C110038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110038>	C107687	Marlboro County, SC|Marlboro County|Marlboro County, South Carolina|SC069				Geographic Area	US Counties Terminology
C110039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110039>	C107687	Newberry County, SC|Newberry County|Newberry County, South Carolina|SC071				Geographic Area	US Counties Terminology
C11003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11003>	C61007	Interferon Alfa/Piroxicam|IFN-A/PXM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110040>	C107687	Oconee County, SC|Oconee County|Oconee County, South Carolina|SC073				Geographic Area	US Counties Terminology
C110041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110041>	C107687	Orangeburg County, SC|Orangeburg County|Orangeburg County, South Carolina|SC075				Geographic Area	US Counties Terminology
C110042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110042>	C107687	Pickens County, SC|Pickens County|Pickens County, South Carolina|SC077				Geographic Area	US Counties Terminology
C110043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110043>	C107687	Richland County, SC|Richland County|Richland County, South Carolina|SC079				Geographic Area	US Counties Terminology
C110044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110044>	C107687	Saluda County, SC|SC081|Saluda County|Saluda County, South Carolina				Geographic Area	US Counties Terminology
C110045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110045>	C107687	Spartanburg County, SC|SC083|Spartanburg County|Spartanburg County, South Carolina				Geographic Area	US Counties Terminology
C110046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110046>	C107687	Sumter County, SC|SC085|Sumter County|Sumter County, South Carolina				Geographic Area	US Counties Terminology
C110047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110047>	C107687	Union County, SC|SC087|Union County|Union County, South Carolina				Geographic Area	US Counties Terminology
C110048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110048>	C107687	Williamsburg County, SC|SC089|Williamsburg County|Williamsburg County, South Carolina				Geographic Area	US Counties Terminology
C110049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110049>	C107687	York County, SC|SC091|York County|York County, South Carolina				Geographic Area	US Counties Terminology
C11004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11004>	C61063	Cyclophosphamide/Interferon Alfa/Prednisone|CTX/IFN-A/PRED			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110050>	C107687	Aurora County, SD|Aurora County|Aurora County, South Dakota|SD003				Geographic Area	US Counties Terminology
C110051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110051>	C107687	Beadle County, SD|Beadle County|Beadle County, South Dakota|SD005				Geographic Area	US Counties Terminology
C110052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110052>	C107687	Bennett County, SD|Bennett County|Bennett County, South Dakota|SD007				Geographic Area	US Counties Terminology
C110053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110053>	C107687	Bon Homme County, SD|Bon Homme County|Bon Homme County, South Dakota|SD009				Geographic Area	US Counties Terminology
C110054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110054>	C107687	Brookings County, SD|Brookings County|Brookings County, South Dakota|SD011				Geographic Area	US Counties Terminology
C110055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110055>	C107687	Brown County, SD|Brown County|Brown County, South Dakota|SD013				Geographic Area	US Counties Terminology
C110056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110056>	C107687	Brule County, SD|Brule County|Brule County, South Dakota|SD015				Geographic Area	US Counties Terminology
C110057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110057>	C107687	Buffalo County, SD|Buffalo County|Buffalo County, South Dakota|SD017				Geographic Area	US Counties Terminology
C110058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110058>	C107687	Butte County, SD|Butte County|Butte County, South Dakota|SD019				Geographic Area	US Counties Terminology
C110059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110059>	C107687	Campbell County, SD|Campbell County|Campbell County, South Dakota|SD021				Geographic Area	US Counties Terminology
C11005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11005>	C61063	Cisplatin/Interferon Alfa|CDDP/IFN-A|Cisplatin/Interferon			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110060>	C107687	Charles Mix County, SD|Charles Mix County|Charles Mix County, South Dakota|SD023				Geographic Area	US Counties Terminology
C110061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110061>	C107687	Clark County, SD|Clark County|Clark County, South Dakota|SD025				Geographic Area	US Counties Terminology
C110062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110062>	C107687	Clay County, SD|Clay County|Clay County, South Dakota|SD027				Geographic Area	US Counties Terminology
C110063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110063>	C107687	Codington County, SD|Codington County|Codington County, South Dakota|SD029				Geographic Area	US Counties Terminology
C110064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110064>	C107687	Corson County, SD|Corson County|Corson County, South Dakota|SD031				Geographic Area	US Counties Terminology
C110065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110065>	C107687	Custer County, SD|Custer County|Custer County, South Dakota|SD033				Geographic Area	US Counties Terminology
C110066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110066>	C107687	Davison County, SD|Davison County|Davison County, South Dakota|SD035				Geographic Area	US Counties Terminology
C110067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110067>	C107687	Day County, SD|Day County|Day County, South Dakota|SD037				Geographic Area	US Counties Terminology
C110068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110068>	C107687	Deuel County, SD|Deuel County|Deuel County, South Dakota|SD039				Geographic Area	US Counties Terminology
C110069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110069>	C107687	Dewey County, SD|Dewey County|Dewey County, South Dakota|SD041				Geographic Area	US Counties Terminology
C11006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11006>	C61063	Interferon Alfa/Interferon Gamma|IFN-A/IFN-G			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110070>	C107687	Douglas County, SD|Douglas County|Douglas County, South Dakota|SD043				Geographic Area	US Counties Terminology
C110071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110071>	C107687	Edmunds County, SD|Edmunds County|Edmunds County, South Dakota|SD045				Geographic Area	US Counties Terminology
C110072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110072>	C107687	Fall River County, SD|Fall River County|Fall River County, South Dakota|SD047				Geographic Area	US Counties Terminology
C110073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110073>	C107687	Faulk County, SD|Faulk County|Faulk County, South Dakota|SD049				Geographic Area	US Counties Terminology
C110074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110074>	C107687	Grant County, SD|Grant County|Grant County, South Dakota|SD051				Geographic Area	US Counties Terminology
C110075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110075>	C107687	Gregory County, SD|Gregory County|Gregory County, South Dakota|SD053				Geographic Area	US Counties Terminology
C110076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110076>	C107687	Haakon County, SD|Haakon County|Haakon County, South Dakota|SD055				Geographic Area	US Counties Terminology
C110077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110077>	C107687	Hamlin County, SD|Hamlin County|Hamlin County, South Dakota|SD057				Geographic Area	US Counties Terminology
C110078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110078>	C107687	Hand County, SD|Hand County|Hand County, South Dakota|SD059				Geographic Area	US Counties Terminology
C110079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110079>	C107687	Hanson County, SD|Hanson County|Hanson County, South Dakota|SD061				Geographic Area	US Counties Terminology
C11007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11007>	C61063	Doxorubicin/Interferon Alfa|DOX/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110080>	C107687	Harding County, SD|Harding County|Harding County, South Dakota|SD063				Geographic Area	US Counties Terminology
C110081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110081>	C107687	Hughes County, SD|Hughes County|Hughes County, South Dakota|SD065				Geographic Area	US Counties Terminology
C110082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110082>	C107687	Hutchinson County, SD|Hutchinson County|Hutchinson County, South Dakota|SD067				Geographic Area	US Counties Terminology
C110083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110083>	C107687	Hyde County, SD|Hyde County|Hyde County, South Dakota|SD069				Geographic Area	US Counties Terminology
C110084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110084>	C107687	Jackson County, SD|Jackson County|Jackson County, South Dakota|SD071				Geographic Area	US Counties Terminology
C110085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110085>	C107687	Jerauld County, SD|Jerauld County|Jerauld County, South Dakota|SD073				Geographic Area	US Counties Terminology
C110086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110086>	C107687	Jones County, SD|Jones County|Jones County, South Dakota|SD075				Geographic Area	US Counties Terminology
C110087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110087>	C107687	Kingsbury County, SD|Kingsbury County|Kingsbury County, South Dakota|SD077				Geographic Area	US Counties Terminology
C110088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110088>	C107687	Lake County, SD|Lake County|Lake County, South Dakota|SD079				Geographic Area	US Counties Terminology
C110089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110089>	C107687	Lawrence County, SD|Lawrence County|Lawrence County, South Dakota|SD081				Geographic Area	US Counties Terminology
C11008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11008>	C61063	Interferon Alfa/Interleukin-2|IFN-A/IL-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110090>	C107687	Lincoln County, SD|Lincoln County|Lincoln County, South Dakota|SD083				Geographic Area	US Counties Terminology
C110091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110091>	C107687	Lyman County, SD|Lyman County|Lyman County, South Dakota|SD085				Geographic Area	US Counties Terminology
C110092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110092>	C107687	McCook County, SD|McCook County|McCook County, South Dakota|SD087				Geographic Area	US Counties Terminology
C110093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110093>	C107687	McPherson County, SD|McPherson County|McPherson County, South Dakota|SD089				Geographic Area	US Counties Terminology
C110094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110094>	C107687	Marshall County, SD|Marshall County|Marshall County, South Dakota|SD091				Geographic Area	US Counties Terminology
C110095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110095>	C107687	Meade County, SD|Meade County|Meade County, South Dakota|SD093				Geographic Area	US Counties Terminology
C110096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110096>	C107687	Mellette County, SD|Mellette County|Mellette County, South Dakota|SD095				Geographic Area	US Counties Terminology
C110097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110097>	C107687	Miner County, SD|Miner County|Miner County, South Dakota|SD097				Geographic Area	US Counties Terminology
C110098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110098>	C107687	Minnehaha County, SD|Minnehaha County|Minnehaha County, South Dakota|SD099				Geographic Area	US Counties Terminology
C110099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110099>	C107687	Moody County, SD|Moody County|Moody County, South Dakota|SD101				Geographic Area	US Counties Terminology
C11009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11009>	C61063	Interferon Alfa/Isotretinoin|13-CRA/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1100>	C357	Cefixime|CEFIXIME|Cefixime Trihydrate|FK 027|Suprax|cefixime	A broad-spectrum, third-generation cephalosporin antibiotic derived semisynthetically from the marine fungus Cephalosporium acremonium with antibacterial activity. As does penicillin, the beta-lactam antibiotic cefixime inhibits bacterial cell wall synthesis by disrupting peptidoglycan synthesis, resulting in a reduction in bacterial cell wall stability and bacterial cell lysis. Stable in the presence of a variety of beta-lactamases, this agent is more active against gram-negative bacteria and less active against gram-positive bacteria compared to second-generation cephalosporins.	Cefixime		Antibiotic|Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C110100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110100>	C107687	Pennington County, SD|Pennington County|Pennington County, South Dakota|SD103				Geographic Area	US Counties Terminology
C110101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110101>	C107687	Perkins County, SD|Perkins County|Perkins County, South Dakota|SD105				Geographic Area	US Counties Terminology
C110102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110102>	C107687	Potter County, SD|Potter County|Potter County, South Dakota|SD107				Geographic Area	US Counties Terminology
C110103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110103>	C107687	Roberts County, SD|Roberts County|Roberts County, South Dakota|SD109				Geographic Area	US Counties Terminology
C110104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110104>	C107687	Sanborn County, SD|SD111|Sanborn County|Sanborn County, South Dakota				Geographic Area	US Counties Terminology
C110105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110105>	C107687	Shannon County, SD|SD113|Shannon County|Shannon County, South Dakota				Geographic Area	US Counties Terminology
C110106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110106>	C107687	Spink County, SD|SD115|Spink County|Spink County, South Dakota				Geographic Area	US Counties Terminology
C110107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110107>	C107687	Stanley County, SD|SD117|Stanley County|Stanley County, South Dakota				Geographic Area	US Counties Terminology
C110108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110108>	C107687	Sully County, SD|SD119|Sully County|Sully County, South Dakota				Geographic Area	US Counties Terminology
C110109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110109>	C107687	Todd County, SD|SD121|Todd County|Todd County, South Dakota				Geographic Area	US Counties Terminology
C11010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11010>	C61063	Carmustine/Interferon Alfa|BCNU/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110110>	C107687	Tripp County, SD|SD123|Tripp County|Tripp County, South Dakota				Geographic Area	US Counties Terminology
C110111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110111>	C107687	Turner County, SD|SD125|Turner County|Turner County, South Dakota				Geographic Area	US Counties Terminology
C110112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110112>	C107687	Union County, SD|SD127|Union County|Union County, South Dakota				Geographic Area	US Counties Terminology
C110113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110113>	C107687	Walworth County, SD|SD129|Walworth County|Walworth County, South Dakota				Geographic Area	US Counties Terminology
C110114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110114>	C107687	Yankton County, SD|SD135|Yankton County|Yankton County, South Dakota				Geographic Area	US Counties Terminology
C110115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110115>	C107687	Ziebach County, SD|SD137|Ziebach County|Ziebach County, South Dakota				Geographic Area	US Counties Terminology
C110116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110116>	C107687	Anderson County, TN|Anderson County|Anderson County, Tennessee|TN001				Geographic Area	US Counties Terminology
C110117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110117>	C107687	Bedford County, TN|Bedford County|Bedford County, Tennessee|TN003				Geographic Area	US Counties Terminology
C110118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110118>	C107687	Benton County, TN|Benton County|Benton County, Tennessee|TN005				Geographic Area	US Counties Terminology
C110119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110119>	C107687	Bledsoe County, TN|Bledsoe County|Bledsoe County, Tennessee|TN007				Geographic Area	US Counties Terminology
C11011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11011>	C61063	Cyclophosphamide/Interferon Alfa|CTX/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110120>	C107687	Blount County, TN|Blount County|Blount County, Tennessee|TN009				Geographic Area	US Counties Terminology
C110121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110121>	C107687	Bradley County, TN|Bradley County|Bradley County, Tennessee|TN011				Geographic Area	US Counties Terminology
C110122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110122>	C107687	Campbell County, TN|Campbell County|Campbell County, Tennessee|TN013				Geographic Area	US Counties Terminology
C110123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110123>	C107687	Cannon County, TN|Cannon County|Cannon County, Tennessee|TN015				Geographic Area	US Counties Terminology
C110124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110124>	C107687	Carroll County, TN|Carroll County|Carroll County, Tennessee|TN017				Geographic Area	US Counties Terminology
C110125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110125>	C107687	Carter County, TN|Carter County|Carter County, Tennessee|TN019				Geographic Area	US Counties Terminology
C110126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110126>	C107687	Cheatham County, TN|Cheatham County|Cheatham County, Tennessee|TN021				Geographic Area	US Counties Terminology
C110127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110127>	C107687	Chester County, TN|Chester County|Chester County, Tennessee|TN023				Geographic Area	US Counties Terminology
C110128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110128>	C107687	Claiborne County, TN|Claiborne County|Claiborne County, Tennessee|TN025				Geographic Area	US Counties Terminology
C110129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110129>	C107687	Clay County, TN|Clay County|Clay County, Tennessee|TN027				Geographic Area	US Counties Terminology
C11012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11012>	C61063	Interferon Alfa/Mercaptopurine/Methotrexate|IFN-A/MP/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110130>	C107687	Cocke County, TN|Cocke County|Cocke County, Tennessee|TN029				Geographic Area	US Counties Terminology
C110131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110131>	C107687	Coffee County, TN|Coffee County|Coffee County, Tennessee|TN031				Geographic Area	US Counties Terminology
C110132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110132>	C107687	Crockett County, TN|Crockett County|Crockett County, Tennessee|TN033				Geographic Area	US Counties Terminology
C110133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110133>	C107687	Cumberland County, TN|Cumberland County|Cumberland County, Tennessee|TN035				Geographic Area	US Counties Terminology
C110134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110134>	C107687	Davidson County, TN|Davidson County|Davidson County, Tennessee|TN037				Geographic Area	US Counties Terminology
C110135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110135>	C107687	Decatur County, TN|Decatur County|Decatur County, Tennessee|TN039				Geographic Area	US Counties Terminology
C110136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110136>	C107687	DeKalb County, TN|DeKalb County|DeKalb County, Tennessee|TN041				Geographic Area	US Counties Terminology
C110137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110137>	C107687	Dickson County, TN|Dickson County|Dickson County, Tennessee|TN043				Geographic Area	US Counties Terminology
C110138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110138>	C107687	Dyer County, TN|Dyer County|Dyer County, Tennessee|TN045				Geographic Area	US Counties Terminology
C110139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110139>	C107687	Fayette County, TN|Fayette County|Fayette County, Tennessee|TN047				Geographic Area	US Counties Terminology
C11013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11013>	C61063	Interferon Alfa/Interleukin-2/Lymphokine-Activated Killer Cells|IFN-A/IL-2/LAK|IL2/LAK/IFN			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110140>	C107687	Fentress County, TN|Fentress County|Fentress County, Tennessee|TN049				Geographic Area	US Counties Terminology
C110141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110141>	C107687	Franklin County, TN|Franklin County|Franklin County, Tennessee|TN051				Geographic Area	US Counties Terminology
C110142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110142>	C107687	Gibson County, TN|Gibson County|Gibson County, Tennessee|TN053				Geographic Area	US Counties Terminology
C110143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110143>	C107687	Giles County, TN|Giles County|Giles County, Tennessee|TN055				Geographic Area	US Counties Terminology
C110144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110144>	C107687	Grainger County, TN|Grainger County|Grainger County, Tennessee|TN057				Geographic Area	US Counties Terminology
C110145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110145>	C107687	Greene County, TN|Greene County|Greene County, Tennessee|TN059				Geographic Area	US Counties Terminology
C110146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110146>	C107687	Grundy County, TN|Grundy County|Grundy County, Tennessee|TN061				Geographic Area	US Counties Terminology
C110147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110147>	C107687	Hamblen County, TN|Hamblen County|Hamblen County, Tennessee|TN063				Geographic Area	US Counties Terminology
C110148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110148>	C107687	Hamilton County, TN|Hamilton County|Hamilton County, Tennessee|TN065				Geographic Area	US Counties Terminology
C110149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110149>	C107687	Hancock County, TN|Hancock County|Hancock County, Tennessee|TN067				Geographic Area	US Counties Terminology
C11014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11014>	C61063	Fluorouracil/Interferon Alfa/Leucovorin Calcium|CF/5-FU/IFN-A|IFN/5FU/Leucovorin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110150>	C107687	Hardeman County, TN|Hardeman County|Hardeman County, Tennessee|TN069				Geographic Area	US Counties Terminology
C110151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110151>	C107687	Hardin County, TN|Hardin County|Hardin County, Tennessee|TN071				Geographic Area	US Counties Terminology
C110152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110152>	C107687	Hawkins County, TN|Hawkins County|Hawkins County, Tennessee|TN073				Geographic Area	US Counties Terminology
C110153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110153>	C107687	Haywood County, TN|Haywood County|Haywood County, Tennessee|TN075				Geographic Area	US Counties Terminology
C110154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110154>	C107687	Henderson County, TN|Henderson County|Henderson County, Tennessee|TN077				Geographic Area	US Counties Terminology
C110155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110155>	C107687	Henry County, TN|Henry County|Henry County, Tennessee|TN079				Geographic Area	US Counties Terminology
C110156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110156>	C107687	Hickman County, TN|Hickman County|Hickman County, Tennessee|TN081				Geographic Area	US Counties Terminology
C110157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110157>	C107687	Houston County, TN|Houston County|Houston County, Tennessee|TN083				Geographic Area	US Counties Terminology
C110158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110158>	C107687	Humphreys County, TN|Humphreys County|Humphreys County, Tennessee|TN085				Geographic Area	US Counties Terminology
C110159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110159>	C107687	Jackson County, TN|Jackson County|Jackson County, Tennessee|TN087				Geographic Area	US Counties Terminology
C11015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11015>	C61007	Carmustine/Cyclophosphamide/Interferon Alfa/Melphalan/Prednisone/Vincristine|BCNU/CTX/IFN-A/L-PAM/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110160>	C107687	Jefferson County, TN|Jefferson County|Jefferson County, Tennessee|TN089				Geographic Area	US Counties Terminology
C110161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110161>	C107687	Johnson County, TN|Johnson County|Johnson County, Tennessee|TN091				Geographic Area	US Counties Terminology
C110162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110162>	C107687	Knox County, TN|Knox County|Knox County, Tennessee|TN093				Geographic Area	US Counties Terminology
C110163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110163>	C107687	Lake County, TN|Lake County|Lake County, Tennessee|TN095				Geographic Area	US Counties Terminology
C110164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110164>	C107687	Lauderdale County, TN|Lauderdale County|Lauderdale County, Tennessee|TN097				Geographic Area	US Counties Terminology
C110165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110165>	C107687	Lawrence County, TN|Lawrence County|Lawrence County, Tennessee|TN099				Geographic Area	US Counties Terminology
C110166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110166>	C107687	Lewis County, TN|Lewis County|Lewis County, Tennessee|TN101				Geographic Area	US Counties Terminology
C110167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110167>	C107687	Lincoln County, TN|Lincoln County|Lincoln County, Tennessee|TN103				Geographic Area	US Counties Terminology
C110168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110168>	C107687	Loudon County, TN|Loudon County|Loudon County, Tennessee|TN105				Geographic Area	US Counties Terminology
C110169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110169>	C107687	McMinn County, TN|McMinn County|McMinn County, Tennessee|TN107				Geographic Area	US Counties Terminology
C11016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11016>	C61063	Cisplatin/Interferon Alfa/Tamoxifen|CDDP/IFN-A/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110170>	C107687	McNairy County, TN|McNairy County|McNairy County, Tennessee|TN109				Geographic Area	US Counties Terminology
C110171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110171>	C107687	Macon County, TN|Macon County|Macon County, Tennessee|TN111				Geographic Area	US Counties Terminology
C110172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110172>	C107687	Madison County, TN|Madison County|Madison County, Tennessee|TN113				Geographic Area	US Counties Terminology
C110173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110173>	C107687	Marion County, TN|Marion County|Marion County, Tennessee|TN115				Geographic Area	US Counties Terminology
C110174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110174>	C107687	Marshall County, TN|Marshall County|Marshall County, Tennessee|TN117				Geographic Area	US Counties Terminology
C110175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110175>	C107687	Maury County, TN|Maury County|Maury County, Tennessee|TN119				Geographic Area	US Counties Terminology
C110176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110176>	C107687	Meigs County, TN|Meigs County|Meigs County, Tennessee|TN121				Geographic Area	US Counties Terminology
C110177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110177>	C107687	Monroe County, TN|Monroe County|Monroe County, Tennessee|TN123				Geographic Area	US Counties Terminology
C110178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110178>	C107687	Montgomery County, TN|Montgomery County|Montgomery County, Tennessee|TN125				Geographic Area	US Counties Terminology
C110179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110179>	C107687	Moore County, TN|Moore County|Moore County, Tennessee|TN127				Geographic Area	US Counties Terminology
C11017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11017>	C61063	Interferon Alfa/Melphalan/Prednisone|IFN-A/L-PAM/PRED			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110180>	C107687	Morgan County, TN|Morgan County|Morgan County, Tennessee|TN129				Geographic Area	US Counties Terminology
C110181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110181>	C107687	Obion County, TN|Obion County|Obion County, Tennessee|TN131				Geographic Area	US Counties Terminology
C110182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110182>	C107687	Overton County, TN|Overton County|Overton County, Tennessee|TN133				Geographic Area	US Counties Terminology
C110183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110183>	C107687	Perry County, TN|Perry County|Perry County, Tennessee|TN135				Geographic Area	US Counties Terminology
C110184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110184>	C107687	Pickett County, TN|Pickett County|Pickett County, Tennessee|TN137				Geographic Area	US Counties Terminology
C110185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110185>	C107687	Polk County, TN|Polk County|Polk County, Tennessee|TN139				Geographic Area	US Counties Terminology
C110186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110186>	C107687	Putnam County, TN|Putnam County|Putnam County, Tennessee|TN141				Geographic Area	US Counties Terminology
C110187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110187>	C107687	Rhea County, TN|Rhea County|Rhea County, Tennessee|TN143				Geographic Area	US Counties Terminology
C110188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110188>	C107687	Roane County, TN|Roane County|Roane County, Tennessee|TN145				Geographic Area	US Counties Terminology
C110189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110189>	C107687	Robertson County, TN|Robertson County|Robertson County, Tennessee|TN147				Geographic Area	US Counties Terminology
C11018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11018>	C61063	Interferon Alfa/Poly ICLC|IFN-A/Poly ICLC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110190>	C107687	Rutherford County, TN|Rutherford County|Rutherford County, Tennessee|TN149				Geographic Area	US Counties Terminology
C110191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110191>	C107687	Scott County, TN|Scott County|Scott County, Tennessee|TN151				Geographic Area	US Counties Terminology
C110192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110192>	C107687	Sequatchie County, TN|Sequatchie County|Sequatchie County, Tennessee|TN153				Geographic Area	US Counties Terminology
C110193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110193>	C107687	Sevier County, TN|Sevier County|Sevier County, Tennessee|TN155				Geographic Area	US Counties Terminology
C110194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110194>	C107687	Shelby County, TN|Shelby County|Shelby County, Tennessee|TN157				Geographic Area	US Counties Terminology
C110195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110195>	C107687	Smith County, TN|Smith County|Smith County, Tennessee|TN159				Geographic Area	US Counties Terminology
C110196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110196>	C107687	Stewart County, TN|Stewart County|Stewart County, Tennessee|TN161				Geographic Area	US Counties Terminology
C110197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110197>	C107687	Sullivan County, TN|Sullivan County|Sullivan County, Tennessee|TN163				Geographic Area	US Counties Terminology
C110198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110198>	C107687	Sumner County, TN|Sumner County|Sumner County, Tennessee|TN165				Geographic Area	US Counties Terminology
C110199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110199>	C107687	Tipton County, TN|TN167|Tipton County|Tipton County, Tennessee				Geographic Area	US Counties Terminology
C11019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11019>	C61063	Cisplatin/Cyclophosphamide/Interferon Alfa|CDDP/CTX/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1101>	C306	Mitoflaxone|2-Phenyl-8-(carboxymethyl)-benzopyran-4-one|4H-1-Benzopyran-8-acetic acid, 4-oxo-2-phenyl-|4H-1-benzopyran-8-acetic Acid, 4-Oxo-2-phenyl|FAA|Flavone Acetic Acid|Flavone acetic acid|Flavone-8-Acetic Acid|LM 975|MITOFLAXONE	A synthetic flavonoid with vascular targeting properties. Flavone acetic acid exhibits an antiproliferative effect on endothelial cells as a result of a superoxide-dependent mechanism, which induces changes in permeability of the vasculature of the tumor. This agent may stimulate tumor necrosis and promote shunting of blood flow to viable regions of the tumor, increasing their oxygenation and rendering them more susceptible to the antitumor effects of hyperthermia and ionizing radiation.  (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C110200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110200>	C107687	Trousdale County, TN|TN169|Trousdale County|Trousdale County, Tennessee				Geographic Area	US Counties Terminology
C110201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110201>	C107687	Unicoi County, TN|TN171|Unicoi County|Unicoi County, Tennessee				Geographic Area	US Counties Terminology
C110202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110202>	C107687	Union County, TN|TN173|Union County|Union County, Tennessee				Geographic Area	US Counties Terminology
C110203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110203>	C107687	Van Buren County, TN|TN175|Van Buren County|Van Buren County, Tennessee				Geographic Area	US Counties Terminology
C110204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110204>	C107687	Warren County, TN|TN177|Warren County|Warren County, Tennessee				Geographic Area	US Counties Terminology
C110205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110205>	C107687	Washington County, TN|TN179|Washington County|Washington County, Tennessee				Geographic Area	US Counties Terminology
C110206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110206>	C107687	Wayne County, TN|TN181|Wayne County|Wayne County, Tennessee				Geographic Area	US Counties Terminology
C110207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110207>	C107687	Weakley County, TN|TN183|Weakley County|Weakley County, Tennessee				Geographic Area	US Counties Terminology
C110208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110208>	C107687	White County, TN|TN185|White County|White County, Tennessee				Geographic Area	US Counties Terminology
C110209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110209>	C107687	Williamson County, TN|TN187|Williamson County|Williamson County, Tennessee				Geographic Area	US Counties Terminology
C11020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11020>	C61063	Cisplatin/Etoposide/Interferon Alfa|CDDP/IFN-A/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110210>	C107687	Wilson County, TN|TN189|Wilson County|Wilson County, Tennessee				Geographic Area	US Counties Terminology
C110211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110211>	C107687	Anderson County, TX|Anderson County|Anderson County, Texas|TX001				Geographic Area	US Counties Terminology
C110212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110212>	C107687	Andrews County, TX|Andrews County|Andrews County, Texas|TX003				Geographic Area	US Counties Terminology
C110213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110213>	C107687	Angelina County, TX|Angelina County|Angelina County, Texas|TX005				Geographic Area	US Counties Terminology
C110214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110214>	C107687	Aransas County, TX|Aransas County|Aransas County, Texas|TX007				Geographic Area	US Counties Terminology
C110215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110215>	C107687	Archer County, TX|Archer County|Archer County, Texas|TX009				Geographic Area	US Counties Terminology
C110216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110216>	C107687	Armstrong County, TX|Armstrong County|Armstrong County, Texas|TX011				Geographic Area	US Counties Terminology
C110217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110217>	C107687	Atascosa County, TX|Atascosa County|Atascosa County, Texas|TX013				Geographic Area	US Counties Terminology
C110218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110218>	C107687	Austin County, TX|Austin County|Austin County, Texas|TX015				Geographic Area	US Counties Terminology
C110219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110219>	C107687	Bailey County, TX|Bailey County|Bailey County, Texas|TX017				Geographic Area	US Counties Terminology
C11021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11021>	C61063	Carboplatin/Interferon Alfa|CBDCA/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110220>	C107687	Bandera County, TX|Bandera County|Bandera County, Texas|TX019				Geographic Area	US Counties Terminology
C110221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110221>	C107687	Bastrop County, TX|Bastrop County|Bastrop County, Texas|TX021				Geographic Area	US Counties Terminology
C110222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110222>	C107687	Baylor County, TX|Baylor County|Baylor County, Texas|TX023				Geographic Area	US Counties Terminology
C110223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110223>	C107687	Bee County, TX|Bee County|Bee County, Texas|TX025				Geographic Area	US Counties Terminology
C110224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110224>	C107687	Bell County, TX|Bell County|Bell County, Texas|TX027				Geographic Area	US Counties Terminology
C110225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110225>	C107687	Bexar County, TX|Bexar County|Bexar County, Texas|TX029				Geographic Area	US Counties Terminology
C110226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110226>	C107687	Blanco County, TX|Blanco County|Blanco County, Texas|TX031				Geographic Area	US Counties Terminology
C110227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110227>	C107687	Borden County, TX|Borden County|Borden County, Texas|TX033				Geographic Area	US Counties Terminology
C110228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110228>	C107687	Bosque County, TX|Bosque County|Bosque County, Texas|TX035				Geographic Area	US Counties Terminology
C110229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110229>	C107687	Bowie County, TX|Bowie County|Bowie County, Texas|TX037				Geographic Area	US Counties Terminology
C11022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11022>	C61063	Cyclophosphamide/Interferon Alfa/Melphalan/Prednisone/Vincristine|CTX/IFN-A/L-PAM/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110230>	C107687	Brazoria County, TX|Brazoria County|Brazoria County, Texas|TX039				Geographic Area	US Counties Terminology
C110231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110231>	C107687	Brazos County, TX|Brazos County|Brazos County, Texas|TX041				Geographic Area	US Counties Terminology
C110232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110232>	C107687	Brewster County, TX|Brewster County|Brewster County, Texas|TX043				Geographic Area	US Counties Terminology
C110233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110233>	C107687	Briscoe County, TX|Briscoe County|Briscoe County, Texas|TX045				Geographic Area	US Counties Terminology
C110234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110234>	C107687	Brooks County, TX|Brooks County|Brooks County, Texas|TX047				Geographic Area	US Counties Terminology
C110235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110235>	C107687	Brown County, TX|Brown County|Brown County, Texas|TX049				Geographic Area	US Counties Terminology
C110236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110236>	C107687	Burleson County, TX|Burleson County|Burleson County, Texas|TX051				Geographic Area	US Counties Terminology
C110237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110237>	C107687	Burnet County, TX|Burnet County|Burnet County, Texas|TX053				Geographic Area	US Counties Terminology
C110238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110238>	C107687	Caldwell County, TX|Caldwell County|Caldwell County, Texas|TX055				Geographic Area	US Counties Terminology
C110239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110239>	C107687	Calhoun County, TX|Calhoun County|Calhoun County, Texas|TX057				Geographic Area	US Counties Terminology
C11023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11023>	C61063	Carmustine/Cisplatin/Dacarbazine/Interferon Alfa/Tamoxifen|BCNU/CDDP/DTIC/IFN-A/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110240>	C107687	Callahan County, TX|Callahan County|Callahan County, Texas|TX059				Geographic Area	US Counties Terminology
C110241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110241>	C107687	Cameron County, TX|Cameron County|Cameron County, Texas|TX061				Geographic Area	US Counties Terminology
C110242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110242>	C107687	Camp County, TX|Camp County|Camp County, Texas|TX063				Geographic Area	US Counties Terminology
C110243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110243>	C107687	Carson County, TX|Carson County|Carson County, Texas|TX065				Geographic Area	US Counties Terminology
C110244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110244>	C107687	Cass County, TX|Cass County|Cass County, Texas|TX067				Geographic Area	US Counties Terminology
C110245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110245>	C107687	Castro County, TX|Castro County|Castro County, Texas|TX069				Geographic Area	US Counties Terminology
C110246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110246>	C107687	Chambers County, TX|Chambers County|Chambers County, Texas|TX071				Geographic Area	US Counties Terminology
C110247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110247>	C107687	Cherokee County, TX|Cherokee County|Cherokee County, Texas|TX073				Geographic Area	US Counties Terminology
C110248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110248>	C107687	Childress County, TX|Childress County|Childress County, Texas|TX075				Geographic Area	US Counties Terminology
C110249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110249>	C107687	Clay County, TX|Clay County|Clay County, Texas|TX077				Geographic Area	US Counties Terminology
C11024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11024>	C61063	Floxuridine/Fluorouracil/Interferon Alfa/Leucovorin Calcium|CF/5-FU/FUDR/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110250>	C107687	Cochran County, TX|Cochran County|Cochran County, Texas|TX079				Geographic Area	US Counties Terminology
C110251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110251>	C107687	Coke County, TX|Coke County|Coke County, Texas|TX081				Geographic Area	US Counties Terminology
C110252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110252>	C107687	Coleman County, TX|Coleman County|Coleman County, Texas|TX083				Geographic Area	US Counties Terminology
C110253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110253>	C107687	Collin County, TX|Collin County|Collin County, Texas|TX085				Geographic Area	US Counties Terminology
C110254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110254>	C107687	Collingsworth County, TX|Collingsworth County|Collingsworth County, Texas|TX087				Geographic Area	US Counties Terminology
C110255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110255>	C107687	Colorado County, TX|Colorado County|Colorado County, Texas|TX089				Geographic Area	US Counties Terminology
C110256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110256>	C107687	Comal County, TX|Comal County|Comal County, Texas|TX091				Geographic Area	US Counties Terminology
C110257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110257>	C107687	Comanche County, TX|Comanche County|Comanche County, Texas|TX093				Geographic Area	US Counties Terminology
C110258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110258>	C107687	Concho County, TX|Concho County|Concho County, Texas|TX095				Geographic Area	US Counties Terminology
C110259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110259>	C107687	Cooke County, TX|Cooke County|Cooke County, Texas|TX097				Geographic Area	US Counties Terminology
C11025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11025>	C61063	Floxuridine/Interferon Alfa/Mitomycin|FUDR/IFN-A/MITO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110260>	C107687	Coryell County, TX|Coryell County|Coryell County, Texas|TX099				Geographic Area	US Counties Terminology
C110261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110261>	C107687	Cottle County, TX|Cottle County|Cottle County, Texas|TX101				Geographic Area	US Counties Terminology
C110262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110262>	C107687	Crane County, TX|Crane County|Crane County, Texas|TX103				Geographic Area	US Counties Terminology
C110263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110263>	C107687	Crockett County, TX|Crockett County|Crockett County, Texas|TX105				Geographic Area	US Counties Terminology
C110264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110264>	C107687	Crosby County, TX|Crosby County|Crosby County, Texas|TX107				Geographic Area	US Counties Terminology
C110265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110265>	C107687	Culberson County, TX|Culberson County|Culberson County, Texas|TX109				Geographic Area	US Counties Terminology
C110266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110266>	C107687	Dallam County, TX|Dallam County|Dallam County, Texas|TX111				Geographic Area	US Counties Terminology
C110267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110267>	C107687	Dallas County, TX|Dallas County|Dallas County, Texas|TX113				Geographic Area	US Counties Terminology
C110268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110268>	C107687	Dawson County, TX|Dawson County|Dawson County, Texas|TX115				Geographic Area	US Counties Terminology
C110269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110269>	C107687	Deaf Smith County, TX|Deaf Smith County|Deaf Smith County, Texas|TX117				Geographic Area	US Counties Terminology
C11026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11026>	C61063	Cisplatin/Fluorouracil/Interferon Alfa/Leucovorin Calcium|CDDP/CF/5-FU/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110270>	C107687	Delta County, TX|Delta County|Delta County, Texas|TX119				Geographic Area	US Counties Terminology
C110271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110271>	C107687	Denton County, TX|Denton County|Denton County, Texas|TX121				Geographic Area	US Counties Terminology
C110272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110272>	C107687	DeWitt County, TX|DeWitt County|DeWitt County, Texas|TX123				Geographic Area	US Counties Terminology
C110273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110273>	C107687	Dickens County, TX|Dickens County|Dickens County, Texas|TX125				Geographic Area	US Counties Terminology
C110274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110274>	C107687	Dimmit County, TX|Dimmit County|Dimmit County, Texas|TX127				Geographic Area	US Counties Terminology
C110275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110275>	C107687	Donley County, TX|Donley County|Donley County, Texas|TX129				Geographic Area	US Counties Terminology
C110276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110276>	C107687	Duval County, TX|Duval County|Duval County, Texas|TX131				Geographic Area	US Counties Terminology
C110277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110277>	C107687	Eastland County, TX|Eastland County|Eastland County, Texas|TX133				Geographic Area	US Counties Terminology
C110278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110278>	C107687	Ector County, TX|Ector County|Ector County, Texas|TX135				Geographic Area	US Counties Terminology
C110279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110279>	C107687	Edwards County, TX|Edwards County|Edwards County, Texas|TX137				Geographic Area	US Counties Terminology
C11027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11027>	C61007	Fluorouracil/Interferon Alfa/Interleukin-2|5-FU/IFN-A/IL-2|IFN/5FU/IL2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110280>	C107687	Ellis County, TX|Ellis County|Ellis County, Texas|TX139				Geographic Area	US Counties Terminology
C110281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110281>	C107687	El Paso County, TX|El Paso County|El Paso County, Texas|TX141				Geographic Area	US Counties Terminology
C110282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110282>	C107687	Erath County, TX|Erath County|Erath County, Texas|TX143				Geographic Area	US Counties Terminology
C110283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110283>	C107687	Falls County, TX|Falls County|Falls County, Texas|TX145				Geographic Area	US Counties Terminology
C110284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110284>	C107687	Fannin County, TX|Fannin County|Fannin County, Texas|TX147				Geographic Area	US Counties Terminology
C110285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110285>	C107687	Fayette County, TX|Fayette County|Fayette County, Texas|TX149				Geographic Area	US Counties Terminology
C110286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110286>	C107687	Fisher County, TX|Fisher County|Fisher County, Texas|TX151				Geographic Area	US Counties Terminology
C110287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110287>	C107687	Floyd County, TX|Floyd County|Floyd County, Texas|TX153				Geographic Area	US Counties Terminology
C110288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110288>	C107687	Foard County, TX|Foard County|Foard County, Texas|TX155				Geographic Area	US Counties Terminology
C110289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110289>	C107687	Fort Bend County, TX|Fort Bend County|Fort Bend County, Texas|TX157				Geographic Area	US Counties Terminology
C11028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11028>	C61007	Cytarabine/Interferon Alfa|ARA-C/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110290>	C107687	Franklin County, TX|Franklin County|Franklin County, Texas|TX159				Geographic Area	US Counties Terminology
C110291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110291>	C107687	Freestone County, TX|Freestone County|Freestone County, Texas|TX161				Geographic Area	US Counties Terminology
C110292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110292>	C107687	Frio County, TX|Frio County|Frio County, Texas|TX163				Geographic Area	US Counties Terminology
C110293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110293>	C107687	Gaines County, TX|Gaines County|Gaines County, Texas|TX165				Geographic Area	US Counties Terminology
C110294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110294>	C107687	Galveston County, TX|Galveston County|Galveston County, Texas|TX167				Geographic Area	US Counties Terminology
C110295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110295>	C107687	Garza County, TX|Garza County|Garza County, Texas|TX169				Geographic Area	US Counties Terminology
C110296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110296>	C107687	Gillespie County, TX|Gillespie County|Gillespie County, Texas|TX171				Geographic Area	US Counties Terminology
C110297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110297>	C107687	Glasscock County, TX|Glasscock County|Glasscock County, Texas|TX173				Geographic Area	US Counties Terminology
C110298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110298>	C107687	Goliad County, TX|Goliad County|Goliad County, Texas|TX175				Geographic Area	US Counties Terminology
C110299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110299>	C107687	Gonzales County, TX|Gonzales County|Gonzales County, Texas|TX177				Geographic Area	US Counties Terminology
C11029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11029>	C61063	Fludarabine/Interferon Alfa|FAMP/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1102>	C2150|C1556	Fludarabine Phosphate|2-F-ara-AMP|9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-|9H-purin-6-amine, 2-fluoro-9-(5-O-phosphono-beta-D-arabinofuranosyl)|Beneflur|FLUDARABINE PHOSPHATE|Fludara|Fludara|Fludarabine-5'-Monophosphate|Oforta|SH T 586|fludarabine phosphate	The phosphate salt of a fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.	Fludarabine Phosphate		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C110300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110300>	C107687	Gray County, TX|Gray County|Gray County, Texas|TX179				Geographic Area	US Counties Terminology
C110301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110301>	C107687	Grayson County, TX|Grayson County|Grayson County, Texas|TX181				Geographic Area	US Counties Terminology
C110302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110302>	C107687	Gregg County, TX|Gregg County|Gregg County, Texas|TX183				Geographic Area	US Counties Terminology
C110303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110303>	C107687	Grimes County, TX|Grimes County|Grimes County, Texas|TX185				Geographic Area	US Counties Terminology
C110304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110304>	C107687	Guadalupe County, TX|Guadalupe County|Guadalupe County, Texas|TX187				Geographic Area	US Counties Terminology
C110305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110305>	C107687	Hale County, TX|Hale County|Hale County, Texas|TX189				Geographic Area	US Counties Terminology
C110306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110306>	C107687	Hall County, TX|Hall County|Hall County, Texas|TX191				Geographic Area	US Counties Terminology
C110307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110307>	C107687	Hamilton County, TX|Hamilton County|Hamilton County, Texas|TX193				Geographic Area	US Counties Terminology
C110308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110308>	C107687	Hansford County, TX|Hansford County|Hansford County, Texas|TX195				Geographic Area	US Counties Terminology
C110309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110309>	C107687	Hardeman County, TX|Hardeman County|Hardeman County, Texas|TX197				Geographic Area	US Counties Terminology
C11030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11030>	C61063	Fluorouracil/Interferon Alfa/Leucovorin Calcium/Methotrexate|CF/5-FU/IFN-A/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110310>	C107687	Hardin County, TX|Hardin County|Hardin County, Texas|TX199				Geographic Area	US Counties Terminology
C110311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110311>	C107687	Harris County, TX|Harris County|Harris County, Texas|TX201				Geographic Area	US Counties Terminology
C110312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110312>	C107687	Harrison County, TX|Harrison County|Harrison County, Texas|TX203				Geographic Area	US Counties Terminology
C110313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110313>	C107687	Hartley County, TX|Hartley County|Hartley County, Texas|TX205				Geographic Area	US Counties Terminology
C110314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110314>	C107687	Haskell County, TX|Haskell County|Haskell County, Texas|TX207				Geographic Area	US Counties Terminology
C110315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110315>	C107687	Hays County, TX|Hays County|Hays County, Texas|TX209				Geographic Area	US Counties Terminology
C110316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110316>	C107687	Hemphill County, TX|Hemphill County|Hemphill County, Texas|TX211				Geographic Area	US Counties Terminology
C110317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110317>	C107687	Henderson County, TX|Henderson County|Henderson County, Texas|TX213				Geographic Area	US Counties Terminology
C110318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110318>	C107687	Hidalgo County, TX|Hidalgo County|Hidalgo County, Texas|TX215				Geographic Area	US Counties Terminology
C110319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110319>	C107687	Hill County, TX|Hill County|Hill County, Texas|TX217				Geographic Area	US Counties Terminology
C11031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11031>	C61063	Cisplatin/Interferon Alfa/interleukin-2/Vinblastine|CDDP/IFN-A/IL-2/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110320>	C107687	Hockley County, TX|Hockley County|Hockley County, Texas|TX219				Geographic Area	US Counties Terminology
C110321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110321>	C107687	Hood County, TX|Hood County|Hood County, Texas|TX221				Geographic Area	US Counties Terminology
C110322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110322>	C107687	Hopkins County, TX|Hopkins County|Hopkins County, Texas|TX223				Geographic Area	US Counties Terminology
C110323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110323>	C107687	Houston County, TX|Houston County|Houston County, Texas|TX225				Geographic Area	US Counties Terminology
C110324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110324>	C107687	Howard County, TX|Howard County|Howard County, Texas|TX227				Geographic Area	US Counties Terminology
C110325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110325>	C107687	Hudspeth County, TX|Hudspeth County|Hudspeth County, Texas|TX229				Geographic Area	US Counties Terminology
C110326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110326>	C107687	Hunt County, TX|Hunt County|Hunt County, Texas|TX231				Geographic Area	US Counties Terminology
C110327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110327>	C107687	Hutchinson County, TX|Hutchinson County|Hutchinson County, Texas|TX233				Geographic Area	US Counties Terminology
C110328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110328>	C107687	Irion County, TX|Irion County|Irion County, Texas|TX235				Geographic Area	US Counties Terminology
C110329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110329>	C107687	Jack County, TX|Jack County|Jack County, Texas|TX237				Geographic Area	US Counties Terminology
C11032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11032>	C61007	Cisplatin/Fluorouracil/Interferon Alfa|CDDP/5-FU/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110330>	C107687	Jackson County, TX|Jackson County|Jackson County, Texas|TX239				Geographic Area	US Counties Terminology
C110331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110331>	C107687	Jasper County, TX|Jasper County|Jasper County, Texas|TX241				Geographic Area	US Counties Terminology
C110332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110332>	C107687	Jeff Davis County, TX|Jeff Davis County|Jeff Davis County, Texas|TX243				Geographic Area	US Counties Terminology
C110333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110333>	C107687	Jefferson County, TX|Jefferson County|Jefferson County, Texas|TX245				Geographic Area	US Counties Terminology
C110334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110334>	C107687	Jim Hogg County, TX|Jim Hogg County|Jim Hogg County, Texas|TX247				Geographic Area	US Counties Terminology
C110335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110335>	C107687	Jim Wells County, TX|Jim Wells County|Jim Wells County, Texas|TX249				Geographic Area	US Counties Terminology
C110336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110336>	C107687	Johnson County, TX|Johnson County|Johnson County, Texas|TX251				Geographic Area	US Counties Terminology
C110337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110337>	C107687	Jones County, TX|Jones County|Jones County, Texas|TX253				Geographic Area	US Counties Terminology
C110338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110338>	C107687	Karnes County, TX|Karnes County|Karnes County, Texas|TX255				Geographic Area	US Counties Terminology
C110339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110339>	C107687	Kaufman County, TX|Kaufman County|Kaufman County, Texas|TX257				Geographic Area	US Counties Terminology
C11033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11033>	C61063	Dacarbazine/Interferon Alfa|DTIC/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110340>	C107687	Kendall County, TX|Kendall County|Kendall County, Texas|TX259				Geographic Area	US Counties Terminology
C110341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110341>	C107687	Kenedy County, TX|Kenedy County|Kenedy County, Texas|TX261				Geographic Area	US Counties Terminology
C110342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110342>	C107687	Kent County, TX|Kent County|Kent County, Texas|TX263				Geographic Area	US Counties Terminology
C110343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110343>	C107687	Kerr County, TX|Kerr County|Kerr County, Texas|TX265				Geographic Area	US Counties Terminology
C110344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110344>	C107687	Kimble County, TX|Kimble County|Kimble County, Texas|TX267				Geographic Area	US Counties Terminology
C110345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110345>	C107687	King County, TX|King County|King County, Texas|TX269				Geographic Area	US Counties Terminology
C110346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110346>	C107687	Kinney County, TX|Kinney County|Kinney County, Texas|TX271				Geographic Area	US Counties Terminology
C110347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110347>	C107687	Kleberg County, TX|Kleberg County|Kleberg County, Texas|TX273				Geographic Area	US Counties Terminology
C110348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110348>	C107687	Knox County, TX|Knox County|Knox County, Texas|TX275				Geographic Area	US Counties Terminology
C110349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110349>	C107687	Lamar County, TX|Lamar County|Lamar County, Texas|TX277				Geographic Area	US Counties Terminology
C11034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11034>	C61063	Dacarbazine/Interferon Alfa/Tamoxifen|DTIC/IFN-A/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110350>	C107687	Lamb County, TX|Lamb County|Lamb County, Texas|TX279				Geographic Area	US Counties Terminology
C110351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110351>	C107687	Lampasas County, TX|Lampasas County|Lampasas County, Texas|TX281				Geographic Area	US Counties Terminology
C110352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110352>	C107687	La Salle County, TX|La Salle County|La Salle County, Texas|TX283				Geographic Area	US Counties Terminology
C110353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110353>	C107687	Lavaca County, TX|Lavaca County|Lavaca County, Texas|TX285				Geographic Area	US Counties Terminology
C110354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110354>	C107687	Lee County, TX|Lee County|Lee County, Texas|TX287				Geographic Area	US Counties Terminology
C110355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110355>	C107687	Leon County, TX|Leon County|Leon County, Texas|TX289				Geographic Area	US Counties Terminology
C110356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110356>	C107687	Liberty County, TX|Liberty County|Liberty County, Texas|TX291				Geographic Area	US Counties Terminology
C110357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110357>	C107687	Limestone County, TX|Limestone County|Limestone County, Texas|TX293				Geographic Area	US Counties Terminology
C110358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110358>	C107687	Lipscomb County, TX|Lipscomb County|Lipscomb County, Texas|TX295				Geographic Area	US Counties Terminology
C110359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110359>	C107687	Live Oak County, TX|Live Oak County|Live Oak County, Texas|TX297				Geographic Area	US Counties Terminology
C11035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11035>	C61063	Carboplatin/Cisplatin/Interferon Alfa/Tamoxifen|CBDCA/CDDP/IFN-A/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110360>	C107687	Llano County, TX|Llano County|Llano County, Texas|TX299				Geographic Area	US Counties Terminology
C110361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110361>	C107687	Loving County, TX|Loving County|Loving County, Texas|TX301				Geographic Area	US Counties Terminology
C110362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110362>	C107687	Lubbock County, TX|Lubbock County|Lubbock County, Texas|TX303				Geographic Area	US Counties Terminology
C110363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110363>	C107687	Lynn County, TX|Lynn County|Lynn County, Texas|TX305				Geographic Area	US Counties Terminology
C110364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110364>	C107687	McCulloch County, TX|McCulloch County|McCulloch County, Texas|TX307				Geographic Area	US Counties Terminology
C110365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110365>	C107687	McLennan County, TX|McLennan County|McLennan County, Texas|TX309				Geographic Area	US Counties Terminology
C110366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110366>	C107687	McMullen County, TX|McMullen County|McMullen County, Texas|TX311				Geographic Area	US Counties Terminology
C110367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110367>	C107687	Madison County, TX|Madison County|Madison County, Texas|TX313				Geographic Area	US Counties Terminology
C110368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110368>	C107687	Marion County, TX|Marion County|Marion County, Texas|TX315				Geographic Area	US Counties Terminology
C110369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110369>	C107687	Martin County, TX|Martin County|Martin County, Texas|TX317				Geographic Area	US Counties Terminology
C11036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11036>	C61063	Interferon Alfa/Interleukin-2/Monoclonal Antibody R24|IFN-A/IL-2/MOAB R24			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110370>	C107687	Mason County, TX|Mason County|Mason County, Texas|TX319				Geographic Area	US Counties Terminology
C110371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110371>	C107687	Matagorda County, TX|Matagorda County|Matagorda County, Texas|TX321				Geographic Area	US Counties Terminology
C110372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110372>	C107687	Maverick County, TX|Maverick County|Maverick County, Texas|TX323				Geographic Area	US Counties Terminology
C110373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110373>	C107687	Medina County, TX|Medina County|Medina County, Texas|TX325				Geographic Area	US Counties Terminology
C110374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110374>	C107687	Menard County, TX|Menard County|Menard County, Texas|TX327				Geographic Area	US Counties Terminology
C110375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110375>	C107687	Midland County, TX|Midland County|Midland County, Texas|TX329				Geographic Area	US Counties Terminology
C110376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110376>	C107687	Milam County, TX|Milam County|Milam County, Texas|TX331				Geographic Area	US Counties Terminology
C110377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110377>	C107687	Mills County, TX|Mills County|Mills County, Texas|TX333				Geographic Area	US Counties Terminology
C110378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110378>	C107687	Mitchell County, TX|Mitchell County|Mitchell County, Texas|TX335				Geographic Area	US Counties Terminology
C110379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110379>	C107687	Montague County, TX|Montague County|Montague County, Texas|TX337				Geographic Area	US Counties Terminology
C11037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11037>	C61063	Filgrastim/Fluorouracil/Interferon Alfa|5-FU/G-CSF/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110380>	C107687	Montgomery County, TX|Montgomery County|Montgomery County, Texas|TX339				Geographic Area	US Counties Terminology
C110381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110381>	C107687	Moore County, TX|Moore County|Moore County, Texas|TX341				Geographic Area	US Counties Terminology
C110382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110382>	C107687	Morris County, TX|Morris County|Morris County, Texas|TX343				Geographic Area	US Counties Terminology
C110383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110383>	C107687	Motley County, TX|Motley County|Motley County, Texas|TX345				Geographic Area	US Counties Terminology
C110384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110384>	C107687	Nacogdoches County, TX|Nacogdoches County|Nacogdoches County, Texas|TX347				Geographic Area	US Counties Terminology
C110385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110385>	C107687	Navarro County, TX|Navarro County|Navarro County, Texas|TX349				Geographic Area	US Counties Terminology
C110386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110386>	C107687	Newton County, TX|Newton County|Newton County, Texas|TX351				Geographic Area	US Counties Terminology
C110387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110387>	C107687	Nolan County, TX|Nolan County|Nolan County, Texas|TX353				Geographic Area	US Counties Terminology
C110388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110388>	C107687	Nueces County, TX|Nueces County|Nueces County, Texas|TX355				Geographic Area	US Counties Terminology
C110389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110389>	C107687	Ochiltree County, TX|Ochiltree County|Ochiltree County, Texas|TX357				Geographic Area	US Counties Terminology
C11038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11038>	C61063	Cyclophosphamide/Doxorubicin/Fluorouracil/Interferon Alfa|CTX/DOX/5-FU/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110390>	C107687	Oldham County, TX|Oldham County|Oldham County, Texas|TX359				Geographic Area	US Counties Terminology
C110391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110391>	C107687	Orange County, TX|Orange County|Orange County, Texas|TX361				Geographic Area	US Counties Terminology
C110392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110392>	C107687	Palo Pinto County, TX|Palo Pinto County|Palo Pinto County, Texas|TX363				Geographic Area	US Counties Terminology
C110393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110393>	C107687	Panola County, TX|Panola County|Panola County, Texas|TX365				Geographic Area	US Counties Terminology
C110394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110394>	C107687	Parker County, TX|Parker County|Parker County, Texas|TX367				Geographic Area	US Counties Terminology
C110395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110395>	C107687	Parmer County, TX|Parmer County|Parmer County, Texas|TX369				Geographic Area	US Counties Terminology
C110396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110396>	C107687	Pecos County, TX|Pecos County|Pecos County, Texas|TX371				Geographic Area	US Counties Terminology
C110397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110397>	C107687	Polk County, TX|Polk County|Polk County, Texas|TX373				Geographic Area	US Counties Terminology
C110398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110398>	C107687	Potter County, TX|Potter County|Potter County, Texas|TX375				Geographic Area	US Counties Terminology
C110399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110399>	C107687	Presidio County, TX|Presidio County|Presidio County, Texas|TX377				Geographic Area	US Counties Terminology
C11039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11039>	C61063	Interferon Alfa/Interleukin-2/Tumor Necrosis Factor|IFN-A/IL-2/TNF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1103>	C521	Fludrocortisone Acetate|FLUDROCORTISONE ACETATE|Florinef|Florinef Acetate|Florinef acetate|Fludrocortisone acetate	The acetate salt of a synthetic fluorinated corticosteroid with antiinflammatory and antiallergic activities. As a glucocorticoid-receptor agonist, fludrocortisone binds to cytoplasmic receptors, translocates to the nucleus, and subsequently initiates the transcription of glucocorticoid-responsive genes such as lipocortins to inhibit phospholipase A2 (PLA2). Inhibition of PLA2 activity prevents the release of arachidonic acid, a precursor of eicosanoids such as prostaglandins and leukotrienes; eicosanoids are important mediators in the pro-inflammatory response mechanism. As a mineralocorticoid-receptor agonist, this agent stimulates Na+ reabsorption and water retention and K+ and H+ secretion in the distal tubules and collecting ducts of the kidney.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C110400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110400>	C107687	Rains County, TX|Rains County|Rains County, Texas|TX379				Geographic Area	US Counties Terminology
C110401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110401>	C107687	Randall County, TX|Randall County|Randall County, Texas|TX381				Geographic Area	US Counties Terminology
C110402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110402>	C107687	Reagan County, TX|Reagan County|Reagan County, Texas|TX383				Geographic Area	US Counties Terminology
C110403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110403>	C107687	Real County, TX|Real County|Real County, Texas|TX385				Geographic Area	US Counties Terminology
C110404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110404>	C107687	Red River County, TX|Red River County|Red River County, Texas|TX387				Geographic Area	US Counties Terminology
C110405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110405>	C107687	Reeves County, TX|Reeves County|Reeves County, Texas|TX389				Geographic Area	US Counties Terminology
C110406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110406>	C107687	Refugio County, TX|Refugio County|Refugio County, Texas|TX391				Geographic Area	US Counties Terminology
C110407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110407>	C107687	Roberts County, TX|Roberts County|Roberts County, Texas|TX393				Geographic Area	US Counties Terminology
C110408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110408>	C107687	Robertson County, TX|Robertson County|Robertson County, Texas|TX395				Geographic Area	US Counties Terminology
C110409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110409>	C107687	Rockwall County, TX|Rockwall County|Rockwall County, Texas|TX397				Geographic Area	US Counties Terminology
C11040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11040>	C61007	Chlorambucil/Interferon Alfa|CLB/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110410>	C107687	Runnels County, TX|Runnels County|Runnels County, Texas|TX399				Geographic Area	US Counties Terminology
C110411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110411>	C107687	Rusk County, TX|Rusk County|Rusk County, Texas|TX401				Geographic Area	US Counties Terminology
C110412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110412>	C107687	Sabine County, TX|Sabine County|Sabine County, Texas|TX403				Geographic Area	US Counties Terminology
C110413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110413>	C107687	San Augustine County, TX|San Augustine County|San Augustine County, Texas|TX405				Geographic Area	US Counties Terminology
C110414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110414>	C107687	San Jacinto County, TX|San Jacinto County|San Jacinto County, Texas|TX407				Geographic Area	US Counties Terminology
C110415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110415>	C107687	San Patricio County, TX|San Patricio County|San Patricio County, Texas|TX409				Geographic Area	US Counties Terminology
C110416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110416>	C107687	San Saba County, TX|San Saba County|San Saba County, Texas|TX411				Geographic Area	US Counties Terminology
C110417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110417>	C107687	Schleicher County, TX|Schleicher County|Schleicher County, Texas|TX413				Geographic Area	US Counties Terminology
C110418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110418>	C107687	Scurry County, TX|Scurry County|Scurry County, Texas|TX415				Geographic Area	US Counties Terminology
C110419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110419>	C107687	Shackelford County, TX|Shackelford County|Shackelford County, Texas|TX417				Geographic Area	US Counties Terminology
C11041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11041>	C61063	Cisplatin/Cyclophosphamide/Doxorubicin/Etoposide/Filgrastim|CDDP/CTX/DOX/G-CSF/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110420>	C107687	Shelby County, TX|Shelby County|Shelby County, Texas|TX419				Geographic Area	US Counties Terminology
C110421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110421>	C107687	Sherman County, TX|Sherman County|Sherman County, Texas|TX421				Geographic Area	US Counties Terminology
C110422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110422>	C107687	Smith County, TX|Smith County|Smith County, Texas|TX423				Geographic Area	US Counties Terminology
C110423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110423>	C107687	Somervell County, TX|Somervell County|Somervell County, Texas|TX425				Geographic Area	US Counties Terminology
C110424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110424>	C107687	Starr County, TX|Starr County|Starr County, Texas|TX427				Geographic Area	US Counties Terminology
C110425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110425>	C107687	Stephens County, TX|Stephens County|Stephens County, Texas|TX429				Geographic Area	US Counties Terminology
C110426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110426>	C107687	Sterling County, TX|Sterling County|Sterling County, Texas|TX431				Geographic Area	US Counties Terminology
C110427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110427>	C107687	Stonewall County, TX|Stonewall County|Stonewall County, Texas|TX433				Geographic Area	US Counties Terminology
C110428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110428>	C107687	Sutton County, TX|Sutton County|Sutton County, Texas|TX435				Geographic Area	US Counties Terminology
C110429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110429>	C107687	Swisher County, TX|Swisher County|Swisher County, Texas|TX437				Geographic Area	US Counties Terminology
C11042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11042>	C61063	Hydroxyurea/Interferon Alfa|HU/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110430>	C107687	Tarrant County, TX|TX439|Tarrant County|Tarrant County, Texas				Geographic Area	US Counties Terminology
C110431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110431>	C107687	Taylor County, TX|TX441|Taylor County|Taylor County, Texas				Geographic Area	US Counties Terminology
C110432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110432>	C107687	Terrell County, TX|TX443|Terrell County|Terrell County, Texas				Geographic Area	US Counties Terminology
C110433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110433>	C107687	Terry County, TX|TX445|Terry County|Terry County, Texas				Geographic Area	US Counties Terminology
C110434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110434>	C107687	Throckmorton County, TX|TX447|Throckmorton County|Throckmorton County, Texas				Geographic Area	US Counties Terminology
C110435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110435>	C107687	Titus County, TX|TX449|Titus County|Titus County, Texas				Geographic Area	US Counties Terminology
C110436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110436>	C107687	Tom Green County, TX|TX451|Tom Green County|Tom Green County, Texas				Geographic Area	US Counties Terminology
C110437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110437>	C107687	Travis County, TX|TX453|Travis County|Travis County, Texas				Geographic Area	US Counties Terminology
C110438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110438>	C107687	Trinity County, TX|TX455|Trinity County|Trinity County, Texas				Geographic Area	US Counties Terminology
C110439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110439>	C107687	Tyler County, TX|TX457|Tyler County|Tyler County, Texas				Geographic Area	US Counties Terminology
C11043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11043>	C61063	Carboplatin/Etoposide/Interferon Alfa/Mitoxantrone|CBDCA/DHAD/IFN-A/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110440>	C107687	Upshur County, TX|TX459|Upshur County|Upshur County, Texas				Geographic Area	US Counties Terminology
C110441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110441>	C107687	Upton County, TX|TX461|Upton County|Upton County, Texas				Geographic Area	US Counties Terminology
C110442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110442>	C107687	Uvalde County, TX|TX463|Uvalde County|Uvalde County, Texas				Geographic Area	US Counties Terminology
C110443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110443>	C107687	Val Verde County, TX|TX465|Val Verde County|Val Verde County, Texas				Geographic Area	US Counties Terminology
C110444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110444>	C107687	Van Zandt County, TX|TX467|Van Zandt County|Van Zandt County, Texas				Geographic Area	US Counties Terminology
C110445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110445>	C107687	Victoria County, TX|TX469|Victoria County|Victoria County, Texas				Geographic Area	US Counties Terminology
C110446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110446>	C107687	Walker County, TX|TX471|Walker County|Walker County, Texas				Geographic Area	US Counties Terminology
C110447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110447>	C107687	Waller County, TX|TX473|Waller County|Waller County, Texas				Geographic Area	US Counties Terminology
C110448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110448>	C107687	Ward County, TX|TX475|Ward County|Ward County, Texas				Geographic Area	US Counties Terminology
C110449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110449>	C107687	Washington County, TX|TX477|Washington County|Washington County, Texas				Geographic Area	US Counties Terminology
C11044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11044>	C61063	Interferon Alfa/Megestrol/Tamoxifen|IFN-A/MEG/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110450>	C107687	Webb County, TX|TX479|Webb County|Webb County, Texas				Geographic Area	US Counties Terminology
C110451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110451>	C107687	Wharton County, TX|TX481|Wharton County|Wharton County, Texas				Geographic Area	US Counties Terminology
C110452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110452>	C107687	Wheeler County, TX|TX483|Wheeler County|Wheeler County, Texas				Geographic Area	US Counties Terminology
C110453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110453>	C107687	Wichita County, TX|TX485|Wichita County|Wichita County, Texas				Geographic Area	US Counties Terminology
C110454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110454>	C107687	Wilbarger County, TX|TX487|Wilbarger County|Wilbarger County, Texas				Geographic Area	US Counties Terminology
C110455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110455>	C107687	Willacy County, TX|TX489|Willacy County|Willacy County, Texas				Geographic Area	US Counties Terminology
C110456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110456>	C107687	Williamson County, TX|TX491|Williamson County|Williamson County, Texas				Geographic Area	US Counties Terminology
C110457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110457>	C107687	Wilson County, TX|TX493|Wilson County|Wilson County, Texas				Geographic Area	US Counties Terminology
C110458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110458>	C107687	Winkler County, TX|TX495|Winkler County|Winkler County, Texas				Geographic Area	US Counties Terminology
C110459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110459>	C107687	Wise County, TX|TX497|Wise County|Wise County, Texas				Geographic Area	US Counties Terminology
C11045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11045>	C61063	Fluorouracil/Interferon Alfa/Leucovorin Calcium/Mitomycin|CF/5-FU/IFN-A/MITO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110460>	C107687	Wood County, TX|TX499|Wood County|Wood County, Texas				Geographic Area	US Counties Terminology
C110461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110461>	C107687	Yoakum County, TX|TX501|Yoakum County|Yoakum County, Texas				Geographic Area	US Counties Terminology
C110462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110462>	C107687	Young County, TX|TX503|Young County|Young County, Texas				Geographic Area	US Counties Terminology
C110463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110463>	C107687	Zapata County, TX|TX505|Zapata County|Zapata County, Texas				Geographic Area	US Counties Terminology
C110464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110464>	C107687	Zavala County, TX|TX507|Zavala County|Zavala County, Texas				Geographic Area	US Counties Terminology
C110465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110465>	C107687	Beaver County, UT|Beaver County|Beaver County, Utah|UT001				Geographic Area	US Counties Terminology
C110466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110466>	C107687	Box Elder County, UT|Box Elder County|Box Elder County, Utah|UT003				Geographic Area	US Counties Terminology
C110467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110467>	C107687	Cache County, UT|Cache County|Cache County, Utah|UT005				Geographic Area	US Counties Terminology
C110468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110468>	C107687	Carbon County, UT|Carbon County|Carbon County, Utah|UT007				Geographic Area	US Counties Terminology
C110469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110469>	C107687	Daggett County, UT|Daggett County|Daggett County, Utah|UT009				Geographic Area	US Counties Terminology
C11046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11046>	C61063	Floxuridine/Interferon Alfa|FUDR/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110470>	C107687	Davis County, UT|Davis County|Davis County, Utah|UT011				Geographic Area	US Counties Terminology
C110471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110471>	C107687	Duchesne County, UT|Duchesne County|Duchesne County, Utah|UT013				Geographic Area	US Counties Terminology
C110472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110472>	C107687	Emery County, UT|Emery County|Emery County, Utah|UT015				Geographic Area	US Counties Terminology
C110473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110473>	C107687	Garfield County, UT|Garfield County|Garfield County, Utah|UT017				Geographic Area	US Counties Terminology
C110474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110474>	C107687	Grand County, UT|Grand County|Grand County, Utah|UT019				Geographic Area	US Counties Terminology
C110475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110475>	C107687	Iron County, UT|Iron County|Iron County, Utah|UT021				Geographic Area	US Counties Terminology
C110476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110476>	C107687	Juab County, UT|Juab County|Juab County, Utah|UT023				Geographic Area	US Counties Terminology
C110477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110477>	C107687	Kane County, UT|Kane County|Kane County, Utah|UT025				Geographic Area	US Counties Terminology
C110478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110478>	C107687	Millard County, UT|Millard County|Millard County, Utah|UT027				Geographic Area	US Counties Terminology
C110479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110479>	C107687	Morgan County, UT|Morgan County|Morgan County, Utah|UT029				Geographic Area	US Counties Terminology
C11047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11047>	C61063	Cisplatin/Etoposide/Fluorouracil/Interferon Alfa|CDDP/5-FU/IFN-A/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110480>	C107687	Piute County, UT|Piute County|Piute County, Utah|UT031				Geographic Area	US Counties Terminology
C110481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110481>	C107687	Rich County, UT|Rich County|Rich County, Utah|UT033				Geographic Area	US Counties Terminology
C110482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110482>	C107687	Salt Lake County, UT|Salt Lake County|Salt Lake County, Utah|UT035				Geographic Area	US Counties Terminology
C110483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110483>	C107687	San Juan County, UT|San Juan County|San Juan County, Utah|UT037				Geographic Area	US Counties Terminology
C110484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110484>	C107687	Sanpete County, UT|Sanpete County|Sanpete County, Utah|UT039				Geographic Area	US Counties Terminology
C110485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110485>	C107687	Sevier County, UT|Sevier County|Sevier County, Utah|UT041				Geographic Area	US Counties Terminology
C110486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110486>	C107687	Summit County, UT|Summit County|Summit County, Utah|UT043				Geographic Area	US Counties Terminology
C110487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110487>	C107687	Tooele County, UT|Tooele County|Tooele County, Utah|UT045				Geographic Area	US Counties Terminology
C110488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110488>	C107687	Uintah County, UT|UT047|Uintah County|Uintah County, Utah				Geographic Area	US Counties Terminology
C110489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110489>	C107687	Utah County, UT|UT049|Utah County|Utah County, Utah				Geographic Area	US Counties Terminology
C11048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11048>	C61063	Allopurinol/Fluorouracil/Interferon Alfa|ALLO/5-FU/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110490>	C107687	Wasatch County, UT|UT051|Wasatch County|Wasatch County, Utah				Geographic Area	US Counties Terminology
C110491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110491>	C107687	Washington County, UT|UT053|Washington County|Washington County, Utah				Geographic Area	US Counties Terminology
C110492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110492>	C107687	Wayne County, UT|UT055|Wayne County|Wayne County, Utah				Geographic Area	US Counties Terminology
C110493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110493>	C107687	Weber County, UT|UT057|Weber County|Weber County, Utah				Geographic Area	US Counties Terminology
C110494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110494>	C107687	Addison County, VT|Addison County|Addison County, Vermont|VT001				Geographic Area	US Counties Terminology
C110495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110495>	C107687	Bennington County, VT|Bennington County|Bennington County, Vermont|VT003				Geographic Area	US Counties Terminology
C110496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110496>	C107687	Caledonia County, VT|Caledonia County|Caledonia County, Vermont|VT005				Geographic Area	US Counties Terminology
C110497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110497>	C107687	Chittenden County, VT|Chittenden County|Chittenden County, Vermont|VT007				Geographic Area	US Counties Terminology
C110498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110498>	C107687	Essex County, VT|Essex County|Essex County, Vermont|VT009				Geographic Area	US Counties Terminology
C110499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110499>	C107687	Franklin County, VT|Franklin County|Franklin County, Vermont|VT011				Geographic Area	US Counties Terminology
C11049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11049>	C61007	Interferon Alfa/Tretinoin|ATRA/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1104>	C314	Fluosol-DA	A perfluorocarbon blood substitute in trials for the treatment of severe anemia			Organic Chemical|Pharmacologic Substance	NCI Drug Dictionary Terminology
C110500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110500>	C107687	Grand Isle County, VT|Grand Isle County|Grand Isle County, Vermont|VT013				Geographic Area	US Counties Terminology
C110501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110501>	C107687	Lamoille County, VT|Lamoille County|Lamoille County, Vermont|VT015				Geographic Area	US Counties Terminology
C110502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110502>	C107687	Orange County, VT|Orange County|Orange County, Vermont|VT017				Geographic Area	US Counties Terminology
C110503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110503>	C107687	Orleans County, VT|Orleans County|Orleans County, Vermont|VT019				Geographic Area	US Counties Terminology
C110504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110504>	C107687	Rutland County, VT|Rutland County|Rutland County, Vermont|VT021				Geographic Area	US Counties Terminology
C110505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110505>	C107687	Washington County, VT|VT023|Washington County|Washington County, Vermont				Geographic Area	US Counties Terminology
C110506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110506>	C107687	Windham County, VT|VT025|Windham County|Windham County, Vermont				Geographic Area	US Counties Terminology
C110507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110507>	C107687	Windsor County, VT|VT027|Windsor County|Windsor County, Vermont				Geographic Area	US Counties Terminology
C110508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110508>	C107687	Accomack County, VA|Accomack County|Accomack County, Virginia|VA001				Geographic Area	US Counties Terminology
C110509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110509>	C107687	Albemarle County, VA|Albemarle County|Albemarle County, Virginia|VA003				Geographic Area	US Counties Terminology
C11050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11050>	C61063	Fluorouracil/Interferon Alfa/Interferon Gamma/Leucovorin Calcium|CF/5-FU/IFN-A/IFN-G			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110510>	C107687	Alleghany County, VA|Alleghany County|Alleghany County, Virginia|VA005				Geographic Area	US Counties Terminology
C110511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110511>	C107687	Amelia County, VA|Amelia County|Amelia County, Virginia|VA007				Geographic Area	US Counties Terminology
C110512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110512>	C107687	Amherst County, VA|Amherst County|Amherst County, Virginia|VA009				Geographic Area	US Counties Terminology
C110513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110513>	C107687	Appomattox County, VA|Appomattox County|Appomattox County, Virginia|VA011				Geographic Area	US Counties Terminology
C110514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110514>	C107687	Arlington County, VA|Arlington County|Arlington County, Virginia|VA013				Geographic Area	US Counties Terminology
C110515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110515>	C107687	Augusta County, VA|Augusta County|Augusta County, Virginia|VA015				Geographic Area	US Counties Terminology
C110516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110516>	C107687	Bath County, VA|Bath County|Bath County, Virginia|VA017				Geographic Area	US Counties Terminology
C110517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110517>	C107687	Bedford County, VA|Bedford County|Bedford County, Virginia|VA019				Geographic Area	US Counties Terminology
C110518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110518>	C107687	Bland County, VA|Bland County|Bland County, Virginia|VA021				Geographic Area	US Counties Terminology
C110519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110519>	C107687	Botetourt County, VA|Botetourt County|Botetourt County, Virginia|VA023				Geographic Area	US Counties Terminology
C11051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11051>	C61063	Bleomycin/Doxorubicin/Vincristine/zalcitabine|BLEO/ddC/DOX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110520>	C107687	Brunswick County, VA|Brunswick County|Brunswick County, Virginia|VA025				Geographic Area	US Counties Terminology
C110521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110521>	C107687	Buchanan County, VA|Buchanan County|Buchanan County, Virginia|VA027				Geographic Area	US Counties Terminology
C110522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110522>	C107687	Buckingham County, VA|Buckingham County|Buckingham County, Virginia|VA029				Geographic Area	US Counties Terminology
C110523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110523>	C107687	Campbell County, VA|Campbell County|Campbell County, Virginia|VA031				Geographic Area	US Counties Terminology
C110524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110524>	C107687	Caroline County, VA|Caroline County|Caroline County, Virginia|VA033				Geographic Area	US Counties Terminology
C110525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110525>	C107687	Carroll County, VA|Carroll County|Carroll County, Virginia|VA035				Geographic Area	US Counties Terminology
C110526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110526>	C107687	Charles City County, VA|Charles City County|Charles City County, Virginia|VA036				Geographic Area	US Counties Terminology
C110527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110527>	C107687	Charlotte County, VA|Charlotte County|Charlotte County, Virginia|VA037				Geographic Area	US Counties Terminology
C110528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110528>	C107687	Chesterfield County, VA|Chesterfield County|Chesterfield County, Virginia|VA041				Geographic Area	US Counties Terminology
C110529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110529>	C107687	Clarke County, VA|Clarke County|Clarke County, Virginia|VA043				Geographic Area	US Counties Terminology
C11052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11052>	C61063	Bleomycin/Cisplatin/Ifosfamide/Interferon Alfa|BLEO/CDDP/IFF/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110530>	C107687	Craig County, VA|Craig County|Craig County, Virginia|VA045				Geographic Area	US Counties Terminology
C110531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110531>	C107687	Culpeper County, VA|Culpeper County|Culpeper County, Virginia|VA047				Geographic Area	US Counties Terminology
C110532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110532>	C107687	Cumberland County, VA|Cumberland County|Cumberland County, Virginia|VA049				Geographic Area	US Counties Terminology
C110533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110533>	C107687	Dickenson County, VA|Dickenson County|Dickenson County, Virginia|VA051				Geographic Area	US Counties Terminology
C110534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110534>	C107687	Dinwiddie County, VA|Dinwiddie County|Dinwiddie County, Virginia|VA053				Geographic Area	US Counties Terminology
C110535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110535>	C107687	Essex County, VA|Essex County|Essex County, Virginia|VA057				Geographic Area	US Counties Terminology
C110536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110536>	C107687	Fairfax County, VA|Fairfax County|Fairfax County, Virginia|VA059				Geographic Area	US Counties Terminology
C110537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110537>	C107687	Fauquier County, VA|Fauquier County|Fauquier County, Virginia|VA061				Geographic Area	US Counties Terminology
C110538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110538>	C107687	Floyd County, VA|Floyd County|Floyd County, Virginia|VA063				Geographic Area	US Counties Terminology
C110539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110539>	C107687	Fluvanna County, VA|Fluvanna County|Fluvanna County, Virginia|VA065				Geographic Area	US Counties Terminology
C11053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11053>	C61063	Interferon Alfa/Mercaptopurine/Methotrexate/Prednisone/Vincristine|IFN-A/MP/MTX/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110540>	C107687	Franklin County, VA|Franklin County|Franklin County, Virginia|VA067				Geographic Area	US Counties Terminology
C110541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110541>	C107687	Frederick County, VA|Frederick County|Frederick County, Virginia|VA069				Geographic Area	US Counties Terminology
C110542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110542>	C107687	Giles County, VA|Giles County|Giles County, Virginia|VA071				Geographic Area	US Counties Terminology
C110543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110543>	C107687	Gloucester County, VA|Gloucester County|Gloucester County, Virginia|VA073				Geographic Area	US Counties Terminology
C110544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110544>	C107687	Goochland County, VA|Goochland County|Goochland County, Virginia|VA075				Geographic Area	US Counties Terminology
C110545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110545>	C107687	Grayson County, VA|Grayson County|Grayson County, Virginia|VA077				Geographic Area	US Counties Terminology
C110546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110546>	C107687	Greene County, VA|Greene County|Greene County, Virginia|VA079				Geographic Area	US Counties Terminology
C110547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110547>	C107687	Greensville County, VA|Greensville County|Greensville County, Virginia|VA081				Geographic Area	US Counties Terminology
C110548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110548>	C107687	Halifax County, VA|Halifax County|Halifax County, Virginia|VA083				Geographic Area	US Counties Terminology
C110549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110549>	C107687	Hanover County, VA|Hanover County|Hanover County, Virginia|VA085				Geographic Area	US Counties Terminology
C11054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11054>	C61063	Busulfan/Interferon Alfa|BU/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110550>	C107687	Henrico County, VA|Henrico County|Henrico County, Virginia|VA087				Geographic Area	US Counties Terminology
C110551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110551>	C107687	Henry County, VA|Henry County|Henry County, Virginia|VA089				Geographic Area	US Counties Terminology
C110552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110552>	C107687	Highland County, VA|Highland County|Highland County, Virginia|VA091				Geographic Area	US Counties Terminology
C110553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110553>	C107687	Isle of Wight County, VA|Isle of Wight County|Isle of Wight County, Virginia|VA093				Geographic Area	US Counties Terminology
C110554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110554>	C107687	James City County, VA|James City County|James City County, Virginia|VA095				Geographic Area	US Counties Terminology
C110555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110555>	C107687	King and Queen County, VA|King and Queen County|King and Queen County, Virginia|VA097				Geographic Area	US Counties Terminology
C110556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110556>	C107687	King George County, VA|King George County|King George County, Virginia|VA099				Geographic Area	US Counties Terminology
C110557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110557>	C107687	King William County, VA|King William County|King William County, Virginia|VA101				Geographic Area	US Counties Terminology
C110558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110558>	C107687	Lancaster County, VA|Lancaster County|Lancaster County, Virginia|VA103				Geographic Area	US Counties Terminology
C110559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110559>	C107687	Lee County, VA|Lee County|Lee County, Virginia|VA105				Geographic Area	US Counties Terminology
C11055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11055>	C61063	Filgrastim/Interferon Alfa|G-CSF/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110560>	C107687	Loudoun County, VA|Loudoun County|Loudoun County, Virginia|VA107				Geographic Area	US Counties Terminology
C110561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110561>	C107687	Louisa County, VA|Louisa County|Louisa County, Virginia|VA109				Geographic Area	US Counties Terminology
C110562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110562>	C107687	Lunenburg County, VA|Lunenburg County|Lunenburg County, Virginia|VA111				Geographic Area	US Counties Terminology
C110563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110563>	C107687	Madison County, VA|Madison County|Madison County, Virginia|VA113				Geographic Area	US Counties Terminology
C110564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110564>	C107687	Mathews County, VA|Mathews County|Mathews County, Virginia|VA115				Geographic Area	US Counties Terminology
C110565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110565>	C107687	Mecklenburg County, VA|Mecklenburg County|Mecklenburg County, Virginia|VA117				Geographic Area	US Counties Terminology
C110566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110566>	C107687	Middlesex County, VA|Middlesex County|Middlesex County, Virginia|VA119				Geographic Area	US Counties Terminology
C110567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110567>	C107687	Montgomery County, VA|Montgomery County|Montgomery County, Virginia|VA121				Geographic Area	US Counties Terminology
C110568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110568>	C107687	Nelson County, VA|Nelson County|Nelson County, Virginia|VA125				Geographic Area	US Counties Terminology
C110569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110569>	C107687	New Kent County, VA|New Kent County|New Kent County, Virginia|VA127				Geographic Area	US Counties Terminology
C11056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11056>	C61063	Hydralazine/Interferon Alfa|hydralazine/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110570>	C107687	Northampton County, VA|Northampton County|Northampton County, Virginia|VA131				Geographic Area	US Counties Terminology
C110571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110571>	C107687	Northumberland County, VA|Northumberland County|Northumberland County, Virginia|VA133				Geographic Area	US Counties Terminology
C110572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110572>	C107687	Nottoway County, VA|Nottoway County|Nottoway County, Virginia|VA135				Geographic Area	US Counties Terminology
C110573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110573>	C107687	Orange County, VA|Orange County|Orange County, Virginia|VA137				Geographic Area	US Counties Terminology
C110574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110574>	C107687	Page County, VA|Page County|Page County, Virginia|VA139				Geographic Area	US Counties Terminology
C110575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110575>	C107687	Patrick County, VA|Patrick County|Patrick County, Virginia|VA141				Geographic Area	US Counties Terminology
C110576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110576>	C107687	Pittsylvania County, VA|Pittsylvania County|Pittsylvania County, Virginia|VA143				Geographic Area	US Counties Terminology
C110577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110577>	C107687	Powhatan County, VA|Powhatan County|Powhatan County, Virginia|VA145				Geographic Area	US Counties Terminology
C110578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110578>	C107687	Prince Edward County, VA|Prince Edward County|Prince Edward County, Virginia|VA147				Geographic Area	US Counties Terminology
C110579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110579>	C107687	Prince George County, VA|Prince George County|Prince George County, Virginia|VA149				Geographic Area	US Counties Terminology
C11057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11057>	C61063	Carmustine/Fluorouracil/Interferon Alfa|BCNU/5-FU/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110580>	C107687	Prince William County, VA|Prince William County|Prince William County, Virginia|VA153				Geographic Area	US Counties Terminology
C110581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110581>	C107687	Pulaski County, VA|Pulaski County|Pulaski County, Virginia|VA155				Geographic Area	US Counties Terminology
C110582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110582>	C107687	Rappahannock County, VA|Rappahannock County|Rappahannock County, Virginia|VA157				Geographic Area	US Counties Terminology
C110583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110583>	C107687	Richmond County, VA|Richmond County|Richmond County, Virginia|VA159				Geographic Area	US Counties Terminology
C110584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110584>	C107687	Roanoke County, VA|Roanoke County|Roanoke County, Virginia|VA161				Geographic Area	US Counties Terminology
C110585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110585>	C107687	Rockbridge County, VA|Rockbridge County|Rockbridge County, Virginia|VA163				Geographic Area	US Counties Terminology
C110586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110586>	C107687	Rockingham County, VA|Rockingham County|Rockingham County, Virginia|VA165				Geographic Area	US Counties Terminology
C110587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110587>	C107687	Russell County, VA|Russell County|Russell County, Virginia|VA167				Geographic Area	US Counties Terminology
C110588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110588>	C107687	Scott County, VA|Scott County|Scott County, Virginia|VA169				Geographic Area	US Counties Terminology
C110589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110589>	C107687	Shenandoah County, VA|Shenandoah County|Shenandoah County, Virginia|VA171				Geographic Area	US Counties Terminology
C11058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11058>	C61063	Carmustine/Doxorubicin/Interferon Alfa/Prednisone/Vincristine|BCNU/DOX/IFN-A/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110590>	C107687	Smyth County, VA|Smyth County|Smyth County, Virginia|VA173				Geographic Area	US Counties Terminology
C110591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110591>	C107687	Southampton County, VA|Southampton County|Southampton County, Virginia|VA175				Geographic Area	US Counties Terminology
C110592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110592>	C107687	Spotsylvania County, VA|Spotsylvania County|Spotsylvania County, Virginia|VA177				Geographic Area	US Counties Terminology
C110593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110593>	C107687	Stafford County, VA|Stafford County|Stafford County, Virginia|VA179				Geographic Area	US Counties Terminology
C110594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110594>	C107687	Surry County, VA|Surry County|Surry County, Virginia|VA181				Geographic Area	US Counties Terminology
C110595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110595>	C107687	Sussex County, VA|Sussex County|Sussex County, Virginia|VA183				Geographic Area	US Counties Terminology
C110596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110596>	C107687	Tazewell County, VA|Tazewell County|Tazewell County, Virginia|VA185				Geographic Area	US Counties Terminology
C110597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110597>	C107687	Warren County, VA|VA187|Warren County|Warren County, Virginia				Geographic Area	US Counties Terminology
C110598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110598>	C107687	Washington County, VA|VA191|Washington County|Washington County, Virginia				Geographic Area	US Counties Terminology
C110599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110599>	C107687	Westmoreland County, VA|VA193|Westmoreland County|Westmoreland County, Virginia				Geographic Area	US Counties Terminology
C11059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11059>	C61063	Busulfan/Cyclophosphamide/Interferon Alfa/Zidovudine|BU/CTX/IFN-A/ZDV			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1105>	C2182	Fosfestrol|(E)-4,4'-(1,2-ethenediyl)-bisphenol bis(dihydrogen phosphate)|Alpha,alpha'-diethyl-4,4'-stilbenediol Diphosphoric Acid Ester|DESP|Diethyldihydroxystilbene Diphosphate|Diethylstilbestrol 4,4'-Diphosphoric Ester|Diethylstilbestrol Diphosphate|Diethylstilbestryl Diphosphate|FOSFESTROL|Fosfestrol Sodium Phosphoestrolum|Honvan|Honvol|ST-52|Stilbestrol Diphosphate|Stilboestrol Diphosphate|Stilphostrol|Stilphostrol	The diphosphate ester of a synthetic, nonsteroidal form of estrogen. A well-known teratogen and carcinogen, diethylstilbestrol inhibits the hypothalamic-pituitary-gonadal axis, thereby blocking the testicular synthesis of testosterone, lowering plasma testosterone, and inducing a chemical castration.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C110600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110600>	C107687	Wise County, VA|VA195|Wise County|Wise County, Virginia				Geographic Area	US Counties Terminology
C110601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110601>	C107687	Wythe County, VA|VA197|Wythe County|Wythe County, Virginia				Geographic Area	US Counties Terminology
C110602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110602>	C107687	York County, VA|VA199|York County|York County, Virginia				Geographic Area	US Counties Terminology
C110603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110603>	C107687	Alexandria City, VA|Alexandria City|Alexandria City, Virginia|VA510				Geographic Area	US Counties Terminology
C110604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110604>	C107687	Bedford City, VA|Bedford City|Bedford City, Virginia|VA515				Geographic Area	US Counties Terminology
C110605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110605>	C107687	Bristol City, VA|Bristol City|Bristol City, Virginia|VA520				Geographic Area	US Counties Terminology
C110606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110606>	C107687	Buena Vista City, VA|Buena Vista City|Buena Vista City, Virginia|VA530				Geographic Area	US Counties Terminology
C110607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110607>	C107687	Charlottesville City, VA|Charlottesville City|Charlottesville City, Virginia|VA540				Geographic Area	US Counties Terminology
C110608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110608>	C107687	Chesapeake City, VA|Chesapeake City|Chesapeake City, Virginia|VA550				Geographic Area	US Counties Terminology
C110609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110609>	C107687	Colonial Heights City, VA|Colonial Heights City|Colonial Heights City, Virginia|VA570				Geographic Area	US Counties Terminology
C11060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11060>	C61063	Fluorouracil/Hydroxyurea/Interferon Alfa|5-FU/HU/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110610>	C107687	Covington City, VA|Covington City|Covington City, Virginia|VA580				Geographic Area	US Counties Terminology
C110611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110611>	C107687	Danville City, VA|Danville City|Danville City, Virginia|VA590				Geographic Area	US Counties Terminology
C110612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110612>	C107687	Emporia City, VA|Emporia City|Emporia City, Virginia|VA595				Geographic Area	US Counties Terminology
C110613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110613>	C107687	Fairfax City, VA|Fairfax City|Fairfax City, Virginia|VA600				Geographic Area	US Counties Terminology
C110614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110614>	C107687	Falls Church City, VA|Falls Church City|Falls Church City, Virginia|VA610				Geographic Area	US Counties Terminology
C110615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110615>	C107687	Franklin City, VA|Franklin City|Franklin City, Virginia|VA620				Geographic Area	US Counties Terminology
C110616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110616>	C107687	Fredericksburg City, VA|Fredericksburg City|Fredericksburg City, Virginia|VA630				Geographic Area	US Counties Terminology
C110617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110617>	C107687	Galax City, VA|Galax City|Galax City, Virginia|VA640				Geographic Area	US Counties Terminology
C110618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110618>	C107687	Hampton City, VA|Hampton City|Hampton City, Virginia|VA650				Geographic Area	US Counties Terminology
C110619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110619>	C107687	Harrisonburg City, VA|Harrisonburg City|Harrisonburg City, Virginia|VA660				Geographic Area	US Counties Terminology
C11061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11061>	C61063	Doxorubicin/Interferon Alfa/Tretinoin|ATRA/DOX/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110620>	C107687	Hopewell City, VA|Hopewell City|Hopewell City, Virginia|VA670				Geographic Area	US Counties Terminology
C110621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110621>	C107687	Lexington City, VA|Lexington City|Lexington City, Virginia|VA678				Geographic Area	US Counties Terminology
C110622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110622>	C107687	Lynchburg City, VA|Lynchburg City|Lynchburg City, Virginia|VA680				Geographic Area	US Counties Terminology
C110623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110623>	C107687	Manassas City, VA|Manassas City|Manassas City, Virginia|VA683				Geographic Area	US Counties Terminology
C110624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110624>	C107687	Manassas Park City, VA|Manassas Park City|Manassas Park City, Virginia|VA685				Geographic Area	US Counties Terminology
C110625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110625>	C107687	Martinsville City, VA|Martinsville City|Martinsville City, Virginia|VA690				Geographic Area	US Counties Terminology
C110626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110626>	C107687	Newport News City, VA|Newport News City|Newport News City, Virginia|VA700				Geographic Area	US Counties Terminology
C110627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110627>	C107687	Norfolk City, VA|Norfolk City|Norfolk City, Virginia|VA710				Geographic Area	US Counties Terminology
C110628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110628>	C107687	Norton City, VA|Norton City|Norton City, Virginia|VA720				Geographic Area	US Counties Terminology
C110629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110629>	C107687	Petersburg City, VA|Petersburg City|Petersburg City, Virginia|VA730				Geographic Area	US Counties Terminology
C11062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11062>	C61063	Cisplatin/Dacarbazine/Interferon Alfa/Tamoxifen|CDDP/DTIC/IFN-A/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110630>	C107687	Poquoson City, VA|Poquoson City|Poquoson City, Virginia|VA735				Geographic Area	US Counties Terminology
C110631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110631>	C107687	Portsmouth City, VA|Portsmouth City|Portsmouth City, Virginia|VA740				Geographic Area	US Counties Terminology
C110632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110632>	C107687	Radford City, VA|Radford City|Radford City, Virginia|VA750				Geographic Area	US Counties Terminology
C110633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110633>	C107687	Richmond City, VA|Richmond City|Richmond City, Virginia|VA760				Geographic Area	US Counties Terminology
C110634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110634>	C107687	Roanoke City, VA|Roanoke City|Roanoke City, Virginia|VA770				Geographic Area	US Counties Terminology
C110635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110635>	C107687	Salem City, VA|Salem City|Salem City, Virginia|VA775				Geographic Area	US Counties Terminology
C110636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110636>	C107687	Staunton City, VA|Staunton City|Staunton City, Virginia|VA790				Geographic Area	US Counties Terminology
C110637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110637>	C107687	Suffolk City, VA|Suffolk City|Suffolk City, Virginia|VA800				Geographic Area	US Counties Terminology
C110638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110638>	C107687	Virginia Beach City, VA|VA810|Virginia Beach City|Virginia Beach City, Virginia				Geographic Area	US Counties Terminology
C110639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110639>	C107687	Waynesboro City, VA|VA820|Waynesboro City|Waynesboro City, Virginia				Geographic Area	US Counties Terminology
C11063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11063>	C61063	Ifosfamide/Interferon Alfa/Pentostatin|DCF/IFF/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110640>	C107687	Williamsburg City, VA|VA830|Williamsburg City|Williamsburg City, Virginia				Geographic Area	US Counties Terminology
C110641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110641>	C107687	Winchester City, VA|VA840|Winchester City|Winchester City, Virginia				Geographic Area	US Counties Terminology
C110642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110642>	C107687	Adams County, WA|Adams County|Adams County, Washington|WA001				Geographic Area	US Counties Terminology
C110643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110643>	C107687	Asotin County, WA|Asotin County|Asotin County, Washington|WA003				Geographic Area	US Counties Terminology
C110644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110644>	C107687	Benton County, WA|Benton County|Benton County, Washington|WA005				Geographic Area	US Counties Terminology
C110645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110645>	C107687	Chelan County, WA|Chelan County|Chelan County, Washington|WA007				Geographic Area	US Counties Terminology
C110646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110646>	C107687	Clallam County, WA|Clallam County|Clallam County, Washington|WA009				Geographic Area	US Counties Terminology
C110647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110647>	C107687	Clark County, WA|Clark County|Clark County, Washington|WA011				Geographic Area	US Counties Terminology
C110648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110648>	C107687	Columbia County, WA|Columbia County|Columbia County, Washington|WA013				Geographic Area	US Counties Terminology
C110649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110649>	C107687	Cowlitz County, WA|Cowlitz County|Cowlitz County, Washington|WA015				Geographic Area	US Counties Terminology
C11064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11064>	C61063	Fluorouracil/Interferon Alfa/Leucovorin Calcium/Sargramostim|CF/5-FU/IFN-A/GM-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110650>	C107687	Douglas County, WA|Douglas County|Douglas County, Washington|WA017				Geographic Area	US Counties Terminology
C110651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110651>	C107687	Ferry County, WA|Ferry County|Ferry County, Washington|WA019				Geographic Area	US Counties Terminology
C110652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110652>	C107687	Franklin County, WA|Franklin County|Franklin County, Washington|WA021				Geographic Area	US Counties Terminology
C110653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110653>	C107687	Garfield County, WA|Garfield County|Garfield County, Washington|WA023				Geographic Area	US Counties Terminology
C110654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110654>	C107687	Grant County, WA|Grant County|Grant County, Washington|WA025				Geographic Area	US Counties Terminology
C110655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110655>	C107687	Grays Harbor County, WA|Grays Harbor County|Grays Harbor County, Washington|WA027				Geographic Area	US Counties Terminology
C110656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110656>	C107687	Island County, WA|Island County|Island County, Washington|WA029				Geographic Area	US Counties Terminology
C110657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110657>	C107687	Jefferson County, WA|Jefferson County|Jefferson County, Washington|WA031				Geographic Area	US Counties Terminology
C110658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110658>	C107687	King County, WA|King County|King County, Washington|WA033				Geographic Area	US Counties Terminology
C110659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110659>	C107687	Kitsap County, WA|Kitsap County|Kitsap County, Washington|WA035				Geographic Area	US Counties Terminology
C11065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11065>	C61063	Carmustine/Cyclophosphamide/Etoposide/Interferon Alfa|BCNU/CTX/IFN-A/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110660>	C107687	Kittitas County, WA|Kittitas County|Kittitas County, Washington|WA037				Geographic Area	US Counties Terminology
C110661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110661>	C107687	Klickitat County, WA|Klickitat County|Klickitat County, Washington|WA039				Geographic Area	US Counties Terminology
C110662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110662>	C107687	Lewis County, WA|Lewis County|Lewis County, Washington|WA041				Geographic Area	US Counties Terminology
C110663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110663>	C107687	Lincoln County, WA|Lincoln County|Lincoln County, Washington|WA043				Geographic Area	US Counties Terminology
C110664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110664>	C107687	Mason County, WA|Mason County|Mason County, Washington|WA045				Geographic Area	US Counties Terminology
C110665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110665>	C107687	Okanogan County, WA|Okanogan County|Okanogan County, Washington|WA047				Geographic Area	US Counties Terminology
C110666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110666>	C107687	Pacific County, WA|Pacific County|Pacific County, Washington|WA049				Geographic Area	US Counties Terminology
C110667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110667>	C107687	Pend Oreille County, WA|Pend Oreille County|Pend Oreille County, Washington|WA051				Geographic Area	US Counties Terminology
C110668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110668>	C107687	Pierce County, WA|Pierce County|Pierce County, Washington|WA053				Geographic Area	US Counties Terminology
C110669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110669>	C107687	San Juan County, WA|San Juan County|San Juan County, Washington|WA055				Geographic Area	US Counties Terminology
C11066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11066>	C61063	Bleomycin/Cyclophosphamide/Cytarabine/Doxorubicin/Etoposide/Filgrastim/Methotrexate/Prednisone/Vincristine|ARA-C/BLEO/CTX/DOX/G-CSF/MTX/PRED/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110670>	C107687	Skagit County, WA|Skagit County|Skagit County, Washington|WA057				Geographic Area	US Counties Terminology
C110671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110671>	C107687	Skamania County, WA|Skamania County|Skamania County, Washington|WA059				Geographic Area	US Counties Terminology
C110672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110672>	C107687	Snohomish County, WA|Snohomish County|Snohomish County, Washington|WA061				Geographic Area	US Counties Terminology
C110673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110673>	C107687	Spokane County, WA|Spokane County|Spokane County, Washington|WA063				Geographic Area	US Counties Terminology
C110674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110674>	C107687	Stevens County, WA|Stevens County|Stevens County, Washington|WA065				Geographic Area	US Counties Terminology
C110675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110675>	C107687	Thurston County, WA|Thurston County|Thurston County, Washington|WA067				Geographic Area	US Counties Terminology
C110676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110676>	C107687	Wahkiakum County, WA|WA069|Wahkiakum County|Wahkiakum County, Washington				Geographic Area	US Counties Terminology
C110677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110677>	C107687	Walla Walla County, WA|WA071|Walla Walla County|Walla Walla County, Washington				Geographic Area	US Counties Terminology
C110678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110678>	C107687	Whatcom County, WA|WA073|Whatcom County|Whatcom County, Washington				Geographic Area	US Counties Terminology
C110679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110679>	C107687	Whitman County, WA|WA075|Whitman County|Whitman County, Washington				Geographic Area	US Counties Terminology
C11067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11067>	C61063	Dexamethasone/Interferon Alfa|DM/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110680>	C107687	Yakima County, WA|WA077|Yakima County|Yakima County, Washington				Geographic Area	US Counties Terminology
C110681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110681>	C107687	Barbour County, WV|Barbour County|Barbour County, West Virginia|WV001				Geographic Area	US Counties Terminology
C110682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110682>	C107687	Berkeley County, WV|Berkeley County|Berkeley County, West Virginia|WV003				Geographic Area	US Counties Terminology
C110683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110683>	C107687	Boone County, WV|Boone County|Boone County, West Virginia|WV005				Geographic Area	US Counties Terminology
C110684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110684>	C107687	Braxton County, WV|Braxton County|Braxton County, West Virginia|WV007				Geographic Area	US Counties Terminology
C110685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110685>	C107687	Brooke County, WV|Brooke County|Brooke County, West Virginia|WV009				Geographic Area	US Counties Terminology
C110686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110686>	C107687	Cabell County, WV|Cabell County|Cabell County, West Virginia|WV011				Geographic Area	US Counties Terminology
C110687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110687>	C107687	Calhoun County, WV|Calhoun County|Calhoun County, West Virginia|WV013				Geographic Area	US Counties Terminology
C110688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110688>	C107687	Clay County, WV|Clay County|Clay County, West Virginia|WV015				Geographic Area	US Counties Terminology
C110689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110689>	C107687	Doddridge County, WV|Doddridge County|Doddridge County, West Virginia|WV017				Geographic Area	US Counties Terminology
C11068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11068>	C61007	Cisplatin/Dacarbazine/Interferon Alfa/interleukin-2/Vinblastine|CDDP/DTIC/IFN-A/IL-2/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110690>	C107687	Fayette County, WV|Fayette County|Fayette County, West Virginia|WV019				Geographic Area	US Counties Terminology
C110691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110691>	C107687	Gilmer County, WV|Gilmer County|Gilmer County, West Virginia|WV021				Geographic Area	US Counties Terminology
C110692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110692>	C107687	Grant County, WV|Grant County|Grant County, West Virginia|WV023				Geographic Area	US Counties Terminology
C110693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110693>	C107687	Greenbrier County, WV|Greenbrier County|Greenbrier County, West Virginia|WV025				Geographic Area	US Counties Terminology
C110694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110694>	C107687	Hampshire County, WV|Hampshire County|Hampshire County, West Virginia|WV027				Geographic Area	US Counties Terminology
C110695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110695>	C107687	Hancock County, WV|Hancock County|Hancock County, West Virginia|WV029				Geographic Area	US Counties Terminology
C110696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110696>	C107687	Hardy County, WV|Hardy County|Hardy County, West Virginia|WV031				Geographic Area	US Counties Terminology
C110697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110697>	C107687	Harrison County, WV|Harrison County|Harrison County, West Virginia|WV033				Geographic Area	US Counties Terminology
C110698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110698>	C107687	Jackson County, WV|Jackson County|Jackson County, West Virginia|WV035				Geographic Area	US Counties Terminology
C110699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110699>	C107687	Jefferson County, WV|Jefferson County|Jefferson County, West Virginia|WV037				Geographic Area	US Counties Terminology
C11069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11069>	C61063	Homoharringtonine/Interferon Alfa|HH/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1106>	C699	Fotemustine|1-[N-(2-chloroethyl)-N-nitrosoureido]ethylphosphonic acid diethyl ester|FOTEMUSTINE|Muphoran|S 10036|[1-[[[(2-chloroethyl)nitrosamino]-carbonyl]amino]ethyl]phosphonic acid diethyl ester|diethyl[1-[3-(2-chloroethyl)-3-nitrosoureido]ethyl]phosphonate|fotemustine	A chloroethylating nitrosourea with antineoplastic activity. Fotemustine alkylates guanine by forming chloroethyl adducts at the 6 position of guanine, resulting in N1-guanine and N3-cytosine cross linkages, inhibition of DNA synthesis, cell cycle arrest, and finally apoptosis. This agent is lipophilic and crosses the blood-brain barrier.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C110700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110700>	C107687	Kanawha County, WV|Kanawha County|Kanawha County, West Virginia|WV039				Geographic Area	US Counties Terminology
C110701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110701>	C107687	Lewis County, WV|Lewis County|Lewis County, West Virginia|WV041				Geographic Area	US Counties Terminology
C110702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110702>	C107687	Lincoln County, WV|Lincoln County|Lincoln County, West Virginia|WV043				Geographic Area	US Counties Terminology
C110703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110703>	C107687	Logan County, WV|Logan County|Logan County, West Virginia|WV045				Geographic Area	US Counties Terminology
C110704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110704>	C107687	McDowell County, WV|McDowell County|McDowell County, West Virginia|WV047				Geographic Area	US Counties Terminology
C110705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110705>	C107687	Marion County, WV|Marion County|Marion County, West Virginia|WV049				Geographic Area	US Counties Terminology
C110706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110706>	C107687	Marshall County, WV|Marshall County|Marshall County, West Virginia|WV051				Geographic Area	US Counties Terminology
C110707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110707>	C107687	Mason County, WV|Mason County|Mason County, West Virginia|WV053				Geographic Area	US Counties Terminology
C110708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110708>	C107687	Mercer County, WV|Mercer County|Mercer County, West Virginia|WV055				Geographic Area	US Counties Terminology
C110709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110709>	C107687	Mineral County, WV|Mineral County|Mineral County, West Virginia|WV057				Geographic Area	US Counties Terminology
C11070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11070>	C61007	Filgrastim/Fluorouracil/Hydroxyurea/Interferon Alfa|5-FU/G-CSF/HU/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110710>	C107687	Mingo County, WV|Mingo County|Mingo County, West Virginia|WV059				Geographic Area	US Counties Terminology
C110711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110711>	C107687	Monongalia County, WV|Monongalia County|Monongalia County, West Virginia|WV061				Geographic Area	US Counties Terminology
C110712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110712>	C107687	Monroe County, WV|Monroe County|Monroe County, West Virginia|WV063				Geographic Area	US Counties Terminology
C110713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110713>	C107687	Morgan County, WV|Morgan County|Morgan County, West Virginia|WV065				Geographic Area	US Counties Terminology
C110714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110714>	C107687	Nicholas County, WV|Nicholas County|Nicholas County, West Virginia|WV067				Geographic Area	US Counties Terminology
C110715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110715>	C107687	Ohio County, WV|Ohio County|Ohio County, West Virginia|WV069				Geographic Area	US Counties Terminology
C110716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110716>	C107687	Pendleton County, WV|Pendleton County|Pendleton County, West Virginia|WV071				Geographic Area	US Counties Terminology
C110717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110717>	C107687	Pleasants County, WV|Pleasants County|Pleasants County, West Virginia|WV073				Geographic Area	US Counties Terminology
C110718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110718>	C107687	Pocahontas County, WV|Pocahontas County|Pocahontas County, West Virginia|WV075				Geographic Area	US Counties Terminology
C110719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110719>	C107687	Preston County, WV|Preston County|Preston County, West Virginia|WV077				Geographic Area	US Counties Terminology
C11071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11071>	C61063	Cisplatin/Dacarbazine/Interferon Alfa/Interleukin-2/Tamoxifen/Tumor Infiltrating Lymphocytes|CDDP/DTIC/IFN-A/IL-2/TIL/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110720>	C107687	Putnam County, WV|Putnam County|Putnam County, West Virginia|WV079				Geographic Area	US Counties Terminology
C110721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110721>	C107687	Raleigh County, WV|Raleigh County|Raleigh County, West Virginia|WV081				Geographic Area	US Counties Terminology
C110722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110722>	C107687	Randolph County, WV|Randolph County|Randolph County, West Virginia|WV083				Geographic Area	US Counties Terminology
C110723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110723>	C107687	Ritchie County, WV|Ritchie County|Ritchie County, West Virginia|WV085				Geographic Area	US Counties Terminology
C110724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110724>	C107687	Roane County, WV|Roane County|Roane County, West Virginia|WV087				Geographic Area	US Counties Terminology
C110725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110725>	C107687	Summers County, WV|Summers County|Summers County, West Virginia|WV089				Geographic Area	US Counties Terminology
C110726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110726>	C107687	Taylor County, WV|Taylor County|Taylor County, West Virginia|WV091				Geographic Area	US Counties Terminology
C110727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110727>	C107687	Tucker County, WV|Tucker County|Tucker County, West Virginia|WV093				Geographic Area	US Counties Terminology
C110728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110728>	C107687	Tyler County, WV|Tyler County|Tyler County, West Virginia|WV095				Geographic Area	US Counties Terminology
C110729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110729>	C107687	Upshur County, WV|Upshur County|Upshur County, West Virginia|WV097				Geographic Area	US Counties Terminology
C11072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11072>	C61063	Epoetin Alfa/Interleukin-6/Sargramostim|EPO/GM-CSF/IL-6			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110730>	C107687	Wayne County, WV|WV099|Wayne County|Wayne County, West Virginia				Geographic Area	US Counties Terminology
C110731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110731>	C107687	Webster County, WV|WV101|Webster County|Webster County, West Virginia				Geographic Area	US Counties Terminology
C110732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110732>	C107687	Wetzel County, WV|WV103|Wetzel County|Wetzel County, West Virginia				Geographic Area	US Counties Terminology
C110733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110733>	C107687	Wirt County, WV|WV105|Wirt County|Wirt County, West Virginia				Geographic Area	US Counties Terminology
C110734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110734>	C107687	Wood County, WV|WV107|Wood County|Wood County, West Virginia				Geographic Area	US Counties Terminology
C110735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110735>	C107687	Wyoming County, WV|WV109|Wyoming County|Wyoming County, West Virginia				Geographic Area	US Counties Terminology
C110736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110736>	C107687	Adams County, WI|Adams County|Adams County, Wisconsin|WI001				Geographic Area	US Counties Terminology
C110737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110737>	C107687	Ashland County, WI|Ashland County|Ashland County, Wisconsin|WI003				Geographic Area	US Counties Terminology
C110738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110738>	C107687	Barron County, WI|Barron County|Barron County, Wisconsin|WI005				Geographic Area	US Counties Terminology
C110739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110739>	C107687	Bayfield County, WI|Bayfield County|Bayfield County, Wisconsin|WI007				Geographic Area	US Counties Terminology
C11073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11073>	C61063	Interferon Alfa/Interleukin-2/Tamoxifen|IFN-A/IL-2/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110740>	C107687	Brown County, WI|Brown County|Brown County, Wisconsin|WI009				Geographic Area	US Counties Terminology
C110741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110741>	C107687	Buffalo County, WI|Buffalo County|Buffalo County, Wisconsin|WI011				Geographic Area	US Counties Terminology
C110742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110742>	C107687	Burnett County, WI|Burnett County|Burnett County, Wisconsin|WI013				Geographic Area	US Counties Terminology
C110743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110743>	C107687	Calumet County, WI|Calumet County|Calumet County, Wisconsin|WI015				Geographic Area	US Counties Terminology
C110744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110744>	C107687	Chippewa County, WI|Chippewa County|Chippewa County, Wisconsin|WI017				Geographic Area	US Counties Terminology
C110745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110745>	C107687	Clark County, WI|Clark County|Clark County, Wisconsin|WI019				Geographic Area	US Counties Terminology
C110746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110746>	C107687	Columbia County, WI|Columbia County|Columbia County, Wisconsin|WI021				Geographic Area	US Counties Terminology
C110747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110747>	C107687	Crawford County, WI|Crawford County|Crawford County, Wisconsin|WI023				Geographic Area	US Counties Terminology
C110748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110748>	C107687	Dane County, WI|Dane County|Dane County, Wisconsin|WI025				Geographic Area	US Counties Terminology
C110749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110749>	C107687	Dodge County, WI|Dodge County|Dodge County, Wisconsin|WI027				Geographic Area	US Counties Terminology
C11074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11074>	C61063	Fluorouracil/Interferon Alfa/Leucovorin Calcium/Raltitrexed|CF/5-FU/ICI D1694/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110750>	C107687	Door County, WI|Door County|Door County, Wisconsin|WI029				Geographic Area	US Counties Terminology
C110751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110751>	C107687	Douglas County, WI|Douglas County|Douglas County, Wisconsin|WI031				Geographic Area	US Counties Terminology
C110752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110752>	C107687	Dunn County, WI|Dunn County|Dunn County, Wisconsin|WI033				Geographic Area	US Counties Terminology
C110753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110753>	C107687	Eau Claire County, WI|Eau Claire County|Eau Claire County, Wisconsin|WI035				Geographic Area	US Counties Terminology
C110754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110754>	C107687	Florence County, WI|Florence County|Florence County, Wisconsin|WI037				Geographic Area	US Counties Terminology
C110755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110755>	C107687	Fond du Lac County, WI|Fond du Lac County|Fond du Lac County, Wisconsin|WI039				Geographic Area	US Counties Terminology
C110756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110756>	C107687	Forest County, WI|Forest County|Forest County, Wisconsin|WI041				Geographic Area	US Counties Terminology
C110757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110757>	C107687	Grant County, WI|Grant County|Grant County, Wisconsin|WI043				Geographic Area	US Counties Terminology
C110758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110758>	C107687	Green County, WI|Green County|Green County, Wisconsin|WI045				Geographic Area	US Counties Terminology
C110759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110759>	C107687	Green Lake County, WI|Green Lake County|Green Lake County, Wisconsin|WI047				Geographic Area	US Counties Terminology
C11075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11075>	C61063	Carmustine/Cisplatin/Dacarbazine/Interferon Alfa/interleukin-2/Tamoxifen|BCNU/CDDP/DTIC/IFN-A/IL-2/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110760>	C107687	Iowa County, WI|Iowa County|Iowa County, Wisconsin|WI049				Geographic Area	US Counties Terminology
C110761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110761>	C107687	Iron County, WI|Iron County|Iron County, Wisconsin|WI051				Geographic Area	US Counties Terminology
C110762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110762>	C107687	Jackson County, WI|Jackson County|Jackson County, Wisconsin|WI053				Geographic Area	US Counties Terminology
C110763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110763>	C107687	Jefferson County, WI|Jefferson County|Jefferson County, Wisconsin|WI055				Geographic Area	US Counties Terminology
C110764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110764>	C107687	Juneau County, WI|Juneau County|Juneau County, Wisconsin|WI057				Geographic Area	US Counties Terminology
C110765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110765>	C107687	Kenosha County, WI|Kenosha County|Kenosha County, Wisconsin|WI059				Geographic Area	US Counties Terminology
C110766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110766>	C107687	Kewaunee County, WI|Kewaunee County|Kewaunee County, Wisconsin|WI061				Geographic Area	US Counties Terminology
C110767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110767>	C107687	La Crosse County, WI|La Crosse County|La Crosse County, Wisconsin|WI063				Geographic Area	US Counties Terminology
C110768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110768>	C107687	Lafayette County, WI|Lafayette County|Lafayette County, Wisconsin|WI065				Geographic Area	US Counties Terminology
C110769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110769>	C107687	Langlade County, WI|Langlade County|Langlade County, Wisconsin|WI067				Geographic Area	US Counties Terminology
C11076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11076>	C61063	Etoposide/Fluorouracil/Interferon Alfa/Leucovorin Calcium|CF/5-FU/IFN-A/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110770>	C107687	Lincoln County, WI|Lincoln County|Lincoln County, Wisconsin|WI069				Geographic Area	US Counties Terminology
C110771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110771>	C107687	Manitowoc County, WI|Manitowoc County|Manitowoc County, Wisconsin|WI071				Geographic Area	US Counties Terminology
C110772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110772>	C107687	Marathon County, WI|Marathon County|Marathon County, Wisconsin|WI073				Geographic Area	US Counties Terminology
C110773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110773>	C107687	Marinette County, WI|Marinette County|Marinette County, Wisconsin|WI075				Geographic Area	US Counties Terminology
C110774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110774>	C107687	Marquette County, WI|Marquette County|Marquette County, Wisconsin|WI077				Geographic Area	US Counties Terminology
C110775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110775>	C107687	Menominee County, WI|Menominee County|Menominee County, Wisconsin|WI078				Geographic Area	US Counties Terminology
C110776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110776>	C107687	Milwaukee County, WI|Milwaukee County|Milwaukee County, Wisconsin|WI079				Geographic Area	US Counties Terminology
C110777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110777>	C107687	Monroe County, WI|Monroe County|Monroe County, Wisconsin|WI081				Geographic Area	US Counties Terminology
C110778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110778>	C107687	Oconto County, WI|Oconto County|Oconto County, Wisconsin|WI083				Geographic Area	US Counties Terminology
C110779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110779>	C107687	Oneida County, WI|Oneida County|Oneida County, Wisconsin|WI085				Geographic Area	US Counties Terminology
C11077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11077>	C61063	Interferon Alfa/Interleukin-2/Isotretinoin|13-CRA/IFN-A/IL-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110780>	C107687	Outagamie County, WI|Outagamie County|Outagamie County, Wisconsin|WI087				Geographic Area	US Counties Terminology
C110781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110781>	C107687	Ozaukee County, WI|Ozaukee County|Ozaukee County, Wisconsin|WI089				Geographic Area	US Counties Terminology
C110782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110782>	C107687	Pepin County, WI|Pepin County|Pepin County, Wisconsin|WI091				Geographic Area	US Counties Terminology
C110783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110783>	C107687	Pierce County, WI|Pierce County|Pierce County, Wisconsin|WI093				Geographic Area	US Counties Terminology
C110784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110784>	C107687	Polk County, WI|Polk County|Polk County, Wisconsin|WI095				Geographic Area	US Counties Terminology
C110785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110785>	C107687	Portage County, WI|Portage County|Portage County, Wisconsin|WI097				Geographic Area	US Counties Terminology
C110786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110786>	C107687	Price County, WI|Price County|Price County, Wisconsin|WI099				Geographic Area	US Counties Terminology
C110787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110787>	C107687	Racine County, WI|Racine County|Racine County, Wisconsin|WI101				Geographic Area	US Counties Terminology
C110788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110788>	C107687	Richland County, WI|Richland County|Richland County, Wisconsin|WI103				Geographic Area	US Counties Terminology
C110789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110789>	C107687	Rock County, WI|Rock County|Rock County, Wisconsin|WI105				Geographic Area	US Counties Terminology
C11078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11078>	C61063	Fluorouracil/Interferon Alfa/Interleukin-2/Isotretinoin|13-CRA/5-FU/IFN-A/IL-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110790>	C107687	Rusk County, WI|Rusk County|Rusk County, Wisconsin|WI107				Geographic Area	US Counties Terminology
C110791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110791>	C107687	St. Croix County, WI|St. Croix County|St. Croix County, Wisconsin|WI109				Geographic Area	US Counties Terminology
C110792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110792>	C107687	Sauk County, WI|Sauk County|Sauk County, Wisconsin|WI111				Geographic Area	US Counties Terminology
C110793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110793>	C107687	Sawyer County, WI|Sawyer County|Sawyer County, Wisconsin|WI113				Geographic Area	US Counties Terminology
C110794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110794>	C107687	Shawano County, WI|Shawano County|Shawano County, Wisconsin|WI115				Geographic Area	US Counties Terminology
C110795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110795>	C107687	Sheboygan County, WI|Sheboygan County|Sheboygan County, Wisconsin|WI117				Geographic Area	US Counties Terminology
C110796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110796>	C107687	Taylor County, WI|Taylor County|Taylor County, Wisconsin|WI119				Geographic Area	US Counties Terminology
C110797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110797>	C107687	Trempealeau County, WI|Trempealeau County|Trempealeau County, Wisconsin|WI121				Geographic Area	US Counties Terminology
C110798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110798>	C107687	Vernon County, WI|Vernon County|Vernon County, Wisconsin|WI123				Geographic Area	US Counties Terminology
C110799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110799>	C107687	Vilas County, WI|Vilas County|Vilas County, Wisconsin|WI125				Geographic Area	US Counties Terminology
C11079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11079>	C61063	Cyclophosphamide/Interleukin-2/Monoclonal Antibody OKT3/Tumor Necrosis Factor|CTX/IL-2/MOAB OKT3/TNF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1107>	C674	Fumonisin B1|FB1|FUMONISIN B1|Fumonisin B(1)|Macrofusine	A mycotoxin produced by Fusarium moniliforme.  It is a contaminant of cereals, especially corn.  It has been epidemiologically linked to high incidence of human esophageal cancer in South Africa and China and to hepatocarcinogenesis in animal models.	Fumonisin B1		Hazardous or Poisonous Substance|Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C110800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110800>	C107687	Walworth County, WI|WI127|Walworth County|Walworth County, Wisconsin				Geographic Area	US Counties Terminology
C110801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110801>	C107687	Washburn County, WI|WI129|Washburn County|Washburn County, Wisconsin				Geographic Area	US Counties Terminology
C110802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110802>	C107687	Washington County, WI|WI131|Washington County|Washington County, Wisconsin				Geographic Area	US Counties Terminology
C110803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110803>	C107687	Waukesha County, WI|WI133|Waukesha County|Waukesha County, Wisconsin				Geographic Area	US Counties Terminology
C110804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110804>	C107687	Waupaca County, WI|WI135|Waupaca County|Waupaca County, Wisconsin				Geographic Area	US Counties Terminology
C110805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110805>	C107687	Waushara County, WI|WI137|Waushara County|Waushara County, Wisconsin				Geographic Area	US Counties Terminology
C110806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110806>	C107687	Winnebago County, WI|WI139|Winnebago County|Winnebago County, Wisconsin				Geographic Area	US Counties Terminology
C110807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110807>	C107687	Wood County, WI|WI141|Wood County|Wood County, Wisconsin				Geographic Area	US Counties Terminology
C110808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110808>	C107687	Albany County, WY|Albany County|Albany County, Wyoming|WY001				Geographic Area	US Counties Terminology
C110809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110809>	C107687	Big Horn County, WY|Big Horn County|Big Horn County, Wyoming|WY003				Geographic Area	US Counties Terminology
C11080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11080>	C61063	Cyclophosphamide/Interleukin-2/Monoclonal Antibody OKT3|CTX/IL-2/MOAB OKT3			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110810>	C107687	Campbell County, WY|Campbell County|Campbell County, Wyoming|WY005				Geographic Area	US Counties Terminology
C110811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110811>	C107687	Carbon County, WY|Carbon County|Carbon County, Wyoming|WY007				Geographic Area	US Counties Terminology
C110812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110812>	C107687	Converse County, WY|Converse County|Converse County, Wyoming|WY009				Geographic Area	US Counties Terminology
C110813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110813>	C107687	Crook County, WY|Crook County|Crook County, Wyoming|WY011				Geographic Area	US Counties Terminology
C110814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110814>	C107687	Fremont County, WY|Fremont County|Fremont County, Wyoming|WY013				Geographic Area	US Counties Terminology
C110815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110815>	C107687	Goshen County, WY|Goshen County|Goshen County, Wyoming|WY015				Geographic Area	US Counties Terminology
C110816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110816>	C107687	Hot Springs County, WY|Hot Springs County|Hot Springs County, Wyoming|WY017				Geographic Area	US Counties Terminology
C110817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110817>	C107687	Johnson County, WY|Johnson County|Johnson County, Wyoming|WY019				Geographic Area	US Counties Terminology
C110818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110818>	C107687	Laramie County, WY|Laramie County|Laramie County, Wyoming|WY021				Geographic Area	US Counties Terminology
C110819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110819>	C107687	Lincoln County, WY|Lincoln County|Lincoln County, Wyoming|WY023				Geographic Area	US Counties Terminology
C11081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11081>	C63524	BOLD Regimen|BLEO/CCNU/DTIC/VCR|BOLD|BOLD|Bleomycin-Vincristine-Lomustine-Dacarbazine|Bleomycin/Dacarbazine/Lomustine/Vincristine|Bleomycin/Oncovin/Lomustine/Dacarbazine|Bleomycin/Vincristine/Lomustine/Dacarbazine|Bleomycin/Vincristine/Lomustine/Dacarbazine Regimen	A regimen consisting of bleomycin, vincristine, lomustine, and dacarbazine for the treatment of melanoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C110820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110820>	C107687	Natrona County, WY|Natrona County|Natrona County, Wyoming|WY025				Geographic Area	US Counties Terminology
C110821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110821>	C107687	Niobrara County, WY|Niobrara County|Niobrara County, Wyoming|WY027				Geographic Area	US Counties Terminology
C110822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110822>	C107687	Park County, WY|Park County|Park County, Wyoming|WY029				Geographic Area	US Counties Terminology
C110823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110823>	C107687	Platte County, WY|Platte County|Platte County, Wyoming|WY031				Geographic Area	US Counties Terminology
C110824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110824>	C107687	Sheridan County, WY|Sheridan County|Sheridan County, Wyoming|WY033				Geographic Area	US Counties Terminology
C110825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110825>	C107687	Sublette County, WY|Sublette County|Sublette County, Wyoming|WY035				Geographic Area	US Counties Terminology
C110826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110826>	C107687	Sweetwater County, WY|Sweetwater County|Sweetwater County, Wyoming|WY037				Geographic Area	US Counties Terminology
C110827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110827>	C107687	Teton County, WY|Teton County|Teton County, Wyoming|WY039				Geographic Area	US Counties Terminology
C110828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110828>	C107687	Uinta County, WY|Uinta County|Uinta County, Wyoming|WY041				Geographic Area	US Counties Terminology
C110829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110829>	C107687	Washakie County, WY|WY043|Washakie County|Washakie County, Wyoming				Geographic Area	US Counties Terminology
C11082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11082>	C61063	Bleomycin/Dacarbazine/Interferon Alfa/Lomustine/Vincristine|BLEO/CCNU/DTIC/IFN-A/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110830>	C107687	Weston County, WY|WY045|Weston County|Weston County, Wyoming				Geographic Area	US Counties Terminology
C110831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110831>	C107687	Eastern District, AS|AS010|Eastern District|Eastern District, American Samoa				Geographic Area	US Counties Terminology
C110832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110832>	C107687	Manu'a District, AS|AS020|Manu'a District|Manu'a District, American Samoa				Geographic Area	US Counties Terminology
C110833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110833>	C107687	Rose Island, AS|AS030|Rose Island|Rose Island, American Samoa				Geographic Area	US Counties Terminology
C110834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110834>	C107687	Swains Island, AS|AS040|Swains Island|Swains Island, American Samoa				Geographic Area	US Counties Terminology
C110835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110835>	C107687	Western District, AS|AS050|Western District|Western District, American Samoa				Geographic Area	US Counties Terminology
C110836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110836>	C107687	Guam, GU|GU010|Guam|Guam, Guam				Geographic Area	US Counties Terminology
C110837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110837>	C107687	Northern Islands Municipality, MP|MP085|Northern Islands Municipality|Northern Islands Municipality, Northern Mariana Islands				Geographic Area	US Counties Terminology
C110838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110838>	C107687	Rota Municipality, MP|MP100|Rota Municipality|Rota Municipality, Northern Mariana Islands				Geographic Area	US Counties Terminology
C110839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110839>	C107687	Saipan Municipality, MP|MP110|Saipan Municipality|Saipan Municipality, Northern Mariana Islands				Geographic Area	US Counties Terminology
C11083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11083>	C61063	Interleukin-2/Zinc Oxide|IL-2/ZnO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110840>	C107687	Tinian Municipality, MP|MP120|Tinian Municipality|Tinian Municipality, Northern Mariana Islands				Geographic Area	US Counties Terminology
C110841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110841>	C107687	Adjuntas Municipio, PR|Adjuntas Municipio|Adjuntas Municipio, Puerto Rico|PR001				Geographic Area	US Counties Terminology
C110842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110842>	C107687	Aguada Municipio, PR|Aguada Municipio|Aguada Municipio, Puerto Rico|PR003				Geographic Area	US Counties Terminology
C110843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110843>	C107687	Aguadilla Municipio, PR|Aguadilla Municipio|Aguadilla Municipio, Puerto Rico|PR005				Geographic Area	US Counties Terminology
C110844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110844>	C107687	Aguas Buenas Municipio, PR|Aguas Buenas Municipio|Aguas Buenas Municipio, Puerto Rico|PR007				Geographic Area	US Counties Terminology
C110845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110845>	C107687	Aibonito Municipio, PR|Aibonito Municipio|Aibonito Municipio, Puerto Rico|PR009				Geographic Area	US Counties Terminology
C110846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110846>	C107687	Anasco Municipio, PR|Anasco Municipio|Anasco Municipio, Puerto Rico|PR011				Geographic Area	US Counties Terminology
C110847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110847>	C107687	Arecibo Municipio, PR|Arecibo Municipio|Arecibo Municipio, Puerto Rico|PR013				Geographic Area	US Counties Terminology
C110848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110848>	C107687	Arroyo Municipio, PR|Arroyo Municipio|Arroyo Municipio, Puerto Rico|PR015				Geographic Area	US Counties Terminology
C110849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110849>	C107687	Barceloneta Municipio, PR|Barceloneta Municipio|Barceloneta Municipio, Puerto Rico|PR017				Geographic Area	US Counties Terminology
C11084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11084>	C61063	Cisplatin/Dacarbazine/Interferon Alfa/interleukin-2|CDDP/DTIC/IFN-A/IL-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110850>	C107687	Barranquitas Municipio, PR|Barranquitas Municipio|Barranquitas Municipio, Puerto Rico|PR019				Geographic Area	US Counties Terminology
C110851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110851>	C107687	Bayamon Municipio, PR|Bayamon Municipio|Bayamon Municipio, Puerto Rico|PR021				Geographic Area	US Counties Terminology
C110852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110852>	C107687	Cabo Rojo Municipio, PR|Cabo Rojo Municipio|Cabo Rojo Municipio, Puerto Rico|PR023				Geographic Area	US Counties Terminology
C110853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110853>	C107687	Caguas Municipio, PR|Caguas Municipio|Caguas Municipio, Puerto Rico|PR025				Geographic Area	US Counties Terminology
C110854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110854>	C107687	Camuy Municipio, PR|Camuy Municipio|Camuy Municipio, Puerto Rico|PR027				Geographic Area	US Counties Terminology
C110855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110855>	C107687	Canovanas Municipio, PR|Canovanas Municipio|Canovanas Municipio, Puerto Rico|PR029				Geographic Area	US Counties Terminology
C110856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110856>	C107687	Carolina Municipio, PR|Carolina Municipio|Carolina Municipio, Puerto Rico|PR031				Geographic Area	US Counties Terminology
C110857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110857>	C107687	Catano Municipio, PR|Catano Municipio|Catano Municipio, Puerto Rico|PR033				Geographic Area	US Counties Terminology
C110858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110858>	C107687	Cayey Municipio, PR|Cayey Municipio|Cayey Municipio, Puerto Rico|PR035				Geographic Area	US Counties Terminology
C110859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110859>	C107687	Ceiba Municipio, PR|Ceiba Municipio|Ceiba Municipio, Puerto Rico|PR037				Geographic Area	US Counties Terminology
C11085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11085>	C61063	Cisplatin/Dacarbazine/Interferon Alfa|CDDP/DTIC/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110860>	C107687	Ciales Municipio, PR|Ciales Municipio|Ciales Municipio, Puerto Rico|PR039				Geographic Area	US Counties Terminology
C110861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110861>	C107687	Cidra Municipio, PR|Cidra Municipio|Cidra Municipio, Puerto Rico|PR041				Geographic Area	US Counties Terminology
C110862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110862>	C107687	Coamo Municipio, PR|Coamo Municipio|Coamo Municipio, Puerto Rico|PR043				Geographic Area	US Counties Terminology
C110863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110863>	C107687	Comerio Municipio, PR|Comerio Municipio|Comerio Municipio, Puerto Rico|PR045				Geographic Area	US Counties Terminology
C110864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110864>	C107687	Corozal Municipio, PR|Corozal Municipio|Corozal Municipio, Puerto Rico|PR047				Geographic Area	US Counties Terminology
C110865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110865>	C107687	Culebra Municipio, PR|Culebra Municipio|Culebra Municipio, Puerto Rico|PR049				Geographic Area	US Counties Terminology
C110866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110866>	C107687	Dorado Municipio, PR|Dorado Municipio|Dorado Municipio, Puerto Rico|PR051				Geographic Area	US Counties Terminology
C110867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110867>	C107687	Fajardo Municipio, PR|Fajardo Municipio|Fajardo Municipio, Puerto Rico|PR053				Geographic Area	US Counties Terminology
C110868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110868>	C107687	Florida Municipio, PR|Florida Municipio|Florida Municipio, Puerto Rico|PR054				Geographic Area	US Counties Terminology
C110869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110869>	C107687	Guanica Municipio, PR|Guanica Municipio|Guanica Municipio, Puerto Rico|PR055				Geographic Area	US Counties Terminology
C11086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11086>	C61063	Cyclophosphamide/Cytarabine/Thioguanine/Vincristine|ARA-C/CTX/TG/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110870>	C107687	Guayama Municipio, PR|Guayama Municipio|Guayama Municipio, Puerto Rico|PR057				Geographic Area	US Counties Terminology
C110871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110871>	C107687	Guayanilla Municipio, PR|Guayanilla Municipio|Guayanilla Municipio, Puerto Rico|PR059				Geographic Area	US Counties Terminology
C110872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110872>	C107687	Guaynabo Municipio, PR|Guaynabo Municipio|Guaynabo Municipio, Puerto Rico|PR061				Geographic Area	US Counties Terminology
C110873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110873>	C107687	Gurabo Municipio, PR|Gurabo Municipio|Gurabo Municipio, Puerto Rico|PR063				Geographic Area	US Counties Terminology
C110874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110874>	C107687	Hatillo Municipio, PR|Hatillo Municipio|Hatillo Municipio, Puerto Rico|PR065				Geographic Area	US Counties Terminology
C110875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110875>	C107687	Hormigueros Municipio, PR|Hormigueros Municipio|Hormigueros Municipio, Puerto Rico|PR067				Geographic Area	US Counties Terminology
C110876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110876>	C107687	Humacao Municipio, PR|Humacao Municipio|Humacao Municipio, Puerto Rico|PR069				Geographic Area	US Counties Terminology
C110877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110877>	C107687	Isabela Municipio, PR|Isabela Municipio|Isabela Municipio, Puerto Rico|PR071				Geographic Area	US Counties Terminology
C110878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110878>	C107687	Jayuya Municipio, PR|Jayuya Municipio|Jayuya Municipio, Puerto Rico|PR073				Geographic Area	US Counties Terminology
C110879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110879>	C107687	Juana Diaz Municipio, PR|Juana Diaz Municipio|Juana Diaz Municipio, Puerto Rico|PR075				Geographic Area	US Counties Terminology
C11087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11087>	C61063	Cyclophosphamide/Daunorubicin/Pegaspargase/Prednisone/Vincristine|CTX/DNR/PEG-ASP/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110880>	C107687	Juncos Municipio, PR|Juncos Municipio|Juncos Municipio, Puerto Rico|PR077				Geographic Area	US Counties Terminology
C110881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110881>	C107687	Lajas Municipio, PR|Lajas Municipio|Lajas Municipio, Puerto Rico|PR079				Geographic Area	US Counties Terminology
C110882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110882>	C107687	Lares Municipio, PR|Lares Municipio|Lares Municipio, Puerto Rico|PR081				Geographic Area	US Counties Terminology
C110883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110883>	C107687	Las Marias Municipio, PR|Las Marias Municipio|Las Marias Municipio, Puerto Rico|PR083				Geographic Area	US Counties Terminology
C110884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110884>	C107687	Las Piedras Municipio, PR|Las Piedras Municipio|Las Piedras Municipio, Puerto Rico|PR085				Geographic Area	US Counties Terminology
C110885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110885>	C107687	Loiza Municipio, PR|Loiza Municipio|Loiza Municipio, Puerto Rico|PR087				Geographic Area	US Counties Terminology
C110886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110886>	C107687	Luquillo Municipio, PR|Luquillo Municipio|Luquillo Municipio, Puerto Rico|PR089				Geographic Area	US Counties Terminology
C110887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110887>	C107687	Manati Municipio, PR|Manati Municipio|Manati Municipio, Puerto Rico|PR091				Geographic Area	US Counties Terminology
C110888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110888>	C107687	Maricao Municipio, PR|Maricao Municipio|Maricao Municipio, Puerto Rico|PR093				Geographic Area	US Counties Terminology
C110889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110889>	C107687	Maunabo Municipio, PR|Maunabo Municipio|Maunabo Municipio, Puerto Rico|PR095				Geographic Area	US Counties Terminology
C11088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11088>	C61063	Cyclophosphamide/Cytarabine/Mercaptopurine/Pegaspargase/Vincristine|ARA-C/CTX/MP/PEG-ASP/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110890>	C107687	Mayaguez Municipio, PR|Mayaguez Municipio|Mayaguez Municipio, Puerto Rico|PR097				Geographic Area	US Counties Terminology
C110891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110891>	C107687	Moca Municipio, PR|Moca Municipio|Moca Municipio, Puerto Rico|PR099				Geographic Area	US Counties Terminology
C110892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110892>	C107687	Morovis Municipio, PR|Morovis Municipio|Morovis Municipio, Puerto Rico|PR101				Geographic Area	US Counties Terminology
C110893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110893>	C107687	Naguabo Municipio, PR|Naguabo Municipio|Naguabo Municipio, Puerto Rico|PR103				Geographic Area	US Counties Terminology
C110894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110894>	C107687	Naranjito Municipio, PR|Naranjito Municipio|Naranjito Municipio, Puerto Rico|PR105				Geographic Area	US Counties Terminology
C110895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110895>	C107687	Orocovis Municipio, PR|Orocovis Municipio|Orocovis Municipio, Puerto Rico|PR107				Geographic Area	US Counties Terminology
C110896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110896>	C107687	Patillas Municipio, PR|PR109|Patillas Municipio|Patillas Municipio, Puerto Rico				Geographic Area	US Counties Terminology
C110897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110897>	C107687	Penuelas Municipio, PR|PR111|Penuelas Municipio|Penuelas Municipio, Puerto Rico				Geographic Area	US Counties Terminology
C110898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110898>	C107687	Ponce Municipio, PR|PR113|Ponce Municipio|Ponce Municipio, Puerto Rico				Geographic Area	US Counties Terminology
C110899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110899>	C107687	Quebradillas Municipio, PR|PR115|Quebradillas Municipio|Quebradillas Municipio, Puerto Rico				Geographic Area	US Counties Terminology
C11089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11089>	C61063	Etoposide/Mitoxantrone/Tretinoin Liposome|DHAD/L-ATRA/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1108>	C29756	Gabapentin|1-(aminomethyl)cyclohexaneacetic Acid|GABAPENTIN|Gralise|Neurontin|gabapentin	A synthetic analogue of the neurotransmitter gamma-aminobutyric acid with anticonvulsant activity. Although its exact mechanism of action is unknown, gabapentin appears to inhibit excitatory neuron activity. This agent also exhibits analgesic properties. (NCI04)	Gabapentin		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HL Authorized Value Terminology|HL Concomitant Medication Table|NCI Drug Dictionary Terminology
C110900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110900>	C107687	Rincon Municipio, PR|PR117|Rincon Municipio|Rincon Municipio, Puerto Rico				Geographic Area	US Counties Terminology
C110901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110901>	C107687	Rio Grande Municipio, PR|PR119|Rio Grande Municipio|Rio Grande Municipio, Puerto Rico				Geographic Area	US Counties Terminology
C110902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110902>	C107687	Sabana Grande Municipio, PR|PR121|Sabana Grande Municipio|Sabana Grande Municipio, Puerto Rico				Geographic Area	US Counties Terminology
C110903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110903>	C107687	Salinas Municipio, PR|PR123|Salinas Municipio|Salinas Municipio, Puerto Rico				Geographic Area	US Counties Terminology
C110904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110904>	C107687	San German Municipio, PR|PR125|San German Municipio|San German Municipio, Puerto Rico				Geographic Area	US Counties Terminology
C110905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110905>	C107687	San Juan Municipio, PR|PR127|San Juan Municipio|San Juan Municipio, Puerto Rico				Geographic Area	US Counties Terminology
C110906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110906>	C107687	San Lorenzo Municipio, PR|PR129|San Lorenzo Municipio|San Lorenzo Municipio, Puerto Rico				Geographic Area	US Counties Terminology
C110907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110907>	C107687	San Sebastian Municipio, PR|PR131|San Sebastian Municipio|San Sebastian Municipio, Puerto Rico				Geographic Area	US Counties Terminology
C110908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110908>	C107687	Santa Isabel Municipio, PR|PR133|Santa Isabel Municipio|Santa Isabel Municipio, Puerto Rico				Geographic Area	US Counties Terminology
C110909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110909>	C107687	Toa Alta Municipio, PR|PR135|Toa Alta Municipio|Toa Alta Municipio, Puerto Rico				Geographic Area	US Counties Terminology
C11090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11090>	C61063	Cytarabine/Tretinoin Liposome|ARA-C/L-ATRA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110910>	C107687	Toa Baja Municipio, PR|PR137|Toa Baja Municipio|Toa Baja Municipio, Puerto Rico				Geographic Area	US Counties Terminology
C110911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110911>	C107687	Trujillo Alto Municipio, PR|PR139|Trujillo Alto Municipio|Trujillo Alto Municipio, Puerto Rico				Geographic Area	US Counties Terminology
C110912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110912>	C107687	Utuado Municipio, PR|PR141|Utuado Municipio|Utuado Municipio, Puerto Rico				Geographic Area	US Counties Terminology
C110913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110913>	C107687	Vega Alta Municipio, PR|PR143|Vega Alta Municipio|Vega Alta Municipio, Puerto Rico				Geographic Area	US Counties Terminology
C110914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110914>	C107687	Vega Baja Municipio, PR|PR145|Vega Baja Municipio|Vega Baja Municipio, Puerto Rico				Geographic Area	US Counties Terminology
C110915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110915>	C107687	Vieques Municipio, PR|PR147|Vieques Municipio|Vieques Municipio, Puerto Rico				Geographic Area	US Counties Terminology
C110916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110916>	C107687	Villalba Municipio, PR|PR149|Villalba Municipio|Villalba Municipio, Puerto Rico				Geographic Area	US Counties Terminology
C110917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110917>	C107687	Yabucoa Municipio, PR|PR151|Yabucoa Municipio|Yabucoa Municipio, Puerto Rico				Geographic Area	US Counties Terminology
C110918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110918>	C107687	Yauco Municipio, PR|PR153|Yauco Municipio|Yauco Municipio, Puerto Rico				Geographic Area	US Counties Terminology
C110919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110919>	C107687	Midway Islands, UM|925|925|MIDWAY ISLANDS|Midway Islands|Midway Islands, U.S. Minor Outlying Islands|QM|QM|UM300|XMW|XMW	An atoll in the North Pacific Ocean near the end of the Hawaiian Archipelago.			Geographic Area	Geopolitical Entities, Names, and Codes Terminology|US Counties Terminology
C11091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11091>	C61063	Ketoconazole/Tretinoin|ATRA/KCZ			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110920>	C107687	St. Croix Island, VI|St. Croix Island|St. Croix Island, Virgin Islands|VI010				Geographic Area	US Counties Terminology
C110921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110921>	C107687	St. John Island, VI|St. John Island|St. John Island, Virgin Islands|VI020				Geographic Area	US Counties Terminology
C110922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110922>	C107687	St. Thomas Island, VI|St. Thomas Island|St. Thomas Island, Virgin Islands|VI030				Geographic Area	US Counties Terminology
C110923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110923>	C26909	Chorioretinitis	Inflammation of the distal posterior uveal tract (choroid) and its structural and vascular attachments to the retina. It is usually caused by infection and though rare, it is clinically significant due to its most serious sequela: loss of vision.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Infectious Disease Terminology
C110924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110924>	C50316	Single Chamber Power Injector|Single Chamber Contrast Agent Power Injector	A pump system with one enclosed reservoir, designed to deliver intravenous contrast agent.			Manufactured Object	
C110927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110927>	C99235	Physiologic Hyperbilirubinemia|Physiological Hyperbilirubinemia	Elevated bilirubin levels in the blood of a newborn infant. It is a normal response due to the limited ability to excrete bilirubin until the maturation of the neonatal liver is complete.			Laboratory or Test Result	Neonatal Research Network Terminology|NICHD Terminology|Perinatal Terminology
C110928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110928>	C222259	6-Item Orientation-Memory-Concentration Test|OMC|Orientation-Memory-Concentration Test	A screening test for cognitive impairment that is administered by a non-physician. This test is designed to discriminate between mild, moderate, and severe cognitive deficits.			Intellectual Product	
C110929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110929>	C91103	What Year is It Question|What Year is It|What year is it now	A question asking an individual to state the current year.			Intellectual Product	6-Item Orientation-Memory-Concentration Test
C11092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11092>	C61063	Disulfiram/Tretinoin|ATRA/DS			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110930>	C91103	What Month is it Question|What Month is it|What month is it now	A question asking an individual to state the current month.			Intellectual Product	6-Item Orientation-Memory-Concentration Test
C110931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110931>	C91103	About What Time is it Question|About What Time is it|About what time is it, within 1 hour	A question asking an individual to state the current time, to within 1 hour.			Intellectual Product	6-Item Orientation-Memory-Concentration Test
C110932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110932>	C91103	Count Backwards from 20 to 1 Question|Count backwards 20 to 1	A question that requesta that an individual count backwards from 20 to 1.			Intellectual Product	6-Item Orientation-Memory-Concentration Test
C110933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110933>	C91103	Say the Months in Reverse Order Question|Say the Months in Reverse Order|Say the months in reverse order	A question that requests that an individual say the months of the year in reverse order.			Intellectual Product	6-Item Orientation-Memory-Concentration Test
C110934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110934>	C91103	Repeat the Memory Phrase Question|Repeat the Memory Phrase|Repeat the Memory Phrase	A question that requests that an individual repeat a memory phrase.			Intellectual Product	6-Item Orientation-Memory-Concentration Test
C110935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110935>	C90505	Estimated Glomerular Filtration Rate|GFRE|Glomerular Filtration Rate, Estimated|Glomerular Filtration Rate, Estimated|eGFR|eGFR	A laboratory test that estimates kidney function. It is calculated using an individual's serum creatinine measurement, age, sex, and race. Actual results are reported when the estimated glomerular filtration rate is less than 60 ml/min.	Estimated Glomerular Filtration Rate		Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C110936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110936>	C98805	Toxic Methemoglobinemia with Cyanosis	Blue skin coloration due to elevated blood levels of methemoglobin. The degree of cyanosis is directly correlated to the concentration of methemoglobin in the blood. As methemoglobin is not suitable for carrying oxygen, hypoxemia becomes a serious sequela.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C110937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110937>	C36288	Musculoskeletal Finding|Musculoskeletal|Unspecified Musculoskeletal problem	Symptoms, physical examination results, and/or laboratory rest results related to the muscles and bones.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|Neonatal Research Network Terminology|NICHD Terminology
C110938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110938>	C2881	Tachyarrhythmia	A disorder characterized by an arrhythmia with an above normal rate.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C110939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110939>	C81181	Plantar Grasp Reflex|PLTGRRFX|Plantar Grasp Reflex Finding	A newborn reflex that is characterized by flexion of the toes when the sole of the foot is stroked.			Finding	CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|Neonatal Research Network Terminology|NICHD Terminology
C11093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11093>	C61063	Carmustine/Cytarabine/Methotrexate/Vincristine|ARA-C/BCNU/MTX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110940>	C62591	Panhypopituitarism|Complete Hypopituitarism|Complete Hypopituitarism	Insufficient production of all the anterior pituitary hormones.			Disease or Syndrome	Cellosaurus Disease Terminology|Neonatal Research Network Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C110941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110941>	C2978	Allantoic Cyst	An umbilical cyst that arises from allantoic tissue that did not regress during gestational development. Most cases involve a patent urachus that allows for communication to the urinary bladder.			Finding	Neonatal Research Network Terminology|NICHD Terminology
C110942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110942>	C99137	Congenital Anomaly of Pulmonary Veins	Aberrant drainage of one or more of the pulmonary veins which causes the return of oxygen-rich blood to the right atrium.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C110943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110943>	C98904	Musculoskeletal Injury|Muscle/Tendon Damage	Damage to the muscles, bones and their supportive structural attachments.			Finding	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology
C110944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110944>	C50316	Dual Chamber Power Injector|Dual Chamber Contrast Agent Power Injector	A pump system with two enclosed reservoirs, designed to deliver various concentrations of intravenous contrast media.			Manufactured Object	
C110945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110945>	C49236	Saline Flush	A saline solution used to force an agent from tubing and peripheral veins into the central blood volume.			Health Care Activity	
C110946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110946>	C91105	Older Americans Resource Scale Multidimensional Functional Assessment Questionnaire|OARS Multidimensional Functional Assessment Questionnaire|OMFAQ|Older Americans Resource Scale (OARS) Multidimensional Functional Assessment Questionnaire (OMFAQ)	A questionnaire that seeks information both on a person's level of functioning and on their need and utilization of services.			Intellectual Product	
C110947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110947>	C91105	Activities of Daily Living Dimension of Functioning Questionnaire|Activities of Daily Living Dimension of Functioning|Activities of Daily Living Questionnaire	A section of the Older Americans Resource Scale Multidimensional Functional Assessment Questionnaire (OMFAQ) that seeks information on a person's level of functioning on daily activities of living.			Intellectual Product	Older Americans Resource Scale Multidimensional Functional Assessment Questionnaire
C110948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110948>	C173458	Use the Telephone Ability Question|Ability to Use Telephone|Ability to Use the Telephone|Can you use the telephone|Use the Telephone|Use the Telephone Ability	A question about whether an individual is able to use a telephone.			Intellectual Product	Lawton-Brody Instrumental Activities of Daily Living Scale|Older Americans Resource Scale Multidimensional Functional Assessment Questionnaire
C110949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110949>	C91103	Can Get to Places Out of Walking Distance Question|Can Get to Places Out of Walking Distance|Can you get to places out of walking distance|Get to Places Out of Walking Distance	A question about whether an individual is able to get to places beyond walking distance.			Intellectual Product	Older Americans Resource Scale Multidimensional Functional Assessment Questionnaire
C11094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11094>	C61063	Human Chorionic Gonadotropin/Staphage Lysate|HCG/SPL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110950>	C121254	Go Shopping for Groceries or Clothes Question|Can you go shopping for groceries or clothes|Go Shopping for Groceries or Clothes	A question about whether an individual is able to go shopping for groceries or clothes.			Intellectual Product	Older Americans Resource Scale Multidimensional Functional Assessment Questionnaire
C110951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110951>	C91103	Prepare Your Meals Question|Ability to Prepare Food|Can you prepare your own meals|Food Preparation|Prepare Your Meals	A question about whether an individual is able to prepare meals for themselves.			Intellectual Product	Lawton-Brody Instrumental Activities of Daily Living Scale|Older Americans Resource Scale Multidimensional Functional Assessment Questionnaire
C110952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110952>	C173458	Do Housework Question|Ability to Do Housekeeping|Can you do your housework|Do Housework|Housekeeping	A question about whether an individual is able to do housework.			Intellectual Product	Lawton-Brody Instrumental Activities of Daily Living Scale|Older Americans Resource Scale Multidimensional Functional Assessment Questionnaire
C110953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110953>	C91103	Take Your Medicines Question|Can you take your own medicines|Take Your Medicines	A question about whether an individual is able to take their medicine.			Intellectual Product	Older Americans Resource Scale Multidimensional Functional Assessment Questionnaire
C110954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110954>	C91103	Handle Your Money Question|Can you handle your own money|Handle Your Money	A question about whether an individual is able to handle their money.			Intellectual Product	Older Americans Resource Scale Multidimensional Functional Assessment Questionnaire
C110955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110955>	C173509	Have Current Illness Question|Currently Have Illness|Do you have any of the following illnesses at the present time|Have Current Illness|Have Current Illness or Condition	A question about whether an individual currently has a disease.			Intellectual Product	Healthy Volunteer Medical History Questionnaire|Older Americans Resource Scale Multidimensional Functional Assessment Questionnaire
C110956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110956>	C226656|C178389	Without Help|without help	A response indicating that an individual is able to do something without assistance.			Intellectual Product	Older Americans Resource Scale Multidimensional Functional Assessment Questionnaire|Rotterdam Symptom Checklist
C110957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110957>	C226656|C178389	With Some Help|with some help	A response indicating that an individual is able to do something only with assistance.			Intellectual Product	Older Americans Resource Scale Multidimensional Functional Assessment Questionnaire
C110958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110958>	C121744	Completely Unable|Unable to Do|completely unable	A response indicating that an individual is completely unable to do something.			Intellectual Product	Older Americans Resource Scale Multidimensional Functional Assessment Questionnaire
C110959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110959>	C48655	Not Answered|Not answered	Indicates that no answer was given.			Qualitative Concept	Older Americans Resource Scale Multidimensional Functional Assessment Questionnaire
C11095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11095>	C61063	Cisplatin/Fluorouracil/L-Leucovorin|CDDP/5-FU/L-CF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110960>	C80693	Bone Marrow Aplasia	Depletion of stem cells in the bone marrow that results in the lack of production of hematopoietic cells.			Disease or Syndrome	
C110961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110961>	C3824	Index Lesion	The most clinically significant tumor lesion targeted by therapy. The lesion is typically the largest or highest graded of the tumor foci detected.			Finding	
C110962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110962>	C3824	Non-Index Lesion	Any tumor lesion other than the largest tumor lesion targeted by therapy.			Finding	
C110963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110963>	C190004	BCR-ABL TKI-Resistant Mutation|BCR-ABL Tyrosine Kinase Inhibitor-Resistant Mutation|BCR-ABL1 TKI-Resistant Mutation|BCR-ABL1 Tyrosine Kinase Inhibitor-Resistant Mutation|BCR/ABL TKI-Resistant Mutation|BCR/ABL1 TKI-Resistant Mutation|BCR/ABL1 Tyrosine Kinase Inhibitor-Resistant Mutation|BCR::ABL TKI-Resistant Mutation	A molecular genetic abnormality in the kinase domain of the BCR-ABL fusion gene that results in resistance to tyrosine kinase inhibitors.	BCR-ABL TKI-Resistant Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C110964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110964>	C20189	Not Meeting Criteria	Indicates that an individual fails to meet the criteria for a particular study.			Conceptual Entity	
C110965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110965>	C222045	Medical Outcomes Study Physical Functioning Scale|MOS	A survey of multiple dimensions of support, representing the physical functioning scale.			Intellectual Product	
C110966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110966>	C91105	Instrumental Activities of Daily Living|IADL	A section of the Older Americans Resource Scale Multidimensional Functional Assessment Questionnaire (OMFAQ) that seeks information about a person's functional ability to conduct the complex activities of daily living that allow for independent living within a community.			Intellectual Product	Older Americans Resource Scale Multidimensional Functional Assessment Questionnaire
C110967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110967>	C217121	Older Americans Resources and Services Comorbidity Scale|OARS Comorbidity Scale|Older Americans Resources and Services (OARS) Comorbidity Scale	A section of the Older Americans Resources and Services (OARS) physical health questionnaire that rates the type of comorbidity and the impact of that comorbidity on an individual's daily function.			Intellectual Product	Older Americans Resource Scale Multidimensional Functional Assessment Questionnaire
C110968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110968>	C222045	Medical Outcomes Study Social Activities|Medical Outcomes Study Social Activities Survey	A survey of multiple dimensions of quality of life, representing the social activities scale.			Intellectual Product	
C110969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110969>	C222045	Medical Outcomes Study Social Support Survey	A survey of multiple dimensions of social support.			Intellectual Product	
C11096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11096>	C61063	Dexamethasone/Melphalan|DM/L-PAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110970>	C199143	Organ Procurement and Transplantation Network|OPTN	The transplant network established by the U.S. Congress under the National Organ Transplant Act of 1984. It is a public-private partnership, linking all professionals involved in the national donation and transplantation system.			Professional or Occupational Group	
C110971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110971>	C53452	Limited by Health|Health Limitation	An indication that a person's activities are limited by their health condition.			Natural Phenomenon or Process	Medical Outcomes Study Physical Functioning Scale
C110972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110972>	C199143	United Network for Organ Sharing|UNOS	The organization that administers the Organ Procurement and Transplantation Network under contract with the Health Resources and Services Administration of the U.S. Department of Health and Human Services.			Professional or Occupational Group	
C110973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110973>	C173458	Vigorous Activities Such As Running, Lifting Heavy Objects, or Participating In Strenuous Sports Question|Vigorous Activities Such As Running, Lifting Heavy Objects, or Participating In Strenuous Sports|Vigorous activities such as: running, lifting heavy objects, participating in strenuous sports	A question about vigorous activities such as running, lifting heavy objects, or participating in strenuous sports.			Intellectual Product	Medical Outcomes Study Physical Functioning Scale
C110974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110974>	C173458	Moderate Activities Such As Moving a Table, Pushing a Vacuum Cleaner, Bowling, or Playing Golf Question|Moderate Activities Such As Moving a Table, Pushing a Vacuum Cleaner, Bowling, or Playing Golf|Moderate activities such as: moving a table, pushing a vacuum cleaner, bowling, or playing golf	A question about moderate activities such as moving a table, pushing a vacuum cleaner, bowling, or playing golf.			Intellectual Product	Medical Outcomes Study Physical Functioning Scale
C110975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110975>	C173458	Lifting or Carrying Groceries Question|Lifting or Carrying Groceries|Lifting or carrying groceries	A question about lifting or carrying groceries.			Intellectual Product	Medical Outcomes Study Physical Functioning Scale
C110976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110976>	C173082	Climbing Several Flights of Stairs Question|Climbing Several Flights of Stairs|Climbing several flights of stairs	A question about climbing several flights of stairs.			Intellectual Product	Medical Outcomes Study Physical Functioning Scale
C110977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110977>	C173082	Climbing One Flight of Stairs Question|Climbing One Flight of Stairs|Climbing one flight of stairs	A question about climbing one flight of stairs.			Intellectual Product	Medical Outcomes Study Physical Functioning Scale
C110978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110978>	C91103	Bending, Kneeling, or Stooping Question|Bending, Kneeling, or Stooping|Bending, kneeling, or stooping	A question about bending, kneeling, or stooping.			Intellectual Product	Medical Outcomes Study Physical Functioning Scale
C110979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110979>	C173135	Walking More Than a Mile Question|Walking More Than a Mile|Walking more than a mile	A question about walking more than a mile.			Intellectual Product	Medical Outcomes Study Physical Functioning Scale
C11097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11097>	C61007	Cyclophosphamide/Filgrastim/Paclitaxel|CTX/G-CSF/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110980>	C173135	Walking Several Blocks Question|Walking Several Blocks|Walking several blocks	A question about walking several blocks.			Intellectual Product	Medical Outcomes Study Physical Functioning Scale
C110981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110981>	C173135	Walking One Block Question|Walking One Block|Walking one block	A question about walking one block.			Intellectual Product	Medical Outcomes Study Physical Functioning Scale
C110982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110982>	C131925|C131923	Bathing or Dressing Yourself Question|Bathing or Dressing Yourself|Bathing or dressing yourself	A question about bathing or dressing yourself.			Intellectual Product	Medical Outcomes Study Physical Functioning Scale
C110983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110983>	C177163	Limited a Lot|Very Limited|Yes, Limited A Lot	A response indicating that an individual feels limited a lot.			Intellectual Product	Medical Outcomes Study Physical Functioning Scale|QuickDASH Outcome Measure
C110984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110984>	C177163	Limited a Little|Hardly Limited|Hardly limited at all|Slightly Limited|Yes, Limited A Little	A response indicating that an individual feels limited a little.			Intellectual Product	Food Allergy Quality of Life - Parental Burden|Medical Outcomes Study Physical Functioning Scale|QuickDASH Outcome Measure
C110985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110985>	C177163	Not Limited at All|No, Not Limited At All|Not limited	A response indicating that an individual does not feel limited at all.			Intellectual Product	Food Allergy Quality of Life - Parental Burden|Medical Outcomes Study Physical Functioning Scale
C110986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110986>	C25616	Past 4 Weeks|Last 4 Weeks	A period of time consisting of the 28 days before the present.			Temporal Concept	Medical Outcomes Study Social Activities
C110987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110987>	C25616	Past 6 Months|Last 6 Months	A period of time consisting of the 6 months before the present.			Temporal Concept	Medical Outcomes Study Social Activities
C110988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110988>	C25178	Physical Health or Emotional Problems|Physical Health or Emotional Well-Being|Physical health or emotional problems	The state of a person's physical and emotional well-being.			Idea or Concept	Medical Outcomes Study Social Activities
C110989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110989>	C72886	Interference with Social Activities|Interference with social activities	The act of impeding a person from their normal social activities.			Activity	Medical Outcomes Study Social Activities
C11098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11098>	C61007	Cyclophosphamide/Paclitaxel/Sargramostim|CTX/GM-CSF/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C110990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110990>	C175311	All of the Time|All of the time|All of time|Always	A response indicating that something happens or happened all of the time.			Intellectual Product	Bowel Function Diary for Assessing Opioid-Induced Constipation|Medical Outcomes Study Social Activities|Medical Outcomes Study Social Support Survey
C110991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110991>	C175311	Most of the Time|More than Half the Time|Most Times|Most Times (Much More Than Half the Time)|Most of the time|Most of the time|Most of time|Most times (more than half the time)|Much More Than Half the Time	A response indicating that something happens or happened most of the time.			Intellectual Product	Bowel Function Diary for Assessing Opioid-Induced Constipation|Female Sexual Function Index|Hospital Anxiety and Depression Scale Questionnaire|Medical Outcomes Study Social Activities|Medical Outcomes Study Social Support Survey|Ped-PRO-CTCAE Attribute Value Terminology|Ped-PRO-CTCAE Version 1.0 Questionnaire Terminology|Sexual Health Inventory for Men
C110992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110992>	C175311	Some of the Time|Some of the time|Some of time|Sometimes	A response indicating that something happens or happened some of the time.			Intellectual Product	Bowel Function Diary for Assessing Opioid-Induced Constipation|Medical Outcomes Study Social Activities|Medical Outcomes Study Social Support Survey
C110993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110993>	C175311	A Little of the Time|A Little Bit|A Little Bit of the Time|A little of the time	A response indicating that something happens or happened a little of the time.			Intellectual Product	Medical Outcomes Study Social Activities|Medical Outcomes Study Social Support Survey
C110994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110994>	C175311	None of the Time|Never|None of the time	A response indicating that something happens or happened none of the time.			Intellectual Product	Medical Outcomes Study Social Activities|Medical Outcomes Study Social Support Survey
C110995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110995>	C226620	Much Less Socially Active Than Before|Much less socially active than before	A response indicating that an individual has been much less socially active than before.			Intellectual Product	Medical Outcomes Study Social Activities
C110996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110996>	C226620	Somewhat Less Socially Active Than Before|Somewhat less socially active than before	A response indicating that an individual has been somewhat less socially active than before.			Intellectual Product	Medical Outcomes Study Social Activities
C110997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110997>	C226620	About As Socially Active As Before|About as socially active as before	A response indicating that an individual has been about as socially active as before.			Intellectual Product	Medical Outcomes Study Social Activities
C110998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110998>	C226620	Somewhat More Socially Active As Before|Somewhat more socially active as before	A response indicating that an individual has been somewhat more socially active than before.			Intellectual Product	Medical Outcomes Study Social Activities
C110999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C110999>	C226620	Much More Socially Active Than Before|Much more socially active than before	A response indicating that an individual has been much more socially active than before.			Intellectual Product	Medical Outcomes Study Social Activities
C11099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11099>	C61063	Busulfan/Dexamethasone/Thiotepa|BU/DM/TSPA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1109>	C2136	Gallium Nitrate|GALLIUM NITRATE|GaN|Gallium nitrate|Ganite|WR-135675|gallium nitrate	A hydrated nitrate salt of the group IIIa element gallium with potential use in the treatment of malignancy-associated hypercalcemia.  Gallium nitrate localizes preferentially to areas of bone resorption and remodeling and inhibits osteoclast-mediated resorption by enhancing hydroxyapatite crystallization and reduction of bone mineral solubility.  This agent also increases calcium and phosphorous deposition into bone and may increase collagen synthesis. (NCI04)			Inorganic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C111000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111000>	C177163	Much More Limited Than Others|Much more limited than others	A response indicating that an individual feels much more limited than others.			Intellectual Product	Medical Outcomes Study Social Activities
C111001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111001>	C177163	Somewhat More Limited Than Others|Somewhat more limited than others	A response indicating that an individual feels somewhat more limited than others.			Intellectual Product	Medical Outcomes Study Social Activities
C111002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111002>	C226684|C226671	About The Same As Others|About the same as others	A response indicating that an individual feels about the same limitations as others.			Intellectual Product	Medical Outcomes Study Social Activities
C111003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111003>	C177163	Somewhat Less Limited Than Others|Somewhat less limited than others	A response indicating that an individual feels somewhat less limited than others.			Intellectual Product	Medical Outcomes Study Social Activities
C111004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111004>	C177163	Much Less Limited Than Others|Much less limited than others	A response indicating that an individual feels much less limited than others.			Intellectual Product	Medical Outcomes Study Social Activities
C111005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111005>	C172728	Someone to Help You If You Were Confined to Bed Question|Someone to Help You If You Were Confined to Bed|Someone to help you if you were confined to bed	A question about whether an individual has someone to help them if they were confined to bed.			Intellectual Product	Medical Outcomes Study Social Support Survey
C111006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111006>	C172728	Someone Who Will Listen When You Need to Talk Question|I have someone who will listen to me when I need to talk|Someone Who Will Listen When You Need to Talk|Someone You Can Count On to Listen to You When You Need to Talk|Someone you can count on to listen to you when you need to talk	A question about whether an individual has or had someone who will listen when they need to talk.			Intellectual Product	Medical Outcomes Study Social Support Survey
C111007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111007>	C172728	Someone to Give You Good Advice About a Crisis Question|Someone to Give You Good Advice About a Crisis|Someone to give you good advice about a crisis	A question about whether an individual has someone to give them good advice about a crisis.			Intellectual Product	Medical Outcomes Study Social Support Survey
C111008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111008>	C172728	Someone to Take You to the Doctor If You Needed it Question|Someone to Take You to the Doctor If You Needed it|Someone to take you to the doctor if you needed it	A question about whether an individual has someone to take them to the doctor when needed.			Intellectual Product	Medical Outcomes Study Social Support Survey
C111009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111009>	C176537|C172728	Someone to Give You Information to Help You Understand a Situation Question|Someone to Give You Information to Help You Understand a Situation|Someone to give you information to help you understand a situation	A question about whether an individual has someone to give them information to help them understand a situation.			Intellectual Product	Medical Outcomes Study Social Support Survey
C11100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11100>	C61007	Cyclosporine/Methylprednisolone|CYSP/MePRDL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111010>	C172728	Someone to Confide in or Talk to About Yourself or Your Problem Question|How often is there someone to confide in or talk to about yourself or your problems|I have someone to confide in or talk to about myself or my problems|Someone There to Confide in or Talk About Yourself or Your Problems|Someone to Confide in or Talk to About Yourself or Your Problem|Someone to confide in or talk to about yourself or your problem	A question about whether an individual has or had someone to confide in or talk to about themself or their problems.			Intellectual Product	Medical Outcomes Study Social Support Survey
C111011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111011>	C173045	Someone to Prepare Your Meals if You Were Unable to Do it Yourself Question|Someone to Prepare Your Meals if You Were Unable to Do it Yourself|Someone to prepare your meals if you were unable to do it yourself	A question about whether an individual has someone to prepare their meals if they were unable to do it themselves.			Intellectual Product	Medical Outcomes Study Social Support Survey
C111012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111012>	C172728	Someone Whose Advice You Really Want Question|Someone Whose Advice You Really Want|Someone whose advice you really want	A question about whether an individual has someone whose advice they really want.			Intellectual Product	Medical Outcomes Study Social Support Survey
C111013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111013>	C172728	Someone to Help You With Daily Chores if You Were Sick Question|Someone to Help You With Daily Chores if You Were Sick|Someone to help you with daily chores if you were sick	A question about whether an individual has someone to help them with daily chores if they were sick.			Intellectual Product	Medical Outcomes Study Social Support Survey
C111014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111014>	C172728	Someone to Share Your Most Private Worries and Fears With Question|Someone to Share Your Most Private Worries and Fears With|Someone to share your most private worries and fears with	A question about whether an individual has someone to share their most private worries and fears with.			Intellectual Product	Medical Outcomes Study Social Support Survey
C111015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111015>	C172728	Someone to Turn to For Suggestions About How to Deal With a Personal Problem Question|Someone to Turn to For Suggestions About How to Deal With a Personal Problem|Someone to turn to for suggestions about how to deal with a personal problem	A question about whether an individual has someone to turn to for suggestions about how to deal with a personal problem.			Intellectual Product	Medical Outcomes Study Social Support Survey
C111016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111016>	C172728	Someone Who Understands Your Problems Question|Someone Who Understands Your Problems|Someone who understands your problems	A question about whether an individual has someone who understands their problems.			Intellectual Product	Medical Outcomes Study Social Support Survey
C111017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111017>	C37927	Amber	A yellowish-orange color.			Qualitative Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form|GDC Terminology|GDC Value Terminology
C111018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111018>	C37927	Hazel	A color that consists of brown-gold and green.			Qualitative Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form|GDC Terminology|GDC Value Terminology
C111019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111019>	C37927	Violet	A bluish-purple color.			Qualitative Concept	
C11101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11101>	C61063	Dexamethasone/Doxorubicin/Pegaspargase/Vincristine|DM/DOX/PEG-ASP/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111020>	C111030	Uveal Class 1 Melanoma|Class 1 Uveal Melanoma|Class 1 Uveal Melanoma	Gene expression profiling that classifies uveal melanomas into a low-grade group.			Neoplastic Process	
C111021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111021>	C111030	Uveal Class 2 Melanoma|Class 2 Uveal Melanoma|Class 2 Uveal Melanoma	Gene expression profiling that classifies uveal melanomas into a high-grade group.			Neoplastic Process	
C111022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111022>	C111020	Uveal Class 1a Melanoma|Class 1a Uveal Melanoma|Class 1a Uveal Melanoma	A uveal melanoma with low metastatic risk as defined by gene expression profiling.			Neoplastic Process	
C111023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111023>	C111020	Uveal Class 1b Melanoma|Class 1b Uveal Melanoma|Class 1b Uveal Melanoma	A uveal melanoma with intermediate metastatic risk as defined by gene expression profiling.			Neoplastic Process	
C111024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111024>	C35867	Presence of Extravascular Matrix Patterns	A microscopic finding indicating the presence of patterns formed by malignant cells outside the blood vessel circulation in uveal melanoma.  The patterns are detectable using PAS stain without counterstaining with hematoxylin.			Finding	GDC Terminology|GDC Value Terminology
C111025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111025>	C111024	Extravascular Matrix Loops	A microscopic finding indicating the presence or absence of extravascular matrix loops in uveal melanoma.			Finding	GDC Terminology|GDC Value Terminology
C111026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111026>	C111024	Loops Forming Networks	A microscopic finding indicating the presence or absence of loops forming networks in uveal melanoma.			Finding	
C111027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111027>	C12558	Tumor Infiltrating Macrophages|TIM|Tumor Infiltrating Macrophage|Tumor-Infiltrating Macrophage	Non-neoplastic macrophages that infiltrate a tumor.	Tumor Infiltrating Macrophages		Cell	CTRP Biomarker Terminology|CTRP Terminology
C111028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111028>	C99208	Extrascleral Extension of Uveal Melanoma|extrascleral extension|extrascleral_extension	Spread of uveal melanoma beyond the sclera.			Finding	GDC Deprecated Terminology|GDC Terminology
C111029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111029>	C3824	Mushroom-Shaped Lesion|Mushroom	A lesion having the shape of a mushroom.			Finding	GDC Terminology|GDC Value Terminology
C11102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11102>	C63588	Dexamethasone/Pegaspargase/Vincristine Regimen|DM/PEG-ASP/VCR|Dexamethasone-Pegaspargase-Vincristine|Dexamethasone/Pegaspargase/Vincristine|Pegaspargase/Vincristine/Dexamethasone	A regimen consisting of dexamethasone, pegaspargase, and vincristine that may be used in the treatment of acute lymphoblastic leukemia (ALL).			Therapeutic or Preventive Procedure	
C111030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111030>	C7712	Uveal Melanoma by Gene Expression Profile	Classification of uveal melanoma into molecular subtypes as defined by gene expression profiling.			Neoplastic Process	
C111031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111031>	C199001|C198999	Genetic Carrier|Carrier	An individual who carries an inheritable genetic mutation without manifestation of the associated condition.			Group Attribute	
C111032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111032>	C12680	Antecubital Region|Antecubital Space	The area of the body that is anterior to the elbow.			Body Location or Region	
C111033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111033>	C12680	Carpal Region|Wrist Region|Wrist Region	The area of the body located between the antebrachial and metacarpal regions.			Body Location or Region	
C111034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111034>	C2873	Minimal Aneuploidy	A numerical chromosomal abnormality characterized by the presence of copy number variations in less than five percent of chromosomal arms.			Cell or Molecular Dysfunction	
C111035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111035>	C29730	Oral Rehydration Solution OS-1|OS-1|OS1	An aqueous solution composed of glucose and electrolytes, including sodium, potassium, chloride, magnesium, and phosphorus, with dehydration preventative and rehydration activities. Upon oral administration of the oral rehydration solution (ORS), water, electrolytes and glucose are absorbed from the gastrointestinal (GI) tract into the systemic circulation.  This replenishes the body's supply of water, carbohydrates and electrolytes, and prevents both dehydration and renal dysfunction.			Inorganic Chemical|Pharmacologic Substance	NCI Drug Dictionary Terminology
C111036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111036>	C1752	Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|CMV-MVA Triplex Vaccine|Multi-antigen CMV-Modified Vaccinia Ankara Vaccine	A vaccine consisting of an inactivated, Modified Vaccinia Ankara (MVA) viral vector encoding three herpes virus cytomegalovirus (CMV) tumor-associated antigens (TAAs), including UL83 (pp65), UL123 (IE1) and UL122 (IE2), with potential immunostimulating activity. The viral peptides expressed after administration of the multi-peptide CMV-MVA vaccine, may stimulate the immune system to mount both cytotoxic T-lymphocyte (CTL) and helper T-cell responses against CMV-infected cells. This results in cell lysis and prevents viral replication and the development of CMV disease. This vaccine also provides active immunization and protective immunity against CMV infection in CMV-negative patients. CMV infection can cause serious complications in patients receiving either allogeneic hematopoietic cell transplants (HCT) or solid organ transplants.	Multi-peptide CMV-Modified Vaccinia Ankara Vaccine		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111037>	C1752|C1663	Synthetic Long E6/E7 Peptides Vaccine HPV-01|HPV-01|ISA101|SLP-HPV-01	A therapeutic peptide vaccine consisting of thirteen synthetic long peptides (SLPs), which are 25-35 amino acids in size, derived from the human papillomavirus (HPV) type 16 oncoproteins E6 and E7, with potential immunostimulating and antitumor activities. Upon administration, synthetic long E6/E7 peptides vaccine HPV-01 is taken up and degraded into small pieces by dendritic cells. The processed viral epitopes are presented by dendritic cells, which may stimulate the host immune system to mount both cytotoxic T-cell lymphocyte (CTL) and helper T cell responses against HPV E6/E7-expressing tumor cells. This results in the destruction of tumor cells and leads to decreased tumor growth. The E6 and E7 oncoproteins are implicated in the tumorigenesis in a variety of cancers. The SLPs allow for optimal presentation by antigen-presenting cells.	Synthetic Long E6/E7 Peptides Vaccine HPV-01		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111038>	C200766	Anti-VEGFR2-CAR Retroviral Vector-transduced Autologous T-lymphocytes|Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes|Autologous Anti-VEGFR2 CD8+ CAR T Cells	Autologous human CD8-positive T-lymphocytes transduced with a recombinant retroviral vector encoding a chimeric T cell receptor (chimeric antigen receptor or CAR) consisting of an anti-vascular endothelial growth factor receptor type 2 (VEGFR2) scFv (single chain variable fragment), linked to the transmembrane domain of human CD8alpha and coupled to the costimulatory signaling domains of both CD28 and 4-1BB (CD137), and the CD3 zeta chain of the T-cell receptor (TCR), with potential immunostimulating and antineoplastic activities. Autologous peripheral blood lymphocytes (PBLs) from a patient with VEGFR2-positive cancer are pulsed with a retroviral vector that encodes the CAR gene specific for VEGFR2. After expansion in culture and reintroduction into the patient, the anti-VEGFR2 CAR-gene engineered CD8+ lymphocytes express anti-VEGFR2-CAR on their cell surfaces and bind to the VEGFR2 antigen on tumor cell surfaces. Subsequently, VEGFR2-expressing tumor cells are lysed. VEGFR2, a receptor tyrosine kinase (RTK) overexpressed by a variety of cancer cell types, belongs to the VEGFR superfamily and plays key roles in tumor cell proliferation, survival, invasion and tumor angiogenesis. The co-stimulatory molecules are required for optimal T-cell activation.	Anti-VEGFR2-CAR Retroviral Vector-transduced Autologous T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111039>	C2333	Vadastuximab Talirine|SGN CD33A|SGN-CD33A|SGNCD33A|VADASTUXIMAB TALIRINE|Vadastuximab talirine	An immunoconjugate consisting of a humanized monoclonal antibody that is engineered to contain cysteine residues that are conjugated to the synthetic, DNA cross-linking, pyrrolobenzodiazepine dimer SGD-1882, via the protease-cleavable linker maleimidocaproyl-valine-alanine dipeptide, with potential antineoplastic activity. The monoclonal antibody portion of vadastuximab talirine specifically binds to the cell surface antigen CD33. This causes the internalization of SGN-CD33A, and the release of the cytotoxic moiety SGD-1882. SGD-1882 binds to and crosslinks DNA, which results in both cell cycle arrest and the induction of apoptosis in CD33-expressing tumor cells. CD33, a transmembrane receptor, is expressed on myeloid leukemia cells.	Vadastuximab Talirine		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11103>	C61007	Carmustine/Cytarabine/Etoposide/Melphalan|ARA-C/BCNU/L-PAM/VP-16|BEAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111040>	C1511	Zirconium Zr 89 Df-IAB2M|[89Zr]Df-IAB2M	A radioimmunoconjugate comprised of an antibody fragment (IAB2M) against prostate-specific membrane antigen (PSMA), conjugated to the chelator desferrioxamine (Df) and labeled with the radioisotope zirconium Zr 89, with potential positron emission tomography (PET) imaging activity. Upon administration of zirconium Zr 89 Df-IAB2M, the antibody moiety binds to the extracellular domain of PSMA expressed on cancer cells. This may enable PET detection of the radioisotope moiety, and allows the imaging and quantification of PSMA-expressing tumor cells. PSMA is a cell surface peptidase highly expressed by malignant prostate epithelial cells and vascular endothelial cells in various solid tumor malignancies.	Zirconium Zr 89 Df-IAB2M		Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C111041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111041>	C200765|C176018	Anti-CD19-CAR FMC63-28Z Retroviral Vector-transduced Allogeneic T-lymphocytes|FMC63-28Z CAR-transduced Allogeneic T-lymphocytes|MSGV1-FMC63-28Z Anti-CD19 CAR-transduced Allogeneic T-lymphocytes	Allogeneic T-lymphocytes derived from peripheral blood mononuclear cells (PBMC) transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) consisting of both the light and heavy chain variable regions of anti-CD19 monoclonal antibody FMC63, coupled to the molecule CD28 and the signaling domain of the zeta chain of the T-cell receptor (TCR) (FMC63-28Z), with potential immunomodulating and antineoplastic activities. Upon transfusion, the anti-CD19-CAR FMC63-28Z retroviral vector-transduced allogeneic T lymphocytes specifically recognize and kill CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen, which is expressed in all B-cell lineage malignancies and normal B-cells.	Anti-CD19-CAR FMC63-28Z Retroviral Vector-transduced Allogeneic T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111042>	C200712	STAT3 Inhibitor WP1066|(S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide|WP 1066|WP-1066|WP-1066|WP1066	An orally bioavailable, small molecule inhibitor of signaling transducer and activator 3 (STAT3), with potential antineoplastic and immunomodulatory activities. Upon administration, STAT3 inhibitor WP1066 blocks the intranuclear translocation of p-STAT, thereby suppressing STAT3 signaling and decreasing the levels of downstream products including c-Myc. Additionally, WP1066 may upregulate costimulatory molecules including CD80 and CD86 on human microglia, and reverse glioma cancer stem cell (gCSC)-mediated innate and adaptive immune suppression allowing for the restoration of antitumor effector immune responses. The STAT3 pathway is overly active in many cancer types and is implicated in CSC-mediated growth, recurrence and resistance to conventional chemotherapies.	STAT3 Inhibitor WP1066		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111043>	C173981	Have Had Seizures Question|Did you have seizures|Have Had Seizures|Have Seizures|History of Seizures|I have had seizures	A question about whether an individual has or had seizures.			Intellectual Product	FACT-BR Questionnaire|Quality of Life Questionnaire-Brain Neoplasm 20 Items
C111044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111044>	C91103	Can Remember New Things Question|Can Remember New Things|I can remember new things	A question about whether an individual can remember new things.			Intellectual Product	FACT-BR Questionnaire
C111045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111045>	C241	Trimebutine 3-Thiocarbamoylbenzenesulfonate|Benzoic Acid, 3,4,5-Trimethoxy-, 2-(Dimethylamino)-2-phenylbutyl Ester, 3-(Aminothioxomethyl)benzenesulfonate (1:1)|GIC-1001|TB-905-02|TRIMEBUTINE 3-THIOCARBAMOYLBENZENESULFONATE	A sulfonate-based salt form of a trimebutine derivative, an orally available, peripherally-acting opioid agonist and muscarinic antagonist, with potential visceral analgesic activity. Upon oral administration of GIC-1001, this agent may exert its therapeutic effects through the potential mechanisms of action for the trimebutine and sulfonate moieties: The trimebutine moiety can act as a motility enhancer in the gastrointestinal (GI) tract, as an antispasmodic agent to reduce colonic spasms, as an agonist of colonic mu and kappa opioid receptors, which could provide an analgesic effect, and blocks sodium channels and the release of a variety of GI peptides, which modulates the activity of visceral afferents. The sulfonate moiety releases hydrogen sulfide (H2S), which is involved, through an as of yet not fully elucidated mechanism of action, in the modulation of visceral perception and pain, possibly through the activation of ATP-sensitive potassium (KATP) ion channels and mu opioid receptors. Altogether, administration of this agent may both facilitate the insertion of the colonoscope during a colonoscopy and reduce colonic spasms and pain.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C111046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111046>	C91103	Get Frustrated That I Cannot Do Things I Used To Question|Get Frustrated That I Cannot Do Things I Used To|I get frustrated that I cannot do things I used to	A question about whether an individual gets frustrated because they can't do things that they used to be able to do.			Intellectual Product	FACT-BR Questionnaire
C111047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111047>	C91103	Afraid of Having a Seizure Question|Afraid of Having a Seizure|I am afraid of having a seizure	A question about whether an individual is or was afraid of having a seizure.			Intellectual Product	FACT-BR Questionnaire
C111048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111048>	C173790|C173398	Have Trouble with Eyesight Question|Have Trouble with Eyesight|I have trouble with my eyesight	A question about whether an individual has or had trouble with their eyesight.			Intellectual Product	FACT-BR Questionnaire
C111049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111049>	C173160	Feel Independent Question|Feel Independent|I feel independent	A question about whether an individual feels or felt independent.			Intellectual Product	FACT-BR Questionnaire
C11104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11104>	C61063	Idarubicin/Tretinoin Liposome|IDA/L-ATRA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111050>	C173398|C173059	Have Trouble Hearing Question|Did you have difficulty hearing|Have Difficulty Hearing|Have Difficulty Hearing Question|Have Trouble Hearing|I have trouble hearing	A question about whether an individual has or had trouble hearing.			Intellectual Product	FACT-BR Questionnaire|FACT-NP Questionnaire|FACT-Taxane Questionnaire|Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20 Items
C111051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111051>	C173045	Able to Find the Right Words to Say Question|Able to Find the Right Words to Say|I am able to find the right word or words to say what I mean	A question about whether an individual is or was able to find the right words to say what they mean.			Intellectual Product	FACT-BR Questionnaire
C111052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111052>	C173597|C173398	Difficulty Expressing Thoughts Question|Difficulty Expressing Thoughts|I have difficulty expressing my thoughts	A question about whether an individual has or had difficulty expressing their thoughts.			Intellectual Product	FACT-BR Questionnaire
C111053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111053>	C172982	Bothered by Change in Personality Question|Bothered by Change in Personality|I am bothered by the change in my personality	A question about whether an individual is or was bothered by the change in their personality.			Intellectual Product	FACT-BR Questionnaire
C111054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111054>	C174127|C173045	Able to Make Decisions and Take Responsibility Question|Able to Make Decisions and Take Responsibility|I am able to make decisions and take responsibility	A question about whether an individual is or was able to make decisions and take responsibility.			Intellectual Product	FACT-BR Questionnaire
C111055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111055>	C173151|C172982	Bothered by Drop in Contribution to the Family Question|Bothered by Drop in Contribution to the Family|I am bothered by the drop in my contribution to the family	A question about whether an individual is or was bothered by the drop in their contribution to the family.			Intellectual Product	FACT-BR Questionnaire
C111056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111056>	C173597|C173045	Able to Put Thoughts Together Question|Able to Put Thoughts Together|I am able to put my thoughts together	A question about whether an individual is or was able to put their thoughts together.			Intellectual Product	FACT-BR Questionnaire
C111057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111057>	C178350	Need Help in Caring for Self Question|I need help in caring for myself|Need Help in Caring for Self	A question about whether an individual needs or needed help in caring for themselves.			Intellectual Product	FACT-BR Questionnaire
C111058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111058>	C173597|C173045	Able to Put Thoughts into Actions Question|Able to Put Thoughts into Actions|I am able to put my thoughts into action	A question about whether an individual is or was able to put their thoughts into action.			Intellectual Product	FACT-BR Questionnaire
C111059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111059>	C176426|C173045	Able to Read Like They Used To Question|Able to Read Like They Used To|I am able to read like I used to	A question about whether an individual is or was able to read like they used to.			Intellectual Product	FACT-BR Questionnaire
C11105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11105>	C61063	Docetaxel/Vinorelbine|TXT/VNB			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111060>	C173045	Able to Write Like They Used To Question|Able to Write Like They Used To|I am able to write like I used to	A question about whether an individual is or was able to write like they used to.			Intellectual Product	FACT-BR Questionnaire
C111061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111061>	C173045	Able to Drive a Vehicle Question|Able to Drive a Vehicle|I am able to drive a vehicle	A question about whether an individual is or was able to drive a vehicle.			Intellectual Product	FACT-BR Questionnaire
C111062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111062>	C173398|C173219	Have Trouble Feeling Sensations in Limbs Question|Have Trouble Feeling Sensations in Limbs|I have trouble feeling sensations in my arms, hands or legs	A question about whether an individual has or had trouble feeling sensations in their arms, hands, or legs.			Intellectual Product	FACT-BR Questionnaire
C111063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111063>	C173219	Have Weakness in Limbs Question|Did you feel weak in your arms and legs|Feel Weak in Arms and Legs|Have Weakness in Limbs|I have weakness in my arms or legs	A question about whether an individual has or had weakness in their arms or legs.			Intellectual Product	FACT-BR Questionnaire|Quality of Life Questionnaire - Pancreatic Cancer 26
C111064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111064>	C173398	Trouble with Coordination Question|Did you have trouble with your coordination|Have Trouble with Coordination|I have trouble with coordination|Trouble with Coordination	A question about whether an individual has or had trouble with their coordination.			Intellectual Product	FACT-BR Questionnaire|Quality of Life Questionnaire-Brain Neoplasm 20 Items
C111065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111065>	C173981	Get Headaches Question|Did you have headaches|Get Headaches|Had Headaches|Have Headaches|Have Headaches|Have you had headaches|I get headaches	A question about whether an individual gets headaches.			Intellectual Product	Dexamethasone Symptom Questionnaire-Chronic|Dexamethasone Symptom Questionnaire|FACT-BR Questionnaire|Quality of Life Questionnaire BR-23|Quality of Life Questionnaire-Brain Neoplasm 20 Items
C111066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111066>	C15333	Orchiopexy	A surgical procedure in which a testicle is fixated inside the scrotum.			Therapeutic or Preventive Procedure	GDC Terminology|GDC Value Terminology
C111067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111067>	C36292	Testicular Cancer Serum Markers Test Result|ajcc serum tumor markers|ajcc_serum_tumor_markers	A laboratory test result in which markers for testicular cancer are tested in a blood sample for staging purposes.			Laboratory or Test Result	GDC Property Terminology
C111068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111068>	C111067	SX	Marker studies not available or not performed. (AJCC 7th ed.)			Laboratory or Test Result	GDC Terminology|GDC Value Terminology
C111069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111069>	C111067	S0	Marker study levels within normal limits. (AJCC 7th ed.)			Laboratory or Test Result	GDC Terminology|GDC Value Terminology
C11106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11106>	C61007	Docetaxel/Filgrastim/Vinorelbine|G-CSF/TXT/VNB			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111070>	C111067	S1	LDH less than 1.5 x N and hCG (mIu/ml) less than 5,000 and AFP (ng/ml) less than 1,000.  N indicates the upper limit of normal for the LDH assay. (AJCC 7th ed.)			Laboratory or Test Result	GDC Terminology|GDC Value Terminology
C111071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111071>	C111067	S2	LDH 1.5-10 x N or hCG (mIu/ml) 5,000-50,000 or AFP (ng/ml) 1,000-10,000. N indicates the upper limit of normal for the LDH assay. (AJCC 7th ed.)			Laboratory or Test Result	GDC Terminology|GDC Value Terminology
C111072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111072>	C111067	S3	LDH more than 10 x N or hCG (mIu/ml) more than 50,000 or AFP (ng/ml) more than 10,000. N indicates the upper limit of normal for the LDH assay. (AJCC 7th ed.)			Laboratory or Test Result	GDC Terminology|GDC Value Terminology
C111073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111073>	C25161	International Germ Cell Consensus Risk Classification|IGCCC|IGCCC_RISK_GROUP|International Germ Cell Consensus Classification|igcccg stage|igcccg_stage	A risk classification system for malignant germ cell tumors developed by the International Germ Cell Cancer Collaborative Group.			Classification	GCT Disease Characteristics Table|GCT Variable Terminology|GDC Property Terminology|GDC Terminology
C111074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111074>	C27993	Micro	A prefix meaning very small in scale or scope.			Conceptual Entity	
C111075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111075>	C41328	Arrhythmia by ECG Finding|Arrhythmia by EKG Finding	An arrhythmia that is detected on an electrocardiograph.			Finding	
C111076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111076>	C54443	US Counties Terminology	A list of all the counties in the United States, and the states in which they are located.			Intellectual Product	
C111077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111077>	C45273	Human Prescription Drug Distribution|Distributes human prescription drug products	The process of distributing prescription medications for human use.	Human Prescription Drug Distribution		Activity	CTRP Intervention Terminology|CTRP Terminology|FDA Structured Product Labeling Terminology|SPL Business Operation Qualifier Terminology
C111078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111078>	C45273	Human Over-the-Counter Drug Distribution|Distributes human over-the-counter drug products	The process of distributing non-prescription medications for human use.			Activity	FDA Structured Product Labeling Terminology|SPL Business Operation Qualifier Terminology
C111079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111079>	C25335	Critical Organ Volume	The portion of the total volume of a critical organ that is exposed to a specified dose of radiation therapy.			Quantitative Concept	
C11107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11107>	C61063	Floxuridine/Gemcitabine/Leucovorin Calcium|CF/dFdC/FUDR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111081>	C198998	Emancipated Minor	A person under the age of majority who has been granted the legal status of adulthood.			Group Attribute	
C111083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111083>	C36110	Modified Overall Immune Related Response Criterion, New Non-Measurable Lesion|Modified irRC, New Non-Measurable Lesion	The finding of a growth smaller than 5 mm x 5 mm that was not present at the previous evaluation. Its presence does not indicate disease progession but precludes a determination of complete remission based on the modified overall immune related response criteria.			Finding	
C111084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111084>	C4870	Modified Overall Immune Related Response Criterion, Complete Remission|Modified irCR	The evaluation of the antitumor response shows a complete disappearance of all lesions (whether measurable or not) and no new lesions. All measurable lymph nodes also have a reduction in short axis diameter to 10 mm.			Finding	
C111085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111085>	C18058	Modified Overall Immune Related Response Criterion, Partial Response|Modified irPR	The evaluation of the antitumor response shows that the sum of the longest diameters of target and new measurable lesions has decreased by at least 30%.			Finding	
C111086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111086>	C18213	Modified Overall Immune Related Response Criterion, Stable Disease|Modified irSD	The evaluation of the antitumor response shows that the sum of the longest diameters of target and new measurable lesions do not meet the criteria for complete remission, partial response (compared to baseline) or progressive disease (compared to nadir).			Finding	
C111087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111087>	C8510	Modified Overall Immune Related Response Criterion, Progressive Disease|Modified irPD	The evaluation of the antitumor response shows that the sum of the longest diameters of target and new measurable lesions increases by at least 20% (compared to nadir), and is confirmed by repeated, consecutive observations at least 4 weeks (normally done at 6 weeks) from the date first documented.			Finding	
C111088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111088>	C26703	AV Block First Degree by ECG Finding|1ST DEGREE AV BLOCK|1st degree AV block|AV Block First Degree|AV Block First Degree by EKG Finding|First Degree AV Block|First Degree Atrioventricular Block|PR Prolongation|Prolonged AV Conduction|Prolonged PR Interval|Prolonged PR interval	An electrocardiographic finding of prolonged PR interval for a specific population. For adults one common threshold is a PR interval greater than 0.20 seconds. Note that other thresholds may be applicable. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111089>	C80503|C62016	AV Block Second Degree Mobitz Type I by ECG Finding|AV Block Second Degree Mobitz Type I|AV Block Second Degree Mobitz Type I by EKG Finding|AV Block Second Degree Möbitz Type I|AV Block Second Degree Möbitz Type I by ECG Finding|AV Block Second Degree Möbitz Type I by EKG Finding|AV MOBITZ I|AV Mobitz I|Mobitz I|Mobitz I Second Degree AV Block|Mobitz Type I Second Degree AV Block|Möbitz I|Möbitz Type I Second Degree AV Block|Second Degree Atrioventricular Block Mobitz Type I|Second Degree Atrioventricular Block Möbitz Type I|Second degree AV block- Mobitz type I|Second-degree AV block, Mobitz type I (Wenckebach)|Type 1 2nd degree AV Block|Type 1 Second Degree AV Block|Type 1 Second Degree Atrioventricular Block|Wenckebach|Wenckebach Block	An electrocardiographic finding of intermittent failure of atrial electrical impulse conduction to the ventricles, characterized by a progressively lengthening PR interval prior to the block of an atrial impulse. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11108>	C61063	Filgrastim/Losoxantrone/Paclitaxel|DuP-941/G-CSF/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111090>	C80503|C62016	AV Block Second Degree Mobitz Type II by ECG Finding|AV Block Second Degree Mobitz Type II|AV Block Second Degree Mobitz Type II by EKG Finding|AV Block Second Degree Möbitz Type II|AV Block Second Degree Möbitz Type II by ECG Finding|AV Block Second Degree Möbitz Type II by EKG Finding|AV MOBITZ II|Mobitz II|Mobitz II AV Block|Mobitz II Second Degree AV Block|Mobitz Type II Second Degree AV Block|Möbitz II|Möbitz Type II Second Degree AV Block|Second Degree Atrioventricular Block Mobitz Type II|Second Degree Atrioventricular Block Möbitz Type II|Type 2 2nd degree AV Block|Type 2 Second Degree AV Block|Type II Second Degree AV Block|Type II Second Degree Atrioventricular Block	An electrocardiographic finding of intermittent non-conducted P waves with normal preceding and subsequent PR intervals.			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111091>	C26703	AV Block Third Degree by ECG Finding|3RD DEGREE AV BLOCK|3rd Degree Heart Block|AV Block Third Degree|AV Block Third Degree by EKG Finding|AV block, complete (third-degree)|Complete AV Block|Complete Heart Block|Complete Heart Block|Third Degree AV Block|Third Degree Atrioventricular Block	An electrocardiographic finding of complete failure of atrial electrical impulse conduction to the ventricles. This is manifested on the ECG by disassociation of atrial and ventricular rhythms. The atrial rate must be faster than the ventricular rate. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111092>	C80503	Atrial Fibrillation by ECG Finding|AF|AF|AFib|ATRIAL FIBRILLATION|Atrial Fibrillation|Atrial Fibrillation by EKG Finding|Atrial fibrillation	An electrocardiographic finding of a supraventricular arrhythmia characterized by the replacement of consistent P waves by rapid oscillations or fibrillatory waves that vary in size, shape and timing and are accompanied by an irregularly irregular ventricular response. (CDISC)			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 7: Diagnostic Procedures Terminology|CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111093>	C25714	Software Version|SFTWRVER|SFTWRVER	A form or variant of software; one of a sequence of copies of a software program, each incorporating new modifications.			Conceptual Entity	CDISC DDF Medical Device Attribute Terminology|CDISC DDF Terminology|CDISC SDTM Device Properties Test Code Terminology|CDISC SDTM Device Properties Test Name Terminology|CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111094>	C80503	Atrial Flutter by ECG Finding|ATRIAL FLUTTER|Atrial Flutter|Atrial Flutter by EKG Finding|Atrial flutter|Atrial flutter	An electrocardiographic finding of an organized, regular atrial rhythm with atrial rate of 240-340 beats per minute. Multiple P waves typically appear in the inferior leads in a saw tooth like pattern between the QRS complexes. (CDISC)			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 7: Diagnostic Procedures Terminology|CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111095>	C62662	Clot Detection|CLOT DETECTION	Any of several methods used to detect the presence of or quantify the formation of a thrombus in a specimen.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111096>	C64546	Colorimetry|COLORIMETRY	An assessment used to quantify and describe the colors within the visible spectrum of light.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111097>	C80503	Sinus Bradycardia by ECG Finding|SINUS BRADYCARDIA|Sinus Bradycardia|Sinus Bradycardia by EKG Finding|Sinus bradycardia	An electrocardiographic finding of abnormally slow heart rate with its origin in the sinus node. Thresholds for different age, sex, and patient populations exist.			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111098>	C85927	Slackia	A genus of obligate anaerobic, Gram positive, cocci, coccobacilli or short bacilli shaped bacterium assigned to the phylum Actinobacteria and the family Coriobacteriaceae.			Bacterium	
C111099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111099>	C85936	Wautersiella	A genus of aerobic, Gram negative, rod shaped bacterium assigned to the phylum Bacteroidetes and the family Flavobacteriaceae.			Bacterium	
C11109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11109>	C61063	Cyclophosphamide/Daunorubicin/Dexamethasone/Vincristine|CTX/DM/DNR/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1110>	C912|C518	Ganglioside GD2|DISIALOGANGLIOSIDE GD-2|Disialoganglioside GD-2|GANGLIOSIDE GD2|GD2|GD2 Ganglioside|GalNAc(beta 1->4)-[NeuAc(alpha 2->8)NeuAc(alpha 2->3)]Gal(beta 1->4)GlcCer|Ganglioside, GD2	A cell surface antigen expressed on all tumors of neuroectodermal origin, including melanoma, neuroblastomas, sarcoma, astrocytomas, and small cell lung cancer. GD2, an O-acetylated disialoganglioside, belongs to the group of glycosphingolipids that are widely expressed in many tissues and organs in vertebrates and have been suggested to be involved in the regulation of development and differentiation as recognition molecules or signal modulators. Due to its high level of expression in neuroblastoma, GD2 has the potential to be used as a component of anti-neuroblastoma vaccines, in addition to being used in polyvalent anti-melanoma vaccines.	Ganglioside GD2		Immunologic Factor|Organic Chemical|Pharmacologic Substance	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|Pediatric Oncology Target Cell Lineage Determinant Terminology
C111100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111100>	C27158	Supraventricular Tachycardia by ECG Finding|SUPRAVENTRICULAR TACHYCARDIA|SVT|Supraventricular Tachycardia|Supraventricular Tachycardia by EKG Finding|Supraventricular tachycardia|Supraventricular tachycardia	An electrocardiographic finding of a tachycardia which does not originate in the ventricles or His Purkinje system. There is an abnormally high heart rate and QRS complexes are typically narrow, but aberration or preexcitation may be present. (CDISC)			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 7: Diagnostic Procedures Terminology|CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111101>	C111075	Ventricular Arrhythmia by ECG Finding|Ventricular Arrhythmia|Ventricular Arrhythmia by EKG Finding|Ventricular arrhythmia	An electrocardiographic finding of an atypical cardiac rhythm resulting from a pathologic process in the cardiac ventricles.			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 7: Diagnostic Procedures Terminology
C111102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111102>	C111101	Ventricular Fibrillation by ECG Finding|VENTRICULAR FIBRILLATION|VF|VFib|Ventricular Fibrillation|Ventricular Fibrillation by EKG Finding|Ventricular fibrillation	An electrocardiographic finding of a rapid grossly irregular ventricular rhythm with marked variability in QRS cycle length, morphology, and amplitude. The rate is typically greater than 300 bpm. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111103>	C111101	Ventricular Tachycardia by ECG Finding|VENTRICULAR TACHYCARDIA|Ventricular Tachycardia|Ventricular Tachycardia by EKG Finding|Ventricular tachycardia	An electrocardiographic finding of three or more consecutive complexes of ventricular organ with a rate greater than a certain threshold (100 or 120 beats per minute are commonly used). The QRS complexes are wide and have an abnormal morphology. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111104>	C111100	Sinus Tachycardia by ECG Finding|SINUS TACHYCARDIA|Sinus Tachycardia|Sinus Tachycardia by EKG Finding|Sinus tachycardia	An electrocardiographic finding of abnormally rapid heart rate with its origin in the sinus node. Thresholds for different age, sex, and patient populations exist.			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111105>	C111100	Atrial Tachycardia by ECG Finding|ATRIAL TACHYCARDIA|Atrial Tachycardia|Atrial Tachycardia by EKG Finding|Atrial tachycardia	An electrocardiographic finding of an organized, regular atrial rhythm with atrial rate between 101 and 240 beats per minute. The P wave morphology must be distinct from the sinus P wave morphology. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111106>	C66830	CDISC SDTM Respiratory Test Code Terminology|RETESTCD|Respiratory Test Code|SDTM-RETESTCD	Terminology associated with the respiratory test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111107>	C66830	CDISC SDTM Respiratory Test Name Terminology|RETEST|Respiratory Test Name|SDTM-RETEST	Terminology associated with the respiratory test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111108>	C66830	CDISC SDTM Employment Status Terminology|EMPSTAT|Employment Status|SDTM-EMPSTAT	Terminology associated with the employment status codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111109>	C66830	CDISC SDTM Device Events Category Terminology|Category of Device Events|DECAT|SDTM-DECAT	Terminology associated with the device events category codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11110>	C61063	Cytarabine/Idarubicin/Thioguanine|ARA-C/IDA/TG			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111110>	C66830	CDISC SDTM Device Events Action Taken with Device Terminology|DEACNDEV|Device Events Action Taken with Device|SDTM-DEACNDEV	Terminology associated with the device events action taken with device codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111111>	C66830	CDISC SDTM Device Properties Test Code Terminology|DOTESTCD|Device Properties Test Code|SDTM-DOTESTCD	Terminology associated with the device properties test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111112>	C66830	CDISC SDTM Device Properties Test Name Terminology|DOTEST|Device Properties Test Name|SDTM-DOTEST	Terminology associated with the device properties test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111113>	C77526	CDISC SEND Domain Abbreviation Terminology|SDOMAIN|SEND Domain Abbreviation|SEND-SDOMAIN	Terminology associated with the SEND domain abbreviation codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111114>	C66830	CDISC SDTM Genetic Sample Type Terminology|GENSMP|Genetic Sample Type|SDTM-GENSMP	Terminology associated with the genetic sample type codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111115>	C111103	Ventricular Flutter by ECG Finding|VENTRICULAR FLUTTER|VFl|Ventricular Flutter|Ventricular Flutter by EKG Finding|Ventricular flutter	A ventricular tachyarrhythmia characterized by a high ventricular rate (180 and 250 beats per minute) with a regular rhythm. The electrocardiogram shows large oscillating sine wave-like complexes occurring as a result of QRS complexes and T waves being merged. The P wave is not visible.			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111116>	C20117	Diffusion Weighted Imaging|DIFFUSION WEIGHTED MRI|DW-MRI|DWI|DWI|DWI|DWI MRI|DWI-MRI|Diffusion Weighted MRI|Diffusion-Weighted MR Imaging|Diffusion-Weighted MRI|Diffusion-Weighted Magnetic Resonance Imaging|MR Diffusion-Weighted Imaging	A diffusion MRI technique in which diffusion-sensitizing gradients are applied to the imaging sequence.	Diffusion Weighted Imaging		Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF6 DIPG Imaging Assessment Signal Characteristics Table|CRF6 DMG Imaging Assessment Signal Characteristics Table|CTRP Intervention Terminology|CTRP Terminology
C111117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111117>	C50547	Arterial Embolus|Arterial Embolism|Arterial Embolism	The passage of an embolus from its site of formation in the arterial system to another location within the circulatory system.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111118>	C27083	Atrial Thrombus|Atrial thrombosis	Presence of a blood clot in the atria of the heart.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111119>	C2881	AV Block Second Degree|Atrioventricular Block Second Degree|Atrioventricular Block, Second Degree|Second Degree AV Block|Second Degree Atrioventricular Block	Intermittent failure of atrial electrical impulse conduction to the ventricles.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11111>	C61063	Interferon Alfa/Interleukin-2/Paclitaxel|IFN-A/IL-2/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111120>	C111075	Bradycardia by ECG Finding|BRADYCARDIA|Bradycardia|Bradycardia|Bradycardia by EKG Finding	An electrocardiographic finding of abnormally slow heart rate. Thresholds for different age, sex, and patient populations exist.			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111121>	C111075	Tachycardia by ECG Finding|TACHYCARDIA|Tachycardia|Tachycardia|Tachycardia by EKG Finding	An electrocardiographic finding of abnormally rapid heart rate. Thresholds for different age, sex, and patient populations exist.			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111122>	C13031	Neostriatum	The brain area that is composed of the caudate nucleus and putamen.			Body Part, Organ, or Organ Component	
C111123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111123>	C74804	A Proliferation-Inducing Ligand Measurement|A Proliferation-Inducing Ligand|A Proliferation-Inducing Ligand|APRIL|APRIL Measurement|Soluble CD256|TNFSF13|TNFSF13 Measurement|Tumor Necrosis Factor Ligand Superfamily Member 13	The determination of the amount of a proliferation-inducing ligand present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111124>	C48938	Abnormal Cell Count|ABNCE|ABNCE|Abnormal Cells|Abnormal Cells|Abnormal Cells|Abnormal Cells	The determination of the amount of abnormal cells present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C111125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111125>	C210012|C210010	Adenovirus Antibody Measurement	The determination of the amount of adenovirus antibody present in a sample.			Laboratory Procedure	
C111126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111126>	C64430	Alpha Hydroxybutyrate Dehydrogenase Measurement|AHBDH|Alpha Hydroxybutyrate Dehydrogenase|Alpha Hydroxybutyrate Dehydrogenase	The determination of the amount of alpha-hydroxybutyrate dehydrogenase present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111127>	C49237	Aluminum Measurement|ALUMINUM|Al|Aluminum|Aluminum	A measurement of aluminum present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111128>	C75385	Angiopoietin 1 Measurement|ANG-1 Measurement|ANGPT1|ANGPT1 Measurement|Angiopoietin 1|Angiopoietin 1	A measurement of angiopoietin 1 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111129>	C67375|C48463	Antibody Unit|AU|Antibody Concentration Unit|Standardized Antibody Concentration Unit|{Antibody Unit}|{Antibody Unit}	A unit of antibody concentration measured by comparison against a known concentration of antibodies in a standard reference specimen.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11112>	C61063	Mercaptopurine/Methotrexate/Tretinoin|ATRA/MP/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111130>	C74760	Apolipoprotein J to Creatinine Ratio Measurement|APOJCRT|ApoJ Measurement|Apolipoprotein J/Creatinine|Apolipoprotein J/Creatinine|Clusterin/Creatinine|Clusterin/Creatinine Measurement	The determination of the ratio of the apolipoprotein J compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111131>	C83146	Atrioventricular Conduction ECG Assessment|AVCOND|AVCOND|Atrioventricular Conduction|Atrioventricular Conduction|Atrioventricular Conduction	An electrocardiographic assessment of the transmission of electrical impulses between the atria and ventricles.			Intellectual Product	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Holter ECG Test Code Terminology|CDISC SDTM Holter ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111132>	C83146	Axis and Voltage ECG Assessment|AXISVOLT|AXISVOLT|Axis and Voltage|Axis and Voltage|Axis and Voltage	An electrocardiographic assessment of the mean cardiac electrical vector and ECG voltage.			Intellectual Product	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Holter ECG Test Code Terminology|CDISC SDTM Holter ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111133>	C76204	Bacteroides dorei|BACTEROIDES DOREI	A species of anaerobic, gram-negative, rod shaped bacteria assigned to the phylum Bacteroidetes. This specis is non-spore forming, non-motile, does not hydrolyze esculin, is indole negative and nitrate is not reduced.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111134>	C76204	Bacteroides faecis|BACTEROIDES FAECIS	A species of anaerobic, gram-negative, rod shaped bacteria assigned to the phylum Bacteroidetes. This species is non-motile, spore forming, oxidase, urease and catalase negative, indole positive and hydrolyzes esculin. B. faecis was originally isolated from human feces.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111135>	C74804	B-Cell Activating Factor Measurement|B-Cell Activating Factor|B-Cell Activating Factor|BAFF|TNFSF13B Measurement|Tumor Necrosis Factor Ligand Superfamily Member 13B Measurement	The determination of the amount of B-cell activating factor present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111136>	C64430	Bence-Jones Protein Measurement|BJPROT|Bence Jones Protein Measurement|Bence-Jones Protein|Bence-Jones Protein	The determination of the amount of Bence-Jones protein present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111137>	C49556	Biospecimen Domain|BS|Biospecimen Findings	A findings domain that documents biospecimen handling information.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111138>	C49556	Biospecimen Events Domain|BE|Biospecimen Events	An events domain that documents biospecimen collection and storage information.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111139>	C48470	Biscuit Dosing Unit|BISCUIT|{BISCUIT}|{BISCUIT}|{Biscuit}|{Biscuit}	A dosing unit equal to the amount of ingredient(s) in a biscuit.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11113>	C61063	Carboplatin/Cisplatin/Interferon Alfa/interleukin-2/Paclitaxel|CBDCA/CDDP/IFN-A/IL-2/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111140>	C42578	Block Unit of Distance|BLOCKS|{BLOCKS}|{BLOCKS}	A unit of measure to quantify the number of rectangular areas in a city surrounded by streets that the patient has traveled.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111141>	C22188	Bursa of Fabricius|BURSA OF FABRICIUS	An epithelial outgrowth of lymphoid tissue in the cloaca of young birds, responsible for B-lymphocyte maturation. It undergoes atrophy and involution at six months of age.			Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111142>	C64430	Butyrylcholinesterase Measurement|Acylcholine Acylhydrolase|BCHE Measurement|BUCHE|Butyrylcholinesterase|Butyrylcholinesterase|Non-neuronal Cholinesterase|Plasma Cholinesterase|Pseudocholinesterase	The determination of the amount of total butyrylcholinesterase present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111143>	C64430|C209976	Cancer Antigen 27-29 Measurement|CA2729AG|Cancer Antigen 27-29|Cancer Antigen 27-29	The determination of the amount of cancer antigen 27-29 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111144>	C81971	Cardiolipin IgG Antibody Measurement|Anitcardiolipin IgG Antibody Measurement	The determination of the amount of cardiolipin IgG antibody present in a sample.			Laboratory Procedure	
C111145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111145>	C64430	Cartilage Oligomeric Matrix Protein Measurement|COMP|COMP Measurement|Cartilage Oligomeric Matrix Protein|Cartilage Oligomeric Matrix Protein	The determination of the amount of cartilage oligomeric matrix protein present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111146>	C48938	CD10 Expressing Cell Count|MME Expressing Cell Count|Neprilysin Expressing Cell Count	The determination of the amount of CD10 expressing cells per unit present in a sample.			Laboratory Procedure	
C111147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111147>	C48938	CD13 Expressing Cell Count|ANPEP Expressing Cell Count|Aminopeptidase N Expressing Cell Count	The determination of the amount of CD13 expressing cells per unit present in a sample.			Laboratory Procedure	
C111148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111148>	C48938	CD22 Expressing Cell Count|B-Cell Receptor CD22 Expressing Cell Count	The determination of the amount of CD22 expressing cells per unit present in a sample.			Laboratory Procedure	
C111149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111149>	C48938	CD23 Expressing Cell Count|FCER2 Expressing Cell Count|Low Affinity Immunoglobulin Epsilon Fc Receptor Expressing Cell Count	The determination of the amount of CD23 expressing cells per unit present in a sample.			Laboratory Procedure	
C11114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11114>	C61007	Interleukin-2/Melatonin|IL-2/MLT			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111150>	C48938	CD33 Expressing Cell Count|Myeloid Cell Surface Antigen CD33 Expressing Cell Count|SIGLEC3 Expressing Cell Count|Siglec-3 Expressing Cell Count	The determination of the amount of CD33 expressing cells per unit present in a sample.			Laboratory Procedure	
C111151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111151>	C48938	CD38 Expressing Cell Count|ADP-Ribosyl Cyclase 1 Expressing Cell Count|CD38 Antigen Expressing Cell Count	The determination of the amount of CD38 expressing cells per unit present in a sample.	CD38 Expressing Cell Count		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111152>	C48938	CD79A Expressing Cell Count|B-Cell Antigen Receptor Complex-Associated Protein Alpha Chain Expressing Cell Count	The determination of the amount of CD79A expressing cells per unit present in a sample.			Laboratory Procedure	
C111153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111153>	C48938	Cellularity Measurement|CELLULAR|CELLULAR|Cellularity|Cellularity|Cellularity|Cellularity|Cellularity Grade|Cellularity Index|Cellularity Index|Percent Cellularity	The determination of the amount of degree, quality or condition of cells present in a sample.	Cellularity Index		Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C111154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111154>	C210010	Centromere B Antibody Measurement|CENPB Antibody Measurement|Centromere Protein B Antibody Measurement	A measurement of centromere B antibodies present in a sample.			Laboratory Procedure	
C111155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111155>	C83146	Chamber Hypertrophy or Enlargement ECG Assessment|CHYPTENL|CHYPTENL|Chamber Hypertrophy or Enlargement|Chamber Hypertrophy or Enlargement|Chamber Hypertrophy or Enlargement	An electrocardiographic assessment of chamber hypertrophy or enlargement.			Intellectual Product	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Holter ECG Test Code Terminology|CDISC SDTM Holter ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111156>	C22188	Cheek Pouch|CHEEK POUCH	An evagination of the oral mucosa within the cheek of some mammals, which forms a pocket.			Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111157>	C20985	Chemical Ablation|ABLATION, CHEMICAL	Removal, separation, detachment, extirpation, or eradication of a body part, pathway, or function by chemical means.			Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111158>	C449	Chloroplast DNA|cpDNA|cpDNA	The DNA that is located in the photosynthetic, chlorophyll-containing organelle in the cells of young leaves and stems of higher plants.			Nucleic Acid, Nucleoside, or Nucleotide	CDISC SDTM Genetic Sample Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111159>	C64430	Chymotrypsin Measurement|CHYTRYP|Chymotrypsin|Chymotrypsin	The determination of the amount of chymotrypsin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11115>	C61007	Paclitaxel/Vinorelbine|TAX/VNB	A combination of agents containing paclitaxel and vinorelbine.		Obsolete_Concept	Therapeutic or Preventive Procedure	
C111160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111160>	C210010	Coccidioides Antibody Measurement	The determination of the amount of coccidioides antibody present in a sample.			Laboratory Procedure	
C111161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111161>	C49237	Copper Measurement|COPPER|Copper|Copper|Cu	The determination of the amount of copper present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111162>	C22188	Crop|CROP|Ingluvies|Ingluvies	A saccular diverticulum of the esophagus in bird species that is used for food storage prior to digestion.			Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111163>	C19830	Cross-Linking and Immunoprecipitation|CLIP	A type of immunoprecipitation protocol that employs UV-light induced covalent cross-linking of molecules (for instance protein and RNA) prior to the immunoprecipitation and purification steps.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111164>	C64430	Cryoglobulin Measurement|CRYOGLBN|Cryoglobulin|Cryoglobulin	The determination of the amount of cryoglobulin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111165>	C49237	Cyclic Guanosine Monophosphate Measurement|CGMP|Cyclic Guanosine Monophosphate|Cyclic Guanosine Monophosphate|cGMP Measurement	The determination of the amount of cyclic guanosine 3,5-monophosphate present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111166>	C51950	Cytoplasmic Basophilia Neutrophil Count|Cytoplasmic Basophilia Neutrophil|Cytoplasmic Basophilia Neutrophil|NEUTCYBS	The determination of the amount of neutrophils in a biological specimen showing a dark staining pattern in the cytoplasm due to increased acidic content.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111167>	C92571	Day Times Femtogram per Milliliter per Kilogram per Meter Squared|d.fg/mL/(kg/m2)|d.fg/mL/(kg/m2)|d.fg/ml/(kg/m2)|d.fg/ml/(kg/m2)|day*fg/mL/(kg/m2)|day*fg/mL/(kg/m2)	Days times femtograms per milliliter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111168>	C92571	Day Times Femtogram per Milliliter per Meter Squared|d.fg/mL/m2|d.fg/mL/m2|d.fg/ml/m2|d.fg/ml/m2|day*fg/mL/m2|day*fg/mL/m2	Days times femtograms per milliliter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111169>	C92571	Day Times Gram per Milliliter per Kilogram per Meter Squared|d.g/mL/(kg/m2)|d.g/mL/(kg/m2)|d.g/ml/(kg/m2)|d.g/ml/(kg/m2)|day*g/mL/(kg/m2)|day*g/mL/(kg/m2)	Days times grams per milliliter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11116>	C61063	Asparaginase/Cyclophosphamide/Cytarabine/Etoposide/Mercaptopurine/Methotrexate|ARA-C/ASP/CTX/MP/MTX/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111170>	C92571	Day Times Gram per Milliliter per Meter Squared|d.g/mL/m2|d.g/mL/m2|d.g/ml/m2|d.g/ml/m2|day*g/mL/m2|day*g/mL/m2	Days times grams per milliliter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111171>	C92571	Day Times Microgram per Milliliter per Kilogram per Meter Squared|d.ug/mL/(kg/m2)|d.ug/mL/(kg/m2)|d.ug/ml/(kg/m2)|d.ug/ml/(kg/m2)|day*ug/mL/(kg/m2)|day*ug/mL/(kg/m2)	Days times micrograms per milliliter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111172>	C92571	Day Times Microgram per Milliliter per Meter Squared|d.ug/mL/m2|d.ug/mL/m2|d.ug/ml/m2|d.ug/ml/m2|day*ug/mL/m2|day*ug/mL/m2	Days times micrograms per milliliter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111173>	C92571	Day Times Micromole per Liter per Kilogram per Meter Squared|d.umol/L/(kg/m2)|d.umol/L/(kg/m2)|d.umol/l/(kg/m2)|d.umol/l/(kg/m2)|day*umol/L/(kg/m2)|day*umol/L/(kg/m2)	Days times micromoles per liter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111174>	C92571	Day Times Micromole per Liter per Meter Squared|d.umol/L/m2|d.umol/L/m2|d.umol/l/m2|d.umol/l/m2|day*umol/L/m2|day*umol/L/m2	Days times micromoles per liter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111175>	C92571	Day Times Milligram per Milliliter per Kilogram per Meter Squared|d.mg/mL/(kg/m2)|d.mg/mL/(kg/m2)|d.mg/ml/(kg/m2)|d.mg/ml/(kg/m2)|day*mg/mL/(kg/m2)|day*mg/mL/(kg/m2)	Days times milligrams per milliliter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111176>	C92571	Day Times Milligram per Milliliter per Meter Squared|d.mg/mL/m2|d.mg/mL/m2|d.mg/ml/m2|d.mg/ml/m2|day*mg/mL/m2|day*mg/mL/m2	Days times milligrams per milliliter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111177>	C92571	Day Times Millimole per Liter per Kilogram per Meter Squared|d.mmol/L/(kg/m2)|d.mmol/L/(kg/m2)|d.mmol/l/(kg/m2)|d.mmol/l/(kg/m2)|day*mmol/L/(kg/m2)|day*mmol/L/(kg/m2)	Days times millimoles per liter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111178>	C92571	Day Times Millimole per Liter per Meter Squared|d.mmol/L/m2|d.mmol/L/m2|d.mmol/l/m2|d.mmol/l/m2|day*mmol/L/m2|day*mmol/L/m2	Days times millimoles per liter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111179>	C92571	Day Times Mole per Liter per Kilogram per Meter Squared|d.mol/L/(kg/m2)|d.mol/L/(kg/m2)|d.mol/l/(kg/m2)|d.mol/l/(kg/m2)|day*mol/L/(kg/m2)|day*mol/L/(kg/m2)	Days times moles per liter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11117>	C61007	Cisplatin/Gemcitabine|CDDP/dFdC|Cisplatin-Gemcitabine|Cisplatin-Gemcitabine Regimen|gemcitabine/cisplatin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111180>	C92571	Day Times Mole per Liter per Meter Squared|d.mol/L/m2|d.mol/L/m2|d.mol/l/m2|d.mol/l/m2|day*mol/L/m2|day*mol/L/m2	Days times moles per liter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111181>	C92571	Day Times Nanogram per Milliliter per Kilogram per Meter Squared|d.ng/mL/(kg/m2)|d.ng/mL/(kg/m2)|d.ng/ml/(kg/m2)|d.ng/ml/(kg/m2)|day*ng/mL/(kg/m2)|day*ng/mL/(kg/m2)	Days times nanograms per milliliter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111182>	C92571	Day Times Nanogram per Milliliter per Meter Squared|d.ng/mL/m2|d.ng/mL/m2|d.ng/ml/m2|d.ng/ml/m2|day*ng/mL/m2|day*ng/mL/m2	Days times nanograms per milliliter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111183>	C92571	Day Times Nanomole per Liter per Kilogram per Meter Squared|d.nmol/L/(kg/m2)|d.nmol/L/(kg/m2)|d.nmol/l/(kg/m2)|d.nmol/l/(kg/m2)|day*nmol/L/(kg/m2)|day*nmol/L/(kg/m2)	Days times nanomoles per liter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111184>	C92571	Day Times Nanomole per Liter per Meter Squared|d.nmol/L/m2|d.nmol/L/m2|d.nmol/l/m2|d.nmol/l/m2|day*nmol/L/m2|day*nmol/L/m2	Days times nanomoles per liter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111185>	C92571	Day Times Picogram per Milliliter per Kilogram per Meter Squared|d.pg/mL/(kg/m2)|d.pg/mL/(kg/m2)|d.pg/ml/(kg/m2)|d.pg/ml/(kg/m2)|day*pg/mL/(kg/m2)|day*pg/mL/(kg/m2)	Days times picograms per milliliter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111186>	C92571	Day Times Picogram per Milliliter per Meter Squared|d.pg/mL/m2|d.pg/mL/m2|d.pg/ml/m2|d.pg/ml/m2|day*pg/mL/m2|day*pg/mL/m2	Days times picograms per milliliter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111187>	C92571	Day Times Picomole per Liter|d.pmol/L|d.pmol/L|d.pmol/l|d.pmol/l|day*pmol/L|day*pmol/L	Days times picomoles per liter.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111188>	C92571	Day Times Picomole per Liter per Kilogram per Meter Squared|d.pmol/L/(kg/m2)|d.pmol/L/(kg/m2)|d.pmol/l/(kg/m2)|d.pmol/l/(kg/m2)|day*pmol/L/(kg/m2)|day*pmol/L/(kg/m2)	Days times picomoles per liter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111189>	C92571	Day Times Picomole per Liter per Meter Squared|d.pmol/L/m2|d.pmol/L/m2|d.pmol/l/m2|d.pmol/l/m2|day*pmol/L/m2|day*pmol/L/m2	Days times picomoles per liter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11118>	C61063	Carboplatin/RMP-7|CBDCA/RMP-7			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111190>	C51948	Degenerated Leukocyte Count|DGNWBC|Degenerated Leukocytes|Degenerated Leukocytes|Degenerated WBC|Degenerated White Blood Cells	The determination of the amount of degenerated leukocytes (leukocytes that show deterioration in form or function) present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111191>	C50286	Electrical Lead Locking Type|SECURLD|Secure Lead Type|Secure Lead Type	The type of locking device used to securely fasten the electrical leads to the device.			Functional Concept	CDISC SDTM Device Identifier Parameter Long Name Terminology|CDISC SDTM Device Identifier Parameter Short Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111192>	C15199	Electrocauterization|ELECTROCAUTERIZATION	To destroy tissue using an electrical current. This process may be used to kill certain types of small tumors or to seal off blood vessels to stop bleeding.	Electrocauterization		Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C111193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111193>	C65109	Electrochemiluminescence|ELECTROCHEMILUMINESCENCE	A method in which electromagnetic radiation, in the form of light emission, is generated from an electrochemical reaction in a solution.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111194>	C111235	Electrochemiluminescence Immunoassay|ELECTROCHEMILUMINESCENCE IMMUNOASSAY	A method in which electromagnetic radiation, in the form of light emission, is generated from an electrochemical reaction in a solution due to the formation of antigen-antibody complexes.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111195>	C111096	Enzymatic Colorimetry|ENZYMATIC COLORIMETRY	A type of colorimetry that makes use of an enzymatic reaction to induce a color change.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111196>	C17455	Enzyme Multiplied Immunoassay Technique|EMIT|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE	A type of homogenous immunoassay in which sample is applied to a reagent mixture of enzyme-labeled ligand, antibody, and substrate. Substrate binding to enzyme leads to inactivation and unlabeled-ligand in the sample can be quantified by colorimetric analysis.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111197>	C49286	Erythrocyte Agglutination Measurement|Autoagglutination|Erythrocyte Agglutination|Erythrocyte Agglutination|RBC Agglutination|RBCAGGLU	The determination of the amount of erythrocyte agglutination present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111198>	C134576	Experimental Organism Basal Cell Adenoma|Adenoma, Basal Cell, Benign|BASAL CELL TUMOR, BENIGN	A benign epithelial neoplasm with a uniform, monomorphic appearance that is dominated by basal cells. (SEND)			Classification	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C111199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111199>	C134576	Experimental Organism Basal Cell Carcinoma|BCC|Basal Cell Cancer|Basal Cell Carcinoma|Basal Cell Epithelioma|Basal Cell Skin Carcinoma|CARCINOMA, BASAL CELL, MALIGNANT	A malignant epithelial neoplasm arising from basal cells. (SEND)			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C11119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11119>	C61063	Epirubicin/Vinorelbine|EPI/VNB			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111200>	C38081	Expiratory Reserve Volume|ERV|ERV	The maximum volume of air a subject can exhale from the lungs after a tidal exhalation.			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111201>	C96570|C71390	Full Brother|BROTHER, FULL	A male who shares with his sibling the genetic makeup inherited from both of the biological parents.			Human	CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C111202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111202>	C96586|C71390	Full Sister|SISTER, FULL	A female who shares with her sibling the genetic makeup inherited from both of the biological parents.			Human	CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C111203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111203>	C17156	Gas Chromatography Mass Spectrometry|GC/MS|GC/MS|Gas Chromatography/Mass Spectrometry	An analytical technique wherein gas chromatography is coupled to mass spectrometry in order to separate, identify, and quantify substances in a sample.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111204>	C86425	Granulicatella elegans|Abiotrophia elegans|Abiotrophia elegans|GRANULICATELLA ELEGANS	A species of facultative anaerobic, gram-positive, cocci shaped bacteria assigned to the phylum Firmicutes. This species is non-motile, non-spore forming and catalase and oxidase negative. G. elegans is commensal, being found in normal human oral flora, but may be associated with infective endocarditis.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111205>	C23044	Hansel Staining Method|HANSEL STAIN	A microscopy staining method that utilizes Hansel reagent to differentiate eosinophils and neutrophils in a specimen. (NCI)			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111206>	C67208	Heinz Body to Erythrocyte Ratio Measurement|HEINZRBC|Heinz Bodies/Erythrocytes|Heinz Bodies/Erythrocytes	The determination of the ratio of the erythrocytes that contain heinz bodies compared to total erythrocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111207>	C64848	Hemoglobin A1C to Hemoglobin Ratio Measurement|Glycated Hemoglobin/Hemoglobin|HBA1CHGB|HbA1c/Hemoglobin|Hemoglobin A1C/Hemoglobin|Hemoglobin A1C/Hemoglobin	The determination of the ratio of the  glycated hemoglobin A1C to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111208>	C49286	Hemolytic Index|HEMOLYSI|Hemolysis	The determination of the amount of destruction of red blood cells present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111209>	C210010	Histone Antibody Measurement	A measurement of histone antibodies present in a sample.			Laboratory Procedure	
C11120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11120>	C61063	Allovectin-7/Interleukin-2|allovectin-7/IL-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111210>	C92571	Hour Times Femtogram per Milliliter per Kilogram per Meter Squared|h*fg/mL/(kg/m2)|h*fg/mL/(kg/m2)|h.fg/mL/(kg/m2)|h.fg/mL/(kg/m2)|h.fg/ml/(kg/m2)|h.fg/ml/(kg/m2)	Hours times femtograms per milliliter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111211>	C92571	Hour Times Femtogram per Milliliter per Meter Squared|h*fg/mL/m2|h*fg/mL/m2|h.fg/mL/m2|h.fg/mL/m2|h.fg/ml/m2|h.fg/ml/m2	Hours times femtograms per milliliter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111212>	C92571	Hour Times Gram per Milliliter per Kilogram per Meter Squared|h*g/mL/(kg/m2)|h*g/mL/(kg/m2)|h.g/mL/(kg/m2)|h.g/mL/(kg/m2)|h.g/ml/(kg/m2)|h.g/ml/(kg/m2)	Hours times grams per milliliter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111213>	C92571	Hour Times Gram per Milliliter per Meter Squared|h*g/mL/m2|h*g/mL/m2|h.g/mL/m2|h.g/mL/m2|h.g/ml/m2|h.g/ml/m2	Hours times grams per milliliter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111214>	C92571	Hour Times Microgram per Milliliter per Kilogram per Meter Squared|h*ug/mL/(kg/m2)|h*ug/mL/(kg/m2)|h.ug/mL/(kg/m2)|h.ug/mL/(kg/m2)|h.ug/ml/(kg/m2)|h.ug/ml/(kg/m2)	Hours times micrograms per milliliter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111215>	C92571	Hour Times Microgram per Milliliter per Meter Squared|h*ug/mL/m2|h*ug/mL/m2|h.ug/mL/m2|h.ug/mL/m2|h.ug/ml/m2|h.ug/ml/m2	Hours times micrograms per milliliter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111216>	C92571	Hour Times Micromole per Liter per Kilogram per Meter Squared|h*umol/L/(kg/m2)|h*umol/L/(kg/m2)|h.umol/L/(kg/m2)|h.umol/L/(kg/m2)|h.umol/l/(kg/m2)|h.umol/l/(kg/m2)	Hours times micromoles per liter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111217>	C92571	Hour Times Micromole per Liter per Meter Squared|h*umol/L/m2|h*umol/L/m2|h.umol/L/m2|h.umol/L/m2|h.umol/l/m2|h.umol/l/m2	Hours times micromoles per liter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111218>	C92571	Hour Times Milligram per Milliliter per Kilogram per Meter Squared|h*mg/mL/(kg/m2)|h*mg/mL/(kg/m2)|h.mg/mL/(kg/m2)|h.mg/mL/(kg/m2)|h.mg/ml/(kg/m2)|h.mg/ml/(kg/m2)	Hours times milligrams per milliliter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111219>	C92571	Hour Times Milligram per Milliliter per Meter Squared|h*mg/mL/m2|h*mg/mL/m2|h.mg/mL/m2|h.mg/mL/m2|h.mg/ml/m2|h.mg/ml/m2	Hours times milligrams per milliliter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11121>	C61063	Cyclophosphamide/Losoxantrone|CTX/DuP-941			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111220>	C92571	Hour Times Millimole per Liter per Kilogram per Meter Squared|h*mmol/L/(kg/m2)|h*mmol/L/(kg/m2)|h.mmol/L/(kg/m2)|h.mmol/L/(kg/m2)|h.mmol/l/(kg/m2)|h.mmol/l/(kg/m2)	Hours times millimoles per liter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111221>	C92571	Hour Times Millimole per Liter per Meter Squared|h*mmol/L/m2|h*mmol/L/m2|h.mmol/L/m2|h.mmol/L/m2|h.mmol/l/m2|h.mmol/l/m2	Hours times millimoles per liter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111222>	C92571	Hour Times Mole per Liter per Kilogram per Meter Squared|h*mol/L/(kg/m2)|h*mol/L/(kg/m2)|h.mol/L/(kg/m2)|h.mol/L/(kg/m2)|h.mol/l/(kg/m2)|h.mol/l/(kg/m2)	Hours times moles per liter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111223>	C92571	Hour Times Mole per Liter per Meter Squared|h*mol/L/m2|h*mol/L/m2|h.mol/L/m2|h.mol/L/m2|h.mol/l/m2|h.mol/l/m2	Hours times moles per liter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111224>	C92571	Hour Times Nanogram per Milliliter per Kilogram per Meter Squared|h*ng/mL/(kg/m2)|h*ng/mL/(kg/m2)|h.ng/mL/(kg/m2)|h.ng/mL/(kg/m2)|h.ng/ml/(kg/m2)|h.ng/ml/(kg/m2)	Hours times nanograms per milliliter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111225>	C92571	Hour Times Nanogram per Milliliter per Meter Squared|h*ng/mL/m2|h*ng/mL/m2|h.ng/mL/m2|h.ng/mL/m2|h.ng/ml/m2|h.ng/ml/m2	Hours times nanograms per milliliter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111226>	C92571	Hour Times Nanomole per Liter per Kilogram per Meter Squared|h*nmol/L/(kg/m2)|h*nmol/L/(kg/m2)|h.nmol/L/(kg/m2)|h.nmol/L/(kg/m2)|h.nmol/l/(kg/m2)|h.nmol/l/(kg/m2)	Hours times nanomoles per liter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111227>	C92571	Hour Times Nanomole per Liter per Meter Squared|h*nmol/L/m2|h*nmol/L/m2|h.nmol/L/m2|h.nmol/L/m2|h.nmol/l/m2|h.nmol/l/m2	Hours times nanomoles per liter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111228>	C92571	Hour Times Picogram per Milliliter per Kilogram per Meter Squared|h*pg/mL/(kg/m2)|h*pg/mL/(kg/m2)|h.pg/mL/(kg/m2)|h.pg/mL/(kg/m2)|h.pg/ml/(kg/m2)|h.pg/ml/(kg/m2)	Hours times picograms per milliliter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111229>	C92571	Hour Times Picogram per Milliliter per Meter Squared|h*pg/mL/m2|h*pg/mL/m2|h.pg/mL/m2|h.pg/mL/m2|h.pg/ml/m2|h.pg/ml/m2	Hours times picograms per milliliter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11122>	C61007	Doxorubicin/Losoxantrone|DOX/DuP-941			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111230>	C92571	Hour Times Picomole per Liter per Kilogram per Meter Squared|h*pmol/L/(kg/m2)|h*pmol/L/(kg/m2)|h.pmol/L/(kg/m2)|h.pmol/L/(kg/m2)|h.pmol/l/(kg/m2)|h.pmol/l/(kg/m2)	Hours times picomoles per liter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111231>	C92571	Hour Times Picomole per Liter per Meter Squared|h*pmol/L/m2|h*pmol/L/m2|h.pmol/L/m2|h.pmol/L/m2|h.pmol/l/m2|h.pmol/l/m2	Hours times picomoles per liter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111232>	C49237	Icteric Index|ICTERUSI|Icterus	The determination of the amount of yellow color of a biological specimen, due to the presence of bile pigments.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111233>	C81869	IgG IgM IgA Total Measurement|IGAGM|IgG IgM IgA Total|IgG IgM IgA Total|Quantitative Immunoglobulins|Total Ig|Total Immunoglobulins Measurement	The determination of the total amount of IgG, IgM, and IgA present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|SeroNet Assay Metadata|SeroNet Authorized Values
C111234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111234>	C67208	Immature Cell to Total Cell Ratio Measurement|CEIMCE|Immature Cells to Total Cells Ratio Measurement|Immature Cells/Total Cells|Immature Cells/Total Cells	The determination of the ratio of the immature hematopoietic cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111235>	C225692	Chemiluminescent Immunoassay|CLIA|CLIA|Chemiluminescence Immunoassay|ICMA|ICMA|IMMUNOCHEMILUMINOMETRIC ASSAY|Immunochemiluminometric Assay	A type of immunoassay in which the antigen-antibody complex is quantified using light emission, which is generated from a chemical reaction.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|SeroNet Authorized Values|SeroNet Study Descriptors
C111236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111236>	C17057	Immunoradiometric Assay|IMMUNORADIOMETRIC ASSAY|IRMA	A type of antibody-excess, non-competition radioimmunometric assay in which ligand is sandwiched between an immobilized antibody on a solid phase and a radiolabeled antibody raised against a different epitope of the ligand.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111237>	C38081	Inspiratory Reserve Volume|IRV|IRV	The maximum volume of air a subject can inhale into the lungs after a tidal inhalation.			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111238>	C83146	Intraventricular and Intraatrial Conduction ECG Assessment|IVTIACD|IVTIACD|Intraventricular-Intraatrial Conduction|Intraventricular-Intraatrial Conduction|Intraventricular-Intraatrial Conduction	An electrocardiographic assessment of the transmission of electrical impulses through the cardiac atria and ventricles.			Intellectual Product	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Holter ECG Test Code Terminology|CDISC SDTM Holter ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111239>	C49237	Ketone Body Measurement|KETONEBD|Ketone Bodies|Ketone Bodies	The determination of the amount of ketone bodies (acetone, acetoacetic acid, beta-hydroxybutyric acid, beta-ketopentanoate and beta-hydroxypentanoate) present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11123>	C61063	Cyclophosphamide/Daunorubicin|CTX/DNR|Cyclophosphamide/Daunomycin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111240>	C116640	Kinetic Microparticle Immunoassay|KINETIC MICROPARTICLE IMMUNOASSAY	A type of immunoassay in which the antigen of interest found in a biological specimen competes with a lattice of antigen-antibody complexes. Competing antigen inhibits lattice formation and decreases absorbance in proportion to the amount of antigen present in a biological specimen.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111241>	C20985	Laser Ablation|ABLATION, LASER|Photoablation	Removal, separation, detachment, extirpation, or eradication of a body part, pathway, or function by light amplification by stimulated emission of radiation.	Laser Ablation		Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C111242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111242>	C74949	Lipemic Index|LIPEMIAI|Lipemia	The determination of the amount of abnormally high concentration of lipid present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111243>	C64430	Macroamylase Measurement|AMYLASEM|Macroamylase|Macroamylase	A measurement of macroamylase present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111244>	C67208	Macrophage to Total Cell Ratio Measurement|MCPHGCE|MCPHGCE|Macrophages to Total Cells Ratio Measurement|Macrophages/Total Cells|Macrophages/Total Cells|Macrophages/Total Cells	The determination of the ratio of the macrophages compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Cell Phenotyping Test Code Terminology|CDISC SDTM Cell Phenotyping Test Name Terminology|CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111245>	C111095	Manual Clot Detection|MANUAL CLOT DETECTION	A clot detection method that uses a manual means (visual discernment) to detect the presence and/or quantify the formation of a thrombus in a specimen.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111246>	C48938	Mast Cell Count|MASTCE|MASTCE|Mast Cells|Mast Cells|Mast Cells|Mastocytes	The determination of the amount of mast cells present in a sample.			Laboratory Procedure	CDISC SDTM Cell Phenotyping Test Code Terminology|CDISC SDTM Cell Phenotyping Test Name Terminology|CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111247>	C67208	Mast Cell to Total Cell Ratio Measurement|MASTCECE|MASTCECE|MASTCECE|Mast Cells to Total Cells Ratio Measurement|Mast Cells/Total Cells|Mast Cells/Total Cells|Mast Cells/Total Cells|Mast Cells/Total Cells	The determination of the ratio of the mast cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Cell Phenotyping Test Code Terminology|CDISC SDTM Cell Phenotyping Test Name Terminology|CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111248>	C71383|C100806	Maternal Biological Grandparent|GRANDPARENT, BIOLOGICAL MATERNAL	A relative who is the biological parent of the biological mother.			Human	CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C111249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111249>	C111095	Mechanical Clot Detection|MECHANICAL CLOT DETECTION	A clot detection method that uses a mechanical means (electromagnetic mechanical or electromechanical) to detect the presence and/or quantify the formation of a thrombus in a specimen.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11124>	C61063	Asparaginase/Cytarabine/Methotrexate|ARA-C/ASP/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111250>	C48938	Meningeal Cell Count|MENGL|Meningeal Cells|Meningeal Cells	The determination of the amount of meningeal cells present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111251>	C67208	Meningeal Cell to Total Cell Ratio Measurement|MENGLCE|Meningeal Cells to Total Cells Ratio Measurement|Meningeal Cells/Total Cells|Meningeal Cells/Total Cells	The determination of the ratio of the meningeal cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111252>	C17455	Microparticle Enzyme Immunoassay|MEIA|MICROPARTICLE ENZYME IMMUNOASSAY	A type of enzyme immunoassay that uses antigen-coated microparticles as a substrate for antibody binding.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111253>	C70454	Millimole per Mole|Femtomole per Picomole|Micromole per Millimole|Nanomole per Micromole|Picomole per Nanomole|fmol/pmol|micromole per millimole|millimole per mole|mmol/mol|mmol/mol|mmol/mol|mmol/mol|nmol/umol|pmol/nmol|umol/mmol|umol/mmol|umol/mmol	A unit of fraction expressed as the ratio of the amount of substance of solute in millimoles to the amount of substance of the mixture in moles.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C111254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111254>	C92571	Minute Times Femtogram per Milliliter per Kilogram per Meter Squared|min*fg/mL/(kg/m2)|min*fg/mL/(kg/m2)|min.fg/mL/(kg/m2)|min.fg/mL/(kg/m2)|min.fg/ml/(kg/m2)|min.fg/ml/(kg/m2)	Minutes times femtograms per milliliter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111255>	C92571	Minute Times Femtogram per Milliliter per Meter Squared|min*fg/mL/m2|min*fg/mL/m2|min.fg/mL/m2|min.fg/mL/m2|min.fg/ml/m2|min.fg/ml/m2	Minutes times femtograms per milliliter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111256>	C92571	Minute Times Gram per Milliliter per Kilogram per Meter Squared|min*g/mL/(kg/m2)|min*g/mL/(kg/m2)|min.g/mL/(kg/m2)|min.g/mL/(kg/m2)|min.g/ml/(kg/m2)|min.g/ml/(kg/m2)	Minutes times grams per milliliter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111257>	C92571	Minute Times Gram per Milliliter per Meter Squared|min*g/mL/m2|min*g/mL/m2|min.g/mL/m2|min.g/mL/m2|min.g/ml/m2|min.g/ml/m2	Minutes times grams per milliliter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111258>	C92571	Minute Times Microgram per Milliliter per Kilogram per Meter Squared|min*ug/mL/(kg/m2)|min*ug/mL/(kg/m2)|min.ug/mL/(kg/m2)|min.ug/mL/(kg/m2)|min.ug/ml/(kg/m2)|min.ug/ml/(kg/m2)	Minutes times micrograms per milliliter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111259>	C92571	Minute Times Microgram per Milliliter per Meter Squared|min*ug/mL/m2|min*ug/mL/m2|min.ug/mL/m2|min.ug/mL/m2|min.ug/ml/m2|min.ug/ml/m2	Minutes times micrograms per milliliter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11125>	C61063	Daunorubicin/Dexamethasone|DM/DNR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111260>	C92571	Minute Times Micromole per Liter per Kilogram per Meter Squared|min*umol/L/(kg/m2)|min*umol/L/(kg/m2)|min.umol/L/(kg/m2)|min.umol/L/(kg/m2)|min.umol/l/(kg/m2)|min.umol/l/(kg/m2)	Minutes times micromoles per liter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111261>	C92571	Minute Times Micromole per Liter per Meter Squared|min*umol/L/m2|min*umol/L/m2|min.umol/L/m2|min.umol/L/m2|min.umol/l/m2|min.umol/l/m2	Minutes times micromoles per liter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111262>	C92571	Minute Times Milligram per Milliliter per Kilogram per Meter Squared|min*mg/mL/(kg/m2)|min*mg/mL/(kg/m2)|min.mg/mL/(kg/m2)|min.mg/mL/(kg/m2)|min.mg/ml/(kg/m2)|min.mg/ml/(kg/m2)	Minutes times milligrams per milliliter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111263>	C92571	Minute Times Milligram per Milliliter per Meter Squared|min*mg/mL/m2|min*mg/mL/m2|min.mg/mL/m2|min.mg/mL/m2|min.mg/ml/m2|min.mg/ml/m2	Minutes times milligrams per milliliter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111264>	C92571	Minute Times Millimole per Liter per Kilogram per Meter Squared|min*mmol/L/(kg/m2)|min*mmol/L/(kg/m2)|min.mmol/L/(kg/m2)|min.mmol/L/(kg/m2)|min.mmol/l/(kg/m2)|min.mmol/l/(kg/m2)	Minutes times millimoles per liter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111265>	C92571	Minute Times Millimole per Liter per Meter Squared|min*mmol/L/m2|min*mmol/L/m2|min.mmol/L/m2|min.mmol/L/m2|min.mmol/l/m2|min.mmol/l/m2	Minutes times millimoles per liter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111266>	C92571	Minute Times Mole per Liter per Kilogram per Meter Squared|min*mol/L/(kg/m2)|min*mol/L/(kg/m2)|min.mol/L/(kg/m2)|min.mol/L/(kg/m2)|min.mol/l/(kg/m2)|min.mol/l/(kg/m2)	Minutes times moles per liter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111267>	C92571	Minute Times Mole per Liter per Meter Squared|min*mol/L/m2|min*mol/L/m2|min.mol/L/m2|min.mol/L/m2|min.mol/l/m2|min.mol/l/m2	Minutes times moles per liter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111268>	C92571	Minute Times Nanogram per Milliliter per Kilogram per Meter Squared|min*ng/mL/(kg/m2)|min*ng/mL/(kg/m2)|min.ng/mL/(kg/m2)|min.ng/mL/(kg/m2)|min.ng/ml/(kg/m2)|min.ng/ml/(kg/m2)	Minutes times nanograms per milliliter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111269>	C92571	Minute Times Nanogram per Milliliter per Meter Squared|min*ng/mL/m2|min*ng/mL/m2|min.ng/mL/m2|min.ng/mL/m2|min.ng/ml/m2|min.ng/ml/m2	Minutes times nanograms per milliliter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11126>	C61063	Fluorouracil/Octreotide Pamoate|5-FU/SMS 201-995 pa			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111270>	C92571	Minute Times Nanomole per Liter per Kilogram per Meter Squared|min*nmol/L/(kg/m2)|min*nmol/L/(kg/m2)|min.nmol/L/(kg/m2)|min.nmol/L/(kg/m2)|min.nmol/l/(kg/m2)|min.nmol/l/(kg/m2)	Minutes times nanomoles per liter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111271>	C92571	Minute Times Nanomole per Liter per Meter Squared|min*nmol/L/m2|min*nmol/L/m2|min.nmol/L/m2|min.nmol/L/m2|min.nmol/l/m2|min.nmol/l/m2	Minutes times nanomoles per liter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111272>	C92571	Minute Times Picogram per Milliliter per Kilogram per Meter Squared|min*pg/mL/(kg/m2)|min*pg/mL/(kg/m2)|min.pg/mL/(kg/m2)|min.pg/mL/(kg/m2)|min.pg/ml/(kg/m2)|min.pg/ml/(kg/m2)	Minutes times picograms per milliliter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111273>	C92571	Minute Times Picogram per Milliliter per Meter Squared|min*pg/mL/m2|min*pg/mL/m2|min.pg/mL/m2|min.pg/mL/m2|min.pg/ml/m2|min.pg/ml/m2	Minutes times picograms per milliliter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111274>	C92571	Minute Times Picomole per Liter per Kilogram per Meter Squared|min*pmol/L/(kg/m2)|min*pmol/L/(kg/m2)|min.pmol/L/(kg/m2)|min.pmol/L/(kg/m2)|min.pmol/l/(kg/m2)|min.pmol/l/(kg/m2)	Minutes times picomoles per liter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111275>	C92571	Minute Times Picomole per Liter per Meter Squared|min*pmol/L/m2|min*pmol/L/m2|min.pmol/L/m2|min.pmol/L/m2|min.pmol/l/m2|min.pmol/l/m2	Minutes times picomoles per liter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111276>	C48938	Monocytoid Cell Count|MOCYCE|Monocytoid Cells|Monocytoid Cells	The determination of the amount of monocytoid cells present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111277>	C67208	Monocytoid Cell to Total Cell Ratio Measurement|MOCYCECE|Monocytoid Cells to Total Cells Ratio Measurement|Monocytoid Cells/Total Cells|Monocytoid Cells/Total Cells	The determination of the ratio of the monocytoid cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111278>	C26549	msdRNA|MSR|MSR	The RNA portion of the msDNA molecule, which contains two stem-loop structures and varies widely in length across bacterial species.			Nucleic Acid, Nucleoside, or Nucleotide	CDISC SDTM Genetic Sample Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111279>	C706	Multicopy Single-stranded DNA|msDNA|msDNA	A DNA/RNA chimera comprised of a single-stranded DNA molecule covalently bound to an internal guanosine of a RNA molecule.			Nucleic Acid, Nucleoside, or Nucleotide	CDISC SDTM Genetic Sample Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11127>	C61063	9-cis-Retinoic Acid/Tamoxifen|9-CRA/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111280>	C83146	Myocardial Infarction ECG Assessment|MI|MI|Myocardial Infarction|Myocardial Infarction|Myocardial Infarction	An electrocardiographic assessment of findings that suggest the occurrence of a myocardial infarction.			Intellectual Product	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Holter ECG Test Code Terminology|CDISC SDTM Holter ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111281>	C65109	Nephelometry|NEPHELOMETRY	A method to quantify the concentration of particulate matter suspended in a liquid or gas using a nephelometer.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111282>	C49556	Non-Compliant ADaM Datasets Domain	An analysis domain that contains analyses done on non-compliant ADaM datasets.			Idea or Concept	
C111283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111283>	C150841	Nucleated Thrombocyte Count|Nucleated Thrombocytes|THROMNUC|Thrombocytes|Thrombocytes	The determination of the amount of nucleated thrombocytes present in a sample. This is typically measured in birds and other non-mammalian vertebrates.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111284>	C49237	Oxygen Measurement|O2CT|Oxygen Content|Oxygen Content	The determination of the amount of oxygen content present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111285>	C83146	Pacemaker ECG Assessment|PACEMAKR|PACEMAKR|Pacemaker|Pacemaker|Pacemaker	An electrocardiographic assessment of the rate of firing of a an artificial, mechanical pacemaker.			Intellectual Product	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Holter ECG Test Code Terminology|CDISC SDTM Holter ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111286>	C132451|C100806	Paternal Biological Grandparent|GRANDPARENT, BIOLOGICAL PATERNAL	A relative who is the biological parent of the biological father.			Human	CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C111287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111287>	C32674	Periurethral Region|PERIURETHRAL REGION	The area surrounding the urethra.			Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111289>	C103175	Pharmacogenomics Findings Domain	A findings domain for gene expression and genetic variation assessments.			Idea or Concept	
C11128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11128>	C61063	Dexrazoxane/Doxorubicin/Paclitaxel|ADR-529/DOX/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111290>	C49556	Pharmacogenomics Trial Characteristics Domain	A special purpose domain that contains design parameters used in performing pharmacogenomic assessments.			Idea or Concept	
C111291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111291>	C111095	Photometric Clot Detection|Optical Density Clot Detection|PHOTOMETRIC CLOT DETECTION	A clot detection method that uses a photometric means (measuring the absorbancy of monochromatic light) to detect the presence and/or quantify the formation of a thrombus in a specimen.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111292>	C96623	Platelet Activating Factor Measurement|PAF|Platelet Activating Factor|Platelet Activating Factor	The determination of the amount of platelet activating factor present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111293>	C49286	Platelet Aggregation Amplitude Measurement|PLTAGAMP|Platelet Aggregation Amplitude|Platelet Aggregation Amplitude	The determination of the amount or magnitude of the platelet aggregation present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111294>	C49286	Platelet Component Distribution Width Measurement|PCDW|Platelet Component Distribution Width|Platelet Component Distribution Width	The determination of the amount of platelet shape changes present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111295>	C49286	Platelet Function Closure Time Measurement|PFCT|PFCT|Platelet Function Closure Time|Platelet Function Closure Time	The determination of the collagen closure time, as a surrogate of platelet function, present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111296>	C49286|C184342	Platelet Morphology Measurement|PLTMORPH|Platelet Morphology|Platelet Morphology	An examination or assessment of the form and structure of platelets.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111297>	C17007	Positron Emission Tomography and Single Photon Emission Computed Tomography Scan|PET/SPECT SCAN	An imaging technique that utilizes positron emission tomography and single-photon emission computed tomography in a single machine.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111298>	C26548	Precursor mRNA|pre-mRNA|pre-mRNA	A primary RNA transcript synthesized from a DNA template in eukaryotic nuclei which is post-transcriptionally modified and spliced to produce a mature mRNA.			Nucleic Acid, Nucleoside, or Nucleotide	CDISC SDTM Genetic Sample Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111299>	C74788	Proinsulin to Insulin Ratio Measurement|PRINSINS|Proinsulin/Insulin Ratio|Proinsulin/Insulin Ratio	The determination of the ratio of the proinsulin compared to insulin present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11129>	C61063	Dexrazoxane/Doxorubicin/Filgrastim/Paclitaxel|ADR-529/DOX/G-CSF/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1112>	C1003	Geldanamycin|Antibiotic (U-29,135)|Antibiotic U 29135|GELDANAMYCIN|GELDANAMYCIN	A benzoquinone antineoplastic antibiotic isolated from the bacterium Streptomyces hygroscopicus.  Geldanamycin binds to and inhibits the cytosolic chaperone functions of heat shock protein 90 (HSP90).  HSP90 maintains the stability and functional shape of many oncogenic signaling proteins; the inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins that may be over-expressed or overactive in tumor cells. (NCI04)			Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C111300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111300>	C49556	Protocol Summary for Pharmacogenomic Assessments Domain	A special purpose domain that contains the protocol summary information for pharmacogenomics assessments.			Idea or Concept	
C111301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111301>	C22188	Proventriculus|PROVENTRICULUS	A portion of the digestive system of birds, insects and invertebrates lying between the crop and the gizzard. It is responsible for the secretion of gastric enzymes and moving food into the gizzard.			Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111302>	C86712	Ralstonia mannitolilytica|Pseudomonas thomasii|RALSTONIA MANNITOLILYTICA|Ralstonia pickettii biovar 3	A species of xaerobic, gram-negative, rod shaped bacteria assigned to the phylum Proteobacteria. This species is urease, catalase and oxidase positive, does not reduce nitrate and acidifies D-arabitol and mannitol. This species was formerly, incorrectly identified as R. pickettii and is associated with nosocomial infections.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111303>	C47925	Reconstruction of Raw Data Type|RECONDAT	The type of mathematical process used to produce the displayed image from the raw k-space data obtained from the receiver circuitry.			Functional Concept	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111304>	C65109	Refractometry|REFRACTOMETRY	A method to measure the refractive index (propensity for light to bend) of a sample.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111305>	C74893	Renin Activity Measurement|RENINA|Renin Activity|Renin Activity	The determination of the amount of renin activity present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111306>	C25404	Reprogram|REPROGRAMMING|Reprogrammed|Reprogramming	The act of rewritting program code or application software.			Activity	CDISC SDTM Device Events Action Taken with Device Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111307>	C83146	Rhythm Not Otherwise Specified ECG Assessment|RHYNOS|RHYNOS|Rhythm Not Otherwise Specified|Rhythm Not Otherwise Specified|Rhythm Not Otherwise Specified	An electrocardiographic assessment of a cardiac rhythm that is not specified in a particular list.			Intellectual Product	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Holter ECG Test Code Terminology|CDISC SDTM Holter ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111308>	C32889	Scapulohumeral Joint|JOINT, SCAPULOHUMERAL	The synovial ball and socket joint involving the articulation of the glenoid fossa of the scapula and the head of the humerus.			Anatomical Structure	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111309>	C53297	Scheduled Maintenance|SCHEDULED MAINTENANCE	An inspection and/or surveillance activity that has been anticipated to occur and was assigned a time or date when that activity is to be performed.			Activity	CDISC SDTM Device Events Category Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11130>	C61063	Amsacrine/Carmustine/Cytarabine/Etoposide|AMSA/ARA-C/BCNU/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111310>	C62164	Semi-Recumbent|Inclined|SEMI-RECUMBENT|Semi-Supine	A semi-sitting or semi-reclined body position in which the head is elevated to some degree above horizontal.			Spatial Concept	CDISC SDTM Body Position Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C111311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111311>	C449	Single-stranded DNA|SINGLE STRANDED DNA|ssDNA|ssDNA	A long linear single-stranded polymer formed from nucleotides attached to a deoxyribose backbone.			Nucleic Acid, Nucleoside, or Nucleotide	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Genetic Sample Type Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111312>	C83146	Sinus Node Rhythm and Arrhythmia ECG Assessment|SNRARRY|SNRARRY|SNRARRY|Sinus Node Rhythms and Arrhythmias|Sinus Node Rhythms and Arrhythmias|Sinus Node Rhythms and Arrhythmias|Sinus Node Rhythms and Arrhythmias	An electrocardiographic assessment of the typical and atypical cardiac rhythms originating from the sinoatrial node.			Intellectual Product	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Holter ECG Test Code Terminology|CDISC SDTM Holter ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111313>	C111098	Slackia exigua|Eubacterium exiguum|Eubacterium exiguum|SLACKIA EXIGUA	A species of obligately anaerobic, gram-positive, rod shaped bacteria assigned to the phylum Actinobacteria. This species is non-motile, non-spore forming, indole, urease and catalase negative, non-hemolytic, does not hydrolyze esculin and nitrate is note reduced. S. exigua was previously classified as Eubacterium exiguum.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111314>	C25337	Slice Number|SLICNUM	The numeric identifier used to identify an image slice.			Quantitative Concept	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111315>	C38081	Slow Vital Capacity|SVC|SVC	The maximum volume of air that can be exhaled after slow maximum inhalation.			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111316>	C26549	Small Nucleolar RNA|SMALL NUCLEOLAR RNA|snoRNA|snoRNA|snoRNA	Small RNA molecules that are present in the nucleolus. They associate with proteins to form small nucleolar ribonucleoprotein particles that are involved in modification of other RNAs.			Nucleic Acid, Nucleoside, or Nucleotide	CDISC SDTM Genetic Sample Type Terminology|CDISC SDTM Genomic Symbol Type Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111317>	C210010	Smooth Muscle Antibody Measurement	The determination of the amount of smooth muscle antibody present in a sample.			Laboratory Procedure	
C111318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111318>	C42578	Step Unit of Distance|STEPS|{STEP}|{STEP}|{Step}|{Step}	A unit of measure to quantify the number of strides taken during a normal walking gait.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11131>	C61063	Cyclophosphamide/Etoposide/Mitoxantrone|CTX/DHAD/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111320>	C83146	Supraventricular Arrhythmia ECG Assessment|SPRARRY|SPRARRY|SPRARRY|Supraventricular Arrhythmias|Supraventricular Arrhythmias|Supraventricular Arrhythmias|Supraventricular Arrhythmias	An electrocardiographic assessment of the atypical cardiac rhythms originating in the atrium, AV node or AV junction.			Intellectual Product	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Holter ECG Test Code Terminology|CDISC SDTM Holter ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111321>	C83146	Supraventricular Tachyarrhythmia ECG Assessment|SPRTARRY|SPRTARRY|SPRTARRY|Supraventricular Tachyarrhythmias|Supraventricular Tachyarrhythmias|Supraventricular Tachyarrhythmias|Supraventricular Tachyarrhythmias	An electrocardiographic assessment of the abnormally fast cardiac rhythms originating above the ventricles.			Intellectual Product	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Holter ECG Test Code Terminology|CDISC SDTM Holter ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111322>	C64430	Surfactant Protein D Measurement|SFTPD|SP-D|Surfactant Protein D|Surfactant Protein D	The determination of the amount of surfactant protein D present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111323>	C22188	Syrinx|SYRINX	The vocal organ of a bird that is located in the lower portion of the larynx.			Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111324>	C38081	Tidal Volume|TIDALVOL|TV|TV	The volume of air moved into and out of the lungs during breathing at rest.			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Respiratory Test Code Terminology|CDISC SEND Respiratory Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111325>	C38081	Total Lung Capacity|Lung volume test|TLC|TLC|TLUNGCAP|Total lung capacity	The total volume of air in the lungs after maximum inhalation.			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Respiratory Test Code Terminology|CDISC SEND Respiratory Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL Authorized Value Terminology|HL Function Test Table
C111326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111326>	C38114	Transmammary Route of Administration|TRANSMAMMARY|Transmammary	Administration into the body through colostrum or milk.			Functional Concept	CDISC SDTM Route of Administration Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EDQM Health Care Terminology|EDQM-HC Routes and Methods of Administration Terminology
C111327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111327>	C64430	Troponin Measurement|TROPONIN|Troponin|Troponin	The determination of the amount of total troponin present in a sample.	Troponin Measurement		Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111328>	C65109	Turbidimetry|TURBIDIMETRY	A method to quantify the opaqueness of a liquid using a turbidimeter, by measuring the decrease in light intensity due to the scattering effect of suspended particles in the liquid sample.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111329>	C48938	Vacuolated Lymphocyte Count|LYMVAC|Vacuolated Lymphocytes|Vacuolated Lymphocytes	The determination of the amount of vacuolated lymphocytes present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11132>	C61063	Fluorouracil/Leucovorin Calcium/Topotecan|CF/5-FU/TOPO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111330>	C83146	Ventricular Arrhythmia ECG Assessment|VTARRY|VTARRY|VTARRY|Ventricular Arrhythmias|Ventricular Arrhythmias|Ventricular Arrhythmias|Ventricular Arrhythmias	An electrocardiographic assessment of the atypical cardiac rhythms originating in the ventricle.			Intellectual Product	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Holter ECG Test Code Terminology|CDISC SDTM Holter ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111331>	C83146	Ventricular Tachyarrhythmia ECG Assessment|VTTARRY|VTTARRY|VTTARRY|Ventricular Tachyarrhythmias|Ventricular Tachyarrhythmias|Ventricular Tachyarrhythmias|Ventricular Tachyarrhythmias	An electrocardiographic assessment of the abnormally fast cardiac rhythms originating within the ventricles.			Intellectual Product	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Holter ECG Test Code Terminology|CDISC SDTM Holter ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111333>	C70917	Volume of Distribution for Dosing Interval|VZTAU|Vz for Dose Int|Vz for Dose Int	The volume of distribution associated with the terminal slope following intravascular administration, calculated using AUCTAU.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111334>	C111099	Wautersiella falsenii|Empedobacter falsenii|WAUTERSIELLA FALSENII	A species of aerobic, gram-negative, rod shaped bacteria assigned to the phylum Bacteroidetes. This species is urease and indole positive, does not reduce nitrates, Citrate negative and alkaline phosphatase positive. W. falsenii has only been isolated in the clinical setting.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111335>	C100110	CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CSS06TN|Columbia-Suicide Severity Rating Scale Children's Baseline Questionnaire Test Name|QS-C-SSRS Children's Baseline TEST	Test names of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111336>	C100110	CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CSS06TC|Columbia-Suicide Severity Rating Scale Children's Baseline Questionnaire Test Code|QS-C-SSRS Children's Baseline TESTCD	Test codes of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111337>	C100110	CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CSS07TN|Columbia-Suicide Severity Rating Scale Children's Baseline/Screening Questionnaire Test Name|QS-C-SSRS Children's Baseline/Screening TEST	Test names of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111338>	C100110	CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CSS07TC|Columbia-Suicide Severity Rating Scale Children's Baseline/Screening Questionnaire Test Code|QS-C-SSRS Children's Baseline/Screening TESTCD	Test codes of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111339>	C100110	CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CSS08TN|Columbia-Suicide Severity Rating Scale Children's Since Last Visit Questionnaire Test Name|QS-C-SSRS Children's Since Last Visit TEST	Test names of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11133>	C61063	Carmustine/Etoposide|BCNU/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111340>	C100110	CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CSS08TC|Columbia-Suicide Severity Rating Scale Children's Since Last Visit Questionnaire Test Code|QS-C-SSRS Children's Since Last Visit TESTCD	Test codes of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111341>	C100110	CDISC Questionnaire C-SSRS Screening Test Name Terminology|CSS09TN|Columbia-Suicide Severity Rating Scale Screening Questionnaire Test Name|QS-C-SSRS Screening TEST	Test names of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Screening (C-SSRS Screening) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111342>	C100110	CDISC Questionnaire C-SSRS Screening Test Code Terminology|CSS09TC|Columbia-Suicide Severity Rating Scale Screening Questionnaire Test Code|QS-C-SSRS Screening TESTCD	Test codes of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Screening (C-SSRS Screening) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111343>	C118970	CDISC Clinical Classification FAQ Test Name Terminology|FAQ01TN|Functional Activities Questionnaire Clinical Classification Test Name|QS-FAQ TEST	Test names of clinical classification questions associated with the Functional Activities Questionnaire (FAQ) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111344>	C118970	CDISC Clinical Classification FAQ Test Code Terminology|FAQ01TC|Functional Activities Questionnaire Clinical Classification Test Code|QS-FAQ TESTCD	Test codes of clinical classification questions associated with the Functional Activities Questionnaire (FAQ) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111345>	C118970	CDISC Clinical Classification FAQ-NACC UDS Version 2.0 Test Name Terminology|FAQNA1TN|Functional Assessment Questionnaire-NACC UDS V2.0 Clinical Classification Test Name|QS-FAQ-NACC Version TEST	Test names of clinical classification questions associated with the Functional Activities Questionnaire-NACC UDS Version 2.0 (FAQ-NACC UDS Version 2.0) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111346>	C118970	CDISC Clinical Classification FAQ-NACC UDS Version 2.0 Test Code Terminology|FAQNA1TC|Functional Assessment Questionnaire-NACC UDS V2.0 Clinical Classification Test Code|QS-FAQ-NACC Version TESTCD	Test codes of clinical classification questions associated with the Functional Activities Questionnaire-NACC UDS Version 2.0 (FAQ-NACC UDS Version 2.0) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111347>	C118970	CDISC Clinical Classification MRS Test Name Terminology|MRS01TN|Modified Rankin Scale Clinical Classification Test Name|QS-MRS TEST	Test names of clinical classification questions associated with the Modified Rankin Scale (MRS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111348>	C118970	CDISC Clinical Classification MRS Test Code Terminology|MRS01TC|Modified Rankin Scale Clinical Classification Test Code|QS-MRS TESTCD	Test codes of clinical classification questions associated with the Modified Rankin Scale (MRS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111349>	C100110	CDISC Questionnaire SDS Test Name Terminology|QS-SDS TEST|SDS01TN|Sheehan Disability Scale Questionnaire Test Name	Test names of questionnaire questions associated with the Sheehan Disability Scale (SDS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11134>	C63358	Tamoxifen/Letrozole Regimen|Letrozole-Tamoxifen|Letrozole-Tamoxifen|Letrozole/Tamoxifen|Tam Letrozole|Tamoxifen-Letrozole|Tamoxifen-Letrozole|Tamoxifen/Letrozole|letrozole/TMX	A regimen consisting of tamoxifen and letrozole that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C111350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111350>	C100110	CDISC Questionnaire SDS Test Code Terminology|QS-SDS TESTCD|SDS01TC|Sheehan Disability Scale Questionnaire Test Code	Test codes of questionnaire questions associated with the Sheehan Disability Scale (SDS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111351>	C211913	C-SSRS Children's Baseline Questionnaire Question	A question associated with the C-SSRS Children's Baseline questionnaire.			Intellectual Product	
C111352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111352>	C211913	C-SSRS Children's Baseline/Screening Questionnaire Question	A question associated with the C-SSRS Children's Baseline/Screening questionnaire.			Intellectual Product	
C111353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111353>	C211913	C-SSRS Children's Since Last Visit Questionnaire Question	A question associated with the C-SSRS Children's Since Last Visit questionnaire.			Intellectual Product	
C111354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111354>	C211913	C-SSRS Screening Questionnaire Question	A question associated with the C-SSRS Screening questionnaire.			Intellectual Product	
C111355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111355>	C211913	FAQ Questionnaire Question	A question associated with the FAQ questionnaire.			Intellectual Product	
C111356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111356>	C211913	FAQ-NACC UDS Version 2.0 Clinical Classification Question	A question associated with the FAQ-NACC UDS Version 2.0 clinical classification.			Intellectual Product	
C111357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111357>	C211913	MRS Clinical Classification Question	A question associated with the MRS clinical classification.			Intellectual Product	
C111358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111358>	C211913	SDS Questionnaire Question	A question associated with the SDS questionnaire.			Intellectual Product	
C111359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111359>	C38081	Forced Expiratory Volume in 1 Second to Forced Vital Capacity Ratio Measurement|FEV1/FVC|FEV1/FVC|FEV1/FVC|FEV1FVC	The proportion of total forced vital capacity that is expelled during the first second of a forced exhalation.			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11135>	C61007	Cyclosporine/Prednisone|CYSP/PRED			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111360>	C38081	Forced Inspiratory Volume in 1 Second|FIV1|FIV1	The volume of air that a subject can breathe in during the first second of inhalation after maximum exhalation.			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111361>	C38081	Forced Vital Capacity|FVC|FVC|FVC	The maximum volume of air that can be exhaled after forced maximum inhalation.			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|HL Authorized Value Terminology|HL Function Test Table
C111362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111362>	C38081	Inspiratory Capacity|IC|IC	The maximum volume of air a subject can inhale into the lungs after a tidal exhalation (IRV plus TV).			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111363>	C83146	ST Segment, T wave, and U wave ECG Assessment|ST Segment, T wave, and U wave|ST Segment, T wave, and U wave|ST Segment, T wave, and U wave|STSTWUW|STSTWUW	An electrocardiographic assessment of the characteristics of the ST segment, T wave, and U wave.			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Holter ECG Test Code Terminology|CDISC SDTM Holter ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111364>	C111333	Volume of Distribution for Dosing Interval by Fraction|VZFTAU|Vz for Dose Int by F|Vz for Dose Int by F	The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using AUCTAU.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111365>	C111333	Volume of Distribution for Dosing Interval by Fraction Normalized by Body Mass Index|VZFTAUB|Vz for Dose Int by F Norm by BMI|Vz for Dose Int by F Norm by BMI	The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using AUCTAU, divided by the body mass index.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111366>	C111333	Volume of Distribution for Dosing Interval by Fraction Normalized by Dose|VZFTAUD|Vz for Dose Int by F Norm by Dose|Vz for Dose Int by F Norm by Dose	The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using AUCTAU, divided by the dose.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111367>	C111333	Volume of Distribution for Dosing Interval by Fraction Normalized by Surface Area|VZFTAUS|Vz for Dose Int by F Norm by SA|Vz for Dose Int by F Norm by SA	The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using AUCTAU, divided by the surface area.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111368>	C111333	Volume of Distribution for Dosing Interval by Fraction Normalized by Weight|VZFTAUW|Vz for Dose Int by F Norm by WT|Vz for Dose Int by F Norm by WT	The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using AUCTAU, divided by the weight.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111369>	C111333	Volume of Distribution for Dosing Interval Normalized by Body Mass Index|VZTAUB|Vz for Dose Int Norm by BMI|Vz for Dose Int Norm by BMI	The volume of distribution associated with the terminal slope following intravascular administration, calculated using AUCTAU, divided by the body mass index.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11136>	C61063	Doxorubicin/Estramustine|DOX/EM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111370>	C111333	Volume of Distribution for Dosing Interval Normalized by Dose|VZTAUD|Vz for Dose Int Norm by Dose|Vz for Dose Int Norm by Dose	The volume of distribution associated with the terminal slope following intravascular administration, calculated using AUCTAU, divided by the dose.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111371>	C111333	Volume of Distribution for Dosing Interval Normalized by Surface Area|VZTAUS|Vz for Dose Int Norm by SA|Vz for Dose Int Norm by SA	The volume of distribution associated with the terminal slope following intravascular administration, calculated using AUCTAU, divided by the surface area.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111372>	C111333	Volume of Distribution for Dosing Interval Normalized by Weight|VZTAUW|Vz for Dose Int Norm by WT|Vz for Dose Int Norm by WT	The volume of distribution associated with the terminal slope following intravascular administration, calculated using AUCTAU, divided by the weight.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111373>	C209878	CYP3A4 Inhibitor|Cytochrome P450 3A4 Inhibitor	Any substance capable of decreasing the activity of cytochrome P450 3A4.			Chemical Viewed Functionally	
C111374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111374>	C120268	CYP3A4 Inducer|Cytochrome P450 3A4 Inducer	Any substance capable of increasing the activity of cytochrome P450 3A4.			Chemical Viewed Functionally	
C111375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111375>	C71314	Chlorhexidine Gluconate Cleansing|CHG Cleansing	The process of washing the skin using chlorhexidine gluconate.			Therapeutic or Preventive Procedure	
C111376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111376>	C49647	Control Cleansing	The process of washing the skin using a cleaning agent that functions as a standard of comparison in a control experiment.			Research Activity	
C111377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111377>	C91105	Columbia-Suicide Severity Rating Scale Children's Baseline Questionnaire|C-SSRS CHILDREN'S BASELINE|C-SSRS Children's Baseline|CSS06	A standardized rating scale developed by Posner et al (version 6/23/10), which is used to determine the presence of suicidal ideation or behavior. The children's baseline version questionnaire contains 20 items across 4 domains; suicidal ideation, intensity of ideation, suicidal behavior and actual attempts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111378>	C91105	Columbia-Suicide Severity Rating Scale Children's Baseline/Screening Questionnaire|C-SSRS CHILDREN'S BASELINE/SCREENING|C-SSRS Children's Baseline/Screening|CSS07	A standardized rating scale developed by Posner et al (version 6/23/10), which is used to determine the presence of suicidal ideation or behavior. The children's baseline/screening version questionnaire contains 20 items across 4 domains; suicidal ideation (lifetime and past 6 months), intensity of ideation (lifetime and past 6 months), suicidal behavior and actual attempts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111379>	C91105	Columbia-Suicide Severity Rating Scale Children's Since Last Visit Questionnaire|C-SSRS CHILDREN'S SINCE LAST VISIT|C-SSRS Children's Since Last Visit|CSS08	A standardized rating scale developed by Posner et al (version 6/23/10), which is used to determine the presence of suicidal ideation or behavior. The children's since last visit version questionnaire contains 19 items across 4 domains; suicidal ideation, intensity of ideation, suicidal behavior and actual attempts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11137>	C61063	Etoposide/Ifosfamide/Mesna/Mitoxantrone|DHAD/IFF/mesna/VP-16|MINE			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111380>	C91105	Columbia-Suicide Severity Rating Scale Screening Questionnaire|C-SSRS SCREENING|C-SSRS Screening|CSS09	A standardized rating scale developed by Posner et al (version 1/14/09), which is used to determine the presence of suicidal ideation or behavior. The screening version questionnaire contains 23 items across 4 domains; suicidal ideation, intensity of ideation, suicidal behavior and actual attempts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111381>	C118969	Functional Activities Questionnaire Clinical Classification|FAQ|FAQ|FAQ01	A standardized questionnaire developed by Pfeiffer et al in 1982, which is used to measure instrumental activities of daily living such as preparing meals and managing personal finances in older adults with dementia. The questionnaire contains 11 items. For each activity, six levels of scores are specified: 'dependent' (scored 3), 'requires assistance' (scored 2), 'has difficulty but does by self' (scored 1), 'normal' (scored 0), 'never did but could do now' (scored 0), and 'never did and would have difficulty now' (scored 1).			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111382>	C118969	Functional Assessment Questionnaire-NACC UDS Version 2.0 Clinical Classification|FAQ-NACC UDS V2.0|FAQ-NACC UDS Version 2.0|FAQNA1	A standardized questionnaire developed by Pfeiffer et al in 1982 and adapted by National Alzheimer's Coordinating Center (NACC), which is used to measure instrumental activities of daily living such as preparing meals and managing personal finances in older adults with dementia. The questionnaire contains 10 items. For each activity, five levels of scores are specified: 'not applicable' (scored 8), 'normal' (scored 0), 'has difficulty, but does by self' (scored 1), 'requires assistance' (scored 2), and 'dependent' (scored 3).			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111383>	C118969	Modified Rankin Scale Clinical Classification|MRS|MRS|MRS01|Modified Rankin Scale	A standardized clinical classification originally developed by John Rankin in 1957, and later modified by Van Swieten et al in 1988, which is used to assess the degree of disability or dependence in the daily activities of individuals who have suffered a stroke. It also allows comparison between subjects with different kinds of neurologic deficits. The questionnaire contains a '0 to 6' scale, ranging from 'no symptoms at all' (scored 0) to 'dead' (scored 6).			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111384>	C91105	Sheehan Disability Scale Questionnaire|SDS|SDS|SDS01	A standardized questionnaire developed by David Sheehan in 1983, which is used to measure functional impairments caused by panic, anxiety, phobic, or depressive symptoms in three inter-related domains; work/school, social and family life. It is also used in many other chronic medical illnesses due to its generic design. The Sheehan Disability Scale generates 4 scores: a work disability score, a social life disability score, a family life disability score and a total score. This questionnaire contains 6 items, with which patients can rate the extent of their functional impairments on a 10-point visual analog scale.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111385>	C111352	C-SSRS Children's Baseline/Screening - Wish to be Dead (Lifetime)|CSS07-Wish to be Dead-Life|CSS07-Wish to be Dead-Life|CSS0701A	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Have you thought about being dead or what it would be like to be dead? Have you wished you were dead or wished you could go to sleep and never wake up? Do you ever wish you weren't alive anymore? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111386>	C111352	C-SSRS Children's Baseline/Screening - Wish to be Dead (Past 6 Months)|CSS07-Wish to be Dead-P6M|CSS07-Wish to be Dead-P6M|CSS0701B	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Have you thought about being dead or what it would be like to be dead? Have you wished you were dead or wished you could go to sleep and never wake up? Do you ever wish you weren't alive anymore? (Past 6 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111387>	C111352	C-SSRS Children's Baseline/Screening - Description of Wish to be Dead|CSS07-Wish to be Dead, Describe|CSS07-Wish to be Dead, Describe|CSS0701C	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Description of wishing to be dead.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111388>	C111352	C-SSRS Children's Baseline/Screening - Non-Specific Active Suicidal Thoughts (Lifetime)|CSS07-Non-Spec Suicid Thought-Life|CSS07-Non-Spec Suicid Thought-Life|CSS0702A	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Have you thought about doing something to make yourself not alive anymore? Have you had any thoughts about killing yourself? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111389>	C111352	C-SSRS Children's Baseline/Screening - Non-Specific Active Suicidal Thoughts (Past 6 Months)|CSS07-Non-Spec Suicid Thought-P6M|CSS07-Non-Spec Suicid Thought-P6M|CSS0702B	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Have you thought about doing something to make yourself not alive anymore? Have you had any thoughts about killing yourself? (Past 6 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11138>	C61063	Interferon Gamma/Monoclonal Antibody CC49|IFN-G/MOAB CC49			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111390>	C111352	C-SSRS Children's Baseline/Screening - Description of Non-Specific Active Suicidal Thoughts|CSS07-Non-Spec Suicid Thought, Describe|CSS07-Non-Spec Suicid Thought, Describe|CSS0702C	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Description of non-specific active suicidal thoughts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111391>	C111352	C-SSRS Children's Baseline/Screening - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act (Lifetime)|CSS07-Idea, No Intent, No Plan-Life|CSS07-Idea, No Intent, No Plan-Life|CSS0703A	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Have you thought about how you would do that or how you would make yourself not alive anymore (kill yourself)? What did you think about? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111392>	C111352	C-SSRS Children's Baseline/Screening - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act (Past 6 Months)|CSS07-Idea, No Intent, No Plan-P6M|CSS07-Idea, No Intent, No Plan-P6M|CSS0703B	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Have you thought about how you would do that or how you would make yourself not alive anymore (kill yourself)? What did you think about? (Past 6 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111393>	C111352	C-SSRS Children's Baseline/Screening - Description of Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act|CSS07-Idea, No Intent, No Plan, Describe|CSS07-Idea, No Intent, No Plan, Describe|CSS0703C	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Description of active suicidal ideation with any methods (not plan) without intent to act.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111394>	C111352	C-SSRS Children's Baseline/Screening - Active Suicidal Ideation with Some Intent to Act, without Specific Plan (Lifetime)|CSS07-Idea, Intent, No Plan-Life|CSS07-Idea, Intent, No Plan-Life|CSS0704A	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) When you thought about making yourself not alive anymore (or killing yourself), did you think that this was something you might actually do? This is different from (as opposed to) having the thoughts but knowing you wouldn't do anything about it. (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111395>	C111352	C-SSRS Children's Baseline/Screening - Active Suicidal Ideation with Some Intent to Act, without Specific Plan (Past 6 Months)|CSS07-Idea, Intent, No Plan-P6M|CSS07-Idea, Intent, No Plan-P6M|CSS0704B	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) When you thought about making yourself not alive anymore (or killing yourself), did you think that this was something you might actually do? This is different from (as opposed to) having the thoughts but knowing you wouldn't do anything about it. (Past 6 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111396>	C111352	C-SSRS Children's Baseline/Screening - Description of Active Suicidal Ideation with Some Intent to Act, without Specific Plan|CSS07-Idea, Intent, No Plan, Describe|CSS07-Idea, Intent, No Plan, Describe|CSS0704C	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Description of active suicidal ideation with some intent to act, without specific plan.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111397>	C111352	C-SSRS Children's Baseline/Screening - Active Suicidal Ideation with Specific Plan and Intent (Lifetime)|CSS07-Idea, Plan, Intent-Life|CSS07-Idea, Plan, Intent-Life|CSS0705A	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Have you ever decided how or when you would make yourself not alive anymore/kill yourself? Have you ever planned out (worked out the details of) how you would do it? What was your plan? When you made this plan (or worked out these details), was any part of you thinking about actually doing it? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111398>	C111352	C-SSRS Children's Baseline/Screening - Active Suicidal Ideation with Specific Plan and Intent (Past 6 Months)|CSS07-Idea, Plan, Intent-P6M|CSS07-Idea, Plan, Intent-P6M|CSS0705B	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Have you ever decided how or when you would make yourself not alive anymore/kill yourself? Have you ever planned out (worked out the details of) how you would do it? What was your plan? When you made this plan (or worked out these details), was any part of you thinking about actually doing it? (Past 6 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111399>	C111352	C-SSRS Children's Baseline/Screening - Description of Active Suicidal Ideation with Specific Plan and Intent|CSS07-Idea, Plan, Intent, Describe|CSS07-Idea, Plan, Intent, Describe|CSS0705C	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Description of active suicidal ideation with specific plan and intent.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11139>	C61063	Cyclosporine/Cytarabine/Daunorubicin/Etoposide|ARA-C/CYSP/DNR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1113>	C599|C1967|C1821|C1742	Genistein|4',5, 7-Trihydroxyisoflavone|4',5,7-Trihydroxyisoflavone|5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one|GENISTEIN|Genestein|Genisteol|Genisteol|Prunetol|Prunetol|genistein	A soy-derived isoflavone and phytoestrogen with antineoplastic activity. Genistein binds to and inhibits protein-tyrosine kinase, thereby disrupting signal transduction and inducing cell differentiation.  This agent also inhibits topoisomerase-II, leading to DNA fragmentation and apoptosis, and induces G2/M cell cycle arrest.  Genistein exhibits antioxidant, antiangiogenic, and immunosuppressive activities. (NCI04)	Genistein		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111400>	C111352	C-SSRS Children's Baseline/Screening - Most Severe Ideation|CSS07-Most Severe Idea|CSS07-Most Severe Idea|CSS0706A	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Most severe ideation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111401>	C111352	C-SSRS Children's Baseline/Screening - Describe Most Severe Ideation|CSS07-Most Severe Idea, Desc|CSS07-Most Severe Idea, Desc|CSS0706B	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Description of most severe ideation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111402>	C111352	C-SSRS Children's Baseline/Screening - Frequency of Most Severe Ideation (Lifetime)|CSS07-Most Severe Idea, Frequency-Life|CSS07-Most Severe Idea, Frequency-Life|CSS0707A	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) How many times have you had these thoughts? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111403>	C111352	C-SSRS Children's Baseline/Screening - Frequency of Most Severe Ideation (Past 6 Months)|CSS07-Most Severe Idea, Frequency-P6M|CSS07-Most Severe Idea, Frequency-P6M|CSS0707B	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) How many times have you had these thoughts? (Past 6 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111404>	C111352	C-SSRS Children's Baseline/Screening - Frequency, Write Response|CSS07-Frequency, Write Response|CSS07-Frequency, Write Response|CSS0707C	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Frequency, write response.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111405>	C111352	C-SSRS Children's Baseline/Screening - Actual Suicide Attempt|CSS07-Actual Attempt|CSS07-Actual Attempt|CSS0708	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Did you ever do anything to try to kill yourself or make yourself not alive anymore? What did you do? Did you ever hurt yourself on purpose? Why did you do that?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111406>	C111352	C-SSRS Children's Baseline/Screening - Number of Actual Suicide Attempts|CSS07-Number of Actual Attempts|CSS07-Number of Actual Attempts|CSS0709	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Total number of actual attempts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111407>	C111352	C-SSRS Children's Baseline/Screening - Description of Actual Suicide Attempt|CSS07-Actual Attempt, Describe|CSS07-Actual Attempt, Describe|CSS0709A	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Description of actual attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111408>	C111352	C-SSRS Children's Baseline/Screening - Non-suicidal Self-injurious Behavior|CSS07-Non-suicidal Self-injur Behav|CSS07-Non-suicidal Self-injur Behav|CSS0710	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Has subject engaged in non-suicidal self-injurious behavior?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111409>	C111352	C-SSRS Children's Baseline/Screening - Self-injurious Behavior, Intent Unknown|CSS07-Self-injur Behav, Intent Unknown|CSS07-Self-injur Behav, Intent Unknown|CSS0711	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Has subject engaged in self-injurious behavior, intent unknown?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11140>	C61063	Cyclosporine/Cytarabine/Etoposide/Idarubicin|ARA-C/CYSP/IDA/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111410>	C111352	C-SSRS Children's Baseline/Screening - Interrupted Suicide Attempt|CSS07-Interrupted Attempt|CSS07-Interrupted Attempt|CSS0712	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Has there been a time when you started to do something to make yourself not alive anymore (end your life or kill yourself) but someone or something stopped you before you actually did anything? What did you do?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111411>	C111352	C-SSRS Children's Baseline/Screening - Number of Interrupted Suicide Attempts|CSS07-Number of Interrupt Attempts|CSS07-Number of Interrupt Attempts|CSS0713	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Total number of interrupted.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111412>	C111352	C-SSRS Children's Baseline/Screening - Description of Interrupted Suicide Attempt|CSS07-Interrupted Attempt, Describe|CSS07-Interrupted Attempt, Describe|CSS0713A	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Description of interrupted attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111413>	C111352	C-SSRS Children's Baseline/Screening - Aborted Suicide Attempt|CSS07-Aborted Attempt|CSS07-Aborted Attempt|CSS0714	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Has there been a time when you started to do something to make yourself not alive anymore (end your life or kill yourself) but you changed your mind (stopped yourself) before you actually did anything? What did you do?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111414>	C111352	C-SSRS Children's Baseline/Screening - Number of Aborted Suicide Attempts|CSS07-Number of Aborted Attempts|CSS07-Number of Aborted Attempts|CSS0715	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Total number of aborted.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111415>	C111352	C-SSRS Children's Baseline/Screening - Description of Aborted Suicide Attempt|CSS07-Aborted Attempt, Describe|CSS07-Aborted Attempt, Describe|CSS0715A	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Description of aborted attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111416>	C111352	C-SSRS Children's Baseline/Screening - Preparatory Acts or Behaviors Toward Suicide Attempt|CSS07-Preparatory Acts/Behavior|CSS07-Preparatory Acts/Behavior|CSS0716	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Have you done anything to get ready to make yourself not alive anymore (to end your life or kill yourself) - like giving things away, writing a goodbye note, getting things you need to kill yourself?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111417>	C111352	C-SSRS Children's Baseline/Screening - Description of Preparatory Acts or Behaviors Toward Suicide Attempt|CSS07-Preparatory Acts/Behavior, Descr|CSS07-Preparatory Acts/Behavior, Descr|CSS0716A	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Description of preparatory acts or behaviors.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111418>	C111352	C-SSRS Children's Baseline/Screening - Suicidal Behavior|CSS07-Suicidal Behavior|CSS07-Suicidal Behavior|CSS0717	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Suicidal behavior was present during the assessment period?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111419>	C111352	C-SSRS Children's Baseline/Screening - Most Recent Suicide Attempt Date|CSS07-Most Recent Attempt Date|CSS07-Most Recent Attempt Date|CSS0718A	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Most recent attempt date.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11141>	C61063	Asparaginase/Dexrazoxane/Doxorubicin/Mercaptopurine/Prednisone/Vincristine|ADR-529/ASP/DOX/MP/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111420>	C111352	C-SSRS Children's Baseline/Screening - Most Recent Suicide Attempt Actual Lethality/Medical Damage|CSS07-Most Recent Attempt Damage|CSS07-Most Recent Attempt Damage|CSS0718B	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Most recent attempt actual lethality/medical damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111421>	C111352	C-SSRS Children's Baseline/Screening - Most Recent Suicide Attempt Potential Lethality|CSS07-Most Recent Attempt Potential|CSS07-Most Recent Attempt Potential|CSS0718C	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Most recent attempt potential lethality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111422>	C111352	C-SSRS Children's Baseline/Screening - Most Lethal Suicide Attempt Date|CSS07-Most Lethal Attempt Date|CSS07-Most Lethal Attempt Date|CSS0719A	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Most lethal attempt date.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111423>	C111352	C-SSRS Children's Baseline/Screening - Most Lethal Suicide Attempt Actual Lethality/Medical Damage|CSS07-Most Lethal Attempt Damage|CSS07-Most Lethal Attempt Damage|CSS0719B	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Most lethal attempt actual lethality/medical damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111424>	C111352	C-SSRS Children's Baseline/Screening - Most Lethal Suicide Attempt Potential Lethality|CSS07-Most Lethal Attempt Potential|CSS07-Most Lethal Attempt Potential|CSS0719C	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Most lethal attempt potential lethality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111425>	C111352	C-SSRS Children's Baseline/Screening - First Suicide Attempt Date|CSS07-First Attempt Date|CSS07-First Attempt Date|CSS0720A	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Initial/first attempt date.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111426>	C111352	C-SSRS Children's Baseline/Screening - First Suicide Attempt Actual Lethality/Medical Damage|CSS07-First Attempt Damage|CSS07-First Attempt Damage|CSS0720B	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Initial/first attempt actual lethality/medical damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111427>	C111352	C-SSRS Children's Baseline/Screening - First Suicide Attempt Potential Lethality|CSS07-First Attempt Potential|CSS07-First Attempt Potential|CSS0720C	Columbia-Suicidality Severity Rating Scale Children's Baseline/Screening (C-SSRS Children's Baseline/Screening) Initial/first attempt potential lethality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline/Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111428>	C111353	C-SSRS Children's Since Last Visit - Wish to be Dead|CSS08-Wish to be Dead|CSS08-Wish to be Dead|CSS0801	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Have you thought about being dead or what it would be like to be dead? Have you wished you were dead or wished you could go to sleep and never wake up? Do you ever wish you weren't alive anymore?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111429>	C111353	C-SSRS Children's Since Last Visit - Description of Wish to be Dead|CSS08-Wish to be Dead, Describe|CSS08-Wish to be Dead, Describe|CSS0801A	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Description of wishing to be dead.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11142>	C61063	Asparaginase/dexrazoxane/Doxorubicin/Mercaptopurine/Methotrexate/Prednisone/Vincristine|ADR-529/ASP/DOX/MP/MTX/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111430>	C111353	C-SSRS Children's Since Last Visit - Non-Specific Active Suicidal Thoughts|CSS08-Non-Specific Suicidal Thought|CSS08-Non-Specific Suicidal Thought|CSS0802	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Have you thought about doing something to make yourself not alive anymore? Have you had any thoughts about killing yourself?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111431>	C111353	C-SSRS Children's Since Last Visit - Description of Non-Specific Active Suicidal Thoughts|CSS08-Non-Specific Suicid Thought, Descr|CSS08-Non-Specific Suicid Thought, Descr|CSS0802A	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Description of non-specific active suicidal thoughts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111432>	C111353	C-SSRS Children's Since Last Visit - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act|CSS08-Idea, No Intent, No Plan|CSS08-Idea, No Intent, No Plan|CSS0803	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Have you thought about how you would do that or how you would make yourself not alive anymore (kill yourself)? What did you think about?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111433>	C111353	C-SSRS Children's Since Last Visit - Description of Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act|CSS08-Idea, No Intent, No Plan, Describe|CSS08-Idea, No Intent, No Plan, Describe|CSS0803A	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Description of active suicidal ideation with any methods (not plan) without intent to act.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111434>	C111353	C-SSRS Children's Since Last Visit - Active Suicidal Ideation with Some Intent to Act, without Specific Plan|CSS08-Ideation With Intent, No Plan|CSS08-Ideation With Intent, No Plan|CSS0804	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) When you thought about making yourself not alive anymore (or killing yourself), did you think that this was something you might actually do? This is different from (as opposed to) having the thoughts but knowing you wouldn't do anything about it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111435>	C111353	C-SSRS Children's Since Last Visit - Description of Active Suicidal Ideation with Some Intent to Act, without Specific Plan|CSS08-Ideation With Intent No Plan Descr|CSS08-Ideation With Intent No Plan Descr|CSS0804A	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Description of active suicidal ideation with some intent to act, without specific plan.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111436>	C111353	C-SSRS Children's Since Last Visit - Active Suicidal Ideation with Specific Plan and Intent|CSS08-Ideation With Plan/Intent|CSS08-Ideation With Plan/Intent|CSS0805	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Have you decided how or when you would make yourself not alive anymore/kill yourself? Have you planned out (worked out the details of) how you would do it? What was your plan? When you made this plan (or worked out these details), was any part of you thinking about actually doing it?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111437>	C111353	C-SSRS Children's Since Last Visit - Description of Active Suicidal Ideation with Specific Plan and Intent|CSS08-Ideation With Plan/Intent, Descr|CSS08-Ideation With Plan/Intent, Descr|CSS0805A	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Description of active suicidal ideation with specific plan and intent.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111438>	C111353	C-SSRS Children's Since Last Visit - Most Severe Ideation|CSS08-Most Severe Ideation|CSS08-Most Severe Ideation|CSS0806	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Most severe ideation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111439>	C111353	C-SSRS Children's Since Last Visit - Describe Most Severe Ideation|CSS08-Most Severe Ideation, Description|CSS08-Most Severe Ideation, Description|CSS0806A	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Description of most severe ideation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11143>	C61063	Asparaginase/Doxorubicin/Mercaptopurine/Methotrexate/Prednisone/Vincristine|ASP/DOX/MP/MTX/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111440>	C111353	C-SSRS Children's Since Last Visit - Frequency of Most Severe Ideation|CSS08-Most Severe Ideation, Frequency|CSS08-Most Severe Ideation, Frequency|CSS0807	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) How many times have you had these thoughts?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111441>	C111353	C-SSRS Children's Since Last Visit - Frequency, Write Response|CSS08-Frequency, Write Response|CSS08-Frequency, Write Response|CSS0807A	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Frequency, write response.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111442>	C111353	C-SSRS Children's Since Last Visit - Actual Suicide Attempt|CSS08-Actual Attempt|CSS08-Actual Attempt|CSS0808	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Did you do anything to try to kill yourself or make yourself not alive anymore? What did you do? Did you hurt yourself on purpose? Why did you do that?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111443>	C111353	C-SSRS Children's Since Last Visit - Number of Actual Suicide Attempts|CSS08-Number of Actual Attempts|CSS08-Number of Actual Attempts|CSS0809	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Total number of actual attempts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111444>	C111353	C-SSRS Children's Since Last Visit - Description of Actual Suicide Attempt|CSS08-Actual Attempt, Describe|CSS08-Actual Attempt, Describe|CSS0809A	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Description of actual attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111445>	C111353	C-SSRS Children's Since Last Visit - Non-suicidal Self-injurious Behavior|CSS08-Non-suicidal Self-injurious Behav|CSS08-Non-suicidal Self-injurious Behav|CSS0810	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Has subject engaged in non-suicidal self-injurious behavior?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111446>	C111353	C-SSRS Children's Since Last Visit - Self-injurious Behavior, Intent Unknown|CSS08-Self-injur Behav, Intent Unknown|CSS08-Self-injur Behav, Intent Unknown|CSS0811	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Has subject engaged in self-injurious behavior, intent unknown?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111447>	C111353	C-SSRS Children's Since Last Visit - Interrupted Suicide Attempt|CSS08-Interrupted Attempt|CSS08-Interrupted Attempt|CSS0812	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Has there been a time when you started to do something to make yourself not alive anymore (end your life or kill yourself) but someone or something stopped you before you actually did anything? What did you do?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111448>	C111353	C-SSRS Children's Since Last Visit - Number of Interrupted Suicide Attempts|CSS08-Number of Interrupt Attempts|CSS08-Number of Interrupt Attempts|CSS0813	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Total number of interrupted.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111449>	C111353	C-SSRS Children's Since Last Visit - Description of Interrupted Suicide Attempt|CSS08-Interrupted Attempt, Describe|CSS08-Interrupted Attempt, Describe|CSS0813A	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Description of interrupted attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11144>	C61063	Dexrazoxane/Doxorubicin/Mercaptopurine/Methotrexate/Prednisone/Vincristine|ADR-529/DOX/MP/MTX/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111450>	C111353	C-SSRS Children's Since Last Visit - Aborted or Self-interrupted Suicide Attempt|CSS08-Aborted/Self-Interrupted Attempt|CSS08-Aborted/Self-Interrupted Attempt|CSS0814	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Has there been a time when you started to do something to make yourself not alive anymore (end your life or kill yourself) but you changed your mind (stopped yourself) before you actually did anything? What did you do?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111451>	C111353	C-SSRS Children's Since Last Visit - Number of Aborted or Self-interrupted Suicide Attempts|CSS08-Number of Aborted Attempts|CSS08-Number of Aborted Attempts|CSS0815	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Total number of aborted or self-interrupted.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111452>	C111353	C-SSRS Children's Since Last Visit - Description of Aborted or Self-interrupted Suicide Attempt|CSS08-Aborted Attempt, Describe|CSS08-Aborted Attempt, Describe|CSS0815A	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Description of aborted attempt or self-interrupted attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111453>	C111353	C-SSRS Children's Since Last Visit - Preparatory Acts or Behaviors Toward Suicide Attempt|CSS08-Preparatory Acts/Behavior|CSS08-Preparatory Acts/Behavior|CSS0816	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Have you done anything to get ready to make yourself not alive anymore (to end your life or kill yourself) - like giving things away, writing a goodbye note, getting things you need to kill yourself?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111454>	C111353	C-SSRS Children's Since Last Visit - Description of Preparatory Acts or Behaviors Toward Suicide Attempt|CSS08-Preparatory Acts/Behavior, Descr|CSS08-Preparatory Acts/Behavior, Descr|CSS0816A	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Description of preparatory acts or behavior.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111455>	C111353	C-SSRS Children's Since Last Visit - Suicidal Behavior|CSS08-Suicidal Behavior|CSS08-Suicidal Behavior|CSS0817	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Suicidal behavior was present during the assessment period?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111456>	C111353	C-SSRS Children's Since Last Visit - Suicide|CSS08-Suicide|CSS08-Suicide|CSS0818	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Suicide.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111457>	C111353	C-SSRS Children's Since Last Visit - Most Lethal Suicide Attempt Date|CSS08-Most Lethal Attempt Date|CSS08-Most Lethal Attempt Date|CSS0819A	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Most lethal attempt date.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111458>	C111353	C-SSRS Children's Since Last Visit - Most Lethal Suicide Attempt Actual Lethality/Medical Damage|CSS08-Most Lethal Attempt Damage|CSS08-Most Lethal Attempt Damage|CSS0819B	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Most lethal attempt actual lethality/medical damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111459>	C111353	C-SSRS Children's Since Last Visit - Most Lethal Suicide Attempt Potential Lethality|CSS08-Most Lethal Attempt Potential|CSS08-Most Lethal Attempt Potential|CSS0819C	Columbia-Suicidality Severity Rating Scale Children's Since Last Visit (C-SSRS Children's Since Last Visit) Most lethal attempt potential lethality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Code Terminology|CDISC Questionnaire C-SSRS Children's Since Last Visit Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11145>	C63588	Cyclophosphamide/Cytarabine/Dexamethasone/Doxorubicin/Pegaspargase/Thioguanine/Vincristine Regimen|ARA-C/CTX/DM/DOX/PEG-ASP/TG/VCR|Cyclophosphamide-Cytarabine-Dexamethasone-Doxorubicin-Pegaspargase-Thioguanine-Vincristine|Cyclophosphamide/Cytarabine/Dexamethasone/Doxorubicin/Pegaspargase/Thioguanine/Vincristine|Cyclophosphamide/Cytarabine/Doxorubicin/Pegaspargase/Thioguanine/Vincristine/Dexamethasone	A regimen consisting of cyclophosphamide, cytarabine, dexamethasone, doxorubicin, pegaspargase, thioguanine, and vincristine that may be used in the treatment of acute lymphoblastic leukemia (ALL).			Therapeutic or Preventive Procedure	
C111460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111460>	C111354	C-SSRS Screening - Wish to be Dead|CSS09-Wish to be Dead|CSS09-Wish to be Dead|CSS0901	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Have you wished you were dead or wished you could go to sleep and not wake up?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111461>	C111354	C-SSRS Screening - Description of Wish to be Dead|CSS09-Wish to be Dead, Describe|CSS09-Wish to be Dead, Describe|CSS0901A	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Description of wishing to be dead.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111462>	C111354	C-SSRS Screening - Non-Specific Active Suicidal Thoughts|CSS09-Non-Spec Suicid Thought|CSS09-Non-Spec Suicid Thought|CSS0902	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Have you actually had any thoughts of killing yourself?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111463>	C111354	C-SSRS Screening - Description of Non-Specific Active Suicidal Thoughts|CSS09-Non-Spec Suicid Thought, Describe|CSS09-Non-Spec Suicid Thought, Describe|CSS0902A	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Description of non-specific active suicidal thoughts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111464>	C111354	C-SSRS Screening - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act|CSS09-Idea, No Intent, No Plan|CSS09-Idea, No Intent, No Plan|CSS0903	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Have you been thinking about how you might do this?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111465>	C111354	C-SSRS Screening - Description of Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act|CSS09-Idea, No Intent, No Plan, Describe|CSS09-Idea, No Intent, No Plan, Describe|CSS0903A	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Description of active suicidal ideation with any methods (not plan) without intent to act.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111466>	C111354	C-SSRS Screening - Active Suicidal Ideation with Some Intent to Act, without Specific Plan|CSS09-Idea, Intent, No Plan|CSS09-Idea, Intent, No Plan|CSS0904	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Have you had these thoughts and had some intention of acting on them?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111467>	C111354	C-SSRS Screening - Description of Active Suicidal Ideation with Some Intent to Act, without Specific Plan|CSS09-Idea, Intent, No Plan, Describe|CSS09-Idea, Intent, No Plan, Describe|CSS0904A	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Description of active suicidal ideation with some intent to act, without specific plan.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111468>	C111354	C-SSRS Screening - Active Suicidal Ideation with Specific Plan and Intent|CSS09-Idea, Plan, Intent|CSS09-Idea, Plan, Intent|CSS0905	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111469>	C111354	C-SSRS Screening - Description of Active Suicidal Ideation with Specific Plan and Intent|CSS09-Idea, Plan, Intent, Describe|CSS09-Idea, Plan, Intent, Describe|CSS0905A	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Description of active suicidal ideation with specific plan and intent.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11146>	C63588	Methotrexate/Pegaspargase/Vincristine Regimen|MTX/PEG-ASP/VCR|Methotrexate-Pegaspargase-Vincristine|Methotrexate/Pegaspargase/Vincristine|capi33i I				Therapeutic or Preventive Procedure	
C111470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111470>	C111354	C-SSRS Screening - Most Severe Ideation|CSS09-Most Severe Idea|CSS09-Most Severe Idea|CSS0906	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Most severe ideation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111471>	C111354	C-SSRS Screening - Describe Most Severe Ideation|CSS09-Most Severe Idea, Desc|CSS09-Most Severe Idea, Desc|CSS0906A	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Description of most severe ideation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111472>	C111354	C-SSRS Screening - Frequency of Most Severe Ideation|CSS09-Most Severe Idea, Frequency|CSS09-Most Severe Idea, Frequency|CSS0907	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) How many times have you had these thoughts?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111473>	C111354	C-SSRS Screening - Duration of Most Severe Ideation|CSS09-Most Severe Idea, Duration|CSS09-Most Severe Idea, Duration|CSS0908	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) When you have the thoughts, how long do they last?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111474>	C111354	C-SSRS Screening - Controllability of Most Severe Ideation|CSS09-Most Severe Idea, Controllability|CSS09-Most Severe Idea, Controllability|CSS0909	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Could/can you stop thinking about killing yourself or wanting to die if you want to?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111475>	C111354	C-SSRS Screening - Deterrents to Most Severe Ideation|CSS09-Most Severe Idea, Deterrents|CSS09-Most Severe Idea, Deterrents|CSS0910	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Are there things-anyone or anything (e.g., family, religion, pain of death) - that stopped you from wanting to die or acting on thoughts of committing suicide?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111476>	C111354	C-SSRS Screening - Reasons for Most Severe Ideation|CSS09-Most Severe Idea, Reasons|CSS09-Most Severe Idea, Reasons|CSS0911	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) What sort of reasons did you have for thinking about wanting to die or killing yourself? Was it to end the pain or stop the way you were feeling (in other words you couldn't go on living with this pain or how you were feeling) or was it to get attention, revenge or a reaction from others? Or both?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111477>	C111354	C-SSRS Screening - Actual Suicide Attempt|CSS09-Actual Attempt|CSS09-Actual Attempt|CSS0912	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Have you made a suicide attempt? Have you done anything to harm yourself? Have you done anything dangerous where you could have died?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111478>	C111354	C-SSRS Screening - Number of Actual Suicide Attempts|CSS09-Number of Actual Attempts|CSS09-Number of Actual Attempts|CSS0913	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Total number of actual attempts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111479>	C111354	C-SSRS Screening - Description of Actual Suicide Attempt|CSS09-Actual Attempt, Describe|CSS09-Actual Attempt, Describe|CSS0913A	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Description of actual attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11147>	C61063	Mercaptopurine/Vincristine|MP/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111480>	C111354	C-SSRS Screening - Non-suicidal Self-injurious Behavior|CSS09-Non-suicidal Self-injur Behav|CSS09-Non-suicidal Self-injur Behav|CSS0914	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Has subject engaged in non-suicidal self-injurious behavior?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111481>	C111354	C-SSRS Screening - Interrupted Suicide Attempt|CSS09-Interrupted Attempt|CSS09-Interrupted Attempt|CSS0915	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Has there been a time when you started to do something to end your life but someone or something stopped you before you actually did anything?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111482>	C111354	C-SSRS Screening - Number of Interrupted Suicide Attempts|CSS09-Number of Interrupt Attempts|CSS09-Number of Interrupt Attempts|CSS0916	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Total number of interrupted.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111483>	C111354	C-SSRS Screening - Description of Interrupted Suicide Attempt|CSS09-Interrupted Attempt, Describe|CSS09-Interrupted Attempt, Describe|CSS0916A	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Description of interrupted attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111484>	C111354	C-SSRS Screening - Aborted Suicide Attempt|CSS09-Aborted Attempt|CSS09-Aborted Attempt|CSS0917	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Has there been a time when you started to do something to try to end your life but you stopped yourself before you actually did anything?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111485>	C111354	C-SSRS Screening - Number of Aborted Suicide Attempts|CSS09-Number of Aborted Attempts|CSS09-Number of Aborted Attempts|CSS0918	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Total number of aborted.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111486>	C111354	C-SSRS Screening - Description of Aborted Suicide Attempt|CSS09-Aborted Attempt, Describe|CSS09-Aborted Attempt, Describe|CSS0918A	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Description of aborted attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111487>	C111354	C-SSRS Screening - Preparatory Acts or Behaviors Toward Suicide Attempt|CSS09-Preparatory Acts/Behavior|CSS09-Preparatory Acts/Behavior|CSS0919	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Have you taken any steps towards making a suicide attempt or preparing to kill yourself (such as collecting pills, getting a gun, giving valuables away or writing a suicide note)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111488>	C111354	C-SSRS Screening - Description of Preparatory Acts or Behaviors Toward Suicide Attempt|CSS09-Preparatory Acts/Behavior, Descr|CSS09-Preparatory Acts/Behavior, Descr|CSS0919A	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Description of preparatory acts or behavior.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111489>	C111354	C-SSRS Screening - Suicidal Behavior|CSS09-Suicidal Behavior|CSS09-Suicidal Behavior|CSS0920	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Suicidal behavior was present during the assessment period?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11148>	C61007	Estramustine/Strontium Chloride Sr 89/Vinblastine|EM/Strontium Chloride Sr 89/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111490>	C111354	C-SSRS Screening - Most Recent Suicide Attempt Date|CSS09-Most Recent Attempt Date|CSS09-Most Recent Attempt Date|CSS0921A	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Most recent attempt date.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111491>	C111354	C-SSRS Screening - Most Recent Suicide Attempt Actual Lethality/Medical Damage|CSS09-Most Recent Attempt Damage|CSS09-Most Recent Attempt Damage|CSS0921B	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Most recent attempt actual lethality/medical damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111492>	C111354	C-SSRS Screening - Most Recent Suicide Attempt Potential Lethality|CSS09-Most Recent Attempt Potential|CSS09-Most Recent Attempt Potential|CSS0921C	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Most recent attempt potential lethality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111493>	C111354	C-SSRS Screening - Most Lethal Suicide Attempt Date|CSS09-Most Lethal Attempt Date|CSS09-Most Lethal Attempt Date|CSS0922A	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Most lethal attempt date.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111494>	C111354	C-SSRS Screening - Most Lethal Suicide Attempt Actual Lethality/Medical Damage|CSS09-Most Lethal Attempt Damage|CSS09-Most Lethal Attempt Damage|CSS0922B	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Most lethal attempt actual lethality/medical damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111495>	C111354	C-SSRS Screening - Most Lethal Suicide Attempt Potential Lethality|CSS09-Most Lethal Attempt Potential|CSS09-Most Lethal Attempt Potential|CSS0922C	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Most lethal attempt potential lethality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111496>	C111354	C-SSRS Screening - First Suicide Attempt Date|CSS09-First Attempt Date|CSS09-First Attempt Date|CSS0923A	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Initial/first attempt date.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111497>	C111354	C-SSRS Screening - First Suicide Attempt Actual Lethality/Medical Damage|CSS09-First Attempt Damage|CSS09-First Attempt Damage|CSS0923B	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Initial/first attempt actual lethality/medical damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111498>	C111354	C-SSRS Screening - First Suicide Attempt Potential Lethality|CSS09-First Attempt Potential|CSS09-First Attempt Potential|CSS0923C	Columbia-Suicidality Severity Rating Scale Screening (C-SSRS Screening) Initial/first attempt potential lethality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Screening Test Code Terminology|CDISC Questionnaire C-SSRS Screening Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111499>	C111355	FAQ - Write checks, Pay bills, Balance checkbook|FAQ01-Write Checks/Pay Bills/Checkbook|FAQ01-Write Checks/Pay Bills/Checkbook|FAQ0101	Functional Activities Questionnaire (FAQ) Writing checks, paying bills, balancing checkbook.			Intellectual Product	CDISC Clinical Classification FAQ Test Code Terminology|CDISC Clinical Classification FAQ Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11149>	C61063	AG337/Cisplatin|AG337/CDDP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1114>	C1974	Glaucarubolone	A polycyclic lactone quassinoid phytochemical isolated from the seeds of Hannoa undulata and other plant species with potential antineoplastic activity.  This agent also has antiviral and antitumor properties. (NCI04)			Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C111500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111500>	C111355	FAQ - Assemble|FAQ01-Assembling|FAQ01-Assembling|FAQ0102	Functional Activities Questionnaire (FAQ) Assembling tax records, business affairs, or papers.			Intellectual Product	CDISC Clinical Classification FAQ Test Code Terminology|CDISC Clinical Classification FAQ Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111501>	C111355	FAQ - Shop Alone|FAQ01-Shopping Alone|FAQ01-Shopping Alone|FAQ0103	Functional Activities Questionnaire (FAQ) Shopping alone for clothes, household necessities, or groceries.			Intellectual Product	CDISC Clinical Classification FAQ Test Code Terminology|CDISC Clinical Classification FAQ Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111502>	C111355	FAQ - Play Game of Skill, Work on Hobby|FAQ01-Playing a Game of Skill|FAQ01-Playing a Game of Skill|FAQ0104	Functional Activities Questionnaire (FAQ) Playing a game of skill, working on a hobby.			Intellectual Product	CDISC Clinical Classification FAQ Test Code Terminology|CDISC Clinical Classification FAQ Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111503>	C111355	FAQ - Heat water, Make Coffee, Turn Off Stove|FAQ01-Heat Water/Make Coffee/Stove Off|FAQ01-Heat Water/Make Coffee/Stove Off|FAQ0105	Functional Activities Questionnaire (FAQ) Heating water, making a cup of coffee, turning off stove after use.			Intellectual Product	CDISC Clinical Classification FAQ Test Code Terminology|CDISC Clinical Classification FAQ Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111504>	C111355	FAQ - Prepare a Meal|FAQ01-Preparing a Balanced Meal|FAQ01-Preparing a Balanced Meal|FAQ0106	Functional Activities Questionnaire (FAQ) Preparing a balanced meal.			Intellectual Product	CDISC Clinical Classification FAQ Test Code Terminology|CDISC Clinical Classification FAQ Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111505>	C111355	FAQ - Keep Track of Current Events|FAQ01-Keeping Track of Current Events|FAQ01-Keeping Track of Current Events|FAQ0107	Functional Activities Questionnaire (FAQ) Keeping track of current events.			Intellectual Product	CDISC Clinical Classification FAQ Test Code Terminology|CDISC Clinical Classification FAQ Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111506>	C111355	FAQ - Pay Attention, Understand, Discuss|FAQ01-Paying Attention|FAQ01-Paying Attention|FAQ0108	Functional Activities Questionnaire (FAQ) Paying attention to, understanding, discussing TV, book, magazine.			Intellectual Product	CDISC Clinical Classification FAQ Test Code Terminology|CDISC Clinical Classification FAQ Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111507>	C111355	FAQ - Remember|FAQ01-Remembering|FAQ01-Remembering|FAQ0109	Functional Activities Questionnaire (FAQ) Remembering appointments, family occasions, holidays, medications.			Intellectual Product	CDISC Clinical Classification FAQ Test Code Terminology|CDISC Clinical Classification FAQ Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111508>	C111355	FAQ - Travel|FAQ01-Traveling|FAQ01-Traveling|FAQ0110	Functional Activities Questionnaire (FAQ) Traveling out of neighborhood, driving, arranging to take buses.			Intellectual Product	CDISC Clinical Classification FAQ Test Code Terminology|CDISC Clinical Classification FAQ Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111509>	C111355	FAQ - Total Score|FAQ01-Total Score|FAQ01-Total Score|FAQ0111	Functional Activities Questionnaire (FAQ) Total Score.			Intellectual Product	CDISC Clinical Classification FAQ Test Code Terminology|CDISC Clinical Classification FAQ Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11150>	C61063	Cyclophosphamide/Cytarabine/Daunorubicin/Dexamethasone/Vincristine|ARA-C/CTX/DM/DNR/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111510>	C111356	FAQ-NACC UDS Version 2.0 - Write checks, Pay bills, Balance checkbook|FAQNA1-Write Checks/Pay Bills/Checkbook|FAQNA1-Write Checks/Pay Bills/Checkbook|FAQNA101	Functional Assessment Questionnaire-NACC UDS Version 2.0 (FAQ-NACC UDS Version 2.0) Writing checks, paying bills, balancing checkbook.			Intellectual Product	CDISC Clinical Classification FAQ-NACC UDS Version 2.0 Test Code Terminology|CDISC Clinical Classification FAQ-NACC UDS Version 2.0 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111511>	C111356	FAQ-NACC UDS Version 2.0 - Assemble|FAQNA1-Assembling|FAQNA1-Assembling|FAQNA102	Functional Assessment Questionnaire-NACC UDS Version 2.0 (FAQ-NACC UDS Version 2.0) Assembling tax records, business affairs, or papers.			Intellectual Product	CDISC Clinical Classification FAQ-NACC UDS Version 2.0 Test Code Terminology|CDISC Clinical Classification FAQ-NACC UDS Version 2.0 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111512>	C111356	FAQ-NACC UDS Version 2.0 - Shop Alone|FAQNA1-Shopping Alone|FAQNA1-Shopping Alone|FAQNA103	Functional Assessment Questionnaire-NACC UDS Version 2.0 (FAQ-NACC UDS Version 2.0) Shopping alone for clothes, household necessities, or groceries.			Intellectual Product	CDISC Clinical Classification FAQ-NACC UDS Version 2.0 Test Code Terminology|CDISC Clinical Classification FAQ-NACC UDS Version 2.0 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111513>	C111356	FAQ-NACC UDS Version 2.0 - Play Game of Skill, Work on Hobby|FAQNA1-Playing a Game of Skill|FAQNA1-Playing a Game of Skill|FAQNA104	Functional Assessment Questionnaire-NACC UDS Version 2.0 (FAQ-NACC UDS Version 2.0) Playing a game of skill, working on a hobby.			Intellectual Product	CDISC Clinical Classification FAQ-NACC UDS Version 2.0 Test Code Terminology|CDISC Clinical Classification FAQ-NACC UDS Version 2.0 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111514>	C111356	FAQ-NACC UDS Version 2.0 - Heat water, Make Coffee, Turn Off Stove|FAQNA1-Heat Water/Make Coffee/Stove Off|FAQNA1-Heat Water/Make Coffee/Stove Off|FAQNA105	Functional Assessment Questionnaire-NACC UDS Version 2.0 (FAQ-NACC UDS Version 2.0) Heating water, making a cup of coffee, turning off stove after use.			Intellectual Product	CDISC Clinical Classification FAQ-NACC UDS Version 2.0 Test Code Terminology|CDISC Clinical Classification FAQ-NACC UDS Version 2.0 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111515>	C111356	FAQ-NACC UDS Version 2.0 - Prepare a Meal|FAQNA1-Preparing a Balanced Meal|FAQNA1-Preparing a Balanced Meal|FAQNA106	Functional Assessment Questionnaire-NACC UDS Version 2.0 (FAQ-NACC UDS Version 2.0) Preparing a balanced meal.			Intellectual Product	CDISC Clinical Classification FAQ-NACC UDS Version 2.0 Test Code Terminology|CDISC Clinical Classification FAQ-NACC UDS Version 2.0 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111516>	C111356	FAQ-NACC UDS Version 2.0 - Keep Track of Current Events|FAQNA1-Keeping Track of Current Events|FAQNA1-Keeping Track of Current Events|FAQNA107	Functional Assessment Questionnaire-NACC UDS Version 2.0 (FAQ-NACC UDS Version 2.0) Keeping track of current events.			Intellectual Product	CDISC Clinical Classification FAQ-NACC UDS Version 2.0 Test Code Terminology|CDISC Clinical Classification FAQ-NACC UDS Version 2.0 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111517>	C111356	FAQ-NACC UDS Version 2.0 - Pay Attention, Understand, Discuss|FAQNA1-Paying Attention|FAQNA1-Paying Attention|FAQNA108	Functional Assessment Questionnaire-NACC UDS Version 2.0 (FAQ-NACC UDS Version 2.0) Paying attention to, understanding, discussing TV, book, magazine.			Intellectual Product	CDISC Clinical Classification FAQ-NACC UDS Version 2.0 Test Code Terminology|CDISC Clinical Classification FAQ-NACC UDS Version 2.0 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111518>	C111356	FAQ-NACC UDS Version 2.0 - Remember|FAQNA1-Remembering|FAQNA1-Remembering|FAQNA109	Functional Assessment Questionnaire-NACC UDS Version 2.0 (FAQ-NACC UDS Version 2.0) Remembering appointments, family occasions, holidays, medications.			Intellectual Product	CDISC Clinical Classification FAQ-NACC UDS Version 2.0 Test Code Terminology|CDISC Clinical Classification FAQ-NACC UDS Version 2.0 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111519>	C111356	FAQ-NACC UDS Version 2.0 - Travel|FAQNA1-Traveling|FAQNA1-Traveling|FAQNA110	Functional Assessment Questionnaire-NACC UDS Version 2.0 (FAQ-NACC UDS Version 2.0) Traveling out of neighborhood, driving, arranging to take buses.			Intellectual Product	CDISC Clinical Classification FAQ-NACC UDS Version 2.0 Test Code Terminology|CDISC Clinical Classification FAQ-NACC UDS Version 2.0 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11151>	C61063	Cyclophosphamide/Cytarabine/Methylprednisolone|ARA-C/CTX/MePRDL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111520>	C111357	MRS - Modified Rankin Scale Score|MRS01-Modified Rankin Scale Score|MRS01-Modified Rankin Scale Score|MRS0101	Modified Rankin Scale (MRS) Modified Rankin Scale Score.			Intellectual Product	CDISC Clinical Classification MRS Test Code Terminology|CDISC Clinical Classification MRS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111521>	C111358	SDS - Symptoms Disrupted Work/School Work|SDS01-Work/School|SDS01-Work/School|SDS0101	Sheehan Disability Scale (SDS) The symptoms have disrupted your work/school work.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SDS Test Code Terminology|CDISC Questionnaire SDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111522>	C111358	SDS - Not Worked/Studied in Past Week for Reason Unrelated to Disorder|SDS01-No Work/Study - Unrelated Disorder|SDS01-No Work/Study - Unrelated Disorder|SDS0101A	Sheehan Disability Scale (SDS) I have not worked/studied at all during the past week for reasons unrelated to the disorder.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SDS Test Code Terminology|CDISC Questionnaire SDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111523>	C111358	SDS - Symptoms Disrupted Social Life/Leisure Activities|SDS01-Social Life|SDS01-Social Life|SDS0102	Sheehan Disability Scale (SDS) The symptoms have disrupted your social life/leisure activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SDS Test Code Terminology|CDISC Questionnaire SDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111524>	C111358	SDS - Symptoms Disrupted Family Life/Home Responsibilities|SDS01-Family Life/Home Responsibilities|SDS01-Family Life/Home Responsibilities|SDS0103	Sheehan Disability Scale (SDS) The symptoms have disrupted your family life/home responsibilities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SDS Test Code Terminology|CDISC Questionnaire SDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111525>	C111358	SDS - Days Lost|SDS01-Days Lost|SDS01-Days Lost|SDS0104	Sheehan Disability Scale (SDS) On how many days in the last week did your symptoms cause you to miss school or work or leave you unable to carry out your normal daily responsibilities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SDS Test Code Terminology|CDISC Questionnaire SDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111526>	C111358	SDS - Days Underproductive|SDS01-Days Underproductive|SDS01-Days Underproductive|SDS0105	Sheehan Disability Scale (SDS) On how many days in the last week did you feel so impaired by your symptoms, that even though you went to school or work or had other daily responsibilities, your productivity was reduced?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SDS Test Code Terminology|CDISC Questionnaire SDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111527>	C111351	C-SSRS Children's Baseline - Wish to be Dead|CSS06-Wish to be Dead|CSS06-Wish to be Dead|CSS0601	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Have you thought about being dead or what it would be like to be dead? Have you wished you were dead or wished you could go to sleep and never wake up? Do you ever wish you weren't alive anymore?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111528>	C111351	C-SSRS Children's Baseline - Description of Wish to be Dead|CSS06-Wish to be Dead, Describe|CSS06-Wish to be Dead, Describe|CSS0601A	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Description of wishing to be dead.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111529>	C111351	C-SSRS Children's Baseline - Non-Specific Active Suicidal Thoughts|CSS06-Non-Specific Suicidal Thought|CSS06-Non-Specific Suicidal Thought|CSS0602	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Have you thought about doing something to make yourself not alive anymore? Have you had any thoughts about killing yourself?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11152>	C61063	Hydrocortisone/Methotrexate|HC/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111530>	C111351	C-SSRS Children's Baseline - Description of Non-Specific Active Suicidal Thoughts|CSS06-Non-Specific Suicid Thought, Descr|CSS06-Non-Specific Suicid Thought, Descr|CSS0602A	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Description of non-specific active suicidal thoughts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111531>	C111351	C-SSRS Children's Baseline - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act|CSS06-Idea, No Intent, No Plan|CSS06-Idea, No Intent, No Plan|CSS0603	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Have you thought about how you would do that or how you would make yourself not alive anymore (kill yourself)? What did you think about?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111532>	C111351	C-SSRS Children's Baseline - Description of Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act|CSS06-Idea, No Intent, No Plan, Describe|CSS06-Idea, No Intent, No Plan, Describe|CSS0603A	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Description of active suicidal ideation with any methods (not plan) without intent to act.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111533>	C111351	C-SSRS Children's Baseline - Active Suicidal Ideation with Some Intent to Act, without Specific Plan|CSS06-Ideation With Intent, No Plan|CSS06-Ideation With Intent, No Plan|CSS0604	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) When you thought about making yourself not alive anymore (or killing yourself), did you think that this was something you might actually do? This is different from (as opposed to) having the thoughts but knowing you wouldn't do anything about it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111534>	C111351	C-SSRS Children's Baseline - Description of Active Suicidal Ideation with Some Intent to Act, without Specific Plan|CSS06-Ideation With Intent No Plan Descr|CSS06-Ideation With Intent No Plan Descr|CSS0604A	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Description of active suicidal ideation with some intent to act, without specific plan.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111535>	C111351	C-SSRS Children's Baseline - Active Suicidal Ideation with Specific Plan and Intent|CSS06-Ideation With Plan/Intent|CSS06-Ideation With Plan/Intent|CSS0605	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Have you ever decided how or when you would make yourself not alive anymore/kill yourself? Have you ever planned out (worked out the details of) how you would do it? What was your plan? When you made this plan (or worked out these details), was any part of you thinking about actually doing it?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111536>	C111351	C-SSRS Children's Baseline - Description of Active Suicidal Ideation with Specific Plan and Intent|CSS06-Ideation With Plan/Intent, Descr|CSS06-Ideation With Plan/Intent, Descr|CSS0605A	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Description of active suicidal ideation with specific plan and intent.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111537>	C111351	C-SSRS Children's Baseline - Most Severe Ideation|CSS06-Most Severe Ideation|CSS06-Most Severe Ideation|CSS0606	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Most severe ideation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111538>	C111351	C-SSRS Children's Baseline - Describe Most Severe Ideation|CSS06-Most Severe Ideation, Description|CSS06-Most Severe Ideation, Description|CSS0606A	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Description of most severe ideation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111539>	C111351	C-SSRS Children's Baseline - Frequency of Most Severe Ideation|CSS06-Most Severe Ideation, Frequency|CSS06-Most Severe Ideation, Frequency|CSS0607	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) How many times have you had these thoughts?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11153>	C61063	Asparaginase/Dexamethasone/Epirubicin/Vincristine|ASP/DM/EPI/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111540>	C111351	C-SSRS Children's Baseline - Frequency, Write Response|CSS06-Frequency, Write Response|CSS06-Frequency, Write Response|CSS0607A	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Frequency, write response.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111541>	C111351	C-SSRS Children's Baseline - Actual Suicide Attempt|CSS06-Actual Attempt|CSS06-Actual Attempt|CSS0608	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Did you ever do anything to try to kill yourself or make yourself not alive anymore? What did you do? Did you ever hurt yourself on purpose? Why did you do that?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111542>	C111351	C-SSRS Children's Baseline - Number of Actual Suicide Attempts|CSS06-Number of Actual Attempts|CSS06-Number of Actual Attempts|CSS0609	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Total number of actual attempts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111543>	C111351	C-SSRS Children's Baseline - Description of Actual Suicide Attempt|CSS06-Actual Attempt, Describe|CSS06-Actual Attempt, Describe|CSS0609A	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Description of actual attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111544>	C111351	C-SSRS Children's Baseline - Non-suicidal Self-injurious Behavior|CSS06-Non-suicidal Self-injurious Behav|CSS06-Non-suicidal Self-injurious Behav|CSS0610	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Has subject engaged in non-suicidal self-injurious behavior?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111545>	C111351	C-SSRS Children's Baseline - Self-injurious Behavior, Intent Unknown|CSS06-Self-injur Behav, Intent Unknown|CSS06-Self-injur Behav, Intent Unknown|CSS0611	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Has subject engaged in self-injurious behavior, intent unknown?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111546>	C111351	C-SSRS Children's Baseline - Interrupted Suicide Attempt|CSS06-Interrupted Attempt|CSS06-Interrupted Attempt|CSS0612	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Has there been a time when you started to do something to make yourself not alive anymore (end your life or kill yourself) but someone or something stopped you before you actually did anything? What did you do?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111547>	C111351	C-SSRS Children's Baseline - Number of Interrupted Suicide Attempts|CSS06-Number of Interrupt Attempts|CSS06-Number of Interrupt Attempts|CSS0613	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Total number of interrupted.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111548>	C111351	C-SSRS Children's Baseline - Description of Interrupted Suicide Attempt|CSS06-Interrupted Attempt, Describe|CSS06-Interrupted Attempt, Describe|CSS0613A	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Description of interrupted attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111549>	C111351	C-SSRS Children's Baseline - Aborted Suicide Attempt|CSS06-Aborted Attempt|CSS06-Aborted Attempt|CSS0614	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Has there been a time when you started to do something to make yourself not alive anymore (end your life or kill yourself) but you changed your mind (stopped yourself) before you actually did anything? What did you do?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11154>	C61063	Cytarabine/Etoposide/Vincristine|ARA-C/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111550>	C111351	C-SSRS Children's Baseline - Number of Aborted Suicide Attempts|CSS06-Number of Aborted Attempts|CSS06-Number of Aborted Attempts|CSS0615	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Total number of aborted.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111551>	C111351	C-SSRS Children's Baseline - Description of Aborted Suicide Attempt|CSS06-Aborted Attempt, Describe|CSS06-Aborted Attempt, Describe|CSS0615A	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Description of aborted attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111552>	C111351	C-SSRS Children's Baseline - Preparatory Acts or Behaviors Toward Suicide Attempt|CSS06-Preparatory Acts/Behavior|CSS06-Preparatory Acts/Behavior|CSS0616	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Have you done anything to get ready to make yourself not alive anymore (to end your life or kill yourself) - like giving things away, writing a goodbye note, getting things you need to kill yourself?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111553>	C111351	C-SSRS Children's Baseline - Description of Preparatory Acts or Behaviors Toward Suicide Attempt|CSS06-Preparatory Acts/Behavior, Descr|CSS06-Preparatory Acts/Behavior, Descr|CSS0616A	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Description of preparatory acts or behaviors.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111554>	C111351	C-SSRS Children's Baseline - Suicidal Behavior|CSS06-Suicidal Behavior|CSS06-Suicidal Behavior|CSS0617	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Suicidal behavior was present during the assessment period?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111555>	C111351	C-SSRS Children's Baseline - Most Recent Suicide Attempt Date|CSS06-Most Recent Attempt Date|CSS06-Most Recent Attempt Date|CSS0618A	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Most recent attempt date.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111556>	C111351	C-SSRS Children's Baseline - Most Recent Suicide Attempt Actual Lethality/Medical Damage|CSS06-Most Recent Attempt Damage|CSS06-Most Recent Attempt Damage|CSS0618B	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Most recent attempt actual lethality/medical damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111557>	C111351	C-SSRS Children's Baseline - Most Recent Suicide Attempt Potential Lethality|CSS06-Most Recent Attempt Potential|CSS06-Most Recent Attempt Potential|CSS0618C	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Most recent attempt potential lethality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111558>	C111351	C-SSRS Children's Baseline - Most Lethal Suicide Attempt Date|CSS06-Most Lethal Attempt Date|CSS06-Most Lethal Attempt Date|CSS0619A	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Most lethal attempt date.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111559>	C111351	C-SSRS Children's Baseline - Most Lethal Suicide Attempt Actual Lethality/Medical Damage|CSS06-Most Lethal Attempt Damage|CSS06-Most Lethal Attempt Damage|CSS0619B	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Most lethal attempt actual lethality/medical damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11155>	C61063	Cytarabine/Etoposide/Thioguanine/Vincristine|ARA-C/CTX/TG/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111560>	C111351	C-SSRS Children's Baseline - Most Lethal Suicide Attempt Potential Lethality|CSS06-Most Lethal Attempt Potential|CSS06-Most Lethal Attempt Potential|CSS0619C	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Most lethal attempt potential lethality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111561>	C111351	C-SSRS Children's Baseline - First Suicide Attempt Date|CSS06-First Attempt Date|CSS06-First Attempt Date|CSS0620A	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Initial/first attempt date.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111562>	C111351	C-SSRS Children's Baseline - First Suicide Attempt Actual Lethality/Medical Damage|CSS06-First Attempt Damage|CSS06-First Attempt Damage|CSS0620B	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Initial/first attempt actual lethality/medical damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111563>	C111351	C-SSRS Children's Baseline - First Suicide Attempt Potential Lethality|CSS06-First Attempt Potential|CSS06-First Attempt Potential|CSS0620C	Columbia-Suicidality Severity Rating Scale Children's Baseline (C-SSRS Children's Baseline) Initial/first attempt potential lethality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Code Terminology|CDISC Questionnaire C-SSRS Children's Baseline Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111564>	C14329	Multi-Drug Resistant Organism|MDRO|MDRO|Multi-drug resistant organisms	A microorganism, often a bacterium, that is not susceptible to standard antimicrobial therapies.	Multi-Drug Resistant Organism		Organism	CTRP Biomarker Terminology|CTRP Terminology
C111565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111565>	C200765	Anti-EGFRvIII CAR-transduced Allogeneic T-lymphocytes|Anti-EGFRvIII CAR PG13-139-CD8-CD28BBZ- transduced T-lymphocytes	Allogeneic human T-lymphocytes transduced with a retroviral vector encoding an anti-epidermal growth factor receptor (EGFR) variant III (EGFRvIII) mutant chimeric T cell receptor (chimeric antigen receptor or CAR) gene coupled to the signaling domains from CD8, CD28, 4-1BB (CD137) and CD3 zeta, with potential immunostimulatory and antineoplastic activities. Upon administration, the anti-EGFRvIII CAR-transduced allogeneic T lymphocytes bind to the EGFRvIII antigen on tumor cell surfaces; subsequently, EGFRvIII-expressing tumor cells may be lysed. EGFRvIII, an in-frame deletion of exons 2-7 in the EGFR gene, is overexpressed by a variety of cancer cell types and absent in normal, healthy cells; it plays a key role in tumor cell proliferation, tumor angiogenesis and radio- and chemoresistance.	Anti-EGFRvIII CAR-transduced Allogeneic T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111566>	C2124	Carbon C 14-labeled Ixazomib|[14C]-1,4-(R,S)-(carboxymethyl)-2-((R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-6-oxo-1,3,2-dioxaborinane-4-carboxylic Acid|[14C]-Ixazomib|[14C]-MLN9708	A radioconjugate comprised of the orally available reversible 20S proteasome inhibitor ixazomib and labeled with the isotope carbon C 14. Upon administration, the ixazomib moiety hydrolyzes and generates its active form, MLN2238, which inhibits the activity of the 20S catalytic core subunit of the proteasome. This blocks the targeted proteolysis normally performed by the proteasome, which results in an accumulation of unwanted or misfolded proteins. The accumulation of protein may disrupt various cell signaling pathways, induce apoptosis, and inhibit tumor growth. In addition, this agent targets tumor suppressor microRNA-33b (miR-33b). Labeling with the radioactive tracer carbon C 14 allows for evaluation of ixazomib's absorption, distribution, metabolism and excretion (ADME).	Carbon C 14-labeled Ixazomib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C111567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111567>	C27993	Detectable	The capability of being noticed, identified or discovered.			Clinical Attribute	
C111568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111568>	C20189	Undetectable	The inability to be noticed, identified or discovered.			Clinical Attribute	
C111569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111569>	C61074	MELK Inhibitor OTS167|OTS-167|OTS-167|OTS167	An orally available inhibitor of maternal embryonic leucine zipper kinase (MELK) with potential antineoplastic activity. Upon administration, OTS167 binds to MELK, which prevents both MELK phosphorylation and activation; thus inhibiting the phosphorylation of downstream MELK substrates. This may lead to an inhibition of both cell proliferation and survival in MELK-expressing tumor cells. MELK, a serine/threonine kinase, is involved in cancer cell survival, invasiveness and cancer-stem cell formation and maintenance; it is highly upregulated in various types of cancer cells and absent in normal, healthy cells.	MELK Inhibitor OTS167		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11156>	C61063	Asparaginase/Cyclophosphamide/Cytarabine/Dexamethasone/Epirubicin/Etoposide/Thioguanine/Vincristine|ARA-C/ASP/CTX/DM/EPI/TG/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111570>	C67437	Nanosomal Docetaxel Lipid Suspension|DTX-LNS|NDLS	A lipid-based nanosomal formulation of the poorly soluble, semi-synthetic, second-generation taxane docetaxel, with potential antineoplastic activity. Upon intravenous injection, docetaxel binds to and stabilizes tubulin, which inhibits microtubule disassembly and results in both cell cycle arrest at the G2/M phase and cell death. This liposomal formulation solubilizes docetaxel without the use of toxic solvents, such as polysorbate 80. This permits the administration of larger doses of docetaxel and improves the drug's safety profile by avoiding solvent-associated toxicities, such as hypersensitivity reactions and neurotoxicity. In addition, the nanosomal lipid-based delivery of docetaxel improves drug penetration into tumors and decreases drug clearance, all of which prolong the duration of docetaxel's therapeutic effects.	Nanosomal Docetaxel Lipid Suspension		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111571>	C203000	Spanlecortemlocel|Allogeneic UCB-derived HSPCs MGTA 456|Allogeneic Umbilical Cord Blood-derived Hematopoietic Stem and Progenitor Cells MGTA-456|Expanded Umbilical Cord Blood Product HSC835|HSC 835|HSC835|MGTA 456|MGTA-456|SPANLECORTEMLOCEL	A preparation of allogeneic umbilical cord blood (UCB)-derived hematopoietic stem and progenitor cells (HSPCs) expanded in culture with the stimulatory cytokines stem cell factor (SCF; Kit ligand; mast cell growth factor; MGF), FMS-like tyrosine kinase 3 ligand (Flt3L), interleukin 6 (IL-6), and thrombopoietin, in the presence of an aryl hydrocarbon receptor (AHR) antagonist LHD221 (StemRegenin-1; SR-1), with potential to improve hematopoietic recovery following myeloablative conditioning. Upon administration of Spanlecortemlocel, these cells increase and restore the number of HSPCs, which may prevent or decrease the risk of infection and other complications of chemotherapy-induced neutropenia (CIN) or cord blood transplantation. LHD221, an AHR antagonist facilitates the expansion of CD34-positive hematopoietic progenitors and impedes HSPC differentiation during cytokine-driven expansion in culture.	Spanlecortemlocel		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology
C111572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111572>	C2124	Carbon C 14 Oxaliplatin|[14C] Oxaliplatin	A radioconjugate composed of the platinum agent oxaliplatin labeled with the isotope carbon C 14, that can be used to predict the response to oxaliplatin therapy using accelerator mass spectrometry (AMS). Upon intravenous administration of a microdose of carbon C 14 oxaliplatin, the oxaliplatin moiety covalently links to DNA and forms mono- and di-DNA adducts. The platinum-DNA adduct formation can be measured through quantification of C14-labeled drug-DNA adducts by using AMS. By measuring the microdose-induced DNA damage, the response to oxaliplatin-based chemotherapy can be assessed and predicted. Measurements that indicate either low drug-DNA adduct formation or increased DNA repair (C14 removal from DNA) are correlated with increased resistance to platinum-based chemotherapeutics.	Carbon C 14 Oxaliplatin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C111573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111573>	C168619	Enasidenib|AG 221|AG-221|AG221|CC-90007 Free Base|ENASIDENIB	An orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits various mutant forms of IDH2, including the IDH2 variants R140Q, R172S, and R172K, which inhibits the formation of 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH2-expressing tumor cells. IDH2, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by blocking differentiation and the production of the oncometabolite 2HG.	Enasidenib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCIt Antineoplastic Agent Terminology
C111574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111574>	C181141	mRNA-derived Lung Cancer Vaccine BI 1361849|BI 1361849|BI1361849|CV9202	A non-small cell lung cancer (NSCLC) vaccine containing six modified mRNAs, which encode six different NSCLC associated antigens, with potential antitumor and immunomodulatory activities. Upon intradermal administration, mRNA-derived lung cancer vaccine BI 1361849 may stimulate the immune system to mount both humoral and cellular responses against NSCLC cells. The six tumor-associated antigens (TAAs) encoded by these mRNAs are frequently expressed by NSCLC cells and are minimally expressed or absent in normal, healthy cells.			Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111575>	C155764	AKT 1/2 Inhibitor BAY1125976|BAY-1125976|BAY1125976	An orally bioavailable inhibitor of the serine/threonine protein kinase AKT (protein kinase B) isoforms 1 and 2 (AKT1/2) with potential antineoplastic activity. AKT1/2 inhibitor BAY1125976 selectively binds to and inhibits the phosphorylation and activity of AKT1/2 in a non-ATP competitive manner, which may result in the inhibition of the phosphatidylinositol 3 (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway. This may lead to both the reduction of cell proliferation and the induction of cell apoptosis in AKT-overexpressing tumor cells. The AKT signaling pathway is often deregulated in cancer and is associated with tumor cell proliferation, survival and migration.	AKT 1/2 Inhibitor BAY1125976		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111576>	C2124	Fluorine F 18 Dasatinib|F-SKI249380|FLUORO-DASATINIB F-18|Fluorine F 18 SKI-249380|Fluorine F 18 SKI-249380|Fluoro(F18)-Dasatinib|SKI-249380 F-18|[18F] SKI-249380|[18F]-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-fluoroethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide	A radioconjugate composed of a derivative of the multi-targeted kinase inhibitor dasatinib conjugated to the radioisotope fluorine F 18, with potential imaging activity during positron emission tomography (PET). Upon administration of fluorine F 18 dasatinib, dasatinib targets and binds to Bcr/Abl, SRC-family protein-tyrosine kinases, c-Kit and platelet-derived growth factor receptor (PDGFR). Upon binding, the fluorine F 18 moiety allows PET imaging of tumor cells and can be used as a tracer for the biodistribution of dasatinib.	Fluorine F 18 Dasatinib		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C111577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111577>	C105142	DAD - Sub-Total Initiation|DAD01-Sub-Total Initiation|DAD01-Sub-Total Initiation|DAD0141	Disability Assessment for Dementia (DAD) Sub-total initiation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111578>	C105142	DAD - Total Initiation Number of Applicable Items|DAD01-Initiation Num Applic Items|DAD01-Initiation Num Applic Items|DAD0142	Disability Assessment for Dementia (DAD) Total initiation number of applicable items.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111579>	C105142	DAD - Sub-Total Planning and Organization|DAD01-Sub-Total Planning & Organization|DAD01-Sub-Total Planning & Organization|DAD0143	Disability Assessment for Dementia (DAD) Sub-total planning and organization.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11157>	C61063	Cyclophosphamide/Cytarabine/Etoposide/Mercaptopurine/Methotrexate/Prednisolone/Thioguanine/Vincristine|ARA-C/CTX/MP/MTX/PRDL/TG/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111580>	C105142	DAD - Sub-Total Effective Performance|DAD01-Sub-Total Effective Performance|DAD01-Sub-Total Effective Performance|DAD0145	Disability Assessment for Dementia (DAD) Sub-total effective performance.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111581>	C105142	DAD - Sub-Total Effective Performance Number of Applicable Items|DAD01-Effective Perf Num Applic Items|DAD01-Effective Perf Num Applic Items|DAD0146	Disability Assessment for Dementia (DAD) Sub-total effective performance number of applicable items.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111582>	C105142	DAD - Total Score|DAD01-Total Score|DAD01-Total Score|DAD0147	Disability Assessment for Dementia (DAD) Total score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111583>	C105142	DAD - Total Number of Applicable Items|DAD01-Total Num of Applic Items|DAD01-Total Num of Applic Items|DAD0148	Disability Assessment for Dementia (DAD) Total number of applicable items.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111584>	C105142	DAD - Total Percent|DAD01-Total %|DAD01-Total %|DAD0149	Disability Assessment for Dementia (DAD) DAD total in percent.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111585>	C100126	UPDRS - Motor Examination: Tremor at Rest, Face, Lips, Chin|UPD1-Motor:Tremor at Rest:Face Lips Chin|UPD1-Motor:Tremor at Rest:Face Lips Chin|UPD120A	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: tremor at rest, face, lips, chin.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111586>	C100126	UPDRS - Motor Examination: Tremor at Rest, Hands, Right|UPD1-Motor:Tremor at Rest:Hands: Right|UPD1-Motor:Tremor at Rest:Hands: Right|UPD120B	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: tremor at rest, hands, right.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111587>	C100126	UPDRS - Motor Examination: Tremor at Rest, Hands, Left|UPD1-Motor:Tremor at Rest:Hands: Left|UPD1-Motor:Tremor at Rest:Hands: Left|UPD120C	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: tremor at rest, hands, Left.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111588>	C100126	UPDRS - Motor Examination: Tremor at Rest, Feet, Right|UPD1-Motor:Tremor at Rest:Feet: Right|UPD1-Motor:Tremor at Rest:Feet: Right|UPD120D	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: tremor at rest, feet, right.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111589>	C100126	UPDRS - Motor Examination: Tremor at Rest, Feet, Left|UPD1-Motor:Tremor at Rest:Feet: Left|UPD1-Motor:Tremor at Rest:Feet: Left|UPD120E	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: tremor at rest, feet, left.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11158>	C61063	Carboplatin/Filgrastim|CBDCA/G-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111590>	C100126	UPDRS - Motor Examination: Action Tremor, Hand, Right|UPD1--Motor:Action Tremor:Hand: Right|UPD1--Motor:Action Tremor:Hand: Right|UPD121A	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: action tremor, hand, right.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111591>	C100126	UPDRS - Motor Examination: Action Tremor, Hand, Left|UPD1--Motor:Action Tremor:Hand: Left|UPD1--Motor:Action Tremor:Hand: Left|UPD121B	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: action tremor, hand, left.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111592>	C100126	UPDRS - Motor Examination: Rigidity Neck|UPD1-Motor:Rigidity Neck|UPD1-Motor:Rigidity Neck|UPD122A	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: rigidity neck.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111593>	C100126	UPDRS - Motor Examination: Rigidity Upper Extremity, Right|UPD1-Motor:Rigidity Upper Extrem: Right|UPD1-Motor:Rigidity Upper Extrem: Right|UPD122B	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: rigidity upper extremity, right.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111594>	C100126	UPDRS - Motor Examination: Rigidity Upper Extremity, Left|UPD1-Motor:Rigidity Upper Extrem: Left|UPD1-Motor:Rigidity Upper Extrem: Left|UPD122C	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: rigidity upper extremity, left.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111595>	C100126	UPDRS - Motor Examination: Rigidity Lower Extremity, Right|UPD1-Motor:Rigidity Lower Extrem: Right|UPD1-Motor:Rigidity Lower Extrem: Right|UPD122D	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: rigidity lower extremity, right.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111596>	C100126	UPDRS - Motor Examination: Rigidity Lower Extremity, Left|UPD1-Motor:Rigidity Lower Extrem: Left|UPD1-Motor:Rigidity Lower Extrem: Left|UPD122E	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: rigidity lower extremity, left.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111597>	C100126	UPDRS - Motor Examination: Finger Taps, Right|UPD1-Motor:Finger Taps: Right|UPD1-Motor:Finger Taps: Right|UPD123A	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: finger taps, right.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111598>	C100126	UPDRS - Motor Examination: Finger Taps, Left|UPD1-Motor:Finger Taps: Left|UPD1-Motor:Finger Taps: Left|UPD123B	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: finger taps, left.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111599>	C100126	UPDRS - Motor Examination: Hand Grips, Right|UPD1-Motor:Hand Grips: Right|UPD1-Motor:Hand Grips: Right|UPD124A	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: hand grips, right.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11159>	C61063	Cimetidine/Tumor Infiltrating Lymphocytes|cimetidine/TIL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1115>	C68442|C29596	Glutamic Acid|(S)-2-Aminopentanedioic acid|GLUTAMIC ACID|Glu|Glutamate|L-Glutamate|L-Glutamic Acid|L-Glutamic Acid|L-glutamic acid|glutamic acid	A non-essential alpha-amino acid and excitatory neurotransmitter. Glutamic acid can serve as a precursor for the synthesis of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA).	Glutamic Acid		Amino Acid, Peptide, or Protein	CTRP Agent Terminology|CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C111600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111600>	C100126	UPDRS - Motor Examination: Hand Grips, Left|UPD1-Motor:Hand Grips: Left|UPD1-Motor:Hand Grips: Left|UPD124B	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: hand grips, left.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111601>	C100126	UPDRS - Motor Examination: Hand Pronate/Supinate, Right|UPD1-Motor:Hand Pronate/Supinate: Right|UPD1-Motor:Hand Pronate/Supinate: Right|UPD125A	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: hand pronate/supinate, right.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111602>	C100126	UPDRS - Motor Examination: Hand Pronate/Supinate, Left|UPD1-Motor:Hand Pronate/Supinate: Left|UPD1-Motor:Hand Pronate/Supinate: Left|UPD125B	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: hand pronate/supinate, left.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111603>	C100126	UPDRS - Motor Examination: Leg Agility, Right|UPD1-Motor:Leg Agility: Right|UPD1-Motor:Leg Agility: Right|UPD126A	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: leg agility, right.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111604>	C100126	UPDRS - Motor Examination: Leg Agility, Left|UPD1-Motor:Leg Agility: Left|UPD1-Motor:Leg Agility: Left|UPD126B	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination: leg agility, left.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111605>	C100126	UPDRS - Symptomatic Orthostasis: Blood Pressure, Seated|UPD1-Blood Pressure: Seated|UPD1-Blood Pressure: Seated|UPD142A	Unified Parkinson's Disease Rating Scale (UPDRS) Symptomatic orthostasis: blood pressure, seated.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111606>	C100126	UPDRS - Symptomatic Orthostasis: Blood Pressure, Supine|UPD1-Blood Pressure: Supine|UPD1-Blood Pressure: Supine|UPD142B	Unified Parkinson's Disease Rating Scale (UPDRS) Symptomatic orthostasis: blood pressure, supine.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111607>	C100126	UPDRS - Symptomatic Orthostasis: Blood Pressure, Standing|UPD1-Blood Pressure: Standing|UPD1-Blood Pressure: Standing|UPD142C	Unified Parkinson's Disease Rating Scale (UPDRS) Symptomatic orthostasis: blood pressure, standing.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111608>	C100126	UPDRS - Symptomatic Orthostasis: Weight|UPD1-Weight|UPD1-Weight|UPD142D	Unified Parkinson's Disease Rating Scale (UPDRS) Symptomatic orthostasis: weight.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111609>	C100126	UPDRS - Symptomatic Orthostasis: Pulse, Seated|UPD1-Pulse: Seated|UPD1-Pulse: Seated|UPD142E	Unified Parkinson's Disease Rating Scale (UPDRS) Symptomatic orthostasis: pulse, seated.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11160>	C61063	Asparaginase/Cyclophosphamide/Daunorubicin/Dexamethasone/Vincristine|ASP/CTX/DM/DNR/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111610>	C100126	UPDRS - Symptomatic Orthostasis: Pulse, Standing|UPD1-Pulse: Standing|UPD1-Pulse: Standing|UPD142F	Unified Parkinson's Disease Rating Scale (UPDRS) Symptomatic orthostasis: pulse, standing.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111611>	C100126	UPDRS - Schwab and England % ADL Score (PD)|UPD1-Schwab/England % ADL Score (PD)|UPD1-Schwab/England % ADL Score (PD)|UPD144A	Unified Parkinson's Disease Rating Scale (UPDRS) Schwab and England % ADL score (PD).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111612>	C100126	UPDRS - Schwab and England % ADL (With Dyskinesia)|UPD1-Schwab/England % ADL (Dyskinesia)|UPD1-Schwab/England % ADL (Dyskinesia)|UPD144B	Unified Parkinson's Disease Rating Scale (UPDRS) Schwab and England % ADL (with dyskinesia).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111613>	C100126	UPDRS - Mentation, Behavior and Mood Sub-total|UPD1-Mentation, Behavior, Mood Sub-Total|UPD1-Mentation, Behavior, Mood Sub-Total|UPD145	Unified Parkinson's Disease Rating Scale (UPDRS) Mentation, behavior and mood sub-total.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111614>	C100126	UPDRS - Activities of Daily Living Sub-total|UPD1-Activities Daily Living Sub-Total|UPD1-Activities Daily Living Sub-Total|UPD146	Unified Parkinson's Disease Rating Scale (UPDRS) Activities of daily living sub-total.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111615>	C100126	UPDRS - Motor Examination Sub-total|UPD1-Motor Examination Sub-Total|UPD1-Motor Examination Sub-Total|UPD147	Unified Parkinson's Disease Rating Scale (UPDRS) Motor examination sub-total.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111616>	C100126	UPDRS - UPDRS Total|UPD1-UPDRS Total|UPD1-UPDRS Total|UPD148	Unified Parkinson's Disease Rating Scale (UPDRS) UPDRS total.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UPDRS Test Code Terminology|CDISC Clinical Classification UPDRS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111617>	C105142	DAD - Plan and Organize Number of Applicable Items|DAD01-Plan & Org Num Applic Items|DAD01-Plan & Org Num Applic Items|DAD0144	Disability Assessment for Dementia (DAD) Sub-Total Planning and Organization Number of Applicable Items.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DAD Test Code Terminology|CDISC Questionnaire DAD Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C111618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111618>	C101143	Epstein-Barr Virus Early RNA|EBER|EBER|Epstein-Barr Early RNA|Epstein-Barr Early Region RNA|Epstein-Barr Encoded RNA|Epstein-Barr Virus, Early RNA|Epstein-Barr Virus-Associated Early RNA|Epstein-Barr Virus-Encoded Small RNA	Small non-coding RNA that is encoded by Epstein-Barr virus DNA and transcribed by virally-infected cells throughout the latent cycle. Expression of these oligonucleotides may be associated with the regulation of host ribosome function.	Epstein-Barr Virus Early RNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology
C111619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111619>	C69035	ALK Break Apart FISH Probe Kit	A fluorescence in situ hybridization kit that detects the rearrangements between the ALK gene which is located at 2p23 and all known translocation partner loci in lymphomas and carcinomas.			Manufactured Object	
C11161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11161>	C61063	GM2-KLH Vaccine/Interferon Alfa|GM2-KLH/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111620>	C91105	FACT-Taxane Questionnaire|FACT-Tax|FACT-Tax Questionnaire|FACT-Taxane|Functional Assessment of Cancer Therapy-Taxane	A subscale complement to the FACT-G developed specifically for evaluating the potential side effects of taxane therapy on cancer patients.			Intellectual Product	
C111621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111621>	C105777	Have Numbness or Tingling in Hands Question|Have Numbness or Tingling in Hands|I have numbness or tingling in my hands	A question about whether an individual feels or felt numbness or tingling in their hands.			Intellectual Product	FACT-Taxane Questionnaire
C111622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111622>	C105777	Have Numbness or Tingling in Feet Question|Have Numbness or Tingling in Feet|I have numbness or tingling in my feet	A question about whether an individual feels or felt numbness or tingling in their feet.			Intellectual Product	FACT-Taxane Questionnaire
C111623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111623>	C173518	Feel Discomfort in Hands Question|Feel Discomfort in Hands|I feel discomfort in my hands	A question about whether an individual feels or felt discomfort in their hands.			Intellectual Product	FACT-Taxane Questionnaire
C111624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111624>	C173518	Feel Discomfort in Feet Question|Feel Discomfort in Feet|I feel discomfort in my feet	A question about whether an individual feels or felt discomfort in their feet.			Intellectual Product	FACT-Taxane Questionnaire
C111625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111625>	C173346	Have Joint Pain or Muscle Cramps Question|Have Joint Pain or Muscle Cramps|I have joint pain or muscle cramps	A question about whether an individual has or had joint pain or muscle cramps.			Intellectual Product	FACT-Taxane Questionnaire
C111626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111626>	C173981	Get Ringing or Buzzing in Ears Question|Get Ringing or Buzzing in Ears|I get a ringing or buzzing in my ears	A question about whether an individual gets or has gotten a ringing or buzzing in their ears.			Intellectual Product	FACT-Taxane Questionnaire
C111627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111627>	C173398	Have Trouble Buttoning Buttons Question|Have Trouble Buttoning Buttons|I have trouble buttoning buttons	A question about whether an individual has or had trouble buttoning buttons.			Intellectual Product	FACT-Taxane Questionnaire
C111628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111628>	C173398|C173219	Have Trouble Feeling Shape of Small Objects in Hand Question|Have Trouble Feeling Shape of Small Objects in Hand|I have trouble feeling the shape of small objects when they are in my hand	A question about whether an individual has or had trouble feeling the shape of small objects when they are in their hand.			Intellectual Product	FACT-Taxane Questionnaire
C111629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111629>	C173398|C173135	Have Trouble Walking Question|Have Trouble Walking|I have trouble walking	A question about whether an individual has or had trouble walking.			Intellectual Product	FACT-Taxane Questionnaire|Functional Assessment of Chronic Illness Therapy - Abdominal Discomfort
C11162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11162>	C61063	Cisplatin/Fluorouracil/Tirapazamine|CDDP/5-FU/SR-4233			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111630>	C173219	Feel Bloated Question|Feel Bloated|Feeling bloated|I feel bloated	A question about whether an individual feels or felt bloated.			Intellectual Product	FACT-Taxane Questionnaire|Memorial Symptom Assessment Scale - Short Form
C111631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111631>	C173593	Hands Are Swollen Question|Hands Are Swollen|My hands are swollen	A question about whether an individual's hands are or were swollen.			Intellectual Product	FACT-Taxane Questionnaire
C111632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111632>	C173593	Legs or Feet Are Swollen Question|Legs or Feet Are Swollen|My legs or feet are swollen	A question about whether an individual's legs or feet are or were swollen.			Intellectual Product	FACT-Taxane Questionnaire
C111633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111633>	C91126	Have Pain in Fingertips Question|Have Pain in Fingertips|I have pain in my fingertips	A question about whether an individual has or had pain in their fingertips.			Intellectual Product	FACT-Taxane Questionnaire
C111634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111634>	C172982	Bothered by Look of Hands or Nails Question|Bothered by Look of Hands or Nails|I am bothered by the way my hands or nails look	A question about whether an individual is or was bothered by the look of their hands or nails.			Intellectual Product	FACT-Taxane Questionnaire
C111635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111635>	C91105	FACT-NP Questionnaire|FACT-Nasopharyngeal Cancer|Functional Assessment of Cancer Therapy-Nasopharyngeal Cancer	A subscale complement to the FACT-G developed specifically for evaluating the quality of life of nasopharyngeal cancer patients.			Intellectual Product	
C111636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111636>	C173398	Difficulty Moving Neck and Shoulders due to Stiffness Question|Difficulty Moving Neck and Shoulders due to Stiffness|I have difficulty moving my neck and shoulders because of stiffness	A question about whether an individual has or had difficulty moving their neck or shoulders because of stiffness.			Intellectual Product	FACT-NP Questionnaire
C111637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111637>	C172982	Bothered by Ringing in Ears Question|Bothered by Ringing in Ears|I am bothered by ringing in my ear(s)	A question about whether an individual is or was bothered by ringing in their ears.			Intellectual Product	FACT-NP Questionnaire
C111638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111638>	C173790|C172982	Bothered by Worsening Eyesight Question|Bothered by Worsening Eyesight|I am bothered by worsening eyesight	A question about whether an individual is or was bothered by worsening eyesight.			Intellectual Product	FACT-NP Questionnaire
C111639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111639>	C173398	Have Trouble Smelling Question|Have Trouble Smelling|I have trouble smelling	A question about whether an individual has or had trouble smelling.			Intellectual Product	FACT-NP Questionnaire
C11163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11163>	C61063	Cytarabine/Etoposide/Methotrexate/Pegaspargase/Prednisone/Thioguanine/Vincristine|ARA-C/MTX/PEG-ASP/PRED/TG/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111640>	C173063	Can Enjoy Taste of Food Question|Can Enjoy Taste of Food|I can enjoy the taste of food	A question about whether an individual can or could enjoy the taste of food.			Intellectual Product	FACT-NP Questionnaire
C111641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111641>	C172982	Bothered by Blocked Nose Question|Bothered by Blocked Nose|I am bothered by having a blocked nose	A question about whether an individual is or was bothered by having a blocked nose.			Intellectual Product	FACT-NP Questionnaire
C111642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111642>	C78254	Device Embolization	Movement of a medical device to an unintended location within the body with resulting obstruction of an organ or vessel.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111643>	C35729	Ectopia Cordis	A rare congenital anomaly where the heart is formed outside of the thoracic cavity. It is associated with intracardiac lesions and other structural malformations.			Disease or Syndrome	
C111644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111644>	C26791	Hemopericardium	An accumulation of blood within the pericardial sac.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111645>	C98643	Inferior Vena Cava Stenosis	Abnormal narrowing of the lumen of the inferior vena cava.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111646>	C38029	Junctional Ectopic Tachycardia	A tachycardia originating in or adjacent to the AV junction.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111647>	C53543	Levocardia|LEVOCARDIA	A condition where the heart is in the correct anatomic position but some or all of the other thoracoabdominal viscera are in the opposite lateral orientation.			Disease or Syndrome	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C111648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111648>	C50802	Polymorphic Ventricular Tachycardia	A ventricular tachycardia that is irregular in rate and rhythm.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111649>	C35741|C28193	Post-Pericardiotomy Syndrome	An inflammatory disorder of the pericardium and pleura seen as a post-operative complication of cardiovascular surgery.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11164>	C61063	Asparaginase/Prednisolone/Vincristine|ASP/PRDL/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111650>	C35552	Prosthetic Valve Dysfunction	Malfunction of a surgically-placed cardiac valve related to the valve itself or the area around the valve.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111651>	C35552|C3284	Pulmonary Vein Obstruction	Blockage of the lumen of the pulmonary vein.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111652>	C114397	Vascular Shunt Thrombosis|Shunt Thrombosis	The presence of a thrombus within a vascular shunt.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111653>	C98643	Superior Vena Cava Stenosis	Abnormal narrowing of the lumen of the superior vena cava.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111654>	C50547	Venous Embolism	The passage of an embolus from its site of formation to another location within the venous system.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111655>	C35552	Ventricular Dysfunction|Ventricular functional abnormalities	Impairment of the ventricle to either fill or eject adequately.			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 7: Diagnostic Procedures Terminology|HL Authorized Value Terminology|HL Late Effects Table|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111656>	C113824	Twin Reversed Arterial Perfusion Sequence Malformation|Acardiac Malformation|Acardiac Malformation|Acardiac Twin|Acardiac Twin|TRAP Sequence|TRAP Sequence	A severe form of twin-twin transfusion syndrome that occurs in monochorionic pregnancies. The normal twin (pump twin) supplies the blood flow to its sibling that lacks heart or brain or both (acardiac/acephalic twin). Untreated, it may lead to the demise of the pump twin in some cases.			Congenital Abnormality	NICHD Terminology|Perinatal Terminology
C111657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111657>	C5036	Desquamation|EXFOLIATION	Shedding of the outer layer of skin or mucosal tissue.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111658>	C35143	Rigor|Repeated shaking with chills|Rigors	Severe chills accompanied by vigorous shaking.			Sign or Symptom	NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|SeroNet Research Participant Metadata|SeroNet Variables
C111659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111659>	C62754	Poor Weight Gain|Failure to Gain Weight|Inadequate Weight Gain|Low Weight Gain	Slower than normal rate of weight increase.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11165>	C61063	Mercaptopurine/Prednisolone/Vincristine|MP/PRDL/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111660>	C54452	SPL Equivalence Codes Terminology|Equivalence Codes|Structured Product Labeling Equivalence Codes Terminology	Terminology used for representation of the information on pharmaceutical product equivalence codes in the framework of the Structured Product Labeling documents.	SPL Equivalence Codes Terminology		Intellectual Product	FDA Structured Product Labeling Terminology
C111661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111661>	C54452	SPL Contributing Factor-General Terminology|Structured Product Labeling Contributing Factor-General Terminology	Terminology used for representation of the information on pharmaceutical product contributing factors in the framework of the Structured Product Labeling documents.	SPL Contributing Factor-General Terminology		Intellectual Product	FDA Structured Product Labeling Terminology
C111663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111663>	C226710	No Problems Walking|I have no problems in walking about|I have no problems walking|I have no problems walking about	A response indicating that an individual has or had no problems walking.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire|European Quality of Life Five Dimension Three Level Questionnaire|European Quality of Life Five Dimension Three Level Youth Questionnaire
C111664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111664>	C226710	Some Problems Walking|I have some problems in walking about|I have some problems walking about	A response indicating that an individual has or had some problems walking.			Intellectual Product	European Quality of Life Five Dimension Three Level Questionnaire|European Quality of Life Five Dimension Three Level Youth Questionnaire
C111665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111665>	C226573	Confined to Bed|I am confined to bed	A response indicating that an individual is confined to bed.			Intellectual Product	European Quality of Life Five Dimension Three Level Questionnaire
C111666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111666>	C177913	No Problems with Self-Care|I have no problems washing or dressing myself|I have no problems with self-care	A response indicating that an individual has or had no problems with self-care.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire|European Quality of Life Five Dimension Three Level Questionnaire|European Quality of Life Five Dimension Three Level Youth Questionnaire
C111667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111667>	C226711	Some Problems with Washing and Dressing|I have some problems washing or dressing myself	A response indicating that an individual has or had some problems with washing or dressing their self.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire|European Quality of Life Five Dimension Three Level Questionnaire|European Quality of Life Five Dimension Three Level Youth Questionnaire
C111668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111668>	C226711	Unable to Wash or Dress|I am unable to wash or dress myself	A response indicating that an individual is unable to wash or dress their self.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire|European Quality of Life Five Dimension Three Level Questionnaire
C111669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111669>	C226617	No Problems Performing Usual Activities|I have no problems doing my usual activities|I have no problems with performing my usual activities	A response indicating that an individual has or had no problems with performing their usual activities.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire|European Quality of Life Five Dimension Three Level Questionnaire|European Quality of Life Five Dimension Three Level Youth Questionnaire
C11166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11166>	C61063	Fludarabine/Octreotide|FAMP/SSTN			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111670>	C226617	Some Problems Performing Usual Activities|I have some problems doing my usual activities|I have some problems with performing my usual activities	A response indicating that an individual has or had some problems with performing their usual activities.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire|European Quality of Life Five Dimension Three Level Questionnaire|European Quality of Life Five Dimension Three Level Youth Questionnaire
C111671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111671>	C226561	Unable to Perform Usual Activities|I am unable to perform my usual activities	A response indicating that an individual is unable to perform their usual activities.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire|European Quality of Life Five Dimension Three Level Questionnaire
C111672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111672>	C175455	No Pain or Discomfort|I have no pain or discomfort|No hurt	A response indicating that an individual has or had no pain or discomfort.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire|European Quality of Life Five Dimension Three Level Questionnaire|European Quality of Life Five Dimension Three Level Youth Questionnaire
C111673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111673>	C175455	Moderate Pain or Discomfort|Hurts even more|I have moderate pain or discomfort	A response indicating that an individual has or had moderate pain or discomfort.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire|European Quality of Life Five Dimension Three Level Questionnaire
C111674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111674>	C175455	Extreme Pain or Discomfort|Hurts worst|I have extreme pain or discomfort	A response indicating that an individual has or had extreme pain or discomfort.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire|European Quality of Life Five Dimension Three Level Questionnaire
C111675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111675>	C175320	Not Anxious or Depressed|I am not anxious or depressed|I am not worried, sad or unhappy	A response indicating that an individual has or had no anxiety or depression.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire|European Quality of Life Five Dimension Three Level Questionnaire|European Quality of Life Five Dimension Three Level Youth Questionnaire
C111676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111676>	C175320	Moderately Anxious or Depressed|I am moderately anxious or depressed	A response indicating that an individual has or had moderate anxiety or depression.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire|European Quality of Life Five Dimension Three Level Questionnaire
C111677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111677>	C175320	Extremely Anxious or Depressed|I am extremely anxious or depressed	A response indicating that an individual is extremely anxious or depressed.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire|European Quality of Life Five Dimension Three Level Questionnaire
C111678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111678>	C217121	Health State Thermometer Scale	A scale marked off like a thermometer from 0 to 100 that is used to help people indicate how good or bad their health state is; the best state that can be imagined is marked 100 and the worst state that can be imagined is marked 0.			Intellectual Product	European Quality of Life Five Dimension Three Level Questionnaire
C111679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111679>	C25178	Worst Imaginable Health|Worst imaginable health state	The worst state of well-being an individual can conceive of experiencing.			Idea or Concept	European Quality of Life Five Dimension Three Level Questionnaire
C11167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11167>	C61063	Cytarabine/Hydroxyurea/Interferon Alfa|ARA-C/HU/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111680>	C25178	Best Imaginable Health|Best imaginable health state	The best state of well-being an individual can conceive of experiencing.			Idea or Concept	European Quality of Life Five Dimension Three Level Questionnaire
C111681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111681>	C1505	Sorghum bicolor Supplement|Jobelyn|Sorghum bicolor Extract	An herbal-based nutritional supplement containing the leaf sheaths of the plant Sorghum bicolor, with potential antioxidant, anti-inflammatory, chemopreventive and immunomodulating activities. Sorghum bicolor supplement contains various phytochemicals, including phenolic acids and polyphenols such as proanthocyanidins. Sorghum bicolor supplement is particularly rich in 3-deoxyanthocyanins, such as luteolinidin and apigeninidin, and appears to induce apoptosis and inhibit cell proliferation in cancer cells through the stimulation of various apoptosis promoter genes and the downregulation of certain apoptosis inhibitor genes. In addition, due to the strong antioxidant nature of the phytochemicals, these compounds are able to scavenge free radicals and prevent tissue damage. Also, intake of this supplement modulates the immune system by both increasing the activity of natural killer (NK) cells and initiating the activation of macrophages.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111682>	C2124	Fluorine F 18 5-Fluoro-2-deoxycytidine|[F-18]-5-fluoro-2'-deoxycytidine|[F-18]-FdCyd	A radioconjugate composed of a fluorinated pyrimidine analog, linked to the radioisotope fluorine F 18 with potential imaging activity using positron emission tomography/computed tomography (PET/CT). Upon administration of fluorine F 18 5-fluoro-2-deoxycytidine ([F-18]-FdCyd), the FdCyd moiety is phosphorylated by deoxycytidine kinase to 5-fluoro-2'-deoxycytidylate (FdCMP) and deaminated by deoxycytidylate (dCMP) deaminase, an enzyme overexpressed by tumor cells, to 5-fluoro-2-deoxyuridine monophosphate (FdUMP). Eventually, FdUMP is metabolized to the triphosphate forms 5-fluoro-2'-deoxycytidine-triphosphate (FdCTP) and fluorodeoxyuridine triphosphate (FdUTP). FdCTP and FdUTP inhibit DNA methyltransferase (DNMT) and DNA methylation, and induce DNA strand breaks, respectively. FdCyd is coadministered with tetrahydrouridine (THU), an inhibitor of cytidine/deoxycytidine deaminase, which prevents FdCyd breakdown and increases its efficacy. The fluorine F 18 moiety can be imaged upon PET/CT, thereby allowing for the evaluation of the biodistribution of FdCyd and its uptake by tumor cells.	Fluorine F 18 5-Fluoro-2-deoxycytidine		Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C111683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111683>	C28681	MART-1 Reactive CD8+ T-lymphocytes	Human CD8-positive T-lymphocytes that are engineered to recognize melanoma tumor associated antigen MART-1 (Melanoma Antigen Recognized by T cells, also called Melan-A) in a human leukocyte antigen (HLA)-A2-restricted manner, with potential antineoplastic activity. Human peripheral blood lymphocytes (PBLs) are isolated from a melanoma patient, exposed to the MART-1:27-35(27L) peptide and MART-1 specific T-lymphocytes are isolated and expanded. Upon infusion, these lymphocytes recognize and exert a cytotoxic T-cell-mediated immune response against MART-1-expressing melanoma cells. The synthetic MART-1:27-35 HLA-A2-restricted peptide has an amino acid substitution, leucine to alanine at position 27, to increase its immunogenicity.	MART-1 Reactive CD8+ T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111684>	C275	Imisopasem Manganese|GC4403|IMISOPASEM MANGANESE|M40403|Manganese, dichloro[(4aR,13aR,17aR,21aR)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7Hdibenzo[b,h][1,4,7,10]tetraazacycloheptadecine-kN5,kN13,kN18,kN21,kN22]-, (PB-7-11-2344'3')-|SC-72325	A manganese-based non-peptidyl mimetic of the human mitochondrial manganese superoxide dismutase (MnSOD), with potential antioxidant and chemo/radioprotective activities. Upon administration, imisopasem manganese mimics the activity of MnSOD and scavenges reactive oxygen species (ROS), such as superoxide anion, which prevents oxygen free radical damage to macromolecules such as DNA. This reduces ROS-mediated lipid peroxidation, prevents apoptosis and protects against oxygen free radical-induced toxicity in normal tissues.	Imisopasem Manganese		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C111685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111685>	C199169|C141136	ALK-FAK Inhibitor CEP-37440|CEP-37440|CEP-37440	An orally available dual kinase inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and focal adhesion kinase (FAK), with potential antineoplastic activity. Upon administration, ALK-FAK inhibitor CEP-37440 selectively binds to and inhibits ALK kinase and FAK kinase. The inhibition leads to disruption of ALK- and FAK-mediated signal transduction pathways and eventually inhibits tumor cell growth in ALK- and FAK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; its dysregulation and gene rearrangements are associated with a variety of tumors. The cytoplasmic tyrosine kinase FAK, a signal transducer for integrins, is upregulated and constitutively activated in various tumor types; it plays a key role in tumor cell migration, proliferation, survival, and tumor angiogenesis.	ALK-FAK Inhibitor CEP-37440		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111686>	C1892	Rice Bran|RICE BRAN	The nutrient-rich hard outer layer of the rice cereal grain, with potential chemopreventive, antioxidant, iron chelating, anticholesterol and anti-inflammatory activities. Rice bran is rich in fiber, such as beta-glucan, pectin and gum; it also comprises vitamins and minerals, such as iron, magnesium and phosphorus, and essential fatty acids. In addition, Rice bran contains various bioactive components, including ferulic acid, tricin, beta-sitosterol, gamma-oryzanol, phytic acid, and inositol hexaphosphate (IP6). The potential anticancer activity of rice bran may be due to the synergistic effects of these phytochemicals on their ability to induce apoptosis, inhibit cell proliferation, and alter cell cycle progression in cancer cells. Rice bran's bioactive components also protect against tissue damage by scavenging free radicals and blocking chronic inflammatory responses. In addition, they are able to modulate the gut microflora and carcinogen-metabolizing enzymes, thereby further exerting a chemopreventive effect.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111687>	C1892	Navy Bean Powder	The powder form of the cooked navy bean with potential antioxidant and chemopreventive activities. Navy beans are rich in fiber, minerals, vitamins, and phytochemicals such as flavonoids and phytosterols. They appear to prevent carcinogenesis by inducing tumor cell apoptosis. Intake of navy bean powder may have a beneficial effect on intestinal microflora.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111688>	C1752	Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101|PDS0101|mmunoMAPK-RDOTAP /HPV-16 E6/E7 Peptide Antigen Vaccine	A liposomal nanoparticle-based therapeutic vaccine composed of the cationic lipid R-DOTAP (R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride) encapsulating six human papillomavirus 16 (HPV-16) E6 and E7 peptides, with potential immunostimulating activity. Upon subcutaneous administration of the liposomal HPV-16 E6 and E7 multipeptide vaccine, the nanoparticles are taken up by antigen presenting cells (APCs), specifically dendritic cells (DCs), which may stimulate the immune system to induce a cytotoxic T-lymphocyte response (CTL) against HPV-16 E6 and E7-expressing tumor cells. HPV-16 E6 and E7 are oncoproteins that play a key role in the tumorigenesis of a variety of cancers.	Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111689>	C1663	HLA-A*0201 Restricted TERT(572Y)/TERT(572) Peptides Vaccine Vx-001|HLA-A*0201 Restricted Telomerase-specific Vaccine Vx-001|Vx-001|Vx001	A peptide-based cancer vaccine consisting of two human leukocyte antigen (HLA)-A*0201 restricted 9-mer epitopes derived from the human telomerase reverse transcriptase (hTERT), TERT 572Y (YLFFYRKSV; TYR-Vx001) and TERT 572 (RLFFYRKSV; ARG-Vx001), with potential immunostimulating and antineoplastic activities. Subcutaneous injection of TERT(572Y) peptide followed by subcutaneous administration of the TERT(572) peptide may elicit a specific and possibly optimal cytotoxic T cell (CTL) response against hTERT-expressing tumor cells. hTERT, the catalytic subunit of human telomerase, is an human leukocyte antigen-A*0201-restricted cryptic epitope of telomerase. TERT is expressed in the majority of human cancer cells, is not expressed or is expressed at very low levels in normal cells and plays a key role in tumorigenesis. TERT572Y is the optimized variant of the native cryptic peptide TERT572 in which tyrosine has been substituted for an arginine at position 1; TERT572Y shows increased HLA-A*0201 binding affinity compared to TERT572.			Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11168>	C61063	BCG/Dacarbazine|BCG/DTIC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111690>	C97927	Immunoglobulin Heavy Chain Locus Variable Region Mutation|IGHV Gene Mutation|IGHV Locus Mutation|IgVH Mutation|Immunoglobulin Heavy Chain Variable Region Mutation	A change in the nucleotide sequence of the variable region of the immunoglobulin heavy chain locus.	Immunoglobulin Heavy Chain Locus Variable Region Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111691>	C3058	Glioblastoma by Gene Expression Profile	Classification of glioblastoma into molecular subtypes as defined by gene expression profiling.			Neoplastic Process	NCIt Neoplasm Core Terminology
C111692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111692>	C111691	Proneural Glioblastoma	A molecular subtype of glioblastoma that is associated with younger age at presentation and is characterized by p53 mutations and PDGFRa amplifications.			Neoplastic Process	NCIt Neoplasm Core Terminology
C111693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111693>	C111691	Neural Glioblastoma	A molecular subtype of glioblastoma characterized by the expression of the neural markers NEFL, GABRA1, SYT1, and SLC12A5.			Neoplastic Process	NCIt Neoplasm Core Terminology
C111694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111694>	C111691	Classical Glioblastoma	A molecular subtype of glioblastoma characterized by lack of p53 mutations, chromosome 7 amplifications or deletions, and high levels of EGFR amplification.			Neoplastic Process	NCIt Neoplasm Core Terminology
C111695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111695>	C111691	Mesenchymal Glioblastoma	A molecular subtype of glioblastoma characterized by the presence of NF1 mutations.			Neoplastic Process	NCIt Neoplasm Core Terminology
C111696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111696>	C115767	Your Health State Today Question|How Good or Bad Your Health is Today|How good or bad your own health is today, in your opinion|Your Health State Today|Your own health state today	A question asking an individual about how good or bad they rate their own health today.			Intellectual Product	European Quality of Life Five Dimension Three Level Questionnaire
C111697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111697>	C91105	Medical Outcomes Study Your Feelings Questionnaire	A survey of multiple dimensions of functioning and well being, representing the feelings scale.			Intellectual Product	
C111698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111698>	C173792	How Happy, Satisfied, or Pleased Are You With Your Personal Life Question|How Happy, Satisfied, or Pleased Are You With Your Personal Life|How happy, satisfied, or pleased have you been with your personal life	A question about the frequency or intensity an individual feels or felt happy, satisfied, or pleased with their personal life.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111699>	C17054	Radionuclide Specific Activity|Specific Activity|Specific Activity for Radioactivity	The radioactivity per unit mass of a stated element or compound.			Phenomenon or Process	
C11169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11169>	C61063	Amifostine/Paclitaxel|TAX/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1116>	C743	Glycosylphosphatidylinositol|GPI	A glycolipid that functions as a protein modifier and has a core structure composed of a phosphatidylinositol (PI) bound, through a carbohydrate linker comprised of glucosamine and three mannose residues, to an ethanolamine phosphate (EtNP), which can be covalently linked to the carboxy-terminal amino acid of the modified protein. Glycosylphosphatidylinositol moieties anchor extracellular proteins to the cell surface by insertion of the PI fatty acid chains into the membrane bilayer.			Biologically Active Substance|Organic Chemical	
C111700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111700>	C173160|C118873	How Often Did You Feel There Were People You Were Close To Question|Frequency You Felt There Were People You Were Close To|How Often Did You Feel There Were People You Were Close To|How often did you feel there were people you were close to	A question about the frequency an individual feels or felt there were people close to them.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111701>	C173584|C173160|C118873	How Often has Feeling Depressed Interfered with What You Usually Do Question|Frequency Feeling Depressed has Interfered with What You Usually Do|How Often has Feeling Depressed Interfered with What You Usually Do|How often has feeling depressed interfered with what you usually do	A question about the frequency an individual feels or felt that depression interfered with what they usually do.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111702>	C91102	How Much of the Time Question|How Much of the Time|How Much of the Time	A question about how much of the time something is occurring or has occurred.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111703>	C173398	Did You Have Difficulty Reasoning and Solving Problems Question|Did You Have Difficulty Reasoning and Solving Problems|Did you have difficulty reasoning and solving problems	A question about whether an individual has or had difficulty reasoning and solving problems.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111704>	C91102	Have You Generally Enjoyed the Things You Do Question|Have You Generally Enjoyed the Things You Do|Have you generally enjoyed the things you do	A question about whether an individual has or had generally enjoyed the things they do.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111705>	C176020|C173597	Have You Had Reason to Wonder If You Were Losing Your Mind, or Losing Control Over the Way You Act, Talk, Think, Feel, or of Your Memory Question|Have You Had Reason to Wonder If You Were Losing Your Mind, or Losing Control Over the Way You Act, Talk, Think, Feel, or of Your Memory|Have you had any reason to wonder if you were losing your mind, or losing control over the way you act, talk, think, feel or of your memory	A question about whether an individual has or had reason to wonder if they were losing their mind or control over the way they act, talk, think, feel or of their memory.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111706>	C91102	Has Your Daily Life Been Full of Things That Were Interesting to You Question|Has Your Daily Life Been Full of Things That Were Interesting to You|Has your daily life been full of things that were interesting to you	A question about whether an individual's life has or had been full of things that were interesting.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111707>	C173160	Have You Felt Loved and Wanted Question|Have You Felt Loved and Wanted|Have you felt loved and wanted	A question about whether an individual feels or felt loved and wanted.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111708>	C173981	Have You Been a Very Nervous Person Question|Have You Been a Very Nervous Person|Have you been a very nervous person	A question about whether an individual is or has been very nervous.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111709>	C173597|C173398	Did You Have Difficulty Doing Activities Involving Concentration and Thinking Question|Did You Have Difficulty Doing Activities Involving Concentration and Thinking|Did you have difficulty doing activities involving concentration and thinking	A question about whether an individual has or had difficulty doing activities involving concentration and reasoning.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C11170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11170>	C61063	Cisplatin/Isotretinoin|CDDP/13-CRA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111710>	C173597	Have You Been in Firm Control of Your Behavior, Thoughts, Emotions, and Feelings Question|Have You Been in Firm Control of Your Behavior, Thoughts, Emotions, and Feelings|Have you been in firm control of your behavior, thoughts, emotions, feelings	A question about whether an individual has or had been in firm control of their behavior, thoughts, emotions, or feelings.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111711>	C173981	Did You Become Confused and Start Several Actions at a Time Question|Did You Become Confused and Start Several Actions at a Time|Did you become confused and start several actions at a time	A question about whether an individual does or did become confused and start several actions at a time.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111712>	C173160	Did You Feel That You Had Nothing to Look Forward To Question|Did You Feel That You Had Nothing to Look Forward To|Did you feel that you had nothing to look forward to	A question about whether an individual feels or felt that they had nothing to look forward to.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111713>	C173160	Have You Felt Calm and Peaceful Question|Feel Calm and Peaceful|Have You Felt Calm and Peaceful|Have you felt calm and peaceful|I feel calm	A question about whether an individual feels or felt calm and peaceful.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire|Multidimensional Fatigue Symptom Inventory-Short Form
C111714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111714>	C173160	Have You Felt Emotionally Stable Question|Feel Emotionally Stable|Have You Felt Emotionally Stable|Have you felt emotionally stable	A question about whether an individual feels or felt emotionally stable.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111715>	C173160	Have You Felt Downhearted and Blue Question|Feel Blue|Feel Downhearted|Have You Felt Downhearted and Blue|Have you felt downhearted and blue	A question about whether an individual feels or felt downhearted and blue.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111716>	C173160	Have You Felt Like Crying Question|Feel Like Crying|Have You Felt Like Crying|Have you felt like crying	A question about whether an individual feels or felt like crying.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111717>	C173160	Feel Left Out Question|Did You Feel Left Out|Did you feel left out|Feel Left Out|I feel left out|Left Out	A question about whether an individual feels or felt left out.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire|PROMIS Short Form-Social Isolation-4a
C111718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111718>	C176020|C173981	Did You Forget Things That Happened Recently or Where You Put Things or Appointments Question|Did You Forget Things That Happened Recently or Where You Put Things or Appointments|Did you forget, for example, things that happened recently, where you put things, appointments	A question about whether an individual does or did forget things that happened recently.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111719>	C173160	Did You Feel That Others Would Be Better Off If You Were Dead Question|Did You Feel That Others Would Be Better Off If You Were Dead|Did you feel that others would be better off if you were dead	A question about whether an individual feels or felt that others would be better off if they were dead.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C11171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11171>	C61063	Cyclophosphamide/Cyclosporine/Cytarabine/Daunorubicin|ARA-C/CTX/CYSP/DNR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111720>	C173160	Did You Feel That Your Love Relationships Were Full and Complete Question|Did You Feel That Your Love Relationships Were Full and Complete|Did you feel that your love relationships, loving and being loved, were full and complete	A question about whether an individual feels or felt that their love relationships are full and complete.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111721>	C172982	Have You Been Bothered By Nervousness or Your Nerves Question|Have You Been Bothered By Nervousness or Your Nerves|Have you been bothered by nervousness, or your nerves	A question about whether an individual has or had been bothered by nervousness or their nerves.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111722>	C91102	Has Living Been a Wonderful Adventure Question|Has Living Been a Wonderful Adventure|Has living been a wonderful adventure for you	A question about whether an individual has or had been living a wonderful adventure.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111723>	C173160	Have You Felt So Down in the Dumps That Nothing Could Cheer You Up Question|Have You Felt So Down in the Dumps That Nothing Could Cheer You Up|Have you felt so down in the dumps that nothing could cheer you up	A question about whether an individual feels or felt so down in the dumps that nothing could cheer them up.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111724>	C173597	Did You Ever Think About Taking Your Own Life Question|Did You Ever Think About Taking Your Own Life|Did you ever think about taking your own life	A question about whether an individual does or did ever think about taking their own life.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111725>	C173160	Have You Felt Restless, Fidgety, or Impatient Question|Have You Felt Restless, Fidgety, or Impatient|Have you felt restless, fidgety, or impatient	A question about whether an individual feels or felt restless, fidgety, or impatient.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111726>	C173981	Have You Been Moody or Brooded About Things Question|Have You Been Moody or Brooded About Things|Have you been moody or brooded about things	A question about whether an individual is or has been moody or brooded about things.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111727>	C173981	Did You Get Rattled, Upset, or Flustered Question|Did You Get Rattled, Upset, or Flustered|Did you get rattled, upset, or flustered	A question about whether an individual does or did get rattled or flustered.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111728>	C176021|C173398	Did You Have Trouble Keeping Your Attention On Any Activity For Long Question|Did You Have Trouble Keeping Your Attention On Any Activity For Long|Did you have trouble keeping your attention on any activity for long	A question about whether an individual does or did have trouble keeping their attention on any activity for long.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111729>	C173386	Have You Been Anxious or Worried Question|Have You Been Anxious or Worried|Have you been anxious or worried	A question about whether an individual is or has been anxious or worried.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C11172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11172>	C61063	Cyclophosphamide/Etoposide/Mitoxantrone/Pegaspargase/Prednisone/Vincristine|CTX/DHAD/PEG-ASP/PRED/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111730>	C173160	Have You Been a Happy Person Question|Have You Been a Happy Person|Have you been a happy person	A question about whether an individual is or has been a happy person.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111731>	C173398	Did You Find Yourself Having Difficulty Trying to Calm Down Question|Did You Find Yourself Having Difficulty Trying to Calm Down|Did you find yourself having difficulty trying to calm down	A question about whether an individual does or did have difficulty trying to calm down.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111732>	C173981	Have You Been in Low or Very Low Spirits Question|Have You Been in Low or Very Low Spirits|Have you been in low or very low spirits	A question about whether an individual is or has been in low or very low spirits.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111733>	C173160	Have You Felt Cheerful or Lighthearted Question|Have You Felt Cheerful or Lighthearted|Have you felt cheerful or lighthearted	A question about whether an individual feels or felt cheerful or lighthearted.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111734>	C173160|C107401	How Depressed Have You Felt at its Worst Question|How Depressed Have You Felt at its Worst|How depressed at its worst have you felt	A question about how intense an individual's depression feels or felt at its worst.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111735>	C173981	Did You React Slowly to Things That Were Said or Done Question|Did You React Slowly to Things That Were Said or Done|Did you react slowly to things that were said or done	A question about whether an individual reacts or reacted slowly to things that were said or done.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111736>	C173160	Feel Isolated From Others Question|Did You Feel Isolated From Others|Did you feel isolated from others|Feel Isolated From Others|I feel isolated from others|Isolated From Others	A question about whether an individual feels or felt isolated from others.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire|PROMIS Short Form-Social Isolation-4a
C111737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111737>	C25716	Adverse Event Emergency Room Visit|ER	The situation that occurs when an individual must visit the Emergency Room or Department because of an adverse event.			Event	Adverse Event Outcome ICSR Terminology|FDA Individual Case Safety Report Terminology
C111738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111738>	C25716	Adverse Event Doctor Visit|Doctor Visit	The situation that occurs when an individual must visit a physician because of an adverse event.			Event	Adverse Event Outcome ICSR Terminology|FDA Individual Case Safety Report Terminology
C111739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111739>	C226674	Extremely Happy|Extremely happy, could not have been more satisfied or pleased	A response indicating that an individual is or has been extremely happy and could not have been more satisfied or pleased.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C11173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11173>	C61063	Suramin/Topotecan|SUR/TOPO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111740>	C226674	Very Happy|Very happy most of the time	A response indicating that an individual is or has been very happy most of the time.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111741>	C176250	Generally Satisfied or Pleased|Generally Satisfied, Pleased|Generally satisfied, pleased|Generally satisfied, pleased|Pleased	A response indicating that an individual is or has been generally satisfied or pleased.			Intellectual Product	American Urological Association Symptom Score|Chronic Respiratory Questionnaire Self-Administered Standardized Format|Medical Outcomes Study Your Feelings Questionnaire
C111742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111742>	C176250	Sometimes Fairly Satisfied|Sometimes fairly satisfied, sometimes fairly unhappy	A response indicating that an individual is or has been sometimes fairly satisfied and sometimes fairly unhappy.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111743>	C176250	Generally Dissatisfied and Unhappy|Generally dissatisfied, unhappy	A response indicating that an individual is or has been generally dissatisfied or unhappy.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111744>	C176250	Very Dissatisfied and Unhappy|Very dissatisfied, unhappy most of the time	A response indicating that an individual is or has been very dissatisfied and unhappy most of the time.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111745>	C175311	A Good Bit of the Time|A good bit of the time	A response indicating that something happens or happened a good bit of the time.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111746>	C226693|C175346	Not Enough to Be Concerned or Worried|Yes, but not enough to be concerned or worried	A response indicating that an individual is or has experienced something but that it was not enough to cause them concern or worry.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111747>	C175302	A Little Concerned|Yes, and I have been a little concerned	A response indicating that an individual is or has experienced something and that they are a little concerned.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111748>	C175302	Quite Concerned|Yes, and I am quite concerned	A response indicating that an individual is or has experienced something and that they are quite concerned.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111749>	C175302	Very Much Concerned|Yes, and I am very much concerned	A response indicating that an individual is or has experienced something and that they are very much concerned.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C11174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11174>	C61063	Doxorubicin/VX-710|DOX/VX-710			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111750>	C175303	Extremely Bothered|Extremely so, to the point where I could not take care of things	A response indicating that an individual is or was extremely bothered, to the point where they could not take care of things.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111751>	C175303	Bothered Very Much|A lot|Very Bothered|Very much bothered	A response indicating that an individual is or was very bothered.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire|Symptom Screening in Pediatrics
C111752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111752>	C175303	Bothered Quite a Bit|Bothered quite a bit|Quite a Bit Bothered	A response indicating that an individual is or was quite a bit bothered.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111753>	C175303	Bothered Some|Bothered some, enough to notice	A response indicating that an individual is or was bothered some, enough to notice.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire
C111754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111754>	C175303	Bothered a Little|Bothered a little bit|Bothered just a little	A response indicating that an individual is or was bothered just a little.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire|PhenX
C111755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111755>	C175303	Not Bothered at All|Bothered Not at All|Not at All Bothered|Not at all bothered|Not bothered at all	A response indicating that an individual is or was not bothered at all.			Intellectual Product	Medical Outcomes Study Your Feelings Questionnaire|Symptom Screening in Pediatrics
C111756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111756>	C111774	Absent Fetal Heart Rate Variability|Absent Baseline Variability|Absent Baseline Variability|Absent FHR Variability	A baseline fetal heart rate with an undetectable amplitude range.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C111757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111757>	C1556	Mercaptopurine Oral Suspension|6-MP Oral Suspension|Purixan|Xaluprine	An oral suspension containing the thiopurine-derivative antimetabolite 6-mercaptopurine, with potential antineoplastic activity. Upon oral administration, mercaptopurine is metabolized by hypoxanthine-guanine phosphoribosyltransferase (HGPRTase) to its active metabolite 6-thioinosine monophosphate (TIMP); TIMP inhibits nucleotide interconversions and de novo purine ribonucleotide synthesis, which both blocks the formation of purine nucleotides and inhibits DNA synthesis. This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. By blocking DNA synthesis and replication, cancer cells are unable to proliferate. Compared to the tablet formulation, the liquid is easier to swallow and offers more flexibility and accuracy in dosing, which is beneficial for use in pediatric patients.			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111758>	C177285	Mitochondrial Oxidative Phosphorylation Inhibitor ATR-101	An orally bioavailable inhibitor of mitochondrial oxidative phosphorylation with potential antineoplastic activity. Upon administration, ATR-101 inhibits the activity of F1F0-ATP synthase, elevates the mitochondrial membrane potential and depletes ATP in adrenocortical cells. The mitochondrial dysfunction caused by the release of reactive oxygen and triggered cytochrome c release leads to caspase-mediated cell death. ATR-101 may be useful in treating certain types of adrenocortical carcinoma.	Mitochondrial Oxidative Phosphorylation Inhibitor ATR-101		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111759>	C28681|C129826	Activated Marrow Infiltrating Lymphocytes|aMIL	A preparation of cells, which consists of autologous marrow infiltrating lymphocytes (MILs), that are manipulated in vitro, with potential antitumor and immune stimulating activities. MILs are harvested from autologous bone marrow from multiple myeloma patients and, in vitro, are exposed to and activated by anti-CD3/anti-CD28 monoclonal antibodies covalently attached to super-paramagnetic microbeads. After removal of the beads and expansion of the cells in culture, the activated MILs (aMILs) are re-introduced into the patient. The aMILs possess enhanced myeloma specificity, and are able to infiltrate the tumor microenvironment and initiate tumor cell lysis. CD3 and CD28, co-stimulatory molecules expressed on the surface of T-lymphocytes, play a key role in the activation of T-cells.	Activated Marrow Infiltrating Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11175>	C61007	Cyclosporine/Interferon Gamma/Interleukin-2|CYSP/IFN-G/IL-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111760>	C67413|C1506	Fentanyl Citrate-containing Nasal Spray|Instanyl|Intranasal Fentanyl Spray	A nasal spray containing a phosphate-buffered solution of the citrate salt form of fentanyl, a short-acting, synthetic, lipophilic anilidopiperidine opioid, with analgesic activity. Upon applying one puff in the nostril, the fentanyl is rapidly absorbed through the nasal mucosa and selectively binds to and activates mu-opioid receptors in the central nervous system (CNS), mimicking the effects of endogenous opiates. Due to its quick onset and short duration of action, the administration of fentanyl nasal spray may relieve breakthrough pain in adults already receiving maintenance opioid therapy for chronic pain.	Fentanyl Citrate-containing Nasal Spray		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C111761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111761>	C172200|C129825	JAK Inhibitor INCB047986|INCB 047986|INCB-047986|INCB047986	An orally bioavailable inhibitor of Janus-associated kinases (JAK), with potential antineoplastic activity. Upon oral administration, INCB047986 specifically binds to and inhibits the phosphorylation of JAK, which affects JAK-dependent signaling and may lead to an inhibition of cellular proliferation in JAK-overexpressing tumor cells. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111762>	C74526	Triptolide Analog|MINNELIDE|Minnelide	A water soluble analog of the diterpenoid triepoxide triptolide isolated from the Chinese herb Tripterygium wilfordii Hook.f., with potential antineoplastic activity. Upon intravenous administration, the triptolide analog inhibits heat shock protein 70 (HSP70) and prevents HSP70-mediated inhibition of apoptosis. This leads to both the induction of apoptosis and a reduction of cancer cell growth. HSP70, a molecular chaperone upregulated in various cancer cells, plays a key role in the inhibition of caspase-dependent and -independent apoptosis.	Triptolide Analog		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111763>	C2124	Carbon C 14 Selumetinib|SELUMETINIB C-14|[14C] Selumetinib	A radioconjugate containing the orally available selumetinib, an inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) types 1 and 2, labeled with the radioisotope carbon C 14. Upon oral administration, selumetinib selectively inhibits MEK1/2, which prevents the activation of MEK1/2 dependent effector proteins and transcription factors. This leads to an inhibition of cellular proliferation in MEK1/2-overexpressing tumor cells. MEK 1 and 2 are dual specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in various cancer cells. Selumetinib radiolabeled with carbon C-14 may be used as a radiotracer for pharmacokinetic studies of this agent, including its absorption, distribution, metabolism and excretion (ADME).			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C111764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111764>	C2167|C159156	Selatinib Ditosilate|SELATINIB DITOSILATE	An orally bioavailable ditosilate salt form of selatinib, an analog of the quinazoline lapatinib and dual inhibitor of epidermal growth factor receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (ErbB-2 or HER-2), with potential antineoplastic activity. Upon administration, selatinib reversibly blocks phosphorylation of both EGFR and ErbB2, thereby suppressing tumor growth in EGFR/ErbB-2-overexpressing tumor cells. The tyrosine kinases EGFR and ErbB2 have been implicated in the growth of various tumor types.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111765>	C92790	Marked Baseline Fetal Heart Rate Variability|Exaggerated Baseline Variability|Exaggerated Baseline Variability|Hypervariability|Hypervariability|Marked Baseline Variability|Marked Baseline Variability	A baseline fetal heart rate with an amplitude range that is greater than 25 beats per minute.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C111766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111766>	C92715	Fetal Arrhythmia	A variation from the normal heart rhythm in a fetus.			Clinical Attribute	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111767>	C92790	Minimal Baseline Fetal Heart Rate Variability|Minimal Baseline Variability|Minimal Baseline Variability	A baseline fetal heart rate with a detectable amplitude range that is greater than undetectable but less than or equal to five beats per minute.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C111768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111768>	C111774	Sinusoidal Fetal Heart Rate Pattern	A fetal heart rate pattern characterized by a smooth, sine wave-like undulating pattern with a cycle frequency of 3 to 5 beats per minute that continues for at least 20 minutes or more.			Clinical Attribute	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C111769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111769>	C111766	Fetal Tachyarrhythmia	An abnormality in the fetal heart rhythm associated with an increase in fetal heart rate above 160 beats per minute.			Clinical Attribute	NICHD Terminology|Perinatal Terminology
C11176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11176>	C61063	Carmustine/Interferon Alfa/Tamoxifen|BCNU/IFN-A/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111770>	C111766	Fetal Bradyarrhythmia	An abnormality in the fetal heart rhythm associated with a decrease in fetal heart rate below 110 beats per minute.			Clinical Attribute	NICHD Terminology|Perinatal Terminology
C111771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111771>	C92715	Normal Continuous Cardiotocography Pattern|Category I Tracing|Category I Tracing	Normal fetal heart pattern. Strongly predictive of normal acid-base status at time of observation. Characterized by baseline fetal heart rate 110 to 160 beats per minute, moderate baseline variability, absent late or variable decelerations, absent or present early decelerations, and absent or present accelerations.			Diagnostic Procedure	NICHD Terminology|Perinatal Terminology
C111772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111772>	C92715	Indeterminate Continuous Cardiotocography Pattern|Category II Tracing|Category II Tracing	Indeterminate fetal heart rate pattern. Not predictive of abnormal acid-base status at time of observation but insufficient to classify pattern as Category I or III. Example patterns include: minimal or marked variability, absent variability without recurrent decelerations, absence of induced accelerations after fetal stimulation, recurrent variable decelerations with minimal or moderate variability, prolonged decelerations, recurrent late decelerations with moderate variability and variable decelerations with slow return to baseline, overshoots or shoulders.			Diagnostic Procedure	NICHD Terminology|Perinatal Terminology
C111773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111773>	C92715|C167416	Abnormal Continuous Cardiotocography Pattern|Category III Tracing|Category III Tracing	Abnormal fetal heart rate pattern. Predictive of abnormal acid-base status at time of observation. Patterns include sinusoidal pattern or absent fetal heart rate variability with any of the following: recurrent late decelerations, recurrent variable decelerations, or bradycardia.			Diagnostic Procedure	NICHD Terminology|Perinatal Terminology
C111774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111774>	C92715	Fetal Heart Rate Pattern	The sequence of a fetal heart rhythm and rate.			Clinical Attribute	
C111775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111775>	C111774	Periodic Fetal Heart Rate Pattern	Fetal heart rate patterns associated with maternal uterine contractions.			Clinical Attribute	NICHD Terminology|Perinatal Terminology
C111776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111776>	C111774	Episodic Fetal Heart Rate Pattern	Fetal heart rate patterns not associated with maternal uterine contractions.			Clinical Attribute	NICHD Terminology|Perinatal Terminology
C111777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111777>	C92790	Moderate Baseline Fetal Heart Rate Variability|Moderate Baseline Variability|Moderate Baseline Variability	A baseline fetal heart rate with a detectable amplitude range that is greater than or equal to 6 but less than or equal to 25 beats per minute.			Finding	NICHD Terminology|Perinatal Terminology
C111778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111778>	C92914|C92866	Recurrent Variable Fetal Heart Rate Deceleration|Recurrent Variable Deceleration|Recurrent Variable Fetal Heart Rate Decelerations	Variable decelerations that occur with greater than or equal to 50 percent of uterine contractions. They are usually associated with umbilical cord compression.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111779>	C92719	Ductus Venosus Agenesis	Congenital absence of the fetal ductus venosus.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C11177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11177>	C61063	Bleomycin/Carboplatin/Cisplatin/Vincristine|BLEO/CBDCA/CDDP/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111780>	C50455	Antepartum Obstetric Air Embolism	Presence of a large air bubble in the maternal vascular system which originated from a distant site during the antepartum period.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C111781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111781>	C50455	Postpartum Obstetric Air Embolism	Presence of a large air bubble in the maternal vascular system which originated from a distant site during the postpartum period.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C111782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111782>	C26759	Antepartum Obstetric Septic Embolism	Presence of bacterially-infected tissue in the maternal vascular system which originated from a distant site during the antepartum period.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C111783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111783>	C28195	Antepartum Obstetric Thromboembolism	Presence of a blood clot in the maternal vascular system which originated from a distant site during the antepartum period.	Antepartum Obstetric Thromboembolism		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Perinatal Terminology
C111784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111784>	C27993	Done	Indicates a task, process or examination that has been performed and completed.			Qualitative Concept	
C111785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111785>	C35867	Ductopenia	A morphologic finding indicating reduction in the numbers of interlobular and septal bile ducts in the liver tissue.			Finding	
C111786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111786>	C35867	Ductal or Ductular Proliferation	A morphologic finding indicating the presence of typical or atypical proliferation of biliary epithelial cells in the portal tracts of the liver.			Finding	
C111787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111787>	C3044	Concentric Fibrosis of Intrahepatic Duct	A morphologic finding indicating the presence of fibrosis around an intrahepatic bile duct in the liver tissue.			Finding	
C111788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111788>	C123598	Minimal Response of Multiple Myeloma	Patients in whom some, but not all, the criteria for partial response are fulfilled are classified as minimal response (MR), provided the remaining criteria satisfy the requirements for minimal response.  MR requires all of the following: 1. 25-49% reduction in the level of the serum monoclonal paraprotein maintained for a minimum of 6 weeks; 2. 50-89% reduction in 24 h urinary light chain excretion, which still exceeds 200 mg/24 h, maintained for a minimum of 6 weeks; 3. for patients with non-secretory myeloma only, 25-49% reduction in plasma cells in a bone marrow aspirate and on trephine biopsy, if biopsy is performed, maintained for a minimum of 6 weeks; 4. 25-49% reduction in the size of soft tissue plasmacytomas (by radiography or clinical examination); 5. no increase in size or number of lytic bone lesions (development of a compression fracture does not exclude response) (adapted from National Comprehensive Cancer Network).			Finding	
C111789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111789>	C6827	inv(3)	A chromosomal rearrangement where a genetic segment of chromosome 3 has been inverted.	inv(3)		Cell or Molecular Dysfunction	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11178>	C61007	Cyclophosphamide/Dexamethasone/Etoposide/Mercaptopurine/Methotrexate/Vincristine|CTX/DM/MP/MTX/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111790>	C17307	Lamin B|B-Type Lamin|B-Type Lamins|Lamin-B	A family of class V intermediate filaments that interact with nuclear membrane-associated proteins to form the nuclear lamina. This family of lamins has two members (Lamin-B1 and -B2), are present in all cells and play a role in the disintegration and reformation of the nuclear envelop during mitosis.	Lamin B		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111791>	C26070	PGP Gene|PGP|PGP|Phosphoglycolate Phosphatase Gene	This gene may be involved in regulating oxygen transport.	PGP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111792>	C111791	PGP wt Allele|Phosphoglycolate Phosphatase wt Allele	Human PGP wild-type allele is located in the vicinity of 16p13.3 and is approximately 3 kb in length. This allele, which encodes phosphoglycolate phosphatase protein, may play a role in the regulation of oxygen transport by red blood cells.	PGP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111793>	C16981	Phosphoglycolate Phosphatase|EC 3.1.3.18|PGP|PGPase	Phosphoglycolate phosphatase (321 aa, ~34 kDa) is encoded by the human PGP gene. This protein may be involved in regulating oxygen transport by red blood cells.	Phosphoglycolate Phosphatase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111794>	C28566	Notch Receptor Intracellular Domain|NICD|Neurogenic Locus Notch Homolog Protein ICD|Neurogenic Locus Notch Homolog Protein Intracellular Domain|Notch ICD|Notch Intracellular Domain	The free carboxy-terminal intracellular domain (ICD) of a notch family protein, which is a product of regulated intramembrane proteolysis mediated by the gamma-secretase enzyme complex. This protein fragment is involved in transcriptional regulation of target genes.			Amino Acid, Peptide, or Protein	
C111795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111795>	C21165	TNFRSF13C Gene|TNF Receptor Superfamily Member 13C Gene|TNFRSF13C|TNFRSF13C	This gene plays a role in peripheral B-cell survival.	TNFRSF13C Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111796>	C111795	TNFRSF13C wt Allele|BAFF-R|BAFFR|BR3|BROMIX|CD268|CVID4|Prolixin Gene|TNF Receptor Superfamily Member 13C wt Allele|Tumor Necrosis Factor Receptor Superfamily, Member 13C Gene	Human TNFRSF13C wild-type allele is located within 22q13.1-q13.31 and is approximately 2 kb in length. This allele, which encodes tumor necrosis factor receptor superfamily member 13C protein, is involved in promoting peripheral B-cell survival. Mutations in this gene are associated with common variable immunodeficiency-4.	TNFRSF13C wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111797>	C19285	Tumor Necrosis Factor Receptor Superfamily Member 13C|B Cell-Activating Factor Receptor|B-Cell-Activating Factor Receptor|BAFF Receptor|BAFF-R|BLyS Receptor 3|CD268 Antigen|Prolixin	Tumor necrosis factor receptor superfamily member 13C (184 aa, ~19 kDa) is encoded by the human TNFRSF13C gene. This protein plays a role in regulating the survival of peripheral B-cells.	Tumor Necrosis Factor Receptor Superfamily Member 13C		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111798>	C62439	Eighteen|18	A natural number greater than seventeen and less than nineteen and the quantity that it denotes.	Eighteen		Quantitative Concept	CTRP Biomarker Terminology|CTRP Terminology
C111799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111799>	C16295	TG3 Antibody|Monoclonal Antibody TG-3|TG-3|TG-3 Antibody|TG-3 Monoclonal Antibody|TG3	A monoclonal antibody that recognizes phosphorylated nucleolin. Nucleolin phosphorylation is mediated by the Cdk1/Cyclin B1 complex and is a marker for cells undergoing mitosis.	TG3 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11179>	C61063	Dacarbazine/Doxorubicin/Ifosfamide/Mesna|DOX/DTIC/IFF/mesna|MAID			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1117>	C1905	Glycyrrhizin|(3beta,20beta)-20-Carboxy-11-oxo-30-norolean-12-en-3-yl-2-O-beta-D-glucopyranuronosyl-alpha-D-glucopyranosiduronic Acid|Dipotassium Glycyrrhizate|Dipotassium Glycyrrhizate|GLYCYRRHIZIN|Glycyrrhizic Acid	A saponin-like compound that provides the main sweet flavor for Glycyrrhiza glabra (licorice), with potential immunomodulating, anti-inflammatory, hepato- and neuro-protective, and antineoplastic activities. Glycyrrhizin modulates certain enzymes involved in inflammation and oxidative stress, and downregulates certain pro-inflammatory mediators, thereby protecting against inflammation- and reactive oxygen species (ROS)-induced damage. Glycerrhizin may also suppress the growth of susceptible tumor cells.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C111800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111800>	C16615	SIX2 Gene|SIX Homeobox 2 Gene|SIX2|SIX2	This gene is involved in transcription regulation.	SIX2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111801>	C16295	IL7 Antibody|Anti-IL-7 Antibody|Anti-IL7 Antibody|Anti-Interleukin 7 Antibody|Anti-Interleukin-7 Antibody|Anti-Lymphopoietin-1 Antibody|IL-7 Antibody|Interleukin 7 Antibody|Interleukin-7 Antibody|Lymphopoietin-1 Antibody	Any immunoglobulin that recognizes interleukin-7.	IL7 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111802>	C156032	Dyskeratosis Congenita|DKC|Zinsser-Engman-Cole Syndrome	A rare genetic disorder characterized by nail dystrophy, reticulated skin pigmentation especially on the neck and chest, and oral leukoplakia.  In about half the cases mutations in the TERT, TERC, DKC1, or TINF2 genes are identified.  Patients are at an increased risk of developing bone marrow failure, myelodysplastic syndrome, leukemia, or cancer, especially in the head and neck region.	Dyskeratosis Congenita		Disease or Syndrome	CCPS Disease Terminology|Cellosaurus Disease Terminology|Childhood Cancer Predisposition Study Terminology|CTRP Disease Terminology|CTRP Terminology
C111803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111803>	C111800	SIX2 wt Allele|SIX Homeobox 2 wt Allele|Sine Oculis Homeobox (Drosophila) Homolog 2 Gene|Sine Oculis Homeobox Homolog 2 (Drosophila) Gene|Sine Oculis Homeobox, Drosophila, Homolog of, 2 Gene	Human SIX2 wild-type allele is located in the vicinity of 2p21 and is approximately 4 kb in length. This allele, which encodes Homeobox protein SIX2, plays a role in the regulation of transcription and may be involved in limb or eye development.	SIX2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111804>	C17207	Homeobox Protein SIX2|Sine Oculis Homeobox (Drosophila) Homolog 2|Sine Oculis Homeobox Homolog 2|Sine Oculis Homeobox Homolog 2 (Drosophila)	Homeobox protein SIX2 (291 aa, ~32 kDa) is encoded by the human SIX2 gene. This protein is involved in the regulation of transcription.	Homeobox Protein SIX2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111805>	C16615	SIX4 Gene|SIX Homeobox 4 Gene|SIX4|SIX4	This gene plays a role in transcription regulation.	SIX4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111806>	C16295	MART1 Antibody|Anti-MART1 Antibody|Anti-MLANA Antibody|Anti-Melan-A Antibody|Anti-Melanoma Antigen Recognized by T-Cells 1 Antibody|MLANA Antibody|Melan-A Antibody|Melanoma Antigen Recognized by T-Cells 1 Antibody	Any immunoglobulin that recognizes melanoma antigen recognized by T-cells 1.	MART1 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111807>	C111805	SIX4 wt Allele|AREC3|SIX Homeobox 4 wt Allele|Sine Oculis Homeobox, Drosophila, Homolog of, 4 Gene	Human SIX4 wild-type allele is located in the vicinity of 14q23.1 and is approximately 15 kb in length. This allele, which encodes homeobox protein SIX4, is involved in the regulation of transcription and may play a role in the differentiation and maturation of neuronal cells.	SIX4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111808>	C16295	CTAG2 Antibody|Anti-CTAG2 Antibody|Anti-Cancer/Testis Antigen 2 Antibody|Anti-L Antigen Family Member 1 Antibody|Anti-LAGE Antibody|Anti-LAGE1 Antibody|Anti-NY-ESO-2 Antibody|Cancer/Testis Antigen 2 Antibody|L Antigen Family Member 1 Antibody|LAGE Antibody|LAGE1 Antibody|NY-ESO-2 Antibody	Any immunoglobulin that recognizes cancer/testis antigen 2.	CTAG2 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111809>	C16295	NLRP4 Antibody|Anti-NACHT, LRR and PYD Domains-Containing Protein 4 Antibody|Anti-NALP4 Antibody|Anti-NLRP4 Antibody|NACHT, LRR and PYD Domains-Containing Protein 4 Antibody|NALP4 Antibody	Any immunoglobulin that recognizes NACHT, LRR and PYD domains-containing protein 4.	NLRP4 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11180>	C61063	Cyclosporine/Methylprednisolone/Prednisone|CYSP/MePRDL/PRED			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111810>	C17207	Homeobox Protein SIX4|Sine Oculis Homeobox (Drosophila) Homolog 4|Sine Oculis Homeobox Homolog 4|Sine Oculis Homeobox Homolog 4 (Drosophila)	Homeobox protein SIX4 (781 aa, ~83 kDa) is encoded by the human SIX4 gene. This protein plays a role in both transcription regulation and eye development.	Homeobox Protein SIX4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111811>	C16295	TSGA10 Antibody|Anti-CT79 Antibody|Anti-TSGA10 Antibody|Anti-Testis-Specific Gene 10 Protein Antibody|CT79 Antibody|Testis-Specific Gene 10 Protein Antibody	Any immunoglobulin that recognizes testis-specific gene 10 protein.	TSGA10 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111812>	C16615	SIX5 Gene|SIX Homeobox 5 Gene|SIX5|SIX5	This gene is involved in transcription regulation.	SIX5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111813>	C111812	SIX5 wt Allele|BOR2|DMAHP|SIX Homeobox 5 wt Allele|Sine Oculis Homeobox, Drosophila, Homolog of, 5 Gene	Human SIX5 wild-type allele is located in the vicinity of 19q13.32 and is approximately 4 kb in length. This allele, which encodes homeobox protein SIX5, plays a role in both the regulation of transcription and the regulation of organogenesis. Mutations in this gene are associated with branchiootorenal syndrome type 2.	SIX5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111814>	C53543|C28193	Griscelli Syndrome Type 2|GS2|PAID Syndrome|Partial Albinism and Immunodeficiency Syndrome	A rare, autosomal recessive genetic syndrome caused by mutations in the RAB27A gene.  It is characterized by hypopigmentation of the skin, hair and eyes, recurrent infections, neutropenia, and immune system abnormalities.  Patients are prone to develop hemophagocytic lymphohistiocytosis.			Disease or Syndrome	
C111815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111815>	C78453	Shakes|Shakiness|Shakiness	Unsteadiness or trembling movements of the whole body or a body part.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111816>	C17207	Homeobox Protein SIX5|DM Locus-Associated Homeodomain Protein|Dystrophia Myotonica-Associated Homeodomain Protein|Sine Oculis Homeobox (Drosophila) Homolog 5|Sine Oculis Homeobox Homolog 5|Sine Oculis Homeobox Homolog 5 (Drosophila)	Homeobox protein SIX5 (739 aa, ~75 kDa) is encoded by the human SIX5 gene. This protein is involved in both transcription regulation and organogenesis regulation.	Homeobox Protein SIX5		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111817>	C176698	Hyperpyrexia	Body temperature of 106 degrees Fahrenheit (41.1 degrees Celsius) or higher.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111818>	C20710	CTCFL Gene|CCCTC-Binding Factor (Zinc Finger Protein)-Like Gene|CTCFL|CTCFL	This gene plays a role in gene regulation.	CTCFL Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111819>	C111818	CTCFL wt Allele|BORIS|CCCTC-Binding Factor (Zinc Finger Protein)-Like wt Allele|CT27|CTCF-T|DJ579F20.2|HMG-1L1|HMGB1L1	Human CTCFL wild-type allele is located in the vicinity of 20q13.31 and is approximately 30 kb in length. This allele, which encodes transcriptional repressor CTCFL protein, is involved in both gene regulation and X-chromosome inactivation.	CTCFL wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11181>	C61063	Cyclophosphamide/Cytarabine/Daunorubicin|ARA-C/CTX/DNR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111820>	C20194	SLC2A3P1 Gene|GLUT3P1|GLUT6|SLC2A3P|SLC2A3P1|SLC2A3P1|Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 3 Pseudogene|Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 3 Pseudogene 1	Human SLC2A3P1 gene is located in the vicinity of 5q34 and is approximately 1 kb in length. The product is a processed pseudogene, which produces an RNA transcript but does not encode a protein product and has no apparent cellular function.	SLC2A3P1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111821>	C20194	HTC2 Gene|CGH|CXINSq27.1|Chromosome Xq27.1 Interchromosomal Insertion Syndrome Gene|HCG|HTC2|HTC2|Hypertrichosis 2 (Generalized, Congenital) Gene|Hypertrichosis, Congenital Generalized Gene|Hypertrichosis, Congenital Generalized, 2 Gene	Human HTC2 gene is located within Xq24-q27.1 and the size of this phenotypic locus is not reported. This gene region has no known protein product. Palindrome-mediated interchromosomal insertion in this locus is associated with congenital generalized hypertrichosis.	HTC2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111822>	C25939	ADH1C Gene|ADH1C|ADH1C|Alcohol Dehydrogenase 1C (Class I), Gamma Polypeptide Gene	This gene is involved in the metabolism of alcohols.	ADH1C Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111823>	C17207	Transcriptional Repressor CTCFL|BORIS-Like Protein|Brother of the Regulator of Imprinted Sites|CCCTC-Binding Factor|CTCF Paralog|CTCF-Like Protein|Cancer/Testis Antigen 27|Putative High Mobility Group Protein 1-Like 1|Putative High Mobility Group Protein B1-Like 1|Zinc Finger Protein CTCF-T	Transcriptional repressor CTCFL (663 aa, ~76 kDa) is encoded by the human CTCFL gene. This protein plays a role in gene regulation through transcriptional repression.	Transcriptional Repressor CTCFL		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111824>	C111822	ADH1C wt Allele|ADH3|Alcohol Dehydrogenase 1C (Class I), Gamma Polypeptide wt Allele|Alcohol Dehydrogenase 3 (Class I), Gamma Polypeptide Gene	Human ADH1C wild-type allele is located in the vicinity of 4q23 and is approximately 17 kb in length. This allele, which encodes alcohol dehydrogenase 1C protein, plays a role in alcohol oxidation.	ADH1C wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111825>	C20710	EMSY Gene|C11orf30|EMSY|EMSY|EMSY Transcriptional Repressor, BRCA2 Interacting Gene	This gene is involved in transcription repression.	EMSY Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111826>	C16946	Alcohol Dehydrogenase 1C|ADH, Gamma Subunit|ADH1C|Alcohol Dehydrogenase 1C, Gamma Polypeptide|Alcohol Dehydrogenase 3|Alcohol Dehydrogenase 3, Gamma Polypeptide|Alcohol Dehydrogenase Subunit Gamma|EC 1.1.1.1	Alcohol dehydrogenase 1C (375 aa, ~40 kDa) is encoded by the human ADH1C gene. This protein is involved in the oxidation of alcohols.	Alcohol Dehydrogenase 1C		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111827>	C111825	EMSY wt Allele|C11orf30|Chromosome 11 Open Reading Frame 30 Gene|EMSY Transcriptional Repressor, BRCA2 Interacting wt Allele|EMSY, BRCA2 Interacting Transcriptional Repressor Gene|EMSY, BRCA2-Interacting Transcriptional Repressor Gene|GL002	Human EMSY wild-type allele is located in the vicinity of 11q13.5 and is approximately 108 kb in length. This allele, which encodes protein EMSY, plays a role in repression of transcription and may play a role in DNA repair.	EMSY wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111828>	C26199	Protein EMSY|BRCA2-Interacting Transcriptional Repressor EMSY|EMSY	Protein EMSY (1322 aa, ~141 kDa) is encoded by the human EMSY gene. This protein is involved in transcription repression and may be involved in DNA repair.	Protein EMSY		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111829>	C25939	ADH4 Gene|ADH4|ADH4|Alcohol Dehydrogenase 4 (Class II), Pi Polypeptide Gene	This gene plays a role in the oxidation of alcohols.	ADH4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C11182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11182>	C61063	Cisplatin/interleukin-2/Paclitaxel/Tumor Infiltrating Lymphocytes|CDDP/IL-2/TAX/TIL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111830>	C20103	LRP1B Gene|LRP1B|LRP1B|LRP1B|Low Density Lipoprotein Receptor-Related Protein 1B Gene	This gene plays a role in low density lipoprotein metabolism.	LRP1B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C111831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111831>	C111829	ADH4 wt Allele|ADH-2|ADH2|Alcohol Dehydrogenase 4 (Class II), Pi Polypeptide wt Allele	Human ADH4 wild-type allele is located in the vicinity of 4q22 and is approximately 34 kb in length. This allele, which encodes all-trans-retinol dehydrogenase [NAD(+)] ADH4 protein, is involved in the metabolism of alcohols.	ADH4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111832>	C111830	LRP1B wt Allele|LRP-1B|LRP-DIT|LRPDIT|Low Density Lipoprotein Receptor-Related Protein 1B wt Allele	Human LRP1B wild-type allele is located in the vicinity of 2q21.2 and is approximately 1900 kb in length. This allele, which encodes low-density lipoprotein receptor-related protein 1B, is involved in both the metabolism of low density lipoproteins and receptor-mediated endocytosis.	LRP1B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111833>	C16946	All-Trans-Retinol Dehydrogenase [NAD(+)] ADH4|ADH, Class II|ADH4|Alcohol Dehydrogenase 2|Alcohol Dehydrogenase 4|Alcohol Dehydrogenase 4|Alcohol Dehydrogenase Class II Pi Chain|Alcohol Dehydrogenase, Pi Isozyme|EC 1.1.1.1|EC:1.1.1.105	All-trans-retinol dehydrogenase [NAD(+)] ADH4  (380 aa, ~40 kDa) is encoded by the human ADH4 gene. This protein plays a role in alcohol oxidation.	Alcohol Dehydrogenase 4		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111834>	C18106	Low-Density Lipoprotein Receptor-Related Protein 1B|LRP-1B|LRP-DIT|LRP-Deleted In Tumors|LRP1B|Low Density Lipoprotein Receptor Related Protein-Deleted In Tumor|Low Density Lipoprotein-Related Protein 1B (Deleted In Tumors)|Low Density Lipoprotein-Related Protein 1B Deleted In Tumors|Low-Density Lipoprotein Receptor Related Protein 1B|Low-Density Lipoprotein Receptor-Related Protein-Deleted In Tumor	Low-density lipoprotein receptor-related protein 1B (4599 aa, ~515 kDa) is encoded by the human LRP1B gene. This protein plays a role in the metabolism of low density lipoproteins.	Low-Density Lipoprotein Receptor-Related Protein 1B		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111835>	C25873	PRKCG Gene|PRKCG|PRKCG|Protein Kinase C, Gamma Gene	This gene is involved in signal transduction.	PRKCG Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111836>	C111835	PRKCG wt Allele|MGC57564|PKCC|PKCG|Protein Kinase C, Gamma wt Allele|SCA14	Human PRKCG wild-type allele is located in the vicinity of 19q13.4 and is approximately 28 kb in length. This allele, which encodes Protein kinase C gamma type protein, plays a role in the regulation of cellular signaling pathways. Mutations in this gene are associated with spinocerebellar ataxia 14.	PRKCG wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111837>	C17325	Protein Kinase C Gamma Type|EC 2.7.11.13|PKC-Gamma	Protein kinase C gamma type (697 aa, ~78 kDa) is encoded by the human PRKCG gene. This protein is involved in cellular signaling.	Protein Kinase C Gamma Type		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111838>	C20194	NDRG4 Gene|NDRG Family Member Gene|NDRG4|NDRG4	This gene is involved in vascular smooth muscle cell mitogenesis, spatial learning and neuronal survival.	NDRG4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111839>	C111838	NDRG4 wt Allele|BDM1|KIAA1180|NDRG Family Member wt Allele|NMYC Downstream-Regulated Gene 4|SMAP-8|SMAP8	Human NDRG4 wild-type allele is located within 16q21-q22.1 and is approximately 51 kb in length. This allele, which encodes protein NDRG4, plays a role in both vascular smooth muscle cell growth and neuronal survival.	NDRG4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11183>	C61007	Carboplatin/Paclitaxel/Topotecan|CBDCA/TAX/TOPO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111840>	C18466	Protein NDRG4|Brain Development-Related Molecule 1|N-Myc Downstream-Regulated Gene 4 Protein|SMAP-8|Smooth Muscle Associated Protein 8|Smooth Muscle-Associated Protein 8|Vascular Smooth Muscle Cell-Associated Protein 8	Protein NDRG4 (352 aa, ~38 kDa) is encoded by the human NDRG4 gene. This protein is involved in the inhibition of neuronal cell death and the growth of vascular smooth muscle cell.	Protein NDRG4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111841>	C20719	EPHA7 Gene|EPH Receptor A7 Gene|EPHA7|EPHA7|EPHA7	This gene plays a role in mediation of developmental processes.	EPHA7 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C111842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111842>	C29936	TFPI2 Gene|TFPI2|TFPI2|Tissue Factor Pathway Inhibitor 2 Gene	This gene plays a role in serine proteinase inhibition.	TFPI2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111843>	C111841	EPHA7 wt Allele|EHK-3|EHK3|EK11|EPH Receptor A7 wt Allele|HEK11	Human EPHA7 wild-type allele is located in the vicinity of 6q16.1 and is approximately 180 kb in length. This allele, which encodes ephrin type-A receptor 7 protein, is involved in regulation of developmental processes.	EPHA7 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111844>	C17660	Ephrin Type-A Receptor 7|EC 2.7.10.1|EPH Homology Kinase 3|EPH-Like Kinase 11|Eph Homology Kinase-3|Ephrin Receptor EphA7|Receptor Protein-Tyrosine Kinase HEK11|Tyrosine-Protein Kinase Receptor EHK-3	Ephrin type-A receptor 7 (998 aa, ~112 kDa) is encoded by the human EPHA7 gene. This protein plays a role in development.	Ephrin Type-A Receptor 7		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111845>	C111842	TFPI2 wt Allele|PP5|REF1|TFPI-2|Tissue Factor Pathway Inhibitor 2 wt Allele	Human TFPI2 wild-type allele is located in the vicinity of 7q22 and is approximately 6 kb in length. This allele, which encodes tissue factor pathway inhibitor 2 protein, is involved in the negative regulation of serine proteinase activity.	TFPI2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111846>	C17122	Tissue Factor Pathway Inhibitor 2|PP5|Placental Protein 5|Retinal Pigment Epithelium Cell Factor 1|TFPI-2	Tissue factor pathway inhibitor 2 (235 aa, ~27 kDa) is encoded by the human TFPI2 gene. This protein plays a role in the inhibition of serine proteinases.	Tissue Factor Pathway Inhibitor 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111847>	C28533	SLC38A3 Gene|SLC38A3|SLC38A3|Solute Carrier Family 38, Member 3 Gene	This gene is involved in neutral amino acid transport.	SLC38A3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111848>	C111847	SLC38A3 wt Allele|G17|NAT1|SN1|SNAT3|Solute Carrier Family 38 (Amino Acid Transporter), Member 3 Gene|Solute Carrier Family 38, Member 3 wt Allele	Human SLC38A3 wild-type allele is located in the vicinity of 3p21.31 and is approximately 16 kb in length. This allele, which encodes sodium-coupled neutral amino acid transporter 3 protein, plays a role in neutral amino acid transport and may play a role in both synaptic transmission and nitrogen metabolism.	SLC38A3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111849>	C16386	Sodium-Coupled Neutral Amino Acid Transporter 3|N-System Amino Acid Transporter 1|Na(+)-Coupled Neutral Amino Acid Transporter 3|SLC38A3|Solute Carrier Family 38 Member 3|System N Amino Acid Transporter 1|System N1 Na+ And H+-Coupled Glutamine Transporter|Transport System N, Protein 1	Sodium-coupled neutral amino acid transporter 3 (504 aa, ~56 kDa) is encoded by the human SLC38A3 gene. This protein is involved in neutral amino acid transport.	Sodium-Coupled Neutral Amino Acid Transporter 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11184>	C61063	Carboplatin/filgrastim/Paclitaxel/Topotecan|CBDCA/G-CSF/TAX/TOPO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111850>	C21295	ZMYND10 Gene|ZMYND10|ZMYND10|Zinc Finger, MYND-Type Containing 10 Gene	This gene plays a role in ciliary function.	ZMYND10 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111851>	C111850	ZMYND10 wt Allele|BLU|CILD22|FLU|LUCA12.4|Zinc Finger, MYND-Type Containing 10 wt Allele	Human ZMYND10 wild-type allele is located in the vicinity of 3p21.3 and is approximately 6 kb in length. This allele, which encodes zinc finger MYND domain-containing protein 10, is involved in motile ciliary function. Mutations in this gene are associated with primary ciliary dyskinesia-22.	ZMYND10 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111852>	C17728	Zinc Finger MYND Domain-Containing Protein 10|Protein Blu|ZMYND10|Zinc Finger, MYND Domain Containing 10	Zinc finger MYND domain-containing protein 10 (440 aa, ~50 kDa) is encoded by the human ZMYND10 gene. This protein plays a role in ciliary function.	Zinc Finger MYND Domain-Containing Protein 10		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111853>	C16729	Sudden Unexplained Infant Death|SUID	Unexpected death of an infant less than one year of age, whose cause of death is not immediately obvious prior to investigation.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111854>	C60811	Sudden Unexplained Death in Childhood	Unexpected death of a child over one year of age, which remains unexplained when all known and possible causes of death have been ruled out.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111855>	C80520	Neonatal Neutropenia	A condition characterized by a decrease in the number of neutrophils in the blood below established reference ranges in a newborn.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C111856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111856>	C2992	Disseminated Intravascular Coagulation in Newborn|Neonatal Disseminated Intravascular Coagulation|Neonatal Disseminated Intravascular Coagulation	A clotting condition characterized as a disruption in the homeostatic balance of the coagulation and fibrinolytic systems presenting as a pathological activation of coagulation mechanisms leading to the formation of small clots inside the blood vessels throughout the body of the newborn.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C111857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111857>	C99108|C98996	Hemorrhagic Disease of Newborn|Vitamin K Deficiency Bleeding in Newborn|Vitamin K Deficiency Bleeding in Newborn	A condition characterized as a coagulation disturbance in newborns due to vitamin K deficiency resulting in impaired production of coagulation factors II, VII, IX, and X, and proteins C and S by the liver.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C111858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111858>	C111860	Direct Maternal Death	Death resulting from conditions or complications which are unique to pregnancy and occur during the antepartum, intrapartum, or postpartum period.			Finding	NICHD Terminology|Perinatal Terminology
C111859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111859>	C111860	Indirect Maternal Death	Death resulting from previously existing disease or a disease developing during pregnancy which was not associated with gestation, but which was aggravated by the unique physiologic changes of pregnancy. Examples of indirect deaths include those associated with epilepsy, diabetes, cardiac disease and hormone-dependent malignancies.			Finding	NICHD Terminology|Perinatal Terminology
C11185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11185>	C61063	P-30 Protein/Tamoxifen|Onconase/TAM|Onconase/TMX|Onconase/Tamoxifen|P-30 Protein/TAM|P-30 Protein/TMX|Ranpirnase/Tamoxifen			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111860>	C28554	Maternal Mortality|Maternal Death|Maternal Death	The death of a woman while pregnant or within 42 days of the end of the pregnancy, irrespective of the duration or anatomic site of the pregnancy, due to any cause related to or aggravated by the pregnancy or its management, but not from accidental or incidental causes.			Finding	GAIA Postpartum Hemorrhage Level of Diagnostic Certainty Terminology|GAIA Terminology|NICHD Terminology|Perinatal Terminology
C111861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111861>	C26759	Postpartum Obstetric Septic Embolism	Presence of bacterially-infected tissue in the maternal vascular system which originated from a distant site during the postpartum period.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C111862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111862>	C20731	DUSP5 Gene|DUSP5|DUSP5|Dual Specificity Phosphatase 5 Gene	This gene is involved in the dephosphorylation of ERK family proteins.	DUSP5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111863>	C111862	DUSP5 wt Allele|DUSP|Dual Specificity Phosphatase 5 wt Allele|Dual-Specificity Phosphatase 5 Gene|HVH3|VH3	Human DUSP5 wild-type allele is located in the vicinity of 10q25 and is approximately 14 kb in length. This allele, which encodes dual specificity protein phosphatase 5 protein, plays a role in kinase dephosphorylation.	DUSP5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111864>	C25880	Dual Specificity Protein Phosphatase 5|DUSP5|Dual Specificity Protein Phosphatase HVH3|Dual Specificity Protein Phosphatase hVH3|Dual-Specificity Protein Phosphatase 5|EC 3.1.3.16|EC 3.1.3.48|VH1-Like Phosphatase 3	Dual specificity protein phosphatase 5 (384 aa, ~42 kDa) is encoded by the human DUSP5 gene. This protein is involved in the dephosphorylation of MAP kinase family proteins.	Dual Specificity Protein Phosphatase 5		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111865>	C28195	Postpartum Obstetric Thromboembolism	Presence of a blood clot in the maternal vascular system which originated from a distant site during the postpartum period.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C111866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111866>	C30073	KRT18 Gene|KRT18|KRT18|Keratin 18 Gene	This gene plays a role in keratin filament structure.	KRT18 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111867>	C111866	KRT18 wt Allele|CK18|CYK18|Cell Proliferation-Inducing Gene 46|K18|Keratin 18 wt Allele|PIG46	Human KRT18 wild-type allele is located in the vicinity of 12q13 and is approximately 4 kb in length. This allele, which encodes keratin, type I cytoskeletal 18 protein, is involved in both the negative regulation of apoptosis and intermediate filament structure. Mutations in the gene are associated with cryptogenic cirrhosis.	KRT18 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111868>	C20694	Keratin, Type I Cytoskeletal 18|CK-18|Cell Proliferation-Inducing Gene 46 Protein|Cell Proliferation-Inducing Protein 46|Cytokeratin 18|Cytokeratin-18|K18|KRT18|Keratin-18	Keratin, type I cytoskeletal 18 (430 aa, ~48 kDa) is encoded by the human KRT18 gene. This protein plays a role in both intermediate filament structure and the inhibition of apoptosis.	Keratin, Type I Cytoskeletal 18		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111869>	C28533	SEC14L1 Gene|SEC14-Like 1 (S. cerevisiae) Gene|SEC14L1|SEC14L1	This gene is involved in transport.	SEC14L1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C11186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11186>	C61063	Cladribine/Etoposide|2-CdA/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111870>	C111869	SEC14L1 wt Allele|PRELID4A|SEC14 (S. cerevisiae)-Like 1 Gene|SEC14, S. cerevisiae, Homolog of, 1 Gene|SEC14-Like 1 (S. cerevisiae) wt Allele|SEC14-Like 1 Gene|SEC14L	Human SEC14L1 wild-type allele is located in the vicinity of 17q25.2 and is approximately 130 kb in length. This allele, which encodes SEC14-like protein 1, may play a role in intracellular transport. Aberrant elevated expression of the gene may be associated with a poor prognosis for prostate adenocarcinoma.	SEC14L1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111871>	C16386	SEC14-Like Protein 1|SEC14L1	SEC14-like protein 1 (715 aa, ~81 kDa) is encoded by the human SEC14L1 gene. This protein may be involved in intracellular transport.	SEC14-Like Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111872>	C25870	ALAS1 Gene|ALAS1|ALAS1|Aminolevulinate, Delta-, Synthase 1 Gene	This gene plays a role in both lipid metabolism and heme biosynthesis.	ALAS1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111873>	C111872	ALAS1 wt Allele|ALAS|ALAS, Housekeeping Type Gene|ALAS3|ALASH|Aminolevulinate, Delta-, Synthase 1 wt Allele|MIG4|OK/SW-cl.121	Human ALAS1 wild-type allele is located in the vicinity of 3p21.1 and is approximately 16 kb in length. This allele, which encodes 5-aminolevulinate synthase, nonspecific, mitochondrial protein, is involved in both heme biosynthesis and lipid metabolism.	ALAS1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111874>	C16259	5-Aminolevulinate Synthase, Nonspecific, Mitochondrial|5-Aminolevulinic Acid Synthase 1|ALAS-H|ALAS1|Delta-ALA Synthase 1|Delta-Aminolevulinate Synthase 1|EC 2.3.1.37|Migration-Inducing Protein 4	5-aminolevulinate synthase, nonspecific, mitochondrial (640 aa, ~71 kDa) is encoded by the human ALAS1 gene. This protein plays a role in both protoporphyrin biosynthesis and lipid metabolism.	5-Aminolevulinate Synthase, Nonspecific, Mitochondrial		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111875>	C20420	ATOH1 Gene|ATOH1|ATOH1|Atonal Homolog 1 (Drosophila) Gene	This gene is involved in E-box dependent gene transcription.	ATOH1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111876>	C111875	ATOH1 wt Allele|ATH1|Atonal Homolog 1 (Drosophila) wt Allele|Atonal, Drosophila, Homolog of, 1 Gene|BHLHA14|HATH1|MATH-1|MATH1, Mouse, Homolog of Gene|bHLHa14	Human ATOH1 wild-type allele is located in the vicinity of 4q22 and is approximately 1 kb in length. This allele, which encodes protein atonal homolog 1, plays a role in the modulation of E-box dependent transcription.	ATOH1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111877>	C17207	Protein Atonal Homolog 1|Class A Basic Helix-Loop-Helix Protein 14|Helix-Loop-Helix Protein HATH-1|bHLHa14|hATH1	Protein atonal homolog 1 (354 aa, ~38 kDa) is encoded by the human ATOH1 gene. This protein is involved in the activation of E-box dependent gene expression.	Protein Atonal Homolog 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111878>	C20921	DKK2 Gene|DKK2|DKK2|Dickkopf WNT Signaling Pathway Inhibitor 2 Gene	This gene plays a role in the regulation of Wnt signaling.	DKK2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111879>	C111878	DKK2 wt Allele|DKK-2|Dickkopf (Xenopus Laevis) Homolog 2 Gene|Dickkopf 2 Homolog (Xenopus Laevis) Gene|Dickkopf Homolog 2 Gene|Dickkopf WNT Signaling Pathway Inhibitor 2 wt Allele|Dickkopf, Xenopus, Homolog of, 2 Gene|UNQ682/PRO1316	Human DKK2 wild-type allele is located in the vicinity of 4q25 and is approximately 362 kb in length. This allele, which encodes dickkopf-related protein 2, is involved in the negative regulation of Wnt signaling.	DKK2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11187>	C61007	Prednisone/Tacrolimus|FK506/PRED			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111880>	C18515	Dickkopf-Related Protein 2|Dickkopf 2|Dickkopf Related Protein-2|Dickkopf-2|Dkk-2|hDkk-2	Dickkopf-related protein 2 (259 aa, ~28 kDa) is encoded by the human DKK2 gene. This protein plays a role in the inhibition of the Wnt signaling pathway.	Dickkopf-Related Protein 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111881>	C20921	DKK4 Gene|DKK4|DKK4|Dickkopf WNT Signaling Pathway Inhibitor 4 Gene	This gene is involved in the inhibition of the Wnt signaling pathway.	DKK4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111882>	C111881	DKK4 wt Allele|DKK-4|Dickkopf (Xenopus Laevis) Homolog 4 Gene|Dickkopf 4 Homolog (Xenopus Laevis) Gene|Dickkopf Homolog 4 Gene|Dickkopf, Xenopus, Homolog of, 4 Gene	Human DKK4 wild-type allele is located within 8p11.2-p11.1 and is approximately 3 kb in length. This allele, which encodes dickkopf-related protein 4, plays a role in the modulation of Wnt signaling.	DKK4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111883>	C18515	Dickkopf-Related Protein 4|Dickkopf 4|Dickkopf Related Protei-42|Dickkopf-4|Dkk-4|hDkk-4	Dickkopf-related protein 4 (224 aa, ~25 kDa) is encoded by the human DKK4 gene. This protein is involved in the negative regulation of Wnt signaling.	Dickkopf-Related Protein 4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111884>	C39594	Exanthem	A widespread, acute rash.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111885>	C5036	Dermatographism	A raised, inflamed skin reaction to pressure from rubbing or scratching.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111886>	C2983	Diaper Dermatitis|Diaper Rash|Diaper Rash|Nappy Rash|Nappy Rash	An inflammatory skin condition in the diaper area that may be caused by irritation or infection.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Infectious Disease Terminology
C111887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111887>	C111886	Candida Diaper Dermatitis|Candida Diaper Rash|Candida Diaper Rash|Candida Nappy Rash|Candida Nappy Rash	An inflammatory skin condition in the diaper area superimposed with Candida infection, characterized by a bright red rash with a sharply demarcated edge and satellite lesions. Skin folds are often involved.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Infectious Disease Terminology
C111888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111888>	C3001	Seborrheic Dermatitis|Cradle Cap|Cradle Cap|Seborrhea|Seborrhea|Seborrheic Eczema|Seborrheic Eczema	A chronic, inflammatory skin disorder that affects the scalp, central face and skin folds; it is characterized by scaling and itching.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111889>	C91105	Naranjo Adverse Drug Reaction Probability Scale|NADRPS|Naranjo ADR Probability Scale|Naranjo Checklist|Naranjo Scale	A questionnaire developed by Naranjo et al that is designed to assess the likelihood that an adverse event is due to the drug administered rather than the result of other factors.			Intellectual Product	
C11188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11188>	C61063	Fluorouracil/Phenylbutyrate|5-FU/PBA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111890>	C43583	Objective Evidence	Information proven as true based on documentation, measurement, or facts; not subjective or speculative.			Idea or Concept	
C111891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111891>	C2124	Carbon C 14 Telotristat Etiprate|14C-telotristat Etiprate|[14C]-LX1606|[14C]-telotristat Etiprate	An orally bioavailable, tryptophan hydroxylase (TPH) inhibitor prodrug labeled with carbon C 14, which could be used to evaluate the pharmacokinetic profile of telotristat etiprate. Upon administration, telotristat etiprate is converted to its active moiety, telotristat (LP-778902), which binds to and blocks the activity of TPH. This may result in a reduction in peripheral serotonin (5-HT) production and improvement of serotonin-mediated gastrointestinal adverse side effects, such as severe diarrhea. TPH, the rate-limiting enzyme in serotonin biosynthesis, is overexpressed in carcinoid tumor cells. Telotristat radiolabeled with carbon C 14 facilitates the evaluation of the pharmacokinetic characteristics of this agent, including its absorption, distribution, metabolism, and excretion (ADME).			Pharmacologic Substance	NCI Drug Dictionary Terminology
C111892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111892>	C2491	Ropeginterferon Alfa-2B|AOP 2014|AOP-2014|AOP2014|Besremi|P-1101|P1101|PEG-P-IFN-Alfa-2b|PEG-P-IFN-Alpha-2b|PEG-Proline-Interferon Alfa-2b|ROPEGINTERFERON ALFA-2B|Ropeginterferon alfa-2b	A long-acting formulation of recombinant interferon alpha subtype 2b (IFN-a2b), in which IFN-a2b is coupled, via proline, to polyethylene glycol (PEG), with antiviral, immunomodulating and antineoplastic activities. Upon administration of ropeginterferon alfa-2b, IFN-a2b targets and binds to specific IFN cell-surface receptors. This activates IFN-mediated signal transduction pathways and induces the transcription and translation of genes with IFN-specific response elements (ISREs). Their protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety inhibits proteolytic breakdown and clearance of IFN-a2b, which prolongs its half-life, extends the duration of its therapeutic effects and allows less frequent dosing. The proline linker facilitates the synthesis of a single positional isomer which further increases its stability and half-life.	Ropeginterferon Alfa-2B		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111893>	C2139|C213381	Oncolytic Herpes Simplex Virus-1-encoding GM-CSF|HSV-encoding GM-CSF|OrienX010|Recombinant hGM-CSF	An ICP34.5-, ICP47-deleted, oncolytic herpes simplex type-1 virus (HSV-1) isolated from the mouth of an HSV-1-infected patient of Chinese Han ethnicity, and encoding the immunostimulating factor cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with potential immunostimulating and antineoplastic activities. Upon administration, the recombinant human GM-CSF HSV-1 selectively infects and replicates in tumor cells, thereby inducing tumor cell lysis. In addition, GM-CSF attracts dendritic cells (DCs) and may stimulate a cytotoxic T cell response against tumor cells, which results in immune-mediated tumor cell death. Deletion of the gene encoding for ICP34.5 provides tumor selectivity and prevents replication in healthy cells. As ICP47 blocks antigen presentation in HSV-infected cells, deletion of this gene may induce a more potent antitumor immune response in the tumor cells. Additionally, deletion of ICP47 causes increased expression of the HSV US11 gene and allows US11 to be expressed as an immediate early and not a late gene. This further enhances the degree of viral replication and oncolysis of tumor cells. Interruption of the ICP6 gene, which encodes the large subunit of the viral ribonucleotide reductase, in the viral vector also enhances selective replication in tumor cells.			Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111894>	C28676	Donor Regulatory T-lymphocytes|Donor CD4+CD25+FoxP3+ T Cells	Donor-derived regulatory T-cells (Tregs), with potential immunomodulating activity.  Tregs are a subset of CD4+ T cells that express high levels of CD25 (interleukin 2 receptor) and the transcription factor Foxp3. The donor CD4+CD25+ Tregs modulate immune responses and may induce tolerance to allogeneic organ transplants, such as hematopoietic stem cell transplants (HSCTs), thereby preventing graft-versus-host disease (GVHD).	Donor Regulatory T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C111895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111895>	C2167|C213472|C159156	Pyrotinib|PYROTINIB|SHR 1258|SHR-1258|SHR1258	An orally bioavailable, dual kinase inhibitor of the epidermal growth factor receptor (EGFR or HER-1) and the human epidermal growth factor receptor 2 (ErbB2 or HER-2), with potential antineoplastic activity. Upon oral administration, pyrotinib binds to and inhibits both EGFR and HER2, which may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumor cells. EGFR and HER2 are receptor tyrosine kinases that are upregulated in various tumor cell types and play major roles in tumor cell proliferation and tumor vascularization.	Pyrotinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111896>	C1505	Olive Oil/Soya Oil/Egg Lecithin-based Emulsion|ClinOleic	An injectable, isotonic, nutritional lipid emulsion composed of approximately 80% refined olive oil and 20% refined soybean oil, used for parenteral nutrition. The olive oil/soya oil/egg lecithin emulsion provides about 15% of saturated fatty acids (SFA), 65% of mono-unsaturated fatty acids (MUFA) and 20% of essential poly-unsaturated fatty acids (EPUFA). Upon parenteral administration, the emulsion supplies calories, for energy, and essential fatty acids that can be incorporated into cell membranes. The fatty acids may decrease the production of certain pro-inflammatory cytokines, including interleukin 1 (IL-1), IL-6 and tumor necrosis factor (TNF). In addition to olive oil and soya oil, this lipid emulsion contains egg lecithin and provides phosphorus and choline, which are needed to maintain cell membrane integrity.			Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111897>	C2189|C129986	Yangzheng Xiaoji Extract|DME25|YZXJ Extract	A traditional Chinese medicine (TCM)-based formulation containing the Yangzheng Xiaoji (YZXJ) extract, consisting of various components, with potential antineoplastic and anti-angiogenic activities. Some of the main components in Yangzheng Xiaoji are Radix Astragali, Fructus Ligustri Lucidi, Radix Ginseng, Ganoderma, Rhizoma Curcumac, Fried Rhizoma Atractylodis, Macrocephalae and Herba Hedyotidis. Although the exact mechanism(s) through which Yangzheng Xiaoji exerts its effects have yet to be fully elucidated, this agent, upon administration, inhibits the activation of various signaling protein kinases, such as focal adhesion kinase (FAK) and paxillin. This prevents signal transduction pathways that are upregulated in cancer, prevents the adhesion and migration of tumor cells and inhibits tumor cell growth.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111898>	C2201|C2152|C129825	Bimiralisib|2-Pyridinamine, 5-(4,6-Di-4-morpholinyl-1,3,5-triazin-2-yl)-4-(trifluoromethyl)-|BIMIRALISIB|PQR-309|PQR309	An orally bioavailable pan inhibitor of phosphoinositide-3-kinases (PI3K) and inhibitor of the mammalian target of rapamycin (mTOR), with potential antineoplastic activity. Bimiralisib inhibits the PI3K kinase isoforms alpha, beta, gamma and delta and, to a lesser extent, mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to both chemotherapy and radiotherapy. As mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K, this agent may potentially be more potent than an agent that inhibits either PI3K kinase or mTOR kinase. By inhibiting mTOR to a lesser extent than PI3K, PQR309 does not interfere with the mTOR-mediated negative feedback loop on PI3K signaling. Blocking the negative feedback loop would potentially increase PI3K signaling and decrease therapeutic efficacy.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111899>	C932|C67422	Liposomal Eribulin Mesylate|E7389 Liposomal Formulation|E7389-LF	A liposome-encapsulated formulation of the mesylate salt form of eribulin, a synthetic, macrocyclic ketone analogue of halichondrin B, a substance derived from the marine sponge genus Halichondria, with potential antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits both the polymerization of tubulin and the assembly of microtubules. This results in the inhibition of mitotic spindle assembly, the induction of cell cycle arrest at G2/M phase, as well as tumor cell apoptosis. Compared to the administration of eribulin alone, liposomal delivery of eribulin allows for a longer half-life, which allows increased drug concentration in target tissues while decreasing systemic toxicity.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11189>	C61063	Etoposide/Methylprednisolone|MePRDL/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1118>	C2089|C1931	Gossypol Acetic Acid|GOSSYPOL ACETIC ACID|Gossypol Acetate|gossypol acetic acid	The naturally occurring acetic acid form of gossypol, and an orally available polyphenolic aldehyde derived mostly from cottonseed with potential antineoplastic activity.  The biologic activities of gossypol acetic acid are similar to those of gossypol and include suppression of DNA replication, inhibition of tumor cell proliferation, and male contraceptive effects. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C111900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111900>	C28310	Autologous Melanoma Lysate/NY-ESO-1-pulsed Autologous Dendritic Cell Vaccine	A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with both a lysate from autologous melanoma cells containing tumor associated antigens (TAAs) and a synthetic peptide derived from the tumor associated antigen human cancer-testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon administration, autologous melanoma lysate/NY-ESO-1-pulsed autologous DC vaccine may stimulate the immune system to mount anti-tumoral cytotoxic T lymphocyte (CTL) and antibody-mediated immune responses against melanoma cells, which may result in melanoma cell lysis. NY-ESO-1 is expressed in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival.			Cell|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111901>	C128462	Pelabresib Anhydrous|BET Inhibitor CPI-0610|CPI-0610 Anhydrous|CPI-232|CPI-267232|PELABRESIB ANHYDROUS|Pelabresib	The anhydrous form of pelabresib, a small molecule inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, pelabresib binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histone peptides. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of two bromodomains at the N-terminus, the BET proteins (BRD2, BRD3, BRD4 and BRDT) are transcriptional regulators that play an important role during development and cellular growth.	Pelabresib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111902>	C203001|C119988	Lenti-D/ABCD1-transduced Autologous Hematopoietic Stem Cells	Autologous CD34+ hematopoietic stem cells transduced with Lenti-D lentiviral vector encoding the human ATP-binding cassette, sub-family D, member 1 (ABCD1) cDNA, for the potential treatment of childhood cerebral adrenoleukodystrophy (CCALD). Upon administration of the lenti-D/ABCD1-transduced autologous hematopoietic stem cells, the cells proliferate, and some travel to the brain and differentiate into microglial cells. The expressed ABCD1 restores the function of ALD protein (ALDP) and aids in the treatment of CCALD.  In CCALD, the ABCD1 gene is mutated, leading to the inability of patients to metabolize very long chain fatty acids in cells of the brain.	Lenti-D/ABCD1-transduced Autologous Hematopoietic Stem Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C111903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111903>	C39619	CMVpp65/gB Plasmid Vaccine ASP0113|ASP0113|TransVax	A poloxamer-formulated, bivalent DNA vaccine containing two plasmids encoding both the human cytomegaloviral (CMV) tegument phosphoprotein 65 (pp65), a major internal matrix protein, and glycoprotein B (gB), an important CMV component responsible for attachment and entry into cells, with potential immunostimulatory properties. Upon intramuscular injection of CMVpp65/gB plasmid vaccine ASP0113, the expressed proteins may activate the immune system to mount both cellular and humoral immune responses against CMV-positive cells. This results in cell lysis of CMV-infected cells and prevents both viral replication and the development of CMV disease. This vaccine also provides active immunization and protective immunity against CMV infection in CMV-negative patients exposed to infected donor cells or tissues in transplant recipients. CMV infection can cause serious complications in patients receiving either allogeneic hematopoietic cell transplants (HCT) or solid organ transplants. The poloxamer-based delivery system enhances DNA delivery.	CMVpp65/gB Plasmid Vaccine ASP0113		Immunologic Factor|Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C111904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111904>	C84767	Immune Hydrops Fetalis	Fluid accumulation in multiple fetal anatomic cavities attributable to a maternal immune response against fetal blood cell antigens.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C111905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111905>	C84767	Non-Immune Hydrops Fetalis	Fluid accumulation in multiple fetal anatomic cavities that is of non-immune origin.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C111906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111906>	C214992|C201551	Laprituximab Emtansine|Anti-EGFR-SMCC-DM1|IMGN289|LAPRITUXIMAB EMTANSINE	A targeted antibody payload (TAP)-based immunoconjugate consisting of a human monoclonal antibody directed against the epidermal growth factor receptor (EGFR) conjugated, via a nonreducible thioether linker (succinimidyl trans-4-(maleimidylmethyl)cyclohexane-1-carboxylate or SMCC), to the cytotoxic agent maytansinoid mertansine (DM1), with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of laprituximab emtansine binds to and inhibits EGFR on tumor cell surfaces. Inhibition of EGFR prevents EGFR-mediated signaling and may inhibit tumor cell proliferation. After internalization, the mertansine moiety binds to tubulin and interferes with microtubule assembly/disassembly dynamics. This inhibits both cell division and the proliferation of cancer cells that express EGFR. EGFR, overexpressed by a variety of cancers, plays a key role in tumor cell proliferation and survival. Linkage of the antibody and drug, through a nonreducible linker, appears to contribute to the improved efficacy and reduced toxicity of this antibody-drug conjugate (ADC) compared to similar ADCs constructed with reducible linkers.	Laprituximab Emtansine		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111907>	C226473	HO/02/02	A topical formulation that can be used to relieve radiation dermatitis.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C111908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111908>	C92719	Angiotensin Converting Enzyme Inhibitor Fetopathy|ACE Fetopathy|ACE Inhibitor Fetopathy|ACE Inhibitor Fetopathy	Fetal embryopathy associated with maternal angiotensis converting enzyme (ACE) inhibitor use during pregnancy that may include fetal acute renal failure, growth restriction, oligohydramnios, calvaria abnormalities, preterm birth, and pulmonary hypoplasia with respiratory distress.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C111909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111909>	C92719	Diabetic Fetopathy	A constellation of features seen in the hyperinsulinemic fetus of a diabetic mother that include macrosomia, postnatal hypoglycemia and polycythemia.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C11190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11190>	C61063	Melphalan/Mitoxantrone|DHAD/L-PAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111910>	C79859	Fetal Virilization|Fetal Virilism|Fetal Virilism	Inappropriate secondary sex characteristics in the neonate usually due to in utero androgen exposure.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C111911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111911>	C26759	Amniotic Fluid Embolism|Amniotic Fluid Embolism Syndrome|Amniotic Fluid Embolism Syndrome	Acute hypotension or cardiac arrest, acute hypoxia or coagulopathy in the absence of any other potential explanation related to the presence of amniotic fluid or the fetal debris within the maternal vascular system during the antepartum or intrapartum period.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C111912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111912>	C21176	Chromatin Assembly Factor I|CAF-1|CAF-1 Complex|CAF-I|CAF1|Chromatin Assembly Factor 1|Chromatin Assembly Factor 1 Complex|Chromatin Assembly Factor I Complex	A heterotrimeric protein complex that mediates chromatin assembly by promoting histone H3 and H4 deposition onto newly synthesized DNA during replication or DNA repair. This complex is comprised of chromatin assembly factor 1 subunit A, chromatin assembly factor 1 subunit B and histone-binding protein RBBP4.			Amino Acid, Peptide, or Protein	
C111913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111913>	C2985	Pre-Gestational Diabetes|Pregestational Diabetes|Pregestational Diabetes|Unspecified pre-existing diabetes mellitus in pregnancy, unspecified trimester	Diabetes diagnosed before current pregnancy. (reVITALize)			Disease or Syndrome	mCode Elixhauser Diabetes without Chronic Complications Value Set|mCode Terminology|NICHD Terminology|Perinatal Terminology
C111914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111914>	C26764	Postpartum Endometritis|Puerperal Endometritis|Puerperal Endometritis|Puerperal Endomyometritis	Infection of the endometrium, decidua and/or myometrium occurring at any time between birth and 42 days postpartum.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C111915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111915>	C3364	Severe Sepsis|Sepsis with Organ Dysfunction|Sepsis with Organ Dysfunction	Clinical syndrome defined by the presence of both infection and a systemic inflammatory response that progresses to multi-organ failure.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C111916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111916>	C20194	NLRP4 Gene|NLR Family, Pyrin Domain Containing 4 Gene|NLRP4|NLRP4	This gene may be involved in inflammation.	NLRP4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111917>	C111916	NLRP4 wt Allele|CLR19.5|CT58|NACHT, Leucine Rich Repeat and PYD Containing 4 Gene|NLR Family, Pyrin Domain Containing 4 wt Allele|NLR Family, Pyrin Domain-Containing 4 Gene|Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat and Pyrin Domain Containing 4 Gene|PAN2|PYPAF4|RNH2	Human NLRP4 wild-type allele is located in the vicinity of 19q13.43 and is approximately 45 kb in length. This allele, which encodes NACHT, LRR and PYD domains-containing protein 4, may play a role in the negative regulation of signaling by type I interferon.	NLRP4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111918>	C18466	NACHT, LRR and PYD Domains-Containing Protein 4|CT58|Cancer/Testis Antigen 58|NACHT Domain-, Leucine-Rich Repeat-, and PYD-Containing Protein 4|NACHT, LRR and PYD Containing Protein 4|NLRP4|PAAD and NACHT-Containing Protein 2|PYRIN Domain- and NACHT Domain-Containing Protein 2|PYRIN Domain-Containing APAF1-Like Protein 4|PYRIN and NACHT-Containing Protein 2|PYRIN-Containing APAF1-Like Protein 4|Ribonuclease Inhibitor 2	NACHT, LRR and PYD domains-containing protein 4 (994 aa, ~113 kDa) is encoded by the human NLRP4 gene. This protein may be involved in the modulation of signaling in inflammation.	NACHT, LRR and PYD Domains-Containing Protein 4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111919>	C20194	NLRP2 Gene|NLR Family, Pyrin Domain Containing 2 Gene|NLRP2|NLRP2	This gene plays a role in the modulation of apoptotic signaling.			Gene or Genome	
C11191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11191>	C61063	Carboplatin/Etoposide/Paclitaxel|CBDCA/TAX/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111920>	C111919	NLRP2 wt Allele|CLR19.9|FLJ20510|NACHT, Leucine Rich Repeat and PYD Containing 2 Gene|NALP2|NBS1|NLR Family, Pyrin Domain Containing 2 wt Allele|NLR Family, Pyrin Domain-Containing 2 Gene|Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat and Pyrin Domain Containing 2 Gene|PAN1|PYPAF2|XXbac-BPG230H20.8	Human NLRP2 wild-type allele is located in the vicinity of 19q13.42 and is approximately 48 kb in length. This allele, which encodes NACHT, LRR and PYD domains-containing protein 2, is involved in the regulation of signaling.			Gene or Genome	
C111921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111921>	C18466	NACHT, LRR and PYD Domains-Containing Protein 2|NACHT Domain-, Leucine-Rich Repeat-, and PYD-Containing Protein 2|NACHT, LRR and PYD Containing Protein 2|NLRP2|Nucleotide-Binding Site Protein 1|PYRIN Domain and NACHT Domain-Containing Protein 1|PYRIN Domain- and NACHT Domain-Containing Protein 1|PYRIN Domain-Containing APAF1-Like Protein 2|PYRIN-Containing APAF1-Like Protein 2	NACHT, LRR and PYD domains-containing protein 2 (1062 aa, ~121 kDa) is encoded by the human NLRP2 gene. This protein plays a role in signaling pathways involved in apoptosis and inflammation.			Amino Acid, Peptide, or Protein	
C111922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111922>	C20194	TSGA10 Gene|TSGA10|TSGA10|Testis Specific, 10 Gene	This gene plays a role in spermatogenesis.	TSGA10 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111923>	C111922	TSGA10 wt Allele|CEP4L|CT79|Cancer/Testis Antigen 79 Gene|Testis Specific, 10 wt Allele	Human TSGA10 wild-type allele is located in the vicinity of 2q11.2 and is approximately 158 kb in length. This allele, which encodes testis-specific gene 10 protein, may be involved in the formation of the fibrous sheath of the sperm tail.	TSGA10 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111924>	C18466	Testis-Specific Gene 10 Protein|Cancer/Testis Antigen 79|Testis Development Protein NYD-SP7|Testis-Specific Protein 10	Testis-specific gene 10 protein (698 aa, ~81 kDa) is encoded by the human TSGA10 gene. This protein may play a role in sperm tail morphogenesis.	Testis-Specific Gene 10 Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111925>	C28533|C25941	CFTR Gene|CFTR|CFTR|Cystic Fibrosis Transmembrane Conductance Regulator (ATP-Binding Cassette Sub-Family C, Member 7) Gene	This gene is involved in ion transport.			Gene or Genome	
C111926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111926>	C111925	CFTR wt Allele|ABC35|ABCC7|CF|CFTR/MRP|Cystic Fibrosis Transmembrane Conductance Regulator (ATP-Binding Cassette Sub-Family C, Member 7) wt Allele|Cystic Fibrosis Transmembrane Conductance Regulator, ATP-Binding Cassette (Sub-Family C, Member 7) Gene|MRP7|TNR-CFTR|dJ760C5.1	Human CFTR wild-type allele is located in the vicinity of 7q31.2 and is approximately 203 kb in length. This allele, which encodes cystic fibrosis transmembrane conductance regulator protein, plays a role in the transport of chloride ions. Mutation of the gene is associated with cystic fibrosis and congenital bilateral absence of the vas deferens.			Gene or Genome	
C111927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111927>	C17750|C16759	Cystic Fibrosis Transmembrane Conductance Regulator|ATP-Binding Cassette Sub-Family C Member 7|CFTR|Channel Conductance-Controlling ATPase|EC 3.6.3.49, Formerly|EC 5.6.1.6|cAMP-Dependent Chloride Channel	Cystic fibrosis transmembrane conductance regulator (1480 aa, ~168 kDa) is encoded by the human CFTR gene. This protein is involved in chloride transport and the regulation of other ion transport pathways.			Amino Acid, Peptide, or Protein|Enzyme	
C111928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111928>	C133710	UBR5 Gene|UBR5|UBR5|UBR5|Ubiquitin Protein Ligase E3 Component N-Recognin 5 Gene	This gene plays a role in protein ubiquitination.	UBR5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C111929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111929>	C111928	UBR5 wt Allele|DD5|E3 Identified By Differential Display Gene|E3 Ubiquitin Protein Ligase, HECT Domain Containing, 1 Gene|E3 Ubiquitin Protein Ligase, HECT Domain-Containing, 1 Gene|EDD|EDD1|HYD|Hyperplastic Discs, Drosophila, Homolog of Gene|KIAA0896|Ubiquitin Protein Ligase E3 Component N-Recognin 5 wt Allele	Human UBR5 wild-type allele is located in the vicinity of 8q22 and is approximately 161 kb in length. This allele, which encodes E3 ubiquitin-protein ligase UBR5 protein, is involved in the initiation of protein degradation.	UBR5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11192>	C61063	Carboplatin/Cyclosporine/Doxorubicin|CBDCA/CYSP/DOX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111930>	C21254	E3 Ubiquitin-Protein Ligase UBR5|E3 Identified By Differential Display|E3 Ubiquitin-Protein Ligase, HECT Domain-Containing 1|EC 2.3.2.26|EC 6.3.2.-, Formerly|HECT-Type E3 Ubiquitin Transferase UBR5|Hyperplastic Discs Protein Homolog|Progestin Induced Protein|Progestin-Induced Protein|UBR5|hHYD	E3 ubiquitin-protein ligase UBR5 (2799 aa, ~309 kDa) is encoded by the human UBR5 gene. This protein plays a role in the promotion of both protein ubiquitination and protein catabolism.	E3 Ubiquitin-Protein Ligase UBR5		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111931>	C133710	RNF130 Gene|RNF130|RNF130|Ring Finger Protein 130 Gene	This gene is involved in the ubiquitination of proteins.	RNF130 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111932>	C111931	RNF130 wt Allele|G1RP|G1RZFP|GOLIATH|GP|Ring Finger Protein 130 wt Allele	Human RNF130 wild-type allele is located in the vicinity of 5q35.3 and is approximately 153 kb in length. This allele, which encodes E3 ubiquitin-protein ligase RNF130 protein, plays a role in protein ubiquitylation. A fusion of this gene and the BRAF gene may be associated with pilocytic astrocytoma.	RNF130 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111933>	C21254	E3 Ubiquitin-Protein Ligase RNF130|EC 2.3.2.27|EC 6.3.2.-, Formerly|G1-Related Protein|G1-Related Zinc Finger Protein|Goliath|Goliath Homolog|H-Goliath|Ring Finger Protein 130	E3 ubiquitin-protein ligase RNF130 (419 aa, ~46 kDa) is encoded by the human RNF130 gene. This protein is involved in post-translational protein ubiquitination.	E3 Ubiquitin-Protein Ligase RNF130		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111934>	C133710	MKRN1 Gene|MKRN1|MKRN1|Makorin Ring Finger Protein 1 Gene	This gene is involved in ubiquitylation.	MKRN1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111935>	C111934	MKRN1 wt Allele|Makorin Ring Finger Protein 1 wt Allele|RING Finger Protein 61 Gene|RNF61	Human MKRN1 wild-type allele is located in the vicinity of 7q34 and is approximately 27 kb in length. This allele, which encodes E3 ubiquitin-protein ligase makorin-1 protein, plays a role in post-translational protein ubiquitination. A fusion of this gene and the BRAF gene may be associated with pilocytic astrocytoma.	MKRN1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111936>	C21254	E3 Ubiquitin-Protein Ligase Makorin-1|EC 2.3.2.27|EC 6.3.2.-, Formerly|Makorin 1|Makorin Ring Finger Protein 1|Makorin-1|RING Finger Protein 61	E3 ubiquitin-protein ligase makorin-1 (482 aa, ~53 kDa) is encoded by the human MKRN1 gene. This protein is involved in the ubiquitination of proteins that regulate both cell survival and gene expression.	E3 Ubiquitin-Protein Ligase Makorin-1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111937>	C21295	QKI Gene|QKI|QKI|QKI|QKI, KH Domain Containing, RNA Binding Gene	This gene is involved in both the biosynthesis and maintenance of mRNA.	QKI Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C111938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111938>	C111937	QKI wt Allele|HKQ|Hqk|QK|QK1|QK3|QKI, KH Domain Containing, RNA Binding wt Allele|Quaking Homolog, KH Domain RNA Binding (Mouse) Gene|Quaking, Mouse, Homolog of Gene|hqkI	Human QKI wild-type allele is located in the vicinity of 6q26 and is approximately 165 kb in length. This allele, which encodes protein quaking, plays a role in mRNA biosynthesis, mRNA splicing, mRNA stabilization, oligodendrocyte differentiation and myelination. A fusion of this gene and the NTRK2 gene may be associated with non-cerebellar pilocytic astrocytoma.	QKI wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111939>	C21298	Protein Quaking|Homolog Of Mouse Quaking QKI (KH Domain RNA Binding Protein)|Quaking Homolog, KH Domain RNA Binding|RNA Binding Protein HQK	Protein quaking (341 aa, ~38 kDa) is encoded by the human QKI gene. This protein is involved in mRNA biosynthesis, mRNA splicing, mRNA stabilization and protein translation.	Protein Quaking		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11193>	C61063	Cytarabine/Deoxycytidine|ARA-C/dC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111940>	C20194	NACC2 Gene|NACC Family Member 2 Gene|NACC2|NACC2	This gene plays a role in the modulation of cell proliferation.	NACC2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111941>	C111940	NACC2 wt Allele|BEND9|BTB (POZ) Domain Containing 14A Gene|BTBD14|BTBD14A|BTBD31|MGC23427|NACC Family Member 2 wt Allele|NACC Family Member 2, BEN and BTB (POZ) Domain Containing Gene|NACC Family Member 2, BEN and BTB/POZ Domains-Containing Gene|RBB	Human NACC2 wild-type allele is located in the vicinity of 9q34.3 and is approximately 89 kb in length. This allele, which encodes nucleus accumbens-associated protein 2, is involved in the regulation of cell proliferation. A fusion of this gene and the NTRK2 gene may be associated with non-cerebellar pilocytic astrocytoma.	NACC2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111942>	C18466	Nucleus Accumbens-Associated Protein 2|BEN Domain Containing 9|BTB/POZ Domain-Containing Protein 14A|NAC-2|NACC2|Repressor with BTB Domain and BEN Domain	Nucleus accumbens-associated protein 2 (587 aa, ~63 kDa) is encoded by the human NACC2 gene. This protein plays a role in the regulation of both cell proliferation and mitosis.	Nucleus Accumbens-Associated Protein 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111943>	C26720	Clinical Chorioamnionitis	Inflammation of the fetal sac membranes, characterized by otherwise unexplained fever (at or above 38 degree C (100.4F)) with one or more of the following: uterine tenderness and/or irritability, leukocytosis, fetal tachycardia, maternal tachycardia, or malodorous vaginal discharge.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C111944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111944>	C35867|C117337	Histologic Chorioamnionitis|Acute Amnionitis|Acute Chorioamnionitis|Acute Choriodeciduitis|Acute Chorionitis|Microscopic Chorioamnionitis	Inflammation of the fetal sac membranes that is characterized by neutrophilic infiltration of the amnion and chorion.			Finding	NICHD Terminology|Perinatal Terminology
C111945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111945>	C35867	Deciduitis	Acute inflammation characterized by neutrophilic infiltration of the decidua.			Finding	NICHD Terminology|Perinatal Terminology
C111946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111946>	C16669	Group B Streptococcus Risk|GBS Risk Status|GBS Risk Status|Group B Streptococcus Risk Status	Categorization for likelihood of perinatal transmission of group B Streptococcus to neonate.			Qualitative Concept	NICHD Terminology|Perinatal Terminology
C111947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111947>	C111946	Positive GBS Risk Status|Positive Group B Streptococcus Risk Status|Positive Group B Streptococcus Status	Rectal/vaginal culture positive for group B Streptococcus (GBS) within 5 weeks.			Qualitative Concept	NICHD Terminology|Perinatal Terminology
C111948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111948>	C111946	Negative GBS Risk Status|Negative Group B Streptococcus Risk Status|Negative Group B Streptococcus Risk Status	Rectal/vaginal culture negative for group B Streptococcus (GBS) within 5 weeks.			Qualitative Concept	NICHD Terminology|Perinatal Terminology
C111949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111949>	C111946	Unknown GBS Risk Status|Unknown Group B Streptococcus Risk Status|Unknown Group B Streptococcus Risk Status	Rectal/vaginal culture not taken within 5 weeks prior to birth, or urine GBS culture not taken.			Qualitative Concept	NICHD Terminology|Perinatal Terminology
C11194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11194>	C61007	Octreotide Pamoate/Tamoxifen|SMS 201-995 pa/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111950>	C34941	Pregnancy with Intrauterine Device|IUD Pregnancy|IUD Pregnancy	Co-existence of an intrauterine pregnancy with an intrauterine device.			Finding	NICHD Terminology|Perinatal Terminology
C111951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111951>	C19332	Nulliparous	A woman with a parity of zero.	Nulliparous		Organism Attribute	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Perinatal Terminology
C111952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111952>	C25993	CLCN6 Gene|CLCN6|CLCN6|Chloride Voltage-Gated Channel 6 Gene	This gene plays a role in chloride ion transport.	CLCN6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111953>	C111952	CLCN6 wt Allele|CLC-6|CLC6|CONRIBA|Chloride Channel, Voltage-Sensitive 6 Gene|Chloride Voltage-Gated Channel 6 wt Allele|ClC-6|KIAA0046|RP5-934G17.1	Human CLCN6 wild-type allele is located in the vicinity of 1p36 and is approximately 37 kb in length. This allele, which encodes H(+)/Cl(-) exchange transporter 6 protein, is involved in the antiport of chloride. A fusion of this gene and the BRAF gene may be associated with pilocytic astrocytoma.	CLCN6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111954>	C28505	H(+)/Cl(-) Exchange Transporter 6|CLCN6|Chloride Channel 6|Chloride Channel Protein 6|Chloride Transport Protein 6|Chloride Transport Protein 6|ClC-6	H(+)/Cl(-) exchange transporter 6 (869 aa, ~97 kDa) is encoded by the human CLCN6 gene. This protein plays a role in ion exchange-based transport.	Chloride Transport Protein 6		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111955>	C54362	EPC1 Gene|EPC1|EPC1|Enhancer of Polycomb Homolog 1 (Drosophila) Gene	This gene plays a role in both transcriptional regulation and histone acetylation.	EPC1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111956>	C111955	EPC1 wt Allele|Enhancer of Polycomb Homolog 1 (Drosophila) wt Allele|Enhancer of Polycomb, Drosophila, Homolog of, 1 Gene|Epl1	Human EPC1 wild-type allele is located in the vicinity of 10p11 and is approximately 111 kb in length. This allele, which encodes enhancer of polycomb homolog 1 protein, is involved in both the regulation of histone acetylation and gene transcription. A fusion of this gene and the PHF1 gene may be associated with low-grade endometrial stromal sarcomas.	EPC1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111957>	C92931	Triplet Pregnancy	A pregnancy involving three fetuses.			Organism Function	NICHD Terminology|Perinatal Terminology
C111958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111958>	C26199	Enhancer of Polycomb Homolog 1|EPC1	Enhancer of polycomb homolog 1 (836 aa, ~93 kDa) is encoded by the human EPC1 gene. This protein plays a role in both histone acetyltransferase activity and transcriptional regulation.	Enhancer of Polycomb Homolog 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111959>	C92931	Quadruplet Pregnancy	A pregnancy involving four fetuses.			Organism Function	NICHD Terminology|Perinatal Terminology
C11195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11195>	C61063	Carboplatin/9-cis-Retinoic Acid|CBDCA/9-CRA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111960>	C54362	MEAF6 Gene|MEAF6|MEAF6|MYST/Esa1-Associated Factor 6 Gene	This gene is involved in chromatin modification.	MEAF6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111961>	C111960	MEAF6 wt Allele|C1orf149|CENP-28|Chromosome 1 Open Reading Frame 149 Gene|EAF6|EAF6, S. cerevisiae, Homolog of Gene|MYST/Esa1-Associated Factor 6 wt Allele|NY-SAR-91|RP3-423B22.2	Human MEAF6 wild-type allele is located within 1p35.3-p33 and is approximately 22 kb in length. This allele, which encodes chromatin modification-related protein MEAF6, plays a role in histone acetylation. A fusion of this gene and the PHF1 gene may be associated with low-grade endometrial stromal sarcomas.	MEAF6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111962>	C26199	Chromatin Modification-Related Protein MEAF6|Centromere Protein 28|Esa1-Associated Factor 6 Homolog|MEAF6|Protein EAF6 Homolog|Sarcoma Antigen NY-SAR-91|hEAF6	Chromatin modification-related protein MEAF6 (191 aa, ~22 kDa) is encoded by the human MEAF6 gene. This protein is involved in histone acetylation.	Chromatin Modification-Related Protein MEAF6		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111963>	C3001	Neurodermatitis|Lichen Simplex Chronicus|Lichen Simplex Chronicus	Skin findings arising from repeated rubbing, picking or scratching of a real or imagined irritation of the skin.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111964>	C147533	Sustained Engraftment	Sustained donor-derived neutrophil recovery with achievement of donor chimerism equal or greater than 90%.			Finding	
C111965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111965>	C111964	Sustained Engraftment at Day 100|Sustained Engraftment	Sustained donor-derived neutrophil recovery with achievement of donor chimerism equal or greater than 90% at day 100.			Finding	
C111966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111966>	C75570	Primary Graft Failure After Hematopoietic Cell Transplantation|Primary Graft Failure	Failure of initial engraftment of donor hematopoietic cells.			Finding	
C111967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111967>	C5036	Pustular Eruption	A diffuse or generalized outbreak of numerous pustules.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111968>	C75570	Secondary Graft Failure After Hematopoietic Cell Transplantation|Secondary Graft Failure	Loss of donor hematopoietic cells following initial engraftment.			Finding	
C111969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111969>	C75564	Skin Vesicle|Vesicle|Vesicle	A small (less than 5-10 mm) intraepidermal/subepidermal cavity filled with clear, serosanguineous or cloudy fluid.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11196>	C61063	Bleomycin/Dexrazoxane/Doxorubicin/Etoposide/Vincristine|ADR-529/BLEO/DOX/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111970>	C75564	Bulla|Bullae	A large (greater than 5-10 mm) intraepidermal/subepidermal cavity filled with clear, serosanguineous or cloudy fluid.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111971>	C3824	Annular Lesion	A ring-shaped skin finding with clear central area.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111972>	C3824	Targetoid Lesion|Iris Lesion|Iris Lesion	A red, edematous ring skin finding that may have a central dusky disk and an erythematous halo.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111973>	C20194	MBTD1 Gene|MBTD1|MBTD1|Mbt Domain Containing 1 Gene	This gene may play a role in transcriptional regulation.	MBTD1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111974>	C5036	Lichenification	Thickening and hardening of the skin associated with chronic inflammation or irritation.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111975>	C111973	MBTD1 wt Allele|FLJ20055|Mbt Domain Containing 1 wt Allele|SA49P01	Human MBTD1 wild-type allele is located in the vicinity of 17q21.33 and is approximately 83 kb in length. This allele, which encodes MBT domain-containing protein 1, may be involved in transcriptional regulation. A fusion of this gene and the CXorf67 gene may be associated with low-grade endometrial stromal sarcomas.	MBTD1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111976>	C18466	MBT Domain-Containing Protein 1|MBTD1	MBT domain-containing protein 1 (628 aa, ~71 kDa) is encoded by the human MBTD1 gene. This protein may play a role in the regulation of gene transcription.	MBT Domain-Containing Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111977>	C29938	EZHIP Gene|CXorf67|CXorf67 Gene|EZH Inhibitory Protein Gene|EZHIP|EZHIP	This gene is involved in the negative regulation of histone-lysine N-methyltransferase EZH2 activity.	CXorf67 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111978>	C111977	EZHIP wt Allele|CATACOMB|CXorf67|CXorf67 wt Allele|Catalytic Antagonist of Polycomb Gene|Chromosome X Open Reading Frame 67 Gene|EZH Inhibitory Protein wt Allele|KIP75|MGC47837	Human EZHIP wild-type allele is located in the vicinity of Xp11.22 and is approximately 2 kb in length. This allele, which encodes EZH inhibitory protein, plays a role in the modulation of histone H3-K27 methylation. A fusion of this gene and the MBTD1 gene may be associated with low-grade endometrial stromal sarcomas.	CXorf67 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111979>	C18072	EZH Inhibitory Protein|CXorf67|Catalytic Antagonist of Polycomb|EZHIP|Uncharacterized Protein CXorf67|Uncharacterized Protein CXorf67	EZH inhibitory protein (503 aa, ~52 kDa) is encoded by the human EZHIP gene. This protein is involved in the inhibition of histone H3-K27 methylation by histone-lysine N-methyltransferase EZH2.	Uncharacterized Protein CXorf67		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11197>	C63586|C203473	FOLFOX Regimen|CF/5-FU/L-OHP|FOLFOX|FOLFOX|FOLFOX|FOLFOX chronotherapy|FOLFOX regimen|Fluorouracil/Leucovorin Calcium/Oxaliplatin	One of several chemotherapy regimens that include leucovorin calcium (calcium folinate), 5-fluorouracil and oxaliplatin and which may be used in the treatment of advanced-stage and metastatic colorectal cancer. FOLFOX regimens differ in agent dosing and administration schedule and include FOLFOX 4, FOLFOX 6, modified FOLFOX 6 (mFOLFOX 6) and FOLFOX 7.	FOLFOX Regimen		Therapeutic or Preventive Procedure	CTRP Agent Terminology|CTRP Terminology|HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|NCI Drug Dictionary Terminology|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C111980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111980>	C21295	ZC3H7B Gene|ZC3H7B|ZC3H7B|Zinc Finger CCCH-Type Containing 7B Gene	This gene plays a role in binding to rotaviral proteins.	ZC3H7B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C111981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111981>	C111980	ZC3H7B wt Allele|DKFZp434K0920|FLJ13787|KIAA1031|ROXAN1|RoXaN|Zinc Finger CCCH-Type Containing 7B wt Allele	Human ZC3H7B wild-type allele is located in the vicinity of 22q13.2 and is approximately 59 kb in length. This allele, which encodes zinc finger CCCH domain-containing protein 7B, is involved in binding to non-structural protein NSP3. A fusion of this gene and the BCOR gene may be associated with low-grade endometrial stromal sarcomas.	ZC3H7B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111982>	C17728	Zinc Finger CCCH Domain-Containing Protein 7B|RoXaN|Rotavirus 'X' Associated Non-Structural Protein|Rotavirus 'X'-Associated Non-Structural Protein|Rotavirus X Protein Associated With NSP3|Rotavirus X Protein Associated With NSP3 1|Ubiquitous Tetratricopeptide Containing Protein RoXaN|ZC3H7B	Zinc finger CCCH domain-containing protein 7B (993 aa, ~112 kDa) is encoded by the human ZC3H7B gene. This protein plays a role in binding to rotavirus protein NSP3.	Zinc Finger CCCH Domain-Containing Protein 7B		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C111983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111983>	C27993	Haploidentical|Half-Matched Related Donor|Haploidentical Donor|Haploidentical Donor|PMRD|Partially-Matched Related Donor	A donor who has only one haplotype in common with the recipient.			Clinical Attribute	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C111984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111984>	C48470	Pump Dosing Unit|PUMP|Pump|Pump|{PUMP}|{PUMP}	A dosing unit equal to the amount of active ingredient(s) contained in one actuation of a pumping device.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|NCPDP Dose Unit of Measure Terminology
C111986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111986>	C5036	Fixed Drug Eruption	Round areas of red-purple reaction in the skin that result after drug exposure; these recur in the same location when the medication is readministered.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111987>	C36281	Skin Fissure|Fissuring|Fissuring	A narrow break in the skin.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C111989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111989>	C201491|C200766	Autologous iC9-GD2-CAR-expressing VZV-specific T Lymphocytes|Autologous iC9-GD2-CAR-VZV-CTLs	Genetically modified, autologous varicella zoster virus (VZV)-specific T-lymphocytes transduced with a retroviral vector encoding a chimeric antigen receptor (CAR) specific for the disialoganglioside GD2, which contains the signaling domains for the co-stimulatory molecules CD28 and CD134 (OX-40), and the suicide gene, inducible caspase 9 (iCasp9 or iC9), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, iC9-GD2-CD28-OX40-expressing T lymphocytes target the GD2 antigen on tumor cells for selective toxicity against GD2-expressing tumor cells. iCasp9 consists of a full-length caspase 9, including its caspase recruitment domain, linked to a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V). If the administered T cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered, which binds to the FKBP12-F36V drug binding domain, activates caspase 9, and results in apoptosis of the administered T-cells. Expression of the iCasp9 gene in T cells for adoptive transfer increases safety and broadens the scope for their clinical applications. The tumor associated antigen GD2 is overexpressed on the surface of almost all tumors of neuroectodermal origin. OX40 and CD28, both T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation. An additional VZV vaccine can be administered to increase T-cell activity.	Autologous iC9-GD2-CAR-expressing VZV-specific T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11198>	C61063	Fluorouracil/Gemcitabine|dFdC/5-FU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C111990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111990>	C206073	Ocifisertib Fumarate|CFI 400945 Fumarate|CFI-400945|CFI-400945 Fumarate|OCIFISERTIB FUMARATE|PLK4 Inhibitor CFI-400945 Fumarate|Polo-like Kinase 4 Inhibitor CFI-400945 Fumarate	An orally available fumarate salt form of CFI-400945, a polo-like kinase 4 (PLK4) inhibitor with potential antineoplastic activity. Upon oral administration, polo-like kinase 4 inhibitor CFI-400945 selectively inhibits PLK4, which results in the disruption of mitosis and the induction of apoptosis. PLK4 inhibition also prevents cell division and inhibits proliferation of PLK4-overexpressing tumor cells. PLK4, a member of the polo family of serine/threonine kinases overexpressed in a variety of cancer cell types, plays a crucial role in the regulation of centriole duplication during the cell cycle.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111991>	C1978	Autologous GM-CSF-secreting Lethally Irradiated Colorectal Cancer Cell Vaccine|GVAX Colorectal Cancer Vaccine	A lethally irradiated, autologous colorectal cancer vaccine consisting of patient-specific colorectal cancer cells genetically modified to secrete the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Upon vaccination, the autologous GM-CSF-secreting lethally irradiated colorectal cancer cell vaccine releases GM-CSF. In turn, GM-CSF may increase the body's immune response against tumor cells by promoting the maturation and activation of dendritic cells (DCs), and enhancing tumor-specific antigen presentation to both B- and T-cells, which leads to better recognition of tumors by the immune system. In addition, GM-CSF promotes antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function.	Autologous GM-CSF-secreting Lethally Irradiated Colorectal Cancer Cell Vaccine		Cell|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111992>	C28681|C213868|C201547	TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes|TGFbDNRII-transduced Autologous TILs	A preparation of tumor infiltrating lymphocytes (TILs) that are transduced with a retroviral vector encoding a gene for a dominant-negative form of the transforming growth factor beta (TGFb) receptor, TGFbDNRII, with potential immunomodulating activity. Upon administration, the TGFbDNRII-transduced autologous TILs recognize and kill tumor cells. The expression of TGFbDNRII allows for the TILs to be resistant to TGF-b-mediated inhibition of T cell proliferation and activation, which allows optimal TIL activity. The immunosuppressant TGF-b is produced by tumor cells and plays a key role in the repression of the immune system.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111993>	C155926	Ceralasertib|AZD6738|CERALASERTIB	An orally available morpholino-pyrimidine-based inhibitor of ataxia telangiectasia and rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration, Ceralasertib selectively inhibits ATR activity by blocking the downstream phosphorylation of the serine/threonine protein kinase CHK1. This prevents ATR-mediated signaling, and results in the inhibition of DNA damage checkpoint activation, disruption of DNA damage repair, and the induction of tumor cell apoptosis. In addition, AZD6738 sensitizes tumor cells to chemo- and radiotherapy. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression and survival; it is activated by DNA damage caused during DNA replication-associated stress.	Ceralasertib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111994>	C114757	Encequidar|4-Oxo-4H-chromene-2-carboxylic acid [2-(2-4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl]-phenyl-2H-tetrazol-5-yl)-4,5-dimethoxy-phenyl]-amide|ENCEQUIDAR|HM30181AK|Pgp Inhibitor HM30181AK	An inhibitor of the adenosine triphosphate (ATP)-binding cassette (ABC) transporter P-glycoprotein (P-gp), with adjuvant activity. Upon oral administration, encequidar selectively binds to and inhibits the multidrug resistance (MDR) efflux pump P-gp, which prevents the efflux of various chemotherapeutic agents from intestinal epithelial cells to the gastrointestinal tract. This leads to an increase in both oral bioavailability and therapeutic efficacy. P-gp prevents the intestinal uptake and intracellular accumulation of various cytotoxic agents. Encequidar is not systemically absorbed.	Encequidar		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C111996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111996>	C28681	Autologous Cultured Acute Myeloid Leukemia-specific Cytotoxic T Lymphocytes|Autologous AML-reactive Cultured CTL|Autologous AML-specific CTLs	A preparation of cytotoxic, autologous acute myelogenous leukemia (AML)-reactive T lymphocytes (CTL), with potential immunomodulating and antineoplastic activities. The autologous cultured AML-specific CTLs are prepared using a specific AML-CTL culture method. Autologous peripheral blood lymphocytes are taken from an AML patient and the autologous AML blasts are treated with granulocyte macrophage colony-stimulating factor (GM-CSF) and interleukin 4 (IL-4), both of which promote ex vivo differentiation of AML blasts into dendritic cells (DCs). In the same culture, T cells are treated and activated by low-dose interleukin 2 (IL-2), and expanded using anti-CD3. This results in cultured AML-reactive CTLs which are administered back into the patient after autologous hematopoietic stem cell transplant (AHSCT). The autologous cultured AML-specific CTLs may eradicate residual AML cells.	Autologous Cultured Acute Myeloid Leukemia-specific Cytotoxic T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111997>	C199386	Anti-HER3 Monoclonal Antibody GSK2849330|GSK2849330	A monoclonal antibody directed against the human epidermal growth factor receptor 3 (HER3; ERBB3) with potential antineoplastic activity. Anti-HER3 monoclonal antibody GSK2849330 binds to HER3 and inhibits its activation. This may prevent HER3-mediated signaling and inhibit HER3-dependent tumor cell proliferation and differentiation. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors and is associated with poor prognosis and drug resistance; it has no active kinase domain but is activated through heterodimerization with other members of the EGFR receptor family, such as HER2.	Anti-HER3 Monoclonal Antibody GSK2849330		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111998>	C62761|C1663	Live-attenuated Listeria monocytogenes-encoding EGFRvIII-NY-ESO-1 Vaccine ADU-623|ADU-623	A live-attenuated, double-deleted strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding a mutant form of the tumor associated antigens, epidermal growth factor receptor (EGFRvIII) and the cancer/testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, live-attenuated Listeria monocytogenes encoding EGFRvIII-NY-ESO-1 vaccine targets dendritic cells and expresses EGFRvIII and NY-ESO-1. This promotes both a potent innate immune response and an adaptive immune response involving the recruitment and activation of T lymphocytes against EGFRvIII and NY-ESO-1-expressing tumor cells, which results in tumor cell lysis.			Bacterium|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C111999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C111999>	C134305	Relatlimab|BMS 986016|BMS-986016|BMS986016|Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer|RELATLIMAB	A monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with potential immunomodulating and antineoplastic activities. Upon administration, relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs). This may activate antigen-specific T-lymphocytes and enhance cytotoxic T cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG-3 is a member of the immunoglobulin superfamily (IgSF) and binds to major histocompatibility complex (MHC) class II. LAG-3 expression on TILs is associated with tumor-mediated immune suppression.	Relatlimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11199>	C61063	Carboplatin/Cyclosporine/Dipyridamole/Etoposide/Prochlorperazine|CBDCA/CYSP/DP/PCPZ/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1119>	C94726	Ondansetron|ONDANSETRON|Zofran ODT|Zuplenz|ondansetron|ondansetron	A carbazole derivative with antiemetic activity.  As a selective serotonin receptor antagonist, ondansetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting. (NCI04)	Ondansetron		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C112000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112000>	C61078	Oraxol|Paclitaxel-HM30181 Methanesulfonate Monohydrate|Paclitaxel/HM30181A	A combination formulation composed of a capsule containing the taxane compound paclitaxel and a tablet containing the multidrug resistance (MDR) efflux pump P-glycoprotein (P-gp) inhibitor HM30181A, with potential antineoplastic activity. Upon oral administration of oraxol, the HM30181A moiety binds to and inhibits P-gp, which prevents P-gp-mediated efflux of paclitaxel, therefore enhancing its oral bioavailability. In turn, paclitaxel binds to and stabilizes microtubules, preventing their depolymerization, which results in the inhibition of cellular motility, mitosis, and replication. Altogether, this may result in greater intracellular concentration of paclitaxel, and enhanced cytotoxicity against tumor cells, when compared to the administration of paclitaxel alone.  P-gp, encoded by the MDR-1 gene, is a member of the ATP-binding cassette (ABC) superfamily of transmembrane transporters; it prevents the intestinal uptake and intracellular accumulation of various cytotoxic agents.	Oraxol		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C112001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112001>	C211912	Ladiratuzumab Vedotin|LADIRATUZUMAB VEDOTIN|SGN-LIV1A	An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the anti-solute carrier family 39 zinc transporter member 6 (SLC39A6; LIV-1; ZIP6) protein that is conjugated, via a protease-cleavable linker, to the cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration and internalization by LIV-1-positive tumor cells, ladiratuzumab vedotin undergoes enzymatic cleavage to release MMAE into the cytosol. In turn, MMAE binds to and inhibits tubulin polymerization, which may result in G2/M phase cell cycle arrest and apoptosis in LIV-1-expressing tumor cells. LIV-1, a member of the zinc transporter family, is expressed in several types of solid tumors and plays a key role in tumor cell progression and metastasis. The linkage system in ladiratuzumab vedotin is highly stable in plasma, resulting in cytotoxic specificity against LIV-1-positive cells.	Ladiratuzumab Vedotin		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C112002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112002>	C241	Cebranopadol|CEBRANOPADOL|GRT 6005|GRT-6005|GRT6005|Spiro[cyclohexane-1,1'(3'H)-pyrano[3,4-b]indol]-4-amine, 6'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenyl-, (1alpha,4beta)-	An orally available benzenoid that acts as an opioid peptide receptor agonist for the nociceptin/orphanin FQ peptide receptor (opioid receptor like -1; OPRL1; ORL-1; NOP; kappa-type 3 opioid receptor) and the classical opioid receptors, mu, delta and kappa, with potential anti-nociceptive activity. Upon oral administration, cebranopadol binds to NOP and the mu, delta and kappa opioid receptors, which enhances NOP- and opioid receptor-mediated signaling, interferes with the sensation of pain and results in an analgesic effect. NOP, a member of the opioid receptor family, and its endogenous ligand nociceptin play key roles in the regulation of various brain activities including pain, and some inflammatory and immune responses.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C112003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112003>	C2517	Neoantigen-based Melanoma-Poly-ICLC Vaccine|NeoVax Melanoma Vaccine	A peptide-based melanoma cancer vaccine consisting of neoantigens and peptides derived from patient-specific melanoma immunogenic epitopes, combined with the immunostimulant poly-ICLC with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-based melanoma vaccine stimulates the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. The adjuvant poly-ICLC, composed of double-stranded RNA molecules of polyinosinic-polycytidylic acid stabilized with poly L-lysine in carboxymethylcellulose, is a ligand for toll-like receptor-3 (TLR3) and induces the release of cytokines which may help to boost the immune response against the selected neoantigens.			Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C112004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112004>	C155764	Rupitasertib|M-2698|MSC-2363318A|MSC2363318A|RUPITASERTIB|p70S6K/Akt Inhibitor M-2698|p70S6K/Akt Inhibitor MSC2363318A	An orally available inhibitor of the serine/threonine protein kinases ribosomal protein S6 Kinase (p70S6K) and Akt (protein kinase B), with potential antineoplastic activity. Upon administration, rupitasertib binds to and inhibits the activity of p70S6K and Akt. This prevents the activation of the PI3K/Akt/p70S6K signaling pathway and inhibits tumor cell proliferation in cancer cells that have an overactivated PI3K/Akt/p70S6K signaling pathway. Constitutive activation and dysregulated signaling of the PI3K/Akt/p70S6K pathway are frequently associated with tumorigenesis of many tumor types; targeting multiple kinases in this pathway is more efficacious than targeting a single kinase.	Rupitasertib		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C112005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112005>	C204256|C1663	Adenovirus 5-Human Guanylyl Cyclase C-PADRE Vaccine|Ad5-hGCC-PADRE Vaccine	A replication-defective, recombinant adenoviral serotype 5 (Ad5) encoding human guanylyl cyclase C (hGCC) and the synthetic Pan DR epitope (PADRE), with potential antineoplastic and immunomodulating activities. Upon intramuscular administration, the Ad5-hGCC-PADRE vaccine expresses hGCC, which may induce both humoral and cellular immune responses against tumor cells expressing the hGCC antigen. This results in the immune-mediated inhibition of tumor cell proliferation, and leads to tumor death. The hGCC protein is normally restricted to intestinal epithelial cells but is overexpressed by metastatic colorectal tumors. PADRE is a helper T-lymphocyte epitope that is able to augment the magnitude and duration of the cytotoxic T-lymphocyte (CTL) response.	Adenovirus 5-Human Guanylyl Cyclase C-PADRE Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C112006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112006>	C3411	Thymoma by Masaoka-Koga Stage|Masaoka Staging|Masaoka Staging System|Masaoka Staging System for Thymoma|Masaoka-Koga Staging System for Thymoma	A staging system for thymoma based on the anatomic extent of disease at the time of surgery.			Neoplastic Process	
C112007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112007>	C112006	Masaoka-Koga Stage I|Masaoka Stage I|Masaoka Stage I|Stage I	The tumor is completely encapsulated.	Masaoka Stage I		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C112008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112008>	C115033	Masaoka-Koga Stage IIa|Masaoka Stage IIa|Stage IIa	The tumor shows microscopic invasion into the capsule.			Neoplastic Process	GDC Terminology|GDC Value Terminology
C112009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112009>	C115033	Masaoka-Koga Stage IIb|Masaoka Stage IIb|Masaoka Stage IIb|Stage IIb	The tumor shows invasion through the capsule and into the surrounding fatty tissue.			Neoplastic Process	GDC Terminology|GDC Value Terminology
C11200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11200>	C61063	Carboplatin/Cyclosporine/Interferon Alfa|CBDCA/CYSP/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112010>	C112006	Masaoka-Koga Stage III|Masaoka Stage III|Masaoka Stage III|Masaoka Stage III|Stage III	The tumor shows invasion into the neighboring tissues and organs of the lower neck or upper chest.	Masaoka Stage III		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C112011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112011>	C115034	Masaoka-Koga Stage IVa|Masaoka Stage IVa|Masaoka Stage IVa|Masaoka Stage IVa|Stage IVa	The tumor shows metastasis throughout the pleural and/or pericardial spaces.	Masaoka Stage IVa		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C112012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112012>	C115034	Masaoka-Koga Stage IVb|Masaoka Stage IVb|Masaoka Stage IVb|Masaoka Stage IVb|Stage IVb	The tumor shows lymphogenous or hematogenous metastasis to distant sites.	Masaoka Stage IVb		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C112013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112013>	C25161	Myasthenia Gravis Foundation of America Clinical Classification System|MGFA Clinical Classification|Myasthenia Class|Myasthenia Gravis Foundation of America Clinical Classification	A classification system developed by the Myasthenia Gravis Foundation of America (MGFA) for grading myasthenia gravis that divides the disease into 5 main classes and several subclasses.			Classification	
C112014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112014>	C187352	Myasthenia Gravis Foundation of America Class I|MGFA Class I|Myasthenia Class I	Myasthenia gravis presenting with any ocular weakness; may have weakness of eye closure. All other muscles strength is normal.			Finding	GDC Terminology|GDC Value Terminology
C112015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112015>	C187352	Myasthenia Gravis Foundation of America Class II|MGFA Class II|Myasthenia Class II	Myasthenia gravis presenting with mild weakness affecting non-ocular muscles. May also have ocular muscle weakness of any severity.			Finding	GDC Terminology|GDC Value Terminology
C112016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112016>	C187352	Myasthenia Gravis Foundation of America Class III|MGFA Class III|Myasthenia Class III	Myasthenia gravis presenting with moderate weakness affecting non-ocular muscles. May also have ocular muscle weakness of any severity.			Finding	GDC Terminology|GDC Value Terminology
C112017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112017>	C187352	Myasthenia Gravis Foundation of America Class IV|MGFA Class IV|Myasthenia Class IV	Myasthenia gravis presenting with severe weakness affecting non-ocular muscles. May also have ocular muscle weakness of any severity.			Finding	GDC Terminology|GDC Value Terminology
C112018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112018>	C187352	Myasthenia Gravis Foundation of America Class V|MGFA Class V|Myasthenia Class V	Myasthenia gravis presenting with severe muscle weakness that requires intubation, with or without mechanical ventilation, except when employed during routine postoperative management.			Finding	GDC Terminology|GDC Value Terminology
C112019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112019>	C27583	Surgical Site Infection	An infection that occurs at a surgical site within 30 days after an operation.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C11201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11201>	C61063	Cisplatin/Toremifene|CDDP/TOR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112020>	C15384	Superficial Incision	An incision that involves only the skin or subcutaneous tissue.			Health Care Activity	
C112021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112021>	C15384	Deep Incision	An incision that involves deep soft tissues.			Health Care Activity	
C112022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112022>	C164323	Surgical Organ or Space	Any part of the anatomy, other than the incision, which was opened or manipulated during an operation.			Body Location or Region	
C112023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112023>	C66830	CDISC SDTM Skin Response Test Name Terminology|SDTM-SRTEST|SRTEST|Skin Response Test Name	Terminology associated with the skin response test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112024>	C66830	CDISC SDTM Skin Response Test Code Terminology|SDTM-SRTESTCD|SRTESTCD|Skin Response Test Code	Terminology associated with the skin response test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112025>	C124351	Mass Measurement	A measurement of the mass of an item of interest.			Diagnostic Procedure	
C112026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112026>	C28518	Reoviridae|Reovirus|Respiratory Enteric Orphan Virus	A family of double stranded RNA viruses that carry 10-12 unique segments, which encode one to three proteins each. The RNA is surrounded by a three-layered icosahedral protein capsid and the viral particles are not enveloped. Members of this family can be transmitted orofecally, or via infected ticks or mosquitoes.	Reoviridae		Virus	CTRP Biomarker Terminology|CTRP Terminology
C112027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112027>	C14346	Rhabdoviridae	A family of bullet-shaped, negative-sense viruses capable of infect a broad range of hosts in both the animal and plant kingdoms.			Virus	
C112028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112028>	C14346	Bunyaviridae	A family of negative-sense, enveloped RNA viruses that infect arthropods or rodents, but that can be transmitted to humans.			Virus	
C112029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112029>	C14304	Sapovirus|SAPOVIRUS	A genus of non-enveloped viruses with a capsid with T=3 icosahedral symmetry, in the family Caliciviridae. The genome is composed of a linear, single-strand of positive sense RNA. Sapoviruses are found in humans and swine and cause gastroenteritis in humans.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11202>	C61063	Dexamethasone/Etoposide/Ifosfamide/Pegaspargase/Vincristine|DM/IFF/PEG-ASP/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112030>	C77197	Alphavirus|ALPHAVIRUS|Arboviruses Group A	A genus of enveloped, spherical, or pleomorphic viruses with T=4 icosahedral symmetry, in the family Togaviridae. The genome is composed of a linear, single-strand of positive sense RNA. Alphaviruses are spread by insect vector, able to infect vertebrates and invertebrates, and cause arthritis, encephalitis, rashes and fever in humans.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112031>	C14346	Filoviridae|FILOVIRIDAE|Filovirus	A family of filamentous viruses with helical capsids and glycoprotein projections on their surface. The virus may have a branched morphology of varying length. The genome is composed of a linear single-strand of negative sense RNA. Filoviridae infect primates, pigs and bats in nature and are a causative agent of viral hemorrhagic fevers in humans and primates.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112032>	C85832	Amount Recovered Infinity Observed|Amt Rec Infinity Obs|Amt Rec Infinity Obs|RCAMIFO	The cumulative amount recovered extrapolated to infinity, calculated using the observed value of the last non-zero concentration.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112033>	C85832	Amount Recovered Infinity Predicted|Amt Rec Infinity Pred|Amt Rec Infinity Pred|RCAMIFP	The cumulative amount recovered extrapolated to infinity, calculated using the predicted value of the last non-zero concentration.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112034>	C85777	Percent Recovered Infinity Observed|Pct Rec Infinity Obs|Pct Rec Infinity Obs|RCPCIFO	The percentage of the recovered administered dose extrapolated to infinity, calculated using the observed value of the last non-zero concentration.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112035>	C85777	Percent Recovered Infinity Predicted|Pct Rec Infinity Pred|Pct Rec Infinity Pred|RCPCIFP	The percentage of the recovered administered dose extrapolated to infinity, calculated using the predicted value of the last non-zero concentration.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112036>	C14208	Dengue Virus|DENGUE VIRUS	A species of enveloped and spherical viruses with a capsid with T=3 icosahedral symmetry in the Flaviviridae family and Flavivirus genus. The genome is composed of non-segmented, single-stranded, positive-sense RNA. Dengue viruses are found in non-human primates and humans and cause dengue fever in humans. Dengue viruses are transmitted mainly via the bite of infected mosquitoes of the genus Aedes.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112037>	C66830	CDISC SDTM Device Tracking and Disposition Event Dictionary Derived Term Terminology|DTDECOD|Device Tracking and Disposition Event Dictionary Derived Term|SDTM-DTDECOD	Terminology associated with the Device Tracking and Disposition Event Dictionary Derived Term codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112038>	C41184	Trial Indication|Disease/Condition Indication Description|INDC|INDIC|Indication for Use|Indication for Use|Population Diagnosis or Condition|Trial Disease/Condition Indication|Trial Disease/Condition Indication|Trial Disease/Condition Indication Description	The disease under study which serves as the basis for initiation of a study treatment in a clinical trial.			Functional Concept	CDISC DDF Indication Attribute Terminology|CDISC DDF Terminology|CDISC SDTM Device Properties Test Code Terminology|CDISC SDTM Device Properties Test Name Terminology|CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology|ICH M11 Protocol Section 1 Data Element Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C112039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112039>	C38434	Recent Thymic Emigrant|RTE|RTEs|Recent Thymic Emigrants|Thymic Recent Emigrant|Thymic Recent Emigrants	A T-lymphocyte that has completed intrathymic development and has exited the thymus. These cells are the youngest peripheral T-lymphocytes and migrate to secondary lymphoid organs where they slowly mature to become naive T-cells.	Recent Thymic Emigrant		Cell	CTRP Biomarker Terminology|CTRP Terminology
C11203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11203>	C61063	Dexamethasone/Methotrexate/Pegaspargase/Vincristine|DM/MTX/PEG-ASP/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112040>	C1745	Anthocyanin|Anthocyanins	A flavonoid that is a glycoside derivative of anthocyanidin. They are water-soluble plant pigments that exhibit bright coloration. Their color is dependent on the pH of the solvent; therefore, these polyphenols are used as pH indicators.	Anthocyanin		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C112042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112042>	C542	Urolithin|Urolithins	Hydroxy-6H-dibenzo[b,d]pyran-6-one derivatives that are the products of the metabolism of ellagitannins by intestinal bacteria. The biological activity of urothilins is unknown; however, these compounds are under investigation to determine if they have a mechanism of action that is similar to other phytoestrogens.	Urolithin		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C112043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112043>	C157134	Prostaglandin E2|(5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-Oxoprosta-5,13-Dien-1-Oic Acid|(5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-Oxoprost-13-Enoate|(5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-Oxoprosta-5,13-Dienoate|(5Z,13E,15S)-11alpha,15-Dihydroxy-9-Oxoprosta-5,13-Dien-1-Oic Acid|(E,Z)-(1R,2R,3R)-7-(3-Hydroxy-2-((3S)-(3-Hydroxy-1-Octenyl))-5-Oxocyclopentyl)-5-Heptenoic Acid|(Z)-7-((1R,2R,3R)-3-Hydroxy-2-((S,E)-3-Hydroxyoct-1-Enyl)-5-Oxocyclopentyl)Hept-5-Enoic Acid|5-Heptenoic Acid, 7-(3-Hydroxy-2-(3-Hydroxy-1-Octenyl)-5-Oxocyclopentyl)- (8CI)|7-(3-Hydroxy-2-(3-Hydroxy-1-Octenyl)-5-Oxocyclopentyl)-5-Heptenoic Acid|PGE(2)|PGE2|Prosta-5,13-Dien-1-Oic Acid, (5Z,11-Alpha,13E,15S)-11,15-Dihydroxy-9-Oxo-|Prosta-5,13-Dien-1-Oic Acid, 11,15-Dihydroxy-9-Oxo-, (5Z,11alpha,13E,15S)-|Prostaglandin E(2)	A prostaglandin with 2 double bonds that is generated by the action of prostaglandin E synthases on prostaglandin H2. Prostaglandin E2 is a mediator of active inflammation, and has important biologic effects including potent vasodilation, smooth muscle relaxation, stimulation of osteoclast-dependent bone resorption and induction of both pain and fever. It is also used as a vaginal suppository during labor to soften the cervix and promote uterine contractions.	Prostaglandin E2		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C112044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112044>	C912	Tn Antigen|CD175|Tn	A protein antigen that is comprised of the monosaccharide N-acetylgalactosamine (GalNAc) bound to serine or threonine by O-linked glycosylation. Aberrant expression of Tn antigen by all blood cell lineages is associated with a rare hematological disorder called Tn-syndrome. Increased expression of this monosaccharide modification is also associated with some cancers and this antigen is being investigated for use as either a biomarker or therapeutic target for these associated malignancies.	Tn Antigen		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C112045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112045>	C2463	Replication Competent Retrovirus|RCR|Replication Competent Retroviruses|Replication-Competent Retrovirus|Replication-Competent Retroviruses	A retroviral vector that contains all the genes that are required for virion synthesis and is able to propagate after the host is infected.	Replication Competent Retrovirus		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology
C112046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112046>	C45597	Furanocoumarin|Furanocoumarins|Furocoumarin|Furocoumarins	A class of organic phytochemicals that consists of a furan ring fused with coumarin. Furanocoumarins are produced by plants as defensive toxins and, when ingested by humans, they can affect the metabolism of drugs by cytochrome P450 isoform CYP3A4.	Furanocoumarin		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C112047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112047>	C45653	Glucosinolate|GLS|Glucosinolates	A class of organic compounds that are derived from a glucose that has been modified by an amino acid. These compounds are anionic sulfur-containing glucosides, produced as secondary metabolites by plants of the order Brassicales, which includes cruciferous vegetables. Glucosinolates can be toxic if ingested at high doses but lower doses are under investigation as potential tumor inhibitors.	Glucosinolate		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C112048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112048>	C171083	Delta13C|Carbon-13:Carbon-12 Isotopic Signature	The ratio of the stable isotopes carbon-13 and carbon-12, reported in parts per thousand. In plant tissues, this ratio varies between those plants that utilize the C3 carbon fixation pathway and those that utilize the C4 pathway.	Delta13C		Quantitative Concept	CTRP Biomarker Terminology|CTRP Terminology
C112049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112049>	C21176	Succinate Dehydrogenase|Complex II|EC 1.3.5.1|Mitochondrial Complex II|Mitochondrial Respiratory Chain Complex II|Respiratory Complex II|SDH|SQR|Succinate-CoQ Reductase|Succinate-Coenzyme Q Reductase|Succinic Dehydrogenase	A heterotetrameric enzyme complex found in the inner mitochondrial membrane. This protein complex catalyzes the oxidation of succinate and reduction of ubiquinone and plays a role in both the citric acid cycle and the electron transport chain.	Succinate Dehydrogenase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11204>	C61063	Cyclophosphamide/Dexamethasone/Idarubicin/Pegaspargase/Vincristine|CTX/DM/IDA/PEG-ASP/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112050>	C20130	3-Hydroxyacyl-CoA Dehydrogenase|(S)-3-Hydroxyacyl-CoA:NAD+ Oxidoreductase|1-Specific DPN-Linked Beta--Hydroxybutyric Dehydrogenase|3-Hydroxyacetyl-Coenzyme A Dehydrogenase|3-Hydroxyacyl CoA Dehydrogenase|3-Hydroxyacyl Coenzyme A Dehydrogenase|3-Hydroxybutyryl-CoA Dehydrogenase|3-Hydroxyisobutyryl-CoA Dehydrogenase|3-Hydroxyl-Co-A Dehydrogenase|3-Keto Reductase|3-L-Hydroxyacyl-CoA Dehydrogenase|3Beta--Hydroxyacyl Coenzyme A Dehydrogenase|3Beta—Hydroxyacyl Coenzyme A Dehydrogenase|Beta--Hydroxy Acid Dehydrogenase|Beta--Hydroxyacyl CoA Dehydrogenase|Beta--Hydroxyacyl Dehydrogenase|Beta--Hydroxyacyl-Coenzyme A Synthetase|Beta--Hydroxyacylcoenzyme A Dehydrogenase|Beta--Hydroxybutyrylcoenzyme A Dehydrogenase|Beta--Keto-Reductase|Beta--Ketoacyl-CoA Reductase|Beta—Hydroxy Acid Dehydrogenase|Beta—Hydroxyacyl CoA Dehydrogenase|Beta—Hydroxyacyl Dehydrogenase|Beta—Hydroxyacyl-Coenzyme A Synthetase|Beta—Hydroxyacylcoenzyme A Dehydrogenase|Beta—Hydroxybutyrylcoenzyme A Dehydrogenase|Beta—Keto-Reductase|Beta—Ketoacyl-CoA Reductase|EC 1.1.1.35|L-3-Hydroxyacyl CoA Dehydrogenase|L-3-Hydroxyacyl Coenzyme A Dehydrogenase	A family of enzymes that oxidize (S)-3-hydroxyacyl-CoA and NAD+ and produce 3-oxoacyl-CoA, NADH, and H+. These proteins are involved in the metabolism of both fatty acids and amino acids.	3-Hydroxyacyl-CoA Dehydrogenase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112051>	C20130	Carboxylesterase|B-Esterase|Butyrate Esterase|Butyryl Esterase|Carboxyesterase|Carboxyl Ester Hydrolase|Carboxylate Esterase|Carboxylic Acid Esterase|Carboxylic Ester Hydrolase|Carboxylic Esterase|Carboxylic-Ester Hydrolase|EC 3.1.1-|Methylbutyrase|Methylbutyrate Esterase	A family of enzymes that hydrolyze carboxylic esters.	Carboxylesterase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112052>	C20130	Macrophage Inflammatory Protein|MIP|MIP-1|Macrophage Inflammatory Protein-1|Macrophage Inhibitory Protein-1	A family of CC-motif cytokines that are produced by macrophages in response to endotoxin exposure. This family has two members C-C motif chemokine 3 and C-C motif chemokine 4. These chemokines promote the inflammatory response through the activation of human granulocytes and induction of the synthesis and release of other pro-inflammatory cytokines.	Macrophage Inflammatory Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112053>	C20745	DNAI7 Gene|CASC1|CASC1 Gene|CFAP94|DNAI7|Dynein Axonemal Intermediate Chain 7 Gene	This gene plays a role in cellular processes involving the axonemal dynein complex.	CASC1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C112054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112054>	C112053	DNAI7 wt Allele|CASC1 wt Allele|CFAP94|Cancer Susceptibility 1 Gene|Cancer Susceptibility Candidate 1 Gene|Dynein Axonemal Intermediate Chain 7 wt Allele|FLJ10921|LAS1|Lung Adenoma Susceptibility Gene 1|PPP1R54|Protein Phosphatase 1, Regulatory Subunit 54 Gene	Human DNAI7 wild-type allele is located in the vicinity of 12p12.1 and is approximately 88 kb in length. This allele, which encodes dynein axonemal intermediate chain 7 protein, is involved in axonemal dynein complex activities.	CASC1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112055>	C16295	BCG Antibody|Anti-BCG Antibodies|Anti-BCG Antibody|Anti-Bacillus Calmette-Guerin Antibodies|Anti-Bacillus Calmette-Guerin Antibody|BCG Antibodies|Bacillus Calmette-Guerin Antibodies|Bacillus Calmette-Guerin Antibody	Any immunoglobulin that recognizes Bacillus Calmette-Guerin antigen.	BCG Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C112056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112056>	C16861	Dynein Axonemal Intermediate Chain 7|Cancer Susceptibility Candidate Gene 1 Protein|Cancer Susceptibility Candidate Protein 1|Cancer Susceptibility Candidate Protein 1|Cilia and Flagella Associated Protein 94|DNAI7|Dynein Intermediate Chain CFAP94, Axonemal|Lung Adenoma Susceptibility 1-Like Protein|Protein CASC1|Protein Phosphatase 1 Regulatory Subunit 54|Protein Phosphatase 1, Regulatory Subunit 54	Dynein axonemal intermediate chain 7 (716 aa, ~83 kDa) is encoded by the human DNAI7 gene. This protein plays a role in microtubule processes that depend on axonemal dynein activity.	Cancer Susceptibility Candidate Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112057>	C16295	PSA Antibody|Anti-PSA Antibodies|Anti-PSA Antibody|Anti-Prostate Specific Antigen Antibodies|Anti-Prostate Specific Antigen Antibody|PSA Antibodies|Prostate Specific Antigen Antibodies|Prostate Specific Antigen Antibody	Any immunoglobulin that recognizes prostate-specific antigen.	PSA Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112058>	C16295	ACPP Antibody|ACPP Antibodies|Anti-ACPP Antibodies|Anti-ACPP Antibody|Anti-PAP Antibodies|Anti-PAP Antibody|Anti-Prostatic Acid Phosphatase Antibodies|Anti-Prostatic Acid Phosphatase Antibody|PAP Antibodies|PAP Antibody|Prostatic Acid Phosphatase Antibodies|Prostatic Acid Phosphatase Antibody	Any immunoglobulin that recognizes prostatic acid phosphatase.	ACPP Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112059>	C16295	FOLH1 Antibody|Anti-FOLH1 Antibodies|Anti-FOLH1 Antibody|Anti-Folate Hydrolase 1 Antibodies|Anti-Folate Hydrolase 1 Antibody|Anti-Glutamate Carboxypeptidase 2 Antibodies|Anti-Glutamate Carboxypeptidase 2 Antibody|Anti-PSMA Antibodies|Anti-PSMA Antibody|Anti-Prostate-Specific Membrane Antigen Antibodies|Anti-Prostate-Specific Membrane Antigen Antibody|FOLH1 Antibodies|Folate Hydrolase 1 Antibodies|Folate Hydrolase 1 Antibody|Glutamate Carboxypeptidase 2 Antibodies|Glutamate Carboxypeptidase 2 Antibody|PSMA Antibodies|PSMA Antibody|Prostate-Specific Membrane Antigen Antibodies|Prostate-Specific Membrane Antigen Antibody	Any immunoglobulin that recognizes glutamate carboxypeptidase 2 (folate hydrolase 1).	FOLH1 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11205>	C61063	Cytarabine/Pegaspargase/Thioguanine/Vincristine|ARA-C/PEG-ASP/TG/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112060>	C16295	PSCA Antibody|Anti-PSCA Antibodies|Anti-PSCA Antibody|Anti-Prostate Stem Cell Antigen Antibody|PSCA Antibodies|Prostate Stem Cell Antigen Antibodies|Prostate Stem Cell Antigen Antibody	Any immunoglobulin that recognizes prostate stem cell antigen.	PSCA Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112061>	C19928	CFLAR Gene Product	A protein encoded by the CFLAR gene.	CFLAR Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112062>	C26006	WASHC5 Gene|KIAA0196|WASH Complex Subunit 5 Gene|WASHC5|WASHC5	This gene is involved in actin polymerization.	WASHC5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C112063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112063>	C112062	WASHC5 wt Allele|KIAA0196|RTSC|RTSC1|SPG8|Spastic Paraplegia 8 (Autosomal Dominant) Gene|WASH Complex Subunit 5 wt Allele	Human WASHC5 wild-type allele is located in the vicinity of 8q24.13 and is approximately 68 kb in length. This allele, which encodes WASH complex subunit strumpellin protein, plays a role in the induction of actin polymerization. Mutations in this gene are associated with autosomal dominant spastic paraplegia 8.	WASHC5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112064>	C112061	CASP8 and FADD-Like Apoptosis Regulator Isoform 2|CASH Beta|CFLAR Isoform 2|CLARP2|Caspase Homolog Beta|Cellular FLICE-Like Inhibitory Protein Isoform 2|Cellular FLICE-Like Inhibitory Protein Short Isoform|FLIP-S|FLIPS|MACH-Related Inducer of Toxicity Beta-1|MRIT Beta-1|c-FLIP(S)|c-FLIPS|cFLIP(S)|cFLIPS	CASP8 and FADD-like apoptosis regulator isoform 2 (221 aa, ~25 kDa) is encoded by the human CFLAR gene. This protein is involved in the regulation of caspase-dependent apoptosis.	CASP8 and FADD-Like Apoptosis Regulator Isoform 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112065>	C16386	WASH Complex Subunit Strumpellin|Strumpellin	WASH complex subunit strumpellin (1159 aa, ~134 kDa) is encoded by the human WASHC5 gene. This protein is involved in actin polymerization.	WASH Complex Subunit Strumpellin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112066>	C21295	STIP1 Gene|STIP1|STIP1|Stress-Induced-Phosphoprotein 1 Gene	This gene plays a role in chaperone protein function.	STIP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C112067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112067>	C112066	STIP1 wt Allele|HOP|STI1|STI1, Yeast, Homologe of Gene|STI1L|Stress-Induced-Phosphoprotein 1 wt Allele	Human STIP1 wild-type allele is located in the vicinity of 11q13 and is approximately 19 kb in length. This allele, which encodes stress-induced-phosphoprotein 1, is involved in chaperone protein function as a bridge between HSP70 and HSP90.	STIP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112068>	C17728	Stress-Induced-Phosphoprotein 1|Hsc70/Hsp90-Organizing Protein|Hsp70/Hsp90-Organizing Protein|IEF-SSP-3521|NY-REN-11 Antigen|P60|Renal Carcinoma Antigen NY-REN-11|STIP1|Stress-Induced Phosphoprotein 1|Transformation-Sensitive Protein IEF SSP 3521	Stress-induced-phosphoprotein 1 (543 aa, ~63 kDa) is encoded by the human STIP1 gene. This protein plays a role in chaperone protein function.	Stress-Induced-Phosphoprotein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112069>	C20194	CTHRC1 Gene|CTHRC1|CTHRC1|Collagen Triple Helix Repeat Containing 1 Gene	This gene is involved in the cellular response to arterial injury.	CTHRC1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C11206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11206>	C61063	Pegaspargase/Vincristine|PEG-ASP/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112070>	C112069	CTHRC1 wt Allele|Collagen Triple Helix Repeat Containing 1 wt Allele|UNQ762/PRO1550	Human CTHRC1 wild-type allele is located in the vicinity of 8q22.3 and is approximately 11 kb in length. This allele, which encodes collagen triple helix repeat-containing protein 1, plays a role in the cellular response to arterial injury through involvement in vascular remodeling. Mutations in this gene are associated with Barrett esophagus/esophageal adenocarcinoma.	CTHRC1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112071>	C18466	Collagen Triple Helix Repeat-Containing Protein 1|Collagen Triple Helix Repeat Containing 1|Collagen Triple-Helix Repeat-Containing Protein 1|Protein NMTC1	Collagen triple helix repeat-containing protein 1 (243 aa, ~26 kDa) is encoded by the human CTHRC1 gene. This protein is involved in the cellular response to arterial injury.	Collagen Triple Helix Repeat-Containing Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112072>	C25870	GSTM3 Gene|GSTM3|GSTM3|Glutathione S-Transferase Mu 3 (Brain) Gene	This gene is involved in both glutathione metabolism and cellular detoxification.	GSTM3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C112073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112073>	C112072	GSTM3 wt Allele|GST5|GSTB|GSTM3-3|GTM3|Glutathione S-Transferase M3 (Brain) Gene|Glutathione S-Transferase Mu 3 (Brain) wt Allele	Human GSTM3 wild-type allele is located in the vicinity of 1p13.3 and is approximately 8 kb in length. This allele, which encodes glutathione S-transferase Mu 3 protein, plays a role in both nitrogen detoxification and glutathione metabolism.	GSTM3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112074>	C20075	Glutathione S-Transferase Mu 3|Brain GST|Brain Type Mu-Glutathione S-Transferase|EC 2.5.1.18|GST Class-Mu 3|GSTM3-3|Glutathione S-Aralkyltransferase M3|Glutathione S-Aryltransferase M3|Glutathione S-Transferase 5|Glutathione S-Transferase M3|Glutathione S-Transferase, Mu-3|S-(Hydroxyalkyl)Glutathione Lyase M3|hGSTM3-3	Glutathione S-transferase Mu 3 (225 aa, ~27 kDa) is encoded by the human GSTM3 gene. This protein is involved in cellular detoxification of glutathione, nitrogenous compounds and other xenobiotics.	Glutathione S-Transferase Mu 3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112075>	C26003	PSMB8 Gene|PSMB8|PSMB8|Proteasome (Prosome, Macropain) Subunit, Beta Type, 8 Gene	This gene plays a role in both protein catabolism and antigen processing.	PSMB8 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C112076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112076>	C112075	PSMB8 wt Allele|ALDD|D6S216|D6S216E|JMP|LMP7|Large Multifunctional Peptidase 7 Gene|Large Multifunctional Protease 7 Gene|NKJO|PSMB5i|Proteasome (Prosome, Macropain) Subunit, Beta Type, 8 (Large Multifunctional Peptidase 7) Gene|Proteasome (Prosome, Macropain) Subunit, Beta Type, 8 (Large Multifunctional Protease 7) Gene|Proteasome (Prosome, Macropain) Subunit, Beta Type, 8 wt Allele|Proteasome-Related Gene 7|RING10|Y2|beta5i	Human PSMB8 wild-type allele is located in the vicinity of 6p21.3 and is approximately 4 kb in length. This allele, which encodes proteasome subunit beta type-8 protein, is involved in both antigen processing and protein catabolism. Mutation of the gene is associated with Nakajo syndrome and chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome (CANDLE syndrome).	PSMB8 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112077>	C16965	Proteasome Subunit Beta Type-8|EC 3.4.25.1|Large Multifunctional Peptidase 7|Large Multifunctional Protease 7|Low Molecular Mass Protein 7|Low Molecular Weight Protein 7|Macropain Subunit C13|Multicatalytic Endopeptidase Complex Subunit C13|PSMB8|Protease Component C13|Proteasome Component C13|Proteasome Subunit Beta 5i|Proteasome Subunit Beta-5i|Proteasome Subunit Y2|Really Interesting New Gene 10 Protein	Proteasome subunit beta type-8 (276 aa, ~30 kDa) is encoded by the human PSMB8 gene. This protein plays a role in both protein metabolism and the generation of MHC class I-binding peptides.	Proteasome Subunit Beta Type-8		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112078>	C26003	PSMB10 Gene|PSMB10|PSMB10|Proteasome (Prosome, Macropain) Subunit, Beta Type, 10 Gene	This gene is involved in antigen processing by the proteasome.	PSMB10 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C112079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112079>	C112078	PSMB10 wt Allele|LMP10|MECL1|MGC1665|Proteasome (Prosome, Macropain) Subunit, Beta Type, 10 wt Allele|beta2i	Human PSMB10 wild-type allele is located in the vicinity of 16q22.1 and is approximately 3 kb in length. This allele, which encodes proteasome subunit beta type-10 protein, plays a role in proteasomal protein catabolism.	PSMB10 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11207>	C61063	Carboplatin/Ifosfamide/Paclitaxel|CBDCA/IFF/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112080>	C16965	Proteasome Subunit Beta Type-10|EC 3.4.25.1|Low Molecular Mass Protein 10|Macropain Subunit MECl-1|Multicatalytic Endopeptidase Complex Subunit MECl-1|PSMB10|Proteasome Catalytic Subunit 2i|Proteasome MECl-1|Proteasome Subunit Beta-2i|Proteasome Subunit MECL1	Proteasome subunit beta type-10 (273 aa, ~29 kDa) is encoded by the human PSMB10 gene. This protein is involved in the formation of peptide antigens by the immunoproteasome.	Proteasome Subunit Beta Type-10		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112081>	C28533	SLC44A1 Gene|SLC44A1|SLC44A1|Solute Carrier Family 44 (Choline Transporter), Member 1 Gene	This gene plays a role in choline transport.	SLC44A1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C112082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112082>	C112081	SLC44A1 wt Allele|CD92|CDW92|CHTL1|CTL1|Solute Carrier Family 44 (Choline Transporter), Member 1 wt Allele	Human SLC44A1 wild-type allele is located in the vicinity of 9q31.2 and is approximately 195 kb in length. This allele, which encodes choline transporter-like protein 1, is involved in choline transporter and may be involved in membrane synthesis and myelin production.	SLC44A1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112083>	C16386	Choline Transporter-Like Protein 1|CD92 Antigen|CDW92 Antigen|RP11-287A8.1|SLC44A1|Solute Carrier Family 44 Member 1|Solute Carrier Family 44, Member 1	Choline transporter-like protein 1 (657 aa, ~73 kDa) is encoded by the human SLC44A1 gene. This protein plays a role in choline transport.	Choline Transporter-Like Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112084>	C20923	LPAR3 Gene|LPAR3|LPAR3|Lysophosphatidic Acid Receptor 3 Gene	This gene is involved in calcium mobilization.	LPAR3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C112085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112085>	C112084	LPAR3 wt Allele|EDG7|Edg-7|Endothelial Cell Differentiation Gene 7|Endothelial Differentiation Gene 7|GPCR|HOFNH30|LP-A3|LPA-3|LPA3|Lysophosphatidic Acid Receptor 3 wt Allele|RP4-678I3	Human LPAR3 wild-type allele is located in the vicinity of 1p22.3 and is approximately 82 kb in length. This allele, which encodes lysophosphatidic acid receptor 3 protein, plays a role as a cellular receptor for lysophosphatidic acid and mediates lysophosphatidic acid-evoked calcium mobilization.	LPAR3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112086>	C18239	Lysophosphatidic Acid Receptor 3|Calcium-Mobilizing Lysophosphatidic Acid Receptor LP-A3|Endothelial Cell Differentiation Gene 7 Protein|Endothelial Differentiation, Lysophosphatidic Acid G-Protein-Coupled Receptor, 7|LPA Receptor 3|LPA Receptor EDG7|Lysophosphatidic Acid Receptor Edg-7	Lysophosphatidic acid receptor 3 (353 aa, ~40 kDa) is encoded by the human LPAR3 gene. This protein is involved in the regulation of calcium mobilization.	Lysophosphatidic Acid Receptor 3		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112087>	C217464	Intent to Compound 506E Drug|Intent to compound 506E (drug shortage) drugs	A compounder intends to produce a drug classified as 506E.			Activity	FDA Structured Product Labeling Terminology|SPL Business Operation Qualifier Terminology
C112088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112088>	C20921	CYRIB Gene|CYFIP Related Rac1 Interactor B Gene|CYRIB|CYRIB|FAM49B|FAM49B Gene	This gene plays a role in the regulation of RAC1 activity.	FAM49B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C112089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112089>	C112088	CYRIB wt Allele|BM-009|CYFIP Related Rac1 Interactor B wt Allele|CYRI|CYRI-B|FAM49B|FAM49B wt Allele|Family with Sequence Similarity 49 Member B Gene|Family with Sequence Similarity 49, Member B Gene|L1	Human CYRIB wild-type allele is located in the vicinity of 8q24.21 and is approximately 178 kb in length. This allele, which encodes CYFIP-related Rac1 interactor B protein, is involved in the modulation of RAC1-dependent signaling and cytoskeletal remodeling.	FAM49B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11208>	C61063	Carboplatin/Cyclophosphamide/Cyclosporine/Paclitaxel|CBDCA/CTX/CYSP/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112090>	C18515	CYFIP-Related Rac1 Interactor B|CYFIP Related Rac1 Interactor B|CYRIB|L1|Protein FAM49B|Protein FAM49B	CYFIP-related Rac1 interactor B (324 aa, ~37 kDa) is encoded by the human CYRIB gene. This protein plays a role in the downregulation of RAC1-dependent signaling and cytoskeletal remodeling.	Protein FAM49B		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112091>	C217464	No Intent to Compound 506E Drug|No intent to compound 506E (drug shortage) drugs	A compounder does not intend to produce a drug classified as 506E.			Activity	FDA Structured Product Labeling Terminology|SPL Business Operation Qualifier Terminology
C112092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112092>	C15653	Compounding from Bulk Ingredient|Compounding from bulk ingredient	A compounder produces a drug with bulk ingredients.			Activity	FDA Structured Product Labeling Terminology|SPL Business Operation Qualifier Terminology
C112093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112093>	C217464	Not Compounding from Bulk Ingredient|Not compounding from bulk ingredient	A compounder produces a drug without bulk ingredients.			Activity	FDA Structured Product Labeling Terminology|SPL Business Operation Qualifier Terminology
C112094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112094>	C15653	Compounding Sterile Product|Compounding sterile products	A compounder produces a sterile product.			Activity	FDA Structured Product Labeling Terminology|SPL Business Operation Qualifier Terminology
C112095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112095>	C217464	Not Compounding Sterile Product|Not compounding sterile products	A compounder does not produce a sterile product.			Activity	FDA Structured Product Labeling Terminology|SPL Business Operation Qualifier Terminology
C112096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112096>	C26016	UTP23 Gene|UTP23|UTP23|UTP23, Small Subunit (SSU) Processome Component, Homolog (Yeast) Gene	This gene is involved in rRNA-processing and ribosome biogenesis.	UTP23 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C112097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112097>	C112096	UTP23 wt Allele|C8orf53|MGC14595|UTP23, Small Subunit (SSU) Processome Component, Homolog (Yeast) wt Allele	Human UTP23 wild-type allele is located in the vicinity of 8q24.11 and is approximately 83 kb in length. This allele, which encodes rRNA-processing protein UTP23 homolog, plays a role in rRNA-processing and ribosome biogenesis.	UTP23 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112098>	C18466	rRNA-Processing Protein UTP23 Homolog|C8orf53|Chromosome 8 Open Reading Frame 53	rRNA-processing protein UTP23 homolog (249 aa, ~28 kDa) is encoded by the human UTP23 gene. This protein is involved in rRNA-processing and ribosome biogenesis.	rRNA-Processing Protein UTP23 Homolog		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112099>	C25802	CANX Gene|CANX|CANX|Calnexin Gene	This gene plays a role in both protein folding and antigen presentation.	CANX Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C11209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11209>	C61063	Cisplatin/Cyclophosphamide/Cyclosporine/Paclitaxel|CDDP/CTX/CYSP/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1120>	C221|C1971	Halofuginone|HALOFUGINONE|trans-(+/-)-7-Bromo-6-chloro-3-[3-(3-hydroxy-2-piperidinyl)-2-oxopropyl]-4(3H)-quinazolinone	An orally-active quinazolinone alkaloid with potential antineoplastic activity. Halofuginone interferes with the signaling pathway of transforming growth factor beta (TGF beta) and inhibits expression of matrix metalloproteinase 2, thereby inhibiting collagen type I synthesis and inducing extracellular matrix degradation, resulting in inhibition of angiogenesis, tumor growth, or metastasis.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C112100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112100>	C112099	CANX wt Allele|CNX|Calnexin wt Allele|IP90|P90	Human CANX wild-type allele is located in the vicinity of 5q35 and is approximately 53 kb in length. This allele, which encodes calnexin protein, is involved in both antigen presentation and protein folding.	CANX wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112101>	C25939	AKR1A1 Gene|AKR1A1|AKR1A1|Aldo-Keto Reductase Family 1, Member A1 (Aldehyde Reductase) Gene	This gene plays a role in the reduction of biogenic and xenobiotic aldehydes.	AKR1A1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C112102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112102>	C112101	AKR1A1 wt Allele|ALDR1|ALR|ARM|Aldo-Keto Reductase Family 1, Member A1 (Aldehyde Reductase) wt Allele|DD3|HEL-S-6	Human AKR1A1 wild-type allele is located in the vicinity of 1p34.1 and is approximately 20 kb in length. This allele, which encodes alcohol dehydrogenase [NADP(+)] protein, is involved in the reduction of biogenic and xenobiotic aldehydes.	AKR1A1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112103>	C17764	Calnexin|CANX|IP90|Major Histocompatibility Complex Class I Antigen-Binding Protein p88|p90	Calnexin (592 aa, ~68 kDa) is encoded by the human CANX gene. This protein plays a role in antigen presentation, protein folding and complex assembly.	Calnexin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112104>	C16946	Alcohol Dehydrogenase [NADP(+)]|AKR1A1|Alcohol Dehydrogenase|Aldehyde Reductase|Aldo-Keto Reductase Family 1 Member A1|Aldo-Keto Reductase Family 1, Member A1|Dihydrodiol Dehydrogenase 3|EC 1.1.1.2	Alcohol dehydrogenase [NADP(+)] (325 aa, ~37 kDa) is encoded by the human AKR1A1 gene. This protein plays a role in the reduction of biogenic and xenobiotic aldehydes.	Alcohol Dehydrogenase [NADP(+)]		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112105>	C20194	KEAP1 Gene|KEAP1|KEAP1|KEAP1|Kelch-Like ECH-Associated Protein 1 Gene	This gene is involved in ubiquitin-mediated protein degradation.	KEAP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C112106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112106>	C112105	KEAP1 wt Allele|INRF2|INrf2|KIAA0132|KLHL19|Kelch-Like ECH-Associated Protein 1 wt Allele|MGC10630|MGC1114|MGC20887|MGC4407|MGC9454	Human KEAP1 wild-type allele is located in the vicinity of 19p13.2 and is approximately 18 kb in length. This allele, which encodes kelch-like ECH-associated protein 1, plays a role in targeting NFE2L2/NRF2 for ubiquitin-mediated protein degradation.	KEAP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112107>	C95242	Kelch-Like ECH-Associated Protein 1|Cytosolic Inhibitor Of Nrf2|KEAP1|Kelch-Like Family Member 19|Kelch-Like Protein 19	Kelch-like ECH-associated protein 1 (624 aa, ~70 kDa) is encoded by the human KEAP1 gene. This protein is involved in ubiquitin-mediated protein degradation.	Kelch-Like ECH-Associated Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112108>	C25941	PTGES Gene|PTGES|PTGES|Prostaglandin E Synthase Gene	This gene may play a role in TP53 induced apoptosis.	PTGES Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C112109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112109>	C112108	PTGES wt Allele|MGST-IV|MGST1-L1|MGST1L1|MPGES|MPGES-1|MPGES1|PGES|PIG12|PP102|PP1294|Prostaglandin E Synthase wt Allele|TP53I12	Human PTGES wild-type allele is located in the vicinity of 9q34.3 and is approximately 15 kb in length. This allele, which encodes prostaglandin E synthase protein, may be involved in TP53 induced apoptosis.	PTGES wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11210>	C63358	Docetaxel/Epirubicin Regimen|Docetaxel and Epirubicin (DE)|Docetaxel-Epirubicin|Docetaxel/Epirubicin|EPI/TXT|ET|ET	A regimen consisting of docetaxel and epirubicin that can be used for the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C112110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112110>	C36281	Skin Sloughing	Peeling or shedding of skin in sheets.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112111>	C16759	Prostaglandin E Synthase|EC 5.3.99.3|Glutathione Peroxidase PTGES|Glutathione S-Transferase 1-Like 1|Glutathione Transferase PTGES|MGST1-Like 1|Microsomal Glutathione S-Transferase 1-Like 1|Microsomal Prostaglandin E Synthase 1|Microsomal Prostaglandin E Synthase-1|P53-Induced Apoptosis Protein 12|P53-Induced Gene 12 Protein|PTGES|Tumor Protein P53 Inducible Protein 12	Prostaglandin E synthase (152 aa, ~17 kDa) is encoded by the human PTGES gene. This protein may play a role in TP53 induced apoptosis.	Prostaglandin E Synthase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112112>	C5036	Panniculitis	Inflammation of the subcutaneous adipose tissue.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112113>	C38186	Human Drug Compounding Outsourcing Facility	A site designated as an establishment for outsourcing of human drug compounding.			Organization	FDA Structured Product Labeling Terminology|SPL Business Operation Terminology
C112114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112114>	C36281	Skin Necrosis|Necrosis	Death of one or more layers of skin.			Finding	Modified Radiation-induced Skin Reaction Assessment Scale|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112115>	C50706	Chronic Decubitus|Chronic Decubitus Ulcer|Chronic Decubitus Ulcer|Chronic Pressure Sore|Chronic Pressure Sore|Chronic Pressure Ulcer|Chronic Pressure Ulcer	A longstanding lesion caused by death of tissue due to external pressure.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112116>	C50559	Eosinophilic Fasciitis|Shulman Syndrome	Inflammation and induration of the fascia related to an accumulation of white blood cells, including eosinophils.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Rheumatology Terminology
C112117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112117>	C35740|C35729	Vascular Malformation	A congenital abnormality of the arteries and veins, lymph vessels or veins and lymph vessels.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112118>	C25941	PDIA3 Gene|PDIA3|PDIA3|Protein Disulfide Isomerase Family A, Member 3 Gene	This gene is involved in both antigen presentation and formation of disulfide bonds in proteins.	PDIA3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C112119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112119>	C9435	Umbilical Granuloma	Excessive granulation tissue at the base of the umbilicus after separation.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C11211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11211>	C61063	Docetaxel/Epirubicin/Filgrastim|EPI/G-CSF/TXT			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112120>	C112118	PDIA3 wt Allele|ER60|ERp57|ERp60|ERp61|GRP57|GRP58|Glucose Regulated Protein, 58kDa Gene|Glucose-Regulated Protein, 58kD Gene|HsT17083|P58|PI-PLC|Protein Disulfide Isomerase Family A, Member 3 wt Allele|Protein Disulfide Isomerase-Associated 3 Gene	Human PDIA3 wild-type allele is located in the vicinity of 15q15 and is approximately 27 kb in length. This allele, which encodes protein disulfide-isomerase A3 protein, plays a role in both the rearrangement of protein disulfide bonds and antigen presentation.	PDIA3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112121>	C16759	Protein Disulfide-Isomerase A3|58 kDa Glucose-Regulated Protein|58 kDa Microsomal Protein|Disulfide Isomerase ER-60|EC 5.3.4.1|ER Protein 57|ER Protein 60|ERp57|ERp60|Endoplasmic Reticulum Resident Protein 57|Endoplasmic Reticulum Resident Protein 60|Endoplasmic Reticulum p58|PDIA3|Protein Disulfide Isomerase-Associated 3|p58	Protein disulfide-isomerase A3 (505 aa, ~57 kDa) is encoded by the human PDIA3 gene. This protein is involved in both the activity of the MHC class I peptide-loading complex and post-translational disulfide bond formation.	Protein Disulfide-Isomerase A3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112122>	C2983	Acute Generalized Exanthematous Pustulosis	A widespread acute rash characterized by fever and multiple small pustules on a reddish background.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112123>	C21295	LGALS9 Gene|LGALS9|LGALS9|Lectin, Galactoside-Binding, Soluble, 9 Gene	This gene plays a role in carbohydrate binding.	LGALS9 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C112124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112124>	C27554	Pseudoporphyria	A drug-induced photodermatosis characterized by skin fragility, erythema, and the appearance of tense bullae, erosions and scarring in the absence of abnormalities in porphyrin metabolism.	Pseudoporphyria		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112125>	C112123	LGALS9 wt Allele|HUAT|LGALS9A|Lectin, Galactoside-Binding, Soluble, 9 wt Allele	Human LGALS9 wild-type allele is located in the vicinity of 17q11.2 and is approximately 20 kb in length. This allele, which encodes galectin-9 protein, is involved in carbohydrate binding and may be an eosinophil chemoattractant. Overexpression of the gene may be associated with Hodgkin lymphoma.	LGALS9 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112126>	C17728	Galectin-9|Ecalectin|Gal-9|Galectin 9|LGALS9|Tumor Antigen HOM-HD-21|Urate Transporter/Channel Protein	Galectin-9 (355 aa, ~40 kDa) is encoded by the human LGALS9 gene. This protein plays a role in galactoside binding and as an eosinophil chemoattractant.	Galectin-9		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112127>	C20731	DUSP4 Gene|DUSP4|DUSP4|Dual Specificity Phosphatase 4 Gene	This gene is involved in the dephosphorylation of MAPK1 and MAPK3.	DUSP4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C112128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112128>	C112127	DUSP4 wt Allele|Dual Specificity Phosphatase 4 wt Allele|HVH2|MKP-2|MKP2|TYP|VH2	Human DUSP4 wild-type allele is located within 8p12-p11 and is approximately 18 kb in length. This allele, which encodes dual specificity protein phosphatase 4 protein, plays a role in the dephosphorylation of MAP kinases.	DUSP4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112129>	C25880	Dual Specificity Protein Phosphatase 4|DUSP4|Dual Specificity Protein Phosphatase HVH2|Dual-Specificity Phosphatase 4|Dual-Specificity Protein Phosphatase 4|EC 3.1.3.16|EC 3.1.3.48|MAP Kinase Phosphatase 2|MKP-2|Mitogen-Activated Protein Kinase Phosphatase 2|VH1 Homologous Phosphatase 2|VH1-Like Phosphatase 2	Dual specificity protein phosphatase 4 (394 aa, ~43 kDa) is encoded by the human DUSP4 gene. This protein is involved in the dephosphorylation of mitogen-activated protein kinase-1 and -3.	Dual Specificity Protein Phosphatase 4		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11212>	C61063	Dronabinol/Megestrol|MEG/THC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112130>	C20745	MYH1 Gene|MYH1|MYH1|Myosin, Heavy Chain 1, Skeletal Muscle, Adult Gene	This gene plays a role in muscle contraction.	MYH1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C112131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112131>	C112130	MYH1 wt Allele|MGC133384|MHC IIx/d|MYH2X/D|MYHC IIx/d|MYHC2X/D|MYHSA1|MYHa|MyHC-2X/D|MyHC-2x|Myosin, Heavy Chain 1, Skeletal Muscle, Adult wt Allele|Myosin, Heavy Polypeptide 1, Skeletal Muscle, Adult Gene	Human MYH1 wild-type allele is located in the vicinity of 17p13.1 and is approximately 26 kb in length. This allele, which encodes myosin-1 protein, is involved in the contraction of skeletal muscles.	MYH1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112132>	C16492	Myosin-1|MyHC-2x|MyHC-IIx/D|Myosin Heavy Chain 1|Myosin Heavy Chain 2x|Myosin Heavy Chain IIx/D|Myosin Heavy Chain, Skeletal Muscle, Adult 1|Myosin, Heavy Chain, IIx/D|Myosin, Skeletal, Heavy Chain, Adult 1	Myosin-1 (1939 aa, ~223 kDa) is encoded by the human MYH1 gene. This protein plays a role in skeletal muscle contraction.	Myosin-1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112133>	C20745	MYH2 Gene|MYH2|MYH2|Myosin, Heavy Chain 2, Skeletal Muscle, Adult Gene	This gene is involved in skeletal muscle contraction.	MYH2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C112134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112134>	C112133	MYH2 wt Allele|MHC IIa|MYH2A|MYHC IIa|MYHC2A|MYHSA2|MYHas8|MyHC-2A|MyHC-IIa|Myosin, Heavy Chain 2, Skeletal Muscle, Adult wt Allele|Myosin, Heavy Polypeptide 2, Skeletal Muscle, Adult Gene	Human MYH2 wild-type allele is located in the vicinity of 17p13.1 and is approximately 85 kb in length. This allele, which encodes myosin-2 protein, plays a role in muscle contraction.	MYH2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112135>	C16492	Myosin-2|Fast 2a Myosin Heavy Chain|MyHC-2a|MyHC-IIa|Myosin Heavy Chain 2|Myosin Heavy Chain 2a|Myosin Heavy Chain IIa|Myosin Heavy Chain, Skeletal Muscle, Adult 2|Myosin, Heavy Chain, IIa|Myosin, Skeletal, Heavy Chain, Adult 2|Type IIA Myosin Heavy Chain	Myosin-2 (1941 aa, ~223 kDa) is encoded by the human MYH2 gene. This protein is involved in the contraction of skeletal muscles.	Myosin-2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112136>	C20988	L1CAM Gene|L1 Cell Adhesion Molecule Gene|L1CAM|L1CAM	This gene plays a role in the development of the nervous system.	L1CAM Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C112137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112137>	C112136	L1CAM wt Allele|Antigen Identified By Monoclonal Antibody R1 Gene|CAML1|CD171|HSAS|HSAS1|L1 Cell Adhesion Molecule wt Allele|L1-CAM|MASA|MIC5|N-CAM-L1|N-CAML1|NCAM-L1|S10|SPG1	Human L1CAM wild-type allele is located in the vicinity of Xq28 and is approximately 48 kb in length. This allele, which encodes neural cell adhesion molecule L1 protein, is involved in neuron-neuron cell adhesion, axon guidance and bundling of neurons. Mutation of the gene is associated with hydrocephalus due to stenosis of the aqueduct of Sylvius (HSAS), mental retardation, aphasia, shuffling gait, and adducted thumbs syndrome (MASA or CRASH syndrome), spastic paraplegia 1, X-linked and agenesis of the corpus callosum, X-linked, partial and may contribute to intestinal aganglionosis in Hirschsprung disease.	L1CAM wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112138>	C16393	Neural Cell Adhesion Molecule L1|CD171|CD171 Antigen|L1-CAM|L1CAM|N-CAM-L1|NCAM-L1	Neural cell adhesion molecule L1 (1257 aa, ~140 kDa) is encoded by the human L1CAM gene. This protein plays a role in neurogenesis.	Neural Cell Adhesion Molecule L1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112139>	C21295	TAPBP Gene|TAP Binding Protein (Tapasin) Gene|TAPBP|TAPBP	This gene is involved in antigen presentation.	TAPBP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C11213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11213>	C61063	Cisplatin/Doxorubicin/Edatrexate/Filgrastim/Vinblastine|CDDP/DOX/EDAM/G-CSF/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112140>	C112139	TAPBP wt Allele|DADB-159G18.7|NGS17|TAP Binding Protein (Tapasin) wt Allele|TAPA|TPN|TPSN	Human TAPBP wild-type allele is located in the vicinity of 6p21.3 and is approximately 15 kb in length. This allele, which encodes tapasin protein, plays a role in antigen presentation. Variation of the gene is associated with bare lymphocyte syndrome, type I.	TAPBP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112141>	C17728	Tapasin|NGS-17|TAP-Associated Protein|TAP-Binding Protein|TPN|TPSN	Tapasin (448 aa, ~48 kDa) is encoded by the human TAPBP gene. This protein is involved in activity of the MHC class I peptide-loading complex.	Tapasin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112142>	C21295	VASP Gene|VASP|VASP|Vasodilator-Stimulated Phosphoprotein Gene	This gene is involved in both cell adhesion and motility.	VASP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C112143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112143>	C112142	VASP wt Allele|Vasodilator-Stimulated Phosphoprotein wt Allele	Human VASP wild-type allele is located in the vicinity of 19q13.32 and is approximately 20 kb in length. This allele, which encodes vasodilator-stimulated phosphoprotein, plays a role in cell adhesion, motility, and regulation of platelet aggregation.	VASP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112144>	C17728	Vasodilator-Stimulated Phosphoprotein|VASP	Vasodilator-stimulated phosphoprotein (380 aa, ~40 kDa) is encoded by the human VASP gene. This protein is involved in both cell motility and cell adhesion.	Vasodilator-Stimulated Phosphoprotein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112145>	C20744	LORICRIN Gene|LOR|LOR Gene|LORICRIN|LORICRIN|Loricrin Cornified Envelope Precursor Protein Gene	This gene plays a role in the structure of keratinocyte cell envelopes.	LOR Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C112146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112146>	C112145	LORICRIN wt Allele|LOR|LOR wt Allele|LRN|Loricrin Cornified Envelope Precursor Protein wt Allele|Loricrin Gene	Human LORICRIN wild-type allele is located in the vicinity of 1q21.3 and is approximately 2 kb in length. This allele, which encodes loricrin protein, is involved in the cell envelope structure of mature keratinocytes. Mutations in this gene are associated with progressive symmetric erythrokeratoderma and Vohwinkel syndrome with ichthyosis.	LOR wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112147>	C18073	Loricrin|LOR|LORICRIN|Loricrin Cornified Envelope Precursor Protein	Loricrin (312 aa, 26 kDa) is encoded by the human LORICRIN gene. This protein plays a role in the cell envelope structure of terminally differentiated epidermal cells.	Loricrin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112148>	C20744	FLG Gene|FLG|FLG|Filaggrin Gene	This gene is involved in intermediate filament structure.	FLG Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C112149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112149>	C112148	FLG wt Allele|ATOD2|Filaggrin wt Allele	Human FLG wild-type allele is located in the vicinity of 1q21.3 and is approximately 23 kb in length. This allele, which encodes filaggrin protein, plays a role in promoting disulfide-bond formation in intermediate filaments. Mutations in this gene are associated with ichthyosis vulgaris and with susceptibility to atopic dermatitis type 2.	FLG wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11214>	C61063	Doxorubicin/PSC 833|DOX/PSC 833			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112150>	C18073	Filaggrin|Epidermal Filaggrin|FLG	Filaggrin (4061 aa, ~435 kDa) is encoded by the human FLG gene. This protein is involved in the structure of intermediate filaments.	Filaggrin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112151>	C30073	KRT10 Gene|KRT10|KRT10|Keratin 10 Gene	This gene plays a role in intermediate filament structure.	KRT10 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C112152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112152>	C112151	KRT10 wt Allele|BCIE|BIE|CK-10|CK10|EHK|Epidermolytic Hyperkeratosis Gene|K10|KPP|Keratin 10 wt Allele	Human KRT10 wild-type allele is located in the vicinity of 17q21 and is approximately 4 kb in length. This allele, which encodes keratin, type I cytoskeletal 10 protein, is involved in the intermediate filament structure of terminally differentiated epidermal cells. Mutations in this gene are associated with epidermolytic hyperkeratosis, ichthyosis with confetti, and cyclic ichthyosis with epidermolytic hyperkeratosis.	KRT10 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112153>	C20694	Keratin, Type I Cytoskeletal 10|Cytokeratin 10|Cytokeratin-10|KRT10|Keratin-10|Keratosis Palmaris Et Plantaris	Keratin, type I cytoskeletal 10 (584 aa, ~59 kDa) is encoded by the human KRT10 gene. This protein plays a role in the structure of intermediate filaments.	Keratin, Type I Cytoskeletal 10		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112154>	C26147	C1GALT1 Gene|C1GALT1|C1GALT1|Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine 3-beta-Galactosyltransferase, 1 Gene	This gene is involved in generation of the common core 1 O-glycan structure.	C1GALT1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C112155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112155>	C112154	C1GALT1 wt Allele|C1GALT|Core 1 Synthase, Glycoprotein-N-Acetylgalactosamine 3-beta-Galactosyltransferase, 1 wt Allele	Human C1GALT1 wild-type allele is located in the vicinity of 7p21.3 and is approximately 92 kb in length. This allele, which encodes glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 protein, plays a role in mucin-type O-glycan metabolism.	C1GALT1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112156>	C17434	Glycoprotein-N-Acetylgalactosamine 3-Beta-Galactosyltransferase 1|B3Gal-T8|Beta-1,3-Galactosyltransferase|C1GALT1|Core 1 Beta1,3-Galactosyltransferase 1|Core 1 Beta3-Gal-T|Core 1 Beta3-Gal-T1|Core 1 O-Glycan T-Synthase|Core 1 UDP-Galactose:N-Acetylgalactosamine-Alpha-R Beta 1,3-Galactosyltransferase 1|EC 2.4.1.122|T Synthase|T-Synthase	Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (363 aa, ~42 kDa) is encoded by the human C1GALT1 gene. This protein is involved in mucin-type O-glycan metabolism.	Glycoprotein-N-Acetylgalactosamine 3-Beta-Galactosyltransferase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112157>	C25802	C1GALT1C1 Gene|C1GALT1-Specific Chaperone 1 Gene|C1GALT1C1|C1GALT1C1	This gene plays a role as a chaperone in generation of the common core 1 O-glycan structure.	C1GALT1C1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C112158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112158>	C112157	C1GALT1C1 wt Allele|C1GALT1-Specific Chaperone 1 wt Allele|C1GALT2|C1Gal-T2|C38H2-L1|COSMC|MST143|TNPS	Human C1GALT1C1 wild-type allele is located in the vicinity of Xq24 and is approximately 4 kb in length. This allele, which encodes C1GALT1-specific chaperone 1 protein, plays a chaperone role in mucin-type O-glycan metabolism. Mutations in this gene are associated with somatic Tn polyagglutination syndrome.	C1GALT1C1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112159>	C17764	C1GALT1-Specific Chaperone 1|Beta 1,3-Galactosyltransferase 2|C1GALT1C1|C38H2-Like Protein 1|Core 1 Beta-3-Galactosyltransferase-Specific Molecular Chaperone|Core 1 Beta1,3-Galactosyltransferase 2|Core 1 Beta3-Gal-T2|Core 1 Beta3-Galactosyltransferase-Specific Molecular Chaperone	C1GALT1-specific chaperone 1 (318 aa, ~36 kDa) is encoded by the human C1GALT1C1 gene. This protein plays a chaperone role in mucin-type O-glycan metabolism.	C1GALT1-Specific Chaperone 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11215>	C61063	Cyclophosphamide/Melphalan/Mitoxantrone|CTX/DHAD/L-PAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112160>	C54695	Type 0: Not a Combination Product	A designation assigned when a product is not manufactured as a combination product.			Manufactured Object	FDA Structured Product Labeling Terminology|SPL Combination Product Type Terminology
C112161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112161>	C173925|C173603|C173398	Worst Severity Past Seven Days Insomnia Question|Over the past seven days what was the severity of your insomnia, including difficulty falling asleep, staying asleep, or waking up early, at its WORST|Worst Severity Past Seven Days Insomnia	A question about an individual's observation of the worst severity they have experienced related to insomnia over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C112162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112162>	C173604|C173603	Worst Severity Past Seven Days Vomiting Question|Over the past seven days what was the severity of your vomiting at its WORST|Worst Severity Past Seven Days Vomiting	A question about an individual's observation of the worst severity they have experienced related to vomiting over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C112163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112163>	C173603	Worst Severity Past Seven Days Palmar-Plantar Erythrodysthesia Question|In the past 7 days, what was the severity of your hand-foot syndrome at its worst|Over the past seven days what was the severity of your hand-foot syndrome at its WORST|What was the severity of your hand-foot syndrome at its worst|Worst Severity Hand-Foot Syndrome|Worst Severity Last Seven Days Hand-Foot Syndrome|Worst Severity Past Seven Days Hand-Foot Syndrome|Worst Severity Past Seven Days Palmar-Plantar Erythrodysthesia	A question about an individual's observation of the worst severity they have experienced related to hand-foot syndrome over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C112164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112164>	C173603	Worst Severity Past Seven Days Decreased Appetite Question|Over the past seven days what was the severity of your decreased appetite at its worst|Worst Severity Past Seven Days Decreased Appetite|Worst Severity Past Seven Days Loss of Appetite	A question about an individual's observation of the worst severity they have experienced related to decreased appetite over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C112165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112165>	C173603	Worst Severity Past Seven Days Mouth or Throat Sores Question|Over the past seven days what was the severity of your mouth or throat sores at their worst|Worst Severity Past Seven Days Mouth or Throat Sores	A question about an individual's observation of the worst severity they have experienced related to mouth or throat sores over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C112166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112166>	C173603|C173130	Worst Severity Past Seven Days Nausea Question|Over the past seven days what was the severity of your nausea at its worst|Worst Severity Past Seven Days Nausea	A question about an individual's observation of the worst severity they have experienced related to nausea over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C112167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112167>	C173925|C173787|C173584	Past Seven Days Insomnia Interfering with Usual or Daily Activities Question|Over the past seven days how much did insomnia, including difficulty falling asleep, staying asleep, or waking up early, INTERFERE with your usual or daily activities|Past Seven Days Insomnia Interfering with Usual or Daily Activities	A question about how much an individual's insomnia interfered with usual or daily activities over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C112168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112168>	C173787|C173737|C173584	Past Seven Days Palmar-Plantar Erythrodysthesia Interfering with Usual or Daily Activities Question|Over the past seven days how much did hand-foot syndrome INTERFERE with your usual or daily activities|Past Seven Days Hand-Foot Syndrome Interfering with Usual or Daily Activities|Past Seven Days Palmar-Plantar Erythrodysthesia Interfering with Usual or Daily Activities	A question about how much an individual's hand-foot syndrome interfered with usual or daily activities over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C112169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112169>	C173787|C173737|C173584	Past Seven Days Decreased Appetite Interfering with Usual or Daily Activities Question|Over the past seven days how much did decreased appetite INTERFERE with your usual or daily activities|Past Seven Days Decreased Appetite Interfering with Usual or Daily Activities|Past Seven Days Loss of Appetite Interfering with Usual or Daily Activities	A question about how much an individual's decreased appetite interfered with usual or daily activities over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C11216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11216>	C61063	Aminoglutethimide/Bicalutamide/Hydrocortisone|AGT/CDX/HC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112170>	C173737|C173604|C173358	Past Seven Days Frequency of Vomiting Question|Over the past seven days how often did you have vomiting|Past Seven Days Frequency of Vomiting	A question about an individual's frequency of vomiting over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C112171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112171>	C173936|C173737|C173358	Past Seven Days Frequency of Diarrhea Question|Over the past seven days how often did you have diarrhea|Past Seven Days Frequency of Diarrhea	A question about an individual's frequency of diarrhea over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C112172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112172>	C173737|C173358|C173130	Past Seven Days Frequency of Nausea Question|Over the past seven days how often did you have nausea|Past Seven Days Frequency of Nausea	A question about an individual's frequency of nausea over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C112173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112173>	C173737	Past Seven Days Rash Question|Over the past seven days did you have any rash|Past Seven Days Rash	A question about whether an individual had a rash over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C112174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112174>	C99062|C37921	Skin Bruise|Bruise|Bruise|Ecchymosis|Ecchymosis	Extravasation of blood into the subcutaneous space.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112175>	C36281	Angioedema	Rapid swelling of the deep layers of the skin due to transient vascular leakage of serous fluid.			Finding	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112176>	C3327	Blanching	Transient pallor of the skin caused by reduced blood flow to the affected region.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112177>	C1946|C129825	Zabadinostat|AZD 9468|AZD9468|CXD101|HDAC Inhibitor CXD101|Histone Deacetylase Inhibitor CXD101|ZABADINOSTAT	A novel histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Although the exact therapeutic mechanism of action for CXD101 is not known, oral administration of this agent should inhibit the catalytic activity of HDAC, which results in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling and an altered pattern of gene expression. HDAC, a family of enzymes upregulated in many tumor types, deacetylates chromatin-associated histone proteins.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C112178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112178>	C2124	Fluorine F 18 Galacto-RGD Peptide|18F-Galacto-RGD|Fluorine F 18 Glycosylated RGD Peptide|[18F]Galacto-RGD	A radiotracer composed of a cyclic Arg-Gly-Asp (RGD) peptide that is conjugated with galactose and radiolabeled with fluorine 18, for potential noninvasive positron emission tomography (PET) imaging of alphaVbeta3 integrin expression. Upon administration, the RGD moiety of the fluorine 18 galacto-RGD peptide selectively binds to alphaVbeta3 integrin. During PET imaging, alphaVbeta3-expressing tumor cells can be visualized and the degree of tumor angiogenesis can be determined. Use of a hydrophilic glycopeptide-based agent may increase retention in the blood and reduce clearance by the liver. This leads to both increased uptake of fluorine 18 galacto-RGD peptide by tumor cells and enhanced PET imaging efficiency, when compared to other agents that are constructed using lipophilic conjugates. AlphaVbeta3 integrin, a cell adhesion and signaling receptor, is upregulated in tumor vessel endothelial cells and has been associated with proliferation of tumor cells, tumor angiogenesis and metastasis.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C112179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112179>	C28676|C201933	Anti-CD19-CAR-CD3zeta-4-1BB-Expressing Allogenic Natural Killer Cells|Anti-CD19 Redirected NK Cells|Anti-CD19-CAR-CD3zeta-4-1BB-Expressing Allogenic NK Cells|Anti-CD19-CAR-CD3zeta-4-1BB-Expressing Donor NK Cells|Anti-CD19-CAR-CD3zeta-4-1BB-Expressing Donor Natural Killer Cells|Anti-CD19-CAR-CD3zeta-4-1BB-Expressing NK Cells|Anti-CD19-CAR-CD3zeta-4-1BB-Expressing Natural Killer Cells|NKCARCD19	Allogeneic natural killer (NK) cells transduced with an mRNA expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. NK cells from haploidentical donors are expanded in culture and electroporated with the CAR mRNA. Upon transfusion of the transduced cultured cells, CD19CAR-CD3zeta-4-1BB-expressing allogeneic NK cells bind to and induce selective cytotoxicity in CD19-expressing tumor cells. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19. Its inclusion may also increase antitumor activity, when compared to the inclusion of the CD3-zeta chain alone. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11217>	C61063	Aminoglutethimide/Hydrocortisone|AGT/HC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112180>	C26901	Acral Erythema|Erythema of the palms and/or soles	Reddening of the palmar and plantar regions of the body with occasional involvement of the distal extremities.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112181>	C35025	Tinea Infection|Tinea	A skin infection caused by a fungus.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Infectious Disease Terminology
C112182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112182>	C26901	Toxic Erythema of Chemotherapy	Painful red or purple patches, edematous plaques or blisters on the hands, feet, extremities or intertriginous regions; the onset can occur days to months after receiving chemotherapy.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112183>	C27604	Blepharitis	Inflammation of the eyelids near the eyelashes.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Infectious Disease Terminology
C112184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112184>	C91126	Have Pain Other Than Everyday Kind of Pain Question|Have Pain Other Than Everyday Kind of Pain|Have Pain Other Than Everyday Kind of Pain	A question about whether an individual has or had pain other than everyday kinds of pain.			Intellectual Product	Brief Pain Inventory Short Form Questionnaire
C112185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112185>	C173346	Pain at its Least Question|Pain at its Best|Pain at its Least|Pain at its Least	A question about an individual's pain at its least.			Intellectual Product	Brief Pain Inventory Short Form Questionnaire
C112186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112186>	C173346	Pain Right Now Question|Have Pain Right Now|Pain Right Now	A question about an individual's pain right now.			Intellectual Product	Brief Pain Inventory Short Form Questionnaire
C112187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112187>	C173812|C173346	Treatment or Medication Received for Pain Question|Pain Treatment or Medication Received|Treatment or Medication Received for Pain|Treatment or Medication Receiving for Pain	A question about which treatments or medications an individual is receiving or has received for pain.			Intellectual Product	Brief Pain Inventory Short Form Questionnaire
C112188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112188>	C173346	How Much Relief Received from Treatment or Medication Question|How Much Pain Relief Received from Treatment or Medication|How Much Relief Received from Treatment or Medication|How Much Relief Received from Treatment or Medication	A question about how much pain relief an individual is receiving or has received from treatment or medication.			Intellectual Product	Brief Pain Inventory Short Form Questionnaire
C112189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112189>	C34504	Bulbar Conjunctivitis|Episcleritis|Episcleritis	Inflammation of the thin layer of tissue lining the sclera of the eye characterized by redness in the white portion of the eye.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Rheumatology Terminology
C11218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11218>	C63358|C159458	Docetaxel/Doxorubicin Regimen|AT|AT|AT Regimen|Adriamycin-Taxotere Regimen|Adriamycin/Taxotere|DOX/TXT|Docetaxel and Doxorubicin (AT)|Docetaxel-Doxorubicin|Docetaxel/Doxorubicin|Doxorubicin-Docetaxel|Doxorubicin/Docetaxel|Doxorubicin/Docetaxel Regimen	A regimen consisting of doxorubicin and docetaxel that may be used in the treatment of breast cancer and anaplastic carcinoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C112190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112190>	C36281	Hidradenitis	Inflammation of the apocrine sweat glands, characterized by redness, itching, pain or swelling of the sweat glands, usually in the axillae or groin.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Infectious Disease Terminology
C112191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112191>	C176021|C173584|C173346	Pain Interferes with General Activity Question|Pain Interference with General Activity|Pain Interferes with General Activity	A question about whether a person's pain interferes or interfered with their general activities.			Intellectual Product	Brief Pain Inventory Short Form Questionnaire
C112192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112192>	C173584|C173346	Pain Interferes with Mood Question|Pain Interference with Mood|Pain Interferes with Mood	A question about whether a person has or had pain that interfered with their mood.			Intellectual Product	Brief Pain Inventory Short Form Questionnaire
C112193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112193>	C173584|C173346|C173135	Pain Interferes with Walking Ability Question|Pain Interference with Walking Ability|Pain Interferes with Walking Ability	A question about whether a person has or had pain that interfered with their ability to walk.			Intellectual Product	Brief Pain Inventory Short Form Questionnaire
C112194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112194>	C173584|C173346	Pain Interferes with Relations with Other People Question|Pain Interference with Relations with Other People|Pain Interferes with Relations with Other People	A question about whether a person has or had pain that interfered with their relationships with other people.			Intellectual Product	Brief Pain Inventory Short Form Questionnaire
C112195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112195>	C173925|C173584|C173346	Pain Interferes with Sleep Question|Pain Interference with Sleep|Pain Interferes with Sleep	A question about whether a person has or had pain that interfered with sleep.			Intellectual Product	Brief Pain Inventory Short Form Questionnaire
C112196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112196>	C173584|C173346	Pain Interferes with Enjoyment of Life Question|Pain Interference with Enjoyment of Life|Pain Interferes with Enjoyment of Life	A question about whether a person has or had pain that interfered with their enjoyment of life.			Intellectual Product	Brief Pain Inventory Short Form Questionnaire
C112197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112197>	C27651	Enanthem	An acute eruption of ulcerative lesions on the mucous membrane of the oropharynx.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112198>	C79545	Angular Cheilitis|Cheilosis|Cheilosis|Perleche|Perleche|Perlèche	Inflammation of the skin at the corners of the mouth characterized by redness, fissures or crusts.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112199>	C60925	Glossitis	Inflammation of the tongue.			Finding	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11219>	C61063	Cisplatin/Doxorubicin/Ifosfamide/Mitomycin|CDDP/DOX/IFF/MITO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1121>	C1946	HC-Toxin|Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl)|Cyclo(D-Pro-L-Ala-D-Ala-L-Aeo)	A host-specific toxin from the maize pathogen Cochliobolus carbonum.  An inhibitor of histone deacetylase, it is a cyclic tetrapeptide containing an epoxide alpha-amino acid.  Inhibition of histone deacetylase is sensitive to mercaptoethanol treatment.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C112200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112200>	C215371	Telogen Effluvium	A scalp hair loss condition characterized by excessive shedding of hair in the resting phase of growth, usually following a fever or major body stress.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112201>	C39594	Polymorphous Light Eruption	A red, edematous rash that occurs on areas of the skin with recent exposure to sunlight.			Finding	
C112202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112202>	C28193	Red Man Syndrome	An abrupt onset drug reaction characterized by a red rash that involves the face, neck, and upper torso.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112203>	C26819|C114354	Drug Induced Cutaneous Lupus Erythematosus	A reaction to a drug characterized by skin findings common to lupus including photosensitivity and butterfly rash; typically it resolves after drug discontinuation.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112204>	C112210	Drug Induced Cutaneous Vasculitis|Drug Induced Vasculitis|Drug Induced Vasculitis	A skin hypersensitivity reaction due to exposure to a pharmacologic substance that is characterized by raised purpuric lesions, red macules, hemorrhagic blisters and ulcerations.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112205>	C1742|C155727	Rogaratinib|4-((4-Amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo(2,1-f)(1,2,4)triazin-7-yl)methyl)piperazin-2-one|BAY-1163877|BAY1163877|ROGARATINIB	A pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. Rogaratinib inhibits the activities of FGFRs, which may result in the inhibition of both tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. FGFRs are a family of receptor tyrosine kinases, which may be upregulated in various tumor cell types and may be involved in tumor cell differentiation and proliferation, tumor angiogenesis, and tumor cell survival.	Rogaratinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C112206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112206>	C2023	Autologous Tumor Cell Proteoliposome Chronic Lymphocytic Leukemia Vaccine|Oncoquest-CLL Vaccine|Oncoquest-L Vaccine	An autologous chronic lymphocytic leukemia cancer vaccine consisting of patient-specific membrane proteins directly extracted from patient autologous tumor cells and incorporated into liposomes along with Interleukin 2 (IL-2) to produce membrane-patched proteoliposomes, with potential immunostimulating and antineoplastic activities. After subcutaneous injection of the autologous tumor cell proteoliposomes chronic lymphocytic leukemia vaccine, liposomes deliver the encapsulated tumor antigens into the cytosol of antigen presenting cells (APCs). Subsequently, the APCs process the antigens and present antigen-derived peptides to the immune system. This may enhance recognition of tumors by the immune system, and activate both cytotoxic CD8+ T cells and CD4+ helper T cells against tumor cells. IL-2 is incorporated into the vaccine to leverage its ability to expand activated T cells.			Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C112207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112207>	C1663	Bivalent HPV16/18 Therapeutic Cervical Cancer Vaccine|ProCervix	A bivalent human papillomavirus (HPV) therapeutic vaccine containing recombinant inactivated adenylate cyclase (CyaA) from Bordetella pertussis carrying a sequence encoding the E7 antigen of both HPV16 and 18, with potential immunostimulatory and antiviral properties. Upon administration of bivalent HPV16/18 therapeutic cervical cancer vaccine, the expressed proteins may activate cell-mediated immunity and induce both cytotoxic CD8+ T cells and CD4+ helper T cells against the target antigens HPV16-E7 and HPV18-E7, which leads to HPV viral clearance. Adenylate cyclase is a virulence factor of Bordetella pertussis. Its ability to bind to CD11b-expressing dendritic cells and deliver antigens directly to the cytosol allows the activation and induction of T-cell immunity. CyaA may also induce a B cell response.			Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C112208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112208>	C28193	Drug Hypersensitivity Syndrome|DHS|DRESS|DRESS|Drug Reaction with Eosinophilia and Systemic Symptoms|Drug Reaction with Eosinophilia and Systemic Symptoms	A potentially life-threatening hypersensitivity reaction to a pharmacologic substance that is characterized by rash, lymphadenopathy, fever, hematologic abnormalities and involvement of one or more internal organs.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112209>	C112208	Anticonvulsant Hypersensitivity Syndrome|Anti-Convulsant Hypersensitivity Syndrome	A form of drug hypersensitivity syndrome caused by anti-convulsants.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11220>	C61063	Cisplatin/Doxorubicin/Ifosfamide/Mitomycin/Sargramostim|CDDP/DOX/GM-CSF/IFF/MITO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112210>	C26912	Cutaneous Vasculitis	Inflammation of the blood vessel wall characterized by palpable purpura.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112211>	C112190	Neutrophilic Eccrine Hidradenitis	Painful red or pink edematous nodules most commonly found on the palmar and/or plantar regions.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112212>	C78494	Onycholysis	A nail condition characterized by spontaneous separation of a fingernail or toenail from its nail bed.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112213>	C95556	Onychodystrophy	Deformity or discoloration of a fingernail or toenail.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112214>	C78493	Onychomycosis|Tinea Unguium|Tinea Unguium	Fungal infection of a fingernail or toenail.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Infectious Disease Terminology
C112215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112215>	C95556	Paronychial Inflammation	Swelling and redness of the nail folds.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112216>	C36280	Pain Relief	A lessening of pain following an intervention.			Finding	
C112217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112217>	C49237	5-Hydroxyindoleacetic Acid Measurement|5-Hydroxyindoleacetate|5-Hydroxyindoleacetic Acid|5-Hydroxyindoleacetic Acid|5-Hydroxyindoleacetic Acid|IAA5OH	The determination of the amount of 5-hydroxyindoleacetic acid present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C112218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112218>	C103347	Absolute Change from Nadir in Sum of Diameter|ACNSD|Absolute Change Nadir in Sum of Diam|Absolute Change Nadir in Sum of Diam	The most recently recorded sum of diameters minus the lowest sum of diameters previously recorded.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C112219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112219>	C112286	Active Ghrelin Measurement|Active Ghrelin|Active Ghrelin|GHRELINA	The determination of the amount of active ghrelin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11221>	C61063	Doxorubicin/DPPE|DOX/DPPE			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112220>	C221406	Aggrecan Chondroitin Sulfate Epitope 846 Measurement|846-Epitope|Aggrecan Chondroitin Sulfate Epitope 846|Aggrecan Chondroitin Sulfate Epitope 846|CS-846|CS846|CSEPI846|Chondroitin Sulfate Epitope 846|Chondroitin Sulfate Proteoglycan 1 Epitope 846	The determination of the amount of aggrecan chondroitin sulfate epitope 846 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112221>	C209975|C15260	Allergen Skin Response Index Measurement|ASRINDEX|ASRINDEX|Allergen Skin Response Index|Allergen Skin Response Index|Allergen Skin Response Index	The ratio measurement of the allergen wheal size to the positive control wheal size in an allergen skin test.			Laboratory Procedure	CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Skin Response Test Code Terminology|CDISC SDTM Skin Response Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112222>	C209975|C15260	Allergen Skin Response Intensity Measurement|ASRINT|ASRINT|Allergen Skin Response Intensity|Allergen Skin Response Intensity|Allergen Skin Response Intensity	The semiquantitative assessment of the wheal-and-flare index that measures the intensity of the reaction.			Laboratory Procedure	CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Skin Response Test Code Terminology|CDISC SDTM Skin Response Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112223>	C112032	Amount Recovered Infinity Observed Normalized by Body Mass Index|Amt Rec Infinity Obs Norm by BMI|Amt Rec Infinity Obs Norm by BMI|RCAMIFOB	The cumulative amount recovered extrapolated to infinity, calculated using the observed value of the last non-zero concentration, divided by the body mass index.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112224>	C112032	Amount Recovered Infinity Observed Normalized by Surface Area|Amt Rec Infinity Obs Norm by SA|Amt Rec Infinity Obs Norm by SA|RCAMIFOS	The cumulative amount recovered extrapolated to infinity, calculated using the observed value of the last non-zero concentration, divided by the surface area.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112225>	C112032	Amount Recovered Infinity Observed Normalized by Weight|Amt Rec Infinity Obs Norm by WT|Amt Rec Infinity Obs Norm by WT|RCAMIFOW	The cumulative amount recovered extrapolated to infinity, calculated using the observed value of the last non-zero concentration, divided by the weight.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112226>	C112033	Amount Recovered Infinity Predicted Normalized by Body Mass Index|Amt Rec Infinity Pred Norm by BMI|Amt Rec Infinity Pred Norm by BMI|RCAMIFPB	The cumulative amount recovered extrapolated to infinity, calculated using the predicted value of the last non-zero concentration, divided by the body mass index.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112227>	C112033	Amount Recovered Infinity Predicted Normalized by Surface Area|Amt Rec Infinity Pred Norm by SA|Amt Rec Infinity Pred Norm by SA|RCAMIFPS	The cumulative amount recovered extrapolated to infinity, calculated using the predicted value of the last non-zero concentration, divided by the surface area.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112228>	C112033	Amount Recovered Infinity Predicted Normalized by Weight|Amt Rec Infinity Pred Norm by WT|Amt Rec Infinity Pred Norm by WT|RCAMIFPW	The cumulative amount recovered extrapolated to infinity, calculated using the predicted value of the last non-zero concentration, divided by the weight.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112229>	C14256	Aphthovirus|APHTHOVIRUS	A genus of non-enveloped, spherical viruses with T=pseudo3 icosahedral capsid, in the family Picornaviridae. The genome is composed of a linear, single-strand of positive sense, naked RNA. Aphthoviruses are found in cloven-hooved animals and cause foot-and-mouth disease in humans.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11222>	C61063	Dacarbazine/Doxorubicin/Ifosfamide/Vincristine|DOX/DTIC/IFF/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112230>	C14349	Arbovirus|ARBOVIRUS|Arthropod-borne Virus	A non-taxonomic grouping of viruses that are transmitted through an arthropod vector and replicate in a vertebrate host. These include a variety of species from the families Bunyaviridae, Flaviviridae and Reoviridae.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112231>	C14351	Astroviridae|ASTROVIRIDAE|Astrovirus	A family of non-enveloped, spherical-shaped, capsid-enclosed viruses. The virus is icosahedral in shape with characteristic star-like surface projections. The genome is composed of a linear, non-segmented single-strand of positive sense RNA. Astroviridae infect vertebrates and are a causative agent of gastroenteritis in humans.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112232>	C112030	Barmah Forest Virus|BARMAH FOREST VIRUS	A species of enveloped, spherical or pleomorphic viruses with a capsid with T=4 icosahedral symmetry in the Togaviridae family and Alphavirus genus. The genome is composed of single-stranded, positive-sense RNA. Barmah forest viruses are found in both vertebrates and invertebrates, and cause infectious arthritis, encephalitis, rashes and fever in humans. Barmah forest viruses are transmitted mainly via the bite of infected mosquitoes.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112233>	C19332	Breast Fed Indicator|BRFEDIND	An indication as to whether the subject was breast fed (received mother's milk) as an infant.			Organism Attribute	CDISC SDTM Subject Characteristic Test Code Terminology|CDISC SDTM Subject Characteristic Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112234>	C33300	Bulbospongiosus|Bulbocavernosus|MUSCLE, BULBOSPONGIOSUS	A superficial muscle located in the midline of the perineum and anterior to the anus. It covers the bulb of the penis in males and the vestibular bulb in females. The origin and insertion differs between males and females.			Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112235>	C17610	Capillary Blood|CAPILLARY BLOOD	A mixture of arterial blood, venous blood and interstitial fluid, which is found in the capillaries.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112236>	C81867	Chemokine (C-C Motif) Ligand 17 Measurement|ABCD-2|CCL17|Chemokine (C-C Motif) Ligand 17|Chemokine (C-C Motif) Ligand 17|SCYA17|TARC|Thymus and Activation Regulated Chemokine	The determination of the amount of chemokine (C-C Motif) ligand 17 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112237>	C81867	Chemokine (C-C Motif) Ligand 18 Measurement|AMAC-1|AMAC1|CCL18|CKB7|Chemokine (C-C Motif) Ligand 18|Chemokine (C-C Motif) Ligand 18|DC-CK1|DCCK1|MIP4|Macrophage inflammatory protein-4|PARC|Pulmonary and Activation-Regulated Chemokine|SCYA18	The determination of the amount of chemokine (C-C Motif) ligand 18 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112238>	C81867	Chemokine (C-X-C Motif) Ligand 10 Measurement|CXCL10|Chemokine (C-X-C Motif) Ligand 10|Chemokine (C-X-C Motif) Ligand 10|IP-10|Interferon Gamma-induced Protein 10|Interferon-inducible Protein-10|Small-inducible Cytokine B10	The determination of the amount of chemokine (C-X-C Motif) ligand 10 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112239>	C62662	Coagulation Index Measurement|CI|COAGIDX|Coagulation Index|Coagulation Index	A measurement of the efficiency of coagulation of a biological specimen. This is calculated by a mathematical formula that takes into account the R value, K value, angle and maximum amplitude of clot formation.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11223>	C61063	Dexamethasone/Doxorubicin/PSC 833/Vincristine|DM/DOX/PSC 833/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112240>	C112026	Colorado Tick Fever Virus|COLORADO TICK FEVER VIRUS|CTFV	A species of non-enveloped, spherical viruses with an icosahedral symmetry of triple capsid structure in the Reoviridae family and Coltivirus genus. The genome is composed of segmented, double-stranded RNA. Colorado tick fever viruses are found in adult wood ticks, humans and mammals, and cause Colorado tick fever in humans. Colorado tick fever viruses are transmitted mainly via the bite of infected Rocky Mountain wood ticks (Dermacentor andersoni).			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112241>	C48938	Count of Unspecified Cells|UNSPCE|UNSPCE|Unspecified Cells|Unspecified Cells|Unspecified Cells	The determination of the amount of unspecified cells, those not otherwise identified, present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112242>	C14203	Coxsackie A Virus|COXSACKIE A VIRUS|Coxsackie Virus A|Coxsackievirus A|Enterovirus A|Enterovirus EV-A|Human Coxsackievirus A|Human Enterovirus A	A species of non-enveloped, spherical viruses with a capsid with T=3 icosahedral symmetry in the Picornaviridae family and Enterovirus genus. The genome is composed of single-stranded, positive-sense RNA. Coxsackie A viruses are found in humans and cause hand, foot, and mouth disease, acute hemorrhagic conjunctivitis and herpangina via fecal-oral contamination.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112243>	C14203	Coxsackie B Virus|COXSACKIE B VIRUS|Coxsackie Virus B|Enterovirus B|Enterovirus EV-B|Human Enterovirus B	A species of non-enveloped, spherical viruses with a capsid with T=3 icosahedral symmetry in the Picornaviridae family and Enterovirus genus. The genome is composed of single-stranded, positive-sense RNA. Coxsackie B viruses are found in humans and cause aseptic meningitis, Bornholm disease, arrhythmias and heart failure via fecal-oral contamination.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112244>	C92571	Day Times Femtogram Per Milliliter Per Gram|Day Times Picogram Per Milliliter Per Kilogram|d.fg/mL/g|d.fg/mL/g|d.fg/ml/g|d.fg/ml/g|d.pg/mL/kg|d.pg/mL/kg|d.pg/ml/kg|d.pg/ml/kg|day*fg/mL/g|day*fg/mL/g|day*fg/mL/g|day*pg/mL/kg|day*pg/mL/kg	Days times femtograms per milliliter, divided by grams.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112245>	C92571	Day Times Femtogram Per Milliliter Per Kilogram|d.fg/mL/kg|d.fg/mL/kg|d.fg/ml/kg|d.fg/ml/kg|day*fg/mL/kg	Days times femtograms per milliliter, divided by kilograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112246>	C92571	Day Times Gram Per Milliliter Per Gram|d.g/mL/g|d.g/mL/g|d.g/ml/g|d.g/ml/g|day*g/mL/g|day*g/mL/g	Days times grams per milliliter, divided by grams.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112247>	C92571	Day Times Gram Per Milliliter Per Kilogram|Day Times Milligram Per Milliliter Per Gram|d.g/mL/kg|d.g/mL/kg|d.g/ml/kg|d.g/ml/kg|d.mg/mL/g|d.mg/mL/g|d.mg/ml/g|d.mg/ml/g|d.ng/mL/ug|d.ng/mL/ug|d.ng/ml/ug|d.ng/ml/ug|d.ug/mL/mg|d.ug/mL/mg|d.ug/ml/mg|d.ug/ml/mg|day*g/mL/kg|day*g/mL/kg|day*g/mL/kg|day*mg/mL/g|day*mg/mL/g|day*ng/mL/ug|day*ng/mL/ug|day*ug/mL/mg|day*ug/mL/mg	Days times grams per milliliter, divided by kilograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112248>	C92571	Day Times Microgram Per Milliliter Per Gram|Day Times Milligram Per Milliliter Per Kilogram|d.mg/mL/kg|d.mg/mL/kg|d.mg/ml/kg|d.mg/ml/kg|d.ug/mL/g|d.ug/mL/g|d.ug/ml/g|d.ug/ml/g|day*mg/mL/kg|day*mg/mL/kg|day*ug/mL/g|day*ug/mL/g|day*ug/mL/g	Days times micrograms per milliliter, divided by grams.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112249>	C92571	Day Times Microgram Per Milliliter Per Kilogram|Day Times Nanogram Per Milliliter Per Gram|d.ng/mL/g|d.ng/mL/g|d.ng/ml/g|d.ng/ml/g|d.ug/mL/kg|d.ug/mL/kg|d.ug/ml/kg|d.ug/ml/kg|day*ng/mL/g|day*ng/mL/g|day*ug/mL/kg|day*ug/mL/kg|day*ug/mL/kg	Days times micrograms per milliliter, divided by kilograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11224>	C61007	Cyclosporine/Methotrexate/Sirolimus|CYSP/MTX/sirolimus			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112250>	C92571	Day Times Micromole Per Liter Per Gram|Day Times Millimole Per Liter Per Kilogram|d.mmol/L/kg|d.mmol/L/kg|d.mmol/l/kg|d.mmol/l/kg|d.umol/L/g|d.umol/L/g|d.umol/l/g|d.umol/l/g|day*mmol/L/kg|day*mmol/L/kg|day*umol/L/g|day*umol/L/g|day*umol/L/g	Days times micromoles per liter, divided by grams.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112251>	C92571	Day Times Micromole Per Liter Per Kilogram|Day Times Nanomole Per Liter Per Gram|d.nmol/L/g|d.nmol/L/g|d.nmol/l/g|d.nmol/l/g|d.umol/L/kg|d.umol/L/kg|d.umol/l/kg|d.umol/l/kg|day*nmol/L/g|day*nmol/L/g|day*umol/L/kg|day*umol/L/kg|day*umol/L/kg	Days times micromoles per liter, divided by kilograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112254>	C92571	Day Times Millimole Per Liter Per Gram|Day Times Mole Per Liter Per Kilogram|d.mmol/L/g|d.mmol/L/g|d.mmol/l/g|d.mmol/l/g|d.mol/L/kg|d.mol/L/kg|d.mol/l/kg|d.mol/l/kg|day*mmol/L/g|day*mmol/L/g|day*mmol/L/g|day*mol/L/kg|day*mol/L/kg	Days times millimoles per liter, divided by grams.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112256>	C92571	Day Times Mole Per Liter Per Gram|d.mol/L/g|d.mol/L/g|d.mol/l/g|d.mol/l/g|day*mol/L/g|day*mol/L/g	Days times moles per liter, divided by grams.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112259>	C92571	Day Times Nanogram Per Milliliter Per Kilogram|Day Times Picogram Per Milliliter Per Gram|d.ng/mL/kg|d.ng/mL/kg|d.ng/ml/kg|d.ng/ml/kg|d.pg/mL/g|d.pg/mL/g|d.pg/ml/g|d.pg/ml/g|day*ng/mL/kg|day*ng/mL/kg|day*ng/mL/kg|day*pg/mL/g|day*pg/mL/g	Days times nanograms per milliliter, divided by kilograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11225>	C61007	Interferon Gamma/Interleukin-1-Beta/Interleukin-2/Sargramostim/Tumor Necrosis Factor|GM-CSF/IFN-G/IL-1B/IL-2/TNF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112261>	C92571	Day Times Nanomole Per Liter Per Kilogram|Day Times Picomole Per Liter Per Gram|d.nmol/L/kg|d.nmol/L/kg|d.nmol/l/kg|d.nmol/l/kg|d.pmol/L/g|d.pmol/L/g|d.pmol/l/g|d.pmol/l/g|day*nmol/L/kg|day*nmol/L/kg|day*nmol/L/kg|day*pmol/L/g|day*pmol/L/g	Days times nanomoles per liter, divided by kilograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112265>	C92571	Day Times Picomole Per Liter Per Kilogram|d.pmol/L/kg|d.pmol/L/kg|d.pmol/l/kg|d.pmol/l/kg|day*pmol/L/kg|day*pmol/L/kg	Days times picomoles per liter, divided by kilograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112266>	C112036	Dengue Virus 1|DEN-1|DENGUE VIRUS 1|DENV-1|Dengue Virus Type 1	The serotype labeled 1 of the viral species Dengue virus, which is a single-stranded, positive-sense RNA virus of the Flaviviridae family and Flavivirus genus, and causes dengue fever.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112267>	C112036	Dengue Virus 2|DEN-2|DENGUE VIRUS 2|DENV-2|Dengue Virus Type 2	The serotype labeled 2 of the viral species Dengue virus, which is a single-stranded, positive-sense RNA virus of the Flaviviridae family and Flavivirus genus, and causes dengue fever.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112268>	C112036	Dengue Virus 3|DEN-3|DENGUE VIRUS 3|DENV-3|Dengue Virus Type 3	The serotype labeled 3 of the viral species Dengue virus, which is a single-stranded, positive-sense RNA virus of the Flaviviridae family and Flavivirus genus, and causes dengue fever.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112269>	C112036	Dengue Virus 4|DEN-4|DENGUE VIRUS 4|DENV-4|Dengue Virus Type 4	The serotype labeled 4 of the viral species Dengue virus, which is a single-stranded, positive-sense RNA virus of the Flaviviridae family and Flavivirus genus, and causes dengue fever.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11226>	C61007	Cyclophosphamide/Indomethacin/Zinc Sulfate|CTX/indomethacin/zinc sulfate			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112270>	C160943	Destroyed Medical Device	A finding referring to a medical device that has been demolished.			Finding	
C112271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112271>	C112031	Ebola Virus|EBOLA VIRUS|EBOV	A genus of filamentous, enveloped viruses with glycoprotein surface spikes, in the family Filoviridae. The genome is composed of a linear single-strand of negative sense RNA. The primary product of gene transcription of the fourth gene is a small glycoprotein (sGP), while RNA editing allows expression of full length glycoprotein. The Ebolavirus natural reservoir is considered to be fruit bats of the Pteropodidae family and cause severe hemorrhagic fevers in humans.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112272>	C14203	Echovirus|ECHOVIRUS	A species of non-enveloped, spherical and icosahedral viruses in the Picornaviridae family and Enterovirus genus. The genome is composed of single-stranded, positive-sense RNA. Echoviruses are found in humans and cause aseptic meningitis, encephalitis, paralysis and myocarditis via direct fecal-oral contamination, respiration and oral secretions, or indirect routes.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112273>	C64430	Epidermal Growth Factor Receptor Measurement|EGFR|EGFR|ERBB1|Epidermal Growth Factor Receptor|Epidermal Growth Factor Receptor|Epidermal Growth Factor Receptor|HER1	The determination of the amount of epidermal growth factor receptor present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112274>	C64430	Estrogen Receptor Measurement|ER|ESR|ESTRCPT|ESTRCPT|Estrogen Receptor|Estrogen Receptor|Estrogen Receptor|Oestrogen Receptor	The determination of the amount of estrogen receptor present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112275>	C134576	Experimental Organism Benign Polyp|POLYP, BENIGN	A benign polypoid neoplasm of an epithelial lining projecting into a lumen or cavity. (CDISC)			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C112276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112276>	C134576	Experimental Organism Benign Seminoma|SEMINOMA, BENIGN	A benign germ cell neoplasm of the testis. (CDISC)			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C112277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112277>	C92745|C62662	Factor XIII Measurement|FACTXIII|Factor XIII|Factor XIII|Fibrin Stabilizing Factor	The determination of the amount of factor XIII present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112278>	C25161	FDA Device Classification|FDADEVCL	The class of medical device as determined by the US Food and Drug Administration, based upon the level of control necessary to ensure safety and effectiveness (21 CFR 860).			Classification	CDISC SDTM Device Properties Test Code Terminology|CDISC SDTM Device Properties Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112279>	C155868	FDA Unique Device Identifier|FDA Unique Device Identification|FDA Unique Device Identification|FDA Unique Device Identification|FDAUDI	A unique numeric or alphanumeric code that contains the device identifier and a production identifier such as the lot or batch number, the serial number and/or expiration date.			Intellectual Product	CDISC DDF Medical Device Identifier Type Value Set Terminology|CDISC DDF Terminology|CDISC SDTM Device Identifier Parameter Long Name Terminology|CDISC SDTM Device Identifier Parameter Short Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11227>	C61063	Cisplatin/Hydroxyurea/Vinblastine|CDDP/HU/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112280>	C64430	Fibroblast Growth Factor 21 Measurement|FGF 21|FGF21|Fibroblast Growth Factor 21|Fibroblast Growth Factor 21	The determination of the amount of fibroblast growth factor 21 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112281>	C209975|C15260	Antigenic Skin Flare Longest Diameter Measurement|FLRLDIAM|FLRLDIAM|FLRLDIAM|Flare Longest Diameter|Flare Longest Diameter|Flare Longest Diameter|Flare Longest Diameter|Flare Longest Diameter Measurement	The determination of the longest diameter for the area of redness that forms around the site of an antigenic challenge to the skin.			Laboratory Procedure	CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Skin Response Test Code Terminology|CDISC SDTM Skin Response Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Skin Test Code Terminology|CDISC SEND Skin Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112282>	C209975|C15260	Antigenic Skin Flare Mean Diameter Measurement|FLRMDIAM|FLRMDIAM|Flare Mean Diameter|Flare Mean Diameter|Flare Mean Diameter|Flare Mean Diameter Measurement	The determination of the mean diameter for the area of redness that forms around the site of an antigenic challenge to the skin.			Quantitative Concept	CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Skin Response Test Code Terminology|CDISC SDTM Skin Response Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112283>	C209975|C15260	Antigenic Skin Flare Size Measurement|FLARESZ|FLARESZ|Flare Size|Flare Size|Flare Size|Flare Size Measurement	The determination of the size of the area of redness that forms around the site of an antigenic challenge to the skin.			Laboratory Procedure	CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Skin Response Test Code Terminology|CDISC SDTM Skin Response Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112284>	C65109	Flow Microscopy|FLOW MICROSCOPY	A method of measuring the number of cells in a sample by placing the cells in a fluid and passing them, in a stream, through a special light microscope that can record and analyze images of the cells (presence of foreign particles, cell counts, protein aggregates, morphology information).			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112285>	C38081	Forced Expiratory Volume in 1 Second Reversibility|FEV1 Reversibility|FEV1 Reversibility|FEV1 Reversibility|FEV1REV	The change in FEV1 following administration of a bronchodilator relative to the pre-treatment FEV1 value. (CDISC)			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112286>	C75385	Ghrelin Measurement|GHRELIN|Ghrelin|Ghrelin|Growth Hormone Secretagogue Receptor Ligand|Motilin-related Peptide|Total Ghrelin	The determination of the amount of ghrelin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112287>	C74972	Hemodialysis Clearance|HDCL	The rate at which a substance is removed from the blood via hemodialysis.			Laboratory Procedure	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112288>	C64848	Hemoglobin C Crystals Measurement|CYHGBC|Hemoglobin C Crystals|Hemoglobin C Crystals	The determination of the amount of hemoglobin c crystals present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112289>	C112290	Hendra Virus|HENDRA VIRUS	A species of enveloped and pleomorphic viruses in the Paramyxoviridae family and Henipavirus genus. The genome is composed of non-segmented, negative-sense, single-stranded RNA. Hendra viruses are found naturally in Pteropid fruit bats, and are zoonotic pathogens in domestic animals (mainly in horses) and humans. Hendra viruses cause respiratory diseases, meningitis and fatal encephalitis in humans.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11228>	C61063	Cisplatin/Etoposide/Hydroxyurea|CDDP/HU/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112290>	C14307	Henipavirus|HENIPAVIRUS	A genus of enveloped, pleomorphically spherical viruses in the family Paramyxoviridae. The genome is composed of a linear single-strand of negative sense RNA. The Henipavirus natural reservoir is considered to be fruit bats of the Pteropodidae family and cause influenza-like illness in humans.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112291>	C112312	Soluble HER2 Antigen Measurement|HER2 Antigen|HER2/NEU Antigen|HER2/NEU Shed Antigen|HER2S|Soluble HER2|Soluble HER2|Soluble HER2/NEU	The determination of the amount of soluble HER2 antigen, including peptides, epitopes, and receptor, present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112292>	C210012|C210010	Herpes Simplex Virus 6 Antibody Measurement	The determination of the amount of herpes simplex virus 6 antibody present in a sample.			Laboratory Procedure	
C112293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112293>	C111209	Histone 1 Antibody Measurement	The determination of the amount of histone 1 antibody present in a sample.			Laboratory Procedure	
C112294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112294>	C111209	Histone 2A Antibody Measurement	The determination of the amount of histone 2a antibody present in a sample.			Laboratory Procedure	
C112295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112295>	C111209	Histone 2B Antibody Measurement	The determination of the amount of histone 2b antibody present in a sample.			Laboratory Procedure	
C112296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112296>	C111209	Histone 3 Antibody Measurement	The determination of the amount of histone 3 antibody present in a sample.			Laboratory Procedure	
C112297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112297>	C111209	Histone 4 Antibody Measurement	The determination of the amount of histone 4 antibody present in a sample.			Laboratory Procedure	
C112299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112299>	C92571	Hour Times Femtogram Per Milliliter Per Kilogram|h*fg/mL/kg|h.fg/mL/kg|h.fg/mL/kg|h.fg/ml/kg|h.fg/ml/kg	Hours times femtograms per milliliter, divided by kilograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11229>	C61063	Cisplatin/Hydroxyurea/Vinorelbine|CDDP/HU/VNB			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1122>	C530	Recombinant Hepatocyte Growth Factor|HEPATOPOIETIN-A|HGF|HGF/SF|Hepatopoietin|Scatter Factor	A recombinant therapeutic agent which is chemically identical to or similar to the endogenous glycoprotein cytokine hepatocyte growth factor (HGF), which is produced by the liver and the pancreas.  Endogenous HGF synthesis is stimulated by injuries affecting liver tissues.  This agent, a potent angiogenic and neurotrophic factor and a multifunctional cytokine that acts as a mitogen, motogen and a morphogen, is important for organogenesis and tissue regeneration.  Therapeutic HGF has been shown to attenuate brain ischemic injury in animal models through angiogenic and neuroprotective actions. (NCI04)			Chemical Viewed Functionally	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C112300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112300>	C92571	Hour Times Gram Per Milliliter Per Gram|h*g/mL/g|h*g/mL/g|h.g/mL/g|h.g/mL/g|h.g/ml/g|h.g/ml/g	Hours times grams per milliliter, divided by grams.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112304>	C92571	Hour Times Micromole Per Liter Per Kilogram|Hour Times Nanomole per Liter per Gram|h*nmol/L/g|h*nmol/L/g|h*nmol/L/g|h*umol/L/kg|h*umol/L/kg|h*umol/L/kg|h.nmol/L/g|h.nmol/L/g|h.nmol/l/g|h.nmol/l/g|h.umol/L/kg|h.umol/L/kg|h.umol/l/kg|h.umol/l/kg	Hours times micromoles per liter, divided by kilograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112307>	C92571	Hour Times Millimole Per Liter Per Kilogram|Hour Times Micromole per liter per Gram|h*mmol/L/kg|h*mmol/L/kg|h*mmol/L/kg|h*nmol/L/mg|h*nmol/L/mg|h*pmol/L/ug|h*pmol/L/ug|h*umol/L/g|h*umol/L/g|h*umol/L/g|h.mmol/L/kg|h.mmol/L/kg|h.mmol/l/kg|h.mmol/l/kg|h.nmol/L/mg|h.nmol/L/mg|h.nmol/l/mg|h.nmol/l/mg|h.pmol/L/ug|h.pmol/L/ug|h.pmol/l/ug|h.pmol/l/ug|h.umol/L/g|h.umol/L/g|h.umol/l/g|h.umol/l/g	Hours times millimoles per liter, divided by kilograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11230>	C61063	Cisplatin/Hydroxyurea/Vindesine|CDDP/DAVA/HU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112311>	C92571	Hour Times Picomole Per Liter Per Kilogram|h*pmol/L/kg|h*pmol/L/kg|h.pmol/L/kg|h.pmol/L/kg|h.pmol/l/kg|h.pmol/l/kg	Hours times picomoles per liter, divided by kilograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112312>	C64430	Human Epidermal Growth Factor Receptor 2 Measurement|ERBB2|ErbB-2|HER2|HER2|HER2/NEU|Human Epidermal Growth Factor Receptor 2|Human Epidermal Growth Factor Receptor 2|Human Epidermal Growth Factor Receptor 2|Receptor Tyrosine-Protein Kinase erbB-2 Measurement	The determination of the amount of human epidermal growth factor receptor 2 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112313>	C112419	Human Herpesvirus 2|HERPES SIMPLEX VIRUS 2|HHV-2|HSV-2|Herpes Simplex Virus 2|Herpes Simplex Virus Type 2|Human Alphaherpesvirus 2|Human alphaherpesvirus 2	A species of enveloped and spherical viruses with a capsid with T=16 icosahedral symmetry and surrounded by amorphous tegument, in the Herpesviridae family and Simplexvirus genus. The genome is composed of monopartite, linear double-stranded DNA. Human herpesvirus 2 is found in humans and causes genital herpes in the form of watery blisters. Human herpesvirus 2 is transmitted mainly via direct sexual contact.	Human Herpesvirus 2		Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C112314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112314>	C14196	Human Herpesvirus 5|HCMV|HCMV|HHV-5|HHV-5|HUMAN CYTOMEGALOVIRUS|HUMAN HERPESVIRUS 5|Human Betaherpesvirus 5|Human Cytomegalovirus	A species of enveloped and spherical viruses with a capsid with T=16 icosahedral symmetry and surrounded by amorphous tegument, in the Herpesviridae family and Cytomegalovirus genus. The genome is composed of monopartite, linear double-stranded DNA. Human herpesvirus 5 is found in humans and causes mononucleosis-like symptoms in healthy individuals and pneumonia, hepatitis, encephalitis, myelitis, colitis, retinitis, neuropathy, mucoepidermoid carcinoma as well as other malignancies in immunocompromised persons, organ transplant recipients and newborn infants. Human herpesvirus 5 is transmitted congenitally or via direct person-to-person contact.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112315>	C112410	Human Herpesvirus 7|HHV-7|HUMAN HERPESVIRUS 7|Herpes Simplex Virus 7|Herpes Virus 7|Human Betaherpesvirus 7	A species of enveloped and spherical viruses with a capsid with T=16 icosahedral symmetry and surrounded by amorphous tegument, in the Herpesviridae family and Roseolovirus genus. The genome is composed of monopartite, linear double-stranded DNA. Human herpesvirus 7 is found in humans and causes exanthema subitum in infants. Human herpesvirus 7 is transmitted via direct person-to-person contact.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112316>	C14326|C125641	Human Parainfluenza Virus 2|HPIV-2|HUMAN PARAINFLUENZA VIRUS 2|Human Parainfluenza Virus Type 2|Human Rubulavirus 2|Human orthorubulavirus 2	The serotype labeled 2 of the viral species Human parainfluenza virus, which is a single-stranded, negative-sense RNA virus of the Paramyxoviridae family and Rubulavirus genus, and causes croup and respiratory infections in humans.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112317>	C125641|C117721	Human Parainfluenza Virus 3|HPIV-3|HUMAN PARAINFLUENZA VIRUS 3|Human Parainfluenza Virus Type 3|Human Respirovirus 3	The serotype labeled 3 of the viral species Human parainfluenza virus, which is a single-stranded, negative-sense RNA virus of the Paramyxoviridae family and Respirovirus genus, and causes croup and respiratory infections in humans.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112318>	C14326|C125641	Human Parainfluenza Virus 4|HPIV Type 4|HPIV-4|HUMAN PARAINFLUENZA VIRUS 4|Human Parainfluenza Virus Type 4|Human Rubulavirus 4|Human orthorubulavirus 4	The serotype labeled 4 of the viral species Human parainfluenza virus, which is a single-stranded, negative-sense RNA virus of the Paramyxoviridae family and Rubulavirus genus, and causes bronchiolitis and pneumonia in humans.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112319>	C49237	Hyaluronic Acid Measurement|HYALUAC|Hyaluronic Acid|Hyaluronic Acid	The determination of the amount of hyaluronic acid present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11231>	C61063	Cisplatin/Hydroxyurea|CDDP/HU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112320>	C49556	Immunogenicity Specimen Assessments Domain|IS|Immunogenicity Specimen Assessments	A findings about domain for submitting dermal responses to antigens.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|CDISC SEND Domain Abbreviation Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112321>	C38081	Inspiratory Capacity Reversibility|IC Reversibility|IC Reversibility|IC Reversibility|ICREV	The change in IC following administration of a bronchodilator relative to the pre-treatment IC value. (CDISC)			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112322>	C165773	Insulin-Like Growth Factor Binding Protein 3 Measurement|IGFBP3|Insulin-Like Growth Factor Binding Prot3|Insulin-Like Growth Factor Binding Prot3|Insulin-Like Growth Factor Binding Protein 3	The determination of the amount of insulin-like growth factor binding protein 3 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112323>	C74805	Interleukin 1 Beta Measurement|IL-1B|IL1Beta|INTLK1B|Interleukin 1 Beta|Interleukin 1 Beta|Interleukin 1B	The determination of the amount of interleukin 1 beta present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112324>	C74804	Interleukin 1 Receptor Antagonist Measurement|IL-1RA|INTLK1RA|Interleukin 1 Receptor Antagonist|Interleukin 1 Receptor Antagonist	The determination of the amount of interleukin 1 receptor antagonist present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112325>	C74949	Intermediate Density Lipoprotein Cholesterol Measurement|IDL|IDL Cholesterol|IDL Cholesterol|Intermediate Density Lipoprotein	The determination of the amount of intermediate density lipoprotein present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112326>	C210012|C210010	JC Virus Antibody Measurement	The determination of the amount of JC Virus antibody present in a sample.			Laboratory Procedure	
C112327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112327>	C33904	L2-L3 Intervertebral Space|L2-L3 INTERVERTEBRAL SPACE	The space between the L2 and L3 vertebrae.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112328>	C33904	L3-L4 Intervertebral Space|L3-L4 INTERVERTEBRAL SPACE	The space between the L3 and L4 vertebrae.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112329>	C160943	Lost Medical Device|LOST	A finding referring to a medical device that is no longer held or possessed; incapable of being recovered or regained.			Finding	CDISC SDTM Device Tracking and Disposition Event Dictionary Derived Term Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11232>	C61063	Carboplatin/Epirubicin/Vincristine|CBDCA/EPI/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112330>	C112027	Lyssavirus|LYSSAVIRUS	A genus of enveloped, bullet or cylindrical shaped viruses in the family Rhabdoviridae. The genome is composed of a linear single-strand of negative sense RNA. Lyssavirus species 1 can be carried by any warm-blooded mammal while species 2-7 have specific hosts. Species in the genus Lyssavirus cause Rabies in humans.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112331>	C112031	Marburgvirus|MARBURGVIRUS	A genus of filamentous, enveloped viruses with glycoprotein surface spikes, in the family Filoviridae. The genome is composed of a linear single-strand of negative sense RNA. The primary product of the fourth gene is the GP1,2 glycoprotein, which does not require cotranscriptional editing. Marburgviruses humans and primates and cause hemorrhagic fevers in humans.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112332>	C25681	Material Pore Size|PORESIZE|Pore Size|Pore Size|Pore Size	A quantitative or qualitative measurement of the physical dimensions of the pores in a material.			Quantitative Concept	CDISC SDTM Device Properties Test Code Terminology|CDISC SDTM Device Properties Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA CDRH GUDID Terminology
C112333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112333>	C38081	Maximum Forced Inspiratory Flow|FIFMAX|FIFmax	Forced inspiratory flow for a portion of the FVC curve at the point where the maximum portion of FVC is already inhaled. (CDISC)			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112334>	C92571	Minute Times Femtogram Per Milliliter Per Gram|Minute Times Picogram Per Milliliter Per Kilogram|min*fg/mL/g|min*fg/mL/g|min*fg/mL/g|min*pg/mL/kg|min*pg/mL/kg|min.fg/mL/g|min.fg/mL/g|min.fg/ml/g|min.fg/ml/g|min.pg/mL/kg|min.pg/mL/kg|min.pg/ml/kg|min.pg/ml/kg	Minutes times femtograms per milliliter, divided by grams.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112335>	C92571	Minute Times Femtogram Per Milliliter Per Kilogram|min*fg/mL/kg|min.fg/mL/kg|min.fg/mL/kg|min.fg/ml/kg|min.fg/ml/kg	Minutes times femtograms per milliliter, divided by kilograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112336>	C92571	Minute Times Gram Per Milliliter Per Gram|min*g/mL/g|min*g/mL/g|min.g/mL/g|min.g/mL/g|min.g/ml/g|min.g/ml/g	Minutes times grams per milliliter, divided by grams.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112337>	C92571	Minute Times Gram Per Milliliter Per Kilogram|Minute Times Milligram Per Milliliter Per Gram|min*g/mL/kg|min*g/mL/kg|min*g/mL/kg|min*mg/mL/g|min*mg/mL/g|min.g/mL/kg|min.g/mL/kg|min.g/ml/kg|min.g/ml/kg|min.mg/mL/g|min.mg/mL/g|min.mg/ml/g|min.mg/ml/g	Minutes times grams per milliliter, divided by kilograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112338>	C92571	Minute Times Microgram Per Milliliter Per Gram|Minute Times Milligram Per Milliliter Per Kilogram|min*mg/mL/kg|min*mg/mL/kg|min*ug/mL/g|min*ug/mL/g|min*ug/mL/g|min.mg/mL/kg|min.mg/mL/kg|min.mg/ml/kg|min.mg/ml/kg|min.ug/mL/g|min.ug/mL/g|min.ug/ml/g|min.ug/ml/g	Minutes times micrograms per milliliter, divided by grams.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112339>	C92571	Minute Times Microgram Per Milliliter Per Kilogram|Minute Times Nanogram Per Milliliter Per Gram|min*ng/mL/g|min*ng/mL/g|min*ug/mL/kg|min*ug/mL/kg|min*ug/mL/kg|min.ng/mL/g|min.ng/mL/g|min.ng/ml/g|min.ng/ml/g|min.ug/mL/kg|min.ug/mL/kg|min.ug/ml/kg|min.ug/ml/kg	Minutes times micrograms per milliliter, divided by kilograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11233>	C1663	gp100 Antigen/MART-1 Antigen|gp100/MART-1				Pharmacologic Substance	
C112340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112340>	C92571	Minute Times Micromole Per Liter Per Gram|Minute Times Millimole Per Liter Per Kilogram|min*mmol/L/kg|min*mmol/L/kg|min*umol/L/g|min*umol/L/g|min*umol/L/g|min.mmol/L/kg|min.mmol/L/kg|min.mmol/l/kg|min.mmol/l/kg|min.umol/L/g|min.umol/L/g|min.umol/l/g|min.umol/l/g	Minutes times micromoles per liter, divided by grams.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112341>	C92571	Minute Times Micromole Per Liter Per Kilogram|Minute Times Nanomole Per Liter Per Gram|min*nmol/L/g|min*nmol/L/g|min*umol/L/kg|min*umol/L/kg|min*umol/L/kg|min.nmol/L/g|min.nmol/L/g|min.nmol/l/g|min.nmol/l/g|min.umol/L/kg|min.umol/L/kg|min.umol/l/kg|min.umol/l/kg	Minutes times micromoles per liter, divided by kilograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112344>	C92571	Minute Times Millimole Per Liter Per Gram|Minute Times Mole Per Liter Per Kilogram|min*mmol/L/g|min*mmol/L/g|min*mmol/L/g|min*mol/L/kg|min*mol/L/kg|min.mmol/L/g|min.mmol/L/g|min.mmol/l/g|min.mmol/l/g|min.mol/L/kg|min.mol/L/kg|min.mol/l/kg|min.mol/l/kg	Minutes times millimoles per liter, divided by grams.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112346>	C92571	Minute Times Mole Per Liter Per Gram|min*mol/L/g|min*mol/L/g|min.mol/L/g|min.mol/L/g|min.mol/l/g|min.mol/l/g	Minutes times moles per liter, divided by grams.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112349>	C92571	Minute Times Nanogram Per Milliliter Per Kilogram|Minute Times Picogram Per Milliliter Per Gram|min*ng/mL/kg|min*ng/mL/kg|min*ng/mL/kg|min*pg/mL/g|min*pg/mL/g|min.ng/mL/kg|min.ng/mL/kg|min.ng/ml/kg|min.ng/ml/kg|min.pg/mL/g|min.pg/mL/g|min.pg/ml/g|min.pg/ml/g	Minutes times nanograms per milliliter, divided by kilograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11234>	C61007	Bryostatin 1/Vincristine|BRYO/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112351>	C92571	Minute Times Nanomole Per Liter Per Kilogram|Minute Times Picomole Per Liter Per Gram|min*nmol/L/kg|min*nmol/L/kg|min*nmol/L/kg|min*pmol/L/g|min*pmol/L/g|min.nmol/L/kg|min.nmol/L/kg|min.nmol/l/kg|min.nmol/l/kg|min.pmol/L/g|min.pmol/L/g|min.pmol/l/g|min.pmol/l/g	Minutes times nanomoles per liter, divided by kilograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112355>	C92571	Minute Times Picomole Per Liter Per Kilogram|min*pmol/L/kg|min*pmol/L/kg|min.pmol/L/kg|min.pmol/L/kg|min.pmol/l/kg|min.pmol/l/kg	Minutes times picomoles per liter, divided by kilograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112356>	C187440	Molluscipoxvirus|MOLLUSCIPOXVIRUS|Molluscipox Virus	A genus of enveloped, brick-shaped viruses in the family Poxviridae. The genome is composed of linear, double-stranded DNA and the virus is capable of infection either with or without its external membrane envelope. Molluscipoxviruses may be sexually transmitted and cause molluscum contagiosum in humans.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112357>	C112356	Molluscum Contagiosum Virus|MCV|MOCV|MOLLUSCUM CONTAGIOSUM VIRUS	A species of enveloped and brick-shaped viruses in the Poxviridae family and Molluscipoxvirus genus. The genome is composed of non-segmented, linear double-stranded DNA. Molluscum contagiosum viruses are found in humans and can cause the disease Molluscum contagiosum. Molluscum contagiosum viruses are transmitted via direct person-to-person contact and contact with infected fomites.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112358>	C112028	Nairovirus|NAIROVIRUS	A genus of enveloped, spherical viruses in the family Bunyaviridae. The genome is composed of a circular single-strand of negative sense RNA. Nairoviruses are tick-borne with human and animal hosts and cause hemorrhagic fevers and gastroenteritis in humans.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112359>	C112290	Nipah Virus|NIPAH VIRUS|NiV	A species of enveloped and pleomorphic viruses in the Paramyxoviridae family and Henipavirus genus. The genome is composed of non-segmented, negative-sense, single-stranded RNA. Nipah viruses are found naturally in Pteropid fruit bats, and are zoonotic pathogens in domestic animals (mainly in pigs) and humans. Nipah viruses cause respiratory diseases, relapse and fatal encephalitis in humans.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11235>	C61063	Doxorubicin/Progesterone|DOX/progesterone			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112360>	C49237	Nitric Oxide Measurement|NITRICOX|NO|Nitric Oxide|Nitric Oxide	The determination of the amount of nitric oxide present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112361>	C54026	Non-Study Device Issue|NON-STUDY EQUIPMENT ISSUE|Non-Study Equipment Malfunction	Issue associated with any deviations from specifications relating to non-study device or equipment operations.			Phenomenon or Process	CDISC SDTM Device Events Category Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112362>	C14304	Norovirus|NOROVIRUS|NoV|Norwalk-like virus	A genus of non-enveloped, capsid covered viruses with T=3 icosahedral symmetry, in the family Caliciviridae. The genome is composed of a linear, single-strand of positive sense RNA. Noroviruses are transmitted by the fecal-oral route and cause gastroenteritis in humans.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112363>	C112362	Norwalk Virus|NORWALK VIRUS|NV|Norwalk calicivirus	A species of non-enveloped and spherical viruses with a capsid with T=3 icosahedral symmetry in the Caliciviridae family and Norovirus genus. The genome is composed of single-stranded, positive-sense RNA. Norwalk viruses are found in humans and causes acute viral gastroenteritis. Norwalk viruses are transmitted via oral ingestion or fecal-oral contamination.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112364>	C25337	Number of Coil Channels|COILNUM	The number of channels, or elements, in the head coil component of the device.			Quantitative Concept	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112365>	C112026	Orbivirus|ORBIVIRUS	A genus of non-enveloped, non-turreted viruses with a triple capsid structure, in the family Reoviridae. The genome is composed of linear, segmented double-stranded RNA. Orbiviruses are infective in a wide range of arthropod and vertebrate hosts and primarily cause disease in animals.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112366>	C112028	Orthobunyavirus|Bunyavirus|ORTHOBUNYAVIRUS	A genus of enveloped, spherical viruses in the family Bunyaviridae. The genome is composed of three linear, segmented single-strands of negative sense RNA. Orthobunyaviruses are mostly transmitted by gnats and cause encephalitis in humans.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112367>	C187440	Parapoxvirus|PARAPOXVIRUS	A genus of enveloped, oval-shaped virions with surface filaments, in the family Poxviridae. The genome is composed of non-segmented, double-stranded DNA. Two distinct infection virus particles exist for Parapoxviruses and cause non-serious infection in humans.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112368>	C38081	Peak Expiratory Flow Reversibility|PEF Reversibility|PEF Reversibility|PEF Reversibility|PEFREV	The change in PEF following administration of a bronchodilator relative to the pre-treatment PEF value. (CDISC)			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112369>	C96621	Percent Change From Baseline in Sum of Area|Percent Change Baseline in Sum of Area	The most recently recorded sum of areas minus the baseline sum of areas divided by the baseline sum of areas, multiplied by 100.			Quantitative Concept	
C11236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11236>	C61063	Cyclophosphamide/Doxorubicin/Filgrastim/Paclitaxel|CTX/DOX/G-CSF/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112370>	C96621	Percent Change From Baseline in Sum of Diameter|PCBSD|Percent Change Baseline in Sum of Diam|Percent Change Baseline in Sum of Diam	The most recently recorded sum of diameters minus the baseline sum of diameters divided by the baseline sum of diameters, multiplied by 100.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C112371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112371>	C96621	Percent Change From Baseline in Sum of Longest Diameter|PCBSLD|Percent Change Baseline Sum Longest Diam|Percent Change Baseline Sum Longest Diam	The most recently recorded sum of longest diameters minus the baseline sum of longest diameters divided by the baseline sum of longest diameters, multiplied by 100.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C112372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112372>	C96621	Percent Change From Baseline in Sum of Volume|PCBSV|Percent Change Baseline in Sum of Volume|Percent Change Baseline in Sum of Volume	The most recently recorded sum of volumes minus the baseline sum of volumes divided by the baseline sum of volumes, multiplied by 100.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C112373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112373>	C96622	Percent Change From Nadir in Sum of Diameter|PCNSD|Percent Change Nadir in Sum of Diam|Percent Change Nadir in Sum of Diam	The most recently recorded sum of diameters minus the lowest sum of diameters previously recorded divided by the lowest sum of diameters previously recorded, multiplied by 100.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C112374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112374>	C96622	Percent Change From Nadir in Sum of Longest Diameter|PCNSLD|Percent Change Nadir in Sum Longest Diam|Percent Change Nadir in Sum Longest Diam	The most recently recorded sum of longest diameters minus the lowest sum of longest diameters previously recorded divided by the lowest sum of longest diameters previously recorded, multiplied by 100.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C112375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112375>	C38081	Percent Predicted Expiratory Reserve Volume|ERVPP|Percent Predicted ERV|Percent Predicted ERV|Percent Predicted ERV	The maximum volume of air a subject can exhale from the lungs after a tidal exhalation as a proportion of the predicted normal value. (CDISC)			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112376>	C38081	Percent Predicted Forced Expiratory Volume in 1 Second|FEV1PP|Percent Predicted FEV1|Percent Predicted FEV1|Percent Predicted FEV1	Forced expiratory volume in one second as a proportion of the predicted normal value. (CDISC)			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112377>	C38081	Percent Predicted Forced Expiratory Volume in 1 Second Divided by Forced Vital Capacity|FEV1FVCP|Percent Predicted FEV1/FVC|Percent Predicted FEV1/FVC|Percent Predicted FEV1/FVC	The proportion of total forced vital capacity that is expelled during the first second of a forced exhalation as a proportion of the predicted normal value. (CDISC)			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112378>	C38081	Percent Predicted Forced Expiratory Volume in 6 Seconds|FEV6PP|Percent Predicted FEV6|Percent Predicted FEV6|Percent Predicted FEV6	Forced expiratory volume in six seconds as a proportion of the predicted normal value. (CDISC)			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112379>	C38081	Percent Predicted Forced Inspiratory Flow Maximum|FIFMAXPP|Percent Predicted FIFmax|Percent Predicted FIFmax|Percent Predicted FIFmax	Forced inspiratory flow for a portion of the FVC curve at the point where the maximum portion of FVC is already inhaled as a proportion of the predicted normal value. (CDISC)			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11237>	C61063	Irinotecan/Raltitrexed|CPT-11/ICI D1694			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112380>	C38081	Percent Predicted Forced Inspiratory Volume in 1 Second|FIV1PP|Percent Predicted FIV1|Percent Predicted FIV1|Percent Predicted FIV1	The volume of air that a subject can breathe in during the first second of inhalation after maximum exhalation as a proportion of the predicted normal value. (CDISC)			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112381>	C38081	Percent Predicted Forced Vital Capacity|FVCPP|Percent Predicted FVC	Forced vital capacity as a proportion of the predicted normal value. (CDISC)			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112382>	C38081	Percent Predicted Inspiratory Capacity|ICPP|Percent Predicted IC	The maximum volume of air a subject can inhale into the lungs after a tidal exhalation (IRV plus TV) as a proportion of the predicted normal value. (CDISC)			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112383>	C38081	Percent Predicted Inspiratory Reserve Volume|IRVPP|Percent Predicted IRV|Percent Predicted IRV|Percent Predicted IRV	The maximum volume of air a subject can inhale into the lungs after a tidal inhalation as a proportion of the predicted normal value. (CDISC)			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112384>	C38081	Percent Predicted Peak Expiratory Flow|PEFPP|Percent Predicted PEF	The maximal flow achieved during the maximally forced expiration initiated at maximum inhalation as a proportion of the predicted normal value. (CDISC)			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112385>	C38081	Percent Predicted Residual Volume|RVPP	The volume of air remaining in the lungs after maximum exhalation as a proportion of the predicted normal value. (CDISC)			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112386>	C38081	Percent Predicted Slow Vital Capacity|Percent Predicted SVC|SVCPP	The maximum volume of air that can be exhaled after slow maximum inhalation as a proportion of the predicted normal value. (CDISC)			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112387>	C38081	Percent Predicted Tidal Volume|TVPP	The volume of air moved into and out of the lungs during breathing at rest as a proportion of the predicted normal value. (CDISC)			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112388>	C38081	Percent Predicted Total Lung Capacity|TLCPP	The total volume of air in the lungs after maximum inhalation as a proportion of the predicted normal value. (CDISC)			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112389>	C112034	Percent Recovered Infinity Observed Normalized by Body Mass Index|Pct Rec Infinity Obs Norm by BMI|Pct Rec Infinity Obs Norm by BMI|RCPCIFOB	The percentage of the recovered administered dose extrapolated to infinity, calculated using the observed value of the last non-zero concentration, divided by the body mass index.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11238>	C61063	Cisplatin/Filgrastim/Paclitaxel/Topotecan|CDDP/G-CSF/TAX/TOPO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112390>	C112034	Percent Recovered Infinity Observed Normalized by Surface Area|Pct Rec Infinity Obs Norm by SA|Pct Rec Infinity Obs Norm by SA|RCPCIFOS	The percentage of the recovered administered dose extrapolated to infinity, calculated using the observed value of the last non-zero concentration, divided by the surface area.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112391>	C112034	Percent Recovered Infinity Observed Normalized by Weight|Pct Rec Infinity Obs Norm by WT|Pct Rec Infinity Obs Norm by WT|RCPCIFOW	The percentage of the recovered administered dose extrapolated to infinity, calculated using the observed value of the last non-zero concentration, divided by the weight.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112392>	C112035	Percent Recovered Infinity Predicted Normalized by Body Mass Index|Pct Rec Infinity Pred Norm by BMI|Pct Rec Infinity Pred Norm by BMI|RCPCIFPB	The percentage of the recovered administered dose extrapolated to infinity, calculated using the predicted value of the last non-zero concentration, divided by the body mass index.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112393>	C112035	Percent Recovered Infinity Predicted Normalized by Surface Area|Pct Rec Infinity Pred Norm by SA|Pct Rec Infinity Pred Norm by SA|RCPCIFPS	The percentage of the recovered administered dose extrapolated to infinity, calculated using the predicted value of the last non-zero concentration, divided by the surface area.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112394>	C112035	Percent Recovered Infinity Predicted Normalized by Weight|Pct Rec Infinity Pred Norm by WT|Pct Rec Infinity Pred Norm by WT|RCPCIFPW	The percentage of the recovered administered dose extrapolated to infinity, calculated using the predicted value of the last non-zero concentration, divided by the weight.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112395>	C64430	Periostin Measurement|OSF2|Osteoblast Specific Factor 2|PERIOSTN|POSTN|Periostin|Periostin	The determination of the amount of periostin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112396>	C38114	Perivenous Route of Administration|PERIVENOUS	Administration into the area surrounding a vein. (NCI)			Functional Concept	CDISC SDTM Route of Administration Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112397>	C112028	Phlebovirus|PHLEBOVIRUS	A genus of enveloped, spherical shaped viruses with surface glycoproteins that are arranged in a T=12 icosahedral symmetrical lattice, in the family Bunyaviridae. The genome is composed of three linear, segmented single-strands of negative sense RNA.  Phelboviruses are mosquito-borne and humans, ruminants and camels are natural hosts. This genus causes influenza-like illness and rarely hemorrhagic fevers in humans.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112398>	C14308	Pneumovirus|PNEUMOVIRUS	A genus of enveloped, spherical viruses in the family Paramyxoviridae. The genome is composed of a linear single-strand of negative sense RNA.  Pneumoviruses are found in human, cattle and rodents and cause disease of the respiratory tract in humans.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112399>	C13031	Precuneus|PRECUNEUS	The medial aspect of the posterior parietal lobe, which is bounded anteriorly by the marginal branch of the cingulate sulcus, posteriorly by the medial portion of the parieto-occipital fissure and inferiorly by the subparietal sulcus. It is involved in a wide range of higher-order cognitive function, such as episodic memory, visuospatial processing, reflections upon self, and aspects of consciousness.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11239>	C61063	Cisplatin/Paclitaxel/Topotecan|CDDP/TAX/TOPO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1123>	C222	Hepsulfam|1,7-Heptanediyl Ester Sulfamic Acid|HEPSULFAM|HEPSULFAM|Sulfamic acid, 1,7-heptanediyl ester	A bisulfamic ester which is similar in structure to busulfan and belongs to the family of drugs known as alkylsulfonate alkylating agents.  Hepsulfam forms covalent linkages with nucleophilic centers in DNA, resulting in depurination, base miscoding, strand scission, DNA-DNA and DNA-protein cross-linking, and cytotoxicity. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C112400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112400>	C19332	Premature Birth Indicator|PREMBRTH|premature at birth|premature_at_birth	An indication as to whether the subject was born prior to 38 weeks gestation.			Organism Attribute	CDISC SDTM Subject Characteristic Test Code Terminology|CDISC SDTM Subject Characteristic Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Property Terminology|GDC Terminology
C112401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112401>	C112367	Pseudocowpox Virus|PSEUDOCOWPOX VIRUS|Paravaccinia virus|Pseudocowpoxvirus	A species of viruses in the Poxviridae family and Parapoxvirus genus. Pseudocowpox viruses are mainly found in cattle and cause mild sores on cow teats and udders. Pseudocowpox viruses can also infect humans via direct contact with infected dairy cattle during the milking process, and cause the skin disease milker's nodule.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112402>	C41328	QTcB Shortened|SHORT QTCB	An electrocardiographic finding in which the QT interval corrected for heart rate using Bazett's formula is shortened. Thresholds for different age, sex, and patient populations exist.			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112403>	C41328	QTcF Shortened|SHORT QTCF	An electrocardiographic finding in which the QT interval corrected for heart rate using Fridericia's formula is shortened. Thresholds for different age, sex, and patient populations exist.			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112404>	C49579	Quadrate Lobe of Liver|LIVER, QUADRATE LOBE|Quadrate Lobe	An oblong shaped area of the liver that is situated inferior to the right lobe, bounded by the anterior margin of the liver and the porta hepatis.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C112405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112405>	C112330	Rabies Virus|RABIES VIRUS	A species of enveloped, rod- or bullet-shaped viruses in the Rhabdoviridae family and Lyssavirus genus. The genome is composed of single-stranded, negative-sense RNA. Rabies viruses are neurotropic and zoonotic. They are found in mammals and humans and causes acute infection of the central nervous system, neural degeneration, and fatal encephalitis in humans. Rabies viruses are transmitted via direct contact with saliva from infected animal or human bites.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112406>	C70848	Reagent Lot Number|REAGLOT|Reagent Lot|Reagent Lot|Reagent_Lot_Number	The lot number of the reagent.			Intellectual Product	CDISC SDTM Device Properties Test Code Terminology|CDISC SDTM Device Properties Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|SeroNet Reagent Metadata|SeroNet Variables
C112407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112407>	C77200	Rhinovirus A|Human Rhinovirus A|RHINOVIRUS A	A species of non-enveloped, spherical viruses with a capsid with quasi T=3 icosahedral symmetry in the Picornaviridae family and Enterovirus genus. The genome is composed of single-stranded, positive-sense RNA. Rhinovirus A is found in humans and causes respiratory infections and the common cold. Rhinovirus A is transmitted via direct person-to-person contact and aerosols of respiratory droplets.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112408>	C77200	Rhinovirus B|Human Rhinovirus B|RHINOVIRUS B	A species of non-enveloped, spherical viruses with a capsid with quasi T=3 icosahedral symmetry in the Picornaviridae family and Enterovirus genus. The genome is composed of single-stranded, positive-sense RNA. Rhinovirus B is found in humans and causes respiratory infections and the common cold. Rhinovirus B is transmitted via direct person-to-person contact and aerosols of respiratory droplets.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112409>	C77200	Rhinovirus C|Human Rhinovirus C|RHINOVIRUS C	A species of non-enveloped, spherical viruses with a capsid with quasi T=3 icosahedral symmetry in the Picornaviridae family and Enterovirus genus. The genome is composed of single-stranded, positive-sense RNA. Rhinovirus C is found in humans and causes respiratory infections and the common cold. Rhinovirus C is transmitted via direct person-to-person contact and aerosols of respiratory droplets.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11240>	C61063	Chlorodihydroxypyridine/Potassium Oxonate/Tegafur|CDHP/FT/Oxo			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112410>	C14217	Roseolovirus|ROSEOLOVIRUS	A genus of enveloped, spherical or pleomorphic viruses with a capsid that is surrounded by an amorphous tegument, in the family Herpesviridae. The genome is composed of monopartite, linear double-stranded DNA. Roseoloviruses are found in humans and cause Roseola in humans.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112411>	C77197	Ross River Virus|ROSS RIVER VIRUS|RRV	A species of enveloped, spherical viruses with a capsid with T=4 icosahedral symmetry in the Togaviridae family and Alphavirus genus. The genome is composed of monopartite, single-stranded, positive-sense RNA. Ross river viruses are found in both vertebrates and invertebrates, and cause Ross River Fever in humans. Ross river viruses are transmitted via the bite of infected mosquitoes.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112412>	C81971	Rubeola IgG Antibody Measurement	The determination of the amount of Rubeola IgG antibody present in a sample.			Laboratory Procedure	
C112413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112413>	C81972	Rubeola IgM Antibody Measurement	The determination of the amount of Rubeola IgM antibody present in a sample.			Laboratory Procedure	
C112414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112414>	C77197	Rubivirus|RUBIVIRUS	A genus of enveloped, spherical viruses with a capsid with T=4 icosahedral symmetry, in the family Togaviridae. The genome is composed of a linear, single-strand of positive sense RNA. Rubiviruses are found in humans and cause respiratory disease in humans.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112415>	C112029	Sapporo Virus|Human Calicivirus SLV|Human Calicivirus Sapporo-like Virus|SAPPORO VIRUS	A species of non-enveloped viruses in the Caliciviridae family and Sapovirus genus that have characteristic cup-shaped depressions on their spherical capsid surface and a distinctive structure of "Star-of-David" configuration. The genome is composed of single-stranded, positive-sense RNA. Sapporo viruses are found in humans and cause gastroenteritis mainly in young children. Sapporo viruses are transmitted via oral ingestion.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112416>	C70831	Signal Amplitude|SIGAMP	A measurement of the height of the signal such as a magnetic pulse.			Spatial Concept	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112417>	C25515	Signal Frequency|Frequency|SIGFREQ	A measurement of the number of cycles of a periodic wave or pulse per unit of time.			Quantitative Concept	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112418>	C25345	Signal Width|SIGW	A measurement of the range of values seen in the time interval between the beginning and end of the pulse wave. This is usually calculated at the point where the amplitude is at 50% of the wave peak.			Quantitative Concept	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112419>	C14217	Simplex Virus|HHV|HSV|HSV|Herpes Simplex Virus|SIMPLEXVIRUS|herpes simplex virus|human herpesvirus	A genus of enveloped, spherical or pleomorphic viruses with a capsid with T=16 icosahedral symmetry and surrounded by amorphous tegument, in the family Herpesviridae. The genome is composed of monopartite, linear double-stranded DNA. Simplexviruses are found in humans and mammals, may remain latent in neurons and cause skin blisters and mucosal ulcers in humans.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11241>	C61063	Bleomycin/Cyclophosphamide/Idarubicin/Methylprednisolone/Methotrexate/Vincristine|BLEO/CTX/IDA/MEPRDL/MTX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112420>	C49556	Skin Response Domain|SR|Skin Response	A findings domain for assessments that determine whether a therapy induced an immune response.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112421>	C25244	Surgical Mesh Open Area|SRGMSHOA	A quantitative or qualitative measurement of the physical dimensions of the open spaces in a loosely woven sheet of inorganic or biological materials, which is used to physically support organs or tissue during a surgical procedure.			Spatial Concept	CDISC SDTM Device Properties Test Code Terminology|CDISC SDTM Device Properties Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112422>	C14208	Tick-Borne Encephalitis Virus|FSME virus|TBEV|TICK-BORNE ENCEPHALITIS VIRUS	A species of enveloped, spherical and icosahedral viruses in the Flaviviridae family and Flavivirus genus. The genome is composed of non-segmented, single-stranded, positive-sense RNA. Tick-borne encephalitis viruses are found in ticks of the Ixodes species and humans and cause tick-borne encephalitis in humans. Tick-borne encephalitis viruses are transmitted via the bite of infected ticks, primarily Ixodes ricinus or Ixodes persulcatus.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112423>	C67332	Torr|{Torr}|{Torr}	A non-SI unit of pressure equal to 1/760 of a standard atmosphere (a standard atmosphere being defined as equal to 101 325 pascals). One Torr is equal to 133.3223684 pascals.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112424>	C19332	Twin Type|TWINTYP	The classification of the two offspring born from the same pregnancy.			Organism Attribute	CDISC SDTM Subject Characteristic Test Code Terminology|CDISC SDTM Subject Characteristic Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112425>	C22188	Tympanic Bulla|TYMPANIC BULLA	The bony cavities located on the posterior ventral portion of the skull, which house the sensory receptors of the middle and inner ear.			Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112426>	C14217	Varicellovirus|VARICELLOVIRUS|Varicellavirus	A genus of enveloped, spherical or pleomorphic viruses with a capsid with T=16 icosahedral symmetry and surrounded by amorphous tegument, in the family Herpesviridae. The genome is composed of monopartite, linear double-stranded DNA. Varicelloviruses are found in mammals and cause chickenpox and shingles in humans.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112427>	C96684	Wheal Longest Diameter|WHLLDIAM|WHLLDIAM|WHLLDIAM	The longest diameter of the flat, circular, slightly raised area that forms around the site of an antigenic challenge to the skin.			Quantitative Concept	CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Skin Response Test Code Terminology|CDISC SDTM Skin Response Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Skin Test Code Terminology|CDISC SEND Skin Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112428>	C120716	Wheal Mean Diameter|WHLMDIAM|WHLMDIAM	The mean diameter of the flat, circular, slightly raised area that forms around the site of an antigenic challenge to the skin.			Quantitative Concept	CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Skin Response Test Code Terminology|CDISC SDTM Skin Response Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112429>	C209975|C15260	Wheal Size Measurement|WHEALSZ|WHEALSZ|Wheal Size|Wheal Size|Wheal Size	The determination of the size of the flat, circular, slightly raised area that forms around the site of an antigenic challenge to the skin.			Laboratory Procedure	CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Skin Response Test Code Terminology|CDISC SDTM Skin Response Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11242>	C61007	Methotrexate/Tacrolimus|FK506/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112430>	C19697	Levator Ani/Bulbospongiosus|MUSCLE, LEVATOR ANI/BULBOSPONGIOSUS	A laboratory specimen consisting of the bulbocavernosus and the levator ani.			Tissue	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112431>	C19996	Oncogenicity|ONCOGENICITY	A measurement of the cell immortalization potential of an agent.			Pathologic Function	CDISC SEND Study Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112432>	C113207	SARS Coronavirus|HCoV-SARS|SARS|SARS CORONAVIRUS|SARS-CoV|SARS-CoV|SARS-CoV-1|SEVERE ACUTE RESPIRATORY SYNDROME-RELATED CORONAVIRUS|Severe Acute Respiratory Syndrome Coronavirus	A species of enveloped, spherical or pleomorphic, kidney-shaped or rod-shaped viruses in the Coronaviridae family and Coronavirus genus. The genome is composed of linear, single-stranded, positive-sense RNA. SARS coronaviruses are found in humans and cause severe acute respiratory syndrome (SARS). SARS coronaviruses are transmitted via direct person-to-person contact with infected secretions or excretions, and aerosols of respiratory droplets.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112433>	C48470	Shockwave Dosing Unit|Shock Wave|{SHOCK WAVE}|{SHOCK WAVE}|{Shock Wave}|{Shock Wave}	A dosing measurement based on the shock wave unit.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C112434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112434>	C100110	CDISC Questionnaire AQ20 Test Name Terminology|AQ01TN|Airway Questionnaire 20 Questionnaire Test Name|QS-AQ20 TEST	Test names of questionnaire questions associated with the Airway Questionnaire 20 (AQ20) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112435>	C100110	CDISC Questionnaire AQ20 Test Code Terminology|AQ01TC|Airway Questionnaire 20 Questionnaire Test Code|QS-AQ20 TESTCD	Test codes of questionnaire questions associated with the Airway Questionnaire 20 (AQ20) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112436>	C118970	CDISC Clinical Classification DS Test Name Terminology|DS01TN|Disease Steps Clinical Classification Test Name|QS-DS TEST	Test names of clinical classification questions associated with the Disease Steps (DS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112437>	C118970	CDISC Clinical Classification DS Test Code Terminology|DS01TC|Disease Steps Clinical Classification Test Code|QS-DS TESTCD	Test codes of clinical classification questions associated with the Disease Steps (DS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112438>	C118970	CDISC Clinical Classification EDSS Test Name Terminology|EDSS01TN|Kurtzke Expanded Disability Status Scale Clinical Classification Test Name|QS-EDSS TEST	Test names of clinical classification questions associated with the Kurtzke Expanded Disability Status Scale (EDSS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112439>	C118970	CDISC Clinical Classification EDSS Test Code Terminology|EDSS01TC|Kurtzke Expanded Disability Status Scale Clinical Classification Test Code|QS-EDSS TESTCD	Test codes of clinical classification questions associated with the Kurtzke Expanded Disability Status Scale (EDSS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11243>	C61063	Indinavir/Lamivudine/Stavudine|3TC/d4T/IDV			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112440>	C100110	CDISC Questionnaire FAMS Test Name Terminology|FAMS01TN|Functional Assessment of Multiple Sclerosis Version 4 Questionnaire Test Name|QS-FAMS TEST	Test names of questionnaire questions associated with the Functional Assessment of Multiple Sclerosis (FAMS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112441>	C100110	CDISC Questionnaire FAMS Test Code Terminology|FAMS01TC|Functional Assessment of Multiple Sclerosis Version 4 Questionnaire Test Code|QS-FAMS TESTCD	Test codes of questionnaire questions associated with the Functional Assessment of Multiple Sclerosis (FAMS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112442>	C118970	CDISC Clinical Classification KFSS Test Name Terminology|KFSS1TN|Kurtzke Functional Systems Scores Clinical Classification Test Name|QS-KFSS TEST	Test names of clinical classification questions associated with the Kurtzke Functional Systems Scores (KFSS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112443>	C118970	CDISC Clinical Classification KFSS Test Code Terminology|KFSS1TC|Kurtzke Functional Systems Scores Clinical Classification Test Code|QS-KFSS TESTCD	Test codes of clinical classification questions associated with the Kurtzke Functional Systems Scores (KFSS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112444>	C100110	CDISC Questionnaire MHIS-NACC Test Name Terminology|MHIS01TN|Modified Hachinski Ischemic Scale-NACC Version Questionnaire Test Name|QS-MHIS-NACC TEST	Test names of questionnaire questions associated with the Modified Hachinski Ischemic Scale-NACC Version (MHIS-NACC) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112445>	C100110	CDISC Questionnaire MHIS-NACC Test Code Terminology|MHIS01TC|Modified Hachinski Ischemic Scale-NACC Version Questionnaire Test Code|QS-MHIS-NACC TESTCD	Test codes of questionnaire questions associated with the Modified Hachinski Ischemic Scale-NACC Version (MHIS-NACC) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112446>	C100110	CDISC Questionnaire PDDS Test Name Terminology|PDDS01TN|Patient Determined Disease Steps Questionnaire Test Name|QS-PDDS TEST	Test names of questionnaire questions associated with the Patient Determined Disease Steps (PDDS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112447>	C100110	CDISC Questionnaire PDDS Test Code Terminology|PDDS01TC|Patient Determined Disease Steps Questionnaire Test Code|QS-PDDS TESTCD	Test codes of questionnaire questions associated with the Patient Determined Disease Steps (PDDS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112448>	C100110	CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|QS-SGRQ Past 3 Months Version TEST|SGRQ01TN|St. George's Respiratory Questionnaire Past 3 Months Version Questionnaire Test Name	Test names of questionnaire questions associated with the St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112449>	C100110	CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|QS-SGRQ Past 3 Months Version TESTCD|SGRQ01TC|St. George's Respiratory Questionnaire Past 3 Months Version Questionnaire Test Code	Test codes of questionnaire questions associated with the St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11244>	C61063	Cyclophosphamide/Doxorubicin/Prednisone/Sargramostim/Vincristine|CTX/DOX/GM-CSF/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112450>	C100110	CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|QS-SGRQ Past 4 Weeks Version TEST|SGRQ02TN|St. George's Respiratory Questionnaire Past 4 Weeks Version Questionnaire Test Name	Test names of questionnaire questions associated with the St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112451>	C100110	CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|QS-SGRQ Past 4 Weeks Version TESTCD|SGRQ02TC|St. George's Respiratory Questionnaire Past 4 Weeks Version Questionnaire Test Code	Test codes of questionnaire questions associated with the St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112452>	C100110	CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|National Eye Institute Visual Functioning Questionnaire - 25 Version 2000 Interviewer-Administered Format Questionnaire Test Name|QS-VFQ25-Interviewer Administered Format TEST|VFQ1TN	Test names of questionnaire questions associated with the Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112453>	C100110	CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|National Eye Institute Visual Functioning Questionnaire - 25 Version 2000 Interviewer-Administered Format Questionnaire Test Code|QS-VFQ25-Interviewer Administered Format TESTCD|VFQ1TC	Test codes of questionnaire questions associated with the Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112454>	C100110	CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|National Eye Institute Visual Functioning Questionnaire - 25 Version 2000 Self-Administered Format Questionnaire Test Name|QS-VFQ25-Self Administered Format TEST|VFQ2TN	Test names of questionnaire questions associated with the Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112455>	C100110	CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|National Eye Institute Visual Functioning Questionnaire - 25 Version 2000 Self-Administered Format Questionnaire Test Code|QS-VFQ25-Self Administered Format TESTCD|VFQ2TC	Test codes of questionnaire questions associated with the Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112456>	C211913	AQ20 Questionnaire Question	A question associated with the AQ20 questionnaire.			Intellectual Product	
C112457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112457>	C211913	DS Clinical Classification Question	A question associated with the DS questionnaire.			Intellectual Product	
C112458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112458>	C211913	EDSS Clinical Classification Question	A question associated with the EDSS clinical classification.			Intellectual Product	
C112459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112459>	C211913	FAMS Questionnaire Question	A question associated with the FAMS questionnaire.			Intellectual Product	
C11245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11245>	C61063	Carboplatin/Cyclophosphamide/Etoposide/Filgrastim/Paclitaxel|CBDCA/CTX/G-CSF/TAX/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112460>	C211913	KFSS Questionnaire Question	A question associated with the KFSS questionnaire.			Intellectual Product	
C112461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112461>	C211913	MHIS-NACC Questionnaire Question	A question associated with the MHIS-NACC questionnaire.			Intellectual Product	
C112462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112462>	C211913	PDDS Questionnaire Question	A question associated with the PDDS questionnaire.			Intellectual Product	
C112463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112463>	C211913	St George's Respiratory Questionnaire Past 3 Months Version Questionnaire Question	A question associated with the SGRQ Past 3 Months Version questionnaire.			Intellectual Product	
C112464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112464>	C211913	St George's Respiratory Questionnaire Past 4 Weeks Version Questionnaire Question	A question associated with the SGRQ Past 4 Weeks Version questionnaire.			Intellectual Product	
C112465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112465>	C211913	VFQ25-Interviewer Administered Format Questionnaire Question	A question associated with the VFQ25-Interviewer Administered Format questionnaire.			Intellectual Product	
C112466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112466>	C211913	VFQ25-Self Administered Format Questionnaire Question	A question associated with the VFQ25-Self Administered Format questionnaire.			Intellectual Product	
C112467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112467>	C101873	COWS - Resting Pulse Rate: Beats/Minute|COWS1-Resting Pulse Rate Beats/Minute|COWS1-Resting Pulse Rate Beats/Minute|COWS101A	Clinical Opiate Withdrawal Scale (COWS) Resting Pulse Rate: beats/minute.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COWS Test Code Terminology|CDISC Questionnaire COWS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112468>	C101873	COWS - Total Score|COWS1-Total Score|COWS1-Total Score|COWS112	Clinical Opiate Withdrawal Scale (COWS) Total score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire COWS Test Code Terminology|CDISC Questionnaire COWS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112469>	C100120	NPI - Delusions FxS Score|NPI1-Delusions FxS Score|NPI1-Delusions FxS Score|NPI1AFS	Neuropsychiatric Inventory (NPI) Delusions: (frequency score x severity score).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11246>	C61063	Cyclophosphamide/Epirubicin/Filgrastim/Fluorouracil|CTX/EPI/5-FU/G-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112470>	C100120	NPI - Hallucinations FxS Score|NPI1-Hallucinations FxS Score|NPI1-Hallucinations FxS Score|NPI1BFS	Neuropsychiatric Inventory (NPI) Hallucinations: (frequency score x severity score).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112471>	C100120	NPI - Agitation/Aggression FxS Score|NPI1-Agitation/Aggression FxS Score|NPI1-Agitation/Aggression FxS Score|NPI1CFS	Neuropsychiatric Inventory (NPI) Agitation/Aggression: (frequency score x severity score).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112472>	C100120	NPI - Depression/Dysphoria FxS Score|NPI1-Depression/Dysphoria FxS Score|NPI1-Depression/Dysphoria FxS Score|NPI1DFS	Neuropsychiatric Inventory (NPI) Depression/Dysphoria: (frequency score x severity score).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112473>	C100120	NPI - Anxiety FxS Score|NPI1-Anxiety FxS Score|NPI1-Anxiety FxS Score|NPI1EFS	Neuropsychiatric Inventory (NPI) Anxiety: (frequency score x severity score).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112474>	C100120	NPI - Elation/Euphoria FxS Score|NPI1-Elation/Euphoria FxS Score|NPI1-Elation/Euphoria FxS Score|NPI1FFS	Neuropsychiatric Inventory (NPI) Elation/Euphoria: (frequency score x severity score).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112475>	C100120	NPI - Apathy/Indifference FxS Score|NPI1-Apathy/Indifference FxS Score|NPI1-Apathy/Indifference FxS Score|NPI1GFS	Neuropsychiatric Inventory (NPI) Apathy/Indifference: (frequency score x severity score).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112476>	C100120	NPI - Disinhibition FxS Score|NPI1-Disinhibition FxS Score|NPI1-Disinhibition FxS Score|NPI1HFS	Neuropsychiatric Inventory (NPI) Disinhibition: (frequency score x severity score).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112477>	C100120	NPI - Irritability/Lability FxS Score|NPI1-Irritability/Lability FxS Score|NPI1-Irritability/Lability FxS Score|NPI1IFS	Neuropsychiatric Inventory (NPI) Irritability/Lability: (frequency score x severity score).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112478>	C100120	NPI - Aberrant Motor Behavior FxS Score|NPI1-Aberrant Motor Behavior FxS Score|NPI1-Aberrant Motor Behavior FxS Score|NPI1JFS	Neuropsychiatric Inventory (NPI) Aberrant Motor Behavior: (frequency score x severity score).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112479>	C100120	NPI - Sleep/Night Behavior Disorder FxS Score|NPI1-Sleep/Night Behav Disord FxS Score|NPI1-Sleep/Night Behav Disord FxS Score|NPI1KFS	Neuropsychiatric Inventory (NPI) Sleep and Nighttime Behavior Disorders: (frequency score x severity score).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11247>	C61063	Irinotecan/Paclitaxel|CPT-11/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112480>	C100120	NPI - Appetite/Eating Disorders FxS Score|NPI1-Appetite/Eating Disorders FxS Score|NPI1-Appetite/Eating Disorders FxS Score|NPI1LFS	Neuropsychiatric Inventory (NPI) Appetite and Eating Disorders: (frequency score x severity score).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112481>	C100120	NPI - NPI Total Score|NPI1-NPI Total Score|NPI1-NPI Total Score|NPI1TOT	Neuropsychiatric Inventory (NPI) Total of (Frequency Sub-total) x (Severity Sub-total).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112482>	C100120	NPI - NPI Total Distress Score|NPI1-NPI Total Distress Score|NPI1-NPI Total Distress Score|NPI1DIST	Neuropsychiatric Inventory (NPI) Sub-total of distress score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NPI Test Code Terminology|CDISC Questionnaire NPI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112483>	C80699	MIR22 Gene|MIR22|MIR22|MicroRNA 22 Gene	This gene may be involved in the regulation of target gene transcription.			Gene or Genome	
C112484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112484>	C112483	MIR22 wt Allele|MIRN22|MicroRNA 22 wt Allele|hsa-mir-22|miR-22|miRNA22	Human MIR22 wild-type allele is located in the vicinity of 17p13.3 and is approximately 5 kb in length. This allele, which encodes MIR22 pre-miRNA, may play a role in the negative regulation of gene expression.			Gene or Genome	
C112485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112485>	C25968	MIR22 Pre-miRNA|Pre-MIR22|Pre-MicroRNA 22|Pre-miRNA 22|Pre-miRNA MIR22|Pre-miRNA22	MIR22 pre-miRNA (85 bases) is encoded by the human MIR22 gene. This ribonucleotide may be involved in the regulation of transcription.			Nucleic Acid, Nucleoside, or Nucleotide	
C112486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112486>	C20923	P2RY2 Gene|P2RY2|P2RY2|Purinergic Receptor P2Y, G-Protein Coupled, 2 Gene	This gene plays a role in nucleotide receptor signaling.			Gene or Genome	
C112487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112487>	C112486	P2RY2 wt Allele|HP2U|P2RU1|P2U|P2U1|P2UR|P2Y2|P2Y2R|Purinergic Receptor P2Y, G Protein-Coupled, 2 Gene|Purinergic Receptor P2Y, G-Protein Coupled, 2 wt Allele	Human P2RY2 wild-type allele is located within 11q13.5-q14.1 and is approximately 18 kb in length. This allele, which encodes P2Y purinoceptor 2, is involved in both purine binding and signal transduction.			Gene or Genome	
C112488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112488>	C18239	P2Y Purinoceptor 2|ATP Receptor|P2U Nucleotide Receptor|P2U Purinoceptor 1|P2U Receptor 1|P2U1|P2Y2|P2YR2|Purinergic Receptor|Purinergic Receptor P2Y2|Purinoceptor P2Y2	P2Y purinoceptor 2 (377 aa, ~42 kDa) is encoded by the human P2RY2 gene. This protein plays a role in ligand-dependent activation of second messenger signaling pathways.			Amino Acid, Peptide, or Protein|Receptor	
C112489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112489>	C20194	CCSER1 Gene|CCSER1|CCSER1|Coiled-Coil Serine-Rich Protein 1 Gene	This gene may be involved in mitosis.			Gene or Genome	
C11248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11248>	C61007	Cisplatin/Mitomycin/Vincristine|CDDP/MITO/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112490>	C112489	CCSER1 wt Allele|Coiled-Coil Serine-Rich Protein 1 wt Allele|FAM190A|Family With Sequence Similarity 190, Member A Gene|KIAA1680	Human CCSER1 wild-type allele is located 4q22.1 and is approximately 1475 kb in length. This allele, which encodes serine-rich coiled-coil domain-containing protein 1, may play a role in mitosis. Deletion mutation of the gene is associated with various neoplasms.			Gene or Genome	
C112491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112491>	C18466	Serine-Rich Coiled-Coil Domain-Containing Protein 1|CCSER1|Coiled-Coil Serine-Rich Protein 1|Protein FAM190A	Serine-rich coiled-coil domain-containing protein 1 (900 aa, ~100 kDa) is encoded by the human CCSER1 gene. This protein may be involved in mitosis.			Amino Acid, Peptide, or Protein	
C112492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112492>	C28533	UCP1 Gene|UCP1|UCP1|Uncoupling Protein 1 (Mitochondrial, Proton Carrier) Gene	This gene plays a role in proton transport.			Gene or Genome	
C112493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112493>	C112492	UCP1 wt Allele|SLC25A7|UCP|Uncoupling Protein 1 (Mitochondrial, Proton Carrier) wt Allele	Human UCP1 wild-type allele is located within 4q28-q31 and is approximately 9 kb in length. This allele, which encodes mitochondrial brown fat uncoupling protein 1, is involved in thermogenic proton transport. Polymorphism in the gene is associated with susceptibility to both obesity and type II diabetes mellitus.			Gene or Genome	
C112494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112494>	C16386	Mitochondrial Brown Fat Uncoupling Protein 1|Brown Adipose Tissue Uncoupling Protein|Solute Carrier Family 25 Member 7|Thermogenin|UCP 1|UCP1	Mitochondrial brown fat uncoupling protein 1 (307 aa, ~33 kDa) is encoded by the human UCP1 gene. This protein plays a role in thermogenesis.			Amino Acid, Peptide, or Protein	
C112495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112495>	C28681|C129826	Autologous Lymphoid Effector Cells Specific Against Tumor Cells|ALECSAT|AUTOLOGOUS EX VIVO EXPANDED CD4+-ENRICHED LEUKOCYTES TREATED WITH THE DE-METHYLATING AGENT 5-AZA-DEOXYCYTIDINE|Autologous Activated Cytotoxic T Lymphocytes/Natural Killer Cells	A preparation of cytotoxic, autologous lymphoid effector cells specifically targeted towards tumor cells, with potential immunomodulating and antineoplastic activities. The autologous lymphoid effector cells are prepared by drawing a blood sample containing the required precursors for CD4+ helper T-cells, CD8+ cytotoxic T-cells, and natural killer (NK) cells from a cancer patient. The precursor cells are activated, selected and expanded to generate mature autologous lymphoid effector cells with the potential for enhanced tumor recognition. Upon readministration into the patient, the autologous lymphoid effector cells may induce both humoral and cellular immune responses against tumor cells. This may result in the immune-mediated inhibition of tumor cell proliferation, which leads to tumor cell death.			Cell|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C112496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112496>	C2124	Fluorine F 18 FDHT|(18)F-16beta-Fluoro-5alpha-Dihydrotestosterone|(18)F-FDHT|16Beta-18F-Fluoro-5alpha-Dihydrotestosterone|18F-FDHT|Fluorine F 18 16-Beta-Fluoro-5-Alpha-Dihydrotestosterone|Fluorine F 18-FDHT|Fluorine F18 16-Beta-Fluoro-5-Alpha-Dihydrotestosterone|Fluorine F18-FDHT	A radioconjugate containing a derivative of the androgen testosterone, 16-beta-fluoro-5-alpha-dihydrotestosterone (FDHT), labeled with the radioisotope fluorine F18 (18F-FDHT), with potential use as an imaging agent for positron emission tomography (PET). Upon administration, 18F-FDHT binds to the androgen receptor (AR). Upon PET imaging, AR-expressing prostate tumor cells can be imaged and assessed.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C112497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112497>	C2201|C2152|C129825	PI3K/mTOR Kinase Inhibitor VS-5584|2-Pyrimidinamine, 5-[8-Methyl-9-(1-Methylethyl)-2-(4-Morpholinyl)-9H-Purin-6-Yl]-2-|5-[8-Methyl-9-(1-Methylethyl)-2-(4-Morpholinyl)-9H-Purin-6-Yl]-2-Pyrimidinamine|PI3K/mTOR Inhibitor VS-5584|SB 2343|SB-2343|SB2343|VS 5584|VS-5584|VS-5584|VS5584	A potent and selective inhibitor of both phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinase in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. PI3K/mTOR kinase inhibitor VS-5584 inhibits mTOR kinase and all class I PI3K isoforms. Consequently, this disrupts phosphorylation of substrates downstream of PI3K and mTOR and may result in apoptosis and growth inhibition in susceptible tumor cells. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy. mTOR is a serine/threonine kinase downstream of PI3K, which also has PI3K-independent activity. Consequently, this agent may potentially be more potent than an agent that inhibits either PI3K kinase or mTOR kinase.	PI3K/mTOR Kinase Inhibitor VS-5584		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C112498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112498>	C1557	Extended Release Flucytosine|Extended Release 5-FC|Extended Release 5-Fluorocytosine|Extended-Release 5-FC|Extended-Release 5-Fluorocytosine|Extended-Release Flucytosine|Toca FC	An extended release (ER) oral tablet that contains flucytosine (5-FC), a fluorinated cytosine analog, with antifungal activity and potential anti-cancer activity. Following oral administration of ER 5-FC, the 5-FC is deaminated to its active metabolite 5-fluorouracil (5-FU). 5-FU replaces uracil during RNA synthesis, which consequently inhibits downstream protein synthesis. In addition, 5-FU is metabolized further to 5-fluorodeoxyuridylic acid monophosphate, which inhibits thymidylate synthetase. Inhibition of this enzyme interrupts nucleotide synthesis, DNA replication and cell proliferation. Negative regulation of protein synthesis, DNA replication and cell proliferation can lead to cell death. Following ingestion of ER 5-FC, intravenous injection of a retroviral vector encoding cytosine deaminase (TC 511) at a tumor site may result in higher local concentrations of 5-FU and its metabolites, and increased tumor cell death than other 5-FU treatment regimens.	Extended Release Flucytosine		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C112499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112499>	C1512	Cetuximab-IRDye 800CW|Cetuximab-IRDye 800|Cetuximab-IRDye800|Cetuximab-IRDye800CW	An immunoconjugate comprised of the recombinant chimeric monoclonal antibody cetuximab conjugated to the N-hydroxysuccinamide (NHS) ester form of the near-infrared (NIR) fluorescent dye IRDye 800CW (cetuximab-IRDye 800) with potential imaging use. The antibody moiety of cetuximab-IRDye 800 binds to the extracellular domain of the epidermal growth factor receptor (EGFR). Upon binding, IRDye 800 may be detected using NIR imaging, which facilitates the visualization and quantification of EGFR-expressing tumor cells. EGFR is a receptor tyrosine kinase that may be overexpressed on the cell surfaces of various tumor types.	Cetuximab-IRDye 800CW		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C11249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11249>	C61063	Lomustine/Procarbazine/Thioguanine/Vincristine|CCNU/PCB/TG/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1124>	C2516	Herbimycin|17-Demethoxy-15-methoxy-11-O-methylgeldanamycin, (15R)-|HERBIMYCIN A|Herbimycin A|Herbimycin A	A benzoquinone antineoplastic antibiotic isolated from the bacterium Streptomyces hygroscopicus.  Herbimycin binds to and inhibits the cytosolic chaperone functions of heat shock protein 90 (HSP90).  HSP90 maintains the stability and functional shape of many oncogenic signaling proteins; the inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins that may be over-expressed or overactive in tumor cells. (NCI04)			Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C112500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112500>	C128462	BET Inhibitor RO6870810|Bromodomain and Extra-Terminal Protein Inhibitor RO6870810|RG 6146|RG6146|RO-6870810|RO6870810|TEN 010|TEN-010	A small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins with potential antineoplastic activity. Upon administration, the BET inhibitor RO6870810 binds to the acetylated lysine recognition motifs found in the bromodomain of BET proteins, which prevents the interaction between BET proteins and acetylated histones. This interaction disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomains at the N-terminus, BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during cellular development and growth.	BET Inhibitor RO6870810		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C112501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112501>	C25871	DGKA Gene|DGKA|DGKA|Diacylglycerol Kinase, Alpha 80kDa Gene	This gene is involved in phospholipid metabolism.	DGKA Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C112502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112502>	C112501	DGKA wt Allele|DAGK|DAGK1|DGK-alpha|Diacylglycerol Kinase, Alpha 80kDa wt Allele	Human DGKA wild-type allele is located in the vicinity of 12q13.3 and is approximately 27 kb in length. This allele, which encodes diacylglycerol kinase alpha protein, plays a role in lipid phosphorylation and the attenuation of second messenger signaling.	DGKA wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112503>	C16984	Diacylglycerol Kinase Alpha|80 kDa Diacylglycerol Kinase|DAG Kinase Alpha|DGKA|Diacylglycerol Kinase, Alpha|Diglyceride Kinase Alpha|EC 2.7.1.107	Diacylglycerol kinase alpha (735 aa, ~83 kDa) is encoded by the human DGKA gene. This protein is involved in the negative regulation of second messenger signaling through lipid phosphorylation.	Diacylglycerol Kinase Alpha		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112504>	C20103	MSR1 Gene|MSR1|MSR1|Macrophage Scavenger Receptor 1 Gene	This gene plays a role in the transport of both lipoproteins and cholesterol.	MSR1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C112505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112505>	C112504	MSR1 wt Allele|CD204|Macrophage Scavenger Receptor 1 wt Allele|Macrophage Scavenger Receptor Gene|SCARA1|SR-A|SRA|phSR1|phSR2	Human MSR1 wild-type allele is located in the vicinity of 8p22 and is approximately 450 kb in length. This allele, which encodes macrophage scavenger receptor types I and II protein, is involved in the modulation of cholesterol and lipoprotein transport. Mutation of the gene is associated with Barrett esophagus and prostate cancer.	MSR1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112506>	C25207	Daylight-Savings Time|DST|Daylight Savings Time	A seasonal time adjustment in which clocks are set one hour ahead of local standard time.			Temporal Concept	
C112507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112507>	C18106	Macrophage Scavenger Receptor Types I and II|CD204 Antigen|Macrophage Acetylated LDL Receptor I and II|Macrophage Scavenger Receptor|Macrophage Scavenger Receptor Type III|Scavenger Receptor Class A Member 1|Scavenger Receptor Class A, Member 1	Macrophage scavenger receptor types I and II (451 aa, ~50 kDa) is encoded by the human MSR1 gene. This protein plays a role in cholesterol and lipoprotein transport.	Macrophage Scavenger Receptor Types I and II		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112508>	C16742	Water Bath|Water-bath|Waterbath	A device designed to regulate the temperature of a vessel by bathing it in water held at the desired temperature.			Manufactured Object	
C112509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112509>	C16742	Electric Warmer	A device that converts electricity to heat.			Manufactured Object	
C112510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112510>	C20709	NR5A2 Gene|NR5A2|NR5A2|Nuclear Receptor Subfamily 5, Group A, Member 2 Gene	This gene is involved in ligand-dependent transcriptional regulation.			Gene or Genome	
C112511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112511>	C112510	NR5A2 wt Allele|B1F|B1F2|CPF|FTF|FTZ-F1|FTZ-F1beta|LRH-1|LRH1|Nuclear Receptor Subfamily 5, Group A, Member 2 wt Allele|hB1|hB1F-2	Human NR5A2 wild-type allele is located in the vicinity of 1q32.1 and is approximately 150 kb in length. This allele, which encodes nuclear receptor subfamily 5 group A member 2 protein, plays a role in ligand-dependent regulation of gene transcription.			Gene or Genome	
C112512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112512>	C17671	Nuclear Receptor Subfamily 5 Group A Member 2|Alpha-1-Fetoprotein Transcription Factor|B1-Binding Factor|B1-Binding Factor, Hepatocyte Transcription Factor which Activates Enhancer II of Hepatitis B Virus|CYP7A Promoter-Binding Factor|Fetoprotein Transcription Factor|Fetoprotein-Alpha 1 (AFP) Transcription Factor|Hepatocytic Transcription Factor|Human B1-Binding Factor|LRH-1|Liver Receptor Homolog 1|Liver Receptor Homolog-1|NR5A2|Nuclear Receptor NR5A2|hB1F	Nuclear receptor subfamily 5 group A member 2 (541 aa, ~61 kDa) is encoded by the human NR5A2 gene. This protein is involved in both transcriptional regulation and hormone binding.			Amino Acid, Peptide, or Protein|Receptor	
C112513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112513>	C21282|C20103	NPR1 Gene|NPR1|NPR1|Natriuretic Peptide Receptor A/Guanylate Cyclase A (Atrionatriuretic Peptide Receptor A) Gene	This gene plays a role in ligand-dependent cyclic GMP synthesis.			Gene or Genome	
C112514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112514>	C112513	NPR1 wt Allele|ANPRA|ANPa|GUC2A|GUCY2A|NPRA|Natriuretic Peptide Receptor A/Guanylate Cyclase A (Atrionatriuretic Peptide Receptor A) wt Allele|RP11-354A16.3	Human NPR1 wild-type allele is located within 1q21-q22 and is approximately 15 kb in length. This allele, which encodes atrial natriuretic peptide receptor 1 protein, is involved in both natriuretic peptide binding and GTP metabolism.			Gene or Genome	
C112515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112515>	C18106|C16804	Atrial Natriuretic Peptide Receptor 1|ANP-A|ANPR-A|Atrial Natriuretic Peptide Receptor Type A|Atrial Natriuretic Peptide Receptor, Type A|Atrionatriuretic Peptide Receptor A|Atrionatriuretic Peptide Receptor, Type A|EC 4.6.1.2|GC-A|Guanylate Cyclase 2A|Guanylate Cyclase A|NPR-A|Natriuretic Peptide A Type Receptor|Natriuretic Peptide Receptor A|Natriuretic Peptide Receptor A/Guanylate Cyclase A	Atrial natriuretic peptide receptor 1 (1061 aa, ~119 kDa) is encoded by the human NPR1 gene. This protein plays a role in both guanylate cyclase activity and natriuretic peptide binding.			Amino Acid, Peptide, or Protein|Enzyme|Receptor	
C112516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112516>	C93022|C15389	Endoscopic Ultrasound Biopsy	The use of ultrasound imaging for real-time guidance of an endoscope for a biopsy procedure.			Diagnostic Procedure	
C112517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112517>	C67287|C51686	Ultrasound-Guided Transesophageal Endoscopic Fine-Needle Aspiration|Transesophageal Endoscopic Ultrasound-Guided Fine-Needle Aspiration|Transesophageal needle biopsy using endoscopic ultrasound	The use of endoscopic ultrasound imaging for real-time guidance of transesophageal fine-needle aspiration.			Diagnostic Procedure	
C112518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112518>	C91105	Airway Questionnaire 20|AQ01|AQ20|AQ20	A standardized rating scale developed by Barley et al in 1988 to measure health status and detect changes in quality of life in asthmatic patients. The questionnaire contains 20 questions and each can be answered with Yes, No, or N/A (Not Applicable).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112519>	C118969	Disease Steps Clinical Classification|DISEASE STEPS|DS|DS01	A standardized rating scale developed by Hohol et al in 1995, which is a self-assessment scale of functional disability in multiple sclerosis patients primarily based on ambulation. The questionnaire contains 1 question which is scored ranging from 0 (normal) to 6 (confined to wheelchair). There is an additional score for 'U' (unclassifiable) for patients who do not fit into the 0 to 6 classification categories.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11251>	C61063	Carmustine/Cyclophosphamide/Etoposide/Mesna|BCNU/CTX/Mesna/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112520>	C118969	Kurtzke Expanded Disability Status Scale Clinical Classification|EDSS|EDSS|EDSS01	A standardized rating scale developed by John F. Kurtzke in 1983 to measure the disability status and level of functioning in people with multiple sclerosis primarily based on ambulation. The questionnaire contains 1 question which is scored in half point scores ranging from 0 (Normal neurological exam) to 10 (Death due to MS). A score of 0 to 4.5 refers to people with a high degree of ambulatory ability; a score of 5 to 9.5 indicates the loss of ambulatory ability.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112521>	C91105	Functional Assessment of Multiple Sclerosis Questionnaire|FAMS|FAMS|FAMS|FAMS Questionnaire|FAMS01	A standardized, disease-specific rating scale developed by Cella et al in 1996 to assess quality of life and functional status of individuals with multiple sclerosis. The questionnaire contains 58 items across 7 categories; mobility, symptoms, emotional well-being, general contentment, thinking and fatigue, family/social well-being, and additional concerns. The scoring algorithm for this questionnaire assigns a value from 0 (not at all) to 4 (very much) to each item in the response categories, and the total score ranges between 0 and 176.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112522>	C118969	Kurtzke Functional Systems Scores Clinical Classification|KFSS|KFSS|KFSS1	A standardized rating scale developed by John F. Kurtzke in 1983 to measure the level of functioning in people with multiple sclerosis based on a standard neurological examination. The questionnaire contains 7 functional system; pyramidal functions, cerebellar functions, brainstem functions, sensory function, bowel and bladder function, visual function, and cerebral (or mental) functions. The functional system (FS) scores collected from this questionnaire are used in conjunction with observations and information regarding ambulation and the use of assistive devices to rate the EDSS.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112523>	C91105	Modified Hachinski Ischemic Scale-NACC Version Questionnaire|MHIS-NACC|MHIS-NACC|MHIS01	A standardized rating scale originally developed by Hachinski et al in 1975 and later modified by Rosen et al in 1980 to clinically differentiate two most common types of dementia: senile dementia of the Alzheimer type (SDAT), a primary degenerative disease, and primary degenerative disease (MID), a vascular disorder. The modified version of the questionnaire contains 8 features for more accurate diagnosis of MID, the vascular dementia type. This questionnaire can be scored between 0 and 18, where a score greater than 7 suggests vascular involvement.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112524>	C91105	Patient Determined Disease Steps Questionnaire|PDDS|PDDS|PDDS01	A standardized rating scale developed by Hohol et al in 1995, which is a self-assessment scale of functional disability in multiple sclerosis patients primarily based on ambulation. The questionnaire contains 1 question which is scored ranging from 0 (normal) to 8 (bedridden). A score of 0 to 2 indicates mild disability; a score of 3 to 5 indicates moderate disability; a score of 6 to 8 indicates severe disability.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112525>	C91105	St. George's Respiratory Questionnaire Past 3 Months Version|SGRQ PAST 3 MONTHS VERSION|SGRQ Past 3 Months Version|SGRQ01	A standardized, disease-specific rating scale developed by Jones et al in 1992, which is used to determine the impact on overall health, daily life and perceived well-being in patients with obstructive airway disease. The questionnaire contains 51 items across 2 parts; Symptoms component (frequency and severity with a 3-month performance recall); Impact component (activities that are causes to, or limited by breathlessness).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112526>	C91105	St. George's Respiratory Questionnaire Past 4 Weeks Version|SGRQ PAST 4 WEEKS VERSION|SGRQ Past 4 Weeks Version|SGRQ02	A standardized, disease-specific rating scale developed by Jones et al in 1992, which is used to determine the impact on overall health, daily life and perceived well-being in patients with obstructive airway disease. The questionnaire contains 51 items across 2 parts; Symptoms component (frequency and severity with a 4-week performance recall); Impact component (activities that are causes to, or limited by breathlessness).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112527>	C91105	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000|VFQ-25 INTERVIEWER ADMINISTERED|VFQ1|VFQ25-Interviewer Administered Format	A standardized rating scale developed by RAND and sponsored by the National Eye Institute (NEI) to assess the dimensions of self-reported vision-targeted health status that are most important for individuals with chronic eye disease. It also measures the influence of visual disability and symptoms on emotional well-being, mental health, social and daily visual functioning. This questionnaire is in the Interviewer Administered Format and contains 25 multiple choice questions across 3 domains; general health and vision, difficulty with activates, and response to vision problems. It also includes an appendix of additional 13 questions researchers can use to expand the scales up to 38 total items.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112528>	C91105	Visual Functioning Questionnaire 25-Self Administered Format Version 2000|VFQ-25 SELF ADMINISTERED|VFQ2|VFQ25-Self Administered Format	A standardized rating scale developed by RAND and sponsored by the National Eye Institute (NEI) to assess the dimensions of self-reported vision-targeted health status that are most important for individuals with chronic eye disease. It also measures the influence of visual disability and symptoms on emotional well-being, mental health, social and daily visual functioning. This questionnaire is in the Self or Patient Administered Format and contains 25 multiple choice questions across 3 domains; general health and vision, difficulty with activates, and response to vision problems. It also includes an appendix of additional 13 questions researchers can use to expand the scales up to 38 total items.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112529>	C112456	AQ20 - Cough Often During the Day|AQ01-Cough Often During Day|AQ01-Cough Often During Day|AQ0101	Airway Questionnaire 20 (AQ20) Do you cough often during the day?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AQ20 Test Code Terminology|CDISC Questionnaire AQ20 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11252>	C1557|C129825	Eniluracil/5-FU Combination Tablet|776C85/5-FU|Ethynyluracil/Fluorouracil|GW776/5-FU|GW776/5-Fluorouracil	A combination tablet of ethynyluracil and fluorouracil. Fluorouracil is an antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Ethynyluracil is an orally-active fluoropyrimidine analog that inhibits dihydropyrimidine dehydrogenase, the rate-limiting enzyme that catabolizes and inactivates 5-fluorouracil in the liver. This may lead to an increase in the bioavailability and, effectiveness of fluorouracil.			Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C112530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112530>	C112456	AQ20 - Chest Trouble Make You Feel Restless|AQ01-Feel Restless Due to Chest Trouble|AQ01-Feel Restless Due to Chest Trouble|AQ0102	Airway Questionnaire 20 (AQ20) Does your chest trouble often make you feel restless?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AQ20 Test Code Terminology|CDISC Questionnaire AQ20 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112531>	C112456	AQ20 - Gardening Make You Breathless|AQ01-Gardening Make You Breathless|AQ01-Gardening Make You Breathless|AQ0103	Airway Questionnaire 20 (AQ20) Does gardening make you breathless?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AQ20 Test Code Terminology|CDISC Questionnaire AQ20 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112532>	C112456	AQ20 - Worry When Going to Friend House Something Will Upset Your Chest|AQ01-Chest Upset at Friend House|AQ01-Chest Upset at Friend House|AQ0104	Airway Questionnaire 20 (AQ20) Do you worry when going to a friend's house that there might be something there that will upset your chest?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AQ20 Test Code Terminology|CDISC Questionnaire AQ20 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112533>	C112456	AQ20 - Get Chest Problems When Contact With Strong Smells|AQ01-Chest Prob Smell/Fume/Smoke/Perfume|AQ01-Chest Prob Smell/Fume/Smoke/Perfume|AQ0105	Airway Questionnaire 20 (AQ20) Do you get chest problems when you come into contact with strong smells, exhaust fumes, cigarette smoke, perfume etc?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AQ20 Test Code Terminology|CDISC Questionnaire AQ20 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112534>	C112456	AQ20 - Partner Find Your Chest Trouble Upsetting|AQ01-Partner Upset by Your Chest Trouble|AQ01-Partner Upset by Your Chest Trouble|AQ0106	Airway Questionnaire 20 (AQ20) Does your partner find your chest trouble upsetting?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AQ20 Test Code Terminology|CDISC Questionnaire AQ20 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112535>	C112456	AQ20 - Feel Breathless When Trying to Sleep|AQ01-Breathless When Trying to Sleep|AQ01-Breathless When Trying to Sleep|AQ0107	Airway Questionnaire 20 (AQ20) Do you feel breathless when trying to sleep?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AQ20 Test Code Terminology|CDISC Questionnaire AQ20 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112536>	C112456	AQ20 - Worry About Long Term Effects of Drugs for Chest Trouble|AQ01-Long Term Effects of Drugs|AQ01-Long Term Effects of Drugs|AQ0108	Airway Questionnaire 20 (AQ20) Do you worry about the long term effects of the drugs you take for your chest trouble?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AQ20 Test Code Terminology|CDISC Questionnaire AQ20 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112537>	C112456	AQ20 - Getting Emotionally Upset Make Chest Trouble Worse|AQ01-Emotional Upset Worse Chest Trouble|AQ01-Emotional Upset Worse Chest Trouble|AQ0109	Airway Questionnaire 20 (AQ20) Does getting emotionally upset make your chest trouble worse?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AQ20 Test Code Terminology|CDISC Questionnaire AQ20 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112538>	C112456	AQ20 - Difficulty Getting Around the House Because of Chest Trouble|AQ01-Difficulty Getting Around the House|AQ01-Difficulty Getting Around the House|AQ0110	Airway Questionnaire 20 (AQ20) Are there times when you have difficulty getting around the house because of your chest trouble?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AQ20 Test Code Terminology|CDISC Questionnaire AQ20 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112539>	C112456	AQ20 - Chest Problem Make You Breathless at Work|AQ01-Breathless Carry out Work Activity|AQ01-Breathless Carry out Work Activity|AQ0111	Airway Questionnaire 20 (AQ20) Does your chest problem make you breathless when you do things at work? (Paid employment).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AQ20 Test Code Terminology|CDISC Questionnaire AQ20 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11253>	C61063	Ethynyluracil/Fluorouracil/Leucovorin Calcium|776C85/CF/5-FU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112540>	C112456	AQ20 - Walking Upstairs Make You Breathless|AQ01-Breathless Walking Upstairs|AQ01-Breathless Walking Upstairs|AQ0112	Airway Questionnaire 20 (AQ20) Does walking upstairs make you breathless?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AQ20 Test Code Terminology|CDISC Questionnaire AQ20 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112541>	C112456	AQ20 - Get Breathless Doing Housework|AQ01-Get Breathless Doing Housework|AQ01-Get Breathless Doing Housework|AQ0113	Airway Questionnaire 20 (AQ20) Do you get breathless doing housework?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AQ20 Test Code Terminology|CDISC Questionnaire AQ20 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112542>	C112456	AQ20 - Chest Trouble Make You Go Home Sooner Than Others|AQ01-Go Home Sooner Than Others|AQ01-Go Home Sooner Than Others|AQ0114	Airway Questionnaire 20 (AQ20) Does your chest trouble make you go home sooner than others after a night out?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AQ20 Test Code Terminology|CDISC Questionnaire AQ20 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112543>	C112456	AQ20 - Suffer From Breathlessness When Laugh|AQ01-Breathlessness When Laugh|AQ01-Breathlessness When Laugh|AQ0115	Airway Questionnaire 20 (AQ20) Do you suffer from breathlessness when you laugh?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AQ20 Test Code Terminology|CDISC Questionnaire AQ20 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112544>	C112456	AQ20 - Chest Trouble Make You Feel Impatient|AQ01-Impatient Due to Chest Trouble|AQ01-Impatient Due to Chest Trouble|AQ0116	Airway Questionnaire 20 (AQ20) Does your chest trouble often make you feel impatient?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AQ20 Test Code Terminology|CDISC Questionnaire AQ20 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112545>	C112456	AQ20 - Fullness of Life is Limited by Chest Trouble|AQ01-Full Life Limited by Chest Trouble|AQ01-Full Life Limited by Chest Trouble|AQ0117	Airway Questionnaire 20 (AQ20) Do you think the fullness of your life is limited by your chest trouble?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AQ20 Test Code Terminology|CDISC Questionnaire AQ20 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112546>	C112456	AQ20 - Feel Drained After a Cold Because of Chest Trouble|AQ01-Drained After a Cold|AQ01-Drained After a Cold|AQ0118	Airway Questionnaire 20 (AQ20) Do you feel drained after a cold because of your chest trouble?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AQ20 Test Code Terminology|CDISC Questionnaire AQ20 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112547>	C112456	AQ20 - Feeling of Chest Heaviness|AQ01-Feeling of Chest Heaviness|AQ01-Feeling of Chest Heaviness|AQ0119	Airway Questionnaire 20 (AQ20) Do you have a feeling of chest heaviness?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AQ20 Test Code Terminology|CDISC Questionnaire AQ20 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112548>	C112456	AQ20 - Worry a Lot About Chest Trouble|AQ01-Worry About Chest Trouble|AQ01-Worry About Chest Trouble|AQ0120	Airway Questionnaire 20 (AQ20) Do you worry a lot about your chest trouble?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AQ20 Test Code Terminology|CDISC Questionnaire AQ20 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112549>	C112457	DS - Disease Steps Classification|DS01-Disease Steps Classification|DS01-Disease Steps Classification|DS0101	Disease Steps (DS) Methods: For Disease Steps, classification of a patient is determined by history and neurologic examination as well as course of MS.			Intellectual Product	CDISC Clinical Classification DS Test Code Terminology|CDISC Clinical Classification DS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11254>	C61063	Epirubicin/Paclitaxel|EPI/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112550>	C112458	EDSS - Expanded Disability Score|EDSS01-Expanded Disability Score|EDSS01-Expanded Disability Score|EDSS0101	Kurtzke Expanded Disability Status Scale (EDSS) Expanded disability score.			Intellectual Product	CDISC Clinical Classification EDSS Test Code Terminology|CDISC Clinical Classification EDSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112551>	C112459	FAMS - Have Trouble Meeting Needs of Family Because of My Condition|FAMS01-Trouble Meeting Needs of Family|FAMS01-Trouble Meeting Needs of Family|FAMS0101	Functional Assessment of Multiple Sclerosis (FAMS) Mobility: Because of my physical condition, I have trouble meeting the needs of my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112552>	C112459	FAMS - I Am Able to Work|FAMS01-I Am Able to Work|FAMS01-I Am Able to Work|FAMS0102	Functional Assessment of Multiple Sclerosis (FAMS) Mobility: I am able to work (include work at home).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112553>	C112459	FAMS - I Have Trouble Walking|FAMS01-I Have Trouble Walking|FAMS01-I Have Trouble Walking|FAMS0103	Functional Assessment of Multiple Sclerosis (FAMS) Mobility: I have trouble walking.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112554>	C112459	FAMS - Limit Social Activity Because of Condition|FAMS01-Limit My Social Activity|FAMS01-Limit My Social Activity|FAMS0104	Functional Assessment of Multiple Sclerosis (FAMS) Mobility: I have to limit my social activity because of my condition.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112555>	C112459	FAMS - I Have Strength in My Legs|FAMS01-I Have Strength in My Legs|FAMS01-I Have Strength in My Legs|FAMS0105	Functional Assessment of Multiple Sclerosis (FAMS) Mobility: I have strength in my legs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112556>	C112459	FAMS - Trouble Getting Around in Public Places|FAMS01-Trouble Getting Around in Public|FAMS01-Trouble Getting Around in Public|FAMS0106	Functional Assessment of Multiple Sclerosis (FAMS) Mobility: I have trouble getting around in public places.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112557>	C112459	FAMS - Have to Take Condition Into Account When Making Plans|FAMS01-Take My Condition Into Account|FAMS01-Take My Condition Into Account|FAMS0107	Functional Assessment of Multiple Sclerosis (FAMS) Mobility: I have to take my condition into account when making plans.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112558>	C112459	FAMS - I Have Nausea|FAMS01-I Have Nausea|FAMS01-I Have Nausea|FAMS0108	Functional Assessment of Multiple Sclerosis (FAMS) Symptoms: I have nausea.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112559>	C112459	FAMS - I Have Pain|FAMS01-I Have Pain|FAMS01-I Have Pain|FAMS0109	Functional Assessment of Multiple Sclerosis (FAMS) Symptoms: I have pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11255>	C61007	Dexamethasone/Fludarabine/Mitoxantrone|DHAD/DM/FAMP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112560>	C112459	FAMS - I Feel Ill|FAMS01-I Feel Ill|FAMS01-I Feel Ill|FAMS0110	Functional Assessment of Multiple Sclerosis (FAMS) Symptoms: I feel ill.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112561>	C112459	FAMS - I Feel Weak All Over|FAMS01-I Feel Weak All Over|FAMS01-I Feel Weak All Over|FAMS0111	Functional Assessment of Multiple Sclerosis (FAMS) Symptoms: I feel weak all over.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112562>	C112459	FAMS - I Have Pain in My Joints|FAMS01-I Have Pain in My Joints|FAMS01-I Have Pain in My Joints|FAMS0112	Functional Assessment of Multiple Sclerosis (FAMS) Symptoms: I have pain in my joints.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112563>	C112459	FAMS - Bothered by Headaches|FAMS01-I Am Bothered by Headaches|FAMS01-I Am Bothered by Headaches|FAMS0113	Functional Assessment of Multiple Sclerosis (FAMS) Symptoms: I am bothered by headaches.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112564>	C112459	FAMS - Bothered by Muscle Pains|FAMS01-I Am Bothered by Muscle Pains|FAMS01-I Am Bothered by Muscle Pains|FAMS0114	Functional Assessment of Multiple Sclerosis (FAMS) Symptoms: I am bothered by muscle pains.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112565>	C112459	FAMS - I Feel Sad|FAMS01-I Feel Sad|FAMS01-I Feel Sad|FAMS0115	Functional Assessment of Multiple Sclerosis (FAMS) Emotional Well-Being: I feel sad.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112566>	C112459	FAMS - Losing Hope in Fight Against My Illness|FAMS01-Losing Hope Against Illness|FAMS01-Losing Hope Against Illness|FAMS0116	Functional Assessment of Multiple Sclerosis (FAMS) Emotional Well-Being: I am losing hope in the fight against my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112567>	C112459	FAMS - I Am Able to Enjoy Life|FAMS01-I Am Able to Enjoy Life|FAMS01-I Am Able to Enjoy Life|FAMS0117	Functional Assessment of Multiple Sclerosis (FAMS) Emotional Well-Being: I am able to enjoy life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112568>	C112459	FAMS - Feel Trapped by My Condition|FAMS01-I Feel Trapped by My Condition|FAMS01-I Feel Trapped by My Condition|FAMS0118	Functional Assessment of Multiple Sclerosis (FAMS) Emotional Well-Being: I feel trapped by my condition.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112569>	C112459	FAMS - Depressed About My Condition|FAMS01-I Am Depressed About My Condition|FAMS01-I Am Depressed About My Condition|FAMS0119	Functional Assessment of Multiple Sclerosis (FAMS) Emotional Well-Being: I am depressed about my condition.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11256>	C61063	Paclitaxel/VX-710|TAX/VX-710			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112570>	C112459	FAMS - I Feel Useless|FAMS01-I Feel Useless|FAMS01-I Feel Useless|FAMS0120	Functional Assessment of Multiple Sclerosis (FAMS) Emotional Well-Being: I feel useless.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112571>	C112459	FAMS - Feel Overwhelmed by My Condition|FAMS01-Feel Overwhelmed by My Condition|FAMS01-Feel Overwhelmed by My Condition|FAMS0121	Functional Assessment of Multiple Sclerosis (FAMS) Emotional Well-Being: I feel overwhelmed by my condition.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112572>	C112459	FAMS - My Work is Fulfilling|FAMS01-My Work Is Fulfilling|FAMS01-My Work Is Fulfilling|FAMS0122	Functional Assessment of Multiple Sclerosis (FAMS) General Contentment: My work (include work at home) is fulfilling.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112573>	C112459	FAMS - I Have Accepted My Illness|FAMS01-I Have Accepted My Illness|FAMS01-I Have Accepted My Illness|FAMS0123	Functional Assessment of Multiple Sclerosis (FAMS) General Contentment: I have accepted my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112574>	C112459	FAMS - Enjoying Things I Usually Do for Fun|FAMS01-Enjoy Things I Usually Do for Fun|FAMS01-Enjoy Things I Usually Do for Fun|FAMS0124	Functional Assessment of Multiple Sclerosis (FAMS) General Contentment: I am enjoying the things I usually do for fun.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112575>	C112459	FAMS - Content With Quality of My Life Now|FAMS01-Content With Quality of My Life|FAMS01-Content With Quality of My Life|FAMS0125	Functional Assessment of Multiple Sclerosis (FAMS) General Contentment: I am content with the quality of my life right now.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112576>	C112459	FAMS - I Am Frustrated by My Condition|FAMS01-I Am Frustrated by My Condition|FAMS01-I Am Frustrated by My Condition|FAMS0126	Functional Assessment of Multiple Sclerosis (FAMS) General Contentment: I am frustrated by my condition.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112577>	C112459	FAMS - Feel Sense of Purpose in My Life|FAMS01-Feel Sense of Purpose in My Life|FAMS01-Feel Sense of Purpose in My Life|FAMS0127	Functional Assessment of Multiple Sclerosis (FAMS) General Contentment: I feel a sense of purpose in my life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112578>	C112459	FAMS - Feel Motivated to Do Things|FAMS01-I Feel Motivated to Do Things|FAMS01-I Feel Motivated to Do Things|FAMS0128	Functional Assessment of Multiple Sclerosis (FAMS) General Contentment: I feel motivated to do things.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112579>	C112459	FAMS - Have a Lack of Energy|FAMS01-I Have a Lack of Energy|FAMS01-I Have a Lack of Energy|FAMS0129	Functional Assessment of Multiple Sclerosis (FAMS) Thinking and Fatigue: I have a lack of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11257>	C61063	Docetaxel/Estramustine/Hydrocortisone|EM/HC/TXT			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112580>	C112459	FAMS - I Feel Tired|FAMS01-I Feel Tired|FAMS01-I Feel Tired|FAMS0130	Functional Assessment of Multiple Sclerosis (FAMS) Thinking and Fatigue: I feel tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112581>	C112459	FAMS - Trouble Starting Things Because I Am Tired|FAMS01-Trouble Starting Things|FAMS01-Trouble Starting Things|FAMS0131	Functional Assessment of Multiple Sclerosis (FAMS) Thinking and Fatigue: I have trouble starting things because I am tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112582>	C112459	FAMS - Trouble Finishing Things Because I Am Tired|FAMS01-Trouble Finishing Things|FAMS01-Trouble Finishing Things|FAMS0132	Functional Assessment of Multiple Sclerosis (FAMS) Thinking and Fatigue: I have trouble finishing things because I am tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112583>	C112459	FAMS - Need to Rest During the Day|FAMS01-I Need to Rest During the Day|FAMS01-I Need to Rest During the Day|FAMS0133	Functional Assessment of Multiple Sclerosis (FAMS) Thinking and Fatigue: I need to rest during the day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112584>	C112459	FAMS - Trouble Remembering Things|FAMS01-I Have Trouble Remembering Things|FAMS01-I Have Trouble Remembering Things|FAMS0134	Functional Assessment of Multiple Sclerosis (FAMS) Thinking and Fatigue: I have trouble remembering things.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112585>	C112459	FAMS - Trouble Concentrating|FAMS01-I Have Trouble Concentrating|FAMS01-I Have Trouble Concentrating|FAMS0135	Functional Assessment of Multiple Sclerosis (FAMS) Thinking and Fatigue: I have trouble concentrating.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112586>	C112459	FAMS - My Thinking is Slower Than Before|FAMS01-My Thinking Is Slower Than Before|FAMS01-My Thinking Is Slower Than Before|FAMS0136	Functional Assessment of Multiple Sclerosis (FAMS) Thinking and Fatigue: My thinking is slower than before.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112587>	C112459	FAMS - Trouble Learning New Tasks or Directions|FAMS01-I Have Trouble Learning New Tasks|FAMS01-I Have Trouble Learning New Tasks|FAMS0137	Functional Assessment of Multiple Sclerosis (FAMS) Thinking and Fatigue: I have trouble learning new tasks or directions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112588>	C112459	FAMS - Feel Close to My Friends|FAMS01-I Feel Close to My Friends|FAMS01-I Feel Close to My Friends|FAMS0138	Functional Assessment of Multiple Sclerosis (FAMS) Family/Social Well-Being: I feel close to my friends.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112589>	C112459	FAMS - Get Emotional Support From Family|FAMS01-Get Emotional Support From Family|FAMS01-Get Emotional Support From Family|FAMS0139	Functional Assessment of Multiple Sclerosis (FAMS) Family/Social Well-Being: I get emotional support from my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11258>	C61063	Busulfan/Cyclophosphamide/Decitabine|BU/CTX/DAC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112590>	C112459	FAMS - Get Support From Friends|FAMS01-I Get Support From My Friends|FAMS01-I Get Support From My Friends|FAMS0140	Functional Assessment of Multiple Sclerosis (FAMS) Family/Social Well-Being: I get support from my friends.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112591>	C112459	FAMS - Family Has Accepted My Illness|FAMS01-My Family Has Accepted My Illness|FAMS01-My Family Has Accepted My Illness|FAMS0141	Functional Assessment of Multiple Sclerosis (FAMS) Family/Social Well-Being: My family has accepted my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112592>	C112459	FAMS - Satisfied With Family Communication About My Illness|FAMS01-Satisfied Communication Illness|FAMS01-Satisfied Communication Illness|FAMS0142	Functional Assessment of Multiple Sclerosis (FAMS) Family/Social Well-Being: I am satisfied with family communication about my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112593>	C112459	FAMS - Family Has Trouble Understanding When My Condition Gets Worse|FAMS01-Trouble Understanding Worsening|FAMS01-Trouble Understanding Worsening|FAMS0143	Functional Assessment of Multiple Sclerosis (FAMS) Family/Social Well-Being: My family has trouble understanding when my condition gets worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112594>	C112459	FAMS - Feel Left Out of Things|FAMS01-I Feel Left Out of Things|FAMS01-I Feel Left Out of Things|FAMS0144	Functional Assessment of Multiple Sclerosis (FAMS) Family/Social Well-Being: I feel 'left out' of things.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112595>	C112459	FAMS - Bothered by Side Effects of Treatment|FAMS01-Bothered by Treatment Side Effect|FAMS01-Bothered by Treatment Side Effect|FAMS0145	Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: I am bothered by side effects of treatment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112596>	C112459	FAMS - Forced to Spend Time in Bed|FAMS01-I Am Forced to Spend Time in Bed|FAMS01-I Am Forced to Spend Time in Bed|FAMS0146	Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: I am forced to spend time in bed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112597>	C112459	FAMS - Feel Close to My Partner|FAMS01-I Feel Close to My Partner|FAMS01-I Feel Close to My Partner|FAMS0147	Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: I feel close to my partner (or the person who is my main support).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112598>	C112459	FAMS - Satisfied With My Sex Life|FAMS01-I Am Satisfied With My Sex Life|FAMS01-I Am Satisfied With My Sex Life|FAMS0148	Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: I am satisfied with my sex life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112599>	C112459	FAMS - Satisfied With How I Am Coping With Illness|FAMS01-Satisfied With How I Am Coping|FAMS01-Satisfied With How I Am Coping|FAMS0149	Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: I am satisfied with how I am coping with my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11259>	C61063	Cladribine/Cytarabine|ARA-C/2-CdA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1125>	C292|C1934	Hexamethylene Bisacetamide|Acetamide, N,N'-1, 6-hexanediylbis-|Acetamide, N,N'-hexamethylenebis-|HEXAMETHYLENE BISACETAMIDE|HMBA|HMBA|Hexamethylene bisacetamide|Hexamethylenebisacetamide|Hexamethylenediacetamide|N, N'-Diacetylhexamethylenediamine|N,N'-1,6-Hexanediylbisacetamide|N,N'-Hexamethylenebisacetamide	A hybrid polar-planar compound with potential antineoplastic activity that induces terminal differentiation, inhibits cell growth, and causes apoptosis in several tumor cell lines.  Its precise mechanism of action is unknown. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C112600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112600>	C112459	FAMS - I Feel Nervous|FAMS01-I Feel Nervous|FAMS01-I Feel Nervous|FAMS0150	Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: I feel nervous.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112601>	C112459	FAMS - Worry My Condition Will Get Worse|FAMS01-Worry My Condition Will Get Worse|FAMS01-Worry My Condition Will Get Worse|FAMS0151	Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: I worry that my condition will get worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112602>	C112459	FAMS - I Am Sleeping Well|FAMS01-I Am Sleeping Well|FAMS01-I Am Sleeping Well|FAMS0152	Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: I am sleeping well.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112603>	C112459	FAMS - Heat Worsens My Symptoms|FAMS01-Heat Worsens My Symptoms|FAMS01-Heat Worsens My Symptoms|FAMS0153	Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: Heat worsens my symptoms.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112604>	C112459	FAMS - Trouble Controlling My Urine|FAMS01-Have Trouble Controlling My Urine|FAMS01-Have Trouble Controlling My Urine|FAMS0154	Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: I have trouble controlling my urine.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112605>	C112459	FAMS - Urinate More Frequently Than Usual|FAMS01-I Urinate More Frequently|FAMS01-I Urinate More Frequently|FAMS0155	Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: I urinate more frequently than usual.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112606>	C112459	FAMS - Bothered by Chills|FAMS01-I Am Bothered by the Chills|FAMS01-I Am Bothered by the Chills|FAMS0156	Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: I am bothered by the chills.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112607>	C112459	FAMS - Bothered by Fevers|FAMS01-I Am Bothered by Fevers|FAMS01-I Am Bothered by Fevers|FAMS0157	Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: I am bothered by fevers (episodes of high body temperature).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112608>	C112459	FAMS - Bothered by Muscle Spasms|FAMS01-I Am Bothered by Muscle Spasms|FAMS01-I Am Bothered by Muscle Spasms|FAMS0158	Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: I am bothered by muscle spasms.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FAMS Test Code Terminology|CDISC Questionnaire FAMS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112609>	C112460	KFSS - Pyramidal Functions|KFSS1-Pyramidal Functions|KFSS1-Pyramidal Functions|KFSS101	Kurtzke Functional Systems Scores (KFSS) Pyramidal functions.			Intellectual Product	CDISC Clinical Classification KFSS Test Code Terminology|CDISC Clinical Classification KFSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11260>	C61063	Cisplatin/Ifosfamide/Mesna/Mitomycin|CDDP/IFF/mesna/MITO|MIMIC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112610>	C112460	KFSS - Cerebellar Functions|KFSS1-Cerebellar Functions|KFSS1-Cerebellar Functions|KFSS102	Kurtzke Functional Systems Scores (KFSS) Cerebellar functions.			Intellectual Product	CDISC Clinical Classification KFSS Test Code Terminology|CDISC Clinical Classification KFSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112611>	C112460	KFSS - Weakness Interferes With Testing|KFSS1-Weakness Interferes With Testing|KFSS1-Weakness Interferes With Testing|KFSS102A	Kurtzke Functional Systems Scores (KFSS) Record number 1 in small box when weakness (grade 3 or worse on pyramidal) interferes with testing.			Intellectual Product	CDISC Clinical Classification KFSS Test Code Terminology|CDISC Clinical Classification KFSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112612>	C112460	KFSS - Brain Stem Functions|KFSS1-Brain Stem Functions|KFSS1-Brain Stem Functions|KFSS103	Kurtzke Functional Systems Scores (KFSS) Brainstem functions.			Intellectual Product	CDISC Clinical Classification KFSS Test Code Terminology|CDISC Clinical Classification KFSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112613>	C112460	KFSS - Sensory Functions|KFSS1-Sensory Functions|KFSS1-Sensory Functions|KFSS104	Kurtzke Functional Systems Scores (KFSS) Sensory function.			Intellectual Product	CDISC Clinical Classification KFSS Test Code Terminology|CDISC Clinical Classification KFSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112614>	C112460	KFSS - Bowel and Bladder Functions|KFSS1-Bowel and Bladder Functions|KFSS1-Bowel and Bladder Functions|KFSS105	Kurtzke Functional Systems Scores (KFSS) Bowel and bladder function.			Intellectual Product	CDISC Clinical Classification KFSS Test Code Terminology|CDISC Clinical Classification KFSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112615>	C112460	KFSS - Visual (or Optic) Functions|KFSS1-Visual or Optic Functions|KFSS1-Visual or Optic Functions|KFSS106	Kurtzke Functional Systems Scores (KFSS) Visual function.			Intellectual Product	CDISC Clinical Classification KFSS Test Code Terminology|CDISC Clinical Classification KFSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112616>	C112460	KFSS - Presence of Temporal Pallor|KFSS1-Presence of Temporal Pallor|KFSS1-Presence of Temporal Pallor|KFSS106A	Kurtzke Functional Systems Scores (KFSS) Record number 1 in small box for presence of temporal pallor.			Intellectual Product	CDISC Clinical Classification KFSS Test Code Terminology|CDISC Clinical Classification KFSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112617>	C112460	KFSS - Cerebral (or Mental) Functions|KFSS1-Cerebral or Mental Functions|KFSS1-Cerebral or Mental Functions|KFSS107	Kurtzke Functional Systems Scores (KFSS) Cerebral (or mental) functions.			Intellectual Product	CDISC Clinical Classification KFSS Test Code Terminology|CDISC Clinical Classification KFSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112618>	C112461	MHIS-NACC - Abrupt Onset|MHIS01-Abrupt Onset|MHIS01-Abrupt Onset|MHIS0101	Modified Hachinski Ischemic Scale-NACC Version (MHIS-NACC) Abrupt onset (re: cognitive status).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MHIS-NACC Test Code Terminology|CDISC Questionnaire MHIS-NACC Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112619>	C112461	MHIS-NACC - Stepwise Deterioration|MHIS01-Stepwise Deterioration|MHIS01-Stepwise Deterioration|MHIS0102	Modified Hachinski Ischemic Scale-NACC Version (MHIS-NACC) Stepwise deterioration (re: cognitive status).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MHIS-NACC Test Code Terminology|CDISC Questionnaire MHIS-NACC Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11261>	C61007	Anti-thymocyte Globulin/Melphalan|ATG/L-PAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112620>	C112461	MHIS-NACC - Emotional Incontinence|MHIS01-Emotional Incontinence|MHIS01-Emotional Incontinence|MHIS0104	Modified Hachinski Ischemic Scale-NACC Version (MHIS-NACC) Emotional incontinence.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MHIS-NACC Test Code Terminology|CDISC Questionnaire MHIS-NACC Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112621>	C112461	MHIS-NACC - History or Presence of Hypertension|MHIS01-History or Presence Hypertension|MHIS01-History or Presence Hypertension|MHIS0105	Modified Hachinski Ischemic Scale-NACC Version (MHIS-NACC) History or presence of hypertension.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MHIS-NACC Test Code Terminology|CDISC Questionnaire MHIS-NACC Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112622>	C112461	MHIS-NACC - History of Stroke|MHIS01-History of Stroke|MHIS01-History of Stroke|MHIS0106	Modified Hachinski Ischemic Scale-NACC Version (MHIS-NACC) History of stroke.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MHIS-NACC Test Code Terminology|CDISC Questionnaire MHIS-NACC Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112623>	C112461	MHIS-NACC - Focal Neurological Symptoms|MHIS01-Focal Neurological Symptoms|MHIS01-Focal Neurological Symptoms|MHIS0107	Modified Hachinski Ischemic Scale-NACC Version (MHIS-NACC) Focal neurological symptoms.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MHIS-NACC Test Code Terminology|CDISC Questionnaire MHIS-NACC Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112624>	C112461	MHIS-NACC - Focal Neurological Signs|MHIS01-Focal Neurological Signs|MHIS01-Focal Neurological Signs|MHIS0108	Modified Hachinski Ischemic Scale-NACC Version (MHIS-NACC) Focal neurological signs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MHIS-NACC Test Code Terminology|CDISC Questionnaire MHIS-NACC Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112625>	C112461	MHIS-NACC - Total Score|MHIS01-Total Score|MHIS01-Total Score|MHIS0109	Modified Hachinski Ischemic Scale-NACC Version (MHIS-NACC) Sum all circled answers for a total score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MHIS-NACC Test Code Terminology|CDISC Questionnaire MHIS-NACC Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112626>	C112462	PDDS - Category Describing Situation|PDDS01-Category Describing Situation|PDDS01-Category Describing Situation|PDDS0101	Patient Determined Disease Steps (PDDS) This scale focuses mainly on how well you walk. You might not find a description that reflects your condition exactly, but please mark the one category that describes your situation the closest.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PDDS Test Code Terminology|CDISC Questionnaire PDDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112627>	C112463	SGRQ Past 3 Months Version - Describe Your Current Health|SGRQ01-Describe Your Current Health|SGRQ01-Describe Your Current Health|SGRQ0101	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) Please check one box to show how you describe your current health.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112628>	C112463	SGRQ Past 3 Months Version - I Have Coughed|SGRQ01-I Have Coughed|SGRQ01-I Have Coughed|SGRQ0102	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) Over the past 3 months, I have coughed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112629>	C112463	SGRQ Past 3 Months Version - I Have Brought Up Phlegm|SGRQ01-I Have Brought Up Phlegm|SGRQ01-I Have Brought Up Phlegm|SGRQ0103	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) Over the past 3 months, I have brought up phlegm (sputum).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11262>	C61007	Carmustine/Cisplatin/Filgrastim/Thiotepa|BCNU/CTX/G-CSF/TSPA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112630>	C112463	SGRQ Past 3 Months Version - I Have Had Shortness of Breath|SGRQ01-I Have Had Shortness of Breath|SGRQ01-I Have Had Shortness of Breath|SGRQ0104	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) Over the past 3 months, I have had shortness of breath.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112631>	C112463	SGRQ Past 3 Months Version - I Have Had Wheezing Attacks|SGRQ01-I Have Had Wheezing Attacks|SGRQ01-I Have Had Wheezing Attacks|SGRQ0105	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) Over the past 3 months, I have had wheezing attacks.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112632>	C112463	SGRQ Past 3 Months Version - Times Suffered From Severe Respiratory Attacks|SGRQ01-Times Suffered Sev Resp Attacks|SGRQ01-Times Suffered Sev Resp Attacks|SGRQ0106	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) How many times during the past 3 months have you suffered from severe or very unpleasant respiratory attacks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112633>	C112463	SGRQ Past 3 Months Version - How Long Did Worst Respiratory Attack Last|SGRQ01-How Long Worst Resp Attack Last|SGRQ01-How Long Worst Resp Attack Last|SGRQ0107	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) How long did the worst respiratory attack last?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112634>	C112463	SGRQ Past 3 Months Version - How Many Good Days You Had|SGRQ01-How Many Good Days Have You Had|SGRQ01-How Many Good Days Have You Had|SGRQ0108	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) Over the past 3 months, in a typical week, how many good days (with few respiratory problems) have you had?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112635>	C112463	SGRQ Past 3 Months Version - Wheeze Worse When Get Up in the Morning|SGRQ01-Wheeze Worse in the Morning|SGRQ01-Wheeze Worse in the Morning|SGRQ0109	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) If you wheeze, is it worse when you get up in the morning?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112636>	C112463	SGRQ Past 3 Months Version - Describe Your Respiratory Condition|SGRQ01-Describe Your Resp Condition|SGRQ01-Describe Your Resp Condition|SGRQ0110	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) How would you describe your respiratory condition?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112637>	C112463	SGRQ Past 3 Months Version - Held a Job|SGRQ01-If You Have Ever Held a Job|SGRQ01-If You Have Ever Held a Job|SGRQ0111	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) If you have ever held a job.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112638>	C112463	SGRQ Past 3 Months Version - Sitting or Lying Still|SGRQ01-Sitting or Lying Still|SGRQ01-Sitting or Lying Still|SGRQ0112	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about what activities usually make you feel short of breath these days: Sitting or lying still.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112639>	C112463	SGRQ Past 3 Months Version - Washing or Dressing Yourself|SGRQ01-Washing or Dressing Yourself|SGRQ01-Washing or Dressing Yourself|SGRQ0113	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about what activities usually make you feel short of breath these days: Washing or dressing yourself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11263>	C61063	Cyclophosphamide/Dexamethasone/Etoposide|CTX/DM/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112640>	C112463	SGRQ Past 3 Months Version - Walking Around the House|SGRQ01-Walking Around the House|SGRQ01-Walking Around the House|SGRQ0114	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about what activities usually make you feel short of breath these days: Walking around the house.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112641>	C112463	SGRQ Past 3 Months Version - Walking Outside on Level Ground|SGRQ01-Walking Outside on Level Ground|SGRQ01-Walking Outside on Level Ground|SGRQ0115	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about what activities usually make you feel short of breath these days: Walking outside on level ground.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112642>	C112463	SGRQ Past 3 Months Version - Walking Up a Flight of Stairs|SGRQ01-Walking Up a Flight of Stairs|SGRQ01-Walking Up a Flight of Stairs|SGRQ0116	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about what activities usually make you feel short of breath these days: Walking up a flight of stairs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112643>	C112463	SGRQ Past 3 Months Version - Walking Up Hills|SGRQ01-Walking Up Hills|SGRQ01-Walking Up Hills|SGRQ0117	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about what activities usually make you feel short of breath these days: Walking up hills.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112644>	C112463	SGRQ Past 3 Months Version - Playing Sports or Other Physical Activities|SGRQ01-Playing Sports|SGRQ01-Playing Sports|SGRQ0118	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about what activities usually make you feel short of breath these days: Playing sports or other physical activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112645>	C112463	SGRQ Past 3 Months Version - Coughing Hurts|SGRQ01-Coughing Hurts|SGRQ01-Coughing Hurts|SGRQ0119	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are more questions about your cough and shortness of breath these days: Coughing hurts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112646>	C112463	SGRQ Past 3 Months Version - Coughing Makes Me Tired|SGRQ01-Coughing Makes Me Tired|SGRQ01-Coughing Makes Me Tired|SGRQ0120	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are more questions about your cough and shortness of breath these days: Coughing makes me tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112647>	C112463	SGRQ Past 3 Months Version - Short of Breath When I Talk|SGRQ01-Short of Breath When I Talk|SGRQ01-Short of Breath When I Talk|SGRQ0121	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are more questions about your cough and shortness of breath these days: I am short of breath when I talk.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112648>	C112463	SGRQ Past 3 Months Version - Short of Breath When Bend Over|SGRQ01-Short of Breath When Bend Over|SGRQ01-Short of Breath When Bend Over|SGRQ0122	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are more questions about your cough and shortness of breath these days: I am short of breath when I bend over.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112649>	C112463	SGRQ Past 3 Months Version - Coughing Disturbs My Sleep|SGRQ01-Coughing Disturbs My Sleep|SGRQ01-Coughing Disturbs My Sleep|SGRQ0123	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are more questions about your cough and shortness of breath these days: My coughing or breathing disturbs my sleep.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11264>	C61063	Fluorouracil/Marimastat|BB-2516/5-FU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112650>	C112463	SGRQ Past 3 Months Version - I Get Exhausted Easily|SGRQ01-I Get Exhausted Easily|SGRQ01-I Get Exhausted Easily|SGRQ0124	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are more questions about your cough and shortness of breath these days: I get exhausted easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112651>	C112463	SGRQ Past 3 Months Version - My Cough is Embarrassing in Public|SGRQ01-Cough Is Embarrassing in Public|SGRQ01-Cough Is Embarrassing in Public|SGRQ0125	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about other effects that your respiratory problems may have on you these days: My cough or breathing is embarrassing in public.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112652>	C112463	SGRQ Past 3 Months Version - Respiratory Problems a Nuisance to Family|SGRQ01-Respiratory Problems a Nuisance|SGRQ01-Respiratory Problems a Nuisance|SGRQ0126	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about other effects that your respiratory problems may have on you these days: My respiratory problems are a nuisance to my family, friends or neighbors.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112653>	C112463	SGRQ Past 3 Months Version - Get Afraid When Cannot Catch My Breath|SGRQ01-Afraid When Cannot Catch Breath|SGRQ01-Afraid When Cannot Catch Breath|SGRQ0127	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about other effects that your respiratory problems may have on you these days: I get afraid or panic when I cannot catch my breath.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112654>	C112463	SGRQ Past 3 Months Version - Not in Control of My Respiratory Problems|SGRQ01-Not in Control of Resp Problems|SGRQ01-Not in Control of Resp Problems|SGRQ0128	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about other effects that your respiratory problems may have on you these days: I feel that I am not in control of my respiratory problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112655>	C112463	SGRQ Past 3 Months Version - Not Expect Respiratory Problems Get Better|SGRQ01-Not Expect Probs to Get Better|SGRQ01-Not Expect Probs to Get Better|SGRQ0129	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about other effects that your respiratory problems may have on you these days: I do not expect my respiratory problems to get any better.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112656>	C112463	SGRQ Past 3 Months Version - Become Frail or Invalid Because of My Respiratory Problems|SGRQ01-I Have Become Frail|SGRQ01-I Have Become Frail|SGRQ0130	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about other effects that your respiratory problems may have on you these days: I have become frail or an invalid because of my respiratory problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112657>	C112463	SGRQ Past 3 Months Version - Exercise Is Not Safe for Me|SGRQ01-Exercise Is Not Safe for Me|SGRQ01-Exercise Is Not Safe for Me|SGRQ0131	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about other effects that your respiratory problems may have on you these days: Exercise is not safe for me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112658>	C112463	SGRQ Past 3 Months Version - Everything Too Much Effort|SGRQ01-Everything Too Much Effort|SGRQ01-Everything Too Much Effort|SGRQ0132	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about other effects that your respiratory problems may have on you these days: Everything seems too much of an effort.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112659>	C112463	SGRQ Past 3 Months Version - Treatment Does Not Help Me Much|SGRQ01-Treatment Does Not Help Me Much|SGRQ01-Treatment Does Not Help Me Much|SGRQ0133	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about your respiratory treatment: My treatment does not help me very much.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11265>	C61063	Cytarabine/Lomustine/Methotrexate/Methylprednisolone/Procarbazine|ARA-C/CCNU/MePRDL/MTX/PCB			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112660>	C112463	SGRQ Past 3 Months Version - Embarrassed Using Medication in Public|SGRQ01-Embarrassed Using Med in Public|SGRQ01-Embarrassed Using Med in Public|SGRQ0134	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about your respiratory treatment: I get embarrassed using my medication in public.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112661>	C112463	SGRQ Past 3 Months Version - Unpleasant Side Effects From Medication|SGRQ01-Unpleasant Side Effect From Med|SGRQ01-Unpleasant Side Effect From Med|SGRQ0135	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about your respiratory treatment: I have unpleasant side effects from my medication.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112662>	C112463	SGRQ Past 3 Months Version - Treatment Interferes With My Life|SGRQ01-Treatment Interferes With Life|SGRQ01-Treatment Interferes With Life|SGRQ0136	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about your respiratory treatment: My treatment interferes with my life a lot.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112663>	C112463	SGRQ Past 3 Months Version - Take Long Time to Get Washed or Dressed|SGRQ01-Take a Long Time to Get Washed|SGRQ01-Take a Long Time to Get Washed|SGRQ0137	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about how your activities might be affected by your respiratory problems: I take a long time to get washed or dressed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112664>	C112463	SGRQ Past 3 Months Version - Cannot Take a Bath or Shower|SGRQ01-I Cannot Take a Bath or Shower|SGRQ01-I Cannot Take a Bath or Shower|SGRQ0138	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about how your activities might be affected by your respiratory problems: I cannot take a bath or shower, or I take a long time to do it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112665>	C112463	SGRQ Past 3 Months Version - Walk Slower Than Other People My Age|SGRQ01-I Walk Slower Than Other People|SGRQ01-I Walk Slower Than Other People|SGRQ0139	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about how your activities might be affected by your respiratory problems: I walk slower than other people my age, or I stop to rest.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112666>	C112463	SGRQ Past 3 Months Version - Jobs Take Long Time or I Have to Stop|SGRQ01-Jobs Take a Long Time|SGRQ01-Jobs Take a Long Time|SGRQ0140	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about how your activities might be affected by your respiratory problems: Jobs such as household chores take a long time, or I have to stop to rest.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112667>	C112463	SGRQ Past 3 Months Version - If Walk Up One Flight of Stairs I Have to Go Slow|SGRQ01-Walk Up Flight of Stairs Slowly|SGRQ01-Walk Up Flight of Stairs Slowly|SGRQ0141	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about how your activities might be affected by your respiratory problems: If I walk up one flight of stairs, I have to go slowly or stop.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112668>	C112463	SGRQ Past 3 Months Version - If Walk Fast I Have to Stop or Slow Down|SGRQ01-If I Hurry, I Have to Stop|SGRQ01-If I Hurry, I Have to Stop|SGRQ0142	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about how your activities might be affected by your respiratory problems: If I hurry or walk fast, I have to stop or slow down.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112669>	C112463	SGRQ Past 3 Months Version - Breathing Makes Difficult to Walk Up Hills|SGRQ01-Difficult to Walk Up Hills|SGRQ01-Difficult to Walk Up Hills|SGRQ0143	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about how your activities might be affected by your respiratory problems: My breathing makes it difficult to do things such as walk up hills, carry things up stairs, light gardening such as weeding, dance, bowl or play golf.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11266>	C67338|C63510|C63358|C159440	Etoposide/Ifosfamide/Mesna Regimen|Etoposide-Ifosfamide-Mesna|Etoposide/Ifosfamide/Mesna|IFF/Mesna/VP-16|IFoVP|IfoVP|Ifosfa/Mesna/Etop	A regimen consisting of etoposide, ifosfamide and mesna that may be used in the treatment of breast cancer, bone cancer, and recurrent sarcomas.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C112670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112670>	C112463	SGRQ Past 3 Months Version - Breathing Makes Difficult to Carry Heavy Loads|SGRQ01-Difficult to Carry Heavy Loads|SGRQ01-Difficult to Carry Heavy Loads|SGRQ0144	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about how your activities might be affected by your respiratory problems: My breathing makes it difficult to do things such as carry heavy loads, dig in the garden or shovel snow, jog or walk briskly (5 miles per hour), play tennis or swim.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112671>	C112463	SGRQ Past 3 Months Version - Breathing Makes Difficult to Do Heavy Manual Work|SGRQ01-Difficult to Do Very Heavy Work|SGRQ01-Difficult to Do Very Heavy Work|SGRQ0145	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) These are questions about how your activities might be affected by your respiratory problems: My breathing makes it difficult to do things such as very heavy manual work, ride a bike, run, swim fast, or play competitive sports.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112672>	C112463	SGRQ Past 3 Months Version - Cannot Play Sports or Do Physical Activities|SGRQ01-I Cannot Play Sports|SGRQ01-I Cannot Play Sports|SGRQ0146	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) We would like to know how your respiratory problems usually affect your daily life: I cannot play sports or do other physical activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112673>	C112463	SGRQ Past 3 Months Version - Cannot Go Out for Entertainment|SGRQ01-Cannot Go Out for Entertainment|SGRQ01-Cannot Go Out for Entertainment|SGRQ0147	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) We would like to know how your respiratory problems usually affect your daily life: I cannot go out for entertainment or recreation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112674>	C112463	SGRQ Past 3 Months Version - Cannot Go Out to Do Shopping|SGRQ01-Cannot Go Out to Do Shopping|SGRQ01-Cannot Go Out to Do Shopping|SGRQ0148	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) We would like to know how your respiratory problems usually affect your daily life: I cannot go out of the house to do the shopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112675>	C112463	SGRQ Past 3 Months Version - Cannot Do Household Chores|SGRQ01-I Cannot Do Household Chores|SGRQ01-I Cannot Do Household Chores|SGRQ0149	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) We would like to know how your respiratory problems usually affect your daily life: I cannot do household chores.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112676>	C112463	SGRQ Past 3 Months Version - Cannot Move Far From Bed or Chair|SGRQ01-I Cannot Move Far From My Bed|SGRQ01-I Cannot Move Far From My Bed|SGRQ0150	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) We would like to know how your respiratory problems usually affect your daily life: I cannot move far from my bed or chair.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112677>	C112463	SGRQ Past 3 Months Version - How Respiratory Problems Affect You|SGRQ01-How Resp Problems Affect You|SGRQ01-How Resp Problems Affect You|SGRQ0151	St. George's Respiratory Questionnaire Past 3 Months Version (SGRQ Past 3 Months Version) Best describe how your respiratory problems affect you.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Code Terminology|CDISC Questionnaire SGRQ Past 3 Months Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112678>	C112464	SGRQ Past 4 Weeks Version - Describe Your Current Health|SGRQ02-Describe Your Current Health|SGRQ02-Describe Your Current Health|SGRQ0201	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) Please check one box to show how you describe your current health.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112679>	C112464	SGRQ Past 4 Weeks Version - I Have Coughed|SGRQ02-I Have Coughed|SGRQ02-I Have Coughed|SGRQ0202	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) Over the past 4 weeks, I have coughed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11267>	C61063	Ifosfamide/Mesna/Mitoxantrone|DHAD/IFF/mesna			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112680>	C112464	SGRQ Past 4 Weeks Version - I Have Brought Up Phlegm|SGRQ02-I Have Brought Up Phlegm|SGRQ02-I Have Brought Up Phlegm|SGRQ0203	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) Over the past 4 weeks, I have brought up phlegm (sputum).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112681>	C112464	SGRQ Past 4 Weeks Version - I Have Had Shortness of Breath|SGRQ02-I Have Had Shortness of Breath|SGRQ02-I Have Had Shortness of Breath|SGRQ0204	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) Over the past 4 weeks, I have had shortness of breath.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112682>	C112464	SGRQ Past 4 Weeks Version - I Have Had Wheezing Attacks|SGRQ02-I Have Had Wheezing Attacks|SGRQ02-I Have Had Wheezing Attacks|SGRQ0205	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) Over the past 4 weeks, I have had wheezing attacks.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112683>	C112464	SGRQ Past 4 Weeks Version - Times Suffered From Severe Respiratory Attacks|SGRQ02-Times Suffered Sev Resp Attacks|SGRQ02-Times Suffered Sev Resp Attacks|SGRQ0206	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) How many times during the past 4 weeks have you suffered from severe or very unpleasant respiratory attacks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112684>	C112464	SGRQ Past 4 Weeks Version - How Long Did Worst Respiratory Attack Last|SGRQ02-How Long Worst Resp Attack Last|SGRQ02-How Long Worst Resp Attack Last|SGRQ0207	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) How long did the worst respiratory attack last?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112685>	C112464	SGRQ Past 4 Weeks Version - How Many Good Days You Had|SGRQ02-How Many Good Days Have You Had|SGRQ02-How Many Good Days Have You Had|SGRQ0208	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) Over the past 4 weeks, in a typical week, how many good days (with few respiratory problems) have you had?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112686>	C112464	SGRQ Past 4 Weeks Version - Wheeze Worse When Get Up in the Morning|SGRQ02-Wheeze Worse in the Morning|SGRQ02-Wheeze Worse in the Morning|SGRQ0209	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) If you wheeze, is it worse when you get up in the morning?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112687>	C112464	SGRQ Past 4 Weeks Version - Describe Your Respiratory Condition|SGRQ02-Describe Your Resp Condition|SGRQ02-Describe Your Resp Condition|SGRQ0210	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) How would you describe your respiratory condition?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112688>	C112464	SGRQ Past 4 Weeks Version - Held a Job|SGRQ02-If You Have Ever Held a Job|SGRQ02-If You Have Ever Held a Job|SGRQ0211	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) If you have ever held a job.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112689>	C112464	SGRQ Past 4 Weeks Version - Sitting or Lying Still|SGRQ02-Sitting or Lying Still|SGRQ02-Sitting or Lying Still|SGRQ0212	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about what activities usually make you feel short of breath these days: Sitting or lying still.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11268>	C61063	Cyclophosphamide/Doxorubicin/Octreotide Pamoate/Tamoxifen|CTX/DOX/SMS 201-995 pa/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112690>	C112464	SGRQ Past 4 Weeks Version - Washing or Dressing Yourself|SGRQ02-Washing or Dressing Yourself|SGRQ02-Washing or Dressing Yourself|SGRQ0213	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about what activities usually make you feel short of breath these days: Washing or dressing yourself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112691>	C112464	SGRQ Past 4 Weeks Version - Walking Around the House|SGRQ02-Walking Around the House|SGRQ02-Walking Around the House|SGRQ0214	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about what activities usually make you feel short of breath these days: Walking around the house.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112692>	C112464	SGRQ Past 4 Weeks Version - Walking Outside on Level Ground|SGRQ02-Walking Outside on Level Ground|SGRQ02-Walking Outside on Level Ground|SGRQ0215	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about what activities usually make you feel short of breath these days: Walking outside on level ground.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112693>	C112464	SGRQ Past 4 Weeks Version - Walking Up a Flight of Stairs|SGRQ02-Walking Up a Flight of Stairs|SGRQ02-Walking Up a Flight of Stairs|SGRQ0216	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about what activities usually make you feel short of breath these days: Walking up a flight of stairs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112694>	C112464	SGRQ Past 4 Weeks Version - Walking Up Hills|SGRQ02-Walking Up Hills|SGRQ02-Walking Up Hills|SGRQ0217	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about what activities usually make you feel short of breath these days: Walking up hills.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112695>	C112464	SGRQ Past 4 Weeks Version - Playing Sports or Other Physical Activities|SGRQ02-Playing Sports|SGRQ02-Playing Sports|SGRQ0218	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about what activities usually make you feel short of breath these days: Playing sports or other physical activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112696>	C112464	SGRQ Past 4 Weeks Version - Coughing Hurts|SGRQ02-Coughing Hurts|SGRQ02-Coughing Hurts|SGRQ0219	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are more questions about your cough and shortness of breath these days: Coughing hurts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112697>	C112464	SGRQ Past 4 Weeks Version - Coughing Makes Me Tired|SGRQ02-Coughing Makes Me Tired|SGRQ02-Coughing Makes Me Tired|SGRQ0220	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are more questions about your cough and shortness of breath these days: Coughing makes me tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112698>	C112464	SGRQ Past 4 Weeks Version - Short of Breath When I Talk|SGRQ02-Short of Breath When I Talk|SGRQ02-Short of Breath When I Talk|SGRQ0221	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are more questions about your cough and shortness of breath these days: I am short of breath when I talk.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112699>	C112464	SGRQ Past 4 Weeks Version - Short of Breath When Bend Over|SGRQ02-Short of Breath When Bend Over|SGRQ02-Short of Breath When Bend Over|SGRQ0222	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are more questions about your cough and shortness of breath these days: I am short of breath when I bend over.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11269>	C61063	Cyclophosphamide/Filgrastim/Vincristine|CTX/G-CSF/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1126>	C1455	Haemophilus Influenzae B Vaccine|ActHIB|Haemophilus b conjugate vaccine|Haemophilus b oligosaccharide conjugate vacccine|Haemophilus influenzae B Polysaccharide Conjugate Vaccine (PRP-OMP)|Haemophilus influenzae B Polysaccharide Conjugate Vaccine (PRP-T)|Hib TITER vaccine|Hib Vaccine|HibTITER|PRP vaccine|PedvaxHIB	A vaccine against serotype b of the Gram-negative bacterium H. influenzae (Hib). Hib vaccines contain polysaccharide-protein conjugate antigens that produce greater host immune responses than first-generation purified polysaccharide vaccine. These vaccines may differ with regard to use of protein carriers, polysaccharides, diluents, and preservatives.			Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NICHD Terminology|Pediatric Immunization Terminology
C112700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112700>	C112464	SGRQ Past 4 Weeks Version - Coughing Disturbs My Sleep|SGRQ02-Coughing Disturbs My Sleep|SGRQ02-Coughing Disturbs My Sleep|SGRQ0223	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are more questions about your cough and shortness of breath these days: My coughing or breathing disturbs my sleep.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112701>	C112464	SGRQ Past 4 Weeks Version - I Get Exhausted Easily|SGRQ02-I Get Exhausted Easily|SGRQ02-I Get Exhausted Easily|SGRQ0224	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are more questions about your cough and shortness of breath these days: I get exhausted easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112702>	C112464	SGRQ Past 4 Weeks Version - My Cough is Embarrassing in Public|SGRQ02-Cough Is Embarrassing in Public|SGRQ02-Cough Is Embarrassing in Public|SGRQ0225	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about other effects that your respiratory problems may have on you these days: My cough or breathing is embarrassing in public.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112703>	C112464	SGRQ Past 4 Weeks Version - Respiratory Problems a Nuisance to Family|SGRQ02-Respiratory Problems a Nuisance|SGRQ02-Respiratory Problems a Nuisance|SGRQ0226	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about other effects that your respiratory problems may have on you these days: My respiratory problems are a nuisance to my family, friends or neighbors.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112704>	C112464	SGRQ Past 4 Weeks Version - Get Afraid When Cannot Catch My Breath|SGRQ02-Afraid When Cannot Catch Breath|SGRQ02-Afraid When Cannot Catch Breath|SGRQ0227	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about other effects that your respiratory problems may have on you these days: I get afraid or panic when I cannot catch my breath.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112705>	C112464	SGRQ Past 4 Weeks Version - Not in Control of My Respiratory Problems|SGRQ02-Not in Control of Resp Problems|SGRQ02-Not in Control of Resp Problems|SGRQ0228	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about other effects that your respiratory problems may have on you these days: I feel that I am not in control of my respiratory problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112706>	C112464	SGRQ Past 4 Weeks Version - Not Expect Respiratory Problems Get Better|SGRQ02-Not Expect Probs to Get Better|SGRQ02-Not Expect Probs to Get Better|SGRQ0229	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about other effects that your respiratory problems may have on you these days: I do not expect my respiratory problems to get any better.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112707>	C112464	SGRQ Past 4 Weeks Version - Become Frail or Invalid Because of My Respiratory Problems|SGRQ02-I Have Become Frail|SGRQ02-I Have Become Frail|SGRQ0230	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about other effects that your respiratory problems may have on you these days: I have become frail or an invalid because of my respiratory problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112708>	C112464	SGRQ Past 4 Weeks Version - Exercise Is Not Safe for Me|SGRQ02-Exercise Is Not Safe for Me|SGRQ02-Exercise Is Not Safe for Me|SGRQ0231	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about other effects that your respiratory problems may have on you these days: Exercise is not safe for me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112709>	C112464	SGRQ Past 4 Weeks Version - Everything Too Much Effort|SGRQ02-Everything Too Much Effort|SGRQ02-Everything Too Much Effort|SGRQ0232	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about other effects that your respiratory problems may have on you these days: Everything seems too much of an effort.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11270>	C61063	Carboplatin/Ifosfamide/Mesna|CBDCA/IFF/mesna|carboplatin/ifosfamide/mercaptoethane sulfonate			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112710>	C112464	SGRQ Past 4 Weeks Version - Treatment Does Not Help Me Much|SGRQ02-Treatment Does Not Help Me Much|SGRQ02-Treatment Does Not Help Me Much|SGRQ0233	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about your respiratory treatment: My treatment does not help me very much.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112711>	C112464	SGRQ Past 4 Weeks Version - Embarrassed Using Medication in Public|SGRQ02-Embarrassed Using Med in Public|SGRQ02-Embarrassed Using Med in Public|SGRQ0234	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about your respiratory treatment: I get embarrassed using my medication in public.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112712>	C112464	SGRQ Past 4 Weeks Version - Unpleasant Side Effects From Medication|SGRQ02-Unpleasant Side Effect From Med|SGRQ02-Unpleasant Side Effect From Med|SGRQ0235	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about your respiratory treatment: I have unpleasant side effects from my medication.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112713>	C112464	SGRQ Past 4 Weeks Version - Treatment Interferes With My Life|SGRQ02-Treatment Interferes With Life|SGRQ02-Treatment Interferes With Life|SGRQ0236	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about your respiratory treatment: My treatment interferes with my life a lot.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112714>	C112464	SGRQ Past 4 Weeks Version - Take Long Time to Get Washed or Dressed|SGRQ02-Take a Long Time to Get Washed|SGRQ02-Take a Long Time to Get Washed|SGRQ0237	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about how your activities might be affected by your respiratory problems: I take a long time to get washed or dressed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112715>	C112464	SGRQ Past 4 Weeks Version - Cannot Take A Bath or Shower|SGRQ02-I Cannot Take a Bath or Shower|SGRQ02-I Cannot Take a Bath or Shower|SGRQ0238	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about how your activities might be affected by your respiratory problems: I cannot take a bath or shower, or I take a long time to do it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112716>	C112464	SGRQ Past 4 Weeks Version - Walk Slower Than Other People My Age|SGRQ02-I Walk Slower Than Other People|SGRQ02-I Walk Slower Than Other People|SGRQ0239	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about how your activities might be affected by your respiratory problems: I walk slower than other people my age, or I stop to rest.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112717>	C112464	SGRQ Past 4 Weeks Version - Jobs Take Long Time or I Have to Stop|SGRQ02-Jobs Take a Long Time|SGRQ02-Jobs Take a Long Time|SGRQ0240	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about how your activities might be affected by your respiratory problems: Jobs such as household chores take a long time, or I have to stop to rest.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112718>	C112464	SGRQ Past 4 Weeks Version - If Walk Up One Flight of Stairs I Have to Go Slow|SGRQ02-Walk Up Flight of Stairs Slowly|SGRQ02-Walk Up Flight of Stairs Slowly|SGRQ0241	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about how your activities might be affected by your respiratory problems: If I walk up one flight of stairs, I have to go slowly or stop.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112719>	C112464	SGRQ Past 4 Weeks Version - If Walk Fast I Have to Stop or Slow Down|SGRQ02-If I Hurry, I Have to Stop|SGRQ02-If I Hurry, I Have to Stop|SGRQ0242	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about how your activities might be affected by your respiratory problems: If I hurry or walk fast, I have to stop or slow down.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11271>	C61063	Carboplatin/filgrastim/Ifosfamide/Mesna|CBDCA/G-CSF/IFF/mesna|carboplatin/filgrastim/ifosfamide/mercaptoethane sulfonate			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112720>	C112464	SGRQ Past 4 Weeks Version - Breathing Makes Difficult to Walk Up Hills|SGRQ02-Difficult to Walk Up Hills|SGRQ02-Difficult to Walk Up Hills|SGRQ0243	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about how your activities might be affected by your respiratory problems: My breathing makes it difficult to do things such as walk up hills, carry things up stairs, light gardening such as weeding, dance, bowl or play golf.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112721>	C112464	SGRQ Past 4 Weeks Version - Breathing Makes Difficult to Carry Heavy Loads|SGRQ02-Difficult to Carry Heavy Loads|SGRQ02-Difficult to Carry Heavy Loads|SGRQ0244	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about how your activities might be affected by your respiratory problems: My breathing makes it difficult to do things such as carry heavy loads, dig in the garden or shovel snow, jog or walk briskly (5 miles per hour), play tennis or swim.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112722>	C112464	SGRQ Past 4 Weeks Version - Breathing Makes Difficult to Do Heavy Manual Work|SGRQ02-Difficult to Do Very Heavy Work|SGRQ02-Difficult to Do Very Heavy Work|SGRQ0245	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) These are questions about how your activities might be affected by your respiratory problems: My breathing makes it difficult to do things such as very heavy manual work, ride a bike, run, swim fast, or play competitive sports.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112723>	C112464	SGRQ Past 4 Weeks Version - Cannot Play Sports or Do Physical Activities|SGRQ02-I Cannot Play Sports|SGRQ02-I Cannot Play Sports|SGRQ0246	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) We would like to know how your respiratory problems usually affect your daily life: I cannot play sports or do other physical activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112724>	C112464	SGRQ Past 4 Weeks Version - Cannot Go Out for Entertainment|SGRQ02-Cannot Go Out for Entertainment|SGRQ02-Cannot Go Out for Entertainment|SGRQ0247	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) We would like to know how your respiratory problems usually affect your daily life: I cannot go out for entertainment or recreation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112725>	C112464	SGRQ Past 4 Weeks Version - Cannot Go Out to Do Shopping|SGRQ02-Cannot Go Out to Do Shopping|SGRQ02-Cannot Go Out to Do Shopping|SGRQ0248	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) We would like to know how your respiratory problems usually affect your daily life: I cannot go out of the house to do the shopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112726>	C112464	SGRQ Past 4 Weeks Version - Cannot Do Household Chores|SGRQ02-I Cannot Do Household Chores|SGRQ02-I Cannot Do Household Chores|SGRQ0249	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) We would like to know how your respiratory problems usually affect your daily life: I cannot do household chores.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112727>	C112464	SGRQ Past 4 Weeks Version - Cannot Move Far From Bed or Chair|SGRQ02-I Cannot Move Far From My Bed|SGRQ02-I Cannot Move Far From My Bed|SGRQ0250	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) We would like to know how your respiratory problems usually affect your daily life: I cannot move far from my bed or chair.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112728>	C112464	SGRQ Past 4 Weeks Version - How Respiratory Problems Affect You|SGRQ02-How Resp Problems Affect You|SGRQ02-How Resp Problems Affect You|SGRQ0251	St. George's Respiratory Questionnaire Past 4 Weeks Version (SGRQ Past 4 Weeks Version) Best describe how your respiratory problems affect you.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Code Terminology|CDISC Questionnaire SGRQ Past 4 Weeks Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112729>	C112465	VFQ25-Interviewer Administered Format - Overall Health|VFQ1-Your Overall Health Is|VFQ1-Your Overall Health Is|VFQ101	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) General Heath and Vision: In general, would you say your overall health is:			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11272>	C61063	Cisplatin/Paclitaxel/Tirapazamine|CDDP/SR-4233/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112730>	C112465	VFQ25-Interviewer Administered Format - Eyesight Using Both Eyes|VFQ1-Eyesight Using Both Eyes Is|VFQ1-Eyesight Using Both Eyes Is|VFQ102	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) General Heath and Vision: at the present time, would you say your eyesight using both eyes (with glasses or contact lenses, if you wear them) is excellent, good, fair, poor, or very poor or are you completely blind?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112731>	C112465	VFQ25-Interviewer Administered Format - Time Spent Worry About Eyesight|VFQ1-How Often You Worry About Eyesight|VFQ1-How Often You Worry About Eyesight|VFQ103	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) General Heath and Vision: How much of the time do you worry about your eyesight?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112732>	C112465	VFQ25-Interviewer Administered Format - Pain or Discomfort You Had in and Around Eyes|VFQ1-How Much Pain in and Around Eyes|VFQ1-How Much Pain in and Around Eyes|VFQ104	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) General Heath and Vision: How much pain or discomfort have you had in and around your eyes (for example, burning, itching, or aching)? Would you say it is:			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112733>	C112465	VFQ25-Interviewer Administered Format - Difficulty Reading Ordinary Print in Newspapers|VFQ1-Difficulty Reading Newspapers|VFQ1-Difficulty Reading Newspapers|VFQ105	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Difficulty With Activities: How much difficulty do you have reading ordinary print in newspapers? Would you say you have:			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112734>	C112465	VFQ25-Interviewer Administered Format - Difficulty Doing Work or Hobbies|VFQ1-Difficulty Doing Work/Hobbies|VFQ1-Difficulty Doing Work/Hobbies|VFQ106	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Difficulty With Activities: How much difficulty do you have doing work or hobbies that require you to see well up close, such as cooking, sewing, fixing things around the house, or using hand tools? Would you say:			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112735>	C112465	VFQ25-Interviewer Administered Format - Difficulty Finding Something On a Shelf|VFQ1-Difficulty Finding on Crowded Shelf|VFQ1-Difficulty Finding on Crowded Shelf|VFQ107	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Difficulty With Activities: Because of your eyesight, how much difficulty do you have finding something on a crowded shelf?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112736>	C112465	VFQ25-Interviewer Administered Format - Difficulty Reading Street Signs|VFQ1-Difficulty Reading Street Signs|VFQ1-Difficulty Reading Street Signs|VFQ108	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Difficulty With Activities: How much difficulty do you have reading street signs or the names of stores?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112737>	C112465	VFQ25-Interviewer Administered Format - Difficulty Going Down Steps at Night|VFQ1-Difficulty Going Down Step at Night|VFQ1-Difficulty Going Down Step at Night|VFQ109	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Difficulty With Activities: Because of your eyesight, how much difficulty do you have going down steps, stairs, or curbs in dim light or at night?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112738>	C112465	VFQ25-Interviewer Administered Format - Difficulty Noticing Objects Off to the Side While Walking|VFQ1-Difficulty Noticing Objects to Side|VFQ1-Difficulty Noticing Objects to Side|VFQ110	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Difficulty With Activities: Because of your eyesight, how much difficulty do you have noticing objects off to the side while you are walking along?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112739>	C112465	VFQ25-Interviewer Administered Format - Difficulty Seeing How People React|VFQ1-Difficulty Seeing How People React|VFQ1-Difficulty Seeing How People React|VFQ111	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Difficulty With Activities: Because of your eyesight, how much difficulty do you have seeing how people react to things you say?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11273>	C61063	Carmustine/Topotecan|BCNU/TOPO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112740>	C112465	VFQ25-Interviewer Administered Format - Difficulty Picking Out and Matching Own Clothes|VFQ1-Difficulty Picking Out Own Clothes|VFQ1-Difficulty Picking Out Own Clothes|VFQ112	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Difficulty With Activities: Because of your eyesight, how much difficulty do you have picking out and matching your own clothes?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112741>	C112465	VFQ25-Interviewer Administered Format - Difficulty Visiting People|VFQ1-Difficulty Visiting With People|VFQ1-Difficulty Visiting With People|VFQ113	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Difficulty With Activities: Because of your eyesight, how much difficulty do you have visiting with people in their homes, at parties, or in restaurants?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112742>	C112465	VFQ25-Interviewer Administered Format - Difficulty Going Out to See Movies|VFQ1-Difficulty Going Out to See Movies|VFQ1-Difficulty Going Out to See Movies|VFQ114	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Difficulty With Activities: Because of your eyesight, how much difficulty do you have going out to see movies, plays, or sports events?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112743>	C112465	VFQ25-Interviewer Administered Format - Are You Currently Driving|VFQ1-Are You Currently Driving|VFQ1-Are You Currently Driving|VFQ115	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Difficulty With Activities: Are you currently driving, at least once in a while?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112744>	C112465	VFQ25-Interviewer Administered Format - Never Driven or Given Up Driving|VFQ1-Never Driven or Given Up Driving|VFQ1-Never Driven or Given Up Driving|VFQ115A	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Difficulty With Activities: If no, have you never driven a car or have you given up driving?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112745>	C112465	VFQ25-Interviewer Administered Format - Main Reason You Gave Up Driving|VFQ1-Main Reason You Gave Up Driving|VFQ1-Main Reason You Gave Up Driving|VFQ115B	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Difficulty With Activities: If gave up driving, was that mainly because of your eyesight, mainly for some other reason, or because of both your eyesight and other reasons?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112746>	C112465	VFQ25-Interviewer Administered Format - Difficulty Driving During Daytime|VFQ1-Difficulty Driving During Daytime|VFQ1-Difficulty Driving During Daytime|VFQ115C	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Difficulty With Activities: If currently driving, how much difficulty do you have driving during the daytime in familiar places? Would you say you have:			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112747>	C112465	VFQ25-Interviewer Administered Format - Difficulty Driving at Night|VFQ1-Difficulty Driving at Night|VFQ1-Difficulty Driving at Night|VFQ116	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Difficulty With Activities: How much difficulty do you have driving at night? Would you say you have:			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112748>	C112465	VFQ25-Interviewer Administered Format - Driving in Difficult Condition|VFQ1-Driving in Difficult Conditions|VFQ1-Driving in Difficult Conditions|VFQ116A	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Difficulty With Activities: How much difficulty do you have driving in difficult conditions, such as in bad weather, during rush hour, on the freeway, or in city traffic? Would you say you have:			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112749>	C112465	VFQ25-Interviewer Administered Format - Accomplish Less Because of Vision|VFQ1-Accomplish Less Than You Would Like|VFQ1-Accomplish Less Than You Would Like|VFQ117	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Responses to Vision Problems: Do you accomplish less than you would like because of your vision?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11274>	C61007	Carmustine/Irinotecan|BCNU/CPT-11			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112750>	C112465	VFQ25-Interviewer Administered Format - Limited in How Long You Can Work Because of Vision|VFQ1-Limited in How Long You Can Work|VFQ1-Limited in How Long You Can Work|VFQ118	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Responses to Vision Problems: Are you limited in how long you can work or do other activities because of your vision?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112751>	C112465	VFQ25-Interviewer Administered Format - Pain in Eyes Keep You From Doing What You Like|VFQ1-Eye Pain Keep From Doing What Like|VFQ1-Eye Pain Keep From Doing What Like|VFQ119	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Responses to Vision Problems: How much does pain or discomfort in or around your eyes, for example, burning, itching, or aching, keep you from doing what you'd like to be doing? Would you say:			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112752>	C112465	VFQ25-Interviewer Administered Format - Stay Home Because of Eyesight|VFQ1-I Stay Home Most of the Time|VFQ1-I Stay Home Most of the Time|VFQ120	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Responses to Vision Problems: I stay home most of the time because of my eyesight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112753>	C112465	VFQ25-Interviewer Administered Format - Feel Frustrated Because of Eyesight|VFQ1-I Feel Frustrated a Lot of the Time|VFQ1-I Feel Frustrated a Lot of the Time|VFQ121	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Responses to Vision Problems: I feel frustrated a lot of the time because of my eyesight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112754>	C112465	VFQ25-Interviewer Administered Format - Have Less Control Because of Eyesight|VFQ1-Much Less Control Over What I Do|VFQ1-Much Less Control Over What I Do|VFQ122	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Responses to Vision Problems: I have much less control over what I do, because of my eyesight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112755>	C112465	VFQ25-Interviewer Administered Format - Have to Rely On Other People Because of Eyesight|VFQ1-Rely Too Much on What Others Tell|VFQ1-Rely Too Much on What Others Tell|VFQ123	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Responses to Vision Problems: Because of my eyesight, I have to rely too much on what other people tell me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112756>	C112465	VFQ25-Interviewer Administered Format - Need Help From Others Because of Eyesight|VFQ1-I Need a Lot of Help From Others|VFQ1-I Need a Lot of Help From Others|VFQ124	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Responses to Vision Problems: I need a lot of help from others because of my eyesight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112757>	C112465	VFQ25-Interviewer Administered Format - Worry About Embarrass Myself or Others Because of Eyesight|VFQ1-Worry I'll Do Embarrassing Things|VFQ1-Worry I'll Do Embarrassing Things|VFQ125	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Responses to Vision Problems: I worry about doing things that will embarrass myself or others, because of my eyesight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112758>	C112465	VFQ25-Interviewer Administered Format - Rate Your Overall Health|VFQ1-Rate Your Overall Health|VFQ1-Rate Your Overall Health|VFQ1A01	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) General Health: How would you rate your overall health, on a scale where zero is as bad as death and 10 is best possible health?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112759>	C112465	VFQ25-Interviewer Administered Format - Rate Your Eyesight Now|VFQ1-Rate Your Eyesight Now|VFQ1-Rate Your Eyesight Now|VFQ1A02	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) General Vision: How would you rate your eyesight now (with glasses or contact lens on, if you wear them), on a scale of from 0 to 10, where zero means the worst possible eyesight, as bad or worse than being blind, and 10 means the best possible eyesight?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11275>	C61063	Bleomycin/Cyclophosphamide/Doxorubicin/Etoposide/Prednisolone/Vincristine|BLEO/CTX/DOX/PRDL/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112760>	C112465	VFQ25-Interviewer Administered Format - Difficulty Reading Small Print|VFQ1-Difficulty Reading Small Print|VFQ1-Difficulty Reading Small Print|VFQ1A03	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Near Vision: Wearing glasses, how much difficulty do you have reading the small print in a telephone book, on a medicine bottle, or on legal forms? Would you say:			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112761>	C112465	VFQ25-Interviewer Administered Format - Difficulty Figure Out Bill Accuracy|VFQ1-Difficulty Figure Out Bill Accuracy|VFQ1-Difficulty Figure Out Bill Accuracy|VFQ1A04	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Near Vision: Because of your eyesight, how much difficulty do you have figuring out whether bills you receive are accurate?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112762>	C112465	VFQ25-Interviewer Administered Format - Difficulty Shaving or Styling Hair or Putting On Makeup|VFQ1-Difficulty Shaving or Styling Hair|VFQ1-Difficulty Shaving or Styling Hair|VFQ1A05	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Near Vision: Because of your eyesight, how much difficulty do you have doing things like shaving, styling your hair, or putting on makeup?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112763>	C112465	VFQ25-Interviewer Administered Format - Difficulty Recognizing People You Know|VFQ1-Difficulty Recognizing People|VFQ1-Difficulty Recognizing People|VFQ1A06	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Distance Vision: Because of your eyesight, how much difficulty do you have recognizing people you know from across a room?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112764>	C112465	VFQ25-Interviewer Administered Format - Difficulty Taking Part in Sports or Outdoor Activities|VFQ1-Difficulty Taking Part in Sports|VFQ1-Difficulty Taking Part in Sports|VFQ1A07	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Distance Vision: Because of your eyesight, how much difficulty do you have taking part in active sports or other outdoor activities that you enjoy (like golf, bowling, jogging, or walking)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112765>	C112465	VFQ25-Interviewer Administered Format - Difficulty Seeing and Enjoying Programs on TV|VFQ1-Difficulty Seeing Programs on TV|VFQ1-Difficulty Seeing Programs on TV|VFQ1A08	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Distance Vision: Because of your eyesight, how much difficulty do you have seeing and enjoying programs on TV?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112766>	C112465	VFQ25-Interviewer Administered Format - Difficulty Entertaining Friends and Family in Home|VFQ1-Difficulty Entertaining Friends|VFQ1-Difficulty Entertaining Friends|VFQ1A09	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Social Function: Because of your eyesight, how much difficulty do you have entertaining friends and family in your home?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112767>	C112465	VFQ25-Interviewer Administered Format - Do You Have More Help From Others|VFQ1-Do You Have More Help From Others|VFQ1-Do You Have More Help From Others|VFQ1A11A	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Role Limitations: Do you have more help from others because of your vision?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112768>	C112465	VFQ25-Interviewer Administered Format - Limited in Kinds of Things Can Do|VFQ1-Limited in Kinds of Things Can Do|VFQ1-Limited in Kinds of Things Can Do|VFQ1A11B	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Role Limitations: Are you limited in the kinds of things you can do because of your vision?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112769>	C112465	VFQ25-Interviewer Administered Format - Often Irritable Because of Eyesight|VFQ1-Often Irritable Because Eyesight|VFQ1-Often Irritable Because Eyesight|VFQ1A12	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Well-Being or Distress: I am often irritable because of my eyesight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11276>	C61063	Interferon Alfa/Ritonavir/Stavudine|d4T/IFN-A/RIT			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112770>	C112465	VFQ25-Interviewer Administered Format - Don't Go Out of Home Alone Because of Eyesight|VFQ1-I Don't Go Out of My Home Alone|VFQ1-I Don't Go Out of My Home Alone|VFQ1A13	Visual Functioning Questionnaire 25-Interviewer Administered Format Version 2000 (VFQ25-Interviewer Administered Format) Dependency: I don't go out of my home alone, because of my eyesight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Interviewer Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112771>	C112466	VFQ25-Self Administered Format - Overall Health|VFQ2-Your Overall Health Is|VFQ2-Your Overall Health Is|VFQ201	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) General Health and Vision: In general, would you say your overall health is:			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112772>	C112466	VFQ25-Self Administered Format - Eyesight Using Both Eyes|VFQ2-Eyesight Using Both Eyes Is|VFQ2-Eyesight Using Both Eyes Is|VFQ202	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) General Health and Vision: At the present time, would you say your eyesight using both eyes (with glasses or contact lenses, if you wear them) is excellent, good, fair, poor, or very poor or are you completely blind?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112773>	C112466	VFQ25-Self Administered Format - Time Spent Worry About Eyesight|VFQ2-How Often You Worry About Eyesight|VFQ2-How Often You Worry About Eyesight|VFQ203	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) General Health and Vision: How much of the time do you worry about your eyesight?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112774>	C112466	VFQ25-Self Administered Format - Pain or Discomfort You Had in and Around Eyes|VFQ2-How Much Pain in and Around Eyes|VFQ2-How Much Pain in and Around Eyes|VFQ204	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) General Health and Vision: How much pain or discomfort have you had in and around your eyes (for example, burning, itching, or aching)? Would you say it is:			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112775>	C112466	VFQ25-Self Administered Format - Difficulty Reading Ordinary Print in Newspapers|VFQ2-Difficulty Reading Newspapers|VFQ2-Difficulty Reading Newspapers|VFQ205	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: How much difficulty do you have reading ordinary print in newspapers? Would you say you have:			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112776>	C112466	VFQ25-Self Administered Format - Difficulty Doing Work or Hobbies|VFQ2-Difficulty Doing Work/Hobbies|VFQ2-Difficulty Doing Work/Hobbies|VFQ206	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: How much difficulty do you have doing work or hobbies that require you to see well up close, such as cooking, sewing, fixing things around the house, or using hand tools? Would you say:			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112777>	C112466	VFQ25-Self Administered Format - Difficulty Finding Something On a Shelf|VFQ2-Difficulty Finding on Crowded Shelf|VFQ2-Difficulty Finding on Crowded Shelf|VFQ207	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: Because of your eyesight, how much difficulty do you have finding something on a crowded shelf?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112778>	C112466	VFQ25-Self Administered Format - Difficulty Reading Street Signs|VFQ2-Difficulty Reading Street Signs|VFQ2-Difficulty Reading Street Signs|VFQ208	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: How much difficulty do you have reading street signs or the names of stores?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112779>	C112466	VFQ25-Self Administered Format - Difficulty Going Down Steps at Night|VFQ2-Difficulty Going Down Step at Night|VFQ2-Difficulty Going Down Step at Night|VFQ209	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: Because of your eyesight, how much difficulty do you have going down steps, stairs, or curbs in dim light or at night?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11277>	C61063	Cordycepin/Pentostatin|COR/DCF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112780>	C112466	VFQ25-Self Administered Format - Difficulty Noticing Objects Off to the Side While Walking|VFQ2-Difficulty Noticing Objects to Side|VFQ2-Difficulty Noticing Objects to Side|VFQ210	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: Because of your eyesight, how much difficulty do you have noticing objects off to the side while you are walking along?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112781>	C112466	VFQ25-Self Administered Format - Difficulty Seeing How People React|VFQ2-Difficulty Seeing How People React|VFQ2-Difficulty Seeing How People React|VFQ211	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: Because of your eyesight, how much difficulty do you have seeing how people react to things you say?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112782>	C112466	VFQ25-Self Administered Format - Difficulty Picking Out and Matching Own Clothes|VFQ2-Difficulty Picking Out Own Clothes|VFQ2-Difficulty Picking Out Own Clothes|VFQ212	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: Because of your eyesight, how much difficulty do you have picking out and matching your own clothes?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112783>	C112466	VFQ25-Self Administered Format - Difficulty Visiting People|VFQ2-Difficulty Visiting With People|VFQ2-Difficulty Visiting With People|VFQ213	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: Because of your eyesight, how much difficulty do you have visiting with people in their homes, at parties, or in restaurants?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112784>	C112466	VFQ25-Self Administered Format - Difficulty Going Out to See Movies|VFQ2-Difficulty Going Out to See Movies|VFQ2-Difficulty Going Out to See Movies|VFQ214	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: Because of your eyesight, how much difficulty do you have going out to see movies, plays, or sports events?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112785>	C112466	VFQ25-Self Administered Format - Are You Currently Driving|VFQ2-Are You Currently Driving|VFQ2-Are You Currently Driving|VFQ215	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: Are you currently driving, at least once in a while?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112786>	C112466	VFQ25-Self Administered Format - Never Driven or Given Up Driving|VFQ2-Never Driven or Given Up Driving|VFQ2-Never Driven or Given Up Driving|VFQ215A	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: If no: Have you never driven a car or have you given up driving?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112787>	C112466	VFQ25-Self Administered Format - Main Reason You Gave Up Driving|VFQ2-Main Reason You Gave Up Driving|VFQ2-Main Reason You Gave Up Driving|VFQ215B	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: If you gave up driving: Was that mainly because of your eyesight, mainly for some other reason, or because of both your eyesight and other reasons?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112788>	C112466	VFQ25-Self Administered Format - Difficulty Driving During Daytime|VFQ2-Difficulty Driving During Daytime|VFQ2-Difficulty Driving During Daytime|VFQ215C	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: If currently driving: How much difficulty do you have driving during the daytime in familiar places? Would you say you have:			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112789>	C112466	VFQ25-Self Administered Format - Difficulty Driving at Night|VFQ2-Difficulty Driving at Night|VFQ2-Difficulty Driving at Night|VFQ216	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: How much difficulty do you have driving at night? Would you say you have:			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11278>	C61007	Flavopiridol/Paclitaxel|FLAVO/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112790>	C112466	VFQ25-Self Administered Format - Driving in Difficult Condition|VFQ2-Driving in Difficult Conditions|VFQ2-Driving in Difficult Conditions|VFQ216A	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Difficulty With Activities: How much difficulty do you have driving in difficult conditions, such as in bad weather, during rush hour, on the freeway, or in city traffic? Would you say you have:			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112791>	C112466	VFQ25-Self Administered Format - Accomplish Less Because of Vision|VFQ2-Accomplish Less Than You Would Like|VFQ2-Accomplish Less Than You Would Like|VFQ217	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Responses to Vision Problems: Do you accomplish less than you would like because of your vision?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112792>	C112466	VFQ25-Self Administered Format - Limited in How Long You Can Work Because of Vision|VFQ2-Limited in How Long You Can Work|VFQ2-Limited in How Long You Can Work|VFQ218	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Responses to Vision Problems: Are you limited in how long you can work or do other activities because of your vision?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112793>	C112466	VFQ25-Self Administered Format - Pain in Eyes Keep You From Doing What You Like|VFQ2-Eye Pain Keep From Doing What Like|VFQ2-Eye Pain Keep From Doing What Like|VFQ219	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Responses to Vision Problems: How much does pain or discomfort in or around your eyes, for example, burning, itching, or aching, keep you from doing what you'd like to be doing? Would you say:			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112794>	C112466	VFQ25-Self Administered Format - Stay Home Because of Eyesight|VFQ2-I Stay Home Most of the Time|VFQ2-I Stay Home Most of the Time|VFQ220	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Responses to Vision Problems: I stay home most of the time because of my eyesight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112795>	C112466	VFQ25-Self Administered Format - Feel Frustrated Because of Eyesight|VFQ2-I Feel Frustrated a Lot of the Time|VFQ2-I Feel Frustrated a Lot of the Time|VFQ221	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Responses to Vision Problems: I feel frustrated a lot of the time because of my eyesight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112796>	C112466	VFQ25-Self Administered Format - Have Less Control Because of Eyesight|VFQ2-Much Less Control Over What I Do|VFQ2-Much Less Control Over What I Do|VFQ222	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Responses to Vision Problems: I have much less control over what I do, because of my eyesight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112797>	C112466	VFQ25-Self Administered Format - Have to Rely On Other People Because of Eyesight|VFQ2-Rely Too Much on What Others Tell|VFQ2-Rely Too Much on What Others Tell|VFQ223	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Responses to Vision Problems: Because of my eyesight, I have to rely too much on what other people tell me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112798>	C112466	VFQ25-Self Administered Format - Need Help From Others Because of Eyesight|VFQ2-I Need a Lot of Help From Others|VFQ2-I Need a Lot of Help From Others|VFQ224	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Responses to Vision Problems: I need a lot of help from others because of my eyesight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112799>	C112466	VFQ25-Self Administered Format - Worry About Embarrass Myself or Others Because of Eyesight|VFQ2-Worry I'll Do Embarrassing Things|VFQ2-Worry I'll Do Embarrassing Things|VFQ225	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Responses to Vision Problems: I worry about doing things that will embarrass myself or others, because of my eyesight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11279>	C61063	Bleomycin/Doxorubicin/Vindesine|BLEO/DAVA/DOX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1127>	C1934|C1931	Omacetaxine Mepesuccinate|CGX-635|Ceflatonin|Cephalotaxine, 4-Methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (Ester)|Cephalotaxine, 4-Methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (Ester), [3(R)]- (9CI)|Cephalotaxine, 4-methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (ester), [3(R)]- (9CI)|HHT|OMACETAXINE MEPESUCCINATE|Omapro|Synribo|homoharringtonine	A semisynthetic formulation of the cytotoxic plant alkaloid homoharringtonine isolated from the evergreen tree Cephalotaxus with potential antineoplastic activity. Omacetaxine binds to the 80S ribosome in eukaryotic cells and inhibits protein synthesis by interfering with chain elongation. This agent also induces differentiation and apoptosis in some cancer cell types.	Omacetaxine Mepesuccinate		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C112800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112800>	C112466	VFQ25-Self Administered Format - Rate Your Overall Health|VFQ2-Rate Your Overall Health|VFQ2-Rate Your Overall Health|VFQ2A01	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) General Health: How would you rate your overall health, on a scale where zero is as bad as death and 10 is best possible health?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112801>	C112466	VFQ25-Self Administered Format - Rate Your Eyesight Now|VFQ2-Rate Your Eyesight Now|VFQ2-Rate Your Eyesight Now|VFQ2A02	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) General Vision: How would you rate your eyesight now (with glasses or contact lens on, if you wear them), on a scale of from 0 to 10, where zero means the worst possible eyesight, as bad or worse than being blind, and 10 means the best possible eyesight?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112802>	C112466	VFQ25-Self Administered Format - Difficulty Reading Small Print|VFQ2-Difficulty Reading Small Print|VFQ2-Difficulty Reading Small Print|VFQ2A03	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Near Vision: Wearing glasses, how much difficulty do you have reading the small print in a telephone book, on a medicine bottle, or on legal forms? Would you say:			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112803>	C112466	VFQ25-Self Administered Format - Difficulty Figure Out Bill Accuracy|VFQ2-Difficulty Figure Out Bill Accuracy|VFQ2-Difficulty Figure Out Bill Accuracy|VFQ2A04	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Near Vision: Because of your eyesight, how much difficulty do you have figuring out whether bills you receive are accurate?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112804>	C112466	VFQ25-Self Administered Format - Difficulty Shaving or Styling Hair or Putting On Makeup|VFQ2-Difficulty Shaving or Styling Hair|VFQ2-Difficulty Shaving or Styling Hair|VFQ2A05	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Near Vision: Because of your eyesight, how much difficulty do you have doing things like shaving, styling your hair, or putting on makeup?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112805>	C112466	VFQ25-Self Administered Format - Difficulty Recognizing People You Know|VFQ2-Difficulty Recognizing People|VFQ2-Difficulty Recognizing People|VFQ2A06	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Distance Vision: Because of your eyesight, how much difficulty do you have recognizing people you know from across a room?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112806>	C112466	VFQ25-Self Administered Format - Difficulty Taking Part in Sports or Outdoor Activities|VFQ2-Difficulty Taking Part in Sports|VFQ2-Difficulty Taking Part in Sports|VFQ2A07	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Distance Vision: Because of your eyesight, how much difficulty do you have taking part in active sports or other outdoor activities that you enjoy (like golf, bowling, jogging, or walking)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112807>	C112466	VFQ25-Self Administered Format - Difficulty Seeing and Enjoying Programs on TV|VFQ2-Difficulty Seeing Programs on TV|VFQ2-Difficulty Seeing Programs on TV|VFQ2A08	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Distance Vision: Because of your eyesight, how much difficulty do you have seeing and enjoying programs on TV?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112808>	C112466	VFQ25-Self Administered Format - Difficulty Entertaining Friends and Family in Home|VFQ2-Difficulty Entertaining Friends|VFQ2-Difficulty Entertaining Friends|VFQ2A09	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Social Function: Because of your eyesight, how much difficulty do you have entertaining friends and family in your home?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112809>	C112466	VFQ25-Self Administered Format - Do You Have More Help From Others|VFQ2-Do You Have More Help From Others|VFQ2-Do You Have More Help From Others|VFQ2A11A	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Role Limitations: Do you have more help from others because of your vision?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112810>	C112466	VFQ25-Self Administered Format - Limited in Kinds of Things Can Do|VFQ2-Limited in Kinds of Things Can Do|VFQ2-Limited in Kinds of Things Can Do|VFQ2A11B	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Role Limitations: Are you limited in the kinds of things you can do because of your vision?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112811>	C112466	VFQ25-Self Administered Format - Often Irritable Because of Eyesight|VFQ2-Often Irritable Because Eyesight|VFQ2-Often Irritable Because Eyesight|VFQ2A12	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Well-Being or Distress: I am often irritable because of my eyesight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112812>	C112466	VFQ25-Self Administered Format - Don't Go Out of Home Alone Because of Eyesight|VFQ2-I Don't Go Out of My Home Alone|VFQ2-I Don't Go Out of My Home Alone|VFQ2A13	Visual Functioning Questionnaire 25-Self Administered Format Version 2000 (VFQ25-Self Administered Format) Dependency: I don't go out of my home alone, because of my eyesight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Code Terminology|CDISC Questionnaire VFQ25-Self Administered Format Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112813>	C112461	MHIS-NACC - Somatic Complaints|MHIS01- Somatic Complaints|MHIS01- Somatic Complaints|MHIS0103	Modified Hachinski Ischemic Scale-NACC Version (MHIS-NACC) Somatic complaints.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MHIS-NACC Test Code Terminology|CDISC Questionnaire MHIS-NACC Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C112814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112814>	C78499	Horizontal Nail Ridging|Beau's Lines|Beau's Lines	Linear transverse/horizontal groove of one or more nail plates that migrate distally from the proximal nail fold with nail growth, usually secondary to illness, trauma or malnutrition.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112815>	C78492	Leukonychia	Any white discoloration of the nails or nail plates.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112816>	C71615	Dose Volume Histogram|DVH|DVH Curve	A plot of a cumulative dose-volume frequency distribution that graphically summarizes the simulated radiation distribution within a volume of interest of a patient which would result from a proposed radiation treatment plan.			Intellectual Product	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C112817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112817>	C124224	Depigmentation	Loss of all color from the skin.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112818>	C48572	Monitor Unit|MU	A unit of measure of ionization in a linear accelerator treatment beam within the treatment head.			Quantitative Concept	
C112819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112819>	C44175	Cumulative Meterset Weight	A factor used to determine at what point in the beam delivery the next change in setup is to take place.			Conceptual Entity	
C11281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11281>	C61063	Fluorouracil/Hydroxyurea/Paclitaxel|5-FU/HU/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112821>	C3327	Leukoderma	Localized loss of skin pigmentation, often in patches.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112822>	C105822	HOXB13 Gene|HOXB13|HOXB13|Homeobox B13 Gene	This gene is involved in anterior-posterior axis formation.	HOXB13 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C112823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112823>	C112822	HOXB13 wt Allele|HPC9|Homeo Box B13 Gene|Homeobox B13 wt Allele|PSGD	Human HOXB13 wild-type allele is located in the vicinity of 17q21.32 and is approximately 4 kb in length. This allele, which encodes homeobox protein Hox-B13, plays a role in transcriptional regulation.	HOXB13 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112824>	C79731	Melasma	Symmetrical patches of tan or brown discoloration on the skin of the face that darken with sun exposure.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112825>	C113122	Serum Separator Tube|Gold-Topped Tube|Red/Black Tiger Top Tube|SST|Serum-Separating Tube	A blood collection tube that contains a gel that separates blood cells from serum.			Manufactured Object	
C112826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112826>	C17207	Homeobox Protein Hox-B13|HOXB13	Homeobox protein Hox-B13 (284 aa, ~31 kDa) is encoded by the human HOXB13 gene. This protein is involved in both transcriptional regulation and anterior-posterior axis formation.	Homeobox Protein Hox-B13		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112827>	C35541	Phrynoderma	Rough, dry, hypertrophic eruption of the skin associated with vitamin A deficiency.			Finding	
C112828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112828>	C26006	CPNE1 Gene|CPNE1|CPNE1|Copine I Gene	This gene plays a role in both calcium binding and vesicle transport.			Gene or Genome	
C112829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112829>	C5036	Harlequin Reaction	Transient blanching of the lower half of the body while in the lateral recumbent position, most commonly seen in premature or low birth weight infants.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11282>	C61063	Epoetin Alfa/Fluorouracil/Hydroxyurea/Paclitaxel|EPO/5-FU/HU/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112830>	C112828	CPNE1 wt Allele|COPN1|CPN1|Copine I wt Allele|RP1-309K20.2	Human CPNE1 wild-type allele is located in the vicinity of 20q11.22 and is approximately 39 kb in length. This allele, which encodes copine-1 protein, is involved in both vesicle transport and calcium binding.			Gene or Genome	
C112831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112831>	C84776	Ichthyosis Acquisita|Acquired Ichthyosis|Acquired Ichthyosis	A non-hereditary form of ichthyosis characterized by plate-like scales on the legs, arms and occasionally the torso.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112832>	C16386	Copine-1|Copine I	Copine-1 (537 aa, ~59 kDa) is encoded by the human CPNE1 gene. This protein plays a role in both calcium binding and vesicle trafficking.			Amino Acid, Peptide, or Protein	
C112833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112833>	C27555	Tinea Versicolor	A skin condition characterized by hypopigmented, pink or tan, confetti-like, discrete and confluent scaly macules distributed on the chest, shoulders and upper back.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C112834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112834>	C92809	Growth Hormone Excess	Overproduction of growth hormone, a protein-based peptide that stimulates growth, cell reproduction, and cell regeneration.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C112835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112835>	C92809	Growth Hormone Deficiency|GH Deficiency|Somatotropin Deficiency	Insufficient production of growth hormone.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C112836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112836>	C3123	Thyroid Storm	Acute onset of severe, life-threatening hyperthyroidism caused by a sudden release of excessive thyroid hormone.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C112837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112837>	C26147	QPRT Gene|QPRT|QPRT|Quinolinate Phosphoribosyltransferase Gene	This gene is involved in cofactor nucleotide metabolism.			Gene or Genome	
C112838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112838>	C112837	QPRT wt Allele|QPRTase|Quinolinate Phosphoribosyltransferase wt Allele	Human QPRT wild-type allele is located in the vicinity of 16p11.2 and is approximately 20 kb in length. This allele, which encodes nicotinate-nucleotide pyrophosphorylase [carboxylating] protein, plays a role in NAD biosynthesis.			Gene or Genome	
C112839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112839>	C17434	Nicotinate-Nucleotide Pyrophosphorylase [Carboxylating]|EC 2.4.2.19|Nicotinate-Nucleotide Pyrophosphorylase (Carboxylating)|QAPRTase|QPRTase|Quinolinate Phosphoribosyltransferase [Decarboxylating]	Nicotinate-nucleotide pyrophosphorylase [carboxylating] (297 aa, ~31 kDa) is encoded by the human QPRT gene. This protein is involved in the synthesis of nicotinamide adenine dinucleotide.			Amino Acid, Peptide, or Protein|Enzyme	
C11283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11283>	C61063	Cisplatin/Docetaxel/Gemcitabine|CDDP/dFdC/TXT			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112840>	C27569	Adrenal Crisis|Acute Adrenal Insufficiency|Addisonian Crisis	A life threatening condition due to inadequate levels of glucocorticoids in an individual with adrenal insufficiency.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C112841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112841>	C3117	Chronic Maternal Hypertension|Pre-existing essential hypertension complicating pregnancy, unspecified trimester|Unspecified pre-existing hypertension complicating pregnancy, unspecified trimester	Hypertension that predates pregnancy.			Disease or Syndrome	mCode Elixhauser Hypertension, Complicated Value Set|mCode Elixhauser Hypertension, Uncomplicated Value Set|mCode Terminology|NICHD Terminology|Perinatal Terminology
C112842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112842>	C3117	Chronic Maternal Hypertension with Superimposed Preeclampsia|Pre-existing hypertension with pre-eclampsia, unspecified trimester	Chronic hypertension in association with preeclampsia.			Disease or Syndrome	mCode Elixhauser Hypertension, Complicated Value Set|mCode Terminology|NICHD Terminology|Perinatal Terminology
C112843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112843>	C85021	Severe Preeclampsia|Preeclampsia with Severe Features|Preeclampsia with Severe Features	Preeclampsia with a systolic blood pressure of 160 mmHg or higher, or a diastolic blood pressure of 110 mmHg or higher on two occasions at least 4 hours apart while on bedrest. It is associated with thrombocytopenia (platelets less than 100,000 per microliter), impaired liver function (twice normal elevation of hepatic transaminases; severe, persistent right upper quadrant or epigastric pain), progressive renal insufficiency (serum creatinine greater than 1.1 mg/dL or doubling of baseline in the absence of other renal disease), pulmonary edema, or new-onset cerebral or visual disturbances.			Disease or Syndrome	GAIA Preeclampsia Level of Diagnostic Certainty Terminology|GAIA Terminology|NICHD Terminology|Perinatal Terminology
C112844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112844>	C34942	Gestational Diabetes Mellitus, A1|Gestational Diabetes Mellitus, A1 White Classification|Gestational Diabetes, A1 White Classification	Carbohydrate intolerance first diagnosed during pregnancy. Diagnosis from abnormal oral glucose tolerance test (OGTT) but normal glucose levels when fasting and two hours post-prandial. Euglycemia achieved with diet and/or exercise.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C112845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112845>	C34942	Gestational Diabetes Mellitus, A2|Gestational Diabetes Mellitus, A2 White Classification|Gestational Diabetes, A2 White Classification	Carbohydrate intolerance first diagnosed during pregnancy. Diagnosis from abnormal oral glucose tolerance test (OGTT) and abnormal fasting or post-prandial glucose levels. Euglycemia achieved with medication.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C112846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112846>	C117720	Chronic Villitis|VUE|VUE|Villitis of Unknown Etiology|Villitis of Unknown Etiology	T-cell immune response with diffuse perivillous fibrin deposition associated with intrauterine growth restriction, pre-term birth and recurrent fetal loss.			Finding	NICHD Terminology|Perinatal Terminology
C112847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112847>	C62754	Maternal Weight Gain in Pregnancy|Maternal Weight Gain During Pregnancy	The last recorded maternal weight prior to birth minus the last recorded weight immediately prior to pregnancy. (reVITALize)			Finding	NICHD Terminology|Perinatal Terminology
C112848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112848>	C62754	Excessive Weight Gain in Pregnancy	In a woman with a normal weight pre-pregnancy body mass index (BMI), i.e. 18.5-24.9, the weight gained during pregnancy exceeds a total weight gain of 35 lbs. In a woman with an underweight pre-pregnancy body mass index (BMI), i.e. less than 18.5, the weight gained during pregnancy exceeds a total weight gain of 40 lbs. In a woman with an overweight pre-pregnancy body mass index (BMI), i.e. 25.0-29.9, the weight gained during pregnancy exceeds a total weight gain of 25 lbs. In a woman with an obese pre-pregnancy body mass index (BMI), i.e. greater than 30, the weight gained during pregnancy exceeds a total weight gain of 20 lbs. These standards are supported for the whole population irrespective of height, race or ethnicity.			Finding	NICHD Terminology|Perinatal Terminology
C112849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112849>	C62754	Low Weight Gain in Pregnancy	In a woman with a normal weight pre-pregnancy body mass index (BMI), i.e. 18.5-24.9, the weight gained during pregnancy does not exceed a total weight gain of 25 lbs. In a woman with an underweight pre-pregnancy body mass index (BMI), i.e. less than 18.5, the weight gained during pregnancy does not exceed a total weight gain of 28 lbs. In a woman with an overweight pre-pregnancy body mass index (BMI), i.e. 25.0-29.9, the weight gained during pregnancy does not exceed a total weight gain of 15 lbs. In a woman with an obese pre-pregnancy body mass index (BMI), i.e. greater than 30, the weight gained during pregnancy does not exceed a total weight gain of 11 lbs. These standards are supported for the whole population irrespective of height, race or ethnicity.			Finding	NICHD Terminology|Perinatal Terminology
C11284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11284>	C61063	Cytarabine/Etoposide/Mitoxantrone/PSC 833|ARA-C/DHAD/PSC 833/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112850>	C35594	Symphysis Pubis Dysfunction|SPD	Pelvic pain due to physiological pelvic ligament relaxation and increased joint mobility.			Finding	NICHD Terminology|Perinatal Terminology
C112851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112851>	C34941	Post Term Pregnancy|Prolonged Pregnancy|Prolonged Pregnancy	A gestation that lasts greater than or equal to 42 weeks and 0 days.			Finding	NICHD Terminology|Perinatal Terminology
C112852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112852>	C117720	Twin Pregnancy	A pregnancy involving two fetuses.			Finding	NICHD Terminology|Perinatal Terminology
C112853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112853>	C112852	Monochorionic Monoamniotic Twin Pregnancy	A pregnancy involving two fetuses that share both the chorion and amniotic sac. These twins are invariably identical.			Finding	NICHD Terminology|Perinatal Terminology
C112854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112854>	C112852	Monochorionic Diamniotic Twin Pregnancy	A pregnancy involving two fetuses that share the same chorion but have separate amniotic sacs.			Finding	NICHD Terminology|Perinatal Terminology
C112855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112855>	C112852	Dichorionic Diamniotic Twin Pregnancy	A pregnancy involving two fetuses that each have separate chorions and amniotic sacs.			Finding	NICHD Terminology|Perinatal Terminology
C112856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112856>	C117720	Non-Cesarean Uterine Surgical Scarring|Non-Caesarean Uterine Surgical Scarring|Non-Cesarean Uterine Surgery Scar|Non-Cesarean Uterine Surgical Scar	A scar/healing of the myometrium that occurs after uterine injury or after non-cesarean surgery.			Finding	NICHD Terminology|Perinatal Terminology
C112857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112857>	C35221	Threatened Abortion	Vaginal bleeding preceding the 20th week of gestation.			Finding	NICHD Terminology|Perinatal Terminology
C112858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112858>	C35221	Early Pregnancy Loss	Pregnancy loss before 10th week of gestation with documentation of a confirmed pregnancy.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C112859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112859>	C34941	Peri-Implantational Loss|Chemical Pregnancy|Chemical Pregnancy|Peri-Implantational Failure|Peri-Implantational Failure	Pregnancy loss before 5th week of gestation with no gestational sac visible on ultrasonogram.			Finding	NICHD Terminology|Perinatal Terminology
C11285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11285>	C61007	Carboplatin/Estramustine/Paclitaxel|CBDCA/EM/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112860>	C34941	Pre-Embryonic Loss|Anembryonic Pregnancy|Anembryonic Pregnancy	Pregnancy loss with visible gestational sac or yolk sac or both but no visible embryo on ultrasonogram.			Finding	NICHD Terminology|Perinatal Terminology
C112861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112861>	C34941	Embryonic Loss	Pregnancy loss at 6 weeks, 0 days to 9 weeks, 6 days of gestation of an embryo with crown-rump length less than 10 mm and no cardiac activity visible on ultrasonogram.			Finding	NICHD Terminology|Perinatal Terminology
C112862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112862>	C50620	Early Fetal Death	Death of a fetus at 10 weeks, 0 days to 15 weeks, 6 days of gestation.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C112863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112863>	C50620	Late Fetal Death	Death of a fetus at 16 weeks, 0 days to 19 weeks, 6 days of gestation.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C112864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112864>	C92861	Spontaneous Preterm Birth	Preterm birth from 20 weeks to 36 weeks, 6 days of gestation associated with one of the following: classic preterm labor or preterm premature rupture of membranes.			Finding	NICHD Terminology|Perinatal Terminology
C112865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112865>	C98996	Transient Myocardial Ischemia of Newborn	A condition characterized by a temporary imbalance between the oxygen supply and demand of the heart muscle in the newborn.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C112866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112866>	C44175	Control Point	Any one of a set of linear accelerator parameters that define the segments from which a radiation beam is applied.			Conceptual Entity	
C112867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112867>	C54401|C20194	ZIM2 Gene|ZIM2|ZIM2|Zinc Finger, Imprinted 2 Gene	This gene may play a role in transcriptional regulation.			Gene or Genome	
C112868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112868>	C112867	ZIM2 wt Allele|ZNF656|Zinc Finger, Imprinted 2 wt Allele	Human ZIM2 wild-type allele is located in the vicinity of 19q13.4 and is approximately 66 kb in length. This allele, which encodes zinc finger imprinted 2 protein, may be involved in the regulation of transcription.			Gene or Genome	
C112869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112869>	C54674|C18466	Zinc Finger Imprinted 2|ZIM2|Zinc Finger Protein 656	Zinc finger imprinted 2 (527 aa, ~61 kDa) is encoded by the human ZIM2 gene. This protein may play a role in gene expression.			Amino Acid, Peptide, or Protein	
C11286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11286>	C61007	Amifostine/Cisplatin/Paclitaxel|CDDP/TAX/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112870>	C54401|C20462	PEG3 Gene|PEG3|PEG3|Paternally Expressed 3 Gene	This gene is involved in both tumor suppression and apoptosis.			Gene or Genome	
C112871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112871>	C112870	PEG3 wt Allele|KIAA0287|PW1|Paternally Expressed 3 wt Allele|Paternally Expressed Gene 3|Paternally-Expressed Gene 3|ZKSCAN22|ZNF904|ZSCAN24|hCG_1685807	Human PEG3 wild-type allele is located in the vicinity of 19q13.4 and is approximately 31 kb in length. This allele, which encodes paternally-expressed gene 3 protein, plays a role in both apoptosis and tumor suppression.			Gene or Genome	
C112872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112872>	C54674|C19928	Paternally-Expressed Gene 3 Protein|PEG3|Paternally Expressed Gene 3 Protein|Zinc Finger and SCAN Domain-Containing Protein 24	Paternally-expressed gene 3 protein (1588 aa, ~181 kDa) is encoded by the human PEG3 gene. This protein is involved in both tumor suppression and the regulation of apoptosis.			Amino Acid, Peptide, or Protein	
C112873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112873>	C26000	DCN Gene|DCN|DCN|Decorin Gene	This gene plays a role in proteoglycan synthesis.	DCN Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C112874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112874>	C112873	DCN wt Allele|CSCD|DSPG2|Decorin wt Allele|PG40|PGII|PGS2|SLRR1B	Human DCN wild-type allele is located in the vicinity of 12q21.33 and is approximately 38 kb in length. This allele, which encodes decorin protein, is involved in extracellular matrix collagen fibril formation. A genetic deletion in this gene is associated with congenital stromal corneal dystrophy.	DCN wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112875>	C17351	Decorin|Bone Proteoglycan II|Decorin Proteoglycan|Dermatan Sulphate Proteoglycans II|PG II|PG-S2|PG40|Proteoglycan Core Protein|Proteoglycan II|Small Leucine-Rich Protein 1B	Decorin (359 aa, ~40 kDa) is encoded by the human DCN gene. This protein plays a role in both the metabolism of proteoglycans and collagen fibril formation.	Decorin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112876>	C21275	IDE Gene|IDE|IDE|Insulin-Degrading Enzyme Gene	This gene is involved in the catabolism of insulin and other bioactive peptides.			Gene or Genome	
C112877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112877>	C112876	IDE wt Allele|INSULYSIN|Insulin-Degrading Enzyme wt Allele|RP11-366I13.1	Human IDE wild-type allele is located within 10q23-q25 and is approximately 122 kb in length. This allele, which encodes insulin-degrading enzyme protein, plays a role in the degradation of insulin and other bioactive peptides.			Gene or Genome	
C112878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112878>	C16843	Insulin-Degrading Enzyme|Abeta-Degrading Protease|EC 3.4.24.56|IDE|Insulin Protease|Insulinase|Insulysin	Insulin-degrading enzyme (1019 aa, ~118 kDa) is encoded by the human IDE gene. This protein is involved in the metabolism of bioactive peptides.			Amino Acid, Peptide, or Protein|Enzyme	
C112879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112879>	C25994	IAPP Gene|IAPP|IAPP|Islet Amyloid Polypeptide Gene	This gene plays a role in insulin-mediated glucose metabolism.			Gene or Genome	
C11287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11287>	C61007	Amifostine/Carboplatin/Paclitaxel|CBDCA/TAX/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112880>	C112879	IAPP wt Allele|AMYLIN|DAP|IAP|IAPDAP|Islet Amyloid Polypeptide (Diabetes-Associated Peptide; Amylin) Gene|Islet Amyloid Polypeptide wt Allele	Human IAPP wild-type allele is located in the vicinity of 12p12.1 and is approximately 25 kb in length. This allele, which encodes islet amyloid polypeptide protein, is involved in the modulation of insulin-stimulated glycogen formation.			Gene or Genome	
C112881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112881>	C1746	Islet Amyloid Polypeptide|Amylin|DAP|Diabetes-Associated Peptide|Insulinoma Amyloid Peptide	Islet amyloid polypeptide (89 aa, ~10 kDa) is encoded by the human IAPP gene. This protein plays a role in the regulation of glucose metabolism.			Amino Acid, Peptide, or Protein|Hormone	
C112882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112882>	C20401	Anti-CD2 Monoclonal Antibody	Any monoclonal antibody directed against the cell surface glycoprotein CD2, regardless of the antibody type.			Chemical Viewed Functionally	
C112883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112883>	C20401	Anti-CD3 Monoclonal Antibody	Any monoclonal antibody directed against the cell surface glycoprotein CD3.	Anti-CD3 Monoclonal Antibody		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C112884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112884>	C20401	Anti-CD4 Monoclonal Antibody	Any monoclonal antibody directed against the cell surface glycoprotein CD4, regardless of the antibody type.			Chemical Viewed Functionally	
C112885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112885>	C20401	Anti-CD5 Monoclonal Antibody	Any monoclonal antibody directed against the cell surface glycoprotein CD5, regardless of the antibody type.			Chemical Viewed Functionally	
C112886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112886>	C20401	Anti-CD6 Monoclonal Antibody	Any monoclonal antibody directed against the cell surface glycoprotein CD6, regardless of the antibody type.			Chemical Viewed Functionally	
C112887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112887>	C20401	Anti-CD7 Monoclonal Antibody	Any monoclonal antibody directed against the cell surface glycoprotein CD7, regardless of the antibody type.			Chemical Viewed Functionally	
C112888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112888>	C20401	Anti-CD8 Monoclonal Antibody	Any monoclonal antibody directed against the cell surface glycoprotein CD8, regardless of the antibody type.			Chemical Viewed Functionally	
C112889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112889>	C20401|C198634|C129822	Anti-CD19 Monoclonal Antibody|Anti-CD19 MoAb	Any monoclonal antibody directed against the cell surface glycoprotein CD19.			Chemical Viewed Functionally	
C11288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11288>	C61063	Amifostine/Topotecan|TOPO/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112890>	C26003	BACE2 Gene|BACE2|BACE2|Beta-Site APP-Cleaving Enzyme 2 Gene	This gene is involved in proteolytic processing.			Gene or Genome	
C112891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112891>	C112890	BACE2 wt Allele|AEPLC|ALP56|ASP1|ASP21|BAE2|Beta-Site APP-Cleaving Enzyme 2 wt Allele|CDA13|CEAP1|DRAP|UNQ418/PRO852	Human BACE2 wild-type allele is located in the vicinity of 21q22.3 and is approximately 108 kb in length. This allele, which encodes beta-secretase 2 protein, plays a role in protein cleavage.			Gene or Genome	
C112892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112892>	C28411	Beta-Secretase 2|56 kDa Aspartic-Like Protease|ASP1|Asp 1|Aspartic-Like Protease 56 kDa|Aspartic-Like Protease, 56 kD|Aspartyl Protease 1|BACE2|Beta-Site Amyloid Beta A4 Precursor Protein-Cleaving Enzyme 2|Beta-Site Amyloid Precursor Protein Cleaving Enzyme 2|DRAP|Down Region Aspartic Protease|Down Syndrome Region Aspartic Protease|EC 3.4.23.45|Memapsin 1|Memapsin-1|Membrane-Associated Aspartic Protease 1|Theta-Secretase|Transmembrane Aspartic Proteinase Asp1	Beta-secretase 2 (518 aa, ~56 kDa) is encoded by the human BACE2 gene. This protein is involved in the cleavage of membrane bound proteins.			Amino Acid, Peptide, or Protein|Enzyme	
C112893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112893>	C26003	BACE1 Gene|BACE1|BACE1|Beta-Site APP-Cleaving Enzyme 1 Gene	This gene plays a role in protein cleavage.			Gene or Genome	
C112894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112894>	C112893	BACE1 wt Allele|ASP2|BACE|Beta-Site APP-Cleaving Enzyme 1 wt Allele|Beta-Site APP-Cleaving Enzyme Gene|HSPC104|KIAA1149|Secretase, Beta Gene	Human BACE1 wild-type allele is located within 11q23.2-q23.3 and is approximately 31 kb in length. This allele, which encodes beta-secretase 1 protein, is involved in proteolytic processing.			Gene or Genome	
C112895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112895>	C28411	Beta-Secretase 1|APP Beta-Secretase|ASP2|Asp 2|Aspartyl Protease 2|BACE1|Beta-Site APP Cleaving Enzyme 1|Beta-Site Amyloid Beta A4 Precursor Protein-Cleaving Enzyme|Beta-Site Amyloid Beta A4 Precursor Protein-Cleaving Enzyme 1|Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1|EC 3.4.23.46|Memapsin 2|Memapsin-2|Membrane-Associated Aspartic Protease 2|Transmembrane Aspartic Proteinase Asp2	Beta-secretase 1 (501 aa, ~56 kDa) is encoded by the human BACE1 gene. This protein plays a role in the proteolysis of ectodomains of membrane proteins.			Amino Acid, Peptide, or Protein|Enzyme	
C112896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112896>	C20338	TERF2IP Gene|TERF2 Interacting Protein Gene|TERF2IP|TERF2IP	This gene is involved in both telomere maintenance and gene transcription.			Gene or Genome	
C112897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112897>	C112896	TERF2IP wt Allele|DRIP5|PP8000|RAP1|RAP1, Yeast, Homolog of Gene|TERF2 Interacting Protein wt Allele|TRF2-Interacting Telomeric RAP1 Protein Gene|Telomeric Repeat Binding Factor 2, Interacting Protein Gene	Human TERF2IP wild-type allele is located in the vicinity of 16q23.1 and is approximately 113 kb in length. This allele, which encodes telomeric repeat-binding factor 2-interacting protein 1, plays a role in both the regulation of gene expression and the modulation of telomere recombination.			Gene or Genome	
C112898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112898>	C18466	Telomeric Repeat-Binding Factor 2-Interacting Protein 1|Dopamine Receptor Interacting Protein 5|Dopamine Receptor-Interacting Protein 5|RAP1 Homolog|Repressor/Activator Protein 1 Homolog|TERF2 Interacting Protein|TERF2-Interacting Telomeric Protein|TERF2-Interacting Telomeric Protein 1|TERF2IP|TRF2-Interacting Telomeric Protein|TRF2-Interacting Telomeric Protein 1|TRF2-Interacting Telomeric RAP1 Protein|hRap1	Telomeric repeat-binding factor 2-interacting protein 1 (399 aa, ~44 kDa) is encoded by the human TERF2IP gene. This protein is involved in both the negative regulation of telomere recombination and the modulation of gene transcription.			Amino Acid, Peptide, or Protein	
C112899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112899>	C54362	PAGR1 Gene|PAGR1|PAGR1|PAXIP1 Associated Glutamate-Rich Protein 1 Gene	This gene plays a role in both transcriptional regulation and histone methylation.	PAGR1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C11289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11289>	C61063	Marimastat/Tamoxifen|BB-2516/TMX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1128>	C2169|C1971|C1557	Leflunomide|4-Isoxazolecarboxamide, 5-Methyl-N-(4-(trifluoromethyl)phenyl)-|Arava|LEFLUNOMIDE|SU101|SU101|leflunomide	A derivative of isoxazole used for its immunosuppressive and anti-inflammatory properties.  As a prodrug, leflunomide is converted to an active metabolite, A77 1726, which blocks dihydroorotate dehydrogenase, a key enzyme of de novo pyrimidine synthesis, thereby preventing the expansion of activated T lymphocytes.  This agent also inhibits various protein tyrosine kinases, such as protein kinase C (PKC), thereby inhibiting cell proliferation. (NCI04)	Leflunomide		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C112900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112900>	C112899	PAGR1 wt Allele|C16orf53|Chromosome 16 Open Reading Frame 53 Gene|GAS|PA1|PAXIP1 Associated Glutamate-Rich Protein 1 wt Allele	Human PAGR1 wild-type allele is located in the vicinity of 16p11.2 and is approximately 6 kb in length. This allele, which encodes PAXIP1-associated glutamate-rich protein 1, is involved in the regulation of both gene transcription and histone methylation.	PAGR1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112901>	C26199	PAXIP1-Associated Glutamate-Rich Protein 1|Glutamate-Rich Coactivator Associated With SRC1|Glutamate-Rich Coactivator Interacting With SRC1/NCOA1|PAGR1|PAXIP1-Associated Protein 1|PTIP-Associated 1 Protein|PTIP-Associated Protein 1	PAXIP1-associated glutamate-rich protein 1 (254 aa, ~28 kDa) is encoded by the human PAGR1 gene. This protein plays a role in the modulation of both histone methyltransferase activity and gene expression.	PAXIP1-Associated Glutamate-Rich Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112902>	C54362	PAXIP1 Gene|PAX Interacting (With Transcription-Activation Domain) Protein 1 Gene|PAXIP1|PAXIP1	This gene is involved in the regulation of both histone methylation and gene expression.	PAXIP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C112903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112903>	C112902	PAXIP1 wt Allele|CAGF28|CAGF29|PACIP1|PAX Interacting (With Transcription-Activation Domain) Protein 1 wt Allele|PAXIP1L|PTIP|TNRC2	Human PAXIP1 wild-type allele is located in the vicinity of 7q36 and is approximately 59 kb in length. This allele, which encodes PAX-interacting protein 1, plays a role in the modulation of both gene transcription and the response to DNA damage.	PAXIP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112904>	C26199	PAX-Interacting Protein 1|PAX Transactivation Activation Domain-Interacting Protein|PAX Transactivation Domain-Interacting Protein|PAX Transcription Activation Domain Interacting Protein 1 Like|PAXIP1|Protein Encoded By CAG Trinucleotide Repeats	PAX-interacting protein 1 (1069 aa, ~121 kDa) is encoded by the human PAXIP1 gene. This protein is involved in both DNA damage responses and transcription regulation.	PAX-Interacting Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C112905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112905>	C20420	SALL4 Gene|SALL4|SALL4|SALL4|Spalt Like Transcription Factor 4 Gene	This gene plays a role in both transcriptional regulation and stem cell maintenance.			Gene or Genome	GDC Terminology|GDC Value Terminology
C112906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112906>	C131123	FDA eManufacturing Terminology	Terminology developed to support manufacturing efforts of the FDA.			Intellectual Product	
C112907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112907>	C112905	SALL4 wt Allele|DRRS|HSAL4|IVIC|Sal (Drosophila)-Like 4 Gene|Sal-Like 4 (Drosophila) Gene|Sal-Like 4 Gene|Spalt Like Transcription Factor 4 wt Allele|Spalt-Like Transcription Factor 4 Gene|ZNF797|dJ1112F19.1	Human SALL4 wild-type allele is located in the vicinity of 20q13.2 and is approximately 18 kb in length. This allele, which encodes Sal-like protein 4, is involved in both the positive and negative regulation of transcription. Mutation of the gene is associated with Duane-radial ray syndrome.			Gene or Genome	
C112908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112908>	C17207	Sal-Like Protein 4|SALL4|Spalt-Like Transcription Factor 4|Zinc Finger Protein 797|Zinc Finger Protein SALL4	Sal-like protein 4 (1053 aa, ~112 kDa) is encoded by the human SALL4 gene. This protein plays a role in self-renewal and maintenance of both embryonic and hematopoietic stem cells.			Amino Acid, Peptide, or Protein	
C112909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112909>	C20401	Alpha-Beta T-Cell Receptor Antibody|Anti-Alpha-Beta T-Cell Receptor Antibody|a/b T-Cell Receptor Antibody	Any monoclonal antibody directed against an alpha-beta T-Cell receptor.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	
C11290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11290>	C61063	Amifostine/Cisplatin/Fluorouracil|CDDP/5-FU/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112910>	C25335	Treated Volume|TV	A volume enclosed by an isodose surface, selected and specified as being appropriate to achieve the purpose of treatment.			Quantitative Concept	
C112911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112911>	C25335	Irradiated Volume	A tissue volume which receives a dose that is considered significant in relation to healthy tissue tolerance.			Quantitative Concept	
C112912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112912>	C25335	Clinical Target Volume|CTV|Clinical target volume (observable entity)	The tissue volume that contains a demonstrable gross target volume and/or sub-clinical microscopic malignant disease, which has to be eliminated. This volume must be treated adequately in order to achieve the aim of therapy, cure or palliation.			Quantitative Concept	mCode Radiotherapy Volume Type Value Set|mCode Terminology
C112913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112913>	C25335	Gross Target Volume|GTV	The gross palpable or visible/demonstrable extent and location of malignant growth.			Quantitative Concept	
C112914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112914>	C16830	Radiotherapy Bolus|Bolus	A tissue-equivalent material placed in contact with the skin to increase the surface dose and/or compensate for missing tissue. A bolus can also be used to compensate for lack of scatter, such as near the extremities or the head during total-body irradiation.			Medical Device	
C112915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112915>	C54362	HEXIM1 Gene|HEXIM1|HEXIM1|Hexamethylene Bis-Acetamide Inducible 1 Gene	This gene is involved in the modulation of gene transcription.			Gene or Genome	
C112916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112916>	C112915	HEXIM1 wt Allele|CLP-1|CLP1|EDG1|HIS1|Hexamethylene Bis-Acetamide Inducible 1 wt Allele|Hexamethylene-Bis-Acetamide-Inducible Transcript 1 Gene|MAQ1	Human HEXIM1 wild-type allele is located in the vicinity of 17q21.31 and is approximately 5 kb in length. This allele, which encodes protein HEXIM1, plays a role in transcriptional repression.			Gene or Genome	
C112917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112917>	C26199	Protein HEXIM1|Cardiac Lineage Protein 1|Estrogen Down-Regulated Gene 1 Protein|HEXIM1|Hexamethylene Bis-Acetamide-Inducible Protein 1|Hexamethylene Bisacetamide-Inducible Protein|Menage A Quatre 1|Menage A Quatre Protein 1	Protein HEXIM1 (359 aa, ~41 kDa) is encoded by the human HEXIM1 gene. This protein is involved in the inhibition of transcription by RNA polymerase II.			Amino Acid, Peptide, or Protein	
C112918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112918>	C20181	Accessory	Something added to extend a whole and to make an addition.			Classification	
C112919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112919>	C20420	SOX4 Gene|SOX4|SOX4|SRY (Sex Determining Region Y)-Box 4 Gene	This gene plays a role in the positive regulation of transcription.			Gene or Genome	
C11291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11291>	C61007	Doxorubicin HCl Liposome/VX-853|LipoDox/VX-853			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112920>	C112919	SOX4 wt Allele|EVI16|Ecotropic Viral Integration Site 16|SRY (Sex Determining Region Y)-Box 4 wt Allele|SRY-Box 4 Gene|SRY-Related HMG-Box Gene 4	Human SOX4 wild-type allele is located in the vicinity of 6p22.3 and is approximately 5 kb in length. This allele, which encodes transcription factor SOX-4 protein, is involved in both transcriptional regulation and T-cell differentiation.			Gene or Genome	
C112921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112921>	C17207	Transcription Factor SOX-4|SOX-4|SOX4	Transcription factor SOX-4 (474 aa, ~47 kDa) is encoded by the human SOX4 gene. This protein plays a role in both T-cell differentiation and transcriptional activation.			Amino Acid, Peptide, or Protein	
C112922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112922>	C61408	Cell Culture-Based Biosynthesis	A process that synthesizes a material of interest using cell culture techniques.			Laboratory Procedure	
C112923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112923>	C19236	Drying Method	A process that removes water or volatile solvents from a bed of solids.			Laboratory Procedure	
C112924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112924>	C19236	Filling Method	A process that fills a dosage unit.			Laboratory Procedure	
C112925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112925>	C25404	Granulation	The act of forming something into grains.			Activity	PQ/CMC Unit Operations Category Terminology
C112926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112926>	C19236	Particle Sizing|Particle Separation	Separation of particles into size-differentiated fractions.			Laboratory Procedure	FDA eManufacturing Terminology|PQ/CMC Unit Operations Category Terminology
C112927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112927>	C25404	Production	The creation of goods and services by a manufacturing process.			Activity	
C112928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112928>	C15657	Red Blood Cell Processing|Processing, Blood Products Red Blood Cell	Any procedure used to process or manipulate units of red blood cells.			Laboratory Procedure	FDA eManufacturing Terminology
C112929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112929>	C70700	Animal Blood Product-Derived Intermediate Paste Production|Production/Fractionation, Intermediate Paste/Animal Blood, Blood Products	The production of concentrated proteins from animal plasma during a protein purification process.			Laboratory Procedure	FDA eManufacturing Terminology
C11292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11292>	C61063	Cyclophosphamide/Doxorubicin/Marimastat|BB-2516/CTX/DOX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112930>	C70700	Antigen Reagent Production|Production, Antigen/Reagent	A procedure to manufacture blood group antigens or cellular reagents for donor and recipient typing of blood or organs.			Laboratory Procedure	FDA eManufacturing Terminology
C112931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112931>	C70700	Anti-Human Globulin Preparation|Preparation, Anti-Human Globulin	A procedure to isolate one or more anti-globulin antibodies from either serum derived from animals immunized with human serum globulins or from fluids harvested from stable immunoglobulin-secreting cell lines.			Laboratory Procedure	FDA eManufacturing Terminology
C112932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112932>	C70700	Blood Product Collection|Collection, Blood Products	Any process that harvests blood or blood products for clinical or manufacturing purposes.			Laboratory Procedure	FDA eManufacturing Terminology
C112933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112933>	C70700	Bone Marrow Collection|Collection, Bone Marrow	Any process that harvests bone marrow for clinical or manufacturing purposes.			Laboratory Procedure	FDA eManufacturing Terminology
C112934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112934>	C70700	Cell Separation by Density Gradient Centrifugation|Centrifugation, Cell Product Buoyant Density	A method of separating cells by either their differential rate of sedimentation in a centrifugal gradient or their differential buoyancy in a density gradient.			Laboratory Procedure	FDA eManufacturing Terminology
C112935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112935>	C70700	Collection of Non-Human Source Plasma|Production, Non-Human Source Plasma	The collection of the fluid portion of non-human blood intended as a source material for further manufacture.			Laboratory Procedure	FDA eManufacturing Terminology
C112936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112936>	C70700	Harvest of Product from Cell Media|Cell Culture, Harvest/Recovery, Extraction from Cell- Culture|Harvest of Product from Cell Supernatant	Collection of a material of interest from a cell culture supernatant.			Laboratory Procedure	FDA eManufacturing Terminology
C112937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112937>	C70700	Harvest of Product from Whole Cell Lysate|Cell Culture, Harvest/Recovery, Extraction- Cells/Inclusion Bodies	Collection of a material of interest from a cell lysate.			Laboratory Procedure	FDA eManufacturing Terminology
C112938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112938>	C70700	Human Blood Product-Derived Intermediate Paste Production|Production/Fractionation, Intermediate Paste/Human Blood, Blood Products	The production of concentrated proteins from human plasma during a protein purification process.			Laboratory Procedure	FDA eManufacturing Terminology
C112939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112939>	C70700	Plasma Protein Cold Ethanol Fractionation|Fractionation, Blood Products Cold Ethanol	A multistep purification process that isolates plasma proteins based upon the differential solubility of proteins in ethanol solutions.			Laboratory Procedure	FDA eManufacturing Terminology
C11293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11293>	C61063	Floxuridine/Leucovorin Calcium/Melphalan|CF/FUDR/L-PAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112940>	C70700	Plasma Protein Cryoprecipitation|Production, Blood Products Cyroprecipitate	A process to isolate plasma proteins by cooling the plasma to form a precipitate.			Laboratory Procedure	FDA eManufacturing Terminology
C112941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112941>	C70700	Preparation of Blood Products Grouping Reagent|Preparation, Blood Products Grouping Reagent	A procedure to isolate blood group antigens for use in serological testing.			Laboratory Procedure	FDA eManufacturing Terminology
C112942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112942>	C70700	Production of Blood Serological Test Device|Production, Agglutination or Gel or Column Test, Blood Serological Testing	A procedure to manufacture devices or components used in blood serological testing.			Laboratory Procedure	FDA eManufacturing Terminology
C112943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112943>	C70700	Sample Purification from Cell Culture|Cell Culture, Purification	A process that isolates a material of interest from a cell culture using a biomolecular separation technique.			Laboratory Procedure	FDA eManufacturing Terminology
C112944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112944>	C70700	Sample Recovery from Cell Culture, Not Otherwise Specified|Cell Culture, Harvest/Recovery, Other	A cell culture sample collection process that is not otherwise specified.			Laboratory Procedure	FDA eManufacturing Terminology
C112945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112945>	C70700	Sedimentation Sample Separation from Cell Culture|Cell Culture, Harvest/Recovery, Sedimentation	A process that collects a material of interest from a cell culture sample by allowing the materials harvested from the culture to separate by sedimentation.			Laboratory Procedure	FDA eManufacturing Terminology
C112946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112946>	C70700	Sterile Cell Culture Product Processing|Processing, Sterile Cell Culture	Cell culture techniques done under aseptic conditions.			Laboratory Procedure	FDA eManufacturing Terminology
C112947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112947>	C113056	Tissue Decellularization|Processing, Decellularized Tissue	The physical, chemical and/or enzymatic processing of tissue samples to remove cells and leave behind the extracellular matrix or natural scaffold made up of collagen and other fibers and proteins.			Laboratory Procedure	FDA eManufacturing Terminology
C112948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112948>	C15657	Recovery of Plasma from Blood Products|Recovery, Blood Products Human Plasma	A process that derives plasma from single units of whole blood or as a by-product from the preparation of blood components from whole blood.			Health Care Activity	FDA eManufacturing Terminology
C112949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112949>	C19161	Mineral Sources|Derivation, Extraction, Mineral Source	Indicates that a product is derived from a specified mineral material.			Qualitative Concept	FDA eManufacturing Terminology
C11294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11294>	C61063	Etoposide/Ifosfamide/Mesna/Topotecan|VP-16/IFF/Mesna/TOPO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112950>	C16396	Cell Bank Characterization|Cell Banking, Characterization and/or Qualification	A process that takes a single pool of cells prepared from a selected cell clone and determines the characteristics of a sample of the cells including, but not limited to, checking for microbial or viral contaminants, the optimal growth conditions, and levels of expression of biologics.			Laboratory Procedure	FDA eManufacturing Terminology
C112951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112951>	C16396	Cell Bank Maintenance|Cell Banking, Master and Working Cell Bank Preparation and/or Maintenance	A process that generates and maintains a single pool of cells prepared from a selected cell clone under specific conditions. This involves dispensing the cell sample into multiple containers and storing the sample under specific conditions.			Laboratory Procedure	FDA eManufacturing Terminology
C112952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112952>	C16396	Cell Culture Pooling|Harvest/Pooling, Cell Product Final	The expansion of a cell line in multiple vessels followed by the harvesting and pooling of the expanded culture into one vessel for holding or storage.			Laboratory Procedure	FDA eManufacturing Terminology
C112953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112953>	C16396	Disposable Bag Culture|Cell Culture, Expansion, Disposable Bags	A type of culture in which cells are grown in single use bags.			Laboratory Procedure	FDA eManufacturing Terminology
C112954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112954>	C16396	Flask or Bottle Culture|Cell Culture, Expansion, Flask or Bottle	A type of culture in which cells are grown in flasks or bottles.			Laboratory Procedure	FDA eManufacturing Terminology
C112955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112955>	C16396	Perfusion Culture|Cell Culture, Perfusion	A type of culture in which cells are grown and are continuously fed new culture media.			Laboratory Procedure	FDA eManufacturing Terminology
C112956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112956>	C16396	Scaffold Seeding|Seeding, Scaffold	Addition of living cells to a biocompatible scaffold.			Laboratory Procedure	FDA eManufacturing Terminology
C112957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112957>	C19147	Feeder Layer|Production, Feeder Cell Layer	A layer of supportive cells that are irradiated to prevent replication but can still secrete growth enhancing factors for use in co-culture			Manufactured Object	FDA eManufacturing Terminology
C112958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112958>	C112922	Bioreactor Culture Biosynthesis|Derivation, Fermentation, Bioreactor	A process that synthesizes a material of interest using a large scale cell culture that is grown in a bioreactor.			Laboratory Procedure	FDA eManufacturing Terminology
C112959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112959>	C112922	Cell Culture-Based Biosynthesis, Not Otherwise Specified|Derivation, Fermentation/Culture, Other	A process that synthesizes a material of interest using cell culture that is not otherwise specified.			Laboratory Procedure	FDA eManufacturing Terminology
C11295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11295>	C61063	Etoposide Phosphate/Topotecan|ETOP/TOPO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112960>	C112922	Disposable Bag Culture Biosynthesis|Derivation, Fermentation, Disposable Bags	A process that synthesizes a material of interest using a disposable bag cell culture.			Laboratory Procedure	FDA eManufacturing Terminology
C112961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112961>	C112922	Perfusion Culture Biosynthesis|Derivation, Fermentation, Perfusion	A process that synthesizes a material of interest using a continuously fed cell culture.			Laboratory Procedure	FDA eManufacturing Terminology
C112962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112962>	C112922	Shaker Flask or Roller Bottle Culture Biosynthesis|Derivation, Fermentation, Shaker Flask or Roller Bottle	A process that synthesizes a material of interest using shaker flask or roller bottle cell culture.			Laboratory Procedure	FDA eManufacturing Terminology
C112963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112963>	C16475	Cell or Vector Cryopreservation|Production, Cryopreserved Cell/Gene Therapy Intermediate	Preservation of cells or genetic vectors by storage at low temperatures.			Laboratory Procedure	FDA eManufacturing Terminology
C112964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112964>	C43358	Design and Specification of Software Platform or Architecture for in Vitro Diagnostics Device|Design/Specification, Software Platform/Architecture, in Vitro Diagnostics Device	The act of specifying the operational and physical requirements, respectively, for the software and hardware of an in vitro diagnostic device.			Occupational Activity	FDA eManufacturing Terminology
C112965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112965>	C45273	Blood Product Distribution|Distribution, Blood Products	The shipment of blood products under controlled conditions.			Laboratory Procedure	FDA eManufacturing Terminology
C112966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112966>	C19236	Cell Product Encapsulation|Encapsulation, Cell Product	A method that coats a cellular product with a layer of another material.			Laboratory Procedure	FDA eManufacturing Terminology
C112967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112967>	C19236	Coating of Device with Immunologic Reagents|Coating/Application, Biological Reagent Device	A procedure used to immobilize antigens or immunoglobulins on a device.			Laboratory Procedure	FDA eManufacturing Terminology
C112968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112968>	C15653	Compression Formulation Process|Dosage Formation, Compression	A process that forms a solid dosage unit by applying mechanical forces to bind the formulation.			Laboratory Procedure	FDA eManufacturing Terminology
C112969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112969>	C15653	Die Cutting Formulation Process|Dosage Formation, Die Cutting	A process that forms a solid dosage unit by continuously cutting a uniform material into equally sized segments.			Laboratory Procedure	FDA eManufacturing Terminology
C11296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11296>	C61007	Doxorubicin/Etoposide/Ifosfamide|DOX/IFF/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112970>	C15653	Drug Formulation Process, Not Otherwise Specified|Dosage Formation, Other	A process that forms a dosage that is not otherwise specified.			Laboratory Procedure	FDA eManufacturing Terminology
C112971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112971>	C19236	Fluidized Bed Coating Method|Coating, Fluid Bed	A method that suspends a substrate in a fluidized bed while it is sprayed with a layer of coating material.			Laboratory Procedure	FDA eManufacturing Terminology
C112972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112972>	C15653	Lamination Formulation Process|Dosage Formation, Lamination	A process that forms a solid dosage unit consisting of discrete layers that are bound together.			Laboratory Procedure	FDA eManufacturing Terminology
C112973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112973>	C15653	Laser Drill Formulation Process|Dosage Formation, Drilling, Laser|Laser Drilling	A process that uses a laser to drill holes in a tablet.			Laboratory Procedure	FDA eManufacturing Terminology|PQ/CMC Unit Operations Subcategory Terminology
C112974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112974>	C15653	Molded Formulation Process|Dosage Formation, Molding	A process that forms a solid dosage unit by pouring or casting a melted agent into a prefabricated form.			Laboratory Procedure	FDA eManufacturing Terminology
C112975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112975>	C19236	Roller Coating Method|Coating, Roller	A method that rolls a substrate such that it comes into contact with the coating material.			Laboratory Procedure	FDA eManufacturing Terminology
C112976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112976>	C19236	Rotating Pan Coating Method|Coating, Pan|Pan Coating	A method that agitates a substrate in a rotating pan while it is sprayed with a layer of coating material.			Laboratory Procedure	FDA eManufacturing Terminology|PQ/CMC Unit Operations Subcategory Terminology
C112977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112977>	C19236	Vapor Disposition Coating Method|Coating, Vapor Disposition	A method that condenses a vaporized coating material onto a substrate.			Laboratory Procedure	FDA eManufacturing Terminology
C112978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112978>	C112923	Drying Method, Not Otherwise Specified|Drying, Other	A process that is not otherwise specified, which removes water or a volatile solvent by evaporation.			Laboratory Procedure	FDA eManufacturing Terminology
C112979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112979>	C112923	Flash Drying Method|Direct Heating, Dilute Solids Bed, Flash Drying|Drying, Flash	A process that removes water or volatile solvents from a bed of solids by relying on absorption of heat radiation by those solvents.			Laboratory Procedure	FDA eManufacturing Terminology|PQ/CMC Unit Operations Subcategory Terminology
C11297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11297>	C61063	Doxorubicin/Raltitrexed|DOX/ICI D1694			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112980>	C112923	Fluid Bed Drying Method|Direct Heating, Fluidized Solids Bed|Drying, Fluid Bed	A process that removes water or volatile solvents using large volumes of hot air to suspend a bed of solids.			Laboratory Procedure	FDA eManufacturing Terminology|PQ/CMC Unit Operations Subcategory Terminology
C112981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112981>	C112923	Moving Bed Drying Method|Drying, Moving Bed	A process that removes water or volatile solvents from an agitated or tumbling bed of solids by relying on heat transfer from the equipment surface or a hot gas to the solid sample.			Laboratory Procedure	FDA eManufacturing Terminology
C112982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112982>	C112923	Radiant Heating Drying Method|Drying, Radiant Heating	A process that removes water or volatile solvents from a bed of solids by relying on absorption of heat radiation by those solvents			Laboratory Procedure	FDA eManufacturing Terminology
C112983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112983>	C112923	Spray Heating Drying Method|Drying, Spray	A process that removes water or volatile solvents from a bed of solids or a slurry using a large volumetric flow of hot air			Laboratory Procedure	FDA eManufacturing Terminology
C112984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112984>	C112923	Stationary Bed Heating Drying Method|Drying, Stationary Bed	A process that removes water or volatile solvents from a bed of solids by relying on heat transfer from the equipment surface or a hot gas to the solid sample.			Laboratory Procedure	FDA eManufacturing Terminology
C112985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112985>	C61575	Tissue Protein Extraction|Extraction, Tissue Protein	The isolation of proteins or protein solutions from a biological source material.			Laboratory Procedure	FDA eManufacturing Terminology
C112986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112986>	C112924	Isolated Aseptic Liquid Filling Method|Filling, Aseptic, Liquid, Isolator Process	A process that fills a dosage unit with a liquid, which is performed in a closed environment under sterile conditions and without human intervention.			Laboratory Procedure	FDA eManufacturing Terminology
C112987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112987>	C112924	Isolated Aseptic Powder Filling Method|Filling, Aseptic, Powder, Isolator Process	A process that fills a dosage unit with a powder, which is performed in a closed environment under sterile conditions and without human intervention.			Laboratory Procedure	FDA eManufacturing Terminology
C112988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112988>	C112924	Liquid Filling Method, Not Otherwise Specified|Filling, Liquid, Other	A process that fills a dosage unit with a liquid in a method not otherwise specified.			Laboratory Procedure	FDA eManufacturing Terminology
C112989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112989>	C112924	Manual Aseptic Liquid Filling Method|Filling, Aseptic, Liquid, Manual Process	A process that fills a dosage unit with a liquid, which is performed under sterile conditions and is likely to involve human intervention.			Laboratory Procedure	FDA eManufacturing Terminology
C11298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11298>	C61007	Anti-thymocyte Globulin/Cyclophosphamide|ATG/CTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C112990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112990>	C112924	Manual Aseptic Powder Filling Method|Filling, Aseptic, Powder, Manual Process	A process that fills a dosage unit with a powder, which is performed under sterile conditions and is likely to involve human intervention.			Laboratory Procedure	FDA eManufacturing Terminology
C112991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112991>	C112924	Non-Sterile Augur Powder Filling Method|Filling, Powder, Nonsterile, Augur	A process that fills a dosage unit using an augur to deliver the powder, which is not performed under sterile conditions.			Laboratory Procedure	FDA eManufacturing Terminology
C112992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112992>	C112924	Non-Sterile Dosing Disk Powder Filling Method|Filling, Powder, Nonsterile, Dosing Disk	A process that fills a dosage unit using a dosing disk to deliver the powder, which is not performed under sterile conditions.			Laboratory Procedure	FDA eManufacturing Terminology
C112993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112993>	C112924	Non-Sterile Medical Gas Filling Method|Filling, Nonsterile, Medical Gas	A process that fills a container with a purified medical gas, which is not performed under sterile conditions.			Laboratory Procedure	FDA eManufacturing Terminology
C112994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112994>	C112924	Non-Sterile Piston Powder Filling Method|Filling, Powder, Nonsterile, Dosator	A process that fills a dosage unit using a piston to deliver the powder, which is not performed under sterile conditions.			Laboratory Procedure	FDA eManufacturing Terminology
C112995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112995>	C112924	Non-Sterile Vacuum Powder Filling Method|Filling, Powder, Nonsterile, Vacuum	A process that fills a dosage unit using a vacuum to deliver a powder, which is not performed under sterile conditions.			Laboratory Procedure	FDA eManufacturing Terminology
C112996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112996>	C112924	Non-Sterile Vibratory Powder Filling Method|Filling, Powder, Nonsterile, Vibratory	A process that fills a dosage unit using a vibrating perforated plate to deliver a powder, which is not performed under sterile conditions.			Laboratory Procedure	FDA eManufacturing Terminology
C112997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112997>	C112924	Non-Sterile Volumetric Powder Filling Method|Filling, Nonsterile, Powder, Volumetric	A process that fills a dosage unit with a powder by volume using gravity flow, which is not performed under sterile conditions.			Laboratory Procedure	FDA eManufacturing Terminology
C112998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112998>	C112924	Powder Filling Method, Not Otherwise Specified|Filling, Powder, Other	A process that fills a dosage unit with a powder in a method not otherwise specified.			Laboratory Procedure	FDA eManufacturing Terminology
C112999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112999>	C112924	Pressurized Liquid Filling Method|Filling, Nonsterile, Liquid, Pressure	A process that fills a dosage unit with a pressurized liquid, which is not performed under sterile conditions.			Laboratory Procedure	FDA eManufacturing Terminology
C11299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11299>	C63468	Estramustine/Etoposide/Paclitaxel Regimen|EM/TAX/VP-16|Estramustine/Etoposide/Paclitaxel|TEE|TEE|TEE regimen|Taxol-Estramustine-Etoposide|Taxol/Estramustine/Etoposide	A regimen consisting of estramustine, etoposide, and paclitaxel that may be used in the treatment of hormone-refractory prostate cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C1129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1129>	C667|C1935	Hydrazine Sulfate|HYDRAZINE SULFATE|Sehydrin|hydrazine sulfate	The synthetic sulfate salt of hydrazine, a derivative of ammonia. Hydrazine inhibits the enzyme phosphoenol pyruvate carboxykinase, thereby blocking gluconeogenesis. This agent has been reported to decrease the excessive energy needs and cachexia of cancer patients.  Classified as a likely human carcinogen, hydrazine sulfate is also a weak inhibitor of mono-amine oxidase (MAO). (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C113000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113000>	C16583	Centrifugal Filtration|Filtration, Centrifugal	The use of a spinning filter mounted in a drum periphery to purify a slurry.			Laboratory Procedure	FDA eManufacturing Terminology
C113001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113001>	C16583	Moving Filter Filtration|Filtration, Moving Filter	The use of a rotary drum, belt, or other moving filter to purify a slurry.			Laboratory Procedure	FDA eManufacturing Terminology
C113002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113002>	C16583	Stationary Filter Filtration|Filtration, Stationary Filter	The use of an immobilized filter unit to purify a slurry.			Laboratory Procedure	FDA eManufacturing Terminology
C113003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113003>	C16585|C116640	Immunological Flow Cytometry|Sorting, Flow Cytometry/Immunological, Cell Products	A technique for counting, examining or sorting microscopic particles suspended in a stream of fluid based on tagging the population of interest with antibody-based reagents.			Laboratory Procedure	FDA eManufacturing Terminology
C113004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113004>	C48151	Radioisotope Formation|Formation, Radioisotope	The formation of radioactive compounds by the use of a cyclotron or nuclear reactor.			Laboratory Procedure	FDA eManufacturing Terminology
C113005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113005>	C112925	Dry Roller Compaction Granulation|Dry Granulation|Granulation, Dry, Roller Compaction	The act of forming granules by mechanically applying pressure by rollers to form a compact that is subsequently milled and screened resulting in dry granules.			Laboratory Procedure	FDA eManufacturing Terminology|PQ/CMC Unit Operations Subcategory Terminology
C113006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113006>	C112925	Dry Slugging Granulation|Granulation, Dry, Slugging	The act of forming granules by mechanically applying pressure by punch and die to form a compact that is subsequently milled and screened resulting in dry granules.			Laboratory Procedure	FDA eManufacturing Terminology
C113007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113007>	C112925	Extrusion Granulation|Granulation, Extrusion	The use of a series of integrated steps whereby a dry powder is conditioned to form a plasticized mass that is forced through a screen and cut into sections, ultimately to yield granules possessing characteristic dimensions and density.			Laboratory Procedure	FDA eManufacturing Terminology|PQ/CMC Unit Operations Subcategory Terminology
C113008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113008>	C112925	Fluid Bed Granulation|Granulation, Fluid Bed	The process of forming granules involving the addition of liquid to bind particles as they are suspended in a fluidized state by a flowing gas stream, resulting in dry granules suitable for filling or compression.			Laboratory Procedure	FDA eManufacturing Terminology|PQ/CMC Unit Operations Subcategory Terminology
C113009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113009>	C112925	Fluidized Hot Melt Granulation|Granulation, Fluidized Hot Melt|Hot-melt Granulation	The process of forming granules using meltable binders to agglomerate dry powders under elevated temperatures resulting in granules suitable for filling or compression.			Laboratory Procedure	FDA eManufacturing Terminology|PQ/CMC Unit Operations Subcategory Terminology
C11300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11300>	C63468	KAVE Regimen|DOX/EM/KCZ/VBL|Doxorubicin/Estramustine/Ketoconazole/Vinblastine|KAVE|KAVE|Ketoconazole-Doxorubicin-Vinblastine-Estramustine|Ketoconazole/Adriamycin/Vinblastine/Estramustine|Ketoconazole/Doxorubicin/Vinblastine/Estramustine|Ketoconazole/Doxorubicin/Vinblastine/Estramustine Regimen	A regimen consisting of estramustine, doxorubicin, ketoconazole, and vinblastine that may be used in the treatment of androgen-independent prostate cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C113010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113010>	C112925	Granulation, Not Otherwise Specified|Granulation, Other	The act of forming something into grains.			Laboratory Procedure	FDA eManufacturing Terminology
C113011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113011>	C112925	High Shear Granulation|Granulation, High Shear|Wet High-Shear Granulation	The use of a series of integrated steps whereby a dry powder is conditioned by wetting, or is melted, to form a plasticized mass that with the aid of high shear forces yields relatively dense particles.			Laboratory Procedure	FDA eManufacturing Terminology|PQ/CMC Unit Operations Subcategory Terminology
C113012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113012>	C112925	Low Shear Granulation|Granulation, Low Shear|Low-Shear Tumble Granulation	The use of a series of integrated steps whereby a dry powder is conditioned by wetting or is melted to form a plasticized mass that with the aid of low shear forces, yields particles possessing characteristic dimensions and density.			Laboratory Procedure	FDA eManufacturing Terminology|PQ/CMC Unit Operations Subcategory Terminology
C113013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113013>	C112925	Spray Granulation|Granulation, Spray|Spray Dry Granulation	Granulation involving the atomization of a slurry of fine particles that are bound as they are suspended and conveyed by a flowing hot gas stream, resulting in dry granules suitable for filling or compression.			Laboratory Procedure	FDA eManufacturing Terminology|PQ/CMC Unit Operations Subcategory Terminology
C113014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113014>	C113055	Final Harvest and Pooling of Viral Vectors|Harvest/Pooling, Viral Vectors Final	Procedures for extraction and collection of viral vectors from cultured cells.			Laboratory Procedure	FDA eManufacturing Terminology
C113015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113015>	C37963	Human Cell or Tissue Harvest|Recovery, Human Cell/Tissue	The process by which human donor cells or tissues are obtained for use in human implantation, transplantation, infusion, or transfer.			Laboratory Procedure	FDA eManufacturing Terminology
C113016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113016>	C84732	Container/Closure Labeling	The action of affixing an identifier to a container or closure of an item.			Activity	FDA eManufacturing Terminology
C113017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113017>	C84732	Labeling, Not Otherwise Specified|Labeling Other	Any labeling operation not elsewhere described.			Activity	FDA eManufacturing Terminology
C113018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113018>	C43360	Device or Device Component Manufacturing|Manufacture/Assemble, Device or Device Component	A process that involves designing, fabrication, assembly and/or processing of a device or device component.			Activity	FDA eManufacturing Terminology
C113019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113019>	C43360	Manufacture or Assemble Software Platform or Architecture for in Vitro Diagnostics Device|Manufacture/Assemble, Software Platform/Architecture, in Vitro Diagnostics Device	Fabrication of the physical structure of an in vitro diagnostic device.			Laboratory Procedure	FDA eManufacturing Terminology
C11301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11301>	C61063	Amifostine/Ciprofloxacin/Pentoxifylline|CPFX/PTX/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113020>	C217464	Recombinant Protein Manufacture|Manufacture, Recombinant Protein	In vivo synthesis of recombinant proteins through recombinant DNA techniques, followed by purification.			Laboratory Procedure	FDA eManufacturing Terminology
C113021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113021>	C49188	Laboratory Testing for Bacteria, Virus, or Mycoplasma|Laboratory Testing, Bacterial, Viral and Mycoplasma	Testing of specimens or materials for the presence of microbial contamination.			Laboratory Procedure	FDA eManufacturing Terminology
C113022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113022>	C49188	Working Cell Bank Release Laboratory Testing|Laboratory Testing, Working Cell Bank Release Testing	Testing of cell bank specimens for microbial contamination.			Laboratory Procedure	FDA eManufacturing Terminology
C113023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113023>	C64925	Dissolution Mixing|Dissolution|Mixing, Dissolution	Mixing by adding solids to agitated liquids.			Laboratory Procedure	EDQM Health Care Terminology|EDQM-HC Transformation Terminology|FDA eManufacturing Terminology
C113024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113024>	C64925	Dry Powder Conditioning Mixing|Mixing, Dry Powder, Conditioning	Mixing of dry ingredients with the addition of a small amount of liquid, done to increase binding capability.			Laboratory Procedure	FDA eManufacturing Terminology
C113025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113025>	C64925	Dry Powder Convection Mixing|Convection Mixing|Mixing, Dry Powder, Convection	Mixing of dry ingredients by mechanical agitation within a containment zone.			Laboratory Procedure	FDA eManufacturing Terminology|PQ/CMC Unit Operations Subcategory Terminology
C113026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113026>	C64925	Dry Powder Diffusion Mixing|Mixing, Dry Powder, Diffusion	Mixing of dry ingredients by repetitive tumbling.			Laboratory Procedure	FDA eManufacturing Terminology
C113027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113027>	C64925	Dry Powder Pneumatic Mixing|Mixing, Dry Powder, Pneumatic|Pneumatic Mixing	Mixing of dry ingredients by dispersion and turbulence within a flowing stream of gas.			Laboratory Procedure	FDA eManufacturing Terminology|PQ/CMC Unit Operations Subcategory Terminology
C113028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113028>	C64925	High Shear Wet Milling Mixing|Mixing, High Shear/Wet Milling	Mixing of solids into liquid or of immiscible liquids by shear and impact within high velocity streams.			Laboratory Procedure	FDA eManufacturing Terminology
C113029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113029>	C64925	Low Shear Mixing|Mixing, Low Shear	Mixing of solids into liquid, without appreciable size reduction, to form a stable suspension.			Laboratory Procedure	FDA eManufacturing Terminology
C11302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11302>	C61063	Amifostine/Ciprofloxacin/Dexamethasone/Pentoxifylline|CPFX/DM/PTX/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113030>	C64925	Miscible Liquids Mixing|Mixing, Miscible Liquids	Mixing of miscible liquids to form a homogeneous solution.			Laboratory Procedure	FDA eManufacturing Terminology
C113031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113031>	C64925	Mixing, Not Otherwise Specified|Mixing, Other	Any mixing operation not otherwise specified.			Laboratory Procedure	FDA eManufacturing Terminology
C113032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113032>	C88213	Operation, Not Otherwise Specified	Performance of a practical work or of something involving the practical application of principles or processes that is not otherwise specified.			Activity	FDA eManufacturing Terminology
C113033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113033>	C84731	Container/Closure Packaging	Placement of product into its primary container/closure system.			Activity	FDA eManufacturing Terminology
C113034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113034>	C84731	Packaging Other	Any packaging operation not elsewhere described.			Activity	FDA eManufacturing Terminology
C113035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113035>	C84731	Repackaging	Placement of an already-marketed product from its original primary container or closure system into a new container or closure system.			Activity	FDA eManufacturing Terminology
C113036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113036>	C84731	Secondary Packaging|Packaging, Secondary	The process of placing a finished product within an additional container or closure system.			Activity	FDA eManufacturing Terminology
C113037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113037>	C112926	Air Classification Particle Sizing|Particle Sizing, Air Classification	Separation of dry particles into size-differentiated fraction by conveying the particles in a stream of gas.			Laboratory Procedure	FDA eManufacturing Terminology
C113038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113038>	C112926	Cooling/Congealing Particle Sizing|Particle Sizing, Cooling/Congealing	Formation of particles by solidification of dispersed droplets within a cooler gas.			Laboratory Procedure	FDA eManufacturing Terminology
C113039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113039>	C112926	Particle Sizing, Not Otherwise Specified|Particle Sizing, Other	A particle sizing operation not otherwise specified.			Laboratory Procedure	FDA eManufacturing Terminology
C11303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11303>	C61007	Docetaxel/Estramustine|EM/TXT			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113040>	C112926	Screening Particle Sizing|Particle Sizing, Screening|Separating	Separation of dry particles into size-differentiated fractions by mechanical movement through fixed mesh screens.			Laboratory Procedure	FDA eManufacturing Terminology|PQ/CMC Unit Operations Subcategory Terminology
C113041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113041>	C112926	Size Reduction Particle Sizing|Particle Sizing, Size Reduction (Coarse or Fine)	A process to reduce the particle size of a material by mechanical grinding, attrition, or impact.			Laboratory Procedure	FDA eManufacturing Terminology
C113042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113042>	C84386	Wet Milling Particle Sizing|Particle Sizing, Wet Milling|Wet Low-Shear Granulation	A process to reduce the particle size of a slurry material by attrition using either grinding or mechanical shear.			Laboratory Procedure	FDA eManufacturing Terminology|PQ/CMC Unit Operations Subcategory Terminology
C113043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113043>	C15304	Plasmapheresis for Human Source Plasma|Collection, Human Source Plasma for Further Manufacture, Blood Products	Collection of the fluid portion of human blood for use in blood products by plasmapheresis.			Laboratory Procedure	FDA eManufacturing Terminology
C113044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113044>	C25625	Coating of Solid Phase with Antigen, Antibody, or Nucleic Acid for in Vitro Diagnostics Device|Coating, Solid Phase Antigen/Antibody/Nucleic Acid for in Vitro Diagnostic Device	The act of immobilizing one or more detection agents to a solid-phase support for an in vitro diagnostic device.			Laboratory Procedure	FDA eManufacturing Terminology
C113045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113045>	C25625	Nanoparticle Production|Production, Nanoparticle	The production of small, stable particles whose size is measured in nanometers.			Laboratory Procedure	FDA eManufacturing Terminology
C113046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113046>	C25625	Plasmid Production|Production, Plasmid	The production of DNA plasmids.			Laboratory Procedure	FDA eManufacturing Terminology
C113047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113047>	C128947	Polysaccharide Preparation from Bacterial Cells|Preparation, Polysaccharide from Bacterial Cells	Separation and purification of bacterial membrane polysaccharides from target bacterial cultures.			Laboratory Procedure	FDA eManufacturing Terminology
C113048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113048>	C25625	Production of Immunoassay Detection Reagent|Immunoassay Detection Reagent Production|Production, Immunoassay Detection Reagent	The production of antigen and antibody detection components.			Laboratory Procedure	FDA eManufacturing Terminology
C113049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113049>	C25625	Production of In Vitro Diagnostics|In Vitro Diagnostics Production|Production, in Vitro Diagnostic	The production an in vitro testing system or kit to detect viral or bacterial agents in donor blood.			Laboratory Procedure	FDA eManufacturing Terminology
C11304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11304>	C61063	Oltipraz/Vitamin A|OPZ/VIT-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113050>	C25625	Production of Individual Vaccine Component|Individual Vaccine Component Production|Production, Individual Vaccine Component	The preparation of material from one virus or bacteria strain for use as a component of a vaccine.			Laboratory Procedure	FDA eManufacturing Terminology
C113051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113051>	C25625	Production of Nucleic Acid Detection Reagent|Production, Nucleic Acid Detection Reagent	The production of nucleic acid probes and reagents to detect the presence of specific nucleic acids.			Laboratory Procedure	FDA eManufacturing Terminology
C113052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113052>	C25625	Production of Nucleic Acid Extraction Reagent|Production, Nucleic Acid Extraction Reagent	The production of chemical agents to purify specific nucleic acids.			Laboratory Procedure	FDA eManufacturing Terminology
C113053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113053>	C128947	Stem Cell Isolation|Isolation, Stem Cell|Stem Cell Collection|Stem Cell Recovery	Recovery and purification of stem cells from human sources, including umbilical cord blood.	Stem Cell Isolation		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology|FDA eManufacturing Terminology
C113054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113054>	C25625	Synthetic Scaffold Production|Production, Scaffold Synthetic	Creation of a synthetic, biocompatible scaffold for the generation of bioengineered structures.			Laboratory Procedure	FDA eManufacturing Terminology
C113055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113055>	C25625	Viral Vector Preparation|Banking, Viral Vectors	Cloning and isolation of viral vectors from producer cell lines or transiently infected cells.			Laboratory Procedure	FDA eManufacturing Terminology
C113056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113056>	C48177	Tissue Processing|Processing, Tissue	Cleaning and preparation of tissues for further use in biological products.			Laboratory Procedure	FDA eManufacturing Terminology
C113057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113057>	C112927	Viral Vector Expansion and Production|Expansion/Production, Viral Vectors	The use of cell culture techniques to expand a cell line in the production of viral vectors.			Laboratory Procedure	FDA eManufacturing Terminology
C113058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113058>	C68780	Blood or Viral Antigen Purification|Purification, Blood or Viral Antigen	Purification of either blood-grouping antigens or viral proteins.			Laboratory Procedure	FDA eManufacturing Terminology
C113059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113059>	C68780	Crystallization Purification|Purification, Crystallization	Separation of a product from a saturated solution by cooling the liquid or adding precipitants which lower the solubility of the desired product so that it forms crystals.			Laboratory Procedure	FDA eManufacturing Terminology
C11305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11305>	C61063	Fenretinide/Vitamin A|HPR/VIT-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113060>	C68780	Evaporation Purification|Purification, Evaporation	Isolation of pure liquids by virtue of their different evaporation characteristics.			Laboratory Procedure	FDA eManufacturing Terminology
C113061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113061>	C68780	Extraction Purification|Purification, Extraction	Isolation of materials from solution based on their differential solubility in different liquids.			Laboratory Procedure	FDA eManufacturing Terminology
C113062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113062>	C68780	Medical Gas Purification|Purification, Medical Gas	Separation of a gas mixture into purified component gases for medical use.			Laboratory Procedure	FDA eManufacturing Terminology
C113063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113063>	C68780	Oligonucleotide Purification|Purification, Oligonucleotide	The processing of separating full-length oligonucleotides from incomplete chains and reagents.			Laboratory Procedure	FDA eManufacturing Terminology
C113064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113064>	C68780	Polyclonal Antisera Purification|Purification, Polyclonal Antisera	Antibody purification through immobilization, washing, and release.			Laboratory Procedure	FDA eManufacturing Terminology
C113065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113065>	C68780	Protein Precipitation|Precipitation	The process of precipitating proteins from solution. Protein precipitation may be bulk and general or specific.			Laboratory Procedure	FDA eManufacturing Terminology
C113066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113066>	C68780	Protein Purification|Purification, Protein	Separation of protein fractions by precipitation, chromatography, or other methods.			Laboratory Procedure	FDA eManufacturing Terminology
C113067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113067>	C68780	Purification, Not Otherwise Specified|Purification, Other	Any isolation method not otherwise specified.			Laboratory Procedure	FDA eManufacturing Terminology
C113068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113068>	C68780	Synthetic Peptide Purification|Peptide Purification, Synthetic	The processing of separating full-length peptides from incomplete chains and reagents.			Laboratory Procedure	FDA eManufacturing Terminology
C113069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113069>	C68780	Whole Organism Lysate Purification|Purification, Whole Organism Lysate	Lysis of whole organisms for the collection and purification of specific target fractions or molecules.			Laboratory Procedure	FDA eManufacturing Terminology
C11306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11306>	C61063	Calcium Carbonate/Cholecalciferol|CACO3/VIT-D|Calcium Carbonate + Cholecalciferol			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113070>	C112928	Red Blood Cell Reagent Preparation|Preparation, Blood Products Red Blood Cell Reagent	Preparation of human red blood cells used to detect or identify blood-group antibodies for blood group determination.			Laboratory Procedure	FDA eManufacturing Terminology
C113071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113071>	C84382	Terminal Sterilization|Sterilization, Terminal	Sterilization of a finished product.			Laboratory Procedure	FDA eManufacturing Terminology|PQ/CMC Unit Operations Subcategory Terminology
C113072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113072>	C164363	Blood Product Storage|Storage, Blood Products	Keeping a stock of blood products under conditions that ensure those products are suitable for future use.			Laboratory Procedure	FDA eManufacturing Terminology
C113073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113073>	C61408	Derivation, Not Otherwise Specified|Derivation, Other	The synthesis of a material of interest using a process that is not otherwise specified.			Laboratory Procedure	FDA eManufacturing Terminology
C113074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113074>	C61408	Oligonucleotide Synthesis|Synthesis, Oligonucleotide	The process of producing oligonucleotides by the union of simpler chemical compounds.			Laboratory Procedure	FDA eManufacturing Terminology
C113075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113075>	C16966	Synthetic Peptide Synthesis|Peptide Synthesis, Synthetic	The process of producing peptides by the polymerization of amino acids.			Laboratory Procedure	FDA eManufacturing Terminology
C113076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113076>	C25294|C15336	Analytical Laboratory Testing, Not Otherwise Specified|Analytical Laboratory Testing, Other	Any analytical testing operation not otherwise specified.			Laboratory Procedure	FDA eManufacturing Terminology
C113077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113077>	C25294|C15336	Blood Products Laboratory Testing|Laboratory Testing, Blood Products|Test	In vitro testing of donor blood for safety prior to use in patients.			Laboratory Procedure	FDA eManufacturing Terminology|FDA Structured Product Labeling Terminology|SPL Blood Form Establishment Functions Terminology
C113078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113078>	C15336	Chemical Laboratory Testing|Laboratory Testing, Chemical	Testing of specimens or materials for various chemical properties.			Laboratory Procedure	FDA eManufacturing Terminology
C113079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113079>	C15336	Physical Laboratory Testing|Laboratory Testing, Physical	Testing of specimens or materials for various physical properties.			Laboratory Procedure	
C11307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11307>	C61063	Bryostatin 1/Cytarabine|ARA-C/BRYO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113080>	C67226	Code Writing of Software Platform or Architecture for in Vitro Diagnostics Device|Write Code, Software Platform/Architecture, in Vitro Diagnostics Device	The act of writing code for the software of an in vitro diagnostic device.			Occupational Activity	FDA eManufacturing Terminology
C113081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113081>	C25873	MAPKAPK5 Gene|MAPKAPK5|MAPKAPK5|Mitogen-Activated Protein Kinase-Activated Protein Kinase 5 Gene	This gene is involved in protein phosphorylation, mTORC1-mediated signaling and tumor suppression.			Gene or Genome	
C113082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113082>	C113081	MAPKAPK5 wt Allele|MAPKAP-K5|MK-5|MK5|Mitogen-Activated Protein Kinase-Activated Protein Kinase 5 wt Allele|PRAK	Human MAPKAPK5 wild-type allele is located in the vicinity of 12q24.13 and is approximately 55 kb in length. This allele, which encodes MAP kinase-activated protein kinase 5 protein, plays a role in both the inhibition of mTORC1 signaling and serine/threonine phosphorylation.			Gene or Genome	
C113083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113083>	C17325	MAP Kinase-Activated Protein Kinase 5|EC 2.7.11.1|MAPK-Activated Protein Kinase 5|MAPKAP Kinase 5|MAPKAP-K5|MAPKAPK-5|MK-5|MK5|PRAK|p38-Regulated/Activated Kinase|p38-Regulated/Activated Protein Kinase	MAP kinase-activated protein kinase 5 (473 aa, ~54 kDa) is encoded by the human MAPKAPK5 gene. This protein is involved in serine/threonine phosphorylation, tumor growth suppression and signaling regulation.			Amino Acid, Peptide, or Protein|Enzyme	
C113084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113084>	C42677	Clockwise	Circular movement in the direction of the rotation of the hands of a clock.			Functional Concept	
C113085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113085>	C42677	Counterclockwise	Circular movement in the direction opposite to the rotation of the hands of a clock.			Functional Concept	
C113086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113086>	C20462	NOD1 Gene|NOD1|NOD1|Nucleotide-Binding Oligomerization Domain Containing 1 Gene	This gene plays a role in both apoptosis and immunity.			Gene or Genome	
C113087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113087>	C113086	NOD1 wt Allele|CARD4|CLR7.1|Caspase Recruitment Domain Family, Member 4 Gene|NLR Family, CARD Domain Containing 1 Gene|NLRC1|Nucleotide-Binding Oligomerization Domain Containing 1 wt Allele	Human NOD1 wild-type allele is located within 7p15-p14 and is approximately 54 kb in length. This allele, which encodes nucleotide-binding oligomerization domain-containing protein 1, is involved in both inflammation and the positive regulation of apoptosis.			Gene or Genome	
C113088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113088>	C19928	Nucleotide-Binding Oligomerization Domain-Containing Protein 1|Caspase Recruitment Domain-Containing Protein 4|NOD1|Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat and CARD Domain Containing 1	Nucleotide-binding oligomerization domain-containing protein 1 (953 aa, ~108 kDa) is encoded by the human NOD1 gene. This protein plays a role in both apoptosis and host-defense responses.			Amino Acid, Peptide, or Protein	
C113089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113089>	C91105	MD Anderson Symptom Inventory - Brain Tumor|MDASI-BT	A self-administered questionnaire designed specifically for evaluating the severity of symptoms related to a brain tumor.			Intellectual Product	
C11308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11308>	C61063	Amifostine/Cyclophosphamide/Mitoxantrone/Thiotepa|CTX/DHAD/TSPA/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113090>	C107401	Weakness on One Side of the Body at its Worst Question|Weakness on One Side of the Body at its Worst|Weakness on one side of the body at its worst	A question about an individual's weakness on one side of the body at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Brain Tumor
C113091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113091>	C173398|C107401	Difficulty Understanding at its Worst Question|Difficulty Understanding at its Worst|Difficulty understanding at its worst	A question about an individual's difficulty understanding at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Brain Tumor
C113092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113092>	C173398|C107401	Difficulty Speaking at its Worst Question|Difficulty Speaking at its Worst|Difficulty Speaking or Finding Words at its Worst|Difficulty speaking at its worst	A question about an individual's difficulty speaking at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Brain Tumor
C113093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113093>	C107401	Seizure at its Worst Question|Seizure at its Worst|Seizure at its worst	A question about an individual's seizures at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Brain Tumor
C113094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113094>	C173398|C107401	Difficulty Concentrating at its Worst Question|Difficulty Concentrating at its Worst|Difficulty concentrating at its worst	A question about an individual's difficulty concentrating at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Brain Tumor
C113095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113095>	C173790|C107401	Vision at its Worst Question|Vision at its Worst|Vision at its worst	A question about an individual's vision at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Brain Tumor
C113096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113096>	C107401	Change in Appearance at its Worst Question|Change in Appearance at its Worst|Change in appearance at its worst	A question about an individual's change in appearance at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Brain Tumor
C113097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113097>	C173938|C107401	Change in Bowel Pattern at its Worst Question|Change in Bowel Pattern at its Worst|Change in bowel pattern at its worst|Your change in bowel pattern (diarrhea/constipation) at its worst	A question about an individual's change in bowel pattern at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Brain Tumor|MD Anderson Symptom Inventory - Spine Tumor
C113098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113098>	C107401	Irritability at its Worst Question|Irritability at its Worst|Irritability at its worst	A question about an individual's irritability at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Brain Tumor
C113099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113099>	C107587	Pediatric Failure to Thrive|Failure to Thrive|Failure to Thrive|Failure to Thrive	Less than normal weight gain in an infant or child, which may include poor linear and head growth.			Finding	GAIA Failure to Thrive Level of Diagnostic Certainty Terminology|GAIA Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C11309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11309>	C61063	Fluorouracil/Raltitrexed|5-FU/ICI D1694			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1130>	C1421	Hydroxyl Radical	A monovalent radical consisting of one hydrogen and oxygen atom found in bases, carboxylic acids, and alcohols.			Inorganic Chemical	
C113100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113100>	C168182	Growth Failure|Linear Growth Failure	Less than normal linear growth in an infant or child.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C113101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113101>	C147564	Insulin Resistance	Decreased sensitivity to circulating insulin which may result in acanthosis nigicrans, elevated insulin level or hyperglycemia.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C113102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113102>	C81326|C187275	Hyperglucagonemia	Abnormally high levels of glucagon in the blood, which may manifest as hyperglycemia and/or necrolytic migratory erythema.			Laboratory or Test Result	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113103>	C36279	Fish-Mouth Papilla with Mucin Hypersecretion|Fish-Mouth Papilla with Mucin	An endoscopic finding indicating the presence of a wide-opened papilla filled with mucin.			Finding	
C113104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113104>	C81326|C187275	Hyperinsulinemia	Abnormally high levels of insulin in the blood.			Laboratory or Test Result	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C113105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113105>	C51701	Extended Template Biopsy|Extended Template Prostate Biopsy	Biopsy of the prostate that extends beyond the standard 10 to 12 cores.			Diagnostic Procedure	
C113106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113106>	C64898|C42946	Injectable Foam Dosage Form|INJECTABLE FOAM|Injectable Foam	A foam intended for parenteral administration.			Biomedical or Dental Material	FDA Structured Product Labeling Terminology|SPL Pharmaceutical Dosage Form Terminology
C113107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113107>	C26059	UBASH3B Gene|UBASH3B|UBASH3B|Ubiquitin Associated and SH3 Domain Containing B Gene	This gene plays a role in the dephosphorylation of protein kinases.			Gene or Genome	
C113108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113108>	C113107	UBASH3B wt Allele|KIAA1959|STS-1|STS1|TULA-2|Ubiquitin Associated and SH3 Domain Containing B wt Allele|p70	Human UBASH3B wild-type allele is located in the vicinity of 11q24.1 and is approximately 159 kb in length. This allele, which encodes ubiquitin-associated and SH3 domain-containing protein B, is involved in both the modulation of receptor half-life and protein tyrosine phosphatase activity.			Gene or Genome	
C113109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113109>	C17444	Ubiquitin-Associated and SH3 Domain-Containing Protein B|Cbl-Interacting Protein Sts-1|Cbl-Interacting Protein p70|EC 3.1.3.48|Nm23-Phosphorylated Unknown Substrate|SH3 Domain-Containing 70 kDa Protein|STS1|Suppressor of T-Cell Receptor Signaling 1|T-Cell Ubiquitin Ligand 2|TULA2|Tyrosine-Protein Phosphatase STS1/TULA2|UBASH3B	Ubiquitin-associated and SH3 domain-containing protein B (649 aa, ~73 kDa) is encoded by the human UBASH3B gene. This protein plays a role in the dephosphorylation of tyrosine kinases.			Amino Acid, Peptide, or Protein|Enzyme	
C11310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11310>	C61063	Bryostatin 1/Cisplatin|BRYO/CDDP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113110>	C28533	CPTP Gene|CPTP|CPTP|Ceramide-1-Phosphate Transfer Protein Gene|GLTPD1	This gene is involved in sphingolipid transport.			Gene or Genome	
C113111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113111>	C113110	CPTP wt Allele|CPTP|Ceramide-1-Phosphate Transfer Protein wt Allele|GLTPD1|Glycolipid Transfer Protein Domain Containing 1 Gene|MGC10334	Human CPTP wild-type allele is located in the vicinity of 1p36.33 and is approximately 4 kb in length. This allele, which encodes ceramide-1-phosphate transfer protein, plays a role in glycolipid transport.			Gene or Genome	
C113112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113112>	C16386	Ceramide-1-Phosphate Transfer Protein|CPTP|GLTP Domain-Containing Protein 1|Glycolipid Transfer Protein Domain-Containing Protein 1	Ceramide-1-phosphate transfer protein (214 aa, ~24 kDa) is encoded by the human CPTP gene. This protein is involved in intercellular transport of sphingolipids.			Amino Acid, Peptide, or Protein	
C113113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113113>	C35869	Arterial Hypervascularization	A radiologic finding indicating the presence of new vessels on arterial phase imaging within or surrounding a lesion.			Finding	
C113114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113114>	C20194	GPNMB Gene|GPNMB|GPNMB|Glycoprotein Nmb Gene	This gene may play a role in the regulation of cell proliferation.	GPNMB Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|Pediatric Oncology Target Cell Lineage Determinant Terminology
C113115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113115>	C113114	GPNMB wt Allele|Glycoprotein (Transmembrane) Nmb Gene|Glycoprotein Nmb wt Allele|Glycoprotein Nonmetastatic Melanoma Protein B Gene|HGFIN|Hematopoietic Growth Factor Inducible Neurokinin-1 Gene|NMB|UNQ1725/PRO9925	Human GPNMB wild-type allele is located in the vicinity of 7p15 and is approximately 39 kb in length. This allele, which encodes transmembrane glycoprotein NMB, may be involved in the modulation of cell proliferation. Aberrant expression of the gene is associated with glioblastoma multiforme and other neoplasms.	GPNMB wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113116>	C18466	Transmembrane Glycoprotein NMB|Glycoprotein NMB|Glycoprotein Nmb-Like Protein|Glycoprotein Nonmetastatic B|Osteoactivin|Transmembrane Glycoprotein HGFIN|gpNMB	Transmembrane glycoprotein NMB (572 aa, ~64 kDa) is encoded by the human GPNMB gene. This protein may play a role in cell proliferation.	Transmembrane Glycoprotein NMB		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Cell Lineage Determinant Terminology
C113117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113117>	C26131	OGFR Gene|OGFR|OGFR|Opioid Growth Factor Receptor Gene	This gene is involved in binding to Met-enkephalin.			Gene or Genome	
C113118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113118>	C113117	OGFR wt Allele|7-60|Opioid Growth Factor Receptor wt Allele|RP5-885L7.2	Human OGFR wild-type allele is located in the vicinity of 20q13.3 and is approximately 9 kb in length. This allele, which encodes opioid growth factor receptor protein, plays a role in Met-enkephalin-dependent signaling.			Gene or Genome	
C113119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113119>	C17664	Opioid Growth Factor Receptor|7-60 Protein|OGFr|Protein 7-60|Zeta-Type Opioid Receptor	Opioid growth factor receptor (677 aa, ~73 kDa) is encoded by the human OGFR gene. This protein is involved in Met-enkephalin binding and downstream effects.			Amino Acid, Peptide, or Protein|Receptor	
C11311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11311>	C61063	Carboplatin/Cyclophosphamide/Doxorubicin|CBDCA/CTX/DOX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113121>	C20745	TPM1 Gene|TPM1|TPM1|Tropomyosin 1 (Alpha) Gene	This gene plays a role in muscle contraction.			Gene or Genome	
C113122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113122>	C200488	Blood Collection Tube|BCT	A test tube, capillary tube, or other tube designed for the collection of blood.			Manufactured Object	
C113123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113123>	C113121	TPM1 wt Allele|C15orf13|CMD1Y|CMH3|Cardiomyopathy, Hypertrophic 3 Gene|Chromosome 15 Open Reading Frame 13 Gene|HTM-alpha|LVNC9|TMSA|Tropomyosin 1 (Alpha) wt Allele	Human TPM1 wild-type allele is located in the vicinity of 15q22.1 and is approximately 29 kb in length. This allele, which encodes tropomyosin alpha-1 chain protein, is involved in the regulation of muscle contraction. Mutation of the gene is associated with left ventricular non-compaction 9 and cardiomyopathy types familial hypertrophic 3 and dilated 1Y.			Gene or Genome	
C113124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113124>	C113122	Evacuated Blood Specimen Collection Tube	A blood collection tube that contains a vacuum, allowing it to draw blood through a needle to fill the tube.			Manufactured Object	
C113125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113125>	C16492	Tropomyosin Alpha-1 Chain|Alpha-Tropomyosin|Sarcomeric Tropomyosin Kappa|TPM1|Tropomyosin, Skeletal Muscle Alpha|Tropomyosin-1	Tropomyosin alpha-1 chain (284 aa, ~33 kDa) is encoded by the human TPM1 gene. This protein plays a role in muscle contraction.			Amino Acid, Peptide, or Protein	
C113126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113126>	C28533	EXOC7 Gene|EXOC7|EXOC7|Exocyst Complex Component 7 Gene	This gene is involved in vesicle exocytosis.			Gene or Genome	
C113127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113127>	C35869	Hypoechoic Focus	A radiologic finding describing a region in an image with a signal lower than that of the surrounding regions.			Finding	
C113128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113128>	C113126	EXOC7 wt Allele|2-5-3p|EX070|EXO70|EXO70, S. cerevisiae, Homolog of Gene|EXOC1|Exo70p|Exocyst Complex Component 7 wt Allele|KIAA1067|YJL085W	Human EXOC7 wild-type allele is located in the vicinity of 17q25.3 and is approximately 41 kb in length. This allele, which encodes exocyst complex component 7 protein, plays a role in the mediation of exocytosis.			Gene or Genome	
C113129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113129>	C16386	Exocyst Complex Component 7|EXOC7|Exocyst Complex Component Exo70	Exocyst complex component 7 (735 aa, ~83 kDa) is encoded by the human EXOC7 gene. This protein is involved in the regulation of exocytosis.			Amino Acid, Peptide, or Protein	
C11312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11312>	C67290	Doxorubicin/Gemcitabine Regimen|Adriamycin/Gemzar|Doxorubicin and Gemcitabine|Doxorubicin-Gemcitabine|Doxorubicin/Gemcitabine|dFdC/DOX	A regimen consisting of doxorubicin and gemcitabine that may be used in the treatment of certain types of renal cell carcinoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C113130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113130>	C20338	NAF1 Gene|NAF1|NAF1|Nuclear Assembly Factor 1 Ribonucleoprotein Gene	This gene plays a role in the assembly of ribosomes and other riboproteins.			Gene or Genome	
C113131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113131>	C113130	NAF1 wt Allele|NAF1, S. cerevisiae, Homolog of Gene|Nuclear Assembly Factor 1 Homolog (S. cerevisiae) Gene|Nuclear Assembly Factor 1 Ribonucleoprotein wt Allele	Human NAF1 wild-type allele is located in the vicinity of 4q32.2 and is approximately 57 kb in length. This allele, which encodes H/ACA ribonucleoprotein complex non-core subunit NAF1 protein, is involved in riboprotein assembly.			Gene or Genome	
C113132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113132>	C21298	H/ACA Ribonucleoprotein Complex Non-Core Subunit NAF1|NAF1|Nuclear Assembly Factor 1 Homolog|Nuclear Assembly Factor 1 Ribonucleoprotein|hNAF1	H/ACA ribonucleoprotein complex non-core subunit NAF1 (494 aa, ~54 kDa) is encoded by the human NAF1 gene. This protein plays a role in riboprotein formation.			Amino Acid, Peptide, or Protein	
C113133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113133>	C21295	CISD1 Gene|CDGSH Iron Sulfur Domain 1 Gene|CISD1|CISD1	This gene is involved in both iron-sulfur cluster binding and electron transport.			Gene or Genome	
C113134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113134>	C113133	CISD1 wt Allele|C10orf70|CDGSH Iron Sulfur Domain 1 wt Allele|Chromosome 10 Open Reading Frame 70 Gene|MDS029|ZCD1|Zinc Finger, CDGSH-Type Domain 1 Gene|mitoNEET	Human CISD1 wild-type allele is located in the vicinity of 10q21.1 and is approximately 21 kb in length. This allele, which encodes CDGSH iron-sulfur domain-containing protein 1, plays a role in the modulation of both cellular respiration and iron-sulfur cluster-dependent redox reactions.			Gene or Genome	
C113135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113135>	C17728	CDGSH Iron-Sulfur Domain-Containing Protein 1|CDGSH Iron Sulfur Domain-Containing Protein 1|CISD1|MitoNEET|Mitochondrial Asn-Glu-Glu-Thr (NEET)|Zinc Finger CDGSH-Type Domain 1	CDGSH iron-sulfur domain-containing protein 1 (108 aa, ~12 kDa) is encoded by the human CISD1 gene. This protein is involved in both iron-sulfur cluster binding and the regulation of cell respiration.			Amino Acid, Peptide, or Protein	
C113136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113136>	C25404	Dilation|DILATATION|Dilatation|Dilated	The condition of being dilated or stretched.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C113137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113137>	C26057	HELQ Gene|HELQ|HELQ|Helicase, POLQ-Like Gene	This gene plays a role in DNA unwinding.			Gene or Genome	
C113138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113138>	C113137	HELQ wt Allele|HEL308|Helicase, POLQ-Like wt Allele	Human HELQ wild-type allele is located in the vicinity of 4q21.23 and is approximately 49 kb in length. This allele, which encodes helicase POLQ-like protein, is involved in the modulation of DNA duplex unwinding.			Gene or Genome	
C113139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113139>	C16517	Helicase POLQ-Like|DNA Helicase HEL308|EC 3.6.4.12|HELQ|Mus308-Like Helicase|POLQ-Like Helicase	Helicase POLQ-like (1101 aa, ~124 kDa) is encoded by the human HELQ gene. This protein plays a role in ATP-dependent DNA helicase activity.			Amino Acid, Peptide, or Protein|Enzyme	
C11313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11313>	C61063	Fluorouracil/Gemcitabine/Leucovorin Calcium|5FU/Leucovorin/Gemcitabine|CF/dFdC/5-FU			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113140>	C21295	MORC3 Gene|MORC Family CW-Type Zinc Finger 3 Gene|MORC3|MORC3	This gene is involved in binding to both RNA and nuclear matrix proteins.			Gene or Genome	
C113141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113141>	C113140	MORC3 wt Allele|KIAA0136|MORC Family CW-Type Zinc Finger 3 wt Allele|NXP2|ZCW5|ZCWCC3|Zinc Finger, CW Type With Coiled-Coil Domain 3 Gene|Zinc Finger, CW-Type With Coiled-Coil Domain 3 Gene	Human MORC3 wild-type allele is located in the vicinity of 21q22.13 and is approximately 66 kb in length. This allele, which encodes MORC family CW-type zinc finger protein 3, plays a role in binding to both nuclear matrix proteins and RNA.			Gene or Genome	
C113142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113142>	C17728	MORC Family CW-Type Zinc Finger Protein 3|MJ ANTIGEN|MORC3|MORC3|NXP-2|NXP2|Nuclear Matrix Protein 2|Nuclear Matrix Protein 2|Nuclear Matrix Protein NXP-2|Nuclear Matrix Protein NXP2|Zinc Finger CW-Type Coiled-Coil Domain Protein 3	MORC family CW-type zinc finger protein 3 (939 aa, ~107 kDa) is encoded by the human MORC3 gene. This protein is involved in both RNA binding and nuclear matrix protein binding.			Amino Acid, Peptide, or Protein	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C113143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113143>	C26800	Primary Hypothyroidism	Abnormally low levels of thyroid hormones due to a disorder originating within the thyroid gland.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C113144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113144>	C26800	Central Hypothyroidism|Hypothalamic-Pituitary Hypothyroidism|Secondary Hypothyroidism|TSH Deficiency|Thyroid Stimulating Hormone Deficiency|Thyrotropin Deficiency	Abnormally low levels of thyroid hormones due to a disorder originating within the hypothalamic-pituitary axis.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C113145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113145>	C3123	Primary Hyperthyroidism	Overproduction of thyroid hormone due to a disorder originating within the thyroid gland.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113146>	C3123	Central Hyperthyroidism	Overproduction of thyroid hormones due to a disorder originating within the hypothalamic-pituitary axis.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C113147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113147>	C61469	Hashitoxicosis|Hashimoto Toxicosis	Severe, transient hyperthyroidism associated with Hashimoto thyroiditis.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C113148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113148>	C50470	Fetal Blood Loss	Loss of blood from the fetal circulation.			Finding	NICHD Terminology|Perinatal Terminology
C113149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113149>	C26791	Fetal-Maternal Hemorrhage|Fetal-Maternal Bleed|Fetomaternal Hemorrhage|Fetomaternal Hemorrhage	Loss of fetal blood into the maternal circulation.			Finding	NICHD Terminology|Perinatal Terminology
C11314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11314>	C61063	Cyclophosphamide/Etoposide/Lomustine/Procarbazine|CCNU/CTX/PCB/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113150>	C34941	Rhesus Isoimmunization|Rh Isoimmunization|Rh Isoimmunization	The mother develops antibodies against red blood cell Rhesus antigens. This may lead to potential fetal adverse outcomes such as anemia.			Finding	NICHD Terminology|Perinatal Terminology
C113151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113151>	C28228	Fetal Acidosis|Fetal Acidemia|Fetal Acidemia	An abnormally high hydrogen ion concentration (umbilical arterial blood pH less than 7.00) in fetal blood or tissue.			Finding	NICHD Terminology|Perinatal Terminology
C113152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113152>	C117360	Short Umbilical Cord	An umbilical cord at term that is less than 35 cm in length.			Finding	NICHD Terminology|Perinatal Terminology
C113153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113153>	C117360	Nuchal Cord	An umbilical cord that has become looped around the fetus's neck from movement in utero.			Finding	NICHD Terminology|Perinatal Terminology
C113154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113154>	C117360	Umbilical Cord Occlusion	Blockage of blood flow in the umbilical vessels.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C113155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113155>	C92720	Meconium Stained Amniotic Fluid|Meconium in Amniotic Fluid|Meconium in Amniotic Fluid	Presence of meconium into amniotic fluid.			Finding	NICHD Terminology|Perinatal Terminology
C113156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113156>	C98996	Transient Myocardial Dysfunction of Newborn	A condition in a newborn characterized by a temporary decrease in right ventricular and/or left ventricular output.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C113157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113157>	C25790	BTNL2 Gene|BTNL2|BTNL2|Butyrophilin Like 2 Gene	This gene plays a role in the regulation of T-cell proliferation.			Gene or Genome	
C113158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113158>	C113157	BTNL2 wt Allele|BTL-II|BTN7|Butyrophilin Like 2 wt Allele|Butyrophilin-Like 2 (MHC Class II Associated) Gene|Butyrophilin-Like 2 Gene|DAAP-282D22.2|HSBLMHC1|SS2	Human BTNL2 wild-type allele is located in the vicinity of 6p21.3 and is approximately 13 kb in length. This allele, which encodes butyrophilin-like protein 2, is involved in the negative regulation of T-cell proliferation. Variation in the gene is associated with susceptibility to sarcoidosis 2.			Gene or Genome	
C113159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113159>	C27557	Pneumonitis	An inflammatory process affecting the lung parenchyma. It is a milder form of lung inflammation compared to pneumonia.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Infectious Disease Terminology|Pediatric Rheumatology Terminology
C11315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11315>	C61063	Bacitracin/Clotrimazole/Gentamicin|BAC/CLOT/GM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113160>	C16725	Butyrophilin-Like Protein 2|BTL II|BTL-II|BTNL2|Butyrophilin-Like Protein, Major Histocompatibility Complex Class II-Associated	Butyrophilin-like protein 2 (455 aa, ~50 kDa) is encoded by the human BTNL2 gene. This protein plays a role in the inhibition of T-cell proliferation.			Amino Acid, Peptide, or Protein	
C113161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113161>	C28681|C138180|C129826	Autologous Peripheral Blood Lymphocytes Cotransduced with Retroviral Vectors Encoding Inducible IL-12 and Anti-NY-ESO-1 TCR|Autologous Lymphocytes Cotransduced with Genes Encoding IL-12 and Anti-NY-ESO-1 TCR|Autologous PBL Cotransduced with Retroviral Vectors Encoding Inducible IL-12 and Anti-NY-ESO-1 TCR|IL-12 Plus anti-ESO-1 TCR PBL|IL-12/Anti-NY-ESO-1 TCR-Expressing Autologous PBL|IL-12/Anti-NY-ESO-1 TCR-Expressing Autologous Peripheral Blood Lymphocytes|Inducible IL-12/Anti-NY-ESO-1 TCR-Expressing Autologous PBL|Inducible IL-12/Anti-NY-ESO-1 TCR-Expressing Autologous Peripheral Blood Lymphocytes	Human autologous peripheral blood lymphocytes (PBLs) transduced with two retroviral vectors, one encoding a T-cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1 and a second that encodes an inducible single chain form of interleukin-12 (IL-12) driven by a nuclear factor of activated T-cells (NFAT)-responsive promoter, with potential immunomodulating and antineoplastic activities. Following isolation of lymphocytes, retroviral vector transduction, and expansion of the cells ex vivo, the inducible IL-12/anti-NY-ESO-1 TCR-expressing autologous PBLs are re-administered into the patient by intravenous injection. As the transduced PBLs traverse the patient's circulation, they can bind to NY-ESO-1-overexpressing tumor cells. This binding activates the TCR signaling pathway in the transduced PBLs, which promotes NFAT-dependent gene transcription and induces expression of the cotransduced IL-12. IL-12 expression activates the immune system by promoting the secretion of interferon-gamma, activating natural killer cells (NKs), and inducing cytotoxic T-cell responses, which may result in both decreased cell proliferation and increased cell death for the NY-ESO-1-overexpressing tumor cells. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types. NFAT, a family of transcription factors involved in immune responses, is activated by calcium signaling, which can occur downstream of TCR activation. Use of a retroviral vector to express an inducible IL-12 may remove the requirement for concomitant administration of interleukin-2 (IL-2) as is the case for conventional cell transfer immunotherapies.	Autologous Peripheral Blood Lymphocytes Cotransduced with Retroviral Vectors Encoding Inducible IL-12 and Anti-NY-ESO-1 TCR		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113162>	C211609|C129825	Mivavotinib|3H-Pyrrolo(3,4-C)pyridin-3-one, 6-(((1R,2S)-2-aminocyclohexyl)amino)-7-fluoro-1,2-dihydro-4-(1-methyl-1H-pyrazol-4-yl)-|MIVAVOTINIB|Spleen Tyrosine Kinase Inhibitor TAK659|TAK-659 Free Base|TAK659 Free Base|syk Inhibitor TAK-659|syk Inhibitor TAK659|syk-Inhibitor TAK-659|syk-Inhibitor TAK659	An inhibitor of spleen tyrosine kinase (syk), with potential anti-inflammatory, immunomodulating, and antineoplastic activities. Upon administration, mivavotinib may inhibit the activity of syk, which abrogates downstream B-cell receptor (BCR) signaling and leads to an inhibition of B-cell activation, chemotaxis, adhesion and proliferation. Syk, a BCR-associated non-receptor tyrosine kinase that mediates diverse cellular responses, including proliferation, differentiation, and phagocytosis, is expressed in hematopoietic tissues and is often overexpressed in hematopoietic malignancies.	Mivavotinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113163>	C78273	Oplunofusp|273-666-Neuraminidase [273-Methionine] (Actinomyces viscosus Clone DAS181) Fusion Protein With 125-145-Preproamphiregulin (Human)|DAS181|DAS181-F02|Fludase|OPLUNOFUSP|Recombinant Cell-Surface Anchored Sialidase DAS181	A recombinant sialidase fusion protein composed of a sialidase catalytic domain derived from Actinomyces viscosus, a constituent of the normal oral and gastrointestinal flora in humans, fused to a cell surface-anchoring domain, with potential anti-viral activity. Following administration by oral inhalation, oplunofusp proteolytically removes sialic acid from the airway epithelium, which inhibits viral binding to and internalization by cells of the respiratory epithelium and prevents viral replication. The cell surface anchoring-domain of this agent may increase retention time and drug potency. Sialic acids in the respiratory tract are used by influenza and parainfluenza viruses to invade airway epithelial cells.	Oplunofusp		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C113164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113164>	C226424|C211912	Tisotumab Vedotin|HuMax-TF-ADC|TISOTUMAB VEDOTIN|Tisotumab Vedotin-tftv|Tisotumab vedotin|Tivdak	An antibody-drug conjugate (ADC) comprised of tisotumab, a monoclonal antibody against human tissue factor (TF) covalently coupled, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and potent microtubule disrupting agent, with potential antiangiogenic, anticoagulant and antineoplastic activities. Upon administration of tisotumab vedotin, the tisotumab moiety binds to cell surface TF and is internalized. Tisotumab binds to factor VIIa (FVIIa), which interferes with the activation of factor X (FX) into FXa. This may prevent thrombin formation and cancer-associated venous thromboembolism, and may inhibit angiogenesis and tumor cell proliferation. After internalization of the agent, the MMAE moiety is released by proteolytic cleavage. It then binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and apoptosis. TF, a transmembrane protein and initiator of the coagulation cascade, is overexpressed in many tumor cells and tumor-resident endothelial cells. Expression of TF is correlated with metastasis, angiogenesis, tumor cell growth and tumor-associated thrombosis.	Tisotumab Vedotin		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113165>	C25939	HSD11B1 Gene|HSD11B1|HSD11B1|Hydroxysteroid (11-Beta) Dehydrogenase 1 Gene	This gene is involved in corticosteroid metabolism.	HSD11B1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113166>	C113165	HSD11B1 wt Allele|11-DH|11-beta-HSD1|CORTRD2|HDL|HSD11|HSD11B|HSD11L|Hydroxysteroid (11-Beta) Dehydrogenase 1 wt Allele|SDR26C1|Short Chain Dehydrogenase/Reductase Family 26C, Member 1 Gene	Human HSD11B1 wild-type allele is located within 1q32-q41 and is approximately 49 kb in length. This allele, which encodes 11-beta-hydroxysteroid dehydrogenase 1 protein, plays a role in the metabolism of cortisol. Mutation of the gene is associated with cortisone reductase deficiency.	HSD11B1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113167>	C16946	11-Beta-Hydroxysteroid Dehydrogenase 1|11-Beta-HSD1|11-Beta-Hydroxysteroid Dehydrogenase Type 1|11-Beta-Hydroxysteroid Dehydrogenase, Type I|11-DH|7-Oxosteroid Reductase|Corticosteroid 11-Beta-Dehydrogenase Isozyme 1|EC 1.1.1.146|EC 1.1.1.201|HSD11B1|Short Chain Dehydrogenase/Reductase Family 26C Member 1	11-beta-hydroxysteroid dehydrogenase 1 (292 aa, ~32 kDa) is encoded by the human HSD11B1 gene. This protein is involved in cortisone metabolism.	11-Beta-Hydroxysteroid Dehydrogenase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113168>	C78217	Hyperprolactinemia	Abnormally high level of prolactin in the blood.			Laboratory or Test Result	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C113169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113169>	C27564	Insulin Resistance Syndrome	A cluster of closely related metabolic abnormalities associated with insulin resistance that confer an increased risk of the development of type 2 diabetes and cardiovascular disease. These abnormalities may include obesity, high blood pressure, abnormal cholesterol levels, proteinuria, and/or polycystic ovary syndrome.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11316>	C61063	AUT-OV-ALVAC-hB7.1/Interferon Gamma|ALVAC hB7.1/IFN-G|ALVAC-hB7.1/Interferon Gamma			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113170>	C28193	Sick Euthyroid Syndrome|Euthyroid Sick Syndrome	Abnormal thyroid function tests, low triiodothyronine with elevated reverse triiodothyronine, in the setting of non-thyroidal illness.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C113171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113171>	C27566	Transient Hypothyroxinemia of Prematurity|Hypothyroxinemia of Prematurity|THOP|Transient Congenital Hypothyroidism	A common, self-limiting thyroid disorder seen in preterm infants that is characterized by abnormally low serum levels of thyroxine and free thyroxine with normal serum levels of thyroid stimulating hormone.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C113172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113172>	C26691	Primary Adrenal Insufficiency	A hormonal disorder that occurs when the adrenal glands fail to release adequate amounts of glucocorticoids (cortisol), mineralocorticoids (aldosterone, 11-deoxycorticosterone), and androgens (dehydroepiandrosterone) to meet physiologic needs, despite release of ACTH from the pituitary.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C113173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113173>	C213472|C211609|C172200|C129825	Cerdulatinib|CERDULATINIB|Cerdulatini|PRT-062070|PRT062070|Syk/JAK Inhibitor PRT062070	An orally bioavailable dual inhibitor of spleen tyrosine kinase (Syk) and Janus-associated kinases (JAK), with potential anti-inflammatory and antineoplastic activity. Upon oral administration, cerdulatinib specifically binds to and inhibits the activity of Syk, JAK1, and JAK3 with preferential inhibition of JAK1 and JAK3-dependent cytokine-mediated signaling and functional responses. This negatively affects the downstream JAK-STAT (signal transducer and activator of transcription) pathway, and leads to both reduced inflammation in various animal models and enhanced antiproliferative activity towards non-Hodgkin's lymphoma (NHL) cell lines. Syk is a non-receptor cytoplasmic tyrosine kinase involved in signal transduction in cells of hematopoietic origin including B cells, macrophages, basophils and neutrophils. Abnormal function of Syk has been implicated in several hematopoietic malignancies including NHL and chronic lymphocytic leukemia (CLL). The JAK-STAT pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.	Cerdulatinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113174>	C2594	Autologous CT7/MAGE-A3/WT1 mRNA-Electroporated Langerhans-Type Dendritic Cells|CT7/MAGE-A3/WT1 mRNA-Electroporated LCs	An autologous tumor cell vaccine containing CD34+ hematopoietic progenitor cell (HPC)-derived Langerhans-type dendritic cells (LCs) electroporated with mRNA encoding the full-length cancer-testis antigens, CT7 and melanoma-associated antigen 3 (MAGE-A3), and the self-differentiation tumor antigen, Wilms tumor 1 (WT1) with potential immunomodulating and antineoplastic activity. The autologous CT7/MAGE-A3/WT1 mRNA-electroporated Langerhans-type dendritic cells are prepared by drawing a blood sample containing the CD34+ HPCs from a cancer patient. The CD34+ HPCs are treated with a combination of cytokines which specifically support LC development, and the LC population is enriched and expanded ex vivo. The cultured LCs are allowed to mature for one day and then electroporated separately with CT7, MAGE-A3 or WT1 mRNA before final maturation. Upon intradermal administration into the patient, the mature LCs may activate cell-mediated immunity and induce both cytotoxic CD8+ T cells and CD4+ helper T cells against cancer cells expressing CT7, MAGE-A3 and WT1 tumor antigens. This may result in the immune-mediated inhibition of tumor cell proliferation, leading to tumor cell death. CT7 and MAGE-A3 are tumor-specific proteins overexpressed in a number of cancers but not in healthy tissues other than testis and placenta. WT1 is a transcription factor important in development and cancer pathogenesis, which is overexpressed in a variety of cancers, including multiple myeloma, leukemia, ovarian cancer, malignant mesothelioma, neural tumors and renal carcinoma.	Autologous CT7/MAGE-A3/WT1 mRNA-Electroporated Langerhans-Type Dendritic Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113175>	C1450	DACH-Platin Micelle NC-4016|DACH-Pt/m NC-4016|Dach-Platin Micelle NC-4016|Diaminocyclohexane Platinum Micelle NC-4016|NC-4016	Polymeric micellar nanoparticles containing diaminocyclohexane platinum (DACH-platin or DACH-Pt) with potential antineoplastic activity. DACH-platin micelle NC-4016 is prepared through the formation of a polymer-metal complex between DACH-platin and the polyethylene glycol-poly (glutamic acid) block copolymer, PEG-P(Glu). DACH-platin, an active metabolite of the platinum-based antineoplastic agent oxaliplatin, is highly hydrophobic and toxic when administered systemically. The use of polymeric micelles incorporating DACH-platin may both increase cell permeability and enhance the retention of the agent. This allows an extended half-life in the blood circulation and a selective and high accumulation of DACH-platin at tumor sites. This results in increased anticancer efficacy while reducing side effects due to DACH-platin toxicity. Upon intravenous administration and internalization by tumor cells, DACH-platin binds to and causes both inter- and intra-strand cross-links in DNA, forming platinum adducts and triggering tumor cell apoptosis.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113176>	C25974|C200114	Folate Receptor-Targeted Tubulysin Conjugate EC1456|EC1456|Folate Receptor-Targeting Folate-Tubulysin Conjugate EC1456	An injectable targeted small molecule drug conjugate (SMDC) consisting of folate (vitamin B9) covalently linked to the potent mitotic poison and cytotoxic agent, tubulysin B hydrazide (Tub-B-H) with potential antineoplastic activity. Upon administration, the folate moiety of folate receptor-targeted tubulysin conjugate EC1456 preferentially binds to tumor cells expressing folate receptors (FR). After binding to FR, the agent is internalized by tumor cells and the Tub-B-H moiety inhibits the polymerization of tubulin into microtubules. This may lead to both cell cycle arrest and tumor cell apoptosis. FR, the membrane-bound, high-affinity receptor for folate, is overexpressed on a wide range of primary and metastatic human cancers.	Folate Receptor-Targeted Tubulysin Conjugate EC1456		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113177>	C307	Zinpentraxin Alfa|PRM 151|PRM-151|PRM151|Pentraxin 2|Pentraxin 2|Recombinant Human PTX2|Recombinant Human Pentraxin 2|Recombinant Human Serum Amyloid P|ZINPENTRAXIN ALFA	A fully recombinant form of the human pentraxin 2 (PTX2) protein with potential antifibrotic activity. Upon intravenous administration, zinpentraxin alfa may inhibit myofibroblast generation by preventing the differentiation of circulating monocytes into fibrocytes and profibrotic macrophages. PTX2 is a circulating plasma protein that belongs to the class of pattern recognition receptors (PRR) of the innate immune system.	Zinpentraxin Alfa		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C113178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113178>	C113192	Difficulty Swallowing Solid Foods Question|Difficulty Swallowing Solid Foods|I have difficulty swallowing solid foods	A question about whether an individual has or had difficulty swallowing solid foods.			Intellectual Product	FACT-E Questionnaire
C113179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113179>	C113192	Difficulty Swallowing Soft or Mashed Foods Question|Difficulty Swallowing Soft or Mashed Foods|I have difficulty swallowing soft or mashed foods	A question about whether an individual has or had difficulty swallowing soft or mashed foods.			Intellectual Product	FACT-E Questionnaire
C11317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11317>	C61007	Gemcitabine/Irinotecan|CPT-11/dFdC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113180>	C125410	Difficulty Swallowing Liquids Question|Difficulty Swallowing Liquids|I have difficulty swallowing liquids	A question about whether an individual has or had difficulty swallowing liquids.			Intellectual Product	FACT-E Questionnaire
C113181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113181>	C173454|C173346	Pain in Chest When Swallowing Question|I have pain in my chest when I swallow|Pain in Chest When Swallowing	A question about whether an individual has or had chest pain when swallowing.			Intellectual Product	FACT-E Questionnaire
C113182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113182>	C173454	Choke When Swallowing Question|Choke When Swallowing|I choke when I swallow	A question about whether an individual chokes or has choked when swallowing.			Intellectual Product	FACT-E Questionnaire
C113183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113183>	C173151|C173045	Able to Enjoy Meals with Family or Friends Question|Able to Enjoy Meals with Family or Friends|I am able to enjoy meals with family or friends	A question about whether an individual is or has been able to enjoy meals with family or friends.			Intellectual Product	FACT-E Questionnaire
C113184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113184>	C173134	Wake at Night Because of Coughing Question|I wake at night because of coughing|Wake at Night Because of Coughing	A question about whether an individual awakens or has been awoken at night because of coughing.			Intellectual Product	FACT-E Questionnaire
C113185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113185>	C91105	FACT-Ga Questionnaire|FACT-Ga|Functional Assessment of Cancer Therapy - Gastric Cancer	A subscale complement to the FACT-G developed specifically for evaluating the quality of life of gastric cancer patients.			Intellectual Product	FACT-G Questionnaire
C113186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113186>	C91105	FACT-C Questionnaire|FACT-C|Functional Assessment of Cancer Therapy - Colorectal Cancer	A subscale complement to the FACT-G developed specifically for evaluating the quality of life of colorectal cancer patients.			Intellectual Product	FACT-G Questionnaire
C113187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113187>	C91105	FACT-An Questionnaire|FACT-An|Functional Assessment of Cancer Therapy - Anemia/Fatigue	A subscale complement to the FACT-G developed specifically for evaluating the quality of life of cancer patients with anemia and fatigue.			Intellectual Product	FACT-G Questionnaire
C113188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113188>	C91105	FACT-Leu Questionnaire|FACT-Leu|Functional Assessment of Cancer Therapy - Leukemia	A subscale complement to the FACT-G developed specifically for evaluating the quality of life of leukemia patients.			Intellectual Product	FACT-G Questionnaire
C113189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113189>	C172982	Bothered by Reflux or Heartburn Question|Bothered by Acid Indigestion|Bothered by Reflux or Heartburn|Have you, during the past week, been bothered by acid indigestion|I am bothered by reflux or heartburn	A question about whether an individual is or was bothered by reflux or heartburn.			Intellectual Product	FACT-Ga Questionnaire|Rotterdam Symptom Checklist
C11318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11318>	C61063	Amifostine/Carboplatin/Cyclophosphamide|CBDCA/CTX/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113190>	C156140	Discomfort or Pain When Eating Question|Discomfort or Pain When Eating|I have discomfort or pain when I eat	A question about whether an individual has or had discomfort or pain when eating.			Intellectual Product	FACT-Ga Questionnaire
C113191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113191>	C173981|C173219	Have Feeling of Fullness or Heaviness in Stomach Area Question|Have Feeling of Fullness or Heaviness in Stomach Area|I have a feeling of fullness or heaviness in my stomach area	A question about whether an individual has or had a feeling of fullness or heaviness in the area of the stomach.			Intellectual Product	FACT-Ga Questionnaire
C113192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113192>	C125410	Have Trouble Swallowing Food Question|Have Trouble Swallowing Food|I have trouble swallowing food	A question about whether an individual has or had trouble swallowing food.			Intellectual Product	FACT-Ga Questionnaire
C113193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113193>	C172982	Bothered By a Change in Eating Habits Question|Bothered By a Change in Eating Habits|I am bothered by a change in my eating habits	A question about whether an individual is or was bothered by a change in their eating habits.			Intellectual Product	FACT-Ga Questionnaire
C113194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113194>	C173584	Digestive Problems Interfere with Usual Activities Question|Digestive Problems Interfere with Usual Activities|My digestive problems interfere with my usual activities	A question about whether an individual has or had digestive problems that interfered with their usual activities.			Intellectual Product	FACT-Ga Questionnaire
C113195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113195>	C188083|C175989	Avoid Going Out to Eat Because of Illness Question|Avoid Going Out to Eat Because of Illness|I avoid going out to eat because of my illness	A question about whether an individual avoids or has avoided going out to eat because of their illness.			Intellectual Product	FACT-Ga Questionnaire
C113196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113196>	C173934	Have Stomach Problems That Worry Me Question|Have Stomach Problems That Worry Me|I have stomach problems that worry me	A question about whether an individual has or had stomach problems that caused them to worry.			Intellectual Product	FACT-Ga Questionnaire
C113197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113197>	C172982	Bothered by Gas or Flatulence Question|Bothered by Gas|Bothered by Gas or Flatulence|I am bothered by gas (flatulence)|Were you bothered by gas (flatulence)	A question about whether an individual is or was bothered by gas or flatulence.			Intellectual Product	FACT-Ga Questionnaire|Quality of Life Questionnaire - Pancreatic Cancer 26
C113198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113198>	C173398	Have Difficulty Planning for Future Due to Illness Question|Because of my illness, I have difficulty planning for the future|Have Difficulty Planning for Future Due to Illness	A question about whether an individual has or had difficulty planning for the future because of their illness.			Intellectual Product	FACT-Ga Questionnaire
C113199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113199>	C35869	Hyperechoic Focus	A radiologic finding describing a region in an image with a signal higher than that of the surrounding regions.			Finding	
C11319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11319>	C61007	Cyclosporine/Mycophenolate Mofetil|CYSP/MMF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1131>	C94726	Tropisetron|ICS 205 930|ICS 205-930|ICS 205930|TROPISETRON|tropisetron	An indole derivative with antiemetic activity.  As a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy-and radiotherapy-induced nausea and vomiting. (NCI04)	Tropisetron		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C113200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113200>	C35869	Hyperechoic Strand	A radiologic finding describing thin lines in an image with a signal higher than that of the surrounding tissue.			Finding	
C113201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113201>	C14351	Flaviviridae	A family of enveloped viruses with a genome consisting of a single molecule of linear positive-sense single-stranded RNA. They infect molluscs, mammals, and birds and some are transmitted by arthropod vectors. The family includes the hepatitis C and hepatitis G viruses.			Virus	
C113202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113202>	C113201	Hepacivirus	A genus a Flaviviridae with the Hepatitis C virus as its type species.			Virus	
C113203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113203>	C92809	Adrenal Androgen Deficiency|Adrenal Hypoandrogenism|Adrenal Hypoandrogenism	Abnormally low or absent secretion of the androgen precursor hormones dehydroepiandrosterone (DHEA), DHEA sulfate, and androstenedione, from the adrenal gland.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C113204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113204>	C113201	Pegivirus				Virus	
C113205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113205>	C14351	Coronaviridae|CORONAVIRIDAE	A family of positive sense ssRNA viruses of zoonotic origin. They are the cause of respiratory, enteric, hepatic, and neurological diseases of varying severity in humans and animals. Bats, birds, and pigs act as major reservoirs of coronaviruses.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113206>	C92809	Hypoaldosteronemia|Aldosterone Deficiency|Hypoaldosteronism|Hypoaldosteronism|Mineralocorticoid Deficiency	Abnormally low levels of aldosterone in the blood.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C113207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113207>	C26431	Betacoronavirus|BETACORONAVIRUS|Beta-CoV|Coronavirus Group 2	A genus of enveloped and spherical positive sense ssRNA viruses in the subfamily Coronavirinae of the family Coronaviridae with a diameter of about 120 nm. Betacoronaviruses have a nonopartite, linear genome of 27-32 kb. Bats are the most common reservoir for betacoronaviruses.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113208>	C92809	Hypercortisolemia|Cortisol Excess	Abnormally high level of cortisol in the blood.			Finding	GDC Terminology|GDC Value Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113209>	C113215	Adrenal Androgen Excess|Adrenal Hyperandrogenism|Adrenal Hyperandrogenism	Excessive secretion of the androgen hormones dehydroepiandrosterone (DHEA), DHEA sulfate, and androstenedione, from the adrenal gland. Clinical manifestations may include virilization.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11320>	C61007	gp100 Antigen/Incomplete Freund's Adjuvant/MART-1 Antigen/Sargramostim/Tyrosinase Peptide|GM-CSF/GP100/IFA/MART-1/TYRP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113210>	C171538	Cushing Disease|ACTH Producing Pituitary Adenoma|Cushing disease|Cushing's Disease|Cushing's Disease	Cushing's syndrome due to abnormally high secretion of adrenocorticotropic hormone (ACTH) from the pituitary gland.	Cushing Disease		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C113211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113211>	C92809	Hypocortisolemia|Hypocortisolism|Hypocortisolism	Abnormally low level of cortisol in the blood.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113212>	C92809	Hyperaldosteronemia	Abnormally high levels of aldosterone in the blood.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113213>	C92809	Hyperaldosteronism|Aldosteronism|Aldosteronism	Overproduction of aldosterone by the adrenal glands, which may lead to hypokalemia and/or hypernatremia.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology|Pediatric Nephrology Terminology
C113214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113214>	C78350	Primary Hypoparathyroidism	Abnormally low levels of parathyroid hormone due to a disorder originating within the parathyroid glands.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C113215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113215>	C92809	Androgen Excess|Hyperandrogenism|Hyperandrogenism	Excessive secretion of androgens from the adrenal glands or gonads. Clinical manifestations may include virilization.			Finding	GDC Terminology|GDC Value Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C113216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113216>	C21295	TXNIP Gene|TXNIP|TXNIP|Thioredoxin Interacting Protein Gene	This gene plays a role in the regulation of stress response signaling.	TXNIP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113217>	C79704	Gonadotropin-Dependent Precocious Puberty|Central Precocious Puberty|Central Precocious Puberty|Gonadotropin-releasing Hormone-dependent Precocious Puberty|True Precocious Puberty	Premature onset of sexual development triggered by the premature secretion of gonadotropins.			Finding	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C113218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113218>	C113216	TXNIP wt Allele|EST01027|HHCPA78|RP11-315I20.4|THIF|Thioredoxin Interacting Protein wt Allele|Upregulated By 1,25-Dihydroxyvitamin D-3 Gene|VDUP1	Human TXNIP wild-type allele is located in the vicinity of 1q21.1 and is approximately 4 kb in length. This allele, which encodes thioredoxin-interacting protein, is involved in the modulation of immunity and oxidative stress responses.	TXNIP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113219>	C79704	Gonadotropin-Independent Precocious Puberty|Peripheral Precocious Puberty|Peripheral Precocious Puberty|Pseudoprecocious Puberty	Premature development of secondary sexual characteristics due to the presence of sex steroids independent of pituitary gonadotropin release.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C11321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11321>	C61063	Bismuth Subcitrate/Metronidazole/Omeprazole/Tetracycline|BISSUBCIT/METRO/OMEP/TETRA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113220>	C17728	Thioredoxin-Interacting Protein|TXNIP|Thioredoxin Binding Protein 2|Thioredoxin-Binding Protein 2|Vitamin D3 Up-Regulated Protein 1	Thioredoxin-interacting protein (391 aa, ~44 kDa) is encoded by the human TXNIP gene. This protein plays a role in the immune response and oxidative stress-stimulated signaling.	Thioredoxin-Interacting Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113221>	C20194	UVRAG Gene|UV Radiation Resistance Associated Gene|UVRAG|UVRAG	This gene is involved in both autophagy and DNA repair.			Gene or Genome	
C113222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113222>	C113221	UVRAG wt Allele|DHTX|Disrupted In Heterotaxy Gene|UV Radiation Resistance Associated wt Allele|UV Radiation Resistance-Associated Gene|VPS38|p63	Human UVRAG wild-type allele is located in the vicinity of 11q13.5 and is approximately 329 kb in length. This allele, which encodes UV radiation resistance-associated gene protein, plays a role in the modulation of both DNA repair and autophagy. A chromosomal inversion inv(11)(q13.5;q25), which involves the gene, is associated with heterotaxy.			Gene or Genome	
C113223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113223>	C18466	UV Radiation Resistance-Associated Gene Protein|Beclin 1 Binding Protein|p63	UV radiation resistance-associated gene protein (699 aa, ~78 kDa) is encoded by the human UVRAG gene. This protein is involved in both DNA repair and the positive regulation of autophagy.			Amino Acid, Peptide, or Protein	
C113224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113224>	C20194	WASL Gene|WASL|WASL|Wiskott-Aldrich Syndrome-Like Gene	This gene plays a role in actin polymerization.			Gene or Genome	
C113225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113225>	C113224	WASL wt Allele|N-WASP|NWASP|Wiskott-Aldrich Syndrome Gene-Like Gene|Wiskott-Aldrich Syndrome-Like wt Allele	Human WASL wild-type allele is located in the vicinity of 7q31.3 and is approximately 67 kb in length. This allele, which encodes neural Wiskott-Aldrich syndrome protein, is involved in the regulation of actin polymerization.			Gene or Genome	
C113226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113226>	C18466	Neural Wiskott-Aldrich Syndrome Protein|N-WASP	Neural Wiskott-Aldrich syndrome protein (505 aa, ~55 kDa) is encoded by the human WASL gene. This protein plays a role in the modulation of actin fibril formation.			Amino Acid, Peptide, or Protein	
C113227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113227>	C25804	MFN2 Gene|MFN2|MFN2|Mitofusin 2 Gene	This gene is involved in mitochondrial fusion.			Gene or Genome	
C113228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113228>	C113227	MFN2 wt Allele|CMT2A|CMT2A2|CPRP1|HSG|Hyperplasia Suppressor Gene|KIAA0214|MARF|Mitofusin 2 wt Allele	Human MFN2 wild-type allele is located in the vicinity of 1p36.22 and is approximately 33 kb in length. This allele, which encodes mitofusin-2 protein, plays a role in both GTP hydrolysis and mitochondrial fusion. Mutation of the gene is associated with Charcot-Marie-Tooth disease types 2A2 and 6.			Gene or Genome	
C113229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113229>	C16701	Mitofusin-2|EC 3.6.5.-|MFN2|Mitochondrial Assembly Regulatory Factor|Transmembrane GTPase MFN2	Mitofusin-2 (757 aa, ~86 kDa) is encoded by the human MFN2 gene. This protein is involved in both mitochondrial fusion and GTP hydrolysis.			Amino Acid, Peptide, or Protein|Enzyme	
C11322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11322>	C61063	Amoxicillin/Clarithromycin/Omeprazole|AMOX/CLARITH/OMEP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113230>	C80699	MIR31 Gene|MIR31|MIR31|MicroRNA 31 Gene	This gene may play a role in both the regulation of gene expression and tumor suppression.			Gene or Genome	
C113231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113231>	C113230	MIR31 wt Allele|MIRN31|MicroRNA 31 wt Allele|hsa-mir-31|miR-31|miRNA31	Human MIR31 wild-type allele is located in the vicinity of 9p21.3 and is approximately 0.1 kb in length. This allele, which encodes MIR31 pre-miRNA, may be involved in both tumor suppression and the modulation of transcription.			Gene or Genome	
C113232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113232>	C25968	MIR31 Pre-miRNA|Pre-MicroRNA 31|Pre-miRNA 31|Pre-miRNA MIR31	MIR31 pre-miRNA (71 bases) is encoded by the human MIR31 gene. This ribonucleotide may play a role in both the regulation of gene transcription and tumor suppression.			Nucleic Acid, Nucleoside, or Nucleotide	
C113233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113233>	C21275	MYSM1 Gene|MYSM1|MYSM1|Myb-Like, SWIRM and MPN Domains 1 Gene	This gene is involved in both the deubiquitination of histone 2A and transcriptional regulation.			Gene or Genome	
C113234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113234>	C113233	MYSM1 wt Allele|2A-DUB|2ADUB|KIAA1915|Myb-Like, SWIRM and MPN Domains 1 wt Allele|RP4-592A1.1	Human MYSM1 wild-type allele is located in the vicinity of 1p32.1 and is approximately 45 kb in length. This allele, which encodes deubiquitinase MYSM1 protein, plays a role in histone 2A deubiquitination and chromatin remodeling.			Gene or Genome	
C113235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113235>	C16843	Deubiquitinase MYSM1|2A-DUB|EC 3.4.19.-|Histone H2A Deubiquitinase MYSM1|MYSM1|Myb-Like, SWIRM and MPN Domain-Containing Protein 1|Myb-Like, SWIRM and MPN Domains-Containing Protein 1	Deubiquitinase MYSM1 (828 aa, ~95 kDa) is encoded by the human MYSM1 gene. This protein is involved in the deubiquitination of histone 2A, which leads to chromatin remodeling and transcriptional activation.			Amino Acid, Peptide, or Protein|Enzyme	
C113236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113236>	C542	Quinolinic Acid|2,3-Pyridinedicarboxylic Acid|Pyridine-2,3-Dicarboxylic Acid|QA|QUIN|QUINOLINIC ACID	An intermediate product of the kynurenine pathway, which is responsible for the conversion of the amino acid tryptophan into nicotinamide adenine dinucleotide, with potential neurotoxic activity. If produced in excess, quinolinic acid can cross the blood-brain barrier (BBB) and function as an N-methyl-D-aspartate (NMDA) receptor agonist, which may lead to both neuronal damage and neurodegenerative brain disease. The NMDA receptor, a heterotetrameric, ligand-gated and voltage-dependent glutamate receptor, is critical for synaptic plasticity, learning and memory.	Quinolinic Acid		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C113237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113237>	C51949	Absolute Blood Lymphocyte Count|ALC|Absolute Lymphocyte Count	The number of lymphocytes found in a given volume of blood.	Absolute Blood Lymphocyte Count		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Terminology
C113238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113238>	C42700	Uterine Malignant Mixed Mesodermal (Mullerian) Tumor, Homologous Type	A malignant mixed mesodermal (Mullerian) tumor of the uterus characterized by the presence of sarcomatous elements that arise from the tissues of the uterus.			Neoplastic Process	NCIt Neoplasm Core Terminology
C113239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113239>	C42700	Uterine Malignant Mixed Mesodermal (Mullerian) Tumor, Heterologous Type	A malignant mixed mesodermal (Mullerian) tumor of the uterus characterized by the presence of sarcomatous elements composed of tissues that are not found in the uterus (e.g., bone, cartilage, skeletal muscle).			Neoplastic Process	NCIt Neoplasm Core Terminology
C11323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11323>	C61063	Incomplete Freund's Adjuvant/Interleukin-2/Tyrosinase Peptide|IFA/IL-2/TYRP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113240>	C48938	Cobblestone Area-Forming Cells|CAFC|Cobble Stone Area-Forming Cells|Cobblestone Forming Units	The number of hematopoietic stem cells (HSCs) that migrate between or beneath a co-cultured feeder cell layer and become trapped. When HSCs are cultured with a feeder layer and observed using phase contrast microscopy, the trapped cells appear less spherical and less refractile than the HSCs that are floating loosely on top of the feeder layer.	Cobblestone Area-Forming Cells		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Terminology
C113241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113241>	C48938	Colony-Forming Unit-Fibroblasts|CFU-F|Fibroblast Colony-Forming Units	A population of adherent cells in bone marrow cultures that resemble fibroblasts.	Colony-Forming Unit-Fibroblasts		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Terminology
C113242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113242>	C209927	Minimal Disseminated Disease|MDD	A clinical finding that refers to the spread of a neoplastic disease to anatomic sites or systems other than the original neoplastic site through the detection of low or subclinical levels of a neoplastic marker.	Minimal Disseminated Disease		Finding	CTRP Biomarker Terminology|CTRP Terminology
C113243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113243>	C129665|C128274	Circulating Tumor-Derived DNA|Cell-Free Circulating Tumor DNA|Circulating Tumor DNA|Circulating Tumor DNA|Circulating Tumor DNA|ctDNA|ctDNA|ctdDNA	Neoplasm-derived DNA found in blood plasma and other bodily fluids that is not associated with cells.	Circulating Tumor DNA		Nucleic Acid, Nucleoside, or Nucleotide	CDISC SDTM Genetic Sample Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C113244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113244>	C16295	CpG Antibody|Anti-CpG Antibodies|Anti-CpG Antibody|CpG Antibodies	Any immunoglobulin that recognizes cytosine/guanine (CpG) rich sequences in chromosomal DNA.	CpG Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C113245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113245>	C21176	Creatine Kinase|ATP:Creatine N-Phosphotransferase|ATP:Creatine Phosphotransferase|Adenosine Triphosphate-Creatine Transphosphorylase|CK|CPK|Creatine Phosphokinase|Creatine Phosphotransferase|Phosphocreatine Kinase	An enzyme complex that can reversibly convert ATP and creatine to phosphocreatine and ADP. Cytosolic creatine kinases are comprised of homodimers or heterodimers of creatine kinase B-type protein and creatine kinase M-type protein. Mitochondrial creatine kinases are octomers comprised of either four homodimers of creatine kinase U-type, mitochondrial protein or four creatine kinase S-type, mitochondrial protein homodimers.	Creatine Kinase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113246>	C20130	Angiokine|Angiogenic Lymphokine|Angiogenic Lymphokines|Angiokines	A family of soluble proteins that initiate signaling pathways involved in the process of new blood vessel formation. These proteins may be secreted by lymphocytes in response to tumor-related inflammation.	Angiokine		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Terminology
C113247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113247>	C20130	Ephrin-A|EFNA|Ephrin A|Ephrin-A Family|Ephrin-A Ligands|Ephrin-A Protein Family	A family of glycosylphosphatidylinositol (GPI)-anchored proteins that are involved in forward and reverse cell-cell signaling through binding to ephrin-A receptors (EPHA).	Ephrin-A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113248>	C20130	Receptor-Activated SMAD|R-SMAD|R-SMADs|Receptor-Activated SMADs|Receptor-Regulated SMAD|Receptor-Regulated SMADs|rSMAD|rSMADs	A family of transcription factors that are activated by signaling mediated by tumor growth factor-beta (TGF-beta) superfamily ligand-receptor interactions. Once activated, R-SMADs play a role in the positive regulation of TGF-beta responsive gene expression.	Receptor-Activated SMAD		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113249>	C1746	GRP Gene Product	A protein encoded by the GRP gene.	GRP Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11324>	C61063	gp100 Antigen/Incomplete Freund's Adjuvant/Sargramostim|GM-CSF/gp100/IFA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113250>	C113249	Pre-Progastrin-Releasing Peptide|Gastrin-Releasing Peptide Precursor|Prepro-GRP|PreproGRP|Pro-GRP|ProGRP	Pre-progastrin-releasing peptide (148 aa, ~16 kDa) is encoded by the human GRP gene. This protein is involved in the regulation of both the gastrointestinal and nervous systems.	Pre-Progastrin-Releasing Peptide		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113251>	C113249	Neuromedin-C|GRP-10|Neuromedin C	Neuromedin-C (10 aa, ~1 kDa) is encoded by the human GRP gene. This protein plays a role in hormone signaling.	Neuromedin-C		Amino Acid, Peptide, or Protein|Hormone	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113252>	C20103	KLRC2 Gene|KLRC2|KLRC2|Killer Cell Lectin-Like Receptor Subfamily C, Member 2 Gene	This gene plays a role in natural killer cell targeting.	KLRC2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113253>	C113252	KLRC2 wt Allele|CD159c|Killer Cell Lectin-Like Receptor Subfamily C, Member 2 wt Allele|Killer Cell Lectin-Like Receptor, Subfamily C, Member 2 Gene|NKG2-C|NKG2C	Human KLRC2 wild-type allele is located in the vicinity of 12p13 and is approximately 15 kb in length. This allele, which encodes NKG2-C type II integral membrane protein, is involved in the regulation of cell-mediated immunity.	KLRC2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113254>	C18106	NKG2-C Type II Integral Membrane Protein|CD159 Antigen-Like Family Member C|CD159c|CD159c Antigen|KLRC2|NK Cell Receptor C|NKG2-C-Activating NK Receptor	NKG2-C type II integral membrane protein (231 aa, ~26 kDa) is encoded by the human KLRC2 gene. This protein plays a role in the recognition of MHC class I antigens by natural killer cells.	NKG2-C Type II Integral Membrane Protein		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113255>	C25941	ECI2 Gene|ECI2|ECI2|Enoyl-CoA Delta Isomerase 2 Gene	This gene is involved in the metabolism of unsaturated fatty acids.			Gene or Genome	
C113256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113256>	C113255	ECI2 wt Allele|ACBD2|DBI-Related Sequence 1 Gene|DRS-1|DRS1|Diazepam-Binding Inhibitor-Related Sequence 1 Gene|Enoyl-CoA Delta Isomerase 2 wt Allele|HCA88|PECI|RP5-1013A10.1|dJ1013A10.3	Human ECI2 wild-type allele is located in the vicinity of 6p24.3 and is approximately 20 kb in length. This allele, which encodes enoyl-CoA delta isomerase 2, mitochondrial protein, plays a role in fatty acid metabolism.			Gene or Genome	
C113257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113257>	C16759	Enoyl-CoA Delta Isomerase 2, Mitochondrial|Acyl-Coenzyme A Binding Domain Containing|D3,D2-Enoyl-CoA Isomerase|DBI-Related Protein 1|DRS-1|Delta(3),Delta(2)-Enoyl-CoA Isomerase|Diazepam-Binding Inhibitor-Related Protein 1|Dodecenoyl-CoA Isomerase|EC 5.3.3.8|ECI2|Hepatocellular Carcinoma-Associated Antigen 88|Peroxisomal 3,2-Trans-Enoyl-CoA Isomerase|Peroxisomal D3,D2-Enoyl-CoA Isomerase|Renal Carcinoma Antigen NY-REN-1|pECI	Enoyl-CoA delta isomerase 2, mitochondrial (394 aa, ~44 kDa) is encoded by the human ECI2 gene. This protein is involved in enoyl-CoA metabolism.			Amino Acid, Peptide, or Protein|Enzyme	
C113258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113258>	C21345	ARTN Gene|ARTN|ARTN|Artemin Gene	This gene plays a role in both neurogenesis and Peyer patch morphogenesis.			Gene or Genome	
C113259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113259>	C113258	ARTN wt Allele|Artemin wt Allele|ENOVIN|EVN|NBN	Human ARTN wild-type allele is located within 1p33-p32 and is approximately 4 kb in length. This allele, which encodes artemin protein, is involved in both the morphogenesis of Peyer patches and neuroblast proliferation.			Gene or Genome	
C11325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11325>	C61063	Incomplete Freund's Adjuvant/Sargramostim/Tyrosinase Peptide|GM-CSF/IFA/TYRP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113260>	C20455	Artemin|Enovin|Neublastin|Neurotrophic Factor	Artemin (220 aa, ~23 kDa) is encoded by the human ARTN gene. This protein plays a role in the development of both lymphoid tissue and the peripheral nervous system.			Amino Acid, Peptide, or Protein	
C113261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113261>	C26000	VCAN Gene|VCAN|VCAN|Versican Gene	This gene is involved in both cell adhesion and proteoglycan metabolism.			Gene or Genome	
C113262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113262>	C113261	VCAN wt Allele|CSPG2|ERVR|GHAP|PG-M|Versican wt Allele|WGN|WGN1	Human VCAN wild-type allele is located in the vicinity of 5q14.3 and is approximately 111 kb in length. This allele, which encodes versican core protein, plays a role in both proteoglycan metabolism and cell-matrix signaling.			Gene or Genome	
C113263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113263>	C17351	Versican Core Protein|Chondroitin Sulfate Proteoglycan Core Protein 2|Chondroitin Sulfate Proteoglycan Core Protein, Cartilage|GHAP|Glial Hyaluronate-Binding Protein|Large Fibroblast Proteoglycan|PG-M	Versican core protein (3396 aa, ~373 kDa) is encoded by the human VCAN gene. This protein is involved in both environmental signaling and proteoglycan metabolism.			Amino Acid, Peptide, or Protein	
C113264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113264>	C25994	ADM Gene|ADM|ADM|Adrenomedullin Gene	This gene plays a role in both hormone signaling and vasodilation.			Gene or Genome	
C113265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113265>	C113264	ADM wt Allele|AM|Adrenomedullin wt Allele	Human ADM wild-type allele is located in the vicinity of 11p15.4 and is approximately 3 kb in length. This allele, which encodes ADM protein, is involved in both vasodilation and hormone-mediated signaling. Aberrant high levels of expression are associated with pheochromocytoma.			Gene or Genome	
C113266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113266>	C1746	ADM|ADM Precursor|Adrenomedullin|PreproAM|Preproadrenomedullin|ProAM	ADM (185 aa, ~20 kDa) is encoded by the human ADM gene. This protein plays a role in both signal transduction and vasodilation.			Amino Acid, Peptide, or Protein	
C113267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113267>	C33904	Papilla	A small protruding portion of tissue.			Conceptual Entity	
C113268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113268>	C94346	Volume Doubling Time|VDT	The number of days that it takes for a nodule to double in volume.			Temporal Concept	
C113269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113269>	C25952	LIPG Gene|LIPG|LIPG|Lipase, Endothelial Gene	This gene is involved in the metabolism of high density lipoproteins, triglycerides and phospholipids.			Gene or Genome	
C11326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11326>	C61063	Incomplete Freund's Adjuvant/Interleukin-12/Tyrosinase Peptide|IFA/IL-12/TYRP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113270>	C113269	LIPG wt Allele|EDL|EL|Lipase, Endothelial wt Allele|PRO719|UNQ387/PRO719	Human LIPG wild-type allele is located in the vicinity of 18q21.1 and is approximately 32 kb in length. This allele, which encodes endothelial lipase protein, plays a role in the catabolism of phospholipids, high density lipoproteins and triglycerides.			Gene or Genome	
C113271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113271>	C18068	milliGray-Centimeter|mGy x cm|mGy-cm|mGy-cm|mGyCm|milligray x centimeter	A derived unit of measure for dose length product calculated by multiplying the radiation dose in milliGrays by the travel length in centimeters.			Quantitative Concept	
C113272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113272>	C16561	Endothelial Lipase|EC 3.1.1.3|EDL|EL|Endothelial Cell-Derived Lipase|LIPG|Lipoprotein Lipase H|Phospholipase A1	Endothelial lipase (500 aa, ~57 kDa) is encoded by the human LIPG gene. This protein is involved in the hydrolysis of triglycerides, phospholipids and high density lipoproteins.			Amino Acid, Peptide, or Protein|Enzyme	
C113273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113273>	C20745	CFAP251 Gene|CFAP251|CFAP251|Cilia and Flagella Associated Protein 251 Gene|WDR66	This gene plays a role in cilium motility.			Gene or Genome	
C113274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113274>	C113273	CFAP251 wt Allele|CaM-IP4|Cilia and Flagella Associated Protein 251 wt Allele|MGC33630|SPGF33|WD Repeat Domain 66 Gene|WDR66	Human CFAP251 wild-type allele is located in the vicinity of 12q24.31 and is approximately 86 kb in length. This allele, which encodes cilia- and flagella-associated protein 251, is involved in cilia assembly and sperm motility. Mutation of the gene is associated with spermatogenic failure 33 and polymorphisms in the gene have been associated with variance in mean platelet volume.			Gene or Genome	
C113275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113275>	C16492	Cilia- and Flagella-Associated Protein 251|CFAP251|Cilia and Flagella Associated Protein 251|WD Repeat-Containing Protein 66|WDR66	Cilia- and flagella-associated protein 251 (1149 aa, ~130 kDa) is encoded by the human CFAP251 gene. This protein plays a role in cilium assembly.			Amino Acid, Peptide, or Protein	
C113276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113276>	C25870	PSAT1 Gene|PSAT1|PSAT1|Phosphoserine Aminotransferase 1 Gene	This gene is involved in amino acid synthesis.			Gene or Genome	
C113277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113277>	C113276	PSAT1 wt Allele|EPIP|PSA|PSAT|Phosphoserine Aminotransferase 1 wt Allele	Human PSAT1 wild-type allele is located in the vicinity of 9q21.2 and is approximately 33 kb in length. This allele, which encodes phosphoserine aminotransferase protein, plays a role in the biosynthesis of amino acids. Mutation of the gene is associated with phosphoserine aminotransferase deficiency.			Gene or Genome	
C113278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113278>	C21489	Phosphoserine Aminotransferase|EC 2.6.1.52|PSAT|Phosphohydroxythreonine Aminotransferase	Phosphoserine aminotransferase (370 aa, ~40 kDa) is encoded by the human PSAT1 gene. This protein is involved in amino acid biosynthesis.			Amino Acid, Peptide, or Protein|Enzyme	
C113279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113279>	C20194	B9D2 Gene|B9 Protein Domain 2 Gene|B9D2|B9D2	This gene plays a role in cilia formation.			Gene or Genome	
C11327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11327>	C61063	Incomplete Freund's Adjuvant/Interleukin-2/Tyrosinase Related Protein-1|IFA/IL-2/TRP-1|Incomplete Freund's Adjuvant/Interleukin-2/Tyrosinase-Related Protein-1			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113280>	C113279	B9D2 wt Allele|B9 Protein Domain 2 wt Allele|ICIS-1|MGC4093|MKS10|MKSR2|Stumpy, Mouse, Homolog of Gene	Human B9D2 wild-type allele is located in the vicinity of 19q13.2 and is approximately 10 kb in length. This allele, which encodes B9 domain-containing protein 2, is involved in ciliogenesis. Mutation of the gene is associated with Meckel syndrome 10.			Gene or Genome	
C113281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113281>	C18466	B9 Domain-Containing Protein 2|Involved In Cilia Stability-1|MKS1-Related Protein 2	B9 domain-containing protein 2 (175 aa, ~19 kDa) is encoded by the human B9D2 gene. This protein plays a role in the maintenance of cilia.			Amino Acid, Peptide, or Protein	
C113282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113282>	C20194	WBP1L Gene|WBP1L|WBP1L|WW Domain Binding Protein 1-Like Gene	This gene may be involved in heme binding.			Gene or Genome	
C113283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113283>	C113282	WBP1L wt Allele|C10orf26|Chromosome 10 Open Reading Frame 26 Gene|FLJ20154|OPA1L|OPAL1|RP11-753C18.10-001|WW Domain Binding Protein 1-Like wt Allele	Human WBP1L wild-type allele is located in the vicinity of 10q24.32 and is approximately 72 kb in length. This allele, which encodes WW domain binding protein 1-like, may play a role in heme binding.			Gene or Genome	
C113284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113284>	C18466	WW Domain Binding Protein 1-Like|Chromosome 10 Open Reading Frame 26|Outcome Predictor In Acute Leukemia 1|WBP1L	WW domain binding protein 1-like (342 aa, ~38 kDa) is encoded by the human WBP1L gene. This protein may be involved in binding to heme.			Amino Acid, Peptide, or Protein	
C113285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113285>	C25954	ELAC2 Gene|ELAC2|ELAC2|ElaC Ribonuclease Z 2 Gene	This gene plays a role in the processing of transfer RNA.	ELAC2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113286>	C113285	ELAC2 wt Allele|COXPD17|ELAC, E. coli, Homolog of, 2 Gene|ELC2|ElaC (E. coli) Homolog 2 Gene|ElaC Homolog 2 (E. coli) Gene|ElaC Ribonuclease Z 2 wt Allele|FLJ10530|HPC2	Human ELAC2 wild-type allele is located in the vicinity of 17p11.2 and is approximately 27 kb in length. This allele, which encodes zinc phosphodiesterase ELAC protein 2, is involved in tRNA maturation. Mutation of the gene is associated with combined oxidative phosphorylation deficiency 17 and susceptibility to hereditary prostate cancer 2.	ELAC2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113287>	C25959	Zinc Phosphodiesterase ELAC Protein 2|EC 3.1.26.11|ELAC2|ElaC Homolog Protein 2|Heredity Prostate Cancer Protein 2|Putative Prostate Cancer Susceptibility Protein HPC2/ELAC2|RNase Z 2|RNase ZL|Ribonuclease Z 2|Ribonuclease Z, Long Form|tRNA 3 Endonuclease 2|tRNase Z (Long Form)|tRNase Z 2	Zinc phosphodiesterase ELAC protein 2 (826 aa, ~92 kDa) is encoded by the human ELAC2 gene. This protein plays a role in endoribonuclease activity.	Zinc Phosphodiesterase ELAC Protein 2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113288>	C93199	Prostate Saturation Biopsy|Extensive Prostate Biopsy|Prostate Saturation Needle Biopsy|Saturation Biopsy|Transperineal Template-Guided Stereotactic Saturation Prostate Biopsy	Transperineal prostate biopsy that removes more than 20 cores. This is typically reserved for high-risk patients.			Diagnostic Procedure	
C113289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113289>	C35869	Hot Lesion|Hot Spot|Hot Target	An area where large amounts of the radiotracer have accumulated and where there is a high level of chemical or metabolic activity.			Finding	
C11328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11328>	C61063	Incomplete Freund's Adjuvant/Sargramostim/Tyrosinase Related Protein-1|GM-CSF/IFA/TRP-1|Incomplete Freund's Adjuvant/Sargramostim/Tyrosinase-Related Protein-1			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113290>	C21295	EXOSC5 Gene|EXOSC5|EXOSC5|Exosome Component 5 Gene	This gene is involved in RNA processing.	EXOSC5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113291>	C113290	EXOSC5 wt Allele|CML28|Exosome Component 5 wt Allele|MGC12901|RRP41B|RRP46|Ribosomal RNA-Processing Protein 46, S. cerevisiae, Homolog of Gene|Rrp46p|hRrp46p|p12B	Human EXOSC5 wild-type allele is located in the vicinity of 19q13.1 and is approximately 11 kb in length. This allele, which encodes exosome complex component RRP46 protein, plays a role in RNA metabolism.	EXOSC5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113292>	C21298	Exosome Complex Component RRP46|Chronic Myelogenous Leukemia Tumor Antigen 28|EXOSC5|Exosome Complex Exonuclease RRP46|Exosome Component 5|Exosome Component Rrp46|Ribosomal RNA-Processing Protein 46|p12B	Exosome complex component RRP46 (235 aa, ~25 kDa) is encoded by the human EXOSC5 gene. This protein is involved in RNA metabolism.	Exosome Complex Component RRP46		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113293>	C471	Supinoxin|P-p68 Inhibitor RX-5902|RX-5902|SUPINOXIN	An orally bioavailable small molecule inhibitor of phosphorylated-p68 RNA helicase (P-p68), with potential anti-proliferative and antineoplastic activity. Upon oral administration, supinoxin may both inhibit the activity of the anti-apoptotic B-cell lymphoma 2 (Bcl-2) protein and facilitate the induction of cyclin-dependent kinase inhibitor 1 (p21). This may prevent G2/M cell cycle progression and lead to growth inhibition in tumor cells. P-p68 is overexpressed in various types of solid tumors but absent in normal tissues, and plays a role in tumor progression and metastasis. p21 is a potent cyclin-dependent kinase inhibitor which regulates cell cycle progression and mediates both growth arrest and cellular senescence.	Supinoxin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113294>	C155700	Metatinib Tromethamine|BCR-ABL Tyrosine Kinase Inhibitor BL001|BL001|Metatinib	An orally bioavailable tyrosine kinase inhibitor of the BCR-ABL fusion oncoprotein, with potential antineoplastic activity. Upon oral administration, BCR-ABL tyrosine kinase inhibitor BL001 may inhibit the BCL-ABL protein, which may lead to decreased proliferation and enhanced apoptosis in tumor cells. BCR-ABL oncoprotein is generated by a reciprocal translocation between chromosome 9 and 22 specifically t(9;22)(q34;q11). The resulting fusion gene produces proteins with constitutively active tyrosine kinase activity, which stimulate both abnormal cell division and increased cellular proliferation. This fusion is associated with both chronic myeloid leukemia and acute lymphoblastic leukemia.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113295>	C1320	Pegilodecakin|AM-0010|AM0010|PEG-rHuIL-10 AM0010|PEGILODECAKIN	A covalent conjugate of recombinant human interleukin-10 (IL-10) and polyethylene glycol (PEG), with potential anti-fibrotic, anti-inflammatory, immunomodulating and antineoplastic activities. Upon subcutaneous administration, pegilodecakin may activate cell-mediated immunity against cancer cells by stimulating the differentiation and expansion of tumor specific cytotoxic CD8+ T cells. This agent may also lower serum cholesterol levels and reduce atherosclerotic plaques by inhibiting the synthesis of pro-inflammatory cytokines, such as Interferon-gamma, IL-2, IL-3, TNF-alpha, and GM-CSF. The PEG moiety inhibits proteolytic breakdown and clearance of AM0010, which prolongs its half-life, extends the duration of its therapeutic effects and allows less frequent dosing.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113296>	C28310	Allogeneic Glioblastoma Stem-like Cell Line Lysate-pulsed Autologous Dendritic Cell Vaccine	A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from an allogeneic glioblastoma (GBM) stem-like cell line, with potential immunostimulatory and antineoplastic activities. Upon administration allogeneic glioblastoma stem-like cell line lysate-pulsed autologous dendritic cell vaccine exposes the immune system to GBM stem cell antigens, which may result in cytotoxic T lymphocyte (CTL) and antibody responses against GBM cells. This leads to GBM cell lysis. GBM stem-like cells contain a specific range of antigens that are essential for the neoplastic growth and survival of GBM cells.			Cell|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113297>	C129986	Radix Angelicae Sinensis/Radix Astragali Herbal Supplement|DB1|Danggui Buxue Decoction No.1	A traditional Chinese medicine comprising of Radix Angelicae Sinensis (RAS) and Radix Astragali (RA), with potential anti-inflammatory, immunostimulatory, neuroprotective, anti-hepatotoxic and antineoplastic activities. The main chemical constituents of RAS include ferulic acid, Z-ligustilide, butylidenephthalide and various polysaccharides. RA is the dried root of Astragalus membranaceus with primary constituents such polysaccharides, triterpenoids as well as isoflavones. Though their mechanisms of action remain largely elusive, Radix Angelicae Sinensis/Radix Astragali herbal supplements are commonly used for the treatment of various health conditions affecting women including premenstrual syndrome, dysmenorrhea, pelvic pain, recovery from childbirth and menopausal symptoms. These agents are also used for alleviating constipation, preventing and treating anemia and allergic attacks, and for the management of hypertension, joint pain and ulcers.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113298>	C18959	Circulating Proteasome|Circulating Proteasomes|cProteasome	Cell free proteasome enzyme complexes. Elevated levels of these protein complexes in serum, plasma or blood may be associated with either increased tumor burden or a poor disease prognosis.	Circulating Proteasome		Clinical Attribute	CTRP Biomarker Terminology|CTRP Terminology
C113299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113299>	C20103	LRP2 Gene|LRP2|LRP2|Low Density Lipoprotein Receptor-Related Protein 2 Gene	This gene plays a role in receptor-mediated endocytosis.	LRP2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C11329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11329>	C61063	Carboplatin/Cisplatin/Floxuridine|CBDCA/CDDP/FUDR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1132>	C2139	IMREG-1|IMREG 1	A low molecular weight fraction of human leukocyte dialysates with potential immunostimulatory activity. IMREG-1 is shown to augment and accelerate human delayed type hypersensitivity (DTH) to recall antigen in vivo, potentiate production of interleukin-2 (IL-2) and interferon gamma, and induce expression of IL-2 receptor in peripheral blood mononuclear cells. These effects are attributed to the peptides Tyr-Gly and Tyr-Gly-Gly, which are identical to the N-terminal end of the enkephalins. Studies in HIV patients have shown that this agent may delay progression to more serious disease and improve laboratory markers.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C113300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113300>	C113299	LRP2 wt Allele|DBS|GP330|Low Density Lipoprotein Receptor-Related Protein 2 wt Allele	Human LRP2 wild-type allele is located in the vicinity of 2q31.1 and is approximately 236 kb in length. This allele, which encodes low-density lipoprotein receptor-related protein 2, is involved in the endocytosis of lipoproteins, extracellular matrix proteins and secreted proteases. Mutation of the gene is associated with Donnai-Barrow syndrome.	LRP2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113301>	C91105	FAACT Questionnaire|FAACT|Functional Assessment of Anorexia/Cachexia Treatment Questionnaire	A questionnaire used to assess general aspects of quality of life related to anorexia and cachexia.			Intellectual Product	
C113302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113302>	C18106	Low-Density Lipoprotein Receptor-Related Protein 2|Glycoprotein 330|Heymann Nephritis Antigen Homolog|LRP-2|Low Density Lipoprotein Receptor-Related Protein 2|Megalin|gp330	Low-density lipoprotein receptor-related protein 2 (4655 aa, ~200 kDa) is encoded by the human LRP2 gene. This protein plays a role in receptor-mediated endocytosis.	Low-Density Lipoprotein Receptor-Related Protein 2		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113303>	C9442	Adipose Tissue Deposition	The deposition of lipids in tissue.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113304>	C174459	WHO Classification of Tumors|Histologic Type (WHO)	A classification of benign and malignant tumors by World Health Organization (WHO) experts based primarily on histologic findings.			Classification	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C113305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113305>	C133710	MARCHF9 Gene|MARCH9|MARCH9 Gene|MARCHF9|MARCHF9|Membrane Associated Ring-CH-Type Finger 9 Gene	This gene is involved in protein ubiquitination.	MARCH9 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113306>	C113305	MARCHF9 wt Allele|FLJ36578|MARCH IX|MARCH-IX|MARCH9|MARCH9 wt Allele|Membrane Associated Ring-CH-Type Finger 9 wt Allele|Membrane-Associated Ring Finger (C3HC4) 9 Gene|RNF179	Human MARCHF9 wild-type allele is located in the vicinity of 12q14.1 and is approximately 5 kb in length. This allele, which encodes E3 ubiquitin-protein ligase MARCH9 protein, plays a role in protein ubiquitination and may mediate the internalization of plasma membrane proteins.	MARCH9 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113307>	C802	Embedding Medium|Embedding Agent|Embedding Media	A material that infiltrates and supports a specimen and preserves its shape and structure for sectioning and microscopy.			Indicator, Reagent, or Diagnostic Aid	
C113308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113308>	C21254	E3 Ubiquitin-Protein Ligase MARCH9|EC 2.3.2.27|EC 6.3.2.-, Formerly|MARCH-IX|Membrane Associated Ring Finger 9|Membrane Associated Ring-CH-Type Finger 9|Membrane-Associated RING Finger Protein 9|Membrane-Associated RING-CH Finger Protein 9|Membrane-Associated RING-CH Protein IX|RING Finger Protein 179|RING-Type E3 Ubiquitin Transferase MARCH9	E3 ubiquitin-protein ligase MARCH9 (346 aa, ~38 kDa) is encoded by the human MARCHF9 gene. This protein is involved in the ubiquitination of plasma membrane proteins.	E3 Ubiquitin-Protein Ligase MARCH9		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113309>	C25804|C25790	MX1 Gene|MX1|MX1|Myxovirus (Influenza Virus) Resistance 1, Interferon-Inducible Protein p78 (Mouse) Gene	This gene plays a role in GTP hydrolysis, interferon signaling and apoptosis.	MX1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C11330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11330>	C61063	Carboplatin/Floxuridine|CBDCA/FUDR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113310>	C113309	MX1 wt Allele|IFI-78K|IFI78|MX|MxA|Myxovirus (Influenza Virus) Resistance 1, Interferon-Inducible Protein p78 (Mouse) wt Allele|Myxovirus (Influenza) Resistance 1, Homolog of Murine (Interferon-Inducible Protein p78) Gene|Myxovirus Resistance 1, Mouse, Homolog of Gene	Human MX1 wild-type allele is located in the vicinity of 21q22.3 and is approximately 39 kb in length. This allele, which encodes interferon-induced GTP-binding protein Mx1, is involved in the regulation of apoptosis, hydrolysis of GTP, the modulation of interferon-regulated signaling.	MX1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113311>	C16725|C16701	Interferon-Induced GTP-Binding Protein Mx1|Human Interferon-Regulated Resistance GTP-Binding Protein MXA|IFI-78K|Interferon-Inducible Protein p78|Interferon-Regulated Resistance GTP-Binding Protein MxA|MX1|Myxoma Resistance Protein 1|Myxovirus Resistance Protein 1	Interferon-induced GTP-binding protein Mx1 (662 aa, ~76 kDa) is encoded by the human MX1 gene. This protein plays a role in GTP hydrolysis, apoptosis regulation and interferon signaling.	Interferon-Induced GTP-Binding Protein Mx1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113312>	C16615	POU5F1B Gene|POU Class 5 Homeobox 1B Gene|POU5F1B|POU5F1B	This gene is involved in transcriptional regulation and DNA binding.	POU5F1B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113313>	C113312	POU5F1B wt Allele|OCT4-PG1|OCT4PG1|OTF3C|OTF3P1|Octamer Binding Protein 3-Like Sequence Gene|Octamer Binding Protein 3_like Sequence Gene|POU Class 5 Homeobox 1 Pseudogene 1|POU Class 5 Homeobox 1B wt Allele|POU Domain Class 5, Transcription Factor 1 Pseudogene 1|POU Domain Transcription Factor OCT4-Pg1 Gene|POU Domain, Class 5, Transcription Factor 1B Gene|POU5F1P1|POU5F1P4|POU5FLC20|POU5FLC8	Human POU5F1B wild-type allele is located in the vicinity of 8q24.21 and is approximately 6 kb in length. This allele, which encodes putative POU domain, class 5, transcription factor 1B protein, plays a role in the regulation of transcription.	POU5F1B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113314>	C17207	Putative POU Domain, Class 5, Transcription Factor 1B|Oct4-pg1|Octamer-Binding Protein 3-Like|Octamer-Binding Transcription Factor 3-Like|POU Domain, Class 5, Transcription Factor 1B|POU5F1B	Putative POU domain, class 5, transcription factor 1B (359 aa, ~39 kDa) is encoded by the human POU5F1B gene. This protein is involved in the regulation of target gene expression.	Putative POU Domain, Class 5, Transcription Factor 1B		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113315>	C21295	CCN1 Gene|CCN1|CCN1|CYR61|CYR61 Gene|Cellular Communication Network Factor 1 Gene	This gene plays a role in apoptosis, angiogenesis, heart development and many other processes.	CYR61 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113316>	C113315	CCN1 wt Allele|CCN Family, Member 1 Gene|CYR61|CYR61 wt Allele|Cellular Communication Network Factor 1 wt Allele|Cysteine Rich, Angiogenic Inducer 61 Gene|Cysteine-Rich Protein 61, Mouse, Homolog of Gene|Cysteine-Rich, Angiogenic Inducer, 61 Gene|GIG1|IGFBP10	Human CCN1 wild-type allele is located in the vicinity of 1p22.3 and is approximately 3 kb in length. This allele, which encodes CCN family member 1 protein, is involved in heart morphogenesis, angiogenesis, cell proliferation, cell adhesion and the positive regulation of apoptosis.	CYR61 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113317>	C17332	CCN Family Member 1|CCN1|Cellular Communication Network Factor 1|Cysteine-Rich Angiogenic Inducer 61|Cysteine-Rich Heparin-Binding Protein 61|Cysteine-Rich Protein 61|IBP-10|IGF-Binding Protein 10|IGFBP-10|Insulin-Like Growth Factor-Binding Protein 10|Protein CYR61|Protein CYR61|Protein GIG1	CCN family member 1 (381 aa, ~42 kDa) is encoded by the human CCN1 gene. This protein plays a role in cell adhesion, cell proliferation, angiogenesis, heart morphogenesis and apoptosis.	Protein CYR61		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113318>	C28533	SLC28A2 Gene|SLC28A2|SLC28A2|Solute Carrier Family 28 (Concentrative Nucleoside Transporter), Member 2 Gene	This gene is involved in the transport of purines.	SLC28A2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113319>	C113318	SLC28A2 wt Allele|CNT2|HCNT2|HsT17153|SPNT1|Solute Carrier Family 28 (Concentrative Nucleoside Transporter), Member 2 wt Allele|Solute Carrier Family 28 (Sodium-Coupled Nucleoside Transporter), Member 2 Gene	Human SLC28A2 wild-type allele is located in the vicinity of 15q15 and is approximately 24 kb in length. This allele, which encodes sodium/nucleoside cotransporter 2 protein, plays a role in the transport of purine nucleosides.	SLC28A2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11331>	C61063	Cisplatin/Floxuridine|CDDP/FUDR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113320>	C16386	Sodium/Nucleoside Cotransporter 2|CNT 2|Concentrative Nucleoside Transporter 2|Na(+)/Nucleoside Cotransporter 2|SLC28A2|SPNT|Sodium-Coupled Nucleoside Transporter 2|Sodium/Purine Nucleoside Co-Transporter|Solute Carrier Family 28 Member 2|hCNT2	Sodium/nucleoside cotransporter 2 (658 aa, ~72 kDa) is encoded by the human SLC28A2 gene. This protein is involved in purine nucleoside transport.	Sodium/Nucleoside Cotransporter 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113321>	C28533	SLC28A3 Gene|SLC28A3|SLC28A3|Solute Carrier Family 28 (Concentrative Nucleoside Transporter), Member 3 Gene	This gene plays a role in sodium-dependent nucleoside transport.	SLC28A3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113322>	C113321	SLC28A3 wt Allele|CNT3|Solute Carrier Family 28 (Concentrative Nucleoside Transporter), Member 3 wt Allele|Solute Carrier Family 28 (Sodium-Coupled Nucleoside Transporter), Member 3 Gene	Human SLC28A3 wild-type allele is located in the vicinity of 9q22.2 and is approximately 93 kb in length. This allele, which encodes solute carrier family 28 member 3 protein, is involved in sodium-mediated transport of nucleobases.	SLC28A3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113323>	C16386	Solute Carrier Family 28 Member 3|CNT 3|Concentrative Na(+)-Nucleoside Cotransporter 3|Concentrative Na+-Nucleoside Cotransporter 3|Concentrative Nucleoside Transporter 3|Na(+)/Nucleoside Cotransporter 3|SLC28A3|Sodium/Nucleoside Cotransporter 3|hCNT3	Solute carrier family 28 member 3 (691 aa, ~77 kDa) is encoded by the human SLC28A3 gene. This protein plays a role in the mediation of sodium dependent transport of nucleosides.	Solute Carrier Family 28 Member 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113324>	C20745	CALD1 Gene|CALD1|CALD1|Caldesmon 1 Gene	This gene is involved in the stabilization of actin filaments.	CALD1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113325>	C113324	CALD1 wt Allele|CAD|CDM|Caldesmon 1 wt Allele|H-CAD|HCAD|L-CAD|LCAD|NAG22	Human CALD1 wild-type allele is located in the vicinity of 7q33 and is approximately 226 kb in length. This allele, which encodes caldesmon protein, plays a role in actin filament stability.	CALD1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113326>	C16492	Caldesmon|CALD1|CDM	Caldesmon (793 aa, ~93 kDa) is encoded by the human CALD1 gene. This protein is involved in binding to and stabilization of filamentous actin.	Caldesmon		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113327>	C28533	ABCF2 Gene|ABCF2|ABCF2|ATP-Binding Cassette, Sub-Family F (GCN20), Member 2 Gene	This gene plays a role in ATP catabolism.	ABCF2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113328>	C113327	ABCF2 wt Allele|ABC28|ATP-Binding Cassette, Sub-Family F (GCN20), Member 2 wt Allele|EST133090|HUSSY-18|HUSSY18|Human Sequence Similar to Yeast 18 Gene	Human ABCF2 wild-type allele is located in the vicinity of 7q36 and is approximately 19 kb in length. This allele, which encodes ATP-binding cassette sub-family F member 2 protein, is involved in ATP hydrolysis.	ABCF2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113329>	C17750	ATP-Binding Cassette Sub-Family F Member 2|ABCF2|ATP-Binding Cassette, Sub-Family F, Member 2|Iron-Inhibited ABC Transporter 2	ATP-binding cassette sub-family F member 2 (623 aa, ~71 kDa) is encoded by the human ABCF2 gene. This protein plays a role in ATP metabolism.	ATP-Binding Cassette Sub-Family F Member 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11332>	C61063	Amifostine/Cisplatin/Gemcitabine|CDDP/dFdC/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113330>	C155322	Plixorafenib|BRAF Inhibitor FORE8394|BRAF Inhibitor PLX8394|FORE 8394|FORE-8394|FORE8394|PL -8394|PLIXORAFENIB|PLX8394	An orally bioavailable inhibitor and specific dimer breaker of the serine/threonine-protein kinase B-raf (BRAF) protein, with potential antineoplastic activity. Upon oral administration, plixorafenib selectively binds to and inhibits the activity of dimeric BRAF mutants, including BRAF fusions and splice variants, and BRAFV600 monomers, while sparing RAF function in normal cells. This inhibits the proliferation of tumor cells which express these mutated forms of BRAF. BRAF, a member of the raf family of serine/threonine protein kinases, plays a role in the regulation of mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK) signaling pathways, which may be constitutively activated due to BRAF gene mutations. Mutated forms and fusions of BRAF are associated with a number of neoplastic diseases.	Plixorafenib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113332>	C129822|C128037	Anti-PD-1 Monoclonal Antibody MEDI0680|AMP-514|MEDI0680	A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody MEDI0680 binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the Ig superfamily expressed on T cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.	Anti-PD-1 Monoclonal Antibody MEDI0680		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113333>	C199386	Anti-ErbB3 Monoclonal Antibody CDX-3379|CDX 3379|CDX-3379|CDX-3379|CDX3379|KTN 3379|KTN-3379|KTN3379	A human monoclonal antibody directed against the human epidermal growth factor receptor ErbB3 (HER3), with potential antineoplastic activity. Upon administration, the anti-ErbB3 monoclonal antibody CDX-3379 targets and binds to a unique epitope on ErbB3, thereby preventing ErbB3 phosphorylation and both ligand-dependent and ligand-independent ErbB3 signaling. This inhibits cellular proliferation and survival of ErbB3-expressing tumor cells. ErbB3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in a variety of tumors and its overexpression generally correlates with poor prognosis and tumor resistance.	Anti-ErbB3 Monoclonal Antibody CDX-3379		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113334>	C156804	Histone-Lysine N-Methyltransferase EZH2 Inhibitor GSK2816126|EZH2 Inhibitor GSK2816126|GSK2816126	A small molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone-lysine N-methyltransferase EZH2, with potential antineoplastic activity. Upon administration, histone-lysine N-methyltransferase EZH2 inhibitor GSK2816126 inhibits the activity of EZH2 and specifically prevents the methylation of histone H3 lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased tumor cell proliferation in cancer cells that overexpress this enzyme. EZH2, which belongs to the class of histone methyltransferases (HMTs), is overexpressed or mutated in a variety of cancers and plays a key role in tumor cell proliferation.	Histone-Lysine N-Methyltransferase EZH2 Inhibitor GSK2816126		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113335>	C48259	Secondary Hyperparathyroidism	Overproduction of parathyroid hormone in response to influence external to the parathyroid glands.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C113336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113336>	C36284	Pubertal Failure	Abnormally absent or incomplete sexual development.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C113337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113337>	C36284	Premature Adrenarche	Premature onset of adrenal androgen-mediated secondary sexual characteristics.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C113338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113338>	C34815	Premature Menarche	Occurrence of the first menstrual period in a female before the usual or expected age.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113339>	C61443	Primary Amenorrhea|Delayed Menarche|Delayed Menarche	Abnormally late or absent menarche in a female with normal secondary sexual characteristics.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C11333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11333>	C61063	Bryostatin 1/Cladribine|BRYO/2-CdA			Obsolete_Concept	Therapeutic or Preventive Procedure	NCI Drug Dictionary Terminology
C113340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113340>	C61443	Secondary Amenorrhea	The cessation of menstruation for six months or more in a female that is not pregnant, breastfeeding or menopausal.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C113341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113341>	C34815	Oligomenorrhea	Infrequent menstrual periods.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113342>	C117720	Premature Thelarche	Isolated breast development prior to the normal age of pubertal onset in females.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C113343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113343>	C36284	Galactorrhea|Nipple Discharge	Excessive secretion of breast milk.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology|Perinatal Terminology
C113344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113344>	C92809	Hyperestrogenism|Estrogen Excess|Estrogen Excess|Estrogen Excess	Abnormally high level of estrogen.			Finding	GDC Terminology|GDC Value Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113345>	C92809	Hyperprogesteronism|Progesterone Excess|Progesterone Excess	Abnormally high level of progesterone.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113346>	C92809	Hypoprogesteronism|Progesterone Deficiency|Progesterone Deficiency	Abnormally low level of progesterone.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113347>	C9227	Hypogonadotropic Hypogonadism|Central Hypogonadism|Central Hypogonadism|Secondary Hypogonadism|Secondary Hypogonadism	Abnormal ovarian or testicular function due to insufficient hormonal stimulation from the hypothalamic-pituitary axis.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C113348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113348>	C9227	Hypergonadotropic Hypogonadism|Primary Gonadal Failure|Primary Gonadal Failure	Ovarian or testicular dysfunction associated with high levels of gonadotropins.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C113349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113349>	C113215	Testosterone Excess	Abnormally high level of testosterone.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11334>	C61063	Cladribine/Idarubicin|2-CdA/IDA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113350>	C54452	SPL Sex Terminology|Structured Product Labeling Sex Terminology	Terminology used in the framework of Structured Product Labeling documents to distinguish the sex of an individual.	SPL Sex Terminology		Intellectual Product	FDA Structured Product Labeling Terminology
C113351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113351>	C27627	Ovarian Failure|Ovarian Hypofunction|Ovarian Insufficiency	The inability of the ovaries to function.	Ovarian Failure		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C113352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113352>	C113351	Primary Ovarian Failure|Hypergonadotropic Hypogonadism (Female)|primary ovarian insufficiency	Absent or premature cessation of ovarian function due to a pathologic process originating within the ovaries.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C113353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113353>	C102557	Exposure Planned Occurrence|EXPOCCUR	An instance of an exposure event or incident that is intended to take place.			Event	CDISC CDASH Variable Terminology
C113354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113354>	C41202	Clinical Events Completion Status|CESTAT	A term used to describe the state or condition of the completeness of the clinical events data.			Qualitative Concept	CDISC Variable Terminology
C113355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113355>	C82510	Concomitant Medication Pre-specified|CMPRESP	An indication or description that concomitant medication was previously determined, characterized, or detailed.			Conceptual Entity	CDISC Variable Terminology
C113356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113356>	C25164	Drug Accountability Date|DADAT	The date that the drug accountability assessments occurred on.			Temporal Concept	CDISC CDASH Variable Terminology
C113357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113357>	C41202	Drug Accountability Completion Status|DASTAT	A term used to describe the state or condition of the completeness of the drug accountability data.			Qualitative Concept	CDISC Variable Terminology
C113358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113358>	C82531	Exposure Reference Identifier|EXREFID	A character or string used to name, or characterize an exposure reference.			Intellectual Product	CDISC CDASH Variable Terminology
C113359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113359>	C82526	Findings About Events or Interventions Baseline Flag|FABLFL	An indication or description that a finding about an event or intervention is a baseline value.			Functional Concept	CDISC Variable Terminology
C11335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11335>	C61007	Buserelin/Flutamide|BSRL/FLUT			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113360>	C82515	Findings About Events or Interventions Collection Date Time|FADTC	The date and time that a finding about an event or intervention was collected.			Temporal Concept	CDISC Variable Terminology
C113361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113361>	C82437	Findings About Events or Interventions Data Collection Day|FADY	The day of the week the findings about an event or intervention was collected.			Temporal Concept	CDISC Variable Terminology
C113362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113362>	C51824	Findings About Events or Interventions Evaluator|FAEVAL	A person who determines the significance of a finding about an event or intervention.			Professional or Occupational Group	CDISC Variable Terminology
C113363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113363>	C25341	Findings About Events or Interventions Location|FALOC	The physical portion of the body at which the findings about the event or intervention assessment takes place.			Spatial Concept	CDISC Variable Terminology
C113364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113364>	C117221	Findings About Events or Interventions Original Result|FAORRES	The outcome of the findings about events or interventions assessment.			Quantitative Concept	CDISC Variable Terminology
C113365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113365>	C82586	Findings About Events or Interventions Original Result Unit|FAORRESU	The unit of measure for the original findings about events or interventions result.			Quantitative Concept	CDISC Variable Terminology
C113366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113366>	C82556	Findings About Events or Interventions Reason Not Done|FAREASND	The explanation given as to why findings about events or interventions were not collected.			Idea or Concept	CDISC Variable Terminology
C113367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113367>	C41202	Findings About Events or Interventions Completion Status|FASTAT	A term used to describe the state or condition of the completeness of the findings about events or interventions data.			Qualitative Concept	CDISC Variable Terminology
C113368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113368>	C117222	Findings About Events or Interventions Character Result in Standard Format|FASTRESC	The standard character or string for representation and reporting of findings about events or interventions data.			Quantitative Concept	CDISC Variable Terminology
C113369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113369>	C70952	Findings About Events or Interventions Numeric Result in Standard Unit|FASTRESN	The numerical identifier of findings about events or interventions result in standard units.			Quantitative Concept	CDISC Variable Terminology
C11336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11336>	C61007	Buserelin/Nilutamide|ANAN/BSRL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113370>	C82587	Findings About Events or Interventions Result Standard Unit|FASTRESU	The standard unit of measure for findings about events or interventions results.			Quantitative Concept	CDISC Variable Terminology
C113371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113371>	C41202	Laboratory Data Completion Status|LBSTAT	A term used to describe the state or condition of the completeness of the laboratory data.			Qualitative Concept	CDISC Variable Terminology
C113372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113372>	C41202	Microbiology Completion Status|MBSTAT	A term used to describe the state or condition of the completeness of the microbiology data.			Qualitative Concept	CDISC Variable Terminology
C113373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113373>	C41202	Microbiology Susceptibility Completion Status|MSSTAT	A term used to describe the state or condition of the completeness of the microbiology susceptibility data.			Qualitative Concept	CDISC Variable Terminology
C113374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113374>	C41202	Pharmacokinetic Concentration Completion Status|PCSTAT	A term used to describe the state or condition of the completeness of the pharmacokinetic concentration data.			Qualitative Concept	CDISC Variable Terminology
C113375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113375>	C82535	Physical Exam Method|PEMETHOD	A systematic course of action that is performed in order to complete a physical examination.			Activity	CDISC Variable Terminology
C113376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113376>	C82525	Physical Exam Performed|PEPERF|physical exam performed|physical_exam_performed	An indication or description that a subject physical examination test has occurred.			Finding	CDISC CDASH Variable Terminology|ICDC Property Terminology|ICDC Terminology
C113377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113377>	C41202	Pharmacokinetic Parameters Completion Status|PPSTAT	A term used to describe the state or condition of the completeness of the pharmacokinetic parameters data.			Qualitative Concept	CDISC Variable Terminology
C113378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113378>	C82587	Pharmacokinetic Parameters Result Standard Unit|PPSTRESU	The standard unit of measure for pharmacokinetic parameters results.			Quantitative Concept	CDISC Variable Terminology
C113379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113379>	C82525	Subject Characteristic Performed|SCPERF	An indication or description that a subject characteristics test has occurred.			Finding	CDISC CDASH Variable Terminology
C11337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11337>	C61007	Bicalutamide/Buserelin|BSRL/CDX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113380>	C52680	Disabling Adverse Event|AESDISAB	An adverse event, and/or its immediate sequelae which is associated with physical or mental disabilities that affect or limit the ability of a person to perform activities of daily living (eating, ambulation, toileting, etc.).			Finding	CDISC CDASH Variable Terminology|CDISC Variable Terminology
C113381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113381>	C49151	Antepartum Stillbirth	Fetal death greater than or equal to 20 weeks of gestation prior to labor with Apgar scores of 0 at 1 minute, 5 minutes and beyond.			Finding	GAIA Stillbirth Level of Diagnostic Certainty Terminology|GAIA Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C113382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113382>	C49151	Intrapartum Stillbirth	Fetal death greater than or equal to 20 weeks of gestation during labor with Apgar scores of 0 at 1 minute, 5 minutes and beyond.			Finding	GAIA Stillbirth Level of Diagnostic Certainty Terminology|GAIA Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C113383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113383>	C92861	Indicated Preterm Birth	Preterm birth from 20 weeks to 36 weeks, and 6 days of gestation that is necessitated by the medical condition of the mother or fetus.			Finding	NICHD Terminology|Perinatal Terminology
C113385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113385>	C27619	Placenta Increta	Histologically-confirmed deep attachment of the placenta into the myometrium that does not cross the serosa.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C113386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113386>	C27619	Placenta Percreta	Histologically-confirmed deep attachment of the placenta into the myometrium and serosa. It may further extend into an adjacent organ such as the bladder.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C113387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113387>	C27619	Low-Lying Placenta	A condition in which the placental edge is within 2 cm of but not covering the cervical os.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C113389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113389>	C92718	Duration of Rupture of Membrane|Duration of Rupture of Membranes|Duration of Rupture of Membranes|Latency Interval|Latency Interval	Duration from rupture of membranes to birth (in hours and minutes). (reVITALize)			Finding	NICHD Terminology|Perinatal Terminology
C11338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11338>	C61007	Leuprolide/Nilutamide|ANAN/LEUP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113390>	C92718	Number of Centimeters Dilated on Admission	The last documented cervical dilation, in centimeters, when the provider orders admission. (reVITALize)			Finding	NICHD Terminology|Perinatal Terminology
C113391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113391>	C36279	Blood in Stool	A finding indicating the presence of blood in stool. It is the result of gastrointestinal hemorrhage and it may be easily seen in stool or may be identified microscopically.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113392>	C113122	Whole Blood Collection Tube|Yellow Top Blood Collection Tube|Yellowtop Blood Collection Tube	A blood collection tube used for the collection of whole blood.			Manufactured Object	
C113393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113393>	C25404	Personal Contact|Contact|Contact	Direct or indirect interaction between individuals or organizations.			Activity	
C113394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113394>	C20993	Model for End-Stage Liver Disease|MELD|MELD Score	A scoring system of disease severity in patients with end-stage liver disease. It is used to help prioritize allocation of liver allografts for transplantation and replaces the Child-Pugh score.			Classification	
C113395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113395>	C3368|C208312	Feeding Intolerance	Inability to achieve a full feeding volume.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113396>	C3835|C118807	Infantile Gastroesophageal Reflux|Gastroesophageal Reflux|Gastroesophageal Reflux|Infant Reflux|Infant Regurgitation|Spilling|Spilling|Spitting Up|Spitting Up	Effortless regurgitation of gastric contents that commonly occurs in infants, usually right after feeding or burping.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113397>	C28193	Sandifer's Syndrome|Sandifer Syndrome|Sandifer Syndrome	A condition associated with gastro-esophageal reflux disease that presents in infancy and early childhood and is characterized by spastic torticollis and dystonic body movements.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113398>	C86571	Melena Neonatorum|Melena Neonatal|Melena Neonatal|Neonatal Melena|Neonatal Melena	Abnormally dark tarry feces containing blood, usually due to gastrointestinal bleeding or swallowed maternal blood in neonates.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C113399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113399>	C28076	Scarff-Bloom-Richardson Grading System|SBR	A breast cancer grading system that was the precursor of the Nottingham system.			Classification	
C11339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11339>	C61063	Histamine Dihydrochloride/Interleukin-2|HIST/IL-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1133>	C2139	ImuVert|Serratia Marcescens Extract	A membrane vesicle/ribosome preparation derived from the bacterium Serratia marcescens with immunomodulatory activity. ImuVert triggers interferon (IFN) gamma production through binding the low affinity IgG Fc receptor type III (CD16) on natural killer (NK) cells. This agent works synergistically with interleukin-2 further enhancing IFN gamma production. In addition, ImuVert is capable of inducing peripheral blood mononuclear cells (PBMC), from the cord blood of newborn infants lacking NK activity, to exhibit NK activity.			Organic Chemical|Pharmacologic Substance	NCI Drug Dictionary Terminology
C113400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113400>	C28193	Hepatorenal Syndrome|Hepatorenal syndrome	A syndrome characterized by progressive kidney failure in a patient with cirrhosis or fulminant liver failure.			Disease or Syndrome	mCode Elixhauser Moderate to Severe Liver Disease Value Set|mCode Terminology|NICHD Terminology|Pediatric Nephrology Terminology
C113401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113401>	C91105	Healthy Volunteer Medical History Questionnaire|HVMHQ	A predetermined set of questions designed to identify individuals without significant health related issues to participate in a research study.			Intellectual Product	
C113402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113402>	C91103	Have Undergone a Transplant Question|Had a Transplant|Have Undergone a Transplant|Have you ever undergone an Organ, Bone Marrow or Peripheral Blood Stem Cell Transplant	A question about whether an individual has ever had a transplant.			Intellectual Product	Healthy Volunteer Medical History Questionnaire
C113403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113403>	C173981	Have Chronic Infection Question|Do you have a chronic infection such as HIV/AIDS, Herpes Simplex Virus, Mononucleosis, etc.|Have Chronic Infection	A question about whether an individual has a chronic infection.			Intellectual Product	Healthy Volunteer Medical History Questionnaire
C113404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113404>	C173981	Have Had Cold Sores Question|Do you have a history of "cold sores" on your lips or in your mouth|Have Had Cold Sores|History of Cold Sores	A question about whether an individual has a history of cold sores.			Intellectual Product	Healthy Volunteer Medical History Questionnaire
C113405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113405>	C173981	Have Autoimmune or Inflammatory Condition Question|Do you have any Autoimmune or Inflammatory conditions|Have Autoimmune or Inflammatory Condition	A question about whether an individual has any autoimmune or inflammatory conditions.			Intellectual Product	Healthy Volunteer Medical History Questionnaire
C113406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113406>	C173981	Have Arthritis, Rheumatism, Bursitis, Lupus or Sjogren Syndrome Question|Do you have Arthritis, Rheumatism, Bursitis, Lupus or Sjogren's Syndrome|Have Arthritis, Rheumatism, Bursitis, Lupus or Sjogren Syndrome|Have Arthritis, Rheumatism, Bursitis, Lupus or Sjögren Syndrome	A question about whether an individual has arthritis, rheumatism, bursitis, lupus or Sjogren's syndrome.			Intellectual Product	Healthy Volunteer Medical History Questionnaire
C113407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113407>	C173981	Have Diabetes Question|Are you Diabetic|Have Diabetes	A question about whether an individual has diabetes.			Intellectual Product	Dexamethasone Symptom Questionnaire-Chronic|Dexamethasone Symptom Questionnaire|Healthy Volunteer Medical History Questionnaire
C113408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113408>	C173981	Have History of Opportunistic or Frequent Infection Question|Do you have a history of opportunistic or frequent infections|Have History of Opportunistic or Frequent Infection	A question about whether an individual has a history of opportunistic or frequent infections.			Intellectual Product	Healthy Volunteer Medical History Questionnaire
C113409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113409>	C173981|C173509	Have Immunodeficiency Question|Are you currently immunodeficient|Currently Immunodeficient|Have Immunodeficiency	A question about whether an individual is currently immunodeficient.			Intellectual Product	Healthy Volunteer Medical History Questionnaire
C11340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11340>	C61063	Carboplatin/Etoposide/Fluorouracil|CBDCA/5-FU/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113410>	C173981	Have Had a Tumor, Growth, Cyst, or Cancer Question|Have Had a Tumor, Growth, Cyst, or Cancer|Have you ever had a tumor, growth, cyst or cancer	A question about whether an individual has or had a tumor, growth, cyst, or cancer.			Intellectual Product	Healthy Volunteer Medical History Questionnaire
C113411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113411>	C173981	Have Allergy Question|Do you have any allergies|Have Allergies|Have Allergy	A question about whether an individual has allergies.			Intellectual Product	Healthy Volunteer Medical History Questionnaire
C113412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113412>	C173398	Have Had Severe Tooth or Gum Trouble Question|Had Severe Tooth or Gum Trouble|Have Had Severe Tooth or Gum Trouble|Have you ever had severe tooth or gum trouble	A question about whether an individual has or had severe tooth or gum trouble.			Intellectual Product	Healthy Volunteer Medical History Questionnaire
C113413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113413>	C173981	Have Adequate Moisture in Mouth Question|Do you feel like you have adequate moisture in your mouth right now|Have Adequate Moisture in Mouth	A question about whether an individual currently has adequate moisture in their mouth.			Intellectual Product	Healthy Volunteer Medical History Questionnaire
C113414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113414>	C45822	Quantitative Trait Locus|QTL	A stretch of DNA at a particular chromosomal location that contains or is linked to genes that are associated with the expression of a variable phenotypic trait.			Gene or Genome	
C113415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113415>	C113414	Expression Quantitative Trait Locus|eQTL	A stretch of DNA at a particular chromosomal location that is able to regulate the expression of a specific mRNA or protein.			Gene or Genome	
C113416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113416>	C16840	Consideration	Careful thought or deliberation.			Mental Process	
C113417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113417>	C25404	Nap	A short sleep, usually during normal waking hours.			Activity	
C113418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113418>	C53462	Car Ride	A journey in an automobile.			Activity	
C113419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113419>	C199000|C198996	Housemate|Roommate	A person who shares a house with another person.			Human	
C11341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11341>	C61063	Amifostine/Fludarabine|FAMP/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113420>	C49165	Nerve-Sparing Surgery	Any surgery that attempts to preserve nerve function near the surgery site.			Health Care Activity	
C113421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113421>	C98996|C28193	Gray Baby Syndrome|Gray Syndrome|Gray Syndrome|Grey Syndrome|Grey Syndrome	A disorder observed in a newborn who was exposed to chloramphenicol. Manifestations include hypotension, cyanosis, cardiovascular collapse and/or death.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C113422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113422>	C28193	Diethylstilbestrol Syndrome|Fetal Diethylstilbestrol Syndrome	A disorder likely to occur in children and grandchildren of a woman treated with diethylstilbestrol during pregnancy. Manifestations include vaginal adenosis, cervical malformations, vaginal septae, genital tract anomalies or Fallopian tube anomalies causing subsequent fertility problems.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C113423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113423>	C92720	Labor After Cesarean|LAC|LAC|Labor After Caesarean	Labor in a woman who has had one or more previous cesarean births.			Finding	NICHD Terminology|Perinatal Terminology
C113424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113424>	C34941	Threatened Preterm Labor|Threatened Premature Labor|Threatened Premature Labor	Frequent painful contractions prior to 37 weeks of gestation without cervical change.			Finding	NICHD Terminology|Perinatal Terminology
C113425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113425>	C62439	Eleven|11	A natural number greater than 10 and less than 12 and the quantity that it denotes.			Quantitative Concept	
C113426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113426>	C62439	Twelve|12|12	A natural number greater than 11 and less than 13 and the quantity that it denotes.			Quantitative Concept	GDC Terminology|GDC Value Terminology
C113427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113427>	C62439	Thirteen|13|13	A natural number greater than 12 and less than 14 and the quantity that it denotes.			Quantitative Concept	GDC Terminology|GDC Value Terminology
C113428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113428>	C62439	Fourteen|14	A natural number greater than 13 and less than 15 and the quantity that it denotes.			Quantitative Concept	
C113429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113429>	C62439	Fifteen|15	A natural number greater than 14 and less than 16 and the quantity that it denotes.			Quantitative Concept	
C11342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11342>	C61063	Flt3 Ligand/gp100 Antigen|Flt3L/gp100			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113430>	C62439	Sixteen|16	A natural number greater than 15 and less than 17 and the quantity that it denotes.			Quantitative Concept	
C113431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113431>	C62439	Seventeen|17	A natural number greater than 16 and less than 18 and the quantity that it denotes.	Seventeen		Quantitative Concept	CTRP Biomarker Terminology|CTRP Terminology
C113432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113432>	C1663	NY-ESO-1/GLA-SE Vaccine ID-G305|ID-G305|IDC-G305	A cancer vaccine composed of a recombinant form of the tumor antigen NY-ESO-1 and glucopyranosyl lipid adjuvant (GLA)-stable emulsion (GLA-SE), with potential antineoplastic and immunomodulating activities. Upon intramuscular injection, the adjuvant portion of the NY-ESO-1/GLA-SE vaccine ID-G30 binds to toll-like receptor subtype 4 (TLR-4) expressed on dendritic cells (DCs), monocytes, macrophages and B cells. The activated DCs present the NY-ESO-1 antigen to Th1 CD4 T-lymphocytes. This leads to the induction of cytotoxic T lymphocytes (CTLs) and the killing of NY-ESO-1-expressing tumor cells. This vaccine also induces specific antibody responses and increases the production of inflammatory cytokines.	NY-ESO-1/GLA-SE Vaccine ID-G305		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113433>	C2152|C129825	Tenalisib|3-(3-Fluorophenyl)-2-((1S)-1-((7H-purin-6-yl)amino)propyl)-4H-1-benzopyran-4-one|4H-1-Benzopyran-4-one, 3-(3-fluorophenyl)-2-((1S)-1-(9H-purin-6-ylamino)propyl)-|RP 6530|RP-6530|RP6530|TENALISIB	An orally active, highly selective, small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. Upon administration, tenalisib inhibits the PI3K delta and gamma isoforms and prevents the activation of the PI3K/AKT-mediated signaling pathway. This may lead to a reduction in cellular proliferation in PI3K delta/gamma-expressing tumor cells. In addition, this agent modulates inflammatory responses through various mechanisms, including the inhibition of both the release of reactive oxygen species (ROS) from neutrophils and tumor necrosis factor (TNF)-alpha activity. Unlike other isoforms of PI3K, the delta and gamma isoforms are overexpressed primarily in hematologic malignancies and in inflammatory and autoimmune diseases. By selectively targeting these isoforms, PI3K signaling in normal, non-neoplastic cells is minimally impacted or not affected at all, which minimizes the side effect profile for this agent.	Tenalisib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113434>	C2152|C129825	Parsaclisib|(4R)-4-(3-((1S)-1-(4-Amino-3-methyl-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one|IBI376|INCB 50465|INCB-50465|INCB050465|INCB50465|PARSACLISIB|WHO 10589	An inhibitor of the delta isoform of phosphoinositide-3 kinase (PI3K) with potential antineoplastic activity. Parsaclisib inhibits the delta isoform of PI3K and prevents the activation of the PI3K/AKT signaling pathway. This both decreases proliferation and induces cell death in PI3K-delta-overexpressing tumor cells. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic disease and cell lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.	Parsaclisib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113435>	C2196	Wnt-5a Mimic Hexapeptide Foxy-5|FOXY-5|Foxy-5	A formylated, six amino acid, Wnt5a-derived peptide and wnt-5a mimetic with potential anti-metastatic activity. Upon intravenous administration, Wnt-5a mimic hexapeptide foxy-5 binds to and activates the wnt-5a receptors, Frizzled-2 and -5, which activates wnt-5a-mediated signaling. Increased wnt-5a signaling may inhibit endothelial tumor cell migration and invasion. This may decrease metastasis of susceptible tumor cells. However, foxy-5 does not affect tumor cell proliferation or apoptosis. Foxy-5 lacks a heparan sulfate-binding domain and contains a formyl group on its NH2-terminal methionine residue which decreases in vivo degradation. Decreased expression of wnt-5a protein is associated with increased motility of certain tumor cell types.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113436>	C91105	American Urological Association Symptom Score|AUA SI|AUA SS|AUA Symptom Score|American Urological Association BPH Symptom Score Index|American Urological Association Symptom Index Score|American Urological Association Symptom Index for Benign Prostatic Hyperplasia	A questionnaire designed to help men determine how bothersome their benign prostatic hyperplasia urinary symptoms are and to determine how effective their treatment is.			Intellectual Product	
C113437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113437>	C574	Dusquetide|DUSQUETIDE|IMX 942|Innate Defense Regulator SGX942|L-Alaninamide, L-arginyl-L-isoleucyl-L-valyl-L-prolyl-|SGX942	A synthetic, 5-amino acid peptide and Innate Defense Regulator (IDR), with immunomodulating, anti-inflammatory, anti-infective and anti-mucositis activities. Upon intravenous administration, dusquetide binds to the ZZ domain of sequestosome-1, also called p62, and activates regulatory signaling transduction pathways involved in the modulation of the innate immune system, such as those mediated by mitogen-activated protein kinase (MAPK) p38 and CCAAT-enhancer-binding protein. This agent promotes monocyte and macrophage recruitment to, and accelerates healing in damaged and infected tissue; it suppresses inflammation through the regulation of the expression of multiple cytokines. This agent may prevent or decrease chemo- or radiotherapy-induced mucositis as well as other types of infection. p62, an intracellular adaptor protein that functions downstream of certain signaling receptors, plays a key role in the activation of the innate immune system.	Dusquetide		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C113438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113438>	C28681|C119988	EFS-ADA Lentiviral Vector-transduced CD34-positive Autologous Lymphocytes	A preparation of autologous, CD34-positive stem/progenitor cells transduced with a lentrivral vector encoding the human adenosine deaminase (ADA) gene under the control of the human elongation factor alpha short promoter (EFS), with potential to restore ADA expression and function. Autologous hematopoietic CD34+ cells are isolated from the patient's own bone marrow, peripheral blood or cord blood, and transduced with the EFS-ADA lentiviral vector ex vivo. Upon re-infusion of the EFS-ADA vector-transduced lymphocytes back into the patient, these cells may both restore ADA activity and prevent severe combined immunodeficiency (SCID) due to ADA deficiency. ADA, an enzyme that catalyzes the deamination of adenosine to inosine, plays a key role in the development and functioning of the immune system.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology
C113439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113439>	C1966	PSMA-targeting Fluorescent Imaging Agent MDX1201-A488|MDX1201-A488	A recombinant, human monoclonal antibody targeting an extracellular epitope of human prostate specific membrane antigen (PSMA) that is conjugated with A488, a photostable fluorescent dye with a high quantum yield, with potential imaging activity. Upon intravenous administration of PSMA-targeting fluorescent imaging agent MDX1201-A488, the MDX1201 moiety targets PSMA expressed on cancer cells. Subsequently, the A488 moiety can then be visualized by fluorescence-based imaging and the amount of PSMA-expressing tumor cells can be assessed. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.	PSMA-targeting Fluorescent Imaging Agent MDX1201-A488		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11343>	C63442	VACOP-B Regimen|BLEO/CTX/DOX/PRED/VCR/VP-16|Bleomycin/Cyclophosphamide/Doxorubicin/Etoposide/Prednisone/Vincristine|Bleomycin/Cyclophosphamide/Doxorubicin/Etoposide/Prednisone/Vincristine Regimen|P-VABEC|VACOP-B|VACOP-B	A regimen consisting of bleomycin, cyclophosphamide, doxorubicin, etoposide, prednisone and vincristine that can be used for the treatment of non-Hodgkin lymphoma (NHL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C113440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113440>	C2124	Copper Cu 62-PTSM|62Cu-PTSM	A radioconjugate consisting of a lipophilic, bioreductive copper(II)bis(thiosemicarbazone) complex, copper-pyruvaldehyde-bis(N4-methylthiosemicarbazone) (Cu-PTSM), linked to the beta-emitting, radioisotope copper Cu 62, with potential perfusion and positron emitting tomography (PET) tumor imaging activities. Upon injection, the distribution of copper Cu 62-PTSM correlates with blood flow. This agent's high membrane permeability allows for rapid diffusion into cells. Once it enters the cell, 62Cu-PTSM is then reduced by the mitochondria, which prevents diffusion of the agent out of the cell. Upon PET imaging, tumor blood flow can be visualized and tumor perfusion can be assessed. Compared with other copper radionuclides, the short half-life of copper Cu 62 (9.7 minutes) reduces the amount of radiation a patient is subjected to and allows for several imaging studies to be performed. PTSM lacks selectivity for hypoxic cells.	Copper Cu 62-PTSM		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C113441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113441>	C2124	Copper Cu 62-ATSM|62Cu-ATSM	A radioconjugate consisting of a lipophilic, neutral, bioreductive copper-bis(thiosemicarbazone) complex, copper-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM), labeled with the beta-emitting radioisotope copper Cu 62, with hypoxia-selective and positron emitting tomography (PET) radioimaging activities. With a high membrane permeability and low reduction potential, copper Cu 62-ATSM easily enters cells. This agent can only be reduced by mitochondria found in hypoxic cells with abnormally high electron concentrations. This chemical reaction traps Cu 62-ATSM in the cell, which allows for the selective accumulation of this agent in hypoxic cells compared to normoxic cells. The extent of copper Cu 62-ATSM retention in tissue is inversely related to the state of tissue oxygenation allowing the quantitation of tissue hypoxia with PET. This provides information about diagnosis, prognosis, treatment options and outcomes for certain cancers. The short half-life of copper Cu 62 (9.7 minutes) reduces the amount of radiation a patient is subjected to and allows for several imaging studies to be performed.  Hypoxic tumors are associated with increased malignancy and resistance to radiation and chemotherapy.	Copper Cu 62-ATSM		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C113442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113442>	C213665|C129825	Acalabrutinib|ACALABRUTINIB|ACP 196|ACP-196|ACP196|Benzamide, 4-(8-Amino-3-((2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl)imidazo(1,5-a)pyrazin-1-yl)-N-2-pyridinyl-|Bruton Tyrosine Kinase Inhibitor ACP-196	An orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, acalabrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.	Acalabrutinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C113443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113443>	C2080	Omaveloxolone|OMAVELOXOLONE|Propanamide, N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoro-|RTA 408|RTA-408	A member of the synthetic oleanane triterpenoid class of compounds and an activator of nuclear factor erythroid 2 [NF-E2]-related factor 2 (Nrf2, Nfe2l2), with potential chemopreventive activity. Upon administration, omaveloxolone activates the cytoprotective transcription factor Nrf2. In turn, Nrf2 translocates to the nucleus, dimerizes with a small Maf protein (sMaf), and binds to the antioxidant response element (ARE). This induces the expression of a number of cytoprotective genes, including NAD(P)H quinone oxidoreductase 1 (NQO1), sulfiredoxin 1 (Srxn1), heme oxygenase-1 (HO1, HMOX1), superoxide dismutase 1 (SOD1), gamma-glutamylcysteine synthetase (gamma-GCS), thioredoxin reductase-1 (TXNRD1), glutathione S-transferase (GST), glutamate-cysteine ligase catalytic subunit (Gclc) and glutamate-cysteine ligase regulatory subunit (Gclm), and increases the synthesis of the antioxidant glutathione (GSH). Nrf2, a leucine zipper transcription factor, plays a key role in the maintenance of redox balance and cytoprotection against oxidative stress.	Omaveloxolone		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C113444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113444>	C2150|C1557	Roducitabine|4-Amino-1-((1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl)pyrimidin-2(1H)-one|Cytidine Analog RX-3117|Fluorocyclopentenylcytosine|RODUCITABINE|RX-3117|TV-1360	An orally available small molecule and nucleoside antimetabolite with potential antineoplastic activity. Upon administration, roducitabine is taken up by cells through a carrier-mediated transporter, phosphorylated by uridine cytidine kinase (UCK) and then further phosphorylated to its diphosphate (RX-DP) and triphosphate forms (RX-TP). The triphosphate form is incorporated into RNA and inhibits RNA synthesis. The diphosphate RX-DP is reduced by ribonucleotide reductase (RR) to dRX-DP; its triphosphate form (dRX-TP) is incorporated into DNA. In addition, roducitabine also inhibits DNA methyltransferase 1 (DNMT1). This eventually leads to cell cycle arrest and the induction of apoptosis. UCK is the rate-limiting enzyme in the pyrimidine-nucleotide salvage pathway.	Roducitabine		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113445>	C21514	Ever|At Any Time	At any time in the past, present, or future.			Qualitative Concept	
C113446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113446>	C217122	International Prostate Symptom Score|I-PSS|I-PSS|IPS01|IPSS	A screening tool used to screen for, diagnose, track, and manage the symptoms of benign prostatic hyperplasia.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113447>	C85969	Megamonas|MEGAMONAS	A genus of anaerobic, Gram negative, rod shaped bacteria assigned to the phylum Firmicutes and the family Veillonellaceae.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113448>	C91105|C21154	Dexamethasone Symptom Questionnaire|DSQ	A self-administered questionnaire designed to determine the incidence, severity, and change of side effects between cycles of chemotherapy.			Intellectual Product	
C113449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113449>	C91105|C21154	Dexamethasone Symptom Questionnaire-Chronic|DSQ-Chronic	A self-administered questionnaire for patients with brain tumors that is designed to determine the incidence, severity, and change of side effects between cycles of chemotherapy.			Intellectual Product	
C11344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11344>	C61063	Bleomycin/Cyclophosphamide/Dexrazoxane/Doxorubicin/Etoposide/Prednisone/Vincristine|ADR-529/BLEO/CTX/DOX/PRED/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113450>	C173518	Have Indigestion, Heartburn, Reflux, or Discomfort in Upper Abdomen Question|Did you have indigestion/heartburn/reflux or discomfort in the upper abdomen|Have Indigestion, Heartburn, Reflux, or Discomfort in Upper Abdomen	A question about whether an individual has or had indigestion, heartburn, reflux, or discomfort in the upper abdomen.			Intellectual Product	Dexamethasone Symptom Questionnaire-Chronic|Dexamethasone Symptom Questionnaire
C113451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113451>	C173981	Have Increased Appetite Question|Have Increased Appetite|Have you had increased appetite|Increased Appetite|Increased Appetite	A question about whether an individual has or had increased appetite.			Intellectual Product	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|Dexamethasone Symptom Questionnaire-Chronic|Dexamethasone Symptom Questionnaire
C113452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113452>	C173981	Have Hiccups Question|Have Hiccups|Have you had hiccups	A question about whether an individual has or had hiccups.			Intellectual Product	Dexamethasone Symptom Questionnaire-Chronic|Dexamethasone Symptom Questionnaire
C113453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113453>	C173981	Have Gained Weight Question|Gained Weight|Gaining Weight|Have Gained Weight|Have Weight Gain|Have you gained weight|I have gained weight|Weight Gain	A question about whether an individual is gaining or has gained weight.			Intellectual Product	Dexamethasone Symptom Questionnaire-Chronic|Dexamethasone Symptom Questionnaire|FACT-ES Questionnaire|Quality of Life Questionnaire - Head & Neck 35
C113454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113454>	C173981	Have Rash or Acne on Face Question|Have Rash or Acne on Face|Have you had a rash/acne on your face	A question about whether an individual has or had a rash or acne on their face.			Intellectual Product	Dexamethasone Symptom Questionnaire-Chronic|Dexamethasone Symptom Questionnaire
C113455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113455>	C173981	Have Thrush Question|Have Thrush|Have you had thrush/yeast infection in your mouth	A question about whether an individual has or had an oral yeast infection.			Intellectual Product	Dexamethasone Symptom Questionnaire-Chronic|Dexamethasone Symptom Questionnaire
C113456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113456>	C175990|C173160	Depression After Stopping Dexamethasone Question|Depression After Stopping Dexamethasone|Did you experience feelings of depression on stopping the dexamethasone	A question about whether an individual had depression after stopping the use of dexamethasone.			Intellectual Product	Dexamethasone Symptom Questionnaire-Chronic|Dexamethasone Symptom Questionnaire
C113457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113457>	C173981	Have Increased Roundness of Face Question|Have Increased Roundness of Face|Have you noticed increased roundness of your face	A question about whether an individual has or had an increased roundness of their face.			Intellectual Product	Dexamethasone Symptom Questionnaire-Chronic|Dexamethasone Symptom Questionnaire
C113458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113458>	C173981	Have Low Mood, Sadness, or Depression Question|Have Low Mood, Sadness, or Depression|Have you experienced low mood, sadness, depression and/or easy crying	A question about whether an individual has or had a low mood, sadness, depression, or easy crying.			Intellectual Product	Dexamethasone Symptom Questionnaire-Chronic|Dexamethasone Symptom Questionnaire
C113459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113459>	C173981	Have Increased Anger or Irritability Question|Have Inability to Complete Hobbies or Leisure Activities|Have Increased Anger or Irritability|Have you experienced increased levels of anger or irritability	A question about whether an individual has or had an increase in anger or irritability.			Intellectual Product	Dexamethasone Symptom Questionnaire-Chronic|Dexamethasone Symptom Questionnaire
C11345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11345>	C61063	Doxorubicin HCl Liposome/PSC 833|Lipodox/PSC 833			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113460>	C173398	Have Difficulty Standing from a Seated Position or Walking Up Stairs Question|Have Difficulty Standing from a Seated Position or Walking Up Stairs|Have you had difficulty standing from a seated position or walking up stairs	A question about whether an individual has or had difficulty standing from a seated position or walking up stairs.			Intellectual Product	Dexamethasone Symptom Questionnaire-Chronic|Dexamethasone Symptom Questionnaire
C113461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113461>	C173981	Have Problem with Fragile Skin or Bruising Question|Have Problem with Fragile Skin or Bruising|Have you had problems with your skin being fragile, developed stretch marks or easily bruised	A question about whether an individual has or had a problem with their skin being fragile, easily bruised, or developing stretch marks.			Intellectual Product	Dexamethasone Symptom Questionnaire-Chronic|Dexamethasone Symptom Questionnaire
C113463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113463>	C173812	Diabetes Diagnosis Since Steroid Treatment Question|Diabetes Diagnosis Since Steroid Treatment|Was the diabetes diagnosed since you started steroids (e.g. dexamethasone, prednisone)	A question about whether an individual's diabetes was diagnosed after they started steroid treatment.			Intellectual Product	Dexamethasone Symptom Questionnaire-Chronic|Dexamethasone Symptom Questionnaire
C113464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113464>	C173398	Have Trouble Controlling Blood Sugar Question|Have Trouble Controlling Blood Sugar|Have you had trouble controlling your blood sugars	A question about whether an individual has or had trouble controlling their blood sugar.			Intellectual Product	Dexamethasone Symptom Questionnaire-Chronic|Dexamethasone Symptom Questionnaire
C113465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113465>	C173981	Have Problems Attributed to Steroids Question|Have Problems Attributed to Steroids|Have Problems Due to Steroids|Problem Noticed due to Steriod Use|What other problems have you noticed due to steroids	A question about whether an individual has or had other problems they attribute to their steroid use.			Intellectual Product	Dexamethasone Symptom Questionnaire-Chronic|Dexamethasone Symptom Questionnaire
C113466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113466>	C173457|C172982	Most Bothersome Symptom Attributed to Steroids Question|List the most bothersome symptom you've experienced due to steriods|Most Bothersome Symptom Attributed to Steroids|Most Bothersome Symptom Due to Steroids	A question about an individual's most bothersome symptom attributed to steroid use.			Intellectual Product	Dexamethasone Symptom Questionnaire-Chronic|Dexamethasone Symptom Questionnaire
C113467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113467>	C637	Platinum-Group Metal|PGE|PGM|Platidise|Platinide|Platinoid|Platinum Family|Platinum Group|Platinum Metal|Platinum-Group Element	Six transition metals (iridium, osmium, palladium, platinum, rhodium, and ruthenium) clustered in the d-block of the periodic table (groups 8, 9, and 10, periods 5 and 6) with potential antibiotic and chemotherapeutic activities. Administration of agents containing platinum-group metals can produce DNA crosslinks and adducts in rapidly dividing cells, which can lead to bacterial lysis or eukaryotic cell apoptosis. Additionally, these elements are highly resistant to chemical and thermal challenges, which allow these metals to be used in many industrial applications.	Platinum-Group Metal		Inorganic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C113468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113468>	C91105	Hearing Handicap Inventory for the Elderly, Screening Version|HHIE-S|Hearing Handicap Inventory for the Elderly Screening Version|Screening Version of the Hearing Handicap Inventory for the Elderly	A 10-item questionnaire developed to assess how an individual perceives the social and emotional effects of hearing loss. It is designed to be administered face-to-face but can be given as a paper, self-reported instrument.			Intellectual Product	
C113469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113469>	C2980	Esophageal Dysphagia	Difficulty in swallowing due to an abnormality in the esophagus.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11346>	C61063	Amifostine/Busulfan/Melphalan/Thiotepa|BU/L-PAM/TSPA/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113470>	C173601|C173059	Hearing Problem Causes Embarrassment When Meeting New People Question|Does a hearing problem cause you to feel embarrassed when you meet new people|Feel Embarrassed When Meeting New People Due to Hearing Problem	A question about whether an individual's hearing problem causes them embarrassment when meeting new people.			Intellectual Product	Hearing Handicap Inventory for the Elderly, Screening Version|Hearing Handicap Inventory for the Elderly
C113471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113471>	C173151|C173059	Hearing Problem Causes Frustration When Talking with Family Question|Does a hearing problem cause you to feel frustrated when talking to members of your family|Feel Frustrated When Talking to Members of Family Due to Hearing Problem|Hearing Problem Causes Frustration When Talking with Family	A question about whether an individual's hearing problem causes them frustration when talking with family members.			Intellectual Product	Hearing Handicap Inventory for the Elderly, Screening Version|Hearing Handicap Inventory for the Elderly
C113472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113472>	C173398|C173059	Difficulty Hearing a Whisper Question|Difficulty Hearing a Whisper|Do you have difficulty hearing when someone speaks in a whisper|Have Difficulty Hearing When Someone Speaks in a Whisper	A question about whether an individual has or had difficulty hearing when someone speaks in a whisper.			Intellectual Product	Hearing Handicap Inventory for the Elderly, Screening Version|Hearing Handicap Inventory for the Elderly
C113473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113473>	C173160|C173059	Feel Handicapped by Hearing Problem Question|Do you feel handicapped by a hearing problem|Feel Handicapped by Hearing Problem	A question about whether an individual feels handicapped by their hearing problem.			Intellectual Product	Hearing Handicap Inventory for the Elderly, Screening Version|Hearing Handicap Inventory for the Elderly
C113474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113474>	C173398|C173059	Hearing Problem Causes Difficulty When Visiting with People Question|Difficulty Visiting Friends, Relatives or Neighbors Due to Hearing Problem|Does a hearing problem cause you difficulty when visiting friends, relatives or neighbors|Hearing Problem Causes Difficulty When Visiting with People	A question about whether an individual's hearing problem causes difficulty when visiting with people.			Intellectual Product	Hearing Handicap Inventory for the Elderly, Screening Version|Hearing Handicap Inventory for the Elderly
C113475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113475>	C173059|C173058	Hearing Problem Causes Problem Attending Religious Services Question|Attend Religious Services Less Often than Like Due to Hearing Problem|Does a hearing problem cause you to attend religious services less often than you would like|Hearing Problem Causes Problem Attending Religious Services	A question about whether an individual's hearing problem causes them to attend religious services less often than desired.			Intellectual Product	Hearing Handicap Inventory for the Elderly, Screening Version|Hearing Handicap Inventory for the Elderly
C113476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113476>	C173151|C173059	Hearing Problem Causes Arguments with Family Question|Does a hearing problem cause you to have arguments with family members|Hearing Problem Causes Arguments with Family|Hearing Problem Causes Arguments with Family Members	A question about whether an individual's hearing problem causes arguments with family members.			Intellectual Product	Hearing Handicap Inventory for the Elderly, Screening Version|Hearing Handicap Inventory for the Elderly
C113477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113477>	C173398|C173059	Hearing Problem Causes Difficulty When Listening to TV or Radio Question|Difficulty Listening to TV or Radio Due to Hearing Problem|Does a hearing problem cause you difficulty when listening to TV or radio|Hearing Problem Causes Difficulty When Listening to TV or Radio	A question about whether an individual's hearing problem causes difficulty when listening to TV or radio.			Intellectual Product	Hearing Handicap Inventory for the Elderly, Screening Version|Hearing Handicap Inventory for the Elderly
C113478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113478>	C173695|C173398|C173059	Hearing Problem Limits Personal or Social Life Question|Do you feel that any difficulty with your hearing limits or hampers your personal or social life|Hearing Problem Limits Personal or Social Life|Personal or Social Life Hampered Due to Hearing Problem	A question about whether an individual's difficulty with hearing limits their personal or social life.			Intellectual Product	Hearing Handicap Inventory for the Elderly, Screening Version|Hearing Handicap Inventory for the Elderly
C113479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113479>	C173398|C173059	Hearing Problem Causes Difficulty in a Restaurant Question|Difficulty in Restaurant with Relatives or Friends Due to Hearing Problem|Does a hearing problem cause you difficulty when in a restaurant with relatives or friends|Hearing Problem Causes Difficulty in a Restaurant	A question about whether an individual's hearing problem causes difficulty when in a restaurant.			Intellectual Product	Hearing Handicap Inventory for the Elderly, Screening Version|Hearing Handicap Inventory for the Elderly
C11347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11347>	C61063	Ifosfamide/Topotecan|IFF/TOPO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113480>	C3442	Projectile Vomiting	Forceful expulsion of the contents of the stomach through the mouth.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113481>	C34494|C118807	Infantile Colic|Colic|Infant Colic|Infant Colic	Paroxysms of irritability, fussing or crying that starts and stops without obvious cause in an infant up to four months of age without failure to thrive. Episodes last three or more hours per day for at least three days per week for at least on week.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C113482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113482>	C26682	Abdominal Migraine	Paroxysmal episodes of intense, acute periumbilical pain that lasts for one or more hours with intervening periods of usual health lasting weeks to months, with no evidence of an inflammatory, anatomic, metabolic, or neoplastic process that explains the symptoms. The pain interferes with normal activities and is associated with at least two of the following symptoms: anorexia, nausea, vomiting, headache, photophobia, and/or pallor.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113483>	C36279	Malabsorption	Inadequate absorption of nutrients in the small intestine.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113484>	C36279	Intussusception|INTUSSUSCEPTION	Telescoping or invagination of a part of the intestine into an adjacent segment.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113485>	C98996	Diabetic Embryopathy	A condition in which the offspring of a mother with diabetes predating pregnancy develops congenital malformations that can affect multiple organ systems including the brain and spinal cord, the heart and major vessels, the kidneys, the gut, and skeletal structures.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C113486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113486>	C92711	Fetal Macrosomia	A fetus exceeding 4500 grams.			Finding	NICHD Terminology|Perinatal Terminology
C113487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113487>	C34941	Non-Rh Blood Group Isoimmunization|Blood Group Isoimmunization	The mother develops antibodies against red blood cell non-Rhesus antigens. This may lead to potential fetal adverse outcomes such as anemia.			Finding	NICHD Terminology|Perinatal Terminology
C113488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113488>	C92720	Braxton-Hicks Contraction|Braxton-Hicks Contractions|Braxton-Hicks Contractions|False Labor|Preterm Contractions	Irregular infrequent uterine contractions typically characteristic of the third trimester of pregnancy that do not result in cervical change or labor.			Finding	NICHD Terminology|Perinatal Terminology
C113489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113489>	C92718	Time of Onset of Labor|Time of the Onset of Labor|Time of the Onset of Labor	The time when regular uterine contractions began that resulted in labor with or without the use of pharmacological and/or mechanical interventions. (reVITALize)			Finding	NICHD Terminology|Perinatal Terminology
C11348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11348>	C61063	Cytarabine/Daunorubicin/Etoposide/PSC 833|ARA-C/DNR/PSC 833/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113490>	C92718	Spontaneous Onset of Labor	Labor without the use of pharmacological and/or mechanical interventions to initiate labor. Does not apply if artificial rupture of membranes is performed before the onset of labor. (reVITALize)			Finding	NICHD Terminology|Perinatal Terminology
C113491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113491>	C34941	Precipitous Birth	Unexpectedly sudden vaginal delivery.			Finding	NICHD Terminology|Perinatal Terminology
C113492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113492>	C92718	Dysfunctional Labor|Arrest of Dilatation|Arrest of Dilatation|Failure to Progress|Failure to Progress|Labor Dystocia|Labor Dystocia	Uterine contractions (less than 3 in 10 minutes or inadequate strength) that do not result in progressive cervical dilation.			Finding	GAIA Dysfunctional Labor Level of Diagnostic Certainty Terminology|GAIA Terminology|NICHD Terminology|Perinatal Terminology
C113493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113493>	C92904	Tetanic Contraction	A single uterine contraction lasting greater than 2 minutes.			Sign or Symptom	NICHD Terminology|Perinatal Terminology
C113494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113494>	C92724	Funic Presentation|Cord Presentation|Cord Presentation|Funis Presentation|Funis Presentation	The positioning of the umbilical cord before the main presenting part of the fetus.			Finding	NICHD Terminology|Perinatal Terminology
C113495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113495>	C92793	Brow Presentation	A fetal presentation during delivery in which the brow of the fetus is first to descend into the birth canal.			Finding	NICHD Terminology|Perinatal Terminology
C113496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113496>	C26797	Neonatal Hyperglycemia	Blood glucose concentration above the upper limit of established reference ranges in a newborn.			Laboratory or Test Result	NICHD Terminology|Perinatal Terminology
C113497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113497>	C16048	Terminology Value Set|Value Set|Value Set	Terms drawn from one or more terminologies and defined as a separate set, generally for specific coding purposes and given a formal designation.			Intellectual Product	CareLex eTMF Terminology
C113498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113498>	C709	AICA-Ribotide|1-(5'-Phosphoribosyl)-5-Amino-4-Imidazolecarboxamide|1H-Imidazole-4-Carboxamide, 5-Amino-1-(5-O-Phosphono-Beta-D-Ribofuranosyl)- (9CI)|5'-Phospho-Ribosyl-5-Amino-4-Imidazole Carboxamide|5'-Phosphoribosyl-5-Amino-4-Imidazolecarboxamide|5-Amino-1-(5-O-Phosphono-Beta-D-Ribofuranosyl)-1H-Imidazole-4-Carboxamide|5-Amino-1-(5-Phospho-D-Ribosyl)Imidazole-4-Carboxamide|5-Amino-4-Imidazole Carboxamide Ribonucleotide|5-Amino-4-Imidazolecarboxamide Ribonucleoside 5'-Monophosphate|5-Amino-4-Imidazolecarboxamide Ribotide|5-Aminoimidazole-4-Carboxamide Ribonucleotide|5-Phosphoribosyl-4-Carbamoyl-5-Aminoimidazole|AICA Ribonucleotide|AICA Ribotide|AICAR|Aminoimidazole Carboxamide Ribonucleotide|Imidazole-4-Carboxamide, 5-Amino-1-Beta-D-Ribofuranosyl-, 5'-(Dihydrogen Phosphate) (8CI)|ZMP|[(2R,3S,4R,5R)-5-(4-Carbamoyl-5-Aminoimidazol-1-yl)-3,4-Dihydroxyoxolan-2-yl]Methyl Dihydrogen Phosphate	A ribonucleotide analog of adenosine monophosphate that is an intermediate in the synthesis of inosine monophosphate with potential cardioprotective activity. During myocardial ischemia, AICA-ribotide activates AMP-dependent protein kinase (AMPK), inhibits adenosine deaminase (ADA) and causes increased synthesis of both adenosine and adenosine triphosphate (ATP). These activities prevent calcium overload, increase AMPK-dependent glucose uptake and improve blood flow to the heart. AMPK, a protein kinase complex, regulates several cellular systems including the uptake of glucose, the beta-oxidation of fatty acids, protein synthesis, and the biogenesis of both glucose transporter 4 (GLUT4) and mitochondria. ADA is a key enzyme involved in purine metabolism.	AICA-Ribotide		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology
C113499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113499>	C48572	Point|POINT|{POINT}|{POINT}|{point}|{point}	A numeric unit used to quantify a score.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11349>	C61063	Mitoxantrone/Vinorelbine|DHAD/VNB			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1134>	C25760	Indicine-N-Oxide|2,3-Dihydroxy-2-(1-methylethyl)butanoic Acid (2,3,5,7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl)methyl Ester N-Oxide|Butanoic Acid, 2,3-Dihydroxy-2-(1-methylethyl)- (2,3,5, 7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl) Methyl Ester, N-Oxide,(1R-(1alpha,7(2R*,3S*),7a-beta))-(9CI)|Butanoic acid, 2,3-dihydroxy-2-(1-methylethyl)- (2,3,5, 7a-tetrahydro-1-hydroxy-1H-pyrrolizin-7-yl) methyl ester, N-oxide, (1R-(1alpha,7(2R*,3S*),7a-beta))-(9CI)|INDICINE N-OXIDE|Indicine N-Oxide|Indicine N-oxide|Indicine, N-oxide	A natural pyrrolizidine alkaloid with antineoplastic properties.  Indicine-N-oxide alkylates and crosslinks DNA. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113500>	C25256	Prepared Material|Preparation	The amount of material produced by an activity.			Quantitative Concept	
C113501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113501>	C231	Sarcosine|(Methylamino)Acetic Acid|(Methylamino)Ethanoic Acid|Acetic Acid, (Methylamino)-|Glycine, N-Methyl-|Methylglycine|N-Methylaminoacetic Acid|N-Methylglycine|SARCOSINE|Sarcosinic Acid	An amino acid that is an intermediate and byproduct in glycine synthesis and degradation with potential anti-depressant and anti-schizophrenic activities. Sarcosine is a product of dietary consumption of choline and creatine and is rapidly converted into glycine. Oral administration of sarcosine with certain antipsychotics may cause increased glycine concentration in the brain, which may lead to increased NMDA receptor activation and a reduction in symptoms.	Sarcosine		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C113502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113502>	C33058	Regulatory B Cell|Breg|Bregs|Regulatory B Lymphocyte|Regulatory B-Cell|Regulatory B-Lymphocyte	A subset of B-cells that can negatively regulate immune responses mediated by T-cells. These B-lymphocytes produce interleukin-10.	Regulatory B Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C113503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113503>	C12549	Immature Myeloid Cell|IMC|ImC	Hematopoietic cells that express the common myeloid marker CD33 but do not express the MHC class II molecule HLA-DR or other markers of mature myeloid or lymphoid cells. An accumulation of these cells may be associated with a decreased number of dendritic cells in the peripheral blood of patients with head and neck, lung or breast cancer.	Immature Myeloid Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C113504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113504>	C95146|C199394|C188129|C186904	t(14;16)(q32;q23)|IGH-MAF Translocation|IGH/MAF Translocation	A chromosomal translocation between 14q32 and 16q23. This rearrangement is associated with MAF protein overexpression in plasma cell myeloma.	t(14;16)(q32;q23)		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113505>	C3420|C180942	t(9;11)	A translocation between chromosome 9 and chromosome 11.	t(9;11)		Cell or Molecular Dysfunction	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C113506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113506>	C36448	Absence of Biallelic TCRgamma Deletion|ABD|Absence of Biallelic TCRgamma Locus Deletion	The absence of rearrangement of at least one allele of the T-cell receptor gamma gene locus. This lack of rearrangement is characteristic of early thymocyte precursors and a lack of V(D)J recombination. This genetic profile is a predictor of induction therapy failure in children with T-cell acute lymphoblastic leukemia.	Absence of Biallelic TCRgamma Deletion		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113507>	C198980|C122623	KMT2A Partial Tandem Duplication|KMT2A PTD|KMT2A Partial-Tandem Duplication|KMT2A-PTD|MLL PTD|MLL Partial Tandem Duplication|MLL-PTD|Partial Tandem Duplication of MLL	A chromosomal rearrangement where exons 5 through 11 or 5 through 12 of the MLL gene are duplicated and inserted upstream of exon 4 of the gene. This duplication results in transcripts and proteins that have the N-terminal region, which contains the AT hook DNA-binding motifs, and the transcriptional repression domain duplicated. This mutation is associated with myelodysplastic syndrome (MDS) and susceptibility of MDS progression to acute myeloid leukemia.	MLL Partial Tandem Duplication		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C113508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113508>	C101143	Cytomegalovirus MicroRNA|CMV miRNA|CMV microRNA|Cytomegalovirus miRNA	A sequence of single-stranded RNA, which is 20-25 nucleotides in length, that is transcribed from cytomegalovirus DNA but is not translated into a protein. This nucleic acid may regulate the transcription or translation of other cytomegalovirus or host genes.	Cytomegalovirus MicroRNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology
C113509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113509>	C813	Cytomegalovirus mRNA|CMV mRNA|Cytomegalovirus Messenger RNA	Any RNA molecule expressed by a cytomegalovirus strain that contains protein-coding information in its nucleotide sequence that can be translated into the amino acid sequence of a protein.	Cytomegalovirus mRNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology
C11350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11350>	C61007	Docetaxel/Fluorouracil|5-FU/TXT			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113510>	C16295	ROR1 Antibody|Anti-NTRKR1 Antibody|Anti-ROR1 Antibody|Anti-Receptor Tyrosine Kinase-Like Orphan Receptor 1 Antibody|Anti-Tyrosine-Protein Kinase Transmembrane Receptor ROR1 Antibody|NTRKR1 Antibody|Receptor Tyrosine Kinase-Like Orphan Receptor 1 Antibody|Tyrosine-Protein Kinase Transmembrane Receptor ROR1 Antibody	Any immunoglobulin that recognizes tyrosine-protein kinase transmembrane receptor ROR1.	ROR1 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113511>	C212851	TMPRSS2/ETS Family Fusion Gene|TMPRSS2-ETS Family Fusion Gene|TMPRSS2-ETS Fusion Gene|TMPRSS2-ETS Transcription Factor Family Fusion Gene|TMPRSS2-ETS Transcription Factor Gene Fusion Gene|TMPRSS2/ETS Fusion Gene|TMPRSS2/ETS Transcription Factor Family Fusion Gene|TMPRSS2/ETS Transcription Factor Gene Fusion Gene|TMPRSS2::ETS Family Fusion Gene	A fusion gene that results from a chromosomal translocation which fuses the 5' end of the TMPRSS2 gene upstream of the coding region of an ETS family gene. This rearrangement is associated with prostate carcinoma and androgen-dependent expression of this fusion gene results in overexpression of ETS transcription factor family proteins.	TMPRSS2/ETS Family Fusion Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113512>	C188022	IGH/CRLF2 Fusion Gene|IGH-CRLF2 Fusion Gene|IGH::CRLF2 Fusion Gene	A fusion gene that results from a chromosomal translocation, either t(X;14)(p22;q32) or t(Y;14)(p11;q32), which fuses the transcriptional enhancers of the IGH gene locus with regulatory regions of the CRLF2 gene. This rearrangement is associated with acute lymphoblastic leukemia and expression of this fusion gene results in overexpression of the cytokine receptor-like factor 2 protein.	IGH/CRLF2 Fusion Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113513>	C20706	HLA-A Gene Product	A protein encoded by the human HLA-A gene.	HLA-A Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113514>	C105976	HLA Class I Histocompatibility Antigen, A-2402 Alpha Chain|A*24:02|A*24:02:01:01|HLA Class I Histocompatibility Antigen, A*24:02 Alpha Chain|HLA-A*2402|HLA-A*2402101|HLA-A24.2|HLA-A2402|HLA-A2402 Antigen|Leukocyte Antigen Class I-A2402|MHC Class I Antigen A*2402|MHC Class I Antigen HLA-A2402 Heavy Chain|Major Histocompatibility Complex, Class I, A*2402|Major Histocompatibility Complex, Class I, A2402	HLA class I histocompatibility antigen, A-2402 alpha chain (365 aa, ~41 kDa) is encoded by the human HLA-A gene. This protein is involved in the presentation of foreign antigens to the immune system. This isoform is associated with increased risk of type 1 diabetes and thymoma-induced myasthenia gravis.	HLA Class I Histocompatibility Antigen, A-2402 Alpha Chain		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113515>	C18520	Bone Specific Alkaline Phosphatase|Alkaline Phosphatase, Bone Specific|BAP|BSAP|Bone Alkaline Phosphatase|Bone-Specific Alkaline Phosphatase|bALP	An isoform of alkaline phosphatase found on the surface of osteoblasts. The level of this enzyme in a patient's serum is proportional to the amount of bone formation. This marker is used for monitoring the efficacy of both bone formation therapies and antiresorptive therapies.	Bone Specific Alkaline Phosphatase		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113516>	C1746	INS Gene Product	A protein encoded by the human INS gene.	INS Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113517>	C113516	Proinsulin|INS|Insulin Precursor	Proinsulin (110 aa, ~12 kDa) is encoded by the human INS gene. This protein plays a role in the modulation of glucose metabolism.	Proinsulin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113518>	C21295	SCGB2A2 Gene|SCGB2A2|SCGB2A2|Secretoglobin Family 2A Member 2 Gene	This gene may be involved in mammary development.	SCGB2A2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113519>	C25404	Apply|Application|Applied	Putting something to a special use or purpose.			Activity	
C11351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11351>	C61063	Carboplatin/Thiotepa/Topotecan|CBDCA/TOPO/TSPA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113520>	C113518	SCGB2A2 wt Allele|MGB1|Secretoglobin Family 2A Member 2 wt Allele|Secretoglobin, Family 2A, Member 2 Gene|UGB2	Human SCGB2A2 wild-type allele is located in the vicinity of 11q13 and is approximately 3 kb in length. This allele, which encodes mammaglobin-A protein, may play a role in mammary gland development and differentiation.	SCGB2A2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113521>	C17728	Mammaglobin-A|Mammaglobin 1|Mammaglobin A|Mammaglobin-1|SCGB2A2|Secretoglobin 2A2|Secretoglobin Family 2A Member 2	Mammaglobin-A (93 aa, ~10 kDa) is encoded by the human SCGB2A2 gene. This protein may be involved in the development of mammary glands.	Mammaglobin-A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113522>	C25790	JCHAIN Gene|IGJ|JCHAIN|JCHAIN|Joining Chain of Multimeric IgA and IgM Gene	This gene plays a role in antibody-mediated immunity.	JCHAIN Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113523>	C113522	JCHAIN wt Allele|IGCJ|IGJ|Immunoglobulin J Polypeptide, Linker Protein for Immunoglobulin Alpha and Mu Polypeptides Gene|JCH|Joining Chain of Multimeric IgA and IgM wt Allele	Human JCHAIN wild-type allele is located the vicinity of 4q13.3 and is approximately 23 kb in length. This allele, which encodes immunoglobulin J chain protein, is involved in the joining of antibody monomer chains. Mutations in this gene are associated with both renal artery obstruction and fibromuscular dysplasia.	JCHAIN wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113524>	C28533	SLC6A3 Gene|SLC6A3|SLC6A3|Solute Carrier Family 6 (Neurotransmitter Transporter), Member 3 Gene	This gene plays a role in dopamine uptake.	SLC6A3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113525>	C16725	Immunoglobulin J Chain|IgJ Chain|J Chain|JCHAIN|Joining Chain of Multimeric IgA and IgM	Immunoglobulin J chain (159 aa, ~18 kDa) is encoded by the human JCHAIN gene. This protein plays a role in the joining of antibody structures.	Immunoglobulin J Chain		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113526>	C20194	SPATS2L Gene|SPATS2L|SPATS2L|Spermatogenesis Associated, Serine-Rich 2-Like Gene	This gene is involved in protection from oxidative stress.	SPATS2L Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113527>	C113524	SLC6A3 wt Allele|DAT|DAT1|PKDYS|Solute Carrier Family 6 (Neurotransmitter Transporter), Member 3 wt Allele|Solute Carrier Family 6 (Neurotransmitter Transporter, Dopamine), Member 3 Gene	Human SLC6A3 wild-type allele is located in the vicinity of 5p15.3 and is approximately 53 kb in length. This allele, which encodes sodium-dependent dopamine transporter protein, is involved in sodium-dependent internalization of dopamine. Mutation of the gene is associated with infantile Parkinsonism-dystonia.	SLC6A3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113528>	C113526	SPATS2L wt Allele|DNAPTP6|SGNP|Spermatogenesis Associated, Serine-Rich 2-Like wt Allele|Spermatogenesis-Associated, Serine-Rich 2-Like Gene	Human SPATS2L wild-type allele is located in the vicinity of 2q33.1 and is approximately 201 kb in length. This allele, which encodes SPATS2-like protein, plays a role in protecting myoblasts from oxidative stress.	SPATS2L wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113529>	C18466	SPATS2-Like Protein|DNA Polymerase Transactivated Protein 6|DNA Polymerase-Transactivated Protein 6|Stress Granule And Nucleolar Protein	SPATS2-Like protein (558 aa, ~62 kDa) is encoded by the human SPATS2L gene. This protein is involved in oxidative stress protection in myoblasts.	SPATS2-Like Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11352>	C61063	Amifostine/Cisplatin/Cytarabine/Dexamethasone|ARA-C/CDDP/DM/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113530>	C16386	Sodium-Dependent Dopamine Transporter|DA Transporter|DAT|Dopamine Transporter|Dopamine Transporter 1|SLC6A3|Solute Carrier Family 6 Member 3	Sodium-dependent dopamine transporter (620 aa, ~68 kDa) is encoded by the human SLC6A3 gene. This protein plays a role in the downregulation of dopamine signaling.	Sodium-Dependent Dopamine Transporter		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113531>	C21282	CA6 Gene|CA6|CA6|Carbonic Anhydrase VI Gene	This gene plays a role in the reversible hydration of carbon dioxide.	CA6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113532>	C113531	CA6 wt Allele|CA-VI|Carbonic Anhydrase VI wt Allele|GUSTIN|RP3-477M7.7	Human CA6 wild-type allele is located in the vicinity of 1p36.2 and is approximately 29 kb in length. This allele, which encodes carbonic anhydrase 6 protein, is involved in the reversible hydration of carbon dioxide. Mutations in this gene are associated with both multilocular clear cell renal cell carcinoma and herpangina.	CA6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113533>	C21295	SCGB1D2 Gene|SCGB1D2|SCGB1D2|Secretoglobin, Family 1D, Member 2 Gene	This gene is involved in steroid binding.	SCGB1D2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113534>	C16804	Carbonic Anhydrase 6|CA-IV|CA6|Carbonate Dehydratase VI|Carbonic Anhydrase IV|Carbonic Anhydrase, Secreted|EC 4.2.1.1|GUSTIN|Salivary Carbonic Anhydrase|Secreted Carbonic Anhydrase	Carbonic anhydrase 6 (308 aa, ~35 kDa) is encoded by the human CA6 gene. This protein plays a role in the reversible hydration of carbon dioxide.	Carbonic Anhydrase 6		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113535>	C113533	SCGB1D2 wt Allele|LIPB|LIPHB|LPHB|LPNB|Lipophilin B (Uteroglobin Family Member), Prostatein-Like Gene|Secretoglobin, Family 1D, Member 2 wt Allele	Human SCGB1D2 wild-type allele is located in the vicinity of 11q13 and is approximately 3 kb in length. This allele, which encodes secretoglobin family 1D member 2 protein, plays a role in androgen binding.	SCGB1D2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113536>	C20988	NRXN3 Gene|NRXN3|NRXN3|Neurexin 3 Gene	This gene is involved in cell recognition and cell adhesion.	NRXN3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113537>	C17728	Secretoglobin Family 1D Member 2|Lipophilin B|Lipophilin-B|Prostatein-Like Lipophilin B|Secretoglobin 1D2	Secretoglobin family 1D member 2 (90 aa, ~10 kDa) is encoded by the human SCGB1D2 gene. This protein is involved in binding to androgens and other steroids.	Secretoglobin Family 1D Member 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113538>	C113536	NRXN3 wt Allele|C14orf60|Chromosome 14 Open Reading Frame 60 Gene|KIAA0743|Neurexin 3 wt Allele	Human NRXN3 wild-type allele is located in the vicinity of 14q31 and is approximately 1622 kb in length. This allele, which encodes neurexin-3 protein, plays a role in cell adhesion and cell recognition. Genetic variations at this locus have been associated with alcohol dependence and autism spectrum disorder.	NRXN3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113539>	C126710	Neurexin-3|Neurexin III|Neurexin III-Alpha|Neurexin-3-Alpha	Neurexin-3 (1643 aa, ~181 kDa) is encoded by the human NRXN3 gene. This protein is involved in cell recognition and cell adhesion.	Neurexin-3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11353>	C61063	Interleukin-2/Sargramostim/Vinblastine|GM-CSF/IL-2/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113540>	C20923	GPR101 Gene|G Protein-Coupled Receptor 101 Gene|GPR101|GPR101	This gene may play a role in receptor signaling.	GPR101 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113541>	C113540	GPR101 wt Allele|G Protein-Coupled Receptor 101 wt Allele|GPCR6	Human GPR101 wild-type allele is located in the vicinity of Xq26.3 and is approximately 2 kb in length. This allele, which encodes probable G-protein coupled receptor 101 protein, may be involved in G protein-coupled receptor signaling.	GPR101 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113542>	C18239	Probable G-Protein Coupled Receptor 101|G Protein-Coupled Receptor 101|G-Protein Coupled Receptor 101|GPR101|Probable G Protein-Coupled Receptor 101	Probable G-protein coupled receptor 101 (508 aa, ~57 kDa) is encoded by the human GPR101 gene. This protein may play a role in neuronal G protein-coupled receptor signaling pathways.	Probable G-Protein Coupled Receptor 101		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113543>	C20923	ADGRF1 Gene|ADGRF1|ADGRF1|Adhesion G Protein-Coupled Receptor F1 Gene|GPR110	This gene plays an unknown role in cellular function.	ADGRF1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113544>	C113543	ADGRF1 wt Allele|Adhesion G Protein-Coupled Receptor F1 wt Allele|G Protein-Coupled Receptor 110 Gene|GPR110|KPG_012|PGR19|RP11-39C2.1|hGPCR36	Human ADGRF1 wild-type allele is located in the vicinity of 6p12.3 and is approximately 45 kb in length. This allele, which encodes adhesion G-protein coupled receptor F1 protein, has an unknown cellular function. Mutations in this gene are associated with both prostate cancer and prostatitis.	ADGRF1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113545>	C18239	Adhesion G Protein-Coupled Receptor F1|ADGRF1|G Protein-Coupled Receptor 110|G Protein-Coupled Receptor PGR19|G-Protein Coupled Receptor 110|G-Protein Coupled Receptor KPG_012|G-Protein Coupled Receptor PGR19|Probable G-Protein Coupled Receptor 110|Seven Transmembrane Helix Receptor	Adhesion G-protein coupled receptor F1 (910 aa, ~101 kDa) is encoded by the human ADGRF1 gene. This protein is involved in G protein-coupled receptor signaling, which may be dependent on the removal of its extracellular domain.	Adhesion G Protein-Coupled Receptor F1		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113546>	C26147	UGT8 Gene|UDP Glycosyltransferase 8 Gene|UGT8|UGT8	This gene is involved in galactocerebroside synthesis.	UGT8 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113547>	C20921	CHN2 Gene|CHN2|CHN2|Chimerin 2 Gene	This gene is involved in both the proliferation and migration of smooth muscle cells.	CHN2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113548>	C113547	CHN2 wt Allele|ARHGAP3|BCH|CHN2-3|Chimerin 2 wt Allele|RHOGAP3	Human CHN2 wild-type allele is located in the vicinity of 7p15.3 and is approximately 392 kb in length. This allele, which encodes beta-chimaerin protein, plays a role in both the proliferation and migration of smooth muscle cells. Decreased expression of this gene is associated with high-grade gliomas and breast tumors, and increased expression of this gene is associated with lymphomas. Mutations in this gene have been associated with schizophrenia in men.	CHN2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113549>	C113546	UGT8 wt Allele|CGT|UDP Glycosyltransferase 8 wt Allele|UGT4	Human UGT8 wild-type allele is located in the vicinity of 4q26 and is approximately 80 kb in length. This allele, which encodes 2-hydroxyacylsphingosine 1-beta-galactosyltransferase protein, plays a role in the synthesis of galactocerebrosides.	UGT8 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11354>	C61063	Peptide 946 Melanoma Vaccine/QS21|p946/QS21			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113550>	C17434	2-Hydroxyacylsphingosine 1-Beta-Galactosyltransferase|Ceramide UDP-Galactosyltransferase|Cerebroside Synthase|EC 2.4.1.45|UDP-Galactose Ceramide Galactosyltransferase|UDP-Galactose-Ceramide Galactosyltransferase|UGT8|Uridine Diphosphate Glycosyltransferase 8	2-hydroxyacylsphingosine 1-beta-galactosyltransferase (541 aa, ~61 kDa) is encoded by the human UGT8 gene. This protein is involved in the transfer of galactose to ceramide.	2-Hydroxyacylsphingosine 1-Beta-Galactosyltransferase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113551>	C17298	Beta-Chimaerin|Beta Chimerin|Beta-Chimerin|Beta3-Chimaerin|Chimaerin 2|Chimerin (Chimaerin) 2|Chimerin, Beta-2|GTPase-Activating Protein, Rho, 3|Rho GTPase-Activating Protein 3|Rho-GTPase-Activating Protein 3	Beta-chimaerin (468 aa, ~54 kDa) is encoded by the human CHN2 gene. This protein is involved in both the proliferation and migration of smooth muscle cells.	Beta-Chimaerin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113552>	C20921	SEMA6A Gene|SEMA6A|SEMA6A|Sema Domain, Transmembrane Domain (TM), and Cytoplasmic Domain, (Semaphorin) 6A Gene	This gene plays a role in development of the central nervous system.	SEMA6A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113553>	C113552	SEMA6A wt Allele|HT018|KIAA1368|SEMA|SEMA6A-1|SEMA6A1|SEMAQ|Sema Domain, Transmembrane Domain (TM), and Cytoplasmic Domain, (Semaphorin) wt Allele|VIA	Human SEMA6A wild-type allele is located in the vicinity of 5q23.1 and is approximately 131 kb in length. This allele, which encodes semaphorin-6A protein, is involved in cell-cell signaling and axon guidance in the developing central nervous system. Mutations in this gene are associated with both neuroaxonal dystrophy and mouth disease.	SEMA6A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113554>	C18515	Semaphorin-6A|SEMA6A|Sema VIA|Semaphorin 6A|Semaphorin 6A-1|Semaphorin VIA|Semaphorin-6A-1	Semaphorin-6A (1030 aa, ~114 kDa) is encoded by the human SEMA6A gene. This protein plays a role in axon guidance in the developing central nervous system.	Semaphorin-6A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113555>	C25952	PON2 Gene|PON2|PON2|Paraoxonase 2 Gene	This gene may play a role as a cellular antioxidant.	PON2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113556>	C113555	PON2 wt Allele|PON 2|Paraoxonase 2 wt Allele	Human PON2 wild-type allele is located in the vicinity of 7q21.3 and is approximately 30 kb in length. This allele, which encodes serum paraoxonase/arylesterase 2 protein, may play a role as a cellular antioxidant.	PON2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113557>	C16561	Serum Paraoxonase/Arylesterase 2|A-Esterase 2|Aromatic Esterase 2|EC 3.1.1.2|EC 3.1.1.81|PON2|Paraoxonase 2|Paraoxonase Nirs|Serum Aryldialkylphosphatase 2	Serum paraoxonase/arylesterase 2 (354 aa, ~39 kDa) is encoded by the human PON2 gene. This protein may play a role as a cellular antioxidant.	Serum Paraoxonase/Arylesterase 2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113558>	C20849	S100Z Gene|S100 Calcium Binding Protein Z Gene|S100Z|S100Z	This gene plays a role in calcium ion binding.	S100Z Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113559>	C113558	S100Z wt Allele|Gm625|S100 Calcium Binding Protein Z wt Allele	Human S100Z wild-type allele is located in the vicinity of 5q13.3 and is approximately 72 kb in length. This allele, which encodes protein S100-Z, is involved in calcium ion binding. Mutations in this gene are associated with ulcerative colitis.	S100Z wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11355>	C61063	Peptide 946 Melanoma Vaccine/QS21/Tetanus Peptide Melanoma Vaccine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113560>	C29924	Protein S100-Z|S100 Calcium Binding Protein, Zeta|S100 Calcium-Binding Protein Z|S100 Calcium-Binding Protein, Zeta|S100-zeta|S100Z	Protein S100-Z (99 aa, ~116 kDa) is encoded by the human S100Z gene. This protein plays a role in calcium ion binding.	Protein S100-Z		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113561>	C28533	SLC22A3 Gene|SLC22A3|SLC22A3|Solute Carrier Family 22 (Organic Cation Transporter), Member 3 Gene	This gene is involved in membrane potential-dependent transport of organic cations.	SLC22A3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113562>	C113561	SLC22A3 wt Allele|EMT|EMTH|OCT3|Solute Carrier Family 22 (Organic Cation Transporter), Member 3 wt Allele	Human SLC22A3 wild-type allele is located in the vicinity of 6q25.3 and is approximately 107 kb in length. This allele, which encodes Solute carrier family 22 member 3 protein, plays a role in the disposition of cationic neurotoxins and neurotransmitters in the brain. Mutations in this gene are associated with extragonadal seminoma and placental choriocarcinoma.	SLC22A3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113563>	C16386	Solute Carrier Family 22 Member 3|EMT|Extraneuronal Monoamine Transporter|Organic Cation Transporter 3|SLC22A3|Solute Carrier Family 22 (Extraneuronal Monoamine Transporter), Member 3	Solute carrier family 22 member 3 (556 aa, ~61 kDa) is encoded by the human SLC22A3 gene. This protein is involved in mediating membrane potential-dependent transport of organic cations and may play a role in the disposition of cationic neurotoxins and neurotransmitters in the brain.	Solute Carrier Family 22 Member 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113564>	C28533	SLC47A1 Gene|SLC47A1|SLC47A1|Solute Carrier Family 47 (Multidrug and Toxin Extrusion), Member 1 Gene	This gene plays a role in secretion of cationic drugs across brush border membranes.	SLC47A1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113565>	C113564	SLC47A1 wt Allele|FLJ10847|MATE-1|MATE1|Solute Carrier Family 47 (Multidrug and Toxin Extrusion), Member 1 wt Allele|hMATE-1	Human SLC47A1 wild-type allele is located in the vicinity of 17p11.2 and is approximately 84 kb in length. This allele, which encodes multidrug and toxin extrusion protein 1, is involved in solute transport of cationic drugs across brush border membranes. Mutations in this gene are associated with Smith-Magenis syndrome and lactic acidosis.	SLC47A1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113566>	C16386	Multidrug and Toxin Extrusion Protein 1|MATE-1|Multidrug And Toxin Extrusion 1|SLC47A1|Solute Carrier Family 47 Member 1|Solute Carrier Family 47, Member 1|hMATE-1	Multidrug and toxin extrusion protein 1 (570 aa, ~62 kDa) is encoded by the human SLC47A1 gene. This protein plays a role in transport of cationic drugs across membranes.	Multidrug and Toxin Extrusion Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113567>	C28533	SLC47A2 Gene|SLC47A2|SLC47A2|Solute Carrier Family 47 (Multidrug and Toxin Extrusion), Member 2 Gene	This gene is involved in excretion of toxic electrolytes.	SLC47A2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113568>	C113567	SLC47A2 wt Allele|FLJ31196|MATE-2|MATE2|MATE2-B|MATE2-K|MATE2K|Solute Carrier Family 47 (Multidrug and Toxin Extrusion), Member 2 wt Allele|hMATE-2|hMATE2-K	Human SLC47A2 wild-type allele is located in the vicinity of 17p11.2 and is approximately 41 kb in length. This allele, which encodes multidrug and toxin extrusion protein 2, plays a role in both secretion of cationic drugs across brush border membranes and excretion of toxic electrolytes through urine and bile.	SLC47A2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113569>	C16386	Multidrug and Toxin Extrusion Protein 2|H+/Organic Cation Antiporter|Kidney-Specific H(+)/Organic Cation Antiporter|MATE-2|Multidrug And Toxin Extrusion 2|SLC47A2|Solute Carrier Family 47 Member 2|Solute Carrier Family 47, Member 2|hMATE-2	Multidrug and toxin extrusion protein 2 (602 aa, ~65 kDa) is encoded by the human SLC47A2 gene. This protein is involved in both excretion of toxic electrolytes and secretion of cationic drugs.	Multidrug and Toxin Extrusion Protein 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11356>	C61063	Interleukin-2/Monoclonal Antibody 3622W94/Sargramostim|GM-CSF/IL-2/MOAB 3622W94			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113570>	C28533	SLC29A4 Gene|SLC29A4|SLC29A4|Solute Carrier Family 29 (Equilibrative Nucleoside Transporter), Member 4 Gene	This gene plays a role in transport of monoamines.	SLC29A4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113571>	C113570	SLC29A4 wt Allele|ENT4|PMAT|PSEC0113|Solute Carrier Family 29 (Equilibrative Nucleoside Transporter), Member 4 wt Allele|hENT4	Human SLC29A4 wild-type allele is located 7p22.1 and is approximately 30 kb in length. This allele, which encodes equilibrative nucleoside transporter 4 protein, is involved in reuptake of monoamines into presynaptic neurons. Mutations in this gene are associated with desmoplastic small round cell tumor.	SLC29A4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113572>	C16386	Equilibrative Nucleoside Transporter 4|PMAT|Plasma Membrane Monoamine Transporter|SLC29A4|Solute Carrier Family 29 (Monoamine Transporter), Member 4|Solute Carrier Family 29 (Nucleoside Transporters), Member 4|Solute Carrier Family 29 Member 4|hENT4	Equilibrative nucleoside transporter 4 (530 aa, ~58 kDa) is encoded by the human SLC29A4 gene. This protein plays a role in regulating homeostasis of monoamine neurotransmitters in the central nervous system.	Equilibrative Nucleoside Transporter 4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113573>	C28480	CD177 Gene|CD177|CD177|CD177 Molecule Gene	This gene is involved in platelet function.	CD177 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113574>	C113573	CD177 wt Allele|CD177 Molecule wt Allele|HNA-2a|HNA2A|NB1|PRV-1|PRV1	Human CD177 wild-type allele is located in the vicinity of 19q13.31 and is approximately 10 kb in length. This allele, which encodes CD177 antigen protein, plays a role in platelet function and coagulation. Mutations in this gene are associated with polycythemia and hemorrhagic thrombocythemia.	CD177 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113575>	C16354	CD177 Antigen|Human Neutrophil Alloantigen 2a|NB1 GP|NB1 Glycoprotein|Neutrophil-Specific Antigen 1|Polycythemia Rubra Vera 1|Polycythemia Rubra Vera Protein 1|Polycythemia Rubra Vera-1	CD177 antigen (437 aa, ~46 kDa) is encoded by the human CD177 gene. This protein is involved in coagulation.	CD177 Antigen		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113576>	C20921	RGL4 Gene|RGL4|RGL4|Ral Guanine Nucleotide Dissociation Stimulator-Like 4 Gene	This gene plays a role in guanyl-nucleotide metabolism.	RGL4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113577>	C113576	RGL4 wt Allele|RALGDS-Related, Rabbit, Homolog of Gene|RGR|Ral Guanine Nucleotide Dissociation Stimulator-Like 4 wt Allele|hRGR	Human RGL4 wild-type allele is located in the vicinity of 22q11.23 and is approximately 11 kb in length. This allele, which encodes ral-GDS-related protein, is involved in guanyl-nucleotide metabolism.	RGL4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113578>	C17494	Ral-GDS-Related Protein|RGL4|Ral-GDS Related Protein|Ral-GDS Related Protein Rgr|RalGDS Related Oncogene|RalGDS-Like 4	Ral-GDS-related protein (473 aa, ~52 kDa) is encoded by the human RGL4 gene. This protein plays a role in in the metabolism of guanine nucleotides.	Ral-GDS-Related Protein		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113579>	C25804	ENTPD1 Gene|ENTPD1|ENTPD1|Ectonucleoside Triphosphate Diphosphohydrolase 1 Gene	This gene is involved in platelet activation.	ENTPD1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C11357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11357>	C61063	Interleukin-2/Monoclonal Antibody 3622W94|IL-2/MOAB 3622W94			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113580>	C113579	ENTPD1 wt Allele|ATP-DPH|ATPDase|CD39|Ectonucleoside Triphosphate Diphosphohydrolase 1 wt Allele|NTPDase-1|SPG64	Human ENTPD1 wild-type allele is located in the vicinity of 10q24.1 and is approximately 165 kb in length. This allele, which encodes ectonucleoside triphosphate diphosphohydrolase 1 protein, plays a role in modulating hemostasis and thrombotic reactions.	ENTPD1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113581>	C16701	Ectonucleoside Triphosphate Diphosphohydrolase 1|ATP Diphosphohydrolase|ATPDase|Apyrase|CD39|CD39 Antigen|EC 3.6.1.5|ENTPD1|Ecto-ATP Diphosphohydrolase 1|Ecto-ATPDase 1|Ecto-ATPase 1|Ecto-apyrase|Lymphoid Cell Activation Antigen|NTPDase 1|NTPDase-1|NTPDase1|Nucleoside Triphosphate Diphosphohydrolase 1|Vascular ATP Diphosphohydrolase	Ectonucleoside triphosphate diphosphohydrolase 1 (510 aa, ~58 kDa) is encoded by the human ENTPD1 gene. This protein is involved in the activation of platelets.	Ectonucleoside Triphosphate Diphosphohydrolase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113582>	C21275	CPA1 Gene|CPA1|CPA1|Carboxypeptidase A1 (Pancreatic) Gene	This gene plays a role in enzyme metabolism.	CPA1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113583>	C113582	CPA1 wt Allele|CPA|Carboxypeptidase A1 (Pancreatic) wt Allele|Procarboxypeptidase A1, Pancreatic Gene	Human CPA1 wild-type allele is located in the vicinity of 7q32 and is approximately 8 kb in length. This allele, which encodes carboxypeptidase A1 protein, is involved in enzyme metabolism.	CPA1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113584>	C16843	Carboxypeptidase A1|CPA1|EC 3.4.17.1|Pancreatic Carboxypeptidase A	Carboxypeptidase A1 (419 aa, ~47 kDa) is encoded by the human CPA1 gene. This protein plays a role in enzyme metabolism.	Carboxypeptidase A1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113585>	C20744	FLNA Gene|FLNA|FLNA|FLNA|Filamin A, Alpha Gene	This gene is involved in remodeling of the cytoskeleton.	FLNA Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C113586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113586>	C113585	FLNA wt Allele|ABP-280|ABPX|CSBS|CVD1|FLN|FLN-A|FLN1|FMD|Filamin A, Alpha wt Allele|MNS|NHBP|OPD|OPD1|OPD2|XLVD|XMVD	Human FLNA wild-type allele is located in the vicinity of Xq28 and is approximately 26 kb in length. This allele, which encodes filamin-A protein, plays a role in actin structure and function. Mutations in this gene are associated with several syndromes, including periventricular nodular heterotopias, otopalatodigital syndrome type 1 and type 2, frontometaphyseal dysplasia, Melnick-Needles syndrome, and X-linked congenital idiopathic intestinal pseudoobstruction.	FLNA wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113587>	C18073	Filamin-A|Actin Binding Protein 280|Actin-Binding Protein 280|Alpha-Filamin|Endothelial Actin-Binding Protein|FLNA|Filamin 1|Filamin A|Filamin A, Alpha (Actin Binding Protein 280)|Filamin, Alpha|Filamin-1|Non-Muscle Filamin	Filamin-A (2647 aa, ~281 kDa) is encoded by the human FLNA gene. This protein is involved in cytoskeletal remodeling.	Filamin-A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113588>	C2980	Oropharyngeal Dysphagia	Difficulty in swallowing due to an abnormality in the mouth or throat.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113589>	C26003	REN Gene|REN|REN|Renin Gene	This gene plays a role in angiotensin metabolism.	REN Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C11358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11358>	C61063	ALVAC-CEA Vaccine/Sargramostim|ALVAC-CEA/GM-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113590>	C113589	REN wt Allele|HNFJ2|Renin wt Allele	Human REN wild-type allele is located in the vicinity of 1q32 and is approximately 12 kb in length. This allele, which encodes renin protein, is involved in angiotensin activation and blood pressure homeostasis. Mutations in this gene are associated with both familial juvenile hyperuricemic nephropathy 2 and renal tubular dysgenesis.	REN wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113591>	C28411	Renin|Angiotensin-Forming Enzyme|Angiotensinogenase|EC 3.4.23.15|REN|Renin Precursor, Renal	Renin (406 aa, ~45 kDa) is encoded by the human REN gene. This protein plays a role in activation of angiotensin.	Renin		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113592>	C20462	OLFM4 Gene|OLFM4|OLFM4|Olfactomedin 4 Gene	This gene is involved in apoptosis regulation.	OLFM4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113593>	C113592	OLFM4 wt Allele|GC1|GCSF-Stimulated Clone 1 Gene|GW112|OLM4|OlfD|Olfactomedin 4 wt Allele|UNQ362|hGC-1|hOLfD	Human OLFM4 wild-type allele is located in the vicinity of 13q14.3 and is approximately 23 kb in length. This allele, which encodes olfactomedin-4 protein, plays a role in apoptosis inhibition.	OLFM4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113594>	C19928	Olfactomedin-4|Antiapoptotic Protein GW112|G-CSF-Stimulated Clone 1 Protein|bA209J19.1	Olfactomedin-4 (510 aa, ~57 kDa) is encoded by the human OLFM4 gene. This protein is involved in regulation of apoptosis.	Olfactomedin-4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113595>	C25873	EIF2AK4 Gene|EIF2AK4|EIF2AK4|Eukaryotic Translation Initiation Factor 2-Alpha Kinase 4 Gene	This gene plays a role in protein phosphorylation.	EIF2AK4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113596>	C113595	EIF2AK4 wt Allele|Eukaryotic Translation Initiation Factor 2 Alpha Kinase 4 wt Allele|GCN2|General Control Nonderepressible 2 Gene|KIAA1338	Human EIF2AK4 wild-type allele is located in the vicinity of 15q13.1 and is approximately 101 kb in length. This allele, which encodes eukaryotic translation initiation factor 2-alpha kinase 4 protein, is involved in both protein phosphorylation and the negative regulation of protein synthesis.	EIF2AK4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113597>	C17325	Eukaryotic Translation Initiation Factor 2-Alpha Kinase 4|EC 2.7.11.1|GCN2 EIF2alpha Kinase|GCN2-Like Protein|eIF-2-Alpha Kinase GCN2	Eukaryotic translation initiation factor 2-alpha kinase 4 (1649 aa, ~187 kDa) is encoded by the human EIF2AK4 gene. This protein plays a role in both translational regulation and protein phosphorylation.	Eukaryotic Translation Initiation Factor 2-Alpha Kinase 4		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113598>	C28533|C158414	ABCG1 Gene|ABCG1|ABCG1|ATP-Binding Cassette, Sub-Family G (WHITE), Member 1 Gene	This gene is involved in lipid transport.	ABCG1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113599>	C33904	Cul-de-sac	A pouch or tube that is open only at one end.			Conceptual Entity	
C11359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11359>	C61063	Amifostine/Irinotecan|CPT-11/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1135>	C54060	Indole-3-Carbinol|1H-indole-3-methanol|3-Hydroxymethylindole|I3C|INDOLE-3-CARBINOL|Indole-3-carbinol|Indole-3-carbinol|Indole-3-carbinol|Indole-3-methanol|indole-3-carbinol	A naturally occurring, orally available cleavage product of the glucosinolate glucobrassicanin, a natural compound present in a wide variety of plant food substances including members of the family Cruciferae with antioxidant and potential chemopreventive properties. Indole-3-carbinol scavenges free radicals and induces various hepatic cytochrome P450 monooxygenases. Specifically, this agent induces the hepatic monooxygenase cytochrome P4501A1 (CYP1A1), resulting in increased 2-hydroxylation of estrogens and increased production of the chemoprotective estrogen 2-hydroxyestrone.	Indole-3-Carbinol		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113600>	C113598	ABCG1 wt Allele|ABC8|ATP-Binding Cassette, Sub-Family G (WHITE), Member 1 wt Allele|ATP-Binding Cassette, Subfamily G, Member 1 Gene|Homolog of Drosophila White Gene|WHITE1|WHT1|White Protein Homolog (ATP-Binding Cassette Transporter 8) Gene|White, Drosophila, Homolog of Gene	Human ABCG1 wild-type allele is located in the vicinity of 21q22.3 and is approximately 98 kb in length. This allele, which encodes ATP-binding cassette sub-family G member 1 protein, plays a role in lipid homeostasis. Aberrant expression of the gene in macrophages is associated with Tangier disease.	ABCG1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113601>	C17750|C158419	ATP-Binding Cassette Sub-Family G Member 1|ABC Transporter 8|ABCG1|ATP-Binding Cassette Transporter 8|ATP-Binding Cassette Transporter Member 1 of Subfamily G|White Protein Homolog	ATP-binding cassette sub-family G member 1 (678 aa, ~76 kDa) is encoded by the human ABCG1 gene. This protein is involved in the transport of cholesterol and phospholipids.	ATP-Binding Cassette Sub-Family G Member 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113602>	C21295	HJV Gene|HFE2|HFE2 Gene|HJV|Hemojuvelin BMP Co-Receptor Gene	This gene plays a role in iron metabolism and bone morphogenetic protein (BMP) receptor signaling.	HFE2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113603>	C113602	HJV wt Allele|HFE2|HFE2 wt Allele|HFE2A|Hemochromatosis Type 2 (Juvenile) Gene|Hemojuvelin BMP Co-Receptor wt Allele|JH|RGMC	Human HJV wild-type allele is located in the vicinity of 1q21.1 and is approximately 19 kb in length. This allele, which encodes hemojuvelin protein, is involved in both bone morphogenetic protein signaling and iron metabolism. Mutation of the gene is associated with hemochromatosis type 2A.	HFE2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113604>	C17728	Hemojuvelin|HFE2|HJV|Hemochromatosis Type 2 Protein|Hemojuvelin BMP Coreceptor|RGM Domain Family Member C|Repulsive Guidance Molecule C	Hemojuvelin (426 aa, ~45 kDa) is encoded by the human HJV gene. This protein plays a role in both iron metabolism and bone morphogenetic protein signaling pathways.	Hemojuvelin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113605>	C25804	HDAC8 Gene|HDAC8|HDAC8|Histone Deacetylase 8 Gene	This gene is involved in the modification of histone proteins.	HDAC8 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113606>	C113605	HDAC8 wt Allele|CDA07|CDLS5|HD8|HDACL1|Histone Deacetylase 8 wt Allele|Histone Deacetylase-Like 1 Gene|MRXS6|RPD3|WTS	Human HDAC8 wild-type allele is located in the vicinity of Xq13 and is approximately 244 kb in length. This allele, which encodes histone deacetylase 8 protein, plays a role in post-translational modification of histones. Mutation of the gene is associated with both Wilson-Turner X-linked mental retardation syndrome and Cornelia de Lange syndrome 5.	HDAC8 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113607>	C16682	Histone Deacetylase 8|EC 3.5.1.98|HD8|HDAC8|Histone Deacetylase-Like 1	Histone deacetylase 8 (377 aa, ~24 kDa) is encoded by the human HDAC8 gene. This protein is involved in the deacetylation of core histones.	Histone Deacetylase 8		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113608>	C20921	NRARP Gene|NOTCH-Regulated Ankyrin Repeat Protein Gene|NRARP|NRARP	This gene plays a role in both signal transduction and blood vessel patterning.	NRARP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113609>	C53550	Chronic Liver Disease|Chronic liver disease	Hepatic necrosis, inflammation, or scarring due to any cause that persists for more than 6 months. Manifestations may include signs and symptoms of cholestasis, portal hypertension, and/or abnormal liver function tests.			Disease or Syndrome	CPTAC Causes of Death Codelist|CPTAC Codelists Terminology|CPTAC Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|SeroNet Authorized Values|SeroNet Research Participant Metadata|SeroNet Study Descriptors|SeroNet Variables
C11360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11360>	C61063	Dexamethasone/Metoclopramide|DM/MCP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113610>	C113608	NRARP wt Allele|MGC61598|NOTCH-Regulated Ankyrin Repeat Protein wt Allele|RP13-122B23.6	Human NRARP wild-type allele is located in the vicinity of 9q34.3 and is approximately 3 kb in length. This allele, which encodes Notch-regulated ankyrin repeat-containing protein, is involved in both endothelial cell proliferation and Notch signaling pathways.	NRARP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113611>	C18515	Notch-Regulated Ankyrin Repeat-Containing Protein|NRARP	Notch-regulated ankyrin repeat-containing protein (114 aa, ~12 kDa) is encoded by the human NRARP gene. This protein plays a role in the modulation of Notch signaling pathways.	Notch-Regulated Ankyrin Repeat-Containing Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113612>	C25954|C25873	ERN1 Gene|ERN1|ERN1|Endoplasmic Reticulum To Nucleus Signaling 1 Gene	This gene is involved in both protein phosphorylation and mRNA splicing.	ERN1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113613>	C113612	ERN1 wt Allele|ER To Nucleus Signalling 1 Gene|Endoplasmic Reticulum To Nucleus Signaling 1 wt Allele|IRE1|IRE1P|IRE1a|Inositol-Requiring 1 Gene|Inositol-Requiring Enzyme 1, S. cerevisiae, Homolog of Gene|hIRE1p	Human ERN1 wild-type allele is located in the vicinity of 17q24.2 and is approximately 88 kb in length. This allele, which encodes serine/threonine-protein kinase/endoribonuclease IRE1, plays a role in the unfolded protein response.	ERN1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113614>	C25959|C17325	Serine/Threonine-Protein Kinase/Endoribonuclease IRE1|ERN1|Endoplasmic Reticulum-To-Nucleus Signaling 1|IRE1a|Inositol-Requiring Enzyme 1|Inositol-Requiring Protein 1|Ire1-alpha|hIRE1p	Serine/threonine-protein kinase/endoribonuclease IRE1 (977 aa, ~110 kDa) is encoded by the human ERN1 gene. This protein is involved in both protein phosphorylation and mRNA processing in response to endoplasmic reticulum stress-dependent signaling.	Serine/Threonine-Protein Kinase/Endoribonuclease IRE1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113615>	C53494	Proctalgia Fugax	Recurrent episodes of pain localized to the anus or lower rectum which lasts seconds to minutes. There is no pain between episodes.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113616>	C20420	ATF6 Gene|ATF6|ATF6|Activating Transcription Factor 6 Gene	This gene plays a role in both transcriptional regulation and the unfolded protein response.	ATF6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113617>	C113616	ATF6 wt Allele|Activating Transcription Factor 6 wt Allele|Activating Transcription Factor 6, Alpha Gene	Human ATF6 wild-type allele is located within 1q22-q23 and is approximately 198 kb in length. This allele, which encodes cyclic AMP-dependent transcription factor ATF-6 alpha protein, is involved in the activation of unfolded protein responsive genes.	ATF6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113618>	C17286	Cyclic AMP-Dependent Transcription Factor ATF-6 Alpha|ATF6|ATF6-Alpha|Activating Transcription Factor 6|Activating Transcription Factor 6 Alpha|cAMP-Dependent Transcription Factor ATF-6 Alpha	Cyclic AMP-dependent transcription factor ATF-6 alpha (670 aa, ~75 kDa) is encoded by the human ATF6 gene. This protein plays a role in the expression of unfolded protein responsive genes.	Cyclic AMP-Dependent Transcription Factor ATF-6 Alpha		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113619>	C25941|C20338	DKC1 Gene|DKC1|DKC1|DKC1|Dyskerin Pseudouridine Synthase 1 Gene	This gene is involved in both H/ACA small nucleolar RNA ribonucleoprotein assembly and telomerase stabilization and maintenance.	DKC1 Gene		Gene or Genome	CCPS Genetics Terminology|Childhood Cancer Predisposition Study Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C11361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11361>	C61007	Dexamethasone/Granisetron|DM/GRAN			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113620>	C113619	DKC1 wt Allele|CBF5|DKC|DKCX|Dyskeratosis Congenita 1, Dyskerin Gene|Dyskerin Pseudouridine Synthase 1 wt Allele|NAP57|NOLA4|XAP101	Human DKC1 wild-type allele is located in the vicinity of Xq28 and is approximately 15 kb in length. This allele, which encodes H/ACA ribonucleoprotein complex subunit 4 protein, plays a role in the stabilization and maintenance of telomerase and H/ACA small nucleolar RNA ribonucleoprotein biogenesis. Mutation of the gene is associated with both Hoyeraal-Hreidarsson syndrome and X-linked dyskeratosis congenita.	DKC1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113621>	C21298|C16759	H/ACA Ribonucleoprotein Complex Subunit 4|CBF5 Homolog|Cbf5p Homolog|DKC1|Dyskerin|EC 5.4.99.-|NOPP140-Associated Protein, 57-kD|Nopp140-Associated Protein of 57 kDa|Nucleolar Protein Family A Member 4|Nucleolar Protein NAP57|SnoRNP Protein DKC1	H/ACA ribonucleoprotein complex subunit 4 (514 aa, ~58 kDa) is encoded by the human DKC1 gene. This protein is involved in telomerase stabilization and maintenance and the processing of ribosomal RNA.	H/ACA Ribonucleoprotein Complex Subunit 4		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113622>	C154299	MACROH2A1 Gene|H2AFY|H2AFY Gene|MACROH2A1|MACROH2A1|MacroH2A.1 Histone Gene	This gene plays a role in nucleosome structure.	H2AFY Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113623>	C113622	MACROH2A1 wt Allele|H2A Histone Family Member Y Gene|H2A Histone Family, Member Y Gene|H2A.y|H2A/y|H2A1.1|H2AF12M|H2AFY|H2AFY wt Allele|MACRO H2A|MACRO H2A1|MACROH2A1.1|MH2A1|MacroH2A.1 Histone wt Allele|mH2A1|macroH2A1.2	Human MACROH2A1 wild-type allele is located in the vicinity of 5q31.1 and is approximately 66 kb in length. This allele, which encodes core histone macro-H2A.1 protein, is involved in both chromatin modification and nucleosome assembly.	H2AFY wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113624>	C95407	Core Histone Macro-H2A.1|H2A/y|H2A1.1|Histone H2A.Y|Histone MacroH2A1|Histone MacroH2A1.1|Histone MacroH2A1.2|MACROH2A1|MACROH2A1.1|Medulloblastoma Antigen MU-MB-50.205|mH2A.1|mH2A1	Core histone macro-H2A.1 (372 aa, ~40 kDa) is encoded by the human MACROH2A1 gene. This protein plays a role in chromatin modification.	Core Histone Macro-H2A.1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C113625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113625>	C20103	PLXNC1 Gene|PLXNC1|PLXNC1|Plexin C1 Gene	This gene is involved in both semaphorin recognition and signal transduction.	PLXNC1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113626>	C113625	PLXNC1 wt Allele|CD232|PLXN-C1|Plexin C1 wt Allele|VESPR	Human PLXNC1 wild-type allele is located in the vicinity of 12q23.3 and is approximately 159 kb in length. This allele, which encodes plexin-C1 protein, plays a role in semaphorin-dependent signaling leading to cytoskeletal remodeling.	PLXNC1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113627>	C18106	Plexin-C1|CD232 Antigen|Plexin (Semaphorin Receptor)|Receptor For Viral Semaphorin Protein|Receptor For Virally-Encoded Semaphorin|Virus-Encoded Semaphorin Protein Receptor	Plexin-C1 (1568 aa, ~176 kDa) is encoded by the human PLXNC1 gene. This protein is involved in ligand binding, signal transduction and cytoskeletal remodeling.	Plexin-C1		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113628>	C26072	PIK3CD Gene|PI3K-Delta|PIK3CD|PIK3CD|Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Delta Gene	This gene plays a role in the initiation of second messenger signaling.	PIK3CD Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|Pediatric Oncology Target Cell Lineage Determinant Terminology
C113629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113629>	C113628	PIK3CD wt Allele|APDS|IMD14|P110DELTA|PI3K|PI3K-DELTA|PIK3-DELTA|Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Delta wt Allele|Phosphoinositide-3-Kinase, Catalytic, 110-kD Delta Gene|Phosphoinositide-3-Kinase, Catalytic, Delta Gene|Phosphoinositide-3-Kinase, Catalytic, Delta Polypeptide Gene|RP11-558F24.3|p110-DELTA|p110D	Human PIK3CD wild-type allele is located in the vicinity of 1p36.2 and is approximately 77 kb in length. This allele, which encodes phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform protein, is involved in both immunity and second messenger signaling.	PIK3CD wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11362>	C61063	Bryostatin 1/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113630>	C173981	Loss of Appetite Question|I have a loss of appetite|Loss of Appetite	A question about whether an individual has or had a loss of appetite.			Intellectual Product	FACT-Ga Questionnaire
C113631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113631>	C16984	Phosphatidylinositol 4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta Isoform|EC 2.7.1.153|PI3-Kinase Subunit Delta|PI3-Kinase p110 Subunit Delta|PI3K-Delta|PI3Kdelta|PIK3 Delta|PIK3CD|Phosphatidylinositol 4,5-Bisphosphate 3-Kinase 110 kDa Catalytic Subunit Delta|Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 110 kDa Catalytic Subunit Delta|Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta Isoform|Phosphoinositide-3-Kinase C|PtdIns-3-Kinase Subunit Delta|PtdIns-3-Kinase Subunit p110-Delta|p110-Delta|p110delta	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (1044 aa, ~119 kDa) is encoded by the human PIK3CD gene. This protein plays a role in both signal transduction and cell-mediated immunity.	Phosphatidylinositol 4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta Isoform		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Cell Lineage Determinant Terminology
C113632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113632>	C26147	UGT1A4 Gene|UDP Glucuronosyltransferase 1 Family, Polypeptide A4 Gene|UGT1A4|UGT1A4	This gene is involved in xenobiotic metabolism.	UGT1A4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113633>	C113632	UGT1A4 wt Allele|HUG-BR2|UDP Glucuronosyltransferase 1 Family, Polypeptide A4 wt Allele|UDP Glycosyltransferase 1 Family, Polypeptide A4 Gene|UDP-Glycosyltransferase 1 Family, Polypeptide A4 Gene|UDPGT|UDPGT 1-4|UGT-1D|UGT1-04|UGT1.4|UGT1D	Human UGT1A4 wild-type allele is located in the vicinity of 2q37 and is approximately 55 kb in length. This allele, which encodes UDP-glucuronosyltransferase 1-4 protein, plays a role in the catabolism of xenobiotics. Mutation of the gene is associated with Gilbert syndrome and Crigler-Najjar syndrome types 1 and 2.	UGT1A4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113634>	C17434	UDP-Glucuronosyltransferase 1-4|Bilirubin UDP-Glucuronosyltransferase Isozyme 2|Bilirubin-Specific UDPGT Isozyme 2|EC 2.4.1.17|UDP-Glucuronosyltransferase 1-D|UDP-Glucuronosyltransferase 1A4|UDPGT 1-4|UGT-1D|UGT1*4|UGT1-04|UGT1.4|UGT1A4|UGT1D|hUG-BR2	UDP-glucuronosyltransferase 1-4 (534 aa, ~60 kDa) is encoded by the human UGT1A4 gene. This protein is involved in glucuronidation of toxins.	UDP-Glucuronosyltransferase 1-4		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113635>	C29936	SERPIND1 Gene|SERPIND1|SERPIND1|Serpin Peptidase Inhibitor, Clade D (Heparin Cofactor), Member 1 Gene	This gene plays a role in thrombin inhibition.	SERPIND1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113636>	C113635	SERPIND1 wt Allele|D22S673|HC2|HCF2|HCII|HLS2|LS2|Serine (Or Cysteine) Proteinase Inhibitor, Clade D (Heparin Cofactor), Member 1 Gene|Serpin Peptidase Inhibitor, Clade D (Heparin Cofactor), Member 1 wt Allele|THPH10	Human SERPIND1 wild-type allele is located in the vicinity of 22q11.21 and is approximately 14 kb in length. This allele, which encodes heparin cofactor 2 protein, is involved in heparin-dependent inhibition of thrombin. Mutation of the gene is associated with thrombophilia due to heparin cofactor 2 deficiency.	SERPIND1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113637>	C17122	Heparin Cofactor 2|HC-II|HLS2|Heparin Cofactor II|Leuserpin 2|Leuserpin-2|Protease Inhibitor Leuserpin-2|Serpin D1	Heparin cofactor 2 (499 aa, ~57 kDa) is encoded by the human SERPIND1 gene. This protein plays a role in the glycosaminoglycan-dependent inhibition of thrombin.	Heparin Cofactor 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113638>	C20194	BASP1 Gene|BASP1|BASP1|Brain Abundant, Membrane Attached Signal Protein 1 Gene	This gene may be involved in neurite outgrowth.	BASP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113639>	C113638	BASP1 wt Allele|Brain Abundant, Membrane Attached Signal Protein 1 wt Allele|Brain-Abundant Signal Protein, Membrane-Attached, 1 Gene|CAP-23|CAP23|CAP23, Chicken, Homolog of Gene|NAP-22|NAP22|NAP22, Rat, Homolog of Gene	Human BASP1 wild-type allele is located in the vicinity of 5p15.1 and is approximately 211 kb in length. This allele, which encodes brain acid soluble protein 1, may play a role in signal transduction.	BASP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11363>	C61063	Interferon Alfa/Isotretinoin/Vitamin E|13-CRA/IFN-A/VIT-E			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113640>	C18466	Brain Acid Soluble Protein 1|22 kDa Neuronal Tissue-Enriched Acidic Protein|Brain Acid-Soluble Protein 1|Neuronal Axonal Membrane Protein NAP-22|Neuronal Tissue-Enriched Acidic Protein	Brain acid soluble protein 1 (227 aa, ~23 kDa) is encoded by the human BASP1 gene. This protein may be involved in both signal transduction and neurite outgrowth.	Brain Acid Soluble Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113641>	C25994	RETN Gene|RETN|RETN|Resistin Gene	This gene plays a role in the modulation of insulin activity.	RETN Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113642>	C113641	RETN wt Allele|ADSF|FIZZ3|Found In Inflammatory Zone 3 Gene|HXCP1|RETN1|RSTN|Resistin wt Allele|UNQ407/PRO1199|XCP1	Human RETN wild-type allele is located in the vicinity of 19p13.2 and is approximately 1 kb in length. This allele, which encodes resistin protein, is involved in the regulation of glucose metabolism. Mutation of the gene is associated with increased susceptibility to both non-insulin dependent diabetes mellitus and insulin resistance-related hypertension.	RETN wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113643>	C1746	Resistin|Adipose Tissue-Specific Secretory Factor|C/EBP-Epsilon Regulated Myeloid-Specific Secreted Cysteine-Rich Protein Precursor 1|C/EBP-Epsilon-Regulated Myeloid-Specific Secreted Cysteine-Rich Protein|Cysteine-Rich Secreted Protein A12-Alpha-Like 2|Cysteine-Rich Secreted Protein FIZZ3	Resistin (108 aa, ~11 kDa) is encoded by the human RETN gene. This protein plays a role in the regulation of insulin-mediated glucose metabolism.	Resistin		Amino Acid, Peptide, or Protein|Hormone	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113644>	C19067	Person Role Title|Person Role|Role Title|Role Title|Title|title	An identifying designation assigned to an individual that corresponds with their function.			Qualitative Concept	CareLex eTMF Terminology
C113645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113645>	C93144	Lactobacillus rhamnosus/L. jensenii/L. crispatus/L. gasseri Oral Supplement|L. rhamnosus/L. jensenii/L. crispatus/L. gasseri Oral Supplement	A A nutritional supplement containing the probiotic Lactobacillus strains, L. rhamnosus, L. jensenii, L. crispatus and L. gasseri, with protective and immunomodulating activities. The bacteria in this probiotic supplement colonize the vaginal tract and help to maintain as well as restore the composition of the normal, healthy vaginal flora. The four Lactobacillus species form a protective barrier that helps both to maintain the integrity of the vaginal tract and prevent the attachment of pathogenic bacteria and other harmful substances, thereby protecting against genitourinary infections.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C113646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113646>	C214440	LSD1 Inhibitor GSK2879552|GSK2879552	An orally available, irreversible, inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity. Upon administration, GSK2879552 binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the dimethylated form of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor-suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. LSD1, overexpressed in certain tumor cells, plays a key role in tumor cell growth and survival.	LSD1 Inhibitor GSK2879552		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113647>	C1983	Alpha-1,3-galactosyltransferase-expressing Allogeneic Renal Cell Carcinoma Vaccine|HAR|HyperAcute Renal	An allogeneic renal cell cancer (RCC) vaccine composed of cell line-derived RCCs that are genetically engineered to express the murine alpha-1,3-galactosyltransferase (GalT), with potential immunostimulatory and antineoplastic activities. Not naturally occurring in humans, GalT catalyzes the expression of foreign alpha-1,3-galactosyl (alpha-gal) carbohydrate epitopes on the cell membranes of the allogeneic RCCs present in the vaccine. This induces a hyperacute rejection reaction involving pre-existing human anti-alpha-gal antibodies, which bind to the foreign alpha-gal epitopes expressed by the allogeneic RCCs. This results in complement-mediated cytotoxicity (CMC) and antibody-dependent cell-mediated cytotoxicity (ADCC) towards endogenous RCCs with unmodified carbohydrate epitopes.			Cell|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113648>	C390	Contrast Agent CS-1000|CS-1000	An aqueous colloidal nanoemulsion containing perfluorocarbon (PFC) polymers that can be used as a tracer for cell tracking purposes during fluorine-19 (19F) magnetic resonance imaging (MRI). Upon administration of the contrast agent CS-1000 to cells ex vivo, this agent freely enters the cells. Upon introduction of these cells into the patient and subsequent 19F MRI, the amount of fluorine can be detected and cellular persistence, survival and distribution of the treated cells can be assessed. The emulsion allows for fast entry of the fluorinated polymers into cells; the polymers do not degrade and remain in the cells.			Indicator, Reagent, or Diagnostic Aid	NCI Drug Dictionary Terminology
C113649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113649>	C2554|C177174	TLR4 Agonist G100|G100|GLA-SE|Glucopyranosyl Lipid A Stable Emulsion|Glucopyranosyl Lipid Adjuvant-Stable Emulsion|TLR 4 Agonist G100|TLR-4 Agonist G100|TLR-4 Agonist GLA-SE|Toll-like Receptor 4 Agonist G100|Toll-like Receptor 4 Agonist GLA-SE	A synthetic lipid A derivative and selective toll-like receptor 4 (TLR4) agonist composed of glucopyranosyl lipid-A (GLA) in a stable, oil-in-water emulsion (GLA-SE), with potential immunostimulating and antineoplastic activities. Upon intratumoral administration into the immunosuppressed tumor microenvironment (TME), TLR4 agonist G100 binds to and activates TLR4 on various immune cells, thereby stimulating dendritic cells (DCs), monocytes and macrophages. This activation results in the production of pro-inflammatory cytokines and chemokines. This induces a T helper cell-1 (Th1) immune response and activates a cytotoxic T-lymphocyte (CTL) response against tumor-associated antigens (TAAs) that were released in the TME by tumor cells lysed during cytotoxic treatments, such as radiotherapy. TLR4, a member of the TLR family, plays a key role in the activation of innate immunity.	TLR4 Agonist G100		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C11364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11364>	C61063	Cytarabine/Homoharringtonine/Interferon Alfa|ARA-C/HH/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113650>	C1980	IVAC Mutanome Vaccine	An individualized, poly-neo-epitopic encoding, ribonucleic acid (RNA)-based cancer vaccine that targets a variety of patient-specific, immunogenic mutant epitopes, with potential immunostimulatory and antineoplastic activities. Upon intranodal administration, the RNA in the individualized mutanome vaccine is translated by antigen presenting cells (APCs) and the expressed protein is presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL) and memory T-cell immune responses against the patient-specific neoantigens.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113651>	C2594	Ovapuldencel-T|OVAPULDENCEL-T	A cancer vaccine consisting of autologous dendritic cells (DCs) loaded with autologous, lethally irradiated cancer cells and mixed with the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulatory and antineoplastic activities. Upon vaccination, ovapuldencel-T may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against the repertoire of tumor associated antigens (TAAs) found in the irradiated cancer cells. GM-CSF enhances the activation of dendritic cells (DCs) and promotes antigen presentation to both B- and T-lymphocytes.			Cell|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113652>	C147923|C129818	Seviteronel|1H-1,2,3-Triazole-5-methanol, Alpha-(6,7-bis(difluoromethoxy)-2-naphthalenyl)-alpha-(1-methylethyl)-, (AlphaS)-|SEVITERONEL|VT-464	An orally available non-steroidal, lyase-selective inhibitor of the steroid 17-alpha-hydroxylase/C17,20 lyase (CYP17A1 or CYP17), with potential anti-androgenic and antineoplastic activities. Upon oral administration, seviteronel selectively inhibits the enzymatic activity of the cytochrome P450 C17,20 lyase in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells. The cytochrome P450 enzyme CYP17A1, localized to the endoplasmic reticulum, exhibits both 17alpha-hydroxylase and 17,20-lyase activities; it plays a key role in the steroidogenic pathway. The lyase-selective activity of seviteronel prevents the increased synthesis of mineralocorticoids that is normally seen with non-selective CYP17 inhibitors, which also inhibit the 17-alpha-hydroxylase activity of CYP17A1.	Seviteronel		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113653>	C1983	Vesigenurtucel-L|HS-410|VESIGENURTUCEL-L	An allogeneic urothelial bladder cancer cell vaccine expressing a recombinant secretory form of the immunoadjuvant heat shock protein gp96 fused with an immunoglobulin Fc domain (gp96-Ig) protein, with potential antineoplastic activity. Upon administration of vesigenurtucel-L, the live, irradiated tumor cells continuously secrete gp96-Ig along with its chaperoned tumor associated antigens (TAAs). This enhances antigen cross presentation to cytotoxic T-lymphocytes (CTLs) and, upon expansion, leads to the induction of a potent CTL response against the TAAs on the endogenous bladder cancer cells. This vaccine also induces a memory T cell response that could fight recurring cancer cells. gp96-Ig is constructed by replacing the KDEL endoplasmic reticulum (ER) retention sequence of gp96 with the Fc portion of the IgG1 protein. This allows for gp96, normally an ER-resident chaperone peptide, to be released from cells.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113654>	C1012	Midazolam-containing Buccal Liquid|Epistatus	An oromucosal solution containing the maleate salt form of midazolam, a short-acting benzodiazepine derivative, with anxiolytic, hypnotic, anticonvulsant and sedative activities. Upon administration of the solution into the buccal cavity, midazolam exerts its effect by binding to the benzodiazepine receptor at the gamma-aminobutyric acid (GABA) receptor-chloride ionophore complex in the central nervous system (CNS). This leads to an increase in the permeability of chloride channels, membrane hyperpolarization and enhances the inhibitory effect of GABA in the CNS. Midazolam may also interfere with the reuptake of GABA, thereby causing accumulation of GABA in the synaptic cleft. The oromucosal formulation facilitates administration to patients that are unable to swallow. The ethanol in this formulation improves the buccal absorption of midazolam.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C113655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113655>	C141136|C129825	Lorlatinib|2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-|7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile|LORLATINIB|Lorbrena|Lorviqua|PF 06463922|PF-06463922|PF06463922	An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, lorlatinib binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK- and ROS1-mediated signaling and eventually inhibits tumor cell growth in ALK- and ROS1-overexpressing tumor cells. In addition, PF-06463922 is able to cross the blood brain barrier. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells.	Lorlatinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113656>	C62799	Long-acting Release Pasireotide|LAR Pasireotide|SOM230 LAR	A long-acting release (LAR) formulation containing pasireotide, a synthetic long-acting cyclohexapeptide, with somatostatin-like activity. Upon intramuscular administration of the LAR formulation of pasireotide, this somatostatin analog strongly binds to and activates somatostatin receptor (SSTR) subtypes 1, 2, 3, and 5. This leads to an inhibition in the secretion of human growth hormone (hGH) and results in decreased production of insulin-like growth factor (IGF-1), which may inhibit IGF-1-mediated cell signaling pathways. This may lead to an inhibition in tumor cell growth and an increase in apoptosis in IGF-1-overexpressing tumor cells. In addition, this agent causes a reduction in adrenocorticotropic hormone (ACTH), which leads to an inhibition of cortisol secretion. ACTH-producing tumors cause hypersecretion of cortisol which results in many unwanted symptoms. This agent may also block other key survival pathways such as the phosphatidylinositol 3-kinase (PI3K) and the mitogen-activated protein kinase (MAPK) signaling pathways. Pasireotide also inhibits vascular endothelial growth factor (VEGF) secretion, thereby decreasing angiogenesis and tumor cell growth in VEGF-overexpressing tumor cells. The long-acting form of pasireotide allows for less frequent administration as compared to the original form of this agent. SSTRs are overexpressed by some neuroendocrine and non-neuroendocrine tumor cells.	Long-acting Release Pasireotide		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113657>	C2140	Carboxylesterase-expressing Allogeneic Neural Stem Cells|CE-secreting Allogeneic NSCs|hCE1m6-NSC	A preparation of allogeneic neural stem cells (NSC), derived from a human fetal cell line, that are adenovirally-transduced to express a modified form of the human enzyme carboxylesterase (CE) hCE1m6, with potential adjuvant activity. Upon intracranial administration, NSCs localize to tumor sites, due to their tumor-trophic nature, and transiently express hCE1m6. Intravenous co-administration of the prodrug irinotecan allows for the selective conversion by hCE1m6 to its active metabolite and topoisomerase I inhibitor, SN-38, in the vicinity of tumor sites. This leads to a local anti-neoplastic effect and causes reduced toxicity and increased therapeutic efficacy of irinotecan. Since NSCs freely cross the blood-brain barrier, these cells can also be intravenously administered to target brain tumor cells. hCE1m6 shows increased activity as compared to unmodified human CE.	Carboxylesterase-expressing Allogeneic Neural Stem Cells		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C113658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113658>	C155764	Immediate-release Tablet Afuresertib|GSK2110183 IR Tablet|IR Afuresertib	An immediate-release (IR) tablet formulation containing afuresertib, an inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Upon oral administration of the IR formulation, afuresertib binds to and inhibits the activity of Akt, which may result in the inhibition of PI3K/Akt signaling pathway, decreased tumor cell proliferation and the induction of tumor cell apoptosis in Akt-expressing tumor cells. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113659>	C20401|C129822	Anti-CD98 Monoclonal Antibody IGN523|IGN-523|IGN523	A humanized, monoclonal antibody targeting the CD98 (gp125) antigen, with potential immunomodulatory and antineoplastic activities. Upon intravenous administration, IGN523 binds to CD98 expressed on the tumor cell surface and elicits both natural killer (NK)-cell mediated antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity towards CD98-expressing tumor cells. In addition, IGN523 inhibits essential amino acid uptake by rapidly proliferating tumor cells. CD98, a type II transmembrane glycoprotein, is involved in both integrin signaling and amino acid transport processes; it is overexpressed in certain cancer cells and plays a key role in the proliferation, survival and metastasis of tumor cells.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11365>	C61007	Leucovorin Calcium/Methotrexate/Vincristine|CF/MTX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113660>	C1663	Folate Binding Protein J65 Peptide Vaccine|FBP J65 Peptide Vaccine|J65 Peptide Vaccine	A cancer vaccine comprised of human leukocyte antigen (HLA)-A2-restricted folate binding protein (FBP) epitope J65 (9 amino acids; EIWTFSTKV), with potential immunostimulatory and antineoplastic activities. Upon intradermal injection, FBP J65 peptide vaccine may induce a specific cytotoxic T-lymphocyte (CTL) response against J65 FBP-expressing tumor cell types. FBP is a membrane-bound, tumor-associated antigen overexpressed in various tumor types, including breast, ovarian and endometrial cancers. J65 is a strongly immunogenic peptide.	Folate Binding Protein J65 Peptide Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113662>	C93221	Coffee Dietary Supplement	A dietary supplement containing coffee, with potential gastrointestinal (GI) tract stimulating activity. Following consumption of the dietary supplement, the coffee may both stimulate peristalsis and may increase bowel movement. The supplement also may also stimulate the central nervous system, suppress appetite and cause weight loss.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C113663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113663>	C62439	Twenty Five|25|Twenty-Five	A natural number greater than twenty-four and less than twenty-six and the quantity that it denotes.			Quantitative Concept	
C113664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113664>	C38342	Main Duct Pancreatic Intraductal Papillary-Mucinous Neoplasm|Pancreatic MD-IPMN	An intraductal papillary-mucinous neoplasm of the pancreas that arises from the main pancreatic duct.			Neoplastic Process	
C113665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113665>	C38342	Branch Duct Pancreatic Intraductal Papillary-Mucinous Neoplasm|Pancreatic BD-IPMN|Pancreatic SB-IPMN|Side Branch Pancreatic Intraductal Papillary-Mucinous Neoplasm	An intraductal papillary-mucinous neoplasm of the pancreas that arises in one of the branches of the main pancreatic duct.  It usually has an indolent behavior.			Neoplastic Process	
C113666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113666>	C27993	Wrong|Incorrect	Not accurate, correct, or appropriate.			Qualitative Concept	
C113667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113667>	C38342	Mixed Type Pancreatic Intraductal Papillary-Mucinous Neoplasm|Mixed Type Pancreatic IPMN	An intraductal papillary-mucinous neoplasm of the pancreas that arises primarily from the main pancreatic duct and extends to the branch ducts.			Neoplastic Process	
C113668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113668>	C12948	Branch Duct	A small duct that originates from the main duct.			Body Part, Organ, or Organ Component	
C113669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113669>	C2890	Disseminated Bacillus Calmette-Guerin Infection|BCGosis|Disseminated BCG Infection|Disseminated BCGitis|Disseminated BCGitis|Disseminated Bacillus Calmette-Guérin Infection	A rare systemic and life-threatening infection associated with vaccination with the live attenuated strain of Mycobacterium bovis, bacillus Calmette-Guerin.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Infectious Disease Terminology
C11366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11366>	C61063	Clodronate/Mitoxantrone/Prednisone|CLOD/DHAD/PRED			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113670>	C3837	Hypotonic-Hyporesponsive Episode|HHE	Acute onset of unresponsiveness or diminished level of consciousness, associated with loss of muscle tone and pallor or cyanosis, that occurs within 48 hours after childhood immunizations. It is primarily associated with pertussis-containing vaccines administered to children under two years of age.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113671>	C35550	Vaccine-Associated Paralytic Poliomyelitis|OPV associated Paralytic Poliomyelitis|VAPP|VAPP	A rare, paralytic poliomyelitis associated with the orally administered live attenuated strain of the poliovirus, OPV.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Infectious Disease Terminology
C113672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113672>	C96407	Disseminated Oka Varicella Zoster Virus Infection|Disseminated Oka VZV Infection|Disseminated Varicella Zoster Vaccine Virus Infection|Disseminated Varicella Zoster Vaccine Virus Infection	A rare systemic and life-threatening infection associated with vaccination with the live attenuated strain of the Varicella-zoster virus, Oka.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Infectious Disease Terminology
C113673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113673>	C27557	Reactive Airway Disease|Hyperactive Airway Disease|Reactive Airway Disease (AQ)	Coughing, wheezing, or shortness of breath that is triggered by allergens, infection, or other irritants.			Disease or Syndrome	HL Authorized Value Terminology|HL Late Effects Table|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113674>	C33904	Cadaver	The dead body of a human being.			Conceptual Entity	
C113675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113675>	C113122	Serum Collection Tube|Red Top Tube	A blood collection tube that contains a coagulant, designed for the collection of serum.			Manufactured Object	
C113676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113676>	C113122	Complete Blood Count Collection Tube|Lavender Top Tube|Purple Top Tube	A blood collection tube that contains the anti-coagulant EDTA, designed for complete blood counts and blood films.			Manufactured Object	
C113677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113677>	C70699	Sediment	Material that has settled out of solution.			Body Substance	
C113678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113678>	C1709	Coal Dust	Fine powder derived by the crushing of coal.			Substance	
C113679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113679>	C348	Diesel Exhaust|Diesel exhaust	The airborne components that result from the combustion of diesel fuel. It includes both gaseous products of complete and incomplete combustion and particulates.			Classification	CPTAC Codelists Terminology|CPTAC Environmental/Occupational Exposure Codelist|CPTAC Terminology
C11367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11367>	C61007	Mitoxantrone/Prednisone|DHAD/PRED			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113680>	C35461	Flare-up|FLARE|Flare Episode	A sudden worsening of a condition.			Finding	CDISC SDTM Medical History Event Date Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113681>	C90435	Skin Tattoo|Tattoo|Tattoo	A permanent mark created by the insertion of pigment below the skin.			Qualitative Concept	GDC Terminology|GDC Value Terminology
C113682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113682>	C27993	Hard	Solid and firm to the touch; unyielding to pressure.			Qualitative Concept	
C113683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113683>	C21514	Abrupt|Sudden	Marked by sudden change.			Qualitative Concept	
C113684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113684>	C16830	Indwelling Device|Indwelling	A device designed to be left in the body for an extended time.			Medical Device	
C113685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113685>	C25404	Judgment|Judgement	The act of assessing a situation or event.			Activity	
C113686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113686>	C20917	HAUS7 Gene|HAUS Augmin-Like Complex, Subunit 7 Gene|HAUS7|HAUS7	This gene is involved in cell division.			Gene or Genome	
C113687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113687>	C68805	Decimal Point	A dot placed between the integer part and fractional part of a number in the decimal system.			Qualitative Concept	
C113688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113688>	C113686	HAUS7 wt Allele|HAUS Augmin-Like Complex, Subunit 7 wt Allele|UCHL5IP|UIP1	Human HAUS7 wild-type allele is located in the vicinity of Xq28 and is approximately 48 kb in length. This allele, which encodes HAUS augmin-like complex subunit 7 protein, plays a role in mitotic spindle assembly, centrosome integrity and cytokinesis.			Gene or Genome	
C113689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113689>	C17761	HAUS Augmin-Like Complex Subunit 7|26S Proteasome-Associated UCH Interacting Protein 1|26S Proteasome-Associated UCH37-Interacting Protein 1|Three Prime Repair Exonuclease 2 Isoform UIP1|UCH37 Interacting Protein 1|UCH37-Interacting Protein 1|UCHL5 Interacting Protein|UCHL5-Interacting Protein|UIP1|X-Linked Protein STS1769	HAUS augmin-like complex subunit 7 (368 aa, ~41 kDa) is encoded by the human HAUS7 gene. This protein is involved in centrosome maintenance, mitotic spindle assembly and cytokinesis.			Amino Acid, Peptide, or Protein	
C11368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11368>	C61063	Cladribine/Cyclophosphamide/Prednisone|2-CdA/CTX/PRED			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113690>	C263	Heparin Potassium|Clarin|HEPARIN POTASSIUM|KHep|Potassium Acid Heparin	The potassium salt form of heparin, a sulfur-rich glycosaminoglycan with anticoagulant activity. Heparin binds to antithrombin III to form a heparin-antithrombin III complex. The complex binds to and inactivates thrombin (factor IIa) and other activated clotting factors, such as factors IXa, Xa, XIa, and XIIa. The inactivation of thrombin prevents the polymerization of fibrinogen to fibrin and the subsequent formation of blood clots.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C113691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113691>	C121007	Child-Pugh Class A|A|Grade A (5-6 points) Well Compensated Disease	Child-Pugh score indicating one-year survival of 100% in patients with chronic liver disease and cirrhosis.  This score is determined by the study of the following five factors: bilirubin, albumin, international normalized ratio, presence and degree of ascites, and presence and degree of encephalopathy.	Child-Pugh Class A		Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C113692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113692>	C121007	Child-Pugh Class B|B|Grade B (7-9 points) Significant Functional Compromise	Child-Pugh score indicating one-year survival of 80% in patients with chronic liver disease and cirrhosis.  This score is determined by the study of the following five factors: bilirubin, albumin, international normalized ratio, presence and degree of ascites, and presence and degree of encephalopathy.	Child-Pugh Class B		Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C113693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113693>	C1746	NPPB Gene Product	A protein encoded by the NPPB gene.	NPPB Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113694>	C121007	Child-Pugh Class C|C|Grade C (10-15 points) Decompensated Disease	Child-Pugh score indicating one-year survival of 45% in patients with chronic liver disease and cirrhosis.  This score is determined by the study of the following five factors: bilirubin, albumin, international normalized ratio, presence and degree of ascites, and presence and degree of encephalopathy.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C113695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113695>	C33073	Inferior Mediastinal Lymph Node|INFERIOR MEDIASTINAL LYMPH NODE	A group of lymph nodes located in the inferior part of the mediastinum.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C113696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113696>	C802	Fetal Bovine Serum|FBS|FCS|Fetal Calf Serum	The serum blood fraction obtained from cow fetuses and used as a component of growth medium.			Indicator, Reagent, or Diagnostic Aid	SeroNet Authorized Values|SeroNet Reagent Metadata
C113697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113697>	C54266	Delight|Delighted	A feeling of extreme pleasure or satisfaction.			Mental Process	
C113698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113698>	C27993	Terrible	Exceptionally bad or displeasing.			Qualitative Concept	
C113699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113699>	C69035	Roche Diagnostics Free PSA Test	A proprietary in vitro diagnostic laboratory test designed to measure free prostate-specific antigen (fPSA) in human serum.			Manufactured Object	
C11369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11369>	C61007	Cytarabine/Cyclophosphamide/Dexamethasone/Doxorubicin/Methotrexate/Vincristine|ARA-C/CTX/DM/DOX/MTX/VCR|Cyclophosphamide/Cytarabine/Dexamethasone/Doxorubicin/Methotrexate/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1136>	C1556	Inosine Dialdehyde|9H-Purine-9-acetaldehyde, .alpha.-(1-formyl-2-hydroxyethoxy)-1,6-dihydro-6-oxo-, (R,R)- (8CI)|9H-Purine-9-acetaldehyde, .alpha.-(1-formyl-2-hydroxyethoxy)-1,6-dihydro-6-oxo-, (R-(R*, R*))- (9CI)|9H-purine-9-acetaldehyde, alpha-(1-formyl-2-hydroxyethoxy)-1,6-dihydro-6-oxo-, (R,R)- (8CI)|9H-purine-9-acetaldehyde, alpha-(1-formyl-2-hydroxyethoxy)-1,6-dihydro-6-oxo-, (R-(R*, R*))- (9CI)|Diglycoaldehyde|Diglycolaldehyde, .alpha.-(hydroxymethyl)-.alpha.'-(6-hydroxy-9H-purin-9-yl)-|INOSINE DIALDEHYDE|IdA|Inosine dialdehyde|Inox|Inox|Wy-5321|diglycolaldehyde, alpha-(hydroxymethyl)-alpha'-(6-hydroxy-9H-purin-9-yl)	A toxic purine analogue. Inosine dialdehyde inhibits ribonucleotide reductase, resulting in decreased synthesis of DNA, RNA, and proteins, and G2/M-phase cell cycle arrest.  This agent also forms stable covalent crosslinks in proteins, thereby inhibiting the activity of enzymes involved in nucleic acid synthesis. (NCI04)			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C113700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113700>	C69035	Hybritech PSA Test|Access Hybritech PSA Test	A proprietary immunoenzymatic assay system designed to measure prostate-specific antigen in serum samples.			Manufactured Object	
C113701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113701>	C69035	Bayer Immuno-1 PSA Test	A proprietary system designed to measure protein-complexed prostate-specific antigen (cPSA) in the blood.			Manufactured Object	
C113702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113702>	C498	Methanol/Water-based Buffered Preservative Solution|Methanol/Water-based Buffered Transport Medium|PreservCyt	A methanol-water solution for the preservation of cervical cells for automated Pap testing.			Indicator, Reagent, or Diagnostic Aid	
C113703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113703>	C498	Alcohol/Polyethylene Glycol-based Cytology Fixative|Saccomanno Fixative|Saccomanno's Cytology Fixative	A partial fixative used for the preparation of cytology specimens from sputum samples.			Indicator, Reagent, or Diagnostic Aid	
C113704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113704>	C54131	Tosoh Bioscience	A manufacturer of reagents and instruments for the separation, purification, and analysis of biospecimens.			Organization	
C113705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113705>	C54131	Abbott Diagnostics	A manufacturer of in vitro diagnostic instrument systems.			Organization	
C113706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113706>	C54131	Beckman Coulter, Inc	A manufacturer of biomedical laboratory instruments.			Organization	
C113707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113707>	C54131	Roche Diagnostics	A manufacturer of instruments and assay systems for clinical analysis and diagnosis.			Organization	
C113708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113708>	C113391	Fecal Occult Blood	Blood in the feces that is not visibly apparent.			Finding	
C113709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113709>	C36279	Tortuous Colon	A colon that is longer than a normal colon, with additional bends and twists.			Finding	
C11370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11370>	C61063	Interferon Alfa/Ritonavir|IFN-A/RIT			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113710>	C2979	Reticulocytopenia	Abnormally low level of immature red blood cells in the blood.			Laboratory or Test Result	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113711>	C35877	Erythrocytosis	Abnormally high level of red blood cells in the blood.			Laboratory or Test Result	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113712>	C2863	Eosinophilopenia	Abnormally low level of eosinophils in the blood.			Laboratory or Test Result	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113713>	C2863	Basophilopenia	Abnormally low level of basophils in the blood.			Laboratory or Test Result	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113714>	C2863	Monocytopenia	Abnormally low level of monocytes in the blood.			Laboratory or Test Result	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113715>	C35867	Scattered Microscopic Foci	A microscopic finding indicating the presence of scattered islands of pathologic processes in a tissue sample.  The pathologic processes may refer to various abnormalities, including the presence of islands of malignant cells, presence of necrotic foci, and presence of islands of connective tissue that lack fibers.			Finding	
C113716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113716>	C51783	Low Anterior Resection|Anterior Resection of Rectum|LAR|LAR|LOW ANTERIOR RESECTION|Lower Anterior Rectal Resection	Resection of the rectum for cancer through an incision in the lower abdomen.	Low Anterior Resection		Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C113717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113717>	C84415	End Organ Damage from Diabetes	Irreparable damage to multiple organs/systems which is the result of chronic complications of diabetes.  The affected organs/systems include the cardiovascular system, kidneys, eyes, nervous system, joints and feet.			Finding	
C113718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113718>	C35869	Ground Glass Opacity|GGO	A CT scan finding in the lungs indicating the presence of hazy areas of attenuation in the air spaces.  It is caused by interstitial fibrosis, alveolar collapse, edema, inflammation, or cancer with lepidic spread.			Finding	
C113719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113719>	C138144	Part-Solid Ground-Glass Pulmonary Nodule|PSN|Part Solid Nodule|Partly Solid Ground-Glass Pulmonary Nodule	A term that refers to a pulmonary nodule in which part of the ground-glass opacity completely obscures the parenchyma on CT scan examination.			Finding	
C11371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11371>	C61007	Fludarabine/Rituximab|FAMP/MOAB IDEC-C2B8|rituximab/fludarabine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113720>	C113722	Abnormal Colorectal Exam, Suspicious for Malignancy|Abnormal Colorectal Exam, Suspicious for Cancer|Abnormal Colorectal Examination, Suspicious for Malignancy	A clinical finding indicating the presence of a firm, indurated, or nodular lesion, which is suspicious for malignancy, during colorectal examination.			Finding	
C113721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113721>	C113722	Abnormal Colorectal Exam, Highly Suspicious for Malignancy|Abnormal Colorectal Exam, Highly Suspicious for Cancer|Abnormal Colorectal Examination, Highly Suspicious for Malignancy	A clinical finding indicating the presence of a lesion, which is highly suspicious for malignancy, during colorectal examination.			Finding	
C113722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113722>	C36279	Colorectal Examination Finding|Colorectal Exam Finding	The result of an examination of the colon and rectum.			Finding	
C113723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113723>	C27204|C116801	Scleroderma Polymyositis Overlap Syndrome|Scleroderma Polymyositis	A rare autoimmune disorder in which patients present with overlapping symptoms of systemic scleroderma and polymyositis or dermatomyositis.			Disease or Syndrome	
C113724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113724>	C28020	Unable to Draw Blood|Blood draw not successful	Indicates that a phlebotomist was unable to find or penetrate a blood vessel or was unable to acquire a blood sample following a successful vein stick.			Finding	
C113725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113725>	C28102	Undiagnosed	Refers to an underlying pathologic process that has not been identified.			Classification	
C113726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113726>	C28020	Unable to Collect Voided Urine	Indicates that an individual is unable to self-collect a urine specimen.			Finding	
C113727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113727>	C201726	Transurethral Incision of the Prostate|TIBN|TUIP|Transurethral Incision of Bladder Neck|Transurethral Incision of the Bladder Neck	A surgical procedure performed in patients with benign prostatic hyperplasia.  An instrument is inserted in the urethra that generates electric current or laser beam, which create incisions in the bladder neck. The incisions result in decreased resistance to the flow of the urine out of the urinary bladder.	Transurethral Incision of the Prostate		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C113728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113728>	C16546	Balloon Dilation	An endoscopic therapeutic procedure in which a balloon device is used to dilate a narrowed lumen.			Diagnostic Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C113729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113729>	C18000	Grade B|Borderline Grade|Borderline Histologic Grade|GB|GB|GB Borderline	A morphologic qualifier indicating that a neoplasm is of borderline malignancy.			Classification	GDC Terminology|GDC Value Terminology
C11372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11372>	C61063	Cyclophosphamide/Mercaptopurine/Methotrexate|CTX/MP/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113730>	C18000	Grade X|GX|GX|GX|GX Grade Cannot Be Assessed|GX Grade cannot be assessed|Grade Cannot Be Assessed|Grade cannot be assessed	A morphologic qualifier indicating that the grade of a neoplasm cannot be assessed.			Classification	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C113731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113731>	C3064	Non-Necrotizing Granuloma|Granuloma, non necrotizing	A granuloma that is not associated with necrotic changes.  The majority of cases are of non-infectious origin.  Causes include sarcoidosis, hypersensitivity pneumonitis, drug reactions, and Crohn disease.			Finding	
C113732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113732>	C3064	Necrotizing Granuloma|Granuloma, necrotizing	A granuloma that contains areas of necrosis.  The majority of cases are of infectious origin.			Finding	
C113733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113733>	C35867	Paneth Cell-Like Change|PCLC	A morphologic finding indicating the presence of single cells or small groups of cells with prominent eosinophilic cytoplasmic granules in a tissue sample.			Finding	
C113734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113734>	C35886	Poorly Formed Pattern	A morphologic finding indicating the presence of a malignant cellular infiltrate with poorly defined glands in a tissue sample.			Finding	
C113735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113735>	C35867	Transition Zone-Like|Transition zone like	A morphologic finding indicating the presence of an epithelial infiltrate resembling the cells of the transition zone of the prostate gland.			Finding	
C113736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113736>	C2978	Retention Cyst	A cyst that is formed because of the blockage of the duct of a glandular organ. This results in the retention of the glandular secretions.			Finding	
C113737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113737>	C16742	ADVIA Centaur|Siemens ADVIA Centaur	A proprietary high-throughput chemiluminescent immunoassay system manufactured by Siemens.			Manufactured Object	
C113738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113738>	C16742	Dimension with Heterogeneous Module|Dimension with HM|Siemens Dimension HM	A proprietary integrated chemistry system for high-throughput integration of chemistry and immunoassay testing manufactured by Siemens.			Manufactured Object	
C113739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113739>	C16742	Immulite|Siemens Immulite	A proprietary instrument for immunoassay analysis manufactured by Siemens.			Manufactured Object	
C11373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11373>	C61063	Carboxyamidotriazole/Ketoconazole|CAI/KCZ			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113740>	C131659	Hyperfibrinogenemia|Fibrinogenemia	Abnormally high level of fibrinogen in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113741>	C16742	Vitros ECi	A proprietary immunodiagnostic chemiluminescent system manufactured by Ortho Clinical Diagnostics.			Manufactured Object	
C113742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113742>	C26791	Excessive Bleeding	Abnormally heavy or prolonged loss of blood.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113743>	C37921	Excessive Bruising	Bruising that is disproportionately high to the amount of trauma received or reported.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113744>	C19157	Homogenate	Material that has been treated so as to be largely uniform throughout.			Physical Object	
C113745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113745>	C192998	Cell Pellet|CELL PELLET|Whole Cell Pellet	A cell sample collected and compacted by centrifugation of a liquid suspension.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113746>	C17610	Dried Blood Spot|Blood Spot Card	Capillary blood collected on blotting paper, typically from heel or finger stick.			Body Substance	SeroNet Authorized Values|SeroNet Study Descriptors
C113747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113747>	C70700	Buccal Swab|Buccal Scraping|Buccal Smear|Buccal Swabbing|Buccal swab/scraping	The collection of cells from the inside of a person's cheek using a swab collection device.			Laboratory Procedure	
C113748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113748>	C16205	Chart Abstraction	The process of reading the record of a health encounter to determine and document the condition the patient had, the cause, and the treatment prescribed. This information is typically assigned standard clinical terminology codes.			Health Care Activity	
C113749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113749>	C112210	Acute Hemorrhagic Edema of Infancy	A self-limiting cutaneous vasculitis that typically presents as a clinical triad of purpura, edema, and fever in children between the ages of four months and two years old. It is usually associated with a recent history of upper respiratory infection and/or antibiotic therapy.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11374>	C61007	Mycophenolate Mofetil/Tacrolimus|FK506/MMF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113750>	C35553	Hyperphosphatemia	Abnormally high level of phosphate in the blood.			Laboratory or Test Result	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113751>	C81326|C187275	Transaminitis|Elevated Transaminases|Elevated Transaminases|Hypertransaminasemia|Hypertransaminasemia	Abnormally high levels of alanine transaminase (ALT) and/or aspartate transaminase (AST) in the blood.			Laboratory or Test Result	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113753>	C62439	Twenty Four|24|Twenty-Four	A natural number greater than twenty-three and less than twenty-five and the quantity that it denotes.			Quantitative Concept	
C113754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113754>	C35867	Granulomatosis	A general term that refers to non-neoplastic and neoplastic disorders characterized by the presence of granulomas in various anatomic sites.			Finding	
C113755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113755>	C81326|C187275	Hyperamylasemia|Elevated Amylase|Elevated Amylase	Abnormally high level of amylase in the blood.			Laboratory or Test Result	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113756>	C81326	Pleocytosis	Abnormally high cell count in a body fluid.			Laboratory or Test Result	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C113757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113757>	C26003	PRSS1 Gene|PRSS1|PRSS1|Protease, Serine, 1 (Trypsin 1) Gene	This gene is involved in protein catabolism.	PRSS1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113758>	C113757	PRSS1 wt Allele|Protease, Serine, 1 (Trypsin 1) wt Allele|Protease, Serine, 1 Gene|TRP1|TRY1|TRY4|TRYP1|Trypsinogen, Cationic Gene	Human PRSS1 wild-type allele is located in the vicinity of 7q34 and is approximately 4 kb in length. This allele, which encodes trypsin-1 protein, plays a role in proteolysis and digestion. Mutations in this gene are associated with both hereditary pancreatitis and trypsinogen deficiency.	PRSS1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113759>	C17123	Trypsin-1|Beta-trypsin|Cationic Trypsinogen|Digestive Zymogen|EC 3.4.21.4|Nonfunctional Trypsin 1|PRSS1|Serine Protease 1|Trypsin 1|Trypsin I|Trypsinogen 1|Trypsinogen A	Trypsin-1 (247 aa, ~27 kDa) is encoded by the human PRSS1 gene. This protein is involved in proteolysis.	Trypsin-1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11375>	C61063	Omeprazole/Porfimer Sodium|DHE/OMEP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113760>	C154302	H3-3B Gene|H3-3B|H3-3B|H3.3 Histone B Gene|H3F3B|H3F3B|H3F3B Gene	This gene plays a role in nucleosome assembly.	H3F3B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C113761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113761>	C113760	H3-3B wt Allele|H3 Histone Family Member 3B Gene|H3 Histone, Family 3B (H3.3B) Gene|H3 Histone, Family 3B Gene|H3.3 Histone B wt Allele|H3.3B|H3F3B|H3F3B wt Allele	Human H3-3B wild-type allele is located in the vicinity of 17q25.1 and is approximately 9 kb in length. This allele, which encodes histone H3.3 protein, is involved in nucleosomal structure.	H3F3B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113762>	C28533|C158414	ATP1A1 Gene|ATP1A1|ATP1A1|ATP1A1|ATPase Na+/K+ Transporting Subunit Alpha 1 Gene	This gene is involved in both ion transport and ATP metabolism.	ATP1A1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C113763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113763>	C113762	ATP1A1 wt Allele|ATPase Na+/K+ Transporting Subunit Alpha 1 wt Allele|ATPase, Na+/K+ Transporting, Alpha 1 Polypeptide Gene|ATPase, Na+/K+ Transporting, Alpha-1 Polypeptide Gene|CMT2DD|RP4-655J12.1	Human ATP1A1 wild-type allele is located in the vicinity of 1p21 and is approximately 38 kb in length. This allele, which encodes sodium/potassium-transporting ATPase subunit alpha-1 protein, plays a role in both ATP metabolism and cation transport.	ATP1A1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113764>	C16386|C158419	Sodium/Potassium-Transporting ATPase Subunit Alpha-1|ATP1A1|EC 3.6.3.9|Na(+)/K(+) ATPase Alpha-1 Subunit|Na+, K+ ATPase Alpha Subunit|Na+/K+ ATPase 1|Na, K-ATPase, Alpha-A Catalytic Polypeptide|Na,K-ATPase Alpha-1 Subunit|Na,K-ATPase Catalytic Subunit Alpha-A Protein|Sodium Pump 1|Sodium Pump Subunit Alpha-1|Sodium-Potassium ATPase Catalytic Subunit Alpha-1|Sodium-Potassium-ATPase, Alpha 1 Polypeptide|Sodium-Potassium-ATPase, Alpha-1 Polypeptide	Sodium/potassium-transporting ATPase subunit alpha-1 (1023 aa, ~113 kDa) is encoded by the human ATP1A1 gene. This protein is involved in both cation transport and ATP hydrolysis.	Sodium/Potassium-Transporting ATPase Subunit Alpha-1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113765>	C28533|C158414	ATP2B3 Gene|ATP2B3|ATP2B3|ATP2B3|ATPase Plasma Membrane Ca2+ Transporting 3 Gene	This gene plays a role in ATP-dependent calcium transport.	ATP2B3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C113766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113766>	C113765	ATP2B3 wt Allele|ATPase Plasma Membrane Ca2+ Transporting 3 wt Allele|ATPase, Ca(2+)-Transporting, Plasma Membrane, 3 Gene|ATPase, Ca++ Transporting, Plasma Membrane 3 Gene|CLA2|Cerebellar Ataxia 2 (X-Linked) Gene|OPCA|PMCA3|PMCA3a|Plasma Membrane Ca(2+)-ATPase, Type 3 Gene|SCAX1|Spinocerebellar Ataxia, X-Linked 1 Gene	Human ATP2B3 wild-type allele is located within Xq28 and is approximately 65 kb in length. This allele, which encodes plasma membrane calcium-transporting ATPase 3 protein, is involved in both cation transport and ATP hydrolysis. Mutation of the gene is associated with spinocerebellar ataxia, X-linked type 1.	ATP2B3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113767>	C16386|C158419	Plasma Membrane Calcium-Transporting ATPase 3|ATP2B3|Cilia and Flagella Associated Protein 39|EC 3.6.3.8, Formerly|EC 7.2.2.10|PMCA3|Plasma Membrane Calcium ATPase|Plasma Membrane Calcium ATPase Isoform 3|Plasma Membrane Calcium Pump|Plasma Membrane Calcium Pump Isoform 3	Plasma membrane calcium-transporting ATPase 3 (1220 aa, ~134 kDa) is encoded by the human ATP2B3 gene. This protein plays a role in both ATP hydrolysis and calcium transport.	Plasma Membrane Calcium-Transporting ATPase 3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113768>	C27088	Direct Hyperbilirubinemia|Conjugated Hyperbilirubinemia|Conjugated Hyperbilirubinemia	Abnormally high level of conjugated bilirubin in the blood.			Laboratory or Test Result	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C113769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113769>	C25993	CACNA1D Gene|CACNA1D|CACNA1D|CACNA1D|Calcium Voltage-Gated Channel Subunit Alpha1 D Subunit Gene	This gene is involved in voltage-dependent calcium transport.	CACNA1D Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C11376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11376>	C61007	Cisplatin/Docetaxel/Fluorouracil|CDDP/5-FU/TXT			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113770>	C113769	CACNA1D wt Allele|CACH3|CACN4|CACNL1A2|CCHL1A2|Calcium Channel, Voltage-Dependent, L Type, Alpha 1D Subunit Gene|Calcium Channel, Voltage-Dependent, L Type, Alpha-1D Subunit Gene|Calcium Voltage-Gated Channel Subunit Alpha1 D wt Allele|Cav1.3|PASNA|SANDD	Human CACNA1D wild-type allele is located in the vicinity of 3p14.3 and is approximately 318 kb in length. This allele, which encodes voltage-dependent L-type calcium channel subunit alpha-1D protein, plays a role in voltage-dependent membrane polarization. Mutation of the gene is associated with sinoatrial node dysfunction and deafness.	CACNA1D wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113771>	C28505	Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1D|CACNA1D|Calcium Channel, L Type, Alpha-1 Polypeptide|Calcium Channel, L Type, Alpha-1 Polypeptide, Isoform 2|Calcium Channel, Neuroendocrine/Brain-Type, Alpha 1 Subunit|Voltage-Gated Calcium Channel Alpha 1 Subunit|Voltage-Gated Calcium Channel Alpha Subunit Cav1.3|Voltage-Gated Calcium Channel Subunit Alpha Cav1.3	Voltage-dependent L-type calcium channel subunit alpha-1D (2161 aa, ~245 kDa) is encoded by the human CACNA1D gene. This protein is involved in calcium transport.	Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1D		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113772>	C62438	Positive Number|Positive	A quantity having a value greater than zero.			Conceptual Entity	
C113773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113773>	C217133|C15190	Transthoracic Needle Biopsy|TTNA|TTNB|Transthoracic Needle Aspiration Biopsy	A diagnostic procedure in which a needle is inserted in the thoracic cavity to detect lesions of the pleura, lung parenchyma, or mediastinum.	Transthoracic Needle Biopsy		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C113774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113774>	C23020	Nickel Peroxidase Method|Nickel method	An immunohistochemistry staining method using horseradish peroxidase, DAB substrate, and nickel chloride.			Laboratory Procedure	
C113775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113775>	C16809	Magnetic Resonance Cholangiopancreatography|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|MRCP|MRCP	A non-invasive procedure in which magnetic resonance imaging is used to visualize the intrahepatic and extrahepatic bile ducts, the pancreatic duct, and the surrounding parenchyma.	Magnetic Resonance Cholangiopancreatography		Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C113776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113776>	C13442	Punctate	Having tiny spots or depressions.			Spatial Concept	
C113777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113777>	C19498	Waiver	A formal statement that says a right, claim, law, or rule can be ignored.			Intellectual Product	
C113778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113778>	C25341	Off-Site	Taking place or located away from the study site.			Spatial Concept	
C113779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113779>	C21514	Timely	Happening at the appropriate time; not happening too late.			Qualitative Concept	
C11377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11377>	C61063	Amifostine/Cisplatin/Cyclophosphamide/Etoposide|CDDP/CTX/VP-16/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113780>	C94852	Live in Own Home|Live in own home|Living in Own Home	An indication that an individual is living in their home.			Conceptual Entity	
C113781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113781>	C94852	Live in Assisted Living Facility|Live in assisted living|Living in Assisted Living Facility	An indication that an individual is living in an assisted living facility.			Conceptual Entity	
C113782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113782>	C94852	Live in a Nursing Home|Live in a nursing home|Living in a Nursing Home	An indication that an individual is living in a nursing home.			Conceptual Entity	
C113783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113783>	C94852	Live with Child or Children|Live with child/children|Living with Child or Children	An indication that an individual is living in the home of their child.			Conceptual Entity	
C113784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113784>	C94852	Live with Friends|Live with friends|Living with Friends	An indication that an individual is living in the home of a friend.			Conceptual Entity	
C113785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113785>	C27088	Indirect Hyperbilirubinemia|Unconjugated Hyperbilirubinemia|Unconjugated Hyperbilirubinemia	Abnormally high level of unconjugated bilirubin in the blood.			Laboratory or Test Result	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C113786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113786>	C717|C49146|C222795	Enadenotucirev|Chimeric Oncolytic Adenovirus Ad3/Ad11p Containing Two Deletions in the Viral Genome in the E3 Region (2444 bp) and in the E4 Region (24 bp) and 197 Non-homologous Nucleotides in the E2B Region|ColoAd-1|ColoAd1|ColoAd1 Oncolytic Virus|ENADENOTUCIREV|EnAd	A complex, replication-selective, chimeric adenovirus type 11p (Ad11p)/Ad3 oncolytic virus vaccine, with potential antineoplastic and immunomodulating activities. Enadenotucirev has the Ad11p backbone with a large deletion in the E3-region and a small E4-domain (E4orf4) deleted, in addition to a partial E2B substitution by the Ad3 E2B genes. Upon intravenous administration of enadenotucirev, the adenovirus selectively reaches the tumor cells due to the leaky tumor vasculature and replicates in cancer cells; however, it is unable to replicate in normal, healthy cells. This induces a selective adenovirus-mediated cytotoxicity in cancer cells, which leads to cancer lysis. Following the lysis of infected cells, the replicated virus is released and can infect adjacent cells, which both induces further tumor cell oncolysis and may activate, through the release of tumor-associated antigens (TAAs) and inflammatory mediators from the lysed tumor cells, the immune system to mount an anti-tumor immune response. This further kills tumor cells. This may also stimulate long-term anti-tumor immunity. Although the cancer-selectivity of enadenotucirev is not entirely understood, the virus does not efficiently infect normal cells.	Enadenotucirev		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113787>	C471	6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatases Isoform 3 Inhibitor ACT-PFK-158|ACT-PFK-158|PFK-158|PFKFB3 Inhibitor PFK-158	An inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases (PFK-2/FBPase) isoform 3 (PFKFB3) and derivative of 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), with potential antineoplastic activity. Upon administration, PFKFB3 inhibitor PFK-158 binds to and inhibits the activity of PFKFB3, which leads to the inhibition of both the glycolytic pathway in and glucose uptake by cancer cells. This prevents the production of macromolecules and energy that causes the enhanced cellular proliferation in cancer cells as compared to that of normal, healthy cells. Depriving cancer cells of nutrients and energy leads to the inhibition of cancer cell growth. PFKFB3, an enzyme that catalyzes the conversion of fructose-6-phosphate to fructose-2,6-bisphosphate, is highly expressed and active in human cancer cells; it plays a key role in increasing both glycolytic flux in and proliferation of cancer cells.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113788>	C471	UAE Inhibitor TAK-243|AOB87172|MLN7243|TAK-243|TAK-243	A small molecule inhibitor of ubiquitin-activating enzyme (UAE), with potential antineoplastic activity. UAE inhibitor TAK-243 binds to and inhibits UAE, which prevents both protein ubiquitination and subsequent protein degradation by the proteasome. This results in an excess of proteins in the cells and may lead to endoplasmic reticulum (ER) stress-mediated apoptosis. This inhibits tumor cell proliferation and survival. UAE, also called ubiquitin E1 enzyme (UBA1; E1), is more active in cancer cells than in normal, healthy cells.	UAE Inhibitor TAK-243		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113789>	C2153	IGF-methotrexate Conjugate|765IGF-MTX|IGF/MTX|IGF/MTX Conjugate	A conjugate containing the antimetabolite and antifolate agent methotrexate conjugated to insulin-like growth factor (IGF), with potential antineoplastic activity. After intravenous administration, the IGF moiety of the IGF-methotrexate conjugate binds to and is internalized by IGF receptors (IGFR) on the surface of tumor cells. Following cell entry, the methotrexate then binds to and inhibits the enzyme dihydrofolate reductase, which catalyzes the conversion of dihydrofolate to tetrahydrofolate. This results in both the inhibition of DNA and RNA synthesis and the induction of death in rapidly dividing cells. Binding to IGFR can localize the cytotoxic effect of methotrexate in tumor cells. This may increase its efficacy while decreasing its toxicity to normal, healthy cells. IGFR is overexpressed on many types of cancer cells and has been implicated in metastasis and resistance to apoptosis.	IGF-methotrexate Conjugate		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11378>	C61007	Cyproterone/Luteinizing Hormone-Releasing Factor|CPTR/LHRH			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113791>	C65141	Wheatgrass Juice|TRITICUM AESTIVUM IMMATURE TOP JUICE|Wheat Germ Juice	The juice extracted from the mature sprouts of wheatgrass, Triticum aestivum, which is a member of the Poaceae family, with potential anti-inflammatory, immunomodulating and chemopreventive activities. Wheatgrass juice contains many vitamins, including A, B vitamins, C and E, minerals, including selenium, iron, magnesium, calcium, manganese, copper and zinc, amino acids, chlorophyll and a number of antioxidant enzymes, including superoxide dismutase and cytochrome oxidase. Although the exact mechanism(s) of action through which wheatgrass juice exerts its effect(s) has yet to be fully elucidated, the components in the juice may scavenge free radicals, reduce chemotherapy-induced myelotoxicity, neutralize toxins and carcinogens and modulate the levels of certain pro-inflammatory cytokines, such as interleukin (IL)- 6, IL-8, IL-10 and IL-12.			Food	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C113792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113792>	C174048|C155764	Dordaviprone|Akt/ERK Inhibitor ONC201|DORDAVIPRONE|ONC201|TIC10	A water soluble, orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) and extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon administration, dordaviprone binds to and inhibits the activity of Akt and ERK, which may result in inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt signal transduction pathway as well as the mitogen-activated protein kinase (MAPK)/ERK-mediated pathway. This may lead to the induction of tumor cell apoptosis mediated by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)/TRAIL death receptor type 5 (DR5) signaling in AKT/ERK-overexpressing tumor cells. The PI3K/Akt signaling pathway and MAPK/ERK pathway are upregulated in a variety of tumor cell types and play a key role in tumor cell proliferation, differentiation and survival by inhibiting apoptosis. In addition, ONC201 is able to cross the blood-brain barrier.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113793>	C141137|C129820	Navoximod|5H-Imidazo(5,1-a)isoindole-5-ethanol, 6-Fluoro-alpha-(trans-4-hydroxycyclohexyl)-, (AlphaR,5S)-|GDC-0919|NAVOXIMOD|NLG-919|NLG919|RG6078|RO7077339-001	An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon administration, navoximod targets and binds to IDO1, a cytosolic enzyme responsible for the oxidation of the essential amino acid tryptophan into kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, this agent increases tryptophan levels, restores the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes, and causes a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL) response against the IDO1-expressing tumor cells. IDO1 is overexpressed by a variety of tumor cell types and plays an important role in immunosuppression. Tryptophan depletion is associated with immunosuppression caused by T-cell suppression.	Navoximod		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113794>	C28310	CD133 Antigen Peptide-pulsed Autologous Dendritic Cell Vaccine|CD-133 Dendritic Cell Vaccine|CD133 DC Vaccine	A cell-based cancer vaccine comprised of autologous dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A2-restricted peptides derived from the CD133 antigen, with potential antineoplastic activity. Upon intradermal administration, the CD133 antigen peptide-pulsed autologous DC vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against CD133-expressing tumor cells, resulting in tumor cell lysis. CD133, a cancer stem cell marker, is expressed on hematopoietic stem and progenitor cells and overexpressed on many types of cancer cells; it is associated with resistance to chemotherapy and increased cancer survival. HLA-A2 is an MHC class I molecule that presents antigenic peptides to CD8+ T-cells. Epitope design that is restricted to those epitopes that bind most efficiently to HLA-A2 may improve antigenic peptide immunogenicity.			Cell|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113795>	C1891	Immediate-release Onapristone|IR Onapristone	An immediate-release (IR) formulation of onapristone, an orally bioavailable progesterone receptor (PR) antagonist, with antineoplastic activity. Onapristone binds to the PR and inhibits both PR activation and the associated expression of PR-responsive genes. This may inhibit PR-mediated proliferative effects in cancer cells overexpressing PR. PR is expressed on certain cancer cell types and plays a key role in proliferation and survival.			Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113796>	C1327	Anti-von Willebrand Factor Nanobody|Anti-vWf Nanobody	A humanized, bivalent anti-von Willebrand factor (VWF) nanobody with potential anti-platelet activity. Anti-von Willebrand factor nanobody specifically binds to the A1 domain of the VWF molecule, thereby inhibiting and neutralizing VWF activity. This prevents the interaction of VWF with the platelet glycoprotein (Gp)Ib-IX-V receptor and prevents VWF-mediated platelet aggregation. VWF is a glycoprotein and plays a key role in blood coagulation. Increased VWF, which is seen in a number of diseases, is associated with an increased risk in thrombosis. The nanobody formulation allows for rapid distribution, onset of action and clearance. The nanobody is based on the smallest functional fragments of single-chain antibodies that naturally occur in the Camelidae family.	Anti-von Willebrand Factor Nanobody		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C113797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113797>	C1891	Extended-release Onapristone|ER Onapristone	An extended-release (ER) formulation of onapristone, an orally bioavailable progesterone receptor (PR) antagonist, with antineoplastic activity. Onapristone binds to the PR and inhibits both PR activation and the associated expression of PR-responsive genes. This may inhibit PR-mediated proliferative effects in cancer cells overexpressing PR. PR is expressed on certain cancer cell types and plays a key role in proliferation and survival.			Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113798>	C2139	Recombinant Globulin Component Macrophage-activating Factor|Recombinant GC Protein-derived Macrophage-activating Factor|Recombinant GC-MAF	A recombinant form of naturally-occurring GC (group-specific component) protein-derived macrophage-activating factor (GC-MAF). GC is also known as vitamin D binding protein (VDBP). GC-MAF promotes macrophage activation.			Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113799>	C797|C275|C2080|C129820	Uncaria tomentosa Extract|CAT'S CLAW|Cat's Claw Herbal Extract	An extract of Uncaria tomentosa (U. tomentosa), also called Cat's claw, a native Amazonian plant belonging to the Rubiaceae species, with potential anti-inflammatory, immunomodulating, antioxidant and antineoplastic activities. Although the exact mechanism(s) by which U. tomentosa extract exerts its effect(s) has yet to be fully elucidated, this extract may inhibit the proliferation of certain types of cancer cells. This extract may modulate inflammatory and immune responses through the stimulation of T- and B-lymphocytes and certain cytokines, including interleukin (IL)-1, IL-6 and tumor necrosis factor-alpha (TNF-a). Components in U. tomentosa may both induce repair of chemically-induced DNA damage and scavenge free radicals, which may protect against reactive oxygen species (ROS)-mediated cellular damage. In addition, this extract stimulates myelopoiesis, which may prevent chemotherapy-induced neutropenia.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11379>	C61063	Octreotide/Prednisone|PRED/SSTN			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1137>	C28500	Iopromide|IOPROMIDE|Ultravist	A contrast medium.			Indicator, Reagent, or Diagnostic Aid|Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C113800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113800>	C224843	Oxidized Avidin|AvidinOX	An oxidized form of the glycoprotein avidin, that can be used as a linking agent for tissue-pretargeted radionuclide therapy. Upon intralesional administration, the aldehyde groups of oxidized avidin strongly bind to the amino groups on tissue proteins, via the formation of Schiff bases.  As avidin is able to strongly bind to biotin, intravenous administration of radiolabeled biotin may lead to the selective eradication of the pre-targeted tumor cells.			Indicator, Reagent, or Diagnostic Aid	NCI Drug Dictionary Terminology
C113801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113801>	C2124|C129819	Lutetium Lu 177 DOTA-biotin|177Lu-ST2210|CABIOTRAXETAN LUTETIUM LU-177|[177Lu]DOTA-biotin	A radioconjugate of biotin conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and labeled with the beta-emitting isotope lutetium Lu 177 (Lu-177) that can be used for radioimmunotherapeutic purposes.  Lutetium Lu 177 DOTA-biotin could be used in pre-targeting radioimmunotherapy, which pretreats the lesion with oxidized avidin that binds to protein amino groups on cells. As avidin binds to biotin, the radioisotope can be selectively delivered to cancer cells leading to tumor cell eradication.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113802>	C164001|C129822	Anti-c-Met Monoclonal Antibody ARGX-111|ARGX-111	A human monoclonal antibody targeting c-Met, with potential antineoplastic activity. Anti-c-Met monoclonal antibody ARGX-111 binds to c-Met, and blocks both ligand-dependent and -independent activation of c-Met-mediated signaling pathways. In addition, this agent enhances antibody dependent cellular cytotoxicity (ADCC). This leads to a reduction in cell proliferation of c-Met-expressing cancer cells. c-Met, a receptor tyrosine kinase overexpressed in certain cancer cell types, is involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors. Compared to other c-Met targeting monoclonal antibodies, ARGX-111 shows increased antibody circulation time, enhanced tissue distribution and increased efficacy. ARGX-111 is obtained through active immunization with C-met antigen in Camelids and utilizes the Camelid V-domains fused with human antibody backbones.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113803>	C201556|C129826	Autologous Mesenchymal Stem Cells Apceth_101|Agenmestencel-T|Autologous MSC_Apceth_101	Human autologous mesenchymal stem cells (MSCs) harvested from the bone marrow of a patient and genetically modified with a self-inactivating retroviral vector expressing the suicide gene herpes simplex virus thymidine kinase (HSV-TK), that can be used to activate synthetic acyclic guanosine analogues when co-administered. Upon intravenous administration of autologous mesenchymal stem cells apceth_101, the cells are actively recruited to the tumor stroma, differentiate into more mature mesenchymal cells, and become part of the tumor microenvironment. When a synthetic acyclic guanosine analogue, such as ganciclovir, is co-administered, the HSV-TK within the HSV-TK-transduced MSCs will monophosphorylate this prodrug. Subsequently the monophosphate form is further converted to the diphosphate form and then to its active triphosphate form by cellular kinases. The active form of ganciclovir kills the HSV-TK-transduced MSCs and leads to a bystander effect, which eliminates neighboring cancer cells. Therefore, synthetic acyclic guanosine analogues are activated only at the tumor site, which increases their local efficacy and reduces systemic toxicity.			Cell|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113804>	C1892	Sulforaphane-cyclodextrin Complex|SFX-01|Stabilized Sulforaphane|Sulforadex|Sulforadex	An orally available, stable powder formulation composed of sulforaphane, a naturally-occurring phytochemical belonging to the class of isothiocyanates, encapsulated within alpha-cyclodextrin, with chemopreventive activity. Upon administration of sulforaphane/alpha-cyclodextrin complex SFX-01, sulforaphane activates the transcription factor NF-E2-related factor 2 (Nrf2; NFE2L2), a member of the basic leucine zipper family, which binds to and activates antioxidant-response elements (AREs). Subsequently, activated AREs mediate the transcription of various cytoprotective genes and antioxidant enzymes, particularly phase II detoxification enzymes, such as glutathione-S-transferase and quinone oxidoreductase, resulting in the detoxification of highly reactive carcinogens. Cyclodextrin is able to prevent sulforaphane's rapid breakdown, which improves its stability and half-life.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C113805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113805>	C1511	Gallium Ga 68-labeled MLN6907|[68Ga]MLN6907	A radioconjugate containing a monoclonal antibody directed against guanylyl cyclase C (GCC) labeled with the radioisotope gallium Ga 68, with positron emission tomography (PET) imaging activity. The monoclonal antibody moiety of MLN6907 selectively binds to GCC, a transmembrane receptor normally found on intestinal cells and dopaminergic neurons in the brain, that is also overexpressed on the surface of a variety of cancer cells. Upon internalization of the agent and PET, tumors expressing GCC can be visualized.	Gallium Ga 68-labeled MLN6907		Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C113806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113806>	C2124	Carbon C11 Temozolomide|[11C] Temozolomide	A radioconjugate composed of temozolomide, a imidazotetrazine analog of dacarbazine, labeled with the radioisotope carbon C11, with potential positron emission tomography (PET) imaging activity. As a cytotoxic alkylating agent, temozolomide is hydrolyzed at physiologic pH to the pharmacologically active compound, 5-(3-methyl-(triazen-1-yl)-imidazole)-4-carboxamide (MTIC). MTIC is further hydrolyzed to 5-aminoimidazole-4-carboxamide (AIC) and a methyldiazonium cation. The cation is able to methylate DNA, particularly at the O6 and N7 positions of guanine residues, resulting in cell cycle arrest, inhibition of DNA replication and the induction of apoptosis. Temozolomide is metabolized to MITC at all sites, crosses the blood-brain-barrier and penetrates well into the central nervous system. Upon PET, the biodistribution, uptake in cancer cells and the efficacy of temozolomide can be assessed.	Carbon C11 Temozolomide		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113807>	C28310	DLK1/EPHA2/HBB/NRP1/RGS5/TEM1 Peptide-pulsed Alpha-type-1 Polarized Dendritic Cell Vaccine|Tumor Blood Vessel Antigen Peptide-pulsed Alpha-type-1 Polarized Dendritic Cell Vaccine|alphaDC1-TBVA Vaccine	A cell based cancer vaccine composed of mature polarized dendritic cells (alphaDC1) pulsed with six human leukocyte antigen (HLA)-A2-presented tumor blood vessel antigen (TBVA)-derived peptides, with potential immunostimulatory and antineoplastic activities. Dendritic cells (DCs) were treated with a "type-1 polarizing cytokine cocktail", including interleukin-1beta, tumor necrosis factor alpha (TNF-a), interferon-alpha (IFN-a), IFN-gamma and polyinosinic:polycytidylic acid (pI:C) to produce mature alpha type-1 polarized DCs (alphaDC1) that are capable of producing high levels of interleukin-12p70 (IL-12p70). The alphaDC1 are subsequently pulsed with TBVA-derived peptides, including delta-like homologue 1 (DLK1) 310-318, EPH receptor A2 (EPHA2) 883-891, beta-globin (HBB) 31-39, neuropilin-1 (NRP1) 433-441, regulator of G-protein signaling 5 (RGS5) 5-13 and tumor endothelial marker 1 (TEM1) 691-700. Upon administration, these DCs are able to induce a potent cytotoxic T-lymphocyte (CTL) response against the TBVAs expressed on tumor-associated stromal cells, which results in stromal cell lysis and inhibition of angiogenesis. Disrupting the surrounding tumor vasculature inhibits tumor cell growth and survival. alphaDC1 are able to induce a potent tumor antigen-specific CTL response due to their high co-stimulatory activity and the secretion of anti-cancer cytokines, such as IL-12p70.	DLK1/EPHA2/HBB/NRP1/RGS5/TEM1 Peptide-pulsed Alpha-type-1 Polarized Dendritic Cell Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C113808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113808>	C38440|C35682|C175007	Monoclonal Band|M Protein Present|M Spike Present|M-Band|M-Band Present|M-Protein|M-Protein Present|M-Spike|M-Spike Present|Monoclonal Band Present|Monoclonal Protein Detected|Monoclonal Protein Positive|Monoclonal Protein Present|Monoclonal Spike|Monoclonal Spike Present|Paraprotein Present	Monoclonal immunoglobulin or monoclonal light chain that is present in the serum and/or urine. It is the result of a clonal B-cell or plasma cell proliferation.	Monoclonal Band		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113809>	C38440|C175007	Oligoclonal Bands|OCBs|Oligoclonal Band|Oligoclonal Bands Present	The presence of more than one immunoglobulin band in the serum, urine, or cerebrospinal fluid. It usually results from infectious or immunologic disorders.			Laboratory or Test Result	
C11380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11380>	C61063	Carboplatin/Estramustine/Filgrastim/Paclitaxel|CBDCA/EM/G-CSF/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113810>	C74750|C15958	High Sensitivity Troponin T Assay|HS-TROP-T|High Sensitivity Troponin T|High Sensitivity Troponin T|High-Sensitivity Cardiac Troponin T Assay|High-Sensitivity Troponin T Assay|Trop-T HS|Troponin-T HS|hs-cTnT|hsTnT	A chemiluminescence immunoassay capable of detecting very low levels of troponin T in serum.	High Sensitivity Troponin T		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113811>	C15313	Extended-Field Radiation Therapy|EFRT|Extended field radiation	Radiation treatment delivered to large areas of the body, used primarily in patients with Hodgkin lymphoma. It involves the treatment of the lymph nodes that are affected by the disease, as well as the surrounding lymph node areas that the disease may have affected but is not clinically detected.			Therapeutic or Preventive Procedure	
C113812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113812>	C15313	Involved-Field Radiation Therapy|IFRT|Involved field radiotherapy	Radiation treatment delivered only to the areas of the body that are affected, used primarily in the treatment of lymphoma.	Involved-Field Radiation Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C113813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113813>	C15313	Involved Node Radiation Therapy|INRT|Involved node radiation therapy	Radiation treatment delivered only to the lymph nodes originally involved, used primarily in the treatment of Hodgkin lymphoma.	Involved Node Radiation Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C113814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113814>	C26689	Autoimmune Primary Adrenal Insufficiency|Autoimmune Addison's Disease|Autoimmune Adrenalitis|Autoimmune Adrenalitis	Diminished production of adrenocortical hormones due to autoimmune destruction of the adrenal glands.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C113815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113815>	C12538	T Helper 17 Cell|Th17|Th17 Cell|Th17 cells	A subset of helper T-lymphocytes which synthesize and secrete the interleukins (IL), IL-17A, -21 and -22. These cytokines mediate inflammation by increasing chemokine production, which leads to the recruitment of both monocytes and neutrophils to sites of infection or inflammation. Th17 cells modulate both host immunity against extracellular bacteria and fungi and inflammation. Overexpression of these cells is associated with tissue injury caused by autoimmune diseases.	T Helper 17 Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C113816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113816>	C2289	2-Hydroxyestrogen|2-Hydroxyestrogen Compound|2-Hydroxyestrogens	Any metabolite formed during the catabolism of estrogens by the liver through the hydroxylation of the carbon at position 2 by various cytochrome P450 (CYP) enzymes, including CYP3A4, 1A1 and 1A2. The 2-hydroxyestrogens have minimal estrogenic activity compared to the parent compounds.	2-Hydroxyestrogen		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C113817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113817>	C2289	16-Hydroxyestrogen|16-Hydroxyestrogen Compound|16-Hydroxyestrogens	Any metabolite formed during the catabolism of estrogens by the liver through the hydroxylation of the carbon at position 16 by the enzymes, cytochrome P450 3A4 and 1B1. The 16-hydroxyestrogens may have high estrogenic activity and preferential formation of 16-hydroxyestrogen metabolites may be associated with an elevated risk for breast cancer.	16-Hydroxyestrogen		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C113818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113818>	C20194	HPX Gene|HPX|HPX|Hemopexin Gene	This gene plays a role in both heme binding and iron metabolism.	HPX Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113819>	C113818	HPX wt Allele|HX|Hemopexin wt Allele	Human HPX wild-type allele is located within 11p15.5-p15.4 and is approximately 12 kb in length. This allele, which encodes hemopexin protein, is involved in the metabolism of both iron and hemoglobin.	HPX wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11381>	C61063	BCG/Monoclonal Antibody BEC2|BCG/MOAB BEC2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113820>	C18466	Hemopexin|Beta-1B-Glycoprotein|HPX	Hemopexin (462 aa, ~52 kDa) is encoded by the human HPX gene. This protein plays a role in iron and heme metabolism.	Hemopexin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113821>	C20194	AHSG Gene|AHSG|AHSG|Alpha-2-HS-Glycoprotein Gene	This gene is involved in bone mineralization.	AHSG Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113822>	C113821	AHSG wt Allele|A2HS|AHS|Alpha-2-HS-Glycoprotein wt Allele|FETUA|Feutin, Mouse, Homolog of Gene|HSGA|PRO2743	Human AHSG wild-type allele is located in the vicinity of 3q27 and is approximately 8 kb in length. This allele, which encodes alpha-2-HS-glycoprotein, plays a role in the modulation of bone formation.	AHSG wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113823>	C18466	Alpha-2-HS-Glycoprotein|Alpha-2-Z-Globulin|Ba-Alpha-2-Glycoprotein|Fetuin A|Fetuin-A	Alpha-2-HS-glycoprotein (367 aa, ~39 kDa) is encoded by the human AHSG gene. This protein is involved in the regulation of bone mineralization.	Alpha-2-HS-Glycoprotein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113824>	C2849	Twin-Twin Transfusion Syndrome|Placental Transfusion Syndrome|Placental Transfusion Syndrome|Stuck Twin Syndrome|Stuck Twin Syndrome|TTTS|TTTS	A condition which occurs in monozygotic twins in which one of the fetuses supplies the majority of the cardiac output to its co-twin through its umbilical artery. The recipient twin has only rudimentary organs and structure and is not viable.			Congenital Abnormality	Cellosaurus Disease Terminology|NICHD Terminology|Perinatal Terminology
C113825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113825>	C34941	Vanishing Twin Syndrome|Vanishing Twin|Vanishing Twin	A multiple pregnancy that over time is spontaneously reduced by one or more embryos which are then resorbed.			Finding	NICHD Terminology|Perinatal Terminology
C113826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113826>	C63496|C159461	Bortezomib/Cyclophosphamide/Dexamethasone Regimen|CyBor-D|CyBorD|VCD|VDC|VDC|Velcade-Cyclophosphamide-Dexamethasone	A regimen consisting of bortezomib, cyclophosphamide and dexamethasone that can be used in the treatment of plasma cell (multiple) myeloma and systemic light chain amyloidosis. A dose-modified version may be used for the treatment of systemic light chain amyloidosis.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C113827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113827>	C63496|C159461	RVD Regimen|Bortezomib/Dexamethasone/Lenalidomide|Bortezomib/Dexamethasone/Lenalidomide Regimen|Bortezomib/Lenalidomide/Dexamethasone|Lenalidomide/Bortezomib/Dexamethasone Regimen|RVD|RVD|RVD|Revlimid/Velcade/Dexamethasone|VRD|VRd|Velcade/Revlimid/Dexamethasone	A regimen consisting of bortezomib, dexamethasone and lenalidomide that can be used in the treatment of plasma cell (multiple) myeloma and systemic light chain amyloidosis.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C113828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113828>	C63496	Bortezomib/Dexamethasone/Pegylated Liposomal Doxorubicin Regimen|Bortezomib/Doxil/Dexamethasone|Bortezomib/Liposomal Doxorubicin/Dexamethasone|Bortezomib/Pegylated Liposomal Doxorubicin/Dexamethasone|DVD|PAD (Pegylated liposomal doxorubicin substituted)|VDD|VDD|Velcade/Doxil/Dexamethasone	A regimen consisting of bortezomib, dexamethasone and pegylated liposomal doxorubicin that can be used in the treatment of plasma cell (multiple) myeloma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C113829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113829>	C34941	Discordant Twin|Discordant Growth|Discordant Growth	A twin whose estimated fetal weight is determined to have 20% or greater difference from its sibling.			Finding	NICHD Terminology|Perinatal Terminology
C11382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11382>	C61007	Cyclophosphamide/Tirapazamine|CTX/SR-4233			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113830>	C20719	EPHB4 Gene|EPH Receptor B4 Gene|EPHB4|EPHB4	This gene plays a role in both ephrin-B binding and signal transduction.	EPHB4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113831>	C113830	EPHB4 wt Allele|EPH Receptor B4 wt Allele|EphB4|HTK|MYK, Mouse, Homolog of Gene|MYK1|TYRO11	Human EPHB4 wild-type allele is located in the vicinity of 7q22 and is approximately 25 kb in length. This allele, which encodes ephrin type-B receptor 4 protein, is involved in ligand-dependent signaling pathways.	EPHB4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113832>	C17660	Ephrin Type-B Receptor 4|EC 2.7.10.1|EphB4|Ephrin Receptor EphB4|Tyrosine-Protein Kinase Receptor HTK|Tyrosine-Protein Kinase TYRO11	Ephrin type-B receptor 4 (987 aa, ~108 kDa) is encoded by the human EPHB4 gene. This protein plays a role in ephrin-B binding, tyrosine phosphorylation, and signal transduction.	Ephrin Type-B Receptor 4		Amino Acid, Peptide, or Protein|Enzyme|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113833>	C93047|C92711	Fetal Hypoxemia	Abnormally low arterial blood oxygen concentration in a fetus.			Finding	NICHD Terminology|Perinatal Terminology
C113834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113834>	C25982	IL31 Gene|IL31|IL31|Interleukin 31 Gene	This gene is involved in immunity.	IL31 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C113835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113835>	C2017	4-Hydroxytestosterone|4-HYDROXYTESTOSTERONE|4-Hydroxyandrost-4-ene-3,17-dione|4-Hydroxyandrostenedione|CR1447				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C113836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113836>	C113834	IL31 wt Allele|IL-31|Interleukin 31 wt Allele	Human IL31 wild-type allele is located in the vicinity of 12q24.31 and is approximately 2 kb in length. This allele, which encodes interleukin-31 protein, plays a role in both signal transduction and immunity.	IL31 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113837>	C20497	Interleukin-31|IL-31|IL31|Interleukin 31	Interleukin-31 (164 aa, ~18 kDa) is encoded by the human IL31 gene. This protein is involved in signaling during the immune response.	Interleukin-31		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113838>	C20130	Notch Family|DSL Protein|Notch Protein|Notch Receptor Family|Notch Receptors	A family of transmembrane receptors with multiple extracellular EGF repeats and a DSL (notch) domain. These proteins interact with their cell-bound ligands (from the delta and serrate protein families). This interaction stimulates cell-cell signaling pathways that regulate cell fate decisions during embryogenesis.	Notch Family		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113839>	C20130	Hypoxia Inducible Factor Family|HIF|HIF Factor|HIF Family|Hypoxia Inducible Factor|Hypoxia-Inducible Factor|Hypoxia-Inducible Factor Family	A family of basic helix-loop-helix heterodimeric transcription factors that activate gene expression when oxygen levels decrease in the cellular environment. Each HIF complex is comprised of an alpha subunit and beta subunit, which are encoded by separate genes.	Hypoxia Inducible Factor Family		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11383>	C61063	Amifostine/Cytarabine/Idarubicin|ARA-C/IDA/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113840>	C16295	Brachyury Protein Antibody|Anti-Brachyury|Anti-Brachyury Antibody|Anti-Brachyury Protein|Anti-Brachyury Protein Antibody|Anti-Protein T|Anti-Protein T Antibody|Anti-T|Anti-T Antibody|Anti-T Protein|Anti-T Protein Antibody|Brachyury Antibody|Protein T Antibody|T Protein Antibody	Any immunoglobulin that recognizes brachyury protein (protein T).	Brachyury Protein Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113841>	C20130	Melanoma-Associated Antigen Family|MAGE|MAGE Family|Melanoma-Associated Antigen	A family of proteins that were first detected in male germ cells, placenta and various tumors that were originally not found in normal tissues. Their genes are located in four clusters on the X chromosome. All of the members of the family share a stretch of about 200 amino acids, called the MAGE conserved domain, which is usually located near the C-terminal end of the protein and may allow MAGE proteins to interact with cellular receptors. For most members their entire coding sequences are located in the last exon of their respective genes.	Melanoma-Associated Antigen Family		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C113842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113842>	C35869	Enhancing Lesion|Contrast-Enhancing Lesion	A well-defined area of unequivocally increased signal intensity on MRI or CT scan images compared with the normal-appearing surrounding tissues, following intravenous injection of an enhancing agent.			Finding	
C113843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113843>	C70663	Donation Identification Number Production Identifier	A number assigned to a device that contains human cells or tissue. The number can be found on the device label or packaging.			Intellectual Product	FDA CDRH GUDID Terminology
C113844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113844>	C54694	Labeling does not Contain MRI Safety Information|Labeling does not contain MRI Safety Information	Information on the safety of using a device in a magnetic resonance (MR) environment has not been provided in the labeling by the labeler.			Intellectual Product	FDA CDRH GUDID Terminology
C113845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113845>	C100110	CDISC Questionnaire Borg CR10 Test Name Terminology|BCR101TN|Borg CR10 Scale Questionnaire Test Name|QS-Borg CR10 TEST	Test names of questionnaire questions associated with the Borg CR10 Scale for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113846>	C100110	CDISC Questionnaire Borg CR10 Test Code Terminology|BCR101TC|Borg CR10 Scale Questionnaire Test Code|QS-Borg CR10 TESTCD	Test codes of questionnaire questions associated with the Borg CR10 Scale for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113847>	C100110	CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CSS10TN|Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent Questionnaire Test Name|QS-C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent TEST	Test names of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113848>	C100110	CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CSS10TC|Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent Questionnaire Test Code|QS-C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent TESTCD	Test codes of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113849>	C100110	CDISC Questionnaire Fatigue Severity Scale Test Name Terminology|FSS01TN|Fatigue Severity Scale Questionnaire Test Name|QS-FSS TEST	Test names of questionnaire questions associated with the Fatigue Severity Scale for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11384>	C61063	Fluorouracil/Trimetrexate Glucuronate|5-FU/TMTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113850>	C100110	CDISC Questionnaire Fatigue Severity Scale Test Code Terminology|FSS01TC|Fatigue Severity Scale Questionnaire Test Code|QS-FSS TESTCD	Test codes of questionnaire questions associated with the Fatigue Severity Scale for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113851>	C100110	CDISC Questionnaire Bladder Control Scale Test Name Terminology|BLCS01TN|Bladder Control Scale Questionnaire Test Name|QS-BLCS TEST	Test names of questionnaire questions associated with the Bladder Control Scale for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113852>	C100110	CDISC Questionnaire Bladder Control Scale Test Code Terminology|BLCS01TC|Bladder Control Scale Questionnaire Test Code|QS-BLCS TESTCD	Test codes of questionnaire questions associated with the Bladder Control Scale for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113853>	C100110	CDISC Questionnaire Bowel Control Scale Test Name Terminology|BWCS01TN|Bowel Control Scale Questionnaire Test Name|QS-BWCS TEST	Test names of questionnaire questions associated with the Bowel Control Scale for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113854>	C100110	CDISC Questionnaire Bowel Control Scale Test Code Terminology|BWCS01TC|Bowel Control Scale Questionnaire Test Code|QS-BWCS TESTCD	Test codes of questionnaire questions associated with the Bowel Control Scale for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113855>	C100110	CDISC Questionnaire Impact of Visual Impairment Scale Test Name Terminology|IVIS01TN|Impact of Visual Impairment Scale Questionnaire Test Name|QS-IVIS TEST	Test names of questionnaire questions associated with the Impact of Visual Impairment Scale for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113856>	C100110	CDISC Questionnaire Impact of Visual Impairment Scale Test Code Terminology|IVIS01TC|Impact of Visual Impairment Scale Questionnaire Test Code|QS-IVIS TESTCD	Test codes of questionnaire questions associated with the Impact of Visual Impairment Scale for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113857>	C100110	CDISC Questionnaire Modified Fatigue Impact Scale Test Name Terminology|MFIS01TN|Modified Fatigue Impact Scale Questionnaire Test Name|QS-MFIS TEST	Test names of questionnaire questions associated with the Modified Fatigue Impact Scale for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113858>	C100110	CDISC Questionnaire Modified Fatigue Impact Scale Test Code Terminology|MFIS01TC|Modified Fatigue Impact Scale Questionnaire Test Code|QS-MFIS TESTCD	Test codes of questionnaire questions associated with the Modified Fatigue Impact Scale for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113859>	C100110	CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|MSQL1TN|Multiple Sclerosis Quality of Life-54 Instrument Questionnaire Test Name|QS-MSQOL-54 TEST	Test names of questionnaire questions associated with the Multiple Sclerosis Quality of Life-54 Instrument for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11385>	C61063	Cisplatin/Fluorouracil/ONYX-015|CDDP/5-FU/ONYX-015			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113860>	C100110	CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|MSQL1TC|Multiple Sclerosis Quality of Life-54 Instrument Questionnaire Test Code|QS-MSQOL-54 TESTCD	Test codes of questionnaire questions associated with the Multiple Sclerosis Quality of Life-54 Instrument for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113861>	C100110	CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|QS-RAND-36 V1.0 TEST|R3601TN|RAND 36-Item Health Survey 1.0 Questionnaire Test Name	Test names of questionnaire questions associated with the RAND 36-Item Health Survey 1.0 for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113862>	C100110	CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|QS-RAND-36 V1.0 TESTCD|R3601TC|RAND 36-Item Health Survey 1.0 Questionnaire Test Code	Test names of questionnaire questions associated with the RAND 36-Item Health Survey 1.0 for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113863>	C211913	Borg CR10 Questionnaire Question	A question associated with the Borg CR10 questionnaire.			Intellectual Product	
C113864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113864>	C211913	C-SSRS Pediatric Cognitively Impaired Lifetime Recent Questionnaire Question	A question associated with the C-SSRS Pediatric Cognitively Impaired Lifetime Recent questionnaire.			Intellectual Product	
C113865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113865>	C211913	FSS Questionnaire Question	A question associated with the FSS questionnaire.			Intellectual Product	
C113866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113866>	C211913	BLCS Questionnaire Question	A question associated with the BLCS questionnaire.			Intellectual Product	
C113867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113867>	C211913	BWCS Questionnaire Question	A question associated with the BWCS questionnaire.			Intellectual Product	
C113868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113868>	C211913	IVIS Questionnaire Question	A question associated with the IVIS questionnaire.			Intellectual Product	
C113869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113869>	C211913	MFIS Questionnaire Question	A question associated with the MFIS questionnaire.			Intellectual Product	
C11386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11386>	C61063	Mitoxantrone/Thiotepa/Topotecan|DHAD/TOPO/TSPA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113870>	C211913	MSQOL-54 Questionnaire Question	A question associated with the MSQOL-54 questionnaire.			Intellectual Product	
C113871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113871>	C211913	RAND-36 Questionnaire Question	A question associated with the RAND-36 questionnaire.			Intellectual Product	
C113872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113872>	C91105	Borg Category-Ratio 10 Scale Questionnaire|BCR101|BORG CR10|Borg CR10	A standardized rating scale developed by Gunnar Borg in 1998, which is used primarily in clinical diagnosis to measure perceived exertion or intensities of most kinds of experiences and feelings, such as breathlessness. The questionnaire contains 1 item which is scored ranging from 0 (nothing at all) to infinity.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113873>	C91105	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent Questionnaire|C-SSRS PEDIATRIC/COGNITIVELY IMPAIRED LIFETIME/RECENT|C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent|CSS10	A standardized rating scale developed by Posner et al (version 6/23/10), which is used to determine the presence of suicidal ideation or behavior in pediatric patients. The pediatric/cognitively impaired lifetime/recent version questionnaire contains 20 items across 4 domains; suicidal ideation, intensity of ideation, suicidal behavior and actual attempts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113874>	C91105	Bladder Control Scale Questionnaire|BLCS|BLCS|BLCS01	A standardized rating scale developed by Turnbull et al in 1992, which measures the level of bladder function and control, as well as the extent to which bladder problems have an impact on everyday activities. The questionnaire contains 4 questions which are scored ranging from 0 (not at all) to 4 (daily).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113875>	C91105	Bowel Control Scale Questionnaire|BWCS|BWCS|BWCS01	A standardized rating scale developed by Turnbull et al in 1992, which measures the level of bowel function and control, as well as the extent to which bowel problems have an impact on everyday activities. The questionnaire contains 5 questions which are scored ranging from 0 (not at all) to 4 (daily).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113876>	C91105	Impact of Visual Impairment Scale Questionnaire|IVIS|IVIS|IVIS01	A standardized rating scale developed by the National Multiple Sclerosis Society in 1997, which was based on items derived from the Functional Capacities Assessment developed by the Michigan Commission for the Blind. This questionnaire measures the level of visual function and difficulties with simple visual tasks such as reading and watching television. The questionnaire contains 5 questions which are scored ranging from 0 (not at all difficult) to 3 (could not do due to visual problems).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113877>	C91105	Modified Fatigue Impact Scale Questionnaire|MFIS|MFIS|MFIS01	A standardized rating scale developed by Fisk et al in 1994, which assesses how fatigue may affect a person and the impact of fatigue on quality of life. The questionnaire contains 21 questions which are scored ranging from 0 (never) to 4 (almost always).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113878>	C91105	Multiple Sclerosis Quality of Life-54 Instrument Questionnaire|MSQL1|MSQOL-54|MSQOL-54	A standardized rating scale developed by Vickrey et al in 1995 and 1997, which combines items that are generic and disease-specific to assess quality of life and the level of physical, emotional, and cognitive functions in patients with multiple sclerosis. The questionnaire contains 54 questions and generates 12 subscales: physical function, role limitations due to physical problems, role limitations due to emotional problems, pain, emotional well-being, energy, health perceptions, social function, cognitive function, health distress, sexual function and overall quality of life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113879>	C91105	RAND 36-Item Health Survey 1.0 Questionnaire|R3601|RAND-36 V1|RAND-36 V1.0	A standardized rating scale developed by Hays et al in 1993 and the RAND corporation as part of the Medical Outcome Study, which is a generic measurement of health-related quality of life. This questionnaire contains 36 questions and generates 8 subscales: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, general mental health, social functioning, energy/fatigue, and general health perceptions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11387>	C61007	Amifostine/Carboplatin/Filgrastim/Paclitaxel|CBDCA/G-CSF/TAX/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113880>	C101872	CDR - Sum of Boxes|CDR01-Sum of Boxes|CDR01-Sum of Boxes|CDR0107	Clinical Dementia Rating (CDR) Sum of Boxes.			Intellectual Product	CDISC Clinical Classification CDR Test Code Terminology|CDISC Clinical Classification CDR Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113881>	C101872	CDR - Global CDR|CDR01-Global CDR|CDR01-Global CDR|CDR0108	Clinical Dementia Rating (CDR) Global CDR.			Intellectual Product	CDISC Clinical Classification CDR Test Code Terminology|CDISC Clinical Classification CDR Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113882>	C100117	MDS-UPDRS - Postural Tremor of Left Hand|UPD2-Postural Tremor of Left Hand|UPD2-Postural Tremor of Left Hand|UPD2315B	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Postural Tremor of the Left Hand.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113883>	C100117	MDS-UPDRS - Kinetic Tremor of Right Hand|UPD2-Kinetic Tremor of Right Hand|UPD2-Kinetic Tremor of Right Hand|UPD2316A	The Movement Disorder Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Kinetic Tremor of the Right Hand.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MDS-UPDRS Test Code Terminology|CDISC Questionnaire MDS-UPDRS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113884>	C112460	KFSS - Other Functions|KFSS1-Other Functions|KFSS1-Other Functions|KFSS108	Kurtzke Functional Systems Scores (KFSS) Other functions.			Intellectual Product	CDISC Clinical Classification KFSS Test Code Terminology|CDISC Clinical Classification KFSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113885>	C112460	KFSS - Other Functions Specify|KFSS1-Other Functions Specify|KFSS1-Other Functions Specify|KFSS108A	Kurtzke Functional Systems Scores (KFSS) Any other neurologic findings attributed to MS (specify).			Intellectual Product	CDISC Clinical Classification KFSS Test Code Terminology|CDISC Clinical Classification KFSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113886>	C103494	GAD-7 - Total Score|GAD01-Total Score|GAD01-Total Score|GAD0109	Generalized Anxiety Disorder - 7 (GAD-7) Total score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GAD-7 Test Code Terminology|CDISC Questionnaire GAD-7 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113887>	C103501	PHQ-9 - Total Score|PHQ01-Total Score|PHQ01-Total Score|PHQ0111	Patient Health Questionnaire - 9 (PHQ-9) Total score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ-9 Test Code Terminology|CDISC Questionnaire PHQ-9 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113888>	C113863	Borg CR10 - Rating|BCR101-Rating|BCR101-Rating|BCR10101	Borg Category-Ratio10 Scale (Borg CR10) Rating.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Borg CR10 Test Code Terminology|CDISC Questionnaire Borg CR10 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113889>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Wish to be Dead (Lifetime)|CSS10-Wish to be Dead-Life|CSS10-Wish to be Dead-Life|CSS1001A	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Have you thought about being dead or what it would be like to be dead? Have you wished you were dead or wished you could go to sleep and never wake up? Do you ever wish you weren't alive anymore? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11388>	C61063	Cytarabine/Daunorubicin/Interleukin-11/Sargramostim|ARA-C/DNR/GM-CSF/IL-11			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113890>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Wish to be Dead (Past 1 Month)|CSS10-Wish to be Dead-P1M|CSS10-Wish to be Dead-P1M|CSS1001B	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Have you thought about being dead or what it would be like to be dead? Have you wished you were dead or wished you could go to sleep and never wake up? Do you ever wish you weren't alive anymore? (Past 1 Month).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113891>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Description of Wish to be Dead|CSS10-Wish to be Dead, Describe|CSS10-Wish to be Dead, Describe|CSS1001C	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Description of wishing to be dead.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113892>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Non-Specific Active Suicidal Thoughts (Lifetime)|CSS10-Non-Spec Suicid Thought-Life|CSS10-Non-Spec Suicid Thought-Life|CSS1002A	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Have you thought about doing something to make yourself not alive anymore? Have you had any thoughts about killing yourself? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113893>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Non-Specific Active Suicidal Thoughts (Past 1 Month)|CSS10-Non-Spec Suicid Thought-P1M|CSS10-Non-Spec Suicid Thought-P1M|CSS1002B	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Have you thought about doing something to make yourself not alive anymore? Have you had any thoughts about killing yourself? (Past 1 Month).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113894>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Description of Non-Specific Active Suicidal Thoughts|CSS10-Non-Spec Suicid Thought, Describe|CSS10-Non-Spec Suicid Thought, Describe|CSS1002C	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Description of non-specific active suicidal thoughts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113895>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Active Suicidal Ideation With Any Methods (Not Plan) Without Intent to Act (Lifetime)|CSS10-Idea, No Intent, No Plan-Life|CSS10-Idea, No Intent, No Plan-Life|CSS1003A	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Have you thought about how you would do that or how you would make yourself not alive anymore (kill yourself)? What did you think about? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113896>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Active Suicidal Ideation With Any Methods (Not Plan) Without Intent to Act (Past 1 Month)|CSS10-Idea, No Intent, No Plan-P1M|CSS10-Idea, No Intent, No Plan-P1M|CSS1003B	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Have you thought about how you would do that or how you would make yourself not alive anymore (kill yourself)? What did you think about? (Past 1 Month).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113897>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Description of Active Suicidal Ideation With Any Methods (Not Plan) Without Intent to Act|CSS10-Idea, No Intent, No Plan, Describe|CSS10-Idea, No Intent, No Plan, Describe|CSS1003C	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Description of active suicidal ideation with any methods (not plan) without intent to act.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113898>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Active Suicidal Ideation With Some Intent to Act, Without Specific Plan (Lifetime)|CSS10-Idea, Intent, No Plan-Life|CSS10-Idea, Intent, No Plan-Life|CSS1004A	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) When you thought about making yourself not alive anymore (or killing yourself), did you think that this was something you might actually do? This is different from (as opposed to) having the thoughts but knowing you wouldn't do anything about it. (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113899>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Active Suicidal Ideation With Some Intent to Act, Without Specific Plan (Past 1 Month)|CSS10-Idea, Intent, No Plan-P1M|CSS10-Idea, Intent, No Plan-P1M|CSS1004B	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) When you thought about making yourself not alive anymore (or killing yourself), did you think that this was something you might actually do? This is different from (as opposed to) having the thoughts but knowing you wouldn't do anything about it. (Past 1 Month).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11389>	C61063	Interleukin-11/Sargramostim|GM-CSF/IL-11			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1138>	C514	Itraconazole|(+-)-1-sec-Butyl-4-(p-(4-(p-(((2R*,4S*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-delta(sup 2)-1,2,4-triazolin-5-one|ITRACONAZOLE|Lozanoc|Oriconazole|R 51,211|Sporanox|itraconazole	A synthetic triazole agent with antimycotic properties. Formulated for both topical and systemic use, itraconazole preferentially inhibits fungal cytochrome P450 enzymes, resulting in a decrease in fungal ergosterol synthesis.  Because of its low toxicity profile, this agent can be used for long-term maintenance treatment of chronic fungal infections. (NCI04)	Itraconazole		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C113900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113900>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Description of Active Suicidal Ideation With Some Intent to Act, Without Specific Plan|CSS10-Idea, Intent, No Plan, Describe|CSS10-Idea, Intent, No Plan, Describe|CSS1004C	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Description of active suicidal ideation with some intent to act, without specific plan.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113901>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Active Suicidal Ideation With Specific Plan and Intent (Lifetime)|CSS10-Idea, Plan, Intent-Life|CSS10-Idea, Plan, Intent-Life|CSS1005A	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Have you ever decided how or when you would make yourself not alive anymore/kill yourself? Have you ever planned out (worked out the details of) how you would do it? What was your plan? When you made this plan (or worked out these details), was any part of you thinking about actually doing it? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113902>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Active Suicidal Ideation With Specific Plan and Intent (Past 1 Month)|CSS10-Idea, Plan, Intent-P1M|CSS10-Idea, Plan, Intent-P1M|CSS1005B	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Have you ever decided how or when you would make yourself not alive anymore/kill yourself? Have you ever planned out (worked out the details of) how you would do it? What was your plan? When you made this plan (or worked out these details), was any part of you thinking about actually doing it? (Past 1 Month).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113903>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Description of Active Suicidal Ideation With Specific Plan and Intent|CSS10-Idea, Plan, Intent, Describe|CSS10-Idea, Plan, Intent, Describe|CSS1005C	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Description of active suicidal ideation with specific plan and intent.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113904>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Most Severe Ideation (Lifetime)|CSS10-Most Severe Idea-Life|CSS10-Most Severe Idea-Life|CSS1006A	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Most severe Ideation. (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113905>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Describe Most Severe Ideation (Lifetime)|CSS10-Most Severe Idea, Desc-Life|CSS10-Most Severe Idea, Desc-Life|CSS1006B	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Description of most severe ideation. (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113906>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Most Severe Ideation (Past 1 Month)|CSS10-Most Severe Idea-P1M|CSS10-Most Severe Idea-P1M|CSS1006C	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Most severe Ideation. (Past 1 Month).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113907>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Describe Most Severe Ideation (Past 1 Month)|CSS10-Most Severe Idea, Desc-P1M|CSS10-Most Severe Idea, Desc-P1M|CSS1006D	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Description of most severe ideation. (Past 1 Month).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113908>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Frequency (Lifetime)|CSS10-Most Severe Idea, Frequency-Life|CSS10-Most Severe Idea, Frequency-Life|CSS1007A	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) How many times have you had these thoughts? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113909>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Frequency (Past 1 Month)|CSS10-Most Severe Idea, Frequency-P1M|CSS10-Most Severe Idea, Frequency-P1M|CSS1007B	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) How many times have you had these thoughts? (Past 1 Month).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11390>	C61063	gp100 Antigen/Tyrosinase Peptide|gp100/TYRP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113910>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Frequency Write Response|CSS10-Frequency, Write Response|CSS10-Frequency, Write Response|CSS1007C	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Frequency, write response.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113911>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Actual Suicide Attempt (Lifetime)|CSS10-Actual Attempt-Life|CSS10-Actual Attempt-Life|CSS1008A	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Did you ever do anything to try to kill yourself or make yourself not alive anymore? What did you do? Did you ever hurt yourself on purpose? Why did you do that? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113912>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Actual Suicide Attempt (Past 3 Month)|CSS10-Actual Attempt-P3M|CSS10-Actual Attempt-P3M|CSS1008B	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Did you ever do anything to try to kill yourself or make yourself not alive anymore? What did you do? Did you ever hurt yourself on purpose? Why did you do that? (Past 3 Month).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113913>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Number of Actual Suicide Attempts (Lifetime)|CSS10-Number of Actual Attempts-Life|CSS10-Number of Actual Attempts-Life|CSS1009A	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Total number of actual attempts. (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113914>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Number of Actual Suicide Attempts (Past 3 Months)|CSS10-Number of Actual Attempts-P3M|CSS10-Number of Actual Attempts-P3M|CSS1009B	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Total number of actual attempts. (Past 3 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113915>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Description of Actual Suicide Attempt|CSS10-Actual Attempt, Describe|CSS10-Actual Attempt, Describe|CSS1009C	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Description of actual attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113916>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Non-suicidal Self-injurious Behavior (Lifetime)|CSS10-Non-suicidal Self-injur Behav-Life|CSS10-Non-suicidal Self-injur Behav-Life|CSS1010A	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Has subject engaged in non-suicidal self-injurious behavior? (Lifetime)			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113917>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Non-suicidal Self-injurious Behavior (Past 3 Months)|CSS10-Non-suicidal Self-injur Behav-P3M|CSS10-Non-suicidal Self-injur Behav-P3M|CSS1010B	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Has subject engaged in non-suicidal self-injurious behavior? (Past 3 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113918>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Self-injurious Behavior, Intent Unknown (Lifetime)|CSS10-Self-injur Behav, Intent Unk-Life|CSS10-Self-injur Behav, Intent Unk-Life|CSS1011A	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Has subject engaged in self-injurious behavior, intent unknown? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113919>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Self-injurious Behavior, Intent Unknown (Past 3 Months)|CSS10-Self-injur Behav, Intent Unk-P3M|CSS10-Self-injur Behav, Intent Unk-P3M|CSS1011B	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Has subject engaged in self-injurious behavior, intent unknown? (Past 3 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11391>	C61063	Bryostatin 1/Interleukin-2/Ionomycin|BRYO/IL-2/IONO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113920>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Interrupted Suicide Attempt (Lifetime)|CSS10-Interrupted Attempt-Life|CSS10-Interrupted Attempt-Life|CSS1012A	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Has there been a time when you started to do something to make yourself not alive anymore (end your life or kill yourself) but someone or something stopped you before you actually did anything? What did you do? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113921>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Interrupted Suicide Attempt (Past 3 Months)|CSS10-Interrupted Attempt-P3M|CSS10-Interrupted Attempt-P3M|CSS1012B	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Has there been a time when you started to do something to make yourself not alive anymore (end your life or kill yourself) but someone or something stopped you before you actually did anything? What did you do? (Past 3 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113922>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Number of Interrupted Suicide Attempts (Lifetime)|CSS10-Number of Interrupt Attempts-Life|CSS10-Number of Interrupt Attempts-Life|CSS1013A	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Total number of interrupted. (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113923>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Number of Interrupted Suicide Attempts (Past 3 Months)|CSS10-Number of Interrupt Attempts-P3M|CSS10-Number of Interrupt Attempts-P3M|CSS1013B	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Total number of interrupted. (Past 3 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113924>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Description of Interrupted Suicide Attempt|CSS10-Interrupted Attempt, Describe|CSS10-Interrupted Attempt, Describe|CSS1013C	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Description of interrupted attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113925>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Aborted or Self-interrupted Suicide Attempt (Lifetime)|CSS10-Aborted Attempt-Life|CSS10-Aborted Attempt-Life|CSS1014A	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Has there been a time when you started to do something to make yourself not alive anymore (end your life or kill yourself) but you changed your mind (stopped yourself) before you actually did anything? What did you do? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113926>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Aborted or Self-interrupted Suicide Attempt (Past 3 Months)|CSS10-Aborted Attempt-P3M|CSS10-Aborted Attempt-P3M|CSS1014B	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Has there been a time when you started to do something to make yourself not alive anymore (end your life or kill yourself) but you changed your mind (stopped yourself) before you actually did anything? What did you do? (Past 3 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113927>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Number of Aborted or Self-interrupted Suicide Attempt (Lifetime)|CSS10-Number of Aborted Attempts-Life|CSS10-Number of Aborted Attempts-Life|CSS1015A	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Total number of aborted or self-interrupted. (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113928>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Number of Aborted or Self-interrupted Suicide Attempt (Past 3 Months)|CSS10-Number of Aborted Attempts-P3M|CSS10-Number of Aborted Attempts-P3M|CSS1015B	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Total number of aborted or self-interrupted. (Past 3 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113929>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Description of Aborted Suicide Attempt|CSS10-Aborted Attempt, Describe|CSS10-Aborted Attempt, Describe|CSS1015C	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Description of aborted or self-interrupted attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11392>	C61063	Finasteride/Flutamide|FLUT/MK-906			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113930>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Preparatory Acts or Behaviors Toward Suicide Attempt (Lifetime)|CSS10-Preparatory Acts/Behavior-Life|CSS10-Preparatory Acts/Behavior-Life|CSS1016A	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Have you done anything to get ready to make yourself not alive anymore (to end your life or kill yourself) - like giving things away, writing a goodbye note, getting things you need to kill yourself? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113931>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Preparatory Acts or Behaviors Toward Suicide Attempt (Past 3 Months)|CSS10-Preparatory Acts/Behavior-P3M|CSS10-Preparatory Acts/Behavior-P3M|CSS1016B	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Have you done anything to get ready to make yourself not alive anymore (to end your life or kill yourself) - like giving things away, writing a goodbye note, getting things you need to kill yourself? (Past 3 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113932>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Description of Preparatory Acts or Behaviors Toward Suicide Attempt|CSS10-Preparatory Acts/Behavior, Descr|CSS10-Preparatory Acts/Behavior, Descr|CSS1016C	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Description of preparatory acts or behaviors.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113933>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Suicidal Behavior (Lifetime)|CSS10-Suicidal Behavior-Life|CSS10-Suicidal Behavior-Life|CSS1017A	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Suicidal behavior was present during the assessment period? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113934>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Suicidal Behavior (Past 3 Months)|CSS10-Suicidal Behavior-P3M|CSS10-Suicidal Behavior-P3M|CSS1017B	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Suicidal behavior was present during the assessment period? (Past 3 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113935>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Most Recent Suicide Attempt Date|CSS10-Most Recent Attempt Date|CSS10-Most Recent Attempt Date|CSS1018A	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Most recent attempt date.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113936>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Most Recent Suicide Attempt Actual Lethality/Medical Damage|CSS10-Most Recent Attempt Damage|CSS10-Most Recent Attempt Damage|CSS1018B	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Most recent attempt actual lethality/medical damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113937>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Most Recent Suicide Attempt Potential Lethality|CSS10-Most Recent Attempt Potential|CSS10-Most Recent Attempt Potential|CSS1018C	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Most recent attempt potential lethality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113938>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Most Lethal Suicide Attempt Date|CSS10-Most Lethal Attempt Date|CSS10-Most Lethal Attempt Date|CSS1019A	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Most lethal attempt date.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113939>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Most Lethal Suicide Attempt Actual Lethality/Medical Damage|CSS10-Most Lethal Attempt Damage|CSS10-Most Lethal Attempt Damage|CSS1019B	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Most lethal attempt actual lethality/medical damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11393>	C61063	Cyclophosphamide/DPPE|CTX/DPPE			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113940>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - Most Lethal Suicide Attempt Potential Lethality|CSS10-Most Lethal Attempt Potential|CSS10-Most Lethal Attempt Potential|CSS1019C	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Most lethal attempt potential lethality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113941>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - First Suicide Attempt Date|CSS10-First Attempt Date|CSS10-First Attempt Date|CSS1020A	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Initial/first attempt date.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113942>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - First Suicide Attempt Actual Lethality/Medical Damage|CSS10-First Attempt Damage|CSS10-First Attempt Damage|CSS1020B	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Initial/first attempt actual lethality/medical damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113943>	C113864	C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent - First Suicide Attempt Potential Lethality|CSS10-First Attempt Potential|CSS10-First Attempt Potential|CSS1020C	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired Lifetime/Recent (C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent) Initial/first attempt potential lethality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Code Terminology|CDISC Questionnaire C-SSRS Pediatric/Cognitively Impaired Lifetime/Recent Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113944>	C113865	FSS - Motivation is Lower When Fatigued|FSS01-Motivation Is Lower When Fatigued|FSS01-Motivation Is Lower When Fatigued|FSS0101	Fatigue Severity Scale (FSS) My motivation is lower when I am fatigued.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Fatigue Severity Scale Test Code Terminology|CDISC Questionnaire Fatigue Severity Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113945>	C113865	FSS - Exercise Brings on My Fatigue|FSS01-Exercise Brings on My Fatigue|FSS01-Exercise Brings on My Fatigue|FSS0102	Fatigue Severity Scale (FSS) Exercise brings on my fatigue.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Fatigue Severity Scale Test Code Terminology|CDISC Questionnaire Fatigue Severity Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113946>	C113865	FSS - I Am Easily Fatigued|FSS01-I Am Easily Fatigued|FSS01-I Am Easily Fatigued|FSS0103	Fatigue Severity Scale (FSS) I am easily fatigued.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Fatigue Severity Scale Test Code Terminology|CDISC Questionnaire Fatigue Severity Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113947>	C113865	FSS - Fatigue Interferes With Physical Functioning|FSS01-Interferes With Phys Function|FSS01-Interferes With Phys Function|FSS0104	Fatigue Severity Scale (FSS) Fatigue interferes with my physical functioning.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Fatigue Severity Scale Test Code Terminology|CDISC Questionnaire Fatigue Severity Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113948>	C113865	FSS - Fatigue Causes Frequent Problems|FSS01-Fatigue Causes Frequent Problems|FSS01-Fatigue Causes Frequent Problems|FSS0105	Fatigue Severity Scale (FSS) Fatigue causes frequent problems for me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Fatigue Severity Scale Test Code Terminology|CDISC Questionnaire Fatigue Severity Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113949>	C113865	FSS - Fatigue Prevents Sustained Physical Functioning|FSS01-Prevents Sustained Phys Function|FSS01-Prevents Sustained Phys Function|FSS0106	Fatigue Severity Scale (FSS) My fatigue prevents sustained physical functioning.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Fatigue Severity Scale Test Code Terminology|CDISC Questionnaire Fatigue Severity Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11394>	C61007	Busulfan/Cyclophosphamide/Anti-Thymocyte Globulin|ATG/BU/CTX|Anti-Thymocyte Globulin/Busulfan/Cyclophosphamide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113950>	C113865	FSS - Fatigue Interferes With Carrying Out Duties|FSS01-Fatigue Interferes With Duties|FSS01-Fatigue Interferes With Duties|FSS0107	Fatigue Severity Scale (FSS) Fatigue interferes with carrying out certain duties and responsibilities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Fatigue Severity Scale Test Code Terminology|CDISC Questionnaire Fatigue Severity Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113951>	C113865	FSS - Fatigue is Among Most Disabling Symptoms|FSS01-Among My 3 Most Disabling Symptoms|FSS01-Among My 3 Most Disabling Symptoms|FSS0108	Fatigue Severity Scale (FSS) Fatigue is among my three most disabling symptoms.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Fatigue Severity Scale Test Code Terminology|CDISC Questionnaire Fatigue Severity Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113952>	C113865	FSS - Fatigue Interferes With Work|FSS01-Fatigue Interferes With My Life|FSS01-Fatigue Interferes With My Life|FSS0109	Fatigue Severity Scale (FSS) Fatigue interferes with my work, family, or social life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Fatigue Severity Scale Test Code Terminology|CDISC Questionnaire Fatigue Severity Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113953>	C113866	BLCS - Lost Control of Your Bladder|BLCS01-Lost Control of Bladder|BLCS01-Lost Control of Bladder|BLCS0101	Bladder Control Scale (BLCS) During the past 4 weeks, how often have you lost control of your bladder or had an accident?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Bladder Control Scale Test Code Terminology|CDISC Questionnaire Bladder Control Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113954>	C113866	BLCS - Almost Lost Control of Your Bladder|BLCS01-Almost Lost Control of Bladder|BLCS01-Almost Lost Control of Bladder|BLCS0102	Bladder Control Scale (BLCS) During the past 4 weeks, how often have you almost lost control of your bladder or had an accident?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Bladder Control Scale Test Code Terminology|CDISC Questionnaire Bladder Control Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113955>	C113866	BLCS - Altered Activities Because Bladder Problems|BLCS01-Altered Activity Because Bladder|BLCS01-Altered Activity Because Bladder|BLCS0103	Bladder Control Scale (BLCS) During the past 4 weeks, how often have you altered your activities because of bladder problems?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Bladder Control Scale Test Code Terminology|CDISC Questionnaire Bladder Control Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113956>	C113866	BLCS - Bladder Problems Restrict Overall Lifestyle|BLCS01-Bladder Restricted Lifestyle|BLCS01-Bladder Restricted Lifestyle|BLCS0104	Bladder Control Scale (BLCS) During the past 4 weeks, how much have bladder problems restricted your overall lifestyle?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Bladder Control Scale Test Code Terminology|CDISC Questionnaire Bladder Control Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113957>	C113867	BWCS - Been Constipated|BWCS01-Been Constipated|BWCS01-Been Constipated|BWCS0101	Bowel Control Scale (BWCS) During the past 4 weeks, how often have you been constipated?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Bowel Control Scale Test Code Terminology|CDISC Questionnaire Bowel Control Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113958>	C113867	BWCS - Lost Control of Your Bowels|BWCS01-Lost Control of Bowels|BWCS01-Lost Control of Bowels|BWCS0102	Bowel Control Scale (BWCS) During the past 4 weeks, how often have you lost control of your bowels or had an accident?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Bowel Control Scale Test Code Terminology|CDISC Questionnaire Bowel Control Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113959>	C113867	BWCS - Almost Lost Control of Your Bowels|BWCS01-Almost Lost Control of Bowels|BWCS01-Almost Lost Control of Bowels|BWCS0103	Bowel Control Scale (BWCS) During the past 4 weeks, how often have you almost lost control of your bowels or almost had an accident?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Bowel Control Scale Test Code Terminology|CDISC Questionnaire Bowel Control Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11395>	C61007	Cyclophosphamide/Methylprednisolone|CTX/MePRDL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113960>	C113867	BWCS - Altered Activities Because Bowel Control Problems|BWCS01-Altered Activity Because Bowels|BWCS01-Altered Activity Because Bowels|BWCS0104	Bowel Control Scale (BWCS) During the past 4 weeks, how often have you altered your activities because of bowel control problems?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Bowel Control Scale Test Code Terminology|CDISC Questionnaire Bowel Control Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113961>	C113867	BWCS - Bowel Problems Restrict Overall Lifestyle|BWCS01-Bowels Restricted Lifestyle|BWCS01-Bowels Restricted Lifestyle|BWCS0105	Bowel Control Scale (BWCS) During the past 4 weeks, how much have bowel problems restricted your overall lifestyle?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Bowel Control Scale Test Code Terminology|CDISC Questionnaire Bowel Control Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113962>	C113868	IVIS - Read or Access Personal Letters|IVIS01-Read or Access Personal Letters|IVIS01-Read or Access Personal Letters|IVIS0101	Impact of Visual Impairment Scale (IVIS) During the past 4 weeks, how difficult did you find it to read or access personal letters or notes?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Impact of Visual Impairment Scale Test Code Terminology|CDISC Questionnaire Impact of Visual Impairment Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113963>	C113868	IVIS - Read or Access Printed Materials|IVIS01-Read or Access Printed Materials|IVIS01-Read or Access Printed Materials|IVIS0102	Impact of Visual Impairment Scale (IVIS) During the past 4 weeks, how difficult did you find it to read or access printed materials, such as books, magazines, newspaper, etc.?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Impact of Visual Impairment Scale Test Code Terminology|CDISC Questionnaire Impact of Visual Impairment Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113964>	C113868	IVIS - Read or Access Dials|IVIS01-Read or Access Dials|IVIS01-Read or Access Dials|IVIS0103	Impact of Visual Impairment Scale (IVIS) During the past 4 weeks, how difficult did you find it to read or access dials, such as on stoves, thermostats, etc.,?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Impact of Visual Impairment Scale Test Code Terminology|CDISC Questionnaire Impact of Visual Impairment Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113965>	C113868	IVIS - Watch TV or Identify Faces From Distance|IVIS01-Watch TV/ID Faces From Distance|IVIS01-Watch TV/ID Faces From Distance|IVIS0104	Impact of Visual Impairment Scale (IVIS) During the past 4 weeks, how difficult did you find it to watch television or identify faces from a distance?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Impact of Visual Impairment Scale Test Code Terminology|CDISC Questionnaire Impact of Visual Impairment Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113966>	C113868	IVIS - Identify House Numbers or Street Signs|IVIS01-Identify House Number/Street Sign|IVIS01-Identify House Number/Street Sign|IVIS0105	Impact of Visual Impairment Scale (IVIS) During the past 4 weeks, how difficult did you find it to identify house numbers, street signs, etc.?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Impact of Visual Impairment Scale Test Code Terminology|CDISC Questionnaire Impact of Visual Impairment Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113967>	C113869	MFIS - Have Been Less Alert|MFIS01-I Have Been Less Alert|MFIS01-I Have Been Less Alert|MFIS0101	Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have been less alert.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Code Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113968>	C113869	MFIS - Have Difficulty Paying Attention for Long Time|MFIS01-Have Difficulty Paying Attention|MFIS01-Have Difficulty Paying Attention|MFIS0102	Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have had difficulty paying attention for long periods of time.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Code Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113969>	C113869	MFIS - Unable to Think Clearly|MFIS01-Have Been Unable to Think Clearly|MFIS01-Have Been Unable to Think Clearly|MFIS0103	Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have been unable to think clearly.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Code Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11396>	C61063	Busulfan/Cyclophosphamide/Methylprednisolone|BU/CTX/MePRDL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113970>	C113869	MFIS - Have Been Clumsy and Uncoordinated|MFIS01-Been Clumsy and Uncoordinated|MFIS01-Been Clumsy and Uncoordinated|MFIS0104	Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have been clumsy and uncoordinated.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Code Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113971>	C113869	MFIS - Have Been Forgetful|MFIS01-I Have Been Forgetful|MFIS01-I Have Been Forgetful|MFIS0105	Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have been forgetful.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Code Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113972>	C113869	MFIS - Pace Myself in Physical Activities|MFIS01-Pace Myself in Physical Activity|MFIS01-Pace Myself in Physical Activity|MFIS0106	Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have had to pace myself in my physical activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Code Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113973>	C113869	MFIS - Less Motivated to Do Anything That Requires Physical Effort|MFIS01-Less Motivated, Physical Effort|MFIS01-Less Motivated, Physical Effort|MFIS0107	Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have been less motivated to do anything that requires physical effort.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Code Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113974>	C113869	MFIS - Less Motivated to Participate in Social Activities|MFIS01-Less Motivated, Social Activity|MFIS01-Less Motivated, Social Activity|MFIS0108	Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have been less motivated to participate in social activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Code Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113975>	C113869	MFIS - Limited in My Abilities to Do Things Away From Home|MFIS01-Limited in Ability Away From Home|MFIS01-Limited in Ability Away From Home|MFIS0109	Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have been limited in my ability to do things away from home.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Code Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113976>	C113869	MFIS - Have Trouble Maintain Physical Effort|MFIS01-Trouble Maintain Physical Effort|MFIS01-Trouble Maintain Physical Effort|MFIS0110	Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have had trouble maintaining physical effort for long periods.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Code Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113977>	C113869	MFIS - Have Difficulty Making Decisions|MFIS01-Have Difficulty Making Decisions|MFIS01-Have Difficulty Making Decisions|MFIS0111	Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have had difficulty making decisions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Code Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113978>	C113869	MFIS - Less Motivated to Do Anything That Requires Thinking|MFIS01-Less Motivated, Thinking|MFIS01-Less Motivated, Thinking|MFIS0112	Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have been less motivated to do anything that requires thinking.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Code Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113979>	C113869	MFIS - Muscles Have Felt Weak|MFIS01-My Muscles Have Felt Weak|MFIS01-My Muscles Have Felt Weak|MFIS0113	Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks my muscles have felt weak.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Code Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11397>	C61063	AG3340/Carboplatin/Paclitaxel|AG3340/CBDCA/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113980>	C113869	MFIS - Been Physically Uncomfortable|MFIS01-Been Physically Uncomfortable|MFIS01-Been Physically Uncomfortable|MFIS0114	Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have been physically uncomfortable.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Code Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113981>	C113869	MFIS - Have Trouble Finishing Tasks That Require Thinking|MFIS01-Trouble Finishing Thinking Tasks|MFIS01-Trouble Finishing Thinking Tasks|MFIS0115	Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have had trouble finishing tasks that require thinking.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Code Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113982>	C113869	MFIS - Difficulty Organizing My Thoughts|MFIS01-Difficulty Organizing My Thoughts|MFIS01-Difficulty Organizing My Thoughts|MFIS0116	Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have had difficulty organizing my thoughts when doing things at home or at work.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Code Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113983>	C113869	MFIS - Less Able to Complete Tasks That Require Physical Effort|MFIS01-Less Able Complete Physical Tasks|MFIS01-Less Able Complete Physical Tasks|MFIS0117	Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have been less able to complete tasks that require physical effort.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Code Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113984>	C113869	MFIS - My Thinking Has Been Slowed Down|MFIS01-My Thinking Has Been Slowed Down|MFIS01-My Thinking Has Been Slowed Down|MFIS0118	Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks my thinking has been slowed down.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Code Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113985>	C113869	MFIS - Have Trouble Concentrating|MFIS01-I Have Had Trouble Concentrating|MFIS01-I Have Had Trouble Concentrating|MFIS0119	Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have had trouble concentrating.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Code Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113986>	C113869	MFIS - Have Limited My Physical Activities|MFIS01-Have Limited My Physical Activity|MFIS01-Have Limited My Physical Activity|MFIS0120	Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have limited my physical activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Code Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113987>	C113869	MFIS - Need to Rest More Often or Longer|MFIS01-Need to Rest More Often or Longer|MFIS01-Need to Rest More Often or Longer|MFIS0121	Modified Fatigue Impact Scale (MFIS) Because of my fatigue during the past 4 weeks I have needed to rest more often or for longer periods.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Code Terminology|CDISC Questionnaire Modified Fatigue Impact Scale Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113988>	C113870	MSQOL-54 - Would You Say Your Health Is|MSQL1-Would You Say Your Health Is|MSQL1-Would You Say Your Health Is|MSQL101	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) In general, would you say your health is:			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113989>	C113870	MSQOL-54 - Health Now Compared to One Year Ago|MSQL1-Health Now Compared to 1 Year Ago|MSQL1-Health Now Compared to 1 Year Ago|MSQL102	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) Compared to one year ago, how would you rate your health in general now?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11398>	C61063	Docetaxel/Doxorubicin HCl Liposome|LipoDox/TXT			Obsolete_Concept	Therapeutic or Preventive Procedure	
C113990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113990>	C113870	MSQOL-54 - Health Limit Vigorous Activities|MSQL1-Health Limit Vigorous Activities|MSQL1-Health Limit Vigorous Activities|MSQL103	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) Does your health limit you in these activities: Vigorous activities, such as running, lifting heavy objects, participating in strenuous sports.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113991>	C113870	MSQOL-54 - Health Limit Moderate Activities|MSQL1-Health Limit Moderate Activities|MSQL1-Health Limit Moderate Activities|MSQL104	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) Does your health limit you in these activities: Moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or playing golf.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113992>	C113870	MSQOL-54 - Health Limit Lifting or Carrying Groceries|MSQL1-Health Limit Carrying Groceries|MSQL1-Health Limit Carrying Groceries|MSQL105	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) Does your health limit you in these activities: Lifting or carrying groceries.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113993>	C113870	MSQOL-54 - Health Limit Climbing Several Stairs|MSQL1-Health Limit Climb Several Flights|MSQL1-Health Limit Climb Several Flights|MSQL106	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) Does your health limit you in these activities: Climbing several flights of stairs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113994>	C113870	MSQOL-54 - Health Limit Climbing One Stair|MSQL1-Health Limit Climb One Flight|MSQL1-Health Limit Climb One Flight|MSQL107	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) Does your health limit you in these activities: Climbing one flight of stairs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113995>	C113870	MSQOL-54 - Health Limit Bending, Kneeling or Stooping|MSQL1-Health Limit Bending or Kneeling|MSQL1-Health Limit Bending or Kneeling|MSQL108	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) Does your health limit you in these activities: Bending, kneeling, or Stooping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113996>	C113870	MSQOL-54 - Health Limit Walking More than A Mile|MSQL1-Health Limit Walk More Than Mile|MSQL1-Health Limit Walk More Than Mile|MSQL109	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) Does your health limit you in these activities: Walking more than a mile.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113997>	C113870	MSQOL-54 - Health Limit Walking Several Blocks|MSQL1-Health Limit Walk Several Blocks|MSQL1-Health Limit Walk Several Blocks|MSQL110	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) Does your health limit you in these activities: Walking several blocks.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113998>	C113870	MSQOL-54 - Health Limit Walking One Block|MSQL1-Health Limit Walk One Block|MSQL1-Health Limit Walk One Block|MSQL111	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) Does your health limit you in these activities: Walking One Block.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C113999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C113999>	C113870	MSQOL-54 - Health Limit Bathing and Dressing Yourself|MSQL1-Health Limit Bathing/Dressing Self|MSQL1-Health Limit Bathing/Dressing Self|MSQL112	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) Does your health limit you in these activities: Bathing and dressing yourself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11399>	C61063	Carboplatin/Lomustine/Procarbazine/Vincristine|CBDCA/CCNU/PCB/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1139>	C2139	Keyhole Limpet Hemocyanin|KEYHOLE LIMPET HEMOCYANIN|KLH|KLH|keyhole limpet hemocyanin	A natural protein isolated from the marine mollusc keyhole limpet.  Keyhole limpet hemocyanin is an immunogenic carrier protein that, in vivo, increases antigenic immune responses to haptens and other weak antigens such as idiotype proteins. (NCI04)	Keyhole Limpet Hemocyanin		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C114000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114000>	C113870	MSQOL-54 - Physical Health Cut Down Time on Work|MSQL1-Phys Health: Cut Work Time|MSQL1-Phys Health: Cut Work Time|MSQL113	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of your physical health: Cut down on the amount of time you could spend on work or other activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114001>	C113870	MSQOL-54 - Physical Health Accomplish Less|MSQL1-Phys Health: Accomplish Less|MSQL1-Phys Health: Accomplish Less|MSQL114	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of your physical health: Accomplished less than you would like.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114002>	C113870	MSQOL-54 - Physical Health Limited in the Kind of Work|MSQL1-Phys Health: Limit Kind of Work|MSQL1-Phys Health: Limit Kind of Work|MSQL115	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of your physical health: Were limited in the kind of work or other activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114003>	C113870	MSQOL-54 - Physical Health Difficulty Perform Work|MSQL1-Phys Health: Difficulty Performing|MSQL1-Phys Health: Difficulty Performing|MSQL116	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of your physical health: Had difficulty performing the work or other activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114004>	C113870	MSQOL-54 - Emotional Problem Cut Down Time on Work|MSQL1-Emotional Problem: Cut Work Time|MSQL1-Emotional Problem: Cut Work Time|MSQL117	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of any emotional problems: Cut down on the amount of time you could spend on work or other activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114005>	C113870	MSQOL-54 - Emotional Problem Accomplish Less|MSQL1-Emotional Problem: Accomplish Less|MSQL1-Emotional Problem: Accomplish Less|MSQL118	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of any emotional problems: Accomplished less than you would like.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114006>	C113870	MSQOL-54 - Emotional Problem Did Not Do Work Carefully|MSQL1-Emotional Problem: Less Careful|MSQL1-Emotional Problem: Less Careful|MSQL119	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of any emotional problems: Didn't do work or other activities as carefully as usual.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114007>	C113870	MSQOL-54 - Extend Physical Health or Emotional Problem Interfere With Social Activities|MSQL1-Extent Interfered Social Activity|MSQL1-Extent Interfered Social Activity|MSQL120	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) During the past 4 weeks, to what extent has your physical health or emotional problems interfered with your normal social activities with family, friends, neighbors, or groups?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114008>	C113870	MSQOL-54 - Bodily Pain|MSQL1-How Much Bodily Pain Have You Had|MSQL1-How Much Bodily Pain Have You Had|MSQL121	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much bodily pain have you had during the past 4 weeks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114009>	C113870	MSQOL-54 - Pain Interfere With Normal Work|MSQL1-Did Pain Interfere With Your Work|MSQL1-Did Pain Interfere With Your Work|MSQL122	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) During the past 4 weeks, how much did pain interfere with your normal work?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11400>	C61063	Cisplatin/Cyclophosphamide/Etoposide/Leucovorin calcium/Methotrexate/Vincristine|CDDP/CF/CTX/MTX/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114010>	C113870	MSQOL-54 - Feel Full of Pep|MSQL1-Did You Feel Full of Pep|MSQL1-Did You Feel Full of Pep|MSQL123	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Did you feel full of pep?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114011>	C113870	MSQOL-54 - Been a Nervous Person|MSQL1-Have Been a Very Nervous Person|MSQL1-Have Been a Very Nervous Person|MSQL124	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Have you been a very nervous person?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114012>	C113870	MSQOL-54 - Felt So Down Nothing Could Cheer You Up|MSQL1-Have Felt So Down in the Dumps|MSQL1-Have Felt So Down in the Dumps|MSQL125	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Have you felt so down in the dumps that nothing could cheer you up?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114013>	C113870	MSQOL-54 - Felt Calm and Peaceful|MSQL1-Have You Felt Calm and Peaceful|MSQL1-Have You Felt Calm and Peaceful|MSQL126	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Have you felt calm and peaceful?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114014>	C113870	MSQOL-54 - Have a Lot of Energy|MSQL1-Did You Have a Lot of Energy|MSQL1-Did You Have a Lot of Energy|MSQL127	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Did you have a lot of energy?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114015>	C113870	MSQOL-54 - Felt Downhearted and Blue|MSQL1-Have Felt Downhearted and Blue|MSQL1-Have Felt Downhearted and Blue|MSQL128	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Have you felt downhearted and blue?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114016>	C113870	MSQOL-54 - Feel Worn Out|MSQL1-Did You Feel Worn Out|MSQL1-Did You Feel Worn Out|MSQL129	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Did you feel worn out?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114017>	C113870	MSQOL-54 - Been a Happy Person|MSQL1-Have You Been a Happy Person|MSQL1-Have You Been a Happy Person|MSQL130	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Have you been a happy person?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114018>	C113870	MSQOL-54 - Feel Tired|MSQL1-Did You Feel Tired|MSQL1-Did You Feel Tired|MSQL131	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Did you feel tired?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114019>	C113870	MSQOL-54 - Feel Rested Waking in the Morning|MSQL1-Did You Feel Rested on Waking|MSQL1-Did You Feel Rested on Waking|MSQL132	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Did you feel rested on waking in the morning?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11401>	C61063	Doxorubicin HCl Liposome/Paclitaxel|LipoDox/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114020>	C113870	MSQOL-54 - Time Physical Health or Emotional Problem Interfere With Social Activities|MSQL1-Amt Time Interfere Social Activity|MSQL1-Amt Time Interfere Social Activity|MSQL133	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your social activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114021>	C113870	MSQOL-54 - Get Sick Easier Than Other|MSQL1-Get Sick Easier Than Other People|MSQL1-Get Sick Easier Than Other People|MSQL134	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How true or false is each of the following statements for you: I seem to get sick a little easier than other people.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114022>	C113870	MSQOL-54 - As Healthy as Anybody|MSQL1-I Am as Healthy as Anybody I Know|MSQL1-I Am as Healthy as Anybody I Know|MSQL135	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How true or false is each of the following statements for you: I am as healthy as anybody I know.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114023>	C113870	MSQOL-54 - Expect Health to Get Worse|MSQL1-I Expect My Health to Get Worse|MSQL1-I Expect My Health to Get Worse|MSQL136	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How true or false is each of the following statements for you: I expect my health to get worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114024>	C113870	MSQOL-54 - Health is Excellent|MSQL1-My Health Is Excellent|MSQL1-My Health Is Excellent|MSQL137	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How true or false is each of the following statements for you: My health is excellent.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114025>	C113870	MSQOL-54 - Discouraged by Health Problem|MSQL1-Discouraged by Health Problems|MSQL1-Discouraged by Health Problems|MSQL138	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Were you discouraged by your health problems?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114026>	C113870	MSQOL-54 - Frustrated With Health|MSQL1-Were Frustrated About Your Health|MSQL1-Were Frustrated About Your Health|MSQL139	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Were you frustrated about your health?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114027>	C113870	MSQOL-54 - Health a Worry in Life|MSQL1-Was Health a Worry in Your Life|MSQL1-Was Health a Worry in Your Life|MSQL140	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Was your health a worry in your life? Was your health a worry in your life?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114028>	C113870	MSQOL-54 - Feel Weighed Down by Health Problem|MSQL1-Weighed Down by Health Problems|MSQL1-Weighed Down by Health Problems|MSQL141	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Did you feel weighed down by your health problems?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114029>	C113870	MSQOL-54 - Difficulty Concentrating and Thinking|MSQL1-Difficulty Concentrating/Thinking|MSQL1-Difficulty Concentrating/Thinking|MSQL142	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Have you had difficulty concentrating and thinking?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11402>	C61007	Carboplatin/Thalidomide|CBDCA/THAL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114030>	C113870	MSQOL-54 - Trouble Keep Attention for Long|MSQL1-Trouble Keep Attention for Long|MSQL1-Trouble Keep Attention for Long|MSQL143	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Did you have trouble keeping your attention on an activity for long?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114031>	C113870	MSQOL-54 - Trouble With Memory|MSQL1-Have Had Trouble With Your Memory|MSQL1-Have Had Trouble With Your Memory|MSQL144	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Have you had trouble with your memory?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114032>	C113870	MSQOL-54 - Others Notice Your Problems With Memory or Concentration|MSQL1-Others Notice Your Memory Trouble|MSQL1-Others Notice Your Memory Trouble|MSQL145	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of the time during the past 4 weeks: Have others, such as family members or friends, noticed that you have trouble with your memory or problems with your concentration?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114033>	C113870	MSQOL-54 - Lack of Sexual Interest|MSQL1-Lack of Sexual Interest|MSQL1-Lack of Sexual Interest|MSQL146	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of a problem was each of the following for you during the past 4 weeks: Lack of sexual interest.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114034>	C113870	MSQOL-54 - Difficulty Keeping an Erection|MSQL1-Difficult Getting/Keeping Erection|MSQL1-Difficult Getting/Keeping Erection|MSQL147M	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of a problem was each of the following for you during the past 4 weeks: Difficulty getting or keeping an erection.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114035>	C113870	MSQOL-54 - Inadequate Lubrication|MSQL1-Inadequate Lubrication|MSQL1-Inadequate Lubrication|MSQL147W	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of a problem was each of the following for you during the past 4 weeks: Inadequate lubrication.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114036>	C113870	MSQOL-54 - Difficulty Having Orgasm|MSQL1-Difficulty Having Orgasm|MSQL1-Difficulty Having Orgasm|MSQL148	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of a problem was each of the following for you during the past 4 weeks: Difficulty having orgasm.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114037>	C113870	MSQOL-54 - Ability to Satisfy Sexual Partner|MSQL1-Ability to Satisfy Sexual Partner|MSQL1-Ability to Satisfy Sexual Partner|MSQL149	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) How much of a problem was each of the following for you during the past 4 weeks: Ability to satisfy sexual partner.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114038>	C113870	MSQOL-54 - Satisfied With Sexual Function|MSQL1-Satisfied With Sexual Function|MSQL1-Satisfied With Sexual Function|MSQL150	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) Overall, how satisfied were you with your sexual function during the past 4 weeks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114039>	C113870	MSQOL-54 - Bowel or Bladder Function Interfere With Social Activities|MSQL1-Bowel/Bladder Interfered Activity|MSQL1-Bowel/Bladder Interfered Activity|MSQL151	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) During the past 4 weeks, to what extent have problems with your bowel or bladder function interfered with your normal social activities with family, friends, neighbors, or groups?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11403>	C61063	Filgrastim/Pegylated Recombinant Human Megakaryocyte Growth and Development Factor|Filgrastim/Pegylated Recombinant Human Megakaryocyte Growth and developmentfactor|G-CSF/PEG-MGDF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114040>	C113870	MSQOL-54 - Pain Interfere Enjoyment of Life|MSQL1-Pain Interfere Enjoyment of Life|MSQL1-Pain Interfere Enjoyment of Life|MSQL152	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) During the past 4 weeks, how much did pain interfere with your enjoyment of life?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114041>	C113870	MSQOL-54 - Rate Your Own Quality of Life|MSQL1-Rate Your Own Quality-of-Life|MSQL1-Rate Your Own Quality-of-Life|MSQL153	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) Overall, how would you rate your own quality-of-life?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114042>	C113870	MSQOL-54 - Describe How You Feel About Your Life|MSQL1-Describe How Feel About Your Life|MSQL1-Describe How Feel About Your Life|MSQL154	Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) Which best describes how you feel about your life as a whole?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Code Terminology|CDISC Questionnaire Multiple Sclerosis Quality of Life-54 Instrument Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114043>	C113871	RAND-36 - Rate Your Health|R3601-Would You Say Your Health Is|R3601-Would You Say Your Health Is|R360101	RAND 36-Item Health Survey 1.0 (RAND-36) In general, would you say your health is:			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114044>	C113871	RAND-36 - Rate Your Health Compared to One Year Ago|R3601-Health Now Compared to 1 Year Ago|R3601-Health Now Compared to 1 Year Ago|R360102	RAND 36-Item Health Survey 1.0 (RAND-36) Compared to one year ago, how would you rate your health in general now?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114045>	C113871	RAND-36 - Health Limit Vigorous Activities|R3601-Health Limit Vigorous Activities|R3601-Health Limit Vigorous Activities|R360103	RAND 36-Item Health Survey 1.0 (RAND-36) Does your health now limit you in these activities: Vigorous activities, such as running, lifting heavy objects, participating in strenuous sports.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114046>	C113871	RAND-36 - Health Limit Moderate Activities|R3601-Health Limit Moderate Activities|R3601-Health Limit Moderate Activities|R360104	RAND 36-Item Health Survey 1.0 (RAND-36) Does your health now limit you in these activities: Moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or playing golf.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114047>	C113871	RAND-36 - Health Limit Lifting Groceries|R3601-Health Limit Carrying Groceries|R3601-Health Limit Carrying Groceries|R360105	RAND 36-Item Health Survey 1.0 (RAND-36) Does your health now limit you in these activities: Lifting or carrying groceries.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114048>	C113871	RAND-36 - Health Limit Climbing Several Flights|R3601-Health Limit Climb Several Flights|R3601-Health Limit Climb Several Flights|R360106	RAND 36-Item Health Survey 1.0 (RAND-36) Does your health now limit you in these activities: Climbing several flights of stairs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114049>	C113871	RAND-36 - Health Limit Climbing One Flight|R3601-Health Limit Climb One Flight|R3601-Health Limit Climb One Flight|R360107	RAND 36-Item Health Survey 1.0 (RAND-36) Does your health now limit you in these activities: Climbing one flight of stairs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11404>	C61063	gp100 Antigen/Incomplete Freund's Adjuvant/Interleukin-12/Tyrosinase Peptide|gp100/IFA/IL-12/TYRP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114050>	C113871	RAND-36 - Health Limit Bending or Stooping|R3601-Health Limit Bending or Kneeling|R3601-Health Limit Bending or Kneeling|R360108	RAND 36-Item Health Survey 1.0 (RAND-36) Does your health now limit you in these activities: Bending, kneeling, or stooping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114051>	C113871	RAND-36 - Health Limit Walking More Than A Mile|R3601-Health Limit Walk More Than Mile|R3601-Health Limit Walk More Than Mile|R360109	RAND 36-Item Health Survey 1.0 (RAND-36) Does your health now limit you in these activities: Walking more than a mile.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114052>	C113871	RAND-36 - Health Limit Walking Several Blocks|R3601-Health Limit Walk Several Blocks|R3601-Health Limit Walk Several Blocks|R360110	RAND 36-Item Health Survey 1.0 (RAND-36) Does your health now limit you in these activities: Walking several blocks.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114053>	C113871	RAND-36 - Health Limit Walking One Block|R3601-Health Limit Walk One Block|R3601-Health Limit Walk One Block|R360111	RAND 36-Item Health Survey 1.0 (RAND-36) Does your health now limit you in these activities: Walking one block.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114054>	C113871	RAND-36 - Health Limit Bathing or Dressing|R3601-Health Limit Bathing/Dressing Self|R3601-Health Limit Bathing/Dressing Self|R360112	RAND 36-Item Health Survey 1.0 (RAND-36) Does your health now limit you in these activities: Bathing or dressing yourself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114055>	C113871	RAND-36 - Physical Health Cut Down Time Spent on Work|R3601-Phys Health: Cut Work Time|R3601-Phys Health: Cut Work Time|R360113	RAND 36-Item Health Survey 1.0 (RAND-36) During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of your physical health: Cut down the amount of time you spent on work or other activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114056>	C113871	RAND-36 - Physical Health Accomplished Less|R3601-Phys Health: Accomplish Less|R3601-Phys Health: Accomplish Less|R360114	RAND 36-Item Health Survey 1.0 (RAND-36) During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of your physical health: Accomplished less than you would like.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114057>	C113871	RAND-36 - Physical Health Limited in the Kind of Work|R3601-Phys Health: Limit Kind of Work|R3601-Phys Health: Limit Kind of Work|R360115	RAND 36-Item Health Survey 1.0 (RAND-36) During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of your physical health: Were limited in the kind of work or other activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114058>	C113871	RAND-36 - Physical Health Difficulty Performing Work|R3601-Phys Health: Difficulty Performing|R3601-Phys Health: Difficulty Performing|R360116	RAND 36-Item Health Survey 1.0 (RAND-36) During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of your physical health: Had difficulty performing the work or other activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114059>	C113871	RAND-36 - Emotional Problem Cut Down Time Spent on Work|R3601-Emotional Problem: Cut Work Time|R3601-Emotional Problem: Cut Work Time|R360117	RAND 36-Item Health Survey 1.0 (RAND-36) During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of any emotional problems: Cut down the amount of time you spent on work or other activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11405>	C61063	gp100 Antigen/Incomplete Freund's Adjuvant/Tyrosinase Peptide|gp100/IFA/TYRP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114060>	C113871	RAND-36 - Emotional Problem Accomplished Less|R3601-Emotional Problem: Accomplish Less|R3601-Emotional Problem: Accomplish Less|R360118	RAND 36-Item Health Survey 1.0 (RAND-36) During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of any emotional problems: Accomplished less than you would like.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114061>	C113871	RAND-36 - Emotional Problem Did Not Do Work as Carefully|R3601-Emotional Problem: Less Careful|R3601-Emotional Problem: Less Careful|R360119	RAND 36-Item Health Survey 1.0 (RAND-36) During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of any emotional problems: Didn't do work or other activities as carefully as usual.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114062>	C113871	RAND-36 - Extend Physical Health or Emotional Problems Interfere With Social Activities|R3601-Extent Interfered Social Activity|R3601-Extent Interfered Social Activity|R360120	RAND 36-Item Health Survey 1.0 (RAND-36) During the past 4 weeks, to what extent has your physical health or emotional problems interfered with your normal social activities with family, friends, neighbors, or groups?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114063>	C113871	RAND-36 - Bodily Pain|R3601-How Much Bodily Pain Have You Had|R3601-How Much Bodily Pain Have You Had|R360121	RAND 36-Item Health Survey 1.0 (RAND-36) How much bodily pain have you had during the past 4 weeks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114064>	C113871	RAND-36 - Pain Interfere With Normal Work|R3601-Did Pain Interfere With Your Work|R3601-Did Pain Interfere With Your Work|R360122	RAND 36-Item Health Survey 1.0 (RAND-36) During the past 4 weeks, how much did pain interfere with your normal work?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114065>	C113871	RAND-36 - Feel Full of Pep|R3601-Did You Feel Full of Pep|R3601-Did You Feel Full of Pep|R360123	RAND 36-Item Health Survey 1.0 (RAND-36) How much of the time during the past 4 weeks: Did you feel full of pep?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114066>	C113871	RAND-36 - Been a Nervous Person|R3601-Have Been a Very Nervous Person|R3601-Have Been a Very Nervous Person|R360124	RAND 36-Item Health Survey 1.0 (RAND-36) How much of the time during the past 4 weeks: Have you been a very nervous person?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114067>	C113871	RAND-36 - Felt Nothing Could Cheer You Up|R3601-Have Felt So Down in the Dumps|R3601-Have Felt So Down in the Dumps|R360125	RAND 36-Item Health Survey 1.0 (RAND-36) How much of the time during the past 4 weeks: Have you felt so down in the dumps that nothing could cheer you up?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114068>	C113871	RAND-36 - Felt Calm and Peaceful|R3601-Have You Felt Calm and Peaceful|R3601-Have You Felt Calm and Peaceful|R360126	RAND 36-Item Health Survey 1.0 (RAND-36) How much of the time during the past 4 weeks: Have you felt calm and peaceful?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114069>	C113871	RAND-36 - Have a Lot of Energy|R3601-Did You Have a Lot of Energy|R3601-Did You Have a Lot of Energy|R360127	RAND 36-Item Health Survey 1.0 (RAND-36) How much of the time during the past 4 weeks: Did you have a lot of energy?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11406>	C61063	Acetaminophen/Acetylcysteine/Carmustine|ACMP/BCNU/NAC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114070>	C113871	RAND-36 - Felt Downhearted and Blue|R3601-Have Felt Downhearted and Blue|R3601-Have Felt Downhearted and Blue|R360128	RAND 36-Item Health Survey 1.0 (RAND-36) How much of the time during the past 4 weeks: Have you felt downhearted and blue?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114071>	C113871	RAND-36 - Feel Worn Out|R3601-Did You Feel Worn Out|R3601-Did You Feel Worn Out|R360129	RAND 36-Item Health Survey 1.0 (RAND-36) How much of the time during the past 4 weeks: Did you feel worn out?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114072>	C113871	RAND-36 - Been a Happy Person|R3601-Have You Been a Happy Person|R3601-Have You Been a Happy Person|R360130	RAND 36-Item Health Survey 1.0 (RAND-36) How much of the time during the past 4 weeks: Have you been a happy person?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114073>	C113871	RAND-36 - Feel Tired|R3601-Did You Feel Tired|R3601-Did You Feel Tired|R360131	RAND 36-Item Health Survey 1.0 (RAND-36) How much of the time during the past 4 weeks: Did you feel tired?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114074>	C113871	RAND-36 - Time Physical Health or Emotional Problems Interfere With Social Activities|R3601-Amt Time Interfere Social Activity|R3601-Amt Time Interfere Social Activity|R360132	RAND 36-Item Health Survey 1.0 (RAND-36) During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your social activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114075>	C113871	RAND-36 - Get Sick Easier Than Other|R3601-Get Sick Easier Than Other People|R3601-Get Sick Easier Than Other People|R360133	RAND 36-Item Health Survey 1.0 (RAND-36) How true or false is each of the following statements for you: I seem to get sick a little easier than other people.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114076>	C113871	RAND-36 - As Healthy as Anybody|R3601-I Am as Healthy as Anybody I Know|R3601-I Am as Healthy as Anybody I Know|R360134	RAND 36-Item Health Survey 1.0 (RAND-36) How true or false is each of the following statements for you: I am as healthy as anybody I know.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114077>	C113871	RAND-36 - Expect Health to Get Worse|R3601-I Expect My Health to Get Worse|R3601-I Expect My Health to Get Worse|R360135	RAND 36-Item Health Survey 1.0 (RAND-36) How true or false is each of the following statements for you: I expect my health to get worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114078>	C113871	RAND-36 - My Health is Excellent|R3601-My Health Is Excellent|R3601-My Health Is Excellent|R360136	RAND 36-Item Health Survey 1.0 (RAND-36) How true or false is each of the following statements for you: My health is excellent.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Code Terminology|CDISC Questionnaire RAND 36-Item Health Survey 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114079>	C16525	Fetal Echocardiography Test|Fetal Echocardiography	An antenatal ultrasonographic procedure used to evaluate the structure and function of the fetal heart.			Diagnostic Procedure	NICHD Terminology|Perinatal Terminology
C11407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11407>	C61063	Acetaminophen/Acetylcysteine|ACMP/NAC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114080>	C62781	Fetal Doppler Velocimetry	An antenatal ultrasonographic method that measures blood flow velocity through either maternal or fetal vessels.			Diagnostic Procedure	NICHD Terminology|Perinatal Terminology
C114081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114081>	C92929|C62781	Fetal Doppler Monitoring|EFM|EFM|External Fetal Heart Rate Monitoring|External Fetal Heart Rate Monitoring	A technique that utilizes a Doppler transducer to monitor fetal heart rate. The transducer is placed on the maternal abdomen and detects fetal cardiac motion using ultrasound.			Diagnostic Procedure	NICHD Terminology|Perinatal Terminology
C114082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114082>	C86587	Chlorophyta	A phylum of paraphyletic, photosynthetic and autotrophic green algae.			Plant	
C114083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114083>	C92929	Internal Fetal Heart Rate Monitoring|FSE|FSE|Fetal Scalp Electrode Monitoring|Fetal Scalp Electrode Monitoring	A technique that utilizes a wire attached to the fetal scalp to monitor fetal heart rate. The wire detects fetal cardiac electrical activity to determine the baseline fetal heart rate and variability.			Diagnostic Procedure	NICHD Terminology|Perinatal Terminology
C114084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114084>	C89340	Intrapartum Fetal Stimulation	Any method used to elicit a fetal heart rate acceleration response during labor.			Therapeutic or Preventive Procedure	NICHD Terminology|Perinatal Terminology
C114085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114085>	C114084	Vibroacoustic Stimulation|VAS	A fetal stimulation technique that uses vibratory sound applied to the maternal abdomen to elicit a fetal heart rate acceleration response before or during labor.			Therapeutic or Preventive Procedure	NICHD Terminology|Perinatal Terminology
C114086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114086>	C114084	Allis Clamp Fetal Scalp Stimulation	A fetal stimulation technique that uses an Allis clamp applied transvaginally to the fetal head to elicit a fetal heart rate acceleration response during labor.			Therapeutic or Preventive Procedure	NICHD Terminology|Perinatal Terminology
C114087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114087>	C114084	Digital Fetal Scalp Stimulation|Scalp Stim	A fetal stimulation technique that uses transvaginal digital pressure or rubbing to the fetal head to elicit a fetal heart rate acceleration response during labor.			Therapeutic or Preventive Procedure	NICHD Terminology|Perinatal Terminology
C114088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114088>	C25150	Conception Age|Conceptional Age|Conceptional Age|Conceptual Age|Conceptual Age|Post-Conceptional Age|Post-Conceptional Age|Post-Conceptual Age|Post-Conceptual Age	The time elapsed between the day of conception and the day of delivery.			Organism Attribute	NICHD Terminology|Perinatal Terminology
C114089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114089>	C25150	Corrected Age|Adjusted Age|Adjusted Age|Corrected Gestational Age|Corrected Gestational Age	Chronological age reduced by the number of weeks born before 40 weeks of gestation; most appropriately used to describe children up to 3 years of age who were born preterm.			Organism Attribute	INC Demographic and Maternal Terminology|INC Terminology|NICHD Terminology|Perinatal Terminology
C11408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11408>	C61063	Filgrastim/Promegapoietin|G-CSF/PMP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114090>	C69260	Postmenstrual Age	Best estimate of the first day of last menstrual period to birth plus time elapsed from day of birth.			Organism Attribute	INC Demographic and Maternal Terminology|INC Terminology|NICHD Terminology|Perinatal Terminology
C114091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114091>	C90491	Live Birth	The complete expulsion or extraction from the mother of a fetus, irrespective of the duration of pregnancy, which, after such expulsion or extraction, breathes or shows any other evidence of life, such as beating of the heart, pulsation of the umbilical cord, or definite movement of voluntary muscles.			Finding	GAIA Neonatal Death Level of Diagnostic Certainty Terminology|GAIA Terminology|GDC Terminology|GDC Value Terminology|NICHD Terminology|Perinatal Terminology
C114092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114092>	C92861	Late Preterm Birth|Late Pre-Term|Late Pre-Term	Birth when a fetus is between 34 weeks and 0 days through 36 weeks and 6 days gestational age.			Finding	NICHD Terminology|Perinatal Terminology
C114093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114093>	C90491	Term Birth|Term|Term|Term	Birth at greater than or equal to 37 weeks using best estimated due date.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|NICHD Terminology|Perinatal Terminology
C114094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114094>	C114093	Early Term Birth|Early Term|Early Term	Birth at 37 weeks and 0 days through 38 weeks and 6 days.			Finding	NICHD Terminology|Perinatal Terminology
C114095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114095>	C114093	Full Term Birth|Full Term|Full Term|Full Term Pregnancy	Birth at 39 weeks and 0 days through 40 weeks and 6 days.			Finding	GDC Terminology|GDC Value Terminology|NICHD Terminology|Perinatal Terminology
C114096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114096>	C114093	Late Term Birth|Late Term|Late Term	Birth at 41 weeks and 0 days through 41 weeks and 6 days.			Finding	NICHD Terminology|Perinatal Terminology
C114097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114097>	C90491	Post Term Birth|Post Term|Post Term|Postterm	Birth at greater than or equal to 42 weeks and 0 days.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|NICHD Terminology|Perinatal Terminology
C114098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114098>	C92929|C85573	Intermittent Auscultation	A method of assessing intrapartum fetal heart rate during set intervals using an external device, such as a Doppler, fetoscope or stethoscope.			Diagnostic Procedure	NICHD Terminology|Perinatal Terminology
C114099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114099>	C50822	Intrauterine Resuscitation	Treatments or maneuvers applied to the mother to improve uterine perfusion or oxygen delivery to the fetus in response to abnormal fetal heart rate patterns.			Therapeutic or Preventive Procedure	NICHD Terminology|Perinatal Terminology
C11409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11409>	C61063	Doxorubicin HCl Liposome/Topotecan|LipoDox/TOPO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1140>	C663	Mitomycin C Analog KW-2149|7-N-(2-((2-(gamma-L-Glutamylamino)ethyl)dithio)ethyl)mitomycin C|KT6149|KW 2149|KW-2149	A semisynthetic water-soluble disulfide derivative of the antineoplastic antibiotic mitomycin C.  Activated by serum and glutathione, KW-2149 causes interstrand DNA cross-links and DNA-protein cross-links, resulting in single-strand DNA breaks and inhibition of DNA synthesis. (NCI04)			Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C114100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114100>	C25662	Fetal Scalp Sampling|Fetal Scalp pH Measurement	A technique used to evaluate fetal acid-base status during labor by obtaining a capillary blood specimen from the fetus.			Diagnostic Procedure	NICHD Terminology|Perinatal Terminology
C114101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114101>	C63719|C63522|C63502|C63361|C203473	OFF Regimen|Fluorouracil/Leucovorin Calcium/Oxaliplatin Regimen|Fluorouracil/Leucovorin/Oxaliplatin|OLF|OLF Regimen|Oxaliplatin/Folinic Acid/Fluorouracil Regimen|Oxaliplatin/Leucovorin/Fluorouracil	A regimen that includes leucovorin, 5-fluorouracil and oxaliplatin that can be used in the treatment of ampullary and pancreatic adenocarcinoma, and esophageal and esophagogastric junction and gastric cancer, and mucinous neoplasms of the ovary.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|NCI Drug Dictionary Terminology|Pharmacotherapy Regimens
C114102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114102>	C81303	Spontaneous Labor and Birth	Initiation of labor without the use of pharmacological and/or mechanical interventions, resulting in a non-operative vaginal birth. (reVITALize)			Organism Function	NICHD Terminology|Perinatal Terminology
C114103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114103>	C2017	Transdermal 4-Hydroxytestosterone|Transdermal 4-OHT|Transdermal CR1447	A transdermal formulation containing 4-hydroxytestosterone (4-OHT), a steroidal aromatase inhibitor (AI) and androgen receptor (AR) antagonist, with potential antineoplastic activity. 4-OHT is largely converted into 4-hydroxyandrostenedione (4-OHA) and irreversibly binds to and inhibits aromatase, thereby blocking the conversion of androstenedione to estrone, and testosterone to estradiol. This may inhibit tumor cell proliferation in estrogen-dependent tumor cells. In addition, 4-OHT binds to the AR and may inhibit AR-mediated tumor cell growth. Aromatase, a cytochrome P-450 enzyme, is overexpressed in a variety of cancer cells; it plays a key role in estrogen biosynthesis. Compared to oral 4-OHT, the transdermal formulation allows for continuous release of 4-OHT into the bloodstream and prevents first pass metabolism by the liver.			Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C114104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114104>	C50446|C206570	First Degree Perineal Laceration	Injury to perineal skin only. (reVITALize)			Injury or Poisoning	NICHD Terminology|Perinatal Terminology
C114105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114105>	C50446|C206570	Second Degree Perineal Laceration	Injury to perineum involving perineal muscles but not involving anal sphincter. (reVITALize)			Injury or Poisoning	NICHD Terminology|Perinatal Terminology
C114106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114106>	C50446|C206570	Third Degree Perineal Laceration	Injury to perineum involving anal sphincter complex. (adapted from reVITALize)			Injury or Poisoning	NICHD Terminology|Perinatal Terminology
C114107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114107>	C50446|C206570	Fourth Degree Perineal Laceration	Injury to perineum involving anal sphincter complex and internal anal sphincter and anal epithelium. (reVITALize)			Injury or Poisoning	NICHD Terminology|Perinatal Terminology
C114108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114108>	C134576	Experimental Organism Islet Cell Adenoma Neoplasm|ADENOMA, ISLET CELL, BENIGN|Islet Cell Adenoma	A benign neoplasm arising from the islet cells of the pancreas.			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C114109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114109>	C134576	Experimental Organism Acidophil Carcinoma|Acidophil Adenocarcinoma|Acidophil Carcinoma|CARCINOMA, ACIDOPHIL, MALIGNANT|Eosinophil Adenocarcinoma|Eosinophil Carcinoma	A malignant epithelial neoplasm of the anterior pituitary gland in which the neoplastic cells stain positive with acidic dyes.			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C11410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11410>	C61063	Ciprofloxacin/Dexamethasone/Pentoxifylline|CPFX/DM/PTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114110>	C134576	Experimental Organism Histiocytic Lymphoma Neoplasm|LYMPHOMA, HISTIOCYTIC, MALIGNANT|Lymphoma, Large Cell, Malignant	A malignant neoplasm of large lymphocytes, which resemble histiocytes.			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C114111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114111>	C134576	Experimental Organism Mixed Lymphoma Neoplasm|LYMPHOMA, MIXED, MALIGNANT	A malignant neoplasm composed of a mixed lymphocyte population.			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C114112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114112>	C134576	Experimental Organism Lymphosarcoma Neoplasm|LYMPHOSARCOMA, MALIGNANT	An antiquated term referring to a malignant lymphoma that is diffused and composed of small and large lymphocytes.			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C114113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114113>	C134576	Experimental Organism Benign Stromal Tumor Neoplasm|STROMAL TUMOR, BENIGN	A benign neoplasm composed of mesenchymal stromal cells.			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C114114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114114>	C134576	Experimental Organism Benign Teratoma Neoplasm|TERATOMA, BENIGN	A benign germ-cell neoplasm derived from pluripotent cells and consisting of components from one or more of the three germ-cell layers.			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C114115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114115>	C134576	Experimental Organism Benign Thymoma Neoplasm|THYMOMA, BENIGN	A benign neoplasm of the thymus, originating from epithelial thymus cells.			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C114116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114116>	C103175	CDISC SDTM Morphology Test Name Terminology|SDTM-MOTEST	Terminology associated with the morphology test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	
C114117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114117>	C103175	CDISC SDTM Morphology Test Code Terminology|SDTM-MOTESTCD	Terminology associated with the morphology test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	
C114118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114118>	C66830	CDISC SDTM Protocol Milestone Terminology|PROTMLST|Protocol Milestone|SDTM-PROTMLST	Terminology associated with the protocol milestone codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114119>	C103175	CDISC SDTM Pharmacogenomics Biomarker Medical Statement Terminology|SDTM-PBSTMT	Terminology associated with the pharmacogenomics biomarker medical statement codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	
C11411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11411>	C61063	Cisplatin/LY231514|CDDP/LY231514			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114120>	C62996	ECG Recording Quality	A finding pertaining to the quality of an ECG recording.			Finding	
C114121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114121>	C70914	Total Body Clearance by Fraction of Dose for Dose Interval|CLFTAU|Total CL by F for Dose Int|Total CL by F for Dose Int	The total body clearance for extravascular administration for dose interval, where F is the fraction of dose absorbed.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114122>	C70914	Total Body Clearance for Dose Interval|CLTAU|Total CL for Dose Int|Total CL for Dose Int	The total body clearance for intravascular administration for dose interval.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114123>	C77167	Kluyveromyces	A genus of yeasts in the family Saccharomycetaceae and phylum Ascomycota.			Fungus	
C114124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114124>	C77167	Yarrowia	A genus of yeasts in the family Dipodascaceae and phylum Ascomycota.			Fungus	
C114125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114125>	C77167	Wickerhamomyces	A genus of yeasts in the family Phaffomycetaceae and phylum Ascomycota.			Fungus	
C114126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114126>	C77167	Magnusiomyces	A genus of yeasts in the family Dipodascaceae and phylum Ascomycota.			Fungus	
C114127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114127>	C77169	Filobasidium	A genus of yeasts in the family Filobasidiaceae and phylum Basidiomycota.			Fungus	
C114128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114128>	C114082	Prototheca	A genus of green algae in the family Chlorellaceae and phylum Chlorophyta.			Plant	
C114129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114129>	C77169	Trichosporon|TRICHOSPORON	A genus of yeasts in the family Trichosporonaceae and phylum Basidiomycota.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11412>	C61063	Etoposide/Gemcitabine|dFdC/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114130>	C27619	Placental Retention|Retained Placenta|Retained Placenta	After delivery of neonate, placental retention that requires clinical intervention such as manual extraction, curettage or uterotonic medications.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C114131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114131>	C15370	Antenatal Steroid Therapy Initiated|Antenatal Steroids Initiated|Antenatal Steroids Initiated	At least one dose of corticosteroids administered to accelerate fetal maturation. (adapted from reVITALize)			Therapeutic or Preventive Procedure	NICHD Terminology|Perinatal Terminology
C114132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114132>	C92738	Augmentation of Labor	The stimulation of uterine contractions using pharmacologic methods or artificial rupture of membranes (AROM) to increase their frequency and/or strength following the onset of spontaneous labor or contractions following spontaneous rupture of membranes. Does not apply if induction of labor is performed. (reVITALize)			Therapeutic or Preventive Procedure	NICHD Terminology|Perinatal Terminology
C114133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114133>	C89340	Manual Fetal Rotation	A procedure during labor in which the occiput is manually rotated from posterior to anterior.			Therapeutic or Preventive Procedure	NICHD Terminology|Perinatal Terminology
C114134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114134>	C114102	Spontaneous Vertex Delivery	The birth of a cephalically presenting fetus without operative instrumentation or assistance.			Therapeutic or Preventive Procedure	NICHD Terminology|Perinatal Terminology
C114135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114135>	C114102	Spontaneous Breech Delivery|Spontaneous Vaginal Breech Birth	The birth of a breech-presenting fetus without operative instrumentation or assistance.			Therapeutic or Preventive Procedure	NICHD Terminology|Perinatal Terminology
C114136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114136>	C81303	Breech Extraction|BREECH EXTRACTION	The delivery of a breech-presenting fetus with that is manually pulled through the birth canal.			Therapeutic or Preventive Procedure	CDISC CDASH Terminology|CDISC SDTM Mode of Delivery Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|NICHD Terminology|Perinatal Terminology
C114137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114137>	C81301	Assisted Breech Delivery	The birth of a breech-presenting fetus with operative instrumentation or assistance.			Therapeutic or Preventive Procedure	NICHD Terminology|Perinatal Terminology
C114138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114138>	C92743	Trial of Birth Labor after Cesarean|TOLAC|Trial of Birth Labor after Caesarean|Trial of Labor after Caesarean|Trial of Labor after Cesarean|Trial of Labor after Cesarean Delivery	Trial of labor in a woman with a previous cesarean delivery regardless of ultimate route of delivery.			Finding	NICHD Terminology|Perinatal Terminology
C114139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114139>	C46088	Primary Cesarean Birth|Primary Caesarean Birth|Primary Caesarean Birth	The first surgical delivery of one or more intrauterine fetuses though an abdominal incision in a woman without prior cesarean delivery.			Therapeutic or Preventive Procedure	NICHD Terminology|Perinatal Terminology
C11413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11413>	C61063	Carboplatin/Doxorubicin HCl Liposome/Paclitaxel|CBDCA/LipoDox/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114140>	C46088	Repeat Cesarean Birth|Repeat Caesarean Birth|Repeat Caesarean Birth	The surgical delivery of one or more intrauterine fetuses though an abdominal incision in a woman who has had prior cesarean delivery(ies).			Therapeutic or Preventive Procedure	NICHD Terminology|Perinatal Terminology
C114141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114141>	C46088	Elective Cesarean Delivery|Elective Caesarean Delivery|Elective Caesarean Section|Elective Cesarean Section	A cesarean delivery scheduled at a patient's request or provider preference without medical or obstetric indications.			Therapeutic or Preventive Procedure	NICHD Terminology|Perinatal Terminology
C114142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114142>	C46088	Indicated Cesarean Delivery|Indicated Caesarean Delivery|Indicated Caesarean Section|Indicated Cesarean Section	A cesarean delivery that is performed for specific, medical or obstetric indications, which may be scheduled or unscheduled.			Therapeutic or Preventive Procedure	NICHD Terminology|Perinatal Terminology
C114143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114143>	C81179	Delivery by Destructive Operation|DELIVERY BY DESTRUCTIVE OPERATION|Destructive Procedure|Destructive Procedure	Extraction of a fetus through the cervix using destructive surgical techniques.			Health Care Activity	CDISC CDASH Terminology|CDISC SDTM Mode of Delivery Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|NICHD Terminology|Perinatal Terminology
C114144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114144>	C20993	Controlled Oral Word Association Test|COWA|COWAT|COWAT|COWAT1|Controlled Oral Word Association	A test that measures the verbal fluency of an individual. This tool measures both semantic fluency and phonetic fluency.			Intellectual Product	CDISC Functional Test Category Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114145>	C49936	Electrical Stimulation Electrode Type|STIMPARM|Stimulation Parameter|Stimulation Parameter	The type of electrode used on the subject during electrical stimulation of the body or organ.			Manufactured Object	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114146>	C160939	Explanted Medical Device|Device Explantation|Inactive (Removed)	A finding referring to a medical device that has been removed from the body, usually during a surgical procedure.			Finding	CDRH Health Effects - Health Impact Terminology|FDA CDRH GUDID Terminology
C114147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114147>	C114120	Baseline Wander by ECG Finding|BASELINE WANDER	An electrocardiographic recording in which the isoelectric line in one or more leads is vertically displaced resulting in low frequency upward and downward movements of the signal with varying amplitudes. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114148>	C114120	Muscle Tremor Artifact|MUSCLE TREMOR	An electrocardiographic recording with intermittent mid to high frequency artifact in one or more leads due to muscular tremor or movement rather than cardiac activity. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114149>	C114120	Alternating Current Noise by ECG Finding|AC NOISE|AC Noise	An electrocardiographic recording showing power line interference with the electrocardiographic signal. The artifact amplitude modulation has the same frequency as the AC power system present (usually 50 Hz or 60 Hz). (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11414>	C63360	Carboplatin/Gemcitabine/Paclitaxel Regimen|CBDCA/dFdC/TAX|Carboplatin and Gemcitabine (GCb) and Paclitaxel|Carboplatin-Gemcitabine-Paclitaxel|Carboplatin/Gemcitabine/Paclitaxel|GCP	A regimen consisting of carboplatin, gemcitabine, and paclitaxel that may be used in the treatment of advanced ovarian carcinoma and non-small cell lung cancer (NSCLC).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C114150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114150>	C114120	Interchanged Limb Electrodes by ECG Finding|LIMB ELECTRODES INTERCHANGED|Limb Lead Reversal	An electrocardiographic recording in which two or more of the limb electrodes are switched resulting in improper representation of the affected leads. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114151>	C114120	Disconnected Limb Electrodes by ECG Finding|LIMB ELECTRODE(S) DISCONNECTED	An electrocardiographic recording in which one or more of the limb electrodes are disconnected resulting in missing waveforms (often flat lines) of the respective leads. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114152>	C114120	Interchanged Precordial Electrodes by ECG Finding|PRECORDIAL ELECTRODES INTERCHANGED|Precordial Lead Reversal	An electrocardiographic recording in which two or more of the precordial electrodes are switched resulting in improper representation of the affected leads. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114153>	C114120	Disconnected Precordial Electrode V1 by ECG Finding|PRECORDIAL ELECTRODE V1 DISCONNECTED	An electrocardiographic recording in which the electrode for lead V1 is disconnected resulting in missing waveforms (flat line) for lead V1. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114154>	C114120	Disconnected Precordial Electrode V2 by ECG Finding|PRECORDIAL ELECTRODE V2 DISCONNECTED	An electrocardiographic recording in which the electrode for lead V2 is disconnected resulting in missing waveforms (flat line) for lead V2. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114155>	C114120	Disconnected Precordial Electrode V3 by ECG Finding|PRECORDIAL ELECTRODE V3 DISCONNECTED	An electrocardiographic recording in which the electrode for lead V3 is disconnected resulting in missing waveforms (flat line) for lead V3. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114156>	C114120	Disconnected Precordial Electrode V4 by ECG Finding|PRECORDIAL ELECTRODE V4 DISCONNECTED	An electrocardiographic recording in which the electrode for lead V4 is disconnected resulting in missing waveforms (flat line) for lead V4. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114157>	C114120	Disconnected Precordial Electrode V5 by ECG Finding|PRECORDIAL ELECTRODE V5 DISCONNECTED	An electrocardiographic recording in which the electrode for lead V5 is disconnected resulting in missing waveforms (flat line) for lead V5. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114158>	C114120	Disconnected Precordial Electrode V6 by ECG Finding|PRECORDIAL ELECTRODE V6 DISCONNECTED	An electrocardiographic recording in which the electrode for lead V6 is disconnected resulting in missing waveforms (flat line) for lead V6. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114159>	C114120	All Precordial Electrodes Are Disconnected by ECG Finding|ALL PRECORDIAL ELECTRODES DISCONNECTED	An electrocardiographic recording in which all precordial electrodes are disconnected resulting in missing waveforms (flat line) of all leads V1 - V6. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11415>	C61063	gp100 Antigen/Sargramostim/Tyrosinase Peptide|gp100/GM-CSF/TYRP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114160>	C114120	Incorrectly Positioned Precordial Electrodes by ECG Finding|PRECORDIAL ELECTRODE(S) POSITIONED INCORRECTLY	An electrocardiographic recording in which one or more precordial electrodes are placed incorrectly with respect to the standard chest electrode positions resulting in improper representation of the affected leads. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114161>	C114120	Quality Problem Not Otherwise Specified by ECG Finding|QUALITY PROBLEM NOT OTHERWISE SPECIFIED|Unknown Quality Problem	An electrocardiographic artifact or recording error with unknown origin or which is not described otherwise. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114162>	C114120	Artifact Lead Signal by ECG Finding|ARTIFACT	An electrocardiographic recording in which one or more leads display extraneous signals which do not represent cardiac electrical activity. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114163>	C114120	ECG Waveforms Not Present|NO ECG WAVEFORMS PRESENT	An electrocardiographic recording that displays flat lines (no waveforms are visible) in all leads present. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114164>	C114120	60 Hertz Noise by ECG Finding|60 Hz Artifact|60 Hz NOISE|60 Hz Noise	An electrocardiographic recording showing power line interference with the electrocardiographic signal. The artifact amplitude modulation has the same frequency as the AC power system present (60 Hz). (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114165>	C114120	50 Hertz Noise by ECG Finding|50 Hz Artifact|50 Hz NOISE|50 Hz Noise	An electrocardiographic recording showing power line interference with the electrocardiographic signal. The artifact amplitude modulation has the same frequency as the AC power system present (50 Hz). (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114166>	C114120	Low Amplitude QRS Complex by ECG Finding|LOW AMPLITUDE SIGNAL|Low Amplitude QRS Complex	An electrocardiographic recording showing smaller than usual QRS complexes in one or more leads. This may represent a technical issue with the ECG acquisition or characteristics of the individual. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114167>	C114120	Incomplete ECG|INCOMPLETE ECG	An electrocardiographic recording which is limited in duration or which does not display all of the expected leads. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114168>	C114120	Incorrectly Scaled ECG|INCORRECTLY SCALED ECG	An electrocardiographic recording in which the ECG signal is not displayed at the indicated recording speed and/or amplitude resolution. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114169>	C114120	Incompletely Digitized ECG Leads|INCOMPLETELY DIGITIZED ECG LEAD(S)	A digital electrocardiographic recording which was digitized from paper ECG tracings and which does not contain all leads present on the original paper printout. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11416>	C61007	Fluorouracil/Paclitaxel|5-FU/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114170>	C114120	Inability to Digitize ECG Leads|UNABLE TO DIGITIZE ECG LEADS	A statement indicating the inability to digitize a paper ECG. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114171>	C114120	Invalid ECG Waveforms|INVALID ECG WAVEFORMS	An electrocardiographic recording for which the displayed leads do not represent the individual's true ECG lead information. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114172>	C114120	Poor Quality ECG|POOR QUALITY ECG	An electrocardiographic recording that does not show proper quality for reasons that are not otherwise described. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114173>	C114120	Suspicion of Limb Electrodes Reversal But Interpretation Assumes No Reversal by ECG Finding|SUSPECT LIMB ELECTRODES REVERSED, INTERPRETATION ASSUMES NO REVERSAL	An electrocardiographic recording in which an interchange of one or more limb lead electrodes is suspected, but for which an interpretation is performed as though the lead placement is correct. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114174>	C114120	Suspicion of Limb Electrodes Reversal But Interpretation Assumes Reversal by ECG Finding|SUSPECT LIMB ELECTRODES REVERSED, INTERPRETATION ASSUMES REVERSAL	An electrocardiographic recording in which an interchange of one or more limb lead electrodes is suspected, and for which an interpretation is performed as though the leads have in fact been interchanged. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114175>	C114120	ECG Acquired with Precordial Electrodes Placed on the Right Chest|ECG ACQUIRED WITH PRECORDIAL ELECTRODES PLACED ON RIGHT CHEST	An electrocardiographic recording in which the precordial electrodes have been placed over the right chest and record a right sided ECG. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114176>	C114120	Other Incorrect Electrode Placement|OTHER INCORRECT ELECTRODE PLACEMENT	An electrocardiographic recording in which one or more electrodes are incorrectly placed but further details are not provided. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114177>	C114120	Insufficient Number of Beats for Complete ECG Evaluation|INSUFFICIENT NUMBER OF BEATS TO COMPLETELY EVALUATE ECG	An electrocardiographic recording in which fewer than the required number of cardiac complexes are available for measurement and/or interpretation due to a shorter than planned recording or due to cardiac complexes which are present but are not suitable for measurement and/or interpretation. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114178>	C114120	ECG Evaluation Not Performed Due to Unknown ECG Amplitude Gain or Recording Speed|ECG EVALUATION NOT PERFORMED DUE TO UNKNOWN ECG AMPLITUDE GAIN OR RECORDING SPEED	An electrocardiographic recording in which measurements and/or interpretation are not performed because the ECG amplitude gain and/or recording speed are not known. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114179>	C114120	Incomplete ECG Measurements Due to Truncation of QRS Complexes|INCOMPLETE MEASUREMENTS DUE TO TRUNCATION OF QRS COMPLEXES	An electrocardiographic recording in which measurements (particularly of QRS amplitudes) and/or interpretations are not performed because QRS complexes have been truncated. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11417>	C61063	Bryostatin 1/Fludarabine|BRYO/FAMP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114180>	C114120	ECG Evaluation Not Performed Due to Poor Quality of Printed ECG|ECG EVALUATION NOT PERFORMED DUE TO POOR QUALITY OF PRINTED ECG	A printed electrocardiographic recording with poor printout quality (e.g. a faded paper ECG tracing or ECG with inconsistent printing speed) such that measurements and/or interpretation cannot be performed. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114181>	C114120	ECG Evaluation Not Performed Due to Corrupted Digital ECG File|ECG EVALUATION NOT PERFORMED DUE TO CORRUPTED DIGITAL ECG FILE	A digital electrocardiographic recording which is corrupted (i.e. ECG signal cannot be restored) such that measurements and/or interpretation cannot be performed. (CDISC)			Qualitative Concept	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114182>	C19332	Dominant Hand|HANDDOM	The preferred hand of use for controlled and efficient performance of motor tasks.			Organism Attribute	CDISC SDTM Subject Characteristic Test Code Terminology|CDISC SDTM Subject Characteristic Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114183>	C25209	Boundary Shift Integral|BSI|BSI	A measurement of change in volume of an organ or anatomical feature as determined by a shift in tissue boundary over time.			Conceptual Entity	CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114184>	C16809	MRI Without Contrast|MRI WITHOUT CONTRAST|Magnetic Resonance Imaging Without Contrast	A technique that uses radiofrequency waves and a magnet to image the body, in which the images are not enhanced by the addition of contrast agents.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114185>	C215118	Polysomnography|POLYSOMNOGRAPHY|PSG|PSG	A group of tests taken during sleep to capture and record brain wave changes, eye movements, breathing rate, blood pressure, heart rate, and the electrical activity of the heart and other muscles.	Polysomnography		Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C114186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114186>	C83002	Femoral Condyle|FEMORAL CONDYLE	A rounded bony projection at the distal end of the femur.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114187>	C69300	Humeral Epicondyle|HUMERAL EPICONDYLE	A bone prominence at the distal end of the humerus to which ligaments and tendons of the joints are attached.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114188>	C32868|C102291	Distal Interphalangeal Joint 2 of the Hand|DIP2 of the Hand|DISTAL INTERPHALANGEAL JOINT 2 OF THE HAND	A ginglymoid (hinge) synovial joint within the second digit of the hand connecting the middle and distal phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114189>	C32868|C102292	Distal Interphalangeal Joint 3 of the Hand|DIP3 of the Hand|DISTAL INTERPHALANGEAL JOINT 3 OF THE HAND	A ginglymoid (hinge) synovial joint within the third digit of the hand connecting the middle and distal phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11418>	C61063	BMS-182751/Prednisone|BMS-182751/PRED			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114190>	C32868|C102302	Interphalangeal Joint 2 of the Hand|INTERPHALANGEAL JOINT 2 OF THE HAND|IP2 of the Hand	A ginglymoid (hinge) synovial joint between the phalanges of the second digit of the hand.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114191>	C32868|C102303	Interphalangeal Joint 3 of the Hand|INTERPHALANGEAL JOINT 3 OF THE HAND|IP3 of the Hand	A ginglymoid (hinge) synovial joint between the phalanges of the third digit of the hand.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114192>	C32868|C102304	Interphalangeal Joint 4 of the Hand|INTERPHALANGEAL JOINT 4 OF THE HAND|IP4 of the Hand	A ginglymoid (hinge) synovial joint between the phalanges of the fourth digit of the hand.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114193>	C32868|C102305	Interphalangeal Joint 5 of the Hand|INTERPHALANGEAL JOINT 5 OF THE HAND|IP5 of the Hand	A ginglymoid (hinge) synovial joint between the phalanges of the fifth digit of the hand.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114194>	C32868|C102332	Proximal Interphalangeal Joint 2 of the Hand|PIP2 of the Hand|PROXIMAL INTERPHALANGEAL JOINT 2 OF THE HAND	A ginglymoid (hinge) synovial joint within the second digit of the hand connecting the proximal and middle phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114195>	C32868|C102333	Proximal Interphalangeal Joint 3 of the Hand|PIP3 of the Hand|PROXIMAL INTERPHALANGEAL JOINT 3 OF THE HAND	A ginglymoid (hinge) synovial joint within the third digit of the hand connecting the proximal and middle phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114196>	C32868|C102334	Proximal Interphalangeal Joint 4 of the Hand|PIP4 of the Hand|PROXIMAL INTERPHALANGEAL JOINT 4 OF THE HAND	A ginglymoid (hinge) synovial joint within the fourth digit of the hand connecting the proximal and middle phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114197>	C32868|C102335	Proximal Interphalangeal Joint 5 of the Hand|PIP5 of the Hand|PROXIMAL INTERPHALANGEAL JOINT 5 OF THE HAND	A ginglymoid (hinge) synovial joint within the fifth digit of the hand connecting the proximal and middle phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114198>	C32867|C102291	Distal Interphalangeal Joint 2 of the Foot|DIP2 of the Foot|DISTAL INTERPHALANGEAL JOINT 2 OF THE FOOT	A ginglymoid (hinge) synovial joint within the second digit of the foot connecting the middle and distal phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114199>	C32867|C102292	Distal Interphalangeal Joint 3 of the Foot|DIP3 of the Foot|DISTAL INTERPHALANGEAL JOINT 3 OF THE FOOT	A ginglymoid (hinge) synovial joint within the third digit of the foot connecting the middle and distal phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11419>	C61063	Doxorubicin HCl Liposome/Etoposide|LipoDox/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1141>	C333|C1971	Carboxyamidotriazole|1H-1,2,3-Triazole-4-carboxamide, 5-amino-1-((3,5-dichloro-4(4-chlorobenzoyl)phenyl)methyl)|5-Amino-1-((3,5-dichloro-4-(4-chlorobenzoyl)phenyl)methyl)-1H-1,2,3-triazole-4-carboxamide|CAI|CARBOXYAMIDOTRIAZOLE|Carboxyamido-triazole|Carboxyaminoimidazole|L651582|carboxyamidotriazole	An orally-active agent with potential antineoplastic activity.  Carboxyamidotriazole binds to and inhibits non-voltage-operated Ca2+ channels, blocking both Ca2+ influx into cells and Ca2+ release from intracellular stores and resulting in the disruption of calcium channel-mediated signal transduction and inhibition of vascular endothelial growth factor (VEGF) signaling, endothelial proliferation, and angiogenesis.  This agent may also inhibit tumor cell growth, invasion and metastasis. (NCI04)	Carboxyamidotriazole		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C114200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114200>	C32867|C102301	Interphalangeal Joint 1 of the Foot|INTERPHALANGEAL JOINT 1 OF THE FOOT|IP1 of the Foot	A ginglymoid (hinge) synovial joint within the first digit of the foot connecting the proximal and distal phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114201>	C32867|C102302	Interphalangeal Joint 2 of the Foot|INTERPHALANGEAL JOINT 2 OF THE FOOT|IP2 of the Foot	A ginglymoid (hinge) synovial joint between the phalanges of the second digit of the foot.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114202>	C32867|C102303	Interphalangeal Joint 3 of the Foot|INTERPHALANGEAL JOINT 3 OF THE FOOT|IP3 of the Foot	A ginglymoid (hinge) synovial joint between the phalanges of the third digit of the foot.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114203>	C32867|C102304	Interphalangeal Joint 4 of the Foot|INTERPHALANGEAL JOINT 4 OF THE FOOT|IP4 of the Foot	A ginglymoid (hinge) synovial joint between the phalanges of the fourth digit of the foot.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114204>	C32867|C102305	Interphalangeal Joint 5 of the Foot|INTERPHALANGEAL JOINT 5 OF THE FOOT|IP5 of the Foot	A ginglymoid (hinge) synovial joint between the phalanges of the fifth digit of the foot.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114205>	C32867|C102332	Proximal Interphalangeal Joint 2 of the Foot|PIP2 of the Foot|PROXIMAL INTERPHALANGEAL JOINT 2 OF THE FOOT	A ginglymoid (hinge) synovial joint within the second digit of the foot connecting the proximal and middle phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114206>	C32867|C102333	Proximal Interphalangeal Joint 3 of the Foot|PIP3 of the Foot|PROXIMAL INTERPHALANGEAL JOINT 3 OF THE FOOT	A ginglymoid (hinge) synovial joint within the third digit of the foot connecting the proximal and middle phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114207>	C32867|C102334	Proximal Interphalangeal Joint 4 of the Foot|PIP4 of the Foot|PROXIMAL INTERPHALANGEAL JOINT 4 OF THE FOOT	A ginglymoid (hinge) synovial joint within the fourth digit of the foot connecting the proximal and middle phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114208>	C32867|C102335	Proximal Interphalangeal Joint 5 of the Foot|PIP5 of the Foot|PROXIMAL INTERPHALANGEAL JOINT 5 OF THE FOOT	A ginglymoid (hinge) synovial joint within the fifth digit of the foot connecting the proximal and middle phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114209>	C25196	Subject is Randomized|RANDOMIZED	A status indication that a subject is already assigned to an arm of a clinical trial by chance.			Health Care Activity	CDISC SDTM Protocol Milestone Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11420>	C61007	Anti-Thymocyte Globulin/Busulfan/Melphalan|ATG/BU/L-PAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114210>	C49286	Platelet Aggregometry Curve Type|PLAGGCVT|Platelet Aggregation Curve Type|Platelet Aggregation Curve Type	The classification of the curve pattern that is formed as a result of platelet aggregation.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114211>	C49286	Platelet Aggregometry Mean Amplitude|PLAGMAMP|Platelet Aggregation Mean Amplitude|Platelet Aggregation Mean Amplitude	An average of the measurements of the magnitude of the platelet aggregation in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114212>	C49286	Platelet Aggregometry Mean Curve Type|PLAGMCVT|Platelet Aggregation Mean Curve Type|Platelet Aggregation Mean Curve Type	The average curve type resulting from platelet aggregometry.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114213>	C49286	Nuclear Swelling Measurement|NUCSWELL|Nuclear Swelling|Nuclear Swelling	The determination of the expansion of the nucleus of the cells in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114214>	C49286	Mean Platelet Dry Mass|MPM	The determination of the amount of mean platelet dry mass present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114215>	C49286	Reticulocyte Mean Corpuscular Volume|MCV Reticulocytes|MCV Reticulocytes|MCVRETIC|MCVr|Mean Corpuscular Volume Reticulocytes	The determination of the average reticulocyte volume in a blood sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114216>	C64550	Eosinophil Band Form Count|EOSB|Eosinophils Band Form|Eosinophils Band Form	The determination of the number of band eosinophils in a blood sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114217>	C67208	Eosinophil Band Form to Leukocyte Ratio|EOSBLE|Eosinophils Band Form/Leukocytes|Eosinophils Band Form/Leukocytes	The determination of the ratio of band eosinophils compared to leukocytes in a blood sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114218>	C49286	Reticulocyte Distribution Width	The determination of the range of reticulocyte sizes in a blood specimen.			Laboratory Procedure	
C114219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114219>	C64488	Fractional Excretion of Calcium|FECA|FECa|Fractional Calcium Excretion|Fractional Calcium Excretion|Fractional Excretion of Ca	The determination of the fractional excretion of calcium that is computed based upon the concentrations of calcium and creatinine in both blood and urine.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11421>	C61007	Busulfan/Melphalan/Methylprednisolone|BU/L-PAM/MePRDL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114220>	C64495	Fractional Excretion of Chloride|FECL|FECl|Fractional Chloride Excretion|Fractional Chloride Excretion|Fractional Excretion of Cl	The determination of the fractional excretion of chloride that is computed based upon the concentrations of chloride and creatinine in both blood and urine.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114221>	C64857	Fractional Excretion of Phosphate|FEPI|Fractional Excretion of P|Fractional Inorganic Phosphate Excretion|Fractional Phosphorus Excretion|Fractional Phosphorus Excretion	The determination of the fractional excretion of hosphate that is computed based upon the concentrations of hosphate and creatinine in both blood and urine.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114222>	C64853	Fractional Excretion of Potassium|FEK|FEK|Fractional Excretion of K|Fractional Potassium Excretion|Fractional Potassium Excretion	The determination of the fractional excretion of potassium that is computed based upon the concentrations of potassium and creatinine in both blood and urine.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114223>	C209976	Sialyl SSEA-1 Antigen Measurement|SLXAG|SLeX|Sialyl Lewis X Antigen|Sialyl Lex|Sialyl SSEA-1 Antigen|Sialyl SSEA-1 Antigen|Sialyl-CD15|Sialyl-CD15 Antigen|Sialyl-Lewis X Antigen	The determination of the amount of sialyl SSEA-1 antigen present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114224>	C49237	Sulfur Dioxide Measurement|SO2|Sulfur Dioxide|Sulfur Dioxide	The determination of the amount of sulfur dioxide present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114225>	C67208	Unspecified Cells to Total Cell Ratio Measurement|UNSPCECE|Unspecified Cells to Total Cells Ratio Measurement|Unspecified Cells/Total Cells|Unspecified Cells/Total Cells	The determination of the ratio of the cells not otherwise identified or specified compared to total cells in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114226>	C114121	Total Body Clearance by Fraction of Dose for Dose Interval Normalized by Dose|CLFTAUD|Total CL by F for Dose Int Norm by Dose|Total CL by F for Dose Int Norm by Dose	The total body clearance for extravascular administration for dose interval based on the fraction of dose absorbed and divided by the dose.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114227>	C114121	Total Body Clearance by Fraction of Dose for Dose Interval Normalized by Body Mass Index|CLFTAUB|Total CL by F for Dose Int Norm by BMI|Total CL by F for Dose Int Norm by BMI	The total body clearance for extravascular administration for dose interval based on the fraction of dose absorbed and divided by the body mass index.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114228>	C114121	Total Body Clearance by Fraction of Dose for Dose Interval Normalized by Surface Area|CLFTAUS|Total CL by F for Dose Int Norm by SA|Total CL by F for Dose Int Norm by SA	The total body clearance for extravascular administration for dose interval based on the fraction of dose absorbed and divided by the surface area.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114229>	C114121	Total Body Clearance by Fraction of Dose for Dose Interval Normalized by Weight|CLFTAUW|Total CL by F for Dose Int Norm by WT|Total CL by F for Dose Int Norm by WT	The total body clearance for extravascular administration for dose interval based on the fraction of dose absorbed and divided by the weight.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11422>	C61063	Interleukin-2/Rituximab|IL-2/MOAB IDEC-C2B8			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114230>	C114122	Total Body Clearance for Dose Interval Normalized by Dose|CLTAUD|Total CL for Dose Int Norm by Dose|Total CL for Dose Int Norm by Dose	The total body clearance for intravascular administration for dose interval divided by the dose.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114231>	C114122	Total Body Clearance for Dose Interval Normalized by Body Mass Index|CLTAUB|Total CL for Dose Int Norm by BMI|Total CL for Dose Int Norm by BMI	The total body clearance for intravascular administration for dose interval divided by the body mass index.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114232>	C114122	Total Body Clearance for Dose Interval Normalized by Surface Area|CLTAUS|Total CL for Dose Int Norm by SA|Total CL for Dose Int Norm by SA	The total body clearance for intravascular administration for dose interval divided by the surface area.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114233>	C114122	Total Body Clearance for Dose Interval Normalized by Weight|CLTAUW|Total CL for Dose Int Norm by WT|Total CL for Dose Int Norm by WT	The total body clearance for intravascular administration for dose interval divided by the weight.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114234>	C64774	Accumulation Index using Lambda z|AILAMZ	The predicted accumulation ratio for area under the curve (AUC) calculated using the Lambda z estimated from single dose data.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114235>	C134576	Experimental Organism Benign Nephroblastoma Neoplasm|NEPHROBLASTOMA, BENIGN	A benign embryonal neoplasm of the kidney.			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C114236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114236>	C22188	Ventriculus|VENTRICULUS	A thick-walled muscular pouch located beneath the proventriculus that is responsible for digestion in birds, insects and invertebrates.			Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114237>	C48367	Virtual Pixel|VIRTUAL PIXEL|{VIRTUAL PIXEL}|{VIRTUAL PIXEL}	A type of pixel created from overlying two adjacent real pixels to create an additional virtual image of a pixel that is visible to the human eye.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114238>	C48367	Pixels per Centimeter|PIXELS/cm|PPCM|{PIXELS}/cm|{PIXELS}/cm|{Pixel}/cm|{Pixel}/cm	A unit of image resolution expressed in the numbers of pixels per centimeter in the horizontal or vertical direction.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114239>	C48367	Pixels per Inch|PIXELS/in|PPI|{PIXELS}/[in_i]|{PIXELS}/[in_i]|{Pixel}/[in_i]|{Pixel}/[in_i]	A unit of image resolution expressed in the numbers of pixels per inch in the horizontal or vertical direction.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11423>	C61063	Amifostine/Cytarabine/Mitoxantrone|ARA-C/DHAD/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114240>	C67313	Percent per Minute|%/min|%/min|%/min	A unit of frequency expressed as the percentage of entities or events per minute.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114241>	C67319	Millivolt Squared per Hertz|Millivolt^2/Hertz|mV2/Hz|mV2/Hz|mV2/Hz	A unit equal to one thousandth of a volt squared per unit of frequency equal to one Hertz.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114242>	C48572	Grating Cycles per Centimeter|cpcm|cy/cm|{cy}/cm|{cy}/cm	A unit of measure for the number of repeating vertical or horizontal bars per unit of length equal to one centimeter on a visual acuity testing card.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114243>	C76311	Enterococcus thailandicus|ENTEROCOCCUS THAILANDICUS|Enterococcus sanguinicola	A species of facultatively anaerobic, Gram-positive, spherical or ovoid shaped bacteria arranged in pairs or chains, in the phylum Firmicutes. This species is nonmotile, non-spore forming, catalase negative, hydrolyzes arginine and esculin, but not starch or gelatin, weakly positive for blood hemolysis, does not reduce nitrate, and ferments glucose. E. thailandicus has been isolated from fermented sausages produced in Thailand and is not yet known to be pathogenic to humans.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114244>	C85972	Atopobium rimae|ATOPOBIUM RIMAE|Lactobacillus rimae	A species of strictly anaerobic, Gram-positive, rod or elliptical shaped bacteria arranged in single element, pairs or chains, in the phylum Actinobacteria. This species is nonmotile, non-spore forming, negative for indole production and nitrate reduction, ferments glucose to yield lactic acid, acetic acid and formic acid, and does not produce gas from glucose fermentation. A. rimae is found in the normal gingival flora but can cause odontogenic infection, chronic periodontitis and bacteremia in humans.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114245>	C86902	Peptoniphilus harei|PEPTONIPHILUS HAREI|Peptostreptococcus harei|Schleiferella harei	A species of obligately anaerobic, Gram-positive, cocci shaped bacteria arranged in pairs, short chains, tetrads or small clusters, in the phylum Firmicutes. This species is nonmotile, non-spore forming, indole positive, produce butyric acid and gas in peptone yeast extract medium with glucose, negative for urease and nitrate reduction, produces coagulase, and does not ferment carbohydrates. P. harei is an opportunistic pathogen and has been isolated from antral washout specimens, pus from the peritoneal cavity, infected sacral sores, and abscesses of the face, neck, breast, and thigh.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114246>	C86870	Alistipes shahii|ALISTIPES SHAHII	A species of strictly anaerobic, Gram negative, pigment-producing, rod shaped bacteria assigned to the phylum Bacteroidetes. This bacteria is non-motile, non-spore forming, bile-resistant, indole positive, catalase negative, hydrolyzes esculin, and does not reduce nitrate. A. shahii is a commensal organism of the human gastrointestinal tract.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114247>	C113447	Megamonas funiformis|MEGAMONAS FUNIFORMIS	A species of anaerobic, Gram negative, rod shaped bacteria assigned to the phylum Firmicutes. This bacteria is non-motile, non-spore forming, filamentous, weakly hemolytic, indole positive, negative for oxidase and catalase, hydrolyzes esculin and gelatin, and does not reduce nitrate. M. funiformis has been isolated from human feces and is a normal part of the human intestinal flora.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114248>	C86155	Arthrobacter cumminsii|ARTHROBACTER CUMMINSII	A species of obligately aerobic, Gram positive, irregular shaped bacteria assigned to the phylum Actinobacteria. This bacteria is non-motile, non-spore forming, catalase positive, hydrolyzes gelatin, and does not reduce nitrate. A. cumminsii is widely distributed in the environment, especially in soil. It may cause opportunistic infections in humans.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114249>	C76308	Corynebacterium tuberculostearicum|CORYNEBACTERIUM TUBERCULOSTEARICUM	A species of aerobic, Gram positive, rod shaped bacteria assigned to the phylum Actinobacteria. This bacteria is non-motile, non-spore forming, lipophilic, catalase positive, produces tuberculostearic acid, reduces nitrate and ferments saccharose. C. tuberculostearicum is a part of the normal human skin flora, but may also be involved in the development of inflammatory breast diseases.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11424>	C61063	Gemcitabine/Topotecan|dFdC/TOPO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114250>	C76275	Clostridium bolteae|CLOSTRIDIUM BOLTEAE	A species of obligately anaerobic, Gram positive, rod shaped bacteria assigned to the phylum Firmicutes. This bacteria is non-motile, non-spore forming, negative for indole, lecithinase, lipase, catalase and urease, does not hydrolyze esculin or gelatin, does not reduce nitrate, and ferments carbohydrate to produce acetic acid and lactic acid. C. bolteae is a part of the normal human intestinal microflora, but may also be involved in the development of autism and bacteremia.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114251>	C76275	Clostridium hathewayi|CLOSTRIDIUM HATHEWAYI	A species of strictly anaerobic, Gram negative, rod shaped bacteria assigned to the phylum Firmicutes. This bacteria is spore forming, negative for indole, catalase, lecithinase and lipase, hydrolyzes esculin and starch, but not gelatin, does not reduce nitrate, ferments carbohydrate to produce acetate, ethanol, carbon dioxide and hydrogen, and exhibits variable motility. C. hathewayi is a part of the normal human intestinal microflora, but may also be involved in the development of acute appendicitis and bacteremia.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114252>	C76323	Fusobacterium naviforme|Bacillus naviformis|FUSOBACTERIUM NAVIFORME|Fusibacterium naviforme|Pseudobacterium naviformis|Ristella naviformis	A species of obligately anaerobic, Gram negative, rod shaped bacteria assigned to the phylum Fusobacteria. This bacteria is non-spore forming, indole positive, non-fermentative, and characteristically produce butyrate as a major end product of its metabolism. F. naviforme has been isolated in human clinical samples and may cause infections in humans.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114253>	C86828	Tsukamurella pulmonis|TSUKAMURELLA PULMONIS	A species of aerobic, Gram positive, slightly acid-alcohol-fast, rod shaped bacteria assigned to the phylum Actinobacteria. This bacteria is non-motile, non-spore forming, catalase and urease positive, resistant to streptomycin, rifampin and capreomycin, utilizes glucose, hydrolyzes esculin but not gelatin, and does not reduce nitrate. T. pulmonis has been isolated from patients with pulmonary tuberculosis and is an opportunistic pathogen which may cause pulmmonary infections in immunosuppressed indiviuals.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114254>	C77163	Candida rugosa|Azymocandida rugosa|C. rugosa|CANDIDA RUGOSA|Diutina rugosa|Mycoderma rugosum	A dimorphic yeast in the phylum Ascomycota. This species is ovoid, ellipsoidal or cylindrical shaped, and forms pseudohyphae. The lipase produced by this yeast is used commercially in biotransformation to catalyze hydrolysis reactions, especially for the production of ricinoleic acid. C. rugosa is also a human pathogen and can cause fungemia, with reduced susceptibility to the azole antifungal agents.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114255>	C77163	Candida dubliniensis|C. dubliniensis|CANDIDA DUBLINIENSIS	A dimorphic yeast consisting of ovoid or spherical blastospores in the phylum Ascomycota. This species is germ-tube positive, produces thick-walled blastospores arranged in triplets or contiguous pairs, and pseudohyphae with short unilateral, bilateral or multilateral branches at the septa, assimilates carbohydrates, hydrolyzes esculin, and does not utilize potassium nitrate. C. dubliniensis is an opportunistic pathogen and has been isolated from immunocompromised individuals and the oral cavities of HIV-infected patients. It can cause candidosis and systematic fungemia in humans.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114256>	C114123	Kluyveromyces marxianus|C. pseudotropicalis|Candida pseudotropicalis|K. cicerisporus|K. fragilis|KLUYVEROMYCES MARXIANUS|Kluyveromyces cicerisporus|Kluyveromyces fragilis	A dimorphic, homothallic and hemiascomycetous yeast in the phylum Ascomycota. This species is respiro-fermentative, Crabtree negative, thermotolerant, and assimilate lactose and insulin. This species also has a characteristically high growth rate and secretory capacity. K. marxianus is a biocatalyst and used industrially to produce beta-galactosidase, beta-glucosidase, inulinase, and polygalacturonases. It is also used as baker's yeast and an anticholesterolemic agent.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114257>	C114124	Yarrowia lipolytica|Candida lipolytica|M. lipolytica|Mycotorula lipolytica|Y. lipolytica|YARROWIA LIPOLYTICA	A dimorphic yeast in the phylum Ascomycota. This species is strictly aerobic, degrades hydrophobic substrates, assimilates glucose, fructose and mannose, and utilizes ethanol and glycerol as carbon sources. Y. lipolytica is a biocatalyst and used commercially in biotransformation to catalyze hydrolysis, esterification, interesterification and transesterification reactions. It is also used for the production of citric acid.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114258>	C77163	Candida pararugosa|C. pararugosa|CANDIDA PARARUGOSA	A yeast in the phylum Ascomycota. This species assimilates glucose, xylitol, galactose and sorbitol. C. pararugosa has been isolated from human feces and is a normal part of the oral microflora.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114259>	C123544	Pichia norvegensis|C. mycoderma var. annulata|Candida mycoderma var. annulata|P. norvegensis|PICHIA NORVEGENSIS	A dimorphic yeast in the phylum Ascomycota. This species is ovoid or ellipsoidal shaped, arranged in single or pairs, ferments glucose and assimilates cellobiose but not galactose, sucrose, maltose, lactose, D-mannitol and D-glucitol, produces ascospores and utilizes thiamine, biotin and pyridoxine. P. norvegensis has been isolated from the normal vaginal flora.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11425>	C61007	Cyclophosphamide/Docetaxel/Doxorubicin|CTX/DOX/TXT			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114260>	C77163	Candida orthopsilosis|C. orthopsilosis|CANDIDA ORTHOPSILOSIS|Candida parapsilosis group II	A yeast in the phylum Ascomycota. This species is oval, round, or cylindrical shaped, ferments glucose, does not form true hyphae and exists in either a yeast phase or a pseudohyphal form. C. orthopsilosis a commensal of human skin, and an opportunistic human pathogen which may cause superficial cutaneous infections.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114261>	C77163	Candida zeylanoides|C. krissii|C. zeylanoides|CANDIDA ZEYLANOIDES|Candida krissii	A yeast in the phylum Ascomycota. This species is urease-negative, forms feather-like pseudohyphae consisting of chains of cells with oval blastospores, assimilates glucose, and does not grow in the presence of cycloheximide. C. zeylanoides is an opportunistic human pathogen which may cause fungemia and arthritis.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114262>	C114125	Wickerhamomyces anomalus|C. pelliculosa|Candida pelliculosa|H. anomala|Hansenula anomala|P. anomala|Pichia anomala|W. anomalus|WICKERHAMOMYCES ANOMALUS	A yeast in the phylum Ascomycota. This species is spheroidal to elongate shaped, forms pseudohyphae and produces hat-shaped ascospores, can grow anaerobically, ferments glucose and sucrose, assimilates glucose, galactose, fructose, raffinose and mannose but not formic acid and methanol, and utilizes nitrate and urea. W. anomalus is used in food and feed processing and functions as a biopreservation agent, phytase producer, and for folate biofortification. It is also the causative agent of opportunistic mycoses that develop in immunocompromised individuals as well as neonates.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114263>	C114126	Magnusiomyces capitatus|Blastoschizomyces capitatus|Dipodascus capitatus|Geotrichum capitatum|M. capitatus|MAGNUSIOMYCES CAPITATUS|Saprochaete capitata|Trichosporon capitatum	A yeast in the phylum Ascomycota. This species forms branched hyphae, and hyaline, ellipsoidal ascospores, and assimilates glucose, galactose, ethanol and glycerol. M. capitatus is an opportunistic pathogen and has been isolated from the human digestive and respiratory tracts as well as the blood of immunocompromised hosts.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114264>	C124370	Rhodotorula glutinis|R. glutinis|RHODOTORULA GLUTINIS	A yeast in the phylum Basidiomycota. This species is globose to ovoid, or cylindrical to fusiform shaped, forms distinctive orange/red colonies, assimilates glucose, ethanol and glycerol, and utilizes nitrate. R. glutinis is a common environmental inhabitant and an opportunistic pathogen which may cause meningitis, fungemia, and sepsis.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114265>	C114127	Filobasidium uniguttulatum|C. neoformans var. uniguttulatus|C. uniguttulatus|Cryptococcus neoformans var. uniguttulatus|Cryptococcus uniguttulatus|E. uniguttulata|Eutorulopsis uniguttulata|F. uniguttulatum|FILOBASIDIUM UNIGUTTULATUM	A heterothallic yeast in the phylum Basidiomycota. This species is basidia hyaline, urease-positive, produces hyphae and smooth, ovate or kidney shaped basidiospores, and assimilates glucose, sucrose and maltose. F. uniguttulatum may cause meningitis.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114266>	C77184	Cryptococcus randhawii|C. randhawii|CRYPTOCOCCUS RANDHAWII	An anamorphic yeast in the phylum Basidiomycota. This species is globose to ovoid shaped, assimilates glucose, galactose, xylose, arabinose, sucrose and maltose, does not produce hyphae or pseudohyphae, and utilizes nitrate. C. randhawii is originally isolated from the decaying wood samples in North-western India.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114267>	C77184	Cryptococcus albidus|C. albidus|CRYPTOCOCCUS ALBIDUS|R. albida|Rhodotorula albida|T. albida|T. nadaensis|T. neoformans var. albida|Torula albida|Torulopsis albida|Torulopsis nadaensis|Torulopsis neoformans var. albida	A yeast in the phylum Basidiomycota. This species is globose to ovoid shaped, urease- and nitrate-positive, does not produce hyphae or pseudohyphae, assimilates glucose and sucrose. C. albidus is a common transient on human skin, and may cause cutaneous, pulmonary, CNS and vaginal infections.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114268>	C77184	Cryptococcus gattii|C. bacillisporus|C. gattii|CRYPTOCOCCUS GATTII|Cryptococcus bacillisporus	An encapsulated yeast in the phylum Basidiomycota. This species is globose to ovoid shaped, urease-positive, pseudohyphae- and nitrate-negative, does not ferment sugars, and assimilates glucose, maltose, sucrose, galactose, trehalose, raffinose, inositol, cellobiose, rhamnose, arabinose, melezitose and xylose. C. gattii is a human opportunistic pathogen and causes pulmonary cryptococcosis, basal meningitis and cerebral cryptococcomas in immunocompromised hosts. It is also associated with skin, soft tissue, lymph node, bone, and joint infections.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114269>	C77184	Cryptococcus laurentii|C. laurentii|CRYPTOCOCCUS LAURENTII	An encapsulated yeast in the phylum Basidiomycota. This species is spherical and elongate shaped, urease-positive, pseudohyphae- and nitrate-negative, does not ferment sugars, and assimilates glucose, galactose, maltose, sucrose, trehalose and lactose. C. laurentii is isolated from palm wine and may cause pulmonary and cutaneous infection and CAPD associated peritonitis in humans.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11426>	C61063	Cyclophosphamide/Doxorubicin HCl Liposome/Prednisone/Vincristine|CTX/LipoDox/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114270>	C123544	Pichia kluyveri|P. kluyveri|PICHIA KLUYVERI	A yeast in the phylum Ascomycota. This species is ovoidal to cylindroidal shaped, produces pseudohyphae, ferments glucose and does not assimilate nitrate. P. kluyveri is used in alcoholic fermentation to boost fruit flavors in wine.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114271>	C114128	Prototheca wickerhamii|P. wickerhamii|PROTOTHECA WICKERHAMII	A species of achlorophyllous, spherular green alga that grows in aggregates with multiple internal cleavages, in the phylum Chlorophyta. This alga is non-spore forming, non-fermentative, metabolizes glucose, galactose and trehalose, does not utilize potassium nitrate, and reproduces asexually by internal septation and cleavage. P. wickerhamii are found saprophytically on decaying organic matters and can cause protothecosis and systemic algaemia in humans.			Plant	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114272>	C114129	Trichosporon asahii|T. asahii|TRICHOSPORON ASAHII	A yeast in the phylum Basidiomycota. This species is round to oval shaped, with budding yeast-like cells, produces true hyphae forming cylindrical arthroconidia, and hydrolyzes urea. T. asahii is a common soil inhabitant and colonizes the skin and gastrointestinal tract of humans. It may cause superficial infections, disseminated trichosporonosis in immunocompromised individuals, fungemia and fatal septic shock.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C114273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114273>	C32868|C102293	Distal Interphalangeal Joint 4 of the Hand|DIP4 of the Hand|DISTAL INTERPHALANGEAL JOINT 4 OF THE HAND	A ginglymoid (hinge) synovial joint within the fourth digit of the hand connecting the middle and distal phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114274>	C32868|C102294	Distal Interphalangeal Joint 5 of the Hand|DIP5 of the Hand|DISTAL INTERPHALANGEAL JOINT 5 OF THE HAND	A ginglymoid (hinge) synovial joint within the fifth digit of the hand connecting the middle and distal phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114275>	C32867|C102293	Distal Interphalangeal Joint 4 of the Foot|DIP4 of the Foot|DISTAL INTERPHALANGEAL JOINT 4 OF THE FOOT	A ginglymoid (hinge) synovial joint within the fourth digit of the foot connecting the middle and distal phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114276>	C32867|C102294	Distal Interphalangeal Joint 5 of the Foot|DIP5 of the Foot|DISTAL INTERPHALANGEAL JOINT 5 OF THE FOOT	A ginglymoid (hinge) synovial joint within the fifth digit of the foot connecting the middle and distal phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114277>	C221	Anatabine|(-)-Anatabine|(S)-1,2,3,6-Tetrahydro-2,3'-bipyridine|1,2,3,6-Tetrahydro-2,3'-bipyridine|2,3'-Bipyridine, 1,2,3,6-tetrahydro-, (S)- (9CI)|ANATABINE	An alkaloid found in low concentrations in plants in the Solanaceae family, which includes tobacco and tomato plants, with potential nicotine mimetic and anti-inflammatory activities. Following oral administration, anatabine may mimic the neurological effects of nicotine exposure. This agent may not have the addictive properties of nicotine; therefore, it may be appropriate for use in treating nicotine withdrawal symptoms during smoking cessation. Anatabine may also exert its anti-inflammatory effect by the inhibition of the signal transducer and activator of transcription 3 (STAT3) which then prevents the activation of the nuclear factor kappa B (NF-kB), which is a key regulator of proinflammatory cytokine release. Urine concentrations of anatabine can be used to assess the extent of tobacco use.	Anatabine		Organic Chemical|Pharmacologic Substance	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C114278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114278>	C37077	Circulating Plasma Cell|CMMC|Circulating Multiple Myeloma Cell|Circulating PC	A plasma cell myeloma-derived cell found in the peripheral blood.	Circulating Plasma Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C114279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114279>	C12551	SCID-Repopulating Cell|SCID Repopulating Cell|SRC|SRCs|Severe Combined Immunodeficient Repopulating Cell	A human hematopoietic stem cell that is able to repopulate the hematopoietic system of non-obese diabetic/severe combined immunodeficient mice (NOD/SCID). Ex vivo culture conditions that can enrich these stem cells from peripheral blood samples could potentially be used to treat immunodeficiency in human patients.	SCID-Repopulating Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C11427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11427>	C61063	Cyclophosphamide/Daunorubicin/Prednisone/Vincristine|CTX/DNR/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114280>	C39594	Drug Skin Rash|Drug Rash|Drug Rash|Drug-Induced Rash	An eruption in the skin due to exposure to a pharmacologic substance.	Drug Skin Rash		Finding	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114281>	C27662	Parotitis	Inflammation of the parotid glands.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Infectious Disease Terminology|Pediatric Rheumatology Terminology
C114282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114282>	C50527	Uterine Dehiscence	Asymptomatic separation of the uterine wall, usually at the site of a prior uterine scar, that does not include the overlying serosa.			Anatomical Abnormality|Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C114283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114283>	C155727	Futibatinib|2-Propen-1-one, 1-((3S)-3-(4-Amino-3-(2-(3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)-1-pyrrolidinyl)-|FUTIBATINIB|Lytgobi|TAS 120|TAS-120|TAS120	An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. Futibatinib selectively and irreversibly binds to and inhibits FGFR, which may result in the inhibition of both the FGFR-mediated signal transduction pathway and tumor cell proliferation, and increased cell death in FGFR-overexpressing tumor cells. FGFR is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival and its expression is upregulated in many tumor cell types.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C114284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114284>	C1663	H1299 Tumor Cell Lysate Vaccine|H1299 Lysate Vaccine	A cell lysate derived from a lung cancer cell line, H1299, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration, the H1299 tumor cell lysate exposes the immune system to an undefined amount of tumor associated antigens (TAA), particularly cancer testis antigens (CTAs), which may result in the induction of both anti-tumoral cytotoxic T-lymphocytes (CTL) and antibody-dependent responses against TAA-expressing cells, leading to tumor cell lysis. CTAs, such as MAGE, are selectively expressed in a variety of cancers but are not expressed in normal, healthy cells outside the testis.			Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C114285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114285>	C28310	Survivin/p53/HER2 Antigen-loaded Autologous Dendritic Cell Vaccine|Survivin/p53/HER2 Antigen-loaded Autologous DC Vaccine	An autologous dendritic cell (DC) vaccine loaded with tumor-associated antigens (TAAs) derived from survivin, p53 and human epidermal growth factor receptor 2 (HER2 or ERBB2), with immunostimulating and antineoplastic activities. Upon administration, this DC vaccine may elicit a potent cytotoxic T-cell (CTL) response against tumor cells expressing these TAAs, resulting in tumor cell death. Survivin, p53 and HER2 are essential in neoplastic growth, and are considered to be universal tumor antigens.			Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C114286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114286>	C211940|C20401|C129822	Anti-CLDN6 Monoclonal Antibody ASP1650|ASP 1650|ASP-1650|ASP1650|Anti-Claudin 6 Monoclonal Antibody ASP1650|IMAB027	A monoclonal antibody directed against the cell surface protein claudin 6 (CLDN6), with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CLDN6 monoclonal antibody ASP1650 binds to CLDN-6 and may stimulate the immune system to exert both an antibody-dependent cellular cytotoxicity (ADCC) and a complement-dependent cytotoxicity (CDC) mediated immune response against CLDN-6-expressing tumor cells. This may inhibit tumor cell growth. CLDN-6, a tight-junction protein and embryonic antigen, is expressed on a variety of tumor cells but is not expressed on normal, healthy adult cells.	Anti-CLDN6 Monoclonal Antibody ASP1650		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C114288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114288>	C93144	Bifidobacterium lactis/Lactobacillus acidophilus/L. plantarum/L. salivarius Probiotic Supplement|Lactibiane Tolerance	An orally available, probiotic supplement containing the non-pathogenic microorganisms Lactobacillus acidophilus, L. plantarum, L. salivarius and Bifidobacterium lactis, with potential anti-inflammatory, immunomodulating and protective activities. Upon oral ingestion, the naturally-occurring bacterial components in this dietary supplement may improve digestion and help maintain adequate colonization of the gastrointestinal (GI) tract by modulating the composition of the normal microflora. During colonization in the GI tract, the bacteria may form a protective intestinal barrier that may prevent both damage to the mucosal epithelia caused by toxins and attachment of potential pathogens, which protects against bacterial translocation and infections. In addition, this agent may both reduce the secretion of pro-inflammatory cytokines, including interleukin-10, and potentiate natural and acquired immunity.			Bacterium|Pharmacologic Substance	NCI Drug Dictionary Terminology
C114289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114289>	C222318|C1663	PSA/IL-2/GM-CSF Vaccine|ProscaVax|Prostatac	A prostate cancer vaccine containing prostate specific antigen (PSA) combined with the cytokines, interleukin-2 (IL-2) and granulocyte macrophage-colony-stimulating factor (GM-CSF), with potential antineoplastic activity. Upon intradermal vaccination, PSA/IL-2/GM-CSF vaccine may activate the immune system to induce a cytotoxic T-cell (CTL) response against prostate cancer cells expressing this antigen, thereby decreasing tumor cell growth. PSA, a glycoprotein secreted by prostatic epithelial and ductal cells, is overexpressed by prostate cancer cells. IL-2 stimulates natural killer (NK) cells and cytotoxic T-cells against the PSA-expressing tumor cells. GM-CSF promotes antigen presentation to dendritic cells and further stimulates a tumor-specific cytotoxic T-lymphocyte (CTL) response.	PSA/IL-2/GM-CSF Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11428>	C61063	Incomplete Freund's Adjuvant/Peptide 946 Melanoma Vaccine|IFA/p946			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114290>	C74536	Pronase Oral Solution	An oral solution containing a mixture of proteinases, which are produced by Streptomyces griseus, with mucolytic activity and potential diagnostic applications. Upon oral administration, pronase is able to cleave peptide chains of polypeptides into individual amino acids, thereby dissolving mucus. The removal of mucus may improve the visibility of parts of the digestive tract, such as the esophagus and the stomach, during endoscopy. Pre-treatment with pronase before endoscopic examination may help in the detection of certain cancers, such as esophageal and gastric cancer.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C114291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114291>	C275	Concentrated Beet Crystals|BEETELITE NeoShot	A formulation containing concentrated beetroot crystals, with potential antioxidant and protective activities. Concentrated beetroot crystals contain antioxidants, including betacyanin, which scavenge free radicals, and high levels of nitrates and folic acid. Intake of concentrated beetroot crystals leads to the conversion of nitrate to nitric oxide (NO). This may have a beneficial effect on blood flow and blood pressure through the stimulation of NO-mediated vasodilation. Additionally, this agent may decrease fatigue and increase physical performance.			Organic Chemical|Pharmacologic Substance	NCI Drug Dictionary Terminology
C114292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114292>	C1937	Lugol's Solution|Lugol's Iodine	A solution composed of iodine and potassium iodide, which can be used as a reagent and antiseptic, with potential use in cancer diagnosis. The iodine in Lugol's solution selectively binds to alpha-1,4 glucans found in polysaccharides, such as glycogen. Lugol's solution reacts with glycogen in normal, healthy non-keratinized, squamous epithelium and the iodine-glucan complex stains the glycogen-containing cells dark brown. Cancer cells are devoid of glycogen, so these cells will stay unstained. The presence of cancer cells can be detected by the degree of staining and the neoplastic cells can be surgically removed. High-grade intraepitheial neoplasia has almost no glycogen-containing epithelium.	Lugol's Solution		Indicator, Reagent, or Diagnostic Aid	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C114293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114293>	C28310	HER2-pulsed Autologous Type-1 Polarized Dendritic Cell Vaccine|HER-2 pulsed DC1 Vaccine	A dendritic cell (DC)-based cancer vaccine composed of autologous, type-1 polarized dendritic cells (DCs) pulsed with human leukocyte antigen (HLA)-A2-restricted HER-2-derived peptides, with potential immunomodulatory and antineoplastic activities. Autologous DCs were treated with GM-CSF, interleukin-4, interferon-gamma and bacterial lipopolysaccharide (LPS), a toll-like receptor type 4 agonist, to produce highly polarized DCs (alphaDC1) that are capable of producing high levels of interleukin-12p70 (IL-12p70). Upon administration, HER2-pulsed autologous DC vaccine may stimulate a potent cytotoxic T-lymphocyte (CTL) response against HER-2-positive tumor cells, which may result in tumor cell death and decreased tumor growth. HER-2, a tyrosine kinase receptor for epidermal growth factor (EGF) (also known as neu and ErbB2), is overexpressed by a variety of cancers.			Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C114294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114294>	C213431|C213381	IL-12-expressing HSV-1 NSC 733972|M032|NSC 733972	A genetically engineered, replication selective, infected cell protein (ICP) 34.5 gene-deleted, oncolytic human simplex virus type 1 (HSV-1) expressing the human immunostimulating cytokine interleukin-12 (IL-12), with potential antineoplastic activity. Upon intratumoral administration of HSV-1 expressing IL-12 NSC 733972, the IL-12-expressing HSV-1 preferentially infects and replicates in tumor cells of neuronal origin causing viral-mediated tumor cell lysis. The released virus particles, in turn, infect and replicate in neighboring tumor cells. In addition, the IL-12-expressing HSV-1 promotes the secretion of IL-12 by the tumor cells. IL-12 promotes the activation of natural killer cells, which induces both the secretion of interferon-gamma and a cytotoxic T-lymphocyte (CTL) response against the tumor cells. This results in both immune-mediated tumor cell death and further inhibition of tumor cell proliferation. Deletion of the gene encoding for ICP34.5 imparts tumor selectivity by preventing replication in healthy cells.	IL-12-expressing HSV-1 NSC 733972		Pharmacologic Substance|Virus	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C114295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114295>	C28681|C138180|C129826	Anti-NY-ESO1 TCR-transduced Autologous CD62L+-derived T-Lymphocytes|Autologous CD62L+-derived T Lymphocytes Transduced With NY-ESO-1-specific TCR	Human autologous CD62L-positive T-lymphocytes transduced with a retroviral vector encoding a T cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1, with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and reintroduction into the patient, the anti-NY-ESO1 TCR-transduced autologous CD62L+-derived T-Lymphocytes bind to NY-ESO-1-overexpressing tumor cells. This may result in cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1-positive cancer cells. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types. CD62L, also called L-selectin, is a lymphoid homing receptor and differentiation marker and is expressed on a subset of CD8-positive T-lymphocytes; it is involved in the migration of T-lymphocytes to lymph nodes and may improve the efficacy for ex vivo-expanded T-cells following adoptive cell therapy.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C114296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114296>	C254	Opebacan|132-L-Alanine-1-193-bactericidal/Permeability-increasing Protein (Human)|Neuprex|OPEBACAN|Recombinant BPI 21 Fragment|rBPI 21|rBPI- 21	An injectable formulation composed of opebacan, a 21 kDa recombinant fragment of human bactericidal/permeability-increasing protein (BPI), with potential anti-infective activity. Upon intravenous administration, opebacan is able to mimic BPI and binds to and neutralizes lipopolysaccharides (LPS or endotoxins), which are components of the cell wall of gram-negative bacteria that induce a potent innate immune response. This may prevent an endotoxin-mediated inflammatory response and may prevent graft-versus-host-disease (GvHD) after myeloablative allogeneic hematopoietic stem cell transplantation (aHSCT). BPI, a host-defense protein against microbial infection, is naturally produced by neutrophils. Chemo- and radio-therapy induce neutropenia and depletion of endogenous BPI. These therapies also cause intestinal damage and release of bacterial endotoxins into the bloodstream, which initiate a systemic inflammatory response, activate donor T-lymphocytes and possibly cause GvHD following aHSCT.	Opebacan		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C114297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114297>	C275	Beetroot Juice|BEET JUICE|Beet Juice	The juice of the beetroot, with potential antioxidant and protective activities. Beetroot juice contains antioxidants, including betacyanin, which scavenge free radicals. In addition, beetroot contains high levels of nitrates and folic acid. Consumption of beetroot juice leads to the conversion of nitrate to nitric oxide (NO) in the body. This juice may have a beneficial effect on blood flow and blood pressure through the induction of NO-mediated vasodilation. Additionally, this agent may decrease fatigue and increase physical performance.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C114298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114298>	C308|C2140	Cridanimod Sodium|CRIDANIMOD SODIUM|Sodium 2-(9-Oxoacridin-10yl) Acetate|Virexxa	The sodium salt form of cridanimod, a small molecule that can increase progesterone receptor (PR) expression, with potential antineoplastic adjuvant activity. Upon intramuscular administration, cridanimod is able to induce the expression of PR in endometrial cancer. This could increase the sensitivity of endometrial cancer cells to progestin monotherapy. In combination with a progestin, cancer cells could be eradicated through increased PR-mediated signaling, leading to an inhibition of luteinizing hormone (LH) release from the pituitary gland, via a negative feedback mechanism, and, eventually, an inhibition of estrogen release from the ovaries. This leads to an inhibition of cellular growth in estrogen-dependent tumor cells. In addition, this agent is able to increase the production and release of interferon (IFN) alpha and beta. PR is often downregulated in endometrial cancer and makes it resistant to progestin-mediated hormone therapy.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C114299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114299>	C213143|C181108	Belantamab Mafodotin|BELANTAMAB MAFODOTIN|Belantamab Mafodotin-blmf|Belantamab mafodotin|Blenrep|GSK 2857916|GSK-2857916|GSK2857916|J6M0-mcMMAF	An antibody-drug conjugate (ADC) consisting of belantamab, an afucosylated, humanized monoclonal antibody, directed against the B-cell maturation antigen (BCMA), conjugated to mafodotin, an auristatin analogue and microtubule inhibitor monomethyl auristatin phenylalanine (MMAF), with potential antineoplastic activity. Upon administration of belantamab mafodotin, the anti-BCMA antibody moiety selectively binds to BCMA on tumor cell surfaces. Upon internalization, the MMAF moiety binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces tumor cell apoptosis. In addition, belantamab mafodotin induces antibody-dependent cellular cytotoxicity (ADCC). Altogether, this results in the inhibition of cellular proliferation in tumor cells that overexpress BCMA. BCMA, a receptor for a proliferation-inducing ligand and B-cell activating factor, is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in plasma cell survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells. Afucosylation of the antibody moiety increases ADCC.	Belantamab Mafodotin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11429>	C61007	Carmustine/Melphalan|BCNU/L-PAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1142>	C1967	Lavendustin A|5-(((2,5-Dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxy Benzoic Acid|Benzoic acid, 5-[[(2, 5-dihydroxyphenyl)methyl][(2-hydroxyphenyl)methyl]amino]-2-hydroxy -|LAVENDUSTIN A	A compound isolated from strains of Streptomyces griseolavendus that may exert antitumor activity by inhibition of protein tyrosine kinase and tubulin polymerization. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C114300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114300>	C16676	Carboxyhemoglobin|COHb	Hemoglobin where the heme group has formed a stable complex with carbon monoxide (CO). This complex is produced after CO has been inhaled or as a byproduct of hemoglobin, protoporphyrin or dichloromethane catabolism. The heme-CO complex is approximately 200 times more stable than heme-oxygen complexes. Thus, high levels of carboxyhemoglobin in the circulation can lead to tissue hypoxia and death.	Carboxyhemoglobin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114301>	C115146	PDGFRA Antibody|Anti-CD140A Antibody|Anti-PDGFR-Alpha Antibody|Anti-PDGFRA Antibody|Anti-Platelet-Derived Growth Factor Receptor Alpha Antibody|CD140A Antibody|PDGFR-Alpha Antibody|Platelet-Derived Growth Factor Receptor Alpha Antibody	Any immunoglobulin that recognizes platelet-derived growth factor receptor alpha protein.	PDGFRA Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114302>	C16295	H-Y Antibody|Anti-H-Y Antibody	Any immunoglobulin that recognizes male specific cellular antigens.	H-Y Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C114303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114303>	C28404	CTSV Gene|CTSV|CTSV|Cathepsin V Gene	This gene plays a role in protein catabolism.	CTSV Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114304>	C114303	CTSV wt Allele|CATL2|CTSL2|CTSU|Cathepsin V wt Allele|UNQ268/PRO305	Human CTSV wild-type allele is located in the vicinity of 9q22.2 and is approximately 10 kb in length. This allele, which encodes cathepsin L2 protein, is involved in proteolysis.	CTSV wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114305>	C16481|C16389	Cathepsin L2|CTSV|Cathepsin U|Cathepsin V|EC 3.4.22.43	Cathepsin L2 (334 aa, ~37 kDa) is encoded by the human CTSV gene. This protein plays a role in proteolysis.	Cathepsin L2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114306>	C20194	SCUBE2 Gene|SCUBE2|SCUBE2|Signal Peptide, CUB Domain, EGF-Like 2 Gene	This gene may be involved in both cell proliferation and cell-cell adhesion.	SCUBE2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114307>	C114306	SCUBE2 wt Allele|CEGB1|CEGF1|CEGP1|Signal Peptide, CUB Domain, EGF-Like 2 wt Allele	Human SCUBE2 wild-type allele is located in the vicinity of 11p15.3 and is approximately 119 kb in length. This allele, which encodes signal peptide, CUB and EGF-like domain-containing protein 2, may play a role in both cell-cell adhesion and cell proliferation.	SCUBE2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114308>	C18466	Signal Peptide, CUB and EGF-Like Domain-Containing Protein 2	Signal peptide, CUB and EGF-like domain-containing protein 2 (999 aa, ~110 kDa) is encoded by the human SCUBE2 gene. This protein may be involved in the modulation of both cell-cell adhesion and cell proliferation.	Signal Peptide, CUB and EGF-Like Domain-Containing Protein 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114309>	C49238	HOTS Gene|H19 Opposite Tumor Suppressor Gene|HOTS	This gene may play a role in tumor suppression.	HOTS Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C11430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11430>	C61007	Gemcitabine/Paclitaxel|Gemcitabine-Paclitaxel|Gemcitabine-Paclitaxel Regimen|dFdC/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114310>	C114309	HOTS wt Allele|H19 Opposite Tumor Suppressor wt Allele	Human HOTS wild-type allele is located in the vicinity of 11p15 and is approximately 6 kb in length. This allele, which encodes H19 opposite tumor suppressor protein, may be involved in tumor suppression.	HOTS wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114311>	C54673	H19 Opposite Tumor Suppressor|HOTS	H19 opposite tumor suppressor (151 aa, ~17 kDa) is encoded by the human HOTS gene. This protein may play a role in tumor suppression.	H19 Opposite Tumor Suppressor		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114312>	C19540	IGF2-AS Gene|IGF2 Antisense RNA Gene|IGF2-AS|IGF2-AS	This gene is involved in Wilms tumor and may play a role in kidney development.	IGF2-AS Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114313>	C114312	IGF2-AS wt Allele|IGF2 Antisense RNA (Non-Protein Coding) Gene|IGF2 Antisense RNA 1 (Non-Protein Coding) Gene|IGF2 Antisense RNA wt Allele|IGF2, Antisense Gene|IGF2-AS1|IGF2AS|Insulin-Like Growth Factor 2 Antisense 1 (Non-Protein Coding) Gene|Insulin-Like Growth Factor 2, Antisense Gene|Insulin-Like Growth Factor II, Antisense Gene|PEG8|hCG_1995804	Human IGF2-AS wild-type allele is located in the vicinity of 11p15.5 and is approximately 8 kb in length. This allele, which encodes IGF2 Antisense RNA and may encode putative insulin-like growth factor 2 antisense gene protein, plays a role in Wilms tumor and may be involved in embryotic kidney development.	IGF2-AS wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114314>	C54672	Putative Insulin-Like Growth Factor 2 Antisense Gene Protein|IGF2 Antisense Gene Protein 1|IGF2-AS1|PEG8/IGF2AS Protein|Putative Insulin-Like Growth Factor 2 Antisense Gene Protein 1	Putative insulin-like growth factor 2 antisense gene protein (168 aa, ~18 kDa) is encoded by the human IGF2-AS gene. This protein may play a role in Wilms tumor formation.	Putative Insulin-Like Growth Factor 2 Antisense Gene Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114315>	C88924	IGF2 Antisense RNA|IGF2 Antisense RNA 1|IGF2-AS|IGF2AS|Insulin-Like Growth Factor 2 Antisense|Insulin-Like Growth Factor 2 Antisense 1|Insulin-Like Growth Factor 2, Antisense|PEG8	IGF2 Antisense RNA (~2 kb) is encoded by the human IGF2-AS gene. This non-coding RNA is involved in Wilms tumor and may play a role in renal development.	IGF2 Antisense RNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114316>	C54362	KCNQ1OT1 Gene|KCNQ1 Opposite Strand/Antisense Transcript 1 (Non-Protein Coding) Gene|KCNQ1OT1|KCNQ1OT1|KCNQ1OT1	This gene plays a role in the epigenetic regulation of gene transcription.	KCNQ1OT1 Gene		Gene or Genome	CCPS Genetics Terminology|Childhood Cancer Predisposition Study Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114317>	C114316	KCNQ1OT1 wt Allele|KCNQ1 Antisense RNA 2 (Non-Protein Coding) Gene|KCNQ1 Opposite Strand/Antisense Transcript 1 (Non-Protein Coding) wt Allele|KCNQ1 Overlapping Transcript 1 (Non-Protein Coding) Gene|KCNQ1-AS2|KCNQ10T1|KvDMR1|KvLQT1-AS|LIT1|NCRNA00012|Non-Protein Coding RNA 12 Gene	Human KCNQ1OT1 wild-type allele is located in the vicinity of 11p15 and is approximately 92 kb in length. This allele, which encodes KCNQ1 opposite strand/antisense transcript 1 non-coding RNA, is involved in the regulation of gene transcription through epigenetic modification of DNA. Aberrant expression of the gene is associated with Beckwith-Wiedemann syndrome.	KCNQ1OT1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114318>	C88924	KCNQ1 Opposite Strand/Antisense Transcript 1|KCNQ1 Antisense RNA 2|KCNQ1 Overlapping Transcript 1|KCNQ1OT1|LIT1|Long QT Intronic Transcript 1|NCRNA00012|Non-Protein Coding RNA 12	KCNQ1 opposite strand/antisense transcript 1 (~92 kb) is encoded by the human KCNQ1OT1 gene. This non-coding RNA plays a role in epigenetic processes.	KCNQ1 Opposite Strand/Antisense Transcript 1		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114319>	C20420	AIRE Gene|AIRE|AIRE|Autoimmune Regulator Gene	This gene is involved in both self-tolerance and the positive regulation of transcription.	AIRE Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C11431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11431>	C61063	Chlorambucil/Doxorubicin/Etoposide/Prednisolone/Procarbazine/Vinblastine/Vincristine|CLB/DOX/PCB/PRDL/VBL/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114320>	C114319	AIRE wt Allele|AIRE1|APECED|APS1|APSI|Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy Gene|Autoimmune Regulator (Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy) Gene|Autoimmune Regulator wt Allele|PGA1	Human AIRE wild-type allele is located in the vicinity of 21q22.3 and is approximately 12 kb in length. This allele, which encodes autoimmune regulator protein, plays a role in both transcriptional activation and the negative regulation of autoimmune responses. Mutation of the gene is associated with autoimmune polyendocrine syndrome 1.	AIRE wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114321>	C17207	Autoimmune Regulator|AIRE|APECED Protein|Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy Protein|Autoimmune Regulator (APECED Protein)	Autoimmune regulator (545 aa, ~58 kDa) is encoded by the human AIRE gene. This protein is involved in both the activation of gene transcription and the inhibition of autoimmunity.	Autoimmune Regulator		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114322>	C20744	PDZK1 Gene|PDZ Domain Containing 1 Gene|PDZK1|PDZK1	This gene plays a role in the regulation of protein localization.	PDZK1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114323>	C114322	PDZK1 wt Allele|CAP70|CLAMP|NHERF-3|NHERF3|PDZ Domain Containing 1 wt Allele|PDZ Domain-Containing 1 Gene|PDZD1	Human PDZK1 wild-type allele is located in the vicinity of 1q21 and is approximately 37 kb in length. This allele, which encodes Na(+)/H(+) exchange regulatory cofactor NHE-RF3 protein, is involved in the modulation of ion channel and signaling protein localization. Variations and aberrant expression of this gene may be associated with metabolic syndrome and drug resistance of multiple myeloma, respectively.	PDZK1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114324>	C18073	Na(+)/H(+) Exchange Regulatory Cofactor NHE-RF3|C-Terminal Linking and Modulating Protein|CFTR-Associated Protein of 70 kDa|CFTR-Associated Protein, 70 kDa|NHERF-3|Na(+)/H(+) Exchanger Regulatory Factor 3|Na/Pi Cotransporter C-Terminal-Associated Protein 1|NaPi-Cap1|PDZ Domain-Containing Protein 1|PDZ-Containing Kidney Protein 1|Sodium-Hydrogen Exchanger Regulatory Factor 3	Na(+)/H(+) exchange regulatory cofactor NHE-RF3 (519 aa, ~57 kDa) is encoded by the human PDZK1 gene. This protein plays a role in the localization of ion transporters and signaling proteins.	Na(+)/H(+) Exchange Regulatory Cofactor NHE-RF3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114325>	C25784	RHOU Gene|RHOU|RHOU|Ras Homolog Family Member U Gene	This gene is involved in GTP binding, signal transduction and cell migration.	RHOU Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114326>	C114325	RHOU wt Allele|2310026M05Rik|ARHU|CDC42L1|DJ646B12.2|FLJ10616|Ras Homolog Family Member U wt Allele|Ras Homolog Gene Family, Member U Gene|Ras-Like Gene Family Member U Gene|WRCH1|fJ646B12.2|hG28K	Human RHOU wild-type allele is located within 1q42.11-q42.3 and is approximately 102 kb in length. This allele, which encodes Rho-related GTP-binding protein RhoU, plays a role in signal transduction that modulates cytoskeletal organization and cell migration.	RHOU wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114327>	C18277	Rho-Related GTP-Binding Protein RhoU|CDC42-Like GTPase|CDC42-Like GTPase 1|GTP-Binding Protein Like 1|GTP-Binding Protein SB128|GTP-Binding Protein-Like 1|Rho GTPase-Like Protein ARHU|Ryu GTPase|WRCH-1|Wnt-1 Responsive Cdc42 Homolog|Wnt-1 Responsive Cdc42 Homolog 1	Rho-related GTP-binding protein RhoU (258 aa, ~28 kDa) is encoded by the human RHOU gene. This protein is involved in the regulation of cell migration.	Rho-Related GTP-Binding Protein RhoU		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114328>	C26191	GNG2 Gene|GNG2|GNG2|Guanine Nucleotide Binding Protein (G Protein), Gamma 2 Gene	This gene plays a role in GTPase-dependent signaling.	GNG2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114329>	C114328	GNG2 wt Allele|Guanine Nucleotide Binding Protein (G Protein), Gamma 2 wt Allele|Guanine Nucleotide-Binding Protein, Gamma-2 Gene	Human GNG2 wild-type allele is located in the vicinity of 14q21 and is approximately 153 kb in length. This allele, which encodes guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2 protein, is involved in G protein-dependent signal transduction.	GNG2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11432>	C61007	Gemcitabine/Vinorelbine|dFdC/VNB			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114330>	C19273	Guanine Nucleotide-Binding Protein G(I)/G(S)/G(O) Subunit Gamma-2|G Gamma-I|G Protein Gamma-2 Subunit|Guanine Nucleotide Binding Protein Gamma 2|Guanine Nucleotide-Binding Protein G(I)/G(O)|Guanine Nucleotide-Binding Protein G(I)/G(O) Gamma-2 Subunit	Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2 (71 aa, ~8 kDa) is encoded by the human GNG2 gene. This protein plays a role in G protein GTPase activity.	Guanine Nucleotide-Binding Protein G(I)/G(S)/G(O) Subunit Gamma-2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114331>	C26191	GNG11 Gene|GNG11|GNG11|Guanine Nucleotide Binding Protein (G Protein), Gamma 11 Gene	This gene is involved in both GTPase activity and signal transduction.	GNG11 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114332>	C114331	GNG11 wt Allele|GNGT11|Guanine Nucleotide Binding Protein (G Protein), Gamma 11 wt Allele|Guanine Nucleotide-Binding Protein, Gamma-11 Gene	Human GNG11 wild-type allele is located in the vicinity of 7q21 and is approximately 5 kb in length. This allele, which encodes guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-11 protein, plays a role in the mediation of G protein-dependent signaling.	GNG11 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114333>	C19273	Guanine Nucleotide-Binding Protein G(I)/G(S)/G(O) Subunit Gamma-11|G Protein Gamma-11 Subunit|Guanine Nucleotide-Binding Protein G(I)/G(S)/G(O) Gamma-11 Subunit	Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-11 (73 aa, ~8 kDa) is encoded by the human GNG11 gene. This protein is involved in GTPase-dependent signal transduction.	Guanine Nucleotide-Binding Protein G(I)/G(S)/G(O) Subunit Gamma-11		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114334>	C26191	GNG12 Gene|GNG12|GNG12|Guanine Nucleotide Binding Protein (G Protein), Gamma 12 Gene	This gene plays a role in signal transduction mediated by G proteins.	GNG12 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114335>	C114334	GNG12 wt Allele|Guanine Nucleotide Binding Protein (G Protein), Gamma 12 wt Allele|Guanine Nucleotide-Binding Protein, Gamma-12 Gene|RP5-975D15.2	Human GNG12 wild-type allele is located in the vicinity of 1p31.3 and is approximately 132 kb in length. This allele, which encodes guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-12 protein, is involved in GTPase-dependent signaling.	GNG12 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114336>	C19273	Guanine Nucleotide-Binding Protein G(I)/G(S)/G(O) Subunit Gamma-12|G Protein Gamma-12 Subunit|Guanine Nucleotide-Binding Protein G(I)/G(S)/G(O) Gamma-12 Subunit	Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-12 (72 aa, ~8 kDa) is encoded by the human GNG12 gene. This protein plays a role in G protein-mediated signal transduction.	Guanine Nucleotide-Binding Protein G(I)/G(S)/G(O) Subunit Gamma-12		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114337>	C25873	PRKCE Gene|PRKCE|PRKCE|Protein Kinase C, Epsilon Gene	This gene plays a role in diacylglycerol-dependent signaling.	PRKCE Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114338>	C114337	PRKCE wt Allele|PKCE|Protein Kinase C, Epsilon wt Allele|nPKC-Epsilon	Human PRKCE wild-type allele is located in the vicinity of 2p21 and is approximately 537 kb in length. This allele, which encodes protein kinase C epsilon type protein, is involved in diacylglycerol-dependent protein phosphorylation and signal transduction.	PRKCE wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114339>	C17325	Protein Kinase C Epsilon Type|EC 2.7.11.13|nPKC-Epsilon	Protein kinase C epsilon type (737 aa, ~84 kDa) is encoded by the human PRKCE gene. This protein plays a role in diacylglycerol-dependent serine/threonine phosphorylation.	Protein Kinase C Epsilon Type		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11433>	C61063	Cytarabine/Daunorubicin/Etoposide/Methotrexate/Prednisolone/Thioguanine/Vincristine|ARA-C/DNR/MTX/PRDL/TG/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114340>	C54362	POLR2L Gene|POLR2L|POLR2L|Polymerase (RNA) II (DNA Directed) Polypeptide L, 7.6kDa Gene	This gene plays a role in DNA-dependent RNA synthesis.	POLR2L Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114341>	C114340	POLR2L wt Allele|Polymerase (RNA) II (DNA Directed) Polypeptide L, 7.6kDa wt Allele|RBP10|RPABC5|RPB10|RPB7.6	Human POLR2L wild-type allele is located in the vicinity of 11p15 and is approximately 5 kb in length. This allele, which encodes DNA-directed RNA polymerases I, II, and III subunit RPABC5 protein, is involved in the DNA-directed biosynthesis of RNA.	POLR2L wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114342>	C15172	LIS, Rat Strain|LISTER HOODED	This rat comes from Lister stock at the Lister Institute in the 1920s, but the derivation origin is unknown. It has a white body coat color and black coat color over the head.			Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114343>	C26199	DNA-Directed RNA Polymerases I, II, and III Subunit RPABC5|DNA-Directed RNA Polymerase III Subunit L|POLR2L|RNA Polymerase II 7.6 KDa Subunit|RNA Polymerase II, 7.6-kD Subunit|RNA Polymerases I, II, and III Subunit ABC5|RPB10 Homolog|RPB7.6	DNA-directed RNA polymerases I, II, and III subunit RPABC5 (67 aa, ~8 kDa) is encoded by the human POLR2L gene. This protein plays a role in the synthesis of RNA from a DNA template.	DNA-Directed RNA Polymerases I, II, and III Subunit RPABC5		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114344>	C161039	New Zealand Rabbit|NEW ZEALAND	One of the larger rabbit breeds, the New Zealand was derived by Don Johnson in 1916 by crossing unknown breeds. This rabbit weighs between 9-12 lbs. fully grown and may come in a variety of coat colors.			Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C114345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114345>	C3114	Type II Hypersensitivity|Type 2 Hypersensitivity Reaction|Type 2 Hypersensitivity Reaction|Type II Hypersensitivity Reaction|Type II Hypersensitivity Reaction	A hypersensitivity reaction mediated by antibodies formed against cell surface antigens.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114346>	C3114	Type III Hypersensitivity|Type 3 Hypersensitivity Reaction|Type 3 Hypersensitivity Reaction|Type III Hypersensitivity Reaction|Type III Hypersensitivity Reaction	A hypersensitivity reaction resulting from the deposition of antigen-antibody immune complexes in tissues, which trigger activation of the complement system.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114347>	C116778	Juvenile Spondyloarthritis|JSpA|Juvenile Spondyloarthropathy	A group of chronic, inflammatory childhood diseases characterized by arthritis and enthesitis. This disorder can affect the axial skeleton in late childhood or young adulthood.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Rheumatology Terminology
C114348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114348>	C26191	GNAO1 Gene|GNAO1|GNAO1|Guanine Nucleotide Binding Protein (G Protein), Alpha Activating Activity Polypeptide O Gene	This gene is involved in the modulation of G protein signaling.	GNAO1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114349>	C114348	GNAO1 wt Allele|EIEE17|G-ALPHA-o|GNAO|Go, Alpha Subunit Gene|Guanine Nucleotide Binding Protein (G Protein), Alpha Activating Activity Polypeptide O wt Allele|Guanine Nucleotide-Binding Protein, Alpha-'Other' Gene|Guanine Nucleotide-Binding Protein, Alpha-Activating Activity Polypeptide O Gene	Human GNAO1 wild-type allele is located in the vicinity of 16q13 and is approximately 166 kb in length. This allele, which encodes guanine nucleotide-binding protein G(o) subunit alpha protein, plays a role in the mediation of G protein-dependent signaling.	GNAO1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11434>	C61063	Cyclophosphamide/Cytarabine/Methotrexate/Thioguanine|ARA-C/CTX/MTX/TG			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114350>	C19273	Guanine Nucleotide-Binding Protein G(o) Subunit Alpha|G-ALPHA-o|GNAO1	Guanine nucleotide-binding protein G(o) subunit alpha (354 aa, ~40 kDa) is encoded by the human GNAO1 gene. This protein is involved in the regulation of G protein signaling.	Guanine Nucleotide-Binding Protein G(o) Subunit Alpha		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114351>	C20194	TGFB1I1 Gene|TGFB1I1|TGFB1I1|Transforming Growth Factor Beta 1 Induced Transcript 1 Gene	This gene plays a role in both adaptor molecule signaling and nuclear receptor coactivation.	TGFB1I1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114352>	C114351	TGFB1I1 wt Allele|ARA55|Androgen Receptor Coactivator Gene|HIC-5|HIC5|TSC-5|Transforming Growth Factor Beta 1 Induced Transcript 1 wt Allele|Transforming Growth Factor, Beta-1-Induced 1 Gene|Transforming Growth Factor, Beta-Induced, 55-kD Gene	Human TGFB1I1 wild-type allele is located in the vicinity of 16p11.2 and is approximately 6 kb in length. This allele, which encodes transforming growth factor beta-1-induced transcript 1 protein, is involved in the modulation of both signaling and nuclear receptor-dependent gene expression.	TGFB1I1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114353>	C18466	Transforming Growth Factor Beta-1-Induced Transcript 1 Protein|Androgen Receptor Coactivator 55 kDa Protein|Androgen Receptor Coactivator ARA55|Androgen Receptor-Associated Protein of 55 kDa|Hic-5|Hydrogen Peroxide-Inducible Clone 5 Protein	Transforming growth factor beta-1-induced transcript 1 protein (461 aa, ~50 kDa) is encoded by the human TGFB1I1 gene. This protein plays a role in the regulation of both nuclear receptor-dependent transcription and signal transduction.	Transforming Growth Factor Beta-1-Induced Transcript 1 Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114354>	C27153	Drug Induced Lupus Erythematosus|Drug Induced Lupus|Drug Induced Lupus|Drug-Induced Lupus|Drug-induced systemic lupus erythematosus	An autoimmune disorder, similar to systemic lupus erythematosus, that is caused by certain drugs.			Disease or Syndrome	mCode Elixhauser Rheumatoid Arthritis and Collagen Vascular Disease Value Set|mCode Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Rheumatology Terminology
C114355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114355>	C25873	MAPKAPK2 Gene|MAPKAPK2|MAPKAPK2|Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 Gene	This gene is involved in signal transduction induced by cellular stress.	MAPKAPK2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114356>	C114355	MAPKAPK2 wt Allele|MAPKAP-K2|MK-2|MK2|Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 wt Allele	Human MAPKAPK2 wild-type allele is located in the vicinity of 1q32 and is approximately 49 kb in length. This allele, which encodes MAP kinase-activated protein kinase 2 protein, plays a role in MAPK-dependent signaling.	MAPKAPK2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114357>	C2883	Juvenile Idiopathic Arthritis|JIA|JIA	A group of chronic, inflammatory childhood disorders of unknown etiology that primarily involve joints.			Disease or Syndrome	HL Authorized Value Terminology|HL Medical History Table|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Rheumatology Terminology
C114358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114358>	C26925|C213012	Juvenile Polymyositis|JPM	An idiopathic inflammatory myopathy of childhood resulting in muscle weakness.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114359>	C17325	MAP Kinase-Activated Protein Kinase 2|EC 2.7.11.1|MAPK-Activated Protein Kinase 2|MAPKAP Kinase 2|MAPKAP-K2|MAPKAPK-2|MK-2|MK2	MAP kinase-activated protein kinase 2 (400 aa, ~46 kDa) is encoded by the human MAPKAPK2 gene. This protein is involved in stress responsive signaling.	MAP Kinase-Activated Protein Kinase 2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11435>	C61063	BAY 12-9566/Doxorubicin|BAY 12-9566/DOX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114360>	C26072	PIK3C3 Gene|PIK3C3|PIK3C3|Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3 Gene	This gene plays a role in autophagosome formation and transport to lysosomes and late endosomes.	PIK3C3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114361>	C61277	Juvenile Psoriatic Arthritis|JPsA	Childhood arthritis typically associated with psoriasis.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114362>	C114360	PIK3C3 wt Allele|Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3 wt Allele|Phosphatidylinositol 3-Kinase, Catalytic Subunit Type 3 Gene|Phosphatidylinositol 3-Kinase, Class 3 Gene|Phosphoinositide-3-Kinase, Class 3 Gene|VPS34|VPS34, Yeast, Homolog of Gene|hVps34	Human PIK3C3 wild-type allele is located in the vicinity of 18q12.3 and is approximately 133 kb in length. This allele, which encodes phosphatidylinositol 3-kinase catalytic subunit type 3 protein, is involved in second messenger molecule metabolism.	PIK3C3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114363>	C16984	Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3|EC 2.7.1.137|PI3-Kinase Type 3|PI3K Type 3|PIK3C3|Phosphatidylinositol 3-Kinase p100 Subunit|Phosphoinositide-3-Kinase Class 3|PtdIns-3-Kinase Type 3|hVps34	Phosphatidylinositol 3-kinase catalytic subunit type 3 (887 aa, ~102 kDa) is encoded by the human PIK3C3 gene. This protein plays a role in the phosphorylation of second messengers.	Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C114364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114364>	C25939|C21282	HSD17B4 Gene|HSD17B4|HSD17B4|Hydroxysteroid (17-Beta) Dehydrogenase 4 Gene	This gene is involved in fatty acid oxidation.	HSD17B4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114365>	C114364	HSD17B4 wt Allele|DBP|EDH17B4|Hydroxysteroid (17-Beta) Dehydrogenase 4 wt Allele|MFE-2|MPF-2|PRLTS1|SDR8C1	Human HSD17B4 wild-type allele is located in the vicinity of 5q21 and is approximately 185 kb in length. This allele, which encodes peroxisomal multifunctional enzyme type 2 protein, plays a role in the oxidation of fatty acids. Mutation of the gene is associated with D-bifunctional protein deficiency and Perrault syndrome 1.	HSD17B4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114366>	C16946|C16804	Peroxisomal Multifunctional Enzyme Type 2|17-Beta-HSD 4|17-Beta-HSD IV|17-Beta-Hydroxysteroid Dehydrogenase 4|17beta-Estradiol Dehydrogenase Type IV|3-Alpha,7-Alpha,12-Alpha-Trihydroxy-5-Beta-Cholest-24-Enoyl-CoA Hydratase|Beta-Hydroxyacyl Dehydrogenase|Beta-Keto-Reductase|D-3-Hydroxyacyl-CoA Dehydratase|D-3-Hydroxyacyl-CoA Dehydratase/D-3-Hydroxyacyl-CoA Dehydrogenase Bifunctional Protein|D-Bifunctional Protein, Peroxisomal|DBP|DBP, Peroxisomal|HSD17B4|MFE-2|MPF-2|Multifunctional Protein 2|Peroxisomal Multifunctional Protein 2|Short Chain Dehydrogenase/Reductase Family 8C, Member 1	Peroxisomal multifunctional enzyme type 2 (736 aa, ~80 kDa) is encoded by the human HSD17B4 gene. This protein is involved in the peroxisomal beta-oxidation pathway for fatty acids.	Peroxisomal Multifunctional Enzyme Type 2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114367>	C25941|C25939	HSD3B1 Gene|HSD3B1|HSD3B1|Hydroxy-Delta-5-Steroid Dehydrogenase, 3 Beta- and Steroid Delta-Isomerase 1 Gene	This gene plays a role in both ketosteroid metabolism and hormonal steroid biosynthesis.	HSD3B1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114368>	C114367	HSD3B1 wt Allele|3-Beta-HSD, Placental Type Gene|3-Beta-Hydroxysteroid Dehydrogenase 1 Gene|3-Beta-Hydroxysteroid Dehydrogenase/Delta-Isomerase, Type I Gene|3BETAHSD|3BETAHSDI|3BH|HSD3B|HSDB3|HSDB3A|Hydroxy-Delta-5-Steroid Dehydrogenase, 3 Beta- and Steroid Delta-Isomerase 1 wt Allele|RP5-920G3.4|SDR11E1	Human HSD3B1 wild-type allele is located in the vicinity of 1p13.1 and is approximately 8 kb in length. This allele, which encodes 3 beta-hydroxysteroid dehydrogenase/delta 5->4-isomerase type 1 protein, is involved in both oxidative conversion of ketosteroids and the biosynthesis of hormonal steroids.	HSD3B1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114369>	C16946|C16759	3 Beta-Hydroxysteroid Dehydrogenase/Delta 5->4-Isomerase Type 1|3 Beta-Hydroxysteroid Dehydrogenase/Delta 5-->4-Isomerase Type 1|3 Beta-Hydroxysteroid Dehydrogenase/Delta 5-->4-Isomerase Type I|3 Beta-Hydroxysteroid Dehydrogenase/Delta 5->4-Isomerase Type I|3 Beta-Hydroxysteroid Dehydrogenase/Delta 5—>4-Isomerase Type 1|3 Beta-Hydroxysteroid Dehydrogenase/Delta 5—>4-Isomerase Type I|3-Beta-HSD I|3-Beta-Hydroxy-5-Ene Steroid Dehydrogenase|3-Beta-Hydroxy-Delta(5)-Steroid Dehydrogenase|3-Beta-Hydroxysteroid 3-Dehydrogenase|Delta-5-3-Ketosteroid Isomerase|EC 1.1.1.145|EC 5.3.3.1|HSD3B1|Hydroxy-Delta-5-Steroid Dehydrogenase, 3 Beta-and Steroid Delta-Isomerase 1|Progesterone Reductase|Short Chain Dehydrogenase/Reductase Family 11E|Short Chain Dehydrogenase/Reductase Family 11E, Member 1|Steroid Delta-Isomerase|Trophoblast Antigen FDO161G	3 beta-hydroxysteroid dehydrogenase/Delta 5->4-isomerase type 1 (373 aa, ~42 kDa) is encoded by the human HSD3B1 gene. This protein plays a role in both the biosynthesis of hormonal steroids and the oxidative conversion of ketosteroids.	3 Beta-Hydroxysteroid Dehydrogenase/Delta 5->4-Isomerase Type 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11436>	C61007	BAY 12-9566/Fluorouracil/Leucovorin Calcium			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114370>	C9445|C34941	Antepartum Uterine Rupture	An acute symptomatic tearing of the uterine wall prior to the onset of labor.			Finding	NICHD Terminology|Perinatal Terminology
C114371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114371>	C79472|C34941	Antepartum Hemorrhage|Antenatal Bleeding	Excessive blood loss prior to onset of labor.			Finding	GAIA Antenatal Bleeding Level of Diagnostic Certainty Terminology|GAIA Terminology|NICHD Terminology|Perinatal Terminology
C114372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114372>	C9445	Intrapartum Uterine Rupture	An acute symptomatic tearing of the uterine wall after the onset of labor.			Finding	NICHD Terminology|Perinatal Terminology
C114373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114373>	C35016	Intrapartum Shock	Severe loss of blood pressure leading to inadequate tissue perfusion after the onset of labor but prior to the delivery of the fetus.			Finding	NICHD Terminology|Perinatal Terminology
C114374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114374>	C3038	Intrapartum Pyrexia|Intrapartum Fever	Elevated body temperature greater than or equal to 38C (100.4F) after the onset of labor but prior to the delivery of the fetus.			Sign or Symptom	NICHD Terminology|Perinatal Terminology
C114375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114375>	C92853	Early Postpartum Hemorrhage|Primary Postpartum Hemorrhage|Primary Postpartum Hemorrhage	Cumulative blood loss of greater than or equal to 1000 ML or blood loss accompanied by signs or symptoms of hypovolemia within 24 hours following the birth process (includes intrapartum loss). (reVITALize)			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C114376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114376>	C92853	Late Postpartum Hemorrhage|Delayed Postpartum Hemorrhage|Delayed Postpartum Hemorrhage|Secondary Postpartum Hemorrhage|Secondary Postpartum Hemorrhage	Excessive blood loss between 24 hours after delivery through four weeks that requires intervention.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C114377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114377>	C35108	Postpartum Uterine Inversion	Protrusion of the uterine fundus through the cervix when the placenta fails to detach from the uterus as it exits.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C114378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114378>	C28681	DNR-expressing Nasopharyngeal Carcinoma-specific Cytotoxic T-Lymphocytes|DNR NPC-specific CTLs	A preparation of autologous, dominant-negative receptor (DNR)-expressing nasopharyngeal carcinoma (NPC)-specific cytotoxic T-lymphocytes (CTLs), with potential antineoplastic activity. The DNR-expressing NPC-specific CTLs specifically target Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1), latent membrane proteins (LMP) and BamHIA rightward frame 1 (BARF1), and are transduced with a retroviral vector expressing DNR, a dominant-negative form of the transforming growth factor beta (TGFb) receptor, which blocks TGF-beta-mediated signaling. Upon administration, the CTLs recognize and target NPC cells, which may result in both CTL-mediated cell lysis and the inhibition of tumor cell proliferation. Tumor-expressed TGF-beta inhibits T-lymphocyte activation and expansion; resistance to TGF-beta allows for optimal CTL activity. EBV infection plays a key role in NPC tumorigenesis.	DNR-expressing Nasopharyngeal Carcinoma-specific Cytotoxic T-Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C114379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114379>	C2124	Copper Cu 64 Plerixafor|64-Cu-plerixafor	A radioconjugate labeled with the positron-emitting radioisotope, copper Cu 64, and also composed of plerixafor, a bicyclam and hematopoietic stem cell-mobilizing agent that targets the chemokine receptor CXCR4, with tumor imaging potential using positron emission tomography (PET)/computed tomography (CT). Upon administration, the plerixafor moiety blocks the binding of stromal cell-derived factor-1alpha (SDF-1alpha or CXCL12) to the cellular receptor CXCR4. In turn, the CXCR4-expressing tumor cells can be visualized using PET/CT and the resulting images could be used to predict a tumor's response to certain treatments. The expression of CXCR4 on cancer cells has been correlated with increased tumor cell survival, tumor progression, and increased metastatic potential.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C11437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11437>	C61063	Asparaginase/Methotrexate/Prednisolone/Vincristine|ASP/MTX/PRDL/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114380>	C28310	NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine|Autologous NY-ESO-1 (157-165) Peptide-pulsed DC Vaccine	A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with a peptide derived from the tumor associated antigen human cancer-testis antigen NY-ESO-1 (NY-ESO-1(157-165)), with potential immunostimulatory and antineoplastic activities. Upon administration, the NY-ESO-1(157-165) peptide-pulsed autologous dendritic cell vaccine may stimulate the immune system to mount both an anti-tumoral cytotoxic T-lymphocyte (CTL)- and an antibody-mediated immune response against NY-ESO-1-expressing tumor cells, which may result in tumor cell lysis. NY-ESO-1 is expressed both in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival.	NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine		Cell|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C114381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114381>	C223184	Telaglenastat|CB-839|TELAGLENASTAT|WHO 10815	An orally bioavailable inhibitor of glutaminase, with potential antineoplastic activity. Upon oral administration, CB-839 selectively and irreversibly inhibits glutaminase, a mitochondrial enzyme that is essential for the conversion of the amino acid glutamine into glutamate. By blocking glutamine utilization, proliferation in rapidly growing cells is impaired. Glutamine-dependent tumors rely on the conversion of exogenous glutamine into glutamate and glutamate metabolites to both provide energy and generate building blocks for the production of macromolecules, which are needed for cellular growth and survival.	Telaglenastat		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C114382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114382>	C1420	Redaporfin|LUZ 11|REDAPORFIN	A bacteriochlorin-based photosensitizer, with antineoplastic activity upon photodynamic therapy (PDT). Following intravenous administration, redaporfin preferentially accumulates in hyperproliferative tissues, such as tumors. Local application of laser light at the tumor site results in the absorption of light by this agent and a photodynamic reaction between LUZ 11 and oxygen. This results in the production of reactive oxygen species (ROS), which includes singlet oxygen molecules, the superoxide ion, and other cytotoxic free radicals. The formation of ROS induces free radical-mediated DNA damage and cell death.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C114383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114383>	C168618	Ivosidenib|AG 120|AG-120|AG120|IVOSIDENIB|Tibsovo	An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Upon administration, AG-120 specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhibits the formation of the oncometabolite, 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1-expressing tumor cells. IDH1, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.	Ivosidenib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C114384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114384>	C129839	BH3 Mimetic ABT-737|ABT-737|ABT-737|Benzamide, 4-(4-((4'-Chloro(1,1'-biphenyl)-2-yl)methyl)-1-piperazinyl)-n-((4-(((1r)-3-(dimethylamino)-1-((phenylthio)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-	An orally bioavailable, selective small molecule B-cell lymphoma 2 (Bcl-2) Homology 3 (BH3) mimetic, with potential pro-apoptotic and antineoplastic activities. ABT-737 binds to the hydrophobic groove of multiple members of the anti-apoptotic Bcl-2 protein family, including Bcl-2, Bcl-xl and Bcl-w. This inhibits the activity of these pro-survival proteins and restores apoptotic processes in tumor cells, via activation of Bak/Bax-mediated apoptosis. The pro-survival Bcl-2 proteins are overexpressed in many cancers and play important roles in the regulation of apoptosis. Their expression is associated with increased drug resistance and tumor cell survival. ABT-737 does not inhibit the pro-survival proteins Mcl-1, Bcl-B, Bfl-1 (A1); therefore, tumors that overexpress these Bcl-2 family proteins are resistant to ABT-737.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C114385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114385>	C62712|C213431|C201556	IL-12-expressing Mesenchymal Stem Cell Vaccine GX-051|GX-051|MSCs/IL-12M	Human mesenchymal stem cells (MSCs) transduced with a retroviral vector encoding a modified form of the cytokine interleukin-12 (IL-12), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration, IL-12-expressing MSC vaccine GX-051 secretes IL-12. IL-12 activates the immune system by both promoting the secretion of interferon-gamma, which activates natural killer cells (NKs), and inducing cytotoxic T-cell responses, which may result in both decreased cell proliferation and increased cell death in tumor cells.			Cell|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C114386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114386>	C1892	Artichoke Whole Phytocomplex Concentrate|Artichoke Extract|Artichoke W.P.C.	A whole phytocomplex concentrate (W.P.C.) composed of a standardized extract of the Cynara scolymus (artichoke) leaf with potential antioxidant, protective and chemopreventive activities. The artichoke W.P.C. is high in flavonoids and polyphenols, such as caffeoylquinic acids, which are mainly responsible for the pharmacological effects of the extract. Artichoke W.P.C. also contains protein, fiber, vitamins, minerals, numerous enzymes, volatile oils, phytosterols and polyunsaturated fatty acids.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C114387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114387>	C63496	PAD Regimen|Bortezomib/ Dexamethasone/Doxorubicin|Bortezomib/Dexamethasone/Doxorubicin|Bortezomib/Doxorubicin/Dexamethasone Regimen|PAD|PAD|PS-341/Adriamycin/Dexamethasone Regimen|Velcade/Adriamycin/Dexamethasone Regimen	A regimen containing bortezomib, doxorubicin and dexamethasone regimen used in the treatment of plasma cell myeloma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|NCI Drug Dictionary Terminology|Pharmacotherapy Regimens
C114388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114388>	C26808	Postpartum Acute Renal Failure	Renal failure that occurs postpartum due to any partum problem (hemorrhage, sepsis, preeclampsia).			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C114389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114389>	C26894	Postpartum Thyroiditis|Postpartum thyroiditis	Inflammatory disorder of thyroid gland that occurs postpartum due to any partum problem.			Disease or Syndrome	mCode Elixhauser Other Thyroid Disorder Value Set|mCode Terminology|NICHD Terminology|Perinatal Terminology
C11438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11438>	C61063	Interferon Alfa/Interleukin-12|IFN-A/IL-12			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114390>	C136375	Kininogen-1|Alpha-2-Thiol Proteinase Inhibitor|Fitzgerald Factor|HMWK|High Molecular Weight Kininogen|KNG1|Kininogen|Kininogen 1|Williams-Fitzgerald-Flaujeac Factor	Kininogen-1 (644 aa, ~72 kDa) is encoded by the human KNG1 gene. This protein is involved in the positive regulation of fibrinolysis.	Kininogen-1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114391>	C25873	MARK4 Gene|MAP/Microtubule Affinity-Regulating Kinase 4 Gene|MARK4|MARK4	This gene plays a role in protein phosphorylation.	MARK4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114392>	C114391	MARK4 wt Allele|FLJ90097|KIAA1860|MAP/Microtubule Affinity-Regulating Kinase 4 wt Allele|MARK4L|MARK4S|MARKL1|MARKL1L|Nbla00650|PAR-1D	Human MARK4 wild-type allele is located in the vicinity of 19q13.3 and is approximately 226 kb in length. This allele, which encodes MAP/microtubule affinity-regulating kinase 4 protein, is involved in the phosphorylation of microtubule-associated proteins. Aberrant overexpression of the gene is associated with hepatocellular carcinoma.	MARK4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114393>	C17325	MAP/Microtubule Affinity-Regulating Kinase 4|EC 2.7.11.1|MAP/Microtubule Affinity-Regulating Kinase Like 1|MAP/Microtubule Affinity-Regulating Kinase-Like 1|MARK4|MARK4 Serine/Threonine Protein Kinase	MAP/microtubule affinity-regulating kinase 4 (752 aa, ~83 kDa) is encoded by the human MARK4 gene. This protein plays a role in microtubule-associated protein phosphorylation.	MAP/Microtubule Affinity-Regulating Kinase 4		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114394>	C21240	RRP15 Gene|RRP15|RRP15|Ribosomal RNA Processing 15 Homolog (S. cerevisiae) Gene	This gene is involved in ribosomal RNA processing.	RRP15 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114395>	C114394	RRP15 wt Allele|CGI-115|KIAA0507|Ribosomal RNA Processing 15 Homolog (S. cerevisiae) wt Allele|Ribosomal RNA-Processing 15, S. cerevisiae, Homolog of Gene	Human RRP15 wild-type allele is located in the vicinity of 1q41 and is approximately 53 kb in length. This allele, which encodes RRP15-like protein, plays a role in the processing of ribosomal RNAs.	RRP15 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114396>	C38576	RRP15-Like Protein|Ribosomal RNA-Processing Protein 15	RRP15-like protein (282 aa, ~31 kDa) is encoded by the human RRP15 gene. This protein is involved in ribosomal RNA maturation.	RRP15-Like Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114397>	C26891	Vascular Thrombosis|thrombosis	The formation of a blood clot in the lumen of a vessel; causes include coagulation disorders, and vascular endothelial injury.			Disease or Syndrome	
C114398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114398>	C20744	SYCP1 Gene|SYCP1|SYCP1|Synaptonemal Complex Protein 1 Gene	This gene plays a role in meiotic prophase.	SYCP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114399>	C114398	SYCP1 wt Allele|CT8|HOM-TES-14|RP11-109G4.1|SCP-1|SCP1|Synaptonemal Complex Protein 1 wt Allele	Human SYCP1 wild-type allele is located within 1p13-p12 and is approximately 141 kb in length. This allele, which encodes synaptonemal complex protein 1, is involved in the formation of the synaptonemal complex in meiosis.	SYCP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11439>	C61063	Carcinoembryonic Antigen Peptide 1/Hepatitis B Antigen Peptide|CAP-1/HBsAg			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1143>	C1283	Recombinant Leukoregulin	A formulated therapeutic analog of the endogenous lymphokine leukoregulin with potential antineoplastic activity.  Leukoregulin displays direct and indirect cytotoxicity through tumor cell lysis and enhancing tumor cell susceptibility to natural killer cell-mediated cytotoxicity.  This agent enhances membrane permeability and decreases p-glycoprotein expression, thereby promoting cytotoxic drug uptake into tumor cells.  Leukoregulin also induces the synthesis of collagenase and hyaluronan, expression and secretion of interleukin-8, and upregulates stromelysin-1 gene expression in human fibroblasts, thereby regulating extracellular matrix degradation. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C114400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114400>	C18073	Synaptonemal Complex Protein 1|CT8|Cancer/Testis Antigen 8|SCP-1	Synaptonemal complex protein 1 (976 aa, ~114 kDa) is encoded by the human SYCP1 gene. This protein plays a role in the structure of the synaptonemal complex during meiotic prophase.	Synaptonemal Complex Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114401>	C21295	SUSD1 Gene|SUSD1|SUSD1|Sushi Domain Containing 1 Gene	This gene is involved in calcium binding.	SUSD1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114402>	C114401	SUSD1 wt Allele|RP11-4O1.1|Sushi Domain Containing 1 wt Allele|UNQ2438/PRO4999	Human SUSD1 wild-type allele is located within 9q31.3-q33.1 and is approximately 135 kb in length. This allele, which encodes sushi domain-containing protein 1, plays a role in calcium binding.	SUSD1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114403>	C21214	Sushi Domain-Containing Protein 1|SUSD1|Sushi Domain Containing 1	Sushi domain-containing protein 1 (747 aa, ~83 kDa) is encoded by the human SUSD1 gene. This protein is involved in calcium binding.	Sushi Domain-Containing Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114404>	C35016	Postpartum Shock	Severe loss of blood pressure leading to inadequate tissue perfusion after the delivery of the fetus.			Finding	NICHD Terminology|Perinatal Terminology
C114405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114405>	C3038	Postpartum Pyrexia|Postpartum Fever	A sustained temperature of 38C (100.4F) or greater beyond the first 24 hours following birth, or a temperature of 39C (102.2F) within the first 24 hours following birth. (adapted from ACOG)			Sign or Symptom	NICHD Terminology|Perinatal Terminology
C114406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114406>	C20194	USH1G Gene|USH1G|USH1G|Usher Syndrome 1G (Autosomal Recessive) Gene	This gene plays a role in both sight and hearing.	USH1G Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114407>	C114406	USH1G wt Allele|ANKS4A|FLJ33924|SANS|Sans|Usher Syndrome 1G (Autosomal Recessive) wt Allele	Human USH1G wild-type allele is located in the vicinity of 17q25.1 and is approximately 7 kb in length. This allele, which encodes Usher syndrome type-1G protein, is involved in the development of both the retina and cochlear hair cells. Mutation of the gene is associated with Usher syndrome 1G.	USH1G wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114408>	C18466	Usher Syndrome Type-1G Protein|Scaffold Protein Containing Ankyrin Repeats and SAM Domain|USH1G	Usher syndrome type-1G protein (461 aa, ~51 kDa) is encoded by the human USH1G gene. This protein plays a role in retinal and cochlear development.	Usher Syndrome Type-1G Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114409>	C5033	Agalactia|Agalactorrhea|Agalactorrhea	Lack of production or secretion of breast milk.			Sign or Symptom	NICHD Terminology|Perinatal Terminology
C11440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11440>	C61063	Carmustine/Gemcitabine/Melphalan|BCNU/dFdC/L-PAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114410>	C20103	PLXND1 Gene|PLXND1|PLXND1|Plexin D1 Gene	This gene is involved in semaphorin binding and signaling.	PLXND1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114411>	C114410	PLXND1 wt Allele|KIAA0620|PLEXD1|Plexin D1 wt Allele	Human PLXND1 wild-type allele is located in the vicinity of 3q22.1 and is approximately 52 kb in length. This allele, which encodes plexin-D1 protein, plays a role in semaphorin-mediated signaling.	PLXND1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114412>	C18106	Plexin-D1|Plexin D1	Plexin-D1 (1925 aa, ~212 kDa) is encoded by the human PLXND1 gene. This protein is involved in the mediation of semaphorin-dependent signal transduction.	Plexin-D1		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114413>	C20194	TMCC1 Gene|TMCC1|TMCC1|Transmembrane and Coiled-Coil Domain Family 1 Gene	This gene has no known function.	TMCC1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114414>	C114413	TMCC1 wt Allele|KIAA0779|Transmembrane and Coiled-Coil Domain Family, Member 1 Gene|Transmembrane and Coiled-Coil Domain wt Allele|Transmembrane and Coiled-Coil Domains 1 Gene	Human TMCC1 wild-type allele is located in the vicinity of 3q21.1 and is approximately 246 kb in length. This allele, which encodes transmembrane and coiled-coil domains protein 1, has no known function.	TMCC1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114415>	C18466	Transmembrane and Coiled-Coil Domains Protein 1|TMCC1|Transmembrane and Coiled-Coil Domains 1	Transmembrane and coiled-coil domains protein 1 (653 aa, ~72 kDa) is encoded by the human TMCC1 gene. This protein has no known function.	Transmembrane and Coiled-Coil Domains Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114416>	C26000	TECTA Gene|TECTA|TECTA|Tectorin Alpha Gene	This gene plays a role in hearing.	TECTA Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114417>	C114416	TECTA wt Allele|DFNA12|DFNA8|DFNB21|Tectorin Alpha wt Allele|Tectorin, Alpha Gene	Human TECTA wild-type allele is located within 11q22-q24 and is approximately 90 kb in length. This allele, which encodes alpha-tectorin protein, is involved in the structure of the tectorial membrane. Mutation of the gene is associated with autosomal dominant deafness 8/12 and autosomal recessive deafness 21.	TECTA wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114418>	C17351	Alpha-Tectorin|TECTA|Tectorin Alpha	Alpha-tectorin (2155 aa, ~240 kDa) is encoded by the human TECTA gene. This protein plays a role in hearing.	Alpha-Tectorin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114419>	C49236	Lactation Suppression	Active suspension of lactation using a medical or physical intervention.			Therapeutic or Preventive Procedure	NICHD Terminology|Perinatal Terminology
C11441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11441>	C61063	Cisplatin/Cyclophosphamide/Dexamethasone/Etoposide/Gemcitabine|CDDP/CTX/dFdC/DM/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114420>	C25375	Operative Report	A detailed record of a surgical procedure by the clinician who performed the operation.			Intellectual Product	
C114421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114421>	C25802	TBCEL Gene|TBCEL|TBCEL|Tubulin Folding Cofactor E-Like Gene	This gene is involved in tubulin turnover.	TBCEL Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114422>	C114421	TBCEL wt Allele|EL|El|LRRC35|Leucine Rich Repeat Containing 35 Gene|MGC10233|Tubulin Folding Cofactor E-Like wt Allele	Human TBCEL wild-type allele is located in the vicinity of 11q23.3 and is approximately 67 kb in length. This allele, which encodes tubulin-specific chaperone cofactor E-like protein, plays a role in the modulation of tubulin metabolism.	TBCEL wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114423>	C17764	Tubulin-Specific Chaperone Cofactor E-Like Protein|Catastrophin|E-Like|E-Like Protein|EL|Leucine-Rich Repeat-Containing Protein 35|TBCEL|Tubulin-Specific Chaperone E-Like	Tubulin-specific chaperone cofactor E-like protein (424 aa, ~48 kDa) is encoded by the human TBCEL gene. This protein is involved in the regulation of microtubule dynamics through the modulation of tubulin degradation.	Tubulin-Specific Chaperone Cofactor E-Like Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114424>	C20731	SSH2 Gene|SSH2|SSH2|Slingshot Protein Phosphatase 2 Gene	This gene plays a role in both actin filament dynamics and protein dephosphorylation.	SSH2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114425>	C114424	SSH2 wt Allele|KIAA1725|SSH-2|SSH-2L|SSH2L|Slingshot Homolog 2 (Drosophila) Gene|Slingshot Protein Phosphatase 2 wt Allele|Slingshot, Drosophila, Homolog of 2 Gene	Human SSH2 wild-type allele is located in the vicinity of 17q11.2 and is approximately 304 kb in length. This allele, which encodes protein phosphatase Slingshot homolog 2 protein, is involved in both the dephosphorylation of proteins and the modulation of actin filament formation.	SSH2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114426>	C25880	Protein Phosphatase Slingshot Homolog 2|EC 3.1.3.16|EC 3.1.3.48|SSH-2L|SSH-Like Protein 2|SSH2|Slingshot Homolog 2|hSSH-2L	Protein phosphatase Slingshot homolog 2 (1423 aa, ~158 kDa) is encoded by the human SSH2 gene. This protein plays a role in both the regulation of actin polymerization and the dephosphorylation of proteins.	Protein Phosphatase Slingshot Homolog 2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114427>	C28533	SLC26A6 Gene|SLC26A6|SLC26A6|Solute Carrier Family 26 (Anion Exchanger), Member 6 Gene	This gene is involved in acid-base homeostasis.	SLC26A6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114428>	C114427	SLC26A6 wt Allele|DKFZp586E1422|Solute Carrier Family 26 (Anion Exchanger), Member 6 wt Allele|Solute Carrier Family 26, Member 6 Gene	Human SLC26A6 wild-type allele is located in the vicinity of 3p21.3 and is approximately 10 kb in length. This allele, which encodes solute carrier family 26 member 6 protein, plays a role in the modulation of chloride transport.	SLC26A6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114429>	C16386	Solute Carrier Family 26 Member 6|Anion Exchange Transporter|Anion Transporter 1|Pendrin L1|Pendrin-L1|Pendrin-Like Protein 1|SLC26A6|SLC26A6b|Sulfate Anion Transporter	Solute carrier family 26 member 6 (759 aa, ~83 kDa) is encoded by the human SLC26A6 gene. This protein is involved in chloride exchange activity.	Solute Carrier Family 26 Member 6		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11442>	C63586|C63502|C191676	IROX Regimen|CPT-11/L-OHP|IROX|IROX|IROX|Irinotecan-Oxaliplatin|Irinotecan-Oxaliplatin Regimen|Irinotecan/Oxaliplatin|Irinotecan/Oxaliplatin Regimen|Oxaliplatin-Irinotecan|Oxaliplatin/Irinotecan	A regimen consisting of irinotecan and oxaliplatin that can be used in the treatment of pancreatic and colorectal cancers, and appendiceal adenocarcinoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C114430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114430>	C20745	SEPTIN8 Gene|SEPT8|SEPT8 Gene|SEPTIN8|Septin 8 Gene	This gene plays a role in cytoskeletal filament formation.	SEPT8 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114431>	C114430	SEPTIN8 wt Allele|KIAA0202|SEP2|SEPT8|SEPT8 wt Allele|Septin 8 wt Allele	Human SEPTIN8 wild-type allele is located in the vicinity of 5q31.1 and is approximately 56 kb in length. This allele, which encodes septin-8 protein, is involved in cytoskeletal filament assembly.	SEPT8 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114432>	C16492	Septin-8|SEPT8|SEPTIN8|Septin 8	Septin-8 (483 aa, ~56 kDa) is encoded by the human SEPTIN8 gene. This protein plays a role in cytoskeletal filament dynamics.	Septin-8		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114433>	C20194	GEMIN2 Gene|GEMIN2|GEMIN2|Gem (Nuclear Organelle) Associated Protein 2 Gene	This gene is involved in spliceosome formation.	GEMIN2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114434>	C114433	GEMIN2 wt Allele|Gem (Nuclear Organelle) Associated Protein 2 wt Allele|SIP1	Human GEMIN2 wild-type allele is located in the vicinity of 14q13 and is approximately 23 kb in length. This allele, which encodes gem-associated protein 2, plays a role in the formation of the spliceosome.	GEMIN2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114435>	C18466	Gem-Associated Protein 2|Component of Gems 2|Gemin-2|SMN Interacting Protein 1|SMN-Interacting Protein 1|Survival of Motor Neuron Protein Interacting Protein 1|Survival of Motor Neuron Protein-Interacting Protein 1	Gem-associated protein 2 (280 aa, ~32 kDa) is encoded by the human GEMIN2 gene. This protein is involved in the assembly of small nuclear ribonucleoproteins that build the spliceosome.	Gem-Associated Protein 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114436>	C21295	PTBP3 Gene|PTBP3|PTBP3|Polypyrimidine Tract Binding Protein 3 Gene	This gene plays a role in RNA splicing, cellular differentiation and erythropoiesis.	PTBP3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114437>	C114436	PTBP3 wt Allele|DKFZp781I1117|Polypyrimidine Tract Binding Protein 3 wt Allele|ROD1|ROD1 Regulator of Differentiation 1 (S. pombe) Gene|RP11-165N19.1|Regulator of Differentiation (In S. pombe) 1 Gene	Human PTBP3 wild-type allele is located in the vicinity of 9q32 and is approximately 115 kb in length. This allele, which encodes polypyrimidine tract-binding protein 3, is involved in the modulation of both RNA splicing and erythropoiesis.	PTBP3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114438>	C21298	Polypyrimidine Tract-Binding Protein 3|Fission Yeast Differentiation Regulator|PTBP3|ROD1 Regulator Of Differentiation 1|Regulator of Differentiation 1|Rod1	Polypyrimidine tract-binding protein 3 (552 aa, ~60 kDa) is encoded by the human PTBP3 gene. This protein plays a role in both erythropoiesis and RNA splicing.	Polypyrimidine Tract-Binding Protein 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114439>	C133710	RNF216 Gene|RNF216|RNF216|Ring Finger Protein 216 Gene	This gene is involved in promoting the degradation of substrates by the proteasome.	RNF216 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C11443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11443>	C61063	Cisplatin/Floxuridine/Paclitaxel|CDDP/FUDR/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114440>	C114439	RNF216 wt Allele|CAHH|Ring Finger Protein 216 wt Allele|TRIAD3|U7I1|UBCE7IP1|ZIN	Human RNF216 wild-type allele is located in the vicinity of 7p22.1 and is approximately 162 kb in length. This allele, which encodes E3 ubiquitin-protein ligase RNF216 protein, plays a role in both protein ubiquitination and catabolism. Mutation of the protein is associated with cerebellar ataxia and hypogonadotropic hypogonadism.	RNF216 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114441>	C21254	E3 Ubiquitin-Protein Ligase RNF216|EC 2.3.2.27|EC 6.3.2.-, Formerly|Ring Finger Protein 216|Triad Domain-Containing Protein 3|Ubiquitin-Conjugating Enzyme 7-Interacting Protein 1|Zinc Finger Protein Inhibiting NF-Kappa-B|Zinc Finger Protein Inhibiting NFKB	E3 ubiquitin-protein ligase RNF216 (866 aa, ~99 kDa) is encoded by the human RNF216 gene. This protein is involved in ubiquitination and degradation of proteins.	E3 Ubiquitin-Protein Ligase RNF216		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114442>	C26048	RGS22 Gene|RGS22|RGS22|Regulator of G-Protein Signaling 22 Gene	This gene plays a role in the inhibition of G-protein coupled receptor signaling.	RGS22 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114443>	C114442	RGS22 wt Allele|CT145|DKFZP434I092|PRTD-NY2|Regulator of G-Protein Signaling 22 wt Allele|Regulator of G-Protein Signalling 22 Gene	Human RGS22 wild-type allele is located in the vicinity of 8q22.2 and is approximately 170 kb in length. This allele, which encodes regulator of G-protein signaling 22 protein, is involved in the positive regulation of GTPase activity and the negative regulation of receptor signaling.	RGS22 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114444>	C18166	Regulator of G-Protein Signaling 22|RGS22	Regulator of G-protein signaling 22 (1264 aa, ~147 kDa) is encoded by the human RGS22 gene. This protein plays a role in the modulation of both GTPase activity and signal transduction.	Regulator of G-Protein Signaling 22		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114445>	C20194	RBMS1 Gene|RBMS1|RBMS1|RNA Binding Motif, Single Stranded Interacting Protein 1 Gene	This gene is involved in both DNA replication and single-stranded DNA binding.	RBMS1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114446>	C114445	RBMS1 wt Allele|C2orf12|Cervical Cancer Oncogene 4|Chromosome 2 Open Reading Frame 12 Gene|HCC-4|MSSP|MSSP-1|MSSP-2|MSSP-3|RNA Binding Motif, Single Stranded Interacting Protein 1 wt Allele|RNA-Binding Motif, Single Strand-Interacting Protein, 1 Gene|SCR2|Suppressor of Cdc 2 (Cdc13) With RNA Binding Motif 2 Gene|YC1	Human RBMS1 wild-type allele is located in the vicinity of 2q24.2 and is approximately 222 kb in length. This allele, which encodes RNA-binding motif, single-stranded-interacting protein 1, plays a role in DNA replication.	RBMS1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114447>	C18466	RNA-Binding Motif, Single-Stranded-Interacting Protein 1|Single-Stranded DNA-Binding Protein MSSP-1|Suppressor of CDC2 With RNA-Binding Motif 2|c-Myc Gene Single Strand Binding Protein 2	RNA-binding motif, single-stranded-interacting protein 1 (406 aa, ~45 kDa) is encoded by the human RBMS1 gene. This protein is involved in both single-stranded DNA binding and DNA replication.	RNA-Binding Motif, Single-Stranded-Interacting Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114448>	C20710	RBM14 Gene|RBM14|RBM14|RNA Binding Motif Protein 14 Gene	This gene plays a role in transcriptional modulation.	RBM14 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114449>	C114448	RBM14 wt Allele|COAA|DKFZp779J0927|PSP2|RNA Binding Motif Protein 14 wt Allele|SIP|SYTIP1|TMEM137	Human RBM14 wild-type allele is located in the vicinity of 11q13.2 and is approximately 22 kb in length. This allele, which encodes RNA-binding protein 14, is involved in the modulation of gene transcription.	RBM14 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11444>	C61063	Cisplatin/Cyclophosphamide/Dexamethasone/Etoposide|CDDP/CTX/DM/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114450>	C26199|C21298	RNA-Binding Protein 14|Coactivator Activator|PSP2|Paraspeckle Protein 2|RBM14|RNA Binding Motif Protein 14|RNA-Binding Motif Protein 14|RRM-Containing Coactivator Activator/Modulator|SYT Interacting Protein|SYT-Interacting Protein|Synaptotagmin-Interacting Protein|Transmembrane Protein 137	RNA-binding protein 14 (669 aa, ~69 kDa) is encoded by the human RBM14 gene. This protein plays a role in the modulation of gene expression.	RNA-Binding Protein 14		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114451>	C7201|C4005	Rare Childhood Malignant Neoplasm|Rare Malignant Childhood Neoplasm|Rare Malignant Neoplasm	An infrequent malignant neoplasm that occurs during childhood.	Rare Malignant Childhood Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114452>	C25870|C20819	RANBP2 Gene|RAN Binding Protein 2 Gene|RANBP2|RANBP2|RANBP2	This gene is involved in both SUMOylation and nuclear transport.	RANBP2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C114453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114453>	C114452	RANBP2 wt Allele|ADANE|ANE1|IIAE3|NUP358|RAN Binding Protein 2 wt Allele|TRP1|TRP2	Human RANBP2 wild-type allele is located in the vicinity of 2q12.3 and is approximately 66 kb in length. This allele, which encodes E3 SUMO-protein ligase RanBP2 protein, plays a role in both nuclear transport and protein SUMOylation. Mutation of the gene is associated with acute infection-induced encephalopathy 3. A chromosomal translocation t(2;2)(p23;q13) involving this gene and the ALK gene is associated with both inflammatory myofibroblastic tumor and, more rarely, myeloproliferative disorders.	RANBP2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114454>	C21183|C16259	E3 SUMO-Protein Ligase RanBP2|358 kDa Nucleoporin|EC 2.3.2.-|EC 6.3.2.-, Formerly|Nuclear Pore Complex Protein Nup358|Nucleoporin 358|Nucleoporin Nup358|Ran-Binding Protein 2|RanBP2|Transformation-Related Protein 2|p270	E3 SUMO-protein ligase RanBP2 (3224 aa, ~358 kDa) is encoded by the human RANBP2 gene. This protein is involved in both protein SUMOylation and nuclear import.	E3 SUMO-Protein Ligase RanBP2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114455>	C25372	Content Classification System Term Indicator|Term Type	An indicator of a particular meaning of a term in relation to the Content Classification System.			Qualitative Concept	CareLex eTMF Terminology
C114456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114456>	C42743	Term Uniform Resource Locator|Term Source URL|Term Source URL|Term URL	The unique address of a terminology entity on the world wide internet.			Intellectual Product	CareLex eTMF Terminology
C114457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114457>	C16048	Digital Data Repository|Repository	A storage location for digital data.			Manufactured Object	CareLex eTMF Terminology
C114458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114458>	C42698	Annotation Property	An attribute that can be used with an entity to relate it to a value.			Intellectual Product	CareLex eTMF Terminology
C114459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114459>	C16866	Content Model	A structured representation of a collection of data.			Intellectual Product	CareLex eTMF Terminology
C11445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11445>	C61063	Interferon Alfa/Interleukin-2/Sargramostim|GM-CSF/IFN-A/IL-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114460>	C25162	electronic Trial Master File Code|eTMF Code	The symbol assigned to terms in the eTMF Content Model.			Intellectual Product	
C114461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114461>	C25284	Category Description Type	A functional description of a classification type.			Functional Concept	
C114462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114462>	C25180	Content Requirement Indicator	An indication as to the necessity of a particular content type within a content model.			Conceptual Entity	
C114463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114463>	C114457	Digital Archive|Archive	A storage location for historical digital data.			Intellectual Product	CareLex eTMF Terminology
C114464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114464>	C42614	Category Name	The designation for a collection of related, classified entities.			Conceptual Entity	
C114465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114465>	C25284	Metadata Use Type|Metadata Type	A description of the implementation of metadata.			Functional Concept	CareLex eTMF Terminology
C114466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114466>	C25284	Metadata Content Type|Content Type	A description of the kind of metadata.			Functional Concept	CareLex eTMF Terminology
C114467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114467>	C12370	Breast Fibroglandular Tissue	Breast tissue that contains glandular epithelial and fibrous tissue.			Tissue	
C114468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114468>	C42698	Data Property	A type of metadata category used to describe attributes of entities.			Intellectual Product	CareLex eTMF Terminology
C114469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114469>	C2181	4-Hydroxyestrone|3,4-Dihydroxyestra-1,3,5(10)-trien-17-one|4-HYDROXYESTRONE|4-OHE(1)|4-OHE1|Estra-1,3,5(10)-trien-17-one, 3,4-dihydroxy-	A metabolite formed during the catabolism of estrone by the liver through the hydroxylation of the carbon at position 4 by cytochrome P450 (CYP) family enzymes, with potential carcinogenic activity. The mechanism of action for the tumor promoting activity of 4-hydroxyestrone is not known but this metabolic product has increased estrogenic activity compared to the parent compound. Additionally, oxidation of 4-hydroxyestrone generates compounds with free radicals that are capable of removing purines from DNA, which can cause mutagenesis and can lead to tumorigenesis.	4-Hydroxyestrone		Organic Chemical|Pharmacologic Substance	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C11446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11446>	C61063	Amifostine/Epoetin Alfa|EPO/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114470>	C27572	Enthesitis	Inflammation at the site of insertion of ligaments, tendons, and other fibrous structures into bone.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Rheumatology Terminology
C114471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114471>	C28193	Macrophage Activation Syndrome|MAS|MAS|Reactive Hemophagocytic Lymphohistiocytosis	A complication of rheumatic disease that is caused by excessive activation and uncontrolled proliferation of T lymphocytes and well-differentiated macrophages. It is characterized by fever, pancytopenia, liver insufficiency, coagulopathy and neurologic symptoms.	Macrophage Activation Syndrome		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Rheumatology Terminology
C114472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114472>	C3671	Radiation Damage	Injury resulting from exposure to ionizing radiation.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114473>	C6825	Haploidy|Haploid	A chromosomal abnormality in which a somatic cell has a single member of each pair of homologous chromosomes.			Cell or Molecular Dysfunction	
C114474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114474>	C6825	Near-Haploidy|Near-Haploid	A chromosomal abnormality in which there are less than thirty chromosomes in a cell.			Cell or Molecular Dysfunction	
C114475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114475>	C6825	Masked Near-Haploidy	A chromosomal abnormality in which a near-haploid cell line is masked by a co-existing hyperdiploid line.			Cell or Molecular Dysfunction	
C114476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114476>	C3114	Allergic Reaction|Allergic reaction|Allergies|Allergy|allergic response	An immune response that occurs following re-exposure to an innocuous antigen, and that requires the presence of existing antibodies against that antigen. This response involves the binding of IgE to mast cells, and may worsen with repeated exposures.			Disease or Syndrome	GDC Terminology|GDC Value Terminology|HL Adverse Events Table|HL Authorized Value Terminology|HL Protocol Treatment Modifications Table|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Immunization Terminology
C114477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114477>	C34843	Proximal Tubulopathy|Proximal Renal Tubule Defect	A proximal renal tubular disorder resulting in diminished reabsorption of phosphate, glucose, amino acids, urate, and low molecular weight proteins.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114478>	C37909	Metabolic Alkalosis	Abnormally increased pH levels in the blood due to excessive loss of acid and/or accumulation of base.			Finding	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114479>	C79805	Ureter Compression|Ureteral Compression|Ureteral Compression	Narrowing of the luminal diameter of one or both ureters due to extrinsic pressure.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11447>	C61063	Incomplete Freund's Adjuvant/Von Hippel-Lindau Peptide Vaccine|IFA/VHL peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114480>	C16622	Radiosensitivity Index|RSI	A set of genetic markers that predicts the fraction of cells that could survive radiotherapy based on the expression levels of 10 genes (AR, JUN, STAT1, PKC, RELA, ABL, SUMO1, CDK1, HDAC1, and IRF1) in a patient's tumor.	Radiosensitivity Index		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114481>	C25982	IL17F Gene|IL17F|IL17F|Interleukin 17F Gene	This gene plays a role in the negative regulation of angiogenesis and the stimulation of the production of other cytokines.	IL17F Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114482>	C114481	IL17F wt Allele|CANDF6|IL-17F|Interleukin 17F wt Allele|ML-1|ML1	Human IL17F wild-type allele is located in the vicinity of 6p12 and is approximately 8 kb in length. This allele, which encodes interleukin-17F protein, is involved in cytokine production, cartilage turnover and the regulation of angiogenesis. Mutation of the gene is associated with familial Candidiasis type 6.	IL17F wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114483>	C9431|C3107	Childhood Langerhans Cell Histiocytosis|Langerhans Cell Histiocytosis	Langerhans cell histiocytosis that occurs during childhood.	Childhood Langerhans Cell Histiocytosis		Neoplastic Process	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C114484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114484>	C20497	Interleukin-17F|Cytokine ML-1|IL-17F|IL17F|Interleukin 17F	Interleukin-17F (163 aa, ~18 kDa) is encoded by the human IL17F gene. This protein plays a role in the inhibition of angiogenesis, the promotion of cartilage turnover and the positive regulation of cytokine production.	Interleukin-17F		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C114485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114485>	C20673	MAML1 Gene|MAML1|MAML1|Mastermind Like Transcriptional Coactivator 1 Gene	This gene is involved in notch-dependent gene expression.	MAML1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114486>	C114485	MAML1 wt Allele|KIAA0200|Mam-1|Mam1|Mastermind (Drosophila)-Like 1 Gene|Mastermind Like Transcriptional Coactivator 1 wt Allele|Mastermind, Drosophila, Homolog of, 1 Gene|Mastermind-Like 1 (Drosophila) wt Allele	Human MAML1 wild-type allele is located in the vicinity of 5q35 and is approximately 64 kb in length. This allele, which encodes mastermind-like protein 1, plays a role in the modulation of notch signaling-dependent transcription.	MAML1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114487>	C26199	Mastermind-Like Protein 1|MAML1|Mam-1|Mastermind Homolog|Mastermind-Like 1	Mastermind-like protein 1 (1016 aa, ~108 kDa) is encoded by the human MAML1 gene. This protein is involved in the regulation of notch-dependent gene transcription.	Mastermind-Like Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114488>	C16620	HHV8 ORF73 Gene|HHV-8 LANA|HHV-8 ORF73|HHV8 LANA|HHV8 ORF73|Human Herpesvirus 8 ORF73 Gene|Human Herpesvirus 8 Open Reading Frame 73 Gene|Human Herpesvirus-8 ORF73 Gene|Human Herpesvirus-8 Open Reading Frame 73 Gene|KSHV LANA|Kaposi Sarcoma Herpes Virus ORF73 Gene|Kaposi Sarcoma Herpes Virus Open Reading Frame 73 Gene|LANA|ORF73	HHV8 ORF73, which encodes latent nuclear antigen protein, is involved in both transcriptional regulation and the inhibition of apoptosis.	HHV8 ORF73 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114489>	C17254	Latent Nuclear Antigen|LANA|LANA-1|LNA|LNA-1|Latency-Associated Nuclear Antigen|ORF 73|Protein ORF73	Latent nuclear antigen (1036 aa, ~119 kDa) is encoded by the human herpesvirus 8 ORF73 gene. This protein plays a role in both viral latency and the transcriptional regulation of host genes that modulate apoptosis and cell proliferation.	Latent Nuclear Antigen		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11448>	C61063	Incomplete Freund's Adjuvant/Sargramostim/Von Hippel-Lindau Peptide Vaccine|GM-CSF/IFA/VHL peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114490>	C16620	HHV8 ORF71 Gene|HHV-8 vFLIP|HHV8 ORF71|HHV8 vFLIP|Human Herpesvirus 8 ORF71 Gene|Human Herpesvirus 8 Open Reading Frame 71 Gene|Human Herpesvirus-8 ORF71 Gene|Human Herpesvirus-8 Open Reading Frame 71 Gene|KSHV ORF71|KSHV vFLIP|Kaposi Sarcoma Herpes Virus ORF71 Gene|Kaposi Sarcoma Herpes Virus Open Reading Frame 71 Gene|ORF71|ORF71/K13	HHV8 ORF71, which encodes FLICE inhibitory protein, plays a role in the regulation of host signaling pathways	HHV8 ORF71 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114491>	C17254	FLICE Inhibitory Protein|Flice Inhibitory Protein|ORF71 Protein|ORF71/K13|Putative Apoptosis Inhibitor Protein|Viral FLICE Protein|vFLIP	FLICE inhibitory protein (188 aa, ~21 kDa) is encoded by the human HHV8 ORF71 gene. This protein is involved in the modulation of host signaling pathways.	FLICE Inhibitory Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114492>	C16620	HHV8 ORF50 Gene|HHV-8 ORF50|HHV-8 RTA|HHV8 ORF50|HHV8 RTA|Human Herpesvirus 8 ORF50 Gene|Human Herpesvirus 8 Open Reading Frame 50 Gene|Human Herpesvirus 8 Replication Transactivation Activator Gene|Human Herpesvirus-8 ORF50 Gene|Human Herpesvirus-8 Open Reading Frame 50 Gene|Human Herpesvirus-8 Replication Transactivation Activator Gene|KIE-1|KSHV ORF50|KSHV RTA|Kaposi Sarcoma Herpes Virus ORF50 Gene|Kaposi Sarcoma Herpes Virus Open Reading Frame 50 Gene|Kaposi Sarcoma Herpes Virus Replication Transactivation Activator Gene|ORF50|RTA	HHV8 ORF50, which encodes putative transcription activator ORF50 protein, is involved in the conversion from the latent phase to the lytic phase of viral replication.	HHV8 ORF50 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114493>	C17254	Putative Transcription Activator ORF50|ORF50 Protein|Replication Transactivation Activator|Transcription Activator ORF50	Putative transcription activator ORF50 (691 aa, ~74 kDa) is encoded by the human herpesvirus 8 ORF50 gene. This protein plays a role in the initiation of the lytic phase of the viral life cycle.	Putative Transcription Activator ORF50		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114494>	C1967|C129825	Asciminib|ABL 001|ABL-001|ABL001|ASCIMINIB	An orally bioavailable, allosteric Bcr-Abl1 tyrosine kinase inhibitor, with antineoplastic activity. Upon administration, asciminib targets and binds to the myristoyl pocket of the Bcr-Abl1 fusion protein at a location that is distinct from the ATP-binding domain, thereby inhibiting the activity of both wild-type Bcr-Abl and certain mutation forms, including the T315I mutation. This binding results in the inhibition of Bcr-Abl1-mediated proliferation and enhanced apoptosis of Philadelphia chromosome-positive (Ph+) hematological malignancies. The Bcr-Abl1 fusion protein tyrosine kinase is an abnormal enzyme produced by leukemia cells that contain the Philadelphia chromosome.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCIt Antineoplastic Agent Terminology
C114495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114495>	C129819	Yttrium Y 90 Colloid|90Y Colloid	An injectable, colloidal formulation of the radioisotope yttrium Y 90, with potential antineoplastic activity. When injected into the tumor, the yttrium Y 90 colloid selectively delivers a cytotoxic dose of beta-emitting yttrium Y 90 to the tumor site, which may result in both tumor cell death and tumor regression.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C114496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114496>	C28310	Glioma-associated Peptide-loaded Dendritic Cell Vaccine SL-701|SL-701	A cell-based cancer vaccine comprised of dendritic cells (DCs) pulsed with various, synthetic glioma-associated antigen (GAA) peptides, with potential antineoplastic activity. Upon subcutaneous administration, the glioma-associated peptide-loaded DC vaccine SL-701 exposes the immune system to various GAA peptides. This may stimulate both anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against the GAA-expressing glioma cells, which may result in tumor cell lysis.			Cell|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C114497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114497>	C1327	Anagrelide Prolonged-release Formulation|Anagrelide Retard	A prolonged-release tablet formulation containing the quinazoline anagrelide, with antiplatelet activity. Although the exact mechanism of action through which anagrelide exerts its effect has yet to be fully elucidated, this agent inhibits the maturation of megakaryocytes into platelets, which reduces platelet production. Anagrelide also inhibits cyclic AMP phosphodiesterase III (PDEIII), which prevents PDEIII-mediated platelet aggregation. This may prevent essential thrombocythemia and thrombosis.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C114498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114498>	C2092	Relugolix|N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea|Orgovyx|RELUGOLIX|Relumina|TAK 385|TAK-385|TAK385|Urea, N-(4-(1-((2,6-difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxy-	An orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation.	Relugolix		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C114499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114499>	C2124|C129819	Lutetium Lu 177 PP-F11N|177Lu-PP-F11N|PP-F11N LUTETIUM LU-177	A radioconjugate composed of PP-F11N, a gastrin analog, conjugated to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and potential use as an imaging agent for scintigraphy. Following intravenous administration, the PP-F11N moiety binds to the cholecystokinin-2 (CCK-2) receptor. Subsequently, the CCK-2 receptor-expressing tumor cells can be visualized scintigraphically. In addition, the radioisotope moiety delivers a cytotoxic dose of beta radiation to CCK-2 receptor-expressing tumor cells. CCK-2 receptors are expressed on a variety of tumor cell types.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11449>	C61063	Carmustine/Fluorouracil/Streptozocin/Vincristine|BCNU/5-FU/SZC/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1144>	C1910	Nafarelin Acetate|(6-D-(2-Naphthyl)alanine)LHRH Acetate|NAFARELIN ACETATE|RS-94991298|Synarel|Synarela|Synrelina	The acetate salt form of nafarelin, a modified synthetic porcine luteinizing hormone (LH)-releasing hormone peptide analog, with gonadotropin-releasing hormone (GnRH) agonist activity. Upon nasal inhalation, nafarelin acetate binds to the GnRH receptor. This initially results in the release of the gonadotropins, follicle-stimulating hormone (FSH) and LH, from the pituitary gland; however, prolonged stimulation of the GnRH receptor desensitizes the receptor, which leads to decreased secretion of FSH and LH. In females, the inhibition of gonadotropin secretion causes hypogonadotropic hypogonadism leading to decreased production of estrogen and progesterone and anovulation. In males, the inhibition of LH secretion prevents the production and release of testosterone from Leydig cells in the testes and causes a significant decline in testosterone production that is near the levels seen following castration.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C114500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114500>	C211912|C209888	Enfortumab Vedotin|AGS 22ME|AGS-22M6E|ASG 22CE|ASG-22CE|ASG22CE|Anti-Nectin 4 ADC ASG-22CE|Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E|ENFORTUMAB VEDOTIN|Enfortumab Vedotin-ejfv|Enfortumab vedotin|Padcev	An antibody drug conjugate (ADC) containing a human monoclonal antibody AGS-22 targeting the cell adhesion molecule nectin-4 and conjugated to the cytotoxic agent monomethyl auristatin E (MMAE), via a proprietary enzyme-cleavable linker (AGS-22CE), with potential antineoplastic activity. The monoclonal antibody moiety of enfortumab vedotin selectively binds to nectin-4. After internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces apoptosis in nectin-4 overexpressing tumor cells. Nectin-4, a tumor associated antigen belonging to the nectin family, is overexpressed in a variety of cancers, including breast, bladder, lung and pancreatic cancer.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C114501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114501>	C1511	Iodine I 124-labeled Anti-PSCA A11 Minibody|124I-A11 PSCA Minibody	A radioconjugate composed of an affinity-matured antibody fragment, the A11 minibody, directed against human prostate stem cell antigen (PSCA), and conjugated with the radioisotope iodine I 124, that can potentially be used as an imaging agent for positron emission tomography (PET)/computed tomography (CT). The minibody moiety of iodine I 124-labeled anti-PSCA A11 minibody selectively targets and binds to PSCA. The PSCA-expressing tumor cells can then be visualized using PET/CT. PSCA, a cell surface antigen expressed in normal human prostate and bladder, is overexpressed in a variety of cancers, including bladder, pancreatic, and prostate cancer. The A11 minibody is formed by the fusion of a single chain Fv fragment with the immunoglobulin G1 CH3 domain.	Iodine I 124-labeled Anti-PSCA A11 Minibody		Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C114502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114502>	C16620	HHV8 K2 Gene|HHV-8 K2|HHV-8 vIL6|HHV8 K2|HHV8 vIL6|Human Herpesvirus 8 Viral Interleukin-6 Gene|Human Herpesvirus-8 Viral Interleukin-6 Gene|K2|KSHV K2|KSHV vIL6|Kaposi Sarcoma Herpes Virus Interleukin-6 Gene|vIL-6	HHV8 K2, which encodes viral interleukin-6 homolog protein, plays a role in cell proliferation, cell differentiation and the prevention of apoptosis.	HHV8 K2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114503>	C17254	Viral Interleukin-6 Homolog|Interleukin-6 Homolog|K2|ORF K2|Putative Interleukin 6|Viral Interleukin-6|vIL-6	Viral interleukin-6 homolog (204 aa, ~23 kDa) is encoded by the human herpesvirus 8 K2 gene. This protein is involved in the negative regulation of apoptosis and the positive regulation of both cell proliferation and cell differentiation.	Viral Interleukin-6 Homolog		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114504>	C16620	HHV8 ORF74 Gene|HHV-8 ORF74|HHV-8 vGPCR|HHV8 ORF74|HHV8 vGPCR|Human Herpesvirus 8 ORF74 Gene|Human Herpesvirus 8 Open Reading Frame 74 Gene|Human Herpesvirus 8 Viral G-Protein Coupled Receptor Gene|Human Herpesvirus-8 ORF74 Gene|Human Herpesvirus-8 Open Reading Frame 74 Gene|Human Herpesvirus-8 Viral G-Protein Coupled Receptor Gene|KSHV ORF74|KSHV vGPCR|Kaposi Sarcoma Herpes Virus ORF74 Gene|Kaposi Sarcoma Herpes Virus Open Reading Frame 74 Gene|Kaposi Sarcoma Herpes Virus Viral G-Protein Coupled Receptor Gene|ORF74|vGPCR	HHV8 ORF74, which encodes viral G-protein coupled receptor protein, is involved in the modulation of cell proliferation, cell migration, angiogenesis and cell survival.	HHV8 ORF74 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114505>	C17254	Viral G-Protein Coupled Receptor|G Protein-Coupled Receptor|HHV8 G Protein-Coupled Receptor|IL-8 Receptor-Like G Protein Coupled Receptor Homolog|IL-8 Receptor-Like Protein|Protein ORF74|Putative G-Protein Coupled Receptor|vGPCR	Viral G-protein coupled receptor (342 aa, ~39 kDa) is encoded by the human herpesvirus 8 ORF74 gene. This protein plays a role in the positive regulation of angiogenesis, cell migration, cell proliferation and cell survival.	Viral G-Protein Coupled Receptor		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114506>	C16620	HHV8 ORF59 Gene|HHV-8 ORF59|HHV8 ORF59|Human Herpesvirus 8 ORF59 Gene|Human Herpesvirus 8 Open Reading Frame 59 Gene|Human Herpesvirus-8 ORF59 Gene|Human Herpesvirus-8 Open Reading Frame 59 Gene|KSHV ORF59|Kaposi Sarcoma Herpes Virus ORF59 Gene|Kaposi Sarcoma Herpes Virus Open Reading Frame 59 Gene|ORF59	HHV8 ORF59, which encodes DNA polymerase processivity factor protein, plays a role in viral DNA replication.	HHV8 ORF59 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114507>	C17254	DNA Polymerase Processivity Factor|Core Gene UL42 Family Protein|ORF 59|ORF59	DNA polymerase processivity factor (396 aa, ~42 kDa) is encoded by the human herpesvirus 8 ORF59 gene. This protein is involved in the replication of viral DNA.	DNA Polymerase Processivity Factor		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114508>	C54362	RBPJ Gene|RBPJ|RBPJ|Recombination Signal Binding Protein For Immunoglobulin Kappa J Region Gene	This gene plays a role in both cell-cell communication and transcriptional regulation.	RBPJ Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114509>	C114508	RBPJ wt Allele|AOS3|CBF1|IGKJRB|IGKJRB1|KBF2|RBP-J|RBPJK|RBPSUH|Recombination Signal Binding Protein For Immunoglobulin Kappa J Region wt Allele|Recombination Signal-Binding Protein Suppressor of Hairless, Drosophila, Homolog of Gene|Recombining Binding Protein Suppressor of Hairless (Drosophila) Gene|SUH|Suppressor of Hairless Homolog (Drosophila) Gene|csl	Human RBPJ wild-type allele is located in the vicinity of 4p15.2 and is approximately 271 kb in length. This allele, which encodes recombining binding protein suppressor of hairless protein, is involved in both transcriptional regulation and intercellular communication. Mutation of the gene is associated with Adams-Oliver syndrome 3.	RBPJ wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11450>	C61063	Adenovirus 5-CD40-L Vector/Interleukin-2|AD-CD40-L/IL-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114510>	C26199	Recombining Binding Protein Suppressor of Hairless|C Promoter-Binding Factor 1|CBF-1|Immunoglobulin Kappa J Region Recombination Signal Binding Protein 1|Immunoglobulin Kappa J Region Recombination Signal-Binding Protein 1|J Kappa-Recombination Signal-Binding Protein|RBP-J|RBP-J Kappa|RBP-JK|RBPJ|Recombination Signal-Binding Protein 1 for J-Kappa|Recombination Signal-Binding Protein for Immunoglobulin Kappa J Region|Renal Carcinoma Antigen NY-REN-30	Recombining binding protein suppressor of hairless (500 aa, ~56 kDa) is encoded by the human RBPJ gene. This protein plays a role in both transcriptional regulation and signaling.	Recombining Binding Protein Suppressor of Hairless		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114511>	C20791	ADAM19 Gene|ADAM Metallopeptidase Domain 19 Gene|ADAM19|ADAM19	This gene is involved in proteolytic processing.	ADAM19 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114512>	C114511	ADAM19 wt Allele|A Disintegrin and Metalloproteinase Domain 19 (Meltrin Beta) Gene|ADAM Metallopeptidase Domain 19 wt Allele|FKSG34|MADDAM|MLTNB|Meltrin-Beta, Mouse, Homolog of Gene	Human ADAM19 wild-type allele is located in the vicinity of 5q33.3 and is approximately 180 kb in length. This allele, which encodes disintegrin and metalloproteinase domain-containing protein 19, plays a role in proteolysis.	ADAM19 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114513>	C16843	Disintegrin and Metalloproteinase Domain-Containing Protein 19|A Disintegrin and Metalloproteinase Domain 19|ADAM 19|ADAM19|EC 3.4.24.-|MADDAM|Meltrin Beta|Meltrin-Beta|Metalloprotease and Disintegrin Dendritic Antigen Marker|Metalloprotease-Disintegrin Meltrin Beta	Disintegrin and metalloproteinase domain-containing protein 19 (955 aa, ~105 kDa) is encoded by the human ADAM19 gene. This protein is involved in proteolysis.	Disintegrin and Metalloproteinase Domain-Containing Protein 19		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114514>	C20921	DVL1 Gene|DVL1|DVL1|Dishevelled Segment Polarity Protein 1 Gene	This gene plays a role in signaling modulated by the Wnt and frizzled protein families.	DVL1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114515>	C114514	DVL1 wt Allele|DSH, Drosophila, Homolog of, 1 Gene|DVL|DVL1L1|DVL1P1|Dishevelled 1 (Homologous to Drosophila dsh) Gene|Dishevelled Segment Polarity Protein 1 wt Allele|Dishevelled, Dsh Homolog 1 (Drosophila) Gene|Dishevelled, Dsh Homolog 1 Gene|RP5-890O3.5	Human DVL1 wild-type allele is located in the vicinity of 1p36 and is approximately 14 kb in length. This allele, which encodes segment polarity protein dishevelled homolog DVL-1 protein, is involved in Wnt signaling.	DVL1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114516>	C18515	Segment Polarity Protein Dishevelled Homolog DVL-1|DSH Homolog 1|DVL1|Dishevelled 1|Dishevelled Segment Polarity Protein 1|Dishevelled-1	Segment polarity protein dishevelled homolog DVL-1 (695 aa, ~75 kDa) is encoded by the human DVL1 gene. This protein plays a role in signal transduction.	Segment Polarity Protein Dishevelled Homolog DVL-1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114517>	C20420	HES2 Gene|HES2|HES2|Hes Family bHLH Transcription Factor 2 Gene	This gene is involved in the negative regulation of gene expression.	HES2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114518>	C114517	HES2 wt Allele|BHLHB40|HES-2|Hairy and Enhancer of Split 2 (Drosophila) Gene|Hairy/Enhancer of Split, Drosophila, Homolog of Gene|Hes Family bHLH Transcription Factor 2 wt Allele|bHLHb40	Human HES2 wild-type allele is located in the vicinity of 1p36.31 and is approximately 12 kb in length. This allele, which encodes transcription factor HES-2 protein, plays a role in transcriptional repression.	HES2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114519>	C17207	Transcription Factor HES-2|Class B Basic Helix-Loop-Helix Protein 40|HES-2|HES2|Hairy and Enhancer of Split 2|bHLHb40	Transcription factor HES-2 (173 aa, ~18 kDa) is encoded by the human HES2 gene. This protein is involved in the repression of transcription.	Transcription Factor HES-2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11451>	C61063	Cyclophosphamide/Prednisone/Sargramostim/Vincristine|CTX/GM-CSF/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114520>	C20703	HEYL Gene|HEYL|HEYL|Hes-Related Family bHLH Transcription Factor With YRPW Motif-Like Gene	This gene plays a role in both transcriptional regulation and cardiac development.	HEYL Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114521>	C114520	HEYL wt Allele|BHLHB33|HESR3|HEY3|HRT3|Hairy/Enhancer-of-Split Related With YRPW Motif 3 Gene|Hairy/Enhancer-of-Split Related With YRPW Motif-Like Gene|Hes-Related Family bHLH Transcription Factor With YRPW Motif-Like wt Allele|bHLHb33	Human HEYL wild-type allele is located in the vicinity of 1p34.3 and is approximately 17 kb in length. This allele, which encodes hairy/enhancer-of-split related with YRPW motif-like protein, is involved in the modulation of both cardiac development and transcriptional regulation.	HEYL wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114522>	C26199	Hairy/Enhancer-of-Split Related With YRPW Motif-Like Protein|Class B Basic Helix-Loop-Helix Protein 33|HEY-Like Protein|HEYL|HRT-3|Hairy-Related Transcription Factor 3|bHLHb33|hHRT3|hHeyL	Hairy/enhancer-of-split related with YRPW motif-like protein (328 aa, ~35 kDa) is encoded by the human HEYL gene. This protein plays a role in both cardiac development and the negative regulation of transcription.	Hairy/Enhancer-of-Split Related With YRPW Motif-Like Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114523>	C20744	TAGLN Gene|TAGLN|TAGLN|Transgelin Gene	This gene is involved in actin crosslinking.	TAGLN Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114524>	C114523	TAGLN wt Allele|DKFZp686P11128|SM22|SMCC|TAGLN1|Transgelin wt Allele|WS3-10	Human TAGLN wild-type allele is located in the vicinity of 11q23.2 and is approximately 5 kb in length. This allele, which encodes transgelin protein, plays a role in actin binding.	TAGLN wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114525>	C18073	Transgelin|22 kDa Actin-Binding Protein|Protein WS3-10|SM22-Alpha|Smooth Muscle Protein 22-Alpha|TAGLN	Transgelin (201 aa, ~23 kDa) is encoded by the human TAGLN gene. This protein is involved in both actin binding and cell contractility.	Transgelin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114526>	C20923	GRM2 Gene|GRM2|GRM2|Glutamate Receptor, Metabotropic 2 Gene	This gene plays a role in the inhibition of adenylate cyclase signaling.	GRM2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114527>	C114526	GRM2 wt Allele|GLUR2|GPRC1B|Glutamate Receptor, Metabotropic 2 wt Allele|Glutamate Receptor, Metabotropic, 2 Gene|MGLUR2|mGlu2	Human GRM2 wild-type allele is located in the vicinity of 3p21.2 and is approximately 12 kb in length. This allele, which encodes metabotropic glutamate receptor 2 protein, is involved in G protein-coupled receptor signaling.	GRM2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114528>	C18239	Metabotropic Glutamate Receptor 2|GRM2|Glutamate Metabotropic Receptor 2|Glutamate Receptor Homolog|mGluR2	Metabotropic glutamate receptor 2 (872 aa, ~96 kDa) is encoded by the human GRM2 gene. This protein plays a role in neurotransmitter-dependent signaling.	Metabotropic Glutamate Receptor 2		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114529>	C20923	GRM3 Gene|GRM3|GRM3|GRM3|Glutamate Receptor, Metabotropic 3 Gene	This gene is involved in ligand-depending signaling.	GRM3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C11452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11452>	C61063	Isotretinoin/Procarbazine|13-CRA/PCB			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114530>	C114529	GRM3 wt Allele|GLUR3|GPRC1C|Glutamate Receptor, Metabotropic 3 wt Allele|Glutamate Receptor, Metabotropic, 3 Gene|MGLUR3|mGlu3	Human GRM3 wild-type allele is located within 7q21.1-q21.2 and is approximately 221 kb in length. This allele, which encodes metabotropic glutamate receptor 3 protein, plays a role in the negative regulation of adenylate cyclase-mediated signaling.	GRM3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114531>	C18239	Metabotropic Glutamate Receptor 3|GRM3|Glutamate Metabotropic Receptor 3|mGluR3	Metabotropic glutamate receptor 3 (879 aa, ~99 kDa) is encoded by the human GRM3 gene. This protein is involved in G protein-coupled receptor signaling.	Metabotropic Glutamate Receptor 3		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114532>	C20923	GRM4 Gene|GRM4|GRM4|Glutamate Receptor, Metabotropic 4 Gene	This gene plays a role in neurotransmitter signaling.	GRM4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114533>	C114532	GRM4 wt Allele|GPRC1D|Glutamate Receptor, Metabotropic 4 wt Allele|Glutamate Receptor, Metabotropic, 4 Gene|MGLUR4|mGlu4	Human GRM4 wild-type allele is located in the vicinity of 6p21.3 and is approximately 134 kb in length. This allele, which encodes metabotropic glutamate receptor 4 protein, is involved in ligand-dependent signal transduction.	GRM4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114534>	C18239	Metabotropic Glutamate Receptor 4|GRM4|mGluR4	Metabotropic glutamate receptor 4 (912 aa, ~102 kDa) is encoded by the human GRM4 gene. This protein plays a role in the regulation of G protein-dependent signaling.	Metabotropic Glutamate Receptor 4		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114535>	C20923	GRM7 Gene|GRM7|GRM7|Glutamate Receptor, Metabotropic 7 Gene	This gene is involved in neurotransmitter binding.	GRM7 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114536>	C114535	GRM7 wt Allele|GLUR7|GPRC1G|Glutamate Receptor, Metabotropic 7 wt Allele|Glutamate Receptor, Metabotropic, 7 Gene|MGLU7|MGLUR7	Human GRM7 wild-type allele is located in the vicinity of 3p26.1-p25.1 and is approximately 972 kb in length. This allele, which encodes metabotropic glutamate receptor 7 protein, plays a role in the modulation of G protein-coupled receptor signaling.	GRM7 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114537>	C18239	Metabotropic Glutamate Receptor 7|GRM7|mGluR7	Metabotropic glutamate receptor 7 (915 aa, ~102 kDa) is encoded by the human GRM7 gene. This protein is involved in ligand-mediated signaling.	Metabotropic Glutamate Receptor 7		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114538>	C20923	GRM8 Gene|GRM8|GRM8|Glutamate Receptor, Metabotropic 8 Gene	This gene plays a role in G protein-coupled receptor signaling.	GRM8 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114539>	C114538	GRM8 wt Allele|GLUR8|GPRC1H|Glutamate Receptor, Metabotropic 8 wt Allele|Glutamate Receptor, Metabotropic, 8 Gene|MGLUR8|mGlu8	Human GRM8 wild-type allele is located within 7q31.3-q32.1 and is approximately 815 kb in length. This allele, which encodes metabotropic glutamate receptor 8 protein, is involved in glutamate-dependent signal transduction.	GRM8 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11453>	C61007	Anti-Thymocyte Globulin/Cyclophosphamide/Fludarabine|ATG/CTX/FAMP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114540>	C18239	Metabotropic Glutamate Receptor 8|GRM8|mGluR8	Metabotropic glutamate receptor 8 (908 aa, ~102 kDa) is encoded by the human GRM8 gene. This protein plays a role in the negative regulation of adenylate cyclase activity.	Metabotropic Glutamate Receptor 8		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114541>	C7707|C4247	Adult Undifferentiated Pleomorphic Sarcoma|Adult Malignant Fibrous Histiocytoma|Undifferentiated Pleomorphic Sarcoma	An undifferentiated pleomorphic sarcoma that occurs during adulthood.	Adult Undifferentiated Pleomorphic Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114542>	C20194	PRKAR2A Gene|PRKAR2A|PRKAR2A|Protein Kinase, cAMP-Dependent, Regulatory, Type II, Alpha Gene	This gene is involved in the regulation of cyclic AMP-dependent signaling.	PRKAR2A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114543>	C114542	PRKAR2A wt Allele|PKR2|PRKAR2|Protein Kinase, cAMP-Dependent, Regulatory, Type II, Alpha wt Allele	Human PRKAR2A wild-type allele is located within 3p21.3-p21.2 and is approximately 103 kb in length. This allele, which encodes cAMP-dependent protein kinase type II-alpha regulatory subunit protein, plays a role in the modulation of cyclic AMP-dependent signaling.	PRKAR2A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114544>	C18466	cAMP-Dependent Protein Kinase Type II-Alpha Regulatory Subunit|PRKAR2A|Protein Kinase A, RII-Alpha Subunit|cAMP-Dependent Protein Kinase Regulatory Subunit RII Alpha	cAMP-dependent protein kinase type II-alpha regulatory subunit (404 aa, ~46 kDa) is encoded by the human PRKAR2A gene. This protein is involved in the positive regulation of cyclic AMP-dependent signaling.	cAMP-Dependent Protein Kinase Type II-Alpha Regulatory Subunit		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114545>	C20103	PLA2R1 Gene|PLA2R1|PLA2R1|Phospholipase A2 Receptor 1 Gene	This gene plays a role in the localization of phospholipases.	PLA2R1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114546>	C114545	PLA2R1 wt Allele|CLEC13C|PLA2-R|PLA2G1R|PLA2IR|PLA2R|Phospholipase A2 Receptor 1 wt Allele|Phospholipase A2 Receptor 1, 180kD Gene|Phospholipase A2 Receptor 1, 180kDa Gene|Phospholipase A2 Receptor, 180-kD Gene	Human PLA2R1 wild-type allele is located within 2q23-q24 and is approximately 131 kb in length. This allele, which encodes secretory phospholipase A2 receptor protein, is involved in phospholipase activity and endocytosis.	PLA2R1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114547>	C18106	Secretory Phospholipase A2 Receptor|180 kDa Secretory Phospholipase A2 Receptor|C-Type Lectin Domain Family 13 Member C|M-Type Phospholipase A2 Receptor|M-Type Receptor|PHOSPHOLIPASE A2 RECEPTOR|PLA2-R|PLA2R|PLA2R|Phospholipase A2 Receptor 1	Secretory phospholipase A2 receptor (1463 aa, ~169 kDa) is encoded by the human PLA2R1 gene. This protein plays a role in the modulation of phospholipase activity.	Secretory Phospholipase A2 Receptor		Amino Acid, Peptide, or Protein|Receptor	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114548>	C54443	CareLex eTMF Terminology|CareLex electronic Trial Master File Terminology	A controlled vocabulary developed to support content interoperability between electronic Trial Master File systems for clinical trials.			Intellectual Product	
C114549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114549>	C42698	Content Type Name	The text label assigned to a content type.			Conceptual Entity	
C11454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11454>	C61063	Dexamethasone/Methotrexate/Thioguanine/Vincristine|DM/MTX/TG/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114550>	C25164	Data Change Date|Modification|Modified	The date of data modification.			Temporal Concept	CareLex eTMF Terminology
C114551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114551>	C48835	Organization Role	A title that describes the function of a designated group, governing body, or institution.			Functional Concept	CareLex eTMF Terminology
C114552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114552>	C70865	Digital Signature Status|eSign Status|eSign Status|eSignature Status|electronic Signature Status	An indication of the standing of a digital signature.			Qualitative Concept	CareLex eTMF Terminology
C114553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114553>	C25993	PKD1L1 Gene|PKD1L1|PKD1L1|Polycystic Kidney Disease 1 Like 1 Gene	This gene is involved in the modulation of calcium transport.	PKD1L1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114554>	C114553	PKD1L1 wt Allele|PRO19563|Polycystic Kidney Disease 1 Like 1 wt Allele|Polycystin 1-Like 1 Gene|UNQ5785/PRO19563	Human PKD1L1 wild-type allele is located in the vicinity of 7p12.3 and is approximately 174 kb in length. This allele, which encodes polycystic kidney disease protein 1-like 1 protein, plays a role in the modulation of ciliary calcium concentration.	PKD1L1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114555>	C28505	Polycystic Kidney Disease Protein 1-Like 1|PC1-Like 1 Protein|PKD1L1|Polycystin-1L1	Polycystic kidney disease protein 1-like 1 (2849 aa, ~315 kDa) is encoded by the human PKD1L1 gene. This protein is involved in ciliary calcium concentration modulation.	Polycystic Kidney Disease Protein 1-Like 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114556>	C25952	PDE8B Gene|PDE8B|PDE8B|Phosphodiesterase 8B Gene	This gene plays a role in the metabolism of cyclic AMP.	PDE8B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114557>	C114556	PDE8B wt Allele|ADSD|PIG22|PPNAD3|Phosphodiesterase 8B wt Allele	Human PDE8B wild-type allele is located in the vicinity of 5q13.3 and is approximately 219 kb in length. This allele, which encodes high affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8B protein, is involved in second messenger metabolism. Mutation of the gene is associated with both autosomal dominant striatal degeneration and primary pigmented nodular adrenocortical disease 3.	PDE8B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114558>	C16561	High Affinity cAMP-Specific and IBMX-Insensitive 3',5'-Cyclic Phosphodiesterase 8B|3',5' Cyclic Nucleotide Phosphodiesterase 8B|Cell Proliferation-Inducing Gene 22 Protein|EC 3.1.4.17|High Affinity cAMP-Specific and IBMX-Insensitive 3,5-Cyclic Phosphodiesterase 8B|HsPDE8B|PDE8B	High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8B (885 aa, ~99 kDa) is encoded by the human PDE8B gene. This protein plays a role in cyclic AMP catabolism.	High Affinity cAMP-Specific and IBMX-Insensitive 3,5-Cyclic Phosphodiesterase 8B		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114559>	C36345	Loss of BAF250a Expression	Loss of protein expression of the BRG-associated factor 250a (BAF250a).  It is caused by mutation of the tumor-suppressor gene ARID1A. It is linked to tumor progression and poor prognosis in various cancers.			Cell or Molecular Dysfunction	
C11455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11455>	C61063	Methotrexate/Prednisolone/Thioguanine/Vincristine|MTX/PRDL/TG/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114560>	C27290|C211669	Childhood L1 Acute Lymphoblastic Leukemia|L1 Acute Lymphoblastic Leukemia|Pediatric L1 Acute Lymphoblastic Leukemia	L1 acute lymphoblastic leukemia that occurs during childhood.	Childhood L1 Acute Lymphoblastic Leukemia	Obsolete_Concept	Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114561>	C3143	Breastfeeding Jaundice	Yellow coloring of skin, mucous membranes and eyes in an otherwise healthy breast-fed newborn due to insufficient intake of maternally-expressed milk. It commonly appears four to seven days after birth.			Finding	NICHD Terminology|Perinatal Terminology
C114562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114562>	C27281|C211669	Childhood L2 Acute Lymphoblastic Leukemia|L2 Acute Lymphoblastic Leukemia|Pediatric L2 Acute Lymphoblastic Leukemia	L2 acute lymphoblastic leukemia that occurs during childhood.	Childhood L2 Acute Lymphoblastic Leukemia	Obsolete_Concept	Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114563>	C26006	PACS1 Gene|PACS1|PACS1|Phosphofurin Acidic Cluster Sorting Protein 1 Gene	This gene is involved in protein trafficking.	PACS1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114564>	C114563	PACS1 wt Allele|FLJ10209|KIAA1175|MRD17|Phosphofurin Acidic Cluster Sorting Protein 1 wt Allele	Human PACS1 wild-type allele is located within 11q13.1-q13.2 and is approximately 174 kb in length. This allele, which encodes phosphofurin acidic cluster sorting protein 1, plays a role in targeting proteins to the Golgi. Mutation of the gene is associated with autosomal dominant mental retardation 17.	PACS1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114565>	C1580	Anti-ds DNA Antibody|Anti-Double Stranded DNA Antibody|Anti-Double Stranded DNA Antibody|Anti-Double-Stranded DNA Antibody|Anti-dsDNA Antibody|Anti-dsDNA Antibody	A type of antinuclear antibody that specifically targets double stranded DNA; while these antibodies are sometimes detectable in multiple different autoimmune disorders, their presence is generally considered highly specific for systemic lupus erythematosus.	Anti-ds DNA Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology|NICHD Terminology|Pediatric Rheumatology Terminology
C114566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114566>	C16386	Phosphofurin Acidic Cluster Sorting Protein 1|Cytosolic Sorting Protein PACS-1|PACS-1	Phosphofurin acidic cluster sorting protein 1 (963 aa, ~105 kDa) is encoded by the human PACS1 gene. This protein is involved in mediating the localization of proteins to the Golgi.	Phosphofurin Acidic Cluster Sorting Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114567>	C1580	Anti-ss DNA Antibody|Anti-single stranded DNA Antibody|Anti-ssDNA Antibody	A type of antinuclear antibody that specifically targets single stranded (denatured) DNA; these antibodies are often detectable in multiple different autoimmune and rheumatologic disorders, but their presence is neither sensitive nor specific to diagnosing any one of these diseases.			Amino Acid, Peptide, or Protein|Immunologic Factor	
C114568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114568>	C20917	MCPH1 Gene|MCPH1|MCPH1|Microcephalin 1 Gene	This gene plays a role in both mitotic checkpoints and brain development.	MCPH1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114569>	C114568	MCPH1 wt Allele|BRCT-Repeat Inhibitor of TERT Expression 1 Gene|BRIT1|FLJ12847|MCT|Microcephalin 1 wt Allele|Microcephaly, Primary Autosomal Recessive 1 Gene	Human MCPH1 wild-type allele is located in the vicinity of 8p23.1 and is approximately 237 kb in length. This allele, which encodes microcephalin protein, is involved in both brain development and DNA damage checkpoints. Mutation of the gene is associated with primary, autosomal-recessive microcephaly 1.	MCPH1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11456>	C61063	Flt3 Ligand/gp100 Antigen/MART-1 Antigen/Tyrosinase|Flt3L/gp100/MART-1/TYR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114570>	C17761	Microcephalin|MCPH1	Microcephalin (835 aa, ~93 kDa) is encoded by the human MCPH1 gene. This protein plays a role in both cell cycle regulation and neuronal development.	Microcephalin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114571>	C25870	MBOAT2 Gene|MBOAT2|MBOAT2|Membrane Bound O-Acyltransferase Domain Containing 2 Gene	This gene is involved in lysophospholipid metabolism.	MBOAT2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114572>	C114571	MBOAT2 wt Allele|FLJ14415|FLJ90298|LPCAT4|Membrane Bound O-Acyltransferase Domain Containing 2 wt Allele|O-Acyltransferase (Membrane Bound) Domain Containing 2 Gene|OACT2	Human MBOAT2 wild-type allele is located in the vicinity of 2p25.1 and is approximately 151 kb in length. This allele, which encodes lysophospholipid acyltransferase 2 protein, plays a role in glycophospholipid metabolism.	MBOAT2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114573>	C16259	Lysophospholipid Acyltransferase 2|1-Acylglycerophosphate O-Acyltransferase|1-Acylglycerophosphoethanolamine O-Acyltransferase|EC 2.3.1.-|EC 2.3.1.51|EC 2.3.1.n7|LPAAT|LPEAT|LPLAT 2|Lyso-PA Acyltransferase|Lyso-PE Acyltransferase|Lysophosphatidic Acid Acyltransferase|Lysophosphatidylcholine Acyltransferase 4|Lysophosphatidylethanolamine Acyltransferase|Membrane-Bound O-Acyltransferase 2|Membrane-Bound O-Acyltransferase Domain-Containing 2|Membrane-Bound O-Acyltransferase Domain-Containing Protein 2|O-Acyltransferase Domain-Containing Protein 2	Lysophospholipid acyltransferase 2 (520 aa, ~60 kDa) is encoded by the human MBOAT2 gene. This protein is involved in lysophospholipid metabolism.	Lysophospholipid Acyltransferase 2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114574>	C27356	Adult Non-T Non-B Acute Lymphoblastic Leukemia|Non-T Non-B Acute Lymphoblastic Leukemia	Non-T non-B acute lymphoblastic leukemia that occurs during adulthood.	Adult Non-T Non-B Acute Lymphoblastic Leukemia	Obsolete_Concept	Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114575>	C20103	ITPR2 Gene|ITPR2|ITPR2|Inositol 1,4,5-Trisphosphate Receptor, Type 2 Gene	This gene plays a role in second messenger signaling.	ITPR2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114576>	C27356|C211669	Childhood Non-T Non-B Acute Lymphoblastic Leukemia|Non-T Non-B Acute Lymphoblastic Leukemia|Pediatric Non-T Non-B Acute Lymphoblastic Leukemia	Non-T non-B acute lymphoblastic leukemia that occurs during childhood.	Childhood Non-T Non-B Acute Lymphoblastic Leukemia	Obsolete_Concept	Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114577>	C114575	ITPR2 wt Allele|IP3R2|Inositol 1,4,5-Triphosphate Receptor, Type 2 Gene|Inositol 1,4,5-Trisphosphate Receptor, Type 2 wt Allele	Human ITPR2 wild-type allele is located in the vicinity of 12p11 and is approximately 498 kb in length. This allele, which encodes inositol 1,4,5-trisphosphate receptor type 2 protein, is involved in intracellular calcium release.	ITPR2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114578>	C18106	Inositol 1,4,5-Trisphosphate Receptor Type 2|IP3 Receptor Isoform 2|IP3R 2|Inositol 1,4,5-Triphosphate Receptor 2|Inositol 1,4,5-Triphosphate Receptor Type 2|InsP3R2|Type 2 Inositol 1,4,5-Trisphosphate Receptor|Type 2 InsP3 Receptor	Inositol 1,4,5-trisphosphate receptor type 2 (2701 aa, ~308 kDa) is encoded by the human ITPR2 gene. This protein plays a role in in second messenger signaling.	Inositol 1,4,5-Trisphosphate Receptor Type 2		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114579>	C114576	Non-T Non-B CALLA Negative Childhood Acute Lymphoblastic Leukemia|Non-T Non-B CALLA Negative Acute Lymphoblastic Leukemia	Non-T non-B, CALLA negative acute lymphoblastic leukemia that occurs during childhood.	Non-T Non-B CALLA Negative Childhood Acute Lymphoblastic Leukemia	Obsolete_Concept	Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114580>	C114574	Non-T Non-B CALLA Negative Adult Acute Lymphoblastic Leukemia|Non-T Non-B CALLA Negative Acute Lymphoblastic Leukemia	Non-T non-B, CALLA negative acute lymphoblastic leukemia that occurs during adulthood.	Non-T Non-B CALLA Negative Adult Acute Lymphoblastic Leukemia	Obsolete_Concept	Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114581>	C27281	Adult L2 Acute Lymphoblastic Leukemia|L2 Acute Lymphoblastic Leukemia	L2 acute lymphoblastic leukemia that occurs during adulthood.	Adult L2 Acute Lymphoblastic Leukemia	Obsolete_Concept	Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114582>	C54362	INTS4 Gene|INTS4|INTS4|Integrator Complex Subunit 4 Gene	This gene is involved in the transcription of small nuclear RNAs.	INTS4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114583>	C34843	Drug-Induced Nephropathy|Drug-Induced Kidney Injury|Drug-Induced Kidney Injury|Drug-Induced Renal Failure|Drug-Induced Renal Failure|Toxic Nephropathy|Toxic Nephropathy	Kidney damage resulting from exposure to drugs.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Nephrology Terminology
C114584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114584>	C114582	INTS4 wt Allele|INT4|Integrator Complex Subunit 4 wt Allele|MGC16733|MST093|MSTP093	Human INTS4 wild-type allele is located in the vicinity of 11q14.1 and is approximately 116 kb in length. This allele, which encodes integrator complex subunit 4 protein, plays a role in small nuclear RNA transcription.	INTS4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114585>	C114583	Calcineurin Nephrotoxicity|Calcineurin Inhibitor Nephrotoxicity|Calcineurin Inhibitor Nephrotoxicity	Kidney injury caused by calcineurin inhibitor immunosuppressive therapy which may lead to diminished kidney function.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114586>	C26199	Integrator Complex Subunit 4|INTS4|Int4	Integrator complex subunit 4 (963 aa, ~108 kDa) is encoded by the human INTS4 gene. This protein is involved in the transcription and processing of small nuclear RNAs.	Integrator Complex Subunit 4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114589>	C20194	JPT1 Gene|HN1|JPT1|JPT1|Jupiter Microtubule Associated Homolog 1 Gene	This gene plays a role in signaling, cell cycle and cell adhesion.	JPT1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C11458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11458>	C61007	Carboplatin/Docetaxel|CBDCA/TXT			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114590>	C114589	JPT1 wt Allele|ARM2|HN1|HN1A|Hematologic- and Neurologic-Expressed 1 Gene|Hematological and Neurological Expressed 1 Gene|Jupiter Microtubule Associated Homolog 1 wt Allele	Human JPT1 wild-type allele is located in the vicinity of 17q25.1 and is approximately 33 kb in length. This allele, which encodes Jupiter microtubule associated homolog 1 protein, is involved in the modulation of cell adhesion, cell cycle progression and signal transduction.	JPT1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114591>	C18466	Jupiter Microtubule Associated Homolog 1|Androgen-Regulated Protein 2|Hematological and Neurological Expressed 1 Protein|JPT1|OPMRX60 Antigen	Jupiter microtubule associated homolog 1 (154 aa, ~16 kDa) is encoded by the human JPT1 gene. This protein plays a role in signal transduction, cell adhesion and cell cycle regulation.	Jupiter Microtubule Associated Homolog 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114592>	C36286	Renal Impairment|Kidney Impairment	Diminished kidney function.			Finding	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114593>	C68689	Adult TdT Positive Acute Lymphoblastic Leukemia|TdT Positive Acute Lymphoblastic Leukemia	TdT positive acute lymphoblastic leukemia that occurs during adulthood.	Adult TdT Positive Acute Lymphoblastic Leukemia	Obsolete_Concept	Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114594>	C68689|C211669	Childhood TdT Positive Acute Lymphoblastic Leukemia|Pediatric TdT Positive Acute Lymphoblastic Leukemia|TdT Positive Acute Lymphoblastic Leukemia	TdT positive acute lymphoblastic leukemia that occurs during childhood.	Childhood TdT Positive Acute Lymphoblastic Leukemia	Obsolete_Concept	Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114595>	C67519	Adult TdT Negative Acute Lymphoblastic Leukemia|TdT Negative Acute Lymphoblastic Leukemia	TdT negative acute lymphoblastic leukemia that occurs during adulthood.	Adult TdT Negative Acute Lymphoblastic Leukemia	Obsolete_Concept	Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114596>	C67519|C211669	Childhood TdT Negative Acute Lymphoblastic Leukemia|Pediatric TdT Negative Acute Lymphoblastic Leukemia|TdT Negative Acute Lymphoblastic Leukemia	TdT negative acute lymphoblastic leukemia that occurs during childhood.	Childhood TdT Negative Acute Lymphoblastic Leukemia	Obsolete_Concept	Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114597>	C25300	Shell Vial Culture	A method for virus culture and detection in which a virus sample is mixed with a susceptible cell type and then centrifuged into a single layer of cells. Following a short incubation, viral growth is determined using immunological detection techniques.			Laboratory Procedure	
C114598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114598>	C62277	Mixed Osteosarcoma|Combined Type Osteosarcoma|Mixed Type Osteosarcoma	A term referring to conventional osteosarcomas which do not have a dominant matrix pattern and contain a mixture of osteoid matrix in combination with chondroid matrix and/or collagen fibers.	Mixed Osteosarcoma	Obsolete_Concept	Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114599>	C27798	Adult Pre-B Acute Lymphoblastic Leukemia|Pre-B Acute Lymphoblastic Leukemia	Pre-B acute lymphoblastic leukemia that occurs during adulthood.	Adult Pre-B Acute Lymphoblastic Leukemia	Obsolete_Concept	Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C11459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11459>	C61063	Cisplatin/Dexamethasone/Paclitaxel|CDDP/DM/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1145>	C70553	Lignan|lignan		Lignan		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C114600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114600>	C27798|C211669	Childhood Pre-B Acute Lymphoblastic Leukemia|Pediatric Pre-B Acute Lymphoblastic Leukemia|Pre-B Acute Lymphoblastic Leukemia	Pre-B acute lymphoblastic leukemia that occurs during childhood.	Childhood Pre-B Acute Lymphoblastic Leukemia	Obsolete_Concept	Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C114601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114601>	C21282	GMDS Gene|GDP-Mannose 4,6-Dehydratase Gene|GMDS|GMDS	This gene is involved in the metabolism of nucleotide-sugar complexes.	GMDS Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114602>	C114601	GMDS wt Allele|GDP-Mannose 4,6-Dehydratase wt Allele|GMD|RP1-118B18.1|SDR3E1|Short Chain Dehydrogenase/Reductase Family 3E, Member 1 Gene	Human GMDS wild-type allele is located in the vicinity of 6p25 and is approximately 622 kb in length. This allele, which encodes GDP-mannose 4,6 dehydratase protein, plays a role in nucleotide-sugar complex metabolism.	GMDS wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114603>	C16804	GDP-Mannose 4,6 Dehydratase|EC 4.2.1.47|GDP-D-Mannose Dehydratase|GDP-Mannose 4,6-Dehydratase|Short Chain Dehydrogenase/Reductase Family 3E, Member 1	GDP-mannose 4,6 dehydratase (372 aa, ~42 kDa) is encoded by the human GMDS gene. This protein is involved in the metabolism of nucleotide-sugar complexes.	GDP-Mannose 4,6 Dehydratase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114604>	C20194	FHDC1 Gene|FH2 Domain Containing 1 Gene|FHDC1|FHDC1	This gene may play a role in cellular filament polymerization.	FHDC1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114605>	C114604	FHDC1 wt Allele|FH2 Domain Containing 1 wt Allele|INF1|KIAA1727	Human FHDC1 wild-type allele is located in the vicinity of 4q31.3 and is approximately 43 kb in length. This allele, which encodes FH2 domain-containing protein 1, may be involved in cytoskeletal and microtubule dynamics.	FHDC1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114606>	C18466	FH2 Domain-Containing Protein 1|FHDC1|Inverted Formin-1	FH2 domain-containing protein 1 (1143 aa, ~125 kDa) is encoded by the human FHDC1 gene. This protein may play a role in both cell shape and microtubule polymerization.	FH2 Domain-Containing Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114607>	C20744	FERMT2 Gene|FERMT2|FERMT2|Fermitin Family Member 2 Gene	This gene is involved in focal adhesion formation.	FERMT2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114608>	C114607	FERMT2 wt Allele|Fermitin Family (Drosophila) Homolog 2 Gene|Fermitin Family Homolog 2 (Drosophila) Gene|Fermitin Family Member 2 wt Allele|KIND2|MIG2|Mitogen-Inducible Gene 2|PLEKHC1|Pleckstrin Homology Domain Containing, Family C (With FERM Domain) Member 1 Gene|UNC112|UNC112B|Unc112, C. Elegans, Homolog of Gene|mig-2	Human FERMT2 wild-type allele is located in the vicinity of 14q22.1 and is approximately 95 kb in length. This allele, which encodes fermitin family homolog 2 protein, plays a role in both the assembly of focal adhesions and integrin signaling.	FERMT2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114609>	C18073	Fermitin Family Homolog 2|FERMT2|Kindlin 2|Kindlin-2|MIG-2|Mitogen Inducible Gene 2 Protein|Mitogen-Inducible Gene 2 Protein|PH Domain-Containing Family C Member 1|Pleckstrin Homology Domain Containing, Family C Member 1|Pleckstrin Homology Domain-Containing Family C Member 1|Pleckstrin Homology Domain-Containing Protein, Family C, Member 1	Fermitin family homolog 2 (680 aa, ~78 kDa) is encoded by the human FERMT2 gene. This protein is involved in both integrin signaling and focal adhesion assembly.	Fermitin Family Homolog 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11460>	C61063	Cisplatin/Cyclophosphamide/Epirubicin/Etoposide|CDDP/CTX/EPI/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114610>	C20194	FBXO38 Gene|F-Box Protein 38 Gene|FBXO38|FBXO38	This gene may play a role in protein ubiquitination.	FBXO38 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114611>	C114610	FBXO38 wt Allele|F-Box Protein 38 wt Allele|FLJ13962|Fbx38|HMN2D|MOKA|Modulator of Klf7 Activity, Mouse, Homolog of Gene|SP329	Human FBXO38 wild-type allele is located in the vicinity of 5q32 and is approximately 59 kb in length. This allele, which encodes F-box only protein 38, may be involved in protein ubiquitination.	FBXO38 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114612>	C95242	F-Box Only Protein 38|F-Box Protein 38|FBXO38|MoKA|Modulator of KLF7 Activity Homolog	F-box only protein 38 (1188 aa, ~134 kDa) is encoded by the human FBXO38 gene. This protein may play a role in ubiquitination.	F-Box Only Protein 38		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114613>	C28533	UNC13D Gene|UNC13D|UNC13D|Unc-13 Homolog D (C. elegans) Gene	This gene is involved in vesicle maturation and secretion.	UNC13D Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114614>	C114613	UNC13D wt Allele|FHL3|FHL3 / MUNC 13-4 (UNC13D)|HLH3|HPLH3|Munc13-4|Unc-13 Homolog D (C. elegans) wt Allele	Human UNC13D wild-type allele is located in the vicinity of 17q25.1 and is approximately 17 kb in length. This allele, which encodes protein unc-13 homolog D protein, plays a role in the regulation of cytolytic granule secretion. Mutations in this gene are associated with familial hemophagocytic lymphohistiocytosis type 3.	UNC13D wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114615>	C20194	FBXL18 Gene|F-Box and Leucine-Rich Repeat Protein 18 Gene|FBXL18|FBXL18	This gene is involved in protein ubiquitination.	FBXL18 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114616>	C114615	FBXL18 wt Allele|F-Box and Leucine-Rich Repeat Protein 18 wt Allele|FBL18|FLJ11467|Fbl18	Human FBXL18 wild-type allele is located in the vicinity of 7p22.2 and is approximately 82 kb in length. This allele, which encodes F-box/LRR-repeat protein 18, plays a role in both substrate recognition and the regulation of ubiquitination.	FBXL18 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114617>	C16386	Protein Unc-13 Homolog D|UNC13D	Protein unc-13 homolog D (1090 aa, ~123 kDa) is encoded by the human UNC13D gene. This protein is involved in maturation and secretion of cytolytic granules.	Protein Unc-13 Homolog D		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114618>	C26006	STX11 Gene|STX11|STX11|Syntaxin 11 Gene	This gene plays a role in the targeting and fusion of intracellular transport vesicles.	STX11 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114619>	C95242	F-Box/LRR-Repeat Protein 18|F-Box and Leucine-Rich Repeat Protein 18|FBL18|FBXL18	F-box/LRR-repeat protein 18 (805 aa, ~88 kDa) is encoded by the human FBXL18 gene. This protein is involved in the modulation of protein ubiquitination.	F-Box/LRR-Repeat Protein 18		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11461>	C61063	Interferon Alfa/Sargramostim|GM-CSF/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114620>	C114618	STX11 wt Allele|FHL4|FHL4 / Syntaxin 11 (STX11)|HLH4|HPLH4|Syntaxin 11 wt Allele	Human STX11 wild-type allele is located in the vicinity of 6q24.2 and is approximately 41 kb in length. This allele, which encodes syntaxin-11 protein, is involved in the regulation of protein transport between late endosomes and the trans-Golgi network. Mutations in this gene are associated with familial hemophagocytic lymphohistiocytosis type 4.	STX11 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114621>	C16386	Syntaxin-11|STX11	Syntaxin-11 (287 aa, ~33 kDa) is encoded by the human STX11 gene. This protein plays a role in the regulation of both targeting and fusion of intracellular transport vesicles.	Syntaxin-11		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114622>	C28533	STXBP2 Gene|STXBP2|STXBP2|Syntaxin Binding Protein 2 Gene	This gene is involved in intracellular vesicle trafficking.	STXBP2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114623>	C114622	STXBP2 wt Allele|FHL5|FHL5 / MUNC18-2 (STXBP2)|Hunc18b|MUNC18-2|Syntaxin Binding Protein 2 wt Allele|UNC18, C. elegans, Homolog of, 2 Gene|UNC18-2|UNC18B|pp10122|unc-18B	Human STXBP2 wild-type allele is located within 19p13.3-p13.2 and is approximately 11 kb in length. This allele, which encodes syntaxin-binding protein 2, plays a role in intracellular vesicle trafficking and vesicle fusion with membranes. Mutations in this gene are associated with familial hemophagocytic lymphohistiocytosis type 5.	STXBP2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114624>	C16386	Syntaxin-Binding Protein 2|Protein Unc-18 Homolog 2|Protein Unc-18 Homolog B|STXBP2|Unc-18B|Unc18-2|pp10122	Syntaxin-binding protein 2 (593 aa, ~66 kDa) is encoded by the human STXBP2 gene. This protein is involved in intracellular vesicle trafficking and membrane fusion.	Syntaxin-Binding Protein 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114625>	C25939	ERO1A Gene|ERO1A|ERO1A|ERO1L|Endoplasmic Reticulum Oxidoreductase 1 Alpha Gene	This gene plays a role in both protein oxidation and disulfide bond formation.	ERO1A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114626>	C114625	ERO1A wt Allele|ERO1 (S. cerevisiae)-Like Gene|ERO1, S. cerevisiae, Homolog of Gene|ERO1-Alpha|ERO1-Like (S. cerevisiae) Gene|ERO1-Like, Alpha Gene|ERO1L|ERO1LA|Endoplasmic Reticulum Oxidoreductase 1 Alpha wt Allele|Endoplasmic Reticulum Oxidoreductin 1-Like Gene|Ero1alpha|UNQ434/PRO865	Human ERO1A wild-type allele is located in the vicinity of 14q22.1 and is approximately 56 kb in length. This allele, which encodes ERO1-like protein alpha, is involved in protein folding.	ERO1A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114627>	C16946	ERO1-Like Protein Alpha|EC 1.8.4.-|ERO1-L|ERO1-L-Alpha|ERO1A|ERO1L|Endoplasmic Oxidoreductin-1-Like Protein|Oxidoreductin-1-L-Alpha	ERO1-like protein alpha (468 aa, ~54 kDa) is encoded by the human ERO1A gene. This protein plays a role in the modulation of both oxidation of and disulfide bond formation in proteins.	ERO1-Like Protein Alpha		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114628>	C21240	EIF3K Gene|EIF3K|EIF3K|Eukaryotic Translation Initiation Factor 3, Subunit K Gene	This gene is involved in translation initiation.	EIF3K Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114629>	C163725	Mast Cell Degranulation|Degranulation|Mast Cell Granule Exocytosis	The regulated exocytosis of secretory granules by a mast cell.			Cell Function	
C11462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11462>	C61063	Cisplatin/Dimesna/Paclitaxel|CDDP/DIM/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114630>	C114628	EIF3K wt Allele|ARG134|EIF3-p28|EIF3S12|Eukaryotic Translation Initiation Factor 3, Subunit 12 Gene|Eukaryotic Translation Initiation Factor 3, Subunit K wt Allele|HSPC029|M9|MSTP001|PLAC-24|PLAC24|PRO1474|PTD001|eIF3k	Human EIF3K wild-type allele is located in the vicinity of 19q13.2 and is approximately 18 kb in length. This allele, which encodes eukaryotic translation initiation factor 3 subunit K protein, plays a role in the initiation of protein synthesis.	EIF3K wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114631>	C17461	Eukaryotic Translation Initiation Factor 3 Subunit K|EIF3K|Eukaryotic Translation Initiation Factor 3 Subunit 12|Muscle-Specific Gene M9 Protein|PLAC-24|eIF-3 p25|eIF-3 p28	Eukaryotic translation initiation factor 3 subunit K (218 aa, ~25 kDa) is encoded by the human EIF3K gene. This protein is involved in both ribosomal binding and preinitiation complex formation.	Eukaryotic Translation Initiation Factor 3 Subunit K		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114632>	C21295	DAZL Gene|DAZL|DAZL|Deleted In Azoospermia Like Gene	This gene plays a role in gametogenesis	DAZL Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114633>	C114632	DAZL wt Allele|DAZH|DAZL1|DAZLA|Deleted In Azoospermia Homolog Gene|Deleted In Azoospermia Like wt Allele|Deleted In Azoospermia-Like Gene|MGC26406|SPGYLA|Spermatogenesis Gene On The Y-Like Autosomal Gene	Human DAZL wild-type allele is located in the vicinity of 3p24 and is approximately 84 kb in length. This allele, which encodes deleted in azoospermia-like protein, is involved in male and female gametogenesis.	DAZL wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114634>	C21298	Deleted In Azoospermia-Like|DAZ Homolog|DAZ-Like Autosomal|Deleted In Azoospermia-Like 1|Germline Specific RNA Binding Protein|SPGY-Like-Autosomal	Deleted in azoospermia-like (295 aa, ~33 kDa) is encoded by the human DAZL gene. This protein plays a role in gametogenesis.	Deleted In Azoospermia-Like		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114635>	C91103	Still Enjoy the Things I Used to Enjoy Question|I still enjoy the things I used to enjoy|Still Enjoy the Things I Used to Enjoy	A question about whether an individual still enjoys the things they used to enjoy.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C114636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114636>	C173160	Get a Frightened Feeling Like Something Awful will Happen Question|Get a Frightened Feeling Like Something Awful will Happen|I get a sort of frightened feeling as if something awful is about to happen	A question about whether an individual feels or has felt frightened, as if something awful is about to happen.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C114637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114637>	C91103	Can Laugh Question|Can Laugh|I can laugh and see the funny side of things	A question about whether an individual feels or has felt that they can laugh at things.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C114638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114638>	C173934|C173597	Have Worrying Thoughts Question|Have Worrying Thoughts|Worrying thoughts go through my mind	A question about whether an individual has or had worrying thoughts.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C114639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114639>	C173160	Feel Cheerful Question|Feel Cheerful|I feel cheerful	A question about whether an individual feels or has felt cheerful.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C11463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11463>	C61063	Etoposide/Idarubicin|IDA/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114640>	C173160	Can Sit at Ease and Feel Relaxed Question|Can Sit at Ease and Feel Relaxed|I can sit at ease and feel relaxed	A question about whether an individual feels or has felt that they can sit at ease and feel relaxed.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C114641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114641>	C38052	Periodontal Screening and Recording|PSR	A system for assessing the health of the gums as based on the depth of the gingival sulci. The periodontal screening and recording (PSR) index divides the mouth into 6 segments (sextants) and the greatest probe depth in each sextant of the mouth is determined and recorded.			Health Care Activity	
C114642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114642>	C26511	CYP39A1 Gene|CYP39A1|CYP39A1|Cytochrome P450, Family 39, Subfamily A, Polypeptide 1 Gene	This gene is involved in bile acid metabolism.	CYP39A1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114643>	C62058	Ball-Tipped Periodontal Probe	A periodontal probe with a 0.5mm diameter ball tip and a color-coded band extending 3.5mm to 5.5 mm from the tip. It is typically used to determine sulcus depth for periodontal screening and recording.			Medical Device	
C114644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114644>	C114642	CYP39A1 wt Allele|Cytochrome P450, Family 39, Subfamily A, Polypeptide 1 wt Allele|Cytochrome P450, Subfamily XXXIX (Oxysterol 7 Alpha-Hydroxylase), Polypeptide 1 Gene	Human CYP39A1 wild-type allele is located within 6p21.1-p11.2 and is approximately 103 kb in length. This allele, which encodes 24-hydroxycholesterol 7-alpha-hydroxylase protein, plays a role in the metabolism of both cholesterol and bile acids.	CYP39A1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114645>	C38617	Gingival Sulcus	The space between a tooth and the surrounding gingival tissue and lined by the sulcular epithelium.			Body Part, Organ, or Organ Component	
C114646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114646>	C16484	24-Hydroxycholesterol 7-Alpha-Hydroxylase|CYP39A1|Cytochrome P450 39A1|Cytochrome P450, Subfamily XXXIX Polypeptide 1|EC 1.14.13.99|Oxysterol 7-Alpha-Hydroxylase|hCYP39A1	24-hydroxycholesterol 7-alpha-hydroxylase (469 aa, ~54 kDa) is encoded by the human CYP39A1 gene. This protein is involved in the conversion of cholesterol to bile acids.	24-Hydroxycholesterol 7-Alpha-Hydroxylase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114647>	C25338	Periodontal Screening and Recording Code	A score that indicates the health of the gums based on the depth of the gingival sulci.			Quantitative Concept	
C114648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114648>	C114647	Periodontal Screening and Recording Code 0|Code 0|PSR Code 0	Indicates that all probing depth in the sextant is less than 3.5mm, with no calculus or defective margins or bleeding on probing detected.			Quantitative Concept	
C114649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114649>	C114647	Periodontal Screening and Recording Code 1|Code 1|PSR Code 1	Indicates that all probing depth in the sextant is less than 3.5mm, but with bleeding present upon probing.			Quantitative Concept	
C11464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11464>	C61063	Cytarabine/Idarubicin/Recombinant Human Thrombopoietin|ARA-C/IDA/rhTPO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114650>	C114647	Periodontal Screening and Recording Code 2|Code 2|PSR Code 2	Indicates that all probing depth in the sextant is less than 3.5mm, but with supragingival or subgingival calculus and/or defective margins present.			Quantitative Concept	
C114651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114651>	C114647	Periodontal Screening and Recording Code 3|Code 3|PSR Code 3	Indicates that the deepest probing depth in the sextant is greater than 3.5mm but less than 5.5mm.			Quantitative Concept	
C114652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114652>	C114647	Periodontal Screening and Recording Code 4|Code 4|PSR Code 4	Indicates that the deepest probing depth in the sextant is greater than 5.5mm.			Quantitative Concept	
C114653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114653>	C20194	CUTA Gene|CUTA|CUTA|CutA Divalent Cation Tolerance Homolog Gene	This gene may play a role in acetylcholine metabolism.	CUTA Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114654>	C114653	CUTA wt Allele|ACHAP|C6orf82|Chromosome 6 Open Reading Frame 82 Gene|CutA Divalent Cation Tolerance Homolog (E. coli) Gene|CutA Divalent Cation Tolerance Homolog wt Allele|CutA, E. coli, Homolog of Gene|DASS-97D12.5	Human CUTA wild-type allele is located in the vicinity of 6p21.32 and is approximately 2 kb in length. This allele, which encodes protein CutA, may be involved in acetylcholinesterase localization.	CUTA wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114655>	C18466	Protein CutA|Acetylcholinesterase-Associated Protein|Brain Acetylcholinesterase Putative Membrane Anchor|Divalent Cation Tolerant Protein CUTA	Protein CutA (179 aa, ~19 kDa) is encoded by the human CUTA gene. This protein may play a role in acetylcholinesterase activity.	Protein CutA		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114656>	C7558|C215423	Endometrial Adenosquamous Carcinoma|Endometrial Adenosquamous Cancer	A rare endometrial carcinoma characterized by the presence of both malignant glandular and malignant squamous cellular components.	Endometrial Adenosquamous Carcinoma		Neoplastic Process	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology|NCIt Neoplasm Core Terminology
C114657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114657>	C26006	CTAGE5 Gene|CTAGE Family, Member 5 Gene|CTAGE5|CTAGE5	This gene is involved in endoplasmic reticulum-to-Golgi protein transport and tumor induction of immune responses.	CTAGE5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114658>	C114657	CTAGE5 wt Allele|CTAGE Family Member 5, ER Export Factor Gene|CTAGE Family, Member 5 wt Allele|Cutaneous T-Cell Lymphoma-Associated Antigen 5 Gene|MEA11|MEA6|MGEA|MGEA11|MGEA6|MIA2|Meningioma Expressed Antigen 6 (Coiled-Coil Proline-Rich) Gene|cTAGE-5A|cTAGE-5B|cTAGE-5C|cTAGE-5D	Human CTAGE5 wild-type allele is located in the vicinity of 14q13.3 and is approximately 122 kb in length. This allele, which encodes endoplasmic reticulum export factor CTAGE5 protein, plays a role in the protein transport and induction of the immune response.	CTAGE5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114659>	C16386	Endoplasmic Reticulum Export Factor CTAGE5|CTAGE Family Member 5 ER Export Factor|CTAGE5|Cutaneous T-Cell Lymphoma-Associated Antigen 5|Meningioma-Expressed Antigen 6/11|Protein cTAGE-5|cTAGE Family Member 5|cTAGE Family Member 5	Endoplasmic reticulum export factor CTAGE5 (804 aa, ~91 kDa) is encoded by the human CTAGE5 gene. This protein is involved in intracellular protein transport and tumor induced immune responses.	cTAGE Family Member 5		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11465>	C61063	Cyclophosphamide/Cytarabine/Hydrocortisone/Leucovorin Calcium|ARA-C/CF/CTX/HC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114660>	C20194	BBS9 Gene|BBS9|BBS9|Bardet-Biedl Syndrome 9 Gene	This gene plays a role in ciliogenesis.	BBS9 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114661>	C114660	BBS9 wt Allele|B1|Bardet-Biedl Syndrome 9 wt Allele|C18|D1|PTH-Responsive B1 Gene|PTHB1|Parathyroid Hormone Responsive B1 Gene|Parathyroid Hormone-Responsive B1 Gene	Human BBS9 wild-type allele is located in the vicinity of 7p14 and is approximately 477 kb in length. This allele, which encodes protein PTHB1, is involved in ciliogenesis. Mutation of both copies of this gene is associated with Bardet-Biedl syndrome 9.	BBS9 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114662>	C18466	Protein PTHB1|BBS9|Bardet-Biedl Syndrome 9 Protein|PTH-Responsive Osteosarcoma B1 Protein|Parathyroid Hormone-Responsive B1 Gene Protein	Protein PTHB1 (887 aa, ~99 kDa) is encoded by the human BBS9 gene. This protein plays a role in cilium formation.	Protein PTHB1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114663>	C28533|C158414	ATP8B2 Gene|ATP8B2|ATP8B2|ATPase, Aminophospholipid Transporter, Class I, Type 8B, Member 2 Gene	This gene is involved in phospholipid transport.	ATP8B2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114664>	C114663	ATP8B2 wt Allele|ATPID|ATPase, Aminophospholipid Transporter, Class I, Type 8B, Member 2 wt Allele|ATPase, Class I, Type 8B, Member 2 Gene|KIAA1137|RP11-350G8.2	Human ATP8B2 wild-type allele is located in the vicinity of 1q21.3 and is approximately 26 kb in length. This allele, which encodes probable phospholipid-transporting ATPase ID protein, plays a role in aminophospholipid translocation.	ATP8B2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114665>	C16386|C158419	Phospholipid-Transporting ATPase ID|ATP8B2|ATPase Class I Type 8B Member 2|EC 3.6.3.1, Formerly|EC 7.6.2.1|P4-ATPase Flippase Complex Alpha Subunit ATP8B2|Probable Phospholipid-Transporting ATPase ID	Phospholipid-transporting ATPase ID (1209 aa, ~137 kDa) is encoded by the human ATP8B2 gene. This protein is involved in the translocation of aminophospholipids.	Phospholipid-Transporting ATPase ID		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114666>	C26738	Hemorrhagic Cystitis	Inflammation of the bladder resulting in bloody urine.			Disease or Syndrome	GDC Terminology|GDC Value Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114667>	C27600|C114688	Nephrolithiasis|Kidney Stone|Kidney Stone|Renal Calculi|Renal Calculi	The presence of a calculus in the pelvis of the kidney; this is most often composed of mineral salts and proteins.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114668>	C173160	Feel Slowed Down Question|Feel Slowed Down|I feel as if I am slowed down	A question about whether an individual feels or has felt that they are slowed down.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C114669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114669>	C173160	Get a Frightened Feeling Like Butterflies in the Stomach Question|Get a Frightened Feeling Like Butterflies in the Stomach|I get a sort of frightened feeling like 'butterflies' in the stomach	A question about whether an individual feels or has felt frightened, like butterflies in the stomach.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C11466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11466>	C61063	Fenretinide/Tretinoin|ATRA/HPR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114670>	C91103	Have Lost Interest in Appearance Question|Have Lost Interest in Appearance|I have lost interest in my appearance	A question about whether an individual feels or has felt that they have lost interest in their appearance.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C114671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114671>	C173160	Feel Restless Question|Feel Restless|I feel restless as if I have to be on the move	A question about whether an individual feels or has felt restless.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C114672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114672>	C28404	ATG4C Gene|ATG4C|ATG4C|Autophagy Related 4C, Cysteine Peptidase Gene	This gene plays a role in autophagy.	ATG4C Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114673>	C114672	ATG4C wt Allele|APG4 Autophagy 4 Homolog C (S. cerevisiae) Gene|APG4, S. cerevisiae, Homolog of, C Gene|APG4-C|APG4C|ATG4 Autophagy Related 4 Homolog C (S. cerevisiae) Gene|AUT (S. cerevisiae)-Like 1, Cysteine Endopeptidase Gene|AUT-Like 1, Cysteine Endopeptidase (S. cerevisiae) Gene|AUTL1|AUTL3|Autophagy 4, S. cerevisiae, Homolog of, C Gene|Autophagy Related 4C, Cysteine Peptidase wt Allele|FLJ14867	Human ATG4C wild-type allele is located in the vicinity of 1p31.3 and is approximately 81 kb in length. This allele, which encodes cysteine protease ATG4C protein, is involved in proteolysis during autophagy.	ATG4C wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114674>	C91103	Look Forward with Enjoyment Question|I look forward with enjoyment to things|Look Forward with Enjoyment	A question about whether an individual looks forward to things with enjoyment.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C114675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114675>	C16481	Cysteine Protease ATG4C|APG4 Autophagy 4 Homolog C|ATG4 Autophagy Related 4 Homolog C|ATG4C|AUT-Like 1, Cysteine Endopeptidase|AUT-Like 3 Cysteine Endopeptidase|Autophagin 3|Autophagin-3|Autophagy-Related Cysteine Endopeptidase 3|Autophagy-Related Protein 4 Homolog C|EC 3.4.22.-	Cysteine protease ATG4C (458 aa, ~52 kDa) is encoded by the human ATG4C gene. This protein plays a role in proteolysis of autophagy-regulatory proteins.	Cysteine Protease ATG4C		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114676>	C173160	Get Feelings of Panic Question|Get Feelings of Panic|I get sudden feelings of panic	A question about whether an individual feels or has felt sudden feelings of panic.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C114677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114677>	C91103	Can Enjoy a Book, Radio, or TV Program Question|Can Enjoy a Book, Radio, or TV Program|I can enjoy a good book or radio or TV program	A question about whether an individual feels or has felt that they can enjoy a book, radio, or TV program.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C114678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114678>	C175311	A Lot of the Time|A lot|A lot of the time	A response indicating that something happens or happened a lot of the time.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire|Memorial Symptom Assessment Scale (MSAS) 7-12
C114679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114679>	C226684|C226671	Definitely as Much|Definitely as much	A response indicating a certainty that something occurs with the same frequency or intensity as previously.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C11467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11467>	C61063	Melphalan/Prednisolone|L-PAM/PRDL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114680>	C226693	Not Quite so Much|Not quite so much|Not quite so much now	A response indicating that something occurs with a bit less frequency or intensity as previously.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C114681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114681>	C26006	ARFIP1 Gene|ADP-Ribosylation Factor Interacting Protein 1 Gene|ARFIP1|ARFIP1	This gene may be involved in vesicle trafficking.	ARFIP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114682>	C114681	ARFIP1 wt Allele|ADP-Ribosylation Factor Interacting Protein 1 wt Allele|HSU52521	Human ARFIP1 wild-type allele is located in the vicinity of 4q31.3 and is approximately 139 kb in length. This allele, which encodes arfaptin-1 protein, may play a role in vesicular transport.	ARFIP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114683>	C16386	Arfaptin-1|ADP-Ribosylation Factor-Interacting Protein 1|ARFIP1|Arfaptin 1	Arfaptin-1 (373 aa, ~42 kDa) is encoded by the human ARFIP1 gene. This protein may be involved in intracellular vesicle trafficking.	Arfaptin-1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114684>	C226692	Only a Little|A Little|A Little|Little|Only a little	A response indicating that something occurs with little frequency or intensity.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire|Memorial Symptom Assessment Scale (MSAS) 7-12
C114685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114685>	C226693	Hardly at All|Hardly|Hardly at all|barely at all	A response indicating that something occurs rarely or with very little intensity.			Intellectual Product	Food Allergy Quality of Life Questionnaire - Parent Form 10|Hospital Anxiety and Depression Scale Questionnaire
C114686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114686>	C226684|C226633	Very Definitely and Quite Badly|Very definitely and quite badly	A response indicating a certainty that something occurs with high intensity.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C114687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114687>	C25870	AGPAT5 Gene|1-Acylglycerol-3-Phosphate O-Acyltransferase 5 Gene|AGPAT5|AGPAT5	This gene plays a role in phospholipid metabolism.	AGPAT5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114688>	C27599	Urolithiasis|Urinary Stones	Stone(s) within the urinary tract.			Disease or Syndrome	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|Cellosaurus Disease Terminology|CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Nephrology Terminology
C114689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114689>	C114687	AGPAT5 wt Allele|1-Acylglycerol-3-Phosphate O-Acyltransferase 5 (Lysophosphatidic Acid Acyltransferase, Epsilon) Gene|1-Acylglycerol-3-Phosphate O-Acyltransferase 5 wt Allele|1AGPAT5|FLJ11210|LPAAT-Epsilon|LPAAT-e|LPAATE	Human AGPAT5 wild-type allele is located in the vicinity of 8p23.1 and is approximately 53 kb in length. This allele, which encodes 1-acyl-sn-glycerol-3-phosphate acyltransferase epsilon protein, is involved in lysophosphatidic acid metabolism.	AGPAT5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11468>	C61063	Dexamethasone/Idarubicin/Lomustine|CCNU/DM/IDA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114690>	C16259	1-Acyl-Sn-Glycerol-3-Phosphate Acyltransferase Epsilon|1-AGP Acyltransferase 5|1-AGPAT 5|1-Acyl-Sn-Glycerol-3-Phosphate O-Acyltransferase 5|1-Acylglycerol-3-Phosphate O-Acyltransferase 5|AGPAT5|EC 2.3.1.51|LPAAT-Epsilon|Lysophosphatidic Acid Acyltransferase Epsilon|Lysophosphatidic Acid Acyltransferase, Epsilon|Lysophosphatidic Acid Acyltransferase-Epsilon	1-acyl-sn-glycerol-3-phosphate acyltransferase epsilon (364 aa, ~42 kDa) is encoded by the human AGPAT5 gene. This protein plays a role in the synthesis of phosphatidic acid from lysophosphatidic acid.	1-Acyl-Sn-Glycerol-3-Phosphate Acyltransferase Epsilon		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114691>	C25993	ASIC2 Gene|ASIC2|ASIC2|Acid-Sensing (Proton-Gated) Ion Channel 2 Gene	This gene is involved in both cation transport and membrane potential.	ASIC2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114692>	C176244	Yes, But Not Too Badly|Yes, but not too badly	A response indicating that something occurs with moderate intensity.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C114693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114693>	C114691	ASIC2 wt Allele|ACCN|ACCN1|ASIC2a|Acid-Sensing (Proton-Gated) Ion Channel 2 wt Allele|BNC1|BNaC1|Cation Channel, Amiloride-Sensitive, Neuronal, 1 Gene|MDEG|Mammalian Degenerin Gene|Sodium Channel, Nonvoltage-Gated, Neuronal, 1 Gene|hBNaC1	Human ASIC2 wild-type allele is located in the vicinity of 17q12 and is approximately 1162 kb in length. This allele, which encodes acid-sensing ion channel 2 protein, plays a role in the modulation of membrane potential through proton-gated cation transport.	ASIC2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114694>	C175346	A Little, But it Doesn't Worry Me|A little, but it doesn't worry me	A response indicating that something occurs, but causes little concern.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C114695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114695>	C226684|C226671	As Much as Always|As much as I always could|As much as ever I did	A response indicating that something occurs with the same frequency or intensity as previously.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C114696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114696>	C27603|C114688	Ureterolithiasis	The presence of a calculus in the ureter of the kidney; this is most often composed of mineral salts and proteins.			Disease or Syndrome	
C114697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114697>	C28505	Acid-Sensing Ion Channel 2|ASIC2|Amiloride-Sensitive Brain Sodium Channel|Amiloride-Sensitive Cation Channel 1, Neuronal|Amiloride-Sensitive Cation Channel Neuronal 1|BNC1|BNaC1|Brain Sodium Channel 1|Degenerin|Mammalian Degenerin Homolog|Neuronal Amiloride-Sensitive Cation Channel 1	Acid-sensing ion channel 2 (512 aa, ~58 kDa) is encoded by the human ASIC2 gene. This protein is involved in both synaptic transmission and cation transport.	Acid-Sensing Ion Channel 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114698>	C36286	Oliguria|Decreased Urine Output	Abnormally low urine output.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114699>	C36286	Anuria	Absence of urine output.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11469>	C61007	Carboplatin/Gemcitabine|CBDCA/dFdC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1146>	C798|C1744	Lonidamine|AF 1890|Diclondazolic Acid|Doridamina|LONIDAMINE	An indazole carboxylic acid derivative that exhibits radiosensitizing and antiparasitic effects and interferes with the multidrug resistance mechanism.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C114700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114700>	C21295	ACBD6 Gene|ACBD6|ACBD6|Acyl-CoA Binding Domain Containing 6 Gene	This gene plays a role in lipid binding.	ACBD6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114701>	C114700	ACBD6 wt Allele|Acyl-CoA Binding Domain Containing 6 wt Allele|MGC2404	Human ACBD6 wild-type allele is located in the vicinity of 1q25.1 and is approximately 228 kb in length. This allele, which encodes acyl-CoA-binding domain-containing protein 6, is involved in binding to acylated coenzyme A.	ACBD6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114702>	C3090	Gross Hematuria|Visible Hematuria|Visible Hematuria	The visible presence of blood in the urine.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114703>	C17728	Acyl-CoA-Binding Domain-Containing Protein 6|ACBD6|Acyl-Coenzyme A Binding Domain Containing 6	Acyl-CoA-binding domain-containing protein 6 (282 aa, ~31 kDa) is encoded by the human ACBD6 gene. This protein plays a role in acyl-coenzyme A binding.	Acyl-CoA-Binding Domain-Containing Protein 6		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114704>	C226684|C226671	Definitely Not So Much|Definitely not so much now	A response indicating a certainty that something occurs with little frequency or intensity.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C114705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114705>	C35457	Myoglobinuria	The presence of myoglobin in the urine.			Laboratory or Test Result	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114706>	C175311	A Great Deal of the Time|A great deal of the time	A response indicating that something happens or happened much of the time.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C114707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114707>	C35457	Hypercalciuria|Hypercalcuria	Abnormally high level of calcium in the urine.			Laboratory or Test Result	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114708>	C35457	Hypocitraturia	Abnormally low level of citrate in the urine.			Laboratory or Test Result	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114709>	C226671	Not Often|Not often	A response indicating that something happens or happened infrequently.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C11470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11470>	C61007	Filgrastim/Sargramostim|G-CSF/GM-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114711>	C226671	Usually	A response indicating that something happens or happened most of the time.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C114712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114712>	C175311	Nearly All the Time|Nearly All of the Time|Nearly all the time	A response indicating that something happens or happened nearly all of the time.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C114713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114713>	C226671	Quite Often|Quite often	A response indicating that something happens or happened frequently.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C114714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114714>	C78254	Dialysis Membrane Reaction|Dialyzer Reaction|Dialyzer Reaction	A severe hypersensitivity-like reaction occurring during dialysis due to exposure to the dialysis membrane.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114715>	C226644	Don't Take Much Care|I don't take so much care as I should	A response indicating that an individual does not take as much care as they should.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C114716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114716>	C226644	May Not Take as Much Care|I may not take quite as much care	A response indicating that an individual may not take as much care as they should.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C114717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114717>	C78254	Dialysis Catheter Fracture	A crack or break in a dialysis catheter caused by material weakness or mechanical compression.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114718>	C226644	Take as Much Care|I take just as much care as ever	A response indicating that an individual takes as much care as they always have.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C114719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114719>	C226693	Not Very Much|Not very much	A subjective answer of disagreement.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C11471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11471>	C61063	gp209-2M Antigen/Incomplete Freund's Adjuvant/Interleukin-2|gp209-2M/IFA/IL-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114720>	C226684|C226671	Rather Less|Rather less than I used to	A response indicating that something occurs with less frequency or intensity as previously.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C114721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114721>	C226684|C226671	Definitely Less|Definitely less than I used to	A response indicating a certainty that something occurs with much less frequency or intensity as previously.			Intellectual Product	Hospital Anxiety and Depression Scale Questionnaire
C114722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114722>	C26759	Dialysis Catheter Embolism	An obstruction of a vessel caused by a detached fragment of an indwelling dialysis catheter.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114723>	C78232	Dialysis Catheter Infection	A local or systemic infection associated with the use of a dialysis catheter.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114724>	C114723	Hemodialysis Catheter Infection	A local or systemic infection associated with the use of a hemodialysis catheter.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114725>	C114723	Peritoneal Dialysis Catheter Infection	A local or systemic infection associated with the use of a peritoneal dialysis catheter.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114726>	C114723	Dialysis Catheter Tunnel Infection|Tunnel Infection Associated with Dialysis Access|Tunnel Infection Associated with Dialysis Access	Local infection involving the subcutaneously tunneled portion of a dialysis catheter.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114727>	C114723	Dialysis Catheter Exit Site Infection	Local infection at the dialysis catheter exit site.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114728>	C114724	Hemodialysis Catheter-Associated Bacteremia	The presence of bacteria in the blood caused by an infected hemodialysis catheter.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114729>	C41515	Pyroptosis	An inflammatory form of programmed cell death characterized by caspase-dependent formation of plasma-membrane pores, which leads to pathological changes in osmotic potential that ultimately result in cellular lysis and release of pro-inflammatory cytokines. It occurs most frequently following infection with intracellular pathogens, but also has a role in tumor suppression and the initiation of anti-tumor immune responses, as well as in autoimmune and cardiovascular diseases.			Phenomenon or Process	
C11472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11472>	C61007	Cyclophosphamide/Rituximab|CTX/MOAB IDEC-C2B8			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114730>	C16263	Plasma Membrane Calcium-Transporting ATPase|ATP2B|EC 3.6.3.8|PMCA|Plasma Membrane Ca2+ ATPase|Plasma Membrane Calcium ATPase|Plasma Membrane Calcium Pump	A family of plasma membrane resident proteins that hydrolyze ATP to facilitate the transport of calcium ions out of the cytoplasm into the extracellular space.			Amino Acid, Peptide, or Protein|Enzyme	
C114731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114731>	C21295	MPRIP Gene|MPRIP|MPRIP|Myosin Phosphatase Rho Interacting Protein Gene	This gene plays a role in myosin function.			Gene or Genome	
C114732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114732>	C114731	MPRIP wt Allele|KIAA0864|M-RIP|MRIP|Myosin Phosphatase Rho Interacting Protein wt Allele|RHOIP3|RIP3|p116Rip	Human MPRIP wild-type allele is located in the vicinity of 17p11.2 and is approximately 175 kb in length. This allele, which encodes myosin phosphatase Rho-interacting protein, is involved in the modulation of myosin phosphorylation.			Gene or Genome	
C114733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114733>	C17728	Myosin Phosphatase Rho-Interacting Protein|M-RIP|MPRIP|RIP3|Rho Interacting Protein 3|Rho-Interacting Protein 3|p116 Rho-Interacting Protein|p116Rip	Myosin phosphatase Rho-interacting protein (1025 aa, ~117 kDa) is encoded by the human MPRIP gene. This protein plays a role in the recruitment of myosin phosphatase to the cytoskeleton.			Amino Acid, Peptide, or Protein	
C114734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114734>	C20917	WAPL Gene|WAPL|WAPL|WAPL Cohesin Release Factor Gene	This gene is involved in both DNA replication and sister chromatid cohesion.			Gene or Genome	
C114735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114735>	C114734	WAPL wt Allele|FOE|Friend of EBNA2 (Epstein-Barr Virus Nuclear Protein 2) Gene|Friend of EBNA2 Gene|KIAA0261|RP11-396M20.1|WAPAL|WAPL Cohesin Release Factor wt Allele|Wings Apart-Like Homolog (Drosophila) Gene|Wings Apart-Like Protein, Drosophila, Homolog of Gene	Human WAPL wild-type allele is located in the vicinity of 10q23.2 and is approximately 87 kb in length. This allele, which encodes wings apart-like protein homolog, plays a role in mitosis, meiosis and DNA replication.			Gene or Genome	
C114736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114736>	C17761	Wings Apart-Like Protein Homolog|Friend of EBNA2 Protein|WAPL|WAPL Cohesin Release Factor	Wings apart-like protein homolog (1190 aa, ~133 kDa) is encoded by the human WAPL gene. This protein is involved in meiosis, mitosis and DNA replication.			Amino Acid, Peptide, or Protein	
C114737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114737>	C26070	SYNJ1 Gene|SYNJ1|SYNJ1|Synaptojanin 1 Gene	This gene plays a role in clathrin-mediated endocytosis.			Gene or Genome	
C114738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114738>	C114737	SYNJ1 wt Allele|INPP5G|Inositol 5'-Phosphatase (Synaptojanin 1) Gene|KIAA0910|PARK20|Synaptojanin 1 wt Allele	Human SYNJ1 wild-type allele is located in the vicinity of 21q22.2 and is approximately 99 kb in length. This allele, which encodes synaptojanin-1 protein, is involved in the modulation of clathrin-coated vesicle endocytosis. Mutation of the gene is associated with early onset Parkinson disease 20.			Gene or Genome	
C114739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114739>	C16981	Synaptojanin-1|EC 3.1.3.36|SYNJ1|Synaptic Inositol 1,4,5-Trisphosphate 5-Phosphatase 1|Synaptic Inositol-1,4,5-Trisphosphate 5-Phosphatase 1|Synaptojanin 1|Synaptojanin-1, Polyphosphoinositide Phosphatase	Synaptojanin-1 (1573 aa, ~173 kDa) is encoded by the human SYNJ1 gene. This protein plays a role in vesicle endocytosis.			Amino Acid, Peptide, or Protein|Enzyme	
C11473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11473>	C61063	Docetaxel/Estramustine/Mitoxantrone/Prednisone|EM/DHAD/PRED/TXT			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114740>	C20420	ZNF281 Gene|ZNF281|ZNF281|Zinc Finger Protein 281 Gene	This gene is involved in both transcriptional repression and cell differentiation.			Gene or Genome	
C114741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114741>	C114740	ZNF281 wt Allele|GZP1|ZBP-99|ZBP99|ZNP-99|Zinc Finger Protein 281 wt Allele	Human ZNF281 wild-type allele is located in the vicinity of 1q32.1 and is approximately 4 kb in length. This allele, which encodes zinc finger protein 281, plays a role in the regulation of cell differentiation and the modulation of gene transcription.			Gene or Genome	
C114742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114742>	C17207	Zinc Finger Protein 281|GC-Box-Binding Zinc Finger Protein 1|Transcription Factor ZBP-99|ZNF281|ZNP-99 Transcription Factor|Zinc Finger DNA-Binding Protein 99	Zinc finger protein 281 (895 aa, ~97 kDa) is encoded by the human ZNF281 gene. This protein is involved in the modulation of both gene expression and cell differentiation.			Amino Acid, Peptide, or Protein	
C114743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114743>	C20409|C20347	BCL2L12 Gene|BCL2-Like 12 (Proline Rich) Gene|BCL2L12|BCL2L12|BCL2L12	This gene is involved in the regulation of apoptosis.	BCL2L12 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C114744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114744>	C114743	BCL2L12 wt Allele|BCL2-Like 12 (Proline Rich) wt Allele|BCL2-Like 12 Gene|BPR	Human BCL2L12 wild-type allele is located in the vicinity of 19q13.3 and is approximately 9 kb in length. This allele, which encodes Bcl-2-like protein 12, plays a role in the negative regulation of apoptosis. Aberrant expression of the gene is associated with various cancers.	BCL2L12 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114745>	C19928	Bcl-2-Like Protein 12|Bcl-2 Related Proline-Rich Protein|Bcl-2-Related Proline-Rich Protein|Bcl2-L-12	Bcl-2-like protein 12 (334 aa, ~37 kDa) is encoded by the human BCL2L12 gene. This protein is involved in the inhibition of apoptosis.	Bcl-2-Like Protein 12		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114746>	C25873	PDK4 Gene|PDK4|PDK4|Pyruvate Dehydrogenase Kinase, Isozyme 4 Gene	This gene plays a role in the regulation of glucose and fatty acid metabolism.	PDK4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114747>	C114746	PDK4 wt Allele|PDHK4|Pyruvate Dehydrogenase Kinase, Isoenzyme 4 Gene|Pyruvate Dehydrogenase Kinase, Isozyme 4 wt Allele	Human PDK4 wild-type allele is located in the vicinity of 7q21.3 and is approximately 13 kb in length. This allele, which encodes [pyruvate dehydrogenase [lipoamide]] kinase isozyme 4, mitochondrial protein, is involved in the modulation of pyruvate dehydrogenase activity.	PDK4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114748>	C17325	[Pyruvate Dehydrogenase [Lipoamide]] Kinase Isozyme 4, Mitochondrial|EC 2.7.11.2|PDK4|Pyruvate Dehydrogenase Kinase Isoform 4|Pyruvate Dehydrogenase, Lipoamide, Kinase Isozyme 4, Mitochondrial|[Pyruvate Dehydrogenase (Acetyl-Transferring)] Kinase Isozyme 4, Mitochondrial	[Pyruvate dehydrogenase [lipoamide]] kinase isozyme 4, mitochondrial (411 aa, ~46 kDa) is encoded by the human PDK4 gene. This protein plays a role in the inhibition of pyruvate dehydrogenase activity.	[Pyruvate Dehydrogenase [Lipoamide]] Kinase Isozyme 4, Mitochondrial		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114749>	C7715|C4247	Childhood Undifferentiated Pleomorphic Sarcoma|Childhood Malignant Fibrous Histiocytoma|Childhood Unclassified Pleomorphic Sarcoma|Undifferentiated Pleomorphic Sarcoma	An undifferentiated pleomorphic sarcoma that occurs during childhood.	Childhood Undifferentiated Pleomorphic Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C11474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11474>	C61063	Cyclosporine/Etoposide/Vincristine|CYSP/VCR/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114750>	C8563|C189017	Childhood Undifferentiated High Grade Pleomorphic Sarcoma of Bone|Childhood Malignant Fibrous Histiocytoma of Bone|Childhood Undifferentiated High Grade Pleomorphic Sarcoma|Childhood Undifferentiated High-Grade Pleomorphic Sarcoma of Bone|Undifferentiated High Grade Pleomorphic Sarcoma of Bone	An undifferentiated high-grade pleomorphic sarcoma that arises from the bone and occurs during childhood.	Childhood Undifferentiated High Grade Pleomorphic Sarcoma of Bone		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114751>	C26849	Peritoneal Dialysis Catheter-Associated Peritonitis	Infection of the peritoneum related to a peritoneal dialysis catheter.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114752>	C26849	Chemical Peritonitis	A non-infectious inflammation of the peritoneum.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114753>	C26693	AV Fistula Aneurysm|Arteriovenous Fistula Aneurysm|Arteriovenous Fistula Aneurysm	A bulge in a weakened vessel wall segment of an arteriovenous fistula.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114754>	C35740	AV Fistula Stenosis|Arteriovenous Fistula Stenosis|Arteriovenous Fistula Stenosis	Narrowing of the lumen of an arteriovenous fistula.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114755>	C1752|C1663	EGFRvIII Peptide Vaccine|EGFRvIII Vaccine	An antineoplastic vaccine directed against a peptide found in the epidermal growth factor receptor class III variant (EGFRvIII), a constitutively activated mutant of the wild-type tyrosine kinase. This protein variant is present in a substantial proportion of malignant gliomas and other human cancers.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	
C114756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114756>	C114397	AV Fistula Thrombosis|Arteriovenous Fistula Thrombosis|Arteriovenous Fistula Thrombosis	Partial or complete occlusion of the lumen within an arteriovenous fistula by a thrombus.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114757>	C1744	P-glycoprotein Inhibitor|P-gp Inhibitor|P-gp inhibitor	Any agent that inhibits the efflux pump p-glycoprotein (P-gp).			Chemical Viewed Functionally	
C114758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114758>	C26693	AV Graft Aneurysm|Arteriovenous Graft Aneurysm|Arteriovenous Graft Aneurysm	A bulge in a weakened wall segment of an arteriovenous graft.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114759>	C9042|C5097|C147901|C114968	Childhood Brain Stem Gliosarcoma|Brain Stem Gliosarcoma	A gliosarcoma that arises from the brain stem and occurs during childhood.	Childhood Brain Stem Gliosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C11475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11475>	C61007	Bleomycin/Cisplatin/Etoposide/Paclitaxel|BLEO/CDDP/TAX/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114760>	C9042|C115195	Childhood Brain Stem Mixed Glioma|Brain Stem Mixed Glioma	A mixed glioma that arises from the brain stem and occurs during childhood.	Childhood Brain Stem Mixed Glioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C114761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114761>	C66897|C16135	Intensity-Modulated Spot-Scanning Proton Therapy|Spot Scan Intensity-Modulated Proton Therapy	A form of intensity-modulated radiation therapy that uses narrow pencil beams of protons to deliver radiation to a precise target while sparing surrounding tissues.	Intensity-Modulated Spot-Scanning Proton Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C114762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114762>	C115152	AV Graft Stenosis|Arteriovenous Graft Stenosis|Arteriovenous Graft Stenosis	Narrowing of the lumen of an arteriovenous graft.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114763>	C114397	AV Graft Thrombosis|Arteriovenous Graft Thrombosis|Arteriovenous Graft Thrombosis	Partial or complete occlusion of the lumen of an arteriovenous graft by a thrombus.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114764>	C3284	Dialysis Catheter Obstruction	Blockage of a dialysis catheter by a thrombus or other substance.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114765>	C3421	Trisomy 22	A chromosomal abnormality consisting of the presence of a third copy of chromosome 22 in somatic cells.			Cell or Molecular Dysfunction	Cellosaurus Disease Terminology
C114766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114766>	C53543|C117115	Carnitine Palmitoyltransferase II Deficiency|CPT II Deficiency	A rare, autosomal recessive inherited disorder of long-chain fatty-acid oxidation caused by mutations in the CPT2 gene. The disease includes three main types: a lethal neonatal form, a severe infantile hepatocardiomuscular form, and a myopathic form.			Disease or Syndrome	Cellosaurus Disease Terminology
C114767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114767>	C84723	Galactokinase Deficiency|GALK Deficiency|Galactosemia Type 2	An autosomal recessive disorder caused by mutations in the GALK1 gene. The disorder is characterized by an accumulation of galactose and galactitol secondary to the decreased conversion of galactose to galactose-1-phosphate by galactokinase. Its major clinical symptom is the development of cataracts during the first weeks or months of life.			Disease or Syndrome	Cellosaurus Disease Terminology
C114768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114768>	C75006	Loeys-Dietz Syndrome Type 2|Loeys-Dietz Syndrome Type II|Marfan Syndrome Type 2|Marfan Syndrome Type II	A rare autosomal dominant inherited disorder of connective tissue caused by mutations in either the TGFBR1 or TGFBR2 gene. Like Loeys-Dietz syndrome type I the disease is characterized by enlargement of the aorta and other arteries, and arterial tortuosity, but skeletal signs are typically less severe or absent in type 2. Skin abnormalities, such as velvety skin are often present in type 2.			Disease or Syndrome	Cellosaurus Disease Terminology
C114769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114769>	C2985	Maturity-Onset Diabetes of the Young|MODY|Maturity Onset Diabetes of the Young	A rare autosomal dominant form of diabetes mellitus affecting young people with a positive family history. MODY is a form of monogenic diabetes, resulting from mutations in a single gene. The most common forms are HNF1alpha-MODY (MODY3) and GCK-MODY (MODY2), due to mutations in the HNF1A and GCK genes, respectively.			Disease or Syndrome	Cellosaurus Disease Terminology
C11476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11476>	C61063	Cytarabine/Fludarabine/Topotecan|ARA-C/FAMP/TOPO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114770>	C3452	Xeroderma Pigmentosum, Complementation Group C|XP-C|Xeroderma Pigmentosum Group C	Xeroderma pigmentosum caused by bi-allelic mutations in XPC gene.			Disease or Syndrome	Cellosaurus Disease Terminology
C114771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114771>	C3452	Xeroderma Pigmentosum, Complementation Group E|XP-E|Xeroderma Pigmentosum Group E	Xeroderma pigmentosum caused by bi-allelic mutations in DDB2 gene.			Disease or Syndrome	Cellosaurus Disease Terminology
C114772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114772>	C26891	Extracorporeal Circuit Clot	Thrombus formation within an apparatus that carries blood outside of the body, such as pheresis, dialysis or extracorporeal membrane oxygenation (ECMO).			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114773>	C9377|C7703|C4045	Childhood Brain Oligodendroglioma|Brain Oligodendroglioma	An oligodendroglioma that arises from the brain and occurs during childhood.	Childhood Brain Oligodendroglioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114774>	C6968|C5961|C5960|C187207	Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified|Childhood Supratentorial Embryonal Tumor, NOS|Childhood Supratentorial PNET|Childhood Supratentorial Primitive Neuroectodermal Tumor|Childhood Supratentorial Primitive Neuroectodermal Tumor|Supratentorial Embryonal Tumor, NOS	A supratentorial embryonal tumor, not otherwise specified that occurs in childhood.	Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C114775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114775>	C5960|C187207|C186547|C124270	Childhood Central Nervous System Neuroblastoma, FOXR2-Activated|Central Nervous System Neuroblastoma|Childhood Brain Neuroblastoma|Childhood Brain Neuroblastoma, FOXR2-Activated|Childhood Central Nervous System Neuroblastoma	A rare central nervous system neoplasm with neuroblastic and/or neuronal differentiation that arises from the supratentorial brain and occurs during childhood. It is characterized by the presence of structural rearrangements of FOXR2 gene that result in the activation of the transcription factor FOXR2.	Childhood Central Nervous System Neuroblastoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C114776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114776>	C40416	Dialyzer Blood Leakage|Dialyzer Blood Leak|Dialyzer Blood Leak	Leakage of blood into the dialysate during hemodialysis due to apparatus malfunction.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114777>	C3708	Adult Germ Cell Tumor|Germ Cell Tumor	A germ cell tumor that occurs during adulthood.	Adult Germ Cell Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114778>	C6285|C5478	Adult Intracranial Germ Cell Tumor|Intracranial Germ Cell Tumor	A germ cell tumor that arises within the cranium and occurs during adulthood.	Adult Intracranial Germ Cell Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114779>	C9301|C212064	Primary Central Nervous System Non-Hodgkin Lymphoma	A non-Hodgkin lymphoma that arises from the central nervous system.	Primary Central Nervous System Non-Hodgkin Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C11477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11477>	C61063	Chlorambucil/Dexamethasone/Idarubicin|CLB/DM/IDA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114780>	C78709	AV Fistula Maturation Failure|Arteriovenous Fistula Maturation Failure|Arteriovenous Fistula Maturation Failure	Inadequate development of an arteriovenous fistula within three months of creation.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114781>	C28193	Dialysis Disequilibrium Syndrome|Disequilibrium Syndrome|Disequilibrium Syndrome	A complication occurring during hemodialysis that is thought to be due to a rapid decrease in blood urea nitrogen, and is characterized by an increase in intracranial pressure resulting in nausea, headache, vomiting, restlessness, and/or a decreased level of consciousness.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114782>	C8563	Adult Undifferentiated High Grade Pleomorphic Sarcoma of Bone|Adult Malignant Fibrous Histiocytoma of Bone|Adult Undifferentiated High Grade Pleomorphic Sarcoma|Adult Undifferentiated High-Grade Pleomorphic Sarcoma of Bone|Undifferentiated High Grade Pleomorphic Sarcoma of Bone	An undifferentiated high-grade pleomorphic sarcoma that arises from the bone and occurs during adulthood.	Adult Undifferentiated High Grade Pleomorphic Sarcoma of Bone		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114783>	C7702	Hodgkin Lymphoma During Pregnancy	Hodgkin lymphoma that occurs during pregnancy.	Hodgkin Lymphoma During Pregnancy		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114784>	C7704	Non-Hodgkin Lymphoma During Pregnancy	Non-Hodgkin lymphoma that occurs during pregnancy.	Non-Hodgkin Lymphoma During Pregnancy		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114785>	C7703|C3696|C202299|C124275	Childhood Subependymal Giant Cell Astrocytoma|Subependymal Giant Cell Astrocytoma	A subependymal giant cell astrocytoma that occurs during childhood.	Childhood Subependymal Giant Cell Astrocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114786>	C13057	CXCL12-Abundant Reticular Cell|CAR Cell|CAR Cells|CXCL12-Abundant Reticular Cells	A fibroblast that expresses high levels of stromal cell-derived factor 1 (CXCL12), secretes type III collagen and forms processes that contact those of other similar cells to form a network of reticular fibers. These cells may play a role in hematopoietic stem cell maintenance.	CXCL12-Abundant Reticular Cell		Body Part, Organ, or Organ Component	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114787>	C28203	Dimethyl Ellagic Acid|DMEA|Dimethyl-Ellagic Acid|Dimethylellagic Acid	An antioxidant and a methylated derivative of ellagic acid that is a product of the metabolism of ellagitannins by intestinal bacteria.	Dimethyl Ellagic Acid		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C114788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114788>	C28203	Dimethyl Ellagic Acid Glucuronide|DMEAG|Dimethyl-Ellagic Acid Glucuronide|Dimethylellagic Acid Glucuronide	An antioxidant and a methylated and glucuronidated derivative of ellagic acid that is a product of the metabolism of ellagitannins by intestinal bacteria.	Dimethyl Ellagic Acid Glucuronide		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C114789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114789>	C34827	Tetany	Sudden and involuntary contraction of a muscle of group of muscles due to hypocalcemia.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11478>	C61063	Chlorambucil/Dexamethasone|CLB/DM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114790>	C16342	Apoptosis Marker|Apoptosis Biomarker|Marker of Apoptosis	A molecule or collection of biological compounds that can be objectively measured to evaluate the extent of programmed cell death occurring in a biological sample.	Apoptosis Marker		Functional Concept	CTRP Biomarker Terminology|CTRP Terminology
C114791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114791>	C49131	Basement Membrane Coverage Measurement|Basement Membrane Coverage	The determination of the percentage of a blood vessel that is comprised of intact basement membrane structures.	Basement Membrane Coverage Measurement		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Terminology
C114792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114792>	C49131	Pericyte Coverage Measurement|Pericyte Coverage|Pericyte-Coverage	The determination of the percentage of a blood vessel that is comprised of pericyte processes or cell bodies.	Pericyte Coverage Measurement		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Terminology
C114793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114793>	C16499	Alkaline DNase|Alkaline Deoxyribonuclease	An enzyme that is present in human serum and catalyzes the hydrolytic cleavage of phosphodiester bond linkages in the DNA backbone. The relative activity of this enzyme can be used as a marker of therapeutic responses or disease relapse.	Alkaline DNase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114794>	C16295	EGFRvIII Antibody|Anti-EGFRvIII|Anti-EGFRvIII Antibody	An antibody directed against the epidermal growth factor receptor class III variant (EGFRvIII).	EGFRvIII Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114795>	C1746	POMC Gene Product	A protein encoded by the POMC gene.	POMC Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114796>	C114795	Pro-Opiomelanocortin|Corticotropin-Lipotropin|Opiomelanocortin Prepropeptide|POMC|Proopiomelanocortin|Proopiomelanocortin Preproprotein	Pro-opiomelanocortin (267 aa, ~29 kDa) is encoded by the human POMC gene. This protein plays a role in peptide hormone-dependent signaling.	Pro-Opiomelanocortin		Amino Acid, Peptide, or Protein|Hormone	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114797>	C114795	Melanotropin Alpha|ACTH (1-13)|ACTH(1-13)|Alpha-Intermedin|Alpha-MSH|Alpha-Melanocortin|Alpha-Melanocyte-Stimulating Hormone|Alpha-Melanotropin|Melanocyte-Stimulating Hormone Alpha	Melanotropin alpha (13 aa, ~2 kDa) is encoded by the human POMC gene. This protein is involved in the positive regulation of melanin production.	Melanotropin Alpha		Amino Acid, Peptide, or Protein|Hormone	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114798>	C81326	Elevated Blood Pressure Measurement	An abnormally high blood pressure reading.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114799>	C213050	KIF5B/RET Fusion Gene|KIF5B-RET Fusion Gene|KIF5B::RET Fusion Gene	A fusion gene that results from a chromosomal inversion between the p and q arms of chromosome 10 which fuses the 5' portion of the KIF5B gene and the 3' portion of the RET gene. This rearrangement is associated with lung adenocarcinoma.	KIF5B/RET Fusion Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11479>	C61063	Cytarabine/Etoposide/Melphalan|ARA-C/L-PAM/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1147>	C593|C1712	Recombinant Interleukin-16|IL-16|Interleukin-16|Lymphocyte Chemoattractant Factor|Lymphotactin	A recombinant chemokine of human lymphotactin which is produced by activated progenitor T cells and characterized by specific chemotactic activity for lymphocytes. (NCI)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C114800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114800>	C213263	KIF5B/RET Fusion Protein|KIF5B-RET Fusion Protein|KIF5B::RET Fusion Protein|Kinesin-1 Heavy Chain/Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret Fusion Protein	A fusion protein encoded by the KIF5B/RET fusion gene. This protein is comprised of the motor domain and various portions the coiled-coil domain of the kinesin-1 heavy chain protein, fused with the C-terminal cytoplasmic domain of the proto-oncogene tyrosine-protein kinase receptor Ret protein, including the tyrosine kinase domain.	KIF5B/RET Fusion Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114801>	C68627|C189258	Childhood Gonadal Germ Cell Tumor|Gonadal Germ Cell Tumor	A germ cell tumor that arises from the testis or ovary and occurs during childhood.	Childhood Gonadal Germ Cell Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C114802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114802>	C3117	Page Kidney	Hypertension resulting from activation of the renin-angiotensin system in response to prolonged compression of the renal parenchyma and blood vessels.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114803>	C25939	ALOX15B Gene|ALOX15B|ALOX15B|Arachidonate 15-Lipoxygenase, Type B Gene	This gene plays a role in fatty acid oxidation.	ALOX15B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114804>	C114803	ALOX15B wt Allele|15-LOX-2|15-Lipoxygenase, Reticulocyte, Arachidonate, Second Type Gene|Arachidonate 15-Lipoxygenase, Second Type Gene|Arachidonate 15-Lipoxygenase, Type B wt Allele	Human ALOX15B wild-type allele is located in the vicinity of 17p13.1 and is approximately 10 kb in length. This allele, which encodes arachidonate 15-lipoxygenase B protein, is involved in the oxidation of fatty acids.	ALOX15B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114805>	C28459	Arachidonate 15-Lipoxygenase B|15-LOX-2|15-LOX-B|15-Lipoxygenase 2|15S-Lipoxygenase|ALOX15B|Arachidonate 15-Lipoxygenase 2|Arachidonate 15-Lipoxygenase Type II|Arachidonate Omega(6) Lipoxygenase|EC 1.13.11.33|Linoleate 13-Lipoxygenase 15-Lob	Arachidonate 15-lipoxygenase B (676 aa, ~76 kDa) is encoded by the human ALOX15B gene. This protein plays a role in fatty acid metabolism.	Arachidonate 15-Lipoxygenase B		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114806>	C7714|C68660	Childhood Favorable Prognosis Hodgkin Lymphoma|Favorable Prognosis Hodgkin Lymphoma	A Hodgkin lymphoma with favorable prognosis that occurs during childhood.	Childhood Favorable Prognosis Hodgkin Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114807>	C7702|C68660	Adult Favorable Prognosis Hodgkin Lymphoma|Favorable Prognosis Hodgkin Lymphoma	A Hodgkin lymphoma with favorable prognosis that occurs during adulthood.	Adult Favorable Prognosis Hodgkin Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114808>	C7714|C68663	Childhood Unfavorable Prognosis Hodgkin Lymphoma|Unfavorable Prognosis Hodgkin Lymphoma	A Hodgkin lymphoma with unfavorable prognosis that occurs during childhood.	Childhood Unfavorable Prognosis Hodgkin Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114809>	C7702|C68663	Adult Unfavorable Prognosis Hodgkin Lymphoma|Unfavorable Prognosis Hodgkin Lymphoma	A Hodgkin lymphoma with unfavorable prognosis that occurs during adulthood.	Adult Unfavorable Prognosis Hodgkin Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C11480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11480>	C61063	Cytarabine/Daunorubicin/Filgrastim|ARA-C/DNR/G-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114810>	C25993	SCN9A Gene|SCN9A|SCN9A|Sodium Voltage-Gated Channel Alpha Subunit 9 Gene	This gene is involved in the perception of pain.	SCN9A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114811>	C114810	SCN9A wt Allele|ETHA|FEB3B|GEFSP7|HSAN2D|NE-NA|NENA|Nav1.7|PN1|SFNP|Sodium Channel, Voltage Gated, Type IX, Alpha Subunit Gene|Sodium Channel, Voltage-Gated, Type IX, Alpha Polypeptide Gene|Sodium Channel, Voltage-Gated, Type IX, Alpha Subunit Gene|Sodium Voltage-Gated Channel Alpha Subunit 9 wt Allele	Human SCN9A wild-type allele is located in the vicinity of 2q24 and is approximately 181 kb in length. This allele, which encodes sodium channel protein type 9 subunit alpha protein, plays a role in sodium transport. Mutation of the gene is associated with several pain and seizure disorders.	SCN9A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114812>	C9344|C187207|C115196|C114833	Childhood Pineoblastoma	A pineoblastoma that occurs during childhood.	Childhood Pineoblastoma		Neoplastic Process	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C114813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114813>	C28505	Sodium Channel Protein Type 9 Subunit Alpha|Neuroendocrine Sodium Channel|PN1|Peripheral Sodium Channel 1|SCN9A|Sodium Channel Protein Type IX Subunit Alpha|Voltage-Gated Sodium Channel Alpha Subunit Nav1.7|Voltage-Gated Sodium Channel Subunit Alpha Nav1.7|hNE-Na	Sodium channel protein type 9 subunit alpha (1988 aa, ~226 kDa) is encoded by the human SCN9A gene. This protein is involved in sodium ion transport.	Sodium Channel Protein Type 9 Subunit Alpha		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114814>	C20917	NUF2 Gene|NUF2|NUF2|NUF2, NDC80 Kinetochore Complex Component Gene	This gene is involved in mitosis.	NUF2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114815>	C114814	NUF2 wt Allele|CDCA1|CT106|Cell Division Cycle Associated 1 Gene|NUF2, NDC80 Kinetochore Complex Component wt Allele|NUF2, NDC80 Kinetochore Complex Component, Homolog (S. cerevisiae) Gene|NUF2, NDC80 Kinetochore Complex Component, Homolog Gene|NUF2, S. cerevisiae, Homolog of Gene|NUF2R	Human NUF2 wild-type allele is located in the vicinity of 1q23.3 and is approximately 89 kb in length. This allele, which encodes kinetochore protein Nuf2, plays a role in the progression of mitosis.	NUF2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114816>	C17761	Kinetochore Protein Nuf2|Cancer/Testis Antigen 106|Cell Division Cycle-Associated Protein 1|NUF2|hNuf2|hNuf2R|hsNuf2	Kinetochore protein Nuf2 (464 aa, ~54 kDa) is encoded by the human NUF2 gene. This protein is involved in mitosis.	Kinetochore Protein Nuf2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114817>	C21240	IMP3 Gene|IMP3|IMP3|IMP3, U3 Small Nucleolar Ribonucleoprotein Gene	This gene plays a role in RNA processing.	IMP3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114818>	C114817	IMP3 wt Allele|BRMS2|C15orf12|Chromosome 15 Open Reading Frame 12 Gene|FLJ10968|IMP3, S. cerevisiae, Homolog of Gene|IMP3, U3 Small Nucleolar Ribonucleoprotein wt Allele|IMP3, U3 Small Nucleolar Ribonucleoprotein, Homolog (Yeast) Gene|MRPS4	Human IMP3 wild-type allele is located in the vicinity of 15q24 and is approximately 10 kb in length. This allele, which encodes U3 small nucleolar ribonucleoprotein protein IMP3, is involved in the maturation of ribosomal RNA.	IMP3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114819>	C9143|C36312	Adult B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1|Adult B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR::ABL1|Adult B Acute Lymphoblastic Leukemia with t(9;22)(q34;q11.2); BCR-ABL1|B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1	A B acute lymphoblastic leukemia that occurs during adulthood. It is characterized by the presence of lymphoblasts that carry a translocation between the BCR gene on chromosome 22 and the ABL1 gene on chromosome 9. It results in the production of the p190 kd or p210 kd fusion protein. It has an unfavorable clinical outcome.	Adult B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1		Neoplastic Process	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology
C11481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11481>	C61007	Antineoplaston A10/Methotrexate|A10/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114820>	C38576|C21298	U3 Small Nucleolar Ribonucleoprotein Protein IMP3|BRMS2|Mitochondrial Ribosomal Protein S4|Mitochondrial Ribosomal Subunit Component 4|Ribonucleoprotein Protein IMP3|U3 SnoRNP Protein 3 Homolog|U3 SnoRNP Protein IMP3	U3 small nucleolar ribonucleoprotein protein IMP3 (184 aa, ~22 kDa) is encoded by the human IMP3 gene. This protein plays a role in ribosomal RNA processing.	U3 Small Nucleolar Ribonucleoprotein Protein IMP3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114821>	C48259	Tertiary Hyperparathyroidism	An overproduction of parathyroid hormone that is autonomous and often associated with chronic secondary hyperparathyroidism.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C114822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114822>	C25981|C20988	TJP1 Gene|TJP1|TJP1|Tight Junction Protein 1 Gene	This gene plays a role in cell-cell adhesion.	TJP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114823>	C114822	TJP1 wt Allele|DKFZp686M05161|MGC133289|Tight Junction Protein 1 wt Allele|ZO-1|ZO1|Zona Occludens 1 Gene	Human TJP1 wild-type allele is located in the vicinity of 15q13 and is approximately 269 kb in length. This allele, which encodes tight junction protein ZO-1, is involved in the signal transduction and the formation of cell-cell junctions.	TJP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114824>	C16393	Tight Junction Protein ZO-1|TJP1|Tight Junction Protein 1|Zona Occludens Protein 1|Zonula Occludens 1 Protein|Zonula Occludens Protein 1	Tight junction protein ZO-1 (1748 aa, ~195 kDa) is encoded by the human TJP1 gene. This protein plays a role in tight junction formation and signal transduction.	Tight Junction Protein ZO-1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114825>	C21295	EVL Gene|EVL|EVL|Enah/Vasp-Like Gene	This gene is involved in actin dynamics.	EVL Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114826>	C114825	EVL wt Allele|Enah/Vasp-Like wt Allele|RNB6	Human EVL wild-type allele is located in the vicinity of 14q32.2 and is approximately 173 kb in length. This allele, which encodes Ena/VASP-like protein, plays a role in actin polymerization.	EVL wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114827>	C110937	Renal Osteodystrophy|ROD	Abnormalities of bone mineral metabolism associated with chronic kidney disease.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Nephrology Terminology
C114828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114828>	C8711	Mucosal Melanoma	A melanoma that arises from a mucosal site.	Mucosal Melanoma		Neoplastic Process	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology
C114829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114829>	C17728	Ena/VASP-Like Protein|EVL|Ena/Vasodilator-Stimulated Phosphoprotein-Like|Enah/Vasp-Like Protein	Ena/VASP-like protein (416 aa, ~45 kDa) is encoded by the human EVL gene. This protein is involved in actin binding and cytoskeletal remodeling.	Ena/VASP-Like Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11482>	C61063	Cyclophosphamide/Theratope STn-KLH Vaccine|CTX/THERATOPE			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114830>	C35772	Vitamin D Deficiency	Abnormally low level of 25-hydroxyvitamin D in the blood.	Vitamin D Deficiency		Disease or Syndrome	CTRP Biomarker Terminology|CTRP Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114831>	C4867|C36263	Metastatic Malignant Neoplasm in the Soft Tissue|Metastatic Malignant Neoplasm in Soft Tissue|Metastatic Malignant Neoplasm to Soft Tissue|Metastatic Malignant Neoplasm to Soft Tissues|Metastatic Malignant Neoplasm to the Soft Tissue	A malignant neoplasm that has spread from its original site of growth to the soft tissue.	Metastatic Malignant Neoplasm to Soft Tissues		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114832>	C20420	SOX17 Gene|SOX17|SOX17|SRY (Sex Determining Region Y)-Box 17 Gene	This gene plays a role in both transcriptional regulation and embryonic development.	SOX17 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114833>	C6990|C5448	Childhood Central Nervous System Embryonal Tumor|Central Nervous System Embryonal Neoplasm|Childhood Central Nervous System Embryonal Neoplasm|Childhood Central Nervous System Embryonal Neoplasm	A central nervous system embryonal tumor that occurs during childhood.	Childhood Central Nervous System Embryonal Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C114834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114834>	C114832	SOX17 wt Allele|SOX-17|SRY (Sex Determining Region Y)-Box 17 wt Allele|SRY-Box 17 Gene|SRY-Related HMG-Box Gene 17|VUR3	Human SOX17 wild-type allele is located in the vicinity of 8q11.23 and is approximately 3 kb in length. This allele, which encodes transcription factor SOX-17 protein, is involved in the formation of both the embryonic heart tube and presumptive gut endoderm. Mutation of the gene is associated with vesicoureteral reflux type 3.	SOX17 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114835>	C17207	Transcription Factor SOX-17|SOX17|SRY-Related HMG-Box Transcription Factor SOX17	Transcription factor SOX-17 (414 aa, ~44 kDa) is encoded by the human SOX17 gene. This protein plays a role in organogenesis.	Transcription Factor SOX-17		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114836>	C9045|C162702|C153823|C114833	Recurrent Childhood Central Nervous System Embryonal Tumor|Recurrent Central Nervous System Embryonal Neoplasm|Recurrent Childhood Central Nervous System Embryonal Neoplasm	The reemergence of childhood central nervous system embryonal tumor after a period of remission.	Recurrent Childhood Central Nervous System Embryonal Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114837>	C34915	Uremic Pericarditis	Inflammation of the pericardium associated with chronic kidney failure.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114838>	C34843|C27233	Acute Allograft Nephropathy|Acute Kidney Allograft Nephropathy|Kidney Transplant Rejection|Kidney Transplant Rejection	A sudden immune response occurring after transplantation, directed against donor kidney alloantigens.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114839>	C114838	Acute Cellular Allograft Nephropathy|Acute Cellular Kidney Allograft Nephropathy	A sudden onset of T-cell mediated immune response occurring after transplantation, directed against donor kidney alloantigens.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11483>	C61063	Fluorouracil/Gemcitabine/Interferon Alfa/Interleukin-2|DFdC/5-FU/IFN-A/IL-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114840>	C99567	Lymphomatous Involvement of Non-Cutaneous Extranodal Site	A pathologic and/or clinical finding indicating the spread of a lymphomatous process to an anatomic site other than lymph nodes and skin.	Lymphomatous Involvement of Non-Cutaneous Extranodal Site		Finding	CTRP Disease Terminology|CTRP Terminology
C114841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114841>	C114838	Acute Humoral Allograft Nephropathy|Acute Humoral Kidney Allograft Nephropathy	A sudden onset of B-cell mediated immune response occurring after transplantation, directed against donor kidney alloantigens.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114842>	C27233	Allograft Thrombosis	Thrombus formation within the arterial or venous system of donor tissue post transplantation.			Disease or Syndrome	
C114843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114843>	C35371	Osteolytic Lesions of Multiple Myeloma|Osteolytic Lesions of Multiple Myeloma/Plasma Cell Myeloma	A radiologic finding indicating the presence of multiple radiolucent osteolytic bone lesions observed in a patient with a diagnosis of multiple myeloma.	Osteolytic Lesions of Multiple Myeloma		Finding	CTRP Disease Terminology|CTRP Terminology
C114844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114844>	C114842	Renal Allograft Thrombosis|Kidney Allograft Thrombosis	Thrombus formation within the arterial or venous system of a donor kidney post transplantation.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114845>	C3672	Extraosseous Calcification	Deposition of calcium in tissues outside of bone.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114846>	C3672	Vascular Calcification	Deposition of calcium in vascular structures.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114847>	C45548	Human Leukocyte Antigen Sensitization|HLA Sensitization	Presence of preformed antibodies to donor human leukocyte antigen (HLA).			Molecular Function	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114848>	C27233	Hyperacute Allograft Rejection	An immediate rejection of transplanted tissue caused by the presence of preformed antibodies to donor human leukocyte antigens.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114849>	C111118	Right Atrial Thrombus	A blood clot in the right atrium of the heart.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11484>	C61007	Interferon Alfa/Tretinoin Liposome|IFN-A/L-ATRA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114850>	C98643	Subclavian Vein Stenosis	Narrowing of the lumen of the subclavian vein.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114851>	C78442	Renal Lymphocele|Kidney Lymphocele|Kidney Lymphocele	Encapsulated collection of lymphatic fluid around a transplanted kidney.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114852>	C2985|C27233	New Onset Diabetes After Transplant|NODAT	Development of diabetes after transplant, usually associated with calcineurin inhibitor use.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114853>	C27233	Delayed Graft Function|DGF	The need for dialysis within a week of kidney transplant.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C114854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114854>	C171085	Active Duty Status|Active Duty	The status of an individual who is serving on active duty in any branch of the United States Uniformed Services.			Temporal Concept	FDA Individual Case Safety Report Terminology|Patient Military Status ICSR Terminology
C114855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114855>	C54447	Patient Military Status ICSR Terminology|Patient Military Status Individual Case Safety Report Terminology	Terminology used in Individual Case Safety Reports to specify a the military status of a patient.			Intellectual Product	FDA Individual Case Safety Report Terminology
C114856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114856>	C54447	Type of Vaccination Facility ICSR Terminology|Type of Vaccination Facility Individual Case Safety Report Terminology	Terminology used in Individual Case Safety Reports to specify the type of vaccination facility.			Intellectual Product	FDA Individual Case Safety Report Terminology
C114857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114857>	C171085	Reserve Status|Reserve	The status of an individual who is serving in a reserve branch of any of the United States Uniformed Services.			Temporal Concept	FDA Individual Case Safety Report Terminology|Patient Military Status ICSR Terminology
C114858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114858>	C171085	National Guard Status|National Guard	The status of an individual who is serving in the National Guard.			Temporal Concept	FDA Individual Case Safety Report Terminology|Patient Military Status ICSR Terminology
C114859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114859>	C16960	TRICARE Beneficiary	An individual who receives healthcare coverage for medical and dental services from the Department of Defense health care system (TRICARE).			Patient or Disabled Group	FDA Individual Case Safety Report Terminology|Patient Military Status ICSR Terminology
C11485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11485>	C61063	Doxorubicin/Methylprednisolone|DOX/MePRDL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114860>	C21541	Public Health Department Facility	A healthcare facility that is operated or managed by a local, state or national public health department or program.			Health Care Related Organization	FDA Individual Case Safety Report Terminology|Type of Vaccination Facility ICSR Terminology
C114861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114861>	C211570	Workplace Clinic	An onsite healthcare facility that provides routine preventive services for its employees.			Health Care Related Organization	Type of Vaccination Facility ICSR Terminology
C114862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114862>	C211570	Student Health Clinic|School Student Health Clinic	An onsite healthcare facility that provides routine therapeutic and preventive services to students.			Health Care Related Organization	FDA Individual Case Safety Report Terminology|Type of Vaccination Facility ICSR Terminology
C114863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114863>	C21541	Pharmacy|Pharmacy/Drug Store	A commercial or private facility where medications are prepared, dispensed and/or sold.			Health Care Related Organization	FDA Individual Case Safety Report Terminology|Type of Vaccination Facility ICSR Terminology
C114864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114864>	C60727|C16290	X-ray-Based Angiogram|Angiogram|Fluoroscopic Angiogram|Traditional Angiogram	An X-ray representation of blood vessels made after the injection of a radiopaque substance.			Laboratory or Test Result	
C114865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114865>	C21541	Military Healthcare Facility|Military Site	A healthcare facility that provides routine therapeutic or preventive services on a military installation or one that is off base but is operated under the authority or direction of the Department of Defense or the Department of Homeland Security.			Health Care Related Organization	FDA Individual Case Safety Report Terminology|Type of Vaccination Facility ICSR Terminology
C114866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114866>	C16687	Histone H2|Histone 2	Proteins in the core histone families, histone H2A and histone H2B represent 2 of the 4 families of histones found in the core of nucleosomes. Histones in the H2A family dimerize with those in the H2B family, then two H2A/H2B dimers can associate with a tetramer containing 2 proteins from the histone H3 family and 2 proteins from the histone H4 family to form the octameric nucleosome core. The octameric complex is the basic unit for eukaryotic DNA packaging.	Histone H2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114867>	C16290	MRI-Based Angiogram|MAGNETIC RESONANCE ANGIOGRAPHY|MRA|MRA|Magnetic Resonance Angiogram	An image of blood vessels constructed using magnetic resonance imaging.	MRI-Based Angiogram		Laboratory or Test Result	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C114868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114868>	C113492	Arrest of Labor in Active Phase|Active Phase Arrest|Active Phase Arrest|Prolonged Active Phase of Labor|Prolonged Active Phase of Labor|Prolonged First Stage of Labor|Prolonged First Stage of Labor	More than or equal to 6 cm dilation with membrane rupture and one of the following: 4 hours or more of adequate contractions (e.g. more than 200 Montevideo units), 6 hours or more of inadequate contractions and no cervical change.			Finding	NICHD Terminology|Perinatal Terminology
C114869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114869>	C113492	Arrest of Labor in Second Stage|Prolonged Second Stage of Labor|Prolonged Second Stage of Labor|Second Stage Arrest|Second Stage Arrest	At least 2 hours of pushing in multiparous women and at least 3 hours of pushing in nulliparous women. Longer durations may be appropriate on an individualized basis (e.g., with the use of epidural analgesia or with fetal malposition) as long as progress is being documented.			Finding	NICHD Terminology|Perinatal Terminology
C11486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11486>	C61063	Clarithromycin/Omeprazole/Tinidazole|CLARITH/OMEP/TDZ			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114870>	C80082	Post-Natal Death at 16-20 Weeks Gestation	A fetus of 16-20 weeks gestational age that shows signs of life at birth but dies after delivery.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C114871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114871>	C113492	Prolonged Latent Phase of Labor|Arrest of Labor in the Latent Phase|Arrest of Labor in the Latent Phase|Latent Phase Arrest|Latent Phase Arrest	Greater than 20 hours of labor in nulliparous women and greater than 14 hours in parous women.			Finding	NICHD Terminology|Perinatal Terminology
C114872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114872>	C3890	Acute Intrapartum Hypoxic Event|Acute Intrapartum Hypoxia|Acute Intrapartum Hypoxia	A sentinel hypoxic event occurring during labor, with evidence of fetal metabolic acidosis in the fetal umbilical arterial blood; a sudden and sustained fetal bradycardia or the absence of fetal heart rate variability in the presence of persistent, late, or variable decelerations (category III tracing); previously normal Apgar scores that are 0-3 beyond 5 minutes.			Finding	NICHD Terminology|Perinatal Terminology
C114873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114873>	C87092	Fetus Large for Gestational Age|Fetal LGA|Fetal LGA|Fetal Large for Gestational Age|Fetal Large for Gestational Age	A fetus exceeding 90% of expected weight for gestational age.			Finding	NICHD Terminology|Perinatal Terminology
C114875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114875>	C92719	Fetus Small for Gestational Age|Fetal Growth Restriction|Fetal Growth Restriction|Fetal Growth Retardation|Fetal SGA|Fetal SGA|Fetal Small for Gestational Age|Fetal Small for Gestational Age|Fetal growth retardation|IUGR|IUGR|Intrauterine Growth Restriction|Intrauterine Growth Restriction|Intrauterine Growth Retardation	A fetus that does not grow beyond the 10th percentile of conventionally accepted weight for gestational age.			Disease or Syndrome	GAIA Fetal Growth Restriction Level of Diagnostic Certainty Terminology|GAIA Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology|Perinatal Terminology
C114876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114876>	C114875	Fetus Small for Gestational Age with Oligohydraminos|Fetal SGA with Oligohydraminois|Fetal SGA with Oligohydramnios|Fetal Small for Gestational Age with Oligohydraminos|Fetal Small for Gestational Age with Oligohydramnios	A fetus that does not grow beyond the 10th percentile of conventionally accepted weight for gestational age and shows evidence of oligohydramnios.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C114877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114877>	C114875	Fetus Small for Gestational Age with Abnormal Doppler|Fetal SGA with Abnormal Doppler|Fetal SGA with Abnormal Dopplers|Fetal Small for Gestational Age with Abnormal Doppler|Fetal Small for Gestational Age with Abnormal Dopplers	A fetus that does not grow beyond the 10th percentile of conventionally accepted weight for gestational age and has abnormal Doppler studies.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C114878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114878>	C114875	Fetus Small for Gestational Age with Abdominal Circumference Less than Tenth Percentile|Fetal SGA with Abdominal Circumference Less than Tenth Percentile|Fetal SGA with Abdominal Circumference Less than Tenth Percentile|Fetal Small for Gestational Age with Abdominal Circumference Less than Tenth Percentile|Fetal Small for Gestational Age with Abdominal Circumference Less than Tenth Percentile	A fetus that does not grow beyond the 10th percentile of conventionally accepted weight for gestational age and whose abdominal circumference falls below the tenth percentile.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C114879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114879>	C125932	Response Assessment in Neuro-Oncology Criteria|RANO|RANO|RANO Criteria|RANO Response Criteria|Response Assessment Criteria for Glioblastoma|Response Assessment in Neuro-Oncology (RANO) Response Criteria	An update to the MacDonald criteria for assessing disease progression and treatment response in glioblastoma multiforme (GBM).			Clinical Attribute	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11487>	C61063	Cyclophosphamide/Pentostatin|CTX/DCF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114880>	C21514	One Year Ago	The time period one year before the current time.			Temporal Concept	Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire
C114881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114881>	C71685	Much Better	In a much improved condition.			Qualitative Concept	Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire|University of Washington Quality of Life Scale, Version 4
C114882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114882>	C71685	Somewhat Better|Slightly Better	In a slightly improved condition.			Qualitative Concept	Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire
C114883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114883>	C71686	Somewhat Worse	Showing some signs of deterioration or decline.			Qualitative Concept	Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire
C114884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114884>	C71686	Much Worse	Showing many obvious signs of deterioration or decline.			Qualitative Concept	Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire
C114885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114885>	C173924	Cut Down on Amount of Time Spent on Work or Other Activities Question|Cut Down on Amount of Time Spent on Work or Other Activities|Cut down on the amount of time you spent on work or other activities	A question about whether an individual has decreased the amount of time they have spent on work or other activities.			Intellectual Product	Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire
C114886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114886>	C91103	Accomplished Less Than Liked Question|Accomplished Less Than Liked|Accomplished less than you would like	A question about whether an individual accomplished less than they liked.			Intellectual Product	Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire
C114887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114887>	C173924|C173695	Limited in the Kind of Work or Other Activities Question|Limited in the Kind of Work or Other Activities|Were limited in the kind of work or other activities	A question about whether an individual is or was limited in the kind of work or other activities they could do.			Intellectual Product	Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire
C114888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114888>	C173924|C173398	Have Difficulty Performing Work or Other Activities Question|Had difficulty performing the work or other activities (for example, it took extra effort)|Have Difficulty Performing Work or Other Activities	A question about whether an individual has or had difficulty performing work or other activities.			Intellectual Product	Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire
C114889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114889>	C54597	Manufactures Animal Prescription Drugs|Manufactures animal prescription drug products	A business that makes prescription veterinary products.			Functional Concept	FDA Structured Product Labeling Terminology|SPL Business Operation Qualifier Terminology
C11488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11488>	C61063	Phenylbutyrate/Tretinoin|ATRA/PBA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114890>	C54597	Manufactures Veterinary Feed Directive Type A Drugs|Manufactures veterinary feed directive Type A medicated article drug products	A business that makes veterinary Type A drugs that require a feed directive.			Functional Concept	FDA Structured Product Labeling Terminology|SPL Business Operation Qualifier Terminology
C114891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114891>	C54597	Manufactures Animal Over-the-Counter Drugs|Manufactures animal over-the-counter drug products	A business that makes non-prescription veterinary drugs.			Functional Concept	FDA Structured Product Labeling Terminology|SPL Business Operation Qualifier Terminology
C114892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114892>	C54597	Manufactures Animal Over-the-Counter Type A Drugs|Manufactures animal over-the-counter Type A medicated article drug products	A business that makes non-prescription veterinary Type A drugs which do not require a feed directive.			Functional Concept	FDA Structured Product Labeling Terminology|SPL Business Operation Qualifier Terminology
C114893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114893>	C20744	SPRR1A Gene|SPRR1A|SPRR1A|Small Proline-Rich Protein 1A Gene	This gene is involved in keratinization.			Gene or Genome	
C114894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114894>	C114893	SPRR1A wt Allele|SPRK|Small Proline-Rich Protein 1A wt Allele	Human SPRR1A wild-type allele is located within 1q21-q22 and is approximately 2 kb in length. This allele, which encodes cornifin-A protein, plays a role in keratinocyte differentiation.			Gene or Genome	
C114895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114895>	C18073	Cornifin-A|19 kDa Pancornulin|Cornifin A|SPR-IA|SPRK|Small Proline-Rich Protein 1A|Small Proline-Rich Protein IA	Cornifin-A (89 aa, ~10 kDa) is encoded by the human SPRR1A gene. This protein is involved in cornified envelope development.			Amino Acid, Peptide, or Protein	
C114896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114896>	C20744	SPRR2A Gene|SPRR2A|SPRR2A|Small Proline-Rich Protein 2A Gene	This gene plays a role in the differentiation of keratinocytes.			Gene or Genome	
C114897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114897>	C114896	SPRR2A wt Allele|Small Proline-Rich Protein 2A wt Allele	Human SPRR2A wild-type allele is located within 1q21-q22 and is approximately 1 kb in length. This allele, which encodes small proline-rich protein 2A, is involved in cornified envelope formation.			Gene or Genome	
C114898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114898>	C18073	Small Proline-Rich Protein 2A|2-1|SPR-2A|SPRR2A	Small proline-rich protein 2A (72 aa, ~8 kDa) is encoded by the human SPRR2A gene. This protein plays a role in keratinocyte differentiation.			Amino Acid, Peptide, or Protein	
C114899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114899>	C99248	Transient Neonatal Diabetes Mellitus	Hyperglycemia in the first month of life due to a genetically determined defect in the structure, secretion and/or function of insulin that resolves spontaneously within nine months of onset.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology|Perinatal Terminology
C11489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11489>	C61063	Asparaginase/Dexamethasone/Mercaptopurine/Vincristine|ASP/DM/MP/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1148>	C1712	Recombinant Lymphotactin|Lymphotactin	A recombinant chemokine of human lymphotactin which is produced by activated progenitor T cells and characterized by specific chemotactic activity for lymphocytes. (NCI)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C114900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114900>	C27101	Emotional Problem	A perceived issue with a person's emotional wellbeing.			Finding	Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire
C114901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114901>	C3303	Bodily Pain|Body Pain	The sensation of acute or chronic suffering in a body region.			Sign or Symptom	Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire
C114902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114902>	C99248	Permanent Neonatal Diabetes Mellitus	Hyperglycemia in the first month of life due to a genetically determined defect in the structure, secretion and/or function of insulin that does not resolve spontaneously.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology|Perinatal Terminology
C114903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114903>	C173924	Did Work or Other Activities Less Carefully than Usual Question|Did Work or Other Activities Less Carefully than Usual|Did work or other activities less carefully than usual	A question about whether an individual did work or other activities less carefully than usual.			Intellectual Product	Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire
C114904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114904>	C173924|C173584|C173346	Pain Has Interfered with Normal Work Question|How much did pain interfere with your normal work|Pain Has Interfered with Normal Work	A question about whether an individual has or had pain that interferes with their normal work.			Intellectual Product	Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire
C114905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114905>	C173160	Feel Full of Life Question|Did you feel full of life|Feel Full of Life	A question about whether an individual feels or felt full of life.			Intellectual Product	Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire
C114906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114906>	C98996|C61469	Neonatal Thyrotoxicosis|Infantile Hyperthyroidism	A hypermetabolic syndrome characterized by tachycardia, palpitations, tremor, weight loss, and moist skin that is caused by the elevation of thyroid hormone levels in the serum of the newborn infant or thyroid-axis receptor activation, most commonly due to transplacental passage of thyroid stimulating globulins.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C114907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114907>	C98996|C78350	Transient Neonatal Hypoparathyroidism	A disorder of decreased production of parathyroid hormone by the parathyroid gland in a newborn. It is due to maternal hyperparathyroidism. It may be characterized by hypocalcemic seizures in the first weeks of life.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C114908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114908>	C20709	NR1H4 Gene|NR1H4|NR1H4|Nuclear Receptor Subfamily 1, Group H, Member 4 Gene	This gene is involved in bile acid binding and metabolism.			Gene or Genome	
C114909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114909>	C84915	Necrotizing Enterocolitis Totalis	A severe and often fatal form of necrotizing enterocolitis, in which diffuse ischemia, necrosis, and pneumatosis intestinalis are evident in the small and large intestine. Short bowel syndrome is common among survivors.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C11490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11490>	C61063	Asparaginase/Daunorubicin/Dexamethasone/Vincristine|ASP/DM/DNR/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114910>	C39611	Spontaneous Intestinal Perforation	A focal intestinal perforation without a definite cause, commonly located in the terminal ileum, lacking the transmural inflammation and/or pneumatosis typically seen in necrotizing enterocolitis.			Finding	NICHD Terminology|Perinatal Terminology
C114911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114911>	C114908	NR1H4 wt Allele|BAR|FXR|HRR-1|HRR1|Nuclear Receptor Subfamily 1, Group H, Member 4 wt Allele|RIP14	Human NR1H4 wild-type allele is located in the vicinity of 12q23.1 and is approximately 91 kb in length. This allele, which encodes bile acid receptor protein, plays a role in both the metabolism of bile acids and ligand-dependent transcriptional regulation.			Gene or Genome	
C114912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114912>	C128275	Bile Acid Receptor|Farnesoid X Nuclear Receptor|Farnesoid X-Activated Receptor|Farnesol Receptor HRR-1|NR1H4|Nuclear Receptor Subfamily 1 Group H Member 4|RXR-Interacting Protein 14|Retinoid X Receptor-Interacting Protein 14	Bile acid receptor (486 aa, ~56 kDa) is encoded by the human NR1H4 gene. This protein is involved in both ligand-mediated gene expression and the metabolism of bile acids.			Amino Acid, Peptide, or Protein|Receptor	
C114913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114913>	C173981	Have a Lot of Energy Question|Did you have a lot of energy|Have a Lot of Energy	A question about whether an individual has or had a lot of energy.			Intellectual Product	Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire
C114914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114914>	C173219	Feel Worn Out Question|Am Worn Out|Did you feel worn out|Feel Worn Out|I am worn out	A question about whether an individual feels or felt worn out.			Intellectual Product	Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire
C114915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114915>	C91103	Get Sick Easier Than Others Question|Get Sick Easier Than Others|I seem to get sick a little easier than other people	A question about whether an individual thinks that they get sick easier than other people.			Intellectual Product	Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire
C114916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114916>	C12680	Jaw Region	The body region composed of the jaw bones and supporting structures.			Body Location or Region	
C114917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114917>	C91103	Am as Healthy as Anybody Question|Am as Healthy as Anybody|I am as healthy as anybody I know	A question about whether an individual feels or felt as healthy as other people.			Intellectual Product	Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire
C114918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114918>	C91103	Expect My Health to Get Worse Question|Expect My Health to Get Worse|I expect my health to get worse	A question about whether an individual expects their health to get worse.			Intellectual Product	Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire
C114919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114919>	C26006	RINT1 Gene|RAD50 Interactor 1 Gene|RINT1|RINT1	This gene plays a role in both telomere length maintenance and cellular trafficking.			Gene or Genome	
C11491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11491>	C61063	Dexamethasone/Leucovorin Calcium/Mercaptopurine/Methotrexate/Vincristine|CF/DM/MP/MTX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114920>	C114919	RINT1 wt Allele|FLJ11785|RAD50 Interactor 1 wt Allele|RINT-1	Human RINT1 wild-type allele is located in the vicinity of 7q22.3 and is approximately 36 kb in length. This allele, which encodes RAD50-interacting protein 1, is involved in both the regulation of vesicle transport and the maintenance of telomeres.			Gene or Genome	
C114921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114921>	C16386	RAD50-Interacting Protein 1|HsRINT-1|RINT-1|RINT1	RAD50-interacting protein 1 (792 aa, ~91 kDa) is encoded by the human RINT1 gene. This protein plays a role in both telomere maintenance and vesicle transport.			Amino Acid, Peptide, or Protein	
C114922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114922>	C91103	My Health is Excellent Question|My Health is Excellent|My health is excellent	A question about whether an individual feels or felt that their health is excellent.			Intellectual Product	Short Form 36 Health Survey Standard, US Version 2.0 Questionnaire
C114923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114923>	C3800	Adult Epithelioid Hemangioendothelioma|Epithelioid Hemangioendothelioma	An epithelioid hemangioendothelioma that occurs during adulthood.	Adult Epithelioid Hemangioendothelioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114924>	C25952	NT5E Gene|5'-Nucleotidase, Ecto (CD73) Gene|NT5E|NT5E	This gene is involved in nucleotide hydrolysis.	NT5E Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114925>	C114924	NT5E wt Allele|5' Nucleotidase (CD73) Gene|5'-Nucleotidase, Ecto (CD73) wt Allele|CALJA|CD73|E5NT|NT|NT5|NTE|RP11-321N4.1|eN|eNT	Human NT5E wild-type allele is located within 6q14-q21 and is approximately 46 kb in length. This allele, which encodes 5'-nucleotidase protein, plays a role in nucleoside formation. Mutation of the gene is associated with calcification of joints and arteries.	NT5E wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114926>	C4005|C3800|C188963	Childhood Epithelioid Hemangioendothelioma|Epithelioid Hemangioendothelioma	An epithelioid hemangioendothelioma that occurs during childhood.	Childhood Epithelioid Hemangioendothelioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114927>	C16561	5'-Nucleotidase|5'-NT|5-Nucleotidase|CD73|CD73 Antigen|EC 3.1.3.5|Ecto-5'-Nucleotidase|Ecto-5-Prime Nucleotidase|NT5E|Nucleotidase, Ecto-5-Prime|Purine 5-Prime-Nucleotidase	5'-nucleotidase (574 aa, ~63 kDa) is encoded by the human NT5E gene. This protein is involved in the conversion of nucleotides to nucleosides.	5-Nucleotidase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114928>	C118807|C113395	Infant Formula Intolerance|Breast Milk Substitute Intolerance|Breast Milk Substitute Intolerance	Inability to effectively digest or absorb the components of breast milk substitutes. Symptoms may include emesis, abdominal distension or diarrhea.			Finding	NICHD Terminology|Perinatal Terminology
C114929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114929>	C3107	Adult Langerhans Cell Histiocytosis|Langerhans Cell Histiocytosis	Langerhans cell histiocytosis that occurs during adulthood.	Adult Langerhans Cell Histiocytosis		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C11492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11492>	C61063	Asparaginase/Cyclophosphamide/Cytarabine/Daunorubicin/Dexamethasone/Mercaptopurine/Methotrexate/Thioguanine/Vincristine|ARA-C/ASP/CTX/DM/DNR/MP/MTX/TG/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114930>	C16731	Healthy Term Newborn	An age group comprised of infants delivered after full 37 weeks gestation whose 5 minute Apgar score was above 7, has no major congenital anomalies and was discharged home with mother without any additional diagnoses except for physiologic hyperbilirubinemia.			Age Group	
C114931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114931>	C16731	Healthy Preterm Newborn	An age group comprised of healthy newborns whose only diagnoses are those related to prematurity.			Age Group	
C114932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114932>	C5214	Hormone-Resistant Breast Carcinoma|Hormone-Refractory Breast Cancer|Hormone-Resistant Breast Adenocarcinoma|Hormone-Resistant Breast Cancer|Hormone-Resistant Breast Cancer	Breast adenocarcinoma that does not respond to hormone therapy.	Hormone-Resistant Breast Cancer		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114933>	C4863	Hormone-Resistant Prostate Carcinoma|Hormone-Resistant Prostate Cancer|Hormone-Resistant Prostate Cancer	Prostate carcinoma that does not respond to hormone therapy.	Hormone-Resistant Prostate Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114934>	C118807	Small for Gestational Age|Small For Dates Baby	A newborn infant who has weight and/or length at birth more than two standard deviations below the mean for the reference population of the same sex and gestational age.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology|Perinatal Terminology
C114935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114935>	C76325	Very Low Birth Weight|VLBW	Birth weight less than 1500 grams.			Finding	GAIA Low Birth Weight Level of Diagnostic Certainty Terminology|GAIA Terminology|NICHD Terminology|Perinatal Terminology
C114936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114936>	C76325	Extremely Low Birth Weight|ELBW	Birth weight less than 1000 grams.			Finding	GAIA Low Birth Weight Level of Diagnostic Certainty Terminology|GAIA Terminology|NICHD Terminology|Perinatal Terminology
C114937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114937>	C76325	Ultra Low Birth Weight|ULBW	Birth weight less than 750 grams.			Finding	
C114938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114938>	C16731	Late Preterm Infant|Near Term Infant|Near Term Infant	An age group comprised of infants greater than or equal to 34 weeks, 0 days and less than 37 weeks, 0 days gestational age.			Age Group	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C114939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114939>	C16731	Extremely Preterm Infant|Extreme Immaturity|Extreme Immaturity	An age group comprised of infants less than 28 weeks, 0 days gestational age.			Age Group	GAIA Preterm Birth Level of Diagnostic Certainty Terminology|GAIA Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C11493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11493>	C61007	Dexamethasone/Rituximab|DM/MOAB IDEC-C2B8			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114940>	C9305|C4784	Malignant Cardiovascular Neoplasm	A primary or metastatic malignant neoplasm involving the cardiovascular system.	Malignant Cardiovascular Neoplasm		Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C114941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114941>	C26511	CYP7B1 Gene|CYP7B1|CYP7B1|Cytochrome P450, Family 7, Subfamily B, Polypeptide 1 Gene	This gene plays a role in cholesterol metabolism.			Gene or Genome	
C114942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114942>	C114941	CYP7B1 wt Allele|CBAS3|CP7B|Cytochrome P450, Family 7, Subfamily B, Polypeptide 1 wt Allele|Cytochrome P450, Subfamily VIIB (Oxysterol 7 Alpha-Hydroxylase), Polypeptide 1 Gene|SPG5A|Spastic Paraplegia 5A (Autosomal Recessive) Gene	Human CYP7B1 wild-type allele is located in the vicinity of 8q21.3 and is approximately 211 kb in length. This allele, which encodes 25-hydroxycholesterol 7-alpha-hydroxylase enzyme, is involved in cholesterol catabolism. Mutation of the gene is associated with autosomal recessive spastic paraplegia 5A and congenital bile acid synthesis defect 3.			Gene or Genome	
C114943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114943>	C16484	25-Hydroxycholesterol 7-Alpha-Hydroxylase|CYP7B1|Cytochrome P450 7B1|Cytochrome P450 Family 7 Subfamily B Polypeptide 1|EC 1.14.13.100|Oxysterol 7-Alpha-Hydroxylase|Oxysterol 7-Alpha-Hydroxylase 1|Oxysterol 7alpha-Hydroxylase	25-hydroxycholesterol 7-alpha-hydroxylase (506 aa, ~58 kDa) is encoded by the human CYP7B1 gene. This protein plays a role in the conversion of cholesterol into bile acids.			Amino Acid, Peptide, or Protein|Enzyme	
C114944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114944>	C198033	Leukemic Infiltration of Brain	A finding indicating the presence of leukemic cell infiltrates in the brain tissue.	Leukemic Infiltration of Brain		Finding	CTRP Disease Terminology|CTRP Terminology
C114945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114945>	C25804	ATAD5 Gene|ATAD5|ATAD5|ATPase Family, AAA Domain Containing 5 Gene	This gene is involved in the DNA damage response.	ATAD5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C114946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114946>	C114945	ATAD5 wt Allele|ATPase Family, AAA Domain Containing 5 wt Allele|ATPase Family, AAA Domain-Containing, Member 5 Gene|C17orf41|Chromosome 17 Open Reading Frame 41 Gene|Chromosome Fragility Associated Gene 1|ELG1|Enhanced Level Of Genomic Instability 1 Homolog (S. Cerevisiae) Gene|FLJ12735|FRAG1	Human ATAD5 wild-type allele is located in the vicinity of 17q11.2 and is approximately 64 kb in length. This allele, which encodes ATPase family AAA domain-containing protein 5, plays a role in the cellular response to DNA damage.	ATAD5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114947>	C16731	Postterm Infant|Post Dates|Post Dates|Postmature|Postmature	An age group comprised of infants greater than or equal to 42 weeks, 0 days gestational age.			Age Group	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C114948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114948>	C16701	ATPase Family AAA Domain-Containing Protein 5|ATAD5|Chromosome Fragility-Associated Gene 1 Protein|Enhanced Level of Genomic Instability 1 Homolog	ATPase family AAA domain-containing protein 5 (1844 aa, ~208 kDa) is encoded by the human ATAD5 gene. This protein is involved in the DNA damage checkpoint.	ATPase Family AAA Domain-Containing Protein 5		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C114949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114949>	C9357|C87797	Secondary Central Nervous System Hodgkin Lymphoma	A Hodgkin lymphoma that has spread to the central nervous system following the initial presentation in another nodal or extranodal site.	Secondary Central Nervous System Hodgkin Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C11494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11494>	C61007	Interferon Alfa/Interleukin-2 Liposome/Polyvalent Melanoma Vaccine|IFN-A/IL-2 LIPO/POLYMELVAC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114950>	C87797|C212064	Secondary Central Nervous System Non-Hodgkin Lymphoma	A non-Hodgkin lymphoma that has spread to the central nervous system following the initial presentation in another nodal or extranodal site.	Secondary Central Nervous System Non-Hodgkin Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114951>	C9357|C9301	Primary Central Nervous System Hodgkin Lymphoma	A Hodgkin lymphoma that arises from the central nervous system.	Primary Central Nervous System Hodgkin Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114952>	C16615	EN1 Gene|EN1|EN1|Engrailed Homeobox 1 Gene	This gene plays a role in the regulation of both gene expression and embryo morphogenesis.			Gene or Genome	
C114953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114953>	C114952	EN1 wt Allele|En-1|Engrailed Homeobox 1 wt Allele	Human EN1 wild-type allele is located in the vicinity of 2q14.2 and is approximately 6 kb in length. This allele, which encodes homeobox protein engrailed-1, is involved in both embryonic morphogenesis and transcriptional regulation.			Gene or Genome	
C114954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114954>	C60698	Malignant Biliary Obstruction	Blockage in the biliary tract caused by a malignant neoplasm.	Malignant Biliary Obstruction		Finding	CTRP Disease Terminology|CTRP Terminology
C114955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114955>	C17207	Homeobox Protein Engrailed-1|Engrailed 1|Engrailed Homolog 1|Engrailed-1|Homeobox Protein En-1|Hu-En-1	Homeobox protein engrailed-1 (392 aa, ~40 kDa) is encoded by the human EN1 gene. This protein plays a role in both transcriptional regulation and embryonic development.			Amino Acid, Peptide, or Protein	
C114956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114956>	C9022|C221718|C203274	Recurrent Childhood Astrocytic Tumor|Recurrent Astrocytic Tumor	The reemergence of a childhood astrocytic tumor after a period of remission.	Recurrent Childhood Astrocytic Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114957>	C16615	HHEX Gene|HHEX|HHEX|Hematopoietically Expressed Homeobox Gene	This gene is involved in transcriptional modulation.			Gene or Genome	
C114958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114958>	C114957	HHEX wt Allele|HEX|HMPH|HOX11L-PEN|Hematopoietically Expressed Homeobox wt Allele|PRH|PRHX	Human HHEX wild-type allele is located in the vicinity of 10q23.33 and is approximately 7 kb in length. This allele, which encodes hematopoietically-expressed homeobox protein HHEX, plays a role in transcriptional regulation.			Gene or Genome	
C114959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114959>	C17207	Hematopoietically-Expressed Homeobox Protein HHEX|Homeobox Protein HEX|Homeobox Protein PRH|Homeobox, Hematopoietically Expressed|Proline-Rich Homeodomain-Containing Transcription Factor	Hematopoietically-expressed homeobox protein HHEX (270 aa, ~30 kDa) is encoded by the human HHEX gene. This protein is involved in the negative regulation of transcription.			Amino Acid, Peptide, or Protein	
C11495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11495>	C61063	Asparaginase/Dexamethasone/Etoposide/Mitoxantrone|ASP/DHAD/DM/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114960>	C2849	Congenital Disruption	A morphologic defect of an organ, part of an organ, or a larger region of the body that results from the extrinsic breakdown of, or an interference with, an originally normal developmental process.			Congenital Abnormality	NICHD Terminology|Perinatal Terminology
C114961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114961>	C114994	Untreated Childhood Low Grade Astrocytic Tumor|Untreated Low Grade Astrocytic Tumor	A finding of childhood low grade astrocytic tumor that has not been treated.	Untreated Childhood Low Grade Astrocytic Tumor		Finding	CTRP Disease Terminology|CTRP Terminology
C114962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114962>	C114994	Untreated Childhood High Grade Astrocytic Tumor|Untreated High Grade Astrocytic Tumor	A finding of childhood high grade astrocytic tumor that has not been treated.	Untreated Childhood High Grade Astrocytic Tumor		Finding	CTRP Disease Terminology|CTRP Terminology
C114963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114963>	C4322|C114967	Childhood Fibrillary Astrocytoma|Fibrillary Astrocytoma	A fibrillary astrocytoma that occurs during childhood.	Childhood Fibrillary Astrocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C114964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114964>	C4321|C114967	Childhood Gemistocytic Astrocytoma|Gemistocytic Astrocytoma	A gemistocytic astrocytoma that occurs during childhood.	Childhood Gemistocytic Astrocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C114965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114965>	C35869	Clustered Ring Enhancement	Thin rings of enhancement visible in MRI that are clustered together around breast ducts in an area that is neither a mass nor a foci.			Finding	
C114966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114966>	C5136|C4325	Childhood Giant Cell Glioblastoma|Giant Cell Glioblastoma	A giant cell glioblastoma that occurs during childhood.	Childhood Giant Cell Glioblastoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C114967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114967>	C7173|C202299|C124275	Childhood Diffuse Astrocytoma|Diffuse Astrocytoma|Diffuse Astrocytoma	A diffuse astrocytoma that occurs during childhood.	Childhood Diffuse Astrocytoma		Neoplastic Process	CRF1 Registration Table|CRF3 Diagnosis Biopsy Table|CRF3 Diagnosis Re-Biopsy Table|CRF7 Pathology Review Table|CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C114968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114968>	C5136|C3796	Childhood Gliosarcoma|Gliosarcoma	A gliosarcoma that occurs during childhood.	Childhood Gliosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C114969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114969>	C4318|C187207	Childhood Gliomatosis Cerebri|Gliomatosis Cerebri	Gliomatosis cerebri that occurs during childhood.	Childhood Gliomatosis Cerebri		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C11496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11496>	C61063	Asparaginase/Mercaptopurine/Methotrexate/Vincristine|ASP/MP/MTX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114970>	C40315|C124275	Childhood Pilomyxoid Astrocytoma|Pilomyxoid Astrocytoma	A pilomyxoid astrocytoma that occurs during childhood.	Childhood Pilomyxoid Astrocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C114971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114971>	C4323|C202299|C124275	Childhood Pleomorphic Xanthoastrocytoma|Pleomorphic Xanthoastrocytoma	A pleomorphic xanthoastrocytoma that occurs during childhood.	Childhood Pleomorphic Xanthoastrocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C114972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114972>	C4320|C114967	Childhood Protoplasmic Astrocytoma|Protoplasmic Astrocytoma	A protoplasmic astrocytoma that occurs during childhood.	Childhood Protoplasmic Astrocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C114973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114973>	C6959|C208306|C115195	Childhood Anaplastic Oligoastrocytoma|Anaplastic Oligoastrocytoma	An anaplastic oligoastrocytoma that occurs during childhood.	Childhood Anaplastic Oligoastrocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C114974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114974>	C4050|C202299|C115195	Childhood Oligoastrocytoma|Oligoastrocytoma	An oligoastrocytoma that occurs during childhood.	Childhood Oligoastrocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C114975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114975>	C1291	Bazlitoran|BAZLITORAN|IMO-8400|Oligonucleotide IMO-8400	An oligonucleotide targeted to the mRNA of MYD88 L265P, a mutant form of the linker protein MYD88, with potential antitumor activity. Bazlitoran binds to and inhibits the translation of mutated MYD88 L265P mRNA. This prevents overactivation of signaling pathways mediated by toll-like receptors (TLRs) 7, 8, and 9, nuclear factor-kappa B (NF-kB) activity, Janus-associated kinases-signal transducer and activator of transcription (JAK-STAT) signaling and the production of various cytokines. Together, this leads to an induction of apoptosis and an inhibition of tumor cell proliferation in MYD88 L265P-expressing tumor cells. MYD88, a key adaptor protein in the TLR signaling pathway, is mutated in a variety of B-cell lymphomas, including Waldenstrom's macroglobulinemia (WM) and activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL).			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C114976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114976>	C2150	RNR Inhibitor COH29|COH-29|COH-29|COH29|N-(4-(3,4-dihydroxyphenyl)-5-phenylthiazol-2-yl)-3,4-dihydroxybenzamide|Ribonucleotide Reductase Holoenzyme Inhibitor COH29	An orally available, aromatically substituted thiazole and inhibitor of the human ribonucleotide reductase (RNR), with potential antineoplastic activity. Upon oral administration, the RNR inhibitor COH29 binds to the ligand-binding pocket of the RNR M2 subunit (hRRM2) near the C-terminal tail. This blocks the interaction between the hRRM1 and hRRM2 subunits and interferes with the assembly of the active hRRM1/hRRM2 complex of RNR. Inhibition of RNR activity decreases the pool of deoxyribonucleotide triphosphates available for DNA synthesis. The resulting decrease in DNA synthesis causes cell cycle arrest and growth inhibition. In addition, this agent may inhibit the nuclear enzyme poly (ADP-ribose) polymerase (PARP) 1, which prevents the repair of damaged DNA, and causes both the accumulation of single and double strand DNA breaks and the induction of apoptosis. RNR, an enzyme that catalyzes the conversion of ribonucleoside diphosphate to deoxyribonucleoside diphosphate, is essential for de novo DNA synthesis and plays an important role in cell growth; it is overexpressed in many cancer cell types and is associated with increased drug resistance, cancer cell growth and metastasis.	RNR Inhibitor COH29		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C114977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114977>	C1331	Etoposide Toniribate|CAP7.1|EDO-S7.1|ETOPOSIDE TONIRIBATE	A prodrug of etoposide, a semisynthetic derivative of podophyllotoxin extracted from the mandrake root Podophyllum peltatum, with potential antineoplastic activity. Upon intravenous administration of etoposide toniribate, etoposide is released after enzymatic cleavage of CAP7.1 by specific carboxylesterases (CE) 1 and 2, which are upregulated in certain tumor cell types. Etoposide acts primarily in the G2 and S phases of the cell cycle. This drug binds to and inhibits topoisomerase II, an enzyme elevated in tumor cells. This results in the accumulation of double-strand DNA breaks, the inhibition of DNA replication and transcription and the induction of apoptotic cell death. The tumor-specific activation of etoposide increases its efficacy while lowering its systemic toxicity.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C114978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114978>	C28681|C138180	MAGE-A4-specific TCR Gene-transduced Autologous T Lymphocytes TBI-1201|TBI-1201	Autologous human T-lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the human melanoma antigen A4 (MAGE-A4), with potential immunostimulatory and antineoplastic activities. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, MAGE-A4-specific TCR gene-transduced T-lymphocytes TBI-1201 binds to tumor cells expressing MAGE-A4. This may result in both an inhibition of growth and increased cell death for MAGE-A4-expressing tumor cells. The tumor-associated antigen MAGE-A4 is overexpressed by a variety of cancer cell types.	MAGE-A4-specific TCR Gene-transduced Autologous T Lymphocytes TBI-1201		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C114979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114979>	C1966	Tozuleristide|BLZ-100|TOZULERISTIDE	A tumor targeting imaging agent composed of the tumor-specific peptide chlorotoxin (CTX), a 36-amino acid neurotoxin found in the venom of the Leiurus quinquestriatus scorpion, linked to the fluorescent dye indocyanine green (ICG), with potential tumor imaging activity using a near-infrared (NIR) imaging system. Upon intravenous administration of BLZ-100, the CTX moiety of BLZ-100 specifically binds to and is internalized by cancer cells of neuroectodermal origin. Using a NIR imaging system, the ICG, which emits light in the NIR range, permits the intraoperative visualization of tumor cells. This leads to the clear distinction of healthy tissues from tumor cells, and facilitates the surgical removal of tumor tissue while sparing normal, healthy cells.	Tozuleristide		Indicator, Reagent, or Diagnostic Aid	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C11497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11497>	C61063	Cytarabine/Mercaptopurine/Methotrexate/Prednisone|ARA-C/MP/MTX/PRED			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114980>	C162996	MDM2 Antagonist RO6839921|RO6839921	An MDM2 (human homolog of murine double minute-2; HDM2) antagonist with potential antineoplastic activity. Upon intravenous administration, RO6839921 binds to MDM2 and prevents the binding of the MDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing MDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This may result in the restoration of p53 signaling, followed by p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein, is a negative regulator of the p53 pathway and is often overexpressed in cancer cells; p53 inhibition has been implicated in cancer cell proliferation and survival.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C114981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114981>	C217549	Daclatasvir|BMS-790052|Carbamic Acid, N,N'-((1,1'-biphenyl)-4,4'-diylbis(1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl((1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl)))bis-, C,C'-dimethyl Ester|DACLATASVIR|DCV	An orally available inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex, with potential activity against HCV. Although the exact mechanism of action of daclatasvir has yet to be fully determined, this agent, upon oral administration and after intracellular uptake, appears to bind to domain I of the NS5A protein. This inhibits the activity of the NS5A protein and results in the disruption of the viral RNA replication complex, blockage of viral HCV RNA production, and inhibition of viral replication. NS5A, a zinc-binding and proline-rich hydrophilic phosphoprotein, plays a crucial role in HCV RNA replication. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C114982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114982>	C217517	Asunaprevir|1,1-Dimethylethyl ((1S)-1-(((2S,4R)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2- (((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-ethenylcyclopropyl)carbamoyl) pyrrolidin-1-yl)carbonyl)-2,2-dimethylpropyl)carbamate|ASUNAPREVIR|ASV|BMS-650032	An orally bioavailable inhibitor of the nonstructural protein 3 (NS3), with potential activity against hepatitis C virus (HCV). Upon administration, asunaprevir binds to the active center of the HCV NS3 and prevents NS3 protease-mediated polyprotein maturation. This disrupts the processing of viral proteins required for HCV replication. NS3, a serine protease, is essential for the proteolytic cleavages within the HCV polyprotein and plays a key role during HCV viral RNA replication. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C114983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114983>	C217652	Beclabuvir|(4bS,5aR)-12-Cyclohexyl-N-(dimethylsulfamoyl)-3-methoxy-5a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)-4b,5,5a,6-tetrahydrocyclopropa(d)indolo(2,1-a)(2)benzazepine-9-carboxamide|BECLABUVIR|BMS-791325	A non-nucleoside, polymerase inhibitor of the hepatitis C virus (HCV) nonstructural protein 5B (NS5B), a RNA-dependent RNA polymerase, with potential activity against HCV. Upon administration and after intracellular uptake, beclabuvir allosterically binds to the non-catalytic Thumb 1 site of viral HCV NS5B polymerase and causes a decrease in viral RNA synthesis and replication. The HCV NS5B protein is essential for the replication of the viral HCV RNA genome. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C114984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114984>	C141136|C129825	Entrectinib|ENTRECTINIB|N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide|RXDX 101|RXDX-101|RXDX101|Rozlytrek	An orally bioavailable inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon administration, entrectinib binds to and inhibits TrkA, TrkB, TrkC, ROS1 and ALK. Inhibition of these kinases may result in a disruption of TrkA-, TrkB-, TrkC-, ROS1-, and ALK-mediated signaling. This leads to an induction of apoptosis and an inhibition of tumor cell proliferation in tumor cells that express these kinases. TrkA, TrkB, TrkC, ROS1 and ALK are overexpressed in a variety of cancer cell types.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C114985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114985>	C28681	Ex Vivo-activated Autologous Lymph Node Lymphocytes|X-ACT|X-ACT Autologous Lymph Node Lymphocytes	Autologous human lymph node T-lymphocytes, with potential immunostimulatory and antineoplastic activity. Upon collection of immune cells from the tumor-draining lymph node, the human lymph node lymphocytes are activated with anti-CD3/anti-CD28 microbeads, cultured with recombinant, human interleukin-2 (IL-2), expanded and isolated ex vivo. Upon reintroduction into the patient, the ex vivo-activated autologous lymph node lymphocytes recognize and lyse the tumor cells.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C114986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114986>	C254	E-101 Solution|E-101	An oxidant-generating coupled-enzyme system-based, topical solution comprised of two enzymes, Aspergillus niger-derived glucose oxidase (GO) and porcine myeloperoxidase (p-MPO), as well as glucose, sodium chloride and stabilizing amino acids, with potential broad-spectrum microbicidal activity. Following direct administration of E-101 solution into the surgical incisional wound via microspray, the enzyme GO converts oxygen into hydrogen peroxide (H2O2). In turn, p-MPO catalyzes the reaction of H2O2 with hypochlorous acid (HOCl), which is formed through oxidation of the chloride ion, to generate singlet oxygen (O2*). As p-MPO binds to microorganisms, O2* is able to exert direct oxidative damage to microorganisms, resulting in potent antimicrobial activity. E-101 may act as an anti-bactericidal agent against a variety of microorganisms, including multidrug-resistant strains. This may prevent infection at the surgical site.	E-101 Solution		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C114987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114987>	C7711|C3828	Adult Combined Hepatocellular Carcinoma and Cholangiocarcinoma|Combined Hepatocellular Cancer and Cholangiocarcinoma	A combined hepatocellular carcinoma and cholangiocarcinoma that occurs during adulthood.	Adult Combined Hepatocellular Carcinoma and Cholangiocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114988>	C20130	CD1 Glycoprotein|CD1|Differentiation Antigen CD1-Alpha-3	A family of glycoproteins expressed on the surface of various human antigen-presenting cells. They are related to the class I MHC molecules, and are involved in the presentation of lipid antigens to T-cells. The family is separated into group 1, expressed on cells specialized for antigen presentation, and group 2, expressed on a wider variety of cells.			Amino Acid, Peptide, or Protein	
C114989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114989>	C20401	Anti-HCV E2 Monoclonal Antibody MBL-HCV1|MBL-HCV1	A neutralizing, human monoclonal antibody against the hepatitis C virus (HCV) E2 envelope glycoprotein, with potential immunomodulatory and antiviral activities against HCV. Upon administration, anti-HCV E2 monoclonal antibody MBL-HCV1 recognizes and binds to the E2 glycoprotein of HCV. This suppresses HCV load and provides passive immunization against HCV. This may prevent both infection by HCV in immunocompromised patients and hepatitis C-related liver disease. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology
C11498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11498>	C61007	Methotrexate/Methylprednisolone|MTX/MePRDL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C114990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114990>	C2594	Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine|FRaDC Vaccine|FRalphaDC Vaccine	A cell-based vaccine composed of autologous-monocyte-derived dendritic cells (DCs) loaded with five immunogenic peptide epitopes, derived from the tumor-associated antigen human folate receptor alpha (FR alpha or FOLR1), including FR30, FR56, FR76, FR113, and FR238, with potential immunomodulatory and antineoplastic activity. Ex vivo treatment of the DCs with a p38 inhibitor decreases p38-mediated signaling and enhances ERK activation. This may allow, upon intradermal administration of the multi-epitope FR alpha-loaded DC vaccine into the patient, for decreased activation and expansion of CD4+ regulatory T-cells (Tregs), increased differentiation and expansion of interleukin-17 secreting T helper cells (Th17) and activation of CD8+ CTLs, which induces a strong anti-tumor T-cell immune response against FR alpha-overexpressing tumor cells. FR alpha is a high-affinity folate-binding protein and a member of the folate receptor family; this receptor is overexpressed in the majority of ovarian cancers and in about approximately 50% of breast cancers.	Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine		Cell|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C114991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114991>	C21176	CD79	A transmembrane heterodimer consisting of B-cell antigen receptor complex-associated protein alpha chain (CD79A) and B-cell antigen receptor complex-associated protein beta chain (CD79B). CD79 is expressed almost exclusively on B cells and B-cell neoplasms and its presence is useful in the differential diagnosis of B-cell neoplasms from T-cell neoplasms or myeloid neoplasms.			Amino Acid, Peptide, or Protein|Receptor	
C114992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114992>	C7956|C4131	Adult Fibrolamellar Carcinoma|Fibrolamellar Cancer	A fibrolamellar carcinoma that occurs during adulthood.	Adult Fibrolamellar Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114993>	C7956|C43625	Adult Hepatocellular Pleomorphic Carcinoma|Adult Pleomorphic Hepatocellular Carcinoma|Pleomorphic Hepatocellular Cancer	A hepatocellular pleomorphic carcinoma that occurs during adulthood.	Adult Pleomorphic Hepatocellular Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C114994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114994>	C36280	Untreated Central Nervous System Neoplasm	A finding of central nervous system neoplasm that has not been treated.			Finding	
C114995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114995>	C20745	ANK2 Gene|ANK2|ANK2|Ankyrin 2, Neuronal Gene	This gene plays a role in both cytoskeletal structure and muscle contraction.			Gene or Genome	
C114996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114996>	C114995	ANK2 wt Allele|ANK-2|Ankyrin 2, Neuronal wt Allele|Ankyrin, Brain Gene|Ankyrin, Neuronal Gene|Ankyrin, Nonerythroid Gene|Ankyrin-2, Nonerythrocytic Gene|LQT4|Long (Electrocardiographic) QT Syndrome 4 Gene|brank-2	Human ANK2 wild-type allele is located within 4q25-q27 and is approximately 566 kb in length. This allele, which encodes ankyrin-2 protein, is involved in both neuromuscular junction formation and cytoskeletal remodeling. Mutation of the gene is associated with long QT syndrome 4 and ankyrin-B-related cardiac arrhythmia.			Gene or Genome	
C114997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114997>	C16492	Ankyrin-2|ANK-2|ANK2|Ankyrin 2|Ankyrin B|Ankyrin-B|Brain Ankyrin|Non-Erythroid Ankyrin	Ankyrin-2 (3957 aa, ~434 kDa) is encoded by the human ANK2 gene. This protein plays a role in cytoskeletal remodeling.			Amino Acid, Peptide, or Protein	
C114998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114998>	C20917	POGZ Gene|POGZ|POGZ|Pogo Transposable Element With ZNF Domain Gene	This gene is involved in mitosis.			Gene or Genome	
C114999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C114999>	C114998	POGZ wt Allele|Nbla00003|Pogo Transposable Element With ZNF Domain wt Allele|SUHW5|ZNF280E|ZNF635|ZNF635m	Human POGZ wild-type allele is located in the vicinity of 1q21.3 and is approximately 57 kb in length. This allele, which encodes pogo transposable element with ZNF domain protein, plays a role in the progression of mitosis.			Gene or Genome	
C11499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11499>	C61063	Carboplatin/Melphalan|CBDCA/L-PAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1149>	C29633	Aluminum Hydroxide/Magnesium Hydroxide|Maalox|Mylanta	An oral suspension containing aluminum hydroxide and magnesium hydroxide, with antacid effects. Aluminum hydroxide and magnesium hydroxide neutralizes or reduces gastric acid, thereby relieving symptoms associated with indigestion, gastritis, and gastroesophageal disease (GERD). Combined with other liquid ingredients (such as lidocaine and diphenhydramine), this antacid provides relief for painful stomatitis, mucositis, and esophagitis associated with both chemotherapy and radiation therapy.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C115000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115000>	C17761	Pogo Transposable Element With ZNF Domain|Suppressor of Hairy Wing Homolog 5|Zinc Finger Protein 280E|Zinc Finger Protein 635	Pogo transposable element with ZNF domain (1410 aa, ~155 kDa) is encoded by the human POGZ gene. This protein is involved in cell cycle progression.			Amino Acid, Peptide, or Protein	
C115001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115001>	C20745	TPM2 Gene|TPM2|TPM2|Tropomyosin 2 (Beta) Gene	This gene plays a role in both muscle contraction and actin binding.			Gene or Genome	
C115002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115002>	C115001	TPM2 wt Allele|AMCD1|Arthrogryposis Multiplex Congenital, Distal, Type 1 Gene|DA1|DA2B|HEL-S-273|NEM4|Nemaline Myopathy Type 4 Gene|TMSB|Tropomyosin 2 (Beta) wt Allele|Tropomyosin, Skeletal Muscle Beta Gene	Human TPM2 wild-type allele is located in the vicinity of 9p13 and is approximately 9 kb in length. This allele, which encodes tropomyosin beta chain protein, is involved in muscle contraction. Mutation of the gene is associated with nemaline myopathy type 4, cap myopathy type 2 and distal arthrogryposis types 1A and 2B.			Gene or Genome	
C115003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115003>	C16492	Tropomyosin Beta Chain|Beta-Tropomyosin|TPM2|Tropomyosin 2|Tropomyosin-2	Tropomyosin beta chain (284 aa, ~33 kDa) is encoded by the human TPM2 gene. This protein plays a role in muscle contraction.			Amino Acid, Peptide, or Protein	
C115004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115004>	C28404	USP13 Gene|USP13|USP13|Ubiquitin Specific Peptidase 13 (Isopeptidase T-3) Gene	This gene is involved in promoting protein stability.			Gene or Genome	
C115005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115005>	C115004	USP13 wt Allele|ISOT3|IsoT-3|Ubiquitin Specific Peptidase 13 (Isopeptidase T-3) wt Allele|Ubiquitin Specific Protease 13 (Isopeptidase T-3) Gene	Human USP13 wild-type allele is located within 3q26.2-q26.3 and is approximately 137 kb in length. This allele, which encodes ubiquitin carboxyl-terminal hydrolase 13 protein, plays a role in deubiquitination.			Gene or Genome	
C115006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115006>	C16481	Ubiquitin Carboxyl-Terminal Hydrolase 13|Deubiquitinating Enzyme 13|EC 3.4.19.12|ISOT-3|Isopeptidase T-3|Isopeptidase T3|USP13|Ubiquitin Specific Peptidase 13|Ubiquitin Thioesterase 13|Ubiquitin Thiolesterase 13|Ubiquitin-Specific Protease 13|Ubiquitin-Specific-Processing Protease 13	Ubiquitin carboxyl-terminal hydrolase 13 (863 aa, ~97 kDa) is encoded by the human USP13 gene. This protein is involved in protein deubiquitination.			Amino Acid, Peptide, or Protein|Enzyme	
C115007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115007>	C21295	CAVIN3 Gene|CAVIN3|CAVIN3|Caveolae Associated Protein 3 Gene|PRKCDBP	This gene plays a role in circadian rhythm pathways, caveolae formation and protein kinase C binding.			Gene or Genome	
C115008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115008>	C115007	CAVIN3 wt Allele|CAVIN 3|Caveolae Associated Protein 3 wt Allele|HSRBC|MGC20400|PRKCDBP|Protein Kinase C, Delta Binding Protein Gene|SRBC|Sdr-Related Gene Product That Binds To C-Kinase Gene|cavin-3	Human CAVIN3 wild-type allele is located in the vicinity of 11p15.4 and is approximately 2 kb in length. This allele, which encodes caveolae-associated protein 3, is involved in caveolae functioning, circadian signaling and binding to protein kinase C.			Gene or Genome	
C115009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115009>	C17728	Caveolae-Associated Protein 3|CAVIN3|Cavin 3|Cavin-3|PRKCDBP|Protein Kinase C Delta-Binding Protein|Serum Deprivation Response Factor-Related Gene Product That Binds To C-Kinase|hSRBC	Caveolae-associated protein 3 (261 aa, ~28 kDa) is encoded by the human CAVIN3 gene. This protein plays a role in both circadian clock signaling pathways and caveolae formation.			Amino Acid, Peptide, or Protein	
C11500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11500>	C61007	Cisplatin/Flavopiridol|CDDP/FLAVO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115010>	C21275	RCE1 Gene|RCE1|RCE1|Ras Converting CAAX Endopeptidase 1 Gene	This gene is involved in the modulation of protein prenylation.			Gene or Genome	
C115011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115011>	C115010	RCE1 wt Allele|FACE2|RCE1 (S. cerevisiae) Homolog, Prenyl Protein Protease Gene|RCE1 Homolog, Prenyl Protein Peptidase (S. cerevisiae) Gene|RCE1 Homolog, Prenyl Protein Protease (S. cerevisiae) Gene|RCE1 Homolog, Prenyl Protein Protease Gene|RCE1A|RCE1B|Ras Converting CAAX Endopeptidase 1 wt Allele	Human RCE1 wild-type allele is located in the vicinity of 11q13 and is approximately 4 kb in length. This allele, which encodes CAAX prenyl protease 2 protein, plays a role in the regulation of protein prenylation.			Gene or Genome	
C115012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115012>	C16843	CAAX Prenyl Protease 2|EC 3.4.22.-|FACE-2|Farnesylated Protein-Converting Enzyme 2|Farnesylated Proteins-Converting Enzyme 2|Prenyl Protein Protease RCE1|Prenyl Protein-Specific Endoprotease 2|RCE1 Homolog|Ras Converting CAAX Endopeptidase 1|hRCE1	CAAX prenyl protease 2 (329 aa, ~36 kDa) is encoded by the human RCE1 gene. This protein is involved in the removal of prenylated peptides from proteins.			Amino Acid, Peptide, or Protein|Enzyme	
C115013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115013>	C20103	VLDLR Gene|VLDLR|VLDLR|Very Low Density Lipoprotein Receptor Gene	This gene plays a role in both lipoprotein endocytosis and reelin signaling.			Gene or Genome	
C115014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115014>	C115013	VLDLR wt Allele|CARMQ1|CHRMQ1|RP11-320E16.1|VLDLRCH|Very Low Density Lipoprotein Receptor wt Allele	Human VLDLR wild-type allele is located in the vicinity of 9p24 and is approximately 33 kb in length. This allele, which encodes very low-density lipoprotein receptor protein, is involved in lipoprotein metabolism and the reelin signaling pathway. Mutation of the gene is associated with cerebellar hypoplasia and mental retardation with or without quadrupedal locomotion 1.			Gene or Genome	
C115015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115015>	C18106	Very Low-Density Lipoprotein Receptor|VLDL Receptor|VLDL-R	Very low-density lipoprotein receptor (873 aa, ~96 kDa) is encoded by the human VLDLR gene. This protein plays a role in the modulation of both reeling signaling and lipoprotein endocytosis.			Amino Acid, Peptide, or Protein|Receptor	
C115016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115016>	C20923	HTR2C Gene|5-Hydroxytryptamine (Serotonin) Receptor 2C, G Protein-Coupled Gene|HTR2C|HTR2C	This gene is involved in neurotransmitter-dependent G protein-coupled receptor signaling.			Gene or Genome	
C115017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115017>	C115016	HTR2C wt Allele|5-HT2C|5-HTR2C|5-Hydroxytryptamine (Serotonin) Receptor 2C Gene|5-Hydroxytryptamine (Serotonin) Receptor 2C, G Protein-Coupled wt Allele|5HTR2C|HTR1C|RP11-810O3.1|Serotonin 5-HT-1C Receptor, Formerly Gene	Human HTR2C wild-type allele is located in the vicinity of Xq23 and is approximately 326 kb in length. This allele, which encodes 5-hydroxytryptamine receptor 2C protein, plays a role in serotonin binding and signaling. This gene undergoes RNA deamination at sites designated A, B, C-prime, E, C, and D; RNA editing at sites C, D and C-prime may be associated with depression.			Gene or Genome	
C115018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115018>	C18239	5-Hydroxytryptamine Receptor 2C|5-HT-1C|5-HT-2C|5-HT1C|5-HT2C|5-HTR2C|5-Hydroxytryptamine Receptor 1C|Serotonin 5-HT-2C Receptor|Serotonin Receptor 2C	5-hydroxytryptamine receptor 2C (458 aa, ~52 kDa) is encoded by the human HTR2C gene. This protein is involved in serotonin-mediated neurotransmission pathways.			Amino Acid, Peptide, or Protein|Receptor	
C115019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115019>	C50995	Exceptional Response	An achievement of either a complete disease response, or a partial disease response of at least 6 months duration in a trial or treatment where the overall response rate is less than 10 percent.			Finding	
C11501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11501>	C61063	Amifostine/Etoposide|VP-16/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115020>	C28533	SLC2A3 Gene|SLC2A3|SLC2A3|Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 3 Gene	This gene plays a role in facilitated transport of glucose.	SLC2A3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C115021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115021>	C115020	SLC2A3 wt Allele|GLUT3|Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 3 wt Allele	Human SLC2A3 wild-type allele is located in the vicinity of 12p13.3 and is approximately 17 kb in length. This allele, which encodes solute carrier family 2, facilitated glucose transporter member 3 protein, is involved in glucose transport.	SLC2A3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115022>	C16386	Solute Carrier Family 2, Facilitated Glucose Transporter Member 3|GLUT-3|Glucose Transporter 3|Glucose Transporter Type 3, Brain|Glucose Transporter, Fetal Skeletal Muscle|SLC2A3	Solute carrier family 2, facilitated glucose transporter member 3 (496 aa, ~54 kDa) is encoded by the human SLC2A3 gene. This protein plays a role in the transport of glucose.	Solute Carrier Family 2, Facilitated Glucose Transporter Member 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115023>	C28533	SLC16A11 Gene|SLC16A11|SLC16A11|Solute Carrier Family 16 Member 11 Gene	This gene is involved in transport of carboxylates.			Gene or Genome	
C115024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115024>	C115023	SLC16A11 wt Allele|FLJ90193|MCT11|Solute Carrier Family 16 (Monocarboxylic Acid Transporters), Member 11 Gene|Solute Carrier Family 16 Member 11 wt Allele|Solute Carrier Family 16, Member 11 Gene	Human SLC16A11 wild-type allele is located in the vicinity of 17p13.1 and is approximately 2 kb in length. This allele, which encodes monocarboxylate transporter 11 protein, plays a role in monocarboxylate transport. Variation of the gene is associated with susceptiblility to non-insulin dependent diabetes mellitus.			Gene or Genome	
C115025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115025>	C16386	Monocarboxylate Transporter 11|MCT 11|Monocarboxylic Acid Transporter 11|SLC16A11|Solute Carrier Family 16 Member 11	Monocarboxylate transporter 11 (471 aa, ~48 kDa) is encoded by the human SLC16A11 gene. This protein is involved in the mediation of monocarboxylate transport.			Amino Acid, Peptide, or Protein	
C115026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115026>	C54362|C25790	IFI16 Gene|IFI16|IFI16|Interferon, Gamma-Inducible Protein 16 Gene	This gene plays a role in transcriptional regulation, cell differentiation and immune response-mediated programmed cell death.			Gene or Genome	
C115027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115027>	C115026	IFI16 wt Allele|IFNGIP1|Interferon, Gamma-Inducible Protein 16 wt Allele|PYHIN2	Human IFI16 wild-type allele is located in the vicinity of 1q22 and is approximately 55 kb in length. This allele, which encodes gamma-interferon-inducible protein 16, is involved in both transcriptional regulation and immunity-mediated cell death.			Gene or Genome	
C115028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115028>	C26199	Gamma-Interferon-Inducible Protein 16|IFI 16|IFI16|Ifi-16|Interferon-Gamma Induced Protein|Interferon-Gamma-Inducible Protein 16|Interferon-Inducible Myeloid Differentiation Transcriptional Activator	Gamma-interferon-inducible protein 16 (785 aa, ~88 kDa) is encoded by the human IFI16 gene. This protein plays a role in both immune response-mediated programmed cell death and transcriptional regulation.			Amino Acid, Peptide, or Protein	
C115029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115029>	C94791|C8659|C141292	Ann Arbor Stage I Noncutaneous Childhood Anaplastic Large Cell Lymphoma|Ann Arbor Stage I Childhood Anaplastic Large Cell Lymphoma|Stage I Anaplastic Large Cell Lymphoma|Stage I Childhood Anaplastic Large Cell Lymphoma	Ann Arbor Classification: Stage I: Involvement of a single lymph node region (I); or localized involvement of a single extralymphatic organ or site in the absence of any lymph node involvement (IE).	Ann Arbor Stage I Noncutaneous Childhood Anaplastic Large Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C11502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11502>	C61063	Gemcitabine/R115777|dFdC/R115777			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115030>	C94792|C8660|C141292	Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma|Ann Arbor Stage II Childhood Anaplastic Large Cell Lymphoma|Stage II Anaplastic Large Cell Lymphoma|Stage II Childhood Anaplastic Large Cell Lymphoma	Ann Arbor Classification: Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm (II); or localized involvement of a single extralymphatic organ or site in association with regional lymph node involvement with or without involvement of other lymph node regions on the same side of the diaphragm (IIE).	Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115031>	C94793|C8661|C141292	Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma|Ann Arbor Stage III Childhood Anaplastic Large Cell Lymphoma|Stage III Anaplastic Large Cell Lymphoma|Stage III Childhood Anaplastic Large Cell Lymphoma	Ann Arbor Classification: Stage III: Involvement of lymph node regions on both sides of the diaphragm (III), which also may be accompanied by extralymphatic extension in association with adjacent lymph node involvement (IIIE) or by involvement of the spleen (IIIS) or both (IIIE,S).	Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115032>	C94794|C8662|C141292	Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma|Ann Arbor Stage IV Childhood Anaplastic Large Cell Lymphoma|Stage IV Anaplastic Large Cell Lymphoma|Stage IV Childhood Anaplastic Large Cell Lymphoma	Ann Arbor Classification: Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or isolated extralymphatic organ involvement in the absence of adjacent regional lymph node involvement, but in conjunction with disease in distant site(s); or any involvement of the liver or bone marrow, lungs (other than by direct extension from another site), or cerebrospinal fluid.	Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115033>	C112006	Masaoka-Koga Stage II|Masaoka Stage II|Masaoka Stage II	The tumor shows invasion into the capsule.	Masaoka Stage II		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115034>	C112006	Masaoka-Koga Stage IV|Masaoka Stage IV|Masaoka Stage IV	The tumor shows metastasis throughout the pleural and/or pericardial spaces or metastasis to distant sites.	Masaoka Stage IV		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115035>	C9086|C87546	Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVA Thyroid Gland Follicular Cancer|Stage IVA Thyroid Gland Follicular Carcinoma	Stage IVA includes: (T4a, N0, M0); (T4a, N1a, M0); (T1, N1b, M0); (T2, N1b, M0); (T3, N1b, M0); (T4a, N1b, M0). T4a: Moderately advanced local disease. Tumor of any size extending beyond the thyroid gland capsule to invade subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve. T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland. T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland. T3: Tumor more than 4 cm in greatest dimension and limited to the thyroid gland, or tumor of any size with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues). N0: No regional lymph node metastasis. N1a: Metastasis to pretracheal, paratracheal or prelaryngeal/Delphian lymph nodes (Level VI lymph nodes). N1b: Metastasis to unilateral, bilateral or contralateral cervical (Levels I, II, III, IV, or V) or retropharyngeal or superior mediastinal lymph nodes (Level VII). M0: No distant metastasis. (AJCC 7th ed.)	Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115036>	C9086|C87547	Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVB Thyroid Gland Follicular Cancer|Stage IVB Thyroid Gland Follicular Carcinoma	Stage IVB includes: T4b, Any N, M0. T4b: Very advanced disease. Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels. M0: No distant metastasis. (AJCC 7th ed.)	Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115037>	C9086|C87548	Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7|Stage IVC Thyroid Gland Follicular Cancer|Stage IVC Thyroid Gland Follicular Carcinoma	Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 7th ed.)	Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115038>	C9083|C87546	Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVA Thyroid Gland Papillary Cancer|Stage IVA Thyroid Gland Papillary Carcinoma	Stage IVA includes: (T4a, N0, M0); (T4a, N1a, M0); (T1, N1b, M0); (T2, N1b, M0); (T3, N1b, M0); (T4a, N1b, M0). T4a: Moderately advanced local disease. Tumor of any size extending beyond the thyroid gland capsule to invade subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve. T1: Tumor size 2 cm or less in greatest dimension, limited to the thyroid gland. T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension, limited to the thyroid gland. T3: Tumor more than 4 cm in greatest dimension and limited to the thyroid gland, or tumor of any size with minimal extrathyroid extension (e.g., extension to sternothyroid muscle or perithyroid soft tissues). N0: No regional lymph node metastasis. N1a: Metastasis to pretracheal, paratracheal or prelaryngeal/Delphian lymph nodes (Level VI lymph nodes). N1b: Metastasis to unilateral, bilateral or contralateral cervical (Levels I, II, III, IV, or V) or retropharyngeal or superior mediastinal lymph nodes (Level VII). M0: No distant metastasis. (AJCC 7th ed.)	Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115039>	C9083|C87547	Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVB Thyroid Gland Papillary Cancer|Stage IVB Thyroid Gland Papillary Carcinoma	Stage IVB includes: T4b, Any N, M0. T4b: Very advanced disease. Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels. M0: No distant metastasis. (AJCC 7th ed.)	Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C11503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11503>	C61063	Amifostine/Carboplatin/Etoposide/Ifosfamide|CBDCA/IFF/VP-16/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115040>	C9083|C87548	Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7|Stage IVC Thyroid Gland Papillary Cancer|Stage IVC Thyroid Gland Papillary Carcinoma	Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 7th ed.)	Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115041>	C89990|C87813	Stage IIA Colon Cancer AJCC v7|Stage IIA Colon Cancer|Stage IIA Colon Cancer	Stage IIA includes: T3, N0, M0. T3: Tumor invades through the muscularis propria into pericolorectal tissues. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)	Stage IIA Colon Cancer AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115042>	C89990|C87814	Stage IIB Colon Cancer AJCC v7|Stage IIB Colon Cancer|Stage IIB Colon Cancer	Stage IIB includes: T4a, N0, M0. T4a: Tumor penetrates to the surface of the visceral peritoneum. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)	Stage IIB Colon Cancer AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115043>	C89990|C87815	Stage IIC Colon Cancer AJCC v7|Stage IIC Colon Cancer|Stage IIC Colon Cancer	Stage IIC includes: T4b, N0, M0. T4b: Tumor directly invades or is adherent to other organs or structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)	Stage IIC Colon Cancer AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115044>	C89991|C87813	Stage IIA Rectal Cancer AJCC v7|Stage IIA Rectal Cancer|Stage IIA Rectal Cancer	Stage IIA includes: T3, N0, M0. T3: Tumor invades through the muscularis propria into pericolorectal tissues. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)	Stage IIA Rectal Cancer AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115045>	C89991|C87814	Stage IIB Rectal Cancer AJCC v7|Stage IIB Rectal Cancer|Stage IIB Rectal Cancer	Stage IIB includes: T4a, N0, M0. T4a: Tumor penetrates to the surface of the visceral peritoneum. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)	Stage IIB Rectal Cancer AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115046>	C89991|C87815	Stage IIC Rectal Cancer AJCC v7|Stage IIC Rectal Cancer|Stage IIC Rectal Cancer	Stage IIC includes: T4b, N0, M0. T4b: Tumor directly invades or is adherent to other organs or structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 7th ed.)	Stage IIC Rectal Cancer AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115047>	C89995|C87816	Stage IIIA Colon Cancer AJCC v7|Stage IIIA Colon Cancer|Stage IIIA Colon Cancer	Stage IIIA includes: (T1-T2, N1/N1c, M0); (T1, N2a, M0). T1: Tumor invades submucosa. T2: Tumor invades muscularis propria. N1: Metastasis in 1-3 regional lymph nodes. N1c: Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional lymph node metastasis. N2a: Metastasis in 4-6 regional lymph nodes. M0: No distant metastasis. (AJCC 7th ed.)	Stage IIIA Colon Cancer AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115048>	C89995|C87817	Stage IIIB Colon Cancer AJCC v7|Stage IIIB Colon Cancer|Stage IIIB Colon Cancer	Stage IIIB includes: (T3-T4a, N1/N1c, M0); (T2-T3, N2a, M0); (T1-T2, N2b, M0). T1: Tumor invades submucosa. T2: Tumor invades muscularis propria. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor penetrates to the surface of the visceral peritoneum. N1: Metastasis in 1-3 regional lymph nodes. N1c: Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional lymph node metastasis. N2a: Metastasis in 4-6 regional lymph nodes. N2b: Metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 7th ed.)	Stage IIIB Colon Cancer AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115049>	C89995|C87818	Stage IIIC Colon Cancer AJCC v7|Stage IIIC Colon Cancer|Stage IIIC Colon Cancer	Stage IIIC includes: (T4a, N2a, M0); (T3-T4a, N2b, M0); (T4b, N1-N2, M0). T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor penetrates to the surface of the visceral peritoneum. T4b: Tumor directly invades or is adherent to other organs or structures. N1: Metastasis in 1-3 regional lymph nodes. N2: Metastasis in four or more regional lymph nodes. N2a: Metastasis in 4-6 regional lymph nodes. N2b: Metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 7th ed.)	Stage IIIC Colon Cancer AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C11504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11504>	C61063	Cyclophosphamide/Cytarabine/Methotrexate|ARA-C/CTX/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115050>	C89996|C87816	Stage IIIA Rectal Cancer AJCC v7|Stage IIIA Rectal Cancer|Stage IIIA Rectal Cancer	Stage IIIA includes: (T1-T2, N1/N1c, M0); (T1, N2a, M0). T1: Tumor invades submucosa. T2: Tumor invades muscularis propria. N1: Metastasis in 1-3 regional lymph nodes. N1c: Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional lymph node metastasis. N2a: Metastasis in 4-6 regional lymph nodes. M0: No distant metastasis. (AJCC 7th ed.)	Stage IIIA Rectal Cancer AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115051>	C89996|C87817	Stage IIIB Rectal Cancer AJCC v7|Stage IIIB Rectal Cancer|Stage IIIB Rectal Cancer	Stage IIIB includes: (T3-T4a, N1/N1c, M0); (T2-T3, N2a, M0); (T1-T2, N2b, M0). T1: Tumor invades submucosa. T2: Tumor invades muscularis propria. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor penetrates to the surface of the visceral peritoneum. N1: Metastasis in 1-3 regional lymph nodes. N1c: Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic or perirectal tissues without regional lymph node metastasis. N2a: Metastasis in 4-6 regional lymph nodes. N2b: Metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 7th ed.)	Stage IIIB Rectal Cancer AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115052>	C89996|C87818	Stage IIIC Rectal Cancer AJCC v7|Stage IIIC Rectal Cancer|Stage IIIC Rectal Cancer	Stage IIIC includes: (T4a, N2a, M0); (T3-T4a, N2b, M0); (T4b, N1-N2, M0). T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor penetrates to the surface of the visceral peritoneum. T4b: Tumor directly invades or is adherent to other organs or structures. N1: Metastasis in 1-3 regional lymph nodes. N2: Metastasis in four or more regional lymph nodes. N2a: Metastasis in 4-6 regional lymph nodes. N2b: Metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 7th ed.)	Stage IIIC Rectal Cancer AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115053>	C89999|C87819	Stage IVA Colon Cancer AJCC v7|Stage IVA Colon Cancer|Stage IVA Colon Cancer	Stage IVA includes: Any T, Any N, M1a. M1a: Metastasis confined to one organ or site (e.g., liver, lung, ovary, nonregional node). (AJCC 7th ed.)	Stage IVA Colon Cancer AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115054>	C89999|C87820	Stage IVB Colon Cancer AJCC v7|Stage IVB Colon Cancer|Stage IVB Colon Cancer	Stage IVB includes: Any T, Any N, M1b. M1b: Metastases in more than one organ/site or the peritoneum. (AJCC 7th ed.)	Stage IVB Colon Cancer AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115055>	C90016|C87819	Stage IVA Rectal Cancer AJCC v7|Stage IVA Rectal Cancer|Stage IVA Rectal Cancer	Stage IVA includes: Any T, Any N, M1a. M1a: Metastasis confined to one organ or site (e.g., liver, lung, ovary, nonregional node). (AJCC 7th ed.)	Stage IVA Rectal Cancer AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115056>	C90016|C87820	Stage IVB Rectal Cancer AJCC v7|Stage IVB Rectal Cancer|Stage IVB Rectal Cancer	Stage IVB includes: Any T, Any N, M1b. M1b: Metastases in more than one organ/site or the peritoneum. (AJCC 7th ed.)	Stage IVB Rectal Cancer AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115057>	C8033|C42690	Stage I Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage I Lip and Oral Cavity Squamous Cell Cancer|Stage I Lip and Oral Cavity Squamous Cell Carcinoma|Stage I Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6|Stage I Lip and Oral Cavity Squamous Cell Carcinoma AJCC v7	Stage I includes: T1, N0, M0. T1: Tumor 2 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)	Stage I Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115058>	C8034|C42690	Stage II Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage II Lip and Oral Cavity Squamous Cell Cancer|Stage II Lip and Oral Cavity Squamous Cell Carcinoma|Stage II Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6|Stage II Lip and Oral Cavity Squamous Cell Carcinoma AJCC v7	Stage II includes: T2, N0, M0. T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)	Stage II Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115059>	C8035|C42690	Stage III Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage III Lip and Oral Cavity Squamous Cell Cancer|Stage III Lip and Oral Cavity Squamous Cell Carcinoma|Stage III Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6|Stage III Lip and Oral Cavity Squamous Cell Carcinoma AJCC v7	Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T3: Tumor more than 4 cm in greatest dimension. N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. M0: No distant metastasis. (AJCC 6th and 7th eds.)	Stage III Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C11505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11505>	C61063	Dextromethorphan/Morphine|DEX/MORPH			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115060>	C8036|C42690	Stage IV Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IV Lip and Oral Cavity Squamous Cell Cancer|Stage IV Lip and Oral Cavity Squamous Cell Carcinoma|Stage IV Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6|Stage IV Lip and Oral Cavity Squamous Cell Carcinoma AJCC v7	Stage IV includes: IVA (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0);. IVB (Any T, N3, M0); (T4b, Any N, M0); IVC (Any T, Any N, M1). T4a (lip): Tumor invades through cortical bone, inferior alveolar nerve, floor of mouth, or skin of face, i.e., chin or nose. T4a (oral cavity): Tumor invades adjacent structures (e.g., through cortical bone, into deep [extrinsic] muscles of tongue, maxillary sinus, skin of face). T4b: Tumor invades masticator space, pterygoid plates, or skull base and/or encases internal carotid artery. N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension; or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension; or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. N2a: Metastasis in a single ipsilateral lymph node more than 3 cm but not more than 6 cm in dimension. N2b: Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension. N2c: Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. N3: Metastasis in a lymph node more than 6 cm in greatest dimension. M1: Distant metastasis. (AJCC 6th and 7th eds.)	Stage IV Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115061>	C87301|C115060	Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVA Lip and Oral Cavity Squamous Cell Cancer|Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma|Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v7	Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0). T4a: Lip and oral cavity cancer with moderately advanced local disease. Lip: Tumor invades through cortical bone, inferior alveolar nerve, floor of mouth, or skin of face, i.e., chin or nose. Oral cavity: Tumor invades adjacent structures only (e.g., through cortical bone [mandible or maxilla] into deep [extrinsic] muscle of tongue [genioglossus, hyoglossus, palatoglossus, and styloglossus], maxillary sinus, skin of face). T1: Tumor 2 cm or less in greatest dimension. T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension. T3: Tumor more than 4 cm in greatest dimension. N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension; or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension; or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. M0: No distant metastasis. (AJCC 7th ed.)	Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115062>	C87302|C115060	Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVB Lip and Oral Cavity Squamous Cell Cancer|Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma|Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6|Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v7	Stage IVB includes: (Any T, N3, M0); (T4b, Any N, M0). T4b: Lip and oral cavity cancer with very advanced local disease. Tumor invades masticator space, pterygoid plates, or skull base and/or encases internal carotid artery. N3: Metastasis in a lymph node more than 6 cm in greatest dimension. M0: No distant metastasis. (AJCC 7th ed.)	Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115063>	C87303|C115060	Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVC Lip and Oral Cavity Squamous Cell Cancer|Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6|Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v7	Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 7th ed.)	Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115064>	C105821	HOXA1 Gene|HOXA1|HOXA1|Homeobox A1 Gene	This gene plays a role in embryonic pattern formation.	HOXA1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C115065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115065>	C115064	HOXA1 wt Allele|BSAS|HOX1|HOX1F|Homeo Box A1 Gene|Homeobox 1F Gene|Homeobox A1 wt Allele|Hox-1.6, Mouse, Homolog of Gene|Lab, Drosophila, Homolog of Gene	Human HOXA1 wild-type allele is located in the vicinity of 7p15.3 and is approximately 3 kb in length. This allele, which encodes homeobox protein Hox-A1, is involved in the modulation of embryotic segment patterning. Mutation of the gene is associated with Athabaskan brainstem dysgenesis syndrome and Bosley-Salih-Alorainy syndrome.	HOXA1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115066>	C17207	Homeobox Protein Hox-A1|HOX A1 Homeodomain Protein|Homeobox Protein Hox-1F|Hox 1.6-Like Protein|Lab-Like Protein	Homeobox protein Hox-A1 (335 aa, ~37 kDa) is encoded by the human HOXA1 gene. This protein plays a role in embryonic anterior-posterior pattern formation.	Homeobox Protein Hox-A1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115067>	C25952	PLCE1 Gene|PLCE1|PLCE1|Phospholipase C, Epsilon 1 Gene	This gene is involved in both lipid metabolism and signal transduction.			Gene or Genome	
C115068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115068>	C115067	PLCE1 wt Allele|KIAA1516|NPHS3|Nephrosis Type 3 Gene|PLCE|PPLC|Phospholipase C, Epsilon 1 wt Allele|Phospholipase C, Epsilon-1 Gene|RP11-76P2.1	Human PLCE1 wild-type allele is located in the vicinity of 10q23 and is approximately 334 kb in length. This allele, which encodes 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase epsilon-1 protein, plays a role in signal transduction, cell growth, cell survival and lipid modification. Mutation of the gene is associated with nephrotic syndrome 3.			Gene or Genome	
C115069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115069>	C16980	1-Phosphatidylinositol 4,5-Bisphosphate Phosphodiesterase Epsilon-1|1-Phosphatidylinositol-4,5-Bisphosphate Phosphodiesterase Epsilon-1|EC 3.1.4.11|PLC-Epsilon-1|PLCE1|Phosphoinositide Phospholipase C-Epsilon-1|Phosphoinositide-Specific Phospholipase C Epsilon-1|Phospholipase C-Epsilon-1	1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase epsilon-1 (2302 aa, ~259 kDa) is encoded by the human PLCE1 gene. This protein is involved in phospholipid metabolism, signaling, cell growth and cell survival.			Amino Acid, Peptide, or Protein|Enzyme	
C11506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11506>	C61007	Cytarabine/Hydrocortisone/Leucovorin Calcium/Methotrexate|ARA-C/CF/HC/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115070>	C68611|C67554	Stage I Sinonasal Squamous Cell Carcinoma AJCC v6 and v7|Stage I Nasal Cavity and Paranasal Sinus Squamous Cell Cancer|Stage I Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage I Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6|Stage I Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7|Stage I Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7	Stage I includes: T1, N0, M0.  T1: Maxillary sinus: Tumor limited to the maxillary sinus mucosa with no erosion or destruction of bone.  Nasal cavity and ethmoid sinus: Tumor restricted to any one subsite, with or without bony invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)	Stage I Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115071>	C68611|C67555	Stage II Sinonasal Squamous Cell Carcinoma AJCC v6 and v7|Stage II Nasal Cavity and Paranasal Sinus Squamous Cell Cancer|Stage II Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage II Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6|Stage II Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7|Stage II Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7	Stage II includes: T2, N0, M0.  T2: Maxillary sinus: Tumor causing bone erosion or destruction including extension into the hard palate and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and pterygoid plates.  Nasal cavity and ethmoid sinus: Tumor invading two subsites in a single region or extending to involve an adjacent region within the nasoethmoidal complex, with or without bony invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th ed.)	Stage II Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115072>	C68611|C67556	Stage III Sinonasal Squamous Cell Carcinoma AJCC v6 and v7|Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Cancer|Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6|Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7|Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7	Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0).  T3: Maxillary sinus: Tumor invading any of the following: bone of the posterior wall of maxillary sinus, subcutaneous tissues, floor or medial wall of orbit, pterygoid fossa, or ethmoid sinuses. Nasal cavity and ethmoid sinus: Tumor invading the medial wall or floor of the orbit, maxillary sinus, palate, or cribriform plate.  T1: Maxillary sinus: Tumor limited to the maxillary sinus mucosa with no erosion or destruction of bone.  Nasal cavity and ethmoid sinus: Tumor restricted to any one subsite, with or without bony invasion.  T2: Maxillary sinus: Tumor causing bone erosion or destruction including extension into the hard palate and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and pterygoid plates.  Nasal cavity and ethmoid sinus: Tumor invading two subsites in a single region or extending to involve an adjacent region within the nasoethmoidal complex, with or without bony invasion.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension.  M0: No distant metastasis. (AJCC 6th and 7th eds.)	Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115073>	C89117|C68611	Stage IV Sinonasal Squamous Cell Carcinoma AJCC v7|Stage IV Nasal Cavity and Paranasal Sinus Squamous Cell Cancer|Stage IV Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage IV Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7	Stage IV includes: IVA: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB: (T4b, Any N, M0); (Any T, N3, M0); IVC: (Any T, Any N, M1).  T4a: Maxillary sinus: Moderately advanced local disease. Tumor invades anterior orbital contents, skin of cheek, pterygoid plates, infratemporal fossa, cribriform plate, sphenoid or frontal sinuses.  Nasal cavity and ethmoid sinus: Moderately advanced local disease. Tumor invades any of the following: anterior orbital contents, skin of nose or cheek, minimal extension to anterior cranial fossa, pterygoid plates, sphenoid or frontal sinuses.  T4b: Very advanced local disease.  Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than maxillary division of trigeminal nerve, nasopharynx, or clivus.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension.  N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. N3: Metastasis in a lymph node, more than 6 cm in greatest dimension.  M0: No distant metastasis.  M1: Distant metastasis.  (AJCC 7th ed.)	Stage IV Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115074>	C87501|C115073	Stage IVA Sinonasal Squamous Cell Carcinoma AJCC v7|Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Cancer|Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7	Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); T4a: Maxillary sinus: Moderately advanced local disease. Tumor invades anterior orbital contents, skin of cheek, pterygoid plates, infratemporal fossa, cribriform plate, sphenoid or frontal sinuses.  Nasal cavity and ethmoid sinus: Moderately advanced local disease. Tumor invades any of the following: anterior orbital contents, skin of nose or cheek, minimal extension to anterior cranial fossa, pterygoid plates, sphenoid or frontal sinuses.  T1: Maxillary sinus: Tumor limited to the maxillary sinus mucosa with no erosion or destruction of bone.  Nasal cavity and ethmoid sinus: Tumor restricted to any one subsite, with or without bony invasion.  T2: Maxillary sinus: Tumor causing bone erosion or destruction including extension into the hard palate and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and pterygoid plates.  Nasal cavity and ethmoid sinus: Tumor invading two subsites in a single region or extending to involve an adjacent region within the nasoethmoidal complex, with or without bony invasion.  T3: Maxillary sinus: Tumor invading any of the following: bone of the posterior wall of maxillary sinus, subcutaneous tissues, floor or medial wall of orbit, pterygoid fossa, or ethmoid sinuses. Nasal cavity and ethmoid sinus: Tumor invading the medial wall or floor of the orbit, maxillary sinus, palate, or cribriform plate.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension.  N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. M0: No distant metastasis. (AJCC 7th ed.)	Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115075>	C87502|C115073	Stage IVB Sinonasal Squamous Cell Carcinoma AJCC v7|Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Cancer|Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7	Stage IVB includes: (T4b, Any N, M0); (Any T, N3, M0).  T4b: Very advanced local disease.  Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than maxillary division of trigeminal nerve, nasopharynx, or clivus.  N3: Metastasis in a lymph node, more than 6 cm in greatest dimension.  M0: No distant metastasis. (AJCC 7th ed.)	Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115076>	C87503|C115073	Stage IVC Sinonasal Squamous Cell Carcinoma AJCC v7|Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Cancer|Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7	Stage IVC includes: Any T, Any N, M1.  M1: Distant metastasis.  (AJCC 7th ed.)	Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115077>	C20731	SSH1 Gene|SSH1|SSH1|Slingshot Protein Phosphatase 1 Gene	This gene plays a role in both protein dephosphorylation and cell projection formation.			Gene or Genome	
C115078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115078>	C115077	SSH1 wt Allele|KIAA1298|SSH1L|Slingshot Homolog 1 (Drosophila) Gene|Slingshot Protein Phosphatase 1 wt Allele|Slingshot, Drosophila, Homolog of Gene	Human SSH1 wild-type allele is located in the vicinity of 12q24.12 and is approximately 75 kb in length. This allele, which encodes protein phosphatase Slingshot homolog 1 protein, is involved in both the regulation of cellular projection formation and the modulation of protein phosphorylation.			Gene or Genome	
C115079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115079>	C25880	Protein Phosphatase Slingshot Homolog 1|EC 3.1.3.16|EC 3.1.3.48|SSH-1L|SSH-Like Protein 1|SSH1|Slingshot Homolog 1|hSSH-1L	Protein phosphatase Slingshot homolog 1 (1049 aa, ~116 kDa) is encoded by the human SSH1 gene. This protein plays a role in the modulation of both protein phosphorylation and cellular projection formation.			Amino Acid, Peptide, or Protein|Enzyme	
C11507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11507>	C61063	Irinotecan/Mitomycin|CPT-11/MITO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115080>	C20703	TLE2 Gene|TLE2|TLE2|Transducin-Like Enhancer of Split 2 Gene	This gene is involved in the regulation of Notch and Wnt signaling pathways.			Gene or Genome	
C115081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115081>	C115080	TLE2 wt Allele|ESG|ESG2|FLJ41188|GRG2|Transducin-Like Enhancer of Split 2 (E(Sp1) Homolog, Drosophila) Gene|Transducin-Like Enhancer of Split 2 wt Allele|Transducin-Like Enhancer of Split 2, Homolog of Drosophila E(Sp1) Gene	Human TLE2 wild-type allele is located in the vicinity of 19p13.3 and is approximately 50 kb in length. This allele, which encodes transducin-like enhancer protein 2, plays a role in transcriptional repression.			Gene or Genome	
C115082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115082>	C26199	Transducin-Like Enhancer Protein 2|ESG2|Enhancer of Split Groucho 2|Enhancer of Split Groucho-Like Protein 2|TLE2|Transducin-Like Enhancer of Split 2	Transducin-like enhancer protein 2 (743 aa, ~80 kDa) is encoded by the human TLE2 gene. This protein is involved in Notch and Wnt signaling pathways and transcriptional repression.			Amino Acid, Peptide, or Protein	
C115083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115083>	C20703	TLE4 Gene|TLE4|TLE4|Transducin-Like Enhancer of Split 4 Gene	This gene plays a role in Notch and Wnt signaling pathways and transcriptional repression.			Gene or Genome	
C115084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115084>	C115083	TLE4 wt Allele|B Lymphocyte Gene 1|BCE-1|BCE1|E(spI)|ESG|ESG4|GRG4|KIAA1261|RP11-79D8.3|Transducin-Like Enhancer of Split 4 (E(Sp1) Homolog, Drosophila) Gene|Transducin-Like Enhancer of Split 4 wt Allele|Transducin-Like Enhancer of Split 4, Homolog of Drosophila E(Sp1) Gene	Human TLE4 wild-type allele is located in the vicinity of 9q21.31 and is approximately 155 kb in length. This allele, which encodes transducin-like enhancer protein 4, is involved in the regulation of Notch and Wnt signaling pathways.			Gene or Genome	
C115085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115085>	C26199	Transducin-Like Enhancer Protein 4|ESG4|Enhancer of Split Groucho 4|Enhancer of Split Groucho-Like Protein 4|TLE4|Transducin-Like Enhancer of Split 4	Transducin-like enhancer protein 4 (773 aa, ~84 kDa) is encoded by the human TLE4 gene. This protein plays a role in the repression of both transcription and signal transduction.			Amino Acid, Peptide, or Protein	
C115086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115086>	C8217|C68610	Stage I Oropharyngeal Undifferentiated Carcinoma AJCC v6 and v7|Stage I Oropharyngeal Lymphoepithelioma|Stage I Oropharyngeal Lymphoepithelioma AJCC v6|Stage I Oropharyngeal Lymphoepithelioma AJCC v7|Stage I Oropharyngeal Undifferentiated Carcinoma|Stage I Oropharyngeal Undifferentiated Carcinoma AJCC v6|Stage I Oropharyngeal Undifferentiated Carcinoma AJCC v7|Stage I Undifferentiated Oropharyngeal Throat Cancer	Stage I includes: T1, N0, M0.  T1: Tumor 2 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 6th and 7th eds.)	Stage I Oropharyngeal Undifferentiated Carcinoma AJCC v6 and v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115087>	C8218|C68610	Stage II Oropharyngeal Undifferentiated Carcinoma AJCC v6 and v7|Stage II Oropharyngeal Lymphoepithelioma|Stage II Oropharyngeal Lymphoepithelioma AJCC v6|Stage II Oropharyngeal Lymphoepithelioma AJCC v7|Stage II Oropharyngeal Undifferentiated Carcinoma|Stage II Oropharyngeal Undifferentiated Carcinoma AJCC v6|Stage II Oropharyngeal Undifferentiated Carcinoma AJCC v7|Stage II Undifferentiated Oropharyngeal Throat Cancer	Stage II includes: T2, N0, M0.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th and 7th eds.)	Stage II Oropharyngeal Undifferentiated Carcinoma AJCC v6 and v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115088>	C8219|C68610	Stage III Oropharyngeal Undifferentiated Carcinoma AJCC v7|Stage III Oropharyngeal Lymphoepithelioma|Stage III Oropharyngeal Lymphoepithelioma AJCC v7|Stage III Oropharyngeal Undifferentiated Carcinoma|Stage III Undifferentiated Oropharyngeal Throat Cancer	Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0).  T1: Tumor 2 cm or less in greatest dimension.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension.  T3: Tumor measuring more than 4 centimeters in greatest dimension or extension to lingual surface of epiglottis.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. M0: No distant metastasis. (AJCC 7th ed.)	Stage III Oropharyngeal Undifferentiated Carcinoma AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115089>	C8220|C68610	Stage IV Oropharyngeal Undifferentiated Carcinoma AJCC v7|Stage IV Oropharyngeal Lymphoepithelioma|Stage IV Oropharyngeal Lymphoepithelioma AJCC v7|Stage IV Oropharyngeal Undifferentiated Carcinoma|Stage IV Undifferentiated Oropharyngeal Throat Cancer	Stage IV includes: IVA (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB (T4b, Any N, M0); (Any T, N3, M0); IVC (Any T, Any N, M1). T4a: Tumor with moderately advanced local disease.  Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible.  Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of larynx. T1: Tumor 2 cm or less in greatest dimension.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension.  T3: Tumor measuring more than 4 centimeters in greatest dimension or extension to lingual surface of epiglottis.  T4b: Tumor with very advanced local disease.  Tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base or encases carotid artery. N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. N2: Tumor with metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. N3: Tumor with metastasis in a lymph node more than 6 cm in greatest dimension. M0: No distant metastasis.  M1: Distant metastasis. (AJCC 7th ed.)	Stage IV Oropharyngeal Undifferentiated Carcinoma AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C11508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11508>	C61007	Capecitabine/Docetaxel|CAPE/TXT			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115090>	C6141|C115089	Stage IVA Oropharyngeal Undifferentiated Carcinoma AJCC v7|Stage IVA Oropharyngeal Lymphoepithelioma|Stage IVA Oropharyngeal Lymphoepithelioma AJCC v7|Stage IVA Oropharyngeal Undifferentiated Carcinoma|Stage IVA Undifferentiated Oropharyngeal Throat Cancer	Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0). T4a: Tumor with moderately advanced local disease.  Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible.  Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of larynx. T1: Tumor 2 cm or less in greatest dimension.  T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension.  T3: Tumor measuring more than 4 centimeters in greatest dimension or extension to lingual surface of epiglottis.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. N2: Tumor with metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension, or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension, or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension. M0: No distant metastasis.  (AJCC 7th ed.)	Stage IVA Oropharyngeal Undifferentiated Carcinoma AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115091>	C6139|C115089	Stage IVB Oropharyngeal Undifferentiated Carcinoma AJCC v7|Stage IVB Oropharyngeal Lymphoepithelioma|Stage IVB Oropharyngeal Lymphoepithelioma AJCC v7|Stage IVB Oropharyngeal Undifferentiated Carcinoma|Stage IVB Undifferentiated Oropharyngeal Throat Cancer	Stage IVB includes: (T4b, Any N, M0); (Any T, N3, M0). T4b: Tumor with very advanced local disease.  Tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base or encases carotid artery. N3: Tumor with metastasis in a lymph node more than 6 cm in greatest dimension. M0: No distant metastasis. (AJCC 7th ed.)	Stage IVB Oropharyngeal Undifferentiated Carcinoma AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115092>	C6140|C115089	Stage IVC Oropharyngeal Undifferentiated Carcinoma AJCC v7|Stage IVC Oropharyngeal Lymphoepithelioma|Stage IVC Oropharyngeal Lymphoepithelioma AJCC v7|Stage IVC Oropharyngeal Undifferentiated Carcinoma|Stage IVC Undifferentiated Oropharyngeal Throat Cancer	Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 7th ed.)	Stage IVC Oropharyngeal Undifferentiated Carcinoma AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115093>	C8221|C68610	Recurrent Oropharyngeal Undifferentiated Carcinoma|Recurrent Oropharyngeal Lymphoepithelioma|Recurrent Oropharyngeal Throat Undifferentiated Carcinoma	The reemergence of oropharyngeal undifferentiated carcinoma after a period of remission.	Recurrent Oropharyngeal Undifferentiated Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115094>	C140003	Stage III Primary Peritoneal Cancer AJCC v7|Stage III Primary Peritoneal Cancer|Stage III Primary Peritoneal Cancer	Stage III includes: T3, N0, M0.  T3: Microscopically confirmed peritoneal tumor outside pelvis.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th Ed.)	Stage III Primary Peritoneal Cancer AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115095>	C115094	Stage IIIA Primary Peritoneal Cancer AJCC v7|Stage IIIA Primary Peritoneal Cancer|Stage IIIA Primary Peritoneal Cancer	Stage IIIA includes: T3a, N0, M0.  T3a: Microscopic peritoneal tumor beyond pelvis (no macroscopic tumor). N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th Ed.)	Stage IIIA Primary Peritoneal Cancer AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115096>	C115094	Stage IIIB Primary Peritoneal Cancer AJCC v7|Stage IIIB Primary Peritoneal Cancer|Stage IIIB Primary Peritoneal Cancer	Stage IIIB includes: T3b, N0, M0.  T3b: Macroscopic peritoneal tumor beyond pelvis 2 cm or less in greatest dimension. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th Ed.)	Stage IIIB Primary Peritoneal Cancer AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115097>	C115094	Stage IIIC Primary Peritoneal Cancer AJCC v7|Stage IIIC Primary Peritoneal Cancer|Stage IIIC Primary Peritoneal Cancer	Stage IIIC includes: (T3c, N0, M0); (Any T, N1, M0). T3c: Peritoneal tumor beyond pelvis more than 2cm in greatest dimension and/or regional lymph node metastasis. N0: No regional lymph node metastasis.  N1: Regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th Ed.)	Stage IIIC Primary Peritoneal Cancer AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115098>	C140003	Stage IV Primary Peritoneal Cancer AJCC v7|Stage IV Primary Peritoneal Cancer|Stage IV Primary Peritoneal Cancer	Stage IV includes: Any T, Any N, M1.  M1: Distant metastasis (excludes peritoneal metastasis). (AJCC 7th Ed.)	Stage IV Primary Peritoneal Cancer AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115099>	C281	Letermovir|2-((4S)-8-Fluoro-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-4H-quinazolin-4-yl)acetic Acid|AIC246|LETERMOVIR|MK-8228|Prevymis	An orally bioavailable, non-nucleoside, 3,4-dihydroquinazolinyl acetic acid and inhibitor of the pUL56 subunit of the viral terminase complex of cytomegalovirus (CMV), with potential CMV-specific antiviral activity. Upon oral administration, letermovir binds to the pUL56 subunit of the viral terminase complex of CMV and prevents the cleavage of concatemeric DNA into monomeric genome length DNA. As this agent interferes with viral DNA processing and subsequent viral DNA packaging into procapsids, CMV replication is blocked and CMV infection is prevented.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C11509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11509>	C61063	Cisplatin/Irinotecan/Paclitaxel|CDDP/CPT-11/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1150>	C697	Mafosfamide|MAFOSFAMIDE|mafosfamide	A synthetic oxazaphosphorine derivative with antineoplastic properties.  Mafosfamide alkylates DNA, forming DNA cross-links and inhibiting DNA synthesis.  Although closely related to cyclophosphamide, mafosfamide, unlike cyclophosphamide, does not require hepatic activation to generate its active metabolite 4-hydroxy-cyclophosphamide; accordingly, mafosfamide is potentially useful in the intrathecal treatment of neoplastic meningitis. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C115100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115100>	C1937	Acoustic Coupling Fluid|Acoustic Fluid|BMF|Brain Mimicking Fluid	A brain mimicking fluid with an attenuation coefficient similar to that found in the adult human brain, which can potentially improve the quality of an image acquired during intraoperative ultrasonography. Upon administration into the resection cavity during surgical removal of a brain tumor, the acoustic coupling fluid may both increase the quality of the ultrasound image and improve the visualization of the tumor. This may facilitate the surgical removal of residual tumor while sparing normal, healthy brain tissue.			Indicator, Reagent, or Diagnostic Aid	NCI Drug Dictionary Terminology
C115101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115101>	C201282|C112889	Anti-CD19/CD3 Tetravalent Antibody AFM11|AFM-11|AFM11	An anti-CD19/anti-CD3 bispecific tetravalent antibody with potential immunostimulatory and antineoplastic activities. Anti-CD19/CD3 tetravalent antibody AFM11 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B-cells. Upon bolus infusion of AFM11, this bispecific antibody binds to CD3-expressing T-cells and CD19-expressing cancer cells, thereby crosslinking CD19-expressing tumor B-cells and cytotoxic T-lymphocytes (CTLs). This may result in a potent CTL-mediated cell lysis of CD19-expressing B-lymphocytes. CD19, a B-cell specific membrane antigen, is expressed during both B-cell development and B-cell malignant growth.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C115102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115102>	C2083	Decitabine and Cedazuridine|ASTX 727|ASTX-727|ASTX727|C-DEC|CDA Inhibitor E7727/Decitabine Combination Agent ASTX727|Cedazuridine/Decitabine Combination Agent ASTX727|Cedazuridine/Decitabine Tablet|DEC-C|Decitabine and cedazuridine|Inaqovi|Inqovi	An orally available fixed-dose combination agent containing cedazuridine, a cytidine deaminase (CDA) inhibitor, and the cytidine antimetabolite decitabine, with potential antineoplastic activity. Upon oral administration of tdecitabine and cedazuridine, cedazuridine binds to and inhibits CDA, an enzyme primarily found in the gastrointestinal (GI) tract and liver that catalyzes the deamination of cytidine and cytidine analogs. This prevents the breakdown of decitabine, increases its bioavailability and efficacy while decreasing GI toxicity due to the administration of lower doses of decitabine. Decitabine exerts its antineoplastic activity through the incorporation of its triphosphate form into DNA, which inhibits DNA methyltransferase and results in hypomethylation of DNA. This interferes with DNA replication and decreases tumor cell growth.	Decitabine and Cedazuridine		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C115103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115103>	C1404	Dioscorea nipponica Makino Extract DNE3|DNE3|Dioscorea nipponica Extract with Ethyl Acetate	An extract of the plant Dioscorea nipponica Makino and inhibitor of both the serine/threonine protein kinase Akt (protein kinase B) and members of the phosphatidylinositol 3-kinase (PI3K) family of lipid kinases, with potential antineoplastic and anti-metastatic activities. Dioscorea nipponica Makino extracted with ethyl acetate (DNE3) binds to and inhibits PI3K and Akt. This inhibits PI3K/Akt-mediated signaling and prevents both growth and survival of PI3K/Akt-overexpressing tumor cells. In addition, DNE3 increases the expression of tissue inhibitor of metalloproteinase-2 (TIMP-2), inhibits the secretion of matrix metalloproteinases (MMPs), primarily MMP-2 and MMP-9, and inhibits the serine protease urokinase (urokinase-type plasminogen activator; u-PA). This inhibits tumor cell invasion, migration, motility, and adhesion. This agent also inhibits the activation of both cAMP response element-binding (CREB) and activating protein-1 (AP-1), and increases the expression of IkappaB (IkB), which inhibits the activation of nuclear factor-kappa B (NF-kB). These processes further contribute to this agent's anti-tumor potential in susceptible tumor cells.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C115104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115104>	C1966	Fluorescent cRGDY PEG-Cy5.5 C Dots|cRGDY-PEG-Cy5.5-C Dots	An imaging agent composed of silica-based nanoparticles labeled with a near-infrared (NIR) fluorophore, Cyanine 5.5 (Cy5.5) and surrounded by polyethylene glycol (PEG) chains attached to cyclo-[Arg-Gly-Asp-Tyr] (cRGDY) peptides, with potential use as a tumor-selective fluorescent imaging agent. Upon intradermal administration of the fluorescent cRGDY PEG-Cy5.5 C dots, the cRGD moiety selectively binds to alphaVbeta3 integrin expressed on tumor cells. Upon intraoperative fluorescence imaging, alphaVbeta3-expressing tumor cells can be visualized and the degree of both tumor metastasis and sentinel lymph node (SLN) trafficking can be assessed. Integrins are transmembrane glycoproteins upregulated on proliferating tumor vessel endothelial cells and various cancer cells; their overexpression has been associated with neovascularization, differentiation, proliferation of tumor cells, metastasis and an overall poor prognosis.	Fluorescent cRGDY PEG-Cy5.5 C Dots		Indicator, Reagent, or Diagnostic Aid	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C115105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115105>	C2594	Ovarian Tumor Antigen-activated Autologous Dendritic Cell Vaccine|DCVAC/OvCa	A dendritic cell (DC)-based cancer vaccine composed of autologous dendritic cells (DCs) activated with an ovarian tumor cell lysate containing tumor-associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, the ovarian tumor antigen-activated autologous DC vaccine may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against ovarian cancer cells expressing ovarian tumor cell-specific antigens, which may result in ovarian tumor cell lysis.			Cell|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C115106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115106>	C2594	Stapuldencel-T|DCVAC/PCa|Prostate Tumor Antigen-activated Autologous Dendritic Cell Vaccine|STAPULDENCEL	A dendritic cell (DC)-based cancer vaccine composed of autologous dendritic cells (DCs) activated with a prostate tumor cell lysate containing tumor-associated antigens (TAAs) with potential immunostimulatory and antineoplastic activities. Upon administration, stapuldencel-T  may stimulate an anti-tumoral cytotoxic T-lymphocyte (CTL) response against prostate cancer cells expressing prostate tumor cell-specific antigens, which may result in prostate tumor cell lysis.			Cell|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C115107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115107>	C28676	Allogeneic Multivirus-specific Cytotoxic T Lymphocytes|Allogeneic EBV/CMV/AdV/HHV6/BKV-specific CTLs|Allogeneic Multivirus-specific CTLs	A population of closely human leukocyte antigen (HLA)-matched, donor-derived cytotoxic T lymphocytes (CTLs) that are specifically reactive towards five viruses, Epstein-Barr virus (EBV), cytomegalovirus (CMV), adenovirus (AdV), human herpesvirus 6 (HHV6), and human polyomavirus type I (BKV), with potential antiviral activity. Infusion of the multivirus-specific CTLs into allogeneic hematopoietic stem cell transplant (HSCT) recipients provides virus-specific cellular immunity and causes specific anti-viral effects against active viral infections. The administered CTLs also prevent EBV, CMV, AdV, HHV6, and BKV reactivation and infection as well as inhibiting viral-associated diseases in immunocompromised patients. The allogeneic multivirus-specific CTLs may also provide cellular immunity towards the human polyomavirus type II (JC virus; JCV), which is highly homologous to BKV.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology
C115108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115108>	C129821	MYC-targeting siRNA DCR-MYC|DCR-M1711|DCR-MYC	A lipid nanoparticle-based formulation consisting of small-interfering RNAs (siRNAs) directed against the oncogene c-Myc encapsulated in lipids with potential antineoplastic activity. Upon intravenous administration of MYC-targeting siRNA DCR-MYC, the lipid formulation promotes the uptake by tumor cells where the siRNAs moieties are subsequently released. The siRNAs bind to c-Myc mRNAs, which may result in the inhibition of translation and expression of the c-Myc protein and leads to growth inhibition for tumor cells that are overexpressing c-Myc. c-Myc, a proto-oncogene overexpressed in a variety of cancers, is involved in cellular proliferation, differentiation, and apoptosis.	MYC-targeting siRNA DCR-MYC		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C115109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115109>	C2167|C129825	Nazartinib|EGF 816|EGF816|NAZARTINIB	An orally available, irreversible, third-generation, mutant-selective epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, nazartinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. EGF816 preferentially inhibits mutated forms of EGFR including T790M, a secondarily acquired resistance mutation, and may have therapeutic benefits in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11510>	C61063	Cyclophosphamide/Thalidomide|CTX/THAL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115110>	C2167|C129825	Naquotinib|2-Pyrazinecarboxamide, 6-Ethyl-3-((4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-(((3R)-1-(1-oxo-2-propen-1-yl)-3-pyrrolidinyl)oxy)-|ASP8273|NAQUOTINIB	An orally available, irreversible, third-generation, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, ASP8273 covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. ASP8273 preferentially inhibits mutated forms of EGFR including T790M, a secondarily acquired resistance mutation, and may have therapeutic benefits in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C115111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115111>	C129839	Belapectin|BELAPECTIN|GR-MD-02|Galactoarabino-rhamnogalacturonate	A carbohydrate-based galectin inhibitor, with potential antineoplastic activity. Belapectin binds to the carbohydrate-binding domain of galectins, especially galectin-3, and may result in an induction of apoptosis mediated through activation of both mitochondria and caspases. This may reduce tumor growth in galectin-overexpressing tumor cells. Galectins, often overexpressed on tumor cells, play a key role in cancer cell proliferation, apoptosis, tumor angiogenesis and evasion of immune responses.	Belapectin		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C115112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115112>	C141136|C129825	Ceritinib|2,4-Pyrimidinediamine, 5-chloro-N4-(2-((1-methylethyl)sulfonyl)phenyl)-N2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)-|CERITINIB|LDK 378|LDK-378|LDK378|Zykadia	An orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, ceritinib binds to and inhibits wild-type ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to both the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a variety of tumor cell types.	Ceritinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C115113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115113>	C20744	CRYAB Gene|CRYAB|CRYAB|Crystallin, Alpha B Gene	This gene is involved in lens formation.	CRYAB Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C115114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115114>	C115113	CRYAB wt Allele|CMD1II|CRYA2|CTPP2|CTRCT16|Crystallin, Alpha B wt Allele|Crystallin, Alpha-2 Gene|Crystallin, Alpha-B Gene|HEL-S-101|HSPB5|MFM2	Human CRYAB wild-type allele is located within 11q22.3-q23.1 and is approximately 15 kb in length. This allele, which encodes alpha-crystallin B chain protein, plays a role in maintaining the structure of the lens. Mutation of the gene is associated with myofibrillar myopathy type 2, dilated cardiomyopathy type 1II; cataract 16 and alpha-B crystallin-related, fatal infantile hypertrophy myofibrillar myopathy.	CRYAB wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115115>	C18073	Alpha-Crystallin B Chain|Alpha(B)-Crystallin|Heat Shock Protein Beta-5|Heat-Shock 20 kD Like-Protein|Heat-Shock Protein Beta-5|HspB5|Renal Carcinoma Antigen NY-REN-27|Rosenthal Fiber Component	Alpha-crystallin B chain (175 aa, ~20 kDa) is encoded by the human CRYAB gene. This protein is involved in the stabilization of lens proteins.	Alpha-Crystallin B Chain		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115116>	C12662	Circulating Stem Cell|Circulating Progenitor Cell	A primitive cell found in the peripheral blood that has the ability either to divide and renew the primitive cell pool or to differentiate into various specialized cell types.	Circulating Stem Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C115117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115117>	C89793	Stage IA Esophageal Cancer AJCC v7|Stage IA Esophageal Cancer|Stage IA Esophageal Cancer	Stage IA includes: For squamous cell carcinoma: T1, N0, M0, G1, GX, Tumor location: Any. T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  G1: Well differentiated.  GX: Grade cannot be assessed-stage grouping as G1.  Tumor location: Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumor in the esophagus.  For adenocarcinoma: T1, N0, M0, G1-2, X. T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  G1: Well differentiated.  G2: Moderately differentiated. GX: Grade cannot be assessed-stage grouping as G1. (AJCC 7th ed.)	Stage IA Esophageal Cancer AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115118>	C89793	Stage IB Esophageal Cancer AJCC v7|Stage IB Esophageal Cancer|Stage IB Esophageal Cancer	Stage IB includes: For squamous cell carcinoma: (T1, N0, M0, G2-3, Tumor location: Any); (T2-3, N0, M0, G1, GX, Tumor location: Lower, X). T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  T2: Tumor invades muscularis propria. T3: Tumor invades adventitia. N0: No regional lymph node metastasis.  M0: No distant metastasis.  G1: Well differentiated.  GX: Grade cannot be assessed-stage grouping as G1.  G2: Moderately differentiated.  G3: Poorly differentiated.  Tumor location: Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumor in the esophagus. For adenocarcinoma: (T1, N0, M0, G3); (T2, N0, M0, G1-2, GX).  T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  T2: Tumor invades muscularis propria. N0: No regional lymph node metastasis.  M0: No distant metastasis.  G1: Well differentiated.  G2: Moderately differentiated.  G3: Poorly differentiated.  GX: Grade cannot be assessed-stage grouping as G1. (AJCC 7th ed.)	Stage IB Esophageal Cancer AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115119>	C89795	Stage IIIA Esophageal Cancer AJCC v7|Stage IIIA Esophageal Cancer|Stage IIIA Esophageal Cancer	Stage IIIA includes: For squamous cell carcinoma: (T1-2, N2, M0, Any G, Tumor location: Any); (T3, N1, M0, Any G, Tumor location: Any); (T4a, N0, M0, Any G, Tumor location: Any). T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  T2: Tumor invades muscularis propria. T3: Tumor invades adventitia. T4a: Resectable tumor invading pleura, pericardium, or diaphragm. N0: No regional lymph node metastasis.  N1: Metastasis in 1-2 regional lymph nodes.  N2: Metastasis in 3-6 regional lymph nodes.  M0: No distant metastasis.  Tumor location: Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumor in the esophagus. For adenocarcinoma: (T1-2, N2, M0, Any G); (T3, N1, M0, Any G); (T4a, N0, M0, Any G). T1: Tumor invades lamina propria, muscularis mucosae, or submucosa.  T2: Tumor invades muscularis propria. T3: Tumor invades adventitia. T4a: Resectable tumor invading pleura, pericardium, or diaphragm. N0: No regional lymph node metastasis.  N1: Metastasis in 1-2 regional lymph nodes.  N2: Metastasis in 3-6 regional lymph nodes.  M0: No distant metastasis.  (AJCC 7th ed.)	Stage IIIA Esophageal Cancer AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C11511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11511>	C61063	Dexamethasone/Floxuridine/Irinotecan|CPT-11/DM/FUDR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115120>	C89795	Stage IIIB Esophageal Cancer AJCC v7|Stage IIIB Esophageal Cancer|Stage IIIB Esophageal Cancer	Stage IIIB includes: For squamous cell carcinoma: T3, N2, M0, Any G, Tumor location: Any. T3: Tumor invades adventitia. N2: Metastasis in 3-6 regional lymph nodes.  M0: No distant metastasis.  Tumor location: Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumor in the esophagus. For adenocarcinoma: T3, N2, M0, Any G. T3: Tumor invades adventitia. N2: Metastasis in 3-6 regional lymph nodes.  M0: No distant metastasis.  (AJCC 7th ed.)	Stage IIIB Esophageal Cancer AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115121>	C89795	Stage IIIC Esophageal Cancer AJCC v7|Stage IIIC Esophageal Cancer|Stage IIIC Esophageal Cancer	Stage IIIC includes: For squamous cell carcinoma: (T4a, N1-2, M0, Any G, Tumor location: Any); (T4b, Any N, M0, Any G, Tumor location: Any); (Any T, N3, M0, Any G, Tumor location: Any).  T4a: Resectable tumor invading pleura, pericardium, or diaphragm. T4b: Unresectable tumor invading other adjacent structures, such as aorta, vertebral body, trachea, etc. N1: Metastasis in 1-2 regional lymph nodes.  N2: Metastasis in 3-6 regional lymph nodes.  N3: Metastasis in seven or more regional lymph nodes.  M0: No distant metastasis.  Tumor location: Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumor in the esophagus. For adenocarcinoma: (T4a, N1-2, M0, Any G); (T4b, Any N, M0, Any G); (Any T, N3, M0, Any G).  T4a: Resectable tumor invading pleura, pericardium, or diaphragm. T4b: Unresectable tumor invading other adjacent structures, such as aorta, vertebral body, trachea, etc.  N1: Metastasis in 1-2 regional lymph nodes.  N2: Metastasis in 3-6 regional lymph nodes.  N3: Metastasis in seven or more regional lymph nodes.  M0: No distant metastasis.  (AJCC 7th ed.)	Stage IIIC Esophageal Cancer AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115122>	C25474	Generic Investigational New Animal Drug File	Data submitted to a generic investigational new animal drug file.			Intellectual Product	PQ/CMC Stability Study Reason Terminology
C115123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115123>	C60755	Abbreviated New Animal Drug Application	Data submitted to an abbreviated new animal drug application.			Intellectual Product	PQ/CMC Stability Study Reason Terminology
C115124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115124>	C62601	Central Serous Chorioretinopathy|CSC|Central Serous Retinopathy	A self-resolving eye condition characterized by fluid accumulation under the macula in the retina. It results from leakage of fluid from the choroid. It usually affects one eye only and the vast majority of patients regain full vision.			Disease or Syndrome	
C115125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115125>	C25338	Intelligence Quotient|IQ	A score derived from a standardized test designed to assess an individual's intelligence as compared to the general population.			Quantitative Concept	
C115126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115126>	C222259	Kaufman Assessment Battery for Children|KABC	A clinical tool used to assess a child's strengths and weaknesses in cognitive ability and mental processing.			Intellectual Product	
C115127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115127>	C222259	Raven's Progressive Matrices|RPM|Raven's Matrices	A nonverbal group test typically used in educational settings, consisting of 60 multiple choice questions designed to measure the test-taker's reasoning ability.			Intellectual Product	
C115128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115128>	C122920	Wechsler Adult Intelligence Scale|WAIS	A 60 question test designed to measure intelligence in adults and older adolescents.			Intellectual Product	
C115129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115129>	C222259	Woodcock-Johnson Tests of Cognitive Abilities|WJ III	A comprehensive, individually administered cognitive assessment that identifies strengths and weaknesses in cognitive abilities, processes, and academic performance.			Intellectual Product	
C11512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11512>	C61007	Flutamide/Triptorelin|FLUT/TRIP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115130>	C8259	Stage IIA Uterine Sarcoma AJCC v7|Stage IIA Uterine Sarcoma	Tumor involves adnexa.  No regional lymph node or distant metastasis.	Stage IIA Uterine Sarcoma AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115131>	C8259	Stage IIB Uterine Sarcoma AJCC v7|Stage IIB Uterine Sarcoma	Tumor involves other pelvic tissues.  No regional lymph node or distant metastasis.	Stage IIB Uterine Sarcoma AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115132>	C3099	Hepatocellular Carcinoma by BCLC Stage|BCLC Staging for Hepatocellular Carcinoma|Barcelona Clinic Liver Cancer Staging for Hepatocellular Carcinoma|Hepatocellular Carcinoma BCLC Staging|Hepatocellular Carcinoma Barcelona Clinic Liver Cancer Staging|Hepatocellular Carcinoma by Barcelona Clinic Liver Cancer Stage	A staging classification system for hepatocellular carcinoma that uses variables related to tumor stage, liver functional status, physical status, and cancer-related symptoms, and links the stages with a treatment algorithm. (HPB (Oxford) 2005; 7(1):35-41)			Neoplastic Process	
C115133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115133>	C115132	BCLC Stage 0 Hepatocellular Carcinoma|BCLC Stage 0 Hepatocellular Cancer|Barcelona Clinic Liver Cancer Stage 0 Hepatocellular Carcinoma	Very early hepatocellular carcinoma. Patients are optimal candidates for resection. (HPB (Oxford) 2005; 7(1):35-41)	BCLC Stage 0 Hepatocellular Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115134>	C28108	BCLC Stage|Barcelona Clinic Liver Cancer Stage	A stage for hepatocellular carcinoma defined according to the Barcelona Clinic Liver Cancer (BCLC) criteria.			Classification	
C115135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115135>	C115132	BCLC Stage A Hepatocellular Carcinoma|BCLC Stage A Hepatocellular Cancer|Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma	Early hepatocellular carcinoma.  Patients are candidates for radical therapies (resection, liver transplantation, or percutaneous treatments). (HPB (Oxford) 2005; 7(1):35-41)	BCLC Stage A Hepatocellular Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115136>	C115132	BCLC Stage B Hepatocellular Carcinoma|BCLC Stage B Hepatocellular Cancer|Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma	Intermediate hepatocellular carcinoma.  Patients may benefit from chemoembolization. (HPB (Oxford) 2005; 7(1):35-41)	BCLC Stage B Hepatocellular Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115137>	C115132	BCLC Stage C Hepatocellular Carcinoma|BCLC Stage C Hepatocellular Cancer|Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma	Advanced hepatocellular carcinoma.  Patients may receive new agents in the setting of randomized controlled trials. (HPB (Oxford) 2005; 7(1):35-41)	BCLC Stage C Hepatocellular Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115138>	C115132	BCLC Stage D Hepatocellular Carcinoma|BCLC Stage D Hepatocellular Cancer|Barcelona Clinic Liver Cancer Stage D Hepatocellular Carcinoma	End-stage hepatocellular carcinoma.  Patients will receive symptomatic treatment. (HPB (Oxford) 2005; 7(1):35-41)	BCLC Stage D Hepatocellular Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115139>	C7956|C115133	BCLC Stage 0 Adult Hepatocellular Carcinoma|BCLC Stage 0 Hepatocellular Cancer|Barcelona Clinic Liver Cancer Stage 0 Adult Hepatocellular Carcinoma	Very early hepatocellular carcinoma. Patients are optimal candidates for resection. (HPB (Oxford) 2005; 7(1):35-41)	BCLC Stage 0 Adult Hepatocellular Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C11513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11513>	C61063	Carboplatin/Temozolomide|CBDCA/TMZ			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115140>	C7956|C115135	BCLC Stage A Adult Hepatocellular Carcinoma|BCLC Stage A Hepatocellular Cancer|Barcelona Clinic Liver Cancer Stage A Adult Hepatocellular Carcinoma	Early hepatocellular carcinoma.  Patients are candidates for radical therapies (resection, liver transplantation, or percutaneous treatments). (HPB (Oxford) 2005; 7(1):35-41)	BCLC Stage A Adult Hepatocellular Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115141>	C7956|C115136	BCLC Stage B Adult Hepatocellular Carcinoma|BCLC Stage B Hepatocellular Cancer|Barcelona Clinic Liver Cancer Stage B Adult Hepatocellular Carcinoma	Intermediate hepatocellular carcinoma.  Patients may benefit from chemoembolization. (HPB (Oxford) 2005; 7(1):35-41)	BCLC Stage B Adult Hepatocellular Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115142>	C912	DU-PAN-2|DUPAN-2|Sialyl Le(c)|Sialyl Le(c) Antigen|Sialyl LeC|Sialyl Lewis (c)|Sialyl Lewis C|Sialylated Lewis (c)|Sialylated Lewis (c) Antigen|Sialylated Lewis C|Sialylated Lewis C Antigen|sLeC	A sialylated carbohydrate antigen that is found in serum at elevated levels in pancreatic cancer and other neoplastic diseases. DU-PAN-2 is related to the type 1 Lewis blood antigen family and is a precursor for CA19-9.	DU-PAN-2		Immunologic Factor|Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C115143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115143>	C7956|C115137	BCLC Stage C Adult Hepatocellular Carcinoma|BCLC Stage C Hepatocellular Cancer|Barcelona Clinic Liver Cancer Stage C Adult Hepatocellular Carcinoma	Advanced hepatocellular carcinoma.  Patients may receive new agents in the setting of randomized controlled trials. (HPB (Oxford) 2005; 7(1):35-41)	BCLC Stage C Adult Hepatocellular Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115144>	C7956|C115138	BCLC Stage D Adult Hepatocellular Carcinoma|BCLC Stage D Hepatocellular Cancer|Barcelona Clinic Liver Cancer Stage D Adult Hepatocellular Carcinoma	End-stage hepatocellular carcinoma.  Patients will receive symptomatic treatment. (HPB (Oxford) 2005; 7(1):35-41)	BCLC Stage D Adult Hepatocellular Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115145>	C13432	17pter-q21	A chromosome band that encompasses the entire p arm and part of the q arm of chromosome 17.	17pter-q21		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115146>	C16295	PDGFR Antibody|Anti- Platelet-Derived Growth Factor Receptor Antibody|Anti-CD140 Antibody|Anti-PDGF-R Antibody|Anti-PDGFR Antibody|CD140 Antibody|PDGF-R Antibody|Platelet-Derived Growth Factor Receptor Antibody	Any immunoglobulin that recognizes any member of the platelet-derived growth factor receptor family.	PDGFR Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115147>	C16295	Type V Collagen Antibody|Anti-Collagen Type V Antibody|Anti-Collagen V Antibody|Anti-Type V Collagen Antibody|Anti-Type-V Collagen Antibody|Collagen Type V Antibody|Collagen V Antibody|Type-V Collagen Antibody	Any immunoglobulin that recognizes type V collagen.	Type V Collagen Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115148>	C16295	TUBA1B Antibody|Anti-K-Alpha-1 Tubulin Antibody|Anti-TUBA1B Antibody|Anti-Tubulin Alpha-1B Chain Antibody|K-Alpha-1 Tubulin Antibody|Tubulin Alpha-1B Chain Antibody	Any immunoglobulin that recognizes tubulin alpha-1B chain protein.	TUBA1B Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115149>	C3439	Adenovirus Infection|AdV Infection|Adenoviral Infection	An infectious process caused by adenovirus. The virus may cause respiratory illness, conjunctivitis, gastroenteritis, and cystitis.	Adenovirus Infection		Disease or Syndrome	CTRP Biomarker Terminology|CTRP Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11514>	C61063	Cisplatin/OXi-104|CDDP/OXi-104			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115150>	C8492|C7933|C7615	Adult Grade III Lymphomatoid Granulomatosis|Grade III Lymphomatoid Granulomatosis	Grade III lymphomatoid granulomatosis that occurs in adulthood.	Adult Grade III Lymphomatoid Granulomatosis		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115151>	C16295	BIRC5 Antibody|Anti-BIRC5 Antibody|Anti-Baculoviral IAP Repeat-Containing Protein 5 Antibody|Anti-IAP4 Antibody|Anti-Survivin Antibody|Baculoviral IAP Repeat-Containing Protein 5 Antibody|IAP4 Antibody|Survivin Antibody	Any immunoglobulin that recognizes baculoviral IAP repeat-containing protein 5.	BIRC5 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115152>	C50754|C35552	Vascular Stenosis	Narrowing of the lumen of an artery or vein.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C115153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115153>	C3247	Adult Myelodysplastic Syndrome|Myelodysplastic Syndrome	Myelodysplastic syndrome that occurs in adulthood.	Adult Myelodysplastic Syndrome		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115154>	C8492|C4684	Adult Nasal Type Extranodal NK/T-Cell Lymphoma|Nasal Type Extranodal NK/T-Cell Lymphoma	Nasal type extranodal NK/T-cell lymphoma that occurs in adulthood.	Adult Nasal Type Extranodal NK/T-Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115155>	C16295	TP53 Antibody|Anti-Cellular Tumor Antigen p53 Antibody|Anti-TP53 Antibody|Anti-Tumor Protein p53 Antibody|Anti-p53 Antibody|Cellular Tumor Antigen p53 Antibody|Tumor Protein p53 Antibody|p53 Antibody	Any immunoglobulin that recognizes cellular tumor antigen p53 protein.	TP53 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115157>	C16295	MAGEA3 Antibody|Anti-CT1.3 Antibody|Anti-Cancer/Testis Antigen 1.3 Antibody|Anti-MAGE3 Antibody|Anti-MAGEA3 Antibody|Anti-Melanoma-Associated Antigen 3 Antibody|CT1.3 Antibody|Cancer/Testis Antigen 1.3 Antibody|MAGE3 Antibody|Melanoma-Associated Antigen 3 Antibody	Any immunoglobulin that recognizes melanoma-associated antigen 3 protein.	MAGEA3 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115158>	C9229	Nephrogenic Systemic Fibrosis|NSF	Fibrosis of the skin, joints and other organs usually associated with gadolinium exposure in the setting of kidney failure.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C115159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115159>	C16295	PMEL Antibody|Anti-Melanocyte Protein PMEL Antibody|Anti-PMEL Antibody|Anti-SILV Antibody|Anti-gp100 Antibody|Melanocyte protein PMEL Antibody|SILV Antibody|gp100 Antibody	Any immunoglobulin that recognizes melanocyte protein PMEL.	PMEL Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11515>	C61007	Docetaxel/Gemcitabine|TXT/dFdC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115160>	C168878	Blast Phase|Blast Crisis|Blastic Phase|Blastic Phase|Blastic Phase	Sudden increase of the number of blasts in the bone marrow and/or peripheral blood in a patient with a history of chronic leukemia.	Blastic Phase		Finding	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C115161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115161>	C122439	Dislodged Peritoneal Dialysis Catheter	Malposition of a peritoneal dialysis catheter.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C115162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115162>	C78254	Displaced Peritoneal Dialysis Catheter	Malposition and dysfunction of a peritoneal dialysis catheter.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C115163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115163>	C3333	Community-Acquired Pneumonia|Community-acquired Pneumonia	Pneumonia that is not acquired in a hospital or long-term care facility setting.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C115164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115164>	C26726	Nosocomial Infection|HAI|HAI|Healthcare-Associated Infection|Healthcare-Associated Infection|Hospital-Acquired Infection|Hospital-Acquired Infection|Hospital-Onset Infection	An infection acquired in a hospital or other healthcare setting.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Infectious Disease Terminology
C115165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115165>	C27662	Sialitis|Sialadenitis	Inflammation of the salivary glands.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Infectious Disease Terminology
C115166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115166>	C25994	AGRP Gene|AGRP|AGRP|Agouti Related Protein Homolog (Mouse) Gene	This gene plays a role in feeding behavior.	AGRP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C115167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115167>	C115166	AGRP wt Allele|AGRT|ART|ASIP2|Agouti (Mouse) Related Protein Gene|Agouti Related Protein Homolog (Mouse) wt Allele|Agouti-Related Protein, Mouse, Homolog of Gene|Agouti-Related Transcript, Mouse, Homolog of Gene	Human AGRP wild-type allele is located in the vicinity of 16q22 and is approximately 1 kb in length. This allele, which encodes agouti-related protein, is involved in the regulation of feeding behavior. Mutation of the gene is associated with obesity.	AGRP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115168>	C78208	Spontaneous Bladder Rupture|Spontaneous Bladder Perforation	Rupture in the bladder wall due to a pathologic process, in the absence of trauma.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C115169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115169>	C1746	Agouti-Related Protein|AGRP|Agouti Related Protein	Agouti-related protein (132 aa, ~14 kDa) is encoded by the human AGRP gene. This protein plays a role in the modulation of feeding behavior.	Agouti-Related Protein		Amino Acid, Peptide, or Protein|Hormone	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11516>	C61063	Interleukin-2/Ras Peptide Cancer Vaccine|IL-2/ras pep vac			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115170>	C28533	GJA1 Gene|GJA1|GJA1|Gap Junction Protein, Alpha 1, 43kDa Gene	This gene is involved in gap junction assembly.	GJA1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C115171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115171>	C115170	GJA1 wt Allele|AVSD3|CMDR|CX43|DFNB38|GJAL|Gap Junction Protein, Alpha 1, 43kDa (Connexin 43) Gene|Gap Junction Protein, Alpha 1, 43kDa wt Allele|Gap Junction Protein, Alpha-1 Gene|Gap Junction Protein, Alpha-Like Gene|HLHS1|HSS|ODDD|Oculodentodigital Dysplasia (Syndactyly Type III) Gene	Human GJA1 wild-type allele is located in the vicinity of 6q22.31 and is approximately 14 kb in length. This allele, which encodes gap junction alpha-1 protein, plays a role in the modulation of the activity of gap junctions. Mutation of the gene is associated with atrioventricular septal defect 3, autosomal recessive craniometaphyseal dysplasia, hypoplastic left heart syndrome 1, oculodentodigital dysplasia and syndactyly, type III.	GJA1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115172>	C16386	Gap Junction Alpha-1 Protein|Connexin 43|Connexin-43|Cx43|GJA|Gap Junction 43 kDa Heart Protein|Heart Connexin	Gap junction alpha-1 protein (382 aa, ~43 kDa) is encoded by the human GJA1 gene. This protein is involved in the regulation of the assembly of gap junctions.	Gap Junction Alpha-1 Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115173>	C25993	ANO1 Gene|ANO1|ANO1|Anoctamin 1, Calcium Activated Chloride Channel Gene	This gene plays a role in chloride transport.	ANO1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C115174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115174>	C115173	ANO1 wt Allele|Anoctamin 1, Calcium Activated Chloride Channel wt Allele|Anoctamin 1, Calcium-Activated Chloride Channel Gene|DOG1|ORAOV2|Oral Cancer Overexpressed 2 Gene|TAOS2|TMEM16A	Human ANO1 wild-type allele is located in the vicinity of 11q13.3 and is approximately 111 kb in length. This allele, which encodes anoctamin-1 protein, is involved in the modulation of chloride transport.	ANO1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115175>	C28505	Anoctamin-1|ANO1|Anoctamin 1|DOG1|DOG1 (ANO1)|Discovered on Gastrointestinal Stromal Tumors Protein 1|Oral Cancer Overexpressed Protein 2|Transmembrane Protein 16A|Tumor-Amplified and Overexpressed Sequence 2	Anoctamin-1 (986 aa, ~114 kDa) is encoded by the human ANO1 gene. This protein plays a role in calcium-dependent transport of chloride.	Anoctamin-1		Amino Acid, Peptide, or Protein	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115176>	C26003	CELA1 Gene|CELA1|CELA1|Chymotrypsin-Like Elastase Family, Member 1 Gene	This gene is involved in protein hydrolysis.	CELA1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C115177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115177>	C115176	CELA1 wt Allele|Chymotrypsin-Like Elastase Family, Member 1 wt Allele|ELA1|Elastase 1, Pancreatic Gene	Human CELA1 wild-type allele is located in the vicinity of 12q13 and is approximately 18 kb in length. This allele, which encodes chymotrypsin-like elastase family member 1 protein, plays a role in the mediation of proteolysis.	CELA1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115178>	C17123	Chymotrypsin-Like Elastase Family Member 1|CELA1|EC 3.4.21.36|Elastase 1|Elastase-1|Pancreatic Elastase 1|Pancreatic Elastase-1	Chymotrypsin-like elastase family member 1 (258 aa, ~28 kDa) is encoded by the human CELA1 gene. This protein is involved in protein hydrolysis.	Chymotrypsin-Like Elastase Family Member 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115179>	C25941	PPIB Gene|PPIB|PPIB|Peptidylprolyl Isomerase B (Cyclophilin B) Gene	This gene plays a role in catalyzing protein folding.	PPIB Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C11517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11517>	C61063	Penicillamine/Pyridoxine|penicillamine/VIT-B6			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115180>	C115179	PPIB wt Allele|CYP-S1|CYPB|HEL-S-39|OI9|Peptidylprolyl Isomerase B (Cyclophilin B) wt Allele|SCYLP	Human PPIB wild-type allele is located within 15q21-q22 and is approximately 7 kb in length. This allele, which encodes peptidyl-prolyl cis-trans isomerase B protein, is involved in protein folding. Mutation of the gene is associated with osteogenesis imperfecta type 9.	PPIB wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115181>	C16759	Peptidyl-Prolyl Cis-Trans Isomerase B|CYP-S1|Cyclophilin B|Cyclophilin-Like Protein|EC 5.2.1.8|PPIB|PPIase B|Peptidyl-Prolyl Isomerase B|Peptidylprolyl Isomerase B|Rotamase B|S-Cyclophilin|SCYLP	Peptidyl-prolyl cis-trans isomerase B (216 aa, ~24 kDa) is encoded by the human PPIB gene. This protein plays a role in the mediation of protein folding.	Peptidyl-Prolyl Cis-Trans Isomerase B		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115182>	C21295	MMRN1 Gene|MMRN1|MMRN1|Multimerin 1 Gene	This gene is involved in the storage of coagulation factor V/Va in platelets.	MMRN1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C115183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115183>	C115182	MMRN1 wt Allele|ECM|EMILIN4|GPIa*|MMRN|Multimerin 1 wt Allele|Multimerin Gene	Human MMRN1 wild-type allele is located in the vicinity of 4q22 and is approximately 75 kb in length. This allele, which encodes multimerin-1 protein, plays a role in platelet factor V/Va homeostasis.	MMRN1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115184>	C17728	Multimerin-1|EMILIN-4|Elastin Microfibril Interface Located Protein 4|Elastin Microfibril Interfacer 4|Endothelial Cell Multimerin|Glycoprotein Ia*|MMRN1|Multimerin|Multimerin 1|Platelet Glycoprotein Ia*	Multimerin-1 (1228 aa, ~138 kDa) is encoded by the human MMRN1 gene. This protein is involved in stabilization of platelet-bound factor V/Va.	Multimerin-1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115185>	C21295	MUC2 Gene|MUC2|MUC2|Mucin 2, Oligomeric Mucus/Gel-Forming Gene	This gene plays a role in the lubrication of mucosal surfaces.	MUC2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C115186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115186>	C115185	MUC2 wt Allele|MLP|MUC-2|Mucin 2, Intestinal Gene|Mucin 2, Intestinal/Tracheal Gene|Mucin 2, Oligomeric Mucus/Gel-Forming wt Allele|SMUC	Human MUC2 wild-type allele is located in the vicinity of 11p15.5 and is approximately 30 kb in length. This allele, which encodes mucin-2 protein, is involved in preventing irritation of mucosal surfaces.	MUC2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115187>	C16883	Mucin-2|Intestinal Mucin-2|MUC-2|MUC2|Mucin 2|Mucin-Like Protein	Mucin-2 (5179 aa, ~540 kDa) is encoded by the human MUC2 gene. This protein plays a role in coating the intestinal epithelium.	Mucin-2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115188>	C20194	TFF2 Gene|TFF2|TFF2|Trefoil Factor 2 Gene	This gene is involved in the inhibition of both gastric acid secretion and gastrointestinal motility.	TFF2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C115189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115189>	C115188	TFF2 wt Allele|SML1|SP|Spasmolytic Protein 1 Gene|Trefoil Factor 2 wt Allele	Human TFF2 wild-type allele is located in the vicinity of 21q22.3 and is approximately 5 kb in length. This allele, which encodes trefoil factor 2 protein, plays a role in both gastrointestinal motility and gastric acid secretion.	TFF2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11518>	C61063	Interferon Alfa/Toremifene|IFN-A/TOR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115190>	C18466	Trefoil Factor 2|SP|Spasmolysin|Spasmolytic Polypeptide|Spasmolytic Protein 1|TFF2	Trefoil factor 2 (129 aa, ~14 kDa) is encoded by the human TFF2 gene. This protein is involved in the negative regulation of gastrointestinal motility and gastric acid secretion.	Trefoil Factor 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115191>	C20745	TUBA1B Gene|TUBA1B|TUBA1B|Tubulin, Alpha 1b Gene	This gene plays a role in microtubule assembly and disassembly.	TUBA1B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C115192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115192>	C6770|C221717	Childhood Ependymal Tumor|Ependymal Tumor	An ependymal tumor that occurs during childhood.	Childhood Ependymal Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C115193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115193>	C115191	TUBA1B wt Allele|K-ALPHA-1|Tubulin, Alpha 1b wt Allele|Tubulin, Alpha, Ubiquitous Gene|Tubulin, Alpha-1B Gene	Human TUBA1B wild-type allele is located in the vicinity of 12q13.12 and is approximately 4 kb in length. This allele, which encodes tubulin alpha-1B chain protein, is involved in microtubule dynamics.	TUBA1B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115194>	C129386	Tubulin Alpha-1B Chain|Alpha-Tubulin Ubiquitous|K-Alpha-1 Tubulin|Tubulin Alpha-3C/D Chain|Tubulin Alpha-Ubiquitous Chain|Tubulin K-Alpha-1	Tubulin alpha-1B chain (451 aa, ~50 kDa) is encoded by the human TUBA1B gene. This protein plays a role in microtubule structure.	Tubulin Alpha-1B Chain		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115195>	C3903|C221717	Childhood Mixed Glioma|Mixed Glioma	A mixed glioma that occurs during childhood.	Childhood Mixed Glioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C115196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115196>	C6965|C5960	Childhood Pineal Parenchymal Cell Neoplasm|Childhood Pineocytic Neoplasm|Childhood Pineocytic Tumor|Pineal Parenchymal Cell Neoplasm	A pineal parenchymal cell neoplasm that occurs during childhood.	Childhood Pineal Parenchymal Cell Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C115197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115197>	C93175	BRCA1 Mutation Carrier	A carrier of a mutation in BRCA1 gene.	BRCA1 Mutation Carrier		Human	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115198>	C93175	BRCA2 Mutation Carrier	A carrier of a mutation in BRCA2 gene.	BRCA2 Mutation Carrier		Human	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115199>	C2959	Cardiovascular Complication	Any heart or vascular disorder occurring as a consequence of injury to the cardiovascular system.	Cardiovascular Complication		Finding	CTRP Disease Terminology|CTRP Terminology
C11519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11519>	C61063	Asparaginase/Dexamethasone/Prednisone/Vincristine|ASP/DM/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1151>	C308	Mannose-Binding Lectin|MBL|MBP|Mannan-Binding Lectin|Mannose Binding Protein|Recombinant Human Mannose-binding Lectin	A recombinant protein similar or identical to human mannan-binding lectin (MBL) with opsonin activity. MBL, a soluble pattern recognition receptor (PRR) collectin in the C-type lectin superfamily, is a plasma protein that plays an important role in innate immunity; MBL contains a carbohydrate recognition domain at one end and a collagen-like stalk domain at the other. Upon MBL binding to mannose residues on mannose-containing polysaccharides (mannans) on the surfaces of microorganisms, activation of the complement system results in the deposition of complement components (opsonization) and the clearance of the opsonized microorganisms by phagocytic cells. MBL is part of the mannan-binding lectin pathway (also known as the Ali/Krueger pathway), which has similarities to the classical complement pathway in that activation of C4 and C2 produce activated complement proteins further down the complement cascade. However, unlike the classical complement pathway, activation of this pathway is not antibody dependent.	Mannose-Binding Lectin		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C115200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115200>	C3056	Unicentric Castleman Disease|Localized Angiofollicular Lymphoid Hyperplasia|Localized Angiofollicular Lymphoid Hyperplasia|Localized Castleman Disease|UCD	Castleman disease that presents with localized lymphadenopathy.	Localized Angiofollicular Lymphoid Hyperplasia		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C115201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115201>	C6286|C6252|C3569	Childhood Cerebellar Anaplastic Astrocytoma|Cerebellar Anaplastic Astrocytoma	A cerebellar anaplastic astrocytoma that occurs during childhood.	Childhood Cerebellar Anaplastic Astrocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115202>	C6252|C5123|C4347	Childhood Cerebral Anaplastic Astrocytoma|Anaplastic Hemispheric Astrocytoma	A cerebral anaplastic astrocytoma that occurs during childhood.	Childhood Cerebral Anaplastic Astrocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115203>	C4915|C114833	Childhood Embryonal Tumor with Multilayered Rosettes, C19MC-Altered|Childhood Ependymoblastoma|Childhood Ependymoblastoma|Embryonal Tumor with Multilayered Rosettes, C19MC-Altered	An embryonal tumor with multilayered rosettes, C19MC-altered that occurs during childhood.	Childhood Embryonal Tumor with Multilayered Rosettes, C19MC-Altered		Neoplastic Process	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C115204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115204>	C7933|C7616|C123392	Childhood Grade III Lymphomatoid Granulomatosis|Grade III Lymphomatoid Granulomatosis	Grade III lymphomatoid granulomatosis that occurs during childhood.	Childhood Grade III Lymphomatoid Granulomatosis		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115205>	C114994	Untreated Childhood Pineoblastoma|Untreated Pineoblastoma	A finding of childhood pineoblastoma that has not been treated.	Untreated Childhood Pineoblastoma		Finding	CTRP Disease Terminology|CTRP Terminology
C115206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115206>	C2861	Cognitive Side Effects of Cancer Therapy	Cognitive impairment caused by cancer treatment.	Cognitive Side Effects of Cancer Therapy		Finding	CTRP Disease Terminology|CTRP Terminology
C115207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115207>	C53543	Congenital Amegakaryocytic Thrombocytopenia	A rare, autosomal recessive inherited disorder caused by mutation in the c-Mpl gene.  It is characterized by thrombocytopenia and absence of megakaryocytes.  It presents with bleeding in the first month of life.	Congenital Amegakaryocytic Thrombocytopenia		Disease or Syndrome	CCPS Disease Terminology|Childhood Cancer Predisposition Study Terminology|CTRP Disease Terminology|CTRP Terminology
C115208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115208>	C172688	Crohn Disease-Associated Dysplasia of the Colorectum|Colorectal Crohn Disease-Associated Dysplasia|Dysplasia in Crohn Disease|Dysplasia in Crohn Disease	A morphologic finding indicating the presence of dysplastic epithelial changes in an intestinal tissue sample that is affected by Crohn disease.	Dysplasia in Crohn Disease		Finding	CTRP Disease Terminology|CTRP Terminology
C115209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115209>	C2959	Dermatologic Complication	Any skin disorder occurring as a consequence of injury to the skin tissue.	Dermatologic Complication		Finding	CTRP Disease Terminology|CTRP Terminology
C11520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11520>	C61007	Carboplatin/Paclitaxel/PSC 833|CBDCA/PSC 833/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115210>	C9106	Distal Urethral Carcinoma|Distal Urethra Carcinoma|Distal Urethral Cancer	A carcinoma that arises from the distal part of the urethra.	Distal Urethral Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NCIt Neoplasm Core Terminology
C115211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115211>	C8591	Familial Testicular Germ Cell Tumor|FTGCT	Germ cell tumor that arises from the testis and is diagnosed in at least two relatives.	Familial Testicular Germ Cell Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115212>	C9479|C80307	Familial Waldenstrom Macroglobulinemia|Familial Waldenström Macroglobulinemia	Waldenstrom macroglobulinemia in a patient who has at least one first degree relative with either Waldenstrom macroglobulinemia or another B-cell lymphoproliferative disorder.	Familial Waldenstrom Macroglobulinemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NCIt Neoplasm Core Terminology
C115213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115213>	C4876	Fever, Sweat, and Hot Flashes	Temperature elevation, sweating, and red flushed face.	Fever, Sweat, and Hot Flashes		Finding	CTRP Disease Terminology|CTRP Terminology
C115214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115214>	C2959	Digestive System Complication|Gastrointestinal Complication	Any disorder of the organs of the digestive system occurring as a consequence of injury to the digestive system.	Digestive System Complication		Finding	CTRP Disease Terminology|CTRP Terminology
C115216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115216>	C129906	Invariant Natural Killer T-Cell|Invariant natural killer T-cell|iNKT	A natural killer T-cell subtype bearing an invariant T-cell receptor. Invariant natural killer T-cells recognize a small variety of glycolipid antigens presented in the context of CD1d. These cells play a regulatory role during an immune response by producing cytokines.			Cell	
C115217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115217>	C12476	Mucosal-Associated Invariant T-Cell|MAIT|Mucosal-associated invariant T-cell	A T-cell subtype bearing a semi-invariant T-cell receptor and restricted by the major histocompatibility complex related molecule MR1. These cells occupy peripheral tissues and are noted for their reactivity against various microorganisms of either bacterial or fungal origin.			Cell	
C115218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115218>	C63480	SLAM-Associated Protein Expression Analysis|SH2D1A Expression Analysis|Signaling lymphocyte activation molecule (SLAM)-associated protein (SAP) expression	A laboratory test to determine the presence or absence of SH2 domain-containing protein 1A (SLAM-associated protein, SAP) expression. Loss of SAP expression is associated with X-linked lymphoproliferative syndrome 1.			Laboratory Procedure	
C115219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115219>	C90392	Fair Hair|Fair hair	A human hair color characterized by low levels of eumelanin.			Qualitative Concept	
C11521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11521>	C61063	Amifostine/Carmustine/Cyclophosphamide/Cytarabine/Etoposide|ARA-C/BCNU/CTX/VP-16/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115220>	C36281	Fair Skin|Fair skin	A human skin color characterized by low levels of eumelanin.			Finding	
C115221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115221>	C2902	Bleeding Diathesis|Bleeding Disorder|Bleeding Predisposition|Bleeding Tendency|Bleeding diathesis	A coagulation disorder characterized by a tendency for excessive bleeding.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C115222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115222>	C16669	Health Status Unknown	Indicates that a person's current status of health is not known.	Health Status Unknown		Organism Attribute	CTRP Terminology
C115223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115223>	C48284	Healthy Stem Cell Donor	Indicates that a donor of stem cells is healthy.	Healthy Stem Cell Donor		Qualitative Concept	CTRP Terminology
C115224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115224>	C115214	Hepatic Complication	Any disorder of the liver occurring as a consequence of injury to the liver parenchyma.	Hepatic Complication		Finding	CTRP Disease Terminology|CTRP Terminology
C115225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115225>	C9479|C3270	Hereditary Neuroblastoma|Familial Neuroblastoma|Familial Neuroblastoma	Genetic inheritance of neuroblastoma caused by mutations in the ALK or PHOX2B genes.  Familial neuroblastomas have a higher incidence of multiple primary tumors and are diagnosed at an earlier age.	Familial Neuroblastoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NCIt Neoplasm Core Terminology
C115226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115226>	C41332	Long-Term Effects Secondary to Cancer Therapy	Side effects of cancer treatment occurring a long time after the treatment was completed.	Long-Term Effects Secondary to Cancer Therapy		Finding	CTRP Disease Terminology|CTRP Terminology
C115227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115227>	C115226	Long-Term Effects Secondary to Cancer Therapy in Adults	Side effects of cancer treatment received during adulthood occurring a long time after the treatment was completed.	Long-Term Effects Secondary to Cancer Therapy in Adults		Finding	CTRP Disease Terminology|CTRP Terminology
C115228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115228>	C91105	University of Washington Quality of Life Scale, Version 4|UW QOLv4	A questionnaire designed to assess health-related quality of life in head and neck cancer patients.	University of Washington Quality of Life Scale, Version 4		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C115229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115229>	C91102	Most Important Issue Question|Most Important Issue|Most Important Issues|Which issues have been the most important to you	A question about a person's most important health issues.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C11522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11522>	C61063	Amifostine/Carboplatin/Cyclophosphamide/Thiotepa|CBDCA/CTX/TSPA/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115230>	C176246	Mild Pain Not Needing Medication|There is mild pain not needing medication	A response indicating that an individual has mild pain, but that it does not require medication.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115231>	C176246	Have Moderate Pain that Requires Medication|I have moderate pain - requires regular medication (codeine or nonnarcotic)	A response indicating that an individual has moderate pain that requires medication to control.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115232>	C176246	Have Severe Pain Controlled Only By Narcotics|I have severe pain controlled only by narcotics	A response indicating that an individual has severe pain that is only controlled by narcotic medications.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115233>	C176246	Have Severe Pain Not Controlled By Medication|I have severe pain, not controlled by medication	A response indicating that an individual has severe pain that is not controlled by medication.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115234>	C226627	No Change in Personal Appearance|There is no change in my appearance	A response indicating that an individual has or had no change in their appearance.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115235>	C226627	Minor Change in Appearance|The change in my appearance is minor	A response indicating that an individual has or had a minor change in their appearance.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115236>	C226638|C226611	Bothered by Appearance but Remain Active|My appearance bothers me but I remain active	A response indicating that an individual is bothered by a change in their appearance but that they remain active.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115237>	C226668|C226614|C178371	Feel Significantly Disfigured and Limit Activities Due to Appearance|I feel significantly disfigured and limit my activities due to my appearance	A response indicating that an individual feels disfigured and that this change in their appearance limits their activities.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115238>	C226638	Cannot Be With People Due to Appearance|I cannot be with people due to my appearance	A response indicating that an individual feels that they cannot be with other people due to a change in their appearance.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115239>	C226611	As Active as Have Ever Been|I am as active as I have ever been	A response indicating that an individual is as active as ever.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C11523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11523>	C61007	Fluorouracil/Oxaliplatin|5-FU/L-OHP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115240>	C226561	At Times Can't Keep Up With Usual Pace|There are times when I can't keep up my old pace, but not often	A response indicating that an individual cannot keep up their old pace, but that this is not often.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115241>	C226740|C226620	Often Tired and Have Slowed Down Activities But Still Get Out|I am often tired and have slowed down my activities although I still get out	A response indicating that an individual is often tired and has slowed down, but still gets out.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115242>	C226620	Don't Go Out Because of Lack of Strength|I don't go out because I don't have the strength	A response indicating that an individual does not go out due to a lack of strength.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115243>	C226573	Usually in Bed or Chair and Don't Leave Home|I am usually in bed or chair and don't leave home	A response indicating that an individual does not go out and is usually in bed or a chair.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115244>	C226614	No Limitations to Recreation at Home or Away|There are no limitations to recreation at home or away from home	A response indicating that an individual is not limited in their recreation at home or away.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115245>	C7709|C204037	Metastatic Digestive System Neuroendocrine Tumor G1|Metastatic Gastrointestinal Carcinoid Tumor|Metastatic Gastrointestinal Neuroendocrine Tumor G1|Metastatic Gastrointestinal Neuroendocrine Tumor G1	Digestive system neuroendocrine tumor G1 that has spread to other anatomic sites.	Metastatic Gastrointestinal Neuroendocrine Tumor G1		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115246>	C226614	Few Limitations But Still Go Out and Enjoy Life|There are a few things I can't do but I still get out and enjoy life	A response indicating that an individual has a few things they cannot do, but they still get out and enjoy life.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115247>	C226620	Many Times Wish to Go Out More But Not Up to It|There are many times when I wish I could get out more, but I'm not up to it	A response indicating that an individual wishes to get out more, but is not up to it.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115248>	C122576	Methicillin-Resistant Staphylococcus aureus Infection|MRSA|Methicillin-Resistant Staphylococcus Aureus Infection|Methicillin-Resistant Staphylococcus aureus (MRSA)	A bacterial infection that is caused by Staphylococcus aureus that is not susceptible to methicillin.	Methicillin-Resistant Staphylococcus Aureus Infection		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C115249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115249>	C226614	Severe Limitations, Mostly Stay Home and Watch Television|There are severe limitations to what I can do, mostly I stay at home and watch TV	A response indicating that an individual has severe limitations to what they can do and mostly stays at home watching TV.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C11524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11524>	C61063	gp100 Antigen/MAGE-3.1/MART-1 Antigen/Tyrosinase Peptide|gp100/MAGE-3.1/MART-1/TYRP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115250>	C7710|C3903	Adult Mixed Glioma|Mixed Glioma	A mixed glioma that occurs during adulthood.	Adult Mixed Glioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115251>	C121744	Can't Do Anything Enjoyable|I can't do anything enjoyable	A response indicating that an individual can't do anything enjoyable.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115252>	C25804	IDUA Gene|Alpha-L-Iduronidase Gene|IDUA|IDUA	This gene plays a role in glycosaminoglycan metabolism.	IDUA Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C115253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115253>	C5131|C4661	Adult Central Nervous System Melanocytic Neoplasm|Adult Central Nervous System Melanocytic Tumor|Adult Primary Central Nervous System Melanocytic Neoplasm|Adult Primary Meningeal Melanocytic Neoplasm|Primary Meningeal Melanocytic Neoplasm	A melanocytic neoplasm that arises from the leptomeninges and occurs during adulthood.	Adult Primary Melanocytic Lesion of Meninges		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115254>	C115252	IDUA wt Allele|Alpha-L-Iduronidase wt Allele|IDA|Iduronidase Alpha-L- Gene|Iduronidase, Alpha-L Gene|Iduronidase, Alpha-L- Gene|MPS1|MPSI|Mucopolysaccharidosis Type I Gene	Human IDUA wild-type allele is located in the vicinity of 4p16.3 and is approximately 18 kb in length. This allele, which encodes alpha-L-iduronidase protein, is involved in the metabolism of glycosaminoglycans. Mutation of the gene is associated with mucopolysaccharidosis type 1.	IDUA wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115255>	C16701	Alpha-L-Iduronidase|EC 3.2.1.76|IDUA	Alpha-L-iduronidase (653 aa, ~73 kDa) is encoded by the human IDUA gene. This protein plays a role in glycosaminoglycan metabolism.	Alpha-L-Iduronidase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115256>	C178367	Can Swallow as Well as Ever|I can swallow as well as ever	A response indicating that an individual can swallow as well as ever.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115257>	C20348	PDCD5 Gene|PDCD5|PDCD5|Programmed Cell Death 5 Gene	This gene is involved in the positive regulation of apoptosis.			Gene or Genome	
C115258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115258>	C2959	Musculoskeletal Complication	Any disorder of the muscles and bones occurring as a consequence of injury to the musculoskeletal system.	Musculoskeletal Complication		Finding	CTRP Disease Terminology|CTRP Terminology
C115259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115259>	C115257	PDCD5 wt Allele|MGC9294|Programmed Cell Death 5 wt Allele|TF1 Cell Apoptosis-Related Gene 19|TFAR19	Human PDCD5 wild-type allele is located in the vicinity of 19q13.11 and is approximately 6 kb in length. This allele, which encodes programmed cell death protein 5, plays a role in the regulation of apoptosis.			Gene or Genome	
C11525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11525>	C61063	Flu Matrix/gp100 Antigen/MAGE-3.1/MART-1 Antigen/Tyrosinase Peptide|Flu/Gp100/MAGE-3.1/MART-1/TYRP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115260>	C178367|C121744	Cannot Swallow Certain Solid Foods|I cannot swallow certain solid foods	A response indicating that an individual cannot swallow certain solid foods.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115261>	C19928	Programmed Cell Death Protein 5|PDCD5|Protein TFAR19|TF-1 Cell Apoptosis-Related Protein 19|TFAR19 Novel Apoptosis-Related	Programmed cell death protein 5 (125 aa, ~14 kDa) is encoded by the human PDCD5 gene. This protein is involved in the promotion of apoptosis.			Amino Acid, Peptide, or Protein	
C115262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115262>	C178367	Can Only Swallow Liquid Food|I can only swallow liquid food	A response indicating that an individual can only swallow liquid foods.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115263>	C68690|C3697	Adult Myxopapillary Ependymoma|Myxopapillary Ependymoma	A myxopapillary ependymoma that occurs during adulthood.	Adult Myxopapillary Ependymoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115264>	C178367|C121744	Cannot Swallow Because it Causes Choking|I cannot swallow because it "goes down the wrong way" and chokes me	A response indicating that an individual cannot swallow because it chokes them.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115265>	C202280	Can Chew as Well as Ever|I can chew as well as ever	A response indicating that an individual can chew as well as ever.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115266>	C20744	TAMALIN Gene|GRASP|TAMALIN|TAMALIN|Trafficking Regulator and Scaffold Protein Tamalin Gene	This gene plays a role in receptor localization.			Gene or Genome	
C115267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115267>	C115266	TAMALIN wt Allele|GRASP|GRP1 (General Receptor For Phosphoinositides 1)-Associated Scaffold Protein Gene|General Receptor For Phosphoinositides 1 Associated Scaffold Protein Gene|Trafficking Regulator and Scaffold Protein Tamalin wt Allele	Human TAMALIN wild-type allele is located in the vicinity of 12q13.13 and is approximately 9 kb in length. This allele, which encodes protein TAMALIN, is involved in synaptic receptor localization.			Gene or Genome	
C115268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115268>	C18073	Protein TAMALIN|GRASP|GRP1-Associated Scaffold Protein|General Receptor For Phosphoinositides 1 Associated Scaffold Protein|General Receptor For Phosphoinositides 1-Associated Scaffold Protein|TAMALIN	Protein TAMALIN (395 aa, ~43 kDa) is encoded by the human TAMALIN gene. This protein plays a role in the localization of cell surface receptors.			Amino Acid, Peptide, or Protein	
C115269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115269>	C36160	Newly Diagnosed Carcinoma of Unknown Primary Origin	A recently diagnosed metastatic carcinoma of unknown primary origin.	Newly Diagnosed Carcinoma of Unknown Primary Origin		Finding	CTRP Disease Terminology|CTRP Terminology
C11526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11526>	C61063	Docetaxel/Doxorubicin/Tamoxifen|DOX/TMX/TXT			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115270>	C36160	Newly Diagnosed Childhood Ependymoma|Ependymoma	A recently diagnosed ependymoma during childhood.	Newly Diagnosed Childhood Ependymoma		Finding	CTRP Disease Terminology|CTRP Terminology
C115271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115271>	C202280	Can Eat Soft Solids But Cannot Chew Some Foods|I can eat soft solids but cannot chew some foods	A response indicating that an individual can eat soft solids but cannot chew some foods.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115272>	C202280|C121744	Cannot Even Chew Soft Solids|I cannot even chew soft solids	A response indicating that an individual cannot chew soft solid foods.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115273>	C226566	Speech is Same as Always|My speech is the same as always	A response indicating that an individual's speech has not changed.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115274>	C15220	Non-Cancer Diagnosis	A term that refers to a broad group of diagnoses that may include any disease except for cancer or cancer related disorders.	Non-Cancer Diagnosis		Finding	CTRP Disease Terminology|CTRP Terminology
C115275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115275>	C133710	UHRF1 Gene|UHRF1|UHRF1|Ubiquitin-Like With PHD and Ring Finger Domains 1 Gene	This gene is involved in transcriptional regulation, chromatin remodeling and protein ubiquitination.			Gene or Genome	
C115276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115276>	C226742|C176243	Have Difficulty Saying Some Words But Can Be Understood Over the Phone|I have difficulty saying some words but I can be understood over the phone	A response indicating that an individual has difficulty saying some words, but can be understood over the phone.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115277>	C226742	Only Family and Friends Can Understand Me|Only my family and friends can understand me	A response indicating that an individual can only be understood by friends and family.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115278>	C115275	UHRF1 wt Allele|FLJ21925|ICBP90|Np95|RNF106|Ubiquitin-Like With PHD and Ring Finger Domains 1 wt Allele|Ubiquitin-Like, Containing PHD and RING Finger Domains, 1 Gene|hNP95|hUHRF1|huNp95	Human UHRF1 wild-type allele is located in the vicinity of 19p13.3 and is approximately 59 kb in length. This allele, which encodes E3 ubiquitin-protein ligase UHRF1 protein, plays a role in both protein ubiquitination and epigenetic silencing of gene transcription. Aberrant expression of the gene is associated with many neoplastic diseases.			Gene or Genome	
C115279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115279>	C21254	E3 Ubiquitin-Protein Ligase UHRF1|EC 2.3.2.27|EC 6.3.2.-, Formerly|HuNp95|Inverted CCAAT Box-Binding Protein of 90 kDa|Inverted CCAAT Box-Binding Protein, 90-kD|Nuclear Phosphoprotein, 95-kD|Nuclear Zinc Finger Protein Np95|RING Finger Protein 106|Transcription Factor ICBP90|Ubiquitin-Like PHD and RING Finger Domain-Containing Protein 1|Ubiquitin-Like Protein Containing PHD and Ring Finger Domains 1|Ubiquitin-Like-Containing PHD and RING Finger Domains Protein 1|hNp95|hUHRF1	E3 ubiquitin-protein ligase UHRF1 (793 aa, ~90 kDa) is encoded by the human UHRF1 gene. This protein is involved in the modification of both DNA and proteins.			Amino Acid, Peptide, or Protein|Enzyme	
C11527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11527>	C61063	Cyclophosphamide/Docetaxel/Doxorubicin/Tamoxifen|CTX/DOX/TMX/TXT			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115280>	C226560|C121744	Cannot Be Understood|I cannot be understood	A response indicating that an individual cannot be understood.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115281>	C25784	RHEB Gene|RHEB|RHEB|Ras Homolog, mTORC1 Binding Gene	This gene plays a role in the regulation of MTORC1-dependent signaling.	RHEB Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C115282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115282>	C177913	Have No Problem with Shoulder|I have no problem with my shoulder	A response indicating that an individual has no problem with their shoulder.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115283>	C226611	Shoulder is Stiff But has Not Affected Activity or Strength|My shoulder is stiff but it has not affected my activity or strength	A response indicating that an individual has shoulder stiffness, but this has not affected their activity or strength.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115284>	C115281	RHEB wt Allele|RHEB2|Ras Homolog Enriched In Brain 2 Gene|Ras Homolog Enriched In Brain Gene|Ras Homolog, mTORC1 Binding wt Allele	Human RHEB wild-type allele is located in the vicinity of 7q36 and is approximately 54 kb in length. This allele, which encodes GTP-binding protein Rheb, is involved in the positive regulation of signaling.	RHEB wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115285>	C177166|C176246	Pain or Weakness in Shoulder has Caused Work Change|Pain or weakness in my shoulder has caused me to change my work	A response indicating that an individual has or had shoulder pain or weakness that has caused a work change.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115286>	C226564|C121744	Cannot Work Due to Problems with Shoulder|I cannot work due to problems with my shoulder	A response indicating that an individual cannot work due to shoulder problems.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115287>	C173065	Can Taste Food Normally|I can taste food normally	A response indicating that an individual can taste food normally.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115288>	C173065	Can Taste Most Foods Normally|I can taste most foods normally	A response indicating that an individual can taste most foods normally.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115289>	C173065	Can Taste Some Foods|I can taste some foods	A response indicating that an individual can only taste some foods.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C11528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11528>	C61007	Methotrexate/Prednisolone|MTX/PRDL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115290>	C173065	Cannot Taste Any Foods|I cannot taste any foods	A response indicating that an individual cannot taste any foods.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115291>	C18277	GTP-Binding Protein Rheb|Ras Homolog Enriched In Brain|Ras Homolog Enriched In Brain 2	GTP-binding protein Rheb (184 aa, ~20 kDa) is encoded by the human RHEB gene. This protein plays a role in the positive regulation of MTORC1-mediated signal transduction.	GTP-Binding Protein Rheb		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115292>	C7715|C189240	Localized Childhood Soft Tissue Sarcoma|Non-Metastatic Childhood Soft Tissue Sarcoma|Non-Metastatic Childhood Soft Tissue Sarcoma|Soft Tissue Sarcoma	A soft tissue sarcoma that occurs during childhood and is confined to a specific site without evidence of spread to other anatomic sites.	Non-Metastatic Childhood Soft Tissue Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C115293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115293>	C226714	Saliva is of Normal Consistency|My saliva is of normal consistency	A response indicating that an individual has saliva of normal consistency.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115294>	C226714	Have Less Saliva Than Normal, but it is Enough|I have less saliva than normal, but it is enough	A response indicating that an individual has less, but enough, saliva.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115295>	C226714	Have Too Little Saliva|I have too little saliva	A response indicating that an individual has too little saliva.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115296>	C226714	Have No Saliva|I have no saliva	A response indicating that an individual has no saliva.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115297>	C3333|C26873|C115164	Nosocomial Pneumonia	Pneumonia acquired during a hospital stay.	Nosocomial Pneumonia		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C115298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115298>	C226703	Mood is Excellent and Unaffected by Cancer|My mood is excellent and unaffected by my cancer	A response indicating that an individual is in excellent mood unaffected by their cancer.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115299>	C226703	Mood is Generally Good and Only Occasionally Affected by Cancer|My mood is generally good and only occasionally affected by my cancer	A response indicating that an individual is in generally good mood, only occasionally affected by their cancer.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C11529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11529>	C61007	Dexamethasone/Methotrexate|DM/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1152>	C1594	Marcellomycin|1-Naphthacenecarboxylic acid, 4-[[O-2,6-dideoxy-alpha-L-lyxo-hexopyranosyl-(1-4)-O-2, 6-dideoxy-alpha-L-lyxo-hexopyranosyl-(1-4)-2,3, 6-trideoxy-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl]oxy]-2-e thyl-1,2,3,4,6,11-hexahydro-2,5,7,10-tetrahydroxy-6,11-dioxo-, methyl ester, (1R-(1alpha,2beta,4beta))- (9CI)|MARCELLOMYCIN|MARCELLOMYCIN|Rhodirubin E	An antineoplastic oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Actinosporangium bohemicum.  Marcellomycin intercalates into DNA and induces DNA crosslinks, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also induces differentiation in HL-60 promyelocytic leukemia cells by interfering with glycoprotein synthesis. (NCI04)			Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C115300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115300>	C226703|C226652	Neither in a Good Mood nor Depressed About My Cancer|I am neither in a good mood nor depressed about my cancer	A response indicating that an individual is neither in a good mood nor depressed about their cancer.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115301>	C226652	Somewhat Depressed About My Cancer|I am somewhat depressed about my cancer	A response indicating that an individual is somewhat depressed about their cancer.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115302>	C120166	CDISC Functional Test Terminology	The terminology subset that includes terms pertaining to the CDISC functional test terminology.			Intellectual Product	CDISC QRS Terminology|Clinical Data Interchange Standards Consortium Terminology
C115303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115303>	C226652	Extremely Depressed About My Cancer|I am extremely depressed about my cancer	A response indicating that an individual is extremely depressed about their cancer.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115304>	C115302	CDISC Functional Test Category Terminology|Category of Functional Test|FT-FTCAT|FTCAT	Terminology associated with the functional test domain categories of the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115305>	C226625	Not Anxious About My Cancer|I am not anxious about my cancer	A response indicating that an individual is not anxious about their cancer.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115306>	C226625	A Little Anxious About My Cancer|I am a little anxious about my cancer	A response indicating that an individual is a little anxious about their cancer.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115307>	C226625	Anxious About My Cancer|I am anxious about my cancer	A response indicating that an individual is anxious about their cancer.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115308>	C226625	Very Anxious About My Cancer|I am very anxious about my cancer	A response indicating that an individual is very anxious about their cancer.			Intellectual Product	University of Washington Quality of Life Scale, Version 4
C115309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115309>	C27993	Outstanding	Superior or excellent in nature.			Qualitative Concept	University of Washington Quality of Life Scale, Version 4
C11530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11530>	C61007	Asparaginase/Daunorubicin/Dexamethasone/Methotrexate/Vincristine|ASP/DM/DNR/MTX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115310>	C20710	SPEN Gene|SPEN|SPEN|SPEN|Spen Family Transcriptional Repressor Gene	This gene plays a role in hormone-mediated transcriptional regulation.			Gene or Genome	GDC Terminology|GDC Value Terminology
C115311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115311>	C115310	SPEN wt Allele|HIAA0929|KIAA0929|MINT|Msx2 Interacting Nuclear Target (MINT) Homolog Gene|RBM15C|RP1-134O19.1|SHARP|SPEN, Drosophila, Homolog of Gene|Spen Family Transcriptional Repressor wt Allele|Spen Homolog, Transcriptional Regulator (Drosophila) Gene	Human SPEN wild-type allele is located in the vicinity of 1p36 and is approximately 93 kb in length. This allele, which encodes Msx2-interacting protein, is involved in the repression of gene transcription.			Gene or Genome	
C115312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115312>	C26199	Msx2-Interacting Protein|Msx2 Interacting Nuclear Target|Nuclear Receptor Transcription Cofactor|SMART/HDAC1 Associated Repressor Protein|SMART/HDAC1-Associated Repressor Protein|SPEN|SPEN Homolog	Msx2-interacting protein (3664 aa, ~402 kDa) is encoded by the human SPEN gene. This protein plays a role in the negative regulation of gene transcription.			Amino Acid, Peptide, or Protein	
C115313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115313>	C20988	CDH4 Gene|CDH4|CDH4|Cadherin 4, Type 1, R-Cadherin (Retinal) Gene	This gene is involved in both retinal development and cell adhesion.			Gene or Genome	
C115314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115314>	C115313	CDH4 wt Allele|CAD4|Cadherin 4, Type 1, R-Cadherin (Retinal) wt Allele|Cadherin, Retinal Gene|R-CAD|RCAD	Human CDH4 wild-type allele is located in the vicinity of 20q13.3 and is approximately 688 kb in length. This allele, which encodes cadherin-4 protein, plays a role in both cell adhesion and development of the retina.			Gene or Genome	
C115315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115315>	C16373	Cadherin-4|Cadherin 4|Cadherin 4, Type 1, Preproprotein|R-CAD|R-Cadherin|Retinal Cadherin	Cadherin-4 (916 aa, ~100 kDa) is encoded by the human CDH4 gene. This protein is involved in both cell adhesion and retinal development.			Amino Acid, Peptide, or Protein	
C115316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115316>	C20420	MGA Gene|MAX Dimerization Protein MGA Gene|MGA|MGA	This gene plays a role in the modulation of the expression of MYC and MAX target genes.			Gene or Genome	
C115317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115317>	C115316	MGA wt Allele|FLJ12634|KIAA0518|MAD5|MAX Dimerization Protein MGA wt Allele|MAX Gene Associated Gene|MGA, MAX Dimerization Protein Gene|MXD5	Human MGA wild-type allele is located in the vicinity of 15q14 and is approximately 149 kb in length. This allele, which encodes MAX gene-associated protein, is involved in the regulation of MYC and MAX-dependent gene expression.			Gene or Genome	
C115318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115318>	C17207	MAX Gene-Associated Protein|MAX Dimerization Protein 5|MGA	MAX gene-associated protein (3026 aa, ~332 kDa) is encoded by the human MGA gene. This protein plays a role in the in the modulation of MYC and MAX-dependent gene transcription.			Amino Acid, Peptide, or Protein	
C115319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115319>	C2959	Ophthalmologic Complication	Any eye disorder occurring as a consequence of injury to the eye.	Ophthalmologic Complication		Finding	CTRP Disease Terminology|CTRP Terminology
C11531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11531>	C61007	Asparaginase/Cyclophosphamide/Daunorubicin/Methotrexate/Prednisolone/Vincristine|ASP/CTX/DNR/MTX/PRDL/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115320>	C2959	Oral Complication	Any oral disorder occurring as a consequence of injury to the mouth and lips.	Oral Complication		Finding	CTRP Disease Terminology|CTRP Terminology
C115321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115321>	C8052	Oral Complication of Chemotherapy	Any oral disorder occurring as a consequence of chemotherapy treatment.	Oral Complication of Chemotherapy		Finding	CTRP Disease Terminology|CTRP Terminology
C115322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115322>	C8052	Oral Complication of Radiation Therapy	Any oral disorder occurring as a consequence of radiation therapy.	Oral Complication of Radiation Therapy		Finding	CTRP Disease Terminology|CTRP Terminology
C115323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115323>	C20420	FOXQ1 Gene|FOXQ1|FOXQ1|Forkhead Box Q1 Gene	This gene is involved in both transcriptional regulation and tissue morphogenesis.			Gene or Genome	
C115324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115324>	C115323	FOXQ1 wt Allele|Forkhead Box Q1 wt Allele|HFH1	Human FOXQ1 wild-type allele is located in the vicinity of 6p25 and is approximately 2 kb in length. This allele, which encodes forkhead box protein Q1, plays a role in both tissue development and transcriptional regulation.			Gene or Genome	
C115325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115325>	C17207	Forkhead Box Protein Q1|FOXQ1|HFH-1|HNF-3/Forkhead-Like Protein 1|Hepatocyte Nuclear Factor 3 Forkhead Homolog 1|Winged Helix/Forkhead Transcription Factor	Forkhead box protein Q1 (403 aa, ~42 kDa) is encoded by the human FOXQ1 gene. This protein is involved in embryonic development.			Amino Acid, Peptide, or Protein	
C115326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115326>	C53543|C28193	Pearson Syndrome|Pearson Marrow-Pancreas Syndrome|Pearson Marrow-Pancreas Syndrome	The most severe syndrome in the spectrum of single, large-scale mitochondrial DNA (mtDNA) deletions (SLSMDs), usually presenting shortly after birth with sideroblastic anemia. The condition is often associated with exocrine pancreas insufficiency and multi-system dysfunction including diabetes mellitus, cortisol deficiency, hypothyroidism, hypoparathyroidism, and growth hormone deficiency. Commonly associated clinical findings include the following: failure to thrive, hypotonia, ptosis, ophthalmoparesis, and renal disease.	Pearson Marrow-Pancreas Syndrome		Disease or Syndrome	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C115327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115327>	C8274|C7710|C7049	Adult Pineal Gland Astrocytoma|Pineal Gland Astrocytoma	A pineal gland astrocytoma that occurs during adulthood.	Adult Pineal Gland Astrocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115328>	C26191	GNA13 Gene|GNA13|GNA13|Guanine Nucleotide Binding Protein (G Protein), Alpha 13 Gene	This gene plays a role in heterotrimeric G protein signaling.			Gene or Genome	
C115329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115329>	C115328	GNA13 wt Allele|G13|Guanine Nucleotide Binding Protein (G Protein), Alpha 13 wt Allele|Guanine Nucleotide-Binding Protein, Alpha-13 Gene|MGC46138	Human GNA13 wild-type allele is located in the vicinity of 17q24.3 and is approximately 48 kb in length. This allele, which encodes guanine nucleotide-binding protein subunit alpha-13 protein, is involved in signaling that is regulated by heterotrimeric G proteins.			Gene or Genome	
C11532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11532>	C61007	Asparaginase/Cytarabine/Mercaptopurine/Methotrexate|ARA-C/ASP/MP/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115330>	C19273	Guanine Nucleotide-Binding Protein Subunit Alpha-13|G Alpha-13|G-Alpha-13|G-Protein Subunit Alpha-13	Guanine nucleotide-binding protein subunit alpha-13 (377 aa, ~44 kDa) is encoded by the human GNA13 gene. This protein plays a role in heterotrimeric G protein-mediated signal transduction.			Amino Acid, Peptide, or Protein	
C115331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115331>	C20641	Poor Performance Status	Performance status defined as poor according to the ECOG performance score or Karnofsky performance score.	Poor Performance Status		Clinical Attribute	CTRP Disease Terminology|CTRP Terminology
C115332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115332>	C110937	Previously Treated Childhood Rhabdomyosarcoma|Rhabdomyosarcoma	A childhood rhabdomyosarcoma for which a patient has received treatment in the past.	Previously Treated Childhood Rhabdomyosarcoma		Finding	CTRP Disease Terminology|CTRP Terminology
C115333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115333>	C110937	Untreated Childhood Rhabdomyosarcoma|Untreated Rhabdomyosarcoma	A finding of childhood rhabdomyosarcoma that has not been treated.	Untreated Childhood Rhabdomyosarcoma		Finding	CTRP Disease Terminology|CTRP Terminology
C115334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115334>	C9106	Proximal Urethral Carcinoma|Proximal Urethral Cancer	A carcinoma that arises from the proximal part of the urethra.	Proximal Urethral Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NCIt Neoplasm Core Terminology
C115335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115335>	C160608	Proximal Urethra|PROXIMAL URETHRA	The part of the urethra that is closer to the bladder.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C115336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115336>	C160608	Distal Urethra	The part of the urethra that is closer to the external urethral orifice.			Body Part, Organ, or Organ Component	
C115337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115337>	C2959	Pulmonary Complication	Any pulmonary disorder occurring as a consequence of injury to the lungs.	Pulmonary Complication		Finding	CTRP Disease Terminology|CTRP Terminology
C115338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115338>	C188083	Eat Sufficient Amount to Meet Needs Question|Eat Sufficient Amount to Meet Needs|The amount I eat is sufficient to meet my needs	A question about whether an individual eats enough to meet their needs.			Intellectual Product	FAACT Questionnaire
C115339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115339>	C62601	Radiation Retinopathy	Injury of the retina following exposure to radiation.  The retinal injury results from occlusive microangiopathy caused by endothelial cell loss.	Radiation Retinopathy		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C11533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11533>	C61007	Asparaginase/Cyclophosphamide/Cytarabine/Mercaptopurine|ARA-C/ASP/CTX/MP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115340>	C173934	Worried About Weight Question|I am worried about my weight|Worried About Weight	A question about whether an individual is worried about their weight.			Intellectual Product	FAACT Questionnaire
C115341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115341>	C173063	Most Food Tastes Unpleasant Question|Most Food Tastes Unpleasant|Most food tastes unpleasant to me	A question about whether an individual feels or felt that most food tastes unpleasant.			Intellectual Product	FAACT Questionnaire
C115342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115342>	C176022|C173084	Concerned About Thinness of Appearance Question|Concerned About Thinness of Appearance|I am concerned about how thin I look	A question about whether an individual is or was concerned about how thin they look.			Intellectual Product	FAACT Questionnaire
C115343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115343>	C188083	Lose Interest in Food when Trying to Eat Question|Lose Interest in Food when Trying to Eat|My interest in food drops as soon as I try to eat	A question about whether an individual's interest in food drops as soon as they try to eat.			Intellectual Product	FAACT Questionnaire
C115344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115344>	C104326	Have Difficulty Eating Rich or Heavy Foods Question|Have Difficulty Eating Rich or Heavy Foods|I have difficulty eating rich or "heavy" foods	A question about whether an individual has or had difficulty eating rich or heavy foods.			Intellectual Product	FAACT Questionnaire
C115345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115345>	C175990|C173151	Experience Pressure from Family or Friends to Eat Question|Experience Pressure from Family or Friends to Eat|My family or friends are pressuring me to eat	A question about whether an individual's family or friends are or have been pressuring them to eat.			Intellectual Product	FAACT Questionnaire
C115346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115346>	C173604	Have Been Vomiting Question|Have Been Vomiting|I have been vomiting|Vomiting	A question about whether an individual has been vomiting.			Intellectual Product	FAACT Questionnaire|Memorial Symptom Assessment Scale - Short Form
C115347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115347>	C188083	Seem to Get Full Quickly Question|Seem to Get Full Quickly|When I eat, I seem to get full quickly	A question about whether an individual gets full quickly when they eat.			Intellectual Product	FAACT Questionnaire
C115348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115348>	C91102	General Health is Improving Question|General Health is Improving|My general health is improving	A question about whether an individual feels or felt that their general health is improving.			Intellectual Product	FAACT Questionnaire
C115349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115349>	C8490|C69144|C115150	Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Grade III Lymphomatoid Granulomatosis	The reemergence of grade III lymphomatoid granulomatosis in adulthood after a period of remission.	Recurrent Adult Grade III Lymphomatoid Granulomatosis		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C11534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11534>	C61063	Cytarabine/Methotrexate/Thioguanine|ARA-C/MTX/TG			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115350>	C85501	Centrifuged Smear Slide|Cytospin Slide	A microscope slide prepared by depositing cells directly onto a slide by centrifugation. The cytocentrifuge spins at an angle, at low speeds, allowing the cells to adhere to the slide in a monolayer format.			Body Substance	
C115351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115351>	C222483|C114782	Recurrent Adult Undifferentiated High Grade Pleomorphic Sarcoma of Bone|Recurrent Adult Undifferentiated High Grade Pleomorphic Sarcoma|Recurrent Adult Undifferentiated High-Grade Pleomorphic Sarcoma of Bone|Recurrent Undifferentiated High Grade Pleomorphic Sarcoma of Bone	The reemergence of undifferentiated high-grade pleomorphic sarcoma of bone in adulthood after a period of remission.	Recurrent Adult Undifferentiated High Grade Pleomorphic Sarcoma of Bone		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115352>	C4798|C4783	Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor	The reemergence of borderline ovarian epithelial tumor after a period of remission.	Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115353>	C154267	H1-4 Gene|H1-4|H1-4|H1.4 Linker Histone, Cluster Member Gene|HIST1H1E	This gene is involved in chromatin fiber formation.			Gene or Genome	
C115354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115354>	C115353	H1-4 wt Allele|H1 Histone Family, Member 4 Gene|H1 Histone Family, Member 4, Formerly Gene|H1 Histone Family, Member E Gene|H1.4|H1.4 Linker Histone, Cluster Member wt Allele|H1E|H1F4|H1s-4|HIST1 Cluster, H1E Gene|HIST1H1E|Histone 1, H1e Gene|Histone Cluster 1, H1e Gene|Histone Gene Cluster 1, H1 Gene|Histone Gene Cluster 1, H1E Gene|dJ221C16.5	Human H1-4 wild-type allele is located in the vicinity of 6p21.3 and is approximately 1 kb in length. This allele, which encodes histone H1.4 protein, plays a role in chromatin structure.			Gene or Genome	
C115355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115355>	C16683	Histone H1.4|H1-4|HIST1H1E|Histone H1b|Histone H1s-4	Histone H1.4 (219 aa, ~22 kDa) is encoded by the human H1-4 gene. This protein is involved in chromosome compaction.			Amino Acid, Peptide, or Protein	
C115356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115356>	C6215|C222241|C212994|C136517	Recurrent Childhood Anaplastic Astrocytoma|Recurrent Anaplastic Astrocytoma	The reemergence of anaplastic astrocytoma in childhood after a period of remission.	Recurrent Childhood Anaplastic Astrocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115357>	C9250|C5636|C115369	Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Anaplastic Large Cell Lymphoma	The reemergence of anaplastic large cell lymphoma in childhood after a period of remission.	Recurrent Childhood Anaplastic Large Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115358>	C222241|C142861|C114973	Recurrent Childhood Anaplastic Oligoastrocytoma|Recurrent Anaplastic Oligoastrocytoma	The reemergence of anaplastic oligoastrocytoma in childhood after a period of remission.	Recurrent Childhood Anaplastic Oligoastrocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115359>	C5447|C222241|C142862	Recurrent Childhood Anaplastic Oligodendroglioma|Recurrent Anaplastic Oligodendroglioma	The reemergence of anaplastic oligodendroglioma in childhood after a period of remission.	Recurrent Childhood Anaplastic Oligodendroglioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C11535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11535>	C61007	Asparaginase/Leucovorin Calcium/Mercaptopurine/Methotrexate|ASP/CF/MP/MTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115360>	C217082|C212994|C167081|C114967	Recurrent Childhood Diffuse Astrocytoma|Recurrent Diffuse Astrocytoma	The reemergence of diffuse astrocytoma in childhood after a period of remission.	Recurrent Childhood Diffuse Astrocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115361>	C115360|C114963	Recurrent Childhood Fibrillary Astrocytoma|Recurrent Fibrillary Astrocytoma	The reemergence of fibrillary astrocytoma in childhood after a period of remission.	Recurrent Childhood Fibrillary Astrocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115362>	C115360|C114964	Recurrent Childhood Gemistocytic Astrocytoma|Recurrent Gemistocytic Astrocytoma	The reemergence of gemistocytic astrocytoma in childhood after a period of remission.	Recurrent Childhood Gemistocytic Astrocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115363>	C157600|C115364|C114966	Recurrent Childhood Giant Cell Glioblastoma|Recurrent Giant Cell Glioblastoma	The reemergence of giant cell glioblastoma in childhood after a period of remission.	Recurrent Childhood Giant Cell Glioblastoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115364>	C5136|C222242|C126306|C114956	Recurrent Childhood Glioblastoma|Recurrent Glioblastoma	The reemergence of glioblastoma in childhood after a period of remission.	Recurrent Childhood Glioblastoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115365>	C131209|C115364|C114968	Recurrent Childhood Gliosarcoma|Recurrent Gliosarcoma	The reemergence of gliosarcoma in childhood after a period of remission.	Recurrent Childhood Gliosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115366>	C7834|C179221|C162702|C114969	Recurrent Childhood Gliomatosis Cerebri|Recurrent Gliomatosis Cerebri	The reemergence of gliomatosis cerebri in childhood after a period of remission.	Recurrent Childhood Gliomatosis Cerebri		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115367>	C69144|C210126|C123393|C115204	Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Grade III Lymphomatoid Granulomatosis	The reemergence of grade III lymphomatoid granulomatosis in childhood after a period of remission.	Recurrent Childhood Grade III Lymphomatoid Granulomatosis		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115368>	C222483|C162702|C114750	Recurrent Childhood Undifferentiated High Grade Pleomorphic Sarcoma of Bone|Recurrent Childhood Undifferentiated High Grade Pleomorphic Sarcoma|Recurrent Childhood Undifferentiated High-Grade Pleomorphic Sarcoma of Bone|Recurrent Undifferentiated High Grade Pleomorphic Sarcoma of Bone	The reemergence of undifferentiated high-grade pleomorphic sarcoma of bone in childhood after a period of remission.	Recurrent Childhood Undifferentiated High Grade Pleomorphic Sarcoma of Bone		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115369>	C9251|C7706|C187196	Recurrent Childhood Non-Hodgkin Lymphoma|Recurrent Non-Hodgkin Lymphoma	The reemergence of non-Hodgkin lymphoma in childhood after a period of remission.	Recurrent Childhood Non-Hodgkin Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C11536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11536>	C61007	Asparaginase/Cyclophosphamide/Daunorubicin/Dexamethasone/Leucovorin Calcium/Methotrexate/Thioguanine/Vindesine|ASP/CF/CTX/DAVA/DM/DNR/MTX/TG			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115370>	C217082|C167082|C114974	Recurrent Childhood Oligoastrocytoma|Recurrent Oligoastrocytoma	The reemergence of oligoastrocytoma in childhood after a period of remission.	Recurrent Childhood Oligoastrocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115371>	C4045|C217082|C160737	Recurrent Childhood Oligodendroglioma|Recurrent Oligodendroglioma	The reemergence of oligodendroglioma in childhood after a period of remission.	Recurrent Childhood Oligodendroglioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115372>	C4048|C217082|C212994|C179220	Recurrent Childhood Pilocytic Astrocytoma|Recurrent Pilocytic Astrocytoma	The reemergence of pilocytic astrocytoma in childhood after a period of remission.	Recurrent Childhood Pilocytic Astrocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115373>	C212994|C114970	Recurrent Childhood Pilomyxoid Astrocytoma|Recurrent Pilomyxoid Astrocytoma	The reemergence of pilomyxoid astrocytoma in childhood after a period of remission.	Recurrent Childhood Pilomyxoid Astrocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115374>	C7834|C198951|C179227|C114836|C114812	Recurrent Childhood Pineoblastoma	The reemergence of pineoblastoma in childhood after a period of remission.	Recurrent Childhood Pineoblastoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115375>	C217082|C212994|C176464|C148037|C114971	Recurrent Childhood Pleomorphic Xanthoastrocytoma|Recurrent Pleomorphic Xanthoastrocytoma	The reemergence of pleomorphic xanthoastrocytoma in childhood after a period of remission.	Recurrent Childhood Pleomorphic Xanthoastrocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115376>	C115360|C114972	Recurrent Childhood Protoplasmic Astrocytoma|Recurrent Protoplasmic Astrocytoma	The reemergence of protoplasmic astrocytoma in childhood after a period of remission.	Recurrent Childhood Protoplasmic Astrocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115377>	C21295	MXRA5 Gene|MXRA5|MXRA5|Matrix-Remodelling Associated 5 Gene	This gene may play a role in the structure of the extracellular matrix.			Gene or Genome	
C115378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115378>	C115377	MXRA5 wt Allele|DKFZp564I1922|Matrix-Remodelling Associated 5 wt Allele	Human MXRA5 wild-type allele is located in the vicinity of Xp22.33 and is approximately 38 kb in length. This allele, which encodes matrix-remodeling-associated protein 5, may be involved in extracellular matrix modeling.			Gene or Genome	
C115379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115379>	C17728	Matrix-Remodeling-Associated Protein 5|Adhesion Protein With Leucine-Rich Repeats and Immunoglobulin Domains Related To Perlecan|Adlican|MXRA5	Matrix-remodeling-associated protein 5 (2828 aa, ~312 kDa) is encoded by the human MXRA5 gene. This protein may play a role in remodeling of the extracellular matrix.			Amino Acid, Peptide, or Protein	
C11537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11537>	C61007	Asparaginase/Cytarabine/Dexamethasone/Leucovorin Calcium/Mercaptopurine/Methotrexate/Vincristine|ARA-C/ASP/CF/DM/MP/MTX/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115380>	C7834|C217082|C212994|C177796|C176464|C114785	Recurrent Childhood Subependymal Giant Cell Astrocytoma|Recurrent Subependymal Giant Cell Astrocytoma	The reemergence of subependymal giant cell astrocytoma in childhood after a period of remission.	Recurrent Childhood Subependymal Giant Cell Astrocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115381>	C7834|C198951|C114836|C114774	Recurrent Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified|Recurrent Childhood Supratentorial Embryonal Tumor, NOS|Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor|Recurrent Supratentorial Embryonal Tumor, NOS	The reemergence of supratentorial embryonal tumor, not otherwise specified in childhood after a period of remission.	Recurrent Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115382>	C21295	RBM10 Gene|RBM10|RBM10|RBM10|RNA Binding Motif Protein 10 Gene	This gene is involved in RNA binding and processing.			Gene or Genome	GDC Terminology|GDC Value Terminology
C115383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115383>	C115382	RBM10 wt Allele|CTD-2522E6.5|DXS8237E|GPATC9|GPATCH9|KIAA0122|RNA Binding Motif Protein 10 wt Allele|RNA-Binding Protein S1-1, Rat, Homolog of Gene|S1-1|TARPS|ZRANB5	Human RBM10 wild-type allele is located in the vicinity of Xp11.23 and is approximately 42 kb in length. This allele, which encodes RNA-binding protein 10, plays a role in the binding to and processing of RNA. Mutation of the gene is associated with TARP syndrome.			Gene or Genome	
C115384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115384>	C7837|C3789	Recurrent Olfactory Neuroblastoma	The reemergence of olfactory neuroblastoma after a period of remission.	Recurrent Olfactory Neuroblastoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115385>	C8881|C132853	Recurrent Malignant Extragonadal Germ Cell Tumor	The reemergence of malignant extragonadal germ cell tumor after a period of remission.	Recurrent Malignant Extragonadal Germ Cell Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115386>	C21298	RNA-Binding Protein 10|G Patch Domain-Containing Protein 9|G-Patch Domain-Containing Protein 9|RBM10|RNA Binding Motif Protein 10|RNA-Binding Motif Protein 10|RNA-Binding Protein S1-1|S1-1	RNA-binding protein 10 (930 aa, ~104 kDa) is encoded by the human RBM10 gene. This protein is involved in RNA metabolism.			Amino Acid, Peptide, or Protein	
C115387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115387>	C115302	CDISC Functional Test 6MWT Test Name Terminology|6 Minute Walk Functional Test Test Name|FT- 6MWT TEST|SIXMW1TN	Test names of functional test questions associated with the 6 Minute Walk Test (6MWT) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115388>	C115302	CDISC Functional Test 6MWT Test Code Terminology|6 Minute Walk Functional Test Test Code|FT- 6MWT TESTCD|SIXMW1TC	Test codes of functional test questions associated with the 6 Minute Walk Test (6MWT) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115389>	C115302	CDISC Functional Test HAI Test Name Terminology|FT- HAI TEST|HAI01TN|Hauser Ambulation Index Functional Test Test Name	Test names of functional test questions associated with the Hauser Ambulation Index (HAI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11538>	C61007	Asparaginase/Cytarabine/Dexamethasone/Etoposide/Mitoxantrone|ARA-C/ASP/DHAD/DM/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115390>	C115302	CDISC Functional Test HAI Test Code Terminology|FT- HAI TESTCD|HAI01TC|Hauser Ambulation Index Functional Test Test Code	Test codes of functional test questions associated with the Hauser Ambulation Index (HAI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115391>	C115302	CDISC Functional Test NHPT Test Name Terminology|FT- NHPT TEST|NHPT01TN|Nine-Hole Peg Test Functional Test Test Name	Test names of functional test questions associated with the Nine-Hole Peg Test (NHPT) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115392>	C115302	CDISC Functional Test NHPT Test Code Terminology|FT- NHPT TESTCD|NHPT01TC|Nine-Hole Peg Test Functional Test Test Code	Test codes of functional test questions associated with the Nine-Hole Peg Test (NHPT) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115393>	C115302	CDISC Functional Test PASAT Test Name Terminology|FT- PASAT TEST|PASAT1TN|Paced Auditory Serial Addition Test Functional Test Test Name	Test names of functional test questions associated with the Paced Auditory Serial Addition Test (PASAT) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115394>	C115302	CDISC Functional Test PASAT Test Code Terminology|FT- PASAT TESTCD|PASAT1TC|Paced Auditory Serial Addition Test Functional Test Test Code	Test codes of functional test questions associated with the Paced Auditory Serial Addition Test (PASAT) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115395>	C115302	CDISC Functional Test SDMT Test Name Terminology|FT- SDMT TEST|SDMT01TN|Symbol Digit Modalities Test Functional Test Test Name	Test names of functional test questions associated with the Symbol Digit Modalities Test (SDMT) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115396>	C115302	CDISC Functional Test SDMT Test Code Terminology|FT- SDMT TESTCD|SDMT01TC|Symbol Digit Modalities Test Functional Test Test Code	Test codes of functional test questions associated with the Symbol Digit Modalities Test (SDMT) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115397>	C115302	CDISC Functional Test T25FW Test Name Terminology|FT- T25FW TEST|T25FW1TN|Timed 25-Foot Walk Test Functional Test Test Name	Test names of functional test questions associated with the Timed 25-Foot Walk Test (T25FW) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115398>	C115302	CDISC Functional Test T25FW Test Code Terminology|FT- T25FW TESTCD|T25FW1TC|Timed 25-Foot Walk Test Functional Test Test Code	Test codes of functional test questions associated with the Timed 25-Foot Walk Test (T25FW) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115399>	C115302	CDISC Functional Test TUG Test Name Terminology|FT- TUG TEST|TUG01TN|Timed Up and Go Test Functional Test Test Name	Test names of functional test questions associated with the Timed Up and Go Test (TUG) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11539>	C61007	Asparaginase/Cyclophosphamide/Cytarabine/Daunorubicin/Dexamethasone/Mercaptopurine/Methotrexate/Thioguanine/Vincristine/Vindesine|ARA-C/ASP/CTX/DAVA/DM/DNR/MP/MTX/TG/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1153>	C94726	Dolasetron Mesylate|Anzemet|Anzemet|DOLASETRON MESYLATE|MDL 73,147EF|dolasetron mesylate	An indole derivative with antiemetic activity.  As a selective serotonin receptor antagonist, dolasetron mesylate competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting. (NCI04)	Dolasetron Mesylate		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C115400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115400>	C115302	CDISC Functional Test TUG Test Code Terminology|FT- TUG TESTCD|TUG01TC|Timed Up and Go Test Functional Test Test Code	Test codes of functional test questions associated with the Timed Up and Go Test (TUG) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115401>	C118970	CDISC Clinical Classification DRS Test Name Terminology|DRS01TN|Disability Rating Scale Clinical Classification Test Name|QS-DRS TEST	Test names of clinical classification questions associated with the Disability Rating Scale (DRS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115402>	C118970	CDISC Clinical Classification DRS Test Code Terminology|DRS01TC|Disability Rating Scale Clinical Classification Test Code|QS-DRS TESTCD	Test codes of clinical classification questions associated with the Disability Rating Scale (DRS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115403>	C100110	CDISC Questionnaire GOSE Test Name Terminology|Extended Glasgow Outcome Scale Questionnaire Test Name|GOSE1TN|QS-GOSE TEST	Test names of questionnaire questions associated with the Extended Glasgow Outcome Scale (GOSE) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115404>	C100110	CDISC Questionnaire GOSE Test Code Terminology|Extended Glasgow Outcome Scale Questionnaire Test Code|GOSE1TC|QS-GOSE TESTCD	Test codes of questionnaire questions associated with the Extended Glasgow Outcome Scale (GOSE) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115405>	C100110	CDISC Questionnaire MPAI-4 Test Name Terminology|MPAI1TN|Mayo-Portland Adaptability Inventory-4 Questionnaire Test Name|QS-MPAI-4 TEST	Test names of questionnaire questions associated with the Mayo-Portland Adaptability Inventory-4 (MPAI-4) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115406>	C100110	CDISC Questionnaire MPAI-4 Test Code Terminology|MPAI1TC|Mayo-Portland Adaptability Inventory-4 Questionnaire Test Code|QS-MPAI-4 TESTCD	Test codes of questionnaire questions associated with the Mayo-Portland Adaptability Inventory-4 (MPAI-4) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115407>	C100110	CDISC Questionnaire SWLS Test Name Terminology|QS-SWLS TEST|SWLS01TN|Satisfaction With Life Scale Questionnaire Test Name	Test names of questionnaire questions associated with the Satisfaction With Life Scale (SWLS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115408>	C100110	CDISC Questionnaire SWLS Test Code Terminology|QS-SWLS TESTCD|SWLS01TC|Satisfaction With Life Scale Questionnaire Test Code	Test codes of questionnaire questions associated with the Satisfaction With Life Scale (SWLS) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115409>	C211913	6MWT Functional Test Question	A question associated with the 6MWT functional test.			Intellectual Product	
C11540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11540>	C61063	Asparaginase/Daunorubicin/Methotrexate/Prednisolone/Vincristine|ASP/DNR/MTX/PRDL/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115410>	C211913	HAI Functional Test Question	A question associated with the HAI functional test.			Intellectual Product	
C115411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115411>	C211913	NHPT Functional Test Question	A question associated with the NHPT functional test.			Intellectual Product	
C115412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115412>	C211913	PASAT Functional Test Question	A question associated with the PASAT functional test.			Intellectual Product	
C115413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115413>	C211913	SDMT Functional Test Question	A question associated with the SDMT functional test.			Intellectual Product	
C115414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115414>	C211913	T25FW Functional Test Question	A question associated with the T25FW functional test.			Intellectual Product	
C115415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115415>	C211913	TUG Functional Test Question	A question associated with the TUG functional test.			Intellectual Product	
C115416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115416>	C211913	DRS Questionnaire Question	A question associated with the DRS questionnaire.			Intellectual Product	
C115417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115417>	C211913	GOSE Questionnaire Question	A question associated with the GOSE questionnaire.			Intellectual Product	
C115418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115418>	C211913	MPAI-4 Questionnaire Question	A question associated with the MPAI-4 questionnaire.			Intellectual Product	
C115419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115419>	C211913	SWLS Questionnaire Question	A question associated with the SWLS questionnaire.			Intellectual Product	
C11541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11541>	C61063	Alendronate Sodium/Ketoconazole|KCZ/MK-217			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115420>	C3837	Areflexia|Absent tendon reflex	A finding indicating the complete absence of neurological reflexes.			Finding	
C115421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115421>	C54362	ELOC Gene|ELOC|ELOC|Elongin C Gene|TCEB1	This gene plays a role in transcriptional elongation.	ELOC Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C115422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115422>	C115421	ELOC wt Allele|Elongin C wt Allele|Elongin, 15-kD Subunit Gene|SIII|TCEB1|Transcription Elongation Factor B (SIII), Polypeptide 1 (15kD, Elongin C) Gene|Transcription Elongation Factor B (SIII), Polypeptide 1 (15kDa, Elongin C) Gene|Transcription Elongation Factor B, Polypeptide 1 Gene|eloC	Human ELOC wild-type allele is located in the vicinity of 8q21.11 and is approximately 33 kb in length. This allele, which encodes elongin-C protein, is involved in the promotion of transcriptional elongation.	ELOC wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115423>	C26199	Elongin-C|EloC|Elongin 15 kDa Subunit|Elongin C|RNA Polymerase II Transcription Factor SIII Subunit C|SIII p15|Transcription Elongation Factor B Polypeptide 1|Transcription Elongation Factor B Subunit 1	Elongin-C (112 aa, ~12 kDa) is encoded by the human ELOC gene. This protein plays a role in the positive regulation of transcriptional elongation.	Elongin-C		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115424>	C16615	ZFHX3 Gene|ZFHX3|ZFHX3|ZFHX3|Zinc Finger Homeobox 3 Gene	This gene is involved in myoblast and neuronal differentiation.			Gene or Genome	GDC Terminology|GDC Value Terminology
C115425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115425>	C115424	ZFHX3 wt Allele|AT-Binding Transcription Factor 1 Gene|ATBF1|ATBT|ZNF927|Zinc Finger Homeobox 3 wt Allele	Human ZFHX3 wild-type allele is located in the vicinity of 16q22.3 and is approximately 277 kb in length. This allele, which encodes zinc finger homeobox protein 3, plays a role in transcriptional regulation and the modulation of cellular differentiation.			Gene or Genome	
C115426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115426>	C17207	Zinc Finger Homeobox Protein 3|AT Motif-Binding Factor 1|AT-Binding Transcription Factor 1|Alpha-Fetoprotein Enhancer Binding Protein|Alpha-Fetoprotein Enhancer-Binding Protein|ZFH-3|Zinc Finger Homeodomain Protein 3	Zinc finger homeobox protein 3 (3703 aa, ~404 kDa) is encoded by the human ZFHX3 gene. This protein is involved in cellular differentiation and transcriptional repression.			Amino Acid, Peptide, or Protein	
C115427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115427>	C8885|C177771|C115385	Recurrent Malignant Extragonadal Nongerminomatous Germ Cell Tumor|Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell Tumor|Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell Tumor	The reemergence of a malignant extragonadal nongerminomatous germ cell tumor after a period of remission.	Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115428>	C7327|C115385	Recurrent Extragonadal Seminoma	The reemergence of extragonadal seminoma after a period of remission.	Recurrent Extragonadal Seminoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115429>	C7620|C3867	Recurrent Fallopian Tube Carcinoma|Recurrent Fallopian Tube Cancer	The reemergence of fallopian tube carcinoma after a period of remission.	Recurrent Fallopian Tube Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C11542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11542>	C61063	Amifostine/Bleomycin/Cisplatin/Etoposide|BLEO/CDDP/VP-16/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115430>	C7934|C7931	Recurrent Grade I Lymphomatoid Granulomatosis	The reemergence of grade I lymphomatoid granulomatosis after a period of remission.	Recurrent Grade I Lymphomatoid Granulomatosis		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115431>	C7934|C7932	Recurrent Grade II Lymphomatoid Granulomatosis	The reemergence of grade II lymphomatoid granulomatosis after a period of remission.	Recurrent Grade II Lymphomatoid Granulomatosis		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115432>	C6871|C4798	Recurrent Sinonasal Inverted Papilloma|Recurrent Inverted Schneiderian Papilloma|Recurrent Inverted Schneiderian Papilloma|Recurrent Sinonasal Inverted Schneiderian Papilloma	The reemergence of inverted Schneiderian papilloma after a period of remission.	Recurrent Inverted Schneiderian Papilloma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115433>	C7626|C3770|C155938|C138183	Recurrent Pancreatic Neuroendocrine Carcinoma|Recurrent Pancreatic Neuroendocrine Cancer	The reemergence of pancreatic neuroendocrine carcinoma after a period of remission.	Recurrent Pancreatic Neuroendocrine Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115434>	C48471	Newsletter	A regularly issued printed or electronic report describing a main topic of interest to its subscribers.			Intellectual Product	
C115435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115435>	C48471	Advertisement	An act, practice or form of communication used to encourage, persuade, or manipulate an audience to take or continue to take a certain action.			Intellectual Product	
C115436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115436>	C25997	AJUBA Gene|AJUBA|AJUBA|Ajuba LIM Protein Gene	This gene plays a role in the assembly of protein complexes, which are involved in a number of cellular processes.	AJUBA Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C115437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115437>	C115436	AJUBA wt Allele|Ajuba LIM Protein wt Allele|Ajuba, Mouse, Homolog of Gene|JUB|Jub, Ajuba Homolog (Xenopus Laevis) Gene|Jub, Ajuba Homolog Gene|MGC15563	Human AJUBA wild-type allele is located in the vicinity 14q11.2 and is approximately 11 kb in length. This allele, which encodes LIM domain-containing protein ajuba, is involved in protein complex formation.	AJUBA wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115438>	C26231	LIM Domain-Containing Protein Ajuba|Protein Ajuba	LIM domain-containing protein ajuba (538 aa, ~57 kDa) is encoded by the human AJUBA gene. This protein plays a role in the formation of protein complexes.	LIM Domain-Containing Protein Ajuba		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115439>	C9265|C8688	Recurrent Mycosis Fungoides and Sezary Syndrome|Recurrent Mycosis Fungoides and Sézary Syndrome	The reemergence of mycosis fungoides/Sezary syndrome after a period of remission.	Recurrent Mycosis Fungoides and Sezary Syndrome		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C11543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11543>	C61063	Piperacillin/Tazobactam/Vancomycin|PIPER/TAZO/VANCO			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115440>	C9231|C191978	Recurrent Merkel Cell Carcinoma|Recurrent Merkel Cell Cancer	The reemergence of Merkel cell carcinoma after a period of remission.	Recurrent Merkel Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115441>	C7619|C40022|C131500	Recurrent Primary Peritoneal Carcinoma|Recurrent Primary Peritoneal Cancer	The reemergence of primary peritoneal carcinoma after a period of remission.	Recurrent Primary Peritoneal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115442>	C8037|C42690|C133709	Recurrent Lip and Oral Cavity Squamous Cell Carcinoma|Recurrent Lip and Oral Cavity Squamous Cell Cancer	The reemergence of lip and oral cavity squamous cell carcinoma after a period of remission.	Recurrent Lip and Oral Cavity Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115443>	C68611|C67558|C214955	Recurrent Sinonasal Squamous Cell Carcinoma|Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Cancer|Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma	The reemergence of nasal cavity and paranasal sinus squamous cell carcinoma after a period of remission.	Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115444>	C45722|C131500	Recurrent Combined Thymus Epithelial Neoplasm|Recurrent Combined Thymic Carcinoma|Recurrent Combined Thymic Epithelial Neoplasm|Recurrent Combined Thymic Epithelial Tumor|Recurrent Composite Thymoma-Thymic Carcinoma	The reemergence of combined thymus epithelial neoplasm after a period of remission.	Recurrent Combined Thymic Epithelial Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115445>	C6563|C4798	Recurrent Childhood Kidney Neoplasm|Recurrent Childhood Renal Neoplasm|Recurrent Kidney Neoplasm	The reemergence of renal neoplasm in childhood after a period of remission.	Recurrent Childhood Renal Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115446>	C91105	Prognosis Treatment and Perceptions Questionnaire|PTPQ|Prognosis Treatment and Perceptions Questionnaire (PTPQ)	A 13-item questionnaire used to assess information preferences, perceptions of prognosis and goal of therapy, and communication about end-of-life care.			Intellectual Product	
C115447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115447>	C176537|C173812|C173507	Preference for Details of Information About Diagnosis and Treatment Question|Preference for Details of Information About Diagnosis and Treatment|What is your loved one's preference for details of information about their diagnosis and treatment|What is your preference for details of information about your diagnosis and treatment	A question about a person's preference for details of information about the patient's diagnosis and treatment.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115448>	C176537|C173812	Rating of the Quality of Information from Oncologist About Treatment Choices Question|How would you rate the quality of the information you have been given by your oncologist about treatment and the treatment choices available for you|How would you rate the quality of the information your loved one has been given by their oncologist about treatment and the treatment choices available|Rating of the Quality of Information from Oncologist About Treatment Choices	A question about a person's rating of the quality of information they have received from an oncologist about treatment and treatment choices available.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115449>	C173812	Patient's Primary Goal of Current Cancer Treatment Question|If you had to choose one, what would you say is your loved one's primary goal of their current cancer treatment|If you had to choose one, what would you say is your primary goal of your current cancer treatment|Patient's Primary Goal of Current Cancer Treatment	A question about a person's primary goal of the patient's current cancer treatment.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C11544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11544>	C61063	Fowlpox Virus Vaccine/Interleukin-2|FOWLVAC/IL-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115450>	C173812	Oncologist's Primary Goal of Current Cancer Treatment Question|If you had to choose one, what would you say is your loved one's oncologist's primary goal of their current cancer treatment|If you had to choose one, what would you say is your oncologist's primary goal of your current cancer treatment|Oncologist's Primary Goal of Current Cancer Treatment	A question about an oncologist's primary goal for the patient's current cancer treatment.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115451>	C91102	Importance of Knowing About Cancer Prognosis Question|How important is it for you to know about the likely outcome of your cancer over time (i.e. your prognosis)|Importance of Knowing About Cancer Prognosis	A question about a person's importance in knowing the prognosis of the patient's cancer.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115452>	C91102	Conversation with Oncologist About Cancer Prognosis Question|Conversation with Oncologist About Cancer Prognosis|How often has your loved one had a conversation with their oncologist about the likely outcome of their cancer over time (i.e. their prognosis)|How often have you had a conversation with your oncologist about the likely outcome of your cancer over time (i.e. your prognosis)	A question about whether a person had a conversation with their oncologist about the prognosis of the patient's cancer.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115453>	C176537|C173160	Feelings About the Amount of Information Known About Cancer Prognosis Question|All things considered, how do you feel about the amount of information you know about the likely outcome of your cancer over time (i.e. your prognosis)|All things considered, how do you feel about the amount of information your loved one knows about the likely outcome of their cancer over time (i.e. their prognosis)	A question about a person's feelings about the amount of information they know about the likely outcome of the patient's cancer.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115454>	C176537	Quality of the Information Received About Cancer Prognosis Question|How would you rate the quality of the information you have been given by your oncologist about the likely outcome of your cancer over time (i.e. your prognosis)|How would you rate the quality of the information your loved one has been given by their oncologist about the likely outcome of their cancer over time (i.e. their prognosis)|Quality of the Information Received About Cancer Prognosis	A question about a person's rating of the quality of information they have received from an oncologist about treatment and treatment choices available.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115455>	C174127|C173812|C173563	How Helpful has Knowing Your Prognosis Been for Making Decisions About Treatment Question|How Helpful has Knowing Your Prognosis Been for Making Decisions About Treatment|How helpful has knowing about their prognosis been for your loved one in making decisions about treatment|How helpful has knowing about your prognosis been for making decisions about treatment	A question about helpful it's been to a person to know about the patient's prognosis in making decisions about treatment.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115456>	C173563	How Helpful has Knowing Your Prognosis Been for Preparing for the Future Question|How Helpful has Knowing Your Prognosis Been for Preparing for the Future|How helpful has knowing about their prognosis been for your loved one in preparing for the future|How helpful has knowing about your prognosis been for preparing for the future	A question about helpful it's been to a person to know about the patient's prognosis in preparing for the future.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115457>	C173563	How Helpful has Knowing Your Prognosis Been for Maintaining Hope Question|How Helpful has Knowing Your Prognosis Been for Maintaining Hope|How helpful has knowing about their prognosis been for your loved one in maintaining hope|How helpful has knowing about your prognosis been for maintaining hope	A question about helpful it's been to a person to know about the patient's prognosis in maintaining hope.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115458>	C8836|C7714|C187197	Refractory Childhood Hodgkin Lymphoma|Refractory Hodgkin Lymphoma	A Hodgkin lymphoma that occurs during childhood and is resistant to treatment.	Refractory Childhood Hodgkin Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115459>	C27995	Renal Toxicity|Kidney Toxicity	Toxicity that impairs or damages the kidney. This condition is often caused by the administration of a pharmaceutical agent that causes damage to the kidney.	Renal Toxicity		Sign or Symptom	CTRP Disease Terminology|CTRP Terminology|GCT Adverse Events Table|GCT Authorized Value Terminology|HL Adverse Events Table|HL Authorized Value Terminology|HL Protocol Treatment Modifications Table
C11545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11545>	C63470	Isotretinoin/Temozolomide Regimen|13-CRA/TMZ|Isotretinoin-Temozolomide|Isotretinoin/Temozolomide|Temozolomide + CRA|Temozolomide-Isotretinoin|Temozolomide/13-cis-retinoic Acid|Temozolomide/Isotretinoin|Temozolomide/cRA	A regimen consisting of isotretinoin and temozolomide that may be used in the treatment of glioblastoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C115460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115460>	C9235	Smoldering Systemic Mastocytosis	Slowly progressive systemic mastocytosis with uncertain prognosis. It is characterized by organomegaly and absence of aggressive disease.	Smoldering Systemic Mastocytosis		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115461>	C36159	Slowly Progressive Clinical Course	Clinical course characterized by slow progression without signs of aggressive disease.			Finding	
C115462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115462>	C207067	Clinical Trial Subject Recruitment Advertisement Documentation|Advertisements for Subject Recruitment|Advertisements for Subject Recruitment|Template Advertisement for Subject Recruitment|Templt Subj Ad	Template documentation used in the clinical trial recruitment campaigns.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Central Trial Documents Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115463>	C115435	Institutional Review Board Independent Ethics Committee Advertisement for Subject Recruitment|Advertisements for Subject Recruitment|IRB-IEC Approved Advertisement for Subject Recruitment|Institutional Review Board Independent Ethics Committee Approved Advertisement for Subject Recruitment|Subj Ad	An announcement approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) that is used to locate subjects for participation in a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115464>	C19498	Contractual Agreement|Authorization to Proceed|Change Order|Contract|Contract|Contractl Agrmnt|Contractual|Financial Agreement|Letter of Agreement|Project Work Order|Scope of Work|Service Agreement|contract	A legally binding accord between two or more people that details any and all arrangements regarding a specific situation(s).			Intellectual Product	CareLex eTMF Terminology|CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C115465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115465>	C207067	Clinical Trial Vendor Confidentiality Agreement Documentation|Confidentiality Agreement|Vend Confd Agrmnt|Vendor Confidentiality Agreement	Documentation detailing the agreement between the sponsor or representative of the sponsor and the vendor that contains the provisions governing the access and use of confidential information pertaining to the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Vendor Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115466>	C207067	Clinical Trial Import-Export License Application Documentation|ImEx Lic Appl|Import or Export License Application|Import-Export License Application	Documentation submitted to regulatory authorities requesting a license to import or export an investigational product, and/or clinical supplies.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Regulatory Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115467>	C54125	Sample Size Calculation|SSC|Sample Size Determination|sample size calculation	The mathematical techniques, assumptions, and data used to calculate a sample size.			Activity	CareLex eTMF Terminology|CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|ICH M11 Protocol Section 10 Data Element Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C115468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115468>	C25372	Digital Content Category|Category	A collection of digital content.			Classification	CareLex eTMF Terminology
C115469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115469>	C207067	Audit Certificate Documentation|Audit Cert|Audit Certificate|Audit Certificate	Documentation that confirms an audit has been conducted.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Trial Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C11546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11546>	C61063	Cyclosporine/Interferon Alfa/Sargramostim|CYSP/GM-CSF/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115470>	C81929	Interactive Response Technology User Acceptance Testing Certification Documentation|IRT UAT Scripts and Sign Off|IRT User Acceptance Testing (UAT) Certification|IRT User Acceptance Testing Certification|IRT User Test Certn|Interactive Response Technology User Acceptance Testing Certification	Documentation pertaining to the user acceptance testing performed on the interactive response technology.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IP and Trial Supplies Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115471>	C81929	Interactive Response Technology Validation Certification Documentation|IRT Valid Certn|IRT Validation Certification|IRT Validation Certification|Interactive Response Technology Validation Certification	Documentation confirming the validation of the interactive response technology.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IP and Trial Supplies Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115472>	C207074	Clinical Trial Investigational Product Certificate of Destruction Documentation|Cert Destruction|Certificate of Destruction|Documentation of Destruction|IP Certificate of Destruction	Documentation describing and certifying the destruction of the investigational product(s) for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IP and Trial Supplies Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115473>	C207074	Clinical Trial Investigational Product Certificate of Analysis Documentation|Certificate of Analysis|Certificate of Analysis	Documentation confirming the investigational product(s) are the correct identity, purity and strength for use in the intended clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IP and Trial Supplies Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115474>	C207067	Clinical Trial Data Privacy Agreement Documentation|Data Priv Agrmnt|Data Privacy Agreement|Data Privacy Agreement|Personal Data Consent	Documentation containing the provisions governing the use of, and access to, any and all data obtained from the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115475>	C207067	Clinical Trial Financial Agreement Documentation|Other Finan Agrmnt|Other Financial Agreement|Other Financial Agreement	Documentation detailing the agreement of the clinical trial requirements between sponsor or representative of the sponsor and other parties (excluding the investigator and institution) involved in the conduct of the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115476>	C207073	Clinical Trial Site Investigator Confidentiality Agreement Documentation|Confidentiality Agreement|Confidentiality Agreement|Investigator Confidentiality Agreement|Invstgr Confd Agrmnt|Non-disclosure Agreement	Documentation detailing the agreement between the sponsor or representative of the sponsor and the investigator or institution that contains the provisions governing the access and use of confidential information pertaining to the clinical trial site.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115477>	C207067	Clinical Trial Investigator Regulatory Agreement Documentation|Investigator Regulatory Agreement|Investigator Regulatory Agreement|Invstgr Reg Agrmnt	Documentation containing the agreement by any/all investigators of the clinical trial that all trial activities will conform fully to all regulations as set forth by the law, or any other supervisory authority.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115478>	C25162	eTMF Content Model Code|Code	A designation for use within the eTMF content model.			Intellectual Product	CareLex eTMF Terminology
C115479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115479>	C207067	Clinical Trial Randomization Programming Documentation|RP|Randomization Programming|Randomization Programming	Documentation about the computer code used to generate randomization numbers for treatment assignment in the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Statistics Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C11547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11547>	C61063	Carboplatin/Paclitaxel/SCH-58500|CBDCA/SCH-58500/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115480>	C16452	Institutional Review Board - Independent Ethics Committee Sponsor Communication|IRB-IEC Spons Comm Track Subcat|IRB-IEC Sponsor Communications and Tracking Subcategory|IRB/IEC and other Approvals	Records detailing all trial related communication between the Institutional Review Board (IRB) and/or the independent ethics committee (IEC), and the trial sponsor.			Intellectual Product	CareLex eTMF Terminology
C115481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115481>	C60727	Study Subject Computed Tomography Image|Study Subj CT Rept|Study Subject CT|Study Subject Computed Tomography	A computed tomography image of a study participant for use in the clinical trial.			Manufactured Object	CareLex eTMF Terminology
C115482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115482>	C17146	Edit Check Program|ECP|Edit Check Programming	A computer application that satisfies the edit check specification details in the data validation process.			Intellectual Product	CareLex eTMF Terminology
C115483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115483>	C207067	Clinical Trial Final Analysis Programs Documentation|FinAnaly Prog|Final Analysis Programs|Final Analysis Programs|Program File for Analysis Dataset	Program files used to generate a final analysis dataset and output as referenced by the statistical analysis plan of the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Statistics Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115484>	C207067	Clinical Trial Interim Analysis Programs Documentation|IntAnaly Prog|Interim Analysis Programs|Interim Analysis Programs	Program files used to generate interim analysis dataset and output as referenced by the statistical analysis plan of the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Statistics Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115485>	C97019	Clinical Trial Independent Data Monitoring Committee Correspondence|DMC Correspondence|DSMB Correspondence|Data Monitoring Committee|Data Safety Monitoring Board Correspondence|IDMC Coresp|IDMC Correspondence|IDMC Data Package|Independent Data Monitoring Committee Correspondence	Records that document the correspondence between a clinical trial, and the trial's Independent Data Monitoring Committee.			Intellectual Product	CareLex eTMF Terminology
C115486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115486>	C42628	Content Item Creator|Creator	The name of the entity who created the content item.			Qualitative Concept	CareLex eTMF Terminology
C115487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115487>	C207067	Clinical Trial Principal Investigator Curriculum Vitae Documentation|Investigator CVs|PI CV|Principal Investigator CV|Principal Investigator Curriculum Vitae|Principal Investigator Curriculum Vitae	Documentation detailing the education, qualification and work experience of the principal investigator involved in the conduct of the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115488>	C207067	Clinical Trial Sub-Investigator Curriculum Vitae Documentation|Sub-I CV|Sub-Investigator Curriculum Vitae|Sub-Investigator Curriculum Vitae	Documentation detailing the education, qualification and work experience of the sub-investigator(s) involved in the conduct of the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115489>	C54631	Clinical Trial Team Member Curriculum Vitae|Trial Team CV|Trial Team Curriculum Vitae|Trial Team Member CV|Trial Tm CV	Records detailing the education and work experience of a specific team member, sponsor and or other individual participating in a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C11548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11548>	C61063	Amifostine/Cytarabine/Topotecan|ARA-C/TOPO/WR-2721			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115490>	C54631	Laboratory Director Curriculum Vitae|Head of Facility Curriculum Vitae|Lab Dir CV	Records detailing the education and work experience of the director of the laboratory facility participating in the clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115491>	C25474	Electronic Data Capture Final Output|EDC Fin Data|Final EDC Data	The final data output from the electronic data capture (EDC) system for a clinical study protocol.			Intellectual Product	CareLex eTMF Terminology
C115492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115492>	C207067	Clinical Trial Final Analysis Datasets Documentation|Analysis Datasets|FinAnaly Datsets|Final Analysis Datasets|Final Analysis Datasets	Dataset files generated from a final analysis for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Statistics Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115493>	C207067	Clinical Trial Interim Analysis Datasets Documentation|IntAnaly Datasets|Interim Analysis Datasets|Interim Analysis Datasets	Dataset files generated from an interim analysis for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Statistics Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115494>	C47824	Raw Dataset for Final Analysis|FinAnaly Raw|Final Analysis Raw Datasets|Raw Datasets Final Analysis	The collection of unprocessed data records used for a final analysis of results for a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115495>	C47824	Raw Dataset for Interim Analysis|IntAnaly Raw|Interim Analysis Raw Datasets	The collection of unprocessed data records used for an interim analysis of results during a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115496>	C86035	Study Subject Digital Photograph|Study Subj DigPic|Study Subject Digital Photos	A digital photograph taken of a study participant for use in a clinical trial.			Manufactured Object	CareLex eTMF Terminology
C115497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115497>	C207067	Clinical Trial Operation Documentation|Ops Subcat|Trial Operations Subcategory	Records of plans, policies, and procedures used in a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115498>	C207067	Clinical Trial Unblinding Documentation|Decoding Request|Randomization Release Request|Trial Unblind|Trial Unblinding	Records pertaining to the reversal of randomization code to reveal a specific subject's trial group allocation data.			Intellectual Product	CareLex eTMF Terminology
C115499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115499>	C42883	Computed Tomography Study File|CT|Computed Tomography Subcategory	A collection of computed tomography files pertaining to a clinical study.			Manufactured Object	CareLex eTMF Terminology
C11549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11549>	C61063	Aminopterin/Leucovorin Calcium|APGA/CF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1154>	C67421	Carbendazim|1H-Benzimidazol-2-yl-carbamic Acid, Methyl Ester|1H-benzimidazol-2-ylcarbamic Acid Methyl Ester|2-(Methoxycarbonylamino)benzimidazole|2-Benzimidazolecarcamic Acid Methyl Ester|2-Methyl benzimidazolecarbamate|BAS 3460|BAS-3460|BAS-67054|BCM|BMC|Bavistin|Bavistin|CARBENDAZIM|CTR 6669|CTR-6669|Carbendazole|Carbendazole|Derosal|Derosal|FB642|HOE 17411|HOE-17411|MBC|Methyl 2-Benzimidazolecarbamate|Methyl 2-benzimidazolecarbamate|Methyl Benzimidazol-2-ylcarbamate|Methyl-1H-benzimidazol-2-yl Carbamate|Methyl-2-benzimidazole Carbamate|Methyl-2-benzimidazolecarbamate|Methyl-alpha-benzimidazole Carbamate|carbendazim	A broad-spectrum benzimidazole antifungal with potential antimitotic and antineoplastic activities. Although the exact mechanism of action is unclear, carbendazim appears to binds to an unspecified site on tubulin and suppresses microtubule assembly dynamic. This results in cell cycle arrest at the G2/M phase and an induction of apoptosis.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C115500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115500>	C42883	Digital Photography Study File|DigPic|Digital Photographs Subcategory	A collection of digital photographs pertaining to a clinical study.			Manufactured Object	CareLex eTMF Terminology
C115501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115501>	C42883	Magnetic Resonance Imaging Study File|MRI|Magnetic Resonance Imaging Subcategory	A collection of magnetic resonance image files pertaining to a clinical study.			Manufactured Object	CareLex eTMF Terminology
C115502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115502>	C42883	Nuclear Medicine Study File|NM|Nuclear Medicine Subcategory	A collection of nuclear medicine files pertaining to a clinical study.			Manufactured Object	CareLex eTMF Terminology
C115503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115503>	C42883	Ultrasound Study File|US|Ultrasound Subcategory	A collection of ultrasound image files pertaining to a clinical study.			Manufactured Object	CareLex eTMF Terminology
C115504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115504>	C42619	Centralized Testing Filenote|Centralz Test Flnote|Filenote	A notation regarding the decisions, and/or clarification of any information pertaining to a centralized test.			Intellectual Product	CareLex eTMF Terminology
C115505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115505>	C42619	Data Management Filenote|DM Flnote|Filenote	A notation regarding the decisions, and/or clarification of any information pertaining to data management.			Intellectual Product	CareLex eTMF Terminology
C115506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115506>	C42619	Investigational Product and Clinical Trial Supplies Filenote|General Investigational Product and Trial Supplies Filenote|IP Trial Suppl Flnote|IP and Trial Supplies Filenote	A notation pertaining to the investigational product, and associated trial supplies used in a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115507>	C42619	Safety Filenote|Filenote|Safe Flnote	A notation regarding the decisions, and/or clarification of any information pertaining to the safety report of a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115508>	C42619	Statistics Filenote|Filenote|Stats Flnote	A notation regarding the decisions, and/or clarification of any information pertaining to the statistics used in a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115509>	C42619	Vendor Filenote|Filenote|Vend Flnote	A notation regarding the decisions, and/or clarification of any information pertaining to a vendor.			Intellectual Product	CareLex eTMF Terminology
C11550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11550>	C61063	Carboplatin/Thiotepa/Vincristine|CBDCA/TSPA/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115510>	C25375	Study Subject Computed Tomography Report|Study Subj CT Rept|Study Subject CT Report	Records pertaining to the findings from a study subject's computed tomography images.			Intellectual Product	CareLex eTMF Terminology
C115511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115511>	C25375	Study Subject Medical Imaging Report|Study Subj Med Img Rpt Unsp|Study Subject Medical Imaging Report Unspecified	Records pertaining to the findings from a study subject's medical imaging results.			Intellectual Product	CareLex eTMF Terminology
C115512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115512>	C25375	Study Subject MRI Report|Study Subj MRI Rept|Study Subject Magnetic Resonance Imaging Report	Reports pertaining to the findings from a study subject's magnetic resonance imaging results.			Intellectual Product	CareLex eTMF Terminology
C115513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115513>	C25375	Study Subject Nuclear Medicine Report|Study Subj NM Rept	Records pertaining to the findings from a study subject's nuclear medicine images.			Intellectual Product	CareLex eTMF Terminology
C115514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115514>	C25375	Study Subject Radiography Report|Study Subj RAD Rept	Records pertaining to the findings from a study subject's radiographic images.			Intellectual Product	CareLex eTMF Terminology
C115515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115515>	C25375	Study Subject Ultrasound Report|Study Subj US Rept	Records pertaining to the findings from a study subject's ultrasound images.			Intellectual Product	CareLex eTMF Terminology
C115516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115516>	C25375	Subject Digital Photograph Report|Study Subj DigPic Rept|Study Subject Digital Photos Report	Records pertaining to the findings from a study subject's digital photograph images.			Intellectual Product	CareLex eTMF Terminology
C115517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115517>	C207071	Clinical Trial Subject Information Form Documentation|Subj Info Form|Subject Information Form|Subject Information Sheet|Subject Information Sheet	Documentation used to provide information to the subjects to support their decision about whether or not to participate in the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Central Trial Documents Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115518>	C207071	Clinical Trial Subject Miscellaneous Form Documentation|Other Information Given to Subjects|Other Subject Forms|Other Written Information Given to Subjects|Subj Other Form	Documentation provided to the subject to further assist with understanding the clinical trial requirements or concepts.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Central Trial Documents Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115519>	C207071	Clinical Trial Subject Participation Form Documentation|Clinical Trial Wallet Card|Participant Clinical Trial Wallet Card|Study Wallet Card|Subj Partic|Subject Participation Card|Subject Participation Card|Subject Participation Form|Treatment Information Card	Documentation provided to the subject to carry to document clinical trial participation.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Central Trial Documents Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C11551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11551>	C61063	gp100 Antigen/Incomplete Freund's Adjuvant/MART-1 Antigen|gp100/IFA/MART-1			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115520>	C19464	Completed Case Report Form|Completed CRFs|Completed Case Report Forms|Complt CRF	Documentation completed by an investigator on each subject in a clinical trial; they contain information required by the clinical study protocol, and which is reported to a sponsor.			Intellectual Product	CareLex eTMF Terminology
C115521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115521>	C207067	Clinical Trial Corrections to Entered Data Documentation|Data Clarification Forms|Data Correction Forms|Data Query Forms|Date Clarif Form|Documentation of Corrections to Entered Data|Documentation of Corrections to Entered Data	Documentation used to query database discrepancies and record approved corrections to the clinical trial database.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Data Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115522>	C207074	Clinical Trial Investigational Product Quality Complaint Documentation|IP QA Complt Form|IP Quality Complaint Form|IP Quality Complaint Form|Investigational Product Quality Complaint Form	Documentation of the complaint directed against the investigational product(s) for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IP and Trial Supplies Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115523>	C17369	Study Subject Medical Imaging|Study Subj Med Img Unsp|Study Subject Medical Imaging Unspecified	Medical imaging of a study participant as part of a clinical trial.			Diagnostic Procedure	CareLex eTMF Terminology
C115524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115524>	C48191	Clinical Trial Site Personnel Supporting Information|Site Pers Supt Info|Site Personnel Supporting Information	Documentation of an investigator's qualifications for participating in a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115525>	C207074	Clinical Trial Investigational Product Handling Instruction Documentation|IP Instr Handl|IP Instructions for Handling|IP Instructions for Handling|Investigational Product Instructions for Handling|Storage and Handling of Investigational Trial Intervention	Documentation describing the safe handling, storage, distribution, and return of the investigational product(s) for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IP and Trial Supplies Zone Terminology|Clinical Data Interchange Standards Consortium Terminology|ICH M11 Protocol Section 6 Data Element Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C115526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115526>	C207067	Clinical Trial Investigator Brochure Documentation|IB|Investigator Brochure|Investigator's Brochure	Documentation providing relevant and current clinical and non-clinical data for the investigational product(s) that is related to the study of the product(s) in human subjects.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Central Trial Documents Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115527>	C207074	Clinical Trial Investigational Product Sample Label|IP Sample Label|IP Sample Label|IP Sample Labl|Investigational Product Sample Label	A sample of each investigational product label used in the clinical trial.			Manufactured Object	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IP and Trial Supplies Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115528>	C207067	Clinical Trial Specimen Label Documentation|Sample Label|Specimen Label|Specimen Label|Specm Labl	Documentation detailing the identification and collection of a specimen for the clinical trial.			Manufactured Object	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Central and Local Testing Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115529>	C43611	Clinical Trial Principal Investigator License|Medical License|PI Lic|PI License|PI License|Principal Investigator License	A record of medical and/or other licenses of the principal investigators in a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C11552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11552>	C61063	gp100 Antigen/Incomplete Freund's Adjuvant/Interleukin-2/MART-1 Antigen|gp100/IFA/IL-2/MART-1			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115530>	C207067	Clinical Trial Import or Export Documentation|ImEx Lic|Import or Export Documentation|Import-Export License	Documentation authorizing the import or export of an investigational product, and/or clinical supplies into/out of its territory.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Regulatory Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115531>	C207067	Clinical Trial Filenotes Master List Documentation|Filenote Master List|Filenote Master List|Flnote Mstr List|Note to File Master List	Documentation providing a consolidated list or index of file notes generated during the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Trial Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115532>	C43432	Clinical Trial Independent Data Monitoring Committee Member List|Data Monitoring Committee|Data Safety Monitoring Board Member List|IDMC Mbr list|Independent Data Monitoring Committee Member List	A directory of the current membership of the Independent Data Monitoring Committee.			Intellectual Product	CareLex eTMF Terminology
C115533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115533>	C207067	Clinical Trial Master Randomization List|Master Randomization List|Master Randomization List|Mstr Randomiz List|Randomization Schedule	A document describing the assignment of subjects to the clinical study protocol-specified treatment groups in the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Statistics Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115534>	C207075	Clinical Trial Pharmacovigilance Data Line List Documentation|PV DB Line Listg|Periodic Line Listing|Pharmacovigilance Database Line Listing|Pharmacovigilance Database Line Listing	Documentation containing the clinical trial data used for safety evaluations of investigational product(s).			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Safety Reporting Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115535>	C207067	Clinical Trial Biological Sample Storage Condition Log Documentation|Sample Stor Log|Sample Storage Condition Log|Sample Storage Condition Log|Specimen Storage Condition Log|Temperature Log	Documentation detailing the monitoring and tracking of the specimens storage conditions for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Central and Local Testing Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115536>	C207073	Clinical Trial Site Visit Log Documentation|Monitor visit log|Visit Log|Visit Log|Vlog	Documentation listing all clinical trial site monitoring visit dates and attendees.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115537>	C45279	Clinical Trial Subject Enrollment Log|Subj Enrol Log|Subject Enrollment Log|Subject Log	Records identifying all subjects enrolled in a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115538>	C45279	Clinical Trial Subject Screen Log|Subj Screen Log|Subject Identification Log|Subject Screen Log	Records of all subjects considered for participation in a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115539>	C16809	Study Subject Magnetic Resonance Imaging|Study Subj MRI|Study Subject MRI|Study Subject MRI	Magnetic resonance imaging of a study participant as part of a clinical trial.			Diagnostic Procedure	CareLex eTMF Terminology
C11553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11553>	C61063	Gentamicin/Piperacillin/Vancomycin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115540>	C81929	Interactive Response Technology User Manual Documentation|IRT User Manl|IRT User Manual|IRT User Manual|Interactive Response Technology User Manual	Documentation providing operational instructions for the interactive response technology.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IP and Trial Supplies Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115541>	C62612	Laboratory Sample Manual|Facility Handbook|Facility Manual|Lab Manl|Lab Manual|Manual|User Manual	Documentation describing work processes and procedures for the collection, handling, and shipping of a sample.			Intellectual Product	CareLex eTMF Terminology
C115542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115542>	C71460	Bioanalytical Validation Method|BVM|Bioanalytical Validation Methods|Method validation|precision testing|quality control testing	A process that ensures the use of selective, sensitive, and validated analytical methods for the quantitative evaluation of drugs and their metabolites (analytes) and biomarkers, for the successful conduction of nonclinical and/or clinical trials.			Functional Concept	CareLex eTMF Terminology
C115543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115543>	C42614	Taxonomy Category Name|Category Name	The preferred word(s) used to describe a taxonomic category.			Intellectual Product	CareLex eTMF Terminology
C115544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115544>	C207067	Clinical Trial Investigator Newsletter Documentation|Inv Newsltr|Investigator Newsletter|Investigator Newsletter	Documentation that informs investigative staff of common implementation issues and the progress of the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Trial Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115545>	C19477	Medical Imaging File Not Otherwise Specified|Med Img Unsp|Medical Imaging Unspecified Subcategory	A collection of image files of a study participant, generated by medical imaging techniques that are not otherwise specified.			Intellectual Product	CareLex eTMF Terminology
C115546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115546>	C42619	Central Clinical Trial Filenote|CTrial Flnote|Central Trial Filenote|Filenote	A notation that describes the decisions, and/or clarification of any information pertaining to the central trial.			Intellectual Product	CareLex eTMF Terminology
C115547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115547>	C42619	Clinical Trial Management Filenote|General Trial Filenotes|Trial Filenote|Trial Flnote	A notation that describes the decisions, and/or clarification of any information pertaining to the clinical trial management.			Intellectual Product	CareLex eTMF Terminology
C115548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115548>	C42619	Clinical Trial Regulatory Filenote|Filenote|Reg Flnote|Regulatory Filenote	A notation that describes any regulatory decisions, and/or clarification of any information in a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115549>	C42619	Clinical Trial Site Management Filenote|Filenote|Site Management Filenote|Site Mgmt Flnote	A notation that describes any decisions or clarifications of information pertaining to the site management of a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C11554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11554>	C61063	Asparaginase/Prednisone/Vincristine|ASP/PRED/VCR|PVA|VLP|VPL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115550>	C42619	Institutional Review Board - Independent Ethics Committee Filenote|IRB-IEC Filenote|IRB-IEC Flnote	A notation that describes any decisions or clarifications of information pertaining to the Institutional Review Board (IRB)-Independent Ethics Committee (IEC).			Intellectual Product	CareLex eTMF Terminology
C115551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115551>	C207067	Clinical Trial Notification of Safety or Other Trial Information Documentation|Notf Safe Info|Notification of Safety Information|Notification of Safety or Trial Information|Notification to Regulatory Authority of Safety/Trial Information|Safety Report	Documentation submitted to the regulatory authorities pertaining to any events that may impact the safety of subjects or the conduct of the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Regulatory Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115552>	C19498	Interactive Response Technology User Notification|IRT User Notf|IRT User Notifications|Interactive Response Technology User Notifications	Records of communications between the interactive response technology and the user.			Intellectual Product	CareLex eTMF Terminology
C115553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115553>	C60727	Study Subject Nuclear Medicine Image|Study Subj NM|Study Subject Nuclear Medicine	A nuclear medicine image taken of a study participant for use in a clinical trial.			Manufactured Object	CareLex eTMF Terminology
C115554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115554>	C207067	Clinical Trial Final Analysis Output Documentation|FinAnaly Output|Final Analysis Output|Final Analysis Output|Statistical Output	Tables, listings, and figures output files generated from a final analysis for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Statistics Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115555>	C207067	Clinical Trial Interim Analysis Output Documentation|IntAnaly Output|Interim Analysis Output|Interim Analysis Output|interim clinical trial/study report	Tables, listings, and figures output files generated from an interim analysis for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC Glossary Terminology|CDISC TMF Terminology|CDISC TMF-RM Statistics Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115556>	C207067	Clinical Trial Oversight Committee Information|CTOC|Clinical Trial Oversight Committees|DMC Committee|DSMB|Data Safety Monitoring Board|IDMC Committee	Documentation pertaining to the organization that approves, monitors, and reviews biomedical research to protect the rights, safety and welfare of the study subjects.			Intellectual Product	CareLex eTMF Terminology
C115557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115557>	C207067	Clinical Trial Publication Policy Documentation|Publication Policy|Publication Policy|Pubs Policy	Documentation describing the publication of clinical trial results.			Governmental or Regulatory Activity	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Trial Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115558>	C207075	Clinical Trial Special Events of Interest Documentation|Medical Events of Interest|SEI|Special Events of Interest|Special Events of Interest	Documentation describing an event of special interest experienced by the subject in the clinical trial, which is defined by the clinical study protocol.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Safety Reporting Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115559>	C207067	Clinical Trial Subject Questionnaire Documentation|Subj Quest Form|Subject Questionnaire|Subject Questionnaire|Subject Questionnaire Form	Documentation used to capture specific subject related information through a series of questions.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Central Trial Documents Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C11555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11555>	C61007	Cisplatin/Epirubicin|CDDP-e TI|CDDP/EPI|Cisplatin-e therapeutic implant			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115560>	C17048	Institutional Review Board Independent Ethics Committee Subject Questionnaire|IRB-IEC Approved Subject Questionnaire|Institutional Review Board Independent Ethics Committee Approved Subject Questionnaire|Subj Quest|Subject Questionnaire	A document, approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC), intended to capture specific subject-related information through a series of questions.			Intellectual Product	CareLex eTMF Terminology
C115561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115561>	C60727	Study Subject Radiograph|Study Subj RAD|Study Subject Radiography	A radiographic image taken of a study participant for use in a clinical trial.			Manufactured Object	CareLex eTMF Terminology
C115562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115562>	C38013	Laboratory Normal Ranges|Lab Normals|Laboratory Test Result Reference Range|Local Laboratory Normal Ranges|Locl Lab Norm Range|Reference Ranges	A generally agreed upon set of laboratory values that allow for comparative interpretation of laboratory results, and on which medical decisions are made.			Quantitative Concept	CareLex eTMF Terminology
C115563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115563>	C207074	Clinical Trial Non-Investigational Product Supplies Shipment Documentation|Non-IP Docn Shipmt|Non-IP Documentation of Shipment|Non-IP Shipment Documentation|Non-Investigational Product Documentation of Shipment	Documentation providing information regarding the shipment of the non-investigational product(s) and other supplies for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IP and Trial Supplies Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115564>	C207074	Clinical Trial Investigational Product Accountability Documentation|Accountability Documentation|IP Accountability Documentation|IP Accountability Record|IP Acct Record|Inventory Documentation|Investigational Product Accountability Record	Documentation detailing the dispensing and return of the investigational product(s) for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IP and Trial Supplies Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115565>	C25198	Investigational Product and Clinical Trial Supplies Communication Record|Correspondence|General Investigational Product and Trial Supplies Communications|IP Trial Suppl Comm|IP and Trial Supplies Communications|Relevant Communications	Documentation providing information regarding communications pertaining to the investigational product, and associated trial supplies.			Intellectual Product	CareLex eTMF Terminology
C115566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115566>	C207074	Clinical Trial Investigational Product Return Documentation|IP Documentation Return|IP Return Documentation|IP Return Record|IP Return Record|Investigational Product Return Record	Documentation providing information regarding the return of the investigational product(s) for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IP and Trial Supplies Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115567>	C207074	Clinical Trial Investigational Product Shipment Documentation|IP Documentation of Shipment|IP Shipment Documentation|IP Shipment Record|IP Shipmt Record|Investigational Product Shipment Record	Documentation providing information regarding the shipment of the investigational product(s) for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IP and Trial Supplies Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115568>	C207074	Clinical Trial Investigational Product Transfer Documentation|IP Documentation of Transfer|IP Trans Record|IP Transfer Documentation|IP Transfer Record|Investigational Product Transfer Record	Documentation detailing the transfer of the investigational product(s) for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IP and Trial Supplies Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115569>	C25198	Laboratory Shipment Record|Lab Shipmt Record|Laboratory Shipment Records|Shipment Records|Specimen Shipment Records	Documentation detailing the shipment of a laboratory sample.			Intellectual Product	CareLex eTMF Terminology
C11556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11556>	C61063	Amikacin/Ceftazidime			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115570>	C207067	Clinical Trial Record of Retained Biological Samples Documentation|Record RBF|Record of Retained Body Fluids / Tissue Samples|Record of Retained Body Fluids or Tissue Samples|Record of Retained Samples	Documentation pertaining to the identification and location of retained specimens for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Central and Local Testing Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115571>	C25198	Statistical Report Record|SR Record|Statistical Report Records Subcategory	Records pertaining to the statistical data from a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115572>	C207074	Clinical Trial Investigational Product Treatment Decoding Documentation|Code Break|IP Treatment Decoding Documentation|Subj Unblind Event|Subject Unblinding Event|Treatment Decoding Documentation|Unblinding	Documentation describing the actions taken after breaking the blind for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IP and Trial Supplies Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115573>	C207067	Clinical Trial Bioanalytical Report Documentation|Bioanalytical Documentation|Bioanalytical Report|Bioanalytical Reports|Bioanyl Rept	Documentation describing final or interim results of the bioanalytical aspects of the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Central Trial Documents Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115574>	C207075	Clinical Trial Expedited Safety Report Documentation|CIOMS Report|Exped Safe Rept|Expedited Safety Report|Expedited Safety Report|Investigational New Drug (IND) Safety Report|MedWatch|Suspected Unexpected Serious Adverse Reaction (SUSAR)	Documentation describing unexpected serious adverse events experienced by the subject and other safety information in the clinical trial, which are submitted to regulatory authorities and Institutional Review Boards or Independent Ethics Committees.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Safety Reporting Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115575>	C25375	Clinical Trial Final Report|CTrial Fin Rept Subcat|Central Trial Final Reports Subcategory|Clinical Trial|Reports|final report	Records containing any interim or final results, as well as clinical and statistical descriptions, presentations, analyses and interpretations of any therapeutic, prophylactic, or diagnostic agent used in human subjects in a clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C115576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115576>	C207073	Clinical Trial Site Initiation Monitoring Report Documentation|Site Initiation Visit Report|Trial Initiation Monitoring Report|Trial Initiation Monitoring Report|Trial Initn Mon Rept	Documentation of monitoring activities conducted to ensure the clinical trial site meets requirements to begin participation in the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115577>	C207073	Clinical Trial Site Monitoring Visit Report Documentation|Mon Visit Rept|Monitoring Visit Report|Monitoring Visit Report	Documentation of ongoing monitoring activities conducted for the evaluation of clinical trial conduct, and regulatory compliance of the clinical trial site.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115578>	C207075	Clinical Trial Pregnancy Report Documentation|Preg Rept|Pregnancy Report|Pregnancy Report	Documentation pertaining to a pregnancy and its outcome as experienced by the female subject, or by the partner of the male subject during the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Safety Reporting Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115579>	C25375	Clinical Trial Regulatory Status Report|Trial Reg Stas Rept Subcat|Trial Regulatory Status Reporting Subcategory|Trial Status Reporting	Records informing the regulatory authorities of the progress of a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C11557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11557>	C61063	Amikacin/Ceftriaxone			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115580>	C207067	Clinical Trial Status Report Documentation|Trial Stas Rept|Trial Status Report|Trial Status Report	Documentation that contains routine trial status progress.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Trial Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115581>	C207073	Final Clinical Trial Site Close Out Monitoring Report Documentation|Close Out Monitoring Visit Report|Close Out Visit Report|Fin Trial Close Mon Rept|Final Trial Close Out Monitoring Report|Final Trial Close Out Monitoring Report	Documentation of the monitoring activities conducted to ensure that the clinical trial site meets requirements for closure.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115582>	C207067	Clinical Trial Final Statistical Report Documentation|SR|Statistical Report|Statistical Report	Documentation detailing the statistical aspects of a final analysis for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Statistics Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115583>	C25375	Institutional Review Board Independent Ethics Committee Clinical Trial Status Report|IRB-IEC Trial Stas Subcat|IRB-IEC Trial Status Reporting Subcategory|Institutional Review Board Independent Ethics Committee Clinical Trial Status Reporting|Trial Status Reporting	Records sent to an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) of all findings that may adversely affect the safety of a subject, impact the conduct of a clinical trial, alter the IRB/IEC's willingness to continue the trial.			Intellectual Product	CareLex eTMF Terminology
C115584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115584>	C25375	Institutional Review Board Independent Ethics Committee Report|IRB-IEC Report|IRB-IEC Rept|IRB/IEC Report	Records sent to the Institutional Review Board (IRB) or Independent ethics committee (IEC) at regular intervals, which provides information and updates about a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115585>	C207067	Clinical Trial Interim Statistical Report Documentation|Interim SR|Interim Statistical Report(s)|Interim Statistical Report(s)|Interim Statistical Reports	Documentation detailing the statistical aspects of an interim analysis for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Statistics Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115586>	C207073	Pre-Clinical Trial Site Evaluation Report Documentation|PSSR|PSVR|Pre Trial Monitoring Report|Pre Trial Monitoring Report|Pre-Study Visit Report|PreTrial Mon Rept|Site Evaluation Visit Report	Documentation of monitoring activities conducted to evaluate whether a clinical trial site is qualified to participate in the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115587>	C207075	Clinical Trial Serious Adverse Event Report Documentation|SAE Report|SAE Report|SAE Rept|Serious Adverse Event Report	Documentation describing a serious adverse event experienced by the subject in the clinical trial, which is defined by the clinical study protocol.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Safety Reporting Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115588>	C207072	Institutional Review Board Independent Ethics Committee Subject Diary|IRB-IEC Approved Subject Diary|Institutional Review Board Independent Ethics Committee Approved Subject Diary|Subj Diary|Subject Diary	An instrument approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) that is used to record subject data away from a clinical trial site.			Intellectual Product	CareLex eTMF Terminology
C115589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115589>	C207067	Subject Diary Documentation|Patient Diary|Subj Diary Form|Subject Diary|Subject Diary|Subject Diary Form	Documentation used to capture data recorded by the subject.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Central Trial Documents Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C11558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11558>	C61063	Azacitidine/Carboplatin|AZA/CBDCA|Azacytidine/Carboplatin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115590>	C73537	Database Specification|DB Spec|Database Programming Requirements	A detailed description of the framework, and process required to build a database for paper and electronic data capture (EDC).			Intellectual Product	CareLex eTMF Terminology
C115591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115591>	C73537	External Data Transfer Specification|External Data Transfer Specifications|Extnl DT Spec	A detailed description that specifies the import, export, and transfer of data.			Intellectual Product	CareLex eTMF Terminology
C115592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115592>	C81929	Interactive Response Technology User Specification Documentation|IRT User Reqrt Spec|IRT User Requirement Specification|IRT User Requirement Specification|Interactive Response Technology Specification	Documentation describing the end user requirements of the interactive response technology.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IP and Trial Supplies Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115593>	C207067	Debarment Statement Documentation|Debar Stmt|Debarment Certification|Debarment Statement|Debarment Statement	Documentation verifying that the applicant or any of its principals should be excluded from certain rights, privileges and practices due to debarment or other circumstances.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Trial Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115594>	C207072	Institutional Review Board Independent Ethics Committee Compliance Documentation|IRB or IEC Compliance Documentation|IRB-IEC Attestation Form|IRB-IEC GCP Compliance Statement|IRB-IEC GCP Compliance Statement|IRB-IEC GCP Stmt|Institutional Review Board Independent Ethics Committee Good Clinical Practices Compliance Statement	Documentation confirming the Institutional Review Board or Independent Ethics Committee is in compliance with written operating procedures, Good Clinical Practices, and applicable regulatory requirements.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IRB or IEC and Other Approvals Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115595>	C49154	Transmissible Spongiform Encephalopathy Statement|TSE Statement|TSE Stmt	A declaration that proper measures have been taken to ensure that the risk for spreading transmissible spongiform encephalopathy (TSE) through the use of the Investigational Product (IP) has been minimized, which may include being manufactured with materials of a non-animal origin.			Intellectual Product	CareLex eTMF Terminology
C115596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115596>	C93406	Central Trial Communication Material|CTrial Comm|Central Trial Communications|Correspondence|Relevant Communications	A collection of central trial-related communication agreements, significant discussions, or relevant information.			Intellectual Product	CareLex eTMF Terminology
C115597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115597>	C93406	Central Trial Meeting Material|CTrial Mtg Matl|Meeting Material	A collection of agendas, presentation materials, and other documents generated for attendees during a central trial-related meeting.			Intellectual Product	CareLex eTMF Terminology
C115598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115598>	C93406	Centralized Testing Meeting Material|Centralz Test Mtng Matl|Meeting Material	A collection of agendas, presentation materials, and other documents generated for attendees during a centralized test-related meeting.			Intellectual Product	CareLex eTMF Terminology
C115599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115599>	C207067	Clinical Trial Investigator Meeting Material Documentation|Investigators Meeting Material|Investigators Meeting Material|Invstgr Mtg Matl	Documentation pertaining to the clinical trial investigator meeting.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Trial Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C11559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11559>	C61063	Cyclophosphamide/Detox-B Adjuvant/Interleukin-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1155>	C776	Medroxyprogesterone Acetate|(6alpha)-17-(Acetyloxy)-6-methylpregn-4-ene-3,20-dione|17-(Acetyloxy)-6alpha-methylpregn-4-ene-3,20-dione|17-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione Acetate|17Alpha-acetoxy-6alpha-methylprogesterone|6-Alpha-methyl-17alpha-acetoxyprogesterone|Amen|Aragest|Ciclotal|Clinofem|Clinovir|Cycrin|Depo-Clinovir|Depo-Provera|Depo-provera|Depot-Medroxyprogestereone Acetate|Farlutal|Farlutal|G-Farlutal|Gestapuran|Gestapuran|Hysron|Lutoral|Lutoral|MEDROXYPROGESTERONE ACETATE|MPA|Medroxyprogesterone 17-Acetate|Medroxyprogesterone acetate|Medroxyprogesteroni Acetas|Methylacetoxyprogesterone|Metipregnone|Nadigest|Nadigest (vet)|Nidaxin|Nidaxin (vet)|Oragest|Oragest|Perlutex|Perlutex|Prodasone|Prodasone|Provera|Provera|Sodelut G|Veramix|Veramix|medroxyprogesterone acetate	A synthetic, acetate derivative of the sex hormone progesterone.  Medroxyprogesterone 17-acetate (NCI04)	Medroxyprogesterone Acetate		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C115600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115600>	C207067	Clinical Trial Kick-off Meeting Material Documentation|Boot-up Meeting Material|KO Mtng Matl|Kick-off Meeting Material|Kick-off Meeting Material	Documentation pertaining to the clinical trial kick-off meeting.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Trial Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115601>	C93406	Clinical Trial Management Meeting Material|Meeting Background Materials|Other Meeting Material|Trial Management Meeting Material|Trial Mgmt Mtng	A collection of agendas, presentation materials, and other documents generated for attendees during a clinical trial management meeting.			Intellectual Product	CareLex eTMF Terminology
C115602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115602>	C93406	Clinical Trial Site Management Communication Material|Correspondence|Relevant Communications|Site Management Communications|Site Mgmt Comm	A collection of communications, agreements, significant discussions, and/or relevant information related to clinical trial site management.			Intellectual Product	CareLex eTMF Terminology
C115603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115603>	C93406	Clinical Trial Site Management Meeting Material|Meeting Material|Site Management Meeting Material|Site Mgmt Mtng Matl	A collection of agendas, presentation materials, and other documents generated for attendees during a clinical trial site management meeting.			Intellectual Product	CareLex eTMF Terminology
C115604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115604>	C207073	Clinical Trial Site Training Material Documentation|Site Traing Matl|Site Training Material|Site Training Material	Documentation used to train site personnel involved in the conduct of the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115605>	C93406	Clinical Trial Startup Material|Trial Start Up Subcategory|Trial Startup	A collection of agendas, presentation materials, and other documents related to a clinical trial startup.			Intellectual Product	CareLex eTMF Terminology
C115606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115606>	C207067	Clinical Trial Team Training Material Documentation|Trial Team Training Material|Trial Team Training Material|Trial Tm Training Matl	Documentation pertaining to the training materials for the clinical trial team.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Trial Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115607>	C93406	Data Management Meeting Material|DM Mtng Matl|Meeting Material	A collection of agendas, presentation materials, and other documents that are generated for attendees during a data management meeting.			Intellectual Product	CareLex eTMF Terminology
C115608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115608>	C93406	Institutional Review Board - Independent Ethics Committee Communication Material|Correspondence|IRB-IEC Comm|IRB-IEC Communications|Institutional Review Board - Independent Ethics Committee Communications|Relevant Communications	A collection of communications, significant discussions, and relevant information that transpired with the Institutional Review Board (IRB) and/or the Independent Ethics Committee (IEC).			Intellectual Product	CareLex eTMF Terminology
C115609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115609>	C93406	Institutional Review Board - Independent Ethics Committee Meeting Material|IRB-IEC Meeting Material|IRB-IEC Mtng Matl|Meeting Material	A collection of agendas, presentation materials, and other documents generated for attendees during an Institutional Review Board - Independent Ethics Committee (IRB-IEC) meeting.			Intellectual Product	CareLex eTMF Terminology
C11560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11560>	C61063	Deoxyspergualin/Monoclonal Antibody L6|DSG/MOAB L6			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115610>	C93406	Investigational Product and Clinical Trial Supplies Meeting Material|General Investigational Product and Trial Supplies Meeting Material|IP Trial Suppl Mtng Matl|IP and Trial Supplies Meeting Material	A collection of agendas, presentations, and other documents generated for attendees during a meeting regarding the investigational product and associated trial supplies used in a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115611>	C93406	Regulatory Communication Material|Correspondence|Reg Comm|Regulatory Communications|Relevant Communications	A collection of regulatory-related communications, agreements, significant discussions, or relevant information.			Intellectual Product	CareLex eTMF Terminology
C115612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115612>	C93406	Regulatory Meeting Material|Meeting Material|Reg Mtng Matl	A collection of agendas, presentation materials, and other documents generated for attendees during a regulatory meeting.			Intellectual Product	CareLex eTMF Terminology
C115613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115613>	C93406	Safety Meeting Material|Meeting Material|Safe Mtng Matl	A collection of agendas, presentation materials, and other documents generated for attendees during a safety report meeting.			Intellectual Product	CareLex eTMF Terminology
C115614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115614>	C93406	Statistic Meeting Material|Meeting Material|Statistics Meeting Material|Stats Mtng Matl	A collection of agendas, presentation materials, and other documents generated for attendees during a statistics meeting.			Intellectual Product	CareLex eTMF Terminology
C115615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115615>	C93406	Vendor Meeting Material|Meeting Material|Vend Mtng Matl	A collection of agendas, presentation materials, and other documents generated for attendees during a vendor meeting.			Intellectual Product	CareLex eTMF Terminology
C115616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115616>	C25694	Institutional Review Board Independent Ethics Committee Submission Documentation|IRB or IEC Submission|IRB-IEC Subm|IRB-IEC Submission|IRB/IEC Submission|Institutional Review Board Independent Ethics Committee Submission	Documentation submitted to an Institutional Review Board (IRB) or Independent Ethics Committee (IEC) for approval of the details of a clinical trial, and any changes or updates made to that trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IRB or IEC and Other Approvals Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115617>	C207070	TMF-RM Trial Team Section|Trial Team|Trial Team Subcategory|Trial Tm	The Trial Master File Reference Model section that contains a collection of documents related to the trial team for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Sections Terminology|Clinical Data Interchange Standards Consortium Terminology
C115618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115618>	C25284	Category Type	A description of a category.			Qualitative Concept	CareLex eTMF Terminology
C115619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115619>	C60727	Study Subject Ultrasound Image|Study Subj US|Study Subject Ultrasound	A ultrasound image taken of a study participant for use in a clinical trial.			Manufactured Object	CareLex eTMF Terminology
C11561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11561>	C61063	Fluorouracil/Interferon Alfa/Leucovorin Calcium/Mitoxantrone/Vinblastine|CF/DHAD/5-FU/IFN-A/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115620>	C25619	Database Validation Plan|Data Valid Plan|Data Validation Plan|Data Validation Specification|Data integration|EDC Validation including Validation Test Plan|Edit Check and Logic Check Specifications	A proposed method that defines edit checks, the process of edit checks, and validation tests for database specification.			Intellectual Product	CareLex eTMF Terminology
C115621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115621>	C207067	Clinical Trial Randomization Validation Documentation|RV|Randomization Sign Off|Randomization Sign Off|Randomization Validation	Documentation verifying the correct randomization number and treatment assignment have been generated by the randomization program being used in the clinical trial.			Research Activity	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Statistics Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115622>	C173563	How Helpful has Knowing Your Prognosis Been for Coping with the Disease Question|How Helpful has Knowing Your Prognosis Been for Coping with the Disease|How helpful has knowing about their prognosis been for your loved one in coping with their disease|How helpful has knowing about your prognosis been for coping with the disease	A question about helpful it's been to a person to know about the patient's prognosis in coping with the patient's disease.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115623>	C7710|C68690|C3795	Adult Subependymoma|Subependymoma	A subependymoma that occurs during adulthood.	Adult Subependymoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115624>	C173563	How Helpful has Knowing Your Prognosis Been Overall Question|How Helpful has Knowing Your Prognosis Been Overall|Overall, how helpful has knowing about prognosis been for you|Overall, how helpful has knowing about prognosis been for your loved one	A question about helpful, overall, it's been to a person to know about the patient's prognosis.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115625>	C19700	Exceptional Responder	A cancer patient showing either a complete disease response, or a partial disease response of at least 6 months duration in a trial or treatment where the overall response rate is less than 10 percent.			Patient or Disabled Group	
C115626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115626>	C70799	Database Lock and Unlock Approval|DB LUL Approv	Records that confirm the completion and satisfaction of all the requirements for a database release.			Intellectual Product	CareLex eTMF Terminology
C115627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115627>	C42581	Clinical Trial Protocol Amendment Summary|Prot Amend|Protocol Amendment|Study Amendment Summary|Summary of Changes	A synopsis of changes to, or formal clarification of, a clinical study protocol.			Intellectual Product	CareLex eTMF Terminology|CDISC DDF Study Amendment Attribute Terminology|CDISC DDF Terminology|Clinical Data Interchange Standards Consortium Terminology
C115628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115628>	C207067	Clinical Study Protocol Synopsis Documentation|Prot Synop|Protocol Profile|Protocol Summary|Protocol Synopsis|Protocol Synopsis	Documentation summarizing the key points of the clinical study protocol.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Central Trial Documents Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115629>	C68836	Clinical Study Report Synopsis|CSR Synopsis|result synopsis	A summary of the results from the clinical study report.			Intellectual Product	CareLex eTMF Terminology|CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C11562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11562>	C61063	Doxorubicin/Pegaspargase/Prednisone/Vincristine|DOX/PEG-ASP/PRED/VCR			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115630>	C207070	TMF-RM Safety Documentation Section|Safe Docn Subcat|Safety Documentation|Safety Documentation Subcategory	The Trial Master File Reference Model section that contains a collection of documents related to the safety management and reporting for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Sections Terminology|Clinical Data Interchange Standards Consortium Terminology
C115631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115631>	C207067	Clinical Trial Safety Status Report Documentation|Trial Safe Stas Rept|Trial Safety Status Reporting Subcategory|Trial Status Reporting	Records detailing the standing of the clinical trial as it relates to safety concerns.			Intellectual Product	CareLex eTMF Terminology
C115632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115632>	C207070	TMF-RM Statistics Analysis Section|Analysis|Analysis Subcat|Analysis Subcategory	The Trial Master File Reference Model section that contains a collection of documents related to the statistical analysis of the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Sections Terminology|Clinical Data Interchange Standards Consortium Terminology
C115633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115633>	C19498	Analysis Quality Control Document|Analysis QC Docn|Analysis QC Documentation|Analysis Quality Control Documentation	Records of the quality control (QC) procedures planned for the analysis programs, and the outputs of said QC procedures.			Intellectual Product	CareLex eTMF Terminology
C115634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115634>	C70799	Approval for Database Activation Document|Approv DB Activn|Approval for Database Activation|Approval for Database Go Live|Database Release Approval	Records of the completion of all requirements for a database activation specification.			Intellectual Product	CareLex eTMF Terminology
C115635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115635>	C207067	Clinical Trial Biological Sample Import or Export Documentation|Sample Export Documentation|Sample Expt Docn|Sample Import or Export Documentation	Documentation pertaining to the importation or exportation of specimens for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Central and Local Testing Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115636>	C207070	TMF-RM Central Trial Documents Zone|CTrial Doc Cat|Central Trial Documents|Central Trial Documents Category	The Trial Master File Reference Model zone that contains the collection of documents relating to the clinical study protocol, investigator's brochure, key subject documentation and study reports for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Zones Terminology|Clinical Data Interchange Standards Consortium Terminology
C115637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115637>	C19498	Central Trial Documentation|CTrial Doc Comm Track Subcat|Central Trial Documents Communications and Tracking Subcategory	Records of communications, tracking documents, templates, and forms related to the central trial of a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115638>	C19498	Central Trial Tracking Document|CTrial Track|Tracking Document	Records of the central trial activities during the course of a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115639>	C19498	Centralized Testing Communication Document|Centralized Testing Communications|Centralz Test Comm|Correspondence|Relevant Communications	Records of communications related to a centralized test.			Intellectual Product	CareLex eTMF Terminology
C11563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11563>	C61063	Doxorubicin/Ifosfamide/Methotrexate/Muramyl Tripeptide Phosphatidylethanolamine Liposome|DOX/IFF/MTP-PE Liposome/MTX|Doxorubicin/Ifosfamide/Methotrexate/Muramyl Tripeptide Phosphatidylethanolamine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115640>	C19498	Centralized Testing Documentation|Centralized Testing Communications and Tracking Subcategory|Centralz Test Comm Track|General Centralized Testing documents otherwise unspecified	Records containing information related to a centralized test.			Intellectual Product	CareLex eTMF Terminology
C115641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115641>	C19498	Centralized Testing Tracking Document|Centralz Test Doc|Tracking Document	Records pertaining to activities logged during a centralized test.			Intellectual Product	CareLex eTMF Terminology
C115642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115642>	C207070	TMF-RM Central and Local Testing Zone|Central and Local Testing|Centralized Testing Category|Centralz Test Cat	The Trial Master File Reference Model zone that contains the collection of documents relating to testing vendors and sample management, including central and local testing facilities for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Zones Terminology|Clinical Data Interchange Standards Consortium Terminology
C115643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115643>	C207070	TMF-RM Data Capture Section|DC Subcat|Data Capture|Data Capture Subcategory	The Trial Master File Reference Model section that contains a collection of documents related to data capture for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Sections Terminology|Clinical Data Interchange Standards Consortium Terminology
C115644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115644>	C207067	Clinical Trial Adjudication Committee Document|Adju Cmte|Adjudication Committee Document|End Point Committee Document	Records describing the Adjudication Committee's evaluation process of key events in a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115645>	C207070	TMF-RM Facility Documentation Section|Facility Documentation|Facility Documentation Subcategory|Faclty Docn Subcat	The Trial Master File Reference Model section that contains a collection of documents related to the testing facilities participating in the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Sections Terminology|Clinical Data Interchange Standards Consortium Terminology
C115646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115646>	C207067	Clinical Trial Core Documentation|Core Trial Doc Subcat|Core Trial Documents Subcategory|Trial Documents	Records pertaining to the core trial of a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115647>	C207067	Clinical Trial Dose Escalation Document|Dose Esc|Dose Escalation Documents	Records detailing the correspondence and decisions regarding dose escalation during a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115648>	C207067	Clinical Trial Financial Documentation|Finan Doc|Financial Documentation|Financial Documentation	Documentation containing information pertaining to the finances of the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115649>	C207067	Clinical Trial Indemnity Documentation|Indemnity|Indemnity|Indemnity	Documentation certifying legal protection in the event of any unforeseen adverse circumstance arising during the course of the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C11564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11564>	C61063	Detox-B Adjuvant/Keyhole Limpet Hemocyanin/Sialyl Tn Antigen			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115650>	C207067	Clinical Trial Independent Data Monitoring Committee Charter|DSMB Charter|Data Monitoring Committee|Data Safety Monitoring Board (DSMB) Charter|DataMonitoringCommitteeCharterVersion|IDMC Chart|IDMC Charter|Independent Data Monitoring Committee Charter	Records describing the purpose and operation of the Independent Data Monitoring Committee (IDMC).			Intellectual Product	BRIDG Class Terminology|BRIDG Terminology|CareLex eTMF Terminology
C115651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115651>	C207067	Clinical Trial Insurance Documentation|Ins|Insurance|Insurance	Documentation confirming appropriate insurance coverage is available for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Central Trial Documents Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115652>	C207070	TMF-RM Interactive Response Technology Section|IRT|IRT Subcat|IVR|IVRT|IWR|IWRT|Interactive Response Technology|Interactive Response Technology Subcategory|Interactive Voice Response Technology|Interactive Web Response Technology	The Trial Master File Reference Model section that contains a collection of documents related to the interactive response technology used for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Sections Terminology|Clinical Data Interchange Standards Consortium Terminology
C115653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115653>	C207067	Clinical Trial Interfacility Standardization Methods Documentation|IFSM|Interfacility Standardization Methods|Interlaboratory Comparison Testing|Proficiency Testing|Standardization Methods	Documentation confirming the ability of two or more testing facilities to achieve consistent results when performing the same test or procedure for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Central and Local Testing Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115654>	C207067	Clinical Trial Investigator Site Documentation|Investigator Documents Subcategory|Invstgr Doc Subcat|Site Set-up Documentation	Records pertaining to an investigator site in a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115655>	C207070	TMF-RM Sample Documentation Section|Lab Sample Detl|Laboratory Sample Details Subcategory|Sample Documentation|Sample Documentation	The Trial Master File Reference Model section that contains a collection of documents related to the management of the samples collected for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Sections Terminology|Clinical Data Interchange Standards Consortium Terminology
C115656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115656>	C207067	Clinical Trial Management Communication and Tracking Document|General Trial Management Documents|Trial Management Documents Communications and Tracking Subcategory|Trial Mgmt Doc Comm Track	Records pertaining to the management and tracking of a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115657>	C207067	Clinical Trial Management Communication Documentation|Correspondence|Relevant Communications|Trial Management Communications|Trial Mgmt Comm	Records detailing communications, agreements, significant discussions, or relevant information related to clinical trial management.			Intellectual Product	CareLex eTMF Terminology
C115658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115658>	C207067	Clinical Trial Management Tracking Documentation|Tracking Document|Trial Management Tracking Documents|Trial Mgmt Track	Records detailing the progress of clinical trial activities.			Intellectual Product	CareLex eTMF Terminology
C115659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115659>	C207067	Clinical Trial Team Details Documentation|Members List|Team Roster|Team Structure|Trial Team Details|Trial Team Details|Trial Team Log|Trial Team Roles and Responsibilities|Trial Tm Detl	Documentation defining the structure, roles and contact details of the clinical trial team (both sponsor and vendors).			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Trial Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C11565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11565>	C61063	Keyhole Limpet Hemocyanin/QS21/Sialyl Tn Antigen|KLH/QS21/STn Antigen			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115660>	C207070	TMF-RM Non-IP Documentation Section|Non-IP Docn|Non-IP Documentation|Non-IP Documentation Subcategory|Non-Investigational Product Documentation	The Trial Master File Reference Model section that contains a collection of documents related to the management of non-investigational product(s) for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Sections Terminology|Clinical Data Interchange Standards Consortium Terminology
C115661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115661>	C207074	Clinical Trial Non-Investigational Product Supplies Documentation of Return|Non-IP Docn Return|Non-IP Documentation of Return|Non-IP Return Documentation|Non-Investigational Product Documentation of Return	Documentation providing information regarding the return of the non-investigational product(s) and supplies for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IP and Trial Supplies Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115662>	C207067	Clinical Trial Regulatory Notification of Termination or Closure Documentation|Notification of Discontinuation of Clinical Trial|Reg Notf Trial Termin|Regulatory Notification of Trial Termination|Regulatory Notification of Trial Termination	Documentation detailing the communications to regulatory authorities regarding the termination or closure of the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Regulatory Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115663>	C207067	Clinical Trial Notification to Investigators of Safety Information Documentation|Notf Invstgr Safe Info|Notification to Investigators of Safety Information|Notification to Investigators of Safety Information|SUSAR Notification|Safety Letter	Documentation verifying distribution and receipt of the communications related to the safety of the clinical trial to the investigators.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115664>	C207067	Clinical Study Protocol Deviation Documentation|Deviation Log|Prot Deviate|Protocol Deviation Report|Protocol Deviations|Protocol Deviations|Protocol Violation	Documentation detailing any non-compliance or deviations from the clinical study protocol.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115665>	C207070	TMF-RM Trial Regulatory Approval Section|Trial Approv Subcat|Trial Approval|Trial Approval Subcategory	The Trial Master File Reference Model section that contains a collection of documents related to the regulatory trial approval for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Sections Terminology|Clinical Data Interchange Standards Consortium Terminology
C115666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115666>	C207067	Clinical Trial Regulatory Tracking Document|Reg Track Doc|Regulatory Tracking Document|Tracking Document	Records that track the regulatory activities during the course of a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115667>	C207070	TMF-RM Safety Reporting Zone|Safe Rept Cat|Safety Reporting|Safety Reporting Category	The Trial Master File Reference Model zone that contains the collection of documents relating to safety and pharmacovigilance management for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Zones Terminology|Clinical Data Interchange Standards Consortium Terminology
C115668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115668>	C207073	Clinical Trial Site Feasibility Documentation|Feas Doc|Feasibility Documentation|Feasibility Documentation|Site Selection Documentation	Documentation describing site feasibility for the clinical study protocol.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115669>	C207070	TMF-RM Site Initiation Section|Site Init Subcat|Site Initiation|Site Initiation Subcategory	The Trial Master File Reference Model section that contains a collection of documents related to site initiation for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Sections Terminology|Clinical Data Interchange Standards Consortium Terminology
C11566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11566>	C61063	Cyclophosphamide/Doxorubicin/Monoclonal Antibody HER2|CTX/DOX/MOAB HER2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115670>	C207073	Clinical Trial Site Management Tracking Document|Site Management Tracking Document|Site Mgmt Track Doc|Tracking Document	Records that track the site management activities during the course of a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115671>	C207073	Clinical Trial Site Personnel Contact Detail Documentation|Site Contact Details|Site Contact Details|Study Site Pers Detl|Study Site Personnel Details	Documentation detailing the contact information of the clinical trial site personnel.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115672>	C207070	TMF-RM Site Selection Section|Site Select Mgmt|Site Selection|Site Selection Subcategory	The Trial Master File Reference Model section that contains a collection of documents related to site selection for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Sections Terminology|Clinical Data Interchange Standards Consortium Terminology
C115673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115673>	C207073	Clinical Trial Site Task Assignment Documentation|Delegation of Authority|Site Sig Sheet|Site Signature Sheet|Site Signature Sheet	Documentation tracking the task delegation made by the principal investigator to the site personnel conducting the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115674>	C207073	Clinical Trial Site Training Completion Documentation|Site Evidence of Training|Site Traing Docn|Site Training Documentation|Training completion documentation	Documentation verifying the completion of training of the clinical trial site personnel.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115675>	C207071	Clinical Trial Subject Document Form|Subj Doc Form Subcat|Subject Document Forms Subcategory	Records used to document data on a specific trial subject.			Intellectual Product	CareLex eTMF Terminology
C115676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115676>	C207074	Clinical Trial Supply Storage Condition Document|Storage Condition Documentation|Trial Supl Stor Condit|Trial Supply Storage Conditions	Records that contain the description of the setting and circumstances for storing supplies used in a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115677>	C207070	TMF-RM IP Storage Section|Storage|Supply Storage|Trial Supl Stor|Trial Supply Storage Subcategory	The Trial Master File Reference Model section that contains a collection of documents related to the storage of the investigational product(s) and trial supplies for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Sections Terminology|Clinical Data Interchange Standards Consortium Terminology
C115678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115678>	C207074	Clinical Trial Supply Storage Excursion Document|Storage Condition Excursion Documentation|Trial Supl Stor Condit Excur|Trial Supply Storage Condition Excursions	Records that describe deviations from the clinical trial supply storage plan.			Intellectual Product	CareLex eTMF Terminology
C115679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115679>	C19498	Data Definitions for Analysis Dataset Document|Data Definitions for Analysis Datasets|Data Defs Subcat	Records that define and describe the programming logic required to transform a raw dataset to an analysis dataset.			Intellectual Product	CareLex eTMF Terminology
C115680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115680>	C19498	Data Management Communication Document|Correspondence|DM Comm|Data Management Communications|Relevant Communications	Records of communications pertaining to data management.			Intellectual Product	CareLex eTMF Terminology
C115681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115681>	C19498	Data Management Document|Data Management Communications and Tracking Subcategory|Data Mgmt Comm Trk SubCat	Records pertaining to data management.			Intellectual Product	CareLex eTMF Terminology
C115682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115682>	C207070	TMF-RM Data Management Zone|DM Cat|Data Management|Data Management Category	The Trial Master File Reference Model zone that contains the collection of documents relating to data management activities for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Zones Terminology|Clinical Data Interchange Standards Consortium Terminology
C115683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115683>	C207070	TMF-RM Data Management Oversight Section|DM Ovrsgt Subcat|Data Management|Data Management Oversight|Data Management Oversight Subcategory	The Trial Master File Reference Model section that contains a collection of documents related to data management oversight for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Sections Terminology|Clinical Data Interchange Standards Consortium Terminology
C115684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115684>	C19498	Data Management Tracking Document|DM Track Doc|Tracking Document	Records pertaining to any activities logged that relate to data management during the course of a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115685>	C19498	Data Validation Certification Document|DVC|Data Validation Certification|EDC UAT Sign Off|EDC Validation Certification	Records pertaining to the certification by an authorized accrediting body confirming the successful implantation, and accurate functionality of a data validation program.			Intellectual Product	CareLex eTMF Terminology
C115686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115686>	C19498	Data Validation Test Document|DVT|Data Validation Database Specification QC|Data Validation Testing|Edit Check Validation	Records pertaining to the completion of a data validation test.			Intellectual Product	CareLex eTMF Terminology
C115687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115687>	C207067	Clinical Trial System Account Management Documentation|DB Acct Mgmt|Database Account Management|System Account Management	Documentation providing the account management details for users who require access to a system for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Data Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115688>	C207070	TMF-RM Database Section|DB Subcat|Database|Database Subcategory	The Trial Master File Reference Model section that contains a collection of documents related to the database used for the Electronic Data Capture system for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Sections Terminology|Clinical Data Interchange Standards Consortium Terminology
C115689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115689>	C207070	TMF-RM EDC Management Section|EDC Management|EDC Management Subcategory|EDC Mgmt Subcat|Electronic Data Capture Management	The Trial Master File Reference Model section that contains a collection of documents related to the management of the Electronic Data Capture system for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Sections Terminology|Clinical Data Interchange Standards Consortium Terminology
C11568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11568>	C61063	Fluorouracil/Levamisole/Monoclonal Antibody 17-1A|5-FU/LEV/MOAB 17-1A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115690>	C207067	Clinical Trial Vendor Qualification and Compliance Documentation|Audit Certificate|Documentation of Decision to Utilize Third Party|ECC|Evidence of Contractor Compliance|Qualification and Compliance|Qualification of Vendor	Documentation confirming that a vendor meets all criteria to fulfill a contractual obligation for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Vendor Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115691>	C207070	TMF-RM Institutional Review Board or Independent Ethics Committee and Other Approvals Zone|General IRB/IEC|IRB or IEC and Other Approvals|IRB-IEC Comm Cat|IRB-IEC Sponsor Communication Category|IRB/IEC and other Approvals|Institutional Review Board - Independent Ethics Committee	The Trial Master File Reference Model zone that contains the collection of documents relating to the interactions with the Institutional Review Board (IRB)/Independent Ethics Committee (IEC), including submissions, decisions, acknowledgments, and oversight information about the IRB/IEC for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Zones Terminology|Clinical Data Interchange Standards Consortium Terminology
C115692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115692>	C207072	Institutional Review Board - Independent Ethics Committee Tracking Document|IRB-IEC Track Doc|IRB-IEC Tracking Document|Tracking Document	Records maintained by the regulatory affairs staff or designee, that track the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) activities during the course of a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115693>	C207072	Institutional Review Board Independent Ethics Committee Additional Subject Information Document|IRB-IEC Approved Other Subject Information|Institutional Review Board Independent Ethics Committee Approved Other Subject Information|Other Written Information Given to Subjects|Subj Other	Records by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) that provide a subject with additional information regarding to requirements or concepts of a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115694>	C207072	Institutional Review Board Independent Ethics Committee Composition Documentation|Assurance Number|IRB Membership List|IRB Roster|IRB or IEC Composition|IRB-IEC Comp|IRB-IEC Composition|IRB/IEC Composition|Institutional Review Board Independent Ethics Committee Composition|Reviewer Participant List	Documentation pertaining to the membership of the Institutional Review Board or Independent Ethics Committee regarding their qualifications and experience to review and evaluate the science, medical aspects, and ethics of the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IRB or IEC and Other Approvals Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115695>	C207072	Institutional Review Board Independent Ethics Committee Documentation of Non-Voting Status|IRB or IEC Documentation of Non-Voting Status|IRB-IEC Docn noVote|IRB-IEC Documentation of Non-Voting Status|IRB/IEC Documentation of Non-Voting Status|Institutional Review Board Independent Ethics Committee Documentation of Non-voting Status	Documentation verifying investigator, sub-investigator, or other party of the clinical trial has not voted, if they are members of the Institutional Review Board or Independent Ethics Committee.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IRB or IEC and Other Approvals Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115696>	C207070	TMF-RM IRB or IEC Trial Approval Section|IRB or IEC Trial Approval|IRB-IEC Doc Subcat|IRB-IEC Documents Subcategory|IRB/IEC Trial Approval|Institutional Review Board Independent Ethics Committee Documents	The Trial Master File Reference Model section that contains a collection of documents related to the Institutional Review Board or Independent Ethics Committee decisions for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Sections Terminology|Clinical Data Interchange Standards Consortium Terminology
C115697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115697>	C207072	Institutional Review Board Independent Ethics Committee Informed Consent Document|Assent Template|IRB-IEC Approved Informed Consent|IRB-IEC IC|Informed Consent Template|Institutional Review Board Independent Ethics Committee Approved Informed Consent	Records approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC), explaining study information to assist study volunteers in understanding the expectations and requirements of trial participation.			Intellectual Product	CareLex eTMF Terminology
C115698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115698>	C207072	Institutional Review Board Independent Ethics Committee Notification of Safety Information Documentation|Notf IRB-IEC Safe Info|Notification to IRB or IEC of Safety Information|Notification to IRB-IEC of Safety Information|Notification to Institutional Review Board Independent Ethics Committee of Safety Information|Notification to Regulatory Authority of Safety/Trial Information|Safety Report	Documentation submitted to the Institutional Review Board or Independent Ethics Committee detailing the safety of subjects in the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IRB or IEC and Other Approvals Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115699>	C207072	Institutional Review Board Independent Ethics Committee Notification of Trial Termination or Closure Documentation|IRB or IEC Notification of Trial Termination|IRB-IEC Notf Termin|IRB-IEC Notification of Trial Termination|IRB/IEC Notification of Trial Termination|Institutional Review Board Independent Ethics Committee Notification of Trial Termination|Notification of Discontinuation of Clinical Trial	Documentation detailing the communications to the Institutional Review Board or Independent Ethics Committee regarding the termination or closure of the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IRB or IEC and Other Approvals Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C11569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11569>	C61063	Monoclonal Antibody C225/Paclitaxel|MOAB C225/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1156>	C776	Megestrol Acetate|(9beta,10alpha)-17-(Acetyloxy)-6-methylpregna-4,6-diene-3,20-dione|17 Alpha-acetoxy-6-methylpregna-4,6-diene-3,20-dione|17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione Acetate|17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate|17.alpha.-Acetoxy-6-methylpregna-4,6-diene-3,20-dione|6-Dehydro-6-methyl-17 alpha-acetoxyprogesterone|6-Dehydro-6-methyl-17.alpha.-acetoxyprogesterone|6-Methyl-6-dehydro-17.alpha.-acetoxyprogesterone|6-Methyl-delta-4,6-pregnadien-17 alpha-ol-3,20-dione Acetate|BDH 1298|BDH-1298|MEGESTROL ACETATE|Maygace|Megace|Megace|Megace|Megestat|Megestil|Niagestin|Niagestin|Ovaban|Ovaban|Pallace|SC 10363|SC-10363|SC-10363	The acetate salt form of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone with potential anti-estrogenic and antineoplastic activity. Mimicking the action of progesterone, megestrol acetate binds to and activates nuclear progesterone receptors in the reproductive system, and causes the ligand-receptor complex to be translocated to the nucleus where it binds to and promotes expression of target genes. This leads to an alteration in protein synthesis, which modulates cell growth of reproductive tissues. Due to the negative feedback mechanism seen with progesterone, megestrol also blocks luteinizing hormone (LH) release from the pituitary gland, thereby leading to an inhibition of ovulation and an alteration in the cervical mucus and endometrium. Furthermore, without stimulation of LH, estrogen release from the ovaries is stopped, hence impedes the growth of estrogen-sensitive tumor cells.	Megestrol Acetate		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C115700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115700>	C207072	Institutional Review Board Independent Ethics Committee Subject Information Document|IRB-IEC Approved Subject Information|Institutional Review Board Independent Ethics Committee Approved Subject Information|Subj Info Sheet|Subject Information Sheet	Records approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) that provides a subject with information about a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115701>	C207072	Institutional Review Board Independent Ethics Committee Subject Participation Document|IRB-IEC Approved Subject Participation|Institutional Review Board Independent Ethics Committee Approved Subject Participation|Subj Partic Card|Subject Participation Card	Records approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC), and used by a subject to record participation in a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115702>	C207070	TMF-RM Investigational Medicinal Product Section|Investigational Medicinal Product|Investigational Medicinal Product Subcategory|Invstgtl Med Prod Subcat	The Trial Master File Reference Model section that contains a collection of documents related to the regulatory import and/or export of investigational medicinal product(s) for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Sections Terminology|Clinical Data Interchange Standards Consortium Terminology
C115703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115703>	C207070	TMF-RM Investigational Products and Trial Supplies Zone|IP Trial Suppl Cat|IP and Trial Supplies|IP and Trial Supplies Category|Investigational Product and Trial Supplies	The Trial Master File Reference Model zone that contains the collection of documents relating to the management, shipping, storage, dispensing, and destruction of both Investigational Product(s) and supplies for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Zones Terminology|Clinical Data Interchange Standards Consortium Terminology
C115704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115704>	C19498	Investigational Product and Clinical Trial Supplies Tracking Document|General Investigational Product and Trial Supplies Tracking Document|IP Trial Suppl Track Doc|IP and Trial Supplies Tracking Document	Records that tracks the investigational product, and associated trial supplies, used during the course of the clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115705>	C207070	TMF-RM IP Documentation Section|IP Docn Subcat|IP Documentation|IP Documentation Subcategory|Investigational Product Documentation	The Trial Master File Reference Model section that contains a collection of documents related to the management of investigational product(s) and trial supplies for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Sections Terminology|Clinical Data Interchange Standards Consortium Terminology
C115706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115706>	C19498	Investigational Product Communications and Tracking Documentation|General Investigational Product Documents|IP Doc Comm Track|IP Documents Communications and Tracking Subcategory	Records pertaining to the tracking of, and communications about, the investigational product.			Intellectual Product	CareLex eTMF Terminology
C115707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115707>	C19498	Investigational Product Randomization Documentation|IP Allocation Documentation|IP Random Subcat|IP Randomization Subcategory|Investigational Product Randomization	Records pertaining to the blinding and randomization of an investigational product (IP) and supplies.			Intellectual Product	CareLex eTMF Terminology
C115708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115708>	C207074	Clinical Trial Investigational Product Regulatory Release Documentation|IP Reg Release|IP Regulatory Release|IP Regulatory Release Documentation|Investigational Product Regulatory Release	Documentation detailing the regulatory release of the investigational product(s) for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IP and Trial Supplies Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115709>	C207070	TMF-RM IP Release Process Documentation Section|IP Release Process|IP Release Process Documentation|IP Release Process Subcategory|Investigational Product Release Process	The Trial Master File Reference Model section that contains a collection of documents related to the release process of the investigational product(s) and trial supplies for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Sections Terminology|Clinical Data Interchange Standards Consortium Terminology
C115710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115710>	C207073	Investigational Product Clinical Trial Site Release Documentation|Authorization to Ship Clinical Trial Materials|Drug Release Document|Drug Shipment Approval|IP Site Release Doc|IP Site Release Documentation|IP Site Release Documentation|Investigational Product Site Release Documentation	Documentation approving the clinical trial site to receive a supply of investigational product(s).			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115711>	C207067	Investigator Brochure Acceptance Documentation|Accept Invstgr Broch|Acceptance of Investigator Brochure|Acceptance of Investigator Brochure|IB Receipt Confirmation|IB signature page|Investigator Brochure Acceptance	Documentation confirming the receipt of the investigator brochure at the clinical trial site.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115712>	C19498	Laboratory Certification Document|Certification or Accreditation|Lab Cert|Laboratory Certification|Qualifications	Official records indicating the competence of a laboratory to participate in a given clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115713>	C207073	Local Laboratory Certification or Accreditation Document|Lab Qualifications|Local Laboratory Certification or Accreditation|Locl Lab Certn Accred	Official records of certification by an accredited body that recognizes the competence of a local laboratory to participate in a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115714>	C207067	Clinical Trial Medical Dictionary Coding Documentation|Dictionary Coding|Dictionary Coding|Dictionary Coding|Medical Coding	Documentation describing the process and tools used in the medical coding for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Data Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115715>	C19498	Medical Imaging and Imaging Technique Documentation|Imaging Cat|Medical Imaging Category	Records detailing the proper use of digital medical images, and digital imaging techniques for the capture and interpretation of data in a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115716>	C19498	Non-Institutional Review Board Independent Ethics Committee Approved Submission Document|Subm Non-IRB-IEC|Submissions Non-IRB-IEC Committees	Records that describe the changes and/or updates made to a clinical trial, and are submitted for approval to a committee other than the Institutional Review Board (IRB)/Independent Ethics Committee (IEC).			Intellectual Product	CareLex eTMF Terminology
C115717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115717>	C207067	Clinical Trial Notification of Regulatory Identification Number Documentation|Notf Reg ID Num|Notification of Regulatory Identification Number|Notification of Regulatory Identification Number	Documentation of the unique identification number assigned by a regulatory authority used to identify the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Regulatory Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115718>	C207067	Clinical Study Protocol Amendment Signature Page Documentation|Amendment Signature Page|Prot Amend Sig Pg|Protocol Amendment Signature Page|Protocol Amendment Signature Page|Signature Page	Documentation signed by investigators confirming the agreement of the clinical trial site to follow the amendments to the clinical study protocol.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115719>	C207067	Clinical Study Protocol Signature Page Documentation|Investigator Protocol Acknowledgement|Prot Sig Pg|Protocol Signature Page|Protocol Signature Page|Signature Page	Documentation signed by investigators confirming the agreement of the clinical trial site to follow the clinical study protocol.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C11571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11571>	C226421	GM2-KLH Vaccine/QS21|GM2-KLH/QS-21|GM2-KLH/QS21|GMK	A cancer vaccine based on the immunogenic ganglioside GM2, The GM2-KLH Vaccine/QS21 vaccine consists of GM2 conjugated with KLH keyhole limpet hemocyanin (KLH), a potent immunostimulant, and is admixed with the adjuvant QS21, a saponin fraction extracted from the bark of the South American tree Quillaja saponaria Molina. GM2 is a cell surface carbohydrate antigen expressed by most melanoma cells and various other tumor cell types. (NCI04)			Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C115720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115720>	C207074	Clinical Trial Qualified Person Investigational Product Certification Documentation|QP (Qualified Person) Certification|QP (Qualified Person) Certification|QP Certification|Qual Person Cert|Qualified Person Certification	Documentation from a Qualified Person confirming that the investigational product(s) for the clinical trial have been manufactured according to Good Manufacturing Processes.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IP and Trial Supplies Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115721>	C19498	Radiography Study File|RAD|Radiography Subcategory|X-ray	Records pertaining to radiographic files.			Intellectual Product	CareLex eTMF Terminology
C115722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115722>	C207070	TMF-RM Randomization Section|Randomiz|Randomization|Randomization Record|Randomization Subcategory	The Trial Master File Reference Model section that contains a collection of documents related to the randomization scheme for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Sections Terminology|Clinical Data Interchange Standards Consortium Terminology
C115723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115723>	C207070	TMF-RM Regulatory Zone|Reg Docn Cat|Regulatory|Regulatory Affairs|Regulatory Documentation Category	The Trial Master File Reference Model zone that contains the collection of documents relating to the interactions with regulatory authorities, including submissions, decisions, notifications, and registrations for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Zones Terminology|Clinical Data Interchange Standards Consortium Terminology
C115724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115724>	C19498	Regulatory Documentation Not Other Wise Specified|Reg Doc Comm Track Subcat|Regulatory Documentation Communications and Tracking Subcategory	Records of regulatory communications, tracking records, and documents not otherwise specified.			Intellectual Product	CareLex eTMF Terminology
C115725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115725>	C207067	Clinical Trial Safety and Clinical Database Reconciliation Documentation|SAE Data Reconciliation|SAE Reconciliation|SAE Reconciliation|Serious Adverse Event Data Reconciliation	Documentation verifying that the safety database is consistent with the clinical trial database.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Data Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115726>	C19498	Safety Communication Document|Correspondence|Relevant Communications|Safe Comm|Safety Communications	Records containing information related to a safety report of a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115727>	C19498	Safety Reporting Documentation|General|Safe Rept Comm Track|Safety Reporting Communications and Tracking Subcategory	Records pertaining to the timely report of safety information in a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115728>	C19498	Safety Tracking Document|Safe Track Doc|Tracking Document	Records used to track activities related to safety reporting during the course of a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115729>	C19498	Statistics Communication and Tracking Documentation|Gen Stats Comm Track Subcat|Statistics Communication and Tracking Subcategory	Records pertaining to statistics communication and tracking used in a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C11572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11572>	C61063	Interferon Alfa/Bexarotene|Bexarotene/Interferon Alfa|IFN-A/LGD 1069|interferon alfa/LGD 1069			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115730>	C19498	Statistic Tracking Document|Statistics Tracking Document|Stats Track Doc|Tracking Document	Records used to track statistics during the course of a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115731>	C19498	Statistics Communication Document|Correspondence|Relevant Communications|Statistics Communications|Stats Comm	Records pertaining to communications about statistics used in a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115732>	C207070	TMF-RM Statistics Zone|Statistics|Statistics Category|Stats Cat	The Trial Master File Reference Model zone that contains the collection of documents relating to biostatistics and statistical programming activities for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Zones Terminology|Clinical Data Interchange Standards Consortium Terminology
C115733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115733>	C207070	TMF-RM Statistics Oversight Section|Statistics Oversight|Statistics Oversight Subcategory|Stats Ovrsgt Subcat	The Trial Master File Reference Model section that contains a collection of documents related to the statistics oversight for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Sections Terminology|Clinical Data Interchange Standards Consortium Terminology
C115734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115734>	C207067	Clinical Trial Public Registration Documentation|Public Registration|Public Registration|Study Regis Docs|Study Registry Documents	Documentation pertaining to the registration of the clinical trial in public registries.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Regulatory Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115735>	C207067	Clinical Trial Subject Evaluability Criteria and Subject Classification Documentation|Deviations and Exemptions|Population Definition Criteria|Protocol Deviation Listing|Protocol Violations|Subj Eval Crit|Subject Evaluability Criteria and Subject Classification|Subject Evaluability Criteria and Subject Classification|Subject Evaluability Criteria and Subject Classification	Documentation detailing the decisions that define the criteria used to evaluate and assign subjects to a population group, which are established by the statistical analysis plan of the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Statistics Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115736>	C207067	Clinical Trial Other Committees Decisions Documentation|Other Approv|Other Approvals|Other Approvals	Documentation detailing the decisions made by other committee(s) related to the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IRB or IEC and Other Approvals Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115737>	C207073	Clinical Trial Site Additional Monitoring Activity Documentation|Additional Monitoring Activity|Supplementary Monitoring Activity|Suppmt Mon Actv	Documentation of additional clinical trial site monitoring activities.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115738>	C19498	Supplies and Non-Drug Investigational Product Import Document|Lab Safe Impt Doc|Lab Supply Import Documentation	Records of the import of laboratory supplies, or a non-drug investigational product (IP).			Intellectual Product	CareLex eTMF Terminology
C115739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115739>	C207073	Unselected Clinical Trial Site Documentation|Investigators not used|SENS|Sites Evaluated but not Selected|Sites Evaluated but not Selected	Documentation pertaining to potential clinical trial sites that were evaluated, but not selected, for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C11573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11573>	C61063	Cyclophosphamide/Epirubicin/Monoclonal Antibody HER2|CTX/EPI/MOAB HER2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115740>	C19498	Unspecified non-Independent Data Monitoring Committee Document|Non-IDMC Trial Committee Documents Unspecified|Other non-Independent Data Monitoring Committee Document|non-IDMC Cmte Doc	Records pertaining to committees aside from the Independent Data Monitoring Committee.			Intellectual Product	CareLex eTMF Terminology
C115741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115741>	C19498	Vendor Communication Documentation|Correspondence|Relevant Communications|Vend Comm|Vendor Communications	Records pertaining to vendor communications.			Intellectual Product	CareLex eTMF Terminology
C115742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115742>	C19498	Vendor Documentation|Vend Comm Track Subcat|Vendors Communications and Tracking Subcategory	Records pertaining to a specific vendor.			Intellectual Product	CareLex eTMF Terminology
C115743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115743>	C207070	TMF-RM Vendors Zone|Third Parties|Third parties|Vend Cat|Vendor|Vendors Category	The Trial Master File Reference Model zone that contains the collection of documents relating to the establishment, maintenance and oversight of relationships between sponsors and vendors for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Zones Terminology|Clinical Data Interchange Standards Consortium Terminology
C115744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115744>	C207070	TMF-RM Vendor Oversight Section|Third Party Oversight|Third Party Oversight|Vend Ovrsgt Subcat|Vendor Oversight Subcategory	The Trial Master File Reference Model section that contains a collection of documents related to vendor oversight for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Sections Terminology|Clinical Data Interchange Standards Consortium Terminology
C115745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115745>	C19498	Vendor Record Documentation|Third Party Set-up|Vend Records Subcat|Vendor Records Subcategory	Records detailing the relationship between a vendor and a clinical trial sponsor, or contract research organization (CRO).			Intellectual Product	CareLex eTMF Terminology
C115746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115746>	C19498	Vendor Role and Responsibility Document|Task Ownership Matrix|Technical Agreement|Transfer of Obligations|Transfer of Regulatory Obligation|Vend RR|Vendor Roles and Responsibilities	Records describing the tasks and responsibilities of a vendor in a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115747>	C207067	Clinical Trial Vendor Selection Documentation|Contractor Selection|Vend Selectn|Vendor Selection|Vendor Selection|Vendor Selection Documents	Documentation describing the identification and selection of a vendor for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Vendor Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115748>	C19498	Vendor Tracking Document|Tracking Document|Vend Track Doc	Records used to track activities pertaining to a vendor during the course of a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C115749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115749>	C207067	Case Report Form Annotation Guideline Documentation|Annot CRF|Annotated CRF|Annotated CRF|Annotated Case Report Form|CRF Completion Guidelines	Documentation describing the process to map and assign subject information collected on the case report form into the proper structure of a dataset for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Data Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C11574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11574>	C61063	Monoclonal Antibody HER2/Paclitaxel|MOAB HER2/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115750>	C207067	Case Report Form Guideline Documentation|CRF Completion Guidelines|CRF Completion Requirements|CRF Completion Requirements|CRF Completn Reqrt	Documentation providing the instruction for completing the case report form for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Data Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115751>	C17564	Data Entry Guideline|DE Guidelines|Data Entry Guidelines	Documentation describing the proper entry of data from a paper case report form (CRF) to a database.			Intellectual Product	CareLex eTMF Terminology
C115752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115752>	C207067	Clinical Trial Medical Monitoring Plan Documentation|Med Mon Plan|Medical Monitoring Plan|Medical Monitoring Plan	Documentation describing the medical surveillance of subjects during the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Trial Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115753>	C207067	Clinical Trial Monitoring Plan Documentation|Mon Plan|Monitoring Data Plan|Monitoring Plan|Monitoring Plan	Documentation describing the strategy, methods, responsibilities, and requirements for monitoring the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Trial Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115754>	C207074	Clinical Trial Non-Investigational Product Supplies Plan Documentation|Non-IP Supl Plan|Non-IP Supply Plan|Non-IP Supply Plan|Non-Investigational Product Supply Plan	Documentation describing the supply management of the non-investigational product(s) and other supplies for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IP and Trial Supplies Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115755>	C207075	Clinical Trial Safety Management Plan Documentation|Safe Mgmt Plan|Safety Management Plan|Safety Management Plan|Safety Reporting Plan	Documentation describing the safety evaluation process for investigational product(s) during the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Safety Reporting Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115756>	C207067	Clinical Trial Data Management Plan Documentation|DM Plan|Data Management Operational Plan|Data Management Plan|Data Management Plan|Data Management Plan|Technology Plan	Documentation describing the overall data management process for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Data Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115757>	C25619	Database Quality Plan|DB QA Plan|Database QC/QA Plan & Results|QC/QA Database Documentation	A proposed method to define procedures for the creation and implementation of a quality control (QC) plan.			Intellectual Product	CareLex eTMF Terminology
C115758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115758>	C207074	Clinical Trial Investigational Product Recall Documentation|IP Recall Documentation|IP Recall Plan|IP Recall Plan|Investigational Product Recall Plan	Documentation detailing the recall of the investigational product(s) for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IP and Trial Supplies Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115759>	C207074	Clinical Trial Investigational Product Relabeling Documentation|IP Re-Labl Plan|IP Re-labeling Documentation|IP Re-labeling Plan|Investigational Product Re-labeling Plan	Documentation detailing the re-labeling of the investigational product(s) for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IP and Trial Supplies Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C11575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11575>	C61063	Fluorouracil/Leucovorin Calcium/Monoclonal Antibody 17-1A|CF/5-FU/MOAB 17-1A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115760>	C207074	Clinical Trial Investigational Product Supply Plan Documentation|Clinical Trial Material Distribution Plan|IP Suppl Plan|IP Supply Plan|IP Supply Plan|Investigational Product Supply Plan|Trial Medication Plan	Documentation describing the supply management of the investigational product(s) for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IP and Trial Supplies Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115761>	C207067	Clinical Trial Statistical Analysis Plan Documentation|SA Plan|SAP|Statistical Analysis Plan|Statistical Analysis Plan|Statistical Analysis Plan	Documentation describing the statistical aspects of the clinical trial design; the process of data selection for analyses; the detailed analyses of data items; the procedures and methods employed for analyzing the data; the planned presentation of results in formats such as tables, listings, and figures.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Statistics Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115762>	C41184	Content Type Requirement|Requirement	A directive on whether a Content Type is necessary for a particular activity.			Functional Concept	CareLex eTMF Terminology
C115763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115763>	C223239	Transfusion Hemosiderosis|Transfusional Hemosiderosis	Accumulation of iron in internal organs that results from repeated blood transfusions.	Transfusion Hemosiderosis		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C115764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115764>	C207067	Clinical Trials Operational Procedure Manual Documentation|Operational Procedure Manual|Operational Procedure Manual|Ops Manual|Study Reference Manual|Work Instruction	Documentation describing clinical trial-related work processes.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Trial Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115765>	C207067	Clincial Trial Master File Plan Documentation|File plan|Filing instructions|Records Management Plan|TM File Plan TMF Plan|Trial Master File Plan|Trial Master File Plan	Documentation describing how clinical trial records are managed and stored during and after the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Trial Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115766>	C207070	TMF-RM Trial Management Zone|Trial Management|Trial Management Category|Trial Mgmt	The Trial Master File Reference Model zone that contains the collection of documents relating to the general design, management and oversight of the clinical trial.			Activity	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Zones Terminology|Clinical Data Interchange Standards Consortium Terminology
C115767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115767>	C173509	Current Medical Status Question|Current Medical Status|How would you describe your current medical status|How would you describe your loved one's current medical status	A question about a person's description of the patient's current medical status.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115768>	C173597	Likelihood of Cancer Cure Question|How likely do you think it is that you will be cured of cancer|How likely do you think it is that your loved one will be cured of cancer|Likelihood of Cancer Cure	A question about how likely a person thinks the patient's cancer cure will be.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115769>	C207067	Clinical Trial Recruitment Plan Documentation|Recruit Plan|Recruitment Plan|Recruitment Plan	Documentation describing the subject enrollment and recruitment goals during the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Trial Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C11576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11576>	C61063	UFT/Leucovorin|Orzel|UFT/LV|tegafur/uracil/leucovorin	Orzel, also called UFT, is an oral formulation of uracil (U) and Tegafur (FT), a prodrug that breaks down to 5-FU and releases it slowly.		Obsolete_Concept	Therapeutic or Preventive Procedure	
C115770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115770>	C176545	Wishes About Care if Dying Question|Has your loved one and their oncologist discussed any particular wishes about the care they would want to receive if they were dying|Have you and your oncologist discussed any particular wishes you have about the care you would want to receive if you were dying|Wishes About Care if Dying	A question about whether the patient has discussed with their oncologist the care they want to receive if they are dying.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115771>	C173812	Chosen Course of Treatment Question|Chosen Course of Treatment|Chosen course of treatment	A question about whether a patient would prefer treatment to prolong their life or reduce their discomfort.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115772>	C2959	Urinary Complication	Any disorder of the organs of the urinary system occurring as a consequence of injury to the urinary system.	Urinary Complication		Finding	CTRP Disease Terminology|CTRP Terminology
C115773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115773>	C173507	Prefer Not to Hear a Lot of Details Question|I prefer not to hear a lot of details|Prefer Not to Hear a Lot of Details|They prefer not to hear a lot of details	A question about whether a person would prefer not to hear a lot of details.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115774>	C173812|C173507	Prefer to Hear Details in Certain Situations Question|I want to hear details only in certain situations, such as when tests are abnormal or when treatment decisions need to be made|Prefer to Hear Details in Certain Situations|They want to hear details only in certain situations, such as when tests are abnormal or when treatment decisions need to be made	A question about whether a person would prefer to hear details only in certain circumstances.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115775>	C42581	Financial Disclosure Summary|FD Summary	A synopsis of financial disclosure information.			Intellectual Product	CareLex eTMF Terminology
C115776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115776>	C25619	Investigational Product Randomization Plan|IP Random Plan|IP Randomization Plan|Randomization envelopes|Treatment Allocation Documentation	A proposed method of allocation and randomization of each subject in an investigational product study.			Intellectual Product	CareLex eTMF Terminology
C115777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115777>	C207067	Clinical Trial Quality Assurance Plan Documentation|Joint Vendor Oversight Plan|QA Plan|Quality Plan|Quality Plan	Documentation describing the operational techniques and activities undertaken within the quality management system to verify that the requirements for quality of the clinical trial-related activities have been fulfilled.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Trial Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115778>	C207067	Clinical Trial Randomization Plan Documentation|Randomiz Plan|Randomization Plan|Randomization Plan	Documentation describing the details of the randomization scheme for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Statistics Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115779>	C207067	Clincial Trial Standard Operating Procedure List Documentation|List of SOPs Current During Trial|SOP|SOP List|SOPs|Standard Operating Procedures	Documentation describing the standard operating procedures used during the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Trial Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C11577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11577>	C61063	Epirubicin/Fluorouracil			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115780>	C207067	Clinical Trial Management Plan Documentation|Project Management Plan|TM Plan|Trial Management Plan|Trial Management Plan|Trial Mgmt Plan	Documentation describing the overall strategy for timelines, management and conduct of the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Trial Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115781>	C207073	Clinical Trial Site Communications and Tracking Management Documentation|Site Management Communications and Tracking Subcategory|Site Mgmt Comm Track	Records pertaining to the management of a clinical trial site.			Intellectual Product	CareLex eTMF Terminology
C115782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115782>	C207070	TMF-RM Site Management Zone|Site Management|Site Management Category|Site Mgmt	The Trial Master File Reference Model zone that contains the collection of documents relating to the selection, setup, initiation and management of the investigational sites as well as multi-site records and communications for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Zones Terminology|Clinical Data Interchange Standards Consortium Terminology
C115783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115783>	C207067	Clinical Trial Stakeholder Communication Plan Documentation|Comms Plan|Communication Plan|Communication Plan	Documentation describing the communication strategy between stakeholders of the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Trial Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C115784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115784>	C42883	Trial Master File|TMF|TMF|tmf|trial master file	A formalized system of organizing and storing paper documents, images and other physical assets in a filing system for clinical trials.			Manufactured Object	CareLex eTMF Terminology
C115785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115785>	C115784	Electronic Trial Master File|eTMF|eTMF|electronic TMF|electronic Trial Master File|electronic trial master file	A formalized system of organizing and storing digital content in an electronic record system.			Manufactured Object	CareLex eTMF Terminology
C115786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115786>	C50579	Perinephric Hematoma	A collection of blood around the kidney.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C115787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115787>	C28193	Vascular Access Steal Syndrome|Dialysis Access Steal Syndrome|Steal Syndrome	Shunting of blood flow from the arterial to the venous side of a hemodialysis access.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C115788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115788>	C50579	Subcapsular Renal Hematoma|Subcapsular Hematoma	A collection of blood between the renal capsule and the renal parenchyma.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C115789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115789>	C222260	6 Minute Walk Functional Test 2008 Version|6 Minute Walk Functional Test|6MWT|SIX MINUTE WALK|SIXMW1|Six Minute Walk 2008	A standardized rating scale developed by Bruno Blake in 1963, which is a performance-based evaluation of functional exercise capacity in subjects with chronic respiratory disease and heart failure, as well as other populations such as healthy older adults and people suffering from fibromyalgia and scleroderma. This functional test contains 6 items and measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface.	6 Minute Walk Functional Test		Intellectual Product	CDISC Functional Test Category Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C11578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11578>	C61063	gp100 Antigen/Incomplete Freund's Adjuvant/MART-1 Antigen/Tyrosinase Peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115790>	C222259	Hauser Ambulation Index Functional Test|HAI|HAI01|HAUSER AMBULATION INDEX	A standardized rating scale developed by Hauser et al in 1983 to assess mobility by evaluating the time and degree of assistance required to walk 25 feet. This functional test is scored from 0 (asymptomatic; fully active) to 9 (restricted to wheelchair; unable to transfer self independently).			Intellectual Product	CDISC Functional Test Category Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115791>	C222260	Nine-Hole Peg Functional Test|NHPT|NHPT|NHPT01	A standardized rating scale developed by Mathiowetz et al in 1985 to measure unilateral finger dexterity to determine the extent of fine motor impairment in people experiencing difficulties with functional performance. This functional test requires the use of both dominant and non-dominant hands, and assesses fine motor and hand/eye coordination, as well as ability to follow simple directions. Scoring of this test is based on the average of 4 trials.			Intellectual Product	CDISC Functional Test Category Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115792>	C222260	Paced Auditory Serial Addition Functional Test|PASAT|PASAT|PASAT1	A standardized rating scale developed by DMA Gronwall et al in 1977 to assess auditory information processing speed and flexibility, as well as calculation ability. It is also used as a cognitive function test to evaluate sustained and divided attention. The test involves the presentation of single digits every 3 seconds and a study subject must add each new digit to the one immediately prior to it. Scoring of this test is based on the total number correct out of 60 possible answers.			Intellectual Product	CDISC Functional Test Category Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115793>	C222259	Symbol Digit Modalities Functional Test|SDMT|SDMT|SDMT01	A standardized rating scale developed by Aaron Smith in 1982, which is used to identify individuals with neurological impairment, as well as to assess divided attention, visual scanning and motor speed. This functional test measures the time to pair abstract symbols with specific numbers with a 90 second time limit. Scoring of this test is based on the total number of correctly coded items from 0-110 in 90 seconds.			Intellectual Product	CDISC Functional Test Category Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115794>	C222260	Timed 25-Foot Walk Functional Test|T25FW|T25FW|T25FW1	A standardized rating scale developed to measure walking ability through gait speed. This functional test is a quantitative mobility and leg function performance test where a study subject is asked to walk 25 feet from a marked starting point. The time is calculated from the initiation to the end of walking when the patient has reached the 25-foot mark. Scoring of this test is based on the average of two completed trials.			Intellectual Product	CDISC Functional Test Category Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115795>	C222260	Timed Up and Go Functional Test|TUG|TUG|TUG01	A standardized rating scale developed by Mathias et al in 1986 which is used to test basic mobility skills in frail elderly persons and other populations such as people with arthritis, stroke, and vertigo. This functional test measures the time in seconds for a person to stand up from a standard armchair, walk 3 meters, turn, walk back to the chair, and sit down again. Scoring of this test is based on the average of multiple completed and timed trials.	Timed Up and Go Functional Test		Intellectual Product	CDISC Functional Test Category Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C115796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115796>	C118969	Disability Rating Scale Clinical Classification|DRS|DRS|DRS01	A standardized rating scale developed by Rappaport et al in 1982, which is used to measure general functional changes over the course of recovery in patients with moderate and severe traumatic brain injury (TBI). The questionnaire contains 8 questions and generates 4 subscales: arousability awareness and responsivity, cognitive ability for self-care activities, dependence on others and psychosocial adaptability.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115797>	C91105	Extended Glasgow Outcome Scale Questionnaire|GOS-E|GOSE|GOSE|GOSE1|Glasgow Outcome Scale (Extended)	A standardized rating scale originally developed by Jennett and Bondin in 1975 and later modified by Wilson et al in 1998, which is used to assess outcome after, and level of function in major life areas with head injury and non-traumatic acute brain insults. The questionnaire contains 23 items and generates 7 subscales: consciousness, independence in the home, independence outside the home, work, social and leisure activities, family and friendships, and epilepsy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115798>	C91105	Mayo-Portland Adaptability Inventory-4 Questionnaire|MPAI-4|MPAI-4|MPAI1	A standardized rating scale modified and revised by Muriel et al in 2005, which is used to measure global brain injury outcome and functional status of subjects in the post-acute period following acquired brain injury (ABI)/traumatic brain injury (TBI), as well as to evaluate rehabilitation programs providing services to people with brain injuries. The questionnaire contains 35 questions and generates 3 subscales: ability index, adjustment index, and participation index. This instrument is scored on a 5-point Likert scale.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115799>	C91105	Satisfaction With Life Scale Questionnaire|SWLS|SWLS|SWLS01	A standardized rating scale developed by Diener et al in 1985, which is used to measure global cognitive judgments of satisfaction with one's life. The questionnaire contains 5 questions and is scored ranging from 1 (Strongly disagree) to 7 (Strongly agree).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11579>	C61007	gp100 Antigen/Incomplete Freund's Adjuvant/Interleukin-2/MART-1 Antigen/Tyrosinase Peptide|gp100/IFA/IL-2/MART-1/TYRP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1157>	C1592	Recombinant GRO1 Protein|GRO Protein, Alpha|GRO1 Protein|MGSA|Melanoma Growth Stimulatory Activity|Neutrophil Activating Protein 3	A recombinant peptide chemically identical or similar to the endogenous alpha chemokine GRO1 (MGSA) protein. GRO1 protein belongs to a superfamily of proteins that includes interleukin-8 and platelet factor-4, beta-thromboglobulin (b-TG), IP-10, and ENA-78. It is chemotactic for neutrophils and plays a role in endothelial angiogenesis.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C115800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115800>	C115409	6MWT - Distance at 1 Minute|SIXMW1-Distance at 1 Minute|SIXMW1-Distance at 1 Minute|SIXMW101	6 Minute Walk Test (6MWT) Distance at 1 minute.			Intellectual Product	CDISC Functional Test 6MWT Test Code Terminology|CDISC Functional Test 6MWT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115801>	C115409	6MWT - Distance at 2 Minutes|SIXMW1-Distance at 2 Minutes|SIXMW1-Distance at 2 Minutes|SIXMW102	6 Minute Walk Test (6MWT) Distance at 2 minutes.			Intellectual Product	CDISC Functional Test 6MWT Test Code Terminology|CDISC Functional Test 6MWT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115802>	C115409	6MWT - Distance at 3 Minutes|SIXMW1-Distance at 3 Minutes|SIXMW1-Distance at 3 Minutes|SIXMW103	6 Minute Walk Test (6MWT) Distance at 3 minutes.			Intellectual Product	CDISC Functional Test 6MWT Test Code Terminology|CDISC Functional Test 6MWT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115803>	C115409	6MWT - Distance at 4 Minutes|SIXMW1-Distance at 4 Minutes|SIXMW1-Distance at 4 Minutes|SIXMW104	6 Minute Walk Test (6MWT) Distance at 4 minutes.			Intellectual Product	CDISC Functional Test 6MWT Test Code Terminology|CDISC Functional Test 6MWT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115804>	C115409	6MWT - Distance at 5 Minutes|SIXMW1-Distance at 5 Minutes|SIXMW1-Distance at 5 Minutes|SIXMW105	6 Minute Walk Test (6MWT) Distance at 5 minutes.			Intellectual Product	CDISC Functional Test 6MWT Test Code Terminology|CDISC Functional Test 6MWT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115805>	C115409	6MWT - Distance at 6 Minutes|SIXMW1-Distance at 6 Minutes|SIXMW1-Distance at 6 Minutes|SIXMW106	6 Minute Walk Test (6MWT) Distance at 6 minutes.			Intellectual Product	CDISC Functional Test 6MWT Test Code Terminology|CDISC Functional Test 6MWT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115806>	C115410	HAI - Ambulation Index|HAI01-Ambulation Index|HAI01-Ambulation Index|HAI0101	Hauser Ambulation Index (HAI) Ambulation index.			Intellectual Product	CDISC Functional Test HAI Test Code Terminology|CDISC Functional Test HAI Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115807>	C115411	NHPT - Time to Complete 9-Hole Peg Test|NHPT01-Time to Complete 9-Hole Peg Test|NHPT01-Time to Complete 9-Hole Peg Test|NHPT0101	Nine-Hole Peg Test (NHPT) Time in seconds to complete 9-Hole Peg Test.			Intellectual Product	CDISC Functional Test NHPT Test Code Terminology|CDISC Functional Test NHPT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115808>	C115411	NHPT - More Than Two Attempts|NHPT01-More Than Two Attempts|NHPT01-More Than Two Attempts|NHPT0102	Nine-Hole Peg Test (NHPT) Did it take more than two attempts to get two successful trials?			Intellectual Product	CDISC Functional Test NHPT Test Code Terminology|CDISC Functional Test NHPT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115809>	C115412	PASAT - Total Correct|PASAT1-Total Correct|PASAT1-Total Correct|PASAT101	Paced Auditory Serial Addition Test (PASAT) Total correct.			Intellectual Product	CDISC Functional Test PASAT Test Code Terminology|CDISC Functional Test PASAT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11580>	C61063	gp100 Antigen/Incomplete Freund's Adjuvant/Interleukin-12/MART-1 Antigen/Tyrosinase Peptide|gp100/IFA/IL-12/MART-1/TYRP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115810>	C115412	PASAT - Percent Correct|PASAT1-Percent Correct|PASAT1-Percent Correct|PASAT102	Paced Auditory Serial Addition Test (PASAT) Percent correct.			Intellectual Product	CDISC Functional Test PASAT Test Code Terminology|CDISC Functional Test PASAT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115811>	C115412	PASAT - More Than One Attempt|PASAT1-More Than One Attempt|PASAT1-More Than One Attempt|PASAT103	Paced Auditory Serial Addition Test (PASAT) Did it take more than one attempt to get one successful trial?			Intellectual Product	CDISC Functional Test PASAT Test Code Terminology|CDISC Functional Test PASAT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115812>	C115412	PASAT - Total Correct in First Half|PASAT1-Total Correct in First Half|PASAT1-Total Correct in First Half|PASAT104	Paced Auditory Serial Addition Test (PASAT) Total correct in first half.			Intellectual Product	CDISC Functional Test PASAT Test Code Terminology|CDISC Functional Test PASAT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115813>	C115412	PASAT - Total Correct in Second Half|PASAT1-Total Correct in Second Half|PASAT1-Total Correct in Second Half|PASAT105	Paced Auditory Serial Addition Test (PASAT) Total correct in second half.			Intellectual Product	CDISC Functional Test PASAT Test Code Terminology|CDISC Functional Test PASAT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115814>	C115412	PASAT - Total Commission Errors|PASAT1-Total Commission Errors|PASAT1-Total Commission Errors|PASAT106	Paced Auditory Serial Addition Test (PASAT) Total commission errors.			Intellectual Product	CDISC Functional Test PASAT Test Code Terminology|CDISC Functional Test PASAT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115815>	C115412	PASAT - Total Omission Errors|PASAT1-Total Omission Errors|PASAT1-Total Omission Errors|PASAT107	Paced Auditory Serial Addition Test (PASAT) Total omission errors.			Intellectual Product	CDISC Functional Test PASAT Test Code Terminology|CDISC Functional Test PASAT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115816>	C115413	SDMT - Total Score|SDMT01-Total Score|SDMT01-Total Score|SDMT0101	Symbol Digit Modalities Test (SDMT) Total score.			Intellectual Product	CDISC Functional Test SDMT Test Code Terminology|CDISC Functional Test SDMT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115817>	C115414	T25FW - Time to Complete 25-Foot Walk|T25FW1-Time to Complete 25-Foot Walk|T25FW1-Time to Complete 25-Foot Walk|T25FW101	Timed 25-Foot Walk (T25FW) Time in seconds to complete 25-foot walk.			Intellectual Product	CDISC Functional Test T25FW Test Code Terminology|CDISC Functional Test T25FW Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115818>	C115414	T25FW - More Than Two Attempts|T25FW1-More Than Two Attempts|T25FW1-More Than Two Attempts|T25FW102	Timed 25-Foot Walk (T25FW) Did it take more than two attempts to get two successful trials?			Intellectual Product	CDISC Functional Test T25FW Test Code Terminology|CDISC Functional Test T25FW Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115819>	C115415	TUG - Time to Complete TUG Test|TUG01-Time to Complete TUG Test|TUG01-Time to Complete TUG Test|TUG0101	Timed Up and Go (TUG) Time in seconds to complete TUG test.			Intellectual Product	CDISC Functional Test Terminology|CDISC Functional Test TUG Test Code Terminology|CDISC Functional Test TUG Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11581>	C61063	Incomplete Freund's Adjuvant/Interleukin-12/Tyrosinase Related Protein-1|Incomplete Freund's Adjuvant/Interleukin-12/Tyrosinase-Related Protein-1|Incomplete Freunds Adjuvant/Interleukin-12/Tyrosinase-Related Protein-1			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115820>	C115416	DRS - Eye Opening|DRS01-Eye Opening|DRS01-Eye Opening|DRS0101	Disability Rating Scale (DRS) Eye opening.			Intellectual Product	CDISC Clinical Classification DRS Test Code Terminology|CDISC Clinical Classification DRS Test Name Terminology|CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115821>	C115416	DRS - Communication Ability|DRS01-Communication Ability|DRS01-Communication Ability|DRS0102	Disability Rating Scale (DRS) Communication ability.			Intellectual Product	CDISC Clinical Classification DRS Test Code Terminology|CDISC Clinical Classification DRS Test Name Terminology|CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115822>	C115416	DRS - Motor Response|DRS01-Motor Response|DRS01-Motor Response|DRS0103	Disability Rating Scale (DRS) Motor response.			Intellectual Product	CDISC Clinical Classification DRS Test Code Terminology|CDISC Clinical Classification DRS Test Name Terminology|CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115823>	C115416	DRS - Feeding|DRS01-Feeding|DRS01-Feeding|DRS0104	Disability Rating Scale (DRS) Feeding (cognitive ability only).			Intellectual Product	CDISC Clinical Classification DRS Test Code Terminology|CDISC Clinical Classification DRS Test Name Terminology|CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115824>	C115416	DRS - Toileting|DRS01-Toileting|DRS01-Toileting|DRS0105	Disability Rating Scale (DRS) Toileting (cognitive ability only).			Intellectual Product	CDISC Clinical Classification DRS Test Code Terminology|CDISC Clinical Classification DRS Test Name Terminology|CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115825>	C115416	DRS - Grooming|DRS01-Grooming|DRS01-Grooming|DRS0106	Disability Rating Scale (DRS) Grooming (cognitive ability only).			Intellectual Product	CDISC Clinical Classification DRS Test Code Terminology|CDISC Clinical Classification DRS Test Name Terminology|CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115826>	C115416	DRS - Level of Functioning|DRS01-Level of Functioning|DRS01-Level of Functioning|DRS0107	Disability Rating Scale (DRS) Level of functioning (physical, mental, emotional or social function).			Intellectual Product	CDISC Clinical Classification DRS Test Code Terminology|CDISC Clinical Classification DRS Test Name Terminology|CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115827>	C115416	DRS - Employability|DRS01-Employability|DRS01-Employability|DRS0108	Disability Rating Scale (DRS) Employability (as a full time worker, homemaker, or student).			Intellectual Product	CDISC Clinical Classification DRS Test Code Terminology|CDISC Clinical Classification DRS Test Name Terminology|CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115828>	C115417	GOSE - Consciousness: Obey Simple Commands|GOSE1-Obey Simple Commands or Say Words|GOSE1-Obey Simple Commands or Say Words|GOSE101	Extended Glasgow Outcome Scale (GOSE) Is the head injured person able to obey simple commands, or say any words?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GOSE Test Code Terminology|CDISC Questionnaire GOSE Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115829>	C115417	GOSE - Independence in the Home: Assistance Essential for Daily Living|GOSE1-Daily Assistance at Home Essential|GOSE1-Daily Assistance at Home Essential|GOSE102A	Extended Glasgow Outcome Scale (GOSE) Is the assistance of another person at home essential every day for some activities of daily living?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GOSE Test Code Terminology|CDISC Questionnaire GOSE Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11582>	C61063	Cisplatin/Monoclonal Antibody C225|CDDP/MOAB C225			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115830>	C115417	GOSE - Independence in the Home: Need Frequent Help at Home|GOSE1-Need Frequent Help at Home|GOSE1-Need Frequent Help at Home|GOSE102B	Extended Glasgow Outcome Scale (GOSE) Do they need frequent help or someone to be around at home most of the time?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GOSE Test Code Terminology|CDISC Questionnaire GOSE Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115831>	C115417	GOSE - Independence in the Home: Assistance at Home Before Injury|GOSE1-Assistance at Home Before Injury|GOSE1-Assistance at Home Before Injury|GOSE102C	Extended Glasgow Outcome Scale (GOSE) Was assistance at home essential before the injury?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GOSE Test Code Terminology|CDISC Questionnaire GOSE Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115832>	C115417	GOSE - Independence Outside the Home: Able to Shop Without Assistance|GOSE1-Shop Without Assistance|GOSE1-Shop Without Assistance|GOSE103A	Extended Glasgow Outcome Scale (GOSE) Are they able to shop without assistance?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GOSE Test Code Terminology|CDISC Questionnaire GOSE Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115833>	C115417	GOSE - Independence Outside the Home: Able to Shop Without Assistance Before Injury|GOSE1-Shop Without Assist Before Injury|GOSE1-Shop Without Assist Before Injury|GOSE103B	Extended Glasgow Outcome Scale (GOSE) Were they able to shop without assistance before the injury?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GOSE Test Code Terminology|CDISC Questionnaire GOSE Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115834>	C115417	GOSE - Independence Outside the Home: Travel Locally Without Assistance|GOSE1-Travel Locally Without Assistance|GOSE1-Travel Locally Without Assistance|GOSE104A	Extended Glasgow Outcome Scale (GOSE) Are they able to travel locally without assistance?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GOSE Test Code Terminology|CDISC Questionnaire GOSE Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115835>	C115417	GOSE - Independence Outside the Home: Travel Locally Without Assistance Before Injury|GOSE1-Travel Without Assist Before Inj|GOSE1-Travel Without Assist Before Inj|GOSE104B	Extended Glasgow Outcome Scale (GOSE) Were they able to travel without assistance before the injury?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GOSE Test Code Terminology|CDISC Questionnaire GOSE Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115836>	C115417	GOSE - Work: Able to Work to Previous Capacity|GOSE1-Able to Work to Previous Capacity|GOSE1-Able to Work to Previous Capacity|GOSE105A	Extended Glasgow Outcome Scale (GOSE) Are they currently able to work to their previous capacity?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GOSE Test Code Terminology|CDISC Questionnaire GOSE Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115837>	C115417	GOSE - Work: How Restricted Are They|GOSE1-How Restricted Are They|GOSE1-How Restricted Are They|GOSE105B	Extended Glasgow Outcome Scale (GOSE) How restricted are they?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GOSE Test Code Terminology|CDISC Questionnaire GOSE Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115838>	C115417	GOSE - Work: Working or Seeking Employment Before the Injury|GOSE1-Working Before Injury|GOSE1-Working Before Injury|GOSE105C	Extended Glasgow Outcome Scale (GOSE) Were they either working or seeking employment before the injury (answer 'yes') or were they doing neither (answer 'no')?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GOSE Test Code Terminology|CDISC Questionnaire GOSE Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115839>	C115417	GOSE - Social and Leisure Activities: Resume Regular Social and Leisure Activities|GOSE1-Resume Social/Leisure Outside Home|GOSE1-Resume Social/Leisure Outside Home|GOSE106A	Extended Glasgow Outcome Scale (GOSE) Are they able to resume regular social and leisure activities outside home?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GOSE Test Code Terminology|CDISC Questionnaire GOSE Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11583>	C61063	Incomplete Freund's Adjuvant/Peptide 946-Tetanus Peptide Conjugate Melanoma Vaccine|IFA/p946/Tet p|Incomplete Freund's Adjuvant/Peptide 946 Melanoma Vaccine/Tetanus Peptide Melanoma Vaccine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115840>	C115417	GOSE - Social and Leisure Activities: Extent of Restriction on Social and Leisure Activities|GOSE1-Extent Social/Leisure Restriction|GOSE1-Extent Social/Leisure Restriction|GOSE106B	Extended Glasgow Outcome Scale (GOSE) What is the extent of restriction on their social and leisure activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GOSE Test Code Terminology|CDISC Questionnaire GOSE Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115841>	C115417	GOSE - Social and Leisure Activities: Engage Regular Social and Leisure Activities Before Injury|GOSE1-Engage Social/Leisure Before Inj|GOSE1-Engage Social/Leisure Before Inj|GOSE106C	Extended Glasgow Outcome Scale (GOSE) Did they engage in regular social and leisure activities outside home before the injury?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GOSE Test Code Terminology|CDISC Questionnaire GOSE Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115842>	C115417	GOSE - Family and Friendships: Disruptive Psychological Problems|GOSE1-Disruptive Psychological Problems|GOSE1-Disruptive Psychological Problems|GOSE107A	Extended Glasgow Outcome Scale (GOSE) Have there been psychological problems which have resulted in ongoing family disruption or disruption to friendships?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GOSE Test Code Terminology|CDISC Questionnaire GOSE Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115843>	C115417	GOSE - Family and Friendships: Extent of Disruption or Strain|GOSE1-Extent of Disruption|GOSE1-Extent of Disruption|GOSE107B	Extended Glasgow Outcome Scale (GOSE) What has been the extent of disruption or strain?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GOSE Test Code Terminology|CDISC Questionnaire GOSE Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115844>	C115417	GOSE - Family and Friendships: Problems with Family or Friends Before Injury|GOSE1-Family/Friends Probs Before Injury|GOSE1-Family/Friends Probs Before Injury|GOSE107C	Extended Glasgow Outcome Scale (GOSE) Were there problems with family or friends before the injury?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GOSE Test Code Terminology|CDISC Questionnaire GOSE Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115845>	C115417	GOSE - Return to Normal Life: Other Current Problems Relating to Injury|GOSE1-Other Problems Related to Injury|GOSE1-Other Problems Related to Injury|GOSE108A	Extended Glasgow Outcome Scale (GOSE) Are there any other current problems relating to the injury which affect daily life?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GOSE Test Code Terminology|CDISC Questionnaire GOSE Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115846>	C115417	GOSE - Return to Normal Life: Similar Problems Before Injury|GOSE1-Similar Problems Before Injury|GOSE1-Similar Problems Before Injury|GOSE108B	Extended Glasgow Outcome Scale (GOSE) Were similar problems present before the injury?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GOSE Test Code Terminology|CDISC Questionnaire GOSE Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115847>	C115417	GOSE - Epilepsy: Since Injury Any Epileptic Fits|GOSE1-Since Injury Any Epileptic Fits|GOSE1-Since Injury Any Epileptic Fits|GOSE109	Extended Glasgow Outcome Scale (GOSE) Since the injury has the head injured person had any epileptic fits?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GOSE Test Code Terminology|CDISC Questionnaire GOSE Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115848>	C115417	GOSE - Epilepsy: At Risk of Developing Epilepsy|GOSE1-At Risk of Developing Epilepsy|GOSE1-At Risk of Developing Epilepsy|GOSE110	Extended Glasgow Outcome Scale (GOSE) Have they been told that they are currently at risk of developing epilepsy?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GOSE Test Code Terminology|CDISC Questionnaire GOSE Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115849>	C115417	GOSE - Epilepsy: Most Important Factor in Outcome|GOSE1-Most Important Factor in Outcome|GOSE1-Most Important Factor in Outcome|GOSE111	Extended Glasgow Outcome Scale (GOSE) What is the most important factor in outcome?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GOSE Test Code Terminology|CDISC Questionnaire GOSE Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11584>	C61063	AG3340/Mitoxantrone/Prednisone|AG3340/DHAD/PRED			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115850>	C115417	GOSE - GOSE Overall Score|GOSE1-GOSE Overall Score|GOSE1-GOSE Overall Score|GOSE112	Extended Glasgow Outcome Scale (GOSE) Scoring: The patient's overall rating is based on the lowest outcome category indicated on the scale.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GOSE Test Code Terminology|CDISC Questionnaire GOSE Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115851>	C115418	MPAI-4 - Abilities: Mobility|MPAI1-Mobility|MPAI1-Mobility|MPAI101	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Mobility: Problems walking or moving; balance problems that interfere with moving about.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115852>	C115418	MPAI-4 - Abilities: Use of Hands|MPAI1-Use of Hands|MPAI1-Use of Hands|MPAI102	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Use of hands: impaired strength or coordination in one or both hands.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115853>	C115418	MPAI-4 - Abilities: Vision|MPAI1-Vision|MPAI1-Vision|MPAI103	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Vision: Problems seeing; double vision; eye; brain, or nerve injuries that interfere with seeing.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115854>	C115418	MPAI-4 - Abilities: Audition|MPAI1-Audition|MPAI1-Audition|MPAI104	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Audition: Problems hearing; ringing in the ears.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115855>	C115418	MPAI-4 - Abilities: Dizziness|MPAI1-Dizziness|MPAI1-Dizziness|MPAI105	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Dizziness: Feeling unsteady, dizzy, light-headed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115856>	C115418	MPAI-4 - Abilities: Motor Speech|MPAI1-Motor Speech|MPAI1-Motor Speech|MPAI106	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Motor speech: Abnormal clearness or rate of speech; stuttering.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115857>	C115418	MPAI-4 - Abilities: Verbal Communication|MPAI1-Verbal Communication|MPAI1-Verbal Communication|MPAI107A	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Verbal communication: Problems expressing or understanding language.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115858>	C115418	MPAI-4 - Abilities: Nonverbal Communication|MPAI1-Nonverbal Communication|MPAI1-Nonverbal Communication|MPAI107B	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Nonverbal communication: Restricted or unusual gestures or facial expressions; talking too much or not enough; missing nonverbal cues from others.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115859>	C115418	MPAI-4 - Abilities: Attention or Concentration|MPAI1-Attention/Concentration|MPAI1-Attention/Concentration|MPAI108	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Attention/Concentration: Problems ignoring distractions, shifting attention, keeping more than one thing in mind at a time.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11585>	C61063	QS21/Tn(c)-KLH Conjugate Vaccine|QS21/Tn(c)-KLH			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115860>	C115418	MPAI-4 - Abilities: Memory|MPAI1-Memory|MPAI1-Memory|MPAI109	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Memory: Problems learning and recalling new information.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115861>	C115418	MPAI-4 - Abilities: Fund of Information|MPAI1-Fund of Information|MPAI1-Fund of Information|MPAI110	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Fund of Information: Problems remembering information learned in school or on the job; difficulty remembering information about self and family from years ago.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115862>	C115418	MPAI-4 - Abilities: Novel Problem-Solving|MPAI1-Novel Problem-Solving|MPAI1-Novel Problem-Solving|MPAI111	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Novel problem-solving: Problems thinking up solutions or picking the best solution to new problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115863>	C115418	MPAI-4 - Abilities: Visuospatial Abilities|MPAI1-Visuospatial Abilities|MPAI1-Visuospatial Abilities|MPAI112	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Visuospatial abilities: Problems drawing, assembling things, route-finding, being visually aware on both the left and right sides.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115864>	C115418	MPAI-4 - Adjustment: Anxiety|MPAI1-Anxiety|MPAI1-Anxiety|MPAI113	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Anxiety: Tense, nervous, fearful, phobias, nightmares, flashbacks of stressful events.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115865>	C115418	MPAI-4 - Adjustment: Depression|MPAI1-Depression|MPAI1-Depression|MPAI114	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Depression: Sad, blue, hopeless, poor appetite, poor sleep, worry, self-criticism.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115866>	C115418	MPAI-4 - Adjustment: Irritability, Anger, Aggression|MPAI1-Irritablity, Anger, Aggression|MPAI1-Irritablity, Anger, Aggression|MPAI115	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Irritability, anger, aggression: Verbal or physical expressions of anger.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115867>	C115418	MPAI-4 - Adjustment: Pain and Headache|MPAI1-Pain and Headache|MPAI1-Pain and Headache|MPAI116	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Pain and headache: Verbal and nonverbal expressions of pain; activities limited by pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115868>	C115418	MPAI-4 - Adjustment: Fatigue|MPAI1-Fatigue|MPAI1-Fatigue|MPAI117	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Fatigue: Feeling tired; lack of energy; tiring easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115869>	C115418	MPAI-4 - Adjustment: Sensitivity to Mild Symptoms|MPAI1-Sensitivity to Mild Symptoms|MPAI1-Sensitivity to Mild Symptoms|MPAI118	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Sensitivity to mild symptoms: Focusing on thinking, physical or emotional problems attributed to brain injury; rate only how concern or worry about these symptoms affects current functioning over and above the effects of the symptoms themselves.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11586>	C61063	Cyclophosphamide/Etoposide/iodine I 131 Monoclonal Antibody Anti-B1|CTX/I131-MOAB-B1/VP-16			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115870>	C115418	MPAI-4 - Adjustment: Inappropriate Social Interaction|MPAI1-Inappropriate Social Interaction|MPAI1-Inappropriate Social Interaction|MPAI119	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Inappropriate social interaction: Acting childish, silly, rude, behavior not fitting for time and place.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115871>	C115418	MPAI-4 - Adjustment: Impaired Self-Awareness|MPAI1-Impaired Self-Awareness|MPAI1-Impaired Self-Awareness|MPAI120	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Impaired self-awareness: Lack of recognition of personal limitations and disabilities and how they interfere with everyday activities and work or school.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115872>	C115418	MPAI-4 - Adjustment: Family or Significant Relationships|MPAI1-Family/Significant Relationships|MPAI1-Family/Significant Relationships|MPAI121	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Family or significant relationships: Interactions with close others; describe stress within the family or those closest to the person with brain injury; 'family functioning' means cooperating to accomplish those tasks that need to be done to keep the household running.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115873>	C115418	MPAI-4 - Participation: Initiation|MPAI1-Initiation|MPAI1-Initiation|MPAI122	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Initiation: Problems getting started on activities without prompting.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115874>	C115418	MPAI-4 - Participation: Social Contact with Fiends, Work Associates and Others|MPAI1-Social Contact-Friends/Coworkers|MPAI1-Social Contact-Friends/Coworkers|MPAI123	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Social contact with friends, work associates, and other people who are not family, significant others, or professionals.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115875>	C115418	MPAI-4 - Participation: Leisure and Recreational Activities|MPAI1-Leisure and Recreation Activities|MPAI1-Leisure and Recreation Activities|MPAI124	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Leisure and recreational activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115876>	C115418	MPAI-4 - Participation: Self-Care|MPAI1-Self-Care|MPAI1-Self-Care|MPAI125	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Self-care: Eating, dressing, bathing, hygiene.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115877>	C115418	MPAI-4 - Participation: Residence|MPAI1-Residence|MPAI1-Residence|MPAI126	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Residence: Responsibilities of independent living and homemaking (such as, meal preparation, home repairs and maintenance, personal health maintenance beyond basic hygiene including medication management) but not including managing money.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115878>	C115418	MPAI-4 - Participation: Transportation|MPAI1-Transportation|MPAI1-Transportation|MPAI127	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Transportation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115879>	C115418	MPAI-4 - Participation: Paid Employment|MPAI1-Paid Employment|MPAI1-Paid Employment|MPAI128A	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Hours per week at paid employment when primary desired social role is paid employment. 'Support' means special help from another person with responsibilities (such as, a job coach or shadow, tutor, helper) or reduced responsibilities. Modifications to the physical environment that facilitate employment are not considered as support.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11587>	C61063	gp100 Antigen/QS21/Tyrosinase Peptide|gp100/QS21/TYRP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115880>	C115418	MPAI-4 - Participation: Other Employment|MPAI1-Other Employment|MPAI1-Other Employment|MPAI128B	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Hours per week involved in constructive, role-appropriate activity other than paid employment when primary desired social role is not paid employment. 'Support' means special help from another person with responsibilities (such as, a job coach or shadow, tutor, helper) or reduced responsibilities. Modifications to the physical environment that facilitate employment are not considered as support.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115881>	C115418	MPAI-4 - Participation: Other Employment-Social Role|MPAI1-Other Employment-Social Role|MPAI1-Other Employment-Social Role|MPAI128C	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Primary social role when paid employment is not primary desired social role.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115882>	C115418	MPAI-4 - Participation: Managing Money and Finances|MPAI1-Managing Money and Finances|MPAI1-Managing Money and Finances|MPAI129	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Managing money and finances: Shopping, keeping a check book or other bank account, managing personal income and investments.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115883>	C115418	MPAI-4 - Alcohol Use Pre-Injury|MPAI1-Alcohol Use-Pre-Injury|MPAI1-Alcohol Use-Pre-Injury|MPAI130A	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Pre-Injury use of alcoholic beverages.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115884>	C115418	MPAI-4 - Alcohol Use Post-Injury|MPAI1-Alcohol Use-Post-Injury|MPAI1-Alcohol Use-Post-Injury|MPAI130B	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Post-Injury use of alcoholic beverages.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115885>	C115418	MPAI-4 - Drug Use Pre-Injury|MPAI1-Drug Use-Pre-Injury|MPAI1-Drug Use-Pre-Injury|MPAI131A	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Pre-Injury use of illegal drugs or abuse of prescription drugs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115886>	C115418	MPAI-4 - Drug Use Post-Injury|MPAI1-Drug Use-Post-Injury|MPAI1-Drug Use-Post-Injury|MPAI131B	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Post-Injury use of illegal drugs or abuse of prescription drugs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115887>	C115418	MPAI-4 - Psychotic Symptoms Pre-Injury|MPAI1-Psychotic Symptoms-Pre-Injury|MPAI1-Psychotic Symptoms-Pre-Injury|MPAI132A	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Pre-injury hallucinations, delusions, other persistent severely distorted perceptions of reality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115888>	C115418	MPAI-4 - Psychotic Symptoms Post-Injury|MPAI1-Psychotic Symptoms-Post-Injury|MPAI1-Psychotic Symptoms-Post-Injury|MPAI132B	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Post-injury hallucinations, delusions, other persistent severely distorted perceptions of reality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115889>	C115418	MPAI-4 - Law Violations Pre-Injury|MPAI1-Law Violations-Pre-Injury|MPAI1-Law Violations-Pre-Injury|MPAI133A	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Pre-injury history before and after injury.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11588>	C61063	Carboplatin/Docetaxel/Ifosfamide|CBDCA/DTIC/IFF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115890>	C115418	MPAI-4 - Law Violations Post-Injury|MPAI1-Law Violations-Post-Injury|MPAI1-Law Violations-Post-Injury|MPAI133B	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Post-injury history before and after injury.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115891>	C115418	MPAI-4 - Other Condition Causing Physical Impairment Pre-Injury|MPAI1-Other Physical Cond-Pre-Injury|MPAI1-Other Physical Cond-Pre-Injury|MPAI134A	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Pre-injury physical disability due to medical conditions other than brain injury, such as, spinal cord injury, amputation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115892>	C115418	MPAI-4 - Other Condition Causing Physical Impairment Post-Injury|MPAI1-Other Physical Cond-Post-Injury|MPAI1-Other Physical Cond-Post-Injury|MPAI134B	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Post-injury physical disability due to medical conditions other than brain injury, such as, spinal cord injury, amputation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115893>	C115418	MPAI-4 - Other Condition Causing Cognitive Impairment Pre-Injury|MPAI1-Other Cognitive Cond-Pre-Injury|MPAI1-Other Cognitive Cond-Pre-Injury|MPAI135A	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Pre-injury cognitive disability due to nonpsychiatric medical conditions other than brain injury, such as, dementia, stroke, developmental disability.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115894>	C115418	MPAI-4 - Other Condition Causing Cognitive Impairment Post-Injury|MPAI1-Other Cognitive Cond-Post-Injury|MPAI1-Other Cognitive Cond-Post-Injury|MPAI135B	Mayo-Portland Adaptability Inventory-4 (MPAI-4) Post-injury cognitive disability due to nonpsychiatric medical conditions other than brain injury, such as, dementia, stroke, developmental disability.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire MPAI-4 Test Code Terminology|CDISC Questionnaire MPAI-4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115895>	C115419	SWLS - My Life is Close to Ideal|SWLS01-My Life is Close to Ideal|SWLS01-My Life is Close to Ideal|SWLS0101	Satisfaction With Life Scale (SWLS) In most ways my life is close to my ideal.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SWLS Test Code Terminology|CDISC Questionnaire SWLS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115896>	C115419	SWLS - Life Conditions are Excellent|SWLS01-My Life Conditions are Excellent|SWLS01-My Life Conditions are Excellent|SWLS0102	Satisfaction With Life Scale (SWLS) The conditions of my life are excellent.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SWLS Test Code Terminology|CDISC Questionnaire SWLS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115897>	C115419	SWLS - Satisfied with My Life|SWLS01-I Am Satisfied with My Life|SWLS01-I Am Satisfied with My Life|SWLS0103	Satisfaction With Life Scale (SWLS) I am satisfied with my life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SWLS Test Code Terminology|CDISC Questionnaire SWLS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115898>	C115419	SWLS - Have Gotten Important Things|SWLS01-Have Gotten Important Things|SWLS01-Have Gotten Important Things|SWLS0104	Satisfaction With Life Scale (SWLS) So far I have gotten the important things I want in life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SWLS Test Code Terminology|CDISC Questionnaire SWLS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C115899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115899>	C115419	SWLS - Live Life Over Change Nothing|SWLS01-Live Life Over Change Nothing|SWLS01-Live Life Over Change Nothing|SWLS0105	Satisfaction With Life Scale (SWLS) If I could live my life over, I would change almost nothing.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SWLS Test Code Terminology|CDISC Questionnaire SWLS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11589>	C61063	Incomplete Freund's Adjuvant/Interleukin-2/Von Hippel-Lindau Peptide Vaccine|Incomplete Freund's IFA/IL-2/VHL peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1158>	C481	Mepitiostane|MEPITIOSTANE	An anabolic ether-modified form of the steroid epitiostanol. It has anti-estrogenic effect, which inhibits the progression of estrogen-stimulated cancers by competitive inhibition of estrogen binding to estrogen receptors. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C115900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115900>	C173812|C173507	Prefer to Hear as Many Details as Possible Question|I want to hear as many details as possible in all situations relating to my cancer and its treatment|Prefer to Hear as Many Details as Possible|They want to hear as many details as possible in all situations relating to their cancer and its treatment	A question about whether a person would prefer to hear as many details as possible.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115901>	C173506	Primary Goal to Lessen Suffering|To lessen my suffering as much as possible|To lessen their suffering as much as possible	A response indicating that a person's primary treatment goal is to reduce suffering.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115902>	C173506	Primary Goal to Keep Hoping|For me and/or my family to be able to keep hoping|For them and/or their family to be able to keep hoping	A response indicating that a person's primary treatment goal is to be able to keep hoping.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115903>	C173506	Primary Goal to Have Done Everything|To make sure I have done everything|To make sure they have done everything	A response indicating that a person's primary treatment goal is to make sure that everything has been done.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115904>	C173506	Primary Goal to Extend Life|To extend my life as long as possible|To extend their life as long as possible	A response indicating that a person's primary treatment goal is to extend life as long as possible.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115905>	C167435|C115907	Untreated Hairy Cell Leukemia	A finding of hairy cell leukemia that has not been treated.	Untreated Hairy Cell Leukemia		Finding	CTRP Disease Terminology|CTRP Terminology
C115906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115906>	C173506	Primary Goal to Cure the Cancer|To cure my cancer|To cure their cancer	A response indicating that a person's primary treatment goal is to cure the cancer.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115907>	C36289|C173902	Untreated Hematopoietic and Lymphoid Cell Neoplasm|Untreated Acute Lymphoblastic Leukemia (ALL)	A finding of hematopoietic or lymphoid cell neoplasm that has not been treated.	Untreated Adult Acute Lymphoblastic Leukemia		Finding	CTRP Disease Terminology|CTRP Terminology
C115908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115908>	C173506	Primary Goal to Help Cancer Research|To help cancer research	A response indicating that a person's primary treatment goal is to help cancer research.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115909>	C177743	Want More Information About Prognosis Question|I wish I had more information about my prognosis|They wish they had more information about their prognosis|Want More Information About Prognosis	A response indicating that a person would like more information about the patient's prognosis.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C11590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11590>	C61063	ALVAC-hB7.1/Canarypox-hIL-12 Melanoma Vaccine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115910>	C167435|C115907	Untreated Adult Acute Lymphoblastic Leukemia|Untreated Acute Lymphoblastic Leukemia (ALL)	A finding of acute lymphoblastic leukemia in adulthood that has not been treated.	Untreated Adult Acute Lymphoblastic Leukemia		Finding	CTRP Disease Terminology|CTRP Terminology
C115911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115911>	C91102	Have Right Amount of Information About Prognosis Question|Have Right Amount of Information About Prognosis|I now have about the right amount of information|They now have about the right amount of information	A response indicating that a person has the right amount of information about the patient's prognosis.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115912>	C226330|C115907	Untreated Adult Acute Myeloid Leukemia|Untreated Acute Myeloid Leukemia (AML)	A finding of acute myeloid leukemia in adulthood that has not been treated.	Untreated Adult Acute Myeloid Leukemia		Finding	CTRP Disease Terminology|CTRP Terminology
C115913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115913>	C177743	Want Less Information About Prognosis Question|I wish I had less information about my prognosis|They wish they had less information about their prognosis|Want Less Information About Prognosis	A response indicating that a person would have liked less information about the patient's prognosis.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115914>	C167435|C115907	Untreated Childhood Acute Lymphoblastic Leukemia|Untreated Acute Lymphoblastic Leukemia (ALL)	A finding of acute lymphoblastic leukemia in childhood that has not been treated.	Untreated Childhood Acute Lymphoblastic Leukemia		Finding	CTRP Disease Terminology|CTRP Terminology
C115915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115915>	C167434|C115907	Untreated Childhood Myeloid Neoplasm|Untreated Myeloid Neoplasm	A finding of myeloid neoplasm in childhood that has not been treated.	Untreated Childhood Myeloid Neoplasm		Finding	CTRP Disease Terminology|CTRP Terminology
C115916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115916>	C27993	Important|Importance	Of great significance, value, or consequence.			Qualitative Concept	
C115917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115917>	C36282	Untreated Metastatic Squamous Cell Carcinoma to Neck with Occult Primary|Untreated Metastatic Squamous Cell Cancer to Neck with Occult Primary	A finding of metastatic squamous cell carcinoma to neck with occult primary that has not been treated.	Untreated Metastatic Squamous Cell Cancer to Neck with Occult Primary		Finding	CTRP Disease Terminology|CTRP Terminology
C115918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115918>	C226683	Extremely Important|Extremely important	A subjective answer of extreme agreement regarding the importance of something.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115919>	C114962	Untreated Childhood Anaplastic Astrocytoma|Untreated Anaplastic Astrocytoma	A finding of anaplastic astrocytoma in childhood that has not been treated.	Untreated Childhood Anaplastic Astrocytoma		Finding	CTRP Disease Terminology|CTRP Terminology
C11591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11591>	C61063	Allovectin-7/Dacarbazine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115920>	C114994	Untreated Childhood Anaplastic Oligoastrocytoma|Untreated Anaplastic Oligoastrocytoma	A finding of anaplastic oligoastrocytoma in childhood that has not been treated.	Untreated Childhood Anaplastic Oligoastrocytoma		Finding	CTRP Disease Terminology|CTRP Terminology
C115921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115921>	C226683	Very Important|Very important	A subjective answer of very strong agreement regarding the importance of something.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115922>	C114994	Untreated Childhood Anaplastic Oligodendroglioma|Untreated Anaplastic Oligodendroglioma	A finding of anaplastic oligodendroglioma in childhood that has not been treated.	Untreated Childhood Anaplastic Oligodendroglioma		Finding	CTRP Disease Terminology|CTRP Terminology
C115923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115923>	C114994	Untreated Childhood Brain Stem Glioma|Untreated Brain Stem Glioma	A finding of brain stem glioma in childhood that has not been treated.	Untreated Childhood Brain Stem Glioma		Finding	CTRP Disease Terminology|CTRP Terminology
C115924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115924>	C226683	Somewhat Important|Somewhat important	A subjective answer of mild agreement regarding the importance of something.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115925>	C226683	A Little Important|A little important	A subjective answer of very mild agreement regarding the importance of something.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115926>	C226683	Not at All Important|Not at all important	A subjective answer of non-agreement regarding the importance of something.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115927>	C27993	Helpful	Serving a useful function or giving help.			Qualitative Concept	
C115928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115928>	C226679	Very Helpful	A subjective answer of very strong agreement regarding the helpfulness of something.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115929>	C114994	Untreated Childhood Cerebellar Astrocytoma|Untreated Cerebellar Astrocytoma	A finding of cerebellar astrocytoma in childhood that has not been treated.	Untreated Childhood Cerebellar Astrocytoma		Finding	CTRP Disease Terminology|CTRP Terminology
C11592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11592>	C61063	Carboplatin/Monoclonal Antibody HER2/Paclitaxel|CBDCA/MOAB HER2/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115930>	C114994	Untreated Childhood Cerebral Astrocytoma|Untreated Cerebral Astrocytoma	A finding of cerebral astrocytoma in childhood that has not been treated.	Untreated Childhood Cerebral Astrocytoma		Finding	CTRP Disease Terminology|CTRP Terminology
C115931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115931>	C226679	A Little Helpful	A subjective answer of very mild agreement regarding the helpfulness of something.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115932>	C114961	Untreated Childhood Diffuse Astrocytoma|Untreated Diffuse Astrocytoma	A finding of diffuse astrocytoma in childhood that has not been treated.	Untreated Childhood Diffuse Astrocytoma		Finding	CTRP Disease Terminology|CTRP Terminology
C115933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115933>	C91213|C226679	Not at All Helpful|Not at all Helpful	A subjective answer of non-agreement regarding the helpfulness of something.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115934>	C115932	Untreated Childhood Fibrillary Astrocytoma|Untreated Fibrillary Astrocytoma	A finding of fibrillary astrocytoma in childhood that has not been treated.	Untreated Childhood Fibrillary Astrocytoma		Finding	CTRP Disease Terminology|CTRP Terminology
C115935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115935>	C27992	Healthy|Well	Having no significant health-related issues.			Qualitative Concept	
C115936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115936>	C226677	Relatively Healthy|Relatively healthy	A response indicating that an individual considers themselves to be of fairly good health.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115937>	C115932	Untreated Childhood Gemistocytic Astrocytoma|Untreated Gemistocytic Astrocytoma	A finding of gemistocytic astrocytoma in childhood that has not been treated.	Untreated Childhood Gemistocytic Astrocytoma		Finding	CTRP Disease Terminology|CTRP Terminology
C115938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115938>	C226677	Relatively Healthy and Terminally Ill|Relatively healthy and terminally ill	A response indicating that an individual considers themselves to be of fairly good health but also terminally ill.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115939>	C115942	Untreated Childhood Giant Cell Glioblastoma|Untreated Giant Cell Glioblastoma	A finding of giant cell glioblastoma in childhood that has not been treated.	Untreated Childhood Giant Cell Glioblastoma		Finding	CTRP Disease Terminology|CTRP Terminology
C11593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11593>	C61063	Irinotecan/LY231514|CPT-11/LY231514			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115940>	C226677	Seriously Ill and Not Terminally Ill|Seriously ill and not terminally ill	A response indicating that an individual considers themselves to be in seriously poor health but not terminally ill.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115942>	C114962	Untreated Childhood Glioblastoma|Untreated Glioblastoma	A finding of glioblastoma in childhood that has not been treated.	Untreated Childhood Glioblastoma		Finding	CTRP Disease Terminology|CTRP Terminology
C115943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115943>	C226677	Seriously Ill and Terminally Ill|Seriously ill and terminally ill	A response indicating that an individual considers themselves to be in seriously poor health and also terminally ill.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115944>	C114994	Untreated Childhood Gliomatosis Cerebri|Untreated Gliomatosis Cerebri	A finding of gliomatosis cerebri in childhood that has not been treated.	Untreated Childhood Gliomatosis Cerebri		Finding	CTRP Disease Terminology|CTRP Terminology
C115945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115945>	C226911	Extend Life as Much as Possible|Extend Life as Long as Possible|Extend life as much as possible	A response indicating that an individual would like a course of treatment that focuses on extending their life as long as possible.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115946>	C115942	Untreated Childhood Gliosarcoma|Untreated Gliosarcoma	A finding of gliosarcoma in childhood that has not been treated.	Untreated Childhood Gliosarcoma		Finding	CTRP Disease Terminology|CTRP Terminology
C115947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115947>	C226911	Relieve Pain as Much as Possible|Relieve pain as much as possible	A response indicating that an individual would like a course of treatment that focuses on relieving pain as much as possible.			Intellectual Product	Prognosis Treatment and Perceptions Questionnaire
C115948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115948>	C114994	Untreated Childhood Medulloblastoma|Untreated Medulloblastoma	A finding of medulloblastoma in childhood that has not been treated.	Untreated Childhood Medulloblastoma		Finding	CTRP Disease Terminology|CTRP Terminology
C115949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115949>	C114994	Untreated Childhood Oligoastrocytoma|Untreated Oligoastrocytoma	A finding of oligoastrocytoma in childhood that has not been treated.	Untreated Childhood Oligoastrocytoma		Finding	CTRP Disease Terminology|CTRP Terminology
C11594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11594>	C61063	Interleukin-2/Monoclonal Antibody Anti-Tac|IL-2/MOAB anti-Tac			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115950>	C114994	Untreated Childhood Oligodendroglioma|Untreated Oligodendroglioma	A finding of oligodendroglioma in childhood that has not been treated.	Untreated Childhood Oligodendroglioma		Finding	CTRP Disease Terminology|CTRP Terminology
C115951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115951>	C114961	Untreated Childhood Pilocytic Astrocytoma|Untreated Pilocytic Astrocytoma	A finding of pilocytic astrocytoma in childhood that has not been treated.	Untreated Childhood Pilocytic Astrocytoma		Finding	CTRP Disease Terminology|CTRP Terminology
C115952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115952>	C114994	Untreated Childhood Pilomyxoid Astrocytoma|Untreated Pilomyxoid Astrocytoma	A finding of pilomyxoid astrocytoma in childhood that has not been treated.	Untreated Childhood Pilomyxoid Astrocytoma		Finding	CTRP Disease Terminology|CTRP Terminology
C115953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115953>	C114994	Untreated Childhood Pleomorphic Xanthoastrocytoma|Untreated Pleomorphic Xanthoastrocytoma	A finding of pleomorphic xanthoastrocytoma in childhood that has not been treated.	Untreated Childhood Pleomorphic Xanthoastrocytoma		Finding	CTRP Disease Terminology|CTRP Terminology
C115954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115954>	C115932	Untreated Childhood Protoplasmic Astrocytoma|Untreated Protoplasmic Astrocytoma	A finding of protoplasmic astrocytoma in childhood that has not been treated.	Untreated Childhood Protoplasmic Astrocytoma		Finding	CTRP Disease Terminology|CTRP Terminology
C115955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115955>	C114961	Untreated Childhood Subependymal Giant Cell Astrocytoma|Untreated Subependymal Giant Cell Astrocytoma	A finding of subependymal giant cell astrocytoma in childhood that has not been treated.	Untreated Childhood Subependymal Giant Cell Astrocytoma		Finding	CTRP Disease Terminology|CTRP Terminology
C115956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115956>	C114994	Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor|Untreated Supratentorial Primitive Neuroectodermal Tumor	A finding of supratentorial primitive neuroectodermal tumor in childhood that has not been treated.	Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor		Finding	CTRP Disease Terminology|CTRP Terminology
C115957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115957>	C114994	Untreated Childhood Visual Pathway Glioma|Untreated Visual Pathway Glioma	A finding of visual pathway glioma in childhood that has not been treated.	Untreated Childhood Visual Pathway Glioma		Finding	CTRP Disease Terminology|CTRP Terminology
C115958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115958>	C79476	Ureteral Stenosis	Narrowing of the luminal diameter of one or both ureters due to intrinsic factors.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Nephrology Terminology
C115959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115959>	C177175	TLR9 Agonist DUK-CPG-001|DUK-CPG-001	A synthetic CpG-rich oligonucleotide with potential immunopotentiating activity. TLR9 agonist DUK-CPG-001 binds to and activates intracellular toll-like receptor 9 (TLR9) in monocytes/macrophages, plasmacytoid dendritic cells (DCs), natural killer (NK) cells and B-cells. This initiates immune signaling pathways, activates DCs, NK cells and B-cells, and induces both the production of T-helper 1 cells (Th1) and a Th1-mediated immune response. TLR9 is a member of the TLR family, which plays a key role in both pathogen recognition and the activation of innate immunity.	TLR9 Agonist DUK-CPG-001		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C11595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11595>	C61063	IDEC-In2B8/Rituximab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115960>	C2124	Gallium Ga 68-labeled-NODAGA-MJ9|Ga-68-NODAGA-MJ9	A radiopharmaceutical agent comprised of a peptide targeting the gastrin releasing peptide receptor (GRPR) chelated with 1,4,7-triazacyclononane,1-glutaric acid-4,7 acetic acid (NODAGA) and radiolabeled with gallium Ga 68, with potential tumor imaging activity upon positron emission tomography (PET). After administration of gallium Ga 68-labeled-NODAGA-MJ9, the MJ9 moiety binds to GRPR located on tumor cells. Upon PET imaging, GRPR-expressing tumor cells can be visualized and expression levels can be quantified. GRPR is overexpressed on certain tumor cells and plays a key role in tumor proliferation and survival.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C115961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115961>	C254	Carrageenan-containing Gel|Divine 9 with Carragel	A water-based, vaginal moisturizing gel containing a mixture of lambda- and kappa- carrageenans, sulfated polysaccharides derived from red seaweed (Chondrus crispus), with potential microbicidal activity against various viruses, including human papillomavirus (HPV), human immunodeficiencyvirus (HIV) and human herpes simplex virus (HSV). Upon vaginal insertion via an applicator, carrageenan specifically binds to the viral capsids, which prevents the binding of virions to heparan sulfate proteoglycan (HSPG) receptors or other, as of yet not fully identified, cellular proteins. In addition, the viral binding of carrageenan may also interfere with conformational changes within the virions after cellular attachment. This inhibits viral infection. Certain HPV types cause cervical cancer; therefore, the prevention of HPV infection by this gel may subsequently prevent the development of cervical cancer.			Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C115962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115962>	C26110	KMT2B Gene|KMT2B|KMT2B|Lysine (K)-Specific Methyltransferase 2B Gene	This gene is involved in both histone methylation and transcriptional regulation.			Gene or Genome	
C115963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115963>	C115962	KMT2B wt Allele|CXXC10|HRX2|KIAA0304|Lysine (K)-Specific Methyltransferase 2B wt Allele|MLL1B|MLL2|MLL4|MLL4 Gene|Mixed Lineage Leukemia Gene Homolog 2 Gene|Myeloid/Lymphoid Or Mixed-Lineage Leukemia (Trithorax Homolog, Drosophila) 4 Gene|Myeloid/Lymphoid Or Mixed-Lineage Leukemia 4 Gene|TRX2|Trithorax, Drosophila, Homolog of, 2 Gene|WBP7	Human KMT2B wild-type allele is located in the vicinity of 19q13.1 and is approximately 21 kb in length. This allele, which encodes histone-lysine N-methyltransferase 2B protein, plays a role in both lysine methylation and the positive regulation of gene transcription.			Gene or Genome	
C115964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115964>	C16849	Histone-Lysine N-Methyltransferase 2B|EC 2.1.1.43|Histone-Lysine N-Methyltransferase MLL4|KMT2B|Lysine N-Methyltransferase 2B|Lysine-Specific Methyltransferase 2B|MLL4|Myeloid/Lymphoid Or Mixed-Lineage Leukemia 4|Myeloid/Lymphoid Or Mixed-Lineage Leukemia Protein 4|Trithorax Homolog 2|Trithorax Homologue 2|WBP-7|WW Domain Binding Protein 7|WW Domain-Binding Protein 7	Histone-lysine N-methyltransferase 2B (2715 aa, ~294 kDa) is encoded by the human KMT2B gene. This protein is involved in epigenetic transcriptional activation through the mediation of histone methylation.	Histone-Lysine N-Methyltransferase 2B		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C115965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115965>	C93210	Mucositis	Inflammation of the mucous membranes.			Disease or Syndrome	HL Adverse Events Table|HL Authorized Value Terminology|HL Protocol Treatment Modifications Table|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Infectious Disease Terminology
C115966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115966>	C27885	Invasive Bladder Urothelial Carcinoma Associated with Urethral Carcinoma|Infiltrating Bladder Urothelial Cancer Associated with Urethral Cancer|Infiltrating Bladder Urothelial Carcinoma Associated with Urethral Carcinoma	Invasive urothelial carcinoma of the bladder which is associated with the presence of in situ or infiltrating urethral carcinoma.	Infiltrating Bladder Urothelial Carcinoma Associated with Urethral Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115967>	C118375	Gangrenous Umbilical Hernia	A protrusion of necrotic tissue through the abdominal wall under the skin near the umbilicus.			Anatomical Abnormality	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C115968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115968>	C20103	DNER Gene|DNER|DNER|Delta/Notch-Like EGF Repeat Containing Gene	This gene plays a role in Notch-mediated signaling.			Gene or Genome	
C115969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115969>	C28681|C201545	Hsp70-peptide TKD/IL-2-activated Autologous Natural Killer Cells|Hsp70-peptide TKD/IL-2-activated Autologous NK Cells	A preparation of autologous natural killer (NK) cells that are stimulated ex vivo by a 14-mer heat shock protein 70 (Hsp70) TKD peptide and interleukin-2 (IL-2), with potential tumor-selective cytolytic activity. Upon re-infusion into the patient, the treated NK cells recognize and bind to Hsp70-expressing tumor cells, which induces NK-mediated tumor cell lysis. Hsp70, a membrane-bound, stress-inducible protein, is overexpressed on almost all tumor cells; however, it is absent or minimally present on normal, healthy cells. TKD is the C-terminal substrate-binding domain of Hsp70 and is the structure recognized by the activated NK cells.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11596>	C61063	gp100 Antigen/MAGE-3/MART-1 Antigen/Tyrosinase Peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115970>	C61074	Ibcasertib|CS2164|Chiauranib|IBCASERTIB	An orally available, small molecule inhibitor of select serine-threonine kinases, including aurora kinase B (aurora B), vascular endothelial growth factor receptors (VEGFRs), stem cell factor receptor (c-KIT), and platelet-derived growth factor receptors (PDGFRs), with potential antineoplastic activity. Upon oral administration, ibcasertib binds to and inhibits the activity of aurora B, VEGFRs, c-kit and PDGFRs, which may result in a decrease in the proliferation of tumor cells that overexpress these kinases. These kinases are overexpressed by a variety of cancer cell types.	Ibcasertib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C115971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115971>	C115968	DNER wt Allele|Delta/Notch-Like EGF Repeat Containing wt Allele|UNQ26|UNQ262/PRO299|bet	Human DNER wild-type allele is located in the vicinity of 2q36.3 and is approximately 357 kb in length. This allele, which encodes Delta and Notch-like epidermal growth factor-related receptor protein, is involved in the activation of Notch signaling pathways.			Gene or Genome	
C115972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115972>	C18106	Delta and Notch-Like Epidermal Growth Factor-Related Receptor|DENR|Delta and Notch-like Epidermal Growth Factor-related Receptor|Delta- and Notch-Like EGF-Related Receptor|Delta-Notch-Like EGF Repeat-Containing Transmembrane|PCA-Tr Antigen|PURKINJE CELL CYTOPLASMIC TYPE TR ANTIGEN|Purkinje Cell Cytoplasmic-Tr|Tr Antigen	Delta and Notch-like epidermal growth factor-related receptor (737 aa, ~78 kDa) is encoded by the human DNER gene. This protein plays a role in the positive regulation of Notch signaling.			Amino Acid, Peptide, or Protein|Receptor	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C115973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115973>	C20420	MYOCD Gene|MYOCD|MYOCD|Myocardin Gene	This gene plays a role in both heart development and smooth muscle cell differentiation.			Gene or Genome	
C115974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115974>	C115973	MYOCD wt Allele|MYCD|Myocardin wt Allele	Human MYOCD wild-type allele is located in the vicinity of 17p11.2 and is approximately 103 kb in length. This allele, which encodes myocardin protein, is involved in transcriptional regulation, myogenesis and heart development.			Gene or Genome	
C115975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115975>	C17207	Myocardin|MYOCD	Myocardin (938 aa, ~102 kDa) is encoded by the human MYOCD gene. This protein plays a role in myogenesis, heart development and transcriptional regulation.			Amino Acid, Peptide, or Protein	
C115976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115976>	C1572|C129826	Dendritic Cell-targeting Lentiviral Vector ID-LV305|DCvex-NY-ESO-1|ID-LV305	An engineered lentiviral vector targeting dendritic cells (DCs) and containing nucleic acids encoding for the human tumor-associated cancer-testis antigen NY-ESO-1, with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, the DC-targeting lentiviral vector ID-LV305 targets and binds to dermal DCs via the DC-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) receptor. Upon internalization of the vector, the NY-ESO-1 protein is expressed, stimulates DC maturation and activates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against NY-ESO-1-expressing cells, which may result in tumor cell lysis. NY-ESO-1 is expressed in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival.			Cell|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C115977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115977>	C155765	Larotrectinib|1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-|3S)-N-(5-((2R)-2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide|ARRY 470|LAROTRECTINIB|LOXO 101|LOXO-101|LOXO101	An orally available, tropomyosin receptor kinase (Trk) inhibitor, with potential antineoplastic activity. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Trk, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCIt Antineoplastic Agent Terminology
C115978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115978>	C2124	Fluorine 18 F Fludarabine|18F-Fludarabine|2-[(18)F]fludarabine	A radiopharmaceutical containing the purine analog fludarabine that is labeled with the radioisotope fluorine F18 with potential use as a tumor imaging agent upon positron emission tomography (PET). After intravenous administration, the fludarabine is selectively taken up by tumor cells. The radioisotope moiety is detected using PET, which allows imaging and quantification of both the biodistribution of fludarabine and the presence of tumor cells. This could identify tumors and select patients that will likely respond to fludarabine treatment.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C115979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115979>	C28681|C138180|C129826	HLA-DP0401/0402-Restricted MAGE-A3-Reactive T Cell Receptor-transduced Autologous T Cells|Anti-MAGE-A3-DP4 TCR PBL	Human autologous T-lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the human leukocyte antigen (HLA)-DP0401/0402-restricted, melanoma antigen A3 (MAGE-A3), with potential antineoplastic activity. CD4-positive cells are isolated from a patient, transduced with an anti-MAGE-A3-DP0401/0402 restricted TCR, expanded ex vivo, and reintroduced into the HLA-DP0401/0402 positive patient. Then, the HLA-DP0401/0402-restricted, MAGE-A3-reactive TCR-transduced autologous T cells bind to tumor cells expressing the MAGE-A3 antigen, which may result in both an inhibition of growth and increased cell death for MAGE-A3-expressing cancer cells. The tumor-associated antigen MAGE-A3 is overexpressed by a variety of cancer cell types.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11597>	C61063	Flu Matrix/gp100 Antigen/MAGE-3/MART-1 Antigen/Tyrosinase Peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115980>	C2124	Gallium Ga 68-DOTA-exendin-4|68Ga-DOTA-exendin-4|[Lys40(Ahx-DOTA-68Ga)NH2]-exendin-4	A radiopharmaceutical composed of the glucagon-like peptide 1 receptor (GLP-1R) agonist exendin-4 linked by the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to the positron-emitting radionuclide gallium Ga 68, with potential use in diagnostic imaging upon positron emission tomography (PET). Upon administration of gallium Ga 68-DOTA-exendin-4, the exendin-4 moiety binds to GLP-1R and is subsequently internalized. The radionuclide moiety can be detected using PET and GLP-1R-expressing tumors can be localized. GLP-1R, located on beta cells, is overexpressed on insulinomas, which are insulin-secreting neuroendocrine tumors.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C115981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115981>	C2124	Indium In 111-DOTA-exendin-4|111In-DOTA-exendin-4|[Lys40(Ahx-DOTA-111In)NH2]-exendin-4	A radiopharmaceutical composed of the glucagon-like peptide 1 receptor (GLP-1R) agonist exendin-4 linked by the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to the positron-emitting radionuclide indium In 111, with potential use in diagnostic imaging upon positron emission tomography (PET). Upon administration of indium In 111-DOTA-exendin-4, the exendin-4 moiety binds to GLP-1R and is subsequently internalized. The radionuclide moiety can be detected using PET and GLP-1R-expressing tumors can be localized. GLP-1R, located on beta cells, is overexpressed on insulinomas, which are insulin-secreting neuroendocrine tumors.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C115982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115982>	C25873	ALPK2 Gene|ALPK2|ALPK2|Alpha-Kinase 2 Gene	This gene is involved in protein phosphorylation.			Gene or Genome	
C115983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115983>	C115982	ALPK2 wt Allele|Alpha-Kinase 2 wt Allele|HAK|Heart Alpha-Kinase Gene	Human ALPK2 wild-type allele is located in the vicinity of 18q21.31 and is approximately 148 kb in length. This allele, which encodes alpha-protein kinase 2 protein, plays a role in the phosphorylation of serines and threonines in alpha-helical proteins.			Gene or Genome	
C115984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115984>	C17325	Alpha-Protein Kinase 2|ALPK2|EC 2.7.11.-|Heart Alpha-Kinase|Heart Alpha-Protein Kinase	Alpha-protein kinase 2 (2170 aa, ~237 kDa) is encoded by the human ALPK2 gene. This protein is involved in serine/threonine phosphorylation.			Amino Acid, Peptide, or Protein|Enzyme	
C115985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115985>	C154303	H4C5 Gene|H4 Clustered Histone 5 Gene|H4C5|H4C5|HIST1H4E	This gene is involved in the formation of high order chromatin structures.			Gene or Genome	
C115986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115986>	C1937	Carbon Nanoparticle-based Formulation|CNP|Carbon Nanoparticles	A nanoparticle-based formulation containing carbon, with both a mean size of 150 nm, and potential use as a stain for lymph node draining. Upon injection of the carbon nanoparticles at the tumor site, these nanoparticles travel to regional lymph nodes and stain the lymph nodes black due to the presence of the carbon. This may allow for a more precise surgical removal of tumor-draining lymph nodes.			Indicator, Reagent, or Diagnostic Aid	NCI Drug Dictionary Terminology
C115987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115987>	C115985	H4C5 wt Allele|H4 Clustered Histone 5 wt Allele|H4 Histone Family, Member J Gene|H4/j|H4FJ|HIST1 Cluster, H4E Gene|HIST1H4E|Histone 1, H4e Gene|Histone Cluster 1, H4e Gene|Histone Gene Cluster 1 H4 Family Member E Gene|Histone Gene Cluster 1, H4 Histone Family, Member E Gene|Histone Gene Cluster 1, H4E Gene	Human H4C5 wild-type allele is located in the vicinity of 6p22.1 and is approximately 2 kb in length. This allele, which encodes histone H4 protein, plays a role in the modulation of chromatin structure.			Gene or Genome	
C115988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115988>	C99231|C96411|C155871	Neonatal Herpes Simplex Infection	Infection in the first month of life caused by the Herpes simplex virus.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C115989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115989>	C20420	ZNF750 Gene|ZNF750|ZNF750|Zinc Finger Protein 750 Gene	This gene plays a role in epidermal differentiation.			Gene or Genome	
C11598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11598>	C61063	Gemcitabine/Monoclonal Antibody HER2|dFdC/MOAB HER2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C115990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115990>	C115989	ZNF750 wt Allele|FLJ13841|SLDPE|ZFP750|Zfp750|Zinc Finger Protein 750 wt Allele	Human ZNF750 wild-type allele is located in the vicinity of 17q25.3 and is approximately 11 kb in length. This allele, which encodes zinc finger protein 750, is involved in both transcriptional regulation and differentiation of the epidermis. Mutation of the gene is associated with seborrhea-like dermatitis with psoriasiform elements.			Gene or Genome	
C115991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115991>	C17207	Zinc Finger Protein 750|Protein ZNF750|ZNF750	Zinc finger protein 750 (723 aa, ~77 kDa) is encoded by the human ZNF750 gene. This protein plays a role in transcriptional regulation that drives the development of the epidermis.			Amino Acid, Peptide, or Protein	
C115992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115992>	C26715	Periorbital Cellulitis|Preseptal Cellulitis|Preseptal Cellulitis	An acute infection of the anterior portion of the eyelid and surrounding tissues.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Infectious Disease Terminology
C115993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115993>	C27610	Retinitis	Inflammation of the retina.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Infectious Disease Terminology|Pediatric Rheumatology Terminology
C115994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115994>	C20420	BCLAF1 Gene|BCL2-Associated Transcription Factor 1 Gene|BCLAF1|BCLAF1|BCLAF1	Human BCLAF1 wild-type allele is located within 6q22-q23 and is approximately 33 kb in length. This allele, which encodes Bcl-2-associated transcription factor 1 protein, plays a role in both apoptosis promotion and the repression of transcription.			Gene or Genome	GDC Terminology|GDC Value Terminology
C115995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115995>	C115994	BCLAF1 wt Allele|BCL2-Associated Transcription Factor 1 wt Allele|BTF|KIAA0164|bK211L9.1	Human BCLAF1 wild-type allele is located within 6q22-q23 and is approximately 33 kb in length. This allele, which encodes Bcl-2-associated transcription factor 1 protein, plays a role in both apoptosis promotion and the repression of transcription.			Gene or Genome	
C115996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115996>	C17207	Bcl-2-Associated Transcription Factor 1|BCL2-Associated Transcription Factor 1|BCLAF1|Btf	Bcl-2-associated transcription factor 1 (920 aa, ~106 kDa) is encoded by the human BCLAF1 gene. This protein is involved in the positive regulation of apoptosis and the negative regulation of gene transcription.			Amino Acid, Peptide, or Protein	
C115997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115997>	C222484|C114782	Localized Adult Undifferentiated High Grade Pleomorphic Sarcoma of Bone|Localized Adult Undifferentiated High Grade Pleomorphic Sarcoma|Localized Adult Undifferentiated High-Grade Pleomorphic Sarcoma of Bone|Undifferentiated High Grade Pleomorphic Sarcoma of Bone	An undifferentiated high-grade pleomorphic sarcoma of bone that occurs in adulthood and has not spread to other anatomic sites.	Localized Adult Undifferentiated High Grade Pleomorphic Sarcoma of Bone		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115998>	C222484|C114750	Localized Childhood Undifferentiated High Grade Pleomorphic Sarcoma of Bone|Localized Childhood Undifferentiated High Grade Pleomorphic Sarcoma|Localized Childhood Undifferentiated High-Grade Pleomorphic Sarcoma of Bone|Undifferentiated High Grade Pleomorphic Sarcoma of Bone	An undifferentiated high-grade pleomorphic sarcoma of bone that occurs in childhood and has not spread to other anatomic sites.	Localized Childhood Undifferentiated High Grade Pleomorphic Sarcoma of Bone		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C115999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C115999>	C42645	Content Model Content Type|Content Type Name	The name of the type of content in a content model.			Intellectual Product	CareLex eTMF Terminology
C11599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11599>	C61063	KSA Glycoprotein/QS21			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1159>	C96390	Methanol Extraction Residue of BCG|MER BCG|MER of BCG|MER-BCG|Methanol Extraction Residue of Bacillus Calmette-Guerin	A cell wall fraction of bacillus Calmette-Guerin (BCG) obtained by menthol extraction with immunomodulating properties and potential use in cancer immunotherapy. (NCI04)			Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116000>	C25172	Self-Employed|Self-Employment|Self-employed	The earning of income directly from customers, clients, or other organizations rather than as a specified salary or wages from an employer.			Functional Concept	
C116001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116001>	C25172	Salaried Annual Employment|Salaried Annual Worker|Salaried annual	An employment agreement where the employer pays an arranged amount at a steady yearly interval regardless of hours worked.			Functional Concept	
C116002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116002>	C25172	Hourly Employment|Hourly Wage Employment|Wages hourly	An employment arrangement where a worker is compensated a wage based on the number of hours worked.			Functional Concept	
C116003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116003>	C26851	Streptococcal Pharyngitis|Strep Throat	Inflammation of the throat due to Streptococcus pyogenes.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Infectious Disease Terminology
C116004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116004>	C74944	Cell Culture Procedure	Any laboratory procedure for growing cells or tissues in vitro.	Cell Culture Procedure		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C116005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116005>	C20189	Radioresistance|Radiation Resistance|Radioresistant	The property of being unsusceptible to the usual effects caused by exposure to a given level of radiation.			Conceptual Entity	
C116006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116006>	C173798	Tonsillitis	Inflammation of the tonsillar tissue.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Infectious Disease Terminology
C116007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116007>	C27661	Epiglottitis|Supraglottitis	Inflammation of the epiglottis.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Infectious Disease Terminology
C116008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116008>	C98996	Omphalitis	Inflammation of the umbilical cord stump in newborns.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Infectious Disease Terminology|Perinatal Terminology
C116009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116009>	C12555	Circulating Adipose Stromal Cell|Circulating ASC|Circulating Perivascular Adipocyte Progenitor	A precursor of fat-storing cells, which is located in the blood circulation. Detection of these cells is associated with obesity and elevated risk for obesity-related neoplastic diseases such as breast, colon and prostate carcinomas.	Circulating Adipose Stromal Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C11600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11600>	C61063	KSA-KLH Conjugate Vaccine/QS21|KSA-KLH/QS21			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116010>	C43265	Crown-Like Structure|CLS|Crown-Like Structures	An ultrastructural finding in adipose tissue that indicates macrophage infiltration to sites of adipocyte necrosis.	Crown-Like Structure		Finding	CTRP Biomarker Terminology|CTRP Terminology
C116011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116011>	C116010	Crown-Like Structures of the Breast|CLS-B	An ultrastructural finding in breast adipose tissue that indicates macrophage infiltration to sites of adipocyte necrosis. This finding is associated with obesity and breast tissue inflammation and may be an indicator for increased risk of neoplastic breast disease.	Crown-Like Structures of the Breast		Finding	CTRP Biomarker Terminology|CTRP Terminology
C116012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116012>	C345	Pyruvate|2-Oxopropanoate|Propanoic Acid, 2-Oxo-, Ion(1-)	A 2-oxo monocarboxylic acid anion that is the conjugate base of pyruvic acid, which is an important metabolic product for energy-producing biochemical pathways. Pyruvate is the final product of glycolysis and, when hypoxic conditions arise, can be metabolized anaerobically to form lactate. This chemical is a precursor of both acetyl-coenzyme A and oxaloacetate, which are involved in the citric acid cycle. Additionally, oxaloacetate is a substrate in the gluconeogenesis pathway.	Pyruvate		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C116013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116013>	C782	Prostaglandin D2|(5Z,13E)-(15S)-9alpha,15-Dihydroxy-11-Oxoprosta-5,13-Dienoate|(5Z,13E,15S)-9alpha,15-Dihydroxy-11-Oxoprosta-5,13-Dien-1-Oic Acid|11-Dehydroprostaglandin F2-Alpha|PGD2|PROSTAGLANDIN D2|Prosta-5,13-Dien-1-Oic Acid, 9,15-Dihydroxy-11-Oxo-, (5Z,9-Alpha,13E,15S)-	An eicosanoid that is generated by the action of prostaglandin D2 synthase on prostaglandin H2. Prostaglandin D2 mediates vasodilation, smooth muscle contraction and circadian rhythms. This prostanoid may also play a role in male pattern baldness.	Prostaglandin D2		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C116014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116014>	C113511	TMPRSS2/ETV5 Fusion Gene|TMPRSS2-ETV5 Fusion Gene|TMPRSS2::ETV5 Fusion Gene	A fusion gene that results from a chromosomal translocation t(3;21)(q28;q22) which fuses either the 5' untranslated region or the 5' end including exons 1 and 2 of the TMPRSS2 gene with exon 2 of the ETV5 gene. This rearrangement is associated with prostate carcinoma and androgen-dependent expression of this fusion gene results in overexpression of ETS translocation variant 5 protein activity.	TMPRSS2/ETV5 Fusion Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116015>	C113511	TMPRSS2/ETV4 Fusion Gene|TMPRSS2-ETV4 Fusion Gene|TMPRSS2::ETV4 Fusion Gene	A fusion gene that results from a chromosomal translocation t(17;21)(q21;q22) which fuses the 5' untranslated region of the TMPRSS2 gene upstream of exon 3 of the ETV4 gene. This rearrangement is associated with prostate carcinoma and androgen-dependent expression of this fusion gene results in overexpression of ETS translocation variant 4 protein activity.	TMPRSS2/ETV4 Fusion Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116016>	C3420|C185933	t(14;20)	A chromosomal translocation involving chromosome 14 and chromosome 20.	t(14;20)		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116017>	C113841	Melanoma-Associated Antigen Family A|Class 1 Melanoma-Associated Antigen Family A|MAGE A Family|MAGE-A|MAGEA|Melanoma Antigen, Family A	A family of 12 proteins whose members were first detected in male germ cells, placenta and various tumors but originally not found in normal tissues. Their genes are located in the vicinity of Xq28. All of the members of the family share a stretch of about 200 amino acids, called the MAGE conserved domain, which is usually located near the C-terminal end of the protein and may allow these proteins to interact with cellular receptors.	Melanoma-Associated Antigen Family A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116018>	C18520	Histone H3 Lysine 28|H3K27|H3K28|Histone H3 Lys27|Histone H3 Lys28|Histone H3 Lysine 27|Histone H3 Lysine 27|Lysine 27 of Histone H3|Lysine 28 of Histone H3	The lysine residue found at amino acid position 28 in the histone H3 protein. Methylation of this residue may be a marker for transcriptionally repressed genes.	Histone H3 Lysine 27		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116019>	C28597	5'-AMP-Activated Protein Kinase Catalytic Subunit Alpha|5'-AMP-Activated Protein Kinase, Catalytic Alpha Chain|5-AMP-Activated Protein Kinase Catalytic Subunit Alpha|ACACA Kinase Family|AMP-Activated Protein Kinase Alpha Subunit|AMP-Activated Protein Kinase Catalytic Subunit Alpha|AMPK Alpha|AMPK Subunit Alpha|AMPK-Alpha|AMPKa|AMPKalpha|Acetyl-CoA Carboxylase Kinase Family|EC 2.7.11.1|EC 2.7.11.27|EC 2.7.11.31|HMGCR Kinase Family|Hydroxymethylglutaryl-CoA Reductase Kinase Family|PRKAA	A family comprised of two proteins that can each act as the catalytic alpha subunit for the 5'-AMP-activated protein kinase (AMPK) complex. The AMPK complex is involved in the regulation of glucose uptake, the oxidation of fatty acids and mitochondrial biogenesis through the phosphorylation of metabolic enzymes and transcription regulatory proteins.	5-AMP-Activated Protein Kinase Catalytic Subunit Alpha		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11601>	C61007	QS21/TF(c)-KLH Conjugate Vaccine|QS21/TF(c)-KLH			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116020>	C16447	Procollagen Type I C-Terminal Peptide|Collagen Type 1 C-Terminal Propeptide|Collagen Type I C-Terminal Propeptide|P1CP|PICP|Procollagen Type 1 C-Terminal Peptide	This polypeptide is comprised of the carboxy-terminal portions of procollagen, which are proteolytically removed by bone morphogenetic protein 1 during the intracellular formation of type I collagen fibrils. Increased plasma or serum concentrations of these peptides are associated with both fibrillogenesis of type I collagen and bone formation.	Procollagen Type I C-Terminal Peptide		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116021>	C25966	MicroRNA 181|MIR181|MIRN181|hsa-mir-181|mir-181	A microRNA that has six isoforms that may play a role in the activity of phosphatidylinositol-4,5-bisphosphate 3-kinase and natural killer cells. The MIR181 isoforms have been implicated in a variety of cancers, including chronic lymphocytic leukemia, glioblastoma, multiple myeloma and hepatocellular carcinoma.	MicroRNA 181		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116022>	C20194	LAMP2 Gene|LAMP2|LAMP2|Lysosomal-Associated Membrane Protein 2 Gene	This gene plays a role in lysosomal maintenance.	LAMP2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116023>	C116022	LAMP2 wt Allele|CD107b|LAMP-2|LAMPB|LGP110|Lysosomal-Associated Membrane Protein 2 wt Allele	Human LAMP2 wild-type allele is located in the vicinity of Xq24 and is approximately 43 kb in length. This allele, which encodes lysosome-associated membrane glycoprotein 2, is involved in the maintenance of the lysosome. Mutation of the gene is associated with Danon disease.	LAMP2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116024>	C18466	Lysosome-Associated Membrane Glycoprotein 2|CD107 Antigen-Like Family Member B|CD107b|CD107b Antigen|LAMP-2|LAMP2|Lysosomal Membrane Glycoprotein, 110kD|Lysosomal Membrane Glycoprotein, 110kDa|Lysosomal-Associated Membrane Protein B|Lysosome-Associated Membrane Protein 2	Lysosome-associated membrane glycoprotein 2 (410 aa, ~45 kDa) is encoded by the human LAMP2 gene. This protein plays a role in lysosome function.	Lysosome-Associated Membrane Glycoprotein 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116025>	C25977	SOCS2 Gene|SOCS2|SOCS2|Suppressor of Cytokine Signaling 2 Gene	This gene is involved in the inhibition of cytokine-mediated signaling.	SOCS2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116026>	C116025	SOCS2 wt Allele|CIS2|Cish2|SOCS-2|SSI-2|SSI2|STATI2|Suppressor of Cytokine Signaling 2 wt Allele	Human SOCS2 wild-type allele is located within 12q and is approximately 14 kb in length. This allele, which encodes suppressor of cytokine signaling 2 protein, plays a role in the negative regulation of cytokine signaling pathways.	SOCS2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116027>	C25978	Suppressor of Cytokine Signaling 2|CIS-2|Cytokine-Inducible SH2 Protein 2|SOCS-2|SSI-2|STAT Induced STAT Inhibitor-2|STAT-Induced STAT Inhibitor 2|STAT-Induced STAT Inhibitor-2|Suppressor of Cytokine Signaling-2	Suppressor of cytokine signaling 2 (198 aa, ~22 kDa) is encoded by the human SOCS2 gene. This protein is involved in the modulation of cytokine signaling.	Suppressor of Cytokine Signaling 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116028>	C25790	CLEC2A Gene|C-Type Lectin Domain Family 2, Member A Gene|CLEC2A|CLEC2A	This gene plays a role in both T-cell expansion and natural killer cell-mediated cytotoxicity.	CLEC2A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116029>	C116028	CLEC2A wt Allele|C-Type Lectin Domain Family 2, Member A wt Allele|INPE5792|KACL|PILAR|UNQ5792|UNQ5792/PRO19597	Human CLEC2A wild-type allele is located in the vicinity of 12p13.31 and is approximately 34 kb in length. This allele, which encodes C-type lectin domain family 2 member A protein, is involved in cell-mediated immunity.	CLEC2A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11602>	C63586	XELIRI Regimen|CAPIRI|CAPIRI|CAPIRI|CapIri|Capecitabine-Irinotecan|Capecitabine/Irinotecan|Capecitabine/Irinotecan Regimen|XelIri|Xeloda/Camptosar Regimen	A regimen containing capecitabine and irinotecan used in the treatment of colorectal, esophageal and gastric cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|NCI Drug Dictionary Terminology|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C116030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116030>	C16725	C-Type Lectin Domain Family 2 Member A|CLEC2A|KACL|Keratinocyte-Associated C-Type Lectin|PILAR|Proliferation-Induced Lymphocyte-Associated Receptor	C-type lectin domain family 2 member A (174 aa, ~20 kDa) is encoded by the human CLEC2A gene. This protein plays a role in both T-cell functionality and natural killer cell-mediated cytotoxicity.	C-Type Lectin Domain Family 2 Member A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116031>	C25873	PRKAA1 Gene|PRKAA1|PRKAA1|Protein Kinase, AMP-Activated, Alpha 1 Catalytic Subunit Gene	This gene is involved in serine/threonine phosphorylation.	PRKAA1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116032>	C116031	PRKAA1 wt Allele|AMP-Activated Protein Kinase, Catalytic, Alpha-1 Gene|AMP-Activated, Catalytic, Alpha-1 Gene|AMPK|AMPK1|AMPKa1|Protein Kinase, AMP-Activated, Alpha 1 Catalytic Subunit wt Allele|Protein Kinase, AMP-Activated, Catalytic, Alpha-1 Gene	Human PRKAA1 wild-type allele is located in the vicinity of 5p12 and is approximately 39 kb in length. This allele, which encodes 5'-AMP-activated protein kinase catalytic subunit alpha-1 protein, plays a role in the modulation of many cellular processes through the phosphorylation of metabolic enzymes and transcription regulatory proteins.	PRKAA1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116033>	C17325	5'-AMP-Activated Protein Kinase Catalytic Subunit Alpha-1|5'-AMP-Activated Protein Kinase, Catalytic Alpha-1 Chain|5-AMP-Activated Protein Kinase Catalytic Subunit Alpha-1|ACACA Kinase|AMP-Activated Protein Kinase Catalytic Subunit Alpha-1|AMPK Subunit Alpha-1|AMPK-Alpha-1|Acetyl-CoA Carboxylase Kinase|EC 2.7.11.1|EC 2.7.11.26|EC 2.7.11.27|EC 2.7.11.31|HMGCR Kinase|Hydroxymethylglutaryl-CoA Reductase Kinase|Tau-Protein Kinase PRKAA1	5'-AMP-activated protein kinase catalytic subunit alpha-1 (559 aa, ~64 kDa) is encoded by the human PRKAA1 gene. This protein is involved in the phosphorylation of metabolic enzymes, transcription regulatory proteins and microtubule-associated protein tau.	5-AMP-Activated Protein Kinase Catalytic Subunit Alpha-1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116034>	C25952	CES1 Gene|CES1|CES1|Carboxylesterase 1 Gene	This gene plays a role in the hydrolysis of aromatic and aliphatic esters.	CES1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116035>	C116034	CES1 wt Allele|ACAT|CE-1|CEH|CES2|Carboxylesterase 1 (Monocyte/Macrophage Serine Esterase 1) Gene|Carboxylesterase 1 wt Allele|Carboxylesterase 2 (Liver) Gene|Carboxylesterase 2, Formerly Gene|Carboxylesterase, Liver Gene|HMSE|HMSE1|PCE-1|REH|SES1|TGH|hCE-1	Human CES1 wild-type allele is located in the vicinity of 16q22.2 and is approximately 31 kb in length. This allele, which encodes liver carboxylesterase 1 protein, is involved in the metabolism of xenobiotics and aromatic and aliphatic esters. Mutation of the gene is associated with Carboxylesterase 1 deficiency.	CES1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116036>	C16561	Liver Carboxylesterase 1|ACAT|Acyl Coenzyme A:Cholesterol Acyltransferase|Acyl-Coenzyme A:Cholesterol Acyltransferase|Brain Carboxylesterase HBr1|CE-1|CES1|Cocaine Carboxylesterase|EC 3.1.1.1|EC 3.1.1.56|Egasyn|HMSE|Human Monocyte/Macrophage Serine Esterase 1|Methylumbelliferyl-Acetate Deacetylase 1|Monocyte/Macrophage Serine Esterase|REH|Retinyl Ester Hydrolase|Serine Esterase 1|TGH|Triacylglycerol Hydrolase|hCE-1	Liver carboxylesterase 1 (567 aa, ~63 kDa) is encoded by the human CES1 gene. This protein plays a role in the catabolism of drugs and aromatic and aliphatic esters.	Liver Carboxylesterase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116037>	C25952	CES2 Gene|CES2|CES2|Carboxylesterase 2 Gene	This gene is involved in xenobiotic detoxification.	CES2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116038>	C116037	CES2 wt Allele|CE-2|CES2A1|Carboxylesterase 2 (Intestine, Liver) Gene|Carboxylesterase 2 wt Allele|ICE|PCE-2|iCE	Human CES2 wild-type allele is located in the vicinity of 16q22.1 and is approximately 11 kb in length. This allele, which encodes cocaine esterase protein, plays a role in the catabolism of xenobiotics.	CES2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116039>	C16561	Cocaine Esterase|CE-2|CES2|Carboxylesterase 2|EC 3.1.1.1|EC 3.1.1.56|Intestinal Carboxylesterase|Liver Carboxylesterase-2|Methylumbelliferyl-Acetate Deacetylase 2|hCE-2	Cocaine esterase (559 aa, ~62 kDa) is encoded by the human CES2 gene. This protein is involved in drug catabolism.	Cocaine Esterase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11603>	C61063	Iodine I 125/Polifeprosan 20 With Carmustine Implant			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116040>	C21165	LTBR Gene|LTBR|LTBR|Lymphotoxin Beta Receptor (TNFR Superfamily, Member 3) Gene|TNFRSF3	This gene plays a role in both lymphotoxin binding and the promotion of apoptosis.	LTBR Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116041>	C116040	LTBR wt Allele|D12S370|LT-BETA-R|Lymphotoxin Beta Receptor (TNFR Superfamily, Member 3) wt Allele|TNF-R-III|TNFCR|TNFR-RP|TNFR2-RP|TNFR3|TNFRSF3	Human LTBR wild-type allele is located in the vicinity of 12p13 and is approximately 17 kb in length. This allele, which encodes tumor necrosis factor receptor superfamily member 3 protein, is involved in lymphotoxin-mediated signaling.	LTBR wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116042>	C19285	Tumor Necrosis Factor Receptor Superfamily Member 3|LTBR|Lymphotoxin B Receptor|Lymphotoxin Beta Receptor|Lymphotoxin-Beta Receptor|TNF-RIII|TNFR-III|TNFRSF3|Tumor Necrosis Factor C Receptor|Tumor Necrosis Factor Receptor 2-Related Protein|Tumor Necrosis Factor Receptor Type III	Tumor necrosis factor receptor superfamily member 3 (435 aa, ~47 kDa) is encoded by the human LTBR gene. This protein plays a role in both receptor signaling and the positive regulation of apoptosis.	Tumor Necrosis Factor Receptor Superfamily Member 3		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116043>	C54550	SRSF1 Gene|SRSF1|SRSF1|Serine/Arginine-Rich Splicing Factor 1 Gene	This gene is involved in both RNA processing and transport.	SRSF1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116044>	C116043	SRSF1 wt Allele|ASF|MGC5228|OK/SW-cl.3|SF2|SF2P33|SF2p33|SFRS1|SRp30a|Serine/Arginine-Rich Splicing Factor 1 wt Allele|Splicing Factor, Arginine/Serine-Rich, 1 Gene|Splicing Factor, Arginine/Serine-Rich, 30kD, A Gene|Splicing Factor, Serine/Arginine-Rich, 1 Gene	Human SRSF1 wild-type allele is located in the vicinity of 17q22 and is approximately 6 kb in length. This allele, which encodes serine/arginine-rich splicing factor 1 protein, plays a role in both transcriptional termination and mRNA splicing	SRSF1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116045>	C21298	Serine/Arginine-Rich Splicing Factor 1|ASF-1|Alternate Splicing Factor|Alternative-Splicing Factor 1|Pre-mRNA-Splicing Factor SF2, P33 Subunit|SR Splicing Factor 1|Splicing Factor 2|Splicing Factor, Arginine/Serine-Rich 1	Serine/arginine-rich splicing factor 1 (248 aa, ~28 kDa) is encoded by the human SRSF1 gene. This protein is involved in the regulation of RNA splicing.	Serine/Arginine-Rich Splicing Factor 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116046>	C26884	Central Sleep Apnea|CSA	The periodic cessation of breathing while asleep that occurs secondary to the decreased responsiveness of the respiratory center of the brain to carbon dioxide, resulting in alternating cycles of apnea and hyperpnea.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116047>	C25952	PON1 Gene|PON1|PON1|Paraoxonase 1 Gene	This gene plays a role in the metabolism of organophosphates, lactones and aromatic carboxylic acid esters.	PON1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116048>	C116047	PON1 wt Allele|ESA|MVCD5|PON|Paraoxonase 1 wt Allele|Paraoxonase, Plasma Gene	Human PON1 wild-type allele is located in the vicinity of 7q21.3 and is approximately 99 kb in length. This allele, which encodes serum paraoxonase/arylesterase 1 protein, is involved in detoxification of lactones, aromatic carboxylic acid esters and organophosphates. Genetic variation is associated with microvascular complications of diabetes 5, and increased susceptibility to coronary artery disease, coronary artery spasm 2, and organophosphate poisoning.	PON1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116049>	C16561	Serum Paraoxonase/Arylesterase 1|A-Esterase 1|Aromatic Esterase 1|Arylesterase B-Type|EC 3.1.1.2|EC 3.1.1.81|EC 3.1.8.1|Esterase A|K-45|PON 1|PON1|Paraoxonase B-Type|Serum Aryldiakylphosphatase|Serum Aryldialkylphosphatase 1	Serum paraoxonase/arylesterase 1 (355 aa, ~40 kDa) is encoded by the human PON1 gene. This protein plays a role in the catabolism of aromatic carboxylic acid esters, organophosphates and lactones.	Serum Paraoxonase/Arylesterase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11604>	C61063	Amifostine/Cisplatin/Fluorouracil/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116050>	C159207	SLX4 Gene|SLX4|SLX4|SLX4 Structure-Specific Endonuclease Subunit Gene	This gene is involved in both DNA repair and the positive regulation of endonuclease activity.	SLX4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116051>	C116050	SLX4 wt Allele|BTB (POZ) Domain Containing 12 Gene|BTBD12|FANCP|Fanconi Anemia, Complementation Group P Gene|KIAA1784|KIAA1987|MUS312|MUS312, Drosophila, Homolog of Gene|SLX4 Structure-Specific Endonuclease Subunit Homolog (S. cerevisiae) Gene|SLX4 Structure-Specific Endonuclease Subunit wt Allele|SLX4, S. cerevisiae, Homolog of Gene	Human SLX4 wild-type allele is located in the vicinity of 16p13.3 and is approximately 30 kb in length. This allele, which encodes structure-specific endonuclease subunit SLX4 protein, plays a role in both the regulation of endonuclease activity and the recognition of damaged DNA. Mutation of the gene is associated with Fanconi anemia complementation group P.	SLX4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116052>	C21170	Structure-Specific Endonuclease Subunit SLX4|BTB/POZ Domain-Containing Protein 12|Fanconi Anemia Group P Protein|SLX4|SLX4 Structure-Specific Endonuclease Subunit Homolog	Structure-specific endonuclease subunit SLX4 (1834 aa, ~200 kDa) is encoded by the human SLX4 gene. This protein is involved in the both the recognition of DNA damage and the promotion of endonuclease activity.	Structure-Specific Endonuclease Subunit SLX4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116053>	C20921	DOCK8 Gene|DOCK8|DOCK8|Dedicator of Cytokinesis 8 Gene	This gene plays a role in guanine nucleotide exchange for CDC42.	DOCK8 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116054>	C116053	DOCK8 wt Allele|Dedicator of Cytokinesis 8 wt Allele|FLJ00026|FLJ00152|FLJ00346|HEL-205|MRD2|ZIR8	Human DOCK8 wild-type allele is located in the vicinity of 9p24.3 and is approximately 250 kb in length. This allele, which encodes dedicator of cytokinesis protein 8, may be involved in the activation of small GTPases. Variation in the gene is associated with autosomal recessive hyperimmunoglobulin E recurrent infection syndrome and disruption or deletion of the gene is associated with autosomal dominant mental retardation 2.	DOCK8 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116055>	C17494	Dedicator of Cytokinesis Protein 8|1200017A24Rik|DOCK8|Epididymis Luminal Protein 205	Dedicator of cytokinesis protein 8 (2099 aa, ~239 kDa) is encoded by the human DOCK8 gene. This protein may play a role in the regulation of small GTPase activity.	Dedicator of Cytokinesis Protein 8		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116056>	C25939	ALDH1A1 Gene|ALDH1A1|ALDH1A1|Aldehyde Dehydrogenase 1 Family, Member A1 Gene	This gene is involved in the metabolism of retinal.	ALDH1A1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116057>	C116056	ALDH1A1 wt Allele|ALDC|ALDH, Liver Cytosolic Gene|ALDH-E1|ALDH1|ALDH11|Aldehyde Dehydrogenase 1 Family, Member A1 wt Allele|Aldehyde Dehydrogenase 1, Soluble Gene|Aldehyde Dehydrogenase, Liver Cytosolic Gene|HEL-9|HEL-S-53e|HEL12|PUMB1|RALDH1|RP11-151D14.2	Human ALDH1A1 wild-type allele is located in the vicinity of 9q21.13 and is approximately 180 kb in length. This allele, which encodes retinal dehydrogenase 1 protein, plays a role in retinoic acid metabolism.	ALDH1A1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116058>	C16946	Retinal Dehydrogenase 1|ALDH Class 1|ALDH-E1|ALDH1A1|ALHDII|Aldehyde Dehydrogenase Family 1 Member A1|Aldehyde Dehydrogenase, Cytosolic|EC 1.2.1.36|RALDH 1|RalDH1|Retinaldehyde Dehydrogenase 1	Retinal dehydrogenase 1 (501 aa, ~55 kDa) is encoded by the human ALDH1A1 gene. This protein is involved in the oxidation of retinaldehyde.	Retinal Dehydrogenase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116059>	C21114	TNFSF8 Gene|TNFSF8|TNFSF8|Tumor Necrosis Factor (Ligand) Superfamily, Member 8 Gene	This gene plays a role in the modulation of T-cell proliferation.	TNFSF8 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C11605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11605>	C61063	Cisplatin/Flavopiridol/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116060>	C116059	TNFSF8 wt Allele|CD153|CD30L|CD30LG|Tumor Necrosis Factor (Ligand) Superfamily, Member 8 wt Allele	Human TNFSF8 wild-type allele is located in the vicinity of 9q33 and is approximately 37 kb in length. This allele, which encodes tumor necrosis factor ligand superfamily member 8 protein, is involved in the positive regulation of T-lymphocyte proliferation.	TNFSF8 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116061>	C20500	Tumor Necrosis Factor Ligand Superfamily Member 8|CD153|CD153 Antigen|CD30 Antigen Ligand|CD30 Ligand|CD30-L|TNFSF8	Tumor necrosis factor ligand superfamily member 8 (234 aa, ~26 kDa) is encoded by the human TNFSF8 gene. This protein plays a role in the induction of T-cell proliferation.	Tumor Necrosis Factor Ligand Superfamily Member 8		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116064>	C253	Liposomal Mitoxantrone Hydrochloride|Mitoxantrone Hydrochloride Liposome	A formulation composed of the hydrochloride salt form of the anthracenedione antibiotic mitoxantrone encapsulated within liposomes, with potential antineoplastic activity. Upon intravenous administration, mitoxantrone intercalates into and forms crosslinks with DNA, thereby disrupting DNA and RNA replication. This agent also binds to topoisomerase II, which both results in DNA strand breaks and prevents DNA synthesis. This leads to the induction of apoptosis in the rapidly dividing cancer cells. The liposomal delivery of mitoxantrone improves drug penetration into tumors and decreases drug clearance, thereby increasing drug circulation and therapeutic efficacy while lowering the toxic effects.			Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116065>	C129822|C128058	Anti-GITR Monoclonal Antibody MK-4166|MK-4166	An anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) agonistic monoclonal antibody (MoAb) with potential immunomodulating activity. Anti-GITR monoclonal antibody MK-4166 binds to and activates GITRs found on multiple types of T-cells. This stimulates the immune system and induces both the activation and proliferation of tumor-antigen-specific T effector cells, and suppresses the function of activated T regulatory cells. This leads to tumor cell eradication. Also, this agent is shown to act synergistically with chemotherapeutic drugs in multiple cancer models. GITR, a member of the TNF receptor superfamily, is expressed on the surface of multiple types of immune cells, including regulatory T-cells, effector T-cells, B-cells, and natural killer (NK) cells.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116066>	C93259|C213472|C129825	Sulfatinib|HMPL-012|SURUFATINIB|Surufatinib	An orally bioavailable, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, and the fibroblast growth factor receptor type 1 (FGFR1), with potential antineoplastic and anti-angiogenic activities. Upon oral administration, sulfatinib binds to and inhibits VEGFRs and FGFR1 thereby inhibiting VEGFR- and FGFR1-mediated signal transduction pathways. This leads to a reduction of angiogenesis and tumor cell proliferation in VEGFR/FGFR1-overexpressing tumor cells. Expression of VEGFRs and FGFR1 may be upregulated in a variety of tumor cell types.	Sulfatinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116067>	C1752|C1663	Long Peptide Vaccine 7|LPV7	A peptide vaccine consisting of a combination of seven synthetic long peptides (SLPs), which are each about 30 amino acids in size, and derived from cancer-testis antigens (CTA) and melanocytic differentiation proteins (MDP), with potential immunostimulating and antitumor activities. Upon administration, long peptide vaccine 7 may stimulate the host immune system to mount a cytotoxic T-cell lymphocyte (CTL) response against tumor cells expressing these peptides. CTA and MDP are overexpressed in a variety of cancer cell types.	Long Peptide Vaccine 7		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116068>	C209713	Aurora A Kinase Inhibitor VIC-1911|Aurora A Kinase Inhibitor TAS-119|TAS-119|TAS-119|TAS-2104|VIC 1911|VIC-1911|VIC1911	An orally bioavailable inhibitor of the serine/threonine protein kinase aurora A, with potential antimitotic and antineoplastic activities. Upon intravenous administration, aurora A kinase inhibitor VIC-1911 binds to and inhibits aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, inhibition of cell division and the induction of apoptosis in cells overexpressing aurora A kinase. Aurora A kinase localizes to the spindle poles and to spindle microtubules during mitosis; it plays an essential role in the regulation of spindle assembly. Aurora kinase A is overexpressed in a wide variety of cancers.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116069>	C200766|C176018	CD19CAR-CD3zeta-4-1BB-CD28-expressing Autologous T-Lymphocytes	Autologous T-lymphocytes transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) coupled to three co-stimulatory signaling domains derived from CD28, 4-1BB (CD137), and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3-zeta), with potential immunomodulating and antineoplastic activities. Upon transfusion, the CD19CAR-CD3zeta-4-1BB-CD28-expressing autologous T-lymphocytes direct the T-lymphocytes to CD19-expressing tumor cells and induce their selective toxicity. CD28, a T-cell surface-associated co-stimulatory molecule, is required for T-cell activation, proliferation, and survival. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19. CD3-zeta is a transmembrane signaling adaptor polypeptide that regulates the assembly of TCR complexes, modulates the expression of the complex on the cell surface and plays a key role in antigen recognition. CD19 antigen, a B-cell specific cell surface antigen, is expressed in all B-cell lineage malignancies.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11606>	C61007	Capecitabine/Vinorelbine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116070>	C129823	Lupartumab Amadotin|BAY112-9980|BAY1129980|LUPARTUMAB AMADOTIN	An antibody-drug conjugate (ADC) composed of an antibody against a structural homolog of the urokinase-type plasminogen activator receptor (uPAR) and tumor-associated antigen, C4.4a, and conjugated with a cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, lupartumab amadotin targets and binds to C4.4a-expressing tumor cells. Upon binding and cell entry, the cytotoxic agent kills the tumor cell. C4.4a, a glycolipid-anchored membrane protein and a member of the Ly-6 family, is overexpressed by a variety of cancer cell types whereas it is minimally expressed on healthy cells.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116071>	C1511	Iodine I 124 CPD-1028|[I-124]-CPD-1028	A radioconjugate composed of the insulin-like growth factor 1 receptor (IGF-1R) binding agent CPD-1028 and conjugated to the radionuclide iodine I 124, with potential tumor imaging upon positron emission tomography/computed tomography (PET/CT). Upon administration, iodine I 124 CPD-1028 targets and binds to IGF-1R-expressing tumor cells. Upon PET/CT imaging, the iodine I 124 moiety can be visualized and the quantity of IGF-1R-expressing tumor cells can be assessed. IGF-1R, a receptor tyrosine kinase overexpressed in a variety of human cancers, plays a significant role in the stimulation of cellular proliferation, oncogenic transformation, and the suppression of apoptosis.			Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	NCI Drug Dictionary Terminology
C116072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116072>	C28681|C129826	Autologous CD8+ Melanoma Specific T Cells|Autologous Melanoma Specific Cytotoxic T Lymphocytes	Autologous CD8 T-lymphocytes against melanoma-associated antigens, with potential immunomodulating and antineoplastic activities. Following leukapheresis and the ex vivo expansion of cytotoxic T-lymphocytes, the autologous CD8+ melanoma specific T-cells are re-introduced into the melanoma patient. These cytotoxic T-cells recognize and kill the patient's own melanoma cells.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116073>	C28203	Chlorogenic Acid|3-Caffeoylquinic Acid|5-O-(3,4-Dihydroxycinnamoyl)-L-quinic Acid|CHLOROGENIC ACID	A polyphenol and the ester of caffeic acid and quinic acid that is found in coffee and black tea, with potential antioxidant and chemopreventive activities. Chlorogenic acid scavenges free radicals, which inhibits DNA damage and may protect against the induction of carcinogenesis. In addition, this agent may upregulate the expression of genes involved in the activation of the immune system and enhances activation and proliferation of cytotoxic T-lymphocytes, macrophages, and natural killer cells. Chlorogenic acid also inhibits the activity of matrix metalloproteinases.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C116074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116074>	C200085	Empesertib|(2R)-2-(4-Fluorophenyl)-N-(4-(2-((2-methoxy-4-(methylsulfonyl)phenyl)amino)(1,2,4)triazolo(1,5-a)pyridin-6-yl)phenyl)propanamide|BAY116-1909|BAY1161909|EMPESERTIB	An orally bioavailable, selective inhibitor of the serine/threonine monopolar spindle 1 (Mps1) kinase, with potential antineoplastic activity. Upon administration, empesertib binds to and inhibits the activity of Mps1. This causes inactivation of the spindle assembly checkpoint (SAC), accelerated mitosis, chromosomal misalignment, chromosomal missegregation, mitotic checkpoint complex destabilization, and increased aneuploidy. This leads to the induction of cell death in cancer cells overexpressing Mps1. Mps1, a kinase expressed in proliferating normal tissues and aberrantly overexpressed in a wide range of human tumors, is activated during mitosis and is essential for SAC functioning and controls chromosome alignment.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116075>	C2124	Copper Cu 64-DOTA-AE105|64Cu-DOTA-AE105	A radiotracer composed of AE105, a urokinase-type plasminogen activator receptor (uPAR) peptide antagonist, conjugated with DOTA and labeled with the radionuclide copper Cu 64, with potential imaging activity upon positron emission tomography (PET). Upon administration, the AE105 moiety of copper Cu 64-DOTA-AE105 targets and binds to uPAR-expressing tumor cells. Upon PET imaging, the copper Cu 64 moiety can be visualized, uPAR-expressing tumor cells can be quantified and the degree of tumor aggressiveness can be assessed. uPAR expression is correlated with increased tumor invasiveness and aggressiveness as well as a poor prognosis.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C116076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116076>	C27993	Very|Very much	Existing to a great degree.			Qualitative Concept	Memorial Symptom Assessment Scale (MSAS) 7-12|Prognosis Treatment and Perceptions Questionnaire
C116077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116077>	C92722	Chance	The possibility or likelihood that something will happen.			Conceptual Entity	Prognosis Treatment and Perceptions Questionnaire
C116078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116078>	C20917|C20745	CEP76 Gene|CEP76|CEP76|Centrosomal Protein 76 Gene	This gene is involved in centriole duplication.			Gene or Genome	
C116079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116079>	C116078	CEP76 wt Allele|C18orf9|Centrosomal Protein 76 wt Allele|Centrosomal Protein 76kDa Gene|Centrosomal Protein, 76-kD Gene|Chromosome 18 Open Reading Frame 9 Gene|FLJ12542|HsT1705	Human CEP76 wild-type allele is located in the vicinity of 18p11.21 and is approximately 41 kb in length. This allele, which encodes centrosomal protein of 76 kDa, plays a role in the regulation of centriole duplication.			Gene or Genome	
C11607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11607>	C168794	Fludarabine/Melphalan Regimen|Fludarabine-Melphalan|Fludarabine/Melphalan|Fludarabine/Melphalan|Melphalan-Fludarabine|Melphalan/Fludarabine	A regimen consisting of fludarabine and melphalan that may be used as a conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT).			Therapeutic or Preventive Procedure	
C116080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116080>	C17761|C16492	Centrosomal Protein of 76 kDa|Cep76	Centrosomal protein of 76 kDa (659 aa, ~74 kDa) is encoded by the human CEP76 gene. This protein is involved in the regulation of centriole duplication.			Amino Acid, Peptide, or Protein	
C116081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116081>	C2959	Dialysis Access Complication	Any issue that arises as a consequence of a problem with a patient's dialysis access.			Finding	NICHD Terminology
C116082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116082>	C20917	TPX2 Gene|TPX2|TPX2|TPX2 Microtubule Nucleation Factor Gene	This gene plays a role in the assembly of the mitotic spindle.	TPX2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116083>	C116082	TPX2 wt Allele|C20orf1|C20orf2|Chromosome 20 Open Reading Frame 1 Gene|DIL-2|DIL2|FLS353|GD:C20orf1|HCA519|HCA90|HCTP4|REPP86|RP11-243J16.10-002|TPX2 Microtubule Nucleation Factor wt Allele|TPX2, Microtubule-Associated Gene|TPX2, Microtubule-Associated, Homolog (Xenopus Laevis) Gene|TPX2, Xenopus, Homolog of Gene|p100	Human TPX2 wild-type allele is located in the vicinity of 20q11.2 and is approximately 63 kb in length. This allele, which encodes targeting protein for Xklp2, is involved in mitotic spindle assembly. Aberrant expression is associated with lung carcinoma.	TPX2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116084>	C17761	Targeting Protein for Xklp2|DIL-2|Differentially Expressed In Cancerous and Non-Cancerous Lung Cells 2|Differentially Expressed In Lung Cells|Hepatocellular Carcinoma-Associated Antigen 519|Preferentially Expressed In Colorectal Cancer|Protein Fls353|Restricted Expression Proliferation Associated Protein 100|Restricted Expression Proliferation-Associated Protein 100|TPX2|TPX2, Microtubule-Associated Protein Homolog|p100	Targeting protein for Xklp2 (747 aa, ~86 kDa) is encoded by the human TPX2 gene. This protein plays a role in the formation of mitotic spindles.	Targeting Protein for Xklp2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116085>	C26057|C25952	ZRANB3 Gene|ZRANB3|ZRANB3|Zinc Finger RANBP2-Type Containing 3 Gene	This gene is involved in both DNA damage response and DNA rewinding.			Gene or Genome	
C116086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116086>	C116085	ZRANB3 wt Allele|4933425L19Rik|AH2|DKFZP434B1727|Zinc Finger RANBP2-Type Containing 3 wt Allele|Zinc Finger, RAN-Binding Domain Containing 3 Gene	Human ZRANB3 wild-type allele is located in the vicinity of 2q21.3 and is approximately 394 kb in length. This allele, which encodes DNA annealing helicase and endonuclease ZRANB3 protein, plays a role in both DNA rewinding and the response to DNA damage.			Gene or Genome	
C116087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116087>	C16561|C16517	DNA Annealing Helicase and Endonuclease ZRANB3|AH2|Annealing Helicase 2|DNA Annealing Helicase ZRANB3|EC 3.1.-.-|EC 3.6.4.-|Endonuclease ZRANB3|ZRANB3|Zinc Finger RANBP2-Type Domain-Containing Protein 3|Zinc Finger Ran-Binding Domain-Containing Protein 3	DNA annealing helicase and endonuclease ZRANB3 (1079 aa, ~123 kDa) is encoded by the human ZRANB3 gene. This protein is involved in both the modification of DNA topology and the response to DNA damage.			Amino Acid, Peptide, or Protein|Enzyme	
C116088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116088>	C26006	STX2 Gene|STX2|STX2|Syntaxin 2 Gene	This gene plays a role in epithelial morphogenesis.			Gene or Genome	
C116089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116089>	C116088	STX2 wt Allele|EPM|STX2A|STX2B|STX2C|Syntaxin 2 wt Allele	Human STX2 wild-type allele is located in the vicinity of 12q24.33 and is approximately 50 kb in length. This allele, which encodes syntaxin-2 protein, is involved in both vesicular transport and epithelial morphogenesis.			Gene or Genome	
C11608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11608>	C61063	Cyclophosphamide/Epirubicin/Fluorouracil/Methotrexate			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116090>	C16386	Syntaxin-2|Epimorphin|STX2|Syntaxin 2	Syntaxin-2 (288 aa, ~33 kDa) is encoded by the human STX2 gene. This protein plays a role in both epithelial morphogenesis and vesicle trafficking.			Amino Acid, Peptide, or Protein	
C116091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116091>	C133710	TRIM23 Gene|TRIM23|TRIM23|Tripartite Motif Containing 23 Gene	This gene is involved in the modulation of ubiquitination.			Gene or Genome	
C116092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116092>	C116091	TRIM23 wt Allele|ARD1|ARFD1|RNF46|Tripartite Motif Containing 23 wt Allele	Human TRIM23 wild-type allele is located in the vicinity of 5q12.3 and is approximately 36 kb in length. This allele, which encodes E3 ubiquitin-protein ligase TRIM23 protein, plays a role in both protein ubiquitination and viral processes.			Gene or Genome	
C116093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116093>	C21254	E3 Ubiquitin-Protein Ligase TRIM23|ADP-Ribosylation Factor Domain Protein 1|ADP-Ribosylation Factor Domain Protein 1, 64kDa|ADP-Ribosylation Factor Domain-Containing Protein 1|ARF Domain Protein 1|EC 2.3.2.27|EC 6.3.2.-, Formerly|GTP-Binding Protein ARD-1|RING Finger Protein 46|TRIM23|Tripartite Motif Protein TRIM23|Tripartite Motif-Containing 23|Tripartite Motif-Containing Protein 23	E3 ubiquitin-protein ligase TRIM23 (574 aa, ~64 kDa) is encoded by the human TRIM23 gene. This protein is involved in both viral processes and the ubiquitination of proteins.			Amino Acid, Peptide, or Protein|Enzyme	
C116094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116094>	C35869	FDG-PET Scanning Finding	A nuclear medicine finding obtained using FDG-PET imaging technique.			Finding	
C116095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116095>	C116094	Tumor Complete Metabolic Response by PET|Definite Tumor Complete Metabolic Response|Definite complete metabolic response|FDG-PET Tumor CMR|FDG-PET Tumor Complete Metabolic Response|Tumor CMR	A finding obtained using FDG-PET imaging demonstrating the disappearance of metabolic tumor activity in target and non-target lesions, marked by a decrease in tumor standardized uptake value to the level of surrounding normal tissue.			Finding	
C116096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116096>	C116094	Likely Tumor Complete Metabolic Response by PET|FDG-PET Likely Tumor Complete Metabolic Response|Likely complete metabolic response	A finding of diffuse metabolic activity at the primary tumor or nodal sites that is greater than background uptake but less than liver uptake, detected by PDG-PET.			Finding	
C116097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116097>	C20194	CABCOCO1 Gene|C10orf107|CABCOCO1|CABCOCO1|Ciliary Associated Calcium Binding Coiled-Coil 1 Gene	This gene may play a role in the regulation of blood pressure.			Gene or Genome	
C116098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116098>	C116094	Likely Residual Metabolic Tumor Activity by PET|FDG-PET Likely Residual Metabolic Tumor Activity|Likely Residual Metabolic Disease|Likely residual metabolic disease	A finding of focal metabolic activity at the primary or nodal sites that is greater than liver uptake, as detected by FDG-PET.			Finding	
C116099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116099>	C116097	CABCOCO1 wt Allele|C10orf107|Chromosome 10 Open Reading Frame 107 Gene|Ciliary Associated Calcium Binding Coiled-Coil 1 wt Allele|Em:AC022398.2|MGC44593|RP11-63A2.1|bA63A2.1	Human CABCOCO1 wild-type allele is located in the vicinity of 10q21.2 and is approximately 104 kb in length. This allele, which encodes ciliary-associated calcium-binding coiled-coil protein 1, may be involved in the modulation of blood pressure. Variation in the gene is associated with dichotomous hypertension.			Gene or Genome	
C11609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11609>	C61007	Docetaxel/Irinotecan			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1160>	C260	Meropenem|MEROPENEM|Meropenem Trihydrate|Merrem I.V.|SM-7338	A broad-spectrum carbapenem with antibacterial properties, synthetic Meropenem inhibits cell wall synthesis in gram-positive and gram-negative bacteria. It penetrates cell walls and binds to penicillin-binding protein targets. Meropenem acts against aerobes and anaerobes including Klebsiella, E. coli, Enterococcus, Clostridium sp.. (NCI04)			Antibiotic|Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C116100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116100>	C116094	Definite Residual Metabolic Tumor Activity by PET|Definite Residual Metabolic Disease|Definite residual metabolic disease|FDG-PET Definite Residual Metabolic Tumor Activity	A finding of strong focal metabolic activity at the primary or nodal sites that is greater than liver uptake, as detected by FDG-PET.			Finding	
C116101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116101>	C18466	Ciliary-Associated Calcium-Binding Coiled-Coil Protein 1|CABCOCO1|Calcium Binding Coiled-Coil Protein 1|Calcium Binding Coiled-Coil Protein-1|Ciliary-Associated Calcium-Binding Coiled-Coil 1|Uncharacterized Protein C10orf107	Ciliary-associated calcium-binding coiled-coil protein 1 (208 aa, ~24 kDa) is encoded by the human CABCOCO1 gene. This protein may play a role in blood pressure regulation.			Amino Acid, Peptide, or Protein	
C116102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116102>	C116094	Likely Inflammatory Activity by PET|FDG-PET Likely Inflammatory Activity|FDG-PET Post-Radiation Inflammation Activity|Likely inflammatory|Post-Radiation Inflammation Activity	A finding of metabolic activity at the primary or nodal sites that is greater than liver uptake, but can be attributed to inflammation activity, as detected by FDG-PET.			Finding	
C116103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116103>	C66830	CDISC SDTM Nervous System Physiology Test Name Terminology|NVTEST|Nervous System Findings Test Name|SDTM-NVTEST	Terminology associated with the nervous system physiology test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C116104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116104>	C66830	CDISC SDTM Nervous System Physiology Test Code Terminology|NVTESTCD|Nervous System Findings Test Code|SDTM-NVTESTCD	Terminology associated with the nervous system physiology test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C116105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116105>	C103175	CDISC SDTM Pharmacogenomics Findings Test Name Terminology|SDTM-PFTEST	Terminology associated with the pharmacogenomics findings test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	
C116106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116106>	C103175	CDISC SDTM Pharmacogenomics Findings Test Code Terminology|SDTM-PFTESTCD	Terminology associated with the pharmacogenomics findings test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	
C116107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116107>	C66830	CDISC SDTM Death Diagnosis Test Name Terminology|DTHDX|SDTM Death Diagnosis and Details Test Name|SDTM-DTHDX	Terminology associated with the death detail test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C116108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116108>	C66830	CDISC SDTM Death Diagnosis Test Code Terminology|DTHDXCD|SDTM Death Diagnosis and Details Test Code|SDTM-DTHDXCD	Terminology associated with the death detail test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C116109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116109>	C103175	CDISC SDTM Viral Resistance Findings Test Name Terminology|SDTM-VRTEST	Terminology associated with the viral resistance findings test name of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	
C11610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11610>	C61063	Fowlpox Virus Vaccine/Interleukin-2/Vaccinia-Tyrosinase Vaccine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116110>	C103175	CDISC SDTM Viral Resistance Findings Test Code Terminology|SDTM-VRTESTCD	Terminology associated with the viral resistance findings test code of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	
C116111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116111>	C103175	CDISC SDTM Species Terminology|SDTM-SPCIES	Terminology associated with the SDTM species codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	
C116112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116112>	C34076	Spinous Process|SPINOUS PROCESS	A bony projection arising from the posterior vertebral arch that serves for the attachment of muscles and ligaments.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116113>	C90336	Lethal Injection Euthanasia|LETHAL INJECTION	A method of euthanasia whereby a subject is given a lethal injection to induce death.			Research Activity	CDISC SEND Method of Termination Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116114>	C90336	Lethal Injection and Exsanguination Euthanasia|LETHAL INJECTION EXSANGUINATION	A method of euthanasia whereby a subject is given a lethal injection and the body is drained of blood.			Research Activity	CDISC SEND Method of Termination Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116115>	C26891	Stent Thrombosis	The formation of a blood clot of a vessel or heart chamber after and due to the placement of a stent.			Disease or Syndrome	
C116116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116116>	C12679	Arterial Segment	A segment of a blood vessel that is part of the arterial system.			Body Part, Organ, or Organ Component	
C116117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116117>	C74957	Inhibitory Concentration Test	A laboratory test to determine the concentration of a substance that will inhibit a biological or biochemical function, such as microorganism growth or enzymatic activity.			Laboratory Procedure	
C116118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116118>	C25256	Multiplex Probe Parameter|MULTPLEX	A description of the number of unique molecular probes used in each assay well or tube.			Quantitative Concept	CDISC SDTM Device Properties Test Code Terminology|CDISC SDTM Device Properties Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C116119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116119>	C53265	MRI Coil Type|MRICTYPE	The classification of the coil that is used in an magnetic resonance imaging procedure. Usually refers to the anatomical location for where the coil is placed such as head, body or breast.			Qualitative Concept	CDISC SDTM Device Properties Test Code Terminology|CDISC SDTM Device Properties Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11611>	C61063	Interleukin-2/Vaccinia-Tyrosinase Vaccine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116120>	C25284	Scintillation Crystal Type|SCRYSTYP	The classification of the crystalline material, which emits light in response to radiation exposure, used in the imaging procedure.			Functional Concept	CDISC SDTM Device Properties Test Code Terminology|CDISC SDTM Device Properties Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C116121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116121>	C62954	Data Storage Failure|DATA STORAGE FAILURE	Issue associated with the failure of the software to store collected data.			Event	CDISC SDTM Device Events Category Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C116122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116122>	C48192	Image Weighting Type|IMWGTTYP	A classification of the technique used to enhance image contrast based on differences in magnetic resonance tissue properties. This can be achieved by changing the echo time or repetition time after the tissue has returned to its equilibrium state.			Idea or Concept	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116123>	C25167	Interslice Distance Measurement|INTDISTM|Interslice Distance|Interslice Distance	A measurement of the distance between slices within an image sequence, calculated by subtracting the nominal slice thickness from the couch increment.			Quantitative Concept	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116124>	C82572	Inversion Time|INVRTIME	The time between the inversion and excitation pulses in an inversion recovery pulse sequence. (CDISC)			Quantitative Concept	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116125>	C25337	Number of Slices|NUMSLICE	The total number of image slices that are recorded during an imaging procedure.			Quantitative Concept	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116126>	C42676	Image Acquisition Dimensionality|IMAQDIM	The number of dimensions that the acquired image(s) are presented in.			Spatial Concept	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116127>	C25180	Decay Correction Indicator|DECCORR	An indication as to whether the image reconstruction took into account the time-activity curve during which the radiolabeled tracer decayed as it spread through the body during the image acquisition.			Conceptual Entity	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116128>	C25180	Randoms Correction Indicator|RANDCORR	An indication as to whether the device was set to correct for random noise generated by deflected positrons.			Conceptual Entity	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116129>	C41328	Junctional Escape Complexes by ECG Finding|JUNCTIONAL ESCAPE COMPLEXES|Junctional Escape Beat|Junctional Escape Complex	An electrocardiographic finding of an escape beat following a pause that originates at the AV junction; this manifests as a QRS complex of supraventricular origin not immediately preceded by a P wave. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11612>	C61063	Amifostine/Cyclophosphamide/Doxorubicin/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116130>	C41328	Asystole by ECG Finding|ASYSTOLE|Asystole	An electrocardiographic finding showing no cardiac electrical activity on the monitor or printed strip for the entire duration of the recording. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|Clinical Data Interchange Standards Consortium Terminology
C116131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116131>	C41328	Undetermined Rhythm by ECG Finding|UNDETERMINED RHYTHM	An electrocardiographic finding of a cardiac rhythm whose mechanism cannot be determined from the ECG. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116132>	C41328	Aberrantly Conducted Complexes by ECG Finding|ABERRANTLY CONDUCTED COMPLEXES|Aberrantly Conducted Beats	An electrocardiographic finding of abnormal QRS complex(es) that are supraventricular in origin, and that are wide secondary to aberrant AV conduction. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116133>	C41328	Low Voltage in Limb Leads Only by ECG Finding|LOW VOLTAGE - LIMB LEADS ONLY	An electrocardiographic finding of small QRS amplitudes (less than 500 microvolts) in all limb leads. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116134>	C114120	Non-Diagnostic Q Waves by ECG Finding|NON-DIAGNOSTIC Q WAVES	An electrocardiographic finding of Q waves that are insufficient for the diagnosis of myocardial infarction. In such cases, a myocardial infarction may be suspected even though ECG diagnostic criteria are absent. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116135>	C41328	PR Segment Depression by ECG Finding|PR Depression|PR SEGMENT DEPRESSION	An electrocardiographic finding of PR segment depression below the iso-electric line in multiple precordial and/or limb leads. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116136>	C41328	Short ST Segment by ECG Finding|SHORT ST SEGMENT	An electrocardiographic finding of a short or absent ST segment, resulting in a decreased QT interval, without changes in T wave morphology; this may be observed in hypercalcemia. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116137>	C41328	Prolonged ST Segment by ECG Finding|PROLONGED ST SEGMENT	An electrocardiographic finding of a prolonged ST segment, resulting in an increased QT interval, without lengthening of the T wave duration; this may be observed in hypocalcemia. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116138>	C41328	ACC/AHA Ischemic ECG Changes|CV ENDPOINTS ISCHEMIC ECG CHANGES	An electrocardiographic finding, in the absence of left ventricular hypertrophy (LVH) and left bundle branch block pattern on ECG, of either a) new (or presumed new) ST elevation at the J point in two contiguous leads with the following cut-points: greater than or equal to 0.1 mV in all leads other than leads V2-V3 where the following cut points apply: greater than or equal to 0.2 mV in men age greater than or equal to 40 years, greater than or equal to 0.25 mV in men age greater than 40 years, or greater than or equal to 0.15 mV in women; or b) new (or presumed new) horizontal or down-sloping ST depression greater than or equal to 0.05 mV in two contiguous leads, and/or T wave inversion greater than or equal to 0.1 mV in two contiguous leads with a prominent R wave, or R/S ratio greater than 1. (Thygesen K, Alpert JS, Jaffe AS, et al.: the Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. J Am Coll Cardiol 60(16):1-18, 2012)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116139>	C71100	12 Lead Placement Right-sided Precordial Leads|12 LEAD RIGHT-SIDED PRECORDIAL LEADS|12 Lead Right-sided Precordial Leads|Right-sided Chest Leads	An electrocardiogram (ECG) lead placement whereby the precordial leads are intentionally placed on the right side of the chest. (CDISC)			Spatial Concept	CDISC SDTM ECG Test Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11613>	C61063	Docetaxel/GEM 231			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116140>	C102675	Acute Myocardial Ischemia by ECG Assessment|AMIEGCHG|Acute Myocardial Ischemia ECG Change|Acute Myocardial Ischemia ECG Change	An electrocardiographic finding assessment of new or presumed new significant ST-segment-T wave (ST-T) changes or new left bundle branch block consistent with acute myocardial ischemia. (Thygesen K, Alpert JS, Jaffe AS, et al.: the Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. J Am Coll Cardiol 60(16):1-18, 2012)			Finding	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116141>	C92571	Standard Uptake Value Ratio|SUVR	An effectively dimensionless measure of regional tracer uptake calculated as the ratio between the uptake or binding of a radiopharmaceutical agent in an anatomical region of interest versus the uptake or binding of a radiopharmaceutical agent in a reference anatomical region.			Quantitative Concept	CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C116142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116142>	C81239	Secondary Cause of Death|SECDTH	The second significant event which ultimately led to death.			Finding	CDISC SDTM Death Diagnosis Test Code Terminology|CDISC SDTM Death Diagnosis Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C116143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116143>	C101685	Mean Vessel Diameter|MEANVDIA	The mean of the inside diameters of the normal blood vessel segments.			Spatial Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C116144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116144>	C101685	Minimum Vessel Lumen Diameter|MINLDIAM	The minimum diameter of the inside of a blood vessel (lumen) derived quantitatively in a single view.			Spatial Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C116145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116145>	C25285	Percent Diameter Stenosis|PCTDIAST	The value calculated as 100 x (1 - MLD/RVD), using the mean quantitative values for minimum lumen diameter (MLD) and reference vessel diameter (RVD).			Spatial Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C116146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116146>	C101685	Late Lumen Loss Measurement|LLMLOSS|Late Lumen Loss|Late Lumen Loss	The difference between the mean minimum lumen diameter (MLD) assessed immediately after an index procedure and the MLD assessed at follow-up angiography.			Quantitative Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C116147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116147>	C93593	Lesion Restenosis Indicator|LRSTIND	An indication as to whether there is re-narrowing of a lesion site following treatment of a prior stenosis, to a diameter stenosis of greater than 50% at the previously treated lesion site.			Qualitative Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C116148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116148>	C93593	In-Stent Restenosis Indicator|INRSTIND	An indication as to whether there is re-narrowing of a stent implanted at a lesion site to treat a prior stenosis, to a diameter stenosis of greater than 50% within the stent.			Qualitative Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C116149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116149>	C64493	Every Seven Weeks|EVERY 7 WEEKS|Every 7 weeks|Q7S	Every seven weeks.			Quantitative Concept	CDISC SDTM Frequency Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11614>	C61063	GEM 231/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116150>	C49236	Peripheral Vascular Intervention|PERIPHERAL VASCULAR INTERVENTION|PVI	A catheter-based or open surgical procedure designed to improve arterial or venous blood flow or otherwise modify or revise vascular conduits.	Peripheral Vascular Intervention		Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C116151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116151>	C44282	Single Nucleotide Polymorphism Array|Genotype Chip|SNP ARRAY|SNP Genotyping|SNP Probe	A genomic microarray-based method able to detect single nucleotide polymorphisms.			Molecular Biology Research Technique	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116152>	C18881|C18473	Cross-linking Immunoprecipitation High-throughput Sequencing|CLIP SEQUENCING|CLIP Sequencing|CLIP-Seq|HITS-CLIP	A molecular biology method combining crosslinking-immunoprecipitation and high-throughput sequencing techniques to detect and map RNA-protein interactions. In CLIP, whole tissues, organisms or individual cell types are treated with UV irradiation, which introduces covalent bonds between RNA-protein complexes. This is followed by immunoprecipitation and removal of the protein component of the crosslinked complex. The purified RNAs are then fragmented, reduced in size and subjected to high-throughput sequencing for the identification of RNA binding sites.			Molecular Biology Research Technique	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116153>	C44282	Two Color Microarray|Dual-channel Microarray|TWO-COLOR MICROARRAY|Two-channel Expression Array|Two-channel Microarray|Two-color Microarray-based Gene Expression	A genomic microarray-based method using cDNA from two samples, labeled with two separate fluorophores/dyes at different emission wavelengths, and hybridized to a single microarray for laser excitation in a microarray scanner. Relative fluorescence intensity of each dye can be measured and used in log- or intensity- ratio based comparative analysis for gene expression between the two experimental conditions.			Molecular Biology Research Technique	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116154>	C153598	Direct Sequencing|DIRECT SEQUENCING	A technique used to identify the sequence of individual nucleobases in a single strand of DNA fragment template, which can be a plasmid insert, genomic DNA or a PCR product. In addition, direct sequencing of genomic DNA or PCR products does not require sub-cloning of the gene of interest into a vector.			Molecular Biology Research Technique	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116155>	C17565	Biopolymer Sequencing|SEQUENCING|Sequencing	A process to identify and determine the primary structure of, and the order of constituents in a biopolymer.			Molecular Biology Research Technique	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|pFDA Bioinformatics/Genomics Terminology|precisionFDA Terminology
C116156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116156>	C198497	Oligonucleotide Array-based Comparative Genomic Hybridization|OLIGO ACGH|Oligonucleotide Array-based CGH	A molecular cytogenetic method combining chromosomal comparative genomic hybridization technique and microarray to detect chromosomal aberrations and changes in DNA copy numbers in the genome, using oligonucleotides immobilized on a solid support as targets for hybridization.			Molecular Biology Research Technique	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116157>	C198497	Bacterial Artificial Chromosome Array-based Comparative Genomic Hybridization|BAC ACGH|BAC Array-based CGH|Bacterial Artificial Chromosome Array-based CGH	A molecular cytogenetic method combining chromosomal comparative genomic hybridization technique and microarray to detect chromosomal aberrations and changes in DNA copy numbers, using bacterial artificial chromosome clones containing target DNA fragments for hybridization. This method is especially sensitive in detecting single copy changes in the genome.			Molecular Biology Research Technique	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116158>	C17003	Digital Array|DIGITAL PCR ARRAY	A technique used to deliver high-throughput digital PCR. The digital array partitions a sample premixed with PCR reagents into hundreds of individual PCR reactions, which allows the absolute quantification of target sequences and rare allele detection, as compared to conventional real-time quantitative PCR.			Molecular Biology Research Technique	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116159>	C179019	Multiplex Amplifiable Probe Hybridization|MAPH	A screening method used to determine abnormal DNA copy number changes in complex genomes. This method uses unique short probes which can be quantitatively recovered and amplified after hybridization to genomic DNA. In addition, the probes can be specifically designed for any genomic region of interest (such as locus, telomere, chromosomal segment, whole chromosome or total genome) with high hybridization specificity.			Molecular Biology Research Technique	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11615>	C61063	Fluorouracil/Leucovorin Calcium/SCH 66336			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116160>	C17094	Multiple Complete Digest Restriction Fragment Mapping|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|Multiple Complete Digestion	A DNA mapping technique based on complete restriction enzyme digestion of a set of overlapping clones that provides highly redundant coverage of the mapping target.			Molecular Biology Research Technique	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116161>	C179019|C17003	Multiplex Ligation-dependent Probe Amplification|MLPA|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION	A type of high-throughput, multiplex PCR method used to determine abnormal DNA copy number changes of up to 50 genomic DNA or RNA sequences with a single pair of PCR primers. It is frequently used in the detection of genetic aberrations in tumors, and can distinguish sequences differing in only a single nucleotide.			Molecular Biology Research Technique	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116162>	C17094	Optical Mapping|OPTICAL MAPPING|Optical Map	A technique used for constructing the ordered and high-resolution genome or chromosome sized restriction enzyme map of an organism from a single, stained DNA molecule, digested by the restriction enzyme and imaged by an optical microscope.			Molecular Biology Research Technique	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116163>	C116112	Fifth Lumbar Spinous Process|5TH LUMBAR SPINOUS PROCESS	The spinous process of the 5th lumbar vertebra.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116164>	C12470	Skin of the Axilla|SKIN OF THE AXILLA	The skin or integument surrounding the axilla, or underarm.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C116165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116165>	C33073	Aortopulmonary Window Lymph Node|AORTOPULMONARY WINDOW LYMPH NODE|AP Window Lymph Node|Lymph node of aortopulmonary window (body structure)	A lymph node located in the aortopulmonary window.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C116166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116166>	C34027	Aortoiliac Artery Segment|AORTO-ILIAC PERIPHERAL ARTERY	The segment of the arterial system that includes the iliac artery and its origin from the aorta.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116167>	C116116	Femoropopliteal Artery Segment|FEMORO-POPLITEAL PERIPHERAL ARTERY	The segment of the arterial system that includes the popliteal artery and its origin from the femoral artery.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116168>	C116116	Tibialcrural Artery|TIBIAL-CRURAL PERIPHERAL ARTERY	The blood vessel segment that includes the crural artery and the tibial artery.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116169>	C25762	Right Coronary Artery Ostium|RIGHT CORONARY ARTERY OSTIUM	The opening of the right coronary artery at its origin.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11616>	C61063	Cytarabine/Daunorubicin/Tretinoin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116170>	C12843	Posterolateral Coronary Artery|POSTEROLATERAL SEGMENTAL ARTERY	In an individual with a right-dominant heart, the arterial branch that arises from the distal right coronary artery in the posterior atrioventricular groove after the origin of the right posterior descending artery.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116171>	C12875	Right Ventricular Branch of Right Coronary Artery|RIGHT VENTRICULAR BRANCH	The branch of the right coronary artery that supplies blood to the right ventricular wall.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116172>	C25762	Left Main Coronary Artery Ostium|LEFT MAIN CORONARY ARTERY OSTIUM	The opening of the left coronary artery at its origin.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116173>	C116116	Left Main Coronary Artery Body|LEFT MAIN CORONARY ARTERY BODY	The segment of the left main coronary artery that is bounded by its ostium and bifurcation.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116174>	C116116	Left Main Coronary Artery Bifurcation|LEFT MAIN CORONARY ARTERY BIFURCATION	The portion of the distal end of the left main coronary artery that branches into the left anterior descending artery and the left circumflex artery.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116175>	C25762	Left Anterior Descending Artery Ostium|LEFT ANTERIOR DESCENDING ARTERY OSTIUM	The opening of the left anterior descending coronary artery at its origin.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116176>	C25762	Left Circumflex Artery Ostium|LEFT CIRCUMFLEX ARTERY OSTIUM	The opening of the left circumflex artery at its origin.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116177>	C12372	Left Atrioventricular Artery|LEFT ATRIOVENTRICULAR ARTERY	The first posterolateral branch originating from the posterior atrioventricular left circumflex artery in left dominant and mixed circulations.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116178>	C12843	Left Posterior Descending Artery|LEFT POSTERIOR DESCENDING ARTERY	The second posterolateral branch originating from the posterior atrioventricular left circumflex artery in left dominant and mixed circulations.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116179>	C34027	Infrarenal Aortic Segment|INFRARENAL AORTA	The portion of the abdominal aorta that lies below the kidneys.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11617>	C61063	Daunorubicin/Tretinoin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116180>	C33337	Popliteal Artery Above the Knee|POPLITEAL ARTERY ABOVE KNEE	The segment of the popliteal artery that is located above the knee.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116181>	C33337	Popliteal Artery Below the Knee|POPLITEAL ARTERY BELOW KNEE	The segment of the popliteal artery that is located below the knee.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116182>	C116116	Tibioperoneal Arterial Trunk|TIBIO-PERONEAL TRUNK	An arterial trunk that contains parts of the posterior tibial artery and fibular artery.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116183>	C12778	Accessory Renal Artery|ACCESSORY RENAL ARTERY	An additional renal artery originating from the aorta. Accessory renal arteries are found in 26-30% of humans.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116184>	C49237	Inclusion Body Measurement|INCLBOD|Inclusion Bodies|Inclusion Bodies	A measurement of the protein, lipid or small molecule aggregates located within the cytoplasm.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116185>	C49237	Azurophilic Granule Measurement|AZURGRAN|Azurophilic Granulation|Azurophilic Granules|Azurophilic Granules	The determination of the amount of azurophilic granules present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116186>	C51948	Heterophil Measurement|HETRPH|Heterophils|Heterophils	The determination of the amount of heterophils present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116187>	C67208	Heterophils to Leukocytes Ratio Measurement|HETRPHLE|Heterophils/Leukocytes|Heterophils/Leukocytes	The determination of the ratio of heterophils compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116188>	C51947	High Absorption Reticulocyte Measurement|High Absorption Reticulocytes|High Absorption Reticulocytes|RETIH	The determination of the amount of high absorption reticulocytes present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116189>	C67208	High Absorption Reticulocytes to Total Reticulocytes Ratio Measurement|High Absorption Retic/Reticulocytes|High Absorption Retic/Reticulocytes|RETIHRTC	The determination of the ratio of high absorption reticulocytes compared to total reticulocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11618>	C61063	Fluorouracil-Uracil/Gemcitabine/Leucovorin Calcium			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116190>	C51947	Low Absorption Reticulocyte Measurement|Low Absorption Reticulocytes|Low Absorption Reticulocytes|RETIL	The determination of the amount of low absorption reticulocytes present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116191>	C67208	Low Absorption Reticulocytes to Total Reticulocytes Ratio Measurement|Low Absorption Retic/Reticulocytes|Low Absorption Retic/Reticulocytes|RETILRTC	The determination of the ratio of low absorption reticulocytes compared to total reticulocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116192>	C51947	Medium Absorption Reticulocyte Measurement|Medium Absorption Reticulocytes|Medium Absorption Reticulocytes|RETIM	The determination of the amount of medium absorption reticulocytes present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116193>	C67208	Medium Absorption Reticulocytes to Total Reticulocytes Ratio Measurement|Medium Absorption Retic/Reticulocytes|Medium Absorption Retic/Reticulocytes|RETIMRTC	The determination of the ratio of medium absorption reticulocytes compared to total reticulocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116194>	C81971	Cholera Toxin B Subunit IgG Antibody Measurement	The determination of the amount of cholera toxin B subunit IgG antibody present in a sample.			Laboratory Procedure	
C116195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116195>	C49286	Leukemic Cells Measurement|LEUKCE|Leukemic Cells|Leukemic Cells|Residual Leukemic Cells	The determination of the amount of leukemic cells present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116196>	C210012	Hepatitis C Virus Antigen Measurement|HCAG|Hepatitis C Virus Antigen|Hepatitis C Virus Antigen	The determination of the amount of hepatitis C virus antigen present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C116197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116197>	C74949	IDL Particles Measurement|IDL Particles|IDL Particles|IDLP|Intermediate Density Lipoproteins Particles	The determination of the amount of intermediate density lipoprotein particles present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116198>	C74742	Metanephrine Measurement|METANEPH|Metadrenaline|Metanephrine|Metanephrine	The determination of the amount of metanephrine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116199>	C67208	Mid Cell Fraction Measurement|MIDCEF|Mid Cell Fraction|Mid Cell Fraction|Mid Cells	The determination of the amount of mid cell fraction (including eosinophils, basophils, monocytes and other precursor white blood cells) present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11619>	C61063	CRL 1005/gp100 Antigen/Incomplete Freund's Adjuvant/Tyrosinase Peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1161>	C511|C2153	Metoprine|BW 197U|BW 197U|DDMP|METOPRINE	A diaminopyrimidine folate antagonist with potential antineoplastic activity.  Metoprine inhibits dihydrofolate reductase, resulting in decreased cellular folate metabolism and cell growth; it also inhibits histamine-N-methyltransferase, resulting in decreased histamine catabolism. Lipid-soluble metoprine is capable of crossing the blood-brain barrier. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116200>	C51950	Agranular Neutrophils Measurement|Agranular Neutrophils|Agranular Neutrophils|NEUTAGR	The determination of the amount of agranular neutrophils present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116201>	C51950	Hypogranular Neutrophil Measurement|Hypogranular Neutrophils|Hypogranular Neutrophils|NEUTHYGR	The determination of the amount of hypogranular neutrophils present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116202>	C51950	Left Shift Neutrophil Measurement|Left Shift Neutrophils|Left Shift Neutrophils|NEUTLS	The determination of the presence of left shift neutrophils in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116203>	C49286	Natural Killer Cell Activity Measurement|NKCEFUNC|Natural Killer Cell Activity|Natural Killer Cell Function|Natural Killer Cell Function	The determination of the amount of natural killer cell activity in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116204>	C74949	Non-High Density Lipoprotein Cholesterol Measurement|NONHDL|Non-HDL Cholesterol|Non-HDL Cholesterol|Non-HDL Cholesterol Measurement|Non-High Density Lipoprotein	The determination of the amount of non-high density lipoprotein cholesterol present in a sample.	Non-High Density Lipoprotein Cholesterol Measurement		Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C116205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116205>	C64430	Neuron Specific Enolase Measurement|ENO2 Measurement|Enolase 2|Enolase 2 Measurement|Gamma-Enolase|Gamma-Enolase Measurement|Gamma-enolase|NSE|NSE Measurement|Neuron Specific Enolase|Neuron Specific Enolase|Neuron-Specific Enolase Measurement	The determination of the amount of neuron specific enolase present in a sample.	Neuron Specific Enolase Measurement		Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C116206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116206>	C64430	Osteoprotegerin Measurement|OCIF|OPG|Osteoclastogenesis Inhibitory Factor|Osteoprotegerin|Osteoprotegerin|TNFRS11B|Tumor Necrosis Factor Receptor Superfamily Member 11b	The determination of the amount of osteoprotegerin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116207>	C210010	Parietal Cell Antibody Measurement	The determination of the amount of parietal cell antibody present in a sample.			Laboratory Procedure	
C116208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116208>	C64430	Platelet Derived Growth Factor Isoform AB Measurement|PDGF Isoform AB|PDGFAB|Platelet Derived Growth Factor IsoformAB|Platelet Derived Growth Factor IsoformAB|Platelet Derived Growth Factor-AB Isoform	The determination of the amount of platelet-derived growth factor isoform AB present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116209>	C49286	Platelet Satellitism Assessment|PLATSAT|Platelet Satellitism|Platelet Satellitism	The determination of the presence of platelet satellitism in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11620>	C61063	gp100 Antigen/Incomplete Freund's Adjuvant/Sargramostim/Tyrosinase Peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116210>	C210735|C210010	Panel Reactive Antibody Test|Cross-Matching|Crossmatch|Crossmatching|PRA|PRA Score|PRAB|Panel Reactive Antibody|Panel Reactive Antibody|Percent Panel Reactive Antibody|Percent Reactive Antibody|Percent Reactive Antibody	An assessment of the reactivity between host immune cells and donor human leukocyte antigen. This test is most commonly carried out in subjects awaiting transplant. The recipient's blood or serum is mixed with either a panel of lymphocytes from random blood donations or a potential donor's purified human leukocyte antigens (HLA). Host reactivity is scored as a percent.			Laboratory Procedure	CDISC SDTM Immunogenicity Specimen Assessments Test Code Terminology|CDISC SDTM Immunogenicity Specimen Assessments Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116211>	C74906	Gamma Tocopherol Measurement|GATCPHRL|Gamma Tocopherol|Gamma Tocopherol	The determination of the amount of gamma tocopherol present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116212>	C49286	Erythrocyte Fragment Measurement|Erythrocyte Fragment|Erythrocyte Fragment|RBC Fragment|RBCFRAG	The determination of the amount of red blood cell fragments present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116213>	C47868	Hemodialysis Extraction Ratio|HDER	The determination of the fractional content of a substance removed from the blood during a hemodialysis session.			Laboratory Procedure	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116214>	C134576	Experimental Organism Malignant Neuromyoblastoma|NEUROMYOBLASTOMA, MALIGNANT	A malignant tumor that arises in the brain stem or adjacent cranial nerves, consisting of variable populations of cells which demonstrate both neuronal and myoblast differentiation. (INHAND)			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C116215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116215>	C134576	Experimental Organism Benign Acinar-islet Cell Tumor|ACINAR-ISLET CELL TUMOR, BENIGN	A benign tumor of the pancreas with morphologic characteristics of endocrine, acinar and ductal cells. (INHAND)			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C116216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116216>	C18641	Phototoxicity Study|PHOTOTOXICITY	A study of the effect of an agent on the skin or eyes, such that it induces a sensitivity to sunlight or other forms of light.			Research Activity	CDISC SEND Study Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116217>	C116113	Anesthetized Lethal Injection Euthanasia|ANESTHETIZED LETHAL INJECTION	A method of euthanasia whereby a subject is anesthetized and a lethal chemical is administered by injection to induce death.			Research Activity	CDISC SEND Method of Termination Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116218>	C116113	Anesthetized Intravenous Lethal Injection Euthanasia|ANESTHETIZED LETHAL INJECTION INTRAVENOUS	A method of euthanasia whereby a subject is anesthetized and a lethal chemical is administered by intravenous injection to induce death.			Research Activity	CDISC SEND Method of Termination Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116219>	C116113	Anesthetized Intraperitoneal Lethal Injection Euthanasia|ANESTHETIZED LETHAL INJECTION INTRAPERITONEAL	A method of euthanasia whereby a subject is anesthetized and a lethal chemical is administered by intraperitoneal injection to induce death.			Research Activity	CDISC SEND Method of Termination Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11621>	C61007	Methotrexate/Prednisone			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116220>	C116113	Anesthetized Intracardiac Lethal Injection Euthanasia|ANESTHETIZED LETHAL INJECTION INTRACARDIAC	A method of euthanasia whereby a subject is anesthetized and a lethal chemical is administered by intracardiac injection to induce death.			Research Activity	CDISC SEND Method of Termination Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116221>	C90336	Anesthetized Lethal Injection Exsanguination Euthanasia|ANESTHETIZED LETHAL INJECTION EXSANGUINATION	A method of euthanasia whereby a subject is anesthetized, a lethal chemical is administered by injection and the body is drained of blood.			Research Activity	CDISC SEND Method of Termination Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116222>	C90336	Anesthetized Lethal Injection Intravenous Exsanguination Euthanasia|ANESTHETIZED LETHAL INJECTION INTRAVENOUS EXSANGUINATION	A method of euthanasia whereby a subject is anesthetized, a lethal chemical is administered by intravenous injection and the body is drained of blood.			Research Activity	CDISC SEND Method of Termination Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116223>	C90336	Anesthetized Intraperitoneal Lethal Injection and Exsanguination Euthanasia|ANESTHETIZED LETHAL INJECTION INTRAPERITONEAL EXSANGUINATION	A method of euthanasia whereby a subject is anesthetized, a lethal chemical is administered by intraperitoneal injection and the body is drained of blood.			Research Activity	CDISC SEND Method of Termination Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116224>	C90336	Anesthetized Intracardiac Lethal Injection and Exsanguination Euthanasia|ANESTHETIZED LETHAL INJECTION INTRACARDIAC EXSANGUINATION	A method of euthanasia whereby a subject is anesthetized, a lethal chemical is administered by intracardiac injection and the body is drained of blood.			Research Activity	CDISC SEND Method of Termination Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116225>	C116113	Intravenous Lethal Injection Euthanasia|LETHAL INJECTION INTRAVENOUS	A method of euthanasia whereby a subject is given a lethal intravenous injection to induce death.			Research Activity	CDISC SEND Method of Termination Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116226>	C116113	Intraperitoneal Lethal Injection Euthanasia|LETHAL INJECTION INTRAPERITONEAL	A method of euthanasia whereby a subject is given a lethal intraperitoneal injection to induce death.			Research Activity	CDISC SEND Method of Termination Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116227>	C116113	Intracardiac Lethal Injection Euthanasia|LETHAL INJECTION INTRACARDIAC	A method of euthanasia whereby a subject is given a lethal intracardiac injection to induce death.			Research Activity	CDISC SEND Method of Termination Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116228>	C116114	Intravenous Lethal Injection and Exsanguination Euthanasia|LETHAL INJECTION INTRAVENOUS EXSANGUINATION	A method of euthanasia whereby a subject is given a lethal intravenous injection and the body is drained of blood.			Research Activity	CDISC SEND Method of Termination Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116229>	C116114	Intraperitoneal Lethal Injection and Exsanguination Euthanasia|LETHAL INJECTION INTRAPERITONEAL EXSANGUINATION	A method of euthanasia whereby a subject is given a lethal intraperitoneal injection and the body is drained of blood.			Research Activity	CDISC SEND Method of Termination Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11622>	C61063	Lomustine/Procarbazine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116230>	C116114	Intracardiac Lethal Injection and Exsanguination Euthanasia|LETHAL INJECTION INTRACARDIAC EXSANGUINATION	A method of euthanasia whereby a subject is given a lethal intracardiac injection and the body is drained of blood.			Research Activity	CDISC SEND Method of Termination Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116231>	C70505	Biological Allergy Unit per Milliliter|BE/mL|BE/mL|Biological Unit per Milliliter|{BE}/mL|{BE}/mL|{BE}/ml|{BE}/ml	A unit of allergenic product potency expressed as a number of biological units per one milliliter of formulation.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116232>	C70505	Histamine Equivalent Prick Unit|HEP|HEP|{HEP}|{HEP}	A unit of allergenic product potency expressed as the number of histamine equivalent prick units.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116233>	C70505	Standardized Allergy Biological Unit per Milliliter|SBE/mL|SBE/mL|Standardized Biological Unit per Milliliter|{SBE}/mL|{SBE}/mL|{SBE}/ml|{SBE}/ml	A unit of allergenic product potency expressed as the number of standardized biological units per one milliliter of formulation.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116234>	C70505	Standardized Allergy Quality Unit per Milliliter|SQ-u/mL|SQU/mL|SQU/mL|Standardized Quality Unit per Milliliter|Standardized Quality Unit/mL|{SQU}/mL|{SQU}/mL|{SQU}/ml|{SQU}/ml	A unit of allergenic product potency expressed as the number of standardized quality units per one milliliter of formulation.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116235>	C70505	Bioequivalent Allergy Unit per Milliliter|BAU/mL|BAU/mL|BAU/mL|[BAU]/mL|[BAU]/mL|[BAU]/ml|[BAU]/ml	A unit of allergenic product potency expressed as the number of bioequivalent allergy units per one milliliter of formulation.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116236>	C70505	Allergenic Protein Nitrogen Unit per Milliliter|PNU/mL|PNU/mL|Protein Nitrogen Unit per Milliliter|[PNU]/mL|[PNU]/mL|[PNU]/ml|[PNU]/ml	A unit of allergenic product potency expressed as the number of protein nitrogen units per one milliliter of formulation.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116237>	C67442	Copies per Microliter|copies/uL|copies/uL|{copies}/ul|{copies}/ul	A unit of concentration expressed as a number of copies per unit volume equal to one microliter.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116238>	C67377	Log10 International Units per Milliliter|log10 IU/mL|log10 IU/mL|{log10}.[IU]/mL|{log10}.[IU]/mL|{log10}.[IU]/ml|{log10}.[IU]/ml|{log10}.[iU]/mL|{log10}.[iU]/mL|{log10}.[iU]/ml|{log10}.[iU]/ml	A logarithmic-scale (base 10) unit for measuring international units per unit of volume equal to one milliliter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116239>	C67240	Cells per Kilogram|cells/kg|{cells}/kg|{cells}/kg	A unit of cell concentration expressed as a number of cells per mass unit equal to one kilogram.			Quantitative Concept	
C11623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11623>	C61063	Leflunomide/Mitoxantrone			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116240>	C67442	Per Thousand Cells|/10*3{cells}|/10*3{cells}|/10^3 cells|/10^3{cells}|/10^3{cells}	A unit of measure equal to the instances of an entity per 1000 cells.			Quantitative Concept	
C116241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116241>	C67357	Millijoules per Square Centimeter|mJ/cm2|mJ/cm2|mJoule/cm2|mJoule/cm2	A unit of radiant exposure defined as a unit of energy equal to one millijoule applied to a unit of area equal to one square centimeter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116242>	C67416	Millimoles per Minute per Kilopascal|mmol/min/kPa|mmol/min/kPa|mmol/min/kPa	A unit of gas diffusion capacity equal to one millimole per minute per kilopascal.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116243>	C66973	Per Nanoliter|/nL|/nL|/nl|/nl	A volume unit equal to one nanoliter used as a denominator to build a derived unit expressed as a ratio.			Quantitative Concept	
C116244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116244>	C48470	Cigar Dosing Unit|CIGAR|{CIGAR}|{CIGAR}|{Cigar}|{Cigar}	A dosing unit equal to the amount of ingredient(s) in a cigar.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116245>	C48470	Cigarette Dosing Unit|CIGARETTE|{CIGARETTE}|{CIGARETTE}|{Cigarette}|{Cigarette}	A dosing unit equal to the amount of ingredient(s) in a cigarette.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116246>	C48470	Pipe Dosing Unit|PIPE|{PIPE}|{PIPE}|{Pipe}|{Pipe}	A dosing unit equal to the amount of ingredient(s) in a pipe.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116247>	C116117	Viral Half Maximal Inhibitory Concentration Subject Result Measurement|IC50 Treatment Result	A measurement of titer of a viral organism or biological/biochemical reaction that has been exposed to a concentration of a specific drug expected to produce 50% inhibition of the standard growth of the viral organism, or of a reaction.			Laboratory or Test Result	
C116248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116248>	C116117	Viral Half Maximal Inhibitory Concentration Reference Control Result Measurement|IC50 Reference Control Result	A reference control sample response based on a concentration of a specific drug expected to produce 50% inhibition of the standard growth of a viral organism, or of a biological/biochemical reaction.			Laboratory or Test Result	
C116249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116249>	C116117	Viral Half Maximal Inhibitory Concentration Fold Change from Reference Measurement|IC50 Fold Change from Reference	A fold change based on a concentration of a specific drug expected to produce 50% inhibition of the standard growth of a viral organism, or of a biological/biochemical reaction. It is a ratio calculated by the IC50 Treatment Result divided by the IC50 Reference Control Result.			Laboratory or Test Result	
C11624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11624>	C61063	Fluorouracil/Leucovorin Calcium/SU5416			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116250>	C116117	Viral Half Maximal Inhibitory Concentration Fold Change from Baseline Measurement|IC50 Fold Change from Baseline	A fold change based on a concentration of a specific drug expected to produce 50% inhibition of the standard growth of a viral organism, or of a biological/biochemical reaction. It is a ratio calculated by the current IC50 Treatment Result divided by the IC50 Treatment Result from the baseline visit.			Laboratory or Test Result	
C116251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116251>	C116117	Viral 95 Percent Maximal Inhibitory Concentration Subject Result Measurement|IC95 Treatment Result	A measurement of titer of a viral organism or biological/biochemical reaction that has been exposed to a concentration of a specific drug expected to produce 95% inhibition of the standard growth of the viral organism, or of a reaction.			Laboratory or Test Result	
C116252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116252>	C116117	Viral 95 Percent Maximal Inhibitory Concentration Reference Control Result Measurement|IC95 Reference Control Result	A reference control sample response based on a concentration of a specific drug expected to produce 95% inhibition of the standard growth of a viral organism, or of a biological/biochemical reaction.			Laboratory or Test Result	
C116253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116253>	C116117	Viral 95 Percent Maximal Inhibitory Concentration Fold Change from Reference Measurement|IC95 Fold Change from Reference	A fold change based on a concentration of a specific drug expected to produce 95% inhibition of the standard growth of a viral organism, or of a biological/biochemical reaction. It is a ratio calculated by the IC95 Treatment Result divided by the IC95 Reference Control Result.			Laboratory or Test Result	
C116254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116254>	C116117	Viral 95 Percent Maximal Inhibitory Concentration Fold Change from Baseline Measurement|IC95 Fold Change from Baseline	A fold change based on a concentration of a specific drug expected to produce 95% inhibition of the standard growth of a viral organism, or of a biological/biochemical reaction. It is a ratio calculated by the current IC95 Treatment Result divided by the IC95 Treatment Result from the baseline visit.			Laboratory or Test Result	
C116255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116255>	C116117	Inhibitory Concentration Net Assessment Measurement|ICNETAS|Inhibitory Concentration Net Assessment|Inhibitory Concentration Net Assessment	An indication of reduced or increased susceptibility of a viral organism, or activity of a biological/biochemical reaction in response to the inhibitory concentration (IC50 and/or IC95) of a specific drug.			Laboratory or Test Result	CDISC SDTM Microbiology Susceptibility Test Code Terminology|CDISC SDTM Microbiology Susceptibility Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C116256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116256>	C112506	Atlantic Daylight Time|ADT	Local daylight-savings time, based at the 60th meridian west of the Greenwich Observatory, established as three hours behind Coordinated Universal Time.			Temporal Concept	
C116257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116257>	C112506	Eastern Daylight Time|EDT	Local daylight-savings time, based at the 75th meridian west of the Greenwich Observatory, established as four hours behind Coordinated Universal Time.			Temporal Concept	
C116258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116258>	C112506	Central Daylight Time|CDT	Local daylight-savings time, based at the 90th meridian west of the Greenwich Observatory, established as five hours behind Coordinated Universal Time.			Temporal Concept	
C116259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116259>	C112506	Mountain Daylight Time|MDT	Local daylight-savings time, based at the 105th meridian west of the Greenwich Observatory, established as six hours behind Coordinated Universal Time.			Temporal Concept	
C11625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11625>	C61063	Cyclosporine/Irinotecan			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116260>	C112506	Pacific Daylight Time|PDT	Local daylight-savings time, based at the 120th meridian west of the Greenwich Observatory, established as seven hours behind Coordinated Universal Time.			Temporal Concept	
C116261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116261>	C112506	Alaska Daylight Time|AKDT	Local daylight-savings time, based at the 135th meridian west of the Greenwich Observatory, established as eight hours behind Coordinated Universal Time.			Temporal Concept	
C116262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116262>	C112506	Hawaii-Aleutian Daylight Time|HADT	Local daylight-savings time, based at the 150th meridian west of the Greenwich Observatory, established as nine hours behind Coordinated Universal Time.			Temporal Concept	
C116263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116263>	C104440	Atlantic Standard Time|AST	Local standard time, based at the 60th meridian west of the Greenwich Observatory, established as four hours behind Coordinated Universal Time.			Temporal Concept	
C116264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116264>	C104440	Eastern Standard Time|EST	Local standard time, based at the 75th meridian west of the Greenwich Observatory, established as five hours behind Coordinated Universal Time.			Temporal Concept	
C116265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116265>	C104440	Central Standard Time|CST	Local standard time, based at the 90th meridian west of the Greenwich Observatory, established as six hours behind Coordinated Universal Time.			Temporal Concept	
C116266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116266>	C104440	Mountain Standard Time|MST	Local standard time, based at the 105th meridian west of the Greenwich Observatory, established as seven hours behind Coordinated Universal Time.			Temporal Concept	
C116267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116267>	C104440	Pacific Standard Time|PST	Local standard time, based at the 120th meridian west of the Greenwich Observatory, established as eight hours behind Coordinated Universal Time.			Temporal Concept	
C116268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116268>	C104440	Alaska Standard Time|AKST	Local standard time, based at the 135th meridian west of the Greenwich Observatory, established as nine hours behind Coordinated Universal Time.			Temporal Concept	
C116269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116269>	C104440	Hawaii-Aleutian Standard Time|HAST	Local standard time, based at the 150th meridian west of the Greenwich Observatory, established as ten hours behind Coordinated Universal Time.			Temporal Concept	
C11626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11626>	C61063	Detoxpc/Lung Tumor Associated Antigen			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116270>	C104440	Samoa Standard Time|SST	Local standard time, based at the 165th meridian west of the Greenwich Observatory, established as eleven hours behind Coordinated Universal Time.			Temporal Concept	
C116271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116271>	C104440	Chamorro Standard Time|ChST	Local standard time, based at the 150th meridian east of the Greenwich Observatory, established as ten hours ahead of Coordinated Universal Time.			Temporal Concept	
C116272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116272>	C25952	PLCD3 Gene|PLCD3|PLCD3|Phospholipase C, Delta 3 Gene	This gene is involved in second messenger synthesis.			Gene or Genome	
C116273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116273>	C116272	PLCD3 wt Allele|KIAA1964|PLC-Delta-3|Phospholipase C, Delta 3 wt Allele|Phospholipase C, Delta-3 Gene	Human PLCD3 wild-type allele is located in the vicinity of 17q21.31 and is approximately 24 kb in length. This allele, which encodes 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-3 protein, plays a role in the synthesis of second messenger signaling molecules. Variation in the gene is associated with dichotomous hypertension.			Gene or Genome	
C116274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116274>	C16980	1-Phosphatidylinositol 4,5-Bisphosphate Phosphodiesterase Delta-3|1-Phosphatidylinositol-4,5-Bisphosphate Phosphodiesterase Delta-3|EC 3.1.4.11|PLC Delta3|PLC-Delta-3|PLCD3|Phosphoinositide Phospholipase C-Delta-3|Phospholipase C Delta 3|Phospholipase C-Delta-3	1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-3 (789 aa, ~89 kDa) is encoded by the human PLCD3 gene. This protein is involved in the generation of second messenger molecules from phosphoinositides.			Amino Acid, Peptide, or Protein|Enzyme	
C116275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116275>	C26000	LAMC2 Gene|LAMC2|LAMC2|Laminin, Gamma 2 Gene	This gene plays a role in both extracellular matrix assembly and epidermal development.			Gene or Genome	
C116276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116276>	C116275	LAMC2 wt Allele|B2T|BM600|CSF|EBR2|EBR2A|LAMB2T|LAMNB2|Lam5, Gamma-2 Subunit Gene|Laminin 5, Gamma-2 Subunit Gene|Laminin, Gamma 2 (Nicein (100kD), Kalinin (105kD), BM600 (100kD), Herlitz Junctional Epidermolysis Bullosa)) Gene|Laminin, Gamma 2 wt Allele|Laminin, Gamma-2 Gene|Laminin, Nicein, Beta-2 Gene	Human LAMC2 wild-type allele is located within 1q25-q31 and is approximately 59 kb in length. This allele, which encodes laminin subunit gamma-2 protein, is involved in both the development of the epidermis and extracellular matrix organization. Mutation of the gene is associated with Herlitz junctional epidermolysis bullosa.			Gene or Genome	
C116277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116277>	C17351	Laminin Subunit Gamma-2|BM600-100kDa|CSF 140 kDa Subunit|Cell-Scattering Factor 140 kDa Subunit|Epiligrin Subunit Gamma|Kalinin Subunit Gamma|Kalinin/Nicein/Epiligrin 100 kDa Subunit|Ladsin 140 kDa Subunit|Laminin B2t Chain|Laminin-5 Gamma-2 Chain|Laminin-5 Subunit Gamma|Large Adhesive Scatter Factor 140 kDa Subunit|Nicein Subunit Gamma	Laminin subunit gamma-2 (1193 aa, ~131 kDa) is encoded by the human LAMC2 gene. This protein plays a role in both the organization of the extracellular matrix and the development of the epidermis.			Amino Acid, Peptide, or Protein	
C116278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116278>	C20194	WTAP Gene|WTAP|WTAP|Wilms Tumor 1 Associated Protein Gene	This gene is involved in the modulation of both transcription and mRNA splicing.			Gene or Genome	
C116279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116279>	C116278	WTAP wt Allele|KIAA0105|MGC3925|RP1-56L9.4|Wilms Tumor 1 Associated Protein wt Allele	Human WTAP wild-type allele is located within 6q25-q27 and is approximately 31 kb in length. This allele, which encodes pre-mRNA-splicing regulator WTAP protein, plays a role in the regulation of RNA processing.			Gene or Genome	
C11627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11627>	C61063	Anti-thymocyte globulin/Methylprednisolone			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116280>	C18466	Pre-mRNA-Splicing Regulator WTAP|Female-Lethal(2)D Homolog|Putative Pre-mRNA Splicing Regulator Female-Lethal(2D)|WT1-Associated Protein|WT1-Associating Protein|Wilms Tumor 1 Associated Protein|Wilms Tumor 1-Associated Protein|Wilms Tumor 1-Associating Protein|Wilms' Tumour 1-Associating Protein|hFL(2)D	Pre-mRNA-splicing regulator WTAP (396 aa, ~44 kDa) is encoded by the human WTAP gene. This protein is involved in the modulation of RNA processing.			Amino Acid, Peptide, or Protein	
C116281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116281>	C173737|C173358	Past Seven Days Frequency of Aching Muscles Question|How often did you have aching muscles|Past Seven Days Frequency of Aching Muscles	A question about the frequency of an individual's aching muscles over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C116282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116282>	C173737|C173358	Past Seven Days Frequency of Aching Joints Question|How often did you have aching joints (such as elbows, knees, shoulders)|Past Seven Days Frequency of Aching Joints	A question about the frequency of an individual's aching joints over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C116283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116283>	C173603	Worst Severity Past Seven Days Aching Joints Question|What was the severity of your aching joints (such as elbows, knees, shoulders) at their worst|Worst Severity Past Seven Days Aching Joints	A question about an individual's observation of the worst severity they have experienced related to aching joints over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C116284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116284>	C54362	HOTAIR Gene|HOTAIR|HOTAIR|HOX Transcript Antisense RNA Gene	This gene plays a role in the repression of HOXD gene expression.			Gene or Genome	
C116285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116285>	C116284	HOTAIR wt Allele|HOX Antisense Intergenic RNA Gene|HOX Transcript Antisense RNA (Non-Protein Coding) Gene|HOX Transcript Antisense RNA wt Allele|HOX Transcript Antisense RNA, Noncoding Gene|HOXAS|HOXC Cluster Antisense RNA 4 (Non-Protein Coding) Gene|HOXC Cluster Antisense RNA 4 (Non-Protein Coding), Non-Protein Coding RNA 72 Gene|HOXC-AS4|HOXC11-AS1|Long Intergenic Noncoding RNA HOTAIR Gene|NCRNA00072|Non-Protein Coding RNA 72 Gene|lincRNA HOTAIR	Human HOTAIR wild-type allele is located in the vicinity of 12q13.13 and is approximately 13 kb in length. This allele, which encodes HOX transcript antisense RNA, is involved in the negative regulation of HOXD gene transcription.			Gene or Genome	
C116286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116286>	C173787|C173737|C173584	Past Seven Days Aching Joints Interfering with Usual or Daily Activities Question|How much did aching joints (such as elbows, knees, shoulders) interfere with your usual or daily activities|Past Seven Days Aching Joints Interfering with Usual or Daily Activities	A question about an individual's aching joints interfering with usual or daily activities over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C116287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116287>	C88924	HOX Transcript Antisense RNA|HOX Antisense Intergenic RNA|HOX Transcript Antisense RNA, Noncoding|HOXC Cluster Antisense RNA 4|Long Intergenic Noncoding RNA HOTAIR|NCRNA00072|Non-Protein Coding RNA 72|lincRNA HOTAIR	HOX transcript antisense RNA (~2 kb) is encoded by the human HOTAIR gene. This non-coding RNA plays a role in the repression of HOXD genes.			Nucleic Acid, Nucleoside, or Nucleotide	
C116288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116288>	C173603	Worst Severity Past Seven Days Aching Muscles Question|What was the severity of your aching muscles at their worst|Worst Severity Past Seven Days Aching Muscles	A question about an individual's observation of the worst severity they have experienced related to aching muscles over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C116289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116289>	C173787|C173737|C173584	Past Seven Days Aching Muscles Interfering with Usual or Daily Activities Question|How much did aching muscles interfere with your usual or daily activities|Past Seven Days Aching Muscles Interfering with Usual or Daily Activities	A question about how much an individual's aching muscles interfered with usual or daily activities over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C11628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11628>	C61007	Anti-thymocyte globulin/Cyclophosphamide/Methylprednisolone			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116290>	C173737	Past Seven Days Bruise Easily Question|Did you bruise easily|Past Seven Days Bruise Easily	A question about whether an individual bruised easily over the last seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C116291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116291>	C173737|C173358	Past Seven Days Frequency of Hiccups Question|How often did you have hiccups|Past Seven Days Frequency of Hiccups	A question about the frequency of an individual's hiccups over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C116292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116292>	C173603	Worst Severity Past Seven Days Hiccups Question|What was the severity of your hiccups at their worst|Worst Severity Past Seven Days Hiccups	A question about an individual's observation of the worst severity they have experienced related to hiccups over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C116293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116293>	C20673	PPARGC1A Gene|PPARGC1A|PPARGC1A|Peroxisome Proliferator-Activated Receptor Gamma, Coactivator 1 Alpha Gene	This gene plays a role in the regulation of nuclear receptor-dependent transcription.	PPARGC1A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116294>	C116293	PPARGC1A wt Allele|LEM6|PGC-1(alpha)|PGC-1a|PGC-1v|PGC1|PGC1-Alpha|PGC1A|PPARGC1|Peroxisome Proliferative Activated Receptor, Gamma, Coactivator 1 Gene|Peroxisome Proliferative Activated Receptor, Gamma, Coactivator 1, Alpha Gene|Peroxisome Proliferator-Activated Receptor Gamma, Coactivator 1 Alpha wt Allele|Peroxisome Proliferator-Activated Receptor-Gamma, Coactivator 1 Gene|Peroxisome Proliferator-Activated Receptor-Gamma, Coactivator 1, Alpha Gene	Human PPARGC1A wild-type allele is located in the vicinity of 4p15.1 and is approximately 149 kb in length. This allele, which encodes peroxisome proliferator-activated receptor gamma coactivator 1-alpha protein, is involved in transcriptional regulation mediated by steroid and nuclear receptors.	PPARGC1A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116295>	C122779	Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-Alpha|L-PGC-1alpha|Ligand Effect Modulator 6|Ligand Effect Modulator-6|PGC-1-Alpha|PPAR-Gamma Coactivator 1|PPAR-Gamma Coactivator 1-Alpha|PPARGC-1-Alpha|PPARGC1A|Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1 Alpha	Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (798 aa, ~91 kDa) is encoded by the human PPARGC1A gene. This protein plays a role in the regulation of gene transcription.	Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-Alpha		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116296>	C54362	ASXL2 Gene|ASXL2|ASXL2|ASXL2|Additional Sex Combs Like 2 (Drosophila) Gene	This gene plays a role in both chromatin modification and the positive regulation of transcription.			Gene or Genome	GDC Terminology|GDC Value Terminology
C116297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116297>	C116296	ASXL2 wt Allele|ASXH2|Additional Sex Combs Like 2 (Drosophila) wt Allele|Additional Sex Combs-Like 2 Gene|FLJ10898|KIAA1685	Human ASXL2 wild-type allele is located in the vicinity of 2p24.1 and is approximately 145 kb in length. This allele, which encodes putative Polycomb group protein ASXL2, is involved in both transcriptional regulation and chromatin modification.			Gene or Genome	
C116298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116298>	C26199	Putative Polycomb Group Protein ASXL2|Additional Sex Combs-Like Protein 2|Polycomb Group Protein ASXH2	Putative Polycomb group protein ASXL2 (1435 aa, ~154 kDa) is encoded by the human ASXL2 gene. This protein plays a role in both the activation of transcription and chromatin remodeling.			Amino Acid, Peptide, or Protein	
C116299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116299>	C21295	CISD2 Gene|CDGSH Iron Sulfur Domain 2 Gene|CISD2|CISD2	This gene plays a role in the regulation of autophagy.			Gene or Genome	
C11629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11629>	C61063	Anti-thymocyte globulin/melphalan/methylprednisolone			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1162>	C1590	Methylene Dimethane Sulfonate	A member of the homologous series of dimethane sulphonic acid esters with alkylating properties. Methylene dimethane sulfonate alkylates DNA, resulting in interstrand DNA crosslinking, inhibition of DNA replication, disruption of the cell cycle, and cell death.			Organic Chemical|Pharmacologic Substance	NCI Drug Dictionary Terminology
C116300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116300>	C116299	CISD2 wt Allele|CDGSH Iron Sulfur Domain 2 wt Allele|ERIS|Miner1|MitoNEET Related 1 Gene|NAF-1|WFS2|Wolfram Syndrome 2 Gene|ZCD2|Zinc Finger, CDGSH-Type Domain 2 Gene	Human CISD2 wild-type allele is located in the vicinity of 4q24 and is approximately 24 kb in length. This allele, which encodes CDGSH iron-sulfur domain-containing protein 2, is involved in both iron-sulfur binding and autophagy. Mutation of the gene is associated with Wolfram syndrome 2.			Gene or Genome	
C116301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116301>	C17728	CDGSH Iron-Sulfur Domain-Containing Protein 2|CDGSH Iron-Sulfur Domain Protein 2|CISD2|Endoplasmic Reticulum Intermembrane Small Protein|Miner1|MitoNEET-Related 1 Protein|NAF-1|Nutrient Deprivation Autophagy Factor 1|Nutrient-Deprivation Autophagy Factor-1|Zinc Finger Protein ZCD2	CDGSH iron-sulfur domain-containing protein 2 (135 aa, ~15 kDa) is encoded by the human CISD2 gene. This protein plays a role in the regulation of autophagy.			Amino Acid, Peptide, or Protein	
C116302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116302>	C16615	HOXC10 Gene|HOXC10|HOXC10|Homeobox C10 Gene	This gene is involved in embryonic pattern formation.			Gene or Genome	
C116303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116303>	C116302	HOXC10 wt Allele|HOX3I|Homeo Box C10 Gene|Homeobox C10 wt Allele	Human HOXC10 wild-type allele is located in the vicinity of 12q13.3 and is approximately 5 kb in length. This allele, which encodes homeobox protein Hox-C10, plays a role in embryonic axis determination.			Gene or Genome	
C116304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116304>	C17207	Homeobox Protein Hox-C10|Homeobox Protein Hox-3I|Homeoprotein C10	Homeobox protein Hox-C10 (342 aa, ~38 kDa) is encoded by the human HOXC10 gene. This protein is involved in embryonic pattern specification.			Amino Acid, Peptide, or Protein	
C116305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116305>	C25873	MAP4K3 Gene|MAP4K3|MAP4K3|Mitogen-Activated Protein Kinase Kinase Kinase Kinase 3 Gene	This gene plays a role in both protein phosphorylation and Jun signaling pathways.			Gene or Genome	
C116306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116306>	C116305	MAP4K3 wt Allele|GLK|MAPKKKK3|MEKKK 3|MEKKK3|Mitogen-Activated Protein Kinase Kinase Kinase Kinase 3 wt Allele|RAB8-Interacting Protein-Like 1, Formerly Gene|RAB8IPL1	Human MAP4K3 wild-type allele is located in the vicinity of 2p22.1 and is approximately 188 kb in length. This allele, which encodes mitogen-activated protein kinase kinase kinase kinase 3 protein, is involved in the modulation of Jun signaling.			Gene or Genome	
C116307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116307>	C17325	Mitogen-Activated Protein Kinase Kinase Kinase Kinase 3|EC 2.7.11.1|GLK|Germinal Center Kinase-Like Kinase|Germinal Center Kinase-Related Protein Kinase|MAP4K3|MAPK/ERK Kinase Kinase Kinase 3|MEK Kinase Kinase 3|MEKKK 3|RAB8-Interacting Protein-Like 1	Mitogen-activated protein kinase kinase kinase kinase 3 (894 aa, ~101 kDa) is encoded by the human MAP4K3 gene. This protein plays a role in the Jun signaling pathway.			Amino Acid, Peptide, or Protein|Enzyme	
C116308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116308>	C20921	SOS1 Gene|SOS Ras/Rho Guanine Nucleotide Exchange Factor 1 Gene|SOS1|SOS1|SOS1	This gene is involved in guanine nucleotide exchange.	SOS1 Gene		Gene or Genome	CCPS Genetics Terminology|Childhood Cancer Predisposition Study Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116309>	C116308	SOS1 wt Allele|GF1|GGF1|GINGF|Gingival Fibromatosis, Hereditary, 1 Gene|HGF|NS4|SOS Ras/Rho Guanine Nucleotide Exchange Factor 1 wt Allele|Son of Sevenless Homolog 1 (Drosophila) Gene|Son of Sevenless Homolog 1 Gene|Son of Sevenless, Drosophila, Homolog 1 Gene	Human SOS1 wild-type allele is located in the vicinity of 2p21 and is approximately 143 kb in length. This allele, which encodes son of sevenless homolog 1 protein, plays a role in both signaling and guanine nucleotide exchange. Mutation of the gene is associated with both gingival fibromatosis type 1 and Noonan syndrome type 4.	SOS1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11630>	C61007	Irinotecan/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116310>	C25499	Apparent Life Threatening Event|ALTE|ALTE	An episode during which the patient, usually a child less than one year, experiences a combination of apnea, color change, alteration in muscle tone, choking or gagging. This event can be frightening to the observer.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116311>	C17494	Son of Sevenless Homolog 1|Guanine Nucleotide Exchange Factor SOS1|SOS-1|SOS1 Guanine Nucleotide Exchange Factor	Son of sevenless homolog 1 (1333 aa, ~152 kDa) is encoded by the human SOS1 gene. This protein is involved in the mediation of guanine nucleotide exchange for RAS superfamily proteins.	Son of Sevenless Homolog 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116312>	C85403	Stertor	The sound produced by tissue vibrations in the nasopharynx and pharynx secondary to partial obstruction of the upper airway.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116313>	C35095	Perinatal Depression|Birth Asphyxia|Birth Asphyxia|Birth Depression|Fetal Asphyxia|Intrapartum Asphyxia|Perinatal Asphyxia|Perinatal Asphyxia	A condition characterized by cardiorespiratory and neurological depression following birth.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C116314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116314>	C3676	Respiratory Depression	A decrease in ventilation secondary to impaired signals from the central nervous system.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116315>	C85403	Snoring	A harsh inspiratory sound during sleep.			Sign or Symptom	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116316>	C4126|C161008	Sinonasal Adenocarcinoma, Intestinal-Type|Enteric-Type Sinonasal Adenocarcinoma|Intestinal-Type Sinonasal Adenocarcinoma|Intestinal-Type Sinonasal Adenocarcinoma|Nasal Cavity and Paranasal Sinus Adenocarcinoma, Intestinal-Type	An adenocarcinoma that arises from the nasal cavity and paranasal sinuses. Histologically it resembles intestinal adenocarcinoma. It is associated with lengthy occupational exposure to dust.	Intestinal-Type Sinonasal Adenocarcinoma		Neoplastic Process	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology
C116317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116317>	C159224|C156457	Kidney Small Cell Neuroendocrine Carcinoma|Kidney Small Cell Carcinoma|Kidney Small Cell Carcinoma|Renal Small Cell Carcinoma	A very rare small cell neuroendocrine carcinoma that arises from the kidney.			Neoplastic Process	Cellosaurus Disease Terminology
C116318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116318>	C173089|C160981	Sinonasal Small Cell Neuroendocrine Carcinoma|Nasal Cavity and Paranasal Sinus Small Cell Carcinoma|Nasal Cavity and Paranasal Sinus Small Cell Neuroendocrine Cancer|Nasal Cavity and Paranasal Sinus Small Cell Neuroendocrine Carcinoma|Sinonasal Small Cell Carcinoma|Sinonasal Small Cell Carcinoma	A rare neuroendocrine carcinoma that arises from the nose and paranasal sinuses and is composed of malignant small cells. The mitotic count is more than 10 per 2 mm2 and/or the Ki-67 index is more than 20%.	Nasal Cavity and Paranasal Sinus Small Cell Neuroendocrine Carcinoma		Neoplastic Process	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology
C116319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116319>	C53543	Trisomy 14 Mosaicism	A rare chromosomal disorder characterized by trisomy of chromosome 14 in some cells in the body.  It manifests with intrauterine growth retardation, craniofacial abnormalities, failure to thrive, psychomotor delays, and mental retardation.			Disease or Syndrome	
C11631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11631>	C61063	Rituximab/Vinorelbine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116320>	C29711	Insulin Sensitizer S-707106|S-707106	An orally available protein and insulin sensitizer with anti-hyperglycemic activity. Upon oral administration, S-707106 increases the sensitivity of target organs to insulin, through an as of yet not fully elucidated mechanism. This agent may lower blood glucose levels.			Organic Chemical|Pharmacologic Substance	NCI Drug Dictionary Terminology
C116321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116321>	C39619|C1663	CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|CD105/Yb-1/SOX2/CDH3/MDM2 Plasmid Vaccine|STEMVAC|STEMVAC Th1 Polyepitope Plasmid-based Vaccine	A plasmid DNA vaccine containing the mammalian expression vector pUMVC3 (pNGVL3) encoding epitopes of CD105 (Endoglin), Y-box binding protein 1 (Yb-1), SRY-box 2 (SOX2), cadherin 3 (CDH3), and murine double minute 2 (MDM2) proteins, with potential immunomodulating and antineoplastic activities. Upon intradermal administration of pUMVC3-CD105/Yb-1/SOX2/CDH3/MDM2-epitopes plasmid DNA vaccine, the plasmid transfects cells and the peptides are expressed. This generates a specific memory Th1 (T-helper) cell immune response, stimulates secretion of cytokines by the T cells and leads to a cytotoxic T-lymphocyte (CTL) response against CD105/Yb-1/SOX2/CDH3/MDM2-expressing tumor cells. CD105/Yb-1/SOX2/CDH3/MDM2 proteins are highly immunogenic tumor associated antigens that are overexpressed in breast cancer. Additionally, these antigens are associated with breast cancer stem cells and with epithelial to mesenchymal transformation (EMT).			Immunologic Factor|Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116322>	C1742|C1323	Liposomal Curcumin|Curcumin Liposome	A liposomal formulation containing curcumin, a poorly water-soluble polylphenol pigment isolated from the plant Curcuma longa, with potential antineoplastic, chemopreventive, antioxidant, anti-angiogenic and anti-inflammatory activities. Upon intravenous administration of liposomal curcumin, this agent blocks the formation of reactive-oxygen species, neutralizes free radicals, and exhibits anti-inflammatory properties as a result of inhibition of cyclooxygenases (COX) and other enzymes involved in inflammation. In addition, curcumin disrupts various cell signal transduction pathways involved in carcinogenesis, inhibits the activity of nuclear factor-kappa B (NF-kB), SRC, and annexin A2 (ANXA2), and reduces the expression of both matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor receptor 2 (VEGFR2). This prevents and/or inhibits tumor cell formation and proliferation. Liposome encapsulation of curcumin improves its efficacy, when compared to the administration of unencapsulated curcumin.	Liposomal Curcumin		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116323>	C34941	Postpartum Complication	Any adverse event that arises in the six week period immediately following the delivery of a fetus.			Finding	CPTAC Causes of Death Codelist|CPTAC Codelists Terminology|CPTAC Terminology|NICHD Terminology
C116325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116325>	C162996	Siremadlin|HDM201|NVP-HDM 201|SIREMADLIN	An orally bioavailable human double minute 2 homolog (HDM2) inhibitor with potential antineoplastic activity. Siremadlin inhibits the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited, which may result in the restoration of both p53 signaling and p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger protein and negative regulator of the p53 pathway, is often overexpressed in cancer cells and has been implicated in cancer cell proliferation and survival.	Siremadlin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116326>	C1291	Androgen Receptor Antisense Oligonucleotide AZD5312|AZD-5312|AZD5312|ISIS-ARRx|ISIS-AZ1Rx	An antisense oligonucleotide targeting the androgen receptor (AR) mRNA, with potential antineoplastic activity. Upon intravenous administration, AZD5312 hybridizes with AR mRNA, which blocks translation of the AR protein. This both inhibits AR-induced tumor cell growth and promotes apoptosis in AR-overexpressing tumor cells. AR is overexpressed in certain breast and prostate cancers and is involved in tumor cell proliferation and survival.	Androgen Receptor Antisense Oligonucleotide AZD5312		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116327>	C65141	Tangerine Tomato Juice	Tomato juice derived from the tangerine tomato, with potential antioxidant and chemopreventive activities. Tangerine tomato juice contains higher levels of the cis-isomer of lycopene (cis-LYC) compared to the trans-isomer (trans-LYC). Lycopene, a linear, unsaturated hydrocarbon carotenoid, is the major red pigment in certain fruits such as tomatoes, pink grapefruit, apricots, red oranges, watermelon, rosehips, and guava. As an antioxidant, lycopene scavenges free radicals, which may both inhibit cellular oxidation and prevent free radical damage to cells. cis-LYC is better absorbed than its trans form.			Food	NCI Drug Dictionary Terminology
C116328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116328>	C65141	Red Tomato Juice|Tangerine Tomato Juice	Tomato juice derived from red tomatoes, with potential antioxidant and chemopreventive activities. Red tomato juice contains higher levels of the trans-isomer of lycopene (trans-LYC) compared to the cis-isomer (cis-LYC). Lycopene, a linear, unsaturated hydrocarbon carotenoid, is the major red pigment in certain fruits such as tomatoes, pink grapefruit, apricots, red oranges, watermelon, rosehips, and guava. As an antioxidant, lycopene scavenges free radicals which may both inhibit cellular oxidation and prevent free radical damage to cells. cis-LYC is better absorbed than its trans form.			Food	NCI Drug Dictionary Terminology
C116329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116329>	C201493|C200766	Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes|Anti CD123-CAR/CD28-costimulatory Lentiviral Vector-transduced Autologous T Lymphocytes|CD123R(EQ)28zeta/EGFRt+ T Cells	A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a hinge-optimized, chimeric antigen receptor (CAR), containing a CD28 co-stimulatory signaling domain fused to CD3 zeta, the single-chain variable fragment of CD123 (Interleukin-3 receptor alpha chain or IL3RA) antigen, and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes are directed to and induce selective toxicity in CD123-expressing tumor cells. CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with increased leukemic cell proliferation and aggressiveness. Devoid of both ligand binding domains and tyrosine kinase activity, EGFRt both facilitates detection of the administered T-cells in vivo and can promote elimination of those cells following a cetuximab-induced antibody-dependent cellular cytotoxicity response. The costimulatory signaling domain enhances both proliferation of T-cells and antitumor activity. Hinge optimization prevents recognition of the CAR by Fc receptors (FcRs).			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11632>	C61007	Cisplatin/Dexrazoxane/Doxorubicin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116330>	C28681	Anti-CD3 OKT3/Humanized Anti-GD2 3F8 Bispecific Antibody-activated T Lymphocytes|Anti-CD3 x hu3F8 Bispecific Antibody Armed ATC|GD2Bi-aATC|Hu3F8Bi Armed ATC|OKT3/Humanized 3F8 Bispecific Antibody-activated T Lymphocytes	Autologous activated T cells that have been coated with bispecific antibodies (BiAb) comprised of anti-CD3 murine monoclonal antibody OKT3 heteroconjugated to anti-GD2 humanized monoclonal antibody 3F8 (hu3F8), with potential antineoplastic and immunomodulating activities. In vitro, T cells are exposed to OKT3, which binds to the T cell receptor-CD3 complex on the T cell surface, crosslinks the CD3 receptors and leads to T cell activation. In turn, the hu3F8 monoclonal antibody is heteroconjugated to OKT3. Upon administration, anti-CD3 x anti-GD2 bispecific antibody-armed activated T cells attach to GD2-expressing tumor cells, thereby selectively cross-linking T cells and tumor cells. This results in selective cytotoxicity towards the GD2-expressing tumor cells. In addition, cytokine and chemokine secretion by the T cells further activates the immune system, which leads to the recruitment and activation of cytotoxic T lymphocytes (CTLs), and additional CTL-mediated tumor-specific cell lysis. GD2, a disialoganglioside and tumor-associated antigen, is overexpressed in a variety of tumor cell types. CD3 is part of the functional T cell receptor (TCR) complex, which is necessary for antigen recognition by T cells, and is required for signal transduction.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116331>	C1752|C1663	Synthetic Glioblastoma Tumor-associated Peptides Vaccine Therapy APVAC1|APVAC1	A personalized peptide-based cancer vaccine comprised of five to ten peptides associated with glioblastoma (GB), with potential immunomodulating and antineoplastic activities. Vaccination with synthetic GB tumor-associated peptides vaccine therapy APVAC1 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the tumor associated peptides, and results in decreased GB growth. The peptides are derived from a glioma actively personalized vaccine consortium (GAPVAC) warehouse and are specifically selected based on the patient's expression of tumor-associated antigens.			Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116332>	C1752|C1663	Synthetic Glioblastoma Mutated Tumor-specific Peptides Vaccine Therapy APVAC2|APVAC2	A personalized peptide-based cancer vaccine comprised of one or two de novo synthesized patient-specific tumor-mutated peptides associated with glioblastoma (GB), with potential immunomodulating and antineoplastic activities. Vaccination with synthetic GB mutated tumor-specific peptides vaccine therapy APVAC2 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the selected mutated tumor-associated peptides, which results in decreased GB growth. These peptides are specifically selected and synthesized based on the expression of the patient's own mutated tumor-associated antigens, which were detected during individual tumor genome sequencing.			Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116333>	C28193	Oculo-Respiratory Syndrome|ORS|Oculo-respiratory-syndrome|Oculorespiratory Syndrome	A transient condition that can occur following influenza vaccination that is characterized by bilateral conjunctivitis, facial edema, and upper respiratory symptoms.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116334>	C78596	Pulmonary Alveolar Hemorrhage	Bleeding in the alveoli.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116335>	C26698	Central Apnea	Cessation of air flow due to abnormal central nervous system control.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116337>	C26884	Obstructive Sleep Apnea|Obstructive Apnea|Obstructive Apnea	Cessation of air flow during sleep due to upper airway obstruction.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116338>	C3331	Hydrothorax	The accumulation of serous fluid within the pleural cavity.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116339>	C61043	Hypophonia	The inability to produce speech sounds at normal volume.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11633>	C61063	Dexrazoxane/Doxorubicin/Ifosfamide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116340>	C28554	Brain Death|Brain death	Irreversible absence of cortical and brain stem functioning.			Finding	CDRH Health Effects - Health Impact Terminology|mCode Elixhauser Other Neurological Disorder Value Set|mCode Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116341>	C190808	Oncotype DX DCIS Score|Breast Oncotype DX Recurrence Risk Score|DCIS Score	The derived result of a test that measures the gene expression profile in a tissue sample that contains ductal carcinoma in situ (DCIS). The score is used for treatment decisions tailored to the specific patient and to calculate the chances of recurrence.			Quantitative Concept	
C116342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116342>	C60781|C132067	Low Grade Astrocytoma|Low Grade Astrocytic Neoplasm|Low Grade Astrocytic Tumor|Low-Grade Astrocytic Neoplasm|Low-Grade Astrocytic Tumor|Low-Grade Astrocytoma	A grade I or grade II astrocytoma. This category includes pilocytic astrocytoma (grade I), subependymal giant cell astrocytoma (grade I), and diffuse astrocytoma (grade II).			Neoplastic Process	NCIt Neoplasm Core Terminology
C116343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116343>	C78346	Idiopathic Hypersomnia|Primary Hypersomnia|Primary Hypersomnia	A disorder of central nervous system etiology characterized by excessive sleepiness during the daytime.			Mental or Behavioral Dysfunction	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116344>	C3421|C185933	Trisomy 14	A chromosomal abnormality consisting of the presence of a third copy of chromosome 14 in somatic cells.			Cell or Molecular Dysfunction	Cellosaurus Disease Terminology
C116345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116345>	C99383|C28193|C26790|C189005	Guillain-Barre Syndrome|GBS|Guillain Barre Syndrome|Guillain Barré Syndrome|Guillain-Barré Syndrome|Guillain-Barré syndrome	A rapidly progressive autoimmune disorder of the peripheral nervous system characterized by limb paresthesias, areflexia, and generalized muscle weakness or paralysis that often begins in the legs and spreads to the arms, torso, and face.			Disease or Syndrome	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 6: Symptoms and Signs Terminology|Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Physical Examination Terminology
C116347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116347>	C3111	Non-Communicating Hydrocephalus|Obstructive Hydrocephalus|Obstructive Hydrocephalus|Obstructive hydrocephalus	An abnormal accumulation of cerebrospinal fluid within the ventricles of the brain that occurs as a consequence of an obstruction at any location within the ventricular system that prevents cerebrospinal fluid flowing into the subarachnoid space.			Disease or Syndrome	mCode Elixhauser Other Neurological Disorder Value Set|mCode Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C116348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116348>	C207067	Clinical Trial Randomization Procedure Documentation|Randomiz Proced|Randomization Procedure|Randomization Procedure	Documentation describing how subjects are randomized in the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Statistics Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C116349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116349>	C207074	Clinical Trial Investigational Product Unblinding Plan Documentation|IP Unblinding Plan|Subj Unblind Plan|Subject Unblinding Plan|Unblinding Plan	Documentation describing the processes and procedures for breaking the blind for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IP and Trial Supplies Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C11634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11634>	C61063	Doxorubicin/P-30 Protein			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116351>	C2201|C2152|C129825	PI3K/mTORC1/mTORC2 Inhibitor DCBCI0901|DCBCI0901	An inhibitor of phosphatidylinositide 3-kinase (PI3K), raptor-mTOR (mTOR complex 1 or mTORC1) and rictor-mTOR (mTOR complex 2 or mTORC2) with potential antineoplastic activity. Upon intravenous infusion, PI3K/mTORC1/mTORC2 inhibitor DCBCI0901 binds to and inhibits PI3K as well as both mTORC1 and mTORC2, which may result in both apoptosis and a decrease in cell proliferation in tumor cells overexpressing PI3K, mTORC1, and mTORC2. Activation of the PI3K/mTOR signaling pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116352>	C2124	Fluorine F 18 Piflufolastat|18F-DCFPYL|18F-DCFPyL|2-(3-(1-Carboxy-5-((6-(18f)fluoro-pyridine-3-carbonyl)-amino)-pentyl)-ureido)-pentanedioic Acid|2-(3-{1-Carboxy-5-[(6-[(18)F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic Acid|Fluorine F 18 DCFPyL|PIFLUFOLASTAT F-18|Piflufolastat F 18|Piflufolastat F-18|Piflufolastat F18|Pylarify	A urea-based radiotracer composed of the prostate specific membrane antigen (PSMA) targeting agent DCFPyL and labeled with the positron-emitting isotope, fluorine F 18, that can potentially be used for positron emitting tomography (PET) imaging. Upon administration of fluorine F piflufolastat, piflufolastat binds to PSMA expressed on tumor cells. The fluorine F 18 moiety facilitates PET imaging of PSMA-expressing tumor cells. PSMA, a cell-surface antigen, is abundantly present on the surface of prostate cancer cells and on the neovasculature of most solid tumors.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C116353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116353>	C129826	siRNA-transfected Peripheral Blood Mononuclear Cells APN401|APN401|siRNA-transfected PBMC APN401	Autologous peripheral blood mononuclear cells (PBMCs) transfected ex vivo with small-interfering ribonucleic acid (siRNA) directed against the E3 ubiquitin ligase casitas B-lineage lymphoma-b gene (Cbl-b), with potential immunoactivating and antineoplastic activities. The Cbl-b gene is silenced ex vivo through the binding of Cbl-b siRNA to Cbl-b mRNA, which prevents the translation of the Cbl-b protein in T-lymphocytes. Upon infusion, the activated, Cbl-b-silenced T-lymphocytes are able to increase the production of cytokines, proliferate and activate the immune system, which leads to cancer cell eradication. Cbl-b, a negative regulator of the immune system, is mutated in a variety of cancer cell types. Its expression is inversely correlated with activation of T-lymphocytes and tumor cell eradication.			Cell|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116354>	C2124	5-FITC-labeled Colon-Heptapeptide|KCCFPAQ-GGGSK-(5-FITC)-NH2	A radioconjugate consisting of a 7 amino acid peptide sequence, KCCFPAQ, that specifically targets human colon cancer and labeled, via the linker, GGGSK, with the fluorescent dye, fluorescein isothiocyanate (5-FITC), with potential imaging activity. Following spray application to the colon wall during colonoscopy in areas that look abnormal, the colon heptapeptide moiety of 5-FITC-labeled colon-heptapeptide specifically targets and binds to a cell surface target overexpressed on pre-cancerous or cancerous colon cells. Upon internalization, the FITC moiety allows for fluorescent imaging and the area of interest for biopsies can then be visualized.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C116355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116355>	C155926	Berzosertib|2-Pyrazinamine, 3-(3-(4-((Methylamino)methyl)phenyl)-5-isoxazolyl)-5-(4-((1-methylethyl)sulfonyl)phenyl)-|BERZOSERTIB|M 6620|M6620|VX 970|VX-970|VX970	An inhibitor of ataxia telangiectasia and rad3-related (ATR) kinase, a DNA damage response kinase, with potential antineoplastic activity. Upon administration, berzosertib selectively binds to and inhibits ATR kinase activity and prevents ATR-mediated signaling in the ATR-checkpoint kinase 1 (Chk1) signaling pathway. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, and induces tumor cell apoptosis. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression, and survival; it is activated by DNA damage caused during DNA replication-associated stress.	Berzosertib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116357>	C210989	Vactosertib|TEW-7197|TEW7197|TGFBR1 Inhibitor TEW-7197|VACTOSERTIB	An orally bioavailable inhibitor of the serine/threonine kinase, transforming growth factor (TGF)-beta receptor type 1 (TGFBR1), also known as activin receptor-like kinase 5 (ALK5), with potential antineoplastic activity. Upon oral administration, vactosertib inhibits the activity of TGFBR1 and prevents TGF-beta/TGFBR1-mediated signaling. This suppresses tumor growth in TGFBR1-overexpressing tumor cells. TGFBR1, which is overexpressed in a variety of tumor cell types, plays a key role in tumor cell proliferation. Expression of TGF-beta promotes tumor cell proliferation, enhances the migration of tumor cells and suppresses the response of the host immune system to tumor cells.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116358>	C41009	Amenable|Suitable	Having the appropriate qualities.			Qualitative Concept	
C116359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116359>	C50724	Secondary Raynaud Phenomenon|Raynaud Syndrome|Raynaud's Syndrome|Raynaud's Syndrome|Secondary Raynaud Disease|Secondary Raynaud Disease|Secondary Raynaud's Disease|Secondary Raynaud's Disease|Secondary Raynaud's Phenomenon|Secondary Raynaud's Phenomenon	Raynaud phenomenon associated with an underlying autoimmune disorder.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C11635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11635>	C61007	Capecitabine/Oxaliplatin|XELOX|Xeloda/Oxalipaltin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116360>	C50724	Primary Raynaud Phenomenon|Primary Raynaud Disease|Primary Raynaud Disease|Primary Raynaud's Disease|Primary Raynaud's Disease|Primary Raynaud's Phenomenon|Primary Raynaud's Phenomenon	Raynaud phenomenon without a known underlying autoimmune disorder.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C116361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116361>	C28286	Behavioral Insomnia of Childhood	A childhood disorder characterized by difficulty initiating and maintaining sleep due to negative sleep associations, refusal to go to bed, and/or repeated attempts to delay bedtime.			Mental or Behavioral Dysfunction	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116362>	C28193|C27586	Alice in Wonderland Syndrome	A neurological syndrome characterized by distorted perceptions of shape, loss of sense of time, and visual, auditory, and tactile hallucinations.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116363>	C2889|C28193	Susac Syndrome	An autoimmune microvascular disease that is characterized by the clinical triad of encephalopathy, branch retinal artery occlusions, and hearing loss.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116364>	C3078	Auditory Neuropathy Spectrum Disorder|ANSD|Auditory Dys-synchrony|Auditory Neuropathy|Auditory Neuropathy	A hearing disorder characterized by impaired transmission of signals through the auditory nerve, resulting in mild to severe hearing loss and poor speech perception.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C116365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116365>	C35731	Functional Hearing Loss	Hearing loss in the absence of auditory system pathology.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116366>	C84575	Hyperacusis	A disorder in which an individual has an abnormally low noise tolerance, and increased sensitivity to sounds.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116367>	C35731	Presbycusis	Bilateral hearing loss caused by progressive degeneration of cochlear structures and central auditory pathways, typically associated with the aging process.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116368>	C227040	Hyposmia	Decreased ability to smell.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116369>	C227040	Anosmia|Loss of smell	Inability to smell.			Finding	NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11636>	C61063	Fluorouracil/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116370>	C227040	Dysosmia|Smell Disorder	Abnormal sense of smell.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|SeroNet Authorized Values|SeroNet Study Descriptors
C116371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116371>	C227040	Cacosmia	A hallucination of an unpleasant odor.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116372>	C227040	Phantosmia	Detection of odors that are not present.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116373>	C28145	Hypogeusia	Decreased ability to taste.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116374>	C28145	Ageusia|Loss of taste	Inability to taste.			Finding	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116375>	C28145	Phantogeusia|Phantom Taste Perception|Phantom Taste Perception	A lingering, usually unpleasant, taste without the associated stimulus.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116376>	C34549	Hyperesthesia	Increased sensitivity to tactile stimulation.			Finding	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116377>	C2167|C129825	Osimertinib|2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-|AZD 9291|AZD-9291|AZD9291|Mereletinib|OSIMERTINIB	A third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, osimertinib covalently binds to and inhibits the activity of numerous mutant forms of EGFR, including the secondarily-acquired resistance mutation T790M, L858R, and exon 19 deletions, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.	Osimertinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116378>	C28193	Posterior Fossa Syndrome	A postoperative syndrome, usually presenting after midline posterior fossa tumor resection, that involves a variety of signs and symptoms including aphasia, mutism or speech disturbances, dysphagia, mobility problems, cranial nerve palsies and emotional instability.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116379>	C28193	Cerebellar Mutism	A syndrome, usually presenting after midline posterior fossa tumor resection, which is characterized by abnormalities of speech, behavioral or affective disturbances, and diffuse cerebellar dysfunction.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11637>	C61007	Carboplatin/Paclitaxel/Thalidomide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116380>	C28193	Chronic Infantile Neurological Cutaneous and Articular Syndrome|CINCA|CINCA Syndrome|CINCA/NOMID|NOMID|Neonatal-Onset Multisystem Inflammatory Disease|Neonatal-Onset Multisystem Inflammatory Disease	A congenital autoinflammatory disorder that presents within a few days of birth and is characterized by a clinical triad of skin rash, chronic meningitis, and joint pain with recurrent fever and inflammation.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Rheumatology Terminology
C116381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116381>	C4731|C27587	Neuritis	Inflammation of a nerve.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116382>	C3111	External Hydrocephalus	Abnormal increase of cerebrospinal fluid in the subdural space of the brain.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116383>	C3111	Post-Hemorrhagic Hydrocephalus|Post Hemorrhagic Hydrocephalus	An abnormal accumulation of cerebrospinal fluid within the ventricles of the brain that occurs as a later sequela of an intraventricular or subarachnoid hemorrhage.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C116384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116384>	C3111	Post-Inflammatory Hydrocephalus|Post Inflammatory Hydrocephalus	An abnormal accumulation of cerebrospinal fluid within the ventricles of the brain that occurs as a consequence of a central nervous system inflammation.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C116385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116385>	C20993	Prostate Imaging-Reporting and Data System|PI-RADS|PIRADS	A structured reporting scheme for multiparametric prostate cancer imaging and diagnosis. Prostate images are obtained using multiple MRI techniques including T2 weighted images, a dynamic contrast-enhanced study (DCE), diffusion weighted imaging (DWI), and possibly spectroscopy (MRS). Each lesion receives a score from 1 to 5 for each individual imaging parameter, as well as an overall 1-5 grading score reflecting the likelihood of clinically significant cancer, with 1 being most probably benign and 5 being highly suspicious of malignancy.			Intellectual Product	
C116386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116386>	C36386|C3420|C185933	t(1;14)	A chromosomal translocation involving chromosome 1 and chromosome 14.	t(1;14)		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116387>	C12558	Tumor-Associated Macrophage|TAM|Tumor Associated Macrophage	Non-neoplastic macrophages that are found in close proximity to or within a tumor mass.	Tumor-Associated Macrophage		Cell	CTRP Biomarker Terminology|CTRP Terminology
C116388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116388>	C164009|C12958	Bone Marrow-Derived Cell|BMDC|Bone Marrow Derived Cell	A cell that is isolated from bone marrow.	Bone Marrow-Derived Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C116389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116389>	C48182	EMC-92-Gene Signature|EMC-92|EMC-92 Gene Signature|SKY-92|SKY-92 Gene Signature|SKY92 Gene Signature	A prognostic system used to assess if a patient has high-risk multiple myeloma. This system is based on the expression profile of 92 genes.	EMC-92-Gene Signature		Functional Concept	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11638>	C63356	BEACOPP Regimen|BEACOPP|BEACOPP|BEACOPP|BEACOPP|BEACOPP regimen|Bleomycin-Etoposide-Adriamycin-Cyclophosphamide-Oncovin-Procarbazine-Prednisone Regimen|Bleomycin/Cyclophosphamide/Doxorubicin/Etoposide/Prednisone/Procarbazine/Vincristine	A regimen consisting of bleomycin, etoposide, doxorubicin hydrochloride (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine and prednisone, used for the treatment of advanced-stage Hodgkin lymphoma.	BEACOPP Regimen		Therapeutic or Preventive Procedure	CTRP Agent Terminology|CTRP Terminology|HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|NCI Drug Dictionary Terminology|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C116390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116390>	C120005	Alpha-Hydroxyglutarate|2-HG|2-Hydroxy-Pentanedioic Acid|2-Hydroxyglutarate|2-Hydroxyglutaric Acid|2-Hydroxypentanedioic Acid|2HG|Alpha-Hydroxyglutaric Acid|Pentanedioic Acid, 2-Hydroxy-	The base form of alpha-hydroxyglutaric acid, which is an intermediate in the synthesis of alpha-ketoglutaric acid. Alpha-hydroxyglutarate accumulates in the blood of patients with 2-hydroxyglutaric aciduria; an organic acid metabolism disorder, which is caused by the genetic mutation of one of the enzymes responsible for the conversion of 2-hydroxyglutaric acid to alpha-ketoglutaric acid.	Alpha-Hydroxyglutarate		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C116391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116391>	C616	Deoxysphingolipid|Deoxy-Sphingolipid|dSL	An atypical, cytotoxic sphingolipid produced during abnormal de novo sphingolipid synthesis in which the enzyme serine palmitoyltransferase (SPT) is mutated. During de novo sphingolipid synthesis, SPT normally converts L-serine and palmitoyl-Coenzyme A into 3-keto-dihydrosphingosine, which is processed further to form ceramide. Mutated forms of SPT can accommodate the alternative substrates L-alanine or L-glycine, which leads to the formation of the deoxysphingolipids, deoxysphinganine and deoxymethylsphinganine, respectively. These atypical lipids are neither converted to ceramide nor degraded by the cellular glycosphingolipid hydrolysis pathways. Therefore, deoxysphingolipids can accumulate to neurotoxic levels, which can lead to neuropathy. Elevated plasma levels of deoxysphingolipids may be associated with diabetes or metabolic syndrome.	Deoxysphingolipid		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C116392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116392>	C20030	Cytotoxic Granule Protein|CGP	A protein that is stored in the secretory granules of cytotoxic leukocytes and plays a role in cell-mediated cytolysis.	Cytotoxic Granule Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116393>	C48463	Total Nicotine Equivalent|TNE	The sum of the molecules of nicotine and each of its metabolites, including cotinine, trans 3'-hydroxycotinine and their respective glucuronide conjugates, detected in a biological sample.	Total Nicotine Equivalent		Quantitative Concept	CTRP Biomarker Terminology|CTRP Terminology
C116394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116394>	C21176	PDGFR-AA|Platelet-Derived Growth Factor Receptor Alpha Homodimeric Complex	A homodimeric protein complex comprised of 2 platelet-derived growth factor receptor alpha proteins. Formation of this complex is dependent on the binding of a disulfide-linked homodimer of platelet-derived growth factor alpha. The formation of the receptor dimer activates its intrinsic tyrosine-protein kinase activity and initiates signal transduction pathways.	PDGFR-AA		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116395>	C21176	PDGFR-BB|Platelet-Derived Growth Factor Receptor Beta Homodimeric Complex	A homodimeric protein complex comprised of 2 platelet-derived growth factor receptor beta proteins. Formation of this complex is dependent on the binding of a disulfide-linked homodimer of platelet-derived growth factor beta. The formation of the receptor dimer activates its intrinsic tyrosine-protein kinase activity and initiates signal transduction pathways.	PDGFR-BB		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116396>	C202673	KIT Exon 17 Mutation|CD117 Exon 17 Mutation|CKIT Mutation - Ex17|Exon 17|KIT Proto-Oncogene Tyrosine Protein Kinase Gene Exon 17 Mutation|c-KIT Exon 17 Mutation|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Gene Exon 17 Mutation	A molecular genetic abnormality indicating the presence of a mutation in exon 17 of the KIT gene located within 4q11-q12.	KIT Exon 17 Mutation		Cell or Molecular Dysfunction	AML Authorized Value Terminology|AML Minimal Residual Disease Table|AML Molecular Analysis Table|CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116397>	C39718	PDGFRA Exon 12 Mutation|CD140A Exon 12 Mutation|Exon 12|PDGFR-2 Exon 12 Mutation|PDGFR2 Exon 12 Mutation|RHEPDGFRA Exon 12 Mutation	A molecular genetic abnormality indicating the presence of a mutation in exon 12 of the PDGFRA gene located within 4q11-q13.	PDGFRA Exon 12 Mutation		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116398>	C39718	PDGFRA Exon 14 Mutation|CD140A Exon 14 Mutation|PDGFR-2 Exon 14 Mutation|PDGFR2 Exon 14 Mutation|RHEPDGFRA Exon 14 Mutation	A molecular genetic abnormality indicating the presence of a mutation in exon 14 of the PDGFRA gene located within 4q11-q13.	PDGFRA Exon 14 Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116399>	C39718	PDGFRA Exon 18 Mutation|CD140A Exon 18 Mutation|Exon 18|PDGFR-2 Exon 18 Mutation|PDGFR2 Exon 18 Mutation|RHEPDGFRA Exon 18 Mutation	A molecular genetic abnormality indicating the presence of a mutation in exon 18 of the PDGFRA gene located within 4q11-q13.	PDGFRA Exon 18 Mutation		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11639>	C61007	Autologous Tumor Cell Vaccine/Sargramostim			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1163>	C798|C1934	N-Methylformamide|EK 7011|EK 7011|Formamide, N-methyl|Monomethylformamide|N-METHYLFORMAMIDE|NMF|X 188|X 188|formylmethylamine|monomethylformamide	A water-soluble organic solvent.  As an adjuvant antineoplastic agent, N-methylformamide depletes cellular glutathione, a key molecule involved in the antioxidation of reactive oxygen species (ROS) and other free radicals, thereby enhancing ionizing radiation-induced DNA cross-linking in and terminal differentiation of tumor cells. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116400>	C16295	Hepatitis C Antibody|Anti-HCV Antibody|Anti-Hepatitis C Antibody|HCV Antibody	An antibody produced by B-lymphocytes in response to hepatitis C virus infection.	Hepatitis C Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C116401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116401>	C25966	MicroRNA 9|MIR9|MIRN9|hsa-miR-9-5p|hsa-mir-9|miR-9|miRNA 9|miRNA-9|miRNA9	A 23 ribonucleotide sequence that is a final product of the processing of MIR9-1 pre-miRNA, MIR9-2 pre-miRNA or MIR9-3 pre-miRNA. This oligonucleotide is involved in gene regulation and may play a role in nerve cell differentiation, insulin secretion and nervous system tumors which display neuronal differentiation.	MicroRNA 9		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116402>	C21176	Procollagen-Proline Dioxygenase|Collagen Proline Hydroxylase|EC 1.14.11.2|Hydroxylase, Collagen Proline|P4H|Peptidyl Proline Hydroxylase|Procollagen-Proline 4-Dioxygenase|Proline Hydroxylase|Proline Protocollagen Hydroxylase|Proline, 2-Oxoglutarate Dioxygenase|Proline,2-Oxoglutarate 4-Dioxygenase|Prolyl 4-Hydroxylase|Prolyl Hydroxylase|Prolyl-Glycyl-Peptide, 2-Oxoglutarate:Oxygen Oxidoreductase, 4-Hydroxylating|Prolylprotocollagen Dioxygenase|Prolylprotocollagen Hydroxylase|Protocollagen Hydroxylase|Protocollagen Proline 4-Hydroxylase|Protocollagen Proline Dioxygenase|Protocollagen Proline Hydroxylase|Protocollagen Prolyl Hydroxylase	A tetrameric enzyme complex that catalyzes the post-translational formation of 4-hydroxyproline in the amino acid sequence -Xaa-Pro-Gly-, which is found in collagens and other proteins. The enzyme complex is comprised of two alpha chains and two beta chains. There are 3 separate genes that encode 3 distinct alpha proteins, prolyl 4-hydroxylase subunit alpha-1, -2 and -3. The beta chain is protein disulfide-isomerase.	Procollagen-Proline Dioxygenase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116403>	C16295	Adenovirus Antibody|Anti-Adenovirus Antibody	An antibody produced by B-lymphocytes in response to adenovirus infection.	Adenovirus Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C116405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116405>	C20130	Malate Dehydrogenase|EC 1.1.1.37|L-Malate Dehydrogenase|MDH|Malate (NAD) Dehydrogenase|Malic Acid Dehydrogenase|Malic Dehydrogenase|NAD-Dependent Malate Dehydrogenase|NAD-Dependent Malic Dehydrogenase|NAD-L-Malate Dehydrogenase|NAD-Linked Malate Dehydrogenase|NAD-Malate Dehydrogenase|NAD-Malic Dehydrogenase|NAD-Specific Malate Dehydrogenase	A family of enzymes whose members reversibly catalyze the oxidation of malate to oxaloacetate using the reduction of NAD+ to NADH and are involved in multiple metabolic pathways. There are 2 proteins in this family, malate dehydrogenase, cytoplasmic and malate dehydrogenase, mitochondrial.	Malate Dehydrogenase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116406>	C16295	PASD1 Antibody|Anti-CT63 Antibody|Anti-Cancer/Testis Antigen 63 Antibody|Anti-OX-TES-1 Antibody|Anti-OXTES1 Antibody|Anti-PAS Domain Containing 1 Antibody|Anti-PAS Domain-Containing Protein 1 Antibody|Anti-PASD1 Antibody|CT63 Antibody|Cancer/Testis Antigen 63 Antibody|OX-TES-1 Antibody|OXTES1 Antibody|PAS Domain Containing 1 Antibody|PAS Domain-Containing Protein 1 Antibody	Any immunoglobulin that recognizes PAS domain-containing protein 1.	PASD1 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116407>	C20130	Cytochrome P450 Family 11|CYP11|CYPXI|Cytochrome P450 11|Cytochrome P450 11, Mitochondrial|Cytochrome P450 Subfamily XI|Cytochrome P450, Family 11|Mitochondrial Cytochrome P450 11	A family of mitochondrial enzymes of the cytochrome P450 superfamily whose members are involved in steroidogenesis in the adrenal gland. There are 3 proteins in this family cholesterol side-chain cleavage enzyme, mitochondrial, cytochrome P450 11B1, mitochondrial and cytochrome P450 11B2, mitochondrial.	Cytochrome P450 Family 11		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116408>	C28533|C158414	ABCA1 Gene|ABCA1|ABCA1|ATP-Binding Cassette, Sub-Family A (ABC1), Member 1 Gene	This gene plays a role in intracellular cholesterol transport.	ABCA1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116409>	C116408	ABCA1 wt Allele|ABC-1|ABC1|ATP-Binding Cassette, Sub-Family A (ABC1), Member 1 wt Allele|ATP-Binding Cassette, Subfamily A, Member 1 Gene|CERP|HDLDT1|TGD|Tangier Disease Gene	Human ABCA1 wild-type allele is located in the vicinity of 9q31 and is approximately 147 kb in length. This allele, which encodes ATP-binding cassette sub-family A member 1 protein, is involved in intracellular cholesterol transport. Mutation of the gene is associated with high density lipoprotein deficiency type 2 (autosomal dominant) and Tangier disease.	ABCA1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11640>	C63502|C63467|C159454	GFP Regimen|Cisplatin-Fluorouracil-Gemcitabine|Cisplatin/Fluorouracil/Gemcitabine|Cisplatin/Fluorouracil/Gemcitabine Regimen|GemFLP|GemFLP Regimen|Gemcitabine/Fluorouracil/Leucovorin/Cisplatin|Gemcitabine/Fluorouracil/Platinol|Gemcitabine/Fluorouracil/Platinol Regimen	A regimen consisting of gemcitabine, 5-fluorouracil and cisplatin that can be used in the treatment of bladder, hepatobiliary and pancreatic cancers.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C116410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116410>	C17750|C158419	Phospholipid-Transporting ATPase ABCA1|ABC Transporter 1|ABC-1|ABCA1|ATP Binding Cassette Subfamily A Member 1|ATP-Binding Cassette 1|ATP-Binding Cassette Sub-Family A Member 1|ATP-Binding Cassette Sub-Family A Member 1|ATP-Binding Cassette Transporter 1|ATP-Binding Cassette Transporter A1|Cholesterol Efflux Regulatory Protein|EC 7.6.2.1	ATP-binding cassette sub-family A member 1 (2261 aa, ~254 kDa) is encoded by the human ABCA1 gene. This protein plays a role in intracellular cholesterol transport.	ATP-Binding Cassette Sub-Family A Member 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116411>	C16615	ISX Gene|ISX|ISX|ISX|Intestine-Specific Homeobox Gene	This gene is involved in gene expression regulation in the intestine.	ISX Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C116412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116412>	C116411	ISX wt Allele|Intestine-Specific Homeobox wt Allele|Pix-1|RAXLX	Human ISX wild-type allele is located in the vicinity of 22q12.3 and is approximately 21 kb in length. This allele, which encodes intestine-specific homeobox protein, plays a role in the regulation of transcription in intestinal tissue.	ISX wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116413>	C17207	Intestine-Specific Homeobox|Pancreas-Intestine Homeodomain Transcription Factor|RAX-Like Homeobox	Intestine-specific homeobox (245 aa, ~27 kDa) is encoded by the human ISX gene. This protein is involved in intestine tissue-specific regulation of gene transcription.	Intestine-Specific Homeobox		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116414>	C28533	MTTP Gene|MTTP|MTTP|Microsomal Triglyceride Transfer Protein Gene	This gene plays a role in lipid transport.	MTTP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116415>	C116414	MTTP wt Allele|ABL|MTP|MTP, Large Subunit Gene|Microsomal Triglyceride Transfer Protein (Large Polypeptide, 88kD) Gene|Microsomal Triglyceride Transfer Protein (Large Polypeptide, 88kDa) Gene|Microsomal Triglyceride Transfer Protein wt Allele|Microsomal Triglyceride Transfer Protein, 88-kD Gene	Human MTTP wild-type allele is located in the vicinity of 4q24 and is approximately 60 kb in length. This allele, which encodes microsomal triglyceride transfer protein large subunit protein, is involved in triglyceride, cholesteryl ester, and phospholipid transport. Mutation of the gene is associated with abetalipoproteinemia.	MTTP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116416>	C16386	Microsomal Triglyceride Transfer Protein Large Subunit|MTTP	Microsomal triglyceride transfer protein large subunit (894 aa, ~99 kDa) is encoded by the human MTTP gene. This protein plays a role in the targeting of triglycerides, cholesteryl esters, and phospholipids to membranes or vesicles.	Microsomal Triglyceride Transfer Protein Large Subunit		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116417>	C28533	APOA1 Gene|APOA1|APOA1|Apolipoprotein A1 Gene	This gene is involved in cholesterol transport and metabolism.	APOA1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116418>	C116417	APOA1 wt Allele|Apolipoprotein A-I Gene|Apolipoprotein A1 wt Allele|Apolipoprotein of High Denisity Lipoprotein Gene	Human APOA1 wild-type allele is located within 11q23-q24 and is approximately 2 kb in length. This allele, which encodes apolipoprotein A-I protein, plays a role in cholesterol metabolism and transport. Mutation of the gene is associated with several types of amyloidosis, APOA1 deficiency, hypoalphalipoproteinemia, autosomal recessive corneal clouding, and high density lipoprotein deficiency types 1 (recessive) and 2 (autosomal dominant). Fusion of this gene with the neighboring APOC3 gene is associated with combined apoA-I and apoC-III deficiency.	APOA1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116419>	C16386	Apolipoprotein A-I|APOA1|Apo-AI|ApoA-I|Apolipoprotein A1	Apolipoprotein A-I (267 aa, ~31 kDa) is encoded by the human APOA1 gene. This protein is involved in the transport and metabolism of cholesterol.	Apolipoprotein A-I		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11641>	C61063	Tamoxifen/Trastuzumab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116420>	C18437	SAR1B Gene|SAR1B|SAR1B|Secretion Associated, Ras Related GTPase 1B Gene	This gene plays a role in vesicle transport.	SAR1B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116421>	C116420	SAR1B wt Allele|ANDD|CMRD|GTBPB|SAR1 Homolog B (S. cerevisiae) Gene|SAR1, S. cerevisiae, Homolog B Gene|SAR1A, S. cerevisiae, Homolog 2 Gene|SAR1a Gene Homolog (S. cerevisiae) 2 Gene|SAR1a Gene Homolog 2|SAR1a Gene Homolog 2 (S. cerevisiae) Gene|SARA2|SARB|Secretion Associated, Ras Related GTPase 1B wt Allele	Human SAR1B wild-type allele is located in the vicinity of 5q31.1 and is approximately 48 kb in length. This allele, which encodes GTP-binding protein SAR1b, is involved in both GTPase activity and vesicle transport. Mutation and variation of the gene is associated with chylomicron retention disease.	SAR1B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116422>	C18277	GTP-Binding Protein SAR1b|GTBPB|GTP-Binding Protein B|GTP-Binding Protein Sara|SAR1 Homolog B	GTP-binding protein SAR1b (198 aa, ~22 kDa) is encoded by the human SAR1B gene. This protein plays a role in the regulation of vesicle transport from the endoplasmic reticulum to the Golgi.	GTP-Binding Protein SAR1b		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116423>	C25939	BCO1 Gene|BCMO1|BCO1|BMO1|Beta-Carotene Oxygenase 1 Gene	This gene is involved in the conversion of beta-carotene into retinal.	BCO1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116424>	C116423	BCO1 wt Allele|BCDO|BCDO1|BCMO|BCMO1|BCO|BCO1|Beta-Carotene 15, 15'-Dioxygenase 1 Gene|Beta-Carotene 15,15'-Monooxygenase 1 Gene|Beta-Carotene Oxygenase 1 wt Allele|FLJ10730	Human BCO1 wild-type allele is located in the vicinity of 16q23.2 and is approximately 53 kb in length. This allele, which encodes beta,beta-carotene 15,15'-dioxygenase protein, plays a role in vitamin A biosynthesis.	BCO1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116425>	C28459	Beta,Beta-Carotene 15,15'-Dioxygenase|BCO1|Beta,Beta-Carotene 15, 15'-Dioxygenase 1|Beta,Beta-Carotene 15,15'-Dioxygenase 1|Beta,Beta-Carotene 15,15'-Monooxygenase|Beta,Beta-Carotene 15,15-Dioxygenase|Beta,Beta-Carotene 15,15-Prime-Monooxygenase|Beta,Beta-Carotene 15,15-Prime-Monooxygenase 1|Beta-Carotene 15, 15'-Dioxygenase 1|Beta-Carotene 15,15'-Dioxygenase 1|Beta-Carotene 15,15'-Oxygenase 1|Beta-Carotene 15,15-Prime-Dioxygenase|Beta-Carotene 15,15-Prime-Dioxygenase 1|Beta-Carotene 15,15-Prime-Oxygenase 1|Beta-Carotene Dioxygenase 1|Beta-Carotene Oxygenase 1|EC 1.14.99.36	Beta,beta-carotene 15,15'-dioxygenase (547 aa, ~63 kDa) is encoded by the human BCO1 gene. This protein is involved in the oxidative cleavage of beta-carotene to form retinal.	Beta,Beta-Carotene 15,15-Dioxygenase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116426>	C21295	PLIN2 Gene|PLIN2|PLIN2|Perilipin 2 Gene	This gene plays a role in lipid storage.	PLIN2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116427>	C116426	PLIN2 wt Allele|ADFP|ADRP|Perilipin 2 wt Allele	Human PLIN2 wild-type allele is located in the vicinity of 9p22.1 and is approximately 41 kb in length. This allele, which encodes perilipin-2 protein, is involved in adipose tissue development and maintenance.	PLIN2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116428>	C17728	Perilipin-2|ADRP|Adipophilin|Adipose Differentiation-Related Protein|PLIN2	Perilipin-2 (437 aa, ~48 kDa) is encoded by the human PLIN2 gene. This protein plays a role in cellular lipid storage	Perilipin-2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116429>	C62727	3-Dimensional Ultrasound-Guided Radiation Therapy|3D Ultrasound-Guided Radiation Therapy|3DUS-IGRT	External beam radiation therapy that used 3-dimensional ultrasound images to map a target lesion, improving accuracy and precision and helping to spare unaffected tissues.	3-Dimensional Ultrasound-Guided Radiation Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C11642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11642>	C61063	Fludarabine/UCN-01			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116430>	C15313	4-Dimensional Conformal Radiation Therapy|4D Conformal Radiation Therapy	3-Dimensional conformal radiation therapy that is designed to compensate for motion of the tumor and surrounding normal tissue during each treatment session.	4-Dimensional Conformal Radiation Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116431>	C142779	Active Breathing Coordinator-Mediated Radiation Therapy|ABC|Active Breathing Coordinator	A method for reducing the amount of radiation dose delivered to non-target tissues. The technique involves teaching the patient to hold their breath for short periods of time while the radiation is being applied.	Active Breathing Coordinator-Mediated Radiation Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116432>	C62727	Image-Guided Adaptive Radiation Therapy|IGART	A type of radiation therapy that uses information gathered during the treatment cycle to inform, guide, and alter future radiation treatments with respect to location and dose.	Image-Guided Adaptive Radiation Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116433>	C15313|C15292	Palliative Radiation Therapy|Palliative Radiotherapy	Any radiation treatment done with the intent to relieve symptoms and reduce the suffering caused by the cancer, and not with the intent of curing the cancer.	Palliative Radiation Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116434>	C15848	Radiation Therapy Treatment Planning and Simulation|Radiation Therapy Treatment Planning/Simulation	The creation of a strategy, and the rehearsal of that strategy, for the purpose of identifying and eliminating any problems that may present during treatment.	Radiation Therapy Treatment Planning and Simulation		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C116435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116435>	C16035|C116436	3-Dimensional Conformal Accelerated Partial Breast Irradiation|3D Conformal Accelerated Partial Breast Irradiation	Accelerated partial breast radiation therapy that uses 3-dimensional conformal radiation techniques.	3-Dimensional Conformal Accelerated Partial Breast Irradiation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116436>	C116439	Accelerated Partial Breast Irradiation|APBI|Accelerated Partial Breast Radiation Therapy	Radiation therapy following lumpectomy, that uses highly effective doses of radiation over a reduced treatment time. Radiation may be administered by brachytherapy, or through external radiation beam techniques.	Accelerated Partial Breast Irradiation		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology
C116437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116437>	C15313	Craniospinal Irradiation	The use of radiation therapy directed at the brain and spinal cord to kill cancer cells.	Craniospinal Irradiation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116438>	C15313	Breast Irradiation|Breast Radiation Therapy|Breast Radiotherapy	Localized radiation therapy to the breast.	Breast Irradiation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116439>	C116438	Partial Breast Irradiation	External beam radiation that is focused on a specific part of the breast.	Partial Breast Irradiation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C11643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11643>	C61063	Irinotecan/Trastuzumab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116440>	C116438	Whole Breast Irradiation	External beam radiation that treats the entire breast.	Whole Breast Irradiation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116441>	C17204	4-Dimensional Computed Tomography|4D CT|4D Computed Tomography|4DCT|Time-Resolved CT Data Acquisition	Computed tomography scans designed to minimize motion artifacts. 4DCT can be accomplished by collecting data for the duration of the patient's respiratory cycle and by oversampling CT data acquisition at each slice.	4-Dimensional Computed Tomography		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116442>	C17204	Computed Tomography Perfusion Imaging|COMPUTED TOMOGRAPHY PERFUSION|CT Perfusion|CTP	An application of CT imaging used to assess the quality of blood flow to an organ or tissue.	Computed Tomography Perfusion Imaging		Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF6 DIPG Imaging Assessment Perfusion Table|CRF6 DMG Imaging Assessment Perfusion Table|CTRP Intervention Terminology|CTRP Terminology
C116443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116443>	C17204	Thermoacoustic Computed Tomography|OAT|Opto-Acoustic Tomography|Optoacoustic Tomography|PAT|Photoacoustic Computer Tomography|Photoacoustic Tomography|TAT|Thermoacoustic Tomography	A type of computer tomography that uses radiation to create thermoacustic waves, which are then recorded and translated into a three dimensional image of the tissue.	Thermoacoustic Computed Tomography		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116444>	C51763|C137909	Computed Tomography-Guided Optical Sensor-Guided Percutaneous Needle Biopsy	The use of CT imaging to guide the placement of a needle being used to obtain a tissue sample.	Computed Tomography-Guided Optical Sensor-Guided Percutaneous Needle Biopsy		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116445>	C15666	Computed Tomography-Guided Optical Sensor-Guided Radiofrequency Ablation	The use of CT imaging to guide the placement of the electrode for radiofrequency ablation.	Computed Tomography-Guided Optical Sensor-Guided Radiofrequency Ablation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116446>	C116486	Diffuse Optical Tomography	A type of computer tomography that creates 3D, digital models of objects by constructing images created by interpreting light that has been transmitted and scattered through an object. Because the object being imaged must be at least partially translucent, this technique works best on soft tissues.	Diffuse Optical Tomography		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116447>	C20828	Optical Doppler Tomography	An imaging modality that combines laser Doppler flowmetry with optical coherence tomography to produce high-resolution tissue images that demonstrate direction and velocity of blood flow.	Optical Doppler Tomography		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116448>	C38093|C19337	Ultrasound Tomography	The quantitative computation of data obtained via ultrasonography to create a three dimensional map of the imaged tissue.	Ultrasound Tomography		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116449>	C17007	Positron Emission Tomography with Radiolabeled Targeting Agent|Positron Emission Tomography with Radiolabeled Targeting Agents	A functional nuclear medicine test that utilizes a radioactive tracer, most commonly the radiolabeled sugar fluorodeoxyglucose, to identify tumors and metastasis.	Positron Emission Tomography with Radiolabeled Targeting Agent		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C11644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11644>	C61063	MAGE-3/SB AS-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116450>	C16809	Arterial Spin Labeling Magnetic Resonance Imaging|ARTERIAL SPIN LABELING FUNCTIONAL MRI|ASL|ASL|ASL fMRI|Arterial Spin Labeling MRI	An application of functional MRI used to measure cerebral blood flow. ASL uses magnetically labeled water as the tracer.	Arterial Spin Labeling Magnetic Resonance Imaging		Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF6 DIPG Imaging Assessment Perfusion Table|CRF6 DMG Imaging Assessment Perfusion Table|CTRP Intervention Terminology|CTRP Terminology
C116451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116451>	C16809	Chemical Exchange Saturation Transfer Magnetic Resonance Imaging|Chemical Exchange Saturation Transfer MRI	An acquisition technique of MRI that uses differences in the tissue microenvironment, like protein concentration or intracellular pH, to generate contrast differences.	Chemical Exchange Saturation Transfer Magnetic Resonance Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116453>	C46087	Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|DSC|DSC-MRI|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|Dynamic Susceptibility Contrast-Enhanced MRI	A type of magnetic resonance imaging that uses the transient signal reduction induced by the first pass of gadolinium chelate through the brain vessels to calculate cerebral blood flow maps, and to determine the ratio between the cerebral blood volume in the lesion and the cerebral blood volume in normal tissue.	Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging		Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF6 DMG Imaging Assessment Perfusion Table|CTRP Intervention Terminology|CTRP Terminology
C116454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116454>	C16809	Functional Connectivity Magnetic Resonance Imaging|Functional Connectivity MRI|fcMRI	A technique that monitors blood oxygen level dependent (BOLD) signals to map distant brain regions that work together while performing a task.	Functional Connectivity Magnetic Resonance Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116455>	C16809	High Field Strength Magnetic Resonance Imaging|High Field Strength MRI	A type of magnetic resonance imaging that uses larger, stronger magnets to generate faster scans and higher resolution images.	High Field Strength Magnetic Resonance Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116456>	C16809	Low Field Strength Magnetic Resonance Imaging|Low Field Strength MRI	A type of magnetic resonance imaging that uses a weaker magnet (less than or equal to 0.3 Tesla) than is used in conventional magnetic resonance imaging. This is typical of open MRI machines and office-based MRI units.	Low Field Strength Magnetic Resonance Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116457>	C16809	Magnetization Transfer Magnetic Resonance Imaging|Magnetization Transfer MRI	A type of magnetic resonance imaging that involves the transfer of longitudinal magnetization of hydrogen nuclei between restricted motion water and free motion water, allowing for the calculation of the magnetization transfer ratio (MTR), an indicator of the structural integrity of the imaged tissue.	Magnetization Transfer Magnetic Resonance Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116458>	C16809	Multiparametric Magnetic Resonance Imaging|MP-MRI|Multi-parametric MRI|Multiparametric MRI|mpMRI	The combination of multiple magnetic resonance techniques, including diffusion weighted imaging, dynamic contrast-enhanced imaging, and spectroscopy, to achieve an image that will allow for better identification of tumor size and location, as well as possibly identifying cancer spread and aggressiveness.	Multiparametric Magnetic Resonance Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116459>	C16809	Secretin-Enhanced Magnetic Resonance Imaging|Secretin-Enhanced MRI	An imaging technique that requires the intravenous administration of secretin immediately prior to a magnetic resonance cholangiopancreatography, allowing for a qualitative assessment of exocrine pancreatic function.	Secretin-Enhanced Magnetic Resonance Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C11645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11645>	C61007	Bryostatin 1/Interleukin-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116460>	C16809	Specimen Ultra-High-Field Magnetic Resonance Imaging|Specimen Ultra-High-Field MRI	A type of magnetic resonance imaging that uses very high field stength to provide a very detailed image of the targeted tissue.	Specimen Ultra-High-Field Magnetic Resonance Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116461>	C16809	Superparamagnetic Iron Oxide Magnetic Resonance Imaging|SPIO-MRI|Superparamagnetic Iron Oxide MRI	A magnetic resonance imaging technique that uses superparamagnetic iron oxide particles as a contrast agent to aid in the identification of multiple disorders, including atherosclerosis, blood-brain barrier dysfunction, and cancer.	Superparamagnetic Iron Oxide Magnetic Resonance Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116462>	C46089	Allogeneic Hematopoietic Stem Cell Transplantation with Donor Pretreatment|Myeloablative Allogeneic Hematopoietic Cell Transplantation	Allogeneic stem cell transplantation into a recipient that has received myeloablative therapy.	Allogeneic Hematopoietic Stem Cell Transplantation with Donor Pretreatment		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116463>	C191377|C142985	Autologous Ovarian Tissue Transplantation	Ovarian transplantation using autologous tissue. The goal of this procedure is to restore both endocrine function and reproductive function.	Autologous Ovarian Tissue Transplantation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116464>	C15289	Bone Graft|Bone Graft Procedure|Bone Graft Surgery	A surgical procedure to replace missing or severely damaged bone with healthy, viable bone tissue.	Bone Graft		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology
C116465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116465>	C16039|C116469	Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation|auto-allo HCT	Therapy that combines cytoreductive-therapy from high-dose therapy and autologous hematopoietic cell transplantation with adoptive immunotherapy (from allogeneic hematopoietic cell transplantation) as a treatment strategy for multiple myeloma.	Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116466>	C116469	Autologous-Autologous Tandem Hematopoietic Stem Cell Transplantation|Stem Cell Transplantation, Double Autologous|auto-auto HCT	Therapy that combines cytoreductive-therapy from high-dose therapy and autologous hematopoietic cell transplantation with adoptive immunotherapy (from autologous hematopoietic cell transplantation) as a treatment strategy for multiple myeloma.	Autologous-Autologous Tandem Hematopoietic Stem Cell Transplantation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C116467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116467>	C15431	Mesenchymal Stem Cell Transplantation	The transfer of multipotent stromal cells from donor to recipient for the treatment of a variety of different systemic and localized diseases.	Mesenchymal Stem Cell Transplantation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116468>	C15431	T Cell-Depleted Hematopoietic Stem Cell Transplantation	The removal of T-cells from the donor's hematopoietic stem cell specimen prior to its transfusion into the recipient.	T Cell-Depleted Hematopoietic Stem Cell Transplantation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116469>	C15431	Tandem Hematopoietic Stem Cell Transplantation	A type of autologous stem cell transplant, during which the patient receives two sequential courses of high-dose chemotherapy with stem cell transplant.	Tandem Hematopoietic Stem Cell Transplantation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C11646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11646>	C61007	Cyclophosphamide/Doxorubicin/Etoposide/Fludarabine/Prednisone/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116470>	C15640	Double-Unit Umbilical Cord Blood Transplantation	The transfusion of two units of umbilical cord blood, one unit from each of two patients. This is mostly commonly done as a form of stem cell transplant for patients with leukemia, lymphoma, or other serious blood disease who require a bone marrow transplant, but for whom no suitable donor can be found.	Double-Unit Umbilical Cord Blood Transplantation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116471>	C64468	Reduced-Intensity Transplant Conditioning Procedure|Non-Myeloablative Conditioning|Reduced Intensity Conditioning|Reduced Intensity Conditioning/Reduced Toxicity Conditioning|Reduced Intensity Conditioning/Reduced Toxicity Conditioning|Reduced Intensity Conditioning/Reduced Toxicity Conditioning	A method of preparation for stem cell transplant that uses less than standard doses of chemotherapy and radiation prior to the transfer of stem cells, with the goal of providing protection against graft vs. host disease, while simultaneously minimizing the toxic effects of the conditioning treatment.	Reduced-Intensity Transplant Conditioning Procedure		Therapeutic or Preventive Procedure	ALL Authorized Value Terminology|ALL Stem Cell Transplant Table|AML Authorized Value Terminology|AML Stem Cell Transplant Table|CTRP Intervention Terminology|CTRP Terminology|HL Authorized Value Terminology|HL Stem Cell Transplant Table|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C116472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116472>	C15192	Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion	A procedure to infuse progenitor cells that have been extracted from umbilical cord blood and expanded in culture.	Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116473>	C16145	T Cell-Depleted Donor Lymphocyte Infusion	A lymphocyte transfusion where the donor's T-cells are removed prior infusion into the recipient.	T Cell-Depleted Donor Lymphocyte Infusion		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116475>	C15388	Fresh Frozen Plasma Transfusion	The infusion of fresh frozen plasma into a recipient.	Fresh Frozen Plasma Transfusion		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116476>	C16546	Chromoendoscopy	Endoscopy that employs the use of tissue stains to increase tissue contrast, and enhance the ability to identify various tissue dysplasia and other abnormalities.	Chromoendoscopy		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116477>	C16546	Confocal Laser Endomicroscopy|CLE	An investigative technique that permits high-resolution assessment of the histology of an endoluminal surface at a cellular and sub-cellular level. The technique is based upon the principle of illuminating a tissue with a low-power laser and then detecting fluorescent light reflected from the tissue. The laser is focused at a specific depth and only light reflected back from that plane is refocused and able to pass through the pinhole confocal aperture, increasing spacial resolution.	Confocal Laser Endomicroscopy		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116478>	C79428	Dermoscopy|DMS	A noninvasive diagnostic procedure that allows for in vivo microscopic examination of the epidermis, the dermoepidermal junction, and the papillary dermis. This aids in the identification of specific diagnostic patterns related to color and cell structure to aid in differentiating malignant and benign lesions.	Dermoscopy		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116479>	C189891|C116696	Electromagnetic Navigation Bronchoscopy|Virtual Navigation Bronchoscopy	A two-stage bronchoscopic technique that uses electromagnetic technology to first prepare 3D, digital reconstructions of the patient's airways, and then helps the clinician use those images to guide instruments through the bronchi to the previously identified target. This is most often performed to biopsy lesions or lymph nodes, or place a brachytherapy catheter.	Electromagnetic Navigation Bronchoscopy		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C11647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11647>	C61063	Anti-thymocyte globulin/thiotepa			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116480>	C16546	High-Resolution Microendoscopy|HRME	A low-cost, high-resolution imaging tool consisting of a 1-mm diameter fiber-optic bundle that produces subcellular imaging at 1,000x magnification and 4 micrometer resolution, allowing for minimally invasive bioimaging.	High-Resolution Microendoscopy		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116481>	C116477	Image-Guided Needle Confocal Laser Endomicroscopy	A procedural technique that uses endoscopic ultrasound and confocal laser to obtain real time images, assess blood flow, and gain histopathology samples of the gastrointestinal tract.	Image-Guided Needle Confocal Laser Endomicroscopy		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116482>	C17155	Fiber-Optic Spectroscopy	The use of flexible, translucent fibers to measure the emission and absorption of different wavelengths of visible and non-visible light.	Fiber-Optic Spectroscopy		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C116483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116483>	C17155	Polarized Reflectance Spectroscopy|Light Scattering Spectroscopy with Polarized Light|Polarized Light Scattering Spectroscopy|Reflectance Spectroscopy with Polarized Light	An endoscopic technique that uses polarized light to provide qualitative morphological information of tissue in situ, with reduced background signals, to evaluate epithelial tissue for dysplasia and ischemia.	Polarized Reflectance Spectroscopy		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C116484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116484>	C106517	Acoustic Radiation Force Impulse Imaging	A type of elastography that uses acoustic radiation force to generate images of the mechanical properties of soft tissue.	Acoustic Radiation Force Impulse Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116485>	C16502	Bioelectric Field Imaging	Noninvasive measurement of the bioelectric fields across the epidermis.	Bioelectric Field Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116486>	C16502	Diffuse Optical Imaging	A method of rendering images using near-infrared spectroscopic or fluorescence techniques. It is most commonly used to measure changes in oxygenated and deoxygenated hemoglobin concentrations as an indicator of wound or injury healing.	Diffuse Optical Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116487>	C64862	Diffusion Kurtosis Imaging|DKI	An extension of conventional diffusion tension imaging, which estimates the kurtosis of the water diffusion probability distribution function. This technique is most commonly used to study the brain.	Diffusion Kurtosis Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116488>	C19337|C148281	Dynamic Contrast-Enhanced Ultrasound Imaging	A functional imaging technique that uses the combination of sonography and microbubble contrast agents to render the desired image.	Dynamic Contrast-Enhanced Ultrasound Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116489>	C17369	Fluorescence Imaging	An imaging technique that uses fluorescent dye to achieve the desired image.	Fluorescence Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C11648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11648>	C61063	Leflunomide/Mitoxantrone/Prednisone			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116490>	C16502	Intraoperative Imaging	Any images taken during an operation; this may be done for a variety of reasons, including providing the surgeon with immediate feedback to improve operative outcome or to documentation of the procedure.	Intraoperative Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116491>	C16502	Laser Doppler Imaging|Scanning Laser Doppler	An imaging technique that is used to measure superficial blood flow in the skin.	Laser Doppler Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116492>	C16502	Laser Speckle Imaging|LASER SPECKLE CONTRAST IMAGING|LSCI|LSCI|Laser Speckle Contrast Imaging	A noninvasive, non-scanning optical imaging technique that provides full-field visualization of blood flow to the tissue being imaged, which provides information about tissue perfusion and the efficiency of disease treatment.	Laser Speckle Imaging		Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C116493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116493>	C16502	Kv/Mv Imaging	Any imaging method that makes use of high-energy radiation in the Kv or Mv range.	Kv/Mv Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116494>	C16809	Magnetic Resonance Thermal Imaging	A type of magnetic resonance imaging that provides a temperature map of the tissue being imaged.	Magnetic Resonance Thermal Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116495>	C16502	Multispectral Imaging	An imaging technique that captures data at multiple frequencies across the electromagnetic spectrum, including those from visible and non-visible wavelengths.	Multispectral Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116496>	C17369	Narrow Band Imaging|NBI	A high-resolution endoscopic technique that uses two specific wavelengths of blue and green light, chosen for their differing ability to peneatrate tissue. These wavelengths are strongly absorbed by hemoglobin and separately visualize both superficial and deeper vasculature.	Narrow Band Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116497>	C16502	Real-Time Position-Tracking Imaging|Marker Tracking	An imaging technique that allows for the real-time tracking of an in vivo medical device, allowing for better control, positioning, and use of the device.	Real-Time Position-Tracking Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C116498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116498>	C17369	Robotic-Assisted Imaging	An imaging technique that uses a specially designed robotic system to aid with the imaging of the desired object.	Robotic-Assisted Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116499>	C17230	Ultrasound Elasticity Imaging	The use of ultrasonography to measure the elastic properties of soft tissue.	Ultrasound Elasticity Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C11649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11649>	C61063	L-778,123/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1164>	C663	Mitomycin A|Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-6,8a-dimethoxy-5-methyl-, carbamate (ester)|MITOMYCIN A	A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus.  Bioreduced mitomycin A generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.  Mitomycin A is more toxic than mitomycin C due to increased and nonselective DNA cross-linking in both aerobic and hypoxic cells. (NCI04)			Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C116500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116500>	C38101	X-Ray Phase-Contrast Imaging|Phase-Contrast X-Ray Imaging|Phase-Sensitive X-Ray Imaging|X-Ray PCI	An imaging modality that transforms an x-ray beam's phase shift, caused by the passage of the beam through the object, into variations in intensity which are then used to create images.	X-Ray Phase-Contrast Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116501>	C16502	Video-Based 3-Dimensional Surface Imaging|Surface imaging|Video-Based 3D Surface Imaging	The use of recorded video images during stereotactic procedures to detect motion-induced misalignment, and allow for precise repositioning of the patient.	Video-Based 3-Dimensional Surface Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C116502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116502>	C62781|C148281	Contrast-Enhanced Harmonic Endoscopic Ultrasound|CH-EUS	A type of doppler ultrasound that uses microbubble contrast to image perfusion and microvasculature within tissues.	Contrast-Enhanced Harmonic Endoscopic Ultrasound		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116503>	C2962	Febrile Seizure	A seizure occurring in infants and young children that occurs in the setting of fever.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116504>	C16853	Multiphoton Microscopy|Multi-Photon Microscopy	An imaging technique that uses multiple photons to absorb infrared light, thereby minimizing phototoxicty and photobleaching, making it an ideal method for imaging living specimens, especially those involving deep tissue.	Multiphoton Microscopy		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C116505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116505>	C16853	Diagnostic Microscopy	A diagnostic tool used to view tissues at high magnification, which allows for identification of cellular structures.	Diagnostic Microscopy		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C116506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116506>	C49165	Image-Guided Surgery	An operative technique that uses real time correlation of the operative field with preoperative images in order to establish the precise location of surgical instruments in relation to surrounding anatomical structures.	Image-Guided Surgery		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116507>	C15215	Percutaneous Cryosurgery	An image-guided, minimally invasive surgical technique that uses a probe inserted through the skin to freeze the targeted tissue, causing cell death secondary to cryogenic injury.	Percutaneous Cryosurgery		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116508>	C62734|C140885	Robot-Assisted Endoscopic Surgery	A surgical technique that uses a specially designed robotic system to aid with an endoscopic procedure.	Robot-Assisted Endoscopic Surgery		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116509>	C15725|C140885	Robot-Assisted Laparoscopic Surgery|RoboticLaparoscopic Surgery	A surgical technique that uses a specially designed robotic system to aid with a laparoscopic surgical procedure.	Robot-Assisted Laparoscopic Surgery		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C11650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11650>	C61063	Fluorouracil/UCN-01			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116510>	C51701	Ultrasound-Guided Prostate Biopsy	A diagnostic procedure that uses an ultrasound image to guide the placement of a biopsy needle into the prostate to obtain a tissue sample.	Ultrasound-Guided Prostate Biopsy		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116511>	C116510	Contrast-Enhanced Ultrasound-Guided Prostate Biopsy	A radiologic technique that employs contrast agents to enable a more precise needle placement during a biopsy of the prostate.	Contrast-Enhanced Ultrasound-Guided Prostate Biopsy		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116512>	C51671	Endoscopic Ultrasound-Guided Fine-Needle Aspiration of the Pancreas	The use of endoscopic ultrasound to direct the placement of a needle being used to obtain a sample of cells from the pancreas. The use of the ultrasound allows for more precise needle placement and makes the procedure safer.	Endoscopic Ultrasound-Guided Fine-Needle Aspiration of the Pancreas		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116513>	C21123|C21072	Celiac Plexus Neurolysis|Celiac Nerve Block	A treatment that involves injection of local anesthetic and alcohol to the celiac plexus, causing temporary degeneration of the nerve fibers. The procedure is performed in an effort to alleviate intractable pain, generally caused by cancer or chronic pancreatitis.	Celiac Plexus Neurolysis		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology
C116514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116514>	C116513	Endoscopic Ultrasound-Guided Celiac Plexus Neurolysis	The use of endoscopic ultrasound to guide the injection of local anesthetic and alcohol to the celiac plexus, which causes temporary degeneration to the nerve fibers. The procedure is performed in an effort to alleviate intractable plain, generally caused by cancer or chronic pancreatitis.	Endoscopic Ultrasound-Guided Celiac Plexus Neurolysis		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116515>	C38081	Breath Test|BREATH TEST	A technique to assess the presence and/or amount of analyte(s) in breath exhaled into a device.	Breath Test		Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C116516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116516>	C116515	Nitric Oxide Breath Test	A diagnostic test that measures the amount of nitric oxide in an exhaled breath.	Nitric Oxide Breath Test		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116517>	C16094	Cardiopulmonary Exercise Testing|CPET|CPX	A clinical tool to evaluate exercise capacity and to assess cardiac function under stress.	Cardiopulmonary Exercise Testing		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116518>	C25218	Other Intervention or Procedure	Interventions or procedures not otherwise categorized.			Health Care Activity	
C116519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116519>	C63474	Cognitive Intervention	A set of therapy techniques derived from the school of cognitive psychology, which the practitioner uses to conduct therapy.	Cognitive Intervention		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C11651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11651>	C61063	gp100 Antigen/Montanide ISA-51/Tyrosinase Peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116520>	C116518	Communication Intervention	An act of intercession by an outside party for the purpose of clarifying or improving the exchange of information between individuals, such as between physician and patient or by an individual with a communication disorder.	Communication Intervention		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C116521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116521>	C116518	Computer-Assisted Intervention	The use of a computer to facilitate the processing of complex information, and then aiding in the creation and execution of a plan of action based on that information.	Computer-Assisted Intervention		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C116522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116522>	C116518	Internet-Based Intervention	Any program that uses the internet to alter, modify, or eliminate a behavior.	Internet-Based Intervention		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C116523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116523>	C116518	Caregiver-Related Intervention or Procedure	Any intervention or procedure performed by a caregiver during the course of their duties.	Caregiver-Related Intervention or Procedure		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C116524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116524>	C15372|C116521	Computer-Assisted Smoking Cessation Intervention	The use of a computer for the creation and execution of a plan to help an individual stop smoking.	Computer-Assisted Smoking Cessation Intervention		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C116525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116525>	C116523	Intervention by Caregiver	An act of intercession or assistance for an individual that is performed by their caregiver.	Intervention by Caregiver		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C116526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116526>	C116518	Memory Intervention	Any action taken for the purpose of improving an individual's memory.	Memory Intervention		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C116527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116527>	C116518	Sham Intervention|Sham Comparator|sham (procedure)	A procedure that functions as the control arm of a clinical trial, mimicking the procedure under investigation in every way, including the preprocedure routine, anaesthesia and incisions (if necessary), and post-procedure follow-up, without actually providing or performing the procedure being studied.	Sham Intervention		Health Care Activity	CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C116528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116528>	C116518	Telephone-Based Intervention	Any program that uses interactions over the telephone to alter, modify, or eliminate an undesired behavior.	Telephone-Based Intervention		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C116529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116529>	C2962	Infantile Spasm|Infantile Spasms|Infantile Spasms	Seizures in the first years of life characterized by flexion and extension jerks of the neck, trunk, and extremities.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11652>	C61063	gp100 Antigen/MART-1 Antigen/Montanide ISA-51			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116530>	C17705	Caregiver-Assisted Training	Any focused education provided to a caregiver.	Caregiver-Assisted Training		Educational Activity	CTRP Intervention Terminology|CTRP Terminology
C116531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116531>	C17705	Communication Skills Training	The attempt to improve the techniques and tactics an individual uses to communicate.	Communication Skills Training		Educational Activity	CTRP Intervention Terminology|CTRP Terminology
C116532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116532>	C17705	Computer-Assisted Cognitive Training	The use of a computer to help an individual improve cognitive skills including focus, attention, memory, and information processing.	Computer-Assisted Cognitive Training		Educational Activity	CTRP Intervention Terminology|CTRP Terminology
C116533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116533>	C17705	Partner-Assisted Coping Skills Training	Any program that aims to teach the partner or caregiver of a patient a specific set of skills intended to help relieve the physical, emotional, and/or mental stress experienced by the patient.	Partner-Assisted Coping Skills Training		Educational Activity	CTRP Intervention Terminology|CTRP Terminology
C116534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116534>	C76243|C62721	EGFR Tyrosine Kinase Inhibitor Therapy	The use of EGFR tyrosine kinase inhibitors to disrupt the activation of EGFR, effectively halting the signaling cascade for cell growth, thereby decreasing tumor proliferation and migration.	EGFR Tyrosine Kinase Inhibitor Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116535>	C15180	Electrical Stimulation Pain Therapy	The use of external electrical current to stimulate nerves for the purpose of reducing pain.	Electrical Stimulation Pain Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116536>	C15347	Electroporation-Mediated Plasmid DNA Vaccine Therapy	The use of an external electrical field to facilitate the transfer of a plasmid into a cell for the purpose of introducing genetically modified DNA and stimulating a immunological response.	Electroporation-Mediated Plasmid DNA Vaccine Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116537>	C173582	Fluid Therapy	The administration of fluids, most commonly via an intravenous route, to restore intravascular volume.	Fluid Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116538>	C3020	Benign Rolandic Epilepsy|BECTS|BRE|Benign Childhood Epilepsy With Centrotemporal Spikes|Benign Childhood Epilepsy with Centrotemporal Spikes	A neurological disorder of childhood characterized by partial seizures consisting of twitching, numbness, or tingling of the face or tongue that often progress to secondary generalized seizures.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116539>	C15347	Gene-Modified Tumor Cell Vaccine Therapy	A type of immunotherapy in which tumor cells have been modified to make them more immunogenic, thereby activating the immune system to attack and destroy the tumor.	Gene-Modified Tumor Cell Vaccine Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C11653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11653>	C61063	gp100 Antigen/Interleukin-2/MART-1 Antigen/Montanide ISA-51			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116540>	C15262	Immunomodulation Therapy	Any treatment modality that exercises its effects by inducing, enhancing, or suppressing an immune response.	Immunomodulation Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116541>	C15355	Pretargeted Radioimmunotherapy	A technique used to improve the efficacy of radioimmunotherapy that targets the tumor with both an antibody construct and a radiolabeled hapten prior to the administration of radiation therapy.	Pretargeted Radioimmunotherapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116542>	C15195	Pulsed-Dose Rate Brachytherapy|PDR|Pulsed dose rate brachytherapy (procedure)	A method of delivering internal beam radiotherapy that involves delivering short bursts of radiation over a specified period of time.	Pulsed-Dose Rate Brachytherapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|mCode Brachytherapy Modality Value Set|mCode Radiotherapy Modality Value Set|mCode Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C116543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116543>	C15445	Subcutaneous Hormonal Therapy	The administration of exogenous hormones via bolus injection into the tissue layer immediately deep to the dermis.	Subcutaneous Hormonal Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116544>	C15347	Synthetic Tumor-Associated Peptide Vaccine Therapy	A type of immunotherapy that uses a synthetic peptide to deliver tumor-specific antigens into the body in an effort to induce a targeted immune system response directed at the tumor.	Synthetic Tumor-Associated Peptide Vaccine Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116545>	C15370	Topical Steroid Therapy	The application of steroid medications to the skin for the treatment of various conditions.	Topical Steroid Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116546>	C15347	Tumor Cell Lysate Vaccine Therapy	A method by which dendritic cells are pulsed in vitro with tumor cell lysate to induce maturation with the purpose of inducing a targeted immune system response against the tumor.	Tumor Cell Lysate Vaccine Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116547>	C15657	Acute Normovolemic Hemodilution|Acute Isovolemic Hemodilution|IAD|Intraoperative Autologous Donation	A method of intraoperative blood conservation in which whole blood is drained by gravity into a collection bag where it is mixed with anticoagulants and maintained at room temperature. As the blood is collected, an intravenous fluid is infused to maintain normal blood volume. The collected blood can be transfused to the patient during and/or after surgery as needed.	Acute Normovolemic Hemodilution		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116548>	C2962	Psychogenic Seizure|Psychogenic Non-Epileptic Seizure	Movements, behaviors and sensations similar to a seizure, but due to psychological distress instead of a neurological disorder.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116549>	C51962	Allele-Specific Oligonucleotide Real-Time Quantitative Polymerase Chain Reaction|ASO-RQ-PCR	An application of real time PCR that is capable of detecting and quantifying a specific allelic version of a gene.	Allele-Specific Oligonucleotide Real-Time Quantitative Polymerase Chain Reaction		Molecular Biology Research Technique	CTRP Intervention Terminology|CTRP Terminology
C11654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11654>	C61007	MART-1 antigen/Montanide ISA-51			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116550>	C18020	Bioconductance Measurement	A test that uses electrical current conductance as measured through skin to help diagnose disease, most commonly lung tumors.	Bioconductance Measurement		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116551>	C49235	Case Management	A collaborative process for the coordination of services for an individual undergoing some manner of treatment. This process includes assessment, planning, facilitation, care coordination, evaluation, and advocacy for options and services to meet the comprehensive health needs for the individual and their family.	Case Management		Activity	CTRP Intervention Terminology|CTRP Terminology
C116552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116552>	C122814	Early Infantile Epileptic Encephalopathy with Burst-Suppression|EIEE with Burst-Suppression|EIEE with Burst-Suppression|OS|Ohtahara Syndrome|Ohtahara Syndrome	A neurological disorder characterized by recurring seizures presenting within the first three months of life, progressive cerebral dysfunction, and an EEG pattern of periods of low electrical brain activity interspersed with bursts of high spiky activity.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116553>	C15959	Cell Proliferation Assay|CELLULAR PROLIFERATION ASSAY	Any method to measure the number of dividing cells in a culture, or to measure the change in the proportion of cells that are dividing.	Cell Proliferation Assay		Research Activity	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C116554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116554>	C19770	Circulating Tumor Cell Analysis|Molecular Analysis of Circulating Tumor Cells	Methods to detect and examine metastatic cancer cells found in the peripheral blood.	Circulating Tumor Cell Analysis		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C116555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116555>	C16205	Clinical Observation|observation	The act, by a healthcare worker, of monitoring an identified subject and recording signs, symptoms, or behavior.	Clinical Observation		Health Care Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C116556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116556>	C131331	Cold Ischemia Procedure|Cold Ischemia During Surgery|cold ischemia	The act of decreasing both the temperature and blood flow to an organ or tissue for the purpose of preserving it for transplantation.	Cold Ischemia Procedure		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116557>	C131331	Warm Ischemia Procedure|Warm Ischemia|Warm Ischemia During Surgery|warm ischemia	A surgical procedure during which the blood supply to an organ or tissue is interrupted and then later reestablished, while maintaining the organ at physiologic body temperature.	Warm Ischemia Procedure		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116558>	C49236	Placebo Administration	The use of a medically inactive substance or intervention in substitution for a drug or other medically active treatment.	Placebo Administration		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116559>	C16818	Positron Emission Mammography	An imaging technique that utilizes a radiolabeled sugar given intravenously to help define the size, shape, and location of a breast tumor.	Positron Emission Mammography		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C11655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11655>	C61063	Montanide ISA-51/Peptide 946 melanoma vaccine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116560>	C62667|C16818	Radiomammography	A type of nuclear medicine study that utilizes a radioactive tracer to identify possible tumors.	Radiomammography		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116561>	C21012	Cranial Electrical Stimulation	The use of skin electrodes to pass a low intensity, pulsed electrical current through the scalp and into the brain.  This procedure is used to treat a variety of illnesses including anxiety, depression, and chronic pain.	Cranial Electrical Stimulation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116562>	C38054	Direct Electrocortical Stimulation|DCES|Direct Cortical Electrical Stimulation|ESM|Electrocortical Stimulation Mapping	A method for functional brain mapping that applies electrical stimulation to the exposed cortex of a patient and marks the cortex according to patient response.	Direct Electrocortical Stimulation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116563>	C106517	Shear Wave Elastography|SWE|Transient Elastography|US SWE	An imaging modality that adds the imaging of shear waves to a conventional ultrasound, allowing for a more detailed image, and an accurate measurement of tissue elasticity.	Shear Wave Elastography		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116564>	C106517	Sonoelastography	An ultrasound imaging technique that uses low amplitude, low frequency shear waves to find solid tumors within tissue.	Sonoelastography		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116565>	C25305	Comprehensive Geriatric Assessment	The complete examination of an elderly individual, which includes a full valuation of the physical and cognitive conditions, as well as a check of the patient's emotional state.	Comprehensive Geriatric Assessment		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116566>	C38236	Convection-Enhanced Delivery|CED	The delivery of pharmacological agents to a brain tumor or resection cavity via specially placed catheters that bypass the blood brain barrier.	Convection-Enhanced Delivery		Functional Concept	CTRP Intervention Terminology|CTRP Terminology
C116567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116567>	C15216	Electrodessication and Curettage	A procedure that uses both a curette and hyfrecator for treatment of various skin conditions, including basal cell carcinoma, squamous cell skin carcinoma, viral warts, and pyogenic granulomas.	Electrodessication and Curettage		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology
C116568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116568>	C17137	Erythema Measurement	The use of instruments to quantify the redness of the skin. This is done to measure differences in erythema over time in a single patient and to gauge the stability or progression of a skin disease.	Erythema Measurement		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116569>	C190556	Fluorescence Angiography|FLUORESCENCE ANGIOGRAPHY	An examination technique that uses fluorescent dye and a specialized camera to inspect blood flow in the retina and choroid.	Fluorescence Angiography		Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C11656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11656>	C61063	Montanide ISA-51/Peptide 946-tetanus peptide conjugate melanoma vaccine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116570>	C16033	Follow-Up Care	Any clinical attention received following a diagnosis or treatment, with the specific purpose of monitoring that specific diagnosis or treatment.	Follow-Up Care		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C116571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116571>	C17156	Fourier Transform Ion Cyclotron Resonance Mass Spectrometry	A type of mass spectrometry that uses the cyclotron frequency of ions in a fixed magnetic field to determine their ionic mass-to-charge ratio.	Fourier Transform Ion Cyclotron Resonance Mass Spectrometry		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C116572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116572>	C71316	Gastrointestinal Stenting|Enteral Stenting	The placement of a mesh tube anywhere within the gastrointestinal tract. It is used to keep the lumen open and free of obstruction.	Gastrointestinal Stenting		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116573>	C3020|C28193	Dravet Syndrome|SMEI|Severe Myoclonic Epilepsy of Infancy|Severe Myoclonic Epilepsy of Infancy	A severe form of epilepsy that presents in early childhood and is characterized by frequent, prolonged febrile or myoclonic seizures that may progress to status epilepticus and poor development of language, motor, and socialization skills.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116574>	C110937	Athetosis	Slow, involuntary, and nonpurposeful writhing movements that usually affect the upper limbs.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116575>	C110937	Hyperkinesia	Excessive movement.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116576>	C110937	Hypokinesia	Diminished movement.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116577>	C29936	SERPINA3 Gene|SERPINA3|SERPINA3|Serpin Peptidase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 3 Gene	This gene is involved in the regulation of neutrophil cathepsin G and mast cell chymase activity.	SERPINA3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116578>	C116577	SERPINA3 wt Allele|AACT|ACT|Antichymotrypsin, Alpha-1 Gene|Cell Growth-Inhibiting Gene 24/25|GIG24|GIG25|Serine (Or Cysteine) Proteinase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 3 Gene|Serine (Or Cysteine) Proteinase Inhibitor, Clade A, Member 3 Gene|Serine Proteinase Inhibitor, Clade A, Member 3 Gene|Serpin Peptidase Inhibitor, Clade A (Alpha-1 Antiproteinase, Antitrypsin), Member 3 wt Allele	Human SERPINA3 wild-type allele is located in the vicinity of 14q32.1 and is approximately 33 kb in length. This allele, which encodes alpha-1-antichymotrypsin protein, plays a role in the negative regulation of the activity of both neutrophil cathepsin G and mast cell chymase. Mutation of the gene is associated with alpha-1-antichymotrypsin deficiency and occlusive cerebrovascular disease. Genetic polymorphisms may be associated with increased susceptibility to either Alzheimer disease or Parkinson disease.	SERPINA3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116579>	C17122	Alpha-1-Antichymotrypsin|ACT|Cell Growth-Inhibiting Gene 24/25 Protein|Growth-Inhibiting Protein 24|Growth-Inhibiting Protein 25|Serpin A3	Alpha-1-antichymotrypsin (423 aa, ~48 kDa) is encoded by the human SERPINA3 gene. This protein is involved in the inhibition of neutrophil cathepsin G and mast cell chymase proteolytic activity.	Alpha-1-Antichymotrypsin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11657>	C61063	Docetaxel/Mitoxantrone			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116580>	C25939	GLRX Gene|GLRX|GLRX|Glutaredoxin (Thioltransferase) Gene	This gene plays a role in the reduction of glutathione-disulfides and glutathione-conjugated proteins.	GLRX Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116581>	C116580	GLRX wt Allele|GRX|GRX1|Glutaredoxin (Thioltransferase) wt Allele|Glutaredoxin1 Gene	Human GLRX wild-type allele is located in the vicinity of 5q14 and is approximately 72 kb in length. This allele, which encodes glutaredoxin-1 protein, is involved in cellular redox	GLRX wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116582>	C16946	Glutaredoxin-1|GLRX|Glutaredoxin|Glutaredoxin 1|TTase-1|Thioltransferase|Thioltransferase-1	Glutaredoxin-1 (106 aa, ~12 kDa) is encoded by the human GLRX gene. This protein plays a role in the reduction of glutathione conjugates.	Glutaredoxin-1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116583>	C50579	Subarachnoid Hematoma	A collection of blood into the space between the pia membrane and arachnoid membrane.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116584>	C25943	LIG3 Gene|DNA Ligase 3 Gene|LIG3|LIG3	This gene is involved in DNA double-strand break repair.	LIG3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116585>	C50579	Subdural Hematoma	A collection of blood between the dura mater and the brain.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116586>	C116584	LIG3 wt Allele|DNA Ligase 3 wt Allele|DNA Ligase III Gene|LIG2|LIG3alpha|Ligase II, DNA, ATP-Dependent Gene|Ligase III, DNA, ATP-Dependent Gene	Human LIG3 wild-type allele is located within 17q11.2-q12 and is approximately 25 kb in length. This allele, which encodes DNA ligase 3 protein, plays a role in DNA repair.	LIG3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116587>	C16796	DNA Ligase 3|DNA Ligase III|EC 6.5.1.1|LIG3|Polydeoxyribonucleotide Synthase [ATP] 3	DNA ligase 3 (1009 aa, ~113 kDa) is encoded by the human LIG3 gene. This protein is involved in the repair of double-strand breaks in DNA.	DNA Ligase 3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116588>	C50579	Epidural Hematoma	A collection of blood into the space between the dura mater and the skull.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116589>	C20917|C159207	MAD2L2 Gene|MAD2L2|MAD2L2|Mitotic Arrest Deficient 2 Like 2 Gene	This gene plays a role in both DNA translesion synthesis and the mitotic spindle assembly checkpoint.	MAD2L2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C11658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11658>	C61063	Montanide ISA-51/Peptide 946 melanoma vaccine/Tetanus peptide melanoma vaccine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116590>	C116589	MAD2L2 wt Allele|FANCV|MAD2 (Mitotic Arrest Deficient, Yeast, Homolog)-Like 2 Gene|MAD2 Mitotic Arrest Deficient-Like 2 (Yeast) Gene|MAD2B|Mitotic Arrest Deficient 2 Like 2 wt Allele|Mitotic Arrest-Deficient 2, S. cerevisiae, Homolog of Gene|POLZ2|Polymerase (DNA-Directed), Zeta 2, Accessory Subunit Gene|REV7|REV7, S. cerevisiae, Homolog of Gene|RP3-330O12.4	Human MAD2L2 wild-type allele is located in the vicinity of 1p36 and is approximately 17 kb in length. This allele, which encodes mitotic spindle assembly checkpoint protein MAD2B, is involved in the mitotic spindle assembly checkpoint and the modulation of translesional DNA synthesis.	MAD2L2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116591>	C50579	Subgaleal Hematoma	A collection of blood between the scalp and the skull periosteum.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116592>	C17761	Mitotic Spindle Assembly Checkpoint Protein MAD2B|MAD2-Like Protein 2|Mitotic Arrest Deficient 2-Like Protein 2|Mitotic Arrest Deficient Homolog-Like 2|REV7 Homolog|hREV7	Mitotic spindle assembly checkpoint protein MAD2B (211 aa, ~24 kDa) is encoded by the human MAD2L2 gene. This protein plays a role in DNA repair and the mitotic spindle assembly checkpoint.	Mitotic Spindle Assembly Checkpoint Protein MAD2B		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116593>	C26920	Early Myoclonic Encephalopathy|EME	A neurologic disorder characterized by frequently recurring myoclonic seizures and other seizure types presenting within the first months of life.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116594>	C21344	CLEC11A Gene|C-Type Lectin Domain Family 11, Member A Gene|CLEC11A|CLEC11A	This gene plays a role in the proliferation and differentiation of hematopoietic precursor cells	CLEC11A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116595>	C116594	CLEC11A wt Allele|C-Type (Calcium Dependent, Carbohydrate-Recognition Domain) Lectin, Superfamily Member 3 Gene|C-Type Lectin Domain Family 11, Member A wt Allele|CLECSF3|LSLCL|Lectin, C-Type, Lymphocyte-Secreted Long Form Gene|P47|SCGF	Human CLEC11A wild-type allele is located in the vicinity of 19q13.3 and is approximately 2 kb in length. This allele, which encodes C-type lectin domain family 11 member A protein, is involved in the positive regulation of both proliferation and differentiation of hematopoietic cells.	CLEC11A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116596>	C20424	CLEC11A Gene Product	A protein encoded by the CLEC11A gene.	CLEC11A Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116597>	C116596	C-Type Lectin Domain Family 11 Member A|C-Type Lectin Superfamily Member 3|Lymphocyte Secreted C-Type Lectin|Lymphocyte Secreted Long Form of C-Type Lectin|Lymphocytic Secreted Long Form of C-Type Lectin|SCGF-Alpha|Stem Cell Growth Factor|p47	C-type lectin domain family 11 member A (323 aa, ~36 kDa) is encoded by the human CLEC11A gene. This protein plays a role in carbohydrate binding and hematopoietic cell growth factor activity.	C-Type Lectin Domain Family 11 Member A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116598>	C116596	Stem Cell Growth Factor Beta|C-Type Lectin Domain Family 11 Member A-Beta|SCGF Beta|SCGF-Beta|Stem Cell Growth Factor-Beta	Stem cell growth factor beta (245 aa, ~27 kDa) is encoded by the human CLEC11A gene. This protein is involved in hematopoietic cell growth factor activity.	Stem Cell Growth Factor Beta		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116599>	C27036	Diplegia	Paralysis affecting corresponding parts on both sides of the body.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11659>	C61063	gp100 Antigen/HPV-16 E7(12-20) Peptide Vaccine/Montanide ISA-51			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1165>	C1331	2-Ethylhydrazide	A podophyllic acid derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, 2-ethylhydrazide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.			Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C116600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116600>	C110937	Motor Deficit|Motor Deficits	Loss of movement function.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116601>	C116943	Gross Motor Delay	Abnormally late development of the coordination of the muscles, bones, and/or nerves that produces whole body and large muscle group movements.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116602>	C116943	Fine Motor Delay	Delayed acquisition of age appropriate motor milestones that produce small and precise movements.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116603>	C28533	APOA4 Gene|APOA4|APOA4|Apolipoprotein A4 Gene	This gene is involved in the transport of chylomicrons and very low density lipoproteins.	APOA4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116604>	C116603	APOA4 wt Allele|Apolipoprotein A-IV Gene|Apolipoprotein A4 wt Allele	Human APOA4 wild-type allele is located in the vicinity of 11q23 and is approximately 3 kb in length. This allele, which encodes apolipoprotein A-IV protein, plays a role in the modulation of chylomicron and very low density lipoprotein transport.	APOA4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116605>	C16386	Apolipoprotein A-IV|APOA4|Apo-A4|Apo-AIV|ApoA-IV|Apolipoprotein A4	Apolipoprotein A-IV (396 aa, ~45 kDa) is encoded by the human APOA4 gene. This protein is involved in both the transport and catabolism of chylomicrons and very low density lipoproteins.	Apolipoprotein A-IV		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116606>	C25790|C20103	HAVCR1 Gene|HAVCR1|HAVCR1|Hepatitis A Virus Cellular Receptor 1 Gene	This gene is involved in viral infection, asthma and allergies.	HAVCR1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116607>	C116606	HAVCR1 wt Allele|CD365|HAVCR|HAVCR-1|Hepatitis A Virus Cellular Receptor 1 wt Allele|KIM-1|KIM1|T Cell Immunoglobin Domain and Mucin Domain Protein 1|T-Cell Immunoglobulin Mucin Family Member 1 Gene|TIM|TIM-1|TIM1|TIMD-1|TIMD1	Human HAVCR1 wild-type allele is located in the vicinity of 5q33.2 and is approximately 30 kb in length. This allele, which encodes hepatitis A virus cellular receptor 1 protein, plays a role in asthma, allergic reactions, hepatitis A binding and T-helper cell development. Polymorphism of the gene can modulate susceptibility to both hepatitis A infection and atopy.	HAVCR1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116608>	C18106|C16725	Hepatitis A Virus Cellular Receptor 1|CD365|CD365 Antigen|HAVcr-1|KIM-1|KIM1|Kidney Injury Molecule 1|Kidney Injury Molecule-1|T Cell Immunoglobin Domain and Mucin Domain Protein 1|T-Cell Immunoglobulin Mucin Receptor 1|T-Cell Immunoglobulin and Mucin Domain-Containing Protein 1|T-Cell Immunoglobulin and Mucin Domains-Containing Protein 1|T-Cell Membrane Protein 1|TIM|TIM-1|TIMD-1|TIMD1	Hepatitis A virus cellular receptor 1 (359 aa, ~39 kDa) is encoded by the human HAVCR1 gene. This protein is involved in the modulation of asthma and allergic reactions.	Hepatitis A Virus Cellular Receptor 1		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116609>	C29938	GCKR Gene|GCKR|GCKR|Glucokinase (Hexokinase 4) Regulator Gene	This gene plays a role in the inhibition of carbohydrate phosphorylation.	GCKR Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C11660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11660>	C61007	Dexamethasone/Floxuridine/Leucovorin Calcium/SCH-58500			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116610>	C116609	GCKR wt Allele|FGQTL5|GKRP|Glucokinase (Hexokinase 4) Regulator wt Allele|Glucokinase (Hexokinase 4) Regulatory Protein Gene	Human GCKR wild-type allele is located in the vicinity of 2p23 and is approximately 27 kb in length. This allele, which encodes glucokinase regulatory protein, is involved in the negative regulation of carbohydrate modification. Variation of the gene is associated with fasting plasma glucose levels quantitative trait locus 5.	GCKR wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116611>	C18072	Glucokinase Regulatory Protein|GCKR|GKRP|Glucokinase Regulator	Glucokinase regulatory protein (625 aa, ~69 kDa) is encoded by the human GCKR gene. This protein plays a role in the inhibition of carbohydrate phosphorylation.	Glucokinase Regulatory Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116612>	C25873	ULK1 Gene|ULK1|ULK1|Unc-51 Like Autophagy Activating Kinase 1 Gene	This gene is involved in the regulation of autophagy.	ULK1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116613>	C116612	ULK1 wt Allele|ATG1|ATG1 Autophagy Related 1 Homolog (S. cerevisiae) Gene|ATG1A|KIAA0722|UNC51|UNC51, C. elegans, Homolog of Gene|Unc-51 (C. elegans)-Like Kinase 1 Gene|Unc-51 Like Autophagy Activating Kinase 1 wt Allele|Unc-51-Like Kinase 1 (C. elegans) Gene|Unc51.1|hATG1	Human ULK1 wild-type allele is located in the vicinity of 12q24.3 and is approximately 29 kb in length. This allele, which encodes serine/threonine-protein kinase ULK1 protein, plays a role in both serine/threonine protein phosphorylation and the modulation of autophagy.	ULK1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116614>	C17325	Serine/Threonine-Protein Kinase ULK1|ATG1|ATG1 Autophagy Related 1 Homolog|Autophagy-Related Protein 1 Homolog|EC 2.7.11.1|ULK1|Unc-51-Like Kinase 1|Unc51-Like Kinase 1|hATG1	Serine/threonine-protein kinase ULK1 (1050 aa, ~113 kDa) is encoded by the human ULK1 gene. This protein is involved in protein phosphorylation that mediates the autophagocytotic process.	Serine/Threonine-Protein Kinase ULK1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116615>	C25952|C153246	MUS81 Gene|MUS81|MUS81|MUS81 Structure-Specific Endonuclease Subunit Gene	This gene plays a role in the metabolism of branched DNA structures.	MUS81 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116616>	C116615	MUS81 wt Allele|FLJ44872|MUS81 Endonuclease Homolog (S. cerevisiae) Gene|MUS81 Endonuclease Homolog (Yeast) Gene|MUS81 Structure-Specific Endonuclease Subunit wt Allele|MUS81, S. cerevisiae, Homolog of Gene|SLX3|SLX3 Structure-Specific Endonuclease Subunit Homolog (S. cerevisiae) Gene|SLX3, Yeast, Homolog of Gene	Human MUS81 wild-type allele is located in the vicinity of 11q13 and is approximately 11 kb in length. This allele, which encodes crossover junction endonuclease MUS81 protein, is involved in DNA endonuclease activity.	MUS81 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116617>	C21438	Crossover Junction Endonuclease MUS81|EC 3.1.22.-|EC 3.1.22.4|MUS81 Endonuclease Homolog|SLX3 Structure-Specific Endonuclease Subunit Homolog	Crossover junction endonuclease MUS81 (551 aa, ~61 kDa) is encoded by the human MUS81 gene. This protein plays a role in the catabolism of branched DNA structures.	Crossover Junction Endonuclease MUS81		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116618>	C344	2-Deoxy-D-glucose|2-DEOXYGLUCOSE|2-DG|Deoxyglucose	A non-metabolizable glucose analog in which the hydroxyl group at position 2 of glucose is replaced by hydrogen, with potential glycolysis inhibiting and antineoplastic activities. Although the exact mechanism of action has yet to be fully elucidated, upon administration of 2-deoxy-D-glucose (2-DG), this agent competes with glucose for uptake by proliferating cells, such as tumor cells. 2-DG inhibits the first step of glycolysis and therefore prevents cellular energy production, which may result in decreased tumor cell proliferation.	2-Deoxy-D-glucose		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116619>	C155745	Utomilumab|PF 05082566|PF 5082566|PF-05082566|PF-2566|UTOMILUMAB	A human, agonistic immunoglobulin (Ig) G2 monoclonal antibody (mAb) targeting 4-1BB (CD137, TNFRSF9), with potential immunostimulating activity. Upon administration, utomilumab binds to and activates 4-1BB expressed on various immune cells, such as CD8-positive and CD4-positive T cells and natural killer (NK) cells. This enhances 4-1BB-mediated signaling, induces cytokine production and promotes anti-tumor immune responses. 4-1BB, a member of the tumor necrosis factor (TNF)/nerve growth factor (NGF) family of receptors, plays an important role in the regulation of immune responses.	Utomilumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11661>	C61063	gp100 Antigen/Interleukin-12/Montanide ISA-51/Tyrosinase Peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116620>	C19676	CENPS Gene|APITD1|CENPS|CENPS|Centromere Protein S Gene	This gene is involved in DNA binding and repair.	CENPS Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116621>	C116620	CENPS wt Allele|APITD1|Apoptosis-Inducing, TAF9-Like Domain 1 Gene|CENP-S|Centromere Protein S wt Allele|FAAP16|MHF1	Human CENPS wild-type allele is located in the vicinity of 1p36.22 and is approximately 13 kb in length. This allele, which encodes centromere protein S, plays a role in binding to and repair of DNA.	CENPS wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116622>	C21170	Centromere Protein S|Apoptosis-Inducing TAF9-Like Domain-Containing Protein 1|CENP-S|CENPS|Centromeric Protein S|FANCM-Associated Histone Fold Protein 1|FANCM-Interacting Histone Fold Protein 1|FANCM-Interacting Histone-Fold Protein 1|Fanconi Anemia-Associated Polypeptide of 16 kDa	Centromere protein S (138 aa, ~16 kDa) is encoded by the human CENPS gene. This protein is involved in both DNA binding and DNA damage repair.	Centromere Protein S		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116623>	C65147	Alkaline Water	Water that has a pH above 7, that can be used to alter the conditions in the gastrointestinal (GI) tract and modify absorption of certain therapeutic agents. Upon oral administration, alkaline water provides alkaline conditions within the GI tract. This may decrease absorption of certain therapeutic agents, reduce epithelial damage and may alter bowel movements.	Alkaline Water		Inorganic Chemical	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C116624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116624>	C162996	Navtemadlin|(3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-((1S)-2-methyl-1-(((1-methylethyl)sulfonyl)methyl)propyl)-2-oxo-3-piperidineacetic Acid|AMG 232|AMG-232|KRT 232|KRT-232|KRT232|MDM2 Inhibitor KRT-232|NAVTEMADLIN	An orally available inhibitor of MDM2 (murine double minute 2), with potential antineoplastic activity. Upon oral administration,navtemadlin binds to the MDM2 protein and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the transcriptional activity of p53 is restored. This leads to p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein and a negative regulator of the p53 pathway, is overexpressed in cancer cells; it plays a key role in cancer cell proliferation and survival.	Navtemadlin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116625>	C1742|C1512	Angiopoietin-2-specific Fusion Protein PF-04856884|CVX-060|CVX-060|PF-04856884	A humanized monoclonal antibody fused to two peptides that bind to angiopoietin 2 (Ang2; ANGPT2), with potential anti-angiogenic and antineoplastic activities. Upon intravenous administration, Ang2-targeting PF-04856884 CovX body specifically binds to Ang2 and prevents the binding of Ang2 to its receptor Tie2 expressed on endothelial cells. This inhibits Tie2-mediated signaling, prevents angiogenesis and inhibits tumor cell proliferation.  Ang2, a proangiogenic cytokine and ligand for the Tie2 receptor, plays a key role in the regulation of tumor angiogenesis and tumor cell proliferation; its expression is upregulated by tumor endothelial cells.	Angiopoietin-2-specific Fusion Protein PF-04856884		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116626>	C215102|C213143	Anti-ENPP3/MMAF Antibody-drug Conjugate AGS-16M8F|ADC AGS-16M8F|AGS 16M8F|AGS-16M8F|Anti-ENPP3 ADC AGS-16M8F|Anti-ENPP3/MMAF ADC AGS-16M8F	An antibody-drug conjugate (ADC) containing a human immunoglobulin (Ig) G2k monoclonal antibody (AGS-16C) directed against the ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP3, NPP3, B10, PDNP3 CD203c, or PD-IBETA ), conjugated, via the non-cleavable maleimidocaproyl (mc) linker, to monomethyl auristatin F (MMAF), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity. Upon intravenous administration of anti-ENPP3/MMAF ADC AGS-16M8F, the monoclonal antibody moiety selectively binds to ENPP3 expressed on tumor cells; upon internalization, the ADC is degraded by lysosomal proteases and MMAF is released. In turn, MMAF binds to and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. While normally expressed at low levels in the proximal tubules of the kidney, the type II transmembrane glycoprotein ENPP3 is overexpressed in most renal neoplasms and some liver cancers.	Anti-ENPP3/MMAF Antibody-drug Conjugate AGS-16M8F		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116627>	C20401|C1742|C129822	Anti-angiopoietin Monoclonal Antibody AMG 780|AMG 780|AMG-780	An immunoglobulin (Ig) G2 monoclonal antibody targeting the proangiogenic cytokines angiopoietin 1 (Ang1) and 2 (Ang2), with potential anti-angiogenic and antineoplastic activities. Upon administration, anti-angiopoietin monoclonal antibody AMG 780 binds to Ang1 and Ang2. This prevents the binding of the angiopoietin ligands to their receptor Tie2 (TEK), an endothelial cell-specific receptor tyrosine kinase. This prevents Tie2-mediated signaling and results in an inhibition of Tie2-expressing, tumor-stimulated endothelial cell proliferation, which prevents angiogenesis and inhibits tumor cell proliferation.	Anti-angiopoietin Monoclonal Antibody AMG 780		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116628>	C199386	Duligotuzumab|DULIGOTUZUMAB|Duligotumab|MEHD 7945A|MEHD-7945A|MEHD7945A|RG 7597	An immunoglobulin (Ig) G1 monoclonal antibody directed against both human epidermal growth factor receptor 3 (HER3 or ERBB3) and human epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Duligotuzumab binds to both EGFR and HER3 and inhibits their activation. This may prevent EGFR/HER3-mediated signaling and inhibit EGFR/HER3-dependent tumor cell proliferation. In addition, MEHD7945A induces antibody-dependent cell-mediated cytotoxicity (ADCC) against EGR/HER3-expressing tumor cells. EGFR and HER3, members of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, are frequently overexpressed in tumors; their expression is associated with both poor prognosis and drug resistance.	Duligotuzumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116629>	C20401|C129822	Ifabotuzumab|Fibatuzumab|IFABOTUZUMAB|KB 004|KB-004|KB004	A non-fucosylated monoclonal antibody directed against the ephrin receptor A3 (EphA3), with potential antineoplastic activity. Upon administration, ifabotuzumab selectively binds to tumor cells expressing EphA3. This blocks both EphA3 activation and EphA3-mediated signaling, and induces apoptosis in EphA3-expressing tumor cells. In addition, ifabotuzumab can stimulate antibody dependent cell-mediated cytotoxicity (ADCC) against EphA3-expressing tumor cells. This agent also prevents tumor cell proliferation by inhibiting both EphA3 signaling and proliferation of endothelial cells in the tumor vasculature. The cell-surface receptor EphA3, a member of the ephrin family of receptor tyrosine kinases (RTKs) that are involved in mammalian development, is overexpressed by a variety of tumor types but is not expressed in normal healthy adult tissues. It plays an important role in tumor cell proliferation. Non-fucosylation of the antibody enhances its ADCC activity.	Ifabotuzumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11662>	C61063	gp100 Antigen/Montanide ISA-51/Sargramostim/Tetanus Peptide Melanoma Vaccine/Tyrosinase Peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116630>	C20401|C129822	Anti-hepcidin Monoclonal Antibody LY2787106|LY-2787106|LY2787106	A humanized monoclonal antibody (MoAb) targeting the peptide hormone hepcidin, with potential anti-anemic activity. Upon intravenous administration, anti-hepcidin MoAb LY2787106 binds to hepcidin and prevents it from binding to the iron exporting protein ferroportin, which is expressed on both the basolateral surface of gastrointestinal (GI) enterocytes and the plasma membrane of macrophages. This prevents hepcidin-induced internalization and degradation of ferroportin and increases ferroportin-mediated iron export, thus increasing iron export from macrophages and iron absorption by enterocytes. This normalizes plasma iron levels, increases erythropoiesis and may inhibit anemia. Hepcidin, produced in hepatocytes, plays a key role in the homeostasis of systemic iron; it is upregulated during acute and chronic inflammation in response to cytokines and, in certain cancers, may contribute to cancer-associated anemia.	Anti-hepcidin Monoclonal Antibody LY2787106		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116631>	C19676	CENPX Gene|CENPX|CENPX|Centromere Protein X Gene	This gene plays a role in both DNA fork processing and DNA repair.	CENPX Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116632>	C116631	CENPX wt Allele|CENP-X|Centromere Protein X wt Allele|D9|FAAP10|Fanconi Anemia-Associated Polypeptide, 10-kD Gene|MHF2|Retinoic Acid-Inducible Gene D9|STRA13|Stimulated By Retinoic Acid 13 Gene|Stimulated By Retinoic Acid 13 Homolog (Mouse) Gene|Stimulated By Retinoic Acid 13 Homolog Gene	Human CENPX wild-type allele is located in the vicinity of 17q25.3 and is approximately 5 kb in length. This allele, which encodes centromere protein X, is involved in DNA binding, DNA repair and the resolution of DNA replication forks.	CENPX wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116633>	C21170	Centromere Protein X|CENP-X|CENPX|Centromeric Protein X|FANCM Associated Histone Fold Protein 2|FANCM-Associated Histone Fold Protein 2|FANCM-Interacting Histone Fold Protein 2|FANCM-Interacting Histone-Fold Protein 2|Fanconi Anemia-Associated Polypeptide of 10 kDa|Fanconi Anemia-Associated Polypeptide, 10-kD|Retinoic Acid-Inducible Gene D9 Protein Homolog|Stimulated By Retinoic Acid Gene 13 Protein Homolog	Centromere protein X (81 aa, ~9 kDa) is encoded by the human CENPX gene. This protein is involved in the processing of DNA replication forks, DNA binding and DNA repair.	Centromere Protein X		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116634>	C19676	RPA2 Gene|RPA2|RPA2|Replication Protein A2 Gene	This gene is involved in DNA repair, recombination and replication.	RPA2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116635>	C116634	RPA2 wt Allele|REPA2|RP4-547C9.3|RPA32|RPA34|Replication Protein A2 (32kD) Gene|Replication Protein A2 wt Allele|Replication Protein A2, 32-kD Gene|Replication Protein A2, 32kDa Gene	Human RPA2 wild-type allele is located in the vicinity of 1p35 and is approximately 23 kb in length. This allele, which encodes replication protein A 32 kDa protein, plays a role in DNA replication, repair and recombination.	RPA2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116636>	C21170	Replication Protein A 32 kDa Subunit|RF-A Protein 2|RP-A p32|RP-A p34|RPA2|Replication Factor A Protein 2|Replication Protein A 34 kDa Subunit	Replication protein A 32 kDa (270 aa, ~29 kDa) is encoded by the human RPA2 gene. This protein is involved in DNA recombination, replication and repair.	Replication Protein A 32 kDa Subunit		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116637>	C19676	RPA3 Gene|RPA3|RPA3|Replication Protein A3 Gene	This gene plays a role in DNA replication, recombination and repair.	RPA3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|Pediatric Oncology Biomarkers/Targets Associated with Other Relevant Evidence
C116638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116638>	C116637	RPA3 wt Allele|REPA3|RP-A p14|RPA14|Replication Protein A3 (14kD) Gene|Replication Protein A3 wt Allele|Replication Protein A3, 14-kD Gene|Replication Protein A3, 14kDa Gene	Human RPA3 wild-type allele is located in the vicinity of 7p21.3 and is approximately 82 kb in length. This allele, which encodes replication protein A 14 kDa protein, is involved in DNA repair, replication and recombination.	RPA3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116639>	C21170	Replication Protein A 14 kDa|RF-A Protein 3|RP-A P14|RPA3|Replication Factor A Protein 3	Replication protein A 14 kDa (121 aa, ~14 kDa) is encoded by the human RPA3 gene. This protein plays a role in replication, recombination and repair of DNA.	Replication Protein A 14 kDa		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Biomarkers/Targets Associated with Other Relevant Evidence
C11663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11663>	C61063	Montanide ISA-51/von Hippel-Lindau peptide vaccine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116640>	C20368	Immunologic Technique	Any method that is used to elicit and/or measure an immune response, or to identify and/or measure antigens triggering antibodies.	Immunologic Technique		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C116641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116641>	C16406	Magnetic Affinity Cell Sorting|MACS	A method of cell sorting that uses paramagnetic beads that are coated with antibodies, antigens, receptors, receptor substrates, binding proteins, etc to separate target cells from solution.	Magnetic Affinity Cell Sorting		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C116642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116642>	C25662	Microdialysis	A blood sampling technique that allows for the collecting of low-molecular-weight substances from the interstitial space. It is used to quantify hormones, neurotransmitters, and peptides in the study subject.	Microdialysis		Activity	CTRP Intervention Terminology|CTRP Terminology
C116643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116643>	C15666	Microwave Ablation|Ablation, Microwave	A treatment modality that uses directed electromagnetic waves within the microwave spectrum to heat the targeted tissue for the purpose of causing tissue necrosis within solid tissue tumors.	Microwave Ablation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C116645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116645>	C25870	GSTA4 Gene|GSTA4|GSTA4|Glutathione S-Transferase Alpha 4 Gene	This gene is involved in the metabolism of small molecules and xenobiotics.	GSTA4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116646>	C116645	GSTA4 wt Allele|GSTA4-4|GTA4|Glutathione S-Transferase Alpha 4 wt Allele|Glutathione S-Transferase, Alpha-4 Gene|RP1-214M20.1	Human GSTA4 wild-type allele is located in the vicinity of 6p12.1 and is approximately 17 kb in length. This allele, which encodes glutathione S-transferase A4 protein, plays a role in the metabolism of endogenous and exogenous small hydrophobic molecules.	GSTA4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116647>	C16033	Standard Follow-Up Care	The commonly accepted clinical attention that occurs following a diagnosis or treatment, with the express purpose of monitoring that specific diagnosis or treatment.	Standard Follow-Up Care		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C116648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116648>	C37981	Tracheal Intubation	The insertion of a plastic tube through the mouth or nose that extends past the vocal cords and into the trachea for the purpose of oxygenating and ventilating the patient, and to prevent the passage of unwanted material into the lungs.	Tracheal Intubation		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C116649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116649>	C93340|C66902	Transarterial Radioembolization|Hepatic Radioembolization|TARE|Transarterial Hepatic Radioembolization	A treatment for hepatocellular carcinoma that uses radioactive microspheres to both cause hepatic artery embolization and to deliver regional radiotherapy.	Transarterial Radioembolization		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C11664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11664>	C61063	Interleukin-2/Montanide ISA-51/Von Hippel-Lindau Peptide Vaccine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116650>	C20075	Glutathione S-Transferase A4|EC 2.5.1.18|GST Class-Alpha Member 4|Glutathione S-Alkyltransferase A4|Glutathione S-Aralkyltransferase A4|Glutathione S-Aryltransferase A4|Glutathione S-Transferase A4-4|Glutathione Transferase A4-4|S-(Hydroxyalkyl)Glutathione Lyase A4	Glutathione S-transferase A4 (222 aa, ~26 kDa) is encoded by the human GSTA4 gene. This protein is involved in the conjugation of reduced glutathione to endogenous and exogenous small hydrophobic molecules.	Glutathione S-Transferase A4		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116651>	C15705	Transurethral Resection of Bladder Tumor|TRANSURETHRAL RESECTION OF BLADDER TUMOR|TURBT|TURBT|Transurethral resection (TURBT)	A surgical procedure used to treat bladder tumors, during which a resectoscope is passed through the urethra and into the bladder.	Transurethral Resection of Bladder Tumor		Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C116652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116652>	C21072	Transversus Abdominis Plane Block|TAP Block	The administration of local anesthetic drugs into the transversus abdominal plane as an adjunct treatment for post operative pain following abdominal surgery.	Transversus Abdominis Plane Block		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116653>	C16120|C15330	Pancreatic Surgical Procedure|Pancreatic Surgery	A surgical procedure that involves the removal of the head, middle, distal pancreas or the entire pancreas. It is usually performed for the excision of pancreatic tumors.	Pancreatic Surgical Procedure		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology
C116654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116654>	C25939	PRDX4 Gene|PRDX4|PRDX4|Peroxiredoxin 4 Gene	This gene plays a role in both cellular redox and nuclear factor NF-kappa-B activity.	PRDX4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116655>	C178134	Transcranial Magnetic Stimulation|TMS	A procedure that uses electromagnets to stimulate neuronal activity, allowing for both imaging and study of the brain's functioning.	Transcranial Magnetic Stimulation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116656>	C116654	PRDX4 wt Allele|AOE37-2|HEL-S-97n|PRX-4|Peroxiredoxin 4 wt Allele|Thioredoxin Peroxidase (Antioxidant Enzyme) Gene	Human PRDX4 wild-type allele is located in the vicinity of Xp22.11 and is approximately 22 kb in length. This allele, which encodes peroxiredoxin-4 protein, is involved in the regulation of both nuclear factor NF-kappa-B transcription factor activity and cellular redox.	PRDX4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116657>	C16946	Peroxiredoxin-4|AOE37-2|Antioxidant Enzyme 372|Antioxidant Enzyme AOE372|EC 1.11.1.15|Epididymis Secretory Sperm Binding Protein Li 97n|PRDX4|Peroxiredoxin IV|Prx-IV|Thioredoxin Peroxidase AO372|Thioredoxin-Dependent Peroxide Reductase A0372	Peroxiredoxin-4 (271 aa, ~31 kDa) is encoded by the human PRDX4 gene. This protein plays a role in both redox regulation and nuclear factor NF-kappa-B activation in cells.	Peroxiredoxin-4		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116658>	C20194	MAP1LC3B Gene|MAP1LC3B|MAP1LC3B|Microtubule-Associated Protein 1 Light Chain 3 Beta Gene	This gene is involved in the formation of autophagosomal vacuoles.	MAP1LC3B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116659>	C116658	MAP1LC3B wt Allele|ATG8F|LC3B|MAP1A/1BLC3|MAP1ALC3|MAP1LC3B-a|Microtubule-Associated Protein 1 Light Chain 3 Beta wt Allele|Microtubule-Associated Protein 1, Light Chain 3, Beta Gene	Human MAP1LC3B wild-type allele is located in the vicinity of 16q24.2 and is approximately 21 kb in length. This allele, which encodes microtubule-associated proteins 1A/1B light chain 3B protein, plays a role in autophagocytosis and mitochondrial catabolism.	MAP1LC3B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11665>	C61063	Montanide ISA-51/Sargramostim/von Hippel-Lindau peptide vaccine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116660>	C18466	Microtubule-Associated Proteins 1A/1B Light Chain 3B|Autophagy-Related Protein LC3 B|Autophagy-Related Ubiquitin-Like Modifier LC3 B|LC3-Like Protein 2|MAP1 Light Chain 3-Like Protein 2|MAP1A/MAP1B LC3 B|MAP1A/MAP1B Light Chain 3 B|MAP1LC3B|Microtubule-Associated Protein 1 Light Chain 3 Beta	Microtubule-associated proteins 1A/1B light chain 3B (125 aa, ~15 kDa) is encoded by the human MAP1LC3B gene. This protein is involved in the both catabolism of mitochondria and autophagy.	Microtubule-Associated Proteins 1A/1B Light Chain 3B		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116661>	C20194	MAP1LC3C Gene|MAP1LC3C|MAP1LC3C|Microtubule-Associated Protein 1 Light Chain 3 Gamma Gene	This gene plays a role in the formation of autophagosomes.	MAP1LC3C Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116662>	C116661	MAP1LC3C wt Allele|ATG8J|LC3C|Microtubule-Associated Protein 1 Light Chain 3 Gamma wt Allele|Microtubule-Associated Protein 1, Light Chain 3, Gamma Gene	Human MAP1LC3C wild-type allele is located in the vicinity of 1q43 and is approximately 4 kb in length. This allele, which encodes microtubule-associated proteins 1A/1B light chain 3C protein, is involved in both autophagy and the regulation of mitochondrial quantity and quality.	MAP1LC3C wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116663>	C18466	Microtubule-Associated Proteins 1A/1B Light Chain 3C|Autophagy-Related Protein LC3 C|Autophagy-Related Ubiquitin-Like Modifier LC3 C|LC3-Like Protein 3|MAP1 Light Chain 3-Like Protein 3|MAP1A/MAP1B LC3 C|MAP1A/MAP1B Light Chain 3 C|MAP1LC3C|Microtubule-Associated Protein 1 Light Chain 3 Gamma	Microtubule-associated proteins 1A/1B light chain 3C (147 aa, ~17 kDa) is encoded by the human MAP1LC3C gene. This protein plays a role in the both mitophagy and autophagy.	Microtubule-Associated Proteins 1A/1B Light Chain 3C		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116664>	C38054	Electrocorticography|ECoG	The use of electrodes placed directly on the exposed brain surface to record the electrical activity of the cerebral cortex.	Electrocorticography		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C116665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116665>	C211622	Ex-Vivo Umbilical Cord Blood Expansion	The laboratory process of extracting progenitor cells from a given sample of umbilical cord blood and growing them in culture to increase their total quantity prior to transfusion.	Ex-Vivo Umbilical Cord Blood Expansion		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116666>	C20194	DEXI Gene|DEXI|DEXI|Dexi Homolog Gene	This gene may be involved in inflammation.	DEXI Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116667>	C116666	DEXI wt Allele|Dexamethasone-Induced Gene|Dexamethasone-Induced Transcript Gene|Dexi Homolog (Mouse) Gene|Dexi Homolog wt Allele|MYLE	Human DEXI wild-type allele is located in the vicinity of 16p13.13 and is approximately 14 kb in length. This allele, which encodes dexamethasone-induced protein, may play a role in the inflammatory response. Gene expression is increased in emphysematous lung.	DEXI wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116668>	C18466	Dexamethasone-Induced Protein|DEXI|Protein MYLE	Dexamethasone-induced protein (95 aa, ~10 kDa) is encoded by the human DEXI gene. This protein may be involved in inflammatory processes.	Dexamethasone-Induced Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116669>	C25873	CAMK1 Gene|CAMK1|CAMK1|Calcium/Calmodulin-Dependent Protein Kinase I Gene	This gene plays a role in both protein phosphorylation and calcium/calmodulin-dependent signaling.	CAMK1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C11666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11666>	C61007	gp100 Antigen/Interleukin-2/Montanide ISA-51			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116670>	C116669	CAMK1 wt Allele|CAMKI|CaMKI|Calcium/Calmodulin-Dependent Protein Kinase I wt Allele	Human CAMK1 wild-type allele is located in the vicinity of 3p25.3 and is approximately 13 kb in length. This allele, which encodes calcium/calmodulin-dependent protein kinase type 1 protein, is involved in both serine/threonine protein phosphorylation and calcium/calmodulin-dependent signal transduction.	CAMK1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116671>	C17325	Calcium/Calmodulin-Dependent Protein Kinase Type 1|CaM Kinase I|CaM Kinase I Alpha|CaM-KI|CaMKI-Alpha|EC 2.7.11.17	Calcium/calmodulin-dependent protein kinase type 1 (370 aa, ~41 kDa) is encoded by the human CAMK1 gene. This protein plays a role in both calcium/calmodulin-dependent signaling pathways and protein phosphorylation.	Calcium/Calmodulin-Dependent Protein Kinase Type 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116672>	C21295	ATRN Gene|ATRN|ATRN|Attractin Gene	This gene is involved in both ligand binding and immune cell clustering.	ATRN Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116673>	C116672	ATRN wt Allele|Attractin wt Allele|DPPT-L|KIAA0548|MGCA|Mahogany, Mouse, Homolog of Gene	Human ATRN wild-type allele is located in the vicinity of 20p13 and is approximately 180 kb in length. This allele, which encodes attractin protein, plays a role in both ligand binding and inflammation.	ATRN wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116674>	C17728	Attractin|DPPT-L|Mahogany Homolog|Mahogany Protein	Attractin (1429 aa, ~159 kDa) is encoded by the human ATRN gene. This protein is involved in ligand binding. Secreted forms of the protein are involved in immune cell clustering during inflammation.	Attractin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116675>	C26003	PSMB5 Gene|PSMB5|PSMB5|Proteasome (Prosome, Macropain) Subunit, Beta Type, 5 Gene	This gene plays a role in proteasome-mediated proteolysis.	PSMB5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116676>	C116675	PSMB5 wt Allele|LMPX|MB1|Proteasome (Prosome, Macropain) Subunit, Beta Type, 5 wt Allele|Proteasome Subunit, Beta Type, 5 Gene|Proteasome Subunit, Beta-Type, 5 Gene|X	Human PSMB5 wild-type allele is located in the vicinity of 14q11.2 and is approximately 19 kb in length. This allele, which encodes proteasome subunit beta type-5 protein, is involved in protein catabolism.	PSMB5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116677>	C16965	Proteasome Subunit Beta Type-5|B5 Proteasome Subunit|EC 3.4.25.1|Macropain Epsilon Chain|Multicatalytic Endopeptidase Complex Epsilon Chain|PSMB5|PSX Large Multifunctional Protease X|Proteasome Beta 5 Subunit|Proteasome Catalytic Subunit 3|Proteasome Chain 6|Proteasome Epsilon Chain|Proteasome Subunit Beta-5|Proteasome Subunit MB1|Proteasome Subunit X	Proteasome subunit beta type-5 (263 aa, ~28 kDa) is encoded by the human PSMB5 gene. This protein plays a role in proteasomal protein degradation.	Proteasome Subunit Beta Type-5		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116678>	C25873	SMG1 Gene|SMG1|SMG1|SMG1 Phosphatidylinositol 3-Kinase-Related Kinase Gene	This gene is involved in protein phosphorylation, mRNA surveillance and genotoxic responses.	SMG1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116679>	C116678	SMG1 wt Allele|61E3.4|ATX|KIAA0421|LIP|SMG1 Phosphatidylinositol 3-Kinase-Related Kinase wt Allele|SMG1, C. elegans, Homolog of Gene|Smg-1 Homolog, Phosphatidylinositol 3-Kinase-Related Kinase (C. elegans) Gene|Smg-1 Homolog, Phosphatidylinositol 3-Kinase-Related Kinase Gene	Human SMG1 wild-type allele is located in the vicinity of 16p12.3 and is approximately 122 kb in length. This allele, which encodes serine/threonine-protein kinase SMG1 protein, plays a role in the mediation of both mRNA nonsense-mediated decay and serine/threonine protein phosphorylation.	SMG1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11667>	C61063	Cyclosporine/Irinotecan/Phenobarbital			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116680>	C17325	Serine/Threonine-Protein Kinase SMG1|61E3.4|EC 2.7.11.1|Lambda-Interacting Protein|Lambda/Iota Protein Kinase C-Interacting Protein|PI-3-Kinase-Related Kinase SMG-1|Phosphatidylinositol 3-Kinase-Related Kinase|SMG-1|hSMG-1	Serine/threonine-protein kinase SMG1 (3661 aa, ~411 kDa) is encoded by the human SMG1 gene. This protein is involved in the phosphorylation of proteins that are involved in nonsense-mediated decay of mRNA.	Serine/Threonine-Protein Kinase SMG1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116681>	C49236	Wound Care Management|Wound Care|Wound Care Treatment|Wound Management|Wound Treatment	Any action taken to for the purpose of helping a wound heal; this generally involves keeping the affected area clean and dry, and may involve periodic debridement of any necrotic tissue, or washing of the area with antibacterial solution.	Wound Care Management		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116682>	C16723	Immune Function Testing|Immune Function Test	The use of a variety of different tests, including blood count and chemistry, urinalysis, and imaging to establish the status of an individual's immune system function.	Immune Function Testing		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C116683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116683>	C154300	H2BC5 Gene|H2B Clustered Histone 5 Gene|H2BC5|H2BC5|HIST1H2BD|HIST1H2BD Gene	This gene plays a role in the formation of nucleosomes.	HIST1H2BD Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116684>	C15843	Thromboembolism Prophylaxis|Anticoagulation for VTE prophylaxis	The use of medication to prevent the formation of clots and emboli.	Thromboembolism Prophylaxis		Therapeutic or Preventive Procedure	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|Appendix 8: Pharmacological Therapy Terminology|CTRP Intervention Terminology|CTRP Terminology|Therapies for Supportive Care During COVID-19 Infection Terminology
C116685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116685>	C15843	Microsphere-Mediated Lymphocele Prevention	A surgical technique that uses microspheres at the site of a lymph node resection in an effort to prevent the formation of a lymphocele.	Microsphere-Mediated Lymphocele Prevention		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116686>	C116683	H2BC5 wt Allele|H2B Clustered Histone 5 wt Allele|H2B Histone Family, Member B Gene|H2B.1B|H2B/b|H2BFB|HIRIP2|HIST1H2BD|HIST1H2BD wt Allele|Hist 1 Cluster, H2BD Gene|Histone 1, H2bd Gene|Histone Cluster 1 H2B Family Member D Gene|Histone Cluster 1, H2bd Gene|Histone Gene Cluster 1, H2B Histone Family, Member D Gene|Histone Gene Cluster 1, H2bd Gene|dJ221C16.6	Human H2BC5 wild-type allele is located in the vicinity of 6p21.3 and is approximately 13 kb in length. This allele, which encodes histone H2B type 1-D protein, is involved in nucleosome formation.	HIST1H2BD wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116687>	C15843	Intraoperative Complication Management and Prevention|Intraoperative Complication Management/Prevention	Any action taken during surgery whose purpose is to mitigate and/or prevent the occurrence of an undesirable outcome.	Intraoperative Complication Management and Prevention		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116688>	C17460	Histone H2B Type 1-D|H2B/b|H2BC5|HIRA-Interacting Protein 2|HIST1H2BD|Histone H2B.1 B|Histone H2B.b	Histone H2B type 1-D (126 aa, ~14 kDa) is encoded by the human H2BC5 gene. This protein plays a role in the structure of nucleosomes.	Histone H2B Type 1-D		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116689>	C20917	CLSPN Gene|CLSPN|CLSPN|Claspin Gene	This gene is involved in checkpoint mediated cell cycle arrest.	CLSPN Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C11668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11668>	C61063	gp100 Antigen/Montanide ISA-51			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116690>	C116689	CLSPN wt Allele|Claspin Homolog (Xenopus laevis) Gene|Claspin Homolog Gene|Claspin wt Allele|Claspin, Xenopus, Homolog of Gene	Human CLSPN wild-type allele is located in the vicinity of 1p34.3 and is approximately 5 kb in length. This allele, which encodes claspin protein, plays a role in the G2 cell cycle checkpoint.	CLSPN wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116691>	C17761	Claspin|hClaspin	Claspin (1339 aa, ~151 kDa) is encoded by the human CLSPN gene. This protein is involved in cell cycle arrest in response to errors in DNA replication.	Claspin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116692>	C20917	FBXO5 Gene|F-Box Protein 5 Gene|FBXO5|FBXO5	This gene plays a role in the modulation of cell cycle progression.	FBXO5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116693>	C116692	FBXO5 wt Allele|EMI1|EMI1, Xenopus, Homolog of Gene|F-Box Protein 5 wt Allele|FBX5|Fbxo31|RP1-101K10.5	Human FBXO5 wild-type allele is located within 6q25-q26 and is approximately 13 kb in length. This allele, which encodes F-box only protein 5, is involved in both protein ubiquitination and cell cycle progression.	FBXO5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116694>	C17761	F-Box Only Protein 5|Early Mitotic Inhibitor 1|F-Box Protein Fbx5|FBXO5	F-box only protein 5 (447 aa, ~50 kDa) is encoded by the human FBXO5 gene. This protein plays a role in modulating both protein catabolism and the activity of the anaphase promoting complex.	F-Box Only Protein 5		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116695>	C25391	Communication Analysis	The examination of the different ways that information is exchanged between parties.	Communication Analysis		Activity	CTRP Intervention Terminology|CTRP Terminology
C116696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116696>	C49236	Electromagnetic Tracking Device Procedure	Any procedure that utilizes electromagnetic technology to create detailed, 3D, digital images of a target location, and then uses those images to help the clinician reach the target location via an endoscopic instrument.	Electromagnetic Tracking Device Procedure		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116697>	C49236	Lymphedema Management	Any therapeutic technique that is aimed at reducing and/or preventing obstruction of the lymphatic system.	Lymphedema Management		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116698>	C116699	Psychosocial Support for Caregiver	Any act that provides mental and emotional succor for a caregiver.	Psychosocial Support for Caregiver		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116699>	C15747	Support for Caregiver	Any type of assistance, including emotional, financial, and spiritual, given to a caregiver.	Support for Caregiver		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C11669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11669>	C61063	Montanide ISA-51/Tyrosinase peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1166>	C902	Mitozolomide|Azolastone|Azolastone|Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3-(2-chloroethyl)-3,4-dihydro-4-oxo-|MITOZOLOMIDE|imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3-(2-chloroethyl)-3,4-dihydro-4-oxo	A prodrug of imidazotetrazine alkylating agent with antineoplastic property. Mitozolomide undergoes ring opening upon the nucleophilic attack at C-4 by an activated molecule of water within the major groove of DNA. The resulting bioactive mono-alkyltriazene species are capable of alkylating nucleophilic residues in the immediate vicinity such as N-7 and/or O-6 sites of guanine, thereby causes intra- or inter-stranded DNA cross-links and trigger apoptosis.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116700>	C15475	Radiation Shielding	Materials and practices designed to protect people and the environment from the damaging effects of ionizing radiation.	Radiation Shielding		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116701>	C65109	Spectrophotometry|SPECTROPHOTOMETRY|spectrophotometer method|spectrophotometer_method	A laboratory test that produces a quantitative measurement of the reflection or transmission properties of a material as a function of wavelength.	Spectrophotometry		Occupational Activity	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|GDC Property Terminology|GDC Terminology
C116702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116702>	C64982	Tumor Cell-Encapsulating Diffusion Chamber Implantation	A method by which tumor cells are modified ex vivo to express specific tumor-associated antigens, enveloped in an immunoisolating substance, embedded in a matrix, and implanted at the tumor site where they allow for the diffusion of the desired recombinant proteins.	Tumor Cell-Encapsulating Diffusion Chamber Implantation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116703>	C49236	Tumor Interstitial Fluid Pressure Measurement	The act of quantifying the fluid pressure inside a tumor.	Tumor Interstitial Fluid Pressure Measurement		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C116704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116704>	C20703	PASD1 Gene|PAS Domain Containing Repressor 1 Gene|PASD1|PASD1	This gene may be involved in transcriptional regulation.	PASD1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116705>	C116704	PASD1 wt Allele|CT63|OXTES1|PAS Domain Containing 1 Gene|PAS Domain Containing Repressor 1 wt Allele	Human PASD1 wild-type allele is located in the vicinity of Xq28 and is approximately 113 kb in length. This allele, which encodes circadian clock protein PASD1, may play a role in the modulation of gene expression. Aberrant expression is detected in histologically normal tissues from patients with uterine, pulmonary and small intestinal neoplasms.	PASD1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116706>	C26199	Circadian Clock Protein PASD1|CT63|Cancer/Testis Antigen 63|OX-TES-1|PAS Domain-Containing Protein 1|PAS Domain-Containing Protein 1|PASD1	Circadian clock protein PASD1 (773 aa, ~87 kDa) is encoded by the human PASD1 gene. This protein may be involved in the regulation of transcription.	PAS Domain-Containing Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116707>	C110937	Bradykinesia	Slow movement.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116708>	C98996	Floppy Infant|Congenital Floppy Infant|Floppy Infant Syndrome|Floppy Infant Syndrome|Infantile Hypotonia|Infantile Hypotonia	A syndrome of generalized poor muscle tone and muscle weakness presenting in a newborn infant.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C116709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116709>	C213431|C213366	Rocakinogene Sifuplasmid|DNA Plasmid Encoding Interleukin-12 INO-9012|INO-9012|ROCAKINOGENE SIFUPLASMID	A plasmid DNA vaccine encoding the human pro-inflammatory cytokine interleukin-12 (IL-12) with potential immunoactivating activity. Upon intramuscular delivery by electroporation of rocakinogene sifuplasmid, IL-12 is translated in cells and activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma and promoting cytotoxic T-cell responses against tumor cells. This may result in both immune-mediated tumor cell death and the inhibition of tumor cell proliferation.	Rocakinogene Sifuplasmid		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11670>	C61063	Interleukin-2/Montanide ISA-51/Tyrosinase Peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116710>	C2124	Gallium Ga 68 Satoreotide Trizoxetan|68Ga-NODAGA-JR11|68Ga-OPS202|Gallium Ga 68 NODAGA-JR11|Gallium Ga 68 OPS202|SATOREOTIDE TRIZOXETAN GALLIUM GA-68	A radioconjugate consisting of the somatostatin antagonistic peptide OPS202 that is labeled with the positron-emitting radionuclide gallium Ga 68, which may be used as a somatostatin receptor (SSTR) imaging agent in conjunction with positron emission tomography (PET) to image neuroendocrine tumors (NETs). Gallium Ga 68 satoreotide trizoxetan binds to SSTR subtype 2 present on the cell membranes of many types of NETs. This allows for visualization of SSTR-positive cells upon imaging. SSTR subtypes have been shown to be present in large numbers on NETs and their metastases, while most other normal tissues express low levels of SSTR subtypes.	Gallium Ga 68 Satoreotide Trizoxetan		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C116711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116711>	C28681|C138180|C129826	Autologous MAGE-A3-specific HLA-A*01-Restricted T Cell Receptor Gene Engineered Lymphocytes|Anti-MAGE-A3 HLA-A*01 Restricted TCR-Gene Engineered Lymphocytes	Human autologous T-lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the human leukocyte antigen (HLA)-A*01-restricted, human melanoma-associated antigen A3 (MAGE-A3), with potential antineoplastic activity. Peripheral blood mononuclear cells (PBMCs) are isolated from a patient, transduced with an anti-MAGE-A3-HLA-A*01 restricted TCR, expanded ex vivo, and reintroduced into the HLA-A*01-positive patient. Then, the autologous MAGE-A3-specific, HLA-A*01-restricted TCR gene engineered lymphocytes bind to tumor cells expressing the MAGE-A3 antigen, which may increase cell death and halt the growth of MAGE-A3-expressing cancer cells. The tumor-associated antigen MAGE-A3 is overexpressed by a variety of cancer cell types.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116712>	C797	Hyaluronic Acid-containing Topical Cream|HylaCare Cream	A topical cream formulation containing hyaluronic acid (HA) with wound repair promoting, skin moisturizing and potential radioprotective activities. Upon application of the topical cream, HA adheres to injured tissues, provides hydration to the skin, and protects against dehydration and chemical or mechanical irritation. Hyaluronate, a non-sulfated glucosaminoglycan, is a major component of the extracellular matrix in connective, epithelial, and neural tissues and contributes significantly to cell proliferation and migration.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C116713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116713>	C471	Ethaselen|1, 2-[Bis (1, 2-Benzisoselenazolone-3 (2H) -Ketone)] Ethane|BBSKE|ETHASELEN	An orally bioavailable organoselenium inhibitor of thioredoxin reductase 1 (TrxR1), with potential antineoplastic activity. Upon oral administration, ethaselen specifically binds to the selenocysteine-cysteine redox pair in the C-terminal active site of TrxR1 and inhibits its activity, which may result in growth inhibition and the induction of apoptosis in TrxR1 overexpressing tumor cells. TrxR1, upregulated in many cancer cell types, plays a key role in various redox-dependent cellular pathways, regulates transcription factor activity, inhibits apoptosis, and promotes cell growth and survival.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116714>	C2480	Carbon C 13 Acetate|1,2-13C Acetate|2-13C Acetate	The non-radioactive naturally occurring isotope of acetate, carbon C 13 acetate, with potential use for metabolic tumor imaging upon nuclear magnetic resonance (NMR) spectroscopy. Upon infusion, carbon C 13 acetate is taken up by cancer cells and is utilized by metabolic pathways in the tumor cell. Specifically, the tumor cells oxidize acetate, in the form of acetyl coenzyme A (acetyl-CoA), in the citric acid cycle. Upon 13C-NMR, the metabolic phenotype of a tumor can be assessed. Certain alternative metabolic pathways are activated in tumor cells and use substrates other than glucose, such as acetate, for acetyl-CoA production.			Indicator, Reagent, or Diagnostic Aid	NCI Drug Dictionary Terminology
C116715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116715>	C3390	Venous Stroke|Cerebral Thrombotic Stroke|Cerebral Venous Stroke|Cerebral venous sinus thrombosis	Ischemic or hemorrhagic stroke resulting from cerebral venous thrombosis.			Disease or Syndrome	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Acute Cardiovascular Complications Related to COVID-19 Infection Terminology|Appendix 4: COVID-19 Cardiovascular Complications Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116716>	C461|C390	Indocyanine Green/Albumin Solution	A solution containing a non-toxic, fluorescent tricarbocyanine dye with a peak spectral absorption at 790 nm bound to the plasma protein albumin, that may be used in sentinel node mapping using a near infrared (NIR) imaging system. Upon injection of the indocyanine green (ICG)/albumin solution around the tumor, the ICG/albumin complex, travels though the vascular system. Using a NIR imaging system, the ICG, which emits light in the NIR range, permits the visualization of sentinel nodes and may help in cancer staging.			Indicator, Reagent, or Diagnostic Aid	NCI Drug Dictionary Terminology
C116717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116717>	C797|C226473	Topical Keratin|KeraStat	A topical formulation containing the naturally-derived biomaterial keratin that has wound repair promoting, hemostatic, moisturizing and potential radioprotective activities. Upon topical application to an injured site, keratin adheres to the injured tissue, and forms an extracellular matrix that mimics the structure and function of the native tissue. This exogenous extracellular matrix is able to absorb fluid, accelerate thrombus formation through beta1 integrin-mediated platelet adhesion and forms a physical seal on the wound. This facilitates tissue regeneration by promoting cellular proliferation and migration, reducing pro-inflammatory cytokine and chemokine expression and altering the expression of extracellular matrix components and adhesion molecules. Altogether, this promotes wound healing and provides protection from damage due to thermal or radiation exposure. Keratin is an essential component in nails, hair and skin.	Topical Keratin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C116718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116718>	C35527	Early Onset Primary Dystonia|Early Onset Torsion Dystonia|Early Onset Torsion Dystonia|Oppenheim's Dystonia|Oppenheim's Dystonia	A genetic disorder that usually presents in early childhood and is characterized by muscle contractions in a foot, leg, or arm that gradually spreads to other body regions.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116719>	C35527	Dopa-Responsive Dystonia|Autosomal Dominant Dopa-Responsive Dystonia|Autosomal Dominant Segawa Syndrome|DYT5 Dystonia|Dopa-Responsive Dystonia, Autosomal Dominant|Segawa's Disease	A genetic disorder in females that presents in early childhood and is responsive to dopamine. It is characterized by clubfeet and Parkinsonian symptoms that may progress from lower to upper extremities witha diurnal pattern, and involuntary muscle contractions and other uncontrolled movements in the lower limbs that worsen with excercise and improve with rest.			Disease or Syndrome	Cellosaurus Disease Terminology
C11671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11671>	C61063	Interleukin-12/Montanide ISA-51/Tyrosinase Peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116720>	C2021	Thymidylate Synthase Inhibitor DFP-11207|DFP-11207|DFP-11207|TS Inhibitor DFP-11207	An orally available thymidylate synthase (TS) inhibitor with potential antineoplastic activity. Upon oral administration, DFP-11207 binds to and inhibits TS. This reduces thymine nucleotide synthesis, inhibits DNA synthesis and cell division, causes DNA damage and leads to tumor cell apoptosis. TS catalyzes the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP).			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116721>	C3837	Palsy	Muscle weakness or paralysis of neurologic origin.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116722>	C213472|C200418|C141136|C124800	Gilteritinib|6-Ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide|ASP 2215|ASP-2215|ASP2215|GILTERITINIB	An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), with potential antineoplastic activity. Upon administration, gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL, ALK and LTK. This may result in an inhibition of FLT3-, AXL-, ALK-, and LTK-mediated signal transduction pathways and reduced proliferation in cancer cells that overexpress these RTKs. FLT3, AXL, ALK, and LTK, which are overexpressed or mutated in a variety of cancer cell types, play key roles in tumor cell growth and survival.	Gilteritinib		Organic Chemical|Pharmacologic Substance	AML Authorized Value Terminology|AML Total Dose Table|CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116723>	C98845	Erb's Palsy|Erb-Duchenne Palsy	Weakness or paralysis of muscles in the arm due to damage in the upper brachial plexus.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C116724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116724>	C98845	Klumpke Palsy|Dejerine-Klumpke Palsy|Klumpke's Palsy|Klumpke's Palsy	Weakness or paralysis of muscles in the forearm or hand due to damage of the lower brachial plexus.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C116725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116725>	C38038	Psychogenic Tremor|Tics/Tremor	An involuntary, compulsive, repetitive stereotyped movement.			Finding	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116726>	C146993	Androgen Receptor Downregulator AZD3514|AZD3514|SARD AZD3514	An orally available selective androgen receptor (AR) downregulator (SARD), with potential antineoplastic activity. Upon oral administration, AZD3514 binds to the AR ligand binding domain and inhibits the binding of androgen, thereby preventing androgen-dependent AR signaling. AZD3514 also causes downregulation of AR expression, which further prevents AR-mediated signaling. This results in an inhibition of proliferation in AR-overexpressing tumor cells. AR plays a key role in the proliferation of castration-resistant prostate cancer cells.	Androgen Receptor Downregulator AZD3514		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116727>	C141136	ALK Inhibitor ASP3026|ASP-3026|ASP-3026|ASP3026|N2-[2-Methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-1,3,5-triazine-2,4-diamine	An orally available, small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon oral administration, ASP3026 binds to and inhibits ALK tyrosine kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors. Additionally, ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors.	ALK Inhibitor ASP3026		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116728>	C29574|C129825	iNOS Dimerization Inhibitor FK-330|FK-330|FK-330|FR-260330|iNOS Dimerization Inhibitor ASP9853|iNOS Dimerization Inhibitor ASP9853	An orally bioavailable small molecule inhibitor of inducible nitric oxide synthase (iNOS) with potential antineoplastic activity. Upon administration, iNOS Dimerization Inhibitor FK-330 inhibits iNOS dimerization, which results in decreased nitric oxide (NO) production. iNOS expression is upregulated in certain cancers and may invoke a chronic inflammatory state in tumor cells that promotes metastatic growth.	iNOS Dimerization Inhibitor ASP9853		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116729>	C1404|C129825	Ilorasertib|1-(4-(4-Amino-7-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)thieno[3,2-c]pyridin-3-yl)phenyl)-3-(3-fluorophenyl)urea|A-968660.0|ABT-348|ILORASERTIB	An orally bioavailable, adenosine triphospate mimetic, and inhibitor of Aurora kinases, vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptor (PDGFRs), with potential antineoplastic activity. Upon administration, ilorasertib selectively binds to and inhibits Aurora kinases A, B and C, which may disrupt both the assembly of the mitotic spindle apparatus and chromosome segregation, and inhibit both cellular division and proliferation in Aurora kinase-overexpressing tumor cells. In addition, ilorasertib selectively binds to and inhibits VEGFRs and PDGFRs, which may result in the inhibition of both angiogenesis and tumor cell proliferation in VEGFR/PDGFR-overexpressing tumor cells. This agent also inhibits the Src family of cytoplasmic tyrosine kinases. Aurora kinases A, B and C, are serine/threonine kinases that play essential roles in mitotic checkpoint control and are overexpressed by a wide variety of tumor cell types. Both VEGFRs and PDGFRs are receptor tyrosine kinase families whose members may be upregulated in various tumor cell types.	Ilorasertib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11672>	C61063	Montanide ISA-51/Sargramostim/Tyrosinase peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116730>	C110937	Choreoathetosis|Choreathetosis	Abnormal movement characterized by involuntary jerking and writhing affecting the limbs, trunk, and facial muscles.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116731>	C36280	Stereotypy|STYBEH|Stereotypic Behavior|Stereotypic Behavior	Persistent repetition of non-purposeful speech or movement.			Finding	CDISC SEND Nervous System Findings Test Code Terminology|CDISC SEND Nervous System Findings Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116732>	C28681	Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes|Autologous CMV-specific CTLs	A population of autologous cytotoxic-T lymphocytes (CTLs) specifically reactive to the herpes virus cytomegalovirus (CMV) with potential immunomodulating and antiviral activities. Upon administration with the autologous CMV-specific CTLs, these CTLs lyse CMV-infected cells, thereby preventing or decreasing the occurrence of CMV viral disease, or reducing the amount of antiviral drug therapy needed to eradicate CMV.	Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C116733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116733>	C39619|C1663	Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine|Autologous Lymphoma Immunoglobulin-derived scFV-chemokine DNA Vaccine	A plasmid DNA vaccine encoding an autologous lymphoma-derived idiotype-targeting immunoglobulin (Ig)-derived single chain variable fragment (scFv) fused to the chemokine macrophage inflammatory protein 3 alpha (MIP3a), with potential immunostimulating and antineoplastic activities. Upon intramuscular vaccination, the autologous lymphoma immunoglobulin-derived scFv-chemokine DNA vaccine is taken up by antigen-presenting cells (APCs) and stimulates the immune system to exert a cytotoxic T-lymphocyte (CTL) response against the idiotype expressed on the surface of B lymphoma cells. MIP3a, also called chemokine (C-C motif) ligand 20 (CCL20), is a chemotactic cytokine able to enhance the immune response through binding to chemokine receptors expressed on APCs.	Autologous Lymphoma Immunoglobulin-derived scFV-chemokine DNA Vaccine		Immunologic Factor|Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116734>	C28681|C119988	Autologous TNS9.3.55-transduced CD34-positive Cells|Autologous CD34-positive Cells Transduced with TNS9.3.55	A preparation of autologous, CD34-positive hematopoietic progenitor cells (HPCs) ex vivo transduced with TNS9.3.55, a lentiviral vector encoding the human beta-globin (hemoglobin-beta, HBB) gene, with potential to restore beta-globin expression and function. Autologous CD34-positive stem cells are isolated from the patient's own bone marrow, the deficient HBB gene is removed, and the cells are transduced with the lentiviral vector. Upon re-infusion of the TNS9.3.55-transduced CD34-positive cells back into the patient, these cells express beta-globin, thereby allowing the body to make normal hemoglobin and thus normal, healthy red blood cells. Beta-globin, the beta-chain of the most common form of hemoglobin, is encoded by the HBB gene; mutations in this gene prevent normal beta-globin production.	Autologous TNS9.3.55-transduced CD34-positive Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology
C116736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116736>	C96404	Bacteriophage phi X 174 Vaccine|BACTERIOPHAGE PHI X174|phi X 174	A vaccine composed of the bacteriophage phi X 174, a virus that infects the bacterium Escherichia coli (E. coli), that can be used as a diagnostic agent to measure immune function of immunocompromised patients. Upon administration of the bacteriophage phi X 174 vaccine, the bacteriophage may activate the immune system to induce bacteriophage phi X174 specific antibody responses. The clearance of phage from the blood and the measurement of phage neutralization by antibodies can be used to assess the immune status of patients with suspected antibody-mediated immunodeficiency and to measure the response to certain therapies.	Bacteriophage phi X 174 Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C116737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116737>	C200367	Anti-CD33 Monoclonal Antibody BI 836858|BI 836858|BI-836858	An engineered, fully human, immunoglobulin (Ig) G1 anti-CD33 monoclonal antibody, with potential antineoplastic activity. Upon administration, anti-CD33 monoclonal antibody BI 836858 induces an antibody-dependent cellular cytotoxicity (ADCC) against CD33-expressing tumor cells, leading to cell death. CD33, a cell surface antigen expressed on normal non-pluripotent hematopoietic stem cells, is overexpressed on myeloid leukemia cells.	Anti-CD33 Monoclonal Antibody BI 836858		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116738>	C201513|C200766	CD30 CAR-expressing Autologous T Lymphocytes|Anti-CD30 CAR-expressing Autologous T Lymphocytes|CAR.CD30-expressing Autologous T Lymphocytes	A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the CD30 antigen, with potential immunostimulating and antineoplastic activities. Upon administration, the CD30 CAR-expressing autologous T-lymphocytes specifically recognize and bind to CD30-expressing tumor cells, resulting in tumor cell lysis. CD30, a cell surface receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is transiently expressed on activated lymphocytes and is constitutively expressed in hematologic malignancies.	CD30 CAR-expressing Autologous T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116739>	C65141	Carrot Juice|CARROT JUICE	The juice from carrots, with potential antioxidant and protective activities. Carrot juice, depending on the carrot varieties, may contain nutrients that include the provitamin A carotenoids alpha-carotene and beta-carotene, the non-provitamin A carotenoid lycopene, and the flavonoids anthocyanins, luteolin, quercetin and kaempferol. The antioxidants in carrot juice scavenge free radicals, thereby protecting cells from damage.	Carrot Juice		Food	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C11673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11673>	C61063	gp100 Antigen/Interleukin-12/Montanide ISA-51			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116740>	C28310	CMV pp65 Peptide-pulsed Autologous Dendritic Cell Vaccine|CMV pp65 Peptide-pulsed Autologous DC Vaccine	A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with the human cytomegalovirus (CMV) phosphoprotein pp65, with potential immunostimulatory and antineoplastic activities. Upon administration, the CMV pp65 peptide-pulsed autologous DC vaccine exposes the immune system to the CMV pp65 peptide, which may result in a cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells leading to cell lysis. The CMV pp65 protein, also called the 65 kDa lower matrix phosphoprotein, is the primary component of the enveloped subviral particle of CMV and is expressed in certain tumor types, such as glioblastoma.	CMV pp65 Peptide-pulsed Autologous Dendritic Cell Vaccine		Cell|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116741>	C61101	Dalbavancin|DALBAVANCIN|Dalvance|MDL 63,397|Ristomycin A Aglycone, 5,31-Dichloro-38-de(methoxycarbonyl)-7-demethyl-19-deoxy-56-O-(2-deoxy-2-((10-methyl-1-oxoundecyl)amino)-beta-D-glucopyranuronosyl)-38-(((3-(dimethylamino)propyl)amino)carbonyl)-42-O-alpha-D-mannopyranosyl-N15-methyl-|VER001	A second-generation, semi-synthetic lipoglycopeptide antibiotic, with bactericidal activity against a variety of gram-positive bacteria. Upon administration, dalbavancin binds, at a site different from that of penicillins and cephalosporins, tightly to the D-alanyl-D-alanine portion of peptidoglycan chains, thereby preventing peptidoglycan elongation and interfering with bacterial cell wall synthesis. This leads to activation of bacterial autolysins and induces cell wall lysis.	Dalbavancin		Antibiotic|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C116742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116742>	C211912	Anti-ETBR/MMAE Antibody-drug Conjugate DEDN6526A|ADC DEDN6526A|DEDN6526A	An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin (Ig) G1 monoclonal antibody against anti-endothelin B receptor (ETBR) and covalently linked to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of DEDN6526A binds to ETBR-expressing tumor cells and is internalized, thereby delivering MMAE intracellularly. Proteolytic cleavage releases MMAE, which then binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. ETBR, a G-protein coupled receptor that can activate RAF/MEK signaling, is overexpressed in a variety of tumor cell types and plays a key role in tumor cell proliferation, invasion, epithelial-mesenchymal transition (EMT) and angiogenesis.	Anti-ETBR/MMAE Antibody-drug Conjugate DEDN6526A		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116743>	C54060	Delta-Tocotrienol|.DELTA.-TOCOTRIENOL|Delta Tocotrienol	The delta form of the vitamin E family member tocotrienol, with potential antineoplastic activity. Upon administration, delta-tocotrienol accumulates in cancer cells and may exert their anti-cancer activity in part through 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase downregulation and/or degradation, cell cycle arrest, and induction of caspase-mediated apoptosis. In addition, this agent may inhibit angiogenesis partially through the blockage of vascular endothelial growth factor receptor (VEGFR) and the inhibition of tumor cell-induced vessel formation. Altogether, this may result in the inhibition of tumor cell growth. Tocotrienols contain 3 double bonds, absent in tocopherols, on its farnesyl isoprenoid side chain that likely contribute to its anti-cancer activities.	Delta-Tocotrienol		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C116744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116744>	C1557	Nucleoside Analog DFP-10917|2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine|DFP-10917	A deoxycytosine analog with potential antineoplastic activity. Upon administration, DFP-10917 is phosphorylated to generate its nucleotide form that functions as a deoxycytosine mimic and is incorporated into DNA in tumor cells. This causes DNA strand breaks during polymerization due to beta-elimination during the fidelity checkpoint, which results in G2/M phase-arrest and tumor cell apoptosis.	Nucleoside Analog DFP-10917		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116745>	C129823	Anti-Ly6E Antibody-Drug Conjugate RG 7841|ADC DLYE5953A|Anti-LY6E-VCMMAE|Anti-Ly6E Antibody-Drug Conjugate DLYE5953A|DLYE5953A|RG 7841|RG-7841|RG-7841|RG7841	An antibody-drug conjugate (ADC) composed of an antibody against the tumor-associated antigen (TAA) lymphocyte antigen 6 complex locus E (Ly6E) and linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the antibody moiety of RG 7841 targets and binds to Ly6E expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills, through an as of yet unknown mechanism of action, the Ly6E-expressing cancer cells. Ly6E, an interferon (IFN)-inducible glycosylphosphatidylinositol (GPI)-linked cell membrane protein, is expressed on a variety of tumor cell types.	Anti-Ly6E Antibody-Drug Conjugate RG 7841		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116746>	C211912|C201535	Anti-mesothelin/MMAE Antibody-drug Conjugate DMOT4039A|DMOT-4039A|DMOT4039A|RG 7600|RG7600	An antibody-drug conjugate (ADC) composed of MMOT0530A, a humanized immunoglobulin (Ig) G1 monoclonal antibody directed against the cell surface glycoprotein mesothelin (MSLN), and covalently linked, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of DMOT4039A binds to MSLN-expressing tumor cells and is internalized, thereby delivering MMAE intracellularly. Proteolytic cleavage releases MMAE, which then binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. MSLN, a tumor-associated antigen (TAA), is overexpressed by all mesotheliomas and a variety of other cancers, while it is minimally expressed in normal tissue.	Anti-mesothelin/MMAE Antibody-drug Conjugate DMOT4039A		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116747>	C217337|C211912	Lifastuzumab Vedotin|ADC DNIB0600A|DNIB0600A|LIFASTUZUMAB VEDOTIN|RG-7599	An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the sodium-dependent phosphate transport protein 2B (NaPi2b), and covalently linked to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of DNIB0600A binds to NaPi2b-expressing tumor cells and is internalized, thereby delivering MMAE intracellularly. Proteolytic cleavage releases MMAE, which then binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. NaPi2b, a tumor-associated antigen (TAA), overexpressed in a variety of cancer cell types, plays a key role in transport of inorganic phosphate and the maintenance of phosphate homeostasis.	Lifastuzumab Vedotin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116748>	C212043|C211912	Vandortuzumab Vedotin|DSTP3086S|MSTP2109A|RG7450|Thio-anti-STEAP1-MC-vc-PAB-MMAE|VANDORTUZUMAB VEDOTIN	An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the six transmembrane epithelial antigen of the prostate 1 (STEAP1), and conjugated, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration of vandortuzumab vedotin, the monoclonal antibody moiety of vandortuzumab vedotin binds to STEAP1-expressing tumor cells and is internalized, thereby delivering MMAE intracellularly. Proteolytic cleavage releases MMAE, which then binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. STEAP1, a tumor-associated antigen (TAA), is overexpressed in a variety of cancer cell types.	Vandortuzumab Vedotin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116749>	C16502	Photoacoustic Imaging	An imaging technique during which non-ionizing pulses are delivered into tissue and the resulting ultrasonic waves are detected and converted into images.	Photoacoustic Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C11674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11674>	C61063	gp100 Antigen/Montanide ISA-51/Sargramostim			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116750>	C201598|C129822	Dilpacimab|ABT-165|DILPACIMAB|DVD-Ig ABT-165|Immunoglobulin, Anti-(Notch Ligand DLL4/Vascular Endothelial Growth Factor) (Synthetic Human PR-1283233 Heavy Chain), Disulfide with Synthetic Human PR-1283233 Light Chain, Dimer|PR-1283233|WHO 10863	A bispecific, tetravalent immunoglobulin (Ig) G-like molecule containing the target-binding variable domains of two monoclonal antibodies, one targeting the Notch ligand delta-like 4 (DLL4) and the other one targeting the human tyrosine kinase vascular endothelial growth factor (VEGF), combined via linkers, with potential anti-angiogenic and antineoplastic activities. Upon administration, dilpacimab targets and binds to both DLL4 and VEGF. This prevents the activation of DLL-4/Notch- and VEGF/VEGF receptor (VEGFR)-mediated signaling pathways, which play key roles in angiogenesis and tumor vascularization. This prevents angiogenesis and may halt tumor cell proliferation. Activation of Notch receptors by DLL4 stimulates proteolytic cleavage of the Notch intracellular domain (NICD); after cleavage, NICD is translocated to the nucleus and mediates the transcriptional regulation of a variety of genes involved in vascular development. The expression of DLL4 is highly restricted to the vascular endothelium; DLL4/Notch signaling is required for the development of functional tumor blood vessels. The expression of the pro-angiogenic growth factor VEGF is associated with tumor angiogenesis and tumor cell proliferation and invasion.	Dilpacimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116751>	C521	Fluorometholone Acetate Ophthalmic Suspension	An ophthalmic suspension containing the acetate form of fluorometholone, with potential anti-infective and immunosuppressive activities. Upon ocular administration, fluorometholone binds to glucocorticoid receptors in the cytoplasm and forms a receptor-ligand complex, which translocates to the nucleus where it binds to glucocorticoid response elements (GRE) in the promoter region of target genes. This leads to the expression of specific target genes that control inflammation. Specifically, by inducing the expression of lipocortins that inhibit the enzymatic activity of phospholipase A2, the release of arachidonic acid is blocked, which prevents the production of inflammatory mediators, and inflammatory-induced ocular swelling, redness and itching.	Fluorometholone Acetate Ophthalmic Suspension		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C116752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116752>	C48922	Diffusion Coefficient|Coefficient of Molecular Diffusion of Mass|Diffusivity	The weight of a material, in grams, diffusing across an area of 1 square centimeter in 1 second in a unit concentration gradient.			Conceptual Entity	
C116753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116753>	C116752	Apparent Diffusion Coefficient|ADC|Effective Diffusion Coefficient	A measurement of the magnitude of diffusion of water molecules within tissue.			Conceptual Entity	
C116754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116754>	C111116	High-B-Value Diffusion-Weighted Imaging|High B-Value|High-B-Value Diffusion-Weighted MR Imaging|High-B-Value Diffusion-Weighted Magnetic Resonance Imaging	Diffusion-weighted imaging done under conditions of high diffusion gradients.			Diagnostic Procedure	
C116755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116755>	C91105|C21154	Ocular Surface Disease Index|OSDI	A 12 item questionnaire designed to provide a rapid assessment of the symptoms of ocular irritation consistent with dry eye disease and their impact on vision-related functioning. The OSDI is assessed on a scale of 0 to 100, with higher scores representing greater disability.			Intellectual Product	
C116756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116756>	C155927	Chk1 Inhibitor GDC-0425|GDC-0425|GDC-0425|RG7602	An orally bioavailable inhibitor of checkpoint kinase 1 (chk1), with potential antineoplastic and chemosensitization activities. Upon oral administration, chk1 inhibitor GDC-0425 selectively binds to chk1, thereby preventing activity of chk1 and abrogating the repair of damaged DNA. This may lead to an accumulation of damaged DNA, inhibition of cell cycle arrest, and induction of apoptosis. GDC-0425 may potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapeutic agents. Chk1, an ATP-dependent serine/threonine kinase, mediates cell cycle checkpoint control, is essential for DNA repair, and plays a key role in resistance to chemotherapeutic agents.	Chk1 Inhibitor GDC-0425		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116757>	C27586	Movement Disorder|Movement Disorders	Neurological conditions resulting in abnormal voluntary or involuntary movement, which may impact the speed, fluency, quality and ease of movement.			Disease or Syndrome	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116758>	C36280	Tic	Involuntary sudden, rapid, recurrent, nonrhythmic, stereotyped motor movement or vocalization.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116759>	C116758	Motor Tic	A tic affecting muscle movement.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11675>	C61063	Montanide ISA-51/Tyrosinase-Related Protein-1			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116760>	C116758	Phonic Tic|Vocal Tic|Vocal Tic	A vocal tic.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116761>	C116758	Simple Tic	A tic that involves one muscle or muscle group, or non-word sounds.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116762>	C116758	Complex Tic	A tic that involves multiple muscles or muscle groups, or words or sentences.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116763>	C3858	Corprolalia|Coprolalia	Involuntary and repetitive utterances of obscene or socially inappropriate words or statements.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116764>	C20497	IL16 Gene Product	A protein encoded by the IL16 gene.			Amino Acid, Peptide, or Protein	
C116765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116765>	C116764	Pro-Interleukin-16|Pro-IL-16|Pro-IL16|Pro-Interleukin 16|Prointerleukin 16|Prointerleukin-16|nPro-IL-16	Pro-interleukin-16 (1332 aa, ~142 kDa) is encoded by the human IL16 gene. This protein is involved in both transcriptional repression and cytokine signaling.	Pro-Interleukin-16		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116766>	C116757	Tourettism	Tics that are secondary to an identifiable cause.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116767>	C116757	Transient Tic Disorder|Benign Tic Disorder of Childhood	A neurological disorder presenting in childhood that is characterized by motor and/or phonic tics that occur daily or nearly daily for one to twelve months and are not attributed to an identifiable cause.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116768>	C116757	Chronic Tic Disorder	A neurological disorder presenting in childhood that is characterized by either motor or phonic tics, but not both, that occur daily or nearly daily for at least a year and are not attributed to an identifiable cause.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116769>	C4086	Congenital Dysplasia	Abnormal tissue formation due to abnormal cellular organization, which may result in a morphologic defect.			Finding	NICHD Terminology|Perinatal Terminology
C11676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11676>	C61063	Interleukin-2/Montanide ISA-51/Tyrosinase-Related Protein-1			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116770>	C118300	Retinopathy of Prematurity Stage 0	Prior to the development of ROP in the premature infant, vascularization of the retina is incomplete or immature. In Stage 0, there is no clear demarcation line between vascularized and non-vascularized retina.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C116771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116771>	C98996	Transient Neonatal Pustular Melanosis	A benign, self-limited eruption of vesicles, pustules and macules seen in newborns. The fluid-filled lesions typically rupture and resolve within 48 hours while the macular lesions may persist for months.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C116772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116772>	C80082	Early Neonatal Death|Early Neonatal Mortality|Early Neonatal Mortality	Death of a live newborn during the first 7 days of life.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C116773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116773>	C80082	Late Neonatal Death|Late Neonatal Mortality|Late Neonatal Mortality	Death of live newborn between 7 and 27 days after birth.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C116774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116774>	C101304	Anti-D Hemolytic Disease of the Newborn|Isoimmunization of Newborn with Rhesus Anti-D Antibody|Isoimmunization of Newborn with Rhesus Anti-D Antibody	A condition of the newborn characterized by the destruction of red blood cells initiated by the transmission of antibodies from a mother to the child via the placenta against the D antigen, the most common Rhesus factor.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C116775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116775>	C333	Pinaverium Bromide|4-(6-Bromoveratryl)-4-(2-(2-(6,6-dimethyl-2-norpinyl)ethoxy)ethyl)morpholinium Bromide|Morpholinium, 4-[(2-Bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethylbicyclo[3.1.1]hept-2-yl)ethoxy]ethyl]-, Bromide|PINAVERIUM BROMIDE|Pinverin	An orally available bromide salt form of pinaverium, a calcium channel blocker (CCB) with antispasmodic activity. Upon oral administration, pinaverium blocks the voltage-dependent calcium channels and inhibits calcium ion influx into the smooth muscle cells located in the gastrointestinal (GI) tract. This prevents smooth muscle contraction and relaxes the GI tract. In addition, pinaverium may both reduce bowel uptake of and facilitate the function of locally active, co-administered drugs.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C116776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116776>	C2889	Undifferentiated Connective Tissue Disease|UCTD|UCTD	An autoimmune disorder which does not meet classification criteria used to establish the presence of other well-defined connective tissue diseases.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C116777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116777>	C2685	Brachyury-expressing Modified Vaccinia Ankara-TRICOM Vaccine|MVA Brachyury-TRICOM	A cancer vaccine composed of a replication-deficient, attenuated derivative of the vaccinia virus strain Ankara expressing both a CD8+ T-cell epitope from the brachyury protein and a triad of T-cell co-stimulatory molecules (MVA Brachyury-TRICOM), with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration of the brachyury-expressing modified vaccinia Ankara (MVA)-TRICOM vaccine, the expressed brachyury protein induces specific CD8+ and CD4+ T-cell responses against brachyury-expressing tumor cells. This causes both tumor cell lysis and a decrease in the growth of brachyury-expressing tumor cells. Brachyury, a member of the T-box family of transcription factors that is overexpressed in numerous cancer cell types, is correlated with increased epithelial-mesenchymal transition (EMT), cancer resistance and cancer progression. TRICOM, a triad of three human T-cell co-stimulatory molecules, B7.1, ICAM-1 and LFA-3, enhances antigen-specific T-cell activation.			Immunologic Factor|Pharmacologic Substance|Virus	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116778>	C93210|C2883	Spondyloarthritis|Seronegative Spondyloarthropathy|Spondylitis|Spondylitis|Spondyloarthropathy	A group of inflammatory rheumatic diseases associated with arthritis and enthesitis, and often involving the axial skeleton. The most common form of spondyloarthritis is ankylosing spondylitis. Other forms include axial spondyloarthritis, peripheral spondyloarthritis, reactive arthritis, psoriatic arthritis/spondylitis and enteropathic arthritis/spondylitis.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C11677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11677>	C61063	Interleukin-12/Montanide ISA-51/Tyrosinase Related Protein-1|Interleukin-12/Montanide ISA-51/Tyrosinase-Related Protein-1			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116780>	C72069	Linear Scleroderma|Linear scleroderma	A type of localized scleroderma characterized by a long strip of indurated skin, which is typically found unilaterally on an arm or leg, and sometimes on the forehead or trunk. This disorder often affects the tissues beneath the skin, causing damage to bones, muscle or other organs. It can limit movement, alter growth, and disfigure the affected area.			Disease or Syndrome	mCode Elixhauser Rheumatoid Arthritis and Collagen Vascular Disease Value Set|mCode Terminology|NICHD Terminology|Pediatric Rheumatology Terminology
C116781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116781>	C116780	Scleroderma en Coup de Sabre|Frontal Linear Scleroderma|Frontal Linear Scleroderma	A type of linear scleroderma characterized by a linear, colorless, atrophied band across the forehead or scalp. This disorder can affect the tissues under or near the lesion including brain, bone and eyes.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C116782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116782>	C72069	Generalized Morphea	A type of morphea characterized by four or more plaques found in two or more anatomic locations. The plaques are indurated, generally well-delineated, and may include muscle atrophy in affected areas; there is no visceral involvement.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C116783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116783>	C98996|C27555	Erythema Toxicum Neonatorum|Neonatal Erythema Toxicum|Neonatal Toxic Erythema|Urticaria neonatorum	A benign, self-limited eruption of vesicles, pustules, papules and macules seen in newborns. An eosinophilic infiltrate can be isolated suggesting an immune-mediated reaction in the skin.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C116784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116784>	C72069	Circumscribed Morphea	A type of morphea in which the lesions are circular or ovoid, and may be superficial or deep. The superficial lesions can have an indurated, waxy, ivory colored center with surrounding erythema or violaceous color during the active stage. Deep lesions can be sclerotic and depressed from underlying atrophy, and may show minimal skin color changes. When there are several (greater than or equal to 4), larger (greater than 3cm) lesions on two or more body areas this is classified as "generalized morphea".			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C116785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116785>	C72069	Pansclerotic Morphea	A rare, aggressive form of morphea characterized by sclerosis of the dermis, fascia, and muscle over large parts of the body, resulting in contractures and immobility.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C116786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116786>	C72069	Mixed Morphea	The presence of more than one variant of morphea in a single patient.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C116787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116787>	C72069	Juvenile Localized Scleroderma	Localized scleroderma presenting before the age of eighteen.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C116788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116788>	C20401|C129822	Ianalumab|HuCAL-based Antibody VAY736|Human Combinatorial Antibody Library-based Monoclonal Antibody VAY736|IANALUMAB|VAY 736|VAY736	A fully human combinatorial antibody library (HuCAL)-derived monoclonal antibody targeting the B-cell-activating factor receptor (BAFF-R), with potential anti-inflammatory and antineoplastic activities. Upon administration, ianalumab targets and binds to BAFF-R, which inhibits both BAFF/BAFF-R interaction and BAFF-R-mediated signaling. This may decrease cell growth in tumor cells expressing BAFF-R. BAFF-R, also known as tumor necrosis factor receptor superfamily member 13C, is overexpressed in certain tumor cell types and autoimmune diseases. In cancer cells, BAFF-R plays a key role in B-cell proliferation and survival. VAY736 was developed using HuCAL technology.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116789>	C72070	Systemic Sclerosis without Skin Involvement|SSC without Skin Involvement|SSC without Skin Involvement|Systemic Sclerosis sine Scleroderma|Systemic Sclerosis sine Scleroderma	A condition in which there are visceral manifestations of systemic sclerosis without any cutaneous findings.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C11678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11678>	C61063	Montanide ISA-51/Sargramostim/Tyrosinase-Related Protein-1			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116790>	C2124	Carbon C 11 Sepantronium Bromide|11C-YM155	A radiotracer composed of the bromide salt form of sepantronium, a small-molecule survivin antagonist and proapoptotic agent, labeled with the radionuclide carbon C 11, with potential positron emission tomography (PET) imaging activity. Upon administration, sepantronium is selectively taken up by tumor cells, binds to the survivin promoter and inhibits the transcription of survivin, which results in decreased survivin expression. Upon PET imaging, the tissue distribution of sepantronium and its tumor uptake can be assessed. Survivin, a member of the inhibitor of apoptosis (IAP) gene family, is overexpressed in a variety of human cancers; its expression in tumors is associated with a more aggressive phenotype, increased cancer cell proliferation, shorter survival times, and a decreased response to chemotherapy.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C116791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116791>	C72070	Diffuse Cutaneous Systemic Sclerosis|dSSc|dSSc|dcSSc|dcSSc	A variant of systemic scleroderma characterized by sclerosis of the skin, Raynaud phenomenon, and organ involvement, including pulmonary fibrosis, renal disease, and gastrointestinal tract involvement.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C116792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116792>	C129821	Patisiran|ALN-18328|ALN-TTR02|PATISIRAN|RNAi Therapeutic-targeting Transthyretin ALN-TTR02	A lipid nanoparticle (LNP)-based formulation consisting of small-interfering RNAs (siRNAs) directed against transthyretin (TTR) encapsulated in lipids, which has potential use in the treatment of TTR-mediated amyloidosis (ATTR). Upon intravenous administration of patisiran, the lipid formulation promotes the uptake by cells. The siRNAs bind to TTR mRNAs, which may result in the inhibition of both the translation and expression of the TTR protein. ATTR is caused by mutations in the TTR gene and results in the formation of abnormal amyloid proteins that accumulate in and cause damage to various body organs and tissues.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C116793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116793>	C87168	Group B Streptococcal Infection, Early-Onset|GBS Infection, Early-Onset|GBS Infection, Early-Onset	Infection of an infant from birth to less than seven days of life caused by Group B Streptococcus (Streptococcus agalactiae) from a colonized mother.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C116794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116794>	C28193|C213418	Blau Syndrome|Pediatric Granulomatous Arthritis|Pediatric Granulomatous Arthritis	An autoinflammatory disease caused by a NOD2 gene mutation, usually presenting in children younger than age four, and characterized by granulomatous dermatitis, arthritis with synovitis, and uveitis.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Rheumatology Terminology
C116795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116795>	C87168	Group B Streptococcal Infection, Late-Onset|GBS Infection, Late-Onset|GBS Infection, Late-Onset	Infection of an infant from seven days to three months of life caused by Group B Streptococcus (Streptococcus agalactiae).			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C116796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116796>	C101216	Idiopathic Inflammatory Myopathy|IIM|IIM|Idiopathic Inflammatory Myopathies|Idiopathic Inflammatory Myopathies|Idiopathic Inflammatory Myositis	An umbrella term for diseases which have chronic muscle inflammation and weakness of unknown etiology. The types of idiopathic inflammatory myopathy are further defined by either clinicopathologic criteria or by the presence of certain autoantibodies.	Idiopathic Inflammatory Myopathy		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Rheumatology Terminology
C116797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116797>	C27576	Juvenile Dermatomyositis Sine Myositis|Juvenile Amyopathic Dermatomyositis|Juvenile Amyopathic Dermatomyositis|Juvenile Dermatomyositis sine Myositis|Juvenile dermatomyositis without myopathy	A rare form of juvenile dermatomyositis that manifests with characteristic cutaneous findings for at least six months in the absence of any detectable muscle involvement.			Disease or Syndrome	mCode Elixhauser Rheumatoid Arthritis and Collagen Vascular Disease Value Set|mCode Terminology|NICHD Terminology|Pediatric Rheumatology Terminology
C116798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116798>	C3201	Childhood-Onset Systemic Lupus Erythematosus|CSLE|CSLE|JSLE|JSLE|Juvenile SLE|Juvenile SLE|PSLE|PSLE|Pediatric SLE|Pediatric SLE	Systemic lupus erythematosus (SLE) diagnosed in individuals under the age of eighteen. Children frequently have multi-organ involvement and acute disease onset. Symptoms include fever, arthritis, skin lesions, anemia, and fatigue.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C116799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116799>	C99231|C96411|C96407	Congenital Varicella Zoster Infection	An infection, characterized by the rash of chickenpox or shingles, that is caused by the varicella-zoster virus transmitted directly from the mother to the fetus or neonate during late pregnancy or childbirth.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C11679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11679>	C61007	gp100 Antigen/MART-1 Antigen/Montanide ISA-51/Tyrosinase Peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1167>	C699	Cystemustine|C6H12CLN3O4S|CMSO2EN2|CYSTEMUSTINE|N'-(2-chloroethyl)-N-(2-(methylsulfonyl)ethyl)-N'-nitrosourea|N-(2-chloroethyl)-N'-[2-(methylsulfonyl)ethyl]-N-nitroso-urea	A chloroethylating nitrosourea that causes DNA cross-linking, inhibiting DNA replication. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C116800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116800>	C98996|C28193	Congenital Varicella Syndrome	A condition, whose clinical manifestations include intrauterine growth restriction, scarring cicatricial lesion of the limbs, abnormalities of the limbs, microcephaly, chorioretinitis, microphthalmia, cataracts, cortical atrophy, seizures, and evidence of damage to the autonomic nervous system, that is caused by fetal exposure to the varicella zoster virus during the first trimester of pregnancy.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C116801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116801>	C28193|C213418	Overlap Syndrome	An autoimmune, connective tissue disorder in which the patient exhibits features from two or more diseases. These typically include systemic sclerosis, dermatomyositis, polymyositis, rheumatoid arthritis, systemic lupus erythematosus, and Sjogren syndrome; in pediatrics the respective pediatric entities are encountered.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C116802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116802>	C99231	Neonatal Sepsis	An infectious disorder of newborn infants that is characterized by a systemic inflammatory response most commonly caused by bacteria.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology|NICHD Terminology|Pediatric Infectious Disease Terminology|Perinatal Terminology
C116803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116803>	C116802	Neonatal Sepsis, Early-Onset|Early-Onset Neonatal Sepsis	An infectious disorder of newborn infants that is characterized by a systemic inflammatory response within 72 hours of life and is most commonly caused by bacteria.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C116804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116804>	C798	Perflenapent Emulsion|DDFP LIquid Emulsion|Dodecafluoropentane Emulsion|NVX-108	An oil-in-water nano-emulsion composed of the perfluorocarbon perflenapent, that has oxygen-carrying capacity, can be used as a contrast agent and has potential antihypoxic and radiosensitizing activities. Upon intravenous administration of the perflenapent emulsion, this agent increases the oxygen-carrying capacity of blood, enhances the transport of oxygen to hypoxic and ischemic tissues and increases the oxygen concentration in these tissues. Hypoxic tumors are correlated with increased resistance to radiation treatment; therefore, since perflenapent may increase tumor oxygenation, it may improve the tumor's sensitivity to radiation therapy.	Perflenapent Emulsion		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116805>	C116802	Neonatal Sepsis, Late-Onset|Late-Onset Neonatal Sepsis	An infectious disorder of newborn infants that is characterized by a systemic inflammatory response beyond 72 hours of life and is most commonly caused by bacteria.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C116806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116806>	C99231|C82994	Neonatal Listeriosis	A bacterial infection by Listeria monocytogenes in a newborn infant up to 28 days old.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C116807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116807>	C99231|C82994	Congenital Listeriosis	A bacterial infection by Listeria monocytogenes that is present at birth.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C116808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116808>	C82994	Invasive Listeriosis	A bacterial infection by Listeria monocytogenes in a sterile body compartment.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C116809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116809>	C82994	Disseminated Listeriosis	A bacterial infection by Listeria monocytogenes in two or more non-contiguous sterile body compartments.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C11680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11680>	C61063	gp100 Antigen/Interleukin-2/MART-1 Antigen/Montanide ISA-51/Tyrosinase Peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116810>	C99231|C26711	Neonatal Candidiasis	A fungal infection by any of the Candida species in a newborn infant up to 28 days old.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C116811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116811>	C99231|C26711	Congenital Candidiasis	A fungal infection by any of the Candida species that is present at birth.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C116812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116812>	C26711	Disseminated Candidiasis	A fungal infection by any of the Candida species in two or more non-contiguous sterile body compartments.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C116813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116813>	C26711	Invasive Candidiasis	A fungal infection by any of the Candida species in a sterile body compartment.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology|Perinatal Terminology
C116814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116814>	C99231|C85185	Tetanus Neonatorum|Neonatal Tetanus|Neonatal Tetanus	A syndrome of generalized rigidity with muscle spasms and seizures in the neonatal period resulting from Clostridium tetani toxin production.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C116815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116815>	C34504	Ophthalmia Neonatorum|Neonatal Conjunctivitis|Neonatal Conjunctivitis	Inflammation of the conjunctiva in a newborn due to chemical or infectious causes. Aseptic conjunctivitis is often related to the use of prophylactic medications for infectious conjunctivitis. Septic conjunctivitis is related to perinatal exposure to microorganisms.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C116816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116816>	C99231|C53656	Gonococcal Ophthalmia Neonatorum|Conjunctivitis Gonococcal|Gonococcal Conjunctivitis	Inflammation of the conjunctiva in a newborn due to Neisseria gonorrhoeae which was acquired during labor and delivery.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology|Perinatal Terminology
C116817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116817>	C99231|C220196	Neonatal Chlamydia Conjunctivitis|Neonatal Chlamydial Conjunctivitis|Neonatal Inclusion Conjunctivitis|Neonatal Trachoma	Inflammation of the conjunctiva in a newborn due to Chlamydia trachomatis which was acquired during labor and delivery.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology|Perinatal Terminology
C116818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116818>	C98996|C34504	Neonatal Chemical Conjunctivitis|Chemical Conjunctivitis	Inflammation of the conjunctiva in a newborn due to chemical irritation which was acquired postnatally from iatrogenic causes.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C116819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116819>	C98996|C34521	Neonatal Dacryocystitis	Inflammation of the lacrimal sac in a newborn due to blocked drainage of tears or infection.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C11681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11681>	C61063	gp100 Antigen/MART-1 Antigen/Montanide ISA-51/Sargramostim/Tyrosinase Peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116820>	C101035	Forceps Injury	Birth injury sustained during a forceps-assisted delivery.			Finding	NICHD Terminology|Perinatal Terminology
C116821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116821>	C81236	Vacuum Extraction Chignon	A cone-shaped swelling on the head produced by applying suction during vacuum-assisted delivery. It is temporary and usually resolves without treatment.			Finding	NICHD Terminology|Perinatal Terminology
C116822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116822>	C3046|C101035	Fracture Related to Birth	A broken bone sustained during the birthing process.			Finding	NICHD Terminology|Perinatal Terminology
C116823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116823>	C101035	Occipital Diastasis|Occipital Osteodiastasis|Occipital Osteodiastasis	Birth trauma caused by excessive pressure to the suboccipital region of the skull resulting in separation of the occipital squama from the lateral or condylar parts of the occipital bone. It is a serious injury that may lead to subdural hemorrhage in the posterior fossa.			Finding	NICHD Terminology|Perinatal Terminology
C116824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116824>	C116822	Fracture of Nose Related to Birth	A broken nasal bone sustained during the birthing process.			Finding	NICHD Terminology|Perinatal Terminology
C116825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116825>	C116822	Fracture of Spine Related to Birth	A broken vertebra sustained during the birthing process.			Finding	NICHD Terminology|Perinatal Terminology
C116826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116826>	C116822	Fracture of Humerus Related to Birth	A broken humerus sustained during the birthing process.			Finding	NICHD Terminology|Perinatal Terminology
C116827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116827>	C116822	Fracture of Radius Related to Birth	A broken radius sustained during the birthing process.			Finding	NICHD Terminology|Perinatal Terminology
C116828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116828>	C116822	Fracture of Ulna Related to Birth	A broken ulna sustained during the birthing process.			Finding	NICHD Terminology|Perinatal Terminology
C116829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116829>	C116822	Fracture of Femur Related to Birth	A broken femur sustained during the birthing process.			Finding	NICHD Terminology|Perinatal Terminology
C11682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11682>	C61063	Flt3 Ligand/gp100 Antigen/MART-1 Antigen/Montanide ISA-51/Tyrosinase Peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116830>	C117360	Omphalorrhexis	Rupture of the umbilical cord during labor and delivery.			Finding	NICHD Terminology|Perinatal Terminology
C116831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116831>	C50844	Tentorial Tear Related to Birth	Disruption of the tentorium cerebelli incurred during delivery.			Finding	NICHD Terminology|Perinatal Terminology
C116832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116832>	C28108|C16669	CNS Involvement Status at Leukemia Diagnosis|CNS Leukemia at Diagnosis|CNS Status/Disease Status|CNS_DISEASE_STATUS|CNS_DISEASE_STATUS	The status describing the extent of central nervous system involvement at the time of leukemia diagnosis.			Classification	ALL Disease Characteristics Table|ALL Variable Terminology|AML Disease Characteristics Table|AML Variable Terminology
C116833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116833>	C116832	CNS 1|CNS1|CNS1|CNS1|CNS1|CNS1|CNS1|Central Nervous System Status 1	The status of central nervous system leukemia at diagnosis, where there is an absence of blasts on a cerebral spinal fluid cytospin preparation, regardless of the number of white blood cells.	CNS1		Classification	ALL Authorized Value Terminology|ALL Disease Characteristics Table|AML Authorized Value Terminology|AML Disease Characteristics Table|CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Disease Terminology|CTRP Terminology
C116834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116834>	C116832	CNS 2|CNS2|CNS2|CNS2|CNS2|CNS2|Central Nervous System Status 2	The status of central nervous system leukemia at diagnosis, where there are less than 5 white blood cells per microliter on a cerebral spinal fluid cytospin preparation that is positive for blasts; or greater than 5 white blood cells per microliter on a cerebral spinal fluid cytospin preparation that is considered negative by Steinherz/Bleyer algorithm.			Classification	ALL Authorized Value Terminology|ALL Disease Characteristics Table|AML Authorized Value Terminology|AML Disease Characteristics Table|CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C116835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116835>	C116832	CNS 3|CNS3|CNS3|CNS3|CNS3|Central Nervous System Status 3	The status of central nervous system leukemia at diagnosis, where there are more than 5 white blood cells per microliter on a cerebral spinal fluid cytospin preparation that is positive for blasts; with or without clinical signs of CNS leukemia.			Classification	ALL Authorized Value Terminology|ALL Disease Characteristics Table|AML Authorized Value Terminology|AML Disease Characteristics Table|CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C116836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116836>	C116834	CNS 2a|CNS2a|CNS2a	The status of central nervous system leukemia at diagnosis, where there are less than 10 red blood cells and less than 5 white blood cells per microliter on a cerebral spinal fluid cytospin preparation that is positive for blasts.			Classification	ALL Authorized Value Terminology|ALL Disease Characteristics Table
C116837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116837>	C116834	CNS 2b|CNS2b|CNS2b	The status of central nervous system leukemia at diagnosis, where there are 10 or more red blood cells and less than 5 white blood cells per microliter on a cerebral spinal fluid cytospin preparation that is positive for blasts.			Classification	ALL Authorized Value Terminology|ALL Disease Characteristics Table
C116838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116838>	C116834	CNS 2c|CNS2c|CNS2c	The status of central nervous system leukemia at diagnosis, where there are 10 or more red blood cells and 5 or more white blood cells per microliter on a cerebral spinal fluid cytospin preparation that is positive for blasts and is considered negative by Steinherz/Bleyer algorithm.			Classification	ALL Authorized Value Terminology|ALL Disease Characteristics Table
C116839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116839>	C35032|C101035	Splenic Rupture Related to Birth|Spleen Rupture Related to Birth	Disruption of the spleen incurred during delivery.			Finding	NICHD Terminology|Perinatal Terminology
C11683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11683>	C61063	CRL 1005/gp100 Antigen/Montanide ISA-51/Tyrosinase Peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116840>	C116835	CNS 3a|CNS3a|CNS3a	The status of central nervous system leukemia at diagnosis, where there are less than 10 red blood cells and 5 or more white blood cells per microliter on a cerebral spinal fluid cytospin preparation that is positive for blasts.			Classification	ALL Authorized Value Terminology|ALL Disease Characteristics Table
C116841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116841>	C116835	CNS 3b|CNS3b|CNS3b	The status of central nervous system leukemia at diagnosis, where there are 10 or more red blood cells and 5 or more white blood cells per microliter on a cerebral spinal fluid cytospin preparation that is considered positive by Steinherz/Bleyer algorithm.			Classification	ALL Authorized Value Terminology|ALL Disease Characteristics Table
C116842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116842>	C110943|C101035	Sternocleidomastoid Injury Related to Birth	Disruption of the sternocleidomastoid muscle incurred during delivery.			Finding	NICHD Terminology|Perinatal Terminology
C116843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116843>	C116835	CNS 3c|CNS3c|CNS3c	The status of central nervous system leukemia at diagnosis, where there are clinical signs of central system leukemia (such as facial nerve palsy, brain/eye involvement, or hypothalamic syndrome).			Classification	ALL Authorized Value Terminology|ALL Disease Characteristics Table
C116844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116844>	C213692|C129825	Fenebrutinib|Bruton Tyrosine Kinase Inhibitor GDC-0853|FENEBRUTINIB|GDC-0853	An orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, fenebrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival.	Fenebrutinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116845>	C155927	Chk1 Inhibitor GDC-0575|Checkpoint Kinase 1 Inhibitor GDC-0575|GDC-0575	A small molecule inhibitor of cell cycle checkpoint kinase 1 (Chk1), with potential chemosensitization activity. Chk1 inhibitor GDC-0575 specifically binds to and inhibits Chk1; this may result in tumor cells bypassing Chk1-dependent cell cycle arrest in the S and G2/M phases, which permits the cells to undergo DNA repair prior to entry into mitosis. Therefore, Chk1 inhibition may sensitize tumor cells to the DNA-damaging effects of certain chemotherapeutic agents. Chk1 is an ATP-dependent serine-threonine kinase that phosphorylates cdc25 phosphatases in response to DNA damage. This results in both inhibitory tyrosine phosphorylation of cyclin-dependent kinase (CDK)-cyclin complexes and cell cycle arrest, which facilitates DNA damage repair.	Chk1 Inhibitor GDC-0575		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116846>	C129826	Genetically Engineered NY-ESO-1-specific T Lymphocytes	A preparation of human T-lymphocytes recognizing the tumor-associated antigen (TAA), cancer/testis antigen 1 (NY-ESO-1), with potential immunostimulating and antineoplastic activities. Genetically engineered NY-ESO-1-specific T-lymphocytes target tumor cells expressing the NY-ESO-1 antigen, resulting in tumor cell lysis. NY-ESO-1, an antigen found in normal testis, is overexpressed on the surface of various tumor cell types.	Genetically Engineered NY-ESO-1-specific T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116847>	C308|C213678	Anti-NY-ESO-1 Immunotherapeutic GSK-2241658A|CTAG1A ASCI|GSK-2241658A|GSK2241658A|GSK2241658A Antigen-Specific Cancer Immunotherapeutic	An immunotherapeutic agent targeting the tumor-associated antigen (TAA), cancer/testis antigen NY-ESO-1, with potential antineoplastic activity.	Anti-NY-ESO-1 Immunotherapeutic GSK-2241658A		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116848>	C308	Anti-PRAME Immunotherapeutic GSK2302032A|GSK-2302032A|GSK2302032A|PRAME ASCI	An immunotherapeutic agent targeting the tumor-associated antigen (TAA), preferentially expressed antigen of melanoma (PRAME), with potential antineoplastic activity.	Anti-PRAME Immunotherapeutic GSK2302032A		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116849>	C1404	GSK-3 Inhibitor LY2090314|3-(9-Fluoro-2-(piperidine-1-carbonyl)-1,2,3,4-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-7-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-1H-pyrrole-2,5-dione|LY 2090314|LY-2090314|LY-2090314|LY2090314	An inhibitor of glycogen synthase kinase-3 (GSK-3), with potential antineoplastic activity. Upon administration, LY2090314 binds to and inhibits GSK-3 in an ATP-competitive manner. This prevents GSK-3-mediated phosphorylation of beta-catenin, which inhibits the subsequent ubiquitination and proteasomal degradation of beta-catenin. This leads to the activation of the Wnt/beta-catenin pathway and the induction of apoptosis in susceptible tumor cells. GSK-3, a serine/threonine kinase, plays a key role in numerous pathways involved in protein synthesis, cellular proliferation, differentiation, and apoptosis. The Wnt/beta-catenin signaling pathway plays key roles in both cellular proliferation and differentiation. The increased expression of beta-catenin, a transcriptional activator, correlates with decreased cellular proliferation and improved prognosis in select cancers.	GSK-3 Inhibitor LY2090314		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11684>	C61063	gp100 Antigen/Montanide ISA-51/Sargramostim/Tyrosinase Peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116850>	C1946|C129825	HDAC Inhibitor REC-2282|(S)-N-hydroxy-4-(3-methyl-2-phenylbutanamido)benzamide|AR-42|HDAC-42|OSU-HDAC42|REC-2282|REC-2282	An orally available phenylbutyrate-derived histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon oral administration, REC-2282 inhibits the catalytic activity of HDAC, which results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. This leads to the inhibition of tumor oncogene transcription, and the selective transcription of tumor suppressor genes, which inhibits tumor cell division and induces tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins.	HDAC Inhibitor REC-2282		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116851>	C156880	Hsp90 Inhibitor DS-2248|DS-2248|DS-2248|Heat Shock Protein 90 Inhibitor DS-2248	An orally active and small molecule inhibitor of heat shock protein 90 (Hsp90), with potential antineoplastic activity. Upon oral administration, Hsp90 inhibitor DS-2248 specifically blocks Hsp90, which inhibits its chaperone function and promotes the proteasomal degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. This may lead to an inhibition of tumor cell proliferation. Hsp90, a chaperone complex protein upregulated in a variety of tumor cell types, regulates the folding and degradation of many oncogenic signaling proteins.	Hsp90 Inhibitor DS-2248		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116852>	C20401	Bimagrumab|BIMAGRUMAB|BYM338|HuCAL-based Antibody BYM338|Human Combinatorial Antibody Library-based Monoclonal Antibody BYM338	A human monoclonal antibody directed against type II activin receptors (ActRII; ActR2), with potential muscle-sparing and anti-cachectic activities. Upon administration, bimagrumab binds to ActRII, which prevents the binding of the natural ligands, myostatin and activin, to activin receptors and blocks ActRII-mediated signaling. This increases protein synthesis, decreases protein degradation, stimulates skeletal muscle cell growth, and increases muscle function and strength. Overstimulation of the ActRII-mediated signaling pathway is associated with muscle loss and weakness.	Bimagrumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C116853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116853>	C2124	Hyperpolarized Carbon C 13 Pyruvate|Hyperpolarized 13C-Pyruvate|Hyperpolarized Pyruvate (13C)	A hyperpolarized pyruvate labeled with carbon C 13, with potential usage in the diagnostic imaging of cancer cells. Upon administration, carbon C 13 hyperpolarized pyruvate (13C-pyruvate) is taken up by cancer cells and is further metabolized to lactate and alanine for use in glycolysis, lipogenesis and protein synthesis, to support the enhanced metabolic needs of tumor cells. As tumor cells are rapidly proliferating, their uptake of pyruvate and its subsequent conversion to alanine and lactate are higher than non-proliferating cells. Upon nuclear magnetic resonance (NMR)-based imaging (MRI), both hyperpolarized 13C-pyruvate as well as its metabolites can be detected and visualized in cancer cells; this may aid in the diagnosis of cancer. Hyperpolarization of 13C-pyruvate, using dynamic nuclear polarization (DNP), enhances NMR signals.	Hyperpolarized Carbon C 13 Pyruvate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C116854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116854>	C67413	Immediate-release Oxymorphone Hydrochloride Liquid Formulation|Opana IR	An orally bioavailable, immediate-release (IR), liquid formulation containing the hydrochloride salt form of oxymorphone, a semisynthetic opioid with potent analgesic activity. Upon oral administration, oxymorphone binds to and activates opioid receptors, specifically mu-receptors, in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids and providing analgesia.	Immediate-release Oxymorphone Hydrochloride Liquid Formulation		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C116855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116855>	C129825|C129650	Itacitinib|3-Azetidineacetonitrile, 1-(1-((3-Fluoro-2-(trifluoromethyl)-4-pyridinyl)carbonyl)-4-piperidinyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)-|INCB 039110|INCB-039110|INCB039110|ITACITINIB	An orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1) with potential antineoplastic and immunomodulating activities. Upon oral administration, itacitinib selectively inhibits JAK-1, thereby inhibiting the phosphorylation of signal transducer and activator of transcription (STAT) proteins and the production of proinflammatory factors induced by other cytokines, including interleukin-23 (IL-23) and interleukin-6 (IL-6). The JAK-STAT pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.	Itacitinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116856>	C2124	Indium In 111-labeled Macroaggregated Albumin|In-111-labeled Macroaggregated Albumin	A radiopharmaceutical formulation containing human, serum albumin (HSA) labeled with indium In 111 (In-111) in macroaggregates (MAA) with potential usage as a diagnostic imaging agent. Upon injection of indium In 111-labeled macroaggregated albumin and subsequent imaging, biodistribution patterns can be assessed and the expected distribution of agents with similar particle sizes may be predicted.	Indium In 111-labeled Macroaggregated Albumin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C116857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116857>	C129825|C125450	Gandotinib|3-(4-Chloro-2-fluorobenzyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-8-(Morpholinomethyl)imidazo(1,2-b)pyridazin-6-amine|GANDOTINIB|LY 2784544|LY2784544	An orally bioavailable imidazopyridazine and inhibitor of Janus kinase 2 mutant V617F (JAK2V617F), with potential antineoplastic activity. Upon oral administration, gandotinib selectively and competitively inhibits the activation of JAK2V617F, which may result in the inhibition of the JAK-STAT signaling pathway and the induction of apoptosis in JAK2V617F-expressing tumor cells. JAK2V617F has a substitution of phenylalanine for valine at amino acid position 617 and plays a key role in tumor cell proliferation and survival.	Gandotinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116858>	C62556|C129825|C124800	FLT3/ABL/Aurora Kinase Inhibitor KW-2449|KW-2449|KW-2449	An orally available inhibitor of FMS-related tyrosine kinase 3 (FLT3, STK1, or FLK2), the tyrosine kinase ABL, and aurora kinases, with potential antineoplastic activity. Upon administration, FLT3/ABL/Aurora kinase inhibitor KW-2449 specifically binds to and inhibits both wild-type and mutated forms of FLT3, ABL and aurora kinases, which both interferes with the activation of signal transduction pathways mediated by these kinases and reduces the proliferation of susceptible cancer cells. FLT3 and ABL kinases are upregulated in certain tumor cells and play important roles in tumor cell proliferation and metastasis. Aurora kinases, serine-threonine kinases overexpressed by a wide variety of cancer cell types, play essential roles in mitotic checkpoint control.	FLT3/ABL/Aurora Kinase Inhibitor KW-2449		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116859>	C93144	Lawsonia inermis-based Supplement|Henna-based Supplement		Lawsonia inermis-based Supplement		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C11685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11685>	C61063	Interleukin-12/MART-1 Antigen/Montanide ISA-51			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116860>	C202063	Porcupine Inhibitor WNT974|2-(2,3-Dimethyl-[2,4-bipyridin]-5-yl)-N-(5-(pyrazin-2-yl)pyridin-2-yl)acetamide|LGK 974|LGK-974|LGK974|PORCN inhibitor LGK974|WNT 974|WNT-974|WNT974	An orally available inhibitor of porcupine (PORCN), with potential antineoplastic activity. Upon oral administration, WNT974 binds to and inhibits PORCN in the endoplasmic reticulum (ER), which blocks post-translational acylation of Wnt ligands and inhibits their secretion. This prevents the activation of Wnt ligands, interferes with Wnt-mediated signaling, and inhibits cell growth in Wnt-driven tumors. Porcupine, a membrane-bound O-acyltransferase (MBOAT), is required for the palmitoylation of Wnt ligands, and plays a key role in Wnt ligand secretion and activity. Wnt signaling is dysregulated in a variety of cancers.	Porcupine Inhibitor WNT974		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116861>	C2336	Pan-RAF Inhibitor LY3009120|DP-4978|LY-3009120|LY-3009120|LY3009120	An orally available inhibitor of all members of the serine/threonine protein kinase Raf family, including A-Raf, B-Raf and C-Raf protein kinases, with potential antineoplastic activity. Upon administration, pan-RAF kinase inhibitor LY3009120 inhibits Raf-mediated signal transduction pathways, which may inhibit tumor cell growth. Raf protein kinases play a key role in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway, which is often dysregulated in human cancers and plays a key role in tumor cell proliferation and survival.	Pan-RAF Inhibitor LY3009120		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116862>	C28681|C138180|C129826	MAGE-A3/12-specific TCR Gene-transduced Autologous PBLs|Anti-MAGE A3/12 TCR PBLs|MAGE-A3/12-specific T Cell Receptor Gene-transduced Autologous Peripheral Blood Lymphocytes|MAGE-A3/12-specific T-Cell Receptor Gene-transduced Autologous Peripheral Blood Lymphocytes	Human autologous peripheral blood lymphocytes (PBLs) transduced with a retroviral vector encoding a T-cell receptor (TCR) that recognizes the human melanoma antigens A3 and A12 (MAGE-A3/12), with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the MAGE-A3/12-specific TCR gene-transduced autologous PBLs bind to and lyse tumor cells expressing MAGE-A3/12, which may halt the growth of MAGE-A3/12-expressing cancer cells. MAGE-A3 and MAGE-A12, tumor associated antigens and members of the melanoma-associated antigen gene family, are overexpressed by a variety of cancer cell types.	MAGE-A3/12-specific TCR Gene-transduced Autologous PBLs		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116863>	C133879|C129822	Vofatamab|B-701|MFGR-1877S|MFGR1877A|MFGR1877S|RG-7444|VOFATAMAB	A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the fibroblast growth factor receptor type 3 (FGFR3), with potential antineoplastic activity. Upon intravenous administration, vofatamab specifically binds to and inhibits both wild-type and mutated forms of FGFR3. This may result in the inhibition of FGFR3 phosphorylation, and thereby preventing its activation and FGFR3-mediated signal transduction pathways. This results in the inhibition of cell proliferation and the induction of cell death in FGFR3-expressing tumor cells. FGFR3, a receptor tyrosine kinase upregulated or mutated in many tumor cell types, plays a key role in tumor cell proliferation.	Vofatamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116864>	C307|C1742	Recombinant Human Apolipoprotein(a) Kringle V MG1102|MG1102|Recombinant Human Apo (a) Kringle V MG1102	An 86 amino-acid long polypeptide fragment of a recombinant form of human apolipoprotein (a) (apo(a)) kringle V, with potential anti-angiogenic and antineoplastic activities. Although the exact mechanism of action has yet to be fully elucidated, upon administration, recombinant human apo(a) kringle V MG1102 inhibits the fibronectin-mediated migration of endothelial cells, binds to and blocks the activity of alpha 3 beta 1 integrin (a3b1 integrin), inhibits the activation of focal adhesion kinase (FAK) and FAK-mediated signaling, and leads to the inhibition of the p130 Crk-associated substrate (p130CAS)-c-Jun NH2-terminal kinase (JNK) pathway. This inhibits tumor angiogenesis, induces mitochondrial-mediated apoptosis of tumor cells and tumor-associated endothelial cells, and suppresses tumor growth and metastasis. Apo(a), a glycoprotein component of human lipoprotein(a), contains repeated kringle domains; certain kringle domains of apo(a), including the plasminogen kringle V homolog (KV), have anti-angiogenic effects.	Recombinant Human Apolipoprotein(a) Kringle V MG1102		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116865>	C20401|C1742|C129822	Anti-alpha5beta1 Integrin Antibody MINT1526A|Anti-a5b1 Antibody MINT1526A|MINT-1526A|MINT1526A|RG-7594	An antibody directed against the human alpha5beta1 integrin (a5b1) with potential antiangiogenic and antineoplastic activities. Anti-a5b1 antibody MINT1526A selectively binds to a5b1, thereby preventing the binding of integrin ligands. This may result in the inhibition of endothelial cell-cell interactions, endothelial cell-matrix interactions, and integrin-mediated tumor angiogenesis and metastasis in a5b1-expressing tumor cells. a5b1, a cell adhesion and signaling receptor, is often overexpressed on the surface of tumor vessel endothelial cells and plays a crucial role in both endothelial cell adhesion and migration.	Anti-alpha5beta1 Integrin Antibody MINT1526A		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116866>	C143099|C129825	c-Met Inhibitor MK8033|1-(3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl)-N-(pyridin-2-ylmethyl)methanesulfonamide|MK 8033|MK-8033|MK-8033|MK8033	An orally bioavailable inhibitor of c-Met, with potential antineoplastic activity. Upon administration, c-Met inhibitor MK8033 binds to and inhibits the autophosphorylation of the c-Met protein, which disrupts c-Met signal transduction pathways and may induce cell death in tumor cells overexpressing or expressing constitutively activated c-Met protein. In addition, MK8033 inhibits Ron (receptor originated from nantes, MST1R). c-Met protein, which is encoded by the proto-oncogene MET, is a receptor tyrosine kinase also known as hepatocyte growth factor receptor (HGFR); this protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis. Ron, a member of the Met family of cell surface receptor tyrosine kinases, is also overexpressed on certain tumor cell types.	c-Met Inhibitor MK8033		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116867>	C162996	HDM2 Inhibitor MK-8242|MK-8242|SCH 900242	An orally bioavailable inhibitor of human homolog of double minute 2 (HDM2), with potential antineoplastic activity. Upon oral administration, HDM2 inhibitor MK-8242 inhibits the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the degradation of p53 is inhibited, which may result in the restoration of p53 signaling. This induces p53-mediated tumor cell apoptosis. HDM2 is a member of the RING finger-type family of E3 ubiquitin protein ligases and targets p53 for degradation; it is often overexpressed in cancer cells and has been implicated in cancer cell proliferation and survival.	HDM2 Inhibitor MK-8242		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116868>	C2313|C1663	Modified Vaccinia Virus Ankara Vaccine Expressing p53|MVA-p53|MVA-p53 Vaccine|MVAp53 Vaccine|p53-MVA Vaccine|p53MVA	A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the wild-type form of the tumor protein p53 (wt p53), with potential immunostimulating and antineoplastic activities. Upon subcutaneous vaccination with MVA vaccine expressing p53, the expressed p53 may stimulate the host immune system to mount a p53-specific cytotoxic T-lymphocyte (CTL) response against tumor cells expressing p53, resulting in tumor cell lysis. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attentuated, replication-defective vaccinia strain and is incapable of virion assembly. The p53 gene, a tumor suppressor gene, is mutated in many cancer cell types.	Modified Vaccinia Virus Ankara Vaccine Expressing p53		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116869>	C67437	Pegylated Liposomal Nanoparticle-based Docetaxel Prodrug MNK-010|MNK-010|MP-3549-1|Pegylated Liposomal Docetaxel Prodrug MNK-010	A formulation containing pegylated liposomal nanoparticles encapsulating a prodrug of the poorly water-soluble, second-generation taxane analog docetaxel, with potential antineoplastic activity. Upon intravenous administration of the liposomal docetaxel prodrug MNK-010, docetaxel is slowly released into the systemic circulation and accumulates at the tumor site due to the unique characteristics of the tumor's vasculature. In turn, docetaxel is taken up by tumor cells, and subsequently binds to and stabilizes the beta-subunit of tubulin, thereby stabilizing microtubules and inhibiting microtubule disassembly. This results in cell cycle arrest and induces cell death. Compared to the administration of docetaxel alone, this formulation is able to increase the delivery of docetaxel into tumors, thereby increasing docetaxel's efficacy while minimizing its toxicity. In addition, this formulation solubilizes docetaxel without the use of toxic solvents, thereby permitting the administration of larger doses of docetaxel while avoiding solvent-associated toxicity.	Pegylated Liposomal Nanoparticle-based Docetaxel Prodrug MNK-010		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11686>	C61063	HER-2-neu peptide vaccine/Montanide ISA-51			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116870>	C128057	Avelumab|AVELUMAB|Bavencio|Immunoglobulin G1-lambda1, Anti-(Homo sapiens CD274 (Programmed Death Ligand 1, PDL1, pd-l1, B7 Homolog 1, B7H1)), Homo sapiens Monoclonal Antibody|MSB 0010718C|MSB-0010718C|MSB0010718C	A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T-cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity. PD-L1, a transmembrane protein, is overexpressed on a variety of tumor cell types and is associated with poor prognosis.	Avelumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116871>	C67437|C1490	Simotaxel|5Beta,20-epoxy-1,2alpa,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one-4-acetate 2-benzoate Ester with (2R,3S)-N-Isopropoxycarbonyl-3-(2-thienyl) Isoserine|MST-997|SIMOTAXEL|TL-909|Taxane-997	A semi-synthetic, orally bioavailable, third-generation taxane derivative and microtubule-stabilizing agent, with potential antineoplastic activity. Upon administration, simotaxel binds to tubulin, promotes microtubule assembly and stabilization, and prevents microtubule depolymerization. This results in G2/M arrest, apoptosis and the inhibition of cell proliferation in susceptible tumor cells. This agent is a poor substrate for P-glycoprotein-related drug resistance mechanisms; therefore, it may be useful for treating multi-drug resistant tumors. MST-997 is more potent than paclitaxel and docetaxel and overcomes paclitaxel and docetaxel resistance in certain tumor cell types.	Simotaxel		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116872>	C200529	Osugacestat|AL 101|AL-101|AL101|BM-0018|BM0018|BMS-906024|GS/pan-Notch Inhibitor AL101|OSUGACESTAT	A small-molecule gamma secretase (GS) and pan-Notch inhibitor, with potential antineoplastic activity. Upon intravenous administration, osugacestat binds to GS and blocks activation of Notch receptors, which may inhibit the proliferation of tumor cells with an overly-active Notch pathway. The integral membrane protein GS is a multi-subunit protease complex that cleaves single-pass transmembrane proteins, such as Notch receptors, at residues within their transmembrane domains that lead to their activation. Overactivation of the Notch signaling pathway, often triggered by activating mutations, has been correlated with increased cellular proliferation and poor prognosis in certain tumor types.	Osugacestat		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116873>	C200712	STAT Inhibitor OPB-111077|OPB-111077	An orally bioavailable inhibitor of one or more signal transducer and activator of transcription (STAT) protein(s), with potential antineoplastic activity. Upon oral administration, OPB-111077 binds to and inhibits the phosphorylation of STATs. This prevents binding of STATs to DNA sequences on a variety of STAT-responsive gene promoters, which may result in the inhibition of both STAT-mediated transcription and tumor cell proliferation. STATs are constitutively activated in a variety of cancers and play a key role in tumor cell proliferation.	STAT Inhibitor OPB-111077		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116874>	C155725	Smoothened Antagonist TAK-441|6-Ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide|TAK-441|TAK-441	An orally bioavailable pyrrolopyridine derivative and Smoothened (Smo) antagonist with potential antineoplastic activity. Smo antagonist TAK-441 selectively binds to and inhibits the activity Smo, which is a cell surface co-receptor for ligands in the Hedgehog (Hh) family. This may result in a suppression of Hh-mediated signaling pathways, thereby inhibiting the growth of tumor cells in which this pathway is aberrantly activated.  Smo is a G-protein coupled receptor that lies just downstream of the Hh cell surface receptor Patched-1 in the Hh pathway; in the absence of ligand, Patched-1 (Ptch1) inhibits Smo, and ligand binding to Ptch1 results in increased levels of Smo. The Hh-mediated signaling pathways play an important role in cellular growth and differentiation, and tissue repair; constitutive activation of this pathway is associated with uncontrolled cellular proliferation in a variety of cancers.	Smoothened Antagonist TAK-441		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116876>	C202468|C129825	Taselisib|GDC-0032|RO5537381|TASELISIB	An orally bioavailable inhibitor of the class I phosphatidylinositol 3-kinase (PI3K) alpha isoform (PIK3CA), with potential antineoplastic activity. Taselisib selectively inhibits PIK3CA and its mutant forms in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PIK3CA-expressing tumor cells. By specifically targeting class I PI3K alpha, this agent may be more efficacious and less toxic than pan PI3K inhibitors. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and causes increased tumor cell growth, survival, and resistance to both chemotherapy and radiotherapy. PIK3CA, which encodes the p110-alpha catalytic subunit of the class I PI3K, is mutated in a variety of cancer cell types and plays a key role in cancer cell growth and invasion.	Taselisib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116877>	C2152|C129825	Paxalisib|GDC-0084|GDC0084|PAXALISIB|PI3K Inhibitor GDC-0084	A phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. paxalisib specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in the inhibition of both cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.	Paxalisib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116878>	C16338	Polyethylene Glycol Polymer Surgical Sealant|Adhibit|PEG Polymer Surgical Sealant	A resorbable hydrogel-based formulation containing synthetic, derivatized polyethylene glycol (PEG) polymers, with anti-adhesion activity upon wound application during surgery. Upon application of the PEG polymer surgical sealant to the wound during surgery using a spray, the PEG polymers polymerize and adhere to the wound tissue, thereby forming a protective barrier. This prevents post-operative adhesion formation.	Polyethylene Glycol Polymer Surgical Sealant		Biomedical or Dental Material	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C116879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116879>	C213309|C204256	Recombinant Adenovirus 5 Encoding Tumor Necrosis Factor-related Apoptosis-Inducing Ligand|Ad5-TNFSF10|Ad5-TRAIL	An adenovirus type 5 (Ad5) encoding human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), with potential apoptosis-inducing and antineoplastic activities. Upon administration of recombinant Ad5 encoding TRAIL, the adenovirus selectively infects tumor cells and expresses TRAIL. The virally expressed TRAIL binds to and activates its receptors TRAIL receptor-1 (TRAIL-R1, death receptor 4, DR4) and TRAIL receptor-2 (TRAIL-R2, death receptor 5, DR5), which subsequently activate caspases and induce apoptosis in TRAIL-R1/R2-expressing tumor cells. The pro-apoptotic cell surface receptors TRAIL-R1 and -R2, members of the TNF receptor family, are overexpressed by a variety of cancer cell types.	Recombinant Adenovirus 5 Encoding Tumor Necrosis Factor-related Apoptosis-Inducing Ligand		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11687>	C61063	Bcr-Abl Peptide Vaccine/QS21			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116880>	C1752|C1663	Recombinant Anti-WT1 Immunotherapeutic GSK2302024A|ASCI GSK2302024A|GSK2302024A	An immunotherapeutic composed of the Wilms tumor 1 (WT1) and an as of yet undisclosed adjuvant, with potential antineoplastic activity. Upon administration, the immune system may be stimulated to exert a cytotoxic T-lymphocyte (CTL) response against WT1-expressing tumor cells. The adjuvant stimulates the immune system's response to WT1. WT1, a tumor-associated antigen (TAA) and transcription factor, is overexpressed in a variety of tumor cell types.	Recombinant Anti-WT1 Immunotherapeutic GSK2302024A		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116881>	C20401|C129822	Anti-CD44 Monoclonal Antibody RO5429083|RG 7356|RO-5429083|RO5429083	A recombinant, humanized monoclonal antibody targeting the cancer stem cell (CSC) antigen CD44, with potential immunomodulating and antineoplastic activities. Upon administration, RO5429083 binds to the constant region of the extracellular domain of CD44, thereby preventing the activation of various CD44-mediated signal transduction pathways. This may lead to a reduction in the proliferation of CD44-expressing tumor stem cells. CD44, a transmembrane glycoprotein and hyaluronic acid receptor, is expressed in healthy tissue and overexpressed in numerous cancer cell types; it plays a key role in tumor cell proliferation, migration and survival.	Anti-CD44 Monoclonal Antibody RO5429083		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116882>	C2152|C129825	PI3K-beta Inhibitor SAR260301|(S)-2-(2-(2-Methylindolin-1-yl)-2-oxoethyl)-6-morpholinopyrimidin-4(3H)-one|SAR 260301|SAR-260301|SAR-260301|SAR260301	An orally bioavailable inhibitor of the class I phosphatidylinositol 3-kinase (PI3K) beta isoform with potential antineoplastic activity. PI3K beta inhibitor SAR260301 selectively inhibits PI3K beta kinase activity in the PI3K/Akt/mTOR pathway, which may result in apoptosis and growth inhibition in PI3K beta-expressing and/or phosphatase and tensin homolog (PTEN)-deficient tumor cells. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and contributes to increased tumor cell growth, tumor cell survival, and resistance to both chemotherapy and radiotherapy. PI3K beta is the p110-beta catalytic subunit of the class I PI3K. PTEN, a tumor suppressor protein and negative regulator of PI3K activity, is often mutated in a variety of cancer cells. By specifically targeting class I PI3K beta, this agent may be more efficacious and less toxic than pan-PI3K inhibitors.	PI3K-beta Inhibitor SAR260301		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116883>	C78276|C308|C307	Serum-derived Bovine Immunoglobulin Protein Isolate|EnteraGam|SBI|Serum Bovine Immunoglobulin	A nutritional supplement composed of serum-derived bovine protein concentrate containing high levels of immunoglobulins (Ig), particularly IgG, with the potential to improve nutritional status. Upon oral administration of SBI, the Ig promotes gastrointestinal (GI) health by improving the composition of the GI microflora, enhancing digestive processes, and increasing gut barrier integrity and function. SBI may also improve immune function, maintain immune homeostasis, bind to and neutralize bacterial toxins and antigens, and decrease intestinal inflammation. Altogether, this may enhance the functioning of the GI tract, improve both the digestion and absorption of nutrients, and increase weight gain.	Serum-derived Bovine Immunoglobulin Protein Isolate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C116884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116884>	C1450	Sustained-release Lipid Inhaled Cisplatin|SLIT Cisplatin|SR Inhaled Lipid Cisplatin|Sustained-release Lipid Inhalation Targeting Cisplatin	A sustained-release formulation for inhalation in which the inorganic platinum (Pt) agent cisplatin is encapsulated in lipids, with potential antineoplastic activity. Upon inhalation of the sustained-release lipid inhalation targeting (SLIT) cisplatin into the lungs, this agent forms highly reactive, positively charged, Pt complexes, which covalently bind to nucleophilic groups in DNA, preferably at the N7 position of guanine bases. Pt complex binding introduces intrastrand and interstrand DNA cross-links, and DNA-Pt-protein cross-links. These cross-links result in apoptosis and cell growth inhibition of lung cancer cells. Encasement in liposomes prolongs cisplatin's efficacy when compared to intravenously administered cisplatin; inhalation of cisplatin improves its concentration at tumor sites in the lungs while minimizing its systemic toxicity.	Sustained-release Lipid Inhaled Cisplatin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116885>	C471	dUTPase/DPD Inhibitor TAS-114|TAS-114	An orally bioavailable inhibitor of both deoxyuridine triphosphatase (dUTPase) and dihydropyrimidine dehydrogenase (DPD), with potential antineoplastic adjuvant activity. Upon oral administration in combination with a prodrug of the pyrimidine antagonist 5-fluorouracil (5-FU), TAS-114 inhibits (DPD), the liver enzyme responsible for rapid catabolism of 5-FU into inactive metabolites. This prevents first-pass metabolism of 5-FU, allowing oral administration of the 5-FU prodrug and increasing the efficacy of 5-FU. In addition, as a dUTPase inhibitor, TAS-114 enhances the antitumor activity of 5-FU by preventing the hydrolysis and breakdown of 5-fluoro-deoxyuridine triphosphate (FdUTP) and deoxyuridine triphosphate (dUTP), which are active metabolites of 5-FU. This promotes DNA polymerase-dependent incorporation of these antimetabolites into DNA and leads to DNA damage and tumor cell death. Co-administration with TAS-114 allows lower dosing of 5-FU prodrugs, which decreases 5-FU-related toxicity, while maintaining therapeutic levels of 5-FU at the tumor site.	dUTPase/DPD Inhibitor TAS-114		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116886>	C307|C214800	DR5-targeting Tetrameric Nanobody Agonist TAS266|TAS-266|TAS266|Tetrameric Nanobody Agonist-targeting death receptor 5 TAS266	An agonistic tetravalent nanobody, in which the four single, high affinity heavy chain variable domain (VHH) antibodies are separated by a peptide linker, targeting death receptor type 5 (DR5), with potential antineoplastic activity. Upon administration, DR5-targeting tetrameric nanobody agonist TAS266, with its four DR5-specific single-chain antibodies, specifically binds to and activates DR5 receptors. This results in the activation of caspase cascades and induction of apoptosis in DR5-expressing tumor cells. DR5, a cell surface receptor and member of the tumor necrosis factor (TNF)-receptor superfamily, triggers apoptosis. Compared to certain anti-DR5 antibody agonists, TAS266 shows increased receptor activation.	DR5-targeting Tetrameric Nanobody Agonist TAS266		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116887>	C2124	Technetium Tc 99m Trofolastat|99mTc-MIP 1404|99mTc-MIP-1404|TECHNETIUM TC-99M TROFOLASTAT CATION	A radioconjugate composed of an urea-based human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the gamma-emitting radioisotope technetium Tc 99m, with potential use as a tracer for PSMA-expressing tumors using single photon emission computed tomography/computed tomography (SPECT/CT). Upon intravenous administration of the technetium Tc 99m trofolastat, the trofolastat moiety targets and binds to PSMA-expressing tumor cells. Upon internalization, PSMA-expressing tumor cells can be detected during SPECT/CT imaging. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.	Technetium Tc 99m Trofolastat		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C116888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116888>	C28310|C181141	hTERT-LAMP mRNA-loaded Autologous Dendritic Cell Vaccine GRNVAC1|GRNVAC1|hTERT-LAMP mRNA-loaded Autologous DC Vaccine GRNVAC1	A cancer vaccine containing autologous dendritic cells (DCs) that are pulsed with mRNA encoding the tumor-associated antigens (TAAs) human telomerase reverse transcriptase (hTERT) and lysosome-associated membrane protein 1 (LAMP1), with potential immunostimulatory and antineoplastic activities. Upon administration, hTERT-LAMP mRNA-loaded autologous DC Vaccine GRNVAC1 may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing hTERT and LAMP1. hTERT, the catalytic subunit of human telomerase, is upregulated in certain tumor cell types and plays an important role in tumor cell growth and survival. LAMP1, overexpressed on a variety of tumor cells, plays a key role in cell-cell adhesion and migration.	hTERT-LAMP mRNA-loaded Autologous Dendritic Cell Vaccine GRNVAC1		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C116889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116889>	C273	Lipid Encapsulated Anti-PLK1 siRNA TKM-PLK1|PLK1 SNALP|PLK1424|TKM-080301|TKM-PLK1	short interfering RNAs (siRNAs) directed against polo-like kinase 1 (PLK1, STPK13), with potential antineoplastic activity. Upon administration of lipid-encapsulated anti-PLK1 siRNA TKM-PLK1, siRNA binds to PLK1 mRNA, which results in the inhibition of both the translation and expression of the PLK1 protein. Blockage of PLK1 expression prevents proper tumor cell mitosis, causes cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of PLK1-overexpressing tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase crucial in the regulation of mitosis; its expression is upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation. The pegylated lipid bilayer of SNALP provides stability and protects siRNA degradation; it facilitates uptake into the cell and release from endosomes.	Lipid Encapsulated Anti-PLK1 siRNA TKM-PLK1		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11688>	C61063	E7(86-93) Lipopeptide/HPV-16 E7(12-20) Peptide Vaccine/Montanide ISA-51			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116890>	C1904	Nanoparticle Albumin-bound Thiocolchicine Dimer nab-5404|ABI-011|IDN 5404|IDN-5404|NTB-011|nab-5404|nab-Thiocolchicine Dimer	A nanoparticle albumin-bound formulation of a thiocolchicine dimer, an inhibitor of both microtubule and topoisomerase I (TOP1), with antineoplastic and vascular disrupting activities. Upon administration of nanoparticle albumin-bound thiocolchicine dimer nab-5404, this agent binds to tubulin and inhibits its polymerization, which blocks mitotic spindle formation and leads to cell cycle arrest and tumor endothelial cell apoptosis. This disrupts the tumor vasculature and leads to tumor necrosis. In addition, nab-5404 binds to topoisomerase I (TOPI) and inhibits its activity. This results in the inhibition of the repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations. The nanoparticle albumin-based formulation permits the albumin-mediated endocytosis of the thiocolchicine dimer by tumor cells and endothelial cells.	Nanoparticle Albumin-bound Thiocolchicine Dimer nab-5404		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116891>	C210989	Galunisertib|4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide|GALUNISERTIB|LY-2157299|LY2157299	An orally available, small molecule antagonist of the tyrosine kinase transforming growth factor-beta (TGF-b) receptor type 1 (TGFBR1), with potential antineoplastic activity. Upon administration, galunisertib specifically targets and binds to the kinase domain of TGFBR1, thereby preventing the activation of TGF-b-mediated signaling pathways. This may inhibit the proliferation of TGF-b-overexpressing tumor cells. Dysregulation of the TGF-b signaling pathway is seen in a number of cancers and is associated with increased cancer cell proliferation, migration, invasion and tumor progression.	Galunisertib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116894>	C93259|C213472|C212990|C159199|C155727|C124800	FGFR/VEGFR/PDGFR/FLT3/SRC Inhibitor XL999|SSKI XL999|Spectrum Selective Kinase Inhibitor XL999|XL-999|XL-999|XL999	A small molecule inhibitor of numerous tyrosine kinases (TKs) including fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), FMS-related tyrosine kinase 3 (FLT3), and SRC, with potential antineoplastic activity. Upon administration, XL999 binds to and inhibits the activity of these TKs, thereby preventing both the activation of downstream signaling pathways and the proliferation of tumor cells overexpressing these TKs. FGFR, VEGFR, PDGFR, FLT-3, and SRC are upregulated in a variety of cancer cell types and play key roles in tumor cell proliferation, angiogenesis, and metastasis.	FGFR/VEGFR/PDGFR/FLT3/SRC Inhibitor XL999		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116895>	C78221	Craniotabes	Softening of the skull seen in newborns due to incomplete mineralization.			Finding	NICHD Terminology|Perinatal Terminology
C116896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116896>	C110937	Cranial Suture Separation|Cranial Suture Widening|Cranial Sutures Widening	A finding of increased space between the intersections of a newborn's cranial bones.			Finding	NICHD Terminology|Perinatal Terminology
C116897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116897>	C118807	Fontanelle Bulging|Bulging Fontanel|Bulging Fontanel|Fontanel Bulging	Membranous areas between cranial bones in a newborn that appear elevated or full.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C116898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116898>	C118807	Fontanelle Depressed|Depressed Fontanel|Depressed Fontanel|Fontanel Depressed	Membranous areas between cranial bones in a newborn that appear depressed or sunken.			Finding	NICHD Terminology|Perinatal Terminology
C11689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11689>	C61063	Mutant p53 peptide pulsed dendritic cell vaccine/Sargramostim			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1168>	C49109	Diethylnorspermine|CI-1006|DENSPM|DIETHYLNORSPERMINE|N(1),N(11)-diethylnorspermine|N1,N11-bis(ethyl)norspermine	A synthetic bis-ethyl analogue of spermine with potential antineoplastic activity. N(1),N(11)-bis(ethyl)norspermine (DENSPM), a N-terminally alkylated tetraamine and polyamine mimetics, disrupts polyamine pool homeostasis by modulating the activities of the biosynthetic enzymes, ornithine decarboxylase (ODC), and S-adenosylmethionine decarboxylase (AdoMetDC). This agent also reduces polyamine concentrations through the induction of the catabolic enzyme spermidine/spermine N1-acetyltransferase 1 (SSAT). Polyamines, an integral part of the DNA helix structure, play a critical role in cell division, differentiation and membrane function. Disruption of normal polyamine concentrations by DENSPM may lead to cell growth inhibition.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116900>	C99017	Phrenic Nerve Palsy Related to Birth	A condition characterized by reduced or absent movement of the ipsilateral diaphragm as a consequence of an injury to the phrenic nerve or its origin in cervical roots 3 through 5 sustained during the birthing process.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C116901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116901>	C26769	Facial Nerve Palsy Related to Birth	A condition characterized by reduced or absent movement of the ipsilateral face as a consequence of an injury to the seventh cranial nerve sustained during the birthing process.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C116902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116902>	C26769	Acquired Facial Nerve Palsy	A condition characterized by reduced or absent movement of the ipsilateral face as a consequence of an injury to the seventh cranial nerve that has occurred after birth.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C116903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116903>	C34460	Spastic Cerebral Palsy	A type of cerebral palsy characterized by increased muscle tone.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C116904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116904>	C34460	Spastic Quadriplegia|Spastic quadriplegic cerebral palsy	A type of spastic cerebral palsy characterized by increased muscle tone of all four extremities.			Disease or Syndrome	mCode Elixhauser Paralysis Value Set|mCode Terminology|NICHD Terminology|Perinatal Terminology
C116905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116905>	C34460	Spastic Hemiplegia|Spastic hemiplegia affecting unspecified side|Spastic hemiplegic cerebral palsy	A type of spastic cerebral palsy characterized by increased muscle tone of the arm and leg on the same side of the body.			Disease or Syndrome	mCode Elixhauser Paralysis Value Set|mCode Terminology|NICHD Terminology|Perinatal Terminology
C116906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116906>	C34460	Hypotonic Cerebral Palsy	A type of cerebral palsy characterized by decreased muscle tone.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C116907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116907>	C50761	Subgaleal Hemorrhage Related to Birth|Epicranial Subaponeurotic Hemorrhage Related to Birth|Epicranial Subaponeurotic Hemorrhage Related to Birth	Bleeding in the potential space between the skull periosteum and the scalp galea aponeurosis of a newborn infant due to shearing forces on the tentorium and deep venous system during labor and delivery.			Finding	NICHD Terminology|Perinatal Terminology
C116908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116908>	C50446	Intracranial Laceration Related to Birth	Tearing of the cerebral or cerebellar parenchyma or vessels of a newborn infant due to forces occurring during labor and delivery.			Injury or Poisoning	NICHD Terminology|Perinatal Terminology
C116909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116909>	C50485	Cerebral Hemorrhage Related to Birth	Intracranial bleeding in the tissue of the cerebrum of a newborn infant occurring during labor and/or delivery.			Finding	NICHD Terminology|Perinatal Terminology
C11690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11690>	C61063	Montanide ISA-51/p53 peptide vaccine/Sargramostim			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116910>	C99261	Intracranial Hemorrhage Related to Birth	Bleeding within the skull of a newborn infant occurring during labor and/or delivery.			Finding	NICHD Terminology|Perinatal Terminology
C116911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116911>	C101324	Intraventricular Hemorrhage Related to Birth	Bleeding into the cerebral ventricles that occurs during labor and/or delivery.			Finding	NICHD Terminology|Perinatal Terminology
C116912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116912>	C101324	Intraventricular Hemorrhage of Prematurity	Bleeding within the cerebral ventricles in a preterm infant.			Finding	NICHD Terminology|Perinatal Terminology
C116913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116913>	C28310	Total Tumor RNA-loaded Dendritic Cell Vaccine|TTRNA-loaded DC Vaccine	A cancer vaccine containing autologous dendritic cells (DCs) that are loaded with total tumor RNA (TTRNA) from a specific tumor, with potential immunostimulatory and antineoplastic activities. Upon administration, TTRNA-loaded DC vaccine may elicit a highly specific cytotoxic T-cell (CTL) response against the tumor-associated antigens (TAAs) encoded by the TTRNA.	Total Tumor RNA-loaded Dendritic Cell Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116914>	C200766|C176018	Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes	A preparation of genetically modified CD8+ central memory (Tcm) and CD4+ autologous T-lymphocytes (1:1) transduced with a replication incompetent, self-inactivating (SIN) lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-CD19 single chain variable fragment (scFv) derived from the murine IgG1 monoclonal antibody (mAb) FMC63, fused to the signaling domain of 4-1BB (CD137), the zeta chain of the TCR/CD3 complex (CD3-zeta), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T lymphocytes are directed to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a cetuximab-induced antibody dependent cellular cytotoxicity response. The 4-1BB costimulatory signaling domain enhances both proliferation of T-cells and antitumor activity.	Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C116915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116915>	C7062	Liquid Tumor|Blood Cancer|Blood Cancer	A malignant tumor that originates from myeloid or lymphoid cells i.e., leukemias and lymphomas.			Neoplastic Process	GDC Terminology|GDC Value Terminology
C116916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116916>	C28193	Progressive Hemifacial Atrophy|Parry-Romberg Syndrome|Parry-Romberg Syndrome	A rare disorder of unknown etiology, which is characterized by slowly progressive, unilateral facial atrophy of the skin, soft tissue, muscles, and underlying bony structures. Neurological, ocular, and oral symptoms are also often seen, including migraines, trigeminal neuralgia, enophthalmos, and dental and gingival abnormalities.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C116917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116917>	C2889|C28193	Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis Syndrome|Marshall Syndrome|Marshall Syndrome|PFAPA Syndrome|PFAPA Syndrome	An autoinflammatory syndrome of childhood which often resolves in adolescence, and is characterized by periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis. The fever cycle generally occurs every three to five weeks, and during the interim periods the child appears healthy; diagnosis is exclusionary.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C116918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116918>	C12679	Pulmonary Trunk|Main Pulmonary Artery|PULMONARY TRUNK	An artery arising from the right ventricle of the heart that bifurcates into the left and right pulmonary arteries.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C116919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116919>	C99383|C27153	Central Nervous System Lupus|CNS Lupus|CNS Lupus	Inflammation that includes the brain, spinal cord and surrounding tissues secondary to systemic lupus erythematosus (SLE); it is associated with neurological and/or psychiatric features.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C11691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11691>	C61063	gp100 Antigen/MART-1 Antigen/Tyrosinase Peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116920>	C1752	Montanide ISA-51/Survivin Peptide Vaccine		Montanide ISA-51/Survivin Peptide Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C116921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116921>	C36280	Cognitive Impairment|Cognitive difficulty	Diminished mental function.			Finding	NICHD Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116922>	C4876	Parkinsonism|Parkinsonian Symptoms|Parkinsonian Symptoms	One or more of the following symptoms including bradykinesia associated with rigidity, resting tremor, gait disturbance, which may be due to multiple etiologies.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116923>	C110937	Akinesia	Lack of movement.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116924>	C110937	Myoclonus	A rapid, involuntary jerk of a muscle or group of muscles.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116925>	C116731	Motor Stereotypy|Motor Stereotypies	Persistent volitional repetition of non-purposeful movement.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116926>	C116345	Acute Inflammatory Demyelinating Polyradiculoneuropathy|AIDP|Acute Inflammatory Demyelinating Polyradiculopathy|Acute Inflammatory Demyelinating Polyradiculopathy	A subtype of Guillain-Barre syndrome that targets the myelin sheath, and is characterized by progressive weakness, distal paresthesia and autonomic dysfunction.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116927>	C116345	Acute Motor and Sensory Axonal Neuropathy|Acute Motor And Sensory Axonal Neuropathy|Acute Motor-Sensory Axonal Neuropathy|Acute Motor-Sensory Axonal Neuropathy	A subtype of Guillain-Barre syndrome that targets sensory motor axons, and is characterized by acute onset of quadriparesis, distal sensory loss, areflexia, and respiratory insufficiency.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116928>	C521	Fluocinonide Cream	A topical cream containing the synthetic glucocorticoid fluocinonide, with anti-inflammatory and antipruritic activities. Upon administration of the fluocinonide cream to the affected area(s), fluocinonide binds to the cytosolic glucocorticoid receptor, followed by translocation of the ligand-receptor complex to the nucleus and transcription activation of genes containing glucocorticoid-responsive elements (GREs), which increases the expression of specific target genes, such as lipocortin-1 (annexin A1). The induction of lipocortin-1 expression by fluocinonide leads to an increased interaction and inhibition of cytosolic phospholipase 2 alpha, thereby preventing phospholipase translocation to the perinuclear membrane and subsequent release and conversion of arachidonic acid to inflammatory prostaglandins and leukotrienes. This may relieve symptoms associated with skin inflammation.	Fluocinonide Cream		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C116929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116929>	C116345	Acute Motor Axonal Neuropathy|AMAN	A subtype of Guillain-Barre syndrome that targets motor axons, and is characterized by symmetric limb weakness, diffuse areflexia, facial and oropharyngeal muscle weakness, and respiratory insufficiency.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11692>	C61063	Carboplatin/Vinorelbine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116930>	C20813	RAD51D Gene|RAD51 Paralog D Gene|RAD51D|RAD51D	This gene plays a role in homologous recombination for DNA repair.	RAD51D Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116931>	C116930	RAD51D wt Allele|BROVCA4|HsTRAD|R51H3|RAD51 (S. cerevisiae)-Like 3 Gene|RAD51 Paralog D wt Allele|RAD51, S. cerevisiae, Homolog of, D Gene|RAD51-Like 3 (S. cerevisiae) Gene|RAD51L3|S. cerevisiae RAD51-Like 3 Gene|TRAD	Human RAD51D wild-type allele is located in the vicinity of 17q11 and is approximately 22 kb in length. This allele, which encodes DNA repair protein RAD51 homolog 4 protein, is involved in DNA repair. Mutation of the gene is associated with susceptibility to familial breast-ovarian cancer type 4.	RAD51D wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116932>	C21170	DNA Repair Protein RAD51 Homolog 4|R51H3|RAD51 Homolog D|RAD51-Like Protein 3|RAD51D|TRAD	DNA repair protein RAD51 homolog 4 (328 aa, ~35 kDa) is encoded by the human RAD51D gene. This protein plays a role in homologous recombination repair.	DNA Repair Protein RAD51 Homolog 4		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116933>	C96412|C28193	Double Cortex Syndrome|Subcortical Band Heterotopia|Subcortical Band Heterotopia	A developmental brain abnormality characterized by atypical migration of neurons during cortical development.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116934>	C25870	CHST3 Gene|CHST3|CHST3|Carbohydrate (Chondroitin 6) Sulfotransferase 3 Gene	This gene is involved in proteoglycan sulfation.	CHST3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116935>	C116934	CHST3 wt Allele|C6ST|C6ST1|Carbohydrate (Chondroitin 6) Sulfotransferase 3 wt Allele|HSD	Human CHST3 wild-type allele is located in the vicinity of 10q22.1 and is approximately 49 kb in length. This allele, which encodes carbohydrate sulfotransferase 3 protein, plays a role in the metabolism of proteoglycans. Mutation of the gene is associated with spondyloepiphyseal dysplasia with congenital joint dislocations.	CHST3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116936>	C97172	Polymicrogyria	A developmental brain abnormality characterized by an excessive amount of small convolutions on the surface of the brain and cognitive dysfunction.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116937>	C17210	Carbohydrate Sulfotransferase 3|C6ST-1|CHST3|Chondroitin 6-O-Sulfotransferase 1|Chondroitin 6-Sulfotransferase|EC 2.8.2.17|GST-0|Galactose/N-Acetylglucosamine/N-Acetylglucosamine 6-O-Sulfotransferase 0	Carbohydrate sulfotransferase 3 (479 aa, ~55 kDa) is encoded by the human CHST3 gene. This protein is involved in chondroitin sulfate biosynthesis.	Carbohydrate Sulfotransferase 3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116938>	C76243|C15780	CDK4/6 Inhibition|Cyclin-Dependent Kinases 4 and 6 Inhibition	Inhibition of cyclin-dependent kinases 4 and 6 pathway activity to prevent proliferation of cancer cells and tumor growth.			Therapeutic or Preventive Procedure	GDC Terminology|GDC Value Terminology
C116939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116939>	C76243|C62721|C15780	FGFR Inhibition|Fibroblastic Growth Factor Receptor Inhibition	Inhibition of fibroblastic growth factor receptor signaling pathway activity to prevent tumor growth.			Therapeutic or Preventive Procedure	
C11693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11693>	C61063	Fluorouracil/Gemcitabine/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116940>	C25870	SULT1C2 Gene|SULT1C2|SULT1C2|Sulfotransferase Family, Cytosolic, 1C, Member 2 Gene	This gene plays a role in the metabolism of small molecules and purine ribonucleotides.	SULT1C2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116941>	C116940	SULT1C2 wt Allele|ST1C1|ST1C2|SULT1C1|Sulfotransferase Family 1C, Member 1 Gene|Sulfotransferase Family 1C, Member 2 Gene|Sulfotransferase Family, Cytosolic, 1C, Member 1 Gene|Sulfotransferase Family, Cytosolic, 1C, Member 2 wt Allele|humSULTC2	Human SULT1C2 wild-type allele is located in the vicinity of 2q12.3 and is approximately 21 kb in length. This allele, which encodes sulfotransferase 1C2 protein, is involved in the metabolism of hormones, xenobiotics and ribonucleotides.	SULT1C2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116942>	C89330	Developmental Delay|Delayed developmental milestones	Failure to meet, or late achievement of developmental milestones.			Disease or Syndrome	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116943>	C116942	Motor Developmental Delay	Failure to meet, or late achievement of motor development milestones.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116944>	C17210	Sulfotransferase 1C2|EC 2.8.2.-|ST1C2|SULT1C#1|SULT1C2|Sulfotransferase 1C1|humSULTC2	Sulfotransferase 1C2 (296 aa, ~35 kDa) is encoded by the human SULT1C2 gene. This protein plays a role in the sulfation of xenobiotics, hormones and purine ribonucleotides.	Sulfotransferase 1C2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116945>	C177681	Absence of MYCN Gene Amplification|MYCN Gene Amplification Negative|N-myc Gene Amplification Negative|NMYC Gene Amplification Negative|Neuroblastoma-Derived V-Myc Avian Myelocytomatosis Viral Related Oncogene Amplification Negative|Nonamplified MYCN|V-Myc Avian Myelocytomatosis Viral Oncogene Neuroblastoma Derived Homolog Gene Amplification Negative	A molecular finding indicating the absence of multiple copies of the MYCN gene in a tissue sample.	Absence of MYCN Gene Amplification		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116946>	C28533|C17967|C158414	ABCC6 Gene|ABCC6|ABCC6|ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 6 Gene	This gene is involved in the active transport of xenobiotics and glutathione conjugates into cells.	ABCC6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116947>	C116946	ABCC6 wt Allele|ABC34|ARA|ATP-Binding Cassette, Sub-Family C (CFTR/MRP), Member 6 wt Allele|ATP-Binding Cassette, Subfamily C, Member 6 Gene|EST349056|GACI2|MLP1|MOAT-E|MOATE|MRP6|PXE|PXE1|Pseudoxanthoma Elasticum Gene|URG7	Human ABCC6 wild-type allele is located in the vicinity of 16p13.1 and is approximately 75 kb in length. This allele, which encodes multidrug resistance-associated protein 6, plays a role in the active transport of drugs across the plasma membrane. Mutation of the gene is associated with pseudoxanthoma elasticum and generalized arterial calcification of infancy type 2.	ABCC6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116948>	C17750|C158419	Multidrug Resistance-Associated Protein 6|ABCC6|ATP-Binding Cassette Sub-Family C Member 6|Anthracycline Resistance-Associated Protein|MOAT-E|Multi-Specific Organic Anion Transporter E	Multidrug resistance-associated protein 6 (1503 aa, ~165 kDa) is encoded by the human ABCC6 gene. This protein is involved in the active transport of xenobiotics and glutathione conjugates across the plasma membrane.	Multidrug Resistance-Associated Protein 6		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116949>	C25804	LTA4H Gene|LTA4H|LTA4H|Leukotriene A4 Hydrolase Gene	This gene plays a role in leukotriene metabolism.	LTA4H Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116950>	C116949	LTA4H wt Allele|LTA4|Leukotriene A4 Hydrolase wt Allele	Human LTA4H wild-type allele is located in the vicinity of 12q22 and is approximately 43 kb in length. This allele, which encodes leukotriene A-4 hydrolase, is involved in the biosynthesis of leukotriene B4.	LTA4H wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116951>	C16701	Leukotriene A-4 Hydrolase|EC 3.3.2.6|LTA-4 Hydrolase|LTA4H|Leukotriene A(4) Hydrolase	Leukotriene A-4 hydrolase (611 aa, ~69 kDa) is encoded by the human LTA4H gene. This protein plays a role in the conversion of leukotriene A4 to leukotriene B4.	Leukotriene A-4 Hydrolase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116952>	C25939	FMO3 Gene|FMO3|FMO3|Flavin Containing Dimethylaniline Monoxygenase 3 Gene	This gene is involved in the oxidation of xenobiotics.	FMO3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116953>	C116952	FMO3 wt Allele|FMOII|Flavin Containing Dimethylaniline Monoxygenase 3 wt Allele|Flavin Containing Monooxygenase 3 Gene|TMAU|dJ127D3.1	Human FMO3 wild-type allele is located in the vicinity of 1q24.3 and is approximately 27 kb in length. This allele, which encodes flavin-containing monooxygenase 3 protein, plays a role in the oxygenation of drugs, dietary supplements and pesticides. Mutation of the gene is associated with trimethylaminuria.	FMO3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116954>	C16865	Flavin-Containing Monooxygenase 3|Dimethylaniline Monooxygenase [N-Oxide-Forming] 3|Dimethylaniline Monooxygenase [N-Oxide-Forming] 3|Dimethylaniline Oxidase 3|EC 1.14.13.148|EC 1.14.13.32|EC 1.14.13.8|FMO 3|FMO Form 2|FMO II|FMO3|Flavin Containing Dimethylaniline Monoxygenase 3|Flavin Containing Monooxygenase 3|Flavin-Containing Dimethylaniline Monooxygenase 3|Flavin-Containing Monooxygenase-3|Hepatic Flavin-Containing Monooxygenase 3|Hepatic Flavin-Containing Monooxygenase-3|Trimethylamine Monooxygenase	Flavin-containing monooxygenase 3 (532 aa, ~60 kDa) is encoded by the human FMO3 gene. This protein is involved in the oxygenation primary aliphatic alkylamines and both secondary and tertiary amines.	Dimethylaniline Monooxygenase [N-Oxide-Forming] 3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116955>	C98996|C28193	Diencephalic Syndrome of Infancy|Diencephalic Syndrome|Diencephalic Syndrome	Emaciation in the setting of normal linear growth and intellectual development, which is usually associated with neoplasms involving the anterior hypothalamus in infancy or early childhood.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C116956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116956>	C25790	SLFN11 Gene|SLFN11|SLFN11|Schlafen Family Member 11 Gene	This gene plays a role in anti-viral defense.	SLFN11 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116957>	C116956	SLFN11 wt Allele|FLJ34922|SLFN8/9|Schlafen Family Member 11 wt Allele|Schlafen Family, Member 11 Gene	Human SLFN11 wild-type allele is located in the vicinity of 17q12 and is approximately 23 kb in length. This allele, which encodes Schlafen family member 11 protein, is involved in the response to viral infection.	SLFN11 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116958>	C2889|C28193	Miller Fisher Syndrome|Fisher Syndrome|Fisher Syndrome|Miller-Fisher syndrome	An autoimmune process characterized by the clinical triad of ophthalmoplegia, ataxia, and areflexia.			Disease or Syndrome	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 6: Symptoms and Signs Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Physical Examination Terminology
C116959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116959>	C16725	Schlafen Family Member 11|SLFN11	Schlafen family member 11 (901 aa, ~103 kDa) is encoded by the human SLFN11 gene. This protein plays a role in the inhibition of viral protein synthesis.	Schlafen Family Member 11		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11695>	C61063	gp100 Antigen/Tetanus Peptide Melanoma Vaccine/Tyrosinase Peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116960>	C20103	OPCML Gene|OPCML|OPCML|Opioid Binding Protein/Cell Adhesion Molecule-Like Gene	This gene is involved in opioid binding.	OPCML Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116961>	C116960	OPCML wt Allele|IGLON1|OBCAM|OPCM|Opioid Binding Protein/Cell Adhesion Molecule-Like wt Allele	Human OPCML wild-type allele is located in the vicinity of 11q25 and is approximately 1117 kb in length. This allele, which encodes opioid-binding protein/cell adhesion molecule protein, plays a role in opioid receptor activity. Variation of the gene is associated with increased susceptibility to ovarian cancer.	OPCML wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116962>	C18106	Opioid-Binding Protein/Cell Adhesion Molecule|IgLON Family Member 1|OBCAM|OPCML|Opioid Binding Protein/Cell Adhesion Molecule-Like Preprotein|Opioid-Binding Cell Adhesion Molecule|Opioid-Binding Protein/Cell Adhesion Molecule-Like	Opioid-binding protein/cell adhesion molecule (345 aa, ~38 kDa) is encoded by the human OPCML gene. This protein may be involved in opioid signaling.	Opioid-Binding Protein/Cell Adhesion Molecule		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116963>	C16447	Procollagen Type I N-Terminal Peptide|Amino-Terminal Propeptide of Type 1 Procollagen|Amino-Terminal Propeptide of Type I Procollagen|P1NP|PINP|Procollagen Type 1 Amino-Terminal Peptide|Procollagen Type 1 N-Terminal Peptide|Procollagen Type I Amino-Terminal Peptide|Type 1 Procollagen Amino-Terminal Peptide|Type 1 Procollagen N-Terminal Peptide|Type I Procollagen Amino-Terminal Peptide|Type I Procollagen N-Terminal Peptide	A polypeptide comprised of the amino-terminal portions of procollagen, which are proteolytically removed during the intracellular formation of type I collagen fibrils. Increased plasma or serum concentrations of these peptides are associated with both fibrillogenesis of type I collagen and bone formation.	Procollagen Type I N-Terminal Peptide		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116964>	C88924	Telomeric Repeat-Containing RNA|TERRA	A large, non-coding RNA that can be encoded by any chromosomal telomeric DNA sequence, and is an integral part of the telomeric heterochromatin. These oligoribonucleotides may play a role in the regulation of both telomere replication and chromosomal remodeling. Their sizes are dependent on the telomere sequence length.	Telomeric Repeat-Containing RNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology
C116965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116965>	C84255|C136641	JAK2 NM_004972.3:c.2624C>A|JAK-2 c.2624C>A|JAK2 c.2624C>A|JTK10 c.2624C>A|Janus Kinase 2 c.2624C>A|NM_004972.3:c.2624C>A	A nucleotide substitution at position 2624 of the coding sequence of the JAK2 gene where cytosine has been mutated to adenine.	JAK2 NM_004972.3:c.2624C>A		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116966>	C105906	JAK2 NP_004963.1:p.T875N|JAK2 NP_004963.1:p.Thr875Asn|JAK2 T875N|JAK2 Thr875Asn|JAK2 p.T875N|JAK2 p.Thr875Asn|Janus Kinase 2 T875N|Janus Kinase 2 Thr875Asn|NP_004963.1:p.T875N|NP_004963.1:p.Thr875Asn|Tyrosine-Protein Kinase JAK2 T875N|Tyrosine-Protein Kinase JAK2 Thr875Asn	A change in the amino acid residue at position 875 in the tyrosine-protein kinase JAK2 protein where threonine has been replaced by asparagine.	JAK2 NP_004963.1:p.T875N		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116967>	C21176	EGFR-GRB2 Complex|EGFR-GRB2 Signaling Complex|EGFR:GRB2 Complex|EGFR:GRB2 Signaling Complex|GRB2-EGFR Complex|GRB2:EGFR Complex	A protein complex comprised of two epidermal growth factor receptor (EGFR) family proteins, and one or two growth factor receptor-bound protein 2 (GRB2) adaptor proteins. These complexes form after epidermal growth factor (EGF) family ligands bind to EGFR proteins. Ligand binding triggers receptor dimerization and cross-receptor tyrosine phosphorylation, which allows the SH2 domains of each growth factor receptor-bound protein 2 to form a non-covalent bond with the phosphorylated EGFR proteins.	EGFR-GRB2 Complex		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116968>	C82987	FOXP3 Treg-Specific Demethylated Region|FOXP3 TSDR|FOXP3 Treg Specific Demethylated Region	A genetic marker that distinguishes regulatory T-cells (Tregs) from other T-lymphocytes. This marker is comprised of a demethylated CpG motif that is within the 5' untranslated region of the FOXP3 gene, which is only found in Tregs. This CpG motif is methylated in other T-cell lineages. The methylation status of this region of the FOXP3 gene may influence the expression of the transcription factor, forkhead box protein P3.	FOXP3 Treg-Specific Demethylated Region		Gene or Genome|Indicator, Reagent, or Diagnostic Aid	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116969>	C13338	HSPH1 T17 Repeat|HSP105 T17|HSP105 T17 Repeat|HSP110 T17|HSP110 T17 Repeat|HSPH1 T17	A mononucleotide DNA repeat consisting of 17 thymine bases, which is found within intron 8 of the human HSPH1 gene. Variation in, or somatic mutation of this region causes the expression of an aberrant HSPH1 mRNA transcript that is missing exon 9 (HSPH1-deltaE9), which encodes a protein that lacks the HSPH1 substrate binding domain.	HSPH1 T17 Repeat		Nucleotide Sequence	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11696>	C61063	Carboplatin/Docetaxel/Gemcitabine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116970>	C26511	CYP2A7 Gene|CYP2A7|CYP2A7|Cytochrome P450, Family 2, Subfamily A, Polypeptide 7 Gene	This gene may play a role in both electron transport and the metabolism of lipids and xenobiotics.	CYP2A7 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116971>	C116970	CYP2A7 wt Allele|CPA7|CPAD|CYP2A|CYPIIA7|Cytochrome P450, Family 2, Subfamily A, Polypeptide 7 wt Allele|Cytochrome P450, Subfamily 2A, Polypeptide 7 Gene|Cytochrome P450, Subfamily IIA (Phenobarbital-Inducible), Polypeptide 7 Gene|Cytochrome P450, Subfamily IIA, Polypeptide 7 Gene|P450-IIA4	Human CYP2A7 wild-type allele is located in the vicinity of 19q13.2 and is approximately 7 kb in length. This allele, which encodes cytochrome P450 2A7 protein, may be involved in both the oxidation of steroids, fatty acids and xenobiotics and the NADPH-dependent electron transport pathway.	CYP2A7 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116972>	C16484	Cytochrome P450 2A7|CYP2A7|CYPIIA7|Cytochrome P450 IIA4|Cytochrome P450 IIA7|Cytochrome P450IIA4|Cytochrome P450IIA7|EC 1.14.14.1	Cytochrome P450 2A7 (494 aa, ~56 kDa) is encoded by the human CYP2A7 gene. This protein may play a role in both the NADPH-dependent electron transport pathway and the oxidation of steroids, fatty acids and xenobiotics.	Cytochrome P450 2A7		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116973>	C84353	Bacterial Vaginosis|BV|BV	Infection caused by bacterial overgrowth in the vagina. Most affected women are asymptomatic. When symptoms occur, they include foul-smelling vaginal discharge, vaginal itching, and burning. Risk factors include sexual activity with multiple partners and the use of vaginal douches and intrauterine devices. Up to a third of cases resolve without treatment. Antibiotic treatment is recommended when symptoms are present and for women that are pregnant at the time of infection.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C116974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116974>	C25802	HSPH1 Gene|HSPH1|HSPH1|Heat Shock 105kDa/110kDa Protein 1 Gene	This gene plays a role in the unfolded protein response.	HSPH1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116975>	C116974	HSPH1 wt Allele|HSP105|HSP105A|HSP105B|HSP110|Heat Shock 105kDa/110kDa Protein 1 wt Allele|KIAA0201|NY-CO-25|RP11-173P16.1	Human HSPH1 wild-type allele is located in the vicinity of 13q12.3 and is approximately 26 kb in length. This allele, which encodes heat shock protein 105 kDa protein, is involved in the negative regulation of the aggregation of unfolded proteins.	HSPH1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116976>	C17764	Heat Shock Protein 105 kDa|Antigen NY-CO-25|HSPH1|Heat Shock 110 kDa Protein|Heat-Shock Protein, 105-kD|Heat-Shock Protein, 110-kD	Heat shock protein 105 kDa (858 aa, ~97 kDa) is encoded by the human HSPH1 gene. This protein plays a role in the cellular stress response to unfolded proteins.	Heat Shock Protein 105 kDa		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977>	C54443	CTRP Terminology|Clinical Trials Reporting Program Terminology	Terminology that is used to support NCI's Clinical Trials Reporting Program (CTRP), a database that captures the required reporting data for all NCI-sponsored clinical trials.			Intellectual Product	
C116978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978>	C116977	CTRP Agent Terminology|Clinical Trials Reporting Program Agent Terminology	A subset of terminology about pharmacologic substances and formulations that are currently being used or tested in clinical trials for the treatment of cancer, cancer-related conditions and chemo/radiotherapy-related side effects.			Intellectual Product	
C116979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116979>	C91105	Quality of Life Questionnaire - Testicular Cancer 26|EORTC QLQ-TC26|QLQ-TC26|QLQ-TC26	A questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) consisting of 26 questions designed to assess quality of life in testicular cancer patients.			Intellectual Product	
C11697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11697>	C61063	Estramustine/Paclitaxel/Vinorelbine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116980>	C173981	Have Hair Loss Question|Had Hair Loss|Hair Loss|Hair loss|Have Hair Loss|Have Lost Hair|Have you had hair loss|Have you lost any hair	A question about whether an individual has or had hair loss.			Intellectual Product	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 Items|Memorial Symptom Assessment Scale - Short Form|Quality of Life Questionnaire - Testicular Cancer 26
C116981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116981>	C173981|C173063	Have Problems with Sense of Taste or Smell Question|'Have Problems with Sense of Taste or Smell'|Have you had problems with your sense of taste or smell	A question about whether an individual has or had problems with their sense of taste or smell.			Intellectual Product	Quality of Life Questionnaire - Testicular Cancer 26
C116982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116982>	C25802	HSP90B2P Gene|HSP90B2P|HSP90B2P|Heat Shock Protein 90kDa Beta (Grp94), Member 2, Pseudogene Gene	This gene may play a role in protein folding.	HSP90B2P Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C116983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116983>	C116982	HSP90B2P wt Allele|GRP94B|GRP94P1|GRP94b|HSP|HSPCP2|Heat Shock Protein 90kDa Beta (Grp94), Member 2, Pseudogene wt Allele|TRA1P1|TRAP1|Tumor Rejection Antigen (Gp96) 1 Pseudogene 1|Tumor Rejection Antigen (Gp96) Pseudogene 1	Human HSP90B2P wild-type allele is located in the vicinity of 15q26.3 and is approximately 3 kb in length. This allele, which may encode putative endoplasmin-like protein, may be involved in protein folding.	HSP90B2P wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116984>	C17764	Putative Endoplasmin-Like Protein|HSP90B2P|Putative Heat Shock Protein 90 kDa Beta Member 2	Putative endoplasmin-like protein (399 aa, ~46 kDa) is encoded by the human HSP90B2P gene. This protein may play a role in protein chaperone activity.	Putative Endoplasmin-Like Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C116985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116985>	C26883	Primary Sjogren Syndrome|Primary Sjogren's syndrome|Primary Sjogren's syndrome|Primary Sjögren Syndrome	Sjogren syndrome without a concomitant systemic autoimmune disorder.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C116986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116986>	C26883	Secondary Sjogren Syndrome|Secondary Sjogren's syndrome|Secondary Sjogren's syndrome|Secondary Sjögren Syndrome	Sjogren syndrome that occurs with another systemic autoimmune disorder, such as systemic lupus erythematosus or rheumatoid arthritis.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C116987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116987>	C91126	Have Pain in Stomach Area Question|Have Pain in Stomach Area|Have you had pain in your stomach area	A question about whether an individual has or had pain in their stomach area.			Intellectual Product	Quality of Life Questionnaire - Testicular Cancer 26
C116988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116988>	C173981	Have Acid Reflux Question|Have Acid Reflux|Have you had acid reflux	A question about whether an individual has or had acid reflux.			Intellectual Product	Quality of Life Questionnaire - Testicular Cancer 26
C116989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116989>	C105777	Have Numbness or Tingling in Fingers or Toes Question|Have Numbness or Tingling in Fingers or Toes|Have you had tingling or numbness in your fingers or toes	A question about whether an individual has or had tingling or numbness in their fingers or toes.			Intellectual Product	Quality of Life Questionnaire - Testicular Cancer 26
C11698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11698>	C61007	Oxaliplatin/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C116990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116990>	C173981	Have Skin Problem Question|Have Skin Problem|Have you had skin problems (e.g. itchy, dry)	A question about whether an individual has or had skin problems.			Intellectual Product	Quality of Life Questionnaire - Testicular Cancer 26
C116991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116991>	C173981	Have Pale or Cold Fingers or Toes Question|Have Pale or Cold Fingers or Toes|Have you had pale/cold fingers or toes	A question about whether an individual has or had pale or cold fingers or toes.			Intellectual Product	Quality of Life Questionnaire - Testicular Cancer 26
C116992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116992>	C173059	Have Problem with Hearing Question|Did you have problems with hearing|Have Problem with Hearing	A question about whether an individual has or had problems with hearing.			Intellectual Product	Quality of Life Questionnaire - Testicular Cancer 26
C116993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116993>	C176545|C173792	Satisfied with Medical Care Received Question|Satisfied with Medical Care Received|Were you satisfied with the medical care you received	A question about whether an individual is or was satisfied with the medical care they received.			Intellectual Product	Quality of Life Questionnaire - Testicular Cancer 26
C116994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116994>	C28193	Lupus Anticoagulant Disorder	A hypercoaguable state that results from the presence of the immunoglobulin known as Lupus Anticoagulant. The antibody interacts with cell membrane phospholipids, causing increased aggregation and adhesion of platelets, which causes increased clot formation. Though the majority of patients who test positive for lupus anticoagulant do not have lupus, those individuals afflicted with lupus have a higher probability of developing the antibody.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C116995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116995>	C28533|C25804	DNM1L Gene|DNM1L|DNM1L|Dynamin 1-Like Gene	This gene plays a role in the replication of mitochondria and peroxisomes.			Gene or Genome	
C116996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116996>	C116995	DNM1L wt Allele|DLP1|DRP1|DVLP|DYMPLE|Dynamin 1-Like wt Allele|Dynamin Family Member, Proline-Rich C-Terminal Domain Less Gene|EMPF|HDYNIV|S. cerevisiae DNM1/VPS1-Like Protein Gene	Human DNM1L wild-type allele is located in the vicinity of 12p11.21 and is approximately 66 kb in length. This allele, which encodes dynamin-1-like protein, is involved in the division process of both mitochondria and peroxisomes. Mutation of the gene is associated with lethal encephalopathy due to defective mitochondrial peroxisomal fission.			Gene or Genome	
C116997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116997>	C16701|C16386	Dynamin-1-Like Protein|DNM1L|DVLP|Dnm1p/Vps1p-Like Protein|Dymple|Dynamin Family Member Proline-Rich Carboxyl-Terminal Domain Less|Dynamin-Like Protein|Dynamin-Like Protein 1|Dynamin-Like Protein 4|Dynamin-Like Protein IV|Dynamin-Related Protein 1|EC 3.6.5.5|HdynIV	Dynamin-1-like protein (736 aa, ~82 kDa) is encoded by the human DNM1L gene. This protein plays a role in mitochondrial and peroxisomal division.			Amino Acid, Peptide, or Protein|Enzyme	
C116998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116998>	C25804	APOBEC3A Gene|APOBEC3A|APOBEC3A|Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3A Gene	This gene is involved in cytosine deamination of viral DNA.			Gene or Genome	
C116999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116999>	C116998	APOBEC3A wt Allele|A3A|ARP3|Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3A wt Allele|PHRBN|bK150C2.1	Human APOBEC3A wild-type allele is located within 22q13.1-q13.2 and is approximately 10 kb in length. This allele, which encodes DNA dC->dU-editing enzyme APOBEC-3A protein, plays a role in the modulation of viral DNA modification. A deletion that fuses this gene and the 3' end of the APOBEC3B gene may be associated with increased susceptibility to neoplastic disease.			Gene or Genome	
C11699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11699>	C61007	Bicalutamide/Goserelin/Mitoxantrone/Prednisone			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1169>	C804	Carboxyphenyl Retinamide|4-carboxyphenyl retinamide|N-(4-Carboxyphenyl)retinamide|N-(4-carboxyphenyl)retinamide	A synthetic phenylretinamide analogue of retinol (vitamin A) with potential antineoplastic and chemopreventive activities.  Carboxyphenyl retinamide induces cell differentiation and inhibits tumor cell growth and carcinogenesis.  This agent may also induce cell cycle arrest in the G1 phase in some cancer cell types. (NCI04)			Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C117000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117000>	C16701	DNA dC to dU-Editing Enzyme APOBEC-3A|A3A|APOBEC3A|DNA dC->dU-Editing Enzyme APOBEC-3A|EC 3.5.4.-|Phorbolin 1|Phorbolin I|Phorbolin-1|Probable DNA dC->dU-Editing Enzyme APOBEC-3A	DNA dC->dU-editing enzyme APOBEC-3A (199 aa, ~23 kDa) is encoded by the human APOBEC3A gene. This protein is involved in the modification of viral DNA.			Amino Acid, Peptide, or Protein|Enzyme	
C117001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117001>	C25804	APOBEC3B Gene|APOBEC3B|APOBEC3B|APOBEC3B|Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3B Gene	This gene plays a role in viral DNA cytosine deamination.			Gene or Genome	GDC Terminology|GDC Value Terminology
C117002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117002>	C117001	APOBEC3B wt Allele|A3B|APOBEC1L|ARCD3|ARP4|Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like 3B wt Allele|DJ742C19.2|FLJ21201|PHRBNL|bK150C2.2	Human APOBEC3B wild-type allele is located within 22q13.1-q13.2 and is approximately 10 kb in length. This allele, which encodes DNA dC->dU-editing enzyme APOBEC-3B protein, is involved in the modulation of DNA cytosine deamination. A deletion that fuses the 3' UTR of this gene to the 3' end of the APOBEC3A gene, essentially deletes the APOBEC3B coding sequence, and may be associated with increased susceptibility to neoplastic disease.			Gene or Genome	
C117003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117003>	C16701	DNA dC to dU-Editing Enzyme APOBEC-3B|A3B|APOBEC3B|Apolipoprotein B mRNA Editing Enzyme Catalytic Polypeptide-Like 3B|DNA dC->dU-Editing Enzyme APOBEC-3B|EC 3.5.4.-|Phorbolin 1-Related Protein|Phorbolin 2|Phorbolin 3|Phorbolin-1-Related Protein|Phorbolin-2/3|Phorbolin-3|Probable DNA dC->dU-Editing Enzyme APOBEC-3B	DNA dC->dU-editing enzyme APOBEC-3B (382 aa, ~46 kDa) is encoded by the human APOBEC3B gene. This protein plays a role in the inhibition of replication of viral genomes.			Amino Acid, Peptide, or Protein|Enzyme	
C117004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117004>	C89715	Migraine Without Aura|Common Migraine|Common Migraine	A migraine disorder characterized by episodes that occur in the absence of preceding focal neurological symptoms.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117005>	C89715	Migraine With Aura	A migraine disorder characterized by episodes that are preceded by focal neurological symptoms.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117006>	C28510	APOBEC3A_B Fusion Hybrid Gene|APOBEC3A and APOBEC3B Deletion Hybrid Gene|APOBEC3A_B|APOBEC3A_B|CTA-150C2.14-001	A fusion gene (~10 kb) that results from the deletion of approximately 29.5 kb of sequence between the APOBEC3A gene and the adjacent APOBEC3B gene. The deletion hybrid is predicted to have the promoter and coding region of APOBEC3A, but the 3' UTR of APOBEC3B. This mutation results in an APOBEC3B null phenotype, which would impact antiretroviral defense processes, and may be associated with an increased risk of breast carcinoma and other neoplastic diseases.			Gene or Genome	
C117007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117007>	C26835	Neurovascular Disorder	A disorder of the nervous system related to a vascular etiology.			Disease or Syndrome	
C117008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117008>	C176537|C173812|C173792	Satisfied with Information Received about Disease or Treatment Question|Satisfied with Information Received about Disease or Treatment|Were you satisfied with the information you received about your disease or treatment	A question about whether an individual is or was satisfied with the information they received about their disease or treatment.			Intellectual Product	Quality of Life Questionnaire - Testicular Cancer 26
C117009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117009>	C89715	Familial Hemiplegic Migraine	A migraine disorder characterized by individual and family history of aura that includes motor weakness.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11700>	C61007	Autologous Tumor Cell Vaccine/Keyhole Limpet Hemocyanin/Sargramostim			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117010>	C173160	Feel Uncertain about the Future Question|Did you feel uncertain about the future|Feel Uncertain about the Future	A question about whether an individual feels or felt uncertain about the future.			Intellectual Product	Quality of Life Questionnaire - Testicular Cancer 26
C117011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117011>	C89715	Sporadic Hemiplegic Migraine	A migraine disorder characterized by an aura that includes motor weakness and the absence of family history.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117012>	C173386	Have Been Anxious about Possible Recurrence of Disease Question|Have Been Anxious about Possible Recurrence of Disease|Have you been anxious about a possible recurrence of the disease	A question about whether an individual is or was anxious about a possible recurrence of their disease.			Intellectual Product	Quality of Life Questionnaire - Testicular Cancer 26
C117013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117013>	C89715	Basilar-Type Migraine|Basilar-type Migraine	A migraine disorder characterized by episodes that are preceded by focal neurological symptoms originating in the brainstem.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117014>	C3259	Cyclical Vomiting	A condition characterized by recurrent, self-limiting episodes of vomiting associated with intense nausea, pallor, and lethargy. It is commonly a migraine precursor.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117015>	C89715	Chronic Migraine	Episodes of migraine occurring on 15 or more days per month, for more than three months.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117016>	C173812	Have Problem with Job or Education Because of Disease or Treatment Question|Have Problem with Job or Education Because of Disease or Treatment|Have you had any problems with your job or your education because of your disease or treatment	A question about whether an individual has or had problems with their job or education because of their disease or treatment.			Intellectual Product	Quality of Life Questionnaire - Testicular Cancer 26
C117017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117017>	C173812|C173695	Have Been Physically Limited as a Result of Disease or Treatment Question|Have Been Physically Limited as a Result of Disease or Treatment|Have you been physically limited as a result of your disease or treatment	A question about whether an individual has or had physical limitations as a result of their disease or treatment.			Intellectual Product	Quality of Life Questionnaire - Testicular Cancer 26
C117018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117018>	C173151|C173084	Concerned about Disruption of Family Life Question|Concerned about Disruption of Family Life|Were you concerned about disruption of family life	A question about whether an individual is or was concerned about disruption of family life.			Intellectual Product	Quality of Life Questionnaire - Testicular Cancer 26
C11701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11701>	C61063	Interleukin-2/Vaccine-Sensitized Draining Lymph Node Cells			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117020>	C173045	Ability to Talk about Disease with Partner or Person Closest to You Question|Ability to Talk about Disease with Partner or Person Closest to You|Can you talk about your disease with your partner or the person who is closest to you	A question about whether an individual can talk about their disease with their partner or the person who is closest to them.			Intellectual Product	Quality of Life Questionnaire - Testicular Cancer 26
C117021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117021>	C20189	Mood	The modes that may be applied to an entity as it passes through various phases of a life cycle or business process.			Idea or Concept	
C117022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117022>	C89715	Status Migranosus|Status Migrainosus	An episode of migraine that persists for more than 72 hours.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117023>	C173812|C173160	Feel Less Masculine as a Result of Disease or Treatment Question|Feel Less Masculine as a Result of Disease or Treatment|Have you felt less masculine as a result of your disease or treatment	A question about whether an individual feels or felt less masculine as a result of their disease or treatment.			Intellectual Product	Quality of Life Questionnaire - Testicular Cancer 26
C117024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117024>	C89715	Migrainous Infarction	Migraine associated with an ischemic brain lesion.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117025>	C173704|C173150	Extent of Interest in Sex Question|Extent of Interest in Sex|To what extent were you interested in sex	A question about the extent to which an individual is or was interested in sex.			Intellectual Product	Quality of Life Questionnaire - Testicular Cancer 26
C117026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117026>	C173704|C173150	Extent of Sexual Activity Question|Extent of Sexual Activity|To what extent were you sexually active (with or without intercourse)	A question about the extent to which an individual is or was sexually active, with or without intercourse.			Intellectual Product	Quality of Life Questionnaire - Testicular Cancer 26
C117027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117027>	C173704	Can Talk about Sexuality with Partner or Person Closest to You Question|Can Talk about Sexuality with Partner or Person Closest to You|Can you talk about sexuality with your partner or the person who is closest to you	A question about whether an individual can talk about sexuality with their partner or the person who is closest to them.			Intellectual Product	Quality of Life Questionnaire - Testicular Cancer 26
C117028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117028>	C173398	Have Difficulty Getting or Maintaining an Erection Question|Did you have difficulty getting or maintaining an erection|Have Difficulty Getting or Maintaining an Erection	A question about whether an individual has or had difficulty getting or maintaining an erection.			Intellectual Product	Quality of Life Questionnaire - Testicular Cancer 26
C117029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117029>	C173981|C173704	Have Problem with Ejaculation Question|Did you have ejaculation problems (e.g. dry ejaculation)|Did you have problems with ejaculation|Have Ejaculation Problems|Have Problem with Ejaculation	A question about whether an individual has or had problems with ejaculation.			Intellectual Product	Bladder Cancer Muscle-Invasive 30 Questionnaire|Quality of Life Questionnaire - Testicular Cancer 26
C11702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11702>	C61063	HER-2-Neu Peptide Vaccine/Sargramostim			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117030>	C173704|C173150	Extent of Sexual Enjoyment Question|Extent of Sexual Enjoyment|To what extent was sex enjoyable for you	A question about the extent to which sex is or was enjoyable.			Intellectual Product	Quality of Life Questionnaire - Testicular Cancer 26
C117031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117031>	C173792|C173704	Have Satisfying Sexual Relationship with Partner Question|Has the sexual relationship with your partner been satisfying|Have Satisfying Sexual Relationship with Partner	A question about whether the sexual relationship between an individual and their partner has been satisfying.			Intellectual Product	Quality of Life Questionnaire - Testicular Cancer 26
C117032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117032>	C173792	Satisfied with Testicular Implant Question|Are you satisfied with your testicular implant|Satisfied with Testicular Implant	A question about whether an individual is or was satisfied with the testicular implant.			Intellectual Product	Quality of Life Questionnaire - Testicular Cancer 26
C117033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117033>	C20420	SALL2 Gene|SALL2|SALL2|Spalt-Like Transcription Factor 2 Gene	This gene is involved in the modulation of gene expression.			Gene or Genome	
C117034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117034>	C117033	SALL2 wt Allele|HSAL2|KIAA0360|SAL2|Sal (Drosophila)-Like 2 Gene|Sal-2|Sal-Like 2 (Drosophila) Gene|Sal-Like 2 Gene|Spalt-Like Transcription Factor 2 wt Allele|ZNF795|p150(Sal2)	Human SALL2 wild-type allele is located within 14q11.1-q12 and is approximately 16 kb in length. This allele, which encodes Sal-like protein 2, plays a role in the modulation of gene transcription.			Gene or Genome	
C117035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117035>	C17207	Sal-Like Protein 2|Sal-2|Zinc Finger Protein 795|Zinc Finger Protein SALL2|Zinc Finger Protein Spalt-2|hSal2	Sal-like protein 2 (1007 aa, ~105 kDa) is encoded by the human SALL2 gene. This protein is involved in the regulation of gene expression.			Amino Acid, Peptide, or Protein	
C117036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117036>	C25966	MicroRNA 105|MIR105|MIRN105|hsa-miR-105-5p|hsa-mir-105|miR-105|miR105|miRNA 105|miRNA-105|miRNA105	A 23 ribonucleotide sequence that is a final product of the processing of either MIR105-1 pre-miRNA or MIR105-2 pre-miRNA. This oligonucleotide may be involved in the negative regulation of gene expression, and its expression is associated with metastatic breast cancer.			Nucleic Acid, Nucleoside, or Nucleotide	
C117037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117037>	C25404	Action Taken with Device|ACNDEV|ACNDEV|ACNDEV|Action Taken With Device|Action Taken With Device|Action Taken With Device	Describes changes made with respect to the device in the study in response to an event or protocol change.			Activity	CDISC Root Variable Terminology|CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|CDISC SDTM Type 1 Diabetes Findings About Test Code Terminology|CDISC SDTM Type 1 Diabetes Findings About Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C117038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117038>	C43578	Accepted Record Flag|ACPTFL	An indication that a record that is considered to be the accepted and final evaluation.			Functional Concept	CDISC Root Variable Terminology
C117039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117039>	C71460	Analysis Method|ANMETH	A means, manner of procedure, or systematic course of actions that are performed in order to examine and interpret an event or entity.			Conceptual Entity	CDISC Root Variable Terminology
C11703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11703>	C61007	Rituximab/Yttrium Y 90 ibritumomab tiuxetan			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117040>	C25162	MedDRA Body System or Organ Class Code	A coded value specifying the type of body system or organ class from the Medical Dictionary for Regulatory Activities (MedDRA).			Intellectual Product	CDISC Root Variable Terminology
C117041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117041>	C181040	Dosing Days to Detection|DETECT	The number of days from the start of dosing to the earliest detection of a condition or pathogen.			Quantitative Concept	CDISC Root Variable Terminology
C117042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117042>	C25543	Planned End of Assessment Interval|ENINT	The period of time that the assessment, done over an interval of time, is intended to finish.			Temporal Concept	CDISC Root Variable Terminology
C117043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117043>	C25364	Evaluator Identifier|EVALID	A sequence of characters used to identify, name, or characterize the evaluator.			Intellectual Product	CDISC Root Variable Terminology
C117044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117044>	C25704	Evaluation Interval Text|EVINTX	A textual description of the evaluation interval.			Intellectual Product	CDISC Root Variable Terminology
C117045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117045>	C25180	Exclude from Statistics Indicator|EXCLFL	Specifies whether result values should be excluded from the calculations or statistical analysis.			Functional Concept	CDISC Root Variable Terminology
C117046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117046>	C25162	MedDRA High Level Group Term Code|HLGTCD	A coded value specifying the high level group term from the Medical Dictionary for Regulatory Activities (MedDRA).			Intellectual Product	CDISC Root Variable Terminology
C117047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117047>	C25162	MedDRA High Level Term Code|HLTCD	A coded value specifying the high level term from the Medical Dictionary for Regulatory Activities (MedDRA).			Intellectual Product	CDISC Root Variable Terminology
C117048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117048>	C25162	MedDRA Low Level Term Code|LLTCD	A coded value specifying the low level term from the Medical Dictionary for Regulatory Activities (MedDRA).			Intellectual Product	CDISC Root Variable Terminology
C117049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117049>	C25364	Link Group Identifier|LNKGRP	A sequence of characters used to link multiple records to a single finding.			Intellectual Product	CDISC Root Variable Terminology
C11704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11704>	C61063	LY335979/Vinorelbine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117050>	C25364	Record Link Identifier|LNKID	A sequence of characters used as a linkage between related records.			Intellectual Product	CDISC Root Variable Terminology
C117051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117051>	C117021	Record Mood|MOOD	The modes that may be applied to a record as it passes through various phases of a life cycle or business process.			Qualitative Concept	CDISC Root Variable Terminology
C117052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117052>	C41107	Accountable Party|PARTY	The person or organization responsible for an entity or event.			Organization	CDISC Root Variable Terminology
C117053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117053>	C25364	Subject Pool Identifier|POOLID	A sequence of characters used to identify, name, or characterize the subject pool.			Intellectual Product	CDISC Root Variable Terminology|CDISC Variable Terminology
C117054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117054>	C25364	Accountable Party Identifier|PRTYID	A sequence of characters used to identify, name, or characterize the accountable party.			Intellectual Product	CDISC Root Variable Terminology
C117055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117055>	C48470	Pharmaceutical Strength Unit|PSTRGU	The unit of measure for the content of an active ingredient, expressed quantitatively per dosage unit.			Quantitative Concept	CDISC Root Variable Terminology
C117056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117056>	C25162	MedDRA Preferred Term Code|PTCD|meddra code|meddra_code	A coded value specifying the preferred term from the Medical Dictionary for Regulatory Activities (MedDRA).			Intellectual Product	CDISC Root Variable Terminology|CTDC Property Terminology
C117057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117057>	C25638	Reason for Exclusion from Statistics|REASEX	A rationale for excluding a particular data point or subject from the statistical analysis.			Intellectual Product	CDISC Root Variable Terminology
C117058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117058>	C25364	Run Identifier|RUNID|runIdentifier	A sequence of characters used to uniquely identify a particular run of a test on a particular batch of samples.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology|CDISC Root Variable Terminology
C117059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117059>	C25162	MedDRA Primary System Organ Class Code|SOCCD	A coded value specifying the primary system organ class from the Medical Dictionary for Regulatory Activities (MedDRA).			Intellectual Product	CDISC Root Variable Terminology
C11705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11705>	C61007	gp100 Antigen/Interleukin-2/Montanide ISA-51/Tumor Infiltrating Lymphocytes			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117060>	C25364	Sponsor Device Identifier|SPDEVID	A sponsor-defined sequence of characters used to identify, name, or characterize the device.			Intellectual Product	CDISC Root Variable Terminology
C117061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117061>	C25543	Planned Start of Assessment Interval|STINT	The period of time that the assessment, done over an interval of time, is intended to begin.			Temporal Concept	CDISC Root Variable Terminology
C117062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117062>	C25480	Measurement, Test or Examination Detail|TSTDTL	Particulars considered individually and in relation to a measurement, test or examination.			Idea or Concept	CDISC Root Variable Terminology
C117063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117063>	C80699	MIR135B Gene|MIR135B|MIR135B|MicroRNA 135b Gene	This gene is involved in the regulation of gene expression that modulates cell motility.			Gene or Genome	
C117064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117064>	C117063	MIR135B wt Allele|MIRN135B|MicroRNA 135b wt Allele|hsa-mir-135b|mir-135b	The human MIR135B wild-type allele is located in the vicinity of 1q32.1 and is approximately 97 bases in length. This allele, which encodes MIR135B pre-miRNA, plays a role in the regulation of gene expression. Alteration in the expression of this gene is associated with highly invasive non-small-cell lung cancer.			Gene or Genome	
C117065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117065>	C25968	MIR135B Pre-miRNA	MIR135B pre-miRNA (97 nucleotides) is encoded by the human MIR135B gene. This oligoribonucleotide is involved in the regulation of gene expression.			Nucleic Acid, Nucleoside, or Nucleotide	
C117066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117066>	C21114	TNFSF12 Gene|TNFSF12|TNFSF12|Tumor Necrosis Factor (Ligand) Superfamily, Member 12 Gene	This gene plays a role in angiogenesis.			Gene or Genome	
C117067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117067>	C117066	TNFSF12 wt Allele|APO3L|DR3LG|TWEAK|Tumor Necrosis Factor (Ligand) Superfamily, Member 12 wt Allele|Tumor Necrosis Factor Ligand Superfamily, Member 12 Gene|UNQ181/PRO207	Human TNFSF12 wild-type allele is located in the vicinity of 17p13 and is approximately 13 kb in length. This allele, which encodes tumor necrosis factor ligand superfamily member 12 protein, is involved in the promotion of angiogenesis. A readthrough that fuses this gene and the neighboring TNFSF13 gene may be expressed in activated T-cells and T- or B-cell lymphoma.			Gene or Genome	
C117068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117068>	C20500	Tumor Necrosis Factor Ligand Superfamily Member 12|APO3 Ligand|APO3/DR3 Ligand|TNF Superfamily Member 12|TNF-Related Weak Inducer of Apoptosis|TNFSF12|TWEAK	Tumor necrosis factor ligand superfamily member 12 (249 aa, ~27 kDa) is encoded by the human TNFSF12 gene. This protein plays a role in the positive regulation of angiogenesis.			Amino Acid, Peptide, or Protein	
C117069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117069>	C2962	Migraine-Triggered Seizure|Migraine-triggered Seizure	A seizure triggered by a migraine.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11706>	C61063	BCG/Polyvalent Melanoma Vaccine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117070>	C34661	Tension Headache|Stress Headache|Stress Headache|Tension-type Headache	A headache associated with muscle tightness which may radiate to other parts of the body.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117071>	C21165	TNFRSF12A Gene|TNFRSF12A|TNFRSF12A|Tumor Necrosis Factor Receptor Superfamily, Member 12A Gene	This gene is involved in signal transduction and the promotion of angiogenesis.			Gene or Genome	
C117072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117072>	C117071	TNFRSF12A wt Allele|CD266|FN14|TWEAKR|Tumor Necrosis Factor Receptor Superfamily, Member 12A wt Allele	Human TNFRSF12A wild-type allele is located in the vicinity of 16p13.3 and is approximately 4 kb in length. This allele, which encodes tumor necrosis factor receptor superfamily member 12A protein, plays a role in the modulation of both angiogenesis and apoptosis.			Gene or Genome	
C117073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117073>	C19285	Tumor Necrosis Factor Receptor Superfamily Member 12A|CD266|CD266 Antigen|FGF-Inducible 14|Fibroblast Growth Factor-Inducible Immediate-Early Response Protein 14|Tweak Receptor|Tweak-Receptor|TweakR|Type I Transmembrane Protein Fn14	Tumor necrosis factor receptor superfamily member 12A (129 aa, ~14 kDa) is encoded by the human TNFRSF12A gene. This protein is involved in both apoptosis and angiogenesis.			Amino Acid, Peptide, or Protein|Receptor	
C117074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117074>	C117007	Trigeminal Autonomic Cephalalgia	A headache disorder characterized by episodes of unilateral, short lasting pain and associated ipsilateral cranial autonomic symptoms.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117075>	C20744	FERMT3 Gene|FERMT3|FERMT3|Fermitin Family Member 3 Gene	This gene plays a role in cell adhesion in hematopoietic cells.			Gene or Genome	
C117076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117076>	C117075	FERMT3 wt Allele|Fermitin Family (Drosophila) Homolog 3 Gene|Fermitin Family Homolog 3 (Drosophila) Gene|Fermitin Family Member 3 wt Allele|KIND3|MIG-2|MIG2B|UNC112C|URP2|URP2SF	Human FERMT3 wild-type allele is located in the vicinity of 11q13.1 and is approximately 17 kb in length. This allele, which encodes fermitin family homolog 3 protein, is involved in the modulation of cell adhesion. Mutation of the gene is associated with leukocyte adhesion deficiency-3.			Gene or Genome	
C117077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117077>	C117074	Cluster Headache	A headache disorder that is characterized by periodic severe, unilateral orbital, supraorbital, and/or temporal pain, and is associated with ipsilateral cranial autonomic symptoms.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117078>	C34661	Primary Cough Headache|Valsalva-maneuver Headache|Valsalva-maneuver Headache	Headache triggered by coughing or straining in the absence of an intracranial disorder.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117079>	C34661	Primary Exertional Headache	Headache triggered by exercise.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11707>	C61063	Cisplatin/Cytarabine/Etoposide/Ifosfamide/Yttrium Y 90 Humanized Epratuzumab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117080>	C18073	Fermitin Family Homolog 3|FERMT3|Kindlin 3|Kindlin-3|MIG2-Like Protein|UNC-112 Related Protein 2|Unc-112-Related Protein 2	Fermitin family homolog 3 (667 aa, ~76 kDa) is encoded by the human FERMT3 gene. This protein plays a role in hematopoietic cell adhesion, migration and proliferation.			Amino Acid, Peptide, or Protein	
C117081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117081>	C34661	Hemicrania Continua	A unilateral headache of moderate intensity with exacerbations of severe pain, not attributed to another disorder, that continuously persists for more than three months, and presents with ipsilateral autonomic symptoms during exacerbations.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117082>	C34661	New Daily Persistent Headache	A bilateral, unremitting headache of mild to moderate intensity that occurs daily and may be associated with photophobia, phonophobia, or mild nausea.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117083>	C34661	External Compression Headache	Headache resulting from pressure applied to the cutaneous nerves of the head.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117084>	C79695	Post-Herpetic Neuralgia|PHN|Post-herpetic Neuralgia	Pain that occurs after the disappearance of herpes zoster infection lesions.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117085>	C25982	IL27 Gene|IL27|IL27|Interleukin 27 Gene	This gene is involved in the modulation of cytokine expression and B- and T-cell activities.	IL27 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C117086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117086>	C117085	IL27 wt Allele|IL-27|IL-27A|IL27A|IL27p28|IL30|Interleukin 27 wt Allele|Interleukin 30 Gene|p28	Human IL27 wild-type allele is located in the vicinity of 16p11 and is approximately 13 kb in length. This allele, which encodes interleukin-27 subunit alpha protein, plays a role in the stimulation of innate immunity.	IL27 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117087>	C20497	Interleukin-27 Subunit Alpha|IL-27 Subunit Alpha|IL-27 p28 Subunit|IL-27-A|IL27|IL27-A|IL27A|Interleukin 27, 28-kD Subunit|Interleukin-30|p28	Interleukin-27 subunit alpha (243 aa, ~27 kDa) is encoded by the human IL27 gene. This protein is involved in the modulation of angiogenesis, inflammation and tumorigenesis.	Interleukin-27 Subunit Alpha		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117088>	C25982	EBI3 Gene|EBI3|EBI3|Epstein-Barr Virus Induced 3 Gene	This gene plays a role in innate immunity.	EBI3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C117089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117089>	C117088	EBI3 wt Allele|Epstein-Barr Virus Induced 3 wt Allele|Epstein-Barr Virus Induced Gene 3|Epstein-Barr Virus-Induced Gene|IL-27B|IL27 Subunit B Gene|IL27, EBI3 Subunit|IL27B|IL35 Subunit B Gene|IL35, EBI3 Subunit|Interleukin 27, EBI3 Subunit|Interleukin 35, EBI3 Subunit	Human EBI3 wild-type allele is located in the vicinity of 19p13.3 and is approximately 8 kb in length. This allele, which encodes interleukin-27 subunit beta protein, is involved in the regulation of inflammation, tumorigenesis and angiogenesis.	EBI3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11708>	C61063	Filgrastim/Interleukin-11			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117090>	C20497	Interleukin-27 Subunit Beta|EBI3|EBV-Induced Gene 3 Protein|Epstein-Barr Virus-Induced Gene 3 Protein|IL-27 Subunit Beta|IL-27B|IL27B	Interleukin-27 subunit beta (229 aa, ~25 kDa) is encoded by the human EBI3 gene. This protein plays a role in the regulation of cytokine expression, the modulation of inflammation and the stimulation of innate immunity.	Interleukin-27 Subunit Beta		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117091>	C26057|C25952	DNA2 Gene|DNA Replication Helicase/Nuclease 2 Gene|DNA2|DNA2	This gene is involved in the replication and repair of DNA.			Gene or Genome	
C117092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117092>	C117091	DNA2 wt Allele|DNA Replication Helicase 2 Homolog (Yeast) Gene|DNA Replication Helicase 2, Yeast, Homolog of Gene|DNA Replication Helicase/Nuclease 2 wt Allele|DNA2 DNA Replication Helicase 2-Like (Yeast) Gene|DNA2-Like Gene|DNA2L|PEOA6|RP11-9E13.1|SCKL8|hDNA2	Human DNA2 wild-type allele is located within 10q21.3-q22.1 and is approximately 58 kb in length. This allele, which encodes DNA replication ATP-dependent helicase/nuclease DNA2 protein, plays a role in DNA replication and repair. Mutation of the gene is associated with autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions type 6 and may be associated with Seckel Syndrome 8.			Gene or Genome	
C117093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117093>	C16561|C16517	DNA Replication ATP-Dependent Helicase/Nuclease DNA2|DNA Replication ATP-Dependent Helicase DNA2|DNA Replication ATP-Dependent Helicase-Like Homolog|DNA Replication Helicase 2 Homolog|DNA Replication Nuclease DNA2|DNA2|DNA2-Like Helicase|hDNA2	DNA replication ATP-dependent helicase/nuclease DNA2 (1060 aa, ~120 kDa) is encoded by the human DNA2 gene. This protein is involved in Okazaki fragment processing and DNA double-strand break repair.			Amino Acid, Peptide, or Protein|Enzyme	
C117094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117094>	C20673	MAML3 Gene|MAML3|MAML3|MAML3|Mastermind Like Transcriptional Coactivator 3 Gene	This gene plays a role in both transcriptional activation and signaling.	MAML3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C117095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117095>	C117094	MAML3 wt Allele|CAG Repeat Containing (Glia-Derived Nexin I Alpha) Gene|CAG Repeat Domain Gene|CAGH3|ERDA3|GDN|KIAA1816|MAM-2|MAM2|Mastermind (Drosophila)-Like 3 Gene|Mastermind Like Transcriptional Coactivator 3 wt Allele|Mastermind-Like 3 (Drosophila) Gene|TNRC3|Trinucleotide Repeat Containing 3 Gene	Human MAML3 wild-type allele is located in the vicinity of 4q31.1 and is approximately 438 kb in length. This allele, which encodes mastermind-like protein 3, is involved in both Notch signaling and transcriptional regulation.	MAML3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C117096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117096>	C26199	Mastermind-Like Protein 3|MAML3|Mam-3|Mastermind-Like 3	Mastermind-like protein 3 (1134 aa, ~122 kDa) is encoded by the human MAML3 gene. This protein plays a role in both the positive regulation of transcription and signal transduction.	Mastermind-Like Protein 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117097>	C28533	APOC3 Gene|APOC3|APOC3|Apolipoprotein C3 Gene	This gene is involved in the regulation of lipoprotein metabolism and transport.	APOC3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C117098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117098>	C117097	APOC3 wt Allele|APOCIII|Apolipoprotein C-III Genes|Apolipoprotein C3 wt Allele|HALP2	Human APOC3 wild-type allele is located in the vicinity of 11q23.3 and is approximately 3 kb in length. This allele, which encodes apolipoprotein C-III protein, plays a role in the transport and half-life of very low density lipoproteins and chylomicrons. Mutation of the gene is associated with hyperalphalipoproteinemia 2. Fusion of this gene with the 3' end of the neighboring APOA1 gene is associated with combined apoA-I and apoC-III deficiency.	APOC3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117099>	C16386	Apolipoprotein C-III|APOC3|Apo-CII|ApoC-III|Apolipoprotein C3|Apolipoprotein CIII	Apolipoprotein C-III (99 aa, ~11 kDa) is encoded by the human APOC3 gene. This protein is involved in the modulation of cellular uptake and metabolism of very low density lipoproteins and chylomicrons.	Apolipoprotein C-III		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11709>	C61063	Keyhole Limpet Hemocyanin/MUC-1 Antigen/QS21			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1170>	C2188	Miltefosine|2-[[(Hexadecycloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethylethanaminium Inner Salt|Choline Phosphate Hexadecyl Ester, Hydroxide, Inner Salt|D-18506|Hexadecyl 2-(N,N,N-trimethylamino)ethyl Phosphate|Hexadecylphosphocholine|Hexadecylphosphocholine|MILTEFOSINE|Miltefosin|Miltefosina|Miltefosinum|Miltex|n-Hexadecylphosphorylcholine	An orally- and topically-active alkyl-phosphocholine compound with potential antineoplastic activity.  Miltefosine targets cellular membranes, modulating cell membrane permeability, membrane lipid composition, phospholipid metabolism, and mitogenic signal transduction, resulting in cell differentiation and inhibition of cell growth.  This agent also inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK) pathway and modulates the balance between the MAPK and pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways, thereby inducing apoptosis.  As an immunomodulator, miltefosine stimulates T-cells, macrophages and the expression of interleukin 3 (IL-3), granulocyte-macrophage colony stimulating factor (GM-CSF), and interferon gamma (INF-gamma). (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C117100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117100>	C26070	FBP1 Gene|FBP1|FBP1|Fructose-1,6-Bisphosphatase 1 Gene	This gene plays a role in gluconeogenesis.			Gene or Genome	
C117101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117101>	C117100	FBP1 wt Allele|FBP|Fructose-1,6-Bisphosphatase 1 wt Allele|RP11-342C23.1	Human FBP1 wild-type allele is located in the vicinity of 9q22.3 and is approximately 37 kb in length. This allele, which encodes fructose-1,6-bisphosphatase 1 protein, is involved in gluconeogenesis. Mutation of the gene is associated with fructose-1,6-bisphosphatase deficiency, which can cause life-threatening episodes of hypoglycemia and metabolic acidosis.			Gene or Genome	
C117102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117102>	C16981	Fructose-1,6-Bisphosphatase 1|D-Fructose-1,6-Bisphosphate 1-Phosphohydrolase 1|EC 3.1.3.11|FBP1|FBPase 1|Fructose-1,6-Bisphosphatase, Liver|Fructose-1,6-Diphosphatase|Fructose-Bisphosphatase 1|Growth-Inhibiting Protein 17|Liver FBPase	Fructose-1,6-bisphosphatase 1 (338 aa, ~37 kDa) is encoded by the human FBP1 gene. This protein plays a role in gluconeogenesis.			Amino Acid, Peptide, or Protein|Enzyme	
C117103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117103>	C72070	Juvenile Systemic Sclerosis|JSSc|JSSc|Juvenile Systemic Scleroderma|Juvenile Systemic Scleroderma	Systemic sclerosis that is diagnosed in children. Juvenile systemic sclerosis is more likely to be of the overlap variant and presents with musculoskeletal involvement.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C117104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117104>	C3201	Bullous Systemic Lupus Erythematosus|BSLE|BSLE	A manifestation of systemic lupus erythematosus with a widespread vesiculobullous eruption.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C117105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117105>	C39594	Discoid Rash|Discoid Eruption|Discoid Eruption	A disc-shaped patch(es) of skin inflammation that is red, raised, and scaly; it typically develops on the face, scalp, and neck, and often leaves scars and dyspigmentation as a result of postinflammatory hyperpigmentation.			Finding	NICHD Terminology|Pediatric Rheumatology Terminology
C117106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117106>	C39594	Malar Rash|Malar Eruption|Malar Eruption	An erythematous eruption on the central face, which can be caused by a variety of different conditions.			Finding	NICHD Terminology|Pediatric Rheumatology Terminology
C117107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117107>	C39594	Macular Rash|Macular Eruption|Macular Eruption	An outbreak of small, flat, red spots on the skin.			Finding	NICHD Terminology|Pediatric Rheumatology Terminology
C117108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117108>	C45447	HBV Genotype Assay|HBV Genotype|HBV Genotype|HBV Genotype Measurement|HBV Genotyping|Hepatitis B Virus Genotype Assay	An assay used to determine which hepatitis B virus genome(s) is present in an infection. Seven genotypes of HBV (designated A through G) have been identified. Different genotypes are prevalent in different geographical areas and each carries a different risk of development of hepatocellular carcinoma.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C117109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117109>	C45447	HCV Genotype Assay|HCV Genotype|HCV Genotype|HCV Genotype Measurement|HCV Genotyping|Hepatitis C Virus Genotype Assay	An assay for determining the genotype(s) of hepatitis C virus (HCV) in plasma or serum from HCV-infected individuals. Six major genotypes are recognized and they vary in their response to treatment.			Molecular Biology Research Technique	GDC Terminology|GDC Value Terminology
C11710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11710>	C61063	BCG/Interferon alfa			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117110>	C73600	SPL Business Entity Qualifier Terminology|Business Entity Qualifier|Structured Product Labeling Business Entity Qualifier	Terminology used in the framework of identifying types of business entities.	SPL Business Entity Qualifier Terminology		Intellectual Product	FDA Structured Product Labeling Terminology|SPL Business Operation Terminology
C117111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117111>	C26819	Subacute Cutaneous Lupus Erythematosus	A dermatologic manifestation of lupus involving erythematous, scaly patches or plaques, generally appearing on the upper back, chest, and arms, and often following sun exposure. It most often resolves without scarring.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C117112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117112>	C26819	Lupus Erythematosus Tumidus|LET|LET|Tumid Lupus Erythematosus|Tumid Lupus Erythematosus	A dermatologic manifestation of lupus involving edematous papules and plaques that are typically found on sun-exposed areas of the body. It most often resolves without scarring or pigmentation changes.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C117113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117113>	C25364	Doing Business As	A legal term meaning that the trade name, or fictitious business name, under which the business or operation is conducted and presented to the world is not the legal name of the legal person(s) who actually owns the business and is responsible for it.			Intellectual Product	FDA Structured Product Labeling Terminology|SPL Business Entity Qualifier Terminology
C117114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117114>	C139309	CCRF-CEM	A T-lymphoblastic cell line established by G.E. Foley, et al. from the peripheral blood buffy coat from a four year old female child with acute leukemia.			Experimental Model of Disease	
C117115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117115>	C97092	Fatty Acid Metabolism Disorder	A group of genetic disorders that result from the inability to produce or use an enzyme required to oxidize fatty acids, resulting in an inability to generate energy from fatty acid sources.			Disease or Syndrome	
C117116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117116>	C3420|C180942	t(9;22)	A translocation between chromosome 9 and chromosome 22 that may be associated with Philadelphia chromosome and increased susceptibility to several types of leukemia.	t(9;22)		Cell or Molecular Dysfunction	ALL Authorized Value Terminology|ALL Molecular Analysis Table|CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C117117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117117>	C81315	Classical Phenylketonuria|CPKU|Phenylalanine Hydroxylase Deficiency	A genetic disorder caused by a mutation in the gene that encodes the enzyme phenylalanine hydroxylase, resulting in a severe form of phenylketonuria.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C117118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117118>	C210661	IGKV4-1 Gene|IGKV4-1|IGKV4-1|Immunoglobulin Kappa Variable 4-1 Gene	This gene plays a role in immunoglobulin specificity.	IGKV4-1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C117119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117119>	C139309	MOLT-4	A T-lymphoblastic cell line established from the peripheral blood of a 19 year old male patient with acute lymphoblastic leukemia in relapse.			Experimental Model of Disease	
C11711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11711>	C61063	Bryostatin 1/Gemcitabine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117120>	C117118	IGKV4-1 wt Allele|B3|IGKV41|Immunoglobulin Kappa Variable 4-1 wt Allele	Human IGKV4-1 wild-type allele is located in the vicinity of 2p11.2 and is approximately 1 kb in length. This allele, which encodes immunoglobulin kappa variable 4-1 protein, is involved in antibody structure and antigen specificity.	IGKV4-1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117121>	C210664	Immunoglobulin Kappa Variable 4-1|IGKV4-1|Ig Kappa Chain V-IV Region|Ig Kappa Chain V-IV Region|Ig Kappa Chain V-IV Region B171|Ig Kappa Chain V-IV Region JI1|Ig Kappa Chain V-IV Region Len1|Ig Kappa Chain V-IV Region STH	Immunoglobulin kappa variable 4-1 (121 aa, ~13 kDa) is encoded by the human IGKV4-1 gene. This protein plays a role in antibody specificity.	Ig Kappa Chain V-IV Region		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117122>	C139309	RPMI-8226	A lymphoblast-like cell line established from the peripheral blood of a 61 year old male patient with multiple myeloma (IgG lambda-type).			Experimental Model of Disease	
C117123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117123>	C210661	IGKV1D-13 Gene|IGKV1D-13|IGKV1D-13|Immunoglobulin Kappa Variable 1D-13 Gene	This gene is involved in the modulation of epitope recognition.	IGKV1D-13 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C117124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117124>	C117123	IGKV1D-13 wt Allele|IGKV1D13|Immunoglobulin Kappa Variable 1D-13 wt Allele|L18	Human IGKV1D-13 wild-type allele is located in the vicinity of 2p11.2 and is approximately 1 kb in length. This allele, which encodes immunoglobulin kappa variable 1D-13 protein, plays a role in immunoglobulin epitope specificity.	IGKV1D-13 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117125>	C210664	Immunoglobulin Kappa Variable 1D-13|IGKV1D-13|Ig Kappa Chain V-I Region D-13|Ig Kappa Chain V-I Region D-13	Ig kappa chain V-I region D-13 is encoded by the human IGKV1D-13 gene. This protein is involved in the mediation of antibody-antigen specificity.	Ig Kappa Chain V-I Region D-13		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117126>	C139309	SR	A lymphoma cell line established by Walter J. Urba and Dan L. Longo from the pleural effusion of an 11 year old male patient with childhood immunoblastic lymphoma.			Experimental Model of Disease	
C117127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117127>	C139309	A549/ATCC	An adenocarcinoma cell line established by D.J. Giard in 1972 from lung carcinoma tissue removed from a 58 year old Caucasian male.			Experimental Model of Disease	
C117128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117128>	C20103	FCRL1 Gene|FCRL1|FCRL1|Fc Receptor-Like 1 Gene	This gene may be involved in B-cell function.	FCRL1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C117129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117129>	C117128	FCRL1 wt Allele|CD307a|FCRH1|Fc Receptor-Like 1 wt Allele|IFGP1|IRTA5|Immunoglobulin Superfamily Fc Receptor, Gp42 Gene	Human FCRL1 wild-type allele is located within 1q21-q22 and is approximately 26 kb in length. This allele, which encodes Fc receptor-like protein 1, may play a role in cellular immunity.	FCRL1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11712>	C61063	Carboplatin/Ifosfamide/Thiotepa			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117130>	C18106	Fc Receptor-Like Protein 1|CD307a|CD307a Antigen|Fc Receptor Homolog 1|FcR-Like Protein 1|FcRH1|FcRL1|IFGP Family Protein 1|Immune Receptor Translocation-Associated Protein 5|hIFGP1	Fc receptor-like protein 1 (429 aa, ~47 kDa) is encoded by the human FCRL1 gene. This protein may be involved in B-cell immune functions.	Fc Receptor-Like Protein 1		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117131>	C139309	EKVX	An adenocarcinoma cell line established by the passage of cells from lung carcinoma tissue through nude mice.			Experimental Model of Disease	
C117132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117132>	C20103	FCRL2 Gene|FCRL2|FCRL2|Fc Receptor-Like 2 Gene	This gene may play a role in B-cell development.	FCRL2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C117133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117133>	C117132	FCRL2 wt Allele|CD307b|FCRH2|Fc Receptor-Like 2 wt Allele|IFGP4|IRTA4|Immunoglobulin Superfamily Fc Receptor, Gp42 Gene|SPAP1|SPAP1A|SPAP1B|SPAP1C|UNQ9236/PRO31998	Human FCRL2 wild-type allele is located in the vicinity of 1q23 and is approximately 31 kb in length. This allele, which encodes Fc receptor-like protein 2, may be involved in the development of B-cells.	FCRL2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117134>	C139309	HOP-62	An adenocarcinoma cell line established from lung carcinoma tissue removed from a 60 year old female.			Experimental Model of Disease	
C117135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117135>	C18106	Fc Receptor-Like Protein 2|CD307b|CD307b Antigen|Fc Receptor Homolog 2|FcR-Like Protein 2|FcRH2|FcRL2|IFGP Family Protein 4|Immune Receptor Translocation-Associated Protein 4|Immunoglobulin Receptor Translocation-Associated Protein 4|SH2 Domain Containing Phosphatase Anchor Protein 1|SH2 Domain-Containing Phosphatase Anchor Protein 1	Fc receptor-like protein 2 (508 aa, ~56 kDa) is encoded by the human FCRL2 gene. This protein may play a role in the development of B-cells.	Fc Receptor-Like Protein 2		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117136>	C139309	HOP-92	A large cell carcinoma cell line established from lung carcinoma tissue removed from a 62 year old male.			Experimental Model of Disease	
C117137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117137>	C139309	NCI-H226	A squamous cell carcinoma cell line established in 1980 from the pleural effusion of a male patient with lung carcinoma.			Experimental Model of Disease	
C117138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117138>	C20409	BCL2L10 Gene|BCL2-Like 10 (Apoptosis Facilitator) Gene|BCL2L10|BCL2L10	This gene plays a role in cell survival.	BCL2L10 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C117139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117139>	C117138	BCL2L10 wt Allele|BCL-B|BCL2-Like 10 (Apoptosis Facilitator) wt Allele|BCL2-Like 10 Gene|BCLB|Boo|Diva	Human BCL2L10 wild-type allele is located in the vicinity of 15q21 and is approximately 4 kb in length. This allele, which encodes Bcl-2-like protein 10, is involved in the inhibition of apoptosis.	BCL2L10 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11713>	C61063	Doxorubicin Hcl Liposome/Methotrexate/Prednisone/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117140>	C19928	Bcl-2-Like Protein 10|Anti-Apoptotic Protein NrH|Apoptosis Regulator Bcl-B|Bcl2-L-10	Bcl-2-like protein 10 (194 aa, ~22 kDa) is encoded by the human BCL2L10 gene. This protein plays a role in the promotion of cell survival and the negative regulation of apoptosis.	Bcl-2-Like Protein 10		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117141>	C139309	NCI-H23	An adenocarcinoma cell line established from a 51 year old male patient with lung carcinoma.  The cell sample was removed prior to any treatment for the carcinoma.  NCI-H23 cells have mutations at the amino acid position 12 of GTPase KRas (K-ras) and in codon 246 of the p53 (TP53) gene.			Experimental Model of Disease	
C117142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117142>	C82541	Laboratory Test Name|LAB_TEST|LAB_TEST|LAB_TEST|LAB_TEST|LAB_TEST|LAB_TEST|LBTEST|Lab Name|Lab Test|Laboratory Test	A character or string that represents the full name of the laboratory assessment.			Intellectual Product	ALL Lab Table|ALL Variable Terminology|AML Lab Table|AML Variable Terminology|CDISC CDASH Variable Terminology|CDISC Variable Terminology|EWS Lab Table|EWS Variable Terminology|GCT Lab Table|GCT Variable Terminology|HL Lab Table|HL Variable Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology|OS Lab Table|OS Variable Terminology
C117143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117143>	C20988|C20744	CLDN6 Gene|CLDN6|CLDN6|Claudin 6 Gene	This gene is involved in tight junction formation.	CLDN6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C117144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117144>	C117143	CLDN6 wt Allele|Claudin 6 wt Allele|UNQ757/PRO1488	Human CLDN6 wild-type allele is located in the vicinity of 16p13.3 and is approximately 5 kb in length. This allele, which encodes claudin-6 protein, plays a role in cell-cell adhesion.	CLDN6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117145>	C18073|C16393	Claudin-6|CLDN-6|CLDN6|Claudin 6|Skullin	Claudin-6 (220 aa, ~23 kDa) is encoded by the human CLDN6 gene. This protein is involved in the formation of tight junctions.	Claudin-6		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117146>	C20420	TFAP2E Gene|TFAP2E|TFAP2E|Transcription Factor AP-2 Epsilon (Activating Enhancer Binding Protein 2 Epsilon) Gene	This gene plays a role in the modification of gene expression.	TFAP2E Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C117147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117147>	C117146	TFAP2E wt Allele|AP2E|Transcription Factor AP-2 Epsilon (Activating Enhancer Binding Protein 2 Epsilon) wt Allele	Human TFAP2E wild-type allele is located in the vicinity of 1p34.3 and is approximately 22 kb in length. This allele, which encodes transcription factor AP-2-epsilon protein, is involved in transcriptional regulation.	TFAP2E wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117148>	C17207	Transcription Factor AP-2-Epsilon	Transcription factor AP-2-epsilon (442 aa, ~46 kDa) is encoded by the human TFAP2E gene. This protein plays a role in the regulation of gene transcription.	Transcription Factor AP-2-Epsilon		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117149>	C25966	MicroRNA 19B|MIR19B|MIRN19b|hsa-miR-19b|hsa-miR-19b-3p|miR-19b|miR19b	A 23 ribonucleotide sequence that is a final product of the processing of either MIR19B1 pre-miRNA or MIR19B2 pre-miRNA. This oligonucleotide may be involved in the negative regulation of gene expression.	MicroRNA 19B		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11714>	C61063	Cyclophosphamide/Cytarabine/Fludarabine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117150>	C20921	ARRDC3 Gene|ARRDC3|ARRDC3|Arrestin Domain Containing 3 Gene	This gene plays a role in the positive regulation of receptor signaling.	ARRDC3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C117151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117151>	C117150	ARRDC3 wt Allele|Alpha-Arrestin 3 Gene|Arrestin Domain Containing 3 wt Allele|KIAA1376|TLIMP	Human ARRDC3 wild-type allele is located in the vicinity of 5q14.3 and is approximately 15 kb in length. This allele, which encodes arrestin domain-containing protein 3, is involved in the modulation of adrenergic receptor signaling.	ARRDC3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117152>	C18515	Arrestin Domain-Containing Protein 3|Arrestin Domain-Containing 3|TBP-2-Like Inducible Membrane Protein|Thioredoxin-Binding Protein-2-Like Inducible Membrane	Arrestin domain-containing protein 3 (414 aa, ~46 kDa) is encoded by the human ARRDC3 gene. This protein plays a role in the regulation of adrenergic receptor signaling pathways.	Arrestin Domain-Containing Protein 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117153>	C26511	CYP2A13 Gene|CYP2A13|CYP2A13|Cytochrome P450, Family 2, Subfamily A, Polypeptide 13 Gene	This gene is involved in the oxidation of flavoproteins.	CYP2A13 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C117154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117154>	C117153	CYP2A13 wt Allele|CPAD|CYP2A|CYPIIA13|Cytochrome P450, Family 2, Subfamily A, Polypeptide 13 wt Allele|Cytochrome P450, Subfamily IIA (Phenobarbital-Inducible), Polypeptide 13 Gene|Cytochrome P450, Subfamily IIA, Polypeptide 13 Gene	Human CYP2A13 wild-type allele is located in the vicinity of 19q13.2 and is approximately 8 kb in length. This allele, which encodes cytochrome P450 2A13 protein, plays a role in the metabolism of flavoproteins and xenobiotics.	CYP2A13 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117155>	C139309	NCI-H322M	A bronchioloalveolar carcinoma cell line established from a 52 year old male patient with lung carcinoma.			Experimental Model of Disease	
C117156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117156>	C16484	Cytochrome P450 2A13|CYP2A13|CYPIIA13|EC 1.14.14.1	Cytochrome P450 2A13 (494 aa, ~57 kDa) is encoded by the human CYP2A13 gene. This protein is involved in the oxidation of both flavoproteins and xenobiotics.	Cytochrome P450 2A13		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117157>	C139309	NCI-H460	A large cell carcinoma cell line established by A.F. Gazdar and associates in 1982 from the pleural fluid of a male patient with lung carcinoma.			Experimental Model of Disease	
C117158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117158>	C139309	NCI-H522	An adenocarcinoma cell line established by A.F. Gazdar and associates from a 60 year old male patient with lung carcinoma.			Experimental Model of Disease	
C117159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117159>	C139309	COLO 205	An adenocarcinoma cell line established from the ascites fluid of a 70 year old Caucasian male with colon carcinoma.			Experimental Model of Disease	
C11715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11715>	C61063	Asparaginase/Dexamethasone			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117160>	C139309	HCC-2998	An adenocarcinoma cell line established from a patient with colon carcinoma.			Experimental Model of Disease	
C117161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117161>	C139309	HCT-116	A carcinoma cell line established from an adult male patient with colon carcinoma. HCT-116 cells have a mutation in codon 13 of the ras proto-oncogene.			Experimental Model of Disease	
C117162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117162>	C37942	Emotional Distress	Disturbed mental state characterized by moodiness, irritability, agitation, anxiety, and/or depression resulting from physical or mental stress.			Finding	
C117163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117163>	C139309	HCT-15	An adenocarcinoma cell line established from a male patient with colon carcinoma.			Experimental Model of Disease	
C117164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117164>	C79530	Psychomotor Agitation|Severe Motor Restlessness|Severe Motor Restlessness	Physical restlessness, often associated with increased motor activity.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117165>	C139309	KM12	An adenocarcinoma cell line established from a patient with colon carcinoma.			Experimental Model of Disease	
C117166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117166>	C139309	SW-620	An adenocarcinoma cell line established from a lymph node metastasis from a 51 year old Caucasian male with colon cancer.			Experimental Model of Disease	
C117167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117167>	C74533	Inner Restlessness	A feeling of unrest and/or an inability to feel calm or relaxed.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117168>	C74533	Motor Restlessness	An inability to be still and/or the need to move.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117169>	C139309	SF-268	An astrocytoma cell line established from a 24 year old female patient with right parietal anaplastic astrocytoma.			Experimental Model of Disease	
C11716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11716>	C61063	Dexamethasone/Methotrexate/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117170>	C139309	SF-295	A glioblastoma cell line established from a 67 year old female patient with glioblastoma.			Experimental Model of Disease	
C117171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117171>	C3858	Increased Energy	Feeling of excessive energy, which may be associated with increased activity.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117172>	C20194	THRSP Gene|THRSP|THRSP|Thyroid Hormone Responsive Gene	This gene plays a role in the modulation of lipid biosynthesis.	THRSP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C117173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117173>	C117172	THRSP wt Allele|LPGP1|Lpgp|S14|SPOT14|SPOT14 Homolog (Rat) Gene|THRP|Thyroid Hormone Responsive (SPOT14 Homolog, Rat) Gene|Thyroid Hormone Responsive SPOT14 (Rat) Homolog Gene|Thyroid Hormone Responsive wt Allele|Thyroid Hormone-Responsive SPOT14, Rat, Homolog of Gene	Human THRSP wild-type allele is located in the vicinity of 11q14.1 and is approximately 4 kb in length. This allele, which encodes thyroid hormone-inducible hepatic protein, is involved in the regulation of lipogenesis.	THRSP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117174>	C139309	SF-539	A gliosarcoma cell line established from a 34 year old female patient with gliosarcoma previously treated with radiation and chemotherapy.			Experimental Model of Disease	
C117175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117175>	C18466	Thyroid Hormone-Inducible Hepatic Protein|Lipogenic Protein 1|S14|SPOT14|SPOT14 Homolog|Spot 14 Protein|Thyroid Hormone Responsive SPOT14	Thyroid hormone-inducible hepatic protein (146 aa, ~17 kDa) is encoded by the human THRSP gene. This protein plays a role in lipogenesis.	Thyroid Hormone-Inducible Hepatic Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117176>	C139309	SNB-19	A glioblastoma cell line established from a 47 year old male with left parieto-occipital glioblastoma.			Experimental Model of Disease	
C117177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117177>	C98362	KRAS NP_004976.2:p.G13X|GTPase KRas G13X|GTPase KRas Gly13Xxx|K-Ras 2 G13X|KRAS Codon 13 Mutation|KRAS G13 Mutation|KRAS G13X|KRAS Gly13Xxx|KRAS NP_004976.2:p.Gly13Xxx|KRAS p.G13X|KRAS p.Gly13Xxx|Ki-Ras G13X|NP_004976.2:p.G13X|NP_004976.2:p.Gly13Xxx|Specific codon 13 mutation not stated|c-K-ras G13X	A change in the amino acid residue at position 13 in the GTPase KRas protein where glycine has been replaced by another amino acid.	KRAS NP_004976.2:p.G13X		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117178>	C139309	SNB-75	A glioblastoma cell line established from a 78 year old female with glioblastoma.			Experimental Model of Disease	
C117179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117179>	C139309	U251	A glioblastoma cell line established from a 75 year old male with glioblastoma.			Experimental Model of Disease	
C11717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11717>	C61063	Daunorubicin/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117180>	C98362	KRAS NP_004976.2:p.G12X|GTPase KRas G12X|GTPase KRas Gly12Xxx|K-Ras 2 G12X|KRAS Codon 12 Mutation|KRAS G12 Mutation|KRAS G12X|KRAS Gly12Xxx|KRAS NP_004976.2:p.Gly12Xxx|KRAS p.G12X|KRAS p.Gly12Xxx|Ki-Ras G12X|NP_004976.2:p.G12X|NP_004976.2:p.Gly12Xxx|Specific codon 12 mutation not stated|c-K-ras G12X	A change in the amino acid residue at position 12 in the GTPase KRas protein where glycine has been replaced by another amino acid.	KRAS NP_004976.2:p.G12X		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117181>	C139309	LOX IMVI	A melanoma cell line established from a lymph node metastasis from a 58 year old male patient with cutaneous melanoma.			Experimental Model of Disease	
C117182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117182>	C139309	MALME-3M	A melanoma cell line with fibroblast-like morphology.  It was established in 1975 from a metastasis to the lung from a 43 year old Caucasian male with metastatic melanoma.			Experimental Model of Disease	
C117183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117183>	C139309	M14	A melanoma cell line established from a patient with cutaneous melanoma.			Experimental Model of Disease	
C117184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117184>	C139309	MDA-MB-435	A cell line established at M.D. Anderson Cancer Center in 1976 from the pleural effusion of a 31 year old female patient with history of breast cancer.  Gene expression analysis of the MDA-MB-435 cell line has revealed that the pattern of gene expression resembles that of melanoma cell lines.  Further investigation has revealed that breast-specific genes were not expressed and melanocytic-specific genes were expressed in this cell line.			Experimental Model of Disease	
C117185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117185>	C20466	T-Cell Chemokine|T Cell Chemokine|T Lymphocyte Chemokine|T-Lymphocyte Chemokine	A cytokine with chemoattractant activity that is involved in the recruitment of T-lymphocytes to sites of inflammation.	T-Cell Chemokine		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117186>	C20130	Solute Carrier Family|SLC Family|Solute Carrier Group	A large group of integral membrane proteins that are involved in either facilitated or secondary active transport of solutes across cellular membranes. There are over 300 member proteins organized into approximately 50 families. The members of each family share both substrate preference and at least 20% amino acid sequence identity.	Solute Carrier Family		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117187>	C21176	Amyloid|Amyloid Protein	An insoluble, fibrous aggregate of misfolded proteins or protein fragments. These fibrillar structures usually exhibit a cross-beta-sheet conformation. Deposition of amyloid aggregates is associated with a number of pathologies including amyloidosis and several neurodegenerative disorders.	Amyloid		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Terminology
C117188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117188>	C139309	SK-MEL-2	A melanoma cell line established from a metastatic site on the skin of the thigh of a 60 year old Caucasian male with melanoma.  It expresses wild-type B-Raf and mutant N-Ras.			Experimental Model of Disease	
C117189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117189>	C139309	SK-MEL-28	A hypotetraploid melanoma cell line established from a 51 year old male patient with cutaneous melanoma.			Experimental Model of Disease	
C11718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11718>	C61063	Prinomastat/Temozolomide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117190>	C139309	SK-MEL-5	A melanoma cell line established from an axillary lymph node metastasis from a 24 year old Caucasian female with cutaneous melanoma.			Experimental Model of Disease	
C117191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117191>	C139309	UACC-257	A melanoma cell line established from a patient with cutaneous melanoma.			Experimental Model of Disease	
C117192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117192>	C139309	UACC-62	A melanoma cell line established from a patient with cutaneous melanoma.			Experimental Model of Disease	
C117193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117193>	C3858	Repetitive Behavior|Repetitive Behaviors	Recurring actions that are often non-purposeful.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117194>	C3858	Psychomotor Retardation	Abnormally slow physical movement.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117195>	C3858	Blunted Affect|Restricted Range of Emotion|Restricted Range of Emotion	Restricted range of emotional expressiveness.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117196>	C3858	Flat Affect	The absence of emotional expressiveness.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117197>	C3858	Apathy|Emotional Indifference	An emotional state of indifference characterized by a lack of interest or concern.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117198>	C3858	Tearfulness	Excessive crying.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117199>	C3858	Depressed Mood|Decreased Mood|Decreased Mood|Depressed|Depressed|Low Mood|Low Mood	An emotional state characterized by feelings of sadness, emptiness, and/or tearfulness.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11719>	C61063	Cisplatin/Gemcitabine/Prinomastat			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1171>	C267	Nabilone|Cesamet|Cesamet|Cpd 109514|NABILONE	A synthetic cannabinoid and dibenzopyrane derivative with anti-emetic activity. Although the mechanism of action has not been fully elucidated yet, it has been suggested that nabilone is a highly selective and strong agonist for the cannabinoid receptors CB1 and CB2, both of which are coupled to Gi/o proteins. The CB1 receptors are expressed predominantly in central and peripheral neurons and receptor stimulation has been implicated in the reduction of chemotherapy-induced nausea.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C117200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117200>	C42614	Vendor Name|NAM	The literal identifier of the vendor that performs an assessment or examination.			Intellectual Product	CDISC CDASH Variable Terminology|CDISC Variable Terminology
C117201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117201>	C99065	Perinatal Subependymal Hemorrhage	Bleeding into the thick layer of immature cells under the ependymal lining at the ventrolateral aspect of the lateral cerebral ventricles occurring around the time of birth.			Finding	NICHD Terminology|Perinatal Terminology
C117202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117202>	C101324	Intraventricular Hemorrhage with Parenchymal Hemorrhage of the Newborn|Grade 4 Intraventricular Hemorrhage of the Newborn|Grade 4 Intraventricular Hemorrhage of the Newborn|Intraventricular Hemorrhage of Newborn Grade 4|Intraventricular Hemorrhage with Parenchymal Hemorrhage of Newborn	Bleeding into the lateral cerebral ventricles and the adjacent brain tissue of a newborn infant.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C117203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117203>	C50485|C118807	Intraparenchymal Hemorrhage of the Newborn|Parenchymal Hemorrhage of Newborn|Parenchymal Hemorrhage of the Newborn	Bleeding into the brain tissue of a newborn infant.			Finding	NICHD Terminology|Perinatal Terminology
C117204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117204>	C139309	IGR-OV1	An adenocarcinoma cell line established from a 47 year old female patient with ovarian carcinoma. The sample was removed after the patient had received radiation and cobalt treatment. The carcinoma cells have highly tumorigenic properties, a paracentric inversion of chromosome 3, and a 2;5 translocation.			Experimental Model of Disease	
C117205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117205>	C139309	OVCAR-3	An adenocarcinoma cell line established from a 60 year old Caucasian female patient with ovarian carcinoma previously treated with chemotherapy.			Experimental Model of Disease	
C117206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117206>	C139309	OVCAR-4	An adenocarcinoma cell line established from a 42 year old female patient with ovarian carcinoma previously treated with chemotherapy.			Experimental Model of Disease	
C117207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117207>	C139309	OVCAR-5	An adenocarcinoma cell line established from the ascetic fluid of a 67 year old female patient with ovarian carcinoma.			Experimental Model of Disease	
C117208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117208>	C139309	OVCAR-8	An adenocarcinoma cell line established from a 64 year old female patient with ovarian carcinoma previously treated with chemotherapy.			Experimental Model of Disease	
C117209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117209>	C139309	NCI/ADR-RES	An adriamycin-resistant cell line established by Batist, et al., in 1986, intended to be derived from the breast cancer cell line MCF-7. Recent single nucleotide polymorphism array analysis confirmed that the NCI/ADR-RES cell line is not derived from the MCF-7 cell line, but from the ovarian cancer cell line OVCAR-8.			Experimental Model of Disease	
C11720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11720>	C61063	Gemcitabine/Oxaliplatin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117210>	C139309	SK-OV-3	An adenocarcinoma cell line established from the ascetic fluid of a 64 year old Caucasian female patient with ovarian carcinoma previously treated with chemotherapy. These carcinoma cells are resistant to tumor necrosis factor and to several cytotoxic drugs.			Experimental Model of Disease	
C117211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117211>	C139309	786-0	An adenocarcinoma cell line established from a 58 year old male patient with renal cell carcinoma.			Experimental Model of Disease	
C117212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117212>	C139309	A498	An adenocarcinoma cell line established from a 52 year old female patient with renal cell carcinoma.			Experimental Model of Disease	
C117213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117213>	C139309	ACHN	An adenocarcinoma cell line established in 1979 from the pleural effusion of a 22 year old Caucasian male patient with metastatic renal cell carcinoma.			Experimental Model of Disease	
C117214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117214>	C139309	CAKI-1	A clear cell adenocarcinoma cell line established from a skin metastasis from a 49 year old Caucasian male patient with renal cell carcinoma previously treated with chemotherapy.			Experimental Model of Disease	
C117215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117215>	C139309	RXF 393	A clear cell adenocarcinoma cell line established from a 54 year old male patient with renal cell carcinoma.			Experimental Model of Disease	
C117216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117216>	C139309	SN12C	An adenocarcinoma cell line established from a 43 year old male patient with renal cell carcinoma extensively involving the perinephric fat.			Experimental Model of Disease	
C117217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117217>	C139309	TK-10	An adenocarcinoma cell line established from a 43 year old male patient with renal cell carcinoma.			Experimental Model of Disease	
C117218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117218>	C139309	UO-31	An adenocarcinoma cell line established from a female patient with renal cell carcinoma.			Experimental Model of Disease	
C117219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117219>	C139309	PC-3	An adenocarcinoma cell line established in 1979 from a bone metastasis from a 62 year old Caucasian male patient with stage IV prostate carcinoma.			Experimental Model of Disease	
C11721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11721>	C61063	Cisplatin/Rebeccamycin Analogue|Cisplatin/Rebeccamycin Analog			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117221>	C77140	Original Result or Finding|ORRES	The outcome of the test or finding as originally received or collected.			Finding	CDISC Root Variable Terminology
C117222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117222>	C25375	Character Result or Finding in Standard Format|STRESC	The standardized result of the measurement, test, or examination in character format.			Finding	CDISC Root Variable Terminology
C117223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117223>	C139309	MDA-MB-231/ATCC	An adenocarcinoma cell line established at the M.D. Anderson Cancer Center in 1973 from the pleural effusion of a 51 year old Caucasian female patient with breast carcinoma previously treated with chemotherapy.			Experimental Model of Disease	
C117224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117224>	C139309	MDA-MB-468	An adenocarcinoma cell line established by R. Cailleau, et al. in 1977 from the pleural effusion of a 51 year old female patient with breast carcinoma.			Experimental Model of Disease	
C117225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117225>	C139309	HS 578T	An adenocarcinoma cell line established by A.J. Hackett, et al. from a 74 year old Caucasian female patient with breast carcinoma.			Experimental Model of Disease	
C117226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117226>	C139309	MDA-N	A melanoma cell line derived from the MDA-MB-435 cell line.			Experimental Model of Disease	
C117227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117227>	C139309	BT-549	An adenocarcinoma cell line established from a 72 year old female patient with breast carcinoma.			Experimental Model of Disease	
C117228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117228>	C139309	T-47D	An adenocarcinoma cell line established from the pleural effusion of a 54 year old female patient with ductal breast carcinoma.			Experimental Model of Disease	
C117229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117229>	C214993|C201549	Tusamitamab Ravtansine|ADC SAR408701|Anti-CEACAM5 Antibody-Drug Conjugate SAR408701|SAR408701|TUSAMITAMAB RAVTANSINE	An immunoconjugate consisting of anti-carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) conjugated to a cytotoxic agent, with potential antineoplastic activity. Upon administration of tusamitamab ravtansine the antibody moiety targets CEACAM5 on tumor cells. Upon antibody/antigen binding and internalization, the immunoconjugate releases the cytotoxic agent, which results in tumor cell death. CEACAM5, a member of the CEA family of proteins that plays a key role in cell migration, cell invasion, and cell adhesion, is overexpressed by a variety of cancer cell types.	Anti-5T4 Antibody-Drug Conjugate PF-06263507|Tusamitamab Ravtansine		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11722>	C61063	Alum adjuvant/Monoclonal antibody 4B5 anti-idiotype vaccine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117230>	C2152|C129825	pan-PI3K Inhibitor CLR457|CLR457	An orally bioavailable pan inhibitor of phosphatidylinositol-3-kinase (PI3K), with potential antineoplastic activity. Upon oral administration, pan-PI3K inhibitor CLR457 inhibits all of the PI3K kinase isoforms, which may result in apoptosis and growth inhibition in tumor cells overexpressing PI3K. Activation of the PI3K pathway promotes cell growth, survival, and resistance to both chemotherapy and radiotherapy.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C117231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117231>	C28676|C201545	Allogeneic Natural Killer Cell Line NK-92|HUMAN NATURAL KILLER CELL LINE NK-92|NK-92|NK-92 Cells|haNK	A proprietary, human cytotoxic cell line composed of allogeneic, activated, interleukin-2 (IL-2) dependent-natural killer cells derived from a 50-year old male patient with rapidly progressive non-Hodgkin's lymphoma, with potential antineoplastic activity. As NK-92 cells are devoid of killer inhibitory receptors (KIRs; also called killer cell immunoglobulin-like receptors), which are negative regulators of NK cell activity, cancer cells are unable to suppress the cancer cell killing ability of the NK-92 cells. Upon infusion of the allogeneic NK cell line NK-92, the NKs recognize and bind to tumor cells. This leads to the secretion and release of perforins, granzymes, cytokines and chemokines, which results in cancer cell lysis and apoptosis. In addition, NK-92 cells express high affinity Fc receptors, which bind to therapeutic antibodies; therefore, this agent can enhance antibody dependent cellular cytotoxicity (ADCC) of co-administered therapeutic antibodies.	Allogeneic Natural Killer Cell Line NK-92		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C117232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117232>	C137999|C129826	CD28CAR/CD137CAR-expressing T-Lymphocytes	Third generation, chimeric antigen receptor (CAR) cells composed of T-lymphocytes transduced with a lentiviral vector expressing a CAR consisting of an a single chain variable fragment specific for a particular antigen, coupled to the two co-stimulatory signaling domains Cluster of Differentiation 28 (CD28) and Cluster of Differentiation 137 (CD137; 4-1BB), and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3-zeta), with potential immunomodulating and antineoplastic activities. Upon transfusion, CD28CAR/CD137CAR-expressing T-lymphocytes are directed to, and induce selective toxicity in tumor cells expressing the particular antigen. CD28, a T-cell surface-associated co-stimulatory molecule, is required for T-cell activation, proliferation, and survival. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of the antigen. Furthermore, inclusion of the 4-1BB signaling domain may increase the antitumor activity when compared to the inclusion of the CD28 co-stimulatory domain and CD3-zeta alone.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C117233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117233>	C200766	IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes|Autologous IL13(EQ)BBzeta/CD19t+ TCM-enriched T Cells	A preparation of ex vivo expanded, genetically modified autologous central memory-enriched T-cells (Tcm) transduced with a replication incompetent, self-inactivating (SIN) lentiviral vector expressing a hinge-optimized, chimeric antigen receptor (CAR) specific for interleukin-13 receptor alpha 2 (IL13Ra2), and containing the cluster of differentiation 137 (CD137; 4-1BB) co-stimulatory signaling domain fused to the signaling domain of the T cell antigen receptor complex zeta chain (CD3-zeta), and a truncated form of human cluster of differentiation 19 (CD19t), with potential immunostimulating and antineoplastic activities. Upon intratumoral or intracavitary administration, IL13Ra2-specific, hinge-optimized, 41BB-co-stimulatory CAR/truncated CD19 expressing T-lymphocytes are directed to, and induce selective toxicity and cytolysis in IL13Ra2-expressing tumor cells. IL13Ra2, overexpressed by a variety of tumor cell types, is associated with increased tumor cell proliferation, migration and invasiveness. The costimulatory signaling domain enhances both proliferation of T-cells and antitumor activity. Hinge optimization prevents the recognition and clearance of the CAR by endogenous Fc receptors (FcRs). CD19t is used as a surface marker to both quantify and track the gene modified T-cells in vivo.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C117234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117234>	C129820	Alpha-tocopheryloxyacetic Acid|.ALPHA.-TOCOPHERYLOXYACETIC ACID|2,5,7,8-Tetramethyl-(2R-(4R,8R,12-trimethyltridecyl) chroman-6-yloxy) Acetic Acid|a-TEA|alpha-TEA	An orally bioavailable vitamin E derivative with potential antineoplastic and immunostimulating activities. Upon administration, alpha-tocopheryloxyacetic acid (alpha-TEA) induces tumor autophagy; the autophagosomes formed, which carry tumor associated antigens (TAAs), allow for increased cross-presentation of TAAs by professional antigen-presenting cells (APCs). This activates a T cell-mediated T helper type 1 (TH1) response, generates a cytotoxic T-lymphocyte (CTL) response against cancer cells, and reduces the frequency of regulatory T-cell (Treg) differentiation. In addition, alpha-TEA modulates the release of various cytokines and chemokines and induces tumor cell apoptosis. Altogether, this results in decreased tumor cell proliferation.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C117235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117235>	C1752	IDH1R132H-Specific Peptide Vaccine PEPIDH1M|PEPIDH1M|PEPIDH1M Vaccine	A peptide vaccine consisting of a peptide derived from isocitrate dehydrogenase 1 (IDH1) containing the point mutation R132H (IDH1R132H), with potential antineoplastic activity. Intradermal vaccination with the IDH1R132H-specific peptide vaccine PEPIDH1M may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the IDH1R132H protein. The IDH1 point mutation of amino acid residue 132 is highly expressed in gliomas and is associated with increased production of the oncometabolite R-2-hydroxyglutarate (2HG).	IDH1R132H-Specific Peptide Vaccine PEPIDH1M		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C117236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117236>	C215121|C198860|C1742|C129824	VEGF/HGF-targeting DARPin MP0250|Bispecific VEGF/HGF-targeting Darpin|MP-0250|MP0250	A designed ankyrin repeat proteins (DARPin)-based agent targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), with potential antiangiogenic and antineoplastic activities. Compared to antibodies, DARPins are small in size, have favorable pharmacokinetics and allow for both high affinity binding and efficacy. Upon administration, the VEGF/HGF-targeting DARPin MP0250 binds to and inhibits both HGF and VEGF. This prevents HGF- and VEGF-mediated signaling, and inhibits the growth of HGF/VEGF-overexpressing tumor cells. This agent also prevents osteolysis, due to the inhibitory effect on HGF signaling. HGF and VEGF are overexpressed in a variety of cancer cell types and are associated with increased cell proliferation, migration and adhesion.	VEGF/HGF-targeting DARPin MP0250		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C117237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117237>	C224031|C200766	ROR1 CAR-specific Autologous T-Lymphocytes|Autologous ROR1-CAR-T Cells|Chimeric Anti-ROR1 T-cell Receptor-expressing Autologous T-lymphocytes|ROR1-CAR-T	A mixture of two T-lymphocyte preparations expressing a chimeric antigen receptor (CAR) consisting of an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain variable fragment (scFv) fused to either the co-stimulatory signaling domain cluster of differentiation 28 (CD28), and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3-zeta) (ROR1CD28zeta), or the co-stimulatory signaling domain cluster of differentiation 137 (CD137; 4-1BB), and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3-zeta) (ROR1CD137zeta), with potential immunomodulating and antineoplastic activities. Upon simultaneous administration of the two T-lymphocyte populations ROR1CD28zeta and ROR1CD137zeta , the ROR1 CAR-specific autologous T-lymphocytes are directed to tumor cells expressing ROR1, which may result in a selective toxicity against, and lysis of ROR1-expressing tumor cells. CD28, a T-cell surface-associated co-stimulatory molecule, is required for full T-cell activation, proliferation, and survival. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of ROR1. ROR1, also known as neurotrophic tyrosine kinase, receptor-related 1, is expressed during embryogenesis and by certain leukemias.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C117238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117238>	C201511|C201282|C129822	Flotetuzumab|CD123 x CD3 DART Bi-Specific Antibody MGD006|CD123 x CD3 Dual Affinity Re-Targeting Bi-Specific Antibody MGD006|FLOTETUZUMAB|MGD006|RES234|S80880	An anti-CD123/anti-CD3 bispecific humanized monoclonal antibody with potential immunostimulatory and antineoplastic activities. Flotetuzumab possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD123, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of flotetuzumab, this bispecific antibody simultaneously binds to both CD3-expressing T-cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated cell lysis of CD123-expressing tumor cells. CD123, the interleukin-3 receptor alpha chain, is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells.	Flotetuzumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C117239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117239>	C275|C1892	Anthocyanin-rich Corn Extract	A corn-based, water-soluble extract rich in the polyphenol anthocyanin, with potential antioxidant, anti-inflammatory and chemoprotective activities. Upon administration of the anthocyanin-rich corn extract, the anthocyanins scavenge reactive oxygen species (ROS), which protects healthy cells from radiation-induced oxidative stress and DNA damage. In addition, anthocyanins modulate the expression of various genes and proteins involved in inflammation, tumor cell proliferation, angiogenesis, tumor cell invasion and differentiation. This agent also chelates metals and induces the expression of enzymes involved in Phase II antioxidant and detoxification pathways, which may further protect cells against oxidative stress induced by toxins and carcinogens.			Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11723>	C61063	Monoclonal antibody 4B5 anti-idiotype vaccine/Sargramostim			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117240>	C203670|C1920	HPV 16 E7 Antigen-expressing Lactobacillis casei Vaccine BLS-ILB-E710c|BLS-ILB-E710c|BLS-ILS-E710c|L. casei-E7 BLS_ILB_E710c|L.casei-PgsA-E7|LacE7 Vaccine	An orally available Lactobacillis casei (L. casei)-based vaccine expressing the human papillomavirus (HPV) type 16 isoform E7 protein linked to the poly-gamma-glutamate synthetase complex gene pgsA, with potential immunostimulating activity. Upon oral administration, the expressed HPV 16 E7 may stimulate the immune system to mount a mucosal cytotoxic T-lymphocyte (CTL) response against HPV 16 E7-expressing tumor cells. The poly-glutamic acid synthetase PgsA from Bacillus subtilis acts as an anchoring motif that facilitates the expression of the HPV antigen protein on the surface of the bacteria. HPV 16 E7, a cell surface glycoprotein and tumor associated antigen, is overexpressed in various viral-related cancers.			Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C117241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117241>	C20401	Anselamimab|11-1F4|111F4|ANSELAMIMAB|CAEL 101|CAEL-101|CAEL101|Chimeric Amyloid-reactive Monoclonal Antibody CAEL-101|Chimeric Fibril-reactive Monoclonal Antibody CAEL-101|Chimeric Fibril-reactive Monoclonal Antibody CAEL-101|c11-1F4 mAb|mAb-11-1F4	A chimeric monoclonal antibody specifically targeting human immunoglobulin light chain (LC)-related fibrils, which may potentially be used in the treatment of light chain-associated (AL) amyloidosis. Upon administration, anselamimab targets and binds to the amyloid-related, conformational epitope on LC-related fibrils. This inhibits fibrillogenesis, induces an Fc-mediated cellular inflammatory response, increases degradation and elimination of AL amyloidomas, and prevents systemic LC-associated amyloid deposits. In AL amyloidosis the amyloid fibrils are composed of immunoglobulin light chain fragments.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C117242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117242>	C28533	SLC6A2 Gene|SLC6A2|SLC6A2|Solute Carrier Family 6 (Neurotransmitter Transporter), Member 2 Gene	This gene plays a role in neurotransmitter recycling.	SLC6A2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C117243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117243>	C117242	SLC6A2 wt Allele|NAT1|NET|NET1|Neurotransmitter Transporter, Noradrenalin Gene|SLC6A5|Solute Carrier Family 6 (Neurotransmitter Transporter), Member 2 wt Allele|Solute Carrier Family 6 (Neurotransmitter Transporter, Noradrenalin), Member 2 Gene|Solute Carrier Family 6 Member 5 Gene	Human SLC6A2 wild-type allele is located in the vicinity of 16q12.2 and is approximately 51 kb in length. This allele, which encodes sodium-dependent noradrenaline transporter protein, is involved in the transport of norepinephrine into presynaptic cells. Variation of the gene is associated with orthostatic intolerance.	SLC6A2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117244>	C16386	Sodium-Dependent Noradrenaline Transporter|NET|Neurotransmitter Transporter|Norepinephrine Transporter|Norepinephrine Transporter Protein 1|SLC6A2|Solute Carrier Family 6 Member 2	Sodium-dependent noradrenaline transporter (617 aa, ~69 kDa) is encoded by the human SLC6A2 gene. This protein plays a role in the reuptake of norepinephrine by presynaptic cells.	Sodium-Dependent Noradrenaline Transporter		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117245>	C3858	Decreased Attention	Impaired ability to focus on a subject or idea.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117246>	C3858	Decreased Concentration	Reduced ability to sustain attention.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117247>	C133710	HERC2 Gene|HECT and RLD Domain Containing E3 Ubiquitin Protein Ligase 2 Gene|HERC2|HERC2	This gene is involved in both protein ubiquitination and DNA damage repair.			Gene or Genome	
C117248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117248>	C3858	Manic Mood	An emotional state characterized by marked to extreme elevation of mood with noticeable effect of functioning.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117249>	C117247	HERC2 wt Allele|D15F37S1|HECT Domain and RCC1-Like Domain 2 Gene|HECT and RLD Domain Containing E3 Ubiquitin Protein Ligase 2 wt Allele|Hect Domain and RLD 2 Gene|MRT38|SHEP1|jdf2|p528	Human HERC2 wild-type allele is located in the vicinity of 15q13 and is approximately 211 kb in length. This allele, which encodes E3 ubiquitin-protein ligase HERC2 protein, plays a role in the modulation of both DNA repair and protein ubiquitination. Variation in the gene defines the skin/hair/eye pigmentation variation locus 1, and mutation of the gene is associated with autosomal recessive mental retardation 38.			Gene or Genome	
C11724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11724>	C61007	Anti-thymocyte globulin/Cyclosporine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117251>	C21254	E3 Ubiquitin-Protein Ligase HERC2|EC 2.3.2.26|EC 6.3.2.-, Formerly|HECT Domain and RCC1-Like Domain-Containing Protein 2	E3 ubiquitin-protein ligase HERC2 (4834 aa, ~527 kDa) is encoded by the human HERC2 gene. This protein is involved in ubiquitin-dependent retention of DNA repair proteins.			Amino Acid, Peptide, or Protein|Enzyme	
C117252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117252>	C3858	Mood Lability|Emotional Lability|Emotional Lability|Mood Swing|Mood Swing	A condition of frequent mood changes associated with excessive emotional reactions.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117253>	C3858	Disinhibition|Disinhibited|Disinhibited	Unrestrained behavior, often at odds with social norms.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117254>	C97092|C61250	Sphingolipidosis	An inherited metabolic disorder that affects the metabolism of the spinhgolipids. Representative examples include Gaucher disease, Tay-Sachs disease, and Niemann-Pick disease.	Sphingolipidosis		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology|Neonatal Research Network Terminology|NICHD Terminology
C117255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117255>	C20921	DIXDC1 Gene|DIX Domain Containing 1 Gene|DIXDC1|DIXDC1	This gene plays a role in the positive regulation of the Wnt signaling pathway.			Gene or Genome	
C117256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117256>	C117255	DIXDC1 wt Allele|CCD1|DIX Domain Containing 1 wt Allele|KIAA1735	Human DIXDC1 wild-type allele is located in the vicinity of 11q23.1 and is approximately 95 kb in length. This allele, which encodes dixin protein, is involved in the Wnt signaling pathway.			Gene or Genome	
C117257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117257>	C18515	Dixin|Coiled-Coil DIX1|Coiled-Coil Protein DIX1|Coiled-Coil-DIX1|DIX Domain-Containing Protein 1	Dixin (683 aa, ~77 kDa) is encoded by the human DIXDC1 gene. This protein plays a role in Wnt signaling.			Amino Acid, Peptide, or Protein	
C117258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117258>	C20420	ZNF395 Gene|ZNF395|ZNF395|Zinc Finger Protein 395 Gene	This gene may be involved in transcriptional regulation.			Gene or Genome	
C117259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117259>	C117258	ZNF395 wt Allele|DKFZp434K1210|HDBP-2|HDBP2|HDRF-2|PBF|PRF-1|PRF1|Si-1-8-14|Zinc Finger Protein 395 wt Allele	Human ZNF395 wild-type allele is located in the vicinity of 8p21 and is approximately 57 kb in length. This allele, which encodes zinc finger protein 395, plays a role in DNA binding, and may play a role in transcriptional regulation.			Gene or Genome	
C11725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11725>	C61063	Fluorouracil/Leucovorin Calcium/Triacetyluridine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117260>	C17207	Zinc Finger Protein 395|HD Gene Regulatory Region-Binding Protein 2|HD-Regulating Factor 2|HDRF-2|Huntington Disease Gene Regulatory Region-Binding Protein 2|Huntington's Disease Gene Regulatory Region-Binding Protein 2|PRF-1|Papillomavirus Regulatory Factor 1|Papillomavirus Regulatory Factor PRF-1|Papillomavirus-Binding Factor|Si-1-8-14|ZNF395	Zinc finger protein 395 (513 aa, ~55 kDa) is encoded by the human ZNF395 gene. This protein is involved in DNA binding.			Amino Acid, Peptide, or Protein	
C117261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117261>	C3858	Oppositional Behavior|Oppositionality	Negative, defiant, or hostile behavior directed towards authority.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117262>	C3858	Aggression	A verbal or physical act of hostility.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117263>	C3858	Nightmare	A disturbing dream that occurs during rapid eye movement sleep and results in feelings of strong terror, fear, distress, or anxiety.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117264>	C3858	Disordered Thinking|Disordered Thoughts|Disordered Thoughts|Thought Disorganization|Thought Disorganization	Incoherent, disorganized or illogical thought processes.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117265>	C3858	Racing Thoughts	Abnormally rapid thoughts with or without abrupt changes from one topic to another.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117266>	C3858	Flight of Ideas	Rapid succession of thoughts pertaining to different subjects that are still connected.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117267>	C118807	Infant Irritability|Irritability, Infant|Irritability, Infant	Crying easily, difficult to console.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117268>	C25802	HSP90B1 Gene|HSP90B1|HSP90B1|Heat Shock Protein 90 Beta Family Member 1 Gene	This gene plays a role in both ATP metabolism and protein folding.			Gene or Genome	
C117269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117269>	C117268	HSP90B1 wt Allele|ECGP|GP96|GRP94|Glucose-Regulated Protein, 94-kD Gene|HEL-S-125m|HEL35|Heat Shock Protein 90 Beta Family Member 1 wt Allele|Heat Shock Protein 90kDa Beta (Grp94), Member 1 Gene|Heat-Shock Protein, 90-kD, Beta, 1 Gene|TRA1|Tumor Rejection Antigen (Gp96) 1 Gene	Human HSP90B1 wild-type allele is located within 12q24.2-q24.3 and is approximately 24 kb in length. This allele, which encodes endoplasmin protein, is involved in ATP-hydrolysis dependent post-translational protein processing.			Gene or Genome	
C11726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11726>	C61063	Cytarabine/Leucovorin Calcium			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117270>	C17764	Endoplasmin|94 kDa Glucose-Regulated Protein|Endothelial Cell (HBMEC) Glycoprotein|Epididymis Luminal Protein 35|Epididymis Secretory Sperm Binding Protein Li 125m|GRP-94|Gp96 Homolog|HSP90B1|Heat Shock Protein 90 kDa Beta Member 1|Stress-Inducible Tumor Rejection Antigen Gp96|Tumor Rejection Antigen 1	Endoplasmin (803 aa, ~92 kDa) is encoded by the human HSP90B1 gene. This protein plays a role in both post-translational protein folding and ATP hydrolysis.			Amino Acid, Peptide, or Protein	
C117271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117271>	C3858	Impaired Judgment|Impaired Judgement	Reduced ability to plan, poor decision making.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117272>	C50485|C118807	Periventricular Hemorrhage of the Newborn|PVH|Periventricular Hemorrhage of Newborn	Bleeding into the brain tissue adjacent to the lateral cerebral ventricles of newborn infant.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Perinatal Terminology
C117273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117273>	C53543|C28193	Heterotaxy Syndrome|Heterotaxia Syndrome|Heterotaxia Syndrome	A rare, genetic disorder in which symptoms are generally secondary to the abnormal location of the organs within the thoracic, abdominal, or peritoneal cavities. Anatomic and functional problems can include cardiac defects, intestinal malrotation leading to volvulus, biliary atresia, and various defects of the central nervous system, urinary tract, and skeleton.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C117274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117274>	C29636	Atenolol/Chlorthalidone|Tenoretic	A combination preparation composed of the adrenergic beta-1 receptor antagonist atenolol and thiazide-like diuretic chlorthalidone, with anti-hypertensive activity. Atenolol selectively binds to beta-1 adrenergic receptors in the heart and vascular smooth muscle, thereby inhibiting sympathetic stimulation. This results in a decrease in cardiac rate and muscle contractility, thereby reducing cardiac output. As a diuretic, chlorthalidone directly inhibits sodium and chloride reabsorption on the luminal membrane of the early segment in the distal convoluted tubule (DCT) in the kidney. This leads to an increase in sodium, chloride, bicarbonate, and potassium secretion and results in the excretion of water. Together, these agents lead to a reduction in blood pressure.			Pharmacologic Substance	
C117275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117275>	C129986	Gynostemma pentaphyllum Supplement|Jiao Gu-lan|Jiaogulan	A traditional Chinese medicine (TCM) derived from the plant Gynostemma pentaphyllum, an herbaceous climbing vine found in southern China and Southeast Asia, with potential antioxidant activity. Gynostemma pentaphyllum intake has also been used for its adaptogenic effect, to decrease cholesterol and high blood pressure, to strengthen the immune system, and to increase stamina and to improve memory.			Pharmacologic Substance	
C117276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117276>	C29636	Benazepril/Hydrochlorothiazide|Lotensin HCT	A combination preparation of the synthetic angiotensin-converting enzyme (ACE) inhibitor prodrug benazepril and the thiazide diuretic hydrochlorothiazide, with antihypertensive activity. Benazepril is de-esterified by the liver into its active form benazeprilat, which competitively inhibits ACE. ACE inhibition prevents the formation of angiotensin II, and blocks angiotensin II-mediated activities, including vasoconstriction and stimulation of synthesis and secretion of aldosterone, which leads to an increase in sodium excretion and increases water outflow. Hydrochlorothiazide inhibits electrolyte reabsorption via binding to the Na-Cl cotransporter on the renal distal tubules, thereby increasing excretion of sodium, potassium, chloride, bicarbonate and water. Together, these agents lead to a reduction in blood pressure.			Pharmacologic Substance	
C117277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117277>	C36280	Demyelination|DEMYELINATION|Dysmyelination	Breakdown, or abnormal development, of a nerve fiber myelin sheath.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117278>	C97928	IDH1 Protein Variant|Cytosolic NADP-Isocitrate Dehydrogenase Protein Variant|Isocitrate Dehydrogenase [NADP] Cytoplasmic Protein Variant	A variation in the amino acid sequence for the isocitrate dehydrogenase [NADP] cytoplasmic protein.	IDH1 Protein Variant		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C117279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117279>	C97928	IDH2 Protein Variant|Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial Protein Variant|Isocitrate Dehydrogenase [NADP], Mitochondrial Protein Variant	A variation in the amino acid sequence for the isocitrate dehydrogenase [NADP], mitochondrial protein.	IDH2 Protein Variant		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C11727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11727>	C61063	Cytarabine/Daunorubicin/PSC 833			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117280>	C117278	IDH1 NP_005887.2:p.R132X|Cytosolic NADP-Isocitrate Dehydrogenase Protein Arg132Xxx|Cytosolic NADP-Isocitrate Dehydrogenase Protein R132X|IDH1 Arg132Xxx|IDH1 NP_005887.2:p.Arg132Xxx|IDH1 R132|IDH1 R132|IDH1 R132 Mutation|IDH1 R132X|IDH1 R132X Mutation|IDH1 p.Arg132Xxx|IDH1 p.R132|IDH1 p.R132X|IDH1-R132 Mutation|Isocitrate Dehydrogenase [NADP] Cytoplasmic Arg132Xxx|Isocitrate Dehydrogenase [NADP] Cytoplasmic R132X|NP_005887.2:p.Arg132Xxx|NP_005887.2:p.R132X	A change in the amino acid residue at position 132 in the isocitrate dehydrogenase [NADP] cytoplasmic protein where arginine has been replaced by another amino acid. Mutations at this position occur frequently in high-grade gliomas but not in other solid tumors.	IDH1 NP_005887.2:p.R132X		Cell or Molecular Dysfunction	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117281>	C117279	IDH2 NP_002159.2:p.R140X|IDH2 Arg140Xxx|IDH2 R140|IDH2 R140|IDH2 R140 Mutation|IDH2 R140X|IDH2 p.Arg140Xxx|IDH2 p.R140|Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial Arg140Xxx|Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial R140X|Isocitrate Dehydrogenase [NADP], Mitochondrial Arg140Xxx|Isocitrate Dehydrogenase [NADP], Mitochondrial R140X|NP_002159.2:p.Arg140Xxx|NP_002159.2:p.R140X	A change in the amino acid residue at position 140 in the isocitrate dehydrogenase [NADP], mitochondrial protein where arginine has been replaced by another amino acid. Mutations at this position are found in patients with acute myeloid leukemia following myelodysplastic syndromes and is associated with shorter overall survival.	IDH2 NP_002159.2:p.R140X		Cell or Molecular Dysfunction	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117282>	C117279	IDH2 NP_002159.2:p.R172X|IDH2 Arg172Xxx|IDH2 R172|IDH2 R172|IDH2 R172 Mutation|IDH2 R172X|IDH2 p.Arg172Xxx|IDH2 p.R172|IDH2(R172)|Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial Arg172Xxx|Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial R172X|Isocitrate Dehydrogenase [NADP+], Mitochondrial R172X|Isocitrate Dehydrogenase [NADP], Mitochondrial Arg172Xxx|NP_002159.2:p.Arg172Xxx|NP_002159.2:p.R172X	A change in the amino acid residue at position 172 in the isocitrate dehydrogenase [NADP], mitochondrial protein where arginine has been replaced by another amino acid. Mutations at this position are found in patients with acute myeloid leukemia following myelodysplastic syndromes and is associated with shorter overall survival.	IDH2 NP_002159.2:p.R172X		Cell or Molecular Dysfunction	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117283>	C105906	JAK2 NP_004963.1:p.V617X|JAK2 NP_004963.1:p.Val617Xxx|JAK2 V617|JAK2 V617X|JAK2 Val617Xxx|JAK2 p.V617|JAK2 p.V617X|JAK2 p.Val617Xxx|Janus Kinase 2 V617X|Janus Kinase 2 Val617Xxx|NP_004963.1:p.V617X|NP_004963.1:p.Val617Xxx|Tyrosine-Protein Kinase JAK2 V617X|Tyrosine-Protein Kinase JAK2 Val617Xxx	A change in the amino acid residue at position 617 in the tyrosine-protein kinase JAK2 protein where valine has been replaced by another amino acid. A change to phenylalanine at this position is associated with polycythemia vera.	JAK2 NP_004963.1:p.V617X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117284>	C36345	Cytoplasmic Nucleophosmin Expression|Cytoplasmic NPM1|Cytoplasmic Nucleophosmin|NPM1 Cytoplasmic Localization|NPM1c|NPMc|NPMc	A variant form of nucleophosmin with cytoplasmic expression. These variants have either a 4-base or 9-base insertion in exon 12 of the NPM1 gene. Acute myelogenous leukemia with normal cytogenetics and cytoplasmic nucleophosmin (NPMc+ AML) constitutes about one third of the cases of primary AML in adults.	Cytoplasmic Nucleophosmin Expression		Cell or Molecular Dysfunction	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117285>	C3858	Obsessive Thinking	A series of thoughts that are difficult to suppress and may be a consequence or cause of anxiety.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117286>	C3858	Amotivation	Lack of drive to participate in social activities or goal oriented behavior.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117287>	C3376	Night Terrors|Sleep Terrors	Episodes of abrupt awakening associated with screaming, agitation and hyperarousal.			Mental or Behavioral Dysfunction	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C117288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117288>	C68456	Isoquercetin|2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-chromen-4-one|IQC-950AN|ISOQUERCETIN	An orally bioavailable, glucoside derivative of the flavonoid quercetin and protein disulfide isomerase (PDI) inhibitor, with antioxidant and potential antithrombotic activity. As an antioxidant, isoquercetin scavenges free radicals and inhibits oxidative damage to cells. As a PDI inhibitor, this agent blocks PDI-mediated platelet activation, and fibrin generation, which prevents thrombus formation after vascular injury. In addition, isoquercetin is an alpha-glucosidase inhibitor. PDI, an oxidoreductase secreted by activated endothelial cells and platelets, plays a key role in the initiation of the coagulation cascade. Cancer, in addition to other thrombotic disorders, increases the risk of thrombus formation.	Quercetin		Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C117289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117289>	C1931|C129986	Realgar-Indigo naturalis Formulation|Compound Huangdai|RIF|RIF Formula|Realgar-Indigo naturalis formulation	An orally bioavailable, traditional Chinese medicine (TCM)-based formulation composed of Realgar-Indigo naturalis formula (RIF) with potential antineoplastic activity. The main constituents in RIF are realgar, Indigo naturalis, and Salvia miltiorrhiza, with tetraarsenic tetrasulfide (As4S4), indirubin and tanshinone IIA as the main active ingredients, respectively, which appear to exert synergistic effects on cancer cells. Tetraarsenic tetrasulfide specifically induces the ubiquitination and degradation of promyelocytic leukemia retinoic acid receptor alpha (PML-RARalpha) oncoprotein. In addition, the active ingredients in the Realgar-Indigo naturalis formulation enhance the expression of myeloid differentiation genes, and induce G(1)/G(0) cell cycle arrest. PML-RARalpha, an acute promyelocytic leukemia (APL)-specific fusion gene, inhibits differentiation and promotes survival of myeloid precursor cells			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11728>	C61063	Tamoxifen/Tretinoin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117290>	C129825	Ibrilatazar|2-Hydroxylinoleic Acid|9,12-Octadecadienoic Acid, 2-Hydroxy-, (9Z,12Z)-|ABTL0812|IBRILATAZAR|LP-10218|LP10218|SCLN-0812|SCLN0812|mTORC1/mTORC2/DHFR Inhibitor ABTL0812	An orally bioavailable, lipid analogue and inhibitor of raptor-mammalian target of rapamycin (mTOR) (mTOR complex 1; mTORC1), rictor-mTOR (mTOR complex 2; mTORC2) and dihydrofolate reductase (DHFR) with potential antineoplastic activity. Upon oral administration, ibrilatazar binds to and inhibits both mTORC1 and mTORC2, which may result in apoptosis and a decrease in proliferation in mTORC1/2-expressing tumor cells. mTOR is a serine/threonine kinase that is upregulated in some tumors; it plays an important role in the PI3K/Akt/mTOR signaling pathway which is often deregulated in cancer cells. In addition, ibrilatazar inhibits DHFR, an enzyme that reduces dihydrofolic acid to tetrahydrofolic acid, thereby blocking tetrahydrofolate synthesis, and resulting in both the depletion of nucleotide precursors and the inhibition of DNA, RNA and protein synthesis. This induces autophagy-induced cell death and further inhibition of cell proliferation.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C117291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117291>	C176017|C1512	PSMA-targeted Tubulysin B-containing Conjugate EC1169|EC1169|EC1719	An injectable, water soluble, small molecule drug conjugate (SMDC) containing a ligand specific for prostate-specific membrane antigen (PSMA), conjugated via a stable, enzyme-cleavable linker to the cytotoxic agent tubulysin B hydrazide (TubBH), with potential antineoplastic activity. Upon administration of PSMA-targeted tubulysin B-containing conjugate EC1169, the PSMA ligand specifically targets and binds to PSMA, a protein which is abundantly expressed on the surface of metastatic and hormone-refractory prostate cancer cells as well as on the neovasculature of many solid tumors. This allows for the specific delivery of TubBH to PSMA-expressing cancer cells. Upon internalization and cleavage, tubulysin B binds to tubulin and inhibits microtubule polymerization, which blocks cell division and results in G2/M phase arrest, tumor cell apoptosis and a decrease in PSMA-expressing tumor cells.	PSMA-targeted Tubulysin B-containing Conjugate EC1169		Indicator, Reagent, or Diagnostic Aid|Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C117292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117292>	C281	Boceprevir|3-Azabicyclo(3.1.0)hexane-2-carboxamide, N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-((2S)-2-((((1,1- dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6- dimethyl-, (1R,2S,5S)-|BOCEPREVIR|EBP 520|SCH 503034|Victrelis	An orally bioavailable, synthetic tripeptide inhibitor of the nonstructural protein 3 and 4A complex (NS3/NS4A), with potential activity against hepatitis C virus (HCV) genotype 1. Upon administration, boceprevir reversibly binds to the active center of the HCV NS3/NS4A and prevents NS3/NS4A protease-mediated polyprotein maturation. This disrupts the processing of viral proteins and the formation of a viral replication complex, which inhibits viral replication in HCV genotrype 1-infected host cells. NS3, a serine protease, is essential for the proteolytic cleavages within the HCV polyprotein and plays a key role during HCV viral RNA replication. NS4A is an activating factor for NS3. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family.	Boceprevir		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C117293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117293>	C96040	Agonistic Anti-OX40 Monoclonal Antibody MEDI6469|Agonistic Anti-CD134 Monoclonal Antibody MEDI6469|MEDI-6469|MEDI6469	An agonistic monoclonal antibody against the co-stimulatory receptor OX40 (CD134), with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, anti-OX40 monoclonal antibody MEDI6469 selectively binds to and activates OX40. OX40 activation induces proliferation of effector T-lymphocytes. In the presence of tumor-associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T-cells.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C117294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117294>	C2124	Fluorine F 18 Fluorobenzyl Triphenyl Phosphonium|18F-FBnTP|18F-fluorobenzyl Triphenyl Phosphonium	A radioconjugate and cationic lipophilic agent consisting of fluorobenzyl triphenyl phosphonium (FBnTP), labeled with the radioisotope fluorine F 18, with potential use as a tracer for both mitochondrial membrane potential (MMP) and apoptosis, and as a tumor imaging agent using positron emission tomography (PET). Upon administration, fluorine F 18 FBnTP is taken up by cells and its uptake and accumulation within mitochondria is directly correlated with MMP. Apoptosis causes a loss of membrane potential across the inner mitochondrial membrane which decreases FBnTP mitochondrial uptake. As apoptosis is suppressed in tumor cells, the FBnTP uptake is increased as compared to normal cells. This allows, upon PET, for the imaging of cancer cells. As apoptotic-inducing chemotherapeutic agents cause a collapse of MMP, this agent can also be used to assess the response of tumor cells to those chemotherapeutic agents.	Fluorine F 18 Fluorobenzyl Triphenyl Phosphonium		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C117295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117295>	C26847	Cutaneous Polyarteritis Nodosa|Cutaneous PAN|Cutaneous PAN	A form of vasculitis that involves small to medium size arteries of the dermis and subcutaneous tissue. The disorder manifests with tender subcutaneous nodules, livedo reticularis, cutaneous ulcers and necrosis; while internal organ involvement is typically spared, extra-cutaneous symptoms may be present.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C117296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117296>	C27578	Orbital Myositis	A rare form of myositis that affects only the orbital muscles.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C117297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117297>	C87497	Juvenile Primary Fibromyalgia Syndrome|JPFS	Chronic, diffuse, non-inflammatory musculoskeletal pain disorder associated with fatigue and sleep disturbance that can occur in childhood and adolescence. Tender points are not necessary to make the diagnosis, but if present may be less numerous than found in adults.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C117298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117298>	C201336	Planned Assessment Schedule Sequence Number|ORDER|Sequence of Planned Assessment Schedule	A number that identifies the ordering relations in time of the schedules for planned assessments in a trial.			Intellectual Product	CDISC Root Variable Terminology
C117299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117299>	C42614	Anchor Variable Name|ANCVAR	A reference to the CDISC date variable name that provides the start point from which the planned assessment schedule is measured.			Conceptual Entity	CDISC Root Variable Terminology
C11729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11729>	C61007	Asparaginase/cyclophosphamide/cytarabine/daunorubicin/dexamethasone/methotrexate/thioguanine/vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1172>	C243	Nandrolone Decanoate|Deca-Durabolin|NANDROLONE DECANOATE	The decanoate salt form of nandrolone, an anabolic steroid analog of testosterone with androgenic, anabolic, and erythropoietin stimulating effects. Nandrolone enters the cell and binds to and activates specific nuclear androgen receptors in responsive tissue, including the prostate, seminal vesicles, scrotum, penis, larynx, hair follicles, muscle, and bone. The resulting activated hormone receptor complex translocates into the nucleus and binds to androgen response elements (ARE) in the promoter region of targeted genes, where the complex promotes gene expression necessary for maintaining male sex characteristics. Mimicking the negative feedback mechanism of testosterone, nandrolone decanoate also suppresses the secretion of luteinizing hormone (LH). Furthermore, this agent also stimulates erythropoietin production by enhancing the production of erythropoietic stimulating factors.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C117300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117300>	C25543	Planned Assessment Interval|TGTPAI	A planned period of time between planned assessments.			Temporal Concept	CDISC Root Variable Terminology
C117301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117301>	C25543	Minimum Time Allowed in Planned Assessment Interval|MINPAI	The lower limit in time of a planned period of time between planned assessments.			Temporal Concept	CDISC Root Variable Terminology
C117302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117302>	C25543	Maximum Time Allowed in Planned Assessment Interval|MAXPAI	The upper limit in time of a planned period of time between planned assessments.			Temporal Concept	CDISC Root Variable Terminology
C117303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117303>	C25337	Maximum Number of Actual Assessments|NUMRPT	The upper limit in number of acutal assessments during a planned period of time.			Quantitative Concept	CDISC Root Variable Terminology
C117304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117304>	C49556	Associated Persons Domain|AP	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to associated persons.			Idea or Concept	CDISC Root Variable Terminology
C117305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117305>	C50757	Subarachnoid Hemorrhage Related to Birth	Bleeding within the subarachnoid space occurring during labor and/or delivery.			Finding	NICHD Terminology|Perinatal Terminology
C117306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117306>	C50759	Subdural Hemorrhage Related to Birth	Bleeding within the subdural space occurring during labor and/or delivery.			Finding	NICHD Terminology|Perinatal Terminology
C117307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117307>	C3020	Benign Familial Convulsion|Benign Familal Neonatal Seizures|Benign Familial Convulsions|Benign Familial Neonatal Seizures	A group of genetically-determined conditions characterized by a wide spectrum of seizure types occurring in otherwise healthy newborn infants that start during the first week of life and spontaneously disappear between the first and twelfth months of life.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C117308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117308>	C60989	Transient Neonatal Myasthenia Gravis	A condition characterized as a temporary autoimmune neuromuscular disease leading to fluctuating muscle weakness and fatigue in a newborn infant.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C117309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117309>	C8510	Extranodal Involvement|Extranodal Extension|Present	Extension of a malignant neoplasm beyond the lymph node capsule.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Terminology
C11730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11730>	C61007	Asparaginase/cyclophosphamide/cytarabine/daunorubicin/methotrexate/prednisone/vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117310>	C3837	Poor Sucking Reflex	Uncoordinated or ineffective drawing of saliva or breast milk by a newborn infant.			Finding	NICHD Terminology|Perinatal Terminology
C117311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117311>	C41362	Drug Exposure via Breast Milk|Drug Exposure Via Breast Milk	Ingestion of drugs contained in breast milk.			Finding	NICHD Terminology|Perinatal Terminology
C117312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117312>	C118807	Breast Engorgement in Newborn|Neonatal Breast Enlargement|Neonatal Breast Enlargement	Transient bilateral swelling of breast tissue in a neonate that results from the waning influence of maternal estrogen.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology|Perinatal Terminology
C117313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117313>	C118807	Pseudomenstruation|Pseudomenses	Blood-tinged vaginal secretion in a neonate that results from the residual influence of maternal estrogen.			Finding	NICHD Terminology|Perinatal Terminology
C117314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117314>	C50795	Neonatal Vaginal Discharge	Secretions which may be thin or tenacious, mucoid or glairy, grayish or milky, occasionally blood tinged, that originate in the vagina and are a consequence of the residual influence of maternal estrogen.			Finding	NICHD Terminology|Perinatal Terminology
C117315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117315>	C97117|C36280	Subependymal Pseudocyst|Germinolytic Cyst|Subependymal Cyst	Cerebral periventricular cyst located on the floor of the lateral cerebral ventricle, most commonly in the caudothalamic groove, and results from regression of the germinal matrix or as a sequela of a prior subependymal hemorrhage or germinal matrix infarct.			Finding	NICHD Terminology|Perinatal Terminology
C117316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117316>	C15256	Postpartum Hysterectomy	The removal of the uterus after vaginal delivery of the fetus or in the postpartum period.			Therapeutic or Preventive Procedure	NICHD Terminology|Perinatal Terminology
C117317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117317>	C89340	Selective Reduction of Multifetal Pregnancy|Multifetal Pregnancy Reduction	A medical procedure performed to reduce the number of viable fetuses.			Health Care Activity	NICHD Terminology|Perinatal Terminology
C117318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117318>	C87126	Frank Umbilical Cord Prolapse	A situation in which the umbilical cord is prolapsed through the cervix and into the vagina.			Finding	NICHD Terminology|Perinatal Terminology
C117319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117319>	C87126	Occult Umbilical Cord Prolapse	A situation in which the umbilical cord is prolapsed through the cervical canal but not through external os.			Finding	NICHD Terminology|Perinatal Terminology
C11731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11731>	C61007	Cyclophosphamide/Cytarabine/Mercaptopurine/Methotrexate/Prednisone			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117320>	C27181	Acute Placental Infarction|Acute Placental Infact|Acute Placental Infarct	A focus of necrotic placental parenchyma with clearly visible outlines of necrotic villous structures and absence of any hyalinization and fibrosis, which is frequently 1-2 days of duration.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C117321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117321>	C27181	Subacute Placental Infarction|Subacute Placental Infarct|Subacute Placental Infarct	A focus of necrotic placental parenchyma with moderate hyalinization and fibrosis with partial absence of the necrotic chorionic villi, which is frequently 3-5 days of duration.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C117322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117322>	C27181	Remote Placental Infarction|Remote Placental Infarct|Remote Placental Infarct	A focus of necrotic placental parenchyma with marked hyalinization and fibrosis with complete absence of the necrotic chorionic villi, which is frequently more than 7 days of duration.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C117323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117323>	C97077	Necrotizing Funisitis|Sclerosing Funisitis|Sclerosing Funisitis	A ring of karyorrhectic debris that may exhibit dystrophic mineralization and/or identifiable fetal neutrophil infiltrate in Wharton's jelly that is oriented towards the amniotic surface. The cord has a denser ring externally and a fainter ring centrally.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C117324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117324>	C26912	Fetal Chorionic Vasculitis|Acute Chorionic Vasculitis|Acute Chorionic Vasculitis	A neutrophilic infiltrate arising from fetal vessels in the chorionic plate and oriented towards the amniotic cavity.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C117325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117325>	C26912	Umbilical Vasculitis|Acute Umbilical Vasculitis|Acute Umbilical Vasculitis	A neutrophilic infiltrate arising from fetal vessels of the umbilical cord into the umbilical vessel wall and oriented towards the amniotic cavity.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C117326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117326>	C27083	Intervillous Thrombus	A focus of maternal thrombus within the intervillous space, often with peripheral villous compression. The clot may be wholly or minimally laminated reflecting age.			Finding	NICHD Terminology|Perinatal Terminology
C117327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117327>	C117326	Acute Intervillous Thrombus	A focus of maternal thrombus within the placental intervillous space, often with peripheral villous compression, which is less than 1-2 days in age.			Finding	NICHD Terminology|Perinatal Terminology
C117328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117328>	C117326	Subacute Intervillous Thrombus	A focus of maternal thrombus within the placental intervillous space, often with peripheral villous compression, which is 3-5 days in age.			Finding	NICHD Terminology|Perinatal Terminology
C117329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117329>	C117326	Remote Intervillous Thrombus	A focus of maternal thrombus within the placental intervillous space, often with peripheral villous compression, which is at least 5-7 days in age.			Finding	NICHD Terminology|Perinatal Terminology
C11732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11732>	C61007	Asparaginase/cytarabine/daunorubicin/methotrexate/prednisone/vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117330>	C27083	Subchorial Thrombus|Subchorionic Hematoma|Subchorionic Hematoma	A focus of subchorial thrombus variably extending into the intervillous space, often with peripheral villous compression. The clot may be wholly or minimally laminated reflecting age.			Finding	NICHD Terminology|Perinatal Terminology
C117331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117331>	C27083	Retroplacental Thrombus|Parabasal Hematoma|Parabasal Hematoma|Parabasal Thrombus|Parabasal Thrombus|Retroplacental Hematoma|Retroplacental Hematoma	A focus of retroplacental thrombus variably extending into the intervillous space, often with peripheral villous compression. The clot may be wholly or minimally laminated reflecting age.			Finding	NICHD Terminology|Perinatal Terminology
C117332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117332>	C27083	Fetal Stem Vessel Thrombus	A focus of thrombus adhered to the wall of a fetal stem vessel. It can be completely or partially obstructive and may lead to avascular villi.			Finding	NICHD Terminology|Perinatal Terminology
C117333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117333>	C117332	Fetal Stem Vessel Thrombus with or without Dystrophic Calcification	A focus of thrombus adhered to the wall of a fetal stem vessel. It can be completely or partially obstructive and may lead to downstream villous injury and calcification.			Finding	NICHD Terminology|Perinatal Terminology
C117334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117334>	C27083	Chorionic Plate Vessel Thrombus	A focus of thrombus adhered to the wall of a fetal blood vessel in the chorionic plate.			Finding	NICHD Terminology|Perinatal Terminology
C117335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117335>	C117334	Chorionic Plate Vessel Thrombus with or without Dystrophic Calcification	A focus of thrombus adhered to the wall of a fetal blood vessel in the chorionic plate. It can be completely or partially obstructive and may lead to downstream villous injury and calcification.			Finding	NICHD Terminology|Perinatal Terminology
C117336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117336>	C27083	Uteroplacental Vessel Thrombus	A focus of thrombus adhered to the wall of an uteroplacental vessel.			Finding	NICHD Terminology|Perinatal Terminology
C117337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117337>	C117720	Placental Finding|Placental Findings	Clinical and laboratory findings about the placenta.			Finding	NICHD Terminology
C117338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117338>	C117337	Trimmed Placental Weight|Disc Weight|Disc Weight|Trimmed Placental Mass	The weight of the trimmed placenta to the nearest gram, with membranes severed at the disc edge and the umbilical cord cut to within 1 cm of insertion, after draining the blood from the specimen.			Finding	NICHD Terminology|Perinatal Terminology
C117339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117339>	C117337	Untrimmed Placental Weight|Placental Weight NOS|Untrimmed Placental Mass|Untrimmed Placental Mass	The weight of the placenta after delivery, with membranes intact and some length of the umbilical cord attached, to the nearest gram, before draining the blood from the specimen.			Finding	NICHD Terminology|Perinatal Terminology
C11733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11733>	C61063	Docetaxel/Oxaliplatin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117340>	C117337	Larger Axis of Placenta|Larger Diameter of Placenta|Larger Diameter of Placenta|Longer Diameter of Placenta|Longer Diameter of Placenta	The length, in cm, of the longest axis of the chorionic disc.			Finding	NICHD Terminology|Perinatal Terminology
C117341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117341>	C117337	Shorter Axis of Placenta|Shorter Diameter of Placenta|Shorter Diameter of Placenta|Smaller Diameter of Placenta	The length, in cm, of the shortest axis of the chorionic disc.			Finding	NICHD Terminology|Perinatal Terminology
C117342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117342>	C117337	Placental Disc Thickness	The measured or estimated height of the placental disc perpendicular to the chorionic and basal plates.			Finding	NICHD Terminology|Perinatal Terminology
C117343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117343>	C117337	Fused Placenta|Multifetal Placenta|Multifetal Placenta	In pregnancies with more than one fetus, the composite structure that results from the growth of two (or more) placental chorionic discs such that the placental masses abut one another and are delivered as a single unit but can manually separated into individual units.			Finding	NICHD Terminology|Perinatal Terminology
C117344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117344>	C117337	Bilobate Placenta|Bilobate Chorionic Surface Shape|Bilobate Chorionic Surface Shape|Bipartite Placenta|Bipartite Placenta|Placenta Bipartita|Placenta Bipartita|Placenta Duplex|Placenta Duplex	A variant placenta in which the chorionic tissue is partitioned into two distinct discs, without consistent relationship to umbilical cord insertion.			Finding	NICHD Terminology|Perinatal Terminology
C117345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117345>	C117337	Multilobate Placenta|Multilobate Chorionic Surface Shape|Multilobate Chorionic Surface Shape|Placenta Multipartita|Placenta Multipartita|Placenta Multiplex|Placenta Multiplex	A variant placenta in which the chorionic tissue is partitioned into more than two distinct discs, without consistent relationship to umbilical cord insertion.			Finding	NICHD Terminology|Perinatal Terminology
C117346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117346>	C117337	Circummarginate Placenta|Marginal Placenta|Marginal Placenta|Placenta Marginalis|Placenta Marginalis	A placenta characterized by fetal membranes which extend smoothly off the disc edge, and a subamnionic fibrin ring on all or part of the disc perimeter that delimits the greatest extent of the chorionic surface vessels.			Finding	NICHD Terminology|Perinatal Terminology
C117347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117347>	C117337	Circumvallate Placenta|Placenta Circumvallata|Placenta Circumvallata	A placenta characterized by fetal membranes that are folded along all or part of the disc perimeter. The amnion may or may not be included in the folded tissue.			Finding	NICHD Terminology|Perinatal Terminology
C117348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117348>	C117337	Marginal Cord Insertion|Marginal Umbilical Cord Insertion|Marginal Umbilical Cord Insertion	The location of the umbilical cord insertion at the disc edge.			Finding	NICHD Terminology|Perinatal Terminology
C117349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117349>	C117337	Velamentous Cord Insertion|Membranous Insertion|Membranous Insertion|Velamentous Umbilical Cord Insertion|Velamentous Umbilical Cord Insertion	The location of the umbilical cord insertion on the extraplacental membranes.			Finding	NICHD Terminology|Perinatal Terminology
C11734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11734>	C61063	Amifostine/Cisplatin/Docetaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117350>	C117351	Ruptured Velamentous Vessel|Disrupted Membranous Vessel|Disrupted Membranous Vessel|Disrupted Velamentous Vessel|Disrupted Velamentous Vessel|Ruptured Membranous Vessel|Ruptured Membranous Vessel|Torn Membranous Vessel|Torn Membranous Vessel|Torn Velamentous Vessel|Torn Velamentous Vessel	A fetal blood vessel in the placental membranes that appears torn upon gross inspection of the placenta.			Finding	NICHD Terminology|Perinatal Terminology
C117351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117351>	C117337	Velamentous Vessel|Membranous Vessel|Membranous Vessel	A fetal blood vessel in the placental membranes that extends from the cord insertion to the chorionic plate.			Finding	NICHD Terminology|Perinatal Terminology
C117352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117352>	C223375	Blastomyces dermatitidis|Ajellomyces dermatitidis|Ajellomyces dermatitidis|BLASTOMYCES DERMATITIDIS|Blastomycoides dermatitidis	A species of thermally dimorphic fungus in the family Ajellomycetaceae that behaves diversely at different temperatures and is the causative agent of blastomycosis. It is found in the soil in the midwestern and northern United States and Canada.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117353>	C117360	Umbilical Cord True Knot	A folding of the umbilical cord in the form of a knot.			Finding	NICHD Terminology|Perinatal Terminology
C117354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117354>	C187905	Coccidioides immitis|Ascomycete fungi|COCCIDIOIDES IMMITIS	A species of pathogenic fungus in the family Onygenaceae that is one of the causative agents of coccidioidomycosis. It is found in the soil in southwestern United States and northern Mexico.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117355>	C117360	Hypocoiled Umbilical Cord	Umbilical cord with apparent reduced helical coiling of the arteries around the vein.			Finding	NICHD Terminology|Perinatal Terminology
C117356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117356>	C117360	Hypercoiled Umbilical Cord	Umbilical cord with apparent increased helical coiling of the arteries around the vein.			Finding	NICHD Terminology|Perinatal Terminology
C117357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117357>	C117360	Umbilical Cord Diameter	The longest measured width of the umbilical cord.			Finding	NICHD Terminology|Perinatal Terminology
C117358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117358>	C117360	Umbilical Cord Length	The total length of the umbilical cord as measured from all segments. A cord length less than 30 or 35 cm is considered "short" whereas one greater than 70 cm is "long".			Finding	NICHD Terminology|Perinatal Terminology
C117359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117359>	C117360	Single Umbilical Artery	The absence of one of the two umbilical arteries.			Finding	NICHD Terminology|Perinatal Terminology
C11735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11735>	C61063	Keyhole Limpet Hemocyanin/Polysialic Acid			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117360>	C117720	Umbilical Cord Finding	Clinical and laboratory findings about the umbilical cord.			Finding	
C117361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117361>	C124358	Pneumocystis jirovecii|PNEUMOCYSTIS JIROVECII|Pneumocystis carinii f. sp. Hominis|Pneumocystis carinii f. sp. hominis|Pneumocystis carinii hominis|Pneumocystis jiroveci	A species of yeast-like fungus that is the causative organism of Pneumocystis pneumonia.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117362>	C127297|C127290	Scedosporium prolificans|LOMENTOSPORA PROLIFICANS|Lomentospora prolificans|Scedosporium inflatum|Scedosporium inflatum	A species of dematiaceous filamentous fungi in the phylum Ascomycota with small, delicate annellides with a distinct basal swelling peculiar to this species and absent in closely related species. L. prolificans causes opportunistic infection in immunocompetent and immunosuppressed individuals. The species exhibits varying tolerance to currently available antifungal agents.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117363>	C117360	Umbilical Cord Discoloration|Brown Umbilical Cord|Dusky Umbilical Cord|Red Umbilical Cord	Change in umbilical cord color resulting from postmortem changes. It indicates fetal death occurred at least 6 hours prior to delivery.			Finding	NICHD Terminology|Perinatal Terminology
C117364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117364>	C117337	Green Fetal Membrane|Green Fetal Membranes|Meconium Staining of the Membrane|Meconium Staining of the Membranes	Meconium staining of the fetal membrane.			Finding	NICHD Terminology|Perinatal Terminology
C117365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117365>	C117337	Marginal Insertion of Fetal Membrane|Marginal Insertion of Fetal Membranes	An observation that the fetal membranes are inserted at the edge of the placental disc.			Finding	NICHD Terminology|Perinatal Terminology
C117366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117366>	C117337	Site of Fetal Membrane Rupture	The space that occupies the distance between the shortest free edge of the fetal membranes and the disc edge.			Finding	NICHD Terminology|Perinatal Terminology
C117367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117367>	C117337	Complete Maternal Surface of Placenta	A maternal placental surface that is smooth and without appreciable parenchymal loss.			Finding	NICHD Terminology|Perinatal Terminology
C117368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117368>	C117337	Incomplete Maternal Surface of Placenta|Disrupted Maternal Surface of Placenta|Disrupted Maternal Surface of Placenta|Ragged Maternal Surface of Placenta|Ragged Maternal Surface of Placenta	A maternal placental surface that lacks a smooth basal plate. Missing pieces of the placental parenchyma are appreciable.			Finding	NICHD Terminology|Perinatal Terminology
C117369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117369>	C117337	Uniform Color of Placental Parenchyma	The typical uniform coloring of the placental parenchyma irrespective of gestational age.			Finding	NICHD Terminology|Perinatal Terminology
C11736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11736>	C61063	Keyhole Limpet Hemocyanin/Polysialic Acid/QS21			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117370>	C117337	Mottled Color of Placental Parenchyma	The variable or non-uniform coloring of the placental parenchyma indicating variable contribution of the blood contained within the fetal vessels to the color of the parenchyma.			Finding	NICHD Terminology|Perinatal Terminology
C117371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117371>	C117337	Gross Placental Abruption|Gross Abruption|Gross Abruption|Macroscopic Abruption|Macroscopic Abruption	A separation of the placenta from the uterine wall that is manifested by a retroplacental hematoma with villous compression and change in villous coloration that is reflective of lesion age.			Finding	NICHD Terminology|Perinatal Terminology
C117372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117372>	C3824|C117337	Placental Lesion	Macroscopically identifiable placental parenchymal abnormality.			Finding	NICHD Terminology|Perinatal Terminology
C117373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117373>	C25162	Data Value Code|VALCD	A character or string that represents the information contained in a data field.			Intellectual Product	CDISC Root Variable Terminology
C117374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117374>	C49100	Value Null Flavor|VALNF	A description of the value that describes missing data, eg. unknown, not applicable.			Conceptual Entity	CDISC Root Variable Terminology
C117375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117375>	C42614	Name of the Reference Terminology|VCDREF	The textual description of the terminology system that is being used.			Conceptual Entity	CDISC Root Variable Terminology
C117376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117376>	C25714	Version of the Reference Terminology|VCDVER	The version information of the terminology system that is being used.			Conceptual Entity	CDISC Root Variable Terminology
C117377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117377>	C117040	Adverse Event MedDRA Body System or Organ Class Code|AEBDSYCD	A coded value specifying the type of body system or organ class related to the adverse event from the Medical Dictionary for Regulatory Activities (MedDRA).			Intellectual Product	CDISC Variable Terminology
C117378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117378>	C71889	Adverse Event MedDRA High Level Group Term|AEHLGT	A superordinate descriptor for one or more Medical Dictionary for Regulatory Activities (MedDRA) high level terms (HLT) for the adverse event.			Intellectual Product	CDISC Variable Terminology
C117379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117379>	C117046	Adverse Event MedDRA High Level Group Term Code|AEHLGTCD	A coded value specifying the high level group term for the adverse event from the Medical Dictionary for Regulatory Activities (MedDRA).			Intellectual Product	CDISC Variable Terminology
C11737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11737>	C61063	Exemestane/Raloxifene			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117380>	C71880	Adverse Event MedDRA High Level Term|AEHLT	A superordinate descriptor for one or more Medical Dictionary for Regulatory Activities (MedDRA) preferred terms (PTs) for the adverse event.			Intellectual Product	CDISC Variable Terminology
C117381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117381>	C117047	Adverse Event MedDRA High Level Term Code|AEHLTCD	A coded value specifying the high level term for the adverse event from the Medical Dictionary for Regulatory Activities (MedDRA).			Intellectual Product	CDISC Variable Terminology
C117382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117382>	C71886	Adverse Event MedDRA Low Level Term|AELLT	Adverse event term related to the lowest level of the Medical Dictionary for Regulatory Activities (MedDRA) terminology, related to a single PT as a synonym, lexical variant, or quasi-synonym.			Intellectual Product	CDISC Variable Terminology
C117383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117383>	C117048	Adverse Event MedDRA Low Level Term Code|AELLTCD	A coded value specifying the low level term for the adverse event from the Medical Dictionary for Regulatory Activities (MedDRA).			Intellectual Product	CDISC Variable Terminology
C117384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117384>	C117056	Adverse Event MedDRA Preferred Term Code|AEPTCD	A coded value specifying the preferred term for the adverse event from the Medical Dictionary for Regulatory Activities (MedDRA).			Intellectual Product	CDISC Variable Terminology
C117385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117385>	C71888	Adverse Event MedDRA System Organ Class|AESOC	Adverse event term related to the highest level of the Medical Dictionary for Regulatory Activities (MedDRA) terminology, and distinguished by anatomical or physiological system, etiology, or purpose.			Intellectual Product	CDISC Variable Terminology
C117386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117386>	C117059	Adverse Event MedDRA Primary System Organ Class Code|AESOCCD	A coded value specifying the primary system organ class for the adverse event from the Medical Dictionary for Regulatory Activities (MedDRA).			Intellectual Product	CDISC Variable Terminology
C117387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117387>	C117038	Disease Response Accepted Record Flag|RSACPTFL	An indication or description of a record that is considered to be the accepted and final evaluation for the disease response.			Functional Concept	CDISC Variable Terminology
C117388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117388>	C25372	Disease Response Category|RSCAT	A classification of disease response data.			Classification	CDISC Variable Terminology
C117389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117389>	C82515	Date and Time of Disease Response Assessment|RSDTC	The date and time of disease response data collection.			Temporal Concept	CDISC Variable Terminology
C11738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11738>	C61063	Cytarabine/UCN-01			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117390>	C82437	Study Day of Disease Response|RSDY	The study day that a disease response assessment is performed.			Temporal Concept	CDISC Variable Terminology
C117391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117391>	C51824	Disease Response Evaluator|RSEVAL	A person who determines the significance of a disease response assessment.			Professional or Occupational Group	CDISC Variable Terminology
C117392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117392>	C117043	Disease Response Evaluator Identifier|RSEVALID	A sequence of characters used to identify, name, or characterize the evaluator of the disease response.			Intellectual Product	CDISC Variable Terminology
C117393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117393>	C82529	Disease Response Group Identifier|RSGRPID	A character or string that represents a disease response group.			Intellectual Product	CDISC Variable Terminology
C117394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117394>	C117049	Disease Response Link Group|RSLNKGRP	A sequence of characters used to link multiple disease response records to a single finding.			Intellectual Product	CDISC Variable Terminology
C117395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117395>	C117050	Disease Response Link Identifier|RSLNKID	A sequence of characters used as a linkage between related disease response records.			Intellectual Product	CDISC Variable Terminology
C117396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117396>	C117200	Disease Response Vendor Name|RSNAM	The literal identifier of the vendor or laboratory that performs a disease response assessment.			Intellectual Product	CDISC Variable Terminology
C117397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117397>	C117221	Disease Response Original Result|RSORRES	The outcome of the disease response assessment as originally received or collected.			Finding	CDISC Variable Terminology
C117398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117398>	C82556	Disease Response Reason Not Done|RSREASND	The rationale why a disease response assessment was not performed.			Idea or Concept	CDISC Variable Terminology
C117399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117399>	C82531	Disease Response Reference Identifier|RSREFID	A sequence of characters used to identify, name, or characterize the disease response reference.			Intellectual Product	CDISC Variable Terminology
C11739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11739>	C61063	Interleukin-12/Rituximab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1173>	C146993	Nilutamide|1-(3'-Trifluoromethyl-4'-nitrophenyl)-4,4-dimethylimidazoline-3,5-dione|5,5-Dimethyl-3-[4-nitro-3-(trifluoro-methyl)phenyl]-2,4-imidazolidinedione|Anandron|NILUTAMIDE|Nilandron|RU-23908|nilutamide	A synthetic, nonsteroidal agent with antiandrogenic properties. Nilutamide preferentially binds to androgen receptors and blocks androgen receptor activation by testosterone and other androgens; this agent may inhibit androgen-dependent growth of normal and neoplastic prostate cells. (NCI04)	Nilutamide		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C117400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117400>	C70710	Disease Response Sequence Number|RSSEQ	An identifier that describes the relative position of disease response data within a series.			Quantitative Concept	CDISC Variable Terminology
C117401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117401>	C82530	Disease Response Sponsor Defined Identifier|RSSPID	One or more sponsor defined characters used to identify, name, or characterize the disease response assessment.			Intellectual Product	CDISC Variable Terminology
C117402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117402>	C41202	Disease Response Completion Status|RSSTAT	A term used to describe the state or condition of the completeness of the disease response data.			Qualitative Concept	CDISC Variable Terminology
C117403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117403>	C117222	Disease Response Assessment Character Result in Standard Format|RSSTRESC	The standard character or string for representation and reporting of disease response data.			Quantitative Concept	CDISC Variable Terminology
C117404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117404>	C82541	Disease Response Assessment Test|RSTEST	A character or string that represents the long name of the disease response assessment.			Intellectual Product	CDISC Variable Terminology
C117405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117405>	C82503	Disease Response Assessment Test Code|RSTESTCD	A character or string that represents the short code name of the disease response assessment.			Intellectual Product	CDISC Variable Terminology
C117406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117406>	C117038	Tumor Results Accepted Record Flag|TRACPTFL	An indication or description of a record that is considered to be the accepted and final evaluation for the tumor result.			Functional Concept	CDISC Variable Terminology
C117407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117407>	C82515	Tumor Results Date and Time of Assessment|TRDTC	The date and time of tumor results data collection.			Temporal Concept	CDISC Variable Terminology
C117408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117408>	C82437	Study Day of Tumor Results|TRDY	The study day that a tumor results assessment is performed.			Temporal Concept	CDISC Variable Terminology
C117409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117409>	C51824	Tumor Results Evaluator|TREVAL	A person who determines the significance of a tumor results assessment.			Professional or Occupational Group	CDISC Variable Terminology
C11740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11740>	C61063	Fluorouracil/Gemcitabine/Oxaliplatin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117410>	C117043	Tumor Results Evaluator Identifier|TREVALID	A sequence of characters used to identify, name, or characterize the evaluator of the tumor results.			Intellectual Product	CDISC Variable Terminology
C117411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117411>	C82529	Tumor Results Group Identifier|TRGRPID	A character or string that represents a tumor results group.			Intellectual Product	CDISC Variable Terminology
C117412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117412>	C117049	Tumor Results Link Group|TRLNKGRP	A sequence of characters used to link multiple tumor results records to a single finding.			Intellectual Product	CDISC Variable Terminology
C117413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117413>	C117050	Tumor Results Link Identifier|TRLNKID	A sequence of characters used as a linkage between related tumor results records.			Intellectual Product	CDISC Variable Terminology
C117414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117414>	C82535	Tumor Results Method|TRMETHOD	The technique used to administer the tumor results assessment.			Activity	CDISC Variable Terminology
C117415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117415>	C117200	Tumor Results Vendor Name|TRNAM	The literal identifier of the vendor or laboratory that performs a tumor results assessment.			Intellectual Product	CDISC Variable Terminology
C117416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117416>	C117221	Tumor Results Original Result|TRORRES	The outcome of the tumor results assessment as originally received or collected.			Finding	CDISC Variable Terminology
C117417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117417>	C82586	Tumor Results Original Result Unit|TRORRESU	The unit of measure for the result of the tumor results assessment as originally received or collected.			Quantitative Concept	CDISC Variable Terminology
C117418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117418>	C82556	Tumor Results Reason Not Done|TRREASND	The rationale why a tumor measurement was not performed.			Idea or Concept	CDISC Variable Terminology
C117419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117419>	C82531	Tumor Results Reference Identifier|TRREFID	A sequence of characters used to identify, name, or characterize the tumor results reference.			Intellectual Product	CDISC Variable Terminology
C11741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11741>	C61007	Dactinomycin/Melphalan			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117420>	C70710	Tumor Results Sequence Number|TRSEQ	An identifier that describes the relative position of tumor results data within a series.			Quantitative Concept	CDISC Variable Terminology
C117421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117421>	C82530	Tumor Results Sponsor Defined Identifier|TRSPID	One or more sponsor defined characters used to identify, name, or characterize the tumor results assessment.			Intellectual Product	CDISC Variable Terminology
C117422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117422>	C41202	Tumor Results Completion Status|TRSTAT	A term used to describe the state or condition of the completeness of the tumor results data.			Qualitative Concept	CDISC Variable Terminology
C117423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117423>	C117222	Tumor Results Character Result in Standard Format|TRSTRESC	The standard character or string for representation and reporting of tumor results data.			Quantitative Concept	CDISC Variable Terminology
C117424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117424>	C70952	Tumor Results Numeric Result in Standard Unit|TRSTRESN	The numerical identifier of a tumor result in standard units.			Quantitative Concept	CDISC Variable Terminology
C117425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117425>	C82587	Tumor Results Standard Unit|TRSTRESU	The standard unit of measure for the tumor results.			Quantitative Concept	CDISC Variable Terminology
C117426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117426>	C82541	Tumor Results Assessment Test|TRTEST	A character or string that represents the long name of the tumor assessment.			Intellectual Product	CDISC Variable Terminology
C117427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117427>	C82503	Tumor Results Assessment Test Code|TRTESTCD	A character or string that represents the short code name of the tumor assessment.			Intellectual Product	CDISC Variable Terminology
C117428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117428>	C117038	Tumor Identifier Accepted Record Flag|TUACPTFL	An indication or description of a record that is considered to be the accepted and final evaluation for the tumor identification.			Functional Concept	CDISC Variable Terminology
C117429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117429>	C54215	Tumor Identifier Directionality|TUDIR	A qualifier for the direction on the body the tumor identification is performed.			Functional Concept	CDISC Variable Terminology
C11742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11742>	C61007	Cyclophosphamide/Doxorubicin/Etoposide/Prednisone/Rituximab/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117430>	C82515	Date and Time of Tumor Identification|TUDTC	The date and time of tumor identification data collection.			Temporal Concept	CDISC Variable Terminology
C117431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117431>	C82437	Study Day of Tumor Identification|TUDY	The study day that a tumor identification assessment is performed.			Temporal Concept	CDISC Variable Terminology
C117432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117432>	C51824	Tumor Identifier Evaluator|TUEVAL	A person who determines the significance of a tumor identification assessment.			Professional or Occupational Group	CDISC Variable Terminology
C117433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117433>	C117043	Tumor Identifier Evaluator Identifier|TUEVALID	A sequence of characters used to identify, name, or characterize the evaluator of the tumor identification.			Intellectual Product	CDISC Variable Terminology
C117434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117434>	C82529	Tumor Identifier Group Identifier|TUGRPID	A character or string that represents a tumor identifier group.			Intellectual Product	CDISC Variable Terminology
C117435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117435>	C25185	Tumor Identifier Laterality|TULAT	A qualifier for the side of the body the tumor identification assessment is performed.			Organism Attribute	CDISC Variable Terminology
C117436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117436>	C117050	Tumor Identifier Link Identifier|TULNKID	A sequence of characters used as a linkage between related tumor identifier records.			Intellectual Product	CDISC Variable Terminology
C117437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117437>	C25341	Tumor Identifier Location|TULOC	The site in or on the body at which the tumor identification test or result is performed or collected.			Spatial Concept	CDISC Variable Terminology
C117438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117438>	C82535	Tumor Identifier Method|TUMETHOD|TUMOR_DETECTION_METHOD|TUMOR_DETECTION_METHOD|TUMOR_DETECTION_METHOD	The technique used to administer the tumor identification assessment.			Activity	CDISC Variable Terminology|EWS Tumor Assessment Table|EWS Variable Terminology|GCT Tumor Assessment Table|GCT Variable Terminology|OS Tumor Assessment Table|OS Variable Terminology
C117439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117439>	C117200	Tumor Identifier Vendor Name|TUNAM	The literal identifier of the vendor or laboratory that performs a tumor identification assessment.			Intellectual Product	CDISC Variable Terminology
C11743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11743>	C61063	Irinotecan/Oblimersen			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117440>	C117221	Tumor Identifier Original Result|TUORRES	The outcome of the tumor identification assessment as originally received or collected.			Finding	CDISC Variable Terminology
C117441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117441>	C103166	Tumor Identifier Portion or Totality|TUPORTOT	A qualifier for the arrangement or apportioning of an entity within a body part, region or organ for the tumor identification.			Organism Attribute	CDISC Variable Terminology
C117442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117442>	C82531	Tumor Identifier Reference Identifier|TUREFID	A sequence of characters used to identify, name, or characterize the tumor identifier reference.			Intellectual Product	CDISC Variable Terminology
C117443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117443>	C70710	Tumor Identifier Sequence Number|TUSEQ	An identifier that describes the relative position of tumor identifier data within a series.			Quantitative Concept	CDISC Variable Terminology
C117444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117444>	C82530	Tumor Identifier Sponsor Defined Identifier|TUSPID	One or more sponsor defined characters used to identify, name, or characterize the tumor identification assessment.			Intellectual Product	CDISC Variable Terminology
C117445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117445>	C117222	Tumor Identifier Character Result in Standard Format|TUSTRESC	The standard character or string for representation and reporting of tumor identification data.			Quantitative Concept	CDISC Variable Terminology
C117446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117446>	C82541	Tumor Identifier Test|TUTEST	A character or string that represents the long name of the tumor identification assessment.			Intellectual Product	CDISC Variable Terminology
C117447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117447>	C82503	Tumor Identifier Test Code|TUTESTCD	A character or string that represents the short code name of the tumor identification assessment.			Intellectual Product	CDISC Variable Terminology
C117448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117448>	C93729	Actual Arm Name|ACTARM	The name of the arm in which the subject actually participated.			Intellectual Product	CDISC Variable Terminology
C117449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117449>	C25162	Actual Arm Code|ACTARMCD	A short sequence of characters that represents the arm in which the subject actually participated.			Intellectual Product	CDISC Variable Terminology
C11744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11744>	C63358	Pegylated Liposomal Doxorubicin/Trastuzumab Regimen|Doxil/Herceptin|Doxorubicin HCl Liposome/Trastuzumab|Pegylated Liposomal Doxorubicin-Trastuzumab|Pegylated Liposomal Doxorubicin/Trastuzumab	A regimen consisting of pegylated liposomal doxorubicin and trastuzumab that may be used in the treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C117450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117450>	C37939	Date and Time of Death|DTHDTC	The date or date and time of death.			Temporal Concept	CDISC Variable Terminology
C117451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117451>	C43578	Subject Death Flag|DTHFL	An indication of whether the subject has died.			Conceptual Entity	CDISC Variable Terminology
C117452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117452>	C82515	Date and Time of Informed Consent|RFICDTC	The date and time of informed consent collection.			Temporal Concept	CDISC Variable Terminology
C117453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117453>	C82516	Date and Time of End of Participation|RFPENDTC	The date and time of the end of a subject's participation in the study.			Temporal Concept	CDISC Variable Terminology
C117454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117454>	C82516	Date and Time of Last Study Treatment|RFXENDTC	The date and time of the subject's final study treatment.			Temporal Concept	CDISC Variable Terminology
C117455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117455>	C82517	Date and Time of First Study Treatment|RFXSTDTC	The date and time of the subject's first study treatment.			Temporal Concept	CDISC Variable Terminology
C117456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117456>	C14376	Organism Substrain	A further sub-classification of the organism strain.			Classification	
C117457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117457>	C25162	Trial Sets Code|SETCD	A character or string that represents the trial set.			Intellectual Product	CDISC Variable Terminology
C117458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117458>	C117373	Trial Summary Parameter Value Code|TSVALCD	A character or string that represents the trial summary parameter value.			Intellectual Product	CDISC Variable Terminology
C117459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117459>	C117374	Trial Summary Parameter Value Null Flavor|TSVALNF	A description of the value that describes missing trial summary data values.			Intellectual Product	CDISC Variable Terminology
C11745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11745>	C61063	Amifostine/Cisplatin/Irinotecan			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117460>	C117375	Trial Summary Parameter Name of the Reference Terminology|TSVCDREF	The textual description of the terminology system that is being used for the trial summary parameter.			Intellectual Product	CDISC Variable Terminology
C117461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117461>	C117376	Trial Summary Parameter Version of the Reference Terminology|TSVCDVER	The version information of the terminology system that is being used for the trial summary parameter.			Intellectual Product	CDISC Variable Terminology
C117462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117462>	C70710	Trial Sets Sequence Number|TXSEQ	An identifier that describes the relative position of trials sets data within a series.			Quantitative Concept	CDISC Variable Terminology
C117463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117463>	C71569	Trial Sets Parameter|TXPARM	A character or string that represents the long name of the trial set parameter.			Intellectual Product	CDISC Variable Terminology
C117464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117464>	C82538	Trial Sets Parameter Code|TXPARMCD	A character or string that represents the short code name of the trial set parameter.			Intellectual Product	CDISC Variable Terminology
C117465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117465>	C49100	Trial Sets Value|TXVAL	A factor assigned to a trial set boundary.			Conceptual Entity	CDISC Variable Terminology
C117466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117466>	C49556	Exposure as Collected Domain|EC|Exposure as Collected	This interventions domain model reflects protocol-specified study treatment administrations, as collected.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|CDISC Variable Terminology|Clinical Data Interchange Standards Consortium Terminology
C117467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117467>	C70710	Exposure as Collected Sequence Number|ECSEQ	An identifier that describes the relative position of collected exposure data within a series.			Quantitative Concept	CDISC Variable Terminology
C117468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117468>	C82529	Exposure as Collected Group Identifier|ECGRPID	A character or string that represents a collected exposure group.			Intellectual Product	CDISC Variable Terminology
C117469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117469>	C82531	Exposure as Collected Reference Identifier|ECREFID	A sequence of characters used to identify, name, or characterize the collected exposure reference.			Intellectual Product	CDISC Variable Terminology
C11746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11746>	C61007	Docetaxel/Thalidomide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117470>	C82530	Exposure as Collected Sponsor Defined Identifier|ECSPID	One or more sponsor defined characters used to identify, name, or characterize the collected exposure.			Intellectual Product	CDISC Variable Terminology
C117471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117471>	C117050	Exposure as Collected Link Identifier|ECLNKID	A sequence of characters used as a linkage between related collected exposure records.			Intellectual Product	CDISC Variable Terminology
C117472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117472>	C117049	Exposure as Collected Link Group|ECLNKGRP	A sequence of characters used to link multiple collected exposure records to a single finding.			Intellectual Product	CDISC Variable Terminology
C117473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117473>	C82542	Exposure as Collected Name of Treatment|ECTRT	The literal identifier of the exposure as collected.			Intellectual Product	CDISC Variable Terminology
C117474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117474>	C117021	Exposure as Collected Mood|ECMOOD	A description of the mood of the collected exposure record.			Qualitative Concept	CDISC Variable Terminology
C117475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117475>	C25372	Exposure as Collected Category|ECCAT	A classification of collected exposure data.			Classification	CDISC Variable Terminology
C117476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117476>	C25692	Exposure as Collected Subcategory|ECSCAT	A subdivision of collected exposure data.			Classification	CDISC Variable Terminology
C117477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117477>	C82510	Exposure as Collected Pre-specified|ECPRESP	An indication or description that the collected exposure was previously determined, characterized, or detailed.			Conceptual Entity	CDISC Variable Terminology
C117478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117478>	C25275	Exposure as Collected Occurrence|ECOCCUR	An indication or description of a collected exposure occurrence.			Event	CDISC Variable Terminology
C117479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117479>	C25488	Exposure as Collected Dose|ECDOSE	The amount of substance that the patient or test subject was exposed to at one time, or the total quantity administered.			Quantitative Concept	CDISC Variable Terminology
C11747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11747>	C61063	Cisplatin/Raltitrexed			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117480>	C70961	Exposure as Collected Dose Description|ECDOSTXT	A textual description of the agent dose level(s) or range(s) of the collected exposure for a subject, according to the study protocol.			Intellectual Product	CDISC Variable Terminology
C117481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117481>	C73558	Exposure as Collected Dose Units|ECDOSU	The unit of measure for the dosage form of the collected exposure.			Quantitative Concept	CDISC Variable Terminology
C117482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117482>	C42636	Exposure as Collected Dose Form|ECDOSFRM	The form in which active and/or inert ingredient(s) of the collected exposure are physically presented.			Functional Concept	CDISC Variable Terminology
C117483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117483>	C89081	Exposure as Collected Dosing Frequency per Interval|ECDOSFRQ	The number of doses administered for the collected exposure per a specific interval.			Functional Concept	CDISC Variable Terminology
C117484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117484>	C70888	Exposure as Collected Total Daily Dose|ECDOSTOT	A specified quantity of a therapeutic agent of the collected exposure, during a one-day period.			Quantitative Concept	CDISC Variable Terminology
C117485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117485>	C71137	Exposure as Collected Intended Dose Regimen|ECDOSRGM	A treatment plan that specifies the amount, schedule, and the duration of the collected exposure.			Functional Concept	CDISC Variable Terminology
C117486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117486>	C38114	Exposure as Collected Route of Administration|ECROUTE	The means of entry through which the exposure is taken into the body.			Functional Concept	CDISC Variable Terminology
C117487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117487>	C70848	Exposure as Collected Lot Number|ECLOT	A distinctive alpha-numeric identification code assigned by the manufacturer or distributor to a specific quantity of manufactured material or product within a batch that the subject was exposed to.			Intellectual Product	CDISC Variable Terminology
C117488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117488>	C25341	Exposure as Collected Location|ECLOC	The site in or on the body at which the exposure as collected test or result is performed or collected.			Spatial Concept	CDISC Variable Terminology
C117489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117489>	C25185	Exposure as Collected Laterality|ECLAT	A qualifier for the side of the body the collected exposure assessment is performed.			Organism Attribute	CDISC Variable Terminology
C11748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11748>	C61063	Carboplatin/Epirubicin/Paclitaxel|Carboplatin-Epirubicin-Paclitaxel|Carboplatin-Epirubicin-Paclitaxel Regimen			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117490>	C54215	Exposure as Collected Directionality|ECDIR	A qualifier for the direction on the body the collected exposure assessment is performed.			Functional Concept	CDISC Variable Terminology
C117491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117491>	C103166	Exposure as Collected Portion or Totality|ECPORTOT	A qualifier for the arrangement or apportioning of an entity within a body part, region or organ for the collected exposure assessment.			Organism Attribute	CDISC Variable Terminology
C117492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117492>	C93566	Exposure as Collected Fasting Status|ECFAST	An indication or description of whether a collected exposure specimen was obtained from a subject that has abstained from food and possibly water for the prescribed amount of time.			Finding	CDISC Variable Terminology
C117493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117493>	C53294	Exposure as Collected Pharmaceutical Strength|ECPSTRG	The content of an active ingredient in the exposure expressed quantitatively per dosage unit, per unit of volume, or per unit of weight, according to the pharmaceutical dose form.			Quantitative Concept	CDISC Variable Terminology
C117494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117494>	C117055	Exposure as Collected Pharmaceutical Strength Units|ECPSTRGU	The unit of measure for the content of an active ingredient in the exposure, expressed quantitatively per dosage unit.			Quantitative Concept	CDISC Variable Terminology
C117495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117495>	C82555	Exposure as Collected Reason for Dose Adjustment|ECADJ	The explanation given as to why the collected exposure was adjusted.			Idea or Concept	CDISC Variable Terminology
C117496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117496>	C82517	Exposure as Collected Start Date and Time of Treatment|ECSTDTC	The date and time of the beginning of exposure collection period.			Temporal Concept	CDISC Variable Terminology
C117497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117497>	C82516	Exposure as Collected End Date and Time of Treatment|ECENDTC	The date and time of the end of the exposure collection period.			Temporal Concept	CDISC Variable Terminology
C117498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117498>	C82570	Exposure as Collected Start Day|ECSTDY	The first day of the exposure collection period.			Temporal Concept	CDISC Variable Terminology
C117499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117499>	C82569	Exposure as Collected End Day|ECENDY	The final day of the exposure collection period.			Temporal Concept	CDISC Variable Terminology
C11749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11749>	C61063	Cytarabine/Fludarabine/Oblimersen			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1174>	C697	Novembichin|NOVEMBICHIN	A nitrogen mustard agent that crosslinks with DNA, causing inhibition of DNA synthesis. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C117500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117500>	C25330	Exposure as Collected Duration of Treatment|ECDUR	The period of time from start to finish of the collected exposure.			Temporal Concept	CDISC Variable Terminology
C117501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117501>	C82539	Exposure as Collected Planned Time Point Name|ECTPT	The literal identifier of a planned point in time for exposure collection.			Intellectual Product	CDISC Variable Terminology
C117502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117502>	C82545	Exposure as Collected Planned Time Point Number|ECTPTNUM	The numerical identifier of a collected exposure point in time.			Quantitative Concept	CDISC Variable Terminology
C117503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117503>	C82572	Exposure as Collected Elapsed Time|ECELTM	The interval between two collected exposure reference time points.			Temporal Concept	CDISC Variable Terminology
C117504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117504>	C82576	Exposure as Collected Time Point Reference|ECTPTREF	The point in time that acts as a fixed reference point to an exposure collection.			Temporal Concept	CDISC Variable Terminology
C117505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117505>	C82518	Exposure as Collected Date Time of Reference Timepoint|ECRFTDTC	The date and time of a specific reference point for the collected exposure data.			Temporal Concept	CDISC Variable Terminology
C117506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117506>	C70710	Procedure Sequence Number|PRSEQ	An identifier that describes the relative position of procedures within a series.			Quantitative Concept	CDISC Variable Terminology
C117507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117507>	C82529	Procedure Group Identifier|PRGRPID	A character or string that represents a procedure group.			Intellectual Product	CDISC Variable Terminology
C117508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117508>	C82530	Procedure Sponsor Defined Identifier|PRSPID	One or more sponsor defined characters used to identify, name, or characterize the procedure.			Intellectual Product	CDISC Variable Terminology
C117509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117509>	C117050	Procedure Link Identifier|PRLNKID	A sequence of characters used as a linkage between related procedure records.			Intellectual Product	CDISC Variable Terminology
C11750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11750>	C61063	Docetaxel/MS-209			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117510>	C117049	Procedure Link Group|PRLNKGRP	A sequence of characters used to link multiple procedures to a single finding.			Intellectual Product	CDISC Variable Terminology
C117511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117511>	C82542	Reported Name of Procedure|PRTRT	The literal identifier of the procedure.			Intellectual Product	CDISC Variable Terminology
C117512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117512>	C82977	Standardized Name of Procedure|PRDECOD	A procedure identifier obtained from a dictionary.			Idea or Concept	CDISC Variable Terminology
C117513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117513>	C25372	Procedure Category|PRCAT	A classification of a procedure event.			Classification	CDISC Variable Terminology
C117514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117514>	C25692	Procedure Subcategory|PRSCAT	A subdivision of a procedure event.			Classification	CDISC Variable Terminology
C117515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117515>	C82510	Procedure Pre-specified|PRPRESP	An indication or description that the procedure was previously determined, characterized, or detailed.			Conceptual Entity	CDISC Variable Terminology
C117516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117516>	C25275	Procedure Occurrence|PROCCUR	An indication or description of a procedure occurrence.			Event	CDISC Variable Terminology
C117517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117517>	C41184	Procedure Indication|PRINDC	The condition, disease or disorder that the procedure is intended to investigate or address.			Functional Concept	CDISC Variable Terminology
C117518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117518>	C25488	Procedure Dose|PRDOSE	The amount of substance that the patient or test subject was administered during the procedure, or the total quantity administered.			Quantitative Concept	CDISC Variable Terminology
C117519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117519>	C70961	Procedure Dose Description|PRDOSTXT	A textual description of the agent dose level(s) or range(s) for the procedure per subject, according to the study protocol.			Intellectual Product	CDISC Variable Terminology
C11751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11751>	C61063	MUC-2-KLH Vaccine/QS21			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117520>	C73558	Procedure Dose Units|PRDOSU	The unit of measure for the dosage form of the procedure.			Quantitative Concept	CDISC Variable Terminology
C117521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117521>	C42636	Procedure Dose Form|PRDOSFRM	The form in which active and/or inert ingredient(s) of the procedure are physically presented.			Functional Concept	CDISC Variable Terminology
C117522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117522>	C89081	Procedure Dosing Frequency per Interval|PRDOSFRQ	The number of doses administered for the procedure per a specific interval.			Functional Concept	CDISC Variable Terminology
C117523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117523>	C71137	Procedure Intended Dose Regimen|PRDOSRGM	A treatment plan that specifies the amount, schedule, and the duration of the procedure.			Functional Concept	CDISC Variable Terminology
C117524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117524>	C38114	Procedure Route of Administration|PRROUTE	The means of entry through which the procedure is taken into the body.			Functional Concept	CDISC Variable Terminology
C117525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117525>	C25341	Procedure Location|PRLOC	The site in or on the body at which the procedure is performed.			Spatial Concept	CDISC Variable Terminology
C117526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117526>	C25185	Procedure Laterality|PRLAT|PROCEDURE_LATERALITY|PROCEDURE_LATERALITY|PROCEDURE_LATERALITY	A qualifier for the side of the body the procedure is performed.			Organism Attribute	CDISC Variable Terminology|EWS Biopsy/Surgical Procedures Table|EWS Variable Terminology|GCT Biopsy/Surgical Procedures Table|GCT Variable Terminology|OS Biopsy/Surgical Procedures Table|OS Variable Terminology
C117527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117527>	C54215	Procedure Directionality|PRDIR	A qualifier for the direction on the body the procedure is performed.			Functional Concept	CDISC Variable Terminology
C117528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117528>	C103166	Procedure Portion or Totality|PRPORTOT	A qualifier for the arrangement or apportioning of an entity within a body part, region or organ for the procedure.			Organism Attribute	CDISC Variable Terminology
C117529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117529>	C82517	Start Date and Time of Procedure|PRSTDTC	The date and time of the beginning of the procedure.			Temporal Concept	CDISC Variable Terminology
C11752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11752>	C61063	O6-Benzylguanine/Polifeprosan 20 With Carmustine Implant			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117530>	C82516	End Date and Time of Procedure|PRENDTC	The date and time of the end of the procedure.			Temporal Concept	CDISC Variable Terminology
C117531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117531>	C82570	Procedure Start Day|PRSTDY	The first day of the procedure.			Temporal Concept	CDISC Variable Terminology
C117532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117532>	C82569	Procedure End Day|PRENDY	The final day of the procedure.			Temporal Concept	CDISC Variable Terminology
C117533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117533>	C25330	Procedure Duration of Procedure|PRDUR	The period of time from start to finish of the procedure.			Temporal Concept	CDISC Variable Terminology
C117534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117534>	C82539	Procedure Planned Time Point Name|PRTPT	The literal identifier of a planned point in time for a procedure.			Intellectual Product	CDISC Variable Terminology
C117535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117535>	C82545	Procedure Planned Time Point Number|PRTPTNUM	The numerical identifier of a planned procedure point in time.			Quantitative Concept	CDISC Variable Terminology
C117536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117536>	C82572	Procedure Elapsed Time|PRELTM	The interval between two procedure reference time points.			Temporal Concept	CDISC Variable Terminology
C117537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117537>	C82576	Procedure Time Point Reference|PRTPTREF	The point in time that acts as a fixed reference point to a procedure.			Temporal Concept	CDISC Variable Terminology
C117538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117538>	C82518	Procedure Date Time of Reference Timepoint|PRRFTDTC	The date and time of a specific reference point for the procedure.			Temporal Concept	CDISC Variable Terminology
C117539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117539>	C82560	Procedure Start Relative to Reference Time Point|PRSTRTPT	An indication or description of the start of a procedure in relation to a specific point in time.			Temporal Concept	CDISC Variable Terminology
C11753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11753>	C61063	Ifosfamide/Paclitaxel/Teniposide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117540>	C82575	Procedure Start Reference Time Point|PRSTTPT	A point in time that indicates the beginning of a procedure.			Temporal Concept	CDISC Variable Terminology
C117541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117541>	C82558	Procedure End Relative to Reference Time Point|PRENRTPT	An indication or description that the end of the procedure is before, during or after a reference moment in time.			Temporal Concept	CDISC Variable Terminology
C117542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117542>	C82574	Procedure End Reference Time Point|PRENTPT	A point in time that indicates the conclusion of a procedure.			Temporal Concept	CDISC Variable Terminology
C117543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117543>	C70710	Death Diagnosis Sequence Number|DDSEQ	An identifier that describes the relative position of death diagnoses data within a series.			Quantitative Concept	CDISC Variable Terminology
C117544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117544>	C82503	Death Diagnosis Assessment Test Code|DDTESTCD	A character or string that represents the short code name of the death diagnosis assessment.			Intellectual Product	CDISC Variable Terminology
C117545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117545>	C82541	Death Diagnosis Assessment Test|DDTEST	A character or string that represents the long name of the death diagnosis assessment.			Intellectual Product	CDISC Variable Terminology
C117546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117546>	C117221	Death Diagnosis Original Result|DDORRES	The outcome of the death diagnosis assessment as originally received or collected.			Finding	CDISC Variable Terminology
C117547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117547>	C117222	Death Diagnosis Character Result in Standard Format|DDSTRESC	The standard character or string for representation and reporting of death diagnosis data.			Quantitative Concept	CDISC Variable Terminology
C117548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117548>	C51824	Death Diagnosis Evaluator|DDEVAL	A person who determines the significance of a death diagnosis assessment.			Professional or Occupational Group	CDISC Variable Terminology
C117549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117549>	C82515	Death Diagnosis Data Collection Date Time|DDDTC	The date and time of death diagnosis data collection.			Temporal Concept	CDISC Variable Terminology
C11754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11754>	C61063	Docetaxel/Doxorubicin Hcl Liposome/Trastuzumab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117550>	C82437	Study Day of Death Diagnosis|DDDY	The study day that a death diagnosis assessment is performed.			Temporal Concept	CDISC Variable Terminology
C117551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117551>	C70710	Immunogenicity Specimen Assessments Sequence Number|ISSEQ	An identifier that describes the relative position of immunogenicity specimen assessments data within a series.			Quantitative Concept	CDISC Variable Terminology
C117552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117552>	C82529	Immunogenicity Specimen Assessments Group Identifier|ISGRPID	A character or string that represents an immunogenicity specimen assessments group.			Intellectual Product	CDISC Variable Terminology
C117553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117553>	C82531	Immunogenicity Specimen Assessments Reference Identifier|ISREFID	A sequence of characters used to identify, name, or characterize the immunogenicity specimen assessments reference.			Intellectual Product	CDISC Variable Terminology
C117554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117554>	C82530	Immunogenicity Specimen Assessments Sponsor Defined Identifier|ISSPID	One or more sponsor defined characters used to identify, name, or characterize the immunogenicity specimen assessment.			Intellectual Product	CDISC Variable Terminology
C117555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117555>	C82503	Immunogenicity Specimen Assessments Test Code|ISTESTCD	A character or string that represents the short code name of the immunogenicity specimen assessment.			Intellectual Product	CDISC Variable Terminology
C117556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117556>	C82541	Immunogenicity Specimen Assessments Test|ISTEST	A character or string that represents the long name of the immunogenicity specimen assessment.			Intellectual Product	CDISC Variable Terminology
C117557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117557>	C25372	Immunogenicity Specimen Assessments Category|ISCAT	Classification of immunogenicity specimen assessments data.			Classification	CDISC Variable Terminology
C117558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117558>	C25692	Immunogenicity Specimen Assessments Subcategory|ISSCAT	A subdivision of immunogenicity specimen assessments.			Classification	CDISC Variable Terminology
C117559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117559>	C117221	Immunogenicity Specimen Assessments Original Result|ISORRES	The outcome of the immunogenicity specimen assessment as originally received or collected.			Finding	CDISC Variable Terminology
C11755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11755>	C61007	Tariquidar/Vinorelbine|Vinorelbine/XR9576			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117560>	C82586	Immunogenicity Specimen Assessments Original Result Unit|ISORRESU	The unit of measure for the result of the immunogenicity specimen assessment as originally received or collected.			Quantitative Concept	CDISC Variable Terminology
C117561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117561>	C117222	Immunogenicity Specimen Assessments Character Result in Standard Format|ISSTRESC	The standard character or string for representation and reporting of immunogenicity specimen assessment data.			Quantitative Concept	CDISC Variable Terminology
C117562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117562>	C70952	Immunogenicity Specimen Assessments Numeric Result in Standard Unit|ISSTRESN	The numerical identifier of an immunogenicity specimen assessment result in standard units.			Quantitative Concept	CDISC Variable Terminology
C117563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117563>	C82587	Immunogenicity Specimen Assessments Result Standard Unit|ISSTRESU	The standard unit of measure for the immunogenicity specimen assessment results.			Quantitative Concept	CDISC Variable Terminology
C117564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117564>	C41202	Immunogenicity Specimen Assessments Completion Status|ISSTAT	A term used to describe the state or condition of the completeness of the immunogenicity specimen assessment data.			Qualitative Concept	CDISC Variable Terminology
C117565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117565>	C82556	Immunogenicity Specimen Assessments Reason Not Done|ISREASND	The rationale why an immunogenicity specimen assessment was not performed.			Idea or Concept	CDISC Variable Terminology
C117566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117566>	C117200	Immunogenicity Specimen Assessments Vendor Name|ISNAM	The literal identifier of the vendor or laboratory that performs a immunogenicity specimen assessment.			Intellectual Product	CDISC Variable Terminology
C117567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117567>	C70713	Immunogenicity Specimen Assessments Specimen Type|ISSPEC	The type of a material sample taken from a biological entity for immunogenicity specimen assessment testing.			Qualitative Concept	CDISC Variable Terminology
C117568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117568>	C82535	Immunogenicity Specimen Assessments Method|ISMETHOD	The technique used to administer the immunogenicity specimen assessment.			Activity	CDISC Variable Terminology
C117569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117569>	C82526	Immunogenicity Specimen Assessments Baseline Flag|ISBLFL	An indication or description that immunogenicity specimen assessment data is a baseline value.			Functional Concept	CDISC Variable Terminology
C11756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11756>	C61007	Montanide ISA-51/PR1 leukemia peptide vaccine/Sargramostim			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117570>	C82589	Immunogenicity Specimen Assessments Lower Limit of Quantitation|ISLLOQ	The lowest value in a possible range of values for the immunogenicity specimen assessment.			Quantitative Concept	CDISC Variable Terminology
C117571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117571>	C82515	Immunogenicity Specimen Assessments Data Collection Date Time|ISDTC	The date and time of immunogenicity specimen assessment data collection.			Temporal Concept	CDISC Variable Terminology
C117572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117572>	C82437	Study Day of Immunogenicity Specimen Assessment|ISDY	The study day that an immunogenicity specimen assessment is performed.			Temporal Concept	CDISC Variable Terminology
C117573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117573>	C70710	Microscopic Findings Sequence Number|MISEQ	An identifier that describes the relative position of microscopic findings data within a series.			Intellectual Product	CDISC Variable Terminology
C117574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117574>	C82529	Microscopic Findings Group Identifier|MIGRPID	A character or string that represents a microscopic findings group.			Intellectual Product	CDISC Variable Terminology
C117575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117575>	C82531	Microscopic Findings Reference Identifier|MIREFID	A character or string used to name, or characterize a microscopic findings reference.			Intellectual Product	CDISC Variable Terminology
C117576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117576>	C82530	Microscopic Findings Sponsor Defined Identifier|MISPID	One or more sponsor defined characters used to identify, name, or characterize the microscopic findings.			Intellectual Product	CDISC Variable Terminology
C117577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117577>	C82503	Microscopic Findings Test Code|MITESTCD	A character or string that represents the short code name of the microscopic findings assessment.			Intellectual Product	CDISC Variable Terminology
C117578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117578>	C82541	Microscopic Findings Test|MITEST	A character or string that represents the long name of the microscopic findings assessment.			Intellectual Product	CDISC Variable Terminology
C117579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117579>	C117062	Microscopic Findings Measurement, Test or Examination Detail|MITSTDTL	Particulars considered individually and in relation to a microscopic findings measurement, test or examination.			Idea or Concept	CDISC Variable Terminology
C11757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11757>	C61063	Biomed 101/Interleukin-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117580>	C25372	Microscopic Findings Category|MICAT	A classification of microscopic findings data.			Classification	CDISC Variable Terminology
C117581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117581>	C25692	Microscopic Findings Subcategory|MISCAT	A subdivision of microscopic findings data.			Classification	CDISC Variable Terminology
C117582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117582>	C117221	Microscopic Findings Original Result|MIORRES	The outcome of the microscopic assessment as originally received or collected.			Finding	CDISC Variable Terminology
C117583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117583>	C82586	Microscopic Findings Original Result Unit|MIORRESU	The unit of measure for the result of the microscopic test or finding as originally received or collected.			Quantitative Concept	CDISC Variable Terminology
C117584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117584>	C117222	Microscopic Findings Character Result in Standard Format|MISTRESC	The standard character or string for representation and reporting of microscopic findings data.			Quantitative Concept	CDISC Variable Terminology
C117585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117585>	C70952	Microscopic Findings Numeric Result in Standard Unit|MISTRESN	The numerical identifier of microscopic findings result in standard units.			Quantitative Concept	CDISC Variable Terminology
C117586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117586>	C82587	Microscopic Findings Result Standard Unit|MISTRESU	The standard unit of measure for microscopic findings results.			Quantitative Concept	CDISC Variable Terminology
C117587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117587>	C82498	Microscopic Findings Result Category|MIRESCAT	A classification of a microscopic findings result.			Classification	CDISC Variable Terminology
C117588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117588>	C41202	Microscopic Findings Completion Status|MISTAT	A term used to describe the state or condition of the completeness of the microscopic findings data.			Qualitative Concept	CDISC Variable Terminology
C117589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117589>	C82556	Microscopic Findings Reason Not Done|MIREASND	The rationale why a microscopic finding was not obtained.			Idea or Concept	CDISC Variable Terminology
C11758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11758>	C61063	Anti-thymocyte globulin/methylprednisolone/tacrolimus			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117590>	C117200	Microscopic Findings Vendor Name|MINAM	The literal identifier of the vendor or laboratory that performs a microscopic assessment.			Intellectual Product	CDISC Variable Terminology
C117591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117591>	C70713	Microscopic Findings Specimen Type|MISPEC	The type of a material sample taken from a biological entity for microscopic testing.			Qualitative Concept	CDISC Variable Terminology
C117592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117592>	C70714	Microscopic Findings Specimen Condition|MISPCCND	A characteristic that refers to the physical and organoleptic state of a biospecimen used for a microscopic assessment.			Qualitative Concept	CDISC Variable Terminology
C117593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117593>	C25341	Microscopic Findings Location|MILOC	The site in or on the body at which the microscopic assessment test or result is performed or collected.			Spatial Concept	CDISC Variable Terminology
C117594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117594>	C25185	Microscopic Findings Laterality|MILAT	A qualifier for the side of the body the microscopic findings assessment is performed.			Organism Attribute	CDISC Variable Terminology
C117595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117595>	C54215	Microscopic Findings Directionality|MIDIR	A qualifier for the direction on the body the microscopic findings assessment is performed.			Functional Concept	CDISC Variable Terminology
C117596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117596>	C82535	Microscopic Findings Method|MIMETHOD	The technique used to administer the microscopic assessment.			Activity	CDISC Variable Terminology
C117597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117597>	C82526	Microscopic Findings Baseline Flag|MIBLFL	An indication or description that microscopic findings data is a baseline value.			Functional Concept	CDISC Variable Terminology
C117598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117598>	C51824	Microscopic Findings Evaluator|MIEVAL	A person who determines the significance of a microscopic findings assessment.			Professional or Occupational Group	CDISC Variable Terminology
C117599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117599>	C82515	Microscopic Findings Data Collection Date Time|MIDTC	The date and time microscopic findings data was collected.			Temporal Concept	CDISC Variable Terminology
C11759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11759>	C61063	CI-994/Gemcitabine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1175>	C2562	Olive Oil|OLIVE OIL|Oil, Olive|Olea Europaea Oil	Produced by pressing olives, Olive Oil has a high content of monounsaturated fats, thought beneficial for health. Major components of the phenolic fraction of olive oil, lignans and pinoresinols are potent antioxidants present in extra virgin (first pressed) oils. Containing vitamins E and F, other antioxidant compounds, foods containing high amounts of lignan precursors may be protective against breast, colon, and prostate cancer, as well as heart diseases. Used mainly in cooking today, olive oil has been used for medicines and in cosmetics. (NCI04)	Olive Oil		Food	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C117600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117600>	C82437	Study Day of Microscopic Findings|MIDY	The day that a microscopic findings assessment is performed.			Temporal Concept	CDISC Variable Terminology
C117601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117601>	C70710	Morphology Sequence Number|MOSEQ	An identifier that describes the relative position of morphology data within a series.			Intellectual Product	CDISC Variable Terminology
C117602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117602>	C82529	Morphology Group Identifier|MOGRPID	A character or string that represents a morphology findings group.			Intellectual Product	CDISC Variable Terminology
C117603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117603>	C82531	Morphology Reference Identifier|MOREFID	A character or string used to name, or characterize a morphology reference.			Intellectual Product	CDISC Variable Terminology
C117604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117604>	C82530	Morphology Sponsor Defined Identifier|MOSPID	One or more sponsor defined characters used to identify, name, or characterize the morphology finding.			Intellectual Product	CDISC Variable Terminology
C117605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117605>	C117050	Morphology Record Link Identifier|MOLNKID	A sequence of characters used as a linkage between related records of a morphology assessment.			Intellectual Product	CDISC Variable Terminology
C117606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117606>	C82503	Morphology Test Code|MOTESTCD	A character or string that represents the short code name of the morphology assessment.			Intellectual Product	CDISC Variable Terminology
C117607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117607>	C82541	Morphology Test|MOTEST	A character or string that represents the long name of the morphology assessment.			Intellectual Product	CDISC Variable Terminology
C117608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117608>	C25372	Morphology Category|MOCAT	A classification of morphology data.			Classification	CDISC Variable Terminology
C117609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117609>	C25692	Morphology Subcategory|MOSCAT	A subdivision of morphology data.			Classification	CDISC Variable Terminology
C11760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11760>	C61063	Eniluracil/Fluorouracil/Oxaliplatin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117610>	C62164	Morphology Position|MOPOS	The physical bearing of the body during a morphology assessment.			Spatial Concept	CDISC Variable Terminology
C117611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117611>	C117221	Morphology Original Result|MOORRES	The outcome of the morphology assessment as originally received or collected.			Finding	CDISC Variable Terminology
C117612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117612>	C82586	Morphology Original Result Unit|MOORRESU	The unit of measure for the result of the morphology test or finding as originally received or collected.			Quantitative Concept	CDISC Variable Terminology
C117613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117613>	C117222	Morphology Character Result in Standard Format|MOSTRESC	The standard character or string for representation and reporting of morphology data.			Quantitative Concept	CDISC Variable Terminology
C117614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117614>	C70952	Morphology Numeric Result in Standard Unit|MOSTRESN	The numerical identifier of morphology result in standard units.			Quantitative Concept	CDISC Variable Terminology
C117615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117615>	C82587	Morphology Result Standard Unit|MOSTRESU	The standard unit of measure for morphology results.			Quantitative Concept	CDISC Variable Terminology
C117616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117616>	C41202	Morphology Completion Status|MOSTAT	A term used to describe the state or condition of the completeness of the morphology data.			Qualitative Concept	CDISC Variable Terminology
C117617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117617>	C82556	Morphology Reason Not Done|MOREASND	The rationale why a morphology test was not performed.			Idea or Concept	CDISC Variable Terminology
C117618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117618>	C82536	Morphology External Filename|MOXFN	The literal identifier of an morphology external file name.			Intellectual Product	CDISC Variable Terminology
C117619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117619>	C117200	Morphology Vendor Name|MONAM	The literal identifier of the vendor or laboratory that performs a morphology examination.			Intellectual Product	CDISC Variable Terminology
C11761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11761>	C61063	Cisplatin/Tirapazamine/Vinorelbine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117620>	C25341	Morphology Location|MOLOC	The site in or on the body at which the morphology test or result is performed or collected.			Spatial Concept	CDISC Variable Terminology
C117621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117621>	C25185	Morphology Laterality|MOLAT	A qualifier for the side of the body the morphology assessment is performed.			Organism Attribute	CDISC Variable Terminology
C117622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117622>	C54215	Morphology Directionality|MODIR	A qualifier for the direction on the body the morphology assessment is performed.			Functional Concept	CDISC Variable Terminology
C117623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117623>	C103166	Morphology Portion or Totality|MOPORTOT	A qualifier for the arrangement or apportioning of an entity within a body part, region or organ for a morphology assessment.			Organism Attribute	CDISC Variable Terminology
C117624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117624>	C82535	Morphology Method|MOMETHOD	The technique used to administer the morphologic assessment.			Activity	CDISC Variable Terminology
C117625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117625>	C117039	Morphology Analysis Method|MOANMETH	A means, manner of procedure, or systematic course of actions that are performed in order to examine and interpret a morphology assessment.			Conceptual Entity	CDISC Variable Terminology
C117626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117626>	C82526	Morphology Baseline Flag|MOBLFL	An indication or description that morphology data is a baseline value.			Functional Concept	CDISC Variable Terminology
C117627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117627>	C81197	Morphology Derived Flag|MODRVFL	An indication or description that morphology assessment data is a derived value.			Functional Concept	CDISC Variable Terminology
C117628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117628>	C51824	Morphology Evaluator|MOEVAL	A person who determines the significance of a morphology assessment.			Professional or Occupational Group	CDISC Variable Terminology
C117629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117629>	C82515	Morphology Data Collection Date Time|MODTC	The date and time morphology data was collected.			Temporal Concept	CDISC Variable Terminology
C11762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11762>	C61063	Cetuximab/Irinotecan			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117630>	C82437	Study Day of Morphology Assessment|MODY	The day that a morphology assessment is performed.			Temporal Concept	CDISC Variable Terminology
C117631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117631>	C82539	Morphology Planned Time Point Name|MOTPT	The literal identifier of a planned point in time for a morphological assessment.			Intellectual Product	CDISC Variable Terminology
C117632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117632>	C82545	Morphology Planned Time Point Number|MOTPTNUM	The numerical identifier of a morphology point in time.			Quantitative Concept	CDISC Variable Terminology
C117633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117633>	C82572	Morphology Elapsed Time|MOELTM	The interval between two morphology reference time points.			Temporal Concept	CDISC Variable Terminology
C117634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117634>	C82576	Morphology Time Point Reference|MOTPTREF	The point in time that acts as a fixed reference point to a morphology finding.			Temporal Concept	CDISC Variable Terminology
C117635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117635>	C82518	Morphology Date Time of Reference Timepoint|MORFTDTC	The date and time of a specific reference point for the morphology assessment.			Temporal Concept	CDISC Variable Terminology
C117636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117636>	C70710	Reproductive System Findings Sequence Number|RPSEQ	An identifier that describes the relative position of reproductive system findings data within a series.			Intellectual Product	CDISC Variable Terminology
C117637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117637>	C82529	Reproductive System Findings Group Identifier|RPGRPID	A character or string that represents a reproductive system findings group.			Intellectual Product	CDISC Variable Terminology
C117638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117638>	C82531	Reproductive System Findings Reference Identifier|RPREFID	A character or string used to name, or characterize a reproductive system findings reference.			Intellectual Product	CDISC Variable Terminology
C117639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117639>	C82530	Reproductive System Findings Sponsor Defined Identifier|RPSPID	One or more sponsor defined characters used to identify, name, or characterize the reproductive system finding.			Intellectual Product	CDISC Variable Terminology
C11763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11763>	C61063	Cisplatin/Cyclophosphamide/Etoposide/Mafosfamide/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117640>	C82503	Reproductive System Finding Test Code|RPTESTCD	A character or string that represents the short code name of the reproductive system finding assessment.			Intellectual Product	CDISC Variable Terminology
C117641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117641>	C82541	Reproductive System Finding Test|RPTEST	A character or string that represents the long name of the reproductive system finding assessment.			Intellectual Product	CDISC Variable Terminology
C117642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117642>	C25372	Reproductive System Findings Category|RPCAT	A classification of reproductive system findings data.			Classification	CDISC Variable Terminology
C117643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117643>	C25692	Reproductive System Findings Subcategory|RPSCAT	A subdivision of reproductive system findings data.			Classification	CDISC Variable Terminology
C117644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117644>	C117221	Reproductive System Findings Original Result|RPORRES	The outcome of the reproductive system findings assessment as originally received or collected.			Finding	CDISC Variable Terminology
C117645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117645>	C82586	Reproductive System Findings Original Result Unit|RPORRESU	The unit of measure for the result of the reproductive system findings test or finding as originally received or collected.			Quantitative Concept	CDISC Variable Terminology
C117646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117646>	C117222	Reproductive System Findings Character Result in Standard Format|RPSTRESC	The standard character or string for representation and reporting of reproductive system findings data.			Quantitative Concept	CDISC Variable Terminology
C117647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117647>	C70952	Reproductive System Findings Numeric Result in Standard Unit|RPSTRESN	The numerical identifier of reproductive system findings result in standard units.			Quantitative Concept	CDISC Variable Terminology
C117648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117648>	C82587	Reproductive System Findings Result Standard Unit|RPSTRESU	The standard unit of measure for reproductive system findings results.			Quantitative Concept	CDISC Variable Terminology
C117649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117649>	C41202	Reproductive System Findings Completion Status|RPSTAT	A term used to describe the state or condition of the completeness of the reproductive system findings data.			Qualitative Concept	CDISC Variable Terminology
C11764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11764>	C63586|C63502|C203473|C191676|C159893|C156290	Folfirinox Regimen|FOLFIRINOX|FOLFIRINOX|Fluorouracil with Irinotecan Hydrochloride, Leucovorin Calcium and Oxaliplatin|Fluorouracil/Irinotecan/Leucovorin Calcium/Oxaliplatin|Folinic Acid/Fluorouracil/Irinotecan/Oxaliplatin	A regimen consisting of fluorouracil, irinotecan, leucovorin and oxaliplatin that can be used for the treatment of pancreatic and colorectal cancers; occult primary, ampullary, appendiceal and small bowel adenocarcinomas; well-differentiated grade 3 neuroendocrine tumors (NETs), and extrapulmonary poorly differentiated neuroendocrine carcinoma, large or small cell carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm.	Folfirinox Regimen		Therapeutic or Preventive Procedure	CTRP Agent Terminology|CTRP Terminology|HemOnc Regimen Terminology|NCI Drug Dictionary Terminology|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C117650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117650>	C82556	Reproductive System Findings Reason Not Done|RPREASND	The rationale why a reproductive system finding was not obtained.			Idea or Concept	CDISC Variable Terminology
C117651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117651>	C82526	Reproductive System Findings Baseline Flag|RPBLFL	An indication or description that reproductive system findings data is a baseline value.			Functional Concept	CDISC Variable Terminology
C117652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117652>	C81197	Reproductive System Findings Derived Flag|RPDRVFL	An indication or description that reproductive system findings data is a derived value.			Functional Concept	CDISC Variable Terminology
C117653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117653>	C82515	Reproductive System Findings Data Collection Date Time|RPDTC	The date and time reproductive system findings data was collected.			Temporal Concept	CDISC Variable Terminology
C117654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117654>	C82437	Study Day of Reproductive System Findings|RPDY	The day that a reproductive system findings assessment is performed.			Temporal Concept	CDISC Variable Terminology
C117655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117655>	C49556	Subject Status Domain|SS|Subject Status	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to subject status.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|CDISC Variable Terminology|Clinical Data Interchange Standards Consortium Terminology
C117656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117656>	C70710	Subject Status Sequence Number|SSSEQ	An identifier that describes the relative position of subject status data within a series.			Intellectual Product	CDISC Variable Terminology
C117657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117657>	C82529	Subject Status Group Identifier|SSGRPID	A character or string that represents a subject status findings group.			Intellectual Product	CDISC Variable Terminology
C117658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117658>	C82530	Subject Status Sponsor Defined Identifier|SSSPID	One or more sponsor defined characters used to identify, name, or characterize the subject status.			Intellectual Product	CDISC Variable Terminology
C117659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117659>	C82503	Subject Status Test Code|SSTESTCD	A character or string that represents the short code name of the subject status assessment.			Intellectual Product	CDISC Variable Terminology
C11765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11765>	C61007	Carboplatin/Paclitaxel/Tirapazamine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117660>	C82541	Subject Status Test|SSTEST	A character or string that represents the long name of the subject status assessment.			Intellectual Product	CDISC Variable Terminology
C117661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117661>	C25372	Subject Status Category|SSCAT	A classification of subject status data.			Classification	CDISC Variable Terminology
C117662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117662>	C25692	Subject Status Subcategory|SSSCAT	A subdivision of subject status data.			Classification	CDISC Variable Terminology
C117663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117663>	C117221	Subject Status Original Result|SSORRES	The outcome of the subject status assessment as originally received or collected.			Finding	CDISC Variable Terminology
C117664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117664>	C117222	Subject Status Character Result in Standard Format|SSSTRESC	The standard character or string for representation and reporting of subject status data.			Quantitative Concept	CDISC Variable Terminology
C117665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117665>	C41202	Subject Status Completion Status|SSSTAT	A term used to describe the state or condition of the completeness of the subject status data.			Qualitative Concept	CDISC Variable Terminology
C117666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117666>	C82556	Subject Status Reason Not Done|SSREASND	The rationale why a subject status assessment was not performed.			Idea or Concept	CDISC Variable Terminology
C117667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117667>	C51824	Subject Status Evaluator|SSEVAL	A person who determines the significance of a subject status assessment.			Professional or Occupational Group	CDISC Variable Terminology
C117668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117668>	C82515	Subject Status Data Collection Date Time|SSDTC	The date and time subject status data was collected.			Temporal Concept	CDISC Variable Terminology
C117669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117669>	C82437	Study Day of Subject Status|SSDY	The day that a subject status assessment is performed.			Temporal Concept	CDISC Variable Terminology
C11766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11766>	C61063	Docetaxel/Methotrexate			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117670>	C70710	Skin Response Sequence Number|SRSEQ	An identifier that describes the relative position of skin response data within a series.			Intellectual Product	CDISC Variable Terminology
C117671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117671>	C82529	Skin Response Group Identifier|SRGRPID	A character or string that represents a skin response findings about group.			Intellectual Product	CDISC Variable Terminology
C117672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117672>	C82531	Skin Response Reference Identifier|SRREFID	A character or string used to name, or characterize a Skin Response reference.			Intellectual Product	CDISC Variable Terminology
C117673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117673>	C82530	Skin Response Sponsor Defined Identifier|SRSPID	One or more sponsor defined characters used to identify, name, or characterize the skin response.			Intellectual Product	CDISC Variable Terminology
C117674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117674>	C82503	Skin Response Test Code|SRTESTCD	A character or string that represents the short code name of the skin response assessment.			Intellectual Product	CDISC Variable Terminology
C117675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117675>	C82541	Skin Response Test|SRTEST	A character or string that represents the long name of the skin response assessment.			Intellectual Product	CDISC Variable Terminology
C117676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117676>	C82546	Skin Response Observation Object|SROBJ	The name of the entity that is being assessed in a skin response examination.			Physical Object	CDISC Variable Terminology
C117677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117677>	C25372	Skin Response Category|SRCAT	A classification of skin response data.			Classification	CDISC Variable Terminology
C117678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117678>	C25692	Skin Response Subcategory|SRSCAT	A subdivision of skin response data.			Classification	CDISC Variable Terminology
C117679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117679>	C117221	Skin Response Original Result|SRORRES	The outcome of the skin response assessment as originally received or collected.			Finding	CDISC Variable Terminology
C11767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11767>	C61063	Oblimersen/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117680>	C82586	Skin Response Original Result Unit|SRORRESU	The unit of measure for the result of the skin response test or finding as originally received or collected.			Quantitative Concept	CDISC Variable Terminology
C117681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117681>	C117222	Skin Response Character Result in Standard Format|SRSTRESC	The standard character or string for representation and reporting of skin response data.			Quantitative Concept	CDISC Variable Terminology
C117682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117682>	C70952	Skin Response Numeric Result in Standard Unit|SRSTRESN	The numerical identifier of skin response result in standard units.			Quantitative Concept	CDISC Variable Terminology
C117683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117683>	C82587	Skin Response Result Standard Unit|SRSTRESU	The standard unit of measure for skin response results.			Quantitative Concept	CDISC Variable Terminology
C117684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117684>	C41202	Skin Response Completion Status|SRSTAT	A term used to describe the state or condition of the completeness of the skin response data.			Qualitative Concept	CDISC Variable Terminology
C117685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117685>	C82556	Skin Response Reason Not Done|SRREASND	The rationale why a skin response test was not performed.			Idea or Concept	CDISC Variable Terminology
C117686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117686>	C117200	Skin Response Vendor Name|SRNAM	The literal identifier of the vendor or laboratory that performs a skin response assessment.			Intellectual Product	CDISC Variable Terminology
C117687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117687>	C70713	Skin Response Specimen Type|SRSPEC	The type of a material sample taken from a biological entity for skin response testing.			Qualitative Concept	CDISC Variable Terminology
C117688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117688>	C25341	Skin Response Location|SRLOC	The site in or on the body at which the skin response test or result is performed or collected.			Spatial Concept	CDISC Variable Terminology
C117689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117689>	C25185	Skin Response Laterality|SRLAT	A qualifier for the side of the body the skin response assessment is performed.			Organism Attribute	CDISC Variable Terminology
C11768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11768>	C61063	Cetuximab/Gemcitabine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117690>	C82535	Skin Response Method|SRMETHOD	The technique used to administer the skin response assessment.			Activity	CDISC Variable Terminology
C117691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117691>	C51824	Skin Response Evaluator|SREVAL	A person who determines the significance of a skin response assessment.			Professional or Occupational Group	CDISC Variable Terminology
C117692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117692>	C82515	Skin Response Data Collection Date Time|SRDTC	The date and time skin response data was collected.			Temporal Concept	CDISC Variable Terminology
C117693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117693>	C82437	Study Day of Skin Response Assessment|SRDY	The day that a skin response assessment is performed.			Temporal Concept	CDISC Variable Terminology
C117694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117694>	C82539	Skin Response Planned Time Point Name|SRTPT	The literal identifier of a planned point in time for a skin response assessment.			Intellectual Product	CDISC Variable Terminology
C117695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117695>	C82545	Skin Response Planned Time Point Number|SRTPTNUM	The numerical identifier of a skin response point in time.			Quantitative Concept	CDISC Variable Terminology
C117696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117696>	C82572	Skin Response Elapsed Time|SRELTM	The interval between two skin response reference time points.			Temporal Concept	CDISC Variable Terminology
C117697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117697>	C82576	Skin Response Time Point Reference|SRTPTREF	The point in time that acts as a fixed reference point to a skin response.			Temporal Concept	CDISC Variable Terminology
C117698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117698>	C82518	Skin Response Date Time of Reference Timepoint|SRRFTDTC	The date and time of a specific reference point for the skin reponse assessment.			Temporal Concept	CDISC Variable Terminology
C117699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117699>	C49556	Trial Disease Assessments Domain|TD|Trial Disease Assessments	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to trial disease assessments.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|CDISC Variable Terminology|Clinical Data Interchange Standards Consortium Terminology
C11769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11769>	C61063	Carboplatin/Etoposide/Topotecan			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1176>	C257	Olsalazine|3,3'-Azobis[6-hydroxybenzoic Acid]|3,3'-Azobis[6-hydroxybenzoic Acid]|3,3'-Dicarboxy-4,4'-dihydroxyazobenzene|Azodisalicylate|C.I. Mordant Yellow 5|OLSALAZINE	A prodrug of mesalamine (5-Aminosalicylic acid; 5-ASA) with anti-inflammatory activity. Unabsorbed olsalazine passes through gastrointestinal tract and is cleaved by azoreductases, produced by microflora in colon, into 2 active molecules of 5-ASA. 5-ASA exerts its anti-inflammatory action locally by inhibiting cyclooxygenase and lipoxygenase activities, thereby reducing the production of prostaglandins and leukotrienes. In addition, mesalamine may act as a scavenger of reactive oxygen free radicals.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C117700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117700>	C117298	Planned Trial Disease Assessment Schedule Sequence Number|TDORDER|Trial Disease Sequence of Planned Assessment Schedule	A number that identifies the ordering relations in time of the schedules for planned trial disease assessments in a trial.			Intellectual Product	CDISC Variable Terminology
C117701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117701>	C117299	Trial Disease Anchor Variable Name|TDANCVAR	A reference to the CDISC date variable name that provides the start point from which the planned trial disease assessment schedule is measured.			Conceptual Entity	CDISC Variable Terminology
C117702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117702>	C47923	Trial Disease Offset From Reference|TDSTOFF	The difference between a point and a fixed reference point of a trial disease assessment.			Quantitative Concept	CDISC Variable Terminology
C117703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117703>	C117300	Trial Disease Planned Assessment Interval|TDTGTPAI	A planned period of time between planned trial disease assessments.			Temporal Concept	CDISC Variable Terminology
C117704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117704>	C117301	Trial Disease Minimum Time Allowed in Planned Assessment|TDMINPAI	The lower limit in time of a planned period of time between planned trial disease assessments.			Temporal Concept	CDISC Variable Terminology
C117705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117705>	C117302	Trial Disease Maximum Time Allowed in Planned Assessment Interval|TDMAXPAI	The upper limit in time of a planned period of time between planned trial disease assessments.			Temporal Concept	CDISC Variable Terminology
C117706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117706>	C117303	Trial Disease Maximum Number of Actual Assessments|TDNUMRPT	The upper limit in number of actual trial disease assessments during a planned period of time.			Quantitative Concept	CDISC Variable Terminology
C117707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117707>	C25364	Associated Persons Identifier|APID	A character or string that identifies and represents a single associated person, a group of associated persons, or a pool of associated persons.			Intellectual Product	CDISC Variable Terminology
C117708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117708>	C25364	Related Subject Identifier|RSUBJID	A character or string that identifies and represents a related subject or pool of subjects.			Intellectual Product	CDISC Variable Terminology
C117709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117709>	C25648	Subject, Device, or Study Relationship|SREL	A qualifier to describe the relationships of the associated person(s) to the related subject or pool of subjects, to the related device, or to the study.			Conceptual Entity	CDISC Variable Terminology
C11770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11770>	C61007	Carboplatin/Etoposide/Ifosfamide/Rituximab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117710>	C25364	Related Device Identifier|RDEVID	A character or string that identifies and represents a related device.			Intellectual Product	CDISC Variable Terminology
C117711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117711>	C117712	Bovine Immunodeficiency Virus|BIV	A lentivirus that is similar to human immunodeficiency virus and that infects cattle.			Virus	
C117712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117712>	C14290	Bovine Lentivirus Group|Bovine Lentivirus Serogroup	A non-taxonomic grouping of lentivuruses that infect cattle.			Virus	
C117713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117713>	C14290	Equine Lentivirus Group|Equine Lentivirus Serogroup	A non-taxonomic grouping of lentivuruses that infect horses, asses, and zebras.			Virus	
C117714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117714>	C14290	Feline Lentivirus Group|Feline Lentivirus Serogroup	A non-taxonomic grouping of lentivuruses that infect lions, tigers, jaguars, and other wild and domestic cats.			Virus	
C117715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117715>	C14290	Ovine/Caprine Lentivirus Group|Ovine/Caprine Lentivirus Serogroup	A non-taxonomic grouping of lentivuruses that infect wild and domestic sheep and goats.			Virus	
C117716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117716>	C14290	Primate Lentivirus Group|Primate Lentivirus Serogroup	A non-taxonomic grouping of lentivuruses that infect humans, apes, monkeys, lemurs, lorises, and tarsiers.			Virus	
C117717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117717>	C42883	FDA Master File|Food and Drug Administration Master File|Master File	A submission to the Food and Drug Administration (FDA) that contains information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs or biologics.			Manufactured Object	FDA Structured Product Labeling Terminology|SPL Marketing Category Terminology
C117718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117718>	C25761	Neobladder	A urinary diversion after the removal of the urinary bladder that uses a loop of intestine that is surgically fashioned into a pouch and placed in the location of the original bladder and then attached to the ureters and urethra simulating the function of the original organ.			Anatomical Structure	
C117719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117719>	C36284	Male Reproductive System Finding	Symptoms, physical examination results, and/or laboratory test results related to the male reproductive system.			Finding	
C11771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11771>	C61063	Asparaginase/cyclophosphamide/cytarabine/daunorubicin/thioguanine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117720>	C36284	Female Reproductive System Finding	Symptoms, physical examination results, and/or laboratory test results related to the female reproductive system.			Finding	
C117721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117721>	C14307	Respirovirus	A genus of negative-stranded RNA viruses in the paramyxovirinae subfamily.			Virus	
C117722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117722>	C14307	Avulavirus|Avian Rubulavirus	A genus of negative-sense viruses in the subfamily paramyxovirinae that infect birds.			Virus	
C117723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117723>	C213472|C129825	Flumatinib Mesylate|4-(4-Methyl-piperazin-1-ylmethyl)-N-[6-methyl-5-(4-pyridin-3-yl-pyrimidin-2-ylamino)-pyridin-3-yl]-3-trifluoromethyl-benzamide Mesylate|FLUMATINIB MESYLATE|HH-GV-678 Mesylate|HH-GV678 Mesylate	The orally bioavailable, mesylate salt form of the tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity. Upon administration, flumatinib inhibits the wild-type forms of Bcr-Abl, platelet-derived growth factor receptor (PDGFR) and mast/stem cell growth factor receptor (SCFR; c-Kit) and forms of these proteins with certain point mutations. This results in the inhibition of both Bcr-Abl-, PDGFR- and c-Kit-mediated signal transduction pathways, and the proliferation of tumor cells in which these kinases are overexpressed. Bcr-Abl fusion protein is an abnormal, constitutively active enzyme expressed in Philadelphia chromosome positive chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML). PDGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to cell migration and the development of the microvasculature. c-kit, a receptor tyrosine kinase mutated and constitutively activated in certain tumors, plays a key role in tumor cell survival, proliferation, and differentiation.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C117724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117724>	C129826	NY-ESO-1-specific CD4-positive T Lymphocytes|CD4+ NY-ESO-1-specific T Cells	A preparation of autologous CD4+ T-lymphocytes sensitized to cancer-testis antigen NY-ESO-1, with potential immunostimulating and antineoplastic activities. CD4-positive T-lymphocytes are exposed to a NY-ESO-1 peptide ex vivo, expanded, and introduced into the patient. The NY-ESO-1-specific CD4-positive T-lymphocytes may stimulate the host immune system to produce a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the NY-ESO-1 antigen, which results in tumor cell lysis. NY-ESO-1, an antigen found in normal testis, may be upregulated in various cancers.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C117725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117725>	C1983	Autologous HNSCC DNA-transfected Semi-allogeneic Fibroblasts MRC-5 Vaccine	A vaccine consisting of lethally irradiated human fetal lung fibroblasts (Medical Research Council 5 or MRC-5) transfected with autologous tumor DNA derived from a head and neck squamous cell carcinoma (HNSCC), with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, the autologous HNSCC DNA-transfected semi-allogeneic fibroblasts MRC-5 vaccine expresses HNSCC tumor-associated antigens (TAAs), which may activate the immune system to induce a cytotoxic T-lymphocyte (CTL) response against HNSCC cells. The MRC-5 cell line, established in 1966, is a human diploid lung fibroblast cell line derived from the human lung tissue of a 14-week-old male fetus.			Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C117726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117726>	C133878|C129822	Anti-EGFR Monoclonal Antibody SCT200|SCT200	A recombinant monoclonal antibody against human epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Upon administration, anti-EGFR monoclonal antibody SCT200 targets EGFR, prevents the activation and subsequent dimerization of this receptor and inhibits both EGFR-mediated signal transduction and cellular proliferation of EGFR-expressing tumor cells. In addition, SCT200 may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against EGFR-expressing tumor cells. EGFR, a member of the epidermal growth factor receptor family, is overexpressed on the cell surfaces of various solid tumors.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C117727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117727>	C200766	EGFRvIII-specific CAR-transduced Autologous T Lymphocytes|CART-EGFRvIII Autologous T Cells	Autologous human T-lymphocytes transduced with a retroviral vector encoding an anti-epidermal growth factor receptor variant III (EGFRvIII) mutant chimeric T-cell receptor (chimeric antigen receptor or CAR) gene, with potential immunostimulatory and antineoplastic activities. Upon administration, the EGFRvIII-specific CAR-transduced autologous T-lymphocytes bind to the EGFRvIII antigen on tumor cell surfaces; subsequently, EGFRvIII-expressing tumor cells may be lysed. EGFRvIII, an in-frame deletion of exons 2-7 in the EGFR gene, is overexpressed by a variety of cancer cell types but absent in normal, healthy cells. It plays a key role in tumor cell proliferation, tumor angiogenesis and resistance to both radio- and chemotherapy.	EGFRvIII-specific CAR-transduced Autologous T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C117728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117728>	C29577|C204207|C129825	CAIX Inhibitor SLC-0111|SLC-0111|SLC-0111|U-104|U104	A sulfonamide carbonic anhydrase inhibitor with potential antineoplastic activity. Upon administration, CAIX inhibitor SLC-0111 inhibits tumor-associated carbonic anhydrase IX (CAIX), an hypoxia-inducible transmembrane glycoprotein that catalyzes the reversible reaction and rapid interconversion of carbon dioxide and water to carbonic acid, protons, and bicarbonate ions. This prevents both the acidification of the tumor's extracellular microenvironment and cytoplasmic alkalization. This increases cell death in CAIX-expressing, hypoxic tumors. CAIX is overexpressed in various tumors and plays a key role in intra- and extracellular pH regulation, cancer cell progression, survival, migration and invasion; it is also involved in resistance to both chemo- and radiotherapy.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C117729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117729>	C200766|C176023	Idecabtagene Vicleucel|Abecma|Anti-BCMA CAR T Cells BB2121|Anti-BCMA-CAR-transduced T Cells BB2121|BB2121|BCMA-specific CAR-expressing T Lymphocytes BB2121|IDECABTAGENE VICLEUCEL|Ide-cel|Idecabtagene vicleucel	A preparation of autologous peripheral blood T-lymphocytes (PBTLs) that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the B-cell maturation antigen (BCMA), with potential immunostimulating and antineoplastic activities. Upon administration, idecabtagene vicleucel specifically recognizes and kills BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.	Idecabtagene Vicleucel		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11772>	C61063	Asparaginase/cyclophosphamide/cytarabine/daunorubicin/dexamethasone/leucovorin calcium/mercaptopurine/methotrexate/thioguanine/vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117730>	C159583	Magrolimab|Hu5F9-G4|MAGROLIMAB|ONO 7913|ONO-7913|ONO7913	A humanized monoclonal antibody targeting the human cell surface antigen CD47, with potential immunostimulating and antineoplastic activities. Upon administration, magrolimab selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with its ligand signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling, allows the activation of macrophages, through the induction of pro-phagocytic signaling mediated by calreticulin, which is specifically expressed on the surface of tumor cells, and results in specific tumor cell phagocytosis. In addition, blocking CD47 signaling activates an anti-tumor T-lymphocyte immune response and T-mediated cell killing. CD47, a tumor associated antigen expressed on normal, healthy hematopoietic stem cells (HSC), is overexpressed on the surface of a variety of cancer cells. Expression of CD47, and interaction with SIRP-alpha, leads to inhibition of macrophages and protects cancer cells from phagocytosis thereby allowing cancer cells to proliferate.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C117731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117731>	C29577|C204207|C129825	CAIX Inhibitor DTP348|2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethylsulfamide|DTP-348|DTP348	An orally bioavailable, nitroimidazole-based sulfamide, carbonic anhydrase IX (CAIX) inhibitor with potential antineoplastic activity. Upon administration, CAIX inhibitor DTP348 inhibits tumor-associated CAIX, a hypoxia-inducible transmembrane glycoprotein that catalyzes the reversible reaction and rapid interconversion of carbon dioxide and water to carbonic acid, protons, and bicarbonate ions. This prevents the acidification of the tumor's extracellular microenvironment and decreases the intracellular pH. This results in increased cell death in CAIX-expressing, hypoxic tumors. In addition, DTP348, through its nitroimidazole moiety, is able to sensitize hypoxic tumor cells to irradiation. CAIX is overexpressed in various tumors and plays a key role in intra- and extracellular pH regulation, cancer cell progression, survival, migration and invasion.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C117732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117732>	C201550	Anti-CD70 Antibody-drug Conjugate SGN-CD70A|SGN-CD70A|SGN-CD70A	An antibody-drug conjugate (ADC) containing an engineered cysteine monoclonal antibody (EC-mAb), directed against the extracellular domain of the human CD70 molecule, conjugated to the synthetic, cytotoxic, DNA minor-groove crosslinking agent, pyrrolobenzodiazepine (PBD) dimer, via a stable, protease-cleavable, peptide-based linker, with potential antineoplastic activity. The anti-CD70 antibody moiety of the anti-CD70 antibody-drug conjugate SGN-CD70A selectively binds to the extracellular domain of CD70 on tumor cell surfaces. Upon internalization, the PBD dimer moiety is released and covalently binds, through its imine moieties, to the N2 positions of guanines on opposite strands of DNA. This induces DNA double strand breaks and inhibits DNA replication, which lead to the inhibition of cell growth of tumor cells that overexpress CD70. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on the surfaces of various types of cancer cells. The cysteine moiety of the EC-mAb allows for the stable conjugation of the PBD to the antibody.			Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C117733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117733>	C26170	Electrokinetically Modified Water|EMW|Electro-kinetically Altered Beverage	Orally available, nanobubble-based, electrokinetically modified water (EMW) composed of reverse osmosis water where the minerals calcium chloride, magnesium chloride, and potassium bicarbonate have been added and with an increased oxygen concentration compared to normal water. Upon consumption, the EMW may have a beneficial effect on fatigue. This water may protect muscle cells against damage and may improve skeletal muscle function. The water is pretreated with strong, controlled turbulence to create charge-stabilized nanostructures.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C117734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117734>	C200418|C1742	Sitravatinib|1,1-Cyclopropanedicarboxamide, N-(3-Fluoro-4-((2-(5-(((2-methoxyethyl)amino)methyl)-2-pyridinyl)thieno(3,2-b)pyridin-7-yl)oxy)phenyl)-N'-(4-fluorophenyl)-|MGCD516|SITRAVATINIB	An orally bioavailable, receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Upon administration, sitravatinib binds to and inhibits the activity of several RTKs including hepatocyte growth factor receptor (HGFR; c-Met; MET), tyrosine-protein kinase receptor UFO (AXL receptor tyrosine kinase; AXL), mast/stem cell growth factor receptor (SCFR; c-kit; KIT), the receptor tyrosine kinase MER, discoidin domain receptor 2 (DDR2), vascular endothelial growth factor receptor (VEGFR) types 1 (VEGFR-1; FLT1), 2 (VEGFR-2; KDR; Flk-1) and 3 (VEGFR-3), members of the platelet-derived growth factor receptor (PDGFR) family, RET (rearranged during transfection), tropomyosin-related kinases (TRK) and members of the ephrin (Eph) family of receptor tyrosine kinases. This may result in both the inhibition of signal transduction pathways mediated by these RTKs and the reduction of tumor cell proliferation in cancer cell types that overexpress these RTKs.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C117735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117735>	C213143|C163999	Anti c-KIT Antibody-drug Conjugate LOP628|Anti c-KIT ADC LOP628|LOP628	An antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody against the stem cell factor receptor c-Kit (SCFR) and conjugated, via a non-cleavable linker, to the cytotoxic agent maytansine, with potential antineoplastic activity. The monoclonal antibody moiety of anti c-KIT ADC LOP628 targets and binds to the cell surface antigen c-Kit. After antibody-antigen interaction followed by internalization, the maytansine moiety binds to tubulin, inhibits microtubule assembly, and induces microtubule disassembly. This leads to a disruption of mitosis and the inhibition of cell proliferation in cancer cells expressing c-Kit. c-Kit, a transmembrane protein and receptor tyrosine kinase, is overexpressed in solid tumors and hematological malignancies; it plays a key role in the regulation of cell differentiation and proliferation.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C117736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117736>	C13056	Vastus Medialis Muscle|MUSCLE, VASTUS MEDIALIS|VASTUS MEDIALIS MUSCLE	The portion of the quadriceps femoris muscle group that extends medially from the intertrochanteric line of the femur to the medial aspects of the quadriceps femoris tendon and patella.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology
C117737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117737>	C66830	CDISC SDTM Graft Type Terminology|GRAFTTYP|Graft Type|SDTM-GRAFTTYP	Terminology associated with the graft type codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117738>	C103175	CDISC SDTM Hepatic Findings About Test Name Terminology|SDTM-HEFATS	Terminology associated with the hepatic findings about test names codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	
C117739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117739>	C103175	CDISC SDTM Hepatic Findings About Test Code Terminology|SDTM-HEFATSCD	Terminology associated with the hepatic findings about test codes codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	
C11773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11773>	C61063	Interleukin-2/interleukin-12			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117740>	C66830	CDISC SDTM Multiple Sclerosis Findings About Test Name Terminology|MSFATS|Multiple Sclerosis Findings About Test Name|SDTM-MSFATS	Terminology associated with the multiple sclerosis findings about test names codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117741>	C66830	CDISC SDTM Multiple Sclerosis Findings About Test Code Terminology|MSFATSCD|Multiple Sclerosis Findings About Test Code|SDTM-MSFATSCD	Terminology associated with the multiple sclerosis findings about test codes codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117742>	C66830	CDISC SDTM Ophthalmic Exam Test Name Terminology|OETEST|Ophthalmic Exam Test Name|SDTM-OETEST	Terminology associated with the ophthalmic exam test names codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117743>	C66830	CDISC SDTM Ophthalmic Exam Test Code Terminology|OETESTCD|Ophthalmic Exam Test Code|SDTM-OETESTCD	Terminology associated with the ophthalmic exam test codes codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117744>	C165634	CDISC Define-XML Analysis Reason Terminology|ANLREAS|Analysis Reason|DEFINE-ANLREAS	Terminology associated with the analysis reason codelist of the Clinical Data Interchange Standards Consortium (CDISC) Define-XML standard.			Intellectual Product	CDISC Define-XML Terminology|Clinical Data Interchange Standards Consortium Terminology
C117745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117745>	C165634	CDISC Define-XML Analysis Purpose Terminology|ANLPURP|Analysis Purpose|DEFINE-ANLPURP	Terminology associated with the analysis purpose codelist of the Clinical Data Interchange Standards Consortium (CDISC) Define-XML standard.			Intellectual Product	CDISC Define-XML Terminology|Clinical Data Interchange Standards Consortium Terminology
C117746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117746>	C66830	CDISC SDTM West Haven Hepatic Encephalopathy Grade Terminology|HEPENCGR|SDTM-HEPENCGR|West Haven Hepatic Encephalopathy Grade	Terminology associated with the West Haven hepatic encephalopathy grade codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117747>	C217120	West Haven Criteria - West Haven Hepatic Encephalopathy Grade|WHEG01-WH Hepatic Encephalopathy Grade|WHEG01-WH Hepatic Encephalopathy Grade|WHEG0101	West Haven Hepatic Encephalopathy Grade (West Haven Criteria) Grade.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification West Haven Criteria Test Code Terminology|CDISC Clinical Classification West Haven Criteria Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117748>	C64430	Lipase Measurement|LIPASET|Lipase|Lipase|Lipase|Total Lipase|Triacylglycerol Lipase	The determination of the amount of lipase present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|OS Authorized Value Terminology|OS Lab Table
C117749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117749>	C64430	Soluble Tumor Necrosis Factor Receptor Measurement|Soluble Tumor Necrosis Factor Receptor|Soluble Tumor Necrosis Factor Receptor|TNFR Measurement|TNFSR	The determination of the amount of soluble tumor necrosis factor receptor present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11774>	C61063	Carboplatin/Docetaxel/Estramustine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117750>	C25391	Data Driven Analysis|DATA DRIVEN	The analysis has been performed based on findings in the data.			Activity	CDISC Define-XML Analysis Reason Terminology|CDISC Define-XML Terminology|Clinical Data Interchange Standards Consortium Terminology
C117751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117751>	C25391	Analysis Requested by Regulatory Agency|REQUESTED BY REGULATORY AGENCY	The analysis has been performed based on request from a regulatory agency.			Activity	CDISC Define-XML Analysis Reason Terminology|CDISC Define-XML Terminology|Clinical Data Interchange Standards Consortium Terminology
C117752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117752>	C25391	Analysis Specified in Protocol|SPECIFIED IN PROTOCOL	The analysis has been performed based on the protocol.			Activity	CDISC Define-XML Analysis Reason Terminology|CDISC Define-XML Terminology|Clinical Data Interchange Standards Consortium Terminology
C117753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117753>	C25391	Analysis Specified in Statistical Analysis Plan|SPECIFIED IN SAP	The analysis has been performed based on the statistical analysis plan.			Activity	CDISC Define-XML Analysis Reason Terminology|CDISC Define-XML Terminology|Clinical Data Interchange Standards Consortium Terminology
C117754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117754>	C13442	Temporal Anatomic Qualifier|TEMPORAL	Of, or related to, anatomic sites that are located in the cranium, brain, and eye.			Body Location or Region	CDISC SDTM Directionality Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117755>	C49556	Procedure Agents Domain|AG|Procedure Agents	A domain utilized for the submission of information encompassing and representing data, vocabulary or records related to agents used as part of a procedure.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|CDISC SEND Domain Abbreviation Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117756>	C49556	Functional Tests Domain|FT|Functional Tests	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to a functional test.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117757>	C49556	Healthcare Encounters Domain|HO|Healthcare Encounters	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to a subject's healthcare encounter.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117758>	C160943	Device Intended But Not Used|INTENDED BUT NOT USED	A status indicating that a device was introduced to the subject for use but did not meet its intended goal and was removed.			Finding	CDISC SDTM Device Tracking and Disposition Event Dictionary Derived Term Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117759>	C25681	Checkerboard Square Size|CHCKSIZE	A visual stimulus that uses a checkerboard pattern which reverses every half-second. The check size, field size and field location can be changed to allow for testing of specific segments of the visual pathway.			Quantitative Concept	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11775>	C61063	Capecitabine/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117760>	C87881	Superimposition of Multiple Leads|Global Median Beat|SML	Measurement methodology using multiple leads for the determination of an ECG parameter. This is often visually represented as a superimposition of the median beats from multiple leads. (CDISC)			Spatial Concept	CDISC SDTM Electrocardiogram Lead Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117761>	C62085	Comparison to a Prior ECG|EGCOMP|EGCOMP	A comparative interpretation of an ECG relative to a previous (comparator) ECG. The definition of the comparator ECG may be specified elsewhere. Common comparator result values include improved, no change, deteriorated. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Holter ECG Test Code Terminology|CDISC SDTM Holter ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117762>	C62085	Aggregate JT Interval|JT Interval, Aggregate|JT Interval, Aggregate|JTAG	An aggregate JT value based on the measurement of JT intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117763>	C62085	Aggregate JTCB Interval|JTCBAG|JTcB Interval, Aggregate|JTcB Interval, Aggregate	A JTAG interval corrected for heart rate using Bazett's formula. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117764>	C62085	Single Beat JTCB Interval|JTCBSB|JTcB Interval, Single Beat|JTcB Interval, Single Beat	A JTSB interval corrected for heart rate using Bazett's formula. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117765>	C62085	Aggregate JTCF Interval|JTCFAG|JTcF Interval, Aggregate|JTcF Interval, Aggregate	A JTAG interval corrected for heart rate using Fridericia's formula. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117766>	C62085	Single Beat JTCF Interval|JTCFSB|JTcF Interval, Single Beat|JTcF Interval, Single Beat	A JTSB interval corrected for heart rate using Fridericia's formula. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117767>	C62085	Aggregate J-T Peak Interval|J-Tpeak Interval, Aggregate|J-Tpeak Interval, Aggregate|JTPAG	An aggregate J-Tpeak value based on the measurement of J-Tpeak intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117768>	C62085	Single Beat J-T Peak Interval|J-Tpeak Interval, Single Beat|J-Tpeak Interval, Single Beat|JTPSB	An electrocardiographic interval measured from the J point to the peak of the T wave of a single beat utilizing one or more leads. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117769>	C62085	Single Beat JT Interval|JT Interval, Single Beat|JT Interval, Single Beat|JTSB	An electrocardiographic interval measured from the J point to the offset of the T wave of a single beat utilizing one or more leads. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11776>	C61007	Cisplatin/Cytarabine/Dexamethasone/Rituximab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117770>	C62085	New Q Wave|NEWQWAVE	An electrocardiographic finding assessment of new or presumed new pathologic Q waves suggestive of myocardial infarction. (Thygesen K, Alpert JS, Jaffe AS, et al.: the Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. J Am Coll Cardiol 60(16):1-18, 2012). (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117771>	C62085	Aggregate PP Interval|PP Interval, Aggregate|PP Interval, Aggregate|PPAG	An aggregate PP value based on the measurement of PP intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117772>	C62085	Single Measurement PP Interval|PP Interval, Single Measurement|PP Interval, Single Measurement|PPSM	An electrocardiographic measurement of the interval between the onsets of two consecutive P waves. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117773>	C62085	Aggregate PR Interval|PQ Interval, Aggregate|PQAG|PR Interval, Aggregate|PR Interval, Aggregate|PR Interval, Aggregate|PRAG|PRAG	An aggregate PR value based on the measurement of PR intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117774>	C62085	Single Beat PR Interval|PQ Interval, Single Beat|PQSB|PR Interval, Single Beat|PR Interval, Single Beat|PR Interval, Single Beat|PRSB|PRSB	An electrocardiographic interval measured from the onset of the P wave to the onset of the QRS complex of a single beat utilizing one or more leads. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117775>	C62085	Aggregate P Wave Duration|P Wave Duration, Aggregate|P Wave Duration, Aggregate|P Wave Duration, Aggregate|PWDURAG|PWDURAG	An aggregate P wave duration value based on the measurement of P wave duration intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117776>	C62085	Single Beat P Wave Duration|P Wave Duration, Single Beat|P Wave Duration, Single Beat|P Wave Duration, Single Beat|PWDURSB|PWDURSB	An electrocardiographic interval measured from the onset of the P wave to the offset of the P wave of a single beat utilizing one or more leads. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117777>	C62085	Aggregate P Wave Amplitude|P Wave Amplitude, Aggregate|P Wave Amplitude, Aggregate|PWHTAG	An aggregate P wave amplitude value based on the measurement of P wave amplitudes from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117778>	C62085	Single Beat P Wave Amplitude|P Wave Amplitude, Single Beat|P Wave Amplitude, Single Beat|PWHTSB	An electrocardiographic measurement of the mean amplitude (usually measured in mV) of the P wave measured from the isoelectric baseline to the peak of the P wave of a single beat utilizing one or more leads. Based on the recording gain, this measurement may also be reported in mm. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117779>	C62085	Aggregate QRS Duration|QRS Duration, Aggregate|QRS Duration, Aggregate|QRS Duration, Aggregate|QRSAG|QRSAG	An aggregate QRS value based on the measurement of QRS intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11777>	C61063	Amifostine/Azacitidine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117780>	C62085	Single Beat QRS Duration|QRS Duration, Single Beat|QRS Duration, Single Beat|QRS Duration, Single Beat|QRSSB|QRSSB	An electrocardiographic interval measured from the onset of the QRS complex to the offset of the QRS complex of a single beat utilizing one or more leads. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117781>	C62085	Paced Ventricular Aggregate QRS Duration|QRS Duration, Ventr. Paced, Aggregate|QRS Duration, Ventr. Paced, Aggregate|QRVDVPAG	An aggregate paced QRS duration value based on the measurement of paced QRS duration intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117782>	C62085	Paced Ventricular Single Beat QRS Duration|QRS Duration, Ventr. Paced, Single Beat|QRS Duration, Ventr. Paced, Single Beat|QRVDVPSB	An electrocardiographic interval measured from the onset of the paced QRS complex to the offset of the QRS complex of a single beat utilizing one or more leads. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117783>	C62085	Aggregate QT Interval|QT Interval, Aggregate|QT Interval, Aggregate|QT Interval, Aggregate|QTAG|QTAG	An aggregate QT value based on the measurement of QT intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117784>	C62085	Aggregate QTCB Interval|QTCBAG|QTCBAG|QTcB Interval, Aggregate|QTcB Interval, Aggregate|QTcB Interval, Aggregate	A QT aggregate interval corrected for heart rate using Bazett's formula.			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117785>	C62085	Single Beat QTCB Interval|QTCBSB|QTCBSB|QTcB Interval, Single Beat|QTcB Interval, Single Beat|QTcB Interval, Single Beat	A QT single beat interval corrected for heart rate using Bazett's formula.			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117786>	C62085	Aggregate QTCF Interval|QTCFAG|QTCFAG|QTcF Interval, Aggregate|QTcF Interval, Aggregate|QTcF Interval, Aggregate	A QT aggregate interval corrected for heart rate using Fridericia's formula.			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117787>	C62085	Single Beat QTCF Interval|QTCFSB|QTCFSB|QTcF Interval, Single Beat|QTcF Interval, Single Beat|QTcF Interval, Single Beat	A QT single beat interval corrected for heart rate using Fridericia's formula.			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117788>	C62085	Single Beat QT Interval|QT Interval, Single Beat|QT Interval, Single Beat|QT Interval, Single Beat|QTSB|QTSB	An electrocardiographic interval measured from the onset of the QRS complex to the offset of the T wave of a single beat utilizing one or more leads. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117789>	C62085	Aggregate Q Wave Amplitude|Q Wave Amplitude, Aggregate|Q Wave Amplitude, Aggregate|QWAAG	An aggregate Q wave amplitude value based on the measurement of Q wave amplitudes from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11778>	C61063	Paclitaxel/SU5416			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117790>	C62085	Single Beat Q Wave Amplitude|Q Wave Amplitude, Single Beat|Q Wave Amplitude, Single Beat|QWASB	An electrocardiographic measurement of the mean amplitude (usually measured in mV) of the Q wave measured from the isoelectric baseline to the peak of the Q wave of a single beat utilizing one or more leads. Based on the recording gain, this measurement may also be reported in mm. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117791>	C62085	Aggregate RR Interval|RR Interval, Aggregate|RR Interval, Aggregate|RR Interval, Aggregate|RRAG|RRAG	An aggregate RR value based on the measurement of RR intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117792>	C62085	RR Interval Single Measurement|RR Interval, Single Measurement|RR Interval, Single Measurement|RR Interval, Single Measurement|RRSM|RRSM	An electrocardiographic measurement of the interval between two consecutive R waves. If R waves are not present, this measurement may utilize the interval between the most easily identified components of the QRS complex within two consecutive beats. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117793>	C62085	RS Wave Amplitude Aggregate|RS Wave Amplitude, Aggregate|RS Wave Amplitude, Aggregate|RSAAG	An aggregate RS wave amplitude value based on measurements from multiple beats from a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117794>	C62085	RS Wave Amplitude Single Beat|RS Wave Amplitude, Single Beat|RS Wave Amplitude, Single Beat|RSASB	An electrocardiographic measurement of the sum of the amplitudes of the R and S waves, obtained from a single beat in one particular lead or set of leads. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117795>	C62085	R Wave Amplitude Aggregate|R Wave Amplitude, Aggregate|R Wave Amplitude, Aggregate|RWAAG	An aggregate R wave amplitude value based on the measurement of R wave amplitudes from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117796>	C62085	R Wave Amplitude Single Beat|R Wave Amplitude, Single Beat|R Wave Amplitude, Single Beat|RWASB	An electrocardiographic measurement of the mean amplitude (usually measured in mV) of the R wave measured from the isoelectric baseline to the peak of the R wave of a single beat utilizing one or more leads. Based on the recording gain, this measurement may also be reported in mm. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117797>	C62085	ST Segment Depression Aggregate|ST Segment Depression, Aggregate|ST Segment Depression, Aggregate|STDAG	An aggregate ST segment depression value based on the measurement of ST segment depression from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117798>	C62085	ST Segment Depression Single Beat|ST Segment Depression, Single Beat|ST Segment Depression, Single Beat|STDSB	An electrocardiographic measurement of the mean amplitude (usually measured in mV) of the ST segment depression below the isoelectric baseline measured from the baseline to the ST segment of a single beat utilizing one or more leads. Based on the recording gain, this measurement may also be reported in mm. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117799>	C62085	ST Segment Deviation Aggregate|ST Segment Deviation, Aggregate|ST Segment Deviation, Aggregate|STDVAG	An aggregate ST segment deviation value based on the measurement of ST segment deviation from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11779>	C61063	Carboplatin/Fludarabine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1177>	C54630|C54629|C1742	Oltipraz|3H-1,2-Dithiole-3-thione, 4-methyl-5-pyrazinyl-|3H-1,2-Dithiole-3-thione,4-methyl-5-pyrazinyl|4-Methyl-5-(pyrazinyl)-3H-1,2-dithiole-3-thione|4-Methyl-5-pyrazinyl-3H-1,2-dithiole-3-thione|5-(2-Pyrazinyl)-4-methyl-1,2-dithiol-3-thione|5-[2-Pyrazinyl]-4-methyl-1,2-3-thione|OLTIPRAZ|RP-35,972|oltipraz	A synthetic dithiolethione with potential chemopreventive and anti-angiogenic properties. Oltipraz induces phase II detoxification enzymes, such as glutathione S transferase (GST) and NAD(P)H:quinone oxidoreductase 1 (NQO1). The induction of detoxification enzymes enhances the detoxification of certain cancer-causing agents, thereby enhancing their elimination and preventing carcinogen-induced DNA damages. Although the exact mechanism through which the anti-angiogenesis effect remains to be fully elucidated, oltipraz maybe able to modulate the expression of a number of angiogenic factors, thereby blocking the sustained and focal neovascularization in multiple tumor cell types.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C117800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117800>	C62085	ST Segment Deviation Single Beat|ST Segment Deviation, Single Beat|ST Segment Deviation, Single Beat|STDVSB	An electrocardiographic measurement of the mean amplitude (usually measured in mV) of the ST segment deviation above or below the isoelectric baseline measured from the baseline to the ST segment of a single beat utilizing one or more leads. Based on the recording gain, this measurement may also be reported in mm. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117801>	C62085	ST Segment Elevation Aggregate|ST Segment Elevation, Aggregate|ST Segment Elevation, Aggregate|STEAG	An aggregate ST segment elevation value based on the measurement of ST segment elevation from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117802>	C62085	ST Segment Elevation Single Beat|ST Segment Elevation, Single Beat|ST Segment Elevation, Single Beat|STESB	An electrocardiographic measurement of the mean amplitude (usually measured in mV) of the ST segment elevation above the isoelectric baseline measured from the baseline to the ST segment of a single beat utilizing one or more leads. Based on the recording gain, this measurement may also be reported in mm. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117803>	C62085	ST Segment Duration Aggregate|ST Segment Duration, Aggregate|ST Segment Duration, Aggregate|STSDURAG	An aggregate ST segment duration value based on the measurement of ST segment duration intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117804>	C62085	ST Segment Duration Single Beat|ST Segment Duration, Single Beat|ST Segment Duration, Single Beat|STSDURSB	An electrocardiographic interval measured from the J point to the onset of the T wave of a single beat utilizing one or more leads. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117805>	C62085	S Wave Amplitude Aggregate|S Wave Amplitude, Aggregate|S Wave Amplitude, Aggregate|SWAAG	An aggregate S wave amplitude value based on the measurement of S wave amplitudes from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117806>	C62085	S Wave Amplitude Single Beat|S Wave Amplitude, Single Beat|S Wave Amplitude, Single Beat|SWASB	An electrocardiographic measurement of the mean amplitude (usually measured in mV) of the S wave measured from the isoelectric baseline to the peak of the S wave of a single beat utilizing one or more leads. Based on the recording gain, this measurement may also be reported in mm. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117807>	C62085	ECG Technical Quality|TECHQUAL|TECHQUAL|Technical Quality|Technical Quality|Technical Quality	A statement about an electrocardiographic recording describing technical issues or interference during the recording, processing, or transmission of the data. This does not represent an electrocardiographic diagnosis. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Holter ECG Test Code Terminology|CDISC SDTM Holter ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117808>	C62085	T Peak-T End Interval Aggregate|TPTEAG|Tpeak-Tend Interval, Aggregate|Tpeak-Tend Interval, Aggregate	An aggregate Tpeak-Tend value based on the measurement of Tpeak-Tend from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117809>	C62085	T Peak-T End Interval Single Beat|TPTESB|Tpeak-Tend Interval, Single Beat|Tpeak-Tend Interval, Single Beat	An electrocardiographic interval measured from the peak of the T wave to the offset of the T wave of a single beat utilizing one or more leads. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11780>	C61063	AFP Gene Hepatocellular Carcinoma Vaccine/Montanide ISA-51			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117810>	C62085	T Wave Area Aggregate|T Wave Area, Aggregate|T Wave Area, Aggregate|TWARAG	An aggregate T wave area value based on the measurement of T wave areas from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117811>	C62085	T Wave Area Single Beat|T Wave Area, Single Beat|T Wave Area, Single Beat|TWARSB	An electrocardiographic measurement of the area of the T wave of a single beat utilizing one or more leads. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117812>	C62085	T Wave Duration Aggregate|T Wave Duration, Aggregate|T Wave Duration, Aggregate|T Wave Duration, Aggregate|TWDURAG|TWDURAG	An aggregate T wave duration value based on the measurement of T wave duration intervals from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117813>	C62085	T Wave Duration Single Beat|T Wave Duration, Single Beat|T Wave Duration, Single Beat|T Wave Duration, Single Beat|TWDURSB|TWDURSB	An electrocardiographic interval measured from the onset of the T wave to the offset of the T wave of a single beat utilizing one or more leads. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117814>	C62085	T Wave Amplitude Aggregate|T Wave Amplitude, Aggregate|T Wave Amplitude, Aggregate|TWHAG	An aggregate T wave amplitude value based on the measurement of T wave amplitudes from multiple beats within a single ECG. The method of aggregation, which can vary, is typically a measure of central tendency such as the mean. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117815>	C62085	T Wave Amplitude Single Beat|T Wave Amplitude, Single Beat|T Wave Amplitude, Single Beat|TWHSB	An electrocardiographic measurement of the mean amplitude (usually measured in mV) of the T wave measured from the isoelectric baseline to the peak of the T wave of a single beat utilizing one or more leads. Based on the recording gain, this measurement may also be reported in mm. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117816>	C12981	Free Arterial Graft|ARTERIAL GRAFT, FREE	A vessel graft comprised of an artery that has been completely detached from its original location.			Body Part, Organ, or Organ Component	CDISC SDTM Graft Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117817>	C12981	In Situ Arterial Graft|ARTERIAL GRAFT, IN-SITU	A vessel graft comprised of an artery whose origin remains in place.			Body Part, Organ, or Organ Component	CDISC SDTM Graft Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117818>	C142985	Autologous Vein Graft|AUTOLOGOUS VEIN GRAFT	A vessel graft comprised of a vein harvested from a different anatomical location on the patient.			Body Part, Organ, or Organ Component	CDISC SDTM Graft Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117819>	C12981	Cadaveric Arterial Graft|CADAVERIC GRAFT, ARTERIAL	An arterial graft harvested from a cadaver.			Body Part, Organ, or Organ Component	CDISC SDTM Graft Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11781>	C61063	RAS Peptide Cancer Vaccine/Sargramostim			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117820>	C12981	Cadaveric Venous Graft|CADAVERIC GRAFT, VENOUS	A venous graft harvested from a cadaver.			Body Part, Organ, or Organ Component	CDISC SDTM Graft Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117821>	C12981	Composite Vessel Graft|COMPOSITE GRAFT	A vessel graft comprised of two or more conduit materials.			Body Part, Organ, or Organ Component	CDISC SDTM Graft Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117822>	C12981	Saphenous Vein Graft|SAPHENOUS VEIN GRAFT|SVG	A vessel graft comprised of the saphenous vein.			Body Part, Organ, or Organ Component	CDISC SDTM Graft Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117823>	C12981	Synthetic Vessel Graft|SYNTHETIC GRAFT	A vessel graft comprised of manufactured material.			Body Part, Organ, or Organ Component	CDISC SDTM Graft Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117824>	C117747	West Haven Hepatic Encephalopathy Grade 0|GRADE 0	Minimal - symptoms or pathological characteristics include minimal hepatic encephalopathy, lack of detectable changes in personality or behavior, minimal changes in memory, concentration and intellectual function, and absence of coordination asterixis. (Adapted from: Hepatic Encephalopathy. David C Wolf. http://emedicine.medscape.com/article/186101-overview)			Finding	CDISC SDTM Terminology|CDISC SDTM West Haven Hepatic Encephalopathy Grade Terminology|Clinical Data Interchange Standards Consortium Terminology
C117825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117825>	C117747	West Haven Hepatic Encephalopathy Grade 1|GRADE 1	Mild - symptoms or pathological characteristics include trivial lack of awareness, shortened attention span, impaired ability to perform addition or subtraction, hypersomnia, insomnia, or inversion of sleep pattern, euphoria, depression or irritability, mild confusion, slowing of ability to perform mental tasks. (Adapted from: Hepatic Encephalopathy. David C Wolf. http://emedicine.medscape.com/article/186101-overview.)			Finding	CDISC SDTM Terminology|CDISC SDTM West Haven Hepatic Encephalopathy Grade Terminology|Clinical Data Interchange Standards Consortium Terminology
C117826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117826>	C117747	West Haven Hepatic Encephalopathy Grade 2|GRADE 2	Moderate - symptoms or pathological characteristics include lethargy or apathy, disorientation, inappropriate behavior, slurred speech, obvious asterixis, drowsiness, lethargy, gross deficits in ability to perform mental tasks, obvious personality changes, inappropriate behavior, and intermittent disorientation, unsurely regarding time. (Adapted from: Hepatic Encephalopathy. David C Wolf. http://emedicine.medscape.com/article/186101-overview.)			Finding	CDISC SDTM Terminology|CDISC SDTM West Haven Hepatic Encephalopathy Grade Terminology|Clinical Data Interchange Standards Consortium Terminology
C117827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117827>	C117747	West Haven Hepatic Encephalopathy Grade 3|GRADE 3	Severe - symptoms or pathological characteristics include somnolence with some arousability, inability to perform mental tasks, disorientation about time and place, marked confusion, amnesia, occasional fits of rage, present but incomprehensible speech. (Adapted from: Hepatic Encephalopathy. David C Wolf. http://emedicine.medscape.com/article/186101-overview.)			Finding	CDISC SDTM Terminology|CDISC SDTM West Haven Hepatic Encephalopathy Grade Terminology|Clinical Data Interchange Standards Consortium Terminology
C117828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117828>	C117747	West Haven Hepatic Encephalopathy Grade 4|GRADE 4	Coma - symptoms or pathological characteristics include coma with or without response to painful stimuli. (Adapted from: Hepatic Encephalopathy. David C Wolf. http://emedicine.medscape.com/article/186101-overview.)			Finding	CDISC SDTM Terminology|CDISC SDTM West Haven Hepatic Encephalopathy Grade Terminology|Clinical Data Interchange Standards Consortium Terminology
C117829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117829>	C85534	Albumin Urine Excretion Rate	A determination of the amount of albumin being excreted in urine over a defined period of time.			Quantitative Concept	
C11782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11782>	C61063	Azacitidine/Phenylbutyrate			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117830>	C74760|C64467	Aspartate Aminotransferase to Creatinine Ratio Measurement|ASTCREAT|Aspartate Aminotransferase/Creatinine|Aspartate Aminotransferase/Creatinine	The determination of the ratio of aspartate aminotransferase compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117831>	C85534	Calcium Urine Excretion Rate	A determination of the amount of calcium being excreted in urine over a defined period of time.			Quantitative Concept	
C117832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117832>	C85534	Chloride Urine Excretion Rate	A determination of the amount of chloride being excreted in urine over a defined period of time.			Quantitative Concept	
C117833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117833>	C85534	Creatinine Urine Excretion Rate	A determination of the amount of creatinine being excreted in urine over a defined period of time.			Quantitative Concept	
C117834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117834>	C85534	Glucose Urine Excretion Rate	A determination of the amount of glucose being excreted in urine over a defined period of time.			Quantitative Concept	
C117835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117835>	C81869	Soluble Immunoglobulin Measurement|IGSOL|Soluble Immunoglobulin|Soluble Immunoglobulin	The determination of the amount of soluble immunoglobulin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117836>	C225611	Soluble Interleukin-1 Receptor Type I Measurement|IL1SR1|Soluble Interleukin-1 Receptor Type I|Soluble Interleukin-1 Receptor Type I	The determination of the amount of soluble interleukin-1 receptor type I present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117837>	C64430	Soluble Interleukin 6 Receptor Measurement|IL-6 Measurement|IL6SR|Interleukin-6 Measurement|Soluble Interleukin 6 Receptor|Soluble Interleukin 6 Receptor	The determination of the amount of soluble interleukin 6 Receptor present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117838>	C85534	Iron Urine Excretion Rate	A determination of the amount of iron being excreted in urine over a defined period of time.			Quantitative Concept	
C117839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117839>	C85534	Potassium Urine Excretion Rate	A determination of the amount of potassium being excreted in urine over a defined period of time.			Quantitative Concept	
C11783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11783>	C61063	gp209-2M Antigen/Heat Shock Protein 70/OVA Bip Peptide/Tyrosinase Peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117840>	C64807	Gastric Lipase Measurement|Gastric Triacylglycerol Lipase|Gastric Triacylglycerol Lipase Measurement|LIPASEG|LIPF|LIPF Measurement|Lipase, Gastric|Lipase, Gastric	The determination of the amount of gastric lipase present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117841>	C64807	Pancreatic Lipase Measurement|LIPASEP|Lipase, Pancreatic|Lipase, Pancreatic|PNLIP|PNLIP Measurement|Pancreatic Triacylglycerol Lipase|Pancreatic Triacylglycerol Lipase Measurement	The determination of the amount of pancreatic lipase present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117842>	C117748	Lysosomal Acid Lipase Measurement|Acid Cholesteryl Ester Hydrolase|LAL|LIPA|LIPA Measurement|LIPASLAL|Lipase, Lysosomal Acid|Lipase, Lysosomal Acid|Lysosomal Lipase	The determination of the amount of lysosomal acid lipase present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117843>	C49188	Microfilaria Measurement|MFILARIA|Microfilaria|Microfilaria	The determination of the amount of microfilaria present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117845>	C85534	Phosphorus Urine Excretion Rate	A determination of the amount of phosphorus being excreted in urine over a defined period of time.			Quantitative Concept	
C117846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117846>	C64430	Progesterone Receptor Measurement|NR3C3|PGR|PR|PROGESTR|PROGESTR|PgR|Progesterone Receptor|Progesterone Receptor|Progesterone Receptor	The determination of the amount of progesterone receptor present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117847>	C48938	Promyeloblasts Measurement|PROMYB|Promyeloblasts|Promyeloblasts	The determination of the amount of promyeloblasts present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117848>	C85534	Total Protein Urine Excretion Rate	A determination of the amount of total protein being excreted in urine over a defined period of time.			Quantitative Concept	
C117849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117849>	C49188	Protozoa Measurement|PROTOZOA|Protozoa|Protozoa	The determination of the amount of protozoa present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11784>	C61063	Carboplatin/Paclitaxel/ZD 1839			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117850>	C64430	P-Selectin Measurement|GMP-140|P-Selectin|P-Selectin|PSELECT	The determination of the amount of P-selectin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117851>	C64430	Parathyroid Hormone-related Protein Measurement|PTHRP|Parathyrin Hormone-related Protein|Parathyroid Hormone-related Peptide|Parathyroid Hormone-related Protein|Parathyroid Hormone-related Protein	The determination of the amount of parathyroid hormone-related protein present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117852>	C74804	Receptor Activator Nuclear KappaB Ligand Measurement|Osteoprotegerin Ligand Measurement|RANKL|Receptor Activator Nuclear KappaB Ligand|Receptor Activator Nuclear KappaB Ligand|Receptor Activator of Nuclear Kappa-B Ligand|TNFSF11 Measurement|Tumor Necrosis Factor Ligand Superfamily Member 11 Measurement	The determination of the amount of receptor activator nuclear kappaB ligand present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117853>	C48938	Dimorphic Erythrocyte Population|Dimorphic RBC Population|RBCDIPOP	The determination of the amount of dimorphic erythrocyes present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117856>	C85534	Sodium Urine Excretion Rate	A determination of the amount of sodium being excreted in urine over a defined period of time.			Quantitative Concept	
C117857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117857>	C64430	Sclerostin Measurement|SOST|Sclerostin|Sclerostin	The determination of the amount of sclerostin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117858>	C81971	Strongyloides IgG Antibody Measurement	The determination of the amount of strongyloides IgG antibody present in a sample.			Laboratory Procedure	
C117859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117859>	C64430	Terminal Deoxynucleotidyl Transferase Antigen Measurement|TDTAG|Terminal Deoxynucleotidyl Transferase Ag|Terminal Deoxynucleotidyl Transferase Ag|Terminal Deoxynucleotidyl Transferase Antigen	The determination of the amount of terminal deoxynucleotidyl transferase antigen present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11785>	C61063	Filgrastim/Flt3 Ligand/Milodistim/Sargramostim			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117860>	C75378	Bioavailable Testosterone Measurement|Bioavailable Testosterone|Bioavailable Testosterone|TESTOSBA	The determination of the amount of bioavailable testosterone present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117861>	C122155	Transforming Growth Factor Beta 1 Measurement|TGFB1|TGFB1|Transforming Growth Factor Beta 1|Transforming Growth Factor Beta 1|Transforming Growth Factor Beta 1|Transforming Growth Factor Beta-1 Measurement	The determination of the amount of transforming growth factor Beta 1 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117862>	C64430	TNF-a Production Inhibitory Activity Measurement|TNF-a Production Inhibition|TNF-a Production Inhibition|TNF-a Production Inhibitory Activity|TNFAPI	The determination of the amount of TNF-alpha production inhibitory activity present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117863>	C120666|C117749	Soluble Tumor Necrosis Factor Receptor Type I Measurement|Soluble TNF Receptor Type I|Soluble TNF Receptor Type I|TNFSR1	The determination of the amount of soluble TNF receptor type I present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117864>	C165991|C117749	Soluble Tumor Necrosis Factor Receptor Type II Measurement|Soluble CD120b|Soluble CD120b Antigen Measurement|Soluble TNF Receptor 1B|Soluble TNF Receptor 1B|Soluble TNF Receptor Type II|Soluble TNF Receptor Type II Measurement|Soluble TNF-R-II Measurement|Soluble TNF-R2 Measurement|Soluble TNF-RII Measurement|Soluble TNFBR Measurement|Soluble TNFR-II Measurement|Soluble TNFR1B|Soluble TNFR1B Measurement|Soluble TNFR2 Measurement|Soluble TNFRSF1B|Soluble TNFRSF1B Measurement|Soluble Tumor Necrosis Factor Receptor 2 Measurement|Soluble Tumor Necrosis Factor Receptor Superfamily Member 1B|Soluble Tumor Necrosis Factor Receptor Superfamily Member 1B Measurement|TNFR1BS|sTNFaRII Measurement|sTNFαRII Measurement	The determination of the amount of soluble tumor necrosis factor receptor superfamily member 1B present in a sample.	Soluble Tumor Necrosis Factor Receptor Type II Measurement		Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C117865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117865>	C80163	Tartrate-Resistant Acid Phosphatase 5b Measurement|TRACP5B|TRAP5B|Tartrate-Resistant Acid Phosphatase 5b|Tartrate-Resistant Acid Phosphatase 5b|Tartrate-Resistant Acid Phosphatase Type 5b Measurement	The determination of the amount of tartrate-resistant acid phosphatase 5b present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117866>	C74760	Urate to Creatinine Ratio Measurement|URATECRT|Urate/Creatinine|Urate/Creatinine	The determination of the ratio of urate compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117867>	C210012|C210010	Varicella Zoster Virus Antibody Measurement	The determination of the amount of total Varicella Zoster virus antibody present in a sample.			Laboratory Procedure	
C117868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117868>	C34076	Ankle Mortise|ANKLE MORTISE|Talar Mortise	A rectangular socket or bony arch that connects the ends of the tibia and fibula to the talus.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117869>	C33027	Paracaval Lymph Node|PARACAVAL LYMPH NODE	A lymph node located adjacent to the lumbar region of the spine, along the right lateral aspect of the inferior vena cava.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11786>	C61063	Bispecific Antibody MDX447/Lymphokine-Activated Killer Cells			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117870>	C33027	Pericardial Lymph Node|PERICARDIAL LYMPH NODE	A lymph node located anterior to the pericardium, posterior to the xiphoid process, and in the right and left cardiophrenic fat.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117871>	C33027	Porta Hepatis Lymph Node|PORTA HEPATIS LYMPH NODE|Portahepatis lymph node group (body structure)	A lymph node located in the transverse fissure of the liver.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C117872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117872>	C33027	Portacaval Lymph Node|PORTACAVAL LYMPH NODE|Portocaval Lymph Node	A lymph node located in the space between the portal vein and inferior vena cava, along the hepatoduodenal ligament.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117873>	C33027	Subcarinal Lymph Node|Lymph Node, Subcarinal|SUBCARINAL LYMPH NODE	A lymph node located in the thoracic cavity between the lungs. It is bordered by the carina of the trachea, lower lobe bronchus on the left and the bronchus intermedius on the right.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C117874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117874>	C53076	Tibialis Anterior Muscle|MUSCLE, TIBIALIS ANTERIOR|TIBIALIS ANTERIOR MUSCLE	A muscle that originates from the lateral condyle of tibia, spans the upper two-thirds of the lateral surface of the tibia, and is attached to the first cuneiform and metatarsal bones of the foot. It is a dorsiflexor of the ankle and invertor of the foot.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117875>	C13018	Tracheobronchial Tree|TRACHEOBRONCHIAL TREE	An anatomical structure comprising of trachea, bronchi, and bronchioles that terminate with the alveolar ducts, sacs, and alveoli.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117876>	C13056	Vastus Intermedius Muscle|MUSCLE, VASTUS INTERMEDIUS|VASTUS INTERMEDIUS MUSCLE	The portion of the quadriceps femoris muscle group that is underneath the Rectus Femoris muscle, spans and covers the upper two-thirds of the anterior and lateral surfaces of the femur, and inserts into the lateral border of the patella.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117877>	C38060	Early Treatment of Diabetic Retinopathy Study Eye Chart|ETDRS EYE CHART	A diagrammatic method to test visual acuity which incorporates the Bailey-Lovie layout in conjunction with Sloan optotypes, which was first used in the Early Treatment of Diabetic Retinopathy Study.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117878>	C38060	Pelli-Robson Contrast Sensitivity Eye Chart|PELLI-ROBSON EYE CHART	A diagrammatic method to test visual acuity and contrast sensitivity, which utilizes large letters (at a 20/60 acuity) that decrease in contrast from right to left and top to bottom.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117879>	C20080	Peripheral Angiography|PERIPHERAL ANGIOGRAPHY	A procedure in which the catheter is passed into a peripheral vessel (usually in the groin) for the purpose of angiography of the abdomen, hands, arms, feet and legs.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11787>	C61063	Doxorubicin/SU5416			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117880>	C38060	Sloan Letter Eye Chart 1.25 Percent|SLOAN LETTER EYE CHART 1.25%	A diagrammatic method to test visual acuity that utilizes the Sloan optotypes and a 1.25% contrast level.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117881>	C38060	Sloan Letter Eye Chart 2.5 Percent|SLOAN LETTER EYE CHART 2.5%	A diagrammatic method to test visual acuity that utilizes the Sloan optotypes and a 2.5% contrast level.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117882>	C41145	Average Thickness	The average number in a group of values that represent the thickness of an object at varying points along an axis.			Quantitative Concept	
C117883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117883>	C25365	Which Diagnostic Criteria Met|DXCRITMT|DXCRITMT|Diagnostic Criteria Met|Diagnostic Criteria Met|Diagnostic Criteria Met	A description of the diagnostic criterion that the subject fulfilled in order to establish a medical diagnosis.			Finding	CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Multiple Sclerosis Findings About Test Code Terminology|CDISC SDTM Multiple Sclerosis Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117884>	C25341	Location of Disease Onset|LOCONSET|LOCONSET|Localization of Onset|Localization of Onset|Localization of Onset	The anatomical location of the beginning or early stages of a disease.			Spatial Concept	CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Multiple Sclerosis Findings About Test Code Terminology|CDISC SDTM Multiple Sclerosis Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117885>	C62405	Focality of Disease Onset|Focus of Onset|OUNIMULT|OUNIMULT|Onset Unifocal or Multifocal|Onset Unifocal or Multifocal|Onset Unifocal or Multifocal	The number of disease loci that are seen at the beginning or early stages of that disease.			Qualitative Concept	CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Multiple Sclerosis Findings About Test Code Terminology|CDISC SDTM Multiple Sclerosis Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117886>	C38060	N145 Latency|N145LAT|N2 Latency	An assessment of the latency of the N145 or N2 wave of the visual evoked potential assessment waveform.			Diagnostic Procedure	CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117887>	C38060	N75 to P100 Peak to Peak Amplitude|N1 to P1 Peak to Peak Amplitude|P100 Amplitude|P100 Amplitude|P100 Amplitude|P100AMP	The magnitude, or height, of the P100 wave of the visual evoked potential assessment waveform. This assessment calculates the height from the N75 negative peak to the P100 positive peak.			Diagnostic Procedure	CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117888>	C38060	P100 Latency|P1 Latency|P100LAT	An assessment of the latency of the P100 or P1 wave of the visual evoked potential assessment waveform.			Diagnostic Procedure	CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117889>	C38060	Astigmatism Axis|ASTAXIS	A measurement of the location, in degrees, of the flatter principal meridian on a 180-degree scale, where 90 degrees designates the vertical meridian and 180 degrees designates the horizontal meridian.			Diagnostic Procedure	CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11788>	C61063	Carmustine/RSR13			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117890>	C25338	Log Score|LOGSCORE	A number or range of numeric values on the log scale that measures performance, function, quality, or ability.			Quantitative Concept	CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117891>	C25337	Number of Correct Eye Chart Letters|NUMLCOR|Number of Letters Correct|Number of Letters Correct	The integer that describes the number of letters correctly identified by the subject during an eye chart assessment.			Quantitative Concept	CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117892>	C38060	Cylindrical Refractive Error|Cylindrical Refraction Error|Cylindrical Refraction Error|RECYLDR	A measurement of the extent of defect in vision caused by a mismatch of optical power between the cylindrical and horizontal meridians, resulting in sub-optimal reflection of light onto the retina.			Diagnostic Procedure	CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117893>	C38060	Spherical Refractive Error|RESPHERE|Spherical Refraction Error	A measurement of the extent of defect in vision caused by a mismatch of optimal power between the cornea and/or lens and the length of the eyeball, resulting in sub-optimal reflection of light onto the retina.			Diagnostic Procedure	CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117894>	C92571	Day Times Femtogram Per Milliliter Per Milligram Per Gram|d.fg/mL/(mg/g)|d.fg/mL/(mg/g)|d.fg/ml/(mg/g)|d.fg/ml/(mg/g)|day*fg/mL/(mg/g)|day*fg/mL/(mg/g)	Day times femtogram per milliliter, divided by milligrams per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117895>	C92571	Day Times Femtogram Per Milliliter Per Milligram Per Gram Per Day|d.fg/mL/(mg/g/d)|d.fg/mL/(mg/g/d)|d.fg/ml/(mg/g/d)|d.fg/ml/(mg/g/d)|day*fg/mL/(mg/g/day)|day*fg/mL/(mg/g/day)	Day times femtogram per milliliter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117896>	C92571	Day Times gram Per Milliliter Per Milligram Per Gram|d.g/mL/(mg/g)|d.g/mL/(mg/g)|d.g/ml/(mg/g)|d.g/ml/(mg/g)|day*g/mL/(mg/g)|day*g/mL/(mg/g)	Day times gram per milliliter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117897>	C92571	Day Times gram Per Milliliter Per Milligram Per Gram Per Day|d.g/mL/(mg/g/d)|d.g/mL/(mg/g/d)|d.g/ml/(mg/g/d)|d.g/ml/(mg/g/d)|day*g/mL/(mg/g/day)|day*g/mL/(mg/g/day)	Day times gram per milliliter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117898>	C92571	Day Times Milligram Per Milliliter Per Milligram Per Gram|d.mg/mL/(mg/g)|d.mg/mL/(mg/g)|d.mg/ml/(mg/g)|d.mg/ml/(mg/g)|day*mg/mL/(mg/g)|day*mg/mL/(mg/g)	Day times milligram per milliliter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117899>	C92571	Day Times Milligram Per Milliliter Per Milligram Per Gram Per Day|d.mg/mL/(mg/g/d)|d.mg/mL/(mg/g/d)|d.mg/ml/(mg/g/d)|d.mg/ml/(mg/g/d)|day*mg/mL/(mg/g/day)|day*mg/mL/(mg/g/day)	Day times milligram per milliliter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11789>	C61063	Estramustine/Mitoxantrone/Vinorelbine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1178>	C29574	Tilarginine|L-NMMA|MMA|Monomethylarginine|N-Methylarginine|N5-(Methylamidino)-L-ornithine|NG-Monomethyl-L-Arginine|NG-monomethyl-L-arginine|NMA|TILARGININE|Targinine|omega-N-Monomethylarginine	A pan-nitric oxide synthase (NOS) inhibitor, with potential immunomodulating and antineoplastic activities. Upon administration, tilarginine binds to and inhibits NOS, a free radical signaling molecule that promotes angiogenesis, metastasis, and immunosuppression in the tumor microenvironment (TME). Reduction in NOS activity may abrogate the immunosuppressive TME, enhance tumor antigen-specific immune response and inhibit tumor cell proliferation.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C117900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117900>	C92571	Day Times Millimole Per Liter Per Milligram Per Gram|d.mmol/L/(mg/g)|d.mmol/L/(mg/g)|d.mmol/l/(mg/g)|d.mmol/l/(mg/g)|day*mmol/L/(mg/g)|day*mmol/L/(mg/g)	Day times millimole per liter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117901>	C92571	Day Times Millimole Per Liter Per Milligram Per Gram Per Day|d.mmol/L/(mg/g/d)|d.mmol/L/(mg/g/d)|d.mmol/l/(mg/g/d)|d.mmol/l/(mg/g/d)|day*mmol/L/(mg/g/day)|day*mmol/L/(mg/g/day)	Day times millimole per liter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117902>	C92571	Day Times mole Per Liter Per Milligram Per Gram|d.mol/L/(mg/g)|d.mol/L/(mg/g)|d.mol/l/(mg/g)|d.mol/l/(mg/g)|day*mol/L/(mg/g)|day*mol/L/(mg/g)	Day times mole per liter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117903>	C92571	Day Times mole Per Liter Per Milligram Per Gram Per Day|d.mol/L/(mg/g/d)|d.mol/L/(mg/g/d)|d.mol/l/(mg/g/d)|d.mol/l/(mg/g/d)|day*mol/L/(mg/g/day)|day*mol/L/(mg/g/day)	Day times mole per liter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117904>	C92571	Day Times Nanogram Per Milliliter Per Milligram Per Gram|d.ng/mL/(mg/g)|d.ng/mL/(mg/g)|d.ng/ml/(mg/g)|d.ng/ml/(mg/g)|day*ng/mL/(mg/g)|day*ng/mL/(mg/g)	Day times nanogram per milliliter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117905>	C92571	Day Times Nanogram Per Milliliter Per Milligram Per Gram Per Day|d.ng/mL/(mg/g/d)|d.ng/mL/(mg/g/d)|d.ng/ml/(mg/g/d)|d.ng/ml/(mg/g/d)|day*ng/mL/(mg/g/day)|day*ng/mL/(mg/g/day)	Day times nanogram per milliliter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117906>	C92571	Day Times Nanomole Per Liter Per Milligram Per Gram|d.nmol/L/(mg/g)|d.nmol/L/(mg/g)|d.nmol/l/(mg/g)|d.nmol/l/(mg/g)|day*nmol/L/(mg/g)|day*nmol/L/(mg/g)	Day times nanomole per liter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117907>	C92571	Day Times Nanomole Per Liter Per Milligram Per Gram Per Day|d.nmol/L/(mg/g/d)|d.nmol/L/(mg/g/d)|d.nmol/l/(mg/g/d)|d.nmol/l/(mg/g/d)|day*nmol/L/(mg/g/day)|day*nmol/L/(mg/g/day)	Day times nanomole per liter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117908>	C92571	Day Times Picogram Per Milliliter Per Milligram Per Gram|d.pg/mL/(mg/g)|d.pg/mL/(mg/g)|d.pg/ml/(mg/g)|d.pg/ml/(mg/g)|day*pg/mL/(mg/g)|day*pg/mL/(mg/g)	Day times picogram per milliliter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117909>	C92571	Day Times Picogram Per Milliliter Per Milligram Per Gram Per Day|d.pg/mL/(mg/g/d)|d.pg/mL/(mg/g/d)|d.pg/ml/(mg/g/d)|d.pg/ml/(mg/g/d)|day*pg/mL/(mg/g/day)|day*pg/mL/(mg/g/day)	Day times picogram per milliliter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11790>	C61007	Interferon Alfa/Isotretinoin/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117910>	C92571	Day Times Picomole Per Liter Per Milligram Per Gram|d.pmol/L/(mg/g)|d.pmol/L/(mg/g)|d.pmol/l/(mg/g)|d.pmol/l/(mg/g)|day*pmol/L/(mg/g)|day*pmol/L/(mg/g)	Day times picomole per liter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117911>	C92571	Day Times Picomole Per Liter Per Milligram Per Gram Per Day|d.pmol/L/(mg/g/d)|d.pmol/L/(mg/g/d)|d.pmol/l/(mg/g/d)|d.pmol/l/(mg/g/d)|day*pmol/L/(mg/g/day)|day*pmol/L/(mg/g/day)	Day times picomole per liter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117912>	C92571	Day Times Microgram Per Milliliter Per Milligram Per Gram|d.ug/mL/(mg/g)|d.ug/mL/(mg/g)|d.ug/ml/(mg/g)|d.ug/ml/(mg/g)|day*ug/mL/(mg/g)|day*ug/mL/(mg/g)	Day times microgram per milliliter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117913>	C92571	Day Times Microgram Per Milliliter Per Milligram Per Gram Per Day|d.ug/mL/(mg/g/d)|d.ug/mL/(mg/g/d)|d.ug/ml/(mg/g/d)|d.ug/ml/(mg/g/d)|day*ug/mL/(mg/g/day)|day*ug/mL/(mg/g/day)	Day times microgram per milliliter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117914>	C92571	Day Times Micromole Per Liter Per Milligram Per Gram|d.umol/L/(mg/g)|d.umol/L/(mg/g)|d.umol/l/(mg/g)|d.umol/l/(mg/g)|day*umol/L/(mg/g)|day*umol/L/(mg/g)	Day times micromole per liter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117915>	C92571	Day Times Micromole Per Liter Per Milligram Per Gram Per Day|d.umol/L/(mg/g/d)|d.umol/L/(mg/g/d)|d.umol/l/(mg/g/d)|d.umol/l/(mg/g/d)|day*umol/L/(mg/g/day)|day*umol/L/(mg/g/day)	Day times micromole per liter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117916>	C92571	Hour Times Femtogram Per Milliliter Per Milligram Per Gram|h*fg/mL/(mg/g)|h*fg/mL/(mg/g)|h.fg/mL/(mg/g)|h.fg/mL/(mg/g)|h.fg/ml/(mg/g)|h.fg/ml/(mg/g)	Hour times femtogram per milliliter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117917>	C92571	Hour Times Femtogram Per Milliliter Per Milligram Per Gram Per Day|h*fg/mL/(mg/g/day)|h*fg/mL/(mg/g/day)|h.fg/mL/(mg/g/d)|h.fg/mL/(mg/g/d)|h.fg/ml/(mg/g/d)|h.fg/ml/(mg/g/d)	Hour times femtogram per milliliter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117918>	C92571	Hour Times gram Per Milliliter Per Milligram Per Gram|h*g/mL/(mg/g)|h*g/mL/(mg/g)|h.g/mL/(mg/g)|h.g/mL/(mg/g)|h.g/ml/(mg/g)|h.g/ml/(mg/g)	Hour times gram per milliliter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117919>	C92571	Hour Times gram Per Milliliter Per Milligram Per Gram Per Day|h*g/mL/(mg/g/day)|h*g/mL/(mg/g/day)|h.g/mL/(mg/g/d)|h.g/mL/(mg/g/d)|h.g/ml/(mg/g/d)|h.g/ml/(mg/g/d)	Hour times gram per milliliter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11791>	C61063	Cisplatin/Fluorouracil/Irinotecan			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117920>	C92571	Hour Times Milligram Per Milliliter Per Milligram Per Gram|h*mg/mL/(mg/g)|h*mg/mL/(mg/g)|h.mg/mL/(mg/g)|h.mg/mL/(mg/g)|h.mg/ml/(mg/g)|h.mg/ml/(mg/g)	Hour times milligram per milliliter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117921>	C92571	Hour Times Milligram Per Milliliter Per Milligram Per Gram Per Day|h*mg/mL/(mg/g/day)|h*mg/mL/(mg/g/day)|h.mg/mL/(mg/g/d)|h.mg/mL/(mg/g/d)|h.mg/ml/(mg/g/d)|h.mg/ml/(mg/g/d)	Hour times milligram per milliliter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117922>	C92571	Hour Times Millimole Per Liter Per Milligram Per Gram|h*mmol/L/(mg/g)|h*mmol/L/(mg/g)|h.mmol/L/(mg/g)|h.mmol/L/(mg/g)|h.mmol/l/(mg/g)|h.mmol/l/(mg/g)	Hour times millimole per liter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117923>	C92571	Hour Times Millimole Per Liter Per Milligram Per Gram Per Day|h*mmol/L/(mg/g/day)|h*mmol/L/(mg/g/day)|h.mmol/L/(mg/g/d)|h.mmol/L/(mg/g/d)|h.mmol/l/(mg/g/d)|h.mmol/l/(mg/g/d)	Hour times millimole per liter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117924>	C92571	Hour Times mole Per Liter Per Milligram Per Gram|h*mol/L/(mg/g)|h*mol/L/(mg/g)|h.mol/L/(mg/g)|h.mol/L/(mg/g)|h.mol/l/(mg/g)|h.mol/l/(mg/g)	Hour times mole per liter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117925>	C92571	Hour Times mole Per Liter Per Milligram Per Gram Per Day|h*mol/L/(mg/g/day)|h*mol/L/(mg/g/day)|h.mol/L/(mg/g/d)|h.mol/L/(mg/g/d)|h.mol/l/(mg/g/d)|h.mol/l/(mg/g/d)	Hour times mole per liter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117926>	C92571	Hour Times Nanogram Per Milliliter Per Milligram Per Gram|h*ng/mL/(mg/g)|h*ng/mL/(mg/g)|h.ng/mL/(mg/g)|h.ng/mL/(mg/g)|h.ng/ml/(mg/g)|h.ng/ml/(mg/g)	Hour times nanogram per milliliter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117927>	C92571	Hour Times Nanogram Per Milliliter Per Milligram Per Gram Per Day|h*ng/mL/(mg/g/day)|h*ng/mL/(mg/g/day)|h.ng/mL/(mg/g/d)|h.ng/mL/(mg/g/d)|h.ng/ml/(mg/g/d)|h.ng/ml/(mg/g/d)	Hour times nanogram per milliliter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117928>	C92571	Hour Times Nanomole Per Liter Per Milligram Per Gram|h*nmol/L/(mg/g)|h*nmol/L/(mg/g)|h.nmol/L/(mg/g)|h.nmol/L/(mg/g)|h.nmol/l/(mg/g)|h.nmol/l/(mg/g)	Hour times nanomole per liter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117929>	C92571	Hour Times Nanomole Per Liter Per Milligram Per Gram Per Day|h*nmol/L/(mg/g/day)|h*nmol/L/(mg/g/day)|h.nmol/L/(mg/g/d)|h.nmol/L/(mg/g/d)|h.nmol/l/(mg/g/d)|h.nmol/l/(mg/g/d)	Hour times nanomole per liter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11792>	C61063	Etoposide Phosphate/Melphalan/Topotecan			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117930>	C92571	Hour Times Picogram Per Milliliter Per Milligram Per Gram|h*pg/mL/(mg/g)|h*pg/mL/(mg/g)|h.pg/mL/(mg/g)|h.pg/mL/(mg/g)|h.pg/ml/(mg/g)|h.pg/ml/(mg/g)	Hour times picogram per milliliter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117931>	C92571	Hour Times Picogram Per Milliliter Per Milligram Per Gram Per Day|h*pg/mL/(mg/g/day)|h*pg/mL/(mg/g/day)|h.pg/mL/(mg/g/d)|h.pg/mL/(mg/g/d)|h.pg/ml/(mg/g/d)|h.pg/ml/(mg/g/d)	Hour times picogram per milliliter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117932>	C92571	Hour Times Picomole Per Liter Per Milligram Per Gram|h*pmol/L/(mg/g)|h*pmol/L/(mg/g)|h.pmol/L/(mg/g)|h.pmol/L/(mg/g)|h.pmol/l/(mg/g)|h.pmol/l/(mg/g)	Hour times picomole per liter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117933>	C92571	Hour Times Picomole Per Liter Per Milligram Per Gram Per Day|h*pmol/L/(mg/g/day)|h*pmol/L/(mg/g/day)|h.pmol/L/(mg/g/d)|h.pmol/L/(mg/g/d)|h.pmol/l/(mg/g/d)|h.pmol/l/(mg/g/d)	Hour times picomole per liter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117934>	C92571	Hour Times Microgram Per Milliliter Per Milligram Per Gram|h*ug/mL/(mg/g)|h*ug/mL/(mg/g)|h.ug/mL/(mg/g)|h.ug/mL/(mg/g)|h.ug/ml/(mg/g)|h.ug/ml/(mg/g)	Hour times microgram per milliliter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117935>	C92571	Hour Times Microgram Per Milliliter Per Milligram Per Gram Per Day|h*ug/mL/(mg/g/day)|h*ug/mL/(mg/g/day)|h.ug/mL/(mg/g/d)|h.ug/mL/(mg/g/d)|h.ug/ml/(mg/g/d)|h.ug/ml/(mg/g/d)	Hour times microgram per milliliter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117936>	C92571	Hour Times Micromole Per Liter Per Milligram Per Gram|h*umol/L/(mg/g)|h*umol/L/(mg/g)|h.umol/L/(mg/g)|h.umol/L/(mg/g)|h.umol/l/(mg/g)|h.umol/l/(mg/g)	Hour times micromole per liter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117937>	C92571	Hour Times Micromole Per Liter Per Milligram Per Gram Per Day|h*umol/L/(mg/g/day)|h*umol/L/(mg/g/day)|h.umol/L/(mg/g/d)|h.umol/L/(mg/g/d)|h.umol/l/(mg/g/d)|h.umol/l/(mg/g/d)	Hour times micromole per liter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117938>	C92571	Minute Times Femtogram Per Milliliter Per Milligram Per Gram|min*fg/mL/(mg/g)|min*fg/mL/(mg/g)|min.fg/mL/(mg/g)|min.fg/mL/(mg/g)|min.fg/ml/(mg/g)|min.fg/ml/(mg/g)	Minute times femtogram per milliliter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117939>	C92571	Minute Times Femtogram Per Milliliter Per Milligram Per Gram Per Day|min*fg/mL/(mg/g/day)|min*fg/mL/(mg/g/day)|min.fg/mL/(mg/g/d)|min.fg/mL/(mg/g/d)|min.fg/ml/(mg/g/d)|min.fg/ml/(mg/g/d)	Minute times femtogram per milliliter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11793>	C61063	Cytarabine/Daunorubicin/Etoposide/Topotecan			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117940>	C92571	Minute Times gram Per Milliliter Per Milligram Per Gram|min*g/mL/(mg/g)|min*g/mL/(mg/g)|min.g/mL/(mg/g)|min.g/mL/(mg/g)|min.g/ml/(mg/g)|min.g/ml/(mg/g)	Minute times gram per milliliter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117941>	C92571	Minute Times gram Per Milliliter Per Milligram Per Gram Per Day|min*g/mL/(mg/g/day)|min*g/mL/(mg/g/day)|min.g/mL/(mg/g/d)|min.g/mL/(mg/g/d)|min.g/ml/(mg/g/d)|min.g/ml/(mg/g/d)	Minute times gram per milliliter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117942>	C92571	Minute Times Milligram Per Milliliter Per Milligram Per Gram|min*mg/mL/(mg/g)|min*mg/mL/(mg/g)|min.mg/mL/(mg/g)|min.mg/mL/(mg/g)|min.mg/ml/(mg/g)|min.mg/ml/(mg/g)	Minute times milligram per milliliter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117943>	C92571	Minute Times Milligram Per Milliliter Per Milligram Per Gram Per Day|min*mg/mL/(mg/g/day)|min*mg/mL/(mg/g/day)|min.mg/mL/(mg/g/d)|min.mg/mL/(mg/g/d)|min.mg/ml/(mg/g/d)|min.mg/ml/(mg/g/d)	Minute times milligram per milliliter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117944>	C92571	Minute Times Millimole Per Liter Per Milligram Per Gram|min*mmol/L/(mg/g)|min*mmol/L/(mg/g)|min.mmol/L/(mg/g)|min.mmol/L/(mg/g)|min.mmol/l/(mg/g)|min.mmol/l/(mg/g)	Minute times millimole per liter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117945>	C92571	Minute Times Millimole Per Liter Per Milligram Per Gram Per Day|min*mmol/L/(mg/g/day)|min*mmol/L/(mg/g/day)|min.mmol/L/(mg/g/d)|min.mmol/L/(mg/g/d)|min.mmol/l/(mg/g/d)|min.mmol/l/(mg/g/d)	Minute times millimole per liter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117946>	C92571	Minute Times mole Per Liter Per Milligram Per Gram|min*mol/L/(mg/g)|min*mol/L/(mg/g)|min.mol/L/(mg/g)|min.mol/L/(mg/g)|min.mol/l/(mg/g)|min.mol/l/(mg/g)	Minute times mole per liter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117947>	C92571	Minute Times mole Per Liter Per Milligram Per Gram Per Day|min*mol/L/(mg/g/day)|min*mol/L/(mg/g/day)|min.mol/L/(mg/g/d)|min.mol/L/(mg/g/d)|min.mol/l/(mg/g/d)|min.mol/l/(mg/g/d)	Minute times mole per liter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117948>	C92571	Minute Times Nanogram Per Milliliter Per Milligram Per Gram|min*ng/mL/(mg/g)|min*ng/mL/(mg/g)|min.ng/mL/(mg/g)|min.ng/mL/(mg/g)|min.ng/ml/(mg/g)|min.ng/ml/(mg/g)	Minute times nanogram per milliliter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117949>	C92571	Minute Times Nanogram Per Milliliter Per Milligram Per Gram Per Day|min*ng/mL/(mg/g/day)|min*ng/mL/(mg/g/day)|min.ng/mL/(mg/g/d)|min.ng/mL/(mg/g/d)|min.ng/ml/(mg/g/d)|min.ng/ml/(mg/g/d)	Minute times nanogram per milliliter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11794>	C61063	Cisplatin/Mitomycin/Tretinoin/Vinorelbine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117950>	C92571	Minute Times Nanomole Per Liter Per Milligram Per Gram|min*nmol/L/(mg/g)|min*nmol/L/(mg/g)|min.nmol/L/(mg/g)|min.nmol/L/(mg/g)|min.nmol/l/(mg/g)|min.nmol/l/(mg/g)	Minute times nanomole per liter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117951>	C92571	Minute Times Nanomole Per Liter Per Milligram Per Gram Per Day|min*nmol/L/(mg/g/day)|min*nmol/L/(mg/g/day)|min.nmol/L/(mg/g/d)|min.nmol/L/(mg/g/d)|min.nmol/l/(mg/g/d)|min.nmol/l/(mg/g/d)	Minute times nanomole per liter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117952>	C92571	Minute Times Picogram Per Milliliter Per Milligram Per Gram|min*pg/mL/(mg/g)|min*pg/mL/(mg/g)|min.pg/mL/(mg/g)|min.pg/mL/(mg/g)|min.pg/ml/(mg/g)|min.pg/ml/(mg/g)	Minute times picogram per milliliter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117953>	C92571	Minute Times Picogram Per Milliliter Per Milligram Per Gram Per Day|min*pg/mL/(mg/g/day)|min*pg/mL/(mg/g/day)|min.pg/mL/(mg/g/d)|min.pg/mL/(mg/g/d)|min.pg/ml/(mg/g/d)|min.pg/ml/(mg/g/d)	Minute times picogram per milliliter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117954>	C92571	Minute Times Picomole Per Liter Per Milligram Per Gram|min*pmol/L/(mg/g)|min*pmol/L/(mg/g)|min.pmol/L/(mg/g)|min.pmol/L/(mg/g)|min.pmol/l/(mg/g)|min.pmol/l/(mg/g)	Minute times picomole per liter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117955>	C92571	Minute Times Picomole Per Liter Per Milligram Per Gram Per Day|min*pmol/L/(mg/g/day)|min*pmol/L/(mg/g/day)|min.pmol/L/(mg/g/d)|min.pmol/L/(mg/g/d)|min.pmol/l/(mg/g/d)|min.pmol/l/(mg/g/d)	Minute times picomole per liter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117956>	C92571	Minute Times Microgram Per Milliliter Per Milligram Per Gram|min*ug/mL/(mg/g)|min*ug/mL/(mg/g)|min.ug/mL/(mg/g)|min.ug/mL/(mg/g)|min.ug/ml/(mg/g)|min.ug/ml/(mg/g)	Minute times microgram per milliliter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117957>	C92571	Minute Times Microgram Per Milliliter Per Milligram Per Gram Per Day|min*ug/mL/(mg/g/day)|min*ug/mL/(mg/g/day)|min.ug/mL/(mg/g/d)|min.ug/mL/(mg/g/d)|min.ug/ml/(mg/g/d)|min.ug/ml/(mg/g/d)	Minute times microgram per milliliter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117958>	C92571	Minute Times Micromole Per Liter Per Milligram Per Gram|min*umol/L/(mg/g)|min*umol/L/(mg/g)|min.umol/L/(mg/g)|min.umol/L/(mg/g)|min.umol/l/(mg/g)|min.umol/l/(mg/g)	Minute times micromole per liter, divided by milligram per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117959>	C92571	Minute Times Micromole Per Liter Per Milligram Per Gram Per Day|min*umol/L/(mg/g/day)|min*umol/L/(mg/g/day)|min.umol/L/(mg/g/d)|min.umol/L/(mg/g/d)|min.umol/l/(mg/g/d)|min.umol/l/(mg/g/d)	Minute times micromole per liter, divided by milligram per gram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11795>	C61063	Cisplatin/Tretinoin/Vinorelbine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117960>	C25466	Diagnostic Criteria|DXCRIT	A standard from which a judgment concerning a medical diagnosis can be established.			Idea or Concept	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C117961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117961>	C25466	Relapse Criteria|RLPSCRIT	A standard from which a judgment concerning a disease relapse can be established.			Idea or Concept	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C117962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117962>	C25466	Severity Criteria|SEVCRIT	A standard from which a judgment concerning an event severity can be established.			Idea or Concept	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C117963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117963>	C74925	Percent Inhibition|% INHIBITION|%{INHIBITION}|%{INHIBITION}|%{inhibition}|%{inhibition}	The rate of measured normal activity minus inhibited activity, divided by the rate of normal activity of a given object. It is expressed as a percentage.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117964>	C66973	Per Picoliter|/pL|/pL|/pl|/pl	A volume unit equal to one picoliter used as a denominator to build a derived unit expressed as a ratio.			Quantitative Concept	
C117965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117965>	C67375	Immunoglobin A Phospholipid Unit per Milliliter|APL U/mL|APL U/mL|IgA Phospholipid Unit per Milliliter|Immunoglobin A Phospholipid Units per Milliliter|[APL'U]/mL|[APL'U]/mL|[APL'U]/ml|[APL'U]/ml	A unit for semiquantitative measurement of IgA autoantibodies to proteins associated with negatively charged phospholipids evaluated in ELISA serum anticardiolipin or anionic phospholipid assay against an established reference standard, per unit of volume equal to one milliliter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117966>	C67375	Bethesda Unit|BU|BU|Bethesda unit|Bethesda unit|[beth'U]|[beth'U]|[beth'U]|[beth'U]|beth'U	A unit of measurement for blood coagulation inhibitor activity, expressed in the amount of an inhibitor neutralizing 50% of a coagulant during the incubation period per unit of volume equal to one milliliter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology|UCUM Terminology
C117967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117967>	C67375	Bethesda Unit per Milliliter|BU/mL|BU/mL|[beth'U]/mL|[beth'U]/mL|[beth'U]/ml|[beth'U]/ml	A unit of measurement for blood coagulation inhibitor activity, expressed as a Bethesda Unit per unit of volume equal to one milliliter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117968>	C77605	Disintegration per Minute per 100 milligrams|Disintegrations per Minute per 100 milligrams|dpm/100 mg|dpm/100mg|dpm/cg|dpm/cg|{disintegrations}/min/10*2.mg|{disintegrations}/min/10*2.mg|{disintegrations}/min/10^2.mg|{disintegrations}/min/10^2.mg	A unit of radioactive decay expressed in atoms of radioactive material that decay over a period of time equal to sixty seconds in a mass unit equal to one centigram.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117969>	C77605	Disintegration per Minute per Milligram|Disintegrations per Minute per Milligram|dpm/mg|dpm/mg|{disintegrations}/min/mg|{disintegrations}/min/mg	A unit of radioactive decay expressed in atoms of radioactive material that decay over a period of time equal to sixty seconds in a mass unit equal to one milligram.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11796>	C61063	Cisplatin/Fenretinide/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117970>	C77605	Disintegration per Minute per Milliliter|Disintegrations per Minute per Milliliter|dpm/mL|dpm/mL|{disintegrations}/min/mL|{disintegrations}/min/mL|{disintegrations}/min/ml|{disintegrations}/min/ml	A unit of radioactive decay expressed in atoms of radioactive material that decay over a period of time equal to sixty seconds in a volume unit equal to one milliliter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117971>	C67375	Immunoglobin G Phospholipid Unit per Milliliter|GPL U/mL|GPL U/mL|GPL'U/mL|IgG Phospholipid Units per Milliliter|IgG anticardiolipin unit per milliliter**|Immunoglobin G Phospholipid Units per Milliliter|[GPL'U]/mL|[GPL'U]/mL|[GPL'U]/mL|[GPL'U]/ml|[GPL'U]/ml	A unit for semiquantitative measurement of IgG autoantibodies to proteins associated with negatively charged phospholipids evaluated in ELISA serum anticardiolipin or anionic phospholipid assay against an established reference standard, per unit of volume equal to one milliliter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C117972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117972>	C67375	Log10 Copies per Milliliter|log10 copies/mL|log10 copies/mL|{Log10 copies}/mL|{Log10 copies}/mL|{Log10 copies}/ml|{Log10 copies}/ml	A logarithmic-scale (base 10) unit for measuring copies per unit of volume equal to one milliliter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117973>	C67375	Immunoglobin M Phospholipid Unit per Milliliter|IgM Phospholipid Units per Milliliter|IgM anticardiolipin unit per milliliter**|Immunoglobin M Phospholipid Units per Milliliter|MPL U/mL|MPL U/mL|MPL'u/mL|[MPL'U]/mL|[MPL'U]/mL|[MPL'U]/mL|[MPL'U]/ml|[MPL'U]/ml	A unit for semiquantitative measurement of IgM autoantibodies to proteins associated with negatively charged phospholipids evaluated in ELISA serum anticardiolipin or anionic phospholipid assay against an established reference standard, per unit of volume equal to one milliliter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C117974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117974>	C67375	Nanomole Bone Collagen Equivalent per Liter|Nanomoles Bone Collagen Equivalents per Liter|nmol BCE/L|nmol BCE/L|{nmolBCE}/L|{nmolBCE}/L|{nmolBCE}/l|{nmolBCE}/l	A unit of relative amount of substance concentration equal to nanomoles of bone collagen equivalent weight per unit of volume equal to one liter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117975>	C64569	Microequivalent per Liter|Nanoequivalent per Milliliter|mEq/L|microequivalent per liter|nEq/mL|nEq/mL|uEq/L|uEq/L|ueq/L|ueq/L|ueq/L|ueq/l|ueq/l	A unit of relative amount of substance concentration equal to one billionth of a gram of an equivalent weight per unit of volume equal to one milliliter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C117976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117976>	C81328	Ideal Body Weight|IDEALWT	A person's optimum weight as calculated by a standard methodology.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Vital Sign Test Code Terminology|CDISC SDTM Vital Sign Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117977>	C134576	Experimental Organism Benign Keratoacanthoma|KERATOACANTHOMA, BENIGN	A benign neoplasm in the superficial dermis with direct association to the epidermis, composed of well differentiated squamous epithelium and a central cavity filled with concentric layers of keratin; a pore (opening in the epidermis) may be present. (CDISC)			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C117978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117978>	C19697	Preputial Gland/Clitoral Gland|GLAND, PREPUTIAL/GLAND, CLITORAL	A laboratory specimen consisting of the preputial gland and the clitoral gland.			Tissue	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117979>	C13056	Plantaris Muscle|MUSCLE, PLANTARIS	A small muscle that courses along the posterior aspect of the leg as part of the posterosuperficial compartment of the calf. This muscle originates from the lateral supracondylar line of the femur superior and medial to the lateral head of the gastrocnemius muscle as well as from the oblique popliteal ligament in the posterior aspect of the knee.			Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11797>	C63496	Cisplatin/Cyclophosphamide/Dexamethasone/Etoposide/Thalidomide Regimen|Cisplatin-Cyclophosphamide-Dexamethasone-Etoposide-Thalidomide|Cisplatin/Cyclophosphamide/Dexamethasone/Etoposide/Thalidomide|DCEP-T|DCEP-T	A regimen consisting of cisplatin, cyclophosphamide, dexamethasone, etoposide and thalidomide that can be used for the treatment of plasma cell (multiple) myeloma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C117980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117980>	C13056	Sternocephalicus Muscle|MUSCLE, STERNOCEPHALICUS	A long muscle of the neck that extends from the manubrium sterni to the mandible and branches at the middle of the neck, forming the ventral border of the jugular groove.			Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117981>	C14193	Cornish Cross Chicken|CORNISH CROSS	Derived from a cross between the commercial Cornish chicken and a White Plymouth Rock chicken, this breed grows rapidly and reaches 4-6 pounds in 6 weeks.			Bird	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117982>	C14376	Domestic Animal|DOMESTIC	The name for a domesticated animal that does not have a pedigree nor belong to a specific breed.			Classification	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117983>	C74760	Oxalate to Creatinine Ratio Measurement|OXACREAT|Oxalate/Creatinine|Oxalate/Creatinine	The determination of the ratio of oxalate compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C117984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117984>	C89328|C26726	Pediatric Infectious Disorder|Pediatric Infectious Disease	An infectious disorder that occurs during infancy, childhood, or adolescence.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C117985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117985>	C1663|C129826	Nelipepimut-S|E75 Peptide|Human Receptor Tyrosine-Protein Kinase erbB-2 (Proto-Oncogene Neu, Tyrosine Kinase- type Cell Surface Receptor HER2, CD340)-(347-355)-Peptide|L-Leucine, L-lysyl-L-isoleucyl-L-phenylalanylglycyl-L-seryl-L-leucyl-L-alanyl-L- phenylalanyl-|NELIPEPIMUT-S|Nelipepimut S|NeuVax	A cancer vaccine comprised of a human leukocyte antigen (HLA) A2/A3 restricted HER2/neu (human epidermal growth factor receptor 2; ErbB2) nonapeptide derived from the extracellular domain of the HER2 protein, with potential immunomodulating and antineoplastic activities. Upon intradermal injection, nelipepimut-S may induce a specific cytotoxic T-lymphocyte (CTL) response against HER2/neu-expressing tumor cells. HER2/neu, a tumor-associated antigen and a member of the epidermal growth factor receptor family of tyrosine kinases, is overexpressed in various tumor cell types and plays a key role in tumorigenesis.			Cell|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C117986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117986>	C100110	CDISC Questionnaire CHART-SF Interview Version Test Name Terminology|CHSF1TN|Craig Handicap Assessment and Reporting Technique - Short Form Interview Version Questionnaire Test Name|QS-CHART-SF TEST	Test names of questionnaire questions associated with the Craig Handicap Assessment and Reporting Technique - Short Form Interview Version (CHART-SF Interview Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117987>	C100110	CDISC Questionnaire CHART-SF Interview Version Test Code Terminology|CHSF1TC|Craig Handicap Assessment and Reporting Technique - Short Form Interview Version Questionnaire Test Code|QS-CHART-SF TESTCD	Test codes of questionnaire questions associated with the Craig Handicap Assessment and Reporting Technique - Short Form Interview Version (CHART-SF Interview Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117988>	C100110	CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CSS11TN|Columbia-Suicide Severity Rating Scale Lifetime/Recent Version Questionnaire Test Name|QS-C-SSRS Lifetime/Recent Version TEST	Test names of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117989>	C100110	CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CSS11TC|Columbia-Suicide Severity Rating Scale Lifetime/Recent Version Questionnaire Test Code|QS-C-SSRS Lifetime/Recent Version TESTCD	Test codes of questionnaire questions associated with the Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11798>	C61063	Carboplatin/Paclitaxel/Shark Cartilage			Obsolete_Concept	Therapeutic or Preventive Procedure	
C117990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117990>	C118970	CDISC Clinical Classification ESRS-A Test Name Terminology|ESRSA1TN|Extrapyramidal Symptom Rating Scale-Abbreviated Clinical Classification Test Name|QS-ESRS-A TEST	Test names of questionnaire questions associated with the Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117991>	C118970	CDISC Clinical Classification ESRS-A Test Code Terminology|ESRSA1TC|Extrapyramidal Symptom Rating Scale-Abbreviated Clinical Classification Test Code|QS-ESRS-A TESTCD	Test codes of clinical classification questions associated with the Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117992>	C211913	CHART-SF Interview Version Questionnaire Question	A question associated with the CHART-SF questionnaire.			Intellectual Product	
C117993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117993>	C211913	C-SSRS Lifetime/Recent Version Questionnaire Question	A question associated with the C-SSRS Lifetime/Recent Version questionnaire.			Intellectual Product	
C117994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117994>	C211913	ESRS-A Clinical Classification Question	A question associated with the ESRS-A Clinical Classification.			Intellectual Product	
C117995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117995>	C91105	Craig Handicap Assessment and Reporting Technique-Short Form Interview Version Questionnaire|CHART-SF|CHART-SF INTERVIEW VERSION|CHSF1	A standardized rating scale originally developed by Whiteneck et al in 1992 and modified in 2000, which is used to measure the degree to which impairments and disabilities result in handicaps in the years after initial rehabilitation. The questionnaire contains 19 questions and generates 6 subscales: physical independence, cognitive independence, mobility, occupation, social integration and economic self-sufficiency.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117996>	C91105	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version Questionnaire|C-SSRS LIFETIME/RECENT VERSION|C-SSRS Lifetime/Recent Version|CSS11	A standardized rating scale developed by Posner et al (version 1/14/2009), which is used to determine the presence of suicidal ideation or behavior. The lifetime/recent version questionnaire contains 23 items across 4 domains; suicidal ideation (lifetime and past 1 month), intensity of ideation (lifetime and past 1 month), suicidal behavior (lifetime and past 3 months) and actual attempts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117997>	C118969	Extrapyramidal Symptom Rating Scale-Abbreviated Clinical Classification|ESRS-A|ESRSA|ESRSA1	A standardized rating scale originally developed by Chouinard et al in 1980, which is used to measure drug-induced extrapyramidal symptoms (EPS) or 4 types of drug-induced movement disorders (DIMD): parkinsonism, akathisia, dystonia, and tardive dyskinesia. The questionnaire contains 28 questions and generates 4 subscales and 4 clinical global impression severity (CGI-S) scales.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117998>	C117992	CHART-SF Interview Version - Paid Personal Care per Day|CHSF1-Paid Personal Care per Day|CHSF1-Paid Personal Care per Day|CHSF101A	Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) How many hours in a typical 24-hour day do you have someone with you to provide physical assistance for personal care activities such as eating, bathing, dressing, toileting and mobility? Hours paid assistance.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Interview Version Test Code Terminology|CDISC Questionnaire CHART-SF Interview Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C117999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C117999>	C117992	CHART-SF Interview Version - Unpaid Personal Care per Day|CHSF1-Unpaid Personal Care per Day|CHSF1-Unpaid Personal Care per Day|CHSF101B	Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) How many hours in a typical 24-hour day do you have someone with you to provide physical assistance for personal care activities such as eating, bathing, dressing, toileting and mobility? Hours unpaid (family, others).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Interview Version Test Code Terminology|CDISC Questionnaire CHART-SF Interview Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11799>	C61063	Cisplatin/Shark Cartilage/Vinorelbine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1179>	C19171	Protein E7, Human Papillomavirus Type 16|HPV-16 E7|HPV-16 E7 Protein|HPV-16 E7 peptide|HPV16 E7|Human Papillomavirus Type 16, E7 Protein|Papillomavirus Type 16 Protein E7|Protein E7	Protein E7 (98 aa, ~11 kDa) is encoded by the human papillomavirus type 16 E7 gene. This protein is involved in the modulation of the activity of both retinoblastoma protein and histone deacetylases in the infected host cell, which is associated with viral genome replication and host cell transformation.	Protein E7, Human Papillomavirus Type 16		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118000>	C117992	CHART-SF Interview Version - Cognitive Assistance at Home per Day|CHSF1-Home Cognitive Assistance per Day|CHSF1-Home Cognitive Assistance per Day|CHSF102	Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) How much time is someone with you in your home to assist you with activities that require remembering, decision making, or judgment?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Interview Version Test Code Terminology|CDISC Questionnaire CHART-SF Interview Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118001>	C117992	CHART-SF Interview Version - Cognitive Assistance Away From Home per Day|CHSF1-Away Cognitive Assistance per Day|CHSF1-Away Cognitive Assistance per Day|CHSF103	Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) How much of the time is someone with you to help you with remembering, decision making, or judgment when you go away from your home?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Interview Version Test Code Terminology|CDISC Questionnaire CHART-SF Interview Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118002>	C117992	CHART-SF Interview Version - Hours Out of Bed per Day|CHSF1-Hours Out of Bed per Day|CHSF1-Hours Out of Bed per Day|CHSF104	Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) On a typical day, how many hours are you out of bed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Interview Version Test Code Terminology|CDISC Questionnaire CHART-SF Interview Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118003>	C117992	CHART-SF Interview Version - Days Out of the House per Week|CHSF1-Days Out of the House per Week|CHSF1-Days Out of the House per Week|CHSF105	Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) In a typical week, how many days do you get out of your house and go somewhere?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Interview Version Test Code Terminology|CDISC Questionnaire CHART-SF Interview Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118004>	C117992	CHART-SF Interview Version - Nights Away From Home Last Year|CHSF1-Nights Away From Home Last Year|CHSF1-Nights Away From Home Last Year|CHSF106	Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) In the last year, how many nights have you spent away from your home (excluding hospitalizations)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Interview Version Test Code Terminology|CDISC Questionnaire CHART-SF Interview Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118005>	C117992	CHART-SF Interview Version - Hours of Paid Work per Week|CHSF1-Hours of Paid Work per Week|CHSF1-Hours of Paid Work per Week|CHSF107A	Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) How many hours per week do you spend working in a job for which you get paid?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Interview Version Test Code Terminology|CDISC Questionnaire CHART-SF Interview Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118006>	C117992	CHART-SF Interview Version - Occupation of Paid Work|CHSF1-Occupation of Paid Work|CHSF1-Occupation of Paid Work|CHSF107B	Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) How many hours per week do you spend working in a job for which you get paid? (occupation).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Interview Version Test Code Terminology|CDISC Questionnaire CHART-SF Interview Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118007>	C117992	CHART-SF Interview Version - Hours of Schoolwork per Week|CHSF1-Hours of Schoolwork per Week|CHSF1-Hours of Schoolwork per Week|CHSF108	Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) How many hours per week do you spend in school working toward a degree or in an accredited technical training program (including hours in class and studying)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Interview Version Test Code Terminology|CDISC Questionnaire CHART-SF Interview Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118008>	C117992	CHART-SF Interview Version - Hours of Homemaking per Week|CHSF1-Hours of Homemaking per Week|CHSF1-Hours of Homemaking per Week|CHSF109	Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) How many hours per week do you spend in active homemaking including parenting, housekeeping, and food preparation?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Interview Version Test Code Terminology|CDISC Questionnaire CHART-SF Interview Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118009>	C117992	CHART-SF Interview Version - Hours of Home Maintenance per Week|CHSF1-Hours of Home Maintenance per Week|CHSF1-Hours of Home Maintenance per Week|CHSF110	Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) How many hours per week do you spend in home maintenance activities such as gardening, house repairs or home improvement?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Interview Version Test Code Terminology|CDISC Questionnaire CHART-SF Interview Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11800>	C61063	Docetaxel/Trastuzumab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118010>	C117992	CHART-SF Interview Version - Hours of Recreational Activities per Week|CHSF1-Hours of Recreation per Week|CHSF1-Hours of Recreation per Week|CHSF111	Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) How many hours per week do you spend in recreational activities such as sports, exercise, playing cards, or going to movies? Please do not include time spent watching TV or listening to the radio.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Interview Version Test Code Terminology|CDISC Questionnaire CHART-SF Interview Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118011>	C117992	CHART-SF Interview Version - Number of People You Live With|CHSF1-Number of People You Live With|CHSF1-Number of People You Live With|CHSF112	Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) How many people do you live with?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Interview Version Test Code Terminology|CDISC Questionnaire CHART-SF Interview Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118012>	C117992	CHART-SF Interview Version - Live With Spouse or Significant Other|CHSF1-Live With Spouse or Signif Other|CHSF1-Live With Spouse or Signif Other|CHSF113	Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) Is one of them your spouse or significant other?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Interview Version Test Code Terminology|CDISC Questionnaire CHART-SF Interview Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118013>	C117992	CHART-SF Interview Version - Number of Relatives You Live With|CHSF1-Number of Relatives You Live With|CHSF1-Number of Relatives You Live With|CHSF114	Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) Of the people you live with how many are relatives?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Interview Version Test Code Terminology|CDISC Questionnaire CHART-SF Interview Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118014>	C117992	CHART-SF Interview Version - Associates Contacted per Month|CHSF1-Associates Contacted per Month|CHSF1-Associates Contacted per Month|CHSF115	Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) How many business or organizational associates do you visit, phone, or write to at least once a month?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Interview Version Test Code Terminology|CDISC Questionnaire CHART-SF Interview Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118015>	C117992	CHART-SF Interview Version - Friends Contacted per Month|CHSF1-Friends Contacted per Month|CHSF1-Friends Contacted per Month|CHSF116	Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) How many friends (non-relatives contacted outside business or organizational settings) do you visit, phone, or write to at least once a month?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Interview Version Test Code Terminology|CDISC Questionnaire CHART-SF Interview Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118016>	C117992	CHART-SF Interview Version - Initiated Conversation With Strangers Last Month|CHSF1-Strangers Spoke with Last Month|CHSF1-Strangers Spoke with Last Month|CHSF117	Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) With how many strangers have you initiated a conversation in the last month (for example, to ask information or place an order)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Interview Version Test Code Terminology|CDISC Questionnaire CHART-SF Interview Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118017>	C117992	CHART-SF Interview Version - Combined Annual Household Income Last Year|CHSF1-Combined Household Income Last Yr|CHSF1-Combined Household Income Last Yr|CHSF118	Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) Approximately what was the combined annual income, in the last year, of all family members in your household? (consider all sources including wages and earnings, disability benefits, pensions and retirement income, income from court settlements, investments and trust funds, child support and alimony, contributions from relatives, and any other source).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Interview Version Test Code Terminology|CDISC Questionnaire CHART-SF Interview Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118018>	C117992	CHART-SF Interview Version - Medical Care Expense Last Year|CHSF1-Medical Care Expenses Last Year|CHSF1-Medical Care Expenses Last Year|CHSF119	Craig Handicap Assessment and Reporting Technique-Short Form Interview Version (CHART-SF Interview Version) Approximately how much did you pay last year for medical care expenses? (Consider any amounts paid by yourself or the family members in your household and not reimbursed by insurance or benefits).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Interview Version Test Code Terminology|CDISC Questionnaire CHART-SF Interview Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118019>	C117993	C-SSRS Lifetime/Recent Version - Wish to be Dead (Lifetime)|CSS11-Wish to be Dead-Life|CSS11-Wish to be Dead-Life|CSS1101A	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Have you wished you were dead or wished you could go to sleep and not wake up? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11801>	C61063	Cytarabine/Daunorubicin/Etoposide/Tretinoin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118020>	C117993	C-SSRS Lifetime/Recent Version - Wish to be Dead (Past 1 Month)|CSS11-Wish to be Dead-P1M|CSS11-Wish to be Dead-P1M|CSS1101B	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Have you wished you were dead or wished you could go to sleep and not wake up? (Past 1 Month).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118021>	C117993	C-SSRS Lifetime/Recent Version - Description of Wish to be Dead|CSS11-Wish to be Dead, Describe|CSS11-Wish to be Dead, Describe|CSS1101C	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Description of wishing to be dead.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118022>	C117993	C-SSRS Lifetime/Recent Version - Non-Specific Active Suicidal Thoughts (Lifetime)|CSS11-Non-Spec Suicid Thought-Life|CSS11-Non-Spec Suicid Thought-Life|CSS1102A	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Have you actually had any thoughts of killing yourself? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118023>	C117993	C-SSRS Lifetime/Recent Version - Non-Specific Active Suicidal Thoughts (Past 1 Months)|CSS11-Non-Spec Suicid Thought-P1M|CSS11-Non-Spec Suicid Thought-P1M|CSS1102B	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Have you actually had any thoughts of killing yourself? (Past 1 Month).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118024>	C117993	C-SSRS Lifetime/Recent Version - Description of Non-Specific Active Suicidal Thoughts|CSS11-Non-Spec Suicid Thought, Describe|CSS11-Non-Spec Suicid Thought, Describe|CSS1102C	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Description of non-specific active suicidal thoughts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118025>	C117993	C-SSRS Lifetime/Recent Version - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act (Lifetime)|CSS11-Idea, No Intent, No Plan-Life|CSS11-Idea, No Intent, No Plan-Life|CSS1103A	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Have you been thinking about how you might do this? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118026>	C117993	C-SSRS Lifetime/Recent Version - Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act (Past 1 Month)|CSS11-Idea, No Intent, No Plan-P1M|CSS11-Idea, No Intent, No Plan-P1M|CSS1103B	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Have you been thinking about how you might do this? (Past 1 Month).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118027>	C117993	C-SSRS Lifetime/Recent Version - Description of Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act|CSS11-Idea, No Intent, No Plan, Describe|CSS11-Idea, No Intent, No Plan, Describe|CSS1103C	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Description of active suicidal ideation with any methods (not plan) without intent to act.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118028>	C117993	C-SSRS Lifetime/Recent Version - Active Suicidal Ideation with Some Intent to Act, without Specific Plan (Lifetime)|CSS11-Idea, Intent, No Plan-Life|CSS11-Idea, Intent, No Plan-Life|CSS1104A	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Have you had these thoughts and had some intention of acting on them? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118029>	C117993	C-SSRS Lifetime/Recent Version - Active Suicidal Ideation with Some Intent to Act, without Specific Plan (Past 1 Month)|CSS11-Idea, Intent, No Plan-P1M|CSS11-Idea, Intent, No Plan-P1M|CSS1104B	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Have you had these thoughts and had some intention of acting on them? (Past 1 Month).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11802>	C61063	Cytarabine/Filgrastim/Fludarabine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118030>	C117993	C-SSRS Lifetime/Recent Version - Description of Active Suicidal Ideation with Some Intent to Act, without Specific Plan|CSS11-Idea, Intent, No Plan, Describe|CSS11-Idea, Intent, No Plan, Describe|CSS1104C	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Description of active suicidal ideation with some intent to act, without specific plan.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118031>	C117993	C-SSRS Lifetime/Recent Version - Active Suicidal Ideation with Specific Plan and Intent (Lifetime)|CSS11-Idea, Plan, Intent-Life|CSS11-Idea, Plan, Intent-Life|CSS1105A	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118032>	C117993	C-SSRS Lifetime/Recent Version - Active Suicidal Ideation with Specific Plan and Intent (Past 1 Month)|CSS11-Idea, Plan, Intent-P1M|CSS11-Idea, Plan, Intent-P1M|CSS1105B	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan? (Past 1 Month).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118033>	C117993	C-SSRS Lifetime/Recent Version - Description of Active Suicidal Ideation with Specific Plan and Intent|CSS11-Idea, Plan, Intent, Describe|CSS11-Idea, Plan, Intent, Describe|CSS1105C	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Description of active suicidal ideation with specific plan and intent.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118034>	C117993	C-SSRS Lifetime/Recent Version - Most Severe Ideation (Lifetime)|CSS11-Most Severe Idea-Life|CSS11-Most Severe Idea-Life|CSS1106A	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Most severe ideation. (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118035>	C117993	C-SSRS Lifetime/Recent Version - Describe Most Severe Ideation (Lifetime)|CSS11-Most Severe Idea, Desc-Life|CSS11-Most Severe Idea, Desc-Life|CSS1106B	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Description of most severe ideation. (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118036>	C117993	C-SSRS Lifetime/Recent Version - Recent Most Severe Ideation (Past 1 Month)|CSS11-Most Severe Idea-Recent-P1M|CSS11-Most Severe Idea-Recent-P1M|CSS1106C	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Most severe ideation. (Recent - Past 1 Month).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118037>	C117993	C-SSRS Lifetime/Recent Version - Describe Recent Most Severe Ideation (Past 1 Month)|CSS11-Most Severe Idea, Desc-Recent-P1M|CSS11-Most Severe Idea, Desc-Recent-P1M|CSS1106D	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Description of most severe ideation. (Recent - Past 1 Month).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118038>	C117993	C-SSRS Lifetime/Recent Version - Frequency of Most Severe Ideation (Lifetime)|CSS11-Most Severe Idea, Frequency-Life|CSS11-Most Severe Idea, Frequency-Life|CSS1107A	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) How many times have you had these thoughts? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118039>	C117993	C-SSRS Lifetime/Recent Version - Frequency of Most Severe Ideation (Past 1 Month)|CSS11-Most Severe Idea, Frequency-P1M|CSS11-Most Severe Idea, Frequency-P1M|CSS1107B	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) How many times have you had these thoughts? (Past 1 Month).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11803>	C61063	Cytarabine/Fludarabine/Tretinoin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118040>	C117993	C-SSRS Lifetime/Recent Version - Duration of Most Severe Ideation (Lifetime)|CSS11-Most Severe Idea, Duration-Life|CSS11-Most Severe Idea, Duration-Life|CSS1108A	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) When you have the thoughts how long do they last? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118041>	C117993	C-SSRS Lifetime/Recent Version - Duration of Most Severe Ideation (Past 1 Month)|CSS11-Most Severe Idea, Duration-P1M|CSS11-Most Severe Idea, Duration-P1M|CSS1108B	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) When you have the thoughts how long do they last? (Past 1 Month).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118042>	C117993	C-SSRS Lifetime/Recent Version - Controllability of Most Severe Ideation (Lifetime)|CSS11-Most Severe Idea, Control-Life|CSS11-Most Severe Idea, Control-Life|CSS1109A	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Could/can you stop thinking about killing yourself or wanting to die if you want to? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118043>	C117993	C-SSRS Lifetime/Recent Version - Controllability of Most Severe Ideation (Past 1 Month)|CSS11-Most Severe Idea, Control-P1M|CSS11-Most Severe Idea, Control-P1M|CSS1109B	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Could/can you stop thinking about killing yourself or wanting to die if you want to? (Past 1 Month).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118044>	C117993	C-SSRS Lifetime/Recent Version - Deterrents to Most Severe Ideation (Lifetime)|CSS11-Most Severe Idea, Deterrents-Life|CSS11-Most Severe Idea, Deterrents-Life|CSS1110A	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Are there things - anyone or anything (e.g., family, religion, pain of death) - that stopped you from wanting to die or acting on thoughts of committing suicide? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118045>	C117993	C-SSRS Lifetime/Recent Version - Deterrents to Most Severe Ideation (Past 1 Month)|CSS11-Most Severe Idea, Deterrents-P1M|CSS11-Most Severe Idea, Deterrents-P1M|CSS1110B	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Are there things - anyone or anything (e.g., family, religion, pain of death) - that stopped you from wanting to die or acting on thoughts of committing suicide? (Past 1 Month).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118046>	C117993	C-SSRS Lifetime/Recent Version - Reasons for Most Severe Ideation (Lifetime)|CSS11-Most Severe Idea, Reasons-Life|CSS11-Most Severe Idea, Reasons-Life|CSS1111A	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) What sort of reasons did you have for thinking about wanting to die or killing yourself? Was it to end the pain or stop the way you were feeling (in other words you couldn't go on living with this pain or how you were feeling) or was it to get attention, revenge or a reaction from others? Or both? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118047>	C117993	C-SSRS Lifetime/Recent Version - Reasons for Most Severe Ideation (Past 1 Month)|CSS11-Most Severe Idea, Reasons-P1M|CSS11-Most Severe Idea, Reasons-P1M|CSS1111B	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) What sort of reasons did you have for thinking about wanting to die or killing yourself? Was it to end the pain or stop the way you were feeling (in other words you couldn't go on living with this pain or how you were feeling) or was it to get attention, revenge or a reaction from others? Or both? (Past 1 Month).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118048>	C117993	C-SSRS Lifetime/Recent Version - Actual Suicide Attempt (Lifetime)|CSS11-Actual Attempt-Life|CSS11-Actual Attempt-Life|CSS1112A	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Have you made a suicide attempt? Have you done anything to harm yourself? Have you done anything dangerous where you could have died? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118049>	C117993	C-SSRS Lifetime/Recent Version - Actual Suicide Attempt (Past 3 Months)|CSS11-Actual Attempt-P3M|CSS11-Actual Attempt-P3M|CSS1112B	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Have you made a suicide attempt? Have you done anything to harm yourself? Have you done anything dangerous where you could have died? (Past 3 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11804>	C61063	Carboplatin/Gemcitabine/Paclitaxel/Trastuzumab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118050>	C117993	C-SSRS Lifetime/Recent Version - Number of Actual Suicide Attempts (Lifetime)|CSS11-Number of Actual Attempts-Life|CSS11-Number of Actual Attempts-Life|CSS1113A	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Total number of actual attempts. (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118051>	C117993	C-SSRS Lifetime/Recent Version - Number of Actual Suicide Attempts (Past 3 Months)|CSS11-Number of Actual Attempts-P3M|CSS11-Number of Actual Attempts-P3M|CSS1113B	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Total number of actual attempts. (Past 3 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118052>	C117993	C-SSRS Lifetime/Recent Version - Description of Actual Suicide Attempt|CSS11-Actual Attempt, Describe|CSS11-Actual Attempt, Describe|CSS1113C	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Description of actual attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118053>	C117993	C-SSRS Lifetime/Recent Version - Non-suicidal Self-injurious Behavior (Lifetime)|CSS11-Non-suicid Self-injur Behav-Life|CSS11-Non-suicid Self-injur Behav-Life|CSS1114A	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Has subject engaged in non-suicidal self-injurious behavior? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118054>	C117993	C-SSRS Lifetime/Recent Version - Non-suicidal Self-injurious Behavior (Past 3 Months)|CSS11-Non-suicid Self-injur Behav-P3M|CSS11-Non-suicid Self-injur Behav-P3M|CSS1114B	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Has subject engaged in non-suicidal self-injurious behavior? (Past 3 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118055>	C117993	C-SSRS Lifetime/Recent Version - Interrupted Suicide Attempt (Lifetime)|CSS11-Interrupted Attempt-Life|CSS11-Interrupted Attempt-Life|CSS1115A	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Has there been a time when you started to do something to end your life but someone or something stopped you before you actually did anything? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118056>	C117993	C-SSRS Lifetime/Recent Version - Interrupted Suicide Attempt (Past 3 Months)|CSS11-Interrupted Attempt-P3M|CSS11-Interrupted Attempt-P3M|CSS1115B	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Has there been a time when you started to do something to end your life but someone or something stopped you before you actually did anything? (Past 3 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118057>	C117993	C-SSRS Lifetime/Recent Version - Number of Interrupted Suicide Attempts (Lifetime)|CSS11-Num of Interrupted Attempts-Life|CSS11-Num of Interrupted Attempts-Life|CSS1116A	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Total number of interrupted attempts. (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118058>	C117993	C-SSRS Lifetime/Recent Version - Number of Interrupted Suicide Attempts (Past 3 Months)|CSS11-Num of Interrupted Attempts-P3M|CSS11-Num of Interrupted Attempts-P3M|CSS1116B	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Total number of interrupted attempts. (Past 3 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118059>	C117993	C-SSRS Lifetime/Recent Version - Description of Interrupted Suicide Attempt|CSS11-Interrupted Attempt, Describe|CSS11-Interrupted Attempt, Describe|CSS1116C	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Description of interrupted attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11805>	C61007	Temozolomide/Thalidomide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118060>	C117993	C-SSRS Lifetime/Recent Version - Aborted Suicide Attempt (Lifetime)|CSS11-Aborted Attempt-Life|CSS11-Aborted Attempt-Life|CSS1117A	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Has there been a time when you started to do something to try to end your life but you stopped yourself before you actually did anything? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118061>	C117993	C-SSRS Lifetime/Recent Version - Aborted Suicide Attempt (Past 3 Months)|CSS11-Aborted Attempt-P3M|CSS11-Aborted Attempt-P3M|CSS1117B	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Has there been a time when you started to do something to try to end your life but you stopped yourself before you actually did anything? (Past 3 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118062>	C117993	C-SSRS Lifetime/Recent Version - Number of Aborted Suicide Attempts (Lifetime)|CSS11-Number of Aborted Attempts-Life|CSS11-Number of Aborted Attempts-Life|CSS1118A	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Total number of aborted or self-interrupted attempts. (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118063>	C117993	C-SSRS Lifetime/Recent Version - Number of Aborted Suicide Attempts (Past 3 Months)|CSS11-Number of Aborted Attempts-P3M|CSS11-Number of Aborted Attempts-P3M|CSS1118B	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Total number of aborted or self-interrupted attempts. (Past 3 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118064>	C117993	C-SSRS Lifetime/Recent Version - Description of Aborted Suicide Attempt|CSS11-Aborted Attempt, Describe|CSS11-Aborted Attempt, Describe|CSS1118C	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Description of aborted or self-interrupted attempt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118065>	C117993	C-SSRS Lifetime/Recent Version - Preparatory Acts or Behaviors Toward Suicide Attempt (Lifetime)|CSS11-Preparatory Acts/Behavior-Life|CSS11-Preparatory Acts/Behavior-Life|CSS1119A	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Have you taken any steps towards making a suicide attempt or preparing to kill yourself (such as collecting pills, getting a gun, giving valuables away or writing a suicide note)? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118066>	C117993	C-SSRS Lifetime/Recent Version - Preparatory Acts or Behaviors Toward Suicide Attempt (Past 3 Months)|CSS11-Preparatory Acts/Behavior-P3M|CSS11-Preparatory Acts/Behavior-P3M|CSS1119B	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Have you taken any steps towards making a suicide attempt or preparing to kill yourself (such as collecting pills, getting a gun, giving valuables away or writing a suicide note)? (Past 3 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118067>	C117993	C-SSRS Lifetime/Recent Version - Description of Preparatory Acts or Behaviors Toward Suicide Attempt|CSS11-Preparatory Acts/Behavior, Descr|CSS11-Preparatory Acts/Behavior, Descr|CSS1119C	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Description of preparatory acts or behavior.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118068>	C117993	C-SSRS Lifetime/Recent Version - Suicidal Behavior (Lifetime)|CSS11-Suicidal Behavior-Life|CSS11-Suicidal Behavior-Life|CSS1120A	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Suicidal behavior was present during the assessment period? (Lifetime).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118069>	C117993	C-SSRS Lifetime/Recent Version - Suicidal Behavior (Past 3 Months)|CSS11-Suicidal Behavior-P3M|CSS11-Suicidal Behavior-P3M|CSS1120B	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Suicidal behavior was present during the assessment period? (Past 3 Months).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11806>	C61063	Filgrastim-Fetal Liver Tyrosine Kinase-3 Fusion Protein/gp100 Antigen/MART-1 Antigen/Montanide ISA-51/Tyrosinase Peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118070>	C117993	C-SSRS Lifetime/Recent Version - Most Recent Suicide Attempt Date|CSS11-Most Recent Attempt Date|CSS11-Most Recent Attempt Date|CSS1121A	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Most recent attempt date.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118071>	C117993	C-SSRS Lifetime/Recent Version - Most Recent Suicide Attempt Actual Lethality/Medical Damage|CSS11-Most Recent Attempt Damage|CSS11-Most Recent Attempt Damage|CSS1121B	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Most recent attempt actual lethality/medical damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118072>	C117993	C-SSRS Lifetime/Recent Version - Most Recent Suicide Attempt Potential Lethality|CSS11-Most Recent Attempt Potential|CSS11-Most Recent Attempt Potential|CSS1121C	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Most recent attempt potential lethality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118073>	C117993	C-SSRS Lifetime/Recent Version - Most Lethal Suicide Attempt Date|CSS11-Most Lethal Attempt Date|CSS11-Most Lethal Attempt Date|CSS1122A	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Most lethal attempt date.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118074>	C117993	C-SSRS Lifetime/Recent Version - Most Lethal Suicide Attempt Actual Lethality/Medical Damage|CSS11-Most Lethal Attempt Damage|CSS11-Most Lethal Attempt Damage|CSS1122B	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Most lethal attempt actual lethality/medical damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118075>	C117993	C-SSRS Lifetime/Recent Version - Most Lethal Suicide Attempt Potential Lethality|CSS11-Most Lethal Attempt Potential|CSS11-Most Lethal Attempt Potential|CSS1122C	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Most lethal attempt potential lethality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118076>	C117993	C-SSRS Lifetime/Recent Version - First Suicide Attempt Date|CSS11-First Attempt Date|CSS11-First Attempt Date|CSS1123A	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Initial/first attempt date.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118077>	C117993	C-SSRS Lifetime/Recent Version - First Suicide Attempt Actual Lethality/Medical Damage|CSS11-First Attempt Damage|CSS11-First Attempt Damage|CSS1123B	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Initial/first attempt actual lethality/medical damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118078>	C117993	C-SSRS Lifetime/Recent Version - First Suicide Attempt Potential Lethality|CSS11-First Attempt Potential|CSS11-First Attempt Potential|CSS1123C	Columbia-Suicide Severity Rating Scale Lifetime/Recent Version (C-SSRS Lifetime/Recent Version) Initial/first attempt potential lethality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Code Terminology|CDISC Questionnaire C-SSRS Lifetime/Recent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118079>	C117994	ESRS-A - Rigidity: Upper Limbs|ESRSA1-Rigidity: Upper Limbs|ESRSA1-Rigidity: Upper Limbs|ESRSA101	Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Parkinsonism, Rigidity: Upper limbs.			Intellectual Product	CDISC Clinical Classification ESRS-A Test Code Terminology|CDISC Clinical Classification ESRS-A Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11807>	C61007	Bleomycin/Cyclophosphamide/Etoposide/Mitoxantrone/Prednisolone/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118080>	C117994	ESRS-A - Rigidity: Lower Limbs|ESRSA1-Rigidity: Lower Limbs|ESRSA1-Rigidity: Lower Limbs|ESRSA102	Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Parkinsonism, Rigidity: Lower limbs.			Intellectual Product	CDISC Clinical Classification ESRS-A Test Code Terminology|CDISC Clinical Classification ESRS-A Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118081>	C117994	ESRS-A - Rigidity: Neck|ESRSA1-Rigidity: Neck|ESRSA1-Rigidity: Neck|ESRSA103	Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Parkinsonism, Rigidity: Neck.			Intellectual Product	CDISC Clinical Classification ESRS-A Test Code Terminology|CDISC Clinical Classification ESRS-A Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118082>	C117994	ESRS-A - Tremor: Face/Jaw/Chin/Lips/Head|ESRSA1-Tremor: Face/Jaw/Chin/Lips/Head|ESRSA1-Tremor: Face/Jaw/Chin/Lips/Head|ESRSA104	Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Parkinsonism, Tremor: Face, jaw or chin, lips, head.			Intellectual Product	CDISC Clinical Classification ESRS-A Test Code Terminology|CDISC Clinical Classification ESRS-A Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118083>	C117994	ESRS-A - Tremor: Upper Limbs/Hands|ESRSA1-Tremor: Upper Limbs/Hands|ESRSA1-Tremor: Upper Limbs/Hands|ESRSA105	Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Parkinsonism, Tremor: Upper limbs or hands.			Intellectual Product	CDISC Clinical Classification ESRS-A Test Code Terminology|CDISC Clinical Classification ESRS-A Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118084>	C117994	ESRS-A - Tremor: Lower Limbs/Feet|ESRSA1-Tremor: Lower Limbs/Feet|ESRSA1-Tremor: Lower Limbs/Feet|ESRSA106	Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Parkinsonism, Tremor: Lower limbs or feet.			Intellectual Product	CDISC Clinical Classification ESRS-A Test Code Terminology|CDISC Clinical Classification ESRS-A Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118085>	C117994	ESRS-A - Reduced Facial Expression/Speech|ESRSA1-Reduced Facial Expression/Speech|ESRSA1-Reduced Facial Expression/Speech|ESRSA107	Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Parkinsonism: Reduced facial expression or speech.			Intellectual Product	CDISC Clinical Classification ESRS-A Test Code Terminology|CDISC Clinical Classification ESRS-A Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118086>	C117994	ESRS-A - Impaired Gait/Posture|ESRSA1-Impaired Gait/Posture|ESRSA1-Impaired Gait/Posture|ESRSA108	Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Parkinsonism: Impaired gait/posture.			Intellectual Product	CDISC Clinical Classification ESRS-A Test Code Terminology|CDISC Clinical Classification ESRS-A Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118087>	C117994	ESRS-A - Postural Instability|ESRSA1-Postural Instability|ESRSA1-Postural Instability|ESRSA109	Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Parkinsonism: Postural instability.			Intellectual Product	CDISC Clinical Classification ESRS-A Test Code Terminology|CDISC Clinical Classification ESRS-A Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118088>	C117994	ESRS-A - Bradykinesia/Hypokinesia|ESRSA1-Bradykinesia/Hypokinesia|ESRSA1-Bradykinesia/Hypokinesia|ESRSA110	Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Parkinsonism: Bradykinesia or hypokinesia.			Intellectual Product	CDISC Clinical Classification ESRS-A Test Code Terminology|CDISC Clinical Classification ESRS-A Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118089>	C117994	ESRS-A - Dystonia: Tongue|ESRSA1-Dystonia: Tongue|ESRSA1-Dystonia: Tongue|ESRSA111	Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Dystonia: Tongue.			Intellectual Product	CDISC Clinical Classification ESRS-A Test Code Terminology|CDISC Clinical Classification ESRS-A Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11808>	C61063	Eflornithine/Sulindac			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118090>	C117994	ESRS-A - Dystonia: Jaw|ESRSA1-Dystonia: Jaw|ESRSA1-Dystonia: Jaw|ESRSA112	Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Dystonia: Jaw.			Intellectual Product	CDISC Clinical Classification ESRS-A Test Code Terminology|CDISC Clinical Classification ESRS-A Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118091>	C117994	ESRS-A - Dystonia: Eyes/Upper and Lower Face/Larynx|ESRSA1-Dystonia: Eyes/Face/Larynx|ESRSA1-Dystonia: Eyes/Face/Larynx|ESRSA113	Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Dystonia: Eyes, upper face, lower face, larynx.			Intellectual Product	CDISC Clinical Classification ESRS-A Test Code Terminology|CDISC Clinical Classification ESRS-A Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118092>	C117994	ESRS-A - Dystonia: Shoulder/Upper Limbs/Hands|ESRSA1-Dystonia: Shoulder/Up Limb/Hand|ESRSA1-Dystonia: Shoulder/Up Limb/Hand|ESRSA114	Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Dystonia: Shoulders, upper limbs, hands.			Intellectual Product	CDISC Clinical Classification ESRS-A Test Code Terminology|CDISC Clinical Classification ESRS-A Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118093>	C117994	ESRS-A - Dystonia: Hips/Lower Limbs/Feet|ESRSA1-Dystonia: Hips/Lower Limbs/Feet|ESRSA1-Dystonia: Hips/Lower Limbs/Feet|ESRSA115	Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Dystonia: Hips, lower limbs, feet.			Intellectual Product	CDISC Clinical Classification ESRS-A Test Code Terminology|CDISC Clinical Classification ESRS-A Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118094>	C117994	ESRS-A - Dystonia: Trunk/Neck|ESRSA1-Dystonia: Trunk/Neck|ESRSA1-Dystonia: Trunk/Neck|ESRSA116	Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Dystonia: Trunk, neck.			Intellectual Product	CDISC Clinical Classification ESRS-A Test Code Terminology|CDISC Clinical Classification ESRS-A Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118095>	C117994	ESRS-A - Dyskinesia: Tongue|ESRSA1-Dyskinesia: Tongue|ESRSA1-Dyskinesia: Tongue|ESRSA117	Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Dyskinesia: Tongue.			Intellectual Product	CDISC Clinical Classification ESRS-A Test Code Terminology|CDISC Clinical Classification ESRS-A Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118096>	C117994	ESRS-A - Dyskinesia: Jaw|ESRSA1-Dyskinesia: Jaw|ESRSA1-Dyskinesia: Jaw|ESRSA118	Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Dyskinesia: Jaw.			Intellectual Product	CDISC Clinical Classification ESRS-A Test Code Terminology|CDISC Clinical Classification ESRS-A Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118097>	C117994	ESRS-A - Dyskinesia: Eyes/Upper Face/Lower Face|ESRSA1-Dyskinesia: Eyes/Up Face/Low Face|ESRSA1-Dyskinesia: Eyes/Up Face/Low Face|ESRSA119	Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Dyskinesia: Eyes, upper face, lower face.			Intellectual Product	CDISC Clinical Classification ESRS-A Test Code Terminology|CDISC Clinical Classification ESRS-A Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118098>	C117994	ESRS-A - Dyskinesia: Shoulder/Upper Limbs/Hands|ESRSA1-Dyskinesia: Shoulder/Up Limb/Hand|ESRSA1-Dyskinesia: Shoulder/Up Limb/Hand|ESRSA120	Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Dyskinesia: Shoulders, upper limbs, hands.			Intellectual Product	CDISC Clinical Classification ESRS-A Test Code Terminology|CDISC Clinical Classification ESRS-A Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118099>	C117994	ESRS-A - Dyskinesia: Hips/Lower Limbs/Feet|ESRSA1-Dyskinesia: Hips/Lower Limbs/Feet|ESRSA1-Dyskinesia: Hips/Lower Limbs/Feet|ESRSA121	Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Dyskinesia: Hips, lower limbs, feet.			Intellectual Product	CDISC Clinical Classification ESRS-A Test Code Terminology|CDISC Clinical Classification ESRS-A Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11809>	C61063	Celecoxib/Selenium			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1180>	C1283	Recombinant Oncostatin M|OSM	A recombinant 26.0 kDa protein, containing 227 amino acid residues, a member of the cytokine family and growth and differentiation factor that participates in the regulation of neurogenesis, osteogenesis and hematopoiesis. Produced by activated T cells, monocytes and Kaposi's sarcoma cells, oncostatin M (OSM) can exert both stimulatory and inhibitory effects on cell proliferation. It stimulates the proliferation of fibroblasts, smooth muscle cells and Kaposi's sarcoma cells, but inhibits the growth of some normal and tumor cell lines. It also promotes cytokine release (e.g. IL-6, GM-CSF and G-CSF) from endothelial cells, and enhances the expression of low-density lipoprotein receptor in hepatoma cells.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C118100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118100>	C117994	ESRS-A - Dyskinesia: Trunk/Neck|ESRSA1-Dyskinesia: Trunk/Neck|ESRSA1-Dyskinesia: Trunk/Neck|ESRSA122	Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Dyskinesia: Trunk, neck.			Intellectual Product	CDISC Clinical Classification ESRS-A Test Code Terminology|CDISC Clinical Classification ESRS-A Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118101>	C117994	ESRS-A - Akathisia: Subjective|ESRSA1-Akathisia: Subjective|ESRSA1-Akathisia: Subjective|ESRSA123	Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Akathisia: Subjective.			Intellectual Product	CDISC Clinical Classification ESRS-A Test Code Terminology|CDISC Clinical Classification ESRS-A Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118102>	C117994	ESRS-A - Akathisia: Objective|ESRSA1-Akathisia: Objective|ESRSA1-Akathisia: Objective|ESRSA124	Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Akathisia: Objective.			Intellectual Product	CDISC Clinical Classification ESRS-A Test Code Terminology|CDISC Clinical Classification ESRS-A Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118103>	C117994	ESRS-A - CGI-S Parkinsonism|ESRSA1-CGI-S Parkinsonism|ESRSA1-CGI-S Parkinsonism|ESRSA125	Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Clinical Global Impression (CGI-S): Parkinsonism.			Intellectual Product	CDISC Clinical Classification ESRS-A Test Code Terminology|CDISC Clinical Classification ESRS-A Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118104>	C117994	ESRS-A - CGI-S Dystonia|ESRSA1-CGI-S Dystonia|ESRSA1-CGI-S Dystonia|ESRSA126	Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Clinical Global Impression (CGI-S): Dystonia.			Intellectual Product	CDISC Clinical Classification ESRS-A Test Code Terminology|CDISC Clinical Classification ESRS-A Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118105>	C117994	ESRS-A - CGI-S Dyskinesia|ESRSA1-CGI-S Dyskinesia|ESRSA1-CGI-S Dyskinesia|ESRSA127	Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Clinical Global Impression (CGI-S): Dyskinesia.			Intellectual Product	CDISC Clinical Classification ESRS-A Test Code Terminology|CDISC Clinical Classification ESRS-A Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118106>	C117994	ESRS-A - CGI-S Akathisia|ESRSA1-CGI-S Akathisia|ESRSA1-CGI-S Akathisia|ESRSA128	Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Clinical Global Impression (CGI-S): Akathisia.			Intellectual Product	CDISC Clinical Classification ESRS-A Test Code Terminology|CDISC Clinical Classification ESRS-A Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118107>	C103493	FIQR - Activities Sub-Total|FIQR01-Activities Sub-Total|FIQR01-Activities Sub-Total|FIQR0122	Revised Fibromyalgia Impact Questionnaire (FIQR) Activities sub-total.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FIQR Test Code Terminology|CDISC Questionnaire FIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118108>	C103493	FIQR - Overall Impact Sub-Total|FIQR01-Overall Impact Sub-Total|FIQR01-Overall Impact Sub-Total|FIQR0123	Revised Fibromyalgia Impact Questionnaire (FIQR) Overall impact sub-total.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FIQR Test Code Terminology|CDISC Questionnaire FIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118109>	C103493	FIQR - Symptoms Sub-Total|FIQR01-Symptoms Sub-Total|FIQR01-Symptoms Sub-Total|FIQR0124	Revised Fibromyalgia Impact Questionnaire (FIQR) Symptoms sub-total.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FIQR Test Code Terminology|CDISC Questionnaire FIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11810>	C61007	O6-benzylguanine/Temozolomide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118110>	C103493	FIQR - FIQR Total|FIQR01-FIQR Total|FIQR01-FIQR Total|FIQR0125	Revised Fibromyalgia Impact Questionnaire (FIQR) FIQR total.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FIQR Test Code Terminology|CDISC Questionnaire FIQR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118111>	C103495	HADS - Total Score Anxiety|HADS01-Total Score Anxiety|HADS01-Total Score Anxiety|HADS0115	Hospital Anxiety and Depression Scale (HADS) Total score anxiety.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HADS Test Code Terminology|CDISC Questionnaire HADS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118112>	C103495	HADS - Total Score Depression|HADS01-Total Score Depression|HADS01-Total Score Depression|HADS0116	Hospital Anxiety and Depression Scale (HADS) Total score depression.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HADS Test Code Terminology|CDISC Questionnaire HADS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118113>	C80699	MIR17HG Gene|C13orf25|Chromosome 13 Open Reading Frame 25 Gene|FGLDS2|FLJ14178|LINC00048|Long Intergenic Non-Protein Coding RNA 48 Gene|MIHG1|MIR17 Host Gene (Non-Protein Coding) Gene|MIR17HG|MIR17HG|MIRH1|MIRHG1|MiR-17-92 Cluster Host Gene (Non-Protein Coding) Gene|Micro RNA 17 Host Gene|Micro RNA Host Gene 1|MicroRNA Host Gene 1 (Non-Protein Coding) Gene|Mir17 Host Gene|Mir17-92 Cluster Host Gene|NCRNA00048|Non-Protein Coding RNA 48 Gene|ONCOMIR1 Host Gene|RP11-121J7.2|miR-17-92	This polycistronic gene locus is located in the vicinity of 13q31.3 and is approximately 7 kb in length. This locus encodes at least six microRNA genes. Microdeletions within this locus are associated with Feingold syndrome 2. Amplification of this locus may be associated with various cancers.			Gene or Genome	
C118114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118114>	C21176	Interleukin-27|IL-27|IL27|Interleukin 27	A heterodimeric cytokine that is comprised of interleukin-27 subunits alpha and beta. This protein complex is involved in the regulation of B- and T-lymphocyte activities.	Interleukin-27		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118115>	C20462	ABALON Gene|ABALON|ABALON|Apoptotic BCL2L1-Antisense Long Non-Coding RNA Gene	This gene plays a role in the modulation apoptosis.			Gene or Genome	
C118116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118116>	C118115	ABALON wt Allele|Apoptotic BCL2L1-Antisense Long Non-Coding RNA wt Allele|INXS	Human ABALON wild-type allele is located in the vicinity of 20q11.21. This allele, which encodes apoptotic BCL2L1-antisense long non-coding RNA, is involved in the modulation of BCL2L1 protein expression.			Gene or Genome	
C118117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118117>	C88924	Apoptotic BCL2L1-Antisense Long Non-Coding RNA|ABALON|Apoptotic BCL-X-Associated Long ncRNA|INXS|Intronic BCL-XS-Inducing lncRNA	Apoptotic BCL2L1-antisense long non-coding RNA (~2 kb) is encoded by the human ABALON gene. This non-coding RNA plays a role in the regulation of BCL2L1-mediated apoptosis.			Nucleic Acid, Nucleoside, or Nucleotide	
C118118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118118>	C20194	LUNAR1 Gene|LUNAR1|LUNAR1|Leukemia-Associated Non-Coding IGF1R Activator RNA 1 Gene	This gene may play a role in both Notch signaling pathways and leukemogenesis.			Gene or Genome	
C118119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118119>	C118118	LUNAR1 wt Allele|Leukemia-Associated Non-Coding IGF1R Activator RNA 1 wt Allele|Leukemia-Induced Noncoding Activator RNA 1	Human LUNAR1 wild-type allele is located in the vicinity of 15q26.3. This allele, which encodes leukemia-associated non-coding IGF1R activator RNA 1, may be involved in both acute lymphoblastic leukemia and Notch-mediated signaling.			Gene or Genome	
C11811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11811>	C61063	Irinotecan/SU5416			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118120>	C88924	Leukemia-Associated Non-Coding IGF1R Activator RNA 1|LUNAR1|Leukemia-Induced Noncoding Activator RNA	Leukemia-associated non-coding IGF1R activator RNA 1 is encoded by the human LUNAR1 gene. This non-coding RNA plays a role in both leukemogenesis and Notch signaling.			Nucleic Acid, Nucleoside, or Nucleotide	
C118121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118121>	C80699	MIR4457 Gene|MIR4457|MIR4457|MicroRNA 4457 Gene	This gene may plays role in gene silencing.			Gene or Genome	
C118122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118122>	C118121	MIR4457 wt Allele|MicroRNA 4457 wt Allele|hsa-mir-4457|mir-4457	Human MIR4457 wild-type allele is located within chromosome 5 and is approximately 70 bases in length. This allele, which encodes MIR4457 pre-miRNA, may be involved in transcriptional regulation.			Gene or Genome	
C118123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118123>	C25968	MIR4457 Pre-miRNA|hsa-mir-4457|mir-4457	MIR4457 pre-miRNA (68 bases) is encoded by the human MIR4457 gene. This oligoribonucleotide may play a role in the negative regulation of gene transcription.			Nucleic Acid, Nucleoside, or Nucleotide	
C118124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118124>	C20921	LINC-PINT Gene|LINC-PINT|LINC-PINT|Long Intergenic Non-Protein Coding RNA, p53 Induced Transcript Gene	This gene is involved in signaling pathway regulation.			Gene or Genome	
C118125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118125>	C118124	LINC-PINT wt Allele|FLJ43663|LincRNA-Pint Gene|Long Intergenic Non-Protein Coding RNA, p53 Induced Transcript wt Allele|Long Intergenic Noncoding RNA, p53-Induced Transcript Gene|MKLN1 Antisense RNA 1 (Head To Head) Gene|MKLN1-AS1|PINT|hCG_2038586	Human LINC-PINT wild-type allele is located in the vicinity of 7q32.3 and is approximately 168 kb in length. This allele, which encodes long intergenic non-protein coding RNA, p53 induced transcript, plays a role in the transcriptional regulation of signaling protein genes.			Gene or Genome	
C118126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118126>	C88924	Long Intergenic Non-Protein Coding RNA p53 Induced Transcript|LincRNA-Pint|Long Intergenic Noncoding RNA, p53 Induced Transcript|MKLN1 Antisense RNA 1|MKLN1-AS1|PINT|p53 Induced Noncoding Transcript|p53 Induced Transcript	Long intergenic non-protein coding RNA, p53 induced transcript (~3 kb) is encoded by the human LINC-PINT gene. This non-coding RNA is involved in the regulation of signaling protein gene expression.			Nucleic Acid, Nucleoside, or Nucleotide	
C118127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118127>	C80699	MIR1208 Gene|MIR1208|MIR1208|MicroRNA 1208 Gene	This gene may play a role in the modulation of transcription.			Gene or Genome	
C118128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118128>	C118127	MIR1208 wt Allele|MIRN1208|MicroRNA 1208 wt Allele|hsa-mir-1208|mir-1208	Human MIR1208 wild-type allele is located in the vicinity of 8q24.21 and is approximately 70 bases in length. This allele, which encodes MIR1208 pre-miRNA, may be involved in gene silencing.			Gene or Genome	
C118129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118129>	C25968	MIR1208 Pre-miRNA|hsa-mir-1208|mir-1208	MIR1208 Pre-miRNA (73 bases) is encoded by the human MIR1208 gene. This oligoribonucleotide may play a role in transcriptional silencing.			Nucleic Acid, Nucleoside, or Nucleotide	
C11812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11812>	C61063	Cyclosporine/Filgrastim/Methylprednisolone/Monoclonal Antibody Okt3			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118130>	C25941	PPID Gene|PPID|PPID|Peptidylprolyl Isomerase D Gene	This gene plays a role in the catalysis of protein folding.	PPID Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118131>	C118130	PPID wt Allele|CYP-40|CYP40|CYPD|Peptidylprolyl Isomerase D (Cyclophilin D) Gene|Peptidylprolyl Isomerase D wt Allele	Human PPID wild-type allele is located in the vicinity of 4q31.3 and is approximately 14 kb in length. This allele, which encodes peptidyl-prolyl cis-trans isomerase D protein, is involved in protein folding.	PPID wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118132>	C111945	Chronic Choriodeciduitis|Chronic Chorionitis|Chronic Chorionitis	Increased parietal decidual lymphocytes invading the fetal chorion and/or amnion.			Finding	NICHD Terminology|Perinatal Terminology
C118133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118133>	C16759	Peptidyl-Prolyl Cis-Trans Isomerase D|40 kDa Peptidyl-Prolyl Cis-Trans Isomerase|40 kDa Peptidyl-Prolyl Cis-Trans Isomerase D|CYP-40|Cyclophilin 40|Cyclophilin D|Cyclophilin-40|Cyclophilin-Related Protein|EC 5.2.1.8|PPID|PPIase D|Peptidyl-Prolyl Isomerase D|Peptidylprolyl Isomerase D|Rotamase D	Peptidyl-prolyl cis-trans isomerase D (370 aa, ~41 kDa) is encoded by the human PPID gene. This protein plays a role in the isomerization of imidic peptide bonds.	Peptidyl-Prolyl Cis-Trans Isomerase D		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118134>	C111945	Chronic Plasma Cell Deciduitis	The presence of decidual plasma cells, scattered or in aggregate.			Finding	NICHD Terminology|Perinatal Terminology
C118135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118135>	C16897	Amnion Epithelium Necrosis	Loss of the amnionic epithelial surface.			Pathologic Function	NICHD Terminology|Perinatal Terminology
C118136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118136>	C117720	Parietal Decidual Spiral Vessel with Fibrinoid Necrosis-Atherosis	A parietal decidual spiral vessel with small lumen caliber. The muscular wall of the vessel is not identifiable; its expected location shows foamy macrophages (atherosis).			Finding	NICHD Terminology|Perinatal Terminology
C118137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118137>	C67375	Nanomole Bone Collagen Equivalent per Millimole|Nanomoles Bone Collagen Equivalents per Millimole|nmol BCE/mmol|nmol BCE/mmol|umol BCE/mol|{nmolBCE}/mmol|{nmolBCE}/mmol	A unit of relative amount of substance concentration equal to nanomoles of bone collagen equivalent weight per unit of substance concentration equal to one millimole.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C118138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118138>	C12913	Reactive Amniocyte|Reactive Amniocytes	Proliferation and aggregation of amniocytes due to a meconium exposure.			Cell	NICHD Terminology|Perinatal Terminology
C118139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118139>	C117720	Amnion Nodosum	An amnion with nodular deposits of squamous and cellular debris with varying staging of re-epithelialization.			Finding	NICHD Terminology|Perinatal Terminology
C11813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11813>	C61063	Floxuridine/Leucovorin Calcium/Oxaliplatin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118140>	C35867|C117337	Appropriate Placental Villous Maturation	Placental villous microscopic features that are typical for the gestational age at birth.			Finding	NICHD Terminology|Perinatal Terminology
C118141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118141>	C35877	Fetal Circulation with Increased Nucleated Erythrocytes	Increased nucleated red blood cells within the fetal circulation.			Finding	NICHD Terminology|Perinatal Terminology
C118142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118142>	C35867|C117337	Placental Villous Dysmaturity	Placental villous histology not typical of gestational age, with developmentally abnormal features.			Finding	NICHD Terminology|Perinatal Terminology
C118143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118143>	C35867|C117337	Accelerated Placental Villous Maturation	Placental villous histology not typical of gestational age, with features of more mature villi.			Finding	NICHD Terminology|Perinatal Terminology
C118144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118144>	C35867|C117337	Increased Placental Syncytial Knots	Increased number of syncytiotrophoblasts with clusters of apoptotic bodies compared to what would be expected for gestational age.			Finding	NICHD Terminology|Perinatal Terminology
C118145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118145>	C3044|C117337	Placental Villous Fibrosis	Increased density of placental villous stroma, often with decreased capillarization compared to what would be expected for gestational age.			Finding	NICHD Terminology|Perinatal Terminology
C118146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118146>	C117337	Chorangiosis	An increased number of local terminal placental villous capillary cross-sections, generally with decreased capillary caliber, that shows variable distribution of villi.			Finding	NICHD Terminology|Perinatal Terminology
C118147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118147>	C9442|C117337	Placental Fibrinoid Deposition	The presence of a small clot attached to the epithelial surface of a placental villus.			Finding	NICHD Terminology|Perinatal Terminology
C118149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118149>	C35990	Hemosiderin in Decidua Parietalis	The deposition of hemosiderin along the gravid uterine wall.			Finding	NICHD Terminology|Perinatal Terminology
C11814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11814>	C61063	R115777/Trastuzumab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118150>	C35990	Hemosiderin in Decidua Basalis	The deposition of hemosiderin along the gravid uterine fundus beneath the placenta.			Finding	NICHD Terminology|Perinatal Terminology
C118151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118151>	C117337	Hemosiderin in Intervillous Thrombus	The deposition of hemosiderin in a focus of thrombus within the placental intervillous space.			Finding	NICHD Terminology|Perinatal Terminology
C118152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118152>	C35867|C117337	Avascular Placental Villi	Focus of two or more placental terminal villi showing a total loss of villous capillaries and bland hyaline fibrosis of the villous stroma. Stromal karyorrhexis may or may not be evident.			Finding	NICHD Terminology|Perinatal Terminology
C118153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118153>	C117337	Placental Villous Stromal Hemorrhage	Extravascular blood in the chorionic villi.			Finding	NICHD Terminology|Perinatal Terminology
C118154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118154>	C39616|C117337	Placental Villous Stromal-Vascular Karyorrhexis|Hemorrhagic Placental Endovasculitis|Hemorrhagic Placental Endovasculitis	Three or more foci of two or more placental terminal villi showing karyorrhexis of fetal cells with preservation of the surrounding trophoblast. The villi may also show stromal hypercellularity and mineralization, and can either be hypovascular or only exhibit capillary degenerative changes. Entrapped red blood cells and red blood cell fragments are often seen.			Finding	NICHD Terminology|Perinatal Terminology
C118155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118155>	C9442|C117337	Placental Stromal Dusty Mineralization	The deposition of iron and/or calcium within the supporting tissues of the placenta.			Finding	NICHD Terminology|Perinatal Terminology
C118156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118156>	C117337	Absent Physiologic Conversion of Uteroplacental Vessel|Placental Membrane Arteriole Mural Hypertrophy|Placental Membrane Arteriole Mural Hypertrophy	Failure of the maternal spiral arteries to be transformed by extravillous cytotrophoblast to increase blood flow into the placental intervillous spaces, which may lead to an increased risk of early-onset pre-eclampsia and fetal growth restriction.			Finding	NICHD Terminology|Perinatal Terminology
C118157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118157>	C35867|C117337	Chronic Uteroplacental Vasculitis	A lymphocytic inflammation of the uteroplacental vessels.			Finding	NICHD Terminology|Perinatal Terminology
C118158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118158>	C117337	Uteroplacental Vessel Fibrinoid Necrosis with or without Atherosis	The degeneration of an uteroplacental vessel with or without medial foamy macrophages.			Finding	NICHD Terminology|Perinatal Terminology
C118159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118159>	C36184	Basal Decidual Necrosis	Acellular areas of the basal plate.			Finding	NICHD Terminology|Perinatal Terminology
C11815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11815>	C61063	Interleukin-2/Staphylococcal Enterotoxin B			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118160>	C39616	Basal Decidual Karyorrhexis|Necrotizing Deciduitis|Necrotizing Deciduitis	Collections of degenerated nuclear fragments that are associated with tissue injury during placental abruption.			Finding	NICHD Terminology|Perinatal Terminology
C118161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118161>	C4086|C117337	Placental Mesenchymal Dysplasia|Placental Dysplasia|Placental Dysplasia	Aberrant mesenchymal cell growth within the placenta. It may be associated with Beckwith-Wiedemann Syndrome.			Finding	NICHD Terminology|Perinatal Terminology
C118162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118162>	C3124|C117337	Placental Hypertrophy|Placentomegaly|Placentomegaly	Aberrant growth of the placenta.			Finding	NICHD Terminology|Perinatal Terminology
C118163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118163>	C33904	Basal Myofiber|Basal Myofibers	A small focus of the myometrium that peels away along with the placenta and is delivered as part of the basal plate.			Body Part, Organ, or Organ Component	NICHD Terminology|Perinatal Terminology
C118164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118164>	C62085	P Wave Axis|P_AXIS	A numerical representation of the electrocardiographic vector assessed at maximum deviation of the P wave from the isoelectric baseline, usually reported for the frontal plane. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C118165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118165>	C62085	QRS Axis|QRS axis|QRS_AXIS	A numerical representation of the electrocardiographic vector assessed at maximum deviation of the QRS complex from the isoelectric baseline, usually reported for the frontal plane. (CDISC)			Quantitative Concept	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 7: Diagnostic Procedures Terminology|CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C118166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118166>	C62085	T Wave Axis|T_AXIS	A numerical representation of the electrocardiographic vector assessed at maximum deviation of the T wave from the isoelectric baseline, usually reported for the frontal plane. (CDISC)			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C118167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118167>	C40419|C36286	Urinary Leakage|Urinary Leak	Extravasation of urine outside the urinary collecting system.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118168>	C116977	CTRP Disease Terminology|Clinical Trials Reporting Program Disease Terminology	A set of terminology that includes the diseases and neoplastic processes used in NCI-sponsored clinical trials.			Intellectual Product	
C118169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118169>	C116977	CTRP Intervention Terminology|Clinical Trials Reporting Program Intervention Terminology	A set of terminology that includes the interventions and therapies used in NCI-sponsored clinical trials.			Intellectual Product	
C11816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11816>	C61063	Cisplatin/Lurtotecan Liposome			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118170>	C3858	Confusional Arousal|Excessive Sleep Inertia|Excessive Sleep Inertia|Sleep Drunkeness|Sleep Drunkeness	Disorganized thinking, disorientation, or inappropriate responsiveness to external stimuli that occurs during and after awakening.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118171>	C3858	Sleep Paralysis	Temporary inability to speak or move while waking up or falling asleep.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118172>	C34588	Nocturnal Enuresis|Bedwetting|Sleep Enuresis|Sleep Enuresis	Urination during sleep.			Mental or Behavioral Dysfunction	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118173>	C3858	Pressured Speech	Abnormal increased rate and amount of speech, delivered with urgency.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118174>	C37961	Auditory Hallucination	Perception of sound in the absence of a corresponding stimulus.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118175>	C37961	Olfactory Hallucination	Perception of a smell in the absence of a corresponding stimulus.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118176>	C37961	Tactile Hallucination	Perception of pressure or touch in the absence of a corresponding stimulus.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118177>	C37961	Gustatory Hallucination	Perception of a taste in the absence of a corresponding stimulus.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118178>	C37961	Proprioceptive Hallucination	Perception of the orientation of the body in space, manifesting as a sensation of floating, flying, in the absence of a corresponding stimulus.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118179>	C37961	Visual Hallucination	Optical perception of an object, person or event in the absence of a corresponding stimulus.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11817>	C61063	Cyclophosphamide/Dexamethasone/Mitoxantrone			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118180>	C3858|C3368	Hyperphagia	Excessive appetite.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118181>	C18520	M65-Antigen|M-65|M65|M65 Antigen	An antibody epitope that is part of uncleaved cytokeratin 18 found in blood samples. This antigen may be a biomarker for cell death induced by either alcohol consumption or chemotherapeutics.	M65-Antigen		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118182>	C13432	20q11	A chromosome band present on 20q.	20q11		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118183>	C13432	16q23	A chromosome band present on 16q.	16q23		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118184>	C21176	NADH Dehydrogenase (Ubiquinone)|Coenzyme Q Reductase|Complex 1 Dehydrogenase|Complex I|Complex I (Electron Transport Chain)|Complex I (Mitochondrial Electron Transport)|Complex I (NADH:Q1 Oxidoreductase)|DPNH-Coenzyme Q Reductase|DPNH-Ubiquinone Reductase|Dihydronicotinamide Adenine Dinucleotide-Coenzyme Q Reductase|EC 1.6.5.3|Electron Transfer Complex I|Mitochondrial Complex I|Mitochondrial Electron Transport Complex 1|Mitochondrial Electron Transport Complex I|Mitochondrial Respiratory Chain Complex I|NADH Coenzyme Q1 Reductase|NADH-CoQ Oxidoreductase|NADH-CoQ Reductase|NADH-Coenzyme Q Oxidoreductase|NADH-Coenzyme Q Reductase|NADH-Q6 Oxidoreductase|NADH-Ubiquinone Oxidoreductase|NADH-Ubiquinone Reductase|NADH-Ubiquinone-1 Reductase|NADH2 Dehydrogenase (Ubiquinone)|NADH:Ubiquinone Oxidoreductase|NADH:Ubiquinone Oxidoreductase Complex|NADH:Ubiquinone Reductase (H(+)-Translocating)|Reduced Nicotinamide Adenine Dinucleotide-Coenzyme Q Reductase|Respiratory Complex I|Type 1 Dehydrogenase|Ubiquinone Reductase	A complex of over 40 proteins found in the inner mitochondrial membrane. This protein complex catalyzes the transfer of electrons from NADH to ubiquinone (coenzyme Q10) and plays a role in the initiation of the mitochondrial electron transport chain.	NADH Dehydrogenase (Ubiquinone)		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118185>	C182130	C4d|C4D|Complement C4d|Complement Component 4d|Complement Component-4d	C4d (380 aa, ~41 kDa) is a fragment of complement component-4. This protein plays a role in the regulation of the classical and lectin complement pathways. It may be a biomarker for complement activation during antibody-mediated rejection of transplants and in other pathological conditions.	C4d		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118186>	C3858	Acoria|Akoria	Absence of satiety after eating.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118187>	C3858	Bradyphagia	Abnormally slow eating.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118188>	C89332	Sleep Related Eating Disorder	Eating during sleep.			Mental or Behavioral Dysfunction	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118189>	C213595	Hypersexualism	Excessive sexual behavior.			Mental or Behavioral Dysfunction	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11818>	C61063	Cisplatin/Gemcitabine/ZD 1839			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118190>	C89330	Reactive Attachment Disorder of Infancy or Early Childhood	A condition in which the failure to establish healthy bonds with caregivers in early childhood leads to lifelong impairment of social interactions.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118191>	C16295	Influenza Virus Antibody|Anti-Influenza Virus Antibody	Any immunoglobulin that recognizes the influenza virus.	Influenza Virus Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C118192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118192>	C16295	GD3L Antibody|Anti-GD3L Antibody|Anti-Ganglioside Lactone GD3 Antibody|Ganglioside Lactone GD3 Antibody	Any immunoglobulin that recognizes the lactone form of ganglioside GD3.	GD3L Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C118193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118193>	C16295	GD2L Antibody|Anti-GD2L Antibody|Anti-Ganglioside Lactone GD2 Antibody|Ganglioside Lactone GD2 Antibody	Any immunoglobulin that recognizes the lactone form of ganglioside GD2.	GD2L Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C118194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118194>	C16295	Globo H Antibody|Anti-Globo H Antibody	Any immunoglobulin that recognizes the hexasaccharide antigen Globo H.	Globo H Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C118195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118195>	C16295	Fucosyl GM1 Antibody|Anti-Fucosyl GM1 Antibody|Anti-Fucosyl Ganglioside GM1 Antibody|Fucosyl Ganglioside GM1 Antibody	Any immunoglobulin that recognizes the fucosyl form of ganglioside GM1.	Fucosyl GM1 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C118196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118196>	C16295	N-Propionylated Polysialic Acid Antibody|Anti-N-Propionylated Polysialic Acid Antibody|Anti-NPrPSA Antibody|NPrPSA Antibody	Any immunoglobulin that recognizes N-propionylated polysialic acid (NPrPSA).	N-Propionylated Polysialic Acid Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C118197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118197>	C21518	CFP Gene|CFP|CFP|Complement Factor Properdin Gene	This gene plays a role in the promotion of the alternative complement pathway.	CFP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118198>	C118197	CFP wt Allele|BFD|Complement Factor Properdin wt Allele|PFC|PFD|PROPERDIN|Properdin P Factor, Complement Gene	Human CFP wild-type allele is located in the vicinity of Xp11.4 and is approximately 6 kb in length. This allele, which encodes properdin protein, is involved in the positive regulation of the alternative complement pathway. Point mutations in the gene are associated with properdin deficiency.	CFP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118199>	C21523	Properdin|CFP|Complement Factor P|Factor P	Properdin (469 aa, ~51 kDa) is encoded by the human CFP gene. This protein plays a role in the stabilization of complement convertases of the alternative pathway.	Properdin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11819>	C61063	Cyclophosphamide/Cytarabine/Dexamethasone/Mitoxantrone			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1181>	C1450	Oxaliplatin|1-OHP|1-OHP|Ai Heng|Aiheng|DACPLAT|Dacotin|Dacplat|Diaminocyclohexane Oxalatoplatinum|ELOXATIN|Eloxatin|Eloxatin|Eloxatine|Elplat|JM 83|JM-83|JM83|OXALIPLATIN|Oxalatoplatin|Oxalatoplatin|Oxalatoplatinum|Oxalatoplatinum|RP 54780|RP-54780|RP54780|SR 96669|SR-96669|SR96669|[(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum|[SP-4-2-(1R-trans)]-(1,2,cyclohexanediamine-N,N')[ethanedioato(2--)-O,O']platinum|oxalato (1R,2R-cyclohexanediamine)platinum(II)|oxalato (trans-l-1,2-diaminocyclohexane)platinum(II)|oxaliplatin|trans-l DACH oxalatoplatinum|trans-l diaminocyclohexane oxalatoplatinum	An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)	Oxaliplatin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118200>	C89330	Developmental Regression|Regression	Reversion to an earlier stage of development.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118201>	C3858	Cutting Behavior	Self-injury caused by making cuts into the skin.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118202>	C54444	SCHLAP1 Gene|SCHLAP1|SCHLAP1|SWI/SNF Complex Antagonist Associated With Prostate Cancer 1 (Non-Protein Coding) Gene	This gene is involved in the malignancy of prostate cancer.	SCHLAP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118203>	C118202	SCHLAP1 wt Allele|LINC00913|Long Intergenic Non-Protein Coding RNA 913 Gene|PCAT11|PCAT114|Prostate Cancer Associated Transcript 11 Gene|Prostate Cancer-Associated Transcript 114 Gene|SWI/SNF Complex Antagonist Associated With Prostate Cancer 1 (Non-Protein Coding) wt Allele|SWI/SNF Complex Antagonist Associated With Prostate Cancer 1, Noncoding Gene|Second Chromosome Locus Associated With Prostate 1 Gene	Human SCHLAP1 wild-type allele is located in the vicinity of 2q31.3 and is approximately 225 kb in length. This allele, which encodes SWI/SNF complex antagonist associated with prostate cancer 1 long non-coding RNA, may play a role in metastatic prostate cancer.	SCHLAP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118204>	C88924	SWI/SNF Complex Antagonist Associated With Prostate Cancer 1|LINC00913|LincRNA 913|Long Intergenic Non-Protein Coding RNA 913|Long Intergenic Noncoding RNA 913|Prostate Cancer Associated Transcript 11|Prostate Cancer-Associated Transcript 114|SCHLAP1|SChLAP1|Schalp1	SWI/SNF complex antagonist associated with prostate cancer 1 (~1.4 kb) is encoded by the human SCHLAP1 gene. This non-coding RNA may be involved in prostate cancer metastasis.	SWI/SNF Complex Antagonist Associated With Prostate Cancer 1		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118205>	C3858	Homicidal Ideation	Thinking about ending or making plans to end another's life.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118206>	C3858	Self-Injury|Self-Harm|Self-Harm|Self-harm	Self-inflicted harm without the intent to die.			Sign or Symptom	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118207>	C26006	TOMM20 Gene|TOMM20|TOMM20|Translocase of Outer Mitochondrial Membrane 20 Homolog (Yeast) Gene	This gene plays a role in the transport of proteins into the mitochondrion.	TOMM20 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118208>	C118207	TOMM20 wt Allele|MAS20|MAS20, S. cerevisiae, Homolog of Gene|MOM19|RP4-597N16.2|TOM20|Translocase of Outer Mitochondrial Membrane 20 Homolog (Yeast) wt Allele|Translocase of Outer Mitochondrial Membrane 20, S. Cerevisiae, Homolog of Gene	Human TOMM20 wild-type allele is located in the vicinity of 1q42 and is approximately 20 kb in length. This allele, which encodes mitochondrial import receptor subunit TOM20 homolog protein, is involved in transporting proteins from the cytosol into the mitochondrion.	TOMM20 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118209>	C16386	Mitochondrial Import Receptor Subunit TOM20 Homolog|Mitochondrial 20 kDa Outer Membrane Protein|Outer Mitochondrial Membrane Receptor Tom20|TOM-20|TOMM20|Translocase of Outer Mitochondrial Membrane 20 Homolog Type II	Mitochondrial import receptor subunit TOM20 homolog (145 aa, ~16 kDa) is encoded by the human TOMM20 gene. This protein plays a role in mitochondrial protein localization.	Mitochondrial Import Receptor Subunit TOM20 Homolog		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11820>	C67229|C63510	Irinotecan/Temozolomide Regimen|Irinotecan and Temozolomide|Irinotecan and Temozolomide|Irinotecan-Temozolomide|Irinotecan/Temozolomide|Temozolomide-Irinotecan|Temozolomide/Irinotecan|Temozolomide/Irinotecan Regimen	A regimen consisting of irinotecan and temozolomide that can be used for the treatment of Ewing sarcoma or mesenchymal chondrosarcoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C118210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118210>	C25870	FDPS Gene|FDPS|FDPS|Farnesyl Diphosphate Synthase Gene	This gene plays a role in the biosynthesis of isoprenoids.	FDPS Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118211>	C118210	FDPS wt Allele|FPPS|FPS|Farnesyl Diphosphate Synthase wt Allele|Farnesyl Pyrophosphate Synthetase, Dimethylallyltranstransferase, Geranyltranstransferase Gene	Human FDPS wild-type allele is located in the vicinity of 1q22 and is approximately 12 kb in length. This allele, which encodes farnesyl pyrophosphate synthase protein, is involved in isoprenoid biosynthesis.	FDPS wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118212>	C20075	Farnesyl Pyrophosphate Synthetase|(2E,6E)-Farnesyl Diphosphate Synthase|Dimethylallyltranstransferase|EC 2.5.1.1|EC 2.5.1.10|FPP Synthase|FPP Synthetase|Farnesyl Diphosphate Synthase|Farnesylpyrophosphate Synthetase|Geranyltranstransferase	Farnesyl pyrophosphate synthase (419 aa, ~48 kDa) is encoded by the human FDPS gene. This protein plays a role in the synthesis of geranyl pyrophosphate and farnesyl pyrophosphate.	Farnesyl Pyrophosphate Synthetase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118213>	C20744	PCLO Gene|PCLO|PCLO|Piccolo Presynaptic Cytomatrix Protein Gene	This gene is involved in the organization of proteins at the synapse.	PCLO Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118214>	C118213	PCLO wt Allele|ACZ|DKFZp779G1236|KIAA0559|Piccolo (Presynaptic Cytomatrix Protein) Gene|Piccolo Presynaptic Cytomatrix Protein wt Allele|Piccolo, Mouse, Homolog of Gene	Human PCLO wild-type allele is located within 7q11.23-q21.3 and is approximately 409 kb in length. This allele, which encodes protein piccolo, plays a role in the presynaptic cytoskeleton.	PCLO wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118215>	C18073	Protein Piccolo|Aczonin	Protein piccolo (5065 aa, ~553 kDa) is encoded by the human PCLO gene. This protein is involved in the structure and function of neuronal synapses.	Protein Piccolo		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118216>	C25870	HS3ST1 Gene|HS3ST1|HS3ST1|Heparan Sulfate (Glucosamine) 3-O-Sulfotransferase 1 Gene	This gene plays a role in heparan sulfate metabolism.	HS3ST1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118217>	C118216	HS3ST1 wt Allele|3OST|3OST1|H3ST1|Heparan Sulfate (Glucosamine) 3-O-Sulfotransferase 1 wt Allele	Human HS3ST1 wild-type allele is located in the vicinity of 4p16 and is approximately 37 kb in length. This allele, which encodes heparan sulfate glucosamine 3-O-sulfotransferase 1 protein, plays a role in the synthesis of heparan sulfate.	HS3ST1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118218>	C17210	Heparan Sulfate Glucosamine 3-O-Sulfotransferase 1|EC 2.8.2.23|HS3ST1|Heparan Sulfate 3-O-Sulfotransferase 1|Heparan Sulfate D-Glucosaminyl 3-O-Sulfotransferase 1|Heparin-Glucosamine 3-O-Sulfotransferase|h3-OST-1	Heparan sulfate glucosamine 3-O-sulfotransferase 1 (307 aa, ~36 kDa) is encoded by the human HS3ST1 gene. This protein is involved in the synthesis of heparan sulfate and anticoagulant heparan.	Heparan Sulfate Glucosamine 3-O-Sulfotransferase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118219>	C38187	PNOC Gene|PNOC|PNOC|Prepronociceptin Gene	This gene is involved in the modulation of both pain and locomotion.	PNOC Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C11821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11821>	C61063	Anti-human chorionic gonadotropin vaccine/Gemcitabine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118220>	C118219	PNOC wt Allele|N/OFQ|Nocistatin Gene|OFQ|PPNOC|Prepronociceptin wt Allele	Human PNOC wild-type allele is located in the vicinity of 8p21 and is approximately 26 kb in length. This allele, which encodes prepronociceptin protein, is involved in the regulation of the perception of pain.	PNOC wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118221>	C686	PNOC Gene Product	A protein encoded by the PNOC gene.	PNOC Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118222>	C118221	Prepronociceptin|Propronociceptin	Prepronociceptin (176 aa, ~20 kDa) is encoded by the human PNOC gene. This protein is involved in both locomotion and pain perception.	Prepronociceptin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118223>	C118221	Nociceptin|PPNOC	Nociceptin (17 aa, ~2 kDa) is encoded by the human PNOC gene. This protein plays a role in the perception of pain.	Nociceptin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118224>	C20921	SH2D1B Gene|SH2 Domain Containing 1B Gene|SH2D1B|SH2D1B	This gene plays a role in immune receptor signaling.	SH2D1B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118225>	C118224	SH2D1B wt Allele|EAT2|SH2 Domain Containing 1B wt Allele|SH2 Domain-Containing 1B Gene	Human SH2D1B wild-type allele is located in the vicinity of 1q23.3 and is approximately 17 kb in length. This allele, which encodes SH2 domain-containing protein 1B, is involved in signal transduction.	SH2D1B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118226>	C18515	SH2 Domain-Containing Protein 1B|EAT-2|EWS/FLI1-Activated Transcript 2|SH2 Domain-Containing Molecule EAT2	SH2 domain-containing protein 1B (132 aa, ~15 kDa) is encoded by the human SH2D1B gene. This protein plays a role in the regulation of receptor signaling.	SH2 Domain-Containing Protein 1B		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118227>	C28533	SLC8A1 Gene|SLC8A1|SLC8A1|Solute Carrier Family 8 (Sodium/Calcium Exchanger), Member 1 Gene	This gene is involved in the modulation of cardiac muscle cell relaxation.	SLC8A1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118228>	C118227	SLC8A1 wt Allele|CNC|NCX1|Solute Carrier Family 8 (Sodium/Calcium Exchanger), Member 1 wt Allele	Human SLC8A1 wild-type allele is located in the vicinity of 2p22.1 and is approximately 514 kb in length. This allele, which encodes sodium/calcium exchanger 1 protein, plays a role in calcium ion transport.	SLC8A1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118229>	C16386	Sodium/Calcium Exchanger 1|Na(+)/Ca(2+)-Exchange Protein 1|Na+/Ca++ Exchanger|Na+/Ca2+ Exchanger|SLC8A1|Solute Carrier Family 8 Member 1	Sodium/calcium exchanger 1 (973 aa, ~109 kDa) is encoded by the human SLC8A1 gene. This protein is involved in calcium ion transport that regulates cardiac muscle cell relaxation.	Sodium/Calcium Exchanger 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11822>	C61063	Carboplatin/Pyrazoloacridine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118230>	C25790	IGLL1 Gene|IGLL1|IGLL1|Immunoglobulin Lambda Like Polypeptide 1 Gene	This gene plays a role in B-cell development.	IGLL1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118231>	C118230	IGLL1 wt Allele|14.1|AGM2|CD179b|IGL1|IGL5|IGL5, Mouse, Homolog of Gene|IGLJ14.1|IGLL|IGO|IGVPB|Immunoglobulin Lambda Like Polypeptide 1 wt Allele|Immunoglobulin Lambda-Like Polypeptide 1 Gene|Lambda-5, Mouse, Homolog of Gene|VPREB2	Human IGLL1 wild-type allele is located in the vicinity of 22q11.23 and is approximately 7 kb in length. This allele, which encodes immunoglobulin lambda-like polypeptide 1 protein, is involved in the development and function of B-cells. Mutation of the gene is associated with agammaglobulinemia 2.	IGLL1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118232>	C16725	Immunoglobulin Lambda-Like Polypeptide 1|CD179 Antigen-Like Family Member B|CD179b|CD179b Antigen|IGLL1|Ig Lambda-5|Immunoglobulin Omega Polypeptide|Immunoglobulin Omega Polypeptide Chain|Immunoglobulin-Related 14.1 Protein|Immunoglobulin-Related Protein 14.1|Pre-B Lymphocyte-Specific Protein-2	Immunoglobulin lambda-like polypeptide 1 (213 aa, ~23 kDa) is encoded by the human IGLL1 gene. This protein plays a role in both B-cell development and pre-B-cell receptor complex formation.	Immunoglobulin Lambda-Like Polypeptide 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118233>	C27555	Childhood Linear IgA Disease|Chronic Bullous Disease of Childhood|Chronic Bullous Disease of Childhood	A blistering disorder characterized by linear deposition of IgA at the dermoepidermal junction.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118234>	C25941	PPIF Gene|PPIF|PPIF|Peptidylprolyl Isomerase F Gene	This gene is involved in both protein folding and mitochondrial permeability transition pore activity.			Gene or Genome	
C118235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118235>	C118234	PPIF wt Allele|CYP3|CyP-M|Cyp-D|CypD|Peptidylprolyl Isomerase F (Cyclophilin F) Gene|Peptidylprolyl Isomerase F wt Allele	Human PPIF wild-type allele is located within 10q22-q23 and is approximately 8 kb in length. This allele, which encodes peptidyl-prolyl cis-trans isomerase F, mitochondrial protein, plays a role in the modulation of both protein folding and mitochondrial permeability transition pore-induced cell death.			Gene or Genome	
C118236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118236>	C16759	Peptidyl-Prolyl Cis-Trans Isomerase F, Mitochondrial|CyP-D|CyP-M|Cyclophilin 3|Cyclophilin D|Cyclophilin F|CypD|EC 5.2.1.8|Mitochondrial Cyclophilin|PPIF|PPIase F|Peptidyl-Prolyl Cis-Trans Isomerase, Mitochondrial|Peptidyl-Prolyl Cis/Trans Isomerase, Mitochondrial|Peptidylprolyl Isomerase F|Rotamase F	Peptidyl-prolyl cis-trans isomerase F, mitochondrial (207 aa, ~22 kDa) is encoded by the human PPIF gene. This protein is involved in the regulation of both cell death and protein folding.			Amino Acid, Peptide, or Protein|Enzyme	
C118237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118237>	C28404	USP7 Gene|USP7|USP7|Ubiquitin Specific Peptidase 7 (Herpes Virus-Associated) Gene	This gene is involved in protein deubiquitination.			Gene or Genome	
C118238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118238>	C118237	USP7 wt Allele|HAUSP|TEF1|Ubiquitin Specific Peptidase 7 (Herpes Virus-Associated) wt Allele|Ubiquitin Specific Protease 7 (Herpes Virus-Associated) Gene	Human USP7 wild-type allele is located in the vicinity of 16p13.3 and is approximately 72 kb in length. This allele, which encodes ubiquitin carboxyl-terminal hydrolase 7 protein, plays a role in the deubiquitination of other proteins.			Gene or Genome	
C118239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118239>	C16481	Ubiquitin Carboxyl-Terminal Hydrolase 7|Deubiquitinating Enzyme 7|EC 3.4.19.12|Herpes Virus-Associated Ubiquitin-Specific Protease|Herpesvirus-Associated Ubiquitin-Specific Protease|USP7|Ubiquitin Thioesterase 7|Ubiquitin-Specific Protease, Herpesvirus-Associated|Ubiquitin-Specific-Processing Protease 7|VMW110-Associated Protein, 135-kD	Ubiquitin carboxyl-terminal hydrolase 7 (1102 aa, ~128 kDa) is encoded by the human USP7 gene. This protein is involved in catalyzing protein deubiquitination.			Amino Acid, Peptide, or Protein|Enzyme	
C11823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11823>	C67338	Leucovorin Calcium/Methotrexate Regimen|Leucovorin Calcium-Methotrexate|Leucovorin Calcium/Methotrexate|MTX-CF|MTX-CF|Methotrexate w/Leucovorin	A regimen consisting of leucovorin and methotrexate that can be used for the treatment of osteosarcoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C118240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118240>	C28193	Periodic Fever Syndrome	Fevers of unknown etiology recurring over months or years.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C118241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118241>	C26003	CTRB1 Gene|CTRB1|CTRB1|Chymotrypsinogen B1 Gene	This gene plays a role in gastrointestinal proteolysis.			Gene or Genome	
C118242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118242>	C118241	CTRB1 wt Allele|CTRB|Chymotrypsinogen B1 wt Allele	Human CTRB1 wild-type allele is located in the vicinity of 16q23.1 and is approximately 6 kb in length. This allele, which encodes chymotrypsinogen B protein, is involved in the process of digestion in the gastrointestinal tract.			Gene or Genome	
C118243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118243>	C17123	Chymotrypsinogen B|CTRB1|Chymotrypsinogen B1|EC 3.4.21.1	Chymotrypsinogen B (263 aa, ~28 kDa) is encoded by the human CTRB1 gene. This protein plays a role in proteolytic processes during digestion of nutrients.			Amino Acid, Peptide, or Protein|Enzyme	
C118244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118244>	C26003	CTRB2 Gene|CTRB2|CTRB2|Chymotrypsinogen B2 Gene	This gene is involved in the digestive process.			Gene or Genome	
C118245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118245>	C118244	CTRB2 wt Allele|Chymotrypsin B2 Gene|Chymotrypsinogen B2 wt Allele	Human CTRB2 wild-type allele is located in the vicinity of 16q22.1 and is approximately 3 kb in length. This allele, which encodes chymotrypsinogen B2 protein, plays a role in nutrient digestion.			Gene or Genome	
C118246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118246>	C17123	Chymotrypsinogen B2|CTRB2|EC 3.4.21.1	Chymotrypsinogen B2 (263 aa, ~28 kDa) is encoded by the human CTRB2 gene. This protein is involved in the digestion of nutrients by the gastrointestinal tract.			Amino Acid, Peptide, or Protein|Enzyme	
C118247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118247>	C16615	PDX1 Gene|PDX1|PDX1|Pancreatic and Duodenal Homeobox 1 Gene	This gene plays a role in the regulation of insulin and insulin-responsive genes.			Gene or Genome	
C118248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118248>	C118247	PDX1 wt Allele|GSF|IDX-1|IPF1|IUF1|Insulin Promoter Factor 1, Homeodomain Transcription Factor Gene|MODY4|PAGEN1|PDX-1|Pancreatic and Duodenal Homeobox 1 wt Allele|STF-1	Human PDX1 wild-type allele is located in the vicinity of 13q12.1 and is approximately 6 kb in length. This allele, which encodes pancreas/duodenum homeobox protein 1, is involved in transcriptional regulation of insulin and other pancreatic genes. Mutation of the gene is associated with pancreatic agenesis, susceptibility to early-onset insulin-dependent diabetes mellitus, and maturity onset diabetes of the young type 4.			Gene or Genome	
C118249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118249>	C17207	Pancreas/Duodenum Homeobox Protein 1|GSF|Glucose-Sensitive Factor|Homeodomain Transcription Factor IPF1|IDX-1|IUF-1|Insulin Promoter Factor 1|Insulin Upstream Factor 1|Islet/Duodenum Homeobox-1|PDX-1|Pancreatic-Duodenal Homeobox Factor 1|STF-1|Somatostatin Transcription Factor 1|Somatostatin-Transactivating Factor 1	Pancreas/duodenum homeobox protein 1 (283 aa, ~31 kDa) is encoded by the human PDX1 gene. This protein plays a role in the modulation of insulin expression.			Amino Acid, Peptide, or Protein	
C11824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11824>	C61063	Cisplatin/Irinotecan/SU5416			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118250>	C25616	Past 24 Hours|Last 24 Hours|Past 24 hours|Within last 24 hours	The 24 hour period occurring just before the present time.			Temporal Concept	Myeloproliferative Neoplasm Symptom Assessment Form
C118251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118251>	C91105	Myeloproliferative Neoplasm Symptom Assessment Form|MPN-SAF|Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF)	A self-administered questionnaire for monitoring the most debilitating symptoms experienced by patients with myeloproliferative neoplasms.			Intellectual Product	
C118252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118252>	C25719	Worst Imaginable	The most severe state an individual can conceive of experiencing.			Qualitative Concept	
C118253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118253>	C173981	Early Satiety Question|Early Satiety|Filling Up Quickly|Filling up quickly when you eat (Early satiety)	A question about whether an individual has experienced early satiety.			Intellectual Product	
C118254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118254>	C17708	Inactivity|Inactive	A sedentary activity level.	Inactivity		Daily or Recreational Activity	CTRP Terminology
C118255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118255>	C3837	Lightheadedness|Light-headedness|Lightheaded	A feeling of faintness; a reeling sensation. Lightheadedness is medically distinct from dizziness, unsteadiness, and vertigo.			Finding	Food Allergy Quality of Life Questionnaire - Parent Form
C118256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118256>	C21173	Sexual Function	The bodily processes that include arousal, erection, orgasm, and ejaculation.			Physiologic Function	
C118257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118257>	C27993	Unintentional|Inadvertant|Not Deliberate|Not Intended|Unintended	Not done on purpose.			Qualitative Concept	
C118258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118258>	C3671	Thymic Damage	Anatomic injury or physiologic dysfunction of the thymus gland.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118259>	C226740	No Fatigue	A response indicating that an individual has not experienced any fatigue.			Intellectual Product	Myeloproliferative Neoplasm Symptom Assessment Form
C11825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11825>	C61063	Interleukin-2/Stem Cell Factor			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118260>	C226740	Worst Imaginable Fatigue	A response indicating that an individual has experienced the worst fatigue that they can conceive of experiencing.			Intellectual Product	Myeloproliferative Neoplasm Symptom Assessment Form
C118261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118261>	C177167	Does Not Interfere with Enjoyment of Life|Does Not Interfere	A response indicating that a symptom does not interfere with an individual's enjoyment of life.			Intellectual Product	
C118262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118262>	C177167	Completely Interferes	A response indicating that a symptom completely interferes with an individual's enjoyment of life.			Intellectual Product	
C118263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118263>	C226705	Have Numbness or Tingling in Hands and Feet|Numbness/Tingling (in my hands and feet)|Numbness/tingling in hands/feet	A response indicating that an individual has or had numbness or tingling in their hands and feet.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form
C118264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118264>	C176243	Difficulty Absent	A response indicating that an individual has not experienced a particular difficulty.			Intellectual Product	
C118265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118265>	C176243|C175310	Worst Imaginable Difficulty	A response indicating that a particular difficulty is the worst that an individual can conceive of experiencing.			Intellectual Product	
C118266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118266>	C91105	FACT-ES Questionnaire|FACT-ES|Functional Assessment of Cancer Therapy-Endocrine System	A subscale complement to the FACT-G developed specifically for evaluating the quality of life of patients experiencing specific symptoms related to the endocrine system.			Intellectual Product	
C118267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118267>	C91105	FACT-BRM Questionnaire|FACT-BRM|Functional Assessment of Cancer Therapy Biological Response Modifiers Questionnaire	A subscale complement to the FACT-G developed specifically for evaluating the potential side effects of biological response modifiers on cancer patients.			Intellectual Product	
C118269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118269>	C173981	Have Cold Sweats Question|Have Cold Sweats|I have cold sweats	A question about whether an individual has or had cold sweats.			Intellectual Product	FACT-ES Questionnaire
C11826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11826>	C63719|C63586|C63361	FOLFOX/Trastuzumab Regimen|FOLFOX Plus Herceptin|FOLFOX Plus Trastuzumab|FOLFOX/Herceptin|FOLFOX/Trastuzumab|Fluorouracil/Leucovorin Calcium/Oxaliplatin/Trastuzumab|Folinic Acid/Fluorouracil/Oxaliplatin/Trastuzumab|Folinic Acid/Fluorouracil/Oxaliplatin/Trastuzumab Regimen|Oxaliplatin/Leucovorin/Fluorouracil Plus Trastuzumab	A regimen consisting of leucovorin, 5-fluorouracil and oxaliplatin (FOLFOX), plus trastuzumab that can be used for the treatment of esophageal and esophagogastric junction, gastric and colon cancers.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C118270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118270>	C173981	Have Vaginal Discharge Question|Have Vaginal Discharge|I have vaginal discharge	A question about whether an individual has or had vaginal discharge.			Intellectual Product	FACT-ES Questionnaire
C118271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118271>	C173981|C172828	Have Vaginal Itching or Irritation Question|Have Vaginal Itching or Irritation|I have vaginal itching/irritation	A question about whether an individual has or had vaginal itching or vaginal irritation.			Intellectual Product	FACT-ES Questionnaire
C118272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118272>	C179032|C173981	Have Vaginal Bleeding or Spotting Question|Have Vaginal Bleeding or Spotting|I have vaginal bleeding or spotting	A question about whether an individual has or had vaginal bleeding or spotting.			Intellectual Product	FACT-ES Questionnaire
C118273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118273>	C183350|C173981	Have Vaginal Dryness Question|Dryness|Have Vaginal Dryness|I have vaginal dryness|Vaginal Dryness	A question about whether an individual has or had vaginal dryness.			Intellectual Product	FACT-ES Questionnaire|Vaginal Assessment Scale
C118274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118274>	C91126|C173704|C156140	Have Pain or Discomfort with Intercourse Question|Have Pain or Discomfort with Intercourse|Have you had any pain during intercourse|I have pain or discomfort with intercourse|Pain During Intercourse	A question about whether an individual has or had pain or discomfort with intercourse.			Intellectual Product	FACT-ES Questionnaire|Rectal Cancer Female Sexuality Score
C118275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118275>	C173704	Have Lost Interest in Sex Question|Have Lost Interest in Sex|I have lost interest in sex	A question about whether an individual has lost interest in sex.			Intellectual Product	FACT-ES Questionnaire
C118277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118277>	C173600|C173219	Feel Lightheaded or Dizzy Question|Feel Lightheaded or Dizzy|I feel lightheaded (dizzy)	A question about whether an individual feels or felt lightheaded or dizzy.			Intellectual Product	FACT-ES Questionnaire
C118278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118278>	C173981|C173791	Have Breast Sensitivity or Tenderness Question|Have Breast Sensitivity or Tenderness|I have breast sensitivity/tenderness	A question about whether an individual has or had breast sensitivity or tenderness.			Intellectual Product	FACT-ES Questionnaire
C118279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118279>	C173981	Have Mood Swings Question|Have Mood Swings|I have mood swings	A question about whether an individual has or had mood swings.			Intellectual Product	FACT-ES Questionnaire
C11827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11827>	C61063	Dexamethasone/SU5416			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118280>	C91126	Have Painful Joints Question|Have Pain in Joints|Have Pain in My Joints|Have Painful Joints|I have pain in my joints	A question about whether an individual has or had painful joints.			Intellectual Product	FACT-ES Questionnaire
C118281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118281>	C164001|C133878|C129822	Anti-Met/EGFR Monoclonal Antibody LY3164530|LY-3164530|LY3164530	A monoclonal antibody (MoAb) against human epidermal growth factor receptor (EGFR) and human hepatocyte growth factor receptor (HGFR or c-Met), with potential antineoplastic activity. Upon administration, anti-Met/EGFR MoAb LY3164530 targets and prevents the activation of EGFR and c-Met. This leads to a downstream inhibition of EGFR/c-Met-mediated signal transduction pathways, and prevents cellular proliferation in tumor cells overexpressing EGFR and c-Met. EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surface of various solid tumor cell types. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118282>	C96040	Efizonerimod|EFIZONERIMOD|Efizonerimod Alfa|Immunoglobulin G4 (10-proline) (Human Heavy Chain Fc Fragment) Fusion Protein with Tumor Necrosis Factor Receptor-associated Factor TRAF2 (Human C-C Domain Fragment) Fusion Protein with CD252 Antigen (Human Extracellular Domain Fragment), Hexamer|MEDI6383	An agonistic monoclonal antibody against receptor OX40 (CD134), with potential immunostimulatory activity. Upon administration, efizonerimod selectively binds to and activates the OX40 receptor, by mimicking the action of endogenous OX40 ligand (OX40L). OX40 receptor activation induces proliferation of memory and effector T lymphocytes. In the presence of tumor-associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor family, is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T cells.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118283>	C177285	OxPhos Inhibitor VLX600|1-(2-Pyridinyl)ethanone(6-methyl-5H-[1,2,4]triazino[5,6-b]indol-3-yl)hydrazone|VLX-600|VLX-600	A lipophilic cation-based triazinoindolyl-hydrazone compound and mitochondrial oxidative phosphorylation (OxPhos) inhibitor, with potential antineoplastic activity. Upon infusion, in normal cells and proliferating tumor cells where glucose is readily available, inhibition of OxPhos by VLX600 induces a hypoxia-inducible factor 1-alpha (HIF-1alpha)-dependent shift to, and an increase in glycolysis. Glycolysis alone does not produce enough energy to support the growth of tumor cells in this environment, and the induction of autophagy occurs. In the metabolically compromised tumor microenvironment, the availability of oxygen and glucose is limited due to poor vascularization and perfusion of tumor micro-areas. Tumor cells growing in this environment are thus unable to compensate for decreased mitochondrial function by increasing glycolysis. This leads to nutrient depletion, decreased energy production, induction of autophagy, tumor cell death and an inhibition of cell proliferation in quiescent tumor cells. Mitochondrial OxPhos, which is hyperactivated in cancer cells, plays a key role in the promotion of cancer cell proliferation.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118284>	C20401|C199675|C129822	Zilovertamab|Cirmtuzumab|UC-961|ZILOVERTAMAB	A humanized monoclonal antibody against the extracellular domain of the human receptor tyrosine kinase-like orphan receptor 1 (ROR1), with potential antineoplastic activity. Upon administration, zilovertamab binds to ROR1 and blocks ROR1-mediated signaling. This prevents tumor cell proliferation in cancer cells overexpressing ROR1. ROR1, also known as neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), is normally expressed during embryogenesis.  It is overexpressed in certain leukemias and solid tumors, but minimally expressed in healthy cells.	Zilovertamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118285>	C471	Denifanstat|ASC 40|ASC-40|ASC40|DENIFANSTAT|FASN Inhibitor TVB-2640|TVB 2640|TVB-2640|TVB2640	An orally bioavailable fatty acid synthase (FASN) inhibitor, with potential antineoplastic activity. Upon administration, denifanstat binds to and blocks FASN, which prevents the synthesis of palmitate needed for tumor cell growth and survival. This leads to a reduction in cell signaling, an induction of tumor cell apoptosis and the inhibition of cell proliferation in susceptible tumor cells. FASN, an enzyme responsible for the de novo synthesis of palmitic acid, is overexpressed in tumor cells and plays a key role in tumor metabolism, lipid signaling, tumor cell survival and drug resistance; tumor cells are dependent on increased fatty acid production for their enhanced metabolic needs and rapid growth.	Denifanstat		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118286>	C15696	Stereotactic Body Radiation Therapy|SABR|SBRT|SBRT|Stereotactic Ablative Body Radiation Therapy|stereotactic body radiation therapy	Stereotactic radiation therapy in which one or several maximum dose radiation treatments are delivered targeting cancers of the body, excluding the brain or spine.	Stereotactic Body Radiation Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C118287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118287>	C471	p97 Inhibitor CB-5083|CB-5083|CB-5083	An orally bioavailable inhibitor of valosin-containing protein (VCP) p97, with potential antineoplastic activity. Upon oral administration, CB-5083 specifically binds to and inhibits the activity of p97. This prevents ubiquitin-dependent protein degradation and causes cellular accumulation of poly-ubiquitinated proteins. The inhibition of endoplasmic reticulum (ER)-associated protein degradation activates the ER-dependent stress response pathway, and leads to both an induction of apoptosis and inhibition of cell proliferation in susceptible tumor cells. p97, a type II AAA ATPase, plays a key role in cellular protein homeostasis. Its overexpression in many tumor cell types is associated with increased tumor cell proliferation and survival.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118288>	C1557	Oral Azacitidine|Azacitidine Oral|Azacitidine oral|CC 486|CC-486|CC486|Onureg	An orally bioavailable formulation of azacitidine, a pyrimidine nucleoside analogue of cytidine, with antineoplastic activity. Upon oral administration, azacitidine is taken up by cells and metabolized to 5-azadeoxycitidine triphosphate. The incorporation of 5-azadeoxycitidine triphosphate into DNA reversibly inhibits DNA methyltransferase, and blocks DNA methylation. Hypomethylation of DNA by azacitidine may re-activate tumor suppressor genes previously silenced by hypermethylation, resulting in an antitumor effect. In addition, the incorporation of 5-azacitidine triphosphate into RNA disrupts normal RNA function and impairs tRNA (cytosine-5)-methyltransferase activity, resulting in an inhibition of RNA and protein synthesis.			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118289>	C2167|C129825	Zorifertinib|AZD3759|ZORIFERTINIB	An orally available inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration,  zorifertinib binds to and inhibits the activity of EGFR as well as certain mutant forms of EGFR. This prevents EGFR-mediated signaling, and may lead to both induction of cell death and inhibition of tumor growth in EGFR-overexpressing cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.	Zorifertinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11828>	C61007	Gemcitabine/Pemetrexed Disodium			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118290>	C213472|C1742|C129825	Altiratinib|1,1-Cyclopropanedicarboxamide, N-(4-((2-((cyclopropylcarbonyl)amino)-4-pyridinyl)oxy)-2,5-difluorophenyl)-N'-(4-fluorophenyl)-|ALTIRATINIB|DCC-2701	An orally bioavailable inhibitor of c-Met/hepatocyte growth factor receptor (HGFR), vascular endothelial growth factor receptor type 2 (VEGFR2), Tie2 receptor tyrosine kinase (TIE2), and tropomyosin receptor kinase (Trk), with potential antiangiogenic and antineoplastic activities. Upon administration, altiratinib selectively binds to c-Met, VEGFR2, Tie2 and Trk tyrosine kinases, which may lead to the inhibition of endothelial cell migration, proliferation and survival. This also results in both an inhibition of tumor cell proliferation and increased tumor cell death in c-Met/VEGFR2/Tie2/Trk-expressing cells. These receptor tyrosine kinases (RTKs), frequently overexpressed or mutated by a variety of tumor cell types, play crucial roles in the regulation of angiogenesis, tumor cell growth and survival.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118291>	C29631|C226455	Diphenhydramine/Lidocaine/Antacid Mouthwash|DLA Mouthwash	An oral rinse containing the antihistamine diphenhydramine hydrochloride, the topical anesthetic agent lidocaine, and the antacids aluminum hydroxide and magnesium hydroxide (DLA), with potential analgesic and anti-mucositic activities. Upon swishing and gargling with the DLA rinse, the diphenhydramine may provide analgesia; the lidocaine exerts an anesthetic activity which may further relieve mucositis-associated pain; the antacids, aluminum and magnesium hydroxide, are able to provide a coating of the rinse over the lesions in the oral mucosa and neutralize acids. Altogether, this rinse may reduce the symptoms of chemo- and radiotherapy-induced mucositis.	Diphenhydramine/Lidocaine/Antacid Mouthwash		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C118292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118292>	C129821|C129820	Ropocamptide|Antimicrobial Peptide, Human LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES|Cathelicidin LL-37|LL-37|ROPOCAMPTIDE	A synthetic form of a human antimicrobial peptide (37 amino acids), belonging to the cathelicidin family, with antimicrobial, anti-inflammatory, immunostimulating and potential antineoplastic activities. Upon intratumoral injection of the ropocamptide, this peptide increases p53 expression, and induces phosphatidylserine externalization, DNA fragmentation, cell cycle arrest and caspase-independent apoptosis-inducing factor (AIF)/ endonuclease G (EndoG)-mediated apoptotic cell death in susceptible cancer cells. This suppresses tumor cell proliferation.  LL-37, a protein secreted by bone marrow cells, circulating leukocytes, and various epithelial tissues, plays a crucial role in the innate host immune defense via the regulation of leukocyte chemotaxis and cytokine production; it also promotes wound healing.	Ropocamptide		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118293>	C29631|C226455	Miracle Mouthwash Plus Hydrocortisone|MMW Plus HC	An oral rinse containing miracle mouthwash and the corticosteroid hydrocortisone, with potential anti-mucositic activity. Upon rinsing with this mouthwash, the ingredients in the miracle mouthwash may provide analgesia; the hydrocortisone modulates the production of pro-inflammatory cytokines which may prevent inflammation of the oral mucosa, and reduce chemotherapy- and/or radiation-induced oral mucositis.			Organic Chemical|Pharmacologic Substance	NCI Drug Dictionary Terminology
C118294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118294>	C2336	Donafenib|2-Pyridinecarboxamide, 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-(methyl-d3)-|4-(4-((4-Chloro-3-(trifluoromethyl)phenyl)carbamoylamino)phenoxy)-N-(trideuteriomethyl)pyridine-2-carboxamide|CM 4307|CM-4307|CM4307|DONAFENIB|Zepsun	An orally available multikinase inhibitor that targets Raf kinase and various receptor tyrosine kinases (RTKs), with potential antineoplastic activity. Upon oral administration, donafenib binds to and blocks the activity of Raf kinase, and inhibits Raf-mediated signal transduction pathways. This inhibits cell proliferation in Raf-expressing tumor cells. In addition, this agent may inhibit unidentified RTKs, and thus may further block tumor cell proliferation in susceptible tumor cells. Raf, a serine/threonine protein kinase, plays a key role in the Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway. Deregulation of this pathway often results in tumor cell proliferation and survival.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118295>	C1511	Zirconium Zr 89 Girentuximab|89Zr-DFO-TFP-girentuximab|89Zr-TLX250|89Zr-girentuximab|Zirconium Zr 89 cG250|Zirconium Zr 89-TLX250	A radioimmunoconjugate comprised of the recombinant chimeric monoclonal antibody girentuximab, that binds an extracellular epitope of carbonic anhydrase IX (CAIX), and labeled with the radioisotope zirconium 89 (Zr 89) with potential use as an imaging agent upon positron emission tomography (PET). The antibody moiety of zirconium Zr 89 girentuximab binds to CAIX expressed on tumor cells. Upon binding, the radioisotope moiety may be detected using PET, which enables the imaging and quantification of CAIX-expressing tumor cells. CAIX, a hypoxia-inducible transmembrane glycoprotein, is overexpressed on renal cell carcinoma (RCC) and various other tumors; it plays a key role in intra- and extracellular pH regulation, cancer cell progression, survival, migration and invasion.	Zirconium Zr 89 Girentuximab		Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C118296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118296>	C797|C2081|C1509|C1505	Palm Extract Phytonutrient Supplement|PALM OIL TOCOTRIENOL-RICH EXTRACT|PPALM-Palm Oil|Tocovid SupraBio	A nutritional supplement composed of a palm oil extract containing high concentrations of mixed tocotrienols, tocopherols, carotenoids, phytosterols, and squalene, with antioxidant and potential hepato-, neuro-, and radio-protective activities. Upon oral administration, the palm extract phytonutrient supplement exerts an antioxidant effect by scavenging free radicals and inhibiting lipid peroxidation. This extract also prevents inflammation by inhibiting the expression of pro-inflammatory cytokines. Altogether, this prevents oxidative stress in cells and may improve symptoms of radiation-induced fibrosis. In addition, this supplement may modulate enzymes that play key roles in neuronal cell degeneration and fatty acid accumulation.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C118297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118297>	C79598|C2890	Bacterial Meningitis	Inflammation of the membranes surrounding the brain and spinal cord due to a bacterial infection.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118298>	C79598|C3439	Viral Meningitis	Inflammation of the membranes surrounding the brain and spinal cord due to a viral infection.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118299>	C26828	Aseptic Meningitis	Inflammation of the membranes surrounding the brain and spinal cord without a bacterial pathogen.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11829>	C61007	Arsenic trioxide/Ascorbic acid			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1182>	C2107	Piroxantrone|Anthra(1,9-cd)pyrazol-6(2H)-one, 5-((3-aminopropyl)amino)-7,10-dihydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)|CI-942|PD-111815|PIROXANTRONE	An anthrapyrazole antineoplastic antibiotic.  Piroxantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  Although less cardiotoxic than doxorubicin, this agent exhibits a narrow spectrum of antineoplastic activity. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118300>	C99208	Retinopathy of Prematurity Finding	An ophthalmoscopic finding that refers to retinopathy of prematurity.			Finding	
C118301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118301>	C3368	Sialorrhea|Hypersalivation	An increase in saliva secretion.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118302>	C87124	Sedated|Sedation|Sedation	A state of a lowered level of consciousness.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118303>	C5035|C36286	Polyuria	Excessive or frequent urination.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118304>	C5042	Micropsia	An alteration in visual perception that causes objects to appear smaller than their actual size.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118305>	C5042	Macropsia	An alteration in visual perception that causes objects to appear larger than their actual size.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118306>	C35596	Tooth Malformation	Any abnormality in the growth or formation of one or more teeth.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118307>	C50440	White Matter Injury	Focal areas of necrosis, with or without cysts, and diffuse areas of white matter dysmaturation with maturation arrest of the pre-oligodendroglia cells, located in the cerebral white matter.			Finding	NICHD Terminology|Perinatal Terminology
C118308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118308>	C3045	Sacral Fistula	A pathologic communication between the skin and the dural space that is located 5-25 mm from the anal verge.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C118309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118309>	C33556	Coccygeal Sinus|Coccygeal Pit	A blind-ending, epithelial-lined tract that is located less than 5 mm from the anal verge.			Anatomical Structure	NICHD Terminology|Perinatal Terminology
C11830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11830>	C61063	Doxorubicin/Methotrexate/Pegaspargase/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118310>	C28193	Insufficient Breast Milk Syndrome|Insufficient Milk Syndrome	Failure to thrive due to poor intake by the infant, inadequate feeding schedule or insufficient maternal production of breast milk.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C118311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118311>	C94299|C177692	Hormone Receptor/HER2 Positive|ER+PR+HER2/neu+|ER/PR/HER2 Postive|Hormone Receptor/Epidermal Growth Factor Receptor 2 Positive|Triple Positive|Triple-Positive|Triple-Positive Breast Cancer Finding	A finding indicating that the neoplastic cells in a breast cancer tissue sample test positive for estrogen, progesterone, and HER2 receptors.			Laboratory or Test Result	
C118312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118312>	C99232	Neonatal Aspiration Syndrome	Aspiration of meconium, blood, amniotic fluid or gastric contents around the time of delivery resulting in clinical symptoms from airway obstruction, parenchymal injury, and ventilation-perfusion mismatch. This may lead to persistent pulmonary hypertension in the newborn.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C118313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118313>	C98700	Ventral Hernia	The protrusion of abdominal cavity contents through the anterior abdominal wall.			Anatomical Abnormality	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118314>	C241|C1509	L-4-chlorokynurenine|4-Cl-KYN|AV-101|AV-101|L-4-C1-KYN	An orally bioavailable, blood brain barrier (BBB) penetrating, chlorinated analog of the endogenous neuromodulator kynurenic acid and prodrug of 7-chlorokynurenic acid (7-Cl-KYNA), a N-methyl-D-aspartate receptor (NMDA-R) antagonist at the glycine-coagonist (GlyB) site, with potential anti-hyperalgesic, neuroprotective and anti-epileptic activities. Unlike 7-Cl-KYNA, L-4-chlorokynurenine, upon oral administration, crosses the BBB and is enzymatically converted, through transamination, within activated astrocytes located at sites of injury in the central nervous system (CNS) to its active metabolite, 7-Cl-KYNA, which allows for high levels of this active metabolite at these specific sites. In turn, 7-Cl-KYNA selectively binds to and blocks the GlyB site within the NMDA receptors. This inhibits both NMDA-R overstimulation by the excitatory neurotransmitter glutamate and NMDA-R-mediated excitotoxicity, which prevents neuronal damage and induces analgesia. In addition, another metabolite, 4-chloro-3-hydroxyanthranilic acid, inhibits the synthesis of quinolinic acid, an endogenous NMDA receptor agonist, thereby further preventing excitotoxic damage. Compared to conventional NMDA-R antagonists, NMDA-R GlyB-specific antagonists appear to have fewer side effects.	L-4-chlorokynurenine		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C118315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118315>	C333|C245|C241	T-type Calcium Channel Blocker ABT-639|ABT-639|ABT-639|Benzenesulfonamide, 4-Chloro-2-fluoro-N-(2-fluorophenyl)-5-(((8AR)-hexahydropyrrolo(1,2-A)pyrazin-2(1H)-yl)carbonyl)-	An orally bioavailable, CaV3.2 T-type calcium channel blocker with potential anti-hyperalgesic activity. Upon oral administration, ABT-639 selectively binds to and blocks the CaV3.2 isoform of the low voltage-gated T-type calcium channels located in peripheral sensory neurons. This prevents the influx of calcium ions into the cell upon membrane depolarization. The inhibition of both neuronal hyperexcitability and firing of nociceptive, peripheral sensory neurons induces an anti-nociceptive effect. The expression of the CaV3.2 T-type channels plays a key role in nociceptive and neuropathic pain.	T-type Calcium Channel Blocker ABT-639		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C118316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118316>	C3426	Mucosal Ulcer	A circumscribed loss of integrity of the mucous membrane.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Rheumatology Terminology
C118317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118317>	C27573|C214794|C166355	Non-Neoplastic Muscle Disorder	A non-neoplastic disorder that affects the smooth, skeletal, or cardiac muscles.			Disease or Syndrome	
C118318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118318>	C118317	Rhabdomyolysis	A clinical syndrome resulting from direct or indirect muscle injury and subsequent release of myoglobin into the plasma.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Nephrology Terminology|SeroNet Authorized Values|SeroNet Study Descriptors
C118319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118319>	C133710	ZNRF3 Gene|ZNRF3|ZNRF3|ZNRF3|Zinc and Ring Finger 3 Gene	This gene is involved in protein ubiquitination and Wnt pathway inhibition.	ZNRF3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C11831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11831>	C61063	Cyclophosphamide/Methotrexate/Pegaspargase/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118320>	C118319	ZNRF3 wt Allele|BK747E2.3|FLJ22057|KIAA1133|Novel C3HC4 Type Zinc Finger (Ring Finger) Gene|RNF203|Zinc and Ring Finger 3 wt Allele|hCG_40978	Human ZNRF3 wild-type allele is located in the vicinity of 22q12.1 and is approximately 174 kb in length. This allele, which encodes E3 ubiquitin-protein ligase ZNRF3 protein, plays a role in the both Wnt pathway modulation and protein modification.	ZNRF3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118321>	C21254	E3 Ubiquitin-Protein Ligase ZNRF3|EC 2.3.2.27|EC 6.3.2.-, Formerly|RING Finger Protein 203|Zinc Finger and Ring Finger Protein 3|Zinc/RING Finger Protein 3	E3 ubiquitin-protein ligase ZNRF3 (936 aa, ~101 kDa) is encoded by the human ZNRF3 gene. This protein is involved in the ubiquitination of Wnt pathway proteins.	E3 Ubiquitin-Protein Ligase ZNRF3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118322>	C26147	ABO Gene|ABO|ABO|ABO Blood Group (Transferase A, Alpha 1-3-N-Acetylgalactosaminyltransferase; Transferase B, Alpha 1-3-Galactosyltransferase) Gene	This gene is involved in blood group determination.			Gene or Genome	
C118323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118323>	C118322	ABO wt Allele|A3GALNT|A3GALT1|ABO Blood Group (Transferase A, Alpha 1-3-N-Acetylgalactosaminyltransferase; Transferase B, Alpha 1-3-Galactosyltransferase) wt Allele|GTB|NAGAT	Human ABO wild-type allele is located in the vicinity of 9q34.2 and is approximately 2 kb in length. This allele, which encodes histo-blood group ABO system transferase protein, plays a role in blood group determination. Variation of the gene determines whether the protein can catalyze the transfer of carbohydrates to the H antigen to form carbohydrate antigen A or B on the surface of red blood cells.			Gene or Genome	
C118324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118324>	C17434	Histo-Blood Group ABO System Transferase|A Transferase|ABO A3 Transferase|ABO Glycosyltransferase|ABO Histo-Blood Group Glycosyltransferases|ABO Weak Transfer|B Transferase|B(A) Alpha-1,3-Galactosyltransferase|EC 2.4.1.37|EC 2.4.1.40|Fucosylglycoprotein 3-Alpha-Galactosyltransferase|Fucosylglycoprotein Alpha-N-Acetylgalactosaminyltransferase|Glycoprotein-Fucosylgalactoside Alpha-Galactosyltransferase|Glycoprotein-Fucosylgalactoside Alpha-N-Acetylgalactosaminyltransferase|Histo-Blood Group A Transferase|Histo-Blood Group A2 Transferase|Histo-Blood Group B Transferase|NAGAT|Transferase A, Alpha 1-3-N-Acetylgalactosaminyltransferase|Transferase B, Alpha 1-3-Galactosyltransferase	Histo-blood group ABO system transferase (354 aa, ~41 kDa) is encoded by the human ABO gene. This protein is involved in blood group antigen expression.			Amino Acid, Peptide, or Protein|Enzyme	
C118325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118325>	C21275	ADAMTS13 Gene|ADAM Metallopeptidase With Thrombospondin Type 1 Motif, 13 Gene|ADAMTS13|ADAMTS13	This gene plays a role in von Willebrand factor function.	ADAMTS13 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118326>	C118325	ADAMTS13 wt Allele|A Disintegrin-Like and Metalloprotease (Reprolysin Type) With Thrombospondin Type 1 Motif, 13 Gene|A Disintegrin-Like and Metalloprotease With Thrombospondin Type 1 Motif, 13 Gene|ADAM Metallopeptidase With Thrombospondin Type 1 Motif, 13 wt Allele|ADAM-TS13|ADAMTS-13|C9orf8|DKFZp434C2322|MGC118899|MGC118900|UNQ6102/PRO20085|VWFCP|vWF-CP	Human ADAMTS13 wild-type allele is located in the vicinity of 9q34 and is approximately 45 kb in length. This allele, which encodes a disintegrin and metalloproteinase with thrombospondin motifs 13 protein, is involved in the processing of von Willebrand factor multimers. Mutation of the gene is associated with congenital thrombotic thrombocytopenic purpura.	ADAMTS13 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118327>	C16843	A Disintegrin and Metalloproteinase with Thrombospondin Motifs 13|A Disintegrin and Metalloprotease with Thrombospondin Motifs-13|A Disintegrin and Metalloproteinase With Thrombospondin Motifs 13|A Disintegrin and Metalloproteinase with Thrombospondin Type 1 Motif 13|ADAM Metallopeptidase With Thrombospondin Type 1 Motif 13|ADAM-TS 13|ADAM-TS13|ADAMTS-13|ADAMTS13|ADAMTS13|EC 3.4.24.87|Von Willebrand Coagulation Factor Cleaving Protease|vWF-CP|vWF-Cleaving Protease	A disintegrin and metalloproteinase with thrombospondin motifs 13 (1427 aa, ~154 kDa) is encoded by the human ADAMTS13 gene. This protein plays a role in the proteolysis of von Willebrand factor multimers.	A Disintegrin and Metalloproteinase With Thrombospondin Motifs 13		Amino Acid, Peptide, or Protein|Enzyme	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118328>	C25804	TRIP13 Gene|TRIP13|TRIP13|Thyroid Hormone Receptor Interactor 13 Gene	This gene is involved in meiotic recombination.			Gene or Genome	
C118329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118329>	C118328	TRIP13 wt Allele|16E1BP|MVA3|OOMD9|OZEMA9|PCH2|Thyroid Hormone Receptor Interactor 13 wt Allele	Human TRIP13 wild-type allele is located in the vicinity of 5p15.33 and is approximately 27 kb in length. This allele, which encodes pachytene checkpoint protein 2 homolog protein, plays a role in chromosome recombination in meiosis.			Gene or Genome	
C11832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11832>	C61063	Daunorubicin/dexamethasone/methotrexate/vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118330>	C16701	Pachytene Checkpoint Protein 2 Homolog|16E1-BP|HPV16 E1 Protein Binding Protein|HPV16 E1 Protein-Binding Protein|Human Papillomavirus Type 16 E1 Protein-Binding Protein|TR-Interacting Protein 13|TRIP-13|TRIP13|Thyroid Hormone Receptor Interactor 13|Thyroid Receptor Interacting Protein 13|Thyroid Receptor-Interacting Protein 13	Pachytene checkpoint protein 2 homolog (432 aa, ~49 kDa) is encoded by the human TRIP13 gene. This protein plays a role in meiotic chromosome recombination.			Amino Acid, Peptide, or Protein|Enzyme	
C118331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118331>	C21165	TNFRSF25 Gene|TNFRSF25|TNFRSF25|Tumor Necrosis Factor Receptor Superfamily, Member 25 Gene	This gene plays a role in cytokine-mediated apoptosis.			Gene or Genome	
C118332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118332>	C118331	TNFRSF25 wt Allele|APO-3|APO3|DDR3|DR3|LARD|RP4-650H14.2|TNFR25|TNFRSF12|TR3|TRAMP|Tumor Necrosis Factor Receptor Superfamily, Member 12 (Translocating Chain-Association Membrane Protein) Gene|Tumor Necrosis Factor Receptor Superfamily, Member 12 Gene|Tumor Necrosis Factor Receptor Superfamily, Member 25 wt Allele|UNQ455/PRO779|WSL|WSL-1|WSL-LR|WSL1	Human TNFRSF25 wild-type allele is located in the vicinity of 1p36.2 and is approximately 5 kb in length. This allele, which encodes tumor necrosis factor receptor superfamily member 25 protein, is involved in the positive regulation of apoptosis.			Gene or Genome	
C118333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118333>	C19285	Tumor Necrosis Factor Receptor Superfamily Member 25|Apo-3|Apoptosis Inducing Receptor|Apoptosis-Inducing Receptor AIR|Apoptosis-Mediating Receptor DR3|Apoptosis-Mediating Receptor TRAMP|Death Receptor 3|LARD|Lymphocyte-Associated Receptor of Death|Protein WSL|Protein WSL-1|Translocating Chain-Association Membrane Protein	Tumor necrosis factor receptor superfamily member 25 (417 aa, ~45 kDa) is encoded by the human TNFRSF25 gene. This protein plays a role in the promotion of cytokine-mediated apoptosis.			Amino Acid, Peptide, or Protein|Receptor	
C118334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118334>	C28533	ANXA6 Gene|ANXA6|ANXA6|Annexin A6 Gene	This gene is involved in calcium transport and exocytosis.			Gene or Genome	
C118335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118335>	C118334	ANXA6 wt Allele|ANX6|Annexin A6 wt Allele|CBP68	Human ANXA6 wild-type allele is located in the vicinity of 5q33.1 and is approximately 57 kb in length. This allele, which encodes annexin A6 protein, plays a role in calcium binding and transport.			Gene or Genome	
C118336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118336>	C16386	Annexin A6|67 kDa Calelectrin|Annexin VI|Annexin-6|CPB-II|Calcium-Binding Protein p68|Calphobindin II|Calphobindin-II|Chromobindin-20|Lipocortin VI|Protein III|p68|p70	Annexin A6 (673 aa, ~76 kDa) is encoded by the human ANXA6 gene. This protein is involved in both exocytosis and calcium localization.			Amino Acid, Peptide, or Protein	
C118337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118337>	C20194	CCDC170 Gene|CCDC170|CCDC170|Coiled-Coil Domain Containing 170 Gene	This gene may play a role in bone development.			Gene or Genome	
C118338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118338>	C118337	CCDC170 wt Allele|C6orf97|Chromosome 6 Open Reading Frame 97 Gene|Coiled-Coil Domain Containing 170 wt Allele|FLJ23305|bA282P11.1	Human CCDC170 wild-type allele is located in the vicinity of 6q25.1 and is approximately 127 kb in length. This allele, which encodes coiled-coil domain-containing protein 170, may be involved in bone development.			Gene or Genome	
C118339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118339>	C18466	Coiled-Coil Domain-Containing Protein 170	Coiled-coil domain-containing protein 170 (715 aa, ~82 kDa) is encoded by the human CCDC170 gene. This protein may play a role in bone development.			Amino Acid, Peptide, or Protein	
C11833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11833>	C61063	Gemcitabine/SU5416			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118340>	C20194	CTR9 Gene|CTR9|CTR9|CTR9|CTR9, Paf1/RNA Polymerase II Complex Component Gene	This gene is involved in embryonic stem cell pluripotency, transcriptional elongation and histone modification.			Gene or Genome	CCPS Genetics Terminology|Childhood Cancer Predisposition Study Terminology
C118341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118341>	C118340	CTR9 wt Allele|CTR9, Paf1/RNA Polymerase II Complex Component wt Allele|CTR9, S. cerevisiae, Homolog of Gene|Ctr9, Paf1/RNA Polymerase II Complex Component, Homolog (S. cerevisiae) Gene|Ctr9, Paf1/RNA Polymerase II Complex Component, Homolog Gene|KIAA0155|SH2 Domain Binding Protein 1 (Tetratricopeptide Repeat Containing) Gene|SH2BP1|TSBP|p150|p150TSP	Human CTR9 wild-type allele is located in the vicinity of 11p15.3 and is approximately 29 kb in length. This allele, which encodes RNA polymerase-associated protein CTR9 homolog protein, plays a role in histone modification, embryonic stem cell pluripotency and transcriptional elongation.			Gene or Genome	
C118342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118342>	C18466	RNA Polymerase-Associated Protein CTR9 Homolog|SH2 Domain-Binding Protein 1|TPR-Containing, SH2-Binding Phosphoprotein|Tetratricopeptide-Containing SH2-Binding Phosphoprotein, 150-kD|p150(TSP)	RNA polymerase-associated protein CTR9 homolog (1173 aa, ~134 kDa) is encoded by the human CTR9 gene. This protein is involved in transcriptional elongation, histone modification and embryonic stem cell pluripotency.			Amino Acid, Peptide, or Protein	
C118343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118343>	C25942	TENT4B Gene|PAPD5|TENT4B|TENT4B|Terminal Nucleotidyltransferase 4B Gene	This gene is involved in mRNA polyadenylation.			Gene or Genome	
C118344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118344>	C118343	TENT4B wt Allele|GLD4|PAP Associated Domain Containing 5 Gene|PAPD5|Poly(A) RNA Polymerase D5, Non-Canonical Gene|TRF4-2|TUT3|Terminal Nucleotidyltransferase 4B wt Allele	Human TENT4B wild-type allele is located in the vicinity of 16q12.1 and is approximately 82 kb in length. This allele, which encodes non-canonical terminal nucleotidyltransferase 4B protein, plays a role in mRNA modification and stability.			Gene or Genome	
C118345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118345>	C41038	Terminal Nucleotidyltransferase 4B|EC 2.7.7.19|Non-Canonical Poly(A) RNA Polymerase PAPD5|Non-Canonical PolyA RNA Polymerase PAPD5|PAP-Associated Domain-Containing Protein 5|Poly(A) Polymerase-Associated Domain-Containing Protein 5|TENT4B|TRF4-2|TUTase 3|TUTase3|Terminal Guanylyltransferase|Terminal Uridylyltransferase 3|Topoisomerase-Related Function Protein 4-2	Terminal nucleotidyltransferase 4B (572 aa, ~63 kDa) is encoded by the human TENT4B gene. This protein is involved in mRNA quality control processes.			Amino Acid, Peptide, or Protein|Enzyme	
C118346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118346>	C54550	ZC3H11A Gene|ZC3H11A|ZC3H11A|Zinc Finger CCCH-Type Containing 11A Gene	This gene plays a role in nuclear mRNA export.			Gene or Genome	
C118347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118347>	C118346	ZC3H11A wt Allele|KIAA0663|ZC3HDC11A|Zinc Finger CCCH-Type Containing 11A wt Allele|Zinc Finger CCCH-Type Domain Containing 11A Gene	Human ZC3H11A wild-type allele is located in the vicinity of 1q32.1 and is approximately 59 kb in length. This allele, which encodes zinc finger CCCH domain-containing protein 11A, is involved in RNA export.			Gene or Genome	
C118348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118348>	C16386	Zinc Finger CCCH Domain-Containing Protein 11A	Zinc finger CCCH domain-containing protein 11A (810 aa, ~89 kDa) is encoded by the human ZC3H11A gene. This protein plays a role in mRNA export.			Amino Acid, Peptide, or Protein	
C118349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118349>	C20917	PRC1 Gene|PRC1|PRC1|Protein Regulator of Cytokinesis 1 Gene	This gene is involved in cytokinesis.			Gene or Genome	
C11834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11834>	C61063	Cytarabine/Dexamethasone/Leucovorin Calcium/Methotrexate			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118350>	C118349	PRC1 wt Allele|ASE1|Anaphase Spindle Elongation 1 Homolog (S. cerevisiae) Gene|Protein Regulator of Cytokinesis 1 wt Allele	Human PRC1 wild-type allele is located in the vicinity of 15q26.1 and is approximately 30 kb in length. This allele, which encodes protein regulator of cytokinesis 1, plays a role in both mitotic spindle integrity and cytokinesis.			Gene or Genome	
C118351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118351>	C17761	Protein Regulator of Cytokinesis 1|Anaphase Spindle Elongation 1 Homolog|Protein Regulating Cytokinesis 1	Protein regulator of cytokinesis 1 (620 aa, ~72 kDa) is encoded by the human PRC1 gene. This protein is involved in both mitotic spindle crosslinks and cytokinesis.			Amino Acid, Peptide, or Protein	
C118352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118352>	C20917	SKA2 Gene|SKA2|SKA2|Spindle and Kinetochore Associated Complex Subunit 2 Gene	This gene plays a role in microtubule binding and chromosome segregation.			Gene or Genome	
C118353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118353>	C118352	SKA2 wt Allele|FAM33A|FLJ12758|Family With Sequence Similarity 33, Member A Gene|Spindle and Kinetochore Associated Complex Subunit 2 wt Allele|Spindle- and Kinetochore-Associated Complex, Subunit 2 Gene	Human SKA2 wild-type allele is located in the vicinity of 17q23.2 and is approximately 45 kb in length. This allele, which encodes spindle and kinetochore-associated protein 2, is involved in chromosome segregation.			Gene or Genome	
C118354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118354>	C17761	Spindle and Kinetochore-Associated Protein 2|Protein FAM33A|Spindle and KT (Kinetochore) Associated 2|Spindle- and Kinetochore-Associated Protein 2	Spindle and kinetochore-associated protein 2 (121 aa, ~14 kDa) is encoded by the human SKA2 gene. This protein plays a role in both chromosome segregation and microtubule binding.			Amino Acid, Peptide, or Protein	
C118355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118355>	C26057	DDX20 Gene|DDX20|DDX20|DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 20 Gene	This gene is involved in catalyzing the assembly of small nuclear ribonucleoproteins.			Gene or Genome	
C118356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118356>	C118355	DDX20 wt Allele|DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 20 wt Allele|DEAD/H (Asp-Glu-Ala-Asp/His) Box Polypeptide 20, 103kD Gene|DEAD/H Box 20 Gene|DP103|GEMIN3	Human DDX20 wild-type allele is located within 1p21.1-p13.2 and is approximately 13 kb in length. This allele, which encodes probable ATP-dependent RNA helicase DDX20 protein, plays a role in the formation of the spliceosome.			Gene or Genome	
C118357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118357>	C17417	Probable ATP-Dependent RNA Helicase DDX20|Component of Gems 3|DDX20|DEAD Box Protein 20|DEAD Box Protein DP 103|DEAD-Box Protein DP103|EC 3.6.4.13|Gemin-3	Probable ATP-dependent RNA helicase DDX20 (824 aa, ~92 kDa) is encoded by the human DDX20 gene. This protein is involved in spliceosome formation and ATP hydrolysis.			Amino Acid, Peptide, or Protein|Enzyme	
C118358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118358>	C15331	Exoresection	A surgical technique for the transscleral resection of large, anteriorly located uveal melanomas with ciliary body and/or iris involvement. This approach is most common when conservative therapy is either unlikely to help, or likely to cause complications.			Therapeutic or Preventive Procedure	GDC Terminology|GDC Value Terminology
C118359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118359>	C15331	Endoresection	A surgical technique used for the resection of posteriorly located uveal melanomas without ciliary body involvement via pars plana vitrectomy.			Therapeutic or Preventive Procedure	
C11835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11835>	C61063	Dexamethasone/Etoposide/Ifosfamide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118360>	C2124	Carbon C 11 Methylaminoisobutyrate|11C-MeAIB|N-methyl-11C-methylaminoisobutyric Acid	A synthetic neutral amino acid analog radiolabeled with carbon C 11 with potential use for metabolic tumor imaging during positron emission tomography (PET). Upon administration, carbon C 11 methylaminoisobutyrate ([(11)C]MeAIB) is taken up by and accumulates in cancer cells through the A-type (alanine-preferring) amino acid transport system. Upon imaging of the radioisotope, the distribution patterns of MeAIB and its uptake by cancer cells can be further elucidated. This may establish its usefulness as a tumor tracer in the diagnosis of certain cancers. Amino acid transport system A is highly upregulated in malignant cells and facilitates the uptake of amino acids needed for tumor cell proliferation.			Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	NCI Drug Dictionary Terminology
C118361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118361>	C1663	HCV Antigen Therapeutic Bivalent Vaccine V5|V-5 Immunitor	An orally bioavailable, therapeutic bivalent vaccine composed of heat- and chemical-inactivated hepatitis C virus (HCV) antigens derived from the blood of HCV-infected carriers, with potential immunomodulating activity. Upon oral administration of the HCV antigen therapeutic bivalent vaccine V5, the HCV antigens may stimulate the host immune system to mount an immune response against HCV-infected cells, thereby preventing further HCV-infection and HCV-induced liver injury.			Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology
C118362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118362>	C29983|C129822	Anti-MUC1 Monoclonal Antibody BTH1704|BTH1704	A monoclonal antibody against the tumor associated antigen (TAA) mucin-1 (MUC1), with potential antineoplastic activity. Upon administration, anti-MUC1 monoclonal antibody BTH1704 targets and binds to MUC1 expressed on the surface of tumor cells, which can potentially activate the immune system to induce an antibody-dependent cellular cytotoxicity (ADCC) against MUC1-expressing tumor cells. MUC1, a glycoprotein overexpressed on the surface of a variety of cancer cells, plays a key role in tumor cell survival and proliferation.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118363>	C1910	Leuprolide Mesylate Injectable Suspension|LMIS	A depot suspension for injection composed of the mesylate salt of leuprolide, a synthetic, long-acting nonapeptide analog of the endogenous hormone gonadotropin-releasing hormone (GnRH), with potential antineoplastic activity. Upon subcutaneous injection of the depot suspension, leuprolide binds to and activates the gonadotropin-releasing hormone receptor (GnRHR). The continuous stimulation of GnRHR by leuprolide results in both the desensitization of pituitary GnRHR and the inhibition of pituitary secretion of the gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH). In males, this results in a significant decline in testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C118364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118364>	C1752	hVEGF26-104/RFASE Peptide Vaccine|hVEGF26-104/RFASE	A therapeutic cancer vaccine containing a truncated, synthetic peptide mimic of the human angiogenic activator vascular endothelial growth factor (VEGF), consisting of 79 amino acids (amino acids 26-104 of VEGF), and emulsified in the immunoadjuvant RFASE, with potential immunostimulatory and antitumor activities. Upon intramuscular vaccination, the hVEGF26-104 moiety of hVEGF26-104/RFASE acts as an antigen and induces an immune response against VEGF, which results in anti-VEGF antibody binding to and neutralization of endogenous VEGF. This prevents the binding of endogenous VEGF to the VEGF receptor (VEGFR) and blocks VEGFR-mediated endothelial cell signaling, resulting in an inhibition of both angiogenesis and tumor cell proliferation. VEGF plays a key role in angiogenesis, tumor cell proliferation and invasion. RFASE, which belongs to the group of sulpholipopolysaccharides (SLPs), is a synthetic polysaccharide covalently coupled to lipid groups and sulphate groups, and is able to induce a strong humoral immune response upon antigen administration.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118365>	C1505	Ganoderma lucidum Spores Powder Capsule|Ganoderma l. Spores Powder Capsule|Lingzhi Spores Powder Capsule	An orally available powder-based nutritional supplement containing the spores of the mushroom Ganoderma lucidum (Ganoderma l.), a traditional Chinese medicine, with potential protective, sedative, anti-oxidant, immunomodulating, and antineoplastic activities. The spores contain various bioactive components including polysaccharides, triterpenoids, peptidoglycans, amino acids, fatty acids, vitamins, and minerals. Upon oral administration of the Ganoderma lucidum spores powder capsule, the active ingredients may modulate the immune system, may activate dendritic cells, natural killer cells, and macrophages and may modulate the production of certain cytokines, such as tumor necrosis factor-alpha (TNFa), interleukin (IL) 1-beta (IL-1b), IL-2, IL-6 and IL-8. This supplement may improve cancer-related fatigue and may be used as a sleep aid; it may also have a beneficial effect on the heart, lung, liver, pancreas, kidney, and the central nervous system.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118366>	C1505	Olive Oil/Soybean Oil/Multi-amino Acid/Glucose Parenteral Nutrition Emulsion|ZentroOLIMEL	An electrolyte-based parenteral emulsion for infusion consisting of a three chamber bag system containing a glucose solution, an amino acid solution and a lipid emulsion that can be used to provide parenteral nutritional supplementation. The lipid emulsion portion contains 20% refined soybean oil and 80% refined olive oil; the amino acid solution contains alanine, arginine, aspartic acid, glutamic acid, leucine, isoleucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine. The parenteral nutrition emulsion also contains the electrolytes phosphate and acetate. The three separate bags are mixed together before infusion. Upon infusion, the emulsion provides calories for energy. The lipid portion supplies essential fatty acids that can be incorporated into cell membranes. The amino acids facilitate protein synthesis.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C118367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118367>	C28681	NY-ESO-1/MAGE-A4/PRAME/Survivin/SSX2-specific Autologous Cytotoxic T Lymphocytes|Autologous NY-ESO-1/MAGE-A4/PRAME/Survivin/SSX2-specific Cytotoxic T Lymphocytes|NY-ESO-1/MAGE-A4/PRAME/Survivin/SSX2-specific Autologous CTLs	A preparation of autologous cytotoxic T-lymphocytes (CTL) that are specifically reactive to five tumor-associated antigens (TAAs), cancer-testis antigen NY-ESO-1, melanoma-associated antigen 4 (MAGE-A4), preferentially expressed antigen in melanoma (PRAME), survivin and synovial sarcoma X breakpoint 2 (SSX2; cancer/testis antigen 5.2; CT5.2), with potential antineoplastic activity. Autologous peripheral blood mononuclear cells (PBMCs) are collected and exposed ex vivo to autologous dendritic cells (DCs) that are pulsed with pepmixes, which contain overlapping peptide libraries (15 mers overlapping by 11 amino acids) spanning the entire sequence of each of the five target antigens, and simultaneously treated with the Th1-polarizing and pro-proliferative cytokines interleukin (IL) 6 (IL-6), IL-7, IL-12 and IL-15. The treated cells are expanded in culture with IL-2 and IL-15. Upon administration of the NY-ESO-1/MAGE-A4/PRAME/survivin/SSX2-specific autologous CTLs, these cells target tumor cells expressing these TAAs, which leads to cell lysis and inhibition of cell proliferation. These five TAAs are upregulated in a variety of tumor cells and play key roles in tumor cell proliferation and survival, but are absent or minimally expressed on normal, healthy human cells.	NY-ESO-1/MAGE-A4/PRAME/Survivin/SSX2-specific Autologous Cytotoxic T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118368>	C1663	Anti-OFA Immunotherapeutic BB-MPI-03|BB-MPI-03|BBMPI03	A cancer vaccine composed of 3 different cytotoxic T-cell epitopes derived from the tumor-associated antigen oncofetal antigen (OFA), with potential immunostimulating and antineoplastic activities. Upon intradermal administration, anti-OFA immunotherapeutic vaccine BB-MPI-03 activates the immune system to elicit a specific cytotoxic T-lymphocyte (CTL) response against tumor cells expressing OFA. OFA, also called immature laminin receptor protein (iLRP), is expressed in fetal tissues and is overexpressed in various cancers; its expression is correlated with cancer cell survival.	Anti-OFA Immunotherapeutic BB-MPI-03		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118369>	C1595	Doxycycline Hyclate Foam|FDX104|FDX104 Antibiotic Foam	A foam-based formulation composed of the hyclate salt form of doxycycline, a synthetic, broad-spectrum tetracycline antibiotic, with antimicrobial activity. Upon topical application of the foam, doxycycline reversibly binds to the bacterial 30S ribosomal subunit, and blocks the binding of aminoacyl-tRNA to the mRNA-ribosome complex. This leads to an inhibition of bacterial protein synthesis. This may prevent both the bacterial infections and the subsequent infections and pain associated with epidermal growth factor receptor inhibitor (EGFRI)-induced acne-like rash.			Antibiotic|Pharmacologic Substance	NCI Drug Dictionary Terminology
C11836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11836>	C61063	Daunorubicin Liposomal/SU5416			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118370>	C54705	Growing Teratoma Syndrome|GTS	A condition characterized by the presence of a growing mature teratoma in a patient during or after chemotherapy for a non-seminomatous germ cell tumor, with normal serum markers for human chorionic gonadotropin and alpha fetoprotein. Complete surgical resection is the preferred treatment.			Disease or Syndrome	
C118371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118371>	C29701|C275	Polaprezinc|Aprozinate|Carnosine Zinc Complex|POLAPREZINC|Z 103|Zinc L-carnosine|Zinc, (beta-alanyl-kappaN-L-histidinato(2-)-kappaN,kappaO)-	An orally bioavailable chelate composed of zinc and L-carnosine, with potential gastroprotective, anti-oxidant, anti-ulcer and anti-inflammatory activities. Upon administration, polaprezinc increases the expression of various anti-oxidant enzymes, such as superoxide dismutase 1 (SOD-1), SOD-2, heme oxygenase-1 (HO-1), glutathione S-transferase (GST), glutathione peroxidase (GSH-px), peroxidredoxin-1 (PRDX1; PRXI) and PRXD5 (PRXV) in the gastric mucosa, which protect cells against reactive oxygen species (ROS). In addition, this agent inhibits the activity of the transcription factor nuclear factor-kappaB (NF-kappaB) and reduces the expression of several pro-inflammatory cytokines, such as interleukin (IL) 1beta, IL-6, IL-8, and tumor necrosis factor alpha (TNF-a). Polaprezinc also increases the expression of various growth factors, such as platelet-derived growth factor-B (PDGF-B), vascular endothelial growth factor (VEGF), and nerve growth factor (NGF), and various heat shock proteins (HSPs), including HSP90, HSP70, HSP60, HSP47, HSP27, and HSP10. This protects against damages to, and accelerates healing of the gastric mucosa.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C118372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118372>	C20970	BTC Gene Product|BTC Protein	A protein encoded by the BTC gene.			Amino Acid, Peptide, or Protein	
C118373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118373>	C118372	Probetacellulin	Probetacellulin (178 aa, ~20 kDa) is encoded by the human BTC gene. This protein plays a role in cellular proliferation.			Amino Acid, Peptide, or Protein	
C118374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118374>	C98700	Epigastric Hernia	Protrusion of abdominal cavity contents or pre-peritoneal fat through the abdominal wall between the umbilicus and the xiphoid process.			Anatomical Abnormality	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118375>	C98700	Umbilical Hernia	Protrusion of the abdominal cavity contents through the abdominal wall at the umbilicus.			Anatomical Abnormality	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118376>	C45581	FGF Gene Amplification|FGF Amplification	A molecular genetic abnormality indicating the presence of multiple copies of an FGF family gene.			Cell or Molecular Dysfunction	
C118377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118377>	C3420|C153240	FGFR Gene Translocation|FGF Receptor Gene Family Translocation|FGF Receptor Gene Translocation|FGFR Family Gene Translocation|FGFR Family Translocation|FGFR Translocation|Fibroblast Growth Factor Receptor Gene Family Translocation|Fibroblast Growth Factor Receptor Gene Translocation	A cytogenetic abnormality that refers to the translocation of an FGFR family gene to a new chromosomal location.	FGFR Gene Translocation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C118378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118378>	C156029	FGFR Gene Amplification|FGF Receptor Gene Amplification|FGF Receptor Gene Family Amplification|FGFR Amplification|FGFR Family Amplification|FGFR Family Gene Amplification|Fibroblast Growth Factor Receptor Family Gene Amplification|Fibroblast Growth Factor Receptor Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of an FGFR family gene.	FGFR Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118379>	C20970	HBEGF Gene Product	A protein encoded by the HBEGF gene.			Amino Acid, Peptide, or Protein	
C11837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11837>	C61007	Interferon Alfa/Thalidomide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118380>	C118379	Proheparin-Binding EGF-Like Growth Factor|Pro-HB-EGF	Proheparin-binding EGF-like growth factor (208 aa, ~23 kDa) is encoded by the human HBEGF gene. This protein plays a role in both heart valve formation and mitogenesis for fibroblasts and smooth muscle cells.			Amino Acid, Peptide, or Protein	
C118381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118381>	C110937	Apophysitis	Inflammation of a bony outgrowth located near the attachment site for muscles.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118382>	C110937	Epiphysiolysis	Abnormal separation of an epiphysis from the shaft of a bone.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118383>	C45447	Germline Genotype Testing|Germline Genotype Analysis|Germline Genotyping	An assay used to determine the genes and molecular markers present in the germline DNA of an individual.	Germline Genotype Testing		Molecular Biology Research Technique	CTRP Intervention Terminology|CTRP Terminology
C118384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118384>	C110937	Slipped Capital Femoral Epiphysis|SCFE	Separation of the femoral head and neck through the epiphyseal plate.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118385>	C36184	Avascular Necrosis|AVN|Avascular-Necrosis	Tissue death resulting from an interruption to the blood supply.			Finding	GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Late Effects Table|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118386>	C97927	FAP Gene Mutation|FAP Mutation	A change in the nucleotide sequence of the FAP gene.			Cell or Molecular Dysfunction	
C118387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118387>	C97927	MEN1 Gene Mutation|MEA I Gene Mutation|MEAI Gene Mutation|MEN I Gene Mutation|MEN1 Mutation|Menin 1 Gene Mutation|Menin Gene Mutation|Multiple Endocrine Neoplasia 1 Gene Mutation|Multiple Endocrine Neoplasia I Gene Mutation|SCG2 Gene Mutation	A change in the nucleotide sequence of the MEN1 gene.	MEN1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118388>	C97927	NF1 Gene Mutation|NF1 Mutation|NF1 Mutation|NF1 mutation|NFNS Gene Mutation|Neurofibromin 1 Gene Mutation	A change in the nucleotide sequence of the NF1 gene.	NF1 Gene Mutation		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CRF8 Pathology Review Targeted Genomics Table|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C118389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118389>	C97927|C129264	IDH1 Gene Mutation|IDH1 Mutation|Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic Gene Mutation|Isocitrate Dehydrogenase 1 (NADP+), Soluble Gene Mutation	A change in the nucleotide sequence of the IDH1 gene.	IDH1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C11838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11838>	C61063	R115777/Topotecan			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118390>	C97927|C129264	IDH2 Gene Mutation|IDH2 Mutation|Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial Gene Mutation|Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial Gene Mutation	A change in the nucleotide sequence of the IDH2 gene.	IDH2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C118391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118391>	C41361|C128901	KRAS Activating Mutation|Activating KRAS Mutation|KRAS Gene Activation|KRAS Proto-Oncogene, GTPase Activating Mutation|KRAS-2 Activating Mutation|KRAS2 Activating Mutation|c-K-ras Activating Mutation|v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Activating Mutation	A change in the nucleotide sequence of the KRAS gene that results in constitutive signal transduction, which stimulates downstream signaling pathways involved in cell growth, proliferation, invasion, and metastasis. The presence of KRAS activating mutations in colorectal cancer and non-small-cell lung cancer is used identify the subgroup of patients who are most likely to respond to EGFR antagonist chemotherapy.	KRAS Activating Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118392>	C110937	Nonunion of Bone|Nonunion|Nonunion	The permanent failure of bone to heal, commonly due to a fracture or an osteotomy.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118393>	C110937	Malunion of Bone|Malunion|Malunion	Faulty healing of bone, resulting in improper anatomical alignment.			Finding	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118394>	C97927|C133706	MLH1 Gene Mutation|COCA2 Gene Mutation|HNPCC2 Gene Mutation|MLH1 Mutation|MutL Homolog 1 Gene Mutation|MutL, E. coli, Homolog of, 1 Gene Mutation	A change in the nucleotide sequence of the MLH1 gene.	MLH1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C118395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118395>	C97927|C133706	MSH6 Gene Mutation|HNPCC5 Gene Mutation|MSH6 Mutation|MutS Homolog 6 Gene Mutation|MutS, E. coli, Homolog of, 6 Gene Mutation	A change in the nucleotide sequence of the MSH6 gene.	MSH6 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C118396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118396>	C97927	TP53 Gene Mutation|Abnormal|P53 Gene Mutation|Positive|TP53|TP53|TP53 Mutated|TP53 Mutation|Tumor Protein p53 Gene Mutation|Yes|p53 Mutation	A change in the nucleotide sequence of the TP53 gene.	TP53 Gene Mutation		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology|CRF8 Pathology Review Targeted Genomics Table|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|EWS Authorized Value Terminology|EWS Molecular Analysis Table|Pediatric Oncology Target Molecular Abnormalities Terminology
C118397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118397>	C97927|C133706	PMS2 Gene Mutation|HNPCC4 Gene Mutation|MLH4 Gene Mutation|PMS1 Homolog 2, Mismatch Repair System Component Gene Mutation|PMS2 Mutation|PMS2CL Gene Mutation|PMSL2 Gene Mutation|Postmeiotic Segregation Increased (S. cerevisiae) 2 Gene Mutation|Postmeiotic Segregation Increased 2 Gene Mutation	A change in the nucleotide sequence of the PMS2 gene.	PMS2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C118398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118398>	C97927	TSC1 Gene Mutation|Hamartin Gene Mutation|TSC Gene Mutation|TSC1 Mutation|Tuberous Sclerosis 1 Gene Mutation	A change in the nucleotide sequence of the TSC1 gene.	TSC1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C118399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118399>	C97927	TSC2 Gene Mutation|TSC2 Mutation|Tuberin Gene Mutation|Tuberous Sclerosis 2 Gene Mutation	A change in the nucleotide sequence of the TSC2 gene.	TSC2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C11839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11839>	C61063	Doxorubicin Hcl Liposome/Gemcitabine/Vinorelbine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1183>	C784	Ranpirnase|Onconase|Onconase|P-30|P-30 Protein|P-30 Protein|P-30 protein|P30|P30 Protein|RANPIRNASE|RANPIRNASE	A natural homologue of ribonuclease A isolated from the eggs of the frog Rana pipiens.  Ranpirnase primarily degrades cellular transfer RNA with a substrate specificity for uridine-guanidine base-pair sequences, resulting in inhibition of protein synthesis and cytotoxicity. This agent also activates caspase-9 in mitochondria, resulting in tumor cell apoptosis. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118400>	C97927	VHL Gene Mutation|HRCA1 Gene Mutation|RCA1 Gene Mutation|VHL Mutation|VHL1 Gene Mutation|Von Hippel-Lindau Syndrome Gene Mutation|Von Hippel-Lindau Tumor Gene Mutation|Von Hippel-Lindau Tumor Suppressor Gene Mutation|Von Hippel-Lindau Tumor Suppressor Mutation	A change in the nucleotide sequence of the VHL gene.	VHL Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118401>	C23044	Tartrate Resistant Acid Phosphatase Staining Method|TRACP Staining|TRAP Stain|TRAP Staining	A staining method used to demonstrate the presence of acid phosphatase and tartrate resistant acid phosphatase (TRAP) in osteoclasts.			Laboratory Procedure	
C118402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118402>	C20970	EGF Gene Product	A protein encoded by the EGF gene.			Amino Acid, Peptide, or Protein|Hormone	
C118403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118403>	C118402	Pro-Epidermal Growth Factor|ProEGF	Pro-epidermal growth factor (1207 aa, ~134 kDa) is encoded by the human EGF gene. This protein plays a role in the modulation of cell proliferation and differentiation.	Pro-Epidermal Growth Factor		Amino Acid, Peptide, or Protein|Hormone	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118404>	C54452	SPL License Disciplinary Action Terminology|License Disciplinary Action|Structured Product Labeling License Disciplinary Action Terminology	Terminology used for representation of the information regarding license disciplinary actions concerned with medical product development, manufacturing, and marketing in the framework of the Structured Product Labeling documents.	SPL License Disciplinary Action Terminology		Intellectual Product	FDA Structured Product Labeling Terminology
C118405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118405>	C70865	License Status	The standing or condition of the license of an individual or business.			Qualitative Concept	
C118406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118406>	C118405	Suspended License|Suspended	The temporary halt to permissions accorded to an active license.			Qualitative Concept	FDA Structured Product Labeling Terminology|SPL License Disciplinary Action Terminology
C118407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118407>	C118405	Revoked License|Revoked	The permanent cessation to permissions accorded to an active license.			Qualitative Concept	FDA Structured Product Labeling Terminology|SPL License Disciplinary Action Terminology
C118408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118408>	C118405	Active License|Active	A license to an individual or business with all the permissions accorded in good working order.			Qualitative Concept	FDA Structured Product Labeling Terminology|SPL License Disciplinary Action Terminology
C118409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118409>	C20970	EREG Gene Product	A protein encoded by the EREG gene.			Amino Acid, Peptide, or Protein	
C11840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11840>	C61007	Lomustine/Temozolomide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118410>	C118409	Proepiregulin|EREG|Epiregulin	Proepiregulin (169 aa, ~19 kDa) is encoded by the human EREG gene. This protein plays a role in the promotion of cell proliferation.			Amino Acid, Peptide, or Protein	
C118411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118411>	C48289	Wholesale Drug Distributor	An individual or business licensed to distribute drugs in the state where business is conducted.			Human	FDA Structured Product Labeling Terminology|SPL Business Operation Terminology
C118412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118412>	C37900	Third-Party Logistics Provider	An entity that coordinates processes involved in the provision of a product or service.	Third-Party Logistics Provider		Functional Concept	CTRP Intervention Terminology|CTRP Terminology|FDA Structured Product Labeling Terminology|SPL Business Operation Terminology
C118413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118413>	C20433	NRG1 Gene Product	A protein encoded by the NRG1 gene.			Amino Acid, Peptide, or Protein	
C118414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118414>	C118413	Pro-Neuregulin-1, Membrane-Bound Isoform|Pro-NRG1|Pro-Neuregulin-1	Pro-neuregulin-1, membrane-bound isoform (640 aa, ~70 kDa) is encoded by the human NRG1 gene. This protein plays a role in tyrosine kinase receptor-mediated signal transduction.	Pro-Neuregulin-1, Membrane-Bound Isoform		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118415>	C20433	NRG2 Gene Product	A protein encoded by the NRG2 gene.			Amino Acid, Peptide, or Protein	
C118416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118416>	C118415	Pro-Neuregulin-2, Membrane-Bound Isoform|Pro-NRG2|Pro-Neuregulin-2	Pro-neuregulin-2, membrane-bound isoform (850 aa, ~92 kDa) is encoded by the human NRG2 gene. This protein plays a role in receptor signaling.	Pro-Neuregulin-2, Membrane-Bound Isoform		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118417>	C20433	NRG3 Gene Product	A protein encoded by the NRG3 gene.			Amino Acid, Peptide, or Protein	
C118418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118418>	C118417	Pro-Neuregulin-3, Membrane-Bound Isoform|Pro-NRG3|Pro-Neuregulin-3	Pro-neuregulin-3, membrane-bound isoform (720 aa, ~78 kDa) is encoded by the human NRG3 gene. This protein plays a role in signaling.	Pro-Neuregulin-3, Membrane-Bound Isoform		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118419>	C87091	Labor Complication	Any unintended event during the labor process that makes delivery more difficult.			Finding	NICHD Terminology
C11841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11841>	C61063	Fluorouracil/IM-862			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118420>	C27571	Otolaryngologic Disorder	A non-neoplastic or neoplastic disorder that affects the ears, nose, paranasal sinuses, oral cavity, or throat.			Disease or Syndrome	NICHD Terminology
C118421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118421>	C9349|C36025	Anaplastic Plasmacytoma	A plasmacytoma characterized by the presence of malignant plasma cells with anaplastic features.			Neoplastic Process	
C118422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118422>	C28193	Compartment Syndrome|Compartment syndrome	Elevated pressure in a confined space enclosed by fascia or eschar, which may lead to vascular compromise and subsequent ischemic injury to the tissue within the space.			Disease or Syndrome	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118423>	C34712	Infantile Cortical Hyperostosis|Caffey Disease	A self-limited inflammatory disorder of unknown etiology found in infants that causes swelling of the soft tissue, changes to bone, and irritability.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Endocrinology Terminology
C118424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118424>	C13303	Protein Subunit|PROTEIN SUBUNIT|Subunit	A polypeptide chain that associates with itself or at least one other chain to form a functional protein or protein complex.			Amino Acid, Peptide, or Protein	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C118425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118425>	C14134	Structural Modifier|Chemical Modification|STRUCTURAL MODIFICATION	A molecule that binds to a macromolecule and can change the structural properties of that macromolecule.			Chemical Viewed Structurally	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C118426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118426>	C97928	Gene Product Variation Site|AMINO ACID SUBSTITUTION POINT|Protein Substitution Site|Substituted Amino Acid|aa change|aa_change	The amino acid position that is substituted in a gene product variant.			Cell or Molecular Dysfunction	FDA Structured Product Labeling Terminology|GDC Property Terminology|GDC Terminology|SPL Substance Indexing Terminology
C118427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118427>	C157222	Peptide Bond Constituents|AMINO ACID CONNECTION POINTS	The amine group and carboxyl group found in adjacent amino acids that form a peptide bond.			Chemical Viewed Structurally	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C118428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118428>	C118431	Human Glycan|HUMAN TYPE GLYCAN	An oligosaccharide protein modification that is synthesized by human cells.			Organic Chemical	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C118429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118429>	C118425	Avian Glycan|AVIAN TYPE GLYCAN	An oligosaccharide protein modification that is synthesized by avian cells.			Organic Chemical	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C11842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11842>	C61063	IM-862/Irinotecan			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118430>	C118425	Bacterial Glycan|BACTERIAL TYPE GLYCAN	An oligosaccharide protein modification that is synthesized by bacterial cells.			Organic Chemical	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C118431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118431>	C118425	Mammalian Glycan|MAMMALIAN TYPE GLYCAN	An oligosaccharide protein modification that is synthesized by mammalian cells.			Organic Chemical	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C118432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118432>	C118425	Fungal Glycan|FUNGAL TYPE GLYCAN	An oligosaccharide protein modification that is synthesized by fungal cells.			Organic Chemical	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C118433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118433>	C110937	Muscle Stiffness|Stiff Muscles	A feeling of tension or tightness in one or more muscles.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118434>	C53543|C28193	Albright's Hereditary Osteodystrophy|Albright Hereditary Osteodystrophy|Albright's Hereditary Osteodystrophy with Multiple Hormone Resistance|PHP1A|Pseudohypoparathyroidism, Type IA	A rare, autosomal dominant syndrome caused by mutations in the GNAS gene. It is characterized by the presence of short stature, obesity, round face, brachydactyly, subcutaneous ossifications, and pseudohypoparathtyroidism.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C118435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118435>	C53543	Dyschromatosis Symmetrica Hereditaria|DSH1|Dyschromatosis Symmetrica Hereditaria 1|RAD|Reticulate Acropigmentation of Dohi|Symmetric Dyschromatosis of the Extremities	A rare, autosomal dominant inherited disorder caused by heterozygous mutation in the DSRAD gene. Most cases have been reported from countries in East Asia. It is characterized by the presence of hyperpigmented and hypopigmented macules on the dorsal aspect of the extremities and face.			Disease or Syndrome	Cellosaurus Disease Terminology
C118436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118436>	C53543|C28193	Fraser Syndrome|Cryptophthalmos-Syndactyly Syndrome	A rare, autosomal recessive inherited disorder caused by mutations in the FRAS1, FREM2, or GRIP1 genes. It is characterized by the presence of cryptophthalmos, cutaneous syndactyly, and genitourinary abnormalities.			Disease or Syndrome	Cellosaurus Disease Terminology
C118437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118437>	C61272	Glycogen Storage Disease Type VII|GSD7|GSDVII|Glycogen Storage Disease VII|Muscle Phosphofructokinase Deficiency|PFKM Deficiency|Phosphofructokinase Deficiency|Phosphofructokinase Deficiency|Tarui Disease	A rare, autosomal recessive inherited metabolic disorder caused by mutation in the PFKM gene. It results in the deficiency of the M subunit of the phosphofructokinase enzyme. It is characterized by the presence of muscle pain and weakness and sometimes rhabdomyolysis with myoglobinuria, following exercise. Affected infants develop muscle weakness. Patients with the hemolytic form of this disorder develop hemolytic anemia without signs or symptoms of muscle pain and weakness.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C118438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118438>	C53543	Osteopetrosis with Renal Tubular Acidosis|Autosomal Recessive Osteopetrosis 3|Autosomal Recessive Osteopetrosis, Type 3|Carbonic Anhydrase II Deficiency|Guibaud-Vainsel Syndrome|Marble Brain Disease|OPTB3	A rare, autosomal recessive inherited disorder caused by mutation in the CA2 gene. It is characterized by osteopetrosis, renal tubular acidosis, and cerebral calcifications. It results in growth failure, mental retardation, and fractures.			Disease or Syndrome	Cellosaurus Disease Terminology
C118439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118439>	C20424	TGFA Gene Product	A protein encoded by the TGFA gene.	TGFA Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11843>	C61063	Etoposide/Nitrocamptothecin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118440>	C118439	Protransforming Growth Factor Alpha|Pro-Transforming Growth Factor Alpha	Protransforming growth factor alpha (160 aa, ~17 kDa) is encoded by the human TGFA gene. This protein plays a role in cell proliferation.	Protransforming Growth Factor Alpha		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118441>	C20401	Olendalizumab|ALXN 1007|ALXN-1007|ALXN1007|Immunoglobulin, Anti-(human complement C5a) (human-mus musculus ALXN1007 heavy chain), Disulfide with Human-mus Musculus ALXN1007 Kappa-chain, Dimer|Lendalizumab|OLENDALIZUMAB	A humanized monoclonal antibody directed against the complement protein C5a, with potential immunomodulating and anti-inflammatory activities. Upon administration, olendalizumab targets and binds to C5a. This prevents the binding of C5a to its receptor C5a receptor (C5aR) and prevents C5a/C5aR-mediated pro-inflammatory signaling, thereby reducing inflammation and tissue and organ damage. C5a, a factor in the complement cascade, plays important roles in inflammation and immunity.	Olendalizumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C118442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118442>	C201282|C129822	Anti-gpA33/CD3 Monoclonal Antibody MGD007|Humanized gpA33 x CD3 DART (TM) Protein MGD007|MGD-007|MGD007	An anti-glycoprotein A33 (gpA33)/anti-CD3 bispecific humanized monoclonal antibody with potential immunostimulatory and antineoplastic activities. Anti-gpA33/CD3 monoclonal antibody MGD007 possesses two antigen-recognition sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for gpA33, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of MGD007, this bispecific antibody simultaneously binds to both CD3-expressing T-cells and gpA33-expressing cancer cells, thereby crosslinking cytotoxic T-lymphocytes (CTLs) to gpA33-expressing tumor cells. This may result in CTL-mediated cell lysis of the crosslinked tumor cells. The gpA33 antigen, a member of the immunoglobulin superfamily, is expressed in certain malignancies, including colon and gastrointestinal cancers.	Anti-gpA33/CD3 Monoclonal Antibody MGD007		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118443>	C20401|C129822	Atigotatug|ATIGOTATUG|Anti-fucosyl-GM1 Monoclonal Antibody BMS-986012|BMS-986012	A monoclonal antibody directed against the ganglioside fucosyl-GM1, with potential antineoplastic and immunomodulating activities. Upon administration, atigotatug binds to fucosyl-GM1 on cancer cells and may activate both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity against the bound tumor cells. This may inhibit the proliferation of GM1-expressing tumor cells. Fucosyl-GM1, a sphingolipid monosialoganglioside and tumor associated antigen (TAA), is overexpressed on the surface of many cancer cells while its expression is minimal or non-existent in normal tissues.	Atigotatug		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118444>	C1931	Gamboge Resin Extract TSB-9-W1|GARCINIA HANBURYI ROOT RESIN|Garcinia Hanburyi Rhizome Resin|Garcinia Hanburyi Root Resin|TSB-9-W1	An orally bioavailable extract from the yellow to brown gum-resin of the gamboge tree (genus Garcinia) belonging to the Clusiaceae (or Guttiferae) family, with potential anti-inflammatory and antineoplastic activities. Gamboge resin extract TSB-9-W1 contains various active ingredients, including gambogic acid, formoxanthone A, betulin, betulinic acid, morellic acid, isomorellic acid, isogambogic acid, isomorellinol and desoxymorellin. Upon oral administration, the various active components of the gamboge resin extract TSB-9-W1 may bind to and inhibit the activity of a variety of cancer-related proteins, may induce apoptosis, and may exert cytotoxic activity on tumor cells, thereby inhibiting tumor cell proliferation. TSB-9 is derived from TSB-14, which is the acetone-extract of gamboge resin, and pulverized into powder form; TSB-9 is 90% extract and 10% brown sugar. TSB-9-W1 is a milled form of TSB-9 with a particle size of 5 micrometers.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118445>	C308	Mycobacterium tuberculosis Arabinomannan Z-100|MYCOBACTERIUM TUBERCULOSIS (OAYAMA STRAIN) LIPOPOLYSACCHARIDE|Z-100	An extract from Mycobacterium tuberculosis (M. tuberculosis) containing the polysaccharide arabinomannan, with potential immunostimulating activity. Upon administration of M. tuberculosis arabinomannan Z-100, this agent may activate the immune system by increasing the expression of various cytokines, such as interferon-gamma (IFNg) and interleukin-12. This inhibits the activity of suppressor T-cells, increases T helper 1 cell (Th1) activity and may restore the balance between Th1/Th2 cells. Additionally, Z-100 may inhibit metastasis and tumor cell proliferation.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118446>	C98086	Gemigliptin|1-((2S)-2-Amino-4-(2,4-bis(trifluoromethyl)-5,8-dihydropyrido(3,4-d)pyrimidin-7(6H)-yl)-4-oxobutyl-5,5-difluoropiperidin-2-one|GEMIGLIPTIN|LC15-0444	An orally bioavailable inhibitor of the serine protease dipeptidyl peptidase 4 (DPP-4), with hypoglycemic and potential renoprotective activities. Upon administration, gemigliptin binds to DPP-4 and inhibits the breakdown of the incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This prolongs incretin activity, increases postprandial insulin secretion from pancreatic beta cells, decreases glucagon secretion, delays gastric emptying and lowers blood glucose levels. In addition, gemigliptin exerts a renoprotective effect, probably through enhanced GLP-1 signaling, may prevent apoptosis and acute kidney injury induced by nephrotoxic agents, and may protect against diabetic nephropathy.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C118447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118447>	C20401|C129822	Anti-EphA2 Monoclonal Antibody DS-8895a|DS-8895a	A monoclonal antibody directed against the ephrin receptor A2 (EphA2), with potential antineoplastic activity. Upon administration, anti-EphA2 monoclonal antibody DS-8895a selectively binds to cells expressing the EphA2 receptor. This blocks EphA2 activation and EphA2-mediated signaling. In addition, DS-8895a may activate an immune response against EphA2-expressing tumor cells. The cell-surface receptor EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) that are involved in mammalian development, is overexpressed by a variety of cancer cell types and plays an important role in tumor growth.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118448>	C797|C275	Matricaria recutita Gel|Chamomilla recutita Gel|German Chamomile Gel|Matricaria chamomilla L. Gel	A gel-based formulation containing an extract of the herb Matricaria chamomilla (M. recutita or German chamomile), which is native to eastern and southern Europe, belongs to the Asteraceae family and is high in flavonoids, with potential anti-inflammatory, skin protective, moisturizing, anti-bacterial, anti-oxidant and calming activities. M. recutita extract contains flavonoids, including apigenin, luteolin and quercetin, as well as coumarins, herniarin, umbelliferone, anthemic acid, anthemidine, tannin and matricarin. Upon topical application of the Matricaria recutita gel, the active ingredients in the chamomile may exert anti-inflammatory, calming and anti-oxidant effects on the skin and may protect the skin against radiotherapy-induced dermatitis.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C118449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118449>	C275|C226471	Matricaria recutita Topical Infusion|Chamomilla recutita Infuse|German Chamomile Infuse|Matricaria chamomilla L. Topical Infusion	A gel-based formulation containing an extract of the herb Matricaria chamomilla (M. recutita or German chamomile), which is native to eastern and southern Europe, belongs to the Asteraceae family and is high in flavonoids, with potential anti-inflammatory, skin protective, moisturizing, anti-bacterial, anti-oxidant and calming activities. M. recutita extract contains flavonoids, including apigenin, luteolin and quercetin, as well as coumarins, herniarin, umbelliferone, anthemic acid, anthemidine, tannin and matricarin. Upon topical application of the Matricaria recutita infusion, the active ingredients in the chamomile may exert anti-inflammatory, calming and anti-oxidant effects on the skin and may protect the skin against radiotherapy-induced dermatitis.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C11844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11844>	C61063	Cytarabine/Etoposide/Mitoxantrone/Monoclonal Antibody Hug1-M195			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118450>	C25974	Utidelone|Epothilone Analog UTD1|UTD1	A genetically engineered epothilone analog with potential antineoplastic activity. Upon administration, utidelone binds to tubulin, induces microtubule polymerization and stabilizes microtubules against depolymerization, which may result in the inhibition of cell division, the induction of G2/M arrest, and apoptosis. Compared to first-generation epothilones, this agent exhibits greater safety and enhanced activity against certain multidrug-resistant (MDR) tumors.	Utidelone		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118451>	C93221	Cidan Herbal Capsule|Zedoary rhizome/Pseudobulbus cremastrae seu pleiones/Yatantzu/Strychni pulveratum/Beehive/Artificial Bezoar/Bombyx mori/Danshen Root/Radix astragali/Angelica/Camphol Alcohol Capsule	A capsule-based formulation containing artificial bezoar, Strychni pulveratum (strychnos powder), camphol alcohol (borneol or borneo camphor) and extracts from Zedoary rhizome (Rhizoma curcumae), Pseudobulbus cremastrae seu pleiones (dried pseudobulb of Cremastra appendiculata), Yatantzu (seed of Brucca javanica), beehive, Bombyx mori (Bombyx batryticatus or silkworm), Danshen (dried root of Salvia miltiorrhiza or red sage root), Radix astragali, and Angelica, with potential antineoplastic activity. Upon oral administration of the cidan herbal capsule, the active ingredients in the plant extracts may induce tumor cell apoptosis and reduce tumor cell proliferation.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118452>	C2189|C1742|C105578	Cannabidiol|1,3-Benzenediol, 2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-, (1R-trans)-|CANNABIDIOL|CBD|CBD|CBD Oil|Epidiolex|GWP42003-P	A phytocannabinoid derived from Cannabis species, which is devoid of psychoactive activity, with analgesic, anti-inflammatory, antineoplastic and chemopreventive activities. Upon administration, cannabidiol (CBD) exerts its anti-proliferative, anti-angiogenic and pro-apoptotic activity through various mechanisms, which likely do not involve signaling by cannabinoid receptor 1 (CB1), CB2, or vanilloid receptor 1. CBD stimulates endoplasmic reticulum (ER) stress and inhibits AKT/mTOR signaling, thereby activating autophagy and promoting apoptosis. In addition, CBD enhances the generation of reactive oxygen species (ROS), which further enhances apoptosis. This agent also upregulates the expression of intercellular adhesion molecule 1 (ICAM-1) and tissue inhibitor of matrix metalloproteinases-1 (TIMP1) and decreases the expression of inhibitor of DNA binding 1 (ID-1). This inhibits cancer cell invasiveness and metastasis. CBD may also activate the transient receptor potential vanilloid type 2 (TRPV2), which may increase the uptake of various cytotoxic agents in cancer cells. The analgesic effect of CBD is mediated through the binding of this agent to and activation of CB1.	Cannabidiol		Organic Chemical|Pharmacologic Substance	CRF4 Treatment Complementary Table|CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C118453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118453>	C29697	Sodium Sulfate/Potassium Sulfate/Magnesium Sulfate-based Laxative|Suprep|Trisulfate Bowel Cleansing Solution	An oral preparation containing sodium sulfate, potassium sulfate and magnesium sulfate, with osmotic laxative activity. Upon oral administration of the sodium sulfate/potassium sulfate/magnesium sulfate-based laxative, this osmotic laxative promotes the retention of water in the bowel. This increases the water content of stool, which results in increased gastrointestinal motility and facilitates the evacuation of colonic contents. This results in a complete cleansing of the colon.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C118454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118454>	C1511	Copper Cu 64 Anti-CEA Monoclonal Antibody M5A|64Cu-DOTA-M5A|Cu 64-M5A	A radioimmunoconjugate consisting of a humanized monoclonal antibody directed against the human carcinoembryonic antigen, carcinoembryonic antigen-related cell adhesion molecule 5 (CEA or CEACAM5), which is conjugated with the radioisotope copper Cu 64 via the chelator tetra-azacyclododecanetetra-acetic acid (DOTA), with potential use as an imaging agent during positron emission tomography (PET). Upon administration, the antibody moiety of copper Cu 64 anti-CEA monoclonal antibody M5A specifically binds to cells expressing CEA. Upon binding, the radioisotope moiety can be detected using PET, thereby allowing the imaging and quantification of CEA-expressing tumor cells. CEA, a tumor associated antigen and a member of the CEA family of proteins, plays a key role in cell migration, cell invasion, and cell adhesion and is overexpressed by a variety of cancer types.	Copper Cu 64 Anti-CEA Monoclonal Antibody M5A		Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C118455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118455>	C2849	Sirenomelia|SIRENOMELIA|Symmelia	A disorder characterized by the malformation of the legs into a single lower limb.			Congenital Abnormality	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118456>	C28193	Hair Tourniquet|Hair-Thread Tourniquet Syndrome	A condition in which a hair or thread becomes wrapped around a digit obstructing blood flow.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118457>	C21176	N-Methyl-D-Aspartate Receptor|N-Methyl-D-aspartate receptor|NMDA RECEPTOR|NMDA Receptor|NMDA Receptor Complex|NMDAR	A protein complex that plays a role in both NMDA binding and ion transport. It is a heterotetramer consisting of 2 glutamate [NMDA] receptor subunit zeta-1 proteins and 2 epsilon subunits (glutamate [NMDA] receptor subunit epsilon-1, -2, -3 or -4).			Amino Acid, Peptide, or Protein|Receptor	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C118458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118458>	C36291	Cheiromegaly|Chiromegaly	Abnormal enlargement of one or both hands, along with hyperhydrosis.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118459>	C2849	Amastia	Absence of one or both mammary glands.			Congenital Abnormality	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11845>	C53290	MUC1-KLH Vaccine/QS21	A peptide vaccine containing the human tumor-associated antigen epithelial mucin (MUC1 antigen) conjugated with keyhole limpet hemocyanin (KLH) and combined with the nonspecific immunoadjuvant QS21, with potential antineoplastic activity.  MUC1 antigen is linked with KLH, an immunostimulant and a hapten carrier, in order to enhance immune recognition; the co-administration of saponin-derived QS21 potentially amplifies the total immune response to the MUC1 antigen.  Administration of MUC1-KLH vaccine/QS21 may result in both the production of antitumor antibodies and the stimulation of a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the MUC1 antigen. MUC1 antigen, a membrane-bound glycoprotein expressed by most glandular and ductal epithelial cells, is overexpressed as an aberrant or deglycosylated form in various cancers such as breast, prostate and ovarian cancers.			Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118460>	C27572	Blount's Disease|Blount Disease	A growth disorder of the tibia in children and adolescents that presents as progressive bowing of one or both legs.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118461>	C16809	Turbo Field Echo MRI|TFE|TFE MRI|Turbo Field Echo|Turbo field echo MRI	A magnetic resonance imaging modality that uses a gradient echo pulse sequence with data acquisition after an initial 180 degree preparation pulse for contrast enhancement. TFE provides contrast at shorter echo times and acquisition times, thus reducing related image artifacts.			Diagnostic Procedure	
C118462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118462>	C16809	Magnetization-Prepared Rapid Gradient Echo MRI|MP RAGE|MP-RAGE|MP-RAGE MRI|MPRAGE|Magnetization-Prepared Rapid Gradient Echo|Magnetization-prepared rapid gradient echo MRI	A magnetic resonance imaging modality that offers rapid imaging time, easy reconstruction of any plane, and three-dimensional surface contour rendering with cut away postprocessing. Especially useful for imaging brain, MP-RAGE captures high tissue contrast and provides high spatial resolution with whole brain coverage in a short scan time.			Diagnostic Procedure	
C118463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118463>	C219504	Three-Dimensional Spoiled Gradient MRI|3-Dimensional Fast Spoiled Gradient|3D FSPGR|3D Fast Spoiled Gradient Recalled MRI|3DFSPGR|FSPGR|FSPGR MRI|SPGR|SPGR MRI|Three-Dimensional Spoiled Gradient-Echo MR|Three-dimensional spoiled gradient MRI	A magnetic resonance imaging modality that uses acquisition in the steady state with semi-random changes in the phase of the radio frequency pulses to produce a spatially independent phase shift. This optimizes the signal-to-noise ratio to provide high resolution and a decrease in the partial volume phenomenon.	Three-Dimensional Spoiled Gradient MRI		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C118464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118464>	C90259	Pediatric Adverse Events Terminology	Terminology developed by a collaborative effort of the National Cancer Institute's Enterprise Vocabulary Services, the National Institute of Child Health and Human Development, and an international group of clinicians and informaticists to support the reporting of adverse events in the pediatric population.			Intellectual Product	
C118465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118465>	C82392|C180729	T2-Weighted Fluid Attenuated Inversion Recovery MRI|T2 and Fluid Attenuated Inversion Recovery MRI|T2-Weighted FLAIR MRI|T2/FLAIR|T2/FLAIR MRI|T2/FLAIR Signal|Transverse relaxation time/Fluid attenuated inversion recovery MRI	Magnetic resonance imaging (MRI) that utilizes a fluid-attenuated inversion recovery (FLAIR) pulse sequence with T2 relaxation properties to suppress signal from fluid that would otherwise obscure tissue abnormalities. In contrast to standard T2-weighted imaging, fluids appear dark in T2-FLAIR imaging.			Diagnostic Procedure	CRF6 DIPG Imaging Assessment Signal Characteristics Table|CRF6 DMG Imaging Assessment Signal Characteristics Table
C118466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118466>	C90259	Perinatal Terminology	Terminology developed by a collaborative effort of the National Cancer Institute's Enterprise Vocabulary Services, the National Institute of Child Health and Human Development, and an international group of clinicians and informaticists to support the reporting of events in the perinatal population.			Intellectual Product	
C118467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118467>	C90259	Pediatric Endocrinology Terminology|Pediatric Endocrine Terminology	Terminology developed by a collaborative effort of the National Cancer Institute's Enterprise Vocabulary Services, the National Institute of Child Health and Human Development, and an international group of clinicians and informaticists to support the reporting of events in the pediatric population that are related to endocrine disorders.			Intellectual Product	
C118468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118468>	C90259	Pediatric Rheumatology Terminology	Terminology developed by a collaborative effort of the National Cancer Institute's Enterprise Vocabulary Services, the National Institute of Child Health and Human Development, and an international group of clinicians and informaticists to support the reporting of events observed in clinical care and research in children and adolescents seen by experts in diseases of joints, muscles, and bones.			Intellectual Product	
C118469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118469>	C113100	Growth Failure of Unknown Etiology	Subnormal linear growth rate in an infant, child or adolescent based on the normative values for the age and sex of the reference population; the cause of the growth failure is unknown.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C11846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11846>	C61063	Filgrastim/Mycophenolate Mofetil/Tacrolimus			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118470>	C113100	Failure of Catch-Up Growth	Failure to achieve a linear growth rate sufficient to restore height to within the normative range for the reference population.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C118471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118471>	C118405	Resolved License|Resolved	The disciplinary action taken against an active license has been settled and/or removed thus re-instating the permissions previously accorded.			Qualitative Concept	FDA Structured Product Labeling Terminology|SPL License Disciplinary Action Terminology
C118472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118472>	C118405	Other License Status|Other	A disciplinary action has been taken against a license but its status is different from active, suspended, revoked, or resolved.			Qualitative Concept	FDA Structured Product Labeling Terminology|SPL License Disciplinary Action Terminology
C118473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118473>	C17254	Trans-Activator Protein BZLF1|EB1|EBV BZLF-1|EBV BZLF1|Epstein-Barr Virus BZLF-1|Epstein-Barr Virus Trans-Activator Protein BZLF-1|Epstein-Barr Virus Trans-Activator Protein BZLF1|Trans-Activator Protein BZLF-1|Zebra	Trans-activator protein BZLF1 (245 aa, ~27 kDa) is encoded by the Epstein-Barr virus BZLF1 gene. This protein is involved in the induction of both the expression of early lytic cycle genes and the replication of the viral genome.	Trans-Activator Protein BZLF1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118474>	C18520	Damage-Associated Molecular Pattern Molecule|Alarmin|DAMP|Damage Associated Molecular Pattern|Damage-Associated Molecular Pattern|Danger Associated Molecular Pattern|Danger-Associated Molecular Pattern|Danger-Associated Molecular Pattern Molecule	Molecules released during times of cellular stress or necrosis, that can induce or perpetuate the non-infectious immune response.	Damage-Associated Molecular Pattern Molecule		Biologically Active Substance	CTRP Biomarker Terminology|CTRP Terminology
C118475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118475>	C2883	Suppurative Arthritis|Pyogenic Arthritis	Acute inflammation of one or more joints caused by the presence of pus within the joint cavity.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Infectious Disease Terminology
C118476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118476>	C17349	CCND1 Gene Product	A protein encoded by the CCND1 gene.	CCND1 Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118477>	C118476	G1/S-Specific Cyclin-D1b|CCND1b|Cyclin D1b|Cyclin-D1b|G1/S-Specific Cyclin D1b	G1/S-specific cyclin-D1b is encoded by the human CCND1 gene. This protein may play a role in the promotion of tumor cell invasiveness and anchorage-independent growth.	G1/S-Specific Cyclin-D1b		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118478>	C13432	17q13	A chromosome band present on 17q.	17q13		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118479>	C20130	Polycomb-Group Protein|PcG|Polycomb|Polycomb Family|Polycomb Family Protein|Polycomb Group|Polycomb Group Protein|Polycomb-Group	A family of chromatin remodeling factors that contribute to epigenetic silencing during embryonic development.	Polycomb-Group Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11847>	C61063	BMS-214662/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118480>	C20130	Catenin Family Protein|Catenin|Catenin Family	A family of adaptor proteins that bind to cadherin proteins and promote the association of cadherins with the actin cytoskeleton. Catenins play a role in the formation of adherens junctions, the regulation of cell proliferation and the modulation of Wnt signaling pathways.	Catenin Family Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118481>	C20130	Aldehyde Dehydrogenase|ALDH|ALDH Family|Aldehyde Dehydrogenase (NAD)|Aldehyde Dehydrogenase (NADP)|Aldehyde Dehydrogenase Family|Aldehyde Dehydrogenase [NAD(P)+]|Aldehyde Dehydrogenase [NAD(P)]|Aldehyde:NAD(P)+ Oxidoreductase|Aldehyde:NADP+ Oxidoreductase|NAD-Aldehyde Dehydrogenase|NAD-Dependent 4-Hydroxynonenal Dehydrogenase|NAD-Dependent Aldehyde Dehydrogenase|NAD-Linked Aldehyde Dehydrogenase|NADP-Acetaldehyde Dehydrogenase|NADP-Dependent Aldehyde Dehydrogenase|Propionaldehyde Dehydrogenase	A family of enzymes that catalyze the oxidation and detoxification of aldehydes.	Aldehyde Dehydrogenase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118482>	C18520	MINT31|MINT-31	A gene promoter locus that regulates the expression of calcium channels. Methylation of this locus may be associated with colorectal carcinoma and other neoplastic diseases.	MINT31		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118483>	C18239	SSTR2 Gene Product	A protein encoded by the SSTR2 gene.	SSTR2 Gene Product		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118484>	C118483	Somatostatin Receptor Type 2b|SSR(2(b))|SSR2b|SSTR2B|Somatostatin Receptor Subtype 2b|Somatostatin Receptor Type 2 Isoform B	Somatostatin receptor type 2b (356 aa, ~40 kDa) is encoded by the human SSTR2 gene. This protein plays a role in G protein-coupled receptor signaling.	Somatostatin Receptor Type 2b		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118485>	C113513	HLA Class I Histocompatibility Antigen, A-0301 Alpha Chain|A*0301|A*03010101|A*03011|A3.1|HLA Class I Histocompatibility Antigen, A*03:01 Alpha Chain|HLA-A*03|HLA-A*0301|HLA-A*030101|HLA-A*03011|HLA-A0301|HLA-A0301 Antigen|HLA-A3|HLA-A3.1|Leukocyte Antigen Class I-A0301|MHC Class I Antigen A*0301|MHC Class I Antigen HLA-A0301 Heavy Chain|Major Histocompatibility Complex, Class I, A*0301|Major Histocompatibility Complex, Class I, A0301	HLA class I histocompatibility antigen, A-0301 alpha chain (365 aa, ~41 kDa) is encoded by the human HLA-A gene. This protein is involved in the presentation of foreign antigens to the immune system. This isoform is associated with increased risk for multiple sclerosis and is a secondary risk factor for myasthenia gravis.	HLA Class I Histocompatibility Antigen, A-0301 Alpha Chain		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C118486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118486>	C16295	Varicella-Zoster Virus Antibody|Anti-VZV Antibody|Anti-Varicella Zoster Virus Antibody|Anti-Varicella-Zoster Virus Antibody|VZV Antibody|Varicella Zoster Virus Antibody	Any immunoglobulin that recognizes the varicella-zoster virus.	Varicella-Zoster Virus Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C118487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118487>	C16295	Cytomegalovirus Antibody|Anti-CMV Antibody|Anti-Cytomegalovirus Antibody|CMV Antibody	Any immunoglobulin that recognizes the cytomegalovirus virus.	Cytomegalovirus Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C118488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118488>	C16295	Human Herpesvirus 1 Antibody|Anti-HHV-1 Antibody|Anti-HHV1 Antibody|Anti-HSV-1 Antibody|Anti-HSV1 Antibody|Anti-Herpes Simplex Virus 1 Antibody|Anti-Human Herpesvirus 1 Antibody|HHV-1 Antibody|HHV1 Antibody|HSV-1 Antibody|HSV1 Antibody|Herpes Simplex Virus 1 Antibody	Any immunoglobulin that recognizes the human herpesvirus 1.	Human Herpesvirus 1 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C118489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118489>	C16295	Epstein-Barr Virus Antibody|Anti-EBV Antibody|Anti-Epstein-Barr Virus Antibody|Anti-HHV-4 Antibody|Anti-HHV4 Antibody|Anti-Human Herpesvirus 4 Antibody|EBV Antibody|HHV-4 Antibody|HHV4 Antibody|Human Herpesvirus 4 Antibody	Any immunoglobulin that recognizes the Epstein-Barr virus.	Epstein-Barr Virus Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C11848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11848>	C61063	Cytarabine/Gemtuzumab Ozogamicin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118490>	C16295	Cytokine Antibody|Anti-Cytokine Antibody	Any immunoglobulin that recognizes a cytokine.	Cytokine Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118491>	C17444	PTPRC Gene Product	A protein encoded by the human PTPRC gene.	PTPRC Gene Product		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118492>	C118491	CD45RA|CD45RA Antigen|Receptor-Type Tyrosine-Protein Phosphatase C Isoform 6|Receptor-Type Tyrosine-Protein Phosphatase C Isoform CD45RA	CD45RA (1211 aa, ~138 kDa) is encoded by the human PTPRC gene. This protein plays a role in both lymphocyte function and protein dephosphorylation. It is an isoform of receptor-type tyrosine-protein phosphatase C that is missing the amino acids encoded by exons 5 and 6 of the PTPRC gene.	CD45RA		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118493>	C118491	CD45RB|CD45RB Antigen|Receptor-Type Tyrosine-Protein Phosphatase C Isoform 7|Receptor-Type Tyrosine-Protein Phosphatase C Isoform CD45RB	CD45RB (1192 aa, ~136 kDa) is encoded by the human PTPRC gene. This protein is involved in both protein dephosphorylation and lymphocyte activity. It is an isoform of receptor-type tyrosine-protein phosphatase C that is missing the amino acids encoded by exons 4 and 6 of the PTPRC gene.	CD45RB		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118494>	C118491	CD45RC|CD45RC Antigen|Receptor-Type Tyrosine-Protein Phosphatase C Isoform 8|Receptor-Type Tyrosine-Protein Phosphatase C Isoform CD45RC	CD45RC (1193 aa, ~136 kDa) is encoded by the human PTPRC gene. This protein plays a role in both lymphocyte activity and protein dephosphorylation. It is an isoform of receptor-type tyrosine-protein phosphatase C that is missing the amino acids encoded by exons 4 and 5 of the PTPRC gene.	CD45RC		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118495>	C118491	CD45RO|CD45R0|CD45R0 Antigen|CD45RO Antigen|Receptor-Type Tyrosine-Protein Phosphatase C Isoform 2|Receptor-Type Tyrosine-Protein Phosphatase C Isoform CD45RO	CD45RO (1145 aa, ~131 kDa) is encoded by the human PTPRC gene. This protein is involved in both tyrosine dephosphorylation and lymphocyte activity. It is an isoform of receptor-type tyrosine-protein phosphatase C that is missing the amino acids encoded by exons 4, 5 and 6 of the PTPRC gene.	CD45RO		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118496>	C13243	Immunoglobulin Heavy Chain Joining Region|IGH-J	The portion of the heavy chains of immunoglobulin molecules where the variable and constant regions meet.	Immunoglobulin Heavy Chain Joining Region		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118497>	C63797|C36873	Circulating Melanoma Cell|CMC	A melanoma-derived cell found in the peripheral blood.	Circulating Melanoma Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C118498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118498>	C91105	FKSI-15 Questionnaire|FAC039|FKSI-15|FKSI-15|Functional Assessment for Cancer Therapy-Kidney Symptom Index	A 15 item questionnaire developed to assess the symptom burden for patients with kidney cancer.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118499>	C91105	FACT-BP Questionnaire|FACT-BP|FACT-Bone Pain Questionnaire|Functional Assessment of Cancer Therapy-Bone Pain	A subscale complement to the FACT-G developed specifically for evaluating the quality of life of cancer patients with bone pain associated with bone metastases.			Intellectual Product	
C11849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11849>	C61063	Cytarabine/Daunorubicin Liposomal			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1184>	C1931	Pancratistatin|PANCRATISTATIN	A isoquinoline alkaloid from amaryllis with antineoplastic activity.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C118500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118500>	C91105	RCC Symptom Index|RCC-SI|Renal Cell Carcinoma-Symptom Index	A 30 item questionnaire developed to assess the symptom burden and quality of life for patients with renal cell carcinoma.			Intellectual Product	
C118501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118501>	C91126	Have Bone Pain Question|Have Bone Pain|I have bone pain	A question about whether an individual has or had bone pain.			Intellectual Product	FACT-BP Questionnaire
C118502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118502>	C172982	Bothered by Fevers Question|Bothered by Fever|Bothered by Fevers|I am bothered by fevers (episodes of high body temperature)	A question about whether an individual is or was bothered by fevers.			Intellectual Product	FACT-BRM Questionnaire
C118503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118503>	C173981	Have Blood in Urine Question|Blood in Urine|Have Blood in Urine|I have had blood in my urine	A question about whether an individual has or had blood in their urine.			Intellectual Product	FKSI-15 Questionnaire|RCC Symptom Index
C118504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118504>	C1931|C129986	Artemether Sublingual Spray|LON002|Sublingual Artemether Spray	A sublingual spray containing artemether, a semisynthetic derivative of artemisinin, an endoperoxide extracted from the Chinese herb qinghaosu (Artemisia annua or annual wormwood), with antiparasitic and potential antineoplastic activity. Upon sublingual application of the spray, artemether exerts its antineoplastic activity through as of yet not fully elucidated mechanism(s) of action. This agent binds to heme molecules inside cells, thereby inducing reactive oxygen species (ROS)-mediated damage which selectively kills cancer cells. In addition, artemether appears to target and modulate the expression of various proteins involved in cancer cell proliferation, angiogenesis, invasion and metastasis. Also, this agent depletes T regulatory cells, and modulates the production of inflammatory cytokines, such as interleukin-4 and interferon-gamma. Altogether, this inhibits tumor cell proliferation. The sublingual spray allows faster absorption of a higher percentage of the artemether dose, when compared to the oral form, as it avoids first pass metabolism; this results in an increased efficacy.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118505>	C281	Presatovir|GS 5806|GS-5806|GS-5806|Methanesulfonamide, N-(2-(((2S)-2-(5-((3S)-3-amino-1-pyrrolidinyl)-6-methylpyrazolo(1,5-a)pyrimidin-2-yl)-1-piperidinyl)carbonyl)-4-chlorophenyl)-|PRESATOVIR|Respiratory Syncytial Virus Fusion Inhibitor GS-5806	An orally available inhibitor of human respiratory syncytial virus (RSV) fusion protein (F protein), with potential antiviral activity. Upon oral administration of GS-5806, this agent specifically binds to F protein on the viral surface, which inhibits RSV F protein-mediated fusion with the host cell membrane and prevents viral entry. This blocks RSV replication, reduces viral load, and decreases the severity of the disease. RSV F protein, a viral surface glycoprotein, plays a key role in RSV fusion with and entry into target cells.	Presatovir		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C118506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118506>	C91105	FACT-B Questionnaire|FACT-B|Functional Assessment of Cancer Therapy-Breast	A subscale complement to the FACT-G developed specifically for evaluating the quality of life of breast cancer patients.			Intellectual Product	
C118507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118507>	C2962	Neonatal Seizure	Abnormal hypersynchronous electrical activity in the brain of a newborn which may be associated with stereotyped movements or autonomic changes.			Finding	NICHD Terminology|Perinatal Terminology
C118508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118508>	C28193	Gasping Syndrome|Neonatal Gasping Syndrome|Neonatal Gasping Syndrome	A syndrome in preterm neonates exposed to benzyl alcohol preservative in intravascular solutions that is characterized by unremitting gasping respirations and may include anion gap metabolic acidosis, neurologic deterioration, renal failure, convulsions, intraventricular hemorrhage, and cardiovascular collapse.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C118509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118509>	C98996	Neonatal Spell|Neonatal Spells|Neonatal Spells	Cardiorespiratory events that are characterized by variable combinations of cessation of breathing, decrease in blood oxygen saturation, and decreased heart rate.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C11850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11850>	C61007	Cyclophosphamide/Cytarabine/Topotecan			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118510>	C15652	MRI Ultrasound Fusion Guided Biopsy|Fusion Biopsy|Fusion Guided Biopsy|Fusion-Guided Biopsy|MR Fusion Biopsy|MRI-Ultrasound Fusion Biopsy|MRI/US Biopsy|MRI/Ultrasound Fusion Biopsy	A method for targeted biopsy that merges images captured by multiparametric MRI with real-time ultrasound, creating a synthetic, 3D image, which highlights the suspicious area within the image.	MRI Ultrasound Fusion Guided Biopsy		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C118511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118511>	C19151	Satellite Tumor|satellite tumor				Pathologic Function	
C118512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118512>	C93328	Cutaneous Melanoma In-Transit Metastasis|In-Transit Metastasis of Cutaneous Melanoma	Intralymphatic metastasis of cutaneous melanoma between the primary melanoma site and the regional lymph node basin. (from AJCC 7th Ed.)			Pathologic Function	
C118513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118513>	C18568	FGF13 Gene|FGF13|FGF13|Fibroblast Growth Factor 13 Gene	This gene plays a role in neural development.	FGF13 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118514>	C118513	FGF13 wt Allele|FGF-13|FGF2|FHF-2|FHF2|Fibroblast Growth Factor 13 wt Allele|Fibroblast Growth Factor Homologous Factor 2 Gene|RP6-27P15.3	Human FGF13 wild-type allele is located in the vicinity of Xq26.3 and is approximately 591 kb in length. This allele, which encodes fibroblast growth factor 13 protein, is involved in microtubule polymerization, neural development and neuronal migration. Deletion of the region of the X chromosome where the gene is located is associated with Borjeson-Forssman-Lehmann syndrome.	FGF13 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118515>	C20426	Fibroblast Growth Factor 13|FGF-13|FGF13|FHF-2|Fibroblast Growth Factor Homologous Factor 2	Fibroblast growth factor 13 (245 aa, ~28 kDa) is encoded by the human FGF13 gene. This protein plays a role in the regulation of both the development of the nervous system and microtubule polymerization.	Fibroblast Growth Factor 13		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118516>	C20194	BPIFA1 Gene|BPI Fold Containing Family A, Member 1 Gene|BPIFA1|BPIFA1	This gene may be involved in innate immune responses in the upper airway.	BPIFA1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118517>	C118516	BPIFA1 wt Allele|BPI Fold Containing Family A, Member 1 wt Allele|BPI Fold-Containing, Family A, Member 1 Gene|LUNX|NASG|PLUNC|Palate, Lung and Nasal Epithelium Associated Gene|Palate, Lung and Nasal Epithelium Carcinoma Associated Gene|SPLUNC1|SPURT|UNQ787/PRO1606|bA49G10.5	Human BPIFA1 wild-type allele is located in the vicinity of 20q11.21 and is approximately 7 kb in length. This allele, which encodes BPI fold-containing family A member 1 protein, may play a role in anti-bacterial defense in the upper airway. This gene may be associated with micrometastasis in non-small-cell lung carcinoma.	BPIFA1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118518>	C18466	BPI Fold-Containing Family A Member 1|Ligand-Binding Protein RYA3|Lung-Specific Protein X|Nasopharyngeal Carcinoma-Related Protein|Palate Lung and Nasal Epithelium Clone Protein|Palate, Lung and Nasal Epithelium Carcinoma-Associated Protein|Protein Plunc|SPLUNC1|Secretory Protein in Upper Respiratory Tracts|Short PLUNC1|Tracheal Epithelium Enriched Protein|Tracheal Epithelium-Enriched Protein|Von Ebner Protein Hl	BPI fold-containing family A member 1 (256 aa, ~27 kDa) is encoded by the human BPIFA1 gene. This protein may be involved in innate immunity in the upper respiratory tract.	BPI Fold-Containing Family A Member 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118519>	C20420	EGR3 Gene|EGR3|EGR3|Early Growth Response 3 Gene	This gene plays a role in mitogen-dependent transcriptional regulation.	EGR3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C11851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11851>	C61063	Doxorubicin Hcl Liposome/Gemcitabine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118520>	C118519	EGR3 wt Allele|EGR-3|Early Growth Response 3 wt Allele|PILOT	Human EGR3 wild-type allele is located within 8p23-p21 and is approximately 6 kb in length. This allele, which encodes early growth response protein 3, is involved in biological rhythms, muscle development, and the growth and migration of endothelial cells.	EGR3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118521>	C17207	Early Growth Response Protein 3|EGR-3|Zinc Finger Protein Pilot	Early growth response protein 3 (387 aa, ~43 kDa) is encoded by the human EGR3 gene. This protein plays a role in the regulation of muscle development, endothelial tube formation and transcription.	Early Growth Response Protein 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118522>	C25870	CHST15 Gene|CHST15|CHST15|Carbohydrate (N-Acetylgalactosamine 4-Sulfate 6-O) Sulfotransferase 15 Gene	This gene is involved in chondroitin sulfate metabolism.	CHST15 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118523>	C118522	CHST15 wt Allele|B-Cell RAG-Associated Gene|BRAG|Carbohydrate (N-Acetylgalactosamine 4-Sulfate 6-O) Sulfotransferase 15 wt Allele|GALNAC4S-6ST|GALNAC4S6ST|KIAA0598	Human CHST15 wild-type allele is located in the vicinity of 10q26 and is approximately 86 kb in length. This allele, which encodes carbohydrate sulfotransferase 15 protein, plays a role in the metabolism of chondroitin sulfate.	CHST15 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118524>	C17210	Carbohydrate Sulfotransferase 15|B Cell RAG Associated Protein|B-Cell RAG-Associated Gene Protein|CHST15|EC 2.8.2.33|GalNAc4S-6ST|N-Acetylgalactosamine 4-Sulfate 6-O-Sulfotransferase|hBRAG	Carbohydrate sulfotransferase 15 (561 aa, ~65 kDa) is encoded by the human CHST15 gene. This protein is involved in chondroitin sulfate metabolism.	Carbohydrate Sulfotransferase 15		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118525>	C28533|C158414	ATP5F1B Gene|ATP Synthase F1 Subunit Beta Gene|ATP5B|ATP5B Gene|ATP5F1B|ATP5F1B	This gene plays a role in both oxidative phosphorylation and ATP synthesis.	ATP5B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118526>	C118525	ATP5F1B wt Allele|ATP Synthase F1 Subunit Beta wt Allele|ATP Synthase, H+ Transporting, Mitochondrial F1 Complex, Beta Polypeptide Gene|ATP Synthase, H+ Transporting, Mitochondrial F1 Complex, Beta Subunit Gene|ATP5B|ATP5B wt Allele|ATPMB|ATPSB|HEL-S-271|Mitochondrial ATP Synthase, Beta Subunit Gene|Mitochondrial ATP Synthetase, Beta Subunit Gene	Human ATP5F1B wild-type allele is located in the vicinity of 12p13.3 and is approximately 8 kb in length. This allele, which encodes ATP synthase subunit beta, mitochondrial protein, is involved in both ATP synthesis and proton transport.	ATP5B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118527>	C16386|C158419	ATP Synthase Subunit Beta, Mitochondrial|ATP Synthase F1 Subunit Beta|ATP5B|ATP5F1B|EC 3.6.3.14, Formerly|EC 7.1.2.2|Epididymis Secretory Protein Li 271|Mitochondrial ATP Synthase Beta Subunit	ATP synthase subunit beta, mitochondrial (529 aa, ~57 kDa) is encoded by the human ATP5F1B gene. This protein plays a role in ATP synthesis, hydrogen ion exchange and oxidative phosphorylation.	ATP Synthase Subunit Beta, Mitochondrial		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118528>	C21295	NCR3LG1 Gene|NCR3LG1|NCR3LG1|Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1 Gene	This gene is involved in natural killer cell-dependent immunity.	NCR3LG1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118529>	C118528	NCR3LG1 wt Allele|B7-H6|B7H6|DKFZp686O24166|Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1 wt Allele	Human NCR3LG1 wild-type allele is located in the vicinity of 11p15.1 and is approximately 26 kb in length. This allele, which encodes natural cytotoxicity triggering receptor 3 ligand 1 protein, plays a role in both the activation of and cytotoxicity mediated by natural killer cells.	NCR3LG1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11852>	C61063	gp209-2M Antigen/Interleukin-2/Montanide ISA-51			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118530>	C17728	Natural Cytotoxicity Triggering Receptor 3 Ligand 1|B7-H6|NCR3LG1|Putative Ig-Like Domain-Containing Protein DKFZp686O24166/DKFZp686I21167	Natural cytotoxicity triggering receptor 3 ligand 1 (454 aa, ~51 kDa) is encoded by the human NCR3LG1 gene. This protein is involved in the activation of natural killer cell-mediated cytotoxicity.	Natural Cytotoxicity Triggering Receptor 3 Ligand 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118531>	C25804	EP400 Gene|E1A Binding Protein P400 Gene|EP400|EP400	This gene plays a role in the regulation of histone acetylation.	EP400 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118532>	C118531	EP400 wt Allele|CAGH32|DKFZP434I225|Domino, Drosophila, Homolog of Gene|E1A Binding Protein P400 wt Allele|P400|TNRC12|Trinucleotide Repeat-Containing Gene 12	Human EP400 wild-type allele is located in the vicinity of 12q24.33 and is approximately 131 kb in length. This allele, which encodes E1A-binding protein p400, is involved in the regulation of both gene expression and histone acetylation.	EP400 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118533>	C16701	E1A-Binding Protein P400|CAG Repeat Protein 32|Domino Homolog|E1A-Binding Protein, 400-kD|EC 3.6.4.-|EP400|Trinucleotide Repeat Containing 12|Trinucleotide Repeat-Containing Gene 12 Protein|hDomino|p400|p400 SWI2/SNF2-Related Protein|p400 kDa SWI2/SNF2-Related Protein	E1A-binding protein p400 (3159 aa, ~343 kDa) is encoded by the human EP400 gene. This protein plays a role in the modulation of transcription through the regulation of histone acetylation.	E1A-Binding Protein P400		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118534>	C20194	SPATA20 Gene|SPATA20|SPATA20|Spermatogenesis Associated 20 Gene	This gene may be involved in fertility.	SPATA20 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118535>	C118534	SPATA20 wt Allele|FLJ21347|SSP411|Spermatogenesis Associated 20 wt Allele|Tisp78|Transcript Increased in Spermiogenesis 78 Gene	Human SPATA20 wild-type allele is located in the vicinity of 17q21.33 and is approximately 13 kb in length. This allele, which encodes spermatogenesis-associated protein 20, may play a role in germ cell maturation.	SPATA20 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118536>	C18466	Spermatogenesis-Associated Protein 20|Hypothetical Protein FLJ21347|Sperm Protein SSP411|Sperm-Specific Protein 411|Ssp411	Spermatogenesis-associated protein 20 (786 aa, ~88 kDa) is encoded by the human SPATA20 gene. This protein may be involved in fertility.	Spermatogenesis-Associated Protein 20		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118537>	C20194	PEX5L Gene|PEX5L|PEX5L|Peroxisomal Biogenesis Factor 5-Like Gene	This gene plays a role in the regulation of nucleotide-dependent signaling.	PEX5L Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118538>	C118537	PEX5L wt Allele|PEX5R|PEX5RP|PXR2|PXR2B|Peroxisomal Biogenesis Factor 5-Like wt Allele|TRIP8b	Human PEX5L wild-type allele is located in the vicinity of 3q27.33 and is approximately 242 kb in length. This allele, which encodes PEX5-related protein, is involved in the regulation of both hyperpolarization-activated cyclic nucleotide-gated channels and downstream signaling pathways.	PEX5L wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118539>	C18466	PEX5-Related Protein|PEX2-Related Protein|PEX5-Like Protein|Peroxin-5-Related|Peroxisome Biogenesis Factor 5-Like|Pex5Rp|Pex5p-Related Protein|TRIP8b|Tetratricopeptide Repeat-Containing Rab8b-Interacting Protein	PEX5-related protein (626 aa, ~70 kDa) is encoded by the human PEX5L gene. This protein plays a role in the localization of hyperpolarization-activated cyclic nucleotide-gated channels.	PEX5-Related Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11853>	C61007	Cisplatin/Gemcitabine/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118540>	C25943	ASS1 Gene|ASS1|ASS1|Argininosuccinate Synthase 1 Gene	This gene is involved in amino acid biosynthesis.	ASS1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118541>	C118540	ASS1 wt Allele|ASS|Argininosuccinate Synthase 1 wt Allele|CTLN1|RP11-618A20.2	Human ASS1 wild-type allele is located in the vicinity of 9q34.1 and is approximately 57 kb in length. This allele, which encodes argininosuccinate synthase protein, plays a role in amino acid metabolism and blood pressure. Mutation of the gene is associated with citrullinemia type 1.	ASS1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118542>	C16796	Argininosuccinate Synthase|ASS1|Argininosuccinate Synthase 1|Argininosuccinate Synthetase|Argininosuccinate Synthetase 1|Citrulline--Aspartate Ligase|Citrulline-Aspartate Ligase|Citrulline—Aspartate Ligase|EC 6.3.4.5	Argininosuccinate synthase (412 aa, ~47 kDa) is encoded by the human ASS1 gene. This protein is involved in the biosynthesis of arginine.	Argininosuccinate Synthase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118543>	C21072	Paravertebral Block|PVB	A technique where a bolus of local anesthetic is injected in the paravertebral space, in the vicinity of the thoracic spinal nerves, resulting in ipsilateral somatic and sympathetic nerve blockade within the chest or abdomen.	Paravertebral Block		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C118544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118544>	C15643	Central Lymph Node Dissection	Dissection of the lymph nodes that surround the thyroid gland.	Central Lymph Node Dissection		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C118545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118545>	C25952	ABHD12 Gene|ABHD12|ABHD12|Abhydrolase Domain Containing 12 Gene	This gene plays a role in endocannabinoid metabolism.	ABHD12 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118546>	C118545	ABHD12 wt Allele|ABHD12A|Abhydrolase Domain Containing 12 wt Allele|BEM46L2|C20orf22|Chromosome 20 Open Reading Frame 22 Gene|DKFZP434P106|PHARC|RP5-965G21.2|dJ965G21.2	Human ABHD12 wild-type allele is located in the vicinity of 20p11.21 and is approximately 96 kb in length. This allele, which encodes monoacylglycerol lipase ABHD12 protein, is involved in endocannabinoid catabolism. Mutation of the gene is associated with the neurological disorder, polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract.	ABHD12 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118547>	C16561	Monoacylglycerol Lipase ABHD12|2-Arachidonoylglycerol Hydrolase|ABHD12|Abhydrolase Domain-Containing Protein 12|EC 3.1.1.23	Monoacylglycerol lipase ABHD12 (398 aa, ~45 kDa) is encoded by the human ABHD12 gene. This protein plays a role in endocannabinoid hydrolysis.	Monoacylglycerol Lipase ABHD12		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118548>	C20745	PDLIM3 Gene|PDLIM3|PDLIM3|PDZ and LIM Domain 3 Gene	This gene may be involved in cytoskeletal rearrangement.	PDLIM3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118549>	C118548	PDLIM3 wt Allele|ALP|PDZ and LIM Domain 3 wt Allele	Human PDLIM3 wild-type allele is located in the vicinity of 4q35 and is approximately 35 kb in length. This allele, which encodes PDZ and LIM domain protein 3, may play a role in the modulation of actin filament formation. Alternative splicing of the gene may be associated with myotonic dystrophy.	PDLIM3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11854>	C61063	BMS-188797/Carboplatin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118550>	C16492	PDZ and LIM Domain Protein 3|Actinin-Associated LIM Protein|Alpha-Actinin-2-Associated LIM Protein|Enigma Homolog|PDLIM3	PDZ and LIM domain protein 3 (364 aa, ~39 kDa) is encoded by the human PDLIM3 gene. This protein may be involved in the arrangement of the actin cytoskeleton.	PDZ and LIM Domain Protein 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118551>	C20194	SHROOM2 Gene|SHROOM2|SHROOM2|Shroom Family Member 2 Gene	This gene may play a role in the modulation of cell morphology.	SHROOM2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118552>	C118551	SHROOM2 wt Allele|APXL|Apical Protein, Xenopus laevis-Like Gene|Apical Protein-Like (Xenopus laevis) Gene|HSAPXL|Shroom Family Member 2 wt Allele	Human SHROOM2 wild-type allele is located in the vicinity of Xp22.3 and is approximately 163 kb in length. This allele, which encodes protein Shroom2, may be involved in the modulation of cell shape. Deletion of the gene may be associated with ocular albinism type 1.	SHROOM2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118553>	C18466	Protein Shroom2|APX Homolog of Xenopus|Apical Protein of Xenopus-Like|Apical-Like Protein|Protein APXL	Protein Shroom2 (1616 aa, ~176 kDa) is encoded by the human SHROOM2 gene. This protein may play a role in the regulation of cell spreading.	Protein Shroom2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118554>	C20988	PVR Gene|PVR|PVR|PVR Cell Adhesion Molecule Gene	This gene is involved in natural killer cell-adhesion and activation.	PVR Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118555>	C118554	PVR wt Allele|CD155|HVED|NECL5|Necl-5|Nectin-Like 5 Gene|PVR Cell Adhesion Molecule wt Allele|PVS|Poliovirus Receptor Gene|TAGE4	Human PVR wild-type allele is located in the vicinity of 19q13.2 and is approximately 22 kb in length. This allele, which encodes poliovirus receptor protein, plays a role in poliovirus adhesion to host cells and the adhesion and activation of natural killer cells.	PVR wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118556>	C16393	Poliovirus Receptor|CD155|CD155 Antigen|NECL-5|Nectin-Like Protein 5|PVR	Poliovirus receptor (417 aa, ~45 kDa) is encoded by the human PVR gene. This protein is involved in both natural killer cell activation and poliovirus binding.	Poliovirus Receptor		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118557>	C26003	CTRC Gene|CTRC|CTRC|Chymotrypsin C (Caldecrin) Gene	This gene plays a role in zymogen activation.	CTRC Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118558>	C118557	CTRC wt Allele|CLCR|Chymotrypsin C (Caldecrin) wt Allele|ELA4	Human CTRC wild-type allele is located in the vicinity of 1p36.21 and is approximately 11 kb in length. This allele, which encodes chymotrypsin-C protein, is involved in the proteolytic activation of other serine proteinases. Mutation of the gene is associated with hereditary pancreatitis.	CTRC wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118559>	C17123	Chymotrypsin-C|CTRC|Caldecrin|Chymotrypsin C|EC 3.4.21.2|Elastase 4|Elastase IV|Serum Calcium Decreasing Factor	Chymotrypsin-C (268 aa, ~29 kDa) is encoded by the human CTRC gene. This protein plays a role in site-specific proteolysis.	Chymotrypsin-C		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11855>	C61063	Autologous Dendritic Cells/Candida Albicans Skin Test Reagent/CD40-Ligand/gp100 Antigen/Interferon Gamma/Interleukin-4/MART-1 Antigen/Sargramostim/Tyrosinase Peptide	A combination of agents containing autologous dendritic cells, Candida albicans skin test reagent, CD40-ligand, gp100 antigen, interferon gamma, interleukin-4, MART-1 antigen, sargramostim and tyrosinase peptide.		Obsolete_Concept	Therapeutic or Preventive Procedure	
C118560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118560>	C26003	PRSS2 Gene|PRSS2|PRSS2|Protease, Serine, 2 (Trypsin 2) Gene	This gene is involved in proteolysis in the ileum.	PRSS2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118561>	C118560	PRSS2 wt Allele|Protease, Serine, 2 (Trypsin 2) wt Allele|Protease, Serine, 2, Preproprotein Gene|TRY2|TRY8|TRYP2|Trypsinogen, Anionic Gene	Human PRSS2 wild-type allele is located in the vicinity of 7q34 and is approximately 4 kb in length. This allele, which encodes trypsin-2 protein, plays a role in protein metabolism. This gene may be associated with pancreatitis.	PRSS2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118562>	C17123	Trypsin-2|Anionic Trypsinogen|EC 3.4.21.4|PRSS2|Protease Serine 2 Preproprotein|Serine Protease 2|Trypsin 2|Trypsin II|Trypsinogen 2	Trypsin-2 (247 aa, ~26 kDa) is encoded by the human PRSS2 gene. This protein is involved in the catabolism of proteins in the small intestine.	Trypsin-2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118563>	C25939	CBR1 Gene|CBR1|CBR1|Carbonyl Reductase 1 Gene	This gene plays a role in the metabolism of a wide variety of carbonyl compounds.	CBR1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118564>	C118563	CBR1 wt Allele|CBPR1|CBR|CRN|Carbonyl Reductase 1 wt Allele|SDR21C1|Short Chain Dehydrogenase/Reductase Family 21C, Member 1 Gene|hCBR1	Human CBR1 wild-type allele is located in the vicinity of 21q22.1 and is approximately 3 kb in length. This allele, which encodes carbonyl reductase [NADPH] 1 protein, is involved in the reduction of a wide variety of carbonyl compounds.	CBR1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118565>	C16946	Carbonyl Reductase [NADPH] 1|15-Hydroxyprostaglandin Dehydrogenase|15-Hydroxyprostaglandin Dehydrogenase [NADP(+)]|CBR1|Carbonyl Reductase|Carbonyl Reductase (NADPH) 1|Carbonyl Reductase 1|NADPH-Dependent Carbonyl Reductase 1|Prostaglandin 9-Ketoreductase|Prostaglandin-E(2) 9-Reductase	Carbonyl reductase [NADPH] 1 (277 aa, ~30 kDa) is encoded by the human CBR1 gene. This protein plays a role in the reduction of carbonyl compounds.	Carbonyl Reductase [NADPH] 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118566>	C16502	Biodynamic Imaging|BDI	A technique that uses low-coherence laser light scattering (digital holography) to measure cellular motions inside living tissue. This information can be used to map the effects of a drug or xenobiotic within different zones of a tissue or tumor, allowing for near immediate feedback regarding the efficacy of treatment.	Biodynamic Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C118567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118567>	C53607	Health Telemonitoring	The use of video, audio, and other methods of telecommunicating to monitor a patient's health status from a site distant to the patient.	Health Telemonitoring		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C118569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118569>	C213143	Anti-Notch3 Antibody-drug Conjugate PF-06650808|Anti-Notch3 ADC PF-06650808|PF 06650808|PF-06650808|PF06650808	An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the neurogenic locus notch homolog protein 3 (Notch3) receptor conjugated to an auristatin-based cytotoxic payload, with potential antineoplastic activity. Upon administration of anti-Notch3 ADC PF-06650808, the antibody moiety targets and binds to Notch3 expressed on tumor cells. Upon binding and internalization, the auristatin-based cytotoxic agent binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces apoptosis of Notch3-expressing tumor cells. Notch3 is overexpressed on a variety of cancer cells.	Anti-Notch3 Antibody-drug Conjugate PF-06650808		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C11856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11856>	C61063	Capecitabine/Paclitaxel/Trastuzumab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118570>	C213143|C200106	Anti-TROP-2 Antibody-drug Conjugate PF-06664178|Anti-TROP-2 ADC PF-06664178|Anti-TROP-2/Aur0101 ADC PF-06664178|PF 06664178|PF-06664178|PF06664178|RN 927C|RN-927C|RN927C	An antibody-drug conjugate (ADC) composed of PF-06478924 (RN926), a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1), site-specifically conjugated via a valine-citrulline cleavable linker with the auristatin-based cytotoxic agent Aur0101 (PF-06380101), with potential antineoplastic activity. Upon administration of anti-TROP-2 ADC PF-06664178, the anti-TROP-2 monoclonal antibody moiety PF-06478924 targets and binds to TROP-2 expressed on tumor cells. Upon binding, internalization and linker cleavage, Aur0101 binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and apoptosis of TROP-2-expressing tumor cells. TROP-2 is a transmembrane protein overexpressed in various tumors. Its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival.	Anti-TROP-2 Antibody-drug Conjugate PF-06664178		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C118571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118571>	C211912|C201552	Telisotuzumab Vedotin|ABBV 399|ABBV-399|ABT 399|ABT-399|ABT-700-VCMMAE|Emrelis|TELISOTUZUMAB VEDOTIN|Telisotuzumab Vedotin-tllv	An antibody-drug conjugate (ADC) composed of telisotuzumab, a monoclonal antibody against the tumor-associated antigen (TAA) and proto-oncogene, c-Met receptor tyrosine kinase (c-Met; MET; hepatocyte growth factor receptor; HGFR) conjugated to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline (vc) peptide linker (vc-MMAE; vedotin), with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of telisotuzumab vedotin targets and binds to c-Met expressed on tumor cells. Upon binding, internalization and enzymatic cleavage, the cytotoxic agent MMAE is released into the cytosol. MMAE binds to tubulin and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. This kills the c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis.	Telisotuzumab Vedotin		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118572>	C129823	Anti-EFNA4/Calicheamicin Antibody-drug Conjugate PF-06647263|ADC PF-06647263|Anti-EFNA4 Antibody-drug Conjugate PF-06647263|Anti-Ephrin-A4/Calicheamicin Antibody-drug Conjugate PF-06647263|Antibody-drug Conjugate PF-06647263|PF 06647263|PF-06647263|PF06647263	An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against Ephrin-A4 (EFNA4), conjugated, via a hydrazone-based cleavable linker, to the DNA damaging agent calicheamicin, with potential antineoplastic activity. Upon administration of anti-EFNA4/calicheamicin ADC PF-06647263, the anti-EFNA4 monoclonal antibody moiety targets and binds to EFNA4 expressed on tumor cells. Upon binding, internalization and linker cleavage, calicheamicin is released and binds to the minor groove of DNA, causing double strand DNA breaks and may result in the inhibition of DNA synthesis and cell death in EFNA4-expressing tumor cells. EFNA4 is overexpressed by a variety of different cancer cell types and its expression is correlated with increased proliferation, invasion, and metastasis.	Anti-EFNA4/Calicheamicin Antibody-drug Conjugate PF-06647263		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C118573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118573>	C200529|C129825	Varegacestat|AL 102|AL-102|AL102|BMS-986115|GS/pan-Notch Inhibitor AL102|VAREGACESTAT|WHG 626|WHG-626|WHG626	An orally bioavailable, gamma secretase (GS) and pan-Notch inhibitor, with potential antineoplastic activity. Upon administration, varegacestat binds to GS and blocks the proteolytic cleavage and release of the Notch intracellular domain (NICD), which would normally follow ligand binding to the extracellular domain of the Notch receptor. This prevents both the subsequent translocation of NICD to the nucleus to form a transcription factor complex and the expression of Notch-regulated genes. This results in the induction of apoptosis and the inhibition of growth of tumor cells that overexpress Notch. Overexpression of the Notch signaling pathway plays an important role in tumor cell proliferation and survival. The integral membrane protein GS is a multi-subunit protease complex that cleaves single-pass transmembrane proteins, such as Notch receptors, at residues within their transmembrane domains and leads to their activation.	Varegacestat		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118575>	C1966	Plectin-1 Targeting Agent PTP-01|PTP-01	An imaging agent containing a plectin-1 (Plec1; plectin) targeting peptide (PTP), with potential use for the detection of Plec1-expressing tumor cells using single-photon emission computed tomography (SPECT). Upon administration, the Plec1 targeting agent PTP-01 specifically targets and binds to Plec1 on Plec1-expressing cancer cells. Upon SPECT imaging, the Plec1-expressing cancer cells can be visualized. Plec1, a pro-tumorigenic protein, is normally found inside the cytoplasm of healthy cells but is only selectively expressed on the cell surface of various cancer cells and plays an important role in cancer cell proliferation, migration and invasion.	Plectin-1 Targeting Agent PTP-01		Indicator, Reagent, or Diagnostic Aid|Organic Chemical	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C118576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118576>	C28681|C213868	NGFR-transduced Autologous T Lymphocytes	A preparation of autologous, genetically modified T-lymphocytes that are expressing the tumor-associated antigen (TAA) nerve growth factor receptor (NGFR; p75 neurotrophin receptor; p75(NTR); CD271), with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the NGFR-transduced autologous T-lymphocytes may induce an immune response and may kill NGF-expressing tumor cells. Dysregulated NGF signaling may promote proliferation and invasion in certain tumor cell types.	NGFR-transduced Autologous T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C118577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118577>	C804	Trifarotene|3''-Tert-butyl-4'-(2-hydroxyethoxy)-4''-(pyrrolidin-1-yl)(1,1':3',1'')terphenyl-4-carboxylic Acid|Aklief|CD5789|TRIFAROTENE	A selective retinoic acid receptor gamma (RAR gamma) agonist that can be used in the treatment of acne vulgaris.  Upon topical application, trifarotene selectively binds to the RAR gamma receptor, thereby altering the expression of certain genes that are involved in inflammation and cellular differentiation. 	Trifarotene		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C118578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118578>	C28227|C1742|C129822	Vanucizumab|Ang2-VEGF-A CrossMab RO5520985|Immunoglobulin Recombined G1-kappa/lambda, Anti-(Homo sapiens Angpt2 (Angiopoietin 2, Ang2))/Anti-Homo sapiens VEGFa (Vascular Endothelial Growth Factor A, VEGF-a, VEGF)), Humanized Monoclonal Antibody|RG-7221|RG7221|RO-5520985|RO5520985|VANUCIZUMAB	A humanized bispecific immunoglobulin G (IgG1) monoclonal antibody targeting both the vascular endothelial growth factor receptor (VEGFR) ligand VEGF-A and the Tie2 receptor ligand angiopoietin-2 (Ang-2), with potential antineoplastic and anti-angiogenic activities. Upon administration of vanucizumab, the anti-VEGF-A arm, which is based on bevacizumab, targets and binds to VEGF-A and the anti-Ang2 arm, which is based on the anti-Ang-2 antibody LC06, targets and binds to Ang2, thereby simultaneously binding and neutralizing both VEGF-A and Ang2. This prevents the activation of both VEGF-A/VEGFR- and Ang2/Tie2-mediated signaling pathways. Altogether, this results in the inhibition of proliferation of VEGF-A- and/or Ang2-overexpressing tumor cells. VEGF-A and Ang2, both upregulated in a variety of tumor cell types, play key roles in tumor cell proliferation, angiogenesis and metastasis.	Vanucizumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C118579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118579>	C20194	UBQLN4 Gene|UBQLN4|UBQLN4|Ubiquilin 4 Gene	This gene may be involved in the regulation of protein degradation.	UBQLN4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C11857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11857>	C61063	rV-B7.1 Vaccine/Vaccinia-Prostate-Specific-Antigen Vaccine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118580>	C118579	UBQLN4 wt Allele|A1U|C1orf6|CIP75|Chromosome 1 Open Reading Frame 6 Gene|RP11-336K24.8|UBIN|Ubiquilin 4 wt Allele	Human UBQLN4 wild-type allele is located in the vicinity of 1q21 and is approximately 18 kb in length. This allele, which encodes ubiquilin-4 protein, may play a role in the regulation of the proteasome.	UBQLN4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118581>	C18466	Ubiquilin-4|A1Up|Ataxin-1 Interacting Ubiquitin-Like Protein|Ataxin-1 Ubiquitin-Like Interacting Protein|Ataxin-1 Ubiquitin-Like-Interacting Protein A1U|CIP75|Connexin 43-Interacting Protein, 75 kD|Connexin43-Interacting Protein of 75 kDa	Ubiquilin-4 (601 aa, ~64 kDa) is encoded by the human UBQLN4 gene. This protein may be involved in the modulation of proteasome-mediated protein degradation.	Ubiquilin-4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118582>	C20103	PROCR Gene|PROCR|PROCR|Protein C Receptor, Endothelial Gene	This gene plays a role in blood coagulation.	PROCR Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118583>	C118582	PROCR wt Allele|CCCA|CCD41|EPCR|Protein C Receptor, Endothelial wt Allele	Human PROCR wild-type allele is located in the vicinity of 20q11.2 and is approximately 5 kb in length. This allele, which encodes endothelial protein C receptor protein, is involved in the modulation of protein C localization.	PROCR wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118584>	C18106	Endothelial Protein C Receptor|APC Receptor|Activated Protein C Receptor|CD201|CD201 Antigen|Cell Cycle, Centrosome-Associated Protein|Centrocyclin|Endothelial Cell Protein C Receptor|PROCR	Endothelial protein C receptor (238 aa, ~27 kDa) is encoded by the human PROCR gene. This protein plays a role in the regulation of protein C-mediated blood coagulation.	Endothelial Protein C Receptor		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118585>	C25997|C20420	SMAD5 Gene|SMAD Family Member 5 Gene|SMAD5|SMAD5	This gene is involved in signal transduction-mediated transcriptional regulation.	SMAD5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118586>	C118585	SMAD5 wt Allele|DWFC|JV5-1|MAD, Mothers Against Decapentaplegic Homolog 5 (Drosophila) Gene|MAD, Mothers Against Decapentaplegic Homolog 5 Gene|MADH5|Mothers Against Decapentaplegic, Drosophila, Homolog of, 5 Gene|SMAD Family Member 5 wt Allele|SMAD, Mothers Against DPP Homolog 5 (Drosophila) Gene|SMAD, Mothers Against DPP Homolog 5 Gene	Human SMAD5 wild-type allele is located in the vicinity of 5q31 and is approximately 56 kb in length. This allele, which encodes mothers against decapentaplegic homolog 5 protein, plays a role in the regulation of gene expression.	SMAD5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118587>	C26231|C17207	Mothers Against Decapentaplegic Homolog 5|JV5-1|MAD Homolog 5|Mothers Against DPP Homolog 5|SMA- and MAD-Related Protein 5|SMAD 5|Smad5|hSmad5	Mothers against decapentaplegic homolog 5 (465 aa, ~52 kDa) is encoded by the human SMAD5 gene. This protein is involved in transcriptional regulation mediated by receptor signaling.	Mothers Against Decapentaplegic Homolog 5		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118588>	C25900|C20988	CEACAM8 Gene|CEACAM8|CEACAM8|Carcinoembryonic Antigen-Related Cell Adhesion Molecule 8 Gene	This gene may play a role in the modulation of immunity.	CEACAM8 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118589>	C118588	CEACAM8 wt Allele|CD66b|CD67|CGM6|Carcinoembryonic Antigen-Related Cell Adhesion Molecule 8 wt Allele|NCA-95	Human CEACAM8 wild-type allele is located in the vicinity of 19q13.2 and is approximately 15 kb in length. This allele, which encodes carcinoembryonic antigen-related cell adhesion molecule 8 protein, may be involved in immune cell activation.	CEACAM8 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11858>	C61007	Dexamethasone/Idarubicin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118590>	C18466	Carcinoembryonic Antigen-Related Cell Adhesion Molecule 8|CD66b|CD66b Antigen|CD67 Antigen|CEACAM8|Carcinoembryonic Antigen CGM6|Carcinoembryonic Antigen Gene Family Member 6|Non-Specific Cross-Reacting Antigen NCA-95	Carcinoembryonic antigen-related cell adhesion molecule 8 (349 aa, ~38 kDa) is encoded by the human CEACAM8 gene. This protein may play a role in the activation of immune cells.	Carcinoembryonic Antigen-Related Cell Adhesion Molecule 8		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118591>	C20988	F11R Gene|F11 Receptor Gene|F11R|F11R	This gene is involved in the formation of cell-cell junctions.	F11R Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118592>	C118591	F11R wt Allele|CD321|F11 Receptor wt Allele|JAM|JAM1|JAMA|JCAM|Junctional Adhesion Molecule, Mouse, Homolog of Gene|KAT|PAM-1|RP11-544M22.2|UNQ264/PRO301	Human F11R wild-type allele is located within 1q21.2-q21.3 and is approximately 26 kb in length. This allele, which encodes junctional adhesion molecule A protein, plays a role in the modulation of cell-cell junction formation.	F11R wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118593>	C16393	Junctional Adhesion Molecule A|CD321|CD321 Antigen|JAM-1|JAM-A|Junctional Adhesion Molecule 1|PAM-1|Platelet Adhesion Molecule 1|Platelet F11 Receptor	Junctional adhesion molecule A (299 aa, ~33 kDa) is encoded by the human F11R gene. This protein is involved in the regulation of cell-cell junction formation.	Junctional Adhesion Molecule A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118594>	C173160	Feel Listless Question|Feel Listless|I feel listless ("washed out")	A question about whether an individual feels or felt listless.			Intellectual Product	
C118595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118595>	C173935|C173398	Have Trouble Starting Things Because of Tiredness Question|Have Trouble Starting Things Because of Tiredness|I had trouble starting things because I was too tired|I have trouble starting things because I am tired	A question about whether an individual has or had trouble starting things because they are tired.			Intellectual Product	PROMIS Adult Physical Health Domain|PROMIS Pediatric and Parent Proxy Physical Health Domain
C118596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118596>	C173935|C173398	Have Trouble Finishing Things Because of Tiredness Question|Have Trouble Finishing Things Because of Tiredness|I have trouble finishing things because I am tired	A question about whether an individual has or had trouble finishing things because they are tired.			Intellectual Product	PROMIS Pediatric and Parent Proxy Physical Health Domain
C118597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118597>	C20921	ASAP1 Gene|ASAP1|ASAP1|ArfGAP with SH3 Domain, Ankyrin Repeat and PH Domain 1 Gene	This gene plays a role in the regulation of signal transduction pathways.	ASAP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118598>	C118597	ASAP1 wt Allele|AMAP1|ArfGAP with SH3 Domain, Ankyrin Repeat and PH Domain 1 wt Allele|CENTB4|Centaurin, Beta 4 Gene|DDEF1|Development and Differentiation Enhancing Factor 1 Gene|KIAA1249|PAG2|PAP|ZG14P	Human ASAP1 wild-type allele is located within 8q24.1-q24.2 and is approximately 392 kb in length. This allele, which encodes Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1, is involved in the regulation of phosphoinositol-mediated signaling.	ASAP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118599>	C17298	Arf-GAP with SH3 Domain, Ankyrin Repeat and PH Domain-Containing 1|130 kDa Phosphatidylinositol 4,5-Biphosphate-Dependent ARF1 GTPase-Activating Protein|130 kDa Phosphatidylinositol 4,5-Bisphosphate-Dependent ARF1 GTPase-Activating Protein|ADP-Ribosylation Factor-Directed GTPase-Activating Protein 1|ARF GTPase-Activating Protein 1|ASAP1|Arf-GAP with SH3 Domain, Ankyrin Repeat and PH Domain 1|DEF-1|Development and Differentiation-Enhancing Factor 1|Development- and Differentiation-Enhancing Factor 1|Differentiation-Enhancing Factor 1|PIP2-Dependent ARF1 GAP	Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 (1129 aa, ~125 kDa) is encoded by the human ASAP1 gene. This protein plays a role in the activation of GTPases.	Arf-GAP with SH3 Domain, Ankyrin Repeat and PH Domain-Containing 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11859>	C61007	Carboplatin/Temozolomide/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1185>	C530	Recombinant Parathyroid Hormone-Related Protein|PTH-like protein|PTHrP|Parathyroid Hormone Like Tumor Factor|Parathyroid Hormone-Related Peptide|Parathyroid Hormone-Related Protein	A recombinantly produced form of the hormone parathyroid hormone-related protein. Endogenous parathyroid hormone-related protein regulates calcium usage in bone and mammary glands.			Chemical Viewed Functionally	
C118600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118600>	C173981	Have Energy Question|Have Energy|I have energy	A question about whether an individual has or had energy.			Intellectual Product	
C118602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118602>	C173925	Need to Sleep During Day Question|I need to sleep during the day|Need to Sleep During Day	A question about whether an individual needs or needed to sleep during the day.			Intellectual Product	
C118603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118603>	C188083|C173935	Too Tired to Eat Question|I am too tired to eat|Too Tired to Eat	A question about whether an individual is or was too tired to eat.			Intellectual Product	
C118604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118604>	C178350	Need Help Doing Usual Activities Question|I need help doing my usual activities|Need Help Doing Usual Activities	A question about whether an individual needs or needed help doing their usual activities.			Intellectual Product	
C118605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118605>	C173935	Frustrated by Being Too Tired to Do Things Question|Frustrated by Being Too Tired to Do Things|I am frustrated by being too tired to do the things I want to do	A question about whether an individual is or was frustrated by being too tired to do the things they want to do.			Intellectual Product	
C118606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118606>	C176021|C173935|C173695	Have to Limit Social Activities Because of Tiredness Question|Have to Limit Social Activities Because of Tiredness|I have to limit my social activity because I am tired	A question about whether an individual has or had to limit social activity because they are tired.			Intellectual Product	
C118607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118607>	C91105	FACT-En Questionnaire|FACT-En|FACT-En|Functional Assessment of Cancer Therapy-Endometrial Cancer	A subscale complement to the FACT-G developed specifically for evaluating the quality of life of patients with endometrial cancer.			Intellectual Product	
C118608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118608>	C91105	FACT-Cx Questionnaire|FACT-Cx|Functional Assessment of Cancer Therapy-Cervical Cancer	A subscale complement to the FACT-G developed specifically for evaluating the quality of life of patients with cancer of the cervix.			Intellectual Product	
C118609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118609>	C20923	PROKR2 Gene|PROKR2|PROKR2|Prokineticin Receptor 2 Gene	This gene is involved in both ligand binding and G protein-coupled receptor signaling.	PROKR2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C11860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11860>	C61063	Arginine butyrate/Ganciclovir			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118610>	C118609	PROKR2 wt Allele|GPR73L1|GPR73b|GPRg2|HH3|KAL3|Kallmann Syndrome 3 (Autosomal Dominant) Gene|PKR2|Prokineticin Receptor 2 wt Allele|dJ680N4.3	Human PROKR2 wild-type allele is located in the vicinity of 20p12.3 and is approximately 15 kb in length. This allele, which encodes prokineticin receptor 2 protein, plays a role in ligand-dependent G protein-coupled receptor signaling. Mutation of the gene is associated with hypogonadotropic hypogonadism 3 with or without anosmia.	PROKR2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118611>	C18239	Prokineticin Receptor 2|G Protein-Coupled Receptor 73-Like 1|G-Protein Coupled Receptor 73-Like 1|GPR73b|GPRg2|PK-R2	Prokineticin receptor 2 (384 aa, ~44 kDa) is encoded by the human PROKR2 gene. This protein is involved in the modulation of ligand-dependent signaling pathways.	Prokineticin Receptor 2		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118612>	C20988	NECTIN1 Gene|NECTIN1|NECTIN1|Nectin Cell Adhesion Molecule 1 Gene|PVRL1	This gene plays a role in both cell-cell adhesion and viral entry.	NECTIN1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118613>	C118612	NECTIN1 wt Allele|CD111|CLPED1|ED4|Ectodermal Dysplasia 4 (Margarita Island Type) Gene|HIgR|HV1S|HVEC|Herpes Simplex Virus Type 1 Sensitivity Gene|Nectin Cell Adhesion Molecule 1 wt Allele|OFC7|PRR|PRR1|PVRL1|PVRR|PVRR1|Poliovirus Receptor-Related 1 (Herpesvirus Entry Mediator C) Gene|SK-12	Human NECTIN1 wild-type allele is located in the vicinity of 11q23.3 and is approximately 106 kb in length. This allele, which encodes nectin-1 protein, is involved in both viral entry and the promotion of cell-cell adhesion. Mutation of the gene is associated with both cleft lip/palate-ectodermal dysplasia syndrome and orofacial cleft 7.	NECTIN1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118614>	C16393	Nectin-1|CD111 Antigen|HIgR|Herpes Virus Entry Mediator C|Herpesvirus Entry Mediator C|Herpesvirus Ig-Like Receptor|HveC|Nectin|Nectin 1|Nectin Cell Adhesion Molecule 1|PVRL1|Poliovirus Receptor-Like 1|Poliovirus Receptor-Related 1|Poliovirus Receptor-Related Protein 1	Nectin-1 (517 aa, ~57 kDa) is encoded by the human NECTIN1 gene. This protein plays a role in both the formation of cell-cell contact points and host cell entry of herpes simplex virus and pseudorabies virus.	Nectin-1		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118615>	C25939	MAOA Gene|MAOA|MAOA|Monoamine Oxidase A Gene	This gene is involved in the metabolism of neuroactive and vasoactive amines.	MAOA Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118616>	C118615	MAOA wt Allele|MAO-A|Monoamine Oxidase A wt Allele	Human MAOA wild-type allele is located in the vicinity of Xp11.3 and is approximately 91 kb in length. This allele, which encodes amine oxidase [flavin-containing] A, plays a role in the metabolism of neuroactive and vasoactive amines. Mutation of the gene is associated with Brunner syndrome and a variety of other psychiatric disorders.	MAOA wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118617>	C16946	Amine Oxidase [Flavin-Containing] A|Amine Oxidase (Flavin-Containing) A|EC 1.4.3.4|MAO-A|MAOA|Monoamine Oxidase Type A	Amine oxidase [flavin-containing] A (527 aa, ~60 kDa) is encoded by the human MAOA gene. This protein is involved in the deamination of neuroactive and vasoactive amines.	Amine Oxidase [Flavin-Containing] A		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118618>	C64261|C191	Multiple Agent Systemic Chemotherapy|Chemotherapy multiple agents systemic	Systemic chemotherapy with a multiple agent regimen. All routes of administration are acceptable as long as the regimen is intended for systemic therapy.			Therapeutic or Preventive Procedure	
C118619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118619>	C16185|C15687	Image-Guided Local Therapy|Image Directed Local Therapy	The use of imaging techniques to target treatment to a specific anatomic location or region.			Therapeutic or Preventive Procedure	
C11861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11861>	C61007	Chlorambucil/Dexamethasone/Mitoxantrone			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118620>	C15632	Non-Cytotoxic Chemotherapy|Chemotherapy non-cytotoxic|Non-Cytotoxic Drug Therapy	Chemotherapy using a pharmacologic agent that does not directly kill cells.			Therapeutic or Preventive Procedure	
C118621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118621>	C275|C129820	Ubidecarenone Nanodispersion BPM31510n|BP31510|Coenzyme Q10 Injectable Nanosuspension|Ubidecarenone Injectable Nanosuspension|Ubiquinone Injectable Nanosuspension	A nanodispersion containing the benzoquinone ubidecarenone (coenzyme Q10), with potential protective, antioxidant and antineoplastic activities. Upon administration, ubidecarenone nanodispersion BPM31510 modulates tumor cell metabolism and causes an anti-Warburg effect by inducing a shift from lactate dependency towards mitochondrial oxidative phosphorylation, and induces tumor cell apoptosis. This inhibits tumor cell proliferation. BPM 31510 also induces the activation and maturation of T-lymphocytes, and changes the surface expression of certain immune checkpoint modulators. In addition, as an antioxidant, ubidecarenone protects against cell damage, by preventing both the peroxidation of lipid membranes and the oxidation of LDL-cholesterol. Ubidecarenone is an essential coenzyme for mitochondrial enzyme complexes involved in oxidative phosphorylation and the production of adenosine triphosphate (ATP).	Ubidecarenone Injectable Nanosuspension		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118622>	C29639|C226471	Dimethicone/Polymer Barrier Cream|Cavilon Durable Barrier Cream	A topical cream containing the silicon-based polymer dimethicone, with potential skin protective activity. Upon topical application of the dimethicone/polymer barrier cream to the skin, dimethicone protects the skin against damage, and moisturizes and soothes the skin.	Dimethicone/Polymer Barrier Cream		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C118623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118623>	C2139	Lung-targeted Immunomodulator QBKPN|QBKPN|SSI QBKPN|Site Specific Immunomodulator QBKPN	A proprietary, lung-targeted, site specific immunomodulator (SSI), with potential immunostimulating and antineoplastic activities. Although the exact type and composition of the lung-targeted immunomodulator QBKPN has yet to be fully disclosed, upon subcutaneous administration, this agent is able to activate a local innate immune response in the lung tissue. This results in an increased number of M1 macrophages, which induces a shift from M2 to M1 macrophage dominance in the tumor microenvironment, and stimulates the recruitment of other immune cells. The M1 macrophages exert antitumor activity and eradicate lung cancer cells through phagocytosis. QBKPN does not induce a systemic immune response or affect other organs or tissues. Altogether, this SSI may decrease tumor cell growth in the lungs. SSIs contain specific, inactivated components of pathogens, such as bacteria and/or viruses, which normally cause an acute infection in the specific organ or tissue of interest.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118624>	C202468|C129825	PI3Kalpha Inhibitor AZD8835|AZD-8835|AZD8835	An orally bioavailable inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) catalytic subunit alpha (PIK3CA), with potential antineoplastic activity. PI3K alpha inhibitor AZD8835 selectively binds to and inhibits PIK3CA and its mutated forms, in the PI3K/Akt (protein kinase B) /mammalian target of rapamycin (mTOR) pathway. This results in both apoptosis and growth inhibition in PIK3CA-expressing tumor cells. By specifically targeting PIK3CA, this agent may be more efficacious and less toxic than pan-PI3K inhibitors. Dysregulation of the PI3K/Akt/mTOR pathway is often found in solid tumors and results in the promotion of tumor cell growth, survival, and resistance to chemo- and radio-therapy. PIK3CA, one of the most frequently mutated oncogenes, encodes the p110-alpha catalytic subunit of the class I PI3K.	PI3Kalpha Inhibitor AZD8835		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118625>	C2189|C208255	Activin Type 2B Receptor Fc Fusion Protein STM 434|Activin Inhibitor STM 434|STM 434|STM-434	A soluble fusion protein containing the extracellular domain of the activin receptor type 2B (ACVR2B or ActRIIB) fused to a human Fc domain, with potential antineoplastic activity. Upon intravenous administration, STM 434 selectively binds to the growth factor activin A, thereby preventing its binding to and the activation of endogenous ActRIIB. This prevents activin A/ActRIIB-mediated signaling and inhibits the proliferation of activin A-overexpressing tumor cells. Activin A, a member of the transforming growth factor beta (TGF-beta) superfamily, is overexpressed in a variety of cancers and plays a key role in promoting cancer cell proliferation, migration, and survival.	Activin Type 2B Receptor Fc Fusion Protein STM 434		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118626>	C226341|C201282|C129822	Anti-PSMA/CD3 Monoclonal Antibody MOR209/ES414|MOR209/ES414	An anti-prostate specific membrane antigen (PSMA)/anti-CD3 bispecific humanized monoclonal antibody, with potential immunostimulatory and antineoplastic activities. Anti-PSMA/CD3 monoclonal antibody MOR209/ES414 possesses two antigen-recognition sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for PSMA, a tumor-associated antigen (TAA) overexpressed on the surface of prostate tumor cells. Upon intravenous administration of MOR209/ES414, this bispecific antibody simultaneously binds to both CD3-expressing T-cells and PSMA-expressing cancer cells, thereby crosslinking PSMA-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This results in CTL-mediated cancer cell lysis of prostate cancer cells expressing PSMA.	Anti-PSMA/CD3 Monoclonal Antibody MOR209/ES414		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118627>	C1505	Ellagic Acid/Annona muricata Supplement	A nutritional supplement containing the phytochemical polyphenol, ellagic acid, and an extract of Annona muricata, with potential chemopreventive activity. Although the exact mechanism of action for ellagic acid has yet to be fully elucidated, this agent acts as an anti-oxidant and reduces oxidative stress. This agent also appears to protect the body against certain carcinogens, either through preventing DNA binding or by increasing the rate of their metabolism and deactivation. Certain extracts of Annona muricata, a member of the custard apple plants and belonging to the Annonaceae family, may have antiviral activity, potential targets include human papilloma virus (HPV), and may be cytotoxic against various types of cancer cells.			Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118628>	C93259|C213472|C155727	VEGFR/FGFR Inhibitor ODM-203|ODM 203|ODM-203|ODM-203	An orally available inhibitor of the human vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs), with potential antiangiogenic and antineoplastic activities. VEGFR/FGFR inhibitor ODM-203 inhibits both VEGFRs and FGFRs, which may result in the inhibition of VEGFR- and FGFR-mediated signaling. This leads to an inhibition of angiogenesis and cell proliferation in tumor cells overexpressing VEGFR and/or FGFR. Both VEGFRs and FGFRs belong to the superfamily of receptor tyrosine kinases and are upregulated in various tumor cell types.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118629>	C129825|C129650	JAK1 Inhibitor INCB052793|INCB052793	An orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1), with potential antineoplastic activity. Upon oral administration, INCB052793 specifically binds to and inhibits the phosphorylation of JAK1, which interferes with JAK-dependent signaling and may lead to an inhibition of cellular proliferation in JAK1-overexpressing tumor cells. The JAK-STAT (signal transducer and activator of transcription) signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types.	JAK1 Inhibitor INCB052793		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11862>	C61063	Irinotecan/Octreotide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118630>	C7927|C226527	Liver Adenosquamous Carcinoma|Liver Adenosquamous Cancer	A rare carcinoma that arises from the intrahepatic bile ducts and is composed of malignant glandular cells and malignant squamous cells.	Liver Adenosquamous Carcinoma		Neoplastic Process	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology
C118631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118631>	C85865|C84392|C53543|C28193	Alpha Thalassemia X-Linked Intellectual Disability Syndrome|ATRX|Alpha Thalassemia X-Linked Mental Retardation Syndrome|Alpha Thalassemia/Mental Retardation Syndrome X-Linked	A rare, X-linked recessive inherited syndrome caused by mutations in the ATRX gene. It is characterized by intellectual disability, developmental delays, hypotonia, widely spaced eyes, small nose, low-set ears, tented upper lip, skeletal abnormalities, and a mild form of alpha thalassemia.			Disease or Syndrome	Cellosaurus Disease Terminology
C118632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118632>	C28193	Bardet-Biedl Syndrome|BBS|Laurence-Moon Syndrome|Laurence-Moon-Bardet-Biedl Syndrome|Laurence-Moon-Biedl Syndrome	An autosomal recessive inherited syndrome caused by mutations in at least fourteen different genes, called BBS genes. It is characterized by loss of vision, obesity, diabetes, hypertension, hypercholesterolemia, polydactyly, intellectual disability, genital organs abnormalities, and delayed development of motor skills.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology|Pediatric Nephrology Terminology
C118633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118633>	C53543|C3501	Neuropathy, Hereditary Sensory and Autonomic, Type IV|CIPA|Congenital Insensitivity to Pain with Anhidrosis|HSAN4|Hereditary Sensory and Autonomic Neuropathy Type IV	A rare, autosomal recessive inherited disorder caused by mutations in the NTRK1 gene. It is characterized by inability to feel pain and temperature that leads to repeated unintentional self-injuries, and decreased or absent sweating that leads to hyperpyrexia and febrile seizures.			Disease or Syndrome	Cellosaurus Disease Terminology
C118634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118634>	C85865|C53543	Norrie Syndrome	A rare, X-linked recessive inherited syndrome caused by mutations in the NDP gene. It is characterized by developmental retinal abnormalities that result in blindness in male infants at birth or soon after birth. Additional manifestations include progressive hearing loss and developmental motor skills delays.			Disease or Syndrome	Cellosaurus Disease Terminology
C118635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118635>	C53543	Pseudoachondroplasia	A rare, autosomal dominant inherited disorder caused by mutations in the COMP gene. It is characterized by short stature, short arms and legs, waddling walk, osteoarthritis, and limited range of motion at the elbows and hips.			Disease or Syndrome	Cellosaurus Disease Terminology
C118636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118636>	C53543	Stiff Skin Syndrome	A rare, autosomal dominant inherited syndrome caused by mutations in the FBN1 gene. It is characterized by hard and thickened skin, usually over the entire body, and limited joint motility.			Disease or Syndrome	Cellosaurus Disease Terminology
C118637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118637>	C2124	1,2-Carbon C 13-labeled Glucose|D-Glucose-1,2-13C2|Dextrose-1,2-13C2|[1,2-13C]glucose	A radioconjugate composed of glucose that is labeled at carbon position 1 and 2 with carbon C13, with potential metabolic imaging and isotope tracing purposes. Upon administration of 1,2-carbon C 13-labeled glucose, the glucose is taken up and metabolized by tumors and the 13C-containing metabolites can be imaged by 13C nuclear magnetic resonance (NMR) spectroscopy. Since tumor cells take up and metabolize glucose in higher amounts and through different pathways than normal cells, this agent may help assess metabolic tumor pathways.	1,2-Carbon C 13-labeled Glucose		Indicator, Reagent, or Diagnostic Aid|Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology
C118638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118638>	C62973	Broken Component	A part of a device has been fractured or damaged.			Event	
C118639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118639>	C160939	Device Remains Implanted|Active (Implanted)	An appliance or mechanism that continues to be implanted.			Finding	FDA CDRH GUDID Terminology
C11863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11863>	C61063	DX-8951f/Gemcitabine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118640>	C78254	Device or Fragments Remain in Patient	A device or pieces of the device remain in a patient.			Finding	
C118641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118641>	C62973	Tip Breakage	The end of a device is fractured or damaged.			Event	
C118642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118642>	C258	Cadazolid|1-Cyclopropyl-6-fluoro-7-(4-((2-fluoro-4-((R)-5-hydroxymethyl-2-oxooxazolidin-3-yl)phenoxy)methyl)-4-hydroxypiperidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid|ACT-179811|CADAZOLID	An oxazolidinone-type antibiotic, with activity against gram-positive bacteria, including Clostridium difficile. Although the exact mode of action through which cadazolid exerts its effect has yet to be fully elucidated, upon administration, this agent inhibits bacterial protein synthesis and leads to bacterial cell death.	Cadazolid		Antibiotic|Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C118643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118643>	C15342	Fecal Microbiota Transplantation|FMT|Fecal Material Transplantation|Fecal Transplantation|Poo Transplant|Poop Transplant|Stool Transplant	The transplantation of fecal bacteria, via enema, colonoscopy, or other method, from a healthy individual to a recipient.	Fecal Microbiota Transplantation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C118644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118644>	C142985|C118643	Autologous Fecal Microbiota Transplantation|auto-FMT	Fecal transplantation that uses a fecal sample provided by the patient before medical treatment began.	Autologous Fecal Microbiota Transplantation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C118645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118645>	C201922	Immediate/Early Loading	The attachment of a prosthetic to an implant prior to the traditional four-six month wait period.			Health Care Activity	
C118646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118646>	C25340	Transitional Use	Employing something to be used prior to a more permanent solution.			Functional Concept	
C118647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118647>	C25340	Traditional Use	Employing something to be used in an established convention.			Functional Concept	
C118648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118648>	C61078	Nanoparticle-based Paclitaxel Suspension|Nanotax	A nanoparticle-based suspension containing the water-insoluble taxane paclitaxel, with potential antineoplastic activity. Upon intraperitoneal administration, paclitaxel binds to tubulin and inhibits the disassembly of microtubules, which leads to the inhibition of cell division. The nanoparticle-based formulation is devoid of toxic solvents, such as cremophor; therefore, this agent has fewer side effects than the standard, solvent-based paclitaxel formulation.	Nanoparticle-based Paclitaxel Suspension		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C118649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118649>	C25340	Intended Use of Immediate/Early Load	Planned use during the intermediate/early load time.			Functional Concept	
C11864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11864>	C61063	Docetaxel/Cyclophosphamide|Cyclophosphamide/Docetaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118650>	C25340	Intended Use for Traditional Use	Planned to be used in the customary way.			Functional Concept	
C118651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118651>	C25340	Unable to Confirm Conditions of Use	Cannot verify the situation surrounding the condition in which something is used.			Functional Concept	
C118652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118652>	C25340	Intended for Transitional Use	Planned to be used transitionally.			Functional Concept	
C118653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118653>	C91105	FACT/GOG-Ntx Questionnaire|FACT&GOG-Ntx|FACT/GOG-NTX Questionnaire|FACT/GOG-Ntx Subscale|Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Questionnaire	A subscale complement to the FACT-G developed specifically for evaluating platinum/paclitaxel-induced neurologic symptoms in patients with endometrial cancer.			Intellectual Product	
C118654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118654>	C91102	Self-Conscious About the Way I Dress Question|I am self-conscious about the way I dress|Self-Conscious About the Way I Dress	A question about whether an individual is or was self-concious about the way they dress.			Intellectual Product	FACT-B Questionnaire
C118655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118655>	C173593	One or Both Arms Swollen or Tender Question|One or Both Arms Swollen or Tender|One or both of my arms are swollen or tender	A question about whether one or both arms of an individual are or have been swollen or tender.			Intellectual Product	FACT-B Questionnaire
C118656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118656>	C173934|C173151	Worry Other Family Members Might Someday Get Same Illness Question|I worry that other members of my family might someday get the same illness I have|Worry Other Family Members Might Someday Get Same Illness	A question about whether an individual worries or worried that other members of their family might someday get the same illness they have.			Intellectual Product	FACT-B Questionnaire
C118657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118657>	C173160|C173045	Able to Feel Like a Woman Question|Able to Feel Like a Woman|I am able to feel like a woman	A question about whether an individual is or was able to feel like a woman.			Intellectual Product	FACT-B Questionnaire
C118658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118658>	C173597|C173398	Have Trouble Forming Thoughts Question|Have Trouble Forming Thoughts|I have had trouble forming thoughts	A question about whether an individual has or had trouble forming thoughts.			Intellectual Product	FACT-Cognitive Function
C118659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118659>	C173597	Thinking Has Been Slow Question|My thinking has been slow|My thinking was slow|Thinking Has Been Slow	A question about whether an individual's thinking is or has been slow.			Intellectual Product	FACT-Cognitive Function|Quality of Life in Neurological Disorders
C11865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11865>	C61063	Interleukin-2/Trastuzumab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118660>	C173398	Have Trouble Finding Way to Familiar Place Question|Have Trouble Finding Way to Familiar Place|I have had trouble finding my way to a familiar place	A question about whether an individual has or had trouble finding their way to a familiar place.			Intellectual Product	FACT-Cognitive Function
C118661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118661>	C173398	Have Trouble Remembering Where I Put Things Question|Have Trouble Remembering Where I Put Things|I have had trouble remembering where I put things, like my keys or my wallet	A question about whether an individual has or had trouble remembering where they put things.			Intellectual Product	FACT-Cognitive Function|PROMIS Adult Mental Health Domain
C118663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118663>	C176537|C173398	Have Trouble Remembering New Information Question|Have Trouble Remembering New Information|Have Trouble Remembering New Things|I have had trouble remembering new information, like phone numbers or simple instructions	A question about whether an individual has or had trouble remembering new information.			Intellectual Product	FACT-Cognitive Function
C118664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118664>	C173398	Have Trouble Recalling the Name of Objects While Talking to Someone Question|Have Trouble Recalling the Name of Objects While Talking to Someone|I have had trouble recalling the name of an object while talking to someone	A question about whether an individual has or had trouble recalling the name of an object while talking to someone.			Intellectual Product	FACT-Cognitive Function
C118665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118665>	C173398	Have Trouble Finding Right Words to Express Myself Question|Did you have trouble finding the right words to express yourself|Have Trouble Finding Right Words to Express Myself|Have Trouble Finding the Right Words to Express Self|I have had trouble finding the right word(s) to express myself	A question about whether an individual has or had trouble finding the right word(s) to express themselves.			Intellectual Product	FACT-Cognitive Function|Quality of Life Questionnaire-Brain Neoplasm 20 Items
C118666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118666>	C173981	Have Used Wrong Word When Referring to an Object Question|Have Used Wrong Word When Referring to an Object|I have used the wrong word when I referred to an object	A question about whether an individual has or had used the wrong word when they referred to an object.			Intellectual Product	FACT-Cognitive Function
C118667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118667>	C173398	Have Trouble Saying What I Mean in Conversation Question|Have Trouble Saying What I Mean in Conversation|I have had trouble saying what I mean in conversations with others	A question about whether an individual has or had trouble saying what they mean in conversations with others.			Intellectual Product	FACT-Cognitive Function
C118668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118668>	C16338	Polyethylene Glycol Hydrogel|PEG Hydrogel	A 2- or 3-dimensional hydrophilic, cross-linked polymer of polyethylene glycol (PEG). These hydrogels can be used as scaffolds for tissue engineering or as drug delivery carriers.	Polyethylene Glycol Hydrogel		Biomedical or Dental Material	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C118669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118669>	C162996	Sulanemadlin|ALRN-6924|MDM2/MDMX Inhibitor ALRN-6924|SULANEMADLIN	An orally available peptide inhibitor of both murine double minute 2 (MDM2) and murine double minute X (MDMX), with potential antineoplastic activity. Upon oral administration, sulanemadlin binds to both MDM2 and MDMX and interferes with their interaction with the transcriptional activation domain of the tumor suppressor protein p53. By preventing MDM2-p53 and MDMX-p53 interactions, p53 activity is restored, which leads to p53-mediated induction of tumor cell apoptosis. MDM2 and MDMX, negative regulators of p53 function, are often overexpressed in cancer cells.	Sulanemadlin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11866>	C61063	MAGE-12 peptide vaccine/Montanide ISA-51			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118670>	C2124|C129819	Rhenium Re 188 BMEDA-labeled Liposomes|(188) Re-BMEDA-liposomes|188Re-BMEDA-liposomes|188Re-N,N-bis (2-Mercaptoethyl)-N',N'-diethylethylenediamine-labeled Liposomes	A liposome-based preparation consisting of the beta- and gamma-emitting radionuclide rhenium Re 188 (Re 188) linked to the chelator N,N-bis (2-mercaptoethyl)-N',N'-diethylethylenediamine (BMEDA) and encapsulated in liposomes, with potential tumor imaging and antineoplastic activities. Upon intravenous infusion of rhenium Re 188 BMEDA-labeled liposomes, the liposomes selectively target tumor cells, facilitate the retention of the radioisotope by those cells, and cause localized antitumor radiocytotoxicity while sparing surrounding normal, healthy cells. In addition, Re 188 BMEDA-labeled liposomes can be used for imaging purposes. Re 188 has a short half-life and a short path length, which further contribute to limiting the radiotoxicity to the tumor cells.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118671>	C2167|C129825	Abivertinib Maleate Anhydrous|ABIVERTINIB MALEATE ANHYDROUS|AC0010 Maleate|AC0010 Maleate Dihydrate|AC0010MA|Avitinib Maleate|STI-5656	The maleate salt form of abivertinib, an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. Upon oral administration, abivertinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the drug-resistant T790M EGFR mutant, which prevents signaling mediated by mutant forms of EGFR. This may both induce cell death and inhibit tumor growth in EGFR-mutated tumor cells. EGFR, a receptor tyrosine kinase that is mutated in a variety of cancers, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors, which also inhibit wild-type EGFR.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118672>	C155727|C129825	Tasurgratinib|E-7090|E7090|FGF/FGFR Pathway Inhibitor E7090|TASURGRATINIB	An inhibitor of the fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR) pathway, with potential antineoplastic activity. Upon administration, tasurgratinib selectively interferes with the binding of FGF to FGFR through an as of yet not fully elucidated mechanism. This inhibits FGFR-mediated signaling and leads to both cell proliferation inhibition and cell death in FGFR-overexpressing tumor cells. FGFR is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation, and survival; its expression is upregulated in many tumor cell types.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118673>	C241	Opioid Agonist GIC-1002|GIC-1002	An orally available, peripherally-acting opioid agonist, with potential visceral analgesic activity. Upon oral administration of GIC-1002, this agent binds to colonic mu and kappa opioid receptors causing analgesic effects.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C118674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118674>	C155712	Trastuzumab Duocarmazine|ADC SYD985|Antibody-drug Conjugate SYD985|SYD985|TRASTUZUMAB DUOCARMAZINE|Trastuzumab VC-seco-DUBA|Trastuzumab-drug Conjugate SYD985|vic-Trastuzumab Duocarmazine	An antibody-drug conjugate (ADC) composed of the recombinant humanized anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab linked, via a cleavable linker, to the duocarmycin prodrug, seco-duocarmycin-hydroxybenzamide-azaindole (seco-DUBA), with potential antineoplastic activity. Upon administration of trastuzumab duocarmazine, the trastuzumab moiety binds to HER2 on the tumor cell surface, which triggers the endocytosis of this agent. The linker is then cleaved inside the tumor cell by proteases at the dipeptide valine-citrulline (vc), and releases the active moiety, duocarmycin. Duocarmycin binds to the minor groove of DNA, alkylates adenine at the N3 position, and induces cell death. In addition, trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER2. HER2 is overexpressed by many carcinomas and is associated with a poor prognosis.	Trastuzumab Duocarmazine		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118675>	C3235	Mitochondrial Enzyme Deficiency	A constellation of disorders whose common thread is the insufficient quantity of one or more mitochondrial enzymes.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118676>	C60811	Perinatal Mortality|Perinatal Death	Fetal or infant death during the period of time that includes the antepartum, intrapartum, and neonatal stages.			Finding	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118677>	C16731	Very Preterm Infant	An age group comprised of infants greater than 28 weeks, 0 days and less than 34 weeks, 0 days.			Age Group	GAIA Preterm Birth Level of Diagnostic Certainty Terminology|GAIA Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118678>	C112835	Acquired Growth Hormone Deficiency	Growth hormone deficiency that is not present at birth; this condition may result from a variety of causes such as intracranial tumors or their treatment, infection, trauma or other cause.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C118679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118679>	C112835	Congenital Growth Hormone Deficiency	Growth hormone deficiency the cause of which is present at birth.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C11867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11867>	C61063	Interleukin-2/MAGE-12 Peptide Vaccine/Montanide ISA-51			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118680>	C112835	Growth Hormone Neurosecretory Dysfunction	Reduced spontaneous secretion of growth hormone with normal range response to growth hormone provocative stimuli.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C118681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118681>	C173981	Have Walked into Room and Forgotten What I Meant to Get or Do Question|Have Walked into Room and Forgotten What I Meant to Get or Do|I have walked into a room and forgotten what I meant to get or do there	A question about whether an individual has or had walked into a room and forgotten what they meant to get or do there.			Intellectual Product	FACT-Cognitive Function
C118682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118682>	C112835	Idiopathic Isolated Growth Hormone Deficiency	Insufficient secretion of growth hormone for which no underlying cause can be found.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C118683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118683>	C113100	Iatrogenic Growth Failure	Growth failure due to medical intervention.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C118684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118684>	C91102	Have to Work Really Hard to Pay Attention or Would Make Mistake Question|Have to Work Really Hard to Pay Attention or I Make Mistakes|Have to Work Really Hard to Pay Attention or Would Make Mistake|I had to work really hard to pay attention or I would make a mistake|I have had to work really hard to pay attention or I would make a mistake|I have to work really hard to pay attention or I make mistakes	A question about whether an individual has or had to work really hard to pay attention or they would make a mistake.			Intellectual Product	FACT-Cognitive Function|PROMIS Adult Mental Health Domain|Quality of Life in Neurological Disorders
C118685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118685>	C173981	Have Forgotten Names of People Soon After Being Introduced Question|Have Forgotten Names of People Soon After Being Introduced|I have forgotten names of people soon after being introduced	A question about whether an individual has or had forgotten names of people soon after being introduced.			Intellectual Product	FACT-Cognitive Function
C118686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118686>	C94488	Short Stature	Height greater than two standard deviations below the mean of the appropriate reference population for the age and sex of the individual.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C118687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118687>	C91102	Reactions in Everyday Situations Have Been Slow Question|My reactions in everyday situations have been slow|Reactions in Everyday Situations Have Been Slow	A question about whether an individual's reactions in everyday situations have been slow.			Intellectual Product	FACT-Cognitive Function
C118688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118688>	C118689	Familial Idiopathic Short Stature|Constitutional Short Stature	Idiopathic short stature in a child when either one or both parents is short in stature.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C118689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118689>	C118686	Idiopathic Short Stature|ISS	Height greater than two standard deviations below the mean for the age and sex of the reference population.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C11868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11868>	C61063	Dexamethasone/Phenylbutyrate/Sargramostim			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118690>	C118689	Non-familial Idiopathic Short Stature|Non-Familial Idiopathic Short Stature	Idiopathic short stature in a child when neither parent is short in stature.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C118691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118691>	C94488	Tall Stature	Height greater than two standard deviations above the mean of the appropriate reference population for the age and sex of the individual.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C118692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118692>	C118691	Idiopathic Tall Stature	Tall stature for which no underlying cause can be found.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C118693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118693>	C118692	Familial Idiopathic Tall Stature|Constitutional Tall Stature|Familial Tall Stature	Idiopathic tall stature in a child when either one or both parents is tall in stature.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C118694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118694>	C91102	Have to Work Harder than Usual to Keep Track of What I Was Doing Question|Have to Work Harder than Usual to Keep Track of What I Was Doing|Have to Work Harder than Usual to Keep Track of What I am Doing|I have had to work harder than usual to keep track of what I was doing|I have had to work harder than usual to keep track of what I was doing	A question about whether an individual has or had to work harder than usual to keep track of what they were doing.			Intellectual Product	FACT-Cognitive Function|PROMIS Cognitive Function Subordinate Domain
C118695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118695>	C118692	Non-familial Idiopathic Tall Stature|Non-Familial Idiopathic Tall Stature	Idiopathic tall stature in a child when neither parent is tall in stature.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C118696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118696>	C84978	FGFR3 Chondrodysplasia	A constellation of disorders involving mutations of the FGFR3 gene, which result in abnormal growth of bone and cartilage; this includes achondroplasia and hypochondroplasia.			Disease or Syndrome	
C118697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118697>	C84978	Hypochondroplasia	An autosomal dominant disorder that is often caused by a defect in fibroblast growth factor receptor 3, and characterized by short stature, micromelia, and a comparatively large head. The features are milder than those seen in achondroplasia.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C118698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118698>	C114934	Small for Gestational Age for Weight|SGA for Weight	Birth weight greater than two standard deviations below the mean for the reference population of the same sex and gestational age.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C118699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118699>	C114934	Small for Gestational Age for Length|SGA for Length	Birth length greater than two standard deviations below the mean for the reference population of the same sex and gestational age.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C11869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11869>	C61063	Interferon Alfa/Lutetium Lu 177 Monoclonal Antibody CC49/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1186>	C699	PCNU|1-(2-CHLOROETHYL)-3-(2,6-DIOXO-3-PIPERIDYL)-1-NITROSOUREA|1-(2-Chloroethyl)-3-(2,6-Dioxo-3-Piperidyl)-1-Nitrourea|Urea, N-(2-chloroethyl)-N'-(2,6-dioxo-3-piperidinyl)-N-nitroso-	A chloroethylnitrosourea compound and an alkylating agent with antineoplastic property. PCNU inhibits DNA synthesis by alkylating DNA and causing DNA cross links, thereby inducing apoptosis. In addition, this agent may be associated with pulmonary, hepatic, and hematologic toxicities. Unlike other nitrosoureas, PCNU has strong alkylating while weak carbamoylating activity.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118700>	C114934	Small for Gestational Age for Weight and Length|SGA for Weight and Length	Birth weight and length greater than two standard deviations below the mean for the reference population of the same sex and gestational age.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C118701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118701>	C173597	Thinking Has Been Slower than Usual Question|My thinking has been slower than usual|Thinking Has Been Slower than Usual	A question about whether an individual has or had slower than usual thinking.			Intellectual Product	FACT-Cognitive Function
C118702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118702>	C114934	Small for Gestational Age with Failure of Catch-Up Growth|Small for Gestational Age with Failure of Catch-up Growth	A condition in which a child who was born small for gestational age, fails to achieve a linear growth rate sufficient to restore height to within the normal range for the reference population.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C118703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118703>	C91102	Have to Work Harder to Express Myself Clearly Question|Have to Work Harder to Express Myself Clearly|I have had to work harder than usual to express myself clearly	A question about whether an individual has or had to work harder than usual to express themselves clearly.			Intellectual Product	FACT-Cognitive Function
C118704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118704>	C176020	Have to Use Written Lists More Often than Usual to Not Forget Things Question|Have to Use Written Lists More Often than Usual to Not Forget Things|I have had to use written lists more often than usual so I would not forget things	A question about whether an individual has or had to use written lists more often than usual so they would not forget things.			Intellectual Product	FACT-Cognitive Function
C118705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118705>	C173398	Have Trouble Keeping Track of what I am Doing if Interrupted Question|Have Trouble Keeping Track of what I am Doing if Interrupted|I have had trouble keeping track of what I was doing when interrupted|I have trouble keeping track of what I am doing if I am interrupted	A question about whether an individual has or had trouble keeping track of what they are doing if they are interrupted.			Intellectual Product	FACT-Cognitive Function
C118706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118706>	C173597|C173398	Have Trouble Shifting Back and Forth Between Different Activities that Require Thinking Question|Have Trouble Shifting Back and Forth Between Different Activities that Require Thinking|I have trouble shifting back and forth between different activities that require thinking	A question about whether an individual has or had trouble shifting back and forth between different activities that require thinking.			Intellectual Product	FACT-Cognitive Function
C118707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118707>	C97109	Cortical Blindness	Visual impairment due to visual cortex dysfunction.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118708>	C50441	Orbital Contusion	Bruising of the skin and soft tissue surrounding the eye.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118709>	C34602|C34442	Chemical Burn of Eye	Injury to the eye secondary to a chemical substance.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11870>	C61063	Interferon Alfa/Lutetium Lu 177 Monoclonal Antibody CC49/Topotecan			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118710>	C36280	Cerebral Visual Impairment|Central Visual Impairment|Central Visual Impairment	Visual impairment due to central nervous system dysfunction.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118711>	C53543|C4731|C150179	Optic Neuropathy	Disorder of the optic nerve.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118712>	C3891	Acquired Color Blindness	Non-heritable difficulty in distinguishing colors.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118713>	C3891	Inherited Color Blindness	Genetic based difficulty in distinguishing colors.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118714>	C87149	Decreased Visual Acuity|Visual Acuity Decreased|Visual Acuity Decreased	Diminished clarity of vision.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118715>	C118714	Decreased Best Corrected Visual Acuity	Diminished clarity of vision despite optimal optical correction (glasses and/or contacts).			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118716>	C118714	Decreased Uncorrected Visual Acuity	Diminished clarity of vision without optical correction (glasses and/or contacts).			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118717>	C118714	Decreased Visual Acuity with Current Correction	Diminished clarity of vision with current correction (glasses and/or contacts).			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118718>	C37941	Binocular Diplopia	Perception of two images secondary to misalignment of the eyes.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118719>	C37941	Monocular Diplopia	Perception of more than one image when viewing with one eye.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11871>	C61063	Interferon Alfa/Paclitaxel/Yttrium Y 90 Monoclonal Antibody CC49			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118720>	C99208	Opsoclonus	A rapid, multivectorial, conjugate, involuntary eye movement, without an intersaccadic interval.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118722>	C35733	Stye|Hordeolum	An infection of one or more of the glands surrounding the eye.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118723>	C99208	Blepharospasm	Involuntary twitching of the eyelid.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118724>	C99208	Eye Redness|Conjunctival redness	The prominence of the superficial vessels of the sclera or conjunctiva resulting in a red or pink appearance.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118725>	C99208	Iridodialysis|Coredialysis	A separation of the iris from the ciliary body.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118726>	C99208	Pseudostrabismus	The false appearance of misalignment of the eyes.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118727>	C99208	Visual Field Defect	An absolute or relative reduction in the extent of the normal field of vision.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118728>	C118727	Central Visual Field Defect	Reduced or abnormal sight in the central visual field.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118729>	C118727	Congruent Visual Field Defect	Identically shaped visual field defect in the same location in both eyes.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11872>	C61063	BMS-275291/Carboplatin/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118730>	C176537|C173398	Have Been Told that I Have Trouble Remembering Information Question|Have Been Told that I Have Trouble Remembering Information|Other people have told me I seemed to have trouble remembering information	A question about whether an individual has or had been told by other people that they seem to have trouble remembering information.			Intellectual Product	FACT-Cognitive Function
C118731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118731>	C118727	Hemianopsia	Lack of sight in half of the normal field of vision.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118732>	C118727	Heteronymous Visual Field Defect	A bilateral visual field defect on opposite sides of the visual space of each eye (right or left).			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118733>	C118727	Homonymous Visual Field Defect	A bilateral visual field defect on the same side of visual space of each eye (right or left).			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118734>	C118727	Incongruent Visual Field Defect	Non-identically shaped visual field defect in the same location in both eyes.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118735>	C173398	Have Been Told that I Have Trouble Speaking Clearly Question|Have Been Told that I Have Trouble Speaking Clearly|Other people have told me I seemed to have trouble speaking clearly	A question about whether an individual has or had been told by other people that they seem to have trouble speaking clearly.			Intellectual Product	FACT-Cognitive Function
C118736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118736>	C118727	Peripheral Visual Field Defect	Reduced or abnormal sight in the peripheral visual field.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118737>	C118727	Scotoma	An area of impaired sight within the normal visual field.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118738>	C173597|C173398	Have Been Told that I Have Trouble Thinking Clearly Question|Have Been Told that I Have Trouble Thinking Clearly|Other people have told me I seemed to have trouble thinking clearly	A question about whether an individual has or had been told by other people that they seem to have trouble thinking clearly.			Intellectual Product	FACT-Cognitive Function
C118739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118739>	C34620	Ocular Foreign Body	External material that enters the eye.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11873>	C61063	Arsenic trioxide/Tretinoin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118740>	C118739	Conjunctival Foreign Body	External material in or on the conjunctiva.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118741>	C118739	Corneal Foreign Body	External material in or on the cornea.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118742>	C118868|C118739	Intraocular Foreign Body	External material inside the eyeball.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118743>	C91102	Have Been Told that I Seem Confused Question|Have Been Told that I Seem Confused	A question about whether an individual has or had been told by other people that they seem confused.			Intellectual Product	
C118744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118744>	C3046	Orbital Fracture	A break in the orbital bone.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118745>	C26791	Retrobulbar Hemorrhage	Bleeding in the orbital cavity that results in compression of orbital structures, resulting in ischemia of the optic nerve, and possible loss of vision.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118746>	C173045	Have Been Able to Bring to Mind Words While Talking to Someone Question|Have Been Able to Bring to Mind Words While Talking to Someone|I have been able to bring to mind words that I wanted to use while talking to someone	A question about whether an individual has or had been able to bring to mind words that they wanted to use while talking to someone.			Intellectual Product	FACT-Cognitive Function
C118747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118747>	C34602	Closed Globe Injury	Traumatic injury to one or more intraocular structures without full thickness wound of the eyewall (sclera and cornea). (adapted from the Birmingham Eye Trauma Terminology System (BETTS))			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118748>	C34602	Open Globe Injury	A full thickness wound of the eyewall (sclera and cornea). (Birmingham Eye Trauma Terminology System (BETTS))			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118749>	C26805	Infectious Keratitis|Infective Keratitis	Inflammation of the cornea secondary to an infectious process.			Disease or Syndrome	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Infectious Disease Terminology
C11874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11874>	C61063	Cisplatin/Cyclophosphamide/Etoposide/Methotrexate/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118750>	C26805	Photokeratitis|Arc Welder's Eye|Arc eye|Ultraviolet Keratitis|Ultraviolet Keratitis|Welder's Flash	Injury to the cornea secondary to ultraviolet light.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118751>	C105890	Have Been Able to Remember to do Things Question|Have Been Able to Remember to do Things|I have been able to remember to do things, like take medicine or buy something I needed	A question about whether an individual has or had been able to remember to do things, like take medicine or buy something they need.			Intellectual Product	FACT-Cognitive Function
C118752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118752>	C110937	Orbital Muscle Entrapment	The binding of one or more ocular muscles by orbital bone pieces, resulting in decreased eye mobility.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118754>	C36173	Uveal Prolapse	The protrusion of uveal tissue through an opening in the sclera.			Anatomical Abnormality	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118755>	C26874	Rhegmatogenous Retinal Detachment	Retinal detachment secondary to retinal tear or break.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118756>	C26874	Serous Retinal Detachment	Retinal detachment secondary to fluid accumulation under the neurosensory retina without a retinal tear or break.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118758>	C173045	Have Been Able to Pay Attention and Keep Track of What I am Doing Without Extra Effort Question|Have Been Able to Pay Attention and Keep Track of What I am Doing Without Extra Effort|I am able to pay attention and keep track of what I am doing without extra effort	A question about whether an individual is or was able to pay attention and keep track of what they are doing without extra effort.			Intellectual Product	FACT-Cognitive Function
C118759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118759>	C26874	Tractional Retinal Detachment	Retinal detachment secondary to vasoproliferative changes in the retina and/or vitreous.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11875>	C61063	Carboplatin/Doxorubicin HCl Liposome			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118760>	C5040	Abnormal Vision|Vision abnormalities	Disturbance of eyesight.			Finding	CRF2 History and Physical Exam Initial History Table
C118761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118761>	C91102	Mind is as Sharp as it Always Has Been Question|Mind is as Good as it Always Has Been|Mind is as Sharp as Always|Mind is as Sharp as it Always Has Been|My mind is as sharp as it has always been	A question about whether an individual's mind is or was as sharp as it always has been.			Intellectual Product	FACT-Cognitive Function
C118763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118763>	C99208|C100104	Exophthalmos	The anterior displacement of the eye within the orbit, giving a bulging appearance.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118764>	C53534	Amblyopia|Lazy Eye|Lazy Eye	Decreased vision that results from abnormal visual development.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118765>	C27012	Band Keratopathy	The deposition of calcium on the cornea, resulting in pain and decreased visual acuity.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118766>	C176020	Memory is as Good as it Always Has Been Question|Memory as Good as Always|Memory is as Good as Always|Memory is as Good as it Always Has Been|Memory is as Sharp as Always|Memory is as Sharp as it Always Has Been|My memory is as good as it has always been	A question about whether an individual's memory is or was as sharp as it always has been.			Intellectual Product	FACT-Cognitive Function
C118767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118767>	C173597|C173045	Able to Shift Back and Forth Between Two Activities that Require Thinking Question|Able to Shift Back and Forth Between Two Activities that Require Thinking|I am able to shift back and forth between two activities that require thinking	A question about whether an individual is or was able to shift back and forth between two activities that require thinking.			Intellectual Product	FACT-Cognitive Function
C118768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118768>	C173045	Able to Keep Track of What I Am Doing Even When Interrupted Question|Able to Keep Track of What I Am Doing Even When Interrupted|I am able to keep track of what I am doing, even if I am interrupted	A question about whether an individual is or was able to keep track of what they are doing, even if they are interrupted.			Intellectual Product	FACT-Cognitive Function
C118769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118769>	C173083	Have Been Upset About Cognitive Problems Question|Have Been Upset About Cognitive Problems|I have been upset about my problems with memory, concentration, or making mental mistakes|I have been upset about these problems	A question about whether an individual had or has been upset about problems with cognitive function.			Intellectual Product	FACT-Cognitive Function
C11876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11876>	C61063	Ganciclovir/Interleukin-2/Zidovudine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118770>	C173924|C173584|C173083	Cognitive Problems Have Interfered with Ability to Work Question|Cognitive Problems Have Interfered with Ability to Work|My problems with memory, concentration, or making mental mistakes have interfered with my ability to work|These problems have interfered with my ability to work	A question about whether an individual's problems with cognitive function interferes or interfered with their ability to work.			Intellectual Product	FACT-Cognitive Function
C118771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118771>	C173584|C173083	Cognitive Problems Have Interfered with Ability to Do Things I Enjoy Question|Cognitive Problems Have Interfered with Ability to Do Things I Enjoy|My problems with memory, concentration, or making mental mistakes have interfered with my ability to do things I enjoy|These problems have interfered with my ability to do things I enjoy	A question about whether an individual's problems with cognitive function interferes or interfered with their ability enjoy the things they do.			Intellectual Product	FACT-Cognitive Function
C118772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118772>	C173584|C173504|C173083	Cognitive Problems Have Interfered with Quality of Life Question|Cognitive Problems Have Interfered with Quality of Life|My problems with memory, concentration, or making mental mistakes have interfered with the quality of my life|These problems have interfered with the quality of my life	A question about whether an individual's problems with cognitive function interferes or interfered with their quality of life.			Intellectual Product	FACT-Cognitive Function
C118773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118773>	C225418	Precarinal	Of or pertaining to the area in front of the bifurcation of the trachea.			Spatial Concept	
C118774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118774>	C33027	Gastrohepatic Lymph Node	A lymph node located in the gastrohepatic ligament.			Anatomical Structure	
C118775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118775>	C33027	Aortocaval Lymph Node|AORTOCAVAL LYMPH NODE	A lymph node located in the area between the abdominal aorta and inferior vena cava.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C118776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118776>	C129839	Ingenol Mebutate Gel|Ingenol-3-angelate Gel|PEP-005 Topical Gel|PEP005 Gel|Picato	A topical, aqueous gel formulation containing the mebutate salt form of ingenol, a selective small-molecule activator of protein kinase C (PKC) that is isolated from the sap of Euphorbia species, with potential antineoplastic activity. Upon topical application of the ingenol mebutate gel, ingenol activates various PKC isoforms, which induces apoptosis in certain tumor cells, including myeloid leukemia cells, melanoma cells, and basal cell carcinoma cells. The PKC family consists of signaling isoenzymes that regulate many cell processes, including proliferation, differentiation, and apoptosis.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118777>	C54452	SPL Licensing Terminology|Licensing|Structured Product Labeling Licensing Terminology	Terminology used to indicate the authorization of a business to perform specific duties or functions.	SPL Licensing Terminology		Intellectual Product	FDA Structured Product Labeling Terminology
C118778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118778>	C54452	SPL Marketing Status Terminology|Marketing Status|Structured Product Labeling Marketing Status Terminology	Terminology used to indicate whether a product is being marketed.	SPL Marketing Status Terminology		Intellectual Product	FDA Structured Product Labeling Terminology
C118779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118779>	C118405	Licensed as Wholesale Drug Distributor or Third Party Logistics Provider|Licensed	An indication that an entity has been an issued a license to function as a wholesale drug distributor or as a third party logistics provider within a state's territory.			Qualitative Concept	FDA Structured Product Labeling Terminology|SPL Licensing Terminology
C11877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11877>	C61063	Denileukin Diftitox/Dexamethasone			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118780>	C197907|C116718	Autosomal Dominant Torsion Dystonia 1|DYT1	An autosomal dominant inherited disorder caused by mutations in the TOR1A gene. It usually begins in childhood or adolescence and is characterized by involuntary muscle contractions in the arms, legs, trunk, and neck.			Disease or Syndrome	Cellosaurus Disease Terminology
C118781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118781>	C85865|C84648	X-Linked Centronuclear Myopathy|CNMX|MTM|MTM1|Myotubular Myopathy 1|X-Linked Myotubular Myopathy|XLCNM	An X-linked recessive inherited disorder caused by mutations in the MTM1 gene. Primarily it affects males. Female carriers are usually asymptomatic.  It is characterized by skeletal muscle weakness and hypotonia. The muscle weakness ranges from mild to severe. Newborns with severe X-linked centronuclear myopathy develop respiratory distress which may lead to respiratory failure requiring constant ventilator assistance. Patients with mild X-linked centronuclear myopathy usually require ventilator support during the newborn period only.			Disease or Syndrome	Cellosaurus Disease Terminology
C118782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118782>	C75467	Charcot-Marie-Tooth Disease Type 1B	Charcot-Marie-Tooth disease caused by mutations in the MPZ gene (mapped to chromosome 1q23.3). It results in sensorineural peripheral neuropathy.			Disease or Syndrome	Cellosaurus Disease Terminology
C118783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118783>	C84910	Merosin-Deficient Congenital Muscular Dystrophy Type 1A|MDC1A	An autosomal recessive inherited congenital muscular dystrophy caused by mutations in the LAMA2 gene. It is characterized by severe hypotonia, muscle weakness, elevated levels of serum creatinine kinase, and white matter abnormalities.			Disease or Syndrome	Cellosaurus Disease Terminology
C118784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118784>	C101216	Nemaline Myopathy 2|NEM2	An autosomal recessive inherited myopathy caused by mutations in the NEB gene. It is characterized by generalized hypotonia and skeletal muscle weakness.			Disease or Syndrome	Cellosaurus Disease Terminology
C118785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118785>	C85865|C84543	Ocular Albinism Type 1|Nettleship-Falls Syndrome|OA1	An X-linked inherited disorder caused by mutations in the GPR143 gene. It is characterized by reduced visual acuity and reduced stereoscopic vision. Other abnormalities include nystagmus, strabismus, and photophobia.			Disease or Syndrome	Cellosaurus Disease Terminology
C118786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118786>	C53543|C28193	Autosomal Dominant Popliteal Pterygium Syndrome|Facio-Genito-Popliteal Syndrome|Popliteal Pterygium Syndrome 1	A rare, autosomal dominant inherited syndrome caused by mutations in the IRF6 gene. It is characterized by the presence of cleft palate, cleft lip, pits in the lower lip, web behind the knee (popliteal pterygium), syndactyly, cryptorchidism, scrotal malformation, and hypoplasia of the labia majora.			Disease or Syndrome	Cellosaurus Disease Terminology
C118787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118787>	C131002	Simpson Golabi Behmel Syndrome Type 1|SGBS1	A rare, X-linked inherited syndrome caused by mutations in the GPC3 and GPC4 genes. It is characterized by pre-and postnatal overgrowth, coarse facial features, macrocephaly, macroglossia, congenital heart defects, and intellectual disability.			Disease or Syndrome	Cellosaurus Disease Terminology
C118788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118788>	C53543|C140264	Vitelliform Macular Dystrophy	A rare genetic disorder characterized by macular degeneration in the retina resulting in progressive loss of central vision with retention of the peripheral vision. It may be of early onset, autosomal dominant inherited and caused by mutations in the BEST1 gene (BEST disease) or late onset, caused by mutations in the PRPH2 gene.			Disease or Syndrome	Cellosaurus Disease Terminology
C118789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118789>	C39713	Modified-release Calcifediol Capsule|CTAP101|Rayaldee	An orally available, modified-release formulation containing the calcitriol prohormone, calcifediol (25-hydroxyvitamin D), which can potentially be used for vitamin D supplementation. Upon oral administration of the modified-release calcifediol capsule, calcifediol is slowly and gradually released in the gastrointestinal tract. Then it is taken up by the body and converted, in the kidneys, to the active form calcitriol (1,25-dihydroxyvitamin D or 1,25 D). This form increases and normalizes vitamin D plasma levels, which, in turn, regulates calcium plasma levels, and normalizes elevated parathyroid hormone (PTH) levels by suppressing both PTH synthesis, and secretion. This formulation appears to have fewer side effects than supplementation with formulations containing active 1,25 D and does not stimulate the upregulation of vitamin D 24-hydroxylase (CYP24), a cytochrome P-450 family enzyme that inactivates vitamin D.	Modified-release Calcifediol Capsule		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C11878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11878>	C61063	QS21/RAS peptide cancer vaccine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118790>	C28681	Autologous NY-ESO-1-specific CD8-positive T Lymphocytes	A preparation of autologous CD8+ T-lymphocytes specifically reactive to the cancer-testis antigen NY-ESO-1, with potential immunostimulating and antineoplastic activities. Autologous NY-ESO-1-specific CD8+ T-lymphocytes were generated from T-cells isolated from a particular cancer patient, which were made specifically reactive to the NY-ESO-1 antigen, expanded ex vivo, and reintroduced into the patient. These tumor-reactive T-cells may stimulate a host immune response against tumor cells expressing the NY-ESO-1 antigen, resulting in tumor cell lysis. NY-ESO-1, an antigen found in normal testis, may be upregulated in various cancers.	Autologous NY-ESO-1-specific CD8-positive T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118791>	C27993	Adversity	A state of difficulty, misfortune, or affliction.			Conceptual Entity	
C118792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118792>	C217121	Beck Lethality Scale|Lethality	A scale for scoring the potential degree of medical lethality of various means of suicide, consisting of zero, low, medium, or high.			Intellectual Product	
C118793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118793>	C171256	Firearm	A portable weapon that launches a projectile by an explosive force.			Manufactured Object	
C118794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118794>	C103385	Complete Response with Incomplete Platelet Recovery|CRp	The disappearance of all signs of cancer in response to treatment, accompanied by incomplete platelet recovery (platelet count is less than 100,000/uL).			Finding	
C118795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118795>	C21176	Shelterin|Shelterin Complex|Telosome	A protein complex that is physically bound to chromosomal telomeres and plays a role in both the elongation and maintenance of telomeric repeats.			Amino Acid, Peptide, or Protein	
C118796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118796>	C16295	Anti-CD3 Antibody|Anti-T-Cell Surface Glycoprotein CD3 Antibody|CD3 Antibody|CD3 Antibody|T-Cell Surface Glycoprotein CD3 Antibody	Any antibody that recognizes the CD3 protein complex.			Amino Acid, Peptide, or Protein|Immunologic Factor	
C118797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118797>	C16295	Anti-Neprilysin Antibody|Anti-CALLA Antibody|Anti-CD10 Antibody|Anti-MME Antibody|CALLA Antibody|CD10 Antibody|MME Antibody|Neprilysin Antibody	Any antibody that recognizes the neprilysin protein.			Amino Acid, Peptide, or Protein|Immunologic Factor	
C118798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118798>	C16295	Anti-CD20 Antibody|Anti-B-Lymphocyte Antigen CD20 Antibody|B-Lymphocyte Antigen CD20 Antibody|CD20 Antibody	Any antibody that recognizes B-lymphocyte antigen CD20 protein.	Anti-CD20 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118799>	C16295	Anti-CD79a Antibody|Anti-B-Cell Antigen Receptor Complex-Associated Protein Alpha Chain Antibody|B-Cell Antigen Receptor Complex-Associated Protein Alpha Chain Antibody|CD79a Antibody	Any antibody that recognizes B-cell antigen receptor complex-associated protein alpha chain protein.			Amino Acid, Peptide, or Protein|Immunologic Factor	
C11879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11879>	C61063	Interferon Alfa/SU5416			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1187>	C177430	Penberol|PENBEROL|cis-beta-4-pentoxy-benzoyl-beta-bromoacrylic acid|cis-beta-4-pentoxybenzoyl-beta-bromoacrylic acid	A derivative of bromoacrylic acid with cytostatic activity. Although the mechanism of action is unclear, penberol might inhibit tumor growth mediated through inhibition of the cell energetic metabolism.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118800>	C16295	Anti-MUM1 Antibody|Anti-Interferon Regulatory Factor 4 Antibody|Interferon Regulatory Factor 4 Antibody|MUM1 Antibody	Any antibody that recognizes interferon regulatory factor 4.			Amino Acid, Peptide, or Protein|Immunologic Factor	
C118801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118801>	C16295	Anti-BCL2 Antibody|Anti-Apoptosis Regulator Bcl-2 Antibody|Apoptosis Regulator Bcl-2 Antibody|BCL2 Antibody|BCL2 Antibody	Any antibody that recognizes apoptosis regulator Bcl-2 protein.			Amino Acid, Peptide, or Protein|Immunologic Factor	
C118802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118802>	C16295	Anti-BCL6 Antibody|Anti-B-Cell Lymphoma 6 Protein Antibody|B-Cell Lymphoma 6 Protein Antibody|BCL6 Antibody|BCL6 Antibody	Any antibody that recognizes B-cell lymphoma 6 protein.			Amino Acid, Peptide, or Protein|Immunologic Factor	
C118803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118803>	C16295	Anti-KI-67 Antibody|Anti-Antigen KI-67 Antibody|Antigen KI-67 Antibody|KI-67 Antibody|Ki67 Antibody	Any antibody that recognizes antigen KI-67 protein.			Amino Acid, Peptide, or Protein|Immunologic Factor	
C118804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118804>	C16295	Anti-Vimentin Antibody|Anti-VIM Antibody|VIM Antibody|Vimentin Antibody|Vimentin Antibody	Any antibody that recognizes vimentin protein.			Amino Acid, Peptide, or Protein|Immunologic Factor	
C118805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118805>	C16295	Anti-Estrogen Receptor Antibody|Anti-ER Antibody|ER Antibody|Estrogen Receptor Antibody	Any antibody that recognizes estrogen receptor protein.			Amino Acid, Peptide, or Protein|Immunologic Factor	
C118806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118806>	C16295	Anti-Carcinoembryonic Antigen Antibody|Anti-CEA Antibody|CEA Antibody|CEA Antibody|Carcinoembryonic Antigen Antibody	Any antibody that recognizes a member of the carcinoembryonic antigen protein family.			Amino Acid, Peptide, or Protein|Immunologic Factor	
C118807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118807>	C168182	Newborn or Infant Finding	Clinical, laboratory or molecular evidence, or absence of evidence of disease in a neonate or infant.			Finding	NICHD Terminology
C118808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118808>	C2955|C213152|C190275	Childhood Colorectal Carcinoma|Colorectal (Colon or Rectal) Cancer	A rare colorectal carcinoma that occurs during childhood.	Childhood Colorectal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C118809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118809>	C4872|C190575|C190275	Childhood Breast Carcinoma|Breast Cancer	A rare breast carcinoma that occurs during childhood.	Childhood Breast Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C11880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11880>	C61063	Celecoxib/Trastuzumab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118810>	C203250|C190077	Childhood Neuroendocrine Tumor G1|Childhood Carcinoid Tumor|Childhood Carcinoid Tumor|Pediatric Neuroendocrine Tumor G1	A neuroendocrine tumor grade 1 that occurs during childhood.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C118811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118811>	C4855|C190275|C190121	Childhood Laryngeal Carcinoma|Laryngeal Throat Cancer	A rare carcinoma of the larynx that occurs during childhood.	Childhood Laryngeal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C118812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118812>	C3513|C190275|C189870	Childhood Esophageal Carcinoma|Esophageal Cancer	A rare carcinoma of the esophagus that occurs during childhood.	Childhood Esophageal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C118813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118813>	C4911|C190275|C189870	Childhood Gastric Carcinoma|Childhood Carcinoma of the Stomach|Gastric (Stomach) Cancer	A rare carcinoma of the stomach that occurs during childhood.	Childhood Gastric Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C118814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118814>	C2926|C209738	Childhood Lung Non-Small Cell Carcinoma|Childhood Non-Small Cell Lung Cancer|Childhood Non-Small Cell Lung Carcinoma	A rare non-small cell carcinoma of the lung that occurs during childhood.			Neoplastic Process	
C118815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118815>	C4917|C215716|C209738|C190075	Childhood Lung Small Cell Carcinoma|Childhood Small Cell Lung Cancer|Childhood Small Cell Lung Carcinoma	A rare small cell carcinoma of the lung that occurs during childhood.			Neoplastic Process	
C118816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118816>	C4912|C190275|C189269	Childhood Bladder Carcinoma|Bladder Cancer	A rare carcinoma of the bladder that occurs during childhood.	Childhood Bladder Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C118817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118817>	C9336|C190275|C190121	Childhood Nasal Cavity Carcinoma	A rare carcinoma of the nasal cavity that occurs during childhood.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C118818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118818>	C6014|C190275|C190121	Childhood Paranasal Sinus Carcinoma	A rare carcinoma of the paranasal sinus that occurs during childhood.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C118819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118819>	C4906|C215716|C190121	Childhood Parathyroid Gland Carcinoma	A rare carcinoma of the parathyroid gland that occurs during childhood.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C11881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11881>	C61063	Carboplatin/SU5416			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118820>	C9061	Adult Penile Carcinoma|Penile Cancer	A carcinoma of the penis that occurs during adulthood.	Adult Penile Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C118821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118821>	C7547|C189269|C114451	Childhood Malignant Penile Neoplasm|Malignant Childhood Penile Neoplasm	A rare malignant neoplasm of the penis that occurs during childhood.			Neoplastic Process	
C118822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118822>	C3326|C190071	Childhood Adrenal Gland Pheochromocytoma|Childhood Pheochromocytoma|Pediatric Adrenal Gland Pheochromocytoma|Pediatric Pheochromocytoma	A rare pheochromocytoma of the adrenal gland that occurs during childhood.			Neoplastic Process	
C118823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118823>	C9382|C118808	Childhood Rectal Carcinoma|Rectal Cancer	A rare carcinoma of the rectum that occurs during childhood.	Childhood Rectal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C118824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118824>	C9272|C190275|C190121	Childhood Salivary Gland Carcinoma	A rare carcinoma of the salivary gland that occurs during childhood.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C118825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118825>	C9272	Adult Salivary Gland Carcinoma	A carcinoma of the salivary gland that occurs during adulthood.			Neoplastic Process	
C118826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118826>	C7523|C213152|C114451	Childhood Malignant Small Intestinal Neoplasm	A rare malignant small intestinal neoplasm that occurs during childhood.			Neoplastic Process	
C118827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118827>	C4815|C190275|C190121	Childhood Thyroid Gland Carcinoma|Childhood Thyroid Carcinoma|Thyroid Gland Cancer	A rare carcinoma of the thyroid gland that occurs during childhood.	Childhood Thyroid Gland Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C118828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118828>	C3562|C3224	Orbital Melanoma|Primary Orbital Melanoma	A melanoma that arises from the structures of the orbit.			Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology
C118829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118829>	C9479|C7153	Hereditary Nonmedullary Thyroid Gland Carcinoma|FNMTC|Familial Non-medullary Thyroid Gland Carcinoma|Familial Nonmedullary Thyroid Gland Carcinoma|Familial Nonmedullary Thyroid Gland Carcinoma|NSFNMTC|Non-Syndromic Familial Thyroid Cancer	A papillary or follicular thyroid gland carcinoma with a genetic component that develops within the same family. Current studies suggest that it is inherited in an autosomal dominant pattern. It is often multifocal and bilateral and usually affects younger patients.	Familial Nonmedullary Thyroid Gland Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NCIt Neoplasm Core Terminology
C11882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11882>	C61063	Donepezil/Vitamin E			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118830>	C91105	FACT-Bl Questionnaire|FACT-Bl|Functional Assessment of Cancer Therapy - Bladder Cancer	A subscale complement to the FACT-G developed specifically for evaluating the quality of life of patents with bladder cancer.			Intellectual Product	
C118831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118831>	C91105	FACT-CNS Questionnaire|FACT-CNS|Functional Assessment of Cancer Therapy - Cancer in the Central Nervous System	A subscale complement to the FACT-G developed specifically for evaluating the quality of life of patients with cancer in the central nervous system.			Intellectual Product	
C118832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118832>	C179032|C172982	Bothered by Vaginal Discharge or Bleeding Question|Bothered by Vaginal Discharge or Bleeding|I am bothered by discharge or bleeding from my vagina	A question about whether an individual is or was bothered by discharge or bleeding from her vagina.			Intellectual Product	FACT-Cx Questionnaire
C118833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118833>	C172982	Bothered by Vaginal Odor Question|Bothered by Vaginal Odor|I am bothered by odor coming from my vagina	A question about whether an individual is or was bothered by odor coming from her vagina.			Intellectual Product	FACT-Cx Questionnaire
C118834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118834>	C173704|C173047	Afraid to Have Sex Question|Afraid to Have Sex|Afraid to Have Sexual Intercourse|I am afraid to have sex|I am afraid to have sex	A question about whether an individual is or was afraid to have sex.			Intellectual Product	FACT-Cx Questionnaire|Fecal Incontinence Quality of Life Scale
C118835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118835>	C173219	Vagina Feels too Narrow or Short Question|My vagina feels too narrow or short|Vagina Feels too Narrow or Short	A question about whether an individual feels or felt that her vagina is too narrow or short.			Intellectual Product	FACT-Cx Questionnaire
C118836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118836>	C173812|C173047	Afraid Treatment May Harm Body Question|Afraid Treatment May Harm Body|I am afraid the treatment may harm my body	A question about whether an individual is or was afraid the treatment may harm their body.			Intellectual Product	FACT-Cx Questionnaire
C118837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118837>	C173803|C173518	Have Discomfort When Urinating Question|Have Discomfort When Urinating|I have discomfort when I urinate	A question about whether an individual has or had discomfort when urinating.			Intellectual Product	FACT-Cx Questionnaire
C118838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118838>	C173803|C173398	Have Trouble Controlling Urine Question|Have Trouble Controlling Urine|I have trouble controlling my urine	A question about whether an individual has or had trouble controlling their urine.			Intellectual Product	FACT-Bl Questionnaire
C118839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118839>	C173803	Burns When Urinating Question|Burns When Urinating|It burns when I urinate	A question about whether an individual has or had a burning sensation when urinating.			Intellectual Product	FACT-Bl Questionnaire
C11883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11883>	C61063	Oxaliplatin/Topotecan			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118841>	C173398	Have Trouble Digesting Food Question|Have Trouble Digesting Food|Have Trouble with Digestion|I have trouble digesting food	A question about whether an individual has or had trouble digesting food.			Intellectual Product	FACT-En Questionnaire
C118842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118842>	C156140	Have Discomfort or Pain in Pelvic Area Question|Have Discomfort or Pain in Pelvic Area|Have Discomfort or Pain in Pelvic Region|I have discomfort or pain in my pelvic area	A question about whether an individual has or had discomfort or pain in their pelvic area.			Intellectual Product	FACT-En Questionnaire
C118843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118843>	C85865|C53543|C28193	Allan-Herndon-Dudley Syndrome|MCT8-Specific Thyroid Hormone Cell Membrane Transporter Deficiency|Monocarboxylate Transporter 8 Deficiency	A rare, X-linked recessive inherited syndrome caused by mutations in the SLC16A2 (MCT8) gene. It affects exclusively males and is characterized by mental retardation, limited mobility, muscle hypoplasia, hypotonia, contractures, and spasticity.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C118844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118844>	C84683|C53543|C3131	Ectodermal Dysplasia and Immunodeficiency|Anhidrotic Ectodermal Dysplasia with Immune Deficiency|EDA-ID|Hypohidrotic Ectodermal Dysplasia with Immune Deficiency	A rare disorder caused by mutations either in the IKBKG gene resulting in an X-linked recessive inheritance pattern or in the NFKBIA gene resulting in an autosomal dominant inheritance pattern. It is characterized by abnormal development of ectodermal tissues including the skin, hair, teeth, and sweat glands and immune system deficiency. It results in dry and wrinkled skin, sparse scalp and body hair, missing teeth, and reduced ability to sweat. Patients have abnormally low levels of antibodies causing inability to fight infections.			Disease or Syndrome	Cellosaurus Disease Terminology
C118845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118845>	C85865|C53543|C28193	Otopalatodigital Syndrome Type 1	A rare, X-linked dominant inherited syndrome caused by mutations in the FLNA gene. It is characterized by hearing loss caused by malformations in the ossicles, cleft palate, wide-set eyes, prominent brow ridges, small and flat nose, and skeletal abnormalities in the fingers and toes. Males usually experience more severe symptoms than females.			Disease or Syndrome	Cellosaurus Disease Terminology
C118846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118846>	C84910	Miyoshi Muscular Dystrophy 1|MMD1	A rare, autosomal recessive inherited skeletal muscle disorder caused by mutation in the dysferlin gene. It affects young adults and is characterized by weakness and atrophy in the muscles of the upper and lower limbs.			Disease or Syndrome	Cellosaurus Disease Terminology
C118847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118847>	C85075	Spinal Muscular Atrophy Type 3|Juvenile Spinal Muscular Atrophy|Kugelberg-Welander Disease|Kugelberg-Welander Syndrome|Spinal Muscular Atrophy III	A rare, autosomal recessive inherited disorder caused by mutations in the SMN1 gene. It is characterized by progressive degeneration and loss of the anterior horn cells in the spinal cord and brain stem. It is manifested with hypotonia and muscle weakness, usually in late childhood or adolescence.  Affected individuals can stand and walk but walking and climbing stairs becomes progressively difficult.			Disease or Syndrome	Cellosaurus Disease Terminology
C118848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118848>	C82987	Tumor Antigen-reactive CD28+/CCR7+/CD27+/CD45RA- Cytotoxic T-lymphocyte|REHA CTL|Rapidly Expanding High-Avidity Cytotoxic T Cell|Rapidly Expanding High-Avidity Cytotoxic T Lymphocyte|Rapidly Expanding High-Avidity Cytotoxic T-Cell|Rapidly Expanding High-Avidity Cytotoxic T-Lymphocyte	A subset of rapidly expanding, tumor antigen-reactive central memory cytotoxic T-lymphocytes (CTLs) with a broad expression profile for markers of immune function (MIF), and a particular phenotype of CD28+/CCR7+/CD27+/CD45RA-. These CTLs are formed in vivo following administration of AGS-003 (an autologous, CD40L and tumor antigen RNA-transfected dendritic cell (DC) immunotherapeutic agent), secrete multiple cytokines, including interferon-gamma (IFN-g), tumor necrosis factor-alpha (TNF-a), and interleukin-2 (IL-2), and cause cell lysis. These antigen-reactive, CD28+/CCR7+/CD27+/CD45RA- CTLs, and the phenotype changes in the patient's peripheral blood CTL pool, can be used as a marker to evaluate a patient's immune response against the administered immunotherapeutic agent AGS-003.	Tumor Antigen-reactive CD28+/CCR7+/CD27+/CD45RA- Cytotoxic T-lymphocyte		Cell|Indicator, Reagent, or Diagnostic Aid	CTRP Biomarker Terminology|CTRP Terminology
C118849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118849>	C221766|C17369	Radiologic Imaging Procedure	Any imaging procedure that uses radiation to create an image for the purpose of assisting with the execution of an intervention.	Radiologic Imaging Procedure		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C11884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11884>	C61063	Gemcitabine/SCH 66336			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118850>	C28681|C138180|C129826	Autologous Anti-HPV-16 E6 T-cell Receptor Gene-engineered Peripheral Blood Lymphocytes|Autologous Anti-HPV-16 E6 TCR Gene-engineered PBLs|Autologous Anti-HPV-16 E6 TCR Gene-engineered Peripheral Blood Lymphocytes	Human autologous peripheral blood lymphocytes (PBLs) transduced with a retroviral vector encoding a T cell receptor (TCR) that is specifically directed against the viral oncoprotein human papillomavirus type 16 (HPV-16) E6, with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the autologous anti-HPV-16 E6 TCR gene-engineered PBLs bind to HPV-16 E6-expressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of HPV-16 E6-positive cancer cells. HPV-16 E6, a cell surface glycoprotein, is overexpressed by a variety of HPV-associated cancers and is absent from healthy human tissues.	Autologous Anti-HPV-16 E6 T-cell Receptor Gene-engineered Peripheral Blood Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118851>	C222318|C1980	Autologous IL-2-expressing B-CLL Vaccine|Autologous IL2-transduced CLL B Cell Vaccine	A cancer vaccine consisting of autologous, B-chronic lymphocytic leukemia (B-CLL) cells harvested from a patient and transduced ex vivo with an adenoviral vector encoding the gene for the human cytokine interleukin-2 (IL-2), with potential immunostimulating and antineoplastic activities.  Upon reintroduction into the patient, the autologous IL-2-expressing B-CLL vaccine expresses IL-2, stimulates natural killer (NK) cells, and may enhance the cytotoxic T-lymphocyte (CTL) immune response against the patient's B-CLL cells.	Autologous IL-2-expressing B-CLL Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118852>	C1980	Autologous CD40L-expressing B-CLL Vaccine|Autologous hCD40L-transduced CLL B Cell Vaccine	A cancer vaccine consisting of autologous, B-chronic lymphocytic leukemia (B-CLL) cells harvested from a patient and transduced with an adenoviral vector encoding the gene for the human CD40 ligand (CD40L; TRAP; CD154), with potential immunostimulating and antineoplastic activities. Upon reintroduction into the patient, the autologous CD40L-expressing B-CLL vaccine expresses the co-stimulatory molecule CD40L, which binds to its cognate receptor, CD40, on antigen presenting cells (APC). This induces apoptosis, stimulates maturation and proliferation of APCs, and facilitates a cytotoxic T-lymphocyte (CTL) response against tumor cells. CD40L is a type II membrane protein that binds to CD40, which is a cell surface receptor that belongs to the tumor necrosis factor (TNF) receptor superfamily.	Autologous CD40L-expressing B-CLL Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118853>	C64493	About Once Weekly|About Once a Week	Scheduled or occurring at a frequency of approximately once per week.			Quantitative Concept	FACT-Cognitive Function
C118854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118854>	C64493	Two to Three Times Weekly|Two to Three Times a Week	Scheduled or occurring at a frequency of two or three times per week.			Quantitative Concept	FACT-Cognitive Function
C118855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118855>	C64493	Nearly Every Day|Almost Every Day|Nearly Daily	Scheduled or occurring at a frequency bordering on daily.			Quantitative Concept	FACT-Cognitive Function|Revised Dyadic Adjustment Scale
C118856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118856>	C64493	Several Times Daily|Several Times Each Day|Several Times a Day	Scheduled or occurring at a frequency of several times per day.			Quantitative Concept	FACT-Cognitive Function
C118857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118857>	C118747	Lamellar Laceration of the Globe	Traumatic injury to the globe, resulting in a partial thickness wound of the eyewall (cornea and/or sclera). (adapted from the Birmingham Eye Trauma Terminology System (BETTS))			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118858>	C118747	Ocular Contusion	A closed globe injury without violation of the eyewall (cornea and/or sclera), resulting in injury to one or more intraocular structures. (adapted from the Birmingham Eye Trauma Terminology System (BETTS))			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118859>	C34981	Central Retinal Vein Occlusion|Central Retinal Venous Occlusion|Central Retinal Venous Occlusion	Blockage of the central retinal vein.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11885>	C61063	gp100 Antigen/Interferon Alfa/MART-1 Antigen/Montanide ISA-51/Sargramostim/Tyrosinase Peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118860>	C27604	Fat Adherence Syndrome	Violation of Tenon's capsule with prolapse of orbital fat into the sub-Tenon's space.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118861>	C34738	Anterior Segment Ischemia	Compromise of blood supply to the anterior segment of the eye.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118862>	C27608	Corneal Delle|Corneal Dellen|Corneal Dellen|Delle	Corneal thinning just anterior to the limbus secondary to abnormal and/or irregular bulbar conjunctival contour.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118863>	C78342	Oculocardiac Reflex	Slowing or cessation of the heart rate secondary to traction on the extraocular muscle.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118864>	C27604	Crystalline Lens Dislocation|DISLOCATION, LENS	Displacement of the crystalline lens from the visual axis.			Disease or Syndrome	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118865>	C27604	Intraocular Lens Dislocation	Displacement of the intraocular lens from the visual axis.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118866>	C27609	Lid Retraction	Abnormal superior displacement of resting upper lid margin or abnormal inferior displacement of resting lower lid margin.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118867>	C110937	Slipped Extraocular Muscle|Slipped Muscle	Weakness of extraocular muscle function as a result of inadequate securing of the muscle to the sclera during strabismus surgery.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118868>	C118748	Laceration of the Globe	Full-thickness wound of the eyewall (cornea and/or sclera) caused by a sharp object.			Finding	
C118869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118869>	C118868	Penetrating Open Globe Injury	Full thickness wound of the eyewall (cornea and/or sclera) caused by the entry of a sharp object into the eye. (adapted from the Birmingham Eye Trauma Terminology System (BETTS))			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C11886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11886>	C61063	gp100 Antigen/Interferon Alfa/MART-1 Antigen/Montanide ISA-51/Tyrosinase Peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118870>	C118868	Perforating Open Globe Injury	Open globe injury with both entrance and exit wounds in the eyewall (cornea and/or sclera) caused by the same object.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118871>	C118748	Ruptured Globe	Full thickness wound of the eyewall (cornea and/or sclera) due to blunt trauma. (adapted from the Birmingham Eye Trauma Terminology System (BETTS))			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118872>	C99208	Optic Disc Edema	Swelling of the optic disc in the absence of increased intracranial pressure.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C118873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118873>	C173358	How Often Question|Frequency|Frequency Question|How Often	A question about the frequency of an event or behavior.			Intellectual Product	
C118875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118875>	C73539	Cystathionine|2-Amino-4-(2-Amino-2-Carboxy-Ethyl) Thio-Butanoic Acid|2-Amino-4-[(2-Amino-2-Carboxyethyl)Sulfanyl]Butanoic Acid|DL-Allocystathionine|DL-Cystathionine|Homocysteine, S-(2-Amino-2-Carboxyethyl)-|S-(2-Amino-2-Carboxyethyl)Homocysteine	An amino acid derivative that is an intermediate in the biosynthesis of cysteine. It is the product of the ligation of homocysteine and serine by cystathionine beta synthase.	Cystathionine		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Terminology
C118876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118876>	C73539	3-Aminoisobutyric Acid|2-(Aminomethyl)Propionic Acid|2-Methyl-Beta-Alanine|3-Amino-2-Methylpropanoate|3-Amino-2-Methylpropanoic Acid|3-Aminoisobutanoate|3-Aminoisobutanoic Acid|Alpha-Methyl-Beta-Alanine|BAIB|BAIBA|BAIBA|Beta-Aminoisobutyric Acid	A derivative of the amino acid alanine that is a product of thymine metabolism, which has the potential to induce downstream metabolic activity. During exercise, 3-aminoisobutyric acid is secreted by muscle cells into the blood. Once this molecule interacts with adipocytes, it may induce signaling pathways that regulate the metabolism of fats, insulin, and cholesterol.	3-Aminoisobutyric Acid		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C118877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118877>	C73539|C275	Anserine|(2S)-2-(3-Aminopropanamido)-3-(1-Methyl-1H-Imidazol-5-Yl)Propanoic Acid|(2S)-2-[(3-Amino-1-Oxopropyl)Amino]-3-(3-Methyl-4-Imidazolyl)Propanoic Acid|ANSERINE|Beta-Alanyl-3-Methyl-L-Histidine|Beta-Alanyl-3-Methylhistidine|L-Anserine|L-Histidine, N-Beta-Alanyl-3-Methyl-	A dipeptide comprised of a beta-alanine and a methylhistidine that is found in dietary red meat and has antioxidant activity.	Anserine		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C118878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118878>	C73539	5-Hydroxylysine|(2S,5R)-2,6-Diamino-5-Hydroxyhexanoate|(2S,5R)-2,6-Diamino-5-Hydroxyhexanoic Acid|(2S,5R)-5-Hydroxylysine|5-Hydroxy-Lysine|Alpha,Epsilon-Diamino-Delta-Hydroxycaproate|Alpha,Epsilon-Diamino-Delta-Hydroxycaproic Acid|Delta-Hydroxylysine|Erythro-5-Hydroxy-L-Lysine|HYDROXYLYSINE|Hydroxy-Lysine|Hydroxylysine|L-Delta-Hydroxylysine|L-Hydroxylysine	A hydroxylated amino acid derivative of lysine that arises from post-translational modification. Lysine is converted into 5-hydroxylysine by lysyl hydroxylase, an oxoenzyme that catalyzes the hydroxylation of carbon-5 in lysyl residues found in proteins or peptides. Hydroxylysine residues are required for the formation and stability of triple helical collagen fibrils.	5-Hydroxylysine		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C118879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118879>	C73539	Argininosuccinic Acid|L-Aspartic Acid, N-(((4-Amino-4-Carboxybutyl)Amino)Iminomethyl)-, (S)-|N-[{[(4S)-4-Amino-4-Carboxybutyl]Amino}(Imino)Methyl]-L-Aspartic Acid	An amino acid derivative formed through the binding of citrulline to aspartic acid catalyzed by argininosuccinic acid synthetase. Argininosuccinic acid is converted to arginine and fumarate by argininosuccinate lyase in the urea cycle.	Argininosuccinic Acid		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Terminology
C11887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11887>	C61063	Hydrocortisone/Ketoconazole			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118880>	C73539|C275	Carnosine|(2S)-2-[(3-Amino-1-Oxopropyl)Amino]-3-(3H-Imidazol-4-Yl)Propanoic Acid|Beta-Alanyl-L-Histidine|Beta-Alanylhistidine|CARNOSINE|L-Histidine, Beta-Alanyl-|L-Histidine, N-Beta-Alanyl-	A dipeptide comprised of a beta-alanine and a 3-methyl-L-histidine, which is found in dietary red meat, with potential antioxidant, metal-chelating and anti-glycation activities. Carnosine scavenges both reactive oxygen species (ROS) and unsaturated aldehydes produced by cell membrane lipid peroxidation. Additionally, this dipeptide may reduce the rate of formation of advanced glycation end-products (AGE). Altogether, this may protect cells against oxidative damage. In addition, carnosine is able to chelate toxic metals.	Carnosine		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C118881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118881>	C73539	Alpha-Aminoadipic Acid|2-Aminoadipate|2-Aminoadipic Acid|2-Aminohexanedioic Acid|Alpha-Aminoadipate|Alpha-amino Adipic Acid|Hexanedioic Acid, 2-Amino-	An alpha-amino acid that is an intermediate in the lysine degradation pathway. It is synthesized from homoisocitrate and then converted to a semialdehyde that reacts with glutamic acid to form saccharopine. Alpha-aminoadipic acid levels are elevated in tissues of certain cancers and may potentially be used as a cancer biomarker.	Alpha-Aminoadipic Acid		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Terminology
C118882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118882>	C70561	Phosphorylethanolamine|2-Amino-Ethanol Dihydrogen Phosphate|2-Amino-Ethanol Phosphate|2-Aminoethyl Dihydrogen Phosphate|Colamine Phosphate|Colamine Phosphoric Acid|Colaminphosphoric Acid|EAP|Ethanolamine Acid Phosphate|Ethanolamine O-Phosphate|Ethanolamine Phosphate|Mono(2-Aminoethyl) Phosphate|Monoaminoethyl Phosphate|O-Phosphocolamine|O-Phosphoethanolamine|O-Phosphorylethanolamine|OPE|PE|PEA|PETN|PHOSPHORYLCOLAMINE|Phosphoethanolamine|Phosphonoethanolamine|Phosphoric Acid 2-Aminoethyl Phenyl Ester|Phosphoryl-Ethanolamine|pEtN	A monophosphate ethanolamine ester that is an intermediate in the biosynthesis of sphingomyelins.	Phosphorylethanolamine		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C118883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118883>	C73539	Phosphoserine|2-Amino-3-(Oxyphosphinyloxyphosphinyl)Propanoic Acid|2-Amino-3-(Phosphonooxy)Propanoic Acid|2-Amino-3-Phosphonooxypropanoic Acid|3-Phospho-Serine|DL-2-Amino-3-Hydroxypropanoic Acid 3-Phosphate|DL-O-Phosphorylserine|DL-Serine Dihydrogen Phosphate|DL-Serine, Dihydrogen Phosphate (Ester)|O-Phosphonoserine|P-Ser|P-Serine|Phosphorylserine|Serine Dihydrogen Phosphate|Serine-3-Phosphate	A derivative of the amino acid serine where the side chain hydroxyl group has been substituted with a phosphono group. Post-translational phosphorylation of serine residues in proteins or peptides can regulate the progression of multiple intracellular signal transduction pathways. Monomeric phosphoserine is an intermediate in L-serine biosynthesis.	Phosphoserine		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Terminology
C118884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118884>	C73539	Alloisoleucine|(2S,3R)-2-Amino-3-Methylpentanoic Acid|ALLOISOLEUCINE, L-|Allo-Ile|Allo-L-Isoleucine|AlloI|Alloisoleucine, L-|Isoleucine, Allo-|Isoleucine, Threo-|L-Isoleucine, 3-Methyl-, Threo-|L-Isoleucine, Allo-|L-Isoleucine, Threo-|L-Norvaline, 3-Methyl-, Threo-|Norvaline, 3-Methyl-, Threo-|Pentanoic Acid, 2-Amino-3-Methyl-, (S-(R*,S*))-	The optically active form of the amino acid alloisoleucine with an L-(2S,3R)-configuration, derived from endogenous L-isoleucine, that is an intermediate in the metabolism of branched-chain amino acids. Detection of alloisoleucine in plasma is diagnostic for maple-syrup urine disease (MSUD).	Alloisoleucine		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C118885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118885>	C73539	3-Methylhistidine|3 MEH|3-METHYLHISTIDINE|3-MeHis|3-Methyl-L-Histidine|3MH|N(tau)-Methylhistidine|Ntau-Methylhistidine	A post-translationally modified amino acid found in actin and myosin and a derivative of histidine that has a methyl group bound to the nitrogen at position 3. Urinary levels of 3-methylhistidine are proportional to protein turnover and can be an indicator for myofibrillar protein degradation or a high protein diet.	3-Methylhistidine		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C118886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118886>	C73539	1-Methylhistidine|1-METHYLHISTIDINE|1-MeHis|1MH|2-Amino-3-(1-Methyl-1H-Imidazol-4-Yl)Propanoic Acid|Pi-Methylhistidine	A histidine derivative that has a methyl group bound to the nitrogen at position 1 and results from the metabolism of the dipeptide anserine. Urinary levels of 1-methylhistidine may be indicative of myofibrillar protein degradation or a high protein diet.	1-Methylhistidine		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C118887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118887>	C73539	N-Acetylaspartate|2-Acetamidobutanedioic Acid|ACETYL ASPARTIC ACID|Acetylaspartatic Acid|N-Acetyl-L-Aspartic Acid|N-Acetylaspartatic Acid|NAA	The acetylated form of aspartic acid synthesized in the mitochondria of neurons from aspartic acid and acetyl-coenzyme A. Although highly concentrated in neurons, the exact biological role of N-acetylaspartate has yet to be identified. N-acetylaspartate can act as a neuronal marker and brain levels are decreased in many neuropathological conditions.	N-Acetylaspartate		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C118888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118888>	C20130	Leukotriene Receptor Family|Leukotriene Receptor	A diverse group of transmembrane proteins that can initiate intracellular signaling pathways when leukotrienes are bound to their extracellular, ligand binding domains.	Leukotriene Receptor Family		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118889>	C16447	Beta Isomer of C-Terminal Telopeptide of Type I Collagen|Beta Isoform of the Carboxy-Terminal Cross-Linking Telopeptide of Type I Collagen|Beta Isoform of the Cross-Linked C-Terminal Telopeptide of Type I Collagen|Beta-C-Telopeptide of Type I Collagen|Beta-CTX|Beta-CTx|Beta-CrossLaps|BetaCTx	This polypeptide is comprised of the proteolytically released carboxy-terminal portions of fibrillar type I collagen where age has converted the alpha form of aspartic acid to its beta form. These peptides are joined through trivalent crosslinks and are products of the degradation of mature type I collagen. Elevated serum concentrations of beta-CTX are associated with increased bone resorption.	Beta Isomer of C-Terminal Telopeptide of Type I Collagen		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11888>	C61063	Etoposide/Ifosfamide/Topotecan			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118890>	C813	Measles Virus N mRNA|Measles Virus N Protein mRNA|Measles Virus Nucleocapsid Protein mRNA|Measles Virus Nucleoprotein mRNA|N mRNA	An oligoribonucleotide (~1.7 kbp) transcribed by RNA-dependent RNA polymerase from the measles virus N gene negative-sense RNA. This mRNA can be translated by host ribosomes to produce measles virus nucleoprotein, which is involved in viral encapsidation.	Measles Virus N mRNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology
C118891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118891>	C17607	Measles Virus Nucleoprotein|MV Nucleoprotein|Measles Virus N Protein|Measles Virus Nucleocapsid Protein|N Protein|NP|Nucleocapsid Protein|Nucleoprotein|Protein N	Measles virus nucleoprotein (525 aa, ~58 kDa) is encoded by the measles virus N gene. This protein is involved in the encapsidation and mediation of nuclease resistance of the viral RNA genome.	Measles Virus Nucleoprotein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118892>	C20130	FOXO Family|FOXO|Fork Head Box Transcription Factor Class O|Forkhead Box Transcription Factor Class O|FoxO	A subfamily within the forkhead box (FOX) protein family, which is a family of transcription factors that contain a forkhead DNA-binding domain. FOXO proteins regulate apoptosis, cell-cycle progression, oxidative-stress resistance, and tumor suppression. The transcriptional promoter activity of these factors is regulated by post-translational modifications, such as phosphorylation, acetylation, and monoubiquitination.	FOXO Family		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118893>	C20401	HMB-45|HMB45|Human Melanoma Black 45|Melanoma (gp100) Antibody (HMB45)|Monoclonal Mouse Anti-Human Melanocyte Protein PMEL|Monoclonal Mouse Anti-Human Melanosome, Clone HMB-45	A mouse monoclonal antibody that is used in anatomic pathology as a marker for melanocytic tumors. This antibody recognizes melanocyte protein PMEL (PMEL17 or SILV).	HMB-45		Amino Acid, Peptide, or Protein|Immunologic Factor|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118894>	C98307	BRAF NP_004324.2:p.T599_V600insT|BRAF Ins T|BRAF NP_004324.2:p.T599dup|BRAF NP_004324.2:p.Thr599_Val600insThr|BRAF T599 Duplication Mutation|BRAF T599_V600insT|BRAF Thr599_Val600insThr|BRAF ins(T)|BRAF p.T599_V600insT|BRAF p.Thr599_Val600insThr|BRAF p.Thr599dup|BRAFinsT|NP_004324.2:p.T599_V600insT|NP_004324.2:p.T599dup|NP_004324.2:p.Thr599_Val600insThr|NP_004324.2:p.Thr599dup|Serine/Threonine-Protein Kinase B-raf T599_V600insT|Serine/Threonine-Protein Kinase B-raf Thr599_Val600insThr|Serine/Threonine-Protein Kinase B-raf Thr599dup	A change in the amino acid sequence of the serine/threonine protein kinase B-raf protein where a threonine residue has been inserted between the threonine at position 599 and the valine at position 600.	BRAF NP_004324.2:p.T599_V600insT		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118895>	C158854	BRAF NM_004333.4:c.1797_1798insACA|B-RAF1 c.1797_1798insACA|BRAF c.1795_1797dup|BRAF c.1797_1798insACA|NM_004333.4:c.1795_1797dup|NM_004333.4:c.1795_1797dupACA|NM_004333.4:c.1797_1798insACA|v-raf Murine Sarcoma Viral Oncogene Homolog B1 c.1797_1798insACA	A genetic variation where the trinucleotide, adenine-cytosine-adenine, has been inserted between the nucleotides at positions 1797 and 1798 of the coding sequence of the BRAF gene.	BRAF NM_004333.4:c.1797_1798insACA		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118896>	C158854	BRAF NM_004333.4:c.1796_1797insTAC|B-RAF c.1796_1797insTAC|BRAF c.1796_1797insTAC|BRAF c.1798insTAC|NM_004333.4:c.1796_1797insTAC|NM_004333.6:c.1794_1796dup|v-raf Murine Sarcoma Viral Oncogene Homolog B1 c.1796_1797insTAC	A genetic variation where the trinucleotide, thymine-adenine-cytosine, has been inserted between the nucleotides at positions 1796 and 1797 of the coding sequence of the BRAF gene.	BRAF NM_004333.4:c.1796_1797insTAC		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118897>	C32423	Aggresome	A ubiquitin-rich cytoplasmic inclusion encased in vimentin found near the microtubule organizing center. It is formed in response to cellular stresses that cause the production of misfolded proteins at levels that exceed the degradative capacity of the proteasome. This inclusion body is comprised of aggregated misfolded or denatured proteins that have been transported along microtubules to the pericentriolar space where they become encased in vimentin.	Aggresome		Cell Component	CTRP Biomarker Terminology|CTRP Terminology
C118898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118898>	C16295	Fowlpox Virus Antibody|Anti-Fowlpox Virus|Anti-Fowlpox Virus Antibody	Any antibody that recognizes viruses in the fowlpox family.	Fowlpox Virus Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C118899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118899>	C16295	CSF2 Antibody|Anti-CSF2 Antibody|Anti-GM-CSF Antibody|Anti-GMCSF Antibody|Anti-Granulocyte-Macrophage Colony-Stimulating Factor Antibody|GM-CSF Antibody|GMCSF Antibody|Granulocyte-Macrophage Colony-Stimulating Factor Antibody	Any antibody that recognizes the granulocyte-macrophage colony-stimulating factor protein.	CSF2 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11889>	C61007	Fluorouracil/Irinotecan			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1188>	C746	Penclomedine|3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl) pyridine|CRC 88-04|PEN|PENCLOMEDINE|Pyridine, 3,5-dichloro-2,4-dimethoxy-6-(trichloromethyl)-|penclomedine	A synthetic derivative of pyrimidine with antineoplastic activity. Penclomedine alkylates and crosslinks DNA, resulting in DNA strand breaks and inhibition of DNA and RNA synthesis. This agent is more active against tumor cells that are defective in p53 function. (NCI04)			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118900>	C21067	Unfolded Protein Response|Cellular Response to Unfolded Protein|UPR	A cellular stress response process that is activated by the accumulation of unfolded or misfolded proteins in the cell.	Unfolded Protein Response		Phenomenon or Process	CTRP Biomarker Terminology|CTRP Terminology
C118901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118901>	C16295	Measles Virus Antibody|Anti-Measles Virus|Anti-Measles Virus Antibody	Any antibody that recognizes measles virus.	Measles Virus Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C118902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118902>	C14075	ALK Kinase Domain|ALK Tyrosine Kinase Receptor Kinase Domain|Anaplastic Lymphoma Kinase Tyrosine Kinase Domain|CD246 Tyrosine Kinase Domain	The intracellular portion of the ALK tyrosine kinase receptor protein that confers tyrosine kinase enzymatic activity.	ALK Kinase Domain		Amino Acid Sequence	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118903>	C16124	No Prior Therapy|Therapy Naive	No prior treatment for the study disorder.			Clinical Attribute	
C118904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118904>	C20194	IL18BP Gene|IL18BP|IL18BP|Interleukin 18 Binding Protein Gene	This gene plays a role in interleukin sequestration.	IL18BP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118905>	C118904	IL18BP wt Allele|IL18BPa|Interleukin 18 Binding Protein wt Allele	Human IL18BP wild-type allele is located in the vicinity of 11q13 and is approximately 7 kb in length. This allele, which encodes interleukin-18-binding protein, is involved in the inhibition of interleukin-18-mediated signaling.	IL18BP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118906>	C18466	Interleukin-18-Binding Protein|IL-18BP|Interleukin 18-Binding Protein|MC51L-53L-54L Homolog Gene Product	Interleukin-18-binding protein (194 aa, ~21 kDa) is encoded by the human IL18BP gene. This protein plays a role in binding to and sequestration of interleukin-18.	Interleukin-18-Binding Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118907>	C25790	CD1C Gene|CD1C|CD1C|CD1c Molecule Gene	This gene is involved in antigen presentation of lipids or glycolipid antigens.	CD1C Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118908>	C118907	CD1C wt Allele|BDCA1|CD1|CD1A|CD1C Antigen, C Polypeptide Gene|CD1c Molecule wt Allele|R7|RP11-101J8.3	Human CD1C wild-type allele is located in the vicinity of 1q23.1 and is approximately 5 kb in length. This allele, which encodes T-cell surface glycoprotein CD1c, plays a role in the presentation of lipid and glycolipid antigens to T-cells.	CD1C wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118909>	C16725	T-Cell Surface Glycoprotein CD1c|BDCA-1|CD1c|CD1c Antigen|Cortical Thymocyte Antigen CD1C|Differentiation Antigen CD1-Alpha-3|Thymocyte Antigen CD1C	T-cell surface glycoprotein CD1c (333 aa, ~38 kDa) is encoded by the human CD1C gene. This protein is involved in lipid and glycolipid antigen presentation to T-cells.	T-Cell Surface Glycoprotein CD1c		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11890>	C61063	Docetaxel/Oblimersen			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118910>	C20921	CARD14 Gene|CARD14|CARD14|Caspase Recruitment Domain Family, Member 14 Gene	This gene plays a role in both signaling and the inhibition of apoptosis.	CARD14 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118911>	C118910	CARD14 wt Allele|BIMP2|CARMA2|Caspase Recruitment Domain Family, Member 14 wt Allele|PRP|PSORS2|PSS1|Psoriasis Susceptibility 2 Gene	Human CARD14 wild-type allele is located in the vicinity of 17q25 and is approximately 39 kb in length. This allele, which encodes caspase recruitment domain-containing protein 14, is involved in the inhibition of apoptosis. Mutation of the gene is associated with both psoriasis type 2 and autosomal dominant pityriasis rubra pilaris.	CARD14 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118912>	C18515	Caspase Recruitment Domain-Containing Protein 14|Bcl10-Interacting Maguk Protein 2|CARD-Containing MAGUK Protein 2|CARD-MAGUK Protein 2|CARD14|Carma 2	Caspase recruitment domain-containing protein 14 (1004 aa, ~113 kDa) is encoded by the human CARD14 gene. This protein plays a role in the promotion of cell survival.	Caspase Recruitment Domain-Containing Protein 14		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118913>	C28533	SLC9A1 Gene|SLC9A1|SLC9A1|Solute Carrier Family 9, Subfamily A (NHE1, Cation Proton Antiporter 1), Member 1 Gene	This gene is involved in pH regulation.	SLC9A1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118914>	C118913	SLC9A1 wt Allele|APNH|APNH1|Antiporter, Sodium-Hydrogen Ion, Amiloride Sensitive Gene|NHE-1|NHE1|PPP1R143|RP4-633N17.1|Solute Carrier Family 9 (Sodium/Hydrogen Exchanger), Isoform 1 (Antiporter, Na+/H+, Amiloride Sensitive) Gene|Solute Carrier Family 9 (Sodium/Hydrogen Exchanger), Member 1 (Antiporter, Na+/H+, Amiloride Sensitive) Gene|Solute Carrier Family 9 (Sodium/Hydrogen Exchanger), Member 1 Gene|Solute Carrier Family 9, Member 1 Gene|Solute Carrier Family 9, Subfamily A (NHE1, Cation Proton Antiporter 1), Member 1 wt Allele	Human SLC9A1 wild-type allele is located within 1p36.1-p35 and is approximately 68 kb in length. This allele, which encodes sodium/hydrogen exchanger 1 protein, plays a role in the regulation of cellular pH.	SLC9A1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118915>	C16386	Sodium/Hydrogen Exchanger 1|NHE-1|Na(+)/H(+) Antiporter|Na(+)/H(+) Antiporter, Amiloride-Sensitive|Na(+)/H(+) Exchanger 1|SLC9A1|Solute Carrier Family 9 Member 1	Sodium/hydrogen exchanger 1 (815 aa, ~91 kDa) is encoded by the human SLC9A1 gene. This protein is involved in the antiport of sodium ions and hydrogen ions.	Sodium/Hydrogen Exchanger 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118916>	C20103	KIR2DS4 Gene|KIR2DS4|KIR2DS4|Killer Cell Immunoglobulin-Like Receptor, Two Domains, Short Cytoplasmic Tail, 4 Gene	This gene plays a role in the recognition of HLA-bound antigens.	KIR2DS4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118917>	C118916	KIR2DS4 wt Allele|CD158I|KIR-2DS4|KIR1D|KIR412|KKA3|Killer Cell Immunoglobulin-Like Receptor, Two Domains, Short Cytoplasmic Tail, 4 wt Allele|NK-Associated Transcript 8 Gene|NKAT-8|NKAT8|XXbac-BPG230H20.3	Human KIR2DS4 wild-type allele is located in the vicinity of 19q13.4 and is approximately 16 kb in length. This allele, which encodes killer cell immunoglobulin-like receptor 2DS4 protein, is involved in natural killer cell-mediated immunity.	KIR2DS4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118918>	C18106	Killer Cell Immunoglobulin-Like Receptor 2DS4|CD158 Antigen-Like Family Member I|CD158i|CD158i Antigen|KIR Antigen 2DS4|Killer Cell Immunoglobulin-Like Receptor Two Domains Short Cytoplasmic Tail 1|Killer Inhibitory Receptor 4-1-2|MHC Class I NK Cell Receptor Eb6 ActI|NKAT-8|p58 NK Receptor CL-39/CL-17|p58 Natural Killer Cell Receptor Clones CL-39/CL-17	Killer cell immunoglobulin-like receptor 2DS4 (304 aa, ~34 kDa) is encoded by the human KIR2DS4 gene. This protein plays a role in the modulation of natural killer cell activity.	Killer Cell Immunoglobulin-Like Receptor 2DS4		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118919>	C28533	SLC36A1 Gene|SLC36A1|SLC36A1|Solute Carrier Family 36 (Proton/Amino Acid Symporter), Member 1 Gene	This gene is involved in the transport of neutral amino acids.	SLC36A1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C11891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11891>	C61063	Cisplatin/Etoposide/Tirapazamine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118920>	C118919	SLC36A1 wt Allele|Dct1|LYAAT1|PAT1|Solute Carrier Family 36 (Proton/Amino Acid Symporter), Member 1 wt Allele|TRAMD3	Human SLC36A1 wild-type allele is located in the vicinity of 5q33.1 and is approximately 55 kb in length. This allele, which encodes proton-coupled amino acid transporter 1 protein, plays a role in the mediation of pH-dependent transport of small amino acids.	SLC36A1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118921>	C16386	Proton-Coupled Amino Acid Transporter 1|Lysosomal Amino Acid Transporter 1|Proton/Amino Acid Transporter 1|SLC36A1|Solute Carrier Family 36 Member 1	Proton-coupled amino acid transporter 1 (476 aa, ~53 kDa) is encoded by the human SLC36A1 gene. This protein is involved in the transport of small amino acids and hydrogen ions.	Proton-Coupled Amino Acid Transporter 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118922>	C26057	DDX39B Gene|DDX39B|DDX39B|DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 39B Gene	This gene plays a role in both RNA splicing and mRNA transport.	DDX39B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118923>	C118922	DDX39B wt Allele|BAT1|D6S81E|DAAP-97M17.4|DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 39B wt Allele|HLA-B Associated Transcript 1 Gene|HLA-B-Associated Transcript 1 Gene|Nuclear RNA Helicase (DEAD Family) Gene|UAP56	Human DDX39B wild-type allele is located in the vicinity of 6p21.3 and is approximately 12 kb in length. This allele, which encodes spliceosome RNA helicase DDX39B protein, is involved in both mRNA nuclear export and pre-mRNA splicing.	DDX39B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118924>	C17417	Spliceosome RNA Helicase DDX39B|56 kDa U2AF65-Associated Protein|ATP-Dependent RNA Helicase p47|DEAD Box Polypeptide 39B|DEAD Box Protein UAP56|EC 3.6.4.13|HLA-B-Associated Transcript 1 Protein|Spliceosome RNA Helicase BAT1|U2AF65-Associated Protein 56|U2AF65-Associated Protein, 56-kD	Spliceosome RNA helicase DDX39B (428 aa, ~49 kDa) is encoded by the human DDX39B gene. This protein plays a role in spliceosome assembly and the nuclear export of spliced and unspliced mRNA.	Spliceosome RNA Helicase DDX39B		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118925>	C28533	SLC1A5 Gene|SLC1A5|SLC1A5|Solute Carrier Family 1 Member 5 Gene	This gene is involved in both neutral amino acid transport and retrovirus binding.	SLC1A5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118926>	C118925	SLC1A5 wt Allele|AAAT|ASCT2|ATBO|M7V1|M7VS1|R16|RD144 Sensitivity Gene|RDR|RDRC|Solute Carrier Family 1 (Neutral Amino Acid Transporter), Member 5 Gene|Solute Carrier Family 1 Member 5 wt Allele	Human SLC1A5 wild-type allele is located in the vicinity of 19q13.32 and is approximately 14 kb in length. This allele, which encodes neutral amino acid transporter B(0) protein, plays a role in both the transport of neutral amino acids and binding to select retroviruses.	SLC1A5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118927>	C16386	Neutral Amino Acid Transporter B(0)|ASC Amino Acid Transporter-2|ASCT2|ATB(0)|Alanine/Serine/Cysteine Transporter 2|Baboon M7 Virus Receptor|Neutral Amino Acid Transporter B|Neutral Amino Acid Transporter-Like Protein|RD114 Virus Receptor|RD114/Simian Type D Retrovirus Receptor|SLC1A5|Sodium-Dependent Neutral Amino Acid Transporter Type 2|Solute Carrier Family 1 Member 5	Neutral amino acid transporter B(0) (541 aa, ~57 kDa) is encoded by the human SLC1A5 gene. This protein is involved in neutral amino acid transport and as a receptor for select retroviruses.	Neutral Amino Acid Transporter B(0)		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118928>	C30073	KRT16 Gene|KRT16|KRT16|Keratin 16 Gene	This gene plays a role in the formation of both skin and hair.	KRT16 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118929>	C118928	KRT16 wt Allele|CK16|FNEPPK|Focal Non-Epidermolytic Palmoplantar Keratoderma Gene|K16|K1CP|KRT16A|Keratin 16 wt Allele|NEPPK|PC1	Human KRT16 wild-type allele is located in the vicinity of 17q21.2 and is approximately 6 kb in length. This allele, which encodes keratin, type I cytoskeletal 16 protein, is involved in epidermal and hair follicle maturation. Mutation of the gene is associated with type 1 pachyonychia congenita, non-epidermolytic palmoplantar keratoderma and unilateral palmoplantar verrucous nevus.	KRT16 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11892>	C61063	Paclitaxel/Prinomastat			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118930>	C20694	Keratin, Type I Cytoskeletal 16|CK-16|Cytokeratin 16|Cytokeratin-16|K16|KRT16|Keratin-16	Keratin, type I cytoskeletal 16 (473 aa, ~51 kDa) is encoded by the human KRT16 gene. This protein plays a role in the maturation of the epidermis, hair follicles, and some mucosal surfaces.	Keratin, Type I Cytoskeletal 16		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118931>	C76196	Rhodobacteraceae	A taxonomic family of Gram negative bacterium in the phylum Proteobacteria that includes the genera Actibacterium, Agaricicola and Rhodobacter, among others.			Bacterium	
C118932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118932>	C77916	Amoebozoa	An unranked group of ameoboid protozoa that include Mycetozoa (slime-molds) and Archamoebae.			Eukaryote	
C118933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118933>	C25790	ICOSLG Gene|ICOSLG|ICOSLG|Inducible T-Cell Co-Stimulator Ligand Gene	This gene is involved in the regulation of T- and B-cell proliferation.	ICOSLG Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118934>	C118932	Acanthamoeba|ACANTHAMOEBA	A genus of motile, unicellular eukaryotic amoebae within the family of Acanthamoebidae that are characterized with the presence of acanthopodia (spiny surface projections) and are commonly found in air, soil, and water environments. Members of the Acanthamoeba genus are opportunistic and nonopportunistic human pathogens, and may cause granulomatous amoebic encephalitis, cutaneous acanthamebiasis and amoebic keratitis.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118935>	C77167	Acremonium|ACREMONIUM	A genus of slow growing, filamentous and cosmopolitan fungi within the phylum Ascomycota. Members of this genus produce hyaline, septate hyphae, whereas vegetative hyphae form hyphal ropes. Phialides are unbranched, solitary and erect, and form directly on the hyphal tips, the hyphal ropes, or both. Some species within the Acremonium genus are opportunistic pathogens and may cause mycetoma, onychomycosis, and hyalohyphomycosis in humans.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118936>	C35552	Acute Myocardial Infarction Type|ACMITYPE|ACMITYPE	A classification or description of the acute myocardial infarction.			Qualitative Concept	CDISC SDTM Cardiovascular Findings About Test Code Terminology|CDISC SDTM Cardiovascular Findings About Test Name Terminology|CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118937>	C118933	ICOSLG wt Allele|B7-H2|B7H2|B7RP-1|B7RP1|CD275|GL50|ICOS-L|ICOSL|Inducible T-Cell Co-Stimulator Ligand wt Allele|KIAA0653|LICOS	Human ICOSLG wild-type allele is located in the vicinity of 21q22.3 and is approximately 18 kb in length. This allele, which encodes ICOS ligand protein, plays a role in the modulation of T-cell activity, B-cell differentiation, and lymphocyte proliferation.	ICOSLG wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118938>	C118931	Pannonibacter				Bacterium	
C118939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118939>	C85912	Actinobaculum				Bacterium	
C11893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11893>	C61063	Carboplatin/Fluorouracil/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118940>	C25447	Elasticity	A quantitative measurement of an entity's ability to deform in response to physiological force and return to its normal shape by passive elastic recoil.			Conceptual Entity	
C118941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118941>	C17001	Diploidy|Diploid|Diploid	Having two sets of homologous chromosomes.			Quantitative Concept	GDC Terminology|GDC Value Terminology
C118942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118942>	C14248	Mansonella				Animal	
C118943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118943>	C16725	ICOS Ligand|B7 Homologue 2|B7-H2|B7-Like Protein Gl50|B7-Related Protein 1|B7RP-1|CD275|CD275 Antigen|Transmembrane Protein B7-H2|Transmembrane Protein B7-H2 ICOS Ligand	ICOS ligand (302 aa, ~33 kDa) is encoded by the human ICOSLG gene. This protein is involved in lymphocyte proliferation, costimulation of T-cells and the modulation of B-cell proliferation and differentiation.	ICOS Ligand		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118944>	C20921	LAMTOR5 Gene|LAMTOR5|LAMTOR5|Late Endosomal/Lysosomal Adaptor, MAPK and MTOR Activator 5 Gene	This gene plays a role in both guanine nucleotide exchange and the inhibition of hepatitis B virus replication.	LAMTOR5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118945>	C118944	LAMTOR5 wt Allele|HBXIP|Late Endosomal/Lysosomal Adaptor, MAPK and MTOR Activator 5 wt Allele|MGC71071|XIP	Human LAMTOR5 wild-type allele is located in the vicinity of 1p13.3 and is approximately 7 kb in length. This allele, which encodes ragulator complex protein LAMTOR5, is involved in both the inhibition of hepatitis B replication and the regulation of mitogenic signaling pathways.	LAMTOR5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118946>	C17494	Ragulator Complex Protein LAMTOR5|HBV X-Interacting Protein|HBX-Interacting Protein|Hepatitis B Virus X Interacting Protein|Hepatitis B Virus X Protein-Interacting Protein|Hepatitis B Virus X-Interacting Protein|Hepatitis B Virus X-Interacting Protein (9.6kD)|Late Endosomal/Lysosomal Adaptor and MAPK and MTOR Activator 5	Ragulator complex protein LAMTOR5 (91 aa, ~10 kDa) is encoded by the human LAMTOR5 gene. This protein plays a role in both the modulation of mitogenic signaling and the down-regulation of hepatitis B virus replication.	Ragulator Complex Protein LAMTOR5		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118947>	C200766|C176018	RNA Electroporated CD19CAR-CD3zeta-4-1BB-expressing Autologous T-lymphocytes|RNA Anti-CD19 CAR T Cells|RNA CART19	Autologous, genetically engineered T-lymphocytes that have been electroporated with an mRNA encoding for an anti-CD19 chimeric antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv) coupled to the co-stimulatory signaling domain of 4-1BB (CD137) and the zeta chain of the T-cell receptor CD3 complex (CD3-zeta), with potential immunomodulating and antineoplastic activities.  Upon transfusion, the RNA electroporated CD19CAR-CD3zeta-4-1BB-expressing autologous T-lymphocytes attach to cancer cells expressing CD19. This induces selective toxicity against CD19-expressing tumor cells and causes tumor cell lysis. The 4-1BB co-stimulatory molecule signaling domain enhances T-cell activation and signaling after recognition of CD19. CD19 antigen is a B-cell specific cell surface antigen, which is expressed in all B-cell lineage malignancies.	RNA Electroporated CD19CAR-CD3zeta-4-1BB-expressing Autologous T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118948>	C213472	Taletrectinib|AB 106|AB-106|AB106|DS-6051A|TALETRECTINIB	An orally available inhibitor of the receptor tyrosine kinases C-ros oncogene 1 (ROS1) and the neurotrophic tyrosine receptor kinase (NTRK) types 1, 2 and 3, with potential antineoplastic activity. Upon oral administration, taletrectinib binds to and inhibits ROS1 and the NTRK family members. This inhibition leads to a disruption of ROS1- and NTRK-mediated signaling and eventually inhibits the growth of tumor cells that are overexpressing ROS1 and/or NTRKs. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells. NTRK mutations or rearrangements play a key role in cancer progression.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118949>	C28676|C201545	Umbilical Cord Blood-derived Natural Killer Cells|Cord Blood NK Cells|Umbilical Cord Blood-derived NK Cells	A population of allogeneic, cytokine-differentiated, highly lytic natural killer (NK) cells derived from CD34+ cells isolated from human umbilical cord blood (UCB) with potential cytotoxic activity. CD34+ hematopoietic stem cells (HSC) are isolated from human UCB mononuclear cells, differentiated into mature, highly lytic, CD3- CD56+ NK cells, by a specific combination of cytokines that includes stem cell factor (SCF), fms-related tyrosine kinase 3 ligand (Flt3-L), interleukin-15 (IL-15) and insulin-like growth factor-1 (IGF-1), and expanded ex vivo. Upon administration, the UCB-derived NK cells may lyse cancer cells.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11894>	C61063	Gemcitabine/ISIS 2503			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118950>	C20988	SDC3 Gene|SDC3|SDC3|Syndecan 3 Gene	This gene is involved in the metabolism of glycosaminoglycans.	SDC3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118951>	C118950	SDC3 wt Allele|KIAA0468|SDCN|SYND3|Syndecan 3 (N-Syndecan) Gene|Syndecan 3 wt Allele|Syndecan, Neural Type Gene	Human SDC3 wild-type allele is located in the vicinity of 1p35.2 and is approximately 39 kb in length. This allele, which encodes syndecan-3 protein, plays a role in both the biosynthesis and catabolism of glycosaminoglycans. Single-nucleotide polymorphisms in the gene are associated with obesity in some ethnic groups.	SDC3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118952>	C16393	Syndecan-3|N-Syndecan|SDC3|SYND3|Syndecan Neural Type|Syndecan Proteoglycan 3	Syndecan-3 (442 aa, ~45 kDa) is encoded by the human SDC3 gene. This protein is involved in glycosaminoglycan metabolism.	Syndecan-3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118953>	C129821|C129820	HER2-targeting Antibody Fc Fragment FS102|Anti-HER2 FCAB FS102|BMS-986186|FS-102|FS102|Fcab FS102	A proprietary, antibody fragment composed of a constant (Fc) region that is engineered to bind to the tumor-associated antigen human epidermal growth factor receptor-2 (HER2), with potential antineoplastic activity. HER2-targeted antibody Fc fragment FS102 specifically binds to its HER2 epitope, and causes downregulation of HER2-mediated signaling. This leads to tumor cell apoptosis. HER2, a member of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (EGFR) superfamily, is overexpressed on the cell surface of various solid tumors.	HER2-targeting Antibody Fc Fragment FS102		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118954>	C20194	HPP1 Gene|FPH1|Familial Progressive Hyperpigmentation 1 Gene|HPP|HPP1|HPP1|Hyperpigmentation, Familial Progressive, 1 Gene|Hyperpigmentation, Progressive, 1 Gene|MUH	Human HPP1 gene is located within 19pter-p13.1 and the size of this phenotypic locus is not reported. This phenotype-only gene has not been linked to a known protein product. This locus is associated with familial progressive hyperpigmentation.	HPP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118955>	C106317	Low Mitosis-Karyorrhexis Index|Low	An index used in neuroblastic tumors indicating the presence of less than 100 mitoses and karyorrhexis per 5,000 cells.			Quantitative Concept	GDC Terminology|GDC Value Terminology
C118956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118956>	C28676	LMP1/BARF1/EBNA1-specific Cytotoxic T-lymphocytes|LMP1/BARF1/ EBNA1-specific CTLs|LMP1/BARF1/EBNA-1 MABEL CTLs|LMP1/BARF1/EBNA-1 Minimum Anticipated Biological Effect Level Cytotoxic T-lymphocytes	A preparation of allogeneic cytotoxic T-lymphocytes (CTL) made specifically reactive to three Epstein-Barr virus (EBV) proteins, latent membrane protein (LMP) 1, BamH1-A rightward frame-1 (BARF1) and EBV nuclear antigen 1 (EBNA1), with potential antineoplastic activity. Administration of LMP1/BARF1/ EBNA1-specific CTLs to patients with LMP1/BARF1/EBNA1-positive tumors may result in a specific CTL response against the tumor cells expressing these antigens, which can result in both cell lysis and the inhibition of tumor cell proliferation. LMP1, BARF1 and EBNA1 are expressed in various, EBV-associated malignancies, including nasopharyngeal cancer and EBV-positive Hodgkin lymphoma.	LMP1/BARF1/EBNA1-specific Cytotoxic T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118957>	C106317	Intermediate Mitosis-Karyorrhexis Index|Intermediate	An index used in neuroblastic tumors indicating the presence of between 100 and 200 mitoses and karyorrhexis per 5,000 cells.			Quantitative Concept	GDC Terminology|GDC Value Terminology
C118958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118958>	C106317	High Mitosis-Karyorrhexis Index|High	An index used in neuroblastic tumors indicating the presence of more than 200 mitoses and karyorrhexis per 5,000 cells.			Quantitative Concept	GDC Terminology|GDC Value Terminology
C118959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118959>	C48905	Censor|Censored|Censoring	To ban access to or remove portions of a publication, film, letter, etc., usually for moral, religious, or political reasons.			Activity	
C11895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11895>	C61007	Doxorubicin/Hydrocortisone/Methotrexate			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118960>	C1663	Neoantigen-based Glioblastoma Vaccine|NeoVax (TM) Glioblastoma Vaccine|Personalized Neoantigen Glioblastoma Vaccine	A peptide-based, personalized glioblastoma cancer vaccine consisting of patient-specific glioblastoma derived immunogenic mutated epitopes (neoantigens), with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-based glioblastoma vaccine stimulates the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. Neoantigens are tumor-specific antigens derived from mutated proteins that are present only in a specific tumor.	Neoantigen-based Glioblastoma Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118961>	C1511	Gallium Ga 68 Gozetotide|(68)Ga labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC|(68)Ga-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC|(68)Ga-labeled Glu-urea-Lys(Ahx)-HBED-CC|(68)Gallium-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC|(68Ga)Glu-urea-Lys(Ahx)-HBED-CC|68Ga-DKFZ-PSMA-11|68Ga-HBED-CC-PSMA|68Ga-PSMA|68Ga-PSMA-11|68Ga-PSMA-HBED-CC|68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC|AAA 517|AAA-517|AAA517|GA-68 PSMA-11|GALLIUM GA-68 GOZETOTIDE|Ga PSMA|Ga-68 labeled DKFZ-PSMA-11|Ga-68 labeled PSMA-11|GaPSMA|Gallium Ga 68 PSMA-11|Gallium Ga 68-labeled PSMA-11|Gallium-68 PSMA|Gallium-68 PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC|PSMA-HBED-CC GA-68|[68Ga] Prostate-specific Membrane Antigen 11|[68Ga]GaPSMA-11	A radioconjugate composed of a human prostate specific membrane antigen (PSMA)-targeting ligand, Glu-urea-Lys(Ahx) (Glu-NH-CO-NH-Lys(Ahx)), conjugated, via the acyclic radiometal chelator N,N'-bis [2-hydroxy-5-(carboxyethyl)benzyl] ethylenediamine-N,N'-diacetic acid (HBED-CC), to the radioisotope gallium Ga 68, with potential use as a tracer for PSMA-expressing tumors during positron emission tomography (PET). Upon intravenous administration of the gallium Ga 68 gozetotide, the Glu-urea-Lys(Ahx) moiety targets and binds to PSMA-expressing tumor cells. Upon internalization, PSMA-expressing tumor cells can be detected during PET imaging. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.	Gallium Ga 68 Gozetotide		Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C118962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118962>	C118959	Clinical Trial Censoring|Censored|Censored|Censoring	When information on time-to-event is not available due to loss to follow-up or non-occurrence of outcome event before the trial end. The data on that participant is banned or removed from the study data.			Activity	GDC Terminology|GDC Value Terminology
C118963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118963>	C20923	LGR6 Gene|LGR6|LGR6|Leucine-Rich Repeat Containing G Protein-Coupled Receptor 6 Gene	This gene is involved in R-spondin-mediated signaling.	LGR6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118964>	C118963	LGR6 wt Allele|FLJ14471|GPCR|Leucine-Rich Repeat Containing G Protein-Coupled Receptor 6 wt Allele|RP11-572A16.3|UNQ6427/PRO21331|VTS20631	Human LGR6 wild-type allele is located in the vicinity of 1q32.1 and is approximately 126 kb in length. This allele, which encodes leucine-rich repeat-containing G-protein coupled receptor 6 protein, plays a role in the mediation of R-spondin-dependent signaling.	LGR6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118965>	C18239	Leucine-Rich Repeat-Containing G-Protein Coupled Receptor 6|Leucine-Rich Repeat-Containing G Protein-Coupled Receptor 6	Leucine-rich repeat-containing G-protein coupled receptor 6 (967 aa, ~104 kDa) is encoded by the human LGR6 gene. This protein is involved in both binding to R-spondin proteins and potentiating ligand-dependent signaling pathways.	Leucine-Rich Repeat-Containing G-Protein Coupled Receptor 6		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118966>	C20735	FABP6 Gene|FABP6|FABP6|Fatty Acid Binding Protein 6, Ileal Gene	This gene plays a role in the transport of bile salts and acids.	FABP6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118967>	C118966	FABP6 wt Allele|Fatty Acid Binding Protein 6, Ileal wt Allele|I-15P|I-BABP|I-BALB|I-BAP|IBABP|ILBP|ILBP3|ILLBP	Human FABP6 wild-type allele is located within 5q33.3-q34 and is approximately 51 kb in length. This allele, which encodes gastrotropin protein, is involved in bile acid and bile salt transport.	FABP6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118968>	C17728	Gastrotropin|FABP6|Fatty Acid-Binding Protein 6|GT|I-15P|I-BABP|ILBP|Ileal Bile Acid Binding Protein|Ileal Lipid-Binding Protein|Illeal Lipid-Binding Protein|Intestinal 15 kDa Protein|Intestinal Bile Acid-Binding Protein	Gastrotropin (128 aa, ~14 kDa) is encoded by the human FABP6 gene. This protein plays a role in bile salt and bile acid transport.	Gastrotropin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118969>	C20993	Clinical or Research Assessment Classification	A named instrument whose output is an ordinal or categorical score that serves as a surrogate for, or ranking of, disease status or other physiological or biological status.			Intellectual Product	
C11896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11896>	C61007	Cytarabine/Dexamethasone/Etoposide/Ifosfamide/Methotrexate/Vinblastine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118970>	C120166	CDISC Clinical Classification Terminology	The terminology subset that includes terms pertaining to the CDISC clinical classification terminology.			Intellectual Product	CDISC QRS Terminology|Clinical Data Interchange Standards Consortium Terminology
C118971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118971>	C118970	CDISC Clinical Classification Category Terminology|CC-CCCAT|CCCAT|Category of Clinical Classification	Terminology associated with the clinical classification domain categories of the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C118972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118972>	C1931	Annonaceous Acetogenins|Acetogenins	A family of naturally occurring polyketides that consist of C32 or C34 long chain fatty acids and combined with a propan-2-ol unit at C-2 to form a gamma-lactone, which are isolated from various species of the plant family Annonaceae, with potential antineoplastic and antimicrobial activity. Annonaceous acetogenins bind to the ubiquinone catalytic site(s) within the mitochondrial NADH:ubiquinone oxidoreductase (complex I), and block the electron transport chain in mitochondria. In addition, the acetogenins bind to and block the activity of ubiquinone-linked NADH oxidase, an enzyme overexpressed in the plasma membranes of cancer cells. This inhibits adenosine triphosphate (ATP) production, decreases intracellular ATP levels, and induces tumor cell apoptosis. Compared to normal cells, cancer cells have higher ATP demands. The Annonaceous acetogenins also inhibit microbial glucose dehydrogenase 6.			Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118973>	C1920|C1663	Genetically-modified MAGE-A3-expressing MG1 Maraba Virus Vaccine|MG1 Maraba/MAGE-A3|MG1MA3	A vaccine consisting of the attenuated, genetically-modified, oncolytic form of the Maraba virus, MG1, which has been engineered to express a gene encoding the cancer testis antigen melanoma antigen family A3 (MAGE-A3), with potential antineoplastic activity. Upon administration of genetically-modified MAGE-A3-expressing MG1 Maraba virus vaccine, the attenuated Maraba virus selectively and rapidly replicates in cancer cells; however, it is unable to replicate in normal, healthy cells. This induces a selective Maraba virus-mediated cytotoxicity in those cancer cells, and leads to cancer cell lysis. In addition, the expression of MAGE-A3 further stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing MAGE-A3. The tumor-associated antigen MAGE-A3 is overexpressed by a variety of cancer cell types. The attenuated virus is a double mutant strain with single amino acid substitutions occurring in both G protein (Q242R) and M protein (L123W).			Immunologic Factor|Pharmacologic Substance|Virus	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C118974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118974>	C212943	TIPARP Gene|TCDD-Inducible Poly(ADP-Ribose) Polymerase Gene|TIPARP|TIPARP	This gene is involved in ADP-ribosylation of proteins.	TIPARP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118975>	C118974	TIPARP wt Allele|ARTD14|DDF1|DKFZP434J214|DKFZp686N0351|PARP-7|PARP7|RM1|TCDD-Inducible Poly(ADP-Ribose) Polymerase wt Allele|pART14	Human TIPARP wild-type allele is located in the vicinity of 3q25.31 and is approximately 34 kb in length. This allele, which encodes TCDD-inducible poly [ADP-ribose] polymerase protein, plays a role in modifying guanine residues with ADP-ribose.	TIPARP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118976>	C17434	TCDD-Inducible Poly [ADP-Ribose] Polymerase|ADP-Ribosyltransferase Diphtheria Toxin-Like 14|ARTD14|EC 2.4.2.30|PARP-7|Poly [ADP-Ribose] Polymerase 7|TIPARP	TCDD-inducible poly [ADP-ribose] polymerase (657 aa, ~76 kDa) is encoded by the human TIPARP gene. This protein is involved in protein modification.	TCDD-Inducible Poly [ADP-Ribose] Polymerase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118977>	C54362	LZTS1 Gene|LZTS1|LZTS1|Leucine Zipper, Putative Tumor Suppressor 1 Gene	This gene plays a role in gene transcription, cell growth regulation, cell cycle progression, and tumor suppression.	LZTS1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118978>	C118977	LZTS1 wt Allele|F37|FEZ1|Leucine Zipper, Putative Tumor Suppressor 1 wt Allele	Human LZTS1 wild-type allele is located in the vicinity of 8p22 and is approximately 58 kb in length. This allele, which encodes leucine zipper putative tumor suppressor 1 protein, is involved in cell cycle regulation, cell growth modulation, transcriptional regulation, and tumor suppression. Mutation of the gene is associated with esophageal squamous cell carcinoma and several other neoplastic diseases.	LZTS1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118979>	C26199	Leucine Zipper Putative Tumor Suppressor 1|F37/Esophageal Cancer-Related Gene-Coding Leucine-Zipper Motif|Fez1|LZTS1	Leucine zipper putative tumor suppressor 1 (596 aa, ~67 kDa) is encoded by the human LZTS1 gene. This protein plays a role in tumor suppression, cell cycle modulation, cell growth control and transcriptional regulation.	Leucine Zipper Putative Tumor Suppressor 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11897>	C61007	Cyclophosphamide/Dexamethasone/Doxorubicin/Methotrexate/Vinblastine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118980>	C21240	EIF1B Gene|EIF1B|EIF1B|Eukaryotic Translation Initiation Factor 1B Gene	This gene is involved in the initiation of protein translation.			Gene or Genome	
C118981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118981>	C118980	EIF1B wt Allele|Eukaryotic Translation Initiation Factor 1B wt Allele|GC20	Human EIF1B wild-type allele is located in the vicinity of 3p22.1 and is approximately 3 kb in length. This allele, which encodes eukaryotic translation initiation factor 1b protein, plays a role in the translation of proteins.			Gene or Genome	
C118982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118982>	C17461	Eukaryotic Translation Initiation Factor 1b|EIF1B|Protein Translation Factor SUI1 Homolog GC20|Translation Factor Sui1 Homolog|eIF1b	Eukaryotic translation initiation factor 1b (113 aa, ~13 kDa) is encoded by the human EIF1B gene. This protein is involved in both RNA binding and the initiation of protein synthesis.			Amino Acid, Peptide, or Protein	
C118983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118983>	C20923	OPRM1 Gene|OPRM1|OPRM1|Opioid Receptor, Mu 1 Gene	This gene plays a role in opioid-dependent G protein-coupled receptor signaling.	OPRM1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118984>	C118983	OPRM1 wt Allele|LMOR|M-OR-1|MOP|MOR|MOR1|OPRM|Opioid Receptor, Mu 1 wt Allele|Opioid Receptor, Mu-1 Gene	Human OPRM1 wild-type allele is located within 6q24-q25 and is approximately 236 kb in length. This allele, which encodes Mu-type opioid receptor protein, is involved in opioid binding and signaling. A point mutation in the gene may be associated with addiction to opioids and alcohol, and variations in pain sensitivity	OPRM1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118985>	C18239	Mu-Type Opioid Receptor|M-OR-1|MOP|MOR-1|Mu Opiate Receptor|Mu Opioid Receptor|Mu Opioid Receptor hMOR-1a|hMOP	Mu-type opioid receptor (400 aa, ~45 kDa) is encoded by the human OPRM1 gene. This protein plays a role in G protein-coupled receptor signaling.	Mu-Type Opioid Receptor		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118986>	C26000	LUM Gene|LUM|LUM|Lumican Gene	This gene is involved in collagen binding.	LUM Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118987>	C118986	LUM wt Allele|LDC|Lumican wt Allele|SLRR2D	Human LUM wild-type allele is located in the vicinity of 12q21.33 and is approximately 9 kb in length. This allele, which encodes lumican protein, plays a role in the structure of the extracellular matrix.	LUM wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118988>	C17351	Lumican|KSPG Lumican|Keratan Sulfate Proteoglycan Lumican|LUM|Lumican Proteoglycan	Lumican (338 aa, ~38 kDa) is encoded by the human LUM gene. This protein is involved in the structure of interstitial collagen matrices.	Lumican		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118989>	C20917	ASPM Gene|ASPM|ASPM|Asp (Abnormal Spindle) Homolog, Microcephaly Associated (Drosophila) Gene	This gene plays a role in mitotic spindle regulation.	ASPM Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C11898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11898>	C61007	Autologous Lymphocytes/Interleukin-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C118990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118990>	C118989	ASPM wt Allele|ASP|ASP, Drosophila, Homolog of Gene|Abnormal Spindle-Like, Microcephaly-Associated Gene|Asp (Abnormal Spindle) Homolog, Microcephaly Associated (Drosophila)wt Allele|Asp (Abnormal Spindle)-Like, Microcephaly Associated (Drosophila) Gene|Calmbp1|FLJ10517|FLJ10549|MCPH5|Microcephaly, Primary Autosomal Recessive 5 Gene|RP11-32D17.1	Human ASPM wild-type allele is located in the vicinity of 1q31 and is approximately 63 kb in length. This allele, which encodes abnormal spindle-like microcephaly-associated protein, is involved in the regulation of the mitotic spindle. Mutation of the gene is associated with primary microcephaly type 5.	ASPM wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118991>	C17761	Abnormal Spindle-Like Microcephaly-Associated Protein|ASPM|Abnormal Spindle Protein Homolog|Asp Homolog	Abnormal spindle-like microcephaly-associated protein (3477 aa, ~410 kDa) is encoded by the human ASPM gene. This protein plays a role in the activity of the mitotic spindle.	Abnormal Spindle-Like Microcephaly-Associated Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118992>	C28533	SLC7A6 Gene|SLC7A6|SLC7A6|Solute Carrier Family 7 (Amino Acid Transporter Light Chain, y+L System), Member 6 Gene	This gene is involved in the transport of dibasic amino acids.	SLC7A6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118993>	C118992	SLC7A6 wt Allele|KIAA0245|LAT-2|LAT3|Solute Carrier Family 7 (Amino Acid Transporter Light Chain, y+L System), Member 6 wt Allele|Solute Carrier Family 7 (Cationic Amino Acid Transporter, y+ System), Member 6 Gene|y(+)LAT2|y+LAT-2	Human SLC7A6 wild-type allele is located in the vicinity of 16q22.1 and is approximately 37 kb in length. This allele, which encodes y+L amino acid transporter 2 protein, plays a role in the internalization of dibasic amino acids.	SLC7A6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118994>	C16386	Y+L Amino Acid Transporter 2|Cationic Amino Acid Transporter, y+ System|Solute Carrier Family 7 Member 6|Y(+)L-Type Amino Acid Transporter 2|Y+LAT2|y+LAT-2	Y+L amino acid transporter 2 (515 aa, ~57 kDa) is encoded by the human SLC7A6 gene. This protein is involved in dibasic amino acid transport.	Y+L Amino Acid Transporter 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118995>	C28533	SLC7A7 Gene|SLC7A7|SLC7A7|Solute Carrier Family 7 (Amino Acid Transporter Light Chain, y+L System), Member 7 Gene	This gene plays a role in the transport of cationic amino acids.	SLC7A7 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118996>	C118995	SLC7A7 wt Allele|LAT3|LPI|MOP-2|Solute Carrier Family 7 (Amino Acid Transporter Light Chain, y+L System), Member 7 wt Allele|Solute Carrier Family 7 (Cationic Amino Acid Transporter, y+ System), Member 7 Gene|Y+LAT1|y(+)LAT1|y+LAT-1	Human SLC7A7 wild-type allele is located in the vicinity of 14q11.2 and is approximately 57 kb in length. This allele, which encodes y+L amino acid transporter 1 protein, is involved in cationic amino acid transport. Mutation of the gene is associated with lysinuric protein intolerance.	SLC7A7 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118997>	C16386	Y+L Amino Acid Transporter 1|MOP-2|Monocyte Amino Acid Permease 2|Solute Carrier Family 7 Member 7|Y(+)L-Type Amino Acid Transporter 1|Y+LAT1|y+LAT-1	Y+L amino acid transporter 1 (511 aa, ~56 kDa) is encoded by the human SLC7A7 gene. This protein plays a role in the localization of cationic amino acids.	Y+L Amino Acid Transporter 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C118998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118998>	C28533	SLC43A2 Gene|SLC43A2|SLC43A2|Solute Carrier Family 43 (Amino Acid System L Transporter), Member 2 Gene	This gene is involved in the transport of large neutral amino acids.	SLC43A2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C118999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C118999>	C118998	SLC43A2 wt Allele|LAT4|MGC34680|PP7664|Solute Carrier Family 43 (Amino Acid System L Transporter), Member 2 wt Allele|Solute Carrier Family 43 (L-Type Amino Acid Transporter), Member 2 Gene|Solute Carrier Family 43, Member 2 Gene	Human SLC43A2 wild-type allele is located in the vicinity of 17p13.3 and is approximately 60 kb in length. This allele, which encodes large neutral amino acids transporter small subunit 4 protein, plays a role in neutral amino acid transport.	SLC43A2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11899>	C63586	COI Regimen|COI|COI|Capecitabine-Oxaliplatin-Irinotecan|Capecitabine/Irinotecan/Oxaliplatin|Capecitabine/Oxaliplatin/Irinotecan|Capecitabine/Oxaliplatin/Irinotecan Regimen	A regimen consisting of capecitabine, oxaliplatin, and irinotecan that may be used for the treatment of colorectal cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C1189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1189>	C292	Pentamethylmelamine|1,3,5-Triazine-2,4,6-triamine, N,N,N',N', N''-pentamethyl-, monohydrochloride (9CI)|1,3,5-Triazine-2,4,6-triamine, N,N,N',N',N''-pentamethyl-, monohydrochloride (9CI)|Melamine|Melamine, N2,N2,N4,N4,N6-pentamethyl-, monohydrochloride|N,N,N',N',N''-pentamethyl-1,3,5-triazine|PENTAMETHYLMELAMINE|PMM|Pentamethylmelamine MonoHCl|Pentamethylmelamine Monohydrochloride|Pentamethylmelamine monoHCl|Pentamethylmelamine monohydrochloride|melamine, N2,N2,N4,N4,N6-pentamethyl-, monohydrochloride	A principal metabolite of hexamethylmelamine with antineoplastic activity.  Pentamethylmelamine alkylates DNA and other macromolecules and forms DNA intrastrand and DNA-protein crosslinks, thereby preventing DNA replication. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C119000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119000>	C16386	Large Neutral Amino Acids Transporter Small Subunit 4|L-Type Amino Acid Transporter 4|SLC43A2|Solute Carrier Family 43 Member 2	Large neutral amino acids transporter small subunit 4 (569 aa, ~63 kDa) is encoded by the human SLC43A2 gene. This protein is involved in the transport of large neutral amino acids.	Large Neutral Amino Acids Transporter Small Subunit 4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C119001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119001>	C28533	SLC7A8 Gene|SLC7A8|SLC7A8|Solute Carrier Family 7 (Amino Acid Transporter Light Chain, L System), Member 8 Gene	This gene plays a role in the transport of small and large neutral amino acids.	SLC7A8 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C119002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119002>	C119001	SLC7A8 wt Allele|LAT2|LPI-PC1|Solute Carrier Family 7 (Amino Acid Transporter Light Chain, L System), Member 8 wt Allele|Solute Carrier Family 7 (Amino Acid Transporter, L-Type), Member 8 Gene|Solute Carrier Family 7 (Cationic Amino Acid Transporter, y+ System), Member 8 Gene	Human SLC7A8 wild-type allele is located in the vicinity of 14q11.2 and is approximately 58 kb in length. This allele, which encodes large neutral amino acids transporter small subunit 2 protein, is involved in the transport of amino acids.	SLC7A8 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C119003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119003>	C16386	Large Neutral Amino Acids Transporter Small Subunit 2|Integral Membrane Protein E16H|L-Type Amino Acid Transporter 2|SLC7A8|Solute Carrier Family 7 Member 8|hLAT2	Large neutral amino acids transporter small subunit 2 (535 aa, ~58 kDa) is encoded by the human SLC7A8 gene. This protein plays a role in amino acid transport.	Large Neutral Amino Acids Transporter Small Subunit 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C119004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119004>	C28533	SLC5A2 Gene|SLC5A2|SLC5A2|Solute Carrier Family 5 (Sodium/Glucose Cotransporter), Member 2 Gene	This gene is involved in the transport of both glucose and sodium.	SLC5A2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C119005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119005>	C119004	SLC5A2 wt Allele|SGLT2|Sodium-Glucose Cotransporter, Kidney Low Affinity Gene|Sodium-Glucose Cotransporter, Renal Gene|Solute Carrier Family 5 (Sodium/Glucose Cotransporter), Member 2 wt Allele|Solute Carrier Family 5 (Sodium/Glucose Transporter), Member 2	Human SLC5A2 wild-type allele is located in the vicinity of 16p11.2 and is approximately 8 kb in length. This allele, which encodes sodium/glucose cotransporter 2 protein, plays a role in sodium-dependent glucose transport. Mutation of the gene is associated with renal glucosuria.	SLC5A2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C119006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119006>	C16386	Sodium/Glucose Cotransporter 2|Low Affinity Sodium-Glucose Cotransporter|Na(+)/Glucose Cotransporter 2|SGLT2|SLC5A2|Solute Carrier Family 5 Member 2	Sodium/glucose cotransporter 2 (672 aa, ~73 kDa) is encoded by the human SLC5A2 gene. This protein is involved in sodium/glucose symport.	Sodium/Glucose Cotransporter 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C119007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119007>	C28533	SLC2A2 Gene|SLC2A2|SLC2A2|Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 2 Gene	This gene plays a role in carbohydrate transport.	SLC2A2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C119008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119008>	C119007	SLC2A2 wt Allele|GLUT2|Glucose Transporter, Liver/Islet Gene|Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 2 wt Allele	Human SLC2A2 wild-type allele is located within 3q26.2-q27 and is approximately 31 kb in length. This allele, which encodes solute carrier family 2, facilitated glucose transporter member 2 protein, is involved in glucose transport.	SLC2A2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C119009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119009>	C16386	Solute Carrier Family 2, Facilitated Glucose Transporter Member 2|GLUT-2|Glucose Transporter 2|Glucose Transporter Type 2, Liver|SLC2A2	Solute carrier family 2, facilitated glucose transporter member 2 (524 aa, ~57 kDa) is encoded by the human SLC2A2 gene. This protein plays a role in glucose transport.	Solute Carrier Family 2, Facilitated Glucose Transporter Member 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11900>	C61063	Monoclonal antibody 11D10 anti-idiotype vaccine/Monoclonal antibody 3H1 anti-idiotype vaccine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119010>	C225418	Peritumoral	Located in tissues surrounding a tumor.			Spatial Concept	GDC Terminology|GDC Value Terminology
C119011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119011>	C53550	Hepatolithiasis	The presence of solitary or multiple stones in the intrahepatic bile ducts.			Disease or Syndrome	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C119012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119012>	C15330	Hepaticojejunostomy	A reconstructive surgical procedure involving the anastomosis of the hepatic duct to the jejunum.			Therapeutic or Preventive Procedure	
C119013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119013>	C66830	CDISC SDTM Ophthalmic Focus of Study Specific Interest Terminology|OEFOCUS|Ophthalmic Focus of Study Specific Interest|SDTM-OEFOCUS	Terminology associated with the ophthalmic focus of study specific interest codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119014>	C66830	CDISC SDTM Cardiovascular Findings About Test Name Terminology|CVFATS|Cardiovascular Findings About Test Name|SDTM-CVFATS	Terminology associated with the cardiovascular findings about test names codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119015>	C66830	CDISC SDTM Cardiovascular Findings About Test Code Terminology|CVFATSCD|Cardiovascular Findings About Test Code|SDTM-CVFATSCD	Terminology associated with the cardiovascular findings about test codes codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119016>	C66830	CDISC SDTM Cardiovascular Findings About Results Terminology|CVFARS|Cardiovascular Findings About Results|SDTM-CVFARS	Terminology associated with the cardiovascular findings about results codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119017>	C66830	CDISC SDTM Coronary Thrombus TIMI Grade Responses Terminology|CTTIMIRS|Coronary Thrombus TIMI Grade Responses|SDTM-CTTIMIRS	Terminology associated with the coronary thrombus TIMI grade responses codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119018>	C66830	CDISC SDTM NHLBI Coronary Artery Dissection Grade Responses Terminology|CADGRS|Coronary Artery Dissection NHLBI Grade Responses|SDTM-CADGRS	Terminology associated with the NHLBI coronary artery dissection grade responses codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119019>	C66830	CDISC SDTM ARC Coronary Stent Thrombosis Timing Terminology|SDTM-STCTIMRS|STCTIMRS|Stent Thrombosis, Coronary, ARC Timing Responses	Terminology associated with the ARC coronary stent thrombosis timing responses codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11901>	C61063	Bevacizumab/Thalidomide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119020>	C66830	CDISC SDTM ARC Coronary Stent Thrombosis Grade Responses Terminology|SDTM-STCARCRS|STCARCRS|Stent Thrombosis, Coronary ARC Grade Responses	Terminology associated with the ARC coronary stent thrombosis grade responses codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119021>	C2883	Oligoarticular Arthritis|Oligoarthritis|Oligoarthritis|Pauciarthritis|Pauciarthritis	An arthritis affecting fewer than five separate joints.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119022>	C2883	Early Inflammatory Arthritis	Early stages of inflammatory arthritis, when the underlying diagnosis is uncertain, usually little or no joint damage has occurred. Treatment may alter the disease course (e.g., potentially avert progression to full RA or other diagnosis).			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119023>	C2883	Nonerosive Arthritis|Non-Erosive Arthritis|Non-Erosive Arthritis	An inflammation of one or more joints, without loss of articular cartilage or destruction of subchondral bone.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119024>	C114357	Enthesitis-Related Arthritis|ERA|ERA|Enthesitis-Related JIA|Enthesitis-Related JIA|Enthesitis-Related Juvenile Idiopathic Arthritis|Enthesitis-Related Juvenile Idiopathic Arthritis	A category of juvenile idiopathic arthritis associated with arthritis and enthesitis, which may involve the axial skeleton. It is a form of juvenile spondyloarthritis.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119025>	C2883	Post-Streptococcal Arthritis|PSRA|PSRA|Post-Streptococcal Reactive Arthritis|Post-Streptococcal Reactive Arthritis	The occurrence of arthritis after infection with group A streptococcus. It is non-migratory, protracted in course, and poorly responsive to anti-inflammatory agents. (from Textbook of Pediatric Rheumatology, 6th ed. Cassidy, Petty, Laxer, and Lindsley)			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119026>	C2883	Lyme Arthritis	Joint inflammation, most often affecting large joints, associated with Lyme disease, presenting months after infection.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119027>	C37921	Easy Bruising	Appearance of skin bruises following perceived minimal contact or injury.			Finding	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|NICHD Terminology|Pediatric Rheumatology Terminology
C119028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119028>	C5035	Pyuria	The presence of excessive white blood cells in the urine as determined by urinalysis.			Sign or Symptom	NICHD Terminology|Pediatric Rheumatology Terminology
C119029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119029>	C34661	Lupus Headache	A severe, persistent headache that occurs in patients with systemic lupus erythematosus, and is nonresponsive to narcotic analgesia.			Finding	NICHD Terminology|Pediatric Rheumatology Terminology
C11902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11902>	C61063	Ascorbic acid/Selenium			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119030>	C5036|C3280	Rheumatoid Nodule|Rheumatoid nodule, unspecified site	A well circumscribed lump of tissue, firm to touch, typically non-tender, predominantly occurring as a cutaneous manifestation of rheumatoid arthritis localized to extensor surfaces near joints, but may be internal.			Finding	mCode Elixhauser Rheumatoid Arthritis and Collagen Vascular Disease Value Set|mCode Terminology|NICHD Terminology|Pediatric Rheumatology Terminology
C119031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119031>	C114357	Systemic Juvenile Idiopathic Arthritis|Systemic Onset Juvenile Idiopathic Arthritis|Systemic Onset Juvenile Idiopathic Arthritis|sJIA|sJIA	A category of juvenile idiopathic arthritis defined by the presence of arthritis and high fevers, and accompanied by at least 2 of the following systemic features: lymphadenopathy, organomegaly, rash, or serositis. Macrophage activation syndrome is a well known complication.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119032>	C114357	Oligoarticular Juvenile Idiopathic Arthritis|Oligoarticular JIA|Oligoarticular JIA|Pauciarticular JIA|Pauciarticular JIA|Pauciarticular Juvenile Idiopathic Arthritis|Pauciarticular Juvenile Idiopathic Arthritis	A category of juvenile idiopathic arthritis defined by the presence of arthritis affecting between one and four separate joints during the first six months of disease.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119033>	C114357	Polyarticular Juvenile Idiopathic Arthritis, Rheumatoid Factor Negative|Juvenile rheumatoid polyarthritis (seronegative)|Polyarticular JIA, RF-|Polyarticular JIA, RF-|Polyarticular Juvenile Idiopathic Arthritis, RF-|Polyarticular Juvenile Idiopathic Arthritis, RF-	A category of juvenile idiopathic arthritis defined by the presence of arthritis affecting five or more separate joints during the first six months of disease, with negative serologic testing for rheumatoid factor.			Disease or Syndrome	mCode Elixhauser Rheumatoid Arthritis and Collagen Vascular Disease Value Set|mCode Terminology|NICHD Terminology|Pediatric Rheumatology Terminology
C119034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119034>	C114357	Polyarticular Juvenile Idiopathic Arthritis, Rheumatoid Factor Positive|Polyarticular JIA, RF+|Polyarticular JIA, RF+|Polyarticular Juvenile Idiopathic Arthritis, RF+|Polyarticular Juvenile Idiopathic Arthritis, RF+	A category of juvenile idiopathic arthritis defined by the presence of arthritis affecting five or more separate joints during the first six months of disease, with positive serologic testing for rheumatoid factor.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119035>	C114357	Undifferentiated Juvenile Idiopathic Arthritis|Undifferentiated JIA|Undifferentiated JIA	A category of juvenile idiopathic arthritis that does not fulfill any single category or has criteria for more than one category.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119036>	C45161	Early Localized Lyme Disease	An early stage of Lyme disease that may present within 3-30 days after a tick bite with a red, concentrically-expanding rash (erythema migrans), fatigue, chills, fever, headache, muscle and joint aches, and swollen lymph nodes.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119037>	C45161	Early Disseminated Lyme Disease	An early stage of Lyme disease that may present days to weeks after a tick bite with relapsing signs of a red, concentrically-expanding rash (erythema migrans), facial palsy, meningismus, neuralgia, heart palpitations, and dizziness.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119038>	C45161	Late Disseminated Lyme Disease	A late stage of Lyme disease that may present in untreated patients months to years after a tick bite manifested with intermittent bouts of arthralgia, arthritis and neurologic complaints.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119039>	C45161	Post-Treatment Lyme Disease Syndrome|Chronic Lyme Disease|Chronic Lyme Disease|PTLDS|PTLDS	A constellation of symptoms lasting months to years reported by some Lyme disease patients who had undergone previous antibiotic therapy.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C11903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11903>	C61063	Ascorbic acid/Selenium/Vitamin E			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119040>	C119032	Persistent Oligoarticular Juvenile Idiopathic Arthritis|Persistent Oligoarticular JIA|Persistent Oligoarticular JIA	Oligoarticular juvenile idiopathic arthritis that never involves more than four separate joints after six months.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119041>	C119032	Extended Oligoarticular Juvenile Idiopathic Arthritis|Extended Oligoarticular JIA|Extended Oligoarticular JIA	Oligoarticular juvenile idiopathic arthritis that eventually involves more than four separate joints.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119042>	C27577	Chronic Recurrent Multifocal Osteomyelitis|CRMO|CRMO|NBO|NBO|Non-bacterial Osteomyelitis|Non-bacterial Osteomyelitis	An autoinflammatory disease characterized by sterile bone lesions which are multifocal and/or recurrent.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119043>	C118240	NALP12-Associated Hereditary Periodic Fever Syndrome|NLRP12-Associated Hereditary Periodic Fever Syndrome|NLRP12-Associated Hereditary Periodic Fever Syndrome	An autoinflammatory disease caused by mutations in the NLRP12 gene. It is characterized by periodic fevers beginning in the first year of life that are triggered by cold exposure. Episodes occur more than once per month.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119044>	C114357	Psoriatic Juvenile Idiopathic Arthritis|Psoriatic JIA|Psoriatic JIA|psJIA|psJIA	A category of juvenile idiopathic arthritis defined by the presence of arthritis with a personal or family history of psoriasis, and features such as dactylitis and nail dystrophy.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119045>	C2884	Early Rheumatoid Arthritis	Recent diagnosis of rheumatoid arthritis (usually within one to two years of onset) during which treatment may be more effective and possibly improve the disease course.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119046>	C79717	Scleritis	Inflammation of the sclera.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119047>	C39594	Erythema Migrans|Bulls-Eye Rash|Bulls-Eye Rash|Erythema Chronicum Migrans|Erythema Chronicum Migrans	A red, concentrically-expanding rash sometimes with central clearing, that is part of the first stage of Lyme disease caused by infection with Borrelia species.			Finding	NICHD Terminology|Pediatric Rheumatology Terminology
C119048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119048>	C28193	Pain Amplification Syndrome|Amplified Musculoskeletal Pain Syndrome|Amplified Musculoskeletal Pain Syndrome|Chronic Widespread Pain|Chronic Widespread Pain	A condition in which the nerves register normal stimuli (lack of tissue injury) as pain, resulting in feelings of intense pain with even minor sensory input.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119049>	C28193	Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis Syndrome|PPHS|PPHS|Pustulo-Psoriatic Hyperostotic Spondyloarthritis|Pustulo-Psoriatic Hyperostotic Spondyloarthritis|SAPHO Syndrome|SAPHO Syndrome	A syndrome characterized by synovitis, acne, pustulosis, hyperostosis, and non-infectious osteomyelitis. Includes a spectrum of aseptic neutrophilic dermatoses associated with aseptic osteoarticular lesions.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C11904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11904>	C61063	Flavopiridol/irinotecan			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119050>	C28193	Autoinflammatory Syndrome	A group of disorders of the innate immune system characterized by attacks of seemingly unprovoked inflammation without significant levels of either autoantibodies or autoreactive T cells more characteristic of autoimmune disease.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Rheumatology Terminology
C119051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119051>	C119050	Tumor Necrosis Factor Receptor 1-Associated Periodic Syndrome|Familial Hibernian Fever|Familial Hibernian Fever|TNF Receptor 1-Associated Periodic Syndrome|TNF Receptor 1-Associated Periodic Syndrome|TRAPS|TRAPS	An autoinflammatory disease caused by mutations in the TNFRSF1A gene coding for tumor necrosis factor receptor 1 (TNFR1). This results in attacks of fever, rash, peritoneal, pleural, or pericardial serositis and/or synovial inflammation along with increased acute phase reactants. Complications may include amyloidosis.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119053>	C119050	Familial Cold Autoinflammatory Syndrome|FCAS|FCAS	An autoinflammatory disease caused by mutations in the NLRP3 gene which encodes cryopyrin. It is characterized by short episodes of fever, rash, and arthralgia after exposure to cold or rapid decrease in temperature.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119054>	C119050	Muckle-Wells Syndrome|MWS|MWS	An autoinflammatory disease caused by mutations in the NLRP3 gene which encodes cryopyrin. It is characterized by recurrent episodes of urticaria and fever which develop in infancy. It may lead to sensorineural hearing loss and/or amyloidosis.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119055>	C119050	Pyogenic Arthritis, Pyoderma Gangrenosum and Acne|PAPA|PAPA	An autoinflammatory disease caused by mutations in the PSTPIP1 gene. It is characterized by episodes of destructive arthritis, ulcerative skin lesions and cystic acne.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119056>	C119050	Deficiency of the Interleukin-1 Receptor Antagonist|Autoinflammatory Disease due to Interleukin-1 Receptor Antagonist Deficiency|Autoinflammatory Disease due to Interleukin-1 Receptor Antagonist Deficiency|DIRA|DIRA	An autoinflammatory disease caused by mutations in the IL1RN gene, which encodes the IL1 receptor antagonist. It presents in infancy, and is characterized by systemic inflammation, pustular rash, bone pain, sterile osteitis, and periostitis.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119057>	C202121	Deficiency of the Interleukin-36 Receptor Antagonist	An autoinflammatory disease caused by mutations in the IL36RN gene, which encodes the IL36 receptor antagonist. It is characterized by periodic fevers and psoriasiform rash.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119058>	C119050	Majeed Syndrome	An autoinflammatory disease caused by mutations in the LPIN2 gene. It is characterized by early-onset chronic recurrent multifocal osteomyelitis, congenital dyserythropoietic anemia and inflammatory dermatosis.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119059>	C100110	CDISC Questionnaire AUDIT-SR Test Name Terminology|ADT01TN|Alcohol Use Disorder Identification Test: Self-Report Version Questionnaire Test Name|QS-AUDIT-SR TEST	Test names of questionnaire questions associated with the Alcohol Use Disorder Identification Test: Self-Report Version (AUDIT-SR) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11905>	C61063	Indium In 111 Monoclonal Antibody Bre-3/Yttrium Y 90 Monoclonal Antibody Bre-3			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119060>	C100110	CDISC Questionnaire AUDIT-SR Test Code Terminology|ADT01TC|Alcohol Use Disorder Identification Test: Self-Report Version Questionnaire Test Code|QS-AUDIT-SR TESTCD	Test codes of questionnaire questions associated with the Alcohol Use Disorder Identification Test: Self-Report Version (AUDIT-SR) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119061>	C100110	CDISC Questionnaire AUDIT-C Test Name Terminology|ADTC01TN|Alcohol Use Disorder Identification Test-Consumption Questions Questionnaire Test Name|QS-AUDIT-C TEST	Test names of questionnaire questions associated with the Alcohol Use Disorder Identification Test-Consumption Questions (AUDIT-C) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119062>	C100110	CDISC Questionnaire AUDIT-C Test Code Terminology|ADTC01TC|Alcohol Use Disorder Identification Test-Consumption Questions Questionnaire Test Code|QS-AUDIT-C TESTCD	Test codes of questionnaire questions associated with the Alcohol Use Disorder Identification Test-Consumption Questions (AUDIT-C) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119063>	C100110	CDISC Questionnaire CCQ 24 Hour Version Test Name Terminology|CCQ01TN|Clinical COPD Questionnaire 24 Hour Version Questionnaire Test Name|QS-CCQ 24 Hour Version TEST	Test names of questionnaire questions associated with the Clinical COPD Questionnaire 24 Hour Version (CCQ 24 Hour Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119064>	C100110	CDISC Questionnaire CCQ 24 Hour Version Test Code Terminology|CCQ01TC|Clinical COPD Questionnaire 24 Hour Version Questionnaire Test Code|QS-CCQ 24 Hour Version TESTCD	Test codes of questionnaire questions associated with the Clinical COPD Questionnaire 24 Hour Version (CCQ 24 Hour Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119065>	C100110	CDISC Questionnaire CCQ 1 Week Version Test Name Terminology|CCQ02TN|Clinical COPD Questionnaire 1 Week Version Questionnaire Test Name|QS-CCQ 1 Week Version TEST	Test names of questionnaire questions associated with the Clinical COPD Questionnaire 1 Week Version (CCQ 1 Week Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119066>	C100110	CDISC Questionnaire CCQ 1 Week Version Test Code Terminology|CCQ02TC|Clinical COPD Questionnaire 1 Week Version Questionnaire Test Code|QS-CCQ 1 Week Version TESTCD	Test codes of questionnaire questions associated with the Clinical COPD Questionnaire 1 Week Version (CCQ 1 Week Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119067>	C100110	CDISC Questionnaire CHART-SF Paper Version Test Name Terminology|CHSF2TN|Craig Handicap Assessment and Reporting Technique - Short Form Paper Version Questionnaire Test Name|QS-CHART-SF Paper Version TEST	Test names of questionnaire questions associated with the Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119068>	C100110	CDISC Questionnaire CHART-SF Paper Version Test Code Terminology|CHSF2TC|Craig Handicap Assessment and Reporting Technique - Short Form Paper Version Questionnaire Test Code|QS-CHART-SF Paper Version TESTCD	Test codes of questionnaire questions associated with the Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119069>	C100110	CDISC Questionnaire DLQI Test Name Terminology|DLQI1TN|Dermatology Life Quality Index Questionnaire Test Name|QS-DLQI TEST	Test names of questionnaire questions associated with the Dermatology Life Quality Index (DLQI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11906>	C61063	Amifostine/Carboplatin/Epirubicin/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119070>	C100110	CDISC Questionnaire DLQI Test Code Terminology|DLQI1TC|Dermatology Life Quality Index Questionnaire Test Code|QS-DLQI TESTCD	Test codes of questionnaire questions associated with the Dermatology Life Quality Index (DLQI) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119071>	C100110	CDISC Questionnaire RPQ Test Name Terminology|QS-RPQ TEST|RPQ01TN|Rivermead Post Concussion Symptoms Questionnaire Questionnaire Test Name	Test names of questionnaire questions associated with the Rivermead Post-Concussion Symptoms Questionnaire (RPQ) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119072>	C100110	CDISC Questionnaire RPQ Test Code Terminology|QS-RPQ TESTCD|RPQ01TC|Rivermead Post Concussion Symptoms Questionnaire Questionnaire Test Code	Test codes of questionnaire questions associated with the Rivermead Post-Concussion Symptoms Questionnaire (RPQ) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119073>	C118970	CDISC Clinical Classification TIMI Thrombus Grade Test Name Terminology|CC-TIMI Thrombus Grade TEST|Coronary Thrombus TIMI Grade Clinical Classification Test Name|TIMG01TN	Test names of clinical classification questions associated with the Coronary Thrombus TIMI Grade (TIMI Thrombus Grade) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119074>	C118970	CDISC Clinical Classification TIMI Thrombus Grade Test Code Terminology|CC-TIMI Thrombus Grade TESTCD|Coronary Thrombus TIMI Grade Clinical Classification Test Code|TIMG01TC	Test codes of clinical classification questions associated with the Coronary Thrombus TIMI Grade (TIMI Thrombus Grade) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119075>	C118970	CDISC Clinical Classification NHLBI CAD Grade Test Name Terminology|CADG01TN|CC-NHLBI CAD Grade TEST|Coronary Artery Dissection NHLBI Grade Clinical Classification Test Name	Test names of clinical classification questions associated with the Coronary Artery Dissection NHLBI Grade (NHLBI CAD Grade) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119076>	C118970	CDISC Clinical Classification NHLBI CAD Grade Test Code Terminology|CADG01TC|CC-NHLBI CAD Grade TESTCD|Coronary Artery Dissection NHLBI Grade Clinical Classification Test Code	Test codes of clinical classification questions associated with the Coronary Artery Dissection NHLBI Grade (NHLBI CAD Grade) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119077>	C103175	CDISC Clinical Classification ARC STC Timing Test Name Terminology|CC-ARC STC Timing TEST	Test names of clinical classification questions associated with the Stent Thrombosis Coronary ARC Timing (ARC STC Timing) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	
C119078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119078>	C103175	CDISC Clinical Classification ARC STC Timing Test Code Terminology|CC-ARC STC Timing TESTCD	Test codes of clinical classification questions associated with the Stent Thrombosis Coronary ARC Timing (ARC STC Timing) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	
C119079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119079>	C118970	CDISC Clinical Classification ARC STC Grade Test Name Terminology|CC-ARC STC Grade TEST|STCG01TN|Stent Thrombosis Coronary ARC Grade Clinical Classification Test Name	Test names of clinical classification questions associated with the Stent Thrombosis Coronary ARC Grade (ARC STC Grade) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11907>	C61007	Prednisone/Thalidomide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119080>	C118970	CDISC Clinical Classification ARC STC Grade Test Code Terminology|CC-ARC STC Grade TESTCD|STCG01TC|Stent Thrombosis Coronary ARC Grade Clinical Classification Test Code	Test codes of clinical classification questions associated with the Stent Thrombosis Coronary ARC Grade (ARC STC Grade) for the Clinical Data Interchange Standards Consortium (CDISC) Standard Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119081>	C211913	AUDIT Questionnaire Question	A question associated with the AUDIT questionnaire.			Intellectual Product	
C119082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119082>	C211913	AUDIT-C Questionnaire Question	A question associated with the AUDIT-C questionnaire.			Intellectual Product	
C119083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119083>	C211913	CCQ 24 Hour Version Questionnaire Question	A question associated with the CCQ 24 Hour Version questionnaire.			Intellectual Product	
C119084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119084>	C211913	CCQ 1 Week Version Questionnaire Question	A question associated with the CCQ 1 Week Version questionnaire.			Intellectual Product	
C119085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119085>	C211913	CHART-SF Paper Version Questionnaire Question	A question associated with the CHART-SF Paper Version questionnaire.			Intellectual Product	
C119086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119086>	C211913	DLQI Questionnaire Question	A question associated with the DLQI questionnaire.			Intellectual Product	
C119087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119087>	C211913	RPQ Questionnaire Question	A question associated with the RPQ questionnaire.			Intellectual Product	
C119088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119088>	C211913	TIMI Thrombus Grade Clinical Classification Question	A question associated with the TIMI Thrombus Grade clinical classification.			Intellectual Product	
C119089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119089>	C211913	NHLBI CAD Grade Clinical Classification Question	A question associated with the NHLBI CAD Grade clinical classification.			Intellectual Product	
C11908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11908>	C61007	Cyclophosphamide/Doxorubicin/Iodine I 131 Tositumomab/Prednisone/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119090>	C211913	ARC STC Timing Clinical Classification Question	A question associated with the ARC STC Timing clinical classification.			Intellectual Product	
C119091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119091>	C211913	ARC STC Grade Clinical Classification Question	A question associated with the ARC STC Grade clinical classification.			Intellectual Product	
C119092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119092>	C91105	Children's Dermatology Life Quality Index Questionnaire|CDLQ1|CDLQI|CDLQI	A standardized rating scale originally developed by Lewis-Jones and Finlay in 1995. This instrument is used to make quality of life assessment in children with skin conditions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119093>	C91105	Influenza Intensity and Impact Questionnaire Once Daily Version|FLU-IIQ ONCE DAILY|FLUIQ1|Flu-iiQ Once Daily	A standardized rating scale developed by Measured Solutions for Health (MESH) Pty Ltd. This instrument is the once daily version and is used to measure symptoms severity and the impact of influenza.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119094>	C91105	Influenza Intensity and Impact Questionnaire Twice Daily Version|FLU-IIQ TWICE DAILY|FLUIQ2|Flu-iiQ Twice Daily	A standardized rating scale developed by Measured Solutions for Health (MESH) Pty Ltd. This instrument is the twice daily version and is used to measure symptoms severity and the impact of influenza.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119095>	C91105	Ocular Comfort Index Questionnaire|OCI|OCI|OCI01	A standardized rating scale originally developed by Johnson and Murphy in 2007. This instrument is used to assess ocular surface irritation and grade the severity of dry eye syndrome.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119096>	C91105	Work Limitations Questionnaire|WLQ|WLQ|WLQ01	A standardized rating scale originally developed by Lerner et al in 1998. This instrument is used to measure the degree to which health problems interfere with specific aspects of job performance and health-related productivity loss in employed individuals.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119097>	C91105	Alcohol Use Disorder Identification Test Self-Report Version Questionnaire|ADT01|AUDIT|AUDIT-SR	A standardized rating scale developed by the World Health Organization (WHO) to screen for excessive, hazardous or harmful alcohol consumption. The questionnaire contains 10 questions and evaluates the frequency and amount of alcohol use, alcohol-dependence symptoms and alcohol-related problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119098>	C91105	Alcohol Use Disorder Identification Test Alcohol Consumption Questions Questionnaire|ADTC01|AUDIT-C|AUDIT-C	A standardized rating scale developed by the World Health Organization (WHO), which is a modified version of the original Alcohol Use Disorder Identification Test (ADUIT). The questionnaire contains 3 questions, and is used to identify patients who are hazardous drinkers or have active alcohol use disorders.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119099>	C91105	Clinical COPD Questionnaire 24 Hour Version|CCQ 24 HOUR VERSION|CCQ 24 Hour Version|CCQ01	A standardized rating scale originally developed by Thys van der Molen et al in 2003, which is a self-administered instrument used to measure clinical status of the airways and health-related quality of life in subjects with COPD. The 24 hour version questionnaire contains 10 questions which are divided into 3 areas or domains: symptoms, mental state and functional state.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11909>	C61063	Bevacizumab/Fluorouracil/Irinotecan/Leucovorin Calcium			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1190>	C697	Phenesterin|(3-beta)-cholest-5-en-3-ol 4-(bis(2-chloroethyl)amino)benzeneacetate|(4-(bis(2-chloroethyl)amino)phenyl)acetic acid cholesteryl ester|(p-(bis(2-chloroethyl)amino)phenyl) acetate cholesterol|(p-(bis(2-chloroethyl)amino)phenyl)acetic acid cholesteryl ester|5-Cholesten-3-beta-ol 3-(p-(bis(2-chloroethyl)amino)phenyl)acetate|Cholest-5-en-3-ol, (3.beta.)-, 4-[bis(2-chloroethyl)amino]benzeneacetate|Cholest-5-en-3beta-ol 4-(bis(2-chloroethyl)amino)benzeneacetate|Cholesteryl p-bis(2-chloroethyl)aminophenylacetate|Fenesterin|Fenesterin|Fenestrin|Fenestrin|NCI-C01558|NCI-C01558|PHENESTERINE|Phenesterine|Phenesterine|p-bis(2-chloroethyl)amino phenylacetate cholesterol	A steroidal nitrogen mustard with antineoplastic and mutagenic activities. After attachment to cell-surface steroid receptors and uptake, phenesterin enters the nucleus where it alkylates macromolecules, resulting in decreased cell proliferation. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C119100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119100>	C91105	Clinical COPD Questionnaire 1 Week Version|CCQ 1 WEEK VERSION|CCQ 1 Week Version|CCQ02	A standardized rating scale originally developed by Thys van der Molen et al in 2003, which is a self-administered instrument used to measure clinical status of the airways and health-related quality of life in subjects with COPD. The 1 week version questionnaire contains 10 questions which are divided into 3 areas or domains: symptoms, mental state and functional state.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119101>	C91105	Craig Handicap Assessment and Reporting Technique - Short Form Paper Version Questionnaire|CHART-SF PAPER VERSION|CHART-SF Paper Version|CHSF2	A standardized rating scale originally developed by Whiteneck et al in 1992 and modified in 2000, which is used to measure the degree to which impairments and disabilities result in handicaps in the years after initial rehabilitation. The paper version questionnaire contains 19 questions and generates 6 subscales: physical independence, cognitive independence, mobility, occupation, social integration and economic self-sufficiency.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119102>	C91105	Dermatology Life Quality Index Questionnaire|DLQI|DLQI|DLQI1	A standardized rating scale originally developed by Finlay and Khan in 1994, which is a dermatology-specific health-related quality of life instrument. This questionnaire contains 10 questions concerning symptoms and feelings, daily activities, leisure, work, and school, personal relationships and treatment. Each question can be answered with: very much, a lot, a little or not at all.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119103>	C91105	Rivermead Post-Concussion Symptoms Questionnaire|RPQ|RPQ|RPQ01	A standardized rating scale originally developed by King et al in 1995, which is used to measure the severity of symptoms following a mild or moderate traumatic brain injury (TBI). The questionnaire requires a subject to rate the severity of 16 different cognitive, somatic, and emotional symptoms after a TBI on a scale of 0 to 4: not experienced at all (0), no more of a problem (1), a mild problem (2), a moderate problem (3), or a severe problem (4).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119104>	C118969	Coronary Thrombus TIMI Grade Clinical Classification|TIMG01|TIMI THROMBUS GRADE|TIMI Thrombus Grade	A standardized grading system developed by the Thrombolysis in Myocardial Infarction (TIMI) Study Group to detect the presence of, and to describe the relative size of coronary thrombus via angiographic assessments.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119105>	C118969	Coronary Artery Dissection NHLBI Grade Clinical Classification|CADG01|NHLBI CAD GRADE|NHLBI CAD Grade	A standardized grading system developed by the American College of Cardiology American Heart Association to describe coronary artery dissection. This grading system includes 6 classifications of dissection types A through F based on angiographic appearances.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119106>	C118969	Stent Thrombosis Coronary ARC Timing Clinical Classification|ARC STC Timing	A standardized grading system developed by the Academic Research Consortium (ARC) to describe coronary stent thrombosis based on the timing of the event. This grading system includes 4 classifications: acute, subacute, late and very late stent thrombosis.			Intellectual Product	
C119107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119107>	C118969	Stent Thrombosis Coronary ARC Grade Clinical Classification|ARC STC GRADE|ARC STC Grade|STCG01	A standardized grading system developed by the Academic Research Consortium (ARC) to describe coronary stent thrombosis based on the evidence (angiographic or pathological confirmation of thrombus, or unexplained sudden death within 30 days) of the event. This grading system includes 3 classifications: definite, probable and possible stent thrombosis.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119108>	C119081	AUDIT - How Often Have Alcohol Drink|ADT01-How Often Drink Alcohol|ADT01-How Often Drink Alcohol|ADT0101	Alcohol Use Disorder Identification Test Self-Report Version (AUDIT) How often do you have a drink containing alcohol?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AUDIT-SR Test Code Terminology|CDISC Questionnaire AUDIT-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119109>	C119081	AUDIT - How Many Alcohol Drinks on a Typical Day|ADT01-Alcohol Drinks on a Typical Day|ADT01-Alcohol Drinks on a Typical Day|ADT0102	Alcohol Use Disorder Identification Test Self-Report Version (AUDIT) How many drinks containing alcohol do you have on a typical day when you are drinking?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AUDIT-SR Test Code Terminology|CDISC Questionnaire AUDIT-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11910>	C61063	Fluorouracil/Leucovorin Calcium/PS-341			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119110>	C119081	AUDIT - How Often Have Six or More Drinks|ADT01-Six or More Drinks One Occasion|ADT01-Six or More Drinks One Occasion|ADT0103	Alcohol Use Disorder Identification Test Self-Report Version (AUDIT) How often do you have six or more drinks on one occasion?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AUDIT-SR Test Code Terminology|CDISC Questionnaire AUDIT-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119111>	C119081	AUDIT - How Often Last Year You Found Not Able to Stop Drinking|ADT01-Not Able Stop Drinking Once Start|ADT01-Not Able Stop Drinking Once Start|ADT0104	Alcohol Use Disorder Identification Test Self-Report Version (AUDIT) How often during the last year have you found that you were not able to stop drinking once you had started?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AUDIT-SR Test Code Terminology|CDISC Questionnaire AUDIT-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119112>	C119081	AUDIT - How Often Last Year You Failed to Do Normally Expected of You|ADT01-Failed to Do as Expected|ADT01-Failed to Do as Expected|ADT0105	Alcohol Use Disorder Identification Test Self-Report Version (AUDIT) How often during the last year have you failed to do what was normally expected of you because of drinking?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AUDIT-SR Test Code Terminology|CDISC Questionnaire AUDIT-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119113>	C119081	AUDIT - How Often Last Year Need a Drink in the Morning to Get Going|ADT01-Need Drink Morning After Drinking|ADT01-Need Drink Morning After Drinking|ADT0106	Alcohol Use Disorder Identification Test Self-Report Version (AUDIT) How often during the last year have you needed a first drink in the morning to get yourself going after a heavy drinking session?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AUDIT-SR Test Code Terminology|CDISC Questionnaire AUDIT-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119114>	C119081	AUDIT - How Often Last Year You Feel Guilt or Remorse After Drinking|ADT01-Feeling of Guilt or Remorse|ADT01-Feeling of Guilt or Remorse|ADT0107	Alcohol Use Disorder Identification Test Self-Report Version (AUDIT) How often during the last year have you had a feeling of guilt or remorse after drinking?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AUDIT-SR Test Code Terminology|CDISC Questionnaire AUDIT-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119115>	C119081	AUDIT - How Often Last Year You Unable to Remember What Happened the Night Before|ADT01-Unable to Remember What Happened|ADT01-Unable to Remember What Happened|ADT0108	Alcohol Use Disorder Identification Test Self-Report Version (AUDIT) How often during the last year have you been unable to remember what happened the night before because of your drinking?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AUDIT-SR Test Code Terminology|CDISC Questionnaire AUDIT-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119116>	C119081	AUDIT - Injured Because of Drinking|ADT01-Injured Because of Your Drinking|ADT01-Injured Because of Your Drinking|ADT0109	Alcohol Use Disorder Identification Test Self-Report Version (AUDIT) Have you or someone else been injured because of your drinking?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AUDIT-SR Test Code Terminology|CDISC Questionnaire AUDIT-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119117>	C119081	AUDIT - Concerned About Your Drinking|ADT01-Suggested to Cut Down|ADT01-Suggested to Cut Down|ADT0110	Alcohol Use Disorder Identification Test Self-Report Version (AUDIT) Has a relative, friend, doctor, or other health care worker been concerned about your drinking or suggested you cut down?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AUDIT-SR Test Code Terminology|CDISC Questionnaire AUDIT-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119118>	C119081	AUDIT - Total|ADT01-Total|ADT01-Total|ADT0111	Alcohol Use Disorder Identification Test Self-Report Version (AUDIT) Total.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AUDIT-SR Test Code Terminology|CDISC Questionnaire AUDIT-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119119>	C119082	AUDIT-C - How Often Have Alcohol Drink|ADTC01-How Often Drink Alcohol|ADTC01-How Often Drink Alcohol|ADTC0101	Alcohol Use Disorder Identification Test Alcohol Consumption Questions (AUDIT-C) How often do you have a drink containing alcohol?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AUDIT-C Test Code Terminology|CDISC Questionnaire AUDIT-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11911>	C61063	Carboplatin/Paclitaxel/Suramin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119120>	C119082	AUDIT-C - How Many Alcohol Drinks on a Typical Day|ADTC01-Alcohol Drinks on a Typical Day|ADTC01-Alcohol Drinks on a Typical Day|ADTC0102	Alcohol Use Disorder Identification Test Alcohol Consumption Questions (AUDIT-C) How many standard drinks containing alcohol do you have on a typical day?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AUDIT-C Test Code Terminology|CDISC Questionnaire AUDIT-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119121>	C119082	AUDIT-C - How Often Have Six or More Drinks|ADTC01-Six or More Drinks One Occasion|ADTC01-Six or More Drinks One Occasion|ADTC0103	Alcohol Use Disorder Identification Test Alcohol Consumption Questions (AUDIT-C) How often do you have six or more drinks on one occasion?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire AUDIT-C Test Code Terminology|CDISC Questionnaire AUDIT-C Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119122>	C119083	CCQ 24 Hour Version - Short of Breath at Rest|CCQ01-Short of Breath at Rest|CCQ01-Short of Breath at Rest|CCQ0101	Clinical COPD Questionnaire 24 Hour Version (CCQ 24 Hour Version) On average, during the past 24 hours, how often did you feel: Short of breath while at rest?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CCQ 24 Hour Version Test Code Terminology|CDISC Questionnaire CCQ 24 Hour Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119123>	C119083	CCQ 24 Hour Version - Short of Breath Doing Physical Activity|CCQ01-Short of Breath Physical Activity|CCQ01-Short of Breath Physical Activity|CCQ0102	Clinical COPD Questionnaire 24 Hour Version (CCQ 24 Hour Version) On average, during the past 24 hours, how often did you feel: Short of breath while doing physical activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CCQ 24 Hour Version Test Code Terminology|CDISC Questionnaire CCQ 24 Hour Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119124>	C119083	CCQ 24 Hour Version - Concern About Breathing Get Worse|CCQ01-Concern About Breathing Get Worse|CCQ01-Concern About Breathing Get Worse|CCQ0103	Clinical COPD Questionnaire 24 Hour Version (CCQ 24 Hour Version) On average, during the past 24 hours, how often did you feel: Concerned about getting a cold or your breathing getting worse?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CCQ 24 Hour Version Test Code Terminology|CDISC Questionnaire CCQ 24 Hour Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119125>	C119083	CCQ 24 Hour Version - Depressed Because of Breathing Problem|CCQ01-Depressed for Breathing Problem|CCQ01-Depressed for Breathing Problem|CCQ0104	Clinical COPD Questionnaire 24 Hour Version (CCQ 24 Hour Version) On average, during the past 24 hours, how often did you feel: Depressed because of your breathing problems?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CCQ 24 Hour Version Test Code Terminology|CDISC Questionnaire CCQ 24 Hour Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119126>	C119083	CCQ 24 Hour Version - Did You Cough|CCQ01-Cough|CCQ01-Cough|CCQ0105	Clinical COPD Questionnaire 24 Hour Version (CCQ 24 Hour Version) In general, during the past 24 hours, how much of the time: Did you cough?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CCQ 24 Hour Version Test Code Terminology|CDISC Questionnaire CCQ 24 Hour Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119127>	C119083	CCQ 24 Hour Version - Produce Sputum or Phlegm|CCQ01-Produce Sputum or Phlegm|CCQ01-Produce Sputum or Phlegm|CCQ0106	Clinical COPD Questionnaire 24 Hour Version (CCQ 24 Hour Version) In general, during the past 24 hours, how much of the time: Did you produce sputum or phlegm?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CCQ 24 Hour Version Test Code Terminology|CDISC Questionnaire CCQ 24 Hour Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119128>	C119083	CCQ 24 Hour Version - Breathing Problems Limit Strenuous Activity|CCQ01-Breathing Limit Strenuous Activity|CCQ01-Breathing Limit Strenuous Activity|CCQ0107	Clinical COPD Questionnaire 24 Hour Version (CCQ 24 Hour Version) On average, during the past 24 hours, how limited were you in these activities because of your breathing problems: Strenuous physical activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CCQ 24 Hour Version Test Code Terminology|CDISC Questionnaire CCQ 24 Hour Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119129>	C119083	CCQ 24 Hour Version - Breathing Problems Limit Moderate Activity|CCQ01-Breathing Limit Moderate Activity|CCQ01-Breathing Limit Moderate Activity|CCQ0108	Clinical COPD Questionnaire 24 Hour Version (CCQ 24 Hour Version) On average, during the past 24 hours, how limited were you in these activities because of your breathing problems: Moderate physical activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CCQ 24 Hour Version Test Code Terminology|CDISC Questionnaire CCQ 24 Hour Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11912>	C61063	Capecitabine/Cyclophosphamide/Epirubicin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119130>	C119083	CCQ 24 Hour Version - Breathing Problems Limit Daily Activity|CCQ01-Breathing Limit Daily Activity|CCQ01-Breathing Limit Daily Activity|CCQ0109	Clinical COPD Questionnaire 24 Hour Version (CCQ 24 Hour Version) On average, during the past 24 hours, how limited were you in these activities because of your breathing problems: Daily activities at home?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CCQ 24 Hour Version Test Code Terminology|CDISC Questionnaire CCQ 24 Hour Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119131>	C119083	CCQ 24 Hour Version - Breathing Problems Limit Social Activity|CCQ01-Breathing Limit Social Activity|CCQ01-Breathing Limit Social Activity|CCQ0110	Clinical COPD Questionnaire 24 Hour Version (CCQ 24 Hour Version) On average, during the past 24 hours, how limited were you in these activities because of your breathing problems: Social activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CCQ 24 Hour Version Test Code Terminology|CDISC Questionnaire CCQ 24 Hour Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119132>	C119084	CCQ 1 Week Version - Short of Breath at Rest|CCQ02-Short of Breath at Rest|CCQ02-Short of Breath at Rest|CCQ0201	Clinical COPD Questionnaire 1 Week Version (CCQ 1 Week Version) On average, during the past 7 days, how often did you feel: Short of breath while at rest?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CCQ 1 Week Version Test Code Terminology|CDISC Questionnaire CCQ 1 Week Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119133>	C119084	CCQ 1 Week Version - Short of Breath Doing Physical Activity|CCQ02-Short of Breath Physical Activity|CCQ02-Short of Breath Physical Activity|CCQ0202	Clinical COPD Questionnaire 1 Week Version (CCQ 1 Week Version) On average, during the past 7 days, how often did you feel: Short of breath while doing physical activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CCQ 1 Week Version Test Code Terminology|CDISC Questionnaire CCQ 1 Week Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119134>	C119084	CCQ 1 Week Version - Concern About Breathing Get Worse|CCQ02-Concern About Breathing Get Worse|CCQ02-Concern About Breathing Get Worse|CCQ0203	Clinical COPD Questionnaire 1 Week Version (CCQ 1 Week Version) On average, during the past 7 days, how often did you feel: Concerned about getting a cold or your breathing getting worse?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CCQ 1 Week Version Test Code Terminology|CDISC Questionnaire CCQ 1 Week Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119135>	C119084	CCQ 1 Week Version - Depressed Because of Breathing Problem|CCQ02-Depressed for Breathing Problem|CCQ02-Depressed for Breathing Problem|CCQ0204	Clinical COPD Questionnaire 1 Week Version (CCQ 1 Week Version) On average, during the past 7 days, how often did you feel: Depressed because of your breathing problems?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CCQ 1 Week Version Test Code Terminology|CDISC Questionnaire CCQ 1 Week Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119136>	C119084	CCQ 1 Week Version - Did You Cough|CCQ02-Cough|CCQ02-Cough|CCQ0205	Clinical COPD Questionnaire 1 Week Version (CCQ 1 Week Version) In general, during the past 7 days, how much of the time: Did you cough?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CCQ 1 Week Version Test Code Terminology|CDISC Questionnaire CCQ 1 Week Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119137>	C119084	CCQ 1 Week Version - Produce Sputum or Phlegm|CCQ02-Produce Sputum or Phlegm|CCQ02-Produce Sputum or Phlegm|CCQ0206	Clinical COPD Questionnaire 1 Week Version (CCQ 1 Week Version) In general, during the past 7 days, how much of the time: Did you produce sputum or phlegm?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CCQ 1 Week Version Test Code Terminology|CDISC Questionnaire CCQ 1 Week Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119138>	C119084	CCQ 1 Week Version - Breathing Problems Limit Strenuous Activity|CCQ02-Breathing Limit Strenuous Activity|CCQ02-Breathing Limit Strenuous Activity|CCQ0207	Clinical COPD Questionnaire 1 Week Version (CCQ 1 Week Version) On average, during the past 7 days, how limited were you in these activities because of your breathing problems: Strenuous physical activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CCQ 1 Week Version Test Code Terminology|CDISC Questionnaire CCQ 1 Week Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119139>	C119084	CCQ 1 Week Version - Breathing Problems Limit Moderate Activity|CCQ02-Breathing Limit Moderate Activity|CCQ02-Breathing Limit Moderate Activity|CCQ0208	Clinical COPD Questionnaire 1 Week Version (CCQ 1 Week Version) On average, during the past 7 days, how limited were you in these activities because of your breathing problems: Moderate physical activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CCQ 1 Week Version Test Code Terminology|CDISC Questionnaire CCQ 1 Week Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11913>	C61063	Doxorubicin/Octreotide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119140>	C119084	CCQ 1 Week Version - Breathing Problems Limit Daily Activity|CCQ02-Breathing Limit Daily Activity|CCQ02-Breathing Limit Daily Activity|CCQ0209	Clinical COPD Questionnaire 1 Week Version (CCQ 1 Week Version) On average, during the past 7 days, how limited were you in these activities because of your breathing problems: Daily activities at home?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CCQ 1 Week Version Test Code Terminology|CDISC Questionnaire CCQ 1 Week Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119141>	C119084	CCQ 1 Week Version - Breathing Problems Limit Social Activity|CCQ02-Breathing Limit Social Activity|CCQ02-Breathing Limit Social Activity|CCQ0210	Clinical COPD Questionnaire 1 Week Version (CCQ 1 Week Version) On average, during the past 7 days, how limited were you in these activities because of your breathing problems: Social activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CCQ 1 Week Version Test Code Terminology|CDISC Questionnaire CCQ 1 Week Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119142>	C119085	CHART-SF Paper Version - Paid Personal Care per Day|CHSF2-Paid Personal Care per Day|CHSF2-Paid Personal Care per Day|CHSF201A	Craig Handicap Assessment and Reporting Technique-Short Form Paper Version (CHART-SF Paper Version) How many hours in a typical 24-hour day do you have someone with you to provide physical assistance for personal care activities such as eating, bathing, dressing, toileting and mobility? Hours paid assistance.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Paper Version Test Code Terminology|CDISC Questionnaire CHART-SF Paper Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119143>	C119085	CHART-SF Paper Version - Unpaid Personal Care per Day|CHSF2-Unpaid Personal Care per Day|CHSF2-Unpaid Personal Care per Day|CHSF201B	Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) How many hours in a typical 24-hour day do you have someone with you to provide physical assistance for personal care activities such as eating, bathing, dressing, toileting and mobility? Hours unpaid (family, others).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Paper Version Test Code Terminology|CDISC Questionnaire CHART-SF Paper Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119144>	C119085	CHART-SF Paper Version - Cognitive Assistance at Home per Day|CHSF2-Home Cognitive Assistance per Day|CHSF2-Home Cognitive Assistance per Day|CHSF202	Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) How much time is someone with you in your home to assist you with activities that require remembering, decision making, or judgment?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Paper Version Test Code Terminology|CDISC Questionnaire CHART-SF Paper Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119145>	C119085	CHART-SF Paper Version - Cognitive Assistance Away From Home per Day|CHSF2-Away Cognitive Assistance per Day|CHSF2-Away Cognitive Assistance per Day|CHSF203	Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) How much of the time is someone with you to help you with remembering, decision making, or judgment when you go away from your home?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Paper Version Test Code Terminology|CDISC Questionnaire CHART-SF Paper Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119146>	C119085	CHART-SF Paper Version - Hours Out of Bed per Day|CHSF2-Hours Out of Bed per Day|CHSF2-Hours Out of Bed per Day|CHSF204	Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) On a typical day, how many hours are you out of bed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Paper Version Test Code Terminology|CDISC Questionnaire CHART-SF Paper Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119147>	C119085	CHART-SF Paper Version - Days Out of the House per Week|CHSF2-Days Out of the House per Week|CHSF2-Days Out of the House per Week|CHSF205	Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) In a typical week, how many days do you get out of your house and go somewhere?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Paper Version Test Code Terminology|CDISC Questionnaire CHART-SF Paper Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119148>	C119085	CHART-SF Paper Version - Nights Away From Home Last Year|CHSF2-Nights Away From Home Last Year|CHSF2-Nights Away From Home Last Year|CHSF206	Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) In the last year, how many nights have you spent away from your home (excluding hospitalizations)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Paper Version Test Code Terminology|CDISC Questionnaire CHART-SF Paper Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119149>	C119085	CHART-SF Paper Version - Hours of Paid Work per Week|CHSF2-Hours of Paid Work per Week|CHSF2-Hours of Paid Work per Week|CHSF207A	Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) How many hours per week do you spend working in a job for which you get paid?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Paper Version Test Code Terminology|CDISC Questionnaire CHART-SF Paper Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11914>	C61063	Detox-B Adjuvant/Verteporfin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119150>	C119085	CHART-SF Paper Version - Occupation of Paid Work|CHSF2-Occupation of Paid Work|CHSF2-Occupation of Paid Work|CHSF207B	Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) How many hours per week do you spend working in a job for which you get paid? (occupation).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Paper Version Test Code Terminology|CDISC Questionnaire CHART-SF Paper Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119151>	C119085	CHART-SF Paper Version - Hours of Schoolwork per Week|CHSF2-Hours of Schoolwork per Week|CHSF2-Hours of Schoolwork per Week|CHSF208	Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) How many hours per week do you spend in school working toward a degree or in an accredited technical training program (including hours in class and studying)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Paper Version Test Code Terminology|CDISC Questionnaire CHART-SF Paper Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119152>	C119085	CHART-SF Paper Version - Hours of Homemaking per Week|CHSF2-Hours of Homemaking per Week|CHSF2-Hours of Homemaking per Week|CHSF209	Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) How many hours per week do you spend in active homemaking including parenting, housekeeping, and food preparation?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Paper Version Test Code Terminology|CDISC Questionnaire CHART-SF Paper Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119153>	C119085	CHART-SF Paper Version - Hours of Home Maintenance per Week|CHSF2-Hours of Home Maintenance per Week|CHSF2-Hours of Home Maintenance per Week|CHSF210	Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) How many hours per week do you spend in home maintenance activities such as gardening, house repairs or home improvement?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Paper Version Test Code Terminology|CDISC Questionnaire CHART-SF Paper Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119154>	C119085	CHART-SF Paper Version - Hours of Recreational Activities per Week|CHSF2-Hours of Recreation per Week|CHSF2-Hours of Recreation per Week|CHSF211	Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) How many hours per week do you spend in recreational activities such as sports, exercise, playing cards, or going to movies? Please do not include time spent watching TV or listening to the radio.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Paper Version Test Code Terminology|CDISC Questionnaire CHART-SF Paper Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119155>	C119085	CHART-SF Paper Version - Number of People You Live With|CHSF2-Number of People You Live With|CHSF2-Number of People You Live With|CHSF212	Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) How many people do you live with?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Paper Version Test Code Terminology|CDISC Questionnaire CHART-SF Paper Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119156>	C119085	CHART-SF Paper Version - Live With Spouse or Significant Other|CHSF2-Live With Spouse or Signif Other|CHSF2-Live With Spouse or Signif Other|CHSF213	Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) Is one of them your spouse or significant other?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Paper Version Test Code Terminology|CDISC Questionnaire CHART-SF Paper Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119157>	C119085	CHART-SF Paper Version - Number of Relatives You Live With|CHSF2-Number of Relatives You Live With|CHSF2-Number of Relatives You Live With|CHSF214	Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) Of the people you live with how many are relatives?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Paper Version Test Code Terminology|CDISC Questionnaire CHART-SF Paper Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119158>	C119085	CHART-SF Paper Version - Associates Contacted per Month|CHSF2-Associates Contacted per Month|CHSF2-Associates Contacted per Month|CHSF215	Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) How many business or organizational associates do you visit, phone, or write to at least once a month?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Paper Version Test Code Terminology|CDISC Questionnaire CHART-SF Paper Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119159>	C119085	CHART-SF Paper Version - Friends Contacted per Month|CHSF2-Friends Contacted per Month|CHSF2-Friends Contacted per Month|CHSF216	Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) How many friends (non-relatives contacted outside business or organizational settings) do you visit, phone, or write to at least once a month?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Paper Version Test Code Terminology|CDISC Questionnaire CHART-SF Paper Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11915>	C53290	MUC1 Antigen/SB AS-2				Pharmacologic Substance	
C119160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119160>	C119085	CHART-SF Paper Version - Initiated Conversation With Strangers Last Month|CHSF2-Strangers Spoke with Last Month|CHSF2-Strangers Spoke with Last Month|CHSF217	Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) With how many strangers have you initiated a conversation in the last month (for example, to ask information or place an order)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Paper Version Test Code Terminology|CDISC Questionnaire CHART-SF Paper Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119161>	C119085	CHART-SF Paper Version - Combined Annual Household Income Last Year|CHSF2-Combined Household Income Last Yr|CHSF2-Combined Household Income Last Yr|CHSF218	Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) Approximately what was the combined annual income, in the last year, of all family members in your household? (consider all sources including wages and earnings, disability benefits, pensions and retirement income, income from court settlements, investments and trust funds, child support and alimony, contributions from relatives, and any other source).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Paper Version Test Code Terminology|CDISC Questionnaire CHART-SF Paper Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119162>	C119085	CHART-SF Paper Version - Medical Care Expense Last Year|CHSF2-Medical Care Expenses Last Year|CHSF2-Medical Care Expenses Last Year|CHSF219	Craig Handicap Assessment and Reporting Technique - Short Form Paper Version (CHART-SF Paper Version) Approximately how much did you pay last year for medical care expenses? (Consider any amounts paid by yourself or the family members in your household and not reimbursed by insurance or benefits).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CHART-SF Paper Version Test Code Terminology|CDISC Questionnaire CHART-SF Paper Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119163>	C119086	DLQI - Itchy, Sore, Painful or Stinging Skin|DLQI1-How Itchy, Sore, Painful, Stinging|DLQI1-How Itchy, Sore, Painful, Stinging|DLQI101	Dermatology Life Quality Index (DLQI) Over the last week, how itchy, sore, painful or stinging has your skin been?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DLQI Test Code Terminology|CDISC Questionnaire DLQI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119164>	C119086	DLQI - Embarrassed Because of Skin|DLQI1-How Embarrassed, Self Conscious|DLQI1-How Embarrassed, Self Conscious|DLQI102	Dermatology Life Quality Index (DLQI) Over the last week, how embarrassed or self conscious have you been because of your skin?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DLQI Test Code Terminology|CDISC Questionnaire DLQI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119165>	C119086	DLQI - Skin Interfere With Shopping, Looking After Home or Yard|DLQI1-Interfered Shopping, Home, Yard|DLQI1-Interfered Shopping, Home, Yard|DLQI103	Dermatology Life Quality Index (DLQI) Over the last week, how much has your skin interfered with you going shopping or looking after your home or yard?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DLQI Test Code Terminology|CDISC Questionnaire DLQI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119166>	C119086	DLQI - Skin Influence Clothes You Wear|DLQI1-Influenced Clothes You Wear|DLQI1-Influenced Clothes You Wear|DLQI104	Dermatology Life Quality Index (DLQI) Over the last week, how much has your skin influenced the clothes you wear?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DLQI Test Code Terminology|CDISC Questionnaire DLQI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119167>	C119086	DLQI - Skin Affect Social or Leisure Activities|DLQI1-Affected Social, Leisure Activity|DLQI1-Affected Social, Leisure Activity|DLQI105	Dermatology Life Quality Index (DLQI) Over the last week, how much has your skin affected any social or leisure activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DLQI Test Code Terminology|CDISC Questionnaire DLQI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119168>	C119086	DLQI - Skin Made Difficult to Do Sport|DLQI1-Made It Difficult to Do Any Sports|DLQI1-Made It Difficult to Do Any Sports|DLQI106	Dermatology Life Quality Index (DLQI) Over the last week, how much has your skin made it difficult for you to do any sport?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DLQI Test Code Terminology|CDISC Questionnaire DLQI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119169>	C119086	DLQI - Skin Prevent Work or Study|DLQI1-Prevented Working or Studying|DLQI1-Prevented Working or Studying|DLQI107	Dermatology Life Quality Index (DLQI) Over the last week, has your skin prevented you from working or studying?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DLQI Test Code Terminology|CDISC Questionnaire DLQI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11916>	C61063	Cyclosporine/Yttrium Y 90 Monoclonal Antibody M170			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119170>	C119086	DLQI - Skin Has Been a Problem at Work or Study|DLQI1-Problem at Work or Studying|DLQI1-Problem at Work or Studying|DLQI107A	Dermatology Life Quality Index (DLQI) If 'No', over the last week how much has your skin been a problem at work or studying?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DLQI Test Code Terminology|CDISC Questionnaire DLQI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119171>	C119086	DLQI - Skin Create Problem With Partner, Friends or Relatives|DLQI1-Problem Partner, Friends, Relative|DLQI1-Problem Partner, Friends, Relative|DLQI108	Dermatology Life Quality Index (DLQI) Over the last week, how much has your skin created problems with your partner or any of your close friends or relatives?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DLQI Test Code Terminology|CDISC Questionnaire DLQI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119172>	C119086	DLQI - Skin Cause Sexual Difficulties|DLQI1-Caused Any Sexual Difficulties|DLQI1-Caused Any Sexual Difficulties|DLQI109	Dermatology Life Quality Index (DLQI) Over the last week, how much has your skin caused any sexual difficulties?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DLQI Test Code Terminology|CDISC Questionnaire DLQI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119173>	C119086	DLQI - Treatment for Skin Make Home Messy|DLQI1-How Much a Problem is Treatment|DLQI1-How Much a Problem is Treatment|DLQI110	Dermatology Life Quality Index (DLQI) Over the last week, how much of a problem has the treatment for your skin been, for example by making your home messy, or by taking up time?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DLQI Test Code Terminology|CDISC Questionnaire DLQI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119174>	C119086	DLQI - Score|DLQI1-Score|DLQI1-Score|DLQI111	Dermatology Life Quality Index (DLQI) Score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DLQI Test Code Terminology|CDISC Questionnaire DLQI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119175>	C119087	RPQ - Headaches|RPQ01-Headaches|RPQ01-Headaches|RPQ0101	Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Headaches.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RPQ Test Code Terminology|CDISC Questionnaire RPQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119176>	C119087	RPQ - Feelings of Dizziness|RPQ01-Feelings of Dizziness|RPQ01-Feelings of Dizziness|RPQ0102	Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Feelings of dizziness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RPQ Test Code Terminology|CDISC Questionnaire RPQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119177>	C119087	RPQ - Nausea and/or Vomiting|RPQ01-Nausea and/or Vomiting|RPQ01-Nausea and/or Vomiting|RPQ0103	Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Nausea and/or vomiting.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RPQ Test Code Terminology|CDISC Questionnaire RPQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119178>	C119087	RPQ - Noise Sensitivity|RPQ01-Noise Sensitivity/Loud Noise|RPQ01-Noise Sensitivity/Loud Noise|RPQ0104	Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Noise sensitivity, easily upset by loud noise.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RPQ Test Code Terminology|CDISC Questionnaire RPQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119179>	C119087	RPQ - Sleep Disturbance|RPQ01-Sleep Disturbance|RPQ01-Sleep Disturbance|RPQ0105	Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Sleep disturbance.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RPQ Test Code Terminology|CDISC Questionnaire RPQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11917>	C61063	Cyclosporine/Paclitaxel/Yttrium Y 90 Monoclonal Antibody M170			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119180>	C119087	RPQ - Fatigue, Tiring More Easily|RPQ01-Fatigue, Tiring More Easily|RPQ01-Fatigue, Tiring More Easily|RPQ0106	Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Fatigue, tiring more easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RPQ Test Code Terminology|CDISC Questionnaire RPQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119181>	C119087	RPQ - Being Irritable, Easily Angered|RPQ01-Being Irritable, Easily Angered|RPQ01-Being Irritable, Easily Angered|RPQ0107	Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Being irritable, easily angered.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RPQ Test Code Terminology|CDISC Questionnaire RPQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119182>	C119087	RPQ - Feeling Depressed or Tearful|RPQ01-Feeling Depressed or Tearful|RPQ01-Feeling Depressed or Tearful|RPQ0108	Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Feeling depressed or tearful.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RPQ Test Code Terminology|CDISC Questionnaire RPQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119183>	C119087	RPQ - Feeling Frustrated or Impatient|RPQ01-Feeling Frustrated or Impatient|RPQ01-Feeling Frustrated or Impatient|RPQ0109	Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Feeling frustrated or impatient.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RPQ Test Code Terminology|CDISC Questionnaire RPQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119184>	C119087	RPQ - Forgetfulness, Poor Memory|RPQ01-Forgetfulness, Poor Memory|RPQ01-Forgetfulness, Poor Memory|RPQ0110	Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Forgetfulness, poor memory.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RPQ Test Code Terminology|CDISC Questionnaire RPQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119185>	C119087	RPQ - Poor Concentration|RPQ01-Poor Concentration|RPQ01-Poor Concentration|RPQ0111	Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Poor concentration.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RPQ Test Code Terminology|CDISC Questionnaire RPQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119186>	C119087	RPQ - Taking Longer to Think|RPQ01-Taking Longer to Think|RPQ01-Taking Longer to Think|RPQ0112	Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Taking longer to think.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RPQ Test Code Terminology|CDISC Questionnaire RPQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119187>	C119087	RPQ - Blurred Vision|RPQ01-Blurred Vision|RPQ01-Blurred Vision|RPQ0113	Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Blurred vision.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RPQ Test Code Terminology|CDISC Questionnaire RPQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119188>	C119087	RPQ - Light Sensitivity|RPQ01-Light Sensitivity/Bright Light|RPQ01-Light Sensitivity/Bright Light|RPQ0114	Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Light sensitivity, easily upset by bright light.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RPQ Test Code Terminology|CDISC Questionnaire RPQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119189>	C119087	RPQ - Double Vision|RPQ01-Double Vision|RPQ01-Double Vision|RPQ0115	Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Double vision.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RPQ Test Code Terminology|CDISC Questionnaire RPQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11918>	C61063	Cyclosporine/Paclitaxel/Yttrium Y 90 Monoclonal Antibody Lym-1			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119190>	C119087	RPQ - Restlessness|RPQ01-Restlessness|RPQ01-Restlessness|RPQ0116	Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, do you now suffer from: Restlessness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RPQ Test Code Terminology|CDISC Questionnaire RPQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119191>	C119087	RPQ - Any Other Difficulties 1 (Text)|RPQ01-Any Other Difficulties 1 (Text)|RPQ01-Any Other Difficulties 1 (Text)|RPQ0117A	Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, are you experiencing any other difficulties 1? (Text).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RPQ Test Code Terminology|CDISC Questionnaire RPQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119192>	C119087	RPQ - Any Other Difficulties 1 (number)|RPQ01-Any Other Difficulties 1|RPQ01-Any Other Difficulties 1|RPQ0117B	Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, are you experiencing any other difficulties 1? (Number).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RPQ Test Code Terminology|CDISC Questionnaire RPQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119193>	C119087	RPQ - Any Other Difficulties 2 (Text)|RPQ01-Any Other Difficulties 2 (Text)|RPQ01-Any Other Difficulties 2 (Text)|RPQ0118A	Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, are you experiencing any other difficulties 2? (Text).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RPQ Test Code Terminology|CDISC Questionnaire RPQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119194>	C119087	RPQ - Any Other Difficulties 2 (Number)|RPQ01-Any Other Difficulties 2|RPQ01-Any Other Difficulties 2|RPQ0118B	Rivermead Post-Concussion Symptoms Questionnaire (RPQ) Compared with before the accident, are you experiencing any other difficulties 2? (Number).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RPQ Test Code Terminology|CDISC Questionnaire RPQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119195>	C119088	TIMI Thrombus Grade - Coronary Thrombus TIMI Grade|TIMG01-Coronary Thrombus TIMI Grade|TIMG01-Coronary Thrombus TIMI Grade|TIMG0101	Coronary Thrombus TIMI Grade (TIMI Thrombus Grade) A grade corresponding to thrombus development as defined in the grading system by the Thrombolysis in the Myocardial Infarction Group.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification TIMI Thrombus Grade Test Code Terminology|CDISC Clinical Classification TIMI Thrombus Grade Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119196>	C119089	NHLBI CAD Grade - Coronary Artery Dissection NHLBI Grade|CADG01-Coronary Dissection NHLBI Grade|CADG01-Coronary Dissection NHLBI Grade|CADG0101	Coronary Artery Dissection NHLBI Grade (NHLBI CAD Grade) A grading system to describe coronary artery dissection per the NHLBI, American College of Cardiology, American Heart Association.			Intellectual Product	CDISC Clinical Classification NHLBI CAD Grade Test Code Terminology|CDISC Clinical Classification NHLBI CAD Grade Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119197>	C119090	ARC STC Timing - Stent Thrombosis Coronary ARC Timing	Stent Thrombosis Coronary ARC Timing (ARC STC Timing) Categorization of the timing of coronary stent thrombosis occurrence per the classification schema described by the Academic Research Consortium.			Intellectual Product	
C119198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119198>	C119091	ARC STC Grade - Stent Thrombosis Coronary ARC Grade|STCG01-STC ARC Grade|STCG01-STC ARC Grade|STCG0101	Stent Thrombosis Coronary ARC Grade (ARC STC Grade) A grading system to describe the coronary stent thrombosis per the classification schema described by the Academic Research Consortium.			Intellectual Product	CDISC Clinical Classification ARC STC Grade Test Code Terminology|CDISC Clinical Classification ARC STC Grade Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119199>	C49236	Oral Diuretic Therapy Augmentation for Heart Failure|AUGMENTATION OF ORAL DIURETIC THERAPY	Initiation or intensification of oral diuretics to treat heart failure.			Therapeutic or Preventive Procedure	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11919>	C61063	Cyclosporine/Yttrium Y 90 Monoclonal Antibody Lym-1			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1191>	C45494	Phenol|PHENOL|carbolic acid|phenol	Hydroxybenzene; Carbolic Acid. Used as a germicidal agent and as an intermediate in chemical synthesis.  Highly toxic; corrosive to the skin.			Hazardous or Poisonous Substance|Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C119200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119200>	C62754	Weight Gain Due to Fluid Retention|CLINICALLY SIGNIFICANT OR RAPID WEIGHT GAIN	A finding of rapid weight gain due to fluid retention.			Finding	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119201>	C35869	Coronary Lesion by Angiographic Finding|CORONARY LESION ON ANGIOGRAPHY	An angiographic finding of pathologic material in a coronary vessel, which obstructs myocardial perfusion.			Finding	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119202>	C80430	Coronary Revascularization Procedure|CORONARY REVASCULARIZATION|Coronary Reperfusion Procedure	Any procedure that is undertaken to reestablish blood flow to the heart.			Therapeutic or Preventive Procedure	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119203>	C176716	Decreased Exercise Tolerance|DECREASED EXERCISE TOLERANCE|Decreased exercise tolerance|Exercise capacity decreased	A reduction in the ability to perform or withstand activities that induce physical or mental exertion.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|Clinical Data Interchange Standards Consortium Terminology
C119204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119204>	C25179	Hospitalization Due to Heart Failure|HEART FAILURE HOSPITALIZATION	A finding of a hospitalization event due to a heart failure diagnosis.			Finding	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119205>	C81326	Increase in B-type Natriuretic Peptide or N-terminal pro-B-type Natriuretic Peptide|INCREASE IN HEART FAILURE BIOMARKER	A finding of an increased amount of either B-type natriuretic peptide or N-terminal pro-B-type natriuretic peptide			Finding	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119206>	C35552	Increase in Jugular Venous Pressure|INCREASED JUGULAR VENOUS PRESSURE OR HEPATOJUGULAR REFLUX	A finding of an increase in the jugular venous pressure, as measured by the height of the mean jugular venous waveform above the right atrium.			Finding	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119207>	C35552	Inducible Myocardial Ischemia|INDUCIBLE MYOCARDIAL ISCHEMIA	A finding of abnormal heart wall motion contractility in response to stress, and which is not seen at rest.			Finding	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119208>	C49236	Intravenous Diuretic, Inotropic or Vasodilator Augmentation for Heart Failure|INTRAVENOUS DIURETIC, INOTROPE, OR VASODILATOR THERAPY	Initiation or intensification of intravenous diuretics, inotropics or vasodilators to treat heart failure.			Therapeutic or Preventive Procedure	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119209>	C35552	Heart Failure by Invasive Diagnostic Technique|INVASIVE DIAGNOSTIC EVIDENCE OF HEART FAILURE	A finding of heart failure through an invasive diagnostic technique.			Finding	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11920>	C61007	Flavopiridol/Gemcitabine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119210>	C35552	Loss of Patency of Side Branch|LOSS OF A SIDE BRANCH	A decrease in the openness of a side branch of a blood vessel.			Finding	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119211>	C35552	Loss of Patency of Major Vessel|LOSS OF MAJOR CORONARY	A decrease in the openness of a major, or great, blood vessel.			Finding	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119212>	C49236	Vasculature Mechanical or Surgical Intervention|MECHANICAL OR SURGICAL INTERVENTION	That treatment of vessel disease or injury by dialysis, operative procedures, or device placement.			Therapeutic or Preventive Procedure	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119213>	C35552	New Loss of Viable Myocardium by Non-invasive Imaging Technique|NEW LOSS OF VIABLE MYOCARDIUM	A finding of loss of viable myocardium, which is new compared to prior non-invasive imaging techniques.			Finding	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119214>	C35552	New Regional Wall Motion Abnormality by Non-invasive Imaging Technique|NEW REGIONAL WALL MOTION ABNORMALITY	A finding of decreased regional heart wall motion contractility, which is new compared to prior non-invasive imaging techniques.			Finding	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119215>	C35552	Heart Failure by Non-invasive Diagnostic Technique|NON-INVASIVE DIAGNOSTIC EVIDENCE OF HEART FAILURE	A finding of heart failure through a non-invasive diagnostic technique.			Finding	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119216>	C5043	Rales|PULMONARY RALES/CRACKLES/CREPITATIONS|Pulmonary Rales	Abnormal breath sounds (crackles) heard on auscultation, indicating inflammation, fluid, or infection of the lung.			Sign or Symptom	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 6: Symptoms and Signs Terminology|CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|Physical Examination Terminology
C119217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119217>	C35552	Pulmonary Congestion by Radiological Technique|Pulmonary congestion|RADIOLOGICAL EVIDENCE OF PULMONARY CONGESTION	Imaging findings consistent with increased intravascular blood volume in the lungs.			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 7: Diagnostic Procedures Terminology|CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119218>	C41328	Resting ECG Changes|RESTING ECG CHANGES	Any new or worsening ST or T wave changes present in two or more contiguous leads that occur when a patient is experiencing neither physical nor chemical stressors.			Finding	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119219>	C50600	Flow Reduced in Coronary Microcirculation|SLOW-FLOW/NO-FLOW/EMBOLIZATION	A finding of decreased blood flow in the microcirculation of the heart.			Finding	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11921>	C61007	Dexamethasone/Floxuridine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119220>	C118936	Joint Task Force Type 1 Myocardial Infarction|Joint ESC/ACCF/AHA/WHF Task Force Type 1 Myocardial Infarction|TYPE 1 MYOCARDIAL INFARCTION	Spontaneous myocardial infarction related to ischaemia due to a primary coronary event such as plaque erosion and/or rupture, fissuring, or dissection. (Universal definition of myocardial infarction, Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Eur Heart J (2007) 28 (20): 2525-2538.)			Finding	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119221>	C118936	Joint Task Force Type 2 Myocardial Infarction|Joint ESC/ACCF/AHA/WHF Task Force Type 2 Myocardial Infarction|TYPE 2 MYOCARDIAL INFARCTION	Myocardial infarction secondary to ischaemia due to either increased oxygen demand or decreased supply, e.g. coronary artery spasm, coronary embolism, anaemia, arrhythmias, hypertension, or hypotension. (Universal definition of myocardial infarction, Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Eur Heart J (2007) 28 (20): 2525-2538.)			Finding	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119222>	C118936	Joint Task Force Type 3 Myocardial Infarction|Joint ESC/ACCF/AHA/WHF Task Force Type 3 Myocardial Infarction|TYPE 3 MYOCARDIAL INFARCTION	Sudden unexpected cardiac death, including cardiac arrest, often with symptoms suggestive of myocardial ischaemia, accompanied by presumably new ST elevation, or new LBBB, or evidence of fresh thrombus in a coronary artery by angiography and/or at autopsy, but death occurring before blood samples could be obtained, or at a time before the appearance of cardiac biomarkers in the blood. (Universal definition of myocardial infarction, Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Eur Heart J (2007) 28 (20): 2525-2538.)			Finding	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119223>	C118936	Joint Task Force Type 4A Myocardial Infarction|Joint ESC/ACCF/AHA/WHF Task Force Type 4A Myocardial Infarction|TYPE 4A MYOCARDIAL INFARCTION	Myocardial infarction associated with PCI. (Universal definition of myocardial infarction, Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Eur Heart J (2007) 28 (20): 2525-2538.)			Finding	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119224>	C118936	Joint Task Force Type 4B Myocardial Infarction|Joint ESC/ACCF/AHA/WHF Task Force Type 4B Myocardial Infarction|TYPE 4B MYOCARDIAL INFARCTION	Myocardial infarction associated with stent thrombosis as documented by angiography or at autopsy. (Universal definition of myocardial infarction, Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Eur Heart J (2007) 28 (20): 2525-2538.)			Finding	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119225>	C118936	Joint Task Force Type 4C Myocardial Infarction|Joint ESC/ACCF/AHA/WHF Task Force Type 4C Myocardial Infarction|TYPE 4C MYOCARDIAL INFARCTION	Myocardial infarction associated with stent restenosis as detected by coronary angiography or at autopsy. (Universal definition of myocardial infarction, Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Eur Heart J (2007) 28 (20): 2525-2538.)			Finding	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119226>	C118936	Joint Task Force Type 5 Myocardial Infarction|Joint ESC/ACCF/AHA/WHF Task Force Type 5 Myocardial Infarction|TYPE 5 MYOCARDIAL INFARCTION	Myocardial infarction associated with CABG. (Universal definition of myocardial infarction, Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Eur Heart J (2007) 28 (20): 2525-2538.)			Finding	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119227>	C39564	ER or Office Visit Due to Heart Failure|URGENT HEART FAILURE VISIT	A finding of heart failure during a visit to the emergency room or a doctor's office.			Finding	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119228>	C35552	Worsened End-Organ Perfusion|WORSENED END-ORGAN PERFUSION	A finding of a worsening decrease in blood supply to the vital organs.			Finding	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119229>	C111095	Coronary Artery Thrombosis Method of Identification|CATMTHID|CATMTHID|Coronary Artery Thrombosis Method Ident|Coronary Artery Thrombosis Method Ident|Coronary Artery Thrombosis Method Ident	The method used to detect a coronary artery thrombus.			Laboratory Procedure	CDISC SDTM Cardiovascular Findings About Test Code Terminology|CDISC SDTM Cardiovascular Findings About Test Name Terminology|CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11922>	C61063	Dexamethasone/Doxorubicin/Thalidomide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119230>	C25180	Endpoint Event Indicator|ENDPTIND|ENDPTIND	An indication as to whether the event meets the criteria for a clinical endpoint.			Conceptual Entity	CDISC SDTM Cardiovascular Findings About Test Code Terminology|CDISC SDTM Cardiovascular Findings About Test Name Terminology|CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119231>	C25284	Healthcare Encounter Type|Encounter Type|HETYPE|HETYPE	A classification or description of the visit by a patient or study participant to a medical professional.			Qualitative Concept	CDISC SDTM Cardiovascular Findings About Test Code Terminology|CDISC SDTM Cardiovascular Findings About Test Name Terminology|CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C119232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119232>	C36292	Lab Findings of New or Worsening Heart Failure|HFLBFNW|HFLBFNW|Heart Failure New/Worsening Lab Findings|Heart Failure New/Worsening Lab Findings|Heart Failure New/Worsening Lab Findings	A description of the clinical, laboratory or molecular evidence of heart failure that can be classified as new or worsening.			Laboratory or Test Result	CDISC SDTM Cardiovascular Findings About Test Code Terminology|CDISC SDTM Cardiovascular Findings About Test Name Terminology|CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119233>	C83119	Physical Examination Findings of New or Worsening Heart Failure|HFPEFNW|HFPEFNW|Heart Failure New/Worsening PE Findings|Heart Failure New/Worsening PE Findings|Heart Failure New/Worsening PE Findings	A description of the physical examination evidence of heart failure that can be classified as new or worsening.			Laboratory or Test Result	CDISC SDTM Cardiovascular Findings About Test Code Terminology|CDISC SDTM Cardiovascular Findings About Test Name Terminology|CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119234>	C25284	Heart Failure Therapy Intensification Type|HFTHERIN|HFTHERIN|Heart Failure Therapy, Intensification|Heart Failure Therapy, Intensification|Heart Failure Therapy, Intensification	A classification or description of the therapeutic agent or procedure that is being escalated.			Qualitative Concept	CDISC SDTM Cardiovascular Findings About Test Code Terminology|CDISC SDTM Cardiovascular Findings About Test Name Terminology|CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119235>	C25180	Ischemic Discomfort Indicator|ISCDIND|ISCDIND	An indication as to whether the subject has symptoms of ischemic discomfort.			Conceptual Entity	CDISC SDTM Cardiovascular Findings About Test Code Terminology|CDISC SDTM Cardiovascular Findings About Test Name Terminology|CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119236>	C25284	Ischemic Evidence Type|ISCETYP|ISCETYP	A classification or description of the evidence of ischemia in the subject.			Qualitative Concept	CDISC SDTM Cardiovascular Findings About Test Code Terminology|CDISC SDTM Cardiovascular Findings About Test Name Terminology|CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119237>	C181043	Exclusion of Type 1 and Type 2 Myocardial Infarction Diagnosis Indicator|Exclusion of Type 1 and Type 2 MI|Exclusion of Type 1 and Type 2 MI|Exclusion of Type 1 and Type 2 MI|MI12EXC|MI12EXC	An indication as to whether type 1 and type 2 myocardial infarction is excluded as a diagnosis.			Conceptual Entity	CDISC SDTM Cardiovascular Findings About Test Code Terminology|CDISC SDTM Cardiovascular Findings About Test Name Terminology|CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119238>	C4876	New or Worsening Symptom|NWSYMP|NWSYMP|New or Worsening Symptoms|New or Worsening Symptoms|New or Worsening Symptoms	The subjective evidence of disease perceived by the patient that can be classified as new or worsening			Quantitative Concept	CDISC SDTM Cardiovascular Findings About Test Code Terminology|CDISC SDTM Cardiovascular Findings About Test Name Terminology|CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119239>	C25284	Acute Myocardial Infarction From PCI Complication Type|PCI Acute Angiographic Complication|PCI Acute Angiographic Complication|PCI Acute Angiographic Complication|PCIAAC|PCIAAC	A description of the complications from a percutaneous coronary intervention procedure that lead to an acute myocardial ischemic event.			Qualitative Concept	CDISC SDTM Cardiovascular Findings About Test Code Terminology|CDISC SDTM Cardiovascular Findings About Test Name Terminology|CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11923>	C61063	Filgrastim/Melphalan			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119240>	C25180	Procedure Success Indicator|PRSUCIND|PRSUCIND	An indication as to whether the procedure is considered successful.			Conceptual Entity	CDISC SDTM Cardiovascular Findings About Test Code Terminology|CDISC SDTM Cardiovascular Findings About Test Name Terminology|CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119241>	C25180	Symptom Indicator|SYMPINDC|SYMPINDC	An indication as to whether the subject had symptoms related to the clinical event of interest.			Conceptual Entity	CDISC SDTM Cardiovascular Findings About Test Code Terminology|CDISC SDTM Cardiovascular Findings About Test Name Terminology|CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119242>	C93613	Symptom Onset Date|Date_of_Symptom_Onset|SYMSTDTC|SYMSTDTC	The date and time on which the symptoms began or were first noted.			Temporal Concept	CDISC SDTM Cardiovascular Findings About Test Code Terminology|CDISC SDTM Cardiovascular Findings About Test Name Terminology|CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|SeroNet Research Participant Metadata|SeroNet Variables
C119243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119243>	C181043	Vessel Occlusion 48 Hours after CABG Indicator|VOC48IND|VOC48IND|Vessel Occlusion After CABG 48 Ind|Vessel Occlusion After CABG 48 Ind|Vessel Occlusion After CABG 48 Ind	An indication as to whether vessel occlusion occurred 48 hours after a coronary artery bypass graft procedure			Conceptual Entity	CDISC SDTM Cardiovascular Findings About Test Code Terminology|CDISC SDTM Cardiovascular Findings About Test Name Terminology|CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119244>	C41328	Insignificant Disease by ECG Finding|INSIGNIFICANT DISEASE	An electrocardiographic recording that does not demonstrate any significant signs of ischemia or conduction abnormalities.			Finding	CDISC SDTM Coronary Vessel Disease Extent Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119245>	C35552	Cardiac Index|CARDIDX|Cardiac index	The measure of an individual's cardiac output as divided by their body surface area (CI= CO/BSA). This calculation is a useful function to determine an individual's cardiac performance in relation to their body size, providing an overview of global cardiovascular function.			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|Appendix 7: Diagnostic Procedures Terminology|CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119246>	C35552	Cardiac Output|CARDOUT|Cardiac output	The total volume of blood pumped by the heart over a set period of time, conventionally one minute; it is calculated as heart rate times stroke volume (CO= HR x SV), and is additionally dependent on preload and afterload for functional output.			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|Appendix 7: Diagnostic Procedures Terminology|CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119247>	C35552	Pulmonary Vascular Resistance|PVR|Pulmonary vascular resistance	The resistance to blood flow offered by the pulmonary vasculature, which is normally one sixth of SVR. The major determinant of PVR is pulmonary vessel constriction, most often caused by hypoxia and/or hypercarbia. Prolonged elevated PVR can cause right heart failure.			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|Appendix 7: Diagnostic Procedures Terminology|CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119248>	C35552	Systemic Vascular Resistance|SVR|Systemic vascular resistance|TPR|Total Peripheral Resistance|Total Peripheral Resistance|Total Peripheral Resistance	The resistance to blood flow offered by all systemic vasculature, excluding pulmonary vasculature. The major determinant of SVR is arteriolar tone, but blood viscosity and vascular capacitance are also contributing factors.			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|Appendix 7: Diagnostic Procedures Terminology|CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Cardiovascular Test Code Terminology|CDISC SEND Cardiovascular Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119249>	C41328	Atrial Tachycardia With AV Block by ECG Finding|ATRIAL TACHYCARDIA WITH AV BLOCK	An electrocardiographic recording that demonstrates atrial tachycardia without 1:1 atrioventricular conduction.			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C11924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11924>	C61063	Calcitriol/Carboplatin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119250>	C41328	Pause by ECG Finding|PAUSE	An electrocardiographic recording that demonstrates an R-R interval that exceeds a predefined duration threshold, irrespective of the underlying rhythm.			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119251>	C41328	Pause Greater Than Three Seconds by ECG Finding|PAUSE GREATER THAN 3.0 SECONDS	An electrocardiographic recording that demonstrates an R-R interval that exceeds three seconds, irrespective of the underlying rhythm.			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119252>	C41328	Supraventricular Couplet by ECG Finding|SUPRAVENTRICULAR COUPLET	An electrocardiographic recording that demonstrates two sequential premature atrial complexes.			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C119253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119253>	C62085	Maximum Atrial Rate by Electrocardiogram|ECG Maximum Atrial Rate|ECG Maximum Atrial Rate|EGARMAX	An electrocardiographic measurement of the maximum number of atrial depolarizations (P waves) recorded during a specified period of time, and usually expressed in beats per minute.			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119254>	C62085	Median Atrial Rate by Electrocardiogram|ECG Median Atrial Rate|ECG Median Atrial Rate|EGARMED	An assessment of the median atrial depolarization rate as measured and recorded by an electrocardiograph during a specified period of time, and which is usually expressed in beats per minute.			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119255>	C62085	Minimum Atrial Rate by Electrocardiogram|ECG Minimum Atrial Rate|ECG Minimum Atrial Rate|EGARMIN	An electrocardiographic measurement of the minimum rate of atrial depolarizations (P waves) recorded during a specified period of time, and usually expressed in beats per minute.			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119256>	C62085	Mean Atrial Rate by Electrocardiogram|ECG Mean Atrial Rate|ECG Mean Atrial Rate|EGARMN	The calculated average rate of atrial depolarization (P waves) as measured and recorded by an electrocardiograph during a specified period of time, and which is usually expressed in beats per minute.			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119257>	C62085	Maximum Heart Rate by Electrocardiogram|ECG Maximum Heart Rate|ECG Maximum Heart Rate|ECG Maximum Heart Rate|EGHRMAX|EGHRMAX	An electrocardiographic measurement of the maximum number of depolarisations of a specific region of the heart, most often the ventricles, recorded during a specified, extended period of time, and usually expressed in beats per minute.			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119258>	C62085	Minimum Heart Rate by Electrocardiogram|ECG Minimum Heart Rate|ECG Minimum Heart Rate|ECG Minimum Heart Rate|EGHRMIN|EGHRMIN	An electrocardiographic measurement of the minimum number of depolarisations of a specific region of the heart, most often the ventricles, recorded during a specified, extended period of time, and usually expressed in beats per minute.			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119259>	C62085	Mean Heart Rate by Electrocardiogram|ECG Mean Heart Rate|ECG Mean Heart Rate|ECG Mean Heart Rate|EGHRMN|EGHRMN	The calculated average rate of depolarisation of a specific region of the heart, most often the ventricles, as measured and recorded by an electrocardiograph during a specified, extended period of time, and which is usually expressed in beats per minute.			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11925>	C61007	Cyclophosphamide/Doxorubicin/Etoposide/Rituximab/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119260>	C62085	Maximum Ventricular Rate by Electrocardiogram|ECG Maximum Ventricular Rate|ECG Maximum Ventricular Rate|EGVRMAX	An electrocardiographic measurement of the maximum number of ventricular depolarizations (QRS complexes) recorded during a specified, extended period of time, usually expressed in beats per minute.			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119261>	C62085	Median Ventricular Rate by Electrocardiogram|ECG Median Ventricular Rate|ECG Median Ventricular Rate|EGVRMED	An assessment of the median ventricular depolarization rate as measured and recorded by an electrocardiograph during a specified period of time, and which is usually expressed in beats per minute.			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119262>	C62085	Minimum Ventricular Rate by Electrocardiogram|ECG Minimum Ventricular Rate|ECG Minimum Ventricular Rate|EGVRMIN	An electrocardiographic measurement of the minimum number of ventricular depolarizations (QRS complexes) recorded during a specified, extended period of time, and usually expressed in beats per minute.			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119263>	C62085	Mean Ventricular Rate by Electrocardiogram|ECG Mean Ventricular Rate|ECG Mean Ventricular Rate|EGVRMN	The calculated average rate of ventricular depolarisation as measured and recorded by an electrocardiograph during a specified, extended period of time, and which is usually expressed in beats per minute.			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119264>	C93142	Proxy|PROXY|proxy	A type of advance directive that gives a person the authority to make decisions for another individual. It becomes active when that person loses the ability to make decisions for him- or herself.			Manufactured Object	CDISC MRCT Center Clinical Research Glossary|CDISC SDTM Evaluator Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119265>	C41256	Significant Other|SIGNIFICANT OTHER|SO	A sex-neutral term for a person's partner in an intimate or romantic relationship without disclosing or presuming marital status or sexual orientation.			Human	CDISC SDTM Evaluator Terminology|CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119266>	C64432	Intestinal Specific Alkaline Phosphatase Measurement|ALPIS|Intestinal Specific Alkaline Phosphatase|Intestinal Specific Alkaline Phosphatase	The determination of the amount of the intestinal specific alkaline phosphatase in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119267>	C64432	Liver Specific Alkaline Phosphatase Measurement|ALPLS|Liver Specific Alkaline Phosphatase|Liver Specific Alkaline Phosphatase	The determination of the amount of the liver specific alkaline phosphatase in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119268>	C64430	Amyloid Alpha Precursor Protein Measurement|APPA|Amyloid Alpha Precursor Protein|Amyloid Alpha Precursor Protein	The determination of the amount of the amyloid alpha precursor protein in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119269>	C105438	Total Amyloid Precursor Protein Measurement|APPT|Total Amyloid Precursor Protein|Total Amyloid Precursor Protein	The determination of the amount of the total amyloid precursor protein in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11926>	C61063	Cyclosporine/Methylprednisolone/Mycophenolate Mofetil			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119270>	C74957	Base Excess Measurement|Actual Base Excess|BASEEXCS|Base Excess|Base Excess	The determination of the amount of the base excess in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119271>	C80160|C210010	Complement C3d Antibody Measurement	The determination of the amount of the complement C3d antibody in a biological specimen.			Laboratory Procedure	
C119272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119272>	C64488	Calcium Corrected Measurement|CACR|Calcium Corrected|Calcium Corrected	The determination of the amount of the calcium corrected in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119273>	C154736	Soluble E-Selectin Measurement|ESELS|Soluble E-Selectin|Soluble E-Selectin|sE-selectin	The determination of the amount of the soluble E-selectin activity in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119274>	C92256	Beta-1 Globulin Measurement|Beta-1 Globulin|Beta-1 Globulin|GLOBB1	The determination of the amount of the beta-1 globulin activity in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119275>	C119274	Beta-1 Globulin to Total Protein Ratio Measurement|Beta-1 Globulin/Total Protein|Beta-1 Globulin/Total Protein|GLOBB1PT	The determination of the ratio of the beta-1 globulin to albumin in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119276>	C92256	Beta-2 Globulin Measurement|Beta-2 Globulin|Beta-2 Globulin|GLOBB2	The determination of the amount of the beta-2 globulin activity in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119277>	C119276	Beta-2 Globulin to Total Protein Ratio Measurement|Beta-2 Globulin/Total Protein|Beta-2 Globulin/Total Protein|GLOBB2PT	The determination of the ratio of the beta-2 globulin to total protein in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119278>	C79433	Alpha-GST Excretion Rate|Alpha Glutathione-S-Transferase Excretion Rate|GSTALEXR	A determination of the amount of alpha glutathione-s-transferase being excreted over a defined period of time.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119279>	C80203	Pi-GST Excretion Rate|GSTPIEXR	A determination of the amount of pi glutathione-s-transferase being excreted over a defined period of time.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11927>	C61007	Anti-thymocyte globulin/fludarabine/melphalan			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119280>	C96660|C81971	Hepatitis B Virus Core IgG Antibody Measurement	The determination of the amount of hepatitis B virus core IgG antibody in a biological specimen.			Laboratory Procedure	
C119281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119281>	C96664|C81971	Hepatitis D Virus IgG Antibody Measurement	The determination of the amount of hepatitis D virus IgG antibody in a biological specimen.			Laboratory Procedure	
C119282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119282>	C96664|C81972	Hepatitis D Virus IgM Antibody Measurement	The determination of the amount of hepatitis D virus IgM antibody in a biological specimen.			Laboratory Procedure	
C119283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119283>	C210012|C210010	Hepatitis E Virus Antibody Measurement	The determination of the amount of hepatitis E virus antibody in a biological specimen.			Laboratory Procedure	
C119284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119284>	C64430	Insulinoma-Associated Protein 2 Antibody Measurement	The determination of the amount of insulinoma-associated protein 2 antibody in a biological specimen.			Laboratory Procedure	
C119285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119285>	C74760	Immunoglobulin G to Creatinine Ratio Measurement|IGGCREAT|Immunoglobulin G/Creatinine|Immunoglobulin G/Creatinine	The determination of the ratio of immunoglobulin G to creatinine in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119286>	C119287	Insulin Autoantibody Measurement|INS Autoantibody Measurement	The determination of the amount of insulin autoantibody in a biological specimen.	Insulin Autoantibody Measurement		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Intervention Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C119287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119287>	C210010	Insulin Antibody Measurement	The determination of the amount of insulin antibody in a biological specimen.			Laboratory Procedure	
C119288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119288>	C210010	Oxidized LDL Cholesterol Antibody Measurement	The determination of the amount of oxidized low density lipoprotein cholesterol antibody in a biological specimen.			Laboratory Procedure	
C119289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119289>	C48938	Activated Lymphocytes Measurement|LYMA|Lymphocytes Activated|Lymphocytes Activated	The determination of the amount of activated lymphocytes in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11928>	C61063	Selenium/vitamin E			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119290>	C80198|C49286	Neutrophil Myeloperoxidase Index|MPXI|Myeloperoxidase Index|Myeloperoxidase Index	The mean myeloperoxidase staining intensity of the neutrophil population relative to the archetype.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119291>	C74760	8-Iso-Prostaglandin F2 Alpha to Creatinine Ratio Measurement|8-Iso-PGF2alpha/Creatinine|8-Iso-PGF2alpha/Creatinine|PF2AI8CR	The determination of the ratio of the 8-iso-prostaglandin F2 alpha to creatinine in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119292>	C103343	8-Iso-Prostaglandin F2 Alpha Measurement|8-Iso-Prostaglandin F2 Alpha|8-Iso-Prostaglandin F2 Alpha|PGF2AI8	The determination of the amount of 8-iso-prostaglandin F2 alpha in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119293>	C82624	Partial Pressure Arterial Oxygen to Fraction Inspired Oxygen Ratio Measurement|PAO2/FIO2|PO2FIO2|PO2FIO2|PP Arterial O2/Fraction Inspired O2|PP Arterial O2/Fraction Inspired O2|PP Arterial O2/Fraction Inspired O2	The determination of the ratio of the pressure of oxygen dissolved in arterial blood to the percentage oxygen of an inhaled mixture of gasses in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119294>	C67208	Smudge Cells to Leukocytes Ratio Measurement|Basket Cells/Leukocytes|Gumprecht Shadow Cells/Leukocytes|SMDGCELE|Shadow Cells/Leukocytes|Smudge Cells/Leukocytes|Smudge Cells/Leukocytes	The determination of the ratio of smudge cells to leukocytes in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119295>	C133337	Ventricular Wall of the Heart|HEART, VENTRICULAR WALL	The tissue layers that form the cardiac ventricle. They include the endocardium, myocardium and pericardium.			Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119296>	C158239	Radial Immunodiffusion|RADIAL IMMUNODIFFUSION	A quantitative technique used to detect and estimate the concentration of an antigen by measuring the diameter of the ring of precipitation (precipitin ring), which is formed as a result of the interaction of the antigen and an antibody at optimal concentration.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119297>	C118934	Acanthamoeba astronyxis|ACANTHAMOEBA ASTRONYXIS	A species of motile, unicellular eukaryotic amoebae within the family of Acanthamoebidae. A. astronyxis is placed in morphological group I with a 18s rRNA gene sequence type of T7. Members of this group are characterized by the presence of relatively large cysts in comparison to that of species in morphological groups II and III. This species is a human pathogen and may cause granulomatous amoebic encephalitis and amoebic keratitis.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119298>	C118934	Acanthamoeba castellanii|ACANTHAMOEBA CASTELLANII	A species of motile, unicellular eukaryotic amoebae within the family of Acanthamoebidae. A. castellanii is placed in morphological group II with a 18s rRNA gene sequence type of T4. Members of this group are characterized by the presence of wrinkled ectocysts and endocysts which could be stellate, polygonal, triangular, or oval. This species is a human pathogen and may cause granulomatous amoebic encephalitis and amoebic keratitis.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119299>	C118934	Acanthamoeba culbertsoni|ACANTHAMOEBA CULBERTSONI	A species of motile, unicellular eukaryotic amoebae within the family of Acanthamoebidae. A. culbertsoni is placed in morphological group III with a 18s rRNA gene sequence type of T10. Members of this group are characterized by the presence of thin, smooth ectocysts and round endocysts. This species is a human pathogen and may cause granulomatous amoebic encephalitis and amoebic keratitis.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11929>	C61007	Imatinib Mesylate/Interferon Alfa			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1192>	C70568|C1903	Phosphatidylinositol 4,5-bisphosphate|1,2-Diacyl-sn-Glycero-3-Phospho-(1'-myo-Inositol-4',5'-Bisphosphate)|1-O-(3-sn-Phosphatidyl)-1D-myo-Inositol 4,5-Bis(Dihydrogen Phosphate)|1-Phosphatidyl-1D-myo-Inositol 4,5-Bisphosphate|1-Phosphatidyl-D-myo-Inositol 4,5-Bisphosphate|PIP2|PIPP|Phosphatidyl-myo-Inositol 4,5-Bisphosphate|Phosphatidylinositol 4,5-Diphosphate|PtdIns(4,5)P2|PtsIns-4,5-P2	A phospholipid that is a component of the plasma membrane with signal transduction inducing activity. Phosphatidylinositol 4,5-bisphosphate (PIP2) is an intermediate that can be converted into either the second messenger signaling molecules, inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), or phosphatidylinositol (3,4,5)-trisphosphate (PtdIns(3,4,5)P3; PIP3). Both PIP2 and PIP3 can act as docking phospholipids, which recruit signaling proteins to the plasma membrane and promotes the activation of several signaling cascades.			Biologically Active Substance|Organic Chemical	
C119300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119300>	C118934	Acanthamoeba griffini|ACANTHAMOEBA GRIFFINI	A species of motile, unicellular eukaryotic amoebae within the family of Acanthamoebidae. A. griffini is placed in morphological group II with a 18s rRNA gene sequence type of T3. Members of this group are characterized by the presence of wrinkled ectocysts and endocysts which could be stellate, polygonal, triangular, or oval. This species is a human pathogen and may cause granulomatous amoebic encephalitis and amoebic keratitis.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119301>	C118934	Acanthamoeba hatchetti|ACANTHAMOEBA HATCHETTI	A species of motile, unicellular eukaryotic amoebae within the family of Acanthamoebidae. A. hatchetti is placed in morphological group II with a 18s rRNA gene sequence type of T11. Members of this group are characterized by the presence of wrinkled ectocysts and endocysts which could be stellate, polygonal, triangular, or oval. This species is a human pathogen and may cause granulomatous amoebic encephalitis and amoebic keratitis. It may also cause amoebic placentitis in horses.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119302>	C118934	Acanthamoeba lugdunensis|ACANTHAMOEBA LUGDUNENSIS	A species of motile, unicellular eukaryotic amoebae within the family of Acanthamoebidae. A. lugdunensis is placed in morphological group II with a 18s rRNA gene sequence type of T4. Members of this group are characterized by the presence of wrinkled ectocysts and endocysts which could be stellate, polygonal, triangular, or oval. This species is a human pathogen and may cause granulomatous amoebic encephalitis and amoebic keratitis.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119303>	C118934	Acanthamoeba palestinensis|ACANTHAMOEBA PALESTINENSIS	A species of motile, unicellular eukaryotic amoebae within the family of Acanthamoebidae. A. palestinensis is placed in morphological group III with a 18s rRNA gene sequence type of T2. Members of this group are characterized by the presence of thin, smooth ectocysts and round endocysts. This species is a human pathogen and may cause granulomatous amoebic encephalitis and amoebic keratitis.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119304>	C118934	Acanthamoeba polyphaga|ACANTHAMOEBA POLYPHAGA	A species of motile, unicellular eukaryotic amoebae within the family of Acanthamoebidae. A. polyphaga is placed in morphological group II with a 18s rRNA gene sequence type of T4. Members of this group are characterized by the presence of wrinkled ectocysts and endocysts which could be stellate, polygonal, triangular, or oval. This species is a human pathogen and may cause granulomatous amoebic encephalitis and amoebic keratitis. A. polyphaga also serves as a secondary decomposer to remineralize soil with carbon, nitrogen, and phosphorous by consuming bacterial primary decomposers.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119305>	C118934	Acanthamoeba quina|ACANTHAMOEBA QUINA	A species of motile, unicellular eukaryotic amoebae within the family of Acanthamoebidae. A. quina is placed in morphological group II with a 18s rRNA gene sequence type of T4. Members of this group are characterized by the presence of wrinkled ectocysts and endocysts which could be stellate, polygonal, triangular, or oval. This species is a human pathogen and may cause granulomatous amoebic encephalitis and amoebic keratitis.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119306>	C118934	Acanthamoeba rhysodes|ACANTHAMOEBA RHYSODES	A species of motile, unicellular eukaryotic amoebae within the family of Acanthamoebidae. A. rhysodes is placed in morphological group II with a 18s rRNA gene sequence type of T4. Members of this group are characterized by the presence of wrinkled ectocysts and endocysts which could be stellate, polygonal, triangular, or oval. This species is a human pathogen and may cause granulomatous amoebic encephalitis and amoebic keratitis.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119307>	C86079	Achromobacter ruhlandii|ACHROMOBACTER RUHLANDII|Alcaligenes ruhlandii|Hydrogenomonas ruhlandii|Pseudomonas ruhlandii	A species of Gram-negative, non-fermentative, non-hemolytic, and non-halophilic, non-spore forming rod-shaped bacteria, in the phylum Proteobacteria. This species is catalase- and oxidase-positive, urease-, phenylalanine-, deaminase-, and DNase-negative, reduces nitrate to nitrite, assimilates glucose, and does not hydrolyze esculin, gelatin and starch. A. ruhlandii is commonly found in soil.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119308>	C76200	Acinetobacter parvus|ACINETOBACTER PARVUS|Acinetobacter sp. phenon 4	A species of Gram-negative, strictly aerobic, oxidase-negative, non-fermentative, non-motile coccobacilli, in the phylum Proteobacteria. This species is glucose-non-acidifying, non-proteolytic, and is unable to oxidize D-glucose, to hydrolyze gelatin and to utilize DL-lactate, DL-4-aminobutyrate, citrate, azelate, beta-alanine and L-histidine. A. parvus is an opportunistic pathogen associated with nosocomial infections and may cause bacteremia or septicemia in humans.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119309>	C76200	Acinetobacter ursingii|ACINETOBACTER URSINGII|Acinetobacter sp. phenon 1	A species of Gram-negative, strictly aerobic, oxidase-negative, non-fermentative, non-motile coccobacilli, in the phylum Proteobacteria. This species is glucose-non-acidifying, non-proteolytic, and is unable to hydrolyze gelatin. DL-lactate, citrate, azelate, D-malate, ethanol and acetate are utilized. A. ursingii is an opportunistic pathogen associated with nosocomial infections and may cause bacteremia or septicemia in humans.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11930>	C61063	Atamestane/Toremifene			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119310>	C118935	Acremonium atrogriseum|ACREMONIUM ATROGRISEUM|Gliomastix atrogriseum|Phaeoscopulariopsis atrogrisea|Phialemonium atrogriseum	A species of white colored acremonioid fungus in the phylum Ascomycota. A. atrogriseum forms fusoid conidia in long chains.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119311>	C118939	Actinobaculum schaalii|ACTINOBACULUM SCHAALII|Actinotignum schaalii	A species of facultatively anaerobic, Gram-positive, catalase-negative, nonmotile, non-spore forming, non-acid fast, nonhemolytic, straight to curved rod-shaped bacteria, in the phylum Actinobacteria. This species ferments glucose and produces acetate, succinate and acid; hydrolyzes hippurate, but does not reduce nitrate to nitrite; and does not hydrolyze esculin, gelatin or urea. A. schaalii is a part of the commensal flora of the human genitourinary tract and may cause urinary tract infections, urosepsis, bacteremia, cellulitis, spondylodiscitis, and endocarditis in humans.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119312>	C76201	Actinomyces europaeus|ACTINOMYCES EUROPAEUS	A species of facultative anaerobic, Gram-positive, fermentative, catalase-negative, nonmotile, non-spore forming, irregular rod-shaped bacteria arranged in clusters, in the phylum Actinobacteria. This species ferments glucose, maltose, galactose and D-fructose to produce succinic acid, does not hydrolyze urea, and nitrate is not reduced to nitrite. A. europaeus is a human pathogen and may cause infections of the urinary track, of skin and of soft tissue. It has been linked to the development of breast abscesses.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119313>	C76201	Actinomyces neuii Subspecies neuii|ACTINOMYCES NEUII SUBSP. NEUII|Actinomyces neuii subsp. neuii|CDC coryneform group 1	A species of anaerobic rod-shaped or coccoid coryneform group 1 bacteria belonging to the genus Actinomyces that reduces nitrate, ferments carbohydrates, and is commonly found as a human pathogen in tissue, bone and blood stream infections.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119314>	C86121	Aerococcus sanguinicola|AEROCOCCUS SANGUINICOLA	A species of gram-positive, catalase-negative, vancomycin-susceptible coccoid bacteria belonging to the genus Aerococcus that is commonly found as a human pathogen, particularly in urinary tract infections, sepsis, and endocarditis.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119315>	C86134	Aggregatibacter aphrophilus, Beta-lactamase Negative|AGGREGATIBACTER APHROPHILUS, BETA-LACTAMASE NEGATIVE|Haemophilus aphrophilus, Beta-lactamase Negative	Any bacterial species identified as Aggregatibacter aphrophilus that does not produce the enzyme beta-lactamase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119316>	C86134	Aggregatibacter aphrophilus, Beta-lactamase Positive|AGGREGATIBACTER APHROPHILUS, BETA-LACTAMASE POSITIVE|Haemophilus aphrophilus, Beta-lactamase Positive	Any bacterial species identified as Aggregatibacter aphrophilus that produces the enzyme beta-lactamase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119317>	C86134	Aggregatibacter aphrophilus, Penicillinase Negative|AGGREGATIBACTER APHROPHILUS, PENICILLINASE NEGATIVE|Haemophilus aphrophilus, Penicillinase Negative	Any bacterial species identified as Aggregatibacter aphrophilus that does not produce the enzyme penicillinase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119318>	C86134	Aggregatibacter aphrophilus, Penicillinase Positive|AGGREGATIBACTER APHROPHILUS, PENICILLINASE POSITIVE|Haemophilus aphrophilus, Penicillinase Positive	Any bacterial species identified as Aggregatibacter aphrophilus that produces the enzyme penicillinase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119319>	C26431	Alphacoronavirus|ALPHACORONAVIRUS|Coronavirus Group 1	A genus of single-stranded, positive-sense RNA viruses in the family coronaviridae. The alphacoronavirus envelope contains glycoprotein trimers that project outward.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11931>	C63510	Exemestane/Goserelin Regimen|Exemestane-Goserelin|Exemestane/Goserelin|Goserelin-Exemestane|Goserelin/Exemestane	A regimen consisting of exemestane and goserelin that can be used for the treatment of uterine sarcoma.			Therapeutic or Preventive Procedure	
C119320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119320>	C77167	Alternaria|ALTERNARIA	A genus of dematiaceous fungi within the phylum Ascomycota that are ubiquitous in nature and are common allergens in humans. Members of the Alternaria genus produce septate, brown and filamentous hyphae, and may cause opportunistic infections in immunocompromised individuals, such as phaeohyphomycosis, onychomycosis, sinusitis, ulcerated cutaneous infections, keratitis, visceral infections and osteomyelitis.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119321>	C14329	Anaerobic Bacteria|ANAEROBIC BACTERIA|Anaerobe	Any bacteria that does not require oxygen to grow or respirate.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119322>	C119321	Anaerobic Coccus|ANAEROBIC COCCUS	Any spherical shaped bacteria that does not require oxygen to grow or respirate.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119323>	C173514|C119321	Anaerobic Gram-negative Bacteria|ANAEROBIC GRAM-NEGATIVE BACTERIA|Anaerobic Gram Negative Bacteria|Gram-negative Anaerobe	Any bacteria that does not require oxygen to grow or respirate, has a cell wall that contains low levels of peptidoglycan, and stains pink with the Gram staining technique.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119324>	C76204	Bacteroides intestinalis|BACTEROIDES INTESTINALIS	A species of indole-positive, gram negative, anaerobic rod shaped bacteria belonging to the genus Bacteroides that hydrolyses esculin and has been isolated from human feces.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119325>	C76275	Clostridium sartagoforme|CLOSTRIDIUM SARTAGOFORME	A species of gram-positive, anaerobic rod shaped bacteria belonging to the genus Clostridium that hydrolyses esculin and ferments carbohydrates, and has been isolated from human feces.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119326>	C118942	Mansonella perstans|Dipetalonema perstans|MANSONELLA PERSTANS	A nematode transmitted by the bite of Culicoides midges. The larvae mature in serous cavities, and the adult nematodes produce microfilariae that may be found in human blood and cerebrospinal fluid. Infections are typically asymptomatic.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119327>	C86629	Pandoraea sputorum|PANDORAEA SPUTORUM	A species of gram-negative, non-fermenting rod-shaped bacteria belonging to the genus Pandoraea that has been isolated in human sputum.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119328>	C118938	Pannonibacter phragmitetus|Achromobacter group B|Achromobacter group E|PANNONIBACTER PHRAGMITETUS	A species of gram-negative, catalase and oxidase positive, rod-shaped bacteria belonging to the genus Pannonibacter that has been isolated from human blood cultures.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119329>	C86644	Peptostreptococcus stomatis|PEPTOSTREPTOCOCCUS STOMATIS	A species of anaerobic, gram-positive coccoid bacteria belonging to the genus Peptostreptococcus that is weakly saccharolytic and has been isolated from the human oral cavity.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11932>	C61063	Daunorubicin/Imatinib Mesylate/Prednisone/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119330>	C86660	Prevotella bergensis|PREVOTELLA BERGENSIS	A species of gram-negative rod-shaped bacteria belonging to the genus Prevotella that is saccharolytic and ferments carbohydrates; it is a human pathogen in skin and soft tissue infections.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119331>	C181043	Coronary No Reflow at PCI Site Indicator|CANRFIND|Coronary Artery No Reflow Indicator|Coronary Artery No Reflow Indicator	An indication as to whether there is a new acute reduction in flow at the original percutaneous coronary intervention site in the coronary vessel.			Conceptual Entity	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119332>	C118940	Organ Elasticity|ELASTIC|Elasticity|Elasticity	A quantitative measurement of an organ's ability to deform in response to physiological force and return to its normal shape by passive elastic recoil.			Clinical Attribute	CDISC SDTM Gastrointestinal Test Code Terminology|CDISC SDTM Gastrointestinal Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119333>	C12401	Right Eye|OD|Oculus Dexter|Oculus Dexter (Right Eye)	The eye positioned in the right orbit.			Body Part, Organ, or Organ Component	CDISC SDTM Ophthalmic Focus of Study Specific Interest Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119334>	C12401	Left Eye|OS|Oculus Sinister|Oculus Sinister (Left Eye)	The eye positioned in the left orbit.			Body Part, Organ, or Organ Component	CDISC SDTM Ophthalmic Focus of Study Specific Interest Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119335>	C12401	Both Eyes|OU|Oculus Uterque|Oculus Uterque (Both Eyes)	Of or pertaining to both the left and right eyes,			Body Part, Organ, or Organ Component	CDISC SDTM Ophthalmic Focus of Study Specific Interest Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119336>	C48207	Femtogram per Milliliter per Kilogram per Meter Squared|fg/mL/(kg/m2)|fg/mL/(kg/m2)|fg/mL/(kg/m2)|fg/ml/(kg/m2)|fg/ml/(kg/m2)	A unit of concentration equal to femtogram per milliliter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119337>	C48207	Femtogram per Milliliter per Milligram per Day|fg/mL/(mg/d)|fg/mL/(mg/d)|fg/mL/(mg/day)|fg/mL/(mg/day)|fg/mL/(mg/day)|fg/ml/(mg/d)|fg/ml/(mg/d)	A unit of concentration equal to femtogram per milliliter, divided by milligrams per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119338>	C48207	Femtogram per Milliliter per Milligram per Kilogram|fg/mL/(mg/kg)|fg/mL/(mg/kg)|fg/mL/(mg/kg)|fg/mL/(mg/kg)|fg/ml/(mg/kg)|fg/ml/(mg/kg)	A unit of concentration equal to femtogram per milliliter, divided by milligrams per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119339>	C48207	Femtogram per Milliliter per Milligram per Kilogram per Day|fg/mL/(mg/kg/d)|fg/mL/(mg/kg/d)|fg/mL/(mg/kg/day)|fg/mL/(mg/kg/day)|fg/mL/(mg/kg/day)|fg/ml/(mg/kg/d)|fg/ml/(mg/kg/d)	A unit of concentration equal to femtogram per milliliter, divided by milligrams per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11933>	C61063	DC-Chol Liposomes/EGFR Antisense DNA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119340>	C48207	Femtogram per Milliliter per Milligram per Meter Squared|fg/mL/(mg/m2)|fg/mL/(mg/m2)|fg/mL/(mg/m2)|fg/mL/(mg/m2)|fg/ml/(mg/m2)|fg/ml/(mg/m2)	A unit of concentration equal to femtogram per milliliter, divided by milligrams per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119341>	C48207	Femtogram per Milliliter per Milligram per Meter Squared per Day|fg/mL/(mg/m2/d)|fg/mL/(mg/m2/d)|fg/mL/(mg/m2/day)|fg/mL/(mg/m2/day)|fg/mL/(mg/m2/day)|fg/ml/(mg/m2/d)|fg/ml/(mg/m2/d)	A unit of concentration equal to femtogram per milliliter, divided by milligrams per meter squared per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119342>	C92571	Femtogram per Milliliter per Microgram per Day|Picogram per Milliliter per Milligram per Day|fg/mL/(ug/d)|fg/mL/(ug/d)|fg/mL/(ug/day)|fg/mL/(ug/day)|fg/mL/(ug/day)|fg/mL/(ug/day)|fg/ml/(ug/d)|fg/ml/(ug/d)|pg/mL/(mg/d)|pg/mL/(mg/d)|pg/mL/(mg/day)|pg/mL/(mg/day)|pg/mL/(mg/day)|pg/ml/(mg/d)|pg/ml/(mg/d)	A unit of concentration equal to femtogram per milliliter, divided by micrograms per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119345>	C92571	Femtogram per Milliliter per Microgram per Meter Squared|Picogram per Milliliter per Milligram per Meter Squared|fg/mL/(ug/m2)|fg/mL/(ug/m2)|fg/mL/(ug/m2)|fg/mL/(ug/m2)|fg/mL/(ug/m2)|fg/ml/(ug/m2)|fg/ml/(ug/m2)|pg/mL/(mg/m2)|pg/mL/(mg/m2)|pg/mL/(mg/m2)|pg/mL/(mg/m2)|pg/ml/(mg/m2)|pg/ml/(mg/m2)	A unit of concentration equal to femtogram per milliliter, divided by micrograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119346>	C92571	Femtogram per Milliliter per Microgram per Meter Squared per Day|Picogram per Milliliter per Milligram per Meter Squared per Day|fg/mL/(ug/m2/d)|fg/mL/(ug/m2/d)|fg/mL/(ug/m2/day)|fg/mL/(ug/m2/day)|fg/mL/(ug/m2/day)|fg/mL/(ug/m2/day)|fg/ml/(ug/m2/d)|fg/ml/(ug/m2/d)|pg/mL/(mg/m2/d)|pg/mL/(mg/m2/d)|pg/mL/(mg/m2/day)|pg/mL/(mg/m2/day)|pg/mL/(mg/m2/day)|pg/ml/(mg/m2/d)|pg/ml/(mg/m2/d)	A unit of concentration equal to femtogram per milliliter, divided by micrograms per meter squared per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119347>	C48207	Femtogram per Milliliter per Gram|Picogram per Milliliter per Kilogram|fg/mL/g|fg/mL/g|fg/mL/g|fg/mL/g|fg/mL/g|fg/ml/g|fg/ml/g|pg/mL/kg|pg/mL/kg|pg/mL/kg|pg/mL/kg|pg/ml/kg|pg/ml/kg	A unit of concentration equal to femtogram per milliliter, divided by grams.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119348>	C48207	Femtogram per Milliliter per Kilogram|fg/mL/kg|fg/mL/kg|fg/mL/kg|fg/mL/kg|fg/ml/kg|fg/ml/kg	A unit of concentration equal to femtogram per milliliter, divided by kilograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119349>	C48207	Femtogram per Milliliter per Meter Squared|fg/mL/m2|fg/mL/m2|fg/mL/m2|fg/ml/m2|fg/ml/m2	A unit of concentration equal to femtogram per milliliter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11934>	C63359	IC Regimen|Carboplatin and Irinotecan|Carboplatin/Irinotecan|IC|Irinotecan-Carboplatin|Irinotecan/Carboplatin|Irinotecan/Carboplatin Regimen	A regimen consisting of irinotecan and carboplatin that may be used in the treatment of small cell lung cancer (SCLC) and occult primary adenocarcinomas.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C119351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119351>	C48207	Femtogram per Milliliter per Microgram|Microgram per Milliliter per Kilogram|Nanogram per Milliliter per Gram|Picogram per Milliliter per Milligram|fg/mL/ug|fg/mL/ug|fg/mL/ug|fg/mL/ug|fg/mL/ug|fg/ml/ug|fg/ml/ug|ng/mL/g|ng/mL/g|ng/mL/g|ng/mL/g|ng/ml/g|ng/ml/g|pg/mL/mg|pg/mL/mg|pg/mL/mg|pg/mL/mg|pg/ml/mg|pg/ml/mg|ug/mL/kg|ug/mL/kg|ug/mL/kg|ug/mL/kg|ug/ml/kg|ug/ml/kg	A unit of concentration equal to femtogram per milliliter, divided by micrograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119352>	C48207	Gram per Milliliter per Kilogram per Meter Squared|g/mL/(kg/m2)|g/mL/(kg/m2)|g/mL/(kg/m2)|g/ml/(kg/m2)|g/ml/(kg/m2)	A unit of concentration equal to grams per milliliter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119353>	C92571	Gram per Milliliter per Milligram per Day|Milligram per Milliliter per Microgram per Day|g/mL/(mg/d)|g/mL/(mg/d)|g/mL/(mg/day)|g/mL/(mg/day)|g/mL/(mg/day)|g/mL/(mg/day)|g/ml/(mg/d)|g/ml/(mg/d)|mg/mL/(ug/d)|mg/mL/(ug/d)|mg/mL/(ug/day)|mg/mL/(ug/day)|mg/mL/(ug/day)|mg/ml/(ug/d)|mg/ml/(ug/d)	A unit of concentration equal to grams per milliliter, divided by milligrams per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119354>	C92571	Gram per Milliliter per Milligram per Meter Squared|Milligram per Milliliter per Microgram per Meter Squared|g/mL/(mg/m2)|g/mL/(mg/m2)|g/mL/(mg/m2)|g/mL/(mg/m2)|g/mL/(mg/m2)|g/ml/(mg/m2)|g/ml/(mg/m2)|mg/mL/(ug/m2)|mg/mL/(ug/m2)|mg/mL/(ug/m2)|mg/mL/(ug/m2)|mg/ml/(ug/m2)|mg/ml/(ug/m2)	A unit of concentration equal to grams per milliliter, divided by milligrams per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119355>	C92571	Gram per Milliliter per Milligram per Meter Squared per Day|Milligram per Milliliter per Microgram per Meter Squared per Day|g/mL/(mg/m2/d)|g/mL/(mg/m2/d)|g/mL/(mg/m2/day)|g/mL/(mg/m2/day)|g/mL/(mg/m2/day)|g/mL/(mg/m2/day)|g/ml/(mg/m2/d)|g/ml/(mg/m2/d)|mg/mL/(ug/m2/d)|mg/mL/(ug/m2/d)|mg/mL/(ug/m2/day)|mg/mL/(ug/m2/day)|mg/mL/(ug/m2/day)|mg/ml/(ug/m2/d)|mg/ml/(ug/m2/d)	A unit of concentration equal to grams per milliliter, divided by milligrams per meter squared per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119356>	C48207	Gram per Milliliter per Microgram per Day|g/mL/(ug/d)|g/mL/(ug/d)|g/mL/(ug/day)|g/mL/(ug/day)|g/mL/(ug/day)|g/ml/(ug/d)|g/ml/(ug/d)	A unit of concentration equal to grams per milliliter, divided by micrograms per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119357>	C48207	Gram per Milliliter per Microgram per Kilogram|g/mL/(ug/kg)|g/mL/(ug/kg)|g/mL/(ug/kg)|g/mL/(ug/kg)|g/ml/(ug/kg)|g/ml/(ug/kg)	A unit of concentration equal to grams per milliliter, divided by micrograms per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119358>	C48207	Gram per Milliliter per Microgram per Kilogram per Day|g/mL/(ug/kg/d)|g/mL/(ug/kg/d)|g/mL/(ug/kg/day)|g/mL/(ug/kg/day)|g/mL/(ug/kg/day)|g/ml/(ug/kg/d)|g/ml/(ug/kg/d)	A unit of concentration equal to grams per milliliter, divided by micrograms per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119359>	C48207	Gram per Milliliter per Microgram per Meter Squared|g/mL/(ug/m2)|g/mL/(ug/m2)|g/mL/(ug/m2)|g/mL/(ug/m2)|g/ml/(ug/m2)|g/ml/(ug/m2)	A unit of concentration equal to grams per milliliter, divided by micrograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11935>	C61063	Calcitriol/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119360>	C48207	Gram per Milliliter per Microgram per Meter Squared per Day|g/mL/(ug/m2/d)|g/mL/(ug/m2/d)|g/mL/(ug/m2/day)|g/mL/(ug/m2/day)|g/mL/(ug/m2/day)|g/ml/(ug/m2/d)|g/ml/(ug/m2/d)	A unit of concentration equal to grams per milliliter, divided by micrograms per meter squared per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119361>	C48207	Gram per Milliliter per Gram|Microgram per Milliliter per Microgram|Milligram per Milliliter per Milligram|g/mL/g|g/mL/g|g/mL/g|g/mL/g|g/mL/g|g/ml/g|g/ml/g|mg/mL/mg|mg/mL/mg|mg/mL/mg|mg/mL/mg|mg/ml/mg|mg/ml/mg|ug/mL/ug|ug/mL/ug|ug/mL/ug|ug/mL/ug|ug/ml/ug|ug/ml/ug	A unit of concentration equal to grams per milliliter, divided by grams.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119363>	C48207	Gram per Milliliter per Meter Squared|g/mL/m2|g/mL/m2|g/mL/m2|g/ml/m2|g/ml/m2	A unit of concentration equal to grams per milliliter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119364>	C48207	Gram per Milliliter per Milligram|Milligram per Milliliter per Microgram|g/mL/mg|g/mL/mg|g/mL/mg|g/mL/mg|g/mL/mg|g/ml/mg|g/ml/mg|mg/mL/ug|mg/mL/ug|mg/mL/ug|mg/mL/ug|mg/ml/ug|mg/ml/ug	A unit of concentration equal to grams per milliliter, divided by milligrams.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119365>	C48207	Gram per Milliliter per Microgram|g/mL/ug|g/mL/ug|g/mL/ug|g/mL/ug|g/ml/ug|g/ml/ug	A unit of concentration equal to grams per milliliter, divided by micrograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119366>	C48207	International Unit per Milliliter per Kilogram per Meter Squared|IU/mL/(kg/m2)|IU/mL/(kg/m2)|[IU]/mL/(kg/m2)|[IU]/mL/(kg/m2)|[IU]/ml/(kg/m2)|[IU]/ml/(kg/m2)|[iU]/mL/(kg/m2)|[iU]/mL/(kg/m2)|[iU]/ml/(kg/m2)|[iU]/ml/(kg/m2)	A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119367>	C92571	International Unit per Milliliter per Milligram per Day|IU/mL/(mg/day)|IU/mL/(mg/day)|IU/mL/(mg/day)|IU/mL/(mg/day)|Milli-International Unit per Milliliter per Microgram per Day|[IU]/mL/(mg/d)|[IU]/mL/(mg/d)|[IU]/ml/(mg/d)|[IU]/ml/(mg/d)|[iU]/mL/(mg/d)|[iU]/mL/(mg/d)|[iU]/ml/(mg/d)|[iU]/ml/(mg/d)|mIU/mL/(ug/day)|mIU/mL/(ug/day)|mIU/mL/(ug/day)|m[IU]/mL/(ug/d)|m[IU]/mL/(ug/d)|m[IU]/ml/(ug/d)|m[IU]/ml/(ug/d)|m[iU]/mL/(ug/d)|m[iU]/mL/(ug/d)|m[iU]/ml/(ug/d)|m[iU]/ml/(ug/d)	A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by milligrams per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119368>	C92571	International Unit per Milliliter per Milligram per Kilogram|IU/mL/(mg/kg)|IU/mL/(mg/kg)|IU/mL/(mg/kg)|IU/mL/(mg/kg)|Milli-International Unit per Milliliter per Microgram per Kilogram|[IU]/mL/(mg/kg)|[IU]/mL/(mg/kg)|[IU]/ml/(mg/kg)|[IU]/ml/(mg/kg)|[iU]/mL/(mg/kg)|[iU]/mL/(mg/kg)|[iU]/ml/(mg/kg)|[iU]/ml/(mg/kg)|mIU/mL/(ug/kg)|mIU/mL/(ug/kg)|mIU/mL/(ug/kg)|m[IU]/mL/(ug/kg)|m[IU]/mL/(ug/kg)|m[IU]/ml/(ug/kg)|m[IU]/ml/(ug/kg)|m[iU]/mL/(ug/kg)|m[iU]/mL/(ug/kg)|m[iU]/ml/(ug/kg)|m[iU]/ml/(ug/kg)	A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by milligrams per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119369>	C92571	International Unit per Milliliter per Milligram per Kilogram per Day|IU/mL/(mg/kg/day)|IU/mL/(mg/kg/day)|IU/mL/(mg/kg/day)|IU/mL/(mg/kg/day)|Milli-International Unit per Milliliter per Microgram per Kilogram per Day|[IU]/mL/(mg/kg/d)|[IU]/mL/(mg/kg/d)|[IU]/ml/(mg/kg/d)|[IU]/ml/(mg/kg/d)|[iU]/mL/(mg/kg/d)|[iU]/mL/(mg/kg/d)|[iU]/ml/(mg/kg/d)|[iU]/ml/(mg/kg/d)|mIU/mL/(ug/kg/day)|mIU/mL/(ug/kg/day)|mIU/mL/(ug/kg/day)|m[IU]/mL/(ug/kg/d)|m[IU]/mL/(ug/kg/d)|m[IU]/ml/(ug/kg/d)|m[IU]/ml/(ug/kg/d)|m[iU]/mL/(ug/kg/d)|m[iU]/mL/(ug/kg/d)|m[iU]/ml/(ug/kg/d)|m[iU]/ml/(ug/kg/d)	A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by milligrams per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11936>	C61063	Etoposide/Fluorouracil-Uracil/Leucovorin Calcium			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119370>	C92571	International Unit per Milliliter per Milligram per Meter Squared|IU/mL/(mg/m2)|IU/mL/(mg/m2)|IU/mL/(mg/m2)|IU/mL/(mg/m2)|Milli-International Unit per Milliliter per Microgram per Meter Squared|[IU]/mL/(mg/m2)|[IU]/mL/(mg/m2)|[IU]/ml/(mg/m2)|[IU]/ml/(mg/m2)|[iU]/mL/(mg/m2)|[iU]/mL/(mg/m2)|[iU]/ml/(mg/m2)|[iU]/ml/(mg/m2)|mIU/mL/(ug/m2)|mIU/mL/(ug/m2)|mIU/mL/(ug/m2)|m[IU]/mL/(ug/m2)|m[IU]/mL/(ug/m2)|m[IU]/ml/(ug/m2)|m[IU]/ml/(ug/m2)|m[iU]/mL/(ug/m2)|m[iU]/mL/(ug/m2)|m[iU]/ml/(ug/m2)|m[iU]/ml/(ug/m2)	A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by milligrams per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119371>	C92571	International Unit per Milliliter per Milligram per Meter Squared per Day|IU/mL/(mg/m2/day)|IU/mL/(mg/m2/day)|IU/mL/(mg/m2/day)|IU/mL/(mg/m2/day)|Milli-International Unit per Milliliter per Microgram per Meter Squared per Day|[IU]/mL/(mg/m2/d)|[IU]/mL/(mg/m2/d)|[IU]/ml/(mg/m2/d)|[IU]/ml/(mg/m2/d)|[iU]/mL/(mg/m2/d)|[iU]/mL/(mg/m2/d)|[iU]/ml/(mg/m2/d)|[iU]/ml/(mg/m2/d)|mIU/mL/(ug/m2/day)|mIU/mL/(ug/m2/day)|mIU/mL/(ug/m2/day)|m[IU]/mL/(ug/m2/d)|m[IU]/mL/(ug/m2/d)|m[IU]/ml/(ug/m2/d)|m[IU]/ml/(ug/m2/d)|m[iU]/mL/(ug/m2/d)|m[iU]/mL/(ug/m2/d)|m[iU]/ml/(ug/m2/d)|m[iU]/ml/(ug/m2/d)	A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by milligrams per meter squared per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119372>	C48207	International Unit per Milliliter per Microgram per Day|IU/mL/(ug/day)|IU/mL/(ug/day)|IU/mL/(ug/day)|[IU]/mL/(ug/d)|[IU]/mL/(ug/d)|[IU]/ml/(ug/d)|[IU]/ml/(ug/d)|[iU]/mL/(ug/d)|[iU]/mL/(ug/d)|[iU]/ml/(ug/d)|[iU]/ml/(ug/d)	A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by micrograms per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119373>	C48207	International Unit per Milliliter per Microgram per Kilogram|IU/mL/(ug/kg)|IU/mL/(ug/kg)|IU/mL/(ug/kg)|[IU]/mL/(ug/kg)|[IU]/mL/(ug/kg)|[IU]/ml/(ug/kg)|[IU]/ml/(ug/kg)|[iU]/mL/(ug/kg)|[iU]/mL/(ug/kg)|[iU]/ml/(ug/kg)|[iU]/ml/(ug/kg)	A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by micrograms per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119374>	C48207	International Unit per Milliliter per Microgram per Kilogram per Day|IU/mL/(ug/kg/day)|IU/mL/(ug/kg/day)|IU/mL/(ug/kg/day)|[IU]/mL/(ug/kg/d)|[IU]/mL/(ug/kg/d)|[IU]/ml/(ug/kg/d)|[IU]/ml/(ug/kg/d)|[iU]/mL/(ug/kg/d)|[iU]/mL/(ug/kg/d)|[iU]/ml/(ug/kg/d)|[iU]/ml/(ug/kg/d)	A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by micrograms per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119375>	C48207	International Unit per Milliliter per Microgram per Meter Squared|IU/mL/(ug/m2)|IU/mL/(ug/m2)|IU/mL/(ug/m2)|[IU]/mL/(ug/m2)|[IU]/mL/(ug/m2)|[IU]/ml/(ug/m2)|[IU]/ml/(ug/m2)|[iU]/mL/(ug/m2)|[iU]/mL/(ug/m2)|[iU]/ml/(ug/m2)|[iU]/ml/(ug/m2)	A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by micrograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119376>	C48207	International Unit per Milliliter per Microgram per Meter Squared per Day|IU/mL/(ug/m2/day)|IU/mL/(ug/m2/day)|IU/mL/(ug/m2/day)|[IU]/mL/(ug/m2/d)|[IU]/mL/(ug/m2/d)|[IU]/ml/(ug/m2/d)|[IU]/ml/(ug/m2/d)|[iU]/mL/(ug/m2/d)|[iU]/mL/(ug/m2/d)|[iU]/ml/(ug/m2/d)|[iU]/ml/(ug/m2/d)	A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by micrograms per meter squared per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119377>	C48207	International Unit per Milliliter per Gram|IU/mL/g|IU/mL/g|IU/mL/g|IU/mL/g|Micro-International Units per Milliliter per Microgram|Milli-International Unit per Milliliter per Milligram|[IU]/mL/g|[IU]/mL/g|[IU]/ml/g|[IU]/ml/g|[iU]/mL/g|[iU]/mL/g|[iU]/ml/g|[iU]/ml/g|mIU/mL/mg|mIU/mL/mg|mIU/mL/mg|m[IU]/mL/mg|m[IU]/mL/mg|m[IU]/ml/mg|m[IU]/ml/mg|m[iU]/mL/mg|m[iU]/mL/mg|m[iU]/ml/mg|m[iU]/ml/mg|uIU/mL/ug|uIU/mL/ug|uIU/mL/ug|u[IU]/mL/ug|u[IU]/mL/ug|u[IU]/ml/ug|u[IU]/ml/ug|u[iU]/mL/ug|u[iU]/mL/ug|u[iU]/ml/ug|u[iU]/ml/ug	A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by grams.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119378>	C48207	International Unit per Milliliter per Kilogram|IU/mL/kg|IU/mL/kg|IU/mL/kg|IU/mL/kg|Micro-International Units per Milliliter per Milligram|Milli-International Unit per Milliliter per Gram|[IU]/mL/kg|[IU]/mL/kg|[IU]/ml/kg|[IU]/ml/kg|[iU]/mL/kg|[iU]/mL/kg|[iU]/ml/kg|[iU]/ml/kg|mIU/mL/g|mIU/mL/g|mIU/mL/g|m[IU]/mL/g|m[IU]/mL/g|m[IU]/ml/g|m[IU]/ml/g|m[iU]/mL/g|m[iU]/mL/g|m[iU]/ml/g|m[iU]/ml/g|uIU/mL/mg|uIU/mL/mg|uIU/mL/mg|u[IU]/mL/mg|u[IU]/mL/mg|u[IU]/ml/mg|u[IU]/ml/mg|u[iU]/mL/mg|u[iU]/mL/mg|u[iU]/ml/mg|u[iU]/ml/mg	A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by kilograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119379>	C48207	International Unit per Milliliter per Meter Squared|IU/mL/m2|IU/mL/m2|[IU]/mL/m2|[IU]/mL/m2|[IU]/ml/m2|[IU]/ml/m2|[iU]/mL/m2|[iU]/mL/m2|[iU]/ml/m2|[iU]/ml/m2	A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11937>	C61063	Epirubicin/Tamoxifen			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119380>	C48207	International Unit per Milliliter per Milligram|IU/mL/mg|IU/mL/mg|IU/mL/mg|IU/mL/mg|Milli-International Unit per Milliliter per Microgram|[IU]/mL/mg|[IU]/mL/mg|[IU]/ml/mg|[IU]/ml/mg|[iU]/mL/mg|[iU]/mL/mg|[iU]/ml/mg|[iU]/ml/mg|mIU/mL/ug|mIU/mL/ug|mIU/mL/ug|m[IU]/mL/ug|m[IU]/mL/ug|m[IU]/ml/ug|m[IU]/ml/ug|m[iU]/mL/ug|m[iU]/mL/ug|m[iU]/ml/ug|m[iU]/ml/ug	A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by milligrams.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119381>	C48207	International Unit per Milliliter per Microgram|IU/mL/ug|IU/mL/ug|IU/mL/ug|[IU]/mL/ug|[IU]/mL/ug|[IU]/ml/ug|[IU]/ml/ug|[iU]/mL/ug|[iU]/mL/ug|[iU]/ml/ug|[iU]/ml/ug	A unit of concentration (biologic activity) equal to one international unit per milliliter, divided by micrograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119382>	C48207	Milligram per Milliliter per Kilogram per Meter Squared|mg/mL/(kg/m2)|mg/mL/(kg/m2)|mg/mL/(kg/m2)|mg/ml/(kg/m2)|mg/ml/(kg/m2)	A unit of concentration equal to milligrams per milliliter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119383>	C48207	Milligram per Milliliter per Milligram per Day|Microgram per Milliliter per Microgram per Day|mg/mL/(mg/d)|mg/mL/(mg/d)|mg/mL/(mg/day)|mg/mL/(mg/day)|mg/mL/(mg/day)|mg/mL/(mg/day)|mg/ml/(mg/d)|mg/ml/(mg/d)|ug/mL/(ug/d)|ug/mL/(ug/d)|ug/mL/(ug/day)|ug/mL/(ug/day)|ug/mL/(ug/day)|ug/ml/(ug/d)|ug/ml/(ug/d)	A unit of concentration equal to milligrams per milliliter, divided by milligrams per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119384>	C92571	Milligram per Milliliter per Milligram per Meter Squared|Microgram per Milliliter per Microgram per Meter Squared|mg/mL/(mg/m2)|mg/mL/(mg/m2)|mg/mL/(mg/m2)|mg/mL/(mg/m2)|mg/mL/(mg/m2)|mg/ml/(mg/m2)|mg/ml/(mg/m2)|ug/mL/(ug/m2)|ug/mL/(ug/m2)|ug/mL/(ug/m2)|ug/mL/(ug/m2)|ug/ml/(ug/m2)|ug/ml/(ug/m2)	A unit of concentration equal to milligrams per milliliter, divided by milligrams per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119385>	C92571	Milligram per Milliliter per Milligram per Meter Squared per Day|Microgram per Milliliter per Microgram per Meter Squared per Day|mg/mL/(mg/m2/d)|mg/mL/(mg/m2/d)|mg/mL/(mg/m2/day)|mg/mL/(mg/m2/day)|mg/mL/(mg/m2/day)|mg/mL/(mg/m2/day)|mg/ml/(mg/m2/d)|mg/ml/(mg/m2/d)|ug/mL/(ug/m2/d)|ug/mL/(ug/m2/d)|ug/mL/(ug/m2/day)|ug/mL/(ug/m2/day)|ug/mL/(ug/m2/day)|ug/ml/(ug/m2/d)|ug/ml/(ug/m2/d)	A unit of concentration equal to milligrams per milliliter, divided by milligrams per meter squared per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11938>	C61063	Docetaxel/Tamoxifen			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119393>	C48207	Milligram per Milliliter per Meter Squared|mg/mL/m2|mg/mL/m2|mg/mL/m2|mg/ml/m2|mg/ml/m2	A unit of concentration equal to milligrams per milliliter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119396>	C48207	Milli-International Unit per Milliliter per Kilogram per Meter Squared|mIU/mL/(kg/m2)|mIU/mL/(kg/m2)|m[IU]/mL/(kg/m2)|m[IU]/mL/(kg/m2)|m[IU]/ml/(kg/m2)|m[IU]/ml/(kg/m2)|m[iU]/mL/(kg/m2)|m[iU]/mL/(kg/m2)|m[iU]/ml/(kg/m2)|m[iU]/ml/(kg/m2)	A unit of concentration (biologic activity) equal to one milli-international unit per milliliter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119397>	C92571	Milli-International Unit per Milliliter per Milligram per Day|Micro-International Units per Milliliter per Microgram per Day|mIU/mL/(mg/day)|mIU/mL/(mg/day)|mIU/mL/(mg/day)|mIU/mL/(mg/day)|m[IU]/mL/(mg/d)|m[IU]/mL/(mg/d)|m[IU]/ml/(mg/d)|m[IU]/ml/(mg/d)|m[iU]/mL/(mg/d)|m[iU]/mL/(mg/d)|m[iU]/ml/(mg/d)|m[iU]/ml/(mg/d)|uIU/mL/(ug/day)|uIU/mL/(ug/day)|uIU/mL/(ug/day)|u[IU]/mL/(ug/d)|u[IU]/mL/(ug/d)|u[IU]/ml/(ug/d)|u[IU]/ml/(ug/d)|u[iU]/mL/(ug/d)|u[iU]/mL/(ug/d)|u[iU]/ml/(ug/d)|u[iU]/ml/(ug/d)	A unit of concentration (biologic activity) equal to one milli-international unit per milliliter, divided by milligrams per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119398>	C48207	Milli-International Unit per Milliliter per Milligram per Kilogram|Micro-International Units per Milliliter per Microgram per Kilogram|mIU/mL/(mg/kg)|mIU/mL/(mg/kg)|mIU/mL/(mg/kg)|mIU/mL/(mg/kg)|m[IU]/mL/(mg/kg)|m[IU]/mL/(mg/kg)|m[IU]/ml/(mg/kg)|m[IU]/ml/(mg/kg)|m[iU]/mL/(mg/kg)|m[iU]/mL/(mg/kg)|m[iU]/ml/(mg/kg)|m[iU]/ml/(mg/kg)|uIU/mL/(ug/kg)|uIU/mL/(ug/kg)|uIU/mL/(ug/kg)|u[IU]/mL/(ug/kg)|u[IU]/mL/(ug/kg)|u[IU]/ml/(ug/kg)|u[IU]/ml/(ug/kg)|u[iU]/mL/(ug/kg)|u[iU]/mL/(ug/kg)|u[iU]/ml/(ug/kg)|u[iU]/ml/(ug/kg)	A unit of concentration (biologic activity) equal to one milli-international unit per milliliter, divided by milligrams per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119399>	C92571	Milli-International Unit per Milliliter per Milligram per Kilogram per Day|Micro-International Units per Milliliter per Microgram per Kilogram per Day|mIU/mL/(mg/kg/day)|mIU/mL/(mg/kg/day)|mIU/mL/(mg/kg/day)|mIU/mL/(mg/kg/day)|m[IU]/mL/(mg/kg/d)|m[IU]/mL/(mg/kg/d)|m[IU]/ml/(mg/kg/d)|m[IU]/ml/(mg/kg/d)|m[iU]/mL/(mg/kg/d)|m[iU]/mL/(mg/kg/d)|m[iU]/ml/(mg/kg/d)|m[iU]/ml/(mg/kg/d)|uIU/mL/(ug/kg/day)|uIU/mL/(ug/kg/day)|uIU/mL/(ug/kg/day)|u[IU]/mL/(ug/kg/d)|u[IU]/mL/(ug/kg/d)|u[IU]/ml/(ug/kg/d)|u[IU]/ml/(ug/kg/d)|u[iU]/mL/(ug/kg/d)|u[iU]/mL/(ug/kg/d)|u[iU]/ml/(ug/kg/d)|u[iU]/ml/(ug/kg/d)	A unit of concentration (biologic activity) equal to one milli-international unit per milliliter, divided by milligrams per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11939>	C61007	Calcitriol/Dexamethasone			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1193>	C97453	Foscarnet Sodium|FOSCARNET SODIUM|Foscavir|Foscavir|Phosphonoformate Trisodium|foscarnet sodium|phosphonoformate trisodium	The trisodium salt of a synthetic organic analogue of inorganic pyrophosphate with antiviral activity. Foscarnet selectively blocks the pyrophosphate binding site of herpesvirus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases. This agent does not require phosphorylation by thymidine kinase (TK) or other kinases and therefore is active in vitro against herpes simplex virus (HSV) TK deficient mutants and cytomegalovirus (CMV) UL97 mutants. Because foscarnet crosses the blood brain barrier, it may be used in the treatment of viral infections of the CNS.	Foscarnet Sodium		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C119400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119400>	C48207	Milli-International Unit per Milliliter per Milligram per Meter Squared|Micro-International Units per Milliliter per Microgram per Meter Squared|mIU/mL/(mg/m2)|mIU/mL/(mg/m2)|mIU/mL/(mg/m2)|mIU/mL/(mg/m2)|m[IU]/mL/(mg/m2)|m[IU]/mL/(mg/m2)|m[IU]/ml/(mg/m2)|m[IU]/ml/(mg/m2)|m[iU]/mL/(mg/m2)|m[iU]/mL/(mg/m2)|m[iU]/ml/(mg/m2)|m[iU]/ml/(mg/m2)|uIU/mL/(ug/m2)|uIU/mL/(ug/m2)|uIU/mL/(ug/m2)|u[IU]/mL/(ug/m2)|u[IU]/mL/(ug/m2)|u[IU]/ml/(ug/m2)|u[IU]/ml/(ug/m2)|u[iU]/mL/(ug/m2)|u[iU]/mL/(ug/m2)|u[iU]/ml/(ug/m2)|u[iU]/ml/(ug/m2)	A unit of concentration (biologic activity) equal to one milli-international unit per milliliter, divided by milligrams per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119401>	C92571	Milli-International Unit per Milliliter per Milligram per Meter Squared per Day|Micro-International Units per Milliliter per Microgram per Meter Squared per Day|mIU/mL/(mg/m2/day)|mIU/mL/(mg/m2/day)|mIU/mL/(mg/m2/day)|mIU/mL/(mg/m2/day)|m[IU]/mL/(mg/m2/d)|m[IU]/mL/(mg/m2/d)|m[IU]/ml/(mg/m2/d)|m[IU]/ml/(mg/m2/d)|m[iU]/mL/(mg/m2/d)|m[iU]/mL/(mg/m2/d)|m[iU]/ml/(mg/m2/d)|m[iU]/ml/(mg/m2/d)|uIU/mL/(ug/m2/day)|uIU/mL/(ug/m2/day)|uIU/mL/(ug/m2/day)|u[IU]/mL/(ug/m2/d)|u[IU]/mL/(ug/m2/d)|u[IU]/ml/(ug/m2/d)|u[IU]/ml/(ug/m2/d)|u[iU]/mL/(ug/m2/d)|u[iU]/mL/(ug/m2/d)|u[iU]/ml/(ug/m2/d)|u[iU]/ml/(ug/m2/d)	A unit of concentration (biologic activity) equal to one milli-international unit per milliliter, divided by milligrams per meter squared per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119408>	C48207	Milli-International Unit per Milliliter per Kilogram|Micro-International Units per Milliliter per Gram|mIU/mL/kg|mIU/mL/kg|mIU/mL/kg|mIU/mL/kg|m[IU]/mL/kg|m[IU]/mL/kg|m[IU]/ml/kg|m[IU]/ml/kg|m[iU]/mL/kg|m[iU]/mL/kg|m[iU]/ml/kg|m[iU]/ml/kg|uIU/mL/g|uIU/mL/g|uIU/mL/g|u[IU]/mL/g|u[IU]/mL/g|u[IU]/ml/g|u[IU]/ml/g|u[iU]/mL/g|u[iU]/mL/g|u[iU]/ml/g|u[iU]/ml/g	A unit of concentration (biologic activity) equal to one milli-international unit per milliliter, divided by kilograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119409>	C48207	Milli-International Unit per Milliliter per Meter Squared|mIU/mL/m2|mIU/mL/m2|m[IU]/mL/m2|m[IU]/mL/m2|m[IU]/ml/m2|m[IU]/ml/m2|m[iU]/mL/m2|m[iU]/mL/m2|m[iU]/ml/m2|m[iU]/ml/m2	A unit of concentration (biologic activity) equal to one milli-international unit per milliliter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11940>	C61007	Fludarabine/Thalidomide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119412>	C48207	Millimole per Liter per Kilogram per Meter Squared|mmol/L/(kg/m2)|mmol/L/(kg/m2)|mmol/L/(kg/m2)|mmol/l/(kg/m2)|mmol/l/(kg/m2)	A unit of concentration equal to millimoles per liter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119413>	C92571	Millimole per Liter per Milligram per Day|Micromole per Liter per Microgram per Day|mmol/L/(mg/d)|mmol/L/(mg/d)|mmol/L/(mg/day)|mmol/L/(mg/day)|mmol/L/(mg/day)|mmol/L/(mg/day)|mmol/l/(mg/d)|mmol/l/(mg/d)|umol/L/(ug/d)|umol/L/(ug/d)|umol/L/(ug/day)|umol/L/(ug/day)|umol/L/(ug/day)|umol/l/(ug/d)|umol/l/(ug/d)	A unit of concentration equal to millimoles per liter, divided by milligrams per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119414>	C48207	Millimole per Liter per Milligram per Kilogram|Micromole per Liter per Microgram per Kilogram|mmol/L/(mg/kg)|mmol/L/(mg/kg)|mmol/L/(mg/kg)|mmol/L/(mg/kg)|mmol/L/(mg/kg)|mmol/l/(mg/kg)|mmol/l/(mg/kg)|umol/L/(ug/kg)|umol/L/(ug/kg)|umol/L/(ug/kg)|umol/L/(ug/kg)|umol/l/(ug/kg)|umol/l/(ug/kg)	A unit of concentration equal to millimoles per liter, divided by milligrams per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119415>	C92571	Millimole per Liter per Milligram per Kilogram per Day|Micromole per Liter per Microgram per Kilogram per Day|mmol/L/(mg/kg/d)|mmol/L/(mg/kg/d)|mmol/L/(mg/kg/day)|mmol/L/(mg/kg/day)|mmol/L/(mg/kg/day)|mmol/L/(mg/kg/day)|mmol/l/(mg/kg/d)|mmol/l/(mg/kg/d)|umol/L/(ug/kg/d)|umol/L/(ug/kg/d)|umol/L/(ug/kg/day)|umol/L/(ug/kg/day)|umol/L/(ug/kg/day)|umol/l/(ug/kg/d)|umol/l/(ug/kg/d)	A unit of concentration equal to millimoles per liter, divided by milligrams per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119416>	C92571	Millimole per Liter per Milligram per Meter Squared|Micromole per Liter per Microgram per Meter Squared|mmol/L/(mg/m2)|mmol/L/(mg/m2)|mmol/L/(mg/m2)|mmol/L/(mg/m2)|mmol/L/(mg/m2)|mmol/l/(mg/m2)|mmol/l/(mg/m2)|umol/L/(ug/m2)|umol/L/(ug/m2)|umol/L/(ug/m2)|umol/L/(ug/m2)|umol/l/(ug/m2)|umol/l/(ug/m2)	A unit of concentration equal to millimoles per liter, divided by milligrams per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119417>	C92571	Millimole per Liter per Milligram per Meter Squared per Day|Micromole per Liter per Microgram per Meter Squared per Day|mmol/L/(mg/m2/d)|mmol/L/(mg/m2/d)|mmol/L/(mg/m2/day)|mmol/L/(mg/m2/day)|mmol/L/(mg/m2/day)|mmol/L/(mg/m2/day)|mmol/l/(mg/m2/d)|mmol/l/(mg/m2/d)|umol/L/(ug/m2/d)|umol/L/(ug/m2/d)|umol/L/(ug/m2/day)|umol/L/(ug/m2/day)|umol/L/(ug/m2/day)|umol/l/(ug/m2/d)|umol/l/(ug/m2/d)	A unit of concentration equal to millimoles per liter, divided by milligrams per meter squared per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119418>	C92571	Millimole per Liter per Microgram per Day|Mole per Liter per Milligram per Day|mmol/L/(ug/d)|mmol/L/(ug/d)|mmol/L/(ug/day)|mmol/L/(ug/day)|mmol/L/(ug/day)|mmol/L/(ug/day)|mmol/l/(ug/d)|mmol/l/(ug/d)|mol/L/(mg/d)|mol/L/(mg/d)|mol/L/(mg/day)|mol/L/(mg/day)|mol/L/(mg/day)|mol/l/(mg/d)|mol/l/(mg/d)	A unit of concentration equal to millimoles per liter, divided by micrograms per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119419>	C48207	Millimole per Liter per Microgram per Kilogram|Mole per Liter per Milligram per Kilogram|mmol/L/(ug/kg)|mmol/L/(ug/kg)|mmol/L/(ug/kg)|mmol/L/(ug/kg)|mmol/L/(ug/kg)|mmol/l/(ug/kg)|mmol/l/(ug/kg)|mol/L/(mg/kg)|mol/L/(mg/kg)|mol/L/(mg/kg)|mol/L/(mg/kg)|mol/l/(mg/kg)|mol/l/(mg/kg)	A unit of concentration equal to millimoles per liter, divided by micrograms per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11941>	C61007	Carboplatin/Etoposide Phosphate/Ifosfamide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119420>	C92571	Millimole per Liter per Microgram per Kilogram per Day|Mole per Liter per Milligram per Kilogram per Day|mmol/L/(ug/kg/d)|mmol/L/(ug/kg/d)|mmol/L/(ug/kg/day)|mmol/L/(ug/kg/day)|mmol/L/(ug/kg/day)|mmol/L/(ug/kg/day)|mmol/l/(ug/kg/d)|mmol/l/(ug/kg/d)|mol/L/(mg/kg/d)|mol/L/(mg/kg/d)|mol/L/(mg/kg/day)|mol/L/(mg/kg/day)|mol/L/(mg/kg/day)|mol/l/(mg/kg/d)|mol/l/(mg/kg/d)	A unit of concentration equal to millimoles per liter, divided by micrograms per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119421>	C92571	Millimole per Liter per Microgram per Meter Squared|Mole per Liter per Milligram per Meter Squared|mmol/L/(ug/m2)|mmol/L/(ug/m2)|mmol/L/(ug/m2)|mmol/L/(ug/m2)|mmol/L/(ug/m2)|mmol/l/(ug/m2)|mmol/l/(ug/m2)|mol/L/(mg/m2)|mol/L/(mg/m2)|mol/L/(mg/m2)|mol/L/(mg/m2)|mol/l/(mg/m2)|mol/l/(mg/m2)	A unit of concentration equal to millimoles per liter, divided by micrograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119422>	C92571	Millimole per Liter per Microgram per Meter Squared per Day|Mole per Liter per Milligram per Meter Squared per Day|mmol/L/(ug/m2/d)|mmol/L/(ug/m2/d)|mmol/L/(ug/m2/day)|mmol/L/(ug/m2/day)|mmol/L/(ug/m2/day)|mmol/L/(ug/m2/day)|mmol/l/(ug/m2/d)|mmol/l/(ug/m2/d)|mol/L/(mg/m2/d)|mol/L/(mg/m2/d)|mol/L/(mg/m2/day)|mol/L/(mg/m2/day)|mol/L/(mg/m2/day)|mol/l/(mg/m2/d)|mol/l/(mg/m2/d)	A unit of concentration equal to millimoles per liter, divided by micrograms per meter squared per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119423>	C48207	Millimole per Liter per Gram|Micromole per Liter per Milligram|Mole per Liter per Kilogram|Nanomole per Liter per Microgram|mmol/L/g|mmol/L/g|mmol/L/g|mmol/L/g|mmol/L/g|mmol/l/g|mmol/l/g|mol/L/kg|mol/L/kg|mol/L/kg|mol/L/kg|mol/l/kg|mol/l/kg|nmol/L/ug|nmol/L/ug|nmol/L/ug|nmol/L/ug|nmol/l/ug|nmol/l/ug|umol/L/mg|umol/L/mg|umol/L/mg|umol/L/mg|umol/l/mg|umol/l/mg	A unit of concentration equal to millimoles per liter, divided by grams.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119425>	C48207	Millimole per Liter per Meter Squared|mmol/L/m2|mmol/L/m2|mmol/L/m2|mmol/l/m2|mmol/l/m2	A unit of concentration equal to millimoles per liter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119426>	C48207	Millimole per Liter per Milligram|Micromole per Liter per Microgram|Mole per Liter per Gram|mmol/L/mg|mmol/L/mg|mmol/L/mg|mmol/L/mg|mmol/L/mg|mmol/l/mg|mmol/l/mg|mol/L/g|mol/L/g|mol/L/g|mol/L/g|mol/l/g|mol/l/g|umol/L/ug|umol/L/ug|umol/L/ug|umol/L/ug|umol/l/ug|umol/l/ug	A unit of concentration equal to millimoles per liter, divided by milligrams.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119427>	C48207	Millimole per Liter per Microgram|Mole per Liter per Milligram|mmol/L/ug|mmol/L/ug|mmol/L/ug|mmol/L/ug|mmol/L/ug|mmol/l/ug|mmol/l/ug|mol/L/mg|mol/L/mg|mol/L/mg|mol/L/mg|mol/l/mg|mol/l/mg	A unit of concentration equal to millimoles per liter, divided by micrograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119428>	C48207	Mole per Liter per Kilogram per Meter Squared|mol/L/(kg/m2)|mol/L/(kg/m2)|mol/L/(kg/m2)|mol/l/(kg/m2)|mol/l/(kg/m2)	A unit of concentration equal to moles per liter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11942>	C61063	Bevacizumab/Fluorouracil/Leucovorin Calcium|Bevacizumab-Fluorouracil-Leucovorin Calcium|Bevacizumab-Fluorouracil-Leucovorin Calcium Regimen			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119434>	C48207	Mole per Liter per Microgram per Day|mol/L/(ug/d)|mol/L/(ug/d)|mol/L/(ug/day)|mol/L/(ug/day)|mol/L/(ug/day)|mol/l/(ug/d)|mol/l/(ug/d)	A unit of concentration equal to moles per liter, divided by micrograms per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119435>	C48207	Mole per Liter per Microgram per Kilogram|mol/L/(ug/kg)|mol/L/(ug/kg)|mol/L/(ug/kg)|mol/L/(ug/kg)|mol/l/(ug/kg)|mol/l/(ug/kg)	A unit of concentration equal to moles per liter, divided by micrograms per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119436>	C48207	Mole per Liter per Microgram per Kilogram per Day|mol/L/(ug/kg/d)|mol/L/(ug/kg/d)|mol/L/(ug/kg/day)|mol/L/(ug/kg/day)|mol/L/(ug/kg/day)|mol/l/(ug/kg/d)|mol/l/(ug/kg/d)	A unit of concentration equal to moles per liter, divided by micrograms per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119437>	C48207	Mole per Liter per Microgram per Meter Squared|mol/L/(ug/m2)|mol/L/(ug/m2)|mol/L/(ug/m2)|mol/L/(ug/m2)|mol/l/(ug/m2)|mol/l/(ug/m2)	A unit of concentration equal to moles per liter, divided by micrograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119438>	C48207	Mole per Liter per Microgram per Meter Squared per Day|mol/L/(ug/m2/d)|mol/L/(ug/m2/d)|mol/L/(ug/m2/day)|mol/L/(ug/m2/day)|mol/L/(ug/m2/day)|mol/l/(ug/m2/d)|mol/l/(ug/m2/d)	A unit of concentration equal to moles per liter, divided by micrograms per meter squared per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11943>	C61063	Bevacizumab/Irinotecan			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119441>	C48207	Mole per Liter per Meter Squared|mol/L/m2|mol/L/m2|mol/L/m2|mol/l/m2|mol/l/m2	A unit of concentration equal to moles per liter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119443>	C48207	Mole per Liter per Microgram|mol/L/ug|mol/L/ug|mol/L/ug|mol/L/ug|mol/l/ug|mol/l/ug	A unit of concentration equal to moles per liter, divided by micrograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119444>	C48207	Nanogram per Milliliter per Kilogram per Meter Squared|ng/mL/(kg/m2)|ng/mL/(kg/m2)|ng/mL/(kg/m2)|ng/ml/(kg/m2)|ng/ml/(kg/m2)	A unit of concentration equal to nanograms per milliliter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119445>	C92571	Nanogram per Milliliter per Milligram per Day|Picogram per Milliliter per Microgram per Day|ng/mL/(mg/d)|ng/mL/(mg/d)|ng/mL/(mg/day)|ng/mL/(mg/day)|ng/mL/(mg/day)|ng/mL/(mg/day)|ng/ml/(mg/d)|ng/ml/(mg/d)|pg/mL/(ug/d)|pg/mL/(ug/d)|pg/mL/(ug/day)|pg/mL/(ug/day)|pg/mL/(ug/day)|pg/ml/(ug/d)|pg/ml/(ug/d)	A unit of concentration equal to nanograms per milliliter, divided by milligrams per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119446>	C92571	Nanogram per Milliliter per Milligram per Meter Squared|Picogram per Milliliter per Microgram per Meter Squared|ng/mL/(mg/m2)|ng/mL/(mg/m2)|ng/mL/(mg/m2)|ng/mL/(mg/m2)|ng/mL/(mg/m2)|ng/ml/(mg/m2)|ng/ml/(mg/m2)|pg/mL/(ug/m2)|pg/mL/(ug/m2)|pg/mL/(ug/m2)|pg/mL/(ug/m2)|pg/ml/(ug/m2)|pg/ml/(ug/m2)	A unit of concentration equal to nanograms per milliliter, divided by milligrams per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119447>	C92571	Nanogram per Milliliter per Milligram per Meter Squared per Day|Picogram per Milliliter per Microgram per Meter Squared per Day|ng/mL/(mg/m2/d)|ng/mL/(mg/m2/d)|ng/mL/(mg/m2/day)|ng/mL/(mg/m2/day)|ng/mL/(mg/m2/day)|ng/mL/(mg/m2/day)|ng/ml/(mg/m2/d)|ng/ml/(mg/m2/d)|pg/mL/(ug/m2/d)|pg/mL/(ug/m2/d)|pg/mL/(ug/m2/day)|pg/mL/(ug/m2/day)|pg/mL/(ug/m2/day)|pg/ml/(ug/m2/d)|pg/ml/(ug/m2/d)	A unit of concentration equal to nanograms per milliliter, divided by milligrams per meter squared per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119448>	C92571	Nanogram per Milliliter per Microgram per Day|Microgram per Milliliter per Milligram per Day|ng/mL/(ug/d)|ng/mL/(ug/d)|ng/mL/(ug/day)|ng/mL/(ug/day)|ng/mL/(ug/day)|ng/mL/(ug/day)|ng/ml/(ug/d)|ng/ml/(ug/d)|ug/mL/(mg/d)|ug/mL/(mg/d)|ug/mL/(mg/day)|ug/mL/(mg/day)|ug/mL/(mg/day)|ug/ml/(mg/d)|ug/ml/(mg/d)	A unit of concentration equal to nanograms per milliliter, divided by micrograms per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11944>	C61007	Autologous Dendritic Cells/Autologous Tumor Cell Vaccine/Sargramostim			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119451>	C92571	Nanogram per Milliliter per Microgram per Meter Squared|Microgram per Milliliter per Milligram per Meter Squared|ng/mL/(ug/m2)|ng/mL/(ug/m2)|ng/mL/(ug/m2)|ng/mL/(ug/m2)|ng/mL/(ug/m2)|ng/ml/(ug/m2)|ng/ml/(ug/m2)|ug/mL/(mg/m2)|ug/mL/(mg/m2)|ug/mL/(mg/m2)|ug/mL/(mg/m2)|ug/ml/(mg/m2)|ug/ml/(mg/m2)	A unit of concentration equal to nanograms per milliliter, divided by micrograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119452>	C92571	Nanogram per Milliliter per Microgram per Meter Squared per Day|Microgram per Milliliter per Milligram per Meter Squared per Day|ng/mL/(ug/m2/d)|ng/mL/(ug/m2/d)|ng/mL/(ug/m2/day)|ng/mL/(ug/m2/day)|ng/mL/(ug/m2/day)|ng/mL/(ug/m2/day)|ng/ml/(ug/m2/d)|ng/ml/(ug/m2/d)|ug/mL/(mg/m2/d)|ug/mL/(mg/m2/d)|ug/mL/(mg/m2/day)|ug/mL/(mg/m2/day)|ug/mL/(mg/m2/day)|ug/ml/(mg/m2/d)|ug/ml/(mg/m2/d)	A unit of concentration equal to nanograms per milliliter, divided by micrograms per meter squared per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119454>	C48207	Nanogram per Milliliter per Meter Squared|ng/mL/m2|ng/mL/m2|ng/mL/m2|ng/ml/m2|ng/ml/m2	A unit of concentration equal to nanograms per milliliter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119456>	C48207	Nanomole per Liter per Kilogram per Meter Squared|nmol/L/(kg/m2)|nmol/L/(kg/m2)|nmol/L/(kg/m2)|nmol/l/(kg/m2)|nmol/l/(kg/m2)	A unit of concentration equal to nanomoles per liter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119457>	C92571	Nanomole per Liter per Milligram per Day|Picomole per Liter per Microgram per Day|nmol/L/(mg/d)|nmol/L/(mg/d)|nmol/L/(mg/day)|nmol/L/(mg/day)|nmol/L/(mg/day)|nmol/L/(mg/day)|nmol/l/(mg/d)|nmol/l/(mg/d)|pmol/L/(ug/d)|pmol/L/(ug/d)|pmol/L/(ug/day)|pmol/L/(ug/day)|pmol/L/(ug/day)|pmol/l/(ug/d)|pmol/l/(ug/d)	A unit of concentration equal to nanomoles per liter, divided by milligrams per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119458>	C48207	Nanomole per Liter per Milligram per Kilogram|Picomole per Liter per Microgram per Kilogram|nmol/L/(mg/kg)|nmol/L/(mg/kg)|nmol/L/(mg/kg)|nmol/L/(mg/kg)|nmol/L/(mg/kg)|nmol/l/(mg/kg)|nmol/l/(mg/kg)|pmol/L/(ug/kg)|pmol/L/(ug/kg)|pmol/L/(ug/kg)|pmol/L/(ug/kg)|pmol/l/(ug/kg)|pmol/l/(ug/kg)	A unit of concentration equal to nanomoles per liter, divided by milligrams per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119459>	C92571	Nanomole per Liter per Milligram per Kilogram per Day|Picomole per Liter per Microgram per Kilogram per Day|nmol/L/(mg/kg/d)|nmol/L/(mg/kg/d)|nmol/L/(mg/kg/day)|nmol/L/(mg/kg/day)|nmol/L/(mg/kg/day)|nmol/L/(mg/kg/day)|nmol/l/(mg/kg/d)|nmol/l/(mg/kg/d)|pmol/L/(ug/kg/d)|pmol/L/(ug/kg/d)|pmol/L/(ug/kg/day)|pmol/L/(ug/kg/day)|pmol/L/(ug/kg/day)|pmol/l/(ug/kg/d)|pmol/l/(ug/kg/d)	A unit of concentration equal to nanomoles per liter, divided by milligrams per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11945>	C61007	Bevacizumab/Capecitabine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119460>	C92571	Nanomole per Liter per Milligram per Meter Squared|Picomole per Liter per Microgram per Meter Squared|nmol/L/(mg/m2)|nmol/L/(mg/m2)|nmol/L/(mg/m2)|nmol/L/(mg/m2)|nmol/L/(mg/m2)|nmol/l/(mg/m2)|nmol/l/(mg/m2)|pmol/L/(ug/m2)|pmol/L/(ug/m2)|pmol/L/(ug/m2)|pmol/L/(ug/m2)|pmol/l/(ug/m2)|pmol/l/(ug/m2)	A unit of concentration equal to nanomoles per liter, divided by milligrams per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119461>	C92571	Nanomole per Liter per Milligram per Meter Squared per Day|Picomole per Liter per Microgram per Meter Squared per Day|nmol/L/(mg/m2/d)|nmol/L/(mg/m2/d)|nmol/L/(mg/m2/day)|nmol/L/(mg/m2/day)|nmol/L/(mg/m2/day)|nmol/L/(mg/m2/day)|nmol/l/(mg/m2/d)|nmol/l/(mg/m2/d)|pmol/L/(ug/m2/d)|pmol/L/(ug/m2/d)|pmol/L/(ug/m2/day)|pmol/L/(ug/m2/day)|pmol/L/(ug/m2/day)|pmol/l/(ug/m2/d)|pmol/l/(ug/m2/d)	A unit of concentration equal to nanomoles per liter, divided by milligrams per meter squared per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119462>	C92571	Nanomole per Liter per Microgram per Day|Micromole per Liter per Milligram per Day|nmol/L/(ug/d)|nmol/L/(ug/d)|nmol/L/(ug/day)|nmol/L/(ug/day)|nmol/L/(ug/day)|nmol/L/(ug/day)|nmol/l/(ug/d)|nmol/l/(ug/d)|umol/L/(mg/d)|umol/L/(mg/d)|umol/L/(mg/day)|umol/L/(mg/day)|umol/L/(mg/day)|umol/l/(mg/d)|umol/l/(mg/d)	A unit of concentration equal to nanomoles per liter, divided by micrograms per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119463>	C48207	Nanomole per Liter per Microgram per Kilogram|Micromole per Liter per Milligram per Kilogram|nmol/L/(ug/kg)|nmol/L/(ug/kg)|nmol/L/(ug/kg)|nmol/L/(ug/kg)|nmol/L/(ug/kg)|nmol/l/(ug/kg)|nmol/l/(ug/kg)|umol/L/(mg/kg)|umol/L/(mg/kg)|umol/L/(mg/kg)|umol/L/(mg/kg)|umol/l/(mg/kg)|umol/l/(mg/kg)	A unit of concentration equal to nanomoles per liter, divided by micrograms per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119464>	C92571	Nanomole per Liter per Microgram per Kilogram per Day|Micromole per Liter per Milligram per Kilogram per Day|nmol/L/(ug/kg/d)|nmol/L/(ug/kg/d)|nmol/L/(ug/kg/day)|nmol/L/(ug/kg/day)|nmol/L/(ug/kg/day)|nmol/L/(ug/kg/day)|nmol/l/(ug/kg/d)|nmol/l/(ug/kg/d)|umol/L/(mg/kg/d)|umol/L/(mg/kg/d)|umol/L/(mg/kg/day)|umol/L/(mg/kg/day)|umol/L/(mg/kg/day)|umol/l/(mg/kg/d)|umol/l/(mg/kg/d)	A unit of concentration equal to nanomoles per liter, divided by micrograms per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119465>	C92571	Nanomole per Liter per Microgram per Meter Squared|Micromole per Liter per Milligram per Meter Squared|nmol/L/(ug/m2)|nmol/L/(ug/m2)|nmol/L/(ug/m2)|nmol/L/(ug/m2)|nmol/L/(ug/m2)|nmol/l/(ug/m2)|nmol/l/(ug/m2)|umol/L/(mg/m2)|umol/L/(mg/m2)|umol/L/(mg/m2)|umol/L/(mg/m2)|umol/l/(mg/m2)|umol/l/(mg/m2)	A unit of concentration equal to nanomoles per liter, divided by micrograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119466>	C92571	Nanomole per Liter per Microgram per Meter Squared per Day|Micromole per Liter per Milligram per Meter Squared per Day|nmol/L/(ug/m2/d)|nmol/L/(ug/m2/d)|nmol/L/(ug/m2/day)|nmol/L/(ug/m2/day)|nmol/L/(ug/m2/day)|nmol/L/(ug/m2/day)|nmol/l/(ug/m2/d)|nmol/l/(ug/m2/d)|umol/L/(mg/m2/d)|umol/L/(mg/m2/d)|umol/L/(mg/m2/day)|umol/L/(mg/m2/day)|umol/L/(mg/m2/day)|umol/l/(mg/m2/d)|umol/l/(mg/m2/d)	A unit of concentration equal to nanomoles per liter, divided by micrograms per meter squared per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119467>	C48207	Nanomole per Liter per Gram|Micromole per Liter per Kilogram|Picomole per Liter per Milligram|nmol/L/g|nmol/L/g|nmol/L/g|nmol/L/g|nmol/L/g|nmol/l/g|nmol/l/g|pmol/L/mg|pmol/L/mg|pmol/L/mg|pmol/L/mg|pmol/l/mg|pmol/l/mg|umol/L/kg|umol/L/kg|umol/L/kg|umol/L/kg|umol/l/kg|umol/l/kg	A unit of concentration equal to nanomoles per liter, divided by grams.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119468>	C48207	Nanomole per Liter per Kilogram|Picomole per Liter per Gram|nmol/L/kg|nmol/L/kg|nmol/L/kg|nmol/L/kg|nmol/L/kg|nmol/l/kg|nmol/l/kg|pmol/L/g|pmol/L/g|pmol/L/g|pmol/L/g|pmol/l/g|pmol/l/g	A unit of concentration equal to nanomoles per liter, divided by kilograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Gram Weight Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119469>	C48207	Nanomole per Liter per Meter Squared|nmol/L/m2|nmol/L/m2|nmol/L/m2|nmol/l/m2|nmol/l/m2	A unit of concentration equal to nanomoles per liter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11946>	C61063	Doxorubicin Hcl Liposome/Interleukin-12			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119472>	C48207	Picogram per Milliliter per Kilogram per Meter Squared|pg/mL/(kg/m2)|pg/mL/(kg/m2)|pg/mL/(kg/m2)|pg/ml/(kg/m2)|pg/ml/(kg/m2)	A unit of concentration equal to picograms per milliliter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11947>	C61007	Cisplatin/UCN-01			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119483>	C48207	Picogram per Milliliter per Meter Squared|pg/mL/m2|pg/mL/m2|pg/mL/m2|pg/ml/m2|pg/ml/m2	A unit of concentration equal to picograms per milliliter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119485>	C48207	Picomole per Liter per Kilogram per Meter Squared|pmol/L/(kg/m2)|pmol/L/(kg/m2)|pmol/L/(kg/m2)|pmol/l/(kg/m2)|pmol/l/(kg/m2)	A unit of concentration equal to picomoles per liter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119486>	C48207	Picomole per Liter per Milligram per Day|pmol/L/(mg/d)|pmol/L/(mg/d)|pmol/L/(mg/day)|pmol/L/(mg/day)|pmol/L/(mg/day)|pmol/l/(mg/d)|pmol/l/(mg/d)	A unit of concentration equal to picomoles per liter, divided by milligrams per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119487>	C48207	Picomole per Liter per Milligram per Kilogram|pmol/L/(mg/kg)|pmol/L/(mg/kg)|pmol/L/(mg/kg)|pmol/L/(mg/kg)|pmol/l/(mg/kg)|pmol/l/(mg/kg)	A unit of concentration equal to picomoles per liter, divided by milligrams per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119488>	C48207	Picomole per Liter per Milligram per Kilogram per Day|pmol/L/(mg/kg/d)|pmol/L/(mg/kg/d)|pmol/L/(mg/kg/day)|pmol/L/(mg/kg/day)|pmol/L/(mg/kg/day)|pmol/l/(mg/kg/d)|pmol/l/(mg/kg/d)	A unit of concentration equal to picomoles per liter, divided by milligrams per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119489>	C48207	Picomole per Liter per Milligram per Meter Squared|pmol/L/(mg/m2)|pmol/L/(mg/m2)|pmol/L/(mg/m2)|pmol/L/(mg/m2)|pmol/l/(mg/m2)|pmol/l/(mg/m2)	A unit of concentration equal to picomoles per liter, divided by milligrams per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11948>	C61063	Autologous Tumor Cell Vaccine/Interleukin-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119490>	C48207	Picomole per Liter per Milligram per Meter Squared per Day|pmol/L/(mg/m2/d)|pmol/L/(mg/m2/d)|pmol/L/(mg/m2/day)|pmol/L/(mg/m2/day)|pmol/L/(mg/m2/day)|pmol/l/(mg/m2/d)|pmol/l/(mg/m2/d)	A unit of concentration equal to picomoles per liter, divided by milligrams per meter squared per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119497>	C48207	Picomole per Liter per Kilogram|pmol/L/kg|pmol/L/kg|pmol/L/kg|pmol/L/kg|pmol/l/kg|pmol/l/kg	A unit of concentration equal to picomoles per liter, divided by kilograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119498>	C48207	Picomole per Liter per Meter Squared|pmol/L/m2|pmol/L/m2|pmol/L/m2|pmol/l/m2|pmol/l/m2	A unit of concentration equal to picomoles per liter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11949>	C61063	Bryostatin 1/Sargramostim			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1194>	C1894	Phytoestrogen|Phytoestrogens|phytoestrogen	Compounds from plant sources with estrogen-like activities			Pharmacologic Substance	
C119500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119500>	C48207	Microgram per Milliliter per Kilogram per Meter Squared|ug/mL/(kg/m2)|ug/mL/(kg/m2)|ug/mL/(kg/m2)|ug/ml/(kg/m2)|ug/ml/(kg/m2)	A unit of concentration equal to micrograms per milliliter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11950>	C61063	IDEC-In2B8/Rituximab/Yttrium Y 90 Ibritumomab Tiuxetan			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119511>	C48207	Microgram per Milliliter per Meter Squared|ug/mL/m2|ug/mL/m2|ug/mL/m2|ug/ml/m2|ug/ml/m2	A unit of concentration equal to micrograms per milliliter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119513>	C48207	Micro-International Units per Milliliter per Kilogram per Meter Squared|uIU/mL/(kg/m2)|uIU/mL/(kg/m2)|u[IU]/mL/(kg/m2)|u[IU]/mL/(kg/m2)|u[IU]/ml/(kg/m2)|u[IU]/ml/(kg/m2)|u[iU]/mL/(kg/m2)|u[iU]/mL/(kg/m2)|u[iU]/ml/(kg/m2)|u[iU]/ml/(kg/m2)	A unit of concentration (biologic activity) equal to one micro-international unit per milliliter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119514>	C48207	Micro-International Units per Milliliter per Milligram per Day|uIU/mL/(mg/day)|uIU/mL/(mg/day)|uIU/mL/(mg/day)|u[IU]/mL/(mg/d)|u[IU]/mL/(mg/d)|u[IU]/ml/(mg/d)|u[IU]/ml/(mg/d)|u[iU]/mL/(mg/d)|u[iU]/mL/(mg/d)|u[iU]/ml/(mg/d)|u[iU]/ml/(mg/d)	A unit of concentration (biologic activity) equal to one micro-international unit per milliliter, divided by milligrams per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119515>	C48207	Micro-International Units per Milliliter per Milligram per Kilogram|uIU/mL/(mg/kg)|uIU/mL/(mg/kg)|uIU/mL/(mg/kg)|u[IU]/mL/(mg/kg)|u[IU]/mL/(mg/kg)|u[IU]/ml/(mg/kg)|u[IU]/ml/(mg/kg)|u[iU]/mL/(mg/kg)|u[iU]/mL/(mg/kg)|u[iU]/ml/(mg/kg)|u[iU]/ml/(mg/kg)	A unit of concentration (biologic activity) equal to one micro-international unit per milliliter, divided by milligrams per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119516>	C48207	Micro-International Units per Milliliter per Milligram per Kilogram per Day|uIU/mL/(mg/kg/day)|uIU/mL/(mg/kg/day)|uIU/mL/(mg/kg/day)|u[IU]/mL/(mg/kg/d)|u[IU]/mL/(mg/kg/d)|u[IU]/ml/(mg/kg/d)|u[IU]/ml/(mg/kg/d)|u[iU]/mL/(mg/kg/d)|u[iU]/mL/(mg/kg/d)|u[iU]/ml/(mg/kg/d)|u[iU]/ml/(mg/kg/d)	A unit of concentration (biologic activity) equal to one micro-international unit per milliliter, divided by milligrams per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119517>	C48207	Micro-International Units per Milliliter per Milligram per Meter Squared|uIU/mL/(mg/m2)|uIU/mL/(mg/m2)|uIU/mL/(mg/m2)|u[IU]/mL/(mg/m2)|u[IU]/mL/(mg/m2)|u[IU]/ml/(mg/m2)|u[IU]/ml/(mg/m2)|u[iU]/mL/(mg/m2)|u[iU]/mL/(mg/m2)|u[iU]/ml/(mg/m2)|u[iU]/ml/(mg/m2)	A unit of concentration (biologic activity) equal to one micro-international unit per milliliter, divided by milligrams per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119518>	C48207	Micro-International Units per Milliliter per Milligram per Meter Squared per Day|uIU/mL/(mg/m2/day)|uIU/mL/(mg/m2/day)|uIU/mL/(mg/m2/day)|u[IU]/mL/(mg/m2/d)|u[IU]/mL/(mg/m2/d)|u[IU]/ml/(mg/m2/d)|u[IU]/ml/(mg/m2/d)|u[iU]/mL/(mg/m2/d)|u[iU]/mL/(mg/m2/d)|u[iU]/ml/(mg/m2/d)|u[iU]/ml/(mg/m2/d)	A unit of concentration (biologic activity) equal to one micro-international unit per milliliter, divided by milligrams per meter squared per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11951>	C61063	Melphalan/Prednisone/Wobe-Mugos E			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119525>	C48207	Micro-International Units per Milliliter per Kilogram|uIU/mL/kg|uIU/mL/kg|uIU/mL/kg|u[IU]/mL/kg|u[IU]/mL/kg|u[IU]/ml/kg|u[IU]/ml/kg|u[iU]/mL/kg|u[iU]/mL/kg|u[iU]/ml/kg|u[iU]/ml/kg	A unit of concentration (biologic activity) equal to one micro-international unit per milliliter, divided by kilograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119526>	C48207	Micro-International Units per Milliliter per Meter Squared|uIU/mL/m2|uIU/mL/m2|u[IU]/mL/m2|u[IU]/mL/m2|u[IU]/ml/m2|u[IU]/ml/m2|u[iU]/mL/m2|u[iU]/mL/m2|u[iU]/ml/m2|u[iU]/ml/m2	A unit of concentration (biologic activity) equal to one micro-international unit per milliliter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119529>	C48207	Micromole per Liter per Kilogram per Meter Squared|umol/L/(kg/m2)|umol/L/(kg/m2)|umol/L/(kg/m2)|umol/l/(kg/m2)|umol/l/(kg/m2)	A unit of concentration equal to micromoles per liter, divided by kilograms per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C11952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11952>	C61063	Thalidomide/Topotecan			Obsolete_Concept	Therapeutic or Preventive Procedure	
C11953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11953>	C61063	PEG-Interferon Alfa-2b/Temozolomide|PEG-IFNA2b/TMZ			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119542>	C48207	Micromole per Liter per Meter Squared|umol/L/m2|umol/L/m2|umol/L/m2|umol/l/m2|umol/l/m2	A unit of concentration equal to micromoles per liter, divided by meters squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119545>	C38081	Forced Expiratory Flow at 25-75 Percent|FEF2575|Forced Expiratory Flow 25-75%|Forced Expiratory Flow 25-75%	The mean forced expiratory flow rate at 25-75% of the forced vital capacity.			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119546>	C38081	Percent Predicted Forced Expiratory Flow at 25-75 Percent|FEF at 25-75%|FEF2575P|Percent Predicted FEF25-75|Percent Predicted FEF25-75	The mean forced expiratory flow rate at 25-75% of the forced vital capacity as a proportion of the predicted normal value.			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|HL Authorized Value Terminology|HL Function Test Table
C119547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119547>	C38081	Peak Nasal Inspiratory Flow|PNIF	The maximal flow achieved during the maximally forced inspiration through the nose initiated at maximum exhalation.			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119548>	C38114	Intraparenchymal Route of Administration|INTRAPARENCHYMAL	Administration into the parenchyma of an organ.			Functional Concept	CDISC SDTM Route of Administration Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119549>	C25330	Menstrual Cycle Duration|MENSDUR	The length of time of the menses cycle, measured from the beginning of one menstrual period to the beginning of the next.			Temporal Concept	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11954>	C61007	Sulindac/Thalidomide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119550>	C17610	Umbilical Cord Serum|CORD SERUM	The clear portion of the blood that remains after the removal of the blood cells and the clotting proteins from umbilical cord blood.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119551>	C181043	Lesion Failure Indicator|LESFLIND	An indication as to whether lesion failure occurred.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C119552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119552>	C181043	Lesion Revascularization Indicator|LESRVIND	An indication as to whether repeat revascularization of a lesion occurred.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C119553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119553>	C181043	Lesion Success Indicator|LESSCIND	An indication as to whether a performed procedure of a target lesion is considered successful.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C119554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119554>	C25180	Limb Failure Indicator|LMBFLIND	An indication as to whether limb failure occurred.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C119555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119555>	C181043	Lesion Revascularization Ischemia Indicator|LRISCIND|Lesion Revas Ischemia Indicator|Lesion Revas Ischemia Indicator	An indication as to whether clinical or functional ischemia is present before lesion revascularization occurred.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C119556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119556>	C181043	Lesion Revascularization Clinical Indicator|LRVCLIND|Lesion Revas Clinical Indicator|Lesion Revas Clinical Indicator	An indication as to whether an appropriate clinical context was present before lesion revascularization occurred.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C119557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119557>	C181043	Vessel Failure Indicator|VSLFLIND	An indication as to whether vessel failure occurred.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C119558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119558>	C181043	Vessel Patency Indicator|VSLPIND	An indication as to whether an artery is patent (free of TLR or restenosis) following intervention.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C119559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119559>	C181043	Vessel Revascularization Indicator|VSLRVIND	An indication as to whether repeat revascularization of an artery containing a lesion occurred.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C11955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11955>	C61007	Cisplatin/Dexamethasone/Gemcitabine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119560>	C93518	ECG Evaluator Blinding Parameters|ECG Reading Blinded|ECG Reading Blinded|EGBLIND	A description of the parameters to which the ECG assessors were blinded to within the study.			Idea or Concept	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C119561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119561>	C25180	ECG Continuous Monitoring Indicator|ECG Continuous Monitoring|ECG Continuous Monitoring|EGCTMON	An indication as to whether the 10-second ECGs for this study were extracted from a continuous recording.			Idea or Concept	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C119562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119562>	C50282	ECG Planned Primary Lead for Study|ECG Planned Primary Lead|ECG Planned Primary Lead|EGLEADPR	A description of the ECG lead that is planned to be used as the planned, primary lead for the study.			Idea or Concept	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C119563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119563>	C25180	ECG Used Same Lead Indicator|ECG Used Same Lead|ECG Used Same Lead|EGLEADSM	An indication as to whether ECG interval measurements were based on the same lead.			Idea or Concept	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C119564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119564>	C62085	ECG Read Method Degree of Automation|ECG Read Method|ECG Read Method|EGRDMETH	The degree of automation of the method by which the ECG output is read by the evaluator.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C119565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119565>	C25180	ECG Replicates at Baseline Indicator|ECG Replicates at Baseline|ECG Replicates at Baseline|EGREPLBL	An indication as to whether replicate ECGs for time points during the baseline portion of the study were included.			Idea or Concept	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C119566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119566>	C25180	ECG Replicates On-Treatment Indicator|ECG Replicates On-Treatment|ECG Replicates On-Treatment|EGREPLTR	An indication as to whether replicate ECGs for time points during the on-treatment portion of the study were included.			Idea or Concept	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C119567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119567>	C94189	Graft Lesion Identification|GRLIDENT	The identification of a non-neoplastic or neoplastic pathologic process taking place within a graft.			Diagnostic Procedure	CDISC SDTM Terminology|CDISC SDTM Tumor Identification Test Code Terminology|CDISC SDTM Tumor Identification Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C119568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119568>	C94189	Limb Associated Lesion Identification|LMLIDENT|Limb Lesion Identification|Limb Lesion Identification	The identification of the limb that contains a non-neoplastic or neoplastic pathologic process.			Diagnostic Procedure	CDISC SDTM Terminology|CDISC SDTM Tumor Identification Test Code Terminology|CDISC SDTM Tumor Identification Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C119569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119569>	C94189	Vessel Lesion Identification|VSLIDENT	The identification of a non-neoplastic or neoplastic pathologic process taking place within a vessel.			Diagnostic Procedure	CDISC SDTM Terminology|CDISC SDTM Tumor Identification Test Code Terminology|CDISC SDTM Tumor Identification Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C11956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11956>	C63467	M-CAVI Regimen|Carboplatin-Methotrexate-Vinblastine|Carboplatin/Methotrexate/Vinblastine|Carboplatin/Methotrexate/Vinblastine Regimen|M-CAVI	A regimen consisting of methotrexate, carboplatin and vinblastine that may be used in the treatment of certain urothelial cancers.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C119570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119570>	C28076	Batts-Ludwig Fibrosis Score|BATTS-LUDWIG FIBROSIS SCORE	A scoring system for liver fibrosis developed by Batts and Ludwig (Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995;19:1409), based on a four category scale.			Classification	CDISC SDTM Microscopic Findings Test Detail Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119571>	C28076	Knodell Fibrosis Score|KNODELL FIBROSIS SCORE	A scoring system for liver fibrosis developed by Knodell et al (Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431), based on a 4 category scale.			Classification	CDISC SDTM Microscopic Findings Test Detail Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119572>	C28076	METAVIR Fibrosis Score|METAVIR FIBROSIS SCORE|Metavir Fibrosis Score	A scoring system for liver fibrosis developed by Bedossa and Poynard (Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996 Aug; 24(2):289-93.), based on a 5 category scale.			Classification	CDISC SDTM Microscopic Findings Test Detail Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119573>	C28076	Scheuer Fibrosis Score|SCHEUER FIBROSIS SCORE	A scoring system for liver fibrosis developed by Scheuer (Scheuer PJ. Classification of viral hepatitis: a need for reassessment. J Hepatol 1991;13:372-374), based on a 5 category scale.			Classification	CDISC SDTM Microscopic Findings Test Detail Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119574>	C134576	Experimental Organism Malignant Astrocytoma|ASTROCYTOMA, MALIGNANT	A malignant neoplasm of the brain or spinal cord originating from astrocytes.			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C119575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119575>	C134576	Experimental Organism Malignant Ependymoma|EPENDYMOMA, MALIGNANT	A malignant neoplasm of ependymal origin.			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C119576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119576>	C134576	Experimental Organism Benign Ganglioglioma|GANGLIOGLIOMA, BENIGN	A benign neoplasm comprised of neoplastic ganglion and glial cells.			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C119577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119577>	C134576	Experimental Organism Malignant Oligodendroglioma|OLIGODENDROGLIOMA, MALIGNANT	A malignant neoplasm of the central nervous system arising from oligodendrocytes.			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C119578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119578>	C25763	Duodenal Papilla|PAPILLA, DUODENAL	Either one of two openings from the pancreatic ducts into the duodenum. The major duodenal papilla opens from the pancreatic duct into the duodenum. The minor duodenal papilla opens from the accessory pancreatic duct into the descending second section of the duodenum.			Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119579>	C35552	Stroke Type|STROKTYP|STROKTYP	A classification or description of a stroke.			Qualitative Concept	CDISC SDTM Cardiovascular Findings About Test Code Terminology|CDISC SDTM Cardiovascular Findings About Test Name Terminology|CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11957>	C61063	Docetaxel/Filgrastim/XR9576			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119580>	C120539	Absidia|ABSIDIA	A genus of filamentous fungi within the family Mucoraceae that are ubiquitous in nature and may cause mucormycosis in humans.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119581>	C118932	Amoeba|AMOEBA|Ameba	A genus of motile, unicellular eukaryotic amoeboid protists within the family Amoebidae that are commonly found in fresh water environments. Members of the Amoeba genus are not generally considered to be human pathogens.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119582>	C16275	ECG T Wave Algorithm|ECG Twave Algorithm|ECG Twave Algorithm|EGTWVALG	The defined procedure used to identify the end of the T wave.			Intellectual Product	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C119583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119583>	C161615	TIMI Coronary Thrombus Grade 1|CORONARY THROMBUS TIMI GRADE 1	Possible thrombus present - angiography demonstrates characteristics such as reduced contrast density, haziness, irregular lesion contour or a smooth convex 'meniscus' at the site of total occlusion suggestive but not diagnostic of thrombus. (Gibson, C. M., de Lemos, J. A., Murphy, S. A., Marble, S. J., McCabe, C. H., Cannon, C. P., Antman, E. M., Braunwald, E. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy Circulation. 2001;103(21):2550-4.)			Qualitative Concept	CDISC SDTM Coronary Thrombus TIMI Grade Responses Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119584>	C161615	TIMI Coronary Thrombus Grade 2|CORONARY THROMBUS TIMI GRADE 2	Small size definite thrombus, with greatest dimensions less than or equal to 1/2 vessel diameter. (Gibson, C. M., de Lemos, J. A., Murphy, S. A., Marble, S. J., McCabe, C. H., Cannon, C. P., Antman, E. M., Braunwald, E. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy Circulation. 2001;103(21):2550-4.)			Qualitative Concept	CDISC SDTM Coronary Thrombus TIMI Grade Responses Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119585>	C161615	TIMI Coronary Thrombus Grade 3|CORONARY THROMBUS TIMI GRADE 3	Moderate size definite thrombus, with greatest linear dimension greater than 1/2 but less than 2 vessel diameters. (Gibson, C. M., de Lemos, J. A., Murphy, S. A., Marble, S. J., McCabe, C. H., Cannon, C. P., Antman, E. M., Braunwald, E. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy Circulation. 2001;103(21):2550-4.)			Qualitative Concept	CDISC SDTM Coronary Thrombus TIMI Grade Responses Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119586>	C161615	TIMI Coronary Thrombus Grade 4|CORONARY THROMBUS TIMI GRADE 4	Large size definite thrombus, with the largest dimension greater than or equal to 2 vessel diameters. (Gibson, C. M., de Lemos, J. A., Murphy, S. A., Marble, S. J., McCabe, C. H., Cannon, C. P., Antman, E. M., Braunwald, E. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy Circulation. 2001;103(21):2550-4.)			Qualitative Concept	CDISC SDTM Coronary Thrombus TIMI Grade Responses Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119587>	C161615	TIMI Coronary Thrombus Grade 5|CORONARY THROMBUS TIMI GRADE 5	Total vessel occlusion. (Gibson, C. M., de Lemos, J. A., Murphy, S. A., Marble, S. J., McCabe, C. H., Cannon, C. P., Antman, E. M., Braunwald, E. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy Circulation. 2001;103(21):2550-4.)			Qualitative Concept	CDISC SDTM Coronary Thrombus TIMI Grade Responses Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119588>	C161614	NHLBI Coronary Artery Dissection Type A|CORONARY DISSECTION NHLBI GRADE A	Minor radiolucencies within the lumen during contrast injection with no persistence after dye clearance. (Adapted from: Coronary artery angiographic changes after PTCA: Manual of Operations NHLBI PTCA Registry 1985-6:9)			Qualitative Concept	CDISC SDTM NHLBI Coronary Artery Dissection Grade Responses Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119589>	C161614	NHLBI Coronary Artery Dissection Type B|CORONARY DISSECTION NHLBI GRADE B	Parallel tracts or double lumen separated by a radiolucent area during contrast injection with no persistence after dye clearance. (Adapted from: Coronary artery angiographic changes after PTCA: Manual of Operations NHLBI PTCA Registry 1985-6:9)			Qualitative Concept	CDISC SDTM NHLBI Coronary Artery Dissection Grade Responses Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11958>	C61063	Doxorubicin/Filgrastim/XR9576			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119590>	C161614	NHLBI Coronary Artery Dissection Type C|CORONARY DISSECTION NHLBI GRADE C	Extraluminal cap with persistence of contrast after dye clearance from the lumen. (Adapted from: Coronary artery angiographic changes after PTCA: Manual of Operations NHLBI PTCA Registry 1985-6:9)			Qualitative Concept	CDISC SDTM NHLBI Coronary Artery Dissection Grade Responses Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119591>	C161614	NHLBI Coronary Artery Dissection Type D|CORONARY DISSECTION NHLBI GRADE D	Spiral luminal filling defect with delayed but complete distal flow. (Adapted from: Coronary artery angiographic changes after PTCA: Manual of Operations NHLBI PTCA Registry 1985-6:9)			Qualitative Concept	CDISC SDTM NHLBI Coronary Artery Dissection Grade Responses Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119592>	C161614	NHLBI Coronary Artery Dissection Type E|CORONARY DISSECTION NHLBI GRADE E	New persistent filling defect with delayed antegrade flow. May represent thrombus. (Adapted from: Coronary artery angiographic changes after PTCA: Manual of Operations NHLBI PTCA Registry 1985-6:9)			Qualitative Concept	CDISC SDTM NHLBI Coronary Artery Dissection Grade Responses Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119593>	C161614	NHLBI Coronary Artery Dissection Type F|CORONARY DISSECTION NHLBI GRADE F	Non-A-E types with total coronary occlusion and no distal antegrade flow. May represent thrombus. (Adapted from: Coronary artery angiographic changes after PTCA: Manual of Operations NHLBI PTCA Registry 1985-6:9)			Qualitative Concept	CDISC SDTM NHLBI Coronary Artery Dissection Grade Responses Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119594>	C35552	ARC Stent Thrombosis Timing Acute|STENT THROMBOSIS ARC ACUTE	0 to 24 hours after stent implantation. (Cutlip DE, Windecker S, Mehran R, et al. Clinical Endpoints in Coronary Stent Trials : A Case for Standardized Definitions. Circulation. 2007;115:2344-2351)			Finding	CDISC SDTM ARC Coronary Stent Thrombosis Timing Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119595>	C35552	ARC Stent Thrombosis Timing Subacute|STENT THROMBOSIS ARC SUBACUTE	Greater than 24 hours to 30 days after stent implantation. (Cutlip DE, Windecker S, Mehran R, et al. Clinical Endpoints in Coronary Stent Trials : A Case for Standardized Definitions. Circulation. 2007;115:2344-2351)			Finding	CDISC SDTM ARC Coronary Stent Thrombosis Timing Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119596>	C35552	ARC Stent Thrombosis Timing Late|STENT THROMBOSIS ARC LATE	Greater than 30 days to 1 year after stent implantation. (Cutlip DE, Windecker S, Mehran R, et al. Clinical Endpoints in Coronary Stent Trials : A Case for Standardized Definitions. Circulation. 2007;115:2344-2351)			Finding	CDISC SDTM ARC Coronary Stent Thrombosis Timing Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119597>	C35552	ARC Stent Thrombosis Timing Very Late|STENT THROMBOSIS ARC VERY LATE	Greater than 1 year after stent implantation. (Cutlip DE, Windecker S, Mehran R, et al. Clinical Endpoints in Coronary Stent Trials : A Case for Standardized Definitions. Circulation. 2007;115:2344-2351)			Finding	CDISC SDTM ARC Coronary Stent Thrombosis Timing Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119598>	C35552	ARC Definite Stent Thrombosis|STENT THROMBOSIS ARC GRADE DEFINITE	Includes acute ischemic symptoms at rest, acute post ischemic ECG, positive biomarkers and pathological evidence. Definite stent thrombosis is considered to have occurred when there is either angiographic or pathological confirmation. Angiographic confirmation is the presence of a thrombus at coronary angiography that originates in the stent or in the segment 5 mm proximal or distal to the stent, with the presence of at least 1 of 3 clinical criteria within a 48-hour time window: 1) acute onset of ischemic symptoms at rest; 2) new ischemic ECG changes that suggest acute ischemia; or 3) typical rise and fall in cardiac biomarkers. Pathological confirmation is evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following thrombectomy. (Cutlip DE, Windecker S, Mehran R, et al. Clinical End Points in Coronary Stent Trials : A Case for Standardized Definitions. Circulation. 2007;115:2344-2351)			Finding	CDISC SDTM ARC Coronary Stent Thrombosis Grade Responses Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119599>	C35552	ARC Probable Stent Thrombosis|STENT THROMBOSIS ARC GRADE PROBABLE	Includes death within 30 days and myocardial infarction of stent territory. Probable stent thrombosis is considered to have occurred after intracoronary stenting in the following situations: 1) any unexplained death within the first 30 days; or 2) irrespective of the time after the index procedure, any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause. (Cutlip DE, Windecker S, Mehran R, et al. Clinical End Points in Coronary Stent Trials : A Case for Standardized Definitions. Circulation. 2007;115:2344-2351)			Finding	CDISC SDTM ARC Coronary Stent Thrombosis Grade Responses Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C11959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11959>	C61063	Trastuzumab/Vinorelbine|Vinorelbine + Trastuzumab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1195>	C211609	Piceatannol|3,4,3',5'-Tetrahydroxy-trans-stilbene|PICEATANNOL	A polyhydroxylated stilbene extract from the seeds of Euphorbia lagascae, which inhibits protein tyrosine kinase Syk and induces apoptosis. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C119600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119600>	C35552	ARC Possible Stent Thrombosis|STENT THROMBOSIS ARC GRADE POSSIBLE	Possible stent thrombosis is considered to have occurred with any unexplained death more than 30 days after intracoronary stenting. (Cutlip DE, Windecker S, Mehran R, et al. Clinical End Points in Coronary Stent Trials : A Case for Standardized Definitions. Circulation. 2007;115:2344-2351)			Finding	CDISC SDTM ARC Coronary Stent Thrombosis Grade Responses Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C119601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119601>	C25873	PLK4 Gene|PLK4|PLK4|Polo-Like Kinase 4 Gene	This gene plays a role in the formation of centrioles or basal bodies.			Gene or Genome	
C119602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119602>	C119601	PLK4 wt Allele|Polo-Like Kinase 4 (Drosophila) Gene|Polo-Like Kinase 4 wt Allele|SAK|SAK, Mouse, Homolog of Gene|STK18	Human PLK4 wild-type allele is located in the vicinity of 4q28 and is approximately 18 kb in length. This allele, which encodes serine/threonine-protein kinase PLK4 protein, is involved in centriole duplication.			Gene or Genome	
C119603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119603>	C17325	Serine/Threonine-Protein Kinase PLK4|EC 2.7.11.21|PLK-4|Polo-Like Kinase 4|Serine/Threonine Kinase 18|Serine/Threonine Protein Kinase 18|Serine/Threonine Protein Kinase SAK|Serine/Threonine-Protein Kinase 18|Serine/Threonine-Protein Kinase Sak	Serine/threonine-protein kinase PLK4 (970 aa, ~109 kDa) is encoded by the human PLK4 gene. This protein plays a role in the duplication of centrioles during the cell cycle.			Amino Acid, Peptide, or Protein|Enzyme	
C119604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119604>	C133710	COP1 Gene|COP1|COP1|COP1, E3 Ubiquitin Ligase Gene|RFWD2	This gene is involved in the ubiquitination of target proteins.			Gene or Genome	
C119605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119605>	C119604	COP1 wt Allele|COP1, E3 Ubiquitin Ligase wt Allele|Constitutive Photomorphogenesis Protein 1, Arabadopsis, Homolog of Gene|Constitutive Photomorphogenic Protein 1 (Arabidopsis) Gene|FLJ10416|RFWD2|RNF200|RP11-318C24.3|Ring Finger and WD Repeat Domain 2, E3 Ubiquitin Protein Ligase Gene	Human COP1 wild-type allele is located within 1q25.1-q25.2 and is approximately 263 kb in length. This allele, which encodes E3 ubiquitin-protein ligase COP1 protein, plays a role in protein ubiquitination.			Gene or Genome	
C119606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119606>	C21254	E3 Ubiquitin-Protein Ligase COP1|COP1|Constitutive Photomorphogenesis Protein 1 Homolog|E3 Ubiquitin-Protein Ligase RFWD2|EC 2.3.2.27|EC 6.3.2.-, Formerly|Putative Ubiquitin Ligase COP1|RING Finger Protein 200|RING Finger and WD Repeat Domain Protein 2|RING Finger and WD Repeat Domains-Containing Protein 2|RING-Type E3 Ubiquitin Transferase RFWD2|Ring Finger and WD Repeat Domain 2|hCOP1	E3 ubiquitin-protein ligase COP1 (731 aa, ~80 kDa) is encoded by the human COP1 gene. This protein is involved in post-translational ubiquitination of target proteins.			Amino Acid, Peptide, or Protein|Enzyme	
C119607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119607>	C20194	DET1 Gene|DET1|DET1|De-Etiolated Homolog 1 (Arabidopsis) Gene	This gene plays a role in the regulation of both protein ubiquitination and degradation.			Gene or Genome	
C119608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119608>	C3420	t(8;21)	A cytogenetic abnormality that involves a translocation between chromosomes 8 and 21.	t(8;21)		Cell or Molecular Dysfunction	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C119609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119609>	C6827	inv(16)	A chromosomal inversion that involves chromosome 16.	inv(16)		Cell or Molecular Dysfunction	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11960>	C61063	Topotecan/ZD9331			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119610>	C91105|C20995	PROMIS Short Form - Pain Intensity|Patient Reported Outcomes Measurement Information System Short Form - Pain Intensity	A questionnaire that measures a patient's self-reported health status related to the intensity of pain they are experiencing.			Intellectual Product	
C119611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119611>	C91105|C20995	PROMIS Parent Proxy Short Form - Pain Interference|Patient Reported Outcomes Measurement Information System Parent Proxy Short Form - Pain Interference	A questionnaire that measures a patient's health status related to pain and how that pain interferes with the patient's life, as reported by the patient's parent or legal guardian.			Intellectual Product	
C119612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119612>	C91105|C20995	PROMIS Pediatric Short Form - Pain Interference|Patient Reported Outcomes Measurement Information System Pediatric Short Form - Pain Interference	A questionnaire that measures a pediatric patient's self-reported health status related to pain and how that pain interferes with the patient's life.			Intellectual Product	
C119613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119613>	C91105|C20995	PROMIS Adult Short Form - Pain Interference|Patient Reported Outcomes Measurement Information System Adult Short Form - Pain Interference	A questionnaire that measures an adult patient's self-reported health status related to pain and how that pain interferes with the patient's life.			Intellectual Product	
C119614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119614>	C49146	MAGE-A3-expressing Adenovirus Type 5 Vaccine|AdMA3|Adenovirus/MAGE-A3	An oncolytic adenoviral vaccine composed of a replication-defective, E1- and E3-deleted adenovirus serotype 5 (Ad5) with a transgene encoding the human melanoma antigen A3 (MAGE-A3), with potential antineoplastic activity. Upon administration, MAGE-A3-expressing adenovirus type 5 vaccine selectively replicates in cancer cells and expresses MAGE-A3. This induces an immune response against tumor cells expressing the MAGE-A3 antigen, which leads to tumor cell death. The tumor-associated antigen MAGE-A3 is overexpressed by a variety of cancer cell types.			Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C119615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119615>	C200711	Odronextamab|Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody REGN1979|ODRONEXTAMAB|REGN1979|WHO 11035	A bispecific, human monoclonal antibody with potential antineoplastic activity. Anti-CD20/CD3 monoclonal antibody REGN1979 contains two antigen-recognition sites: one for human CD3, a T cell surface antigen, and one for human CD20, a tumor-associated antigen that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, odronextamab binds to both T-cells and CD20-expressing tumor B-cells, which cross-links the T-cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B-cells.	Odronextamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C119616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119616>	C1752	hTERT Multipeptide/Montanide ISA-51 VG/Imiquimod Vaccine GX 301|GX 301|GX301	A therapeutic cancer vaccine consisting of four epitopes derived from the human telomerase reverse transcriptase (hTERT), the catalytic subunit of human telomerase, including hTERT (540-548) acetate, hTERT (611-626) acetate, hTERT (672-686) acetate and hTERT (766-780) acetate, emulsified individually in the adjuvant montanide ISA-51 VG and administered with the immune response modifier (IRM) imiquimod, with potential immunostimulating and antineoplastic activities. Each hTERT peptide emulsion is administered individually by intradermal injection. Subsequently, imiquimod is applied topically to the injection site(s). Vaccination with GX 301 may elicit a cytotoxic T-cell (CTL) response against telomerase-expressing tumor cells. Telomerase is expressed in the majority of human cancer cells, infrequently expressed in normal cells, and is directly linked to tumorigenesis. Imiquimod stimulates cytokine production through the activation of toll-like receptor 7 (TLR-7), and also exhibits antiproliferative effects. Montanide ISA-51, also known as incomplete Freund's adjuvant (IFA), is a stabilized water-in-oil emulsion containing mineral oil with mannide oleate, which contains vegetable-grade (VG) oleic acid derived from olive oil. ISA-51 non-specifically stimulates cell-mediated immune responses to antigens.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C119617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119617>	C213381|C204256	Suratadenoturev|OBP-301|SURATADENOTUREV|Telomelycin|Telomelysin|Telomerase-specific Type 5 Adenovirus OBP-301	A replication-competent oncolytic, telomerase-specific adenovirus serotype 5 (Ad5), with potential antineoplastic activity. Suratadenoturev contains the human telomerase reverse transcriptase (hTERT) gene promoter sequence that drives the expression of the E1A and E1B genes, and is linked to an internal ribosomal entry site (IRES). Upon administration, OBP-301 selectively infects and replicates in cancer cells that are expressing telomerase, which causes cell lysis. This adenovirus does not infect or replicate in normal, healthy cells. OBP-301 may also potentially be used as a chemosensitizer. hTERT, which encodes for the catalytic protein subunit of telomerase, is overexpressed in a variety of cancer cell types but not in normal, healthy cells. The insertion of an IRES further improves selectivity towards telomerase-expressing cancer cells.	Suratadenoturev		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C119618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119618>	C192728	HIF-2alpha Inhibitor PT2385|PT-2385|PT2385	An orally active, small molecule inhibitor of hypoxia inducible factor (HIF)-2alpha, with potential antineoplastic activity. Upon oral administration, HIF-2alpha inhibitor PT2385 allosterically binds to HIF-2alpha, thereby preventing HIF-2alpha heterodimerization and its subsequent binding to DNA. This results in decreased transcription and expression of HIF-2alpha downstream target genes, many of which regulate tumor cell growth and survival. Blocking HIF-2alpha reduces the proliferation of HIF-2alpha-expressing tumor cells. HIF-2alpha, a heterodimeric transcription factor overexpressed in many cancers, promotes tumorigenesis.	HIF-2alpha Inhibitor PT2385		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C119619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119619>	C164001|C129822	Anti-C-met Monoclonal Antibody SAIT301|SAIT301	A humanized monoclonal antibody targeting the alpha chain of the extracellular domain of human hepatocyte growth factor receptor (HGFR or c-Met), with potential antineoplastic activity. Anti-c-Met monoclonal antibody SAIT301 binds to c-Met, thereby preventing both binding of its ligand, HGF, and the subsequent activation of the HGF/c-Met signaling pathway. In addition, SAIT301 induces c-MET internalization and subsequent degradation, which further inhibits c-Met-mediated signaling. This leads to a reduction in the proliferation of c-Met-expressing cancer cells. c-Met, a proto-oncogene receptor tyrosine kinase overexpressed in certain cancer cell types, is involved in various tumors.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11961>	C61063	Palivizumab/Ribavirin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119620>	C28227|C2496|C201598|C129822	Navicixizumab|Immunoglobulin G2-kappa, Anti-(Homo sapiens DLL4(delta-like 4)) and Anti-(Homo sapiens VEGFA (Vascular Endothelial Growth Factor A,VEGF-a, VEGF)), Humanized and Chimeric Monoclonal Antibody, Bispecific|NAVICIXIZUMAB|OMP 305B83|OMP-305B83|OMP305B83	A bispecific monoclonal antibody directed against both the Notch ligand delta-like 4 (DLL4) and the human tyrosine kinase vascular endothelial growth factor (VEGF), with potential anti-angiogenic and antineoplastic activities. The anti-DLL4 moiety of navicixizumab specifically binds to DLL4, prevents its interaction with Notch receptors, and inhibits Notch-mediated signaling and gene transcription, which may both block tumor angiogenesis and inhibit tumor cell growth. The anti-VEGF moiety binds to VEGF and prevents the binding of VEGF to its receptor, which blocks VEGF-mediated signaling and further inhibits the growth and maintenance of tumor blood vessels. The expression of DLL4 is highly restricted to the vascular endothelium; DLL4/Notch signaling is required for the development of functional tumor blood vessels. The expression of the pro-angiogenic growth factor VEGF is associated with tumor angiogenesis and tumor cell proliferation and invasion.	Navicixizumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C119621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119621>	C119607	DET1 wt Allele|De-Etiolated 1, Arabadopsis, Homolog of Gene|De-Etiolated Homolog 1 (Arabidopsis) wt Allele|FLJ10103	Human DET1 wild-type allele is located in the vicinity of 15q25.3 and is approximately 35 kb in length. This allele, which encodes DET1 homolog protein, is involved in the modulation of protein degradation following ubiquitination.			Gene or Genome	
C119622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119622>	C95242	DET1 Homolog|De-Etiolated 1|De-Etiolated-1 Homolog	DET1 homolog (550 aa, ~64 kDa) is encoded by the human DET1 gene. This protein plays a role in the regulation of protein ubiquitination.			Amino Acid, Peptide, or Protein	
C119623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119623>	C98083	Sotagliflozin|Beta-l-Xylopyranoside, methyl 5-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-1-thio-, (5S)-|LP 802034|LX4211|SOTAGLIFLOZIN	An orally bioavailable inhibitor of the sodium-glucose co-transporter subtype 1 (SGLT1) and 2 (SGLT2), with potential antihyperglycemic activity. Upon oral administration, sotagliflozin binds to and blocks both SGLT1 in the gastrointestinal (GI) tract and SGLT2 in the kidneys, thereby suppressing the absorption of glucose from the GI tract and the reabsorption of glucose by the proximal tubule into the bloodstream, respectively. This decreases glucose uptake and enhances the urinary excretion of glucose, which lowers and/or normalizes blood glucose levels. SGLT1 is the primary transporter responsible for glucose absorption from the GI tract. SGLT2, a transport protein exclusively expressed in the proximal renal tubules, mediates approximately 90% of renal glucose reabsorption from tubular fluid.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C119624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119624>	C2167|C129825	Mutant-selective EGFR Inhibitor PF-06459988|PF-06459988|PF-06459988	An orally available, small molecule, third-generation, irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant (EGFRm) forms with potential antineoplastic activity. EGFR inhibitor PF-06459988 specifically binds to and inhibits mutant forms of EGFR, including the secondary acquired resistance mutation T790M, which prevents EGFR-mediated signaling and leads to cell death in EGFRm-expressing tumor cells. Compared to some other EGFR inhibitors, PF-06459988 may have therapeutic benefits in tumors with T790M-mediated drug resistance. This agent shows minimal activity against wild-type EGFR (WT EGFR), and does not cause dose-limiting toxicities that are seen with the use of non-selective EGFR inhibitors, which also inhibit WT EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C119625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119625>	C20194	DDA1 Gene|DDA1|DDA1|DET1 and DDB1 Associated 1 Gene	This gene may be involved in protein ubiquitination and turnover.			Gene or Genome	
C119626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119626>	C119625	DDA1 wt Allele|C19orf58|Chromosome 19 Open Reading Frame 58 Gene|DET1 and DDB1 Associated 1 wt Allele|MGC2594|PCIA1	Human DDA1 wild-type allele is located in the vicinity of 19p13.11 and is approximately 14 kb in length. This allele, which encodes DET1- and DDB1-associated protein 1, may play a role in the regulation of protein ubiquitination.			Gene or Genome	
C119627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119627>	C95242	DET1- and DDB1-Associated Protein 1|Cross-Immune Reaction Antigen PCIA1|PCIA-1|Placenta Cross-Immune Reaction Antigen 1	DET1- and DDB1-associated protein 1 (102 aa, ~12 kDa) is encoded by the human DDA1 gene. This protein may be involved in the ubiquitination of target proteins.			Amino Acid, Peptide, or Protein	
C119628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119628>	C20921	TRIB1 Gene|TRIB1|TRIB1|Tribbles Pseudokinase 1 Gene	This gene plays a role in modulation of MAP kinase-dependent signaling.			Gene or Genome	
C119629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119629>	C119628	TRIB1 wt Allele|C8FW|GIG-2|GIG2|SKIP1|TRB-1|TRB1|Tribbles Homolog 1 (Drosophila) Gene|Tribbles Pseudokinase 1 wt Allele|Tribbles, Drosophila, Homolog of, 1 Gene	Human TRIB1 wild-type allele is located in the vicinity of 8q24.13 and is approximately 8 kb in length. This allele, which encodes tribbles homolog 1 protein, is involved in the regulation of MAP kinase-dependent signaling.			Gene or Genome	
C11962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11962>	C61063	Docetaxel/Fluorouracil/Leucovorin Calcium			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119630>	C18515	Tribbles Homolog 1|G-Protein-Coupled Receptor-Induced Gene 2 Protein|G-Protein-Coupled Receptor-Induced Protein 2|GIG-2|Phosphoprotein Regulated By Mitogenic Pathways|SKIP1|TRB-1|Tribbles-Like Protein 1	Tribbles homolog 1 (372 aa, ~41 kDa) is encoded by the human TRIB1 gene. This protein plays a role in the regulation of MAP kinase activity.			Amino Acid, Peptide, or Protein	
C119631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119631>	C25784	RAB7A Gene|RAB7A|RAB7A|RAB7A, Member RAS Oncogene Family Gene	This gene is involved in the trafficking of endosomes and lysosomes.			Gene or Genome	
C119632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119632>	C119631	RAB7A wt Allele|CMT2B|PRO2706|RAB7|RAB7, Member RAS Oncogene Family Gene|RAB7A, Member RAS Oncogene Family wt Allele	Human RAB7A wild-type allele is located in the vicinity of 3q21 and is approximately 89 kb in length. This allele, which encodes ras-related protein Rab-7a, plays a role in the localization and function of both endosomes and lysosomes. Mutation of the gene is associated with Charcot-Marie-Tooth disease 2B.			Gene or Genome	
C119633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119633>	C18549	Ras-Related Protein Rab-7a|Ras-Associated Protein RAB7	Ras-related protein Rab-7a (207 aa, ~23 kDa) is encoded by the human RAB7A gene. This protein is involved in many cellular processes that involve endosomes or lysosomes.			Amino Acid, Peptide, or Protein|Enzyme	NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C119634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119634>	C25784	RAB27A Gene|RAB27A|RAB27A|RAB27A, Member RAS Oncogene Family Gene	This gene plays a role in the formation and release of lymphocytic granules.	RAB27A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C119635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119635>	C119634	RAB27A wt Allele|GS2|HsT18676|RAB27|RAB27A, Member RAS Oncogene Family wt Allele|RAM|RAS-Related Gene From Megakaryocyte Gene	Human RAB27A wild-type allele is located within 15q15-q21.1 and is approximately 116 kb in length. This allele, which encodes ras-related protein Rab-27A, is involved in the maturation and release of lymphocytic granules. Mutation of the gene is associated with Griscelli syndrome 2.	RAB27A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C119636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119636>	C18549	Ras-Related Protein Rab-27A|GTP-Binding Protein Ram|Rab-27|Ras-Associated Protein RAB27A	Ras-related protein Rab-27A (221 aa, ~25 kDa) is encoded by the human RAB27A gene. This protein plays a role in the exocytosis of cytotoxic granules from lymphocytes.	Ras-Related Protein Rab-27A		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C119637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119637>	C133710	HACE1 Gene|HACE1|HACE1|HECT Domain and Ankyrin Repeat Containing E3 Ubiquitin Protein Ligase 1 Gene	This gene is involved in both protein ubiquitination and Golgi membrane dynamics.			Gene or Genome	
C119638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119638>	C119637	HACE1 wt Allele|HECT Domain and Ankyrin Repeat Containing E3 Ubiquitin Protein Ligase 1 wt Allele|KIAA1320	Human HACE1 wild-type allele is located in the vicinity of 6q16.3 and is approximately 132 kb in length. This allele, which encodes E3 ubiquitin-protein ligase HACE1 protein, plays a role in the modulation of both Golgi membrane dynamics and ubiquitination. Mutations of the gene, including translocations that either reduce expression of the gene (t(6;15)(q21;q21)) or truncate the gene (t(5;6)(q21;q21)), are associated with Wilms tumor.			Gene or Genome	
C119639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119639>	C21254	E3 Ubiquitin-Protein Ligase HACE1|EC 2.3.2.26|EC 6.3.2.-, Formerly|HECT Domain and Ankyrin Repeat-Containing E3 Ubiquitin-Protein Ligase 1|HECT Domain- and Ankyrin Repeat-Containing E3 Ubiquitin Protein Ligase 1	E3 ubiquitin-protein ligase HACE1 (909 aa, ~102 kDa) is encoded by the human HACE1 gene. This protein is involved in the regulation of both the ubiquitination and subsequent degradation of small GTPases, which modulates Golgi membrane dynamics.			Amino Acid, Peptide, or Protein|Enzyme	
C11963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11963>	C61063	Detox-B Adjuvant/RAS Peptide Cancer Vaccine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119640>	C20194	OPTN Gene|OPTN|OPTN|Optineurin Gene	This gene plays a role in both neuroprotection and Golgi maintenance			Gene or Genome	
C119641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119641>	C119640	OPTN wt Allele|ALS12|FIP2|GLC1E|Glaucoma 1, Open Angle, E (Adult-Onset) Gene|HIP7|HYPL|NRP|Optineurin wt Allele|RP11-730A19.1|TFIIIA-INTP	Human OPTN wild-type allele is located in the vicinity of 10p13 and is approximately 39 kb in length. This allele, which encodes optineurin protein, is involved in both Golgi maintenance and neuronal survival. Mutation of the gene is associated with both amyotrophic lateral sclerosis 12 and open angle glaucoma 1E.			Gene or Genome	
C119642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119642>	C18466	Optineurin|E3-14.7K-Interacting Protein|FIP-2|HIP-7|Huntingtin Interacting Protein L|Huntingtin Yeast Partner L|Huntingtin-Interacting Protein 7|Huntingtin-Interacting Protein L|NEMO-Related Protein|Optic Neuropathy-Inducing Protein|TFIIIA-IntP|Transcription Factor IIIA-Interacting Protein|Tumor Necrosis Factor Alpha-Inducible Cellular Protein Containing Leucine Zipper Domains	Optineurin (577 aa, ~66 kDa) is encoded by the human OPTN gene. This protein plays a role in the maintenance of both neurons and the Golgi apparatus.			Amino Acid, Peptide, or Protein	
C119643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119643>	C20921	KLB Gene|KLB|KLB|Klotho Beta Gene	This gene is involved in growth factor signaling.	KLB Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C119644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119644>	C119643	KLB wt Allele|BKL|Klotho Beta Like Gene|Klotho Beta wt Allele|Klotho, Beta Gene	Human KLB wild-type allele is located in the vicinity of 4p14 and is approximately 45 kb in length. This allele, which encodes beta-klotho protein, plays a role in the modulation of growth factor signaling pathways.	KLB wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C119645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119645>	C18515	Beta-Klotho|BKL|BetaKlotho|KLB|Klotho Beta-Like Protein	Beta-klotho (1044 aa, ~120 kDa) is encoded by the human KLB gene. This protein is involved in the regulation of growth factor-dependent signaling.	Beta-Klotho		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C119646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119646>	C133708	UBE2N Gene|UBE2N|UBE2N|Ubiquitin-Conjugating Enzyme E2N Gene	This gene plays a role in polyubiquitination.			Gene or Genome	
C119647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119647>	C119646	UBE2N wt Allele|BLU|Bendless, Drosophila, Homolog of Gene|HEL-S-71|MGC8489|UBC13|UBCHBEN|UbcH-ben|UbcH13|Ubiquitin-Conjugating Enzyme 13, S. cerevisiae, Homolog of Gene|Ubiquitin-Conjugating Enzyme E2N (Homologous To Yeast UBC13) Gene|Ubiquitin-Conjugating Enzyme E2N (UBC13 Homolog, Yeast) Gene|Ubiquitin-Conjugating Enzyme E2N wt Allele|Yeast UBC13 Homolog Gene	Human UBE2N wild-type allele is located in the vicinity of 12q22 and is approximately 37 kb in length. This allele, which encodes ubiquitin-conjugating enzyme E2 N protein, is involved in polyubiquitination of target proteins and may play a role in transcriptional regulation.			Gene or Genome	
C119648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119648>	C133711	Ubiquitin-Conjugating Enzyme E2 N|Bendless-Like Ubiquitin Conjugating Enzyme|Bendless-Like Ubiquitin-Conjugating Enzyme|E2 Ubiquitin-Conjugating Enzyme N|EC 2.3.2.23|EC 6.3.2.19, Formerly|Epididymis Secretory Protein Li 71|UBE2N|Ubc13|UbcH13|Ubiquitin Carrier Protein N|Ubiquitin-Protein Ligase N	Ubiquitin-conjugating enzyme E2 N (152 aa, ~17 kDa) is encoded by the human UBE2N gene. This protein plays a role in the polyubiquitination of protein substrates, which may regulate transcription.			Amino Acid, Peptide, or Protein|Enzyme	
C119649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119649>	C25997	SH3PXD2B Gene|SH3 and PX Domains 2B Gene|SH3PXD2B|SH3PXD2B	This gene is involved in the formation of invadopodia.			Gene or Genome	
C11964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11964>	C61007	Docetaxel/Filgrastim/Gemcitabine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119650>	C119649	SH3PXD2B wt Allele|FAD49|FLJ20831|FTHS|HOFI|KIAA1295|SH3 and PX Domains 2B wt Allele|TKS4|TSK4	Human SH3PXD2B wild-type allele is located in the vicinity of 5q35.1 and is approximately 129 kb in length. This allele, which encodes SH3 and PX domain-containing protein 2B, plays a role in podosome assembly. Mutation of the gene is associated with Frank-Ter Haar syndrome.			Gene or Genome	
C119651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119651>	C26231	SH3 and PX Domain-Containing Protein 2B|Adapter Protein HOFI|Adaptor Protein HOFI|Factor For Adipocyte Differentiation 4|SH3PXD2B|Tyrosine Kinase Substrate With Four SH3 Domains	SH3 and PX domain-containing protein 2B (911 aa, ~102 kDa) is encoded by the human SH3PXD2B gene. This protein is involved in the assembly of invadopodia.			Amino Acid, Peptide, or Protein	
C119652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119652>	C20917	KNSTRN Gene|KNSTRN|KNSTRN|KNSTRN|Kinetochore-Localized Astrin/SPAG5 Binding Protein Gene	This gene plays a role in both mitotic spindle formation and chromosome segregation.			Gene or Genome	GDC Terminology|GDC Value Terminology
C119653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119653>	C119652	KNSTRN wt Allele|C15orf23|Chromosome 15 Open Reading Frame 23 Gene|FLJ14502|HSD11|Kinetochore-Localized Astrin/SPAG5 Binding Protein wt Allele|SKAP|Small Kinetochore-Associated Protein, Kinetochore-Localized Astrin-Binding Protein, TRAF4 Associated Factor 1 Gene|TRAF4AF1	Human KNSTRN wild-type allele is located in the vicinity of 15q15.1 and is approximately 12 kb in length. This allele, which encodes small kinetochore-associated protein, is involved in the metaphase/anaphase transition of the mitotic cell cycle.			Gene or Genome	
C119654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119654>	C17761	Small Kinetochore-Associated Protein|Kinastrin|Kinetochore-Localized Astrin-Binding Protein|Kinetochore-Localized Astrin/SPAG5-Binding Protein|Putative TRAF4-Associated Factor 1|SKAP|Small Kinetochore Associated Protein|TRAF4 Associated Factor 1|TRAF4-Associated Factor 1	Small kinetochore-associated protein (316 aa, ~35 kDa) is encoded by the human KNSTRN gene. This protein plays a role in the progression of mitosis.			Amino Acid, Peptide, or Protein	
C119655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119655>	C20194	FALEC Gene|FALEC|FALEC|Focally Amplified Long Non-Coding RNA in Epithelial Cancer Gene	This gene may be involved in carcinogenesis.			Gene or Genome	
C119656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119656>	C119655	FALEC wt Allele|ENSG00000228126|FAL1|Focally Amplified LncRNA on Chromosome 1 Gene|Focally Amplified Long Non-Coding RNA in Epithelial Cancer wt Allele|LINC00568|Long Intergenic Non-Protein Coding RNA 568 Gene|RP11-54A4.8|ncRNA-a1	Human FALEC wild-type allele is located in the vicinity of 1q21.3 and is approximately 2 kb in length. This allele, which encodes focally amplified long non-coding RNA in epithelial cancer, may play a role in tumorigenesis.			Gene or Genome	
C119657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119657>	C88924	Focally Amplified Long Non-Coding RNA in Epithelial Cancer|FAL1|FALEC|Focally Amplified LncRNA on Chromosome 1|LINC00568|Long Intergenic Non-Protein Coding RNA 568|ncRNA-a1	Focally amplified long non-coding RNA in epithelial cancer (566 bp) is encoded by the human FALEC gene. This non-coding RNA may be involved in oncogenesis.			Nucleic Acid, Nucleoside, or Nucleotide	
C119658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119658>	C25871	DGKH Gene|DGKH|DGKH|Diacylglycerol Kinase, Eta Gene	This gene plays a role in both diacylglycerol phosphorylation and the promotion of cell growth.			Gene or Genome	
C119659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119659>	C119658	DGKH wt Allele|DGKeta|Diacylglycerol Kinase, Eta wt Allele|RP11-215B13.1	Human DGKH wild-type allele is located in the vicinity of 13q14.11 and is approximately 217 kb in length. This allele, which encodes diacylglycerol kinase eta protein, is involved in second messenger signaling to promote cell growth.			Gene or Genome	
C11965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11965>	C61007	Bismuth Bi213 Monoclonal Antibody M195/Cytarabine/Filgrastim			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119660>	C16984	Diacylglycerol Kinase Eta|DAG Kinase Eta|DGK-Eta|DGKH|Diglyceride Kinase Eta|EC 2.7.1.107	Diacylglycerol kinase eta (1220 aa, ~135 kDa) is encoded by the human DGKH gene. This protein plays a role in the phosphorylation of diacylglycerol.			Amino Acid, Peptide, or Protein|Enzyme	
C119661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119661>	C20745	RCSD1 Gene|RCSD Domain Containing 1 Gene|RCSD1|RCSD1	This gene is involved in binding to F-actin.			Gene or Genome	
C119662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119662>	C119661	RCSD1 wt Allele|CAPZIP|MGC21854|MK2S4|RCSD Domain Containing 1 wt Allele|RP3-503M14.1	Human RCSD1 wild-type allele is located in the vicinity of 1q24.2 and is approximately 76 kb in length. This allele, which encodes CapZ-interacting protein, may play a role in the remodeling of F-actin.			Gene or Genome	
C119663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119663>	C16492	CapZ-Interacting Protein|Protein Kinase Substrate CapZIP|Protein Kinase Substrate MK2S4|RCSD Domain-Containing Protein 1|RCSD1	CapZ-interacting protein (416 aa, ~45 kDa) is encoded by the human RCSD1 gene. This protein may be involved in the modulation of actin filament formation.			Amino Acid, Peptide, or Protein	
C119664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119664>	C1572	Recombinant Human Papillomavirus Nonavalent Vaccine|Gardasil 9|Nonavalent HPV VLP Vaccine|Recombinant HPV Nonavalent Vaccine|Recombinant Human Papillomavirus 9-valent Vaccine	A non-infectious, recombinant, nonavalent vaccine prepared from highly purified virus-like particles (VLPs) comprised of the major capsid (L1) proteins from human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, and 58, with active immunizing activity. Upon administration, the recombinant HPV nonavalent vaccine activates the immune system to produce antibodies against the 9 HPV types. This protects against HPV infection and HPV-related cancers. Altogether, HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 account for the majority of the HPV types that cause cervical, vulvar, vaginal and anal cancers.	Recombinant Human Papillomavirus Nonavalent Vaccine		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C119665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119665>	C213472	Gilteritinib Fumarate|2-Pyrazinecarboxamide, 6-ethyl-3-((3-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)-, (2E)-2-Butenedioate (2:1)|ASP-2215 Hemifumarate|ASP2215 Hemifumarate|GILTERITINIB FUMARATE|Gilteritinib Hemifumarate|Xospata	The fumarate salt form of gilteritinib, an orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), with potential antineoplastic activity. Upon administration, gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL, ALK and LTK. This may result in an inhibition of FLT3-, AXL-, ALK-, and LTK-mediated signal transduction pathways and reduced proliferation in cancer cells that overexpress these RTKs. FLT3, AXL, ALK, and LTK, which are overexpressed or mutated in a variety of cancer cell types, play key roles in tumor cell growth and survival.	Gilteritinib Fumarate		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C119666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119666>	C54362	ZMIZ1 Gene|ZMIZ1|ZMIZ1|Zinc Finger, MIZ-Type Containing 1 Gene	This gene plays a role in androgen receptor-mediated gene expression.			Gene or Genome	
C119667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119667>	C119666	ZMIZ1 wt Allele|FLJ00092|FLJ13541|KIAA1224|MIZ|RAI17|RP11-519K18.1|Retinoic Acid Induced 17 Gene|Retinoic Acid-Induced Gene 17|TRAFIP10|ZIMP10|Zinc Finger, MIZ-Type Containing 1 wt Allele|Zinc Finger-Containing, Miz1, PIAS-Like Protein on Chromosome 10 Gene|hZIMP10	Human ZMIZ1 wild-type allele is located in the vicinity of 10q22.3 and is approximately 247 kb in length. This allele, which encodes zinc finger MIZ domain-containing protein 1, is involved in the modulation of androgen receptor-dependent genes.			Gene or Genome	
C119668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119668>	C26199	Zinc Finger MIZ Domain-Containing Protein 1|PIAS-Like Protein Zimp10|Retinoic Acid-Induced Protein 17|ZMIZ1|Zinc Finger MIZ-Domain Containing 1	Zinc finger MIZ domain-containing protein 1 (1067 aa, ~115 kDa) is encoded by the human ZMIZ1 gene. This protein plays a role in the regulation of transcription by mediating the sumoylation of androgen receptor.			Amino Acid, Peptide, or Protein	
C119669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119669>	C16126	Patient Outcomes Registry|Outcomes Registry	A registry that uses observational study methods to collect uniform data to evaluate specified outcomes for a defined patient population, and that serves a scientific, clinical, or policy purpose.	Patient Outcomes Registry		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C11966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11966>	C61063	Autologous Tumor Cell Vaccine/BCG			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119670>	C20710	ATF7IP Gene|ATF7IP|ATF7IP|Activating Transcription Factor 7 Interacting Protein Gene	This gene is involved in the regulation of both histone methylation and transcription.			Gene or Genome	
C119671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119671>	C119670	ATF7IP wt Allele|AM|ATF-IP|ATFA Modulator, Mouse, Homolog of Gene|Activating Transcription Factor 7 Interacting Protein wt Allele|MCAF|MCAF1|p621	Human ATF7IP wild-type allele is located in the vicinity of 12p13.1 and is approximately 133 kb in length. This allele, which encodes activating transcription factor 7-interacting protein 1, plays a role in the modulation of both transcription and histone methylation.			Gene or Genome	
C119672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119672>	C26199	Activating Transcription Factor 7-Interacting Protein 1|ATF-IP|ATF-Interacting Protein|ATF7-Interacting Protein|ATF7IP|ATFa-Associated Modulator|Activating Transcription Factor 7-Interacting Protein|MBD1-Containing Chromatin-Associated Factor 1|P621|hAM	Activating transcription factor 7-interacting protein 1 (1270 aa, ~136 kDa) is encoded by the human ATF7IP gene. This protein is involved in both transcriptional regulation and histone methylation.			Amino Acid, Peptide, or Protein	
C119673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119673>	C20921	IQGAP2 Gene|IQ Motif Containing GTPase Activating Protein 2 Gene|IQGAP2|IQGAP2	This gene plays a role in the regulation of Ras superfamily GTPase activity.			Gene or Genome	
C119674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119674>	C119673	IQGAP2 wt Allele|IQ Motif Containing GTPase Activating Protein 2 wt Allele	Human IQGAP2 wild-type allele is located in the vicinity of 5q13.3 and is approximately 305 kb in length. This allele, which encodes Ras GTPase-activating-like protein IQGAP2, is involved in the modulation of the activity of small GTPases.			Gene or Genome	
C119675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119675>	C17298	Ras GTPase-Activating-Like Protein IQGAP2|IQ Motif Containing GTPase-Activating Protein 2	Ras GTPase-activating-like protein IQGAP2 (1575 aa, ~181 kDa) is encoded by the human IQGAP2 gene. This protein plays a role in the modulation of Ras family-mediated signaling.			Amino Acid, Peptide, or Protein	
C119676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119676>	C53543	D-Bifunctional Protein Deficiency|D-Bifunctional Enzyme Deficiency|Multifunctional Enzyme Deficiency|Peroxisomal Multifunctional Enzyme (MFE2) Deficiency|Peroxisomal Multifunctional Enzyme Deficiency|Pseudo-Zellweger Syndrome	A rare, autosomal recessive inherited disorder caused by mutation in the HSD17B4 gene. It is characterized by neurodegeneration that begins in infancy, hypotonia, and seizures. The majority of the affected individuals lack developmental skills.	D-Bifunctional Protein Deficiency		Disease or Syndrome	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology
C119677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119677>	C53543	Alpha-Methylacyl-CoA Racemase Deficiency|AMACR	A rare disorder caused by mutation in the AMACR gene. It is characterized by neurological abnormalities that appear in adulthood and include cognitive decline, seizures, and sensorimotor neuropathy.	Alpha-Methylacyl-CoA Racemase Deficiency		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C119678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119678>	C53543	Mitochondrial Neurogastrointestinal Encephalopathy|MNGIE	A rare, autosomal recessive inherited disorder caused by mutation in the TYMP gene. It affects several parts of the body, particularly the gastrointestinal tract and nervous system. Signs and symptoms can appear in infancy, but they often begin by age twenty. The gastrointestinal signs and symptoms result from gastrointestinal dysmotility and include fullness after eating small amounts of food, dysphagia, nausea and vomiting after eating, abdominal pain, diarrhea, and intestinal blockage. The nervous system abnormalities include leukoencephalopathy, tingling, numbness, peripheral neuropathy, ptosis, ophthalmoplegia, and hearing loss.	Mitochondrial Neurogastrointestinal Encephalopathy		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C119679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119679>	C130042	Dual-Energy Contrast-Enhanced Digital Spectral Mammography|Dual-Energy CEDM|Dual-Energy Contrast-Enhanced Digital Subtraction Mammography	A technique that uses high-energy and low-energy digital mammography with administration of an iodinated contrast agent. The differences between X-ray attenuation of iodine and breast tissues at these two energy levels are used to suppress the background breast tissue. This technique is useful in identifying lesions in dense breasts that are not visible using standard mammography.	Dual-Energy Contrast-Enhanced Digital Spectral Mammography		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C11967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11967>	C61063	Dacarbazine/Oblimersen			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119680>	C21295	PTX3 Gene|PTX3|PTX3|Pentraxin 3, Long Gene	This gene is involved in complement recognition of pathogens.	PTX3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C119681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119681>	C119680	PTX3 wt Allele|Pentaxin-Related Gene, Rapidly Induced by IL-1 Beta Gene|Pentraxin 3, Long wt Allele|Pentraxin-Related Gene, Rapidly Induced by IL-1 Beta Gene|TNFAIP5|TSG-14|TSG14|Tumor Necrosis Factor, Alpha-Induced Protein 5 Gene|Tumor Necrosis Factor-Inducible Gene 14	Human PTX3 wild-type allele is located in the vicinity of 3q25 and is approximately 7 kb in length. This allele, which encodes pentraxin-related protein PTX3, plays a role in both complement activation and inflammation.	PTX3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C119682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119682>	C17728	Pentraxin-Related Protein PTX3|Pentaxin-Related Protein PTX3|Pentraxin 3|Pentraxin-3|TNF Alpha-Induced Protein 5|TSG-14|Tumor Necrosis Factor Alpha-Induced Protein 5|Tumor Necrosis Factor-Inducible Gene 14 Protein|Tumor Necrosis Factor-Inducible Protein TSG-14	Pentraxin-related protein PTX3 (381 aa, ~42 kDa) is encoded by the human PTX3 gene. This protein is involved in both inflammation and complement recognition of pathogens.	Pentraxin-Related Protein PTX3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C119683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119683>	C20988	AMIGO2 Gene|AMIGO2|AMIGO2|Adhesion Molecule With Ig-Like Domain 2 Gene	This gene plays a role in cell-cell adhesion.			Gene or Genome	
C119684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119684>	C119683	AMIGO2 wt Allele|ALI1|AMIGO-2|Adhesion Molecule With Ig-Like Domain 2 wt Allele|Amphoterin Induced Gene 2|Amphoterin-Induced Gene and Open Reading Frame 2|DEGA	Human AMIGO2 wild-type allele is located in the vicinity of 12q13.11 and is approximately 4 kb in length. This allele, which encodes amphoterin-induced protein 2, is involved in both cell-cell adhesion and the inhibition of apoptosis.			Gene or Genome	
C119685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119685>	C16393	Amphoterin-Induced Protein 2|AMIGO-2|Alivin 1|Alivin-1|DEGA|Differentially Expressed In Gastric Adenocarcinoma|Differentially Expressed In Gastric Adenocarcinomas|Transmembrane Protein AMIGO2	Amphoterin-induced protein 2 (522 aa, ~58 kDa) is encoded by the human AMIGO2 gene. This protein plays a role in both the negative regulation of apoptosis and the mediation of cell-cell adhesion.			Amino Acid, Peptide, or Protein	
C119686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119686>	C28533	SLC7A2 Gene|SLC7A2|SLC7A2|Solute Carrier Family 7 (Cationic Amino Acid Transporter, Y+ System), Member Gene	This gene is involved in the transport of the cationic amino acids.			Gene or Genome	
C119687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119687>	C119686	SLC7A2 wt Allele|ATRC2|Amino Acid Transporter, Cationic 2 Gene|CAT2|HCAT2|Solute Carrier Family 7 (Cationic Amino Acid Transporter, Y+ System), Member 2 wt Allele	Human SLC7A2 wild-type allele is located in the vicinity of 8p22 and is approximately 73 kb in length. This allele, which encodes cationic amino acid transporter 2, plays a role in amino acid transport.			Gene or Genome	
C119688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119688>	C16386	Cationic Amino Acid Transporter 2|CAT-2|Low Affinity Cationic Amino Acid Transporter 2|SLC7A2|Solute Carrier Family 7 Member 2	Cationic amino acid transporter 2 (658 aa, ~72 kDa) is encoded by the human SLC7A2 gene. This protein is involved in the transmembrane transport of cationic amino acids.			Amino Acid, Peptide, or Protein	
C119689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119689>	C25870|C20420	CLOCK Gene|CLOCK|CLOCK|Clock Circadian Regulator Gene	This gene plays a role in the expression of genes involved in circadian rhythm.			Gene or Genome	
C11968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11968>	C61063	3-AP/Cisplatin/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119690>	C119689	CLOCK wt Allele|BHLHE8|Circadian Locomoter Output Cycles Kaput Gene|Clock (Mouse) Homolog Gene|Clock Circadian Regulator wt Allele|Clock Homolog (Mouse) Gene|Clock, Mouse, Homolog of Gene|KAT13D|KIAA0334|bHLHe8	Human CLOCK wild-type allele is located in the vicinity of 4q12 and is approximately 119 kb in length. This allele, which encodes circadian locomoter output cycles protein kaput, is involved in the regulation of circadian rhythms, histone acetylation and gene transcription.			Gene or Genome	
C119691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119691>	C17302|C17207	Circadian Locomoter Output Cycles Protein Kaput|CLOCK|Circadian Locomoter Output Cycles Kaput Protein|Class E Basic Helix-Loop-Helix Protein 8|Clock Homolog|EC 2.3.1.48|bHLHe8|hCLOCK	Circadian locomoter output cycles protein kaput (846 aa, ~95 kDa) is encoded by the human CLOCK gene. This protein plays a role in the modulation of histone acetylation that regulates both gene expression and circadian rhythms.			Amino Acid, Peptide, or Protein|Enzyme	
C119692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119692>	C20420	BMAL1 Gene|ARNTL|BMAL1|BMAL1|Basic Helix-Loop-Helix ARNT Like 1 Gene	This gene is involved in transcriptional activation of genes in the circadian clock pathway.			Gene or Genome	
C119693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119693>	C119692	BMAL1 wt Allele|ARNT-Like Protein 1, Brain and Muscle Gene|ARNTL|Aryl Hydrocarbon Receptor Nuclear Translocator-Like Gene|BHLHE5|BMAL1b|BMAL1c|Basic Helix-Loop-Helix ARNT Like 1 wt Allele|Basic Helix-Loop-Helix Family Member E5 Gene|Cycle, Drosophila, Homolog of Gene|JAP3|MOP3|PAS Domain Containing 3 Gene|PASD3|TIC|TIC, Mouse, Homolog of Gene|bHLHe5	Human BMAL1 wild-type allele is located in the vicinity of 11p15.3 and is approximately 111 kb in length. This allele, which encodes basic helix-loop-helix ARNT-like protein 1, plays a role in the transcriptional activation of genes involved in circadian rhythms.			Gene or Genome	
C119694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119694>	C17207	Basic Helix-Loop-Helix ARNT-Like Protein 1|ARNTL|Aryl Hydrocarbon Receptor Nuclear Translocator-Like Protein|Aryl Hydrocarbon Receptor Nuclear Translocator-Like Protein 1|BHLH-PAS Protein JAP3|BMAL1|BMAL1B|Basic-Helix-Loop-Helix-PAS Protein MOP3|Brain and Muscle ARNT-Like 1|Brain and Muscle ARNT-Like Protein 1|Class E Basic Helix-Loop-Helix Protein 5|Member of PAS Protein 3|Member of PAS Superfamily 3|PAS Domain-Containing Protein 3|bHLH-PAS protein JAP3|bHLHe5	Basic helix-loop-helix ARNT-like protein 1 (626 aa, ~69 kDa) is encoded by the human BMAL1 gene. This protein is involved in the activation of gene transcription that mediates circadian rhythm.			Amino Acid, Peptide, or Protein	NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C119695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119695>	C20420	BMAL2 Gene|ARNTL2|BMAL2|BMAL2|Basic Helix-Loop-Helix ARNT Like 2 Gene	This gene plays a role in the positive regulation of transcription for genes involved in circadian rhythms.			Gene or Genome	
C119696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119696>	C119695	BMAL2 wt Allele|ARNTL2|Aryl Hydrocarbon Receptor Nuclear Translocator Like 2 Gene|BHLHE6|Basic Helix-Loop-Helix ARNT Like 2 wt Allele|CLIF|MOP9|PASD9|bHLHe6	Human BMAL2 wild-type allele is located in the vicinity of 12p11.23 and is approximately 92 kb in length. This allele, which encodes basic helix-loop-helix ARNT-like protein 2, is involved in both transcriptional activation and circadian rhythms.			Gene or Genome	
C119697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119697>	C17207	Basic Helix-Loop-Helix ARNT-Like Protein 2|ARNTL2|Aryl Hydrocarbon Receptor Nuclear Translocator-Like Protein 2|BMAL2|Basic-Helix-Loop-Helix-PAS Protein MOP9|Brain and Muscle ARNT-Like 2|Brain and Muscle ARNT-Like Protein 2|CLIF|CYCLE-Like Factor|Class E Basic Helix-Loop-Helix Protein 6|Member of PAS Protein 9|Member of PAS Superfamily  9|PAS Domain-Containing Protein 9|Transcription Factor BMAL2|bHLHe6	Basic helix-loop-helix ARNT-like protein 2 (636 aa, ~71 kDa) is encoded by the human BMAL2 gene. This protein plays a role in the transcriptional activation of genes involved in circadian rhythms.			Amino Acid, Peptide, or Protein	
C119698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119698>	C105770	Have Swelling in Stomach Area Question|Have Swelling in Stomach Area|I have swelling in my stomach area	A question about whether an individual has or had swelling in the area of the stomach.			Intellectual Product	FACT-O Questionnaire
C119699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119699>	C173981	Have Cramps in Stomach Area Question|Have Cramps in Stomach Area|I have cramps in my stomach area	A question about whether an individual has or had cramps in the area of the stomach.			Intellectual Product	FACT-O Questionnaire
C11969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11969>	C61063	GPI-0100/MUC-2-Globo H-KLH Conjugate Vaccine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1196>	C798	Pimonidazole|1-piperidineethanol, alpha-((2-nitro-1h-imidazol-1-yl)methyl)-|PD 126675|PIMONIDAZOLE|Ro 03-8799	A 2-nitroimidazole with hypoxic selectivity and potential radiosensitizing activities. Pimonidazole is reduced in hypoxic environments such as those found in tumors. In hypoxic cells, reduced pimonidazole binds to thiol-containing proteins. The resulting complexes accumulate in hypoxic tumors, thereby depleting radioprotective thiol compounds and sensitizing tumor cells to be more susceptible for radiation treatment.			Indicator, Reagent, or Diagnostic Aid|Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C119700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119700>	C211912|C206201	Anti-CD37 MMAE Antibody-drug Conjugate AGS67E|AGS67E|Anti-CD37 MMAE ADC AGS67E	An antibody-drug conjugate (ADC) composed of AGS67C, a human anti-CD37 monoclonal antibody covalently linked, via reduced cysteines and a protease cleavable linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of AGS67E binds to CD37 antigens on tumor B-cells and is rapidly internalized, thereby delivering MMAE intracellularly. Upon proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M checkpoint arrest and apoptosis in CD37-expressing tumor cells. CD37, a transmembrane glycoprotein, is overexpressed in B-cell malignancies.	Anti-CD37 MMAE Antibody-drug Conjugate AGS67E		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C119701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119701>	C471	Antroquinonol Capsule|ANTROQUINONOL|Hocena	An orally available capsule containing antroquinonol, a farnesylated quinone derivative isolated from the mycelium of Antrodia camphorata, with potential antineoplastic activity. Upon oral administration, antroquinonol binds to and inhibits protein prenylation mediated by the enzymes farnesyltransferase (FTase) and geranylgeranyltransferase 1 (GGTase-1). This prevents both post-translational prenylation and signaling activity of a number of Ras superfamily proteins, such as Ras and Rho. This results in the inhibition of downstream signaling, such as the PI3K/mTOR signaling pathway, and induces apoptosis in susceptible tumor cells. Ras superfamily proteins are overexpressed in numerous cancer cell types, and play a key role in tumor cell proliferation and survival.	Antroquinonol Capsule		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C119702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119702>	C2124	Carbon C14-labeled Carboplatin|14C Carboplatin|Carbon-14-labeled Carboplatin	A radioconjugate composed of the platinum compound carboplatin conjugated to the isotope carbon C 14 (14C-carboplatin), which can potentially be used to predict chemoresistance to carboplatin using accelerator mass spectrometry (AMS). Upon administration of a microdose of 14C-carboplatin, the carboplatin moiety covalently binds to DNA and forms carboplatin-DNA monoadducts. Using AMS, the 14C-carboplatin-DNA monoadducts can be detected and measured. The levels of microdose-induced carboplatin-DNA monoadducts can be used to assess the degree of chemoresistance to carboplatin and can predict cancer response to carboplatin-based chemotherapy. The carboplatin microdose is defined as 1/100 of the pharmacologically effective concentration of carboplatin. Low levels of carboplatin monoadduct formation and increased DNA repair, measured by a decrease in the detection of carboplatin-DNA monoadducts over a given time period, are correlated with increased resistance to platinum-based chemotherapeutics.	Carbon C14-labeled Carboplatin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C119703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119703>	C28681|C201547	Autologous 4-1BB Selected Tumor Infiltrating Lymphocytes|Autologous 4-1BB selected TILs	A preparation of autologous tumor infiltrating lymphocytes (TILs) expressing the co-stimulatory signaling domain 4-1BB (CD137), with potential antineoplastic activity. TILs are isolated from a patient's tumor and those expressing 4-1BB are selected for expansion in vitro. Upon re-infusion into the patient, the 4-1BB-expressing TILs re-infiltrate the tumor to initiate tumor cell lysis. 4-1BB, a member of the tumor necrosis factor (TNF) receptor superfamily, enhances TIL survival and antitumor cytolytic activity.	Autologous 4-1BB Selected Tumor Infiltrating Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C119704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119704>	C20917	CKAP5 Gene|CKAP5|CKAP5|Cytoskeleton Associated Protein 5 Gene	This gene is involved in the regulation of microtubule organization.			Gene or Genome	
C119705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119705>	C119704	CKAP5 wt Allele|CHTOG|Colonic and Hepatic Tumor Over-Expressed Gene|Colonic and Hepatic Tumor Overexpressed Gene|Cytoskeleton Associated Protein 5 wt Allele|KIAA0097|MSPS|Mini Spindles, Drosophila, Homolog of Gene|TOG|TOGp|ch-TOG	Human CKAP5 wild-type allele is located in the vicinity of 11p11.2 and is approximately 103 kb in length. This allele, which encodes cytoskeleton-associated protein 5, plays a role in the modulation of microtubule polymerization.			Gene or Genome	
C119706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119706>	C17761	Cytoskeleton-Associated Protein 5|Ch-TOG|Colonic and Hepatic Tumor Over-Expressed Gene Protein	Cytoskeleton-associated protein 5 (2032 aa, ~225 kDa) is encoded by the human CKAP5 gene. This protein is involved in mitotic spindle organization.			Amino Acid, Peptide, or Protein	
C119707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119707>	C20338	ACD Gene|ACD|ACD|ACD|ACD, Shelterin Complex Subunit and Telomerase Recruitment Factor Gene	This gene plays a role in telomere maintenance.	ACD Gene		Gene or Genome	CCPS Genetics Terminology|Childhood Cancer Predisposition Study Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C119708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119708>	C119707	ACD wt Allele|ACD, Mouse, Homolog of Gene|ACD, Shelterin Complex Subunit and Telomerase Recruitment Factor wt Allele|Adrenocortical Dysplasia Homolog (Mouse) Gene|PIP1|PTOP|TPP1	Human ACD wild-type allele is located in the vicinity of 16q22.1 and is approximately 3 kb in length. This allele, which encodes adrenocortical dysplasia protein homolog, is involved in telomere protection.	ACD wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C119709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119709>	C18466	Adrenocortical Dysplasia Protein Homolog|ACD|POT1 and TIN2 Organizing Protein|POT1 and TIN2-Interacting Protein|POT1- and TIN2- Organizing Protein|POT1-Interacting Protein 1|TIN2 Interacting Protein 1|TIN2-Interacting Protein 1|Telomere Protein TPP1	Adrenocortical dysplasia protein homolog (544 aa, ~58 kDa) is encoded by the human ACD gene. This protein plays a role in both the elongation and maintenance of telomeres.	Adrenocortical Dysplasia Protein Homolog		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C11970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11970>	C61063	Interleukin-12/PSA Prostate Cancer Vaccine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119710>	C1446	Oxygen 15-labeled Oxygen|15O-O2|15O-labeled Molecular Oxygen|15O2|O2-15	A radiopharmaceutical comprised of oxygen-15 labeled oxygen (15O-O2) used as a tracer molecule during positron emission tomography (PET). Upon inhalation, 15O-O2 binds to hemoglobin in the blood and the labeled red blood cells distribute throughout the vasculature in the body. Upon PET imaging, 15O-O2 can be used to determine both the oxygen extraction fraction (OEF) and the metabolic rate of oxygen.	Oxygen 15-labeled Oxygen		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology
C119711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119711>	C1446	Oxygen 15-labeled Carbon Monoxide|(15)O-labeled Carbon Monoxide|C(15)O|CO-15|O15 Carbon Monoxide|Oxygen-15 Labeled Oxygen Gas|[(15)O]CO|[15O]Carbon Monoxide	A radiopharmaceutical comprised of oxygen-15 (15O)-labeled carbon monoxide (15O-CO) for use as a tracer molecule during positron emission tomography (PET). Upon inhalation, 15O-CO binds to hemoglobin in the blood and the labeled red blood cells distribute evenly throughout the vasculature in the body. Upon PET imaging, tissue blood volume can be quantified.	Oxygen 15-labeled Carbon Monoxide		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology
C119712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119712>	C84343|C20085	Proteogenomics|Proteogenomic Analysis|Proteogenomic Characterization|Proteogenomic Research	A method of study that relates annotated genomic information to global protein expression in order to determine the relationship between genomic sequences and both expressed proteins and predicted peptide sequences; these studies can identify novel coding regions.			Biomedical Occupation or Discipline	
C119713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119713>	C20194	CD5L Gene|CD5 Molecule-Like Gene|CD5L|CD5L	This gene may be involved in the regulation of both apoptosis and immunity.			Gene or Genome	
C119714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119714>	C119713	CD5L wt Allele|AIM|API6|CD5 Antigen-Like (Scavenger Receptor Cysteine Rich Family) Gene|CD5 Molecule-Like wt Allele|Lymphocyte Antigen CD5-Like Gene|PRO229|SP-ALPHA|Scavenger Receptor Cysteine-Rich Family, Member SP-Alpha Gene|Spalpha|UNQ203/PRO229	Human CD5L wild-type allele is located within 1q21-q23 and is approximately 67 kb in length. This allele, which encodes CD5 antigen-like protein, may play a role in both immunity and apoptosis regulation.			Gene or Genome	
C119715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119715>	C19928	CD5 Antigen-Like|Apoptosis Inhibitor 6|Apoptosis Inhibitor of Macrophages|CT-2|IgM-Associated Peptide|SP-Alpha	CD5 antigen-like (347 aa, ~38 kDa) is encoded by the human CD5L gene. This protein may be involved in both immunity and the inhibition of apoptosis.			Amino Acid, Peptide, or Protein	
C119716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119716>	C20917	SGO1 Gene|SGO1|SGO1|SGOL1|Shugoshin 1 Gene	This gene plays a role in chromosome cohesion during mitosis.			Gene or Genome	
C119717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119717>	C119716	SGO1 wt Allele|CAID|NY-BR-85|SGO|SGOL1|Sgo1|Shugoshin 1 wt Allele|Shugoshin-Like 1 (S. pombe) Gene	Human SGO1 wild-type allele is located in the vicinity of 3p24.3 and is approximately 29 kb in length. This allele, which encodes shugoshin 1 protein, is involved in the promotion of chromosome cohesion.			Gene or Genome	
C119718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119718>	C17761	Shugoshin 1|SGO1|Serologically Defined Breast Cancer Antigen NY-BR-85|Shugoshin-Like 1|hSgo1	Shugoshin 1 (561 aa, ~64 kDa) is encoded by the human SGO1 gene. This protein plays a role in the positive regulation of chromosome adhesion during prophase.			Amino Acid, Peptide, or Protein	
C119719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119719>	C26057|C25790	IFIH1 Gene|IFIH1|IFIH1|Interferon Induced With Helicase C Domain 1 Gene	This gene is involved in binding to viral ribonucleic acids.			Gene or Genome	
C11971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11971>	C61007	Leucovorin Calcium/Mercaptopurine/Methotrexate/Prednisolone/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119720>	C119719	IFIH1 wt Allele|AGS7|CADM-140 Autoantigen|Hlcd|IDDM19|Interferon Induced With Helicase C Domain 1|Interferon Induced With Helicase C Domain 1 wt Allele|MDA-5|MDA5|MDA5|Melanoma Differentiation-Associated Gene 5|Melanoma Differentiation-Associated Protein 5|RH116|RLR-2	Human IFIH1 wild-type allele is located in the vicinity of 2q24 and is approximately 52 kb in length. This allele, which encodes interferon-induced helicase C domain-containing protein 1, plays a role in the induction of antiviral responses. Mutation of the gene is associated with Aicardi-Goutieres syndrome 7. Variation in the gene is associated with type 1 diabetes, Graves disease, and systemic lupus erythematosus.			Gene or Genome	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C119721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119721>	C17417	Interferon-Induced Helicase C Domain-Containing Protein 1|CADM-140 Autoantigen|Clinically Amyopathic Dermatomyositis Autoantigen 140 kDa|EC 3.6.4.13|Helicard|Helicase with 2 CARD Domains|IFIH1|Interferon-Induced With Helicase C Domain Protein 1|MDA-5|Melanoma Differentiation Associated Protein-5|Melanoma Differentiation-Associated Protein 5|Murabutide Down-Regulated Protein|RLR-2|RNA Helicase-DEAD Box Protein 116	Interferon-induced helicase C domain-containing protein 1 (1025 aa, ~117 kDa) is encoded by the human IFIH1 gene. This protein is involved in the positive regulation of antiviral responses.			Amino Acid, Peptide, or Protein|Enzyme	NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C119722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119722>	C3368|C26791	Digestive System Hemorrhage	Bleeding originating from any part of the digestive system.			Finding	
C119723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119723>	C20194	ATG16L1 Gene|ATG16L1|ATG16L1|Autophagy Related 16-Like 1 (S. cerevisiae) Gene	This gene plays a role in the regulation of autophagy.			Gene or Genome	
C119724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119724>	C119723	ATG16L1 wt Allele|APG16 Autophagy 16-Like (S. cerevisiae) Gene|APG16L|APG16L Beta|ATG16 Autophagy Related 16-Like (S. cerevisiae) Gene|ATG16 Autophagy Related 16-Like 1 (S. cerevisiae) Gene|ATG16A|ATG16L|Autophagy Related 16-Like 1 (S. cerevisiae) wt Allele|FLJ10035|IBD10|UNQ9393/PRO34307|WDR30|hCG_1817841	Human ATG16L1 wild-type allele is located in the vicinity of 2q37.1 and is approximately 86 kb in length. This allele, which encodes autophagy-related protein 16-1, is involved in the formation of autophagosomes. Mutation of the gene is associated with Crohn disease (inflammatory bowel disease 10).			Gene or Genome	
C119725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119725>	C18466	Autophagy-Related Protein 16-1|APG16-Like|APG16-Like 1|ATG16 Autophagy Related 16-Like 1|Autophagy 16-Like 1|WD Repeat Domain 30	Autophagy-related protein 16-1 (607 aa, ~68 kDa) is encoded by the human ATG16L1 gene. This protein plays a role in the mediation of autophagy.			Amino Acid, Peptide, or Protein	
C119726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119726>	C25873	EEF2K Gene|EEF2K|EEF2K|Eukaryotic Elongation Factor-2 Kinase Gene	This gene is involved in both protein phosphorylation and the inhibition of translation.			Gene or Genome	
C119727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119727>	C119726	EEF2K wt Allele|Eukaryotic Elongation Factor-2 Kinase wt Allele|HSU93850|eEF-2K	Human EEF2K wild-type allele is located in the vicinity of 16p12.2 and is approximately 82 kb in length. This allele, which encodes eukaryotic elongation factor 2 kinase protein, plays a role in the inhibition of protein translation.			Gene or Genome	
C119728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119728>	C17325	Eukaryotic Elongation Factor 2 Kinase|Calcium/Calmodulin-Dependent Eukaryotic Elongation Factor 2 Kinase|Calcium/Calmodulin-Dependent Eukaryotic Elongation Factor-2 Kinase|Calmodulin-Dependent Protein Kinase III|EC 2.7.11.20|EEF-2 Kinase|Elongation Factor-2 Kinase|eEF-2K	Eukaryotic elongation factor 2 kinase (725 aa, ~82 kDa) is encoded by the human EEF2K gene. This protein is involved in both the negative regulation of protein synthesis and serine/threonine protein phosphorylation.			Amino Acid, Peptide, or Protein|Enzyme	
C119729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119729>	C20921	APLP1 Gene|APLP1|APLP1|Amyloid Beta (A4) Precursor-Like Protein 1 Gene	This gene plays a role in synaptic signaling.			Gene or Genome	
C11972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11972>	C61007	Cytarabine/Daunorubicin/Dexamethasone/Prednisolone/Thioguanine/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119730>	C119729	APLP1 wt Allele|APLP|Amyloid Beta (A4) Precursor-Like Protein 1 wt Allele|Amyloid Beta A4 Precursor-Like Protein 1 Gene	Human APLP1 wild-type allele is located in the vicinity of 19q13.1 and is approximately 12 kb in length. This allele, which encodes amyloid-like protein 1, is involved in signal transduction.			Gene or Genome	
C119731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119731>	C18515	Amyloid-Like Protein 1|APLP|APLP-1|Amyloid Precursor-Like Protein|Amyloid Precursor-Like Protein 1	Amyloid-like protein 1 (650 aa, ~72 kDa) is encoded by the human APLP1 gene. This protein plays a role in the mediation of postsynaptic signaling.			Amino Acid, Peptide, or Protein	
C119732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119732>	C175261	Likert Score 0	A subjective score of 0 on a Likert scale.			Intellectual Product	Brief Pain Inventory
C119733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119733>	C175261	Likert Score 10	A subjective score of 10 on a Likert scale.			Intellectual Product	Brief Pain Inventory
C119734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119734>	C4731|C27580	Peripheral Neuropathy|Peripheral Nerve Disorder	A disorder affecting the peripheral nervous system. It manifests with pain, tingling, numbness, and muscle weakness. It may be the result of physical injury, toxic substances, viral diseases, diabetes, renal failure, cancer, and drugs.			Disease or Syndrome	GDC Terminology|GDC Value Terminology|NICHD Terminology|Pediatric Rheumatology Terminology
C119735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119735>	C208191	C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs	Autologous CD34-positive, hematopoietic stem progenitor cells (HSPCs) genetically modified with a lentiviral vector expressing short hairpin RNA that targets human chemokine receptor 5 (CCR5) mRNA (shCCR5), the HIV entry inhibitor C46, a membrane-anchored 46-amino acid sequence found in HIV-1 gp41, and the drug resistance gene P140K, a mutant form of the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT), used to potentially provide resistance against human immunodeficiency virus (HIV) infection. Human autologous CD34+ HSPCs are isolated and transduced ex vivo with the pRSC-H1.shCCR5.Ubic.C46.EF1alpha.P140K.wpre lentiviral vector. shCCR5 binds to CCR5 mRNA and inhibits the expression of CCR5, a HIV-1 co-receptor that mediates HIV attachment and cell entry. Additionally, the expression of C46 blocks HIV-1 fusion to the cellular membrane. Upon re-infusion into the HIV-infected lymphoma patient, the C46/shCCR5/P140K lentiviral vector-transduced autologous HSPCs are resistant to HIV entry, which protects these cells against HIV infection and replication, and increases the amount of HIV-resistant CD4+ T-cells. HIV-resistant HSPCs could provide long-term protection against latent HIV infection and against HIV-associated cancers. In addition, the formation of immune cells resistant to HIV may result in the destruction of HIV-infected cells. P140K expression facilitates the in vivo chemoselection of gene-modified HSPCs, using O6-benzylguanine (O6BG)/bis-chloroethylnitrosourea (BCNU/carmustine), which increases the proportion of these HIV resistant CD34+ cells. P140K also protects these stem cells from future destruction by certain chemotherapeutic agents; if cancer were to develop, P140K is not inactivated by the MGMT inhibitor O6BG.	C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology
C119736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119736>	C697	Mechlorethamine Hydrochloride Gel|Mechlorethamine HCl Gel|Valchlor	A gel formulation composed of the hydrochloride salt form of mechlorethamine, which is a nitrogen mustard alkylating agent and an analog of sulfur mustard, with antineoplastic and immunosuppressive activities. Upon topical application, mechlorethamine is metabolized to an unstable, highly reactive ethyleniminium intermediate that binds to and alkylates DNA, with a high affinity to the N7 nitrogen of guanine residues. This results in DNA base pair mismatching, DNA interstrand crosslinking, the inhibition of DNA repair and synthesis, cell-cycle arrest, and apoptosis.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C119737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119737>	C39619|C1663	hTERT-encoding DNA Vaccine INVAC-1|INVAC-1|INVAC-1, A DOUBLE STRANDED DNA PLASMID VACCINE CONSTRUCT ENCODING UBIQUITIN-HUMAN TELOMERASE REVERSE TRANSCRIPTASE (HTERT) FUSION PROTEIN	A DNA vaccine consisting of a plasmid encoding a modified, inactive form of the human telomerase reverse transcriptase (hTERT), the catalytic subunit of human telomerase which synthesizes telomeric DNA at the chromosome ends, fused to ubiquitin, with potential immunostimulating and antineoplastic activities. Upon intradermal vaccination of the hTERT encoding DNA vaccine INVAC-1 in combination with electroporation, hTERT protein is expressed and activates the immune system to mount a cytotoxic T-cell (CTL) response against telomerase-expressing tumor cells, which may result in tumor cell death. Telomerase prolongs the functional lifespan of cells via the restoration and maintenance of telomere length. Abnormally activated in tumorigenesis, telomerase is expressed in the majority of human cancer cells, but its expression is low or non-existent in normal cells. hTERT conjugation to ubiquitin, a 76 amino-acid peptide involved in the regulation of normal protein intracellular turnover in the cytoplasm, enhances proteasome-dependent degradation of the hTERT protein, increases hTERT presentation by major histocompatibility complex (MHC) class I molecules and results in an increased immune response against hTERT.	hTERT-encoding DNA Vaccine INVAC-1		Immunologic Factor|Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C119738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119738>	C2124|C129819	Yttrium Y 90-DOTA-di-HSG Peptide IMP-288|90-Y-IMP-288|90Y-IMP288	A radiolabeled divalent histamine-succinyl-glycine (HSG) hapten-peptide linked with the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to the beta-emitting radionuclide yttrium 90 (Y-90), with radioimmunotherapeutic activity. After pre-treating and targeting tumor cells with a bi-specific monoclonal antibody (BiMoAB) directed against both a tumor-associated antigen (TAA) and the HSG hapten-peptide, the HSG portion of the administered yttrium Y 90-DOTA-di-HSG peptide IMP-288 binds to the anti-HSG sequence on the BiMoAB. In turn, Y-90 delivers a cytotoxic dose of beta radiation to tumor cells expressing the specific TAA.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C119739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119739>	C575	Immunotoxin D2C7-(scdsFv)-PE38KDEL|D2C7-(scdsFv)-PE38KDEL|D2C7-(scdsFv)-PE38KDEL Immunotoxin|D2C7-IT	A recombinant immunotoxin fusion protein consisting of single-chain variable-region antibody fragments (scFvs), which contain disulfide stabilized heavy- (Vh) and light- (Vl) chain variable regions of the monoclonal antibody D2C7 (D2C7-scdsFv), targeting both the wild-type form (EGFRwt) and the in-frame deletion mutant form (EGFRvIII) of epidermal growth factor receptor (EGFR), and fused, via a 15-amino acid peptide linker to domains II and III of the Pseudomonas exotoxin A (PE38KDEL) (D2C7-(scdsFv)-PE38KDEL), with potential antineoplastic activity. Upon intratumoral administration by convection-enhanced delivery, the scFv moiety of immunotoxin anti-EGFR scFv monoclonal antibody fragment immunotoxin D2C7-(scdsFv)-PE38KDEL targets and binds to a specific amino acid epitope present in the extracellular domain of both the EGFRwt and EGFRvIII proteins. This binding facilitates the internalization of the immunotoxin by tumor cells. Inside the cells, the exotoxin portion of the fusion protein binds to translation elongation factor 2 (EF-2), and deactivates EF-2 through ADP ribosylation. This results in the inhibition of protein synthesis, the induction of apoptosis and a reduction in cell proliferation of EGFRwt/EGFRvIII-expressing tumor cells. Compared to intact IgG antibodies and single-chain antibodies, scFvs are smaller with increased tumor-penetrating capacity which may enhance therapeutic efficacy. The EGFR gene, a transmembrane receptor tyrosine kinase, and its mutant form, EGFRvIII, which contains a deletion of exons 2-7 of the EGFR gene, are frequently amplified and overexpressed in a variety of cancers. KDEL increases the toxin's intracellular retention, thereby enhancing its cytotoxicity.	Immunotoxin D2C7-(scdsFv)-PE38KDEL		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11973>	C61007	Methotrexate/Prednisolone/Prednisone			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119740>	C133877	Selicrelumab|CD40 Agonist Monoclonal Antibody CP-870,893|CP-870,893|RO7009789|SELICRELUMAB	A human immunoglobulin G2 (IgG2) monoclonal antibody agonist of the cell surface receptor CD40, with potential immunostimulatory and antineoplastic activities. Upon administration, selicrelumab targets and binds to CD40 expressed on a variety of immune cell types. This induces CD40-dependent signaling pathways and triggers the cellular proliferation and activation of antigen-presenting cells (APCs), and activates B-cells and T-cells, resulting in an enhanced anti-tumor immune response. CD40, a cell surface receptor and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells and certain cancer cells; it plays a key role in the activation of the immune system.	Selicrelumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C119741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119741>	C308	ChiNing Decoction	A decoction of Liang Ge San, a traditional Chinese herbal medicine, with potential anti-inflammatory and anti-stomatitis activities. Although the complete mechanism of action through which the ChiNing decoction works has yet to be fully elucidated, upon oral administration, the active ingredients may inhibit the inflammatory response, possibly by reducing the levels of pro-inflammatory cytokines, such as interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNFa), in the saliva. This may protect the oral mucosa against these inflammatory mediators, and may reduce and relieve radiation-induced stomatitis and the associated pain.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C119742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119742>	C2124	Carbon C 13/Nitrogen N 15-labeled Valine|(+)-2-Amino-3-Methylbutyric Acid-13C5,15N|C13 N15 Valine|Carbonomic|L-2-Amino-3-methylbutanoic Acid-13C5,15N|L-Valine-13C5,15N	A radioconjugate composed of the essential amino acid valine radiolabeled to carbon C 13 and nitrogen N 15, that can potentially be used as a tracer for protein metabolism in vivo using mass spectrometry (MS). Upon administration of carbon C 13/nitrogen N 15-labeled valine, the exogenous valine is taken up by cells and incorporated into proteins. Upon imaging, protein biomarkers containing radiolabeled valine are secreted by tumor cells and can be identified by MS. This may aid in cancer diagnosis and prognosis. Compared to normal cells, tumor cells rapidly take up amino acids to use as protein building blocks.			Indicator, Reagent, or Diagnostic Aid|Organic Chemical|Pharmacologic Substance	NCI Drug Dictionary Terminology
C119743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119743>	C29750|C129824	Uproleselan|GMI-1271|UPROLESELAN	A synthetic, glycomimetic molecule and E-selectin (CD62E) antagonist, with potential anti-thrombotic, antineoplastic and chemopotentiating activities. Upon administration, uproleselan binds to E-selectin expressed on endothelial cells and prevents their interaction with selectin-E ligand-expressing cancer cells. This may prevent tumor cell activation, migration and metastasis. GMI-1271 also interferes with the binding of selectin E-expressing vascular endothelial cells to selectin-E ligand-expressing monocytes and neutrophils, thereby disrupting their activation. Consequently, this inhibits both the activation of the coagulation cascade and thrombus formation. This agent also prevents both leukocyte activation and inflammation. E-selectin is a cell adhesion molecule involved in cell rolling, signaling and chemotaxis; it also plays a crucial role in inflammatory processes and cancer.	Uproleselan		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C119744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119744>	C20401|C129822	Burosumab|Anti-FGF23 IgG1 Monoclonal Antibody KRN23|BUROSUMAB|Burosumab-TWZA|Crysvita|KRN23|UX023	An orally bioavailable recombinant human immunoglobulin G1 monoclonal antibody directed against human fibroblast growth factor 23 (FGF23), that can be used to increase serum phosphate levels. Upon subcutaneous administration, burosumab binds to and inhibits FGF23, thereby interfering with FGF23 signaling. This increases tubular phosphate reabsorption, decreases excretion of phosphate, and increases serum phosphate levels, resulting in enhanced bone mineralization. FGF23, a member of the fibroblast growth factor (FGF) family produced by osteocytes, plays a key role in hypophosphatemic rickets/osteomalacia, such as X-linked hypophosphatemia (XLH) and tumor-induced rickets/osteomalacia. Increased FGF23 levels lead to decreased expression of the sodium-phosphate co-transporters in the proximal tubules, reduced renal phosphate reabsorption, increased excretion by the kidneys, and low serum phosphate concentration.	Burosumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C119745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119745>	C1663|C1455	Globo H-DT Vaccine OBI-833|Globo H-CRM197 Vaccine|OBI-833|OBI-833	A carbohydrate-based vaccine comprised of the Globo H hexasaccharide 1 (Globo H) antigen conjugated to DT-CRM197, a non-toxic, mutated form of diphtheria toxin (DT), with potential immunostimulating and antineoplastic activities. Upon administration of Globo H-DT vaccine OBI-833, the carbohydrate antigen Globo H may stimulate a cytotoxic T-lymphocyte (CTL) response against Globo H-expressing tumor cells, thereby decreasing tumor cell proliferation. The hexasaccharide Globo H is a tumor-associated antigen (TAA) commonly found on a variety of tumor cells. DT-CRM197, also called diphtheria toxin cross-reacting material 197, is used to increase the immunogenicity of the Globo H carbohydrate antigen.			Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C119746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119746>	C200766	Autologous CD171-specific CAR-CD28 zeta-4-1-BB-EGFRt-expressing T Lymphocytes|CD171 CAR+ T Cells|CE7R CAR T Cells	A preparation of genetically modified autologous human T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) specific for the L1 cell adhesion molecule (L1-CAM/CD171) antigen, and the co-stimulatory signaling domains CD28, 4-1BB (CD137) and CD3 zeta, and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon re-infusion into the patient, the autologous L1-CAM-specific CAR-CD28 zeta-4-1-BB-EGFRt-expressing T-lymphocytes are directed to and induce selective toxicity in L1-CAM-expressing tumor cells. L1-CAM, a neuronal cell adhesion molecule and member of the L1 protein family, plays a key role in the development of the nervous system; it is overexpressed in various tumor cell types and is associated with increased chemoresistance, tumor progression, migration and metastasis. Devoid of both ligand-binding domains and tyrosine kinase activity, EGFRt facilitates both the detection of the administered T-cells in vivo and the elimination of the modified T-cells following a cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) response. The co-stimulatory signaling domains enhance both proliferation of T-cells and antitumor activity.	Autologous CD171-specific CAR-CD28 zeta-4-1-BB-EGFRt-expressing T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C119747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119747>	C174048	ERK Inhibitor CC-90003|CC-90003	An orally available inhibitor of extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon oral administration, CC-90003 inhibits ERK activity, and prevents the activation of ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.	ERK Inhibitor CC-90003		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C119748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119748>	C78311	Absorbable Fibrin Sealant Patch|HFTP|Human Fibrinogen/Thrombin Patch|TachoSil	A sterile, absorbable surgical sealing patch composed of an equine collagen sponge coated with the coagulation factors human fibrinogen and human thrombin, with potential hemostatic activity. Applied on the wound tissue, the absorbable fibrin sealant patch adheres to the tissue and the solid fibrinogen and thrombin dissolve upon contact with the physiological fluid. In turn, fibrinogen is converted to fibrin monomers by thrombin, and polymerize to form a fibrin clot at the wound surface. This causes the patch to adhere to the wound surface and promotes tissue sealing. This may reduce lymphatic drainage and prevent seroma formation.	Absorbable Fibrin Sealant Patch		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C119749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119749>	C1511	Iodine I 124 Monoclonal Antibody 3F8|124 mAb 3F8|124I-Humanized 3F8|124I-hu3F8|I 124 Monoclonal Antibody 3F8	A radioimmunoconjugate consisting of 3F8, a murine anti-GD2 ganglioside monoclonal antibody labeled with iodine I 124 (I-124), with radioimaging activity using positron emission tomography (PET). Upon intravenous administration of iodine I 124 monoclonal antibody 3F8, the 3F8 moiety binds to GD2 expressed on tumor cells. This binding enables both PET imaging via iodine I 124 and the visualization of GD2-expressing tumor cells. GD2 is a ganglioside overexpressed in a variety of cancer cells, including neuroblastoma cells.	Iodine I 124 Monoclonal Antibody 3F8		Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C11974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11974>	C61007	Asparaginase/cytarabine/daunorubicin/dexamethasone/methotrexate/prednisolone/vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119750>	C67413|C1506	Piritramide|(1,4'-Bipiperidine)-4'-carboxamide, 1'-(3-Cyano-3,3-diphenylpropyl)|1'-(3-Cyano-3,3-diphenylpropyl)-(1,4'-bipiperidine)-4'-carboxamide|Dipidolor|PIRITRAMIDE|R 3365	A diphenylpropylamine and opioid receptor agonist, with analgesic activity. Upon administration, piritramide binds to and activates mu-opioid receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids and producing analgesic relief.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C119751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119751>	C35549|C119758	Neonatal Hypoxic Ischemic Encephalopathy|Neonatal HIE	Injury to the central nervous system in the newborn period that occurs when there is insufficient delivery of oxygen to all or part of the brain.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C119752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119752>	C116769	Developmental Dysplasia of Hip|Congenital Dislocation of Hip|DDH|Developmental Dislocation of Hip	A spectrum of hip abnormalities commonly presenting in infancy involving the relationship between the femoral head and the acetabulum and that includes subluxation or dislocation at rest or upon provocation.			Finding	NICHD Terminology|Perinatal Terminology
C119753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119753>	C91103	Shade in the Areas Where You Feel Pain Question|Shade in the Areas Where You Feel Pain|Shade in the areas where you feel pain	A question that Instructs that an individual indicate by shading on a diagram of the body the area where they feel pain.			Intellectual Product	Brief Pain Inventory
C119754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119754>	C91103	Mark the Area of Most Intense Pain Question|Area that hurts the most|Mark the Area of Most Intense Pain	A question that instructs that an individual mark on a diagram of the body the area where they feel the most intense pain.			Intellectual Product	Brief Pain Inventory
C119755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119755>	C25404	Shade	To darken on a drawing or illustration.			Activity	Brief Pain Inventory
C119756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119756>	C90599	Mild Bronchopulmonary Dysplasia|Mild BPD	A chronic lung disorder associated with pulmonary maldevelopment, scarring, and/or inflammation that develops in preterm neonates exposed to supplemental oxygen for at least 28 days. For infants born before 32 weeks gestation with mild BPD, there is no supplemental oxygen requirement at 36 weeks postmenstrual age or earlier discharge. For infants born after 32 weeks with mild BPD, there is no supplemental oxygen requirement at 56 days post-natal age or at earlier discharge.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C119757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119757>	C90599	Moderate Bronchopulmonary Dysplasia|Moderate BPD	A chronic lung disorder associated with pulmonary maldevelopment, scarring, and/or inflammation that develops in preterm neonates exposed to supplemental oxygen for at least 28 days. For infants born before 32 weeks gestation with moderate BPD, there is a supplemental oxygen requirement of less than 30% at 36 weeks postmenstrual age or earlier discharge. For infants born after 32 weeks with moderate BPD, there is a supplemental oxygen requirement of less than 30% at 56 days post-natal age or at earlier discharge.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C119758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119758>	C26920	Neonatal Encephalopathy	Abnormal functioning of the central nervous system in the newborn period that may be due to a variety of etiologies including hypoxia/ischemia, metabolic disturbance, or infection.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology|NICHD Terminology|Perinatal Terminology
C119759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119759>	C1983	Allogeneic Cellular Vaccine 1650-G|1650-G|1650-G Vaccine|1650G	A pluripotent, allogeneic, tumor cell vaccine composed of irradiated tumor cells from the non-small cell lung cancer (NSCLC) cell line 1650 and the immunoadjuvant recombinant granulocyte-macrophage colony stimulating factor (GM-CSF) (1650-G), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic cellular vaccine 1650-G may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against tumor-associated antigens (TAAs) expressed on NSCLC cells. GM-CSF potentiates the antitumor immune response. The 1650 cell line is used as a source for TAAs.	Allogeneic Cellular Vaccine 1650-G		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C11975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11975>	C61007	Leucovorin Calcium/Mercaptopurine/Methotrexate/Prednisolone			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119760>	C83187	CDISC SEND Variable Terminology|CDISC-SEND VARIABLE	The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) variables used by the Standard for the Exchange of Non-clinical Data (SEND) group.			Intellectual Product	
C119761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119761>	C82515	Body Weight Gain Data Collection Date Time|BGDTC	The date and time of body weight gain assessment data collection.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119762>	C82437	Study Day of Body Weight Gain|BGDY	The study day that a body weight gain assessment is performed.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119763>	C82572	Body Weight Gain Elapsed Time|BGELTM	The interval between two body weight gain measurement reference time points.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119764>	C82516	Body Weight Gain End Date Time|BGENDTC	The date and time a body weight gain assessment has concluded.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119765>	C82569	Body Weight Gain End Day|BGENDY	The final day of the body weight gain assessment.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119766>	C117045	Exclude Body Weight Gain Data From Statistics Indicator|BGEXCLFL	Specifies whether the body weight gain result values should be excluded from the statistical analysis.			Functional Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119767>	C117221	Body Weight Gain Original Result|BGORRES	The outcome of the body weight gain assessment as originally received or collected.			Finding	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119768>	C82586	Body Weight Gain Original Result Unit|BGORRESU	The unit of measure for the result of the body weight gain assessment as originally received or collected.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119769>	C117057	Body Weight Gain Reason For Exclusion From Statistics|BGREASEX	A rationale for excluding a particular data point or subject from the body weight gain statistical analysis.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C11976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11976>	C61063	Asparaginase/cytarabine/daunorubicin/dexamethasone/methotrexate/prednisolone/vindesine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119770>	C82556	Body Weight Gain Reason Not Done|BGREASND	The explanation given as to why body weight gain was not assessed.			Idea or Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119771>	C82518	Body Weight Gain Date Time of Reference Timepoint|BGRFTDTC	The date and time of a specific reference point for the body weight gain assessment.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119772>	C70710	Body Weight Gain Sequence Number|BGSEQ	An identifier that describes the relative position of body weight gain data within a series.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119773>	C41202	Body Weight Gain Completion Status|BGSTAT	A term used to describe the state or condition of the completeness of the body weight gain data.			Qualitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119774>	C117222	Body Weight Gain Character Result in Standard Format|BGSTRESC	The standard character or string for representation and reporting of body weight gain data.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119775>	C70952	Body Weight Gain Numeric Result in Standard Unit|BGSTRESN	The numerical identifier of a body weight gain result in standard units.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119776>	C82587	Body Weight Gain Result Standard Unit|BGSTRESU	The standard unit of measure for body weight gain results.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119777>	C82541	Body Weight Gain Test|BGTEST	A character or string that represents the long name of the body weight gain assessment.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119778>	C82503	Body Weight Gain Test Code|BGTESTCD	A character or string that represents the short code name of the body weight gain assessment.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119779>	C82576	Body Weight Gain Time Point Reference|BGTPTREF	The point in time that acts as a fixed reference point to a body weight gain assessment.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C11977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11977>	C61063	Cytarabine/Etoposide/Ifosfamide/Leucovorin Calcium/Methotrexate/Prednisolone			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119780>	C82526	Body Weight Baseline Flag|BWBLFL	An indication or description that body weight data is a baseline value.			Functional Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119781>	C82515	Body Weight Data Collection Date Time|BWDTC	The date and time of body weight assessment data collection.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119782>	C82437	Study Day of Body Weight|BWDY	The study day that a body weight assessment is performed.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119783>	C117045	Exclude Body Weight Data From Statistics Indicator|BWEXCLFL	Specifies whether the body weight result values should be excluded from the statistical analysis.			Functional Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119784>	C93566	Body Weight Fasting Status|BWFAST	An indication or description of whether a body weight measurement was obtained from a subject that has abstained from food and possibly water for the prescribed amount of time.			Finding	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119785>	C117221	Body Weight Original Result|BWORRES	The outcome of the body weight assessment as originally received or collected.			Finding	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119786>	C82586	Body Weight Original Result Unit|BWORRESU	The unit of measure for the result of the body weight assessment as originally received or collected.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119787>	C117057	Body Weight Reason For Exclusion From Statistics|BWREASEX	A rationale for excluding a particular data point or subject from the body weight statistical analysis.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119788>	C82556	Body Weight Reason Not Done|BWREASND	The explanation given as to why body weight was not assessed.			Idea or Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119789>	C70710	Body Weight Sequence Number|BWSEQ	An identifier that describes the relative position of body weight data within a series.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C11978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11978>	C61063	Cyclophosphamide/Dexrazoxane/Doxorubicin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119790>	C41202	Body Weight Completion Status|BWSTAT	A term used to describe the state or condition of the completeness of the body weight data.			Qualitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119791>	C117222	Body Weight Character Result in Standard Format|BWSTRESC	The standard character or string for representation and reporting of body weight data.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119792>	C70952	Body Weight Numeric Result in Standard Unit|BWSTRESN	The numerical identifier of a body weight result in standard units.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119793>	C82587	Body Weight Result Standard Unit|BWSTRESU	The standard unit of measure for body weight results.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119794>	C82541	Body Weight Test|BWTEST	A character or string that represents the long name of the body weight assessment.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119795>	C82503	Body Weight Test Code|BWTESTCD	A character or string that represents the short code name of the body weight assessment.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119796>	C12919	Clinical Observations Body System or Organ Class|CLBODSYS	The body system or organ class associated with a clinical observation.			Finding	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119797>	C25372	Clinical Observations Category|CLCAT	A classification of clinical observation data.			Classification	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119798>	C82515	Clinical Observations Data Collection Date Time|CLDTC	The date and time of clinical observation data collection.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119799>	C82437	Study Day of Clinical Observations|CLDY	The study day that a clinical observation is made.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C11979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11979>	C61063	506U78/Mercaptopurine/Methotrexate			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1197>	C1594	Pirarubicin|(2''R)-4'-O-Tetrahydropyranyladriamycin|(8S,10S)-10-[[3-Amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-3-yl)-alpha-L-lyxo-hexopyranosyl]oxy]-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione|1609-RB|1609RB|4'-O-Tetrahydropyranyl Doxorubicin|PIRARUBICIN|Pinorubicin|THP-ADM|THP-ADM|THP-Adriamycin|THP-DOX|THP-Doxorubicin|Tepirubicin|Tetrahydropyranyl-Doxorubicin|Theprubicin|Theprubicine|Therarubicin|[8S-[8Alpha,10alpha(S*)]]-10-[[3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione	An analogue of the anthracycline antineoplastic antibiotic doxorubicin.  Pirarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent is less cardiotoxic than doxorubicin and exhibits activity against some doxorubicin-resistant cell lines. (NCI04)			Antibiotic|Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C119800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119800>	C82572	Clinical Observations Elapsed Time|CLELTM	The interval between two clinical observation reference time points.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119801>	C51824	Clinical Observations Evaluator|CLEVAL	A person who determines the significance of a clinical observation assessment.			Professional or Occupational Group	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119802>	C117045	Exclude Clinical Observation Data From Statistics Indicator|CLEXCLFL	Specifies whether the clinical observation result values should be excluded from the statistical analysis.			Functional Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119803>	C82529	Clinical Observations Group Identifier|CLGRPID	A character or string that represents a clinical observation findings group.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119804>	C25341	Clinical Observations Location|CLLOC	The site in or on the body at which the clinical observation is made.			Spatial Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119805>	C117221	Clinical Observations Original Result|CLORRES	The outcome of the clinical observation as originally received or collected.			Finding	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119806>	C117057	Clinical Observation Reason For Exclusion From Statistics|CLREASEX	A rationale for excluding a particular data point or subject from the clinical observation statistical analysis.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119807>	C82556	Clinical Observations Reason Not Done|CLREASND	The explanation given as to why a clinical observation was not made.			Idea or Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119808>	C82518	Clinical Observations Date Time of Reference Timepoint|CLRFTDTC	The date and time of a specific reference point for the clinical observation.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119809>	C70710	Clinical Observations Sequence Number|CLSEQ	An identifier that describes the relative position of clinical observation data within a series.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C11980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11980>	C61063	CD40-Ligand/flt3 Ligand			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119810>	C25676	Clinical Observations Severity|CLSEV	The degree of something undesirable as determined by clinical observations.			Qualitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119811>	C82530	Clinical Observations Sponsor Defined Identifier|CLSPID	One or more sponsor defined characters used to identify, name, or characterize the clinical observation.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119812>	C41202	Clinical Observations Completion Status|CLSTAT	A term used to describe the state or condition of the completeness of the clinical observation data.			Qualitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119813>	C117222	Clinical Observations Character Result in Standard Format|CLSTRESC	The standard character or string for representation and reporting of clinical observations data.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119814>	C82541	Clinical Observations Test|CLTEST	A character or string that represents the long name of the clinical observation assessment.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119815>	C82503	Clinical Observations Test Code|CLTESTCD	A character or string that represents the short code name of the clinical observation assessment.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119816>	C82539	Clinical Observations Planned Time Point Name|CLTPT	The literal identifier of a planned point in time for a clinical observation.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119817>	C82545	Clinical Observations Planned Time Point Number|CLTPTNUM	The numerical identifier of a clinical observation point in time.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119818>	C82576	Clinical Observations Time Point Reference|CLTPTREF	The point in time that acts as a fixed reference point to a clinical observation.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119819>	C82437	Study Day of Comment|CODY	The study day that the comment pertains.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C11981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11981>	C61063	Interferon Alfa/Lymphokine-Activated Killer Cells			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119820>	C88429	ECG Test Results Completion Status|EGCSTATE	The level of awareness of an organism during an electrocardiogram assessment.			Finding	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119821>	C82516	ECG Test Results End Date Time|EGENDTC	The date and time an electrocardiogram assessment has concluded.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119822>	C82569	ECG Test Results End Day|EGENDY	The final day of the electrocardiographic test.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119823>	C82534	ECG Test Results Evaluation Interval|EGEVLINT	The period of time during which an electrocardiogram was performed.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119824>	C117045	Exclude ECG Data From Statistics Indicator|EGEXCLFL	Specifies whether the ECG result values should be excluded from the statistical analysis.			Functional Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119825>	C117057	ECG Reason For Exclusion From Statistics|EGREASEX	A rationale for excluding a particular data point or subject from the ECG test results statistical analysis.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119826>	C82535	Exposure Method|EXMETHOD	The technique used to administer the exposure treatment.			Activity	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119827>	C82515	Food and Water Consumption Data Collection Date Time|FWDTC	The date and time of food and water consumption data collection.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119828>	C82437	Study Day of Food and Water Consumption|FWDY	The study day that the food and water consumption data is captured.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119829>	C82516	Food and Water Consumption End Date Time|FWENDTC	The date and time a food and water consumption assessment has concluded.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C11982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11982>	C61063	Doxorubicin Hcl Liposome/ZD0473			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119830>	C82569	Food and Water Consumption End Day|FWENDY	The final day of the food and water consumption assessment.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119831>	C117045	Exclude Food and Water Consumption Data From Statistics Indicator|FWEXCLFL	Specifies whether the food and water consumption result values should be excluded from the statistical analysis.			Functional Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119832>	C82529	Food and Water Consumption Group Identifier|FWGRPID	A character or string that represents a food and water consumption findings group.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119833>	C117221	Food and Water Consumption Original Result|FWORRES	The outcome of the food and water consumption assessment as originally received or collected.			Finding	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119834>	C82586	Food and Water Consumption Original Result Unit|FWORRESU	The unit of measure for the result of the food and water consumption assessment as originally received or collected.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119835>	C117057	Food and Water Consumption Reason For Exclusion From Statistics|FWREASEX	A rationale for excluding a particular data point or subject from the food and water consumption statistical analysis.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119836>	C82556	Food and Water Consumption Reason Not Done|FWREASND	The explanation given as to why food and water consumption was not assessed.			Idea or Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119837>	C70710	Food and Water Consumption Sequence Number|FWSEQ	An identifier that describes the relative position of food and water consumption data within a series.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119838>	C41202	Food and Water Consumption Completion Status|FWSTAT	A term used to describe the state or condition of the completeness of the food and water consumption data.			Qualitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119839>	C117222	Food and Water Consumption Character Result in Standard Format|FWSTRESC	The standard character or string for representation and reporting of food and water consumption data.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C11983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11983>	C61063	Docetaxel/Flavopiridol			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119840>	C70952	Food and Water Consumption Numeric Result in Standard Unit|FWSTRESN	The numerical identifier of a food and water consumption assessment result in standard units.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119841>	C82587	Food and Water Consumption Result Standard Unit|FWSTRESU	The standard unit of measure for food and water consumption results.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119842>	C82541	Food and Water Consumption Test|FWTEST	A character or string that represents the long name of the food and water consumption assessment.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119843>	C82503	Food and Water Consumption Test Code|FWTESTCD	A character or string that represents the short code name of the food and water consumption assessment.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119844>	C13717	Laboratory Test Results Anatomical Region of Specimen|LBANTREG	The specific anatomical or biological region within the tissue or organ specimen used in the laboratory assessment.			Body Part, Organ, or Organ Component	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119845>	C54215	Laboratory Test Results Directionality|LBDIR	A qualifier for the direction on the body the laboratory test is performed.			Functional Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119846>	C82569	Laboratory Test Results End Day|LBENDY	The final day of the laboratory test.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119847>	C117045	Exclude Laboratory Test Data From Statistics Indicator|LBEXCLFL	Specifies whether the laboratory test result values should be excluded from the statistical analysis.			Functional Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119848>	C25185	Laboratory Test Results Laterality|LBLAT	A qualifier for the side of the body the laboratory test is performed.			Organism Attribute	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119849>	C25341	Laboratory Test Results Location|LBLOC	The site in or on the body at which the laboratory test or result is performed or collected.			Spatial Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C11984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11984>	C61063	Bevacizumab/Docetaxel/Estramustine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119850>	C103166	Laboratory Test Results Portion or Totality|LBPORTOT	A qualifier for the arrangement or apportioning of an entity within a body part, region or organ for a laboratory test.			Organism Attribute	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119851>	C117057	Laboratory Tests Reason For Exclusion From Statistics|LBREASEX	A rationale for excluding a particular data point or subject from the laboratory test results statistical analysis.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119852>	C105758	Laboratory Test Results Biospecimen Usability|LBSPCUFL	A qualitative or quantitative measure that describes a biospecimen's suitability for laboratory testing purposes.			Qualitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119853>	C13717	Macroscopic Findings Anatomical Region of Specimen|MAANTREG	The specific anatomical or biological region within the tissue or organ specimen used in the macroscopic findings assessment.			Body Part, Organ, or Organ Component	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119854>	C12919	Macroscopic Findings Body System|MABODSYS	The body system or organ class associated with a macroscopic finding.			Body System	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119855>	C54215	Macroscopic Findings Directionality|MADIR	A qualifier for the direction on the body the macroscopic findings test is performed.			Functional Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119856>	C82515	Macroscopic Findings Collection Date Time|MADTC	The date and time of macroscopic findings data collection.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119857>	C82563	Macroscopic Findings Death Relationship|MADTHREL	An indication or description of a correlation between death and a macroscopic finding.			Finding	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119858>	C82437	Study Day of Macroscopic Findings|MADY	The study day that a macroscopic findings assessment is performed.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119859>	C51824	Macroscopic Findings Evaluator|MAEVAL	A person who determines the significance of a macroscopic findings assessment.			Professional or Occupational Group	CDISC SEND Variable Terminology|CDISC Variable Terminology
C11985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11985>	C61063	Cisplatin/Gemcitabine/Trastuzumab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119860>	C82529	Macroscopic Findings Group Identifier|MAGRPID	A character or string that represents a macroscopic findings group.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119861>	C25185	Macroscopic Findings Laterality|MALAT	A qualifier for the side of the body the macroscopic findings assessment is performed.			Organism Attribute	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119862>	C117200	Macroscopic Findings Vendor Name|MANAM	The literal identifier of the vendor or laboratory that performs a macroscopic findings assessment.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119863>	C117221	Macroscopic Findings Original Result|MAORRES	The outcome of the macroscopic findings assessment as originally received or collected.			Finding	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119864>	C103166	Macroscopic Findings Portion or Totality|MAPORTOT	A qualifier for the arrangement or apportioning of an entity within a body part, region or organ for the macroscopic findings assessment.			Organism Attribute	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119865>	C82556	Macroscopic Findings Reason Not Done|MAREASND	The explanation given as to why a macroscopic findings assessment was not performed.			Idea or Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119866>	C82531	Macroscopic Findings Reference Identifier|MAREFID	A sequence of characters used to identify, name, or characterize the macroscopic findings reference.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119867>	C70710	Macroscopic Findings Sequence Number|MASEQ	An identifier that describes the relative position of macroscopic findings data within a series.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119868>	C25676	Macroscopic Findings Severity|MASEV	The degree of something undesirable as determined by macroscopic findings.			Qualitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119869>	C70714	Macroscopic Findings Specimen Condition|MASPCCND	A characteristic that refers to the physical and organoleptic state of a biospecimen used for a macroscopic findings assessment.			Qualitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C11986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11986>	C61063	Dexamethasone/Ondansetron			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119870>	C105758	Macroscopic Findings Biospecimen Usability|MASPCUFL	A qualitative or quantitative measure that describes a biospecimen's suitability for macroscopic testing purposes.			Qualitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119871>	C70713	Macroscopic Findings Specimen Type|MASPEC	The type of material sample taken from a biological entity for macroscopic findings assessment testing.			Qualitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119872>	C82530	Macroscopic Findings Sponsor Defined Identifier|MASPID	One or more sponsor defined characters used to identify, name, or characterize the macroscopic findings assessment.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119873>	C41202	Macroscopic Findings Completion Status|MASTAT	A term used to describe the state or condition of the completeness of the macroscopic findings data.			Qualitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119874>	C117222	Macroscopic Findings Assessment Character Result in Standard Format|MASTRESC	The standard character or string for representation and reporting of macroscopic findings data.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119875>	C82541	Macroscopic Findings Assessment Test|MATEST	A character or string that represents the long name of the macroscopic findings assessment.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119876>	C82503	Macroscopic Findings Assessment Test Code|MATESTCD	A character or string that represents the short code name of the macroscopic findings assessment.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119877>	C13717	Microscopic Findings Anatomical Region of Specimen|MIANTREG	The specific anatomical or biological region within the tissue or organ specimen used in the microscopic findings assessment.			Body Part, Organ, or Organ Component	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119878>	C12919	Microscopic Findings Body System|MIBODSYS	The body system or organ class associated with a microscopic finding.			Body System	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119879>	C82563	Microscopic Findings Death Relationship|MIDTHREL	An indication or description of a correlation between death and a microscopic finding.			Finding	CDISC SEND Variable Terminology|CDISC Variable Terminology
C11987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11987>	C61063	Asparaginase/cytarabine/dexamethasone/vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119880>	C25676	Microscopic Findings Severity|MISEV	The degree of something undesirable as determined by microscopic findings.			Qualitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119881>	C105758	Microscopic Findings Biospecimen Usability|MISPCUFL	A qualitative or quantitative measure that describes a biospecimen's suitability for microscopic testing purposes.			Qualitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119882>	C33904	Organ Measurements Anatomical Region of Specimen|OMANTREG	The specific anatomical or biological region within the tissue or organ specimen used in the organ measurement.			Body Part, Organ, or Organ Component	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119883>	C54215	Organ Measurements Directionality|OMDIR	A qualifier for the direction on the body the organ measurement is performed.			Functional Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119884>	C82515	Organ Measurements Collection Date Time|OMDTC	The date and time of organ measurements data collection.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119885>	C117045	Exclude Organ Measurements Data From Statistics Indicator|OMEXCLFL	Specifies whether the organ measurement result values should be excluded from the statistical analysis.			Functional Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119886>	C25185	Organ Measurements Laterality|OMLAT	A qualifier for the side of the body the organ measurements assessment is performed.			Organism Attribute	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119887>	C117221	Organ Measurements Original Result|OMORRES	The outcome of the organ measurements as originally received or collected.			Finding	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119888>	C82586	Organ Measurements Original Result Unit|OMORRESU	The unit of measure for the result of the organ measurement as originally received or collected.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119889>	C103166	Organ Measurements Portion or Totality|OMPORTOT	A qualifier for the arrangement or apportioning of an entity within a body part, region or organ for the organ measurements.			Organism Attribute	CDISC SEND Variable Terminology|CDISC Variable Terminology
C11988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11988>	C61063	Asparaginase/cytarabine/prednisolone/vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119890>	C117057	Organ Measurements Reason For Exclusion From Statistics|OMREASEX	A rationale for excluding a particular data point or subject from the organ measurement results statistical analysis.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119891>	C82556	Organ Measurements Reason Not Done|OMREASND	The explanation given as to why an organ measurement was not performed.			Idea or Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119892>	C70710	Organ Measurements Sequence Number|OMSEQ	An identifier that describes the relative position of organ measurement data within a series.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119893>	C70714	Organ Measurements Specimen Condition|OMSPCCND	A characteristic that refers to the physical and organoleptic state of a biospecimen used for an organ measurement.			Qualitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119894>	C105758	Organ Measurements Biospecimen Usability|OMSPCUFL	A qualitative or quantitative measure that describes a biospecimen's suitability for organ measurement purposes.			Qualitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119895>	C70713	Organ Measurements Specimen Type|OMSPEC	The type of material sample taken from a biological entity for organ measurements.			Qualitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119896>	C41202	Organ Measurements Completion Status|OMSTAT	A term used to describe the state or condition of the completeness of the organ measurements data.			Qualitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119897>	C117222	Organ Measurements Assessment Character Result in Standard Format|OMSTRESC	The standard character or string for representation and reporting of organ measurements data.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119898>	C70952	Organ Measurement Numeric Result in Standard Unit|OMSTRESN	The numerical identifier of an organ measurement result in standard units.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119899>	C82587	Organ Measurement Result Standard Unit|OMSTRESU	The standard unit of measure for the organ measurement results.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C11989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11989>	C61063	Asparaginase/Doxorubicin/Methotrexate/Prednisolone/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1198>	C2139	Poly ICLC|HILTONOL|Hiltonol|Poly I:Poly C with Poly-L-Lysine Stabilizer|PolyI:PolyC with Poly-L-Lysine Stabilizer|Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose|Polyriboinosinic-Polyribocytidylic Acid-Polylysine Carboxymethylcellulose|Stabilized Polyriboinosinic/Polyribocytidylic Acid|poly-ICLC	A synthetic complex of carboxymethylcellulose, polyinosinic-polycytidylic acid, and poly-L-lysine double-stranded RNA. Poly ICLC may stimulate the release of cytotoxic cytokines and, by inducing interferon-gamma production, may increase the tumoricidal activities of various immunohematopoietic cells. (NCI04)	Poly ICLC		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C119900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119900>	C82541	Organ Measurements Assessment Test|OMTEST	A character or string that represents the long name of the organ measurements.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119901>	C82503	Organ Measurements Assessment Test Code|OMTESTCD	A character or string that represents the short code name of the organ measurements.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119902>	C82526	Pharmacokinetic Concentration Baseline Flag|PCBLFL	An indication or description that pharmacokinetic concentration data is a baseline value.			Functional Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119903>	C82569	Pharmacokinetic Concentration End Day|PCENDY	The final day of the pharmacokinetic concentration assessment.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119904>	C117045	Exclude Pharmacokinetic Concentration Data From Statistics Indicator|PCEXCLFL	Specifies whether the pharmacokinetic concentration result values should be excluded from the statistical analysis.			Functional Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119905>	C117057	Pharmacokinetic Concentration Reason For Exclusion From Statistics|PCREASEX	A rationale for excluding a particular data point or subject from the pharmacokinetic concentration results statistical analysis.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119906>	C82515	Palpable Masses Collection Date Time|PMDTC	The date and time of palpable masses data collection.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119907>	C82437	Study Day of Palpable Masses|PMDY	The study day that a palpable masses assessment is performed.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119908>	C51824	Palpable Masses Evaluator|PMEVAL	A person who determines the significance of a palpable masses assessment.			Professional or Occupational Group	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119909>	C82529	Palpable Masses Group Identifier|PMGRPID	A character or string that represents a palpable masses group.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C11990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11990>	C61063	Asparaginase/cytarabine/daunorubicin/methotrexate/prednisolone/vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119910>	C25341	Palpable Masses Location|PMLOC	The site in or on the body at which the palpable masses assessment or result is performed or collected.			Spatial Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119911>	C117221	Palpable Masses Original Result|PMORRES	The outcome of the palpable masses assessment as originally received or collected.			Finding	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119912>	C82586	Palpable Masses Original Result Unit|PMORRESU	The unit of measure for the result of the palpable masses assessment as originally received or collected.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119913>	C82556	Palpable Masses Reason Not Done|PMREASND	The explanation given as to why a palpable masses assessment was not performed.			Idea or Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119914>	C70710	Palpable Masses Sequence Number|PMSEQ	An identifier that describes the relative position of palpable masses data within a series.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119915>	C82530	Palpable Masses Sponsor Defined Identifier|PMSPID	One or more sponsor defined characters used to identify, name, or characterize the palpable masses assessment.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119916>	C41202	Palpable Masses Completion Status|PMSTAT	A term used to describe the state or condition of the completeness of the palpable masses data.			Qualitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119917>	C117222	Palpable Masses Assessment Character Result in Standard Format|PMSTRESC	The standard character or string for representation and reporting of palpable masses data.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119918>	C70952	Palpable Masses Numeric Result in Standard Unit|PMSTRESN	The numerical identifier of a palpable masses assessment result in standard units.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119919>	C82587	Palpable Masses Result Standard Unit|PMSTRESU	The standard unit of measure for the palpable masses assessment results.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C11991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11991>	C61063	Cyclophosphamide/cytarabine/mercaptopurine/methotrexate/prednisolone			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119920>	C82541	Palpable Masses Assessment Test|PMTEST	A character or string that represents the long name of the palpable masses assessment.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119921>	C82503	Palpable Masses Assessment Test Code|PMTESTCD	A character or string that represents the short code name of the palpable masses assessment.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119922>	C82576	Pharmacokinetic Parameters Time Point Reference|PPTPTREF	The point in time that acts as a fixed reference point to a pharmacokinetic parameter assessment.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119923>	C33904	Tumor Findings Anatomical Region of Specimen|TFANTREG	The specific anatomical or biological region within the tissue or organ specimen used in the tumor findings assessment.			Body Part, Organ, or Organ Component	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119924>	C117041	Tumor Findings Dosing Days to Detection|TFDETECT	The number of days from the start of dosing to the earliest detection of cancer.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119925>	C54215	Tumor Findings Directionality|TFDIR	A qualifier for the direction on the body the tumor findings assessment is performed.			Functional Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119926>	C82515	Tumor Findings Collection Date Time|TFDTC	The date and time of tumor findings data collection.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119927>	C82563	Tumor Findings Death Relationship|TFDTHREL	An indication or description of a correlation between death and a tumor finding.			Finding	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119928>	C82437	Study Day of Tumor Findings|TFDY	The study day that a tumor findings assessment is performed.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119929>	C51824	Tumor Findings Evaluator|TFEVAL	A person who determines the significance of a tumor findings assessment.			Professional or Occupational Group	CDISC SEND Variable Terminology|CDISC Variable Terminology
C11992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11992>	C61063	Cyclophosphamide/Cytarabine/Dexamethasone/Mercaptopurine/Methotrexate			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119930>	C82529	Tumor Findings Group Identifier|TFGRPID	A character or string that represents a tumor identifier group.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119931>	C25185	Tumor Findings Laterality|TFLAT|TUMOR_LATERALITY|TUMOR_LATERALITY|TUMOR_LATERALITY|Tumor Laterality	A qualifier for the side of the body the tumor findings assessment is performed.			Organism Attribute	CDISC SEND Variable Terminology|CDISC Variable Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form|EWS Tumor Assessment Table|EWS Variable Terminology|GCT Tumor Assessment Table|GCT Variable Terminology|OS Tumor Assessment Table|OS Variable Terminology
C119932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119932>	C82535	Tumor Findings Method|TFMETHOD	The technique used to administer the tumor findings assessment.			Activity	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119933>	C117200	Tumor Findings Vendor Name|TFNAM	The literal identifier of the vendor or laboratory that performs a tumor findings assessment.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119934>	C117221	Tumor Findings Original Result|TFORRES	The outcome of the tumor findings assessment as originally received or collected.			Finding	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119935>	C82556	Tumor Findings Reason Not Done|TFREASND	The explanation given as to why a tumor findings assessment was not performed.			Idea or Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119936>	C82531	Tumor Findings Reference Identifier|TFREFID	A sequence of characters used to identify, name, or characterize the tumor findings reference.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119937>	C82498	Tumor Findings Result Category|TFRESCAT	A classification of a tumor findings result.			Classification	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119938>	C70710	Tumor Findings Sequence Number|TFSEQ	An identifier that describes the relative position of tumor findings data within a series.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology|NAACCR Terminology
C119939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119939>	C70714	Tumor Findings Specimen Condition|TFSPCCND	A characteristic that refers to the physical and organoleptic state of a biospecimen used for a tumor findings assessment.			Qualitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C11993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11993>	C61063	Dexamethasone/Pegaspargase			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119940>	C70713	Tumor Findings Specimen Type|TFSPEC|TUMOR_TISSUE_TYPE|TUMOR_TISSUE_TYPE|Tumor Type	The type of material sample taken from a biological entity for tumor findings assessment testing.			Qualitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology|CRF6 DMG Imaging Assessment Table|EWS Biopsy/Surgical Procedures Table|EWS Radiation Therapy Table|EWS Tumor Assessment Table|EWS Variable Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|OS Variable Terminology
C119941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119941>	C82530	Tumor Findings Sponsor Defined Identifier|TFSPID	One or more sponsor defined characters used to identify, name, or characterize the tumor findings assessment.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119942>	C41202	Tumor Findings Completion Status|TFSTAT	A term used to describe the state or condition of the completeness of the tumor findings data.			Qualitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119943>	C117222	Tumor Findings Character Result in Standard Format|TFSTRESC	The standard character or string for representation and reporting of tumor findings data.			Quantitative Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119944>	C82541	Tumor Findings Test|TFTEST	A character or string that represents the long name of the tumor findings assessment.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119945>	C82503	Tumor Findings Test Code|TFTESTCD	A character or string that represents the short code name of the tumor findings assessment.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119946>	C88429	Vital Signs Consciousness State|VSCSTATE	The level of awareness of an organism during a vital signs assessment.			Finding	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119947>	C82516	Vital Signs End Date Time|VSENDTC	The date and time a vital signs assessment has concluded			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119948>	C82569	Vital Signs End Day|VSENDY	The final day of the vital signs assessment.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119949>	C117045	Exclude Vital Signs Data From Statistics Indicator|VSEXCLFL	Specifies whether the vital signs result values should be excluded from the statistical analysis.			Functional Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C11994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11994>	C61007	Keyhole Limpet Hemocyanin/Sargramostim			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119950>	C117057	Vital Signs Reason For Exclusion From Statistics|VSREASEX	A rationale for excluding a particular data point or subject from the vital signs results statistical analysis.			Intellectual Product	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119951>	C82437	Study Day of Organ Measurements|OMDY	The study day that an organ measurements assessment is performed.			Temporal Concept	CDISC SEND Variable Terminology|CDISC Variable Terminology
C119952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119952>	C20401	Narsoplimab|Anti-MASP-2 Monoclonal Antibody OMS721|NARSOPLIMAB|OMS721|WHO 11174	A monoclonal antibody against mannan-binding lectin (MBL)-associated serine protease-2 (MASP-2), with potential anti-thrombotic and immunomodulating activities. Upon subcutaneous administration, narsoplimab binds to and inhibits MASP-2. This prevents the activation of MASP-2, the cleavage of certain complement components, and the activation of the complement lectin pathway. This inhibits complement deposition and complement-induced thrombus formation. MASP-2, a pro-inflammatory protein, plays a key role in the activation of the lectin complement pathway, which is a key component in the immune system, and is associated with complement-mediated diseases, such as thrombotic microangiopathies (TMAs), which includes hematopoietic stem cell transplant (HSCT)-related TMA, atypical hemolytic uremic syndrome (aHUS), and thrombotic thrombocytopenic purpura (TTP).	Anti-MASP-2 Monoclonal Antibody OMS721		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C119953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119953>	C78275	Icodextrin Solution	An isosmotic solution containing icodextrin, a starch-derived, water-soluble glucose polymer, used in peritoneal dialysis and for the prevention of adhesion after surgery. Due to its iso-osmotic nature and inability to cross the peritoneal membrane, the icodextrin solution, upon administration into the peritoneal cavity, is able to exert osmotic pressure. This allows for the removal of excess fluids and waste products in dialysis patients. In addition, icodextrin can provide a barrier between tissue surfaces when administered during surgery. This physically separates tissues, prevents adhesion after surgery and promotes wound healing.			Organic Chemical|Pharmacologic Substance	NCI Drug Dictionary Terminology
C119954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119954>	C118807	Macrosomia	A newborn infant who has a weight at birth greater than 4500 grams.			Finding	NICHD Terminology|Perinatal Terminology
C119955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119955>	C173346|C107401	Intensity of Pain at its Worst Question|How intense was your pain at its worst|Intensity of Pain at its Worst	A question about the intensity of an individual's pain at its worst.			Intellectual Product	PROMIS Short Form - Pain Intensity
C119956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119956>	C173346	Intensity of Average Pain Question|Average Pain Intensity|How bad was your pain on average|How intense was your average pain|Intensity of Average Pain|Level of Average Pain	A question about the intensity of an individual's average pain.			Intellectual Product	PROMIS Short Form - Pain Intensity
C119957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119957>	C173509|C173346	Level of Current Pain Question|Intensity of Current Pain|Intensity of Pain Right Now|Level of Current Pain|Level of Pain Right Now|What is your level of pain right now	A question about the level of an individual's current pain.			Intellectual Product	PROMIS Short Form - Pain Intensity
C119958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119958>	C173346|C104294	Trouble Sleeping When in Pain Question|I had trouble sleeping when I had pain|Trouble Sleeping Due to Pain|Trouble Sleeping When in Pain	A question about whether a person had trouble sleeping when they had pain.			Intellectual Product	PROMIS Pediatric Short Form - Pain Interference
C119959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119959>	C173346	Felt Angry When in Pain Question|Felt Angry Due to Pain|Felt Angry When in Pain|I felt angry when I had pain	A question about whether a person felt angry when they had pain.			Intellectual Product	PROMIS Pediatric Short Form - Pain Interference
C11995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11995>	C61063	Carboplatin/ISIS 3521/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119960>	C173398|C173346	Trouble Doing Schoolwork When in Pain Question|I had trouble doing schoolwork when I had pain|Trouble Doing Schoolwork Due to Pain|Trouble Doing Schoolwork When in Pain	A question about whether a person had trouble doing schoolwork when they had pain.			Intellectual Product	PROMIS Pediatric Short Form - Pain Interference
C119961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119961>	C173398|C173346	Hard to Pay Attention When in Pain Question|Hard to Pay Attention Due to Pain|Hard to Pay Attention When in Pain|It was hard for me to pay attention when I had pain	A question about whether a person had trouble paying attention when they had pain.			Intellectual Product	PROMIS Pediatric Short Form - Pain Interference
C119962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119962>	C173346|C131225	Hard to Run When in Pain Question|Hard to Run Due to Pain|Hard to Run When in Pain|It was hard for me to run when I had pain	A question about whether a person had trouble running when they had pain.			Intellectual Product	PROMIS Pediatric Short Form - Pain Interference
C119963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119963>	C173398|C173346|C173135	Hard to Walk One Block When in Pain Question|Hard to Walk One Block Due to Pain|Hard to Walk One Block When in Pain|It was hard for me to walk one block when I had pain	A question about whether a person had trouble walking one block when they had pain.			Intellectual Product	PROMIS Pediatric Short Form - Pain Interference
C119964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119964>	C173398|C173346	Hard to Have Fun When in Pain Question|Hard to Have Fun Due to Pain|Hard to Have Fun When in Pain|It was hard to have fun when I had pain	A question about whether a person had trouble having fun when they had pain.			Intellectual Product	PROMIS Pediatric Short Form - Pain Interference
C119965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119965>	C173398|C173346	Hard to Stay Standing When in Pain Question|Hard to Stay Standing Due to Pain|Hard to Stay Standing When in Pain|It was hard to stay standing when I had pain	A question about whether a person had trouble staying standing when they had pain.			Intellectual Product	PROMIS Pediatric Short Form - Pain Interference
C119966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119966>	C173890|C173346|C104294	Child Had Trouble Sleeping When in Pain Question|Child Had Trouble Sleeping Due to Pain|Child Had Trouble Sleeping When in Pain|My child had trouble sleeping when he/she had pain	A question about whether a person's child had trouble sleeping when they had pain.			Intellectual Product	PROMIS Parent Proxy Short Form - Pain Interference
C119967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119967>	C173890|C173346	Child Felt Angry When in Pain Question|Child Felt Angry Due to Pain|Child Felt Angry When They had Pain|Child Felt Angry When in Pain|My child felt angry when he/she had pain	A question about whether a person's child felt angry when they had pain.			Intellectual Product	PROMIS Parent Proxy Pain Interference - Short Form 8a|PROMIS Parent Proxy Short Form - Pain Interference
C119968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119968>	C173890|C173398|C173346	Child Had Trouble Doing Schoolwork When in Pain Question|Child Had Trouble Doing Schoolwork Due to Pain|Child Had Trouble Doing Schoolwork When in Pain|Child had Trouble with Schoolwork When They had Pain|My child had trouble doing schoolwork when he/she had pain	A question about whether a person's child had trouble doing schoolwork when they had pain.			Intellectual Product	PROMIS Parent Proxy Pain Interference - Short Form 8a|PROMIS Parent Proxy Short Form - Pain Interference
C119969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119969>	C173890|C173398|C173346	Child Had Trouble Paying Attention When in Pain Question|Child Had Trouble Paying Attention Due to Pain|Child Had Trouble Paying Attention When in Pain|Hard for Child to Pay Attention When in Pain|Hard for Child to Pay Attention When in Pain Question|It was hard for my child to pay attention when he/she had pain	A question about whether a person's child had trouble paying attention when they had pain.			Intellectual Product	PROMIS Parent Proxy Short Form - Pain Interference|PROMIS Parent Proxy-25 Profile
C11996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11996>	C61007	Carboplatin/IM-862/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119970>	C173890|C173398|C173346	Child Had Trouble Running When in Pain Question|Child Had Trouble Running Due to Pain|Child Had Trouble Running When in Pain|Hard for Child to run When in Pain|It was hard for my child to run when he/she had pain	A question about whether a person's child had trouble running when they had pain.			Intellectual Product	PROMIS Parent Proxy Short Form - Pain Interference|PROMIS Parent Proxy-25 Profile
C119971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119971>	C173890|C173398|C173346|C173135	Child Had Trouble Walking One Block When in Pain Question|Child Had Trouble Walking One Block Due to Pain|Child Had Trouble Walking One Block When in Pain|Hard for Child to Walk One Block When in Pain|It was hard for my child to walk one block when he/she had pain	A question about whether a person's child had trouble walking one block when they had pain.			Intellectual Product	PROMIS Parent Proxy Short Form - Pain Interference|PROMIS Parent Proxy-25 Profile
C119972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119972>	C173890|C173398|C173346	Child Had Trouble Having Fun When in Pain Question|Child Had Trouble Having Fun Due to Pain|Child Had Trouble Having Fun When in Pain|Difficult for Child to Have Fun When They had Pain|It was hard for my child to have fun when he/she had pain	A question about whether a person's child had trouble having fun when they had pain.			Intellectual Product	PROMIS Parent Proxy Pain Interference - Short Form 8a|PROMIS Parent Proxy Short Form - Pain Interference
C119973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119973>	C173890|C173398|C173346	Child Had Trouble Staying Standing When in Pain Question|Child Had Trouble Staying Standing Due to Pain|Child Had Trouble Staying Standing When in Pain|Difficult for Child to Stay Standing When They had Pain|It was hard for my child to stay standing when he/she had pain	A question about whether a person's child had trouble staying standing when they had pain.			Intellectual Product	PROMIS Parent Proxy Pain Interference - Short Form 8a|PROMIS Parent Proxy Short Form - Pain Interference
C119974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119974>	C176021|C173584|C173346	How Much Did Pain Interfere with Day to Day Activity Question|How Much Did Pain Interfere with Day to Day Activity|How Much Did Pain Interfere with General Activity|How much did pain interfere with your day to day activities	A question about how much a person's pain interferes or interfered with their day to day activities.			Intellectual Product	PROMIS Adult Short Form - Pain Interference
C119975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119975>	C173584|C173346	How Much Did Pain Interfere with Work Around the Home Question|How Much Did Pain Interfere with Work Around the Home|How much did pain interfere with work around the home	A question about how much a person's pain interferes or interfered with their work around the home.			Intellectual Product	PROMIS Adult Short Form - Pain Interference
C119976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119976>	C173584|C173346	How Much Did Pain Interfere with Ability to Participate in Social Activities Question|How Much Did Pain Interfere with Ability to Participate in Social Activities|How much did pain interfere with your ability to participate in social activities	A question about how much a person's pain interferes or interfered with their ability to participate in social activities.			Intellectual Product	PROMIS Adult Short Form - Pain Interference
C119977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119977>	C173584|C173346	How Much Did Pain Interfere with Enjoyment of Life Question|How Much Did Pain Interfere with Enjoyment of Life|How much did pain interfere with your enjoyment of life	A question about how much a person's pain interferes or interfered with their enjoyment of life.			Intellectual Product	PROMIS Adult Short Form - Pain Interference
C119978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119978>	C173584|C173346	How Much Did Pain Interfere with Things Usually Done for Fun Question|How Much Did Pain Interfere with Things Usually Done for Fun|How much did pain interfere with the things you usually do for fun	A question about how much a person's pain interferes or interfered with the things they do for fun.			Intellectual Product	PROMIS Adult Short Form - Pain Interference
C119979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119979>	C173584|C173346	How Much Did Pain Interfere with Enjoyment of Social Activities Question|How Much Did Pain Interfere with Enjoyment of Social Activities|How much did pain interfere with your enjoyment of social activities	A question about how much a person's pain interferes or interfered with their enjoyment of social activities.			Intellectual Product	PROMIS Adult Short Form - Pain Interference
C11997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11997>	C61063	Arsenic trioxide/Dexamethasone			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119980>	C173584|C173346	How Much Did Pain Interfere with Household Chores Question|How Much Did Pain Interfere with Household Chores|How much did pain interfere with your household chores	A question about how much a person's pain interferes or interfered with their ability to do their household chores.			Intellectual Product	PROMIS Adult Short Form - Pain Interference
C119981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119981>	C173584|C173346|C173151	How Much Did Pain Interfere with Family Life Question|How Much Did Pain Interfere with Family Life|How much did pain interfere with your family life	A question about how much a person's pain interferes or interfered with family life.			Intellectual Product	PROMIS Adult Short Form - Pain Interference
C119982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119982>	C173584|C173346	How Much Did Pain Interfere with Ability to Concentrate Question|How Much Did Pain Interfere with Ability to Concentrate|How much did pain interfere with your ability to concentrate	A question about how much a person's pain interferes or interfered with their ability to concentrate.			Intellectual Product	PROMIS Adult Short Form - Pain Interference
C119983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119983>	C173584|C173346	How Much Did Pain Interfere with Enjoyment of Recreational Activities Question|How Much Did Pain Interfere with Enjoyment of Recreational Activities|How much did pain interfere with your enjoyment of recreational activities	A question about how much a person's pain interferes or interfered with their enjoyment of recreational activities.			Intellectual Product	PROMIS Adult Short Form - Pain Interference
C119984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119984>	C173584|C173346	How Much Did Pain Interfere with Doing Tasks Away from Home Question|How Much Did Pain Interfere with Doing Tasks Away from Home|How much did pain interfere with doing your tasks away from home (e.g., getting groceries, running errands)	A question about how much a person's pain interferes or interfered with their ability to do tasks outside the home.			Intellectual Product	PROMIS Adult Short Form - Pain Interference
C119985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119985>	C173346|C118873	How Often Did Pain Prevent Socializing Question|How Often Did Pain Prevent Socializing|How often did pain keep you from socializing with others	A question about how often a person's pain kept them from socializing with others.			Intellectual Product	PROMIS Adult Short Form - Pain Interference
C119986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119986>	C175311	Almost All of the Time|Almost All|Almost Always|Almost all the Time|Almost all the time|Almost all the time	A response indicating that something happens or happened almost all of the time.			Intellectual Product	Memorial Symptom Assessment Scale (MSAS) 7-12|Ped-PRO-CTCAE Attribute Value Terminology|Ped-PRO-CTCAE Version 1.0 Questionnaire Terminology
C119987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119987>	C176246	Had No Pain|Had no pain|No Pain	A response indicating that an individual has or had no pain.			Intellectual Product	
C119988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119988>	C201554|C154231	Genetically Engineered Hematopoietic Stem Progenitor Cells|Genetically Engineered HSPCs	Gene modified hematopoietic stem progenitor cells (HSPCs).	Genetically Engineered Hematopoietic Stem Progenitor Cells		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C119989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119989>	C35109	Acute Anterior Uveitis	Sudden onset of anterior uveitis, usually unilateral, and associated with pain, erythema, photophobia, and blurred vision. Often associated with HLA-B27, with or without co-existing spondyloarthritis.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C11998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11998>	C61063	Epirubicin/Gemcitabine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C119990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119990>	C4691	C1q Deficiency	Lack of production of functional C1q proteins, due to a genetic defect. Virtually 100% of patients with a C1q deficiency will develop a severe systemic lupus erythematosus at an early age. Patients also present with frequent sinopulmonary infections often with Streptococcus pneumoniae.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119991>	C4691	C1r/C1s Deficiency	Lack of production of either functional C1r or C1s protein, due to a genetic defect. Approximately 60% of patients with a C1r/C1s deficiency will develop a severe systemic lupus erythematosus at an early age. Patients also present with frequent sinopulmonary infections often with Streptococcus pneumoniae.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119992>	C4691	C2 Deficiency	Lack of production of functional C2 protein, due to a genetic defect. It is the most common genetic complement deficiency. Ten percent of C2 deficient patient will develop systemic lupus erythematosus at an early age. Patients also present with frequent sinopulmonary infections often with Streptococcus pneumoniae.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119993>	C4691	C4 Deficiency	Lack of production of functional C4 protein, due to a genetic defect requiring homozygous loss of both the C4A and C4B genetic paralogs. Approximately 75% of patients with a C4 deficiency will develop a severe systemic lupus erythematosus at an early age. Patients also present with frequent sinopulmonary infections often with Streptococcus pneumoniae.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C119994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119994>	C35681|C159691	Seronegative	A laboratory result which shows no presence of antibodies for which sera are being tested. In rheumatology this typically refers to absence of rheumatoid factor.			Finding	NICHD Terminology|Pediatric Rheumatology Terminology
C119995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119995>	C38440	Low Complement	A decreased amount of complement (e.g. C3, C4, CH50) as determined through quantitative measurement. May be due to a genetic deficiency or from overconsumption due to an infection or a co-morbid autoimmune disorder.			Laboratory or Test Result	NICHD Terminology|Pediatric Rheumatology Terminology
C119996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119996>	C3298	Pediatric Osteoporosis|Idiopathic Juvenile Osteoporosis	The finding of one or more vertebral compression (crush) fractures in the absence of local disease or high-energy trauma or the presence of both a clinically significant fracture history and BMD Z-score less than or equal to -2.0. A clinically significant fracture history is one or more of the following: 1) two or more long bone fractures by age ten years; 2) three or more long bone fractures at any age up to age nineteen years. (from 2013 International Society for Clinical Densitometry definition of Osteoporosis-Pediatric)			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology|Pediatric Rheumatology Terminology
C119997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119997>	C3426	Vasculitic Ulcer	A circumscribed inflammatory lesion associated with underlying ischemic disease.			Finding	NICHD Terminology|Pediatric Rheumatology Terminology
C119998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119998>	C35877	Low Natural Killer Cell Activity	A decrease in the ability of peripheral mononuclear blood cells to lyse MHC I deficient target cells either due to low numbers of natural killer cells, or a reduction of their lytic activity.			Laboratory or Test Result	NICHD Terminology|Pediatric Rheumatology Terminology
C119999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C119999>	C26808|C26746	Scleroderma Renal Crisis	The onset of acute renal failure, normally coupled with marked hypertension in a patient with scleroderma.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C11999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C11999>	C61063	Bevacizumab/Vinorelbine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1199>	C478	Polyestradiol Phosphate|Estradiol Phosphate Polymer|Estradurin|Leo 114|PEP|POLYESTRADIOL PHOSPHATE	A synthetic long-acting polymer derivative of the female sex hormone estradiol.  As the primary, most potent estrogen hormone produced by the ovaries, estradiol binds to and activates specific nuclear receptors.  Estradiol exhibits mild anabolic and metabolic properties, and increases blood coagulability.  Administration of polyestradiol phosphate leads to the marked decrease of testosterone levels and may exhibit a bone mass-preserving effect in patients with prostatic cancer. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C120000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120000>	C104083	Exhausted T-Cell|Exhausted T Cell|Exhausted T Lymphocyte|Exhausted T-Lymphocyte	An effector T-lymphocyte that is losing or has lost the ability to kill virally infected cells. T-cell exhaustion occurs during infections with high viral loads and/or prolonged duration. These T-lymphocytes undergo a gradual phenotype change and in the final stage they are unable to mount a T-cell antiviral response and are highly susceptible to apoptosis.	Exhausted T-Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C120001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120001>	C28681|C213868|C201547	CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes|CXCR2-transduced Autologous TILs	A preparation of autologous tumor infiltrating lymphocytes (TILs) that are transduced, ex vivo, with a retroviral vector encoding a gene for CXC chemokine receptor 2 (CXCR2), with potential antineoplastic activity. Upon administration of the CXCR2-transduced autologous TILs, the CXCR2-expressing T-cells selectively migrate toward tumor cells expressing CXCR2 ligands, which leads to tumor cell killing. CXCR2 expression allows for optimal TIL migration towards tumor cells and enhances the TILs anti-tumor activity. This leads to a reduction in both tumor cell proliferation and survival. CXCR2, a transmembrane protein also known as IL-8 receptor B (IL-8RB), plays a key role in inflammation and cancer progression. Certain CXCR2 ligands, such as CXCL1 and CXCL8 (IL-8), are expressed by tumor cells.	CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120002>	C345	2-Hydroxybutyrate|2-Hydroxybutanoate|2-OH Butyrate|2-OH-Butyrate|Alpha-Hydroxybutanoate|Alpha-Hydroxybutyrate|a-HB	A hydroxy fatty acid anion and conjugate base of 2-hydroxybutyric acid. 2-Hydroxybutyrate is a metabolite produced by the conversion of cystathionine to cysteine in the glutathione biosynthesis pathway. The amount of 2-hydroxybutyrate secreted in the urine can reflect changes in the rate of glutathione synthesis, which is altered by oxidative stress or toxin exposure.	2-Hydroxybutyrate		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C120003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120003>	C345	3-Hydroxybutyrate|3-Hydroxybutanoate|3-OH Butyrate|3-OH-Butyrate|BHB|Beta-Hydroxy-n-Butyrate|Beta-Hydroxybutanoate|b-HB	A hydroxy fatty acid anion and ketone body synthesized in the liver from acetyl-Coenzyme A (acetyl-CoA) by the enzyme 3-hydroxybutyrate dehydrogenase. 3-hydroxybutyrate can be used as an energy source when glucose levels drop. Elevated urine and serum levels of 3-hydroxybutyrate are seen in ketosis and ketoacidosis.	3-Hydroxybutyrate		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C120004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120004>	C66913	Cholate|3alpha,7alpha,12alpha-Trihydroxy-5beta-Cholan-24-Oate|3alpha,7alpha,12alpha-Trihydroxy-5beta-Cholanate	An ester or salt of the bile acid cholic acid that is synthesized in the liver from cholesterol, with surfactant and signaling activities in the liver and intestine. In the intestine, cholate acts as a surfactant that promotes the absorption of dietary lipids and fat-soluble vitamins. In the liver, cholate's surfactant activity facilitates biliary excretion of xenobiotics and metal cations. Cholate binds to nuclear receptors, including farnesoid X receptor (FXR), pregnane X receptor (PXR), and the vitamin D receptor (VDR), which directly modulate gene transcription. Cholate may also be used as a biomarker for hepatotoxicity.	Cholate		Organic Chemical|Pharmacologic Substance	CTRP Biomarker Terminology|CTRP Terminology
C120005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120005>	C345	Dicarboxylic Acid|Dicarboxylic Acids	An organic acid that contains oxygen and two carboxyl groups.	Dicarboxylic Acid		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C120006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120006>	C707	Deoxyuridine|1-(2-Deoxy-Beta-D-Erythro-Pentofuranosyl)Uracil|1-(2-Deoxy-Beta-D-Erythro-Pentofuranoxyl)Uracil|2'-Deoxyuridine|2'-Desoxyuridine|2,4(1H,3H)-Pyrimidinedione, 1-(2-Deoxy-Beta-D-Erythro-Ribofuranosyl)-|2,4(1H,3H)-Pyrimidinedione, 1-(2-Deoxy-Beta-D-Ribofuranosyl)-|2-Deoxyuridine|DEOXYURIDINE|Deoxyribose Uracil|Uracil Deoxyriboside|Uridine, 2'-Deoxy-|dU|dURD	A nucleoside consisting of uracil and deoxyribose, which can act as an intermediate in thymidine synthesis. Deoxyuridine (dU) is used to indirectly determine if there are sufficient levels of folate and cobalamin in cell or tissue samples.	Deoxyuridine		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C120007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120007>	C2298	Androsterone Glucuronide|3alpha-Hydroxy-5alpha-Androstan-17-One Glucuronide|ADT-G|ANDROSTERONE GLUCURONIDE|Androsterone 3-Glucosiduronic Acid|Androsterone 3-Glucuronide|Androsterone Glucosiduronate|Androsterone-G|Beta-D-Glucopyranosiduronic Acid, (3alpha,5alpha)-17-Oxoandrostan-3-Yl|Etiocholanolone Glucuronide	A glucuronosyltransferase-modified, liver metabolite of the steroid androsterone and metabolite of the steroid dihydrotestosterone found in serum, with weak androgenic activity.	Androsterone Glucuronide		Hormone	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C120008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120008>	C2298	Androsterone Sulfate|(5alpha)-17-Oxoandrostan-3alpha-Yl Hydrogen Sulfate|3alpha-Hydroxy-5alpha-Androstan-17-One Monosulfate|3alpha-Hydroxy-5alpha-Androstan-17-One Sulfate|5alpha-Androsterone Sulfate|ANDROSTERONE SULFATE|Andros-S|Androstan-17-One, 3-(Sulfooxy)-, (3alpha,5alpha)-|Androsterone 3alpha-Sulfate|Androsterone Monosulfate|Androsterone, Hydrogen Sulfate|Androsterone-S	A sulfated form of androsterone and a steroid metabolite derived from testosterone found in urine, with weak androgenic activity.	Androsterone Sulfate		Hormone	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C120009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120009>	C843	Dehydroepiandrosterone 3-Glucuronide|(3beta)-17-Oxoandrost-5-En-3-Yl Beta-D-Glucopyranosiduronic Acid|DHEA-G|Dehydroepiandrosterone Glucopyranuronoside|Dehydroisoandrosterone Glucopyranuronoside	A glucuronosyltransferase-catalyzed, liver metabolite of the steroid dehydroepiandrosterone (DHEA), which is an intermediate in the conversion of cholesterol to androgens and estrogens.	Dehydroepiandrosterone 3-Glucuronide		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C12000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12000>	C61063	Carboplatin/Etoposide/Oblimersen			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120010>	C87059	F4-Isoprostane	A prostaglandin-like compound derived from the peroxidation of docosahexaenoic acid. This modified lipid may be used as a marker for oxidative damage and may be associated with neuropathy and aging.	F4-Isoprostane		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C120011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120011>	C73539	N(6)-(1-Carboxyethyl)Lysine|CEL|L-Lysine, N6-(1-Carboxyethyl)-|N(Epsilon)-(1-(1-Carboxy)Ethyl)Lysine|N(Epsilon)-(Carboxyethyl)Lysine	A lysine derivative found in proteins where the epsilon nitrogen of the amino acid residue is modified by a carboxyethyl group. This advanced glycation end product (AGE) is elevated in certain diseases and may be associated with aging.	N(6)-(1-Carboxyethyl)Lysine		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Terminology
C120012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120012>	C73539	Aminoadipic Semialdehyde|AASA	An amino acid derivative that is a product of lysine degradation. This metabolite is associated with oxidative stress. Elevated urine levels of aminoadipic semialdehyde (AASA) are seen in patients with AASA dehydrogenase deficiency.	Aminoadipic Semialdehyde		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Terminology
C120013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120013>	C73539	N(6)-Carboxymethyllysine|CML|L-Lysine, N6-(Carboxymethyl)-|N(6)-CARBOXYMETHYLLYSINE|N(Epsilon)-(Carboxymethyl)Lysine|N(Epsilon)-Carboxymethyl-L-Lysine|NECML	A lysine derivative found in proteins where the epsilon nitrogen of the amino acid residue is modified by a carboxymethyl group. This advanced glycation end product (AGE) is elevated in certain diseases and is associated with aging.	N(6)-Carboxymethyllysine		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C120014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120014>	C73539	Malondialdehyde-Lysine|MDA-Lys|MDAL	A lysine modification found in proteins resulting from a malondialdehyde attachment to the protein lysine residue. This advanced glycation end product (AGE) is elevated in certain diseases and is associated with aging.	Malondialdehyde-Lysine		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Terminology
C120015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120015>	C79089	CA125 II Assay|CA125 II|CA125-II|CA125-II Assay	A second generation radioimmunoassay to measure serum levels of CA-125.	CA125 II Assay		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120016>	C48182	Lymph Node Gene Expression Signature	A gene expression profile that indicates that a patient sample may have originated in or adopted the behavior of lymph node tissue. This gene signature may be associated with a better prognosis for melanoma patients.	Lymph Node Gene Expression Signature		Functional Concept	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120017>	C48182	MHC Class II Gene Expression Signature|Major Histocompatibility Complex Class II Gene Expression Signature	A gene expression profile that provides diagnostic information in diffuse large B-cell lymphoma. Loss of MHC class II expression is correlated with poor patient outcome.	MHC Class II Gene Expression Signature		Functional Concept	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120018>	C48182	Tumor Proliferation Gene Expression Signature	A gene expression profile that predicts survival in mantle cell lymphoma. The lowest expression levels of cyclin D1 were associated with increased survival.	Tumor Proliferation Gene Expression Signature		Functional Concept	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120019>	C48182	Germinal Center B-Cell Gene Expression Signature|Germinal Center B Cell Gene Expression Signature|Germinal Center B Cell-Like Gene Expression Signature|Germinal Center B-Cell-Like Gene Expression Signature	A gene expression profile found in a subset of diffuse large B-cell lymphomas. This expression profile is associated with better overall survival.	Germinal Center B-Cell Gene Expression Signature		Functional Concept	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12001>	C63442|C63356	Dexa-BEAM Regimen|Carmustine/Cytarabine/Dexamethasone/Etoposide/Melphalan|Dexa-BEAM|Dexa-BEAM|DexaBEAM|Dexamethasone-BCNU-Etoposide-Cytarabine-Melphalan|Dexamethasone-Carmustine-Etoposide-Cytarabine-Melphalan|Dexamethasone/BCNU/Etoposide/Ara-C/Melphalan|Dexamethasone/Carmustine/Etoposide/Cytarabine/Melphalan|Dexamethasone/Carmustine/Etoposide/Cytarabine/Melphalan Regimen	A regimen consisting of dexamethasone, carmustine, etoposide, cytarabine, and melphalan that may be used followed by high-dose and stem-cell rescue for the treatment of relapsed or refractory lymphoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C120020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120020>	C13803	Long Interspersed Nucleotide Element-1|L-1|L-1 Element|L1|L1-Element|LINE-1	A long interspersed element (LINE) found in mammals. The LINE-1 element is the only active LINE in humans and is approximately 6,000 base pairs long. This nucleotide sequence consists of two non-overlapping open reading frames (ORF) flanked by a 5' untranslated region (UTR), which contains a strong RNA polymerase II promoter sequence, and target side duplications. The first ORF encodes a 500 amino acid, ~40 kDa leucine zipper-containing RNA-binding protein. The second ORF encodes an ~150 kDa protein that has endonuclease and reverse transcriptase activity. Increased LINE-1 copy number is associated with cancer and neuropathy.	Long Interspersed Nucleotide Element-1		Nucleotide Sequence	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120021>	C17370	ENAH Protein Isoform Expression Assay|Mena Protein Isoform Expression Assay|MenaCalc|MenaCalc Platform|Protein Enabled Homolog Isoform Expression Assay	A proprietary immunofluorescent assay that quantifies the relative expression levels of all isoforms of the actin regulatory protein, protein enabled homolog (Mena or ENAH), including Mena(INV) and Mena11a. Mena(INV) expression is elevated and Mena11a expression is diminished or absent in invasive tumor cells, which may have increased metastatic potential. Therefore, this assay may be able to predict a patient's risk for tumor metastasis.	ENAH Protein Isoform Expression Assay		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120022>	C20130	Acid Phosphatase|Acid Monophosphatase|Acid Nucleoside Diphosphate Phosphatase|Acid Phosphohydrolase|Acid Phosphomonoester Hydrolase|Acid Phosphomonoesterase|EC 3.1.3.2|Glycerophosphatase|Orthophosphoric-Monoester Phosphohydrolase (Acid Optimum)|Phosphate-Monoester Phosphohydrolase (Acid Optimum)|Phosphomonoesterase	A family of phosphatases that add monophosphates to substrates. The optimal pH for activity of these enzymes is below 7.	Acid Phosphatase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120023>	C18520	Histone H3 Acetyl Lys28|H3K27ac|H3K27ac|H3K28ac|Histone H3 Acetyl Lys27|Histone H3 Acetyl Lys27|Histone H3 Acetyl Lysine 28	A post-translationally modified form of histone H3 where the lysine residue at position 28 is acetylated. This modification may be a marker for transcriptional enhancement.	Histone H3 Acetyl Lys27		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C120024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120024>	C18520	Histone H3 Methyl Lys4|H3K4me1|H3K4me1|Histone H3 Methyl Lysine 4|Histone H3 Methyl Lysine 5	A form of histone H3 where the lysine residue at position 4 has been post-translationally modified with a single methyl group. This modification may be a marker for transcriptionally active genes.	Histone H3 Methyl Lys4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C120025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120025>	C153165	Microparticle|Cell-Derived Microparticle|Circulating Microparticle|Circulating Microvesicle|Ectosome|Microvesicle	A small, membrane-bound vesicle between 100 nm to 1000 nm in size found in the circulatory system. These vesicles are plasma membrane fragments shed from cells. The protein composition is similar to that of the cell that shed the particle.	Microparticle		Body Part, Organ, or Organ Component	CTRP Biomarker Terminology|CTRP Terminology
C120026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120026>	C120025	Platelet-Derived Microparticle|PDMP|Platelet Microparticle|Platelet-Derived MP|Pt-MP	A small, membrane bound vesicle circulating in the blood that was shed by a platelet. This is the most abundant type of microparticle in human blood. Since they contain platelet chemokines and surface proteins, these particles may modulate vascular processes, such as blood coagulation.	Platelet-Derived Microparticle		Body Part, Organ, or Organ Component	CTRP Biomarker Terminology|CTRP Terminology
C120027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120027>	C120025	Monocyte-Derived Microparticle|MDMP	A small, membrane bound vesicle circulating in the blood that was shed by a monocyte. These particles may induce coagulation or cell apoptosis.	Monocyte-Derived Microparticle		Body Part, Organ, or Organ Component	CTRP Biomarker Terminology|CTRP Terminology
C120028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120028>	C120025	Endothelial Cell-Derived Microparticle|Endothelial Microparticle	A small, membrane bound vesicle circulating in the blood that was shed by an endothelial cell. Increased concentrations of endothelial microparticles in plasma may be a marker for cardiovascular disease.	Endothelial Cell-Derived Microparticle		Body Part, Organ, or Organ Component	CTRP Biomarker Terminology|CTRP Terminology
C120029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120029>	C120025	Tissue Factor-Derived Microparticle|MP-TF|Microparticle Tissue Factor|Microparticle-Derived Tissue Factor|TFMP|Tissue Factor-Bearing Microparticle|Tissue Factor-Positive Microparticle|Tissue-Factor-Derived Microparticle	A small, membrane bound vesicle circulating in the blood that was shed by a cell that expresses the coagulation protein, tissue factor (factor III). The presence of microparticles with tissue factor in the plasma of cancer patients is associated with an increased risk for venous thrombosis.	Tissue Factor-Derived Microparticle		Body Part, Organ, or Organ Component	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12002>	C61063	Carboplatin/Etoposide Phosphate/Melphalan			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120030>	C20130	Tryptase|EC 3.4.21.59	A family of serine endoproteinases usually expressed in mast cell secretory granules. These enzymes cleave protein substrates after arginine or lysine residues and play a role in allergic responses.	Tryptase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120031>	C16447	CTX|C-Telopeptide|C-Terminal Telopeptide Type 1 Collagen|C-Terminal Telopeptide Type I Collagen|CTX-I|CTXI|Collagen Type 1 Cross-linked C-Telopeptide|Cross-Linked C-Terminal Telopeptide of Type I Collagen	This polypeptide is comprised of the carboxy-terminal portions of fibrillar collagen, which are joined through trivalent crosslinks and released during the degradation of mature type I collagen by cathepsin K. Serum concentrations of these peptides can be correlated with the rate of bone metabolism.	CTX		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120032>	C16295	TARP Antibody|Anti-CD3G Antibody|Anti-T-Cell Receptor Gamma Chain Alternative Reading Frame Protein Antibody|Anti-TARP Antibody|Anti-TCRg Antibody|CD3G Antibody|T-Cell Receptor Gamma Chain Alternative Reading Frame Protein Antibody|TCRg Antibody	Any immunoglobulin that recognizes T-cell receptor gamma chain alternative reading frame protein.	TARP Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120033>	C1505	Gluten-free Compact Nutritional Supplement Drink|Fortimel Compact	A gluten-free, calorie-dense, milkshake-like nutritional supplement drink containing all essential vitamins, minerals, and trace elements, as well as protein, fat and carbohydrates. Upon oral intake, gluten-free compact nutritional supplement drink may aid in the prevention of malnutrition and weight loss. The drink is provided in a reduced volume (125 ml) but with the same complete nutrition as the standard drink (200 ml); the reduced volume may increase patient compliance.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C120034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120034>	C1505	Gluten-free/Fiber-enriched Compact Nutritional Supplement Drink|Fortimel Compact Fibre	A gluten-free, calorie-dense, fiber-enriched milkshake-like nutritional supplement drink containing all essential vitamins, minerals, and trace elements, as well as protein, fat and carbohydrates. Upon oral intake, gluten-free, fiber-enriched compact nutritional supplement drink may aid in the prevention of malnutrition and weight loss. The drink is provided in a reduced volume (125 ml) but with the same complete nutrition as the standard drink (200 ml); the reduced volume may increase patient compliance. The fiber, acting as a prebiotic, promotes beneficial bacterial growth in the gastrointestinal (GI) tract, increases digestive health and may reduce the incidence of constipation and/or diarrhea.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C120035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120035>	C201173|C200766	Anti-CD22-CAR m971-BBz Lentiviral Vector-transduced Autologous T Lymphocytes|Anti-CD22-CAR m971-BBz Cells	Autologous human T-lymphocytes transduced with a recombinant lentiviral vector encoding a chimeric T-cell receptor (chimeric antigen receptor or CAR) consisting of an anti-CD22 single chain variable fragment (scFv) derived from the monoclonal antibody (moAb) 971 (m971), and the co-stimulatory domain 4-1BB (CD137) coupled to the zeta chain of the TCR/CD3 complex (CD3-zeta), with potential immunostimulating and antineoplastic activities. Autologous peripheral blood lymphocytes (PBLs) from a patient with CD22-positive cancer are transduced with this lentiviral vector that encodes the CAR gene specific for CD22. After expansion in culture and reintroduction into the patient, the anti-CD22-CAR m971-BBz lentiviral vector-transduced autologous T-lymphocytes express anti-CD22-CAR on their cell surfaces and bind to the CD22 antigen on tumor cell surfaces. Subsequently, CD22-expressing tumor cells are lysed. CD22, a B-lineage-restricted, transmembrane phosphoglycoprotein, is expressed on malignant B-cells. m971 binds to a membrane proximal epitope on CD22 and has a higher binding affinity compared to other anti-CD22 moAb.	Anti-CD22-CAR m971-BBz Lentiviral Vector-transduced Autologous T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120036>	C192218	Peposertib|(S)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol|3-Pyridazinemethanol, alpha-(2-Chloro-4-fluoro-5-(7-(4-morpholinyl)-4-quinazolinyl)phenyl)-6-methoxy-, (alphaS)-|M 3814|M-3814|M3814|MSC 2490484A|MSC-2490484A|MSC2490484A|Nedisertib|PEPOSERTIB	An orally bioavailable inhibitor of DNA-dependent protein kinase (DNA-PK) with potential antineoplastic activity, and potential sensitizing and enhancing activities for both chemo- and radiotherapies. Upon administration, peposertib binds to and inhibits the activity of DNA-PK, thereby interfering with the non-homologous end joining (NHEJ) process and preventing repair of DNA double strand breaks (DSBs) caused by ionizing radiation or chemotherapeutic treatment. This increases chemo- and radiotherapy cytotoxicity and leads to enhanced tumor cell death. The enhanced ability of tumor cells to repair DSBs plays a major role in the resistance of tumor cells to chemo- and radiotherapy; DNA-PK plays a key role in the NHEJ pathway and DSB repair.	Peposertib		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120037>	C2116	Selective Estrogen Receptor Degrader GDC-0927|GDC 0927|GDC-0927|GDC-0927|GDC0927|RG 6047|RG-6047|RG6047|SERD GDC-0927|SERD RG6047|SERD SRN-927|SRN 927|SRN-927|SRN927	An orally available, nonsteroidal selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, SERD GDC-0927 specifically binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This prevents ER-mediated signaling and inhibits the growth and survival of ER-expressing cancer cells.	Selective Estrogen Receptor Degrader GDC-0927		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120039>	C181141	Antigen-targeted Personalized Breast Cancer Vaccine|IVAC_W_bre1_uID	An individualized, therapeutic cancer vaccine (IVAC) composed of liposomes containing RNA encoding two or three tumor associated antigens (TAAs) that are specifically expressed in the patient's individual cancer selected from a warehouse ("off the shelf") and p53 RNA, with potential immunostimulatory and antineoplastic activities. Upon administration, the antigen-targeted personalized breast cancer vaccines are translated by antigen presenting cells (APCs) and the expressed protein is presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL) and memory T-cell immune responses against the TAAs. The RNAs in the vaccine are specifically selected for an individual patient after RNA profiling of the patient's tumor.			Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12003>	C61063	SU5416/Thalidomide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120040>	C133879|C129822	Bemarituzumab|BEMARITUZUMAB|FPA144	A glycoengineered, humanized monoclonal antibody directed against the fibroblast growth factor receptor type 2b (FGFR2b), with potential antineoplastic activity. Upon administration, bemarituzumab specifically binds to and inhibits FGFR2b on tumor cell surfaces, which prevents FGFR2 from binding to its ligands, FGFR2b activation and the activation of FGFR2b-mediated signal transduction pathways. The binding of FPA144 to FGFR2b protein also induces antibody-dependent cell-mediated cytotoxicity (ADCC) against FGFR2b-expressing tumor cells. This results in the inhibition of cell proliferation and the induction of cell death of FGFR2-expressing tumor cells. FGFR2b, a specific isoform of the receptor tyrosine kinase FGFR2 upregulated in many tumor cell types, is essential to tumor proliferation, differentiation and survival. Glycoengineering enhances the FPA144-mediated ADCC.	Bemarituzumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120041>	C96040	Tavolimab|Anti-OX40 Monoclonal Antibody MEDI0562|MEDI-0562|MEDI0562|TAVOLIMAB|Tavolixizumab	An agonistic, humanized monoclonal antibody against receptor OX40 (CD134), with potential immunostimulatory activity. Upon administration, tavolimab selectively binds to and activates the OX40 receptor. OX40 receptor activation induces proliferation of memory and effector T-lymphocytes. In the presence of tumor-associated antigens (TAAs), this agent may promote an immune response against TAAs-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor family, is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T-cells.	Tavolimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120042>	C210746	Eicosapentaenoic Acid-enriched Nutritional Supplement|EPA-enriched Nutritional Supplement	A nutritional supplement enriched with eicosapentaenoic acid (EPA), which is an essential, polyunsaturated, 20-carbon omega-3 fatty acid found in fish oil, with potential anti-inflammatory and anti-cachectic activities. Upon oral intake of the EPA-enriched nutritional supplement, EPA is incorporated in cell membrane phospholipids and replaces arachidonic acid. This affects the production of pro-inflammatory mediators, such as tumor necrosis factor-alpha (TNF-a), interleukin-1 (IL-1) and IL-6, through the inhibition of nuclear factor kappa B (NF-kB) activity. This inhibits inflammation and may abrogate the cachexia-mediated decrease of lean body mass (LBM), which may lead to increased body weight. Pro-inflammatory mediators, such as TNF-a, interferon-gamma, and certain interleukins, such as IL-6 and IL-1b, play a key role in cachexia.			Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120043>	C308|C226455	Brilacidin Oral Rinse|PMX30063 Oral Rinse	An oral rinse containing brilacidin, a defensin mimetic, with potential antimicrobial and anti-mucositic activities. Upon rinsing with the brilacidin oral rinse, brilacidin imitates defensin as a human host defense protein (HDP), and binds to and disrupts the bacterial cell membrane. This causes bacterial cell membrane lysis and leakage of cellular cytoplasmic contents. This inhibits bacterial activity and may prevent or treat radiation-induced mucositis. Defensins, a family of antimicrobial and cytotoxic peptides expressed mainly by epithelial cells and neutrophils, play a key role in the natural human innate immunity against pathogens.	Brilacidin Oral Rinse		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C120044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120044>	C22152	Mouse Colon Adenocarcinoma|Adenocarcinoma of Mouse Colon|Mouse Model of Colon Adenocarcinoma	An adenocarcinoma arising from the colon of a mouse. It can be used as a mouse model of the human disease.			Neoplastic Process	Cellosaurus Disease Terminology
C120045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120045>	C134526	Canine Osteosarcoma|Dog Osteosarcoma	An osteosarcoma of mesenchymal origin in a dog. It is the most common bone cancer in dogs, most often developing in the limbs of large or giant breed dogs. The morphologic and biologic behavior of canine osteosarcomas is similar to that of human osteosarcomas.			Neoplastic Process	Cellosaurus Disease Terminology
C120046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120046>	C53543|C101216	Congenital Fiber-Type Disproportion|Congenital Fiber-Type Disproportion Myopathy	A rare genetic disorder caused by mutations in the TPM3, ACTA1, RYR1 and SEPN1 genes. It is inherited in an autosomal dominant or recessive pattern and rarely in an X-linked pattern. It manifests with myopathy throughout the body, particularly in the muscles of the shoulders, upper arms, hips, and thighs. Affected individuals may have contractures, lordosis, or scoliosis.  In a minority of cases mild to severe breathing problems may occur.			Disease or Syndrome	Cellosaurus Disease Terminology
C120047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120047>	C23012	Masson Trichrome Staining Method|Masson Trichrome|Masson Trichrome Stain|Masson's Trichrome|Masson's Trichrome Stain|Masson's Trichrome Staining Method	A method that sequentially exposes tissues samples to three acid dyes and acid washes, which can differentiate between collagen and smooth muscle in those samples. The classic recipe for this histological staining method uses Weigert's Iron hematoxylin, which stains nuclei brown or black, Biebrich Scarlet, which dyes the cytoplasm, muscle and keratin pink or red, and aniline blue, which stains collagen and bone blue or green.			Laboratory Procedure	
C120048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120048>	C25941	PIN1 Gene|PIN1|PIN1|Peptidylprolyl Cis/Trans Isomerase, NIMA-Interacting 1 Gene	This gene plays a role in the regulation of the post-phosphorylation conformation of protein substrates.	PIN1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C120049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120049>	C120048	PIN1 wt Allele|DOD|DODO, Drosophila, Homolog of Gene|Peptidyl-Prolyl Cis/Trans Isomerase, NIMA-Interacting, 1 Gene|Peptidylprolyl Cis/Trans Isomerase, NIMA-Interacting 1 wt Allele|Protein (Peptidyl-Prolyl Cis/Trans Isomerase) NIMA-Interacting 1 Gene|UBL5	Human PIN1 wild-type allele is located in the vicinity of 19p13 and is approximately 14 kb in length. This allele, which encodes peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 protein, is involved in protein conformation.	PIN1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12004>	C61063	Cisplatin/Epoetin Alfa			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120050>	C16759	Peptidyl-Prolyl Cis-Trans Isomerase NIMA-Interacting 1|EC 5.2.1.8|PIN1|PPIase Pin1|Peptidyl-Prolyl Cis-Trans Isomerase Pin1|Rotamase Pin1	Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (163 aa, ~18 kDa) is encoded by the human PIN1 gene. This protein plays a role in the modulation of phosphoprotein conformation.	Peptidyl-Prolyl Cis-Trans Isomerase NIMA-Interacting 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120051>	C25804	CHIT1 Gene|CHIT1|CHIT1|Chitinase 1 (Chitotriosidase) Gene	This gene is involved in the catabolism of chitins.	CHIT1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C120052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120052>	C120051	CHIT1 wt Allele|CHI3|CHIT|CHITD|Chitinase 1 (Chitotriosidase) wt Allele|Chitinase, Macrophage Gene	Human CHIT1 wild-type allele is located in the vicinity of 1q32.1 and is approximately 61 kb in length. This allele, which encodes chitotriosidase-1 protein, plays a role in the metabolism of chitins. This gene is associated with Gaucher disease.	CHIT1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120053>	C16701	Chitotriosidase-1|CHIT1|Chitinase-1|Chitotriosidase|EC 3.2.1.14|Methylumbelliferyl-Tetra-N-Acetylchitotetraoside Hydrolase|Plasma Methylumbelliferyl Tetra-N-Acetylchitotetraoside Hydrolase	Chitotriosidase-1 (466 aa, ~52 kDa) is encoded by the human CHIT1 gene. This protein is involved in the degradation of chitins.	Chitotriosidase-1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120054>	C28404	USP17L2 Gene|USP17L2|USP17L2|Ubiquitin Specific Peptidase 17-Like Family Member 2 Gene	This gene plays a role in the deubiquitination of protein substrates.	USP17L2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C120055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120055>	C120054	USP17L2 wt Allele|DUB-3|DUB3|USP17|USP17H|USP17I|USP17J|USP17K|USP17L|USP17M|Ubiquitin Specific Peptidase 17-Like Family Member 2 wt Allele	Human USP17L2 wild-type allele is located in the vicinity of 8p23.1 and is approximately 2 kb in length. This allele, which encodes ubiquitin carboxyl-terminal hydrolase 17 protein, is involved in the modulation of protein ubiquitination.	USP17L2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120056>	C16481	Ubiquitin Carboxyl-Terminal Hydrolase 17|DUB-3|Deubiquitinating Enzyme 17-Like Protein 2|Deubiquitinating Enzyme 3|Deubiquitinating Protein 3|EC 3.4.19.12|USP17|Ubiquitin Carboxyl-Terminal Hydrolase 17-Like Protein 2|Ubiquitin Specific Peptidase 17-Like 2|Ubiquitin Thioesterase 17-Like Protein 2|Ubiquitin Thiolesterase 17-Like Protein 2|Ubiquitin-Specific Peptidase 17-Like Family Member 2|Ubiquitin-Specific-Processing Protease 17-Like Protein 2	Ubiquitin carboxyl-terminal hydrolase 17 (530 aa, ~60 kDa) is encoded by the human USP17L2 gene. This protein plays a role in the mediation of protein deubiquitination.	Ubiquitin Carboxyl-Terminal Hydrolase 17		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120057>	C25939	KDM2B Gene|KDM2B|KDM2B|Lysine Specific Demethylase 2B Gene	This gene is involved in demethylation of histone H3.	KDM2B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C120058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120058>	C120057	KDM2B wt Allele|CXXC2|F-Box and Leucine-Rich Repeat Protein 10 Gene|FBXL10|Fbl10|JEMMA (Jumonji Domain, EMSY-Interactor, Methyltransferase Motif) Protein Gene|JHDM1B|Lysine (K)-Specific Demethylase 2B wt Allele|Lysine Specific Demethylase 2B wt Allele|PCCX2	Human KDM2B wild-type allele is located in the vicinity of 12q24.31 and is approximately 152 kb in length. This allele, which encodes lysine-specific demethylase 2B protein, plays a role in histone demethylation.	KDM2B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120059>	C16946	Lysine-Specific Demethylase 2B|CXXC Finger Protein 2|CXXC-Type Zinc Finger Protein 2|EC 1.14.11.27|F-Box Protein FBL10|F-Box and Leucine-Rich Repeat Protein 10|F-Box/LRR-Repeat Protein 10|JmjC Domain-Containing Histone Demethylation Protein 1B|Jumonji C Domain-Containing Histone Demethylase 1B|Jumonji Domain-Containing EMSY-Interactor Methyltransferase Motif Protein|KDM2B|Protein JEMMA|Protein-Containing CXXC Domain 2|[Histone-H3]-Lysine-36 Demethylase 1B	Lysine-specific demethylase 2B (1336 aa, ~153 kDa) is encoded by the human KDM2B gene. This protein is involved in the demethylation of lysine-4 and lysine-36 in histone H3.	Lysine-Specific Demethylase 2B		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12005>	C61007	Doxorubicin/Etoposide/Ifosfamide/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120060>	C20744	SYNE2 Gene|SYNE2|SYNE2|Spectrin Repeat Containing, Nuclear Envelope 2 Gene	This gene plays a role in organelle localization.	SYNE2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C120061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120061>	C120060	SYNE2 wt Allele|DKFZP434H2235|EDMD5|KIAA1011|NUA|NUANCE|Nesp2|Nesprin-2|SYNE-2|Spectrin Repeat Containing, Nuclear Envelope 2 wt Allele|Synaptic Nuclei Expressed Gene 2|TROPH	Human SYNE2 wild-type allele is located in the vicinity of 14q23.2 and is approximately 373 kb in length. This allele, which encodes nesprin-2 protein, is involved in the structure, organization, and localization of the nucleus. Variation of the gene is associated with Emery-Dreifuss muscular dystrophy type 5.	SYNE2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120062>	C18073	Nesprin-2|Nesprin 2|Nuclear Envelope Spectrin Repeat Protein 2|Nuclear Envelope Spectrin Repeat-2|Nucleus and Actin Connecting Element|Nucleus and Actin Connecting Element Protein|Polytrophin|Protein NUANCE|SYNE2|Spectrin Repeat-Containing Nuclear Envelope Protein 2|Synaptic Nuclear Envelope Protein 2|Syne-2	Nesprin-2 (6885 aa, ~796 kDa) is encoded by the human SYNE2 gene. This protein plays a role in anchoring organelles to the cytoskeleton.	Nesprin-2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120063>	C150623	FLT3 Activation Loop Mutation|FLT3 A-Loop Mutation|FLT3 Tyrosine Kinase Domain Mutation|FLT3 Tyrosine Kinase Domain Mutation|FLT3- TKD mutations|FLT3-ALM|FLT3-TKD Mutation|FLT3/TKD Mutation	A mutation in the region of the FLT3 gene that encodes the second tyrosine kinase domain of the receptor-type tyrosine-protein kinase FLT3 that causes the stabilization of the activation loop of the kinase domain. FLT3 activation loop mutations lead to constitutive tyrosine kinase activity and are associated with acute myeloid leukemia.	FLT3 Tyrosine Kinase Domain Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120064>	C27990	Marrow Toxic Injury|Toxic Marrow Injury	An injury to the bone marrow resulting from exposure to high levels of ionizing radiation or exposure to other hazardous material.			Finding	
C120065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120065>	C26003	PSMA5 Gene|PSMA5|PSMA5|Proteasome (Prosome, Macropain) Subunit, Alpha Type, 5 Gene	This gene is involved in ATP-dependent protein catabolism.	PSMA5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C120066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120066>	C120065	PSMA5 wt Allele|PSC5|Proteasome (Prosome, Macropain) Subunit, Alpha Type, 5 wt Allele|Proteasome Subunit, Alpha-Type, 5 Gene|ZETA	Human PSMA5 wild-type allele is located in the vicinity of 1p13 and is approximately 27 kb in length. This allele, which encodes proteasome subunit alpha type-5 protein, plays a role in protein metabolism.	PSMA5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120067>	C16965	Proteasome Subunit Alpha Type-5|EC 3.4.25.1|Macropain Subunit Zeta|Macropain Zeta Chain|Multicatalytic Endopeptidase Complex Zeta Chain|PSMA5|Proteasome Alpha 5 Subunit|Proteasome Component 5|Proteasome Subunit Zeta|Proteasome Zeta Chain	Proteasome subunit alpha type-5 (241 aa, ~26 kDa) is encoded by the human PSMA5 gene. This protein is involved in ATP-dependent protein catabolism.	Proteasome Subunit Alpha Type-5		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120068>	C129823	Anti-CEACAM6 AFAIKL2 Antibody Fragment/Jack Bean Urease Immunoconjugate L-DOS47|L-DOS47|L-DOS47	A lyophilized formulation of DOS47, an immunoconjugate composed of AFAIKL2, a recombinant camelid single-domain antibody which recognizes carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), and the enzyme urease derived from the plant Canavalia ensiformis (Jack bean), with potential antineoplastic activity. Upon intravenous administration, the AFAIKL2 antibody fragment moiety of L-DOS47 specifically targets and binds to CEACAM6 expressed on certain tumor cells. In turn, the urease moiety of L-DOS47 catalyzes the hydrolysis of urea into ammonia, which is further hydrolyzed to produce hydroxyl ions, and causes a locally increased concentration of the toxic waste product ammonia, which under normal conditions is converted into the nontoxic substance urea via the urea cycle. This increases the pH of the tumor microenvironment and alkalinizes the highly acidic environment that is needed for cancer cell survival and proliferation. In addition, the ammonia diffuses into cancer cells and exerts a cytotoxic effect. Altogether, this leads to cell death of CEACAM6-expressing cancer cells. The naturally-occurring enzyme urease catalyzes the hydrolysis of urea into ammonia and carbon dioxide. CEACAM6, a tumor-associated antigen and CEA family member, is overexpressed in a variety of tumor cells and plays a key role in tumor initiation, progression, metastasis and survival.	Anti-CEACAM6 AFAIKL2 Antibody Fragment/Jack Bean Urease Immunoconjugate L-DOS47		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120069>	C119758	Encephalopathy of Prematurity	A condition affecting premature infants characterized by white matter injury, which is frequently accompanied by neuronal/axonal disease, that may affect all brain parenchymal structures and is due to a combination of destructive processes as well as maturational and trophic disturbances.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C12006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12006>	C61007	Cetuximab/Fluorouracil/Irinotecan/Leucovorin Calcium			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120070>	C2124	Fluorine F 18-labeled 2-FACPC|1-Amino-2-[18F]fluorocyclopentane-1-carboxylic Acid|2-[(18)F]FACPC|2-[18F]FACPC|Anti-1-amino-2-[18F]fluorocyclopentyl-1-carboxylic Acid|Anti-2-[(18)F]FACPC	A radioconjugate composed of an analog of the synthetic, alicyclic amino acid aminocyclopentane carboxylic acid (ACPC) radiolabeled with the positron-emitting isotope fluorine F 18 (2-[18F]FACPC), with potential cancer cell imaging activity during positron emission tomography (PET). As tumor cells have a higher rate of protein synthesis than normal, healthy cells, upon administration, fluorine F 18 labeled 2-FACPC is selectively taken up by rapidly proliferating tumor cells through the sodium-independent subtype L amino acid transport system (AAT) which leads to the accumulation of this tracer in tumor cells. Upon PET, tumor cells can then be visualized.	Fluorine F 18-labeled 2-FACPC		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology
C120071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120071>	C85429	Severity of Symptom Likert Scale|MDASI Severity of Symptom Likert Scale|Severity of Symptom Scale	A scale for the subjective scoring of symptoms that ranges from 0: Not Present to 10: As Bad as You Can Imagine.			Intellectual Product	MD Anderson Symptom Inventory - Core
C120072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120072>	C175278	Severity of Symptom Score 0|0|MDASI Severity of Symptom Score 0|Not Present|Not at all|Score 0	A subjective score of 0 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.			Intellectual Product	Acute Oxaliplatin-Induced Peripheral Neuropathy Measure|MD Anderson Symptom Inventory - Core|Severity of Symptom Likert Scale
C120073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120073>	C175278	Severity of Symptom Score 1|1|MDASI Severity of Symptom Score 1|Score 1	A subjective score of 1 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.			Intellectual Product	Acute Oxaliplatin-Induced Peripheral Neuropathy Measure|MD Anderson Symptom Inventory - Core|Severity of Symptom Likert Scale
C120074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120074>	C175278	Severity of Symptom Score 2|2|MDASI Severity of Symptom Score 2|Score 2	A subjective score of 2 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.			Intellectual Product	Acute Oxaliplatin-Induced Peripheral Neuropathy Measure|MD Anderson Symptom Inventory - Core|Severity of Symptom Likert Scale
C120075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120075>	C175278	Severity of Symptom Score 3|3|MDASI Severity of Symptom Score 3|Score 3	A subjective score of 3 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.			Intellectual Product	Acute Oxaliplatin-Induced Peripheral Neuropathy Measure|MD Anderson Symptom Inventory - Core|Severity of Symptom Likert Scale
C120076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120076>	C175278	Severity of Symptom Score 4|4|MDASI Severity of Symptom Score 4|Score 4	A subjective score of 4 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.			Intellectual Product	Acute Oxaliplatin-Induced Peripheral Neuropathy Measure|MD Anderson Symptom Inventory - Core|Severity of Symptom Likert Scale
C120077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120077>	C175278	Severity of Symptom Score 5|5|MDASI Severity of Symptom Score 5|Score 5	A subjective score of 5 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.			Intellectual Product	Acute Oxaliplatin-Induced Peripheral Neuropathy Measure|MD Anderson Symptom Inventory - Core|Severity of Symptom Likert Scale
C120078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120078>	C175278	Severity of Symptom Score 6|6|MDASI Severity of Symptom Score 6|Score 6	A subjective score of 6 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.			Intellectual Product	Acute Oxaliplatin-Induced Peripheral Neuropathy Measure|MD Anderson Symptom Inventory - Core|Severity of Symptom Likert Scale
C120079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120079>	C175278	Severity of Symptom Score 7|7|MDASI Severity of Symptom Score 7|Score 7	A subjective score of 7 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.			Intellectual Product	Acute Oxaliplatin-Induced Peripheral Neuropathy Measure|MD Anderson Symptom Inventory - Core|Severity of Symptom Likert Scale
C12007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12007>	C61063	Monoclonal antibody Ch14.18/Sargramostim			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120080>	C175278	Severity of Symptom Score 8|8|MDASI Severity of Symptom Score 8|Score 8	A subjective score of 8 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.			Intellectual Product	Acute Oxaliplatin-Induced Peripheral Neuropathy Measure|MD Anderson Symptom Inventory - Core|Severity of Symptom Likert Scale
C120081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120081>	C175278	Severity of Symptom Score 9|9|MDASI Severity of Symptom Score 9|Score 9	A subjective score of 9 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.			Intellectual Product	Acute Oxaliplatin-Induced Peripheral Neuropathy Measure|MD Anderson Symptom Inventory - Core|Severity of Symptom Likert Scale
C120082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120082>	C175278	Severity of Symptom Score 10|10|10|As Bad as You Can Imagine|As bad as it can be|MDASI Severity of Symptom Score 10|Score 10	A subjective score of 10 on a scale that ranges from 0: Not Present to 10: As Bad as You Can Imagine.			Intellectual Product	Acute Oxaliplatin-Induced Peripheral Neuropathy Measure|MD Anderson Symptom Inventory - Core|Severity of Symptom Likert Scale
C120083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120083>	C165470	Hereditary Nonpolyposis Colorectal Cancer Syndrome|Familial Nonpolyposis Colorectal Cancer Syndrome|HNPCC|HNPCC|Hereditary Non-polyposis Colon Cancer|Hereditary Nonpolyposis Colorectal Cancer|Hereditary Nonpolyposis Colorectal Cancer (HNPCC)|hereditary nonpolyposis colon cancer	An inherited syndrome characterized by the development of several cancers, particularly colon and rectal cancers.  It includes Lynch syndrome which is associated with germline mutations in DNA mismatch-repair genes and familial colorectal cancer type X which is characterized by the absence of germline mutations in DNA mismatch-repair genes.	Hereditary Nonpolyposis Colorectal Cancer		Disease or Syndrome	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C120084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120084>	C120083	Hereditary Colorectal Cancer Type X|FCCTX|Familial Colorectal Cancer Type X	Hereditary nonpolyposis colorectal cancer syndrome characterized by the absence of germline mutations in DNA mismatch-repair genes.			Disease or Syndrome	
C120085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120085>	C85429	Symptom Interference with Life Likert Scale|MDASI Symptom Interference with Life Likert Scale|Symptom Interference with Life Scale	A scale for the subjective scoring of a symptom's interference with life that ranges from 0: Did Not Interfere to 10: Interfered Completely.			Intellectual Product	MD Anderson Symptom Inventory - Core
C120086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120086>	C175283	Symptom Interference with Life Score 0|MDASI Symptom Interference with Life Score 0	A subjective score of 0 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.			Intellectual Product	MD Anderson Symptom Inventory - Core|Symptom Interference with Life Likert Scale
C120087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120087>	C175283	Symptom Interference with Life Score 1|MDASI Symptom Interference with Life Score 1	A subjective score of 1 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.			Intellectual Product	MD Anderson Symptom Inventory - Core|Symptom Interference with Life Likert Scale
C120088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120088>	C175283	Symptom Interference with Life Score 2|MDASI Symptom Interference with Life Score 2	A subjective score of 2 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.			Intellectual Product	MD Anderson Symptom Inventory - Core|Symptom Interference with Life Likert Scale
C120089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120089>	C175283	Symptom Interference with Life Score 3|MDASI Symptom Interference with Life Score 3	A subjective score of 3 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.			Intellectual Product	MD Anderson Symptom Inventory - Core|Symptom Interference with Life Likert Scale
C12008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12008>	C61007	Interleukin-2/Monoclonal Antibody Ch14.18			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120090>	C175283	Symptom Interference with Life Score 4|MDASI Symptom Interference with Life Score 4	A subjective score of 4 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.			Intellectual Product	MD Anderson Symptom Inventory - Core|Symptom Interference with Life Likert Scale
C120091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120091>	C175283	Symptom Interference with Life Score 5|MDASI Symptom Interference with Life Score 5	A subjective score of 5 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.			Intellectual Product	MD Anderson Symptom Inventory - Core|Symptom Interference with Life Likert Scale
C120092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120092>	C175283	Symptom Interference with Life Score 6|MDASI Symptom Interference with Life Score 6	A subjective score of 6 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.			Intellectual Product	MD Anderson Symptom Inventory - Core|Symptom Interference with Life Likert Scale
C120093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120093>	C175283	Symptom Interference with Life Score 7|MDASI Symptom Interference with Life Score 7	A subjective score of 7 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.			Intellectual Product	MD Anderson Symptom Inventory - Core|Symptom Interference with Life Likert Scale
C120094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120094>	C175283	Symptom Interference with Life Score 8|MDASI Symptom Interference with Life Score 8	A subjective score of 8 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.			Intellectual Product	MD Anderson Symptom Inventory - Core|Symptom Interference with Life Likert Scale
C120095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120095>	C175283	Symptom Interference with Life Score 9|MDASI Symptom Interference with Life Score 9	A subjective score of 9 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.			Intellectual Product	MD Anderson Symptom Inventory - Core|Symptom Interference with Life Likert Scale
C120096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120096>	C175283	Symptom Interference with Life Score 10|MDASI Symptom Interference with Life Score 10	A subjective score of 10 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.			Intellectual Product	MD Anderson Symptom Inventory - Core|Symptom Interference with Life Likert Scale
C120097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120097>	C201282|C129822	Cibisatamab|CIBISATAMAB|RG-7802|RG7802|RO6958688|WHO 10636	An anti-carcinoembryonic antigen (CEA)/anti-CD3 bispecific monoclonal antibody with potential antineoplastic activity. Cibisatamab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CEA, a tumor-associated antigen that is specifically expressed on certain tumor cells. Upon intravenous administration, cibisatamab binds to both T-cells and CEA-expressing tumor cells, which cross-links the T-cells with the tumor cells. This may result in a potent cytotoxic T-lymphocyte (CTL) response against CEA-expressing tumor cells. CEA is overexpressed in many cancer cell types.	Cibisatamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120098>	C198953	Yq|Chromosome Y Distal Arm|Chromosome Y Long Arm	The distal (long) arm of chromosome Y.			Gene or Genome	
C120099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120099>	C2019|C1557	Tegafur-Gimeracil-Oteracil Potassium-Leucovorin Calcium Oral Formulation|TAS-118	An orally bioavailable granular formulation composed of the fluoropyrimidine antagonist tegafur combined with two modulators of 5-fluorouracil (5-FU) activity, gimeracil and oteracil potassium, and the folic acid derivative leucovorin calcium, with potential antineoplastic activity. Tegafur is a prodrug of 5-fluorouracil (5-FU), an antimetabolite that is further metabolized to 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP inhibits thymidylate synthase, DNA synthesis and cell division; FUTP competes with uridine triphosphate (UTP), thus inhibiting RNA and protein synthesis. Gimeracil is a reversible inhibitor of dihydropyrimidine dehydrogenase (DPD), the liver enzyme responsible for rapid catabolism of 5-FU into inactive metabolites. Oteracil potassium preferentially localizes in the gut and inhibits the enzyme orotate phosphoribosyl-transferase (OPRT), which converts tegafur to 5-FU. This decreases the amount of 5-FU in the gut and prevents activated 5-FU-related gastrointestinal (GI) toxicity. Leucovorin calcium, an active metabolite of folic acid, counteracts the toxic effects of 5-FU, thereby 'rescuing' the patient while permitting the antitumor activity of 5-FU.			Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12009>	C61063	Carboplatin/Epirubicin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1200>	C177280	Pegaspargase|(Monomethoxypolyethylene Glycol Succinimidyl)74-L-Asparaginase|L-Asparaginase with Polyethylene Glycol|Oncaspar|Oncaspar|Oncaspar-IV|Oncaspar-IV|PEG-Asparaginase|PEG-L-Asparaginase|PEG-L-Asparaginase (Enzon - Kyowa Hakko)|PEG-asparaginase|PEGASPARGASE|PEGLA|Polyethylene Glycol L-Asparaginase|Polyethylene Glycol-L-Asparaginase|pegaspargase	A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)	Pegaspargase		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120100>	C2124	Fluorine F 18 Ara-G|(18F)F-Arag|18F-F-Ara-G|2'-Deoxy-2'-[18F]Fluoro-9-beta-D-arabinofuranosylguanine|2-Amino-9-((2R,3S,4R,5R)-3-fluoranyl-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-purin-6-one|F-ARAG F-18|F-ARAG F-18|VisAcT|[18F]-AraG|[18F]F-AraG|[18F]F-ara-G	A radioconjugate composed of the guanosine analog arabinosyl guanine (Ara-G), a high-affinity substrate for both cytoplasmic deoxycytidine kinase (DCK) and mitochondrial deoxyguanosine kinase (dGK), labeled with fluorine F 18, that can potentially be used as a tracer for imaging of activated T-lymphocytes during positron emission tomography (PET). Upon administration, fluorine F 18 ara-G is taken up by and accumulates in activated T-lymphocytes with high levels of DCK and dGK. After phosphorylation by DCK and dGK, the 18F moiety can be visualized by PET imaging. Fluorine F 18 ara-G can potentially be used as an imaging agent to detect anti-tumor immune responses and to predict the therapeutic efficacy of immunotherapies. DCK and dGK, both nucleoside salvage pathway enzymes, are overexpressed in activated T-cells.	Fluorine F 18 Ara-G		Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology
C120101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120101>	C25974|C212990	Src/tubulin Inhibitor KX2-361|KX02|KX2-361|KX2-361|Src/tubulin Inhibitor KX02	A lipophilic, orally available inhibitor of both Src kinase activity and tubulin polymerization, with potential antineoplastic activity. Upon oral administration,Src/tubulin Inhibitor KX2-361 binds to and inhibits the activity of Src kinase. This inhibits both downstream signaling and the proliferation of Src kinase-expressing tumor cells. KX02 also binds to tubulin heterodimers and inhibits microtubule polymerization, thereby disrupting microtubule formation, mitosis, and further proliferation. Src, a non-receptor tyrosine kinase, is overexpressed in a variety of tumor cell types and plays a key role in tumor cell proliferation, angiogenesis, migration, and metastasis.	Src/tubulin Inhibitor KX2-361		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120102>	C155727	Roblitinib|FGF401|FGFR4 Inhibitor FGF401|ROBLITINIB	An inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon administration, roblitinib binds to and inhibits the activity of FGFR4, which leads to an inhibition of tumor cell proliferation in FGFR4-overexpressing cells. FGFR4 is a receptor tyrosine kinase upregulated in certain tumor cells and involved in tumor cell proliferation, differentiation, angiogenesis, and survival.	Roblitinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120103>	C1663	Listeria monocytogenes-LLO-PSA Vaccine ADXS31-142|ADXS-PSA|ADXS31-142|Lm-LLO-PSA	A cancer vaccine containing a live-attenuated strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding a fusion protein composed of the tumor-associated antigen (TAA) human prostate-specific antigen (PSA) fused to a fragment of the immunostimulant listeriolysin O (LLO) protein, with potential immunostimulatory and antineoplastic activities. Upon administration of the Lm-LLO-PSA vaccine ADXS31-142, the expressed LLO-PSA is processed by antigen presenting cells (APCs), presented to the immune system by both major histocompatibility complex (MHC) I and II molecules, and activates the immune system to exert both an innate and adaptive immune response involving the recruitment and activation of T-lymphocytes against PSA-expressing tumor cells as well as the inhibition of tumor-infiltrating T regulatory cells (T regs) and myeloid-derived suppressor cells (MDSCs). This eventually results in tumor cell lysis.	Listeria monocytogenes-LLO-PSA Vaccine ADXS31-142		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120104>	C2124	Gallium Ga 68-RGD|(68)Ga-RGD|RGD (68Ga)	A radiopharmaceutical agent comprised of a cyclic arginine-glycine-aspartic acid (Arg-Gly-Asp/RGD) peptide labeled with gallium Ga 68, with potential alphaVbeta3 integrin (avb3) imaging activity during positron emission topography (PET). After intravenous administration, gallium Ga 68-RGD selectively binds to avb3 on the cell membrane via the cyclic RGD motif. Upon PET imaging, avb3-expressing tumor cells can be visualized and their expression levels can be quantified. avb3, a member of the integrin receptor family, is overexpressed on certain tumor cells and tumor endothelial cells while minimally or not expressed on healthy, normal cells; it plays a key role in angiogenesis, tumor proliferation and survival.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C120105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120105>	C2124	Gallium Ga 68-NOTA-NFB|68Ga-NOTA-NFB	A radioconjugate composed of a derivative of the CXCR4 peptide antagonist T140, in which the N-terminal 4-fluoro-benzoyl group (NFB) is substituted with the chelating agent 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA) and radiolabeled with gallium Ga 68, with potential CXCR4 imaging activity during positron emission topography (PET). Upon administration, gallium Ga 68-NOTA-NFB selectively binds to CXCR4 and CXCR4-expressing tumor cells can then be visualized upon PET imaging. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis, and is upregulated in several tumor cell types. CXCR4 expression is correlated with tumor aggressiveness and high metastatic potential. Unmodified T140 binds non-specifically to red blood cells (RBCs); replacing the fluoro-benzoyl group with NOTA (NOTA-NFB) prevents the RBC binding almost entirely, while only minimally reducing the binding to CXCR4-positive tumor cells.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C120106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120106>	C92809	Insulin Growth Factor I Deficiency|IGF-I Deficiency|IGF-I Deficiency|IGF1 Deficiency|Insulin-like Growth Factor I Deficiency	Insufficient circulating insulin-like growth factor-I.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C120107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120107>	C92809	Insulin Growth Factor I Resistance|IGF-I Resistance|IGF-I Resistance|IGF1R|Somatomedin-C Resistance	Tissue unresponsiveness to insulin-like growth factor-I.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C120108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120108>	C20348	BNIP3 Gene|BCL2/Adenovirus E1B 19kDa Interacting Protein 3 Gene|BNIP3|BNIP3	This gene plays a role in the stimulation of both apoptosis and autophagy.	BNIP3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C120109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120109>	C120108	BNIP3 wt Allele|BCL2/Adenovirus E1B 19kD-Interacting Protein 3 Gene|BCL2/Adenovirus E1B 19kDa Interacting Protein 3 wt Allele|NIP3|Nip3	Human BNIP3 wild-type allele is located in the vicinity of 10q26.3 and is approximately 14 kb in length. This allele, which encodes BCL2/adenovirus E1B 19 kDa protein-interacting protein 3, is involved in the positive regulation of both autophagy and apoptosis.	BNIP3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12010>	C61063	Bevacizumab/Carboplatin/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120110>	C19928	BCL2/Adenovirus E1B 19 kDa Protein-Interacting Protein 3|BCL2/Adenovirus E1B 19-kD Protein-Interacting Protein 3	BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (194 aa, ~22 kDa) is encoded by the human BNIP3 gene. This protein plays a role in the promotion of both apoptosis and autophagy.	BCL2/Adenovirus E1B 19 kDa Protein-Interacting Protein 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120111>	C85429|C20995	BPI Pain Rating Likert Scale|BPI Pain Rating Scale|Brief Pain Inventory Pain Rating Scale	A scale for the subjective scoring of pain that ranges from 0: No Pain to 10: Pain as bad as you can imagine.			Intellectual Product	Brief Pain Inventory Short Form Questionnaire
C120112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120112>	C175255	Pain Rating Score 0|BPI Pain Rating Score 0	A subjective score of 0 on a scale that ranges from 0: No Pain to 10: Pain As Bad As You Can Imagine.			Intellectual Product	BPI Pain Rating Likert Scale|Brief Pain Inventory Short Form Questionnaire
C120113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120113>	C85865|C53543	Short Stature Homeobox Deficiency|SHOX Deficiency|SHOX Deficiency	A rare genetic deficiency characterized by mutations in the SHOX gene and reduced expression or function of the SHOX protein. It results in the disruption of normal bone development and growth starting before birth. It manifests with skeletal abnormalities and short stature.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C120114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120114>	C187275	Acid-Labile Subunit Deficiency|ALS Deficiency	Reduced serum concentration of the acid-labile subunit (ALS, a protein encoded by the IGFALS gene) of the complex usually comprised of IGF-I, IGFBP-3 and ALS.			Laboratory or Test Result	NICHD Terminology|Pediatric Endocrinology Terminology
C120115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120115>	C112835	Organic Growth Hormone Deficiency	Growth hormone deficiency due to an identifiable biological cause.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C120116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120116>	C175255	Pain Rating Score 1|BPI Pain Rating Score 1	A subjective score of 1 on a scale that ranges from 0: No Pain to 10: Pain As Bad As You Can Imagine.			Intellectual Product	BPI Pain Rating Likert Scale|Brief Pain Inventory Short Form Questionnaire
C120117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120117>	C175255	Pain Rating Score 2|BPI Pain Rating Score 2	A subjective score of 2 on a scale that ranges from 0: No Pain to 10: Pain As Bad As You Can Imagine.			Intellectual Product	BPI Pain Rating Likert Scale|Brief Pain Inventory Short Form Questionnaire
C120118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120118>	C39619|C1663	Synthetic hTERT DNA Vaccine INO-1400|INO-1400	A DNA vaccine consisting of a plasmid encoding the full-length sequence of the tumor-associated antigen (TAA) human telomerase reverse transcriptase (hTERT), which is the catalytic subunit of human telomerase and synthesizes telomeric DNA at the chromosome ends, containing two immunogenic mutations, with potential immunostimulating and antineoplastic activities. Upon intradermal vaccination of the hTERT encoding DNA vaccine INO-1400 in combination with electroporation, hTERT protein is expressed and activates the immune system to mount a cytotoxic T-cell (CTL) response against telomerase-expressing tumor cells, which may result in tumor cell death. Telomerase prolongs the functional lifespan of cells via the restoration and maintenance of telomere length. Abnormally activated in tumorigenesis, telomerase is expressed in the majority of human cancer cells, but its expression is low or non-existent in normal cells.	Synthetic hTERT DNA Vaccine INO-1400		Immunologic Factor|Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120119>	C175255	Pain Rating Score 3|BPI Pain Rating Score 3	A subjective score of 3 on a scale that ranges from 0: No Pain to 10: Pain As Bad As You Can Imagine.			Intellectual Product	BPI Pain Rating Likert Scale|Brief Pain Inventory Short Form Questionnaire
C12011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12011>	C61063	Dexamethasone/Isotretinoin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120120>	C175255	Pain Rating Score 4|BPI Pain Rating Score 4	A subjective score of 4 on a scale that ranges from 0: No Pain to 10: Pain As Bad As You Can Imagine.			Intellectual Product	BPI Pain Rating Likert Scale|Brief Pain Inventory Short Form Questionnaire
C120121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120121>	C210691	Branched-chain Amino Acid Supplement|BCAA Supplement	A nutritional supplement containing essential branched-chain amino acids (BCAAs), including leucine, isoleucine and valine, with potential anti-cachectic, antiangiogenic, hepatocellular carcinoma (HCC) inhibiting and hepatoprotective activities. Upon oral administration, BCAAs inhibit the expression of both hypoxia-inducible factor 1-alpha subunit (HIF-1a) and vascular endothelial growth factor (VEGF), which prevents VEGF-mediated angiogenesis in HCC cells. In addition, BCAAs inhibit proliferation and induce apoptosis of HCC cells by both suppressing the expression of insulin-like growth factor (IGF), and inhibiting the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway. BCAAs also correct the plasma amino acid imbalance and promote protein metabolism, including the synthesis of albumin and glycogen. They reduce oxidative stress by inducing the activation of genes involved in antioxidant defenses, which prevent the production of reactive oxygen species (ROS). BCAAs also strengthen the immune system by increasing hepatic lymphocytes and stimulating natural killer (NK) cell activity. This supplement is able to improve insulin resistance and promote ammonia detoxification through increased glutamine (Gln) production.			Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120122>	C175255	Pain Rating Score 5|BPI Pain Rating Score 5	A subjective score of 5 on a scale that ranges from 0: No Pain to 10: Pain As Bad As You Can Imagine.			Intellectual Product	BPI Pain Rating Likert Scale|Brief Pain Inventory Short Form Questionnaire
C120123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120123>	C175255	Pain Rating Score 6|BPI Pain Rating Score 6	A subjective score of 6 on a scale that ranges from 0: No Pain to 10: Pain As Bad As You Can Imagine.			Intellectual Product	BPI Pain Rating Likert Scale|Brief Pain Inventory Short Form Questionnaire
C120124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120124>	C175255	Pain Rating Score 7|BPI Pain Rating Score 7	A subjective score of 7 on a scale that ranges from 0: No Pain to 10: Pain As Bad As You Can Imagine.			Intellectual Product	BPI Pain Rating Likert Scale|Brief Pain Inventory Short Form Questionnaire
C120125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120125>	C175255	Pain Rating Score 8|BPI Pain Rating Score 8	A subjective score of 8 on a scale that ranges from 0: No Pain to 10: Pain As Bad As You Can Imagine.			Intellectual Product	BPI Pain Rating Likert Scale|Brief Pain Inventory Short Form Questionnaire
C120126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120126>	C175255	Pain Rating Score 9|BPI Pain Rating Score 9	A subjective score of 9 on a scale that ranges from 0: No Pain to 10: Pain As Bad As You Can Imagine.			Intellectual Product	BPI Pain Rating Likert Scale|Brief Pain Inventory Short Form Questionnaire
C120127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120127>	C175255	Pain Rating Score 10|BPI Pain Rating Score 10	A subjective score of 10 on a scale that ranges from 0: No Pain to 10: Pain As Bad As You Can Imagine.			Intellectual Product	BPI Pain Rating Likert Scale|Brief Pain Inventory Short Form Questionnaire
C120128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120128>	C78275	Compound Sodium Lactate Solution|CSL Solution|Hartmann's Solution|Sodium Chloride, Potassium Chloride, Calcium Chloride Dihydrate, Sodium Lactate 60% Solution	A multiple electrolyte, isotonic, crystalloid solution for intravenous infusion containing sodium chloride, potassium chloride, calcium chloride dihydrate, and sodium lactate, which can restore the electrolyte balance, normalize pH, and provide water for hydration. Upon intravenous administration, the compound sodium lactate solution will replace any lost body fluids and electrolytes thereby providing hydration as well as normalizing electrolyte concentrations. In addition, conversion of sodium lactate to bicarbonate increases plasma bicarbonate levels, which facilitates the removal of hydrogen ions from the blood stream, raises blood pH and normalizes the acid-base balance.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C120129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120129>	C28310	NY-ESO-1/MART-1 Peptide-pulsed Dendritic Cell Vaccine|NY-ESO-1/MART-1 Peptide-pulsed DC Vaccine	A cell-based cancer vaccine composed of dendritic cells (DC) pulsed with peptides derived from the tumor-associated antigens human cancer/testis antigen NY-ESO-1 and melanoma antigen recognized by T-cells (MART-1/Melan-A), with potential immunostimulatory and antineoplastic activities. Upon administration, the NY-ESO-1/MART-1-peptide pulsed DC vaccine may stimulate the immune system to mount an anti-tumor cytotoxic T-lymphocyte (CTL) response against NY-ESO-1/MART-1-expressing tumor cells, which may result in tumor cell lysis. NY-ESO-1 is expressed both in normal testes and on the surfaces of various tumor cells. MART-1 is expressed by melanoma cells.			Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12012>	C61063	Docetaxel/Exisulind			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120130>	C85429|C20995	BPI Percentage Relief From Pain Treatment or Medication Likert Scale|BPI Percentage Relief From Pain Treatment or Medication Scale|Brief Pain Inventory Percentage Relief From Pain Treatment or Medication Scale	A scale for the subjective scoring of the percentage of relief from pain medication or treatment that ranges from 0%: No Relief to 10: Complete Relief.			Intellectual Product	Brief Pain Inventory Short Form Questionnaire
C120131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120131>	C175276	Percentage Relief From Pain Treatment or Medication Score 0|BPI Percentage Relief From Pain Treatment or Medication Score 0	A subjective score of 0% on a scale that ranges from 0%: No Relief to 100%: Complete Relief.			Intellectual Product	BPI Percentage Relief From Pain Treatment or Medication Likert Scale|Brief Pain Inventory Short Form Questionnaire
C120132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120132>	C175276	Percentage Relief From Pain Treatment or Medication Score 10|BPI Percentage Relief From Pain Treatment or Medication Score 10	A subjective score of 10% on a scale that ranges from 0%: No Relief to 100%: Complete Relief.			Intellectual Product	BPI Percentage Relief From Pain Treatment or Medication Likert Scale|Brief Pain Inventory Short Form Questionnaire
C120133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120133>	C175276	Percentage Relief From Pain Treatment or Medication Score 20|BPI Percentage Relief From Pain Treatment or Medication Score 20	A subjective score of 20% on a scale that ranges from 0%: No Relief to 100%: Complete Relief.			Intellectual Product	BPI Percentage Relief From Pain Treatment or Medication Likert Scale|Brief Pain Inventory Short Form Questionnaire
C120134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120134>	C175276	Percentage Relief From Pain Treatment or Medication Score 30|BPI Percentage Relief From Pain Treatment or Medication Score 30	A subjective score of 30% on a scale that ranges from 0%: No Relief to 100%: Complete Relief.			Intellectual Product	BPI Percentage Relief From Pain Treatment or Medication Likert Scale|Brief Pain Inventory Short Form Questionnaire
C120135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120135>	C175276	Percentage Relief From Pain Treatment or Medication Score 40|BPI Percentage Relief From Pain Treatment or Medication Score 40	A subjective score of 40% on a scale that ranges from 0%: No Relief to 100%: Complete Relief.			Intellectual Product	BPI Percentage Relief From Pain Treatment or Medication Likert Scale|Brief Pain Inventory Short Form Questionnaire
C120136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120136>	C175276	Percentage Relief From Pain Treatment or Medication Score 50|BPI Percentage Relief From Pain Treatment or Medication Score 50	A subjective score of 50% on a scale that ranges from 0%: No Relief to 100%: Complete Relief.			Intellectual Product	BPI Percentage Relief From Pain Treatment or Medication Likert Scale|Brief Pain Inventory Short Form Questionnaire
C120137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120137>	C175276	Percentage Relief From Pain Treatment or Medication Score 60|BPI Percentage Relief From Pain Treatment or Medication Score 60	A subjective score of 60% on a scale that ranges from 0%: No Relief to 100%: Complete Relief.			Intellectual Product	BPI Percentage Relief From Pain Treatment or Medication Likert Scale|Brief Pain Inventory Short Form Questionnaire
C120138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120138>	C175276	Percentage Relief From Pain Treatment or Medication Score 70|BPI Percentage Relief From Pain Treatment or Medication Score 70	A subjective score of 70% on a scale that ranges from 0%: No Relief to 100%: Complete Relief.			Intellectual Product	BPI Percentage Relief From Pain Treatment or Medication Likert Scale|Brief Pain Inventory Short Form Questionnaire
C120139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120139>	C175276	Percentage Relief From Pain Treatment or Medication Score 80|BPI Percentage Relief From Pain Treatment or Medication Score 80	A subjective score of 80% on a scale that ranges from 0%: No Relief to 100%: Complete Relief.			Intellectual Product	BPI Percentage Relief From Pain Treatment or Medication Likert Scale|Brief Pain Inventory Short Form Questionnaire
C12013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12013>	C61063	Epirubicin/Irinotecan			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120140>	C308	Letolizumab|BMS-986004|BMS986004|Fc-Fusion Protein BMS986004|LETOLIZUMAB	A dimeric fusion protein composed of the C-terminus of the domain antibody (dAb) BMS2h-572-633 targeting the CD40 ligand (CD40L or CD154) linked to a modified Fc fragment of immunoglobulin G1 (IgG1), with potential immunomodulatory activity. Upon intravenous administration, the peptide moiety of letolizumab specifically targets and binds to CD40L expressed on T-lymphocytes. This prevents the binding of CD40L to its cognate receptor CD40 expressed on B-lymphocytes, macrophages, and dendritic cells (DCs). This prevents T-cell mediated proliferation and differentiation of B-cells, and prevents the production of antibodies. By inhibiting both the production of anti-glycoprotein (GP) IIb/IIIa antibodies by B-cells and GPIIb/IIIa-dependent T-cell proliferation, letolizumab may prevent platelet destruction and may increase platelet counts in idiopathic thrombocytopenic purpura (ITP). The direct binding of letolizumab to CD40L on platelets further prevents CD40L/CD40-mediated destruction by macrophages and DCs in ITP. The modified Fc domain prevents the binding of letolizumab to the Fc receptor FcgammaRIIA on platelets, thereby preventing FcgammaRIIA-dependent platelet activation and anti-CD40L-induced thromboembolism. CD40L, a transmembrane protein of the tumor necrosis factor (TNF) superfamily, is primarily expressed on activated T-cells, but is also expressed on eosinophils, basophils, natural killer (NK) cells, mast cells, platelets and activated endothelial cells.	Letolizumab		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120141>	C175276	Percentage Relief From Pain Treatment or Medication Score 90|BPI Percentage Relief From Pain Treatment or Medication Score 90	A subjective score of 90% on a scale that ranges from 0%: No Relief to 100%: Complete Relief.			Intellectual Product	BPI Percentage Relief From Pain Treatment or Medication Likert Scale|Brief Pain Inventory Short Form Questionnaire
C120142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120142>	C175276	Percentage Relief From Pain Treatment or Medication Score 100|BPI Percentage Relief From Pain Treatment or Medication Score 100	A subjective score of 100% on a scale that ranges from 0%: No Relief to 100%: Complete Relief.			Intellectual Product	BPI Percentage Relief From Pain Treatment or Medication Likert Scale|Brief Pain Inventory Short Form Questionnaire
C120143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120143>	C79704	Familial Male Precocious Puberty|Familial Testotoxicosis|Gonadotropin-independent Familial Sexual Precocity|Male-limited Precocious Puberty|Testotoxicosis	Early development of isosexual secondary characteristics in boys, due to autosomal dominant mutations in the LHCGR gene.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C120144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120144>	C3492	P450-Aromatase Deficiency|Aromatase Deficiency|Aromatase deficiency	Deficiency of activity of the enzyme aromatase, which converts androgens to estrogens.			Laboratory or Test Result	NICHD Terminology|Pediatric Endocrinology Terminology
C120145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120145>	C113347	Isolated Hypogonadotropic Hypogonadism	Hypogonadotropic hypogonadism not associated with a deficiency of other pituitary hormones.			Disease or Syndrome	
C120146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120146>	C113215	Ovarian Hyperandrogenism	Increased production of androgens by the ovaries.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C120147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120147>	C85429|C20995	BPI Pain Interference Likert Scale|BPI Pain Interference Scale|Brief Pain Inventory Pain Interference Scale	A scale for the subjective scoring of pain interference that ranges from 0: Does Not Interfere to 10: Completely Interferes.			Intellectual Product	Brief Pain Inventory Short Form Questionnaire
C120148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120148>	C3073	Pubertal Gynecomastia|Transient Gynecomastia|Transient Gynecomastia	Gynecomastia that occurs during puberty and is not due to exogenous substances or disease processes.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C120149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120149>	C175258	Pain Interference Score 0|BPI Pain Interference Score 0	A subjective score of 0 on a scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.			Intellectual Product	BPI Pain Interference Likert Scale|Brief Pain Inventory Short Form Questionnaire
C12014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12014>	C61063	Carboplatin/Squalamine Lactate			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120150>	C175258	Pain Interference Score 1|BPI Pain Interference Score 1	A subjective score of 1 on a scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.			Intellectual Product	BPI Pain Interference Likert Scale|Brief Pain Inventory Short Form Questionnaire
C120151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120151>	C175258	Pain Interference Score 2|BPI Pain Interference Score 2	A subjective score of 2 on a scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.			Intellectual Product	BPI Pain Interference Likert Scale|Brief Pain Inventory Short Form Questionnaire
C120152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120152>	C175258	Pain Interference Score 3|BPI Pain Interference Score 3	A subjective score of 3 on a scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.			Intellectual Product	BPI Pain Interference Likert Scale|Brief Pain Inventory Short Form Questionnaire
C120153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120153>	C175258	Pain Interference Score 4|BPI Pain Interference Score 4	A subjective score of 4 on a scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.			Intellectual Product	BPI Pain Interference Likert Scale|Brief Pain Inventory Short Form Questionnaire
C120154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120154>	C175258	Pain Interference Score 5|BPI Pain Interference Score 5	A subjective score of 5 on a scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.			Intellectual Product	BPI Pain Interference Likert Scale|Brief Pain Inventory Short Form Questionnaire
C120155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120155>	C175258	Pain Interference Score 6|BPI Pain Interference Score 6	A subjective score of 6 on a scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.			Intellectual Product	BPI Pain Interference Likert Scale|Brief Pain Inventory Short Form Questionnaire
C120156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120156>	C175258	Pain Interference Score 7|BPI Pain Interference Score 7	A subjective score of 7 on a scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.			Intellectual Product	BPI Pain Interference Likert Scale|Brief Pain Inventory Short Form Questionnaire
C120157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120157>	C175258	Pain Interference Score 8|BPI Pain Interference Score 8	A subjective score of 8 on a scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.			Intellectual Product	BPI Pain Interference Likert Scale|Brief Pain Inventory Short Form Questionnaire
C120158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120158>	C175258	Pain Interference Score 9|BPI Pain Interference Score 9	A subjective score of 9 on a scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.			Intellectual Product	BPI Pain Interference Likert Scale|Brief Pain Inventory Short Form Questionnaire
C120159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120159>	C175258	Pain Interference Score 10|BPI Pain Interference Score 10	A subjective score of 10 on a scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.			Intellectual Product	BPI Pain Interference Likert Scale|Brief Pain Inventory Short Form Questionnaire
C12015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12015>	C61063	Flutamide/Toremifene			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120160>	C79859	Female Virilization|Virilization in Girls	The development of male secondary sexual characteristics (such as hirsutism, deepening of the voice, or clitoral enlargement) in girls or adult females.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C120161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120161>	C113348	Congenital Hypergonadotropic Hypogonadism	Ovarian or testicular dysfunction associated with high levels of gonadotropins, that is present at birth.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C120162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120162>	C113347	Congenital Hypogonadotropic Hypogonadism	Insufficient production of estrogen or testosterone in the ovaries or testes due to decreased secretion of gonadotropins as a result of pituitary or hypothalamus gland dysfunction that is present at birth.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C120163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120163>	C3073	Pathological Gynecomastia	Gynecomastia that is due to exogenous substances or disease processes.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C120164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120164>	C34815	Isolated Premature Menarche|Premature Menarche	Occurrence of the first menstrual period in a girl before the lower limit of the normal age range for the reference population, without other signs of puberty.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C120165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120165>	C79704	Idiopathic Precocious Puberty|Cryptogenic sexual precocity	Precocious puberty for which no underlying cause can be identified.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C120166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120166>	C66830	CDISC QRS Terminology	The terminology subset that includes terms pertaining to the CDISC questionnaires, ratings and scales terminology.			Intellectual Product	
C120168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120168>	C752	GH1 Gene Product	A protein encoded by the GH1 gene.			Amino Acid, Peptide, or Protein	
C120169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120169>	C98541|C3113	Neuroendocrine Cell Hyperplasia of Infancy|NEHI	A form of interstitial lung disease characterized by increased numbers of pulmonary neuroendocrine cells, typically presenting in the first year of life with persistent tachypnea, retractions, crackles and hypoxemia that has a highly specific chest CT pattern that includes ground-glass opacities and air-trapping.			Disease or Syndrome	NICHD Terminology|Perinatal Terminology
C12016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12016>	C61063	Cisplatin/Fluorouracil/G17DT			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120170>	C21154	Functional Assessment of Chronic Illness Therapy-Diarrhea|FACIT-D|Functional Assessment of Chronic Illness Therapy-Diarrhea (FACIT-D)|Functional Assessment of Chronic Illness Therapy-Diarrhea Questionnaire	A symptom-specific subscale of the FACIT scales that is used to assess how diarrhea affects an individual's life.			Intellectual Product	
C120171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120171>	C176021|C173936|C173695	Limit Social Activity Because of Diarrhea Question|I have to limit my social activity because of diarrhea|Limit Social Activity Because of Diarrhea	A question about whether an individual has or had to limit their social activity because of diarrhea.			Intellectual Product	Functional Assessment of Chronic Illness Therapy-Diarrhea
C120172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120172>	C173936|C173695|C173458	Limit Physical Activity Because of Diarrhea Question|I have to limit my physical activity because of diarrhea|Limit Physical Activity Because of Diarrhea	A question about whether an individual has or had to limit their physical activity because of diarrhea.			Intellectual Product	Functional Assessment of Chronic Illness Therapy-Diarrhea
C120173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120173>	C173936|C173704|C173695	Limit Sexual Activity Because of Diarrhea Question|I have to limit my sexual activity because of diarrhea|Limit Sexual Activity Because of Diarrhea	A question about whether an individual has or had to limit their sexual activity because of diarrhea.			Intellectual Product	Functional Assessment of Chronic Illness Therapy-Diarrhea
C120174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120174>	C173936|C173601	Embarrassed by Diarrhea Question|Embarrassed by Diarrhea|I am embarrassed by having diarrhea	A question about whether an individual is or was embarrassed by having diarrhea.			Intellectual Product	Functional Assessment of Chronic Illness Therapy-Diarrhea
C120175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120175>	C173936|C173518	Have Abdominal Cramps or Discomfort Due to Diarrhea Question|Have Abdominal Cramps or Discomfort Due to Diarrhea|I have abdominal cramps or discomfort due to my diarrhea	A question about whether an individual has or had abdominal cramps or discomfort due to diarrhea.			Intellectual Product	Functional Assessment of Chronic Illness Therapy-Diarrhea
C120176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120176>	C173936	Problem with Diarrhea Wakes Me or Keeps Me Awake at Night Question|My problem with diarrhea keeps/wakes me up at night|Problem with Diarrhea Wakes Me or Keeps Me Awake at Night	A question about whether an individual is or was kept awake or awakened at night by diarrhea.			Intellectual Product	Functional Assessment of Chronic Illness Therapy-Diarrhea
C120177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120177>	C21154	Functional Assessment of Incontinence Therapy-Fecal|FAIT-F|Functional Assessment of Incontinence Therapy-Fecal (FAIT-F)|Functional Assessment of Incontinence Therapy-Fecal Questionnaire	A symptom-specific subscale of the FACIT scales that is used to assess how fecal incontinence interferes affects an individual's life.			Intellectual Product	
C120178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120178>	C173938	Move Bowels More Frequently Than Usual Question|I move my bowels more frequently than usual|Move Bowels More Frequently Than Usual	A question about whether an individual moves or moved their bowels more frequently than usual.			Intellectual Product	Functional Assessment of Incontinence Therapy-Fecal
C120179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120179>	C173047	Afraid to be Far from a Toilet Question|Afraid to be Far from a Toilet|I am afraid to be far from a toilet	A question about whether an individual is or was afraid to be far from a toilet.			Intellectual Product	Functional Assessment of Incontinence Therapy-Fecal
C12017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12017>	C61063	Eflornithine/Triamcinolone			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120180>	C175989|C173938	Must Move Bowels Frequently to Avoid Accidents Question|I must move my bowels frequently to avoid accidents|Must Move Bowels Frequently to Avoid Accidents	A question about whether an individual must move their bowels frequently to avoid accidents.			Intellectual Product	Functional Assessment of Incontinence Therapy-Fecal
C120181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120181>	C91102	Wear Protection to Prevent Soiling from Stool Question|I wear pads or protection to prevent soiling my underwear|Wear Pads or Protection to Prevent Soiling Underwear|Wear Protection to Prevent Soiling from Stool	to A question about whether an individual wears or wore protection to prevent soiling from stool.			Intellectual Product	Functional Assessment of Chronic Illness Therapy-Diarrhea|Functional Assessment of Incontinence Therapy-Fecal
C120182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120182>	C142078	Autologous PBMCs in GM-CSF|Autologous Peripheral Blood Mononuclear Cells in Granulocyte-macrophage Colony-stimulating Factor	Autologous peripheral blood mononuclear cells (PBMCs) that are suspended in a solution containing the immunostimulant granulocyte-macrophage colony stimulating factor (GM-CSF).	Autologous PBMCs in GM-CSF		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C120183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120183>	C2594	Eltrapuldencel-T|Autologous DCs Loaded with Irradiated Autologous Tumor Cells in GM-CSF|Autologous Dendritic Cells Loaded with Irradiated Autologous Tumor Cells in Granulocyte-macrophage Colony-stimulating Factor|DC-TC|ELTRAPULDENCEL-T|Melapuldencel-T|NBS-20|NBS20	A therapeutic melanoma vaccine consisting of autologous dendritic cells (DCs) pulsed with antigens from lethally irradiated autologous tumor cells derived from a patient-specific, continuously proliferating and melanoma-initiating cell line and suspended in a solution containing the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration, eltrapuldencel-T may stimulate the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against the patient's repertoire of melanoma-associated antigens, particularly tumor stem cell antigens, found in the irradiated autologous cancer cells. As an immunostimulant, GM-CSF enhances the activation of dendritic cells (DCs) and promotes antigen presentation to both B- and T-lymphocytes.	Eltrapuldencel-T		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C120184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120184>	C78283	Nasal Saline Irrigation Solution|Nasal Saline Rinse|Nasal Saline Wash	A solution containing sodium chloride that can be used to cleanse the nasal passages. Upon nasal irrigation, the saline washes out thick or dry mucus, and irritants, such as pollen, dust particles, pollutants and bacteria, from the nasal cavities. This reduces nasal blockage, improves nasal airflow and helps keep nasal passages clean and clear, which decreases the risk of irritation and inflammation. The saline solution also moisturizes and soothes irritated mucus membranes.	Nasal Saline Irrigation Solution		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C120185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120185>	C28310	WT1 Peptide-loaded Allogeneic Dendritic Cell Vaccine|WT1 Peptide-loaded Allogeneic DC Vaccine|Wilms Tumor 1 Peptide-loaded Allogeneic Dendritic Cell Vaccine	A cell-based cancer vaccine composed of donor-derived dendritic cells (DCs) loaded with three, human leukocyte antigen A2 (HLA-A2)-binding peptides derived from the human tumor-associated antigen (TAA) Wilms tumor protein 1 (WT1), with potential immunomodulating and antineoplastic activities. Upon vaccination, WT1 peptide-loaded allogeneic DC vaccine exposes the immune system to WT1-derived peptides and may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against WT1-expressing cancer cells, which could result in tumor cell lysis. WT1, a transcription factor, is overexpressed in leukemic cells and in various solid tumors, and only minimally in normal tissues; its expression often correlates with disease progression and poor prognosis. HLA-A2 is an MHC class I molecule that presents antigenic peptides to CD8+ T-cells; restricting the peptides to those epitopes that bind most efficiently to HLA-A2 may improve antigenic peptide immunogenicity.	WT1 Peptide-loaded Allogeneic Dendritic Cell Vaccine		Cell|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCIt Antineoplastic Agent Terminology
C120186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120186>	C9305|C7628	Refractory Malignant Neoplasm|Refractory Cancer|clinical resistance|refractory cancer|resistant cancer	A malignant neoplasm that does not respond to treatment.	Refractory Malignant Neoplasm		Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C120187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120187>	C27564	Contrasexual Sexual Development	The development of secondary sexual characteristics contrary to pre-pubertal phenotype (feminization in boys; virilization in girls).			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C120188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120188>	C35107	Persistent Mullerian Duct Syndrome|Hernia Uteri Inguinale|Hernia Uteri Inguinale	The presence of Mullerian duct-derived structures in a phenotypically male individual.			Congenital Abnormality	NICHD Terminology|Pediatric Endocrinology Terminology
C120189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120189>	C120188	Persistent Mullerian Duct Syndrome Type I|Anti-Mullerian Hormone Deficiency|Anti-Mullerian Hormone Deficiency|Persistent Mullerian Duct Syndrome Type 1|Persistent Müllerian Duct Syndrome Type 1	Persistent Mullerian duct syndrome due to deficiency of anti-Mullerian hormone.			Congenital Abnormality	NICHD Terminology|Pediatric Endocrinology Terminology
C12018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12018>	C61007	Autologous Lymphocytes/Interleukin-2/Sargramostim			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120190>	C120188	Persistent Mullerian Duct Syndrome Type II|Anti-Mullerian Hormone Resistance|Anti-Mullerian Hormone Resistance|Persistent Mullerian Duct Syndrome Type 2	Persistent Mullerian duct syndrome due to resistance to anti-Mullerian hormone (AMH), resulting from mutations in the AMH receptor (AMHR) gene.			Congenital Abnormality	NICHD Terminology|Pediatric Endocrinology Terminology
C120191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120191>	C27226	Complete Androgen Insensitivity Syndrome|CAIS|Complete androgen insensitivity syndrome	A genetic disorder associate with a mutation in the AR gene, resulting in the complete resistance to androgenic hormones.			Disease or Syndrome	Cellosaurus Disease Terminology
C120192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120192>	C27226	Partial Androgen Insensitivity Syndrome|PAIS	A genetic disorder associated with a mutation in the AR gene, resulting in partial resistance to androgenic hormones.			Disease or Syndrome	Cellosaurus Disease Terminology
C120194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120194>	C27564	46,XY Disorder of Androgen Action	Conditions in 46,XY individuals in which androgens are produced in typical amounts, but tissue response to androgens is reduced.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C120195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120195>	C27565	Disorder of AMH	Abnormally high or low anti-Müllerian hormone levels.			Disease or Syndrome	
C120196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120196>	C27565	Disorder of AMH Receptor	A defect in the Anti-Muellerian hormone receptor.			Disease or Syndrome	
C120197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120197>	C61420	46,XX Gonadal Dysgenesis|46,XX Ovarian Dysgenesis|46,XX Ovarian Dysgenesis	Gonadal dysgenesis in an individual with 46,XX karyotype and female phenotype.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C120198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120198>	C61420	46,XY Gonadal Dysgenesis|Swyer Syndrome|Swyer Syndrome	Gonadal dysgenesis in an individual with 46.XY karyotype.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C120199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120199>	C61420	45,X/46,XY Mixed Gonadal Dysgenesis|45,X/46,XY Disorder of Sex Development|45,X/46,XY Gonadal Dysgenesis|Mixed Gonadal Dysgenesis	A congenital condition characterized by asymmetrical gonadal development in an individual with mosaic karyotype 45,X/46,XY.  45,X/46,XY mosaic is the most common form of mixed gonadal dysgenesis.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C12019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12019>	C61007	Fluorouracil/Irinotecan/Leucovorin Calcium/SU5416			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1201>	C28188|C268	Polysialic Acid|PolySA	A highly negative-charged carbohydrate composed of a linear polymer of alpha 2,8-linked sialic acid residue with potential immunotherapeutic activity. Polysialic acid (PSA) is mainly attached to the neural cell adhesion molecule (NCAM), a membrane-bound glycoprotein overexpressed in certain types of cancers. In embryonic tissue PSA-NCAM is abundantly expressed and PSA plays an important role in formation and remodeling of the neural system through modulation of the adhesive properties of NCAM, thereby reducing cell-cell interactions and promoting cellular mobility. In adult tissue however, the expression of PSA-NCAM is associated with a variety of malignant tumors, signifying its potential role in tumor metastasis. When administered in a vaccine formulation, PSA may stimulate a cytotoxic T cell response against tumors expressing PSA, thereby resulting in a reduction in tumor size.			Immunologic Factor|Organic Chemical	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120200>	C117719	Testicular Regression|Gonadal Regression|Gonadal Regression|Vanishing Testes|Vanishing Testes	A condition characterized by typical male genital appearance in a 46,XY individual in whom testes are unable to be located.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C120202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120202>	C27619	Placental Aromatase Deficiency	An autosomal recessive condition that results in aromatase deficiency in the placenta, causing temporary virilization of the pregnant woman and virilization of her 46,XX fetus.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C120203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120203>	C27565	17-Beta-Hydroxysteroid Dehydrogenase 3 Deficiency|17 Beta HSD3 Deficiency|17 beta HSD3 Deficiency|Pseudohermaphroditism, Male, with Gynecomastia	Decreased activity of the steroidogenic enzyme, 17-beta-hydroxysteroid dehydrogenase, associated with mutation(s) in the HSD17B3 gene, leading to reduced testosterone production.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C120204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120204>	C36327	Defect in the Gene for MIS Type II Receptor|AMHR2 Gene Defect|Defect in the Gene for MIS Type 2 Receptor	A defect in the MISR II gene.			Cell or Molecular Dysfunction	NICHD Terminology|Pediatric Endocrinology Terminology
C120205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120205>	C84609	Acampomelic Campomelic Dysplasia|Acampomelic Campomelic Dysplasia (AQ)	A variant of campomelic dysplasia characterized by the absence of skeletal dysplasia.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C120206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120206>	C3492	Reductase Deficiency	A deficiency in an enzyme that promotes reduction of an organic compound.			Laboratory or Test Result	NICHD Terminology|Pediatric Endocrinology Terminology
C120207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120207>	C129986	Shu Yu Wan Formula|Pill of Chinese Yam|Shu Yu Wan|Shuyu Wan	A traditional Chinese medicine comprising different herbs that may be used for a variety of medical purposes. Shu Yu Wan contains the following herbs: Da Zao (Fructus Jujubae), Shu Yu (Radix Dioscoreae Quinquelobae), Gan Cao (Radix Glycyrrhizae Uralensis), Shu Di Huang (Radix Rehmanniae Glutinosae Praeparata), Dang Gui (Radix Angelicae Sinensis), Shen Qu (Massa Medica Fermentata), Gui Zhi (Ramulus Cinnamomi Cassiae), Da Dou Juan (Semen Glycines Germinatum), E Jiao (Gelatinum Corii Asini), Ren Shen (Radix Ginseng), Bai Zhu (Rhizoma Atractylodis Macrocephalae), Fu Ling (Sclerotium Poriae Cocos), Chuan Xiong (Radix Ligustici Wallichii), Bai Shao Yao (Radix Paeoniae Lactiflorae), Mai Men Dong (Tuber Ophiopogonis Japonici), Chai Hu (Radix Bupleuri), Fang Feng (Radix Ledebouriellae Divaricatae), Jie Geng (Radix Platycodi Grandiflori), Xing Ren (Semen Pruni Armeniacae), Bai Lian (Radix Ampelopsis Japonicae) and Sheng Jiang (Rhizoma Zingiberis Officinalis Recens). This formula may be used to relieve chemotherapeutic side effects or cancer-related symptoms.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120208>	C219694|C129822	Monalizumab|IPH-2201|IPH2201|Immunoglobulin G4-kappa, Anti-(Homo sapiens KLRC1 (Killer Cell Lectin-like Receptor Subfamily C Member 1, NKG2-a, NKG2a, CD159A, CD94)), Humanized Monoclonal Antibody|MONALIZUMAB|NN-8765|NN8765|NN8765-3658	A humanized immunoglobulin G4 (IgG4) monoclonal antibody against the human natural killer (NK) and T-lymphocyte cell checkpoint inhibitor killer cell lectin-like receptor subfamily C member 1 (NKG2A), with potential antineoplastic activity. Upon administration, monalizumab binds to NKG2A and prevents the binding of NKG2A to its ligand human leukocyte antigen-E (HLA-E), which is overexpressed on tumor cells. This blocks the HLA-E-mediated inhibition of NKG2A-positive infiltrating NK and cytotoxic T-lymphocytes (CTLs) and induces a NK and CTL-mediated immune response against the cancer cells leading to their destruction. Human NKG2A, an inhibitory cell surface receptor covalently bound to CD94, is expressed by NK cells and CTLs. Stimulation of the CD94/NKG2A complex inhibits the cytotoxic activity of these cells. HLA-E, a nonclassical HLA class Ib molecule, is often overexpressed on tumor cells and is associated with poor prognosis.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120209>	C192742|C192741|C124800	FLT3/CDK4/6 Inhibitor FLX925|FLX925	An orally available inhibitor of FMS-related tyrosine kinase 3 (FLT3, STK1, or FLK2) and the cyclin-dependent kinases 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon administration, FLT3/CDK4/6 inhibitor FLX925 specifically binds to and inhibits FLT3, which interferes with the activation of FLT3-mediated signal transduction pathways and reduces cell proliferation in cancer cells that overexpress FLT3. In addition FLX925 inhibits CDK4 and 6 and prevents the phosphorylation of retinoblastoma (Rb) protein in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, which causes G1 phase cell cycle arrest, suppresses DNA synthesis and inhibits cancer cell growth. FLT3, a class III tyrosine kinase receptor, is overexpressed in a variety of cancers. Overexpression of CDK4/6, which is seen in certain types of cancer, causes cell cycle deregulation.	FLT3/CDK4/6 Inhibitor FLX925		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12020>	C61007	Cyclophosphamide/Doxorubicin/Leucovorin Calcium/Methotrexate/Prednisone/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120210>	C25974|C212990	Topical Tirbanibulin|KX2 391 Ointment|KX2-391 Ointment	An ointment containing an inhibitor for both Src tyrosine kinase and tubulin polymerization, with potential antineoplastic activity. Unlike other Src kinase inhibitors which bind to the ATP-binding site, tirbanibulin binds to the peptide substrate binding site of Src kinase, upon topical application. This inhibits both downstream signaling and the proliferation of tumor cells overexpressing Src. Src tyrosine kinase, a non-receptor tyrosine kinase upregulated in many tumor cell types, plays an important role in tumor cell proliferation, motility, invasiveness and survival. Tirbanibulin also binds to tubulin heterodimers and inhibits microtubule polymerization, which disrupts microtubule formation and mitosis, leading to further inhibition of cell proliferation. In addition, Tirbanibulin inhibits T-cell migration.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120211>	C1821	Elacestrant|(6R)-6-(2-(Ethyl((4-(2- (ethylamino)ethyl)phenyl)methyl)amino)-4-methoxyphenyl)- 5,6,7,8-tetrahydronaphthalen-2-ol|ELACESTRANT|ER-306323|RAD 1901|RAD-1901|RAD1901|SERD/SERM RAD1901	An orally available, selective estrogen receptor degrader (SERD), with antineoplastic activity. Upon oral administration, elacestrant acts as a SERD, which binds to the estrogen receptor (ER) and induces a conformational change that results in the proteosomal degradation of the receptor. This prevents ER-mediated signaling and inhibits proliferation of ER-expressing cancer cells.	Elacestrant		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCIt Antineoplastic Agent Terminology
C120212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120212>	C226471	Evaux Spring Water-based Cream|Evoskin Cream	A cream containing Evaux thermal spring water, with potential moisturizing and skin protecting activities. Upon application to the skin, Evaux spring water-based cream forms a protective barrier, which prevents water loss, provides moisture to the skin, protects the skin from damage, and soothes irritated skin. The Evaux thermal spring water contains the trace elements lithium and manganese which may help heal the skin.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C120213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120213>	C1752|C1663	DPT/BCG/Measles/Serratia/Pneumococcus Vaccine|G250 Peptide Vaccine	A proprietary lipid emulsion containing five vaccines: diphtheria, pertussis, tetanus (DPT), Bacille Calmette-Guerin (BCG), measles, Serratia marcescens and pneumococcal, with potential immunostimulating activity. Subcutaneous administration of the DPT/BCG/measles/Serratia/pneumococcus vaccine activates the immune system and may both abrogate tumor-induced immune tolerance and induce an antitumor immune response, which may eradicate the tumor.			Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120214>	C1663	DPT/Typhoid/Staphylococcus aureus/Paratyphoid A/Paratyphoid B Vaccine	A proprietary lipid emulsion containing five vaccines: diphtheria, pertussis, tetanus (DPT), typhoid, Staphylococcus aureus, paratyphoid A and paratyphoid B, with potential immunostimulating activity. Subcutaneous administration of the DPT/typhoid/Staphylococcus aureus/paratyphoid A/paratyphoid B vaccine activates the immune system and may both abrogate tumor-induced immune tolerance and induce an antitumor immune response, which may eradicate the tumor.			Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120216>	C69013	Pen Needle	A single use, hollow needle embedded in a plastic hub, which is then attached to a preloaded syringe (pen) to facilitate the delivery of medication.			Medical Device	NCPDP Quantity Unit of Measure Terminology
C120217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120217>	C21154	Functional Assessment of Chronic Illness Therapy - Abdominal Discomfort|FACIT-AD Questionnaire|Functional Assessment of Chronic Illness Therapy-Abdominal|Functional Assessment of Chronic Illness Therapy-Abdominal	A symptom-specific subscale of the FACIT scales that that uses a 5-point Likert scale to measure a person's self-reported abdominal symptoms.			Intellectual Product	
C120218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120218>	C173584|C173346	Stomach Pain Interferes with Daily Functioning Question|Stomach Pain Interferes with Daily Functioning|Stomach pain interferes with my daily functioning	A question about whether an individual's stomach pain interferes with their daily functioning.			Intellectual Product	Functional Assessment of Chronic Illness Therapy - Abdominal Discomfort
C120219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120219>	C173346	Pain in Hands or Feet When Exposed to Cold Temperatures Question|I have pain in my hands or feet when I am exposed to cold temperatures|Pain in Hands or Feet When Exposed to Cold Temperatures	A question about whether an individual has or had pain in their hands or feet when exposed to cold temperatures.			Intellectual Product	Functional Assessment of Chronic Illness Therapy - Abdominal Discomfort
C12021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12021>	C61007	Cyclophosphamide/Doxorubicin/Leucovorin Calcium/Methotrexate/Prednisone/Rituximab/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120220>	C36346	CIC-DUX4 Fusion Protein Expression	Expression of a fusion protein that results from a t(4;19)(q35;q13) translocation, which involves the human genes CIC (capicua transcriptional suppressor) and DUX4 (double homeobox 4).			Cell or Molecular Dysfunction	
C120221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120221>	C36346	CIC-DUX4L Fusion Protein Expression	Expression of a fusion protein that results from a t(10;19)(q26;q13) translocation, which involves the human genes CIC (capicua transcriptional suppressor) and DUX4L (double homeobox 4-like).			Cell or Molecular Dysfunction	
C120222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120222>	C3420|C165668	t(4;19)(q35;q13)	A cytogenetic abnormality that refers to the translocation involving the genes CIC (capicua transcriptional suppressor) on chromosome 19 and DUX4 (double homeobox 4) on chromosome 4 resulting in CIC-DUX4 fusion.			Cell or Molecular Dysfunction	EWS Authorized Value Terminology|EWS Molecular Analysis Table
C120223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120223>	C3420|C219858|C165668	t(10;19)(q26;q13)	A cytogenetic abnormality that refers to the translocation involving the genes CIC (capicua transcriptional suppressor) on chromosome 19 and DUX4L (double homeobox 4-like) on chromosome 10 resulting in CIC-DUX4L fusion.			Cell or Molecular Dysfunction	EWS Authorized Value Terminology|EWS Molecular Analysis Table
C120224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120224>	C165671	CIC-Rearranged Sarcoma|CIC-DUX Sarcoma	An undifferentiated, high grade small round cell sarcoma affecting predominantly young adults. It is characterized by a recurrent translocation involving the CIC gene on chromosome 19 and either DUX4 gene on chromosome 4 or DUX4L gene on chromosome 10. The translocation results in either CIC-DUX4, t(4;19)(q35;q13) or CIC-DUX4L, t(10;19)(q26;q13) fusions.			Neoplastic Process	
C120225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120225>	C91105	European Quality of Life Five Dimension Three Level Youth Questionnaire|EQ-5D-Y|EQ-5D-Y	A standardized rating scale which is used as a measure of health outcome for children and adolescents aged 8-18. This instrument is a descriptive system consisting of 5 dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. Each dimension has 3 levels ranging from no problem to extreme problem or incapable, which are assessed by the patient.			Intellectual Product	
C120226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120226>	C173135	Walking Mobility Today Question|Mobility (walking about)|Walking Mobility Today	A question about an individual's current walking mobility.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire|European Quality of Life Five Dimension Three Level Youth Questionnaire
C120227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120227>	C226710	Slight Problems Walking|I have slight problems walking	A response indicating that an individual has or had slight problems walking.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire
C120228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120228>	C226710	Moderate Problems Walking|I have moderate problems walking	A response indicating that an individual has or had moderate problems walking.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire
C120229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120229>	C226710	Severe Problems Walking|I have severe problems walking	A response indicating that an individual has or had severe problems walking.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire
C12022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12022>	C61063	Interleukin-2/Montanide ISA-51/Telomerase: 540-548 Peptide Vaccine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120230>	C226710|C226575	Unable to Walk|I am unable to walk|Unable to walk	A response indicating that an individual is or was unable to walk.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire|Nurses' Health Study II Activity and Inactivity Questionnaire
C120231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120231>	C131923	Washing or Dressing Self-Care Today Question|Looking after myself|Washing or Dressing Self-Care Today	A question about an individual's current self-care ability with washing or dressing.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire|European Quality of Life Five Dimension Three Level Youth Questionnaire
C120233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120233>	C226711	Slight Problems with Washing or Dressing|I have slight problems washing or dressing myself	A response indicating that an individual has or had slight problems with washing or dressing.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire
C120234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120234>	C226711	Moderate Problems with Washing or Dressing|I have moderate problems washing or dressing myself	A response indicating that an individual has or had moderate problems with washing or dressing.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire
C120235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120235>	C226711	Severe Problems with Washing or Dressing|I have severe problems washing or dressing myself	A response indicating that an individual has or had severe problems with washing or dressing.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire
C120236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120236>	C91102	Usual Activities Today Question|Doing usual activities (for example, going to school, hobbies, sports, playing, doing things with family or friends)|Usual Activities Today	A question about an individual's current ability to do their usual activities.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire|European Quality of Life Five Dimension Three Level Youth Questionnaire
C120237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120237>	C226617	Slight Problems Performing Usual Activities|I have slight problems doing my usual activities	A response indicating that an individual has or had slight problems with performing their usual activities.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire
C120238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120238>	C226617	Moderate Problems Performing Usual Activities|I have moderate problems doing my usual activities	A response indicating that an individual has or had moderate problems with performing their usual activities.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire
C120239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120239>	C226617	Severe Problems Performing Usual Activities|I have severe problems doing my usual activities	A response indicating that an individual has or had severe problems with performing their usual activities.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire
C12023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12023>	C61007	Carboplatin/Docetaxel/Trastuzumab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120240>	C156140	Pain or Discomfort Today Question|Having pain or discomfort|Pain or Discomfort Today	A question about an individual's current pain or discomfort.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire|European Quality of Life Five Dimension Three Level Youth Questionnaire
C120241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120241>	C175455	Slight Pain or Discomfort|Hurts a little bit|I have slight pain or discomfort	A response indicating that an individual has or had slight pain or discomfort.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire
C120242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120242>	C175455	Severe Pain or Discomfort|Hurts a whole lot|I have severe pain or discomfort	A response indicating that an individual has or had severe pain or discomfort.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire
C120243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120243>	C173386	Anxiety or Depression Today Question|Anxiety or Depression Today|Feeling worried, sad or unhappy	A question about an individual's current anxiety or depression.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire|European Quality of Life Five Dimension Three Level Youth Questionnaire
C120244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120244>	C175320	Slightly Anxious or Depressed|I am slightly anxious or depressed	A response indicating that an individual has or had slight anxiety or depression.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire
C120245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120245>	C175320	Severely Anxious or Depressed|I am severely anxious or depressed	A response indicating that an individual has or had severe anxiety or depression.			Intellectual Product	European Quality of Life Five Dimension Five Level Scale Questionnaire
C120246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120246>	C226710	A Lot of Problems Walking|I have a lot of problems walking about	A response indicating that an individual has or had a lot of problems walking.			Intellectual Product	European Quality of Life Five Dimension Three Level Youth Questionnaire
C120247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120247>	C226711	A Lot of Problems with Washing and Dressing|I have a lot of problems washing or dressing myself	A response indicating that an individual has or had a lot of problems with washing or dressing their self.			Intellectual Product	European Quality of Life Five Dimension Three Level Youth Questionnaire
C120248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120248>	C226617	A Lot of Problems Performing Usual Activities|I have a lot of problems doing my usual activities	A response indicating that an individual has or had a lot of problems with performing their usual activities.			Intellectual Product	European Quality of Life Five Dimension Three Level Youth Questionnaire
C120249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120249>	C175455	Some Pain or Discomfort|Hurts a little more|I have some pain or discomfort	A response indicating that an individual has or had some pain or discomfort.			Intellectual Product	European Quality of Life Five Dimension Three Level Youth Questionnaire
C12024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12024>	C61063	Cisplatin/Docetaxel/Trastuzumab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120250>	C175455	A Lot of Pain or Discomfort|I have a lot of pain or discomfort	A response indicating that an individual has or had a lot of pain or discomfort.			Intellectual Product	European Quality of Life Five Dimension Three Level Youth Questionnaire
C120251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120251>	C175320	A Bit Anxious or Depressed|I am a bit worried, sad or unhappy	A response indicating that an individual has or had a bit of anxiety or depression.			Intellectual Product	European Quality of Life Five Dimension Three Level Youth Questionnaire
C120252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120252>	C175320	Very Anxious or Depressed|I am very worried, sad or unhappy	A response indicating that an individual is or was very anxious or depressed.			Intellectual Product	European Quality of Life Five Dimension Three Level Youth Questionnaire
C120253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120253>	C217121	Children's Memory Scale|CMS	A test designed to make a comprehensive assessment of learning and memory in children and adolescents ranging in age from 5 to 16 years.			Intellectual Product	
C120254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120254>	C122920	Wechsler Adult Intelligence Scale - Fourth Edition|WAIS-IV|Wechsler Adult Intelligence Scale 4th Edition|Wechsler Adult Intelligence Scale IV	The fourth version of the Wechsler Adult Intelligence Scale that was published in 2008. It is a test designed to measure intelligence in individuals ranging in age from 16 to 90 years.			Intellectual Product	
C120255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120255>	C122920	Wechsler Intelligence Scale for Children - Fifth Edition|WISC-V|Wechsler Intelligence Scale for Children 5th Edition|Wechsler Intelligence Scale for Children V	The fifth version of the Wechsler Intelligence Scale for Children that was published in 2014. It is an individually administered clinical instrument for assessing the cognitive ability of children aged 6 years through 16 years 11 months. It is a psychometric test that assesses a child's current cognitive abilities in both verbal and nonverbal areas, including verbal comprehension, perceptual reasoning, working memory, and processing speed.			Intellectual Product	
C120256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120256>	C122920	Wechsler Preschool and Primary Scale of Intelligence - Fourth Edition|WPPSI-IV|Wechsler Preschool & Primary Scale of Intelligence 4th Edition|Wechsler Preschool and Primary Scale of Intelligence IV	The fourth version of the Wechsler Preschool & Primary Scale of Intelligence, published in 2012. It is a test designed for children ages 2 years 6 months to 7 years 3 months that provides subtest and composite scores that represent intellectual functioning in verbal and performance cognitive domains, and provides a composite score that represents a child's general intellectual ability.			Intellectual Product	
C120257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120257>	C20993	California Verbal Learning Test - Second Edition|CVLT-II|California Verbal Learning Test 2nd Edition|California Verbal Learning Test II|California Verbal Learning Test, Second Edition	The second version of California Verbal Learning Test, a neuropsychological test developed to make a comprehensive and detailed assessment of verbal learning and memory in individuals ranging in age from 16 to 89 years.			Intellectual Product	
C120258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120258>	C217121	Wechsler Memory Scale - Fourth Edition|WMS-IV|Wechsler Memory Scale 4th Edition|Wechsler Memory Scale IV	The fourth version of the Wechsler Memory Scale that was published in 2009. It is a neuropsychological test designed to measure different memory functions in individuals ranging in age from 16 to 90 years.			Intellectual Product	
C120259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120259>	C192742|C192741	Palbociclib Isethionate|6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino(pyrido(2,3-d)pyrimidin-7(8h)-one mono(2-hydroxyethanesulfonate)|PALBOCICLIB ISETHIONATE|PD 0332991-0054|PF-00080665-73	The isethionate salt form of palbociclib, an orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.	Palbociclib Isethionate		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C12025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12025>	C61063	Bevacizumab/Docetaxel/Doxorubicin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120260>	C35221	Late Pregnancy Loss	The loss of a pregnancy between 13 and 22 weeks.			Finding	
C120261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120261>	C120262	Normal Virilization	The normal development of male secondary sexual characteristics (such as hirsutism, deepening of the voice) in pubertal boys due to testosterone effects.			Finding	
C120262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120262>	C36285	Virilization	The development of normal male puberty due to testosterone effect or the abnormal development of male secondary sexual characteristics in children and females due to excessive androgens.			Finding	
C120263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120263>	C16830	Lancet|Blood Lancet	A small, sharp, needle-like instrument that is used to puncture the skin.			Medical Device	NCPDP Quantity Unit of Measure Terminology
C120264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120264>	C48807	Substrate	Any chemical that can be modified or consumed during a chemical reaction or biological process.			Substance	
C120265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120265>	C180669	CYP1A2 Substrate	Any substance acted upon by cytochrome P450 1A2.			Substance	
C120266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120266>	C180669	CYP2C9 Substrate	Any substance acted upon by cytochrome P450 2C9.			Substance	
C120267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120267>	C180669	CYP2C19 Substrate	Any substance acted upon by cytochrome P450 2C19.			Substance	
C120268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120268>	C1708	Inducer	A chemical or physical agent that turns on gene expression.			Chemical Viewed Functionally	
C120269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120269>	C120268	CYP2C9 Inducer	Any substance capable of causing an increase in the synthesis of cytochrome P450 2C9.			Chemical Viewed Functionally	
C12026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12026>	C61063	Carboplatin/Cisplatin-epinephrine/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120270>	C18223	Narrow Therapeutic Index|NTI|Narrow Therapeutic Indices	A therapeutic index of less than 2-fold difference between the median lethal dose and median effective dose values, or less than 2-fold difference between the minimum toxic concentration and minimum effective concentrations in the blood.			Quantitative Concept	
C120271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120271>	C19151	Direct Extension|Contiguous Spread|Direct Tumor Extension	The spread or migration of cancer cells through the wall of an organ into surrounding organs and/or adjacent tissues.			Pathologic Function	NAACCR Terminology
C120272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120272>	C225418	Transnasal	Passing through the nose.			Spatial Concept	
C120273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120273>	C225418	Transventricular	Passing through a ventricle.			Spatial Concept	
C120274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120274>	C48620	Macroscopically Positive Surgical Margin	The presence of macroscopically visible residual tumor at the edge of a surgically excised specimen.			Finding	
C120275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120275>	C15655	Intracardiac Pneumonectomy	Excision of a lung and part of the pericardium.			Therapeutic or Preventive Procedure	
C120276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120276>	C225418	Sublobar	Pertaining to a portion of a lobe.			Spatial Concept	
C120277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120277>	C48620	Grossly Negative and Microscopically Positive Surgical Margin|Grossly negative and microscopically positive	The presence of microscopically visible residual tumor at the edge of a surgically excised specimen that otherwise looks macroscopically normal.			Finding	
C120278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120278>	C64493	Every One to Two Hours|Every 1 to 2 hours	Every one to two hours.			Quantitative Concept	
C120279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120279>	C64493	Every Three to Four Hours|Every 3 to 4 hours	Every three to four hours.			Quantitative Concept	
C12027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12027>	C63358	Anastrozole/Trastuzumab Regimen|Anastrozole and Trastuzumab|Anastrozole and Trastuzumab-anns|Anastrozole and Trastuzumab-dkst|Anastrozole and Trastuzumab-dttb|Anastrozole and Trastuzumab-herw|Anastrozole and Trastuzumab-pkrb|Anastrozole and Trastuzumab-qyyp|Anastrozole and Trastuzumab-strf|Anastrozole and Trastuzumab-zerc|Anastrozole-Trastuzumab|Anastrozole-Trastuzumab Regimen|Anastrozole/Trastuzumab|Arimidex-Herceptin|Arimidex/Herceptin|Herceptin-Arimidex|Trastuzumab-Anastrozole|Trastuzumab/Anastrozole|Trastuzumab/Anastrozole Regimen	A regimen consisting of anastrozole and trastuzumab that may be used in the treatment of hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2)-positive breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology
C120280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120280>	C64493	Every Four to Five Hours|Every 4 to 5 hours	Every four to five hours.			Quantitative Concept	
C120281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120281>	C64493	Every Four to Six Hours|Every 4 to 6 hours	Every four to six hours.			Quantitative Concept	
C120282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120282>	C51900	Sentinel Lymph Node Biopsy Followed by Axillary Lymph Node Biopsy|Sentinel node biopsy followed by surgical evaluation of axilla	A staging procedure consisting of sentinel node biopsy followed by surgical evaluation of the axillary lymph nodes.			Diagnostic Procedure	
C120283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120283>	C27993	Uninterpretable|Non-Interpretable	Not able to be understood in terms of meaning or significance.			Qualitative Concept	
C120284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120284>	C171342	Tumor Size	The size of a tumor in its greatest dimension.			Quantitative Concept	
C120285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120285>	C53696	Tumor Less than or Equal to 2.0 cm|Less than or equal to 2.0 cm|Tumor Less than or Equal to 2.0 Centimeters	A tumor where the greatest dimension is less than or equal to 2.0 cm.			Finding	
C120286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120286>	C51138	Tumor Greater than or Equal to 2.1 cm|Greater than or equal to 2.1 cm|Tumor Greater than or Equal to 2.1 Centimeters	A tumor where the greatest dimension is greater than or equal to 2.1 cm.			Finding	
C120287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120287>	C62658	Minimum of 6 Axillary Nodes|With a minimum of 6 axillary nodes	Lymph node dissection of at least 6 axillary lymph nodes.			Diagnostic Procedure	
C120288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120288>	C48621	Grossly Negative and Microscopically Negative Surgical Margin|Grossly negative and microscopically negative	The absence of tumor cells at the edge of a surgically excised specimen, both macroscopically and microscopically.			Finding	
C120289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120289>	C344	Ceramide Dodecasaccharide|CD65|CD65|VIM-2|VIM2	A carbohydrate cell-surface antigen formed by fucosylation of the inner lactosamine unit of alpha-2,3-sialylated polylactosamine by alpha-1,3-fucosyltransferase. Its presence is associated with a high risk for extravascular infiltration of acute myeloid leukemia cells.			Organic Chemical	
C12028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12028>	C61063	Pentoxifylline/vitamin E			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120290>	C20988	ITGAD Gene|ITGAD|ITGAD|Integrin, Alpha D Gene	This gene plays a role in cell-cell and cell-extracellular matrix interactions.			Gene or Genome	
C120291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120291>	C120290	ITGAD wt Allele|ADB2|CD11D|Integrin, Alpha D wt Allele|Integrin, Alpha-D Gene	Human ITGAD wild-type allele is located in the vicinity of 16p11.2 and is approximately 33 kb in length. This allele, which encodes integrin alpha-D protein, is involved in both cell-cell and cell-extracellular matrix interactions and cell communication.			Gene or Genome	
C120292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120292>	C16393	Integrin Alpha-D|CD11 Antigen-Like Family Member D|CD11d|CD11d|CD11d Antigen|ITGAD|Leukointegrin Alpha D	Integrin alpha-D (1161 aa, ~127 kDa) is encoded by the human ITGAD gene. This protein plays a role in cell-cell and cell-extracellular matrix interactions.			Amino Acid, Peptide, or Protein	
C120293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120293>	C102656	SPF10-LiPA PCR Assay|SPF10-LiPA	A PCR technique that uses the SPF10 primer set for HPV detection. It amplifies a 65 bp region from the L1 region of the HPV genome. Genotype identification is achieved by using a reverse line probe assay (LiPA).			Laboratory Procedure	
C120294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120294>	C93141|C17003	GP5+/GP6+ PCR Assay|GP+-PCR|GP5+/GP6+|General Primer Mediated 5+/6+	A PCR technique that uses the GP5+/GP6+ primer set for HPV detection. It amplifies a 150 bp region from the L1 region of the HPV genome.			Laboratory Procedure	
C120295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120295>	C93141|C17003	PGMY09/PGMY11 PCR Assay|PGMY09/PGMY11	A PCR technique that uses a pool of 5 upstream and 13 downstream primers, which are based on the binding sites for the MY09/MY11 degenerate primer set, for HPV detection. It amplifies a 450 bp region from the L1 region of the HPV genome.			Laboratory Procedure	
C120296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120296>	C93141|C17003	MY09/MY11 PCR Assay|MY-PCR|MY09/MY11	A PCR technique that uses the MY09/MY11 degenerate primer set for HPV detection. It amplifies a 450 bp region from the L1 region of the HPV genome.			Laboratory Procedure	
C120297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120297>	C17003|C157255	Linear Array HPV Genotyping Test|HPV Linear Array|HPV Linear Array|LA HPV Genotyping|Roche Linear Array|Roche Linear Array Genotyping Test	A proprietary PCR technique that uses a pool of primers to amplify a 450 bp region in the L1 region of the HPV genome. It is capable of detecting 37 high- and low-risk human papillomavirus genotypes.	HPV Linear Array		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Terminology
C120298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120298>	C134526	Canine Melanoma	Melanoma occurring in a dog. It is the most common malignant tumor found in the mouths of dogs and also occurs frequently on the digits. All canine melanomas are locally invasive and malignant canine melanomas show a high rate of metastasis. Melanoma in dogs has been established as a relevant model for human melanoma.			Neoplastic Process	Cellosaurus Disease Terminology
C120299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120299>	C25364	Medicare Beneficiary ID|HICN|Medicare Beneficiary Identification Number	An identification code, composed of the individual's social security number plus a suffix code, used by the Medicare system to uniquely identify a user and how that user qualifies for Medicare.			Intellectual Product	
C12029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12029>	C61007	Cyclophosphamide/Cytarabine/Mercaptopurine/Methotrexate/Pegaspargase/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1202>	C521	Prednisolone Acetate|Ak-Tate|Articulose-50|Balpred|Deltacortilen|Deltastab|Di-Adreson-F|Diopred|Econopred|Econopred|Flo-Pred|Hexacortone|Hydrocortancyl|Inf-Oph|Inflanefran|Key-Pred|Locaseptil-Neo|Ophtho-Tate|PREDNISOLONE ACETATE|Pred Fort|Pred Forte|Pred Forte|Pred Mild|Pred Mild|Predaject|Predalone|Predate|Predcor|Prednefrin SF|Predni-H|Predni-POS|Prednihexal|Predniocil|Prednisolone acetate	The acetate salt form of prednisolone, a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. As a glucocorticoid receptor agonist, prednisolone acetate binds to specific intracellular glucocorticoid receptors, and causes the ligand-receptor complex to be translocated to the nucleus where it initiates the transcription of glucocorticoid-responsive genes such as various cytokines and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both potent mediators of inflammation. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.	Prednisolone Acetate		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C120300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120300>	C119669	National Radiology Data Registry|NRDR	An information system created and managed by the American College of Radiology that provides accurate, objective measures of both regional and national practice processes and outcomes for the purpose of improving quality and enhancing patient care.			Intellectual Product	
C120301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120301>	C16126	National Death Index|NDI	A centralized database of death record information established as a resource to aid epidemiologists and other health and medical investigators with mortality ascertainment activities.			Intellectual Product	
C120302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120302>	C226773	CCR2 Antagonist CCX872-B|CCX872-B	An orally available human C-C chemokine receptor type 2 (CCR2) antagonist, with potential immunomodulating and antineoplastic activities. Upon oral administration, CCR2 antagonist CCX872-B specifically binds to CCR2 and prevents the binding its cognate endothelium-derived chemokine ligand CCL2 (monocyte chemoattractant protein-1 or MCP1). This may result in the inhibition of both CCR2 activation and CCR2-mediated signal transduction, which may inhibit inflammatory processes, angiogenesis, tumor cell migration, and tumor cell proliferation. The G-protein coupled receptor CCR2 is expressed on the surface of monocytes and macrophages, and stimulates their migration and infiltration; it plays a key role in inflammation. CCR2 is overexpressed in certain cancer cell types, where it is involved in angiogenesis, tumor cell migration and proliferation.	CCR2 Antagonist CCX872-B		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120303>	C213143|C201535	Anti-mesothelin Antibody-drug Conjugate BMS-986148|BMS-986148|BMS-986148	An antibody-drug conjugate (ADC) composed of a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface glycoprotein and tumor-associated antigen (TAA) mesothelin and conjugated, via a valine-citrulline linker, to the cytotoxic agent tubulysin, with potential antineoplastic activity. Upon administration of anti-mesothelin ADC BMS-986148, the monoclonal antibody moiety targets and binds to mesothelin. Upon internalization, the tubulysin moiety inhibits the polymerization of tubulin into microtubules. This leads to cell cycle arrest, induces tumor cell apoptosis, and may inhibit cellular proliferation of mesothelin-expressing tumor cells. Mesothelin is overexpressed by all mesotheliomas and a variety of other cancers, while it is minimally expressed in normal tissue.	Anti-mesothelin Antibody-drug Conjugate BMS-986148		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120304>	C147923|C129818	CYP17/Androgen Receptor Inhibitor ODM 204|ODM 204|ODM-204|ODM-204	An orally available inhibitor of both the steroid 17-alpha-hydroxylase/C17,20 lyase (CYP17A1 or CYP17) and androgen receptor (AR), with potential anti-androgen and antineoplastic activities. Upon oral administration, CYP17/AR inhibitor ODM 204 selectively inhibits the enzymatic activity of CYP17A1 in both the testes and adrenal glands, thereby inhibiting androgen production. This may both decrease androgen-dependent growth signaling and inhibit the proliferation of androgen-dependent tumor cells. In addition, ODM 204 binds to ARs in target tissues and inhibits androgen-induced receptor activation and AR nuclear translocation, which prevents the binding to and transcription of AR-responsive genes. This leads to an inhibition of growth in AR-expressing prostate cancer cells. The cytochrome P450 enzyme CYP17A1, which is localized to the endoplasmic reticulum, exhibits both 17alpha-hydroxylase and 17,20-lyase activities.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120305>	C20401|C129822	Anti-CEACAM1 Monoclonal Antibody CM-24|CM-24|CM-24	A humanized monoclonal immunoglobulin G4 (IgG4) antibody targeting the anti-carcinoembryonic antigen (CEA)-related cell adhesion molecule 1 (CEACAM1; CD66a), with potential immunomodulating and antineoplastic activities. Upon administration of anti-CEACAM1 monoclonal antibody CM-24, this agent binds to CEACAM1 on cancer cells and certain immune cells. This blocks the binding of CEACAM1-expressing cancer cells to CEACAM1-expressing immune cells and abrogates CEACAM1-mediated immunosuppression. This enhances the activation of cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells and increases CTL- and NK-mediated killing of CEACAM1-overexpressing cancer cells. CEACAM1, a member of the CEA family of proteins that plays a key role in cell migration, cell invasion, and cell adhesion, is overexpressed by a variety of cancer cell types. Its overexpression is correlated with both immunosuppression and poor prognosis.	Anti-CEACAM1 Monoclonal Antibody CM-24		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120306>	C1980	Personalized Polyepitope Plasmid DNA Breast Cancer Vaccine	A polyepitope DNA vaccine composed of a DNA plasmid encoding multiple, highly immunogenic tumor associated antigens (TAAs) that are specifically selected after genome profiling of the patient's breast cancer cells, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration and electroporation of the personalized polyepitope plasmid DNA breast cancer vaccine, the expressed TAAs induce cytotoxic T-lymphocyte (CTL) immune responses against tumor cells expressing the TAAs.	Personalized Polyepitope Plasmid DNA Breast Cancer Vaccine		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120307>	C2167|C129825	Mavelertinib|2-Propenamide, N-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)-3-pyrrolidinyl)-|MAVELERTINIB|PF-06747775	An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. Mavelertinib specifically binds to and inhibits EGFR T790M, a secondary acquired resistance mutation, which prevents EGFR-mediated signaling and leads to cell death in EGFR/T790M-expressing tumor cells. Compared to some other EGFR inhibitors, PF-06747775 may have therapeutic benefits in tumors with T790M-mediated drug resistance. This agent shows minimal activity against wild-type EGFR (WT EGFR), and does not cause dose-limiting toxicities that occur during the use of non-selective EGFR inhibitors, which can inhibit WT EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.	Mavelertinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120308>	C478	Transdermal 17beta-Estradiol Gel BHR-200|BHR-200	A proprietary, transdermal, hydroalcoholic gel formulation containing 17beta-estradiol, with potential antineoplastic activity. Upon topical administration, 17beta-estradiol exerts its antineoplastic effect(s) through as of yet not fully elucidated mechanism(s) of action(s). This formulation may induce feedback inhibition via the hypothalamic-pituitary-gonadal axis feedback loop, block the secretion of luteinizing hormone (LH) and prevent the release of testosterone from Leydig cells in the testes, thus suppressing testosterone secretion. In addition, 17beta-estradiol inhibits enzymes involved in steroidogenesis, thereby further inhibiting androgen production. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation. In addition, 17beta-estradiol prevents bone loss, and suppresses andropause symptoms, such as hot flashes, which appear during androgen-deprivation therapy (ADT) where the standard of care is the use of gonadotrophin releasing hormone (GnRH) analogs. Compared to oral estrogens, the topical gel formulation lowers the risk of cardiovascular side effects.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120309>	C200766|C176018	Axicabtagene Ciloleucel|AXICABTAGENE CILOLEUCEL|Axi-cel|Axicabtagene ciloleucel|Axicel|KTE C19|KTE-C19|KTE-C19 CAR|KTEC19|Yescarta	A preparation of autologous peripheral blood T-lymphocytes (PBTL) that have been transduced with a gammaretoviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv) coupled to the costimulatory signaling domain CD28 and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3 zeta), with potential immunostimulating and antineoplastic activities. Upon intravenous infusion and re-introduction of axicabtagene ciloleucel into the patient, these cells bind to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen that is expressed in all B-cell lineage malignancies. CD3 zeta is one of several membrane-bound polypeptides found in the TCR/CD3 complex; it regulates both the assembly and cell surface expression of TCR complexes. CD28 is essential for CD4+ T-cell proliferation, interleukin-2 production, and T-helper type-2 (Th2) development.	Axicabtagene Ciloleucel		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12030>	C61007	Cyclophosphamide/Cytarabine/Dexamethasone/Doxorubicin/Methotrexate/Pegaspargase/Thioguanine/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120310>	C147923|C129818	CYP17 Lyase Inhibitor ASN001|ASN001|EN-3356	An orally available non-steroidal, lyase-selective inhibitor of the steroid 17-alpha-hydroxylase/C17,20 lyase (CYP17A1 or CYP17), with potential anti-androgenic and antineoplastic activities. Upon oral administration, CYP17 lyase inhibitor ASN001 selectively binds to and inhibits the lyase activity of CYP17A1 in both the testes and adrenal glands, resulting in a significant reduction in androgen production to castrate-range levels. This may both decrease androgen-dependent growth signaling and inhibit the proliferation of androgen-dependent tumor cells. The cytochrome P450 enzyme CYP17A1, which is localized to the endoplasmic reticulum, exhibits both 17alpha-hydroxylase and 17,20-lyase activities; it plays a key role in the steroidogenic pathway. The selective inhibition of CYP17A1 lyase activity by ASN001 prevents the increased synthesis of mineralocorticoids that is normally seen with non-selective CYP17 inhibitors, which also inhibit the 17-alpha-hydroxylase activity of CYP17A1.	CYP17 Lyase Inhibitor ASN001		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120311>	C2124	Florbenguane F18|18F meta-Fluoro Benzylguanidine|18F-MFBG|18F-MFBG|FLORBENGUANE F-18|Florbenguane (18F)|IRP 101|IRP-101|Meta-fluoro Benzylguanidine F-18|[(18)F]-MFBG|meta-Fluorine F 18 Fluorobenzylguanidine|meta-[(18)F]-Fluorobenzylguanidine	A radioconjugate composed of the positron-emitting radioisotope fluorine F 18 labeled benzylguanidine, a synthetic analogue of the adrenergic neurotransmitter norepinephrine (NE), with potential use in the diagnostic imaging of human norepinephrine transporter (hNET)-expressing cells by either positron emitting tomography (PET) or computed tomography (CT). Upon administration, florbenguane F18 is taken up by and accumulates in both the granules of adrenal medullary chromaffin cells and the pre-synaptic granules of adrenergic neurons in a manner almost identical to that of NE. In turn, hNET-expressing tumor cells can be imaged by PET or CT. hNET, a transmembrane protein and regulator of catecholamine uptake normally restricted to the central and peripheral sympathetic nervous system, is overexpressed in certain tumor cell types.	Florbenguane F18		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C120312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120312>	C1946|C129825	Imofinostat|(E)-N-hydroxy-3-(1-(phenylsulfonyl)indolin-5-yl)acrylamide|3-(1-Benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxy-acrylamide|HDAC Inhibitor MPT0E028|IMOFINOSTAT|MPT 0E028|MPT-0E028|MPT0E028	An orally bioavailable N-hydroxyacrylamide-derived inhibitor of both human pan-histone deacetylase (HDAC) enzymes and the serine/threonine protein kinase Akt (protein kinase B), with potential antineoplastic activity. Upon administration, imofinostat selectively binds to and inhibits HDACs, which inhibits deacetylation of histone proteins and leads to the accumulation of highly acetylated histones. This may result in both an induction of chromatin remodeling, and the selective transcription of tumor suppressor genes. This prevents cell division and induces both cell cycle arrest and apoptosis, which may inhibit the proliferation of susceptible tumor cells. In addition, imofinostat inhibits the phosphorylation and activation of Akt, which prevents the activation of downstream signaling pathways, independent of its HDAC inhibitory activity. HDACs, upregulated in many tumor cell types, are a family of enzymes that deacetylate histone proteins. Akt, overexpressed in many tumor cell types, plays a key role in tumor cell proliferation and survival.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120313>	C2182	S-equol|(-)-Equol|(3S)-3,4-dihydro-3-(4-hydroxyphenyl)-2H-1-benzopyran-7-ol|2H-1-benzopyran-7-ol, 3,4-Dihydro-3-(4-hydroxyphenyl)-, (3S)-|EQUOL	An orally bioavailable, non-steroidal estrogen naturally produced by the metabolism of the isoflavonoid daidzein by human intestinal microflora, with potential chemoprotective and estrogen receptor (ER) modulating activities. S-equol preferentially binds to and activates the beta isoform of ER in certain target tissues, while having an antagonistic effect in other tissues. This modulates the expression of ER-responsive genes in a tissue-specific manner. This agent may increase bone mineral density, affect vasomotor symptoms, and may decrease the proliferation rate of susceptible cancer cells. In addition, this agent interferes with the activity of enzymes involved in steroid biosynthesis. S-equol inhibits dihydrotestosterone (DHT) production and may inhibit the proliferation of androgen-driven prostate cancer. S-equol is the biologically active enantiomer while R-equol is essentially inactive and has a weak affinity for alpha-ER.	S-equol		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120314>	C2189|C1931|C129986	Compound Kushen Injection|CKI|Yanshu Injection	A traditional Chinese medicine (TCM) formulation composed of compound Kushen injection (CKI) containing aqueous extracts from the roots of Kushen (Radix Sophorae Flavescentis) and Baituling (Rhizoma smilacis Glabrae), with potential antineoplastic and immunomodulating activities. CKI contains numerous chemicals including alkaloids, such as matrine and oxymatrine, flavonoids, alkylxanthones, quinones, triterpene glycosides, fatty acids, and essential oils. Although the exact mechanism(s) of action through which CKI exerts its effects has yet to be fully elucidated, CKI is able to interfere with the activation of various signal transduction pathways, such as the Wnt/beta-catenin signaling pathway, inhibit nuclear factor-kappa B (NF-KB) activation, and block the activity of multiple receptor tyrosine kinases, such as epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR). CKI induces apoptosis in and inhibits proliferation, migration, invasion and adhesion of tumor cells. CKI also modulates the production of inflammatory mediators.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120315>	C1323	Ibuprofen Injection|Caldolor	A formulation for intravenous injection containing ibuprofen, a propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID), with anti-inflammatory, analgesic, and antipyretic activities. Upon intravenous injection, ibuprofen inhibits the activity of the enzymes cyclooxygenase I (COX-1) and II (COX-2), resulting in a decreased formation of precursors of prostaglandins and thromboxanes. Inhibition of COX-2 specifically blocks the conversion of arachidonic acid (AA) to prostaglandins, which mediate inflammation, fever and pain.			Organic Chemical|Pharmacologic Substance	NCI Drug Dictionary Terminology
C120316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120316>	C133878|C129822	Anti-EGFR Monoclonal Antibody GC1118|GC1118	A recombinant, human monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Upon intravenous administration, GC1118 binds to and blocks the ligand binding site of EGFR, which prevents receptor dimerization and activation. This may lead to an inhibition of both EGFR-dependent downstream pathways and EGFR-dependent tumor cell proliferation and metastasis. EGFR, a receptor tyrosine kinase, may be overexpressed on the surfaces of various tumor cell types.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120317>	C20401|C129822	Anti-CD157 Monoclonal Antibody MEN1112|MEN1112	A humanized, Fc engineered, de-fucosylated monoclonal immunoglobulin G1 (IgG1) antibody directed against the bone marrow stromal cell antigen 1 (BST1/CD157), with potential antineoplastic activity. Upon intravenous infusion, anti-CD157 monoclonal antibody MEN1112 specifically binds to and induces an antibody dependent cell cytotoxic (ADCC) response against CD157-expressing tumor cells. CD157, also known as ADP-ribosyl cyclase 2, is a glycosyl-phosphatidylinositol (GPI)-anchored transmembrane protein belonging to the ADP-ribosyl-cyclase family and is overexpressed on certain cancer cell types. Fc-optimization of MEN1112, which involves the removal of fucose residues from its Fc domain, allows for enhanced Fc-gamma receptor binding on effector cells, such as natural killer (NK) cells, and further enhances tumor cell lysis.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120318>	C129839	Procaspase Activating Compound-1 VO-100|PAC-1|PAC-1|PAC-1 VO-100|VO-100	An orally bioavailable procaspase activating compound-1 (PAC-1), with potential proapoptotic and antineoplastic activities. Upon administration, VO-100 binds to and forms a chelating complex with zinc (Zn) ions inside cells, which prevents the binding of Zn ions to procaspase-3 (PC3) and abrogates the Zn-mediated inhibition of PC3. This allows for the proteolytic autoactivation of PC3 into the active form caspase-3. This results in the selective caspase-3-mediated induction of apoptosis and cell death in cancer cells. In addition, VO-100 is able to cross the blood-brain-barrier (BBB). PC3, a Zn-inhibited proenzyme, is upregulated in a variety of cancer cell types, while its expression is minimal in normal healthy cells.	Procaspase Activating Compound-1 VO-100		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120319>	C201688	Cemdisiran|AD-62643 Free Acid|ALN-62643 Free Acid|ALN-CC5|CEMDISIRAN|GalNAc-siRNA Conjugate ALN-CC5	A proprietary formulation composed of small-interfering RNAs (siRNAs) directed against terminal complement component 5 (C5) of the complement pathway conjugated to a N-acetylgalactosamine (GalNAc) ligand, which has potential use in the treatment of complement-mediated diseases, such as paroxysmal nocturnal hemoglobinuria (PNH). Upon subcutaneous administration of cemdisiran, the GalNAc ligand moiety specifically binds to and is taken up by the asialoglycoprotein receptor (ASGPR) expressed on hepatocytes. Inside the cell, the siRNAs bind to C5 mRNAs, which results in the inhibition of both the translation and expression of the C5 protein. This lowers plasma C5 levels, prevents C5 cleavage into pro-inflammatory components and blocks complement-mediated hemolysis. C5, a complement pathway protein, is expressed at high levels by the liver.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C12031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12031>	C61007	EGFR Antisense DNA/Sargramostim			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120320>	C12470	Glabrous Skin	Skin that is naturally hairless.			Anatomical Structure	
C120321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120321>	C12470	Non-Glabrous Skin	Hairy skin.			Anatomical Structure	
C120322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120322>	C12904	Pectoral Lymph Node|PECTORAL LYMPH NODE|Pectoral Nodes|Structure of pectoral axillary lymph node (body structure)	An axillary lymph node located along the lower edge of the pectoralis minor.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL Authorized Value Terminology|HL Biopsy/Surgical Procedures Table|HL Lesion Characteristics Table|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C120323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120323>	C20993	Dot Locations Learning	A component of the Children's Memory Scale. A child is presented with an array of dots (6 or 8 positions depending upon the child's age), which is learned over 3 trials. A distractor array is then presented. The child is then asked to reproduce the initial array either immediately, or following a 30 minute delay.			Intellectual Product	Children's Memory Scale
C120324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120324>	C20993	Dot Locations Short Delay	A component of the Children's Memory Scale. A child is presented with an array of dots (6 or 8 positions depending upon the child's age), which is learned over 3 trials. Immediately following a distractor array the child is asked to reproduce the initial array.			Intellectual Product	Children's Memory Scale
C120325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120325>	C20993	Dot Locations Long Delay	A component of the Children's Memory Scale. A child is presented with an array of dots (6 or 8 positions depending upon the child's age), which is learned over 3 trials. A distractor array is then presented. Following a 30 minute delay, the child is then asked to reproduce the initial array.			Intellectual Product	Children's Memory Scale
C120326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120326>	C20993	Stories Immediate	A component of the Children's Memory Scale. Two stories are read to the child, and the child is asked to repeat each story immediately after it is told.			Intellectual Product	Children's Memory Scale
C120327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120327>	C20993	Stories Delayed	A component of the Children's Memory Scale. Two stories are read to the child. After a delay of about 30 minutes the child is asked to retell each story.			Intellectual Product	Children's Memory Scale
C120328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120328>	C20993	Stories Delayed Recognition	A component of the Children's Memory Scale. Two stories are read to the child. After a delay of about 30 minutes the child is asked yes/no questions about each story.			Intellectual Product	Children's Memory Scale
C120329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120329>	C20993	Faces Immediate	A component of the Children's Memory Scale. A series of faces are presented one at a time. The child is then asked to say yes or no if the face being presented was one of the faces from the initial list.			Intellectual Product	Children's Memory Scale
C12032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12032>	C61007	EGFR Antisense DNA/Keyhole Limpet Hemocyanin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120330>	C20993	Faces Delayed	A component of the Children's Memory Scale. A series of faces are presented one at a time. After a delay of about 30 minutes the child is asked whether or not each face was one of the faces on the initial list.			Intellectual Product	Children's Memory Scale
C120331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120331>	C20993	Word Pairs Learning	A component of the Children's Memory Scale. A child is read a list of paired words and then asked to say the second word after being told the first. The list is presented three times in this fashion.			Intellectual Product	Children's Memory Scale
C120332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120332>	C20993	Word Pairs Immediate	A component of the Children's Memory Scale. A child is read a list of paired words and then asked to say the second word after being told the first. The list is presented three times in this fashion. After the third list/cued recall trial the child is asked to tell the examiner as many word pairs as they can with no cues.			Intellectual Product	Children's Memory Scale
C120333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120333>	C20993	Word Pairs Delayed	A component of the Children's Memory Scale. A child is read a list of paired words and then asked to say the second word after being told the first. The list is presented three times in this fashion. After about 30 minutes the child is given the cued recall trial again.			Intellectual Product	Children's Memory Scale
C120334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120334>	C20993	Word Pairs Delayed Recognition	A component of the Children's Memory Scale. A child is read a list of paired words and then asked to say the second word after being told the first. The list is presented three times in this fashion. After about 30 minutes the child is asked whether or not various pairs were on the list.			Intellectual Product	Children's Memory Scale
C120335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120335>	C20993	Numbers Forward	A component of the Children's Memory Scale. A child is asked to repeat a series of numbers of gradually increasing length.			Intellectual Product	Children's Memory Scale
C120336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120336>	C20993	Numbers Backward	A component of the Children's Memory Scale. A child is asked to repeat a series of numbers of gradually increasing length, but in reverse order.			Intellectual Product	Children's Memory Scale
C120337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120337>	C25338	Dot Locations Total Score	The total score from the Children's Memory Scale Dot Locations Short Delay and Dot Locations Long Delay.			Quantitative Concept	Children's Memory Scale
C120338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120338>	C25338	Word Pairs Total Score	The total score from the Children's Memory Scale Word Pairs Immediate, Word Pairs Delayed, and Word Pairs Delayed Recognition.			Quantitative Concept	Children's Memory Scale
C120339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120339>	C25338	Numbers Total Score	The total score from the Children's Memory Scale Numbers Forward and Numbers Backward.			Quantitative Concept	Children's Memory Scale
C12033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12033>	C61063	Calcium Citrate/Cholecalciferol			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120340>	C25338	Sequences Total Score	The total score from the Children's Memory Scale Sequences subtests.			Quantitative Concept	Children's Memory Scale
C120341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120341>	C25338	Scaled Score	Conversion of a raw score on a test to a common scale that allows for a numerical comparison.			Quantitative Concept	Children's Memory Scale
C120342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120342>	C20993	Logical Memory I Subtest (WMS-IV)|Logical Memory I|WMS-IV Logical Memory I	A subtest of the Wechsler Memory Scale, 4th Edition that assesses narrative memory under a free recall condition. A short story is presented orally. Immediately after presentation of the story the subject is asked to recall the story from memory.			Intellectual Product	Wechsler Memory Scale - Fourth Edition
C120343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120343>	C20993	Logical Memory II Subtest (WMS-IV)|Logical Memory II|WMS-IV Logical Memory II	A subtest of the Wechsler Memory Scale, 4th Edition that assesses narrative memory under a free recall condition. A short story is presented orally. After a delay, the subject is asked to recall the story from memory.			Intellectual Product	Wechsler Memory Scale - Fourth Edition
C120344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120344>	C20993	Verbal Paired Associates I Subtest (WMS-IV)|Verbal Paired Associates I|WMS-IV Verbal Paired Associates I	A subtest of the Wechsler Memory Scale, 4th Edition that evaluates verbal memory for associated word pairs. After 10 or 14 word pairs are read to the subject, the first word of each pair is read, and the subject is asked to provide the corresponding word.			Intellectual Product	Wechsler Memory Scale - Fourth Edition
C120345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120345>	C20993	Verbal Paired Associates II Subtest (WMS-IV)|Verbal Paired Associates II|WMS-IV Verbal Paired Associates II	A subtest of the Wechsler Memory Scale, 4th Edition that evaluates verbal memory for associated word pairs. 10 or 14 word pairs are read to the subject. After a delay, the first word of each pair is read, and the subject is asked to provide the corresponding word.			Intellectual Product	Wechsler Memory Scale - Fourth Edition
C120346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120346>	C20993	Designs I Subtest (WMS-IV)|Designs I|WMS-IV Designs I	A subtest of the Wechsler Memory Scale, 4th Edition that evaluates immediate recall. The subject is shown a grid with 4-8 designs on a page for 10 seconds, which is then removed from view. The subject then selects the designs from a set of cards and places the cards in a grid in the same place as previously shown.			Intellectual Product	Wechsler Memory Scale - Fourth Edition
C120347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120347>	C20993	Designs II Subtest (WMS-IV)|Designs II|WMS-IV Designs II	A subtest of the Wechsler Memory Scale, 4th Edition that evaluates delayed recall as well as delayed recognition. The subject is shown a grid with 4-8 designs on a page for 10 seconds, which is then removed from view. After a delay, the subject is asked to recreate the pages shown in the immediate condition. Then, the subject is shown a series of grids and asked to select the two designs that are correct and in the same place as on the page shown in the immediate condition.			Intellectual Product	Wechsler Memory Scale - Fourth Edition
C120348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120348>	C20993	Visual Reproduction I Subtest (WMS-IV)|Visual Reproduction I|WMS-IV Visual Reproduction I	A subtest of the Wechsler Memory Scale, 4th Edition that assesses memory for nonverbal visual stimuli. A series of five designs is shown, one at a time, for 10 seconds each. After each design is presented, the subject is asked to draw the design from memory.			Intellectual Product	Wechsler Memory Scale - Fourth Edition
C120349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120349>	C20993	Visual Reproduction II Subtest (WMS-IV)|Visual Reproduction II|WMS-IV Visual Reproduction II	A subtest of the Wechsler Memory Scale, 4th Edition that assesses long-term visual-spatial memory for nonverbal visual stimuli. A series of five designs is shown, one at a time, for 10 seconds each. After a delay, the subject is asked to draw the designs shown in any order. Then, the subject is asked to choose which of six designs on a page matches the original design shown.			Intellectual Product	Wechsler Memory Scale - Fourth Edition
C12034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12034>	C61063	Calcium Gluconate/Cholecalciferol			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120350>	C20993	Spatial Addition Subtest (WMS-IV)|Spatial Addition|WMS-IV Spatial Addition	A subtest of the Wechsler Memory Scale, 4th Edition that evaluates visual-spatial working memory using a visual addition task. The subject is shown, sequentially, two grids with blue and red circles. The subject is then asked to add or subtract the location of the circles based on a set of rules.			Intellectual Product	Wechsler Memory Scale - Fourth Edition
C120351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120351>	C20993	Symbol Span Subtest (WMS-IV)|Symbol Span|WMS-IV Symbol Span	A subtest of the Wechsler Memory Scale, 4th Edition. The subject is briefly shown a series of abstract symbols on a page and then asked to select the symbols from an array of symbols, in the same order they were previously presented.			Intellectual Product	Wechsler Memory Scale - Fourth Edition
C120352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120352>	C205232	Block Design Subtest (WPPSI-IV)|BD|Block Design|WPPSI-IV Block Design	A subtest of the Wechsler Preschool and Primary Scale of Intelligence, 4th Edition that measures ability to analyze and synthesize abstract visual stimuli. The child views a model and/or a picture in a book and uses one- or two-color blocks to recreate the design.			Intellectual Product	Wechsler Preschool and Primary Scale of Intelligence - Fourth Edition
C120353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120353>	C205232	Picture Naming Subtest (WPPSI-IV)|PN	A subtest of the Wechsler Preschool and Primary Scale of Intelligence, 4th Edition that measures expressive language ability and language development. The child names depicted objects.			Intellectual Product	Wechsler Preschool and Primary Scale of Intelligence - Fourth Edition
C120354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120354>	C205232	Bug Search Subtest (WPPSI-IV)|BS|Bug Search|WPPSI-IV Bug Search	A subtest of the Wechsler Preschool and Primary Scale of Intelligence, 4th Edition that measures short-term visual memory, visual-motor coordination, cognitive flexibility, visual discrimination, and concentration. Working within a specified time limit, the child marks the bug in the search group that matches the target bug.			Intellectual Product	Wechsler Preschool and Primary Scale of Intelligence - Fourth Edition
C120355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120355>	C205232	Vocabulary Subtest (WPPSI-IV)|Vocabulary Subtest|WPPSI-IV Vocabulary	A subtest of the Wechsler Preschool and Primary Scale of Intelligence, 4th Edition. Depending on the age of the child, this subtest measures either receptive vocabulary or verbal comprehension.			Intellectual Product	Wechsler Preschool and Primary Scale of Intelligence - Fourth Edition
C120356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120356>	C205256	Block Design Subtest (WISC-V)|Block Design|WISC-V Block Design	A subtest of the Wechsler Intelligence Scale for Children, Fifth Edition that measures spatial perception, visual abstract processing, and problem solving.			Intellectual Product	Wechsler Intelligence Scale for Children - Fifth Edition
C120357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120357>	C205256	Digit Span Forward Subtest (WISC-V)|Digit Span Forward|WISC-V Digit Span Forward	A subtest of the Wechsler Intelligence Scale for Children, Fifth Edition. The subject is read a sequence of numbers and recalls the numbers in the same order.			Intellectual Product	Wechsler Intelligence Scale for Children - Fifth Edition
C120358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120358>	C205256	Digit Span Backward Subtest (WISC-V)|Digit Span Backward|WISC-V Digit Span Backward	A subtest of the Wechsler Intelligence Scale for Children, Fifth Edition. The subject is read a sequence of numbers and recalls the numbers in reverse order.			Intellectual Product	Wechsler Intelligence Scale for Children - Fifth Edition
C120359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120359>	C205256	Digit Span Sequencing Subtest (WISC-V)|Digit Span Sequencing|WISC-V Digit Span Sequencing	A subtest of the Wechsler Intelligence Scale for Children, Fifth Edition. The subject is read a sequence of numbers and recalls the numbers in ascending order.			Intellectual Product	Wechsler Intelligence Scale for Children - Fifth Edition
C12035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12035>	C61007	Calcium Gluconate/Cholecalciferol/Zoledronate			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120360>	C205256	Coding Subtest (WISC-V)|Coding|WISC-V Coding	A visual, paper, and pencil task subtest of the Wechsler Intelligence Scale for Children that requires the child to match numbers with symbols based on a "key" at the top of the page by drawing the correct symbol in the boxes provided. Coding measures visual processing speed, short-term visual memory, and the ability to shift the eyes efficiently back and forth between the "key" and the responses. This task requires fine motor skills (using a pencil) but does not require expressive language.			Intellectual Product	Wechsler Intelligence Scale for Children - Fifth Edition
C120361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120361>	C205256	Vocabulary Subtest (WISC-V Subtest)|Vocabulary Subtest|WISC-V Vocabulary	A subtest of the Wechsler Intelligence Scale for Children, Fifth Edition. The subject either names objects presented visually or defines words that are presented visually and orally.			Intellectual Product	Wechsler Intelligence Scale for Children - Fifth Edition
C120362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120362>	C205256	Symbol Search Subtest (WISC-V)|Symbol Search|WISC-V Symbol Search	A subtest of the Wechsler Intelligence Scale for Children that measures visual-perceptual and decision-making speed, as well as short-term visual memory, visual-motor coordination, inhibitory control, visual discrimination, psychomotor speed, sustained attention, and concentration.			Intellectual Product	Wechsler Intelligence Scale for Children - Fifth Edition
C120363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120363>	C205215	Coding Subtest (WAIS-IV)|Coding|WAIS-IV Coding	A subtest of the Wechsler Adult Intelligence Scale, 4th Edition that is sensitive to brain damage, dementia, age and depression. Using a paper key, the subject copies symbols that are paired with numbers within a specified time limit.			Intellectual Product	Wechsler Adult Intelligence Scale - Fourth Edition
C120364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120364>	C205215	Block Design Subtest (WAIS-IV)|Block Design|WAIS-IV Block Design	A subtest of the Wechsler Adult Intelligence Scale, 4th Edition that measures spatial perception, visual abstract processing, and problem solving.			Intellectual Product	Wechsler Adult Intelligence Scale - Fourth Edition
C120365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120365>	C205215	Digit Span Subtest (WAIS-IV)|Digit Span|WAIS-IV Digit Span	A subtest of the Wechsler Adult Intelligence Scale, 4th Edition that measures working memory, mental manipulation, cognitive flexibility, rote memory and learning, attention, and encoding. The subject is asked to recall numbers in the same order presented (digit span forward), reverse order (digit span backward), or recall the numbers in ascending order (digit span sequencing).			Intellectual Product	Wechsler Adult Intelligence Scale - Fourth Edition
C120366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120366>	C205215	Symbol Search Subtest (WAIS-IV)|Symbol Search|WAIS-IV Symbol Search	A subtest of the Wechsler Adult Intelligence Scale, 4th Edition that measures processing speed, short-term visual memory, visual-motor coordination, cognitive flexibility, visual discrimination, psychomotor speed, and speed of mental operation. The subject scans a search group and indicates whether one of the symbols in the target group matches.			Intellectual Product	Wechsler Adult Intelligence Scale - Fourth Edition
C120367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120367>	C205215	Vocabulary Subtest (WAIS-IV)|Vocabulary Subtest|WAIS-IV Vocabulary	Wechsler Adult Intelligence Scale, 4th Edition. The subject either names objects presented visually or defines words that are presented visually and orally.			Intellectual Product	Wechsler Adult Intelligence Scale - Fourth Edition
C120369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120369>	C113347	Acquired Hypogonadotropic Hypogonadism	Hypogonadotropic hypogonadism, the cause of which is not present from birth.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C12036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12036>	C61063	Calcium Citrate/Cholecalciferol/Zoledronate			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120370>	C113348	Follicle Stimulating Hormone Receptor Deficiency|FSH Receptor Deficiency|FSH Receptor Deficiency	Reduced or absent function of the receptor for follicle stimulating hormone associated with a mutation in the FSHR gene.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C120371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120371>	C120168	Bio-Inactive Somatotropin|Bio-Inactive Growth Hormone|Bio-inactive Growth Hormone	Bio-inactive somatotropin is encoded by mutated forms of the human GH1 gene. This protein lacks biological activity and is associated with a phenotype of functional growth hormone deficiency.			Amino Acid, Peptide, or Protein	NICHD Terminology|Pediatric Endocrinology Terminology
C120372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120372>	C120165|C113217	Idiopathic Central Precocious Puberty	Central precocious puberty for which no underlying cause can be identified.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C120373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120373>	C36284	Sex Hormone-Binding Globulin Deficiency	Subnormal concentration of the glycoprotein, sex hormone-binding globulin (SHBG), the primary transport protein for androgens and estrogens in serum, resulting in reduced concentrations of total sex steroids, but minimal change in concentrations of free sex steroids.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C120374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120374>	C36285	DAX1 Deficiency|Cytomegalic Form of AHC|DSS-AHC Critical Region on the X Chromosome 1 Deficiency|Dosage Sensitive Sex Reversal - Adrenal Hypoplasia Congenita Critical Region On The X Chromosome 1 Deficiency|Dosage Sensitive Sex Reversal - Adrenal Hypoplasia Congenita Critical Region on the X Chromosome 1 Deficiency|NR0B1 Deficiency|Nuclear Receptor DAX1 Deficiency|Nuclear Receptor Subfamily 0 Group B Member 1 Deficiency|Nuclear Receptor Subfamily 0 Group B Member 1 Deficiency	Decreased activity of the nuclear receptor protein DAX1, caused by mutation(s) in the NR0B1 gene (on the X chromosome), resulting in adrenal hypoplasia congenita that may be associated with hypogonadotropic hypogonadism.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C120375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120375>	C27565	Disorder of Androgen Synthesis|Androgen Biosynthesis Defect	An enzyme deficiency in the androgen biosynthesis pathway, resulting in the underproduction of one or more androgens by the adrenal glands and/or gonads.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C120376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120376>	C27565	Mullerian Aplasia and Hyperandrogenism|WNT4 Deficiency|WNT4 Deficiency	Deficiency of the glycoprotein WNT4, associated with loss of function mutation(s) in the WNT4 gene. The condition in 46,XX individuals is characterized by mild hyperandrogenism, absence of underdevelopment of the uterus, and sometimes absence of underdevelopment of the vagina.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C120377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120377>	C94250	Childhood Overweight	A condition in which a child's body mass index (BMI) falls at or above the 85th percentile, but below the 95th percentile based on the normative values for the age and sex of the reference population.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C120378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120378>	C3283	Iatrogenic Obesity	Obesity resulting from medical treatment or intervention.			Sign or Symptom	NICHD Terminology|Pediatric Endocrinology Terminology
C120379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120379>	C3283	Polygenic Obesity	Obesity associated with variations in multiple genes.			Sign or Symptom	NICHD Terminology|Pediatric Endocrinology Terminology
C12037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12037>	C61063	Calcium Carbonate/Cholecalciferol/Zoledronate			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120380>	C3283	Exogenous Obesity|Common Obesity|Simple Obesity	Obesity caused by caloric intake greater than caloric expenditures.			Sign or Symptom	NICHD Terminology|Pediatric Endocrinology Terminology
C120381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120381>	C3283	Central Obesity|Central Adiposity|Truncal Obesity	Obesity in which excess fat is accumulated primarily in the area of the abdomen.			Sign or Symptom	NICHD Terminology|Pediatric Endocrinology Terminology
C120382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120382>	C3283	Monogenic Obesity	Obesity associated with an identifiable mutation in a single gene.			Sign or Symptom	NICHD Terminology|Pediatric Endocrinology Terminology
C120383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120383>	C36285	Melanocortin Pathway Defect|Melanocortin Pathway Defects	An abnormality in the biochemical pathway involving the melanocortins, a group of peptide hormones associated with anorexogenic signaling in the brain and hypothalamus.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C120384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120384>	C120383	Leptin Deficiency	Deficiency of the adipose tissue-derived peptide hormone leptin, associated with loss-of-function mutation(s) in the LEP gene.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C120385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120385>	C120383	Brain-Derived Neurotropic Factor Deficiency|BDNF Deficiency	Presumed deficiency of brain-derived neurotropic factor (BDNF), associated with loss-of-function mutation(s) in the BDNF gene.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C120386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120386>	C120383	Leptin Receptor Deficiency	Deficiency or dysfunction of the leptin receptor associated with loss-of-function mutation(s) in the LEPR gene.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C120387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120387>	C451	PML/RARA Single Fusion Probe|PML/RARA Dual Color Single Fusion Probe	A set of two DNA probes designed for use in FISH; one hybridizes to either the 15q22 region containing the PML gene or the 17q21.1 region containing the RARA gene. This probe set detects the PML/RARA fusion gene.			Nucleic Acid, Nucleoside, or Nucleotide	
C120388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120388>	C451	PML/RARa Dual Fusion Probe|PML/RARA Dual Color, Dual Fusion Translocation Probe	A mixture of three FISH DNA probes. Two probes hybridize to the 15q22 region containing the PML gene, one recognizes the 5' side of the break point and the other binds to the 3' side, while the third hybridizes to the 17q21.1 region containing the RARA gene. The PML probes are labeled with one fluorescent dye and the RARA probe is labeled with a different color fluorescence dye; therefore this probe set can uniquely distinguish intact and rearranged genes.			Nucleic Acid, Nucleoside, or Nucleotide	
C120389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120389>	C451	RARA Dual Color Break-Apart Rearrangement Probe|RARA Break-Apart Rearrangement Probe	A DNA FISH probe designed to detect chromosomal rearrangements involving the RARA gene region at chromosome 17q21.1. It is designed to differentially label the proximal and distal regions of RARA and can detect rearrangements between the RARA gene and any translocation partner.			Nucleic Acid, Nucleoside, or Nucleotide	
C12038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12038>	C61007	Etoposide/Ifosfamide/Imatinib Mesylate/Methotrexate			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120390>	C20993	List A Trials 1-5|List A Trials 1-5 (Total Trials)	The first part of the California Verbal Learning Test for Children. For the first five trials, a 15-item list, List A, is read to the child and he or she is asked to recall words from the list after each presentation.			Intellectual Product	California Verbal Learning Test, Children's Version
C120391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120391>	C20993	List A Trial 1 Free Recall	The first free recall task from List A of the California Verbal Learning Test for Children.			Intellectual Product	California Verbal Learning Test, Children's Version
C120392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120392>	C20993	List A Trial 5 Free Recall	The final free recall task from List A of the California Verbal Learning Test for Children.			Intellectual Product	California Verbal Learning Test, Children's Version
C120393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120393>	C120383	Pro-Opiomelanocortin Deficiency|POMC Deficiency|POMC Deficiency	Deficiency of the hormone precursor, pro-opiomelanocortin, associated with loss-of-function mutation(s) in the POMC gene.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C120394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120394>	C120383	Melanocortin 4 Receptor Deficiency|MC4R Deficiency|MC4R Deficiency	Deficiency or dysfunction of the melanocortin 4 receptor, associated with loss-of-function mutation(s) in the MCFR4 gene.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C120395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120395>	C20993	List B Free Recall (CVLT-C)	The second part of the California Verbal Learning Test for Children. A second list, List B, is presented, and the child is asked to recall as many words from this list as he or she can.			Intellectual Product	California Verbal Learning Test, Children's Version
C120396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120396>	C20993	List A Short Delay Free Recall	The third part of the California Verbal Learning Test for Children. Following the List B test, the child is asked to recall words from List A, without an additional presentation of the List A words.			Intellectual Product	California Verbal Learning Test, Children's Version
C120397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120397>	C185158	Long Delay Free Recall (CVLT-C)	The fourth part of the California Verbal Learning Test for Children. After a 20-minute non-verbal task, the child is asked to recall as many words as he or she can from List A.			Intellectual Product	California Verbal Learning Test, Children's Version
C120398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120398>	C20181	Perseverations|Repetitions	Repeats of words that have been previously mentioned on the same trial.			Classification	California Verbal Learning Test - Second Edition|California Verbal Learning Test, Children's Version
C120399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120399>	C20181	Intrusions	Inclusions of words that were not on the test list.			Classification	California Verbal Learning Test - Second Edition|California Verbal Learning Test, Children's Version
C12039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12039>	C61007	Cyclophosphamide/Daunorubicin/Dexamethasone/Imatinib Mesylate/Methotrexate/Pegaspargase/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1203>	C548|C129820	Recombinant Prothymosin Alpha|Prothymosin Alpha	A recombinant form of the endogenous polypeptide hormone that exerts immunomodulatory effects primarily on mononuclear cells.  Prothymosin alpha stimulates the production of various cytokines including granulocyte/macrophage colony stimulating factor (GM-CSF) alpha, gamma interferon (IFN) and interleukins such as IL-2.  This agent may also increase some tumor antigens expression, thus inducing better T lymphocyte responses to tumor cells.  Combined with chemotherapy, prothymosin alpha may exhibit significant anti-tumor effects.  This agent also helps to regenerate lymph node and bone marrow cells after treatment with certain toxic chemotherapeutics. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C120400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120400>	C217122	Discriminability Index	A measure of the ability of a child to identify correct words (hits) relative to the ability to reject wrong words (false positives).			Intellectual Product	California Verbal Learning Test, Children's Version
C120401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120401>	C25338	T-Score|T Score	A method for converting an individual score into a standard form. While similar to a z-score, t-score is used when the conversion is made without knowledge of the population standard deviation and mean.			Quantitative Concept	California Verbal Learning Test, Children's Version
C120402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120402>	C20993	Free Recall Trial 1	The first free recall task from the California Verbal Learning Test, second edition.			Intellectual Product	California Verbal Learning Test - Second Edition
C120403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120403>	C20993	Free Recall Trial 5	The final free recall task from the California Verbal Learning Test, second edition.			Intellectual Product	California Verbal Learning Test - Second Edition
C120404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120404>	C20993	Free Recall Trials 1-5	The first part of the California Verbal Learning Test, second edition. For the first five trials, a 15-item list, List A, is read to the subject and he or she is asked to recall words from the list after each presentation.			Intellectual Product	California Verbal Learning Test - Second Edition
C120405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120405>	C20993	Short Delay Free Recall	A part of the California Verbal Learning Test, second edition. Following a delay, the subject is asked to recall words, without an additional presentation of those words.			Intellectual Product	California Verbal Learning Test - Second Edition
C120406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120406>	C120383	Neurotropic Tyrosine Kinase Receptor Type 2 Deficiency|NTKR2 Deficiency|NTKR2 Deficiency|Neurotrophic Tyrosine Kinase, Receptor Type 2 Deficiency|Receptor Tyrosine Kinase B|TKRB Deficiency|TRKB Deficiency	Deficiency or dysfunction of the type 2 receptor for neurotropic tyrosine kinase associated with loss-of-function mutation(s) in the NTKR2 gene.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C120407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120407>	C120383	Prohormone Convertase 1 Deficiency|PCSK1 Deficiency|PCSK1 Deficiency|Prohormone Convertase 1/3 Deficiency	Deficiency or dysfunction of the enzyme prohormone convertase 1 associated with loss-of-function mutation(s) in the PCSK1 gene.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C120408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120408>	C28193	Chromosome 16p11.2 Deletion Syndrome	A microdeletion at 16p11.2, characterized by a predisposition to obesity, developmental delay and autism spectrum disorders.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C120409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120409>	C28193	Maternal Uniparental Disomy Chromosome 14 Syndrome|Temple Syndrome|Temple Syndrome|mUPD14 Syndrome|mUPD14 Syndrome	A cause of obesity that results from inheritance of two copies of chromosome 14 from the mother, and no copy of chromosome 14 from the father.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C12040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12040>	C61007	Asparaginase/Cytarabine/Imatinib mesylate			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120410>	C173347	Have Felt Unusual Fatigue Question|Have Felt Unusual Fatigue|Have you felt unusually tired or fatigued in the last week	A question about whether an individual feels or felt unusual fatigue.			Intellectual Product	Brief Fatigue Inventory
C120411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120411>	C173347	Fatigue Right Now Question|Fatigue Right Now|Rate your fatigue right now	A question about how an individual rates their fatigue right now.			Intellectual Product	Brief Fatigue Inventory
C120412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120412>	C173347	Usual Level of Fatigue Question|Rate your usual level of fatigue during past 24 hours|Usual Level of Fatigue	A question about how an individual rates their usual level of fatigue.			Intellectual Product	Brief Fatigue Inventory
C120413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120413>	C173347	Worst Level of Fatigue Question|Worst Level of Fatigue	A question about how an individual rates their worst level of fatigue.			Intellectual Product	
C120414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120414>	C176021|C173584|C173347	Fatigue Interferes with General Activity Question|Fatigue Interferes with General Activity|Fatigue Interferes with General Activity	A question about how an individual's fatigue interfered or interferes with their general activity.			Intellectual Product	Brief Fatigue Inventory
C120415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120415>	C173584|C173347	Fatigue Interferes with Mood Question|Fatigue Interferes with Mood|Fatigue Interferes with Mood	A question aboout how an individual's fatigue interfered or interferes with their mood.			Intellectual Product	Brief Fatigue Inventory
C120416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120416>	C173584|C173347|C173135	Fatigue Interferes with Walking Ability Question|Fatigue Interferes with Walking Ability|Fatigue Interferes with Walking Ability	A question aboout how an individual's fatigue interfered or interferes with their ability to walk.			Intellectual Product	Brief Fatigue Inventory
C120417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120417>	C173924|C173584|C173347	Fatigue Interferes with Work Question|Fatigue Interferes with Work|Fatigue Interferes with Work	A question aboout how an individual's fatigue interfered or interferes with their work.			Intellectual Product	Brief Fatigue Inventory
C120418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120418>	C173584|C173347	Fatigue Interferes with Relations with Other People Question|Fatigue Interferes with Relations with Other People|Fatigue Interferes with Relations with Other People	A question aboout how an individual's fatigue interfered or interferes with their relations with other people.			Intellectual Product	Brief Fatigue Inventory
C120419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120419>	C173584|C173347	Fatigue Interferes with Enjoyment of Life Question|Fatigue Interferes with Enjoyment of Life|Fatigue Interferes with Enjoyment of Life	A question aboout how an individual's fatigue interfered or interferes with their enjoyment of life.			Intellectual Product	Brief Fatigue Inventory
C12041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12041>	C61007	Cyclophosphamide/Dexamethasone/Etoposide/Imatinib Mesylate/Mercaptopurine/Methotrexate/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120420>	C85429	BFI Fatigue Rating Likert Scale	A scale for the subjective scoring of fatigue that ranges from 0: No Fatigue to 10: Fatigue As Bad As You Can Imagine.			Intellectual Product	Brief Fatigue Inventory
C120421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120421>	C85429	BFI Fatigue Interference Likert Scale	A scale for the subjective scoring of fatigue interference that ranges from 0: Does Not Interfere to 10: Completely Interferes.			Intellectual Product	Brief Fatigue Inventory
C120422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120422>	C175266	Fatigue Rating Score 0	A subjective score of 0 on a fatigue scale that ranges from 0: No Fatigue to 10: Fatigue as bad as you can imagine.			Intellectual Product	Brief Fatigue Inventory
C120423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120423>	C175266	Fatigue Rating Score 1	A subjective score of 1 on a fatigue scale that ranges from 0: No Fatigue to 10: Fatigue as bad as you can imagine.			Intellectual Product	Brief Fatigue Inventory
C120424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120424>	C175266	Fatigue Rating Score 2	A subjective score of 2 on a fatigue scale that ranges from 0: No Fatigue to 10: Fatigue as bad as you can imagine.			Intellectual Product	Brief Fatigue Inventory
C120425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120425>	C175266	Fatigue Rating Score 3	A subjective score of 3 on a fatigue scale that ranges from 0: No Fatigue to 10: Fatigue as bad as you can imagine.			Intellectual Product	Brief Fatigue Inventory
C120426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120426>	C175266	Fatigue Rating Score 4	A subjective score of 4 on a fatigue scale that ranges from 0: No Fatigue to 10: Fatigue as bad as you can imagine.			Intellectual Product	Brief Fatigue Inventory
C120427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120427>	C175266	Fatigue Rating Score 5	A subjective score of 5 on a fatigue scale that ranges from 0: No Fatigue to 10: Fatigue as bad as you can imagine.			Intellectual Product	Brief Fatigue Inventory
C120428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120428>	C175266	Fatigue Rating Score 6	A subjective score of 6 on a fatigue scale that ranges from 0: No Fatigue to 10: Fatigue as bad as you can imagine.			Intellectual Product	
C120429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120429>	C175266	Fatigue Rating Score 7	A subjective score of 7 on a fatigue scale that ranges from 0: No Fatigue to 10: Fatigue as bad as you can imagine.			Intellectual Product	Brief Fatigue Inventory
C12042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12042>	C61007	Dexamethasone/Imatinib Mesylate/Mercaptopurine/Methotrexate/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120430>	C175266	Fatigue Rating Score 8	A subjective score of 8 on a fatigue scale that ranges from 0: No Fatigue to 10: Fatigue as bad as you can imagine.			Intellectual Product	Brief Fatigue Inventory
C120431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120431>	C175266	Fatigue Rating Score 9	A subjective score of 9 on a fatigue scale that ranges from 0: No Fatigue to 10: Fatigue as bad as you can imagine.			Intellectual Product	Brief Fatigue Inventory
C120432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120432>	C175266	Fatigue Rating Score 10	A subjective score of 10 on a fatigue scale that ranges from 0: No Fatigue to 10: Fatigue as bad as you can imagine.			Intellectual Product	Brief Fatigue Inventory
C120433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120433>	C92809	Adrenocorticotropic Hormone Deficiency|ACTH Deficiency|ACTH Deficiency|Corticotropin Deficiency|Secondary Adrenal Insufficiency|Secondary Hypoadrenalism	Subnormal concentration of adrenocorticotropic hormone (ACTH) resulting in decreased secretion of cortisol by the adrenal gland.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C120434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120434>	C120433	Acquired Adrenocorticotropic Hormone Deficiency|Acquired ACTH Deficiency|Acquired ACTH Deficiency	Adrenocorticotropic hormone (ACTH) deficiency, the cause of which is not present at birth.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C120435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120435>	C175268	Fatigue Interference Score 0	A subjective score of 0 on a fatigue scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.			Intellectual Product	Brief Fatigue Inventory
C120436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120436>	C175268	Fatigue Interference Score 1	A subjective score of 1 on a fatigue scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.			Intellectual Product	Brief Fatigue Inventory
C120437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120437>	C120433	Congenital Isolated Adrenocorticotropic Hormone Deficiency|Congenital Isolated ACTH Deficiency|Congenital Isolated ACTH Deficiency	Adrenocorticotropic hormone (ACTH) deficiency due to mutation(s) in the TBX19 gene.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C120438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120438>	C175268	Fatigue Interference Score 2	A subjective score of 2 on a fatigue scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.			Intellectual Product	Brief Fatigue Inventory
C120439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120439>	C175268	Fatigue Interference Score 3	A subjective score of 3 on a fatigue scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.			Intellectual Product	Brief Fatigue Inventory
C12043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12043>	C61063	BMS-214662/Trastuzumab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120440>	C175268	Fatigue Interference Score 4	A subjective score of 4 on a fatigue scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.			Intellectual Product	Brief Fatigue Inventory
C120441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120441>	C175268	Fatigue Interference Score 5	A subjective score of 5 on a fatigue scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.			Intellectual Product	Brief Fatigue Inventory
C120442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120442>	C113144	Acquired Central Hypothyroidism	Central hypothyroidism, the cause of which is not present at birth.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C120443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120443>	C175268	Fatigue Interference Score 6	A subjective score of 6 on a fatigue scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.			Intellectual Product	Brief Fatigue Inventory
C120444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120444>	C175268	Fatigue Interference Score 7	A subjective score of 7 on a fatigue scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.			Intellectual Product	Brief Fatigue Inventory
C120445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120445>	C175268	Fatigue Interference Score 8	A subjective score of 8 on a fatigue scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.			Intellectual Product	Brief Fatigue Inventory
C120446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120446>	C92809	Isolated Glucocorticoid Deficiency|Familial Glucocorticoid Deficiency	Abnormally low or absent production of glucocorticoids, characterized by unresponsiveness to adrenocorticotropic hormone. It is hereditary and potentially lethal.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C120447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120447>	C175268	Fatigue Interference Score 9	A subjective score of 9 on a fatigue scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.			Intellectual Product	Brief Fatigue Inventory
C120448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120448>	C175268	Fatigue Interference Score 10	A subjective score of 10 on a fatigue scale that ranges from 0: Does Not Interfere to 10: Completely Interferes.			Intellectual Product	Brief Fatigue Inventory
C120449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120449>	C92809	Congenital Isolated Thyroid Stimulating Hormone Deficiency|Congenital Isolated TSH Deficiency|Congenital TSH Deficiency	Thyroid stimulating hormone (TSH) deficiency associated with mutations(s) in the TSHB gene that encodes thyrotropin subunit beta.			Laboratory or Test Result	NICHD Terminology|Pediatric Endocrinology Terminology
C12044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12044>	C61063	Amifostine/Carboplatin/Fluorouracil/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120450>	C13442	Cardiothoracic	Relating to the heart and chest.			Spatial Concept	
C120451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120451>	C41150	Social Security Retirement Benefit|Social Security	The money received by retired workers who have paid in to the Social Security system during their working years.			Group Attribute	
C120452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120452>	C41150	Pension	A fixed sum paid regularly to a person by their former employer.			Group Attribute	
C120453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120453>	C20181	Savings	Money assets set aside, especially in a bank or other financial organization.			Classification	
C120454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120454>	C5213	Male Malignant Nipple Neoplasm|Malignant neoplasm of nipple and areola, unspecified male breast	A malignant neoplasm that affects the area of the nipple in males.			Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|mCode Cancer Disorder Value Set|mCode Elixhauser Malignant Solid Tumors without Metastases Value Set|mCode Primary Cancer Disorder Value Set|mCode Primary Malignant Neoplasm Disorder Value Set|mCode Terminology
C120455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120455>	C5213	Female Malignant Nipple Neoplasm|Malignant neoplasm of nipple and areola, unspecified female breast	A malignant neoplasm that affects the area of the nipple in females.			Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|mCode Cancer Disorder Value Set|mCode Elixhauser Malignant Solid Tumors without Metastases Value Set|mCode Primary Cancer Disorder Value Set|mCode Primary Malignant Neoplasm Disorder Value Set|mCode Terminology
C120456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120456>	C7548	Malignant Kidney Neoplasm Except Renal Pelvis|Malignant Kidney Neoplasm Except Pelvis|Malignant Kidney Neoplasm Except Pelvis|Malignant Neoplasm of Kidney Except Renal Pelvis	A malignant neoplasm that affects the renal parenchyma but not the renal pelvis.			Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology
C120457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120457>	C25338	Total Score	The sum of a set of numeric values.			Quantitative Concept	
C120458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120458>	C198997|C198996	Peer	Persons who are equal in one or more respects, including age, education, religion, sex, or social class.			Human	
C120459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120459>	C15320	Timeline Follow-back Protocol|TLFB	A clinical research method that entails using key calendar events or dates to prompt respondents to provide daily retrospective estimates over a specified time-period.			Research Activity	
C12045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12045>	C61063	Montanide ISA-51/Tyrosinase-related protein-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120460>	C171086	Fasting Status	The state of a subject that represents to what extent they have abstained from consuming food or liquid.			Qualitative Concept	
C120461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120461>	C42614	Clinical Outcome Assessment Subsection Name|COA Subsection Name	The textual header or description used to group a set of questions or tests in a clinical outcome assessment instrument.			Conceptual Entity	
C120462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120462>	C38640	Circulating Clonotypic B-Cell|CCBC|Circulating Clonotypic B Cell|Circulating Clonotypic B Lymphocyte|Circulating Clonotypic B-Lymphocyte	A B-lymphocyte that is hyperdiploid, has clonotypic IgH gene rearrangements, and is found in the peripheral blood of patients with monoclonal gammopathy of undetermined significance or multiple myeloma.	Circulating Clonotypic B-Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C120463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120463>	C12555	Fibrocyte	A quiescent connective tissue cell with minimal cytoplasm and little to no evidence of protein synthesis. These cells may be able to differentiate into fibroblasts.	Fibrocyte		Cell	CTRP Biomarker Terminology|CTRP Terminology
C120464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120464>	C94509	Intratumoral Genetic Heterogeneity|Intratumoral Genetic Diversity	A heterogeneous distribution of mutations within a single neoplasm.	Intratumoral Genetic Heterogeneity		Qualitative Concept	CTRP Biomarker Terminology|CTRP Terminology
C120465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120465>	C36335	Homologous Recombination Deficiency|HRD|HRR Deficiency|Homologous Recombination Repair Deficiency	A DNA repair abnormality caused by mutations in one or more genes that are involved in homologous recombination repair. Deficient homologous recombination is associated with numerous neoplastic diseases and developmental disorders related to chromosomal nondisjunction.	Homologous Recombination Deficiency		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120466>	C85870	Large-Scale State Transition|LST|Large Scale State Transition	Chromosomal breakage that generates 10 Mb or larger fragments. The quantification of these breaks can be used as a surrogate measure for genomic instability, which may be caused by mutation of DNA repair genes, including BRCA1 or BRCA2.	Large-Scale State Transition		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Terminology
C120467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120467>	C1916	Nitrite|NITRITE ION|Nitrite Anion|Nitrite Ion|Nitrite(1-)|Nitrogen Dioxide Ion(1-)|Nitrogen Peroxide Ion(1-)|Nitrogen Protoxide|Nitrous Acid, Ion(1-)	A nitrogen oxoanion that is formed when nitrous acid is deprotonated. As nitrite is a metabolic end product for nitric oxide (NO), which is increased during inflammation; nitrite levels can be used to assess NO production and thus inflammation.	Nitrite		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C120468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120468>	C2289	16alpha-Hydroxyestrone|16 Alpha OHE|16-alphaOHE1|16.ALPHA.-HYDROXYESTRONE|16alpha-Hydroxy E1|16alpha-OH Estrone|16alpha-OHE|3,16alpha-Dihydroxyestra-1,3,5(10)-Trien-17-One|Estra-1,3,5(10)-Trien-17-One, 3,16-Dihydroxy-, (16alpha)-|Estra-1,3,5(10)-Triene-3,16alpha-Diol-17-One|Hydroxyestrone-16alpha	A metabolite formed during the catabolism of estrone by the liver through the hydroxylation of the carbon at position 16 by cytochrome P450 (CYP) family enzymes, including CYP3A4 and 3A5, with potential carcinogenic activity. With increased estrogenic activity compared to the parent compound, 16alpha-hydroxyestrone (16alpha-OHE1) increases the expression of ER-responsive genes, which leads to increased proliferation of susceptible tumor cells. The ratio between the two estrogen metabolites, 2-hydroxyestrone (2-OHE1), a weak estrogen and metabolite from the 2-hydroxylation pathway, and 16alpha-OHE1, a metabolite from the 16-hydroxylation pathway, may be used to assess the risk of certain cancers; a higher ratio of 2-OHE1:16alpha-OHE1 correlates with decreased cancer risk.	16alpha-Hydroxyestrone		Organic Chemical|Pharmacologic Substance	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C120469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120469>	C2181	4-Methoxyestradiol|4-MeE2|4-MeOE2|4-Methoxyestradiol-17 Beta|4-Methoxyestradiol-17beta|Estra-1,3,5(10)-Triene-3,17-Diol, 4-Methoxy-, (17beta)-	An endogenous metabolite formed during the O-methylation of the highly carcinogenic catechol estrogen 4-hydroxyestradiol (4-OHE2) by catechol-O-methyltransferase (COMT), with potential anti-proliferative activity. Even though the exact mechanism of action through which 4-methoxyestradiol (4-MeE2) exerts its effect is not fully elucidated, this chemical appears to have antiproliferative and apoptosis-inducing activities in susceptible tumor cells.	4-Methoxyestradiol		Organic Chemical|Pharmacologic Substance	CTRP Biomarker Terminology|CTRP Terminology
C12046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12046>	C61063	Interleukin-2/Montanide ISA-51/Tyrosinase-Related Protein-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120470>	C843	4-Methoxyestrone|4-MeE1|4-MeOE1|4-OMeE1	A metabolite formed during the methylation of 4-hydroxyestrone (4-OHE1) by catechol-O-methyltransferase (COMT) and devoid of any oncogenic or anticarcinogenic activities. The 4-methoxyestrone (4-MeOE1):4-OHE1 ratio can be used to assess methylation efficiency and cancer risk. Lower 4-MeOE1:4-OHE1 ratios suggest inadequate methylation and increased risk of certain cancers.	4-Methoxyestrone		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C120471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120471>	C616	Sulfatide Compound|SM4|SULFATIDE|Sulfatide|Sulfatides|Sulfatides|Sulphatide|Sulphatide|Sulphatides	A class of sulfated galactosylceramides and a major lipid component in myelin.			Organic Chemical	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120472>	C2289	2-Methoxyestrone|2-METHOXYESTRONE|2-MeE1|2-MeOE1|2-OMeE1|3-Hydroxy-2-Methoxyestra-1,3,5(10)-Trien-17-One	A metabolite formed during the methylation of 2-hydroxyestrone (2-OHE1) by catechol-O-methyltransferase (COMT), with potential anticarcinogenic and minimal estrogen activities. The mechanism of action for the antitumor activity of 2-methoxyestrone (2-OMeE1) is not known. A high 2-methoxyestrone (2-OMeE1)/2-OHE1 ratio indicates higher methylation efficiency and correlates with a lower cancer risk.	2-Methoxyestrone		Organic Chemical|Pharmacologic Substance	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C120473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120473>	C347	4-Hydroxyestradiol|3,4,17beta-Estriol|3,4,17beta-Trihydroxy-1,3,5[10]-Estratriene|4-HYDROXYESTRADIOL|4-Hydroxy-17-Beta-Estradiol|4-Hydroxyestradiol-17beta|4-OH-Estradiol|4-OHE2|4OHE2|Estra-1,3,5(10)-Triene-3,14,17beta-Triol	A metabolite formed during the metabolism of 17beta-estradiol by hydroxylation of the carbon at position 4 by cytochrome P450 1B1, with potential carcinogenic activity. The mechanism of action for the tumor promoting activity of 4-hydroxyestradiol (4-OHE2) is not entirely known but this metabolite undergoes metabolic redox cycling with its oxidized quinoid form, estradiol 3,4-quinone, and generates reactive oxygen species (ROS), which induce oxidative DNA damage. 4-OHE2 also activates nuclear factor-kappaB (NF-kB) and extracellular signal-regulated kinase/mitogen-activated protein kinase pathways, and induces the expression of certain genes through activation of the estrogen receptor (ER), which stimulates cellular proliferation in susceptible cells.	4-Hydroxyestradiol		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C120474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120474>	C2289	2-Hydroxyestradiol|(17beta)-Estra-1,3,5(10)-Triene-2,3,17-Triol|2-HYDROXYESTRADIOL|2-Hydroxy-17beta-Estradiol|2-Hydroxyestradiol-17beta|2-OH-E2|2-OH-Estradiol|2-OHE2	A metabolite formed during the metabolism of 17beta-estradiol by hydroxylation of the carbon at position 2 by the CYP450 enzymes 1A1/1A2. Theoretically, 2-hydroxyestradiol (2-OHE2) is able to undergo redox cycling, which generates active radicals and induces DNA damage; however, this estradiol metabolite is very unstable in vivo and is quickly inactivated by catechol-O-methyltransferase (COMT)-mediated O-methylation and converted to 2-methoxyestradiol (2-MeE2). 2-MeE2 exerts antineoplastic activities through its estrogen receptor antagonistic effect and the induction of apoptosis in susceptible cancer cells.	2-Hydroxyestradiol		Organic Chemical|Pharmacologic Substance	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C120475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120475>	C1906	Neoantigen Peptide|Neo-Antigen Peptide	An immunogenic peptide sequence that is specifically expressed by a tumor and is not found in normal tissues. One or more of these tumor-associated antigens (TAAs) can be used to develop patient-specific tumor vaccines.	Neoantigen Peptide		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Agent Terminology|CTRP Biomarker Terminology|CTRP Terminology
C120476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120476>	C19899	S-Nitrosylation|SNO	A biochemical reaction that covalently attaches nitric oxide to the sulfur atom in an organic thiol.	S-Nitrosylation		Molecular Function	CTRP Biomarker Terminology|CTRP Terminology
C120477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120477>	C212874|C19899	Tyrosine Nitration|NT|Nitration of Tyrosine	A biochemical reaction that covalently attaches a nitro group to the carbon at position 3 of the side chain benzene ring of L-tyrosine.	Tyrosine Nitration		Molecular Function	CTRP Biomarker Terminology|CTRP Terminology
C120478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120478>	C16295	Latent Nuclear Antigen Antibody|Anti-HHV8 ORF73|Anti-KSHV LANA Antibody|Anti-LANA Antibody|Anti-Latency-Associated Nuclear Antigen Antibody|Anti-Latent Nuclear Antigen Antibody|HHV8 ORF73 Antibody|KSHV LANA Antibody|LANA Antibody|Latency-Associated Nuclear Antigen Antibody	Any immunoglobulin that recognizes the human herpesvirus 8 latent nuclear antigen protein.	Latent Nuclear Antigen Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120479>	C16295	Glycoprotein K8.1 Antibody|Anti-Glycoprotein K8.1 Antibody|Anti-KSHV ORF K 8.1 Antibody|Anti-k 8.1 Antibody|K 8.1 Antibody|KSHV ORF K 8.1 Antibody	Any immunoglobulin that recognizes the human herpesvirus 8 glycoprotein K8.1.	Glycoprotein K8.1 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12047>	C61063	Carboplatin/Flavopiridol			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120480>	C116403	Adenovirus Type 5 Antibody|Ad5 Antibody|Adenovirus Serotype 5 Antibody|Anti-Ad5 Antibody|Anti-Adenovirus Serotype 5 Antibody|Anti-Adenovirus Type 5 Antibody	An antibody produced in response to exposure to adenovirus serotype 5.	Adenovirus Type 5 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C120481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120481>	C171257	Personal Vaporizer|Vape Pen|Vaporizer|Vaporizer Device|Vaporizer Pen	A battery-powered atomizer designed to aerosolize a liquid solution for inhalation.			Manufactured Object	
C120482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120482>	C128795	Electronic Cigarette|Electronic Nicotine Delivery System|e-Cigarette	A battery-powered electronic device designed to atomize a nicotine-containing liquid solution for inhalation in a manner that simulates smoking a tobacco cigarette.	Electronic Cigarette		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C120483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120483>	C117186	L-Type Amino Acid Transporter|LAT|Leucine Type Transporter	A family of heterodimeric protein complexes that mediate the transport of neutral amino acids, including L-leucine. These complexes are comprised of an invariant heavy chain 4F2 cell-surface antigen heavy chain, which is encoded by the SLC3A2 gene, and one of four light chains, large neutral amino acids transporter small subunit 1 (SLC7A5), Y+L amino acid transporter 2 (SLC7A6), Y+L amino acid transporter 1 (SLC7A7), or large neutral amino acids transporter small subunit 2 (SLC7A8).	L-Type Amino Acid Transporter		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120484>	C18520	Oxylipin Metabolomic Profile|Oxylipin Metabolome	The identification and quantification of oxidized polyunsaturated fatty acids (oxylipins) in a biospecimen. In humans, the oxidized products are usually eicosanoids and the enzymes that produce specific eicosanoids are well characterized. Therefore, the oxylipin profile can indirectly identify the fatty acid oxidizing enzymes that are active in the sample.	Oxylipin Metabolomic Profile		Functional Concept	CTRP Biomarker Terminology|CTRP Terminology
C120485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120485>	C48182	Androgen Receptor-Dependent Gene Signature|AR Gene Signature|AR-Dependent Gene Signature	A system that specifically determines the expression of genes that are dependent on the hormone-dependent transcriptional activation associated with androgen binding to the androgen receptor.	Androgen Receptor-Dependent Gene Signature		Functional Concept	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120486>	C16295	Tn Antigen-MUC1-32mer Antibody|Anti-Tn Antigen-MUC1-32mer Antibody|Anti-Tn-MUC1-32mer|Anti-Tn-MUC1-32mer Antibody|Tn-MUC1-32mer Antibody	Any immunoglobulin that recognizes a conjugate immunogen comprised of the carbohydrate antigen Tn and 32 amino acids of mucin-1 protein.	Tn Antigen-MUC1-32mer Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120487>	C16295	Tn Antigen Antibody|Anti-Tn Antibody|Anti-Tn Antigen Antibody|Tn Antibody	Any immunoglobulin that recognizes Tn antigen, which is comprised of N-acetylgalactosamine (GalNAc) bound to serine or threonine protein residues by O-linked glycosylation.	Tn Antigen Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C120488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120488>	C16295	Sialyl-Tn Antigen Antibody|Anti-Sialyl Tn Antibody|Anti-Sialyl-Tn Antigen Antibody|Anti-sTn Antibody|Sialyl Tn Antibody|sTn Antibody	Any immunoglobulin that recognizes the sialylated form of the Tn antigen.	Sialyl-Tn Antigen Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C120489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120489>	C16295	Thomsen-Friedenreich Antigen Antibody|Anti-TF Antigen Antibody|Anti-Thomsen-Friedenreich Antigen Antibody|TF Antibody	Any immunoglobulin that recognizes Thomsen-Friedenreich antigen, a disaccharide, comprised of galactose and N-acetylgalactosamine, that is bound through O-linked glycosylation serine or threonine residues in mucin proteins.	Thomsen-Friedenreich Antigen Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C12048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12048>	C61063	Cyclophosphamide/Fludarabine/Oblimersen			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120490>	C16295	Ganglioside GM2 Antibody|Anti-GM2 Antibody|Anti-Ganglioside GM2 Antibody|GM2 Antibody	Any immunoglobulin that recognizes the glycosphingolipid antigen ganglioside GM2.	Ganglioside GM2 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C120491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120491>	C17660|C17530	IGF1R Gene Product	A protein encoded by the IGF1R gene.	IGF1R Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120492>	C120491	Insulin-Like Growth Factor 1 Receptor Beta Chain|CD221 Antigen Beta Chain|IGF-IR Beta|IGF-IR Beta Chain|IGF1R Beta|IGF1R Beta Chain	Insulin-like growth factor 1 receptor beta chain (627 aa, ~71 kDa) is encoded by the human IGF1R gene. This protein plays a role in growth factor-mediated receptor tyrosine kinase activity.	Insulin-Like Growth Factor 1 Receptor Beta Chain		Amino Acid, Peptide, or Protein|Enzyme|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120493>	C20130	Hedgehog Family|Hedgehog Family Protein|Hedgehog Protein	A family of extracellular proteins that act as signaling molecules and regulate embryonic patterning events during development. They are synthesized as inactive precursors with an N-terminal signaling domain linked to a C-terminal autoprocessing domain, which has a structure that resembles intein protein splicing domains.	Hedgehog Family		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120494>	C48182	PAM50 Gene Expression Signature|PAM50|Prediction Analysis of Microarray 50|Prosigna Breast Cancer Prognostic Gene Signature Assay	A diagnostic and prognostic system for breast cancer that can both classify a tumor as one of four intrinsic subtypes (luminal A, luminal B, HER2-enriched, or basal-like) and generate a score that reflects the patient's risk of disease recurrence. This system is based on the expression profile of 50 genes in a surgically resected breast cancer sample.	PAM50 Gene Expression Signature		Functional Concept	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120495>	C16295	Keyhole Limpet Hemocyanin Antibody|Anti-KLH Antibody|Anti-Keyhole Limpet Hemocyanin Antibody|KLH Antibody	Any immunoglobulin that recognizes keyhole limpet hemocyanin protein.	Keyhole Limpet Hemocyanin Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C120496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120496>	C16295	Anti-Yeast Antibody|Yeast Antibody	An antibody produced in response to exposure to yeast.	Anti-Yeast Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C120497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120497>	C217121	EORTC QLQ-C30 Health and Quality of Life Rating Scale|EORTC QLQ-C30|Health and Quality of Life Likert Scale|Health and Quality of Life Rating Scale	A scale used both for the subjective scoring of a person's overall health, and for their quality of life, that ranges from 1: Very Poor to 7: Excellent.			Intellectual Product	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30|OS Authorized Value Terminology|OS Patient Reported Outcomes Metadata Table
C120498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120498>	C221019	Health and Quality of Life Rating Score 1	A subjective score of 1 on a scale that ranges from 1: Very Poor to 7: Excellent.			Intellectual Product	EORTC QLQ-C30 Health and Quality of Life Rating Scale
C120499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120499>	C221019	Health and Quality of Life Rating Score 2	A subjective score of 2 on a scale that ranges from 1: Very Poor to 7: Excellent.			Intellectual Product	EORTC QLQ-C30 Health and Quality of Life Rating Scale
C12049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12049>	C61063	Triapine/Cisplatin|3-AP/cisplatin|3AP/CDDP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1204>	C2141|C2139	Polysaccharide-K|Glycoproteins|KS-2|Krestin|Krestin|PSK	A protein-bound polysaccharide derived from the mushroom Trametes versicolor (Turkey Tail) with immunoadjuvant and potential antitumor activities. Although its mechanism of action has yet to be fully elucidated, in vitro and in vivo studies indicate that polysaccharide-K induces peripheral blood monocyte secretion of IL-8 and TNF-alpha, induces T cell proliferation, and prevents cyclophosphamide-induced immunosuppression. This agent has also been reported to stimulate macrophages to produce reactive nitrogen intermediates and superoxide anions and to promote apoptosis in the promyelocytic leukemia cell line HL-60.	Polysaccharide-K		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120500>	C221019	Health and Quality of Life Rating Score 3	A subjective score of 3 on a scale that ranges from 1: Very Poor to 7: Excellent.			Intellectual Product	EORTC QLQ-C30 Health and Quality of Life Rating Scale
C120501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120501>	C221019	Health and Quality of Life Rating Score 4	A subjective score of 4 on a scale that ranges from 1: Very Poor to 7: Excellent.			Intellectual Product	EORTC QLQ-C30 Health and Quality of Life Rating Scale
C120502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120502>	C221019	Health and Quality of Life Rating Score 5	A subjective score of 5 on a scale that ranges from 1: Very Poor to 7: Excellent.			Intellectual Product	EORTC QLQ-C30 Health and Quality of Life Rating Scale
C120503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120503>	C221019	Health and Quality of Life Rating Score 6	A subjective score of 6 on a scale that ranges from 1: Very Poor to 7: Excellent.			Intellectual Product	EORTC QLQ-C30 Health and Quality of Life Rating Scale
C120504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120504>	C221019	Health and Quality of Life Rating Score 7	A subjective score of 7 on a scale that ranges from 1: Very Poor to 7: Excellent.			Intellectual Product	EORTC QLQ-C30 Health and Quality of Life Rating Scale
C120505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120505>	C217122|C21154	Voice Handicap Index-10|VHI-10|Voice Handicap Index-10 (VHI-10)	A 10 item self-assessment for adults to evaluate a patient's perception of their voice and the effects of their voice on their life.			Intellectual Product	
C120506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120506>	C173937	Voice Makes it Difficult to Hear Me Question|My voice makes it difficult for people to hear me|Voice Makes it Difficult to Hear Me	A question about how often an individual's voice makes it difficult for people to hear them.			Intellectual Product	Voice Handicap Index-10
C120507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120507>	C118873	Run Out of Air When Talking Question|I run out of air when I talk|Run Out of Air When Talking	A question about how often an individual runs out of air when talking.			Intellectual Product	Voice Handicap Index
C120508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120508>	C173398	Difficulty Understanding Me in Noisy Room Question|Difficulty Understanding Me in Noisy Room|People have difficulty understanding me in a noisy room	A question about how often other people have difficulty understanding an individual in a noisy room.			Intellectual Product	Voice Handicap Index-10
C120509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120509>	C173937	Sound of Voice Varies Throughout Day Question|Sound of Voice Varies Throughout Day|The sound of my voice varies throughout the day	A question about how often the sound of an individual's voice varies throughout the day.			Intellectual Product	Voice Handicap Index
C12050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12050>	C61063	Celecoxib/Cisplatin/Fluorouracil			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120510>	C173398|C173151	Family Has Difficulty Hearing Me When I Call Them in the House Question|Family Has Difficulty Hearing Me When I Call Them in the House|My family has difficulty hearing me when I call them throughout the house	A question about how often an individual's family has difficulty hearing them when they call out in the house.			Intellectual Product	Voice Handicap Index
C120511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120511>	C91102	Use Phone Less Often Question|I use the phone less often than I would like to|Use Phone Less Often	A question about how much less an individual uses the phone than they would like.			Intellectual Product	Voice Handicap Index
C120512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120512>	C173937	Tense When Talking Because of Voice Question|I'm tense when talking to others because of my voice|Tense When Talking Because of Voice	A question about how often an individual is tense when talking to others because of their voice.			Intellectual Product	Voice Handicap Index
C120513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120513>	C175989|C173937	Tend to Avoid Groups Because of My Voice Question|I tend to avoid groups of people because of my voice|Tend to Avoid Groups Because of My Voice	A question about how often an individual avoids groups because of their voice.			Intellectual Product	Voice Handicap Index
C120514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120514>	C173937	People Irritated by My Voice Question|Frequency People Irritated by My Voice|People Irritated by My Voice|People seem irritated with my voice	A question about how often people seem irritated by an individual's voice.			Intellectual Product	Voice Handicap Index
C120515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120515>	C173937	People Question Voice Problem Question|People Question Voice Problem|People ask, What's wrong with your voice	A question about how often an individual is questioned about what is wrong with their voice.			Intellectual Product	Voice Handicap Index-10
C120516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120516>	C205215	Digit Span Forward Subtest (WAIS-IV)	A subtest of the Wechsler Adult Intelligence Scale - Fourth Edition. The subject is read a sequence of numbers and recalls the numbers in the same order.			Intellectual Product	Wechsler Adult Intelligence Scale - Fourth Edition
C120517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120517>	C205215	Digit Span Backward Subtest (WAIS-IV)	A subtest of the Wechsler Adult Intelligence Scale - Fourth Edition. The subject is read a sequence of numbers and recalls the numbers in reverse order.			Intellectual Product	Wechsler Adult Intelligence Scale - Fourth Edition
C120518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120518>	C205215	Digit Span Sequencing Subtest (WAIS-IV)	A subtest of the Wechsler Adult Intelligence Scale - Fourth Edition. The subject is read a sequence of numbers and recalls the numbers in ascending order.			Intellectual Product	Wechsler Adult Intelligence Scale - Fourth Edition
C120519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120519>	C205232	Receptive Vocabulary Subtest (WPPSI-IV)	A subtest of the Wechsler Preschool and Primary Scale of Intelligence - Fourth Edition. It tests verbal comprehension by asking the child to select the picture that best represents the word the examiner reads aloud.			Intellectual Product	Wechsler Preschool and Primary Scale of Intelligence - Fourth Edition
C12051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12051>	C61063	Bevacizumab/Fluorouracil/Hydroxyurea			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120520>	C205232	Cancellation Subtest (WPPSI-IV)	A subtest of the Wechsler Preschool and Primary Scale of Intelligence - Fourth Edition. As a test of processing speed the child scans two arrangements of objects (one random, one structured) and marks target objects.			Intellectual Product	Wechsler Preschool and Primary Scale of Intelligence - Fourth Edition
C120521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120521>	C66830	CDISC SDTM Anti-Viral Outcome of Treatment Terminology|AVOUTTRT|Anti-Viral Outcome of Treatment|SDTM-AVOUTTRT	Terminology associated with the anti-viral outcome of treatment codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120522>	C66830	CDISC SDTM Holter ECG Results Terminology|HESTRESC|Holter ECG Results|SDTM-HESTRESC	Terminology associated with the Holter ECG results codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120523>	C66830	CDISC SDTM Holter ECG Test Code Terminology|HETESTCD|Holter ECG Test Code|SDTM-HETESTCD	Terminology associated with the Holter ECG test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120524>	C66830	CDISC SDTM Holter ECG Test Name Terminology|HETEST|Holter ECG Test Name|SDTM-HETEST	Terminology associated with the Holter ECG test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120525>	C77526|C66830	CDISC SDTM Immunogenicity Specimen Assessments Test Code Terminology|ISTESTCD|Immunogenicity Specimen Assessments Test Code|SDTM-ISTESTCD	Terminology associated with the immunogenicity specimen assessments test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120526>	C77526|C66830	CDISC SDTM Immunogenicity Specimen Assessments Test Name Terminology|ISTEST|Immunogenicity Specimen Assessments Test Name|SDTM-ISTEST	Terminology associated with the immunogenicity specimen assessments test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120527>	C66830	CDISC SDTM Microbiology Test Code Terminology|MBTESTCD|Microbiology Test Code|SDTM-MBTESTCD	Terminology associated with the microbiology test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120528>	C66830	CDISC SDTM Microbiology Test Name Terminology|MBTEST|Microbiology Test Name|SDTM-MBTEST	Terminology associated with the microbiology test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120529>	C77526	CDISC SEND Chronicity Terminology|CHRNCTY|Chronicity|SEND-CHRNCTY	Terminology associated with the chronicity codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12052>	C61063	Doxorubicin/PS-341			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120530>	C77526	CDISC SEND Distribution Terminology|DSTRBN|Distribution|SEND-DSTRBN	Terminology associated with the distribution codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120531>	C77526	CDISC SEND Non-Neoplastic Finding Type Terminology|NONNEO|Non-Neoplastic Finding Type|SEND-NONNEO	Terminology associated with the non-neoplastic finding type codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120532>	C77526	CDISC SEND Cardiovascular Test Code Terminology|SCVTSTCD|SEND Cardiovascular Test Code|SEND-SCVTSTCD	Terminology associated with the cardiovascular test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120533>	C77526	CDISC SEND Cardiovascular Test Name Terminology|SCVTST|SEND Cardiovascular Test Name|SEND-SCVTST	Terminology associated with the cardiovascular test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120534>	C77526	CDISC SEND Respiratory Test Code Terminology|SEND Respiratory Test Code|SEND-SRETSTCD|SRETSTCD	Terminology associated with the respiratory test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120535>	C77526	CDISC SEND Respiratory Test Name Terminology|SEND Respiratory Test Name|SEND-SRETST|SRETST	Terminology associated with the respiratory test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120536>	C77526	CDISC SEND Vital Signs Test Code Terminology|SEND Vital Signs Test Code|SEND-SVSTSTCD|SVSTSTCD	Terminology associated with the vital signs test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120537>	C77526	CDISC SEND Vital Signs Test Name Terminology|SEND Vital Signs Test Name|SEND-SVSTST|SVSTST	Terminology associated with the vital signs test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120538>	C45781	Cell Density|CELL DENSITY|CELLDENS|CELLDENS	A measurement of the number of cells per unit volume or area.			Quantitative Concept	CDISC SDTM Microscopic Findings Test Detail Terminology|CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Ophthalmic Examinations Test Code Terminology|CDISC SEND Ophthalmic Examinations Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C120539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120539>	C14209	Mucoromycotina	A taxonomic grouping of saprotrophic fungi in the Mucoromycotina subphylum.			Fungus	
C12053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12053>	C61063	Probenecid/10-Propargyl-10-Deazaaminopterin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120540>	C38060	Pupillometry	A technique used to measure the diameter of the pupil in response to stimuli.			Diagnostic Procedure	
C120541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120541>	C77194	Rhizomucor|RHIZOMUCOR	A genus of fungi within the phylum Zygomycota that are ubiquitous in nature and generally not considered pathogenic. Most members of the Rhizomucor genus are thermophillic, produce sporangiophores, sporangiospores, and sporangia, and produce rudimentary rhizoids. Though rarely shown to be agents of infection, Rhizomucor species may cause zygomycosis.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120542>	C16853	Specular Microscopy|SPECULAR MICROSCOPY	A noninvasive photographic technique used to visualize and examine the corneal endothelium, in which a source of light is projected onto the cornea and the subsequent image reflected from the optical interface between the corneal endothelium and the aqueous humor is captured.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120543>	C38060	Tonometry|Intraocular Pressure Measurement|TONOMETRY	A method in which pressure is applied to the surface of the cornea in order to flatten a prespecified area of the membrane, which is used to calculate intraocular pressure.	Tonometry		Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C120544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120544>	C50995	Virologic Response	A description of the change in viral disease status in response to treatment.			Finding	
C120545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120545>	C122008	Myocardial Contractility Measurement	An assessment of the intrinsic ability of the myocardium to contract, which subsequently determines the force (pressure) with which blood is ejected from both ventricles, and contributes to measured values like blood pressure and cardiac output.			Diagnostic Procedure	
C120546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120546>	C575|C164034	Anti-CD20-engineered Toxin Body MT-3724|MT-3724|MT-3724	An engineered toxin body (ETB) composed of the single-chain variable fragment (ScFv) from an antibody targeting CD20 that is linked to a modified form of the ribosome-inactivating alpha subunit of Shiga-like toxin 1 (Shiga-like Toxin-1 A or SLT-1A), with antineoplastic activity. Upon administration, the ScFv moiety of anti-CD20-engineered toxin body MT-3724 targets and binds to the CD20 antigen expressed on tumor cells. Upon internalization, the SLT-1A moiety is released and acts as an N-glycosidase, which binds to and cleaves an adenine nucleobase in the 28S RNA component of the 60S subunit of ribosomes and prevents ribosome activity. This inhibits protein synthesis and eventually leads to apoptosis of CD20-expressing tumor cells. CD20, a B-cell specific transmembrane protein and tumor-associated antigen (TAA), is expressed during most stages of B-cell development and is often overexpressed in B-cell malignancies.	Anti-CD20-engineered Toxin Body MT-3724		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120547>	C20993	List B Free Recall (CVLT-II)	Part of the second section of the California Verbal Learning Test - Second Edition. A second list, List B, is presented, and the subject is asked to recall as many words from this list as he or she can.			Intellectual Product	California Verbal Learning Test - Second Edition
C120548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120548>	C185158	Long Delay Free Recall (CVLT-II)	The fourth part of the California Verbal Learning Test - Second Edition. After a 20-minute non-verbal task, the subject is asked to recall as many words as he or she can from List A.			Intellectual Product	California Verbal Learning Test - Second Edition
C120549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120549>	C93144	Lactobacillus-based Probiotic Capsule|Lactobacillus-based Capsule	A capsule containing a strain of the probiotic bacterium Lactobacillus with potential antimicrobial and immunomodulatory activities. As a dietary supplement, Lactobacillus, a naturally-occurring bacteria, may improve digestion and help maintain adequate colonization of the gastrointestinal (GI) tract by modulating the composition of the normal microflora. Because it produces lactic acid and hydrogen peroxide and other substances during fermentation, this bacterium creates an acidic environment that is unfavorable for pathogens. In addition, during colonization of the GI tract, this bacterium adheres to human epithelial cells and forms a protective barrier, thereby preventing the attachment of pathogens. Dietary supplementation with this bacterium has been shown to enhance innate and acquired immunity.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C12054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12054>	C61007	Bevacizumab/Cytarabine/Idarubicin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120550>	C2021|C200114	Idetrexed|BGC 945|IDETREXED|N-[4-[2-Propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-l-gamma-glutamyl-d-glutamic Acid|ONX 0801|ONX-0801|alpha-Folate Receptor-targeting Thymidylate Synthase Inhibitor ONX-0801	An alpha-folate receptor (aFR)-mediated inhibitor of thymidylate synthase (TS), with potential antineoplastic activity. Upon intravenous infusion, idetrexed selectively targets and binds to aFR-expressing tumor cells. Upon uptake by aFR, this agent binds to and inhibits TS. This reduces thymine nucleotide synthesis, inhibits both DNA synthesis and cell division, and leads to tumor cell apoptosis. TS catalyzes the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), an essential precursor for DNA synthesis, and plays a key role in cell growth and division. aFR, a cell-surface receptor glycoprotein, is overexpressed on various tumor cell types, but is minimally expressed by normal, healthy tissue.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120551>	C1935	Cannabis Extract Oil SR Capsule|Cannabics SR|Cannabis SR Capsule|Cannabis SR Capsules	A sustained-release (SR), oil-based oral capsule composed of a cannabis extract, which contains a variety of cannabinoids but is comprised mainly of tetrahydrocannabinol (THC), with potential anti-cachexic and analgesic activities. Upon oral administration, the cannabinoids bind to the cannabinoid G-protein coupled receptor CB1, which is located in both central and peripheral neurons; CB1 receptor activation inhibits adenyl cyclase, increases various signal transduction pathways, and modulates the activity of various ion channels. This provides an analgesic effect, increases appetite, decreases chemotherapy-induced nausea and vomiting, and improves weight gain. The formulation allows for the immediate release of cannabinoids and quick onset of action, which is followed by a gradual release of cannabinoids. The SR form facilitates longer lasting therapeutic effects and causes fewer psychoactive side effects when compared to non-SR cannabinoid-containing oral formulations.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C120552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120552>	C28681|C201547	Lifileucel|Amtagvi|Autologous TIL LN-144|Autologous Tumor Infiltrating Lymphocytes LN-144|Contego|LIFILEUCEL|LN 144|LN-144|LN144|Lifileuecel	A preparation of autologous tumor infiltrating lymphocytes (TILs), with potential antineoplastic activity. TILs are isolated from a patient's tumor tissue, cultured in vitro with high-dose interleukin-2 (lL-2), further selected based on antigen specificity and tumor reactivity, and the selected TILs are subsequently expanded. Upon re-introduction of lifileucel into the patient, the TILs re-infiltrate the tumor, specifically recognize the tumor-associated antigens (TAAs), and initiate tumor cell lysis. IL-2 induces the proliferation and expansion of TILs in vitro.	Lifileucel		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120553>	C62554	Pamiparib|5,6,7a,11-Tetraazacyclohepta(def)cyclopenta(a)fluoren-4(7H)-one, 2-Fluoro-5,8,9,10,10a,11-hexahydro-10a-methyl-, (10aR)-|BGB-290|PAMIPARIB|PARP Inhibitor BGB-290	An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP), with potential antineoplastic activity. Upon administration, pamiparib selectively binds to PARP and prevents PARP-mediated repair of single-strand DNA breaks via the base-excision repair (BER) pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability, and eventually leads to apoptosis. PARP is activated by single-strand DNA breaks and, subsequently, catalyzes post-translational ADP-ribosylation of nuclear proteins which then transduce signals to recruit other proteins to repair damaged DNA. Pamiparib may both potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell chemo- and radioresistance.	Pamiparib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120554>	C20401|C129822	Tomaralimab|Anti-TLR2 Monoclonal Antibody OPN-305|OPN-305|TOMARALIMAB	A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against toll-like receptor type 2 (TLR2), with potential anti-inflammatory and antineoplastic activities. Upon intravenous administration, tomaralimab binds to the ligand-binding site on the TLR2 receptor and blocks the activation of TLR2-mediated innate immunity signaling. This prevents the TLR2-mediated production of pro-inflammatory mediators and prevents inflammation. TLR2, a member of the TLR family primarily found on leukocytes, plays a key role in the activation of innate immunity; it is overexpressed in various inflammatory diseases and in certain types of cancer.	Tomaralimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120555>	C1663	MAG-Tn3/AS15 Vaccine|MAG-Tn3 Plus AS15 Cancer Vaccine|MAG-Tn3/AS15	A vaccine containing synthetic multiple antigenic glycopeptide (MAG) composed of tri Tn glycotope (MAG-Tn3), which is comprised of a dendrimeric, nonimmunogenic lysine core linked to a tetravalent peptidic CD4+ T-cell epitope backbone and each attached to three Tn antigens (tri-Tn cluster), combined with the immunoadjuvant AS15, with potential antineoplastic activity. Upon administration of the MAG-Tn3/AS15 vaccine, MAG-Tn3 induces the production of tumor-specific anti-Tn glycosidic antibodies, which results in antibody-dependent cell cytotoxicity (ADCC) against Tn-expressing tumor cells. The Tn carbohydrate antigen, a tumor-associated antigen (TAA), is overexpressed in a number of tumor cell types. The tri-Tn clusters mimic carbohydrate structures found on tumor cells. The T-cell epitope stimulates effective T-cell responses. AS15, a potent adjuvant liposomal formulation that contains CpG 7909, monophosphoryl lipid (MPL), and QS-21, increases the immune response against the Tn antigens.			Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120556>	C211912|C201551	Losatuxizumab Vedotin|ABBV-221|LOSATUXIZUMAB VEDOTIN	An antibody-drug conjugate (ADC) composed of an immunoglobulin G1 (IgG1) monoclonal antibody directed against the epidermal growth factor receptor (EGFR), conjugated, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity.  Upon administration, the monoclonal antibody moiety of losatuxizumab vedotin selectively targets and binds to EGFR. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.	Losatuxizumab Vedotin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120557>	C138180|C129826	NY-ESO-1-specific TCR Gene-transduced T Lymphocytes TBI-1301|NY-ESO-1-specific TCR Gene-transduced T Lymphocytes|TBI-1301	Human peripheral blood T-lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1, with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and introduction into the patient, the NY-ESO-1-specific TCR gene-transduced T lymphocytes TBI-1301 bind to NY-ESO-1 on tumor cells. This may result in cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1-positive cancer cells. NY-ESO-1, a tumor-associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types.			Cell|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C120558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120558>	C45678	Radionuclide Decorporation Agent|Decorporation Agent	Any agent that is able to prevent absorption or facilitate the removal of internal radionuclide contamination.			Chemical Viewed Functionally	
C120559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120559>	C45678	Aluminum Carbonate|ALUMINUM CARBONATE|Carbonic Acid, Aluminum Salt	The aluminum salt form of carbonic acid, an antacid with phosphate binding activity. Upon oral administration of aluminum carbonate, aluminum is able to bind to phosphate in the intestines, including the radionuclide phosphate P-32, thereby preventing phosphate uptake.			Inorganic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C12055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12055>	C61007	Cytarabine/Fludarabine/Isotretinoin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120560>	C45678	Calcium Phosphate|CALCIUM PHOSPHATE, UNSPECIFIED FORM|Phosphoric Acid, Calcium Salt	The calcium salt of phosphoric acid with widely used applications. This agent can be used as a countermeasure for exposure to strontium and radium radionuclides. Upon oral uptake, calcium phosphate competes for and blocks the absorption of radium (Ra-226) and strontium (Sr-90) in the gastrointestinal (GI) tract.			Indicator, Reagent, or Diagnostic Aid|Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C120561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120561>	C29730	Sodium Glycerophosphate|1,2,3-Propanetriol, Mono(dihydrogen Phosphate), Disodium Salt, Hydrate|SODIUM GLYCEROPHOSPHATE	The sodium salt form of an organic phosphate compound that provides phosphate for nutritional purposes. In addition, sodium glycerophosphate can be used as a phosphate diluting agent upon internal contamination with the beta-emiting radioisotope phosphate P 32 (P-32) that competes with P-32 for absorption. As sodium glycerophosphate is administered in high amounts, the absorption of P-32 is prevented or minimalized.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C120563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120563>	C20194	TCERG1L Gene|TCERG1L|TCERG1L|Transcription Elongation Regulator 1-Like Gene	This gene may play a role in insulin activity.	TCERG1L Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C120564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120564>	C120563	TCERG1L wt Allele|5730476P14Rik|FLJ38950|Transcription Elongation Regulator 1-Like wt Allele	Human TCERG1L wild-type allele is located in the vicinity of 10q26.3 and is approximately 219 kb in length. This allele, which encodes transcription elongation regulator 1-like protein, may be involved in insulin resistance.	TCERG1L wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120565>	C18466	Transcription Elongation Regulator 1-Like Protein|TCERG1L	Transcription elongation regulator 1-like protein (586 aa, ~67 kDa) is encoded by the human TCERG1L gene. This protein may plays a role in the modulation of insulin activity.	Transcription Elongation Regulator 1-Like Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120566>	C26000	FBN2 Gene|FBN2|FBN2|Fibrillin 2 Gene	This gene is involved in the formation of extracellular calcium-binding microfibrils.	FBN2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C120567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120567>	C120566	FBN2 wt Allele|CCA|Congenital Contractural Arachnodactyly Gene|DA9|EOMD|Fibrillin 2 wt Allele|Fibrillin 5 Gene	Human FBN2 wild-type allele is located within 5q23-q31 and is approximately 401 kb in length. This allele, which encodes fibrillin-2 protein, plays a role in the formation of extracellular microfibrils and elastic fibers. Mutation of the gene is associated with both congenital contractural arachnodactyly and early-onset macular degeneration.	FBN2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120568>	C17351	Fibrillin-2|Fibrillin 2	Fibrillin-2 (2912 aa, ~315 kDa) is encoded by the human FBN2 gene. This protein is involved in the structure of extracellular calcium-binding microfibrils.	Fibrillin-2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120569>	C360	Pentetate Calcium|Ca-DTPA|Calcium DTPA|Calcium N,N-bis(2-(bis(carboxymethyl)amino)ethyl)glycinate (1:1)|Diethylenetriaminepentaacetic Acid, Calcium Salt|PENTETATE CALCIUM|Pentetic Acid Calcium|pentetic acid calcium	The calcium salt form of diethylene triamine pentaacetate (Ca-DTPA or pentetate calcium), with chelating activity. Upon administration, Ca-DTPA loses the Ca ion to form stable chelates with metal ions because DTPA has a higher affinity for heavy metal ions than for Ca ions. Specifically, this agent is able to bind to and form strong complexes with radioactive plutonium, americium, and cerium after internal contamination. The formation of these heavy metal chelates enhances radionuclide excretion. enhances radionuclide excretion.	Pentetate Calcium		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C12056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12056>	C61063	Folic Acid/Lometrexol/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120570>	C360	Pentetate Zinc|Diethylenetriaminepentaacetic Acid, Zinc Salt|PENTETATE ZINC|Zinc DTPA|Zinc, (((Carboxymethylimino)bis(ethylenenitrilo))tetraacetato)-|Zincate(3-), (N,N-bis(2-(((carboxy-kappaO)methyl)(carboxymethyl)amino-kappaN)ethyl)glycinato(5-)-kappaN,kappaO)-, Trihydrogen|Zn-DTPA|ZnDTPA	The zinc salt form of diethylene triamine pentaacetate (Zn-DTPA or pentetate zinc) with chelating activity. Upon administration, Zn-DTPA loses the Zn ion to form stable chelates with metal ions because DTPA has a higher affinity for heavy metal ions than for Zn ions. Specifically, this agent is able to bind to and form strong complexes with the radioactive plutonium, americium, and cerium after internal contamination. The formation of these heavy metal chelates enhances radionuclide excretion.			Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C120571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120571>	C18545	MAFA Gene|MAF bZIP Transcription Factor A Gene|MAFA|MAFA	This gene plays a role in the regulation of insulin gene expression.	MAFA Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C120572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120572>	C120571	MAFA wt Allele|MAF bZIP Transcription Factor A wt Allele|RIPE3B1|RIPE3b1|hMafA|v-Maf Avian Musculoaponeurotic Fibrosarcoma Oncogene Homolog A Gene|v-Maf Musculoaponeurotic Fibrosarcoma Oncogene Homolog A (Avian) Gene|v-Maf Musculoaponeurotic Fibrosarcoma Oncogene Homolog A Gene	Human MAFA wild-type allele is located in the vicinity of 8q24.3 and is approximately 11 kb in length. This allele, which encodes transcription factor MafA protein, is involved in the modulation of insulin gene expression.	MAFA wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120573>	C17207	Transcription Factor MafA|Pancreatic Beta-Cell-Specific Transcriptional Activator|Transcription Factor RIPE3b1|v-Maf Musculoaponeurotic Fibrosarcoma Oncogene Homolog A	Transcription factor MafA (353 aa, ~37 kDa) is encoded by the human MAFA gene. This protein plays a role in the activation of insulin gene expression in the pancreas.	Transcription Factor MafA		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120574>	C27993	Tolerable	Capable of being endured either physically or mentally.			Qualitative Concept	
C120575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120575>	C27993	Excruciating	Intensely painful.			Qualitative Concept	
C120576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120576>	C63732	Improvised Nuclear Device|IND	A crude nuclear device built from the components of a stolen weapon or from scratch using nuclear material (plutonium or highly enriched uranium).			Manufactured Object	
C120577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120577>	C20103	VSIR Gene|C10orf54|V-Set Immunoregulatory Receptor Gene|VSIR|VSIR	This gene may be involved in the regulation of immunity.	VSIR Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C120578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120578>	C120577	VSIR wt Allele|B7-H5|B7H5|C10orf54|Chromosome 10 Open Reading Frame 54 Gene|DD1alpha|GI24|PD-1 Homolog Gene|PD-H1|PP2135|Programmed Death-1 Homolog Gene|SISP1|UNQ730/PRO1412|V-Domain Ig Suppressor of T Cell Activation Gene|V-Domain Immunoglobulin Suppressor of T Cell Activation Gene|V-Set Immunoregulatory Receptor wt Allele|VISTA	Human VSIR wild-type allele is located in the vicinity of 10q22.1 and is approximately 26 kb in length. This allele, which encodes V-type immunoglobulin domain-containing suppressor of T-cell activation protein, is involved in the modulation of T-cell function.	VSIR wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120579>	C63732	Radiological Exposure Device|Hidden Radioactive Source|RED	A device constructed from partially or fully unshielded radioactive material intended to expose people to significant doses of ionizing radiation without their knowledge.			Manufactured Object	
C12057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12057>	C61063	Trastuzumab/ZD 1839			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120580>	C63732	Radiological Dispersal Device|Dirty Bomb|RDD	A device that disperses radioactive material by conventional explosive or other mechanical means, such as a spray.			Manufactured Object	
C120581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120581>	C18106	V-Type Immunoglobulin Domain-Containing Suppressor of T-Cell Activation|DD1-Alpha|Death Domain 1-Alpha|Death Domain1alpha|PDCD1 Homolog|Platelet Receptor GI24|Platelet Receptor Gi24|Sisp-1|Stress Induced Secreted Protein 1|Stress-Induced Secreted Protein-1|V-Domain Ig Suppressor of T Cell Activation|V-Set Domain-Containing Immunoregulatory Receptor|V-Set Immunoregulatory Receptor|VISTA|VSIR	V-type immunoglobulin domain-containing suppressor of T-cell activation (311 aa, ~34 kDa) is encoded by the human VSIR gene. This protein plays a role in the negative regulation of T-cell function.	V-Type Immunoglobulin Domain-Containing Suppressor of T-Cell Activation		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120582>	C25499	Nuclear Power Plant Accident	A release of nuclides and radiation at a nuclear power plant that has led to significant consequences to people, the environment or the facility.			Event	
C120583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120583>	C49151	Early Stillbirth	Delivery of a dead fetus greater than 22 weeks but less than 28 weeks gestational age, and/or whose birth weight is greater than 500 grams but less than 1,000 grams.			Finding	
C120584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120584>	C28133	Lymphocyte Depletion Kinetics	A method for estimating the dose of an external radiation exposure following whole- or partial- body exposure. Serial CBCs are obtained and the absolute lymphocyte count is calculated and tracked over time. The dose absorbed is correlated with the rate of decline of peripheral blood lymphocytes and the lowest value for absolute lymphocyte depletion.			Diagnostic Procedure	
C120585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120585>	C49151	Late Stillbirth	Delivery of a dead fetus greater than 28 weeks gestational age and/or greater than 1,000 grams birth weight.			Finding	
C120586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120586>	C160962	Portuguese Language|POR|Portuguese|Portuguese	An Indo-European language that originated in Portugal. It is the official language of Portugal, Brazil, Mozambique, Angola, Cape Verde, Guinea-Bissau, and São Tomé and Príncipe.			Language	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C120587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120587>	C161845	Spanish Language|Castilian|Castilian Language|SPA|Spanish|Spanish	An Indo-European Romance language that originated in Spain. It is the primary language of 20 countries worldwide.			Language	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C120588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120588>	C161862	Chinese Language|Chinese|ZHO	A family of languages that originated in China. The major dialect is Mandarin. It is the official language of China and Taiwan.			Language	
C120589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120589>	C160956	German Language|DEU|German|German	An Indo-European, West Germanic language that originated in Germany. It is the official language of Germany, Austria, and Liechtenstein.			Language	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C12058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12058>	C61007	Doxorubicin/Strontium Chloride Sr 89			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120590>	C51277	Korean Language|KOR|Korean|Korean	An East Asian language that originated in the Korean peninsula. It is the official language of South Korea and North Korea.			Language	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C120591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120591>	C161902	Vietnamese Language|VIE|Vietnamese	An Austroasiatic language that is the native and official language of Viet Nam.			Language	
C120592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120592>	C116772	Very Early Neonatal Death	Death of a live newborn during the first 24 hours of life			Finding	
C120593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120593>	C20103	CD160 Gene|CD160|CD160|CD160 Molecule Gene	This gene plays a role in binding to class I major histocompatibility complexes.	CD160 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C120594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120594>	C120593	CD160 wt Allele|BY55|CD160 Molecule wt Allele|NK1|NK28	Human CD160 wild-type allele is located in the vicinity of 1q21.2 and is approximately 20 kb in length. This allele, which encodes CD160 antigen protein, is involved in the recognition of class I major histocompatibility complex proteins.	CD160 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120595>	C226671	Often	A subjective answer that something occurs frequently.			Intellectual Product	
C120596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120596>	C18106	CD160 Antigen|Natural Killer Cell Receptor BY55	CD160 antigen (181 aa, ~20 kDa) is encoded by the human CD160 gene. This protein plays a role in binding to class I major histocompatibility complexes.	CD160 Antigen		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120597>	C120544	Rapid Virologic Response|RAPID VIROLOGIC RESPONSE|RVR|RVR	A finding of aviremia at a specified timepoint, early during the treatment period.			Finding	CDISC SDTM Anti-Viral Outcome of Treatment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120598>	C120544	Sustained Virologic Response|SUSTAINED VIROLOGIC RESPONSE|SVR|SVR	A finding of aviremia at a predetermined time point after the end of planned or actual treatment.			Finding	CDISC SDTM Anti-Viral Outcome of Treatment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120599>	C120544	Viral Breakthrough|VBT|VBT|VIRAL BREAKTHROUGH	The subject becomes viremic during the treatment period after a period of treatment-induced aviremia or has an increase in viral load from nadir above a predetermined threshold during the treatment period.			Finding	CDISC SDTM Anti-Viral Outcome of Treatment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12059>	C61063	Dacarbazine/Doxorubicin/Ifosfamide/SU5416			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1205>	C1967|C1745|C1017	Tectorigenin|4',5,7-Trihydroxy-6-methoxyisoflavone|4H-1-benzopyran-4-one, 5,7-dihydroxy-3-(4-hydroxyphenyl)-8-methoxy-|Psi-Tectorigenin|TECTORIGENIN|psi-Tectorigenin	An isoflavone from Pueraria thunbergiana, which induces differentiation and apoptosis in cancer cells. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C120600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120600>	C120544	Viral Relapse|VIRAL RELAPSE	A recurrence of the same virus after a finding of aviremia at the end of planned or actual treatment.			Finding	CDISC SDTM Anti-Viral Outcome of Treatment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120601>	C120544	Virologic End Of Treatment Response|VIROLOGIC END OF TREATMENT RESPONSE	A finding of aviremia at the end of the planned or actual end of treatment period.			Finding	CDISC SDTM Anti-Viral Outcome of Treatment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120602>	C120544	Virologic Failure|VIROLOGIC FAILURE	A finding of viremia at or after end of planned or actual treatment, excluding treatment discontinuations for non-virologic reasons.			Finding	CDISC SDTM Anti-Viral Outcome of Treatment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120603>	C120544	Virologic Non-Response|VIROLOGIC NON-RESPONSE	The subject remains viremic during the treatment period.			Finding	CDISC SDTM Anti-Viral Outcome of Treatment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120604>	C120544	Virologic Null-Response|VIROLOGIC NULL-RESPONSE	The subject remains viremic during the treatment period and the decrease in viral load from baseline at a specified timepoint is below or equal to a predetermined threshold.			Finding	CDISC SDTM Anti-Viral Outcome of Treatment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120605>	C120544	Virologic Partial Response|VIROLOGIC PARTIAL RESPONSE	The subject remains viremic during the treatment period and the decrease in viral load from baseline at a specified timepoint is above a predetermined threshold.			Finding	CDISC SDTM Anti-Viral Outcome of Treatment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120606>	C53264	Luminescence Type|LUMNCTYP	A description of the type of light emission, which does not involve the release of heat.			Qualitative Concept	CDISC SDTM Device Properties Test Code Terminology|CDISC SDTM Device Properties Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120607>	C116131	Undetermined Supraventricular Rhythm by ECG Finding|UNDETERMINED SUPRAVENTRICULAR RHYTHM	An electrocardiographic finding of a rhythm that cannot be determined from the EKG, but that clearly does not originate in the ventricles or His Purkinje system. Typically, the QRS complexes are narrow, but aberration or preexcitation may be present.			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120608>	C62085	Single Beat RR Extrapolated Heart Rate by ECG Assessment|EGHRSI|Single RR Heart Rate|Single RR Heart Rate	The extrapolation of an individual's heart rate as estimated from a single R-R interval as measured by an electrocardiographic machine.			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120609>	C41328	Defibrillator Discharge by ECG Finding|DEFIBRILLATOR DISCHARGE	An electrocardiographic tracing that is generated by cardioversion or defibrillation.			Finding	CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12060>	C61063	Cisplatin/Doxorubicin/Methotrexate/Trastuzumab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120610>	C62257	Frequent Premature Atrial Complexes by ECG Finding|FREQUENT PREMATURE ATRIAL COMPLEXES	An electrocardiographic tracing demonstrating frequent premature atrial contractions that exceed an acceptable, predetermined threshold. Different thresholds may apply to different patient populations.			Finding	CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120611>	C62256	Frequent Premature Ventricular Complexes by ECG Finding|FREQUENT PREMATURE VENTRICULAR COMPLEXES	An electrocardiographic tracing demonstrating frequent premature ventricular contractions that exceed an acceptable, predetermined threshold. Different thresholds may apply to different patient populations.			Finding	CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120612>	C41328	Holter Lead Fail by ECG Finding|HOLTER LEAD FAIL	A continuous, ambulatory electrocardiographic recording during which one or more electrodes are disconnected, at least temporarily, resulting in one or more invalid ECG waveforms.			Finding	CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120613>	C111097	Marked Sinus Bradycardia by ECG Finding|MARKED SINUS BRADYCARDIA	An electrocardiographic tracing demonstrating sinus bradycardia, with a heart rate lower than an acceptable, predetermined threshold.  Different thresholds, for rate and/or duration, may apply to different patient populations.			Finding	CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120614>	C111100	Nonsustained Supraventricular Tachycardia by ECG Finding|NONSUSTAINED SUPRAVENTRICULAR TACHYCARDIA	An electrocardiographic tracing demonstrating supraventricular tachycardia of less than thirty seconds duration. Different thresholds, for rate and/or duration, may apply to different patient populations.			Finding	CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120615>	C111092	Paroxysmal Atrial Fibrillation by ECG Finding|PAROXYSMAL ATRIAL FIBRILLATION	An electrocardiographic tracing demonstrating intermittent atrial fibrillation in the presence of sinus rhythm, junctional rhythm, or an atrial paced rhythm.			Finding	CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120616>	C111092	Persistent Atrial Fibrillation by ECG Finding|PERSISTENT ATRIAL FIBRILLATION	An electrocardiographic tracing demonstrating atrial fibrillation that is present during the entire recording.			Finding	CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120617>	C41328	Sinus Slowing With AV Block by ECG Finding|SINUS SLOWING WITH AV BLOCK	An electrocardiographic tracing demonstrating the simultaneous occurrence of a slowing sinus rate and AV block.			Finding	CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120618>	C41328	Supraventricular Run by ECG Finding|SUPRAVENTRICULAR RUN	An electrocardiographic tracing demonstrating three or more consecutive QRS complexes of supraventricular origin, irrespective of rate.			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C120619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120619>	C111100	Sustained Supraventricular Tachycardia by ECG Finding|SUSTAINED SUPRAVENTRICULAR TACHYCARDIA	An electrocardiographic tracing demonstrating supraventricular tachycardia of greater than thirty seconds duration. Different thresholds, for rate and/or duration, may apply to different patient populations.			Finding	CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12061>	C61063	Cisplatin/Doxorubicin/Etoposide/Ifosfamide/Methotrexate/Trastuzumab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120620>	C41328	Ventricular Quadrigeminy by ECG Finding|VENTRICULAR QUADRIGEMINY	An electrocardiographic tracing demonstrating three normal QRS complexes followed by a premature ventricular contraction over the course of three or more consecutive cycles; a regularly irregular rhythm of normal to abnormal QRS complexes in a 3-1 ratio.			Finding	CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120621>	C41328	Ventricular Run by ECG Finding|VENTRICULAR RUN	An electrocardiographic tracing demonstrating three or more consecutive QRS complexes of ventricular origin, irrespective of rate.			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C120622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120622>	C181399	Influenza Hemagglutinin 1 Specific IgG Antibody Secreting Cell Count	The determination of the number of influenza hemagglutinin 1 specific IgG antibody secreting cells present in a sample.			Laboratory Procedure	
C120623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120623>	C181399	Influenza Hemagglutinin 3 Specific IgG Antibody Secreting Cell Count	The determination of the number of influenza hemagglutinin 3 specific IgG antibody secreting cells present in a sample.			Laboratory Procedure	
C120624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120624>	C181399	Total IgG Antibody Secreting Cell Count	The determination of the number of IgG antibody secreting cells present in a sample.			Laboratory Procedure	
C120625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120625>	C75385	Anti-Mullerian Hormone Measurement|AMH|AMH Measurement|Anti-Mullerian Hormone|Anti-Mullerian Hormone	The determination of the anti-Mullerian hormone present in a sample.	Anti-Mullerian Hormone Measurement		Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120626>	C176313	Anti-Neutrophil Cytoplasmic Antibody Measurement|ANCAB|Anti-Neutrophil Cytoplasmic Antibody|Anti-Neutrophil Cytoplasmic Antibody|Anti-Neutrophil Cytoplasmic Autoantibody	The determination of the anti-neutrophil cytoplasmic antibody present in a sample.			Laboratory Procedure	CDISC SDTM Immunogenicity Specimen Assessments Test Code Terminology|CDISC SDTM Immunogenicity Specimen Assessments Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120627>	C210010	Anti-Nucleosome Antibody Measurement	The determination of the anti-nucleosome antibody present in a sample.			Laboratory Procedure	
C120628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120628>	C74734	Apolipoprotein B100 Measurement|APOB100|APOB100 Measurement|Apolipoprotein B100|Apolipoprotein B100	The determination of the apolipoprotein B100 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120629>	C74734	Apolipoprotein B48 Measurement|APOB48|APOB48 Measurement|Apolipoprotein B48|Apolipoprotein B48	The determination of the apolipoprotein B48 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12062>	C61007	Cisplatin/Etoposide/Ifosfamide/Prednisolone			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120630>	C64430	Apolipoprotein CI Measurement|APOC1|APOC1 Measurement|Apolipoprotein C-I Measurement|Apolipoprotein C1 Measurement|Apolipoprotein CI|Apolipoprotein CI	The determination of the apolipoprotein CI present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120631>	C210010	Bactericidal/Permeability-Increasing Protein Antibody Measurement	The determination of the bactericidal/permeability-increasing protein antibody present in a sample.			Laboratory Procedure	
C120632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120632>	C64430	Cholesteryl Ester Transfer Protein Measurement|CETP|Cholesteryl Ester Transfer Protein|Cholesteryl Ester Transfer Protein	The determination of the cholesteryl ester transfer protein present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120633>	C74949	Chylomicrons Measurement|CHLMCRN|Chylomicrons|Chylomicrons	The determination of the chylomicrons present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120634>	C210010	Cathepsin Antibody Measurement	The determination of the cathepsin antibody present in a sample.			Laboratory Procedure	
C120635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120635>	C105588	Oxidized LDL Cholesterol Measurement|LDLOXI|Oxidized LDL Cholesterol|Oxidized LDL Cholesterol	The determination of the oxidized LDL cholesterol present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120636>	C74949	LDL Particles Measurement|LDL Particles|LDL Particles|LDLP	The determination of the LDL particles present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120637>	C74949	LDL Subtype Pattern|LDLPATT	A description of the low density lipoprotein particle pattern (an interpretation of the amounts of LDL particles based on size and density) in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120638>	C181405	Lipoprotein Associated Phospholipase A2 Measurement|LPPLA2|Lipoprotein Associated Phospholipase A2|Lipoprotein Associated Phospholipase A2	The determination of the lipoprotein associated phospholipase A2 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120639>	C210010	Lactoferrin Antibody Measurement	The determination of the lactoferrin antibody present in a sample.			Laboratory Procedure	
C12063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12063>	C61063	Carboplatin/Irinotecan/Thalidomide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120640>	C64430	Lysozyme Measurement|LYSOZYME|Lysozyme|Lysozyme	The determination of the lysozyme present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120641>	C67208	Monocytoid Cells to Leukocytes Ratio Measurement|MOCYCELE|Monocytoid Cells/Leukocytes|Monocytoid Cells/Leukocytes	The determination of the ratio of monocytoid cells compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120642>	C67208	Neutrophils Band Form to Neutrophils Ratio Measurement|NEUTBNE|Neutrophils Band Form/ Neutrophils|Neutrophils Band Form/ Neutrophils	The determination of the ratio of neutrophil band form compared to neutrophils present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120643>	C67208	Segmented Neutrophils to Neutrophils Ratio Measurement|NEUTSGNE|Neutrophils, Segmented/Neutrophils|Neutrophils, Segmented/Neutrophils	The determination of the ratio of segmented neutrophils compared to neutrophils present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120644>	C74949	Non-HDL Cholesterol to HDL Cholesterol Ratio Measurement|NOHDLHDL|Non-HDL Cholesterol/HDL Cholesterol|Non-HDL Cholesterol/HDL Cholesterol	The determination of the ratio of non-HDL cholesterol compared to HDL cholesterol present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120645>	C74760	N-telopeptide to Creatinine Ratio Measurement|N-telopeptide/Creatinine|N-telopeptide/Creatinine|NTELOCRT	The determination of the ratio of N-telopeptide compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120646>	C64430	Proliferating Cell Nuclear Antigen Measurement|Cyclin|PCNA Measurement|PCNAG|Proliferating Cell Nuclear Antigen|Proliferating Cell Nuclear Antigen	The determination of the proliferating cell nuclear antigen present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120647>	C64430	Proprotein Convertase Subtilisin/Kexin Type 9 Measurement|PCSK9|Proprotein Convertase Subtilisin/Kexin 9|Proprotein Convertase Subtilisin/Kexin 9	The determination of the proprotein convertase subtilisin/kexin type 9 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120648>	C49237	Porphyrin Measurement|PORPH|Porphyrin|Porphyrin	The determination of the porphyrin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120649>	C210010	Proteinase 3 Antibody Measurement|Myeloblastin Antibody Measurement	The determination of the proteinase 3 antibody present in a sample.			Laboratory Procedure	
C12064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12064>	C61063	Fluorouracil/Leucovorin Calcium/Oxaliplatin/ZD 1839			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120650>	C117850	Soluble P-Selectin Measurement|PSELECTS|Soluble P-Selectin|Soluble P-Selectin	The determination of the soluble P-selectin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120651>	C210010	P100 Polymyositis-scleroderma Autoantigen Antibody Measurement|Exosome Component 10 Antibody Measurement	The determination of the P100 polymyositis-scleroderma autoantigen antibody present in a sample.			Laboratory Procedure	
C120652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120652>	C81969	Rheumatoid Factor Antibody IgA Measurement	The determination of the rheumatoid factor antibody IgA present in a sample.			Laboratory Procedure	
C120653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120653>	C81971	Rheumatoid Factor Antibody IgG Measurement	The determination of the rheumatoid factor antibody IgG present in a sample.			Laboratory Procedure	
C120654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120654>	C81972	Rheumatoid Factor Antibody IgM Measurement	The determination of the rheumatoid factor antibody IgM present in a sample.			Laboratory Procedure	
C120655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120655>	C74949	Remnant-like Particle Cholesterol Measurement|RLP|RLP Cholesterol|RLP Cholesterol	The determination of the RLP cholesterol present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120656>	C64430	Remnant Lipoprotein Measurement|RMNTLP|Remnant Lipoprotein|Remnant Lipoprotein	The determination of the remnant lipoprotein present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120657>	C210010	Ribonucleoprotein-70 Antibody Measurement|SNRNP70 Antibody Measurement	The determination of the ribonucleoprotein-70 antibody present in a sample.			Laboratory Procedure	
C120658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120658>	C210010	Ribonucleoprotein Smith Complex Antibody Measurement	The determination of the ribonucleoprotein Smith complex antibody present in a sample.			Laboratory Procedure	
C120659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120659>	C210010	Ribosomal P Protein Antibody Measurement	The determination of the ribosomal P protein antibody present in a sample.			Laboratory Procedure	
C12065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12065>	C61063	BMS-247550/Estramustine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120660>	C64430	Squamous Cell Carcinoma Antigen Measurement|SCCAG|Serpin B3/B4 Measurement|Squamous Cell Carcinoma Antigen|Squamous Cell Carcinoma Antigen|Squamous Cell Carcinoma Antigen (SCCA)	The determination of the squamous cell carcinoma antigen present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C120661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120661>	C92236	Sjogrens SS-A52 Antibody Measurement|52 kDa Ribonucleoprotein Autoantigen Ro/SS-A Antibody Measurement|E3 Ubiquitin-Protein Ligase TRIM21 Antibody Measurement	The determination of the Sjogrens SS-A52 antibody present in a sample.			Laboratory Procedure	
C120662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120662>	C92236	Sjogrens SS-A60 Antibody Measurement|60 kDa SS-A/Ro Ribonucleoprotein Antibody Measurement	The determination of the Sjogrens SS-A60 antibody present in a sample.			Laboratory Procedure	
C120663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120663>	C181405	Type II Secretory Phospholipase A2 Measurement|SPLA2II|Type II Secretory Phospholipase A2|Type II Secretory Phospholipase A2	The determination of the type II secretory phospholipase A2 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120664>	C74786	Indirect Free Thyroxine Measurement|T4FRIND|Thyroxine, Free, Indirect|Thyroxine, Free, Indirect	The determination of the free thyroxine present in a sample by indirect measure.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120665>	C64430	Thymidine Kinase Measurement|TK|Thymidine Kinase|Thymidine Kinase	The determination of the thymidine kinase present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120666>	C64430	Tumor Necrosis Factor Receptor 1 Measurement|Soluble CD120a|TNFR1|TNFR1 Measurement|TNFRSF1A Measurement|Tumor Necrosis Factor Receptor 1|Tumor Necrosis Factor Receptor 1	The determination of the tumor necrosis factor receptor 1 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120667>	C105589	VLDL Cholesterol Subtype 1 Measurement|VLDL Cholesterol Subtype 1|VLDL Cholesterol Subtype 1|VLDL1	The determination of the very low density lipoprotein cholesterol subtype 1 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120668>	C105589	VLDL Cholesterol Subtype 2 Measurement|VLDL Cholesterol Subtype 2|VLDL Cholesterol Subtype 2|VLDL2	The determination of the very low density lipoprotein cholesterol subtype 2 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120669>	C105589	VLDL Cholesterol Subtype 3 Measurement|VLDL Cholesterol Subtype 3|VLDL Cholesterol Subtype 3|VLDL3	The determination of the very low density lipoprotein cholesterol subtype 3 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12066>	C61007	Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody/gp100 antigen/MART-1 antigen/Montanide ISA-51/tyrosinase peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120670>	C34076	Fibular Shaft|FIBULA SHAFT	The elongated bony body of a fibula compressing of the anterior, posterior, internal and external surfaces separated by the anteroexternal, anterointernal, posteroexternal and posterointernal borders.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120671>	C34076	Humeral Shaft|HUMERUS SHAFT	The cylindrical, elongated bony body of a humerus compressing of the anterior, posterior and external surfaces separated by the anterior, posterior and interosseous borders. The distal portion of the shaft becomes more prismatic and flattened.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120672>	C12680	Intertrochanteric Region|INTERTROCHANTERIC REGION	The bony region in the proximal portion of the femur between the greater, lesser and sub- (also called the third) trochanters.			Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120673>	C89337	Extra Lumbar Vertebra|L6 VERTEBRA|L6 Vertebra	A congenital anomaly of the spine, where an extra or supernumerary lumbar vertebra arises from below the 5th lumbar vertebra.			Congenital Abnormality	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120674>	C34076	Radius Shaft|RADIUS SHAFT	The slightly curved, prismoid, elongated bony body of a radius compressing of the anterior, posterior and external surfaces separated by the anterior, posterior and interosseous borders.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120675>	C34076	Tibial Shaft|TIBIA SHAFT	The triangular prismoid, elongated bony body of a tibia compressing of the anterior, posterior and external surfaces separated by the anterior, posterior and interosseous borders.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120676>	C34076	Ulnar Shaft|ULNA SHAFT	The prismatic, elongated bony body of an ulna which curves from behind forwards, and compresses of the anterior, posterior and external surfaces separated by the anterior, posterior and interosseous borders. The distal portion of the shaft is rounded, smooth and bents outward.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120677>	C210012|C187857	Influenza A Antigen Measurement|INFAAG|Influenza A Antigen|Influenza A Antigen	The determination of the amount of the Influenza A antigen in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120678>	C210012|C184674	Influenza A/B Antigen Measurement|INFABAG|Influenza A/B Antigen|Influenza A/B Antigen	The determination of the amount of the Influenza A/B antigen in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120679>	C210012|C187858	Influenza B Antigen Measurement|INFBAG|Influenza B Antigen|Influenza B Antigen	The determination of the amount of the Influenza B antigen in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12067>	C61007	Docetaxel/Ifosfamide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120680>	C132416	Viral Identification	A diagnostic procedure to identify and characterize a viral organism.			Laboratory Procedure	
C120681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120681>	C16410	Analytical Ultracentrifugation|ANALYTICAL ULTRACENTRIFUGATION	An ultracentrifugation based method that uses an optical detection system to monitor and record data during the centrifugation process.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120682>	C120543	Applanation Tonometry|APPLANATION TONOMETRY	A method in which a constant pressure is applied to the surface of the cornea in order to flatten a prespecified area of the membrane, which is used to calculate intraocular pressure.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120683>	C120542	Contact Specular Microscopy|CONTACT SPECULAR MICROSCOPY	A type of specular microscopy in which the specular microscope makes contact with the cornea of the eye.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120684>	C150876	Endpoint Dilution Assay|ENDPOINT DILUTION ASSAY	An in vitro cell based assay in which plated host cells are inoculated with serial dilutions of an infective agent and observed for cytotoxic effects in order to calculate the titer.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120685>	C30014	Gas Chromatography/Tandem Mass Spectrometry|GC/MS/MS	An analytical technique wherein gas chromatography is coupled to tandem mass spectrometry in order to separate, identify, and quantify substances in a sample.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120686>	C30014	Gas Chromatography/Chemical Ionization Mass Spectrometry|GC/MS-CI	An analytical technique where gas chromatography is coupled with chemical ionization mass spectrometry in order to separate, identify, and quantify substances in a sample.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120687>	C30014	Gas Chromatography/Electron Ionization Mass Spectrometry|GC/MS-EI	An analytical technique where gas chromatography is coupled with electron ionization mass spectrometry in order to separate, identify, and quantify substances in a sample.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120688>	C18640	Hemagglutination Inhibition Assay|HEMAGGLUTINATION INHIBITION ASSAY	An in vitro assay that is used to determine whether antibodies present in serum samples will prevent hemagglutination in a cell culture plate containing red blood cells and influenza virus.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120689>	C25386	Hemocytometry|HEMOCYTOMETRY	A method that uses a thick glass slide containing a chamber with a defined volume, which is etched with a precisely ruled grid and is used to quantify cells or cell-sized particles in suspension.			Research Activity	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12068>	C61063	Carboplatin/Temozolomide/Thiotepa			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120690>	C16434	High-performance Liquid Chromatography/Ion-Exchange Chromatography|HPLC/IEX	A type of high performance liquid chromatography that separates proteins based on net charge.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120691>	C103513	High-performance Liquid Chromatography/Tandem Mass Spectrometry|HPLC/MS/MS	An analytical technique wherein high performance liquid chromatography is coupled to tandem mass spectrometry in order to separate, identify, and quantify substances in a sample.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120692>	C16434	High-performance Liquid Chromatography-Fluorescence|HPLC-FL	An analytical technique where high performance liquid chromatography with a fluorescence detector is used to separate, identify, and quantify substances in a sample.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120693>	C16434	High-performance Liquid Chromatography-UV|HPLC-UV	An analytical technique where high performance liquid chromatography with an ultraviolet light detector is used to separate, identify, and quantify substances in a sample.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120694>	C111096	Jaffe Reaction|JAFFE REACTION	A colorimetric method used to measure creatinine, in which color change is directly related to the amount of creatinine in an alkaline solution containing picric acid.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120695>	C18640	Virus Neutralization Assay|MICRONEUTRALIZATION ASSAY|VNA	An in vitro assay that is used to determine whether antibodies that can block viral infection are present in a biological specimen. Virus is mixed with serum taken from the subject and is incubated in culture with laboratory cells, which are monitored over time for cytotoxicity.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|SeroNet Authorized Values|SeroNet Study Descriptors
C120696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120696>	C18640	Neuraminidase Inhibition Assay|NEURAMINIDASE INHIBITION ASSAY	A type of enzyme-based assay that assesses neuraminidase activity in the presence of an enzyme inhibitor.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120697>	C120542	Non-Contact Specular Microscopy|NON-CONTACT SPECULAR MICROSCOPY	A type of specular microscopy in which the specular microscope does not make contact with the cornea of the eye.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120698>	C17369	Ophthalmoscopy|FS|Fundoscopy|Fundoscopy|Fundoscopy|OPHTHALMOSCOPY	A technique used to examine of the back (fundus) and other anatomical structures of the eye with a magnifying instrument.	Ophthalmoscopy		Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C120699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120699>	C16830	Phoropter|PHOROPTER	An instrument composed of multiple lenses that refract the light going into the subject's eye, allowing the examiner to determine the refractive error of the eye.			Medical Device	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12069>	C61063	Apolizumab/Rituximab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1206>	C511	Pteropterin|PTEROPTERIN	A crystalline conjugate of folic acid, having general properties of a polypeptide. Pteropterin differs from folic acid in that it consists of three molecules of glutamic acid instead of one. Pteropterin can potentially be used as an antimetabolite in the treatment of cancer.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C120700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120700>	C120540	Monocular Pupillometry|PUPILLOMETRY	A technique used to measure the diameter of a single pupil in response to stimuli.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120701>	C100085	Quantitative Coronary Angiography|QUANTITATIVE CORONARY ANGIOGRAPHY	A type of angiographic procedure that allows for direct quantitative assessment of the native coronary arteries or bypass grafts supplying native coronary arteries.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120702>	C117879	Quantitative Peripheral Angiography|QUANTITATIVE PERIPHERAL ANGIOGRAPHY	A type of angiographic procedure that allows for direct quantitative assessment of the vessels of the hands, arms, feet and legs.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120703>	C120543	Rebound Tonometry|REBOUND TONOMETRY	A method in which a probe is bounced off of the surface of the cornea, creating an induction current that is used to calculate intraocular pressure.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120704>	C173515|C119321	Anaerobic Gram Positive Bacteria|ANAEROBIC GRAM-POSITIVE BACTERIA|Gram-positive Anaerobe	Any bacteria that does not require oxygen to grow or respirate and has a peptidoglycan rich cell wall that stains dark purple with the Gram staining technique			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120705>	C123646	Ancylostoma|ANCYLOSTOMA	A genus of parasitic nematodes within the family Ancylostomatidae that are commonly found in dogs and cats. Infestation causes ancylostomiasis.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120706>	C77163	Candida intermedia|Blastodendrion intermedium|Blastodendrion intermedius|CANDIDA INTERMEDIA|Cryptococcus intermedius|Kluyveromyces cellobiovorus|Mycotorula intermedia	A species of pseudohyphae fungus belonging to the genus Candida that has been isolated from human skin, throat, and feces; it is a rare human pathogen in nosocomial infections.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120707>	C68564	Mixed Flora|MIXED FLORA	The presence of more than one fungal and/or bacterial organism in a culture.			Classification	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120708>	C120539	Mucor|MUCOR	A genus of fungi within the phylum Zygomycota that are ubiquitous in nature and generally not considered pathogenic. Members of the Mucor genus produce apical, globular sporangia supported by columella, and do not produce rhizoids. Though generally thermointolerant, at least one species, Mucor indicus, may cause opportunistic infections in immunocompromised individuals to include zygomycosis.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120709>	C120541	Rhizomucor pusillus|Mucor pusillus|RHIZOMUCOR PUSILLUS	A species of grey mycelium fungi belonging to the genus Rhizomucor that is most commonly found in compost heaps; it is a rare human pathogen, causing pulmonary, disseminated or cutaneous infection.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12070>	C61007	Bevacizumab/Fluorouracil/Leucovorin Calcium/Oxaliplatin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120710>	C120538	Maximum Cell Density|CELLDMAX|Cell Density, Maximum|Cell Density, Maximum	The maximum value in a range of values that describe cell density.			Quantitative Concept	CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120711>	C120538	Minimum Cell Density|CELLDMIN|Cell Density, Minimum|Cell Density, Minimum	The minimum value in a range of values that describe cell density.			Quantitative Concept	CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120712>	C120538	Mean Cell Density|CELLDMN|Cell Density, Mean|Cell Density, Mean	The arithmetic mean of a range of values that describe the cell density of an entity.			Quantitative Concept	CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120713>	C53322	Standard Deviation of Cell Density|CELLDSD|Cell Density, Standard Deviation|Cell Density, Standard Deviation	A measure of the range of values in a set of values that describe the cell density.			Quantitative Concept	CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120714>	C19332	Optic Cup to Disc Ratio|CUPDISC|Cup to Disc Ratio|Cup to Disc Ratio	The ratio of the diameter of the optic cup compared to the diameter of the optic disc.			Organism Attribute	CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120715>	C25285	Minimum Diameter|DIAMMIN|Diameter, Minimum|Diameter, Minimum|shortest dimension|shortest_dimension	The minimum value in a range of values that describe the diameter of an entity.			Quantitative Concept	CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Property Terminology|GDC Terminology
C120716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120716>	C25285	Mean Diameter|DIAMMN|Diameter, Mean|Diameter, Mean	The arithmetic mean of a range of values that describe the diameter of an entity.			Quantitative Concept	CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120717>	C53322	Standard Deviation of Diameter|DIAMSD|Diameter, Standard Deviation|Diameter, Standard Deviation	A measure of the range of values in a set of values that describe the diameter of an entity.			Quantitative Concept	CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120718>	C135508	Lens Status|LENSSTAT	The condition or state of the lens of the eye.			Qualitative Concept	CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120719>	C41145	Maximum Thickness|THICKMAX|Thickness, Maximum|Thickness, Maximum	The maximum value in a range of values that describe the thickness of an entity.			Quantitative Concept	CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12071>	C61007	Cyclophosphamide/Doxorubicin/Tirapazamine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120720>	C41145	Minimum Thickness|THICKMIN|Thickness, Minimum|Thickness, Minimum	The minimum value in a range of values that describe the thickness of an entity.			Quantitative Concept	CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120721>	C41145	Mean Thickness|THCKNMN|THICKMN|Thickness, Mean|Thickness, Mean|Thickness, Mean	The arithmetic mean of a range of values that describe the thickness of an entity.			Quantitative Concept	CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Organ Measurement Test Code Terminology|CDISC SEND Organ Measurement Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120722>	C53322	Standard Deviation of Thickness|THICKSD|Thickness, Standard Deviation|Thickness, Standard Deviation	A measure of the range of values in a set of values that describe the thickness of an entity.			Quantitative Concept	CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120723>	C43242	Mean Absorption Time|MAT	The average time that it takes an exogenous compound to enter the circulation.			Temporal Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120724>	C85769	Mean Residence Time Infinity Observed by Extravascular Dose|MRT Extravasc Infinity Obs|MRT Extravasc Infinity Obs|MRTEVIFO	The mean residence time (MRT) extrapolated to infinity for a substance administered by extravascular dosing, calculated using the observed value of the last non-zero concentration. Extravascular MRT includes Mean Absorption Time (MAT). (CDISC)			Temporal Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120725>	C85793	Mean Residence Time Infinity Predicted by Extravascular Dose|MRT Extravasc Infinity Pred|MRT Extravasc Infinity Pred|MRTEVIFP	The mean residence time (MRT) extrapolated to infinity for a substance administered by extravascular dosing, calculated using the predicted value of the last non-zero concentration. Extravascular MRT includes Mean Absorption Time (MAT). (CDISC)			Temporal Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120726>	C85700	Mean Residence Time to Last Nonzero Concentration by Extravascular Dose|MRT Extravasc to Last Nonzero Conc|MRT Extravasc to Last Nonzero Conc|MRTEVLST	Mean residence time (MRT) from the time of dosing to the time of the last measurable concentration for a substance administered by extravascular dosing. Extravascular MRT includes Mean Absorption Time (MAT). (CDISC)			Temporal Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120727>	C66973	Liter per Day per Kilogram per Meter Squared|(L/d)/(kg/m2)|(L/d)/(kg/m2)|(L/day)/(kg/m2)|(L/day)/(kg/m2)|(l/d)/(kg/m2)|(l/d)/(kg/m2)	A unit of concentration equal to liter per day divided by kilogram per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120728>	C66973	Liter per Day per Milligram per Day|(L/d)/(mg/d)|(L/d)/(mg/d)|(L/day)/(mg/day)|(L/day)/(mg/day)|(L/day)/(mg/day)|(L/day)/(mg/day)|(l/d)/(mg/d)|(l/d)/(mg/d)|(mL/d)/(ug/d)|(mL/d)/(ug/d)|(mL/day)/(ug/day)|(mL/day)/(ug/day)|(mL/day)/(ug/day)|(ml/d)/(ug/d)|(ml/d)/(ug/d)|Milliliter per Day per Microgram per Day	A unit of concentration equal to liter per day divided by milligram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120729>	C66973	Liter per Day per Milligram per Kilogram|(L/d)/(mg/kg)|(L/d)/(mg/kg)|(L/day)/(mg/kg)|(L/day)/(mg/kg)|(L/day)/(mg/kg)|(L/day)/(mg/kg)|(l/d)/(mg/kg)|(l/d)/(mg/kg)|(mL/d)/(ug/kg)|(mL/d)/(ug/kg)|(mL/day)/(ug/kg)|(mL/day)/(ug/kg)|(mL/day)/(ug/kg)|(ml/d)/(ug/kg)|(ml/d)/(ug/kg)|Milliliter per Day per Microgram per Kilogram	A unit of concentration equal to liter per day divided by milligram per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12072>	C61063	BCG/Monoclonal Antibody 105AD7 Anti-idiotype Vaccine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120730>	C66973	Liter per Day per Milligram per Kilogram per Day|(L/d)/(mg/kg/d)|(L/d)/(mg/kg/d)|(L/day)/(mg/kg/day)|(L/day)/(mg/kg/day)|(L/day)/(mg/kg/day)|(L/day)/(mg/kg/day)|(l/d)/(mg/kg/d)|(l/d)/(mg/kg/d)|(mL/d)/(ug/kg/d)|(mL/d)/(ug/kg/d)|(mL/day)/(ug/kg/day)|(mL/day)/(ug/kg/day)|(mL/day)/(ug/kg/day)|(ml/d)/(ug/kg/d)|(ml/d)/(ug/kg/d)|Milliliter per Day per Microgram per Kilogram per Day	A unit of concentration equal to liter per day divided by milligram per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120731>	C66973	Liter per Day per Milligram per Meter Squared|(L/d)/(mg/m2)|(L/d)/(mg/m2)|(L/day)/(mg/m2)|(L/day)/(mg/m2)|(L/day)/(mg/m2)|(L/day)/(mg/m2)|(l/d)/(mg/m2)|(l/d)/(mg/m2)|(mL/d)/(ug/m2)|(mL/d)/(ug/m2)|(mL/day)/(ug/m2)|(mL/day)/(ug/m2)|(mL/day)/(ug/m2)|(ml/d)/(ug/m2)|(ml/d)/(ug/m2)|Milliliter per Day per Microgram per Meter Squared	A unit of concentration equal to liter per day divided by milligram per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120732>	C66973	Liter per Day per Milligram per Meter Squared per Day|(L/d)/(mg/m2/d)|(L/d)/(mg/m2/d)|(L/day)/(mg/m2/day)|(L/day)/(mg/m2/day)|(L/day)/(mg/m2/day)|(L/day)/(mg/m2/day)|(l/d)/(mg/m2/d)|(l/d)/(mg/m2/d)|(mL/d)/(ug/m2/d)|(mL/d)/(ug/m2/d)|(mL/day)/(ug/m2/day)|(mL/day)/(ug/m2/day)|(mL/day)/(ug/m2/day)|(ml/d)/(ug/m2/d)|(ml/d)/(ug/m2/d)|Milliliter per Day per Microgram per Meter Squared per Day	A unit of concentration equal to liter per day divided by milligram per meter squared per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120733>	C66973	Liter per Day per Microgram per Day|(L/d)/(ug/d)|(L/d)/(ug/d)|(L/day)/(ug/day)|(L/day)/(ug/day)|(L/day)/(ug/day)|(l/d)/(ug/d)|(l/d)/(ug/d)	A unit of concentration equal to liter per day divided by microgram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120734>	C66973	Liter per Day per Microgram per Kilogram|(L/d)/(ug/kg)|(L/d)/(ug/kg)|(L/day)/(ug/kg)|(L/day)/(ug/kg)|(L/day)/(ug/kg)|(l/d)/(ug/kg)|(l/d)/(ug/kg)	A unit of concentration equal to liter per day divided by microgram per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120735>	C66973	Liter per Day per Microgram per Kilogram per Day|(L/d)/(ug/kg/d)|(L/d)/(ug/kg/d)|(L/day)/(ug/kg/day)|(L/day)/(ug/kg/day)|(L/day)/(ug/kg/day)|(l/d)/(ug/kg/d)|(l/d)/(ug/kg/d)	A unit of concentration equal to liter per day divided by microgram per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120736>	C66973	Liter per Day per Microgram per Meter Squared|(L/d)/(ug/m2)|(L/d)/(ug/m2)|(L/day)/(ug/m2)|(L/day)/(ug/m2)|(L/day)/(ug/m2)|(l/d)/(ug/m2)|(l/d)/(ug/m2)	A unit of concentration equal to liter per day divided by microgram per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120737>	C66973	Liter per Day per Microgram per Meter Squared per Day|(L/d)/(ug/m2/d)|(L/d)/(ug/m2/d)|(L/day)/(ug/m2/day)|(L/day)/(ug/m2/day)|(L/day)/(ug/m2/day)|(l/d)/(ug/m2/d)|(l/d)/(ug/m2/d)	A unit of concentration equal to liter per day divided by microgram per meter squared per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120738>	C66973	Liter per Day per Meter Squared|(L/d)/m2|(L/d)/m2|(L/day)/m2|(L/day)/m2|(l/d)/m2|(l/d)/m2	A unit of concentration equal to liter per day divided by meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120739>	C66973	Liter per Hour per Kilogram per Meter Squared|(L/h)/(kg/m2)|(L/h)/(kg/m2)|(L/h)/(kg/m2)|(l/h)/(kg/m2)|(l/h)/(kg/m2)	A unit of concentration equal to liter per hour divided by kilogram per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12073>	C61063	Alum Adjuvant/Monoclonal Antibody 105AD7 Anti-Idiotype Vaccine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120740>	C66973	Liter per Hour per Milligram per Day|(L/h)/(mg/d)|(L/h)/(mg/d)|(L/h)/(mg/day)|(L/h)/(mg/day)|(L/h)/(mg/day)|(L/h)/(mg/day)|(l/h)/(mg/d)|(l/h)/(mg/d)|(mL/h)/(ug/d)|(mL/h)/(ug/d)|(mL/h)/(ug/day)|(mL/h)/(ug/day)|(mL/h)/(ug/day)|(ml/h)/(ug/d)|(ml/h)/(ug/d)|Milliliter per Hour per Microgram per Day	A unit of concentration equal to liter per hour divided by milligram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120741>	C66973	Liter per Hour per Milligram per Kilogram|(L/h)/(mg/kg)|(L/h)/(mg/kg)|(L/h)/(mg/kg)|(L/h)/(mg/kg)|(L/h)/(mg/kg)|(l/h)/(mg/kg)|(l/h)/(mg/kg)|(mL/h)/(ug/kg)|(mL/h)/(ug/kg)|(mL/h)/(ug/kg)|(mL/h)/(ug/kg)|(ml/h)/(ug/kg)|(ml/h)/(ug/kg)|Milliliter per Hour per Microgram per Kilogram	A unit of concentration equal to liter per hour divided by milligram per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120742>	C66973	Liter per Hour per Milligram per Kilogram per Day|(L/h)/(mg/kg/d)|(L/h)/(mg/kg/d)|(L/h)/(mg/kg/day)|(L/h)/(mg/kg/day)|(L/h)/(mg/kg/day)|(L/h)/(mg/kg/day)|(l/h)/(mg/kg/d)|(l/h)/(mg/kg/d)|(mL/h)/(ug/kg/d)|(mL/h)/(ug/kg/d)|(mL/h)/(ug/kg/day)|(mL/h)/(ug/kg/day)|(mL/h)/(ug/kg/day)|(ml/h)/(ug/kg/d)|(ml/h)/(ug/kg/d)|Milliliter per Hour per Microgram per Kilogram per Day	A unit of concentration equal to liter per hour divided by milligram per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120743>	C66973	Liter per Hour per Milligram per Meter Squared|(L/h)/(mg/m2)|(L/h)/(mg/m2)|(L/h)/(mg/m2)|(L/h)/(mg/m2)|(L/h)/(mg/m2)|(l/h)/(mg/m2)|(l/h)/(mg/m2)|(mL/h)/(ug/m2)|(mL/h)/(ug/m2)|(mL/h)/(ug/m2)|(mL/h)/(ug/m2)|(ml/h)/(ug/m2)|(ml/h)/(ug/m2)|Milliliter per Hour per Microgram per Meter Squared	A unit of concentration equal to liter per hour divided by milligram per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120744>	C66973	Liter per Hour per Milligram per Meter Squared per Day|(L/h)/(mg/m2/d)|(L/h)/(mg/m2/d)|(L/h)/(mg/m2/day)|(L/h)/(mg/m2/day)|(L/h)/(mg/m2/day)|(L/h)/(mg/m2/day)|(l/h)/(mg/m2/d)|(l/h)/(mg/m2/d)|(mL/h)/(ug/m2/d)|(mL/h)/(ug/m2/d)|(mL/h)/(ug/m2/day)|(mL/h)/(ug/m2/day)|(mL/h)/(ug/m2/day)|(ml/h)/(ug/m2/d)|(ml/h)/(ug/m2/d)|Milliliter per Hour per Microgram per Meter Squared per Day	A unit of concentration equal to liter per hour divided by milligram per meter squared per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120745>	C66973	Liter per Hour per Microgram per Day|(L/h)/(ug/d)|(L/h)/(ug/d)|(L/h)/(ug/day)|(L/h)/(ug/day)|(L/h)/(ug/day)|(l/h)/(ug/d)|(l/h)/(ug/d)	A unit of concentration equal to liter per hour divided by microgram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120746>	C66973	Liter per Hour per Microgram per Kilogram|(L/h)/(ug/kg)|(L/h)/(ug/kg)|(L/h)/(ug/kg)|(L/h)/(ug/kg)|(l/h)/(ug/kg)|(l/h)/(ug/kg)	A unit of concentration equal to liter per hour divided by microgram per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120747>	C66973	Liter per Hour per Microgram per Kilogram per Day|(L/h)/(ug/kg/d)|(L/h)/(ug/kg/d)|(L/h)/(ug/kg/day)|(L/h)/(ug/kg/day)|(L/h)/(ug/kg/day)|(l/h)/(ug/kg/d)|(l/h)/(ug/kg/d)	A unit of concentration equal to liter per hour divided by microgram per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120748>	C66973	Liter per Hour per Microgram per Meter Squared|(L/h)/(ug/m2)|(L/h)/(ug/m2)|(L/h)/(ug/m2)|(L/h)/(ug/m2)|(l/h)/(ug/m2)|(l/h)/(ug/m2)	A unit of concentration equal to liter per hour divided by microgram per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120749>	C66973	Liter per Hour per Microgram per Meter Squared per Day|(L/h)/(ug/m2/d)|(L/h)/(ug/m2/d)|(L/h)/(ug/m2/day)|(L/h)/(ug/m2/day)|(L/h)/(ug/m2/day)|(l/h)/(ug/m2/d)|(l/h)/(ug/m2/d)	A unit of concentration equal to liter per hour divided by microgram per meter squared per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12074>	C61063	Pentostatin/Rituximab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120750>	C66973	Liter per Minute per Kilogram per Meter Squared|(L/min)/(kg/m2)|(L/min)/(kg/m2)|(L/min)/(kg/m2)|(l/min)/(kg/m2)|(l/min)/(kg/m2)	A unit of concentration equal to liter per minute divided by kilogram per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120751>	C66973	Liter per Minute per Milligram per Day|(L/min)/(mg/d)|(L/min)/(mg/d)|(L/min)/(mg/day)|(L/min)/(mg/day)|(L/min)/(mg/day)|(L/min)/(mg/day)|(l/min)/(mg/d)|(l/min)/(mg/d)|(mL/min)/(ug/d)|(mL/min)/(ug/d)|(mL/min)/(ug/day)|(mL/min)/(ug/day)|(mL/min)/(ug/day)|(ml/min)/(ug/d)|(ml/min)/(ug/d)|Milliliter per Minute per Microgram per Day	A unit of concentration equal to liter per minute divided by milligram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120752>	C66973	Liter per Minute per Milligram per Kilogram|(L/min)/(mg/kg)|(L/min)/(mg/kg)|(L/min)/(mg/kg)|(L/min)/(mg/kg)|(L/min)/(mg/kg)|(l/min)/(mg/kg)|(l/min)/(mg/kg)|(mL/min)/(ug/kg)|(mL/min)/(ug/kg)|(mL/min)/(ug/kg)|(mL/min)/(ug/kg)|(ml/min)/(ug/kg)|(ml/min)/(ug/kg)|Milliliter per Minute per Microgram per Kilogram	A unit of concentration equal to liter per minute divided by milligram per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120753>	C66973	Liter per Minute per Milligram per Kilogram per Day|(L/min)/(mg/kg/d)|(L/min)/(mg/kg/d)|(L/min)/(mg/kg/day)|(L/min)/(mg/kg/day)|(L/min)/(mg/kg/day)|(L/min)/(mg/kg/day)|(l/min)/(mg/kg/d)|(l/min)/(mg/kg/d)|(mL/min)/(ug/kg/d)|(mL/min)/(ug/kg/d)|(mL/min)/(ug/kg/day)|(mL/min)/(ug/kg/day)|(mL/min)/(ug/kg/day)|(ml/min)/(ug/kg/d)|(ml/min)/(ug/kg/d)|Milliliter per Minute per Microgram per Kilogram per Day	A unit of concentration equal to liter per minute divided by milligram per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120754>	C66973	Liter per Minute per Milligram per Meter Squared|(L/min)/(mg/m2)|(L/min)/(mg/m2)|(L/min)/(mg/m2)|(L/min)/(mg/m2)|(L/min)/(mg/m2)|(l/min)/(mg/m2)|(l/min)/(mg/m2)|(mL/min)/(ug/m2)|(mL/min)/(ug/m2)|(mL/min)/(ug/m2)|(mL/min)/(ug/m2)|(ml/min)/(ug/m2)|(ml/min)/(ug/m2)|Milliliter per Minute per Microgram per Meter Squared	A unit of concentration equal to liter per minute divided by milligram per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120755>	C66973	Liter per Minute per Milligram per Meter Squared per Day|(L/min)/(mg/m2/d)|(L/min)/(mg/m2/d)|(L/min)/(mg/m2/day)|(L/min)/(mg/m2/day)|(L/min)/(mg/m2/day)|(L/min)/(mg/m2/day)|(l/min)/(mg/m2/d)|(l/min)/(mg/m2/d)|(mL/min)/(ug/m2/d)|(mL/min)/(ug/m2/d)|(mL/min)/(ug/m2/day)|(mL/min)/(ug/m2/day)|(mL/min)/(ug/m2/day)|(ml/min)/(ug/m2/d)|(ml/min)/(ug/m2/d)|Milliliter per Minute per Microgram per Meter Squared per Day	A unit of concentration equal to liter per minute divided by milligram per meter squared per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120756>	C66973	Liter per Minute per Microgram per Day|(L/min)/(ug/d)|(L/min)/(ug/d)|(L/min)/(ug/day)|(L/min)/(ug/day)|(L/min)/(ug/day)|(l/min)/(ug/d)|(l/min)/(ug/d)	A unit of concentration equal to liter per minute divided by microgram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120757>	C66973	Liter per Minute per Microgram per Kilogram|(L/min)/(ug/kg)|(L/min)/(ug/kg)|(L/min)/(ug/kg)|(L/min)/(ug/kg)|(l/min)/(ug/kg)|(l/min)/(ug/kg)	A unit of concentration equal to liter per minute divided by microgram per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120758>	C66973	Liter per Minute per Microgram per Kilogram per Day|(L/min)/(ug/kg/d)|(L/min)/(ug/kg/d)|(L/min)/(ug/kg/day)|(L/min)/(ug/kg/day)|(L/min)/(ug/kg/day)|(l/min)/(ug/kg/d)|(l/min)/(ug/kg/d)	A unit of concentration equal to liter per minute divided by microgram per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120759>	C66973	Liter per Minute per Microgram per Meter Squared|(L/min)/(ug/m2)|(L/min)/(ug/m2)|(L/min)/(ug/m2)|(L/min)/(ug/m2)|(l/min)/(ug/m2)|(l/min)/(ug/m2)	A unit of concentration equal to liter per minute divided by microgram per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12075>	C67290	Bevacizumab/Interferon Alfa Regimen|Avastin/Interferon Alfa|Bevacizumab-Interferon Alfa|Bevacizumab-Interferon Alfa Regimen|Bevacizumab/Interferon Alfa|Interferon Alfa-Bevacizumab|Interferon Alfa/Avastin|Interferon Alfa/Bevacizumab|Interferon Alfa/Bevacizumab Regimen	A regimen consisting of bevacizumab and interferon-alfa that can be used for the treatment of advanced renal cell carcinoma (RCC).			Therapeutic or Preventive Procedure	
C120760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120760>	C66973	Liter per Minute per Microgram per Meter Squared per Day|(L/min)/(ug/m2/d)|(L/min)/(ug/m2/d)|(L/min)/(ug/m2/day)|(L/min)/(ug/m2/day)|(L/min)/(ug/m2/day)|(l/min)/(ug/m2/d)|(l/min)/(ug/m2/d)	A unit of concentration equal to liter per minute divided by microgram per meter squared per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120761>	C66973	Milliliter per Day per Kilogram per Meter Squared|(mL/d)/(kg/m2)|(mL/d)/(kg/m2)|(mL/day)/(kg/m2)|(mL/day)/(kg/m2)|(ml/d)/(kg/m2)|(ml/d)/(kg/m2)	A unit of concentration equal to milliliter per day divided by kilogram per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120762>	C66973	Milliliter per Day per Milligram per Day|(mL/d)/(mg/d)|(mL/d)/(mg/d)|(mL/day)/(mg/day)|(mL/day)/(mg/day)|(mL/day)/(mg/day)|(ml/d)/(mg/d)|(ml/d)/(mg/d)	A unit of concentration equal to milliliter per day divided by milligram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120763>	C66973	Milliliter per Day per Milligram per Kilogram|(mL/d)/(mg/kg)|(mL/d)/(mg/kg)|(mL/day)/(mg/kg)|(mL/day)/(mg/kg)|(mL/day)/(mg/kg)|(ml/d)/(mg/kg)|(ml/d)/(mg/kg)	A unit of concentration equal to milliliter per day divided by milligram per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120764>	C66973	Milliliter per Day per Milligram per Kilogram per Day|(mL/d)/(mg/kg/d)|(mL/d)/(mg/kg/d)|(mL/day)/(mg/kg/day)|(mL/day)/(mg/kg/day)|(mL/day)/(mg/kg/day)|(ml/d)/(mg/kg/d)|(ml/d)/(mg/kg/d)	A unit of concentration equal to milliliter per day divided by milligram per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120765>	C66973	Milliliter per Day per Milligram per Meter Squared|(mL/d)/(mg/m2)|(mL/d)/(mg/m2)|(mL/day)/(mg/m2)|(mL/day)/(mg/m2)|(mL/day)/(mg/m2)|(ml/d)/(mg/m2)|(ml/d)/(mg/m2)	A unit of concentration equal to milliliter per day divided by milligram per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120766>	C66973	Milliliter per Day per Milligram per Meter Squared per Day|(mL/d)/(mg/m2/d)|(mL/d)/(mg/m2/d)|(mL/day)/(mg/m2/day)|(mL/day)/(mg/m2/day)|(mL/day)/(mg/m2/day)|(ml/d)/(mg/m2/d)|(ml/d)/(mg/m2/d)	A unit of concentration equal to milliliter per day divided by milligram per meter squared per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12076>	C61007	Bleomycin/Cyclophosphamide/Doxorubicin/Etoposide/Prednisone/Vinblastine/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120773>	C66973	Milliliter per Day per Meter Squared|(mL/d)/m2|(mL/d)/m2|(mL/day)/m2|(mL/day)/m2|(ml/d)/m2|(ml/d)/m2	A unit of concentration equal to milliliter per day divided by meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120776>	C66973	Milliliter per Hour per Kilogram per Meter Squared|(mL/h)/(kg/m2)|(mL/h)/(kg/m2)|(mL/h)/(kg/m2)|(ml/h)/(kg/m2)|(ml/h)/(kg/m2)	A unit of concentration equal to milliliter per hour divided by kilogram per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120777>	C66973	Milliliter per Hour per Milligram per Day|(mL/h)/(mg/d)|(mL/h)/(mg/d)|(mL/h)/(mg/day)|(mL/h)/(mg/day)|(mL/h)/(mg/day)|(ml/h)/(mg/d)|(ml/h)/(mg/d)	A unit of concentration equal to milliliter per hour divided by milligram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120778>	C66973	Milliliter per Hour per Milligram per Kilogram|(mL/h)/(mg/kg)|(mL/h)/(mg/kg)|(mL/h)/(mg/kg)|(mL/h)/(mg/kg)|(ml/h)/(mg/kg)|(ml/h)/(mg/kg)	A unit of concentration equal to milliliter per hour divided by milligram per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120779>	C66973	Milliliter per Hour per Milligram per Kilogram per Day|(mL/h)/(mg/kg/d)|(mL/h)/(mg/kg/d)|(mL/h)/(mg/kg/day)|(mL/h)/(mg/kg/day)|(mL/h)/(mg/kg/day)|(ml/h)/(mg/kg/d)|(ml/h)/(mg/kg/d)	A unit of concentration equal to milliliter per hour divided by milligram per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12077>	C61063	Oxaliplatin/ZD 1839			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120780>	C66973	Milliliter per Hour per Milligram per Meter Squared|(mL/h)/(mg/m2)|(mL/h)/(mg/m2)|(mL/h)/(mg/m2)|(mL/h)/(mg/m2)|(ml/h)/(mg/m2)|(ml/h)/(mg/m2)	A unit of concentration equal to milliliter per hour divided by milligram per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120781>	C66973	Milliliter per Hour per Milligram per Meter Squared per Day|(mL/h)/(mg/m2/d)|(mL/h)/(mg/m2/d)|(mL/h)/(mg/m2/day)|(mL/h)/(mg/m2/day)|(mL/h)/(mg/m2/day)|(ml/h)/(mg/m2/d)|(ml/h)/(mg/m2/d)	A unit of concentration equal to milliliter per hour divided by milligram per meter squared per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120788>	C66973	Milliliter per Hour per Meter Squared|(mL/h)/m2|(mL/h)/m2|(mL/h)/m2|(ml/h)/m2|(ml/h)/m2	A unit of concentration equal to milliliter per hour divided by meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12078>	C61007	Temozolomide/Vinorelbine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120791>	C66973	Milliliter per Minute per Kilogram per Meter Squared|(mL/min)/(kg/m2)|(mL/min)/(kg/m2)|(mL/min)/(kg/m2)|(ml/min)/(kg/m2)|(ml/min)/(kg/m2)	A unit of concentration equal to milliliter per minute divided by kilogram per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120792>	C66973	Milliliter per Minute per Milligram per Day|(mL/min)/(mg/d)|(mL/min)/(mg/d)|(mL/min)/(mg/day)|(mL/min)/(mg/day)|(mL/min)/(mg/day)|(ml/min)/(mg/d)|(ml/min)/(mg/d)	A unit of concentration equal to milliliter per minute divided by milligram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120793>	C66973	Milliliter per Minute per Milligram per Kilogram|(mL/min)/(mg/kg)|(mL/min)/(mg/kg)|(mL/min)/(mg/kg)|(mL/min)/(mg/kg)|(ml/min)/(mg/kg)|(ml/min)/(mg/kg)	A unit of concentration equal to milliliter per minute divided by milligram per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120794>	C66973	Milliliter per Minute per Milligram per Kilogram per Day|(mL/min)/(mg/kg/d)|(mL/min)/(mg/kg/d)|(mL/min)/(mg/kg/day)|(mL/min)/(mg/kg/day)|(mL/min)/(mg/kg/day)|(ml/min)/(mg/kg/d)|(ml/min)/(mg/kg/d)	A unit of concentration equal to milliliter per minute divided by milligram per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120795>	C66973	Milliliter per Minute per Milligram per Meter Squared|(mL/min)/(mg/m2)|(mL/min)/(mg/m2)|(mL/min)/(mg/m2)|(mL/min)/(mg/m2)|(ml/min)/(mg/m2)|(ml/min)/(mg/m2)	A unit of concentration equal to milliliter per minute divided by milligram per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120796>	C66973	Milliliter per Minute per Milligram per Meter Squared per Day|(mL/min)/(mg/m2/d)|(mL/min)/(mg/m2/d)|(mL/min)/(mg/m2/day)|(mL/min)/(mg/m2/day)|(mL/min)/(mg/m2/day)|(ml/min)/(mg/m2/d)|(ml/min)/(mg/m2/d)	A unit of concentration equal to milliliter per minute divided by milligram per meter squared per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12079>	C61007	Erlotinib/Gemcitabine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1207>	C2163	Pyrazine Diazohydroxide|PZDH|Pyrazinamine, N-nitroso-, sodium salt|Pyrazine diazohydroxide|Pyrazineamine, N-nitroso-, sodium salt|pyrazinamine, N-nitroso-, sodium salt|pyrazine diazohydroxide|pyrazine-2-diazohydroxide|pyrazineamine, N-nitroso-, sodium salt	A congener of pyridine 2-diazohydroxide.  Pyrazine diazohydroxide forms DNA adducts via the reactive pyrazine diazonium ion, thereby inhibiting DNA synthesis. (NCI04)			Organic Chemical|Pharmacologic Substance	NCI Drug Dictionary Terminology
C120803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120803>	C66973	Milliliter per Minute per Meter Squared|(mL/min)/m2|(mL/min)/m2|(mL/min)/m2|(ml/min)/m2|(ml/min)/m2	A unit of concentration equal to milliliter per minute divided by meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120806>	C66973	Liter per Kilogram per Meter Squared|L/(kg/m2)|L/(kg/m2)|L/(kg/m2)|l/(kg/m2)|l/(kg/m2)	A unit of concentration equal to liter divided by kilogram per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120807>	C66973	Liter per Milligram per Kilogram|L/(mg/kg)|L/(mg/kg)|L/(mg/kg)|L/(mg/kg)|l/(mg/kg)|l/(mg/kg)	A unit of concentration equal to liter divided by milligram per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120808>	C66973	Liter per Milligram per Kilogram per Day|L/(mg/kg/d)|L/(mg/kg/d)|L/(mg/kg/day)|L/(mg/kg/day)|L/(mg/kg/day)|L/(mg/kg/day)|Milliliter per Microgram per Kilogram per Day|l/(mg/kg/d)|l/(mg/kg/d)|mL/(ug/kg/d)|mL/(ug/kg/d)|mL/(ug/kg/day)|mL/(ug/kg/day)|mL/(ug/kg/day)|ml/(ug/kg/d)|ml/(ug/kg/d)	A unit of concentration equal to liter divided by milligram per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120809>	C66973	Liter per Milligram per Meter Squared per Day|L/(mg/m2/d)|L/(mg/m2/d)|L/(mg/m2/day)|L/(mg/m2/day)|L/(mg/m2/day)|L/(mg/m2/day)|Milliliter per Microgram per Meter Squared per Day|l/(mg/m2/d)|l/(mg/m2/d)|mL/(ug/m2/d)|mL/(ug/m2/d)|mL/(ug/m2/day)|mL/(ug/m2/day)|mL/(ug/m2/day)|ml/(ug/m2/d)|ml/(ug/m2/d)	A unit of concentration equal to liter divided by milligram per meter squared per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12080>	C61063	Conjugated Estrogens/Medroxyprogesterone			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120810>	C66973	Liter per Microgram per Kilogram|L/(ug/kg)|L/(ug/kg)|L/(ug/kg)|L/(ug/kg)|l/(ug/kg)|l/(ug/kg)	A unit of concentration equal to liter divided by microgram per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120811>	C66973	Liter per Microgram per Kilogram per Day|L/(ug/kg/d)|L/(ug/kg/d)|L/(ug/kg/day)|L/(ug/kg/day)|L/(ug/kg/day)|l/(ug/kg/d)|l/(ug/kg/d)	A unit of concentration equal to liter divided by microgram per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120812>	C66973	Liter per Microgram per Meter Squared|L/(ug/m2)|L/(ug/m2)|L/(ug/m2)|L/(ug/m2)|l/(ug/m2)|l/(ug/m2)	A unit of concentration equal to liter divided by microgram per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120813>	C66973	Liter per Microgram per Meter Squared per Day|L/(ug/m2/d)|L/(ug/m2/d)|L/(ug/m2/day)|L/(ug/m2/day)|L/(ug/m2/day)|l/(ug/m2/d)|l/(ug/m2/d)	A unit of concentration equal to liter divided by microgram per meter squared per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120814>	C66973	Liter per Meter Squared|L/m2|L/m2|L/m2|l/m2|l/m2	A unit of concentration equal to liter per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120815>	C66973	Liter per Microgram|L/ug|L/ug|L/ug|L/ug|l/ug|l/ug	A unit of concentration equal to liter per microgram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Microgram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120816>	C66973	Milliliter per Kilogram per Meter Squared|mL/(kg/m2)|mL/(kg/m2)|mL/(kg/m2)|ml/(kg/m2)|ml/(kg/m2)	A unit of concentration equal to milliliter divided by kilogram per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120817>	C66973	Milliliter per Milligram per Day|mL/(mg/d)|mL/(mg/d)|mL/(mg/day)|mL/(mg/day)|mL/(mg/day)|ml/(mg/d)|ml/(mg/d)	A unit of concentration equal to milliliter divided by milligram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120818>	C66973	Milliliter per Milligram per Kilogram|mL/(mg/kg)|mL/(mg/kg)|mL/(mg/kg)|mL/(mg/kg)|ml/(mg/kg)|ml/(mg/kg)	A unit of concentration equal to milliliter divided by milligram per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120819>	C66973	Milliliter per Milligram per Kilogram per Day|mL/(mg/kg/d)|mL/(mg/kg/d)|mL/(mg/kg/day)|mL/(mg/kg/day)|mL/(mg/kg/day)|ml/(mg/kg/d)|ml/(mg/kg/d)	A unit of concentration equal to milliliter divided by milligram per kilogram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12081>	C61007	Isotretinoin/Monoclonal antibody Ch14.18/Sargramostim			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120820>	C66973	Milliliter per Milligram per Meter Squared|mL/(mg/m2)|mL/(mg/m2)|mL/(mg/m2)|mL/(mg/m2)|ml/(mg/m2)|ml/(mg/m2)	A unit of concentration equal to milliliter divided by milligram per meter squared.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120821>	C66973	Milliliter per Milligram per Meter Squared per Day|mL/(mg/m2/d)|mL/(mg/m2/d)|mL/(mg/m2/day)|mL/(mg/m2/day)|mL/(mg/m2/day)|ml/(mg/m2/d)|ml/(mg/m2/d)	A unit of concentration equal to milliliter divided by milligram per meter squared per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120822>	C66973	Milliliter per Microgram per Kilogram|mL/(ug/kg)|mL/(ug/kg)|mL/(ug/kg)|ml/(ug/kg)|ml/(ug/kg)	A unit of concentration equal to milliliter divided by microgram per kilogram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120825>	C38081	Hemoglobin Corrected Diffusion Capacity of the Lung for Carbon Monoxide|DLCOHC|HGB Corrected DLCO|HGB Corrected DLCO	An assessment of the diffusion capacity of the lungs for carbon monoxide adjusted for hemoglobin concentration.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120826>	C38081	Percent Predicted Hemoglobin Corrected Diffusion Capacity of the Lung for Carbon Monoxide|DLCOHCPP|Percent Predicted HGB Corrected DLCO|Percent Predicted HGB Corrected DLCO	The diffusion capacity of the lungs for carbon monoxide adjusted for hemoglobin concentration, expressed as a proportion of the predicted normal value.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120827>	C38081	Hemoglobin Corrected Diffusion Capacity of the Lung for Carbon Monoxide/Alveolar Volume Ratio|DLCOHCVA|HGB Corrected DLCO/VA|HGB Corrected DLCO/VA	The diffusion capacity of the lungs for carbon monoxide adjusted for the ratio of hemoglobin concentration to alveolar volume.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120828>	C38081	Percent Predicted Hemoglobin Corrected Diffusion Capacity of the Lung for Carbon Monoxide/Alveolar Volume Ratio|DLCOHVAP|Percent Predicted HGB Corrected DLCO/VA|Percent Predicted HGB Corrected DLCO/VA	The diffusion capacity of the lungs for carbon monoxide adjusted for the ratio of hemoglobin concentration to alveolar volume, and expressed as a proportion of the predicted normal value.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120829>	C38081	Percent Predicted Diffusion Capacity of the Lung for Carbon Monoxide|DLCOPP|Percent Predicted DLCO|Percent Predicted DLCO	The degree to which inhaled carbon monoxide diffuses from the alveoli into the blood, expressed as a proportion of the predicted normal value.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12082>	C61007	Interleukin-2/Isotretinoin/Monoclonal Antibody Ch14.18			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120830>	C38081	Diffusion Capacity of the Lung for Carbon Monoxide/Alveolar Volume Ratio|DLCO/VA|DLCO/VA|DLCOVA	The calculated ratio of the lung's alveolar volume with respect to its diffusion capacity for carbon monoxide.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120831>	C38081	Percent Predicted Diffusion Capacity of the Lung for Carbon Monoxide/Alveolar Volume Ratio|DLCOVAPP|Percent Predicted DLCO/VA|Percent Predicted DLCO/VA	The calculated ratio of the lung's alveolar volume with respect to its diffusion capacity for carbon monoxide, expressed as a proportion of the predicted normal value.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120832>	C106551	Number of Ectopic Pregnancies|ECTPREGN	A measurement of the total number of ectopic pregnancies experienced by a female subject.			Quantitative Concept	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120833>	C25164	Estimated Date of Conception|EDCDTC	An approximate calculated date at which the conception event took place.			Temporal Concept	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120834>	C25337	Number of Late Fetal Deaths|FETLDTHN	A measurement of the total number of fetal deaths (in which the fetus is greater than or equal to 20 weeks gestational age) experienced by a female subject.			Quantitative Concept	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120835>	C106550	Number of Induced Abortions|INABORTN	A measurement of the total number of induced abortions experienced by a female subject.			Quantitative Concept	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120836>	C106551	Number of Previous Pregnancies|PRVPREGN	A measurement of the total number of pregnancy events experienced by the female subject prior to the current pregnancy.			Quantitative Concept	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120837>	C106550	Number of Spontaneous Abortions|Number of Miscarriages|SPABORTN	A measurement of the total number of spontaneous abortions (in which the fetus is less than 20 weeks gestational age) experienced by a female subject.			Quantitative Concept	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120838>	C13300	Arterial Cord Blood|ARTERIAL CORD BLOOD	Blood present in the umbilical arteries at the time of delivery.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120839>	C13236	Interstitial Fluid|INTERSTITIAL FLUID	The extracellular fluid component found in the spaces between tissues. This excludes plasma and transcellular fluid.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12083>	C61063	Fluorouracil/Irinotecan/Leucovorin Calcium/ZD 1839			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120840>	C13300	Venous Cord Blood|VENOUS CORD BLOOD	Blood present in the umbilical vein at the time of delivery.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120841>	C49647	Dose Response Control|DOSE RESPONSE|Dose Response	A type of control using different doses or regimens of the same treatment (fixed dose) among the study groups. [From ICH E10].			Research Activity	CDISC SDTM Control Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|ICH M11 Control Type Value Set Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C120842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120842>	C49660	Immunogenicity Study|IMMUNOGENICITY	A study that assesses an agent's ability to provoke an immune response (humoral and/or cell-mediated) in the subject.			Research Activity	CDISC SDTM Terminology|CDISC SDTM Trial Type Terminology|Clinical Data Interchange Standards Consortium Terminology
C120843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120843>	C66973	Milligram per Mole|Femtogram per Picomole|Microgram per Millimole|Nanogram per Micromole|Picogram per Nanomole|fg/pmol|mg/mol|mg/mol|mg/mol|microgram per millimole|ng/umol|pg/nmol|ug/mmol|ug/mmol|ug/mmol	A unit of mass commonly used to express the molar mass of a substance in milligram(s) per mole.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C120844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120844>	C66973	Per Kilogram|/kg|/kg|/kg|/kg|kg|per kilogram	A mass unit equal to one kilogram used as a denominator to build a derived unit expressed as a ratio.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C120845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120845>	C67375	50 Percent Cell Culture Infective Dose per Milliliter|CCID 50/mL|[CCID_50]/mL|[CCID_50]/mL|[CCID_50]/ml|[CCID_50]/ml	A potency unit equal to the potency at which one milliliter of preparation contains one 50 percent cell culture infective dose.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120846>	C77605	Disintegrations per Minute per 0.5 Milliliter|dpm/0.5 mL|{Disintegrations}/min/(1/2).mL|{Disintegrations}/min/(1/2).mL|{Disintegrations}/min/(1/2).ml|{Disintegrations}/min/(1/2).ml	A unit of radioactive decay expressed in atoms of radioactive material that decay over a period of time equal to sixty seconds in a volume unit equal to a half milliliter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120847>	C67375	50 Percent Embryo Infective Dose per Milliliter|EID 50/mL|[EID_50]/mL|[EID_50]/mL|[EID_50]/ml|[EID_50]/ml	A potency unit for measuring infectious activity of a biologic product or an infectious agent preparation equal to the potency at which one milliliter of infectious material contains one 50 percent embryo infective dose.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120848>	C67375	International Unit per Deciliter|10 IU/L|IU/dL|IU/dL|International Units per Deciliter|InternationalUnitsPerDeciLiter|[IU]/dL|[IU]/dL|[IU]/dL|[IU]/dl|[IU]/dl|[iU]/dL|[iU]/dL|[iU]/dL|[iU]/dl|[iU]/dl|international unit per deciliter	Unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one international unit per one deciliter of system volume.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C120849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120849>	C66973	Kilogram per Centimeter|kg/cm|kg/cm|kg/cm	A unit of measure equal to kilograms per length unit equal to one centimeter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12084>	C61063	cBR96-Doxorubicin Immunoconjugate/Docetaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120850>	C67375	Spot Forming Units Per Million Peripheral Blood Mononuclear Cells|SFC/10^6 PBMC|SFU/10^6 PBMC|Spots/10^6 PBMC|{SFC}/10*6{PBMC}|{SFC}/10*6{PBMC}|{SFC}/10^6{PBMC}|{SFC}/10^6{PBMC}	A unit of measure equal to the spot forming units per million cells.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120851>	C67375	Carratelli Unit|CARR U|CARR U|U.CARR|U.CARR|{U.CARR}|{U.CARR}	An arbitrary unit of substance concentration expressed in milligrams per a volume of hydrogen peroxide. One Carratelli unit is equal to 0.8mg substance per liter of hydrogen peroxide.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120852>	C66973	Micromole per Liter per Minute|L/mcmol/min|L/min/mcmol|L/min/umol|L/umol/min|L/umol/min|L/umol/min|Liter per Micromole per Minute|l/umol/min|l/umol/min|micromole per minute per liter|umol/L/min|umol/L/min|umol/L/min|umol/L/min|umol/l/min|umol/l/min|umol/min/L|umol/min/L	A concentration unit equal to one micromole of solute in one liter of solution per unit of time equal to one minute.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C120853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120853>	C28102	Chronic Active|CHRONIC ACTIVE	Having characteristics of chronic disease superimposed with areas of acute (active) disease.			Qualitative Concept	CDISC SEND Chronicity Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120854>	C28102	Peracute|PERACUTE	An excessively sharp or violent acute episode.			Qualitative Concept	CDISC SEND Chronicity Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120855>	C28102	Subacute|SUBACUTE	A disease characteristic falling between acute and chronic, but predominantly acute.			Qualitative Concept	CDISC SEND Chronicity Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120856>	C28102	Subchronic|SUBCHRONIC	A disease characteristic falling between acute and chronic, but predominantly chronic.			Qualitative Concept	CDISC SEND Chronicity Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120857>	C28102	Focal/Multifocal|FOCAL/MULTIFOCAL	A finding that generally has features of focal and multifocal distribution.			Classification	CDISC SEND Distribution Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120858>	C28102	Locally Extensive|Focally Extensive|LOCALLY EXTENSIVE|Regionally Extensive	Being widespread throughout a specific area.			Classification	CDISC SEND Distribution Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120859>	C12801	Accessory Tissue|ACCESSORY TISSUE	A supernumerary tissue in addition to normal tissues.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12085>	C61007	Cytarabine/dexamethasone/methotrexate/pegaspargase/vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120860>	C77140	Accumulation|ACCUMULATION	A state characterized by the gradual increase in entities or substances.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120861>	C27573	Adenosis|ADENOSIS	Any disease or disorder of a gland, characterized by abnormal development or enlargement of the gland.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C120862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120862>	C137801	Adnexal Dysplasia|ADNEXAL DYSPLASIA	A finding of dysplasia in the adnexal appendages.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120863>	C137802	Alpha 2u-Globulin Nephropathy|ALPHA 2U-GLOBULIN NEPHROPATHY|Alpha 2mu-globulin Neuropathy	Increase in eosinophilic cytoplasmic droplets of alpha 2u-globulin in the S2 segment of the proximal tubules in the cortex with exfoliation of cells, an increase in mitotic figures in affected portions of the proximal tubules, tubular basophilia in some cases, and formation of granular casts at the junction of the inner and outer stripes of the medulla. (INHAND)			Disease or Syndrome	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120864>	C2849	Agenesis|APLASIA	A congenital abnormality resulting in the absence of an anatomical structure.			Disease or Syndrome	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120865>	C161564	Experimental Organism Astrocytosis|ASTROCYTOSIS|Astrogliosis|Gemistocytosis	Reactive astrocytic proliferation often associated with degenerative, inflammatory or neoplastic changes in the central nervous system.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120866>	C137801	Atypical Residual Bodies|ATYPICAL RESIDUAL BODIES	Abnormally large, misshapen and/or clumped vacuoles containing cell debris in the testis, or present in stages of spermatogenesis when not normally seen.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120867>	C102602	Bacteria Present|BACTERIA|Bacterium	Confirmatory presence of bacterial microorganisms.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120868>	C33315	Basophilic Phagolysosome|BASOPHILIC GRANULES	Intracytoplasmic phagolysosomes that are strongly basophilic. These structures are usually seen within the tubular epithelium and glomeruli of the kidney in response to antisense oligonucleotides.			Classification	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120869>	C35867	Cellular Debris|CELL DEBRIS	An accumulation of cell fragments.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12086>	C61063	Cytarabine/Etoposide/Ifosfamide/Methotrexate/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120870>	C35867	Cholesterol Cleft|Acicular Cleft|CHOLESTEROL CLEFT|Cholesterol Clefts	A finding of an empty space in a histological section of paraffin-embedded tissue created by the dissolution of cholesterol crystals.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120871>	C16956	Chromatolysis|CHROMATOLYSIS	The dissolution of chromatin in a cell.			Phenomenon or Process	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120872>	C137802	Chronic Progressive Nephropathy|CHRONIC PROGRESSIVE NEPHROPATHY	A spontaneous, age-related renal disease of rats, characterized by morphological changes such as degeneration of the epithelium lining of the tubules, thickening of glomerular, Bowman and proximal tubular basement membranes, and lesions in the glomeruli leading to mesangial overload and glomerulosclerosis.			Disease or Syndrome	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120873>	C36281	Cutaneous Crust|CRUST|Scab|Scab	A hard covering or layer of solid matter formed by dried bodily exudate or secretion.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|Clinical Data Interchange Standards Consortium Terminology
C120874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120874>	C35867	Degeneration and Atrophy|Atrophy/Degeneration|DEGENERATION/ATROPHY	A finding that generally has features of degeneration and atrophy.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120875>	C35867	Degeneration and Necrosis|DEGENERATION/NECROSIS|Necrosis/Degeneration	A finding that generally has features of degeneration and necrosis.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120876>	C35867	Degeneration and Regeneration|DEGENERATION/REGENERATION|Regeneration/Degeneration	A finding that generally has features of degeneration and regeneration.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120877>	C16956	Ectasia|ECTASIA	A pathophysiological process characterized by the dilatation or expansion of a hollow, tubular tissue or organ.			Phenomenon or Process	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120878>	C61557	Elastosis|ELASTOSIS	Degenerative changes in elastic tissues.			Phenomenon or Process	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120879>	C35867	Respiratory Tract Epithelial Alteration|EPITHELIAL ALTERATION	A change or slight modification in the epithelial cells along the respiratory tract.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12087>	C61007	Bevacizumab/Cisplatin/Gemcitabine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120880>	C3824	Eroded and Ulcerated Lesion|EROSION/ULCER|Erosion/Ulceration|Ulcer/Erosion	A finding of both erosion and ulceration in the same lesion.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120881>	C16956	Fibroplasia|FIBROPLASIA	The formation of fibrous tissue characterized by an increased number of active, plump fibroblasts and variable amounts of collagen.			Phenomenon or Process	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120882>	C35867	Focus of Cellular Alteration|FOCUS OF CELLULAR ALTERATION|Foci of Cellular Alteration|Focus/foci of Cellular Alteration	A group of cell that show altered characteristics in comparison to normal cell types and are confined to a specific area of the sample.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120883>	C35867	Fungus Present|FUNGUS|Fungi	Confirmatory presence of fungal microorganisms.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120884>	C61557	Germ Cell Degeneration|GERM CELL DEGENERATION	Disturbance of cellular integrity and deterioration of germ cells.			Phenomenon or Process	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120885>	C16956	Germ Cell Depletion|GERM CELL DEPLETION	Reduction in the number of germ cells.			Phenomenon or Process	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120886>	C35867	Germ Cell Depletion and Germ Cell Degeneration|GERM CELL DEPLETION/GERM CELL DEGENERATION|Germ Cell Degeneration/Germ Cell Depletion	A finding of both germ cell depletion and germ cell degeneration.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120887>	C34843	Glomerulopathy|GLOMERULOPATHY	Chronic degenerative changes in the glomeruli characterized by loss of cellularity of glomerular capillary tufts and acellular deposition of immunoglobulins.			Disease or Syndrome	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|NICHD Terminology|Pediatric Nephrology Terminology
C120888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120888>	C34843	Glomerulosclerosis|GLOMERULOSCLEROSIS|Glomerular Sclerosis	A hardening of the kidney glomerulus caused by scarring of the blood vessels.			Disease or Syndrome	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|NICHD Terminology|Pediatric Nephrology Terminology
C120889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120889>	C137801	Hepatodiaphragmatic Nodule|HEPATODIAPHRAGMATIC NODULE	A congenital abnormality found in Fisher 344 rats characterized by grossly visible nodule(s) usually located on the median lobe of the liver.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12088>	C61007	Docetaxel/Estramustine/Thalidomide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120890>	C35867	Hyperplasia and Metaplasia|HYPERPLASIA/METAPLASIA|Metaplasia/Hyperplasia	A finding of both hyperplastic and metaplastic changes in a pathologic process.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120891>	C35867	Hypertrophy and Hyperplasia|HYPERTROPHY/HYPERPLASIA|Hyperplasia/Hypertrophy	A finding of both hypertrophy and hyperplasia in the same lesion.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120892>	C35867	Hypertrophy and Karyomegaly|HYPERTROPHY/KARYOMEGALY|Karyomegaly/Hypertrophy	A finding of both hypertrophy and karyomegaly in the same lesion.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120893>	C16956	Hypoplasia|HYPOPLASIA	Incomplete or underdevelopment of a tissue or organ.	Hypoplasia		Pathologic Function	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Nephrology Terminology
C120894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120894>	C35867	Karyocytomegaly|KARYOCYTOMEGALY	An increase in nuclear size and amount of cytoplasm of a cell. The cells or nucleus may be slightly irregular and/or may be polyploid.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120895>	C35867	Karyocytomegaly and Multinucleated Hepatocytes|KARYOCYTOMEGALY/MULTINUCLEATED HEPATOCYTES|Multinucleated Hepatocytes/Karyocytomegaly	A finding of both karyocytomegaly and multinucleated hepatocytes in the same lesion.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120896>	C16956	Karyomegaly|KARYOMEGALY|Nuclear Enlargement	An increase in the size of a cellular nucleus.			Phenomenon or Process	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120897>	C16956	Mesangiolysis|MESANGIOLYSIS	A process characterized by the degeneration of mesangial cells and the dissolution of the mesangial matrix in the glomerulus of the kidney, in response to injury or disease.			Phenomenon or Process	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120898>	C16956	Microgliosis|MICROGLIOSIS	An accumulation of microglial cells in nervous tissue as a result of injury.			Phenomenon or Process	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120899>	C21124	Mineralization|Calcification|MINERALIZATION|Mineral	The process by which an organic substance is converted into organic minerals, such as in the formation of bone.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12089>	C61007	Alemtuzumab/Fludarabine/Melphalan			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1208>	C2170|C1557	Pyrazofurin|.beta.-Pyrazomycin|1H-Pyrazole-5-carboxamide, 4-Hydroxy-3-beta-D-ribofuranosyl- (9CI)|1H-Pyrazole-5-carboxamide, 4-hydroxy-3-.beta.-D-ribofuranosyl- (9CI)|4-Hydroxy-3-.beta.-D-ribofuranosylpyrazole-5-carboxamide|4-Hydroxy-3-beta-D-ribofuranosylpyrazole-5-carboxamide|47599|47599|Beta-Pyrazomycin|Compound 47599|PRZF|PYRAZOFURIN|PYRAZOFURIN|Pirazofurin|Pirazofurin|Pyrazole, -3-Carboxamide, 4-Hydroxy-5-beta-L-ribofuranosyl|Pyrazole, -3-carboxamide, 4-hydroxy-5-.beta.-L-ribofuranosyl-|Pyrazomycin|Pyrazomycin	A nucleoside analog.  Pyrazofurin potently inhibits orotidine 5'-monophosphate (OMP) decarboxylase, thereby interfering with de novo synthesis of uridine nucleotides and resulting in cytotoxicity.  This agent also causes a rapid depletion of the pyrimidine deoxynucleotide pool, thereby inhibiting DNA synthesis and cell replication. (NCI04)			Antibiotic|Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C120900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120900>	C36788	Multinucleated Hepatocyte|MULTINUCLEATED HEPATOCYTES	A giant hepatocyte with multiple nuclei.			Cell	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120901>	C26115	Neuronophagia|NEURONOPHAGIA	The phagocytic destruction of nerve cells.			Cell Function	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120902>	C34843	Obstructive Nephropathy|OBSTRUCTIVE NEPHROPATHY	Renal damage and impaired renal function secondary to urinary tract obstruction.			Disease or Syndrome	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|NICHD Terminology|Pediatric Nephrology Terminology
C120903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120903>	C35867	Parasite Present|PARASITE|Parasites	Confirmatory presence of parasitic microorganisms.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120904>	C70699	Proteinaceous Plug|PROTEINACEOUS PLUG|Seminal Plug	A loosely organized mass found in the bladder and/or urethra of male rats, composed of eosinophilic material intermingled with exfoliated urothelial cells, and occasionally containing spermatozoa. Plug formation is assumed to be a result of abnormal ejaculation and secretions from the male accessory sex glands, and may occur during euthanasia.			Body Substance	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120905>	C34843	Reflux Nephropathy|RETROGRADE NEPHROPATHY	Chronic kidney damage due to vesicoureteral reflux.			Disease or Syndrome	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|NICHD Terminology|Pediatric Nephrology Terminology
C120906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120906>	C36282	Septal Deviation|Deviated Septum|SEPTAL DEVIATION	An alteration of the septum from the midline.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120907>	C36284	Spermatic Stasis|SPERM STASIS	Stoppage of flow of sperm due to obstruction.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120908>	C117719	Spermatid Retention|SPERMATID RETENTION	Persistence of mature elongating spermatids in the seminiferous tubules after the normal stage of physiologic release.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120909>	C117719	Spermatocele|SPERMATOCELE	A benign cystic dilatation in the head of the epididymis that contains milky or watery fluid and spermatozoa.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120910>	C137801	Tension Lipidosis|TENSION LIPIDOSIS	A focus of hepatocytes containing well delineated circular clear spaces in the liver, often near mesenteric attachments such as the falciform ligament.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120911>	C12913	Alzheimer Type II Astrocyte|TYPE II ASTROCYTES	An abnormal and pathological astrocyte which appears enlarged and metabolically hyperactive. It is characterized by the presence of vesicular and basophilic nuclei. This cell type is not associated with Alzheimer's Disease.			Cell	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120912>	C3824	Vesicle|VESICLE	An abnormal fluid-filled cleft (e.g. as in the epidermis) or membrane-bound space.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120913>	C205055	Yeast Present|YEAST	Confirmatory presence of yeast microorganisms.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120914>	C25209	Physical Activity Measurement|ACTIVITY|Activity|Activity	A measurement of a subject's physical activity or movement.	Physical Activity Measurement		Quantitative Concept	CDISC SEND Cardiovascular Test Code Terminology|CDISC SEND Cardiovascular Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C120915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120915>	C120545	dP/dt Average|DPDTAVG	The average rate of pressure change over time within the left ventricle, which is used as a measurement of left ventricular contractility.			Diagnostic Procedure	CDISC SEND Cardiovascular Test Code Terminology|CDISC SEND Cardiovascular Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120916>	C120545	Left Ventricular Maximum Positive dP/dt|+dPdt|DPDTMAX|dPdt Maximum	The maximum rate of positive pressure (systolic) change within the left ventricle during a unit time.			Diagnostic Procedure	CDISC SEND Cardiovascular Test Code Terminology|CDISC SEND Cardiovascular Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120917>	C120545	Left Ventricular Minimum Positive dP/dt|-dP/dt|DPDTMIN|Left Ventricular Maximum Negative dP/dt	The minimum rate of positive pressure (systolic) change within the left ventricle during a unit time.			Diagnostic Procedure	CDISC SEND Cardiovascular Test Code Terminology|CDISC SEND Cardiovascular Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120918>	C120545	Left Ventricular Maximum Negative dP/dt	The maximum rate of negative pressure (diastolic) change within the left ventricle during a unit time.			Diagnostic Procedure	
C120919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120919>	C25299	Left Ventricular End Diastolic Pressure|LVEDP|LVEDP|Left ventricular end-diastolic pressure (mm Hg)	The pressure within the left ventricle following the completion of diastolic filling, just prior to systole.			Quantitative Concept	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 7: Diagnostic Procedures Terminology|CDISC SEND Cardiovascular Test Code Terminology|CDISC SEND Cardiovascular Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12091>	C61063	Carboplatin/Etoposide/PS-341			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120920>	C25298	Left Ventricular Systolic Pressure|LVSYSBP	The pressure in the left ventricle at any point prior to the ejection of its contents into the aorta (systole).			Quantitative Concept	CDISC SEND Cardiovascular Test Code Terminology|CDISC SEND Cardiovascular Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120921>	C62085	Maximum QA Interval|QAMAX|QAMAX|Summary (Max) QA Interval|Summary (Max) QA Interval|Summary (Max) QA Interval	The maximum time between the recording of a Q wave on ECG and the onset of the aortic blood pressure pulse.			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120922>	C62085	Mean QA Interval|QAMEAN|QAMEAN|Summary (Mean) QA Interval|Summary (Mean) QA Interval|Summary (Mean) QA Interval	The calculated average time period between the recording of a Q wave on ECG and the onset of the aortic blood pressure pulse as determined over a number of cardiac cycles during a given interval of time.			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120923>	C62085	Median QA Interval|QAMEDIAN|QAMEDIAN|Summary (Median) QA Interval|Summary (Median) QA Interval|Summary (Median) QA Interval	The median time period between the recording of a Q wave on ECG and the onset of the aortic blood pressure pulse as determined over a number of cardiac cycles during a given interval of time.			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120924>	C62085	Minimum QA Interval|QAMIN|QAMIN|Summary (Min) QA Interval|Summary (Min) QA Interval|Summary (Min) QA Interval	The minimum time between the recording of a Q wave on ECG and the onset of the aortic blood pressure pulse.			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120925>	C90458	Standard for the Exchange of Nonclinical Data Implementation Guide Version 3.1|SEND IG Version 3.1|SEND IMPLEMENTATION GUIDE VERSION 3.1	The 3.1 version of the standard for exchange of nonclinical data (SEND) implementation guide.			Intellectual Product	CDISC SEND Terminology|CDISC SEND Version Terminology|Clinical Data Interchange Standards Consortium Terminology
C120926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120926>	C22188	Air Sac|AIR SAC	A part of the respiratory system in multiple species (predominantly avian) which are variably connected with the lung.			Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120927>	C38081	Airway Resistance|AIRRES|RAW|Raw	An assessment of the opposition to airflow through the respiratory tract on inspiration and/or expiration.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Respiratory Test Code Terminology|CDISC SEND Respiratory Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120928>	C38081	Depth of Respiration|DEPTHRES	A clinical judgment made based on the apparent volume of gas being inspired or expired.			Diagnostic Procedure	CDISC SEND Respiratory Test Code Terminology|CDISC SEND Respiratory Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120929>	C38081	End Expiratory Pause|ENDEXPPR	The period of time between the end of exhalation and the active start of inspiration.			Diagnostic Procedure	CDISC SEND Respiratory Test Code Terminology|CDISC SEND Respiratory Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12092>	C61063	Pegylated Interferon Alfa/Temozolomide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120930>	C38081	End Inspiratory Pause|ENDINSPR	The period of time between the end of inhalation and the active start of expiration.			Diagnostic Procedure	CDISC SEND Respiratory Test Code Terminology|CDISC SEND Respiratory Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120931>	C38081	Expiration Relaxation Time|EXPRELTM|EXPRELTM	The amount of time required to reach a specific tidal volume as measured from the start of exhalation.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Respiratory Test Code Terminology|CDISC SEND Respiratory Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120932>	C38081	Expiratory Time|EXPTIME|Expiration Time|Expiration Time	The recorded time interval between the initiation of exhalation and the time at which no further lung volume reduction occurs.			Diagnostic Procedure	CDISC SEND Respiratory Test Code Terminology|CDISC SEND Respiratory Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120933>	C38081	Forced Expiratory Volume|FEV	The volume of gas an individual can forcible exhale from the lungs in one breath.			Diagnostic Procedure	CDISC SEND Respiratory Test Code Terminology|CDISC SEND Respiratory Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120934>	C38081	Inspiratory Time|INSTIME|Inspiration Time|Inspiration Time	The recorded time interval between the initiation of inhalation and the point at which no further lung volume expansion occurs.			Diagnostic Procedure	CDISC SEND Respiratory Test Code Terminology|CDISC SEND Respiratory Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120935>	C38081	Mean Pulmonary Arterial Pressure|MPAP|PA mean pressure	The average blood pressure reading in the pulmonary artery as calculated through multiple cardiac cycles.			Diagnostic Procedure	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|Appendix 7: Diagnostic Procedures Terminology|CDISC SEND Respiratory Test Code Terminology|CDISC SEND Respiratory Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120936>	C38081	Minute Volume|MV|MV|Minute Ventilation|VE	The volume of gas inhaled or exhaled from the lungs during sixty seconds.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Respiratory Test Code Terminology|CDISC SEND Respiratory Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120937>	C38081	Enhanced Pause|PENH	A composite lung function endpoint that is composed of peak inspiratory and peak expiratory flows, expiration time, and relaxation time, is used to measure the occurrence and prolongation of apnea periods, and is scaled to inspiratory/expiratory strength to account for breathing variability.			Diagnostic Procedure	CDISC SEND Respiratory Test Code Terminology|CDISC SEND Respiratory Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120938>	C38081	Peak Expiratory Pressure|PKEXPPR	The maximum amount of pressure applied to the lungs during expiration.			Diagnostic Procedure	CDISC SEND Respiratory Test Code Terminology|CDISC SEND Respiratory Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120939>	C38081	Peak Inspiratory Flow Rate|PIF|PKINSFL|Peak Inspiratory Flow|Peak Inspiratory Flow|Peak Inspiratory Flow	The fastest flow rate of gas noted during the inspiratory cycle.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Respiratory Test Code Terminology|CDISC SEND Respiratory Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12093>	C61007	Bevacizumab/Docetaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120940>	C38081	Peak Inspiratory Pressure|PKINSPR	The maximum amount of pressure applied to the lungs during inhalation.			Diagnostic Procedure	CDISC SEND Respiratory Test Code Terminology|CDISC SEND Respiratory Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120941>	C38081	Pulmonary Artery Diastolic Pressure|PA diastolic pressure|PULDIABP|Pulmonary Diastolic Pressure|Pulmonary Diastolic Pressure	The blood pressure in the pulmonary artery during ventricular relaxation (diastole).			Diagnostic Procedure	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|Appendix 7: Diagnostic Procedures Terminology|CDISC SEND Respiratory Test Code Terminology|CDISC SEND Respiratory Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120942>	C38081	Pulmonary Compliance|PULMCOMP	A measure of the lung's ability to stretch and expand, either statically, the change in volume for a given applied pressure, or dynamically, the elasticity of the lung at any given time during the actual movement of air.			Diagnostic Procedure	CDISC SEND Respiratory Test Code Terminology|CDISC SEND Respiratory Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120943>	C38081	Pulmonary Artery Systolic Pressure|PA systolic pressure|PULSYSBP|Pulmonary Systolic Pressure|Pulmonary Systolic Pressure	The blood pressure in the pulmonary artery during the contraction of the left ventricle of the heart.			Diagnostic Procedure	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|Appendix 7: Diagnostic Procedures Terminology|CDISC SEND Respiratory Test Code Terminology|CDISC SEND Respiratory Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120944>	C43578	Good Laboratory Practice Indicator Flag|GLP Flag|GLP Flag|GLPFL|Good Laboratory Practice Flag	An indicator that can be set or unset in order to signal whether the study has been conducted using good laboratory practice standards.			Functional Concept	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C120945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120945>	C35867	Inclusion Body|INCLUSION|Inclusion Bodies|Inclusions	A detectable aggregation of substance in the cytoplasm or nucleus.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C120946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120946>	C25790	GNLY Gene|GNLY|GNLY|Granulysin Gene	This gene is involved in the antimicrobial activity of cytotoxic T-lymphocytes and natural killer cells.	GNLY Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C120947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120947>	C120946	GNLY wt Allele|519|D2S69E|Granulysin wt Allele|LAG-2|LAG2|Lymphocyte-Activation Gene 2|NKG5|T-Lymphocyte Activation Gene 519|TLA519	Human GNLY wild-type allele is located in the vicinity of 2p11.2 and is approximately 14 kb in length. This allele, which encodes granulysin protein, plays a role in defense responses to microbial infection.	GNLY wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120948>	C16725	Granulysin|Lymphokine LAG-2|Protein NKG5|T-Cell Activation Protein 519	Granulysin (145 aa, ~16 kDa) is encoded by the human GNLY gene. This protein is involved in the antimicrobial activity of cytotoxic granules of cytotoxic T-lymphocytes and natural killer cells.	Granulysin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120949>	C20103	CD48 Gene|CD48|CD48|CD48 Molecule Gene	This gene plays a role in the activation and differentiation of lymphocytes, dendritic cells and endothelial cells.	CD48 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C12094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12094>	C61063	NY-ESO-1 peptide vaccine/Sargramostim			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120950>	C120949	CD48 wt Allele|BCM1|BLAST|BLAST1|CD48 Antigen (B-Cell Membrane Protein) Gene|CD48 Molecule wt Allele|MEM-102|SLAM Family, Member 2 Gene|SLAMF2|hCD48|mCD48	Human CD48 wild-type allele is located within 1q21.3-q22 and is approximately 33 kb in length. This allele, which encodes CD48 antigen protein, is involved in CD2 signaling.	CD48 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120951>	C18106	CD48 Antigen|B-Cell Activation Marker|B-Cell Membrane Protein|B-Lymphocyte Activation Marker BLAST-1|BCM1 Surface Antigen|Leukocyte Antigen MEM-102|SLAM Family Member 2|SLAMF2|Signaling Lymphocytic Activation Molecule 2|TCT.1	CD48 antigen (243 aa, ~28 kDa) is encoded by the human CD48 gene. This protein plays a role in both CD2 binding and activation of ligand-dependent signaling pathways.	CD48 Antigen		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120952>	C91105	Outcome Satisfaction Questionnaire|Treatment Outcome Satisfaction Questionnaire	A set of questions and responses designed to evaluate an individual's self-reported satisfaction with the outcome of treatment.			Intellectual Product	
C120953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120953>	C91105	Follow-Up Outcome Expectations Questionnaire	A set of questions and responses designed to evaluate an individual's self-reported expectations with the outcome of treatment.			Intellectual Product	
C120954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120954>	C18568	FGF22 Gene|FGF22|FGF22|Fibroblast Growth Factor 22 Gene	This gene is involved in glucose and lipid metabolism.	FGF22 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C120955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120955>	C120954	FGF22 wt Allele|Fibroblast Growth Factor 22 wt Allele|UNQ2500/PRO5800	Human FGF22 wild-type allele is located in the vicinity of 19p13.3 and is approximately 4 kb in length. This allele, which encodes fibroblast growth factor 22 protein, plays a role in both glucose homeostasis and lipid metabolism.	FGF22 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120956>	C173812|C173045	Ability to do Self-Care After Treatment Question|Ability to do Self-Care After Treatment|Doing self-care, such as washing and dressing	A question about an individual's ability to do self-care since treatment.			Intellectual Product	Outcome Satisfaction Questionnaire
C120957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120957>	C173812|C173045	Ability to Get Out and About After Treatment Question|Ability to Get Out and About After Treatment|Getting out and about	A question about an individual's ability to get out and about since treatment.			Intellectual Product	Outcome Satisfaction Questionnaire
C120958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120958>	C20426	Fibroblast Growth Factor 22|FGF-22	Fibroblast growth factor 22 (170 aa, ~20 kDa) is encoded by the human FGF22 gene. This protein is involved in the regulation of both lipid metabolism and glucose homeostasis.	Fibroblast Growth Factor 22		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120959>	C173812|C173458	Ability to do Household Chores After Treatment Question|Ability to do Household Chores After Treatment|Doing household chores, such as cleaning and yard work	A question about an individual's ability to do household chores since treatment.			Intellectual Product	Outcome Satisfaction Questionnaire
C12095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12095>	C61007	Anti-CD3 x Anti-HER-2-Neu Bispecific Monoclonal Antibody/Autologous Lymphocytes/Interleukin-2/Sargramostim			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120960>	C173812|C173045	Ability to Sleep After Treatment Question|Ability to Sleep After Treatment|Sleeping	A question about an individual's ability to sleep since treatment.			Intellectual Product	Outcome Satisfaction Questionnaire
C120961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120961>	C173812|C173045	Ability to do Recreation and Leisure Activities After Treatment Question|Ability to do Recreation and Leisure Activities After Treatment|Doing recreational and leisure activities, such as hobbies and sports	A question about an individual's ability to do recreation and leisure activities since treatment.			Intellectual Product	Outcome Satisfaction Questionnaire
C120962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120962>	C173812|C173045	Ability to do Social Activities After Treatment Question|Ability to do Social Activities After Treatment|Doing social activities with family, friends, neighbors, and groups	A question about an individual's ability to do social activities since treatment.			Intellectual Product	Outcome Satisfaction Questionnaire
C120963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120963>	C20194	ATG7 Gene|ATG7|ATG7|Autophagy Related 7 Gene	This gene plays a role in both autophagy and the transport of cytoplasmic molecules to vacuoles.	ATG7 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C120964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120964>	C173924|C173812|C173509|C173045	Ability to do Current Work or School Activities After Treatment Question|Ability to do Current Work or School Activities After Treatment|Doing current work or school activities	A question about an individual's ability to do current work or school activities since treatment.			Intellectual Product	Outcome Satisfaction Questionnaire
C120965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120965>	C173812|C173792	Appearance of Arm or Leg After Treatment Question|Appearance of Arm or Leg After Treatment|How satisfied are you with the appearance of your arm/leg	A question about the appearance of an individual's arm or leg since treatment.			Intellectual Product	Outcome Satisfaction Questionnaire
C120966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120966>	C120963	ATG7 wt Allele|APG7|APG7 Autophagy 7-Like (S. cerevisiae) Gene|APG7-LIKE|APG7L|ATG7 Autophagy Related 7 Homolog (S. cerevisiae) Gene|Autophagy 7, S. cerevisiae, Homolog of Gene|Autophagy Related 7 wt Allele|DKFZp434N0735|GSA7	Human ATG7 wild-type allele is located in the vicinity of 3p25.3 and is approximately 285 kb in length. This allele, which encodes ubiquitin-like modifier-activating enzyme ATG7 protein, is involved in the regulation of autophagy.	ATG7 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120967>	C173812|C173792|C173219	Sensations in Arm or Leg After Treatment Question|How satisfied are you with how your arm/leg feels, that is any sensations, such as pain, numbness, tingling|Sensations in Arm or Leg After Treatment	A question about the sensations in an individual's arm or leg since treatment.			Intellectual Product	Outcome Satisfaction Questionnaire
C120968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120968>	C173812|C173792	Overall Satisfaction with Results of Treatment Question|All things considered, how satisfied are you with the results of your treatment|Overall Satisfaction with Results of Treatment	A question about an individual's overall satisfaction with results of treatment since treatment.			Intellectual Product	Outcome Satisfaction Questionnaire
C120969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120969>	C18466	Ubiquitin-Like Modifier-Activating Enzyme ATG7|APG7-Like|ATG12-Activating Enzyme E1 ATG7|ATG7 Autophagy Related 7 Homolog|Autophagy-Related Protein 7|Ubiquitin Activating Enzyme E1-Like Protein|Ubiquitin-Activating Enzyme E1-Like Protein	Ubiquitin-like modifier-activating enzyme ATG7 (703 aa, ~78 kDa) is encoded by the human ATG7 gene. This protein plays a role in both cytoplasm to vacuole transport and autophagy.	Ubiquitin-Like Modifier-Activating Enzyme ATG7		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12096>	C61007	Busulfan/Fludarabine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120970>	C176250	Extremely Satisfied	A subjective response indicating that an individual is extremely satisfied.			Intellectual Product	Outcome Satisfaction Questionnaire
C120971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120971>	C176250	Somewhat Satisfied	A subjective response indicating that an individual is somewhat satisfied.			Intellectual Product	Outcome Satisfaction Questionnaire
C120972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120972>	C176250	Neither Satisfied nor Dissatisfied|Neutral	A subjective response indication that an individual is neither satisfied nor dissatisfied.			Intellectual Product	Outcome Satisfaction Questionnaire
C120973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120973>	C20194	TNFAIP2 Gene|TNFAIP2|TNFAIP2|Tumor Necrosis Factor, Alpha-Induced Protein 2 Gene	This gene may be involved in the mediation of both inflammation and angiogenesis.	TNFAIP2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C120974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120974>	C176250	Somewhat Dissatisfied	A subjective response indicating that an individual is somewhat dissatisfied.			Intellectual Product	Outcome Satisfaction Questionnaire
C120975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120975>	C176250	Extremely Dissatisfied	A subjective response indicating that an individual is extremely dissatisfied.			Intellectual Product	Outcome Satisfaction Questionnaire
C120976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120976>	C120973	TNFAIP2 wt Allele|B94|EXOC3L3|Tumor Necrosis Factor, Alpha-Induced Protein 2 wt Allele	Human TNFAIP2 wild-type allele is located in the vicinity of 14q32 and is approximately 14 kb in length. This allele, which encodes tumor necrosis factor alpha-induced protein 2, may play a role in angiogenesis and inflammation.	TNFAIP2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120977>	C18466	Tumor Necrosis Factor Alpha-Induced Protein 2|Exocyst Complex Component 3-Like 3|Primary Response Gene B94 Protein|TNF Alpha-Induced Protein 2|TNFAIP2|Tumor Necrosis Factor-Alpha-Induced Protein 2	Tumor necrosis factor alpha-induced protein 2 (654 aa, ~73 kDa) is encoded by the human TNFAIP2 gene. This protein may be involved in the regulation of both inflammation and angiogenesis.	Tumor Necrosis Factor Alpha-Induced Protein 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C120978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120978>	C100110	CDISC Questionnaire CRQ-SAS First Administration Version Test Name Terminology|CRQ01TN|Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire Test Name|QS-CRQ-SAS First Administration Version TEST	Test names of questionnaire questions associated with the Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version (CRQ-SAS First Administration Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120979>	C100110	CDISC Questionnaire CRQ-SAS First Administration Version Test Code Terminology|CRQ01TC|Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire Test Code|QS-CRQ-SAS First Administration Version TESTCD	Test codes of questionnaire questions associated with the Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version (CRQ-SAS First Administration Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12097>	C61063	Temozolomide/ZD 1839			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120980>	C100110	CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Name Terminology|CRQ02TN|Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire Test Name|QS-CRQ-SAS Follow-Up Administration Version TEST	Test names of questionnaire questions associated with the Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version (CRQ-SAS Follow-Up Administration Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120981>	C100110	CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Code Terminology|CRQ02TC|Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire Test Code|QS-CRQ-SAS Follow-Up Administration Version TESTCD	Test codes of questionnaire questions associated with the Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version (CRQ-SAS Follow-Up Administration Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120982>	C115302	CDISC Functional Test BACS Test Name Terminology|BACS1TN|Brief Assessment of Cognition in Schizophrenia Functional Test Test Name|FT- BACS TEST	Test names of functional test questions associated with the Brief Assessment of Cognition in Schizophrenia (BACS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120983>	C115302	CDISC Functional Test BACS Test Code Terminology|BACS1TC|Brief Assessment of Cognition in Schizophrenia Functional Test Test Code|FT- BACS TESTCD	Test codes of functional test questions associated with the Brief Assessment of Cognition in Schizophrenia (BACS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120984>	C118970	CDISC Clinical Classification APACHE II Test Name Terminology|APCH1TN|Acute Physiology and Chronic Health Evaluation II Clinical Classification Test Name|CC-APACHE II TEST	Test names of clinical classification questions associated with the Acute Physiology and Chronic Health Evaluation II (APACHE II) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120985>	C118970	CDISC Clinical Classification APACHE II Test Code Terminology|APCH1TC|Acute Physiology and Chronic Health Evaluation II Clinical Classification Test Code|CC-APACHE II TESTCD	Test codes of clinical classification questions associated with the Acute Physiology and Chronic Health Evaluation II (APACHE II) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120986>	C118970	CDISC Clinical Classification BODE Index Test Name Terminology|BODE01TN|CC-BODE Index TEST|The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index Clinical Classification Test Name	Test names of clinical classification questions associated with the The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index (BODE Index) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120987>	C118970	CDISC Clinical Classification BODE Index Test Code Terminology|BODE01TC|CC-BODE Index TESTCD|The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index Clinical Classification Test Code	Test codes of clinical classification questions associated with the The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index (BODE Index) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120988>	C118970	CDISC Clinical Classification Child-Pugh Test Name Terminology|CC-Child-Pugh TEST|CPS01TN|Child-Pugh Classification Clinical Classification Test Name	Test names of clinical classification questions associated with the Child-Pugh Classification (Child-Pugh) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120989>	C118970	CDISC Clinical Classification Child-Pugh Test Code Terminology|CC-Child-Pugh TESTCD|CPS01TC|Child-Pugh Classification Clinical Classification Test Code	Test codes of clinical classification questions associated with the Child-Pugh Classification (Child-Pugh) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12098>	C61007	Carboplatin/Cetuximab/Gemcitabine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C120990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120990>	C118970	CDISC Clinical Classification MELD Test Name Terminology|CC-MELD TEST|MELD01TN|Model for End Stage Liver Disease Clinical Classification Test Name	Test names of clinical classification questions associated with the Model for End Stage Liver Disease (MELD) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120991>	C118970	CDISC Clinical Classification MELD Test Code Terminology|CC-MELD TESTCD|MELD01TC|Model for End Stage Liver Disease Clinical Classification Test Code	Test codes of clinical classification questions associated with the Model for End Stage Liver Disease (MELD) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120992>	C118970	CDISC Clinical Classification NSA-16 Test Name Terminology|CC-NSA-16 TEST|NSA01TN|Negative Symptom Assessment-16 Clinical Classification Test Name	Test names of clinical classification questions associated with the Negative Symptom Assessment-16 (NSA-16) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120993>	C118970	CDISC Clinical Classification NSA-16 Test Code Terminology|CC-NSA-16 TESTCD|NSA01TC|Negative Symptom Assessment-16 Clinical Classification Test Code	Test codes of clinical classification questions associated with the Model for Negative Symptom Assessment-16 (NSA-16) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C120994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120994>	C211913	APACHE II Clinical Classification Question	A question associated with the APACHE II clinical classification.			Intellectual Product	
C120995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120995>	C211913	BODE Index Clinical Classification Question	A question associated with the BODE Index clinical classification.			Intellectual Product	
C120996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120996>	C211913	Child-Pugh Clinical Classification Question	A question associated with the Child-Pugh clinical classification.			Intellectual Product	
C120997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120997>	C211913	MELD Clinical Classification Question	A question associated with the MELD clinical classification.			Intellectual Product	
C120998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120998>	C211913	NSA-16 Clinical Classification Question	A question associated with the NSA-16 clinical classification.			Intellectual Product	
C120999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C120999>	C211913	BACS Functional Test Question	A question associated with the BACS functional test.			Intellectual Product	
C12099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12099>	C61063	APC8015/Bevacizumab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1209>	C1915	Pyrene|Benzo(def)phenanthrene|PYRENE|PYRENE	A parent class of polycyclic aromatic hydrocarbons containing four fused rings. (IUPAC 1998)			Chemical Viewed Functionally|Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C121000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121000>	C211913	CRQ-SAS First Administration Version Questionnaire Question	A question associated with the CRQ-SAS First Administration Version questionnaire.			Intellectual Product	
C121001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121001>	C211913	CRQ-SAS Follow-Up Administration Version Questionnaire Question	A question associated with the SAS Follow-Up Administration Version questionnaire.			Intellectual Product	
C121002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121002>	C126891	Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire|CRQ-SAS FIRST ADMINISTRATION VERSION|CRQ-SAS First Administration Version|CRQ01	A standardized rating scale developed by Schunemann et al in 2003, which is a self-administered instrument used to measure the health-related quality of life (HRQL) in patients with chronic airflow limitation. The first administration version contains 20 items and four domains: dyspnea, fatigue, emotional functioning and mastery.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121003>	C126891	Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire|CRQ-SAS FOLLOW-UP ADMINISTRATION VERSION|CRQ-SAS Follow-Up Administration Version|CRQ02	A standardized rating scale developed by Schunemann et al in 2003, which is a self-administered instrument used to measure the health-related quality of life (HRQL) in patients with chronic airflow limitation. The follow-up administration version contains 20 items and four domains: dyspnea, fatigue, emotional functioning and mastery.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121004>	C222259	Brief Assessment of Cognition in Schizophrenia Functional Test|BACS|BACS|BACS1	A standardized rating scale developed by Keefe et al in 2004 to assess cognitive function and impairment in patients with schizophrenia. This instrument consists 6 tests in the following areas: verbal memory, working memory, motor speed, verbal fluency, attention, and executive function.			Intellectual Product	CDISC Functional Test Category Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121005>	C118969	Acute Physiology and Chronic Health Evaluation II Clinical Classification|APACHE II|APACHE II|APCH1	A standardized rating scale developed by Knaus et al in 1985, which is a classification system used to measure severity of disease. This instrument uses a point score system based on physiological measurements, age and previous health status.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121006>	C118969	The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index Clinical Classification|BODE INDEX|BODE Index|BODE01	A standardized rating scale developed by Celli et al in 2004, which is a multidimensional grading system used to assess the respiratory and systemic expressions of COPD, and to predict the risk of death among patients with COPD. This instrument has a total possible values range from 0 to 10, based on FEV1, body-mass index, the distance walked in six minutes, and the modified MRC dyspnea scale.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121007>	C118969	Child-Pugh Clinical Classification|CHILD-PUGH CLASSIFICATION|CPS01|Child-Pugh|Child-Pugh Classification|Child-Pugh Classification|Child-Pugh Score|child pugh classification|child_pugh_classification	A standardized rating scale used to assess the severity of liver cirrhosis and determine the prognosis, the required strength of treatment, and the necessity of liver transplantation. This instrument uses the following clinical and lab criteria: encephalopathy grade, ascites, bilirubin, albumin, and prothrombin index.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology|GDC Property Terminology|GDC Terminology
C121008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121008>	C118969	Model for End Stage Liver Disease Clinical Classification|MELD|MELD|MELD01	A standardized rating scale developed by Malinchoc et al in 2000, which is a classification system used to assess severity of chronic liver disease and to determine the urgency of a subject needing a liver transplant within the next three months. This instrument uses the values of serum bilirubin and creatinine, and the international normalized ratio for prothrombin time (INR) to predict survival for patients with advanced liver disease.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121009>	C118969	Negative Symptom Assessment-16 Clinical Classification|NSA-16|NSA-16|NSA01	A standardized rating scale developed by Axelrod et al in 1993, which is a classification system used to assess the presence, severity, and various negative symptoms associated with schizophrenia. This instrument contains 16 items and the characterization of negative symptoms is based on a 5-factor model: communication, emotion/affect, social involvement, motivation, and retardation.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12100>	C61063	ALVAC-CEA-B7.1 vaccine/Fluorouracil/Irinotecan/Leucovorin calcium			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121010>	C121000	CRQ-SAS First Administration Version - Feeling Emotional|CRQ01-Feeling Emotional|CRQ01-Feeling Emotional|CRQ0101	Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) Feeling emotional such as angry or upset.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121011>	C121000	CRQ-SAS First Administration Version - Take Care of Basic Needs|CRQ01-Take Care of Basic Needs|CRQ01-Take Care of Basic Needs|CRQ0102	Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) Taking care of your basic needs (bathing, showering, eating or dressing).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121012>	C121000	CRQ-SAS First Administration Version - Walking|CRQ01-Walking|CRQ01-Walking|CRQ0103	Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) Walking.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121013>	C121000	CRQ-SAS First Administration Version - Performing Chores|CRQ01-Performing Chores|CRQ01-Performing Chores|CRQ0104	Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) Performing chores (such as housework, shopping groceries).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121014>	C121000	CRQ-SAS First Administration Version - Participate in Social Activities|CRQ01-Participate in Social Activities|CRQ01-Participate in Social Activities|CRQ0105	Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) Participating in social activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121015>	C121000	CRQ-SAS First Administration Version - Felt Frustrated or Impatient|CRQ01-Felt Frustrated or Impatient|CRQ01-Felt Frustrated or Impatient|CRQ0106	Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) In general, how much of the time during the last 2 weeks have you felt frustrated or impatient?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121016>	C121000	CRQ-SAS First Administration Version - Feeling of Fear or Panic|CRQ01-Feeling of Fear or Panic|CRQ01-Feeling of Fear or Panic|CRQ0107	Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) How often during the last 2 weeks did you have a feeling of fear or panic when you had difficulty getting your breath?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121017>	C121000	CRQ-SAS First Administration Version - Fatigue|CRQ01-Fatigue|CRQ01-Fatigue|CRQ0108	Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) How about fatigue? How tired have you felt over the last 2 weeks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121018>	C121000	CRQ-SAS First Administration Version - Embarrassed by Coughing|CRQ01-Embarrassed by Coughing|CRQ01-Embarrassed by Coughing|CRQ0109	Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) How often during the last 2 weeks have you felt embarrassed by your coughing or heavy breathing?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121019>	C121000	CRQ-SAS First Administration Version - Feel Confident to Deal With Illness|CRQ01-Confident to Deal With Illness|CRQ01-Confident to Deal With Illness|CRQ0110	Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) In the last 2 weeks, how much of the time did you feel very confident and sure that you could deal with your illness?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12101>	C61063	ALVAC-CEA-B7.1 vaccine/Fluorouracil/Irinotecan/Leucovorin calcium/Tetanus toxoid			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121020>	C121000	CRQ-SAS First Administration Version - Energy|CRQ01-Energy|CRQ01-Energy|CRQ0111	Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) How much energy have you had in the last 2 weeks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121021>	C121000	CRQ-SAS First Administration Version - Feel Upset, Worried or Depressed|CRQ01-Feel Upset, Worried or Depressed|CRQ01-Feel Upset, Worried or Depressed|CRQ0112	Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) In general, how much of the time did you feel upset, worried, or depressed during the last 2 weeks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121022>	C121000	CRQ-SAS First Administration Version - Had Control of Breathing Problems|CRQ01-Control of Breathing Problems|CRQ01-Control of Breathing Problems|CRQ0113	Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) How often during the last 2 weeks did you feel you had complete control of your breathing problems?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121023>	C121000	CRQ-SAS First Administration Version - Feel Relaxed and Free of Tension|CRQ01-Feel Relaxed and Free of Tension|CRQ01-Feel Relaxed and Free of Tension|CRQ0114	Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) How much of the time during the last 2 weeks did you feel relaxed and free of tension?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121024>	C121000	CRQ-SAS First Administration Version - Felt Low in Energy|CRQ01-Felt Low in Energy|CRQ01-Felt Low in Energy|CRQ0115	Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) How often during the last 2 weeks have you felt low in energy?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121025>	C121000	CRQ-SAS First Administration Version - Felt Discouraged or Down|CRQ01-Felt Discouraged or Down|CRQ01-Felt Discouraged or Down|CRQ0116	Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) In general, how often during the last 2 weeks have you felt discouraged or down in the dumps?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121026>	C121000	CRQ-SAS First Administration Version - Felt Worn Out or Sluggish|CRQ01-Felt Worn Out or Sluggish|CRQ01-Felt Worn Out or Sluggish|CRQ0117	Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) How often during the last 2 weeks have you felt worn out or sluggish?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121027>	C121000	CRQ-SAS First Administration Version - Happy, Satisfied or Pleased With Life|CRQ01-Happy, Satisfied or Pleased|CRQ01-Happy, Satisfied or Pleased|CRQ0118	Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) How happy, satisfied, or pleased have you been with your personal life during the last 2 weeks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121028>	C121000	CRQ-SAS First Administration Version - Feel Upset When Had Difficulty Getting Breath|CRQ01-Feel Upset Diff Getting Breath|CRQ01-Feel Upset Diff Getting Breath|CRQ0119	Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) How often during the last 2 weeks did you feel upset or scared when you had difficulty getting your breath?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121029>	C121000	CRQ-SAS First Administration Version - Felt Restless, Tense or Uptight|CRQ01-Felt Restless, Tense or Uptight|CRQ01-Felt Restless, Tense or Uptight|CRQ0120	Chronic Respiratory Questionnaire Self-Administered Standardized Format First Administration Version Questionnaire (CRQ-SAS First Administration Version) In general, how often during the last 2 weeks have you felt restless, tense, or uptight?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS First Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12102>	C61063	Anti-thymocyte globulin/Cyclophosphamide/Cytarabine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121030>	C121001	CRQ-SAS Follow-Up Administration Version - Feeling Emotional|CRQ02-Feeling Emotional|CRQ02-Feeling Emotional|CRQ0201	Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) - Feeling emotional such as angry or upset.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121031>	C121001	CRQ-SAS Follow-Up Administration Version - Take Care of Basic Needs|CRQ02-Take Care of Basic Needs|CRQ02-Take Care of Basic Needs|CRQ0202	Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) Taking care of your basic needs (bathing, showering, eating or dressing).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121032>	C121001	CRQ-SAS Follow-Up Administration Version - Walking|CRQ02-Walking|CRQ02-Walking|CRQ0203	Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) Walking.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121033>	C121001	CRQ-SAS Follow-Up Administration Version - Performing Chores|CRQ02-Performing Chores|CRQ02-Performing Chores|CRQ0204	Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) Performing chores (such as housework, shopping groceries).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121034>	C121001	CRQ-SAS Follow-Up Administration Version - Participate in Social Activities|CRQ02-Participate in Social Activities|CRQ02-Participate in Social Activities|CRQ0205	Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) Participating in social activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121035>	C121001	CRQ-SAS Follow-Up Administration Version - Felt Frustrated or Impatient|CRQ02-Felt Frustrated or Impatient|CRQ02-Felt Frustrated or Impatient|CRQ0206	Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) In general, how much of the time during the last 2 weeks have you felt frustrated or impatient?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121036>	C121001	CRQ-SAS Follow-Up Administration Version - Feeling of Fear or Panic|CRQ02-Feeling of Fear or Panic|CRQ02-Feeling of Fear or Panic|CRQ0207	Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) How often during the last 2 weeks did you have a feeling of fear or panic when you had difficulty getting your breath?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121037>	C121001	CRQ-SAS Follow-Up Administration Version - Fatigue|CRQ02-Fatigue|CRQ02-Fatigue|CRQ0208	Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) How about fatigue? How tired have you felt over the last 2 weeks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121038>	C121001	CRQ-SAS Follow-Up Administration Version - Embarrassed by Coughing|CRQ02-Embarrassed by Coughing|CRQ02-Embarrassed by Coughing|CRQ0209	Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) How often during the last 2 weeks have you felt embarrassed by your coughing or heavy breathing?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121039>	C121001	CRQ-SAS Follow-Up Administration Version - Feel Confident to Deal With Illness|CRQ02-Confident to Deal With Illness|CRQ02-Confident to Deal With Illness|CRQ0210	Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) In the last 2 weeks, how much of the time did you feel very confident and sure that you could deal with your illness?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12103>	C61007	Carboplatin/Erlotinib/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121040>	C121001	CRQ-SAS Follow-Up Administration Version - Energy|CRQ02-Energy|CRQ02-Energy|CRQ0211	Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) How much energy have you had in the last 2 weeks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121041>	C121001	CRQ-SAS Follow-Up Administration Version - Feel Upset, Worried or Depressed|CRQ02-Feel Upset, Worried or Depressed|CRQ02-Feel Upset, Worried or Depressed|CRQ0212	Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) In general, how much of the time did you feel upset, worried, or depressed during the last 2 weeks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121042>	C121001	CRQ-SAS Follow-Up Administration Version - Had Control of Breathing Problems|CRQ02-Control of Breathing Problems|CRQ02-Control of Breathing Problems|CRQ0213	Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) How often during the last 2 weeks did you feel you had complete control of your breathing problems?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121043>	C121001	CRQ-SAS Follow-Up Administration Version - Feel Relaxed and Free of Tension|CRQ02-Feel Relaxed and Free of Tension|CRQ02-Feel Relaxed and Free of Tension|CRQ0214	Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) How much of the time during the last 2 weeks did you feel relaxed and free of tension?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121044>	C121001	CRQ-SAS Follow-Up Administration Version - Felt Low in Energy|CRQ02-Felt Low in Energy|CRQ02-Felt Low in Energy|CRQ0215	Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) How often during the last 2 weeks have you felt low in energy?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121045>	C121001	CRQ-SAS Follow-Up Administration Version - Felt Discouraged or Down|CRQ02-Felt Discouraged or Down|CRQ02-Felt Discouraged or Down|CRQ0216	Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) In general, how often during the last 2 weeks have you felt discouraged or down in the dumps?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121046>	C121001	CRQ-SAS Follow-Up Administration Version - Felt Worn Out or Sluggish|CRQ02-Felt Worn Out or Sluggish|CRQ02-Felt Worn Out or Sluggish|CRQ0217	Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) How often during the last 2 weeks have you felt worn out or sluggish?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121047>	C121001	CRQ-SAS Follow-Up Administration Version - Happy, Satisfied or Pleased With Life|CRQ02-Happy, Satisfied or Pleased|CRQ02-Happy, Satisfied or Pleased|CRQ0218	Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) How happy, satisfied, or pleased have you been with your personal life during the last 2 weeks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121048>	C121001	CRQ-SAS Follow-Up Administration Version - Feel Upset When Had Difficulty Getting Breath|CRQ02-Feel Upset Diff Getting Breath|CRQ02-Feel Upset Diff Getting Breath|CRQ0219	Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) How often during the last 2 weeks did you feel upset or scared when you had difficulty getting your breath?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121049>	C121001	CRQ-SAS Follow-Up Administration Version - Felt Restless, Tense or Uptight|CRQ02-Felt Restless, Tense or Uptight|CRQ02-Felt Restless, Tense or Uptight|CRQ0220	Chronic Respiratory Questionnaire Self-Administered Standardized Format Follow-Up Administration Version Questionnaire (CRQ-SAS Follow-Up Administration Version) In general, how often during the last 2 weeks have you felt restless, tense, or uptight?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Code Terminology|CDISC Questionnaire CRQ-SAS Follow-Up Administration Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12104>	C61063	BMS-247550/Carboplatin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121050>	C120999	BACS - Number of Items Recalled|BACS1-Number of Items Recalled|BACS1-Number of Items Recalled|BACS101	Brief Assessment of Cognition in Schizophrenia (BACS) Verbal Memory: Number of items recalled on each trial.			Intellectual Product	CDISC Functional Test BACS Test Code Terminology|CDISC Functional Test BACS Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121051>	C120999	BACS - Number of Items Recalled Total|BACS1-Number of Items Recalled Total|BACS1-Number of Items Recalled Total|BACS101A	Brief Assessment of Cognition in Schizophrenia (BACS) Verbal Memory: Total number of items recalled.			Intellectual Product	CDISC Functional Test BACS Test Code Terminology|CDISC Functional Test BACS Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121052>	C120999	BACS - Number of Correct Sequences|BACS1-Number of Correct Sequences|BACS1-Number of Correct Sequences|BACS102	Brief Assessment of Cognition in Schizophrenia (BACS) Digit Sequencing: Number of correct sequences.			Intellectual Product	CDISC Functional Test BACS Test Code Terminology|CDISC Functional Test BACS Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121053>	C120999	BACS - Number of Tokens Left on the Table|BACS1-Number of Tokens Left on the Table|BACS1-Number of Tokens Left on the Table|BACS103A	Brief Assessment of Cognition in Schizophrenia (BACS) Token Motor Task: Total number of tokens left on the table.			Intellectual Product	CDISC Functional Test BACS Test Code Terminology|CDISC Functional Test BACS Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121054>	C120999	BACS - Total Number Tokens in Container|BACS1-Total Number Tokens in Container|BACS1-Total Number Tokens in Container|BACS103B	Brief Assessment of Cognition in Schizophrenia (BACS) Token Motor Task: Total number of tokens placed in the container.			Intellectual Product	CDISC Functional Test BACS Test Code Terminology|CDISC Functional Test BACS Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121055>	C120999	BACS - Number Tokens Incorrectly Placed|BACS1-Number Tokens Incorrectly Placed|BACS1-Number Tokens Incorrectly Placed|BACS103C	Brief Assessment of Cognition in Schizophrenia (BACS) Token Motor Task: Total number of tokens incorrectly placed in container.			Intellectual Product	CDISC Functional Test BACS Test Code Terminology|CDISC Functional Test BACS Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121056>	C120999	BACS - Number of Tokens Correctly Placed|BACS1-Number of Tokens Correctly Placed|BACS1-Number of Tokens Correctly Placed|BACS103D	Brief Assessment of Cognition in Schizophrenia (BACS) Token Motor Task: Number of tokens correctly placed.			Intellectual Product	CDISC Functional Test BACS Test Code Terminology|CDISC Functional Test BACS Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121057>	C120999	BACS - Category Instances|BACS1-Category Instances|BACS1-Category Instances|BACS104A	Brief Assessment of Cognition in Schizophrenia (BACS) Verbal Fluency: Category instances.			Intellectual Product	CDISC Functional Test BACS Test Code Terminology|CDISC Functional Test BACS Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121058>	C120999	BACS - Letter Fluency 1|BACS1-Letter Fluency 1|BACS1-Letter Fluency 1|BACS104B	Brief Assessment of Cognition in Schizophrenia (BACS) Verbal Fluency: Letter fluency 1.			Intellectual Product	CDISC Functional Test BACS Test Code Terminology|CDISC Functional Test BACS Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121059>	C120999	BACS - Letter Fluency 2|BACS1-Letter Fluency 2|BACS1-Letter Fluency 2|BACS104C	Brief Assessment of Cognition in Schizophrenia (BACS) Verbal Fluency: Letter fluency 2.			Intellectual Product	CDISC Functional Test BACS Test Code Terminology|CDISC Functional Test BACS Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12105>	C61007	Bevacizumab/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121060>	C120999	BACS - Verbal Fluency Total|BACS1-Verbal Fluency Total|BACS1-Verbal Fluency Total|BACS104D	Brief Assessment of Cognition in Schizophrenia (BACS) Verbal Fluency: Total number of Verbal Fluency items.			Intellectual Product	CDISC Functional Test BACS Test Code Terminology|CDISC Functional Test BACS Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121061>	C120999	BACS - Symbol Coding Raw Score|BACS1-Symbol Coding Raw Score|BACS1-Symbol Coding Raw Score|BACS105	Brief Assessment of Cognition in Schizophrenia (BACS) Symbol Coding: Raw score.			Intellectual Product	CDISC Functional Test BACS Test Code Terminology|CDISC Functional Test BACS Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121062>	C120999	BACS - Tower of London Correct Responses|BACS1-Tower of London Correct Responses|BACS1-Tower of London Correct Responses|BACS106	Brief Assessment of Cognition in Schizophrenia (BACS) Tower of London: Number of correct responses.			Intellectual Product	CDISC Functional Test BACS Test Code Terminology|CDISC Functional Test BACS Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121063>	C120995	BODE Index - Body-mass Index|BODE01-Body-mass Index|BODE01-Body-mass Index|BODE0101	The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index (BODE Index) Body-mass index.			Intellectual Product	CDISC Clinical Classification BODE Index Test Code Terminology|CDISC Clinical Classification BODE Index Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121064>	C120995	BODE Index - FEV1 Percent Predicted|BODE01-FEV1 % Predicted|BODE01-FEV1 % Predicted|BODE0102	The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index (BODE Index) FEV1 (% of predicted).			Intellectual Product	CDISC Clinical Classification BODE Index Test Code Terminology|CDISC Clinical Classification BODE Index Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121065>	C120995	BODE Index - MMRC Dyspnea Scale|BODE01-MMRC Dyspnea Scale|BODE01-MMRC Dyspnea Scale|BODE0103	The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index (BODE Index) MMRC dyspnea scale.			Intellectual Product	CDISC Clinical Classification BODE Index Test Code Terminology|CDISC Clinical Classification BODE Index Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121066>	C120995	BODE Index - Distance Walked in 6 Minutes|BODE01-Distance Walked in 6 Minutes|BODE01-Distance Walked in 6 Minutes|BODE0104	The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index (BODE Index) Distance walked in 6 min (in meter).			Intellectual Product	CDISC Clinical Classification BODE Index Test Code Terminology|CDISC Clinical Classification BODE Index Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121067>	C120995	BODE Index - Score|BODE01-BODE Score|BODE01-BODE Score|BODE0105	The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index (BODE Index) BODE score.			Intellectual Product	CDISC Clinical Classification BODE Index Test Code Terminology|CDISC Clinical Classification BODE Index Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121068>	C120996	Child-Pugh - Encephalopathy Grade|CPS01-Encephalopathy Grade|CPS01-Encephalopathy Grade|CPS0101	Child-Pugh Classification (Child-Pugh) Encephalopathy grade.			Intellectual Product	CDISC Clinical Classification Child-Pugh Test Code Terminology|CDISC Clinical Classification Child-Pugh Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121069>	C120996	Child-Pugh - Ascites|CPS01-Ascites|CPS01-Ascites|CPS0102	Child-Pugh Classification (Child-Pugh) Ascites.			Intellectual Product	CDISC Clinical Classification Child-Pugh Test Code Terminology|CDISC Clinical Classification Child-Pugh Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12106>	C61063	Interleukin-12/Paclitaxel/Trastuzumab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121070>	C120996	Child-Pugh - Serum Bilirubin|CPS01-Serum Bilirubin|CPS01-Serum Bilirubin|CPS0103	Child-Pugh Classification (Child-Pugh) Serum bilirubin, mg/dL.			Intellectual Product	CDISC Clinical Classification Child-Pugh Test Code Terminology|CDISC Clinical Classification Child-Pugh Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121071>	C120996	Child-Pugh - Serum Albumin|CPS01-Serum Albumin|CPS01-Serum Albumin|CPS0104	Child-Pugh Classification (Child-Pugh) Serum albumin, g/dL.			Intellectual Product	CDISC Clinical Classification Child-Pugh Test Code Terminology|CDISC Clinical Classification Child-Pugh Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121072>	C120996	Child-Pugh - PT, Sec Prolonged|CPS01-PT, Sec Prolonged|CPS01-PT, Sec Prolonged|CPS0105A	Child-Pugh Classification (Child-Pugh) Prothrombin time, sec prolonged.			Intellectual Product	CDISC Clinical Classification Child-Pugh Test Code Terminology|CDISC Clinical Classification Child-Pugh Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121073>	C120996	Child-Pugh - PT, INR|CPS01-PT, INR|CPS01-PT, INR|CPS0105B	Child-Pugh Classification (Child-Pugh) Prothrombin time, international normalized ratio (INR).			Intellectual Product	CDISC Clinical Classification Child-Pugh Test Code Terminology|CDISC Clinical Classification Child-Pugh Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121074>	C120996	Child-Pugh - Total Score|CPS01-Total Score|CPS01-Total Score|CPS0106	Child-Pugh Classification (Child-Pugh) Child-Pugh total score.			Intellectual Product	CDISC Clinical Classification Child-Pugh Test Code Terminology|CDISC Clinical Classification Child-Pugh Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121075>	C120996	Child-Pugh - Grade|CPS01-Grade|CPS01-Grade|CPS0107	Child-Pugh Classification (Child-Pugh) Child-Pugh grade.			Intellectual Product	CDISC Clinical Classification Child-Pugh Test Code Terminology|CDISC Clinical Classification Child-Pugh Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121076>	C120997	MELD - Score|MELD01-Score|MELD01-Score|MELD0101	Model for End Stage Liver Disease (MELD) MELD score.			Intellectual Product	CDISC Clinical Classification MELD Test Code Terminology|CDISC Clinical Classification MELD Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121077>	C120998	NSA-16 - Prolonged Time to Respond|NSA01-Prolonged Time to Respond|NSA01-Prolonged Time to Respond|NSA0101	Negative Symptom Assessment-16 (NSA-16) Prolonged time to respond.			Intellectual Product	CDISC Clinical Classification NSA-16 Test Code Terminology|CDISC Clinical Classification NSA-16 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121078>	C120998	NSA-16 - Restricted Speech Quantity|NSA01-Restricted Speech Quantity|NSA01-Restricted Speech Quantity|NSA0102	Negative Symptom Assessment-16 (NSA-16) Restricted speech quantity.			Intellectual Product	CDISC Clinical Classification NSA-16 Test Code Terminology|CDISC Clinical Classification NSA-16 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121079>	C120998	NSA-16 - Impoverished Speech Content|NSA01-Impoverished Speech Content|NSA01-Impoverished Speech Content|NSA0103	Negative Symptom Assessment-16 (NSA-16) Impoverished speech content.			Intellectual Product	CDISC Clinical Classification NSA-16 Test Code Terminology|CDISC Clinical Classification NSA-16 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12107>	C61007	Cytarabine/Imatinib Mesylate			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121080>	C120998	NSA-16 - Inarticulate Speech|NSA01-Inarticulate Speech|NSA01-Inarticulate Speech|NSA0104	Negative Symptom Assessment-16 (NSA-16) Inarticulate speech.			Intellectual Product	CDISC Clinical Classification NSA-16 Test Code Terminology|CDISC Clinical Classification NSA-16 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121081>	C120998	NSA-16 - Emotion: Reduced Range|NSA01-Emotion: Reduced Range|NSA01-Emotion: Reduced Range|NSA0105	Negative Symptom Assessment-16 (NSA-16) Emotion: Reduced range.			Intellectual Product	CDISC Clinical Classification NSA-16 Test Code Terminology|CDISC Clinical Classification NSA-16 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121082>	C120998	NSA-16 - Affect: Reduce Modulation Intensity|NSA01-Affect Reduce Modulation Intensity|NSA01-Affect Reduce Modulation Intensity|NSA0106	Negative Symptom Assessment-16 (NSA-16) Affect: Reduced modulation of intensity.			Intellectual Product	CDISC Clinical Classification NSA-16 Test Code Terminology|CDISC Clinical Classification NSA-16 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121083>	C120998	NSA-16 - Affect: Reduced Display on Demand|NSA01-Affect: Reduced Display on Demand|NSA01-Affect: Reduced Display on Demand|NSA0107	Negative Symptom Assessment-16 (NSA-16) Affect: Reduced display on demand.			Intellectual Product	CDISC Clinical Classification NSA-16 Test Code Terminology|CDISC Clinical Classification NSA-16 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121084>	C120998	NSA-16 - Reduced Social Drive|NSA01-Reduced Social Drive|NSA01-Reduced Social Drive|NSA0108	Negative Symptom Assessment-16 (NSA-16) Reduced social drive.			Intellectual Product	CDISC Clinical Classification NSA-16 Test Code Terminology|CDISC Clinical Classification NSA-16 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121085>	C120998	NSA-16 - Poor Rapport With Interviewer|NSA01-Poor Rapport With Interviewer|NSA01-Poor Rapport With Interviewer|NSA0109	Negative Symptom Assessment-16 (NSA-16) Poor rapport with interviewer.			Intellectual Product	CDISC Clinical Classification NSA-16 Test Code Terminology|CDISC Clinical Classification NSA-16 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121086>	C120998	NSA-16 - Interest in Emotional and Physical Intimacy|NSA01-Interest Emotional/Phys Intimacy|NSA01-Interest Emotional/Phys Intimacy|NSA0110	Negative Symptom Assessment-16 (NSA-16) Interest in emotional and physical intimacy.			Intellectual Product	CDISC Clinical Classification NSA-16 Test Code Terminology|CDISC Clinical Classification NSA-16 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121087>	C120998	NSA-16 - Poor Grooming and Hygiene|NSA01-Poor Grooming and Hygiene|NSA01-Poor Grooming and Hygiene|NSA0111	Negative Symptom Assessment-16 (NSA-16) Poor grooming and hygiene.			Intellectual Product	CDISC Clinical Classification NSA-16 Test Code Terminology|CDISC Clinical Classification NSA-16 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121088>	C120998	NSA-16 - Reduced Sense of Purpose|NSA01-Reduced Sense of Purpose|NSA01-Reduced Sense of Purpose|NSA0112	Negative Symptom Assessment-16 (NSA-16) Reduced sense of purpose.			Intellectual Product	CDISC Clinical Classification NSA-16 Test Code Terminology|CDISC Clinical Classification NSA-16 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121089>	C120998	NSA-16 - Reduced Interests|NSA01-Reduced Interests|NSA01-Reduced Interests|NSA0113	Negative Symptom Assessment-16 (NSA-16) Reduced interests.			Intellectual Product	CDISC Clinical Classification NSA-16 Test Code Terminology|CDISC Clinical Classification NSA-16 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12108>	C61007	Cyclophosphamide/Doxorubicin/Filgrastim/Prednisone/Rituximab/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121090>	C120998	NSA-16 - Reduced Daily Activity|NSA01-Reduced Daily Activity|NSA01-Reduced Daily Activity|NSA0114	Negative Symptom Assessment-16 (NSA-16) Reduced daily activity.			Intellectual Product	CDISC Clinical Classification NSA-16 Test Code Terminology|CDISC Clinical Classification NSA-16 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121091>	C120998	NSA-16 - Reduced Expressive Gestures|NSA01-Reduced Expressive Gestures|NSA01-Reduced Expressive Gestures|NSA0115	Negative Symptom Assessment-16 (NSA-16) Reduced expressive gestures.			Intellectual Product	CDISC Clinical Classification NSA-16 Test Code Terminology|CDISC Clinical Classification NSA-16 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121092>	C120998	NSA-16 - Slowed Movements|NSA01-Slowed Movements|NSA01-Slowed Movements|NSA0116	Negative Symptom Assessment-16 (NSA-16) Slowed movements.			Intellectual Product	CDISC Clinical Classification NSA-16 Test Code Terminology|CDISC Clinical Classification NSA-16 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121093>	C120998	NSA-16 - Global Negative Symptoms Rating|NSA01-Global Negative Symptoms Rating|NSA01-Global Negative Symptoms Rating|NSA0117	Negative Symptom Assessment-16 (NSA-16) Global negative symptoms rating.			Intellectual Product	CDISC Clinical Classification NSA-16 Test Code Terminology|CDISC Clinical Classification NSA-16 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121094>	C120998	NSA-16 - Global Negative Symptoms Rating-Severity|NSA01-Global Neg Symptom Rating-Severity|NSA01-Global Neg Symptom Rating-Severity|NSA0118	Negative Symptom Assessment-16 (NSA-16) Global negative symptoms rating - severity.			Intellectual Product	CDISC Clinical Classification NSA-16 Test Code Terminology|CDISC Clinical Classification NSA-16 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121095>	C120998	NSA-16 - Global Level of Functioning|NSA01-Global Level of Functioning|NSA01-Global Level of Functioning|NSA0119	Negative Symptom Assessment-16 (NSA-16) Global level of functioning.			Intellectual Product	CDISC Clinical Classification NSA-16 Test Code Terminology|CDISC Clinical Classification NSA-16 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121096>	C120994	APACHE II - Temperature, Rectal|APCH1-Temperature - Rectal|APCH1-Temperature - Rectal|APCH101	Acute Physiology and Chronic Health Evaluation II (APACHE II) Temperature - rectal (degree C).			Intellectual Product	CDISC Clinical Classification APACHE II Test Code Terminology|CDISC Clinical Classification APACHE II Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121097>	C120994	APACHE II - Mean Arterial Pressure|APCH1-Mean Arterial Pressure|APCH1-Mean Arterial Pressure|APCH102	Acute Physiology and Chronic Health Evaluation II (APACHE II) Mean arterial pressure - mm Hg.			Intellectual Product	CDISC Clinical Classification APACHE II Test Code Terminology|CDISC Clinical Classification APACHE II Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121098>	C120994	APACHE II - Heart Rate|APCH1-Heart Rate|APCH1-Heart Rate|APCH103	Acute Physiology and Chronic Health Evaluation II (APACHE II) Heart rate (ventricular response).			Intellectual Product	CDISC Clinical Classification APACHE II Test Code Terminology|CDISC Clinical Classification APACHE II Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121099>	C120994	APACHE II - Respiratory Rate|APCH1-Respiratory Rate|APCH1-Respiratory Rate|APCH104	Acute Physiology and Chronic Health Evaluation II (APACHE II) Respiratory rate (non-ventilated or ventilated).			Intellectual Product	CDISC Clinical Classification APACHE II Test Code Terminology|CDISC Clinical Classification APACHE II Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12109>	C61063	Bevacizumab/Gemcitabine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1210>	C267	Cisapride|CISAPRIDE|Propulsid|cis-4-Amino-5-Chloro-N-(1-(3- (p-fluorophenoxy)propyl)-3-methoxy-4- piperidyl)-o-Anisamide	A substituted piperidinyl benzamide prokinetic agent.  Cisapride facilitates release of acetylcholine from the myenteric plexus, resulting in increased gastrointestinal motility.  In addition, cisapride has been found to act as a serotonin agonist, stimulating type 4 receptors, and a serotonin 5-HT3 receptor antagonist. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C121100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121100>	C120994	APACHE II - Oxygenation, A-aDO2|APCH1-Oxygenation: A-aDO2|APCH1-Oxygenation: A-aDO2|APCH105A	Acute Physiology and Chronic Health Evaluation II (APACHE II) Oxygenation (mm Hg): FIO2 greater than or equal to 0.5 record A-aDO2.			Intellectual Product	CDISC Clinical Classification APACHE II Test Code Terminology|CDISC Clinical Classification APACHE II Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121101>	C120994	APACHE II - Oxygenation, PaO2|APCH1-Oxygenation: PaO2|APCH1-Oxygenation: PaO2|APCH105B	Acute Physiology and Chronic Health Evaluation II (APACHE II) Oxygenation (mm Hg): FIO2 less than 0.5 record only PaO2.			Intellectual Product	CDISC Clinical Classification APACHE II Test Code Terminology|CDISC Clinical Classification APACHE II Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121102>	C120994	APACHE II - Arterial pH|APCH1-Arterial pH|APCH1-Arterial pH|APCH106A	Acute Physiology and Chronic Health Evaluation II (APACHE II) Arterial pH (preferred).			Intellectual Product	CDISC Clinical Classification APACHE II Test Code Terminology|CDISC Clinical Classification APACHE II Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121103>	C120994	APACHE II - Serum HCO3|APCH1-Serum HCO3|APCH1-Serum HCO3|APCH106B	Acute Physiology and Chronic Health Evaluation II (APACHE II) Serum HCO3 (venous mMol/L) (Not preferred, use if no ABGs).			Intellectual Product	CDISC Clinical Classification APACHE II Test Code Terminology|CDISC Clinical Classification APACHE II Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121104>	C120994	APACHE II - Serum Sodium|APCH1-Serum Sodium|APCH1-Serum Sodium|APCH107	Acute Physiology and Chronic Health Evaluation II (APACHE II) Serum sodium (mMol/L).			Intellectual Product	CDISC Clinical Classification APACHE II Test Code Terminology|CDISC Clinical Classification APACHE II Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121105>	C120994	APACHE II - Serum Potassium|APCH1-Serum Potassium|APCH1-Serum Potassium|APCH108	Acute Physiology and Chronic Health Evaluation II (APACHE II) Serum potassium (mMol/L).			Intellectual Product	CDISC Clinical Classification APACHE II Test Code Terminology|CDISC Clinical Classification APACHE II Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121106>	C120994	APACHE II - Serum Creatinine|APCH1-Serum Creatinine|APCH1-Serum Creatinine|APCH109	Acute Physiology and Chronic Health Evaluation II (APACHE II) Serum creatinine (mg/100 mL) (double point score for acute renal failure).			Intellectual Product	CDISC Clinical Classification APACHE II Test Code Terminology|CDISC Clinical Classification APACHE II Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121107>	C120994	APACHE II - Hematocrit|APCH1-Hematocrit|APCH1-Hematocrit|APCH110	Acute Physiology and Chronic Health Evaluation II (APACHE II) Hematocrit (%).			Intellectual Product	CDISC Clinical Classification APACHE II Test Code Terminology|CDISC Clinical Classification APACHE II Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121108>	C120994	APACHE II - White Blood Count|APCH1-White Blood Count|APCH1-White Blood Count|APCH111	Acute Physiology and Chronic Health Evaluation II (APACHE II) White blood count (total/mm3) (in 1,000s).			Intellectual Product	CDISC Clinical Classification APACHE II Test Code Terminology|CDISC Clinical Classification APACHE II Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121109>	C120994	APACHE II - 15 Minus Glasgow Coma Score|APCH1-15 Minus Glasgow Coma Score|APCH1-15 Minus Glasgow Coma Score|APCH112	Acute Physiology and Chronic Health Evaluation II (APACHE II) Glasgow coma score: Score equals 15 minus actual GCS.			Intellectual Product	CDISC Clinical Classification APACHE II Test Code Terminology|CDISC Clinical Classification APACHE II Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12110>	C61063	Cytarabine/Gemtuzumab Ozogamicin/Mitoxantrone			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121110>	C120994	APACHE II - A, Total Acute Physiology Score|APCH1-A: Total Acute Physiology Score|APCH1-A: Total Acute Physiology Score|APCH113	Acute Physiology and Chronic Health Evaluation II (APACHE II) A: Total acute physiology score.			Intellectual Product	CDISC Clinical Classification APACHE II Test Code Terminology|CDISC Clinical Classification APACHE II Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121111>	C120994	APACHE II - B, Age Points|APCH1-B: Age Points|APCH1-B: Age Points|APCH114	Acute Physiology and Chronic Health Evaluation II (APACHE II) B: Age points (years).			Intellectual Product	CDISC Clinical Classification APACHE II Test Code Terminology|CDISC Clinical Classification APACHE II Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121112>	C120994	APACHE II - C, Chronic Health Points|APCH1-C: Chronic Health Points|APCH1-C: Chronic Health Points|APCH115	Acute Physiology and Chronic Health Evaluation II (APACHE II) C: Chronic health points.			Intellectual Product	CDISC Clinical Classification APACHE II Test Code Terminology|CDISC Clinical Classification APACHE II Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121113>	C120994	APACHE II - Total APACHE II Score|APCH1-Total APACHE II Score|APCH1-Total APACHE II Score|APCH116	Acute Physiology and Chronic Health Evaluation II (APACHE II) Total APACHE II score.			Intellectual Product	CDISC Clinical Classification APACHE II Test Code Terminology|CDISC Clinical Classification APACHE II Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121114>	C20462	TP53AIP1 Gene|TP53AIP1|TP53AIP1|Tumor Protein p53 Regulated Apoptosis Inducing Protein 1 Gene	This gene plays a role in the regulation of p53-induced apoptosis.	TP53AIP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C121115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121115>	C121114	TP53AIP1 wt Allele|P53AIP1|Tumor Protein p53 Regulated Apoptosis Inducing Protein 1 wt Allele|p53AIP1	Human TP53AIP1 wild-type allele is located in the vicinity of 11q24.3 and is approximately 9 kb in length. This allele, which encodes p53-regulated apoptosis-inducing protein 1, is involved in the mediation of apopotosis.	TP53AIP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C121116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121116>	C19928	p53-Regulated Apoptosis-Inducing Protein 1|Tumor Protein p53-Regulated Apoptosis-Inducing Protein 1	p53-regulated apoptosis-inducing protein 1 (124 aa, ~13 kDa) is encoded by the human TP53AIP1 gene. This protein plays a role in the mediation of p53-dependent apoptosis.	p53-Regulated Apoptosis-Inducing Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C121117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121117>	C173812	Expected Length of Time to Recover After Treatment Question|Expected Length of Time to Recover After Treatment|Was the length of time it took you to recover after your treatment what you expected	A question about an individual's expectation of the length of time for recovery after treatment.			Intellectual Product	Follow-Up Outcome Expectations Questionnaire
C121118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121118>	C173812|C173398	Difficulty to Recover After Treatment Question|Difficulty to Recover After Treatment|How difficult was your recovery after your treatment	A question about how difficult it was for an individual to recover after treatment.			Intellectual Product	Follow-Up Outcome Expectations Questionnaire
C121119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121119>	C173812|C173160	Feelings About Ability to Deal with Treatment and Recovery Question|Feelings About Ability to Deal with Treatment and Recovery|How did you feel about your ability to deal with your treatment and recovery	A question about an individual's feelings regarding their ability to deal with treatment and recovery.			Intellectual Product	Follow-Up Outcome Expectations Questionnaire
C12111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12111>	C61063	Asparaginase/Cytarabine/Gemtuzumab ozogamicin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121120>	C173787	Recovered Ability to do Daily Activities as Expected Question|Have you recovered your ability to do your daily activities as you expected|Recovered Ability to do Daily Activities as Expected	A question about whether an individual has recovered their ability to do daily activities as expected.			Intellectual Product	Follow-Up Outcome Expectations Questionnaire
C121121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121121>	C226665|C176242	Took Less Time than Expected|It took less time than I expected	A subjective response indicating that something took less time than expected.			Intellectual Product	Follow-Up Outcome Expectations Questionnaire
C121122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121122>	C226665|C176242	Took the Expected Time|It took the time I expected	A subjective response indicating that something took the time that was expected.			Intellectual Product	Follow-Up Outcome Expectations Questionnaire
C121123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121123>	C226665|C176242	Took Longer Than Expected|It took longer than I expected|Took More Time Than Expected	A subjective response indicating that something took longer than expected.			Intellectual Product	Follow-Up Outcome Expectations Questionnaire
C121124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121124>	C226665	Did Not Know What to Expect|I didn't know what to expect|I don't know what to expect	A subjective response indicating that an individual does or didn't know what to expect.			Intellectual Product	Follow-Up Outcome Expectations Questionnaire
C121125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121125>	C226665	Easier than Expected|It was easier than I expected	A subjective response indicating that something was easier than expected.			Intellectual Product	Follow-Up Outcome Expectations Questionnaire
C121126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121126>	C226665	As Expected|About as Expected|It was about what I expected|Same as Expected|The same as I expected	A subjective response indicating that something was as expected.			Intellectual Product	Follow-Up Outcome Expectations Questionnaire|Was It Worth It Questionnaire
C121127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121127>	C226665|C176243	More Difficult than Expected|Harder than Expected|It was more difficult than I expected	A subjective response indicating that something was more difficult than expected.			Intellectual Product	Follow-Up Outcome Expectations Questionnaire
C121128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121128>	C226665|C175309	Better than Expected|Better than I expected	A subjective response indicating something was better than expected.			Intellectual Product	Follow-Up Outcome Expectations Questionnaire|Was It Worth It Questionnaire
C121129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121129>	C226665|C175310	Worse than Expected|Worse than I expected	A subjective response indicating something was worse than expected.			Intellectual Product	Follow-Up Outcome Expectations Questionnaire|Was It Worth It Questionnaire
C12112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12112>	C61063	Carboplatin/Epoetin alfa/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121130>	C77117	Sigmodon hispidus|Hispid Cotton Rat	From the Sigmodon genus of rodents, Sigmodon hispidus was the first animal model to be used in polio research. It has a stout body, small ears and a dark coat that can be dark brown or mixed buff and black, with a tail length that is 35% of its total body length. As its name suggests, this breed has a proclivity for cotton in its nesting, and is a natural Hanta viral reservoir.			Mammal	
C121131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121131>	C7451|C7450	Infiltrating Intramuscular Lipoma	An infiltrating lipoma that affects skeletal muscle.  It has a higher rate of local recurrence.			Neoplastic Process	
C121132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121132>	C36346	ZFTA-MRTFB Fusion Protein Expression|C11orf95-MKL2 Fusion Protein Expression|C11orf95-MRTFB Fusion Protein Expression	Expression of a fusion protein that results from a t(11;16)(q13;p13) translocation, which involves the human genes ZFTA and MKL2.			Cell or Molecular Dysfunction	
C121133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121133>	C186345|C133693	t(11;16)(q13;p13)	A cytogenetic abnormality that refers to the translocation involving the genes C11orf95 on chromosome 11 and MKL2 on chromosome 16 resulting in C11orf95-MKL2 fusion.			Cell or Molecular Dysfunction	
C121134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121134>	C85769	Mean Residence Time Infinity Observed by Intravascular Bolus Dose|MRT IV Bolus Infinity Obs|MRT IV Bolus Infinity Obs|MRTIBIFO	The mean residence time (MRT) extrapolated to infinity for a substance administered by intravascular dosing, calculated using the observed value of the last non-zero concentration. (CDISC)			Temporal Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C121135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121135>	C199456	Pegcetacoplan|APL 2|APL-2|APL2|Empaveli|PEGCETACOPLAN	A pegylated peptide inhibitor of human complement components C3 and C3b, with potential use as a treatment for various diseases in which excessive complement activation plays a key role, including paroxysmal nocturnal hemoglobinuria (PNH), geographic atrophy (GA), cold agglutinin disease (CAD), and C3 glomerulopathy (C3G). Upon administration, pegcetacoplan selectively binds to C3 and C3b and inhibits their activities. This prevents complement pathway activation, and inhibits complement-mediated inflammation and cell lysis. Excessive complement activation plays a key role in various inflammatory and autoimmune diseases, and leads to tissue destruction. C3 is a key component of the complement system, and the complement system is an integral component of the innate immune response.	Pegcetacoplan		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C121136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121136>	C85793	Mean Residence Time Infinity Predicted by Intravascular Bolus Dose|MRT IV Bolus Infinity Pred|MRT IV Bolus Infinity Pred|MRTIBIFP	The mean residence time (MRT) extrapolated to infinity for a substance administered by intravascular dosing, calculated using the predicted value of the last non-zero concentration. (CDISC)			Temporal Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C121137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121137>	C85700	Mean Residence Time to Last Nonzero Concentration by Intravascular Bolus Dose|MRT IV Bolus to Last Nonzero Conc|MRT IV Bolus to Last Nonzero Conc|MRTIBLST	Mean residence time (MRT) from the time of dosing to the time of the last measurable concentration, for a substance administered by intravascular dosing. (CDISC)			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C121138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121138>	C77180	Aspergillus niger|ASPERGILLUS NIGER	A species of mesophilic fungi belonging to the genus Aspergillus that is a human pathogen, causing lung or ear infections in immunocompromised patients			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121139>	C16135	Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy|IMRT-SIB|Intensity Modulated Radiation Therapy Simultaneous Integrated Boost|SIB-IMRT	A modification of intensity modulated radiation therapy that allows for the simultaneous delivery of different dose levels to different target volumes within a single treatment fraction. This can result in better sparing of critical structures, more efficient delivery, shorter treatment duration, and better biologic effectiveness.	Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C12113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12113>	C61063	Carboplatin/PS-341			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121140>	C187275	Hypoprolactinemia|Lactogenic Hormone Deficiency|Prolactin Deficiency	Subnormal concentration of prolactin.			Laboratory or Test Result	NICHD Terminology|Pediatric Endocrinology Terminology
C121141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121141>	C92809	Follicle Stimulating Hormone Deficiency|FSH Deficiency|FSH Deficiency	Subnormal concentration of follicle stimulating hormone.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C121142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121142>	C121141	Isolated Follicle Stimulating Hormone Deficiency	Subnormal concentration of follicle stimulating hormone (FSH), associated with mutations in the FSHB gene, encoding follitropin subunit beta.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C121143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121143>	C21240	EIF4B Gene|EIF4B|EIF4B|Eukaryotic Translation Initiation Factor 4B Gene	This gene plays a role in the binding of mRNA to ribosomes.	EIF4B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C121144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121144>	C121143	EIF4B wt Allele|EIF-4B|Eukaryotic Translation Initiation Factor 4B wt Allele|PRO1843	Human EIF4B wild-type allele is located in the vicinity of 12q13.13 and is approximately 36 kb in length. This allele, which encodes eukaryotic translation initiation factor 4B protein, is involved in the regulation of translational initiation.	EIF4B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C121145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121145>	C17461	Eukaryotic Translation Initiation Factor 4B|eIF-4B|eIF4B	Eukaryotic translation initiation factor 4B (611 aa, ~69 kDa) is encoded by the human EIF4B gene. This protein plays a role in the initiation of translation through promoting the binding of mRNA to ribosomes.	Eukaryotic Translation Initiation Factor 4B		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C121146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121146>	C3824|C36285	Pituitary Stalk Lesion	An anomaly in the pituitary stalk that can be developmental, inflammatory, infiltrative, iatrogenic or traumatic.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C121147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121147>	C36285	Hypophysitis	An inflammatory process in the pituitary gland.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C121148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121148>	C26686	Pituitary Abscess	An inflammatory or infectious process in the pituitary gland characterized by a circumscribed, walled collection of purulent material.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C121149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121149>	C28510	MYH9/USP6 Fusion Gene|MYH9-USP6 Fusion Gene|MYH9::USP6 Fusion Gene	A fusion gene that results from a chromosomal translocation t(17;22)(p13;q12.3-q13) which fuses the promoter region of the MYH9 gene upstream of the coding region of the USP6 gene. This fusion causes increased expression of the USP6 gene and is associated with nodular fasciitis.			Gene or Genome	
C12114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12114>	C61063	Docetaxel/Laniquidar			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121150>	C28193	Pituitary Stalk Interruption Syndrome|Hypoplastic Anterior Pituitary, Missing Stalk, and Ectopic Posterior Pituitary|PSIS	A syndrome characterized by hypoplastic or aplastic anterior pituitary gland, a very thin or interrupted pituitary stalk, and ectopic or absent posterior pituitary gland, which may be associated with mutation(s) in the HESX1 or LHX4 genes.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C121151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121151>	C27567	Ectopic Posterior Pituitary|Ectopic Neurohypophysis	Atypically located posterior pituitary gland that may be associated with anterior or posterior pituitary hormone deficiencies.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C121152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121152>	C45915	FSH-Producing Pituitary Neuroendocrine Tumor|FSH-Producing Pituitary Gland Adenoma|FSH-producing Adenoma|Follicle Stimulating Hormone-Producing Adenoma|Follicle Stimulating Hormone-Producing Gonadotroph Adenoma	A pituitary neuroendocrine tumor that produces follicle-stimulating hormone (FSH).			Neoplastic Process	NCIt Neoplasm Core Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C121153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121153>	C45915	LH-Producing Pituitary Neuroendocrine Tumor|LH-Producing Pituitary Gland Adenoma|LH-producing Adenoma|Luteinizing Hormone-Producing Adenoma|Luteinizing Hormone-Producing Gonadotroph Adenoma	A pituitary neuroendocrine tumor that produces luteinizing hormone (LH).			Neoplastic Process	NCIt Neoplasm Core Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C121154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121154>	C7147	Proliferative Myositis	A rapidly growing, poorly circumscribed, mass-forming proliferation that arises from the skeletal muscle. It is characterized by the presence of spindle-shaped fibroblasts, round ganglion-like cells, myxoid to collagenous stroma formation, and high mitotic activity. It recurs only rarely following local excision and does not metastasize.			Neoplastic Process	
C121155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121155>	C49236	Genomically-Directed Monotherapy|Genomically Directed Monotherapy	The use of genomic sequencing to direct cancer therapy. A profile of the DNA and RNA expressed by a patient's tumor is obtained and used to select known therapies that will exploit the specific genetic defects found in that tumor.	Genomically-Directed Monotherapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C121156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121156>	C84978	Mesomelic Dysplasia|Mesomelic Dysplasias	A form of skeletal dysplasia characterized by shortening of the bones of the middle segments of the limbs (i.e., the radii, ulnae, tibiae and fibulae).			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C121157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121157>	C45678	Clearing Agent	Any substance that is administered to facilitate the removal of another substance.	Clearing Agent		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C121158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121158>	C171189|C129822	Anti-DR5 Agonistic Antibody DS-8273a|DS 8273|DS-8273A|DS-8273a	An agonistic monoclonal antibody directed against human death receptor type 5 (DR5), also called tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2, with potential pro-apoptotic and antitumor activities. Upon administration, anti-DR5 agonistic antibody DS-8273a mimics the natural receptor ligand TRAIL and binds to DR5. This activates DR5 and leads to the activation of the death receptor signal pathway, which results in the activation of caspase cascades, the induction of tumor cell apoptosis and a reduction in proliferation of DR5-expressing tumor cells. DR5, a member of the TNF receptor superfamily, is expressed on the surfaces of a variety of tumor cells and plays a key role in the induction of tumor cell apoptosis.	Anti-DR5 Agonistic Antibody DS-8273a		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121159>	C1511	Iodine I 124-labeled Albumin|124I-albumin|124I-labeled Albumin	A radioconjugate containing serum albumin labeled with the radioisotope iodine I 124, with potential use as an imaging agent using positron emission tomography (PET). Upon administration, iodine I 124 albumin distributes in a similar manner to endogenous albumin. Upon PET, albumin distribution patterns can be imaged. Specifically, the distribution to and residence time in a tumor can be assessed upon imaging. These findings may predict the distribution patterns of agents with similar particle sizes.	Iodine I 124-labeled Albumin		Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology
C12115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12115>	C61063	Paclitaxel/R101933			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121160>	C173925|C173398|C173348	Distressed by Trouble Falling Asleep Question|Distressed by Trouble Falling Asleep|Trouble falling asleep	A question about whether an individual is or has been distressed because they have trouble falling asleep.			Intellectual Product	
C121161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121161>	C173348	Distressed by Awakening in the Early Morning Question|Awakening in the early morning|Distressed by Awakening in the Early Morning	A question about whether an individual is or has been distressed because they are awakening in the early morning.			Intellectual Product	
C121162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121162>	C173925|C173348	Distressed by Sleep that is Restless and Disturbed Question|Distressed by Sleep that is Restless and Disturbed|Sleep that is restless and disturbed	A question about whether an individual is or has been distressed because they have sleep that is restless and disturbed.			Intellectual Product	
C121163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121163>	C91105	Initial Outcome Satisfaction Questionnaire|Initial Outcome Expectations Questionnaire	A set of questions and responses designed to evaluate an individual's self-reported initial expectations for recovery after treatment.			Intellectual Product	
C121164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121164>	C91102	Do Not Expect a Full Recovery Question|Do Not Expect a Full Recovery|I do not expect a full recovery	A subjective response indicating that an individual does not expect a complete recovery.			Intellectual Product	
C121165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121165>	C176243	Somewhat Difficult|Somewhat difficult	A subjective response indicating that an individual finds something to be somewhat difficult.			Intellectual Product	
C121166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121166>	C176243	Extremely Difficult|Extremely difficult|Very hard	A subjective response indicating that an individual finds something to be extremely difficult.			Intellectual Product	
C121167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121167>	C1512	Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein|Anti-CD20 B9E9 scFv-SA Fusion Protein|Anti-CD20 B9E9-SA Fusion Protein|B9E9 scFvSA Fusion Protein|Recombinant Anti-CD20 B9E9 scFvSA Fusion Protein|scFv B9E9-streptavidin Fusion Protein	An Escherichia coli periplasm-expressed tetrameric fusion protein composed of four single-chain variable regions (scFv) of the murine immunoglobulin (Ig) G2a anti-CD20 monoclonal antibody B9E9 fused to the streptavidin (SA) gene of Streptomyces avidinii (scFv-SA), with potential use in pretargeted radioimmunotherapy (PRIT). Upon intravenous administration of the anti-CD20 B9E9 scFv-SA fusion protein, this agent targets and binds to CD20-expressing tumor cells. Subsequently, a biotinylated N-acetylgalactosamine-containing clearing agent is administered, which binds to the streptavidin moiety of the unbound fusion protein and promotes its hepatic excretion. In turn, radiolabeled DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)-biotin is administered and, due to its small size, quickly distributes. The biotin moiety efficiently binds to the SA moiety of the bound fusion protein, which localizes the biotin-conjugated radionuclide to the tumor site. CD20, a tumor-associated antigen (TAA), is overexpressed on B-cell malignancies. PRIT increases both tumor uptake and renal elimination of the radionuclide conjugate as compared to conventional radioimmunotherapy (RIT), where the radioisotope is bound to the antibody before administration; this increases the dose of radionuclide delivered to the tumor while limiting radiation exposure for normal, healthy tissues.	Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121168>	C91105	EORTC/ROTG Late Radiation Morbidity Scoring Criteria	A set of questions and responses designed to establish criteria and scoring for adverse events occurring greater than 90 days after radiation therapy.			Intellectual Product	
C121169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121169>	C28076	LRMSC Grade 0, Skin|LRMSC Grade 0 Skin	No symptoms.			Classification	EORTC/ROTG Late Radiation Morbidity Scoring Criteria
C12116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12116>	C61063	Chinese Herbs/Cyclophosphamide/Doxorubicin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121170>	C28076	LRMSC Grade 1, Skin|LRMSC Grade 1 Skin	Slight atrophy; pigmentation change; some hair loss.			Classification	EORTC/ROTG Late Radiation Morbidity Scoring Criteria
C121171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121171>	C28076	LRMSC Grade 2, Skin|LRMSC Grade 2 Skin	Patch atrophy; moderate telangiectasia; total hair loss.			Classification	EORTC/ROTG Late Radiation Morbidity Scoring Criteria
C121172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121172>	C28076	LRMSC Grade 3, Skin|LRMSC Grade 3 Skin	Marked atrophy; gross telangiectasia.			Classification	EORTC/ROTG Late Radiation Morbidity Scoring Criteria
C121173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121173>	C28076	LRMSC Grade 4, Skin|LRMSC Grade 4 Skin	Ulceration.			Classification	EORTC/ROTG Late Radiation Morbidity Scoring Criteria
C121174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121174>	C28076	LRMSC Grade 5, Skin|LRMSC Grade 5 Skin	Death directly related to radiation late effects.			Classification	EORTC/ROTG Late Radiation Morbidity Scoring Criteria
C121175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121175>	C28076	LRMSC Grade 0, Subcutaneous Tissue|LRMSC Grade 0 Subcutaneous Tissue	No symptoms.			Classification	EORTC/ROTG Late Radiation Morbidity Scoring Criteria
C121176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121176>	C28076	LRMSC Grade 1, Subcutaneous Tissue|LRMSC Grade 1 Subcutaneous Tissue	Slight induration (fibrosis) and loss of subcutaneous fat.			Classification	EORTC/ROTG Late Radiation Morbidity Scoring Criteria
C121177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121177>	C28076	LRMSC Grade 2, Subcutaneous Tissue|LRMSC Grade 2 Subcutaneous Tissue	Moderate fibrosis but asymptomatic; slight field contracture; 10% linear reduction.			Classification	EORTC/ROTG Late Radiation Morbidity Scoring Criteria
C121178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121178>	C28076	LRMSC Grade 3, Subcutaneous Tissue|LRMSC Grade 3 Subcutaneous Tissue	Severe induration and loss of subcutaneous tissue; field contracture > 10% linear measurement.			Classification	EORTC/ROTG Late Radiation Morbidity Scoring Criteria
C121179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121179>	C28076	LRMSC Grade 4, Subcutaneous Tissue|LRMSC Grade 4 Subcutaneous Tissue	Necrosis.			Classification	EORTC/ROTG Late Radiation Morbidity Scoring Criteria
C12117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12117>	C61063	Carboplatin/Paclitaxel/PS-341			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121180>	C28076	LRMSC Grade 5, Subcutaneous Tissue|LRMSC Grade 5 Subcutaneous Tissue	Death directly related to radiation late effects.			Classification	EORTC/ROTG Late Radiation Morbidity Scoring Criteria
C121181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121181>	C49012	Mammary-Type Myofibroblastoma	A benign mesenchymal neoplasm characterized by the presence of spindle shaped myofibroblasts and mast cells in a collagenous stroma.  It is histologically identical to the myofibroblastoma of breast.  It usually arises from the subcutaneous tissue and the most common sites of involvement are the inguinal/groin, paratesticular, and vulvovaginal areas.			Neoplastic Process	
C121182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121182>	C74949	LDL Cholesterol to HDL Cholesterol Ratio Measurement|LDL Cholesterol/HDL Cholesterol|LDL Cholesterol/HDL Cholesterol|LDLHDL	The determination of the ratio of LDL cholesterol compared to HDL cholesterol present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C121183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121183>	C74949	Triglycerides to HDL Cholesterol Ratio Measurement|TRIGHDL|Triglycerides/HDL Cholesterol|Triglycerides/HDL Cholesterol	The determination of the ratio of triglycerides compared to HDL cholesterol present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C121184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121184>	C34792	Secondary Hemophagocytic Lymphohistiocytosis	Hemophagocytic lymphohistiocytosis due to infections, autoimmune disorders, or underlying malignancies. Signs and symptoms include fever, lymphadenopathy, hepatomegaly, splenomegaly, and pancytopenia.			Disease or Syndrome	
C121185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121185>	C120545	Pressure at dP/dt Maximum|Left Ventricular Pressure Maximum|PDPDTMAX	The positive pressure that correlates with the maximum dP/dt, the rate of change in pressure over time.			Diagnostic Procedure	CDISC SEND Cardiovascular Test Code Terminology|CDISC SEND Cardiovascular Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C121186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121186>	C120545	Pressure at dP/dt Minimum|Left Ventricular Pressure Minimum|PDPDTMIN	The positive pressure that correlates with the minimum dP/dt, the rate of change in pressure over time.			Diagnostic Procedure	CDISC SEND Cardiovascular Test Code Terminology|CDISC SEND Cardiovascular Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C121187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121187>	C20993	Adaptive Behavior Assessment System, Adult Rating Form|Adaptive Behavior Assessment System - Adult Rating Form	A comprehensive norm-referenced assessment of the adaptive skills of individuals ages 16 to 89 years that is used to evaluate adults with intellectual and developmental disabilities. This form is completed by family members, professional caregivers, supervisors, or the individual.			Intellectual Product	
C121188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121188>	C20993	Adaptive Behavior Assessment System, Parent Rating Form|Adaptive Behavior Assessment System - Parent Rating Form	A comprehensive norm-referenced assessment of the adaptive skills of individuals ages 5 to 21 years that is used to evaluate children with intellectual and developmental disabilities. This form is completed by parents or others responsible for the child's primary care.			Intellectual Product	
C121189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121189>	C20993	Communication Skills|ABAS-II	An assessment of the Adaptive Behavior Assessment System, Second Edition where communication skills such as speech, language, listening, and conversation are evaluated.			Intellectual Product	Adaptive Behavior Assessment System, Adult Rating Form|Adaptive Behavior Assessment System, Parent Rating Form
C12118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12118>	C61007	Dexamethasone/Doxorubicin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121190>	C20993	Community Use Skills	An assessment of the Adaptive Behavior Assessment System where community use skills, such as shopping, getting around the community, and using community resources, are evaluated.			Intellectual Product	Adaptive Behavior Assessment System, Adult Rating Form|Adaptive Behavior Assessment System, Parent Rating Form
C121191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121191>	C222260	Functional Pre-Academics Skills	An assessment of the Adaptive Behavior Assessment System, Second Edition where functional pre-academic skills such as the future use of basic reading, writing, and math are evaluated.			Intellectual Product	Adaptive Behavior Assessment System, Adult Rating Form|Adaptive Behavior Assessment System, Parent Rating Form
C121192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121192>	C222260	Functional Academics Skills	An assessment of the Adaptive Behavior Assessment System, Second Edition where functional academic skills such as basic reading, writing, and math are evaluated.			Intellectual Product	Adaptive Behavior Assessment System, Adult Rating Form|Adaptive Behavior Assessment System, Parent Rating Form
C121193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121193>	C20993	Home Living Skills	An assessment of the Adaptive Behavior Assessment System where home living skills such as cleaning, property maintenance, food preparation, and chores are evaluated.			Intellectual Product	Adaptive Behavior Assessment System, Adult Rating Form|Adaptive Behavior Assessment System, Parent Rating Form
C121194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121194>	C20993	Health and Safety Skills	An assessment of the Adaptive Behavior Assessment System where health and safety skills such as response to illness or injury, using medicines, and showing caution are evaluated.			Intellectual Product	Adaptive Behavior Assessment System, Adult Rating Form|Adaptive Behavior Assessment System, Parent Rating Form
C121195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121195>	C20993	Leisure Skills	An assessment of the Adaptive Behavior Assessment System, where leisure skills such as planning recreational activities, playing with others, and following rules of games are evaluated.			Intellectual Product	Adaptive Behavior Assessment System, Adult Rating Form|Adaptive Behavior Assessment System, Parent Rating Form
C121196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121196>	C20993	Self-Care Skills	An assessment of the Adaptive Behavior Assessment System where self-care skills such as eating, dressing, bathing, toileting, grooming, and hygiene are evaluated.			Intellectual Product	Adaptive Behavior Assessment System, Adult Rating Form|Adaptive Behavior Assessment System, Parent Rating Form
C121197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121197>	C25338	Composite Score	A single value that is calculated from multiple scores. This composite score can then be used as a single variable in further analysis and comparison.			Quantitative Concept	
C121198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121198>	C35337	Congenital Nephrotic Syndrome - Diffuse Mesangial Sclerosis|Diffuse Mesangial Sclerosis|Diffuse Mesangial Sclerosis	Nephrotic syndrome within the first three motnhs of life, characterized initially by increased mesangial matrix, with or without hypertrophy and hyperplasia of podocytes, and eventual glomerular sclerosis.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C121199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121199>	C20993	Self-Direction Skills	An assessment of the Adaptive Behavior Assessment System, where self-directed skills needed for independence, responsibility, self-control, starting and completing tasks, following directions, and making choices are evaluated.			Intellectual Product	Adaptive Behavior Assessment System, Adult Rating Form|Adaptive Behavior Assessment System, Parent Rating Form
C12119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12119>	C61007	Cyclophosphamide/Dexamethasone/Doxorubicin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1211>	C1591	Recombinant RANTES|CCL5|RANTES|Regulated on Activation, Normal T Expressed and Secreted|SIS delta|T-Cell RANTES Protein	A member of the IL-8 superfamily of cytokines and released from platelets and activated T-cells, RANTES is a selective chemoattractant for eosinophils, monocytes, and T-lymphocytes.  RANTES is one of the ligands for chemokine receptor CCR5. RANTES expression in peripheral lymphocytes increases exponentially following mitogenic or antigenic stimulation.  RANTES is one of the major HIV-suppressive factors produced by CD8-positive T-cells.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C121200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121200>	C35337	Congenital Nephrotic Syndrome - Focal Segmental Glomerulosclerosis|Congenital FSGS|Congenital FSGS	Nephrotic syndrome within the first three months of life, characterized by scarring of the glomerulus, in which only part of the glomerulus is involved, and less than 50% of the glomeruli are affected.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C121201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121201>	C20993	Social Skills	An assessment of the Adaptive Behavior Assessment System where social skills needed to interact socially, get along with others, have friends, show and recognize emotions, and using manners are evaluated.			Intellectual Product	Adaptive Behavior Assessment System, Adult Rating Form|Adaptive Behavior Assessment System, Parent Rating Form
C121202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121202>	C222260	Motor Skills Assessment|Motor Skills|Motor Skills|Motor Skills	An assessment of the Adaptive Behavior Assessment System, where fine and gross motor skills needed for locomotion, manipulation of the environment and development of more complex activities are evaluated.	Motor Skills		Intellectual Product	Adaptive Behavior Assessment System, Adult Rating Form|Adaptive Behavior Assessment System, Parent Rating Form|CTRP Intervention Terminology|CTRP Terminology
C121203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121203>	C20993	Work Skills	An assessment of the Adaptive Behavior Assessment System where skills needed for successful functioning and holding a job in a work setting are evaluated.			Intellectual Product	Adaptive Behavior Assessment System, Adult Rating Form|Adaptive Behavior Assessment System, Parent Rating Form
C121204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121204>	C217122	General Adaptive Composite Score|GAC|General Adaptive Composite|General Adaptive Composite (GAC) Composite Score	An overall score of the Adaptive Behavior Assessment System that consists of the three domains of conceptual, social, and practical.			Intellectual Product	Adaptive Behavior Assessment System, Adult Rating Form|Adaptive Behavior Assessment System, Parent Rating Form
C121205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121205>	C20993	Conceptual Domain	A domain of the General Adaptive Composite Score that is made up of scores from communication, functional academics, and self-direction skills assessments.			Intellectual Product	Adaptive Behavior Assessment System, Adult Rating Form|Adaptive Behavior Assessment System, Parent Rating Form
C121206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121206>	C20993	Social Domain	A domain of the General Adaptive Composite Score that is made up of scores from social and leisure skills assessments.			Intellectual Product	Adaptive Behavior Assessment System, Adult Rating Form|Adaptive Behavior Assessment System, Parent Rating Form
C121207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121207>	C35719	Pyometra|PYOMETRA	An infectious process characterized by the accumulation of pus within the uterus.			Disease or Syndrome	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C121208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121208>	C20993	Practical Domain	A domain of the General Adaptive Composite Score that is made up of scores from self-care, home/school living, community use, and health and safety skills assessments.			Intellectual Product	Adaptive Behavior Assessment System, Adult Rating Form|Adaptive Behavior Assessment System, Parent Rating Form
C121209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121209>	C84668	Denys-Drash Syndrome, Incomplete	Condition comprising congenital nephrotic syndrome with associated WT1 gene mutation with either intersex disorder or Wilms tumor.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C12120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12120>	C61063	Bexarotene/Cisplatin/Vinorelbine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121210>	C34643	IgA Nephropathy, Liver Disease-associated	IgA nephropathy secondary to hepatobiliary disease.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C121211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121211>	C159583	Anti-CD47 Monoclonal Antibody CC-90002|Anti-CD47 Mab CC-90002|CC 90002|CC-90002	A monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody CC-90002 selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.	Anti-CD47 Monoclonal Antibody CC-90002		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121212>	C213143|C164035	Aprutumab Ixadotin|ADC BAY1187982|APRUTUMAB IXADOTIN|BAY 1187982|BAY1187982	An antibody-drug conjugate (ADC) directed against the fibroblast growth factor receptor type 2 (FGFR2) and conjugated, via a non-cleavable linker, to BAY 1168650, an auristatin W derivative and microtubule-disrupting cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, aprutumab ixadotin binds to FGFR2. Upon binding, BAY 1168650 targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in FGFR2-expressing tumor cells. FGFR2, a receptor tyrosine kinase upregulated in many tumor cell types, plays an essential role in tumor cell proliferation, differentiation and survival.	Aprutumab Ixadotin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121213>	C128462	BET Inhibitor BAY1238097|BAY 1238097|BAY-1238097|BAY-1238097|BAY1238097	An inhibitor of the Bromodomain (BRD) and Extra-Terminal domain (BET) family of proteins, with potential antineoplastic activity. Upon administration, the BET inhibitor BAY1238097 binds to the acetylated lysine recognition motifs on the BRD of BET proteins, thereby preventing the interaction between BET proteins and histones. This disrupts chromatin remodeling and prevents the expression of certain growth-promoting genes. This leads to an inhibition of tumor cell growth. BET proteins (BRD2, BRD3, BRD4 and BRDT) are transcriptional regulators that bind to acetylated lysines on the tails of histones H3 and H4, and regulate chromatin structure and function; they play an important role in the modulation of gene expression during development and cellular growth.	BET Inhibitor BAY1238097		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121214>	C2189|C163952	Nanocell-encapsulated miR-16-based microRNA Mimic|TargomiRs	A nanoparticle-based formulation composed of a microRNA 16 (miR-16) mimic, a double-stranded, 23 base pair, synthetic RNA molecule, encapsulated in nonliving bacterial minicells and coated with anti-epidermal growth factor receptor (EGFR) antibodies, with potential antineoplastic activity. Upon intravenous administration and subsequent transfection, nanocell-encapsulated miR-16-based microRNA mimic targets EGFR-expressing tumor cells and facilitates the restoration of expression of the miR-16 family. This leads to the downregulation of the expression of tumor promoting genes and the inhibition of tumor cell growth. In addition, restoration of miR-16 expression sensitizes the tumor cell to certain chemotherapeutic agents. miR-16, a family of microRNAs, is critical to the regulation of gene expression and appears to have a tumor suppressor function; its expression is downregulated in various cancer cell types.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121215>	C2160	USP14/UCHL5 Inhibitor VLX1570|VLX-1570|VLX1570	An inhibitor of the 19S proteasome-specific deubiquitylating enzymes (DUBs) USP14 and UCHL5, with apoptosis-inducing and antineoplastic activities. Upon administration, VLX1570 specifically binds to both USP14 and UCHL5, thereby blocking their deubiquitylating activity. This blocks the ubiquitin proteasome degradation pathway, prevents the degradation of defective proteins, and leads to an accumulation of poly-ubiquitylated proteins. This induces the unfolded protein response (UPR) and results in both the induction of tumor cell apoptosis and the inhibition of tumor cell growth. USP14 and UCHL5, overexpressed in various tumor cell types, play a key role in the correct folding and deubiquitination of proteins.	USP14/UCHL5 Inhibitor VLX1570		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121216>	C177279	P-cadherin Inhibitor PCA062|P-CAD Inhibitor PCA062|P-cadherin Antagonist PCA062|PCA062	An agent that inhibits p-cadherin, with potential antineoplastic activity. Upon intravenous infusion, PCA062 binds to and inhibits the activity of p-cadherin. Inhibition of the activity of p-cadherin may inhibit both invasion and proliferation of p-cadherin expressing tumor cells. P-cadherin, a cell-surface protein and member of the cadherin family, is overexpressed in a variety of tumors and plays a role in cell adhesion, motility, invasion, and proliferation.	P-cadherin Inhibitor PCA062		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121217>	C133877	Cifurtilimab|Anti-CD40 Monoclonal Antibody SEA-CD40|CIFURTILIMAB|SEA CD40|SEA-CD40	A proprietary, non-fucosylated monoclonal antibody directed against the cell surface receptor CD40 with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, cifurtilimab binds to CD40 on a variety of immune cell types, triggering both cellular proliferation and activation of antigen-presenting cells (APCs), which activates B-cells and T-cells, and enhances the immune response against tumor cells. In addition, this agent binds to the CD40 antigen present on the surfaces of tumor cells, which induces antibody-dependent cytotoxicity (ADCC), and eventually inhibits the proliferation of CD40-expressing tumor cells. CD40, a stimulatory receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells, such as macrophages, dendritic cells and various tumor cell types; it plays a key role in the activation of the immune system. The non-fucosylated antibody shows increased efficacy as compared to its fucosylated counterpart.	Cifurtilimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121218>	C91105	Toronto Extremity Salvage Score, Lower Extremity|Lower Extremity Questionnaire|TESS|TESS Lower|TESS Lower Extremity|Toronto Extremity Salvage Score|Toronto Extremity Salvage Score (TESS) Lower Extremity	A self-administered questionnaire designed to assess physical disability for patients undergoing lower limb salvage sugery for musculoskeletal tumors.			Intellectual Product	OS Authorized Value Terminology|OS Patient Reported Outcomes Metadata Table
C121219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121219>	C91105	Toronto Extremity Salvage Score, Upper Extremity|TESS|TESS Upper|TESS Upper Extremity|Toronto Extremity Salvage Score|Toronto Extremity Salvage Score (TESS) Upper Extremity|Upper Extremity Questionnaire	A self-administered questionnaire designed to assess physical disability for patients undergoing upper limb salvage surgery for musculoskeletal tumors.			Intellectual Product	OS Authorized Value Terminology|OS Patient Reported Outcomes Metadata Table
C12121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12121>	C61063	Doxorubicin Hcl Liposome/Ifosfamide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121220>	C131923	Ability to Put on Shoes Question|Ability to Put on Shoes|Putting on shoes	A question about an individual's ability to tie shoe laces.			Intellectual Product	Toronto Extremity Salvage Score, Lower Extremity
C121221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121221>	C173458	Ability to Do Light Household Chores Question|Ability to Do Light Household Chores|Doing light household chores|Light household chores such as tidying and dusting|light housework/household jobs	A question about an individual's ability to do light household chores such as tidying and dusting.			Intellectual Product	Rotterdam Symptom Checklist|Toronto Extremity Salvage Score, Lower Extremity|Toronto Extremity Salvage Score, Upper Extremity
C121222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121222>	C173458	Ability to Garden or Do Yard Work Question|Ability to Garden or Do Yard Work|Gardening and yard work|Gardening or yard work	A question about an individuals' ability to do gardening and yard work.			Intellectual Product	Toronto Extremity Salvage Score, Lower Extremity|Toronto Extremity Salvage Score, Upper Extremity
C121223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121223>	C173458	Ability to Do Heavy Household Chores Question|Ability to Do Heavy Household Chores|Capacity to Do Heavy Household Chores|Do heavy household chores|Heavier housework|Heavy household chores such as vacuuming and moving furniture|Performing heavy household chores|heavy housework/household jobs	A question about an individual's ability or capacity to do heavy household chores such as vacuuming and moving furniture.			Intellectual Product	QuickDASH Outcome Measure|Rotterdam Symptom Checklist|Toronto Extremity Salvage Score, Lower Extremity|Toronto Extremity Salvage Score, Upper Extremity
C121224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121224>	C131925	Ability to Get In and Out of the Bath Tub Question|Ability to Get In and Out of the Bath Tub|Getting in and out of the bath tub	A question about an individual's ability to get in and out of the bath tub.			Intellectual Product	Toronto Extremity Salvage Score, Lower Extremity
C121225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121225>	C173045	Ability to Get Out of Bed Question|Ability to Get Out of Bed|Getting out of bed	A question about an individual's ability to get out of bed.			Intellectual Product	Toronto Extremity Salvage Score, Lower Extremity
C121226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121226>	C173045	Ability to Rise from a Chair Question|Ability to Rise from a Chair|Ability to Stand Up From Chair|Rising from a chair|Stand up from a straight chair	A question about an individual's ability to rise from a chair.			Intellectual Product	Health Assessment Questionnaire Disability Index|Toronto Extremity Salvage Score, Lower Extremity
C121227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121227>	C173045	Ability to Kneel Question|Ability to Kneel|Kneeling	A question about an individual's ability to kneel.			Intellectual Product	Toronto Extremity Salvage Score, Lower Extremity
C121228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121228>	C173045	Ability to Bend to Pick Something Up Off the Floor Question|Ability to Bend to Pick Something Up Off the Floor|Bending to pick something up off the floor	A question about an individual's ability to pick something up off the floor.			Intellectual Product	Toronto Extremity Salvage Score, Lower Extremity
C121229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121229>	C173082|C156133	Ability to Walk Up Stairs Question|Ability to Climb Stairs|Ability to Walk Up Stairs|Walking upstairs|climb stairs	A question about an individual's ability to walk up stairs.			Intellectual Product	Rotterdam Symptom Checklist|Toronto Extremity Salvage Score, Lower Extremity
C12122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12122>	C61007	Anti-thymocyte globulin/Cyclophosphamide/Fludarabine/methylprednisolone			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121230>	C156133	Ability to Walk Downstairs Question|Ability to Walk Downstairs|Walking downstairs	A question about an individual's ability to walk downstairs.			Intellectual Product	Toronto Extremity Salvage Score, Lower Extremity
C121231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121231>	C20401|C141144|C129822	Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1|Hu-Mik-Beta-1|Hu-Mik-beta1|Hu-Mikb1|HuMikBeta1|Humanized Mik-beta-1	A humanized version of the immunoglobulin (Ig) G1 monoclonal antibody Mik-Beta-1 (Hu-Mik-Beta-1) directed against CD122, the beta-subunit shared by the interleukin-2 (IL-2) and IL-15 receptor (IL-2/IL-15Rbeta). Upon intravenous infusion, Hu-Mik-Beta-1 binds to CD122 expressed on certain tumor cells. This blocks the binding of the inflammatory cytokines IL-2 and IL-15 to IL-2R and IL-15R, respectively, and prevents IL-2/IL-2R- and IL-15/IL-15R-mediated signaling. This may inhibit the proliferation of CD122-expressing tumor cells. In addition, blocking CD122 on T-lymphocytes prevents the over-activation of T-lymphocytes in various T-cell mediated autoimmune diseases, which is predominantly mediated by IL-15/IL-15R signaling. CD122, involved in both IL-2 and IL-15 signaling, is overexpressed on certain cancer cells, such as those found in T-cell large granular lymphocyte (T-LGL) leukemia.	Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121232>	C173045	Ability to Drive Question|Ability to Drive|Driving	A question about an individual's ability to drive.			Intellectual Product	Toronto Extremity Salvage Score, Lower Extremity
C121233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121233>	C156133	Ability to Walk Within the House Question|Ability to Walk Within the House|Capacity to Walk Within the House|Walking a short distance|Walking a short distance indoors, from one room to another|Walking within the house|walk about the house	A question about an individual's ability or capacityto walk within the house.			Intellectual Product	Rotterdam Symptom Checklist|Toronto Extremity Salvage Score, Lower Extremity
C121234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121234>	C156133	Ability to Walk Outdoors Question|Ability to Walk Outdoors|Walk outdoors on flat ground|Walking outdoors|walk out of doors	A question about an individual's ability to walk outdoors.			Intellectual Product	Health Assessment Questionnaire Disability Index|Rotterdam Symptom Checklist|Toronto Extremity Salvage Score, Lower Extremity
C121235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121235>	C173045	Ability to Sit Question|Ability to Sit|Sitting	A question about an individual's ability to sit.			Intellectual Product	Toronto Extremity Salvage Score, Lower Extremity
C121236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121236>	C156133	Ability to Walk Up or Down Hills or a Ramp Question|Ability to Walk Up or Down Hills or a Ramp|Walking up or down hills or a ramp	A question about an individual's ability to walk up or down hills or a ramp.			Intellectual Product	Toronto Extremity Salvage Score, Lower Extremity
C121237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121237>	C173045	Ability to Stand Upright Question|Ability to Stand Upright|Standing upright	A question about an individual's ability to stand upright.			Intellectual Product	Toronto Extremity Salvage Score, Lower Extremity
C121238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121238>	C173045	Ability to Get Up from Kneeling Question|Ability to Get Up from Kneeling|Getting up from kneeling	A question about an individual's ability to get up from kneeling.			Intellectual Product	Toronto Extremity Salvage Score, Lower Extremity
C121239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121239>	C173045	Ability to Get In and Out of a Car Question|Ability to Get In and Out of a Car|Getting in and out of a car	A question about an individual's ability to get in and out of a car.			Intellectual Product	Toronto Extremity Salvage Score, Lower Extremity
C12123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12123>	C61007	Capecitabine/Gemcitabine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121240>	C173704|C173045	Ability to Participate in Sexual Activities Question|Ability to Participate in Sexual Activities|Participating in sexual activities	A question about an individual's ability to participate in sexual activities.			Intellectual Product	Toronto Extremity Salvage Score, Lower Extremity
C121241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121241>	C131923	Ability to Put on a Pair of Pants Question|Ability to Put on a Pair of Pants|Putting on a pair of pants	A question about an individual's ability to put on a pair of pants.			Intellectual Product	Toronto Extremity Salvage Score, Upper Extremity
C121242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121242>	C173045	Ability to Tie Shoe Laces Question|Ability to Tie Shoe Laces|Tying shoe laces	A question about an individual's ability to tie shoe laces.			Intellectual Product	Toronto Extremity Salvage Score, Upper Extremity
C121243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121243>	C131923	Ability to Put on Socks or Stockings Question|Ability to Put on Socks or Stockings|Putting on socks or stockings	A question about an individual's ability to put on socks or stockings.			Intellectual Product	Toronto Extremity Salvage Score, Upper Extremity
C121244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121244>	C173045	Ability to Shower Question|Ability to Shower|Showering	A question about an individual's ability to shower.			Intellectual Product	Human Activity Profile|Toronto Extremity Salvage Score, Upper Extremity
C121245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121245>	C131923	Ability to Dress My Arms and Upper Body Question|Ability to Dress My Arms and Upper Body|Dressing my arms and upper body	A question about an individual's ability to dress their arms and upper body.			Intellectual Product	Toronto Extremity Salvage Score, Upper Extremity
C121246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121246>	C131923	Ability to Button a Shirt Question|Ability to Button a Shirt|Buttoning a shirt	A question about an individual's ability to button a shirt.			Intellectual Product	Toronto Extremity Salvage Score, Upper Extremity
C121247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121247>	C173045	Ability to Tie a Tie or Bow at the Neck of a Blouse Question|Ability to Tie a Tie or Bow at the Neck of a Blouse|Tying a tie or bow at the neck of a blouse	A question about an individual's ability to tie a tie or bow at the neck of a blouse.			Intellectual Product	Toronto Extremity Salvage Score, Upper Extremity
C121248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121248>	C173045	Ability to Put on Make-Up or Shave Question|Ability to Put on Make-Up or Shave|Putting on make-up or shaving	A question about an individual's ability to put on make-up or shave.			Intellectual Product	Toronto Extremity Salvage Score, Upper Extremity
C121249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121249>	C173045	Ability to Brush Your Teeth Question|Ability to Brush Your Teeth|Brush Teeth Ability|Brushing teeth|Brushing your teeth	A question about an individual's ability to brush their teeth.			Intellectual Product	Toronto Extremity Salvage Score, Upper Extremity
C12124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12124>	C61063	Autologous Lymphocytes/Fluorouracil/Pegylated Interferon Alfa/Sargramostim			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121250>	C173045	Ability to Brush Your Hair Question|Ability to Brush Your Hair|Brushing your hair	A question about an individual's ability to brush their hair.			Intellectual Product	Toronto Extremity Salvage Score, Upper Extremity
C121251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121251>	C173045	Ability to Prepare and Serve Meals Question|Ability to Prepare and Serve Meals|Preparing and serving meals	A question about an individual's ability to prepare and serve meals.			Intellectual Product	Toronto Extremity Salvage Score, Upper Extremity
C121252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121252>	C173045	Ability to Cut Food While Eating Question|Ability to Cut Food While Eating|Cutting food while eating	A question about an individual's ability to cut food while eating.			Intellectual Product	Toronto Extremity Salvage Score, Upper Extremity
C121253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121253>	C173045	Ability to Drink From a Glass Question|Ability to Drink From a Glass|Drinking from a glass	A question about an individual's ability to drink from a glass.			Intellectual Product	Toronto Extremity Salvage Score, Upper Extremity
C121254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121254>	C173045	Ability to Go Shopping Question|Ability to Go Shopping|Going shopping|Shopping	A question about an individual's ability to go shopping.			Intellectual Product	Lawton-Brody Instrumental Activities of Daily Living Scale|Toronto Extremity Salvage Score, Upper Extremity
C121255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121255>	C173045	Ability to Give or Receive Change Question|Ability to Give or Receive Change|Giving or receiving change (i.e., coins or bills)	A question about an individual's ability to give or receive change such as coins or bills.			Intellectual Product	Toronto Extremity Salvage Score, Upper Extremity
C121256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121256>	C173458	Ability to Carry a Shopping Bag or Briefcase Question|Ability to Carry a Shopping Bag or Briefcase|Carry a shopping bag or briefcase|Carrying a shopping bag or briefcase	A question about an individual's ability to carry a shopping bag or briefcase.			Intellectual Product	QuickDASH Outcome Measure|Toronto Extremity Salvage Score, Upper Extremity
C121257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121257>	C173045	Ability to Lift a Box to an Overhead Shelf Question|Ability to Lift a Box to an Overhead Shelf|Lifting a box to an overhead shelf	A question about an individual's ability to lift a box to an overhead shelf.			Intellectual Product	Toronto Extremity Salvage Score, Upper Extremity
C121258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121258>	C173045	Ability to Turn a Key in a Lock Question|Ability to Turn a Key in a Lock|Turning a key in a lock	A question about an individual's ability to turn a key in a lock.			Intellectual Product	Toronto Extremity Salvage Score, Upper Extremity
C121259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121259>	C173045	Ability to Push or Pull Open a Door Question|Ability to Push or Pull Open a Door|Pushing or pulling open a door	A question about an individual's ability to push or pull open a door.			Intellectual Product	Toronto Extremity Salvage Score, Upper Extremity
C12125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12125>	C61007	Celecoxib/Docetaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121260>	C173045	Ability to Write Question|Ability to Write|Writing	A question about an individual's ability to write.			Intellectual Product	Toronto Extremity Salvage Score, Upper Extremity
C121261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121261>	C173045	Ability to Pick Up Small Items Question|Ability to Pick Up Small Items|Picking up small items	A question about an individual's ability to pick up small items.			Intellectual Product	Toronto Extremity Salvage Score, Upper Extremity
C121262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121262>	C173924|C173045	Ability to Complete My Usual Duties at Work Question|Ability to Complete My Usual Duties at Work|Completing my usual duties at work (a job outside the home or as a homemaker)	A question about an individual's ability to complete my usual duties at work including a job outside the home or as a homemaker.			Intellectual Product	Toronto Extremity Salvage Score, Upper Extremity
C121263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121263>	C173924|C173045	Ability to Work My Usual Number of Hours Question|Ability to Work My Usual Number of Hours|Working my usual number of hours (a job outside the home or as a homemaker)	A question about an individual's ability to work their usual number of hours including a job outside the home and as a homemaker.			Intellectual Product	Toronto Extremity Salvage Score, Upper Extremity
C121264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121264>	C173045	Ability to Participate in My Usual Leisure Activities Question|Ability to Participate in My Usual Leisure Activities|Participating in my usual leisure activities	A question about an individual's ability to participate in their usual leisure activities.			Intellectual Product	Toronto Extremity Salvage Score, Upper Extremity
C121265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121265>	C173151|C173045	Ability to Socialize with Friends and Family Question|Ability to Socialize with Friends and Family|Socializing with friends and family	A question about an individual's ability to socialize with friends and family.			Intellectual Product	Toronto Extremity Salvage Score, Upper Extremity
C121266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121266>	C173045	Ability to Participate in My Usual Sporting Activities Question|Ability to Participate in My Usual Sporting Activities|Participating in my usual sporting activities	A question about an individual's ability to participate in their usual sporting activities.			Intellectual Product	Toronto Extremity Salvage Score, Upper Extremity
C121267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121267>	C173787|C173045	Ability to Perform all the Activities in Which I Participate in Daily Life Question|Ability to Perform all the Activities in Which I Participate in Daily Life|Ability to perform all the activities in which I participate in daily life	A question about an individual's ability to perform all the activities in which they participate in daily life.			Intellectual Product	Toronto Extremity Salvage Score, Upper Extremity
C121268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121268>	C91102	Rating Myself Question|I would rate myself as being|Rating Myself|Self Rating	A question about an individual's total assessment of their abilities.			Intellectual Product	Toronto Extremity Salvage Score, Upper Extremity
C121269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121269>	C20993	Behavior Assessment System for Children, Second Edition|BASC-2	A comprehensive set of rating scales designed to facilitate the differential diagnosis and classification of a variety of emotional and behavioral disorders of children, aid in the design of treatment plans, and provide insight into an individual's thoughts and feelings.			Intellectual Product	
C12126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12126>	C61007	Isotretinoin/Monoclonal antibody Ch14.18			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121270>	C121269	Self-Report of Personality|Behavior Assessment System for Children, Second Edition, Self-Report of Personality (BASC-2 SRP)|SRP	A clinical assessment tool that uses targeted forms for monitoring changes in behavior or emotional status. It provides insight into a child's or adult's thoughts and feelings.			Intellectual Product	Behavior Assessment System for Children, Second Edition
C121271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121271>	C121269	Self-Report of Personality, College Version|Behavior Assessment System for Children, Second Edition, Self-Report of Personality, College Version (BASC-2 SRP-COL)|SRP-COL	The Self-Report of Personality, College Version provides insight into the thoughts and feelings of college-aged individuals (ages 18 to 25).			Intellectual Product	Behavior Assessment System for Children, Second Edition
C121272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121272>	C121269	Parent Rating Scales|BASC-2 PRS|Behavior Assessment System for Children, Parent Rating Scales	The Parent Rating Scales is used to measure both adaptive behavior and problem behavior in the community and home setting in individuals aged 2-21.			Intellectual Product	Behavior Assessment System for Children, Second Edition
C121273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121273>	C217121	Atypicality Scale|Atypicality	A rating scale included in the Behavior Assessment System for Children that measures mood swings, bizarre thought, subjective experiences associated with obsessive compulsive disorder, and odd behaviors in the subject.			Intellectual Product	Parent Rating Scales|Self-Report of Personality
C121274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121274>	C217121	Locus of Control Scale|Locus of Control	A rating scale included in the Behavior Assessment System for Children that measures the subject's belief that rewards and punishment are controlled by external stimulus.			Intellectual Product	Self-Report of Personality
C121275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121275>	C217121	Social Stress Scale|Social Stress	A rating scale included in the Behavior Assessment System for Children that measures the subject's feelings of stress and tension, and feeling excluded in personal relationships.			Intellectual Product	Self-Report of Personality
C121276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121276>	C217121	Anxiety Scale|Anxiety	A rating scale included in the Behavior Assessment System for Children that measures the tendency of the subject to be nervous, fearful, or worried about real or imagined problems.			Intellectual Product	Parent Rating Scales|Self-Report of Personality
C121277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121277>	C217121	Depression Scale|Depression	A rating scale included in the Behavior Assessment System for Children that measures the tendency of the subject to have feelings of unhappiness, sadness, and stress that may result in an inability to carry out everyday activities.			Intellectual Product	Parent Rating Scales|Self-Report of Personality
C121278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121278>	C217121	Sense of Inadequacy Scale|Sense of Inadequacy	A rating scale included in the Behavior Assessment System for Children that measures the subject's perception of being unsuccessful and inadequate in school.			Intellectual Product	Self-Report of Personality
C121279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121279>	C217121	Somatization Scale|Somatization	A rating scale included in the Behavior Assessment System for Children that measures the tendency of the subject to be overly sensitive or to complain about relatively minor physical problems or discomfort.			Intellectual Product	Parent Rating Scales|Self-Report of Personality
C12127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12127>	C61063	Carboplatin/Erlotinib			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121280>	C217122	Internalizing Problems Composite Score|Internalizing Problems Composite	A composite score of the Behavior Assessment System for Children that combines the anxiety, depression, and somatization scales. This composite measures a broad index of distress that reflects the clinical, internalizing problems a child may be experiencing.			Intellectual Product	Parent Rating Scales|Self-Report of Personality
C121281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121281>	C217121	Attention Problems Scale|Attention Problems	A rating scale included in the Behavior Assessment System for Children that measures the tendency of the subject to be distracted and unable to concentrate.			Intellectual Product	Parent Rating Scales|Self-Report of Personality
C121282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121282>	C217121	Hyperactivity Scale|Hyperactivity	A rating scale included in the Behavior Assessment System for Children that measures the tendency to be overly active, rush through work or activities, and act without thinking.			Intellectual Product	Self-Report of Personality
C121283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121283>	C217122	Emotional Symptoms Index	An index of the Behavior Assessment System for Children that measures the subject's overall emotional development.			Intellectual Product	Self-Report of Personality
C121284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121284>	C217121	Sensation Seeking Scale|Sensation Seeking	A rating scale included in the Behavior Assessment System for Children that measures the tendency of the subject to take risks and seek excitement.			Intellectual Product	Self-Report of Personality
C121285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121285>	C217121	Alcohol Abuse Scale|Alcohol Abuse	A rating scale included in the Behavior Assessment System for Children, College Version, that identifies subjects who engage in drinking behaviors that have the potential to lead to alcohol abuse and those who experience academic, social, or functional problems due to their alcohol consumption.			Intellectual Product	Self-Report of Personality, College Version
C121286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121286>	C217121	School Maladjustment Scale|School Maladjustment	A rating scale included in the Behavior Assessment System for Children, College Version that provides an indication of how the subject is responding to the academic demands of college.			Intellectual Product	Self-Report of Personality, College Version
C121287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121287>	C217121	Relations with Parents Scale|Relations with Parents	A rating scale included in the Behavior Assessment System for Children that measures a subject's positive regard towards parents and a feeling of being esteemed by them.			Intellectual Product	Self-Report of Personality, College Version
C121288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121288>	C217121	Interpersonal Relations Scale|Interpersonal Relations	A rating scale included in the Behavior Assessment System for Children that measures a subject's perception of having good social relationships and friendships with peers.			Intellectual Product	Self-Report of Personality, College Version
C121289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121289>	C217121	Self-Esteem Scale|Self-Esteem	A rating scale included in the Behavior Assessment System for Children that measures a subject's feelings about self, respect, and self-acceptance.			Intellectual Product	Self-Report of Personality, College Version
C12128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12128>	C61007	Cisplatin/Erlotinib			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121290>	C217121	Self-Reliance Scale|Self-Reliance	A rating scale included in the Behavior Assessment System for Children that measures a subject's confidence in their ability to solve problems and their dependability and decisiveness.			Intellectual Product	Self-Report of Personality, College Version
C121291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121291>	C217122	Personal Adjustment Composite Score|Personal Adjustment Composite	A composite score of the Behavior Assessment System for Children that combines the interpersonal relationships, ego strength and identity development scales.			Intellectual Product	Self-Report of Personality, College Version
C121292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121292>	C217121	Aggression Scale|Aggression	A rating scale included in the Behavior Assessment System for Children that measures the tendency of the subject to act in a hostile manner, either verbally or physically, that is threatening to others.			Intellectual Product	Parent Rating Scales
C121293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121293>	C217121	Conduct Problems Scale|Conduct Problems	A rating scale included in the Behavior Assessment System for Children that measures the tendency of the subject to engage in antisocial and rule breaking behavior.			Intellectual Product	Parent Rating Scales
C121294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121294>	C217121	Withdrawal Scale|Withdrawal	A rating scale included in the Behavior Assessment System for Children that measures the tendency of the subject to evade others to avoid social contact.			Intellectual Product	Parent Rating Scales
C121295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121295>	C217121	Adaptability Scale|Adaptability	A rating scale included in the Behavior Assessment System for Children that measures the ability of the subject to adapt readily to changes in the environment.			Intellectual Product	Parent Rating Scales
C121296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121296>	C217121	Social Skills Scale|Social Skills	A rating scale included in the Behavior Assessment System for Children that measures the skills necessary for the subject to interact successfully with peers and adults in home, school, and community settings.			Intellectual Product	Parent Rating Scales
C121297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121297>	C217121	Leadership Scale|Leadership	A rating scale included in the Behavior Assessment System for Children that measures the skills associated with the subject being able to accomplish academic, social, or community goals, including the ability to work well with others.			Intellectual Product	Parent Rating Scales
C121298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121298>	C217121	Activities of Daily Living Scale|Activities of Daily Living	A rating scale included in the Behavior Assessment System for Children that measures the subject's ability to follow through or complete simple daily tasks.			Intellectual Product	Parent Rating Scales
C121299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121299>	C217121	Functional Communication Scale|Functional Communication	A rating scale included in the Behavior Assessment System for Children that measures the subject's ability to express ideas and communicate in a way others can easily understand.			Intellectual Product	Parent Rating Scales
C12129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12129>	C61063	Paclitaxel/PS-341			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1212>	C574|C261|C2201	Sirolimus|9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,2|AY 22989|AY-22989|AY22989|RAPA|RAPAMYCIN|Rapamune|Rapamune|Rapamycin|SILA 9268A|SILA-9268A|SILA9268A|SIROLIMUS|WY 090217|WY-090217|WY090217|rapamycin|sirolimus	A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production. (NCI04)	Sirolimus		Antibiotic|Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C121300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121300>	C217122	Externalizing Problems Composite Score|Externalizing Problems Composite	A composite score of the Behavior Assessment System for Children that combines the hyperactivity, aggression, and conduct problems scales. This composite score measures disruptive behavior problems.			Intellectual Product	Parent Rating Scales
C121301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121301>	C217122	Behavioral Symptoms Index Composite Score|BSI|Behavioral Symptoms Index|Behavioral Symptoms Index Composite	An index of the Behavior Assessment System for Children that combines the hyperactivity, aggression, depression, atypicality, withdrawal, and attention problem scales. This composite score measures the overall level of behavioral problems.			Intellectual Product	Parent Rating Scales
C121302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121302>	C217122	Adaptive Skills Composite Score|Adaptive Skills Composite	A composite score of the Behavior Assessment System for Children that combines the adaptability, social skills, leadership, study skills, and functional communication scales. This composite score summarizes prosocial, organizational, study, and other adaptive skills.			Intellectual Product	Parent Rating Scales
C121303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121303>	C16729	Post Neonatal Death	Death between 28 days and 1 year of life.			Finding	
C121304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121304>	C63732	Military Nuclear Weapon	A military device designed to release energy in an explosive manner as a result of nuclear fission, nuclear fusion, or a combination of the two processes.			Manufactured Object	
C121305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121305>	C92861	Moderate to Late Preterm Birth	Birth when a fetus is between 32 weeks and less than 37 weeks gestational age.			Finding	
C121306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121306>	C92861	Very Preterm Birth	Birth when a fetus is between 28 weeks and less than 32 weeks gestational age.			Finding	
C121307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121307>	C92861	Extreme Preterm Birth	Birth when a fetus is less than 28 weeks gestational age.			Finding	
C121308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121308>	C28681|C138180	Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes	Autologous, human CD8 T-lymphocytes, comprised of both central memory T-cells (Tcm) and naïve T-cells (Tn), that are transduced, ex vivo, with a self-inactivating (SIN) lentiviral vector encoding a high-affinity T-cell receptor (TCRc4) specific for the human tumor antigen Wilms tumor 1 (WT1) epitope 126-134 (RMFPNAPYL), with potential antineoplastic activity. Upon isolation of peripheral blood lymphocytes (PBLs), transduction, expansion ex vivo, priming of the Tn subset, but not the Tcm subset, with interleukin-21 (IL-21) and reintroduction of equal amounts of Tcm and Tn cells into the patient, WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes redirect T-lymphocytes to WT1-expressing tumor cells and specifically bind to and lyse those cells. This inhibits proliferation of WT1-expressing tumor cells. WT1 protein, a zinc finger DNA-binding transcriptional regulator, is overexpressed in most leukemias and various solid tumors, while expression in normal, healthy tissues is very limited; its expression is correlated with aggressiveness and poor prognosis.	Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121309>	C217121	Stern's Rating Scale for Edema	A subjective, physician-rated measure of edema with scores ranging from 0 to 4.			Intellectual Product	
C12130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12130>	C61063	Montanide ISA-51/PSA prostate cancer vaccine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121310>	C221020	Edema Rating 0|Stern's Edema Rating 0	No edema.			Intellectual Product	Stern's Rating Scale for Edema
C121311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121311>	C221020	Edema Rating 1|Stern's Edema Rating 1	Mild edema (slight but definite).			Intellectual Product	Stern's Rating Scale for Edema
C121312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121312>	C221020	Edema Rating 2|Stern's Edema Rating 2	Moderate edema.			Intellectual Product	Stern's Rating Scale for Edema
C121313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121313>	C221020	Edema Rating 3|Stern's Edema Rating 3	Severe edema (considerable swelling).			Intellectual Product	Stern's Rating Scale for Edema
C121314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121314>	C221020	Edema Rating 4|Stern's Edema Rating 4	Very severe edema (skin shiny and tight with or without skin cracking).			Intellectual Product	Stern's Rating Scale for Edema
C121315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121315>	C91105	Follow-Up Embodiment/Outcomes Questionnaire|Follow-Up Embodiment/Outcomes	A set of questions and responses designed to evaluate an individual's self-reported feeling about their limbs.			Intellectual Product	
C121316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121316>	C173160	Feelings About Arm or Leg Question|Feelings About Arm or Leg|Feelings About Arm or Leg Most of the Time|How I feel about my arm or leg most of the time	A question about an individual's feelings about their arm or leg most of the time.			Intellectual Product	Follow-Up Embodiment/Outcomes Questionnaire
C121317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121317>	C175252	Arm or Leg Response Group 1|Group 1|Response Group 1	A response indicating: I don't even know my arm/leg is there; my arm/leg is back to normal as far as I am concerned; I rarely or never think about my arm/leg.			Intellectual Product	Follow-Up Embodiment/Outcomes Questionnaire
C121318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121318>	C175252	Arm or Leg Response Group 2|Group 2|Response Group 2	A response indicating: I'm very aware of my arm/leg; my arm/leg feels like an alien part; my arm/leg has a mind of its own; I hide or cover my arm/leg; it seems that my arm/leg is not part of me.			Intellectual Product	Follow-Up Embodiment/Outcomes Questionnaire
C121319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121319>	C175252	Arm or Leg Response Group 3|Group 3|Response Group 3	A response indicating: I've got to accept my arm/leg the way it is; I'm learning how to use my arm/leg more and just trying to not really concentrate on it, but try to adapt my arm/leg to different ways of life; I'm going to have to learn to live with arm/leg the way it is now.			Intellectual Product	Follow-Up Embodiment/Outcomes Questionnaire
C12131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12131>	C61063	506U78/Asparaginase/Daunorubicin/Methotrexate/Prednisone/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121320>	C175252	Arm or Leg Response Group 4|Group 4|Response Group 4	A response indicating: I never realized I could do so many things with my arm/leg; I'm used to my arm/leg now, it's part of me; it's amazing what you can learn to do.			Intellectual Product	Follow-Up Embodiment/Outcomes Questionnaire
C121321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121321>	C271	Chloroquine Compound	A pharmaceutical agent initially used to cure or prevent malaria. A principal rheumatologic indication is the treatment of autoimmune disease including dermatomyositis, lupus, rheumatoid arthritis, and Sjogren syndrome.			Chemical Viewed Functionally	NICHD Terminology|Pediatric Rheumatology Terminology
C121322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121322>	C70547	Anti-Ro Antibody|Anti-SSA/Ro Antibody|Anti-SSA/Ro Antibody	An antinuclear antibody directed against 52 or 60 kDa RNA-binding proteins in the nucleus. They can be associated with multiple autoimmune disorders, primarily Sjogren syndrome and system lupus erythematosus. Maternal anti-Ro antibody positivity can be associated with neonatal lupus.			Amino Acid, Peptide, or Protein|Immunologic Factor	NICHD Terminology|Pediatric Rheumatology Terminology
C121323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121323>	C70547	Anti-La Antibody|Anti-SSB/La Antibody|Anti-SSB/La Antibody	An antinuclear antibody directed against a 47 kDa RNA-binding protein in the nucleus. They can be associated with Sjogren syndrome and system lupus erythematosus. Maternal anti-La antibody positivity can be associated with neonatal lupus.			Amino Acid, Peptide, or Protein|Immunologic Factor	NICHD Terminology|Pediatric Rheumatology Terminology
C121324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121324>	C70547	Anti-Smith Antibody|Anti-Sm Antibody|Anti-Sm Antibody|Anti-Sm-RNP Antibody|Anti-Sm/RNP Antibody	An antinuclear antibody directed against small nuclear ribonucleoproteins (snRNPs), that is highly specific, but has poor sensitivity for systemic lupus erythematosus (SLE). Presence of anti-Sm antibodies are associated with central nervous system, kidney, lung and cardiac involvement in SLE, but are not indicative of disease activity.	Anti-Smith Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology|NICHD Terminology|Pediatric Rheumatology Terminology
C121325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121325>	C70547	Anti-Ribonucleoprotein Antibody|Anti-RNP|Anti-RNP Antibody|Anti-RNP Antibody|Anti-Ribonucleoprotein|RNP Antibody|Ribonucleoprotein Antibody	An antinuclear antibody directed against U1 snRNP, that is strongly associated with mixed connective tissue disease and commonly detected in lupus.			Amino Acid, Peptide, or Protein|Immunologic Factor	NICHD Terminology|Pediatric Rheumatology Terminology
C121326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121326>	C48966	Cyclic Citrullinated Peptide Antibody|ACPA|ACPA|Anti-Keratin Antibody|Anti-Keratin Antibody|Anti-Perinuclear Factor Antibody|Anti-Perinuclear Factor Antibody|CCP|CCP	An autoantibody directed against peptides or proteins whose arginine residues have been enzymatically converted to citrulline. It is often associated with rheumatoid arthritis.			Amino Acid, Peptide, or Protein|Immunologic Factor	NICHD Terminology|Pediatric Rheumatology Terminology
C121327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121327>	C48966	Antiphospholipid Antibody|APLA|APLA|Anti-Phospholipid Antibody	A class of autoantibodies directed against phospholipids or phospholipoproteins. Its presence may indicate an increased risk for hypercoagulability, pregnancy loss or autoimmune disease.			Amino Acid, Peptide, or Protein|Immunologic Factor	NICHD Terminology|Pediatric Rheumatology Terminology
C121328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121328>	C48966	Anti-Beta-2 Glycoprotein 1 Antibody|AAHA|AAHA|AB2GP|AB2GP|Anti-APOH|Anti-Apolipoprotein H|Anti-Apolipoprotein H|Anti-Apolipoprotein H Antibody|Anti-Apolipoprotein H Antibody|Anti-B2GP1|Anti-B2GP1|Anti-Beta-2 Glycoprotein I Antibody|Anti-Beta-2 Glycoprotein I Antibody	An antiphospholipid autoantibody that reacts with beta-2-glycoprotein 1, and a member of family of autoantibodies that cause antiphospholipid antibody syndrome and may be found in system lupus erythematosus.			Amino Acid, Peptide, or Protein|Immunologic Factor	NICHD Terminology|Pediatric Rheumatology Terminology
C121329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121329>	C91105	Childhood Health Assessment Questionnaire|C-HAQ|C-HAQ|CHAQ|CHAQ	A pediatric modification of the Stanford Health Assessment Questionnaire (HAQ) used in the evaluation of functional disability and discomfort in children.			Intellectual Product	NICHD Terminology|Pediatric Rheumatology Terminology
C12132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12132>	C61007	Irinotecan/UCN-01			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121330>	C91105	Child Health Questionnaire|CHQ|CHQ	A collection of general quality of life surveys that measures physical and psychosocial concepts in children.			Intellectual Product	NICHD Terminology|Pediatric Rheumatology Terminology
C121331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121331>	C15986	Intravenous Immunoglobulin Therapy|Gamma Globulin|Gamma Globulin Therapy|IVIG|IVIG|IVIG Therapy|Immune Globulin|Immune Globulin Therapy|Intravenous Immunoglobulin|Intravenous immunoglobulin	The administration of a blood product derived from pooled IgG antibodies extracted from donor plasma delivered intravenously. It is used to treat multiple disorders, including immunodeficiencies, autoimmune disorders, and active infections.	Intravenous Immunoglobulin Therapy		Therapeutic or Preventive Procedure	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|Appendix 8: Pharmacological Therapy Terminology|CTRP Intervention Terminology|CTRP Terminology|HemOnc Agent Terminology|NICHD Terminology|Pediatric Rheumatology Terminology|Therapies for COVID-19 Terminology
C121332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121332>	C1708	Disease-Modifying Antirheumatic Drug|DMARD|DMARD	A pharmaceutical agent that is categorized by its ability to alter the progression of autoimmune disease.			Chemical Viewed Functionally	NICHD Terminology|Pediatric Rheumatology Terminology
C121333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121333>	C121332	Non-Biologic Disease-Modifying Antirheumatic Drug|Non-Biologic DMARD|Non-Biologic DMARD	A drug used to alter the progression of autoimmune disease that is not a biologic.			Chemical Viewed Functionally	NICHD Terminology|Pediatric Rheumatology Terminology
C121334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121334>	C121332	Biologic Disease-Modifying Antirheumatic Drug|Biologic DMARD|Biologic DMARD	A biologic used to alter the progression of autoimmune disease.			Chemical Viewed Functionally	NICHD Terminology|Pediatric Rheumatology Terminology
C121335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121335>	C199143	International Myositis Assessment and Clinical Studies Group|IMACS|IMACS	A coalition of health care providers and researchers with experience and interest in the myositis syndromes. (adapted from NIEHS website)			Professional or Occupational Group	NICHD Terminology|Pediatric Rheumatology Terminology
C121336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121336>	C20993	American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus|ACR Classification Criteria for SLE|ACR Classification Criteria for SLE	The classification of systemic lupus erythematosus based on eleven criteria. Intended to be used as inclusion criteria for clinical studies, a person is defined as having systemic lupus erythematosus if any four or more of the eleven criteria are present, serially or simultaneously, during any interval of observation.			Intellectual Product	NICHD Terminology|Pediatric Rheumatology Terminology
C121337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121337>	C20993	Systemic Lupus International Collaborating Clinics Classification Criteria|SLICC Criteria|SLICC Criteria|Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus|Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus	A validated revision of American College of Rheumatology (ACR) criteria for systemic lupus erythematosus with extension to seventeen criteria. Intended to be used as inclusion criteria for clinical studies, if the patient has biopsy-proven lupus nephritis with antinuclear antibodies (ANA) or anti-dsDNA, or the patient satisfies four of the criteria, including at least one clinical and one immunologic criterion.			Intellectual Product	NICHD Terminology|Pediatric Rheumatology Terminology
C121338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121338>	C20993	International League of Associations for Rheumatology Classification Criteria for Juvenile Idiopathic Arthritis|ILAR Classification Criteria for JIA|ILAR Classification Criteria for JIA	A set of criteria used to assign children with chronic arthritis to one of the seven mutually exclusive categories of juvenile idiopathic arthritis (JIA), intended to be used for research purposes.			Intellectual Product	NICHD Terminology|Pediatric Rheumatology Terminology
C121339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121339>	C20993	European League Against Rheumatism Classification Criteria for Juvenile Chronic Arthritis|EULAR Classification Criteria for Juvenile Chronic Arthritis|EULAR Classification Criteria for Juvenile Chronic Arthritis	A set of antiquated criteria used to assign children with chronic arthritis to one of six mutually exclusive categories.			Intellectual Product	NICHD Terminology|Pediatric Rheumatology Terminology
C12133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12133>	C61007	Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody/gp100 antigen/Montanide ISA-51			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121340>	C20993	American College of Rheumatology Classification Criteria for Juvenile Rheumatoid Arthritis|ACR Classification Criteria for JRA|ACR Classification Criteria for JRA	A set of antiquated criteria used to assign children with chronic arthritis to one of the three mutually exclusive categories.			Intellectual Product	NICHD Terminology|Pediatric Rheumatology Terminology
C121341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121341>	C20993	American College of Rheumatology Pediatric Core Set for Juvenile Arthritis|ACR Pediatric Core Set for Juvenile Arthritis|ACR Pediatric Core Set for Juvenile Arthritis	A set of criteria used to assess clinical response (improvement) or worsening (flare), in juvenile idiopathic arthritis clinical trials.			Intellectual Product	NICHD Terminology|Pediatric Rheumatology Terminology
C121342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121342>	C217122	Pediatric Vasculitis Activity Score|PVAS|PVAS	A set of criteria used to determine the activity of childhood vasculitis.			Intellectual Product	NICHD Terminology|Pediatric Rheumatology Terminology
C121343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121343>	C217122	Birmingham Vasculitis Activity Score|BVAS|BVAS	A set of criteria used to determine the activity of vasculitis.			Intellectual Product	NICHD Terminology|Pediatric Rheumatology Terminology
C121344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121344>	C217121	Childhood Myositis Assessment Scale|CMAS|CMAS	An observational performance-based instrument developed to evaluate muscle strength, physical function, and endurance in children with juvenile idiopathic inflammatory myopathy.			Intellectual Product	NICHD Terminology|Pediatric Rheumatology Terminology
C121345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121345>	C20993	Patient-Reported Outcomes Measurement Information System Measures|PROMIS Measures|PROMIS Measures|PRO_MEASURES	Psychometrically validated measures designed for precise and efficient self-report measurement of physical, mental, and social health across chronic conditions. Items can be administered in static (short-form) or dynamic form (as computer adaptive tests).			Intellectual Product	HL Patient Reported Outcomes Metadata Table|HL Variable Terminology|NICHD Terminology|Pediatric Rheumatology Terminology
C121346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121346>	C20993	Physician Global Assessment of Disease Activity|MD Global|MD Global|PGA|PGA|Physician's Global Assessment|Physician's Global Assessment	A physician or clinician-scored instrument that estimates the level of activity of a disease at a given time taking into account all disease manifestations. Typically scored on a numeric rating scale or visual analogue scale, or may be recorded using descriptors such as remission, or low, moderate, or high disease activity.			Intellectual Product	NICHD Terminology|Pediatric Rheumatology Terminology
C121347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121347>	C20993	Parent Global Assessment of Disease Activity	A parent-scored instrument that estimates the level of activity of a disease at a given time taking into account all disease manifestations. Typically scored on a numeric rating scale or visual analogue scale, or may be recorded using descriptors such as remission, or low, moderate, or high disease activity.			Intellectual Product	NICHD Terminology|Pediatric Rheumatology Terminology
C121348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121348>	C20993	Parent Assessment of Overall Well-Being|Parent Global Assessment|Parent Global Assessment	A parent's estimation of the overall impact of a disease on their child at a given time. Typically scored on a numeric rating scale or visual analogue scale.			Intellectual Product	NICHD Terminology|Pediatric Rheumatology Terminology
C121349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121349>	C74528	Patient Global Assessment of Disease Activity	A patient-scored instrument that estimates the level of activity of a disease at a given time taking into account all disease manifestations. Typically scored on a numeric rating scale or visual analogue scale, or may be recorded using descriptors such as remission, or low, moderate, or high disease activity.			Intellectual Product	NICHD Terminology|Pediatric Rheumatology Terminology
C12134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12134>	C61063	Alum adjuvant/gp100 antigen/Interleukin-12/MART-1 antigen/Montanide ISA-51/tyrosinase peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121350>	C74528	Patient Assessment of Overall Well-Being|Patient Global Assessment|Patient Global Assessment	A patient's estimation of the overall impact of a disease on him or herself at a given time. Typically scored on a numeric rating scale or visual analogue scale.			Intellectual Product	NICHD Terminology|Pediatric Rheumatology Terminology
C121351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121351>	C15747	Occupational Therapy|OT|OT	Interventions and exercises intended to develop, recover, or maintain the ability of an individual to accomplish their activities of daily living.	Occupational Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|NICHD Terminology|Pediatric Rheumatology Terminology
C121352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121352>	C217122|C21154	British Isles Lupus Assessment Group Index|BILAG Index|BILAG Index	An organ-specific assessment intended as a clinical decision tool. It evaluates specific manifestations over the previous four weeks in a total of eight organs systems, nine in the revised Index: constitutional, mucocutaneous, neuropsychiatric, musculoskeletal, cardiorespiratory, gastrointestinal, ophthalmic, renal, and hematological. Activity in each organ system is scored from most active disease to no previous activity.			Intellectual Product	NICHD Terminology|Pediatric Rheumatology Terminology
C121353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121353>	C217122|C21154	Systemic Lupus International Collaborating Clinics/American College of Rheumatology-Damage Index|SDI|SDI|SLICC/ACR Damage Index for SLE|SLICC/ACR Damage Index for SLE|SLICC/ACR-DI|SLICC/ACR-DI	A clinical index used to measure accumulated organ damage from either the disease process or its sequelae, in twelve organ systems. The index scores damage regardless of cause. The definition of damage is an irreversible change in an organ or system that has occurred since the onset of systemic lupus erythematosus and is present for at least six months.			Intellectual Product	NICHD Terminology|Pediatric Rheumatology Terminology
C121354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121354>	C217122	Juvenile Arthritis Disease Activity Score|JA-DAS|JADAS	A continuous measure of disease activity in juvenile arthritis related to inflammation. This validated measure has established cut points of minimal disease activity, inactive disease and remission.			Intellectual Product	NICHD Terminology|Pediatric Rheumatology Terminology
C121355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121355>	C217122|C21154	Bath Ankylosing Spondylitis Disease Activity Index|BASDAI|BASDAI	A clinical index used to assess the activity of ankylosing spondylitis that has been validated in adults.			Intellectual Product	NICHD Terminology|Pediatric Rheumatology Terminology
C121356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121356>	C21154	Myositis Disease Activity Assessment Tool|MDAAT|MDAAT	A tool that assesses disease activity of extramuscular organ systems and muscle to assess patients with adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis.			Intellectual Product	NICHD Terminology|Pediatric Rheumatology Terminology
C121357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121357>	C217122|C21154	Myositis Damage Index|MDI|MDI	A scoring system used to measure damage from myositis, complications of therapy, or other events.			Intellectual Product	NICHD Terminology|Pediatric Rheumatology Terminology
C121358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121358>	C21154	Myositis Activities Profile|MAP|MAP	An assessment of disease-specific limitations of activities of daily living in patients with polymyositis and dermatomyositis.			Intellectual Product	NICHD Terminology|Pediatric Rheumatology Terminology
C121359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121359>	C217122|C121362	Cutaneous Dermatomyositis Disease Area and Severity Index|CDASI|CDASI	An instrument that measures activity and damage in the skin of dermatomyositis patients.			Intellectual Product	NICHD Terminology|Pediatric Rheumatology Terminology
C12135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12135>	C61063	gp100 Antigen/Interleukin-12/MART-1 Antigen/Montanide ISA-51/Sargramostim/Tyrosinase Peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121360>	C21154	Manual Muscle Testing|MMT|MMT	A graded muscle strength measurement performed as part of a physical examination without the need for specialized equipment.			Intellectual Product	NICHD Terminology|Pediatric Rheumatology Terminology
C121361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121361>	C21154	Quantitative Muscle Testing|QMT|QMT	Measurement of maximum isometric force generation from a muscle group; performed with specialized equipment.			Intellectual Product	NICHD Terminology|Pediatric Rheumatology Terminology
C121362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121362>	C21154	Cutaneous Assessment Tool|CAT|CAT	An assessment of a wide range of cutaneous manifestations reflecting activity and damage from idiopathic inflammatory myopathy in children and adults.			Intellectual Product	NICHD Terminology|Pediatric Rheumatology Terminology
C121363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121363>	C217122|C121362	Dermatomyositis Skin Severity Index|DSSI|DSSI	An assessment of disease activity in the skin of patients with dermatomyositis.			Intellectual Product	NICHD Terminology|Pediatric Rheumatology Terminology
C121364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121364>	C217122|C21154	Valentini Scleroderma Disease Activity Index|Valentini SDAI|Valentini SDAI	A clinical index used to assess the activity of scleroderma that has been validated in adults.			Intellectual Product	NICHD Terminology|Pediatric Rheumatology Terminology
C121365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121365>	C217122|C21154	Juvenile Spondyloarthritis Disease Activity Index|JSpADA|JSpADA	A set of criteria used to determine the activity of juvenile spondyloarthritis related to inflammation.			Intellectual Product	NICHD Terminology|Pediatric Rheumatology Terminology
C121366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121366>	C121367	Intraarticular Corticosteroid Therapy|Intra-articular Corticosteroid|Intra-articular Corticosteroid Therapy|Intraarticular Corticosteroid	Treatment with a corticosteroid formulation designed for and administered into a joint space.			Therapeutic or Preventive Procedure	NICHD Terminology|Pediatric Rheumatology Terminology
C121367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121367>	C15986	Localized Corticosteroid Therapy|Localized Corticosteroid	Treatment with a corticosteroid formulation designed for delivery locally and specified by site of administration (intraarticular, topical, or inhaled).			Therapeutic or Preventive Procedure	NICHD Terminology|Pediatric Rheumatology Terminology
C121368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121368>	C15986	Stress Dose Steroid Therapy|Stress Dose Steroid	The administration of corticosteroids to an individual with either a long term history of corticosteroid use, or a history of or increased risk for adrenal insufficiency during times of increased physiological stress, including surgery or serious illness.			Therapeutic or Preventive Procedure	NICHD Terminology|Pediatric Rheumatology Terminology
C121369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121369>	C97927	PTEN Gene Mutation|MMAC1 Gene Mutation|Mutated in Multiple Advanced Cancers 1 Gene Mutation|PTEN Mutation|PTEN1 Gene Mutation|Phosphatase and Tensin Homolog Gene Mutation|TEP1 Gene Mutation|Yes	A molecular genetic abnormality indicating the presence of a mutation in the PTEN gene on chromosome 10q23.3.	PTEN Gene Mutation		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12136>	C61063	Bicalutamide/Exemestane			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121370>	C78209	Ability to Move Normally	The quality of being able to change positions within regular limits.			Functional Concept	Edmonton Symptom Assessment System-Sarcoma Modified
C121371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121371>	C107391	Edmonton Symptom Assessment System-Sarcoma Modified|ESAS-SM|Edmonton Symptom Assessment System-Sarcoma Modified (ESAS-SM)	A subset of the Edmonton symptom assessment system designed to measure the severity of symptoms in patients being treated for sarcoma.			Intellectual Product	
C121372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121372>	C28020	Biggest Problem	The largest difficulty, disorder, or condition needing resolution.			Phenomenon or Process	Edmonton Symptom Assessment System-Sarcoma Modified
C121373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121373>	C71686	Worse than Ever|Worse than ever	In the all-time most severe or unfavorable condition.			Qualitative Concept	Edmonton Symptom Assessment System-Sarcoma Modified
C121374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121374>	C2152	PI3Kdelta Inhibitor GS-9901|GS-9901|GS-9901	An orally bioavailable, small molecule inhibitor of the delta isoform of phosphoinositide-3 kinase (PI3Kdelta) with potential immunomodulating and antineoplastic activities. Upon oral administration, PI3Kdelta inhibitor GS-9901 selectively binds to the delta isoform of PI3K and inhibits its activity. This inhibits the activation of the PI3Kdelta-mediated signaling pathway and prevents proliferation of PI3Kdelta-overexpressing tumor cells. Unlike other isoforms of PI3K, PI3Kdelta is expressed primarily in certain tumor cell types and plays a key role in tumor cell proliferation, motility and survival. The targeted inhibition of PI3Kdelta is designed to preserve PI3K signaling in normal, non-neoplastic cells and thus reduces toxicity to normal, healthy cells.	PI3Kdelta Inhibitor GS-9901		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C121375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121375>	C1450	Imifoplatin|Cyclohexanediamine Pyrophosphatoplatinum(II), (1R,2R)-|IMIFOPLATIN|PT 112|PT-112|Phosphaplatin PT-112	A platinum (Pt)-based agent belonging to the phosphaplatin family comprised of Pt complexed to a pyrophosphate ligand, with potential antineoplastic activity. Although the exact mechanisms through which imifoplatin exerts its effect have yet to be fully elucidated, this agent, upon intravenous administration, binds to certain transmembrane proteins and activates several genes involved in tumor suppression and apoptosis. This leads to the activation of various signal transduction pathways, induces S/G2 phase cell cycle, and causes tumor cell apoptosis. In addition, imifoplatin may inhibit angiogenesis. Unlike conventional Pt-based chemotherapeutics, imifoplatin does not bind to DNA and is able to overcome drug resistance, which occurs with conventional Pt-based chemotherapeutics; it also has a more favorable side effect profile and is more stable in plasma.	Imifoplatin		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121376>	C96040	Vonlerolizumab|MOXR0916|Pogalizumab|RG 7888|RG-7888|RG7888|RO7021608|VONLEROLIZUMAB	An agonistic humanized monoclonal antibody against the receptor, OX40 (CD134), with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, vonlerolizumab selectively binds to and activates OX40, by mimicking the action of endogenous OX40 ligand (OX40L). OX40 activation induces proliferation of effector T-lymphocytes and inhibits the activity of regulatory T-cells. In the presence of tumor-associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T-cells.	Vonlerolizumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121377>	C49099	Susceptibility Weighted Imaging|BOLD Venographic Imaging|BOLD Venography|SUSCEPTIBILITY WEIGHTED MRI|SWI|SWI|SWI|SWI MRI|SWI-Phase	An imaging technique that uses phase differences between tissues due to differences in magnetic susceptibilities to produce an enhanced contrast magnitude image. These phase differences can provide excellent contrast between gray matter and white matter, iron-laden tissues, venous blood vessels, and other tissues with susceptibilities that are different from the background tissue. The technique is commonly used for imaging in cases of traumatic brain injuries and for high resolution brain venographies.	Susceptibility Weighted Imaging		Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF6 DIPG Imaging Assessment Signal Characteristics Table|CRF6 DMG Imaging Assessment Signal Characteristics Table|CTRP Intervention Terminology|CTRP Terminology
C121378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121378>	C17204	Dual-Energy Computed Tomography|DECT	An application of computed tomography that uses different x-ray spectra to acquire two image sets at the same anatomic location. This technique allows for the analysis of energy-dependent changes in the attenuation of different materials and facilitates the differentiation, characterization, isolation, and distinction of the imaged tissue and material.	Dual-Energy Computed Tomography		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C121379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121379>	C28681|C138180|C129826	Letetresgene Autoleucel|Autologous Anti-NY-ESO-1/LAGE-1 TCR-transduced c259 T Lymphocytes GSK3377794|Autologous T-Cells Expressing Enhanced TCRs Specific for NY-ESO-1/LAGE-1a GSK3377794|Genetically Engineered NY-ESO-1 Specific [c259] T Cells GSK3377794|Genetically Engineered NY-ESO-1/LAGE-1 Specific (c259) T Cells GSK3377794|LETETRESGENE AUTOLEUCEL|NY-ESO-1c259 T Cells GSK3377794	Human autologous T-lymphocytes transduced with a lentiviral vector encoding a T-cell receptor (TCR) specific for the cancer-testis antigens (CTAs) NY-ESO-1 and L antigen family member 1 (LAGE-1; Cancer/Testis Antigen 2; CTAG2; CT2), with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and reintroduction into the patient, letetresgene autoleucel specifically target and bind to NY-ESO-1/LAGE-1-overexpressing tumor cells. This may result in a cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1/LAGE-1-positive cancer cells. NY-ESO-1 and LAGE-1, members of the cancer-testis antigen (CTA) family, are overexpressed on the surface of various tumor cell types.	Letetresgene Autoleucel		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12137>	C61007	Goserelin/Raloxifene			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121380>	C217121	Musculoskeletal Tumor Society Rating Scale|Enneking Score|MSTS Rating Scale|MSTS93|Musculoskeletal Tumor Rating Scale, 1993	A physician-completed measure used to assess extremity function in patients undergoing surgery for musculoskeletal cancer. The scale scores for function and acceptance by 6 variables for upper extremities and 6 variables for lower extremities.			Intellectual Product	
C121381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121381>	C173346|C173159	Extremity Pain Question|Extremity Pain|Extremity Pain	A question about the pain in a person's extremity.			Intellectual Product	Musculoskeletal Tumor Society Rating Scale
C121382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121382>	C176021|C173159	Extremity Functional Activity Question|Extremity Functional Activity|Extremity Functional Activity	A question about the functional activity of a person's extremity.			Intellectual Product	Musculoskeletal Tumor Society Rating Scale
C121383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121383>	C173159	Extremity Emotional Acceptance Question|Extremity Emotional Acceptance|Extremity Emotional Acceptance	A question about a person's emotional acceptance of their extremity.			Intellectual Product	Musculoskeletal Tumor Society Rating Scale
C121384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121384>	C173159	Extremity Hand Positioning Question|Extremity Hand Positioning|Extremity Hand Positioning	A question about the range of movement of a person's upper extremity.			Intellectual Product	Musculoskeletal Tumor Society Rating Scale
C121385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121385>	C173159	Extremity Manual Dexterity Question|Extremity Manual Dexterity|Extremity Manual Dexterity	A question about a person's manual dexterity.			Intellectual Product	Musculoskeletal Tumor Society Rating Scale
C121386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121386>	C173159	Extremity Lifting Ability Question|Extremity Lifting Ability|Extremity Lifting Ability	A question about a person's ability to lift with their upper extremity.			Intellectual Product	Musculoskeletal Tumor Society Rating Scale
C121387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121387>	C173159	Extremity Supports Question|Extremity Supports|Extremity Supports	A question about the physical support that a person requires.			Intellectual Product	Musculoskeletal Tumor Society Rating Scale
C121388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121388>	C173159|C173135	Extremity Walking Ability Question|Extremity Walking Ability|Extremity Walking Ability	A question about a person's walking ability.			Intellectual Product	Musculoskeletal Tumor Society Rating Scale
C121389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121389>	C173159	Extremity Gait Question|Extremity Gait|Extremity Gait	A question about a person's walking gait.			Intellectual Product	Musculoskeletal Tumor Society Rating Scale
C12138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12138>	C61007	Dalteparin/Gemcitabine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121390>	C176247	No Extremity Pain|No Pain|None (no use of medication)	A response indicating that a person has no extremity pain and is using no medication.			Intellectual Product	Extremity Pain Question
C121391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121391>	C176247	Extremity Pain Between None and Modest|Between none and modest|None to Modest Pain	A response indicating that a person's extremity pain is at an intermediate level: between none and modest.			Intellectual Product	Extremity Pain Question
C121392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121392>	C176247	Modest Extremity Pain|Modest|Modest Pain	A response indicating that a person's extremity pain is modest: intermittent but not disabling and requiring intermittent use of anti-inflammatory or non-narcotic medication for pain relief.			Intellectual Product	Extremity Pain Question
C121393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121393>	C176247	Extremity Pain Between Modest and Moderate|Between modest and moderate|Modest to Moderate Pain	A response indicating that a person's extremity pain is at an intermediate level between modest and moderate.			Intellectual Product	Extremity Pain Question
C121394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121394>	C176247	Moderate Extremity Pain|Moderate|Moderate Pain	A response indicating that a person's extremity pain is at a moderate level: not continuous but disabling when present and requiring occasional or intermittent use of narcotic (or equivalent) medication.			Intellectual Product	Extremity Pain Question
C121395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121395>	C176247	Severe Extremity Pain|Severe|Severe Pain	A response indicating that a person's extremity pain is severe: continuous and disabling and requiring continuous use of narcotic (or equivalent) medication.			Intellectual Product	Extremity Pain Question
C121396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121396>	C226578	No Extremity Functional Restrictions|No Functional Restriction|No restrictions	A response indicating no restrictions for functional activity of the person's extremity.			Intellectual Product	Extremity Functional Activity Question
C121397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121397>	C226578	Some Extremity Functional Restrictions|Between no restrictions and recreational restrictions only	A response indicating that a person's functional extremity restrictions are at an intermediate level between no restrictions and recreational restrictions only.			Intellectual Product	Extremity Functional Activity Question
C121398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121398>	C226578	Recreational Extremity Functional Restrictions|Recreational Restriction|Recreational restrictions only	A response indicating that a person's functional extremity restrictions are only recreational: do not seriously affect the person's life-style or occupation.			Intellectual Product	Extremity Functional Activity Question
C121399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121399>	C226578	Increased Extremity Functional Restrictions|Between recreational restrictions only and partial disability	A response indicating that a person's functional extremity restrictions are at an intermediate level between recreational restrictions only and partial disability.			Intellectual Product	Extremity Functional Activity Question
C12139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12139>	C61063	Megestrol/Omega-3 Fatty acids			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1213>	C582|C1904	Rebeccamycin|5H-Indolo[2, 3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione, 1,11-dichloro-12, 13-dihydro-12-(4-O-methyl-.beta.-D-glucopyranosyl)-|5H-indolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7(6H)-dione,1,11-dichloro-12,13-dihydro-12-(4-O-methyl-beta-D-glucopyranosyl)|BRN 4732638|REBECCAMYCIN|rebeccamycin	An indolocarbazole glycoside antineoplastic antibiotic isolated from the bacterium Saccharothrix aerocolonigenes.  Rebeccamycin intercalates into DNA and stabilizes the DNA-topoisomerase I complex, thereby interfering with the topoisomerase I-catalyzed DNA breakage-reunion reaction and initiating DNA cleavage and apoptosis. (NCI04)			Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C121400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121400>	C226578	Extremity Functional Restrictions, Partial Disability|Partial disability	A response indicating that a person's functional extremity restrictions are at a level of partial disability: significantly affecting the person's life-style or producing partial occupational disability.			Intellectual Product	Extremity Functional Activity Question
C121401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121401>	C226578	Extremity Functional Restrictions, Total Disability|Total disability	A response indicating that a person's functional extremity restrictions are at a level of total disability: causing major alterations in life-style or preventing the person from resuming their occupation.			Intellectual Product	Extremity Functional Activity Question
C121402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121402>	C226607	Enthusiastic Acceptance of Extremity|Enthusiastic|Enthusiastic Acceptance	A response indicating that a person has enthusiastic emotional acceptance of their extremity.			Intellectual Product	Extremity Emotional Acceptance Question
C121403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121403>	C226607	Reduced Acceptance of Extremity|Between enthusiastic and satisfied|Reduced Acceptance	A response indicating that a person's emotional acceptance of their extremity is at an intermediate level between enthusiastic and satisfied.			Intellectual Product	Extremity Emotional Acceptance Question
C121404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121404>	C226607|C176250	Emotionally Satisfied with Extremity|Emotional Satisfaction with Extremity|Satisfied|Satisfied with Extremity	A response indicating that a person is emotionally satisfied with their extremity.			Intellectual Product	Extremity Emotional Acceptance Question
C121405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121405>	C226607|C176250	Moderate Satisfaction with Extremity|Between satisfied and accepts	A response indicating that a person's emotional acceptance of their extremity is at an intermediate level between satisfied and acceptable.			Intellectual Product	Extremity Emotional Acceptance Question
C121406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121406>	C226607	Accepting of Extremity|Accepts	A response indicating that a person finds their extremity to be emotionally acceptable.			Intellectual Product	Extremity Emotional Acceptance Question
C121407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121407>	C226607	Emotional Dislike of Extremity|Dislike of Extremity|Dislikes	A response indicating that a person emotionally dislikes their extremity.			Intellectual Product	Extremity Emotional Acceptance Question
C121408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121408>	C175275	Unlimited Hand Positioning|Unlimited	A response indicating that a person has unlimited range of motion for their upper extremity (180 degree elevation for hand positioning).			Intellectual Product	Extremity Hand Positioning Question
C121409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121409>	C175275	Reduced Hand Positioning|Between unlimited and not above shoulder	A response indicating that a person has a reduced range of motion of their upper extremity: able to lift their arm and hand to an intermediate level between unlimited and not above shoulder, with no pronation or supination of the hand.			Intellectual Product	Extremity Hand Positioning Question
C12140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12140>	C61063	Cyclosporine/Hydroxychloroquine/Prednisone			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121410>	C175275	Hand Positioning Not Above Shoulder|Not Above 90 Degrees|Not above shoulder	A response indicating that a person has a reduced range of motion of their upper extremity, unable to lift their arm and hand above the shoulder, with no pronation or supination of the hand.			Intellectual Product	Extremity Hand Positioning Question
C121411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121411>	C175275	Limited Hand Positioning|Between not above shoulder; and not above waist	A response indicating that a person has a limited range of motion of their upper extremity: only able to lift their hand to a level intermediate between their shoulder and their waist, with no pronation or supination of the hand.			Intellectual Product	Extremity Hand Positioning Question
C121412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121412>	C175275	Greatly Limited Hand Positioning|Not Above 30 Degrees|Not above waist	A response indicating that a person has a greatly reduced range of motion of their upper extremity, unable to lift their arm and hand above the waist, 30 degree elevation.			Intellectual Product	Extremity Hand Positioning Question
C121413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121413>	C226578|C226573	No Hand Mobility|0 Degree Elevation|None	A response indicating that a person has no ability to lift their arm and hand.			Intellectual Product	Extremity Hand Positioning Question
C121414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121414>	C175275	Unlimited Manual Dexterity|Manual Dexterity Unlimited|Unlimited	A response indicating that a person has normal manual dexterity and sensitivity.			Intellectual Product	Extremity Manual Dexterity Question
C121415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121415>	C175275	Reduced Manual Dexterity|Between unlimited and loss of fine movements	A response indicating that a person's manual dexterity is at a level between unlimited and loss of fine movements.			Intellectual Product	Extremity Manual Dexterity Question
C121416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121416>	C226578	Loss of Fine Movements|Loss of fine movements	A response indicating that a person has lost their ability for fine movement: cannot button, write, eat, etc., or minor loss of sensitivity.			Intellectual Product	Extremity Manual Dexterity Question
C121417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121417>	C175275	Limited Manual Dexterity|Between loss of fine movement and cannot pinch	A response indicating that a person's manual dexterity is at a level between loss of fine movements and cannot pinch.			Intellectual Product	Extremity Manual Dexterity Question
C121418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121418>	C175275|C121744	Cannot Pinch|Cannot pinch; major sensory loss	A response indicating that a person cannot pinch and has major sensory loss.			Intellectual Product	Extremity Manual Dexterity Question
C121419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121419>	C175275|C121744	Cannot Grasp|Cannot grasp; anesthetic hand	A response indicating that a person cannot grasp and has complete sensory loss.			Intellectual Product	Extremity Manual Dexterity Question
C12141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12141>	C61063	Hydroxychloroquine/Prednisone/Tacrolimus			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121420>	C226580	Normal Lifting Ability|Normal load	A response indicating that a person can lift a normal load, the same as for their unaffected limb.			Intellectual Product	Extremity Lifting Ability Question
C121421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121421>	C226580	Reduced Lifting Ability|Between normal load and intermediate	A response indicating that a person's lifting ability is at a level between normal and limited.			Intellectual Product	Extremity Lifting Ability Question
C121422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121422>	C226614|C226580	Limited Lifting Ability|Limited|Minor Load Only	A response indicating that a person can only lift a minor load.			Intellectual Product	Extremity Lifting Ability Question
C121423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121423>	C226614|C226580	Greatly Limited Lifting Ability|Between limited and helping only	A response indicating that a person's lifting ability is at a level between limited and helping only.			Intellectual Product	Extremity Lifting Ability Question
C121424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121424>	C226580	Helping Only Lifting Ability|Cannot Overcome Gravity|Helping Only	A response indicating that a person cannot overcome gravity and is only able to assist the contralateral extremity.			Intellectual Product	Extremity Lifting Ability Question
C121425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121425>	C226580	No Lifting Ability|Cannot Move|Cannot help	A response indicating that a person has no lifting ability and cannot move their upper extremity.			Intellectual Product	Extremity Lifting Ability Question
C121426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121426>	C226725	No Support Needed|No Support|None	A response indicating that a person requires no physical support.			Intellectual Product	Extremity Supports Question
C121427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121427>	C226725	Occasional Support Needed|Between none and brace used most of the time	A response indicating that a person requires a level of support between none and occasional use of a brace.			Intellectual Product	Extremity Supports Question
C121428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121428>	C226701	Brace Support Needed|Brace used most of the time	A response indicating that a person requires use of a brace most of the time.			Intellectual Product	Extremity Supports Question
C121429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121429>	C186835|C168530	t(11;16)(p11;p11)	A cytogenetic abnormality that refers to the translocation of the short arm (p11) of chromosome 11 and the short arm (p11) of chromosome 16. It results in a FUS-CREB3L1 fusion.			Cell or Molecular Dysfunction	
C12142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12142>	C61063	Bleomycin/Prednisolone/Rituximab/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121430>	C226725	Support Needed Most of Time|Between brace used most of the time and one cane or crutch used most of the time	A response indicating that a person requires a level of support between occasional use of a brace and need for one cane or crutch most of the time.			Intellectual Product	Extremity Supports Question
C121431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121431>	C226701	Cane or Crutch Needed Most of Time|One cane or crutch used most of the time	A response indicating that a person requires use of one cane or crutch most of the time.			Intellectual Product	Extremity Supports Question
C121432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121432>	C226725	Support Always Needed|Two canes or crutches used	A response indicating that a person always requires use of two canes or crutches.			Intellectual Product	Extremity Supports Question
C121433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121433>	C226614|C226575	Unlimited Walking Ability|Unlimited	A response indicating that a person has an unlimited walking ability, the same as their preoperative ability.			Intellectual Product	Extremity Walking Ability Question
C121434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121434>	C226614|C226575	Reduced Walking Ability|Between unlimited and limited	A response indicating that a person's walking ability is between unlimited and limited.			Intellectual Product	Extremity Walking Ability Question
C121435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121435>	C226614|C226575	Limited Walking Ability|Limited	A response indicating that a person's walking ability is limited, significantly less postoperatively.	Limited Walking Ability		Intellectual Product	CTRP Disease Terminology|CTRP Terminology|Extremity Walking Ability Question
C121436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121436>	C226614|C226575	Greatly Limited Walking Ability|Between limited and inside only	A response indicating that a person's walking ability is between limited and inside only.			Intellectual Product	Extremity Walking Ability Question
C121437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121437>	C226575	Inside Only Walking Ability|Inside only	A response indicating that a person's walking ability is limited to inside the home only.			Intellectual Product	Extremity Walking Ability Question
C121438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121438>	C226575	No Independent Walking Ability|Not independent	A response indicating that a person can only walk with assistance or that they are wheelchair-bound.			Intellectual Product	Extremity Walking Ability Question
C121439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121439>	C226672	Normal Gait|Normal	A response indicating that a person's walking is normal postoperatively, with no alteration to gait.			Intellectual Product	Extremity Gait Question
C12143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12143>	C61007	Autologous Lymphocytes/gp100 Antigen/Interleukin-2/Montanide ISA-51			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121440>	C226672	Gait Between Normal and Minor Cosmetic Change|Between normal and minor cosmetic	A response indicating that a person's gait is between normal and having a minor cosmetic alteration.			Intellectual Product	Extremity Gait Question
C121441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121441>	C226672	Minor Cosmetic Gait Change|Minor cosmetic	A response indicating that a person's gait has a minor cosmetic alteration.			Intellectual Product	Extremity Gait Question
C121442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121442>	C226672	Gait Between Minor and Major Cosmetic Change|Between minor cosmetic and major cosmetic	A response indicating that a person's gait is between minor cosmetic alteration and major cosmetic alteration.			Intellectual Product	Extremity Gait Question
C121443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121443>	C226672	Major Cosmetic Gait Change|Major cosmetic	A response indicating that a person's gait has a major cosmetic alteration with a minor functional deficit.			Intellectual Product	Extremity Gait Question
C121444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121444>	C226672	Major Handicap Gait Change|Major Gait Handicap|Major Handicap	A response indicating that a person's gait creates a major handicap with a major functional deficit.			Intellectual Product	Extremity Gait Question
C121445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121445>	C28676|C201545	Allogeneic CD3- CD19- Selected Natural Killer Cells|Allogeneic CD3-/CD19- NK Cell Product|Allogeneic CD3-/CD19- NK Cells|Allogeneic CD3-/CD19- Natural Killer Cells|CD3/CD19-depleted Donor NK Cells	Human leukocyte antigen (HLA)-haploidentical donor-derived natural killer (NK) cells that are activated with the cytokine interleukin-15 (IL-15), with immunomodulating and antineoplastic activities. Upon leukapheresis, the HLA-haploidentical donor peripheral blood mononuclear cells (PBMCs) are treated to remove T-lymphocytes (CD3+) and B-lymphocytes (CD19+) cells. In turn, NK cells are expanded and activated with IL-15. Upon infusion of the allogeneic CD3- CD19- selected NK cells, these cells recognize and bind to tumor cells, and secrete perforins, granzymes, and cytokines, which results in cancer cell lysis.	Allogeneic CD3- CD19- Selected Natural Killer Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121446>	C48276	Clavien-Dindo Classification|Clavien-Dindo Classification of Surgical Complications|Clavien-Dindo Scale	A classification of adverse events that grades complications according to the treatment that is induced to treat the complication. The classification is designed to eliminate subjective interpretation of serious adverse events and tendency to down-rate complications, being based on data that is usually well documented and easy to verify. It is also well suited for retrospective analyses.			Classification	
C121447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121447>	C121446	Clavien-Dindo Grade I|Grade I	Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic, and radiological interventions.			Classification	
C121448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121448>	C121446	Clavien-Dindo Grade II|Grade II	A complication requiring pharmacological treatment with drug other than such allowed for Grade I complications.			Classification	
C121449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121449>	C121446	Clavien-Dindo Grade III|Grade III	A complication requiring surgical, endoscopic, or radiological intervention.			Classification	
C12144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12144>	C61063	Detoxpc/Interleukin-2/RAS Peptide Cancer Vaccine/Sargramostim			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121450>	C121449	Clavien-Dindo Grade IIIa|Grade IIIa	A complication requiring intervention not under general anesthesia.			Classification	
C121451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121451>	C121449	Clavien-Dindo Grade IIIb|Grade IIIb	A complication requiring intervention under general anesthesia.			Classification	
C121452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121452>	C121446	Clavien-Dindo Grade IV|Grade IV	A life-threatening complication.			Classification	
C121453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121453>	C121452	Clavien-Dindo Grade IVa|Grade IVa	Single organ dysfunction.			Classification	
C121454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121454>	C121452	Clavien-Dindo Grade IVb|Grade IVb	Multiorgan dysfunction.			Classification	
C121455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121455>	C121446	Clavien-Dindo Grade V|Grade V	Death of a patient.			Classification	
C121456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121456>	C200258	Atuveciclib|1,3,5-Triazin-2-amine, 4-(4-Fluoro-2-methoxyphenyl)-N-(3-((S-methylsulfonimidoyl)methyl)phenyl)-, (+)-|ATUVECICLIB|BAY 1143572|BAY1143572	An inhibitor of positive transcription elongation factor b (P-TEFb), which is composed of cyclin-dependent kinase 9 (CDK9) and cyclin-T (CycT), with potential antineoplastic activity. Upon administration, atuveciclib binds to and inhibits the activity of P-TEFb, thereby preventing the phosphorylation of its downstream target, the carboxyl terminal domain (CTD) of RNA polymerase II (RNA Pol II), and inhibiting the activation of transcriptional elongation by RNA Pol II. This prevents the transcription of tumor promoting genes, induces tumor cell apoptosis, and inhibits tumor cell proliferation. P-TEFb plays an important role in the regulation of gene transcription; over-activation in cancer cells leads to both the transcription of key tumor-promoting genes and cancer cell proliferation.	Atuveciclib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121457>	C168618	IDH1(R132) Inhibitor IDH305|IDH305	An inhibitor of the citric acid cycle enzyme isocitrate dehydrogenase [NADP] cytoplasmic (isocitrate dehydrogenase 1; IDH1) with mutations at residue R132 (IDH1(R132)), with potential antineoplastic activity. Upon administration, IDH305 specifically inhibits IDH1(R132) mutant forms in the cytoplasm, which inhibits the formation of the oncometabolite 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1(R132)-expressing tumor cells. IDH1(R132) mutations are highly expressed in certain malignancies, including gliomas; they initiate and drive cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.	IDH1(R132) Inhibitor IDH305		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121458>	C121459	Behavior Rating Inventory of Executive Function, Preschool Version|BRIEF-P|Behavior Rating Inventory of Executive Function-Preschool Version (BRIEF-P)	A standardized rating scale designed to specifically measure executive function in children aged 2 to 5 years. Parents, teachers, or other caregivers rate a child's executive functions within the context of the child's home or preschool environments.			Intellectual Product	
C121459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121459>	C20993	Behavior Rating Inventory of Executive Function|BRIEF|Behavior Rating Inventory of Executive Function (BRIEF)	A standardized rating scale designed to assess the executive function behaviors in the school and home environments for children and adolescents as observed by a parent or teacher.			Intellectual Product	
C12145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12145>	C61007	Asparaginase/Leucovorin Calcium/Methotrexate			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121460>	C121459	Behavior Rating Inventory of Executive Function, Adult Version	A standardized measure that assesses the executive functions of adults aged 18-90 years in their everyday environment. Both a self-report and an informant report are used.			Intellectual Product	
C121461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121461>	C91105	BRIEF Parent Form Questionnaire|Parent Form|Parent Form Questionnaire	A questionnaire included in the Behavior Rating Inventory of Executive Function. The parent form is completed by one or both parents who must have recent and extensive contact with the child over the past 6 months.			Intellectual Product	Behavior Rating Inventory of Executive Function
C121462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121462>	C91105	BRIEF Teacher Form Questionnaire|Teacher Form|Teacher Form Questionnaire	A questionnaire included in the Behavior Rating Inventory of Executive Function. The teacher form is completed by any adult with extended contact with the child in an academic setting, typically a teacher, but an aide is acceptable. The adult must have at least 1 month familiarity with the child.			Intellectual Product	Behavior Rating Inventory of Executive Function
C121463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121463>	C217121	Inhibit Scale	A rating scale included in the Behavior Rating Inventory of Executive Function that measures the ability of an individual to control impulses (inhibitory control) and to stop engaging in a behavior at the appropriate time.			Intellectual Product	Behavior Rating Inventory of Executive Function, Adult Version|Behavior Rating Inventory of Executive Function, Preschool Version|Behavior Rating Inventory of Executive Function
C121464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121464>	C217121	Shift Scale	A rating scale included in the Behavior Rating Inventory of Executive Function that measures the ability of an individual to move freely from one activity or situation to another, to tolerate change, to be flexible when solving problems, and to switch or alternate attention.			Intellectual Product	Behavior Rating Inventory of Executive Function, Adult Version|Behavior Rating Inventory of Executive Function, Preschool Version|Behavior Rating Inventory of Executive Function
C121465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121465>	C217121	Emotional Control Scale	A rating scale included in the Behavior Rating Inventory of Executive Function that measures the ability of an individual to regulate emotional responses appropriately.			Intellectual Product	Behavior Rating Inventory of Executive Function, Adult Version|Behavior Rating Inventory of Executive Function, Preschool Version|Behavior Rating Inventory of Executive Function
C121466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121466>	C217121	Self Monitor Scale|Self-Monitor Scale	A rating scale included in the Behavior Rating Inventory of Executive Function (BRIEF) that assesses aspects of social or interpersonal awareness. It captures the degree to which a person is aware of the effect that their behavior has on others and how it compares with standards or expectations for behavior.			Intellectual Product	Behavior Rating Inventory of Executive Function, Adult Version|Behavior Rating Inventory of Executive Function
C121467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121467>	C217121	Initiate Scale	A rating scale included in the Behavior Rating Inventory of Executive Function that reflects an individual's ability to begin a task or activity and to independently generate ideas, responses, or problem-solving strategies.			Intellectual Product	Behavior Rating Inventory of Executive Function, Adult Version|Behavior Rating Inventory of Executive Function
C121468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121468>	C217121	Working Memory Scale	A rating scale included in the Behavior Rating Inventory of Executive Function that measures the ability of an individual to hold information when completing a task, encoding information, or generating goals and plans in a sequential manner.			Intellectual Product	Behavior Rating Inventory of Executive Function, Adult Version|Behavior Rating Inventory of Executive Function, Preschool Version|Behavior Rating Inventory of Executive Function
C121469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121469>	C217121	Plan/Organize Scale	A rating scale included in the Behavior Rating Inventory of Executive Function that measures the ability of an individual to manage current and future-oriented task demands within the situational context. The plan component relates to the ability to anticipate future events, implement instructions or goals, and develop appropriate steps ahead of time in order to carry out a task or activity. The organize component refers to the ability to bring order to information, actions, or materials to achieve a goal or to follow an established organized routine.			Intellectual Product	Behavior Rating Inventory of Executive Function, Adult Version|Behavior Rating Inventory of Executive Function, Preschool Version|Behavior Rating Inventory of Executive Function
C12146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12146>	C61063	Cytarabine/Etoposide/Rituximab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121470>	C217121	Task Monitor Scale|Task-Monitor Scale	A rating scale included in the Behavior Rating Inventory of Executive Function (BRIEF) that reflects the ability to keep track of one's problem-solving success or failure, and to identify and correct mistakes during performance of a goal.			Intellectual Product	Behavior Rating Inventory of Executive Function, Adult Version|Behavior Rating Inventory of Executive Function
C121471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121471>	C217121	Organization of Materials Scale	A rating scale included in the Behavior Rating Inventory of Executive Function that measures orderliness of living, work, play, and storage spaces (e.g., rooms, desks, lockers, backpacks, and bedrooms).			Intellectual Product	Behavior Rating Inventory of Executive Function, Adult Version|Behavior Rating Inventory of Executive Function
C121472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121472>	C217121	Monitor Scale	A rating scale included in the Behavior Rating Inventory of Executive Function that assesses work-checking habits and interpersonal awareness. The task monitoring portion of the scale captures whether a child assesses his or her own performance during or shortly after finishing a task to ensure accuracy or appropriate attainment of a goal. The self-monitoring portion of the scale evaluates whether a child keeps track of the effect that his or her behavior has on others.			Intellectual Product	Behavior Rating Inventory of Executive Function
C121473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121473>	C20993	VeriStrat	A prognostic scoring system designed to predict non-small-cell lung cancer patients who will benefit from treatment with EGFR inhibitor therapy. A serum or plasma sample is obtained from a patient and is subjected to matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry. An algorithm is applied to the absorption peaks obtained and translated into a score of good or poor.	VeriStrat		Intellectual Product	CTRP Biomarker Terminology|CTRP Terminology
C121474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121474>	C217122	Global Executive Composite|GEC|Global Executive Composite (GEC)	An overall index of the Behavior Rating Inventory of Executive Function which takes into account all of the clinical scales and represents the individual's overall executive function.			Intellectual Product	Behavior Rating Inventory of Executive Function, Adult Version|Behavior Rating Inventory of Executive Function, Preschool Version|Behavior Rating Inventory of Executive Function
C121475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121475>	C68742	Granulocyte-Macrophage Colony Forming Unit|CFU-GM|Colony Forming Unit-Granulocyte-Macrophage|GM-CFU	A unit of viable cell concentration defined as the minimum number of hematopoietic stem cells able to produce a detectable colony of granulocyte-macrophage lineage cells.	Granulocyte-Macrophage Colony Forming Unit		Quantitative Concept	CTRP Biomarker Terminology|CTRP Terminology
C121476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121476>	C217122	Inhibitory Self-Control Index|Inhibitory Self-Control Index (ISCI)	An index of the Behavior Rating Inventory of Executive Function, Preschool Version that combines the Inhibit and Emotional Control scales.			Intellectual Product	Behavior Rating Inventory of Executive Function, Preschool Version
C121478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121478>	C68742	Megakaryocyte Colony Forming Unit|CFU-Meg|CFU-Mega|Colony Forming Unit-Megakaryocyte	A unit of viable cell concentration defined as the minimum number of hematopoietic stem cells able to produce a detectable colony of megakaryocyte lineage cells.	Megakaryocyte Colony Forming Unit		Quantitative Concept	CTRP Biomarker Terminology|CTRP Terminology
C121479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121479>	C217122	Flexibility Index|FI|Flexibility Index (FI)	An index of the Behavior Rating Inventory of Executive Function, Preschool Version that combines the Shift and Emotional Control scales.			Intellectual Product	Behavior Rating Inventory of Executive Function, Preschool Version
C12147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12147>	C61063	Epoetin Alfa/Filgrastim/Flt3 Ligand/Interleukin-3/Sargramostim			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121480>	C68742	Erythroid Burst Forming Unit|BFU-E|Burst Forming Unit-Erythroid|Burst-Forming Unit, Erythroid	A unit of viable cell concentration defined as the minimum number of hematopoietic stem cells able to produce a detectable colony of erythroid burst forming cells.	Erythroid Burst Forming Unit		Quantitative Concept	CTRP Biomarker Terminology|CTRP Terminology
C121481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121481>	C217122	Emergent Metacognition Index|EMI|Emergent Metacognition Index (EMI)	An index of the Behavior Rating Inventory of Executive Function, Preschool Version that combines the Working Memory and Plan/Organize scales.			Intellectual Product	Behavior Rating Inventory of Executive Function, Preschool Version
C121482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121482>	C217122	Behavior Regulation Index|Behavior Regulation Index (BRI)	An index of the Behavior Rating Inventory of Executive Function that captures the individual's ability to shift cognitive set and modulate emotions and behavior via appropriate inhibitory control. It combines the Inhibit, Shift, and Emotional Control scales.			Intellectual Product	Behavior Rating Inventory of Executive Function, Adult Version|Behavior Rating Inventory of Executive Function
C121483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121483>	C217122	Metacognition Index|Metacognition Index (MI)	An index of the Behavior Rating Inventory of Executive Function that reflects the individual's ability to initiate, plan, organize, self-monitor, and sustain working memory. It combines the Initiate, Working Memory, Plan/Organize, Organization of Materials, and Monitor scales.			Intellectual Product	Behavior Rating Inventory of Executive Function, Adult Version|Behavior Rating Inventory of Executive Function
C121484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121484>	C68539	Ellagitannin	A class of polyphenols that are formed by the oxidative linkage of galloyl groups to the pentahydroxy gallic acid ester of glucose where the galloyl groups are linked through C-C bonds. Ellagitannins have diverse effects including anti-oxidant, anti-proliferative, anti-viral, and anti-microbial activities.	Ellagitannin		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C121485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121485>	C2294	Estrone Conjugate|E1C|E1c	A metabolite formed during the catabolism of estrone. The levels of estrone metabolites may be used to indirectly measure estrone plasma levels and to assess female reproductive function.	Estrone Conjugate		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C121486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121486>	C2296	Pregnanediol-3alpha-Glucuronide|(3alpha,5beta,20S)-20-Hydroxypregnan-3-Yl Beta-D-Glucopyranosiduronic Acid|20alpha-Hydroxy-5beta-Pregnan-3alpha-Yl-Beta-D-Glucopyranosiduronic Acid|5beta-Pregnane-3alpha,20alpha-Diol-3alpha-Glucuronide|Beta-D-Glucopyranosiduronic Acid, (3alpha,5beta,20S)-20-Hydroxypregnan-3-Yl|PDG|PdG|Pregnanediol Glucuronide|Pregnanediol-3-Glucuronide	A metabolite formed during the catabolism of progesterone. The urinary levels of this progesterone metabolite may be used to indirectly measure progesterone levels and to assess female reproductive function.	Pregnanediol-3alpha-Glucuronide		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C121487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121487>	C173787	Perform Daily Activities Post Limb Therapeutic Procedure Recovery Question|Perform Daily Activities Post Limb Therapeutic Procedure Recovery|Perform Daily Activities Post Limb Therapeutic Procedure Recovery	A question about a person's expected ability to perform daily activities after recovering from treatment for their arm or leg.			Intellectual Product	
C121488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121488>	C26003	GZMA Gene|GZMA|GZMA|Granzyme A (Granzyme 1, Cytotoxic T-Lymphocyte-Associated Serine Esterase 3) Gene	This gene plays a role in natural killer and T-cell activated cytolysis.	GZMA Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C121489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121489>	C121488	GZMA wt Allele|CTLA3|Granzyme A (Cytotoxic T-Lymphocyte-Associated Serine Esterase-3; Hanukah Factor Serine Protease) Gene|Granzyme A (Granzyme 1, Cytotoxic T-Lymphocyte-Associated Serine Esterase 3) wt Allele|HFSP	Human GZMA wild-type allele is located within 5q11-q12 and is approximately 8 kb in length. This allele, which encodes granzyme A protein, is involved in cell-mediated cytolysis.	GZMA wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12148>	C61063	Bleomycin/Cyclophosphamide/Idarubicin/Leucovorin calcium/methotrexate/methylprednisolone/vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121490>	C17123	Granzyme A|CTL Tryptase|Cytolytic T Cell- and Natural Killer Cell-Specific Trypsin-Like Serine Protease|Cytotoxic T-Lymphocyte Proteinase 1|Cytotoxic T-Lymphocyte-Associated Serine Esterase 3|EC 3.4.21.78|Fragmentin-1|GZMA|Granzyme 1|Granzyme-1|H Factor|HF|Hanukah Factor Serine Protease|Hanukkah Factor	Granzyme A (262 aa, ~29 kDa) is encoded by the human GZMA gene. This protein plays a role in both proteolysis and apoptosis.	Granzyme A		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C121491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121491>	C26147	B3GAT2 Gene|B3GAT2|B3GAT2|Beta-1,3-Glucuronyltransferase 2 Gene	This gene is involved in the biosynthesis of glycolipids and glycoproteins.	B3GAT2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C121492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121492>	C121491	B3GAT2 wt Allele|Beta-1,3-Glucuronyltransferase 2 wt Allele|GLCATS|KIAA1963	Human B3GAT2 wild-type allele is located in the vicinity of 6q12 and is approximately 100 kb in length. This allele, which encodes galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 2 protein, plays a role in carbohydrate modification of lipids and proteins.	B3GAT2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C121493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121493>	C17434	Galactosylgalactosylxylosylprotein 3-Beta-Glucuronosyltransferase 2|B3GAT2|Beta-1,3-Glucuronyltransferase 2|EC 2.4.1.135|GlcAT-D|GlcAT-S|Glucuronosyltransferase S|UDP-Glucuronosyltransferase S|UDP-Glucuronyltransferase S|Uridine Diphosphate Glucuronic Acid:Acceptor Glucuronosyltransferase	Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 2 (323 aa, ~37 kDa) is encoded by the human B3GAT2 gene. This protein is involved in glycolipid and glycoprotein synthesis.	Galactosylgalactosylxylosylprotein 3-Beta-Glucuronosyltransferase 2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C121494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121494>	C54362	ZNF793 Gene|ZNF793|ZNF793|Zinc Finger Protein 793 Gene	This gene may play a role in the modulation of transcription.	ZNF793 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C121495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121495>	C121494	ZNF793 wt Allele|Zinc Finger Protein 793 wt Allele	Human ZNF793 wild-type allele is located in the vicinity of 19q13.12 and is approximately 42 kb in length. This allele, which encodes zinc finger protein 793, may be involved in the regulation of transcription.	ZNF793 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C121496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121496>	C26199	Zinc Finger Protein 793|ZNF793	Zinc finger protein 793 (406 aa, ~47 kDa) is encoded by the human ZNF793 gene. This protein may play a role in transcriptional regulation.	Zinc Finger Protein 793		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C121497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121497>	C28533	SLC5A8 Gene|SLC5A8|SLC5A8|Solute Carrier Family 5 (Sodium/Monocarboxylate Cotransporter), Member 8 Gene	This gene is involved in the transport of sodium cations, chloride anions, iodide and monocarboxylates.	SLC5A8 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C121498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121498>	C121497	SLC5A8 wt Allele|AIT|SMCT|SMCT1|Solute Carrier Family 5 (Iodide Transporter), Member 8 Gene|Solute Carrier Family 5 (Sodium/Monocarboxylate Cotransporter), Member 8 wt Allele	Human SLC5A8 wild-type allele is located in the vicinity of 12q23.1 and is approximately 55 kb in length. This allele, which encodes sodium-coupled monocarboxylate transporter 1 protein, plays a role in iodide transport and the sodium ion-dependent transport of monocarboxylates.	SLC5A8 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C121499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121499>	C16386	Sodium-Coupled Monocarboxylate Transporter 1|Apical Iodide Transporter|Electrogenic Sodium Monocarboxylate Cotransporter|SLC5A8|Sodium Iodide-Related Cotransporter|Sodium-Coupled Monocarboxylate Transporter|Solute Carrier Family 5 Member 8	Sodium-coupled monocarboxylate transporter 1 (610 aa, ~67 kDa) is encoded by the human SLC5A8 gene. This protein is involved in the transport of ions and monocarboxylates.	Sodium-Coupled Monocarboxylate Transporter 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12149>	C61007	Allogeneic lymphocytes/Interleukin-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1214>	C2198	Resiniferatoxin|RESINIFERATOXIN|RTX	A naturally occurring capsaicin analog found in the latex of the cactus Euphorbia resinifera with analgesic activity. Resiniferatoxin (RTX) binds to and activates the transient receptor potential vanilloid 1 (TRPV1), a non-selective cation channel in the plasma membrane of primary afferent sensory neurons. This increases the permeability to cations, and leads to an influx of calcium and sodium ions. This results in membrane depolarization, causing an irritant effect, followed by desensitization of the sensory neurons thereby inhibiting signal conduction in afferent pain pathways and causing analgesia. TRPV1, a member of the transient receptor potential channel (TRP) superfamily, is a heat- and chemo-sensitive calcium/sodium ion channel that is selectively expressed in a subpopulation of pain-sensing primary afferent neurons.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C121500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121500>	C9305|C8402	Malignant Fibrohistiocytic Neoplasm	A fibrohistiocytic neoplasm that metastasizes to other anatomic sites.			Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology
C121501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121501>	C28624	CTLA-4 Ligand|CTLA4 Ligand|Cytotoxic T-Lymphocyte-Associated Protein 4 Ligand	Proteins that bind to cytotoxic T-lymphocyte protein 4, which is expressed on T-cells, and stimulate signaling that may play a role in the inhibition of T-cell activation. This group of proteins includes the T-lymphocyte activation antigens CD80 and CD86, which are expressed on antigen-presenting cells.	CTLA-4 Ligand		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C121502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121502>	C16295	LGALS3 Antibody|Anti-Galectin-3 Antibody|Anti-LGALS3 Antibody|Galectin-3 Antibody	Any immunoglobulin that recognizes galectin-3.	LGALS3 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C121503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121503>	C16295	Alpha-Gal Antibody|Alpha Gal Antibody|Anti-Alpha Gal|Anti-Alpha Gal Antibody|Anti-Alpha-Gal|Anti-Alpha-Gal Antibody|Anti-Galactose-Alpha-1,3-Galactose|Anti-Galactose-Alpha-1,3-Galactose Antibody|Galactose-Alpha-1,3-Galactose Antibody	Any immunoglobulin that recognizes the disaccharide epitope galactose-alpha-1,3-galactose (alpha-gal).	Alpha-Gal Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C121504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121504>	C16295	PA2024 Antibody|Anti-PA2024|Anti-PA2024 Antibody|Anti-PAP/GM-CSF|Anti-PAP/GM-CSF Antibody|Anti-PAP/GM-CSF Fusion Protein Antibody|Anti-Prostatic Acid Phosphatase-Granulocyte-Macrophage Colony-Stimulating Factor Fusion Protein Antibody|Anti-Prostatic Acid Phosphatase-Sargramostim Fusion Protein|PAP/GM-CSF Fusion Protein Antibody|Prostatic Acid Phosphatase-Granulocyte-Macrophage Colony-Stimulating Factor Fusion Protein Antibody|Prostatic Acid Phosphatase-Sargramostim Fusion Protein Antibody	Any immunoglobulin that recognizes PA2024, which is a fusion protein comprised of prostatic acid phosphatase fused to granulocyte-macrophage stimulating factor.	PA2024 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C121505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121505>	C17297	Fibroblast Growth Factor Receptor Family Isoform IIIb|FGFR IIIb|FGFR-IIIb|Fgfr(IIIb)	An isoform of fibroblast growth factor receptor-1, -2, or -3, where alternative splicing leads to the expression of the IIIb exon encoding the second half of the third immunoglobulin-like domain, which is located in the extracellular domain of these receptors. This variant is expressed in epithelial lineage cells and has differential ligand binding activity when compared to the IIIa and IIIc forms.	Fibroblast Growth Factor Receptor Family Isoform IIIb		Amino Acid, Peptide, or Protein|Enzyme|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C121506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121506>	C17297	Fibroblast Growth Factor Receptor Family Isoform IIIc|FGFR IIIc|FGFR-IIIc|Fgfr(IIIc)	An isoform of fibroblast growth factor receptor-1, -2, or -3, where alternative splicing leads the expression of the IIIc exon encoding the second half of the third immunoglobulin-like domain, which is located in the extracellular domain of these receptors. This variant is expressed in mesenchymal lineage cells and has differential ligand binding activity when compared to the IIIa and IIIb forms.	Fibroblast Growth Factor Receptor Family Isoform IIIc		Amino Acid, Peptide, or Protein|Enzyme|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C121507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121507>	C104593	Linear Analogue Self-Assessment-6|LASA-6|Linear Analogue Self-Assessment-6 (LASA-6)	A six-item, self-reported questionnaire designed to measure general well-being and the major domains of quality of life (mental, physical, emotional, social, and spiritual well-being) using a linear analogue scale to describe the assessment responses.			Intellectual Product	
C121508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121508>	C217121	LASA-6 Feeling Intensity Scale	A scale for the subjective scoring of the intensity of a person's feelings that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.			Intellectual Product	Linear Analogue Self-Assessment
C121509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121509>	C308	East Indian Sandalwood Oil Mouth Rinse|0.25% EISO Mouth Rinse|EISO Mouth Rinse	A mouth rinse containing 0.25% East Indian sandalwood oil, which is derived from the heartwood of Santalum album, a tree native to southern Asia, with potential anti-inflammatory, anti-infective and anti-mucositis activities. East Indian sandalwood oil (EISO) is primarily comprised of the sesquiterpene alcohols alpha- and beta-santalol. Although the exact mechanisms of action through which EISO exerts its effects have yet to be fully elucidated, upon rinsing the oral cavity with the EISO mouth rinse, the active ingredients in the oil may inhibit the production of pro-inflammatory cytokines and chemokines, most likely through the inhibition of the activity of key inflammatory enzymes, including the cyclooxygenases. This prevents inflammation of the mucosal membranes and may prevent or decrease chemotherapy- and/or radiation-induced oral mucositis.	East Indian Sandalwood Oil Mouth Rinse		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C12150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12150>	C61007	Fowlpox Virus Vaccine/gp100 Antigen/Interleukin-2|fowlpox virus vaccine vector/gp100 antigen/interleukin-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121510>	C175265	Feeling Intensity Score 0	A subjective score of 0 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.			Intellectual Product	Linear Analogue Self-Assessment-6
C121511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121511>	C175265	Feeling Intensity Score 1	A subjective score of 1 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be			Intellectual Product	Linear Analogue Self-Assessment-6
C121512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121512>	C175265	Feeling Intensity Score 2	A subjective score of 2 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.			Intellectual Product	Linear Analogue Self-Assessment-6
C121513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121513>	C175265	Feeling Intensity Score 3	A subjective score of 3 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.			Intellectual Product	Linear Analogue Self-Assessment-6
C121514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121514>	C175265	Feeling Intensity Score 4	A subjective score of 4 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.			Intellectual Product	Linear Analogue Self-Assessment-6
C121515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121515>	C175265	Feeling Intensity Score 5	A subjective score of 5 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.			Intellectual Product	Linear Analogue Self-Assessment-6
C121516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121516>	C175265	Feeling Intensity Score 6	A subjective score of 6 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.			Intellectual Product	Linear Analogue Self-Assessment-6
C121517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121517>	C175265	Feeling Intensity Score 7	A subjective score of 7 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.			Intellectual Product	Linear Analogue Self-Assessment-6
C121518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121518>	C175265	Feeling Intensity Score 8	A subjective score of 8 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.			Intellectual Product	Linear Analogue Self-Assessment-6
C121519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121519>	C175265	Feeling Intensity Score 9	A subjective score of 9 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.			Intellectual Product	Linear Analogue Self-Assessment-6
C12151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12151>	C61007	Alemtuzumab/Cyclophosphamide/Fludarabine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121520>	C175265	Feeling Intensity Score 10	A subjective score of 10 on a scale that ranges from 0: As Bad As It Can Be to 10: As Good As It Can Be.			Intellectual Product	Linear Analogue Self-Assessment-6
C121521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121521>	C17961	Hypomethylation|DNA Hypomethylation	An epigenetic process that either inhibits DNA methyltransferase activity or promotes DNA demethylase activity, and results in a net loss of 5-methylcytosines and a net gain of unmethylated cytosine nucleotides either in specific repetitive DNA sequences or across the bulk of the genome. This phenomenon is associated with aging, genomic instability and tumorigenesis.	Hypomethylation		Phenomenon or Process	CTRP Biomarker Terminology|CTRP Terminology
C121522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121522>	C20993	Pediatric Quality of Life Inventory, Version 4|Pediatric Quality of Life Inventory Version 4 (PedsQL 4.0)|PedsQL 4.0|PedsQL v4|PedsQL-4	A modular instrument for measuring health-related quality of life in children and adolescents ages 2 to 18. The PedsQL combines both generic core scales and disease-specific modules.			Intellectual Product	
C121523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121523>	C20993	PedsQL-4 Child Report|Child Report|Child-Self Report	A self-report questionnaire that assesses health-related quality of life in children and adolescents ages 8 to 12.			Intellectual Product	Pediatric Quality of Life Inventory, Version 4
C121524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121524>	C20993	PedsQL-4 Parent Report|Parent Report|Parent Report for Children|Parent-Proxy Report	A questionnaire, completed by a parent, that assesses health-related quality of life in children and adolescents ages 8 to 12.			Intellectual Product	Pediatric Quality of Life Inventory, Version 4
C121525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121525>	C217121	PedsQL-4 Physical Functioning Scale|Physical Functioning Scale	A rating scale included in the Pediatric Quality of Life Inventory Version 4 (PedsQL 4.0) that measures problems with a child's physical health and activities.			Intellectual Product	Pediatric Quality of Life Inventory, Version 4
C121526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121526>	C217121	PedsQL-4 Emotional Functioning Scale|Emotional Functioning Scale	A rating scale included in the Pediatric Quality of Life Inventory Version 4 (PedsQL 4.0) that measures problems with a child's feelings and emotions.			Intellectual Product	Pediatric Quality of Life Inventory, Version 4
C121527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121527>	C217121	PedsQL-4 Social Functioning Scale|Social Functioning Scale	A rating scale included in the Pediatric Quality of Life Inventory Version 4 (PedsQL 4.0) that measures problems with how well a child gets along with others.			Intellectual Product	Pediatric Quality of Life Inventory, Version 4
C121528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121528>	C217121	PedsQL-4 School Functioning Scale|School Functioning Scale	A rating scale included in the Pediatric Quality of Life Inventory Version 4 (PedsQL 4.0) that measures problems with a child's experiences related to attending school.			Intellectual Product	Pediatric Quality of Life Inventory, Version 4
C121529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121529>	C217122	PedsQL-4 Psychosocial Health Summary Score|Psychosocial Health Summary Score	The mean value computed as the sum of the score of individual items over the number of items answered in the Emotional, Social, and School Functioning Scales.			Intellectual Product	Pediatric Quality of Life Inventory, Version 4
C12152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12152>	C61063	Capecitabine/Carboplatin/Epirubicin			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121530>	C217122	PedsQL-4 Scale Score|Scale Score	The mean value computed as the sum of the individual items in a scale over the number of items answered in that scale.			Intellectual Product	Pediatric Quality of Life Inventory, Version 4
C121531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121531>	C217122	PedsQL-4 Total Scale Score|Total Scale Score	The mean value computed as the sum of all individual items over the number of items answered on all the Scales.			Intellectual Product	Pediatric Quality of Life Inventory, Version 4
C121532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121532>	C18520	Urine Albumin|Microalbumin|Urinary Albumin	Albumin protein in urine samples, which is a marker for kidney dysfunction. Persistently elevated concentrations of albumin in the urine can be diagnostic for kidney damage caused by diabetes, high blood pressure, heart failure, cirrhosis, or lupus.	Urine Albumin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C121533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121533>	C68742	Erythroid Colony Forming Unit|CFU-E|Colony Forming Unit-Erythroid|Colony-Forming Units, Erythroid	A unit of viable cell concentration defined as the minimum number of hematopoietic stem cells able to produce a detectable colony of erythroid lineage cells that are past the burst forming stage.	Erythroid Colony Forming Unit		Quantitative Concept	CTRP Biomarker Terminology|CTRP Terminology
C121534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121534>	C36344	ERG Deregulation	A molecular genetic abnormality indicating deregulation of the ERG oncogene.			Cell or Molecular Dysfunction	
C121536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121536>	C200766	Autologous NKG2D CAR-CD3zeta-DAP10-expressing T-Lymphocytes CYAD-01|Autologous CAR NKG2D|Autologous CAR-T NKG2D|Autologous CAR-T NKR-2|Autologous CM-CS1 T Cells|Autologous NKG2D CAR-CD3zeta-DAP10-expressing T-cells CYAD-01|Autologous NKR 2 T-cells|Autologous NKR-2 CAR-T Cells|CM CS-1|CM-CS-1|CM-CS1|CYAD-01|CYAD-101|NKR 2|NKR-2	A preparation of autologous peripheral blood T-lymphocytes (PBTLs) that have been genetically modified and transduced with a retroviral vector to express a chimeric antigen receptor (CAR) encoding full-length human natural-killer group 2, member D receptor protein (NKG2D or KLRK1) fused to the CD3zeta cytoplasmic signaling domain and containing the naturally-expressed adaptor molecule DNAX-activating protein of 10 kDa (DAP10), with potential immunostimulating and antineoplastic activities. Upon infusion back into the patient, autologous NKG2D CAR-CD3zeta-DAP10-expressing T-lymphocytes CYAD-01 specifically recognize and bind to tumor cells expressing NKG2D ligands. This induces secretion of pro-inflammatory cytokines and results in the lysis of NKG2D ligand-expressing tumor cells. In addition, CYAD-01 targets, binds to and kills NKG2D ligand expressing tumor-associated endothelial cells in the neovasculature and immunosuppressive cells, such as regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TME) that express NKG2D ligands. It also activates macrophages within the TME. Ligands for NKG2D, such as MHC class I chain-related protein A (MICA), MICB, and members of the UL16-binding proteins (ULBP)/retinoic acid early transcript 1 (RAET1) family, are overexpressed on infected cells and most cancer cell types, but are not expressed on most normal, healthy cells. NKG2D, a dimeric, type II transmembrane protein expressed on human natural killer (NK) and certain T-cells, in association with the natural adaptive protein DAP10, promotes the elimination of NKG2D ligand-expressing cells. The CD3zeta signaling domain and DAP10 provide co-stimulatory signaling upon ligand binding, enhance the secretion of pro-inflammatory cytokines in response to binding to NKG2D ligand-expressing tumor cells and enhances T-cell cytotoxicity. DAP10 also associates with and stabilizes NKG2D, which facilitates expression of the NKG2D-CAR-CD3zeta construct at the cell surface.	Autologous NKG2D CAR-CD3zeta-DAP10-expressing T-Lymphocytes CYAD-01		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121537>	C28681|C129826	Autologous HPV-16/18 E6/E7-specific TGF-beta-resistant T Lymphocytes|HPVST Cells	A preparation of autologous transforming growth factor-beta (TGF-beta)-resistant cytotoxic T-lymphocytes (CTL) reactive to human papilloma virus (HPV) types 16 and 18 E6/E7 antigens, with potential antineoplastic activity. Autologous T-lymphocytes from a HPV-positive cancer patient are exposed to and stimulated with dendritic cells (DCs) loaded with the HPV-16/18 proteins E6 and E7. In turn, the HPV-16/18 E6/E7-specific T-lymphocytes are transduced with a retroviral vector expressing a dominant-negative mutant of type II transforming growth factor (TGF)-beta receptor, which blocks signaling mediated by all three TGF-beta isoforms. Following re-administration to patients with HPV-positive tumors, the HPV-16/18 E6/E7-specific TGF-beta-resistant T lymphocytes target HPV16/18 E6/E7-positive cells, which may result in a specific cytotoxic T-lymphocyte (CTL) response, followed by cell lysis and the inhibition of tumor cell proliferation. Tumors expressing TGF-beta inhibit T-lymphocyte activation and expansion.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121538>	C133877	Mitazalimab|ADC 1013|ADC-1013|ADC1013|JNJ 7107|JNJ-64457107|MITAZALIMAB	A human immunoglobulin (Ig) G1 monoclonal antibody directed against the cell surface receptor CD40 with potential immunostimulatory and antineoplastic activities. Upon intratumoral administration, mitazalimab binds to CD40 on antigen-presenting dendritic cells, which leads to the activation and proliferation of effector and memory T-cells, and enhances the immune response against tumor cells. In addition, this agent binds to the CD40 antigen present on the surfaces of tumor cells, which induces antibody-dependent cytotoxicity (ADCC). This eventually inhibits the proliferation of CD40-expressing tumor cells. CD40, a stimulatory receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells, such as macrophages, dendritic cells and various tumor cell types; it plays a key role in the activation of the immune system.	Mitazalimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121539>	C67437	Docetaxel-loaded Nanopharmaceutical CRLX301|CRLX301	A nanoparticle-based formulation containing the poorly water-soluble, second-generation taxane analog docetaxel, with antineoplastic activity. Upon intravenous administration of the docetaxel-loaded nanopharmaceutical CRLX301, the nanoparticles are able to accumulate at the tumor site due to the unique characteristics of the tumor's vasculature, while avoiding normal, healthy tissue. In turn, CRLX301 is taken up by the tumor cell via macropinocytosis. Subsequently, docetaxel is slowly released into the cytoplasm where it binds to and stabilizes the beta-subunit of tubulin, thereby stabilizing microtubules and inhibiting microtubule disassembly. This prevents mitosis and results in cell death. Compared to the administration of docetaxel alone, this formulation is able to increase docetaxel's efficacy while avoiding systemic exposure, which minimizes its toxicity.	Docetaxel-loaded Nanopharmaceutical CRLX301		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12153>	C61063	Gemtuzumab Ozogamicin/Oblimersen			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121540>	C129822|C128037	Cemiplimab|CEMIPLIMAB|Cemiplimab RWLC|Cemiplimab-rwlc|Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal REGN2810 Heavy Chain), Disulfide with Human Monoclonal REGN2810 kappa-chain, Dimer|Libtayo|REGN 2810|REGN-2810|REGN2810	A human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1) protein, with potential immune checkpoint inhibitory and antineoplastic activity. Upon administration, cemiplimab binds to PD-1, inhibits its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-cells. PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.	Cemiplimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121541>	C1663	LmddA-LLO-chHER2 Fusion Protein-secreting Live-attenuated Listeria Cancer Vaccine OST31-164|ADXS 31164|ADXS-HER2|ADXS31-164|OST-HER2|OST31 164|OST31164	A cancer vaccine containing a live, highly attenuated strain of the Gram-positive bacterium Listeria monocytogenes (LmddA) encoding a fusion protein composed of a chimeric peptide comprised of three highly immunogenic epitopes of the human tumor-associated antigen (TAA) HER2/neu (chHER2) fused to a non-hemolytic fragment of the immunostimulant listeriolysin O (LLO) protein, with potential immunostimulatory and antineoplastic activities. Upon administration of the LmddA-LLO-chHER2 vaccine OST31-164, the LmddA is taken up by phagocytic cells; then the listeriolysin portion of the expressed LLO-chHER2 can form pores in the phagolysosomes and the fusion protein can escape into the cytosol. In turn, the LLO-chHER2 is processed and presented to the immune system by major histocompatibility complex (MHC) I on the phagocytic cells. Antigen presentation activates the immune system to exert an immune response involving the recruitment and activation of T-lymphocytes against HER2-expressing tumor cells, and inhibits tumor-infiltrating T regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSCs). This eventually results in tumor cell lysis. HER2/neu, a tyrosine kinase receptor belonging to the epidermal growth factor receptor (EGFR) family, is overexpressed in various tumor cell types.	LmddA-LLO-chHER2 Fusion Protein-secreting Live-attenuated Listeria Cancer Vaccine ADXS31-164		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121542>	C225	Recombinant Super-compound Interferon|Recombinant Super Compound Interferon|rSIFN-co	A recombinant form of the naturally-occurring cytokine interferon-alpha (IFN-a) that has a modified spatial configuration, with immunomodulating, antiviral and antineoplastic activities. Upon administration of recombinant super-compound interferon (rSIFN-co), this agent binds to IFN-specific cell surface receptors, resulting in the transcription and translation of genes whose protein products have antiviral, antiproliferative, anticancer, and immune-modulating effects. The 3-dimensional conformational change improves efficacy and causes less side effects compared to IFN-a.	Recombinant Super-compound Interferon		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121543>	C157401	Dolutegravir|2H-Pyrido(1',2':4,5)pyrazino(2,1-b)(1,3)oxazine-9-carboxamide, N-((2,4-difluorophenyl)methyl)-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS)|DOLUTEGRAVIR|DTG|GSK 1349572|GSK-1349572	An orally bioavailable integrase strand-transfer inhibitor (INSTI), with activity against human immunodeficiency virus type 1 (HIV-1) infection. Upon oral administration, dolutegravir binds to the active site of integrase, an HIV enzyme that catalyzes the transfer of viral genetic material into human chromosomes. This prevents integrase from binding to retroviral deoxyribonucleic acid (DNA), and blocks the strand transfer step, which is essential for the HIV replication cycle. This prevents HIV-1 replication.	Dolutegravir		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C121544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121544>	C49146	Attenuated Chimpanzee Adenovirus 5T4 Vaccine|ChAdOx.5T4 Vaccine|ChAdOx1.5T4 Vaccine	A cancer vaccine comprised of a recombinant, attenuated, replication-defective simian adenovirus vector (ChAdOx1) encoding the human 5T4 fetal oncoprotein (ChAdOx1.5T4), with potential immuno-activating and antineoplastic activities. Upon administration of the recombinant attenuated chimpanzee adenovirus 5T4 vaccine, the viral vector expresses 5T4 and stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing 5T4, which results in tumor cell lysis. 5T4, a transmembrane glycoprotein, is overexpressed by a variety of cancer cell types; its expression is correlated with increased invasiveness.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121546>	C91105	Health Assessment Questionnaire|HAQ|HAQ|Stanford Health Assessment Questionnaire|Stanford Health Assessment Questionnaire	A comprehensive, self-report survey consisting of twenty questions intended as a functional measure of an individual's current ability to accomplish the activities of daily living.	Health Assessment Questionnaire		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology|NICHD Terminology|Pediatric Rheumatology Terminology
C121547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121547>	C217121	Visual Analog Scale|VAS|VAS|VISUAL ANALOG SCALE|Visual Analogue Scale	A psychometric response scale to assess subjective characteristics or symptoms, which relies upon a continuum of possible result values in between two fixed end-points.			Intellectual Product	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C121548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121548>	C217121	Numeric Rating Scale|NRS	A psychometric response scale to assess subjective characteristics or symptoms, which relies upon a scale of numeric result values in between two fixed end-points.			Intellectual Product	
C121549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121549>	C217121	Verbal Rating Scale|VRS	A psychometric response scale to assess subjective characteristics or symptoms, which relies upon a scale of word values along a continuum in between two fixed end-points.			Intellectual Product	
C12154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12154>	C61063	Dexamethasone/Oblimersen			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121550>	C133878|C129822	Anti-EGFR Monoclonal Antibody SYN004|SYN-004 (CETUXIMAB SIMILAR)|SYN004	A glyco-engineered monoclonal antibody directed against the receptor tyrosine kinase epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, anti-EGFR monoclonal antibody SYN004 binds to the extracellular domain of EGFR, which prevents ligand binding and the subsequent activation and dimerization of the receptor. This inhibits the activation of EGFR-mediated signaling pathways and inhibits EGFR-dependent tumor cell proliferation. EGFR, a member of the EGFR receptor tyrosine kinase family, may be overexpressed on the cell surfaces of various tumor cell types.	Anti-EGFR Monoclonal Antibody SYN004		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121551>	C2124	Carbon C 14 Roniciclib|[14C]-BAY1000394|[14C]-roniciclib	An orally bioavailable radioconjugate composed of roniciclib, a cyclin dependent kinase (CDK) inhibitor, radiolabeled with carbon C 14, with potential use for evaluating the pharmacokinetic profile of roniciclib. Roniciclib selectively binds to and inhibits the activity of various CDK subtypes, which leads to cell cycle arrest and an inhibition of tumor cell proliferation. Labeling of roniciclib with the radioactive tracer carbon C 14 allows for the evaluation of roniciclib's pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME). CDKs, serine/threonine kinases overexpressed in various tumor cell types, play key roles in the regulation of both cell cycle progression and cellular proliferation.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C121552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121552>	C28681|C138180|C129826	Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes|Anti-thyroglobulin mTCR-transduced Autologous PBL	Peripheral blood lymphocytes (PBLs) transduced with a gene encoding for a thyroglobulin (TG)-specific murine T-cell receptor (mTCR), with potential antineoplastic activity. PBLs are harvested from a thyroid cancer patient, and transfected with a retroviral vector that encodes the mTCR gene specific for the human TG antigen. The transduced PBLs are then expanded in culture. When reintroduced to the patient, these anti-TG mTCR-expressing PBLs target and bind to TG-overexpressing tumor cells, which results in both cytokine secretion and tumor cell lysis. TG is a thyroid-specific protein.	Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121553>	C155727	Pemigatinib|2H-Pyrrolo(3',2':5,6)pyrido(4,3-d)pyrimidin-2-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-8-(4-morpholinylmethyl)-|INCB 054828|INCB-054828|INCB054828|PEMIGATINIB|Pemazyre	An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), with potential antineoplastic activity. Pemigatinib binds to and inhibits FGFR1/2/3, which may result in the inhibition of FGFR1/2/3-related signal transduction pathways. This inhibits proliferation in FGFR1/2/3-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, plays a key role in cellular proliferation, migration, and survival.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121554>	C1446	Gallium Ga 68 Citrate|(68)Ga-citrate|68Ga-Citrate|GALLIUM CITRATE GA-68|Gallium-68 Citrate	A radiopharmaceutical citrate salt form of the positron-emitting radioisotope gallium Ga 68, with potential imaging activity upon positron emission tomography (PET). Upon administration of Gallium Ga 68 citrate, the gallium Ga 3+ ion dissociates from the weak citrate chelator. As Ga3+ is very similar to iron (Fe3+) in chemical properties, this ion acts as an iron analogue. Ga3+ binds to the iron-binding protein transferrin, distributes in blood, and enters and accumulates in the extracellular fluid space of inflamed or tumor-bearing tissue. In turn, the Ga3+-transferrin complex binds to transferrin receptors and is taken up by tumor cells. Tumor cells can then be imaged upon PET. Compared to healthy cells, tumor cells have increased iron metabolism and transferrin receptor expression. Increased Ga3+ uptake is seen in inflamed and infected tissues as well.	Gallium Ga 68 Citrate		Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C121555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121555>	C12745	Cardiophrenic Lymph Node|CARDIOPHRENIC LYMPH NODE|Cardiophrenic Angle Lymph Node	A lymph node located in the angle between the heart and diaphragm.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C121556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121556>	C3837	Back Arching	A convex curvature of the spine that occurs when an individual thrusts forward the shoulders and pulls back the abdomen.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C121557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121557>	C34548	Bloody Discharge|Bloody Drainage	The leaking of serosanguinous fluids from an orifice or wound.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C121558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121558>	C3676	Breath Holding|Breath Holding Spell|Breath-holding Spell|Breath-holding spell	Episodic apnea, which is more common in young children and usually resolves by age six.			Sign or Symptom	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C121559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121559>	C3671	Bite Injury	A wound inflicted by the teeth or fangs of an individual or animal.			Finding	
C12155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12155>	C61063	Cisplatin/ZD 1839			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121560>	C121559	Cat Bite	A wound received from the teeth of a cat.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C121561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121561>	C1907	Lorenzo's Oil|GTO:GTE Oil	An orally-administered oil composed of the monounsaturated fatty acids glyceryl trioleate (GTO), the triacylglycerol form of oleic acid derived from olive oil, and glyceryl trierucate (GTE), the triacylglycerol form of erucic acid derived from rapeseed oil, in a 4:1 ratio, that can be used in the treatment of adrenoleukodystrophy (ALD). Upon oral administration of Lorenzo's oil, the monounsaturated fatty acids compete with saturated fatty acids as substrates for enzymes in the elongation of very long-chain fatty acids (ELOVL) family. This results in the elongation and production of monounsaturated very long-chain fatty acids (VLCFAs) and reduces the elongation of saturated VLCFAs. This reduces the plasma levels of saturated VLCFAs and prevents their accumulation in the brain, thereby preventing demyelination of cerebral nerves and halting the progression of ALD.			Pharmacologic Substance	
C121562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121562>	C2975	Cystic Fibrosis Pulmonary Exacerbation	An acute episode of worsening pulmonary symptoms related to cystic fibrosis.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C121563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121563>	C53543	Lysinuric Protein Intolerance	A disorder caused by the inability to digest and use lysine, arginine, and ornithine. Lysinuric protein intolerance is caused by mutations in the SLC7A7 gene. y+L amino acid transporter 1, the product of the SLC7A7 gene, is involved in transporting lysine, arginine, and ornithine between cells in the body.			Disease or Syndrome	Cellosaurus Disease Terminology
C121564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121564>	C53543	Adenine Phosphoribosyltransferase Deficiency	An inherited condition caused by mutations in the APRT gene that affects the kidneys and urinary tract. The most common feature of this condition is recurrent kidney stones.			Disease or Syndrome	Cellosaurus Disease Terminology
C121565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121565>	C53543	Neonatal Progeroid Syndrome|Wiedemann-Rautenstrauch Syndrome	A rare autosomal recessive disorder associated with abnormalities in bone maturation, and lipids and hormone metabolism and characterized by intrauterine growth retardation, failure to thrive, short stature, a progeroid appearance, hypotonia, variable mental impairment, and death in childhood. Its cause is unknown.			Disease or Syndrome	Cellosaurus Disease Terminology
C121566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121566>	C60683	Rat Insulinoma	An insulin-producing neuroendocrine tumor arising from beta cells of the rat pancreas.			Neoplastic Process	Cellosaurus Disease Terminology
C121567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121567>	C60681	Rat Neuroblastoma	A tumor of the rat that arises from nerve tissue outside of the central nervous system.			Neoplastic Process	Cellosaurus Disease Terminology
C121568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121568>	C60683	Rat Adrenal Gland Pheochromocytoma|Rat Pheochromocytoma	A benign or malignant neuroendocrine neoplasm of the rat sympathetic nervous system that secretes catecholamines. It arises from the chromaffin cells of the rat adrenal medulla.			Neoplastic Process	Cellosaurus Disease Terminology
C121569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121569>	C94726|C211679	Netupitant/Palonosetron Hydrochloride|Akynzeo|Netupitant and Palonosetron|Netupitant and palonosetron|Netupitant/Palonosetron	An orally available combination formulation containing netupitant, a selective neurokinin 1 (NK1) receptor antagonist, and the hydrochloride salt form of palonosetron, a selective serotonin (5-hydroxytryptamine; 5-HT) receptor subtype 3 (5-HT3) antagonist, with antiemetic activity. Upon oral administration, palonosetron competitively blocks the action of 5-HT at 5-HT3 receptors located on vagal afferent nerves in the chemoreceptor trigger zone (CTZ). This inhibits acute emesis associated with 5-HT secretion and subsequent 5-HT3 activation. Netupitant competitively binds to and blocks the activity of the human NK1 receptors in the central nervous system (CNS), thereby inhibiting NK1 receptor binding of the endogenous tachykinin neuropeptide substance P (SP). This prevents delayed emesis, which is associated with SP secretion. Altogether, this results in the prevention of chemotherapy-induced nausea and vomiting (CINV).	Netupitant/Palonosetron Hydrochloride		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C12156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12156>	C61063	Aspirin/Folic acid|Aspirin + Folic Acid			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121570>	C39619|C1663	HCV DNA Vaccine INO-8000|INO-8000	A multi-antigen DNA vaccine consisting of plasmids encoding the hepatitis C virus (HCV) nonstructural proteins 3 (NS3), 4A (NS4A), 4B (NS4B) and 5A (NS5A), with potential immunomodulating and cancer preventive activities. Administered via intramuscular injection followed by electroporation, cells transfected with the HCV DNA vaccine INO-8000 express the encoded HCV proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against HCV-infected liver cells expressing the NS3, NS4A, NS4B or NS5A proteins. This results in the eradication of HCV-infected cells. HCV, a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family, is associated with the development of hepatocellular carcinoma (HCC).	HCV DNA Vaccine INO-8000		Immunologic Factor|Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121571>	C9306|C3158	Leiomyosarcoma of Deep Soft Tissue|Leiomyosarcoma of the Deep Soft Tissue	A rare leiomyosarcoma that arises from the deep soft tissue in the retroperitoneum or abdominal cavity.			Neoplastic Process	
C121572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121572>	C206547	Complex Regional Pain Syndrome II|CRPS II|Causalgia|Causalgia	A neurologic condition characterized by burning pain, tenderness, swelling, and changes in the skin color and temperature of a body part or extremity associated with demonstrable nerve injury. This form is less frequent in pediatric patients.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C121573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121573>	C36281	Crepitus	Air trapped in the subcutaneous space. It can be palpated or heard as a crackling or grating sensation under the skin.			Finding	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology
C121574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121574>	C3368	Hypophagia|Decreased Oral Intake|Decreased PO Intake|Oral Intake Reduced|Poor Oral Intake	Reduced ingestion of food.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C121575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121575>	C173925	Usual Bedtime at Night Question|Usual Bedtime at Night|What time have you usually gone to bed at night	A question about an individual's usual bedtime at night.			Intellectual Product	Pittsburgh Sleep Quality Index
C121576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121576>	C173925	Usual Time it Takes to Fall Asleep at Night Question|How long (in minutes) has it usually taken you to fall asleep each night|Usual Amount of Time to Fall Asleep at Night|Usual Time it Takes to Fall Asleep at Night	A question about the amount of time it usually takes for an individual to fall asleep at night.			Intellectual Product	Pittsburgh Sleep Quality Index
C121577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121577>	C45233	Pulmonary Function Test Decreased	A decrease in any of the parameters used to measure the mechanical function of the lungs and upper airway.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C121578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121578>	C45233	Pulmonary Function Test Increased	An increase in any of the parameters used to measure the mechanical function of the lungs and associated structures.			Finding	
C121579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121579>	C45233	Pulmonary Function Test Normal	Results that are standard and expected for the reference population with any of the parameters used to measure the mechanical function of the lungs and associated structures.			Finding	
C12157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12157>	C61007	Erlotinib/Trastuzumab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121580>	C91102	Usual Time in Morning to Get Up Question|Usual Morning Waking Time|Usual Time in Morning to Get Up|What time have you usually gotten up in the morning	A question about an individual's usual time to get up in the morning.			Intellectual Product	Pittsburgh Sleep Quality Index
C121581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121581>	C173925	Hours of Actual Sleep at Night Question|Hours of Actual Sleep at Night|How many hours of actual sleep did you get at night	A question about an individual's hours of actual sleep at night.			Intellectual Product	Pittsburgh Sleep Quality Index
C121582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121582>	C3368	Drooling	Saliva spilling out of the mouth.			Finding	CRF2 History and Physical Exam Initial History Table|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C121583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121583>	C62277	Non-Cutaneous Leiomyosarcoma|Leiomyosarcoma (Excluding Skin)	A leiomyosarcoma arising from an anatomic site other than skin.			Neoplastic Process	
C121584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121584>	C104294	Trouble Sleeping, Cannot Get to Sleep Within 30 Minutes Question|Have trouble sleeping because cannot get to sleep within 30 minutes|Trouble Sleeping, Cannot Get to Sleep Within 30 Minutes	A question about an individual's trouble sleeping because they are not able to get to sleep within 30 minutes.			Intellectual Product	Pittsburgh Sleep Quality Index
C121585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121585>	C104294	Trouble Sleeping, Waking Up in the Middle of the Night or Early Morning Question|Have trouble sleeping because of waking up in the middle of the night or early morning|Trouble Sleeping, Waking Up in the Middle of the Night or Early Morning	A question about an individual's trouble sleeping because of waking up in the middle of the night or early morning.			Intellectual Product	Pittsburgh Sleep Quality Index
C121586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121586>	C104294	Trouble Sleeping, Get Up to Use the Bathroom Question|Have Trouble Sleeping Because of Getting Up to Use the Bathroom|Have trouble sleeping because have to get up to use the bathroom|Trouble Sleeping, Get Up to Use the Bathroom	A question about an individual's trouble sleeping because of getting up to use the bathroom.			Intellectual Product	Pittsburgh Sleep Quality Index
C121587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121587>	C104294	Trouble Sleeping, Cannot Breathe Comfortably Question|Have trouble sleeping because cannot breathe comfortably|Trouble Sleeping, Cannot Breathe Comfortably	A question about an individual's trouble sleeping because they cannot breathe comfortably.			Intellectual Product	Pittsburgh Sleep Quality Index
C121588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121588>	C28229	Foreign Body Ingestion	The swallowing of an item not intended for consumption.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C121589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121589>	C71746	Central Line Complication	A problem with a central venous access catheter or site of insertion.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C12158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12158>	C61007	Celecoxib/Eflornithine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121590>	C104294	Trouble Sleeping, Cough or Snoring Loudly Question|Have Trouble Sleeping Because of Coughing or Snoring Loudly|Have trouble sleeping because of cough or snoring loudly|Trouble Sleeping, Cough or Snoring Loudly	A question about an individual's trouble sleeping because of coughing or snoring loudly.			Intellectual Product	Pittsburgh Sleep Quality Index
C121591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121591>	C104294	Trouble Sleeping, Feel Too Cold Question|Have Trouble Sleeping Because of Feeling Too Cold|Have trouble sleeping because feel too cold|Trouble Sleeping, Feel Too Cold	A question about an individual's trouble sleeping because of feeling too cold.			Intellectual Product	Pittsburgh Sleep Quality Index
C121592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121592>	C104294	Trouble Sleeping, Feel Too Hot Question|Have Trouble Sleeping Because of Feeling Too Hot|Have trouble sleeping because feel too hot|Trouble Sleeping, Feel Too Hot	A question about an individual's trouble sleeping because of feeling too hot.			Intellectual Product	Pittsburgh Sleep Quality Index
C121593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121593>	C104294	Trouble Sleeping, Having Bad Dreams Question|Have trouble sleeping because of having bad dreams|Trouble Sleeping, Having Bad Dreams	A question about an individual's trouble sleeping because of having bad dreams.			Intellectual Product	Pittsburgh Sleep Quality Index
C121594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121594>	C173346|C104294	Trouble Sleeping Because of Pain Question|Have trouble sleeping because of pain|Trouble Sleeping Because of Pain	A question about an individual's trouble sleeping because of pain.			Intellectual Product	Pittsburgh Sleep Quality Index
C121595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121595>	C104294	Trouble Sleeping Because of Other Reason Question|Have trouble sleeping because of other reason|Trouble Sleeping Because of Other Reason	A question about an individual's trouble sleeping because of a reason not already mentioned.			Intellectual Product	Pittsburgh Sleep Quality Index
C121596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121596>	C173925	Overall Sleep Quality Rating Question|How would you rate your sleep quality overall|Overall Sleep Quality|Overall Sleep Quality Rating	A question about how an individual would rate their overall sleep quality.			Intellectual Product	Pittsburgh Sleep Quality Index
C121597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121597>	C173925	Take Medicine to Help Sleep Question|Have you taken medicine to help you sleep|Take Medicine to Help Sleep|Take Medicine to Help You Sleep	A question about whether an individual has taken medicine to help them sleep.			Intellectual Product	Pittsburgh Sleep Quality Index
C121598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121598>	C173398	Have Trouble Staying Awake Question|Have Trouble Staying Awake|Have Trouble Staying Awake While Driving, Eating Meals, or Engaging in Social Activity|Have you had trouble staying awake while driving, eating meals, or engaging in social activity	A question about an individual's trouble staying awake while driving, eating meals, or engaging in social activity.			Intellectual Product	Pittsburgh Sleep Quality Index
C121599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121599>	C91102	Enough Enthusiasm to Get Things Done Question|Enough Enthusiasm to Get Things Done|How much of a problem has it been for you to keep up enough enthusiasm to get things done|Keeping Up Enough Enthusiasm to Get Things Done	A question about how much of a problem it has been for an individual to keep up enough enthusiasm to get thing done.			Intellectual Product	Pittsburgh Sleep Quality Index
C12159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12159>	C61007	Dexamethasone/Thalidomide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1215>	C54630|C275	Resveratrol|(E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol|3,4',5-Stilbenetriol|RESVERATROL|RESVERATROL|resveratrol	A phytoalexin derived from grapes and other food products with antioxidant and potential chemopreventive activities. Resveratrol induces phase II drug-metabolizing enzymes (anti-initiation activity); mediates anti-inflammatory effects and inhibits cyclooxygenase and hydroperoxidase functions (anti-promotion activity); and induces promyelocytic leukemia cell differentiation (anti-progression activity), thereby exhibiting activities in three major steps of carcinogenesis. This agent may inhibit TNF-induced activation of NF-kappaB in a dose- and time-dependent manner. (NCI05)	Resveratrol		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C121600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121600>	C173981	Have Bed Partner or Roommate Question|Do you have a bed partner or room mate|Have Bed Partner or Roommate	A question about whether an individual has a bed partner or roommate.			Intellectual Product	Pittsburgh Sleep Quality Index
C121601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121601>	C173981	Have Loud Snoring Question|Has Loud Snoring|Have Loud Snoring|Have loud snoring|Snores Loudly	A question about whether an individual has loud snoring.			Intellectual Product	Pittsburgh Sleep Quality Index
C121602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121602>	C173925	Have Long Pauses Between Breaths While Asleep Question|Have Long Pauses Between Breaths While Asleep|Have long pauses between breaths while asleep|Pauses Between Breaths While Asleep	A question about whether an individual has or had long pauses between breaths while asleep.			Intellectual Product	Pittsburgh Sleep Quality Index
C121603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121603>	C173925	Have Legs Twitching or Jerking While Asleep Question|Have Legs Twitching or Jerking While Asleep|Have legs twitching or jerking while you sleep|Legs Twitch or Jerk While Asleep	A question about whether an individual has or had twitching or jerking legs while asleep.			Intellectual Product	Pittsburgh Sleep Quality Index
C121604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121604>	C93210	Catheter-Related Inflammation	Inflammation associated with the use of a catheter.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C121605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121605>	C173981|C173925	Have Episodes of Disorientation or Confusion During Sleep Question|Disoriented or Confused During Sleep|Have Episodes of Disorientation or Confusion During Sleep|Have episodes of disorientation or confusion during sleep	A question about whether an individual has or had episodes of disorientation or confusion while asleep.			Intellectual Product	Pittsburgh Sleep Quality Index
C121606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121606>	C173925	Have Other Restlessness While Asleep Question|Have Other Restlessness While Asleep|Have other restlessness while you sleep	A question about whether an individual has a type of restlessness while asleep not previously mentioned.			Intellectual Product	Pittsburgh Sleep Quality Index
C121607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121607>	C121589	Central Line Infection	An infectious process related to a central venous catheter.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C121608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121608>	C175311	Not During the Past Month|Not during the past month	An indication that something has not occurred during the past month.			Intellectual Product	Pittsburgh Sleep Quality Index
C121609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121609>	C177913	Only Very Slight Problem|Only a Very Slight Problem|Only very slight problem	A subjective response indicating that something is a minor difficulty requiring resolution.			Intellectual Product	Pittsburgh Sleep Quality Index
C12160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12160>	C61063	Bupropion/Nicotine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121610>	C177913	Somewhat of a Problem|Somewhat of a problem	A subjective response indicating that something is a difficulty requiring resolution.			Intellectual Product	Pittsburgh Sleep Quality Index
C121611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121611>	C177913	A Very Big Problem|A very big problem	A subjective response indicating that something is a major difficulty requiring resolution.			Intellectual Product	Pittsburgh Sleep Quality Index
C121612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121612>	C178374	No Bed Partner or Roommate|No bed partner or room mate	A response indicating that an individual does not have a bed partner or roommate.			Intellectual Product	Pittsburgh Sleep Quality Index
C121613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121613>	C178374	Partner or Roommate in Other Room|Partner/room mate in other room	A response indicating that an individual has a partner or roommate who does not share their bedroom.			Intellectual Product	Pittsburgh Sleep Quality Index
C121614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121614>	C178374	Partner in Same Room, But Not Same Bed|Partner in same room, but not same bed	A response indicating that an individual has a partner who shares their bedroom but does not share the same bed.			Intellectual Product	Pittsburgh Sleep Quality Index
C121615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121615>	C178374	Partner in Same Bed|Partner in same bed	A response indicating that an individual has a partner who shares their bed.			Intellectual Product	Pittsburgh Sleep Quality Index
C121616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121616>	C34548	Wound Discharge|Wound Drainage	The material exuded from a wound, either surgical or traumatic.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C121617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121617>	C29637	Neomycin Sulfate/Polymyxin B Sulfate/Dexamethasone|Maxitrol|Maxitrol Eye Drops	A topical combination preparation containing the sulfate salt form of the aminoglycoside antibiotic neomycin, the sulfate salt form of the polypeptide antibiotic polymyxin B, and the glucocorticoid dexamethasone, with antimicrobial, anti-infective and anti-inflammatory activities. Upon topical application, neomycin irreversibly binds to the bacterial 30S ribosomal subunit, thereby preventing mRNA from binding, causing both misreading and the inhibition of protein synthesis. Polymyxin B binds, with its positively charged amino groups, to negatively charged phospholipids in the outer cell membrane of Gram-negative bacteria, thereby disrupting cell wall integrity and altering the permeability of the bacterial cytoplasmic membrane. Dexamethasone binds to the cytoplasmic glucocorticoid receptor, and this receptor-ligand complex is translocated to the nucleus where it initiates the transcription of genes encoding for anti-inflammatory mediators, such as cytokines and lipocortins.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C121618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121618>	C3708	Germinomatous Germ Cell Tumor|Seminoma/Dysgerminoma/Germinoma	A term that refers to germinoma, seminoma, or dysgerminoma.			Neoplastic Process	GCT Authorized Value Terminology|GCT Histology Table|NICHD Terminology|Pediatric Endocrinology Terminology
C121619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121619>	C3708	Nongerminomatous Germ Cell Tumor|Germ cell tumor, nonseminomatous|Non-dysgerminomatous Germ Cell Tumor|Non-germinomatous Germ Cell Tumor|Non-seminomatous Germ Cell Tumor|Nongerminomatous Germ Cell Tumor Including Central Nervous System|Nonseminoma	A term that refers to teratoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, or mixed forms of these tumors.	Nongerminomatous Germ Cell Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Morphology PT Terminology|Mapped ICDO3.1 Morphology Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C12161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12161>	C61063	Etoposide/Filgrastim/Paclitaxel/Topotecan			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121620>	C16701	Galactocerebrosidase|EC 3.2.1.46|GALC|GALCERase|Galactocerebroside Beta-Galactosidase|Galactosylceramidase|Galactosylceramide Beta-Galactosidase|Testis Tissue Sperm-Binding Protein Li 88E|Testis Tissue Sperm-Binding Protein Li 89A	Galactocerebrosidase (685 aa, ~77 kDa) is encoded by the human GALC gene. This protein is involved in hydrolysis of galactose ester bonds of galactosylceramide, galactosylsphingosine, lactosylceramide, and monogalactosyldiglyceride.			Amino Acid, Peptide, or Protein|Enzyme	
C121621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121621>	C25804	GALC Gene|GALC|GALC|Galactosylceramidase Gene	This gene plays a role in hydrolysis of galactose ester bonds.			Gene or Genome	
C121622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121622>	C121621	GALC wt Allele|Galactocerebrosidase (Krabbe Disease) Gene|Galactocerebrosidase wt Allele	Human GALC wild-type allele is located in the vicinity of 14q31.3 and is approximately 156 kb in length. This allele, which encodes galactocerebrosidase protein, is involved in catabolism of galactosylceramide. Mutations in this gene are associated with Krabbe disease.			Gene or Genome	
C121623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121623>	C3368	Aphagia|Unable to Eat	The inability or refusal to swallow.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C121624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121624>	C45233	Agonal Respiration|Agonal Breathing|Gasping	An abnormal breathing pattern originating from lower brainstem neurons and characterized by labored breaths, gasping, and, often, myoclonus and grunting.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C121625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121625>	C129822|C128037	Spartalizumab|PDR-001|PDR001|SPARTALIZUMAB	A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, spartalizumab binds to PD-1 expressed on activated T-cells and blocks the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation.	Spartalizumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121626>	C45233	Airway Compromise	The inhibition of normal respiration by physical obstruction(s) to the airway.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C121627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121627>	C88429	Altered Level of Consciousness|Altered LOC|Altered State of Consciousness|Altered consciousness|Impaired consciousness	A level of awareness and arousal other than normal.			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 6: Symptoms and Signs Terminology|CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Physical Examination Terminology
C121628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121628>	C36280	Altered Mental Status|Altered mental state	A change to an individual's judgment, orientation (to place, time, and self), intellectual functioning, or mood from their baseline.	Altered Mental Status		Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|Appendix 6: Symptoms and Signs Terminology|CTRP Disease Terminology|CTRP Terminology|Current Symptoms and Signs: Clinical Symptoms Terminology|GDC Terminology|GDC Value Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|SeroNet Authorized Values|SeroNet Study Descriptors
C121629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121629>	C3235	Disturbance of Temperature Regulation	Any condition characterized by an inability to regulate body temperature.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C12162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12162>	C61007	Ethinyl Estradiol/Norgestrel|Cryselle|Ogestrel|Ovral	A combination of two steroid sex hormones, the semisynthetic estrogen ethinyl estradiol and the synthetic progestogen norgestrel, with contraceptive activity.  The combination of ethinyl estradiol with norgestrel suppresses the hypothalamic-pituitary system, leading to an inhibition of the release of follicle stimulating hormone (FSH), thus suppressing the development of ovarian follicles. The release of luteinizing hormone (LH) is also inhibited, thus preventing ovulation. In addition, thickening of the cervical mucus and the endometrium is promoted, thereby altering the endometrium in such a way as to discourage implantation.		Obsolete_Concept	Therapeutic or Preventive Procedure	
C121630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121630>	C40944	Increased Respiratory Secretion|Increased Respiratory Secretions	An increase in respiratory secretions.			Physiologic Function	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C121631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121631>	C175311	Less than Once a Week|Less than Once Weekly|Less than Once per Week|Less than once a week	An indication that something occurs or occurred less than once a week.			Intellectual Product	Pittsburgh Sleep Quality Index
C121632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121632>	C175311	Once or Twice a Week|Once or Twice Weekly|Once or Twice per Week|Once or twice a week	An indication that something occurs or occurred once or twice a week.			Intellectual Product	Pittsburgh Sleep Quality Index|Revised Dyadic Adjustment Scale
C121633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121633>	C175311	Three or More Times a Week|Three or More Times Weekly|Three or More Times per Week|Three or more times a week	An indication that something occurs or occurred three or more times a week.			Intellectual Product	Pittsburgh Sleep Quality Index
C121634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121634>	C226673	Fairly Good|Fairly good	An indication that something has a moderate degree of quality, value or worth.			Qualitative Concept	Pittsburgh Sleep Quality Index
C121635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121635>	C226633	Fairly Bad|Fairly bad	An indication that something has little quality, value or worth.			Qualitative Concept	Pittsburgh Sleep Quality Index
C121636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121636>	C226633	Very Bad|Very bad	An indication that something has very little quality, value or worth.			Qualitative Concept	Pittsburgh Sleep Quality Index
C121637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121637>	C254	Polihexanide Solution|PHMB Solution|Polyhexamethylenebiguanide Solution|Polyhexanide Solution	A solution containing the polymer polihexanide, with potential antimicrobial, disinfectant and wound healing activities. Upon application to a wound, polihexanide strongly binds to the wound surface and exerts an antiseptic effect through the binding of the positively charged guanidine groups of polihexanide with the negatively charged phospholipids of the bacterial cell membrane. This compromises the stability of the bacterial cell membrane, which results in the leakage of cytoplasmic components and leads to bacterial cell death. In addition, polihexanide accelerates wound healing by promoting epithelial cell migration and proliferation.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C121638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121638>	C225034|C200766	Anti-GPC3-CAR Autologous T Lymphocytes|Anti-GPC3 CAR Autologous T Cells|CAR-GPC3 T Cells|GPC3-targeted CAR Autologous T Cells|Glypican-3-specific CAR T Cells	A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for glypican-3 (GPC3), with potential immunostimulating and antineoplastic activities. Upon administration, anti-GPC3-CAR autologous T-lymphocytes specifically target and bind to GPC3-expressing tumor cells, resulting in tumor cell lysis. GPC3, a heparan sulfate proteoglycan and a member of the glypican family, is overexpressed on certain tumor cell types while minimally expressed in normal, healthy cells; GPC3 plays an important role in cellular proliferation and differentiation.	Anti-GPC3-CAR Autologous T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121639>	C156804	Lirametostat|CPI-1205|EZH2 Inhibitor CPI-1205|LIRAMETOSTAT	An orally available selective inhibitor of the histone lysine methyltransferase EZH2, with potential antineoplastic activity. Upon oral administration, lirametostat selectively inhibits the activity of both wild-type and mutated forms of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 on lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased proliferation of EZH2-expressing cancer cells. EZH2, a histone lysine methyltransferase (HMT) class enzyme and the catalytic subunit of the polycomb repressive complex 2 (PRC2), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation; its expression is correlated with tumor initiation, progression, stem cell self-renewal, migration and angiogenesis.	Lirametostat		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12163>	C61063	Cytarabine/Filgrastim/Mitoxantrone			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121640>	C28310	Allogeneic Mesothelioma Tumor Lysate-pulsed Autologous Dendritic Cell Vaccine|Allogeneic Mesothelioma Tumor Lysate-pulsed Autologous DC Vaccine|MesoCancerVac	A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with a mixture of lysates from five allogeneic mesothelioma tumor cell lines, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, DCs are loaded with allogeneic mesothelioma tumor cell lysates. Upon re-administration of the allogeneic mesothelioma tumor lysate-pulsed autologous DC vaccine, the immune system is exposed to an undefined amount of mesothelioma-associated antigens, which stimulates the induction of a specific cytotoxic T-lymphocyte (CTL) response against mesothelioma tumor cells and leads to tumor cell lysis.			Cell|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121641>	C1946|C129825	Citarinostat|2-((2-Chlorophenyl)phenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)-5-pyrimidinecarboxamide|5-Pyrimidinecarboxamide, 2-((2-Chlorophenyl)phenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)-|ACY-241|CC-96241|CITARINOSTAT|HDAC-IN-2|Histone Deacetylase Inhibitor ACY-241	An orally available histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon oral administration, citarinostat inhibits the activity of HDACs; this results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. This leads to the inhibition of tumor oncogene transcription, and the selective transcription of tumor suppressor genes, which inhibit tumor cell division and induce tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins.	Citarinostat		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121642>	C129820	Calculus bovis/Moschus/Olibanum/Myrrha Capsule|Wangbang Pharmaceutical Xihuang Capsule|XHP|Xihuang Capsule	An orally available traditional Chinese medicine (TCM)-based capsule formulation containing Calculus bovis, the dried gallstones of cattle, Moschus, also referred to as deer musk, the resin Olibanum and the resin Myrrha, with potential antineoplastic and chemopreventive activities. Although the exact mechanisms of action through which the active ingredients in the Calculus bovis/Moschus/Olibanum/Myrrha capsule elicit their effects have yet to be fully elucidated, they may, upon intake, exert their antineoplastic activity through modulation of the immune system, inhibition of tumor cell proliferation and induction of apoptosis.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121643>	C210746|C210691	Casein/Whey Protein/Soy Protein/Pea Protein/Fat Mix/EPA/DHA-based Nutritional Supplement|Nutrison	A gluten-free, calorie-rich nutritional supplement containing all essential vitamins, minerals, and trace elements, as well as protein, fat and carbohydrates. The protein contained in this supplement is derived from a variety of sources, including casein, whey, soy and pea; it helps maintain digestive health throughout the gastrointestinal tract and reduces the risk of digestive complications. This supplement contains the essential omega-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexanaeoic acid (DHA). DHA and EPA are incorporated into cell membranes and affect the production of pro-inflammatory mediators, eliciting an anti-inflammatory effect. Medium chain triglycerides (MCT) in this supplement enhance fat absorption. Upon oral intake of this nutritional supplement, the ingredients may prevent both malnutrition and weight loss.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C121644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121644>	C210691	Enzymatically-hydrolyzed Whey Protein-based Nutritional Supplement|Peptamen	An orally available, gluten-free, enzymatically hydrolyzed cysteine-rich whey-protein based nutritional supplement containing essential vitamins, minerals, and trace elements, as well as fat and carbohydrates. Upon oral intake of the nutritional supplement, the whey protein may improve gastric functioning and gastrointestinal health, thereby reducing vomiting and diarrhea. The whey-based hydrolyzed protein helps to alleviate the digestive burden for the pancreas and may be beneficial for patients with a pancreas-associated disease, such as pancreatitis or pancreatic cancer. Due to the high levels of cysteine in the whey protein, this supplement increases levels of the antioxidant glutathione (GSH). The polyunsaturated fatty acids in this supplement are incorporated in cell membranes and affect the production of pro-inflammatory mediators, eliciting an anti-inflammatory effect. Medium chain triglycerides (MCT) in this supplement enhance fat absorption and may aid in the prevention of fat malabsorption. Altogether, this supplement may prevent both malnutrition and weight loss.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C121645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121645>	C129824	Unesbulin|PTC596|Polycomb Ring Finger Oncogene Inhibitor PTC596|UNESBULIN	An orally active inhibitor of the polycomb ring finger oncogene BMI1 (B-cell-specific Moloney murine leukemia virus integration site 1), with potential antineoplastic activity. Upon oral administration, unesbulin targets BMI1 expressed by both tumor cells and cancer stem cells (CSCs), and induces hyper-phosphorylation of BMI1 leading to its degradation. This inhibits BMI1-mediated signal transduction pathways and results in a reduction of proliferation of BMI1-expressing tumor cells.  BMI1, a key protein in the polycomb repressive complex 1 (PRC1), is overexpressed in certain tumor cell types, and plays a key role in CSC survival, proliferation and resistance to chemotherapeutics; its expression is associated with increased tumor aggressiveness and a poor prognosis.	Unesbulin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121646>	C2336	Belvarafenib|BELVARAFENIB|HM95573	An orally available inhibitor of members of the Raf family of serine/threonine protein kinases, with potential antineoplastic activity. Upon administration, belvarafenib binds to and inhibits the B-Raf mutant V600E and C-Raf. This inhibits B-Raf V600E- and C-Raf-mediated signal transduction pathways, thereby inhibiting tumor cell growth of susceptible tumor cells. In addition, belvarafenib may also inhibit mutated Ras proteins. Raf protein kinases play a key role in the Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway, which is often dysregulated in human cancers and plays a key role in tumor cell proliferation and survival. The Raf mutation B-Raf V600E, where the valine at residue 600 is substituted for glutamic acid, is frequently overexpressed in a variety of human tumors and results in the constitutive activation of the Raf/MEK/ERK signaling pathway.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121647>	C159198	Bezuclastinib|BEZUCLASTINIB|CGT 9486|CGT-9486|CGT9486|PLX9486|c-Kit Inhibitor PLX9486	An orally bioavailable protein tyrosine kinase inhibitor of mutated forms of the tumor-associated antigen mast/stem cell factor receptor c-Kit (SCFR), with potential antineoplastic activity. Upon oral administration, bezuclastinib binds to and inhibits specific c-Kit mutants. This may result in an inhibition of tumor cell proliferation in cancer cell types that overexpress these c-Kit mutations. c-Kit, a transmembrane protein and receptor tyrosine kinase, is overexpressed in solid tumors and hematological malignancies; it plays a key role in the regulation of cell differentiation and proliferation.	Bezuclastinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121648>	C203670	HPV16 L2/E6/E7 Fusion Protein Vaccine TA-CIN|TA-CIN|Tissue Antigen-Cervical Intraepithelial Neoplasia Vaccine	A recombinant human papillomavirus (HPV), genetically engineered fusion protein vaccine in which the three HPV16 viral proteins L2, E6 and E7 are fused together in a single tandem fusion protein (TA-CIN; HPV16 L2\E6\E7), with potential immunoprotective and antineoplastic properties. Upon administration, HPV16 L2\E6\E7 fusion protein vaccine TA-CIN may stimulate the immune system to generate HPV16 E6\E7-specific CD4+ and CD8+ T-cell responses as well as the induction of L2-specific antibodies. In addition, this vaccine may prevent infection and the development of other HPV16-associated diseases. L2, a minor viral capsid protein, is able to induce a strong antibody response against certain HPV types.			Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12164>	C61063	Corticotropin/Cyclophosphamide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121650>	C116784	Superficial Circumscribed Morphea|Plaque Morphea|Plaque Morphea	Circumscribed morphea in which the lesions are restricted to the skin and the immediately underlying subcutaneous tissues.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C121651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121651>	C116784	Deep Circumscribed Morphea|Deep Morphea|Deep Morphea	Circumscribed morphea in which the lesions are found in the deep dermis, panniculus, fascia, or superficial muscle.			Disease or Syndrome	NICHD Terminology|Pediatric Rheumatology Terminology
C121652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121652>	C17146	VisionTree|VisonTree Patient Portal	A proprietary system designed to provide a secure cloud-based patient and provider portal system.			Manufactured Object	
C121653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121653>	C210958|C1512	Anti-mesothelin-Pseudomonas Exotoxin 24 Cytolytic Fusion Protein LMB-100|Anti-MSLN-PE24 cFP LMB-100|LMB-100|LMB-100|RG 7787|RG-7787|RG7787|RO 6927005|RO6927005	An anti-mesothelin (MSLN) recombinant cytolytic fusion protein (cFP) composed of a humanized Fab fragment of anti-MSLN monoclonal antibody SS1 linked to a truncated and de-immunized 24 kDa fragment of the Pseudomonas exotoxin (PE) (PE24), with potential antineoplastic activity. Upon intravenous administration of anti-MSLN-PE24 cFP LMB-100, the anti-MSLN moiety targets and binds to MSLN-expressing tumor cells. Upon binding and internalization through endocytosis, the toxin moiety ADP-ribosylates and inactivates eukaryotic elongation factor 2 (eEF2), preventing the elongation step of protein synthesis and leading to both an inhibition of protein synthesis and an induction of MSLN-expressing tumor cell apoptosis. MSLN, a tumor-associated antigen overexpressed in a variety of cancer cell types, plays a key role in tumor cell proliferation and migration. The engineered PE24 portion of LMB-100 does contain the targeting domain and furin cleavage site, which are needed for cytotoxicity, but most of the translocation domain II is deleted and the catalytic domain III contains point mutations, which result in the deletion and silencing of most T- and B-cell epitopes; therefore, the immunogenicity and toxicity is reduced compared to non-engineered PE toxin, which allows for the administration of larger doses of LMB-100.	Anti-mesothelin-Pseudomonas Exotoxin 24 Cytolytic Fusion Protein LMB-100		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121654>	C3359	Spindle Cell/Sclerosing Rhabdomyosarcoma	An uncommon variant of rhabdomyosarcoma with spindle cell or sclerosing morphology. It affects both children and adults and it is more common in males.	Spindle Cell/Sclerosing Rhabdomyosarcoma		Neoplastic Process	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology
C121655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121655>	C121654	Sclerosing Rhabdomyosarcoma|Sclerosing rhabdomyosarcoma	An uncommon variant of rhabdomyosarcoma with sclerosing morphology.  It usually arises from the limbs.			Neoplastic Process	GDC Terminology|GDC Value Terminology|NCIt Neoplasm Core Terminology
C121656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121656>	C28193|C200738	TEMPI Syndrome	A rare syndrome characterized by telangiectasias, elevated erythropoietin level and erythrocytosis, monoclonal gammopathy, perinephric fluid collections, and intrapulmonary shunting.  It is best classified as a type of plasma cell dyscrasia with paraneoplastic manifestations.			Neoplastic Process	
C121657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121657>	C119319	Porcine Epidemic Diarrhea Virus|PEDV	An alphacoronavirus that infects the cells lining the small intestine of the pig. It is the causative agent of porcine epidemic diarrhea.			Virus	
C121658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121658>	C53454	H5N2 Avian Influenza Virus|H5N2 Influenza Virus|Highly Pathogenic Avian Influenza Virus|Highly Pathogenic H5N2 Avian Influenza Virus	A highly pathogenic subtype of avian influenza A virus. This virus was responsible for a large outbreak of avian influenza in commercial flocks, starting in late 2014 and continuing into 2015.			Virus	
C121659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121659>	C25447	Flavor	The distinctive taste of something as detected in the mouth and also by the nose.			Conceptual Entity	
C12165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12165>	C61063	Cisplatin/Dacarbazine/Doxorubicin/Mitomycin/Sargramostim			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121660>	C20189	Influence	The power to have an effect on people, things, or events.			Conceptual Entity	
C121661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121661>	C117264	Intrusive Thought	An unwelcome and persistent idea, image or thought that is upsetting to an individual.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C121662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121662>	C54241	Mixture of Embryonal and Alveolar Features Present	A morphologic finding indicating the presence of a mixture of embryonal and alveolar components in a rhabdomyosarcoma.			Finding	
C121663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121663>	C20993	Growth Chart|Growth Charts	Graphic record of the range of various physical attributes mapped against chronological age. The attributes measured vary according to an individual's age, and the accepted normal values vary within reference populations.			Intellectual Product	
C121664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121664>	C201170	Taminadenant|4-Pyrimidinamine, 5-Bromo-2,6-di-1H-pyrazol-1-yl-|A2AR Antagonist PBF-509|PBF-509|TAMINADENANT	An orally bioavailable adenosine A2A receptor (A2AR) antagonist, with potential antineoplastic activity. Upon administration, A2AR antagonist PBF-509 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This abrogates the adenosine/A2AR-mediated inhibition of T-lymphocytes and activates a T-cell-mediated immune response against tumor cells, thereby reducing proliferation of susceptible tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often produced in excess by cancer cells.	Taminadenant		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121665>	C1946|C129825	HDAC Inhibitor OBP-801|Histone Deacetylase Inhibitor OBP-801|OBP-801|OBP-801|YM753	An inhibitor of histone deacetylase (HDAC) enzymes, with potential antineoplastic activity. Upon administration, OBP-801 inhibits the activity of HDACs; this results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. This leads to selective transcription of tumor suppressor genes, tumor suppressor protein-mediated inhibition of tumor cell division and induction of tumor cell apoptosis. This may inhibit proliferation of susceptible tumor cells. HDAC, which is upregulated in many tumor cell types, deacetylates chromatin histone proteins.	HDAC Inhibitor OBP-801		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121667>	C1291	Inotersen|INOTERSEN|IONIS TTRRx|ISIS 420915|ISIS-TTR Rx|ISIS-TTRRx|TTR ASO ISIS-TTR Rx	An antisense oligonucleotide (ASO) targeting transthyretin (TTR), which has potential use in the treatment of TTR amyloidosis (ATTR). Upon subcutaneous administration, inotersen targets and binds to messenger RNA (mRNA) for both variant and wild-type forms of TTR inside liver cells, thereby inhibiting translation of both mutant and wild-type TTR. Inhibition of TTR protein synthesis lowers TTR blood levels and decreases the amount of and/or prevents TTR amyloid deposits, which accumulate in and cause damage to various body organs and tissues. ATTR is caused by mutations in the TTR gene, which lead to TTR protein misfolding; misfolded wild-type and mutant forms of TTR protein accumulate in tissues as amyloid deposits in most ATTR patients.	Inotersen		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C121668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121668>	C45474	Pseudomyogenic Hemangioendothelioma|Epithelioid Sarcoma-Like Hemangioendothelioma|Pseudomyogenic (Epithelioid Sarcoma-Like) Hemangioendothelioma	An intermediate, rarely metastasizing blood vessel neoplasm that more frequently affects young adult males and usually arises in the lower limbs.  In approximately half of the affected patients the tumor is painful and in two-thirds of the patients the tumor is multifocal.  Morphologically it is characterized by the presence of sheets and fascicles of spindle cells with abundant eosinophilic cytoplasm and vesicular nuclei.  Cytologic atypia is usually mild.  Approximately 60% of the patients develop local recurrences or additional tumors in the same anatomic region.			Neoplastic Process	Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology|NCIt Neoplasm Core Terminology
C121669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121669>	C26836	Disordered Eating	Abnormal eating behaviors, including binge eating, compulsive eating, emotional eating, night eating, and self-induced vomiting, though not at a level that rises to the diagnosis of eating disorder.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C12166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12166>	C61063	Interferon Alfa/Temozolomide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121670>	C36346	WWTR1-CAMTA1 Fusion Protein Expression	A fusion protein that results from a t(1;3)(p36;q23-25).  This fusion protein expression is seen in virtually all cases of epithelioid hemangioendothelioma and is unique to this neoplasm.			Cell or Molecular Dysfunction	
C121671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121671>	C9306|C3088	Soft Tissue Angiosarcoma|Angiosarcoma of Soft Tissue	An angiosarcoma that arises from the soft tissues, usually in the deep muscles of the lower extremities, retroperitoneum, mediastinum, and mesentery.			Neoplastic Process	
C121672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121672>	C28510	WWTR1/CAMTA1 Fusion Gene|TAZ-CAMTA1 Fusion Gene|TAZ/CAMTA1 Fusion Gene|WW Domain Containing Transcription Regulator 1-Calmodulin Binding Transcription Activator 1 Fusion Gene|WW Domain Containing Transcription Regulator 1/Calmodulin Binding Transcription Activator 1 Fusion Gene|WWTR1-CAMTA1 Fusion Gene|WWTR1::CAMTA1 Fusion Gene	A fusion gene that results from a chromosomal translocation t(1;3)(p36;q23-25) which fuses the first 2, 3 or 4 exons of the WWTR1 gene to the upstream side of either exon 8 or exon 9 of the CAMTA1 gene. This fusion is associated with epithelioid hemangioendothelioma.	WWTR1/CAMTA1 Fusion Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C121673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121673>	C17561	WWTR1/CAMTA1 Fusion Protein|WW Domain-Containing Transcription Regulator Protein 1-Calmodulin-Binding Transcription Activator 1 Fusion Protein|WW Domain-Containing Transcription Regulator Protein 1/Calmodulin-Binding Transcription Activator 1 Fusion Protein|WWTR1-CAMTA1 Fusion Protein|WWTR1::CAMTA1 Fusion Protein	A fusion protein that is encoded by the WWTR1/CAMTA1 fusion gene. This protein contains the 14-3-3 protein binding domain and most or all of the WW domain from WW domain-containing transcription regulator protein 1 fused to the transcription factor immunoglobulin-like DNA-binding domain, ankyrin repeats and IQ calmodulin-binding motifs from calmodulin-binding transcription activator 1.			Amino Acid, Peptide, or Protein	
C121674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121674>	C4909	Peritumoral Brain Edema|PTBE	An intracranial edema that develops around a tumor in the meninges or brain.	Peritumoral Brain Edema		Finding	CTRP Disease Terminology|CTRP Terminology
C121675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121675>	C53543	Rhizomelic Dysplasia	A form of skeletal dysplasia characterized by shortening of the bones of the proximal segments of the limbs (i.e. the humeri and femora).			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C121676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121676>	C28264	Radiofrequency-Guided Localization|RFID|RFID Localization|RFID-Guided Localization	A system consisting of an implantable radiofrequency identification (RFID) tag and a hand-held radiofrequency reader to preoperatively mark breast lesions and later surgically retrieve them.	Radiofrequency-Guided Localization		Conceptual Entity	CTRP Intervention Terminology|CTRP Terminology|FDA CDRH GUDID Terminology
C121677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121677>	C3269	Conventional Schwannoma	A common, usually encapsulated benign nerve sheath tumor composed of well-differentiated Schwann cells.			Neoplastic Process	
C121678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121678>	C43541|C4348	Non-Functioning Pituitary Neuroendocrine Tumor/Microadenoma|Non-Functioning PitNET/Microadenoma|Non-Functioning Pituitary Gland Microadenoma|Nonfunctional Pituitary Gland Microadenoma|Nonfunctional Pituitary Microadenoma|Nonfunctioning Pituitary Gland Microadenoma	A pituitary neuroendocrine tumor/microadenoma not associated with a hormonal syndrome.			Neoplastic Process	NICHD Terminology|Pediatric Endocrinology Terminology
C121679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121679>	C8388|C43541	Functioning Pituitary Neuroendocrine Tumor/Microadenoma|Functional Pituitary Microadenoma|Functioning PitNET/Microadenoma|Functioning Pituitary Gland Microadenoma	A pituitary neuroendocrine tumor/microadenoma associated with a hormonal syndrome.			Neoplastic Process	NICHD Terminology|Pediatric Endocrinology Terminology
C12167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12167>	C61063	IDEC-Y2B8 Monoclonal Antibody/Rituximab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121680>	C7158|C7018|C4479	Dermal Nerve Sheath Myxoma	A benign neoplasm with nerve sheath features that arises from the dermis and subcutaneous tissue. It manifests as an asymptomatic nodule and most often arises from the extremities. It is composed of spindle and epithelioid cells in a myxoid stroma.			Neoplastic Process	
C121681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121681>	C4972|C4789	Solitary Circumscribed Neuroma|Palisaded Encapsulated Neuroma|SCN	A benign peripheral nerve sheath tumor characterized by the presence of Schwann cells, axons, and perineurial fibroblasts.  It usually arises from the skin of the head and neck or the oral mucosa.  It presents as a solitary and painless nodular mass.			Neoplastic Process	NCIt Neoplasm Core Terminology
C121682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121682>	C3075	Meningothelial Hamartoma	A hamartoma characterized by the presence of collections of non-neoplastic arachnoidal cells.			Disease or Syndrome	
C121683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121683>	C20993	PROMIS-43 Adult Profile v2.0|PROMIS 43 Adult Profile v2.0|PROMIS-43|PROMIS-43 Profile|PROMIS-43 Profile v2.0	A 43-item multidimensional and universal measure of health intended for use across a variety of conditions. It measures an adult patient's self-reported health status in seven domains: physical function, anxiety, depression, fatigue, sleep disturbance, pain interference, and participation in social roles.			Intellectual Product	
C121684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121684>	C173458	Ability to do Vacuuming and Yardwork Question|Ability to do Household Chores|Ability to do Vacuuming and Yardwork|Able to do Household Chores|Able to do Vacuuming and Yardwork|Are you able to do chores such as vacuuming or yard work	A question about the ability of an individual to do chores such as vacuuming and yardwork.			Intellectual Product	PROMIS-43 Adult Profile v2.0
C121685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121685>	C173082	Ability to Go Up and Down Stairs at a Normal Pace Question|Ability to Go Up and Down Stairs at a Normal Pace|Able to Go Up and Down Stairs at a Normal Pace|Are you able to go up and down stairs at a normal pace	A question about the ability of an individual to go up and down stairs at a normal pace.			Intellectual Product	PROMIS-43 Adult Profile v2.0
C121686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121686>	C6930|C4972|C4789	Hybrid Nerve Sheath Tumor|HNST|Hybrid Nerve Sheath Neoplasm	A benign nerve sheath tumor characterized by the combination of histologic features seen in schwannomas, neurofibromas, and perineuriomas.			Neoplastic Process	NCIt Neoplasm Core Terminology
C121687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121687>	C3075	Benign Triton Tumor|Ectomesenchymal Hamartoma|NMC|Nerve Rhabdomyoma|Neuromuscular Choristoma|Neuromuscular Hamartoma|Rhabdomyoma/Choristoma	A very rare intraneural mass in a large nerve characterized by the interposition of mature skeletal muscle fibers and nerve fibers.			Disease or Syndrome	
C121688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121688>	C36282|C132486	Nasal Glial Heterotopia|Ectopic Glial Tissue|Glial Choristoma|Nasal Glioma|Neuroglial Heterotopia	A collection of heterotopic neuroglial tissue which is isolated from the cranial cavity, usually located in or around the nose. Complete excision is curative.			Finding	
C121689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121689>	C156133	Ability to Walk for Fifteen Minutes Question|Ability to Walk for Fifteen Minutes|Ability to Walk for at least Fifteen Minutes|Able to Walk for Fifteen Minutes|Able to Walk for at least Fifteen Minutes|Are you able to go for a walk of at least 15 minutes	A question about the ability of an individual to go for a walk of at least fifteen minutes.			Intellectual Product	PROMIS-43 Adult Profile v2.0
C12168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12168>	C61063	Aspirin/Clopidogrel Bisulfate			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121690>	C173458	Ability to Run Errands and Shop Question|Ability to Run Errands and Shop|Able to Run Errands and Shop|Are you able to run errands and shop	A question about the ability of an individual to run errands and shop.			Intellectual Product	PROMIS-43 Adult Profile v2.0
C121691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121691>	C173509|C173458|C173090	Current Health Limits Doing Two Hours of Physical Labor Question|Current Health Limits Doing Two Hours of Physical Labor|Does your health now limit you in doing two hours of physical labor	A question about whether an individual's health now limits them in doing two hours of physical labor.			Intellectual Product	PROMIS-43 Adult Profile v2.0
C121692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121692>	C173924|C173509|C173090	Current Health Limits Doing Moderate Work Around the House Question|Current Health Limits Doing Moderate Work Around the House|Does your health now limit you in doing moderate work around the house like vacuuming, sweeping floors or carrying in groceries	A question about whether an individual's health now limits them in doing moderate work around the house.			Intellectual Product	PROMIS-43 Adult Profile v2.0
C121693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121693>	C173160	Feel Fearful Question|Feel Fearful|Felt Fearful|I felt fearful	A question about whether an individual feels or felt fearful.			Intellectual Product	Center for Epidemiologic Studies Depression Scale|PROMIS-43 Adult Profile v2.0
C121694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121694>	C173398	Trouble Focusing Except on Anxiety Question|Hard to Focus Except on Anxiety|I found it hard to focus on anything other than my anxiety|Trouble Focusing Except on Anxiety	A question about whether an individual finds or found it hard to focus on anything other than their anxiety.			Intellectual Product	PROMIS-43 Adult Profile v2.0
C121695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121695>	C173934	Worries Overwhelm Me Question|My worries overwhelmed me|Worries Overwhelm Me|Worries Overwhelmed Me	A question about whether an individual's worries overwhelmed them.			Intellectual Product	PROMIS-43 Adult Profile v2.0
C121696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121696>	C173160	Feel Uneasy Question|Feel Uneasy|Felt Uneasy|I felt uneasy	A question about whether an individual feels or felt uneasy.			Intellectual Product	PROMIS-43 Adult Profile v2.0
C121697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121697>	C173386	Feel Like Help is Needed for Anxiety Question|Feel Like Help is Needed for Anxiety|I felt like I needed help for my anxiety	A question about whether an individual feels or felt like they need help for their anxiety.			Intellectual Product	PROMIS-43 Adult Profile v2.0
C121698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121698>	C173160	Feel Worthless Question|Feel Worthless|Felt Worthless|I felt worthless	A question about whether an individual feels or felt worthless.			Intellectual Product	PROMIS-43 Adult Profile v2.0
C121699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121699>	C173160	Feel Helpless Question|Feel Helpless|Felt Helpless|I felt helpless	A question about whether an individual feels or felt helpless.			Intellectual Product	PROMIS-43 Adult Profile v2.0
C12169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12169>	C61063	Cytarabine/Dexamethasone/Ifosfamide/Leucovorin Calcium/Methotrexate/Teniposide/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1216>	C804	Retinyl Acetate|Retinol Acetate|Retinyl acetate|VITAMIN A ACETATE|Vitamin A, acetate|vitamin A acetate	A naturally-occurring fatty acid ester form of retinol (vitamin A) with potential antineoplastic and chemopreventive activities.  Retinyl acetate binds to and activates retinoid receptors, inducing cell differentiation and decreasing cell proliferation.  This agent also inhibits carcinogen-induced neoplastic transformation in some cancer cell types and exhibits immunomodulatory properties. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121700>	C173160	Feel Hopeless Question|Feel Hopeless|Felt Hopeless|I felt hopeless	A question about whether an individual feels or felt hopeless.			Intellectual Product	PROMIS-43 Adult Profile v2.0
C121701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121701>	C173160	Run Down Feeling on Average Question|How run down did you feel on average|Run Down Feeling on Average	A question about the degree that an individual feels or felt run down on average.			Intellectual Product	PROMIS Adult Physical Health Domain|PROMIS-43 Adult Profile v2.0
C121703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121703>	C173347|C172982	Bothered by Fatigue on Average Question|Bothered by Fatigue on Average|How much were you bothered by fatigue on average	A question about how much an individual is or was bothered by fatigue on average.			Intellectual Product	PROMIS-43 Adult Profile v2.0
C121704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121704>	C173584|C173347	Fatigue Interference with Physical Function Question|Degree Fatigue Interfered with Physical Functioning|Fatigue Interference with Physical Function|To what degree did your fatigue interfere with your physical functioning	A question about the degree to which an individual's fatigue interferes or interfered with their physical functioning.			Intellectual Product	PROMIS Adult Physical Health Domain|PROMIS Short Form v1.0 - Fatigue 8a|PROMIS-43 Adult Profile v2.0
C121705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121705>	C173925	Sleep Quality Question|Insomnia|Insomnia Distress|My sleep quality was|Sleep Quality	A question about an individual's sleep quality.			Intellectual Product	PROMIS-43 Adult Profile v2.0|Symptom Distress Scale
C121706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121706>	C173925	Refreshing Sleep Question|My sleep was refreshing|Refreshing Sleep|Sleep Was Refreshing	A question about whether an individual's sleep is or was refreshing.			Intellectual Product	PROMIS-43 Adult Profile v2.0
C121707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121707>	C173925	Problem with Sleep Question|Have Problem with Sleep|I had a problem with my sleep|Problem with Sleep	A question about whether an individual has or had a problem with their sleep.			Intellectual Product	PROMIS-43 Adult Profile v2.0
C121708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121708>	C173925|C173398	Difficulty Falling Asleep Question|Difficulty Falling Asleep|Have Difficulty Falling Asleep|I had difficulty falling alseep.|I had difficulty falling asleep	A question about whether an individual has or had difficulty falling asleep.			Intellectual Product	PROMIS-43 Adult Profile v2.0
C121709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121709>	C173925	Sleep is Restless Question|My sleep was restless|Sleep Was Restless|Sleep is Restless	A question about whether an individual's sleep is or was restless.			Intellectual Product	Center for Epidemiologic Studies Depression Scale|PROMIS-43 Adult Profile v2.0
C12170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12170>	C61063	Cyclophosphamide/Dexamethasone/Doxorubicin/Leucovorin Calcium/Methotrexate/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121710>	C173925	Try Hard to Get to Sleep Question|I tried hard to get to sleep|Try Hard to Get to Sleep	A question about whether an individual tries or tried hard to get to sleep.			Intellectual Product	PROMIS-43 Adult Profile v2.0
C121711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121711>	C20401	Neihulizumab|AbGn 168H|AbGn-168|AbGn-168H|NEIHULIZUMAB	A humanized, agonistic monoclonal antibody against P selectin glycoprotein ligand-1 (PSGL-1; SELPLG; CD162), with potential immunosuppressive activity. Upon administration, neihulizumab specifically targets and binds to CD162 expressed on activated T-lymphocytes. This induces apoptosis of activated T-cells and reduces T-cell-mediated immune responses. This may halt disease progression of T-cell-mediated autoimmune diseases and acute graft-versus-host disease (GvHD).	Neihulizumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C121712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121712>	C19747	Prostate Mechanical Imager|PMI|Prostate Mechanical Imaging	A transrectal probe equipped with a pressure sensor array and position tracking sensor that translates the prostate's elastic properties into a digital three-dimensional map of the tested organ. Similar in concept to digital rectal examination (DRE), PMI can minimize subjectivity by providing an easy-to-use and accurate tool for visualizing abnormalities of the prostate.	Prostate Mechanical Imager		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C121713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121713>	C66760|C6587	Superficial Acral Fibromyxoma|Acral Fibromyxoma|Cellular Digital Fibroma|Digital Fibromyxoma|SAF	A benign fibroblastic neoplasm that arises from acral sites, usually the periungual area of the digits.  It is characterized by the proliferation of spindled and stellate-shaped fibroblasts in the dermis in a myxoid or collagenous stroma.  Nuclear atypia is usually minimal.  It usually presents as a solitary and slow-growing dome-shaped mass on a digit. The recurrence rate is low.			Neoplastic Process	
C121714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121714>	C173398	Have Trouble Doing Regular Leisure Activities with Others Question|Have Trouble Doing All Regular Leisure Activities with Others|Have Trouble Doing Regular Leisure Activities with Others|I have trouble doing all my regular leisure activities with others|Trouble Doing Regular Leisure Activities with Others	A question about whether an individual has or had trouble doing all of their regular leisure activities with others.			Intellectual Product	PROMIS-43 Adult Profile v2.0
C121715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121715>	C173398|C173151	Have Trouble Doing Regular Family Activities Question|Have Trouble Doing All Regular Family Activities|Have Trouble Doing Regular Family Activities|I have trouble doing all of the family activities that I want to do|Trouble Doing Regular Family Activities	A question about whether an individual has or had trouble doing all of the family activities that they want to do.			Intellectual Product	PROMIS-43 Adult Profile v2.0
C121716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121716>	C173924|C173398	Have Trouble Doing Usual Work Question|Have Trouble Doing All Usual Work|Have Trouble Doing Usual Work|I have trouble doing all of my usual work (include work at home)|Trouble Doing Usual Work	A question about whether an individual has or had trouble doing all of their usual work.			Intellectual Product	PROMIS-43 Adult Profile v2.0
C121717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121717>	C173398	Have Trouble Doing Activities with Friends Question|Have Trouble Doing Activities with Friends|Have Trouble Doing All Activities with Friends|I have trouble doing all of the activities with friends that I want to do|Trouble Doing Activities with Friends	A question about whether an individual has or had trouble doing all of the activities with friends that they want to do.			Intellectual Product	PROMIS-43 Adult Profile v2.0
C121718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121718>	C173695	Have to Limit Things Done for Fun with Others Question|Have to Limit Things Done for Fun with Others|I have to limit the things I do for fun with others	A question about whether an individual has or had to limit the things they do for fun with others.			Intellectual Product	PROMIS-43 Adult Profile v2.0
C121719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121719>	C27567	Lymphocytic Neurohypophysitis	An autoimmune condition affecting the posterior pituitary gland, which is characterized by lymphocytic infiltration, and which often presents as diabetes insipidus.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C12171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12171>	C61063	Bexarotene/Carboplatin/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121720>	C8388|C43542	Functioning Pituitary Neuroendocrine Tumor/Macroadenoma|Functional Pituitary Macroadenoma|Functioning PitNET/Macroadenoma|Functioning Pituitary Gland Macroadenoma	A pituitary neuroendocrine tumor/macroadenoma associated with a hormonal syndrome.			Neoplastic Process	NICHD Terminology|Pediatric Endocrinology Terminology
C121721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121721>	C43542|C4348	Non-Functioning Pituitary Neuroendocrine Tumor/Macroadenoma|Non-Functioning PitNET/Macroadenoma|Non-Functioning Pituitary Gland Macroadenoma|Non-Functioning Pituitary Gland Macroadenoma|Nonfunctional Pituitary Gland Macroadenoma|Nonfunctional Pituitary Macroadenoma|Nonfunctioning Pituitary Gland Macroadenoma	A pituitary neuroendocrine tumor/macroadenoma not associated with a hormonal syndrome.			Neoplastic Process	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C121722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121722>	C173695	Have to Limit Regular Activities with Friends Question|Have to Limit Regular Activities with Friends|I have to limit my regular activities with friends	A question about whether an individual has or had to limit their regular activities with friends.			Intellectual Product	PROMIS-43 Adult Profile v2.0
C121723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121723>	C217121|C20995	PROMIS Pain Rating Scale|PROMIS Pain Rating Linear Analogue Scale	A linear analogue scale for the subjective scoring of a person's average pain rating for the past seven days that ranges from 0: No pain to 10: Worst imaginable pain.			Intellectual Product	PROMIS-43 Adult Profile v2.0
C121724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121724>	C175256	Pain Rating Average Score 0	A subjective score of 0 on a scale for average pain that ranges from 0: No Pain to 10: Worst imaginable pain.			Intellectual Product	PROMIS Pain Rating Scale
C121725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121725>	C175256	Pain Rating Average Score 1	A subjective score of 1 on a scale for average pain that ranges from 0: No Pain to 10: Worst imaginable pain.			Intellectual Product	PROMIS Pain Rating Scale
C121726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121726>	C175256	Pain Rating Average Score 2	A subjective score of 2 on a scale for average pain that ranges from 0: No Pain to 10: Worst imaginable pain.			Intellectual Product	PROMIS Pain Rating Scale
C121727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121727>	C26800	Compensated Hypothyroidism	Hypothyroidism characterized by elevated thyroid-stimulating hormone (TSH) with normal circulating concentrations of thyroid hormones.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C121728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121728>	C175256	Pain Rating Average Score 3	A subjective score of 3 on a scale for average pain that ranges from 0: No Pain to 10: Worst imaginable pain.			Intellectual Product	PROMIS Pain Rating Scale
C121729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121729>	C175256	Pain Rating Average Score 4	A subjective score of 4 on a scale for average pain that ranges from 0: No Pain to 10: Worst imaginable pain.			Intellectual Product	PROMIS Pain Rating Scale
C12172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12172>	C61063	Doxorubicin/Motexafin Gadolinium			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121730>	C175256	Pain Rating Average Score 5	A subjective score of 5 on a scale for average pain that ranges from 0: No Pain to 10: Worst imaginable pain.			Intellectual Product	PROMIS Pain Rating Scale
C121731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121731>	C175256	Pain Rating Average Score 6	A subjective score of 6 on a scale for average pain that ranges from 0: No Pain to 10: Worst imaginable pain.			Intellectual Product	PROMIS Pain Rating Scale
C121732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121732>	C175256	Pain Rating Average Score 7	A subjective score of 7 on a scale for average pain that ranges from 0: No Pain to 10: Worst imaginable pain.			Intellectual Product	PROMIS Pain Rating Scale
C121733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121733>	C175256	Pain Rating Average Score 8	A subjective score of 8 on a scale for average pain that ranges from 0: No Pain to 10: Worst imaginable pain.			Intellectual Product	PROMIS Pain Rating Scale
C121734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121734>	C175256	Pain Rating Average Score 9	A subjective score of 9 on a scale for average pain that ranges from 0: No Pain to 10: Worst imaginable pain.			Intellectual Product	PROMIS Pain Rating Scale
C121735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121735>	C175256	Pain Rating Average Score 10	A subjective score of 10 on a scale for average pain that ranges from 0: No Pain to 10: Worst imaginable pain.			Intellectual Product	PROMIS Pain Rating Scale
C121736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121736>	C226656|C226559|C176243	Can Do Without Any Difficulty|No Difficulty|No difficulty|No difficulty at all|Without Any Difficulty|Without any difficulty	A response indicating that an individual is able to do something without any difficulty.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form|PROMIS-43 Adult Profile v2.0
C121737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121737>	C226656|C226559|C176243	Can Do With a Little Difficulty|A Little Difficulty|A little bit of difficulty|A little difficulty|Little bit hard|With a Little Difficulty|With a little difficulty	A response indicating that an individual is able to do something with a little difficulty.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form|PROMIS-43 Adult Profile v2.0
C121738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121738>	C7653|C7148	Intermediate Soft Tissue Neoplasm of Uncertain Differentiation|Intermediate Soft Tissue Tumor of Uncertain Differentiation	A soft tissue neoplasm of uncertain differentiation which is locally aggressive but rarely metastasizes.			Neoplastic Process	
C121739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121739>	C226656|C226559|C176243	Can Do With Some Difficulty|Little more hard|Some Difficulty|Some difficulty|With Some Difficulty|With some difficulty	A response indicating that an individual is able to do something with some difficulty.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form|PROMIS-43 Adult Profile v2.0
C12173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12173>	C61063	Carboplatin/UCN-01			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121740>	C226656|C226559|C176243	Can Do With Much Difficulty|A lot of difficulty|Even harder|Much Difficulty|Much difficulty|With Much Difficulty|With much difficulty	A response indicating that an individual is able to do something with much difficulty.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form|PROMIS-43 Adult Profile v2.0
C121741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121741>	C113144	Hypothalamic Hypothyroidism|Tertiary Hypothyroidism	Hypothyroidism due to dysfunction of the hypothalamus, assumed to result in reduced secretion of thyrotropin- releasing hormone.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C121742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121742>	C226656	Unable to Do|Not Able|Not Able to Do|Not able to do|Not at All|Not at All Able|Unable To|Unable to do|unable	A response indicating that an individual is unable to do something.			Intellectual Product	Bowel Function Diary for Assessing Opioid-Induced Constipation|PROMIS-43 Adult Profile v2.0|QuickDASH Outcome Measure|Rotterdam Symptom Checklist
C121743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121743>	C113144	Pituitary Hypothyroidism	Hypothyroidism due to dysfunction of the pituitary gland, which results in inadequate secretion of thyroid-stimulating hormone (thyrotropin).			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C121744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121744>	C226559	Cannot Do|Can't Do|Cannot do|I cannot do this	A response indicating that an individual cannot do something.			Intellectual Product	PROMIS-43 Adult Profile v2.0
C121745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121745>	C26734	Pendred Syndrome	A condition associated with reduced export of iodide across the apical membrane of the follicular cells of the thyroid gland that may progress to hypothyroidism. Pendred syndrome is associated with an increased risk of goiter and sensorineural hearing loss due to malformations of the inner ear (vestibular system). Inactivating mutations in the SLC26A4 gene encoding the pendrin transport protein are responsible for the condition.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C121746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121746>	C226559	Can Do Very Little|Very little	A response indicating that an individual is able to do something for the smallest amount of effort or duration of time.			Intellectual Product	PROMIS-43 Adult Profile v2.0
C121747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121747>	C26734	Iodide Transport Defect	A condition associated with reduced active import of iodide across the basolateral membrane of the follicular cells of the thyroid gland. Inactivating mutations in the SLC5A5 gene encoding the sodium-iodide symporter are responsible for the condition.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C121748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121748>	C26734	Dual Oxidase 2 Deficiency	Thyroid peroxidase system defect due to presumed mutation(s) in the DUOX2 gene, resulting in decreased activity of dual oxidase 2.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C121749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121749>	C26734	Thyroglobulin Deficiency	Subnormal production of thyroglobulin, the glycoprotein precursor of thyroid hormones, presumed to result from loss-of-function mutation(s) in the TG gene.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C12174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12174>	C61063	Isotretinoin/Sargramostim			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121750>	C26734	Thyroid Peroxidase Deficiency	Thyroid peroxidase system defect due to presumed mutation(s) in the TPO gene, resulting in decreased activity of thyroid peroxidase.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C121751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121751>	C26734	Thyroid Dyshormonogenesis|Dyshormonogenesis	A defect in any step of the biochemical pathway leading to production of thyroid hormones.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C121752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121752>	C121738	Hemosiderotic Fibrolipomatous Tumor|HFLT|Hemosiderotic Fibrohistiocytic Lipomatous Lesion	A non-encapsulated, slow-growing, locally aggressive subcutaneous tumor characterized by the presence of adipocytes, hemosiderin-laden spindle cells, hemosiderin-laden macrophages, osteoclast-like giant cells, and scattered chronic inflammatory cells. It usually arises from the dorsum of the foot, ankle, dorsum of the hand, thigh, calf, or cheek.  It may recur if it is not completely excised but does not metastasize.			Neoplastic Process	
C121753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121753>	C173160	Feel Like a Failure Question|Feel Like a Failure|Felt Like a Failure|I felt like a failure	A question about whether an individual feels or felt like a failure.			Intellectual Product	PROMIS-43 Adult Profile v2.0
C121754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121754>	C173160	Feel Unhappy Question|Feel Unhappy|Felt Unhappy|I felt unhappy	A question about whether an individual feels or felt unhappy.			Intellectual Product	PROMIS-43 Adult Profile v2.0
C121755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121755>	C173737|C173593|C173358	Past Seven Days Frequency of Arm or Leg Swelling Question|Frequency of Arm or Leg Swelling Past Seven Days|How often did you have arm or leg swelling|Past Seven Days Frequency of Arm or Leg Swelling	A question about the frequency of an individual's arm or leg swelling during the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C121756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121756>	C173603|C173593	Worst Severity Past Seven Days Arm or Leg Swelling Question|What was the severity of your arm or leg swelling at its worst|Worst Severity Past Seven Days Arm or Leg Swelling|Worst Severity of Arm or Leg Swelling Past Seven Days	A question about the worst severity of an individual's arm or leg pain during the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C121757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121757>	C173787|C173737|C173593|C173584	Past Seven Days Arm or Leg Swelling Interfering with Usual or Daily Activities Question|Arm or Leg Swelling Interfering with Usual or Daily Activities Past Seven Days|How much did arm or leg swelling interfere with your usual or daily activities|Past Seven Days Arm or Leg Swelling Interfering with Usual or Daily Activities	A question about how much an individual's arm or leg pain interfered with their usual or daily activities during the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C121758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121758>	C173737|C173358	Past Seven Days Frequency of Shortness of Breath Question|Frequency of Shortness of Breath Past Seven Days|How often did you have shortness of breath|Past Seven Days Frequency of Shortness of Breath	A question about the frequency of an individual's shortness of breath during the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C121759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121759>	C173603	Worst Severity Past Seven Days Shortness of Breath Question|What was the severity of your shortness of breath at its worst|Worst Severity Past Seven Days Shortness of Breath|Worst Severity of Shortness of Breath Past Seven Days	A question about the worst severity of an individual's shortness of breath during the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C12175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12175>	C61063	Cyclophosphamide/Fluorouracil/Methotrexate/Trastuzumab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121760>	C173787|C173737|C173584	Past Seven Days Shortness of Breath Interfering with Usual or Daily Activities Question|How much did your shortness of breath interfere with your usual or daily activities|Past Seven Days Shortness of Breath Interfering with Usual or Daily Activities|Shortness of Breath Interfering with Usual or Daily Activities Past Seven Days	A question about how much an individual's shortness of breath interfered with their usual or daily activities during the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C121761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121761>	C173603|C172828	Worst Severity Past Seven Days Itchy Skin Question|What was the severity of your itchy skin at its worst|Worst Severity Past Seven Days Itchy Skin|Worst Severity of Itchy Skin Past Seven Days	A question about the worst severity of an individual's itchy skin during the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C121762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121762>	C173603|C173134	Worst Severity Past Seven Days Cough Question|What was the severity of your cough at its worst|Worst Severity Past Seven Days Cough|Worst Severity of Cough Past Seven Days	A question about the worst severity of an individual's cough during the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C121763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121763>	C173787|C173737|C173584|C173134	Past Seven Days Cough Interfering with Usual or Daily Activities Question|Cough Interfering with Usual or Daily Activities Past Seven Days|How much does your cough interfere with your usual or daily activities|Past Seven Days Cough Interfering with Usual or Daily Activities	A question about how much an individual's cough interfered with their usual or daily activities during the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C121764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121764>	C173737|C173358	Past Seven Days Frequency of Headache Question|Frequency of Headache Past Seven Days|How often did you have a headache|Past Seven Days Frequency of Headache	A question about the frequency of an individual's headaches over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C121765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121765>	C173603	Worst Severity Past Seven Days Headache Question|What was the severity of your headache at its worst|Worst Severity Past Seven Days Headache|Worst Severity of Headache Past Seven Days	A question about an individual's observation of the worst severity they have experienced related to headache over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C121766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121766>	C173787|C173737|C173584	Past Seven Days Headache Interfering with Usual or Daily Activities Question|Headache Interfering with Usual or Daily Activities Past Seven Days|How Much Headache Interfered with Usual or Daily Activities|How much did your headache interfere with your usual or daily activities|Past Seven Days Headache Interfering with Usual or Daily Activities|Past Seven Days How Much Headache Interfered with Usual or Daily Activities	A question about how much an individual's headaches interfered with their usual or daily activities during the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C121767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121767>	C107406	Past Seven Days Frequency of Pain in the Abdomen Question|Frequency of Abdominal Pain Past Seven Days|Frequency of Pain in the Abdomen Past Seven Days|How often did you have pain in the abdomen (belly)|Past Seven Days Frequency of Pain in the Abdomen	A question about the frequency of an individual's abdominal pain during the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C121768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121768>	C107407	Worst Severity Past Seven Days Pain in the Abdomen Question|What was the severity of your pain in the abdomen (belly) at its worst|Worst Severity Past Seven Days Pain in the Abdomen|Worst Severity of Abdominal Pain Past Seven Days|Worst Severity of Pain in the Abdomen Past Seven Days	A question about the worst severity of an individual's abdominal pain during the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C121769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121769>	C107408	Past Seven Days Pain in the Abdomen Interfering with Usual or Daily Activities Question|Abdominal Pain Interfering with Usual or Daily Activities Past Seven Days|How much did pain in the abdomen (belly) interfere with your usual or daily activities|Pain in the Abdomen Interfering with Usual or Daily Activities Past Seven Days|Past Seven Days Pain in the Abdomen Interfering with Usual or Daily Activities	A question about how much an individual's abdominal pain interfered with their usual or daily activities during the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C12176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12176>	C61063	Cisplatin/Fluoxetine/Gemcitabine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121771>	C48966	Myelin-Associated Glycoprotein Antibody|Anti-MAG|Anti-MAG Antibody|Anti-Myelin-Associated Glycoprotein Antibody|MAG Antibody|Myelin-Associated Glycoprotein Autoantibody|Myelin-associated glycoprotein antibody	An autoantibody directed against myelin-associated glycoprotein (MAG). It is associated with active demyelination in peripheral neuropathy and is detected in about 50% of patients with IgM paraproteinemia and may occur in some patients with multiple sclerosis, Guillain-Barre syndrome, chronic polyneuropathy, or myasthenia gravis.	Myelin-Associated Glycoprotein Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C121772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121772>	C36346	EWSR1-CREB1 Fusion Protein Expression	Expression of fusion protein EWSR1-CREB1 resulting from a t(2;22)(q33;q12).  It is present in the vast majority of angiomatoid fibrous histiocytoma cases.			Cell or Molecular Dysfunction	
C121773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121773>	C201855	Gallium Ga 68-labeled RM2|(68)Ga-DOTA-4-amino-1-carboxymethylpiperidine-d-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2|68-Ga RM2|68Ga-Bombesin Antagonist BAY86-7548|68Ga-DOTA RM2|68Ga-DOTA-Bombesin Analog BAY86-7548|68Ga-RM2|BAY 86-7548|Ga-68-labeled Bombesin Antagonist BAY 86-7548|Gallium Ga 68-labeled GRPR Antagonist BAY86-7548|Gallium Ga68-labeled GRPR Antagonist RM2|RM-2 GA-68|[68Ga]-labeled Bombesin Analog BAY86-7548|[68Ga]RM2	A radioconjugate containing a synthetic bombesin receptor antagonist targeting the gastrin-releasing peptide receptor (GRPR), that is linked by the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to the radionuclide gallium (Ga) 68, with potential use in diagnostic imaging using positron emission tomography/computed tomography (PET/CT). Upon administration of gallium Ga 68 GRPR antagonist BAY86-7548, the peptide moiety targets and binds to GRPR. Upon PET/CT, GRPR-expressing tumor cells can then be visualized. GRPR, also called bombesin receptor 2 (BB2), is a G protein-coupled seven-transmembrane receptor belonging to the bombesin receptor family. It is overexpressed in certain types of cancers.	Gallium Ga 68-labeled RM2		Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C121774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121774>	C6588|C6582	Malignant Ossifying Fibromyxoid Tumor|Ossifying fibromyxoid tumor, malignant	An ossifying fibromyxoid tumor characterized by the presence of high grade nuclear features or increased cellularity and more than two mitotic figures per 50 HPFs.			Neoplastic Process	GDC Terminology|GDC Value Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C121775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121775>	C129822|C128037	Tislelizumab|BGB A317|BGB-A317|BGBA317|TISLELIZUMAB|Tevimbra|Tirelizumab|Tislelizumab-jsgr	A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tislelizumab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.	Tislelizumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121776>	C1663	Cancer Peptide Vaccine S-588410|S-588410	A cancer peptide vaccine containing five human leukocyte antigen (HLA)-A*2402-restricted epitope peptides derived from as of yet not disclosed oncoantigens, with potential immunostimulating and antineoplastic activities. Upon administration of the cancer peptide vaccine S-588410, the peptides may stimulate a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing the antigens. This decreases proliferation of susceptible tumor cells.			Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121777>	C39619|C1663	Androgen Receptor Ligand-binding Domain-encoding Plasmid DNA Vaccine MVI-118|AR LBD-encoding Plasmid DNA Vaccine MVI-118|MVI-118|pTVG-AR|pTVG-AR Vaccine	A cancer vaccine containing pTVG4 plasmid DNA encoding the human androgen receptor (AR) ligand-binding domain (LBD) (pTVG-AR), with potential immunostimulating and antineoplastic activities. Upon intradermal administration of AR LBD-encoding plasmid DNA vaccine MVI-118, the plasmid DNA vaccine expresses AR LBD and may stimulate the host immune system to generate a cytotoxic T-lymphocyte (CTL) response against AR LBD-expressing prostate cancer cells. This reduces proliferation of AR-expressing tumor cells. AR, a tumor-associated antigen (TAA) overexpressed in prostate cancer cells, plays a key role in the development and progression of prostate cancer; its expression is correlated with poor prognosis.			Immunologic Factor|Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121778>	C20401|C129822	Sotevtamab|AB-16B5|Anti-sCLU Monoclonal Antibody AB-16B5|SOTEVTAMAB	A humanized, immunoglobulin (Ig) G2 monoclonal antibody against the secreted form of human clusterin (sCLU) expressed by tumor cells, with potential antineoplastic and anti-metastatic activities. Upon administration, sotevtamab specifically binds to tumor-associated sCLU and inhibits its activity. This inhibits both the sCLU-mediated signal transduction pathways and epithelial-to-mesenchymal transition (EMT), which leads to the inhibition of tumor cell migration and invasion. In addition, sotevtamab enhances chemo-sensitivity. sCLU, a heterodimeric disulfide-linked glycoprotein overexpressed by various types of cancer cells, contributes to proliferation and survival of cancer cells, and stimulates tumor cell EMT.	Sotevtamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121779>	C483	Estriol Vaginal Gel|Blissel|Gelistrol	A vaginal gel formulation containing a very low concentration of the estrogen estriol, that can be used for hormone replacement. Upon topical application to the vagina, estriol maintains adequate levels of estrogen in the vagina, and decreases vaginal atrophy and its associated symptoms, such as vaginal dryness and itching.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C12177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12177>	C61063	Beta-Glucan/Monoclonal Antibody 3F8			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121780>	C52588	Chlorhexidine/Ethyl Alcohol Mouthwash|ChloraPrep|Chlorhexidine/Ethyl Alcohol Mouth Rinse	A mouthwash containing the biguanide chlorhexidine and ethyl alcohol, with topical antibacterial activity. Upon rinsing the oral cavity with the chlorhexidine/ethyl alcohol mouthwash, the positively charged chlorhexidine cation exerts its antibacterial activity through binding to the negatively charged microbial cell surface, which destroys the integrity of the cell membrane. This causes leakage of intracellular components leading to cell death. Ethyl alcohol denatures bacterial proteins, and dissolves and disrupts the bacterial lipid membrane, thereby killing the bacteria. This reduces oral colonization with harmful bacteria and may prevent oral mucositis.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C121781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121781>	C52588	Ethyl Alcohol Mouthwash|Ethyl Alcohol Mouth Rinse	A mouthwash containing ethyl alcohol, with topical antibacterial activity. Upon rinsing the oral cavity with the ethyl alcohol mouthwash, ethyl alcohol denatures bacterial proteins, and dissolves and disrupts the bacterial lipid membrane, thereby killing the bacteria. This reduces oral colonization with harmful bacteria and may prevent oral mucositis.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C121782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121782>	C201275|C200766	Anti-mesothelin iCasp9M28z CAR-transduced Autologous T Lymphocytes|iCasp9M28z T Cells	Genetically modified, autologous T-lymphocytes transduced with a retroviral vector encoding a chimeric antigen receptor (CAR) specific for mesothelin linked to the signaling domains for the co-stimulatory molecules CD28 and CD3 zeta, as well as the suicide gene inducible caspase 9 (iCasp9 or iC9), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, anti-mesothelin iCasp9M28z CAR-transduced autologous T lymphocytes specifically target and kill mesothelin-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, a dimerizing agent can be administered, which binds to the FKBP12-F36V drug-binding domain and activates caspase 9, resulting in the apoptosis of the administered T-cells. Mesothelin, a tumor-associated antigen, is overexpressed in a variety of cancer cell types.	Anti-mesothelin iCasp9M28z CAR-transduced Autologous T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121783>	C1966	Panitumumab-IRDye800|Panitumumab IRDye 800|RDye800-Panitumumab Conjugate	An imaging agent composed of panitumumab, a humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody, conjugated to the near-infrared (NIR) fluorescent dye IRDye800, that can potentially be used for the imaging of EGFR-expressing tumors. Upon administration of panitumumab-IRDye800, the panitumumab moiety targets and binds to EGFR expressed on tumor cells. Upon fluorescence imaging of IRDye800, the tumor cells can be detected.	Panitumumab-IRDye800		Indicator, Reagent, or Diagnostic Aid	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C121784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121784>	C200766	Anti-CEA-CAR Autologous T Lymphocytes|Autologous Anti-CEA CAR-T Cells	Autologous lymphocytes transduced with a retroviral vector encoding a chimeric antigen receptor (CAR) specific for the tumor-associated antigen human carcinoembryonic antigen (CEA), with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CEA-CAR autologous T-lymphocytes target and bind to tumor cells expressing CEA, which results in the cytotoxic T-lymphocyte (CTL)-mediated cell killing of CEA-expressing tumor cells. CEA is overexpressed in various tumor cell types.	Anti-CEA-CAR Autologous T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121785>	C173480	Ectomesenchymal Chondromyxoid Tumor|EMCMT	A rare, well circumscribed, non-encapsulated tumor that arises in the oral cavity, most often the anterior tongue.  It is characterized by the presence of round to spindle cells in a chondromyxoid or hyalinized stroma.  Recurrences have been observed in a minority of patients.			Neoplastic Process	
C121786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121786>	C7442|C6930	Mixed Tumor, Not Otherwise Specified|Mixed Tumor, NOS|Mixed tumor, NOS	A benign myoepithelioma characterized by the presence of a minor ductal component.			Neoplastic Process	GDC Terminology|GDC Value Terminology
C121787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121787>	C7596|C3729	Malignant Mixed Tumor, Not Otherwise Specified	A malignant myoepithelioma characterized by the presence of a minor ductal component.			Neoplastic Process	
C121788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121788>	C67237|C53684	Benign Phosphaturic Mesenchymal Tumor	A phosphaturic mesenchymal tumor with benign histologic features.  It may recur locally but does not metastasize.  Complete excision is curative.			Neoplastic Process	
C121789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121789>	C67237|C27005	Malignant Phosphaturic Mesenchymal Tumor|Phosphaturic mesenchymal tumor, malignant	A phosphaturic mesenchymal tumor characterized by the presence of nuclear atypia, high mitotic activity, increased cellularity, marked pleomorphism, and necrosis. It usually develops in lesions that have recurred locally and metastasizes to other sites.			Neoplastic Process	GDC Terminology|GDC Value Terminology
C12178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12178>	C61063	MUC-2-Globo H-KLH Conjugate Vaccine/QS21			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121790>	C38150	Sclerosing PEComa	A tumor with perivascular epithelioid cell differentiation characterized by the presence of cords of neoplastic cells in a densely collagenous stroma.			Neoplastic Process	
C121791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121791>	C6587|C38150	Benign PEComa|Benign PEComa, NOS|Benign PEComa, Not Otherwise Specified|Typical PEComa	A tumor with perivascular epithelioid cell differentiation characterized by the absence of pleomorphism and scarcity or absence of mitotic figures.			Neoplastic Process	Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C121792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121792>	C6588|C38150	Malignant PEComa|PEComa, malignant|Perivascular epithelioid cell tumor, malignant	A usually large and aggressive tumor with perivascular epithelioid cell differentiation characterized by the presence of marked nuclear atypia, pleomorphism, increased mitotic activity, necrosis, and infiltrative margins.  The most common metastatic sites are liver, lungs, lymph nodes, and bone.			Neoplastic Process	GDC Terminology|GDC Value Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C121793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121793>	C9306	Undifferentiated Soft Tissue Sarcoma|USTS|Undifferentiated Sarcoma|Undifferentiated sarcoma|Undifferentiated/Unclassified Sarcoma|Undifferentiated/Unclassified Soft Tissue Sarcoma	A term that refers to a heterogeneous group of uncommon soft tissue sarcomas that do not show an identifiable line of differentiation using currently available technologies.  This is a diagnosis of exclusion and includes undifferentiated pleomorphic sarcoma (also known as malignant fibrous histiocytoma), undifferentiated spindle cell sarcoma, undifferentiated round cell sarcoma, and undifferentiated epithelioid sarcoma.	Undifferentiated Soft Tissue Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Morphology PT Terminology|Mapped ICDO3.1 Morphology Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C121794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121794>	C91105	Quality of Life Questionnaire-Brain Neoplasm 20 Items|EOR04|EORTC QLQ-BN20|EORTC QLQ-BN20|QLQ-BN20|Quality of Life Questionnaire - Brain Neoplasm 20	A questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) consisting of 20 questions designed to assess quality of life in brain cancer patients.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121796>	C173160	Had Setbacks in Condition Question|Did you feel you had setbacks in your condition|Had Setbacks in Condition	A question about whether an individual feels or felt that they had setbacks in their condition.			Intellectual Product	Quality of Life Questionnaire-Brain Neoplasm 20 Items
C121797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121797>	C27005|C121793	Undifferentiated Spindle Cell Sarcoma|Undifferentiated spindle cell sarcoma	An undifferentiated soft tissue sarcoma characterized by the presence of a malignant spindle cell infiltrate with amphophilic or palely eosinophilic cytoplasm.			Neoplastic Process	GDC Terminology|GDC Value Terminology
C121799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121799>	C121793	Undifferentiated Round Cell Sarcoma|Undifferentiated Ewing Tumor|Undifferentiated round cell sarcoma	An undifferentiated soft tissue sarcoma characterized by the presence of uniform round or ovoid malignant cells with a high nuclear to cytoplasmic ratio.			Neoplastic Process	EWS Authorized Value Terminology|EWS Histology Table|GDC Terminology|GDC Value Terminology
C12179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12179>	C61063	gp100 Antigen/Melan-A/Na17.A2 Antigen/Tyrosinase Peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1217>	C804	Retinyl Palmitate|Palmitate-1-14C|Retinol Hexadecanoate|Retinol Palmitate|Retinol-15-3H|Retinyl-10,11-14C2|VITAMIN A PALMITATE|Vitamin A Palmitate|retinyl palmitate	A naturally-occurring phenyl analogue of retinol (vitamin A) with potential antineoplastic and chemopreventive activities.  As the most common form of vitamin A taken for dietary supplementation, retinyl palmitate binds to and activates retinoid receptors, thereby inducing cell differentiation and decreasing cell proliferation.  This agent also inhibits carcinogen-induced neoplastic transformation, induces apoptosis in some cancer cell types, and exhibits immunomodulatory properties. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C121800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121800>	C91102	Outlook on the Future Worsened Question|Did your outlook on the future worsen|Outlook on the Future Worsened	A question about whether an individual's outlook on the future has or had worsened.			Intellectual Product	Quality of Life Questionnaire-Brain Neoplasm 20 Items
C121801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121801>	C173790	Have Double Vision Question|Did you have double vision|Have Double Vision	A question about whether an individual has or had double vision.			Intellectual Product	Quality of Life Questionnaire-Brain Neoplasm 20 Items
C121802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121802>	C121793	Undifferentiated Sarcoma with Epithelioid Features|Undifferentiated Epithelioid Sarcoma|Undifferentiated epithelioid sarcoma	An undifferentiated soft tissue sarcoma characterized by the presence of a malignant cellular infiltrate with epithelioid morphology.			Neoplastic Process	GDC Terminology|GDC Value Terminology
C121803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121803>	C176426|C173790|C173398	Have Difficulty Reading Because of Vision Question|Did you have difficulty reading because of your vision|Have Difficulty Reading Because of Vision	A question about whether an individual has or had difficulty reading because of vision.			Intellectual Product	Quality of Life Questionnaire-Brain Neoplasm 20 Items
C121804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121804>	C121793	Undifferentiated Sarcoma, Not Otherwise Specified|Undifferentiated Sarcoma, NOS	An undifferentiated soft tissue sarcoma which cannot be further characterized.			Neoplastic Process	
C121805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121805>	C173219	Have Weakness on One Side of Body Question|Did you have weakness on one side of your body|Have Weakness on One Side of Body	A question about whether an individual has or had weakness on one side of the body.			Intellectual Product	Quality of Life Questionnaire-Brain Neoplasm 20 Items
C121806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121806>	C173398	Have Difficulty Speaking Question|Did you have difficulty speaking|Difficulty speaking|Have Difficulty Speaking	A question about whether an individual has or had difficulty speaking.			Intellectual Product	CRF2 History and Physical Exam Initial History Table|Quality of Life Questionnaire-Brain Neoplasm 20 Items
C121807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121807>	C173597|C173398	Have Trouble Communicating Thoughts Question|Did you have trouble communicating your thoughts|Have Trouble Communicating Thoughts	A question about whether an individual has or had trouble communicating their thoughts.			Intellectual Product	Quality of Life Questionnaire-Brain Neoplasm 20 Items
C121808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121808>	C107397	Feel Drowsy During the Daytime Question|Did you feel drowsy during the daytime|Feel Drowsy During the Daytime	A question about whether an individual feels or felt drowsy during the daytime.			Intellectual Product	Quality of Life Questionnaire-Brain Neoplasm 20 Items
C121809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121809>	C170848|C105895	Bothered by Itching Skin Question|Bothered by Itching Skin|Bothered by Itchy Skin|Did itching of your skin bother you	A question about whether an individual is or was bothered by itchy skin.			Intellectual Product	Quality of Life Questionnaire-Brain Neoplasm 20 Items
C12180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12180>	C61063	MAGE-10.A2/Melan-A/NY-ESO-1 peptide vaccine/Tyrosinase peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121810>	C122984	Have Weakness of Both Legs Question|Did you have weakness of both legs|Have Weakness of Both Legs	A question about whether an individual has or had weakness of both legs.			Intellectual Product	Quality of Life Questionnaire-Brain Neoplasm 20 Items
C121811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121811>	C173219	Feel Unsteady on Feet Question|Did you feel unsteady on your feet|Feel Unsteady on Feet	A question about whether an individual feels or felt unsteady on their feet.			Intellectual Product	Quality of Life Questionnaire-Brain Neoplasm 20 Items
C121812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121812>	C173803|C173398	Have Trouble Controlling Bladder Question|Bladder Control|Did you have trouble controlling your bladder|Have Trouble Controlling Bladder|Leaking Urine/ Poor Bladder Control	A question about whether an individual has or had trouble controlling their bladder.			Intellectual Product	Patient Oriented Prostate Utility Scale|Quality of Life Questionnaire-Brain Neoplasm 20 Items
C121813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121813>	C35867	No Identifiable Line of Differentiation	A laboratory finding indicating that the line of differentiation in a cellular infiltrate cannot be identified.			Laboratory or Test Result	
C121814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121814>	C20993	Comprehensive Score for Financial Toxicity|COST|COST-FACIT|Comprehensive Score for Financial Toxicity - FACIT|FACIT-COST	A patient-reported outcome measure designed specifically to evaluate the financial distress experienced by cancer patients.			Intellectual Product	
C121815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121815>	C173812	Have Enough Money to Cover Cost of Treatment Question|Have Enough Money to Cover Cost of Treatment|I know that I have enough money in savings, retirement, or assets to cover the costs of my treatment	A question about whether an individual knows they have enough money in their savings, retirement, or assets to cover the cost of their treatment.			Intellectual Product	Comprehensive Score for Financial Toxicity
C121816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121816>	C198108	Out-of-Pocket Medical Expenses are More Than Expected Question|My out-of-pocket medical expenses are more than I thought they would be|Out-of-Pocket Medical Expenses are More Than Expected	A question about whether an individual's out-of-pocket medical expenses are more than they thought they would be.			Intellectual Product	Comprehensive Score for Financial Toxicity
C121817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121817>	C2201|C2152|C192218	Samotolisib|2H-Imidazo(4,5-C)quinolin-2-one, 1,3-Dihydro-8-(5-(1-hydroxy-1-methylethyl)-3-pyridinyl)-1-((2S)-2-methoxypropyl)-3-methyl-|LY 3023414|LY-3023414|LY3023414|PI3K/mTOR Inhibitor LY3023414|SAMOTOLISIB|WHO 10889	An orally bioavailable, small molecule inhibitor of certain class I phosphoinositide 3-kinase (PI3K) isoforms and mammalian target of rapamycin kinase (mTOR) in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Samotolisib inhibits both certain PI3K isoforms and mTOR in an ATP-competitive manner which may inhibit both the PI3K/mTOR signaling pathway in and proliferation of tumor cells overexpressing PI3K and/or mTOR. The PI3K/mTOR pathway is upregulated in a variety of tumor cells and plays a key role in promoting cancer cell proliferation, and survival, motility and resistance to chemotherapy and radiotherapy. mTOR, a serine/threonine kinase downstream of PI3K, may also be activated in a PI3K-independent fashion; therefore, this agent may be more potent than an agent that inhibits either PI3K or mTOR alone. In addition, LY3023414 may inhibit DNA-dependent protein kinase (DNA-PK), thereby inhibiting the ability of tumor cells to repair damaged DNA. DNA-PK is activated upon DNA damage and plays a key role in repairing double-stranded DNA breaks.	Samotolisib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121818>	C187306|C173934|C173812	Worry about Future Financial Problems as a Result of Illness or Treatment Question|I worry about the financial problems I will have in the future as a result of my illness or treatment|Worry about Future Financial Problems as a Result of Illness or Treatment	A question about whether an individual worries or worried about the financial problems they will have in the future as a result of their illness or treatment.			Intellectual Product	Comprehensive Score for Financial Toxicity
C121819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121819>	C176545|C173160	Feel No Choice about Amount of Money Spent on Care Question|Feel No Choice about Amount of Money Spent on Care|I feel I have no choice about the amount of money I spend on care	A question about whether an individual feels or felt they have no choice about the amount of money they spend on care.			Intellectual Product	Comprehensive Score for Financial Toxicity
C12181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12181>	C61063	MAGE-10.A2/Melan-A/NY-ESO-1 peptide vaccine/Sargramostim/tyrosinase peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121820>	C173924|C173160	Frustrated Cannot Work or Contribute as Much as Usual Question|Frustrated Cannot Work or Contribute as Much as Usual|I am frustrated that I cannot work or contribute as much as I usually do	A question about whether an individual is or was frustrated that they cannot work or contribute as much as they usually do.			Intellectual Product	Comprehensive Score for Financial Toxicity
C121821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121821>	C187306|C173792|C173509	Satisfied with Current Financial Situation Question|I am satisfied with my current financial situation	A question about whether an individual is satisfied with their current financial situation.			Intellectual Product	Comprehensive Score for Financial Toxicity
C121822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121822>	C198108|C173045	Able to Meet Monthly Expenses Question|Able to Meet Monthly Expenses|I am able to meet my monthly expenses	A question about whether an individual is able to meet their monthly expenses.			Intellectual Product	Comprehensive Score for Financial Toxicity
C121823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121823>	C187306|C173160	Feel Financially Stressed Question|Feel Financially Stressed|I feel financially stressed	A question about whether an individual feels or felt financially stressed.			Intellectual Product	Comprehensive Score for Financial Toxicity
C121824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121824>	C173924|C173084	Concerned about Keeping Job and Income Question|Concerned about Keeping Job and Income|I am concerned about keeping my job and income, including work at home	A question about whether an individual is or was concerned about keeping their job and income, including work at home.			Intellectual Product	Comprehensive Score for Financial Toxicity
C121825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121825>	C187306|C173812|C173792	Cancer or Treatment has Reduced Satisfaction with Present Financial Situation Question|Cancer or Treatment has Reduced Satisfaction with Present Financial Situation|My cancer or treatment has reduced my satisfaction with my present financial situation	A question about whether cancer or treatment has reduced an individual's satisfaction with their present financial situation.			Intellectual Product	Comprehensive Score for Financial Toxicity
C121826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121826>	C187306|C173160	Feel in Control of Financial Situation Question|'Feel in Control of Financial Situation'|I feel in control of my financial situation	A question about whether an individual feels or felt in control of their financial situation.			Intellectual Product	Comprehensive Score for Financial Toxicity
C121827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121827>	C82547	Organomegaly	An abnormal enlargement of an organ, particularly an organ of the abdominal cavity.	Organomegaly		Finding	CTRP Disease Terminology|CTRP Terminology
C121828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121828>	C1557	4-Thio-2-deoxycytidine|4'-THIO-2'-DEOXYCYTIDINE|4'-Thio-2'-deoxycytidine|T-dCyd|TdCyd	An orally bioavailable 4-thio modified 2-deoxycytidine analog, with potential antineoplastic activity. Upon administration of 4-thio-2-deoxycytidine (TdCyd), this cytidine analog gets incorporated into DNA during replication and inhibits the activity of DNA methyltransferase 1 (DNMT1), which blocks DNA hypermethylation. This results in DNMT1 depletion, hypomethylation of DNA, and the reactivation of tumor suppressor genes that were silenced by hypermethylation; this results in antitumor activity and an inhibition of tumor cell proliferation.	4-Thio-2-deoxycytidine		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121829>	C128462	Mivebresib|ABBV-075|Ethanesulfonamide, N-(4-(2,4-difluorophenoxy)-3-(6,7-dihydro-6-methyl-7-oxo-1H-pyrrolo(2,3-C)pyridin-4-yl)phenyl)-|MIVEBRESIB	An inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, mivebresib binds to the acetyl-lysine binding site of  BRD-containing protein(s), thereby preventing the interaction between those proteins and acetylated histones. This disrupts chromatin remodeling, prevents the expression of certain growth-promoting genes, and leads to an inhibition of cell growth in susceptible tumors.	Mivebresib		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12182>	C61007	Cyclophosphamide/Pentostatin/Rituximab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121830>	C142078	Fucosylated Umbilical Cord Blood Regulatory T Cells|Fucosylated UCB Tregs	Fucosylated, human umbilical cord blood (UCB)-derived regulatory T-cells (Tregs), with potential immunomodulating activity. Ex vivo, Tregs are isolated from cord blood, expanded, and fucosylated. Upon infusion, the fucosylated UCB Tregs modulate immune responses and induce tolerance to allogeneic transplants, such as hematopoietic stem cell transplants (HSCTs). This suppresses graft-versus-host disease (GVHD). Fucosylation improves the activity of Tregs and reduces the amount of Tregs that need to be expanded and infused.	Fucosylated Umbilical Cord Blood Regulatory T Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology
C121831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121831>	C214795	Bone Tumor of Undefined Neoplastic Nature	A group of lesions that affect the bone and have the appearance and cytogenetic or molecular characteristics of neoplasms but the clinical behavior is suggestive of a non-neoplastic process.			Disease or Syndrome	
C121832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121832>	C54452	SPL Suspect Drug Classification of Notification Terminology|Structured Product Labeling Suspect Drug Classification of Notification Terminology	Terminology used to specify whether a suspect drug or product has been determined to have been fraudulently obtained, produced or altered intentionally to deceive, unfit for distribution, diverted for illicit use, or stolen.	SPL Suspect Drug Classification of Notification Terminology		Intellectual Product	FDA Structured Product Labeling Terminology
C121833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121833>	C54452	SPL Suspect Drug Use Terminology|Structured Product Labeling Suspect Drug Use Terminology	Terminology used to specify in whom a suspect drug or product was approved to be used.	SPL Suspect Drug Use Terminology		Intellectual Product	FDA Structured Product Labeling Terminology
C121834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121834>	C171084	Counterfeit Product|Counterfeit	A product has been determined to be counterfeit.			Qualitative Concept	FDA Structured Product Labeling Terminology|SPL Suspect Drug Classification of Notification Terminology
C121835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121835>	C171084	Diverted Product|Diverted	A product has been determined to have been diverted for illicit use or distribution.			Qualitative Concept	FDA Structured Product Labeling Terminology|SPL Suspect Drug Classification of Notification Terminology
C121836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121836>	C171084	Stolen Product|Stolen	A product has been determined to have been stolen.			Qualitative Concept	FDA Structured Product Labeling Terminology|SPL Suspect Drug Classification of Notification Terminology
C121837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121837>	C171084	Intentionally Adulterated Product|Intentional adulteration	A product has been determined to have been intentionally adulterated.			Qualitative Concept	FDA Structured Product Labeling Terminology|SPL Suspect Drug Classification of Notification Terminology
C121838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121838>	C171084	Unfit for Distribution Product|Product Unfir for Distribution|Unfit for distribution	A product has been determined to be unfit for distribution.			Qualitative Concept	FDA Structured Product Labeling Terminology|SPL Suspect Drug Classification of Notification Terminology
C121839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121839>	C171084	Fraudulently Obtained Product|Fraudulent transaction	A product has been determined to have been obtained fraudulently.			Qualitative Concept	FDA Structured Product Labeling Terminology|SPL Suspect Drug Classification of Notification Terminology
C12183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12183>	C61063	CpG 7909/Trastuzumab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121840>	C171084	Approved for Human Use Product|Human Use|Product Approved for Human Use	A product has been approved for use in humans.			Qualitative Concept	FDA Structured Product Labeling Terminology|SPL Suspect Drug Use Terminology
C121841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121841>	C171084	Approved for Non-Human Use Product|Other than Human Use|Product Approved for Non-Human Use	A product has been approved for use in non-humans.			Qualitative Concept	FDA Structured Product Labeling Terminology|SPL Suspect Drug Use Terminology
C121842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121842>	C8592|C4880	Osteochondromyxoma|Carney Bone Tumor	A rare benign chondroid and osteoid matrix-producing neoplasm of bone characterized by extensive myxoid changes.  It may be a locally destructive neoplasm and has been reported in patients with Carney complex.			Neoplastic Process	Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C121843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121843>	C80441	De Novo Classification Request	A premarket submission made to the FDA for classification of a device for which general controls or general and special controls provide a reasonable assurance of safety and effectiveness, but for which there is no legally marketed predicate device.			Intellectual Product	FDA CDRH GUDID Terminology
C121844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121844>	C8592	Subungual Exostosis|Dupuytren Exostosis	A benign tumor that affects the distal phalanx, most often the great toe. Grossly it consists of a cartilage cap and a bony stalk. Microscopically it is characterized by an osteochondromatous proliferation with a gradual transition of a peripheral spindle-cell proliferation to hyaline cartilage to trabecular bone. Pain and swelling are present. Simple resection is usually curative.			Neoplastic Process	Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C121845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121845>	C8592	Bizarre Parosteal Osteochondromatous Proliferation|BPOP|Nora Lesion|Nora's Lesion	A benign lesion that usually affects the proximal small bones of the hands or feet.  Grossly it consists of a cartilage cap and a bony stalk.  Microscopically it is characterized by the presence of spindle cells, cartilage, and bone, usually in a disorganized pattern compared to subungual exostosis.  Enlarged (bizarre) chondrocytes are present in the cartilage.  Swelling with or without pain is present.  Recurrences following resection have been reported in approximately half of cases.			Neoplastic Process	Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C121846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121846>	C4755	Intermediate Chondrogenic Neoplasm	A locally aggressive or rarely metastasizing cartilaginous matrix-producing neoplasm characterized by the presence of neoplastic chondrocytes.			Neoplastic Process	
C121847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121847>	C89415	NCPDP Dose Unit of Measure Terminology|NCPDP DoseUnitOfMeasure Terminology	A set of terminology for NCPDP that contains concepts of the intended dose unit of measure (e.g.  tablet, drop, puff, mL, lozenge) as presented in the medication directions for use (sig).  The purpose of this subset is to state dosing quantities, therefore the concepts contained within may not be the same, or appropriate, units used for dispensing/billing.			Intellectual Product	NCPDP Terminology
C121848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121848>	C28310	Autologous NSCLC Peptide-specific Dendritic Cell Vaccine|Autologous NSCLC Peptide-specific DC Vaccine	A personalized cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with immunogenic peptides derived from autologous non-small cell lung cancer (NSCLC) cells, with potential immunostimulating and antineoplastic activities. During leukapheresis, mature DCs are loaded with autologous NSCLC-derived peptides. Upon re-administration of the NSCLC peptide-specific DC vaccine, the immune system is exposed to NSCLC-associated antigens. This results in the induction of a specific cytotoxic T-lymphocyte (CTL) response against NSCLC cells and tumor cell lysis.			Cell|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121849>	C128462	Ezobresib|BET Inhibitor BMS-986158|BMS-986158|EZOBRESIB	An inhibitor of the Bromodomain (BRD) and Extra-Terminal domain (BET) family of proteins, with potential antineoplastic activity. Upon administration, ezobresib binds to the acetyl-lysine binding site in the BRD of BET proteins, thereby preventing the interaction between BET proteins and acetylated histones. This disrupts chromatin remodeling and prevents the expression of certain growth-promoting genes, resulting in an inhibition of tumor cell growth. BET proteins (BRD2, BRD3, BRD4 and BRDT) are transcriptional regulators that bind to acetylated lysines on the tails of histones H3 and H4, and regulate chromatin structure and function; they play an important role in the modulation of gene expression during development and cellular growth.	Ezobresib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12184>	C61007	Cytarabine/Daunorubicin/Oblimersen			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121850>	C1512	Cetuximab Sarotalocan Sodium|ASP 1929|ASP-1929|ASP1929|CETUXIMAB SAROTALOCAN SODIUM|Cet-IR700|Cetuximab-IR700 Conjugate RM-1929|RM-1929	The sodium salt form of cetuximab sarotalocan, which consists of a chemical conjugate composed of the dye IR700 linked to cetuximab, a monoclonal antibody directed against the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon injection of cetuximab sarotalocan sodium, the cetuximab moiety targets and binds to EGFR-expressing tumor cells, resulting in the internalization of the conjugate. Upon localized application of near-infrared (NIR) light, the IR700 dye becomes activated, disrupts the cell membrane and selectively kills the EGFR-expressing tumor cells. EGFR, a tyrosine kinase receptor, is overexpressed in a variety of cancers.	Cetuximab Sarotalocan Sodium		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121851>	C93221	Cocoa Extract|COCOA|Cocoa Extract Supplement	A dietary supplement containing cocoa extract derived from the cacao bean, with potential vasodilating, anti-inflammatory, cardiovascular protective, neuroprotective, cognition enhancing and chemopreventive activities. Cocoa extract contains flavonoids, including high levels of epicatechin, catechin, procyanidins and xanthines, such as theobromine. Upon oral administration, the bioactive ingredients in the cocoa extract inhibit angiotensin-converting enzyme (ACE) and increase the production of nitric oxide (NO) through the activation of endothelial nitric oxide synthase (eNOS). This causes vasodilation, improves blood flow, and decreases blood pressure. The cocoa extract also improves insulin sensitivity, enhances cognition, and decreases the production of pro-inflammatory molecules. In addition, this extract exerts antioxidant effects and is able to scavenge reactive oxygen species (ROS). As a result, healthy cells are protected from oxidative stress and DNA damage.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C121852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121852>	C210732	Fursultiamine|FURSULTIAMINE|Formamide, N-((4-amino-2-methyl-5-pyrimidinyl)methyl)-N-(4-hydroxy-1-methyl-2-(((tetrahydro-2-furanyl)methyl)dithio)-1-butenyl)-|TTFD|Thiamine Tetrahydrofurfuryl Disulfide	A nutritional supplement and vitamin B1 derivative, with potential antineoplastic activity. Upon oral administration, fursultiamine inhibits the expressions of octamer-binding transcription factor 4 (OCT-4), SRY (sex determining region Y)-box 2 (SOX-2), and Nanog homeobox (NANOG) in cancer stem cells (CSCs). This may inhibit the proliferation of CSCs thereby preventing tumor cell growth. In addition, fursultiamine inhibits the expression of ATP-binding cassette (ABC) transporters subfamily B member 1 (ABCB1) and subfamily G member 2 (ABCG2) in cancer CSCs, which may abrogate resistance to chemo- and radiotherapy in CSCs. CSCs promote tumor initiation, progression and metastasis; they play a key role in cancer recurrence and resistance to chemotherapy and radiation.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121853>	C91105	FACIT-Dyspnea 10 Item Short Form|FAC084|FACIT-DYSPNEA SF|FACIT-Dyspnea|Functional Assessment of Chronic Illness Therapy-Dyspnea|Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form Questionnaire	A patient-reported outcome measure designed to evaluate an individual's shortness of breath across ten functional activities over the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C121854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121854>	C200418	Bemcentinib|1H-1,2,4-Triazole-3,5-diamine, 1-(6,7-Dihydro-5H-benzo(6,7)cyclohepta(1,2-C)pyridazin-3-yl)-N3-((7S)-6,7,8,9-tetrahydro-7-(1-pyrrolidinyl)-5H-benzocyclohepten-2-yl)-|AXL Inhibitor BGB324|BEMCENTINIB|BGB 324|BGB-324|BGB324|R-428|R428|WHO 10631	An orally available and selective inhibitor of the AXL receptor tyrosine kinase (UFO), with potential antineoplastic activity. Upon administration, bemcentinib targets and binds to the intracellular catalytic kinase domain of AXL and prevents its activity. This blocks AXL-mediated signal transduction pathways and inhibits the epithelial-mesenchymal transition (EMT), which, in turn, inhibits tumor cell proliferation and migration. In addition, bemcentinib enhances chemo-sensitivity. AXL, a member of the TAM (TYRO3, AXL and MER) family of receptor tyrosine kinases overexpressed by many tumor cell types, plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance and poor prognosis.	Bemcentinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C121855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121855>	C173062	Dyspnea Severity Dressing Yourself Without Help Question|Dressing yourself without help|Dyspnea Severity Dressing Yourself Without Help	A question about how short of breath an individual gets or got when dressing themselves without help.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121856>	C28310	Autologous Dendritic Cell Vaccine ACT2001|ACT2001|Autologous DC Vaccine ACT2001	A cell-based cancer vaccine composed of autologous, immature dendritic cells (DCs), with potential immunostimulating and antineoplastic activities. Upon leukapheresis, immature DCs are isolated and re-administered intra-tumorally. The immature DCs internalize and process the tumor-associated antigens (TAAs), migrate to the lymphatic system, and then expose the immune system to the TAAs. This induces a specific cytotoxic T-lymphocyte (CTL) response against the cancer cells leading to tumor cell lysis.			Cell|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121857>	C173062	Dyspnea Severity Walking on Flat Ground Without Stopping Question|Dyspnea Severity Walking 50 Steps or Paces on Flat Ground at Normal Speed Without Stopping|Dyspnea Severity Walking on Flat Ground Without Stopping|Walking 50 steps/paces on flat ground at a normal speed without stopping	A question about how short of breath an individual gets or got when walking 50 steps/paces on flat ground at a normal speed without stopping.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121858>	C173062	Dyspnea Severity Walking up 20 Stairs Without Stopping Question|Dyspnea Severity Walking up 20 Stairs Without Stopping|Walking up 20 stairs (2 flights) without stopping	A question about how short of breath an individual gets or got when walking up 20 stairs without stopping.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121859>	C1505	Multicarotenoid Supplement MCS-8|MCS-8	A supplement containing multiple, as of yet undisclosed, carotenoids, with potential chemopreventive activity. Upon oral administration of the multicarotenoid supplement MCS-8, the carotenoids may be able to exert their chemopreventive activity through multiple mechanisms of action.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C12185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12185>	C61063	BMS-275291/Zoledronate			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121860>	C173062	Dyspnea Severity Preparing Meals Question|Dyspnea Severity Preparing Meals|Preparing meals	A question about how short of breath an individual gets or got when preparing meals.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121861>	C173062	Dyspnea Severity Washing Dishes Question|Dyspnea Severity Washing Dishes|Washing dishes	A question about how short of breath an individual gets or got when washing dishes.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121862>	C173062|C121888	Dyspnea Severity While Sweeping or Mopping Question|Dyspnea Severity While Sweeping or Mopping|Sweeping or mopping	A question about how short of breath an individual gets or got when sweeping or mopping.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121863>	C173062	Dyspnea Severity Making a Bed Question|Dyspnea Severity Making a Bed|Making a bed	A question about how short of breath an individual gets or got when making a bed.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121864>	C173062	Dyspnea Severity Lifting Something Weighing 10-20 Pounds Question|Dyspnea Severity Lifting Something Weighing 10-20 Pounds|Lifting something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries)	A question about how short of breath an individual gets or got when lifting something weighing 10-20 pounds.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121865>	C173062|C173061	Dyspnea Severity Carrying Something Weighing 10-20 Pounds Question|Carrying something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries) from one room to another|Dyspnea Severity Carrying Something Weighing 10-20 Pounds|Dyspnea Severity Carrying Something Weighing 10-20 lbs from One Room to Another	A question about how short of breath an individual gets or got when carrying something weighing 10-20 pounds from one room to another.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121866>	C173062	Dyspnea Severity Walking Faster than Your Normal Speed Without Stopping Question|Dyspnea Severity Walking Faster than Your Normal Speed for Half a Mile Without Stopping|Walking (faster than your usual speed) for a half mile (almost 1 km) without stopping	A question about how short of breath an individual gets or got when walking faster than their usual speed for one half mile without stopping.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121867>	C131923	Did Not Dress Without Help Question|Did Not Dress Without Help|Did Not Dress Yourself Without Help|Please indicate why you did not dress yourself without help in the past 7 days	A question about the reason why an individual did not dress themselves without help.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121868>	C70699	Gallbladder Sludge|Sludge	A mixture of cholesterol and calcium particles in excess bile in the gallbladder.			Body Substance	
C121869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121869>	C35867	Suspicious for Malignancy|Atypical and/or suspicious|Suspicious	A microscopic finding indicating the presence of a cellular infiltrate or isolated cells that have features suspicious for malignancy.			Finding	
C12186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12186>	C61063	Irinotecan/Thalidomide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121870>	C2946	Chondrosarcoma, Grade 2|Grade II Chondrosarcoma|Intermediate Grade Chondrosarcoma|Intermediate-Grade Chondrosarcoma	An intermediate-grade chondrosarcoma arising in the medulla of bone or within the cartilaginous cap of a pre-existing osteochondroma. It is characterized by the presence of increased cellularity and a greater degree of nuclear atypia and hyperchromasia as compared to grade 1 chondrosarcoma. Mitotic activity is present.			Neoplastic Process	Cellosaurus Disease Terminology
C121871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121871>	C9418|C2946	Chondrosarcoma, Grade 3|Grade III Chondrosarcoma|High Grade Chondrosarcoma|High-Grade Chondrosarcoma	A high-grade chondrosarcoma arising in the medulla of bone or within the cartilaginous cap of a pre-existing osteochondroma. It is characterized by the presence of increased cellularity and a greater degree of nuclear atypia, hyperchromasia, and mitotic activity as compared to grade 2 chondrosarcoma.			Neoplastic Process	Cellosaurus Disease Terminology
C121872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121872>	C173135	Did Not Walk on Flat Ground Without Stopping Question|Did Not Walk on Flat Ground Without Stopping|Please indicate why you did not walk 50 steps/paces on flat ground at a normal speed without stopping in the past 7 days	A question about the reason why an individual did not walk 50 steps/paces on flat ground at a normal speed without stopping.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121873>	C173135	Did Not Walk up 20 Stairs Without Stopping Question|Did Not Walk up 20 Stairs Without Stopping|Please indicate why you did not walk up 20 stairs (2 flights) without stopping in the past 7 days	A question about the reason why an individual did not walk up 20 stairs without stopping.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121874>	C173458	Did Not Prepare Meals Reason Question|Did Not Prepare Meals|Did Not Prepare Meals Reason|Please indicate why you did not prepare meals in the past 7 days	A question about the reason why an individual did not prepare meals.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121875>	C173458	Did Not Wash Dishes Reason Question|Did Not Wash Dishes|Did Not Wash Dishes Reason|Please indicate why you did not wash dishes in the past 7 days	A question about the reason why an individual did not wash dishes.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121876>	C121888	Did Not Sweep or Mop Reason Question|Did Not Sweep or Mop|Did Not Sweep or Mop Reason|Please indicate why you did not sweep or mop in the past 7 days	A question about the reason why an individual did not sweep or mop.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121877>	C173458	Did Not Make a Bed Reason Question|Did Not Make a Bed|Did Not Make a Bed Reason|Please indicate why you did not make a bed in the past 7 days	A question about the reason why an individual did not make a bed.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121878>	C173458	Did Not Lift Something Weighing 10-20 Pounds Reason Question|Did Not Lift Something Weighing 10-20 Pounds|Did Not Lift Something Weighing 10-20 Pounds Reason|Please indicate why you did not lift something weighing 10-20 pounds in the past 7 days	A question about the reason why an individual did not lift something weighing 10-20 pounds.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121879>	C173061	Did Not Carry Something Weighing 10-20 Pounds Question|Did Not Carry Something Weighing 10-20 Pounds|Did Not Carry Something Weighing 10-20 Pounds from One Room to Another|Please indicate why you did not carry something weighing 10-20 pounds from one room to another in the past 7 days	A question about the reason why an individual did not carry something weighing 10-20 pounds from one room to another.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C12187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12187>	C61063	Capecitabine/Celecoxib/ZD 1839			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121880>	C173135	Did Not Walk Faster than Normal Speed Without Stopping Question|Did Not Walk Faster than Normal Speed Without Stopping|Did Not Walk Faster than Your Normal Speed for Half a Mile Without Stopping|Please indicate why you did not walk faster than your normal speed without stopping in the past 7 days	A question about the reason why an individual did not walk faster than their usual speed for one half mile without stopping.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121881>	C27482	Secondary Central Chondrosarcoma	A chondrosarcoma that arises in a pre-existing enchondroma.			Neoplastic Process	
C121882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121882>	C27482	Secondary Peripheral Chondrosarcoma	A chondrosarcoma arising within the cartilaginous cap of a pre-existing osteochondroma.			Neoplastic Process	
C121883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121883>	C131923	Dressing Without Help Question|Dressing Without Help|Dressing yourself without help	A question about an individual's difficulty dressing themselves without help.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121884>	C164300	Walking on Flat Ground Without Stopping Question|Walking 50 Steps or Paces on Flat Ground at Normal Speed Without Stopping|Walking 50 steps/paces on flat ground at a normal speed without stopping|Walking on Flat Ground Without Stopping	A question about an individual's difficulty walking 50 steps/paces on flat ground at a normal speed without stopping.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121885>	C173082	Walking up 20 Stairs Without Stopping Question|Walking up 20 Stairs Without Stopping|Walking up 20 stairs (2 flights) without stopping	A question about an individual's difficulty walking up 20 stairs without stopping.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121886>	C91102	Preparing Meals Question|Preparing Meals|Preparing meals	A question about an individual's difficulty preparing meals.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121887>	C173458	Washing Dishes Question|Washing Dishes|Washing dishes	A question about an individual's difficulty washing dishes.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121888>	C173458	Sweeping or Mopping Ability Question|Sweeping or Mopping Ability|Sweeping or mopping	A question about an individual's difficulty sweeping or mopping.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121889>	C91102	Difficulty Making a Bed Question|Difficulty Making a Bed|Making a bed	A question about an individual's difficulty making a bed.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C12188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12188>	C61063	Docetaxel/Sulindac			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121890>	C173458	Lifting Something Weighing 10-20 Pounds Question|Lifting Something Weighing 10-20 Pounds|Lifting something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries)	A question about an individual's difficulty lifting something weighing 10-20 pounds.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121891>	C173061	Carrying Something Weighing 10-20 Pounds Question|Carrying Something Weighing 10-20 Pounds|Carrying something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries) from one room to another	A question about an individual's difficulty carrying something weighing 10-20 pounds from one room to another.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121892>	C173135	Walking Faster than Your Normal Speed Without Stopping Question|Walking (faster than your usual speed) for a half mile (almost 1 km) without stopping|Walking Faster than Your Normal Speed Without Stopping|Walking Faster than Your Normal Speed for Half a Mile Without Stopping	A question about an individual's difficulty walking faster than their usual speed for one half mile without stopping.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121893>	C27477	Giant Cell Lesion of Small Bones|GCLSB|Giant Cell Reparative Granuloma	A rare tumor-like lesion of the hands and feet characterized by the presence of hemorrhagic fibrous tissue, hemosiderin deposition, osteoclast-like giant cells which are irregularly distributed, and reactive bone formation.  Pain and swelling are the most frequent symptoms.  It may recur following curettage, but is usually cured after a second procedure.			Neoplastic Process	
C121894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121894>	C175457	No Shortness of Breath|No shortness of breath	A response indicating that an individual has or had no shortness of breath.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121895>	C175457	Mildly Short of Breath|Mild Shortness of Breath|Mildly short of breath	A response indicating that an individual has or had mild shortness of breath.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121896>	C175457	Moderately Short of Breath|Moderate Shortness of Breath|Moderately short of breath	A response indicating that an individual has or had moderate shortness of breath.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121897>	C175457	Severely Short of Breath|Severe Shortness of Breath|Severely short of breath	A response indicating that an individual has or had severe shortness of breath.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121898>	C226656	Did Not Do This Past 7 Days|Did Not Do This During the Past 7 Days|Did Not Do This in the Past 7 Days|I did not do this in the past 7 days	A response indicating that an individual has not done something in the past 7 days.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C121899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121899>	C226642	Have Stopped Trying Because of Shortness of Breath|Have Stopped Trying or Knew I Could Not Do This Activity Because of Shortness of Breath|I have stopped trying, or knew I could not do this activity because of my shortness of breath	A response indicating that an individual has stopped trying, or knew they could not do this activity because of their shortness of breath.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form
C12189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12189>	C61007	Docetaxel/Ketoconazole			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1218>	C67477	Rhizoxin|RHIZOXIN|WF-1360|rhizoxin	A macrocyclic lactone. Rhizoxin binds to tubulin and inhibits microtubule assembly, thereby inducing cytotoxicity. This agent also may inhibit endothelial cell-induced angiogenic activity, which may result in decreased tumor cell proliferation. (NCI04)			Antibiotic|Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121900>	C226611	Did Not Do This Activity for Some Other Reason|I did not do this activity for some other reason (including not having a chance to do it, other health issues etc)|Some other reason	A response indicating that an individual has not done an activity for some reason not listed.			Intellectual Product	FACIT-Dyspnea 10 Item Short Form|PROMIS v2.0 Brief Profile Sexual Function and Satisfaction (Female)
C121901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121901>	C7063|C4880	Benign Notochordal Cell Tumor|BNCT|Intraosseous Benign Notochordal Cell Tumor	An intraosseous benign tumor of notochord origin that arises in the bones of the base of the skull, vertebral bodies, sacrum or coccyx.  It contains vacuolated tumor cells without atypia, but lacks myxoid matrix, necrosis, and lobular architecture, which are features that characterize its malignant counterpart, chordoma.  Most lesions are incidental findings.			Neoplastic Process	Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology|NCIt Neoplasm Core Terminology
C121902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121902>	C20993	Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-General|FACIT-TS-G|Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General	A patient-reported outcome measure designed specifically to evaluate general satisfaction with treatment.			Intellectual Product	
C121903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121903>	C173812	Treatment Effectiveness So Far Compared to Expected Question|Compared to what you expected, how do you rate the effectiveness of the treatment so far|Treatment Effectiveness So Far Compared to Expected	A question about how an individual would rate the effectiveness of their treatment so far compared to what they expected.			Intellectual Product	Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-General
C121904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121904>	C173933|C173812	Treatment Side Effects So Far Compared to Expected Question|Compared to what you expected, how do you rate the side effects of treatment so far|Treatment Side Effects So Far Compared to Expected	A question about how an individual would rate the side effects of their treatment so far compared to what they expected.			Intellectual Product	Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-General
C121905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121905>	C173812|C173145	Doctor Helped with Evaluation of Treatment Effects Question|Did your doctor(s) help you evaluate the effects of your treatment so far|Doctor Helped with Evaluation of Treatment Effects	A question about whether a doctor helped an individual evaluate the effects of their treatment so far.			Intellectual Product	Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-General
C121906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121906>	C173812|C173160	Feel Treatment was Right Question|'Feel Treatment was Right'|Do you feel you received the treatment that was right for you	A question about whether an individual feels or felt that the treatment they received was right for them.			Intellectual Product	Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-General
C121907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121907>	C173812|C173792	Satisfied with Treatment Effects Question|Are you satisfied with the effects of this treatment so far|Satisfaction with Treatment Effects|Satisfied with Treatment Effects	A question about whether an individual is or was satisfied with the effects of their treatment so far.			Intellectual Product	Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-General
C121908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121908>	C173812	Recommend Treatment to Others with Same Illness Question|Recommend Treatment to Others with Same Illness|Would you recommend this treatment to others with your illness	A question about whether an individual would recommend their treatment to others with their illness.			Intellectual Product	Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-General
C121909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121909>	C173812	Would Choose Treatment Again Question|Choose Treatment Again|Would Choose Treatment Again|Would you choose this treatment again	A question about whether an individual would choose their treatment again.			Intellectual Product	Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-General
C12190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12190>	C61007	Cytarabine/Dexamethasone/Etoposide/Filgrastim/Ifosfamide/Leucovorin Calcium/Methotrexate/Rituximab/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121910>	C173812	Treatment Rating Overall Question|How do you rate this treatment overall|Overall Treatment Rating|Treatment Overall Rating|Treatment Rating Overall	A question about how an individual would rate their treatment overall.			Intellectual Product	Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-General
C121911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121911>	C175310	A Lot Worse|A lot worse	A response indicating that something is a lot worse.			Intellectual Product	Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-General
C121912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121912>	C175310	A Little Worse|A little worse	A response indicating that something is a little worse.			Intellectual Product	Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-General
C121913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121913>	C175309	A Little Better|A little better	A response indicating that something is a little better.			Intellectual Product	Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-General
C121914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121914>	C175309	A Lot Better|A lot better	A response indicating that something is a lot better.			Intellectual Product	Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-General
C121915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121915>	C226693	To Some Extent|To some extent	An indication that something has been accomplished to some degree or has resulted in some amount of satisfaction.			Intellectual Product	Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-General
C121916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121916>	C226693	For the Most Part|For the most part	An indication that something has been mostly accomplished or has been mostly satisfying.			Intellectual Product	Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-General
C121917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121917>	C226690|C176244	Maybe	An indication that something is possible, but not certain.			Intellectual Product	Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-General
C121918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121918>	C17561	HEY1/NCOA2 Fusion Protein|HEY1-NCOA2 Fusion Protein|HEY1::NCOA2 Fusion Protein|Hairy/Enhancer-of-Split Related With YRPW Motif Protein 1-Nuclear Receptor Coactivator 2 Fusion Protein|Hairy/Enhancer-of-Split Related With YRPW Motif Protein 1/Nuclear Receptor Coactivator 2 Fusion Protein	A fusion protein that is encoded by the HEY1/NCOA2 fusion gene. This protein contains the N-terminal basic helix-loop-helix domain of hairy/enhancer-of-split related with YRPW motif protein 1 fused to the C-terminal region of the nuclear receptor coactivator 2 protein, which includes its CREB binding and histone acetyl transferase domains.			Amino Acid, Peptide, or Protein	
C121919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121919>	C28510	HEY1/NCOA2 Fusion Gene|HEY1-NCOA2 Fusion Gene|HEY1::NCOA2 Fusion Gene	A fusion gene that results from a chromosomal rearrangement involving 8q21.1 and 8q13.3 which fuses the first 4 exons of the HEY1 gene in frame with exon 13 of the NCOA2 gene. This fusion is associated with mesenchymal chondrosarcoma.			Gene or Genome	
C12191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12191>	C61007	Cyclophosphamide/Cytarabine/Dexamethasone/Doxorubicin/Filgrastim/Leucovorin Calcium/Methotrexate/Rituximab/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121925>	C6603	Intermediate Osteogenic Neoplasm	A non-metastasizing, locally aggressive, bone-forming neoplasm.			Neoplastic Process	
C121926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121926>	C9343	Intermediate Bone Neoplasm	A locally aggressive or rarely metastasizing neoplasm that arises from the bone.			Neoplastic Process	
C121927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121927>	C96040	Ivuxolimab|Anti-OX40 Agonist Monoclonal Antibody PF-04518600|IVUXOLIMAB|PF-04518600|PF-8600|PF04518600	An agonistic antibody that recognizes the co-stimulatory receptor OX40 (CD134; TNFRSF4), with potential immunostimulatory activity. Upon administration, ivuxolimab selectively binds to and activates OX40; which induces proliferation of memory and effector T-lymphocytes. In the presence of tumor-associated antigens (TAAs), this may promote a T-cell-mediated immune response against TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and plays an essential role in T-cell activation.	Ivuxolimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121928>	C1511	Copper Cu 64-DOTA B-Fab|64 Cu-DOTA B-Fab|64 Cu-DOTA DS6 B-Fab|Cu 64-labeled B-Fab DS6 Antibody-like Binding Protein	A radioimmunoconjugate containing a bivalent monospecific tandem immunoglobulin fragment (B-Fab) derived from the humanized monoclonal antibody DS6 targeting the tumor-associated mucin-1 (MUC1)-sialoglycotope CA6 conjugated with the bifunctional, macrocyclic chelating agent 1,4,7,10-tetra-azacyclododecane-1,4,7,10-tetra-acetic acid (DOTA) and labeled with the radioisotope copper Cu 64 with potential use as an imaging agent for CA6-expressing tumors using positron emission tomography (PET). The B-Fab moiety of Copper Cu 64-DOTA B-Fab binds, with high affinity, to the cell surface antigen CA6. Upon binding, the radioisotope moiety may be detected using PET, thereby allowing the imaging and quantification of CA6-expressing tumor cells. This tracer could be used to select patients who could benefit from and to monitor efficacy of CA6-targeted anti-cancer therapies. Compared to DS6, the antibody fragment allows for increased tumor penetration, faster blood clearance, and more rapid renal elimination. The CA6 epitope is found on a variety of solid tumors.	Copper Cu 64-DOTA B-Fab		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C121929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121929>	C53963	Non-Ossifying Fibroma|NOF	A tumor histologically indistinguishable from, but larger than, benign fibrous histiocytoma of bone.			Neoplastic Process	
C12192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12192>	C61063	Cyclophosphamide/Dexrazoxane/Doxorubicin/Oblimersen			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121930>	C6620|C3211	Primary Bone Non-Hodgkin Lymphoma|Primary Non-Hodgkin Lymphoma of Bone|Primary Non-Hodgkin Lymphoma of the Bone	A non-Hodgkin lymphoma that arises from the bone, without lymph node or other extranodal involvement.  The femur, spine, and pelvic bones are the most frequently affected areas.  The majority of cases are diffuse large B-cell lymphomas.  Most patients present with pain in the affected area.  Systemic symptoms are rare.			Neoplastic Process	
C121931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121931>	C3738|C121926	Intermediate Osteoclastic Giant Cell-Rich Tumor of Bone|Intermediate Osteoclastic Giant Cell-Rich Tumor of the Bone	A benign but locally aggressive giant cell tumor that arises from the bone.			Neoplastic Process	
C121932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121932>	C121931	Giant Cell Tumor of Bone|Benign Bone Giant Cell Tumor|GCTB|GIANT CELL TUMOR, BENIGN|Giant Cell Tumor of the Bone|Giant cell tumor of bone, NOS|Osteoclastoma|Osteoclastoma, Benign	A locally aggressive tumor that arises from the bone and is composed of mononuclear cells admixed with macrophages and osteoclast-like giant cells. It usually arises from the ends of long bones or the vertebrae. Clinical presentation includes pain, edema, and decreased range of motion in the affected joint.			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Cellosaurus Disease Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Morphology PT Terminology|Mapped ICDO3.1 Morphology Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C121933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121933>	C4090|C4016|C3738	Malignant Osteoclastic Giant Cell-Rich Tumor of Bone	A giant cell tumor that arises from the bone and is characterized by the presence of a malignant cellular component.			Neoplastic Process	NCIt Neoplasm Core Terminology
C121934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121934>	C120461	Questionnaire Subsection Name	The textual identifier used to group a set of questions or tests in a questionnaire.			Intellectual Product	
C121935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121935>	C70933	High Reference Range in Text Format	The upper limit of the test reference range, reported in text.			Intellectual Product	
C121936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121936>	C70934	Low Reference Range in Text Format	The lower limit of the test reference range, reported in text.			Intellectual Product	
C121937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121937>	C70933	High Reference Range in Numeric Format	The upper limit of the test reference range, reported in numerals.			Intellectual Product	
C121938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121938>	C70934	Low Reference Range in Numeric Format	The lower limit of the test reference range, reported in numerals.			Intellectual Product	
C121939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121939>	C80236	Questionnaire Subsection	A specific section, grouping or division of questions or tests within a questionnaire.			Intellectual Product	
C12193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12193>	C61063	Flavopiridol/Trastuzumab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121940>	C51824	Questionnaire Evaluator|QSEVAL	A person who determines the significance of a questionnaire assessment.			Professional or Occupational Group	CDISC Variable Terminology
C121941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121941>	C6478|C4016|C3800	Bone Epithelioid Hemangioendothelioma	A low-grade malignant blood vessel neoplasm that arises from the bone. It is characterized by the presence of epithelioid endothelial cells. The neoplastic cells are arranged in cords and nests that are embedded in a myxoid to hyalinized stroma.			Neoplastic Process	
C121942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121942>	C2124	Fluorine F 18 Fluorthanatrace|FLUORTHANATRACE F-18|[18F]FTT|[18F]FluorThanatrace	A radiotracer consisting of an analogue of the poly(ADP-ribose) polymerase 1 (PARP1) inhibitor rucaparib radiolabeled with the positron emitting isotope fluorine F 18, which can potentially be used for the imaging of PARP1 expression using positron emission tomography (PET). Upon administration, fluorine F 18 fluorthanatrace targets and binds to PARP1. Upon PET, PARP1-expressing tumor cells can be visualized. PARP1, which is overexpressed in many cancer cell types, catalyzes post-translational ADP-ribosylation of nuclear proteins and plays a key role in the repair of DNA strand breaks.	Fluorine F 18 Fluorthanatrace		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C121943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121943>	C61074	Selonsertib|GS-4997|SELONSERTIB	An orally bioavailable inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with potential anti-inflammatory, antineoplastic and anti-fibrotic activities. Upon oral administration, selonsertib targets and binds to the catalytic kinase domain of ASK1 in an ATP-competitive manner, thereby preventing its phosphorylation and activation. This prevents the phosphorylation of downstream kinases, such as c-Jun N-terminal kinases (JNKs) and p38 mitogen-activated protein kinase (p38 MAPK). By preventing the activation of ASK1-dependent signal transduction pathways, GS-4997 prevents the production of inflammatory cytokines, down-regulates the expression of genes involved in fibrosis, suppresses excessive apoptosis and inhibits cellular proliferation. ASK1, also called mitogen-activated protein kinase kinase kinase 5 (MAP3K5), is activated in response to oxidative and endoplasmic reticulum (ER) stress, calcium influx and infection. It plays a key role in the development of certain cardiovascular and neurodegenerative diseases, diabetes, as well as certain types of cancer.	Selonsertib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121944>	C35561	Rapid-Onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation|ROHHAD|ROHHAD|ROHHAD Syndrome|Rapid-Onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation Syndrome	A very rare disorder that appears after the first year and a half of life in previously healthy children. It is characterized by rapid-onset weight gain, hypothalamic dysfunction, breathing abnormalities, and autonomic system dysregulation. The hypothalamic dysfunction manifestations include inability to maintain normal water balance, high prolactin levels, low thyroid, low cortisol, and early or late puberty. The breathing abnormalities include sleep apnea and alveolar hypoventilation, requiring ventilation support. The autonomic system dysregulation includes eye abnormalities, intestinal abnormalities, temperature dysregulation, and low heart rhythm. This disorder requires early recognition because it may lead to cardiorespiratory arrest. Up to 40% of the patients develop tumors of neural crest origin.	Rapid-Onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C121945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121945>	C53543	Heritable Pulmonary Arterial Hypertension|HPAH	A rare, progressive, autosomal dominant inherited disorder. It is caused by mutation in the BMPR2 gene in most cases. It is characterized by abnormally high blood pressure in the pulmonary artery, caused by obstruction and obliteration of the small pulmonary arteries.	Heritable Pulmonary Arterial Hypertension		Disease or Syndrome	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology
C121946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121946>	C53543	Drug- and Toxin-Induced Pulmonary Arterial Hypertension	A rare, progressive disorder characterized by abnormally high blood pressure in the pulmonary artery caused by obstruction and obliteration of the small pulmonary arteries due to drugs or toxins. The stimulant appetite suppressant aminorex fumarate and other stimulant anorectics such as the serotonin reuptake inhibitor dexfenfluramine, as well as other agents, including illegal substances have been reported as causative agents.	Drug- and Toxin-Induced Pulmonary Arterial Hypertension		Disease or Syndrome	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology
C121947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121947>	C1663	Personalized Synthetic Long Peptide Breast Cancer Vaccine	A cancer vaccine consisting of one or more long, synthetic peptides derived from patient-specific breast cancer tumor-associated antigens (TAAs), with potential immunomodulating and antineoplastic activities. Upon intramuscular administration of the personalized synthetic long peptide breast cancer vaccine, the peptides stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the TAAs, which results in tumor cell lysis.	Personalized Synthetic Long Peptide Breast Cancer Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121948>	C128462	BET Inhibitor INCB054329|INCB054329	An inhibitor of the Bromodomain and Extra-Terminal (BET) family of bromodomain-containing proteins with potential antineoplastic activity. Upon administration, the BET inhibitor INCB054329 binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomain at the N-terminus, BET proteins, BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during cellular growth.	BET Inhibitor INCB054329		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121949>	C219650|C129823	Camidanlumab Tesirine|ADC ADCT-301|ADCT-301|CAMIDANLUMAB TESIRINE	An immunoconjugate consisting of a human immunoglobulin (Ig) G1 monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha or CD25) and conjugated, via a cleavable linker, to a synthetic, cross-linking agent pyrrolobenzodiazepine (PBD) dimer that targets DNA minor grooves, with potential antineoplastic activity. The monoclonal antibody portion of the anti-CD25 antibody-drug conjugate (ADC) ADCT-301 specifically binds to the cell surface antigen CD25. This causes the internalization of ADCT-301 and the subsequent release of the cytotoxic PBD moiety. The imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces interstrand cross-links in the minor groove of DNA and inhibits DNA replication, which inhibits the proliferation of CD25-overexpressing tumor cells. CD25, a transmembrane receptor and tumor-associated antigen (TAA), is expressed on certain cancer cells.	Camidanlumab Tesirine		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12194>	C61063	Gemcitabine/UCN-01			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121950>	C1892|C107589	Xanthohumol|3'-[3,3-Dimethyl allyl]-2',4',4-trihydroxy-6'-methoxychalcone|XANTHOHUMOL	A prenylated flavonoid derived from the female flowers of the hops plant (Humulus lupulus L), with potential chemopreventive and antineoplastic activities. Upon administration, xanthohumol scavenges reactive oxygen species (ROS), thereby preventing DNA damage due to oxidative stress. In addition, xanthohumol is able to increase the expression of phase II cytoprotective enzymes, thereby inactivating carcinogens. This agent exerts anti-inflammatory activity, through the inhibition of inflammation-inducing enzymes, inhibits DNA synthesis, and induces apoptosis of susceptible cancer cells. Xanthohumol also decreases the expression of C-X-C chemokine receptor 4 (CXCR4), thereby preventing cancer cell invasion.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121951>	C213716|C129839	Mutant p53 Activator COTI-2|COTI-2|COTI2|Coti-2	An orally available third generation thiosemicarbazone and activator of mutant forms of the p53 protein, with potential antineoplastic activity. Upon oral administration, mutant p53 activator COTI-2 targets and binds to the misfolded mutant forms of the p53 protein, which induces a conformational change that normalizes p53 and restores its activity. This induces apoptosis in tumor cells in which the p53 protein is mutated. In addition, COTI-2 inhibits the activation of Akt2 and prevents the activation of the PI3K/AKT/mTOR pathway, thereby inducing apoptosis in cancer cells in which this pathway is overexpressed. p53, a tumor suppressor protein, plays a key role in controlling cellular proliferation and survival. High levels of mutant p53 are seen in many cancers and are associated with uncontrolled cellular growth.	Mutant p53 Activator COTI-2		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121952>	C2336	pan-RAF Kinase Inhibitor CCT3833|BAL 3833|BAL-3833|BAL3833|CCT 3833|CCT-3833|CCT-3833|CCT3833	An orally available inhibitor of the serine/threonine protein kinase family Raf, including A-Raf, B-Raf and C-Raf, with potential antineoplastic activity. Upon administration, pan-RAF kinase inhibitor CCT3833 inhibits Raf-mediated signal transduction pathways, which may inhibit the proliferation of Raf-overexpressing tumor cells. Raf protein kinases play a key role in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway, which is often dysregulated in human cancers and plays a key role in tumor cell proliferation and survival.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121953>	C6803	Ovarian Microcystic Stromal Tumor	A benign, unilateral tumor that arises from the ovary and is characterized by the presence of conspicuous microcystic changes, cellular areas, and a fibrous stroma.			Neoplastic Process	
C121954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121954>	C2124	Gallium Ga 68-NOTA-AE105|68Ga-NOTA-AE105	A radiotracer composed of AE105, an urokinase-type plasminogen activator receptor (uPAR) peptide antagonist, conjugated with the bifunctional, macrocyclic chelating agent 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA) and labeled with the radionuclide gallium Ga 68, with potential imaging activity using positron emission tomography (PET). Upon administration, the AE105 moiety of gallium Ga 68-NOTA-AE105 targets and binds, with high affinity, to uPAR expressed on tumor cells. Upon PET imaging, uPAR-expressing tumor cells can be visualized and the degree of tumor aggressiveness can be assessed. uPAR expression is correlated with increased tumor invasiveness and aggressiveness, as well as a poor prognosis.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C121955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121955>	C4179|C36035|C3150	Clear Cell Papillary Renal Tumor|CCPRCT|Clear Cell Papillary Renal Cell Carcinoma|Clear Cell Papillary Renal Neoplasm|Clear Cell Tubulopapillary Renal Cell Carcinoma|Renal Angiomyoadenomatous Tumor	An encapsulated epithelial neoplasm that arises from the kidney. It is composed of cytologically bland epithelial cells with clear cytoplasm forming tubular and papillary patterns. The nuclei are arranged linearly away from the basement membrane. Tumor necrosis, perirenal invasion, and vascular invasion are not present. The clinical course is indolent.			Neoplastic Process	Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C121956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121956>	C61074|C1742	MKNK1 Inhibitor BAY 1143269|BAY 1143269	An orally bioavailable inhibitor of mitogen-activated protein kinase interacting serine/threonine-protein kinase 1 (MKNK1), with potential antineoplastic activity. Upon oral administration, MKNK1 inhibitor BAY 1143269 binds to MKNK1, thereby preventing its activation and the downstream MKNK1-mediated phosphorylation and activation of eukaryotic translation initiation factor 4E (eIF4E). As eIF4E enhances the synthesis of oncogenic proteins, preventing eIF4E activity inhibits the synthesis of tumor angiogenic factors and leads to both the inhibition of cellular proliferation and apoptosis in susceptible tumor cells. eIF4E, overexpressed in a variety of cancer cells, plays a key role in tumor cell proliferation and survival.	MKNK1 Inhibitor BAY 1143269		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121957>	C1752|C1663	WT1 Protein-derived Peptide Vaccine DSP-7888|DSP-7888	A peptide cancer vaccine comprised of peptides derived from the Wilms tumor gene 1 (WT1) protein, with potential immunomodulating and antineoplastic activities. Upon administration, WT1 protein-derived peptide vaccine DSP-7888 may induce a specific cytotoxic T-lymphocyte (CTL) response against WT1-overexpressing tumor cells. In addition, DSP-7888 induces a helper T-lymphocyte-mediated immune response against WT1 expressing tumor cells. WT1 protein, a zinc finger DNA-binding protein and transcription factor, is overexpressed in leukemic cells and in many non-hematological solid tumors.	WT1 Protein-derived Peptide Vaccine DSP-7888		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121958>	C2124	Carbon C 14 Vemurafenib|14 C-labeled Vemurafenib	A radioconjugate composed of vemurafenib, an ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase, labeled with the radioisotope carbon C 14, with potential use for evaluating the pharmacokinetic profile of vemurafenib. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in both an inhibition of an over-activated MAPK signaling pathway in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Labeling of vemurafenib with the radioactive tracer carbon C 14 allows for the evaluation of vemurafenib's pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME). The BRAF(V600E) gene mutation in which valine is substituted for glutamic acid at residue 600 (V600E), is found in many cancer cell types and plays a key role in the over-activation of the MAPK signaling pathway.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C121959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121959>	C2124	Fluorine F 18 Alfatide II|(18)F-AlF-NOTA-E[PEG4-c(RGDfk)]2|18F-Al-NOTA-PRGD2|18F-AlF-NOTA-PRGD2|18F-Alfatide II	A radiotracer composed of a pegylated, dimeric arginine-glycine-aspartic acid (RGD) peptide (PRGD2), radiolabeled, via the chelating agent 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA), to a fluorine F 18-aluminum complex (AlF), with potential alphaVbeta3 integrin (vitronectin receptor) imaging activity using positron emission topography (PET). Upon administration, the RGD moiety of fluorine F 18 alfatide II selectively binds to alphaVbeta3 integrin. During PET, alphaVbeta3-expressing tumor cells can be visualized and the degree of tumor angiogenesis can be determined. AlphaVbeta3 integrin, a cell adhesion and signaling receptor, is upregulated in tumor vessel endothelial cells and has been associated with neovascularization, differentiation, proliferation of tumor cells, and metastasis. Pegylation provides improved drug penetration into tumors and decreases drug clearance, thereby increasing efficacy while lowering systemic toxicity.			Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	NCI Drug Dictionary Terminology
C12195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12195>	C61063	Cyclophosphamide/Epirubicin/Gemcitabine/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121960>	C2167|C129825	Pirotinib|KBP-5209|KBP5209	An orally bioavailable inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with potential antineoplastic activity. Upon administration, pirotinib selectively and irreversibly binds to and inhibits the epidermal growth factor receptors 1 (ErbB1; EGFR), 2 (ErbB2; HER2), and 4 (ErbB4; HER4). This may result in the inhibition of cell growth and angiogenesis in tumors overexpressing these RTKs. EGFRs play major roles in both tumor cell proliferation and tumor vascularization, and are overexpressed in many cancer cell types.	Pirotinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121961>	C67437	Docetaxel Nanoparticle CPC634|CPC 634|CPC-634|CPC634|CriPec (R) Docetaxel|Docetaxel containing CriPec (R) Nanoparticles|Docetaxel-containing CriPec (R) Nanoparticles CPC634|Nanoparticle-encapsulated Docetaxel CPC634	A polymeric nanoparticle (PNP) formulation containing the poorly water-soluble taxane docetaxel, a semi-synthetic analogue of paclitaxel, with antineoplastic activity. Upon intravenous administration of the docetaxel nanoparticle CPC634, the nanoparticles are able to accumulate at the tumor site due to the unique characteristics of the tumor's vasculature, while avoiding normal, healthy tissue. In turn, docetaxel is released locally at the target tumor site, binds specifically to the beta-tubulin subunit of the microtubule, stabilizing tubulin and inhibiting microtubule disassembly, which results in cell-cycle arrest at the G2/M phase, thereby preventing cell proliferation. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response. Compared to docetaxel alone, this formulation may enhance stability and improve delivery, thereby increasing docetaxel's efficacy while avoiding systemic exposure, which minimizes its toxicity.			Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C121962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121962>	C2124	Carbon C 11 PBR-28|(11C) N-ACETYL-N-(2-METHOXYBENZYL)-2-PHENOXY-5-PYRIDINAMINE|(11C)PBR-28|Acetamide, N-((2-(methoxy-11C)-phenyl)methyl)-N-(6-phenoxy-3-pyridinyl)-|PBR-28 C-11|[11C] PBR28	A radioconjugate composed of a ligand for the 18 kDa translocator protein (TSPO) conjugated to the radioisotope carbon C 11, that can be used as a diagnostic imaging agent to detect TSPO-expressing cells using positron emission tomography (PET). Upon administration of carbon C 11 PBR-28, the PBR-28 moiety targets and binds to TSPO-expressing cells. Upon PET, carbon C 11 can be detected and TSPO-expressing cells can be visualized. This can facilitate detection of inflammatory sites and cancer cells. TSPO, also called the peripheral benzodiazepine receptor (PBR), is found on the outer mitochondrial membrane and is overexpressed on a variety of cancer cells and during inflammation.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C121963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121963>	C6990	Cribriform Neuroepithelial Tumor|CRINET	A very rare, nonrhabdoid, intraventricular tumor with relatively favorable prognosis.  It is characterized by the presence of neuroepithelial cells forming cribriform patterns, trabeculae, epithelial membrane antigen immunopositivity on epithelial surfaces, and loss of nuclear INI 1 expression.			Neoplastic Process	NCIt Neoplasm Core Terminology
C121964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121964>	C70920	Micronucleus|Micronuclei	A toxicology screening result where proliferating cells that are exposed to a genotoxic chemical produce some daughter cells containing cytoplasmic bodies that are comprised of chromosomes or chromosome fragments, which were not sorted properly during mitosis or meiosis, and are bounded by a nuclear membrane.	Micronucleus		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C121965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121965>	C843	Androstane-3,17-Diol Glucuronide|3,17-Androstanediol Glucuronide|3-Alpha-Androstanediol Glucuronide|3-Hydroxyandrostan-17-Yl-Glucopyranosiduronic Acid|3alpha-DIOL-G|3alpha-Diol G|5-Alpha-Androstane-3alpha,17beta-Diol Glucuronide|5-Androstane-3alpha,17beta-Diol Glucuronide	A glucuronosyltransferase-modified, alcohol-conjugated metabolite of the steroid androsterone and metabolite of the steroid dihydrotestosterone produced in visceral adipose tissue, with weak androgenic activity. Androstane-3,17-diol glucuronide may be used as a marker for peripheral androgen activity.	Androstane-3,17-Diol Glucuronide		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C121966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121966>	C38440|C177694	Loss of INI 1 Protein Expression|Loss of BAF47 Protein Expression|Loss of INI1 Protein Expression|Loss of SMARCB1 Protein Expression|Loss of SNF5 Homolog Protein Expression|Loss of SWI/SNF-Related Matrix-Associated Actin Dependent Regulator of Chromatin Subfamily B Member 1 Protein Expression	An immunohistochemical finding indicating negative staining of tumor cells for INI 1 protein, resulting from the inactivation of the INI 1 tumor suppressor gene.	Loss of INI 1 Protein Expression		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C121967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121967>	C4976	Meningioangiomatosis	A rare vascular malformation in the cerebral cortex and overlying leptomeninges.  It can occur sporadically or in association with neurofibromatosis type 2.			Disease or Syndrome	
C121968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121968>	C3075	Cutaneous Neurocristic Hamartoma|CNH	A rare dermal and subcutaneous lesion that results from the aberrant development of neural crest-derived melanocytes.  It affects the head and neck with a predilection for the scalp.  It presents as a slowly enlarging multinodular plaque.  Morphologically is characterized by the presence of melanocytes and structures with schwannian differentiation in the dermis and subcutaneous tissue.			Disease or Syndrome	
C121969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121969>	C15687	Skin-Directed Therapy	Any therapy that treats the skin directly. This includes surgery, radiation therapy, phototherapy, and topical preparations.			Therapeutic or Preventive Procedure	
C12196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12196>	C61007	Cyclophosphamide/Epirubicin/Paclitaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121970>	C97171	Pancreaticobiliary Malunion	An abnormality of the pancreatic and biliary ducts in which their junction occurs above the duodenal wall.			Disease or Syndrome	
C121971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121971>	C157134	Prostaglandin E3|(5Z,11alpha,13E,15S,17Z)-11,15-Dihydroxy-9-Oxoprosta-5,13,17-Trien-1-Oic Acid|(5Z,13E,15S,17Z)-11alpha,15-Dihydroxy-9-Oxoprosta-5,13,17-Trien-1-Oic Acid|9-Oxo-11R,15S-Dihydroxy-5Z,13E,17Z-Prostatrienoic Acid|Delta(17)-PGE1|Delta(17)-Prostaglandin E1|PGE(3)|PGE1, Delta(17)-|PGE3|PROSTAGLANDIN E3|Prosta-5,13,17-Trien-1-Oic Acid, 11,15-Dihydroxy-9-Oxo-, (5Z,11alpha,13E,15S,17Z)-|Prostaglandin E(3)	An eicosanoid that is generated by the action of cyclooxygenases on the omega-3 fatty acid eicosapentaenoic acid (EPA). Prostaglandin E3 regulates ocular pressure, exerts anti-inflammatory activities and may inhibit tumor cell proliferation. Prostaglandin E3 may be used as a biomarker for EPA to evaluate the association between EPA and its antineoplastic activity.	Prostaglandin E3		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C121972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121972>	C48275	Induction Death|Death After Induction Therapy|Death During Induction Therapy	Death of the patient due to the toxic side effects of induction therapy.			Finding	GDC Terminology|GDC Value Terminology
C121973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121973>	C3167	Acute Lymphoblastic Leukemia by Gene Expression Profile|ALL Gene Expression Cluster Subtype|ALL Gene Expression Subtype|ALL by Gene Expression Profile|ALL by Gene Expression Signature|Acute Lymphoblastic Leukemia Gene Expression Subtype|Acute Lymphoblastic Leukemia by Gene Expression Signature	Gene expression-based patient cluster groups in acute lymphoblastic leukemia.			Neoplastic Process	NCIt Neoplasm Core Terminology
C121974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121974>	C199202|C129787	B Acute Lymphoblastic Leukemia, BCR-ABL1-Like|B Acute Lymphoblastic Leukemia with BCR-ABL1-Like Features|B Acute Lymphoblastic Leukemia with BCR::ABL1-Like Features|B Acute Lymphoblastic Leukemia, BCR::ABL1-Like|B Lymphoblastic Leukemia, Philadelphia-like|B-Acute Lymphoblastic Leukemia with BCR-ABL1-Like Features|B-Acute Lymphoblastic Leukemia with BCR::ABL1-Like Features|B-Acute Lymphoblastic Leukemia, BCR-ABL1-Like|B-Acute Lymphoblastic Leukemia, BCR::ABL1-Like|B-Lymphoblastic Leukemia, Philadelphia-like|BCR-ABL1-like ALL|BCR-ABL1-like Acute Lymphoblastic Leukemia|BCR::ABL1-like features|Ph-Like|Ph-Like ALL|Ph-Like Acute Lymphoblastic Leukemia|Ph-Like Acute Lymphoblastic Leukemia|Ph-like ALL|Philadelphia-Like Acute Lymphoblastic Leukemia|Philadelphia-like ALL	B acute lymphoblastic leukemia characterized by a gene-expression profile similar to that of BCR-ABL1-positive B acute lymphoblastic leukemia, absence of the pathognomonic BCR-ABL1 rearrangement, alterations of lymphoid transcription factor genes, and a poor outcome.			Neoplastic Process	NCIt Neoplasm Core Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C121975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121975>	C121973	DDIT4L Acute Lymphoblastic Leukemia|DDIT4L|DDIT4L ALL	A gene expression subtype of acute lymphoblastic leukemia characterized by its expression level of the DDIT4L gene.			Neoplastic Process	NCIt Neoplasm Core Terminology
C121976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121976>	C451	CEP 7 Probe|7p11.1-q11.1|CEP7|Chromosome 7 Centromere Probe	A set of DNA probes designed for use in FISH. This probe set amplifies a region of chromosome 7 spanning from 7p11.1 to 7q11.1 which includes the centromere. This probe set can facilitate the detection of copy number alterations.	CEP 7 Probe		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology
C121977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121977>	C20130	HLA Complex|HLA|HLA Family|Histocompatibility Antigen|Human Leukocyte Antigen|Human Leukocyte Antigen Complex|Human Leukocyte Antigen Family|MHC|Major Histocompatibility Complex	A family of proteins that are essential for the presentation of peptide antigens on cell surfaces that modulate the host defensive activities of T-cells. This protein family includes major histocompatibility complex (MHC) class I and class II proteins.	HLA Complex		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C121978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121978>	C121973	Acute Lymphoblastic Leukemia by ROSE Cluster|ALL Gene Expression Cluster|ALL ROSE Cluster|Acute Lymphoblastic Leukemia Gene Expression Cluster|Acute Lymphoblastic Leukemia ROSE Cluster	Unique gene expression-based patient cluster groups in high-risk B-precursor acute lymphoblastic leukemia determined by Recognition of Outliers by Sampling Ends (ROSE).			Neoplastic Process	NCIt Neoplasm Core Terminology
C121979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121979>	C107495	DT2219 Antibody|Anti-DT2219 Antibody	Any immunoglobulin that recognizes the DT2219 immunotoxin.	DT2219 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C12197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12197>	C61007	Fowlpox-CEA-TRICOM Vaccine/Sargramostim			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121980>	C121978	ROSE Cluster 1|R1	Gene expression cluster 1 as determined by Recognition of Outliers by Sampling Ends (ROSE) in high-risk B-precursor acute lymphoblastic leukemia.			Neoplastic Process	
C121981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121981>	C121978	ROSE Cluster 2|R2	Gene expression cluster 2 as determined by Recognition of Outliers by Sampling Ends (ROSE) in high-risk B-precursor acute lymphoblastic leukemia.			Neoplastic Process	
C121982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121982>	C121978	ROSE Cluster 3|R3	Gene expression cluster 3 as determined by Recognition of Outliers by Sampling Ends (ROSE) in high-risk B-precursor acute lymphoblastic leukemia.			Neoplastic Process	
C121983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121983>	C121978	ROSE Cluster 4|R4	Gene expression cluster 4 as determined by Recognition of Outliers by Sampling Ends (ROSE) in high-risk B-precursor acute lymphoblastic leukemia.			Neoplastic Process	
C121984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121984>	C121978	ROSE Cluster 5|R5	Gene expression cluster 5 as determined by Recognition of Outliers by Sampling Ends (ROSE) in high-risk B-precursor acute lymphoblastic leukemia.			Neoplastic Process	
C121985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121985>	C121978	ROSE Cluster 6|R6	Gene expression cluster 6 as determined by Recognition of Outliers by Sampling Ends (ROSE) in high-risk B-precursor acute lymphoblastic leukemia.			Neoplastic Process	
C121986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121986>	C121978	ROSE Cluster 7|R7	Gene expression cluster 7 as determined by Recognition of Outliers by Sampling Ends (ROSE) in high-risk B-precursor acute lymphoblastic leukemia.			Neoplastic Process	
C121987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121987>	C19896	Angiome|Angiome Profile	The collective identity of the angiogenic and inflammatory factors in an organism or biospecimen.	Angiome		Qualitative Concept	CTRP Biomarker Terminology|CTRP Terminology
C121988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121988>	C121978	ROSE Cluster 8|R8	Gene expression cluster 8 as determined by Recognition of Outliers by Sampling Ends (ROSE) in high-risk B-precursor acute lymphoblastic leukemia.			Neoplastic Process	
C121989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121989>	C48182	BROCA Gene Signature|BROCA - Cancer Risk Panel	A prognostic system used to assess if a patient has an increased risk for developing hereditary cancer, with a focus on ovarian and breast cancers. This system is based on the use of massively parallel DNA sequencing to detect cancer predisposing mutations in a panel of more than 45 specific genes.	BROCA Gene Signature		Functional Concept	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12198>	C61007	Fowlpox-CEA-TRICOM Vaccine/Fowlpox-Sargramostim|Fowlpox-CEA-TRICOM Vaccine/Fowlpox-Sargramostim Vaccine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C121990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121990>	C48182	BROCA-HR Gene Signature|BROCA-HR Gene Test	A prognostic system used to assess if a patient has an increased risk for developing hereditary cancer caused by homologous recombination (HR) deficiency. This system leverages massively parallel DNA sequencing to detect cancer predisposing mutations in the genes in the BROCA panel and several additional genes in the Fanconi anemia-BRCA pathway and other DNA repair pathways.	BROCA-HR Gene Signature		Functional Concept	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C121991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121991>	C63919	Recognition of Outliers by Sampling Ends|ROSE|ROSE Clustering	A hierarchical clustering method for the unsupervised, unbiased selection of gene expression patterns. The ROSE probe set clusters are based on the size of the outlier group they identify as well as the magnitude of the deviation from expected intensity.			Research Activity	
C121992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121992>	C20130	Heterochromatin Protein 1|HP1|Heterochromatin Protein-1	A protein family comprised of chromo and chromo shadow domain-containing, methyl-lysine binding proteins that are localized to heterochromatin. These proteins are involved in gene silencing, transcriptional activation, and the formation and stabilization of heterochromatin.	Heterochromatin Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C121993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121993>	C16748	Integrin Alpha4/Beta7|Alpha 4 Beta 7|Alpha 4 Beta 7 Integrin|Alpha(4)Beta(7) Integrin|Alpha4 Beta7 Integrin|Alpha4-Beta7|Alpha4-Beta7 Integrin|Alpha4/Beta7|Alpha4/Beta7 Integrin|Integrin Alpha-4/Beta-7|Integrin Alpha4 Beta7|Integrin Alpha4-Beta7|Integrin a4b7|LPAM|LPAM-1|Lymphocyte Peyer Patch Adhesion Molecule|alpha4beta7 Integrin	Integrin alpha4/beta7 is a protein complex comprised of a heterodimer of integrin alpha4 and integrin beta7. This complex plays a role in cell-cell adhesion, cell-matrix adhesion, lymphocyte homing and host defense mechanisms.	Integrin Alpha4/Beta7		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C121994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121994>	C223627	PROMIS Adult Mental Health Domain|Adult Mental Health|Adult Mental Health Domain	A Patient Reported Outcomes Measurement Information System (PROMIS) domain that assesses the status of an individual's mental health.			Functional Concept	Patient-Reported Outcomes Measurement Information System Measures
C121995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121995>	C222259	Cognitive Function-Abilities|Applied Cognition Abilities	A patient reported outcome instrument that assesses patient-perceived functional abilities related to cognitive tasks.			Intellectual Product	PROMIS Adult Mental Health Domain
C121996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121996>	C48182	BASE47 Gene Signature|BASE47 Gene Set|Bladder Cancer Analysis of Subtypes by Expression 47	A diagnostic system for high grade bladder cancer that can classify a tumor as one of two intrinsic subtypes (luminal or basal-like). This system is based on the expression profile of 47 genes.	BASE47 Gene Signature		Functional Concept	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C121997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121997>	C91102	Mind Has Been as Sharp as Usual Question|Mind Has Been as Sharp as Usual|My mind has been as sharp as usual	A question about whether an individual's mind is or has been as sharp as usual.			Intellectual Product	Cognitive Function-Abilities
C121998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121998>	C176020	Memory Has Been as Good as Usual Question|Memory Has Been as Good as Usual|My memory has been as good as usual	A question about whether an individual's memory is or has been as good as usual.			Intellectual Product	Cognitive Function-Abilities
C121999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C121999>	C173597	Thinking Has Been as Fast as Usual Question|My thinking has been as fast as usual|Thinking Has Been as Fast as Usual	A question about whether an individual's thinking is or has been as fast as usual.			Intellectual Product	Cognitive Function-Abilities
C12199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12199>	C61007	Ad5CMV-p53 gene/Cisplatin/Fluorouracil			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1219>	C1323	Ketorolac|KETOROLAC|ketorolac	A synthetic pyrrolizine carboxylic acid derivative with anti-inflammatory, analgesic, and antipyretic activities. Ketorolac non-selective inhibits the enzymes cyclooxygenase 1 (COX-1) and COX-2. The inhibition of COX-2, up-regulated at sites of inflammation, prevents conversion of arachidonic acid to pro-inflammatory prostaglandins. The inhibition of COX-1 by this agent prevents the normal steady-state production of prostaglandins that play housekeeping roles in the protection of the gastrointestinal tract, the regulation of renal blood flow, and platelet aggregation. As a result, the inhibition of COX-1 may be associated with gastrointestinal toxicity, nephrotoxicity, and the inhibition of platelet aggregation.	Ketorolac		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C122000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122000>	C173597|C173045	Able to Think Clearly Without Extra Effort Question|Able to Think Clearly Without Extra Effort|I have been able to think clearly without extra effort	A question about whether an individual is or was able to think clearly without extra effort.			Intellectual Product	Cognitive Function-Abilities
C122001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122001>	C173045	Able to Pay Attention and Keep Track of What I am Doing Without Extra Effort Question|Able to Pay Attention and Keep Track of What I am Doing Without Extra Effort|I have been able to pay attention and keep track of what I am doing without extra effort	A question about whether an individual is or was able to pay attention and keep track of what they are doing without extra effort.			Intellectual Product	Cognitive Function-Abilities
C122002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122002>	C105890	Able to Remember Things as Easily as Usual Without Extra Effort Question|Able to Remember Things as Easily as Usual Without Extra Effort|I have been able to remember things as easily as usual without extra effort	A question about whether an individual is or was able to remember things as easily as usual without extra effort.			Intellectual Product	Cognitive Function-Abilities
C122003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122003>	C20988	PCDH7 Gene|PCDH7|PCDH7|Protocadherin 7 Gene	This gene plays a role in calcium-dependent cell-cell adhesion.	PCDH7 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C122004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122004>	C122003	PCDH7 wt Allele|BH-Pcdh|BH-Protocadherin (Brain-Heart) Gene|BHPCDH|PPP1R120|Protein Phosphatase 1, Regulatory Subunit 120 Gene|Protocadherin 7 wt Allele	Human PCDH7 wild-type allele is located in the vicinity of 4p15 and is approximately 426 kb in length. This allele, which encodes protocadherin-7 protein, is involved in the modulation of cell-cell adhesion.	PCDH7 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122005>	C16393	Protocadherin-7|BH-Pcdh|Brain-Heart Protocadherin	Protocadherin-7 (1069 aa, ~116 kDa) is encoded by the human PCDH7 gene. This protein plays a role in the mediation of calcium-dependent cell-cell adhesion.	Protocadherin-7		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122006>	C66830	CDISC SDTM COPD Findings About Test Name Terminology|COPD Findings About Test Name|CPFATS|SDTM-CPFATS	Terminology associated with the COPD findings about test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122007>	C66830	CDISC SDTM COPD Findings About Test Code Terminology|COPD Findings About Test Code|CPFATSCD|SDTM-CPFATSCD	Terminology associated with the COPD findings about test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122008>	C215116	Cardiovascular Examination|Cardiac Examination	Tests and assessments pertaining to the cardiovascular system.			Diagnostic Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C122009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122009>	C76197	Dialister	A genus of Gram-negative rod-shaped bacteria in the phylum Firmicutes.			Bacterium	
C12200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12200>	C61007	Ad5CMV-p53 gene/Docetaxel			Obsolete_Concept	Therapeutic or Preventive Procedure	
C122010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122010>	C192228	Dientamoeba	A genus of nonflagellate trichomonad parasite in the family Dientamoebidae. Unlike most other intestinal protozoa, its life cycle has no cyst stage and infection between humans occurs during the trophozoite stage.			Eukaryote	
C122011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122011>	C14248	Dracunculus	A genus of spiruroid nematode parasites in the family Dracunculidae. Dracunculus worms can reach a meter in length.			Animal	
C122012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122012>	C14248	Enterobius	A genus of parasitic nematode pinworms in the family Oxyuridae. Pinworms spread through animal-to-animal transmission, by ingestion of infectious pinworm eggs, and/or by anal insertion.			Animal	
C122013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122013>	C14248	Wuchereria|WUCHERERIA	A genus of parasitic filarial nematodes in the family Onchocercidae that mainly affects humans in warm climates.  The adult forms live chiefly in lymphatic vessels, causing obstruction to lymph flow and producing microfilariae that disseminate via the bloodstream.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122014>	C14248	Ascaris|ASCARIS	A genus of parasitic nematode in the family Ascarididae. Their eggs are deposited in feces and soil and animals become infected by eating plants that are covered by the eggs.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122015>	C77916	Balantidium	A genus of ciliated intestinal protozoan parasites in the family Balantiididae. Balantidium is the only ciliated protozoan known to infect humans and is the causative agent of balantidiasis. Infection occurs through contact with feces from an infected pig.			Eukaryote	
C122016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122016>	C77916	Blastocystis	A genus of protozoan parasites in the family Blastocystidae. The taxonomic classification of Blastocystis is not well established. Human infection with Blastocystis is usually self-limiting.			Eukaryote	
C122017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122017>	C192228	Chilomastix	A genus of nonpathogenic flagellates in the family Retortamonadidae. Infection occurs by the ingestion of cysts in contaminated water, food, or by the fecal-oral route.			Eukaryote	
C122018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122018>	C118932	Endolimax	A genus of amoebozoa parasites in the phylum Archamoebae. Cysts and trophozoites of these species are passed in stool and excystation occurs in the small intestine.			Eukaryote	
C122019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122019>	C77916	Enteromonas	A genus of flagellate protozoa in the family Enteromonadidae. Both cysts and trophozoites are shed in feces.			Eukaryote	
C12201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12201>	C61063	Fowlpox-CEA-TRICOM Vaccine/Vaccinia-CEA-TRICOM Vaccine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C122020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122020>	C76197	Dolosigranulum	A genus of Gram-positive, rod-shaped bacteria in the family Firmicutes.			Bacterium	
C122021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122021>	C123338	Fasciola	A genus of flatworms in the family Fasciolidae. Fasciola are the causative agents of fasciolosis.			Animal	
C122022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122022>	C123338	Fasciolopsis	A genus of parasitic tremadoda flatworms in the family Fasciolidae. It is the causative agent of faciolopsiasis.			Animal	
C122023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122023>	C14248	Gnathostoma|GNATHOSTOMA	A genus of parasitic nematodes in the family Gnathostomatidae. The Gnathostoma lifecycle involves copepods as the first intermediate host; fish, frogs, or snakes as the second intermediate host; and pigs, cats, dogs, or wild animals as its natural definitive host. Humans may become infested by eating infested fish or fowl. Infestation causes gnathostomiasis.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122024>	C14182	Platyhelminthes|Platyhelminth	The taxanomic phylum of flatworms. Flatworms have simple bilateral symmetry, are unsegmented, soft-bodied, and have no body cavity and no specialized circulatory or respiratory organs.			Animal	
C122025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122025>	C122045	Echinococcus	A genus of cyclophyllid tapeworms in the family Taeniidae. The definitive hosts for echinococcus are carnivorous predators; humans become by zoonotic transfer. Infection with Echinococcus results in hydatid disease, also known as echinococcosis.			Animal	
C122026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122026>	C171256	Chair	A seat, typically for one person, that has a back and legs.			Manufactured Object	
C122027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122027>	C42578	Lap|Laps	One circuit around a track or course.			Quantitative Concept	
C122028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122028>	C20993	Rating of Perceived Exertion|RPE|Rated Perceived Exertion|Relative Perceived Exertion	A scale for a subject to rate their perception of the intensity of their own physical effort.			Intellectual Product	
C122029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122029>	C17708	Warm-Up|Warm-Up Exercise	A period of lower-intensity activity designed to prepare the body for more vigorous exercise.			Daily or Recreational Activity	
C12202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12202>	C61007	Fowlpox-CEA-TRICOM Vaccine/Sargramostim/Vaccinia-CEA-TRICOM Vaccine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C122030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122030>	C17708	Priming Exercise|Priming	High-intensity exercise performed to enhance performance during subsequent high-intensity exercise by accelerating oxygen uptake.			Daily or Recreational Activity	
C122031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122031>	C17708	Seated Rowing|Indoor Rowing|Seated Row|Seated row	An exercise performed by using the arms to pull a bar, lever, or cables toward the body while seated.	Seated Rowing		Daily or Recreational Activity	CTRP Intervention Terminology|CTRP Terminology
C122032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122032>	C94741	Chest Press|Chest press	An exercise performed by using the arms to push a weighted bar or lever away from the chest while seated or reclined.			Daily or Recreational Activity	
C122033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122033>	C94741	Leg Press|Leg press	An exercise performed by using the legs to push a weighted bar or lever away from the body while seated or reclined.			Daily or Recreational Activity	
C122034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122034>	C48572	One Repetition Maximum|1RM|1Rm|One Rep Maximum|One Repetition Maximum Test|One-Rep Maximum|One-Repetition Maximum|One-Repetition Maximum Muscular Strength Test	The maximum amount of force that can be generated in one maximal muscle contraction or the maximum amount of weight that can be cycled through one repetition of a particular movement or exercise.			Quantitative Concept	
C122035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122035>	C69035	Hybrid Capture 2 High-Risk HPV DNA Test|Digene Hybrid Capture 2 High-Risk HPV DNA Test|High-Risk HPV DNA Test Kit|Qiagen - digene HC2|digene HC2|digene HC2 High-Risk HPV DNA Test|hc2 High-Risk HPV DNA Test	A proprietary in vitro nucleic acid hybridization-based assay kit that can demonstrate the absence or presence of DNA from 13 types of human papillomavirus (HPV) in cervical specimens.			Manufactured Object	
C122036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122036>	C2124	Gallium Ga 68-HA-DOTA-TATE|68Ga-DOTA-3-iodo-Tyr3-octreotate|68Ga-DOTA-iodoTyr3-octreotate|68Ga-HA-DOTATATE|[68Ga]DOTA-3-iodo-Tyr3-octreotate|[68Ga]high-affinity DOTATATE	A radioconjugate consisting of consisting of the high affinity somatostatin analogue iodo-tyrosine-3-octreotate (HA-TATE), labeled with the positron emission tomography (PET) tracer gallium Ga 68 via the macrocyclic chelating agent 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra-acetic acid (DOTA), which may be used as a human somatostatin receptor (SSTR) imaging agent in conjunction with PET to image neuroendocrine tumors (NETs). Gallium Ga 68-HA-DOTATATE binds to SSTRs, with high affinity for SSTR2, present on the cell membranes of many types of NETs. This allows for visualization of SSTR-positive cells upon imaging. SSTRs have been shown to be present in large numbers on NETs and their metastases, while most other normal tissues express low levels of SSTRs. HA-TATE is an octreotide derivative in which phenylalanine at position 3 is substituted with iodo-tyrosine and threoninol at position 8 is replaced by threonine. The iodo addition in Gallium Ga 68-HA-DOTA-TATE may allow for higher affinity for the SSTRs when compared to gallium Ga 68-DOTA-TATE.	Gallium Ga 68-HA-DOTA-TATE		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology
C122037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122037>	C28533	GOLPH3 Gene|GOLPH3|GOLPH3|Golgi Phosphoprotein 3 (Coat-Protein) Gene	This gene is involved in cellular trafficking and Golgi shape.	GOLPH3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C122038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122038>	C122008	Aortic Augmentation Index Measurement|AAUGIX|Aortic Augmentation Index|Aortic Augmentation Index|Aortic Augmentation Index	A complex measure of wave reflection calculated as the ratio of aortic augmentation pressure to pulse pressure, and used as an indirect measure of arterial stiffness.			Quantitative Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122039>	C20368	Incision-induced Bleeding Method|INCISION-INDUCED BLEEDING METHOD	Any of multiple methods used to assess bleeding time, in which a controlled incision is made in the dermis and clotting time is measured.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12203>	C61007	Cyclophosphamide/Dexamethasone/Doxorubicin/Rituximab/Vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C122040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122040>	C77916	Babesia|BABESIA|Nuttalia	A genus of apicomplexan parasites in the family Babesiidae. Babesia are spread by ticks and are the causative agent of the hemolytic disease babesiosis.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122041>	C118932	Balamuthia|BALAMUTHIA	A genus of free-living amoeba in the family Balamuthiidae. Its life cycle includes a cystic stage and a trophozoite stage, both of which are infectious.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122042>	C14248	Angiostrongylus|ANGIOSTRONGYLUS	A genus of parasitic nematode in the family Angiostrongylidae. Memebers of the genus can cause severe gastrointestinal or central nervous system disease in humans, depending on the species.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122043>	C14248	Anisakis|ANISAKIS	A genus of parasitic nematode in the family Anisakidae. Members of the genus cause anisakiasis in humans. Their life cycle involves fish, crustaceans, and marine mammals. Humans become infested by eating infested fish.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122044>	C14248	Capillaria|CAPILLARIA|Hairworm	A genus of parasitic nematodes in the family Capillariidae. Members of this genus infect dogs and cats, livestock, poultry, and wild mammals, birds and fish.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122045>	C122024	Cestoda|CESTODA|Tapeworm	A taxonomic grouping of parasitic tapeworms that can be assigned to the class Cestoda.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122046>	C86395	Coliform Bacteria|COLIFORM BACTERIA	Any rod-shaped, Gram-negative, non-spore forming, motile or non-motile bacteria which can ferment lactose with the production of acid and gas.			Organism	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122047>	C192229	Cyclospora|CYCLOSPORA	A genus of obligate intracellular parasites in the family Eimeriidae. Cyclospora are transmitted through contaminated food or water. Infection causes diarrhea, nausea, and vomiting.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122048>	C118932	Entamoeba|ENTAMOEBA	A genus of commensal or parasitic Amoebozoans in the class Archamoebae. Almost all species form cysts; the number of nuclei in the cyst varies from 1 to 8 among species and is one of the characteristics used to tell species apart.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122049>	C75913	Renal Clearance from T1 to T2|RNCLINT|Renal CL from T1 to T2|Renal CL from T1 to T2	The clearance of a substance from the blood by the kidneys over the interval from T1 to T2.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12204>	C61007	Cytarabine/Leucovorin Calcium/Methotrexate/Rituximab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C122050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122050>	C75913	Renal Clearance for Dose Interval|RENCLTAU|Renal CL for Dose Int|Renal CL for Dose Int	The clearance of a substance from the blood by the kidneys, calculated using the area under the curve over the dosing interval.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122051>	C122037	GOLPH3 wt Allele|GOPP1|GPP34|Golgi Peripheral Membrane Protein 1, 34 kDa Gene|Golgi Phosphoprotein 3 (Coat-Protein) wt Allele|Golgi-Associated Protein, 34-kD Gene|MIDAS|Vps74	Human GOLPH3 wild-type allele is located in the vicinity of 5p13.3 and is approximately 50 kb in length. This allele, which encodes Golgi phosphoprotein 3, plays a role in both Golgi morphology and membrane trafficking.	GOLPH3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122052>	C16386	Golgi Phosphoprotein 3|Coat Protein GPP34|Golgi-Associated Protein|MIDAS|Mitochondrial DNA Absence Factor|Mitochondrial DNA Absence-Sensitive Factor	Golgi phosphoprotein 3 (298 aa, ~34 kDa) is encoded by the human GOLPH3 gene. This protein is involved in cellular membrane trafficking.	Golgi Phosphoprotein 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122053>	C20917	RPRM Gene|RPRM|RPRM|Reprimo, TP53 Dependent G2 Arrest Mediator Candidate Gene	This gene plays a role in cell cycle arrest.	RPRM Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C122054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122054>	C122053	RPRM wt Allele|FLJ90327|REPRIMO|Reprimo, TP53 Dependent G2 Arrest Mediator Candidate wt Allele	Human RPRM wild-type allele is located in the vicinity of 2q24.3 and is approximately 2 kb in length. This allele, which encodes protein reprimo, is involved in the mediation of p53-dependent cell cycle arrest.	RPRM wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122055>	C17761	Protein Reprimo|Candidate Mediator of the p53 Dependent G2 Arrest|Candidate Mediator of the p53-Dependent G2 Arrest	Protein reprimo (109 aa, ~12 kDa) is encoded by the human RPRM gene. This protein plays a role in p53-mediated G2 phase arrest.	Protein Reprimo		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122056>	C20917|C20745	CEP72 Gene|CEP72|CEP72|Centrosomal Protein 72 Gene	This gene is involved in mitotic spindle formation.	CEP72 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C122057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122057>	C122056	CEP72 wt Allele|Centrosomal Protein 72 wt Allele|Centrosomal Protein 72kDa Gene|Centrosomal Protein 72kDa wt Allele|Centrosomal Protein, 72-kD Gene|FLJ10565|KIAA1519	Human CEP72 wild-type allele is located in the vicinity of 5p15.33 and is approximately 55 kb in length. This allele, which encodes centrosomal protein of 72 kDa, plays a role in the recruitment of proteins to the centrosome.	CEP72 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122058>	C17761|C16492	Centrosomal Protein of 72 kDa|Cep72	Centrosomal protein of 72 kDa (647 aa, ~72 kDa) is encoded by the human CEP72 gene. This protein is involved in the formation of the mitotic spindle.	Centrosomal Protein of 72 kDa		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122059>	C20988	ITGA6 Gene|ITGA6|ITGA6|Integrin Subunit Alpha 6 Gene	This gene plays a role in both laminin binding and cell adhesion.	ITGA6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C12205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12205>	C61063	Carboplatin/Exisulind/Gemcitabine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C122060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122060>	C122059	ITGA6 wt Allele|CD49f|ITGA6A|ITGA6B|Integrin Subunit Alpha 6 wt Allele|Integrin, Alpha 6 Gene|Integrin, Alpha-6 Gene|JEB6|VLA-6|Very Late Activation Protein 6 Gene	Human ITGA6 wild-type allele is located in the vicinity of 2q31.1 and is approximately 79 kb in length. This allele, which encodes integrin alpha-6 protein, is involved in cell-matrix adhesion. Mutation of the gene is associated with epidermolysis bullosa with pyloric atresia.	ITGA6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122061>	C25404	Outsourcing Animal Drug Compounding	Compounding drug dosage forms for animal consumption under a contract by other sources than the facilities that use the pharmaceutics.			Activity	FDA Structured Product Labeling Terminology|SPL Business Operation Terminology
C122062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122062>	C16393	Integrin Alpha-6|CD49 Antigen-Like Family Member F|CD49f|CD49f Antigen|ITGA6|Integrin Alpha 6|VLA-6	Integrin alpha-6 (1130 aa, ~127 kDa) is encoded by the human ITGA6 gene. This protein plays a role in both cell adhesion and laminin binding.	Integrin Alpha-6		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122064>	C25952	PLA2G7 Gene|PLA2G7|PLA2G7|Phospholipase A2, Group VII (Platelet-Activating Factor Acetylhydrolase, Plasma) Gene	This gene is involved in platelet-activating factor modification.	PLA2G7 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C122065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122065>	C122064	PLA2G7 wt Allele|LDL-PLA2|LP-PLA2|PAFAD|PAFAH|Phospholipase A2, Group VII (Platelet-Activating Factor Acetylhydrolase, Plasma) wt Allele|Platelet-Activating Factor Acetylhydrolase, Plasma Gene	Human PLA2G7 wild-type allele is located within 6p21.2-p12 and is approximately 31 kb in length. This allele, which encodes platelet-activating factor acetylhydrolase protein, plays a role in the modulation of the inflammatory activity of platelet-activating factor. Mutation of the gene is associated with platelet-activating factor acetylhydrolase deficiency and increased susceptibility to asthma or atopy.	PLA2G7 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122066>	C16980	Platelet-Activating Factor Acetylhydrolase|1-Alkyl-2-Acetylglycerophosphocholine Esterase|2-Acetyl-1-Alkylglycerophosphocholine Esterase|EC 3.1.1.47|Group-VIIA Phospholipase A2|LDL-Associated Phospholipase A2|LDL-PLA(2)|Lipoprotein-Associated Phospholipase A2|PAF 2-Acylhydrolase|PAF Acetylhydrolase|PLA2G7|gVIIA-PLA2	Platelet-activating factor acetylhydrolase (441 aa, ~50 kDa) is encoded by the human PLA2G7 gene. This protein is involved in platelet-activating factor metabolism.	Platelet-Activating Factor Acetylhydrolase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122067>	C25982	IL34 Gene|IL34|IL34|Interleukin 34 Gene	This gene plays a role in receptor binding and cytokine-dependent signaling.	IL34 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C122068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122068>	C122067	IL34 wt Allele|C16orf77|Chromosome 16 Open Reading Frame 77 Gene|IL-34|Interleukin 34 wt Allele	Human IL34 wild-type allele is located in the vicinity of 16q22.1 and is approximately 81 kb in length. This allele, which encodes interleukin-34 protein, is involved in cytokine receptor signaling.	IL34 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122069>	C20497	Interleukin-34|IL-34|IL34|Interleukin 34	Interleukin-34 (242 aa, ~27 kDa) is encoded by the human IL34 gene. This protein plays a role in binding to macrophage colony-stimulating factor 1 receptor and the induction of receptor signaling.	Interleukin-34		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12206>	C61007	Docetaxel/Filgrastim/Trastuzumab/Vinorelbine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C122070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122070>	C20194	SPAG11B Gene|SPAG11B|SPAG11B|Sperm Associated Antigen 11B Gene	This gene may be involved in sperm maturation and motility.	SPAG11B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C122071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122071>	C122070	SPAG11B wt Allele|BIN1B, Rat, Homolog of Gene|EDDM2B|EP2|EP2C|EP2D|HE2|HE2C|SPAG11|Sperm Associated Antigen 11B wt Allele	Human SPAG11B wild-type allele is located in the vicinity of 8p23.1 and is approximately 21 kb in length. This allele, which encodes sperm-associated antigen 11B protein, may play a role in sperm development.	SPAG11B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122072>	C18466	Sperm-Associated Antigen 11B|Epididymal Protein 2B|He2|Human Epididymis-Specific Protein 2|Protein EP2|Sperm Antigen HE2	Sperm-associated antigen 11B (103 aa, ~11 kDa) is encoded by the human SPAG11B gene. This protein may be involved in the regulation of sperm motility and maturation.	Sperm-Associated Antigen 11B		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122073>	C21275	MMP16 Gene|MMP16|MMP16|Matrix Metallopeptidase 16 (Membrane-Inserted) Gene	This gene plays a role in both extracellular matrix protein degradation and 72 kDa type IV collagenase activation.	MMP16 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C122074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122074>	C122073	MMP16 wt Allele|C8orf57|Chromosome 8 Open Reading Frame 57 Gene|DKFZp761D112|MMP-X2|MMPX2|MT-MMP2|MT-MMP3|MT3-MMP|Matrix Metallopeptidase 16 (Membrane-Inserted) wt Allele|Matrix Metalloproteinase 16 (Membrane-Inserted) Gene|Matrix Metalloproteinase 16, Membrane-Type Gene	Human MMP16 wild-type allele is located in the vicinity of 8q21.3 and is approximately 296 kb in length. This allele, which encodes matrix metalloproteinase-16 protein, is involved in endoproteolysis.	MMP16 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122075>	C18164	Matrix Metalloproteinase-16|EC 3.4.24.-|MMP-16|MMP-X2|MMP16|MT-MMP 3|MT3-MMP|MT3MMP|MTMMP3|Matrix Metalloprotease 16|Matrix Metalloprotease-16|Matrix Metalloproteinase 16|Membrane-Type Matrix Metalloproteinase 3|Membrane-Type-3 Matrix Metalloproteinase|Putative Transmembrane Protein C8orf57	Matrix metalloproteinase-16 (607 aa, ~70 kDa) is encoded by the human MMP16 gene. This protein plays a role in endoproteolysis that mediates 72 kDa type IV collagenase activation and extracellular matrix remodeling.	Matrix Metalloproteinase-16		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122076>	C20194	FAM3C Gene|FAM3C|FAM3C|Family With Sequence Similarity 3, Member C Gene	This gene is involved in the induction of epithelial-mesenchymal transition.	FAM3C Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C122077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122077>	C122076	FAM3C wt Allele|Family With Sequence Similarity 3, Member C wt Allele|GS3786|ILEI	Human FAM3C wild-type allele is located in the vicinity of 7q31 and is approximately 48 kb in length. This allele, which encodes protein FAM3C, plays a role in cell differentiation.	FAM3C wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122078>	C121367	Topical Corticosteroid Therapy|Topical Corticosteroid	Treatment with a corticosteroid formulation designed for and administered onto a dermal, ocular or mucosal surface.			Therapeutic or Preventive Procedure	NICHD Terminology|Pediatric Rheumatology Terminology
C122079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122079>	C18466	Protein FAM3C|Interleukin-Like EMT Inducer|Interleukin-Like Epithelial-Mesenchymal Transition Inducer|Predicted Osteoblast Protein	Protein FAM3C (227 aa, ~25 kDa) is encoded by the human FAM3C gene. This protein is involved in the regulation of epithelial-to-mesenchymal transition.	Protein FAM3C		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12207>	C61063	Carboplatin/Etoposide/Exisulind			Obsolete_Concept	Therapeutic or Preventive Procedure	
C122080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122080>	C15986|C15698	Systemic Corticosteroid Therapy|Systemic Corticosteroid|Systemic corticosteroid	Treatment with corticosteroids via a delivery method that will affect the entire body (oral, intramuscular, intravenous).	Systemic Corticosteroid Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|HL Authorized Value Terminology|HL Concomitant Medication Table|NICHD Terminology|Pediatric Rheumatology Terminology
C122081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122081>	C35869	Radiologic Impression|Impression	The summary or conclusion of the most important radiologic findings.			Finding	
C122082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122082>	C26780	Collagenous Gastritis	A rare type of gastritis characterized by gastric subepithelial collagen deposition and inflammatory infiltrates in the lamina propria.  The pathogenesis of this disorder is unclear although an association with autoimmune disorders has been reported.  It affects both children and adults.  Children present with iron deficiency anemia and have a nodular stomach on gastroscopy.  Adults present with chronic watery diarrhea and may have an associated collagenous colitis.			Disease or Syndrome	
C122083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122083>	C122038	Aortic Augmentation Index at 75bpm|AAUGIX75	The normalization of aortic augmentation index for heart rate, using a standard rate of seventy five beats per minute.			Quantitative Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122084>	C122008	Aortic Augmentation Pressure|AAUGPR	The calculated difference between the second and first aortic systolic peaks, which is an indirect measure of arterial stiffness.			Quantitative Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122085>	C41328	Augmentation Pressure Point P1|AAUGPRP1|Aortic Augmentation Pressure Peak P1|Aortic Augmentation Pressure Peak P1	The first aortic systolic pressure peak, also referred to as a forward wave, used to calculate the aortic augmentation index.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122086>	C41328	Augmentation Pressure Point P2|AAUGPRP2|Aortic Augmentation Pressure Peak P2|Aortic Augmentation Pressure Peak P2	The second aortic systolic pressure peak, also referred to as a returning pressure wave, used to calculate the aortic augmentation index.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122087>	C122008	Pulse Wave Velocity|PWV	The rate at which a pressure wave moves distally through an artery, which is a direct measure of arterial stiffness. Clinically, this value is calculated by placing two pressure catheters a known distance apart (pulse wave distance), measuring the pressure wave's travel time between sensors (pulse transit time), and then dividing the distance by the transit time.	Pulse Wave Velocity		Quantitative Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C122088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122088>	C122008	Ejection Wave Amplitude|EJWAMP	The magnitude of the ejection wave that occurs during ventricular contraction.			Quantitative Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122089>	C122008	Reflection Magnitude|RFLMAG	The reflected-to-forward pressure wave amplitude ratio. (Hashimoto J et al, J Hypertens. 2008 May;26(5):1017-24)			Quantitative Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12208>	C61007	Decitabine/FR901228			Obsolete_Concept	Therapeutic or Preventive Procedure	
C122090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122090>	C122008	Reflection Wave Amplitude|RFLWAMP	The magnitude of the reflected pulse wave that is created when forward blood flow reaches vascular branching points and points of impedance mismatch.			Quantitative Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122091>	C81183	Alanine Measurement|ALA|Alanine|Alanine	The determination of the amount of alanine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122092>	C64431	Glycated Albumin Measurement|ALBGLYCA|Glycated Albumin|Glycated Albumin	The determination of the amount of glycated albumin related peptide present in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122093>	C81971|C74916	Antinuclear IgG Antibody Measurement	The determination of the amount of antinuclear IgG antibody present in a sample.			Laboratory Procedure	
C122094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122094>	C62662|C103351	Alpha-2 Antiplasmin Activity Measurement|APLSMA2A|Alpha-2 Antiplasmin Activity|Alpha-2 Antiplasmin Activity	The determination of the amount of the biological activity of alpha-2 antiplasmin in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122095>	C81183	Arginine Measurement|ARG|Arginine|Arginine	The determination of the amount of arginine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122096>	C81183	Asparagine Measurement|ASN|Asparagine|Asparagine	The determination of the amount of asparagine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122097>	C81183	Aspartic Acid Measurement|ASP|Aspartate|Aspartic Acid|Aspartic Acid	The determination of the amount of aspartic acid present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122098>	C210011|C210010	Borrelia burgdorferi Antibody Measurement	The determination of the amount of Borrelia burgdorferi antibody present in a sample.			Laboratory Procedure	
C122099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122099>	C81969|C122098	Borrelia burgdorferi IgA Antibody Measurement	The determination of the amount of Borrelia burgdorferi IgA antibody present in a sample.			Laboratory Procedure	
C12209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12209>	C61063	Docetaxel/Infliximab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1220>	C2124	Samarium Sm-153 Lexidronam Pentasodium|Quadramet|Quadramet|SAMARIUM SM-153 LEXIDRONAM PENTASODIUM|Samarium Sm 153 Lexidronam Pentasodium|Samarium Sm-153 EDTMP Pentasodium|Samarium-153 EDTMP Pentasodium|Sm 153 Lexidronam Pentasodium|samarium Sm 153 lexidronam pentasodium	The pentasodium salt of samarium Sm 153 lexidronam, a therapeutic agent consisting of a medium energy beta- and gamma-emitting radioisotope, samarium Sm 153, and a teraphosphonate chelator, ethylenediaminetetramethylene phosphonic acid (EDTMP). The chelator moiety of samarium Sm 153 lexidronam associates with hydroxyapatite crystals concentrated in areas of bone turnover, thereby selectively delivering samarium Sm 153-mediated cytotoxic radiation to osteoblastic bone metastases.	Samarium Sm-153 Lexidronam Pentasodium		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C122100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122100>	C81971|C122098	Borrelia burgdorferi IgG Antibody Measurement	The determination of the amount of Borrelia burgdorferi IgG antibody present in a sample.			Laboratory Procedure	
C122101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122101>	C81972|C122098	Borrelia burgdorferi IgM Antibody Measurement	The determination of the amount of Borrelia burgdorferi IgM antibody present in a sample.			Laboratory Procedure	
C122102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122102>	C64430	Beta-defensin 2 Measurement|BD2|BD2|Beta-defensin 2|Beta-defensin 2|Beta-defensin 2	The determination of the amount of beta-defensin 2 in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122103>	C64430	C-C Chemokine Receptor Type 5 Measurement|C-C Chemokine Receptor Type 5|C-C Chemokine Receptor Type 5|CCR5|Soluble CD195	The determination of the amount of C-C chemokine receptor type 5 in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122104>	C67208	CD161a to Lymphocyte Ratio Measurement	The determination of the ratio of CD161a expressing cells to total lymphocytes present in a sample. The measurement by be expressed as a ratio or percentage.			Laboratory Procedure	
C122105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122105>	C67208	CD161 to Lymphocyte Ratio Measurement	The determination of the ratio of CD161 expressing cells to total lymphocytes present in a sample. The measurement by be expressed as a ratio or percentage.			Laboratory Procedure	
C122106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122106>	C67208	CD45 to Lymphocyte Ratio Measurement|PTPRC to Lymphocyte Ratio Measurement	The determination of the ratio of CD45 expressing cells to total lymphocytes present in a sample. The measurement by be expressed as a ratio or percentage.			Laboratory Procedure	
C122107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122107>	C122106	CD45RA to Lymphocyte Ratio Measurement	The determination of the ratio of CD45RA expressing cells to total lymphocytes present in a sample. The measurement by be expressed as a ratio or percentage.			Laboratory Procedure	
C122108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122108>	C64430	Chromogranin A Measurement|CGA|CHGA Measurement|CgA Measurement|Chromogranin A|Chromogranin A|Chromogranin A|Chromogranin-A Measurement|Parathyroid Secretory Protein 1 Measurement|Pituitary Secretory Protein I Measurement|SP-I Measurement	The determination of the amount of chromogranin A present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C122109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122109>	C81183	Citrulline Measurement|CIT|Citrulline|Citrulline	The determination of the amount of citrulline present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12210>	C61007	Asparaginase/Cytarabine/Dexamethasone/Doxorubicin/methotrexate/thioguanine/vincristine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C122110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122110>	C74760	Citrate to Creatinine Ratio Measurement|CITCREAT|Citrate/Creatinine|Citrate/Creatinine|Citric Acid/Creatinine	The determination of the ratio of citrate to creatinine present in a sample. The measurement by be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122111>	C81971	Centromere IgG Antibody Measurement	The determination of the amount of centromere IgG antibody present in a biological specimen.			Laboratory Procedure	
C122112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122112>	C81969	Cardiolipin IgA Antibody Measurement	The determination of the amount of cardiolipin IgA antibody in a biological specimen.			Laboratory Procedure	
C122113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122113>	C74760	Type II Collagen C-Telopeptides to Creatinine Ratio Measurement|CTXIICRT|Type II Collagen C-Telopeptides/Creat|Type II Collagen C-Telopeptides/Creat|Type II Collagen X-Linked C-Telopeptides/Creatinine	The determination of the ratio of type II collagen C-telopeptides to creatinine present in a sample. The measurement by be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122114>	C210010	Desmoglein 1 Antibody Measurement	The determination of the amount of desmoglein 1 antibody in a biological specimen.			Laboratory Procedure	
C122115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122115>	C210010	Desmoglein 3 Antibody Measurement	The determination of the amount of desmoglein 3 antibody in a biological specimen.			Laboratory Procedure	
C122116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122116>	C81971|C171143	Epstein-Barr Early D Antigen IgG Antibody Measurement	The determination of the amount of Epstein-Barr early D antigen IgG antibody in a biological specimen.			Laboratory Procedure	
C122117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122117>	C98799	von Willebrand Factor Activity Measurement|FACTVWA|von Willebrand Factor Activity|von Willebrand Factor Activity	The determination of the amount of the biological activity of von Willebrand factor in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122118>	C98727	Factor X Activity Measurement|FACTXA|FX Activity Measurement|Factor X Activity|Factor X Activity	The determination of the amount of the biological activity of factor X in a sample.	Factor X Activity Measurement		Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122119>	C64840	Fractional Excretion of Magnesium|FEMG|Fractional Magnesium Excretion|Fractional Magnesium Excretion	The percentage of the total magnesium filtered by the kidney that is excreted in the urine. The fractional excretion is calculated by multiplying urinary magnesium concentration by the plasma creatinine concentration, then dividing by the urinary creatinine concentration multiplied by the plasma magnesium concentration. The resulting ratio is multiplied by 100.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12211>	C61063	CpG 7909/Rituximab			Obsolete_Concept	Therapeutic or Preventive Procedure	
C122120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122120>	C74946	Fluoride Measurement|FLUORIDE|Fluoride|Fluoride	The determination of the amount of fluoride present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122121>	C81183	Glutamine Measurement|GLN|GLN|Glutamine|Glutamine|Glutamine	The determination of the amount of glutamine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122122>	C81183	Glycine Measurement|GLY|Glycine|Glycine	The determination of the amount of glycine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122123>	C64848	Hemoglobin S Measurement|HGBS|Hemoglobin S|Hemoglobin S|Sickle Hemoglobin	The determination of the amount of hemoglobin S present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122124>	C81183	Histidine Measurement|HIS|Histidine|Histidine	The determination of the amount of histidine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122125>	C210012|C210010	HTLV-I HTLV-II Antibody Measurement	The determination of the amount of human T-cell lymphotropic virus I and II antibodies present in a sample.			Laboratory Procedure	
C122126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122126>	C81971	Islet Cell Cytoplasmic IgG Antibody Measurement	The determination of the amount of islet cell cytoplasmic IgG antibody present in a sample.			Laboratory Procedure	
C122127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122127>	C81971	Immunoglobulin G Subclass 1 Measurement|IGG1|IgG1 Measurement|Immunoglobulin G Subclass 1|Immunoglobulin G Subclass 1	The determination of the amount of immunoglobulin G subclass 1 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122128>	C81971	Immunoglobulin G Subclass 2 Measurement|IGG2|IgG2 Measurement|Immunoglobulin G Subclass 2|Immunoglobulin G Subclass 2	The determination of the amount of immunoglobulin G subclass 2 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122129>	C81971	Immunoglobulin G Subclass 3 Measurement|IGG3|IgG3 Measurement|Immunoglobulin G Subclass 3|Immunoglobulin G Subclass 3	The determination of the amount of immunoglobulin G subclass 3 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12212>	C61007	Lycopene/Multivitamins			Obsolete_Concept	Therapeutic or Preventive Procedure	
C122130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122130>	C81971	Immunoglobulin G Subclass 4 Measurement|IGG4|IgG4 Measurement|Immunoglobulin G Subclass 4|Immunoglobulin G Subclass 4	The determination of the amount of immunoglobulin G subclass 4 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122131>	C74805	Interleukin 1 Alpha Measurement|INTLK1A|Interleukin 1 Alpha|Interleukin 1 Alpha	The determination of the amount of interleukin-1 alpha present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122132>	C64430	Leucine Aminopeptidase Measurement|Cytosol Aminopeptidase|LAP|LAP3|Leucine Aminopeptidase|Leucine Aminopeptidase|Leucine Aminopeptidase 3|Leucyl Aminopeptidase	The determination of the amount of leucine aminopeptidase related peptide present in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122133>	C81183	Leucine Measurement|LEU|Leucine|Leucine	The determination of the amount of leucine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122134>	C81183	Lysine Measurement|LYS|Lysine|Lysine	The determination of the amount of lysine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122135>	C64430	Myelin Basic Protein Measurement|MBP|Myelin Basic Protein|Myelin Basic Protein	The determination of the amount of myelin basic protein present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122136>	C81971	Mumps Virus IgG Antibody Measurement	The determination of the amount of mumps virus IgG antibody present in a sample.			Laboratory Procedure	
C122137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122137>	C74946	Sodium to Potassium Ratio Measurement|NAK|Sodium/Potassium|Sodium/Potassium	The determination of the ratio of sodium to potassium present in a sample. The measurement by be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122138>	C74742	Normetanephrine Measurement|NORMETA|Normetanephrine|Normetanephrine	The determination of the amount of normetanephrine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122139>	C64430	Oligoclonal Bands Measurement|OLIGBAND|Oligoclonal Bands|Oligoclonal Bands	The determination of the amount of oligoclonal bands in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12213>	C61063	Interferon Alfa/Lamivudine/Zidovudine			Obsolete_Concept	Therapeutic or Preventive Procedure	
C122140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122140>	C81183	Ornithine Measurement|ORNITHIN|Ornithine|Ornithine	The determination of the amount of ornithine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122141>	C81183	Proline Measurement|PRO|Proline|Proline	The determination of the amount of proline present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122142>	C100436	Free Protein S Measurement|PROTSFR|Protein S, Free|Protein S, Free	The determination of the amount of unbound protein S in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122143>	C81969	Phosphatidylserine Antibody IgA Measurement	The determination of the amount of phosphatidylserine antibody IgA present in a sample.			Laboratory Procedure	
C122144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122144>	C81971	Phosphatidylserine Antibody IgG Measurement	The determination of the amount of phosphatidylserine antibody IgG present in a sample.			Laboratory Procedure	
C122145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122145>	C81972	Phosphatidylserine Antibody IgM Measurement	The determination of the amount of phosphatidylserine antibody IgM present in a sample.			Laboratory Procedure	
C122146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122146>	C49237	Reactive Oxygen Metabolite Measurement|ROM|Reactive Oxygen Metabolite|Reactive Oxygen Metabolite	The determination of the amount of reactive oxygen metabolite present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122147>	C81971	RNA Polymerase III IgG Antibody Measurement	The determination of the amount of RNA polymerase III IgG antibody present in a sample.			Laboratory Procedure	
C122148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122148>	C81971|C100458	Scl-70 IgG Antibody Measurement	The determination of the amount of Scl-70 IgG antibody in a biological specimen.			Laboratory Procedure	
C122149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122149>	C81183	Serine Measurement|SER|Serine|Serine	The determination of the amount of serine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12214>	C61063	Docetaxel/Hypericum perforatum			Obsolete_Concept	Therapeutic or Preventive Procedure	
C122150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122150>	C81971	Soluble Liver Antigen IgG Antibody Measurement	The determination of the amount of soluble liver antigen IgG antibody present in a sample.			Laboratory Procedure	
C122151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122151>	C81971|C111317	Smooth Muscle IgG Antibody Measurement	The determination of the amount of smooth muscle IgG antibody present in a sample.			Laboratory Procedure	
C122152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122152>	C210011|C187872	Streptococcus pneumoniae Antigen Measurement|SPNAG|Streptococcus pneumoniae Antigen|Streptococcus pneumoniae Antigen	The determination of the amount of Streptococcus pneumoniae antigen present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122153>	C74946	Sulfate Measurement|SULFATE|Sulfate|Sulfate|Sulphate	The determination of the amount of sulfate present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122154>	C81183	Taurine Measurement|TAURINE|Tauric Acid|Taurine|Taurine	The determination of the amount of taurine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122155>	C64430	Transforming Growth Factor Beta Measurement|TGFB|Transforming Growth Factor Beta|Transforming Growth Factor Beta	The determination of the amount of total transforming growth factor beta in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122156>	C81183	Threonine Measurement|THR|Threonine|Threonine	The determination of the amount of threonine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122157>	C51949	T-Lymphocyte Count|T Cells|T-Cell Count|T-Cell Lymphocytes|T-Cells|T-Lymphocytes|T-Lymphocytes|T-Lymphocytes|TLYCE|TLYCE	The determination of the amount of T-lymphocytes in a biological specimen.			Laboratory Procedure	CDISC SDTM Cell Phenotyping Test Code Terminology|CDISC SDTM Cell Phenotyping Test Name Terminology|CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122158>	C210010	Thyroid Stimulating Hormone Receptor Antibody Measurement|Thyrotropin Receptor Measurement	The determination of the amount of thyroid stimulating hormone receptor antibody present in a sample.			Laboratory Procedure	
C122159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122159>	C81183	Tyrosine Measurement|TYR|Tyrosine|Tyrosine	The determination of the amount of tyrosine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12215>	C61063	Cisplatin/Cyclophosphamide/Doxorubicin/Teniposide|AVEC|CDDP/CTX/DOX/VM-26|VACP			Obsolete_Concept	Therapeutic or Preventive Procedure	
C122160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122160>	C81183	Valine Measurement|VAL|Valine|Valine	The determination of the amount of valine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122161>	C34076	Ward's Triangle|WARDS TRIANGLE	A radiolucent and fracture-prone triangular zone in the proximal femur.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122162>	C19770	Cryoscopy|CRYOSCOPY	A method for measuring the molar concentration of a substance in solution by determining the freezing point of the solution.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122163>	C122039	Duke Incision Method|DUKE INCISION METHOD	A method for assessing bleeding time in which a controlled stab incision is made with a lancet on the earlobe or finger and blood is drawn off of the incision site with blotting paper every 30 seconds until bleeding stops.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122164>	C16410	Enzymatic Ultracentrifugation|ENZYMATIC ULTRACENTRIFUGATION	An ultracentrifugation based method that uses enzymatic catalytic reaction to quantify a substance, which has been separated in solution by an ultracentrifugation process.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122165>	C38081	Forced Oscillation Technique|FORCED OSCILLATION TECHNIQUE|FOT	A non-invasive method to evaluate respiratory mechanical properties of the lung and airways using small-amplitude pressure oscillations superimposed on the normal, tidal breathing of a subject.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122166>	C38081	Impulse Oscillometry|IMPULSE OSCILLOMETRY|IOS	A non-invasive method to measure pulmonary resistance and reactance, and the impedance of the respiratory system, using small pressure oscillation of a regular square wave of pressure 5 times per second.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122167>	C122039	Ivy Incision Method|IVY INCISION METHOD	A method for assessing bleeding time in which the individual wears a blood pressure cuff inflated to 40mmHg, a controlled incision (10mm long x 1mm deep)is made on the volar surface of the arm, and blood is drawn off of the incision site with blotting paper every 30 seconds until bleeding stops.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122168>	C18475	Liquid Chromatography/Tandem Mass Spectrometry|LC/MS/MS	An analytical technique wherein liquid chromatography is coupled to tandem mass spectrometry in order to separate, identify, and quantify substances in a sample.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122169>	C16435	Liquid Chromatography-Fluorescence|LC-FL	An analytical technique where liquid chromatography with a fluorescence detector is used to separate, identify, and quantify substances in a sample.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122170>	C20368	Liquid Scintillation Counting|LIQUID SCINTILLATION COUNTING|LSC	A method for measuring the amount of ionizing radiation in a liquid substance. Samples are mixed with a mixture of solvent, surfactant and scintillators that can convert beta particles into light energy, which can be measured.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122171>	C38081	Peak Flowmetry|PEAK FLOWMETRY	A method for measuring the flow of air through the bronchi upon expiration.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122172>	C49755	pH Meter	An electronic device used to measure the alkalinity or acidity of a liquid or semi-solid substance.			Medical Device	
C122173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122173>	C38081	Plethysmography|Body Box|PLETHYSMOGRAPHY	A method used to measure changes in volume, pressure and resistance within an organ or whole body by means of a plethysmograph.	Plethysmography		Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C122174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122174>	C122039	Template Incision Method|TEMPLATE INCISION METHOD	A modification of the Ivy method for assessing bleeding time in which the individual wears a blood pressure cuff inflated to 40mmHg, a controlled incision is made using an automatic blade on the volar surface of the arm (thus standardizing the incision size), and blood is drawn off of the incision site with blotting paper every 30 seconds until bleeding stops.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122175>	C20589	Transcription-mediated Amplification|TRANSCRIPTION-MEDIATED AMPLIFICATION	A technique used to selectively replicate nucleic acid sequences from RNA templates using reverse transcriptase and RNA polymerase. Reverse transcriptase generates cDNA from the region of interest using primers and then RNA polymerase generates copies of the original RNA template.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122176>	C18475|C16434	Ultra High-performance Liquid Chromatography/Tandem Mass Spectrometry|U-HPLC/MS/MS	An analytical technique wherein ultra-high performance liquid chromatography is coupled to tandem mass spectrometry in order to separate, identify, and quantify substances in a sample.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122177>	C122014	Ascaris lumbricoides|ASCARIS LUMBRICOIDES|Giant Roundworm	A genus of parasitic nematode in the family Ascarididae. A. lumbricoides is the largest intestinal roundworm infecting humans and is the causative agent of ascariasis.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122178>	C85972	Atopobium vaginae|ATOPOBIUM VAGINAE	A species of facultative anaerobic, Gram-positive, rod-shaped or elliptical coccobacillus in the family Coriobacteriaceae. It is commonly isolated from women with bacterial vaginosis and it is implicated in treatment failures.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122179>	C122040	Babesia divergens|BABESIA DIVERGENS	A species of intraerythrocytic protozoan parasites in the family Babesiidae. B. divergens is transmitted by the tick Ixodes ricinus and it is the main causative agent of bovine babesiosis.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122180>	C122040	Babesia microti|BABESIA MICROTI	A species of intraerythrocytic protozoan parasites in the family Babesiidae. B. microti is transmitted by the tick Ixodes scapularis and is the primary causative agent of human babesiosis.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122181>	C76202	Bacillus pumilus|BACILLUS PUMILUS|Bacillus aminoglucosidicus	A species of a Gram-positive, aerobic, spore-forming bacillus in the family Bacillaceae. The species is positive for protease and lipase but negative for amylase, phosphatase, DNase, gelatinase and chitinase. B. pumilus is commonly found in soil and aquatic environments.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122182>	C76204	Bacteroides salyersiae|BACTEROIDES SALYERSIAE	A species of anaerobic, Gram-negative, non-motile bacterium in the family Bacteroidaceae. B. salyersiae is a normal part of the gut flora and an opportunistic pathogen.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122183>	C76204	Bacteroides xylanisolvens|BACTEROIDES XYLANISOLVENS	A species of a Gram-negative, anaerobic, rod-shaped bacterium in the family Bacteroidaceae. B. xylanisolvens is positive for degradation of xylan but negative for degradation of starch. It was isolated from human fecal samples.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122184>	C122041	Balamuthia mandrillaris|BALAMUTHIA MANDRILLARIS	A species of free-living amoeba in the family Balamuthiidae. B. mandrillaris is the causative agent of granulomatous amoebic encephalitis. It was isolated from the brain of a captive baboon and has not been definitively isolated in nature.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122185>	C38081	Total Respiratory System Resistance|RRS	A calculated value based on all factors that influence the flow of gas from the airway opening to the alveoli, including airway resistance, and tissue resistance of the lung and chest wall.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122186>	C38081	Specific Airway Conductance|SGAW|sGaw	A measurement of the airway conductance relative to lung volume.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122187>	C93491	Congenital Abnormality Indicator|CABNIND	Specifies whether any abnormality was present at birth or during the neonatal period.			Conceptual Entity	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122188>	C25150	Estimated Gestational Age|EGESTAGE|EGESTAGE	An approximate calculation of the gestational age of the fetus.			Organism Attribute	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Subject Characteristic Test Code Terminology|CDISC SDTM Subject Characteristic Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122189>	C25337	Number of Early Term Births|ERLYTRMN	A measurement of the total number of birth events at which the gestational age of the neonate is 37 weeks and 0 days through 38 weeks and 6 days.			Organism Attribute	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12218>		Chemotherapy Regimen or Agent Combination|Combination Chemotherapy Regimen	A combination of multiple drugs used in standard or clinical trial treatments. The order, dosage or dosing interval of the individual ingredients may not be specified.			Therapeutic or Preventive Procedure	
C122190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122190>	C19332	Number of Full Term Births|FULLTRMN	A measurement of the total number of birth events at which the gestational age of the neonate is 39 weeks and 0 days through 40 weeks and 6 days.			Organism Attribute	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122191>	C25180	Miscarriage Indicator|MSCRGIND|Spontaneous Abortion Indicator	Specifies whether any pregnancies resulted in miscarriages.			Conceptual Entity	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122192>	C139264	Pregnancy Confirmed Indicator|PCONFIND	Specifies whether the subject's pregnancy has been confirmed.			Conceptual Entity	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122193>	C19332	Number of Premature Births|PREMBTHN	A measurement of the total number of birth events at which the gestational age of the neonate is less than 37 weeks and 0 days.			Organism Attribute	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122194>	C25180	Stillbirth Indicator|STILBIND	Specifies whether any pregnancies resulted in stillbirths.			Conceptual Entity	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122195>	C119241	Blistering Indicator|BLISTIND|BLISTIND|BLISTIND	Specifies whether blistering occurred.			Conceptual Entity	CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Skin Response Test Code Terminology|CDISC SDTM Skin Response Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122196>	C96684	Induration Longest Diameter|IDRLDIAM|IDRLDIAM	The longest diameter of an area of hardness in the skin.			Quantitative Concept	CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Skin Response Test Code Terminology|CDISC SDTM Skin Response Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122197>	C66973	per 4.0 Milliliters|/4.0 mL|/4.0 mL|/4.mL|/4.mL|/4.ml|/4.ml	A volume unit equal to 4.0 milliliters used as a denominator to build a derived unit expressed as a ratio.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122198>	C66973	per 7.5 Milliliters|/(75/10).mL|/(75/10).mL|/(75/10).ml|/(75/10).ml|/7.5 mL|/7.5 mL	A volume unit equal to 7.5 milliliters used as a denominator to build a derived unit expressed as a ratio.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122199>	C66973	per Square Millimeter|/mm2|/mm2|/mm2	An area unit equal to one millimeter squared used as a denominator to build a derived unit expressed as a ratio.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12219>		Anatomic Structure, System, or Substance|Anatomic Structures and Systems	A human biological structure, fluid or other substance; excludes single molecular entities.	Anatomical Concepts		Classification	NICHD Terminology
C1221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1221>	C514	Saperconazole|(+-)-1-sec-Butyl-4-(p-(4-(p-(((2R*,4S*)-2-(2,4-difluorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-delta(sup 2)-1,2,4-triazolin-5-one|R 66905|R66905|SAPERCONAZOLE	A synthetic broad-spectrum fluorinated triazole with potential antifungal activity. Saperconazole preferentially inhibits fungal cytochrome P450 sterol 14 alpha-demethylase (CYP51), an enzyme responsible for the conversion of lanosterol to ergosterol, an important component of the fungal cell membrane. Enzyme inhibition by this agent leads to a decrease in ergosterol pool that distresses synthesis of fungal cell membrane, thereby increases cell membrane permeability, and promotes loss of essential intracellular elements. This ultimately causes fungal cell lysis and death.			Antibiotic|Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C122200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122200>	C67391	Billion per Gram|/ng|1/ng|10*9/g|10*9/g|10^12/kg|10^3/ug|10^6/mg|10^9/g|10^9/g|10^9/g	A unit of measurement equal to 10 to the ninth power of the number of entities per unit of mass equal to one gram.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122201>	C67364	Anson Unit|AU|Anson U|Anson U|{Anson U}|{Anson U}	A unit of enzyme concentration which is defined as the amount of enzyme that can digest urea-denatured hemoglobin at the same initial rate as one milliequivalent of tyrosine at standard conditions (25C and pH 7.50).			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122202>	C111129	IgA Phospholipid Unit|APL U|APL U|APL unit|APL'U|IgA anticardiolipin unit|Immunoglobin A Phospholipid Units|[APL'U]|[APL'U]|[APL'U]|[APL'U]|[APL'U]	A unit for semiquantitative measurement of IgA autoantibodies to proteins associated with negatively charged phospholipids evaluated against an established reference standard.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology|UCUM Terminology
C122203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122203>	C69429	Candela Second per Square Meter|cd*s/m2|cd*s/m2|cd.s/m2|cd.s/m2	A unit of luminous intensity expressed as one candela in one second of light emittance per square meter of area.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122204>	C69429	Candela per Square Meter|cd/m2|cd/m2|cd/m2	A unit of luminous intensity expressed as one candela per square meter of area.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122205>	C68717	Enzyme Immunoassay Unit|EIA unit|EIA unit|EIA value|{EIA unit}|{EIA unit}	A unit for measuring concentration or/and reactivity of a test substance (an antigen or antibody of interest) as defined in the literature reference standard for the particular quantitative enzyme immunoassay method.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122206>	C66973	Femtomole per Liter per Second|Femtomoles per Liter per Second|fmol/L/s|fmol/L/s|fmol/L/s|fmol/L/sec|fmol/L/sec|fmol/l/s|fmol/l/s	A concentration unit equal to one femtomole of solute in one liter of solution per unit of time equal to one second. (NCI)			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122207>	C67375	International Unit per Gram Hemoglobin|IU/g Hb|IU/g Hb|[IU]/g{HGB}|[IU]/g{HGB}	A unit of concentration (biologic activity) equal to one international unit of substance per gram of hemoglobin.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122208>	C67384	International Unit per Millimole|IU/mmol|IU/mmol|[IU]/mmol|[IU]/mmol	A unit of concentration (biologic activity) equal to one international unit of substance per millimole of substance.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122209>	C67365	King-Armstrong Unit per Deciliter|[ka'U]/dL|[ka'U]/dL|[ka'U]/dl|[ka'U]/dl|ka_u/dL|ka_u/dL	A unit of phosphatase concentration that can free one milligram of phenol from disodium phenylphosphate at standard conditions, per unit volume of the mixture equal to one deciliter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12220>	C38617	Lip|LIP|Lip, NOS|Vermillion of the Lip|lip	Fleshy fold which surrounds the opening of the mouth.	Lip		Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C122210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122210>	C66973	Kilogram per Mole|Microgram per Nanomole|Milligram per Micromole|Picogram per Femtomole|g/mmol|g/mmol|gram per millimole|kg/mol|kg/mol|kg/mol|kg/mol|kilogram per mole|mg/umol|pg/fmol|ug/nmol	A unit of mass commonly used to express the molar mass of a substance in kilogram(s) per mole.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C122211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122211>	C67365	Milli-Anson Unit per Milliliter|mAnson U/mL|mAnson U/mL|{mAnson U}/mL|{mAnson U}/mL|{mAnson U}/ml|{mAnson U}/ml	A unit of enzymatic activity defined a one milli-Anson unit per unit volume equal to one milliliter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122212>	C64571	Square Milligram per Square Deciliter|mg2/dL2|mg2/dL2|mg2/dL2|mg2/dl2|mg2/dl2	A unit of mass concentration defined as one square milligram of a substance in unit volume of the mixture equal to one square deciliter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122213>	C69174	Square Millimole per Square Liter|mmol2/L2|mmol2/L2|mmol2/L2|mmol2/l2|mmol2/l2	A unit of concentration (molarity unit) equal to one square millimole of solute per square liter of solution.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122214>	C67425	Milliosmole per Liter|L|mOsm/L|mOsm/L|milliosmole per liter|mosm/L|mosm/L|mosm/L|mosm/l|mosm/l	A unit of osmotic pressure equal to one thousandth of an osmole per unit of volume equal to one Liter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C122215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122215>	C67375	Milliunit per Gram|g|mU/g|mU/g|mU/g|mU/g|millienzyme Unit per gram	An arbitrary unit of substance content expressed in milliunit(s) per gram.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C122216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122216>	C67319	Millivolt per Second|mV/s|mV/s|mV/s|mV/sec|mV/sec|uV/msec	A SI derived rate unit equal to one millivolt per unit of time equal to one second.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122217>	C67375	Nanomole Bone Collagen Equivalents per Nanomole|Nanomoles Bone Collagen Equivalents per Nanomole|nmol BCE/nmol|nmol BCE/nmol|{nmolBCE}/nmol|{nmolBCE}/nmol	A unit of relative amount of substance concentration equal to nanomoles of bone collagen equivalent weight per unit of substance concentration equal to one nanomole.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122218>	C67395	Nanomole per Liter per Hour|Picomole per Milliliter per Hour|nanomole per hour per liter|nmol/L/h|nmol/L/h|nmol/L/h|nmol/L/h|nmol/h/L|nmol/l/h|nmol/l/h|picomole per hour per milliliter|pmol/h/mL|pmol/mL/h|pmol/mL/h	A rate unit expressed in nanomole(s) per liter of solution per period of time equal to sixty minutes.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C122219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122219>	C66973	Nanomole per Liter per Minute|nmol*min/L|nmol/L/min|nmol/L/min|nmol/L/min|nmol/l/min|nmol/l/min|pmol/mL/min	A rate unit equal to the number of nanomoles per unit of volume equal to one liter per unit of time equal to one minute.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12221>	C12223	External Upper Lip|External upper lip|LIP, UPPER	The external surface of the upper lip.	External Upper Lip		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C122220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122220>	C64568	Nanomole per Mole|Femtomole per Micromole|Picomole per Millimole|fmol/umol|nanomole per mole|nmol/mol|nmol/mol|nmol/mol|nmol/mol|picomole per millimole|pmol/mmol|pmol/mmol|pmol/mmol	A unit of fraction expressed as the ratio of the amount of a substance in solution, in nanomoles, to the amount of a different substance in the mixture, in moles.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C122221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122221>	C66973	Plaque Forming Units per Animal|PFU/animal|PFU/animal|[PFU]/{animal}|[PFU]/{animal}	A unit of measure expressed in plaque forming unit(s) per animal.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122222>	C67365	Picokatal per Liter|pkat/L|pkat/L|pkat/L|pkat/l|pkat/l	A unit of catalytic activity concentration defined as activity equal to a picokatal per one liter of the system volume.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122223>	C64567	Picomole per Ten Billion Cells|pmol/10*10{cells}|pmol/10*10{cells}|pmol/10^10 cells|pmol/10^10 cells|pmol/10^10{cells}|pmol/10^10{cells}	A unit of concentration (molarity unit) equal to one picomole of substance per ten to the tenth power cells.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122224>	C64567	Picomole per Billion Cells|pmol/10*9{cells}|pmol/10*9{cells}|pmol/10^9 cells|pmol/10^9 cells|pmol/10^9{cells}|pmol/10^9{cells}	A unit of concentration (molarity unit) equal to one picomole of substance per ten to the ninth power cells.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122225>	C67395	Picomole per Day|d|picomole per day|pmol/d|pmol/d|pmol/d|pmol/day|pmol/day	A unit of amount of substance flow rate equivalent to the rate at which one picomole of substance travels to a given object or space over a period of time equal to 24 hours.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C122226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122226>	C64567	Picomole per Deciliter|Picomoles per Deciliter|dL|picomole per deciliter|pmol/dL|pmol/dL|pmol/dL|pmol/dL|pmol/dl|pmol/dl	A unit of concentration (molarity unit) equal to one picomole of solute per deciliter of solution.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C122227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122227>	C67395	Picomole per Liter per Hour|Picomoles per Liter per Hour|pmol/L/h|pmol/L/h|pmol/L/h|pmol/l/h|pmol/l/h	A rate unit expressed in picomole(s) per liter of solution per period of time equal to sixty minutes.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122228>	C67375	Unit per Trillion Red Blood Cells|/10*12{RBCs}|U/10*12{RBC}|U/10*12{RBC}|U/10^12 RBC|U/10^12 RBC|U/10^12{RBC}|U/10^12{RBC}|per trillion red blood cells	An arbitrary unit of substance content expressed in units of biological activity per ten to the twelfth power red blood cells.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122229>	C66973	Microgram per Liter per Hour|ng/mL/h|ug/L/h|ug/L/h|ug/L/h|ug/l/h|ug/l/h	A rate unit equal to the number of micrograms per unit of volume equal to one liter per unit of time equal to one hour.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12222>	C12223	External Lower Lip|External lower lip|LIP, LOWER	The external surface of the lower lip.	External Lower Lip		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C122230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122230>	C67375	Microgram Equivalent per Liter|ng.eq/mL|ng.eq/mL|ng.eq/ml|ng.eq/ml|ngEq/mL|ngEq/mL|ug.eq/L|ug.eq/L|ug.eq/l|ug.eq/l|ugEq/L|ugEq/L|ugeq/L	A concentration unit measured as a number of microgram equivalent of solute per liter of solution.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122231>	C64568	Micromole per Mole|Femtomole per Nanomole|Nanomole per Millimole|Picomole per Micromole|fmol/nmol|micromole per mole|mol/umol|nanomole per millimole|nmol/mmol|nmol/mmol|nmol/mmol|picomole per micromole|pmol/umol|umol/mol|umol/mol|umol/mol|umol/mol	A unit of fraction expressed as the ratio of the amount of a substance in solution, in micromoles, to the amount of a different substance in the mixture, in moles.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C122232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122232>	C25209|C19332	Body Fat Measurement|BODYFATM	A measurement of the total fat mass within the subject's body.			Clinical Attribute	CDISC SDTM Terminology|CDISC SDTM Vital Sign Test Code Terminology|CDISC SDTM Vital Sign Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122233>	C22188	Laryngeal Pouch|LARYNGEAL POUCH	An accessory mucosal membranous diverticulum of the laryngeal region, found in certain nonhuman primates.			Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122234>	C14421	Black Swiss Mouse|BS	Developed by Dr. Carl Hansen at the NIH, this strain was derived from a cross between NIH Swiss and C57BL/6N mice. The Black Swiss mouse has genotype  Tyrp1B, (a) and is homozygous for the rd1 mutation of the Pde6b gene.			Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122235>	C14421	db/db Mouse|db/db	The diabetic mutant mouse was derived from a spontaneous mutation in a C57BL/K progenitor mouse at the Jackson Laboratory in 1966. The db/db mouse is characterized by abnormal fat deposition at 3-4 weeks of age followed by hyperglycemia, glucosuria, polyuria and the development of lesions in the islets of Langerhans.			Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122236>	C14421	ob/ob Mouse|ob/ob	The obese mutant mouse was derived from a spontaneous mutation in a V/Le progenitor mouse at the Jackson Laboratory in 1949.			Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122237>	C15172	RNU, Rat Strain|RNU|Rowett Nude Rat	An athymic, nude, outbred rat strain derived at the laboratories of the NIH animal genetic resource in 1979-1980.			Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122238>	C81183	Methionine Measurement|MET|Methionine|Methionine	The determination of the amount of methionine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122239>	C120705	Ancylostoma braziliense|ANCYLOSTOMA BRAZILIENSE|Ancylostoma ceylanicum|Ancylostoma ceylonicum	A species of nematodes in the family Ancylostomatidae. A. braziliense infects domestic dogs and cats, wild canids, and occasionally humans. It is endemic in the southern United States.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12223>	C38617	External Lip|External lip, NOS	One of two visible fleshy folds that surround the orifice of the mouth.	External Lip, NOS		Body Part, Organ, or Organ Component	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C122240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122240>	C120705	Ancylostoma caninum|ANCYLOSTOMA CANINUM|Dog Hookworm	A species of nematodes in the family Ancylostomatidae. A. caninum infects domestic dogs and wild canids. It occasionally infects cats and humans. It is largely restricted to temperate, tropical, and sub-tropical regions.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122241>	C120705	Ancylostoma duodenale|ANCYLOSTOMA DUODENALE|European Hookworm|Old World Hookworm	A species of nematodes in the family Ancylostomatidae. A. duodenale infects humans, cats, and dogs. The species is most commonly found in the Mediterranean region, Southeast Asia, and scattered in the Southern Americas.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122242>	C122042	Angiostrongylus cantonensis|ANGIOSTRONGYLUS CANTONENSIS|Rat Lungworm	A species of parasitic nematode in the family Angiostrongylidae. A. cantonensis causes eosinophilic meningitis and is prevalent in Southeast Asia and tropical Pacific islands.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122243>	C122043	Anisakis simplex|ANISAKIS SIMPLEX|Herring Worm	A species of parasitic nematode in the family Anisakidae. A. simplex is the causative agent of anisakiasis.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122244>	C77180	Aspergillus Flavus Complex|ASPERGILLUS FLAVUS COMPLEX	A non-taxanomic grouping of bacteria that have been assigned to the Aspergillus genus and are morphologically and physiologically similar to Aspergillus flavus.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122245>	C77180	Aspergillus Fumigatus Complex|ASPERGILLUS FUMIGATUS COMPLEX	A non-taxanomic grouping of bacteria that have been assigned to the Aspergillus genus and are morphologically and physiologically similar to Aspergillus fumigatus.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122246>	C122015	Balantidium coli|BALANTIDIUM COLI|Paramecium coli	A species of ciliated intestinal protozoan parasites in the family Balantiididae. Infection occurs by ingestion of a cyst, with the motile trophozoite residing in the large intestine. B. coli is the largest protozoan that infects humans.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122247>	C86194	Bifidobacterium animalis|BIFIDOBACTERIUM ANIMALIS	A species of a Gram-positive, anaerobic, rod-shaped bacterium in the family Bifidobacteriaceae. B. animalis does not ferment alpha-l-fucose, D-glucuronate, amylose, arabinogalactan, porcine gastric mucin, arabic gum, ghatti gum, or tragacanth gum. This bacteria is a normal part of the gut flora and is frequently used as a probiotic.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122248>	C86194	Bifidobacterium breve|BIFIDOBACTERIUM BREVE|Bifidobacterium parvulorum	A bacterial species in the family Bifidobacteriaceae. B. breve ferments alpha-l-fucose but does not ferment D-blucuronate, arabinogalactan, xylan, porcine gastric mucin, or gums. This bacteria is a normal part of the gut flora and is frequently used as a probiotic.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122249>	C86194	Bifidobacterium pseudocatenulatum|BIFIDOBACTERIUM PSEUDOCATENULATUM	A bacterial species in the family Bifidobacteriaceae. B. pseudocatenulatum hydrolyzes phytate and ferments amylopectin and amylose and does not ferment D-galactosamine, D-glucuronate, arabinogalactan, pectin, or gums. This bacteria is a normal part of the gut flora and is frequently used as a probiotic.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12224>	C12226	Mucosa of the Upper Lip|Mucosa of Upper Lip|Mucosa of upper lip	The lining of the superior fleshy fold bordering the mouth. It is comprised of the epithelium, basement membrane, lamina propria mucosae, and lamina muscularis mucosae.	Mucosa of Upper Lip		Body Part, Organ, or Organ Component	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C122250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122250>	C77167	Bipolaris|BIPOLARIS	A genus of moderately fast growing dematiaceous fungi in the family Pleosporaceae with straight, fusiform to ellipsoidal pseudoseptate conidia. The genus contains about 45 species which are mostly subtropical and tropical plant parasites; however several species, notably B. australiensis, B. hawaiiensis, and B. spicifera are well documented human pathogens.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122251>	C122016	Blastocystis hominis|BLASTOCYSTIS HOMINIS	A species of protozoan parasites in the family Blastocystidae. External transmission of B. hominis is believed to occur by infection with a cyst. The cysts infect epithelial cells of the digestive tract and multiply asexually.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122252>	C86206	Borrelia miyamotoi|BORRELIA MIYAMOTOI	A species of Gram-negative, anaerobic, spiral-shaped bacteria in the family Spirochaetaceae. B. miyamotoi can be transferred to humans through the bite of an infected tick and is the causative agent of Borrelia miyamotoi disease, a relapsing fever.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122253>	C86228	Buttiauxella ferragutiae|BUTTIAUXELLA FERRAGUTIAE|CDC Enteric Group 63	A species of facultatively anaerobic, Gram-negative, rod-shaped bacteria in the family Enterobacteriaceae. B. ferragutiae is positive for lysine decarboxylase and D-sorbitol metabolism and negative for ketogluconate and malonate activity. It was originally isolated from soil.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122254>	C86228	Buttiauxella gaviniae|BUTTIAUXELLA GAVINIAE|CDC Enteric Group 64	A species of facultatively anaerobic, Gram-negative, rod-shaped bacteria in the family Enterobacteriaceae. B. gaviniae is positive for arginine dihydrolase, 5-ketogluconate, and palatinose reactions and negative for ornithine decarboxylase and raffinose reactions.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122255>	C86228	Buttiauxella noackiae|BUTTIAUXELLA NOACKIAE|CDC Enteric Group 59	A species of facultatively anaerobic, Gram-negative, rod-shaped bacteria in the family Enterobacteriaceae. B. noackiae is positive for N-acetyl-L-glutamine, L-arginine dihydrolase, melibiose, and L-ornithine decarboxylase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122256>	C122044	Calodium hepaticum|CALODIUM HEPATICUM|Capillaria hepatica	A species of parasitic nematodes in the family Capillariidae. C. hepaticum causes hepatic capillariasis in rodents and other mammals. Its life cycle is completed in a single host species but the eggs must mature outside of the host body prior to infecting a new host.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122257>	C122044	Capillaria philippinensis|CAPILLARIA PHILIPPINENSIS|Paracapillaria philippinensis	A species of parasitic nematodes in the family Capillariidae. C. philippinensis causes intestinal capillariasis. Its life cycle involves fish as intermediate hosts and fish-eating birds as definitive hosts. Humans acquire C. philippinensis by eating infested fish.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122258>	C77167	Chaetomium|CHAETOMIUM	A genus of rapidly growing moniliaceous fungi in the family Chaetomiaceae characterized by the production of solitary, hyaline, smooth walled aleurioconidia. Species in this genus are normally found in soil, air, cellulose and plant debris. Some species within the genus are causative agents of infections in immunocompromised individuals.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122259>	C122017	Chilomastix mesnili|CHILOMASTIX MESNILI	A species of nonpathogenic flagellates in the family Retortamonadidae. C. mesnili trophozoites reside in the human cecum and/or colon and transmission occurs by ingestion of cysts.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12225>	C12226	Mucosa of the Lower Lip|Mucosa of Lower Lip|Mucosa of lower lip	The lining of the inferior fleshy fold bordering the mouth. It is comprised of the epithelium, basement membrane, lamina propria mucosae, and lamina muscularis mucosae.	Mucosa of Lower Lip		Body Part, Organ, or Organ Component	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C122260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122260>	C77167	Chrysosporium|CHRYSOSPORIUM	A genus of of hyaline hyphomycetes fungi in the family Onygenaceae characterized by the production of solitary, hyaline, smooth walled aleurioconidia. Although they are rarely encountered in human skin infections, Chrysosporium species have been identified as an emerging infectious agent in North American snakes.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122261>	C77167	Cladosporium|CLADOSPORIUM	A genus of fungi in the family Davidiellaceae with olive-green to brown or black colonies and dark-pigmented conidia that are formed in simple or branching chains. Cladosporium species occur as a plant pathogens and contaminants for other foods and their airborne spores are significant allergens.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122262>	C123338	Clonorchis sinensis|CLONORCHIS SINENSIS|Chinese Liver Fluke|Oriental liver fluke	A species of liver fluke in the class Trematoda. The life cycle of C. sinensis involves freshwater snails, fish, and humans. In humans they are found mainly in the common bile duct and gall bladder where they feed on bile.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122263>	C76275	Clostridium aldenense|CLOSTRIDIUM ALDENENSE	A species of gram-positive, obligate anaerobic bacteria in the family Clostridiaceae. C. aldenense is differentiated from others in the clostridioforme group by exhibiting a positive indole reaction.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122264>	C76275	Clostridium citroniae|CLOSTRIDIUM CITRONIAE	A species of gram-positive, obligate anaerobic bacteria in the family Clostridiaceae. C. aldenense is indole positive and produces acid from glucose, maltose, mannose, rhamnose, sucrose, trehalose, and xylose but not from cellobiose, esculin, lactose, mannitol, melezitose, raffinose, salicin, sorbitol, or starch. This species does not hydrolyze urea, esculin, starch, or gelatin or reduce nitrate.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122265>	C76275	Clostridium oroticum|CLOSTRIDIUM OROTICUM|Zymobacterium oroticum	A species of mesophilic and nonmotile bacteria in the family Clostridiaceae. C. oroticum is distinguished by its occurrence as oval Gram-positive cells in chains of 100 or more units and its ability to metabolize orotic acid.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122266>	C76275	Clostridium spiroforme|CLOSTRIDIUM SPIROFORME	A species of helically coiled, obligately anaerobic, non-motile, gram-positive, spore-forming, rod-shaped bacteria in the family Clostridiaceae. Unlike most clostridia, C. spiroforme does not produce butyric acid as an end product of glucose fermentation. The species produces a toxin that is associated with severe diarrhea and enterocolitis in rabbits.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122267>	C122046	Coliform Bacteria, Lactose Fermenting|COLIFORM BACTERIA, LACTOSE FERMENTING	Any rod-shaped, gram-negative, non-spore forming bacteria that is capable of fermenting lactose to produce acid and gas.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122268>	C122046	Coliform Bacteria, Non-Lactose Fermenting|COLIFORM BACTERIA, NON-LACTOSE FERMENTING	Any rod-shaped, gram-negative, non-spore forming bacteria that is incapable of fermenting lactose to produce acid and gas.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122269>	C76308	Corynebacterium coyleae|CORYNEBACTERIUM COYLEAE	A species of non-motile, catalase-positive, non-lipophilic, pleomorphic coryneform bacteria in the family Corynebacteriaceae. C. coyleae is characterized by slow fermentative acid production from glucose but no acid production from maltose and sucrose and a strongly positive CAMP reaction. The species produces acid from fructose, glucose, maltose, and sucrose and is urease-positive.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12226>	C77637	Mucosa of the Lip|Labial Mucosa|MUCOSA OF THE LIP|Mucosa of Lip|Mucosa of lip, NOS|Non-Hair Bearing Lip|labial mucosa	The lining of the fleshy folds surrounding the mouth. It is comprised of the epithelium, basement membrane, lamina propria mucosae, and lamina muscularis mucosae.	Mucosa of Lip, NOS		Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C122270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122270>	C86312	Corynebacterium diphtheriae bv. gravis|CORYNEBACTERIUM DIPHTHERIAE TYPE GRAVIS	A biovar of Corynebacterium diphtheriae distinguished by its morphogenic and biochemical properties. Biovar gravis is nitrate positive and positive for fermentation of glucose, maltose, and starch. This biovar is one of the two main disease-causing biovars.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122271>	C86312	Corynebacterium diphtheriae bv. intermedius|CORYNEBACTERIUM DIPHTHERIAE TYPE INTERMEDIUS	A biovar of Corynebacterium diphtheriae. Biovar intermedius is nitrate positive and positive for fermentation of glucose and maltose.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122272>	C86312	Corynebacterium diphtheriae bv. mitis|CORYNEBACTERIUM DIPHTHERIAE TYPE MITIS	A biovar of Corynebacterium diphtheriae. Biovar mitis is nitrate positive and positive for fermentation of glucose and maltose.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122273>	C86312	Corynebacterium diphtheriae bv. belfanti|CORYNEBACTERIUM DIPHTHERIAE VAR. BELFANTI	A biovar of Corynebacterium diphtheriae distinguished by its morphogenic and biochemical properties. Biovar belfanti is positive for fermentation of glucose and maltose. This biovar is one of the two main disease-causing biovars.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122274>	C76308	Corynebacterium mucifaciens|CORYNEBACTERIUM MUCIFACIENS	A species of aerobic, non-motile, non-spore forming, non-partially acid-fast, gram-positive, coryneform bacteria in the family Corynebacteriaceae. C. mucifaciens is catalase positive, nonfermenting, nitrate reduction negative, and urea and esculin hydrolysis negative; acid was produced from glucose but not from maltose, mannitol, and xylose. The species is nonlipophilic and negative for the CAMP reaction.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122275>	C76308	Corynebacterium simulans|CORYNEBACTERIUM SIMULANS	A species of nonlipophilic, non-motile, fermentative, catalase-positive bacteria in the family Corynebacteriaceae. C. simulans is positive for nitrate and the nitrite reductase test, does not ferment maltose, and is unable to acidify ethylene glycol.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122276>	C77214	Cryptosporidium parvum|CRYPTOSPORIDIUM PARVUM	A species of parasitic protozoa in the family Cryptosporidiidae. C. parvum is one of the main agents of cryptosporidiosis. Transmission occurs mainly through contact with contaminated water and infection is generally self-limiting in immunocompetent individuals.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122277>	C77167	Curvularia|CURVULARIA	A genus of hyphomycete fungi in the family Pleosporaceae. Members of the genus are normally found in the soil, but are facultative pathogen of many plant species. Three species have been recovered from human infections, principally from cases of mycotic keratitis.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122278>	C122047	Cyclospora cayetanensis|CYCLOSPORA CAYETANENSIS|Cyclospora cayetanesis	A species of apicomplexan, cyst-forming coccidian protozoa in the family Eimeriidae. C. cayetanensis appears to be the causative agent of all cases of human cyclosporiasis and humans are its only known host.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122279>	C26431	Deltacoronavirus|Coronavirus Group 3|DELTACORONAVIRUS	A genus of enveloped and spherical positive sense ssRNA viruses in the subfamily Coronavirinae of the family Coronaviridae with a diameter of about 120 nm. Deltacoronaviruses have a nonopartite, linear genome of 26-26.5 kb. Birds are the most common reservoir for deltacoronaviruses.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12227>	C38617	Commissure of the Lip|Commissure of Lip|Commissure of lip|LABIAL JUNCTION|Labial Commissure (Mouth)|Labial Junction	The junction of the upper and lower lips at the corner of the mouth.	Commissure of Lip		Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C122280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122280>	C122009	Dialister micraerophilus|DIALISTER MICRAEROPHILUS	A species of Gram-negative, non-motile, non-sporulating, rod-shaped bacteria in the family Veillonellaceae. D. micraerophilus is generally anaerobic but will also grow under microaerophilic conditions. It can be differentiated from other Dialister species by phenylalanine arylamidase activity and tyrosine arylamidase activity.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122281>	C122009	Dialister pneumosintes|Bacillus pneumosintes|Bacteroides pneumosintes|DIALISTER PNEUMOSINTES	A species of Gram-negative, non-fermenting, anaerobic, rod-shaped bacterium in the family Veillonellaceae. The species was first isolated from nasopharyngeal secretions of patients during the flu epidemic of 1918 to 1921.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122282>	C122010	Dientamoeba fragilis|DIENTAMOEBA FRAGILIS	A species of nonflagellate trichomonad parasites in the family Dientamoebidae. Infections occurs through direct fecal-oral spread. Nonhuman primates are its only natural hosts.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122283>	C14248	Dipetalonema|DIPETALONEMA	A genus of hematophagous parasitic nematodes in the superfamily Filarioidea. Species in this genus are transmitted by gnats to humans and other vertebrates, producing microfilariae in the blood or tissue fluids. They live as adults in deep connective tissue or on membranes or visceral surfaces.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122284>	C122045	Diphyllobothrium latum|Broad Fish Tapeworm|DIPHYLLOBOTHRIUM LATUM	A species of tapeworms in the family Diphyllobothriidae. The lifecycle of D. latum involves crustaceans, freshwater fish, and humans. Humans become infested by eating infested fish. The resulting tapeworm is the largest human tapeworm.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122285>	C122045	Dipylidium caninum|Cucumber Tapeworm|DIPYLIDIUM CANINUM|Double-pore Tapeworm|Flea Tapeworm	A species of tapeworms in the family Dipylidiidae. The definitive host for D. caninum is the dog, with intermediate hosts of fleas and chewing lice. Humans can become infected by ingesting an infected flea.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122286>	C122020	Dolosigranulum pigrum|DOLOSIGRANULUM PIGRUM	A species of gram-positive, catalase-negative, non-pigmented, nonmotile, coccus-shaped bacteria in the family Carnobacteriaceae. D. pigrum is positive for pyrrolidonylarylamidase, leucine aminopeptidase, and arginine dehydrogenase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122287>	C76197	Dorea|DOREA	A genus of Gram-positive, obligately anaerobic, non-spore-forming, rod-shaped bacterium in the phylum Firmicutes.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122288>	C122011	Dracunculus medinensis|DRACUNCULUS MEDINENSIS|Guinea worm	A species of parasitic nematode in the family Dracunculidae. The lifecycle of D. medinensis involves copepods and humans. Humans become infected by drinking water containing infected copepods.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122289>	C122025	Echinococcus granulosus|ECHINOCOCCUS GRANULOSUS|Hydatid Worm|Hyper Tapeworm	A species of cyclophyllid tapeworms in the family Taeniidae. The lifecycle for E. granulosus involves ungulates as the intermediate host and canids as the definitive host. Infestation causes cystic echinococcosis. Humans are not a natural host of the parasite, but in very rare cases can be infected by ingesting eggs from canid feces.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12228>	C38626|C38617	Base of Tongue|BASE OF THE TONGUE|Base of the Tongue|Base of tongue|Base of tongue|Base of tongue, NOS|Posterior Tongue|Structure of root of tongue (body structure)|posterior part of tongue	The posterior one third of the tongue behind the terminal sulcus that forms the anterior aspect of the oropharynx responsible for swallowing and modification of the voice in speech.	Base of Tongue		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C122290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122290>	C122025	Echinococcus multilocularis|ECHINOCOCCUS MULTILOCULARIS	A species of cyclophyllid tapeworms in the family Taeniidae. The lifecycle for E. multilocularis involves rodents as the intermediate host and canids as the definitive host. This species causes alveolar echinococcosis.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122291>	C122025	Echinococcus vogeli|ECHINOCOCCUS VOGELI	A species of cyclophyllid tapeworms in the family Taeniidae. Common in the neotropics, E. vogeli has a lifecycle that involves the paca as the intermediate host and the bush dog as the definitive host. This species causes polycystic echinococcosis in humans.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122292>	C76196	Ehrlichia|Cowdria|EHRLICHIA|Kurlovia|Nicollea	A genus of tick-borne bacteria in the family Anaplasmataceae. Ehrlichia are obligately intracellular pathogens and are the causative agent of ehrlichiosis.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122293>	C123335	Encephalitozoon|ENCEPHALITOZOON|Septata	A genus of single-celled microsporidian fungi in the family Unikaryonidae. Members of the genus are obligate intracellular parasites and were once thought to be protozoans or protists. Encephalitozoonosis is rare in healthy people, but it is a common cause of severe infections in immunocompromised individuals.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122294>	C122018	Endolimax nana|ENDOLIMAX NANA	A species of amoebozoa in the phylum Archamoebae. Although E. nana is generally considered nonpathogenic it may be a cause of intermittent or chronic diarrhea.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122295>	C122048	Entamoeba coli|ENTAMOEBA COLI	A species of commensal parasite in the class Archamoebae. E. coli is considered nonpathogenic.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122296>	C122048	Entamoeba hartmanni|ENTAMOEBA HARTMANNI	A species of commensal parasite in the class Archamoebae. E. hartmanni is considered nonpathogenic. Cysts are transmitted through contaminated food or water.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122297>	C122048	Entamoeba histolytica|ENTAMOEBA HISTOLYTICA	A species of anaerobic parasitic protozoa in the class Archamoebae. E. histolytica is the causative agent of invasive amoebiasis. Cysts are transmitted through contaminated food or water.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122298>	C122048	Entamoeba polecki|ENTAMOEBA POLECKI	A species of commensal parasite in the class Archamoebae. E. polecki is considered nonpathogenic. This species is primarily a parasite of pigs and monkeys, and human infection is more prevalent in areas where the people have animal contact.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122299>	C76310	Enterobacter cloacae Complex|ENTEROBACTER CLOACAE COMPLEX	A non-taxonomic grouping of at least six bacterial species that are morphologically similar to the Enterobacter cloacae species.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12229>	C38617	Palate|PALATE|Palate, NOS|palate	The roof of the oral cavity. It separates the oral cavity from the nasal cavity.	Palate		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C1222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1222>	C210976	Miglustat|1,5-(butylimino)-1,5-dideoxy-D-glucitol|3,4,5-Piperidinetriol, 1-butyl-2-(hydroxymethyl)-,(2R-(2alpha,3beta,4alpha,5beta))-|MIGLUSTAT|N-Butyl Deoxynojirimycin|N-Butylmoranoline|SC 48334|SC-48334|Zavesca	A synthetic, N-alkylated imino analogue of D-glucose. Miglustat competitively and reversibly binds to and inhibits the activity of UDP-glucose ceramide glucosyltransferase, which catalyzes the initial step in the synthesis of glycosphingolipids (GSL). This leads to a decrease in the production of glycosphingolipid, which has important roles in various cellular processes. Miglustat can be used in substrate reduction therapy in diseases in which the enzyme glucocerebrosidase, that is responsible for the breakdown of GSL, is deficient.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C122300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122300>	C122012	Enterobius vermicularis|ENTEROBIUS VERMICULARIS	A species of parasitic pinworms in the family Oxyuridae. Infestation with E. vermicularis causes enterobiasis in humans. Its entire lifecycle takes place in the gastrointestinal tract of a single human host.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122301>	C76311	Enterococcus saccharolyticus|ENTEROCOCCUS SACCHAROLYTICUS|Streptococcus saccharolyticus	A species of Gram-positive, catalase-negative, facultatively anaerobic, fermentative, non-motile, coccus-shaped bacteria in the family Enterococcaceae.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122302>	C123335	Enterocytozoon|ENTEROCYTOZOON	A genus of microsporidian fungi in the family Enterocytozoonidae. Members of the genus are obligate intracellular parasites, infectibg intestinal epithelial cells. Cases of intestinal microsporidiosis due to Enterocytozoon are sometimes seen in immunocompromised individuals.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122303>	C122019	Enteromonas hominis|ENTEROMONAS HOMINIS	A species of nonpathogenic flagellate protozoa in the family Enteromonadidae. Trophozoites reside in the large intestine of humans, primates, and rodents, and infection occurs after the ingestion of cysts in fecal-contaminated food or water.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122304>	C77167	Epicoccum|EPICOCCUM	A genus of dematiaceous mitosporic fungi in the family Pleosporaceae. Members of the genus are normally found in soil, plant litter, decaying plants, or damaged plant tissue, but may also occur on building materials. Epicoccum infection in humans or animals has not been documented.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122305>	C14206	Escherichia coli, Extended-spectrum Beta-lactamase Positive|ESCHERICHIA COLI, ESBL|Escherichia coli, Extended-spectrum Beta-lactamases	Any strain of Escherichia coli that is resistant to penicillins, cephalosporins, and aztreonam. These strains are often cross-resistant to trimethoprim/sulfamethoxazole and quinolones.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122306>	C77167	Exserohilum|EXSEROHILUM	A genus of asexual dematiaceous fungi in the family Pleosporaceae which produces conidia with an exserted hilum. Members of the genus live on plant material like grasses, rotten wood, and in the soil, but three species have been identified as human pathogens.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122307>	C86392	Facklamia hominis|FACKLAMIA HOMINIS	A species of gram-positive, catalase-negative, facultatively anaerobic, coccus-shaped bacteria in the family Firmicutes. F. hominis is a normal part of the female genital tract flora but may act as an opportunistic pathogen.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122308>	C122021	Fasciola hepatica|FASCIOLA HEPATICA|Sheep liver fluke	A species of flatworms in the family Fasciolidae. The life cycle of F. hepatica involves snails as the intermediate host and humans and herbivores as the definitive host. Infection usually occurs through consumption of contaminated water plants.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122309>	C122022	Fasciolopsis buski|FASCIOLOPSIS BUSKI	A species of parasitic tremadoda flatworms in the family Fasciolidae. The life cycle of F. buski involes snails as the intermediate host and pigs and humans as the definitive host. It is the largest intestinal fluke of humans.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12230>	C38617	Hard Palate|HARD PALATE|Hard palate|Hard palate|Hard palate structure (body structure)|PALATE, HARD|hard palate|hard palate|palatum durum	The bony anterior part of the roof of the mouth separating the nose from the mouth.	Hard Palate		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C122310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122310>	C76197	Flavonifractor|FLAVONIFRACTOR	A genus of strictly anaerobic, Gram-variable, bacillus-shaped bacteria with variable motility in the family Firmicutes. Bacteria in the genus are asaccharolytic and weakly fermentative on glucose, fructose, and ribose.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122311>	C77167	Fonsecaea|FONSECAEA	A genus of soil fungi in the family Herpotrichiellaceae characterized by indistinct melanised conidiophores with blunt, scattered denticles bearing conidia singly or in short chains that eventually become branched. Both species in this genus can cause chromoblastomycosis following skin damage.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122312>	C76323	Fusobacterium periodonticum|FUSOBACTERIUM PERIODONTICUM	A species of non-motile bacteria in the family Fusobacteriaceae. F. periodonticum is characterized by its ability to ferment only on glucose, fructose, and galactose and an ability to hydrolyze hippurate.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122313>	C26431	Gammacoronavirus|Coronavirus group 3|GAMMACORONAVIRUS	A genus of enveloped and spherical positive sense ssRNA viruses in the subfamily Coronavirinae of the family Coronaviridae with a diameter of about 120 nm. Gammacoronaviruses have a nonopartite, linear genome of 27-32 kb. Birds are the most common reservoir for gammacoronaviruses.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122314>	C77167	Geomyces|GEOMYCES	Either of two genera of filamentous fungi in the phylum Ascomycota that are characterized by conidiophores bearing branched clusters of small oval- or pear-shaped arthroconidia. Geomyces destructans is the causative agent of white-nose syndrome in hibernating bats.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122315>	C77167	Geotrichum|GEOTRICHUM	A genus of fungi in the family Endomycetaceae, found in soil and water and characterized by chains of hyaline, smooth, one-celled, subglobose to cylindrical, slimy arthroconidia. Species within Geotrichum are the causative agents of geotrichosis.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122316>	C77213	Giardia lamblia|GIARDIA LAMBLIA|Giardia duodenalis|Giardia intestinalis|Lamblia intestinalis	A species of flagellated protozoan parasite in the family Hexamitidae. It is the causative agent of giardiasis.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122317>	C77167	Gliocladium|GLIOCLADIUM	A genus of asexual fungi in the family Hypocreaceae characterized by hyphae, conidiophores, and conidia borne from hyaline phialides. Gliocladium is not known to be pathogenic in humans or animals.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122318>	C122023	Gnathostoma spinigerum|GNATHOSTOMA SPINIGERUM	A species of parasitic nematodes in the family Gnathostomatidae. The life cycle of G. spinigerum involves copepods of the genus Cyclops as the first intermediate host, freshwater fish as the second intermediate host, and canine and feline species, and possibly pigs, as the the definitive hosts.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122319>	C173514	Gram-Negative Coccobacillus|GRAM-NEGATIVE COCCOBACILLUS	Any bacteria with a shape between that of a sphere and a rod that contains low levels of peptidoglycan in its cell wall and stains pink with the Gram staining technique.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12231>	C38617	Soft Palate|PALATE, SOFT|SOFT PALATE|Soft palate structure (body structure)|Soft palate, NOS|soft palate|soft palate	The muscular extension of the hard palate which comprises the posterior of the oral cavity and the floor of the nasal cavity.	Soft Palate		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C122320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122320>	C173514	Gram-Negative Diplococcus|GRAM-NEGATIVE DIPLOCOCCUS	Any bacteria appearing as paired spheres that contains low levels of peptidoglycan in its cell wall and stains pink with the Gram staining technique.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122321>	C86421	Gram-Negative Microaerophilic Bacillus|GRAM-NEGATIVE MICROAEROPHILIC BACILLUS	Any rod-shaped bacteria that contains low levels of peptidoglycan in its cell wall and stains pink with the Gram staining technique and that require oxygen to grow but are poisoned by high concentrations of oxygen.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122322>	C86422	Gram-Negative Microaerophilic Coccus|GRAM-NEGATIVE MICROAEROPHILIC COCCUS	Any sphere-shaped bacteria that contains low levels of peptidoglycan in its cell wall and stains pink with the Gram staining technique and that require oxygen to grow but are poisoned by high concentrations of oxygen.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122323>	C124278	Hymenolepis nana|Dwarf Tapeworm|HYMENOLEPIS NANA|Taenia nana|Vampirolepis nana	A species of tapeworm in the family Hymenolepididae. The lifecycle of H. nana involves insects as the intermediate host and rodents or humans as the definitive host. Eggs may also be transferred directly from person to person.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122324>	C76275	Intestinibacter bartlettii|Clostridium bartlettii|INTESTINIBACTER BARTLETTII	A species of obligately anaerobic, Gram-positive, rod-shaped, non-motile, spore-forming bacteria in the family Clostridiaceae. I. bartlettii is negative for lecithinase, lipase, catalase and urease, and is unable to hydrolyze esculin or gelatin, or reduce nitrate to nitrite, but positive for acid phosphatase, galactosidase and beta-glucuronidase. The species was originally isolated from fecal samples.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122325>	C192229	Isospora|ISOSPORA	A genus of coccidian parasites in the family Eimeriidae. They are the causative agents of isosporiasis. Most members of the genus infect a single host species.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122326>	C118942	Mansonella ozzardi|Filaria ozzardi|MANSONELLA OZZARDI|Tetrapetalonema ozzardi	A species of parasitic nematodes in the family Onchocercidae. The lifecycle of M. ozzardi involves biting midges or blackflies and humans. Infestation causes serous cavity filariasis.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122327>	C118942	Mansonella streptocerca|Dipetalonema streptocerca|MANSONELLA STREPTOCERCA	A species of parasitic nematodes in the family Onchocercidae. The lifecycle of M. streptocerca involves biting midges and humans. Infestation causes streptocerciasis.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122328>	C122013	Wuchereria bancrofti|Filaria bancrofti|WUCHERERIA BANCROFTI	A species of parasitic nematodes in the family Onchocercidae. Infestation with W. bancrofti causes lymphatic filariasis. It is spread by a mosquito vector, its intermediate host.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122329>	C102356	Accumulation Ratio Area Under the Curve from T1 to T2|ARAUCINT|Accumulation Ratio AUC from T1 to T2|Accumulation Ratio AUC from T1 to T2	The area under the curve from T1 to T2 at steady state divided by the area under the curve from T1 to T2 during the initial dosing interval.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12232>	C38617	Uvula|PALATINE UVULA|Palatine Uvula|palatine uvula|palatine uvula|uvula|uvula|uvula of palate|uvula palatina	The fleshy lobe that hangs at the back of the soft palate.	Uvula		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C122330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122330>	C122049	Renal Clearance from T1 to T2 Normalized by Body Mass Index|RNCLINTB|Renal CL from T1 to T2 Norm by BMI|Renal CL from T1 to T2 Norm by BMI	The clearance of a substance from the blood by the kidneys over the interval from T1 to T2 divided by the body mass index.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122331>	C122049	Renal Clearance from T1 to T2 Normalized by Dose|RNCLINTD|Renal CL from T1 to T2 Norm by Dose|Renal CL from T1 to T2 Norm by Dose	The clearance of a substance from the blood by the kidneys over the interval from T1 to T2 divided by the dose.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122332>	C122049	Renal Clearance from T1 to T2 Normalized by Surface Area|RNCLINTS|Renal CL from T1 to T2 Norm by SA|Renal CL from T1 to T2 Norm by SA	The clearance of a substance from the blood by the kidneys over the interval from T1 to T2 divided by the surface area.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122333>	C122049	Renal Clearance from T1 to T2 Normalized by Weight|RNCLINTW|Renal CL from T1 to T2 Norm by WT|Renal CL from T1 to T2 Norm by WT	The clearance of a substance from the blood by the kidneys over the interval from T1 to T2 divided by the weight.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122334>	C122050	Renal Clearance for Dose Interval Normalized by Body Mass Index|RNCLTAUB|Renal CL for Dose Int Norm by BMI|Renal CL for Dose Int Norm by BMI	The clearance of a substance from the blood by the kidneys, calculated using the area under the curve over the dosing interval, divided by the body mass index.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122335>	C122050	Renal Clearance for Dose Interval Normalized by Dose|RNCLTAUD|Renal CL for Dose Int Norm by Dose|Renal CL for Dose Int Norm by Dose	The clearance of a substance from the blood by the kidneys, calculated using the area under the curve over the dosing interval, divided by the dose.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122336>	C122050	Renal Clearance for Dose Interval Normalized by Surface Area|RNCLTAUS|Renal CL for Dose Int Norm by SA|Renal CL for Dose Int Norm by SA	The clearance of a substance from the blood by the kidneys, calculated using the area under the curve over the dosing interval, divided by the surface area.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122337>	C122050	Renal Clearance for Dose Interval Normalized by Weight|RNCLTAUW|Renal CL for Dose Int Norm by WT|Renal CL for Dose Int Norm by WT	The clearance of a substance from the blood by the kidneys, calculated using the area under the curve over the dosing interval, divided by the weight.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122338>	C44256	Stationarity Ratio Area Under the Curve|SRAUC|Stationarity Ratio AUC|Stationarity Ratio AUC	The area under the curve (AUCTAU) at steady state divided by the area under the curve extrapolated to infinity for the initial dosing interval.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C122339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122339>	C44256	Trough Peak Ratio|TROUGHPR	The concentration at the start of a dosing interval divided by the maximum concentration during the dosing interval.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12233>	C12999	Submandibular Salivary Gland|GLAND, SALIVARY, SUBMANDIBULAR|Gland, Salivary, Mandibular|SUBMANDIBULAR GLAND|Submandibular|Submandibular Gland|Submandibular Gland|Submandibular Gland|Submandibular gland|Submandibular salivary gland structure (body structure)|Submaxillary Gland|Submaxillary Gland|mandibular gland|mandibular salivary gland|submandibular gland|submandibular salivary gland	One of a pair of major salivary glands located below the floor of the mouth.	Submandibular Gland		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTDC Value Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C122340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122340>	C223627	PROMIS Adult Social Health Domain|Adult Social Health|Adult Social Health Domain	A Patient Reported Outcomes Measurement Information System (PROMIS) domain that assesses the status of an individual's social health.			Functional Concept	Patient-Reported Outcomes Measurement Information System Measures
C122341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122341>	C62289	Ability to Participate in Social Roles and Activities Subordinate Domain|Ability to Participate in Social Roles and Activities|Ability to Participate in Social Roles and Activities Item Bank	The collection of PROMIS item scales that assess an individual's perceived ability to perform their usual social roles and activities.			Functional Concept	PROMIS Adult Social Health Domain
C122342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122342>	C173924|C173398	Have Trouble Doing the Work that is Important to Me Question|Have Trouble Doing the Work that is Important to Me|I have trouble doing all of the work that is really important to me (include work at home)	A question about whether an individual has or had trouble doing all of the work that is really important to them.			Intellectual Product	Ability to Participate in Social Roles and Activities Subordinate Domain
C122343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122343>	C62289	Emotional Distress - Anxiety Subordinate Domain|Emotional Distress-Anxiety|Emotional Distress-Anxiety Item Bank|Emotional Distress-Anxiety Subordinate Domain	The collection of PROMIS item scales that assess fear, anxious misery, hyperarousal, and somatic symptoms related to arousal.			Functional Concept	PROMIS Adult Mental Health Domain
C122344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122344>	C173386	Feel Anxious Question|Feel Anxious|Felt Anxious|Have Anxiety|I felt anxious|I have anxiety	A question about whether an individual feels or felt anxious.			Intellectual Product	ANCHOR Health-Related Symptom Index|Emotional Distress - Anxiety Subordinate Domain
C122346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122346>	C223627	PROMIS Adult Physical Health Domain|Adult Physical Health|Adult Physical Health Domain	A Patient Reported Outcomes Measurement Information System (PROMIS) domain that assesses the status of an individual's physical health.			Functional Concept	Patient-Reported Outcomes Measurement Information System Measures
C122347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122347>	C62289	Fatigue Subordinate Domain|Fatigue|Fatigue Item Bank	The collection of PROMIS item scales that assess fatigue that is likely to decrease an individual's ability to carry out daily activities, including the ability to work effectively and to function at their usual level in family or social roles.			Functional Concept	PROMIS Adult Physical Health Domain
C122348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122348>	C173935|C118873	How Often Feel Tired Question|Frequency Feeling Tired|How Often Feel Tired|How often did you feel tired	A question about how often an individual feels or felt tired.			Intellectual Product	Fatigue Subordinate Domain
C122349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122349>	C175990|C118873	How Often Experience Extreme Exhaustion Question|Frequency Experiencing Extreme Exhaustion|How Often Experience Extreme Exhaustion|How often did you experience extreme exhaustion	A question about how often an individual experiences or experienced extreme exhaustion.			Intellectual Product	Fatigue Subordinate Domain
C12234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12234>	C12999	Sublingual Salivary Gland|GLAND, SALIVARY, SUBLINGUAL|Rivinus' gland|SALIVARY GLAND, SUBLINGUAL|Sublingual Gland|Sublingual Gland|Sublingual gland|Sublingual gland structure (body structure)|ductus sublingualis|sublingual gland	A salivary gland located under the tongue in the floor of the oral cavity.	Sublingual Gland		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C122350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122350>	C118873	How Often Run Out of Energy Question|Frequency Run Out of Energy|How Often Run Out of Energy|How often did you run out of energy	A question about how often an individual ran or runs out of energy.			Intellectual Product	Fatigue Subordinate Domain
C122351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122351>	C173924|C173695|C173347|C118873	How Often Did Fatigue Limit Work Question|Frequency that Fatigue Limited Work|Frequency that Fatigue Limits Work|How Often Did Fatigue Limit Work|How Often Does Fatigue Limit Work|How often did your fatigue limit you at work (include work at home)	A question about how often fatigue limits an individual at work.			Intellectual Product	Fatigue Subordinate Domain
C122352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122352>	C173935|C173597|C118873	How Often Too Tired to Think Clearly Question|Frequency Too Tired to Think Clearly|How Often Too Tired to Think Clearly|How often were you too tired to think clearly	A question about how often an individual is or was too tired to think clearly.			Intellectual Product	Fatigue Subordinate Domain
C122353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122353>	C173935|C118873	How Often Too Tired to Bathe or Shower Question|Frequency Too Tired to Bathe or Shower|How Often Too Tired to Bathe or Shower|How often were you too tired to take a bath or shower	A question about how often an individual is or was too tired to take a bath or shower.			Intellectual Product	Fatigue Subordinate Domain
C122354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122354>	C118873	How Often Have Enough Energy to Exercise Strenuously Question|Frequency Have Enough Energy to Exercise Strenuously|How Often Have Enough Energy to Exercise Strenuously|How often did you have enough energy to exercise strenuously	A question about how often an individual has or had enough energy to exercise strenuously.			Intellectual Product	Fatigue Subordinate Domain
C122355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122355>	C223627	PROMIS Adult Global Health Domain|Adult Global Health|PROMIS Adult Global Health	A Patient Reported Outcomes Measurement Information System (PROMIS) domain that assesses overall health in general, including global ratings of the five primary PROMIS domains (physical function, fatigue, pain, emotional distress, social health) as well as perceptions of general health that cut across domains.			Functional Concept	Patient-Reported Outcomes Measurement Information System Measures
C122356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122356>	C62289	Physical Function Subordinate Domain|Physical Function|Physical Function Item Bank	The collection of PROMIS item scales that assess an individual's ability to carry out activities that require physical actions including more complex activities that require a combination of skills, often within a social context.			Functional Concept	
C122357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122357>	C173509|C173458|C173090	Current Health Limits Vigorous Activities Question|Current Health Limits Vigorous Activities|Does your health now limit you in doing vigorous activities, such as running, lifting heavy objects, participating in strenuous sports	A question about whether an individual's current health limits them in doing vigorous activities.			Intellectual Product	Physical Function Subordinate Domain
C122358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122358>	C173509|C173135|C173090	Current Health Limits Walking More Than a Mile Question|Current Health Limits Walking More Than a Mile|Does your health now limit you in walking more than a mile	A question about whether an individual's current health limits them in walking more than a mile.			Intellectual Product	Physical Function Subordinate Domain
C122359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122359>	C173509|C173090	Current Health Limits Climbing One Flight of Stairs Question|Current Health Limits Climbing One Flight of Stairs|Does your health now limit you in climbing one flight of stairs	A question about whether an individual's current health limits them in climbing one flight of stairs.			Intellectual Product	Physical Function Subordinate Domain
C12235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12235>	C38632|C34007	Tonsillar Fossa|Tonsillar fossa	A triangular shaped space that lies on each side of the oropharynx and houses the palatine tonsils.	Tonsillar Fossa		Body Location or Region	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C122360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122360>	C173509|C173090	Current Health Limits Bending, Kneeling or Stooping Question|Current Health Limits Bending, Kneeling or Stooping|Does your health now limit you in bending, kneeling, or stooping	A question about whether an individual's current health limits them in bending, kneeling, or stooping.			Intellectual Product	Physical Function Subordinate Domain
C122361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122361>	C131923	Ability to Dress Yourself Question|Ability to Dress Yourself|Ability to Dress Yourself Including Tying Shoelaces and Doing Buttons|Are you able to dress yourself, including tying shoelaces and doing buttons	A question about the ability of an individual to dress, including tying shoelaces and doing buttons.			Intellectual Product	Physical Function Subordinate Domain
C122362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122362>	C173045	Ability to Shampoo Your Hair Question|Ability to Shampoo Your Hair|Ability to Shampoo Your Hair	A question about the ability of an individual to shampoo their hair.			Intellectual Product	Physical Function Subordinate Domain
C122363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122363>	C173045	Ability to Wash and Dry Your Body Question|Ability to Wash and Dry Your Body|Ability to Wash and Dry Your Body	A question about the ability of an individual to wash and dry their body.			Intellectual Product	Physical Function Subordinate Domain
C122364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122364>	C173045	Ability to Get On and Off the Toilet Question|Ability to Get On and Off the Toilet|Ability to Get On and Off the Toilet	A question about the ability of an individual to get on and off the toilet.			Intellectual Product	Physical Function Subordinate Domain
C122365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122365>	C223627	PROMIS Cognitive Function Subordinate Domain|Cognitive Function|Cognitive Function Item Bank	The collection of PROMIS item scales that assess perceived difficulties in intellectual processes, capabilities, and deficits.			Functional Concept	PROMIS Adult Mental Health Domain
C122366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122366>	C91102	Seems Like Brain is Not Working as Well as Usual Question|Seems Like Brain is Not Working as Well as Usual	A question about how often it seems like an individual's brain is not working as well as usual.			Intellectual Product	
C122368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122368>	C173398	Have Trouble Adding or Subtracting Numbers in My Head Question|Have Trouble Adding or Subtracting Numbers in My Head|I have had trouble adding or subtracting numbers in my head	A question about how often an individual has or had trouble adding or subtracting numbers in their head.			Intellectual Product	PROMIS Cognitive Function Subordinate Domain
C122369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122369>	C15632	Hypomethylation Therapy|Hypomethylating Agent-Based Therapy|Hypomethylating Therapy	Therapies that target the activity of DNA methyltransferases. Hypomethylating agents, including azacitidine and decitabine, have been used in the therapy of myelodysplastic syndrome and secondary acute myeloid leukemia. Although it is not curative, it can induce an improvement in hematopoiesis and lead to prolonged overall survival. Use of hypomethylating agents in the treatment of sickle cell anemia and other hemoglobin disorders can trigger the expression of fetal hemoglobin, leading to significant improvements in clinical symptoms.	Hypomethylation Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C12236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12236>	C38632	Tonsillar Pillar|Tonsillar pillar	The anterior and posterior borders of the tonsillar fossa.  They are composed of muscle tissue.	Tonsillar Pillar		Body Space or Junction	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C122370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122370>	C91105	Asthma Control Questionnaire|ACQ|ACQ|ACQ01	A standardized rating scale developed by Juniper et al in 1999, which is used to assess both the adequacy of and change in asthma control. This questionnaire contains 7 items using a 7-point scale.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122371>	C91105	ADHD Rating Scale-IV Home Version Questionnaire|ADHD-RS-IV HOME VERSION|ADHD-RS-IV Home Version|ADHD01	A standardized rating scale developed by DuPaul et al in 1998 based on the DSM-IV criteria, which is used for the diagnosis of ADHD in children and adolescents, and for the assessment of treatment response. This questionnaire requires a subject to rate the frequency and severity of inattentive and hyperactive-impulsive symptoms on a scale of 0 to 3: never or rarely (0), sometimes (1), often (2), or very often (3).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122372>	C91105	Asthma Quality of Life Questionnaire|AQLQ|AQLQ|AQLQ01	A standardized rating scale developed by Juniper et al in 1992, which is used to measure the physical and emotional impacts on quality of life in patients with asthma. This questionnaire contains 32 items using a 7-point scale, and the items are grouped into four domains: activity limitations, symptoms, emotional function, and exposure to environmental stimuli.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122373>	C91105	Hemophilia Quality of Life Questionnaire Children's Long Version Age Group I|HAEMO-QOL CHILDREN'S LONG VERSION AGE GROUP I|HAEMO-QOL Children's Long Version Age Group I|HM01	A standardized rating scale developed by the Haemo-QoL Study Group in 2002, which is used to measure the physical and emotional impacts on quality of life in children and adolescents with hemophilia. The children's long version age group I questionnaire contains 21 items for children 4 to 7 years of age.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122374>	C91105	Hemophilia Quality of Life Questionnaire Children's Long Version Age Group II|HAEMO-QOL CHILDREN'S LONG VERSION AGE GROUP II|HAEMO-QOL Children's Long Version Age Group II|HM02	A standardized rating scale developed by the Haemo-QoL Study Group in 2002, which is used to measure the physical and emotional impacts on quality of life in children and adolescents with hemophilia. The children's long version age group II questionnaire contains 64 items for children 8 to 12 years of age.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122375>	C91105	Hemophilia Quality of Life Questionnaire Children's Long Version Age Group III|HAEMO-QOL CHILDREN'S LONG VERSION AGE GROUP III|HAEMO-QOL Children's Long Version Age Group III|HM03	A standardized rating scale developed by the Haemo-QoL Study Group in 2002, which is used to measure the physical and emotional impacts on quality of life in children and adolescents with hemophilia. The children's long version age group III questionnaire contains 77 items for adolescents 13 to 16 years of age.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122376>	C91105	Hemophilia Quality of Life Questionnaire Children's Short Version Age Group I|HAEMO-QOL CHILDREN'S SHORT VERSION AGE GROUP I|HAEMO-QOL Children's Short Version Age Group I|HM04	A standardized rating scale developed by the Haemo-QoL Study Group in 2002, which is used to measure the physical and emotional impacts on quality of life in children and adolescents with hemophilia. The children's short version age group I questionnaire contains 16 items for children 4 to 7 years of age.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122377>	C91105	Hemophilia Quality of Life Questionnaire Children's Short Version Age Group II/III|HAEMO-QOL CHILDREN'S SHORT VERSION AGE GROUP II/III|HAEMO-QOL Children's Short Version Age Group II/III|HM05	A standardized rating scale developed by the Haemo-QoL Study Group in 2002, which is used to measure the physical and emotional impacts on quality of life in children and adolescents with hemophilia. The children's short version age group II/III questionnaire contains 35 items, which can be used for both children 8 to 12 years of age and adolescents 13 to 16 years of age.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122378>	C91105	Hemophilia Quality of Life Questionnaire Parent's Long Version Age Group I|HAEMO-QOL PARENT'S LONG VERSION AGE GROUP I|HAEMO-QOL Parent's Long Version Age Group I|HM06	A standardized rating scale developed by the Haemo-QoL Study Group in 2002, which is used to measure the physical and emotional impacts on quality of life in children and adolescents with hemophilia. The parent's long version age group I questionnaire contains 21 items and corresponds to age group I of children 4 to 7 years of age.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122379>	C91105	Hemophilia Quality of Life Questionnaire Parent's Long Version Age Group II|HAEMO-QOL PARENT'S LONG VERSION AGE GROUP II|HAEMO-QOL Parent's Long Version Age Group II|HM07	A standardized rating scale developed by the Haemo-QoL Study Group in 2002, which is used to measure the physical and emotional impacts on quality of life in children and adolescents with hemophilia. The parent's long version age group II questionnaire contains 64 items and corresponds to age group II of children 8 to 12 years of age.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12237>	C38617	Vallecula	A groove between the base of the tongue and the epiglottis.	Vallecula		Body Part, Organ, or Organ Component	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C122380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122380>	C91105	Hemophilia Quality of Life Questionnaire Parent's Long Version Age Group III|HAEMO-QOL PARENT'S LONG VERSION AGE GROUP III|HAEMO-QOL Parent's Long Version Age Group III|HM08	A standardized rating scale developed by the Haemo-QoL Study Group in 2002, which is used to measure the physical and emotional impacts on quality of life in children and adolescents with hemophilia. The parent's long version age group III questionnaire contains 77 items and corresponds to age group III of adolescents 13 to 16 years of age.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122381>	C91105	Hemophilia Quality of Life Questionnaire Adult Version|HAEM-A-QOL|HAEM-A-QOL|HAEM-A-QOL|HM09|Haem-A-QoL|Haemophilia Quality of Life Questionnaire for Adults|Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL)	A standardized rating scale developed by Mackensen et al in 2005, which is used to measure the physical and emotional impacts on quality of life in adults with hemophilia. The questionnaire contains 46 items which are divided into 10 dimensions: physical health, feelings, self-perception, sports and leisure, work and school, coping, treatment, future, family planning and relationships/partners.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122382>	C118969	Montgomery-Asberg Depression Rating Scale Clinical Classification|MADRS|MADRS|MADRS1	A standardized rating scale developed by Montgomery and Asberg in in 1978, which is used to measure the severity of depressive symptoms in patients with depression. The questionnaire contains 10 items on a scale of 0 to 6.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122384>	C91105	Western Ontario and McMaster Universities Osteoarthritis Index Version 3.1 Likert Scale Format Questionnaire|WOMAC Index Version 3.1 Likert Scale Format|WOMAC LK 3.1 INDEX|WOMAC1	A standardized rating scale developed by Nicholas Bellamy with the Western Ontario and McMaster Universities in 1982, which is used to assess pain, stiffness, and physical function in patients with hip and/or knee osteoarthritis. The questionnaire contains 24 items which are divided into 3 subscales: pain, stiffness and physical function. This version of the questionnaire uses the 5-point Likert scaling format.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122385>	C91105	Western Ontario and McMaster Universities Osteoarthritis Index Version 3.1 Numerical Rating Scale Format Questionnaire|WOMAC Index Version 3.1 Numerical Rating Scale Format|WOMAC NRS 3.1 INDEX|WOMAC2	A standardized rating scale developed by Nicholas Bellamy with the Western Ontario and McMaster Universities in 1982, which is used to assess pain, stiffness, and physical function in patients with hip and/or knee osteoarthritis. The questionnaire contains 24 items which are divided into 3 subscales: pain, stiffness and physical function. This version of the questionnaire uses the 11-point numerical rating scaling format.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122386>	C91105	Western Ontario and McMaster Universities Osteoarthritis Index Version 3.1 Visual Analog Scale Format Questionnaire|WOMAC Index Version 3.1 Visual Analog Scale Format|WOMAC VA 3.1 INDEX|WOMAC3	A standardized rating scale developed by Nicholas Bellamy with the Western Ontario and McMaster Universities in 1982, which is used to assess pain, stiffness, and physical function in patients with hip and/or knee osteoarthritis. The questionnaire contains 24 items which are divided into 3 subscales: pain, stiffness and physical function. This version of the questionnaire uses the 100mm visual analog scaling format.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122388>	C173597|C173358	Frequency Thinking Has Been Slow Question|Frequency Thinking Has Been Slow|How Often Thinking Has Been Slow|My thinking has been slow	A question about how often an individual's thinking has or had been slow.			Intellectual Product	PROMIS Cognitive Function Subordinate Domain
C122389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122389>	C173597|C173398|C173358	Frequency Have Trouble Shifting Back and Forth Between Different Activities that Require Thinking Question|Frequency Have Trouble Shifting Back and Forth Between Different Activities that Require Thinking|How Often Have Trouble Shifting Back and Forth Between Different Activities that Require Thinking|I have had trouble shifting back and forth between different activities that require thinking	A question about how often an individual has or had trouble shifting back and forth between different activities that require thinking.			Intellectual Product	PROMIS Cognitive Function Subordinate Domain
C12238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12238>	C34022	Anterior Surface of the Epiglottis|Anterior surface of epiglottis	The lingual or upper surface of the epiglottis.	Anterior Surface of Epiglottis		Body Location or Region	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C122390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122390>	C16781|C116477	Confocal Laser Microlaryngoscopy|Confocal Endoscopy of the Larynx	An endoscopic modality using confocal laser endomicroscopy to produce high magnification and resolution images during the study of the laryngeal tissues.	Confocal Laser Microlaryngoscopy		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C122391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122391>	C15191	Red Blood Cell Exchange and Depletion Procedure|RBCx|Red Blood Cell Exchange Transfusion|Red Blood Cell Exchange and Depletion	Procedures for the removal of defective, infected, or contaminated red blood cells (RBCs) and their replacement with normal donor RBCs.	Red Blood Cell Exchange and Depletion Procedure		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C122393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122393>	C17468	Number of Years of Education|EDUYRNUM	The number of education years that a subject has competed.			Qualitative Concept	CDISC SDTM Subject Characteristic Test Code Terminology|CDISC SDTM Subject Characteristic Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122394>	C125932	Choi Response Criteria in the Evaluation of Gastrointestinal Stromal Tumors|CHOI GIST 2008|Choi|Choi Criteria|Choi Response Criteria	A composite set of criteria developed by Choi et al. using imaging techniques in the evaluation of gastrointestinal stromal tumors response to imatinib mesylate treatment. These criteria integrate changes in tumor size and tumor density.			Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GCT Authorized Value Terminology|GCT Subject Response Table
C122395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122395>	C78276	Simo Decoction|SMD	A traditional Chinese medicine (TCM) containing simo decoction which contains Fructus aurantii, Radix aucklandiae, Semen arecae and Radix linderae, that can potentially be used to improve gastrointestinal (GI) function following surgery. Upon oral intake of simo decoction, this TCM may stimulate mainly muscarinic M3 receptors, but also muscarinic M2 receptors, calcium channels and nicotinic receptors triggering a release of nitric oxide (NO), while inhibiting adrenergic receptors Altogether, this stimulates the contraction of antral circular smooth muscle, thereby abrogating GI hypomotility and enhances the return of GI function after surgery.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C122396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122396>	C1663	Tetravalent RNA-lipoplex Cancer Vaccine BNT111|BNT 111|BNT-111|BNT111|Cancer Vaccine BNT111|Lipo-MERIT Vaccine|RNA(LIP) BNT111|RNA-LPX BNT111|RNA-lipoplex Vaccine BNT111	A RNA-lipoplex (RNA-LIP)-based cancer vaccine containing four naked ribonucleic acid (RNA)-drug products (DPs) RBL001.1, RBL002.2, RBL003.1, and RBL004.1 encoding the four melanoma-associated antigens (MAAs), the cancer-testis antigen NY-ESO-1, the human melanoma-associated antigen A3 (MAGE-A3), tyrosinase, and putative tyrosine-protein phosphatase (TPTE), encapsulated in liposomes, with potential antineoplastic activity. Upon intravenous administration of the tetravalent RNA-lipoplex cancer vaccine BNT111, the liposomes protect the RNA from degradation in the bloodstream, travel to the spleen and are taken up by antigen-presenting cells (APCs). The RNA is translocated to the cytoplasm and translated into the four tumor-associated proteins. The expressed proteins are processed and the human leukocyte antigen (HLA)-peptide complexes are presented to the immune system. This results in the production of various pro-inflammatory cytokines and induces antigen-specific CD8+ and CD4+ T-cell responses against the four selected MAAs NY-ESO-1, MAGE-A3, tyrosinase, and TPTE.	Tetravalent RNA-lipoplex Cancer Vaccine BNT111		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C122397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122397>	C159583	Chimeric Humanized Anti-CD47 Antibody|Humanized High-chimeric Antibody CD47	A humanized, high-chimeric antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, chimeric humanized anti-CD47 antibody selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C122398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122398>	C93221	Black Raspberry Nectar|BRB Nectar	A concentrated fruit juice containing black raspberries, with potential antioxidant, pro-apoptotic, anti-angiogenic and chemopreventive activities. In addition to vitamins, minerals and phytosterols, black raspberries are rich in phenolic acids, such as gallic acid, ellagic acid, anthocyanidins, and flavonoids. Upon oral administration, the phytochemicals in the black raspberry nectar inhibit the activation of several signal transduction pathways involved in carcinogenesis and the expression of downstream target genes that are upregulated in a variety of cancer cell types. In addition, the phytochemicals in black raspberry may protect the oral microbiome and may enhance the bacterial defense against pathogens.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C122399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122399>	C2848	Diphtheria-Tetanus-Acellular Pertussis-Inactivated Poliomyelitis-Haemophilus influenzae Type B Vaccine|DTaP(5)-IPV-Hib|DTaP-IPV-Hib|Pediacel	A vaccine consisting of detoxified diphtheria toxoid (D), detoxified tetanus toxoid (T), acellular pertussis (aP) antigens, inactivated poliovirus (IPV) types 1, 2 and 3, and Haemophilus influenzae type b (Hib) capsular polysaccharide (polyribosylribitol phosphate; PRP) covalently bound to tetanus protein, suspended in water for injection and with active immunizing activity against diphtheria, tetanus, pertussis, poliomyelitis and H. influenzae type b. The five purified pertussis antigens in this vaccine are pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (PRN) and fimbriae types 2 and 3 (FIM). Upon intramuscular injection of the diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis-Haemophilus influenzae type b vaccine (DTaP-IPV-Hib), this vaccine activates the immune system to develop antibodies against diphtheria toxin, tetanus toxin, B. pertussis antigens, polioviruses and Hib, thereby providing active immunization against these diseases. The diphtheria and tetanus toxoids and pertussis antigens (inactivated PT, FHA, PRN and FIM) are adsorbed separately onto aluminum phosphate and then combined with IPV and PRP.			Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology
C12239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12239>	C38617	Lateral Wall of the Oropharynx|Lateral Wall of Oropharynx|Lateral wall of oropharynx	The aspect of the oropharyngeal wall that is located on the side.	Lateral Wall of Oropharynx		Body Location or Region	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C1223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1223>	C73539	Selenocysteine|3-Selenyl-L-Alanine|SELENOCYSTEINE|SeC	An unusual amino acid of proteins, the selenium analogue of cysteine, in which a selenium atom replaces sulphur. Involved in the catalytic mechanism of seleno enzymes such as formate dehydrogenase of E. coli and mammalian glutathione peroxidase.			Amino Acid, Peptide, or Protein	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C122400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122400>	C1420	Synthetic Hypericin|Topical SGX301	A topical ointment formulation containing a synthetic form of hypericin, an anthraquinone derivative that is naturally found in the yellow flower of Hypericum perforatum (St. John's wort), with potential antineoplastic and photosensitizing activities. Upon topical administration of the ointment to the tumor site, hypericin becomes activated through the application of visible fluorescent light. During photoactivation, hypericin generates singlet oxygen, which induces DNA damage, necrosis and apoptosis, thereby inhibiting tumor cell growth. The use of visible light for activation avoids the risk of developing secondary malignancies, which are frequently associated with other photodynamic therapies that are dependent on ultraviolet A exposure.	Synthetic Hypericin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C122401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122401>	C222322|C129821|C129820	Heterodimeric Interleukin-15|IL-15/sIL-15Ra|hetIL-15	A fusion protein complex composed of heterodimeric IL-15 (hetIL-15), which consists of a synthetic form of the endogenous cytokine interleukin-15 chain (IL-15) complexed to the soluble IL-15 binding protein IL-15 receptor alpha chain (IL-15Ra) (IL15:sIL-15Ra), with potential immunomodulatory, anti-infective and antineoplastic activities. Upon administration, hetIL-15 binds to the IL-2/IL-15 receptor beta-common gamma chain (IL-2Rbeta-gamma) receptor on natural killer (NK) and T-lymphocytes, which activates and increases the levels of NK cells and CD8+ and CD4+ T-cells. The T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. Altogether, this enhances tumor cell killing and decreases tumor cell proliferation. By coupling IL-15 to IL15Ra, this agent has an improved pharmacokinetic profile, shows an increased ability to bind IL-2Rbeta-gamma, and shows increased immunostimulatory activity as compared to IL-15 alone.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C122402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122402>	C1663	Autologous Oxidized Ovarian Tumor Cell Lysate Vaccine|Autologous OC-L Vaccine	An autologous cancer vaccine composed of oxidized ovarian tumor cell lysate, with potential immunostimulatory and antineoplastic activities. Upon administration, the autologous oxidized ovarian tumor cell lysate vaccine exposes the immune system to an undefined amount of tumor-associated antigens (TAAs), which may result in the induction of both anti-tumor cytotoxic T-lymphocytes (CTLs) and antibody-dependent responses against TAA-expressing cells, leading to tumor cell lysis. Compared to non-oxidized tumor cell lysate vaccines, oxidized tumor cell lysate vaccines induce necrotic cell death, increase the immunogenicity of the TAAs and may enhance the anti-tumor immune response.			Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C122403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122403>	C2496	Suvemcitug|APX 003|BD 0801|BD-0801|BD0801|SUVEMCITUG|Sevacizumab	A monoclonal antibody directed against the human vascular endothelial growth factor (VEGF), with potential antiangiogenic activity. Upon administration, suvemcitug specifically binds to and inhibits VEGF, thereby preventing its binding to VEGF receptors (VEGFRs). This prevents VEGF/VEGFR-mediated signaling and inhibits the proliferation of vascular endothelial cells and tumor cells. VEGF, overexpressed in a variety of cancer cells, is associated with increased invasiveness and decreased survival.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C122404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122404>	C1511	Zirconium Zr 89-labeled Atezolizumab|89Zr-DFO-Atezolizumab|89Zr-Desferrioxamine-Atezolizumab|89Zr-MPDL-3280A|89Zr-MPDL3280A|DFO-ATEZOLIZUMAB ZR-89|Zirconium Zr 89 Atezolizumab|Zirconium Zr 89-DFO-Atezolizumab|Zirconium Zr 89-labeled MPDL3280A	A radioimmunoconjugate composed of atezolizumab, a humanized, Fc-optimized, monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1) and labeled with the radioisotope zirconium Zr 89, with potential use for assessing PD-L1-expressing tumor cells using positron emission tomography (PET). Upon administration of zirconium Zr 89-labeled atezolizumab, the antibody moiety targets and binds to PD-L1. Following tumor cell uptake, the radioisotope moiety can be visualized using PET. This may result in the quantification of PD-L1-expressing tumor cells, an assessment of the expected response to treatment with atezolizumab as well as selection of patients that would respond to atezolizumab.  PD-L1 is overexpressed on many human cancer cell types; PD-L1 binding to programmed cell death 1 (PD-1) on T-cells suppresses the immune system and results in increased immune evasion.	Zirconium Zr 89-labeled Atezolizumab		Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C122405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122405>	C1511|C129819	Yttrium Y 90 Anti-CDH3 Monoclonal Antibody FF-21101|FF-21101(90Y)	A radioimmunoconjugate consisting of a chimeric monoclonal antibody targeting human cadherin-3 (CDH3) and labeled, via the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), with the beta-emitting radioisotope yttrium Y 90, with potential antineoplastic activities. Upon administration, the antibody moiety of yttrium Y 90 anti-CDH3 monoclonal antibody FF-21101 binds to CDH3 expressed on tumor cells, thereby specifically delivering cytotoxic beta radiation to CDH3-expressing tumor cells. CDH3, also known as P-cadherin, is a tumor-associated antigen (TAA) and member of the cadherin family; it is overexpressed in a variety of tumors and plays a role in cell adhesion, motility, invasion, and proliferation.	Yttrium Y 90 Anti-CDH3 Monoclonal Antibody FF-21101		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C122406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122406>	C201282|C112889	Duvortuxizumab|CD19 x CD3 DART Protein JNJ-64052781|DUVORTUXIZUMAB|JNJ-64052781|MGD011|RES192M1.2|hBU12(2.4)-hXR32-MP3 M1.2	An anti-CD19/anti-CD3 bispecific, humanized antibody-like protein, with potential immunostimulatory and antineoplastic activities. Duvortuxizumab possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B-cells. Upon administration, duvortuxizumab binds to CD3-expressing T-cells and CD19-expressing cancer cells, thereby crosslinking CD19-expressing tumor B-cells and cytotoxic T-lymphocytes (CTLs). This may result in a potent CTL-mediated cell lysis of CD19-expressing B-lymphocytes. CD19, a B-cell specific membrane antigen, is expressed during normal B-cell development and on B-cell malignancies.	Duvortuxizumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C122407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122407>	C35869	Pulmonary Nodule|Lung Nodule	A benign or malignant small, oval or round growth in the lung. It can be due to infectious, inflammatory or neoplastic processes.	Pulmonary Nodule		Finding	CTRP Disease Terminology|CTRP Terminology
C122408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122408>	C122407	Multiple Pulmonary Nodules|Pulmonary Nodules|Pulmonary Nodules	Multiple, small, round or oval, benign or malignant growths in the lung(s), which can be due to infectious, inflammatory, or neoplastic processes.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122409>	C3303	Ostomy Site Pain	Pain at the site of an ostomy.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C12240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12240>	C38617	Posterior Wall of the Oropharynx|Posterior Wall of Oropharynx|Posterior wall of oropharynx|posterior wall of oropharynx	The dorsal portion of the oropharyngeal cavity that is formed by the muscular pharyngeal wall comprising the superior and middle pharyngeal constrictor muscles.	Posterior Wall of Oropharynx		Body Location or Region	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C122410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122410>	C5034	Absence of Bowel Movement	The lack of any bowel movements.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122411>	C3143	Scleral Icterus	Yellowing of the white part of the eyes, often due to a rise in bilirubin levels.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122412>	C3092	Vaso-Occlusive Crisis|Sickle Cell Crisis	An exacerbation of sickle cell disease.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122413>	C2952	Ulcerative Colitis Flare	An exacerbation of ulcerative colitis.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122414>	C99383|C26760	Autoimmune Encephalitis	Inflammation of the brain secondary to an immune response triggered by the body itself.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122415>	C16546	Near-Infrared Fluorescence Endoscopy|NIR Fluorescence Endoscopy	The use of near-infrared light (700-1000 nm) for biomedical imaging with an endoscope.	Near-Infrared Fluorescence Endoscopy		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C122416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122416>	C4876	Refusal to Bear Weight	A reluctance to place any body weight on a limb, which is most commonly secondary to pain or discomfort.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122417>	C173695|C173151	Have to Limit Regular Activities with Family Question|Have to Limit Regular Activities with Family|I have to limit my regular family activities	A question about whether an individual has or had to limit their regular activities with family.			Intellectual Product	Ability to Participate in Social Roles and Activities Subordinate Domain
C122418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122418>	C70652	Advertising, Marketing, Promotions, Public Relations, and Sales Managers	Workers who plan programs to generate interest in a product or service, plan and direct the creation of material that will maintain or enhance the public image of their employer or client, and/or direct an organization's sales teams.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122419>	C121559	Dog Bite	A wound received from the teeth of a dog.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122420>	C15753	integrated Cancer Repository for Cancer Research|iCaRe2|iCaRe2	A system for the standardized collection, mining and sharing of comprehensive cancer-related data. It consists of registry databases and human biological material. Currently, there are seven registries/tissue banks developed under the umbrella of iCaRe2: the Pancreatic Cancer Collaborative Registry, Thyroid Cancer and Tumor Collaborative Registry, GenitoUrinary Cancer Collaborative Registry, Thoracic Oncology Collaborative Registry, Gastrointestinal and Abdominal Cancer Collaborative Registry, Head and Neck Cancer Collaborative Registry, and the Central Nervous System Tumor Collaborative Registry for collaborative multi-center research.			Intellectual Product	
C122421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122421>	C97632	Agricultural Workers	Workers who maintain the quality of farms, crops, and livestock by operating machinery and doing physical labor under the supervision of farmers, ranchers, and other agricultural managers.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122422>	C122530	Air Transportation Workers	Workers involved with the transportation of passengers and/or cargo using aircraft. This includes aircraft mechanics and service technicians; airline pilots, copilots, and flight engineers; cargo and freight agents; and reservation and transportation ticket agents and travel clerks.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122423>	C25193	Animal Care and Service Workers	Workers who provide care for animals. They feed, water, groom, bathe, and exercise pets and other nonfarm animals. Job tasks vary by position and place of work.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122424>	C97624	Architects, Surveyors, and Cartographers	Workers who plan and design houses, office buildings, and other structures, make precise measurements to determine property boundaries, and/or collect, measure, and interpret geographic information to create maps and charts for political, educational, and other purposes.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122425>	C112019	Port Site Infection	An infection at an anatomic location used for vascular access.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122426>	C53649	Acquired Cytomegaloviral Infection	An infection with the Cytomegalovirus that is not present from birth.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122427>	C99231|C53649	Congenital Cytomegaloviral Infection	An infection with the Cytomegalovirus that is present from birth.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122428>	C97625	Art and Design Workers	Workers who are responsible for the visual style of: consumer and industrial products, movie and television productions, product images in magazines and newspapers, interior design, and visual effects.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122429>	C25193	Assemblers and Fabricators	Workers who use tools, machines, and their hands to assemble finished products and the parts that go into them.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C12242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12242>	C38617	Superior Wall of the Nasopharynx|Nasopharyngeal Roof|Roof of Nasopharynx|Roof of Nasopharynx|Superior Wall of Nasopharynx|Superior wall of nasopharynx	The roof of the nasopharynx.	Superior Wall of Nasopharynx		Body Location or Region|Body Part, Organ, or Organ Component	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C122430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122430>	C3858	Abnormal Behavior|Behavioral Disturbance|Behavioral change|Not Acting Normal|Not Acting Self	Conduct that is unusual for the individual.			Sign or Symptom	CRF2 History and Physical Exam Initial History Table|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122431>	C97626	Building Cleaning and Pest Control Workers	Workers who keep buildings and their surrounding grounds in clean, orderly, and good condition, and/or control unwanted creatures.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122432>	C97627	Business Operations Specialists	Workers whose general job duties include analyzing a business's current operations, identifying customer needs, creating reports, developing improvement plans, assisting departments in implementing changes, management and staffing, fundraising, and/or appraisals and investigations.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122433>	C85487	Communications Equipment Operators	Workers who operate telephone business systems equipment or switchboards, and/or provide information by accessing directories, assist customers with special billing requests.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122434>	C97629	Computer Specialists	Workers who provide help and advice to people and organizations using computer software or equipment. Some support information technology (IT) employees and others assist non-IT users who are having computer problems.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122435>	C5039	Impaired Balance|Balance Problems|Loss of Balance	A deficit in equilibrium, which may manifest as unsteady ambulation or inability to maintain an upright position.			Finding	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122436>	C97630	Construction Trades Workers	A tradesman, laborer (an unskilled tradesman), or professional employed in the physical construction of the built environment and its infrastructure.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122437>	C35682	Positive Blood Culture	A laboratory test result demonstrating the presence of a specific organism in a blood sample after culture.			Laboratory or Test Result	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122438>	C81326|C35553	Blood Urea Nitrogen Increased|Elevated Blood Urea Nitrogen	Laboratory results demonstrating an increase in the concentration of urea nitrogen in a blood sample.			Laboratory or Test Result	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122439>	C78254	Dislodged Catheter	A catheter that has moved from its intended location.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C12243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12243>	C38617	Posterior Wall of the Nasopharynx|Posterior Wall of Nasopharynx|Posterior wall of nasopharynx	The dorsal portion of the nasopharyngeal cavity that contains the pharyngeal tonsil.	Posterior Wall of Nasopharynx		Body Location or Region	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C122440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122440>	C97633	Cooks and Food Preparation Workers|Cook|Cooks	Workers who prepare, season, and cook foods, as well as workers who perform routine tasks under the direction of cooks, chefs, or food service managers.			Occupation or Discipline	GDC Terminology|GDC Value Terminology|integrated Cancer Repository for Cancer Research
C122441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122441>	C97628	Counselors, Social Workers, and Other Community and Social Service Specialists	Workers who make arrangements for needed services and treatments for individuals and families and/or develop and implement specialized treatment programs within a community. Others provide front line support and social assistance for individuals, families, and communities in need.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122442>	C97624	Drafters, Engineering, and Mapping Technicians	Workers who use software to convert the designs of engineers and architects into technical drawings and plans.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122443>	C35682|C175007	Coombs Test Positive|Positive Coombs Test	A laboratory test result demonstrating the presence of antibodies that act against red blood cells.			Laboratory or Test Result	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122444>	C5039	Decreased Physical Activity	A reduction in the normal physical activity for an individual.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122445>	C78254	Feeding Tube Complication	Any problem with a feeding tube or its site of insertion.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122446>	C97636	Electrical and Electronic Equipment Mechanics, Installers, and Repairers|Electrical Equipment Installer and Repairer|Electrical Equipment Installers and Repairers	Workers who install, repair, or replace a variety of electrical equipment in telecommunications, transportation, utilities, and other industries.			Occupation or Discipline	GDC Terminology|GDC Value Terminology|integrated Cancer Repository for Cancer Research
C122447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122447>	C25193	Engineers|Engineering Professional (Excluding Electrotechnology)|Engineering Professionals (excluding Electrotechnology)	A professional practitioner of engineering, concerned with applying scientific knowledge, mathematics, and ingenuity to develop solutions for technical, societal and commercial problems. Engineers design materials, structures, and systems while considering the limitations imposed by practicality, regulation, safety, and cost.			Occupation or Discipline	GDC Terminology|GDC Value Terminology|integrated Cancer Repository for Cancer Research
C122448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122448>	C25193	Entertainers and Performers, Sports and Related Workers	The actors, producers, directors, dancers and choreographers, musicians, singers, directors, and composers employed in the entertainment fields, as well as the athletes, coaches, scouts, managers, trainers, and umpires employed in professional sports.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122449>	C25193	Entertainment Attendants and Related Workers	The ushers, lobby attendants, ticket takers, and projectionists employed in theaters, amusement and recreation attendants, costume attendants, locker room, coatroom, and dressing room attendants, and workers in the gaming and gambling industries.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C12244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12244>	C38617	Lateral Wall of the Nasopharynx|Lateral Wall of Nasopharynx|Lateral wall of nasopharynx|lateral wall of nasopharynx	The aspect of the nasopharyngeal wall that is located on the side.  It contains the pharyngeal opening of the auditory tube.	Lateral Wall of Nasopharynx		Body Location or Region	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C122450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122450>	C97630	Extraction Workers	Any worker involved in extracting resources from the ground or the sea.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122451>	C75552	Financial Clerks|Teller, Money Collector and Related Clerk|Tellers, Money Collectors and Related Clerks	Workers who do administrative work for financial institutions or within the financial industries.			Occupation or Discipline	GDC Terminology|GDC Value Terminology|integrated Cancer Repository for Cancer Research
C122452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122452>	C25193	Financial Specialists|Finance Professional|Finance Professionals	Workers who meet with customers to help them determine their short-term and long-term financial goals and provide insurance, investment services, certificates of deposits and other financial instruments. They also contact prospective customers, evaluate costs and revenue, make financial presentations and review business trends.			Occupation or Discipline	GDC Terminology|GDC Value Terminology|integrated Cancer Repository for Cancer Research
C122453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122453>	C97643	Fire Fighting and Prevention Workers	Workers engaged in fire fighting and fire prevention and control.	Fire Fighting and Prevention Workers		Occupation or Discipline	CPTAC Codelists Terminology|CPTAC Environmental/Occupational Exposure Codelist|CPTAC Terminology|CTRP Intervention Terminology|CTRP Terminology|integrated Cancer Repository for Cancer Research
C122454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122454>	C97647	First-Line Enlisted Military Supervisor and Managers|First-Line Enlisted Military Supervisor/Managers	Workers who directly supervise and coordinate the activities of enlisted military personnel.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122455>	C97643	First-Line Protective Service Worker Supervisors and Managers|First-Line Supervisors/Managers, Protective Service Workers	Workers who directly supervise and coordinate the activities of protective service workers.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122456>	C93018	Minimal Residual Disease-Based Risk Stratification in Acute Leukemia	Risk stratification of acute lymphoblastic leukemia, and less often acute myeloid leukemia, based on minimal residual disease levels.			Health Care Activity	
C122457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122457>	C167435	Standard Risk Acute Leukemia|Standard Risk (MRD <0.05%)	Acute leukemia patients are stratified into the standard risk group when their minimal residual disease levels are lower than 0.05%.			Finding	
C122458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122458>	C167435	High Risk Acute Leukemia|High Risk|High Risk (MRD > 0.05%)	Acute leukemia patients are stratified into the high risk group when their minimal residual disease levels are higher than 0.05%.			Finding	
C122459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122459>	C97632	Fishing and Hunting Workers	Workers who gather fish or other aquatic animals for human consumption or other uses and/or hunt and trap wild animals for human consumption, fur, feed, bait, or other purposes.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C12245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12245>	C38617	Anterior Wall of the Nasopharynx|Anterior Wall of Nasopharynx|Anterior wall of nasopharynx	The anterior aspect of the nasopharynx.	Anterior Wall of Nasopharynx		Body Part, Organ, or Organ Component	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C122460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122460>	C97633	Food and Beverage Serving Workers|Waiter and Bartender|Waiters and Bartenders	Workers who perform a variety of customer service, food preparation, and cleaning duties in restaurants, cafeterias, and other eating and drinking establishments.			Occupation or Discipline	GDC Terminology|GDC Value Terminology|integrated Cancer Repository for Cancer Research
C122461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122461>	C198743	Food Processing Workers	Workers who operate equipment that mixes, cooks, or processes ingredients used in the manufacturing of food.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122462>	C97632	Forest, Conservation, and Logging Workers	Workers who measure and improve the quality of forests, develop, maintain, and protect forests, and/or harvest timber that provides the raw material for many consumer goods and industrial products.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122463>	C25193	Funeral Service Workers	Workers who organize and manage the details of a funeral.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122464>	C97626	Grounds Maintenance Workers	Workers who provide a pleasant outdoor environment by ensuring that the grounds of houses, businesses, and parks are attractive, orderly, and healthy.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122465>	C97634	Health Diagnosing and Treating Practitioners	The group of professions that include chiropractors, dentists, dietitians and nutritionists, optometrists, pharmacists, physicians and surgeons, physicians assistants, podiatrists, registered nurses, therapists, and veterinarians.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122466>	C97634	Health Technologists and Technicians	Technicians who prepare specimens, operate automated analyzers and perform manual tests with detailed instructions, and technologists who problem solve, conduct data interpretation, establish and monitor programs, type and cross match blood samples and act as project managers.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122467>	C122436	Helpers, Construction Trades|Construction Trades Helpers	Workers who perform basic tasks that require physical labor on construction sites.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122468>	C75552	Information and Record Clerks	Workers who perform routine clerical duties such as maintaining records, collecting data, and providing information to customers.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122469>	C97643	Law Enforcement Workers	The group of professions that include bailiffs, correctional officers, and jailers; detectives and criminal investigators; fish and game wardens; parking enforcement workers; and police officers.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C12246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12246>	C38617	Hypopharynx|HYPOPHARYNX|Hypopharyngeal structure (body structure)|Hypopharynx, NOS|Laryngopharynx|Laryngopharynx|hypopharynx|hypopharynx|laryngeal pharynx|laryngopharynx	The lower part of the pharynx that connects to the esophagus.	Hypopharynx		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C122470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122470>	C50437	Fistula Discharge|Fistula Drainage	The leakage of a substance from a fistula.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122471>	C97637	Lawyers, Judges, and Related Workers	Lawyers advise and represent individuals, businesses, and government agencies on legal issues and disputes. Judges and hearing officers apply the law by overseeing the legal process in courts. They also conduct pretrial hearings, resolve administrative disputes, facilitate negotiations between opposing parties, and issue legal decisions.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122472>	C97637	Legal Support Workers	Paralegals and legal assistants assist lawyers by investigating facts, preparing legal documents, or researching legal precedent. Court reporters use verbatim methods and equipment to capture, store, retrieve, and transcribe pretrial and trial proceedings or other information. Title examiners, abstractors, and searchers search real estate records, examine titles, or summarize pertinent legal or insurance documents or details for a variety of purposes.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122473>	C97631	Librarians, Curators, and Archivists|Librarian, Archivist and Curator|Librarians, Archivists and Curators	Workers who appraise, edit, and maintain permanent records and historically valuable documents; oversee collections of artwork and historic items; restore objects and documents in museum collections and exhibits, and/or help people find information and conduct research for personal and professional use.			Occupation or Discipline	GDC Terminology|GDC Value Terminology|integrated Cancer Repository for Cancer Research
C122474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122474>	C97638	Life Scientists|Life Science Professional|Life Science Professionals	The group of science professions that include animal scientists, biochemists and biophysicists, epidemiologists, food scientists and technologists, medical scientists, microbiologists, zoologists and wildlife biologists, and soil and plant scientists.			Occupation or Discipline	GDC Terminology|GDC Value Terminology|integrated Cancer Repository for Cancer Research
C122475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122475>	C97638|C63861	Life, Physical, and Social Science Technicians	Life science technicians typically work in laboratories assisting scientists in the research of living organisms and organic substances. Physical science technicians assist senior resource scientists by collecting, managing, analyzing, and interpreting a wide array of physical science information. Social science technicians do nonprofessional work of a technical, specialized, or support nature in one or more of the social science fields.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122476>	C97645	Material Moving Workers	The group of professions that include delivery truck drivers and driver/sales workers, hand laborers and material movers, heavy and tractor-trailer truck drivers, and material moving machine operators.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122477>	C25193	Material Recording, Scheduling, Dispatching, and Distributing Workers	Workers who compile records concerning quantity, cost, and type of material received, stored or issued, or who schedule and coordinate flow of work within or between departments.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122478>	C78303	Gait Unsteady	A shaky or wobbly manner of walking.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122479>	C45678	Ethylene Chlorohydrin|2-CHLOROETHANOL|2-Chloroethanol|2-Hydroxyethyl Chloride|2-Monochloroethanol|Ethanol, 2-Chloro-|Ethylchlorohydrin|Ethylene Glycol, Chlorohydrin|Ethylene chlorohydrin|Ethylene chlorohydrin|Glycomonochlorhydrin	An organochlorine compound and hazardous substance. Ethylene chlorohydrin is used as a solvent and in the manufacture of a variety of industrial agents.			Hazardous or Poisonous Substance|Organic Chemical	CPTAC Codelists Terminology|CPTAC Environmental/Occupational Exposure Codelist|CPTAC Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|integrated Cancer Repository for Cancer Research
C122480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122480>	C97629	Mathematical Science Occupations	The group of professions that include actuaries, mathematicians, statisticians, and mathematical technicians.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122481>	C85487	Media and Communication Equipment Workers	The group of professions that include broadcast and sound engineering technicians and radio operators; photographers; and television, video, and motion picture camera operators and editors.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122482>	C25193	Media and Communication Workers	The group of professions that include announcers, news analysts, reporters and correspondents, public relations specialists, writers and editors.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122483>	C25193	Metal Workers and Plastic Workers	The group of professions that include computer control programmers and operators; forming machine setters, operators, and tenders; machine tool cutting setters, operators, and tenders; machinists, metal furnace operators, tenders, pourers, and casters; model makers and patternmakers; molders and molding machine setters, operators, and tenders; multiple machine tool setters, operators, and tenders; tool and die makers; and welding, soldering, and brazing workers.			Occupation or Discipline	CPTAC Codelists Terminology|CPTAC Environmental/Occupational Exposure Codelist|CPTAC Terminology|integrated Cancer Repository for Cancer Research
C122484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122484>	C97647	Military Officer Special and Tactical Operations Leaders and Managers|Military Officer Special and Tactical Operations Leaders/Managers	The group of professions that include air crew officers, aircraft launch and recovery officers, armored assault vehicle officers, artillery and missile officers, command and control center officers, infantry officers, and special forces officers.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122485>	C97647	Military Enlisted Tactical Operations and Air/Weapons Specialists and Crew Members	The group of professions that include air crew members, aircraft launch and recovery specialists, armored assault vehicle crew members, artillery and missile crew members, command and control center specialists, infantry members, radar and sonar technicians, and special forces members.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122486>	C97645	Motor Vehicle Operators	The group of professions that include ambulance drivers and attendants, bus drivers, driver/sales workers, heavy and tractor-trailer truck drivers, light truck or delivery service drivers, and taxi drivers and chauffeurs.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122487>	C28398	Nursing, Psychiatric, and Home Health Aides	Nursing aides, orderlies, and attendants provide basic patient care under direction of nursing staff; performed duties include feeding, bathing, dressing, grooming, moving patients, and changing linens. Psychiatric aides assist mentally impaired or emotionally disturbed patients, working under direction of nursing and medical staff. Home health aides provide routine, personal healthcare, such as bathing, dressing, or grooming, to elderly, convalescent, or disabled persons in the home of patients or in a residential care facility.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122488>	C28398	Occupational and Physical Therapist Assistants and Aides	Occupational therapy assistants and aides work under the direction of occupational therapists, helping patients develop, recover, and improve the skills needed for daily living and working. Occupational therapy assistants are directly involved in providing therapy to patients, while occupational therapy aides typically perform support activities. Physical therapist assistants and physical therapist aides work under the direction and supervision of physical therapists, helping patients who are recovering from injuries and illnesses regain movement and manage pain.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122489>	C70652	Operations Specialties Managers	The group of professions that include administrative services managers, computer and information systems managers, financial managers, human resources managers, training and development managers, and transportation, storage, and distribution managers.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122490>	C45678	Propylene Chlorohydrin|1-Hydroxy-2-chloropropane|1-Propanol, 2-Chloro-|2-Chloro-1-propanol|2-Chloropropan-1-ol|2-Chloropropanol|2-Chloropropyl Alcohol|PROPYLENE CHLOROHYDRIN|Propylene chlorohydrin	An organochlorine compound mainly used as a chemical intermediate for the manufacture of propylene oxide.			Hazardous or Poisonous Substance|Organic Chemical	CPTAC Codelists Terminology|CPTAC Environmental/Occupational Exposure Codelist|CPTAC Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|integrated Cancer Repository for Cancer Research
C122491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122491>	C45678	Cutting Fluid|Cutting Compound|Cutting Fluids|Cutting Oil|Cutting fluids	Any fluid that is used for lubrication and cooling during metalworking and machining processes. They may be made from petroleum distillates, animal fats, plant oils, water, or other ingredients. Toxicity or irritation can result from contact with cutting fluids. The hazard can be the result of the fluid itself, the metal particles that are borne in the fluid, the bacterial or fungal contaminants that tend to grow in the fluid over time, the biocides that are added to inhibit those life forms, or the corrosion inhibitors that are added to protect the machine and tooling.			Classification|Hazardous or Poisonous Substance	CPTAC Codelists Terminology|CPTAC Environmental/Occupational Exposure Codelist|CPTAC Terminology|integrated Cancer Repository for Cancer Research
C122492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122492>	C45678	Dry Cleaning Fluid|Dry Cleaning	Any of the non-water-based solvents used to remove soil and stains from clothes. The most common of these is tetrachloroethylene (perchloroethylene), a known human carcinogen. Alternative compounds include glycol ethers, petroleum-based solvents, liquid silicone (decamethylcyclopentasiloxane or D5), modified hydrocarbon blends, brominated solvents, and supercritical CO2.			Classification|Hazardous or Poisonous Substance	CPTAC Baseline Medical Forms Terminology|CPTAC Codelists Terminology|CPTAC Environmental/Occupational Exposure Codelist|CPTAC Medical History Form|CPTAC Terminology|integrated Cancer Repository for Cancer Research
C122493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122493>	C45678	Floor Cleaning Agent|Floor Cleaning Agents|Floor cleaning agents	Any of the compounds used for floor polishing, waxing and stripping. Chemicals in these products include diethylene glycol ethyl ether, aliphatic petroleum distillates and nonylphenol ethoxylate, ethanolamine, butoxyethanol, and sodium hydroxide. Exposure to these chemicals may cause headaches, dizziness, nausea, difficulty concentrating, fatigue, wheezing, coughing, asthma attacks, hypersensitivity pneumonitis, and eye, nose, throat, and skin irritation.			Hazardous or Poisonous Substance	CPTAC Baseline Medical Forms Terminology|CPTAC Codelists Terminology|CPTAC Environmental/Occupational Exposure Codelist|CPTAC Medical History Form|CPTAC Terminology|integrated Cancer Repository for Cancer Research
C122494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122494>	C45678	Paint Thinner|Paint Thinners|Paint derivatives	Any of the solvents used to thin oil-based paints or clean up after their use. These include mineral spirits, acetone, mineral turpentine, true turpentine, naphtha, toluene, methyl ethyl ketone, dimethylformamide, 2-butoxyethanol, ethylbenzene, xylene, n-butyl acetate, and butan-1-ol. Exposure to paint thinner vapors may be hazardous.			Classification|Hazardous or Poisonous Substance	CPTAC Codelists Terminology|CPTAC Environmental/Occupational Exposure Codelist|CPTAC Terminology|integrated Cancer Repository for Cancer Research
C122495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122495>	C45678	Petroleum Hydrocarbon Compound|PHC|Petroleum / petroleum compounds|Petroleum Compound|Petroleum compounds	Any chemical compound that is derived from crude oil. Petroleum hydrocarbon compounds can enter the environment through accidents, industrial releases, or as byproducts of commercial or private uses.			Hazardous or Poisonous Substance	CPTAC Codelists Terminology|CPTAC Environmental/Occupational Exposure Codelist|CPTAC Terminology|integrated Cancer Repository for Cancer Research
C122496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122496>	C97641	Personal Appearance Workers	Barbers provide services, such as cutting, trimming, shampooing, and styling hair, trimming beards, or giving shaves. Hairdressers, hairstylists, and cosmetologists provide beauty services, such as shampooing, cutting, coloring, and styling hair, and massaging and treating scalp. They may also apply makeup, dress wigs, perform hair removal, and provide nail and skin care services. Makeup artists, theatrical and performance apply makeup to performers to reflect period, setting, and situation of their role. Manicurists and pedicurists clean, shape, and decorate customers' fingernails and toenails. Shampooers clean and rinse customers' hair. Skin care specialists provide skin care treatments to face and body to enhance an individual's appearance.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122497>	C28249	Physical Scientists	The group of science professions that include astronomers, physicists, atmospheric and space scientists, chemists, materials scientists, environmental scientists and specialists, geoscientists, and hydrologists.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122498>	C25193	Plant and System Operators	The group of professions that include chemical plant system operators, nuclear power reactor operators, power distributors and dispatchers, power plant operators, water and wastewater treatment plant and system operators, stationary engineers and boiler operators, and gas plant operators, petroleum pump system operators, refinery operators, and gaugers.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122499>	C102873	Postsecondary Teachers|University and Higher Education Teacher|University and Higher Education Teachers	Postsecondary teachers instruct students in a wide variety of academic and vocational subjects beyond the high school level. They also conduct research and publish scholarly papers and books.			Occupation or Discipline	GDC Terminology|GDC Value Terminology|integrated Cancer Repository for Cancer Research
C12249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12249>	C38617	Posterior Wall of the Hypopharynx|Posterior Wall of Hypopharynx|Posterior wall of hypopharynx	The region of the hypopharynx demarcated by a plane drawn at the level of the tip of the epiglottis to a plane at the inferior border of the cricoid.	Posterior Wall of Hypopharynx		Body Location or Region	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C1224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1224>	C2017	Atamestane|ATAMESTANE|atamestane	A synthetic steroidal substance with antineoplastic activity.  Atamestane binds irreversibly to and inhibits the enzyme aromatase, thereby blocking the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C122500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122500>	C102873	Primary, Secondary, and Special Education School Teachers	The teaching professions that include elementary school teachers, middle school teachers, middle school career/technical education teachers, secondary school teachers, secondary school career/technical education teachers, middle school special education teachers, and secondary school special education teachers.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122501>	C25193	Printing Workers|Printing Trades Worker|Printing Trades Workers	Printing workers produce print material in three stages: prepress, press, and binding and finishing. They review specifications, calibrate color settings on printers, identify and fix problems with printing equipment, and assemble pages.			Occupation or Discipline	GDC Terminology|GDC Value Terminology|integrated Cancer Repository for Cancer Research
C122502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122502>	C97645	Rail Transportation Workers	Workers in railroad occupations ensure that passenger and freight trains run on time and travel safely. Some workers drive trains, some coordinate the activities of the trains, while others operate signals and switches in the rail yard.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122503>	C25193	Religious Workers	Clergy conduct religious worship and perform other spiritual functions associated with beliefs and practices of religious faith or denomination. They also provide spiritual and moral guidance and assistance to members. Directors of religious activities and education plan, direct, or coordinate programs designed to promote the religious education or activities of a denominational group. They may provide counseling and guidance relative to marital, health, financial, and religious problems.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122504>	C97644	Retail Sales Workers	Retail sales workers include both those who sell retail merchandise, such as clothing, furniture, and automobiles, (retail salespersons) and those who sell spare and replacement parts and equipment, especially car parts (parts salespersons). Both types of workers help customers find the products they want and process customers' payments.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122505>	C97644	Sales Representatives, Services	Advertising sales agents sell or solicit advertising, including graphic art, advertising space in publications, custom made signs, or TV and radio advertising time. They may obtain leases for outdoor advertising sites or persuade retailer to use sales promotion display items. Insurance sales agents sell life, property, casualty, health, automotive, or other types of insurance. They may refer clients to independent brokers, work as an independent broker, or be employed by an insurance company. Travel agents plan and sell transportation and accommodations for travel agency customers. They help determine destination, modes of transportation, travel dates, costs, and accommodations required.			Occupation or Discipline	
C122506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122506>	C97644	Sales Representatives, Wholesale and Manufacturing	Wholesale and manufacturing sales representatives sell goods for wholesalers or manufacturers to businesses, government agencies, and other organizations. They contact customers, explain product features, answer any questions that their customers may have, and negotiate prices.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122507>	C78333	Hemoglobin A1c Increased|HbA1c Increased|HgbA1c Increased	A laboratory test result demonstrating an increase in the glycosylated hemoglobin in a blood sample.			Laboratory or Test Result	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122508>	C198798	Secretaries and Administrative Assistants	Secretaries and administrative assistants perform routine clerical and administrative duties. They organize files, draft messages, schedule appointments, and support other staff.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122509>	C28398	Social Scientists and Related Workers	The group of professions that include economists, marketing research analysts, survey researchers, clinical, counseling, and school psychologists, industrial-organizational psychologists, sociologists, urban and regional planners, anthropologists and archeologists, geographers, historians, and political scientists.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C12250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12250>	C12680	Cervical Esophagus|Cervical esophagus|Cervical esophagus structure (body structure)|ESOPHAGUS, CERVICAL	Clinical esophageal segment composed of skeletal muscle. It corresponds to the superior part of the upper third topographic segment of the esophagus.	Cervical Esophagus		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C122510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122510>	C97636	Supervisors of Installation, Maintenance, and Repair Workers	Workers who directly supervise and coordinate the activities of mechanics, installers, and repairers.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122511>	C97626	Supervisors, Building and Grounds Cleaning and Maintenance Workers|Supervisors of Building and Grounds Cleaning and Maintenance Workers	Workers who directly supervise housekeeping and janitorial workers, landscaping, lawn service, and groundskeeping workers.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122512>	C35457	Ketonuria	The presence of ketone bodies in the urine.			Laboratory or Test Result	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122513>	C35553	Hyperlactemia|Elevated Lactate|Elevated Lactate Level	Abnormally high level of lactate in the blood.			Laboratory or Test Result	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122514>	C97630	Supervisors, Construction and Extraction Workers|Supervisors of Construction and Extraction Workers	Workers who directly supervise and coordinate activities of construction or extraction workers.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122515>	C97632	Supervisors, Farming, Fishing, and Forestry Workers|Supervisors of Farming, Fishing, and Forestry Workers	Workers who directly supervise and coordinate the activities of agricultural, forestry, aquacultural, and related workers.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122516>	C35553	Abnormal Liver Function Test	Atypical results found on serum liver enzyme testing, which may indicate significant disease and/or disease progression.			Laboratory or Test Result	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122517>	C97633	Supervisors, Food Preparation and Serving Workers|Supervisors of Food Preparation and Serving Workers	Workers who directly supervise and coordinate activities of workers engaged in preparing and serving food.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122518>	C97640	Supervisors, Office and Administrative Support Workers|Supervisors of Office and Administrative Support Workers	Workers who directly supervise and coordinate the activities of clerical and administrative support workers.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122519>	C97641	Supervisors, Personal Care and Service Workers|Supervisors of Personal Care and Service Workers	Workers who directly supervise and coordinate activities of personal service workers, such as flight attendants, hairdressers, or caddies.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C12251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12251>	C12680	Thoracic Esophagus|ESOPHAGUS, THORACIC|Thoracic esophagus|thoracic part of esophagus	Clinical esophageal segment composed of smooth muscle. It includes the middle third topographic segment, as well as parts of the upper and lower thirds.	Thoracic Esophagus		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C122520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122520>	C97642	Supervisors, Production Workers|Supervisors of Production Workers	Workers who directly supervise and coordinate the activities of production and operating workers, such as inspectors, precision workers, machine setters and operators, assemblers, fabricators, and plant and system operators.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122521>	C97644	Supervisors, Sales Workers|Supervisors of Sales Workers	Workers who directly supervise and coordinate activities of sales workers other than retail sales workers. May perform duties, such as budgeting, accounting, and personnel work, in addition to supervisory duties.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122522>	C97645	Supervisors, Transportation and Material Moving Workers|Supervisors of Transportation and Material Moving Workers	Workers who directly supervise and coordinate activities of aircraft cargo handlers; helpers, laborers, and hand material movers; and transportation and material-moving machine and vehicle operators.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122523>	C26704|C115248	Methicillin-Resistant Staphylococcus aureus Pneumonia|MRSA Pneumonia	Pneumonia that is caused by Staphylococcus aureus that is resistant to methicillin treatment.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122524>	C25193	Textile, Apparel, and Furnishings Workers	The group of professions that include laundry and dry-cleaning workers, pressers of textile, garment, and related materials, sewing machine operators, shoe and leather workers, tailors, dressmakers, and sewers, textile machine setters, operators, and tenders, and other miscellaneous textile, apparel, and furnishings workers.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122525>	C97639	Top Executives	Upper-level managers who devise strategies and policies to ensure that an organization meets its goals. They plan, direct, and coordinate operational activities of companies and organizations.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122526>	C26704	Mycoplasmal Pneumonia	Pneumonia caused by Mycoplasma pneumoniae. Signs and symptoms include productive cough, fever, chills, shortness of breath, and chest pain.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122527>	C78719	Disrupted Suture|Stitches Coming Loose|Stitches Coming Loose	The loss of tension or continuity of sutures.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122528>	C3858	Violent Behavior	Any action that results in intimidation, harm, damage, or destruction of someone or something.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122529>	C88429	Unresponsive to Stimuli	An individual whose level of consciousness is such that he is not responsive to any stimulus.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C12252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12252>	C12680	Abdominal Esophagus|Abdominal esophagus|ESOPHAGUS, ABDOMINAL	Clinical esophageal segment composed of smooth muscle. It corresponds to the inferior part of the lower third topographic segment of the esophagus.	Abdominal Esophagus		Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C122530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122530>	C25193	Transportation, Tourism, and Lodging Attendants	The group of professions that include baggage porters, bellhops, and concierges, tour and travel guides, and flight attendants.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122531>	C97636	Vehicle and Mobile Equipment Mechanics, Installers, and Repairers	The group of professions that include aircraft mechanics and service technicians, automotive technicians and repairers, bus and truck mechanics and diesel engine specialists, heavy vehicle and mobile equipment service technicians and mechanics, small engine mechanics, bicycle repairers, recreational vehicle service technicians and tire repairers and changers.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122532>	C97645	Water Transportation Workers	Workers in water transportation occupations who operate and maintain vessels that take cargo and people over water.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122533>	C148248	Woodworkers	Workers who use wood, veneers, and laminates to manufacture a variety of products such as cabinets and furniture.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122534>	C97624	Other Architecture and Engineering Workers	Architecture and engineering workers not specifically identified elsewhere.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122535>	C97625	Other Arts, Design, Entertainment, Sports, and Media Workers	Arts, design, entertainment, sports, and media workers not specifically identified elsewhere.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122536>	C97626	Other Building and Grounds Cleaning and Maintenance Workers	Building and grounds cleaning and maintenance workers not specifically identified elsewhere.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122537>	C97627	Other Business and Financial Operations Workers	Business and financial operations workers not specifically identified elsewhere.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122538>	C97628	Other Community and Social Services Workers	Community and social services workers not specifically identified elsewhere.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122539>	C97629	Other Computer and Mathematical Workers	Computer and mathematical workers not specifically identified elsewhere.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C12253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12253>	C12680	Upper Third of the Esophagus|ESOPHAGUS, UPPER THIRD|Esophageal; Proximal|Upper Third|Upper Third of Esophagus|Upper third of esophagus|upper esophagus	The upper one third of esophagus in which the muscle layer is composed of muscle cells of the striated type.	Upper Third of Esophagus		Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C122540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122540>	C122436	Other Construction and Related Workers	Construction and related workers not specifically identified elsewhere.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122541>	C97631	Other Education, Training, and Library Occupations	Education, training, and library occupations not specifically identified elsewhere.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122542>	C97632	Other Farming, Fishing, and Forestry Workers	Farming, fishing, and forestry workers not specifically identified elsewhere.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122543>	C97633	Other Food Preparation and Serving Related Workers	Food preparation and serving related workers not specifically identified elsewhere.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122544>	C97634	Other Healthcare Practitioners and Technical Occupations	Healthcare practitioners and technical occupations not specifically identified elsewhere.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122545>	C97635	Other Healthcare Support Occupations	Healthcare support occupations not specifically identified elsewhere.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122546>	C97636	Other Installation, Maintenance, and Repair Occupations	Installation, maintenance, and repair occupations not specifically identified elsewhere.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122547>	C97637	Other Legal Workers	Legal workers not specifically identified elsewhere.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122548>	C97638	Other Life, Physical, and Social Science Workers	Life, physical, and social science workers not specifically identified elsewhere.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122549>	C97639	Other Management Occupations	Management occupations not specifically identified elsewhere.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C12254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12254>	C12680	Middle Third of the Esophagus|ESOPHAGUS, MIDDLE THIRD|Esophageal; Mid|Middle Third|Middle Third of Esophagus|Middle third of esophagus|middle part of esophagus	The middle one third of the esophagus in which the muscle layer is composed of muscle cells of the striated and smooth types.	Middle Third of Esophagus		Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C122550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122550>	C97647	Other Military Specific Workers	Military specific workers not specifically identified elsewhere.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122551>	C97640	Other Office and Administrative Support Workers	Office and administrative support workers not specifically identified elsewhere.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122552>	C97641	Other Personal Care and Service Workers	Personal care and service workers not specifically identified elsewhere.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122553>	C97642	Other Production Occupations	Production occupations not specifically identified elsewhere.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122554>	C97643	Other Protective Service Workers	Protective service workers not specifically identified elsewhere.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122555>	C97644	Other Sales and Related Workers|Other Sales Worker|Other Sales Workers	Sales and related workers not specifically identified elsewhere.			Occupation or Discipline	GDC Terminology|GDC Value Terminology|integrated Cancer Repository for Cancer Research
C122556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122556>	C102873	Other Teachers and Instructors|Other Teaching Professional|Other Teaching Professionals	Teachers and instructors not specifically identified elsewhere.			Occupation or Discipline	GDC Terminology|GDC Value Terminology|integrated Cancer Repository for Cancer Research
C122557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122557>	C97645	Other Transportation Workers	Transportation workers not specifically identified elsewhere.			Occupation or Discipline	integrated Cancer Repository for Cancer Research
C122558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122558>	C28510	DNAJB1/PRKACA Fusion Gene|DNAJB1-PRKACA Fusion Gene|DNAJB1::PRKACA Fusion Gene	A fusion gene that results from a heterozygous deletion in chromosome 19 that fuses the first 1 or 2 exons of the DNAJB1 gene in frame with exon 2 of the PRKACA gene. This fusion is associated with fibrolamellar carcinoma.	DNAJB1/PRKACA Fusion Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122559>	C17561	DNAJB1/PRKACA Fusion Protein|DNAJB1-PRKACA Fusion Protein|DNAJB1::PRKACA Fusion Protein|DnaJ Homolog Subfamily B Member 1-cAMP-Dependent Protein Kinase Catalytic Subunit Alpha Fusion Protein|DnaJ Homolog Subfamily B Member 1/cAMP-Dependent Protein Kinase Catalytic Subunit Alpha Fusion Protein|HSP40-PKA C-alpha Fusion Protein|HSP40/PKA C-alpha Fusion Protein	A fusion protein that is encoded by the DNAJB1/PRKACA fusion gene. This protein contains the N-terminus of DnaJ homolog subfamily B member 1 protein fused to almost the entire cAMP-dependent protein kinase catalytic subunit alpha (PKA C-alpha) protein. The chimeric protein lacks the PKA C-alpha domains that interact with PKA regulatory subunits.	DNAJB1/PRKACA Fusion Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12255>	C12680	Lower Third of the Esophagus|ESOPHAGUS, LOWER THIRD|Esophageal; Distal|Lower Third|Lower Third of Esophagus|Lower third of esophagus|lower esophagus	The lower one third of the esophagus in which the muscle layer is composed of muscle cells predominantly of the smooth type.	Lower Third of Esophagus		Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C122560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122560>	C25802	DNAJB1 Gene|DNAJB1|DNAJB1|DNAJB1|DnaJ (Hsp40) Homolog, Subfamily B, Member 1 Gene	This gene plays a role in the regulation of protein folding.	DNAJB1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C122561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122561>	C122560	DNAJB1 wt Allele|DNAJ1|DnaJ (Hsp40) Homolog, Subfamily B, Member 1 wt Allele|DnaJ Homolog, Subfamily B, Member 1 Gene|HDJ1|HSPF1|Hdj1|Hsp40|RSPH16B|Radial Spoke 16 Homolog B (Chlamydomonas) Gene|Radial Spoke 16 Homolog B Gene|Sis1	Human DNAJB1 wild-type allele is located in the vicinity of 19p13.2 and is approximately 15 kb in length. This allele, which encodes DnaJ homolog subfamily B member 1 protein, is involved in the modulation of heat shock protein 70 activity. A chromosomal deletion that fuses this gene and the PRKACA gene is associated with fibrolamellar carcinoma.	DNAJB1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122562>	C17764	DnaJ Homolog Subfamily B Member 1|DNAJB1|DnaJ Protein Homolog 1|HSP40|Heat Shock 40 kDa Protein 1|Heat Shock 40kD Protein 1|Heat Shock Protein 40|Heat-Shock 40-kD Protein 1|Human DnaJ Protein 1|Radial Spoke 16 Homolog B|hDj-1	DnaJ homolog subfamily B member 1 (340 aa, ~38 kDa) is encoded by the human DNAJB1 gene. This protein plays a role in the regulation of both heat shock protein 70 activity and protein folding.	DnaJ Homolog Subfamily B Member 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122563>	C45678	Coal Gas, Coal Tar, Coal Tar Pitch, and Derivatives|Coal Gas/Tar Pitch Derivatives|Coal gas/tar pitch derivatives	A complex chemical mixture of condensed-ring aromatic hydrocarbons produced by the destructive distillation (pyrolysis) of coal. The lower viscosity byproducts are generally regarded as tar, whereas the viscous, semisolid, or solid byproducts are designated as pitch. Coal tar and coal tar pitch are known to be human carcinogens.			Hazardous or Poisonous Substance	CPTAC Baseline Medical Forms Terminology|CPTAC Codelists Terminology|CPTAC Environmental/Occupational Exposure Codelist|CPTAC Medical History Form|CPTAC Terminology|integrated Cancer Repository for Cancer Research
C122564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122564>	C45678	Rubber Chemical|Rubber Chemicals|Rubber Chemicals	Any of the monomers, resins, solvents, emulsifiers, intermediates, additives, and others used in the manufacture of rubber and rubber products. Excess deaths from bladder, stomach, lung, hematopoietic, and other cancers have occurred among workers involved in the manufacture of rubber products.			Chemical Viewed Functionally|Hazardous or Poisonous Substance	CPTAC Codelists Terminology|CPTAC Environmental/Occupational Exposure Codelist|CPTAC Terminology|integrated Cancer Repository for Cancer Research
C122565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122565>	C91105	FACT-N Questionnaire|FACT-N|FACT-N|Functional Assessment of Cancer Therapy-Neutropenia	A subscale complement to the FACT-G developed specifically for evaluating the quality of life of cancer patients with neutropenia.			Intellectual Product	
C122566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122566>	C91105	FACT-MM Questionnaire|FACT-MM|Functional Assessment of Cancer Therapy-Multiple Myeloma	A subscale complement to the FACT-G developed specifically for evaluating the quality of life of patients with multiple myeloma.	FACT-MM Questionnaire		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C122567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122567>	C173934	Worry About Getting Infections Question|I worry about getting infections|Worry About Getting Infections	A question about whether an individual worries or worried about getting infections.			Intellectual Product	FACT-N Questionnaire
C122568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122568>	C173160	Feel Discouraged About Illness Question|Feel Discouraged About Illness|I feel discouraged about my illness	A question about whether an individual feels or felt discouraged about their illness.			Intellectual Product	FACT-Leu Questionnaire
C122569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122569>	C173934|C173457	Worry About Getting New Symptoms Question|I worry that I might get new symptoms of my illness|Worry About Getting New Symptoms|Worry Might Get New Symptoms of My Illness	A question about whether an individual worries or worried that they might get new symptoms of their illness.			Intellectual Product	FACT-BRM Questionnaire|FACT-Leu Questionnaire
C12256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12256>	C25763	Gastric Cardia|Cardia|Cardia|Cardia of the Stomach|Cardia, NOS|GASTRIC CARDIA|STOMACH, CARDIA|cardia of stomach|cardial part of stomach|gastric cardia|pars cardiaca (gaster)|pars cardiaca gastricae|stomach cardiac region	The area around the esophagogastric mucosal junction where the esophageal mucosa transitions into the gastric mucosa.	Cardia, NOS Gastric Cardia		Body Space or Junction	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C122570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122570>	C173981	Have Emotional Ups and Downs Question|Have Emotional Ups and Downs|I have emotional ups and downs	A question about whether an individual has or had emotional ups and downs.			Intellectual Product	FACT-BRM Questionnaire
C122571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122571>	C173346|C111629	Have Trouble Walking Because of Pain Question|Have Trouble Walking Because of Pain|I have trouble walking because of pain	A question about whether an individual has or had trouble walking because of pain.			Intellectual Product	FACT-MM Questionnaire
C122572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122572>	C3439	Rhinovirus Infection	An infectious process caused by rhinovirus. The virus usually causes upper respiratory infections, but can infect the lower tract as well.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122573>	C16326	Screaming	A loud, vociferous cry or yell; it can be the result of many emotions, including pain, excitement, or fear.			Behavior	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122574>	C27153	Lupus Flare	An exacerbation of the chronic disease lupus.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122575>	C35682	Positive Herpes Simplex Virus Culture	Laboratory test results demonstrating the presence of the Herpes Simplex virus in a specimen.			Laboratory or Test Result	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122576>	C35038	Staphylococcus aureus Infection|Staphylococcus aureus	An infectious process in which the bacteria Staphylococcus aureus is present.			Disease or Syndrome	GDC Terminology|GDC Value Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122577>	C28397	Status Asthmaticus	An acute exacerbation of asthma, characterized by inadequate response to initial bronchodilators.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122578>	C4876	Throat Tightening|Throat Tightness|Throat tightness	The sensation of constriction or contraction in the throat area.			Sign or Symptom	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122579>	C92564	Phonophobia	A fear of sounds, which can include fear of voices, including one's own voice, in addition to other sounds.			Mental or Behavioral Dysfunction	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C12257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12257>	C25763	Fundus of the Stomach|FUNDUS OF THE STOMACH|Fundus|Fundus Of Stomach|Fundus of Stomach|Fundus of stomach|STOMACH, FUNDUS|fundus gastricus (ventricularis)|fundus of stomach|gastric fundus|stomach fundus	The portion of the stomach that lies above the cardiac notch. It allows for the accumulation of gases produced by chemical digestion.	Fundus of Stomach		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C122580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122580>	C3368	Pneumatosis Intestinalis	The presence of gas within the wall of the large or small intestine.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122581>	C8280	Postoperative Infection	Any infection documented following a surgical procedure that was not evident or suspected prior to the procedure.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Infectious Disease Terminology
C122582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122582>	C35682	Positive Pseudomonas Culture	A laboratory test result demonstrating the presence of bacteria from the genus Pseudomonas in a sample after culture.			Laboratory or Test Result	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122583>	C50688	Hemiparesis	Weakness or incomplete paralysis of either the left or right side of the body.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122584>	C5226	Borderline Ovarian Serous Tumor/Atypical Proliferative Ovarian Serous Tumor|SBT/APST	A non-invasive serous neoplasm that arises from the ovary and shows greater cellular proliferation and cytologic atypia as compared to benign ovarian serous tumors, but less as compared to low-grade ovarian serous carcinoma.	Borderline Ovarian Serous Tumor/Atypical Proliferative Ovarian Serous Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C122585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122585>	C5226	Borderline Ovarian Serous Tumor-Micropapillary Variant/Non-Invasive Low Grade Ovarian Serous Carcinoma	A non-invasive serous neoplasm that arises from the ovary and shows micropapillary and/or cribriform architectural patterns.  It is composed of round epithelial cells with scant cytoplasm and moderate nuclear atypia.			Neoplastic Process	GDC Terminology|GDC Value Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C122586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122586>	C40036	Borderline Ovarian Mucinous Tumor/Atypical Proliferative Ovarian Mucinous Tumor|MBT/APMT	A non-invasive neoplasm that arises from the ovary and is composed of gastrointestinal-type, mucin-containing epithelial cells.  It shows greater cellular proliferation and cytologic atypia as compared to benign ovarian mucinous tumors.			Neoplastic Process	
C122587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122587>	C54729	Indwelling Urinary Catheter	A hollow tube that is inserted and left in the bladder to promote the drainage of urine.			Medical Device	NICHD Terminology|Pediatric Adverse Events Terminology
C122588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122588>	C50344	Peritoneal Dialysis Catheter	A hollow tube that is inserted in the abdomen to carry fluid into and out of the abdominal cavity.			Medical Device	NICHD Terminology|Pediatric Medical Device Terminology
C122589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122589>	C50344	Hemodialysis Catheter	A hollow tube that is inserted into a large vein to carry blood to and from a dialysis machine.			Medical Device	NICHD Terminology|Pediatric Medical Device Terminology
C12258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12258>	C25763	Body of Stomach|BODY OF STOMACH|Body|Body of stomach|body of stomach	The main section of the digestive tube that connects the esophagus to the small intestine. The body proper excludes the upper and lower sections of the fundus and pyloric portion respectively.	Body of Stomach		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C122590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122590>	C50344	Venous Catheter|Venous Line	A hollow tube that is inserted into a vein.			Medical Device	NICHD Terminology|Pediatric Medical Device Terminology
C122591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122591>	C17612	Peripherally Inserted Central Catheter	A central venous catheter inserted through a peripheral vein.			Medical Device	NICHD Terminology|Pediatric Medical Device Terminology
C122592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122592>	C50344	Arterial Catheter	A hollow tube that is inserted into an artery.			Medical Device	NICHD Terminology|Pediatric Medical Device Terminology
C122593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122593>	C52005	Duodenostomy	Surgical creation of an external opening into the duodenum.			Therapeutic or Preventive Procedure	
C122594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122594>	C17629	Oral Endotracheal Tube	A hollow tube that is directed into the trachea from the mouth.			Medical Device	NICHD Terminology|Pediatric Medical Device Terminology
C122595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122595>	C17629	Nasal Endotracheal Tube	A hollow tube that is directed into the trachea from the nose.			Medical Device	NICHD Terminology|Pediatric Medical Device Terminology
C122596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122596>	C17629	Laryngeal Tube	A supraglottic airway device.			Medical Device	NICHD Terminology|Pediatric Medical Device Terminology
C122597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122597>	C91833	Nasojejunal Tube	A hollow tube that is directed into the jejunum from the nose.			Medical Device	NICHD Terminology|Pediatric Medical Device Terminology
C122598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122598>	C16830	Pericardial Tube	A hollow tube that is inserted into the pericardium through a surgical incision in the chest wall.			Medical Device	NICHD Terminology|Pediatric Medical Device Terminology
C122599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122599>	C16830	Chest Tube	A hollow tube that is inserted into the pleural space through a surgical incision in the chest wall.			Medical Device	NICHD Terminology|Pediatric Medical Device Terminology
C12259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12259>	C25763	Antrum Pylori|ANTRUM PYLORI|Antrum|Gastric Antrum|Gastric antrum|pyloric antrum	The initial part of the pyloric canal of the stomach. This site contains endocrine cells that produce gastrin and somatostatin.	Gastric Antrum		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C1225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1225>	C296	Shiga Toxin	A bacterial toxin produced by Shigella dysenteriae and by some strains of E. coli that inhibits protein synthesis by blocking the interaction of ribosomal RNA with peptide elongation factors.  The non-catalytic beta subunit of Shiga toxin may be useful as a fusion vector for induction of antigen-specific cytotoxic T lymphocyte responses.			Amino Acid, Peptide, or Protein|Hazardous or Poisonous Substance	
C122600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122600>	C16830	Rectal Tube	A hollow tube that is directed into the colon from the rectum.			Medical Device	NICHD Terminology|Pediatric Medical Device Terminology
C122601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122601>	C122602	Extramedullary Involvement	A finding indicating the involvement of sites other than the bone marrow by a hematopoietic neoplasm.			Finding	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C122602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122602>	C36289	Bone Marrow and Extramedullary Involvement|Marrow and Extramedullary Involvement	A finding indicating the involvement of the bone marrow and other anatomic sites, which may include the peripheral blood, lymph nodes, and/or extranodal sites, by a hematopoietic neoplasm.			Finding	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C122603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122603>	C4989	Infant Leukemia|Leukemia in Infancy	An acute lymphoblastic or acute myeloid leukemia that occurs in infancy.			Neoplastic Process	NCIt Neoplasm Core Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C122604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122604>	C60644	Infantile Lesion|Lesion in Infancy	A benign or malignant lesion that occurs in infancy.			Finding	
C122605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122605>	C122604	Neonatal Lesion	A benign or malignant lesion that occurs in the neonatal period.			Finding	
C122606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122606>	C38155	Early Relapse|Early Recurrence|Early Recurrence	Clinical and/or laboratory evidence of early reemergence of a disorder after a period of remission.			Finding	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C122607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122607>	C38155	Late Relapse|Late Recurrence|Late Recurrence	Clinical and/or laboratory evidence of late reemergence of a disorder after a period of remission.			Finding	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C122608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122608>	C16830	Tympanostomy Tube	A hollow tube that is inserted into the eardrum through a surgical incision.			Medical Device	NICHD Terminology|Pediatric Medical Device Terminology
C122609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122609>	C16830	Surgical Wound Drain	A hollow tube inserted into a surgical incision to promote drainage during wound healing.	Surgical Wound Drain		Medical Device	CTRP Intervention Terminology|CTRP Terminology|NICHD Terminology|Pediatric Medical Device Terminology
C12260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12260>	C25763	Pylorus|PYLORUS|STOMACH, PYLORUS|pars pylorica|pars pylorica gastricae|pyloric part of stomach|pyloric region|pylorus|stomach pyloric region	The lower part of the stomach that connects to the duodenum.	Pylorus		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C122610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122610>	C16830	Ventriculostomy Drain	A hollow tube that is surgically placed a cerebral ventricle to drain excess cerebrospinal fluid.			Medical Device	NICHD Terminology|Pediatric Medical Device Terminology
C122611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122611>	C16830	T-Tube	A hollow tube in the shape of a T that is inserted into a body cavity through the skin to promote drainage.			Medical Device	NICHD Terminology|Pediatric Medical Device Terminology
C122612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122612>	C16830	Pigtail Drain	A hollow tube that has holes in the wall of the tube and a coiled tip and is inserted into a body cavity or organ to promote drainage.			Medical Device	NICHD Terminology|Pediatric Medical Device Terminology
C122613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122613>	C16830	Swan Ganz Catheter	A hollow tube with a balloon or sail tip that is advanced into the pulmonary artery to measure right heart pressure and cardiac output, and enable mixed venous blood sampling.			Medical Device	NICHD Terminology|Pediatric Medical Device Terminology
C122614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122614>	C3168|C122603	Infant Acute Lymphoblastic Leukemia|Infant ALL	An acute lymphoblastic leukemia that occurs in infancy.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C122615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122615>	C50190	Biliary Duct Stent	A hollow tube that is advanced into an obstructed bile duct to allow the flow of bile into the bowel.			Medical Device	NICHD Terminology|Pediatric Medical Device Terminology
C122616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122616>	C50190	Coronary Artery Stent	An expandable hollow tube that is advanced into an obstructed or narrow coronary artery to restore blood flow to the heart.			Medical Device	NICHD Terminology|Pediatric Medical Device Terminology
C122617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122617>	C122614	Infant Acute Lymphoblastic Leukemia with KMT2A Rearrangement|Infant ALL with MLL Rearrangement|Infant Acute Lymphoblastic Leukemia with MLL Gene Rearrangement|Infant Acute Lymphoblastic Leukemia with MLL Rearrangement|Infant Acute Lymphoblastic Leukemia with MLL Rearrangement	An acute lymphoblastic leukemia with rearrangement of the KMT2A gene that occurs in infancy.			Neoplastic Process	Cellosaurus Disease Terminology|NCIt Neoplasm Core Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C122618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122618>	C122589	Cuffed Hemodialysis Catheter	A hollow tube that is inserted into a large vein to carry blood to and from a dialysis machine where the exit site is secured just under the skin with a band-like structure to prevent slippage and infection.			Medical Device	NICHD Terminology|Pediatric Medical Device Terminology
C122619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122619>	C122588	Cuffed Peritoneal Dialysis Catheter	A hollow tube that is inserted in the abdomen to carry fluid into and out of the abdominal cavity where the exit site is secured just under the skin with a band-like structure to prevent slippage and infection.			Medical Device	NICHD Terminology|Pediatric Medical Device Terminology
C12261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12261>	C25763	Lesser Curvature of the Stomach|LESSER CURVATURE OF THE STOMACH|Lesser curvature of stomach, NOS|lesser curvature of stomach	The right border of the stomach.  It is concave in shape and extends from the cardiac orifice to the pyloric orifice.			Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C122620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122620>	C50344	Uncuffed Dialysis Catheter	A hemodialysis or peritoneal dialysis catheter that does not utilize a band-like structure at the exit site just under the skin to prevent slippage and infection.			Medical Device	NICHD Terminology|Pediatric Medical Device Terminology
C122621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122621>	C122614	Infant Acute Lymphoblastic Leukemia without KMT2A Rearrangement|Infant ALL without MLL Rearrangement|Infant Acute Lymphoblastic Leukemia without KMT2A Gene Rearrangement|Infant Acute Lymphoblastic Leukemia without MLL Gene Rearrangement|Infant Acute Lymphoblastic Leukemia without MLL Rearrangement	An acute lymphoblastic leukemia without rearrangement of the KMT2A gene that occurs in infancy.			Neoplastic Process	NCIt Neoplasm Core Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C122622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122622>	C91833	Surgically Placed Gastrostomy Tube	A hollow tube that is inserted into a surgically created external opening into the stomach.			Medical Device	NICHD Terminology|Pediatric Medical Device Terminology
C122623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122623>	C79087|C158685|C133155	KMT2A Gene Rearrangement|KMT2A Rearrangement|KMT2Ar|Lysine (K)-Specific Methyltransferase 2A Gene Rearrangement|Lysine Methyltransferase 2A Gene Rearrangement|MLL|MLL Gene Rearrangement|MLL Gene Rearrangement|MLL Gene Rearrangement|MLL Rearrangement|MLL Rearrangement|Mixed Lineage Leukemia Gene Rearrangement|Myeloid/Lymphoid Leukemia Gene Rearrangement|Myeloid/Lymphoid or Mixed Lineage Leukemia Gene Rearrangement|Myeloid/Lymphoid or Mixed-Lineage Leukemia (Trithorax Homolog, Drosophila) Gene Rearrangement	A molecular abnormality indicating rearrangement of the KMT2A (MLL) gene.	MLL Gene Rearrangement		Cell or Molecular Dysfunction	AML Authorized Value Terminology|AML Minimal Residual Disease Table|AML Molecular Analysis Table|CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C122624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122624>	C3168|C212202|C136488	Refractory Childhood Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia (ALL)	An acute lymphoblastic leukemia that occurs in childhood and does not respond to treatment.	Refractory Childhood Acute Lymphoblastic Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C122625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122625>	C9160|C27753	Childhood Acute Myeloid Leukemia Not Otherwise Specified|Childhood AML, NOS|Childhood Acute Myeloid Leukemia Defined by Differentiation|Childhood Acute Myeloid Leukemia, NOC|Childhood Acute Myeloid Leukemia, NOS|Childhood Acute Myeloid Leukemia, Not Otherwise Characterized|Childhood Acute Myeloid Leukemia, Not Otherwise Specified	Acute myeloid leukemias that occur in children and do not fulfill the criteria for inclusion in the group of acute myeloid leukemias with recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related. This category includes entities classified according to the French-American-British classification scheme.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C122626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122626>	C45678	Detergent|Detergents	A water-soluble surfactant that functions to emulsify oils and hold dirt in suspension.			Chemical Viewed Functionally	CPTAC Codelists Terminology|CPTAC Environmental/Occupational Exposure Codelist|CPTAC Terminology|integrated Cancer Repository for Cancer Research
C122627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122627>	C577	Trash|Garbage|Refuse|Rubbish	Anything discarded or thrown away; waste material.			Manufactured Object	integrated Cancer Repository for Cancer Research
C122628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122628>	C38012	Maternal Proteinuria	The presence of excessive protein, chiefly albumin but also globulin, in the urine of a pregnant woman.			Laboratory or Test Result	NICHD Terminology|Perinatal Terminology
C122629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122629>	C48470	Actuation Dosing Unit|ACTUATION|Act Dosing Unit|Actuation|Actuation|actuation|{ACTUATION}|{ACTUATION}|{Actuation}|{Actuation}|{actuation}	A dosing unit equal to the amount of active ingredient(s) contained in an actuation.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EDQM Health Care Terminology|EDQM-HC Units of Presentation Terminology|NCPDP Dose Unit of Measure Terminology|PQ/CMC Units of Measure Terminology
C12262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12262>	C25763	Greater Curvature of the Stomach|GREATER CURVATURE OF THE STOMACH|Greater Curvature|Greater curvature of stomach, NOS	The lateral and inferior border of the stomach. Attached to it is the greater omentum.	Greater Curvature of Stomach, NOS		Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C122630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122630>	C48470	Auto-Injector Dosing Unit|Auto-Injector	A dosing unit equal to the amount of active ingredient(s) contained in an auto-injector.			Quantitative Concept	NCPDP Dose Unit of Measure Terminology
C122631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122631>	C48470	Dropperful Dosing Unit|Dropperful	A dosing unit equal to the amount of active ingredient(s) contained in a dropperful.			Quantitative Concept	NCPDP Dose Unit of Measure Terminology
C122632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122632>	C48470	Injection Dosing Unit|INJECTION|Injection|{INJECTION}|{INJECTION}|{Injection}|{Injection}	A dosing unit equal to the amount of active ingredient(s) contained in an injection.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|NCPDP Dose Unit of Measure Terminology
C122633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122633>	C48470	Lollipop Dosing Unit|Lollipop	A dosing unit equal to the amount of active ingredient(s) contained in a lollipop.			Quantitative Concept	NCPDP Dose Unit of Measure Terminology
C122634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122634>	C48470	Pill Dosing Unit|PILL|Pill|{PILL}|{PILL}	A dosing unit equal to the amount of active ingredient(s) contained in a pill.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|NCPDP Dose Unit of Measure Terminology
C122635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122635>	C48470	Pre-Filled Pen Syringe Dosing Unit|Pre-Filled Pen Syringe	A dosing unit equal to the amount of active ingredient(s) contained in an pre-filled pen syringe.			Quantitative Concept	NCPDP Dose Unit of Measure Terminology
C122636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122636>	C90259	Pediatric Medical Device Terminology	Terminology developed by a collaborative effort of the National Cancer Institute's Enterprise Vocabulary Services, the National Institute of Child Health and Human Development, and an international group of clinicians and informaticists to support the use of medical devices in the pediatric population.			Intellectual Product	
C122637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122637>	C67422	Monomethyl Auristatin E|(S)-N-((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)-N,3-dimethyl-2-((S)-3-methyl-2-(methylamino)butanamido)butanamide|L-Valinamide, N-methyl-L-valyl-N-((1S,2R)-4-((2S)-2-((1R,2R)-3-(((1R,2S)-2-hydroxy-1- methyl-2-phenylethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)-1-pyrrolidinyl)-2- methoxy-1-((1S)-1-methylpropyl)-4-oxobutyl)-N-methyl-|MMAE|MONOMETHYL AURISTATIN E|Monomethylauristatin E|N(sup 2)-(N-methyl-L-valyl)-N(sup 1)-((1S,2R)-4-((2S)-2-((1R,2R)-3-(((1R,2S)-2-hydroxy-1-methyl-2- phenylethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-2-methoxy-1-((1S)-1-methylpropyl)-4-oxobutyl)-N(sup 1)-methyl-L-valinamide	A dolastatin-10 peptide derivative with potent antimitotic activity and potential antineoplastic activity as part of an antibody-drug conjugate (ADC). Monomethyl auristatin E (MMAE) binds to tubulin, blocks tubulin polymerization, and inhibits microtubule formation, which results in both disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. To minimize toxicity and maximize efficacy, MMAE is conjugated, via a cleavable peptide linker, to a monoclonal antibody that specifically targets a patient's tumor. The linker is stable in the extracellular milieu but is readily cleaved to release MMAE following binding and internalization of the ADC by the target cells.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C122638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122638>	C13717	Ostomy Site	The anatomic location of a surgically created ostomy.			Body Part, Organ, or Organ Component	NICHD Terminology
C122639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122639>	C122645	Duodenostomy Site	A surgically created external opening into the duodenum.			Body Part, Organ, or Organ Component	NICHD Terminology|Pediatric Adverse Events Terminology
C12263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12263>	C25763	Duodenum|DUODENUM|Duodenal structure (body structure)|SMALL INTESTINE, DUODENUM|duodenum|duodenum	A jointed tube 25-30 cm long that connects the stomach to the jejunum.	Duodenum		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C122640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122640>	C122645	Colostomy Site	A surgically created external opening into the colon.			Body Part, Organ, or Organ Component	NICHD Terminology|Pediatric Adverse Events Terminology
C122641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122641>	C122638	Cystostomy Site	A surgically created external opening into the anterior wall of the bladder.			Body Part, Organ, or Organ Component	NICHD Terminology|Pediatric Adverse Events Terminology
C122642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122642>	C122645	Ileostomy Site	A surgically created external opening into the ileum.			Body Part, Organ, or Organ Component	NICHD Terminology|Pediatric Adverse Events Terminology
C122643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122643>	C122638	Tracheostomy Site	A surgically created external opening into the trachea.			Body Part, Organ, or Organ Component	NICHD Terminology|Pediatric Adverse Events Terminology
C122644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122644>	C122638	Urostomy Site	A surgically created external opening into the urinary tract.			Body Part, Organ, or Organ Component	NICHD Terminology|Pediatric Adverse Events Terminology
C122645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122645>	C122638	Enterostomy Site	A surgically created external opening into the intestine.			Body Part, Organ, or Organ Component	NICHD Terminology|Pediatric Adverse Events Terminology
C122646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122646>	C122638	Gastrostomy Site	A surgically created external opening into the stomach.			Body Part, Organ, or Organ Component	NICHD Terminology|Pediatric Adverse Events Terminology
C122647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122647>	C122645	Jejunostomy Site	A surgically created external opening into the jejunum.			Body Part, Organ, or Organ Component	NICHD Terminology|Pediatric Adverse Events Terminology
C122648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122648>	C122638	Nephrostomy Site	A surgically created external opening into the renal pelvis.			Body Part, Organ, or Organ Component	NICHD Terminology|Pediatric Adverse Events Terminology
C122649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122649>	C23020	Progesterone Receptor Staining Method|PR Staining Method	An immunohistochemical technique used to detect the presence of progesterone receptor (PR) in a tissue sample.			Laboratory Procedure	
C12264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12264>	C36279|C26753	Meckel Diverticulum|Meckel diverticulum|Meckel's Diverticulum|Meckel's Diverticulum	A congenital pouch in the distal ileum. It may cause painless rectal bleeding and bowel obstruction.			Finding	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|Neonatal Research Network Terminology|NICHD Terminology
C122650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122650>	C23020	Estrogen Receptor Staining Method|ER Staining Method	An immunohistochemical technique used to detect the presence of estrogen receptor (ER) in a tissue sample.			Laboratory Procedure	
C122651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122651>	C23020	Antibody Ki67 Staining Method|Antibody Ki-67 Staining Method|Ki-67 Antibody Staining Method|Ki-67 Staining Method|Ki67 Antibody Staining Method|Ki67 Staining Method	An immunohistochemical technique used to quantify the percent of cells in a tissue sample that can react with monoclonal antibody Ki67. Antibody Ki67 recognizes antigen KI-67 protein, which is a nuclear protein that is exclusively expressed by proliferating cells.			Laboratory Procedure	
C122652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122652>	C173933|C173812	Side Effects of Treatment are Worse than Imagined Question|Side Effects of Treatment are Worse than Imagined|The side effects of treatment are worse than I had imagined	A question about whether an individual feels or felt the treatment side effects are worse than imagined.			Intellectual Product	FACT-BMT Questionnaire
C122653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122653>	C53543|C4802|C176696	Dentatorubral-Pallidoluysian Atrophy|DRPLA|Dentatorubropallidoluysian Atrophy	A rare, autosomal dominant inherited progressive neurodegenerative disorder. It is caused by a mutation in the ATN1 gene, resulting in a combined degeneration of the dentatorubral and pallidoluysian systems. It can appear at any age, but it usually affects individuals between 20 and 30 years and leads to death within 10-15 years. The clinical presentation depends on the age of the affected individual; juvenile patients develop severe progressive myoclonus epilepsy and cognitive decline, whereas adult patients develop ataxia, choreoathetosis and dementia.			Disease or Syndrome	Cellosaurus Disease Terminology
C122654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122654>	C85065	Short-Rib Thoracic Dysplasia 6 with or without Polydactyly|Majewski Syndrome|Polydactyly with Neonatal Chondrodystrophy Type II|Short Rib-Polydactyly Syndrome Type II	A group of rare, autosomal recessive inherited disorders characterized by a constricted thoracic cage, short ribs, and a 'trident' appearance of the acetabular roof. Polydactyly may or may not be present. Other abnormalities include cleft lip and palate and abnormalities of the brain, eye, heart, liver, pancreas, intestine, kidney, and genitalia.			Disease or Syndrome	Cellosaurus Disease Terminology
C122655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122655>	C53543|C27588|C176696	Neuronal Intranuclear Inclusion Disease|NIID	A rare, slowly progressive, multisystem neurodegenerative disorder that usually affects children.  It is characterized by the presence of eosinophilic neuronal intranuclear inclusions and neuronal loss.  It results in abnormalities of the central, peripheral, and autonomic nervous systems.  Patients present with ataxia, extra-pyramidal signs, absent deep tendon reflexes, weakness, muscle wasting, foot deformities, and behavioral or cognitive abnormalities.			Disease or Syndrome	Cellosaurus Disease Terminology
C122656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122656>	C84683	Cleft Lip/Palate-Ectodermal Dysplasia Syndrome|CLPED1	A very rare genetic disorder characterized by cleft lip and palate, sparse scalp hair, and partial syndactyly of the fingers and toes.			Disease or Syndrome	Cellosaurus Disease Terminology
C122657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122657>	C53543|C28193	LIG4 Syndrome	A very rare genetic disorder caused by mutation in the LIG4 gene.  It is characterized by unusual facial features, microcephaly, growth and developmental delay, severe immunodeficiency, and skin abnormalities.			Disease or Syndrome	Cellosaurus Disease Terminology
C122658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122658>	C35561	DNA Ligase I Deficiency	A very rare genetic syndrome characterized by reduced replicative DNA ligase I.  It results in immunodeficiency and cellular hypersensitivity to DNA-damaging agents.			Disease or Syndrome	Cellosaurus Disease Terminology
C122659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122659>	C75467	Charcot-Marie-Tooth Disease Type 2D	Charcot-Marie-Tooth disease inherited in an autosomal dominant pattern.  It is caused by mutations in the GARS gene. It results in axonal peripheral neuropathy.			Disease or Syndrome	Cellosaurus Disease Terminology
C12265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12265>	C25763	Ascending Colon|Ascending colon|Ascending colon structure (body structure)|COLON, ASCENDING|ascending colon|colon ascendens	The first part of the colon (large intestine) that starts in the right lower quadrant of the abdomen and ends at the transverse colon in the right upper quadrant of the abdomen.	Ascending Colon		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C122660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122660>	C35561	Hardcastle's Syndrome|DMS-MFH|Diaphyseal Medullary Stenosis with Malignant Fibrous Histiocytoma	A rare, autosomal dominant inherited dysplasia of the long bones, characterized by symmetrical diaphyseal medullary stenosis, bone infarctions, pathologic fractures, and a high risk of development of malignant fibrous histiocytoma.			Disease or Syndrome	Cellosaurus Disease Terminology
C122661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122661>	C84733	Glycogen Storage Disease Type Ib|Glycogen Storage Disease Type I non-a	Glycogen storage disease type I that is caused by mutations in the SLC37A4 gene.  It is characterized by a deficiency of glucose-6-phosphate translocase.  It may be associated with neutropenia resulting in recurrent bacterial infections, inflammatory bowel disease, gingivitis, periodontal disease, and mouth ulcers.			Disease or Syndrome	Cellosaurus Disease Terminology
C122662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122662>	C61272	Glycogen Storage Disease Type IX|Phosphorylase Kinase Deficiency	Glycogen storage disease usually inherited in an X-linked recessive pattern.  It is characterized by a deficiency of hepatic phosphorylase kinase.			Disease or Syndrome	Cellosaurus Disease Terminology
C122663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122663>	C35561	Inclusion Body Myopathy with Early-Onset Paget Disease with or without Frontotemporal Dementia 1|IBMPFD1	A rare autosomal dominant inherited disorder caused by mutations in the VCP gene. It can affect the muscles, bones, and brain.  Patients may develop myopathy that initially involves the muscles of the hips and shoulders and as the disorder progresses it may affect the cardiac and respiratory muscles, leading to life-threatening cardiac and pulmonary failure.  Approximately half of the adults develop Paget disease of bone, and approximately one-third develop frontotemporal dementia.			Disease or Syndrome	Cellosaurus Disease Terminology
C122664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122664>	C27059	Leukoencephalopathy with Vanishing White Matter	A rare, progressive neurological disorder inherited in an autosomal recessive pattern.  It is caused by mutations in the EIF2B1, EIF2B2, EIF2B3, EIF2B4, and EIF2B5 genes, resulting in deterioration of central nervous system's white matter.  Usually, there are no signs and symptoms of the disorder at birth.  During early childhood, affected individuals develop spasticity and ataxia which may be associated with deterioration of the metal function.  Examination of the brain at autopsy reveals normal gray matter while the white matter is soft and gelatinous with numerous small cavities.			Disease or Syndrome	Cellosaurus Disease Terminology
C122665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122665>	C20134	Cigarette Filter Ventilation Blocking	A smoking behavior characterized by covering the filter ventilation holes on a cigarette with the fingers or lips while smoking.			Individual Behavior	
C122666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122666>	C79097	Illicit Tobacco Product	A product containing or derived from tobacco that is not compliant with legislative requirements.			Chemical Viewed Functionally	
C122667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122667>	C16809	Dixon MRI|Dixon Fat-Suppression MRI	An imaging method that combines in-phase and out-of-phase echoes to create water-only and fat-only images. This technique is particularly useful in abdominal imaging at 3T.	Dixon MRI		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C122668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122668>	C16809	Lipid R1 MRI|MOBILE|Mapping of Oxygen by Imaging Lipids Relaxation Enhancement	An imaging method for the mapping of oxygen in tissues. It is based on higher solubility of oxygen in lipids than in water. By monitoring changes in the R1 relaxation rate of the lipid peak rather than those of water, estimates of variations in tissue oxygenation are obtained.	Lipid R1 MRI		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C122669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122669>	C16840	Recollect|Recall|Recollection|Remember	The act of recalling information by mental effort.			Mental Process	
C12266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12266>	C25763	Hepatic Flexure|Ascending Colon Hepatic Flexure|COLON, HEPATIC FLEXURE|Hepatic Flexure of Colon|Hepatic Flexure of the Colon|Hepatic flexure of colon|Right Colic Flexure|Right Colic Flexure|flexura coli heaptica|hepatic flexure|hepatic flexure of colon|hepatic flexure of colon|right colic flexure	The bend of the colon at the juncture of its ascending and transverse portions.	Hepatic Flexure of Colon		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C122670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122670>	C99758	Point of Sale	A location where products or services can be purchased.			Functional Concept	
C122671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122671>	C892	Dissolvable Tobacco	Any of various proprietary tobacco products that deliver nicotine as they dissolve or melt in the user's mouth.			Hazardous or Poisonous Substance	PhenX
C122672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122672>	C25404	Purchase|Buy	The action of obtaining something by payment.	Purchase		Activity	CTRP Intervention Terminology|CTRP Terminology|PhenX
C122673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122673>	C20181	Sponsorship	Money, or other support, given to an individual or group to help pay for something or carry out an event, usually in return for advertisement.			Classification	PhenX
C122674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122674>	C171257	Hookah	A tobacco pipe with a long flexible tube that cools the smoke by passing it through water.			Manufactured Object	PhenX
C122675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122675>	C171256	Signage	A group or system of signs, used to show information about something.			Manufactured Object	PhenX
C122676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122676>	C115435	Anti-Tobacco Advertisement	Advertisement designed to persuade individuals to cease, or not start, the use of tobacco.			Intellectual Product	PhenX
C122677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122677>	C2124	Carbon C 14 Gilteritinib|14C-labeled Gilteritinib|[14C] ASP2215	A radioconjugate composed of gilteritinib, an inhibitor of the receptor tyrosine kinases (RTKs) FMS-related tyrosine kinase 3 (FLT3, STK1, or FLK2), AXL (UFO or JTK11) and anaplastic lymphoma kinase (ALK or CD246), labeled with the radioisotope carbon C 14, with potential use for evaluating the pharmacokinetic profile of gilteritinib. Gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL and ALK. This may result in an inhibition of FLT3, AXL, and ALK-mediated signal transduction pathways and the reduction of tumor cell proliferation in cancers that overexpress these RTKs. Labeling of gilteritinib with the radioactive tracer carbon C 14 allows for the evaluation of gilteritinib's pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME).	Carbon C 14 Gilteritinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C122678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122678>	C1752	IDH1R132H Mutation-targeting IDH1 Peptide Vaccine|IDH1R132H-specific Peptide Vaccine	A peptide vaccine consisting of a 20-mer peptide derived from isocitrate dehydrogenase type 1 (IDH1) containing the point mutation R132H (IDH1R132H), with potential antineoplastic activity. Upon subcutaneous vaccination with the IDH1R132H mutation-targeting IDH1 peptide vaccine, the vaccine stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells that express the IDH1R132H protein. R132H is a point mutation, which contains an amino acid substitution where arginine is replaced by histidine at position 132 of IDH1, and is highly expressed in gliomas as well as other tumor types; this mutation is associated with increased production of the oncometabolite R-2-hydroxyglutarate (2HG).			Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C122679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122679>	C28681|C138180|C129826	Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes|Anti-HLA-A2/NY-ESO1 TCR-transduced Autologous T cells|Autologous Anti-HLA-A2/NY-ESO1 TCR-transduced T Lymphocytes|Autologous HLA-A2/NY-ESO-1-specific TCR Gene-transduced T-lymphocytes	Autologous human peripheral blood T-lymphocytes transduced with a lentiviral or retroviral vector encoding a human leukocyte antigen A2 (HLA-A2) restricted anti-cancer-testis antigen 1 (NY-ESO-1) T-cell receptor (TCR) gene, with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and re-introduction into the patient, the anti-HLA-A2/NY-ESO-1 TCR-transduced autologous T lymphocytes recognize and bind to NY-ESO-1/HLA-A2-positive tumor cells. This results in cytotoxic T-lymphocyte (CTL)-mediated elimination of NY-ESO-1-positive cancer cells. NY-ESO-1, a tumor-associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types.	Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12267>	C25763	Splenic Flexure|COLON, SPLENIC FLEXURE|Left Colic Flexure|Left Colic Flexure|Splenic Flexure of Colon|Splenic flexure of colon|flexura coli splenica|left colic flexure|splenic flexure|splenic flexure of colon	The bend at the junction of the transverse and descending colon.	Splenic Flexure of Colon		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C122680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122680>	C141215|C129822	Ripertamab|Anti-CD20 Monoclonal Antibody SCT400|RIPERTAMAB|SCT400	A chimeric monoclonal antibody directed against human CD20, with potential antineoplastic activity. Ripertamab binds to the B-cell-specific cell surface antigen CD20, which triggers an immune response against CD20-positive B-cells, leading to apoptosis. CD20, a non-glycosylated cell surface phosphoprotein, is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C122681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122681>	C78281|C129986	Zhongyao Fufang|Zhongyaofufang	A combination formula consisting of two or more unknown Traditional Chinese Medicine (TCM) ingredients, with potential anti-osteoporotic activity. Upon oral administration, this particular formula of zhongyao fufang may promote increased bone strength and density.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C122682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122682>	C78281|C129986	Xianling Gubao|XLGB|Xian Ling Gu Bao|Xian-ling-gu-bao|Xianlinggubao	An orally bioavailable phytoestrogen-rich Traditional Chinese Medicine (TCM) containing extracts from the six herbs Herba epimedii, Radix dipsaci (Dipsacus root), Radix salvia miltiorrhiza (Salvia root, Danshen, red sage root), Rhizoma anemarrhenae (zhi Mu), Fructus Psoraleae (fruit of Psoralea corylifolia L), and Radix Rehmanniae (Rehmannia root, Rehmannia glutinosa, Sheng Di Huang, Rehmannia glutinosa Libosch), with potential anti-osteoporotic and bone-strengthening activities. Xianling gubao (XLGB) contains various phytochemicals, including flavonoids, coumarins, saponins, alkaloids and terpenes. Upon oral administration of XLGB, the active ingredients may strengthen bones and may treat or prevent osteoporosis, osteoarthritis, bone loss and bone fractures.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C122683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122683>	C134305	Ieramilimab|IERAMILIMAB|IMP-701|LAG 525|LAG525	A humanized monoclonal antibody directed against the inhibitory receptor lymphocyte activation gene-3 (LAG-3), with potential immunomodulating and antineoplastic activities. Upon administration, Ieramilimab binds to LAG-3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF) and expressed on various immune cells, negatively regulates cellular proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.	Ieramilimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C122684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122684>	C2124	Carbon C 11 Sarcosine|11C-labeled Sarcosine|11C-sarcosine|SARCOSINE C-11	A radiotracer consisting of sarcosine, the N-methyl derivative of the amino acid glycine, labeled with the positron-emitting isotope carbon C 11, that can be used for tumor imaging upon positron emission tomography/computed tomography (PET/CT). Upon administration, C-11 sarcosine is taken up by and accumulates in tumor cells, thereby allowing tumor imaging with PET/CT. Sarcosine, a non-proteinogenic amino acid and oncometabolite, is elevated in certain tumor cell types. Its expression seems to correlate with increased tumor invasiveness.	Carbon C 11 Sarcosine		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C122685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122685>	C53655	Prediabetes|Borderline Diabetes	A condition in which blood glucose levels are high, but not high enough to be classified as type 2 diabetes.			Disease or Syndrome	
C122686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122686>	C3247	Hypoplastic Myelodysplastic Syndrome|Hypocellular Myelodysplastic Syndrome|MDS-h|Myelodysplastic Neoplasm, Hypoplastic	Myelodysplastic syndrome characterized by decreased cellularity in the bone marrow.			Neoplastic Process	
C122687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122687>	C3171	Cytogenetically Normal Acute Myeloid Leukemia|CN-AML|Normal Karyotype Acute Myeloid Leukemia	Acute myeloid leukemia that is not associated with cytogenetic abnormalities.			Neoplastic Process	NCIt Neoplasm Core Terminology
C122688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122688>	C7175	Core Binding Factor Acute Myeloid Leukemia|CBF-AML	Acute myeloid leukemia characterized by the presence of t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). These cytogenetic abnormalities result in disruption of the transcription factor CBF, which is a regulator of normal hematopoiesis.			Neoplastic Process	NCIt Neoplasm Core Terminology
C122689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122689>	C226401|C186915|C155992	t(7;12)(q36;p13)	A chromosomal translocation involving the ETV6 gene on chromosome 12p13 and HLXB9 gene on chromosome 7q36.			Cell or Molecular Dysfunction	AML Authorized Value Terminology|AML Minimal Residual Disease Table|AML Molecular Analysis Table
C12268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12268>	C25763	Descending Colon|COLON, DESCENDING|Descending colon|Descending colon structure (body structure)|colon descendens|descending colon	The fourth portion of the large intestine (colon) that communicates with the transverse colon in the left-upper quadrant of the abdomen and the rectum below.	Descending Colon		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C122690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122690>	C224907|C122603	Acute Myeloid Leukemia with t(7;12)(q36;p13); HLXB9-ETV6|AML with t(7;12)(q36;p13); HLXB9-ETV6|AML with t(7;12)(q36;p13); MNX1-ETV6|Acute Myeloid Leukemia with t(7;12)(q36;p13); MNX1-ETV6|Acute Myeloid Leukemia with t(7;12)(q36;p13); MNX1-ETV6|Acute Myeloid Leukemia with t(7;12)(q36;p13); MNX1::ETV6	An acute myeloid leukemia in infancy characterized by t(7;12)(q36;p13) and fusion of the homeobox gene HLXB9 (MNX1) with the ETV6 gene.			Neoplastic Process	NCIt Neoplasm Core Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C122691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122691>	C224907|C200411	Childhood Acute Myeloid Leukemia with NUP98 Rearrangement|Childhood AML with NUP98 Rearrangement	An acute myeloid leukemia that occurs in childhood and is characterized by the rearrangement of the NUP98 gene.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C122692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122692>	C171625|C133155	NUP98 Gene Rearrangement|ADAR2 Gene Rearrangement|ADIR2 Gene Rearrangement|NUP196 Gene Rearrangement|NUP96 Gene Rearrangement|Nucleoporin 98 Gene Rearrangement	A molecular abnormality indicating rearrangement of the NUP98 gene.	NUP98 Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122693>	C202064	Wnt Signaling Inhibitor SM04755|SM04755	An orally bioavailable small molecule inhibitor of the Wnt signaling pathway, with potential antineoplastic activity. Upon oral administration, Wnt signaling inhibitor SM04755 targets and binds to an as of yet undisclosed target in the Wnt signaling pathway, thereby preventing Wnt-mediated signaling. This may inhibit growth of tumor cells in which the Wnt signaling pathway is overactivated. The Wnt signaling pathway is upregulated in many cancers and plays a key role in tumor cell proliferation.	Wnt Signaling Inhibitor SM04755		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C122694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122694>	C91105	Quality of Life Questionnaire-Multiple Myeloma 20|EOR19|EORTC Multiple Myeloma Module|EORTC Multiple Myeloma Module (QLQ-MY20)|EORTC QLQ-MY20|EORTC QLQ-MY20|QLQ-MY20	A questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) consisting of 20 questions designed to assess quality of life in multiple myeloma patients.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122695>	C173981|C173346	Have Aches or Pains in Bones Question|Have Aches or Pains in Bones|Have Bone Aches or Pain|Have you had bone aches or pain|I have aches and pains in my bones	A question about whether an individual has or had aches or pains in their bones.			Intellectual Product	FACT-M Questionnaire|Quality of Life Questionnaire-Multiple Myeloma 20
C122696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122696>	C91126	Have Hip Pain Question|Have Hip Pain|Have Pain in Hip|Have you had pain in your hip	A question about whether an individual has or had pain in their hip.			Intellectual Product	Quality of Life Questionnaire-Multiple Myeloma 20
C122697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122697>	C91126	Have Pain in Arm or Shoulder Question|Had Pain in Arm or Shoulder|Have Pain in Arm or Shoulder|Have Shoulder or Arm Pain|Have you had pain in your arm or shoulder	A question about whether an individual has or had pain in their arm or shoulder.			Intellectual Product	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 Items|Quality of Life Questionnaire-Multiple Myeloma 20
C122698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122698>	C173346	Had Pain in Chest Question|Had Pain in Chest|Have Chest Pain|Have Pain in Chest|Have you had pain in your chest	A question about whether an individual has or had pain in their chest.			Intellectual Product	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 Items|Quality of Life Questionnaire-Multiple Myeloma 20
C122699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122699>	C176021|C173346	Have Pain Increase with Activity Question|Have Pain Increase with Activity|If you had pain did it increase with activity	A question about whether an individual's pain increases with activity.			Intellectual Product	Quality of Life Questionnaire-Multiple Myeloma 20
C12269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12269>	C13024	Head of the Pancreas|Head of Pancreas|Head of pancreas|PANCREAS, HEAD|Pancreas Head|Pancreatic Head|Structure of head of pancreas (body structure)|head of pancreas	That portion of the pancreas lying in the concavity of the duodenum.	Head of Pancreas		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C1226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1226>	C912	Sialyl Tn Antigen|CD175s|STn|STn Antigen|Sialyl-Tn|Sialyl-Tn Antigen	A tumor-associated core-region carbohydrate antigen of epithelial mucin, expressed in most colon carcinoma, mucinous carcinoma, pancreatic cancer, gastric, lung, breast, and ovarian carcinoma. Sialosyl-Tn (STn) antigen has been shown to be highly sensitive and a specific marker of colorectal cancer, associated with more aggressive diseases and poor prognosis. STn antigen and its immediate precursor, Tn antigen, are mucin type glycoprotein structures associated with the earliest steps of mucin O-linked glycosylation. When combined with a carrier molecule, keyhole limpet hemocyanin (KLH), this antigen may be co-administered with oral cyclophosphamide as an immune modulator.	Sialyl Tn Antigen		Immunologic Factor|Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C122700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122700>	C173219	Feel Thirsty Question|Did you feel thirsty|Feel Thirsty	A question about whether an individual feels or felt thirsty.			Intellectual Product	Quality of Life Questionnaire-Multiple Myeloma 20
C122701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122701>	C173734	Have Tingling in Hands or Feet Question|Did you have tingling hands or feet|Have Tingling in Hands or Feet	A question about whether an individual has or had tingling in their hands or feet.			Intellectual Product	Quality of Life Questionnaire-Multiple Myeloma 20
C122702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122702>	C173160	Feel Restless or Agitated Question|Did you feel restless or agitated|Feel Restless or Agitated	A question about whether an individual feels or felt restless or agitated.			Intellectual Product	Quality of Life Questionnaire-Multiple Myeloma 20
C122703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122703>	C173981	Have Acid Indigestion or Heartburn Question|Have Acid Indigestion or Heartburn|Have you had acid indigestion or heartburn	A question about whether an individual has or had acid indigestion or heartburn.			Intellectual Product	Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors 21|Quality of Life Questionnaire-Multiple Myeloma 20
C122704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122704>	C173981	Have Burning or Sore Eyes Question|Have Burning or Sore Eyes|Have you had burning or sore eyes	A question about whether an individual has or had burning or sore eyes.			Intellectual Product	Quality of Life Questionnaire-Multiple Myeloma 20
C122705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122705>	C173597	Have Been Thinking About Illness Question|Have Been Thinking About Illness|Have you been thinking about your illness	A question about whether an individual has or had been thinking about their illness.			Intellectual Product	Quality of Life Questionnaire-Multiple Myeloma 20
C122706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122706>	C173509|C173090	Current Health Limits Lifting or Carrying Groceries Question|Current Health Limits Lifting or Carrying Groceries|Does your health now limit you in lifting or carrying groceries	A question about whether an individual's current health limits them in lifting or carrying groceries.			Intellectual Product	PROMIS Adult Physical Health Domain
C122707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122707>	C200085	Mps1 Inhibitor BAY 1217389|BAY 1217389|TTK Inhibitor BAY 1217389	An orally bioavailable, selective inhibitor of the serine/threonine kinase monopolar spindle 1 (Mps1, TTK), with potential antineoplastic activity. Upon administration, the Mps1 inhibitor BAY 1217389 selectively binds to and inhibits the activity of Mps1. This inactivates the spindle assembly checkpoint (SAC), accelerates mitosis, causes chromosomal misalignment and missegregation, and mitotic checkpoint complex destabilization. This induces cell death in Mps1-overexpressing cancer cells. Mps1, a kinase expressed in proliferating normal tissues and aberrantly overexpressed in a wide range of human tumors, is activated during mitosis and is essential for proper SAC functioning and chromosome alignment.	Mps1 Inhibitor BAY 1217389		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C122708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122708>	C1323	Curcumin-based Gel|Curcumin Gel|Psoria-Gold|Topical Curcumin	A proprietary topical gel formulation containing an extract of curcumin, the polyphenol derived from the plant Curcuma longa, with potential anti-inflammatory, antioxidant, and wound healing activities. Upon topical administration to the affected areas, curcumin inhibits a variety of pro-inflammatory enzymes and reduces the production of certain pro-inflammatory mediators. Curcumin also blocks the formation of reactive oxygen species (ROS), neutralizes free radicals and prevents oxidative stress and DNA damage. In addition, curcumin inhibits phosphorylase kinase (PhK) in the skin, which prevents multiple PhK-mediated signal transduction pathways that are induced upon skin injury. This further prevents inflammation, promotes healing and reduces scar tissue formation. The proprietary curcumin-based gel also provides moisture to the skin and contains tetrahydropiperine (THP), which is derived from black pepper fruit and increases skin uptake of curcumin.	Curcumin-based Gel		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C122709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122709>	C16853	Functional Photoacoustic Microscopy|fPAM	A hybrid imaging technique that combines the high-resolution advantage of ultrasonic detection of absorbed photons with the high-contrast advantage of optical imaging. It can provide better spatial resolution than pure optical imaging when the imaging depth is beyond 1 mm.	Functional Photoacoustic Microscopy		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C12270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12270>	C13024	Body of the Pancreas|Body|Body of Pancreas|Body of pancreas|PANCREAS, BODY|Pancreas Body|Pancreatic Body|body of pancreas	The part of the pancreas from the point where it crosses the portal vein to the point where it enters the lienorenal ligament.	Body of Pancreas		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Pancreatic Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C122710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122710>	C62996	Medical Device Failure	A medical device that is no longer functioning.			Event	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122711>	C62996	Medical Device Malfunction|Malfunctioning	A medical device that is functioning incorrectly.			Event	FDA CDRH GUDID Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122712>	C62950	Medical Device Dislodged	A medical device that was placed properly, but which has moved from the intended location.			Event	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122713>	C62950	Medical Device Misplaced	A medical device that was placed in an unintended location.			Event	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122714>	C117719	Testicular Involvement	A finding indicating the involvement of the testis by a malignant neoplasm.			Finding	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C122715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122715>	C36280	Central Nervous System Involvement|CNS Involvement|CNS Involvement	A finding indicating the involvement of the central nervous system by a malignant neoplasm.			Finding	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C122716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122716>	C82426	Acute Myeloid Leukemia with inv(3)(q21.3;q26.2); GATA2, MECOM|Acute Myeloid Leukemia with inv(3) (q21.3;q26.2); GATA2, EVI1|Acute Myeloid Leukemia with inv(3) (q21.3;q26.2); GATA2, MECOM|Acute Myeloid Leukemia with inv(3) (q21.3;q26.2); GATA2, MECOM(EVI1)|Acute Myeloid Leukemia with inv(3)(q21.3;q26.2); GATA2::MECOM|Acute Myeloid Leukemia with inv(3)(q21q26.2); RPN1-EVI1	An acute myeloid leukemia associated with inv(3)(q21.3q26.2) resulting in the reposition of a distal GATA2 enhancer to activate MECOM expression. It may present de novo or follow a myelodysplastic syndrome. The clinical course is aggressive.			Neoplastic Process	NCIt Neoplasm Core Terminology
C122717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122717>	C82426	Acute Myeloid Leukemia with t(3;3)(q21.3;q26.2); GATA2, MECOM|AML with inv(3)(q21;q26.2) or t(3;3) (q21;q26.2);RPNI-EVI1|Acute Myeloid Leukemia with t(3;3) (q21.3;q26.2); GATA2, EVI1|Acute Myeloid Leukemia with t(3;3) (q21.3;q26.2); GATA2, MECOM|Acute Myeloid Leukemia with t(3;3) (q21.3;q26.2); GATA2, MECOM(EVI1)|Acute Myeloid Leukemia with t(3;3)(q21.3;q26.2); GATA2::MECOM|Acute Myeloid Leukemia with t(3;3)(q21;q26.2); RPN1-EVI1	An acute myeloid leukemia associated with t(3;3)(q21.3;q26.2) resulting in the reposition of a distal GATA2 enhancer to activate MECOM expression. It may present de novo or follow a myelodysplastic syndrome. The clinical course is aggressive.			Neoplastic Process	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|NCIt Neoplasm Core Terminology
C122718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122718>	C281|C20401	Anti-human Cytomegalovirus Monoclonal Antibody Combination CSJ-148|Antiviral Agent CSJ148|CSJ 148|CSJ-148|CSJ148|HCMV Neutralizing Human mAb Combination CSJ-148|LJP538 Plus LJP539|LJP538 and LJP539|LJP538/LJP539	A combination agent composed of two human monoclonal antibodies against the human cytomegalovirus (HCMV), LJP538 and LJP539, with potential immunomodulating activity. Upon administration of CSJ-148, both LJP538 and LJP539 bind to and inhibit the function of viral HCMV glycoproteins that are essential for HCMV infection; LJP538 targets and binds to glycoprotein B (gB) and LJP539 targets and inhibits the pentameric complex, consisting of glycoproteins gH, gL, UL128, UL130, and UL131. Human cytomegalovirus (HCMV) can cause significant disease in immunocompromised patients.	Anti-human Cytomegalovirus Monoclonal Antibody Combination CSJ-148		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C122719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122719>	C155727	FGFR Inhibitor ASP5878|ASP-5878|ASP5878	An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR), with potential antineoplastic activity. Upon oral administration, FGFR inhibitor ASP5878 binds to and inhibits FGFR, which results in the inhibition of FGFR-mediated signal transduction pathways. This inhibits proliferation in FGFR-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, plays a key role in cellular proliferation and survival.	FGFR Inhibitor ASP5878		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12271>	C13024	Tail of the Pancreas|PANCREAS, TAIL|Pancreas Tail|Pancreatic Tail|Structure of tail of pancreas (body structure)|Tail|Tail of Pancreas|Tail of pancreas|tail of pancreas	The left extremity of the pancreas within the lienorenal ligament.	Tail of Pancreas		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Pancreatic Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C122720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122720>	C129839	ASP4132	A molecule with potential antineoplastic activity. Upon oral administration, ASP4132 affects oxidative phosphorylation in mitochondria of metabolically-active tumor cells, which reduces both energy production and tumor cell proliferation. Mitochondrial oxidative phosphorylation is hyperactivated in tumor cells and plays a key role in the promotion of tumor cell proliferation.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C122721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122721>	C35553	Hypercarbia|Hypercapnia	Excessive concentration of carbon dioxide in the blood.			Laboratory or Test Result	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122722>	C41362	Accidental Drug Ingestion|Accidental Medicine Ingestion	The unintentional consumption of a drug.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122723>	C542	5-Iodo-2-pyrimidinone|5 Iodo-2-pyrimidinone|IP	A 5-iodo-substituted pyrimidinone and metabolite of 5-iodo-2-pyrimidinone-based deoxyribose analogs, such as 5-iodo-2-pyrimidinone-2'-deoxyribose (IPdR).	5-Iodo-2-pyrimidinone		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C122724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122724>	C542	5-Iodouracil|2,4(1H,3H)-Pyrimidinedione, 5-Iodo-|2,4(1H,3H)-Pyrimidinedione, 5-Iodo-|2,4-Dihydroxy-5-iodopyrimidine|5-IODOURACIL|IU|NSC 57848|Uracil, 5-Iodo-	A halogenated pyrimidine analog containing an iodine atom linked to a pyrimidine ring. 5-Iodouracil (IU) gets incorporated into DNA. IU is a metabolite of idoxuridine (IUdR; 5-iododeoxyuridine) and the IUdR prodrug ropidoxuridine (IPdR).	5-Iodouracil		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C122725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122725>	C9160	Childhood Acute Myeloid Leukemia with Abnormalities of Chromosome 5q|Acute Myeloid Leukemia (AML) with Abnormalities of Chromosome 5q|Childhood AML with Abnormalities of Chromosome 5q	A rare acute myeloid leukemia that occurs in children and is characterized primarily by deletions of 5q.	Childhood Acute Myeloid Leukemia with Abnormalities of Chromosome 5q		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C122726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122726>	C9160	Childhood Acute Myeloid Leukemia with Abnormalities of Chromosome 7|Acute Myeloid Leukemia (AML) with Abnormalities of Chromosome 7|Childhood AML with Abnormalities of Chromosome 7	A rare acute myeloid leukemia that occurs in childhood and is characterized by deletion of chromosome 7.	Childhood Acute Myeloid Leukemia with Abnormalities of Chromosome 7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C122727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122727>	C28533	TSPO Gene|TSPO|TSPO|Translocator Protein (18kDa) Gene	This gene is involved in cholesterol trafficking.	TSPO Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C122728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122728>	C122727	TSPO wt Allele|BPBS|BZRP|Benzodiazepine Receptor (Peripheral) Gene|Benzodiazepine Receptor, Peripheral Gene|DBI|IBP|MBR|MDRC|PBR|PBRS|PBS|PKBS|PTBR|Pk18|Translocator Protein (18kDa) wt Allele|Translocator Protein, 18-kD Gene	Human TSPO wild-type allele is located in the vicinity of 22q13.3 and is approximately 12 kb in length. This allele, which encodes both translocator protein and putative peripheral benzodiazepine receptor-related protein, plays a role in the transport of cholesterol across mitochondrial membranes.	TSPO wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122729>	C16386	Translocator Protein|Benzodiazepine Peripheral Binding Site|Isoquinoline Carboxamide-Binding Protein|Mitochondrial Benzodiazepine Receptor|Peripheral-Type Benzodiazepine Receptor|Peripheral-Type Benzodiazepine Receptor/Recognition Site|Putative Peripheral Benzodiazepine Receptor-related Protein|TSPO	Translocator protein (169 aa, ~19 kDa) is encoded by the human TSPO gene. This protein is involved in cholesterol transport.	Translocator Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12272>	C12948	Pancreatic Duct|Canal of Wirsung|Main Pancreatic Duct|PANCREATIC DUCT|Pancreatic duct|pancreatic duct	A duct joining the pancreas to the common bile duct to supply pancreatic juices.	Pancreatic Duct		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C122730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122730>	C132890	Central Memory Immune Cell	A population of long-lived antigen-specific immune cells, usually T-lymphocytes expressing CD45RO, L-selectin and CCR7, that are maintained by the immune system. Upon subsequent exposure to their target antigen, these cells rapidly proliferate and differentiate into effector cells.	Central Memory Immune Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C122731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122731>	C28241	Effector Memory Immune Cell	A population of long-lived antigen-specific immune cells, usually T-lymphocytes expressing CD8 and effector cytokines, that are maintained by the immune system. Upon subsequent exposure to their target antigen, these cells rapidly become effector cells.	Effector Memory Immune Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C122732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122732>	C12547	Suppressive Monocyte|Monocytic Suppressive Cell	A population of monocytes that express CD14 and low or non-detectable levels of HLA-DR. The cells are able to suppress cellular immunity by inhibiting both T-cell proliferation and dendritic cell maturation.	Suppressive Monocyte		Cell	CTRP Biomarker Terminology|CTRP Terminology
C122733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122733>	C36753	Circulating Epithelial Cell|CEpC	A cell derived from an epithelial membrane that is found in the blood. These cells are associated with epithelial-mesenchymal transition and may be markers for neoplastic diseases.	Circulating Epithelial Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C122734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122734>	C15753	Childhood Cancer Registry|Childhood Cancer Research Network Registry	A North American pediatric cancer research registry established by the Children's Oncology Group for member institutions in the United States and Canada. It provides a centralized pediatric cancer research registry for investigators conducting epidemiology, biology, late effects, and cancer control studies.			Intellectual Product	
C122735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122735>	C28533	SLC35B2 Gene|SLC35B2|SLC35B2|Solute Carrier Family 35 (Adenosine 3'-Phospho 5'-Phosphosulfate Transporter), Member B2 Gene	This gene plays a role in the transport of adenosine 3'-phospho 5'-phosphosulfate (PAPS).	SLC35B2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C122736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122736>	C122735	SLC35B2 wt Allele|PAPST1|SLL|Slalom. Drosophila, Homolog of Gene|Solute Carrier Family 35 (Adenosine 3'-Phospho 5'-Phosphosulfate Transporter), Member B2 wt Allele|Solute Carrier Family 35 (Adenosine 3-Prime-Phospho 5-Prime-Phosphosulfate Transporter), Member B2 Gene	Human SLC35B2 wild-type allele is located in the vicinity of 6p21.1 and is approximately 4 kb in length. This allele, which encodes adenosine 3'-phospho 5'-phosphosulfate transporter 1 protein, is involved in the transport of adenosine 3'-phospho 5'-phosphosulfate (PAPS) from the cytosol into the Golgi lumen.	SLC35B2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122737>	C16386	Adenosine 3'-phospho 5'-phosphosulfate Transporter 1|3'-Phosphoadenosine 5'-Phosphosulfate Transporter|Adenosine 3-phospho 5-phosphosulfate Transporter 1|PAPS Transporter 1|Putative MAPK-Activating Protein PM15|Putative NF-Kappa-B-Activating Protein 48|SLC35B2|Solute Carrier Family 35 Member B2|Solute Carrier Family 35 Member B2 Variant 2|Solute Carrier Family 35, Member B2|UGTrel4	Adenosine 3-phospho 5-phosphosulfate transporter 1 (432 aa, ~48 kDa) is encoded by the human SLC35B2 gene. This protein plays a role in adenosine 3'-phospho 5'-phosphosulfate (PAPS) transport.	Adenosine 3-phospho 5-phosphosulfate Transporter 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122738>	C25873	STK35 Gene|STK35|STK35|Serine/Threonine Kinase 35 Gene	This gene may be involved in the regulation of actin stress fibers in nonmuscle cells.	STK35 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C122739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122739>	C122738	STK35 wt Allele|CLIK-1|CLIK1|PDIK1|STK35L1|Serine/Threonine Kinase 35 wt Allele|bA550O8.2	Human STK35 wild-type allele is located in the vicinity of 20p13 and is approximately 75 kb in length. This allele, which encodes serine/threonine-protein kinase 35 protein, may be a regulator of actin stress fibers in nonmuscle cells.	STK35 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12273>	C33904	Other Specified Parts of Pancreas|Other specified parts of pancreas	Any component associated with the pancreas that is different from the one(s) previously specified or mentioned.	Other Specified Parts of Pancreas		Body Part, Organ, or Organ Component	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C122740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122740>	C17325	Serine/Threonine-Protein Kinase 35|CLIK-1|CLP-36 Interacting Kinase|CLP-36-Interacting Kinase 1|CLP36-Interacting Kinase 1|EC 2.7.11.1|PDLIM1-Interacting Kinase 1|STK35|Serine Threonine Kinase 35 Long Form|Serine/Threonine-Protein Kinase 35 L1	Serine/threonine-protein kinase 35 (534 aa, ~58 kDa) is encoded by the human STK35 gene. This protein may be a regulator of actin stress fibers in nonmuscle cells.	Serine/Threonine-Protein Kinase 35		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122741>	C20744	PLEC Gene|PLEC|PLEC|Plectin Gene	This gene plays a role in hemidesmosome structure.	PLEC Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C122742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122742>	C122741	PLEC wt Allele|EBS1|EBSO|HD1|LGMD2Q|PCN|PLEC1|PLEC1b|PLTN|Plectin wt Allele	Human PLEC wild-type allele is located in the vicinity of 8q24 and is approximately 62 kb in length. This allele, which encodes plectin protein, is involved in anchoring intermediate filaments to desmosomes or hemidesmosomes. Mutations in this gene are associated with epidermolysis bullosa simplex, ogna type and epidermolysis bullosa simplex with pyloric atresia.	PLEC wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122743>	C18073	Plectin|Epidermolysis Bullosa Simplex 1 (Ogna)|Hemidesmosomal Protein 1|PLEC|Plectin 1, Intermediate Filament Binding Protein 500kDa|Plectin-1	Plectin (4684 aa, ~53 kDa) is encoded by the human PLEC gene. This protein plays a role in linking intermediate filaments to desmosomes or hemidesmosomes.	Plectin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122744>	C54362	REST Gene|RE1-Silencing Transcription Factor Gene|REST|REST|REST	This gene is involved in the repression of neuronal gene expression.	REST Gene		Gene or Genome	CCPS Genetics Terminology|Childhood Cancer Predisposition Study Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C122745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122745>	C122744	REST wt Allele|NRSF|RE1-Silencing Transcription Factor wt Allele|XBR	Human REST wild-type allele is located in the vicinity of 4q12 and is approximately 28 kb in length. This allele, which encodes RE1-silencing transcription factor protein, plays a role in repressing neuronal gene expression in non-neuronal tissues.	REST wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122746>	C26199	RE1-Silencing Transcription Factor|Neural-Restrictive Silencer Factor|Neuron Restrictive Silencer Factor|Neuron-Restrictive Silencer Factor|REST|Repressor Binding To The X2 Box|X2 Box Repressor	RE1-silencing transcription factor (1097 aa, ~12 kDa) is encoded by the human REST gene. This protein is involved in repressing neuronal gene expression.	RE1-Silencing Transcription Factor		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122747>	C20744	FLOT1 Gene|FLOT1|FLOT1|Flotillin 1 Gene	This gene may be involved in the structure of caveolae.	FLOT1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C122748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122748>	C122747	FLOT1 wt Allele	Human FLOT1 wild-type allele is located in the vicinity of 6p21.3 and is approximately 15 kb in length. This allele, which encodes flotillin-1 protein, may play a role in caveolae structure.	FLOT1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122749>	C18073	Flotillin-1|FLOT1|Integral Membrane Component Of Caveolae	Flotillin-1 (427 aa, ~47 kDa) is encoded by the human FLOT1 gene. This protein may be involved in caveolae formation.	Flotillin-1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12274>	C13043	Middle Ear|MIDDLE EAR|Middle ear|middle ear	The part of the ear including the eardrum and ossicles. The middle ear leads to the inner ear.	Middle Ear		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C122750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122750>	C20194	PSMD4 Gene|PSMD4|PSMD4|Proteasome (Prosome, Macropain) 26S Subunit, Non-ATPase, 4 Gene	This gene is involved in protein degradation.	PSMD4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C122751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122751>	C122750	PSMD4 wt Allele|AF|AF-1|ASF|MCB1|PUB-R5|Protease 26S, Subunit 5A Gene|Proteasome (Prosome, Macropain) 26S Subunit, Non-ATPase, 4 wt Allele|Proteasome 26S Subunit, Non-ATPase, 4 Gene|RPN10|S5A	Human PSMD4 wild-type allele is located in the vicinity of 1q21.3 and is approximately 13 kb in length. This allele, which encodes 26S proteasome non-ATPase regulatory subunit 4 protein, plays a role in ATP/ubiquitin-dependent proteolysis.	PSMD4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122752>	C18466	26S Proteasome Non-ATPase Regulatory Subunit 4|26S Proteasome Regulatory Subunit RPN10|26S Proteasome Regulatory Subunit S5A|Angiocidin|Antisecretory Factor 1|Multiubiquitin Chain-Binding Protein|PSMD4|S5a/Antisecretory Factor Protein	26S proteasome non-ATPase regulatory subunit 4 (377 aa, ~41 kDa) is encoded by the human PSMD4 gene. This protein is involved in ATP/ubiquitin-dependent protein degradation.	26S Proteasome Non-ATPase Regulatory Subunit 4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122753>	C20745	MARCKS Gene|MARCKS|MARCKS|Myristoylated Alanine-rich Protein Kinase C Substrate Gene	This gene plays a role in actin filament crosslinking.	MARCKS Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C122754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122754>	C122753	MARCKS wt Allele|MAC|MACS|MRACKS|Myristoylated Alanine-Rich Protein Kinase C Substrate (MARCKS, 80K-L) Gene|Myristoylated Alanine-rich Protein Kinase C Substrate wt Allele|PKCSL|PRKCSL	Human MARCKS wild-type allele is located in the vicinity of 6q21 and is approximately 6 kb in length. This allele, which encodes myristoylated alanine-rich C-kinase substrate protein, is involved in the crosslinking of actin filaments and may be involved in cell motility, phagocytosis, membrane trafficking, and mitogenesis.	MARCKS wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122755>	C16492	Myristoylated Alanine-Rich C-Kinase Substrate|80K-L|80K-L Protein|MARCKS|Phosphomyristin|Protein Kinase C Substrate, 80 kDa Protein, Light Chain|Protein Kinase C Substrate, 80-kD, Light Chain	Myristoylated alanine-rich C-kinase substrate (332 aa, ~32 kDa) is encoded by the human MARCKS gene. This protein plays a role in the crosslinking of actin filaments.	Myristoylated Alanine-Rich C-Kinase Substrate		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122756>	C25712	Normal Range Comparison Result	A value that specifies the relationship of a value to a normal range or reference range of values.			Finding	
C122757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122757>	C49156	Reference Range Comparison	The activity of determining whether a test result value is within acceptable reference limits.			Activity	
C122758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122758>	C133710	TRIM63 Gene|TRIM63|TRIM63|Tripartite Motif Containing 63, E3 Ubiquitin Protein Ligase Gene	This gene is involved in myosin protein catabolism.	TRIM63 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C122759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122759>	C122758	TRIM63 wt Allele|IRF|MURF1|MURF2|RNF28|SMRZ|Tripartite Motif Containing 63, E3 Ubiquitin Protein Ligase wt Allele	Human TRIM63 wild-type allele is located within 1p34-p33 and is approximately 17 kb in length. This allele, which encodes E3 ubiquitin-protein ligase TRIM63 protein, plays a role in the degradation of myosin proteins during amino acid starvation.	TRIM63 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12275>	C12763	Maxillary Sinus|Antrum Highmori|Antrum of Highmore|Antrum of Highmori|Antrum, Maxillary|Apertura Sinus Maxillaris|MAXILLARY SINUS|Maxillary sinus|Maxillary sinus structure (body structure)|Sinus(es), Maxillary|Sinus, Maxillary|antrum of Highmore|maxillary sinus|maxillary sinus|sinus maxilliaris	A pyramidal-shaped, thin-walled, air-filled cavity located in the maxilla. It is lined by mucus membrane and periosteum (mucoperiosteum) which contains cilia. It is adjacent to the nasal cavity and communicates with the middle meatus of the nose. It is the largest paranasal sinus and is composed of three recesses: alveolar, zygomatic, and infraorbital.	Maxillary Sinus		Body Space or Junction	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C122760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122760>	C21254	E3 Ubiquitin-Protein Ligase TRIM63|E3 Ubiquitin Protein Ligase TRIM63|EC 2.3.2.27|EC 6.3.2.-, Formerly|Iris Ring Finger Protein|MuRF-1|Muscle Specific Ring Finger Protein 2|Muscle-Specific RING Finger Protein 1|Ring Finger Protein 28|Striated Muscle RING Zinc Finger Protein|Tripartite Motif Containing 63|Tripartite Motif-Containing 63|Tripartite Motif-Containing Protein 63	E3 ubiquitin-protein ligase TRIM63 (353 aa, ~40 kDa) is encoded by the human TRIM63 gene. This protein is involved in the degradation of myosin proteins.	E3 Ubiquitin-Protein Ligase TRIM63		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122761>	C25790	CLEC7A Gene|C-type Lectin Domain Family 7, Member A Gene|CLEC7A|CLEC7A	This gene plays a role in the innate immune response.	CLEC7A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C122762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122762>	C122761	CLEC7A wt Allele|BGR|C-type Lectin Domain Family 7, Member A wt Allele|CANDF4|CD369|CLECSF12|DECTIN1|Lectin, C-Type, Superfamily Member 12 Gene	Human CLEC7A wild-type allele is located in the vicinity of 12p13.2 and is approximately 13 kb in length. This allele, which encodes C-type lectin domain family 7 member A protein, is involved in phagocytosis and in the inflammatory response. Mutations in this gene are associated with autosomal recessive familial candidiasis 4.	CLEC7A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122763>	C16725	C-Type Lectin Domain Family 7 Member A|Beta-Glucan Receptor|C-Type (Calcium Dependent, Carbohydrate-Recognition Domain) Lectin, Superfamily Member 12|C-Type Lectin Superfamily Member 12|CLEC7A|DC-Associated C-Type Lectin 1|Dectin 1|Dectin-1|Dendritic Cell-Associated C-Type Lectin 1|Lectin-Like Receptor 1|hDectin-1	C-type lectin domain family 7 member A (247 aa, ~28 kDa) is encoded by the human CLEC7A gene. This protein plays a role in the innate immune response against pathogenic bacteria and fungi.	C-Type Lectin Domain Family 7 Member A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122764>	C25790	CLEC10A Gene|C-type Lectin Domain Family 10, Member A Gene|CLEC10A|CLEC10A	This gene is involved in regulating adaptive and innate immune responses.	CLEC10A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C122765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122765>	C122764	CLEC10A wt Allele|C-type Lectin Domain Family 10, Member A wt Allele|CD301|CLECSF13|CLECSF14|HML|HML2|Lectin, C-Type, Superfamily Member 14 Gene|MGL|Macrophage Galactose-Type C-Type Lectin Gene|Macrophage Lectin 2 (Macrophage-Derived) Gene	Human CLEC10A wild-type allele is located in the vicinity of 17p13.1 and is approximately 6 kb in length. This allele, which encodes C-type lectin domain family 10 member A protein, plays a role in regulating innate and adaptive immune responses.	CLEC10A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122766>	C16725	C-Type Lectin Domain Family 10 Member A|C-Type (Calcium Dependent, Carbohydrate-Recognition Domain) Lectin, Superfamily Member 13 (Macrophage-Derived)|C-Type (Calcium Dependent, Carbohydrate-Recognition Domain) Lectin, Superfamily Member 14 (Macrophage-Derived)|C-Type Lectin Superfamily Member 14|CD301 Antigen|CLEC10A|Macrophage Lectin 2|Macrophage Lectin 2 (Calcium Dependent)	C-type lectin domain family 10 member A (316 aa, ~35 kDa) is encoded by the human CLEC10A gene. This protein is involved in the regulation of adaptive and innate immune responses.	C-Type Lectin Domain Family 10 Member A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122767>	C16295	Glycan Antibody|Anti-Glycan Antibody	An antibody that recognizes polysaccharide chains, usually those that are associated with cell surfaces.	Glycan Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C122768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122768>	C202673	KIT Exon 14 Mutation|CD117 Exon 14 Mutation|Exon 14|KIT Proto-Oncogene Tyrosine Protein Kinase Gene Exon 14 Mutation|c-KIT Exon 14 Mutation|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Gene Exon 14 Mutation	A molecular genetic abnormality indicating the presence of a mutation in exon 14 of the KIT gene located within 4q11-q12.	KIT Exon 14 Mutation		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122769>	C28624	Leucine-Rich Repeats and Immunoglobulin-Like Domains Protein Family|LIG|LIG Family|LRIG|LRIG Family|Leucine-Rich Repeats and Immunoglobulin-Like Domains Protein	A family of membrane bound proteins comprised of 15 leucine-rich repeats that are flanked both N- and C- terminally by cysteine-rich regions, three C2-type immunoglobulin-like domains, a transmembrane domain, and a cytoplasmic tail. The members of this protein family may be involved in the suppression of growth factor receptor signaling.	Leucine-Rich Repeats and Immunoglobulin-Like Domains Protein Family		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12276>	C12763	Ethmoid Sinus|ETHMOID SINUS|Ethmoid sinus|Ethmoid sinus structure (body structure)|Sinus, Ethmoid|ethmoid sinus	A sinus of the meatuses of the nasal cavity.	Ethmoid Sinus		Body Space or Junction	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C122770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122770>	C70547	Scl-70 Antibody|Anti-Scl 70|Anti-Scl 70 Antibody|Anti-Scl-70|Anti-Scl-70 Antibody|Anti-Topoisomerase 1|Anti-Topoisomerase 1 Antibody|Anti-Topoisomerase I|Anti-Topoisomerase I Antibody|Scl 70 Antibody|Topoisomerase 1 Antibody|Topoisomerase I Antibody	An anti-nuclear autoantibody that recognizes a 70 kDa fragment of DNA topoisomerase 1. It is associated with scleroderma.	Scl-70 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122771>	C21176	VEGF:VEGFR Complex|VEGF-VEGFR Complex|VEGF/VEGFR Complex|Vascular Endothelial Growth Factor-Vascular Endothelial Growth Factor Receptor Complex|Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Complex|Vascular Endothelial Growth Factor:Vascular Endothelial Growth Factor Receptor Complex	A ligand-receptor complex comprised of a homodimer of vascular endothelial growth factor (VEGF) family proteins bound to a heterodimer of vascular endothelial growth factor receptor (VEGFR) family proteins. Ligand binding triggers receptor dimerization and cross-receptor tyrosine phosphorylation, which promotes downstream signal transduction.	VEGF:VEGFR Complex		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122772>	C16295	Poliovirus Receptor Antibody|Anti-CD155 Antibody|Anti-Nectin-Like Protein 5 Antibody|Anti-PVR Antibody|Anti-Poliovirus Receptor Antibody|CD155 Antibody|Nectin-Like Protein 5 Antibody|PVR Antibody	Any immunoglobulin that recognizes the poliovirus receptor protein.	Poliovirus Receptor Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122773>	C88924	REST-003 ncRNA|ENST00000503522|OTTHUMT00000362230|REST-003|REST-003 Non-coding RNA	REST-003 ncRNA (~460 base pairs) is encoded by the human REST gene. This transcript includes all of exon 1 and a portion of exon 2 of the gene and may play a role in the negative regulation of cellular invasiveness.	REST-003 ncRNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122774>	C16295	LCP1 Antibody|Anti-L-Plastin|Anti-L-Plastin Antibody|Anti-LCP1 Antibody|Anti-Lymphocyte Cytosolic Protein 1|Anti-Lymphocyte Cytosolic Protein 1 Antibody|L-Plastin Antibody|Lymphocyte Cytosolic Protein 1 Antibody	Any immunoglobulin that recognizes L-plastin protein.	LCP1 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122775>	C17532	RARA Gene Product	A protein encoded by the RARA gene.	RARA Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122776>	C122775	Retinoic Acid Receptor Alpha Isoform Alpha-2|RAR-alpha 2|RAR-alpha2|RARalpha2|Retinoic Acid Receptor Alpha Isoform 2	Retinoic acid receptor alpha isoform alpha-2 (457 aa, ~51 kDa) is encoded by the human RARA gene. This protein may be involved in the regulation of brain development, retinoic acid-dependent transcription and the cell cycle.	Retinoic Acid Receptor Alpha Isoform Alpha-2		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122777>	C16295	EGFR Antibody|Anti-EGFR|Anti-EGFR Antibody|Anti-ERBB1|Anti-ERBB1 Antibody|Anti-Epidermal Growth Factor Receptor|Anti-Epidermal Growth Factor Receptor Antibody|Anti-HER1|Anti-HER1 Antibody|ERBB1 Antibody|Epidermal Growth Factor Receptor Antibody|HER1 Antibody	Any immunoglobulin that recognizes epidermal growth factor receptor protein.	EGFR Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122778>	C113245	Creatine Kinase MB|CK-MB|CKMB|CPK-MB|Creatine Kinase-MB|Creatine Phosphokinase-MB|MM-CK	An isoenzyme complex comprised of a heterodimer of creatine kinase M-type and B-type.	Creatine Kinase MB		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122779>	C26199	PPARGC1A Gene Product	A protein encoded by the PPARGC1A gene.	PPARGC1A Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12277>	C12763	Frontal Sinus|FRONTAL SINUS|Frontal sinus|Frontal sinus structure (body structure)|Sinus, Frontal|frontal sinus	The paired, mucosal lined air spaces located above the orbit and communicating with the nasal passages.	Frontal Sinus		Body Space or Junction	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C122780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122780>	C122779	Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-Alpha Isoform 4|PGC-1 Alpha 4|PGC-1 Alpha-4|PGC-1alpha4|PPAR-Gamma Coactivator 1-Alpha 4|PPAR-Gamma Coactivator 1-Alpha4|PPARGC-1-Alpha 4|PPARGC-1-Alpha4|Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1 Alpha 4	Peroxisome proliferator-activated receptor gamma coactivator 1-alpha isoform 4 (466 aa, ~29 kDa) is encoded by the human PPARGC1A gene. This protein plays a role in the regulation of both gene transcription in and growth of skeletal muscle.	Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-Alpha Isoform 4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122781>	C451	Chromosome 17 Centromere Probe|CEN-17|CEN17|CEP17|Centromere 17|Centromere 17 Probe|Chromosome 17 Centromere	A DNA probe designed for in situ hybridization. This probe is complementary to DNA sequences found in the centromeric region of chromosome 17. This probe can be used to determine gene copy number alterations.	Chromosome 17 Centromere Probe		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology
C122782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122782>	C85053|C28193	Hurler-Scheie Syndrome|MPS I H-S	An autosomal recessive disorder representing the intermediate form of mucopolysaccharidosis type I. It is characterized by deficiency of the enzyme alpha-L-iduronidase. Signs and symptoms include short stature, cloudy cornea, umbilical hernia, joint stiffening, hepatosplenomegaly, and mental retardation.			Disease or Syndrome	Cellosaurus Disease Terminology
C122783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122783>	C134526	Canine Hemangiosarcoma	Hemangiosarcoma occurring in a dog. It is an incurable tumor of vascular endothelial cells and occurs more commonly in dogs beyond middle age, and is especially common in certain breeds. Most hemangiosarcomas do not have a known cause.			Neoplastic Process	Cellosaurus Disease Terminology
C122784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122784>	C35753	Tracheobronchitis	Inflammation of the tracheobronchial tree.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology|Pediatric Infectious Disease Terminology
C122785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122785>	C100104	Pneumatosis	The presence of gas in an anatomical location where it is not normally found.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122786>	C34690	Incarcerated Inguinal Hernia	The trapping of bowel or omentum inside the inguinal canal that cannot be reduced, resulting in inflammation, pain, nausea, and possible bowel obstruction.			Disease or Syndrome	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122787>	C84913	Non-Dystrophic Myotonia|Non Dystrophic Myotonia	A group of rare skeletal muscle ion-channel disorders caused by genetic mutations in the sodium and chloride channel genes. It is characterized by altered membrane excitability resulting in skeletal muscle stiffness. This group of myotonias is distinct from myotonic dystrophy because of the absence of systemic features or progressive weakness.			Disease or Syndrome	
C122788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122788>	C122787	Potassium Aggravated Myotonia|PAM	A group of autosomal dominant inherited non-dystrophic myotonias caused by mutations of the SCN4A gene, resulting in sodium muscle channelopathy. They are characterized by muscle stiffness, which worsens by ingestion of potassium-rich food.  This group includes myotonia fluctuans, myotonia permanens, and acetazolamide-responsive myotonia.			Disease or Syndrome	
C122789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122789>	C122788	Myotonia Fluctuans|Exercise-Induced Delayed-Onset Myotonia|MF	An autosomal dominant inherited potassium aggravated myotonia caused by mutations of the SCN4A gene. It is characterized by mild muscle stiffness that develops during rest approximately an hour after exercise and lasts for about an hour.  It worsens by ingestion of potassium-rich food.			Disease or Syndrome	
C12278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12278>	C12763	Sphenoid Sinus|SPHENOID SINUS|Sinus, Sphenoid|Sphenoid sinus|Sphenoid sinus structure (body structure)|sphenoid sinus	Either of the paired paranasal sinuses, located in the anterior part of the body of the sphenoid bone and communicating with the superior meatus of the nasal cavity on the same side.	Sphenoid Sinus		Body Space or Junction	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C122790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122790>	C122787	Paramyotonia Congenita|PMC|Paramyotonia Congenita of von Eulenburg	An autosomal dominant inherited non-dystrophic myotonia caused by mutations of the SCN4A gene, resulting in sodium muscle channelopathy. It is characterized by muscle stiffness, which is increased by exposure to cold or activity, and usually eases when the patient warms up through physical activity.			Disease or Syndrome	
C122791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122791>	C122787	Normokalemic Periodic Paralysis|NormoKPP	An autosomal dominant inherited non-dystrophic myotonia caused by mutations of the SCN4A gene, resulting in sodium muscle channelopathy. Currently, it is considered a variant of hyperkalemic periodic paralysis.  Patients with normokalemic periodic paralysis do not have any change in their potassium levels during weakness, but become weak when they ingest potassium.			Disease or Syndrome	
C122792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122792>	C122787	Severe Neonatal Episodic Laryngospasm	Myotonia caused by mutations of the SCN4A gene, resulting in sodium muscle channelopathy. It is characterized by severe episodes of laryngospasm in the neonatal period, which can be alleviated by channel blockers.			Disease or Syndrome	
C122793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122793>	C101216	Critical Illness Myopathy|Critical illness myopathy	Acute muscle weakness and paralysis that develops in critically ill patients who have been treated with multiple drugs during their intensive care unit stay. It is associated with delayed weaning from mechanical ventilation and prolonged rehabilitation.			Disease or Syndrome	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 6: Symptoms and Signs Terminology|Physical Examination Terminology
C122794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122794>	C122790	Paramyotonia Congenita without Cold Paralysis	An autosomal dominant inherited non-dystrophic myotonia caused by mutations of the SCN4A gene. It is characterized by muscle stiffness, which is increased by exposure to cold but does not change to flaccid paralysis with intense cooling.			Disease or Syndrome	
C122795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122795>	C34845	Nephrotic Syndrome - NPHS1 Associated|Congenital Nephrotic Syndrome - Finnish Type	Nephrotic syndrome attributed to mutation(s) in the NPHS1 gene, which encodes the protein nephrin, and most commonly presents during the first three months of life.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Nephrology Terminology
C122796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122796>	C34845	Idiopathic Nephrotic Syndrome	Nephrotic syndrome for which no cause has been identified.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Nephrology Terminology
C122797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122797>	C34845	Nephrotic Syndrome of Childhood - Steroid Sensitive|Steroid-Responsive Nephrotic Syndrome|Steroid-Sensitive Nephrotic Syndrome	Nephrotic syndrome, occurring in the pediatric population, characterized by the normalization of proteinuria with the administration of corticosteroids.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C122798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122798>	C34845	Nephrotic Syndrome of Childhood - Steroid Resistant|Nephrotic Syndrome-Steroid-Resistant|Steroid-Resistant Nephrotic Syndrome	Nephrotic syndrome, occurring in the pediatric population, in which proteinuria does not normalize with administration of steroids; this condition is unresponsive to a minimum of four weeks administration of oral corticosteroids.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C122799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122799>	C34845	Nephrotic Syndrome- Steroid Dependent	Nephrotic syndrome characterized by two or more consecutive relapses during steroid tapering or within fourteen days of discontinuing steroids.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C12279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12279>	C38617	Supraglottis|SUPRAGLOTTIS|supraglottic larynx|supraglottic part of larynx|supraglottis|supraglottis	The upper part of the larynx, including the epiglottis; the area above the vocal cords.	Supraglottis		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C1227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1227>	C1974	Simalikalactone D|(+)-Simalikalactone D|Picras-3-ene-2,16-dione, 13,20-epoxy-1,11,12-trihydroxy-15-(2-methyl-1-oxobutoxy)-, (11beta)-|SIMALIKALACTONE D	A quassinoid phytochemical isolated from Simaba multiflora, Quassia africana and other plant species with potential antineoplastic activity.  This agent also has antimalarial and antiviral properties. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C122800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122800>	C34845	Incident Nephrotic Syndrome	New onset nephrotic syndrome.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C122801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122801>	C34845	Prevalent Nephrotic Syndrome	Pre-existing nephrotic syndrome.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C122802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122802>	C34845	Nephrotic Syndrome - Relapse	Nephrotic syndrome characterized by recurrent proteinuria by dipstick of first morning urine: 2+ or greater for three days or longer, or the presence of edema with proteinuria of any duration following a remission.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C122803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122803>	C34845	Nephrotic Syndrome - Frequently Relapsing|FRNS|Frequently Relapsing Nephrotic Syndrome	Nephrotic syndrome in which there is relapse occurring two or more times in the first six months, or four or more times in a year.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C122804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122804>	C3718	WAGRO Syndrome|WAGRO|WAGRO|Wilms Tumor, Aniridia, Genitourinary Anomalies, Mental Retardation, and Obesity Syndrome|Wilms Tumor-Aniridia-Genitourinary Anomalies-Intellectual Developmental Disorder-Obesity Syndrome|Wilms Tumor-Aniridia-Genitourinary Anomalies-Mental Retardation-Obesity Syndrome|Wilms Tumor-Aniridia-Genitourinary Anomalies-Mental Retardation-Obesity Syndrome	A condition resembling WAGR (Wilms tumor, aniridia, genitourinary anomalies and developmental delay) syndrome that also includes obesity. This is a contiguous gene syndrome due to deletion in the vicinity of chromosome 11p13-p12 in a region containing the WT1, PAX6 and BDNF genes.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology|Pediatric Nephrology Terminology
C122805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122805>	C220634	Frasier Syndrome	A condition, which typically presents during adolescence, that is caused by WT-1 mutation, and is characterized by a developmental sex disorder, FSGS, and may be associated with gonadoblastoma.			Disease or Syndrome	Cellosaurus Disease Terminology|GCT Authorized Value Terminology|GCT Medical History Table|NICHD Terminology|Pediatric Endocrinology Terminology|Pediatric Nephrology Terminology
C122806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122806>	C35799	Diffuse Endocapillary Glomerulonephritis|Diffuse endocapillary proliferative glomerulonephritis	Glomerulonephritis characterized by endocapillary proliferation and the presence of inflammatory cells affecting 50% or more of all glomeruli.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C122807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122807>	C40998	Immunohistochemical Status of PD-L1|CD274 Immunohistochemistry|CD274 Status by Immunohistochemistry|Immunohistochemical Status of CD274|PD-L1 IHC Status|PD-L1 Immunohistochemistry|PD-L1 Immunohistochemistry|PD-L1 Immunohistochemistry Status|PD-L1 Status by Immunohistochemistry	An immunohistochemical test result that refers to the overexpression or lack of expression of PD-L1 in a tissue sample of a primary or metastatic malignant neoplasm.	Immunohistochemical Status of PD-L1		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122808>	C177693|C122807	PD-L1 Overexpression|CD274 Overexpression|PD-L1 Positive	An immunohistochemical test result that indicates overexpression of PD-L1 in a tissue sample of a primary or metastatic malignant neoplasm.	PD-L1 Overexpression		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122809>	C122807	Lack of Expression of PD-L1|B7 Homolog 1 Negative|B7-H Negative|B7H1 Negative|CD274 Antigen Negative|CD274 Molecule Negative|CD274 Negative|Negative|PD-L1 Negative|PDCD1L1 Negative|PDCD1LG1 Negative|PDL1 Negative|Programmed Cell Death 1 Ligand 1 Negative	An immunohistochemical test result that indicates lack of expression of PD-L1 in a tissue sample of a primary or metastatic malignant neoplasm.	Lack of Expression of PD-L1		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12280>	C38617	Subglottis|SUBGLOTTIS|infraglottic part of larynx|subglottic larynx|subglottic region|subglottis|subglottis	The area of the larynx below the vocal cords down to the trachea.	Subglottis		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C122810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122810>	C122807	PD-L1 Status Unknown|CD274 Status Unknown|Unknown: Could not be determined or unsure	Indicates that the immunohistochemical test result for PD-L1 is unknown or the test has not been performed.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C122811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122811>	C3021	Generalized Epilepsy with Febrile Seizures Plus|GEFS+	A rare, genetically heterogeneous disorder caused by mutations in the SCN1A, GABRG2, GABRD, SCN9A, or STX1B genes. It is characterized by early childhood onset febrile seizures, generalized tonic-clonic seizures, absence seizures, myoclonic seizures, and atonic seizures			Disease or Syndrome	
C122812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122812>	C3020	Partial Epilepsy	A seizure caused by a localized disorder.			Disease or Syndrome	Cellosaurus Disease Terminology
C122813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122813>	C84796	Juvenile Myoclonic Epilepsy, Intractable, without Status Epilepticus|Juvenile myoclonic epilepsy, intractable, without status epilepticus	Intractable juvenile myoclonic epilepsy which is not associated with an acute, prolonged epileptic crisis.			Disease or Syndrome	mCode Elixhauser Neurological Seizure Disorder Value Set|mCode Terminology
C122814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122814>	C26920	Developmental and Epileptic Encephalopathy|EIEE|Early Infantile Epileptic Encephalopathy	A neurological disorder characterized by recurring seizures presenting within the first three months of life and progressive cerebral dysfunction.			Disease or Syndrome	Cellosaurus Disease Terminology
C122815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122815>	C26920	Acute Encephalopathy	A life-threatening disorder characterized by delirium, seizures, and neuromuscular changes.			Disease or Syndrome	
C122816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122816>	C211912	Azintuxizumab Vedotin|ABBV-838|ADC ABBV-838|AZINTUXIZUMAB VEDOTIN	An antibody-drug conjugate (ADC) composed of an antibody targeting CS1 (SLAMF7/CD319) that is conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), via a cathepsin-cleavable linker, with potential antineoplastic activity. Upon administration, the antibody moiety of azintuxizumab vedotin binds to CS1-expressing tumor cells and is internalized, thereby delivering MMAE intracellularly. Upon cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M checkpoint arrest and apoptosis in CS1-expressing tumor cells.  CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is expressed with high levels and prevalence on multiple myeloma (MM) cells.	Azintuxizumab Vedotin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C122817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122817>	C20194	BCL5 Gene|B-Cell CLL/Lymphoma 5 Gene|B-Cell Leukemia/Lymphoma 5 Gene|BCL3, Formerly Gene|BCL5|BCL5|Leukemia/Lymphoma, Chronic B-Cell, 5 Gene	Human BCL5 gene is located in the vicinity of 17q22 and is approximately 2 kb in length. This phenotype-only gene has not been linked to a known protein product. This locus may play a role in hematopoiesis. Chromosomal rearrangements involving this gene locus may be associated with both aberrant expression of the MYC gene and leukemia.	BCL5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C122818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122818>	C35552	Closure Patent Ductus Arteriosus	The closing of the ductus arteriosus; this can occur naturally or as a result of a therapeutic procedure.			Finding	NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122819>	C28510	NAB2/STAT6 Fusion Gene|NAB2-STAT6 Fusion Gene|NAB2::STAT6 Fusion Gene|STAT6/NAB2 Fusion Gene	A fusion gene that results from a chromosomal rearrangement involving 12q13.3 and 12q13 which fuses the first 6 exons of the NAB2 gene in frame with exon 3, 17, or 18 of the STAT6 gene. This fusion is associated with solitary fibrous tumors.	NAB2/STAT6 Fusion Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12281>	C12373	Laryngeal Cartilage|Laryngeal cartilage	The nine cartilages that comprise the skeleton of the larynx, including the single thyroid, epiglottic, and cricoid cartilages, and the paired arytenoid, corniculate, and cuneiform cartilages.	Laryngeal Cartilage		Anatomical Structure	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C122820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122820>	C17561	NAB2/STAT6 Fusion Protein|NAB2-STAT6 Fusion Protein|NAB2::STAT6 Fusion Protein|NGFI-A-Binding Protein 2/Signal Transducer and Activator of Transcription 6 Fusion Protein	A fusion protein that is encoded by the NAB2/STAT6 fusion gene. This protein contains the N-terminal early growth response (EGR)-binding domain of NGFI-A-binding protein 2 fused to part of signal transducer and activator of transcription 6 protein that includes its DNA-binding transcriptional activation domain.	NAB2/STAT6 Fusion Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122821>	C81326|C35457	Elevated Urine Alkaline Phosphatase	An elevated concentration of alkaline phosphatase in the urine.			Laboratory or Test Result	
C122822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122822>	C96717	Cholelithiasis|Gallstones	The presence of calculi in the gallbladder.			Disease or Syndrome	CPTAC Causes of Death Codelist|CPTAC Codelists Terminology|CPTAC Terminology|GDC Terminology|GDC Value Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C122823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122823>	C25871	ETNK1 Gene|ETNK1|ETNK1|ETNK1|Ethanolamine Kinase 1 Gene	This gene plays a role in phospholipid biosynthesis.	ETNK1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C122824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122824>	C122823	ETNK1 wt Allele|EKI|EKI 1|EKI1|Ethanolamine Kinase 1 wt Allele|Nbla10396	Human ETNK1 wild-type allele is located in the vicinity of 12p12.1 and is approximately 66 kb in length. This allele, which encodes ethanolamine kinase 1 protein, is involved in phosphatidylethanolamine synthesis. Mutations may be associated with hematological and myeloproliferative diseases.	ETNK1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122825>	C16984	Ethanolamine Kinase 1|EC 2.7.1.82|EKI 1|ETNK1|Putative Protein Product of Nbla10396	Ethanolamine kinase 1 (452 aa, ~51 kDa) is encoded by the human ETNK1 gene. This protein plays a role in lipid phosphorylation.	Ethanolamine Kinase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122826>	C18593	CDKN2D Gene|CDKN2D|CDKN2D|Cyclin-Dependent Kinase Inhibitor 2D (p19, Inhibits CDK4) Gene	This gene is involved in the regulation of both cyclin-dependent kinase activity and cell cycle progression.	CDKN2D Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C122827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122827>	C122826	CDKN2D wt Allele|Cell Cycle Inhibitor, Nur77 Associating Protein Gene|Cyclin-Dependent Kinase Inhibitor 2D (p19, Inhibits CDK4) wt Allele|INK4D|p19|p19-INK4D	Human CDKN2D wild-type allele is located in the vicinity of 19p13 and is approximately 3 kb in length. This allele, which encodes cyclin-dependent kinase 4 inhibitor D protein, plays a role in the negative regulation of cyclin-dependent kinase activity.	CDKN2D wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122828>	C18492	Cyclin-Dependent Kinase 4 Inhibitor D|CDK Inhibitor P19INK4d|CDKN2D|Cyclin-Dependent Kinase 4 Inhibitor D p19|Inhibitor of Cyclin-Dependent Kinase 4d|p19-INK4d	Cyclin-dependent kinase 4 inhibitor D (166 aa, ~18 kDa) is encoded by the human CDKN2D gene. This protein is involved in both cell cycle regulation and the inhibition of cyclin-dependent kinases.	Cyclin-Dependent Kinase 4 Inhibitor D		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122829>	C21295	WDFY2 Gene|WD Repeat and FYVE Domain Containing Gene|WDFY2|WDFY2	This gene may play a role in ligand binding.	WDFY2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C122830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122830>	C122829	WDFY2 wt Allele|PROF|WD Repeat and FYVE Domain Containing wt Allele|WDF2|ZFYVE22	Human WDFY2 wild-type allele is located in the vicinity of 13q14.3 and is approximately 178 kb in length. This allele, which encodes WD repeat and FYVE domain-containing protein 2, may be involved in protein or phospholipid binding.	WDFY2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122831>	C17728	WD Repeat and FYVE Domain-Containing Protein 2|Propeller-FYVE Protein|WD Repeat- and FYVE Domain-Containing Protein 2|WD40 and FYVE Domain Containing 2|WD40- and FYVE Domain-Containing Protein 2|Zinc Finger FYVE Domain-Containing Protein 22	WD repeat and FYVE domain-containing protein 2 (400 aa, ~45 kDa) is encoded by the human WDFY2 gene. This protein may play a role in phospholipid or protein ligand binding.	WD Repeat and FYVE Domain-Containing Protein 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122833>	C206201|C20401|C129822	Anti-CD37 Monoclonal Antibody BI 836826|BI 836826|BI-836826|MAb 37.1	An Fc-engineered, chimeric immunoglobulin (Ig) G1 monoclonal antibody against the tumor-associated antigen (TAA) CD37, with potential antineoplastic activity. Upon administration, the anti-CD37 monoclonal antibody BI 836826 both activates the immune system to induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against CD37-overexpressing tumor cells and induces apoptosis in these tumor cells. BI 836826 is Fc-engineered to improve ADCC activity and enhance affinity for the receptor Fc-gamma-RIIIa, which is expressed on human natural killer (NK) cells. CD37, a member of the tetraspanin superfamily of cell surface antigens, is overexpressed on a variety of cancer cell types and plays a key role in tumor cell proliferation.	Anti-CD37 Monoclonal Antibody BI 836826		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C122834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122834>	C2116	Selective Estrogen Receptor Degrader AZD9496|(E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid|AZD 9496|AZD-9496|AZD-9496|AZD9496|SERD AZD9496	An orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon administration, SERD AZD9496 binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This prevents ER-mediated signaling and inhibits the growth and survival of ER-expressing cancer cells.	Selective Estrogen Receptor Degrader AZD9496		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C122835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122835>	C2087	Inosine 5'-monophosphate Dehydrogenase Inhibitor FF-10501-01|FF-10501|FF-10501-01|IMPDH Inhibitor FF-10501	An orally bioavailable inhibitor of inosine 5'- monophosphate dehydrogenase (IMPDH), with potential antineoplastic activity. Upon administration, IMPDH inhibitor FF-10501-01 competitively inhibits the enzyme IMPDH, thereby preventing the conversion of inosine monophosphate to xanthosine monophosphate. This inhibits the synthesis of guanine nucleotides, deprives cancer cells of guanosine triphosphate (GTP), disrupts DNA and RNA synthesis, and decreases tumor cell proliferation. Tumor cells are highly susceptible to IMPDH inhibition because they are rapidly dividing cells that are dependent on rapid DNA synthesis, which requires a high concentration of nucleotides. IMPDH, an enzyme that catalyzes the rate-limiting step in the synthesis of guanosine triphosphate (GTP), is overexpressed in numerous tumor cell types.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C122836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122836>	C129825	mTORC1/2 Kinase Inhibitor BI 860585|BI 860585	An orally bioavailable inhibitor of raptor-mammalian target of rapamycin (mTOR) complex 1 (mTOR complex 1; mTORC1) and rictor-mTOR complex 2 (mTOR complex 2; mTORC2), with potential antineoplastic activity. Upon oral administration, mTORC1/2 kinase inhibitor BI 860585 binds to the kinase domain of mTOR and inhibits both mTORC1 and mTORC2, in an ATP-competitive manner. This inhibits mTOR-mediated signaling and leads to both an induction of apoptosis and a decrease in the proliferation of mTORC1/2-expressing tumor cells. mTOR is a serine/threonine kinase that is upregulated in certain tumor cell types. It plays an important role in the PI3K/Akt/mTOR signaling pathway, which is often deregulated in cancer cells and promotes cell growth, survival, and resistance to chemotherapy and radiotherapy.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C122837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122837>	C93144	Clostridium butyricum-containing Probiotic|C. butyricum-containing Probiotic	A probiotic containing the anaerobic, butyric acid-forming Gram-positive bacterium Clostridium butyricum (C. butyricum), with potential immunomodulatory activity. Upon oral administration of C. butyricum-containing probiotic, C. butyricum modulates the composition of the normal gastrointestinal (GI) microflora and help maintain adequate colonization of the GI tract, thereby improving digestion and preventing GI disturbances. This bacterium creates an environment unfavorable to pathogens by adhering to human epithelial cells, thereby forming a protective mucosal barrier. This prevents attachment of pathogens and reduces the risk of infection. Dietary supplementation with this bacterium may restore or enhance intestinal immunity.	Clostridium butyricum-containing Probiotic		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C122838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122838>	C23020	Type IV Collagen Staining Method|Collagen 4 Staining Method|Collagen IV Staining Method|Type 4 Collagen Staining Method	An immunohistochemical technique used to detect the presence of type IV collagen in a tissue sample.			Laboratory Procedure	
C122839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122839>	C23020	Type I Collagen Staining Method|Collagen 1 Staining Method|Collagen I Staining Method|Type 1 Collagen Staining Method	An immunohistochemical technique used to detect the presence of type I collagen in a tissue sample.			Laboratory Procedure	
C122840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122840>	C23020	Leucine-Rich Repeat-Containing G-Protein Coupled Receptor 5 Staining Method|LGR5 Staining Method	An immunohistochemical technique used to detect the presence of leucine-rich repeat-containing G-protein coupled receptor 5 in a tissue sample.			Laboratory Procedure	
C122841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122841>	C23020	POU Domain, Class 5, Transcription Factor 1 Staining Method|OCT4 Staining Method|Oct-4 Staining Method|Octomer-Binding Protein 4 Staining Method|POU5F1 Staining Method	An immunohistochemical technique used to detect the presence of POU domain, class 5, transcription factor 1 in a tissue sample.			Laboratory Procedure	
C122842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122842>	C23020	GATA-Binding Factor 3 Staining Method|GATA Binding Factor 3 Staining Method|GATA Binding Protein 3 Staining Method|GATA-3 Staining Method|GATA-Binding Protein 3 Staining Method|GATA3 Staining Method|Trans-Acting T-Cell-Specific Transcription Factor GATA-3 Staining Method	An immunohistochemical technique used to detect the presence of GATA-binding factor 3 in a tissue sample.			Laboratory Procedure	
C122843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122843>	C23020	Programmed Cell Death Protein 1 Staining Method|CD279 Staining Method|PD-1 Staining Method|PD1 Staining Method|PDCD1 Staining Method|Programmed Cell Death 1 Staining Method	An immunohistochemical technique used to detect the presence of programmed cell death protein 1 in a tissue sample.			Laboratory Procedure	
C122844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122844>	C23020	Major Histocompatibility Complex Class II Staining Method|Class II MHC Staining Method|MHC Class II Staining Method|MHC II Staining Method	An immunohistochemical technique used to detect the presence of class II major histocompatibility complex antigens in a tissue sample.			Laboratory Procedure	
C122845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122845>	C23020	Major Histocompatibility Complex Class I Staining Method|Class I MHC Staining Method|MHC Class I Staining Method|MHC I Staining Method	An immunohistochemical technique used to detect the presence of class I major histocompatibility complex antigens in a tissue sample.			Laboratory Procedure	
C122846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122846>	C23020	Adhesion G Protein-Coupled Receptor E1 Staining Method|ADGRE1 Staining Method|Antibody F4/80 Staining Method|EMR1 Staining Method|F4/80 Antibody Staining Method|F4/80 Staining Method	An immunohistochemical technique used to detect the presence of adhesion G protein-coupled receptor E1 in a tissue sample.			Laboratory Procedure	
C122847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122847>	C23020	Forkhead Box Protein P3 Staining Method|Fox3P Staining Method|FoxP3 Staining Method	An immunohistochemical technique used to detect the presence of forkhead box protein P3 in a tissue sample.			Laboratory Procedure	
C122848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122848>	C23020	B220 Staining Method|CD45R Staining Method|PTPRC B220 Staining Method|Receptor-Type Tyrosine-Protein Phosphatase C Isoform B220 Staining Method	An immunohistochemical technique used to detect the presence of the B220 isoform of the receptor-type tyrosine-protein phosphatase C in a tissue sample.			Laboratory Procedure	
C122849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122849>	C23020	Macrosialin Staining Method|CD68 Staining Method	An immunohistochemical technique used to detect the presence of macrosialin (CD68) in a tissue sample.			Laboratory Procedure	
C12284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12284>	C12683	Main Bronchus|Main bronchus|Main bronchus structure (body structure)|Mainstem bronchus|main bronchus	One of two major branches of the trachea. Bifurcation of the trachea at the carina forms the left main bronchus and the right main bronchus.	Main Bronchus		Body Part, Organ, or Organ Component	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C122850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122850>	C23020	CD8 Co-Receptor Staining Method|CD8 Complex Staining Method|CD8 Staining Method|T-Cell Surface Glycoprotein CD8 Staining Method	An immunohistochemical technique used to detect the presence of the heterodimeric T-cell surface glycoprotein CD8 co-receptor protein complex in a tissue sample.			Laboratory Procedure	
C122851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122851>	C23020	T-Cell Surface Glycoprotein CD4 Staining Method|CD4 Staining Method|T-Cell Antigen T4/Leu3 Staining Method|T4/Leu3 Staining Method	An immunohistochemical technique used to detect the presence of T-cell surface glycoprotein CD4 in a tissue sample.			Laboratory Procedure	
C122852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122852>	C23020	CD3 Complex Staining Method|CD3 Staining Method|T-Cell Surface Glycoprotein CD3 Staining Method	An immunohistochemical technique used to detect the presence of the CD3 protein complex in a tissue sample.			Laboratory Procedure	
C122853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122853>	C23020	Tight Junction Protein ZO-1 Staining Method|TJP1 Staining Method|Tight Junction Protein 1 Staining Method|ZO-1 Staining Method|Zona Occludens Protein 1 Staining Method|Zonula Occludens Protein 1 Staining Method	An immunohistochemical technique used to detect the presence of tight junction protein ZO-1 in a tissue sample.			Laboratory Procedure	
C122854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122854>	C23020	Cadherin-2 Staining Method|CDH2 Staining Method|N-cadherin Staining Method|NCAD Staining Method|Neural-Cadherin Staining Method|nCadherin Staining Method	An immunohistochemical technique used to detect the presence of cadherin-2 (N-cadherin) in a tissue sample.			Laboratory Procedure	
C122855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122855>	C23020	Cadherin-3 Staining Method|CDH3 Staining Method|P-cadherin Staining Method|PCAD Staining Method|Placental Cadherin Staining Method|pCadherin Staining Method	An immunohistochemical technique used to detect the presence of cadherin-3 (P-cadherin) in a tissue sample.			Laboratory Procedure	
C122856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122856>	C23020	Claudin-7 Staining Method|CLDN-7 Staining Method|CLDN7 Staining Method|Claudin 7 Staining Method	An immunohistochemical technique used to detect the presence of claudin-7 in a tissue sample.			Laboratory Procedure	
C122857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122857>	C23020	Pan Cytokeratin Staining Method|PCK Staining|PCK Staining Method|Pan-CK Staining Method|Pan-Cytokeratin Staining Method|Pancytokeratin Staining|Pancytokeratin Staining Method|Poly-CK Staining Method	An immunohistochemical technique used to detect the presence of a broad spectrum of acidic and basic cytokeratin proteins in a tissue sample.	Pan Cytokeratin Staining Method		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Terminology
C122858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122858>	C23020	Cytokeratin-6 Staining Method|CK6 Staining Method|Cytokeratin 6|Cytokeratin 6 Staining Method|KRT6 Staining Method|Keratin, Type II Cytoskeletal 6 Staining Method	An immunohistochemical technique used to detect the presence of cytokeratin-6 in a tissue sample.			Laboratory Procedure	GDC Terminology|GDC Value Terminology
C122859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122859>	C23020	Cytokeratin-5 Staining Method|CK5 Staining Method|Cytokeratin 5|Cytokeratin 5 Staining Method|KRT5 Staining Method|Keratin, Type II Cytoskeletal 5 Staining Method	An immunohistochemical technique used to detect the presence of cytokeratin-5 in a tissue sample.			Laboratory Procedure	GDC Terminology|GDC Value Terminology
C12285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12285>	C34021	Upper Lobe of the Lung|Lung Upper Lobe|Superior Lobe of the Lung|Upper Lobe|Upper Lobe|Upper Lobe, Lung|Upper lobe, lung|upper lobe of lung	The upper-most lobe of either lung.	Upper Lobe, Lung		Body Part, Organ, or Organ Component	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C122860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122860>	C23020	Vitamin D3 Receptor Staining Method|NR1I1 Staining Method|VDR Staining Method|Vitamin D Receptor Staining Method	An immunohistochemical technique used to detect the presence of vitamin D3 receptor in a tissue sample.			Laboratory Procedure	
C122861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122861>	C23020	Androgen Receptor Staining Method|AR Staining Method|NR3C4 Staining Method	An immunohistochemical technique used to detect the presence of androgen receptor in a tissue sample.			Laboratory Procedure	
C122862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122862>	C23020	Caspase-3 Staining Method|CASP-3 Staining Method|CASP3 Staining Method|Caspase 3 Staining Method	An immunohistochemical technique used to detect the presence of caspase-3 in a tissue sample.			Laboratory Procedure	
C122863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122863>	C23020	Phosphatase and Tensin Homolog Staining Method|PTEN Staining Method|Phosphatidylinositol-3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN Staining Method	An immunohistochemical technique used to detect the presence of phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN in a tissue sample.			Laboratory Procedure	
C122864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122864>	C23020	Breast Cancer Type 2 Susceptibility Protein Staining Method|BRCA2 Staining Method|BROVCA2 Staining Method|Breast Cancer 2, Early Onset Protein Staining Method|FANCD1 Staining Method|Fanconi Anemia Group D1 Protein Staining Method	An immunohistochemical technique used to detect the presence of breast cancer type 2 susceptibility protein in a tissue sample.			Laboratory Procedure	
C122865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122865>	C23020	Breast Cancer Type 1 Susceptibility Protein Staining Method|BRCA1 Staining Method|BROVCA1 Staining Method|Breast Cancer 1, Early Onset Protein Staining Method|Breast-Ovarian Cancer Protein Staining Method|FANCS Staining Method|Fanconi Anemia Group S Protein Staining Method	An immunohistochemical technique used to detect the presence of breast cancer type 1 susceptibility protein in a tissue sample.			Laboratory Procedure	
C122866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122866>	C133155	BRCA Rearrangement|BRCA Family Gene Rearrangement|BRCA Family Rearrangement|BRCA Gene Rearrangement	A molecular abnormality indicating the presence of rearrangement mutations in either the BRCA1 gene at 17q21 or the BRCA2 gene at 13q12.3.	BRCA Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122867>	C23020	Retinoblastoma-Associated Protein Staining Method|RB Staining Method|RB1 Staining Method|Retinoblastoma Protein Staining Method|p105-Rb Staining Method|pRB Staining Method	An immunohistochemical technique used to detect the presence of retinoblastoma-associated protein in a tissue sample.			Laboratory Procedure	
C122868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122868>	C23020	Cellular Tumor Antigen p53 Staining Method|NY-CO-13 Staining Method|TP53 Staining Method|Tumor Protein p53 Staining Method|p53 Staining Method	An immunohistochemical technique used to detect the presence of cellular tumor antigen p53 in a tissue sample.			Laboratory Procedure	
C122869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122869>	C23020	Neurogenic Locus Notch Homolog Protein 3 Staining Method|NOTCH-3 Staining Method|NOTCH3 Staining Method|Notch 3 Staining Method	An immunohistochemical technique used to detect the presence of neurogenic locus notch homolog protein 3 in a tissue sample.			Laboratory Procedure	
C12286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12286>	C48944	Middle Lobe of the Right Lung|LUNG, RIGHT MIDDLE LOBE|Lung Middle Lobe|Middle Lobe|Middle Lobe|Middle Lobe of Lung|Middle lobe, lung|RML|Right Middle Lobe, Lung	The smallest lobe of the right lung, situated above the oblique fissure and below the horizontal fissure.	Right Middle Lobe, Lung		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C122870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122870>	C23020	Neurogenic Locus Notch Homolog Protein 1 Staining Method|NOTCH-1 Staining Method|NOTCH1 Staining Method|Notch 1 Staining Method|TAN-1 Staining Method	An immunohistochemical technique used to detect the presence of neurogenic locus notch homolog protein 1 in a tissue sample.			Laboratory Procedure	
C122871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122871>	C23020	Signal Transducer and Activator of Transcription 5 Staining Method|STAT-5 Staining Method|STAT5 Staining Method|STAT5A/B Staining Method|Signal Transducer and Activator of Transcription 5A/B Staining Method	An immunohistochemical technique used to detect the presence of one or both isoforms of signal transducer and activator of transcription 5 in a tissue sample.			Laboratory Procedure	
C122872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122872>	C23020	Signal Transducer and Activator of Transcription 3 Staining Method|APRF Staining Method|Acute-Phase Response Factor Staining Method|STAT-3 Staining Method|STAT3 Staining Method	An immunohistochemical technique used to detect the presence of signal transducer and activator of transcription 3 in a tissue sample.			Laboratory Procedure	
C122873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122873>	C23020	Signal Transducer and Activator of Transcription 1 Staining Method|STAT-1 Staining Method|STAT1 Staining Method|STAT1-alpha/beta Staining Method|Signal Transducer and Activator of Transcription 1-alpha/beta Staining Method	An immunohistochemical technique used to detect the presence of one or both isoforms of signal transducer and activator of transcription 1 in a tissue sample.			Laboratory Procedure	
C122875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122875>	C26006	DCTN1 Gene|DCTN1|DCTN1|DCTN1|Dynactin 1 Gene	This gene is involved in the modulation of retrograde transport of cytoplasmic organelles and vesicles.	DCTN1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C122876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122876>	C122875	DCTN1 wt Allele|DAP-150|DP-150|Dynactin 1 (p150, Glued (Drosophila) Homolog) Gene|Dynactin 1 wt Allele|P135|p150 Glued Homolog (Drosophila) Gene|p150(Glued), Drosophila, Homolog of Gene	Human DCTN1 wild-type allele is located in the vicinity of 2p13 and is approximately 31 kb in length. This allele, which encodes dynactin subunit 1 protein, plays a role in the regulation of dynein-dependent transport. Mutation of the gene is associated with Perry syndrome, amyotrophic lateral sclerosis, and distal hereditary motor neuronopathy type VIIB (HMN7B).	DCTN1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122877>	C16386	Dynactin Subunit 1|150 kDa Dynein-Associated Polypeptide|DAP-150|DP-150|p135|p150-glued	Dynactin subunit 1 (1278 aa, ~142 kDa) is encoded by the human DCTN1 gene. This protein is involved in the dynein-mediated retrograde transport of vesicles and organelles along microtubules.	Dynactin Subunit 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122878>	C21295	ZCCHC8 Gene|ZCCHC8|ZCCHC8|ZCCHC8|Zinc Finger CCHC-Type Containing 8 Gene	This gene plays a role in RNA binding.	ZCCHC8 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C122879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122879>	C122878	ZCCHC8 wt Allele|DKFZp434E2220|Zinc Finger CCHC-Type Containing 8 wt Allele|Zinc Finger, CCHC Domain Containing 8 Gene	Human ZCCHC8 wild-type allele is located in the vicinity of 12q24.31 and is approximately 29 kb in length. This allele, which encodes zinc finger CCHC domain-containing protein 8, may be involved in RNA binding and splicing.	ZCCHC8 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12287>	C34021	Lower Lobe of the Lung|Lower Lobe|Lower Lobe|Lower Lobe, Lung|Lower lobe, lung|Lung Lower Lobe|lower lobe of lung	The bottom most subdivision of either the right or left lung.	Lower Lobe, Lung		Body Part, Organ, or Organ Component	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C122880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122880>	C21298	Zinc Finger CCHC Domain-Containing Protein 8|TRAMP-Like Complex RNA-Binding Factor ZCCHC8	Zinc finger CCHC domain-containing protein 8 (707 aa, ~79 kDa) is encoded by the human ZCCHC8 gene. This protein plays a role in RNA binding.	Zinc Finger CCHC Domain-Containing Protein 8		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122881>	C20745	MYO5A Gene|MYO5A|MYO5A|MYO5A|Myosin VA (Heavy Chain 12, Myoxin) Gene	This gene is involved in vesicle transport along actin filaments.	MYO5A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C122882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122882>	C122881	MYO5A wt Allele|Dilute, Mouse, Homolog of Gene|GS1|MYH12|MYO5|MYR12|Myosin VA (Heavy Chain 12, Myoxin) wt Allele|Myosin VA (Heavy Polypeptide 12, Myoxin) Gene|Myosin, Heavy Chain 12 Gene|Myosin, Heavy Polypeptide Kinase Gene	Human MYO5A wild-type allele is located in the vicinity of 15q21 and is approximately 222 kb in length. This allele, which encodes unconventional myosin-Va protein, plays a role in melanosome transport along actin filaments. Mutation of the gene is associated with Elejalde disease and Griscelli syndrome types-1 and -3.	MYO5A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122883>	C16492	Unconventional Myosin-Va|Dilute Myosin Heavy Chain, Non-Muscle|MYO5A|Myosin Heavy Chain 12|Myosin V|Myosin-12|Myoxin	Unconventional myosin-Va (1855 aa, ~215 kDa) is encoded by the human MYO5A gene. This protein is involved in the transport of cytoplasmic cargo along actin filaments.	Unconventional Myosin-Va		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122884>	C21295	LSM14A Gene|LSM14A|LSM14A|LSM14A|LSM14A, SCD6 Homolog A (S. cerevisiae) Gene	This gene plays a role in the storage of mRNA.	LSM14A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C122885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122885>	C122884	LSM14A wt Allele|C19orf13|Chromosome 19 Open Reading Frame 13 Gene|DKFZP434D1335|FAM61A|Family with Sequence Similarity 61, Member A Gene|LSM14 Homolog A (SCD6, S. cerevisiae) Gene|LSM14A, SCD6 Homolog A (S. cerevisiae) wt Allele|RAP55|RAP55A	Human LSM14A wild-type allele is located in the vicinity of 19q13.11 and is approximately 57 kb in length. This allele, which encodes protein LSM14 homolog A protein, is involved in the maintenance of mRNAs.	LSM14A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122886>	C21298	Protein LSM14 Homolog A|AlphaSNBP|LSM14 Homolog A|LSM14A Protein|Protein FAM61A|Protein SCD6 Homolog|Putative Alpha-Synuclein-Binding Protein|RNA Associated Protein 55|RNA Associated Protein 55A|RNA-Associated Protein 55|RNA-Associated Protein 55A|hRAP55|hRAP55A	Protein LSM14 homolog A (463 aa, ~51 kDa) is encoded by the human LSM14A gene. This protein plays a role in RNA maintenance.	Protein LSM14 Homolog A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122887>	C20194	CEP89 Gene|CEP89|CEP89|CEP89|Centrosomal Protein 89kDa Gene	This gene is involved in cilia formation.	CEP89 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C122888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122888>	C122887	CEP89 wt Allele|CCDC123|CEP123|Centrosomal Protein 89kDa wt Allele|Centrosomal Protein, 89-kD Gene|Coiled-Coil Domain-Containing Protein 123, Mitochondrial Gene|FLJ14640	Human CEP89 wild-type allele is located in the vicinity of 19q13.11 and is approximately 93 kb in length. This allele, which encodes centrosomal protein of 89 kDa, plays a role in the modulation of ciliogenesis.	CEP89 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122889>	C18466	Centrosomal Protein of 89 kDa|Centrosomal Protein 123|Cep123|Cep89|Coiled-Coil Domain Containing 123|Coiled-Coil Domain-Containing Protein 123	Centrosomal protein of 89 kDa (783 aa, ~90 kDa) is encoded by the human CEP89 gene. This protein is involved in ciliogenesis.	Centrosomal Protein of 89 kDa		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122890>	C21295	PWWP2A Gene|PWWP Domain Containing 2A Gene|PWWP2A|PWWP2A|PWWP2A	This gene may play a role in protein-protein or protein-DNA interactions.	PWWP2A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C122891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122891>	C122890	PWWP2A wt Allele|KIAA1935|MST101|MSTP101|PWWP Domain Containing 2A wt Allele	Human PWWP2A wild-type allele is located in the vicinity of 5q33.3 and is approximately 58 kb in length. This allele, which encodes PWWP domain-containing protein 2A, may be involved in binding to other proteins or to DNA.	PWWP2A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122892>	C17728	PWWP Domain-Containing Protein 2A|PWWP2A	PWWP domain-containing protein 2A (755 aa, ~82 kDa) is encoded by the human PWWP2A gene. This protein may play a role in protein-DNA or protein-protein interactions.	PWWP Domain-Containing Protein 2A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122893>	C54362	ZSCAN30 Gene|ZSCAN30|ZSCAN30|Zinc Finger and SCAN Domain Containing 30 Gene	This gene may be involved in both transcriptional regulation and DNA binding.	ZSCAN30 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C122894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122894>	C122893	ZSCAN30 wt Allele|ZNF-WYM|ZNF397 Opposite Strand Gene|ZNF397OS|ZNF917|Zinc Finger and SCAN Domain Containing 30 wt Allele	Human ZSCAN30 wild-type allele is located in the vicinity of 18q12.2 and is approximately 39 kb in length. This allele, which encodes zinc finger and SCAN domain-containing protein 30, may play a role in DNA binding and transcriptional regulation.	ZSCAN30 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122895>	C26199	Zinc Finger and SCAN Domain-Containing Protein 30|ZNF-WYM|ZSCAN30|Zinc Finger Protein 397 Opposite Strand|Zinc Finger Protein 397OS	Zinc finger and SCAN domain-containing protein 30 (494 aa, ~56 kDa) is encoded by the human ZSCAN30 gene. This protein may be involved in the modulation of transcription and in DNA binding.	Zinc Finger and SCAN Domain-Containing Protein 30		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122896>	C25870	GATM Gene|GATM|GATM|Glycine Amidinotransferase (L-Arginine:Glycine Amidinotransferase) Gene	This gene plays a role in creatine biosynthesis.	GATM Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C122897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122897>	C122896	GATM wt Allele|AGAT|AT|CCDS3|Glycine Amidinotransferase (L-Arginine:Glycine Amidinotransferase) wt Allele	Human GATM wild-type allele is located in the vicinity of 15q21.1 and is approximately 41 kb in length. This allele, which encodes glycine amidinotransferase, mitochondrial protein, is involved in the synthesis of creatine from L-arginine and glycine.	GATM wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122898>	C17210	Glycine Amidinotransferase, Mitochondrial|EC 2.1.4.1|L-Arginine:Glycine Amidinotransferase|Transamidinase	Glycine amidinotransferase, mitochondrial (423 aa, ~48 kDa) is encoded by the human GATM gene. This protein plays a role in the conversion of L-arginine and glycine to creatine.	Glycine Amidinotransferase, Mitochondrial		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122899>	C43611	Driver's License	A document that authorizes a person to operate a motor vehicle on public roads.			Qualitative Concept	
C1228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1228>	C1505	Sodium Molybdate|Disodium Molybdate|SODIUM MOLYBDATE	A crystalline powder essential for the metabolism and development of plants and animals as a cofactor for enzymes. (NCI)			Inorganic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C122900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122900>	C25943	HACL1 Gene|2-Hydroxyacyl-CoA Lyase 1 Gene|HACL1|HACL1	This gene is involved in fatty acid oxidation.	HACL1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C122901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122901>	C122900	HACL1 wt Allele|1600020H07Rik|2-HPCL|2-Hydroxyacyl-CoA Lyase 1 wt Allele|HPCL|HPCL2|HPCl2|HSPC279|PHYH2	Human HACL1 wild-type allele is located in the vicinity of 3p25.1 and is approximately 41 kb in length. This allele, which encodes 2-hydroxyacyl-CoA lyase 1 protein, plays a role in lipid metabolism.	HACL1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122902>	C16804	2-Hydroxyacyl-CoA Lyase 1|2-HPCL|2-Hydroxyphytanol-CoA Lyase|2-Hydroxyphytanoyl-CoA Lyase|EC 4.1.-.-|Phytanoyl-CoA 2-Hydroxylase 2|Phytanoyl-CoA Hydroxylase 2	2-hydroxyacyl-CoA lyase 1 (578 aa, ~64 kDa) is encoded by the human HACL1 gene. This protein is involved in the metabolism of fatty acids.	2-Hydroxyacyl-CoA Lyase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122903>	C20703	NAB2 Gene|NAB2|NAB2|NAB2|NGFI-A Binding Protein 2 (EGR1 Binding Protein 2) Gene	This gene plays a role in the repression of gene transcription.	NAB2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C122904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122904>	C122903	NAB2 wt Allele|MADER|NGFI-A Binding Protein 2 (EGR1 Binding Protein 2) wt Allele	Human NAB2 wild-type allele is located in the vicinity of 12q13.3 and is approximately 7 kb in length. This allele, which encodes NGFI-A-binding protein 2, is involved in the modulation of early growth response protein-dependent gene transcription.	NAB2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122905>	C26199	NGFI-A-Binding Protein 2|EGR-1-Binding Protein 2|EGR1 Binding Protein 2|Melanoma-Associated Delayed Early Response Protein|NAB2|NAG2|NGFI-A Binding Protein 2|Protein MADER	NGFI-A-binding protein 2 (525 aa, ~57 kDa) is encoded by the human NAB2 gene. This protein plays a role in the inhibition of early growth response protein-dependent gene expression.	NGFI-A-Binding Protein 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122906>	C20194	SHTN1 Gene|KIAA1598|SHTN1|SHTN1|SHTN1|Shootin 1 Gene	This gene is involved in neuronal polarization.	SHTN1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C122907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122907>	C122906	SHTN1 wt Allele|KIAA1598|SHOOTIN1|Shootin 1 wt Allele	Human SHTN1 wild-type allele is located in the vicinity of 10q25.3 and is approximately 242 kb in length. This allele, which encodes shootin-1 protein, plays a role in signaling involved in neuronal polarization.	SHTN1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122908>	C18466	Shootin-1	Shootin-1 (631 aa, ~72 kDa) is encoded by the human SHTN1 gene. This protein is involved in establishing neuronal polarity.	Shootin-1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122909>	C106409	PTPRB Gene|PTPRB|PTPRB|PTPRB|Protein Tyrosine Phosphatase, Receptor Type, B Gene	This gene is involved in dephosphorylation of proteins.	PTPRB Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C12290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12290>	C48821|C32881	Mandible|BONE, MANDIBLE|Bone structure of mandible (body structure)|Bone, Mandibular|Inferior Maxillary Bone|Inferior Maxillary Bone|Lower Jaw|Lower Jaw|MANDIBLE|Mandibular|inferior maxillary bone|mammaliam mandible|mandible|mandibulla	The lower jaw bone holding the lower teeth.	Mandible		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C122910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122910>	C122909	PTPRB wt Allele|HPTP-BETA|HPTPB|PTPB|Protein Tyrosine Phosphatase, Receptor Type, B wt Allele|Protein Tyrosine Phosphatase, Receptor Type, Beta Polypeptide Gene|Protein-Tyrosine Phosphatase, Receptor-Type, B Gene|R-PTP-BETA|VEPTP	Human PTPRB wild-type allele is located within 12q15-q21 and is approximately 121 kb in length. This allele, which encodes receptor-type tyrosine-protein phosphatase beta protein, plays a role in both the removal of phosphate groups from phosphotyrosine and blood vessel maintenance.	PTPRB wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122911>	C17444	Receptor-Type Tyrosine-Protein Phosphatase Beta|EC 3.1.3.48|PTPRB|Protein-Tyrosine Phosphatase Beta|R-PTP-beta|VE-PTP|Vascular Endothelial Protein Tyrosine Phosphatase|Vascular Endothelial Protein-Tyrosine Phosphatase	Receptor-type tyrosine-protein phosphatase beta (1997 aa, ~224 kDa) is encoded by the human PTPRB gene. This protein is involved in both blood vessel maintenance and protein dephosphorylation.	Receptor-Type Tyrosine-Protein Phosphatase Beta		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122912>	C20988	MADCAM1 Gene|MADCAM1|MADCAM1|Mucosal Vascular Addressin Cell Adhesion Molecule 1 Gene	This gene plays a role in leukocyte migration.	MADCAM1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C122913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122913>	C122912	MADCAM1 wt Allele|Addressin, Mucosal Gene|MACAM1|Mucosal Vascular Addressin Cell Adhesion Molecule 1 wt Allele	Human MADCAM1 wild-type allele is located in the vicinity of 19p13.3 and is approximately 16 kb in length. This allele, which encodes mucosal addressin cell adhesion molecule 1 protein, is involved in lymphocyte trafficking.	MADCAM1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122914>	C16393	Mucosal Addressin Cell Adhesion Molecule 1|MADCAM1|MAdCAM-1|Mucosal Addressin Cell Adhesion Molecule-1|hMAdCAM-1	Mucosal addressin cell adhesion molecule 1 (382 aa, ~40 kDa) is encoded by the human MADCAM1 gene. This protein plays a role in both lymphocyte migration and integrin-mediated cell adhesion.	Mucosal Addressin Cell Adhesion Molecule 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122915>	C26003	PCSK9 Gene|PCSK9|PCSK9|Proprotein Convertase Subtilisin/Kexin Type 9 Gene	This gene is involved in both cholesterol metabolism and protein degradation.			Gene or Genome	
C122916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122916>	C122915	PCSK9 wt Allele|FH3|HCHOLA3|Hypercholesterolemia, Autosomal Dominant 3 Gene|LDLCQ1|NARC-1|NARC1|PC9|PSEC0052|Proprotein Convertase Subtilisin/Kexin Type 9 wt Allele|Proprotein Convertase, Subtilisin/Kexin-Type, 9 Gene	Human PCSK9 wild-type allele is located in the vicinity of 1p32.3 and is approximately 25 kb in length. This allele, which encodes proprotein convertase subtilisin/kexin type 9 protein, plays a role in both receptor protein degradation and lipid metabolism. Mutation of the gene is associated with autosomal dominant familial hypercholesterolemia type 3.			Gene or Genome	
C122918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122918>	C17123	Proprotein Convertase Subtilisin/Kexin Type 9|Convertase Subtilisin/Kexin Type 9 Preproprotein|EC 3.4.21.-|NARC-1|Neural Apoptosis Regulated Convertase 1|Neural Apoptosis-Regulated Convertase 1|PC9|PCSK9|Proprotein Convertase 9|Subtilisin/Kexin-Like Protease PC9	Proprotein convertase subtilisin/kexin type 9 (692 aa, ~74 kDa) is encoded by the human PCSK9 gene. This protein is involved in the degradation of low density lipoprotein receptor family proteins.	Proprotein Convertase Subtilisin/Kexin Type 9		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C122919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122919>	C112210	Cutaneous Small Vessel Vasculitis|Cutaneous Leukocytoclastic Vasculitis|Cutaneous Small-Vessel Vasculitis	A skin hypersensitivity reaction characterized by raised purpuric lesions, red macules, hemorrhagic blisters and ulcerations.			Disease or Syndrome	
C12291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12291>	C33561	Skin of the Lip|Hair Bearing Lip|SKIN OF THE LIP|Skin of Lip|Skin of lip, NOS	The skin portion of the lip that contains hair.	Skin of Lip, NOS		Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C122920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122920>	C217121	Intelligence Scale|Intelligence Test	An assessment tool designed to measure an individual's cognitive capabilities. It may be general or it may assess abilities in more discrete cognitive domains.			Intellectual Product	
C122921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122921>	C20401|C129822	Rosmantuzumab|OMP-131R10|ROSMANTUZUMAB	An immunoglobulin (Ig) G1 humanized monoclonal antibody targeting human R-spondin 3 (RSPO3), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, rosmantuzumab targets and binds to RSPO3 expressed on tumor cells. This prevents the activation of RSPO3, and inhibits both the binding of RSPO3 to leucine-rich repeat-containing G-coupled receptors (LGRs) and the activation of the RSPO-LGR pathway. This may result in an inhibition of both cancer stem cell (CSC) survival and the proliferation of cancer cells in which this pathway is overactivated. The RSPO-LGR pathway is a CSC pathway activated in a variety of cancer cell types.	Rosmantuzumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C122922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122922>	C2139	Immunotherapeutic Combination Product CMB305|CMB 305|CMB305|ID-CMB305|ID-LV305 Plus ID G305|LV 305 Plus G 305|LV305 Plus G305	An immunotherapeutic combination product composed of LV305, an engineered lentiviral vector that both targets dendritic cells (DCs) and contains nucleic acids encoding the human tumor-associated cancer-testis antigen NY-ESO-1 (CTAG1), and G305, a cancer vaccine comprised of an NY-ESO-1 recombinant protein and glucopyranosyl lipid adjuvant (GLA)-stable emulsion (GLA-SE), with potential synergistic immunostimulatory and antineoplastic activities. Upon intradermal administration of LV305, the DC-targeting lentiviral vector targets and binds to dermal DCs via the DC-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) receptor. Upon internalization of the vector, the NY-ESO-1 protein is expressed, which stimulates DC maturation, and activates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against NY-ESO-1-expressing cells; this may result in tumor cell lysis. Upon the sequential intramuscular injection of G305, the adjuvant portion of G305 binds to toll-like receptor 4 (TLR-4) expressed on various immune cells, including DCs, monocytes, macrophages and B-cells. The activated DCs present the NY-ESO-1 antigen to CD4-positive Th1 T-lymphocytes. The induction of antigen-specific CD4-positive T-lymphocytes further induces a CTL response against NY-ESO-1-expressing tumor cells. In addition, G305 induces an NY-ESO-1-specific antibody response. NY-ESO-1, expressed in normal testes and on the surfaces of various tumor cells, plays a key role in tumor cell proliferation and survival.	Immunotherapeutic Combination Product CMB305		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C122923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122923>	C4375	Persistent Hyperinsulinemic Hypoglycemia of Infancy|Familial Hyperinsulinemic Hypoglycemia-1|HHF1|PHHI	A genetic condition caused by mutation(s) in the ABCC8 gene, encoding ATP-binding cassette sub-family C member 8.			Disease or Syndrome	Cellosaurus Disease Terminology
C122924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122924>	C207912|C141144|C129822	Anti-B7-H3 Antibody DS-5573a|DS-5573a	An antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, anti-B7-H3 antibody DS-5573a binds to the cell surface antigen B7-H3, thereby blocking B7-H3-mediated signaling. This abrogates the inhibitory effect on T-cell activation and may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It is a negative regulator of the T-cell activation and its overexpression plays a key role in tumor cell invasion and metastasis.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C122925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122925>	C3147	Type A Tylosis|Late Onset Tylosis	An inherited form of tylosis that presents between 5-14 years of age and is characterized by focal areas of nonepidermolytic palmoplantar keratoderma. Individuals have an increased incidence of esophageal carcinoma.			Disease or Syndrome	
C122926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122926>	C3147	Type B Tylosis|Early Onset Tylosis	An inherited form of tylosis that presents by one year and is characterized by benign palmoplantar keratoderma.			Disease or Syndrome	
C122927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122927>	C34748	Unna-Thost Disease	An autosomally dominant inherited form of palmoplantar keratoderma that is characterized by a non-gradient diffuse pattern and often, hyperhidrosis of the palms of the hands and soles of the feet. It does not extend beyond the palms, knucklels pads, nails, and the soles.			Disease or Syndrome	
C122928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122928>	C23020	Antibody MIB-1 Staining Method|Antibody MIB1 Staining Method|MIB-1 Antibody Staining Method|MIB-1 Ki67 Assay|MIB-1 Staining Method|MIB1 Antibody Staining Method|MIB1 Staining Method	An immunohistochemical technique used to quantify the percent of cells in a tissue sample that can react with the monoclonal antibody MIB-1. Antibody MIB-1 recognizes antigen KI-67 protein, which is a nuclear protein that is exclusively expressed by proliferating cells.	Antibody MIB-1 Staining Method		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C122929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122929>	C25492	Impact|Impacted	The effect or consequence of an event or condition.			Phenomenon or Process	
C12292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12292>	C13043	External Ear|Auricle|Auricle|EAR, OUTER|Ear, External|External ear|PINNA|Pinna|Pinna|auricle|auricle of ear|auricle of external ear|auricula|auris externa|pinna|pinna of ear	The external part of the ear.	External Ear		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C122930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122930>	C62781	Transcranial Doppler Ultrasonography|Non-imaging TCD|TCD|Transcranial Doppler|Transcranial Doppler (TCD) Ultrasonography|Transcranial Doppler Sonography|Transcranial Doppler Ultrasound	A diagnostic technique that uses pulsed Doppler ultrasound to measure the velocity of blood flow through the major blood vessels of the brain.	Transcranial Doppler Ultrasonography		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C122931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122931>	C62781	Imaging Transcranial Doppler Ultrasonography|Imaging TCD|Imaging Transcranial Doppler (iTCD) Ultrasonography|Imaging Transcranial Doppler Sonography|TCDI|iTCD	A diagnostic technique that uses pulsed Doppler ultrasound to both identify blood vessels in the brain and measure the velocity of blood flow through those vessels. It allows a more accurate estimation of stroke risk because it allows outlining of parenchymal structures and visualization of the examined vessels.			Diagnostic Procedure	
C122932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122932>	C12981	Ectopic Graft|Ectopic	A graft transferred from one organ site to another, within the same individual or between individuals.			Body Part, Organ, or Organ Component	
C122933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122933>	C12981	Normal Tissue Graft	A graft of normal tissue from one location to another, within the same individual or between individuals.			Body Part, Organ, or Organ Component	
C122934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122934>	C12981	Organ Graft|Organ Transplant	An organ that is transplanted from a donor to a recipient.			Body Part, Organ, or Organ Component	
C122935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122935>	C12981	Orthotopic Graft|Orthotopic	A graft transferred to the same anatomic site in another individual.			Body Part, Organ, or Organ Component	
C122936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122936>	C19812|C19260	Patient Derived Xenograft|PDTX|PDX|PDX|PDX Model|Patient-Derived Xenograft|Patient-Derived Xenograft Model|patient-derived xenograft	A mouse model for human cancer studies in which a human-derived tumor sample is transplanted into an immunodeficient mouse.	Patient Derived Xenograft		Experimental Model of Disease	CTRP Intervention Terminology|CTRP Terminology
C122937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122937>	C12981	Precancerous Tissue Graft|Precancer Tissue Graft	The transfer of premalignant tissue from one anatomic site to another, within the same individual or between individuals.			Body Part, Organ, or Organ Component	
C122938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122938>	C15342	Serial Transplantation	The transfer of a graft from a primary recipient into a secondary recipient.			Therapeutic or Preventive Procedure	
C122939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122939>	C12981	Syngeneic Graft|Isograft|Syngenic Graft	A graft transferred from a donor to a recipient with an identical, or immunologically compatible, genetic profile.			Body Part, Organ, or Organ Component	
C122940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122940>	C12981	Tissue Graft	The transfer of tissue from one anatomic site to another, within the same individual or between individuals, without transfer of the tissue's blood supply.			Body Part, Organ, or Organ Component	
C122941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122941>	C71164|C48686	Tumor Graft|Tumor Explant	The transfer of a tumor fragment into an ectopic or orthotopic site, within the same individual or between individuals.			Research Activity	
C122942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122942>	C120411	Leg Fatigue Right Now Question|Leg Fatigue Right Now|Leg Fatigue Right Now	A question about how an individual rates their leg fatigue right now.			Intellectual Product	Borg Category-Ratio 10 Scale Questionnaire
C122943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122943>	C173062	Dyspnea Right Now Question|Dyspnea Right Now|Dyspnea Right Now|Dyspnea Right Now Rating	A question about how an individual rates their dyspnea right now.			Intellectual Product	Borg Category-Ratio 10 Scale Questionnaire
C122944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122944>	C217121	Borg Category-Ratio 10 Scale Score 11 Point Scale	A scale for the subjective scoring of perceived exertion that ranges from 0: Nothing at all to 10: Maximal.			Intellectual Product	Borg Category-Ratio 10 Scale Questionnaire
C122945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122945>	C175273	Borg Category-Ratio 10 Perceived Exertion Score 0|No Exertion at All|Nothing at all	A subjective score of 0 on a perceived exertion scale that ranges from 0: Nothing at all to 10: Maximal.			Intellectual Product	Borg Category-Ratio 10 Scale Score 11 Point Scale
C122946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122946>	C175273	Borg Category-Ratio 10 Perceived Exertion Score 0.5|Very, Very Slight Exertion|Very, very slight (just noticeable)	A subjective score of 0.5 on a perceived exertion scale that ranges from 0: Nothing at all to 10: Maximal.			Intellectual Product	Borg Category-Ratio 10 Scale Score 11 Point Scale
C122947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122947>	C175273	Borg Category-Ratio 10 Perceived Exertion Score 1|Very Slight Exertion|Very slight	A subjective score of 1 on a perceived exertion scale that ranges from 0: Nothing at all to 10: Maximal.			Intellectual Product	Borg Category-Ratio 10 Scale Score 11 Point Scale
C122948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122948>	C175273	Borg Category-Ratio 10 Perceived Exertion Score 2|Slight|Slight Exertion	A subjective score of 2 on a perceived exertion scale that ranges from 0: Nothing at all to 10: Maximal.			Intellectual Product	Borg Category-Ratio 10 Scale Score 11 Point Scale
C122949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122949>	C175273	Borg Category-Ratio 10 Perceived Exertion Score 3|Moderate|Moderate Exertion	A subjective score of 3 on a perceived exertion scale that ranges from 0: Nothing at all to 10: Maximal.			Intellectual Product	Borg Category-Ratio 10 Scale Score 11 Point Scale
C12294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12294>	C12470	Skin of the Scalp and Neck|Skin of Scalp and Neck|Skin of scalp and neck	The integumentary covering of the scalp and neck.	Skin of Scalp and Neck		Anatomical Structure	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C122950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122950>	C175273	Borg Category-Ratio 10 Perceived Exertion Score 4|Somewhat Severe Exertion|Somewhat severe	A subjective score of 4 on a perceived exertion scale that ranges from 0: Nothing at all to 10: Maximal.			Intellectual Product	Borg Category-Ratio 10 Scale Score 11 Point Scale
C122951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122951>	C175273	Borg Category-Ratio 10 Perceived Exertion Score 5|Severe|Severe Exertion	A subjective score of 5 on a perceived exertion scale that ranges from 0: Nothing at all to 10: Maximal.			Intellectual Product	Borg Category-Ratio 10 Scale Score 11 Point Scale
C122952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122952>	C175273	Borg Category-Ratio 10 Perceived Exertion Score 6|Between Severe and Very severe|Severe to Very Severe Exertion	A subjective score of 6 on a perceived exertion scale that ranges from 0: Nothing at all to 10: Maximal.			Intellectual Product	Borg Category-Ratio 10 Scale Score 11 Point Scale
C122953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122953>	C175273	Borg Category-Ratio 10 Perceived Exertion Score 7|Very Severe Exertion|Very severe	A subjective score of 7 on a perceived exertion scale that ranges from 0: Nothing at all to 10: Maximal.			Intellectual Product	Borg Category-Ratio 10 Scale Score 11 Point Scale
C122954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122954>	C175273	Borg Category-Ratio 10 Perceived Exertion Score 8|Between Very severe and Very, very severe (almost maximal)|Very Severe to Very, Very Severe Exertion	A subjective score of 8 on a perceived exertion scale that ranges from 0: Nothing at all to 10: Maximal.			Intellectual Product	Borg Category-Ratio 10 Scale Score 11 Point Scale
C122955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122955>	C175273	Borg Category-Ratio 10 Perceived Exertion Score 9|Very, Very Severe Exertion|Very, very severe (almost maximal)	A subjective score of 9 on a perceived exertion scale that ranges from 0: Nothing at all to 10: Maximal.			Intellectual Product	Borg Category-Ratio 10 Scale Score 11 Point Scale
C122956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122956>	C175273	Borg Category-Ratio 10 Perceived Exertion Score 10|Maximal|Maximal Exertion	A subjective score of 10 on a perceived exertion scale that ranges from 0: Nothing at all to 10: Maximal.			Intellectual Product	Borg Category-Ratio 10 Scale Score 11 Point Scale
C122957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122957>	C91105	Borg Scale Rating of Perceived Exertion Questionnaire|BORG RPE SCALE|BRPE01|Borg RPE|Borg Scale Rating of Perceived Exertion Score 15 Point Scale	A scale for the subjective scoring of perceived exertion that ranges from 6: No exertion at all to 20: Maximal exertion. This scale was developed for use with healthy individuals where the score, multiplied by 10, might give an approximation of exercise heart rate.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C122958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122958>	C175271	Borg Scale Rating of Perceived Exertion Score 6|No exertion at all	A subjective score of 6 on a perceived exertion scale that ranges from 6: No exertion at all to 20: Maximal exertion.			Intellectual Product	Borg Scale Rating of Perceived Exertion Questionnaire
C122959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122959>	C175271	Borg Scale Rating of Perceived Exertion Score 7|Extremely Light Exertion|Extremely light	A subjective score of 7 on a perceived exertion scale that ranges from 6: No exertion at all to 20: Maximal exertion.			Intellectual Product	Borg Scale Rating of Perceived Exertion Questionnaire
C12295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12295>	C12470	Skin of the Trunk|SKIN OF THE TRUNK|Skin of Trunk|Skin of trunk|Superficial trunk|skin of trunk	The skin or integument surrounding the trunk of the body.	Skin of Trunk		Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C122960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122960>	C175271	Borg Scale Rating of Perceived Exertion Score 8|Between extremely light and very light|Extremely Light to Very Light Exertion	A subjective score of 8 on a perceived exertion scale that ranges from 6: No exertion at all to 20: Maximal exertion.			Intellectual Product	Borg Scale Rating of Perceived Exertion Questionnaire
C122961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122961>	C175271	Borg Scale Rating of Perceived Exertion Score 9|Very Light Exertion|Very light	A subjective score of 9 on a perceived exertion scale that ranges from 6: No exertion at all to 20: Maximal exertion.			Intellectual Product	Borg Scale Rating of Perceived Exertion Questionnaire
C122962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122962>	C175271	Borg Scale Rating of Perceived Exertion Score 10|Between very light and light|Very Light to Light Exertion	A subjective score of 10 on a perceived exertion scale that ranges from 6: No exertion at all to 20: Maximal exertion.			Intellectual Product	Borg Scale Rating of Perceived Exertion Questionnaire
C122963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122963>	C175271	Borg Scale Rating of Perceived Exertion Score 11|Light|Light Exertion	A subjective score of 11 on a perceived exertion scale that ranges from 6: No exertion at all to 20: Maximal exertion.			Intellectual Product	Borg Scale Rating of Perceived Exertion Questionnaire
C122964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122964>	C175271	Borg Scale Rating of Perceived Exertion Score 12|Between light and somewhat hard|Light to Somewhat Hard Exertion	A subjective score of 12 on a perceived exertion scale that ranges from 6: No exertion at all to 20: Maximal exertion.			Intellectual Product	Borg Scale Rating of Perceived Exertion Questionnaire
C122965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122965>	C175271	Borg Scale Rating of Perceived Exertion Score 13|Somewhat Hard Exertion|Somewhat hard	A subjective score of 13 on a perceived exertion scale that ranges from 6: No exertion at all to 20: Maximal exertion.			Intellectual Product	Borg Scale Rating of Perceived Exertion Questionnaire
C122966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122966>	C175271	Borg Scale Rating of Perceived Exertion Score 14|Between somewhat hard and hard (heavy)|Somewhat Hard to Hard Exertion	A subjective score of 14 on a perceived exertion scale that ranges from 6: No exertion at all to 20: Maximal exertion.			Intellectual Product	Borg Scale Rating of Perceived Exertion Questionnaire
C122967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122967>	C175271	Borg Scale Rating of Perceived Exertion Score 15|Hard (heavy)|Hard Exertion	A subjective score of 15 on a perceived exertion scale that ranges from 6: No exertion at all to 20: Maximal exertion.			Intellectual Product	Borg Scale Rating of Perceived Exertion Questionnaire
C122968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122968>	C175271	Borg Scale Rating of Perceived Exertion Score 16|Between hard (heavy) and very hard|Hard to Very Hard Exertion	A subjective score of 16 on a perceived exertion scale that ranges from 6: No exertion at all to 20: Maximal exertion.			Intellectual Product	Borg Scale Rating of Perceived Exertion Questionnaire
C122969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122969>	C175271	Borg Scale Rating of Perceived Exertion Score 17|Very Hard Exertion|Very hard	A subjective score of 17 on a perceived exertion scale that ranges from 6: No exertion at all to 20: Maximal exertion.			Intellectual Product	Borg Scale Rating of Perceived Exertion Questionnaire
C12296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12296>	C12470	Skin of the Upper Limb and Shoulder|Skin of Upper Limb and Shoulder|Skin of upper limb and shoulder	The integumentary covering of the upper limb and shoulder region.	Skin of Upper Limb and Shoulder		Anatomical Structure	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C122970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122970>	C175271	Borg Scale Rating of Perceived Exertion Score 18|Between very hard and extremely hard|Very Hard to Extremely Hard Exertion	A subjective score of 18 on a perceived exertion scale that ranges from 6: No exertion at all to 20: Maximal exertion.			Intellectual Product	Borg Scale Rating of Perceived Exertion Questionnaire
C122971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122971>	C175271	Borg Scale Rating of Perceived Exertion Score 19|Extremely Hard Exertion|Extremely hard	A subjective score of 19 on a perceived exertion scale that ranges from 6: No exertion at all to 20: Maximal exertion.			Intellectual Product	Borg Scale Rating of Perceived Exertion Questionnaire
C122972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122972>	C175271	Borg Scale Rating of Perceived Exertion Score 20|Maximal Exertion|Maximal exertion	A subjective score of 20 on a perceived exertion scale that ranges from 6: No exertion at all to 20: Maximal exertion.			Intellectual Product	Borg Scale Rating of Perceived Exertion Questionnaire
C122973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122973>	C91102	Have Ostomy Appliance Question|Do you have an ostomy appliance|Have Ostomy Appliance	A question about whether an individual has an ostomy appliance.			Intellectual Product	FACT-C Questionnaire
C122974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122974>	C173601	Embarrassed by Ostomy Appliance Question|Embarrassed by Ostomy Appliance|I am embarrassed by my ostomy appliance	A question about whether an individual is or was bothered by their ostomy appliance.			Intellectual Product	FACT-C Questionnaire
C122975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122975>	C173398	Caring for Ostomy Appliance is Difficult Question|Caring for Ostomy Appliance is Difficult|Caring for my ostomy appliance is difficult	A question about whether an individual thinks caring for their ostomy appliance is difficult.			Intellectual Product	FACT-C Questionnaire
C122976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122976>	C91105	FACT-B+4 Questionnaire|FACT-B+4	A subscale complement to the FACT-G developed specifically for use with the FACT-B questionnaire for evaluating the quality of life of breast cancer patients with lymphedema.			Intellectual Product	FACT-B Questionnaire
C122977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122977>	C173791	Side of Breast Operation Question|Breast Operation Laterality|Laterality of Breast Operation|On which side was your breast operation|Side of Breast Operation	A question about on which side an individual had breast surgery.			Intellectual Product	FACT-B+4 Questionnaire
C122978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122978>	C91126|C173791	Have Pain Moving Arm on Side of Breast Operation Question|Have Pain Moving Arm on Side of Breast Operation|Have Pain Moving Arm on Side of Breast Operation|Movement of my arm on this side is painful	A question about whether an individual has or had pain when moving their arm on the side of their breast surgery.			Intellectual Product	FACT-B+4 Questionnaire
C122979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122979>	C173791	Have Poor Range of Arm Movement on Side of Breast Operation Question|Have Poor Range of Arm Movement on Side of Breast Operation|I have a poor range of arm movements on this side	A question about whether an individual has or had poor range of arm movement on the side of their breast surgery.			Intellectual Product	FACT-B+4 Questionnaire
C12297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12297>	C12470	Skin of the Lower Limb and Hip|Skin of Lower Limb and Hip|Skin of lower limb and hip	The integumentary covering of the lower limb and hip region.	Skin of Lower Limb and Hip		Anatomical Structure	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C122980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122980>	C173791|C173734	Arm Feels Numb on Side of Breast Operation Question|Arm Feels Numb on Side of Breast Operation|My arm on this side feels numb	A question about whether an individual's arm feels or felt numb on the side of their breast surgery.			Intellectual Product	FACT-B+4 Questionnaire
C122981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122981>	C173791	Have Stiffness of Arm on Side of Breast Operation Question|Have Stiffness of Arm on Side of Breast Operation|I have stiffness of my arm on this side	A question about whether an individual has or had stiffness of their arm on the side of their breast surgery.			Intellectual Product	FACT-B+4 Questionnaire
C122982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122982>	C173981	Have Mouth Sores Question|Have Mouth Sores|I have mouth sores|Mouth sores	A question about whether an individual has or had mouth sores.			Intellectual Product	FACT-N Questionnaire|Memorial Symptom Assessment Scale - Short Form
C122983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122983>	C217122	National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy Prostate Symptom Index|FACT/NCCN-Prostate Symptom Index|FPSI-17|NCCN-FACT FPSI-17|National Comprehensive Cancer Network - Functional Assessment of Cancer Therapy Prostate Symptom Index	A 10 item symptom index scale developed from the FACT H&N questionnaire with the National Comprehensive Cancer Network to evaluate response to chemotherapy for patients with prostate cancer.			Intellectual Product	
C122984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122984>	C111063	Have Weakness in Legs Question|Have Leg Weakness|Have Weakness in Legs|I have weakness in my legs|My legs feel weak	A question about whether an individual has or had weakness in their legs.			Intellectual Product	Multidimensional Fatigue Symptom Inventory-Short Form|National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy Prostate Symptom Index
C122985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122985>	C27658|C173167	Nasal Chondromesenchymal Hamartoma|NCMH	A very rare benign lesion that arises from the nasal cavity and is characterized by the presence of cartilage, myxoid stroma, and other mesenchymal elements. It presents as a polypoid mass and usually affects infants and children.			Disease or Syndrome	
C122986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122986>	C308	Anti-IL-4/IL-13 Combination Agent QBX258|QBX-258|QBX258|VAK296 Plus QAX576|VAK296/QAX576|VAK694 Plus QAX576|VAK694/QAX576	A combination agent composed of the two human monoclonal antibodies VAK694 (VAK296), targeting interleukin-4 (IL-4), and QAX576, targeting IL-13, that can potentially be used to block signaling mediated by IL-4 and IL-13. Upon intravenous administration of the anti-IL-4/IL-13 co,mbination agent QBX258, the two antibodies VAK694 and QAX576 target and block the activity of the two cytokines IL-4 and IL-13, respectively, which prevents IL-4/IL-13-mediated signaling.  In patients with breast cancer related lymphedema (BCRL), this agent may prevent lymphedema-associated effects, such as fibrosis, hyperkeratosis, the deposition of fibroadipose tissue, fluid accumulation, limb swelling, reduction of skin elasticity, and pain. By reducing the excess volume, QBX258 may improve lymphatic and arm functions. The development of lymphedema after lymphatic injury is associated with tissue inflammation, the infiltration of CD4-positive cells and their differentiation to the type 2 helper T-cell (Th2) phenotype. Th2 cells produce IL-4 and IL-13 that play a key role in the development of lymphedema-associated symptoms as well as other Th2-mediated diseases.	Anti-IL-4/IL-13 Combination Agent QBX258		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C122987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122987>	C1509	Scyllitol|(1r,2r,3r,4r,5r,6r)-Cyclohexane-1,2,3,4,5,6-Hexol|1,3,5/2,4,6-Cyclohexanehexol|AXD 103|AZD-103|AZD103|Cocositol|Cyclohexane-1,2,3,4,5,6-Hexol|ELND005|Quercinitol|SCYLLO-INOSITOL|Scyllo-Inositol	A stereoisomer of inositol and a plant sugar alcohol found most abundantly in coconut palm trees, with potential amyloid plaque formation inhibitory activity. Following oral administration, scyllitol crosses the blood brain barrier and inhibits amyloid beta plaque formation in the brain through as of yet unknown mechanism(s). This may lead to reduced disease progression and improvement in cognitive function in patients with Alzheimer disease.	Scyllitol		Organic Chemical|Pharmacologic Substance	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C122988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122988>	C879	Thromboxane A2|(5Z,13E)-(15S)-9alpha,11alpha-Epoxy-15-Hydroxythromboxa-5,13-Dienoate|(5Z,13E,15S)-9alpha,11alpha-Epoxy-15-Hydroxythromboxa-5,13-Dien-1-Oic Acid|(5Z,9alpha,11alpha,13E,15S)-9,11-Epoxy-15-Hydroxythromboxa-5,13-Dien-1-Oic Acid|5-Heptenoic Acid, 7-(3-(3-Hydroxy-1-Octenyl)-2,6-Dioxabicyclo(3.1.1)Hept-4-Yl)-, (1S-(1alpha,3alpha,3R*),4beta(Z),5alpha)-|9S,11S-Epoxy,15S-Hydroxy-Thromboxa-5Z,13E-Dien-1-Oic Acid|THROMBOXANE A2|TXA-2|TXA2|Thromboxa-5,13-Dien-1-Oic Acid, 9,11-Epoxy-15-Hydroxy-, (5Z,9alpha,11alpha,13E,15S)-	An eicosanoid and short-lived intermediate product between prostaglandin endoperoxides and thromboxane B2, with prothrombotic and vasoconstrictive activities. Thromboxane A (TXA2) binds to its cognate receptor thromboxane A2 receptor (TBXA2R) and stimulates increased expression of glycoprotein IIb/IIIa (GPIIb/IIIa) on platelet membranes, which induces platelet activation and aggregation. Circulating fibrinogen binds to GPIIb/IIIa on platelet surfaces, which promotes clotting. TXA2 also binds to TBXA2R expressed by glomerular cells, which induces signaling pathways that promote vasoconstriction.	Thromboxane A2		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C122989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122989>	C503	DAPI|1H-Indole-6-Carboximidamide, 2-(4-(Aminoiminomethyl)phenyl)-|2-(4-(Aminoiminomethyl)phenyl)-1H-Indole-6-Carboximidamide|2-(4-(Aminoiminomethyl)phenyl)-1H-Indole-6-Carboximidamide|2-(4-Carbamimidoylphenyl)-1H-Indole-6-Carboximidamide|4',6-Diamidino-2-Phenylindole|4',6-Diamidinophenyl-Indole|4',6-Diamino-2-Phenylindol|BRN 3557399|DATI|Indole-6-Carboximidamide, 2-(4-(Aminoiminomethyl)phenyl)-	A lipid soluble fluorochrome dye that binds to adenine-thymine (A-T) rich regions in DNA and, to a lesser extent, RNA. During fluorescence microscopy and flow cytometry, this agent binds to and detects endogenous and exogenous DNA in cellular samples. DAPI is excited with ultraviolet (UV) light (maximum absorption at 358 nm) and upon binding, emits light in the blue portion of the spectrum (461 nm for DNA and ~500 nm for RNA).	DAPI		Indicator, Reagent, or Diagnostic Aid	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C12298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12298>	C12680	Retroperitoneum|RETROPERITONEUM|Retroperitoneal Cavity|Retroperitoneal Space|retroperitoneal space|retroperitoneum|spatium retroperitoneale	The back of the abdomen where the kidneys lie and the great blood vessels run.	Retroperitoneum		Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|GCT Authorized Value Terminology|GCT Biopsy/Surgical Procedures Table|GCT Radiation Therapy Table|GCT Tumor Assessment Table|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C122990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122990>	C117719	Penile Chordee	Congenital curvature of the penis.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C122991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122991>	C27600	Renal Hypertrophy|Hypertrophy of the Kidney	Global enlargement of the renal parenchyma in one or both kidneys.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C122992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122992>	C3970	Solitary Cyst of Kidney|Solitary Renal Cyst	A single cyst located in the kidney.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C122993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122993>	C91105	Duke Psychosocial Questionnaire	A questionnaire designed to evaluate the psychosocial effects of exercise on patients with prostate cancer.			Intellectual Product	
C122994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122994>	C173458	How Motivated to Exercise Question|How Motivated to Exercise|How motivated are you to exercise	A question about an individual's motivation level for exercise.			Intellectual Product	Duke Psychosocial Questionnaire
C122995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122995>	C173086	Confidence that You Could Exercise Question|Confidence that You Could Exercise|How Confident that You Could Exercise|How confident are you that you could exercise	A question about an individual's confidence that they can exercise.			Intellectual Product	Duke Psychosocial Questionnaire
C122996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122996>	C25616	30 Minutes per Day for 5 Days a Week Over Next 24 Weeks|30 minutes a day at least 5 days a week over the next 24 weeks	A time period of 30 minutes per day for 5 days per week over the next 24 weeks.			Temporal Concept	Duke Psychosocial Questionnaire
C122997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122997>	C121547	Motivation Visual Analogue Scale|Motivation VAS	A scale for the subjective scoring of an individual's motivation that ranges from 1: Not at all motivated to 7: Extremely motivated.			Intellectual Product	Duke Psychosocial Questionnaire
C122998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122998>	C121547	Confidence Visual Analogue Scale|Confidence VAS	A scale for the subjective scoring of an individual's confidence that ranges from 1: Not at all confident to 7: Extremely confident.			Intellectual Product	Duke Psychosocial Questionnaire
C122999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C122999>	C175260	Motivation Score 1	A subjective score of 1 on a motivation scale that ranges from 1: Not at all motivated to 7: Extremely motivated.			Intellectual Product	Duke Psychosocial Questionnaire
C12299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12299>	C13020	Nipple|NIPPLE|nipple|nipple	The pigmented protuberance on the surface of the breast through which milk is drawn from the breast.	Nipple		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C1229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1229>	C275	Sodium Selenate|SODIUM SELENATE|Selenate, Sodium	The sodium salt of selenium.  As a trace mineral that is toxic in high doses, selenium is a cofactor for glutathione peroxidase, an anti-oxidant enzyme that neutralizes hydrogen peroxide.  Selenium may be chemoprotective for certain cancers, particularly prostate cancer.  High dietary supplementation with sodium selenate may inhibit the progression of hormone-refractory prostate cancer due, in part, to an antiangiogenesis effect. (NCI04)			Inorganic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C123000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123000>	C175260	Motivation Score 2	A subjective score of 2 on a motivation scale that ranges from 1: Not at all motivated to 7: Extremely motivated.			Intellectual Product	Duke Psychosocial Questionnaire
C123001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123001>	C175260	Motivation Score 3	A subjective score of 3 on a motivation scale that ranges from 1: Not at all motivated to 7: Extremely motivated.			Intellectual Product	Duke Psychosocial Questionnaire
C123002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123002>	C175260	Motivation Score 4	A subjective score of 4 on a motivation scale that ranges from 1: Not at all motivated to 7: Extremely motivated.			Intellectual Product	Duke Psychosocial Questionnaire
C123003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123003>	C175260	Motivation Score 5	A subjective score of 5 on a motivation scale that ranges from 1: Not at all motivated to 7: Extremely motivated.			Intellectual Product	Duke Psychosocial Questionnaire
C123004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123004>	C175260	Motivation Score 6	A subjective score of 6 on a motivation scale that ranges from 1: Not at all motivated to 7: Extremely motivated.			Intellectual Product	Duke Psychosocial Questionnaire
C123005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123005>	C175260	Motivation Score 7	A subjective score of 7 on a motivation scale that ranges from 1: Not at all motivated to 7: Extremely motivated.			Intellectual Product	Duke Psychosocial Questionnaire
C123006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123006>	C175269	Confidence Score 1	A subjective score of 1 on a confidence scale that ranges from 1: Not at all confident to 7: Extremely confident.			Intellectual Product	Duke Psychosocial Questionnaire
C123007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123007>	C175269	Confidence Score 2	A subjective score of 2 on a confidence scale that ranges from 1: Not at all confident to 7: Extremely confident.			Intellectual Product	Duke Psychosocial Questionnaire
C123008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123008>	C175269	Confidence Score 3	A subjective score of 3 on a confidence scale that ranges from 1: Not at all confident to 7: Extremely confident.			Intellectual Product	Duke Psychosocial Questionnaire
C123009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123009>	C175269	Confidence Score 4	A subjective score of 4 on a confidence scale that ranges from 1: Not at all confident to 7: Extremely confident.			Intellectual Product	Duke Psychosocial Questionnaire
C12300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12300>	C13020	Central Portion of the Breast|Central Portion of Breast|Central portion of breast	The part of the breast which is in the center.	Central Portion of Breast		Body Part, Organ, or Organ Component	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C123010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123010>	C175269	Confidence Score 5	A subjective score of 5 on a confidence scale that ranges from 1: Not at all confident to 7: Extremely confident.			Intellectual Product	Duke Psychosocial Questionnaire
C123011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123011>	C175269	Confidence Score 6	A subjective score of 6 on a confidence scale that ranges from 1: Not at all confident to 7: Extremely confident.			Intellectual Product	Duke Psychosocial Questionnaire
C123012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123012>	C175269	Confidence Score 7	A subjective score of 7 on a confidence scale that ranges from 1: Not at all confident to 7: Extremely confident.			Intellectual Product	Duke Psychosocial Questionnaire
C123013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123013>	C34843	Chronic Urate Nephropathy	Chronic kidney disease resulting from deposition of urate crystals or microtophi in the medullary interstitium.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123014>	C26834	Drug-Induced Tubulointerstitial Nephritis	Tubulointerstitial nephritis resulting from a drug exposure.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123015>	C120887	Glomerulocystic Disease|Glomerulocystic Kidney Disease	A condition characterized by dilatation of the Bowman space and affecting more than 5% of the glomeruli.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123016>	C26686	Perinephric Abscess	An abscess that is located outside the renal capsule, but which is within Gerota's space.			Finding	NICHD Terminology|Pediatric Infectious Disease Terminology|Pediatric Nephrology Terminology
C123017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123017>	C26686	Renal Abscess|Kidney Abscess	An abscess that is located within the renal parenchyma.			Finding	NICHD Terminology|Pediatric Infectious Disease Terminology|Pediatric Nephrology Terminology
C123018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123018>	C28193|C129748	Renal Cysts and Diabetes Syndrome|HNF1B-Related Autosomal Dominant Tubulointerstitial Kidney Disease|Hepatocyte Nuclear Factor 1-Beta-Associated Monogenic Diabetes|Hepatocyte Nuclear Factor 1-Beta-Associated Monogenic Diabetes|MODY5|Maturity Onset Diabetes of the Young, Type 5|Maturity Onset Diabetes of the Young, Type 5|RCAD|RCAD|RCAD Syndrome	Monogenic diabetes caused by inactivating mutation(s) in the gene HNF1B, encoding hepatocyte nuclear factor 1-beta. In addition to diabetes, this condition may be associated with renal cysts and urogenital anomalies. Homozygous HNF1B mutations result in permanent neonatal diabetes.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology|Pediatric Nephrology Terminology
C12301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12301>	C13020	Upper-Inner Quadrant of the Breast|Upper-Inner Quadrant of Breast|Upper-inner quadrant of breast|upper inner quadrant of breast	The quarter of the breast which is superior and medial.	Upper-inner Quadrant of Breast		Body Location or Region	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C123020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123020>	C171226	Renal Tuberculosis	Infection of the kidney due to mycobacteria.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123021>	C28193	Tubulointerstitial Nephritis and Uveitis|TINU	An autoimmune disorder comprising tubulointerstitial nephritis and uveitis.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123022>	C26784	IgM - Associated Nephropathy	A condition characterized by deposition of IgM antibody in the glomerulus.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123023>	C34645	Membranous Lupus Nephritis	Membranous nephritis associated with systemic lupus erythematosus.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123024>	C34843	Acute Uric Acid Nephropathy	Kidney damage resulting from uric acid precipitation within the renal tubules.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123025>	C34843	Aristolochic Acid Nephropathy|Balkan Endemic Nephropathy|Balkan Endemic Nephropathy|Balkan Nephropathy|Chinese Herb Endemic Nephropathy|Endemic Nephropathy	Chronic tubulointerstitial disease resulting from aristolochic acid.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123026>	C98885	Congenital Renal Hypoplasia	The underdevelopment of otherwise normal renal parenchyma, characterized by decreased nephron size and possibly a decreased number of nephrons at birth.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123027>	C34843	Hantavirus Nephropathy	Tubulointerstitial hemorrhage resulting from hantavirus infection.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123028>	C34843	Heavy-Metal-Induced Nephropathy	Damage to the kidney and renal tubules resulting from heavy metal exposure.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123029>	C34843	Leptospirosis Nephropathy|Leptospiral Nephropathy	Interstitial nephritis due to Leptospira, which may be associated with non-oliguric acute kidney injury.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C12302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12302>	C13020	Lower-Inner Quadrant of the Breast|Lower-Inner Quadrant of Breast|Lower-inner quadrant of breast|lower inner quadrant of breast	The quarter of the breast which is inferior and medial.	Lower-inner Quadrant of Breast		Body Location or Region	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C123030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123030>	C114688	Magnesium Ammonium Phosphate Urolithiasis|Struvite Urolithiasis	Urolithiasis in which the composition of the stone(s) is predominantly magnesium ammonium phosphate.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123031>	C34750	Multicystic Dysplastic Kidney	Abnormal development of the kidney that is characterized by atretic ureter, multiple cysts of different sizes that are separated by dysplastic parenchyma, and complete lack of function.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123032>	C34843	Pyonephrosis	Pus within the collecting system of the kidney.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123033>	C34843	Radiation Nephropathy	Tissue damage to the glomerulus and renal tubules resulting from irradiation, which is characterized by vascular endothelial damage, mesangial damage, platelet aggregation in the capillary loops, thickening of the glomerular arteriolar intimal layer, and atrophic tubules.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123034>	C3847	Renal Dysplasia Due to Fetal Exposure to ACE Inhibitor or ARB|Tubular Dysgenesis related to Fetal Exposure to ACE Inhibitor or ARB	Tubular dysgenesis resulting from maternal exposure to a class of drugs known as angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB).			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123035>	C34843	Schistosomiasis Nephropathy	Kidney disease associated with Schistosoma infection. Injury to the kidney may be a result of immunologically mediated glomerular or interstitial injury and/or a result of reflux nephropathy.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123036>	C34843	Tubulointerstitial Disease|Tubulointerstitial disease	Disease affecting the renal tubules and interstitium of the kidney.			Disease or Syndrome	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|NICHD Terminology|Pediatric Nephrology Terminology
C123037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123037>	C114667	Uric Acid Nephrolithiasis	Nephrolithiasis in which the composition of the stone(s) is predominantly uric acid.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123038>	C34965	Xanthogranulomatous Pyelonephritis	Chronic, destructive infection of the kidney characterized by lipid-laden macrophages in the setting of obstruction secondary to infected renal stones, most commonly caused by Proteus or Escherichia coli.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123039>	C34644	Dense Deposit Disease|Membranoproliferative Glomerulonephritis Type 2|Mesangiocapillary Glomerulonephritis Type 2	Proliferative glomerulonephritis characterized by activation of the alternative complement pathway, resulting in mesangial hypercellularity, endocapillary proliferation, and glomerular basement membrane intramembranous highly electron dense deposits.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C12303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12303>	C13020	Upper-Outer Quadrant of the Breast|Upper-outer quadrant of breast|upper outer quadrant of breast	The quarter of the breast which is superior and lateral.	Upper-outer Quadrant of Breast		Body Location or Region	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C123040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123040>	C120887	Glomerulomegaly	Glomerular enlargement greater than the fiftieth percentile.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123042>	C37308	Obesity Related Glomerulopathy	Diffuse glomerular (greater than 50% of glomeruli) hypertrophy (greater than 250 micron diameter) that occurs in the context of obesity.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123043>	C26784	C3 Glomerulonephritis|Complement-Mediated Membranoproliferative Glomerulonephritis	Glomerulonephritis characterized by C3 accumulation with little or absent deposition of immunoglobulin, in the absence of ultrastructural electron-dense transformation seen in dense deposit disease.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123044>	C120887	Collapsing Glomerulopathy	Segmental or global glomerulopathy with tuft wrinkling, collapse and contraction without increased matrix or cells, but with adjacent podocyte hypertrophy and hyperplasia.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123045>	C35337	Congenital Nephrotic Syndrome - Cytomegalovirus Associated|Cytomegalovirus Associated Congenital Nephrotic Syndrome	Nephrotic syndrome associated with a cytomegalovirus infection, most commonly presenting in the first three months of life.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123046>	C35337	Congenital Nephrotic Syndrome - Infection Associated|Infection Associated Congenital Nephrotic Syndrome	Nephrotic syndrome presenting within the first three months of life, and which is associated with an infectious process.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123047>	C35337	Congenital Nephrotic Syndrome - Rubivirus Associated|Rubivirus Associated Congenital Nephrotic Syndrome	Nephrotic syndrome associated with rubella, most commonly presenting in the first three months of life.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123048>	C35337	Congenital Nephrotic Syndrome - Toxoplasma Associated|Toxoplasma Associated Congenital Nephrotic Syndrome	Nephrotic syndrome associated with toxoplasmosis, most commonly presenting in the first three months of life.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123049>	C35337	Congenital Nephrotic Syndrome - Treponema Pallidum Associated|Treponema Pallidum Associated Congenital Nephrotic Syndrome	Nephrotic syndrome associated with syphilis, most commonly presenting in the first three months of life.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C12304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12304>	C13020	Lower-Outer Quadrant of the Breast|Lower-Outer Quadrant of Breast|Lower-outer quadrant of breast|lower outer quadrant of breast	The quarter of the breast which is inferior and lateral.	Lower-outer Quadrant of Breast		Body Location or Region	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C123050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123050>	C26784	Cryoglobulinemic Glomerulonephritis	Glomerulonephritis in the context of cryoglobulinemia.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123051>	C37308	Focal Segmental Glomerulosclerosis Cellular Variant|FSGS Cellular Variant	A variant of FSGS characterized by hypercellularity of the glomerulus; this excludes the tip and collapsing FSGS. (D'Agati VD, et al. "Pathologic Classification of Focal Segmental Glomerulosclerosis: A Working Proposal." Am J Kidney Dis 43.2 (2004): 368-82.)			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123052>	C37308	Focal Segmental Glomerulosclerosis Collapsing Variant|FSGS Collapsing Variant	A variant of FSGS characterized by glomerular tuft collapse, which may result in scarring. (D'Agati VD, et al. "Pathologic Classification of Focal Segmental Glomerulosclerosis: A Working Proposal." Am J Kidney Dis 43.2 (2004): 368-82.)			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123053>	C37308	Focal Segmental Glomerulosclerosis Perihilar Variant|FSGS Perihilar Variant	A variant of FSGS characterized by scarring of the glomerulus where at least 50% of the scars are adjacent to the hilum and must have hyalinosis; this excludes cellular, tip and collapsing FSGS. (D'Agati VD, et al. "Pathologic Classification of Focal Segmental Glomerulosclerosis: A Working Proposal." Am J Kidney Dis 43.2 (2004): 368-82.)			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123054>	C37308	Focal Segmental Glomerulosclerosis Tip Lesion Variant|FSGS Tip Lesion Variant	A variant of FSGS characterized by scarring of the glomerulus adjacent to the origin of the proximal convoluted tubule; this occurs in the absence of collapsing and perihilar FSGS. (D'Agati VD, et al. "Pathologic Classification of Focal Segmental Glomerulosclerosis: A Working Proposal." Am J Kidney Dis 43.2 (2004): 368-82.)			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123055>	C34644	Immune Complex Mediated Membranoproliferative Glomerulonephritis|Membranoproliferative Glomerulonephritis Type I|Mesangiocapillary Glomerulonephritis Type 1	Glomerulonephritis characterized by mesangial proliferation, endocapillary proliferation, and glomerular capillary wall remodeling with immune complex deposits from classical complement pathway activation.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123056>	C34644	Membranoproliferative Glomerulonephritis Type 3 (AQ)|Mesangiocapillary Glomerulonephritis Type 3	Glomerulonephritis similar in appearance under light microscopy to membranoproliferative glomerulonephritis (MPGN) I, but with subepithelial or transmembranous and subendothelial deposits on electron microscopy.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123057>	C34645	Membranous Nephropathy - Autoimmune Disorder Associated	Membranous nephropathy associated with an autoimmune disorder.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123059>	C34645	Membranous Nephropathy - Drug Associated|Drug Associated Membranous Nephropathy	Membranous nephropathy associated with exposure to a drug.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C12305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12305>	C13020	Axillary Tail of the Breast|Axillary Process of Breast|Axillary Tail of Breast|Axillary tail of breast|Tail of Spence|axillary tail of breast	The superolateral extension of the mammary gland into the axilla that consists of fibroadipose tissue, lymph nodes, and lymphatics.	Axillary Tail of Breast		Body Part, Organ, or Organ Component	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C123060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123060>	C34645	Membranous Nephropathy - Idiopathic|Idiopathic Membranous Glomerulopathy|Idiopathic Membranous Nephropathy	Membranous nephropathy for which no cause has been identified.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123061>	C34645	Membranous Nephropathy - Infection Associated	Membranous nephropathy associated with infectious disease.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123062>	C34645	Membranous Nephropathy - Malignancy Associated|Malignancy Associate Membranous Nephropathy	Membranous nephropathy in the context of malignancy.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123063>	C34645	Membranous Nephropathy - NEP Induced|NEP Induced Membranous Nephropathy|Neural Endopeptidase Induced Membranous Nephropathy	Membranous nephropathy due to neural endopeptidase (NEP) antibodies.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123064>	C34645	Membranous Nephropathy - PLA2R Induced|PLA2R Induced Membranous Nephropathy|Phospholipase 2 Receptor Membranous Nephropathy	Membranous nephropathy due to phospholipase 2 receptor (PLA2R) antibodies.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123065>	C34645	Membranous Nephropathy - THSD7A Induced|THSD7A Induced Membranous Nephropathy|Thrombospondin Type-1 domain-containing Protein Membranous Nephropathy	Membranous nephropathy due to thrombospondin type-1 domain-containing protein 7A (THSD7A) antibodies.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123066>	C38012	Nephrotic Range Proteinuria	In children, urine protein greater than or equal to 40mg/m^2/h; alternatively, greater than or equal to 0.25gm/mmol creatinine or 2gm/gm creatinine obtained from a first morning specimen.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123067>	C34845	Nephrotic Syndrome - ACTN4 Associated	Nephrotic syndrome attributed to mutation(s) in the ACTN4 gene.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123068>	C34845	Nephrotic Syndrome - ADCK4 Associated	Nephrotic syndrome attributed to mutation(s) in the ADCK4 gene.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123069>	C34845	Nephrotic Syndrome - ANLN Associated	Nephrotic syndrome attributed to mutation(s) in the ANLN gene.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C12306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12306>	C52559	Labium Majus|LABIUM MAJUS|Labia Majora|Labia Majus|Labium majus	One of the two longitudinal folds of skin that form the lateral boundary of the vulva. It extends from the mons pubis to the perineum.	Labium Majus		Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C123070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123070>	C34845	Nephrotic Syndrome - ARHGAP24 Associated	Nephrotic syndrome attributed to mutation(s) in the ARHGAP24 gene.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123071>	C34845	Nephrotic Syndrome - ARHGDIA Associated	Nephrotic syndrome attributed to mutation(s) in the ARHGDIA gene.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123072>	C34845	Nephrotic Syndrome - CD2AP Associated	Nephrotic syndrome attributed to mutation(s) in the CD2AP gene.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123073>	C34845	Nephrotic Syndrome - CFH Associated	Nephrotic syndrome attributed to mutation(s) in the CFH gene.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123074>	C34845	Nephrotic Syndrome - COQ2 Associated	Nephrotic syndrome attributed to mutation(s) in the COQ2 gene.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123075>	C34845	Nephrotic Syndrome - COQ6 Associated	Nephrotic syndrome attributed to mutation(s) in the COQ6 gene.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123076>	C34845	Nephrotic Syndrome - CRB2 Associated	Nephrotic syndrome attributed to mutation(s) in the CRB2 gene.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123077>	C34845	Nephrotic Syndrome - CUBN Associated	Nephrotic syndrome attributed to mutation(s) in the CUBN gene.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123078>	C34845	Nephrotic Syndrome - Cytomegalovirus Associated|Cytomegalovirus Associated Nephrotic Syndrome	Nephrotic syndrome associated with a cytomegalovirus infection.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123079>	C34845	Nephrotic Syndrome - DGKE Associated	Nephrotic syndrome attributed to mutation(s) in the DGKE gene.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C12307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12307>	C52559	Labium Minus|LABIUM MINUS|Labia Minora|Labia Minus|Labium minus	One of the two longitudinal folds of skin located between the labia majora.	Labium Minus		Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C123080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123080>	C34845	Nephrotic Syndrome - EMP2 Associated	Nephrotic syndrome attributed to mutation(s) in the EMP2 gene.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123081>	C34845	Nephrotic Syndrome - Epstein-Barr Virus Associated|Epstein-Barr Virus Associated Nephrotic Syndrome	Nephrotic syndrome associated with Epstein-Barr infection.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123082>	C34845	Nephrotic Syndrome - Hepatitis B Virus Associated|Hepatitis B Virus Associated Nephrotic Syndrome	Nephrotic syndrome associated with hepatitis B.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123083>	C34845	Nephrotic Syndrome - Hepatitis C Virus Associated|Hepatitis C Virus Associated Nephrotic Syndrome	Nephrotic syndrome associated with a hepatitis C infection.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123084>	C34845	Nephrotic Syndrome - Human Immunodeficiency Virus Associated|Human Immunodeficiency Virus Associated Nephrotic Syndrome	Nephrotic syndrome associated with human immunodeficiency virus infection.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123085>	C34845	Nephrotic Syndrome - INF2 Associated	Nephrotic syndrome attributed to mutation(s) in the INF2 gene.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123086>	C34845	Nephrotic Syndrome - Infection Associated|Infection Associated Nephrotic Syndrome	Nephrotic syndrome associated with an infectious process.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123087>	C34845	Nephrotic Syndrome - ITGA3 Associated	Nephrotic syndrome attributed to mutation(s) in the ITGA3 gene.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123088>	C34845	Nephrotic Syndrome - ITGB4 Associated	Nephrotic syndrome attributed to mutation(s) in the ITGB4 gene.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123089>	C34845	Nephrotic Syndrome - LAMB2 Associated	Nephrotic syndrome attributed to mutation(s) in the LAMB2 gene.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C12308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12308>	C13039	Clitoris|CLITORIS|clitoris	The erectile tissue in the vulva. It is composed of the corpora cavernosa and the glans clitoris.	Clitoris		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C123090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123090>	C34845	Nephrotic Syndrome - LMX1B Associated	Nephrotic syndrome attributed to mutation(s) in the LMX1B gene.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123091>	C34845	Nephrotic Syndrome - Malaria Associated|Malaria Associated Nephrotic Syndrome	Nephrotic syndrome associated with malaria.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123092>	C34845	Nephrotic Syndrome - MEFV Associated	Nephrotic syndrome attributed to mutation(s) in the MEFV gene.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123093>	C34845	Nephrotic Syndrome - MYO1E Associated	Nephrotic syndrome attributed to mutation(s) in the MYO1E gene.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123094>	C34845	Nephrotic Syndrome - NEIL1 Associated	Nephrotic syndrome attributed to mutation(s) in the NEIL1 gene.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123095>	C34845	Nephrotic Syndrome - NPHS2 Associated	Nephrotic syndrome attributed to mutation(s) in the NPHS2 gene.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Nephrology Terminology
C123096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123096>	C34845	Nephrotic Syndrome - Parvovirus B19 Associated|Parvovirus B19 Associated Nephrotic Syndrome	Nephrotic syndrome associated with a parvovirus B19 infection.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123097>	C34845	Nephrotic Syndrome - PDSS2 Associated	Nephrotic syndrome attributed to mutation(s) in the PDSS2 gene.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123098>	C34845	Nephrotic Syndrome - PLCE1 Associated	Nephrotic syndrome attributed to mutation(s) in the PLCE1 gene.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123099>	C34845	Nephrotic Syndrome - PTPRO Associated|Nephrotic Syndrome - GLEPP1 Associated	Nephrotic syndrome attributed to mutation(s) in the PTPRO gene.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C12309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12309>	C13039	Endocervix|ENDOCERVIX|Endocervical|endocervix	The portion of the cervix which is lined by single columnar epithelium (mucosa).	Endocervix		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C1230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1230>	C78283|C2459	Sodium Thiosulfate|Cyanide Antidote Package|Disodium Thiosulfate|Disodium thiosulfate|S-Hydril|S-Hydril|SODIUM THIOSULFATE|Sodium Hyposulfate|Sodium Thiosulfate Pentahydrate|Sodium Thiosulphate|Sodium thiosulfate|Sodothiol|Thiosulfate, Sodium, Pentahydrate|Thiosulfuric Acid Disodium Salt|Thiosulfuric acid disodium salt|sodium thiosulfate	A water soluble salt and reducing agent that reacts with oxidizing agents.  Although its exact mechanism of action is unknown, thiosulfate likely provides an exogenous source of sulfur, thereby hastening the detoxification of cyanide through the enzyme rhodanese (thiosulfate cyanide sulfurtransferase) which converts cyanide to the relatively nontoxic, excretable thiocyanate ion. In addition, this agent neutralizes the reactive alkylating species of nitrogen mustard, thereby decreasing skin toxicity related to nitrogen mustard extravasation. (NCI04)	Sodium Thiosulfate		Inorganic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GCT Authorized Value Terminology|GCT Concomitant Medication Table|NCI Drug Dictionary Terminology
C123100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123100>	C34845	Nephrotic Syndrome - SCARB2 Associated	Nephrotic syndrome attributed to mutation(s) in the SCARB2 gene.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123101>	C34845|C188271	Nephrotic Syndrome - Simian Virus 40 Associated|Simian Virus 40 Associated Nephrotic Syndrome	Nephrotic syndrome associated with a simian virus 40 infection.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123102>	C34845	Nephrotic Syndrome - SMARCAL1 Associated	Nephrotic syndrome attributed to mutation(s) in the SMARCAL1 gene.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123103>	C34845	Nephrotic Syndrome - Syphilis Associated|Syphilis Associated Nephrotic Syndrome	Nephrotic syndrome associated with a syphilis infection.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123104>	C34845	Nephrotic Syndrome - Toxoplasmosis Associated|Toxoplasmosis Associated Nephrotic Syndrome	Nephrotic syndrome associated with a toxoplasmosis infection.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123105>	C34845	Nephrotic Syndrome - TRPC6 Associated	Nephrotic syndrome attributed to mutation(s) in the TRPC6 gene.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123106>	C34845	Nephrotic Syndrome - WT1 Associated	Nephrotic syndrome attributed to mutation(s) in the WT1 gene.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Nephrology Terminology
C123108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123108>	C26784	Pauci-Immune Glomerulonephritis - ANCA Negative|Pauci-immune Glomerulonephritis - ANCA Negative	Glomerulonephritis with paucity of glomerular staining for immunoglobulins that may be accompanied by systemic, small vessel vasculitis containing no anti neutrophil cytoplasm antibody (ANCA).			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123109>	C26784	Pauci-Immune Glomerulonephritis - Renal Limited|Pauci-immune Glomerulonephritis - Renal Limited	Glomerulonephritis in which anti-neutrophil cytoplasm antibody (ANCA) is almost always present and vasculitis is limited to the kidney.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C12310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12310>	C13039	Ectocervix|Exocervix|Exocervix|Exocervix|ectocervical|ectocervix	The portion of the cervix that extends into the vaginal vault, and is lined with stratified squamous epithelium.	Exocervix		Body Part, Organ, or Organ Component	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C123110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123110>	C26784	Pauci-Immune Glomerulonephritis associated with Eosinophilic Granulomatosis with Polyangiitis|Churg-Strauss Syndrome Associated Glomerulonephritis|Pauci-immune Glomerulonephritis associated with Eosinophilic Granulomatosis with Polyangiitis	Glomerulonephritis in the context of eosinophilic-rich granulomatosis with polyangiitis, eosinophilia, asthma and commonly anti-neutrophil cytoplasmic antibody.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123111>	C26784	Pauci-Immune Glomerulonephritis associated with Granulomatosis with Polyangiitis|Pauci-immune Glomerulonephritis associated with Granulomatosis with Polyangiitis	Glomerulonephritis in the context of granulomatosis with polyangiitis in which anti-neutrophil cytoplasm antibody (ANCA) is almost always present.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123112>	C26784	Pauci-Immune Glomerulonephritis associated with Microscopic Polyangiitis|Pauci-immune Glomerulonephritis associated with Microscopic Polyangiitis	Glomerulonephritis in the context of systemic, small vessel vasculitis in which anti neutrophil cytoplasm antibody (ANCA) is almost always present.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123113>	C120887	Primary Collapsing Glomerulopathy	Collapsing glomerulopathy for which no underlying cause has been identified.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123114>	C120887	Secondary Collapsing Glomerulopathy	Collapsing glomerulopathy for which an underlying cause has been identified.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123115>	C34789	Systemic Lupus Erythematosus Nephritis Class I|Minimal Mesangial Lupus Nephritis	Systemic lupus erythematosus nephritis that appears normal under light microscopy, but with evidence of immune deposits by immunofluorescence. (Weening, Jan J. et al. (2004). The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited. Journal of the American Society of Nephrology 15(2), 241-50.)			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123116>	C34789	Systemic Lupus Erythematosus Nephritis Class II|Mesangial Proliferative Lupus Nephritis	Systemic lupus erythematosus nephritis exhibiting mesangial hypercellularity or mesangial expansion by light microscopy, with mesangial immune deposits. Isolated subepithelial or subendothelial deposits may be visible by immunofluorescence or electron microscopy, but not by light microscopy. (Weening, Jan J. et al. (2004). The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited. Journal of the American Society of Nephrology 15(2), 241-50.)			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123117>	C34789	Systemic Lupus Erythematosus Nephritis Class III|Focal Lupus Nephritis	Systemic lupus erythematosus nephritis with active of inactive focal, segmental or global endo- or extracapillary glomerulonephritis involving less than 50% of all glomeruli, typically with focal subendothelial immune deposits with or without mesangial alterations. (Weening, Jan J. et al. (2004). The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited. Journal of the American Society of Nephrology 15(2), 241-50.)			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123118>	C34789	Systemic Lupus Erythematosus Nephritis Class IV|Diffuse Lupus Nephritis	Systemic lupus erythematosus nephritis, with active or inactive diffuse, segmental or global endo- or extracapillary glomerulonephritis involving greater than or equal to 50% of all glomeruli, typically with diffuse subendothelial immune deposits, with or without mesangial alterations. (Weening, Jan J. et al. (2004). The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited. Journal of the American Society of Nephrology 15(2), 241-50.)			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123119>	C34789	Systemic Lupus Erythematosus Nephritis Class IV G	Systemic lupus erythematosus nephritis, characterized by active or inactive diffuse, global endo- or extracapillary glomerulonephritis that involves 50% or more of all glomeruli. (Weening, Jan J. et al. (2004). The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited. Journal of the American Society of Nephrology 15(2), 241-50.)			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C12311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12311>	C13039	Cervix Uteri|CERVIX|CERVIX UTERI|Cervix|Cervix|Cervix|Cervix|Cervix uteri|Cervix uteri structure (body structure)|Genital System, Female, Cervix|Uterine Cervix|Uterine Cervix|Uterus, Cervix|canalis cervicis uteri|caudal segment of uterus|cervical canal of uterus|cervix|cervix uteri|neck of uterus|uterine cervix|uterine cervix	The lower part of the uterus occupying the region between the isthmus of the uterus and the vagina. It is divided into supravaginal and vaginal portions.	Cervix Uteri		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Terminology|GCT Authorized Value Terminology|GCT Tumor Assessment Table|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C123120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123120>	C34789	Systemic Lupus Erythematosus Nephritis Class IV S	Systemic lupus erythematosus nephritis characterized by active or inactive diffuse, segmental endo- or extracapillary glomerulonephritis that involves 50% or more of all glomeruli. (Weening, Jan J. et al. (2004). The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited. Journal of the American Society of Nephrology 15(2), 241-50.)			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123121>	C34789	Systemic Lupus Erythematosus Nephritis Class V	Systemic lupus erythematosus nephritis, with global or segmental subepithelial immune deposits or their morphologic sequelae by light microscopy and by immunofluorescence or electron microscopy, with or without mesangial alterations. (Weening, Jan J. et al. (2004). The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited. Journal of the American Society of Nephrology 15(2), 241-50.)			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123122>	C34789	Systemic Lupus Erythematosus Nephritis Class VI|Advanced Sclerotic Lupus Nephritis	Systemic lupus erythematosus nephritis, with 90% or more of glomeruli globally sclerosed without residual activity. (Weening, Jan J. et al. (2004). The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited. Journal of the American Society of Nephrology 15(2), 241-50.)			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123123>	C120887	Tip Lesion Glomerulopathy	Segmental glomerulopathy of localized intracapillary foam cells with adjacent, often vacuolated glomerular epithelial cells confluent to the origin of the proximal tubule.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123124>	C34845	Nephrotic Syndrome-Remission, Partial Remission|Partial Remission Nephrotic Syndrome Remission	Nephrotic syndrome in which proteinuria has decreased by at least 50% and below the nephrotic range cutoff from disease onset, but does not normalize following a defined course of treatment.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123125>	C114583	Antimicrobial - Induced Nephropathy	Kidney damage resulting from exposure to antimicrobials.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123126>	C114583	Bisphosphonate - Induced Nephropathy	Kidney damage resulting from exposure to bisphosphonates.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123127>	C114583	Calcineurin Inhibitor - Induced Nephropathy	Kidney damage resulting from exposure to calcineurin inhibitors.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123128>	C114583	Chemotherapeutic Drug - Induced Nephropathy	Kidney damage resulting from exposure to chemotherapeutic drugs.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123129>	C114583	Contrast - Induced Nephropathy	Kidney damage resulting from exposure to contrast agents.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C12312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12312>	C13039	Isthmus Uteri|Isthmus of Uterus|Isthmus uteri	An elongated constriction of the lower part of the uterus, located at the junction of the body of the uterus and the cervix, that is composed principally of smooth muscle.	Isthmus Uteri		Body Part, Organ, or Organ Component	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C123130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123130>	C114583	Lithium - Induced Nephropathy|Lithium Nephropathy	Kidney damage resulting from lithium which may include distal or collecting tubular cysts, proteinuria, interstitial nephritis and nephrogenic diabetes insipidus.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123131>	C114583	mTOR Inhibitor - Induced Nephropathy	Kidney damage resulting from exposure to mechanistic target of rapamycin (mTOR) kinase inhibitors.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123132>	C114583	Nephropathy due to Aminoglycosides	Kidney damage resulting from aminoglycosides.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123133>	C114583	Nephropathy due to Amphotericin	Kidney damage resulting from amphotericin.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123134>	C114583	Nephropathy due to Analgesic Drugs	Kidney damage resulting from analgesic drugs.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123135>	C114583	Nephropathy due to Ciclosporin	Kidney damage resulting from ciclosporin.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123136>	C114583	Nephropathy due to Cisplatin	Kidney damage resulting from cisplatin.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123137>	C114583	Nephropathy due to Tacrolimus	Kidney damage resulting from tacrolimus.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123138>	C114583	NSAID-Induced Nephropathy|Non-steroidal Anti-inflammatory Drug-Induced Nephropathy	Kidney damage resulting from exposure to non-steroidal anti-inflammatory drugs (NSAIDs).			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123139>	C37308	Focal Segmental Glomerulosclerosis, Not Otherwise Specified|FSGS|FSGS (NOS)|Focal Segmental Glomerulosclerosis (NOS)	Segmental scarring of the glomerulus, which may result in isolated proteinuria or nephrotic syndrome, which affects only part of the glomerulus and only some of the glomeruli. Additionally, the Not Otherwise Specified classification excludes FSGS tip, perihilar, collapsing, and cellular variants. (D'Agati VD, et al. "Pathologic Classification of Focal Segmental Glomerulosclerosis: A Working Proposal." Am J Kidney Dis 43.2 (2004): 368-82.)			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C12313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12313>	C13166	Endometrium|ENDOMETRIUM|Tunica Mucosa|endometrium|endometrium	The mucous membrane comprising the inner layer of the uterine wall; it consists of a simple columnar epithelium and a lamina propria that contains simple tubular uterine glands. The structure, thickness, and state of the endometrium undergo marked change with the menstrual cycle.	Endometrium		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C123140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123140>	C34643	IgA Nephropathy, Familal|IgA Nephropathy, Familial	IgA nephropathy secondary to a genetic mutation that is transmitted from parents to offspring.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123141>	C34643	IgA Nephropathy, Infection-associated	IgA nephropathy co-occurring with infectious disease.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123142>	C35457	Enteric Hyperoxaluria	Excessive urinary oxalate excretion resulting from increased absorption of oxalate.			Laboratory or Test Result	NICHD Terminology|Pediatric Nephrology Terminology
C123143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123143>	C217121	Positive and Negative Perfectionism Scale|PANPS	A 40-item self-report inventory designed to assess levels of positive and negative perfectionism, and distinguish between "normal" and "neurotic" perfectionism. Participants use a 5-point Likert scale that ranges from strongly disagree to strongly agree.			Intellectual Product	
C123144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123144>	C25802	HSPA4L Gene|HSPA4L|HSPA4L|Heat Shock 70kDa Protein 4-Like Gene	This gene is involved in the prevention of protein aggregation.	HSPA4L Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C123145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123145>	C123144	HSPA4L wt Allele|APG-1|APG1|HSPH3|Heat Shock 70kDa Protein 4-Like wt Allele|OSP94|Osp94	Human HSPA4L wild-type allele is located in the vicinity of 4q28 and is approximately 59 kb in length. This allele, which encodes heat shock 70 kDa protein 4L, plays a role in protein chaperone activity.	HSPA4L wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123146>	C17764	Heat Shock 70 kDa Protein 4L|HSPA4L|Heat Shock 70-Related Protein APG-1|Osmotic Stress Protein 94	Heat shock 70 kDa protein 4L (839 aa, ~95 kDa) is encoded by the human HSPA4L gene. This protein is involved in the inhibition of protein aggregation.	Heat Shock 70 kDa Protein 4L		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123147>	C25939	SOD3 Gene|SOD3|SOD3|Superoxide Dismutase 3, Extracellular Gene	This gene plays a role in the metabolism of extracellular superoxides.	SOD3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C123148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123148>	C123147	SOD3 wt Allele|EC-SOD|Superoxide Dismutase 3, Extracellular wt Allele|Superoxide Dismutase, Extracellular Gene	Human SOD3 wild-type allele is located in the vicinity of 4p15.2 and is approximately 11 kb in length. This allele, which encodes extracellular superoxide dismutase [Cu-Zn] protein, is involved in the detoxification of superoxides.	SOD3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12314>	C12437	Myometrium|MYOMETRIUM|myometrium|myometrium	The smooth muscle lining the uterus.	Myometrium		Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C123150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123150>	C17172	Extracellular Superoxide Dismutase [Cu-Zn]|EC 1.15.1.1|EC-SOD|SOD3|Superoxide Dismutase 3	Extracellular superoxide dismutase [Cu-Zn] (240 aa, ~26 kDa) is encoded by the human SOD3 gene. This protein plays a role in the conversion of extracellular superoxides into hydrogen peroxide and oxygen.	Extracellular Superoxide Dismutase [Cu-Zn]		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123151>	C176708	Non-Gaussian Water Diffusion Pattern	The deviation of the existing water-tissue diffusion pattern from that of a perfect Gaussian curve, which is usually demonstrated via an image finding derived from a form of magnetic resonance imaging, known as diffusional kurtosis imaging.	Non-Gaussian Water Diffusion Pattern		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C123152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123152>	C36335	DNA Damage Response Deficiency|DDRD|DNA Damage Repair Deficiency|DNA Damage Response and Repair Deficiency|Deficient DNA Damage Response	A decrease in the ability of cells to respond to damaged DNA and to repair the damage. This DNA repair deficiency can be caused by mutations in the genes involved in the DNA damage response and/or DNA repair.	DNA Damage Response Deficiency		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123153>	C812	Circulating MicroRNA|Circulating Micro RNA|Circulating miRNA	MicroRNA found in the peripheral blood.	Circulating MicroRNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology
C123154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123154>	C13342	Immunoglobulin Heavy Chain Complementarity Determining Region 3|Antibody Heavy Chain Complementarity Determining Region 3|CDR-H3|CDR3	An amino acid sequence within the hypervariable region of an immunoglobulin heavy chain that includes parts of the variable (V), diversity (D), and joining (J) regions.	Immunoglobulin Heavy Chain Complementarity Determining Region 3		Amino Acid Sequence	CTRP Biomarker Terminology|CTRP Terminology
C123155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123155>	C26796	Antenatal Hydronephrosis|Prenatal Hydronephrosis	Hydronephrosis that occurs in a fetus.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123156>	C173151|C173150	Extent of Friend and Family Support of Effort to Increase Amount of Exercise Question|Extent of Friend and Family Support of Effort to Increase Amount of Exercise|To what extent would your friends and family support your efforts to increase your amount of exercise	A question about the extent to which friends and family would support an individual's efforts to increase their amount of exercise.			Intellectual Product	
C123157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123157>	C79805	Congenital Urinary Tract Obstruction	An impediment to the flow of urine along the urinary tract, which is present at birth.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123158>	C3101	Primary Hyperoxaluria	A hereditary disorder characterized by excessive oxalate production, leading to hyperoxaluria.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123159>	C27603	Ureterocele	A cystic and dysplastic dilation of the distal ureter within the bladder that may extend into the bladder neck and urethra.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C12315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12315>	C13039	Fundus Uteri|FUNDUS UTERI|Fundus|Fundus uteri	The upper, rounded portion of the uterus which is opposite from the cervix.	Fundus Uteri		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C123160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123160>	C183109	Lepidic Adenocarcinoma|LPA|Lepidic Predominant Adenocarcinoma|Lepidic Predominant Adenocarcinoma|Lepidic Predominant Lung Adenocarcinoma|Lepidic adenocarcinoma|Lepidic adenocarcinoma|Lepidic predominant adenocarcinoma	A lung adenocarcinoma characterized by the presence of mildly and moderately differentiated adenocarcinoma cells across the alveolar walls with at least one focus of invasive carcinoma measuring more than 5 mm in greatest dimension.			Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology|NCIt Neoplasm Core Terminology
C123161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123161>	C27603	Megaureter	Enlargement of the diameter of the ureter, which can be partial or complete.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123162>	C27601	Voiding Disorders	A group of conditions comprising dysfunction of the storage and elimination of urine.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123163>	C26808	Acute Cortical Necrosis	Acute kidney injury caused by ischemic necrosis of the renal cortex.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123164>	C123155	A1 Hydronephrosis	Antenatal hydronephrosis with the following clinical findings: 1) an anterior-posterior renal pelvis diameter (APRPD) of 4 to less than 7 mm at less than 28 weeks, 2) to less than10 mm at greater than or equal to 28 weeks, and 3) may have central calyceal dilation. (Adapted from: Hiep T. Nguyen, Carol B. Benson, Bryann Bromley, Jeffrey B. Campbell, Jeanne Chow, Beverly Coleman, Christopher Cooper, Jude Crino, Kassa Darge, C.D. Anthony Herndon, Anthony O. Odibo, Michael J.G. Somers, Deborah R. Stein; Multidisciplinary consensus on the classification of prenatal and postnatal urinary tract dilation (UTD classification system); Pediatric Urology; December 2014 Volume 10, Issue 6, Pages 982-998)			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123165>	C123155	A2/3 Hydronephrosis	Antenatal hydronephrosis with the following clinical findings: 1) an anterior-posterior renal pelvis diameter (APRPD) of greater than or equal to 7mm at less than 28 weeks, 2) greater than or equal to10 mm at greater than or equal to 28 weeks, or 3) any one of the following findings: a)dilation of peripheral calyces, b) abnormal parenchymal thickness or appearance, c) visibly dilated ureter, d) an abnormal bladder, or e) the presence of oligohydramnios suspected to be related to the urinary tract. (Adapted from: Hiep T. Nguyen, Carol B. Benson, Bryann Bromley, Jeffrey B. Campbell, Jeanne Chow, Beverly Coleman, Christopher Cooper, Jude Crino, Kassa Darge, C.D. Anthony Herndon, Anthony O. Odibo, Michael J.G. Somers, Deborah R. Stein; Multidisciplinary consensus on the classification of prenatal and postnatal urinary tract dilation (UTD classification system); Pediatric Urology; December 2014 Volume 10, Issue 6, Pages 982-998)			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123166>	C84578	Autosomal Dominant Polycystic Kidney Disease Type 2	Autosomal dominant polycystic kidney disease caused by a mutation in PKD2.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123167>	C84578	Autosomal Dominant Polycystic Kidney Disease Type I	Autosomal dominant polycystic kidney disease caused by a mutation in PKD1.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123168>	C123157	Congenital Ureteropelvic Junction Obstruction	Complete or partial blockage of the ureter at the point where it enters the kidney that is present at birth.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123169>	C123157	Congenital Ureterovesical Junction Obstruction|Congenital Vesicoureteral Obstruction	Complete or partial blockage of the ureter at the point where it enters the bladder that is present at birth.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C12316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12316>	C13039	Corpus Uteri|CORPUS UTERI|Corpus|Corpus uteri|Uterine Body|Uterine Body|Uterus, Corpus|Uterus, Corpus|body of uterus|corpus	The Corpus uteri, or body of uterus, is the part of the uterus above the isthmus, comprising about two thirds of the non-pregnant organ.	Corpus Uteri		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C123170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123170>	C34750	Complex Cyst of Kidney	A heterogeneous and/or septated cyst located in the kidney.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123171>	C34750	Medullary Cystic Kidney Disease Type I|Autosomal Dominant Interstitial Kidney Disease	An inherited form of cystic kidney disease that leads to fibrosis and impaired renal function as a result of defects in the MUC1 gene, which encodes mucin 1.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123172>	C34750	Medullary Cystic Kidney Disease Type II	An inherited form of cystic kidney disease leading to fibrosis and impaired renal function that is caused by mutations in the UMOD gene, which encodes uromodulin/Tamm-Horsfall mucoprotein.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123173>	C34750	Simple Cyst of Kidney	A homogenous cyst located in the kidney.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123174>	C26738	Radiation Cystitis	Inflammation of the bladder due to irradiation.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123175>	C26738	Trigonitis	Inflammation of the trigone of the urinary bladder.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123176>	C26738	Urethrotrigonitis	Inflammation of both the urethra and the trigone of the urinary bladder.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123177>	C98923	Continent Epispadias	Epispadias with urinary continence.			Congenital Abnormality|Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123178>	C98923	Incontinent Epispadias	Epispadias with urinary incontinence.			Congenital Abnormality|Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123179>	C123050	Cryoglobulinemic Glomerulonephritis Secondary to Systemic Disease	Cryoglobulinemia glomerulonephritis associated with chronic disease, often inflammatory conditions.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123180>	C26784	Focal and Segmental Proliferative Glomerulonephritis	Glomerulonephritis characterized by proliferation of endothelial or mesangial cells, affecting the glomeruli in a focal and segmental pattern.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123181>	C26784	Henoch-Schönlein Purpura Nephritis	Glomerulonephritis in the context of Henoch-Schönlein purpura.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123182>	C3090	Terminal Hematuria	Gross hematuria that occurs at the end of, or immediately after voiding.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123183>	C26796	P1 Hydronephrosis	Postnatal Hydronephrosis with the following clinical findings: 1) APRPD is 10 to less than 15 mm, 2) central calyceal dilation may be present, but peripheral calyceal dilation is considered to increase risk, 3) renal parenchyma should have normal thickness and appearance, 4) the ureter is not seen, and 5) the bladder is normal. If there is central calyceal dilation but the APRPD is less than 10 mm, it is still considered UTD P1. (Adapted from: Hiep T. Nguyen, Carol B. Benson, Bryann Bromley, Jeffrey B. Campbell, Jeanne Chow, Beverly Coleman, Christopher Cooper, Jude Crino, Kassa Darge, C.D. Anthony Herndon, Anthony O. Odibo, Michael J.G. Somers, Deborah R. Stein; Multidisciplinary consensus on the classification of prenatal and postnatal urinary tract dilation (UTD classification system); Pediatric Urology; December 2014 Volume 10, Issue 6, Pages 982-998)			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123184>	C26796	P2 Hydronephrosis	Postnatal Hydronephrosis with the following clinical findings: 1) APRPD is greater than or equal to 15 mm, 2) the calyces may be dilated centrally and peripherally, 3) or a dilated ureter is visible, 4) the parenchymal thickness and appearance is normal, and 5) the bladder is normal. Cases in which there is peripheral calyceal dilation but the APRPD is less than 15 mm are classified as UTD P2. (Adapted from: Hiep T. Nguyen, Carol B. Benson, Bryann Bromley, Jeffrey B. Campbell, Jeanne Chow, Beverly Coleman, Christopher Cooper, Jude Crino, Kassa Darge, C.D. Anthony Herndon, Anthony O. Odibo, Michael J.G. Somers, Deborah R. Stein; Multidisciplinary consensus on the classification of prenatal and postnatal urinary tract dilation (UTD classification system); Pediatric Urology; December 2014 Volume 10, Issue 6, Pages 982-998)			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123185>	C26796	P3 Hydronephrosis	Postnatal Hydronephrosis with the following clinical findings: 1) calyceal dilation and the ureter are the same as those in UTD P2, 2) the renal parenchymal is thinned, has increased echogenicity and/or has decreased corticomedullary differentiation, or 3) the bladder is abnormal (wall thickening, ureterocele, posterior urethral dilation). Cases in which there are parenchymal abnormalities but the APRPD is less than 15 mm, are classified as UTD P3. (Adapted from: Hiep T. Nguyen, Carol B. Benson, Bryann Bromley, Jeffrey B. Campbell, Jeanne Chow, Beverly Coleman, Christopher Cooper, Jude Crino, Kassa Darge, C.D. Anthony Herndon, Anthony O. Odibo, Michael J.G. Somers, Deborah R. Stein; Multidisciplinary consensus on the classification of prenatal and postnatal urinary tract dilation (UTD classification system); Pediatric Urology; December 2014 Volume 10, Issue 6, Pages 982-998)			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123186>	C37977	Autosomal Dominant Hypophosphatemia Rickets|Autosomal Dominant Hypophosphatemic Rickets|Autosomal Dominant Vitamin D-resistant Rickets	An autosomal dominant renal phosphate wasting disorder that results in rickets.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology|Pediatric Nephrology Terminology
C123187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123187>	C37977	Autosomal Recessive Hypophosphatemia Rickets|Autosomal Recessive Hypophosphatemic Rickets	An autosomal recessive renal phosphate wasting disorder that results in rickets.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology|Pediatric Nephrology Terminology
C123188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123188>	C123161	Megacystis - Megaureter	A condition characterized by a large capacity, thin-walled bladder and megaureter(s).			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123189>	C123161	Non-Obstructed Megaureter	A megaureter in which there is no obstruction at the ureterovesical junction.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C12318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12318>	C61360	Broad Ligament|BROAD LIGAMENT|Broad ligament|Lateral Ligament|broad ligament of uterus|broad uterine ligament	A wide fold of peritoneum that connects the uterus to the lateral walls and floor of the pelvis, and contains the ovaries, fallopian tubes, ovarian ligaments, round ligament of the uterus, and ovarian and uterine arteries.	Broad Ligament		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C123190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123190>	C123161	Non-Obstructed Non-Refluxing Megaureter	A megaureter in which there is no obstruction at the ureterovesical junction and no vesicoureteral reflux.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123191>	C123161	Obstructed Megaureter	A megaureter in which there is obstruction to the flow of urine at the ureterovesical junction.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123192>	C123161	Refluxing Megaureter|Refluxing Non-Obstructed Megaureter	A megaureter that demonstrates retrograde urine flow without ureteral obstruction.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123193>	C123161	Refluxing Obstructed Megaureter	A megaureter in which there is retrograde flow of urine and a concomitant, episodic obstruction resulting from ureteral folding.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123194>	C34843	Calyceal Diverticulum	An out-pouching of the calyx into the renal parenchyma.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123195>	C34843	Idiopathic Renal Papillary Necrosis	Necrosis of the renal papillae, for which no underlying cause has been identified.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123196>	C34843	Ischemic Nephropathy	Nephropathy due to hypoperfusion of the kidney.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123197>	C34843	Malignant Hypertensive Nephropathy|Accelerated Hypertensive Nephropathy	Hypertensive nephropathy secondary to malignant hypertension.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123198>	C36286	Megacalycosis	Isolated enlargement of renal calyces without obstruction.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123199>	C34843	Nephritic Syndrome	A syndrome characterized by hematuria with dysmorphic red blood cells, red blood cell casts, and proteinuria; systemic manifestations may be present, including hypertension, edema, oliguria.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C12319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12319>	C13046	Round Ligament|ROUND LIGAMENT|Round ligament	Any of the round ligaments including the round ligament of the liver and the round ligament of the uterus.	Round Ligament		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C1231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1231>	C2140	Amilomer|Starch Microspheres	A synthetic microsphere formulation with arterial occlusive properties. Amilomer, a product produced by partially hydrolyzing starch and epichlorohydrin, contains degradable starch microspheres (DSM) with a diameter size of 45 micrometers that are readily degraded by amylase. When used in transcatheter arterial chemoembolization (TACE) procedures, infusion leads to lodging of the microspheres in the precapillary vessels and, consequently, to the occlusion of the hepatic artery. Local occlusion of selected blood vessels in conjunction with intrahepatic chemotherapy administration, results in elevated intracellular hepatocyte drug concentrations and enhances localized cytotoxicity against hepatic tumor lesions.			Organic Chemical|Pharmacologic Substance	NCI Drug Dictionary Terminology
C123200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123200>	C34843	Nephronophthisis	Progressive tubulointerstitial injury, inherited in an autosomal recessive pattern, caused by mutations in genes involved in ciliary function, which may result in an end stage renal failure.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123201>	C34843	Nephropathy Associated with Rhabdomyolysis	Nephropathy associated with rhabdomyolysis.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123202>	C34843	Oligomeganephronia	Congenital renal hypoplasia characterized by small kidneys; reduced nephron number; tubular and glomerular hypertrophy.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123203>	C34843	Sickle Cell Nephropathy	Nephropathy secondary to sickle cell disease, characterized by the presence of sickled erythrocytes in the renal medullary vessels, renal ischemia and microinfarctions, renal papillary necrosis, and renal tubular abnormalities.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123204>	C79696	Acquired Neurogenic Bladder	Neurogenic bladder, the cause of which is not present at birth.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123205>	C79696	Congenital Neurogenic Bladder	Neurogenic bladder, the cause of which is present at birth.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123206>	C79696	Non-Neurogenic Neurogenic Bladder|Hinman Syndrome	Bladder sphincter dysfunction in an individual with normal bladder innervation, which may lead to renal impairment.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123207>	C27601	Bladder Exstrophy|Ectopia Vesicae	A congenital anomaly that involves the protrusion of the exstrophied bladder through the abdominal wall. It is an anomaly that exists along the exstrophy-epispadias complex, which frequently includes urethra exstrophy, separation of the pubic symphysis, external rotation of the pelvic bones, and opening of the puborectal sling and sphincters.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123208>	C27601	Bladder Sphincter Dysfunction|Detrusor Sphincter Dysynergia	Non-coordinated, reflexive contraction of the bladder and sphincter relaxation.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123209>	C27601	Hutch Diverticulum	A congenital out pouching of the bladder involving the ureteral hiatus.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C12320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12320>	C12801	Parametrium|PARAMETRIUM|Parametrium, NOS|Structure of parametrium (body structure)	The subserous connective tissue of the pelvic floor of the supracervical portion of the uterus. The parametrium extends laterally between the layers of the broad ligament.	Parametrium		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C123210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123210>	C99021	Posterior Urethral Valves Type 1	A posterior urethral valve extending from the vera montanum towards the distal meatus.			Congenital Abnormality|Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123211>	C99021	Posterior Urethral Valves Type 3	A posterior urethral valve, presumed to result from incomplete canalization of the urethra, that is located immediately distal to the vera montanum.			Congenital Abnormality|Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123212>	C123158	Primary Hyperoxaluria Type I	Recessively inherited primary hyperoxaluria due to alanine-glyoxylate aminotransferase (AGXT) deficiency.			Finding	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Nephrology Terminology
C123213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123213>	C123158	Primary Hyperoxaluria Type II	Recessively inherited primary hyperoxaluria due to glyoxylate reductase/hydroxypyruvate reductase (GRHPR) deficiency.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123214>	C123158	Primary Hyperoxaluria Type III	Recessively inherited primary hyperoxaluria due to mitochondrial 4-hydroxy-2-oxoglutarate aldolase (HOGA1) gene mutations.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123215>	C34965	Acute Pyelonephritis	Sudden onset pyelonephritis.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123216>	C34965	Chronic Pyelonephritis	Persistent pyelonephritis.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123217>	C28129	Distal Renal Tubular Acidosis	Failure of the renal tubules of the kidney to excrete urine of sufficient acidity, resulting in metabolic acidosis.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123218>	C28129	Proximal Renal Tubular Acidosis|Type II Renal Tubular Acidosis	Impairment in renal proximal tubule bicarbonate reabsorption that results in a hypokalemic hyperchloremic metabolic acidosis, which is most commonly associated with renal Fanconi syndrome.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123219>	C28129	Renal Tubular Acidosis Associated With Deafness	Renal tubular acidosis associated with sensorineural hearing loss, and which is typically associated with recessive mutations.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C12321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12321>	C137974|C13039	Uterine Adnexa|Adnexa of the Uterus|Appendage of the Uterus|Uterine adnexa	The accessory structures of the uterus, including the ovaries, fallopian tubes, broad ligament, and the ovarian and uterine ligaments.	Uterine Adnexa		Body Part, Organ, or Organ Component	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C123220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123220>	C28129	Type I Renal Tubular Acidosis	Impairment in renal collecting tubule acid secretion that results in a hypokalemic hyperchloremic metabolic acidosis.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123221>	C35338	Renal Artery Stenosis	Narrowing of a main artery in the kidney.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123222>	C35338	Renal Artery Thrombosis	The formation of a thrombus in the renal artery.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123223>	C75545|C28193	Atypical Hemolytic Uremic Syndrome|Non-diarrhea-associated Hemolytic Uremic Syndrome	Hemolytic uremic syndrome not associated with shiga toxin-producing enterobacteria.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123225>	C28193	Cardiorenal Syndrome	A disorder of the heart and kidneys in which dysfunction of one of the organs induces dysfunction of the other organ.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123226>	C75545|C28193	Diarrhea-associated Hemolytic Uremic Syndrome	Hemolytic uremic syndrome caused by gastrointestinal infection, usually with shiga toxin-producing enterobacteria.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123227>	C28193	Dysfunctional Elimination Syndrome|Pelvic Elimination Syndrome	Fecal constipation or impaction resulting in bowel and bladder dysfunction.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123228>	C123223	Familial Atypical Hemolytic Uremic Syndrome	Hemolytic uremic syndrome associated with an inherited defect, but which is not associated with shiga toxin-producing enterobacteria.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123229>	C3101|C3034	Primary Fanconi Syndrome	A genetic disorder characterized by impairment of the function of the proximal tubules of the kidney, which results in decreased reabsorption of electrolytes, glucose, amino acids, and other nutrients.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123230>	C28193	Renal Coloboma Syndrome|Papillorenal Syndrome	A genetic disorder caused by PAX2 gene mutations that is characterized by renal hypoplasia and a spectrum of congenital anomalies of the eye and urinary tract.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123231>	C28193	Syndrome of Apparent Mineralocorticoid Excess	An autosomal recessive disorder caused by a deficiency of 11-beta-hydroxysteroid dehydrogenase, which is characterized by hypertension, hypokalemia, low renin, and hypoaldosteronism.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123232>	C27603	Ectopic Ureter	A congenital anomaly in which the ureteral orifice drains into an abnormal location.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123233>	C27603	Ureter Fissus|Partial Ureteral Duplication	A condition in which two ipsilateral ureters unite and drain into the bladder at a single ureteric orifice.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123234>	C27603	Ureteral Kinking	The folding of a ureter, which results in the impediment of urine flow.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123235>	C123159	Cecoureterocele	A ureterocele in which the orifice is located in the bladder, with the ureterocele pouch extending submucosally into the urethra.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123236>	C123159	Ectopic Ureterocele	A ureterocele in which some portion of the ureterocele is situated permanently at the bladder neck or in the urethra. The orifice may be situated in the bladder, at the bladder neck, or in the urethra. (Adapted from Glassberg KI, Braren V, Duckett JW, Jacobs EC, King LR, Lebowitz RL et al. Suggested terminology for duplex systems, ectopic ureters and ureteroceles. J Urol 1984; 132(6):1153-1154.)			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123237>	C123159	Intravesical Ureterocele|Orthotopic Ureterocele	A ureterocele that is located entirely within the bladder, and which may be associated with a single system, with the upper pole ureter of a completely duplicated system, or rarely associated with a lower pole ureter. (Adapted from Glassberg KI, Braren V, Duckett JW, Jacobs EC, King LR, Lebowitz RL et al. Suggested terminology for duplex systems, ectopic ureters and ureteroceles. J Urol 1984; 132(6):1153-1154.)			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123238>	C123159	Obstructive Ureterocele|Stenotic	A ureterocele with a small, obstructive orifice.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123239>	C123159	Sphincteric Ureterocele|Transsphincteric	A ureterocele in which the orifice is distal to the external urinary sphincter.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C12323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12323>	C12470	Prepuce|PREPUCE|Preputium Penis|Preputium Penis	A covering fold of skin, often used alone to designate the preputium penis.	Prepuce		Anatomical Structure	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C123240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123240>	C36286	Decreased Bladder Compliance	The loss of elasticity of the bladder wall with increased urine volume.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123241>	C79805	Acquired Urinary Tract Obstruction	A urinary tract obstruction, the cause of which is not present at birth.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123242>	C114688	Calcium Oxalate Urolithiasis	Urolithiasis in which the composition of the stones is predominantly calcium oxalate.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123243>	C114688	Calcium Phosphate Urolithiasis	Urolithiasis in which the composition of the stones is predominantly calcium phosphate.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123244>	C114688	Cystine Urolithiasis	Urolithiasis in which the composition of the stones is predominantly cystine.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123245>	C114688	Uric Acid Urolithiasis	Urolithiasis in which the composition of the stones is predominantly urate.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123246>	C123162	Urinary Hesitancy	Difficulty in initiating urination.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123247>	C123162	Urinary Straining	The need to increase intra-abdominal pressure in order to initiate and maintain voiding.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123248>	C113213	Glucocorticoid Suppressible Hyperaldosteronism	Excessive production of aldosterone and elevation of blood pressure by the adrenal gland, which is regulated by corticotropin.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123249>	C26876	Idiopathic Retroperitoneal Fibrosis|Ormond's Disease	A condition characterized by abnormal proliferation of fibrous tissue in the compartment posterior to the peritoneum, for which no underlying cause has been identified.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C12324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12324>	C13038	Glans Penis|Glans penis|PENIS, GLANS|glans penis	The most distal portion of the penis covered by the foreskin.	Glans Penis		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C123250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123250>	C27600	Infundibular Stenosis|Infundibular Stenosis of the Calyces of the Kidney	Narrowing of the infundibulum to the calyx, which produces an impediment to urine flow.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123251>	C85034	Pseudohypoaldosteronism Type 1|PHA1B|Pseudohypoaldosteronism Type I Autosomal Recessive	A hereditary, heterogeneous disorder of electrolyte metabolism that is characterized by renal resistance to aldosterone action, resulting in salt wasting, hypotension, hyperkalemia, and metabolic acidosis.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology|Pediatric Nephrology Terminology
C123252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123252>	C85034	Pseudohypoaldosteronism Type 2|Gordon Syndrome	A hereditary renal tubular defect characterized by hypertension and hyperkalemic metabolic acidosis in the presence of suppressed plasma renin levels and relatively low aldosterone levels.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123253>	C3824	Pseudotumor of Kidney	A parenchymal lesion, which may appear neoplastic in origin, that results from abnormal architecture of the renal calyx.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123254>	C98885	Urachal Diverticulum	A condition in which the urachus fails to close proximal to the bladder, resulting in a non-detrusor, blind-ending pouch at the dome of the bladder.			Congenital Abnormality|Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123255>	C98885	Urachal Remnant	Remaining collapsed and obliterated urachal tissue between the bladder dome and umbilicus.			Congenital Abnormality|Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123256>	C36286	Urethral Prolapse	Prolapse of the urethral mucosa from the exterior urethral opening.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123257>	C117719	Ascending Testicle	A condition in which a previously descended testicle permanently moves out of the scrotum.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123258>	C117719	Retractile Testicle	A normal variant in which the testicle may move freely between the scrotum and the groin.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123259>	C117719	Testicular Atrophy	Loss of testicular volume.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C12325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12325>	C13038	Body of the Penis|Body of Penis|Body of penis|PENIS, BODY	The portion of the penis that extends from the site of attachment to the glans, and which is covered by skin. It is formed by the joining of the two proximal free parts of the corpora cavernosa and the related free part of the corpus spongiosum.	Body of Penis		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C123260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123260>	C85865|C84918|C26878	Dent Disease|X-Linked Recessive Hypophosphatemic Rickets|X-linked Recessive Hypophosphatemic Rickets	An X-linked, recessive disorder of the proximal renal tubules that presents during childhood, and is characterized by low-molecular weight proteinuria, hypercalciuria, hypophosphatemia rickets, nephrocalcinosis, nephrolithiasis, and progressive kidney failure.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology|Pediatric Nephrology Terminology
C123261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123261>	C3101	Familial Hypercalciuric Hypocalcemia	A hereditary condition caused by calcium sensing receptor gene mutations, resulting in calcium-hypersensitivity, and compensatory hypocalcemia and hypercalciuria.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123262>	C3101	Familial Hypocalciuric Hypercalcemia|Familial Benign Hypercalcemia	A hereditary condition caused by calcium sensing receptor gene mutations, resulting in calcium-hyposensitivity, and compensatory hypercalcemia and hypocalciuria.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology|Pediatric Nephrology Terminology
C123263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123263>	C3101	Familial Primary Hypomagnesemia	A hereditary disorder that leads to a selective defect in renal or intestinal magnesium absorption, resulting in a low serum magnesium concentration.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C123264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123264>	C117719	Testicular Hypotrophy	Less than expected testicular size.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C123266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123266>	C1323	Diclofenac Epolamine Patch|Flector Patch	A topical patch containing the epolamine salt form of the nonsteroid anti-inflammatory drug (NSAID) diclofenac, with anti-inflammatory, anti-pyretic and analgesic activities.  Upon topical application of the diclofenac epolamine patch to a specific area, the patch releases diclofenac epolamine into the skin. Diclofenac locally binds to cyclooxygenase isoforms 1 and 2 (COX-1 and -2). The inhibition of COX-2 by diclofenac prevents the COX-2-mediated synthesis of proprostaglandins (PGs) and thereby locally relieves PG-mediated pain, fever and inflammation.	Diclofenac Epolamine Patch		Pharmacologic Substance	NCI Drug Dictionary Terminology
C123267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123267>	C141145|C129822	Anti-ICOS Monoclonal Antibody MEDI-570|MEDI-570|MEDI-570	An Fc-optimized humanized immunoglobulin (Ig) G1 monoclonal antibody (MoAb) directed against the inducible T-cell co-stimulator (ICOS, CD278), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-ICOS MoAb MEDI-570 targets and binds to ICOS expressed on tumor infiltrating CD4-positive T-cells. This prevents the interaction between ICOS-positive T-cells and plasmacytoid dendritic cells (pDCs), which express the ICOS ligand (ICOSL). Blocking ICOS activation prevents the pDC-induced proliferation and accumulation of regulatory ICOS-positive T-cells (ICOS+ Tregs) and inhibits interleukin-10 (IL-10) secretion by CD4+ infiltrating T-cells. This may abrogate Treg-mediated immune suppression and may enhance cytotoxic T-lymphocyte (CTL)-mediated immune responses against tumor cells. Fc optimization enhances antibody-dependent cellular cytotoxicity (ADCC). ICOS, a T-cell specific, CD28-superfamily costimulatory molecule and immune checkpoint protein, plays a key role in the proliferation and activation of T-cells. It is normally expressed on both activated CD4+ T-cells, which is a subset of memory T-cells (Tm), and follicular helper T-cells (Tfh). ICOS is highly expressed on Tregs infiltrating various tumors and its expression is associated with a poor prognosis; ICOS-positive Tregs play a key role in immune suppression and tumor immune evasion.	Anti-ICOS Monoclonal Antibody MEDI-570		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123268>	C123273	FDA Establishment Activity Terminology|ACTIVITY|ESTABLISHMENT ACTIVITY	Terminology used in the framework of identifying types of establishment activities.			Intellectual Product	FDA Quality Metrics Terminology
C123269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123269>	C48905	Other Establishment Activity|OTHER	The establishment activity is other than that which already appears in the establishment activity value set.			Activity	FDA Establishment Activity Terminology|FDA Quality Metrics Terminology
C12326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12326>	C27616	Undescended Testes|Cryptorchidism|Cryptorchidism|Undescended Testicle|Undescended Testis|Undescended Testis|Undescended Testis|Undescended testis|cryptorchidism|undescended testicles	The failure of one or both testes of a male fetus to descend from the abdomen into the scrotum during the late part of pregnancy. If not surgically corrected in early childhood, males may be at increased risk for testicular cancer later in life.			Congenital Abnormality|Disease or Syndrome	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|Neonatal Research Network Terminology|Newborn Screening Terminology|NICHD Terminology|Pediatric Endocrinology Terminology|Pediatric Nephrology Terminology
C123270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123270>	C123273	FDA Application Type Terminology|APPLICATION TYPE|APPLTYPE	Terminology used in the framework of identifying types of pharmaceutical application types.			Intellectual Product	FDA Quality Metrics Terminology
C123271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123271>	C70871	No Application Type|NA|Not Applicable	There is no associated application type (e.g., as with an over-the-counter monograph drug), and therefore this field is not applicable.			Intellectual Product	FDA Application Type Terminology|FDA Quality Metrics Terminology
C123272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123272>	C90259	Pediatric Nephrology Terminology	Terminology developed by a collaborative effort of the National Cancer Institute's Enterprise Vocabulary Services, the National Institute of Child Health and Human Development, and an international group of clinicians and informaticists to support the reporting of events in the pediatric population with issues pertaining to nephrology.			Intellectual Product	
C123273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123273>	C131123	FDA Quality Metrics Terminology|Quality Metrics	Terminology developed to support activities regarding quality metrics within the FDA operations.			Intellectual Product	FDA Terminology
C123274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123274>	C60824	Warehouse Human Prescription Drug Products|Warehouses human prescription drug products	Activities that include storing human prescription drug products prior to distribution to the points of dispensing.			Activity	FDA Structured Product Labeling Terminology|SPL Business Operation Qualifier Terminology
C123275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123275>	C70639	Near Complete Response of Multiple Myeloma or Plasma Cell Leukemia|nCR of MM or PCL|nCR of Multiple Myeloma or Plasma Cell Leukemia	A subgroup of complete response of multiple myeloma or plasma cell leukemia.  It is characterized by less than 5% plasma cells in the bone marrow, unmeasurable serum and urine monoclonal proteins by electrophoresis, and positive serum and/or urine immunofixation.	Near Complete Response of Multiple Myeloma or Plasma Cell Leukemia		Finding	CTRP Disease Terminology|CTRP Terminology
C123276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123276>	C188271	BK Virus Infection|BK Viral Infection	An infection caused by the BK virus. It usually causes an asymptomatic infection, except in immunocompromised individuals where it may cause nephropathy or hemorrhagic cystitis.	BK Virus Infection		Disease or Syndrome	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C123277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123277>	C28676	Allogeneic BKV-specific Cytotoxic T-lymphocytes|Allogeneic BK-CTLs|Allogeneic BKV-specific CTLs|Allogeneic BKV-specific Cytotoxic T Lymphocytes|BK Virus-specific T-cells	Allogeneic cytotoxic T-lymphocytes (CTLs) that are specifically reactive to BK virus (BKV), with potential antiviral activity. Upon infusion of allogeneic BK-specific CTLs into immunocompromised patients who were infected with BKV after allogeneic stem cell transplantation, these cells exert a specific CTL response against BKV, thereby killing and eliminating the BKV-infected cells. BKV is a member of the polyomavirus family that may cause mild symptoms in normal, healthy people; however, BKV infection can lead to severe disease in immunocompromised patients.	Allogeneic BKV-specific Cytotoxic T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C123278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123278>	C67159	COPDAC Regimen|COPDAC|COPDAC|Cyclophosphamide/Oncovin/Prednisone/Dacarbazine Regimen|Cyclophosphamide/Vincristine/Prednisone/Dacarbazine Regimen	A regimen consisting of cyclophosphamide, vincristine sulfate, prednisone and dacarbazine used for the treatment of male children with classical Hodgkin's lymphoma (HL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|NCI Drug Dictionary Terminology|Pharmacotherapy Regimens
C123279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123279>	C16393	NRXN1 Gene Product	A protein encoded by the NRXN1 gene.			Amino Acid, Peptide, or Protein	
C123281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123281>	C192742|C192741	Trilaciclib|2'-((5-(4-Methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one|G1T28|Spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-|TRILACICLIB	A small molecule, competitive inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6), with potential antineoplastic and chemoprotective activities. Upon intravenous administration, trilaciclib binds to and inhibits the activity of CDK4/6, thereby blocking the phosphorylation of the retinoblastoma protein (Rb) in early G1. This prevents G1/S phase transition, causes cell cycle arrest in the G1 phase, induces apoptosis, and inhibits the proliferation of CDK4/6-overexpressing tumor cells. In patients with CDK4/6-independent tumor cells, G1T28 may protect against multi-lineage chemotherapy-induced myelosuppression (CIM) by transiently and reversibly inducing G1 cell cycle arrest in hematopoietic stem and progenitor cells (HSPCs) and preventing transition to the S phase. This protects all hematopoietic lineages, including red blood cells, platelets, neutrophils and lymphocytes, from the DNA-damaging effects of certain chemotherapeutics and preserves the function of the bone marrow and the immune system. CDKs are serine/threonine kinases involved in the regulation of the cell cycle and may be overexpressed in certain cancer cell types. HSPCs are dependent upon CDK4/6 for proliferation.	Trilaciclib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123282>	C42607	Regimen-Limiting Toxicity|DLT|Dose Limiting Toxicity|Dose-Limiting Toxicity|RLT|dose limiting toxicity|dose_limiting_toxicity	A side effect of a drug or other treatment that is serious enough to necessitate a dose modification.			Finding	ICDC Property Terminology|ICDC Terminology
C123283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123283>	C39619|C1663	PSA/PSMA DNA Plasmid INO-5150|INO 5150|INO-5150|PSA/PSMA Synthetic DNA Vaccine INO-5150|PSA/PSMA-encoding DNA Plasmid INO-5150	A plasmid DNA vaccine encoding the tumor-associated antigens (TAAs) prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA), with potential immunoactivating and antineoplastic activities. Upon intramuscular delivery and electroporation of the PSA/PSMA DNA plasmid INO-5150, both PSA and PSMA are translated in cells which then activate the immune system. This induces cytotoxic T-lymphocyte (CTL) responses against tumor cells expressing PSA and PSMA. This may result in both immune-mediated tumor cell death and the inhibition of tumor cell proliferation. PSA and PSMA are overexpressed on a variety of cancer cell types. The DNA encoding the TAAs in INO-5150 is based on both human and other primate antigen gene sequences. As the plasmid genes differ from the human gene sequences encoding these antigens, INO-5150 may overcome immune tolerance to human TAAs.	PSA/PSMA DNA Plasmid INO-5150		Immunologic Factor|Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123284>	C216105	Anti-DLL3 Antibody-drug Conjugate SC-002|Anti-DLL3 ADC SC-002|SC 002|SC-002|SC002	An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3), site-specifically conjugated to the cytotoxic pyrrolobenzodiazepine (PBD) dimer SC-DR002 via a plasma-stable valine-alanine dipeptide linker, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of anti-DLL3 ADC SC-002 targets and binds to DLL3 expressed on tumor cells. Upon binding and internalization, the dipeptide linker is cleaved upon cathepsin-mediated proteolysis and SC-DR002 is released. Then the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of DLL3-overexpressing tumor cells. DLL3, a membrane protein that binds to Notch receptors and regulates Notch-mediated signaling and gene transcription, is overexpressed by certain cancers but is rarely expressed by normal, healthy cells.	Anti-DLL3 Antibody-drug Conjugate SC-002		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123285>	C91105	Work Productivity and Activity Impairment General Health V2.0 Questionnaire|WPAI-GH V2.0|WPAI-GH Version 2|WPAI02|WPAI:GH|Work Productivity and Activity Impairment General Health V2.0 Questionnaire (WPAI:GH)|Work Productivity and Activity Impairment General Health Version 2.0 Questionnaire	The second version of a standardized survey originally developed by Margaret C. Reilly in 1993 which is used to evaluate the extent to which a patient's general health problems effects their ability to work and perform daily activities. This instrument consists of 6 questions which can be completed by the patient or in an interview format.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123286>	C206412|C173924	Currently Employed Question|Are you currently employed (working for pay)|Currently Employed|Currently Working for Pay	A question about whether an individual is currently employed.			Intellectual Product	Work Productivity and Activity Impairment General Health V2.0 Questionnaire
C123287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123287>	C173924	Hours Missed from Work Because of Health Problems Question|Hours Missed from Work Because of Health Problems|How many hours did you miss from work because of your health problems	A question about how many hours an individual missed from work because of their health problems.			Intellectual Product	Work Productivity and Activity Impairment General Health V2.0 Questionnaire
C123288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123288>	C173924	Hours Missed From Work Because of other Reasons Question|Hours Missed From Work Because of other Reasons|Hours Missed from Work Because of Any Other Reason|How many hours did you miss from work because of any other reason	A question about how many hours an individual missed from work because of any reason other than their health problems.			Intellectual Product	Work Productivity and Activity Impairment General Health V2.0 Questionnaire
C123289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123289>	C173924	Hours Worked Question|Hours Actually Worked|Hours Worked|How many hours did you actually work	A question about how many hours an individual actually worked.			Intellectual Product	Work Productivity and Activity Impairment General Health V2.0 Questionnaire
C12328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12328>	C13018	Epididymis|EPIDIDYMIS|Epididymal|epididymis|epididymis	A crescent-like structure located in the upper and posterior surfaces of the testis. It consists of the efferent ductules and the duct of the epididymis. It facilitates the maturation of sperm that is produced in the testis.	Epididymis		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C123290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123290>	C173924	Health Problems Affect Productivity While Working Question|Health Problems Affect Productivity While Working|How much did your health problems affect your productivity while you were working	A question about how much an individual's health problems affects or affected their productivity while they were working.			Intellectual Product	Work Productivity and Activity Impairment General Health V2.0 Questionnaire
C123291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123291>	C173924|C173787|C173045	Health Problems Affect Ability to do Regular Daily Activities other than Work at Job Question|Health Problems Affect Ability to do Regular Daily Activities|Health Problems Affect Ability to do Regular Daily Activities other than Work at Job|How much did your health problems affect your ability to do your regular daily activities, other than work at a job	A question about how much an individual's health problems affects or affected their ability to do regular daily activities other than work at a job.			Intellectual Product	Work Productivity and Activity Impairment General Health V2.0 Questionnaire
C123292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123292>	C85429	Effect of Health Problems on Work Likert Scale|Effect of Health Problems on Work Scale|WPAI Effect of Health Problems on Work Scale	A scale for the subjective scoring of the effect of an individual's health problems on their ability to work that ranges from 0: Health problems had no effect on my work to 10: Health problems completely prevented me from working.			Intellectual Product	Work Productivity and Activity Impairment General Health V2.0 Questionnaire
C123293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123293>	C85429	Effect of Health Problems on Daily Activities Likert Scale|Effect of Health Problems on Daily Activities Scale|WPAI Effect of Health Problems on Daily Activities Scale	A scale for the subjective scoring of the effect of an individual's health problems on their ability to do daily activities that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.			Intellectual Product	Work Productivity and Activity Impairment General Health V2.0 Questionnaire
C123294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123294>	C175263	Health Problems Effect on Work Score 0	A subjective score of 0 on a scale that ranges from 0: Health problems had no effect on my work to 10: Health problems completely prevented me from working.			Intellectual Product	
C123295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123295>	C175263	Health Problems Effect on Work Score 1	A subjective score of 1 on a scale that ranges from 0: Health problems had no effect on my work to 10: Health problems completely prevented me from working.			Intellectual Product	Work Productivity and Activity Impairment General Health V2.0 Questionnaire
C123296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123296>	C175263	Health Problems Effect on Work Score 2	A subjective score of 2 on a scale that ranges from 0: Health problems had no effect on my work to 10: Health problems completely prevented me from working.			Intellectual Product	Work Productivity and Activity Impairment General Health V2.0 Questionnaire
C123297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123297>	C175263	Health Problems Effect on Work Score 3	A subjective score of 3 on a scale that ranges from 0: Health problems had no effect on my work to 10: Health problems completely prevented me from working.			Intellectual Product	Work Productivity and Activity Impairment General Health V2.0 Questionnaire
C123298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123298>	C175263	Health Problems Effect on Work Score 4	A subjective score of 4 on a scale that ranges from 0: Health problems had no effect on my work to 10: Health problems completely prevented me from working.			Intellectual Product	Work Productivity and Activity Impairment General Health V2.0 Questionnaire
C123299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123299>	C175263	Health Problems Effect on Work Score 5	A subjective score of 5 on a scale that ranges from 0: Health problems had no effect on my work to 10: Health problems completely prevented me from working.			Intellectual Product	
C12329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12329>	C13018	Spermatic Cord|spermatic cord|spermatic cord|testicular cord	A tube-like structure composed of the vas deferens and surrounding tissue layers, that runs from the abdomen to each of the testicles.	Spermatic Cord		Body Part, Organ, or Organ Component	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C1232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1232>	C2139	Spirogermanium|2-[3-(Dimethyl-amino)propyl]-8,8-diethyl-2-aza-8-germaspiro[4,5]decane|8,8-Diethyl-N,N-dimethyl-3-aza-8-germaspiro[4,5]decane-2-propanamine|S 99 A|S 99 A|SPG|SPIROGERMANIUM|Spiro 32|Spiro-32|Spirogermanium Compound|Spirogermanium compound	A synthetic organometallic compound containing the element germanium with possible antineoplastic activity. Spirogermanium exhibits significant toxicity, particularly neurotoxicity. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123300>	C175263	Health Problems Effect on Work Score 6	A subjective score of 6 on a scale that ranges from 0: Health problems had no effect on my work to 10: Health problems completely prevented me from working.			Intellectual Product	Work Productivity and Activity Impairment General Health V2.0 Questionnaire
C123301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123301>	C175263	Health Problems Effect on Work Score 7	A subjective score of 7 on a scale that ranges from 0: Health problems had no effect on my work to 10: Health problems completely prevented me from working.			Intellectual Product	Work Productivity and Activity Impairment General Health V2.0 Questionnaire
C123302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123302>	C175263	Health Problems Effect on Work Score 8	A subjective score of 8 on a scale that ranges from 0: Health problems had no effect on my work to 10: Health problems completely prevented me from working.			Intellectual Product	Work Productivity and Activity Impairment General Health V2.0 Questionnaire
C123303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123303>	C175263	Health Problems Effect on Work Score 9	A subjective score of 9 on a scale that ranges from 0: Health problems had no effect on my work to 10: Health problems completely prevented me from working.			Intellectual Product	Work Productivity and Activity Impairment General Health V2.0 Questionnaire
C123304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123304>	C175263	Health Problems Effect on Work Score 10	A subjective score of 10 on a scale that ranges from 0: Health problems had no effect on my work to 10: Health problems completely prevented me from working.			Intellectual Product	Work Productivity and Activity Impairment General Health V2.0 Questionnaire
C123305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123305>	C175262	Health Problems Effect on Daily Activities Score 0	A subjective score of 0 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.			Intellectual Product	Work Productivity and Activity Impairment General Health V2.0 Questionnaire
C123306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123306>	C175262	Health Problems Effect on Daily Activities Score 1	A subjective score of 1 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.			Intellectual Product	
C123307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123307>	C175262	Health Problems Effect on Daily Activities Score 2	A subjective score of 2 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.			Intellectual Product	Work Productivity and Activity Impairment General Health V2.0 Questionnaire
C123308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123308>	C84914	Congenital Myotonic Dystrophy	Myotonic dystrophy that is present at birth.			Disease or Syndrome	Neonatal Research Network Terminology|NICHD Terminology
C123309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123309>	C175262	Health Problems Effect on Daily Activities Score 3	A subjective score of 3 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.			Intellectual Product	Work Productivity and Activity Impairment General Health V2.0 Questionnaire
C123310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123310>	C175262	Health Problems Effect on Daily Activities Score 4	A subjective score of 4 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.			Intellectual Product	Work Productivity and Activity Impairment General Health V2.0 Questionnaire
C123311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123311>	C175262	Health Problems Effect on Daily Activities Score 5	A subjective score of 5 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.			Intellectual Product	Work Productivity and Activity Impairment General Health V2.0 Questionnaire
C123312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123312>	C175262	Health Problems Effect on Daily Activities Score 6	A subjective score of 6 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.			Intellectual Product	Work Productivity and Activity Impairment General Health V2.0 Questionnaire
C123313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123313>	C175262	Health Problems Effect on Daily Activities Score 7	A subjective score of 7 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.			Intellectual Product	Work Productivity and Activity Impairment General Health V2.0 Questionnaire
C123314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123314>	C175262	Health Problems Effect on Daily Activities Score 8	A subjective score of 8 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.			Intellectual Product	Work Productivity and Activity Impairment General Health V2.0 Questionnaire
C123315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123315>	C175262	Health Problems Effect on Daily Activities Score 9	A subjective score of 9 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.			Intellectual Product	Work Productivity and Activity Impairment General Health V2.0 Questionnaire
C123316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123316>	C175262	Health Problems Effect on Daily Activities Score 10	A subjective score of 10 on a scale that ranges from 0: Health problems had no effect on my daily activities to 10: Health problems completely prevented me from doing my daily activities.			Intellectual Product	Work Productivity and Activity Impairment General Health V2.0 Questionnaire
C123317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123317>	C3266	DICER1-Related Tumor Predisposition Syndrome|DICER1 Syndrome|DICER1 Syndrome|DICER1 Syndrome	An autosomal dominant inherited tumor predisposition syndrome caused by germline mutations of the DICER1 gene. Carriers are at an increased risk of developing benign and malignant neoplasms, including pleuropulmonary blastoma, childhood cystic nephroma, goiter, thyroid carcinoma, pineoblastoma, DICER1-mutant ovarian Sertoli-Leydig cell tumor, embryonal tumor with multilayered rosettes, and primary intracranial sarcoma, DICER1-mutant.			Disease or Syndrome	CCPS Disease Terminology|Childhood Cancer Predisposition Study Terminology
C123318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123318>	C217121	Rosenberg Self-Esteem Scale|RSES|Rosenberg Self Esteem Scale	A 10-item scale for the subjective scoring of a person's self esteem, developed by Dr. Morris Rosenberg, that ranges from strongly agree to strongly disagree. Five of the items have positively worded statements and five have negatively worded statements.			Intellectual Product	
C123319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123319>	C173792	Satisfied with Myself on the Whole Question|On the whole, I am satisfied with myself|Satisfied with Myself on the Whole	A question about whether an individual is satisfied with themself on the whole.			Intellectual Product	Rosenberg Self-Esteem Scale
C12331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12331>	C13035	Bladder Trigone|BLADDER, TRIGONE|Trigone|Trigone of Bladder|Trigone of bladder|Trigone of the Bladder|Urinary Bladder Trigone|trigone of urinary bladder	The triangular area in the bladder mucosa that is formed by the two ureteral orifices and the urethral orifice.	Trigone of Bladder		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C123320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123320>	C173597	Am No Good at All at Times Question|Am No Good at All at Times|At times, I think I am no good at all	A question about whether an individual thinks they are no good at all at times.			Intellectual Product	Rosenberg Self-Esteem Scale
C123321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123321>	C173160	Have a Number of Good Qualities Question|Have a Number of Good Qualities|I feel that I have a number of good qualities	A question about whether an individual feels they have a number of good qualities.			Intellectual Product	Rosenberg Self-Esteem Scale
C123322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123322>	C173045	Able to do Things as Well as Most People Question|Able to do Things as Well as Most People|I am able to do things as well as most other people	A question about whether an individual is able to do things as well as most other people.			Intellectual Product	Rosenberg Self-Esteem Scale
C123323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123323>	C173160	Do Not Have Much to be Proud of Question|Do Not Have Much to be Proud of|I feel I do not have much to be proud of	A question about whether an individual feels they do not have much to be proud feeling.			Intellectual Product	Rosenberg Self-Esteem Scale
C123324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123324>	C173160	Feel Useless at Times Question|Certainly Feel Useless at Times|Feel Useless at Times|I certainly feel useless at times	A question about whether an individual feels useless at times.			Intellectual Product	Rosenberg Self-Esteem Scale
C123325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123325>	C173160	Am a Person of Worth on Equal Plane with Others Question|Am a Person of Worth on Equal Plane with Others|I feel that I'm a person of worth, at least on an equal plane with others	A question about whether an individual feels they are a person of worth on an equal plane with others.			Intellectual Product	Rosenberg Self-Esteem Scale
C123326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123326>	C91102	Wish I Could Have More Respect for Myself Question|I wish I could have more respect for myself|Wish I Could Have More Respect for Myself	A question about whether an individual wishes they could have more respect for themself.			Intellectual Product	Rosenberg Self-Esteem Scale
C123327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123327>	C173160	Inclined to Feel That I am a Failure Question|All in all, I am inclined to feel that I am a failure|Inclined to Feel That I am a Failure	A question about whether an individual is inclined to feel that they are a failure overall.			Intellectual Product	Rosenberg Self-Esteem Scale
C123328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123328>	C91102	Take a Positive Attitude Toward Myself Question|I take a positive attitude toward myself|Take a Positive Attitude Toward Myself	A question about whether an individual takes a positive attitude towards themselves.			Intellectual Product	Rosenberg Self-Esteem Scale
C123329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123329>	C6432	Multiple Endocrine Neoplasia Type 2	Multiple endocrine neoplasia caused by mutation of the RET gene. It includes the following neoplastic processes: multiple endocrine neoplasia type 2A, multiple endocrine neoplasia type 2B, and hereditary thyroid gland medullary carcinoma.			Neoplastic Process	CCPS Disease Terminology|Cellosaurus Disease Terminology|Childhood Cancer Predisposition Study Terminology
C12332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12332>	C13035	Dome of the Bladder|BLADDER, DOME|Dome|Dome of Bladder|Dome of bladder|Superior Surface of Bladder|Superior Surface of the Bladder	The upper, convex surface of the bladder.	Dome of Bladder		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C123330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123330>	C34979	Macular Degeneration|Maculopathy|macular degeneration	Loss of vision in the central portion of the retina (macula), secondary to retinal degeneration.			Disease or Syndrome	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|Cellosaurus Disease Terminology
C123331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123331>	C35867	Invasive Focus of Carcinoma Cells Measuring More Than 5 mm Present	A morphologic finding indicating the presence of an invasive component of carcinoma cells that measures more than 5 mm in greatest dimension.			Finding	
C123332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123332>	C201282|C200367	Eluvixtamab|AMG 330|AMG-330|AMG330|Anti-CD33/CD3 BiTE Antibody AMG 330|BiTE Antibody AMG 330|Bispecific T-cell Engager Antibody AMG 330|CD33/CD3-directed Bispecific T-cell Engager Antibody AMG 330|ELUVIXTAMAB	A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) CD33 fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of eluvixtamab, this bispecific antibody binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD33 antigen found on CD33-expressing tumor cells. This activates and redirects CTLs to CD33-expressing tumor cells, which results in the CTL-mediated cell death of CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem cells and overexpressed on neoplastic cells in patients with acute myeloid leukemia.	Eluvixtamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123333>	C18004	Reese-Ellsworth Staging System|R-E System|Reese-Ellsworth Classification|Reese-Ellsworth Classification for Intraocular Tumors|Reese-Ellsworth System	A staging system for intraocular retinoblastoma that was developed in the 1960s, when children were treated with external beam radiation therapy. This system can help determine the likelihood of preserving the vision while the tumor is being treated. It is divided into 5 stages, and each stage predicts the potential to save the eye with external beam radiation therapy. Today, radiation therapy is reserved as a last resort to save a second eye, when all other treatments have failed. As a result, the Reese-Ellsworth classification is now rarely used.			Classification	
C123334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123334>	C74676	Red Blood Cell Folate Measurement|RBC Folate|RBC Folate Status|RBC Folic Acid|Red Blood Cell Folate|Red Blood Cell Folate Status|Red Cell Folate	The determination of the concentration of folic acid present in a sample of red blood cells.			Laboratory Procedure	
C123335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123335>	C14209	Microsporidia|MICROSPORIDIA|Microspora|Microspora|Microsporea|Microsporea|Microsporida|Microsporida	A taxonomic grouping of spore-forming, unicellular, and parasitic fungi that can be assigned to the Microsporidia phylum.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123336>	C85908	Paenibacillus	A taxonomic grouping of facultative anaerobic, endospore-forming bacteria that can be assigned to the genus Paenibacillus.			Bacterium	
C123337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123337>	C118931	Paracoccus	A taxonomic grouping of chemoorganoheterotrophic, facultative chemolitoautotrophic, methylotrophic and anaerobic bacteria that can be assigned to the genus of Paracoccus.			Bacterium	
C123338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123338>	C122024	Trematoda|TREMATODA	A taxonomic grouping of parasitic flatworms that can be assigned to the class Trematoda.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123339>	C85934	Solobacterium	A taxonomic grouping of none spore-forming, strict anaerobic Gram positive bacillus that can be assigned to the genus Solobacterium.			Bacterium	
C12333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12333>	C48941	Lateral Wall of the Bladder|Lateral Wall of Bladder|Lateral wall of bladder|Wall, Lateral	The aspect of the bladder wall that is located on the side.	Lateral Wall of Bladder		Body Location or Region	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C123340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123340>	C217121	Adult Hope Scale|AHS|Adult Hope Scale (AHS)	A 12-item measure of a respondent's level of hope. Each item is answered using an 8-point Likert-type scale ranging from Definitely False to Definitely True.			Intellectual Product	
C123341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123341>	C173597	Can Think of Many Ways to Get Out of a Jam Question|Can Think of Many Ways to Get Out of a Jam|I can think of many ways to get out of a jam	A question about whether an individual can think of many ways to get out of a jam.			Intellectual Product	Adult Hope Scale
C123342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123342>	C91102	Energetically Pursue Goals Question|Energetically Pursue Goals|I energetically pursue my goals	A question about whether an individual energetically pursue their goals.			Intellectual Product	Adult Hope Scale
C123343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123343>	C104301	Feel Tired Most of Time Question|Feel Tired Most of Time|I feel tired most of the time	A question about whether an individual feels or felt tired most of the time.			Intellectual Product	Adult Hope Scale
C123344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123344>	C91102	Lots of Ways Around Any Problem Question|Lots of Ways Around Any Problem|There are lots of ways around any problem	A question about whether an individual believes there are lots of ways around any problem.			Intellectual Product	Adult Hope Scale
C123345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123345>	C91102	Easily Downed in Argument Question|Easily Downed in Argument|I am easily downed in an argument	A question about whether an individual is or was easily downed in an argument.			Intellectual Product	Adult Hope Scale
C123346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123346>	C173597	Can Think of Many Ways to Get the Things in Life that are Important to Me Question|Can Think of Many Ways to Get the Things in Life that are Important to Me|I can think of many ways to get the things in life that are important to me	A question about whether an individual can think of many ways to get the things in life that are important to them.			Intellectual Product	Adult Hope Scale
C123347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123347>	C91102	Can Find Way to Solve Problem Even When Others Get Discouraged Question|Can Find Way to Solve Problem Even When Others Get Discouraged|Even when others get discouraged, I know I can find a way to solve the problem	A question about whether an individual can find a way to solve a problem even when others get discouraged.			Intellectual Product	Adult Hope Scale
C123348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123348>	C175990	Past Experiences Have Prepared Me Well for Future Question|My past experiences have prepared me well for my future|Past Experiences Have Prepared Me Well for Future	A question about whether an individual feels of felt their past experiences have prepared them well for the future.			Intellectual Product	Adult Hope Scale
C123349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123349>	C91102	Have Been Pretty Successful in Life Question|Have Been Pretty Successful in Life|I've been pretty successful in life	A question about whether an individual is or has been pretty successful in life.			Intellectual Product	Adult Hope Scale
C12334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12334>	C48941	Anterior Wall of the Bladder|Anterior Wall of Bladder|Anterior wall of bladder|Wall, Anterior	The anterior aspect of the bladder wall.	Anterior Wall of Bladder		Body Location or Region	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C123350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123350>	C173934	Usually Find Myself Worrying About Something Question|I usually find myself worrying about something|Usually Find Myself Worrying About Something	A question about whether an individual usually finds themself worrying about something.			Intellectual Product	Adult Hope Scale
C123351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123351>	C91102	Meet Goals Set for Myself Question|I meet the goals that I set for myself|Meet Goals Set for Myself	A question about whether an individual meets the goals they set for themself.			Intellectual Product	Adult Hope Scale
C123352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123352>	C91781|C173934	Worry About My Health, How True Question|How True Worry About My Health|I worry about my health|Worry About My Health, How True	A question about whether an individual worries about their health.			Intellectual Product	Adult Hope Scale
C123353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123353>	C175347	Definitely False	A subjective response indicating that something is definitely false.			Intellectual Product	Adult Hope Scale
C123354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123354>	C175347	Mostly False	A subjective response indicating that something is mostly false.			Intellectual Product	Adult Hope Scale
C123355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123355>	C175347	Somewhat False	A subjective response indicating that something is somewhat false.			Intellectual Product	Adult Hope Scale
C123356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123356>	C175347	Slightly False	A subjective response indicating that something is slightly false.			Intellectual Product	Adult Hope Scale
C123357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123357>	C175338	Slightly True|A little true	A subjective response indicating that something is slightly true.			Intellectual Product	Adult Hope Scale
C123358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123358>	C175338	Somewhat True	A subjective response indicating that something is somewhat true.			Intellectual Product	Adult Hope Scale
C123359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123359>	C175338	Mostly True	A subjective response indicating that something is mostly true.			Intellectual Product	Adult Hope Scale
C12335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12335>	C48941	Posterior Wall of the Bladder|Posterior Wall of Bladder|Posterior wall of bladder|Wall, Posterior	The posterior aspect of the bladder wall.	Posterior Wall of Bladder		Body Part, Organ, or Organ Component	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C123360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123360>	C175338	Definitely True	A subjective response indicating that something is definitely true.			Intellectual Product	Adult Hope Scale
C123361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123361>	C217122	Peritoneal Cancer Index|PCI|Peritoneal Carcinomatosis Index	A method for detailed evaluation of the peritoneal spread of tumors of gastrointestinal origin. The index is based on tumor size in 13 separate regions, 9 regions in the abdomen and 4 in the small intestine. Each region is given a score from 0 to 3, based on the size of any tumors present, and the cancer index is the sum of all scores, ranging from 0 to 39. This score has been found to be a prognostic indicator of survival.			Intellectual Product	
C123362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123362>	C124800	FLT3 Tyrosine Kinase Inhibitor TTT-3002|TTT-3002	An orally bioavailable indolocarbazole derivative and inhibitor of constitutively active mutant forms of FMS-like tyrosine kinase 3 (FLT3) with potential antineoplastic activity. Following administration, FLT3 tyrosine kinase inhibitor TTT-3002 binds to and inhibits ligand-dependent dimerization and autophosphorylation of mutant forms of FLT3 with constitutively activating mutations, including FLT3 internal tandem duplication (FLT3/ITD) and the activating point mutation D835Y. Prevention of autophosphorylation inhibits uncontrolled FLT3 signaling and may result in the inhibition of proliferation in tumor cells expressing constitutively active mutant forms of FLT3. The ability of TTT-3002 to inhibit FLT3 proteins with activating point mutations may result in increased efficacy because the activity of these mutants are resistant to other FLT3 kinase inhibitors. FLT3, a tyrosine kinase receptor, plays a role in the regulation of hematopoietic progenitor cell proliferation, and in leukemic cell proliferation and survival. Constitutively activating mutations of FLT3 are the most frequent genetic alterations in acute myeloid leukemia.	FLT3 Tyrosine Kinase Inhibitor TTT-3002		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C123363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123363>	C123333	Reese-Ellsworth Classification Group I|Reese-Ellsworth Group I	Very favorable for maintenance of sight.			Classification	
C123364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123364>	C123333	Reese-Ellsworth Classification Group II|Reese-Ellsworth Group II	Favorable for maintenance of sight.			Classification	
C123365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123365>	C123333	Reese-Ellsworth Classification Group III|Reese-Ellsworth Group III	Possible for maintenance of sight.			Classification	
C123366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123366>	C123333	Reese-Ellsworth Classification Group IV|Reese-Ellsworth Group IV	Unfavorable for maintenance of sight.			Classification	
C123367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123367>	C123333	Reese-Ellsworth Classification Group V|Reese-Ellsworth Group V	Very unfavorable for maintenance of sight.			Classification	
C123368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123368>	C123363	Reese-Ellsworth Classification IA|Reese-Ellsworth IA	Solitary tumor, smaller than 4 disc diameters, tumor at or behind the equator.			Classification	
C123369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123369>	C123363	Reese-Ellsworth Classification IB|Reese-Ellsworth IB	Multiple tumors, none larger than 4 disc diameters, all tumors at or behind the equator.			Classification	
C12336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12336>	C13035	Bladder Neck|BLADDER, NECK|Bladder neck|Cervix Vesicae|Neck|Neck of Bladder|Neck of the Bladder|neck of urinary bladder	The inferior portion of the urinary bladder which is formed as the walls of the bladder converge and become contiguous with the proximal urethra.	Bladder Neck		Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C123370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123370>	C123364	Reese-Ellsworth Classification IIA|Reese-Ellsworth IIA	Solitary tumor, 4 to 10 disc diameters, tumor at or behind the equator.			Classification	
C123371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123371>	C123364	Reese-Ellsworth Classification IIB|Reese-Ellsworth IIB	Multiple tumors, 4 to 10 disc diameters, all tumors behind the equator.			Classification	
C123372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123372>	C123365	Reese-Ellsworth Classification IIIA|Reese-Ellsworth IIIA	Any lesion anterior to the equator.			Classification	
C123373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123373>	C123365	Reese-Ellsworth Classification IIIB|Reese-Ellsworth IIIB	Solitary tumor, larger than 10 disc diameters, tumor behind the equator.			Classification	
C123374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123374>	C123366	Reese-Ellsworth Classification IVA|Reese-Ellsworth IVA	Multiple tumors, some larger than 10 disc diameters.			Classification	
C123375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123375>	C123366	Reese-Ellsworth Classification IVB|Reese-Ellsworth IVB	Any lesion extending anteriorly to the ora serrata.			Classification	
C123376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123376>	C123367	Reese-Ellsworth Classification VA|Reese-Ellsworth VA	Massive tumors involving more than one-half of the retina.			Classification	
C123377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123377>	C123367	Reese-Ellsworth Classification VB|Reese-Ellsworth VB	Vitreous seeding.			Classification	
C123378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123378>	C39619|C1951|C1663	HPV-6-targeting Immunotherapeutic Vaccine INO-3106|HPV-6 E6/E7 DNA Vaccine INO-3106|HPV-6-targeting Immunotherapeutic INO-3106|INO-3106	A DNA vaccine consisting of plasmids encoding the E6 and E7 genes of human papilloma virus subtype 6 (HPV-6), with potential immunostimulating and antineoplastic activities. Administered via intramuscular electroporation, HPV-6-targeting immunotherapeutic vaccine INO-3106 expresses the HPV-6 E6 and E7 proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells that are expressing those proteins, resulting in tumor cell lysis. HPV-6 infections are associated with aerodigestive malignancies.	HPV-6-targeting Immunotherapeutic Vaccine INO-3106		Immunologic Factor|Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123379>	C78284	Ingenol Disoxate|4-Isoxazolecarboxylic acid, 3,5-Diethyl-, (1aR,2S,5R,5aS,6S,8aS,9R,10aR)-1a,2,5,5a,6,9,10,10a-octahydro-5,5a-dihydroxy-4-(hydroxymethyl)-1,1,7,9-tetramethyl-11-oxo-1H-2,8a-methanocyclopenta(a)cyclopropa(E)cyclodecen-6-yl Ester|INGENOL DISOXATE|LEO 43204	A topical, aqueous gel formulation containing a derivative of ingenol, a selective small-molecule activator of protein kinase C (PKC) that is isolated from the sap of Euphorbia species, with the potential to treat preneoplastic skin lesions. Upon topical application of the ingenol disoxate gel, the agent presumably activates various PKC isoforms, which may induce apoptosis in abnormal cells found in severely sun-damaged skin with multiple actinic keratoses. This may decrease the number of actinic keratoses and prevent the development of skin neoplasms. The PKC family consists of signaling isoenzymes that regulate many cell processes, including proliferation, differentiation, and apoptosis.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C12337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12337>	C13035	Ureteric Orifice|Orifice of the Ureter|URETERIC ORIFICE|Ureteral Opening|Ureteric orifice|Uteric Orifice|ureteral orifice	The opening of the ureter in the bladder that is situated at the lateral angle of the trigone.	Ureteric Orifice		Body Space or Junction	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C123380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123380>	C201511|C129822	Anti-CD123 Monoclonal Antibody KHK2823|KHK2823	A fully human monoclonal antibody against CD123 (interleukin-3 receptor alpha chain) with potential antineoplastic activity. Anti-CD123 monoclonal antibody KHK2823 binds to and neutralizes CD123, which is upregulated on leukemic stem cells (LSC) found in myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). This agent may inhibit IL-3-dependent signaling and proliferation and may prevent the uncontrolled growth and differentiation of mutated LSC.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123381>	C1752|C1663	Mimotope-P10s-PADRE Peptide Vaccine|P10s-PADRE|P10s-PADRE Vaccine	A peptide-based vaccine containing a carbohydrate mimetic peptide (CMP) P10s fused to the pan HLA DR-binding epitope (PADRE) peptide, with immunomoadjuvant activity and potential antineoplastic activity. Upon injection of the mimotope-P10s-PADRE peptide vaccine, the P10s peptide, which mimics gangliosides and other tumor-associated carbohydrate antigens (TACA), both stimulates a cytotoxic T-lymphocyte (CTL) response towards cells expressing TACAs and induces the production of antibodies that are reactive with a broad set of TACAs. Additionally, the anti-TACA antibodies may interfere with cellular pathways involved in tumor cell survival and may induce antibody-dependent cellular cytotoxicity (ADCC) toward cells expressing TACAs. PADRE is a helper T-cell epitope that is able to increase the magnitude and duration of the CTL response.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123382>	C1663	MVX-1-loaded Macrocapsule/autologous Tumor Cell Vaccine MVX-ONCO-1|MVX-ONCO-1	A two-component, anti-cancer vaccine containing irradiated tumor cells from a patient, and a capsule implanted with a genetically modified allogeneic cell line that continuously releases granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immune-protective and -boosting activities. Upon subcutaneous injection of MVX-1-loaded macrocapsule/autologous tumor cell vaccine MVX-ONCO-1, the GM-CSF-secreting allogeneic cell capsules and the autologous irradiated cells isolated from the patient's tumor are co-localized in the patient's tissue. This permits the production of GM-CSF and exposes the immune system to the tumor-associated antigens (TAA) expressed by the autologous tumor cells at the injection site. Local expression of GM-CSF recruits and activates antigen-presenting cells (APC), which induces both antibody-dependent cell-mediated cytotoxicity (ADCC) and cytotoxic T-lymphocyte responses at the site of the injection and systemically. This may lead to tumor regression. By using the patient's own irradiated cancer cells as vaccine antigens, the patient's immune system is exposed to the entire repertoire of this individual's TAAs. The encapsulated cell technology (ECT) of GM-CSF-secreting allogeneic cell capsules ensures the continuous release of GM-CSF. GM-CSF, a monomeric glycoprotein that functions as a cytokine, is a strong immune booster and plays an important role in the activation of immune system.			Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123383>	C63817	CXC Chemokine Receptor 2 Antagonist AZD5069|AZD-5069|AZD5069|CXCR2 Antagonist AZD5069|N-(2-(((2,3-difluorophenyl)methyl)thio)-6-(((1R,2S)-2,3-dihydroxy-1-methylpropyl)oxy)-4-pyrimidinyl)-1-azetidinesulfonamide	An orally bioavailable, selective and reversible antagonist of CXC chemokine receptor 2 (CXCR2), with potential anti-inflammatory and antineoplastic activities. Upon administration, CXC chemokine receptor 2 antagonist AZD5069 directly binds to CXCR2 and inhibits its activation. This inhibits CXCR2-mediated signaling and may inhibit tumor cell proliferation in CXCR2-overexpressing tumor cells. In addition, AZD5069 reduces both neutrophil recruitment and migration from the systemic circulation into sites of inflammation, including the lung mucosa; it may also prevent neutrophil migration from the bone marrow. This results in the reduction of inflammation, mucus production, and neutrophil proteinase-mediated tissue destruction in the lung. CXCR2, a G protein-coupled receptor protein also known as IL-8 receptor B (IL-8RB), is upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation and progression; it is known to be elevated in several inflammatory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and fibrotic pulmonary disorders.	CXC Chemokine Receptor 2 Antagonist AZD5069		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123384>	C8021|C8012	Salivary Gland Secretory Carcinoma|Mammary Analogue Secretory Carcinoma of Salivary Gland|Salivary Gland MASC	A rare, low-grade carcinoma of the salivary gland that shares histopathologic features and molecular characteristics (ETV6 gene rearrangement) with secretory breast carcinoma. It usually arises from the parotid gland and less often from the minor salivary glands and has a favorable clinical outcome.			Neoplastic Process	
C123385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123385>	C15180	Patient-Controlled Epidural Analgesia|Epidural Patient-Controlled Analgesia|PCEA	A method of analgesia that uses an epidural catheter and a pump to allow the patient to administer predetermined doses of analgesic into the epidural space as needed to maintain adequate pain control.	Patient-Controlled Epidural Analgesia		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C123386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123386>	C91105	Patient Health Questionnaire-2|PHQ-2|PHQ-2|PHQ04|Patient Health Questionnaire (PHQ-2)|Patient Health Questionnaire-2 (PHQ-2)|Patient Health Questionnaire-2 Item	A 2-item scale used to screen for depression and anhedonia over the past 2 weeks. It is comprised of the first 2 items of the Patient Health Questionnaire-9.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123387>	C29767	4-Hydroxy-3-methoxybenzenesulfonic Acid|4-Guaiacolsulfonic Acid|Benzenesulfonic Acid, 4-Hydroxy-3-methoxy-|SULFOGAIACOL|Sulfogaiacol				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C123388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123388>	C29767	Potassium Guaiacolsulfonate Anhydrous|Benzenesulfonic Acid, Hydroxymethoxy-, Potassium Salt (1:1)|Guaiacolsulfonate Potassium Anhydrous|POTASSIUM GUAIACOLSULFONATE ANHYDROUS|Thiocol				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C123389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123389>	C15312	Light Dosimetry	Methods to measure the administered light dose during photodynamic therapy (PDT).	Light Dosimetry		Activity	CTRP Intervention Terminology|CTRP Terminology
C12338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12338>	C34237	Urachus|URACHAL TRACT|median umbilical ligament|urachus|urachus	A cord of fibrous tissue that extends from the urinary bladder to the umbilicus. The urachus is a remnant of the fetal urinary canal.	Urachus		Embryonic Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C123390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123390>	C20993	Muscle Enhancement Product Use|Muscle Enhancement Product(s) Use|Use of Muscle Enhancement Products	This is a single item, three part measure taken from the Growing Up Today Study (GUTS) that assesses use and frequency of various products (e.g., creatine, growth hormone, steroids) to improve muscle mass or strength in the past year.			Intellectual Product	
C123391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123391>	C74804	Adipocytokine Assay|Adipocytokine Detection|Adipocytokine Measurement|Adipokine Assay|Adipokine Detection|Adipokine Measurement	Any bioassay designed to detect and quantify adipose-associated cytokines.			Laboratory Procedure	
C123392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123392>	C7930	Childhood Lymphomatoid Granulomatosis	Lymphomatoid granulomatosis that occurs during childhood.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123393>	C7934|C123392	Recurrent Childhood Lymphomatoid Granulomatosis	The reemergence of lymphomatoid granulomatosis in childhood after a period of remission.			Neoplastic Process	
C123394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123394>	C3898|C210124	Childhood Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Childhood Extranodal Marginal Zone Lymphoma of MALT|Childhood MALT Lymphoma|Childhood MALToma	An extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue that occurs during childhood.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123395>	C114483	Childhood Langerhans Cell Histiocytosis with Risk Organ Involvement|High Risk Childhood Langerhans Cell Histiocytosis|High-Risk Childhood Langerhans Cell Histiocytosis	Langerhans cell histiocytosis that occurs during childhood and involves the bone marrow, spleen, liver, or lung.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123396>	C114483	Childhood Langerhans Cell Histiocytosis without Risk Organ Involvement	Langerhans cell histiocytosis that occurs during childhood and does not involve the bone marrow, spleen, liver, or lung.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123397>	C7705|C6519	Childhood Spindle Cell Rhabdomyosarcoma	A spindle cell rhabdomyosarcoma occurring in children.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123398>	C8970|C189022	Childhood Periosteal Osteosarcoma	A periosteal osteosarcoma occurring in childhood.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123399>	C38155	First Relapse|First Recurrence|First Recurrence|First Recurrence|INITIAL DISEASE RELAPSE|Initial Recurrence|Initial Relapse	The reemergence of a disorder as diagnosed by clinical and/or laboratory evidence following a single documented period of remission.			Finding	CDISC SDTM Medical History Event Date Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C12339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12339>	C12712	Urethral Gland|Urethra Gland	Any of the glands that secrete mucus into the urethra including the Cowper, Skene, and Littre glands.	Paraurethral Gland		Body Part, Organ, or Organ Component	
C1233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1233>	C697	Spiromustine|1,3-diazaspiro(4,5)decane-2,4-dione,3-(2-(bis-chloroethyl)amino)ethyl|SHM|SPIROMUSTINE|Spirohydantoin Mustard|Spirohydantoin mustard	A bifunctional nitrogen alkylating agent with antineoplastic activity and lipophilic properties. Containing a lipophilic hydantoin group that serves as a carrier to cross the blood brain barrier, spiromustine forms covalent linkages with nucleophilic centers in DNA, causing depurination, base-pair miscoding, strand scission, and DNA-DNA cross-linking, which may result in cytotoxicity. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123400>	C38155	Subsequent Relapse|Subsequent Recurrence|Subsequent Recurrence	The reemergence of a disorder as diagnosed by clinical and/or laboratory evidence following two or more documented periods of remission.			Finding	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123401>	C122606	Early Relapse of Acute Lymphoblastic Leukemia|Early Recurrence of ALL|Early Recurrence of ALL|Early Recurrence of Acute Lymphoblastic Leukemia|Early Recurrence of Acute Lymphoblastic Leukemia|Early Relapse of ALL|Early Relapse of ALL	Clinical and/or laboratory evidence of reemergence of acute lymphoblastic leukemia less than 18 months (extramedullary) or 36 months (marrow) from diagnosis.			Finding	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123402>	C122607	Late Relapse of Acute Lymphoblastic Leukemia|Late Recurrence of ALL|Late Recurrence of ALL|Late Recurrence of Acute Lymphoblastic Leukemia|Late Recurrence of Acute Lymphoblastic Leukemia|Late Relapse of ALL|Late Relapse of ALL	Clinical and/or laboratory evidence of reemergence of acute lymphoblastic leukemia greater than or equal to 18 months (extramedullary) or 36 months (marrow) from diagnosis.			Finding	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123403>	C122606	Early Relapse of Acute Myeloid Leukemia|Early Recurrence of AML|Early Recurrence of Acute Myeloid Leukemia|Early Relapse of AML	Clinical and/or laboratory evidence of reemergence of acute myeloid leukemia less than 12 months from diagnosis.			Finding	
C123404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123404>	C122607	Late Relapse of Acute Myeloid Leukemia|Late Recurrence of AML|Late Recurrence of Acute Myeloid Leukemia|Late Relapse of AML	Clinical and/or laboratory evidence of reemergence of acute myeloid leukemia greater than or equal to 12 months from diagnosis.			Finding	
C123405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123405>	C36294	Multi-Organ Involvement	A finding indicating the spread of a neoplastic process to multiple organs.			Finding	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123406>	C177686|C177682	FLT3-Internal Tandem Duplication High Allelic Ratio|FLT3-ITD High Allelic Ratio|FLT3-Internal Tandem Duplication Amplification|FLT3-Internal Tandem Duplication Amplification|FLT3/ITD High Allelic Ratio	A molecular genetic finding in acute myeloid leukemias indicating that FLT3-internal tandem duplication (FLT3-ITD) is the dominant lesion, and which is present in the majority or all of the leukemic cells.	FLT3-Internal Tandem Duplication High Allelic Ratio		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123407>	C35869	Tumor Complete Metabolic Response|CMR|Complete Metabolic Response|Definite Tumor Complete Metabolic Response|Definite complete metabolic response|Tumor CMR	A finding of disappearance of metabolic tumor activity in target and non-target lesions, marked by a decrease in tumor standardized uptake value to the level of surrounding normal tissue.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123408>	C35869	Likely Tumor Complete Metabolic Response|Likely complete metabolic response	A finding of diffuse metabolic activity at the primary tumor or nodal sites that is greater than background uptake but less than liver uptake.			Finding	
C123409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123409>	C35869	Likely Residual Metabolic Tumor Activity|Likely Residual Metabolic Disease|Likely residual metabolic disease	A finding of focal metabolic activity at the primary or nodal sites that is greater than liver uptake.			Finding	
C123410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123410>	C35869	Likely Inflammatory Activity|Likely inflammatory|Post-Radiation Inflammation Activity	A finding of metabolic activity at the primary or nodal sites that is greater than liver uptake, but can be attributed to inflammation activity.			Finding	
C123411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123411>	C35869	Definite Residual Metabolic Tumor Activity|Definite Residual Metabolic Disease|Definite residual metabolic disease	A finding of strong focal metabolic activity at the primary or nodal sites that is greater than liver uptake.			Finding	
C123412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123412>	C2866	Alzheimer's Disease 3|AD3|Familial Alzheimer Disease, Type 3|Familial Alzheimer's Disease, Type 3	Alzheimer's disease with an early onset (starts before the age of 65). It is caused by mutations in the PSEN1 gene.			Mental or Behavioral Dysfunction	Cellosaurus Disease Terminology
C123413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123413>	C2866	Alzheimer's Disease 4|AD4|Familial Alzheimer Disease, Type 4|Familial Alzheimer's Disease, Type 4	Alzheimer's disease with an early onset (starts before the age of 65). It is caused by mutations in the PSEN2 gene.			Mental or Behavioral Dysfunction	Cellosaurus Disease Terminology
C123414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123414>	C111648	Catecholaminergic Polymorphic Ventricular Tachycardia Type 1	Polymorphic ventricular tachycardia induced by adrenergic stress. It is inherited in an autosomal dominant pattern and is caused by mutations in the ryanodine receptor 2 (RYR2) gene.			Disease or Syndrome	Cellosaurus Disease Terminology
C123415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123415>	C197907|C116718	Autosomal Recessive Torsion Dystonia 2|DYT2|Dystonia Musculorum Deformans 2	An autosomal recessive inherited disorder caused by mutation in the HPCA gene. It begins in childhood or adolescence and is characterized by involuntary, sustained muscle contractions and torsions affecting initially distal limbs and later the neck, orofacial, and craniocervical regions.			Disease or Syndrome	Cellosaurus Disease Terminology
C123416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123416>	C34704	Hyperlipoproteinemia, Type IIa|FH|Familial Hypercholesterolemia|Hyperlipidemia Type IIa|Type IIa Hyperlipidemia	An autosomal dominant inherited disorder characterized by very high levels of low-density lipoprotein cholesterol (LDL-C) and total cholesterol in the blood. It is usually caused by mutations in the LDLR gene which is located on the short arm of chromosome 19.			Disease or Syndrome	Cellosaurus Disease Terminology
C123417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123417>	C53543	Mandibuloacral Dysplasia with Type A Lipodystrophy|MADA	A rare, autosomal recessive inherited disorder caused by mutations in the LMNA gene. It is characterized by growth retardation, craniofacial abnormalities with mandibular hypoplasia, skeletal abnormalities with progressive osteolysis of the distal phalanges and clavicles, and mottled or patchy skin pigmentation. The affected individuals have a marked acral loss of adipose tissue with normal or increased adipose tissue in the neck and trunk.			Disease or Syndrome	Cellosaurus Disease Terminology
C123418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123418>	C26170	Vasoprotective Agent	Any agent that is used to prevent or inhibit damage to blood vessels.			Chemical Viewed Functionally	
C123419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123419>	C77916	Cystoisospora				Eukaryote	
C12341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12341>	C32574|C12749	Conjunctiva|CONJUNCTIVA|Conjuctival|conjunctiva|conjunctiva|conjunctivae|conjunctivas|tunica conjunctiva|wall of conjunctival sac	A thin, transparent tissue divided into the palpebral conjunctiva (covering the inner side of the eye lid) and the bulbar conjunctiva (covering the eyeball).	Conjunctiva		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTDC Value Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C123420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123420>	C118932	Iodamoeba	A genus of nonpathogenic parasitic amoeba whose cysts show a characteristic brown color when stained with iodine due to large glycogen inclusions.			Eukaryote	
C123421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123421>	C77916	Leishmania	A genus of parasitic trypanosomatid protozoa in the family Trypanosomatidae. These parasites are transmitted by the bite of a sand fly and they are causative for leishmaniasis.			Eukaryote	
C123422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123422>	C77916	Naegleria|NAEGLERIA	A genus of parasitic amoeba in the family Vahlkampfiidae.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123423>	C76371	Neisseria elongata|NEISSERIA ELONGATA	A species of nonmotile, aerobic, catalase-negative, asaccharolytic, oxidase-positive, urea-negative, gram-negative coccobacillus bacterium in the family Neisseriaceae. It is found in the oral bacterial flora of the human pharynx and throat. In rare cases N. elongata is a causative agent of bacterial endocarditis.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123424>	C35552	Academic Research Council Coronary Stent Thrombosis Timing|STCTIMNG|STCTIMNG|Stent Thrombosis, Coronary, ARC Timing|Stent Thrombosis, Coronary, ARC Timing|Stent Thrombosis, Coronary, ARC Timing	Categorization of the timing of coronary stent thrombosis occurrence per the classification schema described by the Academic Research Consortium (ARC).			Finding	CDISC SDTM Cardiovascular Findings About Test Code Terminology|CDISC SDTM Cardiovascular Findings About Test Name Terminology|CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123425>	C14248	Loa				Animal	
C123426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123426>	C123646	Necator				Animal	
C123427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123427>	C267|C211679	Rolapitant Hydrochloride Anhydrous|ROLAPITANT HYDROCHLORIDE ANHYDROUS				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C123428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123428>	C155653	Naxitamab|Anti-Gd2 IGG3 Monoclonal Antibody 3f8 Humanized|Danyelza|Hu3F8|Humanized Anti-GD2 Antibody 3F8|Humanized Monoclonal Antibody Hu3f8-IGG1|NAXITAMAB|Naxitamab-gqgk	A humanized monoclonal antibody directed against the human tumor-associated antigen GD2, with potential antineoplastic activity. Upon vaccination, naxitamab stimulates antibody-dependent cell-mediated cytotoxicity (ADCC) against GD2-expressing tumor cells. GD2, a disialoganglioside with expression in normal tissues restricted primarily to the cerebellum and peripheral nerves, is commonly expressed at high levels on tumors of neuroectodermal origins such as melanomas and neuroblastomas. Compared to the murine monoclonal antibody 3F8 (m3F8), the humanized form does not cause a human anti-mouse antibody (HAMA) response and shows enhanced ADCC activity.	Naxitamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C123429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123429>	C53543	Hyperkalemic Periodic Paralysis	A rare, autosomal dominant inherited disorder caused by mutations in the SCN4A gene. It is characterized by occasional episodes of muscle weakness or paralysis which are usually accompanied by increased levels of potassium in the blood. In some cases, the episodes of paralysis are associated with normal blood potassium levels.  Ingestion of potassium can trigger attacks in affected individuals.			Disease or Syndrome	
C12342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12342>	C13019	Cornea|CORNEA|Cornea, NOS|Corneal structure (body structure)|EYE, CORNEA|Human Cornea|cornea	A dome-shaped, transparent, avascular tissue covering the front of the eye. It is composed of five layers: squamous epithelium, Bowman's membrane, stroma, Descemet's membrane, and endothelium. Refraction of light contributing to eye's focusing ability is its characteristic function. It contains unmyelinated nerve endings which are responsible for the high sensitivity of the tissue.	Cornea		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Structured Product Labeling Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|SPL Tissue Form Product Type Terminology
C123430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123430>	C97936	Glibornuride|1-((1R)-2-endo-hydroxy-3-endo-bornyl)-3-(p-tolylsulfonyl)urea|GLIBORNURIDE|Glutril|Ro 6-4563|Ro 6-4563/8|Urea, 1-(2-Hydroxy-3-bornyl)-3-(p-tolylsulfonyl)-, (1R,2R,3S,4S)-	An orally bioavailable sulfonamide urea derivative with antihyperglycemic activity. Upon administration, glibornuride binds to and blocks the sulfonylurea receptor type 1 (SUR1) subunit of the ATP-sensitive inwardly-rectifying potassium (K(ATP)) channels on the membranes of pancreatic beta cells. This prevents the inward flow of positively charged potassium (K+) ions into the cell, and induces a calcium ion (Ca2+) influx through voltage-sensitive calcium channels, which triggers exocytosis of insulin-containing granules. Insulin stimulates glycogen synthesis and inhibits gluconeogenesis, which together lower blood glucose levels.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C123431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123431>	C2701	Human Varicella Zoster Immune Globulin|HUMAN VARICELLA-ZOSTER IMMUNE GLOBULIN|Human Varicella-Zoster Immune Globulin|VARIZIG|Varicella Zoster Immune Globulin Human	A human plasma-derived immunoglobulin G (IgG) formulation containing high levels of antibodies against varicella zoster virus (VZV), a double-stranded DNA virus that causes chickenpox and herpes zoster (shingles), with potential immunomodulating and antiviral activities. VZV IgG (VARIZIG) is isolated from donors expressing high amounts of VZV antibodies. Upon intramuscular (IM) administration, the anti-VZV antibodies provide passive immunization against VZV. This may prevent infection by VZV in immunocompromised patients.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C123433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123433>	C53543|C3235	Hyperlysinemia	An autosomal recessive inherited condition caused by mutations in the AASS gene. It is characterized by elevated levels of the amino acid lysine in the blood. It usually does not cause health problems.			Disease or Syndrome	Cellosaurus Disease Terminology
C123434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123434>	C53543|C26964	Immunoglobulin A Deficiency 1|IGAD1	Decreased or absent levels of serum immunoglobulin A, with normal serum levels of immunoglobulin G and immunoglobulin M in a patient who is older than 4 years of age and in whom all other causes of hypogammaglobulinemia have been excluded. Affected individuals may be asymptomatic or have frequent infections, allergic reactions, or autoimmune disorders.			Disease or Syndrome	Cellosaurus Disease Terminology
C123435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123435>	C53543|C3235	Methionine Adenosyltransferase Deficiency|Hypermethioninemia, Isolated Persistent|Isolated Persistent Hypermethioninemia|MAT Deficiency|MAT I/III Deficiency	A metabolic disorder usually inherited in an autosomal recessive pattern and caused by mutations in the MAT1A gene. Affected individuals usually do not have clinical abnormalities.			Disease or Syndrome	Cellosaurus Disease Terminology
C123436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123436>	C53543|C28193	Peters-Plus Syndrome	A rare, autosomal recessive inherited syndrome caused by mutations in the B3GALTL gene. It is characterized by abnormalities in the anterior chamber of the eye, short stature, cleft lip with or without cleft palate, distinctive facial features, and intellectual disability.			Disease or Syndrome	Cellosaurus Disease Terminology
C123437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123437>	C53543|C170732	Multicentric Osteolysis, Nodulosis, and Arthropathy|Hereditary Multicentric Osteolysis|MONA	A rare, autosomal recessive inherited syndrome caused by mutations in the MMP2 gene. It is characterized by the presence of multiple, painless subcutaneous nodules, osteolysis particularly in the hands and feet, osteoporosis, and arthropathy.			Disease or Syndrome	
C123438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123438>	C84910	Ullrich Congenital Muscular Dystrophy|Scleroatonic Ullrich Disease|UCMD	A rare, autosomal recessive inherited disorder caused by mutations in the COL6A1, COL6A2, and COL6A3 genes. Signs and symptoms usually appear at birth or early infancy. Affected individuals have severe muscle weakness, multiple contractures, and hypermobility in their distal joints.			Disease or Syndrome	Cellosaurus Disease Terminology
C123439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123439>	C123424	Academic Research Council Acute Stent Thrombosis|STENT THROMBOSIS ARC ACUTE	The formation of a clot within a stent less than 24 hours after the stent is placed. (Cutlip DE, Windecker S, Mehran R, et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions. Circulation. 2007;115:2344-2351)			Finding	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12343>	C13019	Retina|RETINA|Retinal structure (body structure)|inner layer of eyeball|retina|retina|retina of camera-type eye|tunica interna of eyeball	A light-sensitive membrane that lines the back wall of the eyeball. The retina is continuous with the optic nerve and this way transmits optical images to the brain.	Retina		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C123440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123440>	C123424	Academic Research Council Late Stent Thrombosis|STENT THROMBOSIS ARC LATE	The formation of a clot within a stent greater than thirty days but less than one year after the stent is placed. (Cutlip DE, Windecker S, Mehran R, et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions. Circulation. 2007;115:2344-2351)			Finding	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123441>	C123424	Academic Research Council Subacute Stent Thrombosis|STENT THROMBOSIS ARC SUBACUTE	The formation of a clot within a stent greater than 24 hours but less than thirty days after the stent is placed. (Cutlip DE, Windecker S, Mehran R, et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions. Circulation. 2007;115:2344-2351)			Finding	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123442>	C123424	Academic Research Council Very Late Stent Thrombosis|STENT THROMBOSIS ARC VERY LATE	The formation of a clot within a stent more than one year after the stent is placed. (Cutlip DE, Windecker S, Mehran R, et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions. Circulation. 2007;115:2344-2351)			Finding	CDISC SDTM Cardiovascular Findings About Results Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123443>	C176708	Clinical Change by Non-Invasive Imaging Procedure|NINVIMGC|NINVIMGC|Non-Invasive Imaging Change|Non-Invasive Imaging Change|Non-Invasive Imaging Change	Any clinical change to a subject as determined by a non-invasive imaging procedure.			Finding	CDISC SDTM Cardiovascular Findings About Test Code Terminology|CDISC SDTM Cardiovascular Findings About Test Name Terminology|CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123444>	C38053	12 Lead Continuous ECG|12 LEAD CONTINUOUS ECG	A continuous electrocardiographic (ECG) recording that utilizes twelve leads, though the lead placement may vary from the standard 12 Lead ECG placement. Examples include, but are not limited to, 12 lead Holter with modified Mason-Likar lead placements, 12 lead exercise ECGs, and 12 lead telemetry systems.			Diagnostic Procedure	CDISC SDTM ECG Test Method Terminology|CDISC SDTM Terminology|CDISC SEND ECG Method Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C123445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123445>	C168186	12 Lead ECG Extracted From 12 Lead Continuous ECG Recording|12 LEAD ECG EXTRACTED FROM 12 LEAD CONTINUOUS ECG RECORDING	Any electrocardiogram (ECG) reading excerpted from a continuous, 12 Lead ECG.			Laboratory or Test Result	CDISC SDTM ECG Test Method Terminology|CDISC SDTM Terminology|CDISC SEND ECG Method Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C123446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123446>	C38053	Continuous Ambulatory ECG|CONTINUOUS AMBULATORY ECG	A continuous electrocardiographic (ECG) recording that utilizes one or more leads that both records and stores data directly to a device worn by the subject, such that the subject need not be restricted to a medical facility, and may be able to participate in their customary activities of daily living.			Diagnostic Procedure	CDISC SDTM ECG Test Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C123447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123447>	C62085	ECG Median Heart Rate|EGHRMED	An electrocardiographic measurement of the median rate of depolarization of a specific region of the heart during an interval of time, usually expressed in beats per minute. Unless otherwise specified, this is usually the median ventricular rate.			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C123448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123448>	C62085	Aggregate QTcL Interval|QTCLAG|QTcL Interval, Aggregate|QTcL Interval, Aggregate	The correction of the aggregate of QT intervals using a linear correction formula, which allows for the comparison of QT intervals across a range of heart rates.			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C123449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123449>	C62085	Single Beat QTcL Interval|QTCLSB|QTcL Interval, Single Beat|QTcL Interval, Single Beat	The correction of the QT interval within a single beat using a linear correction formula.			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12344>	C12749	Choroid|CHOROID|EYE, CHOROID|choroid|optic choroid	A blood vessel-containing membrane of the eye that lies between the retina and the sclera.	Choroid		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C123450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123450>	C62085	Aggregate QTcV Interval|QTCVAG|QTCVAG|QTcV Interval, Aggregate|QTcV Interval, Aggregate|QTcV Interval, Aggregate	The correction of the aggregate of QT intervals using the Van der Water's formula, which allows for the comparison of QT intervals across a range of heart rates.			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C123451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123451>	C62085	Single Beat QTcV Interval|QTCVSB|QTCVSB|QTcV Interval, Single Beat|QTcV Interval, Single Beat|QTcV Interval, Single Beat	The correction of the QT interval within a single beat using the Van der Water's formula.			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C123452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123452>	C71738	Continuation Therapy Epoch|CONTINUATION TREATMENT|Continuation|Continuation Phase|Continuation Phase	A period in a clinical study during which subjects receive continuation therapy. This therapy is usually different from the therapy given during the induction phase and administered over a longer period of time.			Research Activity	ALL Authorized Value Terminology|ALL Course Timing Table|ALL Histology Table|ALL Off Protocol Therapy/Study Table|ALL Vitals Table|CDISC SDTM Epoch Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123453>	C71738	Induction Therapy Epoch|INDUCTION TREATMENT|Induction Phase|Induction Phase|Intensive Phase	A period in a clinical study during which subjects receive induction therapy.			Research Activity	CDISC SDTM Epoch Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123454>	C47824	CDISC Occurrence Data Structure|OCCDS|OCCURRENCE DATA STRUCTURE|Occurrence Data Structure	The CDISC ADaM data structure for occurrence analysis. Occurrence analysis is the counting of subjects with a record or term, and often includes a structured hierarchy of dictionary coding categories.			Idea or Concept	CDISC Define-XML General Observation Class Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123455>	C64430	Beta-Cell Function Measurement|BCEFNCTN|Beta-cell Function|Beta-cell Function	The determination of the beta cell function (insulin production and secretion) in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C123456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123456>	C142330	Hepatitis C mRNA Measurement	The determination of the amount of Hepatitis C mRNA present in a sample.			Laboratory Procedure	
C123457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123457>	C142331	Hepatitis E mRNA Measurement	The determination of the amount of Hepatitis E mRNA present in a sample.			Laboratory Procedure	
C123458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123458>	C74957	Insulin Resistance Measurement|INSULINR|Insulin Resistance|Insulin Resistance	The determination of the insulin resistance (cells inability to respond to insulin) in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C123459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123459>	C74957	Insulin Sensitivity Measurement|INSULINS|Insulin Sensitivity|Insulin Sensitivity	The determination of the insulin sensitivity (cells are stimulated by lower than normal insulin levels) in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12345>	C13019	Ciliary Body|CILIARY BODY|Ciliary body|EYE, CILIARY BODY|ciliary body|ciliary body	Tissue located behind the iris and composed of muscle and epithelium. Its functions include the production of aqueous humor and changing the shape of the crystalline lens.	Ciliary Body		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C123460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123460>	C67208	Macrophage to Leukocyte Ratio|MCPHGLE|MCPHGLE|Macrophages/Leukocytes|Macrophages/Leukocytes|Macrophages/Leukocytes	The determination of the ratio of macrophages compared to leukocytes in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Cell Phenotyping Test Code Terminology|CDISC SDTM Cell Phenotyping Test Name Terminology|CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C123461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123461>	C12904	Axillary Lymph Node Level I|AXILLARY LYMPH NODE LEVEL I	Axillary lymph nodes located inferolateral to the pectoralis minor.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C123462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123462>	C12904	Axillary Lymph Node Level II|AXILLARY LYMPH NODE LEVEL II	Axillary lymph nodes located posterior to the pectoralis minor.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C123463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123463>	C12904	Axillary Lymph Node Level III|AXILLARY LYMPH NODE LEVEL III	Axillary lymph nodes located superomedial to pectoralis minor.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C123464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123464>	C38060	Amsler Grid|AMSLER GRID	A diagrammatic method to test visual acuity and presence of macular degeneration, which utilizes a uniform square grid of lines with a dot in the center.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C123465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123465>	C16818	Ductography|DUCTOGRAPHY|Galactography|Galactography	A type of mammography that uses contrast medium to visualize the ducts of the breast.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C123466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123466>	C38060	Ishihara Color Plates|ISHIHARA COLOR PLATES	A diagrammatic method to test color blindness of deficiencies, which utilizes a circular form composed of multiple size circles in varying colors. A number or symbol is present in the middle of the circle and is composed of little circles which are a different color from the circles composing the outer circular form.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C123467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123467>	C38060	Snellen Eye Chart|SNELLEN EYE CHART	A diagrammatic method to test visual acuity, which utilizes a chart containing 11 lines of Sloan optotypes in varying sizes, the largest located at the top of the chart and decreasing in size toward the bottom of the chart.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C123468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123468>	C77167	Coniochaeta|CONIOCHAETA|Lecythophora	A genus of pleomorphic yeasts in the family Coniochaetaceae. Species within this genus are known as pathogens of woody hosts, but some can also cause opportunistic infections in humans.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123469>	C86421	Gram-Negative Pleomorphic Bacillus|GRAM-NEGATIVE PLEOMORPHIC BACILLUS	Any rod-shaped bacteria with variable length or shape that contains low levels of peptidoglycan in its cell wall and stains pink with the Gram staining technique.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12346>	C38617|C12712	Lacrimal Gland|GLAND, LACRIMAL|LACRIMAL GLAND|Lacrimal gland|Lacrimal gland structure (body structure)|glandula lacrimalis|lacrimal gland|lacrimal gland|lacrimal-preorbital gland	Paired, almond-shaped exocrine glands situated superior and posterior to each orbit of the eye that produce and secrete the watery serous component of tears.	Lacrimal Gland		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C123470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123470>	C86424	Gram-Positive Diplococcus|GRAM-POSITIVE DIPLOCOCCUS	Any paired spherical bacteria that has a peptidoglycan rich cell wall that stains dark purple with the Gram staining technique.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123471>	C62589	Gram-Positive Microaerophilic Bacillus|GRAM-POSITIVE MICROAEROPHILIC BACILLUS	Any rod shaped bacteria that requires oxygen, but is poisoned by high concentrations, and has a peptidoglycan rich cell wall that stains dark purple with the Gram staining technique.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123472>	C86424	Gram-Positive Microaerophilic Coccus|GRAM-POSITIVE MICROAEROPHILIC COCCUS	Any spherical shaped bacteria that requires oxygen, but is poisoned by high concentrations, and has a peptidoglycan rich cell wall that stains dark purple with the Gram staining technique.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123473>	C86430	Haemophilus haemolyticus, Beta-Lactamase Negative|HAEMOPHILUS HAEMOLYTICUS, BETA-LACTAMASE NEGATIVE	Any bacterial species identified as Haemophilus haemolyticus that does not produce the enzyme beta-lactamase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123474>	C86430	Haemophilus haemolyticus, Beta-Lactamase Positive|HAEMOPHILUS HAEMOLYTICUS, BETA-LACTAMASE POSITIVE	Any bacterial species identified as Haemophilus haemolyticus that produces the enzyme beta-lactamase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123475>	C86430	Haemophilus haemolyticus, Penicillinase Negative|HAEMOPHILUS HAEMOLYTICUS, PENICILLINASE NEGATIVE	Any bacterial species identified as Haemophilus haemolyticus that does not produce the enzyme penicillinase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123476>	C86430	Haemophilus haemolyticus, Penicillinase Positive|HAEMOPHILUS HAEMOLYTICUS, PENICILLINASE POSITIVE	Any bacterial species identified as Haemophilus haemolyticus that produces the enzyme penicillinase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123477>	C86431	Haemophilus influenzae, Beta-Lactamase Negative|HAEMOPHILUS INFLUENZAE, BETA-LACTAMASE NEGATIVE	Any bacterial species identified as Haemophilus influenzae that does not produce the enzyme beta-lactamase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123478>	C86431	Haemophilus influenzae, Beta-Lactamase Positive|HAEMOPHILUS INFLUENZAE, BETA-LACTAMASE POSITIVE	Any bacterial species identified as Haemophilus influenzae that produces the enzyme beta-lactamase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123479>	C86431	Haemophilus influenzae, Penicillinase Negative|HAEMOPHILUS INFLUENZAE, PENICILLINASE NEGATIVE	Any bacterial species identified as Haemophilus influenzae that does not produce the enzyme penicillinase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12347>	C25444	Orbit|BODY CAVITY, ORBITAL|Eye Socket|Eye Socket|ORBIT|Ocular Orbit|Ocular Orbit|Ocular Orbits|Ocular orbits|Orbit, NOS|Orbital Cavity|Structure of orbit proper (body structure)	The bony cavity of the skull which contains the eye, anterior portion of the optic nerve, ocular muscles and ocular adnexa. Seven bones contribute to the structure of the orbit: the frontal, maxillary, zygomatic, sphenoid, lacrimal, ethmoid, and palatine bones.	Orbit		Body Space or Junction	AML Authorized Value Terminology|AML Myeloid Sarcoma Involvement Table|CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTDC Value Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table
C123480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123480>	C86431	Haemophilus influenzae, Penicillinase Positive|HAEMOPHILUS INFLUENZAE, PENICILLINASE POSITIVE	Any bacterial species identified as Haemophilus influenzae that produces the enzyme penicillinase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123481>	C86432	Haemophilus parahaemolyticus, Beta-Lactamase Negative|HAEMOPHILUS PARAHAEMOLYTICUS, BETA-LACTAMASE NEGATIVE	Any bacterial species identified as Haemophilus parahaemolyticus that does not produce the enzyme beta-lactamase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123482>	C86432	Haemophilus parahaemolyticus, Beta-Lactamase Positive|HAEMOPHILUS PARAHAEMOLYTICUS, BETA-LACTAMASE POSITIVE	Any bacterial species identified as Haemophilus parahaemolyticus that produces the enzyme beta-lactamase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123483>	C86432	Haemophilus parahaemolyticus, Penicillinase Negative|HAEMOPHILUS PARAHAEMOLYTICUS, PENICILLINASE NEGATIVE	Any bacterial species identified as Haemophilus parahaemolyticus that does not produce the enzyme penicillinase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123484>	C86432	Haemophilus parahaemolyticus, Penicillinase Positive|HAEMOPHILUS PARAHAEMOLYTICUS, PENICILLINASE POSITIVE	Any bacterial species identified as Haemophilus parahaemolyticus that produces the enzyme penicillinase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123485>	C86433	Haemophilus parainfluenzae, Beta-Lactamase Negative|HAEMOPHILUS PARAINFLUENZAE, BETA-LACTAMASE NEGATIVE	Any bacterial species identified as Haemophilus parainfluenzae that does not produce the enzyme beta-lactamase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123486>	C86433	Haemophilus parainfluenzae, Beta-Lactamase Positive|HAEMOPHILUS PARAINFLUENZAE, BETA-LACTAMASE POSITIVE	Any bacterial species identified as Haemophilus parainfluenzae that produces the enzyme beta-lactamase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123487>	C86433	Haemophilus parainfluenzae, Penicillinase Negative|HAEMOPHILUS PARAINFLUENZAE, PENICILLINASE NEGATIVE	Any bacterial species identified as Haemophilus parainfluenzae that does not produce the enzyme penicillinase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123488>	C86433	Haemophilus parainfluenzae, Penicillinase Positive|HAEMOPHILUS PARAINFLUENZAE, PENICILLINASE POSITIVE	Any bacterial species identified as Haemophilus parainfluenzae that produces the enzyme penicillinase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123489>	C123338	Heterophyes heterophyes|HETEROPHYES HETEROPHYES	A species of parasitic flatworms in the family Heterophyidae. The lifecycle of H. heterophyes involves snails as the first intermediate host, freshwater fish as the second intermediate host, and humans, fish-eating carnivores, or birds as the definitive host. Infestation causes heterophyiasis.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12348>	C33077	Meninges|MENINGES|Meninges, NOS|meningeal cluster|meninges	Any one of three membranes that surround the brain and spinal cord.	Meninges		Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C123490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123490>	C53454	Influenza A (H5N1) Virus|H5N1 Influenza Virus|HPAI H5N1 Virus|Highly Pathogenic Asian Avian Influenza A (H5N1) Virus|INFLUENZA A VIRUS SUBTYPE H5N1|Influenza A Virus H5N1 Subtype|Influenza A/H5N1	A strain of avian influenza A virus. This strain has caused major outbreaks in domestic poultry in parts of Asia and the Middle East and can cause infections in humans.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|ORCHESTRA Terminology
C123491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123491>	C123420	Iodamoeba butschlii|IODAMOEBA BUTSCHLII|Iodamoeba buetschlii	A species of nonpathogenic parasitic amoeba. Transmission of I. butschlii is by a fecal-oral route and infection is usually asymptomatic.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123492>	C76352	Lactobacillus gasseri|LACTOBACILLUS GASSERI	A species of Gram-positive, rod shaped, anaerobic bacteria in the phylum Firmicutes. This species is nonmotile and non spore forming. L. gasseri is found in the gastrointestinal tract and the vaginal tract where it produces lactic acid by fermentation; it also produces hydrogen peroxide. It is a causative agent of Fournier's gangrene.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123493>	C76352	Lactobacillus oris|LACTOBACILLUS ORIS	A species of Gram-positive, rod shaped, facultatively anaerobic bacteria in the phylum Firmicutes. This species is nonmotile and non spore forming, catalase negative, and obligately heterofermentative, producing both D- and L-lactic acid. L. oris is a normal flora component of the human oral cavity and gastrointestinal tract.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123494>	C76352	Lactobacillus paracasei|LACTOBACILLUS PARACASEI	A species of Gram-positive, rod shaped, facultatively heterofermentative bacteria in the phylum Firmicutes. This species is nonmotile and non spore forming. L. paracasei is a normal flora component of the the human oral cavity and gastrointestinal tract. It may be considered a subspecies of Lactobacillus casei.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123495>	C76352	Lactobacillus rhamnosus|LACTOBACILLUS RHAMNOSUS|Lactobacillus casei rhamnosus	A species of Gram-positive, rod shaped, facultatively heterofermentative bacteria in the phylum Firmicutes. This species is nonmotile and non spore forming. L. paracasei is a normal flora component of the the human gastrointestinal tract and female reproductive tract. It is closely related to L. casei and L. paracasei.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123496>	C76352	Lactobacillus vaginalis|LACTOBACILLUS VAGINALIS	A species of Gram-positive, rod shaped, facultatively anaerobic, heterofermentative bacteria in the phylum Firmicutes that occur singly or in pairs or short chains. This species is nonmotile and non spore forming. L. vaginalis was isolated from the vaginas of patients suffering from trichomoniasis.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123497>	C86485	Lactococcus lactis subsp lactis|LACTOCOCCUS LACTIS SUBSP. LACTIS|Lactobacillus xylosus|Lactococcus lactis subsp. lactis|Streptococcus diacetilactis	A species of Gram positive, cocci shaped, lactic acid bacteria assigned to the phylum Firmicutes. It is used in the manufacturing of cultured milk products and differs from Lactococcus lactis subsp. cremoris by being more hardy to salt, pH, and high temperatures.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123498>	C86489	Legionella pneumophila Serogroup 1|LEGIONELLA PNEUMOPHILA SEROGROUP 1	A subgroup of Legionella pneumophila differentiated by its antigenicity. Serogroup 1 is the serogroup most commonly associated with disease, responsible for 70-90% of cases of legionellosis.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123499>	C86489	Legionella pneumophila Serogroup 2|LEGIONELLA PNEUMOPHILA SEROGROUP 2	Subgroup 2 of Legionella pneumophila, differentiated by its antigenicity. Although this serogroup is rarely identified in infected individuals it causes clinical features similar to the pneumonia caused by other serogroups.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12349>	C12348	Cerebral Meninges|Cerebral meninges	The membranes that envelop and protect the brain.	Cerebral Meninges		Tissue	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C1234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1234>	C1450	Spiroplatin|Cis-1,1-diamino-methylcyclohexane sulfato-platinum|Platinum, (1,1-cyclohexanedimethanamine-n,n')(sulfato(2-)-O,O')-, (sp-4-2)-|SPIROPLATIN|TNO-6	A synthetic derivative of cyclohexane sulfatoplatinum with antineoplastic properties.  Spiroplatin induces DNA cross-links, thereby inhibiting DNA replication and RNA and protein synthesis. Similar to other platinum compounds, this agent has been shown to be mutagenic and carcinogenic. (NCI04)			Inorganic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123500>	C86489	Legionella pneumophila Serogroup 3|LEGIONELLA PNEUMOPHILA SEROGROUP 3	Subgroup 3 of Legionella pneumophila, differentiated by its antigenicity.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123501>	C86489	Legionella pneumophila Serogroup 4|LEGIONELLA PNEUMOPHILA SEROGROUP 4	Subgroup 4 of Legionella pneumophila, differentiated by its antigenicity.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123502>	C86489	Legionella pneumophila Serogroup 5|LEGIONELLA PNEUMOPHILA SEROGROUP 5	Subgroup 5 of Legionella pneumophila, differentiated by its antigenicity.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123503>	C86489	Legionella pneumophila Serogroup 6|LEGIONELLA PNEUMOPHILA SEROGROUP 6	A subgroup of Legionella pneumophila differentiated by its antigenicity. Serogroup 6 is the second most common serogroup causing legionellosis, according to the frequency of isolation from clinical samples.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123504>	C86489	Legionella pneumophila Serogroup 7|LEGIONELLA PNEUMOPHILA SEROGROUP 7	Subgroup 7 of Legionella pneumophila, differentiated by its antigenicity.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123505>	C86489	Legionella pneumophila Serogroup 8|LEGIONELLA PNEUMOPHILA SEROGROUP 8	Subgroup 8 of Legionella pneumophila, differentiated by its antigenicity.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123506>	C86489	Legionella pneumophila Serogroup 9|LEGIONELLA PNEUMOPHILA SEROGROUP 9	Subgroup 9 of Legionella pneumophila, differentiated by its antigenicity.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123507>	C123421	Leishmania braziliensis|LEISHMANIA BRAZILIENSIS|Leishmania brasiliensis|Leishmania viannia	A species of parasitic trypanosomatid protozoa in the family Trypanosomatidae. L. braziliensis is a New World pathogen. As well as causing localized cutaneous lesions in affected people, this species can also result in a destructive, progressive infection of mucosal tissue.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123508>	C123421	Leishmania donovani|LEISHMANIA DONOVANI	A species of parasitic trypanosomatid protozoa in the family Trypanosomatidae. L. donovani causes both visceral and dermal leishmaniasis. This species is the primary cause of visceral leishmaniasis in the Indian subcontinent and East Africa.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123509>	C123421	Leishmania infantum|LEISHMANIA INFANTUM|Leishmania chagasi|Leishmania donovani infantum	A species of parasitic trypanosomatid protozoa in the family Trypanosomatidae. L. infantum is the causative agent of infantile visceral leishmaniasis in the Mediterranean region and in Latin America.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12350>	C12348	Spinal Meninges|Spinal Meninx|Spinal meninges|meninx of spinal cord	Connective tissue membranes that surround and support the spinal cord and cauda equina. They are continuous with cerebral meninges, which surround and support the brain.	Spinal Meninges		Tissue	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C123510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123510>	C123421	Leishmania mexicana|LEISHMANIA MEXICANA	A species of parasitic trypanosomatid protozoa in the family Trypanosomatidae. L. mexicana is endemic in South and Central America and causes the mildest form of leishmaniasis.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123511>	C123421	Leishmania tropica|LEISHMANIA TROPICA|Leishmania tropica minor	A species of parasitic trypanosomatid protozoa in the family Trypanosomatidae. L. tropica infection results in a non-ulcerating disease.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123512>	C123425	Loa loa|Eye Worm|LOA LOA	A species of parasitic nematodes in the family Onchocercidae. The lifecycle of L. loa involves deer flies as the intermediate host and humans as the definitive host. Infestation causes loa loa filariasis (loiasis).			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123513>	C113447	Megamonas hypermegale|Bacteroides hypermegas|MEGAMONAS HYPERMEGALE|Megamonas hypermegas|Sphaerophorus hypermegas	A species of Gram-negative, rod-shaped, non-spore-forming anaerobic bacterium assigned to the phylum Firmicutes. M. hypermegale can ferment glycerol and inositol and possesses key enzymes of the pentose phosphate pathway. It is native to the intestines of poultry.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123514>	C123338	Metagonimus yokogawai|Japanese Fluke|METAGONIMUS YOKOGAWAI	A species of parasitic flatworms in the family Heterophyidae. The lifecycle of M. yokogawai involves snails as the first intermediate host, freshwater fish as the second intermediate host, and humans, fish-eating carnivores, or birds as the definitive host. Infestation causes metagonimiasis.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123515>	C50921	Methicillin Resistant Staphylococcus Aureus|AB MRSA|MRSA|Methicillin-Resistant Staphylococcus aureus|Methicillin-resistant Staphylococcus aureus|STAPHYLOCOCCUS AUREUS, METHICILLIN-RESISTANT	A species of Gram-positive coccus-shaped bacterium in the family Micrococcaceae. This strain of S. aureus is resistant to methicillin and other beta-lactam antibiotics through the expression of penicillin-binding proteins acquired from other species.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123516>	C50921	Methicillin Susceptible Staphylococcus Aureus|METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS|MSSA|Methicillin-Susceptible Staphylococcus aureus	A species of Gram-positive coccus-shaped bacterium in the family Micrococcaceae. This strain of S. aureus retains its native sensitivity to methicillin and other beta-lactam antibiotics.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123517>	C76210	Moraxella catarrhalis, Beta-Lactamase Negative|MORAXELLA CATARRHALIS, BETA-LACTAMASE NEGATIVE	Any bacterial species identified as Moraxella catarrhalis that does not produce the enzyme beta-lactamase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123518>	C76210	Moraxella catarrhalis, Beta-Lactamase Positive|MORAXELLA CATARRHALIS, BETA-LACTAMASE POSITIVE	Any bacterial species identified as Moraxella catarrhalis that produces the enzyme beta-lactamase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123519>	C76210	Moraxella catarrhalis, Penicillinase Negative|MORAXELLA CATARRHALIS, PENICILLINASE NEGATIVE	Any bacterial species identified as Moraxella catarrhalis that does not produce the enzyme penicillinase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12351>	C13031	Cerebral Hemisphere|BRAIN, CEREBRUM|Brain Hemisphere|Brain, Cerebrum|CEREBRUM|Cerebral|Cerebral Hemispheres|Cerebral hemisphere structure (body structure)|Cerebrum|Cerebrum|Structure of cerebrum (body structure)|cerebral hemisphere|cerebral hemisphere|cerebrum	The part of the brain that controls muscle functions and also controls speech, thought, emotions, reading, writing, and learning. The right hemisphere controls the muscles on the left side of the body, and the left hemisphere controls the muscles on the right side of the body.	Cerebral Hemispheres		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C123520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123520>	C76210	Moraxella catarrhalis, Penicillinase Positive|MORAXELLA CATARRHALIS, PENICILLINASE POSITIVE	Any bacterial species identified as Moraxella catarrhalis that produces the enzyme penicillinase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123521>	C86015	Morganella morganii, Lysine-Positive|MORGANELLA MORGANII, LYSINE-POSITIVE	Any bacterial species identified as Morganella morganii that can metabolize lysine.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123522>	C86015	Morganella morganii, Ornithine-Negative|MORGANELLA MORGANII, ORNITHINE-NEGATIVE	Any bacterial species identified as Morganella morganii that is unable to metabolize ornithine.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123523>	C123422	Naegleria fowleri|NAEGLERIA FOWLERI	A species of parasitic amoeba in the family Vahlkampfiidae. N. fowleri is the only species of Naegleria that infects humans. Infection occurs through the nose and causes a very rare, but severe, infection of the brain called primary amoebic meningoencephalitis.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123524>	C123426	Necator americanus|NECATOR AMERICANUS	A species of parasitic nematodes in the family Ancylostomatidae. N. americanus can be passed person-to-person through contact with infested feces.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123525>	C86603	Neisseria gonorrhoeae, Beta-lactamase Negative|NEISSERIA GONORRHOEAE, BETA-LACTAMASE NEGATIVE	Any bacterial species identified as Neisseria gonorrhoeae that does not produce the enzyme beta-lactamase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123526>	C86603	Neisseria gonorrhoeae, Beta-lactamase Positive|NEISSERIA GONORRHOEAE, BETA-LACTAMASE POSITIVE	Any bacterial species identified as Neisseria gonorrhoeae that produces the enzyme beta-lactamase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123527>	C86603	Neisseria gonorrhoeae, Penicillinase Negative|NEISSERIA GONORRHOEAE, PENICILLINASE NEGATIVE	Any bacterial species identified as Neisseria gonorrhoeae that does not produce the enzyme penicillinase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123528>	C86603	Neisseria gonorrhoeae, Penicillinase Positive|NEISSERIA GONORRHOEAE, PENICILLINASE POSITIVE	Any bacterial species identified as Neisseria gonorrhoeae that produces the enzyme penicillinase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123529>	C77167	Nigrospora|NIGROSPORA	A genus of mold fungi in the family Trichosphaeriaceae. Species within this genus are typically found growing on live or dead grasses in tropical, subtropical, and temperate regions, are rarely found growing indoors, and rarely pose a health hazard to humans.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12352>	C13031	Frontal Lobe|Brain, Frontal lobe|FRONTAL LOBE|Frontal lobe|Frontal lobe structure (body structure)|frontal lobe|lobi frontales|lobus frontalis	The part of the brain located anterior to the parietal lobes at the front of each cerebral hemisphere.	Frontal Lobe		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C123530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123530>	C123335	Nosema|NOSEMA	A genus of unicellular obligate parasitic fungi in the family Nosematidae. Most species within this genus are limited to a specific insect or other arthropod host. Nosema apis is a cause of colony collapse in honeybees.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123531>	C77167	Oidiodendron|OIDIODENDRON	A genus of soil fungi in the family Myxotrichaceae with dark, erect conidiophores that terminate in an irregular system of tree-like branches . Species within the genus are commonly isolated from wood, wood pulp, and soil. They are not known to pose a health hazard to humans.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123532>	C77167	Paecilomyces|PAECILOMYCES	A genus of fungi in the subphylum Pezizomycotina with species grouped within orders Sordariales, Hypocreales, and Eurotiales. Some species within these genera cause opportunistic infections and allergic disorders in humans.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123533>	C123336	Paenibacillus glucanolyticus|Bacillus glucanolyticus|PAENIBACILLUS GLUCANOLYTICUS	A species of Gram-positive, motile, spore-forming bacteria in the family Paenibacillaceae. P. glucanolyticus is positive for catalase, hydrolysis of carboxymethyl cellulose, and hydrolysis of starch. It is negative for hydrolysis of chitin and urea. The species is native to soil.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123534>	C86629	Pandoraea apista|PANDORAEA APISTA	A species of aerobic, Gram negative, rod shaped bacterium in the family Burkholderiaceae. This species is positive for catalase, growth on Drigalsky agar, growth in 0.5 and 1.5% NaCl, assimilation of d-gluconate, l-malate and phenylacetate, acid and alkaline phosphatase, and leucine arylamidase activity. P. apista is found in the soil and also in the sputum of cystic fibrosis patients.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123535>	C86633	Parabacteroides goldsteinii|Bacteroides goldsteinii|PARABACTEROIDES GOLDSTEINII	A species of obligately anaerobic, non-spore-forming, non-motile, Gram negative, rod-shaped bacterium in the family Porphyromonadaceae. This species is negative for urease and nitrate reduction. Acid is produced from cellobiose, glucose, rhamnose, sucrose, trehalose and xylose, but not from arabinose or xylan. P. goldsteinii was isolated from human clinical specimens of intestinal origin.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123536>	C86633	Parabacteroides johnsonii|PARABACTEROIDES JOHNSONII	A species of obligately anaerobic, non-spore-forming, non-motile, Gram negative, rod-shaped bacterium in the family Porphyromonadaceae. This species is negative for urease, indole, catalase, and digestion of gelatin; mannose and raffinose are fermented. P. johnsonii was isolated from human feces.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123537>	C123337	Paracoccus yeei|CDC Group EO-2|PARACOCCUS YEEI	A species of aerobic Gram-negative coccobacillus in the family Rhodobacteraceae. This species is catalase and oxidase positive and can reduce nitrate. P. yeei is found naturally in soil and brines and has be identified as an unusual etiologic opportunistic agent of peritonitis.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123538>	C123338	Paragonimus westermani|Japanese Lung Fluke|Oriental Lung Fluke|PARAGONIMUS WESTERMANI	A species of parasitic flatworms in the family Troglotrematidae. The lifecycle of P. westermani involves freshwater snails as the first intermediate host, freshwater crustaceans as the second intermediate host, and humans or cats as the definitive host. Infestation causes paragonimiasis.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123539>	C86641	Pediococcus pentosaceus|PEDIOCOCCUS PENTOSACEUS|Pediococcus hennebergii	A species of Gram positive, facultatively anaerobic, non-motile, non-spore forming, cocci shaped bacterium in the family Lactobacillaceae. This species possesses a strictly fermentative metabolism with lactic acid as the major metabolic end product. P. pentosaceus can be found in plant materials, ripened cheese, and a variety of processed meats.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12353>	C13031	Temporal Lobe|Brain, Temporal lobe|TEMPORAL LOBE|Temporal lobe|Temporal lobe structure (body structure)|temporal lobe	One of the cerebral lobes. It is located inferior to the frontal and parietal lobes and anterior to the occipital lobe.	Temporal Lobe		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C123540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123540>	C77167	Penicillium|PENICILLIUM	A genus of fungi in the family Trichocomaceae characterized by broom-shaped conidia. Several species within this genus are economically important for the production of penicillin and the making of cheese.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123541>	C77916	Pentatrichomonas hominis|PENTATRICHOMONAS HOMINIS	An obligate symbiont, flagellate protozoan in the family Trichomonadidae. P. hominis is found in the intestinal tract of infected individuals, but is considered nonpathogenic.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123542>	C77167	Pestalotiopsis|PESTALOTIOPSIS	A genus of fungi in the family Amphisphaeriaceae with 4-6 celled conidia and 2 or 3 apical appendages. Species within the genus are known as plant pathogens.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123543>	C77167	Phialophora|PHIALOPHORA	A genus of fungi in the family Herpotrichiellaceae with short conidiophores and unicellular conidia. Most species within the genus are saprophytes commonly found in soil or on decaying wood. P. richardsiae is a rare causative agent for subcutaneous phaeohyphomycosis and P. verrucosa can cause chromoblastomycosis.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123544>	C77167	Pichia|Hansenula|PICHIA	A genus of yeasts in the family Saccharomycetaceae with spherical, elliptical or oblong acuminate cells.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123545>	C77167	Piedraia|PIEDRAIA	A genus of fungi in the family Piedraiaceae. Species in this genus are generally nonpathogenic but may cause opportunistic infection of hair shafts in humans.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123546>	C77167	Pithomyces|PITHOMYCES	A genus of fungi in the family Pleosporaceae. Species within this genus are commonly found on dead leaves and stems.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123547>	C98268	Plasmodium falciparum|PLASMODIUM FALCIPARUM	A protozoan parasite in the family Plasmodiidae. P. falciparum is transmitted by the female Anopheles mosquito and is a causative agent of malaria in humans. The malaria caused by this species is the most dangerous form of malaria.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123548>	C98268	Plasmodium malariae|PLASMODIUM MALARIAE	A protozoan parasite in the family Plasmodiidae. P. malariae causes quartan malaria, a milder form of malaria than that caused by P. falciparum or P. vivax.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123549>	C98268	Plasmodium ovale|PLASMODIUM OVALE	A protozoan parasite in the family Plasmodiidae. P. ovale is a rare causative agent of tertian malaria.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12354>	C13031	Parietal Lobe|Brain, Parietal lobe|PARIETAL LOBE|Parietal Lobe of the Brain|Parietal lobe|Parietal lobe structure (body structure)|parietal lobe	One of the lobes of the cerebral hemisphere located superiorly to the occipital lobe and posteriorly to the frontal lobe. Cognition and visuospatial processing are its main functions.	Parietal Lobe		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C123550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123550>	C98268	Plasmodium vivax|PLASMODIUM VIVAX	A protozoan parasite in the family Plasmodiidae. P. vivax is the most frequent and widely distributed causative agent of tertian malaria.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123551>	C86742	Shewanella algae|SHEWANELLA ALGAE	A species of Gram negative, facultatively anaerobic, rod-shaped bacterium in the family Shewanellaceae. This species is motile with a single polar flagellum. S. algae is found in warm marine environments throughout the world and is known to cause peritonitis, obstructive pneumonia, ear infections, bacteremia, and infections of skin, soft tissue, bone, and joints.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123552>	C123339	Solobacterium moorei|SOLOBACTERIUM MOOREI	A species of non-spore-forming, obligately anaerobic, Gram-positive bacillus in the family Erysipelotrichaceae. This species is positive for arginine dihydrolase, alpha- and beta-galactosidase, alpha-glucosidase, arginine arylamidase, proline arylamidase, and leucine arylamidase. S. moorei was initially isolated from human feces, is involved in human infection, and has been implicated as a causative agent of halitosis.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123554>	C76383	Nutritionally Variant Streptococcus|NVS|Nutritionally Variant Streptococci|STREPTOCOCCUS NUTRITIONALLY VARIANT	A bacterium that is assigned to the genus Streptococcus that is incapable of supporting its own growth on standard culture plates but can sustain growth using substances released into the medium by the dominant colonies. These Streptococci require L-cysteine for growth. They have been identified as an etiologic agent of endocarditis and other infections.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123555>	C64430	Breast Cancer Type 1 Susceptibility Protein Measurement|BRCA1|BRCA1 Measurement|Breast Cancer Type 1 Susceptibility Prot|Breast Cancer Type 1 Susceptibility Prot	The determination of the amount of breast cancer type 1 susceptibility protein present in a sample.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123556>	C111153	Cancer Cellularity Measurement|Cancer Cellularity|NEOCECE|Neoplastic Cells/Total Cells|Neoplastic Cells/Total Cells|TUMCECE|Tumor Cells to Total Cells Ratio Measurement|Tumor Cells/Total Cells|Tumor Cells/Total Cells|Tumor Purity|Tumor_Purity|cellularity|tumor purity|tumor_purity	The determination of the ratio of neoplastic cells compared to total cells in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	Canine Glioma Project Property Terminology|CDISC SDTM Biospecimen Characteristics Test Code Terminology|CDISC SDTM Biospecimen Characteristics Test Name Terminology|CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTDC Property Terminology|GDC Property Terminology|GDC Terminology|ICDC Terminology
C123557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123557>	C64430	Ki67 Measurement|Antigen KI-67 Measurement|KI67|KI67|KI67|Ki-67|Ki-67|Ki-67|Ki-67|MKI67|pKi-67	The determination of the amount of Ki-67 protein present in a sample.	Ki67 Measurement		Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Intervention Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123558>	C64430	NK2 Homeobox 1 Measurement|NK2 Homeobox 1|NK2 Homeobox 1|NKX2.1 Measurement|NKX2_1|TEBP|TTF1|Thyroid Transcription Factor 1	The determination of the amount of the NKX2.1 transcription factor present in a sample.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123559>	C35867	Percentage of in situ Carcinoma|PCTISCA|Percentage of In situ Carcinoma|Percentage of In situ Carcinoma	A relative measurement (percentage) of in situ component present in a carcinoma compared to the entire malignant cellular proliferation.			Finding	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12355>	C13031	Occipital Lobe|Brain, Occipital lobe|OCCIPITAL LOBE|Occipital lobe|Occipital lobe structure (body structure)|occipital lobe	One of the four regions of cortex in each cerebral hemisphere. It is located posterior to the temporal lobe and inferior to the parietal lobe.	Occipital Lobe		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C123560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123560>	C125581	Surgical Margins Status|Margin Status|SGMGSTAT|margin status|margin_status	The determination of the presence of actual or potential neoplastic tissue which has been left outside the boundary of a resected specimen within the patient.			Finding	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|GDC Property Terminology|GDC Terminology
C123561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123561>	C66973	Liter Divided by Milligram Per Day|L/(mg/d)|L/(mg/d)|L/(mg/day)|l/(mg/d)|l/(mg/d)|mL/(ug/day)|mL/(ug/day)	A unit of concentration equal to liter per milligram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C123562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123562>	C66973	Liter Divided by Milligram per Meter Squared|L/(mg/m2)|L/(mg/m2)|L/(mg/m2)|l/(mg/m2)|l/(mg/m2)|mL/(ug/m2)|mL/(ug/m2)	A unit of concentration equal to one liter divided by the derived denominator milligram per square meter.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C123563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123563>	C66973	Liter Divided by Microgram per Day|L/(ug/d)|L/(ug/d)|L/(ug/day)|L/(ug/day)|l/(ug/d)|l/(ug/d)|mL/(ng/day)	A unit of concentration equal to one liter divided by the derived denominator microgram per day.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C123564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123564>	C38083	Mean Carbon Monoxide Diffusing Capability Test|DLCOM|Mean Diffusion Capacity of Lung for CO|Mean Diffusion Capacity of Lung for CO|Mean TLCO	The mean volume of the carbon monoxide that is transferred from inspired gas into the pulmonary capillary blood.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123565>	C38081	Forced Expiratory Volume in 1 Second to Forced Vital Capacity in 6 Seconds|FEV1/FVC6|FEV1/FVC6|FEV1FVC6	A calculated ratio of the forced expiratory volume in one second to the largest observed expired volume during the first six seconds of a forced vital capacity (FVC) maneuver.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123566>	C38081	Oxygen Pulse|OXYPULSE	The volume of oxygen consumed by the body per heartbeat while at rest.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123567>	C38081	Pulmonary Reactance|PLMXRS	The measurement of the ability of the lung to store energy, which is required for passive expiration. Reactance consists of two components: the negative component reflects capacitive behavior (C) and corresponds to both the thoraco-pulmonary elasticity and to changes in the available lung volumes in the distal compartments of the lung; the positive component of reactance has inertial characteristics (I) describing the moving air column in the bronchial tree.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123568>	C38081	Respiratory Exchange Ratio|RER	The ratio of the amount of carbon dioxide produced to the amount of oxygen consumed in one breath. This ratio is used to estimate the respiratory quotient, which indicates what type of fuel source the body is metabolising to provide energy.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123569>	C38081	Specific Airway Resistance|SRAW|sRAW	A measurement used to describe airway behavior irrespective of lung volume; it is calculated as airway resistance (Raw) multiplied by functional residual capacity (FRC).			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12356>	C13031	Brain Ventricle|BRAIN VENTRICLE|Brain, Ventricle, NOS|Space of ventricular system of brain (body structure)|Ventricle|Ventricle of Brain|Ventricle, Brain|Ventricle, NOS|Ventricles, Brain|brain ventricle	The four connected cavities (hollow spaces) centrally located within the brain that connect posteriorly with the central canal of the spinal cord.	Brain Ventricle		Body Space or Junction	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C123570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123570>	C38081	Oxygen Consumption|VO2	The rate at which oxygen is absorbed and utilized by any given tissue in the body.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123571>	C50995	Absent Morphologic Response|ABSENT MORPHOLOGIC RESPONSE	The absence of change in the overall attenuation of the metastasis and in the peripheral rim, suggesting a lack of response to treatment.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123572>	C132458	CA125 50% Response|50 Percent Reduction of CA-125|50% Reduction of CA-125|CA-125 Response 50 Percent|CA-125 Response 50%|CA125 50% RESPONSE|Cancer Antigen 125 50% Response	The amount of cancer antigen 125 is reduced by 50% from protocol-defined baseline value(s).	CA125 50% Response		Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123573>	C132458	CA125 75% Response|CA125 75% RESPONSE|Cancer Antigen 125 75% Response	The amount of cancer antigen 125 is reduced by 75% from protocol-defined baseline value(s).			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123574>	C4870	Clinical Complete Response|Clinical Complete Remission|cCR|cCR	The disappearance of all signs of cancer based on physical exam, such as palpation.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123575>	C4870|C123622	Complete Hematologic Response|CHR|CHR|Complete Hematologic Remission	The disappearance of cancer in response to treatment, including platelet and white blood cell counts returning to normal levels, a non-palpable spleen, and no immature white blood cells present in the blood unless it is a regenerating marrow following treatment.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123576>	C18058	Clinical Partial Response|Clinical Partial Remission|Partial|cPR|cPR	A decrease in the size and the extent of tissue involvement by cancer, based on physical exam, such as palpation.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF5 Response Evaluation Image Evaluation Table
C123577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123577>	C4870	Complete Response by Computed Tomography|CR-CT|CR-CT|Complete Remission, CT-Based|Complete Response, CT-Based	The disappearance of all signs of cancer, based on CT scan and criteria-defined assessments.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123578>	C123620	Cytogenetic Complete Response|CCgR|CCgR|CCyR|CCyR|CRc|CRc|CYTOGENETIC CR|Complete Cytogenetic Response|Cytogenetic Complete Remission	The disappearance of all signs of cancer, including the absence of a detectable disease-related genetic abnormality, as determined by techniques such as karyotyping or FISH, in response to treatment.	Cytogenetic Complete Response		Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C123579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123579>	C123620	Cytogenetic Minimal Response|CYTOGENETIC MINIMAL RESPONSE|Minimal CgR|Minimal CgR	A minimal decrease in abnormal karyotype, based on pre-defined thresholds.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C12357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12357>	C33904	Craniopharyngeal Duct|Bucconeural Duct|Craniopharyngeal duct|Hypophysial Duct	The slender tubular part of the hypophysial diverticulum; the stalk of Rathke's pocket.	Craniopharyngeal Duct		Body Part, Organ, or Organ Component	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C123580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123580>	C123620	Cytogenetic Minor Response|CYTOGENETIC MINOR RESPONSE|Minor CgR|Minor CgR	A minor decrease in abnormal karyotype, based on pre-defined thresholds.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123581>	C123620	Cytogenetic No Response|CYTOGENETIC NO RESPONSE|No CgR|No CgR|No Cytogenetic Response	No change in abnormal karyotype, based on pre-defined thresholds.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123582>	C123620	Cytogenetic Partial Response|CYTOGENETIC PR|Cytogenetic PR|Partial CgR|Partial CgR	A partial decrease in abnormal karyotype, based on pre-defined thresholds.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123583>	C50995	Disease Transformation|DISEASE TRANSFORMATION	A conversion from one disease diagnosis to another, which may be considered a progression to a worsening state.			Finding	CDISC SDTM Medical History Event Date Type Terminology|CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123584>	C50995	Favorable Response|FAVORABLE RESPONSE	No new lesions(s) and a decrease in tumor size, or a reduction in central necrosis or attenuation in one or more enhancing lesions, based on pre-defined thresholds.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123585>	C201498	Hematologic Improvement-Erythroid Response|HI-E|HI-E|Hematologic Improvement - Erythroid (HI-E)|Hematological Improvement Erythroid	An improvement in erythrocyte count as a response to treatment.	Hematologic Improvement-Erythroid Response		Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C123586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123586>	C201498	Hematologic Improvement-Neutrophil Response|HI-N|HI-N|Hematologic Improvement - Neutrophil (HI-N)	An improvement of neutrophil count as a response to treatment.	Hematologic Improvement-Neutrophil Response		Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C123587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123587>	C202442|C201498	Hematologic Improvement-Platelet Response|HI-P|HI-P|Hematologic Improvement - Platelet (HI-P)	An improvement of platelet count as a response to treatment.	Hematologic Improvement-Platelet Response		Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C123588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123588>	C50995	Immunophenotypic Complete Response|IMMUNOPHENOTYPIC CR	The disappearance of all signs of cancer, supported by the absence of phenotypically aberrant plasma cells (clonal) in bone marrow. (Rajkumar SV, Harousseau J, Durie B et al, Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011; 117(18):4691-4695)			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123589>	C50995	Indeterminate Response|INDETERMINATE RESPONSE|Indeterminate (possible pseudo-progression)	A response that is neither favorable nor unfavorable.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C12358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12358>	C33027	Head and Neck Lymph Node|Lymph Node of Head, Face and Neck|Lymph Nodes of Head, Face and Neck|Lymph nodes of head, face and neck	Lymph nodes found within the head and neck region of the body, which drain into the deep cervical nodes, either directly or indirectly. These include the occipital, mastoid, parotid, facial, retropharyngeal, submandibular, submental, lingual and cervical lymph nodes. Any lymph node located in the head or neck.	Head and Neck Lymph Node|Lymph Node of Head, Face and Neck		Body Part, Organ, or Organ Component	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C123590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123590>	C123626	Major Pathologic Response|MAJOR PATHOLOGIC RESPONSE|MPR	A major decrease in signs of cancer, supported by pathological examination and based on pre-defined thresholds.	Major Pathologic Response		Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C123591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123591>	C4870|C173307	Marrow Complete Response|Marrow CR|Marrow Complete Remission|mCR|mCR	A decrease in the number of bone marrow plasma cells to protocol-defined level(s).			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123592>	C123598	Minor Pathologic Response|MINOR PATHOLOGIC RESPONSE	A minor decrease in signs of cancer, supported by pathological examination and based on pre-defined thresholds.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123593>	C123624	Molecular Complete Response|CMR|Complete Molecular Response|MOLECULAR CR|Molecular CR|Molecular Complete Remission	The disappearance of all signs of cancer, supported by molecular analysis.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123594>	C123624	Molecular Major Response|MMR|MMR|MMolR|MMolR|MOLECULAR MAJOR RESPONSE|Major Molecular Response	A decrease in signs of cancer, supported by molecular analysis.	Molecular Major Response		Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C123595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123595>	C123625	Morphologic Complete Response|MORPHOLOGIC CR|Morphologic CR|Morphologic Complete Remission	The disappearance of all signs of cancer, supported by morphological analysis.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123596>	C123625	Morphologic Complete Remission with Incomplete Blood Count Recovery|MORPHOLOGIC CRi|Morphologic CRi|Morphologic Complete Remission with Incomplete Bone Marrow Recovery	The disappearance of all cells with morphologic characteristics of cancer, accompanied by incomplete bone marrow recovery, as evidenced by persistent anemia, thrombocytopenia or neutropenia.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123597>	C123625	Morphologic Leukemia-Free State|MORPHOLOGIC LEUKEMIA-FREE STATE|Morphologic Leukemia-Free State (MLFS)|NEL|No Evidence of Leukemia	The disappearance of all cells with morphologic characteristics of leukemia, accompanied by bone marrow recovery, in response to treatment. Hematologic recovery is not required. Leukemia free state can be a hypocellular marrow.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123598>	C50995	Minimal Response|MR|MR|MR-Minimal/Marginal Response|MR-Minimal/Marginal response|Minor Response	A finding indicating that there is an improvement in the measures of disease burden, meeting a predetermined threshold, but not meeting partial response criteria.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C123599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123599>	C50995	Non Progressive Disease|NON-PD|Non-PD	Following a previous assessment of progressive disease unconfirmed (PDu) of non-target lesion(s), the subsequent required assessment does not confirm progressive disease.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C12359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12359>	C33769	Intrathoracic Lymph Node|INTRATHORACIC LYMPH NODE|Intra-Thoracic Lymph Node|Intrathoracic Lymph Nodes|Intrathoracic lymph nodes	Any lymph node within the thoracic cavity.	Intrathoracic Lymph Node		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C1235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1235>	C1967	ST 638|2-Cyano-3-(3-ethoxy-4-hydroxy-5-((phenylthio)methyl)phenyl)-2-propenamide	A tyrosine kinase inhibitor that inhibits phospholipase D activity in human neutrophils at a site between the receptor and phospholipase. (NCI)			Organic Chemical|Pharmacologic Substance	
C123600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123600>	C50995	No Response|NR|NR|NR-No Response	No apparent change or worsening in lesion staging classification.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C123601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123601>	C123625	Optimal Morphologic Response|OPTIMAL MORPHOLOGIC RESPONSE	Hypo-attenuation of the metastases which may appear pseudocystic, perfectly homogeneous, and devoid of a recognizable peripheral rim.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123602>	C18058	Partial Morphologic Response|PARTIAL MORPHOLOGIC RESPONSE	Mixed attenuation and some homogeneity of the metastases with a partially resolved peripheral rim.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123603>	C4870|C123626	Pathologic Complete Response|Complete Pathological Response|Complete Pathological Response|Pathologic Complete Remission|Pathological Complete Remission|pCR|pCR	The disappearance of all signs of cancer, supported by pathological examination.	Pathologic Complete Response		Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C123604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123604>	C50995	Progression from Partial Response|PD FROM PR|PD From PR|Progression from PR|Progressive Disease from Partial Response	Disease progression occurring after a partial response.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123605>	C50995	Progression or Relapse After Hematologic Improvement|PD/RELAPSE AFTER HI|PD/Relapse After HI	Disease progression or the return of a disease after a period of remission, occurring after a hematologic improvement.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123606>	C35571	Progressive Disease by Computed Tomography|PD-CT|PD-CT|Progressive Disease, CT-Based	There is an increase in the size and extent of tissue involvement by cancer, based on CT scan and criteria-defined assessments.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123607>	C50995	Unconfirmed Progressive Disease|PD Unconfirmed|PDu|PDu	A disease process that is increasing in scope or severity but the criteria for progressive disease is not met.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123608>	C35571	Progressive Metabolic Disease|PMD|PMD	An increase of metabolic tumor activity in all relevant lesions, based on pre-defined thresholds, or the development of new lesions.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123609>	C18058	Partial Metabolic Response|PMR|PMR	A decrease of metabolic tumor activity in all relevant lesions, based on a pre-defined threshold.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C12360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12360>	C33027	Abdominal Lymph Node|ABDOMINAL LYMPH NODE|Intra-Abdominal Lymph Node|Intra-Abdominal Lymph Nodes|Intra-abdominal lymph nodes	Any lymph node within the abdomen.	Intra-abdominal Lymph Node		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C123610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123610>	C18058	Partial Response by Computed Tomography|PR-CT|PR-CT|Partial Remission, CT-Based|Partial Response, CT-Based	A decrease in the size and extent of tissue involvement by cancer, based on CT scan and criteria-defined assessments.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123611>	C81326|C138961	PSA Progression|Elevated PSA|Elevated Prostate Specific Antigen|Increasing PSA|PSA Elevated|PSA PROGRESSION|Prostate Specific Antigen Progression|Rising PSA	The amount of prostate specific antigen is increased, based on pre-defined thresholds.	PSA Progression		Laboratory or Test Result	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123612>	C38155	Relapsed Disease From Complete Response|RELAPSED DISEASE FROM CR|Relapse from CR	The return of a disease after a period of complete remission.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123613>	C38155	Relapsed Disease From Complete or Partial Response|RELAPSED DISEASE FROM CR OR PR|Relapsed Disease From Complete Response or Partial Response	The return of a disease after a period of complete remission or partial remission.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123614>	C4870	Stringent Complete Response|Stringent Complete Remission|sCR|sCR|sCR-Stringent Complete Response	The confirmed disappearance of all signs of cancer, and absence of molecular or cytogenetic marker of disease, in response to treatment with additional biochemical, immunological and histopathological analyses to verify the CR.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C123615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123615>	C18213	Stable Disease by Computed Tomography|SD-CT|SD-CT|Stable Disease, CT-Based	The size and extent of tissue involvement by cancer is neither decreasing nor increasing, based on CT scan and criteria-defined assessments.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123616>	C18213	Stable Metabolic Disease|NMR|No Metabolic Response|SMD|SMD	The absence of change or mild changes of metabolic tumor activity in all relevant lesions based on a pre-defined threshold.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123617>	C50995	Unfavorable Response|UNFAVORABLE RESPONSE	An increase in tumor size, based on a pre-defined threshold, or the development of new lesion(s), marked central fill-in of a lesion, or new enhancement of a previously homogeneously hypoattenuating nonenhancing mass.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123618>	C50995	Very Good Partial Response|VGPR|VGPR|VGPR-Very Good Partial Response|Very Good Partial Remission	Partial response with additional serum and urine M-protein reduction, but not meeting complete response.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Subject Response Table
C123619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123619>	C50995	Clinical Response|CLINRESP|Clinical	An evaluation of the clinical changes that result from treatment.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Assessment Test Code Terminology|CDISC SDTM Tumor Response Assessment Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF5 Response Evaluation Time Point Table
C123620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123620>	C50995	Cytogenetic Response|CYTORESP	An evaluation of the cytogenetic response of the disease to the therapy.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Assessment Test Code Terminology|CDISC SDTM Tumor Response Assessment Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C123621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123621>	C93645|C181043	Disease Recurrence Indicator|DRCRIND	An indication as to whether disease recurrence occurred.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Tumor Response Assessment Test Code Terminology|CDISC SDTM Tumor Response Assessment Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C123622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123622>	C50995	Hematologic Response|HEMARESP	An evaluation of the hematologic response of the disease to the therapy.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Assessment Test Code Terminology|CDISC SDTM Tumor Response Assessment Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C123623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123623>	C50995	Metabolic Response|METBRESP	An evaluation of the metabolic response of the disease to the therapy.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Assessment Test Code Terminology|CDISC SDTM Tumor Response Assessment Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C123624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123624>	C50995	Molecular Response|MOLRESP|MR	An evaluation of the molecular response of the disease to the therapy.	Molecular Response		Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Assessment Test Code Terminology|CDISC SDTM Tumor Response Assessment Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C123625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123625>	C50995	Morphologic Response|MRPHRESP	An evaluation of the morphologic response of the disease to the therapy.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Assessment Test Code Terminology|CDISC SDTM Tumor Response Assessment Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C123626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123626>	C50995	Pathologic Response|PATHRESP	An evaluation of the pathologic response of the disease to the therapy.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Assessment Test Code Terminology|CDISC SDTM Tumor Response Assessment Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C123627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123627>	C50995	Radiologic Response|RDIORESP	An evaluation of the radiologic response of the disease to the therapy.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Assessment Test Code Terminology|CDISC SDTM Tumor Response Assessment Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C123628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123628>	C132458	Tumor Antigen Response	An evaluation of the change in tumor antigen quantity in response to the therapy.			Finding	
C123629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123629>	C25180	FDA-Regulated Device Study Indicator|FDADEIND	An indication as to whether the study involves an FDA-regulated device.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C12362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12362>	C33027	Lymph Node of Inguinal Region or Leg|Lymph Nodes of Inguinal Region or Leg|Lymph nodes of inguinal region or leg	Any lymph node that is located in the inguinal region or in either leg.	Lymph Node of Inguinal Region or Leg		Body Part, Organ, or Organ Component	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C123630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123630>	C25180	FDA-Regulated Drug Study Indicator|FDADRIND	An indication as to whether the study involves an FDA-regulated drug.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C123631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123631>	C25180	Pediatric Postmarket Study Indicator|PDPSTIND	An indication as to whether the study is a pediatric postmarket study.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C123632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123632>	C25180	Pediatric Study Indicator|PDSTIND	An indication as to whether the study is a pediatric study.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C123633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123633>	C25341	Disease Recurrence Relative Location|DRCRLTLC	A description of the region or relative location for the disease recurrence.			Spatial Concept	CDISC SDTM Terminology|CDISC SDTM Tumor Identification Test Code Terminology|CDISC SDTM Tumor Identification Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C123634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123634>	C48207	Per Thousand|/10*3|/10*3|/10*3|/10^3|/10^3|/10^3|/10^3|per thousand	A unit equal to one thousand entities used as a denominator to build a derived unit expressed as a ratio.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C123635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123635>	C68781	Non-Moribund Sacrifice|NON-MORIBUND SACRIFICE	An indication that a subject was euthanized due to factors not associated with the general health of the subject.			Activity	CDISC SEND Standardized Disposition Term Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C123636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123636>	C137801	Experimental Organism Decidual Reaction|DECIDUAL REACTION	A primarily uterine reaction with generally indistinct borders and two recognizable regions. These regions are an antimesometrial region containing closely packed mesenchymal cells and a mesometrial region containing mesometrial cells with long cytoplasmic processes and abundant glycogen. (INHAND)			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C123637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123637>	C137801	Experimental Organism Decidualization|DECIDUALIZATION	A focal lesion within the uterus consisting of markedly hypertrophied stromal cells with cytoplasmic glycogen and prominent nuclei.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C123638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123638>	C97110	Hydromyelia|HYDROMYELIA	Abnormal widening of the central spinal canal.			Disease or Syndrome	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C123639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123639>	C53543|C27621	Imperforate Vagina|IMPERFORATE VAGINA	A congenital birth defect characterized by the absence of a normal vaginal opening.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12363>	C33027	Pelvic Lymph Node|Lymph Node(s) Pelvic|PELVIC LYMPH NODE|Pelvic Lymph Node(s)|Pelvic Lymph Nodes|Pelvic lymph node group (body structure)|Pelvic lymph nodes|lymph node of pelvis|pelvic lymph node	Any lymph node within the abdominal pelvic region.	Pelvic Lymph Node		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C123640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123640>	C137801	Experimental Organism Luteinized Unruptured Follicle|LUTEINIZED FOLLICLE|Luteinized Unruptured Follicle	A corpus luteum-like structure with a retained oocyte and variably luteinized granulosa cells.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C123641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123641>	C33244	Polyovular Follicle|POLYOVULAR FOLLICLE	An ovarian follicle that contains more than one oocyte.			Anatomical Structure	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C123642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123642>	C34237	Prostatic Rudiment|PROSTATIC RUDIMENT	An embryological structure composed of epithelial cells surrounded by mesenchyme, which gives rise to the prostate gland.			Embryonic Structure	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C123643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123643>	C85179	Syringomyelia and Hydromyelia|SYRINGOMYELIA/HYDROMYELIA	Syringomyelia associated with accumulation of cerebrospinal fluid in the spinal cord.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C123644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123644>	C15158	Fox Chase SCID Beige Mouse|CB17 SCID BEIGE|CB17 SCID Beige Mouse	A CB17 SCID mouse with an additional mutation on the Lyst gene which results in defective natural killer cells.			Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C123645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123645>	C27993	Unequivocal|UNEQUIVOCAL	Leaving no doubt; not open to question.			Qualitative Concept	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Result Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C123646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123646>	C14248	Ancylostomatoidea|ANCYLOSTOMATOIDEA|Hookworms	A superfamily of parasitic nematodes. Members of this superfamily have a characteristic bent head, giving their buccal cavity a hook shape and providing the superfamily the common name of hookworm.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123647>	C123419	Cystoisospora belli|CYSTOISOSPORA BELLI|Isospora belli	A species of coccidian protozoan parasite in the family Sarcocystidae. C. belli is an opportunistic pathogen in immunocompromised individuals. Transmission occurs by ingestion of fecal-contaminated food or water. This species is the causative agent of cystoisosporiasis.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123648>	C123423	Neisseria elongata subsp nitroreducens|CDC Group M-6|NEISSERIA ELONGATA SUBSP. NITROREDUCENS|Neisseria elongata subsp. nitroreducens	A subspecies of Neisseria elongata with the ability to reduce nitrate.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123649>	C1663	MAGE-A3-specific Immunotherapeutic GSK 2132231A|ASCI GSK 2132231A|Antigen Specific Cancer Immunotherapeutic GSK 2132231A|GSK 2132231A|GSK2132231A|MAGE-A3 ASCI GSK 2132231A	An immunotherapeutic agent composed of a fusion protein containing the human melanoma-associated antigen MAGE-A3 fused to a lipidated protein D derived from Haemophilus influenzae and combined with the immunoadjuvant AS15, with potential immunostimulating and antineoplastic activities. Upon intramuscular (IM) administration, GSK 2132231A may stimulate a specific cytotoxic T-lymphocyte (CTL) response against MAGE-A3-expressing tumor cells, resulting in tumor cell death. MAGE-A3, a tumor-associated antigen, is upregulated in a variety of cancer cell types. This fusion protein may boost antitumoral immune responses. AS15, a liposomal formulation containing the immunostimulating compounds CpG 7909, 3-O-desacyl-4'-monophosphoryl lipid A (MPL), and QS-21, increases the immune response against MAGE-A3-expressing tumors.	MAGE-A3-specific Immunotherapeutic GSK 2132231A		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C123650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123650>	C66830	CDISC SDTM Tumor and Lesion Identification Test Result Terminology|SDTM-TUIDRS|TUIDRS|Tumor or Lesion Identification Test Results	Terminology associated with the tumor and lesion identification test result codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123651>	C15301	Solar Simulated Light|Artificial Sunlight|Full-Spectrum Lighting|SSR|Solar Simulated Radiation	The therapeutic use of a light source that approximates the characteristics of natural sunlight with regard to the radiation spectrum represented as well as the relative contributions of the wavelengths of the spectrum. Artificial sunlight is used to treat seasonal affective disorder and jet lag and may have other beneficial effects on health.	Solar Simulated Light		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C123652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123652>	C100110	CDISC Questionnaire EXACT Test Name Terminology|EXACT1TN|Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome Questionnaire Test Name|QS-EXACT TEST	Test names of questionnaire questions associated with Exacerbations of Chronic Pulmonary Disease Tool (EXACT) Patient-Reported Outcome for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123653>	C100110	CDISC Questionnaire EXACT Test Code Terminology|EXACT1TC|Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome Questionnaire Test Code|QS-EXACT TESTCD	Test codes of questionnaire questions associated with the Exacerbations of Chronic Pulmonary Disease Tool (EXACT) Patient-Reported Outcome for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123654>	C115302	CDISC Functional Test AVLT-REY Test Name Terminology|AVL02TN|FT-AVLT-REY TEST|Rey Auditory Verbal Learning Test Functional Test Test Name	Test names of functional test questions associated with the Rey Auditory Verbal Learning Test (AVLT-REY) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123655>	C115302	CDISC Functional Test AVLT-REY Test Code Terminology|AVL02TC|FT-AVLT-REY TESTCD|Rey Auditory Verbal Learning Test Functional Test Test Code	Test codes of functional test questions associated with the Rey Auditory Verbal Learning Test (AVLT-REY) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123656>	C211913	EXACT Questionnaire Question	A question associated with the EXACT questionnaire.			Intellectual Product	
C123657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123657>	C211913	AVLT-REY Functional Test Question	A question associated with the AVLT-REY functional test.			Intellectual Product	
C123658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123658>	C91105	Asthma Control Test Questionnaire|ACT|ACT|ACT01	A standardized rating scale developed by Nathan et al in 2004, which is used to identify patients with poorly controlled asthma. This questionnaire contains 5 items.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123659>	C91105	Shortness of Breath with Daily Activities Questionnaire|SOBDA|SOBDA|SOBDA1	A standardized rating scale developed by Wilcox et al in 2013, which is used to evaluate the impact of treatment on shortness of breath (SOB) in patients with COPD and to assess how SOB affects daily activities. This questionnaire contains 13 items.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12365>	C34055	Amnion|Amniotic	The innermost layer of membrane that surrounds an embryo and amniotic fluid in mammals, birds, and reptiles.	Amnion		Embryonic Structure	
C123660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123660>	C91105	Menstrual Distress Questionnaire Form-T (Today)|MDQ-T|MDQ-T|MDQ01	A standardized rating scale developed by Rudolf H. Moos in 1968, which is used to measure cyclical perimenstrual symptoms. The form-T version of this questionnaire allows an individual to describe her experiences on a specific day. This questionnaire contains 47 items			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123661>	C91105	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired - Lifetime Recent - Clinical Questionnaire|C-SSRS PEDIATRIC/COGNITIVELY IMPAIRED-LIFETIME RECENT-CLINICAL|C-SSRS Pediatric/Cognitively Impaired - Lifetime Recent - Clinical|CSS12	A standardized rating scale developed by Posner et al (version 6/23/2010), which is used to determine the presence of suicidal ideation or behavior. The pediatric/cognitively impaired - lifetime recent - clinical version questionnaire contains 4 domains; suicidal ideation, intensity of ideation, suicidal behavior and actual attempts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123662>	C91105	Columbia-Suicide Severity Rating Scale Pediatric/Cognitively Impaired - Since Last Visit - Clinical Questionnaire|C-SSRS PEDIATRIC/COGNITIVELY IMPAIRED-SINCE LAST VISIT-CLINICAL|C-SSRS Pediatric/Cognitively Impaired - Since Last Visit - Clinical|CSS13	A standardized rating scale developed by Posner et al (version 6/23/2010), which is used to determine the presence of suicidal ideation or behavior. The pediatric/cognitively impaired - since last visit - clinical version questionnaire contains 4 domains; suicidal ideation, intensity of ideation, suicidal behavior and actual attempts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123663>	C91105	12-Item Multiple Sclerosis Walking Scale Questionnaire|MSWS-12|MSWS-12|MSWS01	A standardized rating scale developed by Hobart et al in 2003, which is used to measure the impact of multiple sclerosis (MS) on an individual's walking ability. The questionnaire contains 12 items on a scale from 1 (not at all) to 5 (extremely).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123664>	C91105	Multiple Sclerosis Impact Scale Version 1 Questionnaire|MSIS-29 V1|MSIS-29v1|MSIS01	A standardized rating scale developed by Hobart et al in 2001, which is used to assess the physical and psychological impact of multiple sclerosis (MS) on an individual's quality of life. The version 1 questionnaire contains 29 questions on a scale from 1 (not at all) to 5 (extremely).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123665>	C91105	Multiple Sclerosis Impact Scale Version 2 Questionnaire|MSIS-29 V2|MSIS-29v2|MSIS02	A standardized rating scale developed by Hobart et al in 2001, which is used to assess the physical and psychological impact of multiple sclerosis (MS) on an individual's quality of life. The version 2 questionnaire contains 29 questions on a scale from 1 (not at all) to 4 (extremely).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123666>	C91105	Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome Questionnaire|EXACT|EXACT|EXACT1	A standardized rating scale developed by Nancy Leidy and Lindsey Murray under the EXACT-PRO Initiative in 2013, which is used to make symptomatic assessment of chronic obstructive pulmonary disease (COPD) exacerbations. The questionnaire contains 14 items and evaluate the frequency, severity, and duration of COPD exacerbations.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123667>	C222259	Montreal Cognitive Assessment Functional Test|MOCA|MOCA|MOCA01|Montreal Cognitive Assessment	A standardized rating scale developed by Ziad Nasreddine in 1996 to screen for mild cognitive dysfunction and impairment. This instrument assesses the following cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation.			Intellectual Product	CDISC Functional Test Category Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123668>	C222260	Rey Auditory Verbal Learning Functional Test|AVL02|AVLT-REY|AVLT-REY	A standardized rating scale modified from A. Rey in 1964 and Ceffen et al in 1994, which is used to evaluate verbal learning and memory abilities in both children and adults. The questionnaire contains 36 items and assesses overall memory performance, immediate span of memory for words, acquisition rate, interference effects, and recognition.			Intellectual Product	CDISC Functional Test Category Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123669>	C123656	EXACT - Chest Feel Congested|EXACT1-Chest Feel Congested|EXACT1-Chest Feel Congested|EXACT101	Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT) Did your chest feel congested today?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EXACT Test Code Terminology|CDISC Questionnaire EXACT Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12366>	C34076	Bone|BONE|Bone, NOS|Bones|Osseous|bone element	The structural organ comprised of specialized connective tissue that forms the skeletal components of the body.	Bone		Body Part, Organ, or Organ Component	AML Authorized Value Terminology|AML Myeloid Sarcoma Involvement Table|CDISC SDTM Anatomical Location Terminology|CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CTDC Value Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Radiation Therapy Table|EWS Tumor Assessment Table|GCT Authorized Value Terminology|GCT Tumor Assessment Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Biopsy/Surgical Procedures Table|HL Lesion Characteristics Table|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Genomic Specimen Type Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C123670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123670>	C123656	EXACT - How Often Cough Today|EXACT1-How Often Cough|EXACT1-How Often Cough|EXACT102	Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT) How often did you cough today?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EXACT Test Code Terminology|CDISC Questionnaire EXACT Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123671>	C123656	EXACT - Bring Up Mucus When Coughing|EXACT1-Bring Up Mucus When Coughing|EXACT1-Bring Up Mucus When Coughing|EXACT103	Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT) How much mucus (phlegm) did you bring up when coughing today?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EXACT Test Code Terminology|CDISC Questionnaire EXACT Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123672>	C123656	EXACT - Difficult to Bring Up Mucus|EXACT1-Difficult to Bring Up Mucus|EXACT1-Difficult to Bring Up Mucus|EXACT104	Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT) How difficult was it to bring up mucus (phlegm) today?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EXACT Test Code Terminology|CDISC Questionnaire EXACT Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123673>	C123656	EXACT - Have Chest Discomfort|EXACT1-Chest Discomfort|EXACT1-Chest Discomfort|EXACT105	Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT) Did you have chest discomfort today?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EXACT Test Code Terminology|CDISC Questionnaire EXACT Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123674>	C123656	EXACT - Chest Feel Tight|EXACT1-Chest Feel Tight|EXACT1-Chest Feel Tight|EXACT106	Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT) Did your chest feel tight today?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EXACT Test Code Terminology|CDISC Questionnaire EXACT Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123675>	C123656	EXACT - Were You Breathless|EXACT1-Breathless|EXACT1-Breathless|EXACT107	Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT) Were you breathless today?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EXACT Test Code Terminology|CDISC Questionnaire EXACT Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123676>	C123656	EXACT - Describe How Breathless|EXACT1-Describe How Breathless|EXACT1-Describe How Breathless|EXACT108	Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT) Describe how breathless you were today.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EXACT Test Code Terminology|CDISC Questionnaire EXACT Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123677>	C123656	EXACT - Short of Breath When Performing Usual Personal Care|EXACT1-Short Breath Personal Care|EXACT1-Short Breath Personal Care|EXACT109	Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT) Were you short of breath today when performing your usual personal care activities like washing or dressing?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EXACT Test Code Terminology|CDISC Questionnaire EXACT Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123678>	C123656	EXACT - Short of Breath When Performing Usual Indoor Activities|EXACT1-Short Breath Indoor Activities|EXACT1-Short Breath Indoor Activities|EXACT110	Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT) Were you short of breath today when performing your usual indoor activities like cleaning or household work?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EXACT Test Code Terminology|CDISC Questionnaire EXACT Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123679>	C123656	EXACT - Short of Breath When Performing Usual Activities Outside|EXACT1-Short Breath Outside Activities|EXACT1-Short Breath Outside Activities|EXACT111	Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT) Were you short of breath today when performing your usual activities outside the home such as yard work or errands?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EXACT Test Code Terminology|CDISC Questionnaire EXACT Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12367>	C13020|C12712	Mammary Gland|GLAND, MAMMARY|MAMMARY GLAND|mammary gland|mammary gland	In humans, the glands of the breast, consisting of fibrous tissue connecting the lobes and fatty tissue in between the lobes.	Mammary Gland		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C123680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123680>	C123656	EXACT - Tired or Weak|EXACT1-Tired or Weak|EXACT1-Tired or Weak|EXACT112	Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT) Were you tired or weak today?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EXACT Test Code Terminology|CDISC Questionnaire EXACT Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123681>	C123656	EXACT - Night Sleep Disturbed|EXACT1-Night Sleep Disturbed|EXACT1-Night Sleep Disturbed|EXACT113	Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT) Last night, was your sleep disturbed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EXACT Test Code Terminology|CDISC Questionnaire EXACT Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123682>	C123656	EXACT - Worried About Lung Problems|EXACT1-Worried About Lung Problems|EXACT1-Worried About Lung Problems|EXACT114	Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT) How scared or worried were you about your lung problems today?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EXACT Test Code Terminology|CDISC Questionnaire EXACT Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123683>	C123657	AVLT-REY - List A Word 1|AVL02-List A Word 1|AVL02-List A Word 1|AVL0201	The Rey Auditory Verbal Learning TEST (AVLT-REY) List A, Word 1.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123684>	C123657	AVLT-REY - List A Word 2|AVL02-List A Word 2|AVL02-List A Word 2|AVL0202	The Rey Auditory Verbal Learning TEST (AVLT-REY) List A, Word 2.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123685>	C123657	AVLT-REY - List A Word 3|AVL02-List A Word 3|AVL02-List A Word 3|AVL0203	The Rey Auditory Verbal Learning TEST (AVLT-REY) List A, Word 3.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123686>	C123657	AVLT-REY - List A Word 4|AVL02-List A Word 4|AVL02-List A Word 4|AVL0204	The Rey Auditory Verbal Learning TEST (AVLT-REY) List A, Word 4.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123687>	C123657	AVLT-REY - List A Word 5|AVL02-List A Word 5|AVL02-List A Word 5|AVL0205	The Rey Auditory Verbal Learning TEST (AVLT-REY) List A, Word 5.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123688>	C123657	AVLT-REY - List A Word 6|AVL02-List A Word 6|AVL02-List A Word 6|AVL0206	The Rey Auditory Verbal Learning TEST (AVLT-REY) List A, Word 6.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123689>	C123657	AVLT-REY - List A Word 7|AVL02-List A Word 7|AVL02-List A Word 7|AVL0207	The Rey Auditory Verbal Learning TEST (AVLT-REY) List A, Word 7.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12368>	C13020	Areola|areola	The pigmented circle or ring of skin that surrounds the nipple.	Areola		Body Part, Organ, or Organ Component	Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C123690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123690>	C123657	AVLT-REY - List A Word 8|AVL02-List A Word 8|AVL02-List A Word 8|AVL0208	The Rey Auditory Verbal Learning TEST (AVLT-REY) List A, Word 8.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123691>	C123657	AVLT-REY - List A Word 9|AVL02-List A Word 9|AVL02-List A Word 9|AVL0209	The Rey Auditory Verbal Learning TEST (AVLT-REY) List A, Word 9.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123692>	C123657	AVLT-REY - List A Word 10|AVL02-List A Word 10|AVL02-List A Word 10|AVL0210	The Rey Auditory Verbal Learning TEST (AVLT-REY) List A, Word 10.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123693>	C123657	AVLT-REY - List A Word 11|AVL02-List A Word 11|AVL02-List A Word 11|AVL0211	The Rey Auditory Verbal Learning TEST (AVLT-REY) List A, Word 11.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123694>	C123657	AVLT-REY - List A Word 12|AVL02-List A Word 12|AVL02-List A Word 12|AVL0212	The Rey Auditory Verbal Learning TEST (AVLT-REY) List A, Word 12.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123695>	C123657	AVLT-REY - List A Word 13|AVL02-List A Word 13|AVL02-List A Word 13|AVL0213	The Rey Auditory Verbal Learning TEST (AVLT-REY) List A, Word 13.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123696>	C123657	AVLT-REY - List A Word 14|AVL02-List A Word 14|AVL02-List A Word 14|AVL0214	The Rey Auditory Verbal Learning TEST (AVLT-REY) List A, Word 14.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123697>	C123657	AVLT-REY - List A Word 15|AVL02-List A Word 15|AVL02-List A Word 15|AVL0215	The Rey Auditory Verbal Learning TEST (AVLT-REY) List A, Word 15.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123698>	C123657	AVLT-REY - List A Total|AVL02-List A Total|AVL02-List A Total|AVL0216	The Rey Auditory Verbal Learning TEST (AVLT-REY) The number of List A words recalled from a trial.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123699>	C123657	AVLT-REY - List A Intrusions|AVL02-List A Intrusions|AVL02-List A Intrusions|AVL0217	The Rey Auditory Verbal Learning TEST (AVLT-REY) The number of List A intrusions while recalling from a trial.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12369>	C13020	Breast Fat Pad|Mammary Gland Fat Pad	A mass of adipose tissue in the breast that is surrounded by fibrous tissue.	Mammary Gland Fat-pad		Tissue	
C1236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1236>	C2139	Staphage Lysate	A preparation of bacterial lysate with potential immunomodulatory activity. Staphage lysate, obtained by phage lysis of Staphylococcal aureus, may be used as an antigenic stimulus to elicit non-specific humoral and cellular immune responses.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	NCI Drug Dictionary Terminology
C123700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123700>	C123657	AVLT-REY - List B Word 1|AVL02-List B Word 1|AVL02-List B Word 1|AVL0218	The Rey Auditory Verbal Learning TEST (AVLT-REY) List B, Word 1.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123701>	C123657	AVLT-REY - List B Word 2|AVL02-List B Word 2|AVL02-List B Word 2|AVL0219	The Rey Auditory Verbal Learning TEST (AVLT-REY) List B, Word 2.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123702>	C123657	AVLT-REY - List B Word 3|AVL02-List B Word 3|AVL02-List B Word 3|AVL0220	The Rey Auditory Verbal Learning TEST (AVLT-REY) List B, Word 3.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123703>	C123657	AVLT-REY - List B Word 4|AVL02-List B Word 4|AVL02-List B Word 4|AVL0221	The Rey Auditory Verbal Learning TEST (AVLT-REY) List B, Word 4.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123704>	C123657	AVLT-REY - List B Word 5|AVL02-List B Word 5|AVL02-List B Word 5|AVL0222	The Rey Auditory Verbal Learning TEST (AVLT-REY) List B, Word 5.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123705>	C123657	AVLT-REY - List B Word 6|AVL02-List B Word 6|AVL02-List B Word 6|AVL0223	The Rey Auditory Verbal Learning TEST (AVLT-REY) List B, Word 6.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123706>	C123657	AVLT-REY - List B Word 7|AVL02-List B Word 7|AVL02-List B Word 7|AVL0224	The Rey Auditory Verbal Learning TEST (AVLT-REY) List B, Word 7.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123707>	C123657	AVLT-REY - List B Word 8|AVL02-List B Word 8|AVL02-List B Word 8|AVL0225	The Rey Auditory Verbal Learning TEST (AVLT-REY) List B, Word 8.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123708>	C123657	AVLT-REY - List B Word 9|AVL02-List B Word 9|AVL02-List B Word 9|AVL0226	The Rey Auditory Verbal Learning TEST (AVLT-REY) List B, Word 9.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123709>	C123657	AVLT-REY - List B Word 10|AVL02-List B Word 10|AVL02-List B Word 10|AVL0227	The Rey Auditory Verbal Learning TEST (AVLT-REY) List B, Word 10.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12370>	C12801	Mammary Gland Tissue|Breast Tissue|Mammary Gland Parenchyma	The glandular tissue of the breast.  In females, it is composed of numerous lobules with alveolar ducts and alveoli.  In males, it is composed of rudimentary glands.	Mammary Gland Parenchyma		Tissue	
C123710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123710>	C123657	AVLT-REY - List B Word 11|AVL02-List B Word 11|AVL02-List B Word 11|AVL0228	The Rey Auditory Verbal Learning TEST (AVLT-REY) List B, Word 11.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123711>	C123657	AVLT-REY - List B Word 12|AVL02-List B Word 12|AVL02-List B Word 12|AVL0229	The Rey Auditory Verbal Learning TEST (AVLT-REY) List B, Word 12.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123712>	C123657	AVLT-REY - List B Word 13|AVL02-List B Word 13|AVL02-List B Word 13|AVL0230	The Rey Auditory Verbal Learning TEST (AVLT-REY) List B, Word 13.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123713>	C123657	AVLT-REY - List B Word 14|AVL02-List B Word 14|AVL02-List B Word 14|AVL0231	The Rey Auditory Verbal Learning TEST (AVLT-REY) List B, Word 14.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123714>	C123657	AVLT-REY - List B Word 15|AVL02-List B Word 15|AVL02-List B Word 15|AVL0232	The Rey Auditory Verbal Learning TEST (AVLT-REY) List B, Word 15.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123715>	C123657	AVLT-REY - List B Total|AVL02- List B Total|AVL02- List B Total|AVL0233	The Rey Auditory Verbal Learning TEST (AVLT-REY) The number of words recalled from List B trial.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123716>	C123657	AVLT-REY - List B Intrusions|AVL02-List B Intrusions|AVL02-List B Intrusions|AVL0234	The Rey Auditory Verbal Learning TEST (AVLT-REY) The number of intrusions while recalling from List B trial.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123717>	C123657	AVLT-REY - Recognition Total|AVL02-Recognition Total|AVL02-Recognition Total|AVL0235	The Rey Auditory Verbal Learning TEST (AVLT-REY) The number of words correct on recognition test.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123718>	C123657	AVLT-REY - Recognition Intrusions|AVL02-Recognition Intrusions|AVL02-Recognition Intrusions|AVL0236	The Rey Auditory Verbal Learning TEST (AVLT-REY) The number of intrusions on recognition test.			Intellectual Product	CDISC Functional Test AVLT-REY Test Code Terminology|CDISC Functional Test AVLT-REY Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C123719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123719>	C29697	Polyethylene Glycol 3350-containing Enema NER1008|Movidra|NER1008|NER1008 Enema|PEG3350-containing Enema NER1008	An enema containing the osmotic agent polyethylene glycol (PEG) 3350, also called macrogol 3350, with laxative activity. Upon rectal administration of the PEG3350-containing enema NER1008, PEG creates an osmotic gradient, which promotes the retention of water in the bowel. This increases the water content of stool, which results in increased gastrointestinal (GI) motility, decreased stool transit time and evacuation of colonic contents.			Organic Chemical|Pharmacologic Substance	NCI Drug Dictionary Terminology
C12371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12371>	C12436	Myocardium|CARDIAC MUSCLE TISSUE|Cardiac Muscle|Heart Muscle|MYOCARDIUM|Myocardial Tissue	The striated muscle tissue of the heart enveloped by the epicardium and the endocardium.	Myocardium		Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C123720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123720>	C28681|C201547	Akt-1/2 Inhibitor-treated Tumor Infiltrating Lymphocytes|AKTi-treated TIL|AKTi-treated TILs|Akti-1/2-treated Tumor Infiltrating Lymphocytes	Autologous tumor infiltrating lymphocytes (TILs) harvested directly from the infiltrate of a patient's tumor and treated with an inhibitor of the serine/threonine kinases Akt-1 and -2 (Akti-1/2) during ex vivo expansion, with potential antineoplastic activity. Upon reintroduction into the patient, the Akti-1/2-treated TILs recognize and kill cancer cells. Akt inhibition promotes the immunologic memory of the TILs and enhances their expansion, in vivo long-term persistence and antitumor activity.	Akt-1/2 Inhibitor-treated Tumor Infiltrating Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123721>	C78276	DWJ1319	An orally available agent that may prevent the formation of gallstones.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C123723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123723>	C43164	Package Type Not Applicable|NA|Not Applicable	There is no associated package type.			Functional Concept	FDA Structured Product Labeling Terminology|SPL Package Type Terminology
C123724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123724>	C201556|C129826	Interferon Beta-secreting Mesenchymal Stem Cells|IFNb-MSC|IFNb-secreting MSCs|IFNbeta-MSC|MSC-IFN beta	Human autologous mesenchymal stem cells (MSCs) harvested from the bone marrow of healthy individuals and transduced with a retroviral vector encoding the human cytokine interferon beta (IFNb), with potential immunomodulating and antineoplastic activities. Upon administration of IFNb-secreting MSCs, the cells are attracted and specifically migrate to tumor sites and become part of the tumor microenvironment. Since the MSCs express IFNb, these cells selectively deliver high levels of IFNb to the tumor site. In turn, IFNb binds to IFN-specific cell surface receptors and modulates the transcription and translation of certain genes whose protein products are involved in tumor cell proliferation. This decreases tumor cell growth.	Interferon Beta-secreting Mesenchymal Stem Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123725>	C85865|C35261	X-Linked Adrenal Hypoplasia Congenita|Adrenal Hypoplasia Congenita	A X-linked condition characterized by underdevelopment of the adrenal gland and adrenal insufficiency caused by mutation(s) in the NR0B1 gene, resulting in decreased activity of the nuclear receptor protein DAX1, which may be associated with hypogonadotropic hypogonadism.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C123726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123726>	C27564	SERKAL Syndrome|46,XX Sex Reversal with Dysgenesis of Kidneys Adrenals and Lungs|46,XX Sex Reversal with Dysgenesis of Kidneys, Adrenals, and Lungs	An autosomal recessive condition characterized by female to male sex reversal and kidney, adrenal, and lung dysgenesis, due to mutation(s) in the WNT4 gene.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C123727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123727>	C120446	Familial Glucocorticoid Deficiency Type 1|ACTH Receptor Defect|GCCD1	Familial glucocorticoid deficiency caused by mutation(s) in the MC2R gene encoding the adrenocorticotropin (ACTH) receptor, also known as the melanocortin-2 receptor.			Finding	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C123728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123728>	C120446	Familial Glucocorticoid Deficiency Type 2|GCCD2|Melanocortin-2 Receptor Accessory Protein Defect	Familial glucocorticoid deficiency caused by mutation(s) in the MRAP gene encoding the melanocortin-2 receptor accessory protein.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C123729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123729>	C3131	Natural Killer Cell and Glucocorticoid Deficiency with DNA Repair Defect|IMD54|Immunodeficiency 54|Mini-chromosome Maintenance 4	A congenital condition characterized by growth retardation, a decreased number of NK cells, glucocorticoid deficiency, and increased chromosome breakage, associated with mutation(s) in the MCM4 gene.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C12372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12372>	C12679	Artery|ARTERY|Arterial|arterial subtree|arterial tree organ part|arteries|artery|artery	A blood vessel that carries blood away from the heart.	Artery		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|UBERON Terminology
C123730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123730>	C20401	Lampalizumab|FCFD4514S|LAMPALIZUMAB|RG 7417				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C123731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123731>	C3749|C123735	Fusion-Positive Alveolar Rhabdomyosarcoma|Fusion Gene Positive Alveolar Rhabdomyosarcoma	An alveolar rhabdomyosarcoma characterized by the presence of chromosomal translocation t(1;13)(p36;q14) that results in PAX7-FOXO1 gene fusion; or translocation t(2;13)(q35;q14) that results in PAX3-FOXO1 gene fusion.  Approximately 80% of alveolar rhabdomyosarcomas are fusion-positive.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123732>	C3749|C123736	Fusion-Negative Alveolar Rhabdomyosarcoma|Fusion Gene Negative Alveolar Rhabdomyosarcoma	An alveolar rhabdomyosarcoma characterized by the absence of chromosomal translocation t(1;13)(p36;q14) or t(2;13)(q35;q14) and therefore the absence of PAX7-FOXO1 or PAX3-FOXO1 gene fusion.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123733>	C128462	BET Inhibitor FT-1101|CC 95775|CC-95775|CC95775|FT-1101|FT1101	An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, the BET inhibitor FT-1101 binds to the acetylated lysine recognition motifs in the bromodomain sites of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to the inhibition of tumor cell growth. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.	BET Inhibitor FT-1101		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123734>	C133877	Sotigalimab|APX 005|APX 005M|APX-005M|APX005M|CD40 Agonistic Monoclonal Antibody APX005M|EPI-0050|SOTIGALIMAB	A humanized monoclonal antibody agonist of the cell surface receptor CD40, with potential immunostimulatory and antineoplastic activities. Similar to the endogenous CD40 ligand (CD40L or CD154), sotigalimab binds to CD40 on a variety of immune cell types. This triggers the cellular proliferation and activation of antigen-presenting cells (APCs), and activates B-cells, and effector and memory T-cells. This results in an enhanced immune response against tumor cells. Sotigalimab also binds to and activates CD40 present on the surfaces of some solid tumor cells, leading to apoptosis and decreased tumor growth. CD40, a cell surface receptor and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells and certain cancer cells; it mediates both indirect tumor cell killing through the activation of the immune system and direct tumor cell apoptosis.	Sotigalimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123735>	C3359	Fusion-Positive Rhabdomyosarcoma	A rhabdomyosarcoma characterized by the presence of chromosomal translocation t(1;13)(p36;q14) that results in PAX7-FOXO1 gene fusion; or translocation t(2;13)(q35;q14) that results in PAX3-FOXO1 gene fusion.			Neoplastic Process	NCIt Neoplasm Core Terminology
C123736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123736>	C3359	Fusion-Negative Rhabdomyosarcoma	A rhabdomyosarcoma characterized by the absence of chromosomal translocation t(1;13)(p36;q14) or t(2;13)(q35;q14) and therefore the absence of PAX7-FOXO1 or PAX3-FOXO1 gene fusion.			Neoplastic Process	NCIt Neoplasm Core Terminology
C123737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123737>	C6541|C162703|C123739	Refractory Childhood Malignant Germ Cell Tumor|Refractory Childhood Malignant Germ Cell Neoplasm|Refractory Malignant Germ Cell Tumor	A malignant germ cell tumor that occurs during childhood and is resistant to treatment.	Refractory Childhood Malignant Germ Cell Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C123738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123738>	C12616	Gitter Cell|Granular Corpuscle	A microglial cell that is unable to phagocytose any further materials. Named for its grainy appearance, gitter cells can indicate post-infection areas that have healed.	Microglia		Cell	
C123739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123739>	C4925|C120186	Refractory Malignant Germ Cell Tumor|Refractory Malignant Germ Cell Neoplasm	A malignant germ cell tumor that is resistant to treatment.			Neoplastic Process	
C12373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12373>	C34076	Cartilage|CARTILAGE|Cartilagenous|Cartilaginous|cartilage	A type of connective tissue composed of chondrocytes and an extracellular matrix, composed of collagen, elastin, and ground substance. There are three types of cartilage; namely elastic, hyaline, and fibrocartilage.	Cartilage		Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C123740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123740>	C25464	Kosovo|901|901|KOSOVO|XK|XK|XKS|XKS	A southeastern European country between Servia and Macedonia.			Geographic Area	GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C123741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123741>	C25464	Ashmore and Cartier Islands|902|ASHMORE AND CARTIER ISLANDS|XA|XA|XAC|XAC	Islands in the Indian Ocean, located midway between northwestern Australia and Timor island.			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C123742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123742>	C25464	Baker Island|903|903|BAKER ISLAND|XB|XB|XBK|XBK	An atoll in the North Pacific Ocean, about halfway between Hawaii and Australia.			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C123743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123743>	C25464	Bassas da India|904|904|BASSAS DA INDIA|QS|QS|XBI|XBI	An atoll in the southern Mozambique Channel that is part of the French Southern and Antartic Lands.			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C123744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123744>	C25464	Clipperton Island|905|905|CLIPPERTON ISLAND|CP|CP|CPT|CPT	An atoll in the North Pacific Ocean, southwest of Mexico.			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C123745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123745>	C25464	Coral Sea Islands|906|906|CORAL SEA ISLANDS|XC|XC|XCS|XCS	Numerous islands scattered over more than three-quarters of a million square kilometers of ocean that are a territory of Australia and located in Oceania, northeast of Austrualia.			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C123746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123746>	C25464	Diego Garcia|908|908|DG|DG|DGA|DGA|DIEGO GARCIA	An atoll and the largest of 60 small islands comprising the Chagos Archipelago.			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C123747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123747>	C16632	GENC Entity 1|909|909|ENTITY 1|XAZ|XAZ	A geopolitical entity designated by the Geopolitical Entities, Names, anc Codes Standard (GENC).			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C123748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123748>	C16632	GENC Entity 2|910|910|ENTITY 2|XCR|XCR	A geopolitical entity designated by the Geopolitical Entities, Names, anc Codes Standard (GENC).			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C123749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123749>	C16632	GENC Entity 3|911|911|ENTITY 3|XCY|XCY	A geopolitical entity designated by the Geopolitical Entities, Names, anc Codes Standard (GENC).			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C12374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12374>	C12964	Connective Tissue|CONNECTIVE TISSUE|connective tissue|connective tissue|portion of connective tissue|textus connectivus	The supporting or framework tissue of the animal body, formed of fibrous and ground substance with more or less numerous cells of various kinds; it is derived from the mesenchyme, and this in turn from the mesoderm; the varieties of connective tissue are: areolar or loose; adipose; dense, regular or irregular, white fibrous; elastic; mucous; and lymphoid tissue; cartilage; and bone; the blood and lymph may be regarded as connective tissues the ground substance of which is a liquid.	Connective Tissue		Tissue	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|NICHD Terminology|Pediatric Rheumatology Terminology|UBERON Terminology
C123750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123750>	C16632	GENC Entity 4|912|912|ENTITY 4|XKM|XKM	A geopolitical entity designated by the Geopolitical Entities, Names, anc Codes Standard (GENC).			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C123751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123751>	C16632	GENC Entity 5|913|913|ENTITY 5|XKN|XKN	A geopolitical entity designated by the Geopolitical Entities, Names, anc Codes Standard (GENC).			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C123752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123752>	C16632	GENC Entity 6|914|914|A3|A3|AX3|AX3|ENTITY 6	A geopolitical entity designated by the Geopolitical Entities, Names, anc Codes Standard (GENC).			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C123753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123753>	C25464	Europa Island|915|915|EUROPA ISLAND|XE|XE|XEU|XEU	An atoll in the Mozambique channel between southern Madagascar and southern Mozambique.			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C123754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123754>	C25464	Gaza Strip|916|916|GAZA STRIP|XG|XG|XGZ|XGZ	360 square kilometers in the Middle East, bordering the Mediterranean Sea, between Egypt and Israel.			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C123755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123755>	C25464	Glorioso Islands|917|917|GLORIOSO ISLANDS|QX|QX|XGL|XGL	A group of French islands and rocks in the northern Mozambique channel, northwest of Madagascar.			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C123756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123756>	C25464	Guantanamo Bay Naval Base|918|918|A2|A2|AX2|AX2|GUANTANAMO BAY NAVAL BASE	A US Navy military base located on Guantanamo Bay in Cuba.			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C123757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123757>	C33904	Diaphragmatic Pinch	The location where the diaphragmatic crura constrict the esophagus as it passes through the diaphragm.			Conceptual Entity	
C123758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123758>	C77537	Suprailiac Skinfold Thickness	A measurement of the thickness of a pinch of skin at a location above the hip bone, used in estimating an individual's body fat.			Diagnostic Procedure	
C123759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123759>	C25464	Howland Island|919|919|HOWLAND ISLAND|XH|XH|XHO|XHO	An island in the North Pacific Ocean, about halfway between Hawaii and Australia.			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C12375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12375>	C25763	Anal Canal|ANAL CANAL|Anal canal|Anal canal structure (body structure)|Functional Anal Canal|Surgical Anal Canal|anal canal	The terminal section of the alimentary canal, which extends from the anorectal junction and ends at the anal opening.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C123760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123760>	C25464	Jan Mayen|920|920|JAN MAYEN|XJ|XJ|XJM|XJM	An island in Northern Europe, between the Greenland Sea and the Norwegian Sea.			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C123761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123761>	C25464	Jarvis Island|921|921|JARVIS ISLAND|XJV|XJV|XQ|XQ	An island in the South Pacific Ocean between Hawaii and the Marshall Islands.			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C123762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123762>	C25464	Johnston Atoll|922|922|JOHNSTON ATOLL|XJA|XJA|XU|XU	An island in the North Pacific Ocean, between Hawaii and the Marshall Islands.			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C123763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123763>	C25464	Juan de Nova Island|923|923|JUAN DE NOVA ISLAND|QU|QU|XJN|XJN	An island in the Mozambique Channel, between Madagascar and Mozambique.			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C123764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123764>	C25464	Kingman Reef|924|924|KINGMAN REEF|XKR|XKR|XM|XM	A reef in the North Pacific Ocean, between Hawaii and American Samoa.			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C123765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123765>	C18520	Phosphorylated Epidermal Growth Factor Receptor|Autophosphorylated Epidermal Growth Factor Receptor|Phospho-EGFR|Phosphorylated EGFR|p-EGFR|pEGFR	Epidermal growth factor receptor protein (EGFR) bearing phosphorylated tyrosine residues within the 194 amino acids of the carboxyl-terminal intracellular domain of the protein. Five ligand-dependent autophosphorylation sites have been identified; overexpression or mutation of EGFR can decouple ligand-binding from autophosphorylation and the subsequent activation of downstream signaling pathways. The presence of phosphorylated EGFR in a malignant tumor is generally correlated with poor prognosis and could be used as a predictive biomarker to identify individuals who may respond to EGFR-tyrosine kinase inhibitor treatment.	Phosphorylated Epidermal Growth Factor Receptor		Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123766>	C25464	Navassa Island|926|926|NAVASSA ISLAND|XNV|XNV|XV|XV	An island in the Caribbean Sea that is west of Haiti.			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C123767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123767>	C25464	Palmyra Atoll|927|927|PALMYRA ATOLL|XL|XL|XPL|XPL	An atoll in the North Pacific Ocean halfway between Hawaii and American Samoa.			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C123768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123768>	C25464	Paracel Islands|928|928|PARACEL ISLANDS|XP|XP|XPR|XPR	A group of small islands and reefs in the South China Sea, between Vietnam and the Philippines.			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C123769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123769>	C25464	Spratly Islands|929|929|SPRATLY ISLANDS|XS|XS|XSP|XSP	More than 100 small islands in the South China Sea, between southern Vietnam and the southern Philippines.			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C12376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12376>	C12948	Bile Duct|BILE DUCT|DUCT, BILE|bile duct|bile duct	Any of the ducts conveying bile between the liver and the intestine, including hepatic, cystic, and common bile duct.	Bile Duct		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C123770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123770>	C25464	Svalbard|930|930|SVALBARD|XR|XR|XSV|XSV	Islands in the Artic Ocean, between Norway and the North Pole.			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C123771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123771>	C25464	Tromelin Island|931|931|TROMELIN ISLAND|XT|XT|XTR|XTR	An island in the Indian Ocean east of Madagascar.			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C123772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123772>	C25464	Unknown GENC|932|932|A1|A1|AX1|AX1|UNKNOWN	Values reserved for a geopolitical name of Unknown by the Geopolitical entities, names and codes (GENC) standard.			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C123773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123773>	C25464	Wake Island|933|933|QW|QW|WAKE ISLAND|XWK|XWK	An atoll in the North Pacific Ocean, between Hawaii and the Northern Mariana Islands.			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C123774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123774>	C25464	West Bank|934|934|WEST BANK|XW|XW|XWB|XWB	5860 square kilometers in the Middle east that is west of Jordan and east of Israel.			Geographic Area	Geopolitical Entities, Names, and Codes Terminology
C123775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123775>	C308	Mosedipimod|1-Palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol|9,12-Octadecadienoic acid (9Z,12Z)-, 1-((Acetyloxy)methyl)-2-((1-oxohexadecyl)oxy)ethyl Ester|EC-18|MOSEDIPIMOD	A synthetic version of a monoacetyldiacylglyceride naturally occurring in various seed oils, bovine udder and milk fat, antlers of sika deer, with potential antineoplastic activity. Although the exact mechanism of action through which EC-18 exerts its pharmacological effect has yet to be fully identified, upon administration, mosedipimod stimulates calcium influx into T-lymphocytes and increases the production of various cytokines, including interleukin (IL) -2, IL-4, IL-12, interferon-gamma (IFN-g), and granulocyte-macrophage colony-stimulating factor (GM-CSF). This stimulates the proliferation of hematopoietic stem cells, bone marrow stromal cells and immune cells, including T- and B-lymphocytes, dendritic cells (DCs) and macrophages. Therefore, EC18 may stimulate the immune system to target cancer cells. In addition, EC-18 enhances the cytolytic activity of natural killer (NK) cells and suppresses the expression of the transmembrane protein tumor cell toll-like receptor 4 (TLR-4) on cancer cells. As activation of TLR-4 enhances immunosuppression and stimulates cancer cell growth, blocking TLR-4 expression suppresses tumor cell proliferation.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C123776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123776>	C91105	MD Anderson Symptom Inventory - Spine Tumor|M. D. Anderson Symptom Inventory - Spine Tumor|MD Anderson Symptom Inventory - Spine Tumor (MDASI-SP)|MDASI-SP	A self-administered questionnaire designed specifically for evaluating the severity of symptoms related to a spine tumor.			Intellectual Product	
C123777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123777>	C173346|C107401	Radiating Spine Pain at its Worst Question|Radiating Spine Pain at its Worst|Your radiating spine pain at its worst	A question about an individual's radiating spine pain at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Spine Tumor
C123778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123778>	C173219|C107401	Weakness in Arms and/or Legs at its Worst Question|Weakness in Arms and/or Legs at its Worst|Your weakness in the arms and/or legs at its worst	A question about an individual's weakness in their arms and/or legs at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Spine Tumor
C123779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123779>	C173938|C107401	Loss of Bowel and/or Bladder Control at its Worst Question|Loss of Bowel and/or Bladder Control at its Worst|Your loss of control of bowel and/or bladder at its worst	A question about an individual's loss of control of bowel and/or bladder at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Spine Tumor
C12377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12377>	C13018	Gallbladder|GALLBLADDER|Gallbladder / Biliar|Gallbladder structure (body structure)|Gastrointestinal Tract, Gall Bladder|cholecyst|gall bladder|gallbladder|gallbladder	A pear-shaped organ located under the liver that stores and concentrates bile secreted by the liver. From the gallbladder the bile is delivered through the bile ducts into the intestine thereby aiding the digestion of fat-containing foods.	Gall Bladder		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C123780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123780>	C173704|C107401	Sexual Function at its Worst Question|Sexual Function at its Worst|Your sexual function at its worst	A question about an individual's sexual function at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Spine Tumor
C123781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123781>	C29697|C210674	Magnesium L-threonate|MAGNESIUM L-THREONATE|Magnesium, Bis((2R,3S)-2,3,4-trihydroxybutanoato-kappaO,kappaO')-, (T-4)-	A nutritional supplement containing the L-threonate form of magnesium (Mg) that can be used to normalize Mg levels in the body. Upon administration, Mg is utilized by the body for many biochemical functions and reactions including: bone and muscle function, protein and fatty acid formation, activation of B vitamins, blood clotting, insulin secretion, and ATP formation. Mg also serves as a catalyst for many enzymes throughout the body. In addition, magnesium improves the functioning of the immune system by enhancing the expression of natural killer activating receptor NKG2D in cytotoxic T-lymphocytes and natural killer (NK) cells. This increases their anti-viral and anti-tumor cytotoxic effects.			Inorganic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C123782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123782>	C12583	Conventional Dendritic Cell|Classical Dendritic Cell|Myeloid Dendritic Cell|cDC|mDC	A subset of dendritic cells that are derived from myeloid precursors. They express toll-like receptors 2 and 4 and secrete interleukin-12.	Conventional Dendritic Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C123783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123783>	C12558	M2 Macrophage	A macrophage that produces high levels of interleukin (IL)-10, TGF-beta and low levels of IL-12 and converts arginine to ornithine. These cells may both encourage tissue repair and inhibit inflammation.	M2 Macrophage		Cell	CTRP Biomarker Terminology|CTRP Terminology
C123784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123784>	C160953	Filipino Language|FIL|Filipino|Pilipino	A standardized form of the Tagalog language spoken as the national language in the Philippines.			Language	
C123785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123785>	C161845	French Language|FRA|French|French	A romance language spoken as the official language in France and 28 other countries.			Language	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C123786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123786>	C51277	Hmong Language|First Vernacular Chuanqiandian Miao|HMN|Hmong|Mong|Mong Language	A dialect of the Hmongic languages spoken by the Hmong people of Sichuan, Yunnan, Guizhou, Guangxi, northern Vietnam, Thailand, and Laos.			Language	
C123787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123787>	C210937	Hungarian Language|HUN|Hungarian|Magyar	A member of the Uralic language family that is spoken as the official language of Hungary.			Language	
C123788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123788>	C161845	Italian Language|ITA|Italian	A romance language spoken as the official language of Italy and San Marino.			Language	
C123789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123789>	C51277	Japanese Language|JPN|Japanese|Japanese	An East Asian language spoken as the official language of Japan.			Language	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C12378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12378>	C12919	Digestive System|Body System, Gastrointestinal|GASTROINTESTINAL SYSTEM|Gastrointestinal|Gastrointestinal Body System|Gastrointestinal Organ System|Gastrointestinal System|Gastrointestinal System|Organ System, Gastrointestinal|digestive system|digestive system	The system that includes the esophagus, stomach, small and large intestine, anus, liver, biliary tract, and pancreas.	Digestive System|Gastrointestinal System		Body System	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|ICDC Terminology|ICDC Value Terminology
C123790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123790>	C161857	Russian Language|RUS|Russian|Russian	An East Slavic language spoken as an official language in Russia, Belarus, Kazakhstan, and Kyrgyzstan.			Language	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C123791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123791>	C160955	Somali Language|SOM|Somali	An Afroasiatic language spoken as the native language by the Somali people within the Horn of Africa. It is an official language of the Federal Republic of Somalia, a national language in Djibouti, and a working language in the Somali region of Ethiopia.			Language	
C123792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123792>	C147920	Selective Androgen Receptor Modulator LY2452473|Isopropyl N-[(2S)-7-cyano-4-(2-pyridylmethyl)-2,3-dihydro-1H-cyclopenta[b]indol-2-yl]carbamate|LY SARM|LY2452473|OPK-88004|SARM LY2452473	An orally bioavailable selective androgen receptor modulator (SARM), with potential tissue-selective androgenic/anti-androgenic activity. Upon oral administration, LY2452473 acts as an agonist in select tissues and organs, including skeletal muscle, bone and the penis, thereby binding to and activating androgen receptor (AR) while acting as an antagonist in the prostate, thereby blocking AR activation and AR-mediated cellular proliferation. This may improve muscle mass and strength, bone formation, and erectile dysfunction while not stimulating growth of the prostate.	Selective Androgen Receptor Modulator LY2452473		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C123793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123793>	C764	Zinc Protoporphyrin|(SP-4-2)-Dihydrogen (7,12-Diethenyl-3,8,13,17-Tetramethyl-21H,23H-Porphine-2,18-Dipropanoato(4-)- N(21),N(22),N(23),N(24))Zincate(2-)|Dihydrogen (3,8,13,17-Tetramethyl-7,12-Divinyl-21H,23H-Porphine-2,18-Dipropionato(4-)-N21,N22,N23,N24)Zincate(4-)|Protoporphyrin IX, Zinc Chelate|ZINC PROTOPORPHYRIN|ZP|ZPP|Zinc Protoporphyrin IX|Zinc-Protoporphyrin|Zincate(2-), (7,12-Diethenyl-3,8,13,17-Tetramethyl-21H,23H-Porphine-2,18-Dipropanoato(4-)-KappaN21,KappaN22,KappaN23,KappaN24)-, Hydrogen (1:2), (SP-4-2)-|ZnPP	An ionized form of the tetrazole protoporphryin IX that contains zinc in the metal ion binding pocket. Zinc protoporphyrin (ZPP) is formed in circulating red blood cells (RBC) either in the presence of lead or in the absence of sufficient iron, as both of these conditions inhibit the insertion of a ferrous ion into protoporphryin IX to form heme. Therefore, elevated levels of ZPP is associated with heme deficiency. Elevated RBC molar ratios of ZPP to heme are indicative of multiple pathologies including lead poisoning, iron deficiency, protoporphyria, and various types of anemia.	Zinc Protoporphyrin		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C123794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123794>	C843	27-Hydroxycholesterol|(25R)-Cholest-5-Ene-3beta,26-Diol|27HC|27OHC|5-Cholestene-3 beta,27-Diol|CHOLEST-5-ENE-3.BETA.,26-DIOL, (25R)-|Cholest-5-Ene-3,26,Diol, (3beta,25R)-|Cholest-5-Ene-3beta,26-Diol, (25R)-|Cholest-5-Ene-3beta,27-Diol	An endogenous metabolite of cholesterol produced by the hydroxylation of the carbon at position 27 by the enzyme sterol 26-hydroxylase, mitochondrial (CYP27A1). Some neoplasms produce excess of 27-hydroxycholesterol (27HC) or inhibit its catabolism, and high cholesterol levels are correlated with elevated levels of 27HC; under these conditions, 27HC may have deleterious selective estrogen receptor modulator (SERM) and liver X receptor (LXR) agonistic activities. As a SERM, 27HC binds to and prevents the activation of estrogen receptors (ERs) in the vasculature. This prevents ER-mediated vasodilation and abrogates the cardiovascular protective effects of estrogen. However, 27HC binds to and activates ERs and LXRs in breast tissue, which stimulates ER-dependent breast cancer cell growth and metastasis.	27-Hydroxycholesterol		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C123795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123795>	C735	Antimicrobial Peptide|AMP	A natural or synthetically-derived peptide that selectively kills or inhibits the growth of microorganisms; it may also have immunomodulatory activity.	Antimicrobial Peptide		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Terminology
C123796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123796>	C2289	Sex Steroid Hormone|Sex Hormone|Sex Steroid	A class of steroid hormones that specifically binds to and activates androgen, progesterone or estrogen receptors. Sex steroids activate various signaling pathways involved in the development and maintenance of secondary sexual characteristics, reproductive processes, blood salt balance, response to stress, neuronal function and a number of metabolic processes.	Sex Steroid Hormone		Chemical Viewed Functionally	CTRP Biomarker Terminology|CTRP Terminology
C123797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123797>	C18606	EphA Receptor Family|EPHA|Ephrin Type-A Receptor|Ephrin Type-A Receptor Family|Ephrin-A Receptor|Ephrin-A Receptor Family	A family of tyrosine kinase receptors that are involved in forward and reverse cell-cell signaling through binding to glycosylphosphatidylinositol (GPI)-anchored ephrin-A family ligands (EFNA) expressed on adjacent cells.	EphA Receptor Family		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123798>	C17634	Prostate Health Index|PHI|phi-index	An assay system that indirectly measures the amount of three forms of prostate-specific antigen (PSA) in a patient serum sample and then uses those values to calculate a score that estimates the patient's probability of having prostate cancer. The PSA forms that are examined are total PSA, free PSA, and an isoform of PSA that has a propeptide comprised of two amino acid residues ([-2]proPSA).	Prostate Health Index		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Terminology
C123799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123799>	C15959	Cell Response Index|CRI	An in vitro assay that determines the magnitude of calcium mobilization by a cellular sample following exposure to various stimuli. A range of concentrations may be used to calculate the amount that yields a 50% response rate.	Cell Response Index		Research Activity	CTRP Biomarker Terminology|CTRP Terminology
C12379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12379>	C25763	Large Intestine|LARGE INTESTINE|Large Bowel|Large Bowel|Large Bowel|Large intestine|Structure of large intestine (body structure)|large intestine|large intestine	A muscular tube that extends from the end of the small intestine to the anus.	Large Intestine		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTDC Value Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C1237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1237>	C221|C1404	Staurosporine|(9alpha,10beta,11beta,13alpha)-(+)-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H-9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one|(9alpha,10beta,11beta,13alpha)-(+)-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H-9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one|8,12-Epoxy-1H,8H-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)trinden-1-one, 2,3,9,10,11,12-hexahydro-9-methoxy-8-methyl-10-(methylamino)-, (8alpha,9beta,10beta,12alpha)-(+)-|AM-2282|Antibiotic 230|Antibiotic AM 2282|CGP-39360|STAUROSPORINE|staurosporine	A cell permeable alkaloid isolated from Streptomyces staurosporeus exhibiting anti-cancer activity.  Staurosporine is a potent, non-selective inhibitor of protein kinases, including protein kinase C.  This agent induces apoptosis by an undetermined mechanism. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C123800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123800>	C16295	Anti-Poliovirus Antibody|Poliovirus Antibody	An antibody produced in response to exposure to poliovirus.	Anti-Poliovirus Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C123801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123801>	C63328	Genome-Wide 5-Hydroxymethylcytosine Profile|Genome-Wide 5-Hydroxymethylcytosine Analysis|Genome-Wide 5-hmC|Genome-Wide 5-hmC Profile	The characterization and quantitation of sites within DNA sequences that contain 5-hydroxymethylcytosine modifications across the entire genome of biological sample or specimen.	Genome-Wide 5-Hydroxymethylcytosine Profile		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Terminology
C123802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123802>	C28624	CD159 Family|CD159|CD159 Antigen|KLRC1/2|Killer-Cell Lectin-Like Receptor Subfamily C 1/2|NKG2-A/NKG2-B/NKG2-C	A family of cell surface receptors found on natural killer cells and some T-lymphocytes that both interact with MHC class I HLA-E molecules and modulate cell-mediated cytotoxicity. There are two CD159 proteins, NKG2-A/NKG2-B type II integral membrane protein and NKG2-C type II integral membrane protein.	CD159 Family		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123803>	C16295	Human Anti-Human Minibody Antibody|HAMBA|Human Anti-Human Minibody	Human antibodies which recognize humanized minibodies. These can develop in response to treatment with therapeutic minibodies and may limit the effectiveness of the treatment.	Human Anti-Human Minibody Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C123804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123804>	C19770	Cytokine and Angiogenic Factor Profile|CAF Profile	A data set that both identifies and quantifies the levels of expression for all the cytokines and angiogenic factors present in a biological sample or specimen.	Cytokine and Angiogenic Factor Profile		Research Activity	CTRP Biomarker Terminology|CTRP Terminology
C123805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123805>	C16295	Anti-Reovirus Antibody|Reovirus Antibody	An antibody produced in response to exposure to reovirus.	Anti-Reovirus Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C123806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123806>	C16295	GUCY2C Antibody|Anti-GC-C Antibody|Anti-GCC Antibody|Anti-GUCY2C Antibody|Anti-Guanylyl Cyclase C Antibody|Anti-Heat-Stable Enterotoxin Receptor Antibody|Anti-STAR Antibody|Anti-hSTAR Antibody|GC-C Antibody|GCC Antibody|Guanylyl Cyclase C Antibody|Heat-Stable Enterotoxin Receptor Antibody|STAR Antibody|hSTAR Antibody	Any immunoglobulin that recognizes heat-stable enterotoxin receptor.	GUCY2C Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123807>	C48966	IGF2BP3 Autoantibody|Anti-IGF-II mRNA-Binding Protein 3 Autoantibody|Anti-IGF2 mRNA-Binding Protein 3 Autoantibody|Anti-IGF2BP3 Autoantibody|Anti-IMP-3 Autoantibody|Anti-IMP3 Antibody|Anti-IMP3 Autoantibody|Anti-Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 Autoantibody|Anti-KOC Autoantibody|IGF-II mRNA-Binding Protein 3 Autoantibody|IGF2 mRNA-Binding Protein 3 Autoantibody|IMP-3 Autoantibody|Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 Autoantibody|KOC Autoantibody	An autoantibody that recognizes insulin-like growth factor 2 mRNA-binding protein 3.	IGF2BP3 Autoantibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123808>	C20130	Phosphoglycerate Mutase Family|BPG-Dependent PGAM|PGAM|Phosphoglycerate Mutase	A family of proteins whose members are involved in glycolysis. This family is comprised of three isozymes that are either homodimers or heterodimers of phosphoglycerate mutase 1 and 2. These enzymes have multiple reversible isomerase and phosphatase activities. During glycolysis these enzymes can interconvert 3-phosphoglycerate to 2-phosphoglycerate through a 2,3-bisphosphoglycerate intermediate.	Phosphoglycerate Mutase Family		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123809>	C20130	Interferon-Induced Protein with Tetratricopeptide Repeats Family|IFIT|IFIT Family|IFN-Induced Protein with Tetratricopeptide Repeats Family|Interferon Induced Protein with Tetratricopeptide Repeats|Interferon Induced Protein with Tetratricopeptide Repeats Family|Interferon Induced Proteins with Tetratricopeptide Repeats Family|Interferon-Induced Proteins with Tetratricopeptide Repeats Family	A family of proteins that are expressed during viral infection, pathogen recognition or during interferon (IFN) treatment. These proteins are localized in the cytoplasm and contain multiple tetratricopeptide repeats; they are involved in antiviral immune processes.	Interferon-Induced Protein with Tetratricopeptide Repeats Family		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12380>	C25763	Appendix|APPENDIX|Appendix structure (body structure)|LARGE INTESTINE, APPENDIX|Vermiform Appendix|appendix|appendix|appendix vermiformis|caecal appendix|cecal appendix|vermiform appendix	Small tissue projection existing as a cecal diverticulum with a questionable history of vestigial versus specialized organ.	Appendix		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C123810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123810>	C20130	Adipokine|Adipocytokine	A cytokine that is expressed and secreted by adipose tissue.	Adipokine		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Terminology
C123812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123812>	C18993	Minibody	An engineered antibody comprised of a dimeric complex consisting of two immunoglobulin fragments. Each fragment consists of a single chain variable fragment (scFv) joined to a heavy CH3 domain by a linker peptide. The dimer is formed by interactions between the two CH3 domains; additionally, the linker peptide may stabilize the dimer.	Minibody		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123813>	C53543|C28193	Beare-Stevenson Cutis Gyrata Syndrome	A rare, autosomal dominant inherited disorder caused by mutations in the FGFR2 gene. It is characterized by the premature fusion of the bones of the skull (craniosynostosis) and a skin abnormality called cutis gyrata. The craniosynostosis results in a cloverleaf-shaped skull, wide-set eyes, ear abnormalities, underdeveloped upper jaw, and developmental delays. Cutis gyrata is characterized by a wrinkled skin appearance, especially on the face, near the ears, and on the palms and soles.			Disease or Syndrome	Cellosaurus Disease Terminology
C123814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123814>	C53543|C28193	Jackson-Weiss Syndrome	A rare, autosomal dominant inherited disorder caused by mutations in the FGFR2 gene. It is characterized by the premature fusion of the bones of the skull (craniosynostosis) and foot abnormalities. The craniosynostosis results in a malformed skull, widely spaced eyes, and a bulging forehead. The foot abnormalities consist of short and wide first toes, which bend away from the other toes. In addition, syndactyly in some toes may be present. The hands are almost always normal.			Disease or Syndrome	Cellosaurus Disease Terminology
C123815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123815>	C53543|C28193	Myhre Syndrome	A rare, autosomal dominant inherited disorder caused by mutations in the SMAD4 gene.  It is characterized by developmental abnormalities, mild to moderate intellectual disability, hearing loss, skin stiffness, skeletal abnormalities, and typical facial features (short palpebral fissures, shortened distance between the nose and upper lip, midface hypoplasia, prognathism, cleft palate, and/or cleft lip).			Disease or Syndrome	Cellosaurus Disease Terminology
C123816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123816>	C129822|C128037	Camrelizumab|AiRuiKa|CAMRELIZUMAB|Carrelizumab|Carrizumab|Erica|HR 301210|HR-301210|HR301210|SHR 1210|SHR-1210|SHR1210	A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody SHR-1210 binds to and blocks the binding of PD-1, expressed on activated T-lymphocytes, B-cells and natural killer (NK) cells, to its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen presenting cells (APCs). This prevents the activation of PD-1 and its downstream signaling pathways. This restores immune function through the activation of cytotoxic T-lymphocytes (CTLs) and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.	Camrelizumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123817>	C28676|C129826	Donor-derived WT1/PRAME/NY-ESO-1/Survivin-specific T-lymphocytes|Donor-derived Multi-Tumor Associated Antigen (multiTAA)-Specific T Cells|Multi-TAA Specific T Cells	Allogeneic T-lymphocytes specifically reactive to the tumor-associated antigens (TAAs) human Wilms tumor protein-1 (WT1), Preferentially Expressed Antigen in Melanoma (PRAME), the cancer-testis antigen NY-ESO-1, and survivin, with potential antineoplastic activity. Donor derived T-cells are mixed, ex vivo, with protein fragments derived from the TAAs WT1, PRAME, NY-ESO-1, and survivin. Upon intravenous administration, the donor-derived WT1/PRAME/NY-ESO-1/Survivin-specific T-lymphocytes recognize and kill cancer cells expressing these TAAs. WT1, NY-ESO-1, PRAME, and survivin, are expressed on certain tumor cell types and play key role in tumor cell proliferation and survival.	Donor-derived WT1/PRAME/NY-ESO-1/Survivin-specific T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123818>	C29714	Cromolyn Sodium Inhalant PA101|PA 101|PA101|Sodium Cromoglicate Inhalant PA10	A solution containing a high concentration of cromolyn sodium, with potential mast cell stabilizing, anti-tussive and anti-inflammatory activities. Upon inhalation of PA101 via a nebulizer, cromolyn blocks calcium ion influx into mast cells, thereby preventing the degranulation of mast cells in the lungs. This blocks the release of pro-inflammatory mediators from mast cells, such as histamine and slow-reacting substance of anaphylaxis (SRS-A), and prevents both bronchoconstriction and an inflammatory response. In indolent systemic mastocytosis (ISM), PA101 may be able to reduce the symptoms associated with this disease			Pharmacologic Substance	NCI Drug Dictionary Terminology
C123819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123819>	C2139|C129826	Therapeutic Dendritic Cells/Cytokine-induced Killer Cells|DC-CIK	A preparation of autologous dendritic cells (DC) mixed with cytokine-induced killer (CIK) cells (DC-CIK), with potential immunopotentiating and antineoplastic activities. DCs were obtained ex vivo by incubation of peripheral blood lymphocytes (PBLs) with granulocyte-macrophage colony-stimulating factor stimulating factor (GM-CSF or CSF2), tumor necrosis factor (TNF), and interleukin (IL)-24 and were sensitized with tumor-associated antigens (TAAs). Cytokine-induced killer (CIK) cells are immune effector cells with both T-cell and natural killer (NK) cell like phenotype. CIKs are non-major histocompatibility complex (MHC)-restricted, NK-like T-lymphocytes, which express both CD3, a T-cell surface marker, and CD56, a natural killer cell surface marker, and have been generated ex vivo by incubation of peripheral blood lymphocytes (PBLs) with anti-CD3 monoclonal antibody, IL-2, IL-1 alpha, and interferon gamma (IFN-gamma) and then expanded. Upon co-culture of DCs and CIKs, and administration of DC-CIK cells into the patient, the DCs are able to stimulate the immune response to exert a specific anti-tumor immune response, while the CIK cells exert direct oncolytic activity.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12381>	C25763	Cecum|CECUM|Cecal|Cecum structure (body structure)|LARGE INTESTINE, CECUM|caecum|cecum|cecum|intestinum crassum caecum	A blind pouch-like commencement of the colon in the right lower quadrant of the abdomen at the end of the small intestine and the start of the large intestine.	Cecum		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C123820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123820>	C201491|C200766	GD2-CAR-expressing Autologous T-lymphocytes|GD2-CAR-expressing autologous T-lymphocytes|tvs-CTL Vaccine	Genetically modified, autologous T-lymphocytes transduced with a retroviral vector encoding a 14g2a.zeta chimeric antigen receptor (CAR) directed against the disialoganglioside GD2, with potential immunomodulating and antineoplastic activities. Upon intravenous administration, the activated T-lymphocytes target the GD2 antigen on tumor cells and selectively kill those cells. The tumor-associated antigen GD2 is overexpressed on the surface of almost all tumors of neuroectodermal origin.	GD2-CAR-expressing autologous T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123821>	C2124	Gallium Ga 68-NEB|68Ga-NEB|68Ga-NOTA Conjugated Truncated Form of Evans Blue	A radiotracer composed of a truncated form of the azo dye Evans blue (EB) conjugated, via a 1,4,7-triazacyclononane-N,N',N"-triacetic acid (NOTA) linker (NEB), to the radioisotope gallium Ga 68, with potential blood pool imaging activity for use in positron emission tomography (PET). Upon administration of gallium Ga 68-NEB, the NEB moiety, which has high affinity for serum albumin, targets and forms a complex with albumin. Upon PET, the lymph nodes (LN) and lymphatic vessels as well as other desired tissues can be visualized.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C123822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123822>	C28681	Autologous CEA-specific Cytotoxic T-lymphocytes|CEA-specific AAV-DC-CTLs|CEA-specific CTLs	Autologous cytotoxic T-lymphocytes (CTLs) specifically reactive to the tumor-associated antigen (TAA) human carcinoembryonic antigen (CEA), with potential antineoplastic activity. Dendritic cells (DCs) isolated from the patient's blood are infected with recombinant adeno-associated virus (AAV) expressing the CEA gene. Exposure of T-lymphocytes to DCs creates CEA-specific CTLs which are expanded. Upon reintroduction of these CTLs into the patient, these cells recognize and kill CEA-expressing tumor cells. CEA, a tumor-associated antigen and a member of the CEA family of proteins, plays a key role in cell migration, cell invasion, and cell adhesion and is overexpressed by a variety of cancer types.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123823>	C213431|C200766	4H11-28z/fIL-12/EGFRt-expressing Autologous T-lymphocytes|4H11-28z/fIL-12/EGFRt+ Genetically-modified T Cells|4H11-28z/fIL-12/EGFRt+ T Cells|Autologous 4H11-28z/fIL-12/EGFRt+ Genetically-modified T Cells|Autologous MUC16ecto-targeting EGFR-secreting T Lymphocytes	A preparation of genetically modified autologous T-lymphocytes transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) targeting the human tumor-associated antigen (TAA) MUC16ecto and encoding the human pro-inflammatory cytokine interleukin-12 (IL-12), fused to the signaling domain of the zeta chain of the TCR/CD3 complex (28z), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, 4H11-28z/fIL-12/EGFRt-expressing autologous T-lymphocytes are directed to and induce selective toxicity in MUC16-expressing tumor cells. In addition, the T-cells secrete IL-12 which induces secretion of interferon-gamma, promotes the activation of natural killer cells (NKs), and induces cytotoxic T-cell responses against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) response. MUC16, a transmembrane protein and glycosylated mucin, is overexpressed on the cell surface of the majority of ovarian cancer cells but not on healthy cells. MUC16ecto is the extracellular portion of MUC-16 and is the part that is retained by cells after cleavage of CA-125.	4H11-28z/fIL-12/EGFRt-expressing Autologous T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123824>	C1742	Foslinanib|4(1H)-Quinolinone, 2-(3-Fluorophenyl)-6-methoxy-5-(phosphonooxy)-|CVM 1118|CVM-1118|CVM1118|FOSLINANIB|TRX 818|TRX-818|TRX818|WHO 10721	An orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry activities. Upon oral administration, foslinanib targets and inhibits the formation of vasculogenic mimicry (VM; vascular mimicry). By destroying the VM channels and network, cancer cells are devoid of perfusion leading to an induction of cancer cell apoptosis and inhibition of cancer cell proliferation. VM is associated with tumor metastasis.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123825>	C1291	Mulnitorsen|Andes-1537|MULNITORSEN|ncmtRNA Oligonucleotide Andes-1537	A proprietary antisense oligonucleotide targeting a novel non-coding mitochondrial RNA (ncmtRNA), with potential antineoplastic activity. Upon administration, mulnitorsen binds to ncmtRNA, which is overexpressed in rapidly proliferating cells, such as cancer cells, and not expressed in resting cells. This may decrease the expression of the ncmtRNA, which may inhibit cell proliferation and eventually induce apoptosis in susceptible cancer cells. The proprietary mitochondrial RNA (mtRNA) belongs to the family of non-coding RNAs (ncRNA); it contains an inverted repeat (IR) of 815 nucleotides (nt), which can form a covalent link to the 5' end of the mitochondrial 16S ribosomal RNA (16S mtrRNA).	Mulnitorsen		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123826>	C155727	Fisogatinib|2-Propenamide, N-((3S,4S)-3-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl)amino)tetrahydro-2H-pyran-4-yl)-|BLU 554|BLU-554|BLU554|CS 3008|CS-3008|CS3008|FISOGATINIB|Fibroblast Growth Factor Receptor 4 Inhibitor BLU-554|N-((3S,4S)-3-((6-(2,6-Dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)oxan-4-yl)prop-2-enamide	An orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon oral administration, fisogatinib specifically binds to and blocks the binding of the ligand FGF19 to FGFR4. This prevents the activation of FGFR4, inhibits FGFR4-mediated signaling and leads to an inhibition of tumor cell proliferation in FGFR4-overexpressing cells. FGFR4 is a receptor tyrosine kinase and is involved in tumor cell proliferation, differentiation, angiogenesis, and survival. FGF19 is overexpressed by certain tumor cell types.	Fisogatinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123827>	C213472|C159199|C159198	Avapritinib|(S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1Hpyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-yl)pyrimidin-5-yl)ethan-1-amine|AVAPRITINIB|AYVAKIT|Ayvakyt|BLU 285|BLU-285|BLU285|CS3007|PDGFR alpha/KIT Mutant-specific Inhibitor BLU-285	An orally bioavailable inhibitor of specific mutated forms of platelet-derived growth factor receptor alpha (PDGFR alpha; PDGFRa) and mast/stem cell factor receptor c-Kit (SCFR), with potential antineoplastic activity. Upon oral administration, avapritinib specifically binds to and inhibits specific mutant forms of PDGFRa and c-Kit, including the PDGFRa D842V mutant and various KIT exon 17 mutants. This results in the inhibition of PDGFRa- and c-Kit-mediated signal transduction pathways and the inhibition of proliferation in tumor cells that express these PDGFRa and c-Kit mutants. PDGFRa and c-Kit, protein tyrosine kinases and tumor-associated antigens (TAAs), are mutated in various tumor cell types; they play key roles in the regulation of cellular proliferation.	Avapritinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123828>	C216982|C213143	Cofetuzumab Pelidotin|ADC PF-06647020|ADC PF-7020|COFETUZUMAB PELIDOTIN|Immunoglobulin G1, Anti-(human protein tyrosine kinase 7) (humanized Mus musculus clone hu24 gamma-chain), Disulfide with humanized Mus musculus clone hu24 kappa-chain, Dimer, Thioether with N-(((4-((N-(6-(2,5-Dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl)-L-valyl-N5-(aminocarbonyl)-L-ornithyl)amino)phenyl)methoxy)carbonyl)-2-methylalanyl-N-((1S,2R)-2-methoxy-4-((2S)-2-((1R,2R)-1-methoxy-2-methyl-3-oxo-3-(((1S)-2-phenyl-1-(2-thiazolyl)ethyl)amino)propyl)-1-pyrrolidinyl)-1-((1S)-1-methylpropyl)-4-oxobutyl)-N-methyl-L-valinamide|PF 06647020|PF 7020|PF-06647020|PF-7020|PF06647020|h6M24-vc0101	An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against human inactive tyrosine-protein kinase 7 (PTK7) linked, via a cleavable valine-citrulline linker, to an analog of the auristatin microtubule inhibitor dolastatin 10, auristatin-0101, with potential antineoplastic activity. Upon administration, cofetuzumab pelidotin targets and binds to PTK7 expressed on tumor cells. Upon binding, internalization and cleavage, auristatin-0101 binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and apoptosis of PTK7-expressing tumor cells. PTK7, a tumor-associated antigen (TAA), is overexpressed on a variety of cancer cells.	Cofetuzumab Pelidotin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123829>	C164035|C129823	Anti-FGFR3 Antibody-drug Conjugate LY3076226|ADC LY3076226|Anti-FGFR3 ADC LY3076226|Anti-fibroblast Growth Factor Receptor 3 Antibody-Drug Conjugate LY3076226|LY-3076226|LY3076226	An antibody-drug conjugate (ADC) composed of a human monoclonal antibody against the fibroblast growth factor receptor type 3 (FGFR3) that is conjugated to an undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration, the antibody moiety of anti-FGFR3 ADC LY3076226 binds to FGFR3. Upon internalization, the cytotoxic moiety causes cell death in FGFR3-expressing tumor cells. FGFR3, a receptor tyrosine kinase upregulated or mutated in many tumor cell types, plays a key role in tumor cell proliferation.	Anti-FGFR3 Antibody-drug Conjugate LY3076226		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12382>	C25763	Colon|COLON|Colon structure (body structure)|Colon, NOS|LARGE INTESTINE, COLON|colon|colon|large bowel	The part of the large intestine measured from the cecum to the rectum consisting of ascending, transverse, descending and sigmoid portions. The purpose of the colon is to remove water from digested food prior to excretion.	Colon		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C123830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123830>	C202063	Porcupine Inhibitor ETC-159|ETC 159|ETC 1922159|ETC-159|ETC-159|ETC-1922159|ETC159|ETC1922159|PORCN Inhibitor ETC-1922159|Porcupine Inhibitor ETC-1922159	An orally bioavailable inhibitor of the membrane-bound O-acyltransferase (MBOAT) porcupine (PORCN), with potential antineoplastic activity. Upon oral administration, ETC-159 binds to and inhibits PORCN in the endoplasmic reticulum (ER), which blocks post-translational palmitoylation of Wnt ligands and inhibits their secretion. This prevents the activation of Wnt ligands, interferes with Wnt-mediated signaling, and inhibits cell growth in Wnt-driven tumors. Porcupine catalyzes the palmitoylation of Wnt ligands, and plays a key role in Wnt ligand secretion. Wnt signaling is dysregulated in a variety of cancers.	Porcupine Inhibitor ETC-159		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123831>	C198645	Cabiralizumab|Anti-CSF1R FPA008|BMS-986227|CABIRALIZUMAB|FPA 008|FPA-008|FPA008	A humanized monoclonal antibody directed against the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R; CSF-1R), also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), with potential antineoplastic activity. Upon administration, anti-CSF1R monoclonal antibody FPA008 binds to CSF1R expressed on monocytes, macrophages, and osteoclasts and inhibits the binding of the CSF1R ligands colony-stimulating factor-1 (CSF-1) and interleukin-34 (IL-34), to CSF1R. This prevents CSF1R activation and CSF1R-mediated signaling in these cells. This blocks the production of inflammatory mediators by macrophages and monocytes and reduces inflammation. By blocking the recruitment to the tumor microenvironment and activity of CSF1R-dependent tumor-associated macrophages (TAMs), FPA008 enhances T-cell infiltration and antitumor T-cell immune responses, which inhibits the proliferation of tumor cells. Additionally, FPA008 prevents the activation of osteoclasts and blocks bone destruction. TAMs play key roles in immune suppression and promoting inflammation, tumor cell proliferation and survival.	Cabiralizumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123832>	C28404	CAPN1 Gene|CAPN1|CAPN1|Calpain 1, (Mu/I) Large Subunit Gene	This gene is involved in proteolytic processing.	CAPN1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C123833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123833>	C123832	CAPN1 wt Allele|CANP|CANP1|CANPL1|Calcium-Activated Neutral Proteinase 1, Catalytic Subunit Gene|Calpain 1, (Mu/I) Large Subunit wt Allele|Calpain I, Large Subunit Gene|Calpain, Large Polypeptide L1 Gene|muCANP|muCL	Human CAPN1 wild-type allele is located in the vicinity of 11q13 and is approximately 31 kb in length. This allele, which encodes calpain-1 catalytic subunit protein, plays a role in limited proteolysis of substrates, which modulates cytoskeletal remodeling and signal transduction.	CAPN1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123834>	C68626|C4286	Childhood Immature Teratoma	An immature teratoma occurring in children.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123835>	C6540|C6353|C123834	Childhood Testicular Immature Teratoma	An immature teratoma that arises from the testis and occurs in children.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123836>	C9015|C68626|C6553	Childhood Mature Teratoma|Childhood Mature Cystic Teratoma	A mature teratoma occurring in children.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123837>	C6540|C6355|C190602|C123836	Childhood Testicular Mature Teratoma	A mature teratoma that arises from the testis and occurs in children.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123838>	C7928|C121618	Childhood Germinomatous Germ Cell Tumor|Germinomatous Germ Cell Tumor	A germinomatous germ cell tumor occurring in children.	Childhood Germinomatous Germ Cell Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123839>	C16481	Calpain-1 Catalytic Subunit|CANP 1|CAPN1|Calcium-Activated Neutral Proteinase 1|Calpain Mu-Type|Calpain-1 Large Subunit|Cell Proliferation-Inducing Gene 30 Protein|Cell Proliferation-Inducing Protein 30|EC 3.4.22.52|Micromolar-Calpain|Mu-Calpain|MuCANP	Calpain-1 catalytic subunit (714 aa, ~82 kDa) is encoded by the human CAPN1 gene. This protein is involved in proteolysis and the regulation of signal transduction and cytoskeletal modeling.	Calpain-1 Catalytic Subunit		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12383>	C25763	Right Colon|COLON, RIGHT	The proximal segment of the large intestine that is located in the right side of the abdominal cavity. It includes the cecum (with the attached appendix) and the ascending colon.	Right Colon		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C123840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123840>	C9309|C6541|C123838	Childhood Seminoma|Childhood Testicular Germinomatous Germ Cell Tumor	A seminoma occurring in children.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123841>	C7928|C121619	Childhood Nongerminomatous Germ Cell Tumor|Childhood Non-Germinomatous Germ Cell Tumor|Childhood Non-Germinomatous Germ Cell Tumor|Nongerminomatous Germ Cell Tumor	A nongerminomatous germ cell tumor occurring in children.	Childhood Nongerminomatous Germ Cell Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123842>	C8588|C123841	Childhood Ovarian Nongerminomatous Germ Cell Tumor|Childhood Ovarian Non-Germinomatous Germ Cell Tumor|Childhood Ovarian Non-Germinomatous Germ Cell Tumor	A nongerminomatous germ cell tumor that arises in the ovary and occurs in children.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123843>	C9313|C6552|C123841	Childhood Testicular Non-Seminomatous Germ Cell Tumor|Childhood Testicular Non-Germinomatous Germ Cell Tumor	A non-seminomatous germ cell tumor that arises in the testis and occurs in children.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123844>	C6541|C2948|C190275|C123841	Childhood Choriocarcinoma	A choriocarcinoma occurring in children.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123845>	C94600	BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.944C>T Mutation|BCR/ABL Fusion Gene with NM_005157.4:c.944C>T|BCR/ABL Fusion Gene with NM_005157.5:c.944C>T|BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.944C>T|BCR/ABL1 Fusion Gene with NM_005157.4:c.944C>T|BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.944C>T Mutation	A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where cytosine has been substituted with thymine at nucleotide position 944 of the ABL1 gene. This mutation is associated with imatinib-resistant leukemias.	BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.944C>T Mutation		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123846>	C16325	BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.T315I|BCR-ABL T315I Mutation|BCR-ABL Thr315Ile Mutation|BCR-ABL1 T315I Mutation|BCR-ABL1 Thr315Ile Mutation|BCR/ABL Fusion Protein with T315I|BCR/ABL Fusion Protein with Thr315Ile|BCR/ABL T315I Mutation|BCR/ABL Thr315Ile Mutation|BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Thr315Ile|BCR/ABL1 Fusion Protein with NP_005148.2:p.T315I|BCR/ABL1 Fusion Protein with NP_005148.2:p.Thr315Ile|BCR/ABL1 T315I Mutation|BCR/ABL1 Thr315Ile Mutation|BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.T315I|T315I|T315I Mutation	A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.944C>T mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the threonine at position 315 of the ABL1 protein has been replaced by isoleucine.	BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.T315I		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123847>	C6541|C3752|C123841	Childhood Embryonal Carcinoma	An embryonal carcinoma occurring in children.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123848>	C6541|C4290|C3729	Childhood Mixed Germ Cell Tumor	A mixed germ cell tumor occurring in children.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123849>	C8114|C68629|C123848	Childhood Ovarian Mixed Germ Cell Tumor	A mixed germ cell tumor that arises from the ovary and occurs in children.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C12384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12384>	C25763	Sigmoid Colon|COLON, SIGMOID|Sigmoid colon|Sigmoid colon structure (body structure)|sigmoid colon|sigmoid colon	The portion of the colon that connects to the descending colon above and the rectum below.	Sigmoid Colon		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C123850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123850>	C21295	GPC2 Gene|GPC2|GPC2|Glypican 2 Gene	This gene is involved in heparin sulfate binding to cell surfaces.	GPC2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|Pediatric Oncology Target Cell Lineage Determinant Terminology
C123851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123851>	C123850	GPC2 wt Allele|DKFZp547M109|FLJ38962|Glypican 2 (Cerebroglycan) Gene|Glypican 2 wt Allele|Glypican Proteoglycan 2, Cerebroglycan Proteoglycan Gene	Human GPC2 wild-type allele is located in the vicinity of 7q22.1 and is approximately 8 kb in length. This allele, which encodes glypican-2 protein, plays a role in the localization of heparin sulfate on cell membranes.	GPC2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123852>	C17728	Glypican-2|Cerebroglycan|Cerebroglycan Proteoglycan|GPC2|Glypican Proteoglycan 2	Glypican-2 (579 aa, ~63 kDa) is encoded by the human GPC2 gene. This protein is involved in heparin sulfate binding.	Glypican-2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Cell Lineage Determinant Terminology
C123853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123853>	C20103	KLRG1 Gene|KLRG1|KLRG1|Killer Cell Lectin-Like Receptor Subfamily G, Member 1 Gene	This gene plays a role in the inhibition of cytotoxic immune cells.	KLRG1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C123854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123854>	C123853	KLRG1 wt Allele|2F1|C-Type Lectin Domain Family 15, Member A Gene|CLEC15A|Killer Cell Lectin-Like Receptor Subfamily G, Member 1 wt Allele|Killer Cell Lectin-Like Receptor, Subfamily G, Member 1 Gene|MAFA|MAFA-2F1|MAFA-L|MAFA-LIKE|Mast Cell Function-Associated Antigen (ITIM-Containing) Gene|Mast Cell Function-Associated Antigen, Rat, Homolog of Gene	Human KLRG1 wild-type allele is located in the vicinity of 12p13.31 and is approximately 108 kb in length. This allele, which encodes killer cell lectin-like receptor subfamily G member 1 protein, is involved in the modulation of T-lymphocyte and natural killer cell-mediated immunity.	KLRG1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123855>	C18106	Killer Cell Lectin-Like Receptor Subfamily G Member 1|C-Type Lectin Domain Family 15 Member A|ITIM-Containing Receptor MAFA-L|KLRG1|MAFA-Like Receptor|Mast Cell Function-Associated Antigen	Killer cell lectin-like receptor subfamily G member 1 (195 aa, ~22 kDa) is encoded by the human KLRG1 gene. This protein plays a role in immunomodulation.	Killer Cell Lectin-Like Receptor Subfamily G Member 1		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123856>	C21295	CALB2 Gene|CALB2|CALB2|CALB2|Calbindin 2 Gene	This gene is involved in calcium ion homeostasis.	CALB2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C123857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123857>	C123856	CALB2 wt Allele|CAB29|CAL2|CR|Calbindin 2 wt Allele|Calbindin 2, (29kD, Calretinin) Gene|Calbindin 2, 29kDa (Calretinin) Gene|Calbindin, 29-kD Gene	Human CALB2 wild-type allele is located in the vicinity of 16q22.2 and is approximately 32 kb in length. This allele, which encodes calretinin protein, plays a role in calcium binding.	CALB2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123858>	C21214	Calretinin|29 kDa Calbindin|CR|Calbindin D29k|Calbindin-D29k	Calretinin (271 aa, ~32 kDa) is encoded by the human CALB2 gene. This protein is involved in calcium homeostasis.	Calretinin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123859>	C28533|C158414	ABCB11 Gene|ABCB11|ABCB11|ATP Binding Cassette Subfamily B Member 11 Gene	This gene plays a role in the secretion of bile salts.	ABCB11 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C12385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12385>	C25763	Transverse Colon|COLON, TRANSVERSE|Transverse colon|Transverse colon structure (body structure)|colon transversum|transverse colon	The third division of the colon (large intestine). It communicates with the ascending colon in the upper right-hand quadrant of the abdomen and the descending colon in the upper left-hand quadrant.	Transverse Colon		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C123860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123860>	C123859	ABCB11 wt Allele|ABC Member 16, MDR/TAP Subfamily Gene|ABC16|ATP Binding Cassette Subfamily B Member 11 wt Allele|ATP-Binding Cassette, Sub-Family B (MDR/TAP), Member 11 Gene|ATP-Binding Cassette, Subfamily B, Member 11 Gene|BRIC2|BSEP|PFIC-2|PFIC2|PGY4|Progressive Familial Intrahepatic Cholestasis 2 Gene|SPGP|Sister of P-Glycoprotein Gene	Human ABCB11 wild-type allele is located in the vicinity of 2q24 and is approximately 108 kb in length. This allele, which encodes bile salt export pump protein, is involved in bile salt transport. Mutation of the gene is associated with hereditary intrahepatic cholestasis.	ABCB11 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123861>	C17750|C158419	Bile Salt Export Pump|ABCB11|ATP-Binding Cassette Sub-Family B Member 11|ATP-Binding Cassette Subfamily B Member 11|Sister P-Glycoprotein	Bile salt export pump (1321 aa, ~146 kDa) is encoded by the human ABCB11 gene. This protein plays a role in bile salt secretion.	Bile Salt Export Pump		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123862>	C28533|C17967|C158414	ABCB4 Gene|ABCB4|ABCB4|ATP Binding Cassette Subfamily B Member 4 Gene	This gene is involved in the cellular export of organic anions and drugs and the intramembrane transport of phosphatidylcholine.	ABCB4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C123863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123863>	C123862	ABCB4 wt Allele|ABC21|ATP-Binding Cassette, Sub-Family B (MDR/TAP), Member 4 wt Allele|ATP-Binding Cassette, Subfamily B, Member 4 Gene|GBD1|ICP3|MDR2|MDR2/3|MDR3|Multidrug Resistance 3 Gene|P Glycoprotein 3/Multiple Drug Resistance 3 Gene|P-Glycoprotein-3/Multiple Drug Resistance-3 Gene|PFIC-3|PGY3	Human ABCB4 wild-type allele is located in the vicinity of 7q21.1 and is approximately 79 kb in length. This allele, which encodes multidrug resistance protein 3, plays a role in the intramembrane transport of phosphatidylcholine and the export of organic anions and drugs across the plasma membrane. Mutation of the gene is associated with progressive familial intrahepatic cholestasis 2, intrahepatic cholestasis of pregnancy 3 and gall bladder disease 3.	ABCB4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123864>	C17750|C158419	Phosphatidylcholine Translocator ABCB4|ABCB4|ATP-Binding Cassette Sub-Family B Member 4|EC 3.6.3.44, Formerly|EC 7.6.2.2|Multidrug Resistance Protein 3|Multidrug Resistance Protein 3|Multiple Drug Resistance 3|P-Glycoprotein 3	Phosphatidylcholine translocator ABCB4 (1286 aa, ~142 kDa) is encoded by the human ABCB4 gene. This protein is involved in the transport of phosphatidylcholine, organic anions and drugs.	Multidrug Resistance Protein 3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123865>	C42076	Malignant Germinomatous Cells Present	A morphologic finding indicating the presence of germinoma, dysgerminoma, or seminoma germ cells.			Finding	
C123866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123866>	C25790	IFI44 Gene|IFI44|IFI44|Interferon-Induced Protein 44 Gene	This gene may play a role in the response to viral infection.	IFI44 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C123867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123867>	C123866	IFI44 wt Allele|Interferon-Induced Protein 44 wt Allele|Interferon-Induced, Hepatitis C-Associated Microtubular Aggregate Protein (44kD) Gene|Interferon-Induced, Hepatitis C-Associated Microtubular Aggregate Protein, 44kD Gene|MTAP44|TLDC5|p44	Human IFI44 wild-type allele is located in the vicinity of 1p31.1 and is approximately 14 kb in length. This allele, which encodes interferon-induced protein 44, may be involved in interferon-mediated viral responses.	IFI44 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123868>	C16725	Interferon-Induced Protein 44|IFI44|Microtubule-Associated Protein 44|TBC/LysM-Associated Domain Containing 5|p44	Interferon-induced protein 44 (444 aa, ~50 kDa) is encoded by the human IFI44 gene. This protein may play a role in interferon-dependent processes.	Interferon-Induced Protein 44		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123869>	C21295	SIGLEC9 Gene|SIGLEC9|SIGLEC9|Sialic Acid Binding Ig-Like Lectin 9 Gene	This gene is involved in sialic acid binding and cell adhesion.	SIGLEC9 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C12386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12386>	C25763	Small Intestine|Gastrointestinal Tract, Small Intestine|SMALL INTESTINE|Small Bowel|Small Bowel|Small intestine|Small intestine|Small intestine, NOS|Structure of small intestine (body structure)|small bowel|small intestine|small intestine|small intestine	The section of the intestines between the pylorus and cecum. The small intestine is approximately 20 feet long and consists of the duodenum, the jejunum, and the ileum. Its main function is to absorb nutrients from food as the food is transported to the large intestine.	Small Intestine		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTDC Value Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C123870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123870>	C123869	SIGLEC9 wt Allele|CD329|CDw329|FOAP-9|OBBP-LIKE|Sialic Acid Binding Ig-Like Lectin 9 wt Allele|Sialic Acid-Binding Immunoglobulin-Like Lectin 9 Gene|siglec-9	Human SIGLEC9 wild-type allele is located in the vicinity of 19q13.41 and is approximately 14 kb in length. This allele, which encodes sialic acid-binding Ig-like lectin 9 protein, plays a role in both cell adhesion and sialic acid binding.	SIGLEC9 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123871>	C17728	Sialic Acid-Binding Ig-Like Lectin 9|CD329 Antigen|CDw329|Protein FOAP-9|Siglec-9	Sialic acid-binding Ig-like lectin 9 (463 aa, ~50 kDa) is encoded by the human SIGLEC9 gene. This protein is involved in sialic acid binding.	Sialic Acid-Binding Ig-Like Lectin 9		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123872>	C20103	FCRL5 Gene|FCRL5|FCRL5|Fc Receptor-Like 5 Gene	This gene may play a role in the development, differentiation and immunoregulation of B-cells.	FCRL5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C123873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123873>	C123872	FCRL5 wt Allele|BXMAS1|CD307|CD307e|FCRH5|Fc Receptor-Like 5 wt Allele|IRTA2|Immunoglobulin Superfamily Receptor Translocation Associated 2 (IRTA2) Gene|Immunoglobulin Superfamily Receptor Translocation-Associated Gene 2|PRO820|UNQ503/PRO820	Human FCRL5 wild-type allele is located in the vicinity of 1q21 and is approximately 39 kb in length. This allele, which encodes Fc receptor-like protein 5, may be involved in the modulation of B-cell development and functionality.	FCRL5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123874>	C18106	Fc Receptor-Like Protein 5|BXMAS1|CD307e|CD307e Antigen|Fc Receptor Homolog 5|FcR-Like Protein 5|FcRH5|FcRL5|Immune Receptor Translocation-Associated Protein 2	Fc receptor-like protein 5 (977 aa, ~106 kDa) is encoded by the human FCRL5 gene. This protein may play a role in the regulation of B-cell-mediated immunity.	Fc Receptor-Like Protein 5		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123875>	C21282|C20103	GUCY2C Gene|GUCY2C|GUCY2C|Guanylate Cyclase 2C Gene	This gene is involved in ligand-dependent cGMP synthase activity.	GUCY2C Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C123876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123876>	C123875	GUCY2C wt Allele|DIAR6|GCC|GUC2C|Guanylate Cyclase 2C (Heat Stable Enterotoxin Receptor) Gene|Guanylate Cyclase 2C wt Allele|Guanylate Cyclase C Gene|MECIL|MUCIL|STAR	Human GUCY2C wild-type allele is located in the vicinity of 12p12 and is approximately 84 kb in length. This allele, which encodes heat-stable enterotoxin receptor protein, plays a role in the mediation of ligand-mediated nucleotide cyclase activity. Mutation of the gene is associated with congenital diarrhea type 6 and meconium ileus.	GUCY2C wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123877>	C18106|C16804	Heat-Stable Enterotoxin Receptor|EC 4.6.1.2|GC-C|GCC|GUCY2C|Guanylate Cyclase 2C|Guanylyl Cyclase 2C|Guanylyl Cyclase C|Heat Stable Enterotoxin Receptor|Intestinal Guanylate Cyclase|STA Receptor|StAR|hSTAR	Heat-stable enterotoxin receptor (1073 aa, ~123 kDa) is encoded by the human GUCY2C gene. This protein is involved in ligand-stimulated guanylate cyclase activity.	Heat-Stable Enterotoxin Receptor		Amino Acid, Peptide, or Protein|Enzyme|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C123878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123878>	C217549	Ombitasvir|ABT 267|ABT-267|ABT267|Carbamic Acid, N,N'-(((2S,5S)-1-(4-(1,1-dimethylethyl)phenyl)-2,5-pyrrolidinediyl)bis(4,1-phenyleneiminocarbonyl-(2S)-2,1-pyrrolidinediyl((1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl)))bis-, C,C'-Dimethyl Ester|L-Prolinamide,2,2'-(((2S,5S)-1-(4-(1,1-dimethylethyl)phenyl)-2,5-pyrrolidinediyl)di-4,1-phenylene)bis(N-(methoxycarbonyl)-L-valy|OMBITASVIR	An orally available inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex, with potential activity against HCV. Upon oral administration and after intracellular uptake, ombitasvir binds to and blocks the activity of the NS5A protein. This results in the disruption of the viral RNA replication complex, blockage of HCV RNA production, and inhibition of viral replication. NS5A, a zinc-binding and proline-rich hydrophilic phosphoprotein, plays a crucial role in HCV RNA replication. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family; HCV infection is associated with the development of hepatocellular carcinoma (HCC).	Ombitasvir		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C123879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123879>	C217517	Paritaprevir|(2R,6S,12Z,13aS,14aR,16aS)-N-(Cyclopropylsulfonyl)-6-{[(5-methyl-2-pyrazinyl)carbonyl]amino}-5,16-dioxo-2-(6-phenanthridinyloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo [1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide|ABT 450|ABT-450|ABT450|PARITAPREVIR|Veruprevir	An orally bioavailable, synthetic acylsulfonamide inhibitor of the hepatitis C virus (HCV) protease complex comprised of non-structural protein 3 and 4A (NS3/NS4A), with potential activity against HCV genotype 1. Upon administration, paritaprevir reversibly binds to the active center and binding site of the HCV NS3/NS4A protease and prevents NS3/NS4A protease-mediated polyprotein maturation. This disrupts both the processing of viral proteins and the formation of the viral replication complex, which inhibits viral replication in HCV genotype 1-infected host cells. NS3, a serine protease, is essential for the proteolytic cleavage of multiple sites within the HCV polyprotein and plays a key role during HCV ribonucleic acid (RNA) replication. NS4A is an activating factor for NS3. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family, and infection is associated with the development of hepatocellular carcinoma (HCC).	Paritaprevir		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C12387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12387>	C25763	Ileum|ILEUM|Ileal structure (body structure)|SMALL INTESTINE, ILEUM|ileum	The final section of the small intestine.	Ileum		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C123880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123880>	C217652	Dasabuvir|ABT 333|ABT-333|ABT333|DASABUVIR|Exviera|Methanesulfonamide, N-(6-(5-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-3-(1,1-dimethylethyl)-2-methoxyphenyl)-2-naphthalenyl)-|N-(6-(3-tert-Butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide	A non-nucleoside inhibitor of the hepatitis C virus (HCV) non-structural protein 5B (NS5B), an RNA-dependent RNA polymerase, with potential activity against HCV. Upon administration and after intracellular uptake, dasabuvir binds HCV NS5B polymerase and blocks viral RNA synthesis and replication. The HCV NS5B protein is essential for the replication of the HCV RNA genome. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family; HCV infection is associated with the development of hepatocellular carcinoma (HCC).	Dasabuvir		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C123881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123881>	C28681|C119988	Betibeglogene Autotemcel|Autologous CD34+ Cells Encoding beta-A-T87Q-globin Gene|Autologous CD34+ HSCs Transduced with LentiGlobin BB305|Autologous CD34+ Hematopoietic Stem Cells Transduced Ex Vivo with Betibeglogene Darolentivec|BETIBEGLOGENE AUTOTEMCEL|LentiGlobin BB305 Drug Product for TDT|LentiGlobin BB305 Lentiviral Vector-transduced Autologous CD34+ HSCs|LentiGlobin BB305-transduced CD34-positive Cells|LentiGlobin Drug Product for Transfusion Dependent beta-Thalassemia|Lentiviral b-A(T87Q)-Globin-transduced CD34-positive Cells|Zynteglo	A preparation of autologous, CD34-positive hematopoietic stem cells (HSCs) transduced ex vivo with the BB305 recombinant replication-defective, self-inactivating lentiviral vector encoding for an engineered form of human beta-globin (hemoglobin-beta, HBB) gene, beta-A-T87Q (b-A-T87Q) where the threonine at position 87 has been substituted with glutamine, with potential to restore beta-globin expression and function. Autologous CD34-positive stem cells are isolated from the patient's own bone marrow and the cells are transduced with the lentiviral vector. Upon re-infusion of betibeglogene autotemcel back into the patient, these cells express b-A-T87Q-globin, thereby allowing the body to make normal hemoglobin and thus normal, healthy red blood cells. Beta-globin, the beta-chain of the most common form of hemoglobin, is encoded by the HBB gene; mutations in this gene prevent normal beta-globin production and are associated with beta-thalassemia and sickle cell anemia. The b-A-T87Q form of beta-globin has increased antisickling activity compared to the wild type protein.	Betibeglogene Autotemcel		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C123882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123882>	C29728	Trodusquemine|(24R)-3beta-((3-((4-((3-aminopropyl)amino)butyl)amino)propyl)amino)-7alpha-hydroxy-5alpha-cholestan-24-yl Hydrogen Sulfate|Cholestane-7,24-diol, 3-((3-((4-((3-aminopropyl)amino)butyl)amino)propyl)amino)-, 24-(Hydrogen Sulfate), (3beta,5alpha,7alpha,24R)-|MSI-1436|MSI-1436C|TRODUSQUEMINE	A naturally-occurring cholestane and non-competitive, allosteric inhibitor of protein tyrosine phosphatase 1B (PTP1B), with potential hypoglycemic, anti-diabetic, anti-obesity, and antineoplastic activities. Upon administration, trodusquemine selectively targets and inhibits PTP1B, thereby preventing PTP1B-mediated signaling. This prevents the dephosphorylation of the insulin receptor, which improves insulin signaling and insulin sensitivity, and decreases blood glucose levels. In susceptible cancer cells, inhibition of PTP1B causes a reduction of tumor cell proliferation. In addition, as trodusquemine can cross the blood-brain barrier (BBB), it centrally suppresses appetite and causes weight loss. PTP1B, a tyrosine phosphatase, is elevated in certain cancer cells; it is specifically upregulated in human epidermal growth factor receptor 2 (HER2)-driven cancers where it promotes cell growth, and is correlated with a poor prognosis and increased metastatic potential. In diabetes, PTP1B upregulation plays a major role in insulin resistance.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123883>	C190764	Differential Methylation|DM-value	Differences in methylation between a test sample and a normal comparison sample.			Molecular Biology Research Technique	
C123884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123884>	C47824	Feature Dataset	A collection of data records from which common expression features can be derived.			Idea or Concept	
C123885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123885>	C54154	Gene Enrichment Probability|Enrichment P-Value|Gene Enrichment	The probability of a cell line being positive for an enriched feature by chance.			Quantitative Concept	
C123886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123886>	C104788	Absolute Genomic Position|Chromosome Start and End	Coordinates corresponding to the start or end of a chromosome.			Conceptual Entity	
C123887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123887>	C25755	Concentration Response	The reaction to a specific amount of a compound.			Phenomenon or Process	
C123888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123888>	C68741	Robust Z-Score|Robust Z Score	A variation of the z-score, which substitutes the outlier-insensitive median and median absolute deviation (MAD) for mean and standard deviation in the z-score calculation.			Quantitative Concept	
C123889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123889>	C17146	GeneData Screener	Proprietary software that is designed to import data from any screening instrument and analyze and manage all types of screening data.			Intellectual Product	
C12388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12388>	C25763	Jejunum|JEJUNUM|Jejunal structure (body structure)|SMALL INTESTINE, JEJUNUM|jejunum	The portion of the small intestine that extends from the duodenum to the ileum.	Jejunum		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C123890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123890>	C25712	Condensed Activity	The value obtained from condensing three replicate measures using a strategy provided by GeneData Screener software.			Conceptual Entity	
C123891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123891>	C164049	Gene Cluster Text Format|GCT|Gene Cluster Text File	A tab delimited, matrix file text format that describes a gene expression dataset; the columns of the matrix correspond to profiles, the rows correspond to genes, and the values of the cells correspond to an expression measurement.			Qualitative Concept	
C123892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123892>	C16402	Growth Behavior|Cell Growth Behavior|Cell Line Growth Behavior	An increase in size or volume of cells in culture.			Cell Function	
C123893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123893>	C812	Short Hairpin RNA|Short Hairpin Sequence RNA|shRNA	An artificial RNA molecule with a tight hairpin turn that can be used to silence target gene expression via RNA interference (RNAi).			Nucleic Acid, Nucleoside, or Nucleotide	
C123894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123894>	C54131	Affymetrix	An American company that manufactures DNA microarrays for the analysis of biological systems at the cell, protein, and gene level.			Organization	
C123895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123895>	C81012	Chemiluminescence	The emission of light as the result of a chemical reaction.			Phenomenon or Process	
C123896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123896>	C117039	Analytic Technique for Assessment of RNAi by Similarity|ATARiS|Analytic Technique for Assessment of RNAi by Similarity (ATARiS)	A computational method designed to analyze phenotypic readouts from multiple-sample RNAi screens in which each gene is targeted by multiple RNAi reagents. ATARiS takes advantage of patterns in RNAi data across multiple samples in order to enrich for RNAi reagents whose phenotypic effects relate to suppression of their intended targets. By summarizing only such reagent effects for each gene, ATARiS produces quantitative, gene-level phenotype values, which provide a measure of the effect of gene suppression in each sample.			Conceptual Entity	
C123897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123897>	C47906	Gene Solution|Gene Solution Output	A type of ATARiS output for RNAi reagents that produce a significantly similar phenotypic pattern across the screened samples. It consists of one phenotype value for each sample, representing the phenotypic outcome of suppressing the target gene in that sample relative to the outcome in other screened samples.			Conceptual Entity	
C123898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123898>	C114397	Hepatic Thrombosis	Formation of a blood clot (thrombus) in the lumen of the veins in the liver or hepatic artery.	Hepatic Thrombosis		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C123899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123899>	C114397	Splenic Thrombosis	Formation of a blood clot (thrombus) in the lumen of the splenic vein or splenic artery.	Splenic Thrombosis		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C12389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12389>	C13018	Esophagus|ESOPHAGUS|Esophageal structure (body structure)|Esophagus, NOS|Gastrointestinal Tract, Esophagus|Oesophagus|esophagus|esophagus|gullet	The portion of the digestive canal between the pharynx and stomach. It is about 25 cm long and consists of three parts: the cervical part, from the cricoid cartilage to the thoracic inlet; thoracic part, from thoracic inlet to the diaphragm; and abdominal part, below the diaphragm to the cardiac opening of the stomach.	Esophagus		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C1238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1238>	C1446	Strontium Chloride Sr-89|Metastron|STRONTIUM CHLORIDE SR-89|strontium chloride Sr 89	The chloride salt of a radioactive isotope of strontium. Strontium chloride Sr 89 is taken up and incorporated preferentially in metastatic lesions in bone where it emits cytotoxic beta radiation, resulting in an inhibition and/or reduction of tumor growth and so tumor-related bone pain. (NCI04)	Strontium Chloride Sr-89		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123900>	C114397	Mesenteric Thrombosis	Formation of a blood clot (thrombus) in the lumen of a mesenteric vein or mesenteric artery.	Mesenteric Thrombosis		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C123901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123901>	C99107	Gonadal Thrombosis|Gonadal Vein Thrombosis	Formation of a blood clot (thrombus) in the lumen of the vein that carries blood away from the testis or ovary.	Gonadal Thrombosis		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C123902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123902>	C2185|C200258|C200052	Fadraciclib|CYC065|Cyclin Dependent Kinase Inhibitor 2/5/9 CYC065|FADRACICLIB	An orally bioavailable inhibitor of cyclin dependent kinases 2, 5 and 9 (CDK2/5/9), with potential antineoplastic and chemoprotective activities. Upon oral administration, fadraciclib selectively binds to and inhibits the activity of CDK2, 5 and 9, which leads to inhibition of CDK2, 5 and 9-dependent cellular pathways, downregulation of genes involved in the pro-survival pathway, prevention of the activation of DNA double-strand break repair pathways, and induction of both cell cycle arrest and apoptosis. This inhibits the proliferation of CDK2/5/9-overexpressing tumor cells. In addition, CYC065 protects hematopoietic stem and progenitor cells (HSPCs), prevents myelosuppression, and preserves the function of the bone marrow. CDKs are serine/threonine kinases involved in the regulation of the cell cycle and may be overexpressed in certain cancer cell types; they play key roles in tumor cell proliferation, the regulation of transcription, and DNA damage repair.	Fadraciclib		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123903>	C4035|C215716|C118827	Childhood Thyroid Gland Papillary Carcinoma|Childhood Papillary Thyroid Carcinoma	A papillary thyroid gland carcinoma occurring during childhood.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123904>	C8054|C215716|C118827	Childhood Thyroid Gland Follicular Carcinoma|Childhood Follicular Thyroid Carcinoma	A follicular thyroid gland carcinoma occurring in childhood.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123905>	C3879|C215716|C190075|C118827	Childhood Thyroid Gland Medullary Carcinoma|Childhood Medullary Thyroid Carcinoma	A medullary thyroid gland carcinoma occurring in childhood.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123906>	C3868|C188963	Childhood Gastrointestinal Stromal Tumor|Childhood GIST|Childhood GIST|Gastrointestinal Stromal Tumor (GIST)	A gastrointestinal stromal tumor (GIST) occurring in childhood. Pediatric GISTs differ biologically from adult GISTs in that only 11% of pediatric GISTs have activating mutations of KIT and PDGFRA.	Childhood Gastrointestinal Stromal Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123907>	C7548|C6563|C189269	Childhood Malignant Kidney Neoplasm|Childhood Malignant Kidney Tumor|Childhood Malignant Kidney Tumor|Childhood Malignant Renal Neoplasm|Childhood Malignant Renal Tumor	A malignant neoplasm that affects the kidney and occurs in childhood.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123908>	C191345	Clinical Relapse of Multiple Myeloma or Plasma Cell Leukemia by IMWG|Clinical Relapse of Multiple Myeloma or Plasma Cell Leukemia (IMWG)|Relapse of Multiple Myeloma or Plasma Cell Leukemia|Relapse of Multiple Myeloma or Plasma Cell Leukemia (IMWG)|Relapse of Multiple Myeloma or Plasma Cell Leukemia by IMWG	Relapse of multiple myeloma or plasma cell leukemia is defined as follows: Development of new soft tissue plasmacytomas or bone lesions; Definite increase in the size of existing plasmacytomas or bone lesions. A definite increase is defined as a 50% (and at least 1 cm) increase as measured serially by the sum of the products of the cross-diameters of the measurable lesion; Hypercalcemia (> 11.5 mg/dL) [2.65 mmol/L]; Decrease in hemoglobin of > 2 g/dL [1.25 mmol/L]; and rise in serum creatinine by 2 mg/dL or more [177 mmol/L or more]. (International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma. <http://myeloma.org/ArticlePage.action?articleId=2994>)			Finding	
C123909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123909>	C5043	Ventilatory Threshold	The point during exercise at which pulmonary ventilation becomes disproportionately high with respect to oxygen consumption.			Sign or Symptom	
C12390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12390>	C25763	Rectum|Hemorrhoidal|LARGE INTESTINE, RECTUM|RECTUM|Rectum structure (body structure)|Rectum, NOS|rectum|rectum|terminal portion of intestine	The terminal portion of the gastrointestinal tract, extending from the rectosigmoid junction to the anal canal.	Rectum		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C123910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123910>	C241	GlyT2/5HT2A Antagonist VVZ-149|VVZ-149	An antagonist of both glycine transporter type 2 (GlyT2) and serotonin receptor 2A (5HT2A), with potential anti-nociceptive activity. Upon administration, GlyT2/5HT2A antagonist VVZ-149 binds to and blocks both GlyT2 and 5HT2A. Blockage of GlyT2 prevents the re-uptake of the inhibitory neurotransmitter glycine in the synaptic cleft, thereby potentiating glycine-mediated inhibitory signaling, and inhibiting the firing of neurons, which suppresses the transmission of pain signals to the brain and induces analgesia. Blockage of 5HT2A prevents both the binding of its ligand serotonin and 5HT/5HT2A-mediated signaling. This also suppresses pain signaling and induces analgesia. GlyT2 and 5HT2A play key roles in the induction and transmission of pain signals. GlyT2, a glycine plasma membrane transporter, modulates glycine-mediated inhibition of synaptic transmission in the spinal cord and mediates pain signal transmission to the brain; inhibition of GlyT2 potentiates glycinergic mediated pain signaling. Serotonin and its 5HT2A receptor are involved in both serotonin receptor-mediated signaling and the perception of pain.			Organic Chemical|Pharmacologic Substance	NCI Drug Dictionary Terminology
C123911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123911>	C28676|C129826	Allodepleted T Cell Immunotherapeutic ATIR101|ATIR101|Allodepleted T-cell ImmunotheRapeutics|Theralux-ATIR	A cell-based immunotherapeutic product containing T-lymphocyte-enriched leukocytes that are devoid of alloreactive T-lymphocytes, that can potentially be used to restore lymphocyte levels after stem cell transplantations and are derived from partially matched (haploidentical) family donors for blood cancer patients who do not have a matching stem cell donor available. Host alloreactive T-cells, which can cause graft-versus-host disease (GVHD), are eliminated from the donor lymphocytes ex vivo using photodynamic therapy. After allogeneic hematopoietic stem cell transplantation (HSCT), allodepleted T cell immunotherapeutic ATIR101 is administered. This maintains a T-cell-mediated immune response against tumor cells and the donor T-cells can prevent opportunistic infections. ATIR101 does not cause severe, acute GVHD. In addition, administration of ATIR101 eliminates the need for immunosuppressants.	Allodepleted T Cell Immunotherapeutic ATIR101		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123912>	C211609	Sovleplenib|(S)-7-(4-(1-(Methylsulfonyl)piperidin-4-yl)phenyl)-N-(morpholin-2-ylmethyl)pyrido(4,3-b)pyrazin-5-amine|HMPL 523|HMPL-523|HMPL523|SOVLEPLENIB|Spleen Tyrosine Kinase Inhibitor HMPL-523|Syk Inhibitor HMPL-523	An orally available inhibitor of spleen tyrosine kinase (Syk), with potential immunomodulating and antineoplastic activities. Upon oral administration of sovleplenib, this agent binds to and inhibits the activity of Syk. This inhibits B-cell receptor (BCR) signaling, which leads to the inhibition of B-cell activation, and prevents tumor cell activation, migration, adhesion and proliferation. Syk, a non-receptor cytoplasmic, BCR-associated tyrosine kinase, is expressed in hematopoietic tissues and is often overexpressed in hematopoietic malignancies; it plays a key role in B-cell receptor signaling.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123913>	C129839	Tolinapant|ASTX 660|ASTX660|TOLINAPANT|XIAP/cIAP1 Antagonist ASTX660	An orally bioavailable, non-peptidomimetic antagonist of both X chromosome-linked inhibitor of apoptosis protein (XIAP) and cellular IAP 1 (cIAP1), with potential antineoplastic and pro-apoptotic activities. Upon administration, tolinapant selectively binds to and inhibits the activity of XIAP and cIAP1. This restores and promotes the induction of apoptotic signaling pathways in cancer cells, and inactivates the nuclear factor-kappa B (NF-kB)-mediated survival pathway. XIAP and cIAP1 are overexpressed by many cancer cell types and suppress apoptosis by inhibiting the activity of certain caspases; they promote both cancer cell survival and chemotherapy resistance.	Tolinapant		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123914>	C176988	Oleclumab|Anti-CD73 Monoclonal Antibody MEDI9447|MEDI9447|OLECLUMAB	A monoclonal antibody against the ectoenzyme CD73 (cluster of differentiation 73), also known as 5'-nucleotidase (5'-NT; ecto-5'-nucleotidase) with potential antineoplastic activity. Upon administration, oleclumab targets and binds to CD73, leading to clustering of and internalization of CD73. This prevents CD73-mediated conversion of adenosine monophosphate (AMP) to adenosine and decreases the amount of free adenosine. This prevents adenosine-mediated lymphocyte suppression and increases the activity of CD8-positive effector cells. This also activates macrophages, and reduces both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes. By abrogating the inhibitory effect on the immune system and enhancing the cytotoxic T-cell-mediated immune response against cancer cells, tumor cell growth decreases. In addition, clustering and internalization of CD73 decreases the migration of cancer cells and prevents metastasis. CD73, a plasma membrane protein upregulated on a number of cancer cell types, catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment.	Oleclumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123915>	C141215|C129822	Eramkafusp Alfa|Anti-CD20 Monoclonal Antibody-IFN-a Fusion Protein IGN002|Anti-CD20 Monoclonal Antibody-Interferon-alpha Fusion Protein IGN002|ERAMKAFUSP ALFA|IGN002	A humanized monoclonal antibody directed against the human B-cell-specific cell surface antigen CD20 and fused to the recombinant cytokine, interferon-alpha (IFN-a), with potential antineoplastic and immunomodulating activities. Upon administration of eramkafusp alfa, the antibody moiety specifically targets and binds to CD20. In turn, the IFN-a moiety binds to the IFN receptor, and activates IFN-mediated signal transduction, which induces the transcription and translation of genes whose protein products mediate anticancer effects. This results in the induction of both G2 cell cycle arrest and apoptosis in CD20-expressing tumor cells. In addition, IGN002 causes the induction of complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B-cells, which leads to B-cell apoptosis and the inhibition of tumor cell proliferation. CD20, a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B-cells during most stages of B-cell development, is often overexpressed in B-cell malignancies.	Eramkafusp Alfa		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123916>	C1505	Cholecalciferol/Whey Protein Isolate/EPA/DHA-based Nutritional Supplement|NutriFriend 1100|Nutrifriend Cachexia	A gluten-free, energy-rich, non-complete nutritional supplement drink composed of juice from the concentrates of apple pear, pomegranate, purple chokeberry and passion fruit, plus fish oil derived from salmon and cod, the minerals potassium, phosphorus and iodine, whey protein isolate derived from cow's milk, tocopherols (vitamin E), and cholecalciferol (vitamin D3) with potential anti-cachexic activity. Upon oral intake of the cholecalciferol/whey protein isolate/EPA/DHA-based nutritional supplement, the protein components maintain digestive health throughout the gastrointestinal (GI) tract and reduce the risk of digestive complications. The essential omega-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) from the fish oil are incorporated into cell membranes and affect the production of pro-inflammatory mediators, which elicits an anti-inflammatory effect. Cholecalciferol plays an important role in maintaining bone mineralization and regulating blood calcium and phosphorus levels. Tocopherols neutralize free radicals, thereby protecting tissues and organs from oxidative damage. In particular, alpha-tocopherol gets incorporated into biological membranes, maintains cell membrane integrity and protects the cell against damage. This nutritional supplement may prevent both malnutrition and weight loss.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C123917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123917>	C213143|C155712	Anvatabart Opadotin|ADC ARX788|ANVATABART OPADOTIN|ARX788|Anti-HER2 ADC ARX788|Anti-HER2 Antibody-drug Conjugate ARX788|Anti-Her2 Mab PAF- MMAF Toxin Oxime Conjugate ARX-788	An antibody-drug conjugate (ADC) composed of anvatabart, a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2) site-specifically conjugated at two engineered residues of para-acetyl-phenylalanine (pAcF) via a stable oxime linker to the monomethyl auristatin F (MMAF) analog and potent microtubule inhibitor opadotin, with potential antineoplastic activity. Upon administration of anvatabart opadotin, the antibody moiety targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, opadotin binds to and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. The site-specific conjugation of the cytotoxic agent to the antibody improves the biophysical properties of anvatabart opadotin, increases payload stability and optimizes its efficacy.	Anvatabart Opadotin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123918>	C2594	Autologous Colorectal Tumor Antigen-pulsed Dendritic Cell Vaccine|APDC Vaccine|Autologous Colorectal Tumor Antigen-pulsed DC Vaccine	A dendritic cell (DC)-based cancer vaccine composed of autologous DCs pulsed with tumor cell lysates from a colorectal cancer patient containing tumor-associated antigens (TAAs), with potential immunostimulatory and antineoplastic activities. Upon administration, autologous colorectal tumor antigen-pulsed DC vaccine exposes the immune system to colorectal tumor cell antigens, which may result in cytotoxic T-lymphocyte (CTL)-mediated immune responses against the colorectal cancer cells. This leads to cancer cell lysis. The tumor cell lysate contains a range of antigens that are essential for the neoplastic growth and survival of the cancer cells.			Cell|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123919>	C39619|C213431|C1663	DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457|INO 3112|INO-3112|INO-3112 Vaccine|MEDI 0457|MEDI-0457|MEDI0457|VGX-3100 Plus INO-9012	A DNA-based combination immunotherapeutic, MEDI0457, composed of VGX-3100, a preparation of DNA plasmids encoding the E6 and E7 genes of human papillomavirus (HPV) subtypes 16 and 18, combined with INO-9012, a DNA plasmid encoding the immune activator and pro-inflammatory cytokine human interleukin-12 (IL-12) with potential immunoactivating and antineoplastic activities. Upon intramuscular delivery by electroporation of VGX-3100, the HPV E6 and E7 proteins are translated in cells and elicit a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing the E6 and E7 antigens, resulting in tumor cell lysis. HPV type 16 and HPV type 18 are associated with the development of certain types of cancer. Upon intramuscular delivery by electroporation of INO-9012, IL-12 is expressed and activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma (IFN-g) and promoting CTL responses against tumor cells. This boosts the immune response and results in increased CTL-mediated tumor cell death as compared with the administration of VGX-3100 alone.	DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457		Immunologic Factor|Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12391>	C13018	Stomach|Gastric|Gastrointestinal Tract, Stomach|STOMACH|Stomach structure (body structure)|Stomach, NOS|stomach|stomach	The primary organ of food digestion. It is located under the diaphragm, between the liver and the spleen as well as between the esophagus and the small intestine.	Stomach		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CTDC Value Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C123920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123920>	C217549	Ombitasvir/Paritaprevir/Ritonavir|OBV/PTV/r|VIEKIRAX	An orally bioavailable combination agent containing ombitasvir, an inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex, paritaprevir, a synthetic acylsulfonamide inhibitor of the HCV protease complex comprised of non-structural protein 3 and 4A (NS3/NS4A), and the cytochrome P450 (CYP) 3A4 inhibitor ritonavir, with potential activity against HCV. Upon oral administration of ombitasvir/paritaprevir/ritonavir, ombitasvir, enters the cell and binds to and blocks the activity of the NS5A protein. This results in the disruption of the viral RNA replication complex, blockage of HCV RNA production, and inhibition of viral replication. After intracellular uptake, paritaprevir reversibly binds to the active center and binding site of the HCV NS3/NS4A protease and prevents NS3/NS4A protease-mediated polyprotein maturation. This disrupts both the processing of viral proteins and the formation of the viral replication complex, which inhibits viral replication in HCV genotype 1-infected host cells. Although ritonavir is not active against HCV, it strongly inhibits the activity of CYP3A4, thereby blocking the degradation of paritaprevir, which is a CYP3A4 substrate. This leads to an increased concentration and half-life of paritaprevir as compared to the administration of paritaprevir without ritonavir. NS5A, a zinc-binding and proline-rich hydrophilic phosphoprotein, plays a crucial role in HCV RNA replication. NS3, a serine protease essential for the proteolytic cleavage of multiple sites within the HCV polyprotein, plays a key role during HCV ribonucleic acid (RNA) replication. NS4A is an activating factor for NS3. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family, and infection is associated with the development of hepatocellular carcinoma (HCC).			Pharmacologic Substance	NCI Drug Dictionary Terminology
C123921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123921>	C28310	MiHA-loaded PD-L1/L2-silenced Dendritic Cell Vaccine|MiHA-loaded PD-L-silenced DC Vaccine	A dendritic cell (DC)-based vaccine composed of program death ligands 1 and 2 (PDL1/L2)-silenced DCs and loaded with the recipient's minor histocompatibility antigens (MiHA), with potential use for graft-versus-tumor (GVT) induction following allogeneic stem cell transplantation (allo-SCT). Donor DCs are electroporated ex vivo with MiHA mRNA and small interfering RNAs (siRNAs) designed to silence the expression of PD L1/L2. After allo-SCT and upon intravenous administration of the MiHA-loaded PD-L1/L2-silenced DC vaccine, the DCs induce the expansion and activation of MiHA-specific CD8-positive T-cells. These tumor antigen-reactive T-cells exert their GVT effect by killing miHA-positive tumor cells. PD-L1/L2, co-inhibitory ligands expressed on DCs, play key roles in preventing MiHA-specific CD8-positive T-cell expansion; silencing enhances MiHA-specific CD8-positive T-cell expansion and activity and improves the GVT effect. The MiHA are human leukocyte antigen (HLA)-bound peptides and are exclusively expressed by the recipient's hematopoietic tumor cells.			Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123922>	C574|C129826	iAPA-based Dendritic Cells/Cytotoxic T Lymphocytes|Inhibition of Antigen Presentation Attenuators-based Dendritic Cells/Cytotoxic T Lymphocytes|iAPA-DC/CTL	A cell-based product composed of dendritic cells (DCs) pulsed with tumor-associated antigens (TAAs) and devoid of the inhibitory effect of antigen presentation attenuators (iAPA) combined with cytotoxic T-lymphocytes (CTLs) (iAPA-DC/CTL), with potential immunostimulating and antineoplastic activities.  DCs are transduced with a viral vector containing small interfering RNAs (siRNAs) against APAs, which prevents the expression of APA genes and inhibits attenuation of antigen presentation. Upon administration of iAPA-DC/CTL, the DCs are able to efficiently present antigens to the immune system, stimulate the immune system against tumor-associated antigens (TAAs) and hyperactivate TAA-specific CTLs and T-helper cells. Also, the iAPA-based DCs inhibit the activity of the T-regulatory cells (Tregs), thereby abrogating their negative effect on CTL activation and preventing their immunosuppressive activity against TAAs. Altogether, this inhibits tumor cell proliferation. Additionally, the administered CTLs induce direct cancer cell lysis. APAs negatively regulate antigen presentation, activate Tregs and their immunosuppressive activity, affect inflammatory cytokine production by DCs, and negatively regulate the immunostimulatory activity of DCs; they have an overall inhibitory effect on the stimulation of the immune system.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123923>	C39619|C203670	Abipapogene Suvaplasmid|ABIPAPOGENE SUVAPLASMID|DNA Vaccine VB10.16|VB-10.16|VB10.16|VB10.16 Vaccine	A therapeutic DNA vaccine composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), the second is a dimerization entity and the third part encodes a protein that specifically binds to antigen presenting cells (APCs), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration, abipapogene suvaplasmid expresses HPV16 E6/7 and a protein that targets receptors on APCs. Upon binding to APCs and subsequent internalization, the APCs mature and the HPV16 E6/7 antigenic protein is presented by the APCs. This attracts and stimulates B-lymphocytes, CD4-positive T-lymphocytes and elicits a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing HPV16-associated E6 and E7 oncoproteins, which result in tumor cell lysis. HPV16 E6/7, a viral antigen, plays a key role in the development of certain types of cancer.	Abipapogene Suvaplasmid		Immunologic Factor|Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123924>	C20401|C129822	Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4|HU8F4|Hu8F4	A T-cell receptor (TCR)-like monoclonal antibody against PR1, a 9 amino-acid (VLQELNVTV) human leukocyte antigen (HLA)-A2-restricted leukemia-associated antigen (LAA) derived from the myeloid leukemia-associated antigens proteinase 3 (P3) and neutrophil elastase (NE), with potential immunostimulating and antineoplastic activities. Upon administration, anti-PR1/HLA-A2 monoclonal antibody Hu8F4 selectively binds to a combined epitope of the PR1/HLA-A2 complex expressed on acute myeloid leukemia (AML) blasts and leukemic stem cells (LSC), and prevents PR1/HLA-A2-mediated signaling. This induces complement-dependent cytotoxicity (CDC), to a lesser extent, antibody-dependent cell-mediated cytotoxicity (ADCC), and CDC/ADCC-independent cytolysis of myeloid leukemia cells. This results in a reduction of cellular proliferation in PR1/HLA-A2-overexpressing leukemic cells. PR1 in combination with the HLA-A2 molecule is highly expressed on AML blasts and LSCs.	Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123925>	C2152|C129825	Zandelisib|ME 401|ME-401|PI3K-delta Inhibitor PWT143|PWT-143|PWT143|ZANDELISIB	An orally bioavailable inhibitor of the delta isoform of phosphatidylinositide 3-kinase (PI3K), with potential antineoplastic activity. Upon oral administration, zandelisib selectively inhibits the delta isoform of PI3K and prevents the activation of the PI3K/AKT signaling pathway. This both decreases proliferation and induces cell death in PI3K-delta-overexpressing tumor cells. PI3K-delta plays a key role in the proliferation and survival of hematologic cancer cells. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.	Zandelisib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123926>	C29703	Ezetimibe/Simvastatin|Butanoic Acid, 2,2-Dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl Ester, Mixture with (3R,4S)-1-(4-Fluorophenyl)-3-((3S)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)-2-azetidinone|Vytorin	An orally bioavailable combination agent containing the cholesterol absorption inhibitor ezetimibe and the hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitor simvastatin, with lipid-lowering activity. Upon oral administration, ezetimibe binds to the sterol transporter Niemann-Pick C1-Like 1 (NPC1L1) at the brush border of the small intestine and inhibits the intestinal absorption of biliary and dietary cholesterol and related phytosterols. This decreases blood cholesterol levels, decreases the delivery of intestinal cholesterol to the liver, reduces hepatic cholesterol stores and enhances the clearance of cholesterol from the bloodstream. Upon administration of simvastatin and subsequent hydrolyzation to its active beta-hydroxyacid form, this statin competitively inhibits HMG-CoA reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, which is an essential step in cholesterol synthesis. Ezetimibe and simvastatin together reduce blood levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides (TGs), very-low-density lipoproteins (VLDL), and apolipoprotein B (Apo B), and increase the plasma concentration of high-density lipoprotein cholesterol (HDL-C). Higher cholesterol blood levels appear to be associated with an increased risk in the proliferation of certain cancer cells, such as prostate cancer cells.	Ezetimibe/Simvastatin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C123927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123927>	C1287	Pegfilgrastim Anti-neutropenic Factor|ANF-Rho|PEG G-CSF ANF|Pegfilgrastim ANF	A long-acting, engineered and pegylated version of human granulocyte-colony stimulating factor (G-CSF), with potential hematopoietic activity. Similar to G-CSF, pegfilgrastim anti-neutropenic factor (ANF) binds to and activates specific cell surface receptors, and stimulates neutrophil progenitor proliferation and differentiation. Therefore, this agent may prevent the duration and incidence of chemotherapy-induced neutropenia. Compared to filgrastim, the conjugation with a branched polyethylene glycol molecule reduces renal clearance and increases its plasma half-life.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	NCI Drug Dictionary Terminology
C123928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123928>	C28310|C129826	Audencel|AUDENCEL|AV0113|AV0113 DC-CIT|AV0113 Dendritic Cell Cancer Immunotherapeutic|Autologous DC-based Immunotherapeutic AV0113	A therapeutic interleukin-12 (IL-12)-expressing dendritic cell (DC)-based vaccine composed of autologous monocyte-derived DCs loaded with autologous tumor cell lysate and exposed to the microbial cell wall component lipopolysaccharide (LPS), with potential immunomodulating and antineoplastic activities. The monocyte-derived immature DCs are loaded with autologous tumor cell lysates and are subsequently exposed to LPS and interferon-gamma (IFN-gamma). Upon administration of audencel, the mature DCs migrate into the lymph nodes, express the immune stimulatory cytokine interleukin-12 (IL-12) and activate the immune system by promoting the activation of natural killer (NK) cells and induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation. Exposure to LPS and IFN-gamma allows the maturation of DCs and optimizes the presentation of tumor-associated antigens (TAAs) by DCs to T-lymphocytes.			Cell|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123929>	C2124	Gallium Ga 68-NOTA-Aca-BBN(7-14)|68Ga-NOTA-Aca-BBN(7-14)|68Gallium-labeled NOTA-Aca-BBN(7-14)|Gallium Ga 68-NOTA-Aca-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2|Gallium Ga 68-NOTA-aminocaproic Acid-bombesin(7-14)	A radioconjugate containing the bombesin (BBN) fragment BBN(7-14) comprised of the amino acid sequence of Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2, which targets the gastrin-releasing peptide receptor (GRPR), bound to aminocaproic acid (Aca), and linked by the macrocyclic chelating agent, 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA), to the radionuclide gallium (Ga) 68, with potential use in diagnostic imaging using positron emission tomography/computed tomography (PET/CT). Upon administration of gallium Ga 68-NOTA-Aca-BBN(7-14), the peptide moiety targets and binds to GRPR. Upon PET/CT, GRPR-expressing tumor cells can then be visualized. GRPR, also called bombesin receptor 2 (BB2), is a seven-transmembrane G protein-coupled receptor belonging to the bombesin receptor family. It is overexpressed in certain types of cancers.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C12392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12392>	C13018	Liver|Body System, Hepatic|Gastrointestinal Tract, Liver|Hepatic Body System|Hepatic Organ System|LIVER|Liver structure (body structure)|Organ System, Hepatic|liver|liver	A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate.	Liver		Body Part, Organ, or Organ Component	AML Adverse Events Table|AML Authorized Value Terminology|CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CTDC Value Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|GCT Authorized Value Terminology|GCT Biopsy/Surgical Procedures Table|GCT Radiation Therapy Table|GCT Tumor Assessment Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Biopsy/Surgical Procedures Table|HL Lesion Characteristics Table|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C123930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123930>	C213431|C213381|C204256	Ad5-yCD/mutTKSR39rep-hIL12|Oncolytic Adenovirus Ad5-yCD/mutTKSR39rep-hIL12	A replication-competent oncolytic adenovirus encoding the murine pro-inflammatory cytokine interleukin-12 (IL-12) gene and two suicide fusion genes, a yeast cytosine deaminase (yCD) and a mutant form of herpes simplex virus type 1 thymidine kinase (HSV-1 TKSR39), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration of Ad5-yCD/mutTKSR39rep-hIL12, the adenovirus selectively infects and replicates in tumor cells, which results in direct tumor cell lysis. Synergistically, IL-12 expressed by the adenovirus may activate the immune system by promoting the activation of natural killer cells (NKs), inducing secretion of interferon-gamma (IFN-g) and inducing cytotoxic T-lymphocyte (CTL) responses against tumor cells, which may result in immune-mediated tumor cell death, inhibition of tumor cell proliferation and inhibition of tumor angiogenesis. In addition, Ad5-yCD/mutTKSR39rep-hIL12-infected cancer cells express yCD and TKSR39; upon administration of the prodrugs 5-fluorocytosine (5-FC) and valganciclovir (vGCV), the yCD and HSV-1 TKSR39 activate these prodrugs to form 5-fluorouracil (5-FU) and ganciclovir, respectively. 5-FU gets converted to 5-fluoro-uridine monophosphate (5-FUMP) and subsequently to 5-fluoro-deoxyuridine monophosphate (5-FdUMP); 5-FdUMP irreversible inhibits thymidylate synthase, inhibits deoxythymidine triphosphate (dTTP) formation and halts DNA synthesis. Once phosphorylated intracellularly, ganciclovir triphosphate competitively inhibits deoxyguanosine triphosphate (dGTP) incorporation into DNA and inhibits DNA synthesis.			Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C123931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123931>	C203001|C119988	Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells|Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive HPCs	Autologous, CD34-positive hematopoietic progenitor cells (HPCs) transduced with a lentiviral vector encoding three anti-human immunodeficiency virus (HIV) genes: a short hairpin RNA (shRNA) that targets human chemokine receptor 5 (CCR5), a human/rhesus macaque chimeric tripartite motif-containing protein 5 alpha isoform (TRIM5alpha), and a TAT activation response (TAR) decoy, as well as a pre-selective cell-surface marker, which is a truncated and mutated form of human CD25, used to potentially provide resistance against human immunodeficiency virus (HIV) infection. Human autologous CD34-positive HPCs are isolated and transduced ex vivo with the lentiviral vector. Upon pre-selection, purification using CD25 immunomagnetic separation, and subsequent administration of effectively transduced HPCs, the HPCs display 3 separate mechanisms of action against HIV infection: CCR5 shRNA binds to CCR5 mRNA and inhibits the expression of CCR5, a HIV-1 co-receptor that mediates HIV attachment and host cell entry; TRIM5alpha prevents HIV genome integration upon cell entry; and the TAR decoy binds to the HIV TAT protein and prevents TAT-dependent viral gene transcription, thereby preventing HIV replication. Upon transfer of the lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive HPCs into the patient, the HPCs are resistant to HIV entry and replication and could provide long-term protection against both HIV infection and HIV-associated cancers.	Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C123932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123932>	C8093|C7085|C118826	Childhood Small Intestinal Leiomyosarcoma|Childhood Small Intestine Leiomyosarcoma	A small intestinal leiomyosarcoma occurring in childhood.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123933>	C7724|C190275|C118826	Childhood Small Intestinal Carcinoma|Small Intestinal Cancer	A small intestinal carcinoma occurring in childhood.	Childhood Small Intestinal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C123934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123934>	C66819	Definitive Host|Primary Host	The host in which a parasite spends the sexual stage of its life cycle.			Organism	
C123935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123935>	C66819	Intermediate Host	A host in which a parasite goes through its larval or developmental stages but does not reach sexual maturity.			Organism	
C123936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123936>	C45419	Chronicity|CHRON	A description or characterization of the duration of a biological process.			Temporal Concept	CDISC Root Variable Terminology
C123937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123937>	C25447	Distribution|DISTR	The placement, arrangement of instance of entities within a space.			Functional Concept	CDISC Root Variable Terminology
C123938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123938>	C82526	Cardiovascular System Findings Baseline Flag|CVBLFL	An indication or description that cardiovascular data is a baseline value.			Functional Concept	CDISC Variable Terminology
C123939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123939>	C82526	Respiratory System Findings Baseline Flag|REBLFL	An indication or description that respiratory data is a baseline value.			Functional Concept	CDISC Variable Terminology
C12393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12393>	C13018	Pancreas|Gastrointestinal Tract, Pancreas|PANCREAS|Pancreas, NOS|Pancreatic structure (body structure)|pancreas|pancreas	An organ behind the lower part of the stomach that is the shape of a fish and about the size of a hand. It is a compound gland composed of both exocrine and endocrine tissues. The endocrine pancreas makes insulin so that the body can use glucose (sugar) for energy. The exocrine pancreas makes enzymes that help the body digest food. Spread all over the pancreas are areas called the Islets of Langerhans. The cells in these areas each have a special purpose. The alpha cells make glucagon, which raises the level of glucose in the blood; the beta cells make insulin; the delta cells make somatostatin. There are also PP cells and D1 cells, about which little is known.	Pancreas		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C123940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123940>	C25372	Healthcare Encounters Category|HOCAT	A classification of healthcare encounters data.			Classification	CDISC Variable Terminology
C123941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123941>	C80484	Microscopic Findings Chronicity|MICHRON	A description or characterization of the duration of a microscopic finding.			Conceptual Entity	CDISC Variable Terminology
C123942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123942>	C102605	Cardiovascular System Findings Consciousness State|CVCSTATE	The level of awareness of an organism during a cardiovascular system assessment.			Finding	CDISC Variable Terminology
C123943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123943>	C95098	Respiratory System Findings Consciousness State|RECSTATE	The level of awareness of an organism during a respiratory system assessment.			Finding	CDISC Variable Terminology
C123944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123944>	C82977	Healthcare Encounters Dictionary-derived Term|HODECOD	A healthcare encounter identifier obtained from a dictionary.			Intellectual Product	CDISC Variable Terminology
C123945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123945>	C54215	Exposure Directionality|EXDIR	A qualifier for the direction on the body the exposure assessment is performed.			Functional Concept	CDISC Variable Terminology
C123946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123946>	C82515	Cardiovascular System Findings Data Collection Date Time|CVDTC	The date and time of cardiovasulcar system data collection.			Temporal Concept	CDISC Variable Terminology
C123947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123947>	C82515	Healthcare Encounters Data Collection Date Time|HODTC	The date and time of healthcare encounters data collection.			Temporal Concept	CDISC Variable Terminology
C123948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123948>	C82515	Respiratory System Findings Data Collection Date Time|REDTC	The date and time of respiratory system data collection.			Temporal Concept	CDISC Variable Terminology
C123949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123949>	C25330	Healthcare Encounters Duration|HODUR	The period of time from start to finish of a healthcare encounter.			Temporal Concept	CDISC Variable Terminology
C12394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12394>	C33224	Ear|EAR|Ear structure (body structure)|ear	A sense organ needed for the detection of sound and for establishing balance. The outer ear consists of the auricle, the ear canal as well as the tympanic membrane. The middle ear is made up of an air-filled cavity behind the tympanic membrane that contains the ossicles (malleus, incus and stapes). The inner ear is made up of the cochlea needed for hearing and the vestibular apparatus required for balance.	Ear		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C123950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123950>	C82437	Study Day of Cardiovascular System Findings|CVDY	The study day that a cardiovascular system assessment is performed.			Temporal Concept	CDISC Variable Terminology
C123951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123951>	C82437	Study Day of Healthcare Encounters|HODY	The study day that a healthcare encounters assessment is performed.			Temporal Concept	CDISC Variable Terminology
C123952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123952>	C82437	Study Day of Respiratory System Findings|REDY	The study day that a respiratory system assessment is performed.			Temporal Concept	CDISC Variable Terminology
C123953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123953>	C82572	Cardiovascular System Findings Elapsed Time|CVELTM	The interval between two cardiovascular system measurement reference time points.			Temporal Concept	CDISC Variable Terminology
C123954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123954>	C82572	Respiratory System Findings Elapsed Time|REELTM	The interval between two respiratory system measurement reference time points.			Temporal Concept	CDISC Variable Terminology
C123955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123955>	C82516	Cardiovascular System Findings End Date Time|CVENDTC	The date and time a cardiovascular system assessment has concluded.			Temporal Concept	CDISC Variable Terminology
C123956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123956>	C82516	Healthcare Encounters End Date Time|HOENDTC	The date and time a healthcare encounter assessment has concluded.			Temporal Concept	CDISC Variable Terminology
C123957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123957>	C82516	Respiratory System Findings End Date Time|REENDTC	The date and time a respiratory system assessment has concluded.			Temporal Concept	CDISC Variable Terminology
C123958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123958>	C82569	Cardiovascular System Findings End Day|CVENDY	The final day of the cardiovascular system assessment.			Temporal Concept	CDISC Variable Terminology
C123959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123959>	C82569	Healthcare Encounters End Day|HOENDY	The final day of the healthcare encounter assessment.			Temporal Concept	CDISC Variable Terminology
C12395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12395>	C13043	Cochlea|Cochlear|Cochlear Organ|Cochlear structure (body structure)|EAR, COCHLEA	The snail shell-shaped auditory component of the inner ear. It contains the sensory organ of hearing.	Cochlea		Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C123960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123960>	C82569	Respiratory System Findings End Day|REENDY	The final day of the respiratory system assessment.			Temporal Concept	CDISC Variable Terminology
C123961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123961>	C117042	Cardiovascular System Findings Planned End of Assessment Interval|CVENINT	The period of time that the cardiovascular system assessment, done over an interval of time, is intended to finish.			Temporal Concept	CDISC Variable Terminology
C123962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123962>	C117042	Electrocardiogram Planned End of Assessment Interval|EGENINT	The period of time that the electrocardiogram assessment, done over an interval of time, is intended to finish.			Temporal Concept	CDISC Variable Terminology
C123963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123963>	C117042	Pharmacokinetic Parameters Planned End of Assessment Interval|PPENINT	The period of time that the pharmacokinetic parameter assessment, done over an interval of time, is intended to finish.			Temporal Concept	CDISC Variable Terminology
C123964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123964>	C117042	Respiratory System Findings Planned End of Assessment Interval|REENINT	The period of time that the respiratory system assessment, done over an interval of time, is intended to finish.			Temporal Concept	CDISC Variable Terminology
C123965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123965>	C82558	Healthcare Encounters End Relative to Reference Time Point|HOENRTPT	An indication or description that the end of the healthcare encounter is before, during or after a reference moment in time.			Temporal Concept	CDISC Variable Terminology
C123966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123966>	C82574	Healthcare Encounters Reference End Time Point End|HOENTPT	A point in time that indicates the conclusion of a healthcare encounter.			Temporal Concept	CDISC Variable Terminology
C123967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123967>	C117045	Exclude Cardiovascular System Findings Data From Statistics Indicator|CVEXCLFL	Specifies whether the cardiovascular system result values should be excluded from the statistical analysis.			Functional Concept	CDISC Variable Terminology
C123968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123968>	C117045	Exclude Respiratory System Findings Data From Statistics Indicator|REEXCLFL	Specifies whether the respiratory system result values should be excluded from the statistical analysis.			Functional Concept	CDISC Variable Terminology
C123969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123969>	C93566	Exposure Fasting Status|EXFAST	An indication or description of whether an exposure assessment was obtained from a subject that has abstained from food and possibly water for the prescribed amount of time.			Finding	CDISC Variable Terminology
C12396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12396>	C45715|C32051	Adrenal Cortex|Cortex of Adrenal Gland|Cortex of adrenal gland|Cortical|adrenal cortex|adrenal cortex	The outer region of the adrenal gland consisting of the zona glomerulosa, the zona fasciculata, and the zona reticularis. The adrenal cortex produces and secretes mineralocorticoids, glucocorticoids, and adrenal androgens.	Adrenal Cortex		Tissue	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C123970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123970>	C82529	Cardiovascular System Findings Group Identifier|CVGRPID	A character or string that represents a cardiovascular system findings group.			Intellectual Product	CDISC Variable Terminology
C123971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123971>	C82529	Healthcare Encounters Group Identifier|HOGRPID	A character or string that represents a healthcare encounters group.			Intellectual Product	CDISC Variable Terminology
C123972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123972>	C82529	Respiratory System Findings Group Identifier|REGRPID	A character or string that represents a respiratory system findings group.			Intellectual Product	CDISC Variable Terminology
C123973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123973>	C25185	Exposure Laterality|EXLAT	A qualifier for the side of the body the exposure assessment is performed.			Organism Attribute	CDISC Variable Terminology
C123974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123974>	C25185	Findings About Laterality|FALAT	A qualifier for the side of the body the findings about test is performed.			Organism Attribute	CDISC Variable Terminology
C123975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123975>	C25185	Vital Signs Laterality|VSLAT	A qualifier for the side of the body vital signs test is performed.			Organism Attribute	CDISC Variable Terminology
C123976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123976>	C50282	Electrocardiogram Lead|EGLEAD	An insulated electrical conductor designed to connect to an electrocardiogram machine.			Manufactured Object	CDISC Variable Terminology
C123977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123977>	C117049	Exposure Link Group Identifier|EXLNKGRP	A sequence of characters used to link multiple exposure assessment records to a single finding.			Intellectual Product	CDISC Variable Terminology
C123978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123978>	C117050	Exposure Record Link Identifier|EXLNKID	A sequence of characters used as a linkage between related exposure records.			Intellectual Product	CDISC Variable Terminology
C123979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123979>	C82535	Cardiovascular System Findings Method|CVMETHOD	The technique used to administer the cardiovascular system assessment.			Activity	CDISC Variable Terminology
C12397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12397>	C48365|C32051	Adrenal Medulla|Medulla of Adrenal Gland|Medulla of adrenal gland|Medullary|adrenal medulla|adrenal medulla	The inner region of the adrenal gland. The adrenal medulla produces, stores, and secretes epinephrine and norepinephrine.	Adrenal Medulla		Tissue	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C123980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123980>	C82535	Respiratory System Findings Method|REMETHOD	The technique used to administer the respiratory system assessment.			Activity	CDISC Variable Terminology
C123981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123981>	C82541	Trial Sets Name|SET	A character or string that represents the long name of the trial set.			Intellectual Product	CDISC Variable Terminology
C123982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123982>	C25275	Healthcare Encounters Occurrence|HOOCCUR	An indication or description of a healthcare encounter occurrence.			Event	CDISC Variable Terminology
C123983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123983>	C117221	Cardiovascular System Findings Original Result|CVORRES	The outcome of the cardiovascular system assessment as originally received or collected.			Finding	CDISC Variable Terminology
C123984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123984>	C117221	Respiratory System Findings Original Result|REORRES	The outcome of the respiratory system assessment as originally received or collected.			Finding	CDISC Variable Terminology
C123985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123985>	C82586	Cardiovascular System Findings Original Result Unit|CVORRESU	The unit of measure for the result of the cardiovascular system assessment as originally received or collected.			Quantitative Concept	CDISC Variable Terminology
C123986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123986>	C82586	Respiratory System Findings Original Result Unit|REORRESU	The unit of measure for the result of the respiratory system assessment as originally received or collected.			Quantitative Concept	CDISC Variable Terminology
C123987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123987>	C171002	Cardiovascular System Findings Body Position|CVPOS	The physical bearing of the body during a cardiovascular system assessment.			Spatial Concept	CDISC Variable Terminology
C123988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123988>	C171002	Respiratory System Findings Body Position|REPOS	The physical bearing of the body during a respiratory system assessment.			Spatial Concept	CDISC Variable Terminology
C123989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123989>	C82510	Healthcare Encounters Pre-specified|HOPRESP	An indication or description that a healthcare encounter was previously determined, characterized, or detailed.			Conceptual Entity	CDISC Variable Terminology
C12398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12398>	C12704	Pineal Gland|GLAND, PINEAL|PINEAL GLAND|Pineal|Pineal|Pineal Body|Pineal Body|Pineal gland|Pineal structure (body structure)|corpus pineale|glandula pinealis|pineal body|pineal body|pineal gland|pineal gland|pineal organ	A small endocrine gland in the brain, situated beneath the back part of the corpus callosum, that secretes melatonin.	Pineal Gland		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GCT Authorized Value Terminology|GCT Biopsy/Surgical Procedures Table|GCT Radiation Therapy Table|GCT Tumor Assessment Table|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C123990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123990>	C117057	Cardiovascular System Findings Reason For Exclusion From Statistics|CVREASEX	A rationale for excluding a particular data point or subject from the cardiovascular system statistical analysis.			Intellectual Product	CDISC Variable Terminology
C123991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123991>	C117057	Respiratory System Findings Reason For Exclusion From Statistics|REREASEX	A rationale for excluding a particular data point or subject from the respiratory system statistical analysis.			Intellectual Product	CDISC Variable Terminology
C123992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123992>	C82556	Cardiovascular System Findings Reason Not Done|CVREASND	The explanation given as to why cardiovascular system test was not performed.			Idea or Concept	CDISC Variable Terminology
C123993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123993>	C82556	Healthcare Encounters Reason Not Done|HOREASND	The explanation given as to why the healthcare encounter was not assessed.			Idea or Concept	CDISC Variable Terminology
C123994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123994>	C82556	Respiratory System Findings Reason Not Done|REREASND	The explanation given as to why respiratory system test was not performed.			Idea or Concept	CDISC Variable Terminology
C123995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123995>	C82531	Healthcare Encounters Reference Identifier|HOREFID	A sequence of characters used to identify, name, or characterize the healthcare encounters reference.			Intellectual Product	CDISC Variable Terminology
C123996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123996>	C82518	Cardiovascular System Findings Date Time of Reference Timepoint|CVRFTDTC	The date and time of a specific reference point for the cardiovascular system assessment.			Temporal Concept	CDISC Variable Terminology
C123997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123997>	C82518	Exposure Date Time of Reference Timepoint|EXRFTDTC	The date and time of a specific reference point for the exposure assessment.			Temporal Concept	CDISC Variable Terminology
C123998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123998>	C82518	Respiratory System Findings Date Time of Reference Timepoint|RERFTDTC	The date and time of a specific reference point for the respiratory system assessment.			Temporal Concept	CDISC Variable Terminology
C123999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123999>	C25692	Healthcare Encounters Subcategory|HOSCAT	A subdivision of healthcare encounters data.			Classification	CDISC Variable Terminology
C12399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12399>	C12704	Pituitary Gland|GLAND, PITUITARY|Hypophysis|Hypophysis|Hypophysis Cerebri|Hypophysis Cerebri|Nervous System, Pituitary|PITUITARY GLAND|Pituitary|Pituitary gland|Pituitary structure (body structure)|glandula pituitaria|pituitary|pituitary body|pituitary gland|pituitary gland	Pea-sized endocrine gland located at the base of the brain in the pituitary fossa. It produces and secretes hormones such as oxytocin and vasopressin, to regulate the activities of the hypothalamus.	Pituitary Gland		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C1239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1239>	C2127	Exisulind|(Z)-5-Fluoro-2-methyl-1-[[4-(methylsulfonyl)phenyl]methylene]-1H-indene-3-acetic Acid|1H-Indene-3-acetic Acid, 5-Fluoro-2-methyl-1-((4-(methylsulfonyl)phenyl)methylene), (Z)|Aptosyn|EXISULIND|FGN-1|Sulindac Sulfone|Sulindac sulfone|exisulind	An inactive metabolite of the nonsteroidal, anti-inflammatory agent sulindac.  After oral administration, sulindac undergoes extensive biotransformation including irreversible oxidation to sulindac sulfone.  Approximately, one half of an administered dose of sulindac is eliminated through the urine, mostly as the conjugated sulfone metabolite. (NCI04)	Exisulind		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124000>	C70710	Cardiovascular System Findings Sequence Number|CVSEQ	An identifier that describes the relative position of cardiovascular system findings data within a series.			Quantitative Concept	CDISC Variable Terminology
C124001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124001>	C70710	Healthcare Encounters Sequence Number|HOSEQ	An identifier that describes the relative position of healthcare encounters data within a series.			Quantitative Concept	CDISC Variable Terminology
C124002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124002>	C70710	Respiratory System Findings Sequence Number|RESEQ	An identifier that describes the relative position of respiratory system findings data within a series.			Quantitative Concept	CDISC Variable Terminology
C124003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124003>	C82530	Cardiovascular System Findings Sponsor Defined Identifier|CVSPID	One or more sponsor defined characters used to identify, name, or characterize the cardiovascular system findings.			Intellectual Product	CDISC Variable Terminology
C124004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124004>	C82530	Healthcare Encounters Sponsor Defined Identifier|HOSPID	One or more sponsor defined characters used to identify, name, or characterize the healthcare encounters.			Intellectual Product	CDISC Variable Terminology
C124005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124005>	C82530	Respiratory System Findings Sponsor Defined Identifier|RESPID|RESPID|Respiratory System Findings Sponsor-Defined Identifier	One or more sponsor defined characters used to identify, name, or characterize the respiratory system findings.			Intellectual Product	CDISC Variable Terminology
C124006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124006>	C41202	Cardiovascular System Findings Completion Status|CVSTAT	A term used to describe the state or condition of the completeness of the cardiovascular system findings data.			Qualitative Concept	CDISC Variable Terminology
C124007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124007>	C41202	Healthcare Encounters Completion Status|HOSTAT	A term used to describe the state or condition of the completeness of the healthcare encounters data.			Qualitative Concept	CDISC Variable Terminology
C124008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124008>	C41202	Respiratory System Findings Completion Status|RESTAT	A term used to describe the state or condition of the completeness of the respiratory system findings data.			Qualitative Concept	CDISC Variable Terminology
C124009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124009>	C82517	Healthcare Encounters Start Date Time|HOSTDTC	The date and time a healthcare encounter began.			Temporal Concept	CDISC Variable Terminology
C12400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12400>	C12704	Thyroid Gland|GLAND, THYROID|Head and Neck, Thyroid|THYROID GLAND|Thyroid|Thyroid|Thyroid|Thyroid gland|Thyroid structure (body structure)|Total Thyroid|thyroid|thyroid|thyroid gland|thyroid gland	An endocrine gland located at the base of the neck that produces and secretes thyroxine and other hormones. Thyroxine is important for metabolic control.	Thyroid		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C124010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124010>	C82570	Healthcare Encounters Start Day|HOSTDY	The day of the week a healthcare encounter began.			Temporal Concept	CDISC Variable Terminology
C124011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124011>	C117061	Cardiovascular System Findings Planned Start of Assessment Interval|CVSTINT	The period of time that the cardiovascular system findings assessment, done over an interval of time, is intended to begin.			Temporal Concept	CDISC Variable Terminology
C124012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124012>	C117061	Electrocardiogram Planned Start of Assessment Interval|EGSTINT	The period of time that the electrocardiogram assessment, done over an interval of time, is intended to begin.			Temporal Concept	CDISC Variable Terminology
C124013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124013>	C117061	Pharmacokinetic Parameters Planned Start of Assessment Interval|PPSTINT	The period of time that the pharmacokinetic parameters assessment, done over an interval of time, is intended to begin.			Temporal Concept	CDISC Variable Terminology
C124014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124014>	C117061	Respiratory System Findings Planned Start of Assessment Interval|RESTINT	The period of time that the respiratory system findings assessment, done over an interval of time, is intended to begin.			Temporal Concept	CDISC Variable Terminology
C124015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124015>	C117222	Cardiovascular System Findings Character Result in Standard Format|CVSTRESC	The standard character or string for representation and reporting of cardiovascular system findings data.			Quantitative Concept	CDISC Variable Terminology
C124016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124016>	C117222	Respiratory System Findings Character Result in Standard Format|RESTRESC	The standard character or string for representation and reporting of respiratory system findings data.			Quantitative Concept	CDISC Variable Terminology
C124017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124017>	C70952	Cardiovascular System Findings Numeric Result in Standard Unit|CVSTRESN	The numerical identifier of a cardiovascular system finding result in standard units.			Quantitative Concept	CDISC Variable Terminology
C124018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124018>	C70952	Respiratory System Findings Numeric Result in Standard Unit|RESTRESN	The numerical identifier of a respiratory system finding result in standard units.			Quantitative Concept	CDISC Variable Terminology
C124019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124019>	C82587	Cardiovascular System Findings Result Standard Unit|CVSTRESU	The standard unit of measure for cardiovascular system findings results.			Quantitative Concept	CDISC Variable Terminology
C12401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12401>	C33224	Eye|EYE|Eye, NOS|Eyeball|Eyeball|Ocular|Ophthalmic|Optic|Structure of eye proper (body structure)|eye|ophthalmic	The organ of sight or vision.	Eye		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C124020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124020>	C82587	Respiratory System Findings Result Standard Unit|RESTRESU	The standard unit of measure for respiratory system findings results.			Quantitative Concept	CDISC Variable Terminology
C124021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124021>	C82560	Healthcare Encounters Start Relative to Reference Timepoint|HOSTRTPT	An indication or description of the start of a healthcare encounter in relation to a specific point in time.			Temporal Concept	CDISC Variable Terminology
C124022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124022>	C82575	Healthcare Encounters Start Timepoint|HOSTTPT	A point in time that indicates the beginning of a healthcare encounter.			Temporal Concept	CDISC Variable Terminology
C124023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124023>	C82571	Healthcare Encounters Verbatim Description|HOTERM	The verbatim description of the healthcare encounter being reported.			Idea or Concept	CDISC Variable Terminology
C124024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124024>	C82541	Cardiovascular System Findings Test|CVTEST	A character or string that represents the long name of the cardiovascular system findings assessment.			Intellectual Product	CDISC Variable Terminology
C124025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124025>	C82541	Respiratory System Findings Test|RETEST	A character or string that represents the long name of the respiratory system findings assessment.			Intellectual Product	CDISC Variable Terminology
C124026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124026>	C82503	Cardiovascular System Findings Test Code|CVTESTCD	A character or string that represents the short code name of the cardiovascular system findings assessment.			Intellectual Product	CDISC Variable Terminology
C124027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124027>	C82503	Respiratory System Findings Test Code|RETESTCD	A character or string that represents the short code name of the respiratory system findings assessment.			Intellectual Product	CDISC Variable Terminology
C124028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124028>	C82539	Cardiovascular System Findings Planned Time Point Name|CVTPT	The literal identifier of a planned point in time for a cardiovascular system findings assessment.			Intellectual Product	CDISC Variable Terminology
C124029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124029>	C82539	Respiratory System Findings Planned Time Point Name|RETPT	The literal identifier of a planned point in time for a respiratory system findings assessment.			Intellectual Product	CDISC Variable Terminology
C12402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12402>	C12841	Female Reproductive System|Body System, Gynecologic|Body System, Reproductive, Female|FEMALE REPRODUCTIVE SYSTEM|Female Genital Tract|Female Reproductive Body System|Female Reproductive Organ System|Female Reproductive Tract|Genital System, Female|Gynecologic Body System|Gynecologic Organ System|Organ System, Female Reproductive|Organ System, Gynecologic|Reproductive System, Female|female reproductive system	The collection of organs and tissues, including the ovaries, genital tract, and breasts, that have several functions, including sexual maturation, pregnancy, and childbirth.	Female Reproductive System		Body System	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C124030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124030>	C82576	Respiratory System Findings Time Point Reference|RETPTREF	The point in time that acts as a fixed reference point to a respiratory system findings assessment.			Temporal Concept	CDISC Variable Terminology
C124031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124031>	C82545	Cardiovascular System Findings Planned Time Point Number|CVTPTNUM	The numerical identifier of a cardiovascular system finding point in time.			Quantitative Concept	CDISC Variable Terminology
C124032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124032>	C82545	Respiratory System Findings Planned Time Point Number|RETPTNUM	The numerical identifier of a respiratory system finding point in time.			Quantitative Concept	CDISC Variable Terminology
C124033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124033>	C82576	Cardiovascular System Findings Time Point Reference|CVTPTREF	The point in time that acts as a fixed reference point to a cardiovascular system findings assessment.			Temporal Concept	CDISC Variable Terminology
C124034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124034>	C85533	Pharmacokinetic Concentration Upper Limit Value|PCULOQ	The highest value in a standard range of pharmacokinetic concentration values.			Quantitative Concept	CDISC Variable Terminology
C124035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124035>	C123937	Microscopic Findings Distribution|MIDISTR	The placement, arrangement or instance of microscopic findings within an anatomical space.			Functional Concept	CDISC Variable Terminology
C124036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124036>	C81197	Cardiovascular System Findings Derived Flag|CVDRVFL	An indication or description that cardiovascular system data is a derived value.			Functional Concept	CDISC Variable Terminology
C124037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124037>	C81197	Respiratory System Findings Derived Flag|REDRVFL	An indication or description that respiratory system data is a derived value.			Functional Concept	CDISC Variable Terminology
C124038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124038>	C16804	Adenylate Cyclase Type 9|AC9|ACIX|ADCY9|ATP Pyrophosphate-Lyase 9|Adenyl Cyclase 9|Adenylate Cyclase Type IX|Adenylyl Cyclase 9|Adenylylcyclase 9|EC 4.6.1.1|Type IX ATP Pyrophosphate-Lyase	Adenylate cyclase type 9 (1353 aa, ~151 kDa) is encoded by the human ADCY9 gene. This protein is involved in the synthesis of cyclic AMP in response to activation of beta-adrenergic receptors.			Amino Acid, Peptide, or Protein|Enzyme	
C124039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124039>	C171457	Biphasic Positive Airway Pressure|BILEVEL POSITIVE AIRWAY PRESSURE VENTILATION|BIPAP Ventilation|BPAP Ventilation|BiPAP|BiPAP|Bilevel Positive Airway Pressure Ventilation|Biphasic positive airway pressure (BiPAP)	A form of non-invasive mechanical pressure support ventilation that uses a time-cycled change of the applied positive airway pressure level to support spontaneous breathing activity.	Biphasic Positive Airway Pressure		Therapeutic or Preventive Procedure	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 9: Therapeutic and Supportive Procedures for COVID-19 Terminology|CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|Mechanical Support Terminology|NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C12403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12403>	C13018|C12321	Fallopian Tube|FALLOPIAN TUBE|Fallopian Tube, NOS|Fallopian Tubes|Fallopian tube|OVIDUCT|Oviduct|fallopian tube|fallopian tube|mammalian oviduct|uterine tube	One of a pair of tubes that extend from the uterus to each of the ovaries. Following ovulation the egg travels down the fallopian tube to the uterus where fertilization may or may not occur.	Fallopian Tube		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C124040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124040>	C171457	Continuous Positive Airway Pressure|CONTINUOUS POSITIVE AIRWAY PRESSURE VENTILATION|CPAP|CPAP|CPAP Ventilation|Continuous positive airway pressure (CPAP)	A form of non-invasive mechanical pressure support ventilation that uses a continuous positive airway pressure level to support spontaneous breathing activity.	Continuous Positive Airway Pressure		Therapeutic or Preventive Procedure	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 9: Therapeutic and Supportive Procedures for COVID-19 Terminology|CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|Mechanical Support Terminology|NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C124041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124041>	C35869	Hypoattenuation|Hypoattenuated	Describes areas on an x-ray or CT scan that show up as darker than surrounding tissues.			Finding	
C124042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124042>	C45233	Air Trapping|Air trapping (gas trapping)|Gas Trapping	An abnormal retention of gas in the lungs during expiration, either as a result of complete or partial airway obstruction or as a result of abnormalities in pulmonary compliance.			Finding	
C124043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124043>	C36279	Portal Flow Reversal|Hepatofugal Flow|Portal Vein Flow Reversal	An abnormal flow pattern where the portal venous flow is from the periphery of the liver towards the porta and backwards along the portal vein. It is most typically associated with liver disease.			Finding	
C124044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124044>	C54131	Fresenius Biotech|Fresenius|Fresenius Biotech GmbH	A German company that researches, develops, and markets biopharmaceuticals for the treatment of severe diseases.			Organization	
C124045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124045>	C16295	IL2 Receptor Antibody|Anti-IL-2R Antibody|Anti-IL2 Receptor|Anti-IL2 Receptor Antibody|Anti-IL2R Antibody|IL-2R Antibody|IL2R Antibody	Any antibody that recognizes an interleukin 2 receptor protein.	IL2 Receptor Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124046>	C16295	IL6 Receptor Antibody|Anti-IL-6R Antibody|Anti-IL6 Receptor|Anti-IL6 Receptor Antibody|Anti-IL6R Antibody|IL-6R Antibody|IL6R Antibody	Any antibody that recognizes an interleukin 6 receptor protein.			Amino Acid, Peptide, or Protein|Immunologic Factor	
C124047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124047>	C1934|C1556	8-Chloroadenosine|8-CHLOROADENOSINE|8-Chloro-adenosine|8-Cl-Ado|8-Cl-adenosine|Adenosine, 8-Chloro-	An antimetabolite and a chlorine derivative of the purine nucleoside adenosine, with potential antineoplastic activity. Upon administration, 8-chloro-adenosine is phosphorylated to form 8-chloro-adenosine triphosphate (8-chloro-ATP), which functions as a ribonucleoside analogue and competes with ATP during transcription. Therefore, this agent causes RNA synthesis inhibition, inhibits cellular proliferation, and induces apoptosis.	8-Chloroadenosine		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124048>	C20194	DUX4L1 Gene|DUX10|DUX4L1|DUX4L1|DUX4L1|Double Homeobox 4 Gene|Double Homeobox 4 Like 1 (Pseudogene) Gene|Double Homeobox 4 Like 1 Gene	Human DUX4L1 gene is located in the vicinity of 4q35 and is approximately 2 kb in length. The product is a processed pseudogene that produces an RNA transcript, but does not encode a protein product. This gene is within a D4Z4 repeat array; contraction of this macrosatellite repeat is associated with facioscapulohumeral muscular dystrophy (FSHD).			Gene or Genome	GDC Terminology|GDC Value Terminology
C124049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124049>	C797|C29639|C275|C226473	Dimethicone-containing Botanicals-based Lotion|Difinsa53	A skin lotion containing various proprietary botanical ingredients and the skin protectant dimethicone, a silicon-based polymer, with potential to prevent radiation dermatitis (RD). Upon topical application to the affected area before and after radiation therapy, the phytochemicals in the dimethicone-containing botanicals-based lotion may act as free radical scavengers and exert an antioxidant effect. The dimethicone component of the skin lotion protects against damage, and moisturizes and soothes the skin.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C12404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12404>	C12725|C12321	Ovary|Genital System, Female, Ovary|OVARY|Ovarian structure (body structure)|Ovaries|Ovary, NOS|animal ovary|female gonad|female organism genitalia gonad|female organism genitalia gonada|female organism reproductive system gonad|female organism reproductive system gonada|female reproductive system gonad|female reproductive system gonada|genitalia of female organism gonad|genitalia of female organism gonada|gonad of female organism genitalia|gonad of female organism reproductive system|gonad of female reproductive system|gonad of genitalia of female organism|gonad of reproductive system of female organism|gonada of female organism genitalia|gonada of female organism reproductive system|gonada of female reproductive system|gonada of genitalia of female organism|gonada of reproductive system of female organism|ovary|ovary|ovum-producing ovary|reproductive system of female organism gonad|reproductive system of female organism gonada	One of the paired female reproductive glands containing the ova or germ cells; the ovary's stroma is a vascular connective tissue containing numbers of ovarian follicles enclosing the ova.	Ovary		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Radiation Therapy Table|GCT Authorized Value Terminology|GCT Biopsy/Surgical Procedures Table|GCT Radiation Therapy Table|GCT Tumor Assessment Table|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C124050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124050>	C1935	Nutrient-rich Whole Wheat Flour Supplement|IAtta|Nutrient-rich Bread Mix IAtta	A nutritional supplement composed of nutrient-rich whole wheat flour-based bread mix, with potential anti-cachexia activity. Following the production of an unleavened bread from the mix and upon oral intake of the nutrient-rich whole wheat flour supplement, the various nutrients in the bread may improve cachexia symptoms. The bread is made from the flour of pulverized whole wheat from an Indian crop.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C124051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124051>	C784|C1420	Racemetyrosine/Methoxsalen/Phenytoin/Sirolimus|Racemetyrosine/Methoxsalen/Phenytoin/Sirolimus Combination|SM-88 Used with MPS|SM-88 Used with Methoxsalen/Phenytoin/Sirolimus|SM-88/Methoxsalen/Phenytoin/Sirolimus|Tyrosine Isomers/Phenytoin/Methoxsalen/Sirolimus	A combination agent containing racemetyrosine, methoxsalen, phenytoin and sirolimus, with potential antineoplastic activity. Upon administration of racemetyrosine/methoxsalen/phenytoin/sirolimus SM-88, racemetyrosine, being a dysfunctional and modified form of the non-essential amino acid tyrosine, is specifically taken up by cancer cells through the transporter L-amino acid transferase-1 (LAT1; CD98). As a tyrosine derivative and faulty amino acid protein building block, racemetyrosine prevents protein synthesis in cancer cells. Specifically, this prevents mucin-1 (MUC1) protein synthesis. MUC1 is highly overexpressed by most cancer cells and regulates the increased reactive oxygen species (ROS) in cancer cells created from the altered metabolism that cancer cells utilize, by upregulating key antioxidant defenses and preventing ROS-mediated apoptosis. In the absence of MUC1, ROS levels are increased, leading to an increase in oxidative stress, and induction of apoptosis. Also, being a protective transmembrane protein, MUC1 is part of the protective layer on the outside of cancer cells and plays a key role in shielding the cancer cell from the immune system. The loss of MUC1 compromises the cell membrane, thereby making the cancer cell more vulnerable to be recognized and attacked by the immune system. Rapamycin, a mammalian target of rapamycin (mTOR) inhibitor, increases the cancer cells' need for tyrosine uptake and increases the uptake of racemetyrosine by LAT1. Phenytoin stimulates the release of reactive lipid species by the liver which accumulate in the tumor microenvironment (TME) and are taken up by cancer cells, thereby further increasing ROS within the cancer cell and increasing oxidative-related apoptosis. Mehoxsalen promotes toxic electron transfer and increases melanin, increases oxidative reactions and production of ROS. This further stimulates oxidative stress-mediated apoptosis. Normal cells do not regularly take up certain non-essential amino acids, such as tyrosine, but readily convert phenylalanine to tyrosine, so normal healthy cells are not expected to consume racemetyrosine.	Racemetyrosine/Methoxsalen/Phenytoin/Sirolimus		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124052>	C94726	Granisetron Hydrochloride Nasal Spray|GNS|Granisetron HCl Nasal Spray|Intranasal Granisetron Hydrochloride	An intranasal formulation containing the hydrochloride salt form of the indazole derivative granisetron, a selective serotonin (5-hydroxytryptamine; 5-HT) receptor antagonist, with antinauseant and antiemetic activities. Upon administration to the nostril, granisetron selectively binds to and inhibits 5-HT subtype 3 receptors (5-HT3R) located peripherally on vagus nerve terminals and centrally in the chemoreceptor trigger zone (CTZ) of the area postrema, which may result in suppression of chemotherapy-induced nausea and vomiting (CINV).			Organic Chemical|Pharmacologic Substance	NCI Drug Dictionary Terminology
C124053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124053>	C697	Bendamustine-containing Nanoparticle-based Formulation RXDX-107|BENDAMUSTINE DODECYL ESTER|CEP-40125|RXDX 107|RXDX-107	A nanoparticle-based formulation containing the alkyl ester of bendamustine, a bifunctional mechlorethamine derivative, encapsulated in human serum albumin (HSA), with potential alkylating and antineoplastic activities. Upon administration of the alkyl ester bendamustine-containing nanoparticle formulation RXDX-107, the nanoparticle formulation permits high concentrations of the alkyl ester of bendamustine be localized at the tumor site. The modified bendamustine alkylates and crosslinks macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and, subsequently, apoptosis.	Bendamustine-containing Nanoparticle-based Formulation RXDX-107		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124054>	C28310	Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107|ICT-107|Multi-glioblastoma-peptide-pulsed Autologous DC Vaccine ICT-107|Multi-glioblastoma-peptide-targeting Autologous DC Vaccine ICT-107	A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with six synthetic glioblastoma (GBM) peptides: absent in melanoma 2 (AIM-2), melanoma-associated antigen 1 (MAGE-1), tyrosinase-related protein 2 (TRP-2), glycoprotein 100 (gp100), epidermal growth factor receptor 2 (HER-2), interleukin-13 receptor subunit alpha-2 (IL-13Ra2), with potential immunostimulatory and antineoplastic activities. Mononuclear cells obtained via leukapheresis are differentiated into DCs, and pulsed with the GBM-associated peptides. Upon administration, multi-glioblastoma-peptide-targeting autologous DC vaccine ICT-107 exposes the immune system to GBM-associated antigens, which activates a specific cytotoxic T-lymphocyte (CTL) response against GBM cells. This leads to GBM cell lysis. The six peptides are derived from tumor associated antigens (TAA) expressed on GBM cells and cancer stem cells (CSCs). GBM stem-like cells contain a specific range of antigens that are essential for the neoplastic growth and survival of GBM cells.	Multi-glioblastoma-peptide-targeting Autologous Dendritic Cell Vaccine ICT-107		Cell|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124055>	C28310|C129826	Tumor Peptide-loaded Myeloid Dendritic Cells|Tumor Peptide-loaded myDC Vaccine	A cell-based cancer vaccine composed of myeloid dendritic cells (myDCs) pulsed with tumor peptides with potential immunostimulatory and antineoplastic activities. Upon administration, the tumor peptide-loaded myDCs stimulate a specific cytotoxic T-lymphocyte (CTL) response against the tumor cells, resulting in tumor cell lysis.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124056>	C84978	Desbuquois Dysplasia|DBQD	A rare osteochondrodysplasia characterized by short stature, joint laxity, multiple dislocations, vertebral and metaphyseal abnormalities, and advanced carpotarsal ossification. Two forms have been identified: type 1 caused by mutation in the gene CANT1 and type 2 caused by mutations in the gene XYLT1.			Disease or Syndrome	
C124057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124057>	C96412	Pontocerebellar Hypoplasia Type 2|PCH2	A rare brain developmental disorder caused by mutations in the TSEN54, TSEN2, TSEN34, or SEPSECS gene. The pons and cerebellum are the brain structures that are more severely affected. It is characterized by microcephaly, lack of voluntary motor skills, dysphagia, inability to communicate, abnormal patterns of movement, and spasticity.			Disease or Syndrome	
C124058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124058>	C129820|C124946	Sasanlimab|Anti-PD-1 PF-06801591|PF-06801591|SASANLIMAB|WHO 11161	An inhibitor of the human inhibitory receptor programmed cell death 1 (PD-1; PDCD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sasanlimab targets and binds to PD-1 and blocks the interaction between PD-1 and its ligands, PD-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs) against tumor cells. PD-1, an inhibitory receptor belonging to the B7-receptor family, is expressed on activated T-lymphocytes, B-cells and NK cells; it functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, and plays an important role in tumor evasion from host immunity.	Sasanlimab		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124059>	C35869	Pulmonary Consolidation|Air Space Opacification|Air-Space Shadowing|Airspace Consolidation|Airspace Opacification|Consolidation	A chest X-ray finding indicating the presence of a radio-opaque area in the lung. The opacification is caused by fluid or solid material within the airways or lung parenchyma.			Finding	
C12405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12405>	C13018	Uterus|Genital System, Female, Uterus|UTERUS|Uterine|Uterine structure (body structure)|Utero|Uterus, NOS|Womb|uterus|uterus|womb	A hollow, thick-walled, muscular organ located within the pelvic cavity of a woman. Within the uterus the fertilized egg implants and the fetus develops during pregnancy.	Uterus		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C124060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124060>	C35869	Peribronchial Cuffing|Bronchial Wall Thickening|Peribronchial Thickening	A radiologic finding that describes haziness around a bronchus or large bronchiole seen end on. It may either represent bronchial wall thickening or fluid around the bronchi.			Finding	
C124061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124061>	C35869	Centrilobular Opacity|Centrilobular Lung Nodules	A radiologic finding indicating the presence of radio-opaque areas in the central parts of lung lobules.			Finding	
C124062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124062>	C35869	Nodular Opacity	A radiologic finding indicating the presence of a solitary, round, circumscribed shadow in the lung on chest x-ray.			Finding	
C124063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124063>	C25404	Reactivation	The restoration of activity to something that has been inactivated.			Activity	
C124064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124064>	C154898	Interleukin Inhibitor	Any agent that inhibits the action of an interleukin. These agents inhibit various immune functions.			Chemical Viewed Functionally	
C124065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124065>	C36279	Liver Iron Concentration|Hepatic Iron Concentration|LIC|Liver/Hepatic Iron Concentration	A measurement of the concentration of iron in the liver as an estimate of body iron load.			Finding	
C124066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124066>	C16742	Superconducting Quantum Interference Device|SQUID|Superconducting Quantum Interference Device (SQUID)	A device designed to measure extremely weak magnetic fields. It is comprised of a Josephson junction with two superconducting loops separated by an insulating layer thin enough to allow electrons to pass through.			Manufactured Object	
C124067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124067>	C213472|C159199|C159198	Ripretinib|1-N'-[2,5-difluoro-4-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxyphenyl]-1-N'-phenylcyclopropane-1,1-dicarboxamide|DCC 2618|DCC-2618|DCC2618|KIT/PDGFR Inhibitor DCC-2618|Qinlock|RIPRETINIB	An orally bioavailable switch pocket control inhibitor of wild-type and mutated forms of the tumor-associated antigens (TAA) mast/stem cell factor receptor (SCFR) KIT and platelet-derived growth factor receptor alpha (PDGFR-alpha; PDGFRa), with potential antineoplastic activity. Upon oral administration, ripretinib targets and binds to both wild-type and mutant forms of KIT and PDGFRa specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. This abrogates KIT/PDGFRa-mediated tumor cell signaling and prevents proliferation in KIT/PDGFRa-driven cancers. DCC-2618 also inhibits several other kinases, including vascular endothelial growth factor receptor type 2 (VEGFR2; KDR), angiopoietin-1 receptor (TIE2; TEK), PDGFR-beta and macrophage colony-stimulating factor 1 receptor (FMS; CSF1R), thereby further inhibiting tumor cell growth. KIT and PDGFRa are tyrosine kinase receptors that are upregulated or mutated in a variety of cancer cell types; mutated forms play a key role in the regulation of tumor cell proliferation and resistance to chemotherapy.	Ripretinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124068>	C33904	Solid Organ	An internal organ with firm consistency without a liquid or hollow structural component.			Conceptual Entity	
C124069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124069>	C3824	Papulosquamous Lesion	A skin lesion characterized by the presence of scaly papules and plaques.			Finding	
C12406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12406>	C12405	Pregnant Uterus	A uterus containing one or more viable embryos or fetuses.	Pregnant Uterus		Body Part, Organ, or Organ Component	
C124070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124070>	C27555	Keratosis Pilaris|KP	A very common, non-neoplastic dermatologic disorder characterized by keratinization of hair follicles of the skin. It manifests as small, rough folliculocentric keratotic papules, usually in the outer-upper arms and thighs. It affects children and adolescents and usually improves with age.			Disease or Syndrome	
C124071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124071>	C73539	Desmosine|4-[(4S)-4-Amino-4-Carboxybutyl]-1-[(5S)-5-Amino-5-Carboxypentyl]-3,5-Bis[(3S)-3-Amino-3-Carboxypropyl]Pyridinium|6-{4-[(4S)-4-Amino-4-Carboxybutyl]-3,5-Bis[(3S)-3-Amino-3-Carboxypropyl]-1-Pyridiniumyl}-L-Norleucine|DESMOSINE|Des|Pyridinium, 4-(4-Amino-4-Carboxybutyl)-1-(5-Amino-5-Carboxypentyl)-3,5-Bis(3-Amino-3-Carboxypropyl)-	An amino acid derivative comprised of three allysyl side chains plus one unaltered lysyl side chain from the same or neighboring polypeptides condensed into a pyridinium ring. Desmosine is found in elastin and its detection in urine, plasma, or sputum samples can be used as a marker for excessive elastin degradation, which is associated with chronic obstructive pulmonary disease (COPD) and other pathologies.	Desmosine		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C124072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124072>	C616	Lipid Hydroperoxide|HO2R|LOOH|LPO|ROOH	Highly reactive, non-radical peroxols comprised of a fatty acid modified by a hydroperoxide group (-OOH) that are produced by lipid peroxidation. Lipid hydroperoxides are formed by sequential abstraction of allylic hydrogens from unsaturated fatty acids, which occurs in the presence of reactive oxygen species. These modified lipids can be further modified to create cytotoxic reactive aldehydes, such as malondialdehyde (MDA) and 4-hydroxy-2-nonenal (HNE). Lipid hydroperoxide levels can be measured to assess the extent of oxidative stress.	Lipid Hydroperoxide		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C124073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124073>	C737|C221	Anabasine|(-)-2-(3'-Pyridyl)piperidine|(S)-3-(2-Piperidinyl)pyridine|-(-)-Anabasine|2-(3'-Pyridyl) Piperidine|3-(2-Piperidinyl)pyridine|ANABASINE|L-3-(2'-Piperidyl)pyridine|Neonicotine|Piperidine, 2-(3-Pyridyl)-|Piperidine, 2-(3-Pyridyl)- (8CI)|Pyridine, 3-(2-Piperidinyl)-, (S)-|Pyridine, 3-(2-Piperidinyl)-, (S)- (9CI)|Pyridine, 3-(2-Piperidyl)-|Pyridine, 3-(2-pyridyl) Piperidine|Pyridine, 3-(2S)-2-Piperidinyl-	A nicotine analog that is an alkaloid found in tree tobacco (Nicotiana glauca) and is comprised of a pyridine substituted by a piperidin-2-yl group at position 3. Anabasine has been used as an industrial insecticide and, since it is present in trace amounts in tobacco smoke, its detection in urine can be used as an indicator of exposure to tobacco smoke.	Anabasine		Hazardous or Poisonous Substance|Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C124074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124074>	C17660	FGFR2 Gene Product	A protein encoded by the FGFR2 gene.	FGFR2 Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124075>	C124074	Fibroblast Growth Factor Receptor 2 Isoform IIIb|BFR-1|FGFR-2 IIIb|FGFR2 IIIb|FGFR2(IIIb)|FGFR2-IIIb|FGFR2IIIb|FGFR2b	An isoform of fibroblast growth factor receptor 2 where alternative splicing leads to the expression of the IIIb exon encoding the second half of the third immunoglobulin-like domain, which is located in the extracellular domain of these receptors. This variant is expressed in epithelial lineage cells and has differential ligand binding activity when compared to the IIIa and IIIc forms.	Fibroblast Growth Factor Receptor 2 Isoform IIIb		Amino Acid, Peptide, or Protein|Enzyme|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124076>	C20921	ITLN1 Gene|ITLN1|ITLN1|Intelectin 1 (Galactofuranose Binding) Gene	This gene is involved in the modulation of insulin-dependent signaling.	ITLN1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C124077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124077>	C124076	ITLN1 wt Allele|HL-1|HL1|INTL|ITLN|Intelectin 1 (Galactofuranose Binding) wt Allele|LFR|UNQ640/PRO1270|hIntL	Human ITLN1 wild-type allele is located in the vicinity of 1q21.3 and is approximately 9 kb in length. This allele, which encodes intelectin-1 protein, plays a role in the regulation of insulin-mediated glucose uptake.	ITLN1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124078>	C18515	Intelectin-1|Endothelial Lectin HL-1|Galactofuranose-Binding Lectin|ITLN1|Intelectin|Intelectin 1|Intestinal Lactoferrin Receptor|Lactoferrin Receptor|Omentin	Intelectin-1 (313 aa, ~35 kDa) is encoded by the human ITLN1 gene. This protein is involved in the enhancement of insulin-dependent signaling.	Intelectin-1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124079>	C21550	IFNL4 Gene|IFNL4|IFNL4|Interferon, Lambda 4 (Gene/Pseudogene) Gene	This gene plays a role in antiviral responses and JAK-STAT pathway activation.	IFNL4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C12407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12407>	C13018	Vagina|Genital System, Female, Vagina|VAGINA|Vagina, NOS|Vaginal structure (body structure)|birth canal|vagina|vagina	The female genital canal, extending from the uterus to the vulva.	Vagina		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GCT Authorized Value Terminology|GCT Biopsy/Surgical Procedures Table|GCT Radiation Therapy Table|GCT Tumor Assessment Table|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C124080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124080>	C124079	IFNL4 wt Allele|IFNAN|Interferon, Lambda 4 (Gene/Pseudogene) wt Allele|Interferon, Lambda-4 Gene	Human IFNL4 wild-type allele is located in the vicinity of 19q13.2 and is approximately 3 kb in length. This allele, which encodes interferon lambda-4 protein, is involved in JAK-STAT pathway activation and the antiviral response. Mutation of the gene is associated with susceptibility to hepatitis C virus (HCV) infection.	IFNL4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124081>	C20464	Interferon Lambda-4|IFN-Lambda-4|IFNL4	Interferon lambda-4 (179 aa, ~20 kDa) is encoded by the human IFNL4 gene. This protein plays a role in JAK-STAT pathway-mediated antiviral responses.	Interferon Lambda-4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124082>	C20912	IL18R1 Gene|IL18R1|IL18R1|Interleukin 18 Receptor 1 Gene	This gene is involved in interleukin-mediated signaling.	IL18R1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C124083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124083>	C124082	IL18R1 wt Allele|CD218a|CDw218a|IL-18 Receptor Alpha Gene|IL-1Rrp|IL18RA|IL1RRP|Interleukin 18 Receptor 1 wt Allele|Interleukin 18 Receptor, Alpha Chain Gene	Human IL18R1 wild-type allele is located in the vicinity of 2q12 and is approximately 87 kb in length. This allele, which encodes interleukin-18 receptor 1 protein, plays a role in interleukin-18 binding and signal transduction.	IL18R1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124084>	C17667	Interleukin-18 Receptor 1|CD218 Antigen-Like Family Member A|CD218a|CD218a Antigen|IL-18R-1|IL-18R1|IL-1Rrp|IL1 Receptor-Related Protein|IL1R-rp	Interleukin-18 receptor 1 (541 aa, ~62 kDa) is encoded by the human IL18R1 gene. This protein is involved in both interleukin-18 binding and the regulation of NF-kB signaling.	Interleukin-18 Receptor 1		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124085>	C54443	Geopolitical Entities, Names, and Codes Terminology|GENC Terminology	Codes for the representation of names of countries and their subdivisions that have been approved by the US Board on Geographic Names.			Intellectual Product	
C124086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124086>	C29936	TIMP4 Gene|TIMP Metallopeptidase Inhibitor 4 Gene|TIMP4|TIMP4	This gene plays a role in the inhibition of matrix metalloproteinases.	TIMP4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C124087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124087>	C124086	TIMP4 wt Allele|TIMP Metallopeptidase Inhibitor 4 wt Allele	Human TIMP4 wild-type allele is located in the vicinity of 3p25 and is approximately 6 kb in length. This allele, which encodes metalloproteinase inhibitor 4 protein, is involved in the regulation of extracellular matrix degradation.	TIMP4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124088>	C17544	Metalloproteinase Inhibitor 4|TIMP-4|Tissue Inhibitor of Metalloproteinase 4|Tissue Inhibitor of Metalloproteinases 4	Metalloproteinase inhibitor 4 (224 aa, ~26 kDa) is encoded by the human TIMP4 gene. This protein plays a role in the inhibition of matrix metalloproteinases.	Metalloproteinase Inhibitor 4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124089>	C28404	USP28 Gene|USP28|USP28|Ubiquitin Specific Peptidase 28 Gene	This gene plays a role in both protein deubiquitination and DNA damage responses.	USP28 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C12408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12408>	C13018	Vulva|External Genitalia|VULVA|Vulva, NOS|Vulval structure (body structure)|female pudendum|mammalian vulva|mammalian vulva|puboperineal region|pudendum femininum|vulva|vulva	The external, visible part of the female genitalia surrounding the urethral and vaginal opening. The vulva includes the clitoris and inner as well as outer labia.	Vulva		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C124090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124090>	C124089	USP28 wt Allele|KIAA1515|Ubiquitin Specific Peptidase 28 wt Allele|Ubiquitin Specific Protease 28 Gene	Human USP28 wild-type allele is located in the vicinity of 11q23 and is approximately 78 kb in length. This allele, which encodes ubiquitin carboxyl-terminal hydrolase 28 protein, is involved in the DNA damage checkpoint and protein deubiquitination.	USP28 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124091>	C16481	Ubiquitin Carboxyl-Terminal Hydrolase 28|Deubiquitinating Enzyme 28|EC 3.4.19.12|USP28|Ubiquitin Thioesterase 28|Ubiquitin-Specific-Processing Protease 28	Ubiquitin carboxyl-terminal hydrolase 28 (1077 aa, ~122 kDa) is encoded by the human USP28 gene. This protein plays a role in both protein deubiquitination and cellular responses to DNA damage.	Ubiquitin Carboxyl-Terminal Hydrolase 28		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124092>	C20917	RIF1 Gene|RIF1|RIF1|Replication Timing Regulatory Factor 1 Gene	This gene is involved in checkpoint-mediated cell cycle arrest.	RIF1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C124093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124093>	C124092	RIF1 wt Allele|FLJ10599|FLJ12870|RAP1 Interacting Factor Homolog (Yeast) Gene|RAP1-Interacting Factor, 1, Yeast, Homolog of Gene|Replication Timing Regulatory Factor 1 wt Allele	Human RIF1 wild-type allele is located in the vicinity of 2q23.3 and is approximately 98 kb in length. This allele, which encodes Telomere-associated protein RIF1, plays a role in the DNA damage checkpoint.	RIF1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124094>	C17761	Telomere-Associated Protein RIF1|Rap1-Interacting Factor 1 Homolog	Telomere-associated protein RIF1 (2472 aa, ~274 kDa) is encoded by the human RIF1 gene. This protein is involved in DNA damage-induced cell cycle arrest.	Telomere-Associated Protein RIF1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124095>	C21282|C19676	NEIL1 Gene|NEIL1|NEIL1|Nei-Like DNA Glycosylase 1 Gene	This gene plays a role in base excision repair of DNA.	NEIL1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C124096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124096>	C124095	NEIL1 wt Allele|DNA Endonuclease Eight-Like Glycosylase 1 Gene|FLJ22402|FPG1|NEI1|Nei Endonuclease VIII-Like 1 (E. coli) Gene|Nei-Like DNA Glycosylase 1 wt Allele|hFPG1	Human NEIL1 wild-type allele is located in the vicinity of 15q24.2 and is approximately 10 kb in length. This allele, which encodes endonuclease 8-like 1 protein, is involved in the repair of damaged or mismatched DNA.	NEIL1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124097>	C21170|C16804	Endonuclease 8-Like 1|DNA Glycosylase/AP Lyase Neil1|DNA-(Apurinic Or Apyrimidinic Site) Lyase Neil1|EC 3.2.2.-|EC 4.2.99.18|Endonuclease VIII|Endonuclease VIII-Like 1|FPG1|NEH1|NEIL1|Nei Homolog 1	Endonuclease 8-like 1 (390 aa, ~44 kDa) is encoded by the human NEIL1 gene. This protein plays a role in base excision-based repair of DNA.	Endonuclease 8-Like 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124098>	C19676	UIMC1 Gene|UIMC1|UIMC1|Ubiquitin Interaction Motif Containing 1 Gene	This gene is involved in ubiquitin binding and DNA damage responses.	UIMC1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C124099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124099>	C124098	UIMC1 wt Allele|RAP80|RXRIP110|Receptor-Associated Protein, 80-kD Gene|Ubiquitin Interaction Motif Containing 1 wt Allele|X2HRIP110	Human UIMC1 wild-type allele is located in the vicinity of 5q35.2 and is approximately 118 kb in length. This allele, which encodes BRCA1-A complex subunit RAP80 protein, plays a role in DNA damage responses and binding to ubiquitinated histones.	UIMC1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12409>	C13018	Penis|Genital System, Male, Penis|PENIS|Penile structure (body structure)|Penis, NOS|penis|penis	The male organ of urination and copulation.	Penis		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C1240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1240>	C47794	Sumatriptan|SUMATRIPTAN	A sulfonamide triptan with vasoconstrictor activity. Sumatriptan selectively binds to and activates serotonin 5-HT1D receptors in the central nervous system (CNS), thereby constricting cerebral blood vessels. This may lead to a relief in pain from vascular headaches. Sumatriptan may also relieve vascular headaches by decreasing the release of vasoactive neuropeptides from perivascular trigeminal axons in the dura mater during a migraine, by reducing extravasation of plasma proteins, and by decreasing the release of other mediators of inflammation from the trigeminal nerve.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C124100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124100>	C21170	BRCA1-A Complex Subunit RAP80|Receptor Associated Protein 80|Receptor-Associated Protein 80|Retinoid X Receptor Interacting Protein|Retinoid X Receptor-Interacting Protein 110|UIMC1|Ubiquitin Interaction Motif-Containing Protein 1	BRCA1-A complex subunit RAP80 (719 aa, ~80 kDa) is encoded by the human UIMC1 gene. This protein is involved in the recognition of damaged DNA.	BRCA1-A Complex Subunit RAP80		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124101>	C25952|C19676	GEN1 Gene|GEN1|GEN1|GEN1 Holliday Junction 5' Flap Endonuclease Gene	This gene plays a role in the resolution of Holliday junctions.	GEN1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C124102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124102>	C124101	GEN1 wt Allele|FLJ40869|GEN1 Holliday Junction 5' Flap Endonuclease wt Allele|GEN1, Drosophila, Homolog of Gene|Gen|Gen Endonuclease Homolog 1 (Drosophila) Gene|Gen Homolog 1, Endonuclease Gene	Human GEN1 wild-type allele is located in the vicinity of 2p24.2 and is approximately 35 kb in length. This allele, which encodes flap endonuclease GEN homolog 1 protein, is involved in chromosome replication.	GEN1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124103>	C21170|C16561	Flap Endonuclease GEN Homolog 1|EC 3.1.-.-|GEN1|GEN1 Holliday Junction 5 Flap Endonuclease|Gen Endonuclease Homolog 1|Holliday Junction Resolvase	Flap endonuclease GEN homolog 1 (908 aa, ~103 kDa) is encoded by the human GEN1 gene. This protein plays a role in homologous recombination and DNA repair.	Flap Endonuclease GEN Homolog 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124104>	C19676	BABAM2 Gene|BABAM2|BABAM2|BRE|BRISC and BRCA1 A Complex Member 2 Gene	This gene is involved in the cellular response to DNA damage and binding to ubiquitinated histones.	BABAM2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C124105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124105>	C124104	BABAM2 wt Allele|BRCC4|BRCC45|BRE|BRISC and BRCA1 A Complex Member 2 wt Allele|Brain and Reproductive Organ-Expressed (TNFRSF1A Modulator) Gene	Human BABAM2 wild-type allele is located in the vicinity of 2p23.2 and is approximately 449 kb in length. This allele, which encodes BRISC and BRCA1-A complex member 2 protein, plays a role in the recognition of damaged DNA.	BABAM2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124107>	C21170	BRISC and BRCA1-A Complex Member 2|BABAM2|BRCA1-A Complex Subunit BRE|BRCA1/BRCA2-Containing Complex Subunit 45|BRCA1/BRCA2-Containing Complex, Subunit 4|Brain and Reproductive Organ-Expressed Protein	BRISC and BRCA1-A complex member 2 (383 aa, ~43 kDa) is encoded by the human BABAM2 gene. This protein is involved in binding to ubiquitinated histones.	BRISC and BRCA1-A Complex Member 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124109>	C21275	BRCC3 Gene|BRCA1/BRCA2-Containing Complex, Subunit 3 Gene|BRCC3|BRCC3	This gene plays a role in the deubiquitination of histones.	BRCC3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C12410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12410>	C12712	Prostate Gland|GLAND, PROSTATE|Genital System, Male, Prostate|PROSTATE GLAND|Prostate|Prostate|Prostate|Prostate|Prostate gland|Prostatic Gland|Prostatic structure (body structure)|male prostate|prostate|prostate|prostate gland	The walnut shaped accessory sex gland of the male reproductive system. It is located in the pelvis just below the bladder, surrounding the prostatic part of the urethra. The prostate gland secretes a fluid which is part of the semen.	Prostate		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C124110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124110>	C124109	BRCC3 wt Allele|BRCA1/BRCA2-Containing Complex, Subunit 3 wt Allele|BRCC36|C6.1A|CXorf53|Chromosome X Open Reading Frame 53 Gene	Human BRCC3 wild-type allele is located in the vicinity of Xq28 and is approximately 52 kb in length. This allele, which encodes Lys-63-specific deubiquitinase BRCC36 protein, is involved in histone deubiquitination and DNA repair.	BRCC3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124111>	C16843	Lys-63-Specific Deubiquitinase BRCC36|BRCA1-A Complex Subunit BRCC36|BRCA1/BRCA2-Containing Complex Subunit 3|BRCA1/BRCA2-Containing Complex Subunit 36|BRCC3|BRISC Complex Subunit BRCC36|EC 3.4.19.-	Lys-63-specific deubiquitinase BRCC36 (316 aa, ~36 kDa) is encoded by the human BRCC3 gene. This protein plays a role in DNA repair and the removal of ubiquitin from histones.	Lys-63-Specific Deubiquitinase BRCC36		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124112>	C19676	BABAM1 Gene|BABAM1|BABAM1|BRISC and BRCA1 A Complex Member 1 Gene	This gene is involved in the formation of the BRISC and BRCA1-A complex.	BABAM1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C124113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124113>	C124112	BABAM1 wt Allele|BRISC and BRCA1 A Complex Member 1 wt Allele|C19orf62|Chromosome 19 Open Reading Frame 62 Gene|FLJ20571|HSPC142|MERIT40|Mediator of Rap80 Interactions and Targeting, 40-KD Gene|NBA1|New Component of BRCAA1 A Complex Gene	Human BABAM1 wild-type allele is located in the vicinity of 19p13.11 and is approximately 14 kb in length. This allele, which encodes BRISC and BRCA1-A complex member 1 protein, plays a role in DNA repair.	BABAM1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124114>	C21170	BRISC and BRCA1-A Complex Member 1|BABAM1|BRCA1-A Complex Subunit MERIT40|Mediator of RAP80 Interactions and Targeting Subunit of 40 kDa|Mediator of Rap80 Interactions and Targeting 40 KD|Mediator of Rap80 Interactions and Targeting 40 kDa|New Component of the BRCA1 A Complex|New Component of the BRCA1-A Complex|New Component of the BRCAA1 A Complex	BRISC and BRCA1-A complex member 1 (329 aa, ~37 kDa) is encoded by the human BABAM1 gene. This protein is involved in the modulation of BRCA1-mediated double-strand break repair.	BRISC and BRCA1-A Complex Member 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124115>	C28533	SLC3A2 Gene|SLC3A2|SLC3A2|Solute Carrier Family 3 Member 2 Gene	This gene plays a role in promoting the transport of amino acids.	SLC3A2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C124116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124116>	C124115	SLC3A2 wt Allele|4F2|4F2HC|4T2HC|Antigen Defined By Monoclonal Antibody 4F2, Heavy Chain Gene|Antigen Identified by Monoclonal Antibodies 4F2, TRA1.10, TROP4, and T43 Gene|CD98|CD98HC|MDU1|NACAE|Solute Carrier Family 3 (Activator of Dibasic and Neutral Amino Acid Transport), Member 2 Gene|Solute Carrier Family 3 (Activators of Dibasic and Neutral Amino Acid Transport), Member 2 Gene|Solute Carrier Family 3 (Amino Acid Transporter Heavy Chain), Member 2 Gene|Solute Carrier Family 3 Member 2 wt Allele	Human SLC3A2 wild-type allele is located in the vicinity of 11q12.3 and is approximately 33 kb in length. This allele, which encodes amino acid transporter heavy chain SLC3A2 protein, is involved in amino acid transport.	SLC3A2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124117>	C16386	Amino Acid Transporter Heavy Chain SLC3A2|4F2 Cell-Surface Antigen Heavy Chain|4F2 Cell-Surface Antigen Heavy Chain|4F2 Heavy Chain|4F2 Heavy Chain Antigen|4F2hc|Antigen Defined By Monoclonal Antibody 4F2|CD98 Antigen|CD98 Heavy Chain|Lymphocyte Activation Antigen 4F2 Large Subunit|Monoclonal Antibody 44D7 Antigen|SLC3A2|Solute Carrier Family 3 Member 2	Amino acid transporter heavy chain SLC3A2 (630 aa, ~68 kDa) is encoded by the human SLC3A2 gene. This protein plays a role in the positive regulation of amino acid transport.	4F2 Cell-Surface Antigen Heavy Chain		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124118>	C16615	HOXC9 Gene|HOXC9|HOXC9|Homeobox C9 Gene	This gene is involved in the regulation of gene transcription and anterior-posterior patterning.	HOXC9 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C124119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124119>	C124118	HOXC9 wt Allele|HOX3|HOX3B|Homeo Box C9 Gene|Homeobox 3B Gene|Homeobox C9 wt Allele|Hox-3.2, Mouse, Homolog of Gene	Human HOXC9 wild-type allele is located in the vicinity of 12q13.3 and is approximately 8 kb in length. This allele, which encodes homeobox protein Hox-C9, plays a role in the modulation of anterior-posterior axis formation.	HOXC9 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124120>	C17207	Homeobox Protein Hox-C9|Homeobox Protein Hox-3B	Homeobox protein Hox-C9 (260 aa, ~29 kDa) is encoded by the human HOXC9 gene. This protein is involved in anterior-posterior axis specification.	Homeobox Protein Hox-C9		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124121>	C16615	HOXC5 Gene|HOXC5|HOXC5|Homeobox C5 Gene	This gene plays a role in anterior-posterior axis specification.	HOXC5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C124122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124122>	C124121	HOXC5 wt Allele|CP11|HOX3|HOX3D|Homeo Box C5 Gene|Homeobox 3D Gene|Homeobox C5 wt Allele|Hox-6.2, Mouse, Homolog of Gene	Human HOXC5 wild-type allele is located in the vicinity of 12q13.3 and is approximately 19 kb in length. This allele, which encodes homeobox protein Hox-C5, is involved in the regulation of gene transcription and anterior-posterior patterning.	HOXC5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124123>	C17207	Homeobox Protein Hox-C5|Homeobox Protein CP11|Homeobox Protein Hox-3D	Homeobox protein Hox-C5 (222 aa, ~25 kDa) is encoded by the human HOXC5 gene. This protein plays a role in the modulation of anterior-posterior axis formation.	Homeobox Protein Hox-C5		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124124>	C28533	SLC16A3 Gene|SLC16A3|SLC16A3|Solute Carrier Family 16 (Monocarboxylate Transporter), Member 3 Gene	This gene is involved in transmembrane transport of monocarboxylates.	SLC16A3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C124125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124125>	C124124	SLC16A3 wt Allele|MCT 3|MCT 4|MCT-3|MCT-4|MCT3|MCT4|Solute Carrier Family 16 (Monocarboxylate Transporter), Member 3 wt Allele|Solute Carrier Family 16 (Monocarboxylic Acid Transporters), Member 3 Gene|Solute Carrier Family 16, Member 3 (Monocarboxylic Acid Transporter 4) Gene	Human SLC16A3 wild-type allele is located in the vicinity of 17q25 and is approximately 33 kb in length. This allele, which encodes monocarboxylate transporter 4 protein, plays a role in monocarboxylate transport.	SLC16A3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124126>	C16386	Monocarboxylate Transporter 4|MCT 4|Monocarboxylate Transporter 3|SLC16A3|Solute Carrier Family 16 Member 3	Monocarboxylate transporter 4 (465 aa, ~49 kDa) is encoded by the human SLC16A3 gene. This protein is involved in the transport of monocarboxylates.	Monocarboxylate Transporter 4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124127>	C20130	Protein Disulfide-Isomerase Family|EC 5.3.4.1|PDI|PDI Family|Protein Disulfide Isomerase|Protein Disulfide Isomerase Family|Protein Disulfide-Isomerase	A family of isomerase enzymes that reside in the endoplasmic reticulum and act as chaperones during protein folding. They catalyze the rearrangement of disulfide bonds between cysteine residues within proteins as they undergo the folding step of protein maturation.	Protein Disulfide-Isomerase Family		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124128>	C16295	Tumor Antigen-specific Antibody|Anti-TAA Antibody|Anti-Tumor Antibody|Anti-Tumor Antigen Antibody|Anti-Tumor-Associated Antigen Antibody|Tumor-Associated Antigen Antibody|Tumor-Specific Antibody	Any antibody that recognizes antigens that are overexpressed by, mutated in, or predominantly expressed by tumors compared with normal tissues.	Tumor Antigen-specific Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Agent Terminology|CTRP Biomarker Terminology|CTRP Terminology
C124129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124129>	C21176|C16447	Type I Collagen|Collagen 1|Collagen I|Collagen Type 1|Collagen Type I|Type 1 Collagen	A heterotrimeric fibrillar protein complex comprised of two collagen alpha-1(I) chains and one collagen alpha-2(I) chains. Type I collagen is the most abundant fibrillar collagen in humans and is present in scar tissue, tendons, ligaments, bone, dermis, dentin, and organ capsules.	Type I Collagen		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12412>	C12725	Testis|Genital System, Male, Testis|TESTIS|Testes|Testicle|Testicle|Testicle|Testicles|Testis structure (body structure)|Testis, NOS|gonad of male genitalia|gonad of male reproductive system|male gonad|testicle|testicle|testis|testis	Either of the paired male reproductive glands that produce the male germ cells and the male hormones.	Testis		Body Part, Organ, or Organ Component	ALL Authorized Value Terminology|ALL Disease Characteristics Table|ALL Radiation Therapy Table|AML Authorized Value Terminology|AML Disease Characteristics Table|AML Myeloid Sarcoma Involvement Table|CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTDC Value Terminology|GCT Authorized Value Terminology|GCT Biopsy/Surgical Procedures Table|GCT Radiation Therapy Table|GCT Tumor Assessment Table|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C124130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124130>	C150493	CXCR4 WHIM-Like Mutation|C-X-C Chemokine Receptor Type 4 WHIM-Like Mutation|CXCR-4 WHIM-Like Mutation|Chemokine (C-X-C Motif) Receptor 4 WHIM-Like Mutation	Somatic point mutations or frameshift mutations in the CXCR4 gene that result in the truncation of between 10 and 19 amino acid residues from the carboxyl terminus of C-X-C chemokine receptor type 4 protein (CXCR-4) and are associated with Waldenstrom Macroglobulinemia. These mutations are similar to those found in the hereditary disease WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome and encode a constitutively active form of the CXCR-4 protein.	CXCR4 WHIM-Like Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124131>	C177182|C129820	Grapiprant|AAT-007|AT-001|CJ 023,423|CJ-023,423|CJ023,423|GRAPIPRANT|N-[[2,4-(2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenylethylamino]carbonyl]-4-methyl-benzenesulfonamide|RQ-00000007|RQ-07	An orally bioavailable antagonist of the prostaglandin E receptor subtype 4 (EP4), with potential analgesic, immunomodulating and antineoplastic activities. Upon administration of grapiprant, this agent selectively binds to and inhibits the binding of prostaglandin E2 (PGE2) and prevents the activation of the EP4 receptor. This inhibits PGE2-EP4 receptor-mediated signaling and prevents proliferation in tumor cells in which the PGE2-EP4 signaling pathway is over-activated. In addition, EP4 receptor inhibition modulates the immune system by preventing both interleukin-23 (IL-23) production and the IL-23-mediated expansion of Th17 cells. As EP4 is expressed by peripheral sensory neurons, blockade of EP4-mediated signaling may induce an analgesic effect. EP4, a prostanoid receptor subtype, is a G protein-coupled receptor that is expressed in certain types of cancers; it promotes tumor cell proliferation and invasion.	Grapiprant		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124132>	C200765	Anti-CD133-CAR Vector-transduced Allogeneic T Lymphocytes|Allogeneic Anti-CD133 CAR T Cells|Allogeneic CART133	A preparation of allogeneic peripheral blood T-lymphocytes (PBTL) that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the chimeric CD (cluster of differentiation) 133 antigen receptor, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD133-CAR vector-transduced allogeneic T-lymphocytes specifically recognize and kill CD133-expressing tumor cells. CD133, a tumor associated antigen (TAA), is overexpressed on a variety of tumor cell types.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124133>	C129823	Tamrintamab Pamozirine|ADC SC-003|Immunoglobulin G1(226-serine), Anti-(Human Dipeptidase 3)(Human-mus musculus Monoclonal sc34.28SS1 Gamma1-chain), Compd. with Human-mus musculus Monoclonal sc34.28SS1 Kappa-chain, Dimer, Bis(thioether) with N-(6-(3-mercapto-2, 5-dioxo-1-pyrrolidinyl)-1|SC 003|SC-003|SC003|TAMRINTAMAB PAMOZIRINE	An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody against dipeptidase 3 (DPEP3) conjugated, via a plasma-stable valine-alanine dipeptide linker, to a cytotoxic pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of tamrintamab pamozirine targets DPEP3 expressed on tumor cells. Upon binding and internalization, the cytotoxic, DNA cross-linking PBD moiety is released. This inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of DPEP3-expressing tumor cells. DPEP3, a membrane-bound glycoprotein, is overexpressed in some ovarian cancers.	Tamrintamab Pamozirine		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124134>	C211912	Samrotamab Vedotin|ABBV-085|ADC ABBV-085|PR-1498487 PAB-MMAE|SAMROTAMAB VEDOTIN	An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against leucine-rich repeat containing 15 (LRRC15) linked, via the protease-cleavable valine-citrulline linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of samrotamab vedotin, the samrotamab moiety targets and binds to LRRC15 expressed on cancer-associated fibroblasts (CAFs) and tumor cells. Upon binding and internalization, MMAE is released after proteolytic cleavage. MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in LRRC15-expressing CAFs and tumor cells. LRRC15, a type I membrane protein and a member of the LRR superfamily, is highly expressed on CAFs in the tumor microenvironment (TME) within some tumor stroma and on tumor cells in certain tumors.	Samrotamab Vedotin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124136>	C25285	Outer Diameter|Outer/Greatest Diameter	The longest possible length of a straight line passing through the center of a circular or spheroid object that connects two points on the outer circumference.			Spatial Concept	FDA CDRH GUDID Terminology
C124137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124137>	C6967|C115196	Childhood Pineal Parenchymal Tumor of Intermediate Differentiation	A pineal parenchymal tumor of intermediate differentiation that occurs during childhood.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C124138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124138>	C25404	Exacerbation|EXACERBATION	A worsening of a problem, condition, or disease.			Activity	CDISC SDTM Medical History Event Date Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124139>	C38186	Production Assistance for Cellular Therapies|PACT	An initiative of the National Heart, Lung, and Blood Institute (NHLBI) for the establishment of a coordinating center and facilities for the production and testing of novel cell therapies.			Organization	
C12413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12413>	C12919	Urinary System|Body System, Renal/Urologic|Organ System, Renal/Urologic|Renal/Urologic Body System|Renal/Urologic Organ System|URINARY SYSTEM|Urinary system, NOS|Urologic/Renal Body System|renal system|urinary system|urinary tract	The organs involved in the creation and excretion of urine.	Urinary System		Body System	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C124141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124141>	C15656	Spinal Cord Decompression|Spinal Decompression Surgery	Any of various procedures intended to relieve symptoms caused by pressure on the spinal cord and/or nerve roots.			Therapeutic or Preventive Procedure	
C124142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124142>	C16502	Cardiac Ventriculography|Invasive contrast left ventriculography	A medical imaging test that involves injecting contrast media into the heart's ventricle(s) to determine a patient's cardiac function.			Diagnostic Procedure	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 7: Diagnostic Procedures Terminology
C124143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124143>	C43419	Cardiac Stem Cell|CPC|Cardiac Progenitor Cell|Cardiac Progenitor Cell|Endogenous Cardiac Stem Cell|eCSC	Multipotent progenitor cells that are found in the fetal and adult heart that provide the myocardium with limited regenerating capability.			Cell	
C124144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124144>	C12977	Induced Pluripotent Stem Cell|iPSC	Adult cells that have been genetically reprogrammed to an embryonic stem cell-like state by the expression of genes and factors important for maintaining the defining properties of embryonic stem cells.			Cell	
C124145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124145>	C115116	Endothelial Progenitor Cell|CEP|Circulating Endothelial Progenitor Cell|EPC|Endothelial Precursor Cell|Endothelial Stem Cell	Circulating cells that express a variety of cell surface markers similar to those expressed by vascular endothelial cells, adhere to endothelium at sites of hypoxia or ischemia, and participate in new vessel formation.			Cell	
C124146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124146>	C43423	Human Umbilical Cord Perivascular Cell|HUCPVC	Mesenchymal stem cells isolated from umbilical cord blood capable of high proliferation potential and colony formation capacity in vitro and the ability to proliferate and differentiate to an osteogenic phenotype in culture.			Cell	
C124147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124147>	C217121	Symptom Distress Scale|SDS|Symptom Distress Scale (SDS)|Symptom Scale	A patient reported questionnaire composed of rating scales developed to measure the degree of distress experienced by the patient for specific symptoms.			Intellectual Product	HL Authorized Value Terminology|HL Patient Reported Outcomes Metadata Table
C124148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124148>	C177162	Seldom Have Nausea|I seldom if ever have nausea	A response indicating that an individual seldom, if ever, has or had nausea.			Intellectual Product	How Much Nausea During This Period Question
C124149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124149>	C177162	Have Nausea Once in a While|I have nausea once in a while	A response indicating that an individual has or had nausea once in a while.			Intellectual Product	How Much Nausea During This Period Question
C12414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12414>	C13018	Bladder|BLADDER|Bladder, NOS|Bladder, NOS|URINARY BLADDER|Urinary Bladder|Urinary Bladder|Urinary System, Bladder|Urinary bladder structure (body structure)|bladder|urinary bladder|vesica urinaria	The distensible sac-like organ that functions as a reservoir of urine, collecting from the kidneys and eliminating via the urethra.	Bladder		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C124150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124150>	C177162	Have Nausea Fairly Often|I have nausea fairly often	A response indicating that an individual has or had nausea fairly often.			Intellectual Product	How Much Nausea During This Period Question
C124151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124151>	C177162	Have Nausea at Least Half the Time|I have nausea half the time at least	A response indicating that an individual has or had nausea half the time at least.			Intellectual Product	How Much Nausea During This Period Question
C124152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124152>	C177162	Have Nausea Continually|I have nausea continually	A response indicating that an individual has or had nausea continually.			Intellectual Product	How Much Nausea During This Period Question
C124153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124153>	C173130	Nausea Distress Question|Nausea Distress|Nausea Effect|Nausea Severity	A question about how nausea effects an individual.			Intellectual Product	Symptom Distress Scale
C124154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124154>	C177162	Have Very Mild Nausea|When I do have nausea, it is very mild	A response indicating that when an individual has or had nausea, it was very mild.			Intellectual Product	Nausea Distress Question
C124155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124155>	C177162	Have Mildly Distressing Nausea|When I do have nausea, it is mildly distressing	A response indicating that when an individual has or had nausea, it was mildly distressing.			Intellectual Product	Nausea Distress Question
C124156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124156>	C177162	Have Nausea Feel Pretty Sick|When I have nausea, I feel pretty sick	A response indicating that when an individual has or had nausea, they felt pretty sick.			Intellectual Product	Nausea Distress Question
C124157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124157>	C177162	Have Nausea Usually Feel Very Sick|When I have nausea, I usually feel very sick	A response indicating that when an individual has or had nausea, they usually felt very sick.			Intellectual Product	Nausea Distress Question
C124158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124158>	C177162	Have Nausea Am as Sick as I Could Possibly Be|When I have nausea, I am as sick as I could possibly be	A response indicating that when an individual has or had nausea, they were as sick as they could possibly be.			Intellectual Product	Nausea Distress Question
C124159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124159>	C173348	Appetite Quality Question|Appetite|Appetite Distress|Appetite Quality	A question about the state of an individual's appetite.			Intellectual Product	Symptom Distress Scale
C12415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12415>	C13018	Kidney|KIDNEY|Kidney structure (body structure)|Kidney, NOS|Kidneys|Urinary System, Kidney|kidney|kidney	One of the two bean-shaped organs located on each side of the spine in the retroperitoneum. The right kidney is located below the liver and the left kidney below the diaphragm. The kidneys filter and secrete metabolic products and minerals from the blood, thus maintaining homeostasis. On the superior pole of each kidney there is an adrenal gland. Each kidney and adrenal gland is surrounded by fat.	Kidney		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Terminology|CTDC Value Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C124160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124160>	C226628	Have Normal Appetite and Enjoy Good Food|I have my normal appetite and enjoy good food	A response indicating that an individual has or had a normal appetite and enjoyed good food.			Intellectual Product	Appetite Quality Question
C124161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124161>	C226628	Appetite is Usually Good but Not Always|My appetite is usually, but not always, pretty good	A response indicating that an individual has or had an appetite that was usually good but not always good.			Intellectual Product	Appetite Quality Question
C124162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124162>	C226628	Don't Really Enjoy Food|I don't really enjoy my food	A response indicating that an individual does not really enjoy food.			Intellectual Product	Appetite Quality Question
C124163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124163>	C226628	Have to Force Myself to Eat|I have to force myself to eat my food	A response indicating that an individual has or had to force themselves to eat their food.			Intellectual Product	Appetite Quality Question
C124164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124164>	C226628	Cannot Stand Thought of Food|I cannot stand the thought of food	A response indicating that an individual cannot stand the thought of food.			Intellectual Product	Appetite Quality Question
C124165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124165>	C172932	Sleep as Well as Always|I sleep as well as I always have	A response indicating that an individual sleeps or slept as well as they always have.			Intellectual Product	Sleep Quality Question
C124166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124166>	C172932	Occasionally Have Trouble Getting to Sleep and Staying Asleep|I occasionally have trouble getting to sleep and staying asleep	A response indicating that an individual occasionally has or had trouble getting to sleep and staying asleep.			Intellectual Product	Sleep Quality Question
C124167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124167>	C172932	Frequently Have Trouble Getting to Sleep|I frequently have trouble getting to sleep	A response indicating that an individual frequently has or had trouble getting to sleep.			Intellectual Product	Sleep Quality Question
C124168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124168>	C176243|C172932	Have Difficulty Getting to Sleep and Staying Asleep	A response indicating that an individual has or had difficulty getting to sleep and staying asleep almost every night.			Intellectual Product	
C124169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124169>	C172932	Almost Impossible to Get a Decent Night's Sleep|It is almost impossible for me to get a decent night's sleep	A response indicating that it is or was almost impossible for an individual to get a decent night's sleep.			Intellectual Product	Sleep Quality Question
C12416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12416>	C13018	Ureter|URETER|Ureteric structure (body structure)|ureter|ureter	The thick-walled tube that carries urine from each kidney to the bladder.	Ureter		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C124170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124170>	C176246|C176245	Almost Never Have Pain|I almost never have pain	A response indicating that an individual almost never has or had pain.			Intellectual Product	Frequency of Pain Question
C124171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124171>	C176246	Have Pain Once in a While|I have pain once in a while	A response indicating that an individual has or had pain once in a while.			Intellectual Product	Frequency of Pain Question
C124172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124172>	C176246	Have Pain Several Times a Week|I have pain several times a week	A response indicating that an individual has or had pain several times a week.			Intellectual Product	Frequency of Pain Question
C124173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124173>	C176246	Usually in Some Degree of Pain|I am usually in some degree of pain|Usually in Some Pain	A response indicating that an individual usually is or was in some degree of pain.			Intellectual Product	Frequency of Pain Question
C124174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124174>	C176246	In Some Degree of Pain Almost Constantly|I am in some degree of pain almost constantly|In Some Pain Almost Constantly	A response indicating that an individual is or was some degree of pain almost constantly.			Intellectual Product	Frequency of Pain Question
C124175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124175>	C173346	Pain Distress Question|Pain|Pain Distress|Pain Intensity|Pain Severity|Severity of Pain	A question about the intensity of an individual's pain.			Intellectual Product	Symptom Distress Scale
C124176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124176>	C176246	Have Very Mild Pain|When I do have pain, it is very mild	A response indicating that when an individual has or had pain, it was very mild.			Intellectual Product	Pain Distress Question
C124177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124177>	C176246	Have Mildly Distressing Pain|When I do have pain, it is mildly distressing	A response indicating that when an individual has or had pain, was mildly distressing.			Intellectual Product	Pain Distress Question
C124178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124178>	C176246	Usually Have Fairly Intense Pain|When I do have pain, it is usually fairly intense	A response indicating that when an individual has or had pain, it was usually fairly intense.			Intellectual Product	Pain Distress Question
C124179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124179>	C176246	Have Very Intense Pain|The pain I have is very intense	A response indicating that an individual's pain is or was very intense.			Intellectual Product	Pain Distress Question
C12417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12417>	C13018	Urethra|URETHRA|Urethral structure (body structure)|urethra|urethra	The tube carrying urine from the bladder to outside of the body.	Urethra		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C124180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124180>	C176246	Have Almost Unbearable Pain|The pain I have is almost unbearable	A response indicating that an individual's pain is or was almost unbearable.			Intellectual Product	Pain Distress Question
C124181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124181>	C226740	Seldom Feel Tired or Fatigued|I seldom feel tired or fatigued	A response indicating that an individual seldom feels or felt tired or fatigued.			Intellectual Product	Feel Fatigue Question
C124182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124182>	C226740	Have Periods When Rather Tired or Fatigued|There are periods when I am rather tired or fatigued	A response indicating that an individual has or had periods when they were rather tired or fatigued.			Intellectual Product	Feel Fatigue Question
C124183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124183>	C226740	Have Periods When Quite Tired or Fatigued|There are periods when I am quite tired and fatigued	A response indicating that an individual has or had periods when they were quite tired and fatigued.			Intellectual Product	Feel Fatigue Question
C124184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124184>	C226740	Usually Very Tired and Fatigued|I am usually very tired and fatigued	A response indicating that an individual is or was usually very tired and fatigued.			Intellectual Product	Feel Fatigue Question
C124185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124185>	C226740|C226668	Feel Exhausted Most of the Time|Most of the time, I feel exhausted	A response indicating that an individual feels or felt exhausted most of the time.			Intellectual Product	Feel Fatigue Question
C124186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124186>	C173938	Pattern of Bowel Movements Question|Bowel|Bowel Pattern|Bowel Pattern Distress|Pattern of Bowel Movements	A question about the pattern of an individual's bowel movements.			Intellectual Product	Symptom Distress Scale
C124187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124187>	C226639	Have Normal Bowel Pattern|Have Normal Pattern of Bowel Movements|I have my normal bowel pattern	A response indicating that an individual has or had a normal pattern of bowel movements.			Intellectual Product	Pattern of Bowel Movements Question
C124188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124188>	C226640	Bowel Pattern Occasionally Causes Some Discomfort|My bowel pattern occasionally causes me some discomfort|Pattern of Bowel Movements Occasionally Causes Some Discomfort	A response indicating that an individual's pattern of bowel movements occasionally causes or caused them some discomfort.			Intellectual Product	Pattern of Bowel Movements Question
C124189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124189>	C226640	Bowel Pattern Causes Considerable Discomfort|My present bowel pattern occasionally causes me considerable discomfort|Pattern of Bowel Movements Causes Considerable Discomfort	A response indicating that an individual's present pattern of bowel movements occasionally causes them considerable discomfort.			Intellectual Product	Pattern of Bowel Movements Question
C12418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12418>	C12680	Head and Neck|H and N|HEAD AND NECK|Head & Neck|craniocervical region	For oncology, an area of the body generally construed to comprise the base of skull and facial bones, sinuses, orbits, salivary glands, oral cavity, oropharynx, larynx, thyroid, facial and neck musculature and lymph nodes draining these areas.	Head and Neck		Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Radiation Therapy Table|EWS Tumor Assessment Table|GCT Authorized Value Terminology|GCT Biopsy/Surgical Procedures Table|GCT Radiation Therapy Table|GCT Tumor Assessment Table|GDC Terminology|GDC Value Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C124190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124190>	C226640	Usually in Considerable Discomfort Because of Bowel Pattern|I am usually in considerable discomfort because of my present bowel pattern|Usually in Considerable Discomfort Because of Pattern of Bowel Movements	A response indicating that an individual's present pattern of bowel movements usually causes them considerable discomfort.			Intellectual Product	Pattern of Bowel Movements Question
C124191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124191>	C226640	In Almost Constant Discomfort Because of Bowel Pattern|I am in almost constant discomfort because of my bowel pattern|In Almost Constant Discomfort Because of Pattern of Bowel Movements	A response indicating that an individual's pattern of bowel movements causes or caused them almost constant discomfort.			Intellectual Product	Pattern of Bowel Movements Question
C124192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124192>	C226648	Have Normal Ability to Concentrate|I have my normal ability to concentrate	A response indicating that an individual has or had their normal ability to concentrate.			Intellectual Product	Able to Concentrate Question
C124193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124193>	C226648	Have Occasional Trouble Concentrating|I occasionally have trouble concentrating	A response indicating that an individual occasionally has or had trouble concentrating.			Intellectual Product	Able to Concentrate Question
C124194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124194>	C226648	Occasionally Have Considerable Trouble Concentrating|I occasionally have considerable trouble concentrating	A response indicating that an individual occasionally has or had considerable trouble concentrating.			Intellectual Product	Able to Concentrate Question
C124195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124195>	C226648	Usually Have Considerable Trouble Concentrating|I usually have considerable difficulty concentrating	A response indicating that an individual usually has or had considerable difficulty concentrating.			Intellectual Product	Able to Concentrate Question
C124196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124196>	C173045	Can't Concentrate at All Question|Am Unable to Concentrate|Can't Concentrate|Can't Concentrate at All|Can't Seem to Concentrate at All|I am unable to concentrate|I just can't seem to concentrate at all|Unable to Concentrate	A response indicating that an individual just can't seem to concentrate at all.			Intellectual Product	Able to Concentrate Question|Multidimensional Fatigue Symptom Inventory-Short Form
C124197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124197>	C173348	Appearance Distress Question|Appearance|Appearance Distress|Concern about Appearance	A question about an individual's concern with their physical appearance.			Intellectual Product	Symptom Distress Scale
C124198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124198>	C226627	Appearance Has Not Changed|Appearance Has Basically Not Changed|My appearance has basically not changed	A response indicating that an individual's appearance has not changed.			Intellectual Product	Appearance Distress Question
C124199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124199>	C175300	Occasionally Concerned about Worsening of Physical Appearance|Occasionally I am concerned about the worsening of my physical appearance	A response indicating that an individual is or was occasionally concerned about worsening of their physical appearance.			Intellectual Product	Appearance Distress Question
C12419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12419>	C12680	Head|HEAD|head	The anterior and superior part of a human bearing the mouth, the brain and sensory organs.	Head		Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Baseline Form|CPTAC Terminology|UBERON Terminology
C1241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1241>	C2562	Sunflower Oil|Oil, Sunflower|SUNFLOWER OIL|Sunflower Seed Oil	Pressed from sunflower seeds (Helianthus annus), Sunflower Oil has a high content of beneficial monounsaturated fats, and antioxidant vitamins E and F, as well as triglycerides and linoleic acids. Used mainly in cooking today, sunflower oil has been used for medicines and in cosmetics. (NCI04)			Food	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C124200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124200>	C175300	Not Often Concerned that Appearance is Worsening|I am not often concerned that my appearance is worsening	A response indicating that an individual is not or was not often concerned that their appearance is worsening.			Intellectual Product	Appearance Distress Question
C124201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124201>	C175300	Most of the Time Concerned that Physical Appearance is Worsening|Most of the time I am concerned that my physical appearance is worsening	A response indicating that most of the time an individual is or was concerned that their physical appearance is worsening.			Intellectual Product	Appearance Distress Question
C124202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124202>	C175300	Worsening of Physical Appearance is Constant Preoccupying Concern|The worsening of my physical appearance is a constant, preoccupying concern	A response indicating that the worsening of an individual's physical appearance is or was a constant, preoccupying concern.			Intellectual Product	Appearance Distress Question
C124203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124203>	C173348	Breathing Distress Question|Breathing|Breathing Ability|Breathing Distress|Breathing Effort	A question about an individual's difficulty with breathing.			Intellectual Product	Symptom Distress Scale
C124204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124204>	C226642	Usually Breathe Normally|I usually breathe normally	A response indicating that an individual usually breathes normally.			Intellectual Product	Breathing Distress Question
C124205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124205>	C226642	Have Occasional Trouble Breathing|I occasionally have trouble breathing	A response indicating that an individual occasionally has of had trouble breathing.			Intellectual Product	Breathing Distress Question
C124206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124206>	C226642	Often Have Trouble Breathing|I often have trouble breathing	A response indicating that an individual often has or had trouble breathing.			Intellectual Product	Breathing Distress Question
C124207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124207>	C226642	Hardly Ever Breathe Easily|Hardly Ever Breathe as Easily as Wanted|I can hardly ever breathe as easily as I want	A response indicating that an individual can hardly ever breathe as easily as they want.			Intellectual Product	Breathing Distress Question
C124208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124208>	C226642	Almost Always Have Severe Trouble Breathing|I almost always have severe trouble with my breathing	A response indicating that an individual almost always has or had severe trouble with their breathing.			Intellectual Product	Breathing Distress Question
C124209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124209>	C91102	Outlook Distress Question|Fear about Future|Outlook|Outlook Distress	A question about an individual's fear about the future.			Intellectual Product	Symptom Distress Scale
C12420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12420>	C38617	Larynx|Head and Neck, Larynx|LARYNX|Laryngeal structure (body structure)|Larynx, NOS|larynx|larynx|voice box	The cartilaginous structure of the respiratory tract between the pharynx and the trachea. It contains elastic vocal cords required for sound production.	Larynx		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C124210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124210>	C175346	Not Worried or Frightened About the Future|I am not worried or frightened about the future	A response indicating that an individual is not or was not worried or frightened about the future.			Intellectual Product	Outlook Distress Question
C124211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124211>	C175346	Slightly Worried but Not Frightened About Things|I am slightly worried but not frightened about things	A response indicating that an individual is or was slightly worried but not frightened about things.			Intellectual Product	Outlook Distress Question
C124212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124212>	C175346	Worried and Frightened About Things|I am worried and frightened about things	A response indicating that an individual is or was worried and frightened about things.			Intellectual Product	Outlook Distress Question
C124213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124213>	C175346	Very Worried and Frightened About Things|I am very worried and frightened about things	A response indicating that an individual is or was very worried and frightened about things.			Intellectual Product	Outlook Distress Question
C124214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124214>	C175346	Terrified by Thoughts of the Future|I am terrified by thoughts of the future	A response indicating that an individual is or was terrified by thoughts of the future.			Intellectual Product	Outlook Distress Question
C124215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124215>	C173358|C173134	Cough Frequency Question|Cough|Cough Distress|Cough Frequency|Frequency of Coughing|How Often Cough	A question about the frequency of an individual's cough.			Intellectual Product	Memorial Symptom Assessment Scale|Symptom Distress Scale
C124216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124216>	C176248	Seldom Cough|I seldom cough	A response indicating that an individual seldom coughs or coughed.			Intellectual Product	Cough Frequency Question
C124217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124217>	C176248	Have Occasional Cough|I have an occasional cough	A response indicating that an individual has or had an occasional cough.			Intellectual Product	Cough Frequency Question
C124218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124218>	C176248	Often Cough|I often cough	A response indicating that an individual often coughs or coughed.			Intellectual Product	Cough Frequency Question
C124219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124219>	C176248	Often Cough and Have Occasionally Severe Coughing Spells|I often cough, and occasionally have severe coughing spells	A response indicating that an individual often coughs or coughed and occasionally has or had severe coughing spells.			Intellectual Product	Cough Frequency Question
C12421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12421>	C25444	Oral Cavity|BODY CAVITY, ORAL|Buccal|Buccal Cavity|Buccal Cavity|Buccal Cavity|Buccal cavity|Mouth|Mouth|Mouth, NOS|ORAL CAVITY|Oral|Oral cavity structure (body structure)|Orally|buccal cavity|cavity of mouth|mouth|oral cavity|oral cavity|regio oralis	The cavity located at the upper end of the alimentary canal, behind the teeth and gums that is bounded on the outside by the lips, above by the hard and soft palates and below by the tongue.	Mouth		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology|EDQM Health Care Terminology|EDQM-HC Intended Site of Administration Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|Oral Mucositis Rating Scale|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C124220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124220>	C176248	Often Have Persistent and Severe Coughing Spells|I often have persistent and severe coughing spells	A response indicating that an individual often has or had persistent and severe coughing spells.			Intellectual Product	Cough Frequency Question
C124221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124221>	C36444	Immunoglobulin Heavy Chain Variable, Diversity, and Joining Region Gene Rearrangement|IGH-VDJ Rearrangement|IGH-VDJ Rearrangement	A molecular abnormality indicating the presence of gene rearrangement(s) of the IGH locus in the regions encoding the variable, diversity and/or joining regions.	Immunoglobulin Heavy Chain Variable, Diversity, and Joining Region Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124222>	C36444	Immunoglobulin Heavy Chain Diversity and Joining Region Gene Rearrangement|IGH-DJ Rearrangement|IGH-DJ Rearrangement	A molecular abnormality indicating the presence of gene rearrangement(s) of the immunoglobulin heavy chain (IGH) locus in the regions encoding the diversity and/or joining regions.	Immunoglobulin Heavy Chain Diversity and Joining Region Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124224>	C5036|C36281	Pigmentary Change in Skin|Pigment Changes|Pigmentary Change of Skin|Pigmentary Change of Skin	Abnormal skin pigmentation.			Finding	HL Authorized Value Terminology|HL Late Effects Table|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C124225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124225>	C1291	Cobomarsen|COBOMARSEN|MRG-106	A locked nucleic acid (LNA)-based oligonucleotide inhibitor of microRNA (miRNA) 155 (miR-155), with potential antineoplastic activity. Upon administration, cobomarsen targets, binds to and inhibits miR-155. This silences miR-155 and prevents the translation of certain tumor promoting genes, which leads to the induction of cancer cell apoptosis and the inhibition of tumor cell growth. miR-155, an oncogenic single-stranded, non-coding RNA that is critical to the regulation of gene expression, is overexpressed in certain tumor cell types. Up-regulation of miR-155 plays a key role in increased tumor cell proliferation and survival. The LNA is an RNA analog in which the ribose ring is locked in a particular confirmation that increases stability. Compared to the unmodified oligonucleotide, the LNA-modified oligonucleotide shows increased affinity for its target miR-155.	Cobomarsen		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124226>	C210987	Uzansertib|INCB 053914|INCB053914|INCB53914|Pan-PIM Inhibitor INCB053914|Pan-PIM Kinase Inhibitor INCB053914|UZANSERTIB	An orally available, small molecule and selective ATP-competitive pan-inhibitor of proviral integration sites for Moloney murine leukemia virus (PIM) kinases, with potential antineoplastic activity. Upon oral administration, uzansertib binds to and inhibits the activities of the three PIM isoforms, PIM1, PIM2 and PIM3. This prevents phosphorylation of their downstream targets and inhibits proliferation in cells that overexpress PIMs. PIMs, constitutively active proto-oncogenic serine/threonine kinases upregulated in various types of cancers, play key roles in tumor cell proliferation and survival.	Uzansertib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124227>	C20401|C129822	Adakitug|ADAKITUG|Anti-IL-8 Monoclonal Antibody BMS-986253|BMS 986253|BMS-986253|BMS986253|HuMax-IL-8|HuMax-IL8|MDX 018|MDX-018	A human monoclonal antibody against the pro-inflammatory mediator interleukin-8 (IL-8; CXCL8), with potential antineoplastic activities. Upon administration, adakitug directly binds to IL-8, thereby inhibiting the binding of IL-8 to its receptors CXCR1 and CXCR2. This inhibits activation of IL-8-mediated signaling transduction pathways, which decreases proliferation of susceptible tumor cells. Also, BMS-986253 effectively blocks binding of IL-8 to neutrophils and inhibits neutrophil activation and recruitment towards sites of inflammation, which reduces inflammation. IL-8, a member of the CXC chemokine family, is upregulated in a variety of cancer cell types and inflammatory diseases; it plays a key role in tumor cell proliferation, endothelial cell proliferation, and cancer stem cell (CSC) renewal.	Adakitug		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C124228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124228>	C13734	High Occupancy Target Region|HOT Region|High Occupancy of TRF Region|High Occupancy of Target Region|High Occupancy of Transcription-Related Factors Region|High-Occupancy Target Region	A regulatory element that is a target for a large number of transcription regulatory proteins. These DNA sequences, which play a role in the regulation of gene expression, bind to transcription factors or coregulatory proteins at a higher density than would be expected by chance.			Nucleotide Sequence	
C124229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124229>	C207756|C129820	Bintrafusp Alfa|Anti-PD-L1/TGFbetaRII Fusion Protein M7824|Anti-PDL1/TGFb Trap MSB0011359C|BINTRAFUSP ALFA|M7824|MSB0011359C	A bifunctional fusion protein composed of an anti-programmed death ligand 1 (PD-L1) human monoclonal antibody, bound to the soluble extracellular domain of human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), with potential antineoplastic and immune checkpoint modulating activities. Upon administration, bintrafusp alfa binds to and neutralizes activated TGFbeta and binds to PD-L1. This prevents TGFbeta- and PD-L1-mediated signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This inhibits tumor cell proliferation in susceptible tumor cells. TGFbeta and PD-L1 are both upregulated in certain types of cancers; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.	Bintrafusp Alfa		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12422>	C33224	Tongue|Entire tongue (body structure)|TONGUE|Tongue structure (body structure)|Tongue, NOS|tongue	The muscular organ located in the floor of the mouth and serving as the principal organ of taste and modification of the voice in speech.	Tongue		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C124230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124230>	C2124	Fluorine F 18 FP-R01-MG-F2|[18F] FP-R01-MG-F2	A radiotracer composed of the integrin alphaVbeta6 (aVb6) ligand and cystine knot peptide R01 variant R01-MG-F2 radiolabeled with [18F]-fluoropropionate (F 18 FP), with potential integrin aVb6 imaging activity using positron emission tomography (PET). Upon administration, the R01-MG-F2 moiety of fluorine F 18 FP-R01-MG-F2 selectively binds to integrin aVb6-positive cancer cells. During PET, aVb6-expressing tumor cells can be visualized. Integrin aVb6, a cell adhesion and signaling receptor, is upregulated in certain cancer cell types and has been associated with increased proliferation of tumor cells. The cystine knot peptide shows high stability and allows for rapid and high uptake into aVb6-expressing tumor cells.	Fluorine F 18 FP-R01-MG-F2		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C124231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124231>	C48470	Inch Strip Dosing Unit|Inch Strip	A dosing unit equal to the amount of active ingredient(s) contained in an inch ribbon of a topical substance.			Quantitative Concept	NCPDP Dose Unit of Measure Terminology
C124232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124232>	C28681	Anti-CD3 OKT3/Anti-EGFR Bispecific Antibody Armed Activated T Lymphocytes|EGFR BATs|EGFRBi-armed Autologous ATCs		Anti-CD3 OKT3/Anti-EGFR Bispecific Antibody Armed Activated T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology
C124233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124233>	C67518	ClinicalTrials.gov	A Web-based resource that provides patients, their family members, health care professionals, researchers, and the public with access to information on publicly and privately supported clinical studies. A service of the National Institutes of Health (NIH), ClinicalTrials.gov is both a registry and a results database.			Intellectual Product	CDISC Dictionary Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124234>	C28533	SLC45A2 Gene|SLC45A2|SLC45A2|SLC45A2|Solute Carrier Family 45 Member 2 Gene	This gene is involved in melanocyte differentiation.	SLC45A2 Gene		Gene or Genome	CCPS Genetics Terminology|Childhood Cancer Predisposition Study Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C124235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124235>	C124234	SLC45A2 wt Allele|1A1|AIM-1|AIM1|MATP|OCA4|SHEP5|Solute Carrier Family 45, Member 2 wt Allele	Human SLC45A2 wild-type allele is located in the vicinity of 5p13.2 and is approximately 40 kb in length. This allele, which encodes membrane-associated transporter protein, plays a role in both melanocyte differentiation and melanin synthesis. Mutation of the gene is associated with oculocutaneous albinism type 4, and polymorphisms in this gene are associated with variations in skin and hair color.	SLC45A2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124236>	C16386	Membrane-Associated Transporter Protein|Melanoma Antigen AIM1|Membrane Associated Transporter|Protein AIM-1|SLC45A2|Solute Carrier Family 45 Member 2|Underwhite	Membrane-associated transporter protein (530 aa, ~58 kDa) is encoded by the human SLC45A2 gene. This protein is involved in the modulation of both melanin synthesis and melanocyte differentiation.	Membrane-Associated Transporter Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124237>	C25997	SKAP1 Gene|SKAP1|SKAP1|Src Kinase Associated Phosphoprotein 1 Gene	This gene plays a role in T-cell receptor signaling.	SKAP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C124238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124238>	C124237	SKAP1 wt Allele|HEL-S-81p|SCAP1|SKAP55|Src Family Associated Phosphoprotein 1 Gene|Src Kinase Associated Phosphoprotein 1 wt Allele	Human SKAP1 wild-type allele is located in the vicinity of 17q21.32 and is approximately 297 kb in length. This allele, which encodes Src kinase-associated phosphoprotein 1, is involved in T-cell receptor signaling and integrin clustering.	SKAP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124239>	C26231	Src Kinase-Associated Phosphoprotein 1|Epididymis Secretory Sperm Binding Protein Li 81p|SCAP1|SKAP-55|Src Family-Associated Phosphoprotein 1|Src Kinase-Associated Phosphoprotein of 55 kDa|Src Kinase-Associated Phosphoprotein, 55-kD|pp55	Src kinase-associated phosphoprotein 1 (359 aa, ~41 kDa) is encoded by the human SKAP1 gene. This protein plays a role in integrin clustering following T-cell receptor signaling.	Src Kinase-Associated Phosphoprotein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12423>	C38617	Nasopharynx|NASOPHARYNX|Nasopharyngeal structure (body structure)|Nasopharynx, NOS|nasal part of pharynx|nasopharynx|nasopharynx|rhinopharynx	The part of the pharynx in the back of the throat, at and above the soft palate. The nasopharynx is continuous with the nasal passages.	Nasopharynx		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C124240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124240>	C20103	LILRB1 Gene|LILRB1|LILRB1|Leukocyte Immunoglobulin-Like Receptor, Subfamily B (With TM and ITIM Domains), Member 1 Gene	This gene is involved in binding to class I MHC antigens.	LILRB1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C124241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124241>	C124240	LILRB1 wt Allele|CD85J|ILT-2|ILT2|LIR-1|LIR1|Leukocyte Immunoglobulin-Like Receptor, Subfamily B (With TM and ITIM Domains), Member 1 wt Allele|Leukocyte Immunoglobulin-Like Receptor, Subfamily B, Member 1 Gene|MIR-7|MIR7	Human LILRB1 wild-type allele is located in the vicinity of 19q13.4 and is approximately 127 kb in length. This allele, which encodes leukocyte immunoglobulin-like receptor subfamily B member 1 protein, plays a role in the inhibition of immune responses.	LILRB1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124242>	C18106	Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 1|CD85 Antigen-Like Family Member J|CD85j|CD85j Antigen|ILT-2|Ig-Like Transcript 2|Immunoglobulin-Like Transcript 2|LILRB1|LIR-1|Leukocyte Immunoglobulin-Like Receptor 1|MIR-7|Monocyte/Macrophage Immunoglobulin-Like Receptor 7	Leukocyte immunoglobulin-like receptor subfamily B member 1 (650 aa, ~71 kDa) is encoded by the human LILRB1 gene. This protein is involved in the modulation of class I MHC-dependent immune responses.	Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 1		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124243>	C26003	CMA1 Gene|CMA1|CMA1|Chymase 1, Mast Cell Gene	This gene plays a role in both extracellular matrix degradation and vasoactive peptide formation.	CMA1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C124244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124244>	C124243	CMA1 wt Allele|CYH|CYM|Chymase 1, Mast Cell wt Allele|Chymase Gene|Chymase, Heart Gene|Chymase, Mast Cell Gene|MCT1	Human CMA1 wild-type allele is located in the vicinity of 14q11.2 and is approximately 3 kb in length. This allele, which encodes chymase protein, is involved in the metabolism of both vasoactive peptides and the extracellular matrix.	CMA1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124245>	C17123	Chymase|Alpha-Chymase|CMA1|EC 3.4.21.39|Mast Cell Protease I	Chymase (247 aa, ~27 kDa) is encoded by the human CMA1 gene. This protein plays a role in vasoactive peptide synthesis and extracellular matrix degradation.	Chymase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124246>	C26003	TPSB2 Gene|TPSB2|TPSB2|Tryptase Beta 2 (Gene/Pseudogene) Gene	This gene is involved in mast cell granule proteolytic activity.	TPSB2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C124247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124247>	C124246	TPSB2 wt Allele|TPS2|Tryptase Beta 2 (Gene/Pseudogene) wt Allele|Tryptase, Beta Gene|Tryptase, Beta-2 Gene|Tryptase, Beta-II Gene|Tryptase, Beta-III Gene|TryptaseB Gene|TryptaseC Gene	Human TPSB2 wild-type allele is located in the vicinity of 16p13.3 and is approximately 3 kb in length. This allele, which encodes tryptase beta-2 protein, plays a role in the proteolytic activity of mast cell granules.	TPSB2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124248>	C17123	Tryptase Beta-2|Chymase|EC 3.4.21.59|Mast Cell Tryptase Beta II|Mast Cell Tryptase Beta III|TPSB2|Tryptase Beta 2|Tryptase Beta III|Tryptase II|Tryptase-2	Tryptase beta-2 (275 aa, ~31 kDa) is encoded by the human TPSB2 gene. This protein is involved in protein degradation.	Tryptase Beta-2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124249>	C134526	Canine Mammary Carcinoma	Mammary carcinoma occurring in a dog.			Neoplastic Process	Cellosaurus Disease Terminology
C12424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12424>	C38617|C25444	Nasal Cavity|BODY CAVITY, NASAL|NASAL CAVITY|Nasal Fossa|Nasal Fossa|Nasal cavity|Nasal cavity|Nasal cavity structure (body structure)|cavity of nose|cavity of olfactory apparatus|nasal canal|nasal cavity|nasal conduit space|nasal fossa|olfactory chamber cavity	The proximal portion of the respiratory passages on either side of the nasal septum lying between the floor of the cranium and the roof of the mouth and extending from the face to the pharynx. The nasal cavity is lined with ciliated mucosa, extending from the nares to the pharynx.	Nasal Cavity		Body Space or Junction	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C124250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124250>	C60695	Rat Malignant Meningioma	Malignant meningioma occurring in a rat. Spontaneously occurring meningiomas in the rat are histologically similar to human meningiomas.			Neoplastic Process	Cellosaurus Disease Terminology
C124251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124251>	C134533	Woodchuck Hepatocellular Carcinoma	Hepatocellular carcinoma (HCC) occurring in a woodchuck, usually as a result of chronic infection by the woodchuck hepatitis virus. The woodchuck model of viral-induced HCC provides an animal model that resembles the complex human liver environment of HCC in the context of chronic hepatitis B viral infection.			Neoplastic Process	Cellosaurus Disease Terminology
C124252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124252>	C14270	Eastern Woodchuck|Ground Hog|Groundhog|Marmota monax|Woodchuck	A burrowing rodent of the family Sciuridae, belonging to the group of large ground squirrels known as marmots. The woodchuck model of viral-induced hepatocellular carcinoma (HCC) provides an animal model that resembles the complex human liver environment of HCC in the context of chronic hepatitis B viral infection.			Mammal	
C124253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124253>	C14216|C14214	Woodchuck Hepatitis Virus|WHV	A species of double-stranded, retro-transcribing viruses in the genus Orthohepadnavirus that is naturally capable of infecting the woodchuck Marmota monax.			Virus	
C124254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124254>	C20194	PIK3R5 Gene|PIK3R5|PIK3R5|Phosphoinositide-3-Kinase Regulatory Subunit 5 Gene	This gene plays a role in the regulation of phosphoinositide-3-kinase gamma activity.	PIK3R5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C124255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124255>	C124254	PIK3R5 wt Allele|F730038I15Rik|FOAP-2|P101-PI3K|Phosphatidylinositol 3-Kinase, Regulatory Subunit 5 Gene|Phosphoinositide-3-Kinase Regulatory Subunit 5 wt Allele|Phosphoinositide-3-Kinase, Regulatory Subunit 5 Gene|p101	Human PIK3R5 wild-type allele is located in the vicinity of 17p13.1 and is approximately 87 kb in length. This allele, which encodes phosphoinositide 3-kinase regulatory subunit 5 protein, is involved in the modulation of phosphoinositide-3-kinase gamma activity. Mutation of the gene is associated with ataxia-oculomotor apraxia 3.	PIK3R5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124256>	C18466	Phosphoinositide 3-Kinase Regulatory Subunit 5|PI3-Kinase P101 Subunit|PI3-Kinase Regulatory Subunit 5|PIK3R5|Phosphatidylinositol 4,5-Bisphosphate 3-Kinase Regulatory Subunit 5|Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Regulatory Subunit 5|Phosphoinositol 3-Kinase Regulatory Subunit 5|Protein FOAP-2|PtdIns-3-Kinase P101|PtdIns-3-Kinase Regulatory Subunit 5|p101-PI3K	Phosphoinositide 3-kinase regulatory subunit 5 (880 aa, ~97 kDa) is encoded by the human PIK3R5 gene. This protein plays a role in the regulation of phospholipid metabolism.	Phosphoinositide 3-Kinase Regulatory Subunit 5		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124258>	C16748	Integrin AlphaV/Beta6|Alpha(V)Beta(6) Integrin|Alpha-V Beta-6|Alpha-V Beta-6 Integrin|Alpha-V/Beta-6|Alpha-V/Beta-6 Integrin|Alpha-VBeta-6|AlphaV Beta6|AlphaV-Beta6|AlphaV/Beta6|Integrin Alpha-V Beta-6|Integrin Alpha-V Beta-6 Protein|Integrin Alpha-V/Beta-6|Integrin Alpha-VBeta-6|Integrin AlphaV Beta6|Integrin AlphaV-Beta6|Integrin aVb6|Integrin alpha (V) beta (6)|Integrin-aVBeta6|aVb6	Integrin alphaV/beta6 is a protein complex comprised of a heterodimer of integrin alpha-V and integrin beta-6. This complex plays a role in cell-matrix adhesion and viral entry.	Integrin AlphaV/Beta6		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124259>	C126416	HPV Regulatory Protein E2 Antibody|Anti-HPV E2 Antibody|Anti-HPV Regulatory Protein E2 Antibody|Anti-Human Papillomavirus E2 Antibody|Anti-Human Papillomavirus Regulatory Protein E2 Antibody|HPV E2 Antibody|Human Papillomavirus E2 Antibody|Human Papillomavirus Regulatory Protein E2 Antibody	Any immunoglobulin that recognizes human papillomavirus regulatory protein E2.	HPV Regulatory Protein E2 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12425>	C38617	Pharynx|PHARYNX|Pharyngeal structure (body structure)|Pharynx, NOS|pharynx|pharynx	A hollow tube that starts posterior to the mouth and nasal cavity and ends superior to the trachea and esophagus.	Pharynx		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C124260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124260>	C126416	HPV Replication Protein E1 Antibody|Anti-HPV ATP-Dependent Helicase E1 Antibody|Anti-HPV E1 Antibody|Anti-HPV Replication Protein E1 Antibody|Anti-Human Papillomavirus ATP-Dependent Helicase E1 Antibody|Anti-Human Papillomavirus E1 Antibody|Anti-Human Papillomavirus Replication Protein E1 Antibody|HPV ATP-Dependent Helicase E1 Antibody|HPV E1 Antibody|Human Papillomavirus ATP-Dependent Helicase E1 Antibody|Human Papillomavirus E1 Antibody	Any immunoglobulin that recognizes human papillomavirus replication protein E1.	HPV Replication Protein E1 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124261>	C192768|C101293	Whole Transcriptome Sequencing|RNA Sequencing|RNA Sequencing|RNA Sequencing|RNA-Seq|RNA-Seq|RNA-seq (transcriptome sequencing)|RNAseq|Sequencing, Total RN|Total RNA Sequencing|Total RNA-Seq|Transcriptome Sequencing|WHOLE TRANSCRIPTOME SEQUENCING|WTSS|Whole Transcriptome Shotgun Sequencing|Whole-Transcriptome Sequencing	A procedure that can determine the nucleotide sequence for all of the RNA transcripts in an individual.	Whole Transcriptome Sequencing		Molecular Biology Research Technique	Canine Glioma Project Property Terminology|CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTDC Value Terminology|CTRP Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|ICDC Terminology|SeroNet Authorized Values|SeroNet Study Descriptors
C124262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124262>	C16342	Flow-Mediated Vasodilation|FMD|Flow-Mediated Vascular Reactivity	The percent change in arterial vessel diameter in response to an increase in blood flow caused by mechanical or chemical stimuli, which is usually measured using ultrasound-based methods. This measurement can reflect the functionality of the endothelium in the observed blood vessels.	Flow-Mediated Vasodilation		Qualitative Concept	CTRP Biomarker Terminology|CTRP Terminology
C124263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124263>	C16295	MAGEA1 Antibody|Anti-CT1.1 Antibody|Anti-Cancer/Testis Antigen 1.1 Antibody|Anti-MAGE1 Antibody|Anti-MAGEA1 Antibody|Anti-Melanoma-Associated Antigen 1 Antibody|Antigen MZ2 E Antibody|Antigen MZ2-E Antibody|CT1.1 Antibody|Cancer/Testis Antigen 1.1 Antibody|MAGE1 Antibody|Melanoma-Associated Antigen 1 Antibody	Any immunoglobulin that recognizes melanoma-associated antigen 1 protein.	MAGEA1 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124264>	C73539	Asymmetric Dimethylarginine|ADMA|Guanidino-N(1),N(1)-Dimethylarginine|Guanidino-N,N-Dimethylarginine|N(G),N(G)-Dimethylarginine|N(G1),N(G1)-Dimethylarginine|N,N-DIMETHYLARGININE	A dimethylated derivative of L-arginine where the two methyl groups are attached to arginine in an asymmetrical configuration. Asymmetric dimethylarginine (ADMA) is a competitive inhibitor of nitric oxide synthase (NOS) that is formed when S-adenosylmethionine protein N-methyltransferases transfer two methyl groups from S-adenosylmethionine to one of the two guanidine nitrogen groups of an arginine residue in a protein. ADMA is released when the protein is degraded and is a substrate for dimethylarginine dimethylaminohydrolase (DDAH). Free ADMA in plasma competes with the L-arginine for binding to the heme in NOS and inhibits nitric oxide (NO) synthesis. Decreased synthesis of NO inhibits vasodilation and leads to endothelial dysfunction. Elevated plasma levels of ADMA are seen in certain types of cancer, cardiovascular disease, hypertension, hyperlipidemia, type 2 diabetes mellitus, and increased oxidative stress.	Asymmetric Dimethylarginine		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C124265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124265>	C20988	ITGB6 Gene|ITGB6|ITGB6|Integrin Beta 6 Gene	This gene plays a role in cell-matrix adhesion.	ITGB6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C124266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124266>	C124265	ITGB6 wt Allele|AI1H|Integrin Beta 6 wt Allele|Integrin, Beta 6 Gene|Integrin, Beta-6 Gene	Human ITGB6 wild-type allele is located in the vicinity of 2q24.2 and is approximately 172 kb in length. This allele, which encodes integrin beta-6, is involved in cell matrix adhesion. Mutation of the gene is associated with amelogenesis imperfecta, type IH.	ITGB6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124267>	C16393	Integrin Beta-6|ITGB6|Integrin Beta 6|Integrin Beta6	Integrin beta-6 (788 aa, ~86 kDa) is encoded by the human ITGB6 gene. This protein plays a role in cell-matrix adhesion.	Integrin Beta-6		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124268>	C82547	Hypermetabolism|Increased Basal Metabolic Rate	A finding indicating an abnormal increase in the body's basal metabolic rate.			Finding	
C124269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124269>	C3697|C202299|C115192	Childhood Myxopapillary Ependymoma	A myxopapillary ependymoma that occurs during childhood.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C12426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12426>	C12712	Salivary Gland|GLAND, SALIVARY|Head and Neck, Salivary Glands|SALIVARY GLAND|Salivary Glands|saliva-secreting gland|salivary gland	An exocrine gland that secretes saliva. Salivary glands are mostly located in and around the oral cavity.	Salivary Gland		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C124270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124270>	C3270|C213156	Childhood Neuroblastoma|Neuroblastoma	A neuroblastoma that occurs during childhood.	Childhood Neuroblastoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C124271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124271>	C3790|C213156	Childhood Ganglioneuroblastoma|Ganglioneuroblastoma	A ganglioneuroblastoma that occurs during childhood.	Childhood Ganglioneuroblastoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C124272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124272>	C92629|C5448|C124271	Childhood Central Nervous System Ganglioneuroblastoma|Central Nervous System Ganglioneuroblastoma|Childhood Cerebral Ganglioneuroblastoma	A central nervous system ganglioneuroblastoma that occurs during childhood.	Childhood Central Nervous System Ganglioneuroblastoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C124273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124273>	C42057|C124271	Childhood Ganglioneuroblastoma, Intermixed|Childhood Intermixed Ganglioneuroblastoma|Childhood Intermixed Ganglioneuroblastoma	An intermixed ganglioneuroblastoma that occurs during childhood.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C124274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124274>	C42058|C124271	Childhood Ganglioneuroblastoma, Nodular|Childhood Nodular Ganglioneuroblastoma|Childhood Nodular Ganglioneuroblastoma	A nodular ganglioneuroblastoma that occurs during childhood.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C124275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124275>	C9022|C60781	Childhood Astrocytoma|Astrocytoma	An astrocytoma that occurs during childhood.	Childhood Astrocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C124276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124276>	C25167	Anogenital Distance|ANGDIST	A measurement of the length of the span between the anus and the base of the genitalia.			Quantitative Concept	CDISC SEND Fetal Measurement Test Code Terminology|CDISC SEND Fetal Measurement Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124277>	C16551	Clinical Trial Setting				Functional Concept	
C124278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124278>	C122045	Hymenolepis				Animal	
C124279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124279>	C62606	Implantation Site Characterization|IMPSCHCT	A description of the condition of an implantation site, embryo, or fetus, which is based on examination.			Activity	CDISC SEND Implantation Findings Test Code Terminology|CDISC SEND Implantation Findings Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12427>	C33539|C12999	Parotid Gland|GLAND, SALIVARY, PAROTID|PAROTID GLAND|Parotid|Parotid Salivary Gland|Parotid gland|Parotid gland structure (body structure)|parotid|parotid gland	The largest of the three paired salivary glands, located in front of the ear.	Parotid		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTDC Value Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C124280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124280>	C25257	Nonclinical Trial Phase	A distinguishable part or stage in a nonclinical study.			Temporal Concept	
C124281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124281>	C25337	Number of Episodes|EPSDNUM|EPSDNUM|EPSDNUM|EPSDNUM|EPSDNUM|EPSDNUM	A measurement of the total number of events that have occurred.			Quantitative Concept	CDISC SDTM CDAD Findings About Test Code Terminology|CDISC SDTM CDAD Findings About Test Name Terminology|CDISC SDTM COVID-19 Findings About Test Code Terminology|CDISC SDTM COVID-19 Findings About Test Name Terminology|CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Schizophrenia Findings About Test Code Terminology|CDISC SDTM Schizophrenia Findings About Test Name Terminology|CDISC SDTM Terminology|CDISC SDTM Type 1 Diabetes Findings About Test Code Terminology|CDISC SDTM Type 1 Diabetes Findings About Test Name Terminology|CDISC SDTM Vaccines Findings About Test Code Terminology|CDISC SDTM Vaccines Findings About Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C124282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124282>	C14248	Onchocerca				Animal	
C124283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124283>	C14248	Pseudoterranova				Animal	
C124284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124284>	C123338	Opisthorchis				Animal	
C124285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124285>	C123338	Schistosoma|Blood Fluke	A genus of trematoda flatworms that are the causative agents of schistosomiasis diseases. The lifecycle of Schistosoma flatworms involves freshwater snails as the intermediate host and humans as the definitive host. They are unique among trematodes, and other flatworms, in that they are dioecious with distinct sexual dimorphism between male and female.			Animal	
C124286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124286>	C77916	Sarcocystis|SARCOCYSTIS	A genus of intracellular protozoan parasites in the class Conoidasida. The life cycle of Sarcocystis species involve a prey animal as the intermediate host and its predator as the definitive host. Infection with this parasite is known as sarcosporidiosis.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124287>	C76196	Spirillaceae				Bacterium	
C124288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124288>	C124287	Spirillum|SPIRILLUM	A genus of Gram-negative, motile bacteria in the family Spirillaceae characterized as large, elongate, rigid, spiral-shaped cells having tufts of flagella at both poles.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124289>	C77916	Retortamonas	A genus of flagellate protozoa in the phylum Metamonada that reside in the intestines of both vertebrate and invertebrate animals.			Classification	
C12428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12428>	C13018	Trachea|TRACHEA|Tracheal structure (body structure)|Windpipe|cartilaginous trachea|trachea|trachea|vertebrate trachea|windpipe|windpipe	The fibrocartilaginous, mucous-lined tube passing from the larynx to the bronchi.	Trachea		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C124290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124290>	C85986	Sarcina				Bacterium	
C124291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124291>	C53686|C42080	Childhood Atypical Choroid Plexus Papilloma	An atypical choroid plexus papilloma that occurs during childhood.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C124292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124292>	C4964|C4715|C42080|C190275|C187207	Childhood Choroid Plexus Carcinoma	A choroid plexus carcinoma that occurs during childhood.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C124293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124293>	C4049|C208306|C115192	Childhood Anaplastic Ependymoma|Anaplastic Ependymoma	An anaplastic ependymoma that occurs during childhood.	Childhood Anaplastic Ependymoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C124294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124294>	C27993	Undetermined|UNDETERMINED	A term referring to the lack of definitive criteria for classification of a finding.			Finding	CDISC SEND Pregnancy Findings Result Category Terminology|CDISC SEND Pregnancy Findings Result Terminology|CDISC SEND Pregnancy Status Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124295>	C69218	Pregnant|PREGNANT	Observed to be or have been pregnant.			Intellectual Product	CDISC SEND Pregnancy Findings Result Category Terminology|CDISC SEND Pregnancy Findings Result Terminology|CDISC SEND Pregnancy Status Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C124296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124296>	C81222	CDISC ADaM Subject Trial Status Terminology|ADaM-SBJTSTAT|SBJTSTAT|Subject Trial Status	Terminology associated with the subject trial status codelist of the Clinical Data Interchange Standards Consortium (CDISC) Analysis Data Model (ADaM).			Intellectual Product	CDISC ADaM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124297>	C66830	CDISC SDTM Biospecimen Events Dictionary Derived Term Terminology|BEDECOD|Biospecimen Events Dictionary Derived Term|SDTM-BEDECOD	Terminology associated with the biospecimen events dictionary derived term codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124298>	C66830	CDISC SDTM Category of Oncology Response Assessment Terminology|Category of Oncology Response Assessment|ONCRSCAT|SDTM-ONCRSCAT	Terminology associated with the category of oncology response assessment codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124299>	C66830	CDISC SDTM Biospecimen Characteristics Test Name Terminology|BSTEST|Biospecimen Characteristics Test Name|SDTM-BSTEST	Terminology associated with the biospecimen characteristics test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12429>	C12680	Limb|Extremities|Extremities|Extremity|Extremity|LIMB|Limbs|free limb|limb|pentadactyl limb|tetrapod limb	A body region referring to an upper or lower extremity.	Limb		Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Terminology|UBERON Terminology
C1242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1242>	C183118	Tazobactam Sodium|TAZOBACTAM SODIUM	The sodium salt form of tazobactam, a penicillanic acid sulfone derivative and beta-lactamase inhibitor with antibacterial activity. Tazobactam contains a beta-lactam ring and irreversibly binds to beta-lactamase at or near its active site. This protects other beta-lactam antibiotics from beta-lactamase catalysis. This drug is used in conjunction with beta-lactamase susceptible penicillins to treat infections caused by beta-lactamase producing organisms.			Antibiotic|Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C124300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124300>	C66830	CDISC SDTM Biospecimen Characteristics Test Code Terminology|BSTESTCD|Biospecimen Characteristics Test Code|SDTM-BSTESTCD	Terminology associated with the biospecimen characteristics test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124301>	C66830	CDISC SDTM Medical History Event Date Type Terminology|MHEDTTYP|Medical History Event Date Type|SDTM-MHEDTTYP	Terminology associated with the medical history event date type codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124302>	C66830	CDISC SDTM Schizophrenia Findings About Test Code Terminology|SDTM-SZFATSCD|SZFATSCD|Schizophrenia Findings About Test Code	Terminology associated with the schizophrenia findings about test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124303>	C66830	CDISC SDTM Schizophrenia Findings About Test Name Terminology|SDTM-SZFATS|SZFATS|Schizophrenia Findings About Test Name	Terminology associated with the schizophrenia findings about test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124304>	C66830	CDISC SDTM Subject Status Response Terminology|SDTM-SSTATRS|SSTATRS|Subject Status Response	Terminology associated with the subject status response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124305>	C66830	CDISC SDTM Subject Status Test Code Terminology|SDTM-SSTESTCD|SSTESTCD|Subject Status Test Code	Terminology associated with the subject status test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124306>	C66830	CDISC SDTM Subject Status Test Name Terminology|SDTM-SSTEST|SSTEST|Subject Status Test Name	Terminology associated with the subject status test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124307>	C66830	CDISC SDTM Treatment Intent Terminology|SDTM-TRTINTNT|TRTINTNT|Treatment Intent	Terminology associated with the treatment intent codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124308>	C66830	CDISC SDTM Treatment Setting Terminology|SDTM-TRTSET|TRTSET|Treatment Setting	Terminology associated with the treatment setting codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124309>	C66830	CDISC SDTM Tumor or Lesion Properties Test Result Terminology|SDTM-TRPROPRS|TRPROPRS|Tumor or Lesion Properties Test Result	Terminology associated with the tumor or lesion properties test result codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124310>	C77526	CDISC SEND Fetal Pathology Findings Result Terminology|FXFINDRS|Fetal Pathology Findings Result|SEND-FXFINDRS	Terminology associated with the fetal pathology findings result codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124311>	C77526	CDISC SEND Fetal Measurement Test Code Terminology|FMTESTCD|Fetal Measurement Test Code|SEND-FMTESTCD	Terminology associated with the fetal measurement test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124312>	C77526	CDISC SEND Fetal Measurement Test Name Terminology|FMTEST|Fetal Measurement Test Name|SEND-FMTEST	Terminology associated with the fetal measurement test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124313>	C77526	CDISC SEND Fetal Pathology Findings Result Category Terminology|FXRESCAT|Fetal Pathology Findings Result Category|SEND-FXRESCAT	Terminology associated with the fetal pathology findings result category codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124314>	C77526	CDISC SEND Fetal Pathology Findings Test Code Terminology|FXTESTCD|Fetal Pathology Findings Test Code|SEND-FXTESTCD	Terminology associated with the fetal pathology findings test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124315>	C77526	CDISC SEND Fetal Pathology Findings Test Name Terminology|FXTEST|Fetal Pathology Findings Test Name|SEND-FXTEST	Terminology associated with the fetal pathology findings test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124316>	C77526	CDISC SEND Implantation Findings Result Category Terminology|ICRESCAT|Implantation Findings Result Category|SEND-ICRESCAT	Terminology associated with the implantation findings result category codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124317>	C77526	CDISC SEND Implantation Findings Result Terminology|ICFINDRS|Implantation Findings Result|SEND-ICFINDRS	Terminology associated with the implantation findings result codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124318>	C77526	CDISC SEND Implantation Findings Test Code Terminology|ICTESTCD|Implantation Findings Test Code|SEND-ICTESTCD	Terminology associated with the implantation findings test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124319>	C77526	CDISC SEND Implantation Findings Test Name Terminology|ICTEST|Implantation Findings Test Name|SEND-ICTEST	Terminology associated with the implantation findings test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12431>	C13018	Bone Marrow|BONE MARROW|Bone marrow|Bone marrow structure (body structure)|Marrow|Reticuloendothelial System, Bone Marrow|bone marrow|bone marrow|medulla ossea|medulla ossium	The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.	Bone Marrow		Body Part, Organ, or Organ Component	ALL Authorized Value Terminology|ALL Disease Characteristics Table|ALL Stem Cell Transplant Table|AML Authorized Value Terminology|AML Disease Characteristics Table|AML Stem Cell Transplant Table|CDISC SDTM Anatomical Location Terminology|CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Terminology|CTDC Value Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Stem Cell Transplant Table|EWS Tumor Assessment Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Biopsy/Surgical Procedures Table|HL Lesion Characteristics Table|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Genomic Specimen Type Value Set|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C124320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124320>	C77526	CDISC SEND Nonclinical DART Sex Terminology|NCDSEX|Nonclinical DART Sex|SEND-NCDSEX	Terminology associated with the nonclinical DART sex codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124321>	C77526	CDISC SEND Nonclinical DART Trial Phases Terminology|NCDPHASE|Nonclinical DART Trial Phases|SEND-NCDPHASE	Terminology associated with the nonclinical DART trial phases codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124322>	C77526	CDISC SEND Pregnancy Findings Result Category Terminology|PYRESCAT|Pregnancy Findings Result Category|SEND-PYRESCAT	Terminology associated with the pregnancy findings result category codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124323>	C77526	CDISC SEND Pregnancy Findings Result Terminology|PYFINDRS|Pregnancy Findings Result|SEND-PYFINDRS	Terminology associated with the pregnancy findings result codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124324>	C77526	CDISC SEND Pregnancy Findings Test Code Terminology|PYTESTCD|Pregnancy Findings Test Code|SEND-PYTESTCD	Terminology associated with the pregnancy findings test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124325>	C77526	CDISC SEND Pregnancy Findings Test Name Terminology|PYTEST|Pregnancy Findings Test Name|SEND-PYTEST	Terminology associated with the pregnancy findings test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124326>	C25404	Aliquotting|ALIQUOTING|Aliquot	The act of dividing a liquid item into multiple items of smaller volume.			Activity	CDISC SDTM Biospecimen Events Dictionary Derived Term Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124327>	C49337	Sectioning|SECTIONING|Section	To cut a an entity into slices.			Laboratory Procedure	CDISC SDTM Biospecimen Events Dictionary Derived Term Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124328>	C124281	Number of Mild Episodes|EPMLDNUM|EPMLDNUM	The number of times an event, which is classified as mild, occurred.			Quantitative Concept	CDISC SDTM COPD Findings About Test Code Terminology|CDISC SDTM COPD Findings About Test Name Terminology|CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124329>	C124281	Number of Moderate Episodes|EPMODNUM|EPMODNUM	The number of times an event, which is classified as moderate, occurred.			Quantitative Concept	CDISC SDTM COPD Findings About Test Code Terminology|CDISC SDTM COPD Findings About Test Name Terminology|CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12432>	C13018	Spleen|Reticuloendothelial System, Spleen|SPLEEN|Splenic|Splenic structure (body structure)|spleen|spleen|splenic	An organ that is part of the hematopoietic and immune systems. It is composed of the white pulp and the red pulp and is surrounded by a capsule. It is located in the left hypochondriac region. Its functions include lymphocyte production, blood cell storage, and blood cell destruction.	Spleen		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Biopsy/Surgical Procedures Table|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C124330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124330>	C124281	Number of Severe Episodes|EPSEVNUM|EPSEVNUM	The number of times an event, which is classified as severe, occurred.			Quantitative Concept	CDISC SDTM COPD Findings About Test Code Terminology|CDISC SDTM COPD Findings About Test Name Terminology|CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124331>	C25341	Location of Death|LOCDTH	The physical place at which the subject ceased to live.			Spatial Concept	CDISC SDTM Death Diagnosis Test Code Terminology|CDISC SDTM Death Diagnosis Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124332>	C62085	Aggregate QTca Interval|QTCAAG|QTCAAG|QTca Interval, Aggregate|QTca Interval, Aggregate|QTca Interval, Aggregate	The correction on the aggregate of QT intervals using individual probabilistic QT/RR slopes for each subject based on the measurement of QT intervals from multiple beats within a single ECG or from a defined time period within a continuous ECG. The method of aggregation, which can vary, is typically a measure of central tendency, such as mean.			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124333>	C62085	Single Beat QTca Interval|QTCASB|QTCASB|QTca Interval, Single Beat|QTca Interval, Single Beat|QTca Interval, Single Beat	The correction of the QT interval within a single beat using individual probabilistic QT/RR slopes for each subject based on a single beat-QT interval from one or more EKG leads.			Quantitative Concept	CDISC SDTM ECG Test Code Terminology|CDISC SDTM ECG Test Name Terminology|CDISC SDTM Terminology|CDISC SEND ECG Test Code Terminology|CDISC SEND ECG Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124334>	C47868	1,5-Anhydroglucitol Measurement|1,5-Anhydroglucitol|1,5-Anhydroglucitol|AG1_5	The determination of the amount of 1,5-anhydroglucitol present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124335>	C81971|C102258	Anti-Phospholipid IgG Antibody Measurement	The determination of the amount of anti-phospholipid IgG antibody present in a sample.			Laboratory Procedure	
C124336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124336>	C81972|C102258	Anti-Phospholipid IgM Antibody Measurement	The determination of the amount of anti-phospholipid IgM antibody present in a sample.			Laboratory Procedure	
C124337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124337>	C64430	Apolipoprotein A Measurement|APOA|APOA Measurement|Apo A Measurement|Apolipoprotein A|Apolipoprotein A	The determination of the amount of apolipoprotein A present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124338>	C75345|C74893	Aldosterone to Renin Activity Ratio Measurement|ARR|Aldosterone/Renin Activity|Aldosterone/Renin Activity	The determination of the ratio of the aldosterone compared to renin activity present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124339>	C49237	Cyclic Adenosine 3,5-Monophosphate Measurement|CAMP|Cyclic AMP Measurement|Cyclic Adenosine 3,5-Monophosphate|Cyclic Adenosine 3,5-Monophosphate|cAMP Measurement	The determination of the amount of cyclic adenosine 3,5-monophosphate present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12433>	C13018	Thymus Gland|Reticuloendothelial System, Thymus|THYMUS|THYMUS GLAND|Thymus|Thymus|Thymus|Thymus gland structure (body structure)|thymus|thymus|thymus gland|thymus organ	A bi-lobed organ surrounded by a connective tissue capsule. It is located in the upper anterior portion of the chest, behind the sternum. It is composed predominantly of lymphocytes and fewer epithelial cells. Connective tissue septa separate the lobes into lobules. The lobules contain an outer portion (cortical zone) which is rich in lymphocytes and an inner portion (medullary zone) which is rich in epithelial cells. It is an organ essential for the development of the immune system. Its function is the maturation of the progenitor lymphoid cells to thymocytes and subsequently to mature T-cells. It reaches its greatest weight at puberty and subsequently begins to involute.	Thymus Gland		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C124340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124340>	C74948	Calcium Sulfate Crystals Measurement|CYCASULF|Calcium Sulfate Crystals|Calcium Sulfate Crystals|Calcium Sulphate Crystals Measurement	The determination of the amount of calcium sulphate crystals present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124341>	C75345	Free Androgen Index|FAI	A measurement of androgen status in a biological specimen, which is calculated by dividing total testosterone by sex hormone binding globulin and multiplying by a constant (usually 100).			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124342>	C74954	Galactose Elimination Capacity|GEC	A liver function test that measures galactose elimination capacity in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124343>	C64848	Deoxyhemoglobin Measurement|Deoxyhemoglobin|Deoxyhemoglobin|HGBDOXY	The determination of the amount of deoxyhemoglobin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124344>	C64430	Intercellular Adhesion Molecule Measurement|ICAM|ICAM Measurement|Intercellular Adhesion Molecule|Intercellular Adhesion Molecule	The determination of the amount of intercellular adhesion molecule present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124345>	C124344	Intercellular Adhesion Molecule 1 Measurement|ICAM1|ICAM1|ICAM1 Measurement|Intercellular Adhesion Molecule 1|Intercellular Adhesion Molecule 1|Intercellular Adhesion Molecule 1|Soluble CD54	The determination of the amount of intercellular adhesion molecule 1 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124346>	C81969	Mycobacterium tuberculosis IgA Antibody Measurement	The determination of the amount of Mycobacterium tuberculosis IgA antibody present in a sample.			Laboratory Procedure	
C124347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124347>	C81970	Mycobacterium tuberculosis IgE Antibody Measurement	The determination of the amount of Mycobacterium tuberculosis IgE antibody present in a sample.			Laboratory Procedure	
C124348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124348>	C81971	Mycobacterium tuberculosis IgG Antibody Measurement	The determination of the amount of Mycobacterium tuberculosis IgG antibody present in a sample.			Laboratory Procedure	
C124349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124349>	C64430	Osteopontin Measurement|OPN|Osteopontin|Osteopontin	The determination of the amount of osteopontin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12434>	C13236	Blood|BLOOD|Peripheral Blood|Reticuloendothelial System, Blood|Whole Blood|blood|blood|peripheral blood|portion of blood|vertebrate blood	A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.	Blood		Body Substance	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CTRP Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|OS Authorized Value Terminology|OS Lab Table|UBERON Terminology
C124350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124350>	C13038	Radix Penis|PENIS, RADIX	The most proximal portion of the penis located between the descending portion of the pubic bone and the body of the penis.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124351>	C85833	Clinical Evaluation|CLINICAL EVALUATION|Clinical Assessment|Clinical examination	The process of assessing an individual's physical, mental, or emotional condition; information can be gathered from multiple sources, including physical exam, personal interview and observation, medical history, laboratory and imaging tests.	Clinical Evaluation		Activity	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C124352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124352>	C38081	Interrupter Technique|INTERRUPTER TECHNIQUE|RINT|RINT	A non-invasive method of measuring airway resistance during which the subject breathes normally while airflow is interrupted at a predetermined rate and volume during the early exhalation phase. Airway resistance is calculated as the ratio of alveolar pressure, which is estimated from mouth pressure during occlusion, to airflow before interruption. This method is used most often in children and other subjects unable to comply with instructions for conventional lung function tests.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124353>	C25279	Symptom Onset|SYMPTOM ONSET	The point at which the symptoms began or were first noted.			Temporal Concept	CDISC SDTM Medical History Event Date Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124354>	C124278	Hymenolepis diminuta|HYMENOLEPIS DIMINUTA|Rat Tapeworm	A species of tapeworm in the family Hymenolepididae with a long cylindrical body, 4 suckers, and an apical organ at its scolex with no rostellar hooks. The lifecycle of H. diminuta involves beetles as the intermediate host and rodents as the definitive host. This tapeworm is prevalent in tropical zones worldwide but only rarely infects humans.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124355>	C124282	Onchocerca volvulus|ONCHOCERCA VOLVULUS	A species of nematode in the family Onchocercidae with a smooth cuticle, blunt anterior and posterior ends, and lacking lips or a buccal capsule. The lifecycle of O. volvulus involves the black fly as the intermediate host and humans as the definitive host. This nematode is the causative agent of onchocerciasis (river blindness).			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124356>	C124284	Opisthorchis felineus|Cat Liver Fluke|OPISTHORCHIS FELINEUS	A species of trematode parasite in the family Opisthorchiidae characterized by a light brownish-to pink color, a cuticle lacking spines, and 2 prominent suckers, an oral sucker and a ventral one. The life cycle of O. felineus involves freshwater snails as the first intermediate host, freshwater fish as the second intermediate host, and fish-eating mammals as the definitive host. Humans may become infested by eating undercooked fish.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124357>	C123335	Pleistophora|PLEISTOPHORA	A genus of unicellular obligate parasitic fungi in the family Pleistophoridae. Members of the species infect the muscle of fish and aquatic arthropods.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124358>	C77167	Pneumocystis|PNEUMOCYSTIS	A genus of yeast-like fungi in the family Pneumocystidaceae. Members of the genus are found in the lungs of terrestrial mammals from almost all geographic regions. Communication between hosts likely happens by an airborne route to uninfected individuals. Latent infections can develop into pneumonia in immunologically impaired individuals.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124359>	C86660	Prevotella amnii|PREVOTELLA AMNII	A species of anaerobic, non-motile, Gram-negative, rod-shaped bacteria in the family Prevotellaceae first isolated from human amniotic fluid. P. amnii is positive for phosphor-6-beta-galactosidase and negative for alpha-fucosidase and glutamyl-glutamic acid arylamidase.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12435>	C12471	Muscle Tissue|MUSCLE TISSUE	Tissue responsible for the body movements and the shape and size changes of internal organs.  Muscle tissue is composed of specialized contractile cells.  There are two types of muscle tissue recognized: striated and smooth muscle.  The striated muscle tissue is further subdivided into skeletal, visceral striated, and cardiac muscle.	Muscle Tissue		Tissue	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C124360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124360>	C86660	Prevotella baroniae|PREVOTELLA BARONIAE|Prevotella Genomospecies E4	A species of obligately anaerobic, non-motile, Gram-negative coccoid and short bacilli bacteria in the family Prevotellaceae first isolated from the human oral cavity. P. baroniae is able to ferment cellobiose, fructose, glucose, lactose, maltose, mannose, melibiose, raffinose, salicin, and sucrose.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124361>	C86660	Prevotella timonensis|PREVOTELLA TIMONENSIS	A species of obligately anaerobic, non-pigmented, non-spore-forming, non-motile, Gram-negative straight rod-shaped bacteria in the family Prevotellaceae first isolated from a human breast abscess. P. timonensis is able to ferment glucose, lactose and maltose.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124362>	C114128	Prototheca stagnora|PROTOTHECA STAGNORUM	A species of achlorophyllic alga in the family Chlorellaceae. P. stagnora is mucoid and grows only at 30 degrees C.			Plant	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124363>	C114128	Prototheca zopfii|PROTOTHECA ZOPFII	A species of achlorophyllic alga in the family Chlorellaceae. P. zopfii is a rare opportunistic pathogen, mostly infecting dogs and cattle.			Plant	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124364>	C86695	Urea-Positive Providencia stuartii|PROVIDENCIA STUARTII, UREA-POSITIVE	A subtype of Providencia stuartii that are positive for urease enzyme activity and are capable of hydrolyzing urea to ammonia and carbon dioxide. The determinant for urease likely resides on a transmissible plasmid.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124365>	C76375	Pseudomonas nitroreducens|PSEUDOMONAS NITROREDUCENS|Pseudomonas azelaica|Pseudomonas multiresinivorans	A species of gram-negative, motile, non-spore-forming, rod-shaped, aerobic soil bacteria in the family Pseudomonadaceae first isolated from oil brine in Japan. P. nitroreducens is negative for beta-galactosidase and hydrolysis of gelatin.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124366>	C124283	Pseudoterranova decipiens|Codworm|PSEUDOTERRANOVA DECIPIENS|Phocanema decipiens|Sealworm	A species of parasitic nematodes in the family Anisakidae. The lifecycle of P. decipiens involves crustaceans as the first intermediate host, fish or squids as the second intermediate host, and marine mammals as the definitive host. Humans may become infested by eating undercooked fish and may also develop anaphylaxis upon contact with the worm in properly prepared fish.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124367>	C77167	Pyrenochaeta|PYRENOCHAETA	A genus of fungi in the family Cucurbitariaceae that is found in soil and plant debris. Some species in the genus can cause mycetoma in humans.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124368>	C86713	Ralstonia pickettii Biovariant 1|Pseudomonas Group CDC Va-1|RALSTONIA PICKETTII BIOVARIANT 1|Ralstonia pickettii biovar 1|Ralstonia pickettii biovar Va-1	A subspecies of R. pickettii positive for tartrate and maleate, fermentation of lactose and maltose, and nitrate reduction.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124369>	C124289	Retortamonas intestinalis|RETORTAMONAS INTESTINALIS	A species of Retortamonas protozoa that form cysts and trophozoites in the large intestines of humans. Infestation with R. intestinalis occurs through ingestion of cysts in fecal-contaminated food or water. The species is considered non-pathogenic.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12436>	C12435	Striated Muscle Tissue|STRIATED MUSCLE TISSUE|Striated Muscle	Striated muscles are appendicular and axial muscles typically connected at either or both ends to the bony skeleton of the body.  Striated muscle fibers contain a highly organized, contractile cytoskeletal apparatus with a striated microscopic appearance; muscle contraction is typically under voluntary control.	Striated Muscle		Tissue	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124370>	C77169	Rhodotorula|RHODOTORULA	A genus of unicellular pigmented yeast in the order Sporidiales that are positive for urease and negative for fermentation of carbohydrates. Rhodotorula species are widespread in the environment with only three species isolated from human clinical samples, usually in hosts with central venous catheters and/or immunosuppression.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124371>	C86726	Roseomonas gilardii|ROSEOMONAS GILARDII	A species of Gram-negative, non-fermentative bacteria in the family Acetobacteraceae characterized as coccoid rods, appearing in pairs or short chains. R. gilardii does not hydrolyze esculin or oxidize salicin; citrate is utilized, and fructose and glycerol are oxidized.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124372>	C86726	Roseomonas mucosa|ROSEOMONAS MUCOSA	A species of Gram-negative cocco bacillus in the family Acetobacteraceae. R. mucosa is characterized by the formation of mucoid, runny colonies. The species has urease activity and assimilates arabinose, maltose, citrate, and glucose.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124373>	C86729	Ruminococcus gnavus|RUMINOCOCCUS GNAVUS	A species of anaerobic, Gram-positive gut microbes in the class Clostridia. R. gnavus is described as a normal part of the human gut flora, but can form opportunistic infections. The species is catalase negative, and growth is inhibited by metronidazole, bile, and vancomycin but not by kanamycin or colistin.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124374>	C86913	Salmonella enterica Serotype choleraesuis var. decatur|SALMONELLA CHOLERAESUIS VAR. DECATUR|Salmonella decatur	A gram-negative, rod-shaped serotype of the bacteria genus Salmonella, species Salmonella enterica, subspecies enterica. Salmonella Decatur, a rare human pathogen, was formerly classified as serotype Choleraesuis variant Decatur.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124375>	C86913	Salmonella enterica subsp. enterica Serovar enteritidis|Bacillus enteritidis|SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR ENTERITIDIS|Salmonella enteritidis	A gram negative, rod shaped non-motile serotype of the bacteria genus Salmonella, species Salmonella enterica, subspecies enterica. Salmonella Enteritidis is one of the most commonly reported pathogens of salmonellosis in humans, with eggs as the primary vehicle for infection.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124376>	C86913	Salmonella enterica subsp. enterica Serovar gallinarum|SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR GALLINARUM|Salmonella gallinarum	A gram negative, rod shaped, non-motile serotype of the bacteria genus Salmonella, species Salmonella enterica, subspecies enterica. Salmonella Gallinarum, one of two poultry-adapted strains of Salmonella bacteria, causes fowl typhoid.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124377>	C86913	Salmonella enterica subsp. enterica Serovar Pullorum|SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR PULLORUM|Salmonella pullorum	A gram negative, rod shaped, non-motile serotype of the bacteria genus Salmonella, species Salmonella enterica, subspecies enterica. Salmonella Pullorum, one of two poultry-adapted strains of Salmonella bacteria, causes Pullorum disease almost exclusively in young chickens.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124378>	C86913	Salmonella enterica subsp. enterica Serovar typhisuis|SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHISUIS|Salmonella typhisuis	A gram negative, rod shaped serotype of the bacteria genus Salmonella, species Salmonella enterica, subspecies enterica that causes swine fever in pigs.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124379>	C76380	Salmonella Serotype Group A|SALMONELLA SEROTYPE GROUP A	Characterization of salmonella bacteria subspecies as serotype group A based on the specific immunologic reactivity of cell surface lipopolysaccharide-protein chains called O antigens.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12437>	C12435	Smooth Muscle Tissue|MUSCLE, SMOOTH|SMOOTH MUSCLE TISSUE|Smooth Muscle	Involuntary muscle tissue of the internal organs. It is composed of elongated muscle cells or fibers that are not arranged in a striated pattern and form layers of muscle tissue. The smooth muscle cells contain a contractile apparatus composed of thin and thick filaments and a cytoskeleton composed of intermediate filaments.	Smooth Muscle		Tissue	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124380>	C76380	Salmonella Serotype Group B|SALMONELLA SEROTYPE GROUP B	Characterization of salmonella bacteria subspecies as serotype group B based on the specific immunologic reactivity of cell surface lipopolysaccharide-protein chains called O antigens.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124381>	C76380	Salmonella Serotype Group C|SALMONELLA SEROTYPE GROUP C	Characterization of salmonella bacteria subspecies as serotype group C based on the specific immunologic reactivity of cell surface lipopolysaccharide-protein chains called O antigens.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124382>	C76380	Salmonella Serotype Group C1|SALMONELLA SEROTYPE GROUP C1	Characterization of salmonella bacteria subspecies as serotype group C1 based on the specific immunologic reactivity of cell surface lipopolysaccharide-protein chains called O antigens.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124383>	C76380	Salmonella Serotype Group C2|SALMONELLA SEROTYPE GROUP C2	Characterization of salmonella bacteria subspecies as serotype group C2 based on the specific immunologic reactivity of cell surface lipopolysaccharide-protein chains called O antigens.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124384>	C124290	Sarcina ventriculi|SARCINA VENTRICULI|Zymosarcina ventriculi	A species of Gram-positive cocci bacteria in the family Clostridiaceae with an obligate anaerobic fermentative metabolism. S. ventriculi found in soil and may be a normal part of the human gut flora.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124385>	C124286	Sarcocystis hominis|SARCOCYSTIS HOMINIS	A species of Sarcocystis protozoa that uses cows as the intermediate host and humans as the definitive host. Infections with S. hominis are rare, are often asymptomatic, and generally clear spontaneously.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124386>	C124286	Sarcocystis suihominis|SARCOCYSTIS SUIHOMINIS	A species of Sarcocystis protozoa that uses pigs as the intermediate host and humans as the definitive host. Infections with S. hominis are rare, are often asymptomatic, and generally clear spontaneously.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124387>	C124285	Schistosoma Cercariae|SCHISTOSOMA CERCARIAE	The free-swimming, freshwater, aquatic form of Schistosoma flatworms. The cercariae is responsible for host finding and invasion, able to penetrate through intact skin rapidly.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124388>	C124285	Schistosoma haematobium|SCHISTOSOMA HAEMATOBIUM	A species of flatworms in the family Schistosomatidae with a strong oral sucker and a smaller posterior ventral sucker. Adult males are around 10 mm and females are 15 mm in length. The life cycle of S. haematobium involves snails as the intermediate host and humans as the definitive host. Within the body infestation is usual seen in the venous plexus of bladder, but it can also be found in the rectal venules.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124389>	C124285	Schistosoma intercalatum|SCHISTOSOMA INTERCALATUM	A species of flatworms in the family Schistosomatidae. S intercalatum is characterized by eggs that have a terminal spine and are intermediate in size between the smaller S. haematobium and larger S. bovis. These eggs are unique because they will stain red when exposed to the Ziehl-Neelsen staining technique. S. intercalatum has two major strains, each with its own preferred snail host: the Zaire strain uses Bulinus africanus as its intermediate host, while the Lower Guinea strain uses B. forskalii. Within the human body infestation is most often seen in the inferior mesenteric vein.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12438>	C13040	Central Nervous System|CENTRAL NERVOUS SYSTEM|CNS|CNS|CNS|Central nervous system|Nervous System, CNS|central nervous system|central nervous system|systema nervosum centrale	The part of the nervous system that consists of the brain, spinal cord, and meninges.	Central Nervous System		Body System	ALL Authorized Value Terminology|ALL Disease Characteristics Table|AML Authorized Value Terminology|AML Disease Characteristics Table|AML Myeloid Sarcoma Involvement Table|CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C124390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124390>	C124285	Schistosoma japonicum|SCHISTOSOMA JAPONICUM	A species of flatworms in the family Schistosomatidae. These flatworms are yellow or yellow-brown and the males are slightly larger than the other Schistosomes. This species' geographic range is restricted to China, Indonesia, and the Philippines. S. japonicum uses snails of the Oncomelania genus as its intermediate host. Within the body infestation is most frequently found in the superior mesenteric veins draining the small intestine.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124391>	C124285	Schistosoma mansoni|SCHISTOSOMA MANSONI	A species of flatworms in the family Schistosomatidae. The lifecycle of S. mansoni involves Biomphalaria snails as the intermediate host and humans as the definitive host. Infestation is most often found in the superior mesenteric veins draining the large intestine. This schistosome is a causative agent of intestinal schistosomiasis.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124392>	C124285	Schistosoma mekongi|SCHISTOSOMA MEKONGI	A species of flatworms in the family Schistosomatidae. S. mekongi is found exclusively in the Mekong river basin of Laos and Cambodia in South-east Asia. The snail Neotricula aperta acts as the intermediate host for this schistosome. Dogs serve as a reservoir for S. mekongi.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124393>	C77169	Schizophyllum|SCHIZOPHYLLUM	A genus of basidiomycete fungi in the family Schizophyllaceae with worldwide distribution. Species in the genus are isolated on rotting wood and only rarely infect humans.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124394>	C77167	Scopulariopsis|SCOPULARIOPSIS	A genus of anamorphic fungi in the family Microascaceae. Species in the genus are commonly found in soil and decaying wood, but some cause opportunistic infections in immunocompromised individuals.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124395>	C86010	Serratia liquefaciens Group|SERRATIA LIQUEFACIENS GROUP	A non-hierarchical grouping of similar bacteria assigned to the Serratia liquifaciens species.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124396>	C86739	Serratia odorifera Biogroup 1|SERRATIA ODORIFERA BIOGROUP 1	A subspecies of Serratia odorifera that is ornithine decarboxylase positive and ferments raffinose and sucrose.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124397>	C86739	Serratia odorifera Biogroup 2|SERRATIA ODORIFERA BIOGROUP 2	A subspecies of Serratia odorifera that is ornithine decarboxylase negative and negative for fermentation of raffinose and sucrose.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124398>	C86742	Shewanella putrefaciens Group	A non-hierarchical grouping of similar bacteria assigned to the Shewamella putrefaciens species.			Bacterium	
C124399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124399>	C124288	Spirillum minus|SPIRILLUM MINUS	A species of Spirillum bacteria that is the causative agent of sodoku, a form of rat-bite fever.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12439>	C33966|C13018	Brain|BRAIN|Brain structure (body structure)|Brain, NOS|CNS-Brain|Nervous System, Brain|brain	An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium.	Brain		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CRF5 Response Evaluation Image Evaluation Table|CRF6 DMG Imaging Assessment Table|CTDC Value Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|GCT Authorized Value Terminology|GCT Tumor Assessment Table|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C1243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1243>	C2124	Technetium Tc-99m Dextran|99m-Tc-Dx|Tc 99m Dextran|Tc-99m Dextran|Technetium 99m Dextran|technetium Tc 99m dextran				Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	NCI Drug Dictionary Terminology
C124400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124400>	C50921	Beta-Lactamase Negative Staphylococcus Aureus|STAPHYLOCOCCUS AUREUS, BETA-LACTAMASE NEGATIVE	A subgroup of S. aureus bacteria that lack the enzymatic function of beta-lactamase and are therefore sensitive to beta-lactam (penicillin) antibiotics.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124401>	C50921	Beta-Lactamase Positive Staphylococcus Aureus|STAPHYLOCOCCUS AUREUS, BETA-LACTAMASE POSITIVE	A subgroup of S. aureus bacteria that produce beta-lactamase and are therefore resistant to beta-lactam (penicillin) antibiotics.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124402>	C50921	Penicillinase Negative Staphylococcus Aureus|STAPHYLOCOCCUS AUREUS, PENICILLINASE NEGATIVE	A subgroup of S. aureus bacteria that lack the enzymatic function of beta-lactamase (penicillinase) and are therefore sensitive to beta-lactam (penicillin) antibiotics.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124403>	C50921	Penicillinase Positive Staphylococcus Aureus|STAPHYLOCOCCUS AUREUS, PENICILLINASE POSITIVE	A subgroup of S. aureus bacteria that produce beta-lactamase (penicillinase) and are therefore resistant to beta-lactam (penicillin) antibiotics.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124404>	C86756	Staphylococcus cohnii subsp. urealyticus|STAPHYLOCOCCUS COHNII SUBSP. UREALYTICUS	A subspecies of Staphylococcus cohnii that is positive for urease, beta-glucuronidase, and beta-galactosidase activities, with delayed alkaline phosphatase activity and the ability to produce acid aerobically from alpha-lactose. This subspecies is most frequently isolated in homes and is only rarely encountered in the hospital setting.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124405>	C86771	Staphylococcus schleiferi subsp. coagulans|STAPHYLOCOCCUS SCHLEIFERI SUBSP. COAGULANS	A subspecies of Staphylococcus schleiferi that is coagulase tube test positive, produces betahemolysin and a heat-stable nuclease but not a clumping factor. This subspecies has not been isolated from humans.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124406>	C62583	Staphylococcus succinus|STAPHYLOCOCCUS SUCCINUS	A species of coagulase-negative, Gram-positive coccoid bacterium in the order Bacillales.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124407>	C77167	Stemphylium|STEMPHYLIUM	A genus of brown-pigmented fungi in the family Pleosporaceae with terminal, multicellular conidia. Species in the genus are commonly found in soil and on decaying plant matter, but several species are plant pathogens.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124408>	C86789	Streptococcus equi subsp. zooepidemicus|STREPTOCOCCUS EQUI SUBSP. ZOOEPIDEMICUS	A subspecies of Streptococcus equi that is positive for beta hemolysis, produces hyaluronic acid but not streptolysin O, and occurs in pairs or long chains. This subspecies is also lactose positive and capable of fermenting sorbitol but not trehalose.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124409>	C76383	Streptococcus lutetiensis|STREPTOCOCCUS LUTETIENSIS	A species of Gram-positive, non-sporulating, non-motile coccus-shaped bacteria in the order Lactobacillales. S.lutetiensis is positive for alpha-galactosidase and beta-glucosidase and negative for catalase, urease, alkaline phosphatase, beta-glactosidase, and beta-glucuronidase. The species has been isolated from human cerebrospinal fluid, urine, and stool.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12440>	C13031	Amygdala|AMYGDALA|Amygdaloid Body|Amygdaloid Body|Amygdaloid Nucleus|Amygdaloid Nucleus|BRAIN, AMYGDALOID BODY	A cluster of nuclei located deep and medially within each temporal lobe of the brain. These limbic system structures serve a role in processing memory, emotional reactions and decision-making.	Amygdala		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124410>	C76383	Streptococcus massiliensis|STREPTOCOCCUS MASSILIENSIS	A species of Gram-positive, non-motile, non-spore-forming coccus-shaped bacteria in the order Lactobacillales. S. massiliensis is negative for beta-glucosidase, beta-galactosidase, beta-glucuronidase, alpha-galactosidase, urease, beta-glucosaminidase and beta-mannosidase. The species ferments maltose but is negative for fermentation of other sugars. It was originally isolated form a human clinical blood sample.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124411>	C86798	Streptococcus mutans|STREPTOCOCCUS MUTANS	A species of Gram-positive coccus-shaped bacteria in the order Lactobacillales. S. mutants is commonly found in the human oral cavity, where is a primary causative agent of tooth decay.	Streptococcus mutans		Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C124412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124412>	C76383	Streptococcus pluranimalium|STREPTOCOCCUS PLURANIMALIUM	A species of Gram-positive coccus-shaped, non-motile bacteria in the order Lactobacillales. S. pluranimalium is positive for acid production from glucose, fructose, and trehalose. This species is primarily responsible for infection in bovine and avian species with only limited identification of infection in human clinical isolates.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124413>	C86811	Streptococcus viridans|STREPTOCOCCUS VIRIDANS|VGS|Viridans Group Streptococci|Viridans Streptococcal Species|Viridans Streptococci	A non-taxonomic grouping of Streptococcal bacteria that are either alpha-hemolytic, producing a green coloration on blood agar plates, or nonhemolytic. Within this heterogeneous group, some species are commensal flora while others are human pathogens.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124414>	C49164	Response Evaluation Criteria in Solid Tumors Version 1.0|RECIST 1.0	A standardized guideline developed by the Response Evaluation Criteria in Solid Tumors (RECIST) Working Group in 2000, which is an objective response criteria used to assess solid tumor response and to measure change in tumor size for use in adult and pediatric cancer clinical trials. RECIST version 1.0 contains the following key features: definitions of minimum size of measurable lesions, instructions on how many lesions to follow, and the use of uni-dimensional rather than bi-dimensional measures for evaluation of tumor burden.			Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124415>	C49164	Response Evaluation Criteria in Solid Tumors Version 1.1|RECIST 1.1	A standardized guideline developed by the Response Evaluation Criteria in Solid Tumors (RECIST) Working Group in 2000 and revised in 2009, which is an objective response criteria used to assess solid tumor response and to measure change in tumor size for use in adult and pediatric cancer clinical trials. Major revisions in RECIST version 1.1 includes lymph node (LN) measurement, the maximum number of target lesions, the definition of disease progression, as well as the inclusion of and guidance on the use of MRI and FDG PET in the detection of new lesions.			Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124417>	C66973	Liter per Milligram|L/mg|L/mg|L/mg|L/mg|L/mg|l/mg|l/mg|mL/ug|mL/ug|nL/pg|uL/ng	A dose calculation unit expressed in liter(s) per milligram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124418>	C38081	Forced Inspiratory Flow at 25%|FIF25	The forced inspiratory flow rate at the point on the inspiratory flow-volume curve where 25 percent of the total volume of gas has been inhaled.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124419>	C38081	Forced Inspiratory Flow at 50%|FIF50	The forced inspiratory flow rate at the point on the inspiratory flow-volume curve where 50 percent of the total volume of gas has been inhaled.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12441>	C13031	Brain Stem|BRAIN STEM|BRAIN, BRAIN STEM|Brain stem|Brain, Brain stem|Brainstem|Brainstem|Brainstem|Brainstem structure (body structure)|brain stem|brain stem|brainstem|truncus encephali	Three sections, the midbrain, pons and medulla oblongata, that are located at the base of the brain. The brain stem regulates the central nervous system, and is vital as a conduit for motor and sensory innervations.	Brain Stem		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF6 DMG Imaging Assessment Table|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C124420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124420>	C38081	Forced Inspiratory Flow at 75%|FIF75	The forced inspiratory flow rate at the point on the inspiratory flow-volume curve where 75 percent of the total volume of gas has been inhaled.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124421>	C38081	Forced Vital Capacity in 6 Seconds|FVC6|FVC6	The volume of gas a subject can forcefully exhale during the first six seconds following maximum inhalation.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124422>	C38081	Airway Conductance|GAW|GAW	The instantaneous rate of gas flow in the airway, expressed as the pressure difference between any given part of the airway and the alveoli; it is the reciprocal of airway resistance (Raw).			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124423>	C38081	Inspiratory Vital Capacity|IVC|IVC	The maximum volume of gas an individual can inhale from the point of maximal exhalation.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124424>	C38081	Percent Predicted Inspiratory Vital Capacity|IVCPP|Percent Predicted IVC|Percent Predicted IVC	The maximum volume of gas an individual can inhale from the point of maximal exhalation expressed as a percentage of the expected result value for healthy individuals of similar age, sex, height, and race.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124425>	C38081	Lung Clearance Index|LCI	A representative measurement of the number of times the volume of gas in the lung at the start of the washout (the Functional Residual Capacity) must be recycled to eliminate the tracer to the pre-defined endpoint. Practically, this is the point where the end tidal concentration of inert gas is less than 1/40th of the opening concentration.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124426>	C38081	Thoracic Gas Volume|TGV	The absolute volume of gas contained in the thoracic cavity at any given point in time and at any level of alveolar pressure.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124427>	C4870|C124433	Complete Measurable Residual Disease Response|Complete MRD Response|Complete Minimal Residual Disease Response	Absence of residual disease based on pre-defined thresholds and MRD negativity by laboratory techniques.	Complete Measurable Residual Disease Response		Finding	CTRP Biomarker Terminology|CTRP Terminology
C124428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124428>	C124433	Measurable Residual Disease Negativity|MRD Negative|MRD Negativity|MRDneg|Measurable Residual Disease Negative|Minimal Residual Disease Negative|Minimal Residual Disease Negativity|Minimal Residual Disease Negativity|U-MRD|Undetectable Measurable Residual Disease|Undetectable Minimal Residual Disease|Undetected Minimal Residual Disease|uMRD	Absence of residual disease based on laboratory techniques.	Minimal Residual Disease Negativity		Finding	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C124429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124429>	C90169|C124433	Measurable Residual Disease Persistence|MRD Persistence|Minimal Residual Disease Persistence|Minimal Residual Disease Persistence	Presence of residual disease based on pre-defined thresholds and quantifiable MRD positivity by laboratory techniques.	Minimal Residual Disease Persistence		Finding	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C12442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12442>	C13031	Medulla Oblongata|BRAIN, MEDULLA OBLONGATA|MEDULLA OBLONGATA|Medulla|Medullary|Myelencephalon|medulla oblongata	The lower portion of the brainstem located between the pons and the spinal cord. This structure contains several descending and ascending tracts, lower cranial nerve nuclei, a significant proportion of the reticular system of the brainstem and other structures.	Medulla Oblongata		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF6 DIPG Imaging Assessment Table|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C124430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124430>	C38155|C124433	Measurable Residual Disease Relapse|MRD RELAPSE|MRD Reappearance|MRD Relapse|Minimal Residual Disease Relapse|Minimal Residual Disease Relapse|Relapse from MRD Negative|Relapsed Disease From Minimal Residual Disease Negativity|Relapsed Disease from MRD Negativity	Presence of residual disease based on pre-defined thresholds and return of quantifiable MRD positivity after a period of MRD negativity.	Measurable Residual Disease Relapse		Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C124431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124431>	C124433	Non-Quantifiable Measurable Residual Disease Positivity|NON-QUANTIFIABLE MRD POSITIVITY|Non-Quantifiable MRD Positivity|Non-Quantifiable Minimal Residual Disease Positivity|Non-Quantifiable Minimal Residual Disease Positivity	Presence of non-quantifiable residual disease based on laboratory techniques.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C124432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124432>	C3896	Quantifiable Measurable Residual Disease Positivity|QUANTIFIABLE MRD POSITIVITY|Quantifiable MRD Positivity|Quantifiable Minimal Residual Disease Positivity|Quantifiable Minimal Residual Disease Positivity|Quantifiable Minimal Residual Disease Positivity	Presence of quantifiable residual disease based on laboratory techniques.	Quantifiable Minimal Residual Disease Positivity		Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C124433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124433>	C50995	Measurable Residual Disease Response|MRD Response|MRD Response|MRDRESP|MRD_RESULT|MRD_RESULT|Minimal Residual Disease Response|Minimal Residual Disease Response|Minimal Residual Disease Response	An assessment of the minimal residual disease response to therapy.	Measurable Residual Disease Response		Finding	ALL Minimal Residual Disease Table|ALL Variable Terminology|AML Minimal Residual Disease Table|AML Variable Terminology|CDISC SDTM Terminology|CDISC SDTM Tumor Response Assessment Test Code Terminology|CDISC SDTM Tumor Response Assessment Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C124434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124434>	C50995	Symptomatic Deterioration|SYMPTDTR	A global deterioration of health status providing evidence of disease progression not covered by disease response criteria (eg. RECIST).			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Assessment Test Code Terminology|CDISC SDTM Tumor Response Assessment Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C124435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124435>	C81253	Gestational Age at Birth|GSTABRTH|weeks gestation at birth|weeks_gestation_at_birth	The gestational age of the subject at birth.			Health Care Activity	CDISC SDTM Subject Characteristic Test Code Terminology|CDISC SDTM Subject Characteristic Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Property Terminology|GDC Terminology
C124436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124436>	C28421	Sex at Birth	The physical sexual characteristics of the neonate at birth.			Organism Attribute	Operational Ontology for Radiation Oncology Prostate Cancer Terminology|SeroNet Study Descriptors|SeroNet Variables
C124437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124437>	C54571	Most Severe Acute Stressor|ACUTSTRS|ACUTSTRS	The agent, stimulus, activity, or event that causes stress with an acute frequency, which has the highest level of severity.			Conceptual Entity	CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Schizophrenia Findings About Test Code Terminology|CDISC SDTM Schizophrenia Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124438>	C213228	Age at First Episode|AGEEPSD1|AGEEPSD1|Age At First Episode|Age At First Episode|Age At First Episode	The age at which the first episode occurred.			Organism Attribute	CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Schizophrenia Findings About Test Code Terminology|CDISC SDTM Schizophrenia Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124439>	C69260	Age at First Hospitalization|AGEHOSP1|AGEHOSP1|Age At First Hospitalization|Age At First Hospitalization|Age At First Hospitalization	The age at which the first hospitalization event occurred.			Organism Attribute	CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Schizophrenia Findings About Test Code Terminology|CDISC SDTM Schizophrenia Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12443>	C13031	Cerebral Cortex|CEREBRAL CORTEX|Cortex|Cortical|cerebral cortex|cortex of cerebral hemisphere	The outer layer of the cerebrum composed of neurons and unmyelinated nerve fibers. It is responsible for memory, attention, consciousness and other higher levels of mental function.	Cortex		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C124440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124440>	C69260	Age at First Treatment|AGETRT1|AGETRT1|Age At First Treatment|Age At First Treatment|Age At First Treatment	The age at which the first treatment event occurred.			Organism Attribute	CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Schizophrenia Findings About Test Code Terminology|CDISC SDTM Schizophrenia Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124441>	C54571	Most Severe Chronic Stressor|CHRNSTRS|CHRNSTRS	The agent, stimulus, activity, or event that causes stress with a chronic frequency, which has the highest level of severity.			Conceptual Entity	CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Schizophrenia Findings About Test Code Terminology|CDISC SDTM Schizophrenia Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124442>	C25180	Clinic Stay Indicator|CLININD|CLININD	An indication as to whether the subject was admitted to a healthcare clinic.			Conceptual Entity	CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Schizophrenia Findings About Test Code Terminology|CDISC SDTM Schizophrenia Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124443>	C25337	Number of Hospitalizations|HOSPNUM|HOSPNUM|Number Of Hospitalizations|Number Of Hospitalizations|Number Of Hospitalizations	A measurement of the total number of hospitalization events that have occurred.			Quantitative Concept	CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Schizophrenia Findings About Test Code Terminology|CDISC SDTM Schizophrenia Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124444>	C19696	Treatment Environmental Setting|Encounter Environment|TRTSETT|TRTSETT|Treatment Setting|Treatment Setting|Treatment Setting	The surroundings or environment within which the subject receives therapeutic treatment.			Classification	CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Schizophrenia Findings About Test Code Terminology|CDISC SDTM Schizophrenia Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C124445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124445>	C28100	Non-Palpable|NONPALPABLE|Nonpalpable	Incapable of being handled, touched or felt through palpation.			Clinical Attribute	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C124446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124446>	C25337	Number of Lymph Nodes Examined|LMNDEXAM|NUMBER_NODES_NUMERIC|Number of Lymph Nodes Tested|lymph nodes tested|lymph_nodes_tested	The number of lymph nodes that were examined.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uveal Melanoma Baseline Form|GDC Property Terminology|GDC Terminology|HL Biopsy/Surgical Procedures Table|HL Variable Terminology
C124447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124447>	C25337	Number of Lymph Nodes Positive|LMNDPNUM|lymph nodes positive|lymph_nodes_positive	The number of subject lymph nodes that were positive for presence of disease.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Property Terminology|GDC Terminology
C124448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124448>	C135508	Lymph Node State|LNSTATE|LNSTATE|Lymph Node Status	A condition or state of a lymph node at a particular time.			Qualitative Concept	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C124449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124449>	C96643	Palpable State|PALPSTAT	A condition or state of the tumor with regards to its palpability status at a particular point in time.			Qualitative Concept	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C12444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12444>	C13031	Hippocampus|BRAIN, HIPPOCAMPUS|HIPPOCAMPUS|Hippocampal|Hippocampal structure (body structure)	A curved gray matter structure of the temporal lobe lying on the floor of the lateral ventricle of the brain.	Hippocampus		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C124450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124450>	C124277	Adjuvant Therapy Clinical Trial Setting|ADJUVANT	A clinical trial or treatment setting in which the therapy of interest is considered adjuvant.			Classification	CDISC SDTM Terminology|CDISC SDTM Treatment Setting Terminology|Clinical Data Interchange Standards Consortium Terminology
C124451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124451>	C124277	Locally Advanced Disease Clinical Trial Setting|LOCALLY ADVANCED	A clinical trial or treatment setting in which the therapy of interest is used to treat locally advanced disease.			Classification	CDISC SDTM Terminology|CDISC SDTM Treatment Setting Terminology|Clinical Data Interchange Standards Consortium Terminology
C124452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124452>	C124277	Metastatic Disease Clinical Trial Setting|METASTATIC	A clinical trial or treatment setting in which the therapy of interest is used to treat metastatic disease.			Classification	CDISC SDTM Terminology|CDISC SDTM Treatment Setting Terminology|Clinical Data Interchange Standards Consortium Terminology
C124453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124453>	C124277	Neoadjuvant Therapy Clinical Trial Setting|NEO-ADJUVANT	A clinical trial or treatment setting in which the therapy of interest is considered neo-adjuvant.			Classification	CDISC SDTM Terminology|CDISC SDTM Treatment Setting Terminology|Clinical Data Interchange Standards Consortium Terminology
C124454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124454>	C124277	Preventative Therapy Clinical Trial Setting|PREVENTATIVE	A clinical trial or treatment setting in which the therapy of interest is considered preventative.			Classification	CDISC SDTM Terminology|CDISC SDTM Treatment Setting Terminology|Clinical Data Interchange Standards Consortium Terminology
C124455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124455>	C16632	Country of Manufacture|MNFCNTRY	The name of the country within which the product under study is made.			Geographic Area	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C124456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124456>	C67281	Milligram per Squared Centimeter|mg/cm2|mg/cm2|mg/cm2	A unit of area density defined as a spread rate at which one milligram of a substance is spread over the area of one square centimeter. The unit is also used as a dose calculation unit.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124457>	C66973	Milligram per Dose|mg/dose|mg/dose|mg/{dose}|mg/{dose}	A unit of measure expressed in milligram(s) per dose.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124458>	C66973	Milligram per Kilogram per Dose|mg/kg/dose|mg/kg/dose|mg/kg/{dose}|mg/kg/{dose}	A dose calculation unit expressed in milligram(s) per kilogram per single dose.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124459>	C66973	Milliliter per Dose|mL/dose|mL/dose|mL/{dose}|mL/{dose}|ml/{dose}|ml/{dose}	A unit of measure expressed in milliliter(s) per dose.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12445>	C13031	Cerebellum|BRAIN, CEREBELLUM|Brain, Cerebellum, NOS|CEREBELLUM|Cerebellar|Cerebellar structure (body structure)|Cerebellum, NOS|cerebellum|cerebellum	The portion of the brain located at the base of the skull that is responsible for balance, equilibrium and movement.	Cerebellum		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF6 DIPG Imaging Assessment Table|CRF6 DMG Imaging Assessment Table|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C124460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124460>	C48463	Transducing Unit|TRANSDUCING UNIT|{TRANSDUCING UNIT}|{TRANSDUCING UNIT}	A unit of biological activity described as the number of viral particles in solution that are capable of infecting a cell and stimulating expression of a transgene.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124461>	C48470|C48463	Transducing Unit per Milliliter|TRANSDUCING UNIT/mL|Transducing Unit/mL|{TRANSDUCING UNIT}/mL|{TRANSDUCING UNIT}/mL|{TRANSDUCING UNIT}/ml|{TRANSDUCING UNIT}/ml	Unit of measure of potency expressed as a number of transducing units per one milliliter of solution.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124462>	C66973	Microgram per Dose|ug/dose|ug/dose|ug/{dose}|ug/{dose}	A unit of measure expressed in microgram(s) per dose.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124463>	C67375	Micro-International Unit per Deciliter|uIU/dL|uIU/dL|u[IU]/dL|u[IU]/dL|u[IU]/dl|u[IU]/dl|u[iU]/dL|u[iU]/dL|u[iU]/dl|u[iU]/dl	A unit of concentration (biologic activity) equal to one micro-international unit of substance per deciliter of solution.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124464>	C67456	Micro-International Unit per Liter|IU|microinternational unit per liter|uIU/L|uIU/L|u[IU]/L|u[IU]/L|u[IU]/L|u[IU]/l|u[IU]/l|u[iU]/L|u[iU]/L|u[iU]/l|u[iU]/l	A unit of concentration (biologic activity) equal to one micro-international unit of substance per liter of solution.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C124465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124465>	C70564	Microkatal per Trillion Erythrocytes|mckat/10^12 RBC|mckat/10^12 RBC|ukat/10*12{RBC}|ukat/10*12{RBC}|ukat/10^12 RBC|ukat/10^12 RBC|ukat/10^12{RBC}|ukat/10^12{RBC}	Unit of catalytic activity concentration defined as activity equal to one millionth of a katal per 10^12 erythrocytes.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124466>	C66973	Microliter per Dose|uL/dose|uL/dose|uL/{dose}|uL/{dose}|ul/{dose}|ul/{dose}	A unit of measure expressed in microliter(s) per dose.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124467>	C67395	Micromole per Hour per Millimole|umol/h/mmol|umol/h/mmol|umol/h/mmol	A unit of fraction expressed as the ratio of the number of micromoles of substance per unit of time equal to one hour, to the amount of a different substance, in millimoles.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124468>	C67395	Micromole per Liter per Hour|Femtomole per Nanoliter per Hour|Nanomole per Milliliter per Hour|Picomole per Microliter per Hour|fmol/nL/h|micromole per hour per liter|micromole per liter per hour|nmol/mL/h|nmol/mL/h|pmol/uL/h|umol/L/h|umol/L/h|umol/L/h|umol/L/h|umol/h/L|umol/l/h|umol/l/h	A concentration unit equal to one micromole of solute in one liter of solution per unit of time equal to one hour.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C124469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124469>	C67375	Micro-Unit per Deciliter|uU/dL|uU/dL|u{Unit}/dL|u{Unit}/dL|u{Unit}/dl|u{Unit}/dl|u{U}/dL|u{U}/dL|u{U}/dl|u{U}/dl	An arbitrary unit of substance content expressed in microunit(s) per deciliter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12446>	C49347	Corpus Callosum|BRAIN, CORPUS CALLOSUM|CORPUS CALLOSUM	A white matter structure within the cleft that separates the left and right cerebral hemispheres in the mammalian brain. It is composed of a wide, flat bundle of 200-250 million axonal projections.	Corpus Callosum		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C124470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124470>	C67375	Micro-Unit per Liter|uU/L|uU/L|u{Unit}/L|u{Unit}/L|u{Unit}/l|u{Unit}/l|u{U}/L|u{U}/L|u{U}/l|u{U}/l	An arbitrary unit of substance content expressed in microunit(s) per liter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124471>	C66973	Vector Genomes per Dose|VGC/dose|Vector Genomes/dose|Vector Genomic Copies/dose|vg/dose|vg/dose|{vg}/{dose}|{vg}/{dose}	A unit for cloning vector amounts expressed as the number of vector genomes per dose.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124472>	C67375|C48463	Vector Genomes per Milliliter|VGC/mL|Vector Genomes/mL|Vector Genomic Copies/mL|vg/mL|vg/mL|{vg}/mL|{vg}/mL|{vg}/ml|{vg}/ml	A unit for cloning vector amounts expressed as the number of vector genomes per milliliter.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124473>	C66973	Viral Particles per Dose|Viral Particles/dose|vp/dose|vp/dose|{vp}/{dose}|{vp}/{dose}	A unit for virus amount expressed as the number of viral particles per dose.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124474>	C67375|C48463	Viral Particles per Milliliter|Viral Particles/mL|vp/mL|vp/mL|{vp}/mL|{vp}/mL|{vp}/ml|{vp}/ml	A unit for virus amount expressed as the number of viral particles per milliliter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124475>	C172255	Mid-Upper Arm Circumference|MUARMCIR	A circumferential measurement of the largest part of the upper arm.			Spatial Concept	CDISC SDTM Terminology|CDISC SDTM Vital Sign Test Code Terminology|CDISC SDTM Vital Sign Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124476>	C62754	Gravid Uterus Adjusted Maternal Body Weight Gain|BWGAINGU|Gravid Uterus Adjusted Body Weight Gain|Gravid Uterus Adjusted Body Weight Gain	The amount of maternal body weight gained over a period of time where the weight at the end of the interval is adjusted for the gravid uterus weight. This is derived by subtracting the maternal body weight adjusted for the gravid uterus from the total maternal body weight.			Finding	CDISC SEND Body Weight Gain Test Code Terminology|CDISC SEND Body Weight Gain Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124477>	C81328	Gravid Uterus Adjusted Maternal Body Weight|BWADJGU|Gravid Uterus Adjusted Body Weight|Gravid Uterus Adjusted Body Weight	The maternal body weight adjusted for the weight of the gravid uterus. This is derived by subtracting the gravid uterus weight from the total maternal body weight.			Conceptual Entity	CDISC SEND Body Weight Test Code Terminology|CDISC SEND Body Weight Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124478>	C25167	Biparietal Distance|BIPADIST	A measurement of the length of the span between the protuberances of the parietal bones of the skull.			Quantitative Concept	CDISC SEND Fetal Measurement Test Code Terminology|CDISC SEND Fetal Measurement Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124479>	C81328	Fetal Body Weight|BWFETAL	An estimate or direct measurement of the heaviness of a fetus.			Conceptual Entity	CDISC SEND Fetal Measurement Test Code Terminology|CDISC SEND Fetal Measurement Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12447>	C13031	Basal Ganglia|BASAL GANGLIA|BRAIN, BASAL GANGLIA|Basal ganglia|collection of basal ganglia	Clusters of neurons comprising the globus pallidus, putamen, caudate, nucleus accumbens, substantia nigra and subthalamic nucleus. They are involved with high level aspects of inhibitory motor activity in coordination with the excitation commands issued from the cerebellum.	Basal Ganglia		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF7 Pathology Review Table|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C124480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124480>	C25335	Fluid Volume|FVOLUME	The amount of three dimensional space occupied by a fluid.			Quantitative Concept	CDISC SEND Fetal Measurement Test Code Terminology|CDISC SEND Fetal Measurement Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124481>	C25285	Occipitofrontal Diameter|OCCFDIAM	A measurement of the skull diameter, measured from the external occipital protuberance to the most prominent point of the frontal bone in the midline.			Spatial Concept	CDISC SEND Fetal Measurement Test Code Terminology|CDISC SEND Fetal Measurement Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124482>	C25337	Number of Ossified Skeletal Elements|OSSKELCT|Ossified Skeletal Element Count|Ossified Skeletal Element Count	A measurement of the number of skeletal elements with ossification centers present.			Quantitative Concept	CDISC SEND Fetal Measurement Test Code Terminology|CDISC SEND Fetal Measurement Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124483>	C90429	Fetal Organ Weight|OWFETAL	An estimate or direct measurement of the heaviness of a fetal organ.			Clinical Attribute	CDISC SEND Fetal Measurement Test Code Terminology|CDISC SEND Fetal Measurement Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124484>	C28421	Sex of Fetus|Fetal Sex|Fetal Sex|SEXFETAL	The determination of the sex of the fetus.			Organism Attribute	CDISC SEND Fetal Measurement Test Code Terminology|CDISC SEND Fetal Measurement Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124485>	C27993	Altered Consistency|ABNORMAL CONSISTENCY	A change resulting in a consistency that is different from the original.			Qualitative Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124486>	C82547	Abnormal Fissure|ABNORMAL FISSURE	An aberrant or malpositioned long, narrow slit or groove that divides a tissue into distinct areas.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124487>	C82547	Abnormal Flexure|ABNORMAL FLEXURE	A flexure that is deviating from the norm or outwith the bounds of what is considered normal.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124488>	C82547	Abnormal Lobation|ABNORMAL LOBATION	The formation of a lobe of tissue that is aberrant in comparison to normal anatomy.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124489>	C82547	Abnormal Origin|ABNORMAL ORIGIN|Malpositioned Origin	An origin that is deviating from the norm or outwith the bounds of what is considered normal.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12448>	C13031	Corpus Striatum|CORPUS STRIATUM|Striate Body|Striate Nucleus|Striatum	The striped grey and white matter that comprises the caudate and the lentiform nuclei, and is located anterior and lateral to the thalamus in each hemisphere of the brain.	Corpus Striatum		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C124490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124490>	C82547	Abnormal Suture Line|ABNORMAL SUTURE	Any line of sutures that deviates from its normal anatomical location.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124491>	C27993	Altered Texture|ABNORMAL TEXTURE|Altered Surface Texture	A change resulting in a texture that is different from the original.			Qualitative Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124492>	C124486	Absent Fissure|ABSENT FISSURE	The lack of a long, narrow slit or groove that divides a tissue into distinct areas.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124493>	C2849	Acephalostomia|ACEPHALOSTOMIA	A congenital defect characterized by the absence of most or all of the head, with the presence of a mouth-like opening on the upper thorax.			Disease or Syndrome	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124494>	C36291	Amniotic Band|AMNIOTIC BAND	One or more strands of fibrous amniotic tissue that can wrap around the fetus, causting constriction resulting in anatomic malformation.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124495>	C84482	Aorticopulmonary Septal Defect	A congenital heart malformation characterised by incomplete separation of the truncus arteriosus and the aorticopulmonary trunk, resulting in communication between the aorta and pulmonary trunk.			Disease or Syndrome	
C124496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124496>	C50680	Asymmetric Ossification|ASYMMETRIC OSSIFICATION|Misaligned Ossification	A finding of a lack of symmetry between two or more bilateral aligned primary ossific nuclei (ossification centers), typically indicated by greater stain uptake in one or more primary ossification centers as compared to others.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124497>	C2849	Atresia|ATRESIA|Atretic	A congenital anatomic defect characterised by the absence of a normally present opening in an organ or tissue.			Disease or Syndrome	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124498>	C27993	Bent|BENT|Bending|Bowed|Curved	A physical quality in which the entity or structure is bowed or curved.			Qualitative Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124499>	C27993	Bilobular|BILOBED	Of or pertaining to two lobes of an anatomic structure; divided into two lobes.			Qualitative Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12449>	C13031	Globus Pallidus|GLOBUS PALLIDUS	A sub-cortical, paired nuclei that, though migrated to the telencephalon, is a critical part of the basal ganglia, along with the caudate nucleus and the putamen, the latter of which it joins to form the lentiform nucleus. Each nucleus is subdivided into internal and external parts, called globus pallidus interna and globus pallidus externa, which are separated by an internal medullary lamina.	Globus Pallidus		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C1244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1244>	C902	Temozolomide|3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide|8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one|CCRG-81045|Gliotem|Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-|M & B 39831|M and B 39831|Methazolastone|Methazolastone|RP-46161|SCH 52365|TEMOZOLOMIDE|TMZ|Temcad|Temizole|Temodal|Temodar|Temodar|Temomedac|imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-|temozolomide	A triazene analog of dacarbazine with antineoplastic activity.  As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of DNA replication. Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. (NCI04)	Temozolomide		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124500>	C50680	Bipartite Ossification|BIPARTITE OSSIFICATION	A finding of two unfused primary ossification centers, as indicated by staining, usually resulting in two separate and distinct bones.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124501>	C13442	Blood-Filled|BLOOD FILLED	A finding indicating that that an anatomic space or cavity is filled with blood.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124502>	C137801	Blunt-Tipped Tail	A finding that the apex of the tail is rounded or dulled.			Finding	
C124503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124503>	C110937	Cartilage Not Fused|CARTILAGE NOT FUSED	A finding referring to incomplete or absent chondrogenesis.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124504>	C110937	Cartilaginous Fusion|CARTILAGINOUS FUSION	Joined together by cartilage.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124505>	C2849	Caudal Dysplasia|CAUDAL DYSPLASIA	A congenital abnormality characterized by the abnormal development of the lower portion of the body. Findings include hypoplastic lower extremities, defects of the caudal vertebrae, sacrum and neural tube, or maldeveloped gastrointestinal or genital organs.			Disease or Syndrome	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124506>	C2849	Cebocephaly|CEBOCEPHALY	A congenital abnormality characterized by a malformation of the head. The eyes are hypoteleric and the nose may be absent or misshapen (small, flattened, single nostril) and defective.			Disease or Syndrome	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124507>	C2849	Celosomy|CELOSOMY	A developmental abnormality characterized by the complex protrusion of viscera outside the abdominal wall.			Disease or Syndrome	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124508>	C2849	Cheilognathopalatoschisis|CHEILOGNATHOPALATOSCHISIS|Cheilognathouranoschisis	A congenital abnormality consisting of a fissure in the midline of the lip, hard and/or soft palate and upper jaw.			Disease or Syndrome	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124509>	C2849	Cheilognathoschisis|CHEILOGNATHOSCHISIS	A congenital abnormality consisting of a fissure in the midline of the lip and upper jaw.			Disease or Syndrome	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124510>	C2849	Facial Cleft	A congenital abnormality consisting of an opening or gap in the face, which results from incomplete fusion of one or more of the embryonic facial prominences.			Disease or Syndrome	
C124511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124511>	C2849	Cleft Jaw	A congenital abnormality consisting of clefting in the jaw, which results from incomplete fusion of the embryonic mandibular prominence.			Disease or Syndrome	
C124512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124512>	C2849	Mandibular Cleft	A congenital abnormality consisting of clefting in the lower face through the midline of the lip and/or mandible, which results from incomplete fusion of the embryonic mandibular prominence.			Disease or Syndrome	
C124513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124513>	C2849	Cleft Maxilla	A congenital abnormality consisting of a fissure in the midline of the upper jawbone.			Disease or Syndrome	
C124514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124514>	C36291	Collapsed Lumen|COLLAPSED LUMEN	A finding in which the walls of a tube or tubular organ have contorted or buckled into its cavity or channel.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124515>	C48187	Red-Brown Material|COLORED MATERIAL	Matter that is red and brown in color.			Substance	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124516>	C35552	Vessel Common Origin|COMMON ORIGIN	A finding that the blood vessels are arising from the same location.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124517>	C105595	Cranial Meningocele|CRANIAL MENINGOCELE	A congenital abnormality in which the meninges protrude through a defect in the cranium.			Disease or Syndrome	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124518>	C2849	Craniofenestria|CRANIOFENESTRIA	A congenital abnormality characterized by round or oval shaped defects in the membranous skull vault resulting in non-ossified, honey comb-like areas in the calvaria.			Disease or Syndrome	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124519>	C2849	Cranioschisis|CRANIOSCHISIS	A congenital abnormality characterized by the failure of the bones of the skull to close.			Disease or Syndrome	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12451>	C49346	Caudate Nucleus|CAUDATE NUCLEUS|Nucleus Caudatus	The grey matter adjacent to each lateral ventricle of the brain that comprises the medial dorsal striatum of the basal ganglia. The caudate nucleus is primarily involved in body and limb posture and movement.	Caudate Nucleus		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124520>	C2849	Cryptophthalmia|CRYPTOPHTHALMIA|Cryptophthalmos	A congenital abnormality characterized by the presence of a continuous layer of skin extending over the eyeballs and the absence of eyelids and the palpebral fissure.			Disease or Syndrome	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124521>	C137801	Curled Tail	A finding that the tail is curved or coiled into a circular shape.			Finding	
C124522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124522>	C2849	Cyclopia|CYCLOPIA|Monophthalmia|Single Eyeball|Synophthalmia	A rare congenital abnormality characterized by the failure of the embryonic prosencephalon to separate the eye orbit into two distinct cavities. Facial features tend to be absent although a proboscis has been seen to develop in conjunction.			Disease or Syndrome	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124523>	C83023	Anogenital Distance Decreased|DECREASED ANOGENITAL DISTANCE	An indication that the anogenital distance is less than the norm.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124524>	C27993	Detached|DETACHED|Floating|Non-articulated	Physically separated or not connected.			Qualitative Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124525>	C27993	Discoloration|DISCOLORED|Discolored	A change in color that deviates from the norm or outwith the bounds of what is considered normal.			Qualitative Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124526>	C27993	Distended|DISTENDED	Expanded out from or swelling from normal boundaries.			Qualitative Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124527>	C36282	Dome-Shaped Head	A head having the shape of a dome.			Finding	
C124528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124528>	C50680	Dumbbell Ossification|DUMBBELL OSSIFICATION	A finding of a fusion of two approximately spherical primary ossification centers at or near the mid-line through an ossified bony bridge, as indicated by staining.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124529>	C2849	Ethmocephaly|ETHMOCEPHALY	A congenital abnormality characterized by the presence of holoprosencephaly, a proboscis, the absence of a nose and microphthalmic, close-set eyes.			Disease or Syndrome	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12452>	C13031	Putamen|PUTAMEN	A structure located in the middle of the brain. The putamen is part of the basal ganglia and together with the caudate forms the striatum that influences motor activity.	Putamen		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C124530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124530>	C36291	Evagination|EVAGINATION	A finding that indicates an anatomic structure is partially or completely turned inside out.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124531>	C2849	Exencephaly|EXENCEPHALY	A congenital abnormality characterized by the extrusion of the brain outside of the skull.			Disease or Syndrome	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124532>	C78552	External Auditory Canal Fistula|EXTERNAL AURAL FISTULA	An abnormal communication between the external auditory canal and the adjacent tissues.			Anatomical Abnormality|Disease or Syndrome	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124533>	C137801	Externalized Heart|EXTERNALIZED HEART|Ectopia Cordis|Exocardia	A type of exocardia in which the heart develops outside of the body.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124534>	C38625	Fleshy Tab|FLESHY TAB	A tag or fold of skin or mucous tissue that extends from an anatomical structure without bony support.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124535>	C27993	Fluid-Filled|FLUID FILLED	Containing fluid.			Qualitative Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124536>	C27993	Fragmented|FRAGMENT	A physical quality in which the entity or structure is broken into pieces.			Qualitative Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124537>	C27993	Fused|FUSED	A physical quality in which the entity or structure is physically attached or combined with another entity or structure to become a whole.			Qualitative Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124538>	C2849	Ankyloglossia|FUSED TO FLOOR OF MOUTH	A developmental abnormality in which the bottom of the tongue is attached to the floor of the mouth.			Disease or Syndrome	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124539>	C27993	Hemicentric|HEMICENTRIC	Of or pertaining to the lateral aspects of the vertebral centrum.			Qualitative Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12453>	C49333	Substantia Nigra|BRAIN, SUBSTANTIA NIGRA|SUBSTANTIA NIGRA	A large cell mass extending forward, over the dorsal surface of the crus cerebri, from the rostral border of the pons into the subthalamic region. It is composed of a dorsal stratum of closely spaced pigmented cells, the pars compacta, and a larger ventral region of widely scattered cells, the pars reticulata. The pars compacta includes numerous cells that project forward to the striatum (caudate nucleus and putamen) and contain dopamine, which acts as the primary neurotransmitter at the synaptic endings. Other, apparently non-dopaminergic cells project to portions of the ventral nucleus of thalamus, the superior colliculus and reticular formation. The nigrostriatal projection is reciprocated by a striatonigral fiber system with multiple neurotransmitters, chief among which is gamma-aminobutyric acid (GABA). The substantia nigra is involved in the metabolic disturbances associated with Parkinson's disease and Huntington's disease.	Substantia Nigra		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124540>	C137801	Hemisternebra|HEMISTERNEBRA	A condition characterized by the absence of either lateral half of a sternebra.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124541>	C2849	Hemivertebra|HEMIVERTEBRA	A congenital abnormality characterized by incomplete development of one side of the vertebrae (arch and hemicentrum), resulting in spinal malformation.			Disease or Syndrome	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124542>	C110937	High Arch|HIGH-ARCHED	Abnormally raised arch.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124543>	C84923	Holorachischisis|HOLORACHISCHISIS	A form of the neural tube defect spina bifida in which the entire spinal column is open.			Disease or Syndrome	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124544>	C137801	Hooked Tail	A finding that the tail has an approximate 180 degree bend or curve.			Finding	
C124545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124545>	C27993	Hyperflexion|HYPERFLEXION	Flexion of a limb or part beyond its normal range.			Qualitative Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124546>	C36288	Incomplete Chondrogenesis|INCOMPLETE CHONDROGENESIS	Incomplete formation of cartilage.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124547>	C50680	Incomplete Ossification|INCOMPLETE OSSIFICATION	A finding of partial or decreased ossification, as indicated by reduced stain uptake.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124548>	C83023	Anogenital Distance Increased|INCREASED ANOGENITAL DISTANCE	An indication that the anogenital distance is greater than the norm.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124549>	C84923	Iniencephaly|INIENCEPHALY	A rare neural tube defect characterized by extreme retroflexion of the head and severe defects of the spine. It is usually associated with other congenital anomalies.			Disease or Syndrome	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12454>	C49346	Subthalamic Nucleus|Luy's nucleus|body of Forel|body of Luys|nucleus of Luys|nucleus of corpus luysii|nucleus subthalamicus|subthalamic nucleus|subthalamic nucleus (of Luys)	The paired, biconvex cluster of neurons located under the thalamus that plays a major role in the motor cortico-basal ganglia-thalamo-cortical circuit. The subthalamic nucleus is primary involved in the control of voluntary movement.	Subthalamic Nucleus		Body Part, Organ, or Organ Component	UBERON Terminology
C124550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124550>	C13442	Discontinuous Anatomic Feature|Discontinuous|INTERRUPTED	An anatomic structure that is disjointed or contains gaps.			Spatial Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124551>	C50680	Isolated Ossification Site|ISOLATED OSSIFICATION SITE	An ossification site not localized to the main ossification area, as indicated by staining, but is still considered to be within the margins of a normal bone precursor.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124552>	C137801	Kinked Tail	A finding that the tail has a localized undulation.			Finding	
C124553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124553>	C27993	Left-Sided|LEFT-SIDED	An abnormal transposition to the left side.			Qualitative Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124554>	C27993	Malpositioned|MALPOSITIONED	A physical quality in which the entity or structure is not appropriately or correctly placed.			Qualitative Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124555>	C27993	Malrotated|MALROTATED	Abnormally or pathologically rotated.			Qualitative Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124556>	C84506	Membranous Ventricular Septal Defect	A congenital heart defect resulting from deficient growth or failure of fusion of the membranous component of the ventricular septum.			Disease or Syndrome	
C124557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124557>	C97172	Encephalomeningocele|MENINGOENCEPHALOCELE|Meningoencephalocele	A congenital neural tube closure defect resulting in the protrusion of the brain and meninges through a skull opening.			Disease or Syndrome	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124558>	C84923	Meningohydroencephalocele|MENINGOHYDROENCEPHALOCELE	A congenital neural tube closure defect resulting in protrusion of the brain, the meninges, and the ventricular system through an opening in the skull, usually involving the squamous part of the occipital bone..			Disease or Syndrome	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124559>	C27993	Misalignment|MISALIGNED|Malaligned|Malaligned|Misaligned	Abnormallly positioned or aligned in relation to another structure.			Qualitative Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124560>	C27993	Misshapen|MISSHAPEN	Improperly or abnormally shaped.			Qualitative Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124561>	C13442	Multiple Malformations|MULTIPLE MALFORMATIONS	The presence of more than one malformed entities or structures.			Qualitative Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124562>	C13442	Multiple Abnormalities|MULTIPLE VARIATIONS	The presence of more than one anomaly.			Qualitative Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124563>	C84506	Muscular Ventricular Septal Defect	A congenital heart defect resulting from deficient growth or failure of fusion of the muscular component of the ventricular septum.			Disease or Syndrome	
C124564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124564>	C27993	Narrow|Coarctation|Constricted|NARROW	Having a width, or side to side dimension, that is less than is normally expected.			Qualitative Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124565>	C60925	Tooth Not Erupted|NOT ERUPTED TOOTH	A finding that a tooth has not emerged.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124566>	C27993	Not Fused|NOT FUSED	Not joined to form a single entity.			Qualitative Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124567>	C118807	Open Eye|Lid Gap	A finding in which the eye appears open at birth, either due to the congenital absence of eyelids or incomplete fusion of the eyelid.			Finding	
C124568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124568>	C2849	Otocephaly|OTOCEPHALY	A fatal, congenital, anatomic defect of the head characterised by a total or near total absence of the lower jaw, resulting in the union or close approach of the ears on the ventral side of the neck.			Disease or Syndrome	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124569>	C95834	Overriding Aorta	A congenital anatomic anomaly in which the aorta is positioned directly above a ventricular septal defect, thus receiving blood from both the right and left ventricles, resulting in an overall decrease In oxygenated haemoglobin and tissue cyanosis.			Disease or Syndrome	
C12456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12456>	C13031	Diencephalon	The portion of the forebrain that is located between the telencephalon and the brainstem; it is composed of the thalamus, hypothalamus, subthalamus, and epithalamus, which functions to help regulate many activities of the autonomic nervous system.	Diencephalon		Body Part, Organ, or Organ Component	
C124570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124570>	C13229	Persistent Embryonic Structure	An embryological structure that is retained past the usual embryonic stage.			Finding	
C124571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124571>	C9440	Premature Closure|PREMATURE CLOSURE	Fusion, stoppage, or loss of patency occurring before the usual or proper time.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124572>	C22188	Proboscis|PROBOSCIS	An elongated appendage originating from the head of an animal; in invertebrates, the term most often references tubular mouthparts used for feeding and sucking, whilst in vertebrates, the term references an elongated nose or snout.			Body Part, Organ, or Organ Component	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124573>	C2849	Prosoposchisis|PROSOPOSCHISIS	A congenital anatomic defect characterised by a facial cleft that extends from the mouth to the orbit of the eye.			Disease or Syndrome	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124574>	C27993	Protruding|PROTRUDING	Extending beyond a surface or boundary.			Qualitative Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124575>	C53543	Pseudohermaphroditism|PSEUDOHERMAPHRODITISM	A condition consisting of possessing the internal reproductive organs of one sex while exhibiting some of the secondary sex characteristics of the opposite sex.			Disease or Syndrome	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124576>	C48187	Red Material|RED MATERIAL	Matter that is red in color.			Substance	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124577>	C25640	Reduced Number|Fewer|Fewer Than Expected|REDUCED NUMBER	A decrease in the quantity of an entity.			Qualitative Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124578>	C26968	Retinal Fold|RETINAL FOLD|Retinal Folds	A crease in the retina.			Disease or Syndrome	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124579>	C225418	Retroesophageal|RETROESOPHAGEAL	Denoting the area behind the esophagus.			Spatial Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12457>	C13031	Epithalamus	A dorsal posterior section of the diencephalon that comprises the trigonum habenula, habenular commissure, stria medullaris, and pineal gland. The epithalamus is the connection between the limbic system and basal ganglia, and is involved in the secretion of melatonin and the regulation of motor pathways and emotions.	Epithalamus		Body Part, Organ, or Organ Component	
C124580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124580>	C2849	Rhinocephaly|RHINOCEPHALY	A congenital anatomic defect characterised by the presence of a proboscis-like nose located above the eyes, which are partially or completely fused.			Disease or Syndrome	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124581>	C27993	Right-Sided|RIGHT-SIDED	Pertaining to the physical area of an object that is located to the right of its center.			Qualitative Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124582>	C117337	Shared Placenta	A condition found in some polyzygotic pregnancies where two or more fetuses share a single placenta.			Finding	
C124583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124583>	C27993	Unilobular|SINGLE LOBE|Single Lobe|Single Lobed	Having or posessing a single lobe.			Qualitative Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124584>	C27993	Splayed|SPLAYED	Spread outward and apart.			Qualitative Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124585>	C124486	Supernumerary Fissure|Additional Fissure|SUPERNUMERARY FISSURE	An extraneous, additional long narrow slit or groove that divides an organ into lobes, or tissues and bone into parts.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124586>	C2849	Thoracogastroschisis|THORACOGASTROSCHISIS|Thoracoceloschisis	A congenital fissure of both the thoracic and abdominal walls.			Disease or Syndrome	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124587>	C2849	Thoracoschisis|THORACOSCHISIS	A congenital fissure of the thoracic wall.			Disease or Syndrome	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124588>	C27993	Thread-Like|Filamentous|THREAD-LIKE	Resembling a thread.			Qualitative Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124589>	C99538	Cor Triloculare	A congenital anatomic anomaly in which the heart has only three chambers.			Disease or Syndrome	
C12458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12458>	C13031	Hypothalamus|BRAIN, HYPOTHALAMUS|HYPOTHALAMUS|Hypothalamic structure (body structure)|hypothalamus|hypothalamus	A small, cone shaped collection of nuclei in the brain that is located below the thalamus and forms the lower side wall and floor of the third ventricle. It regulates homeostasis, the sleep-wake cycle, and metabolism, and plays a role in autonomic, endocrine, and motor function control.	Hypothalamus		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C124590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124590>	C13229	Thymic Cord|Extra Thymic Tissue|THYMIC CORD|Thymic Remnant in the Neck|Thymus Long Cranially	A fibrous band that connects the cervical thymus to the pharynx or mediastinum.			Embryonic Structure	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124591>	C99538	Cor Biloculare	A congenital anatomic anomaly in which the heart has only two chambers.			Disease or Syndrome	
C124592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124592>	C137801	Wavy Rib	A physical quality in which the rib is undulating.			Finding	
C124593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124593>	C27993	Wide|WIDE	Having a width, or side to side dimension, that is greater than is normally expected.			Qualitative Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124594>	C9440	Ossification Abnormality|OSSIFICATION	The abnormal formation of bone or bony substance.			Finding	CDISC SEND Fetal Pathology Findings Result Category Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124595>	C9440	Unclassified Abnormality|UNCLASSIFIED	A non-specified abnormality; an abnormality that is not included in a specified grouping of abnormalities.			Finding	CDISC SEND Fetal Pathology Findings Result Category Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124596>	C85833	External Examination|EXTREXAM	An assessment of the outside of the body.	External Examination		Diagnostic Procedure	CDISC SEND Fetal Pathology Findings Test Code Terminology|CDISC SEND Fetal Pathology Findings Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C124597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124597>	C124351	Maternal-Fetal Examination|MTFTEXAM	An assessment of the shared maternal-fetal structures.			Diagnostic Procedure	CDISC SEND Fetal Pathology Findings Test Code Terminology|CDISC SEND Fetal Pathology Findings Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124598>	C215116	Skeletal Examination|SKELEXAM	An assessment of the bone and cartilage structures.			Diagnostic Procedure	CDISC SEND Fetal Pathology Findings Test Code Terminology|CDISC SEND Fetal Pathology Findings Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124599>	C124351	Visceral Examination|VISCEXAM	An assessment of the internal soft tissue structures.			Diagnostic Procedure	CDISC SEND Fetal Pathology Findings Test Code Terminology|CDISC SEND Fetal Pathology Findings Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12459>	C13031	Thalamus|BRAIN, THALAMUS|Dorsal Thalamus|THALAMUS|dorsal plus ventral thalamus|thalamus	An ovoid mass composed predominantly of gray substance and associated laminae of white substance. The thalamus is divided into anterior, medial, and lateral parts. The function of the thalamus is to relay sensory impulses and cerebellar and basal ganglia projections to the cerebral cortex. The thalamus is positioned within the posterior part of the diencephalon forming most of each lateral wall of the third ventricle.	Thalamus		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF6 DIPG Imaging Assessment Table|CRF6 DMG Imaging Assessment Table|GCT Authorized Value Terminology|GCT Biopsy/Surgical Procedures Table|GCT Radiation Therapy Table|GCT Tumor Assessment Table|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C1245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1245>	C1933	Terephthalamidine|1,4-Benzenedicarboximidamide	A derivative of the phthalanilide compounds. Terephthalamidine belongs to a family of compounds which appear to reversibly bind to the minor groove of the DNA double helix but not intercalate DNA. This agent also has been suggested to form ionic complexes with many biological components in vitro, including nucleic acids, proteins and lipids.			Organic Chemical	NCI Drug Dictionary Terminology
C124600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124600>	C28554	Early Intrauterine Death|EARLY INTRAUTERINE DEATH|Early IUD	A death of the embryo occurring inside the uterus.			Finding	CDISC SEND Implantation Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124601>	C124279	Empty Implantation Site|EMPTY IMPLANTATION SITE	An implantation site that contains no discernible embryonic or placental tissue but may contain remnants of the implantation.			Finding	CDISC SEND Implantation Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124602>	C124280	Non-Clinical Gestation Trial Phase|GESTATION	The period of time in a non-clinical study beginning with evidence of mating observation until cesarean section or delivery.			Classification	CDISC SEND Nonclinical DART Trial Phases Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124603>	C124280	Non-Clinical Pairing Trial Phase|PAIRING	The period of time in a non-clinical study from the start of cohabitation until evidence of mating is observed and/or the subjects are separated.			Classification	CDISC SEND Nonclinical DART Trial Phases Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124604>	C124280	Non-Clinical Postnatal Trial Phase|POSTNATAL	The protocol defined period of time in a study that begins immediately after the birth of the subject.			Classification	CDISC SEND Nonclinical DART Trial Phases Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124605>	C124280	Non-Clinical Postpairing Trial Phase|POSTPAIRING|Post-cohabitation	The period of time in a non-clinical study that occurs after the paired subjects are separated. This includes males and non-confirmed mated females.			Classification	CDISC SEND Nonclinical DART Trial Phases Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124606>	C124280	Non-Clinical Premating Trial Phase|PREMATING|Pre-pairing	The period of time in a non-clinical study prior to cohabitation.			Classification	CDISC SEND Nonclinical DART Trial Phases Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124607>	C134576	Experimental Organism Benign Adenomyoepithelioma|ADENOMYOEPITHELIOMA, BENIGN	A benign neoplasm characterized by the proliferation of cells with myoepithelial differentiation around spaces which are lined by epithelial cells.			Classification	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C124608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124608>	C134576	Experimental Organism Malignant Neuroepithelial Carcinoma|CARCINOMA, NEUROEPITHELIAL, MALIGNANT	A carcinoma that arises from neuroepithelial tissues of the olfactory epithelium.			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C124609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124609>	C134576	Experimental Organism Benign Epithelial Stromal Tumor|EPITHELIAL-STROMAL TUMOR, BENIGN	A benign neoplasm containing two or more cell types arising from the mesenchymal and epithelial components.			Classification	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C12460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12460>	C13031	Tectum Mesencephali|TECTUM MESENCEPHALI	The dorsal part or roof plate of the midbrain, which consists of the pretectal area and the paired superior and inferior colliculi.	Tectum Mesencephali		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124610>	C134576	Experimental Organism Malignant Mesovarial Leiomyoma	A smooth muscle neoplasm with malignant charcateristics that arises from the mesovarium.			Neoplastic Process	
C124611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124611>	C134576	Experimental Organism Mesenchymal Proliferative Lesion|MESENCHYMAL PROLIFERATIVE LESION	A benign neoplasm arising from the submucosa and composed of large eosinophilic epithelioid and spindle cells. (INHAND)			Neoplastic Process	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124612>	C134576	Experimental Organism Glandular Polyp|POLYP, GLANDULAR, BENIGN	A benign polyp with prominent, hyperplastic glandular structures.			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C124613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124613>	C134576	Experimental Organism Malignant Sarcoma Arising From Fibroadenoma|SARCOMA ARISING IN FIBROADENOMA, MALIGNANT	A malignant mesenchymal neoplasm that arises from a pre-existing benign fibroadenoma.			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C124614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124614>	C134576	Experimental Organism Benign Mixed Sex Cord Stromal Tumor|SEX CORD STROMAL TUMOR, MIXED, BENIGN	A sex cord-stromal tumor that arises from the testis or ovary and does not metastasize.			Classification	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C124615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124615>	C134576	Experimental Organism Malignant Mixed Sex Cord Stromal Tumor|SEX CORD STROMAL TUMOR, MIXED, MALIGNANT	A malignant sex cord-stromal neoplasm that arises from the testis or ovary and is composed of a mix of cell types.			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C124616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124616>	C137801	Experimental Organism Aborted|ABORTED	Loss of all or part of the products of conception prior to the scheduled c-section date or expected delivery date.			Finding	CDISC SEND Pregnancy Findings Result Terminology|CDISC SEND Pregnancy Outcome Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124617>	C137801	Early Delivery of Experimental Organism|EARLY DELIVERY	A birth event that occurs prior to the scheduled c-section date or expected delivery date.			Finding	CDISC SEND Pregnancy Findings Result Terminology|CDISC SEND Pregnancy Outcome Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124618>	C137801	Resorbed or Dead Litter|RESORBED OR DEAD LITTER	A pregnancy result for a female that had all intrauterine deaths.			Finding	CDISC SEND Pregnancy Findings Result Terminology|CDISC SEND Pregnancy Outcome Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124619>	C25337	Corpora Lutea Number|CORPLUT|Corpora Lutea Count|Corpora Lutea Count	The number of corpora lutea present in the ovary or ovaries.			Quantitative Concept	CDISC SEND Pregnancy Findings Test Code Terminology|CDISC SEND Pregnancy Findings Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12461>	C13031	Corpora Quadrigemina|Quadrigeminal Body	The two pairs of colliculi located on the dorsal surface of the midbrain known as the inferior and superior colliculus.	Corpora Quadrigemina		Body Part, Organ, or Organ Component	
C124620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124620>	C25337	Number of Dead Fetuses|FETDENUM	A measurement of the number of dead fetuses in the uterus.			Quantitative Concept	CDISC SEND Pregnancy Findings Test Code Terminology|CDISC SEND Pregnancy Findings Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124621>	C44256	Fetal Female Sex Ratio|FETFSEXR	The determination of the ratio of live female fetuses compared to the total number of live fetuses present in the uterus. The measurement may be expressed as a fraction or percentage.			Quantitative Concept	CDISC SEND Pregnancy Findings Test Code Terminology|CDISC SEND Pregnancy Findings Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124622>	C25337	Number of Live Female Fetuses|FETLFNUM	A measurement of the number of live female fetuses present in the uterus.			Quantitative Concept	CDISC SEND Pregnancy Findings Test Code Terminology|CDISC SEND Pregnancy Findings Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124623>	C25337	Number of Live Male Fetuses|FETLMNUM	A measurement of the number of live male fetuses present in the uterus.			Quantitative Concept	CDISC SEND Pregnancy Findings Test Code Terminology|CDISC SEND Pregnancy Findings Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124624>	C25337	Number of Live Fetuses|FETLVNUM	A measurement of the number of live fetuses in the uterus.			Quantitative Concept	CDISC SEND Pregnancy Findings Test Code Terminology|CDISC SEND Pregnancy Findings Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124625>	C44256	Fetal Male Sex Ratio|FETMSEXR	The determination of the ratio of live male fetuses compared to the total number of live fetuses present in the uterus. The measurement may be expressed as a fraction or percentage.			Quantitative Concept	CDISC SEND Pregnancy Findings Test Code Terminology|CDISC SEND Pregnancy Findings Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124626>	C25337	Number of Fetuses|FETNUM	A measurement of the total number of fetuses, which includes alive and dead fetuses, present in the uterus.			Quantitative Concept	CDISC SEND Pregnancy Findings Test Code Terminology|CDISC SEND Pregnancy Findings Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124627>	C81328	Average Live Fetal Weight|FWAVGL	A measurement of the average weight of all live fetuses.			Conceptual Entity	CDISC SEND Pregnancy Findings Test Code Terminology|CDISC SEND Pregnancy Findings Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124628>	C81328	Average Female Live Fetal Weight|FWAVGLF	A measurement of the average weight of all live female fetuses.			Conceptual Entity	CDISC SEND Pregnancy Findings Test Code Terminology|CDISC SEND Pregnancy Findings Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124629>	C81328	Average Male Live Fetal Weight|FWAVGLM	A measurement of the average weight of all live male fetuses.			Conceptual Entity	CDISC SEND Pregnancy Findings Test Code Terminology|CDISC SEND Pregnancy Findings Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12462>	C12719	Dorsal Root Ganglion|GANGLION, DORSAL ROOT|Spinal Ganglion	Ganglion with sensory function within the vertebral column.	Dorsal Root Ganglion		Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124630>	C81328	Total Live Fetal Weight|FWTOTL	A measurement of the total weight of all live fetuses.			Conceptual Entity	CDISC SEND Pregnancy Findings Test Code Terminology|CDISC SEND Pregnancy Findings Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124631>	C25337	Number of Implantations|IMLNUM	A measurement of the number of implantations in the uterus.			Quantitative Concept	CDISC SEND Pregnancy Findings Test Code Terminology|CDISC SEND Pregnancy Findings Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124632>	C25337	Number of Intrauterine Deaths|IUDNUM	A measurement of the total number of deaths (dead fetuses plus resorptions) in the uterus/uterine horn(s).			Quantitative Concept	CDISC SEND Pregnancy Findings Test Code Terminology|CDISC SEND Pregnancy Findings Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124633>	C48570	Pre-implantation Loss Percent|PREIMLSP	The percentage of released ova that failed to implant.			Quantitative Concept	CDISC SEND Pregnancy Findings Test Code Terminology|CDISC SEND Pregnancy Findings Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124634>	C48570	Post-implantation Loss Percent|PSTIMLSP	The percentage of released ova that implanted and died.			Quantitative Concept	CDISC SEND Pregnancy Findings Test Code Terminology|CDISC SEND Pregnancy Findings Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124635>	C25337	Number of Early Resorptions|RSRPENUM	A measurement of the number of early resorptions in the uterus.			Quantitative Concept	CDISC SEND Pregnancy Findings Test Code Terminology|CDISC SEND Pregnancy Findings Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124636>	C25337	Number of Late Resorptions|RSRPLNUM	A measurement of the number of late resorptions in the uterus.			Quantitative Concept	CDISC SEND Pregnancy Findings Test Code Terminology|CDISC SEND Pregnancy Findings Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124637>	C25337	Number of Resorptions|RSRPNUM	A measurement of the total number of resorptions in the uterus.			Quantitative Concept	CDISC SEND Pregnancy Findings Test Code Terminology|CDISC SEND Pregnancy Findings Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124638>	C25714	SEND Developmental and Reproductive Toxicology Implementation Guide Version 1.0|SEND DART IG v1.0|SEND DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY IMPLEMENTATION GUIDE VERSION 1.0|SEND IG DART Version 1.0	The 1.0 version of the standard for exchange of nonclinical data (SEND) developmental and reproductive toxicology (DART) implementation guide.			Intellectual Product	CDISC SEND Terminology|CDISC SEND Version Terminology|Clinical Data Interchange Standards Consortium Terminology
C124639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124639>	C27993	Depression|DEPRESSION	An area that is sunken; lower than the surrounding surface.			Qualitative Concept	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12463>	C34237	Notochord	A rod-shaped embryonic midline structure that is found in all chordates. Notochords, comprised of stiff cartilage-like material, are oriented from head to tail and are the basis for axial skeleton development.	Notochord		Embryonic Structure	
C124640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124640>	C63629	Hole|HOLE	An aperture or hollow space within a solid mass			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124641>	C110937	Unossified|UNOSSIFIED	The absence of bone tissue.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124642>	C110937	Supernumerary Cranial Sutures|Supernumerary Suture|UNOSSIFIED LINE	Sutures commonly found within the parietal and occipital bones of the skull due to their multiple ossification centers. These sutures exhibit a zigzag pattern with interdigitations and sclerotic borders similar to, and join and merge with the major sutures.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124643>	C50620	Late Intrauterine Death|LATE INTRAUTERINE DEATH|Late IUD	A death of the fetus occurring inside the uterus.			Finding	CDISC SEND Implantation Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124644>	C28681|C129826	Therapeutic gamma delta T-lymphocytes|gammadelta T Cells|gd T Cells	A subset of therapeutic autologous T-lymphocytes that express a T-cell receptor (TCR) composed of one gamma chain and one delta chain, with potential immunomodulating and antineoplastic activities. Upon administration of the therapeutic gamma delta T-lymphocytes, these cells secrete interferon-gamma (IFN-g), and exert direct killing of tumor cells. In addition, these cells activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against tumor cells. Gamma delta T-lymphocytes play a key role in the activation of the immune system and do not require major histocompatibility complex (MHC)-mediated antigen presentation to exert their cytotoxic effect.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124645>	C29701|C2080	Ranitidine Hydrochloride/Bismuth Potassium Citrate/Sucralfate Hydrate Formulation|Albis|Ranitidine Hydrochloride/Bismuth Potassium Citrate/Sucralfate Hydrate	A formulation containing the hydrochloride salt form of the non-imidazole histamine H2 receptor antagonist ranitidine, bismuth potassium citrate, and the hydrate form of sucralfate, a basic aluminum complex of sulfated sucrose, with potential antacid, radio- and cytoprotective activities. Upon oral administration of the ranitidine hydrochloride/bismuth potassium citrate/sucralfate hydrate formulation, ranitidine binds to and blocks the activity of the histamine H2 receptors in the parietal cells in the stomach and in the gastrointestinal (GI) tract, thereby decreasing acid secretion. Sucralfate physically binds to the surface of damaged mucosa, thereby forming a protective barrier that shields the GI tract from stomach acid. It also neutralizes stomach acid. Bismuth inhibits peptic activity, increases mucosal secretions and acts as a barrier to prevent damage by acid. Altogether, this protects against ulcer formation and may help to heal existing ulcers.			Inorganic Chemical|Pharmacologic Substance	NCI Drug Dictionary Terminology
C124646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124646>	C200766	Anti-MUC1 CAR-transduced Autologous T-lymphocytes|Anti-MUC1 Autologous CAR T Cells|Anti-MUC1 CAR-transduced Autologous T Cells|Anti-Mucin1 Autologous CAR T Cells	Autologous T-lymphocytes transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) against the human tumor-associated epithelial antigen mucin 1 (MUC1), with potential immunomodulating and antineoplastic activities. Autologous PBLs from a patient with MUC1-positive cancer are transduced with a retroviral vector that encodes the CAR gene specific for MUC1. After expansion in culture and reintroduction into the patient, anti-MUC1 CAR-transduced autologous T-lymphocytes target and induce selective toxicity in MUC1-expressing tumor cells. MUC-1 is a human, hypoglycosylated tumor-associated antigen (TAA) overexpressed by epithelial cancer cells.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124647>	C20401	Anti-nf-P2X7 Antibody Ointment BIL-010t|BIL-010t|BSCT 10 % Ointment	An ointment formulation composed of a purified sheep immunoglobulin G (IgG) antibody against the non-functional form of the purinergic P2X7 receptor (nf-P2X7), with potential antineoplastic activity. Upon topical application of the anti-nf-P2X7 antibody ointment BIL-010t, the antibody binds to nf-P2X7 and inhibits its antiapoptotic activity. This may induce apoptosis and inhibit the growth of nf-P2X7-overexpressing cancer cells. P2X7, an ATP-gated cation-selective channel, plays a role in the induction of apoptosis; nf-P2X7, is upregulated in a variety of cancer cell types while not expressed on normal, healthy cells and is unable to form a large transmembrane, apoptotic pore upon exposure to ATP and prevents apoptosis.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124648>	C201666	ATM Kinase Inhibitor AZD0156|AZD-0156|AZD0156	An orally bioavailable ataxia telangiectasia mutated (ATM) kinase inhibitor, with potential chemo-/radio-sensitizing and antineoplastic activities. Upon oral administration, AZD0156 targets and binds to ATM, thereby inhibiting the kinase activity of ATM and ATM-mediated signaling. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, induces tumor cell apoptosis, and leads to cell death of ATM-overexpressing tumor cells. In addition, AZD0156 sensitizes tumor cells to chemo- and radiotherapy. ATM, a serine/threonine protein kinase, is upregulated in a variety of cancer cell types; it is activated in response to DNA damage and plays a key role in DNA-strand repair.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124649>	C308	Sheng-Yu-Tang|Chinese Medicine Sheng-Yu-Tang|Sagacious Cure Decoction	A Traditional Chinese Medicine (TCM) containing Radix Rehmanniae Praeparata, Radix Paeoniae Alba, Radix Astragali, Radix Ginseng, Radix Angelicae Sinensis, and Rhizoma Chuanxiong, with potential immunomodulating activity. Although the exact mechanism of action through which Sheng-Yu-Tang exerts its effect has yet to be fully elucidated, upon oral administration, this TCM may have a beneficial effect on the immune system.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C12464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12464>	C33966|C13018	Spinal Cord|Medulla Spinalis|Medulla Spinalis|SPINAL CORD|Spinal cord|Spinal cord|Spinal cord structure (body structure)|spinal cord|spinal cord	The elongated, approximately cylindrical part of the central nervous system of vertebrates that lies in the vertebral canal and from which the spinal nerves emerge.	Spinal Cord		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF6 DMG Imaging Assessment Table|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|GCT Authorized Value Terminology|GCT Biopsy/Surgical Procedures Table|GCT Radiation Therapy Table|GCT Tumor Assessment Table|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C124650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124650>	C200766	Anti-mesothelin CAR Vector-transduced Autologous T-lymphocytes|Anti-meso-CAR Vector-transduced Autologous T Cells	Genetically modified, autologous T-lymphocytes transduced with a retroviral vector encoding a chimeric antigen receptor (CAR) consisting of an anti-human tumor-associated antigen (TAA) mesothelin single chain variable fragment (scFv), the intracellular CD3 zeta T-cell receptor domain and the 4-1BB (cd137) costimulatory domain, with potential immunomodulating and antineoplastic activities. After isolation, transduction, expansion in culture, and reintroduction into the patient, the anti-mesothelin CAR vector-transduced autologous T-lymphocytes specifically target and kill mesothelin-expressing tumor cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124652>	C2594	ICT-121 Dendritic Cell Vaccine|CD133 Peptides-pulsed Autologous DC Vaccine|CD133 Peptides-pulsed Autologous Dendritic Cell Vaccine|ICT-121|ICT-121 DC Vaccine	A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with purified peptides derived from the tumor-associated antigen (TAA) CD133, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, monocytes are differentiated into DCs and are mixed with the CD133 peptides. Upon intradermal re-administration of the ICT-121 DC vaccine, the DCs present the CD133 peptides to the immune system, which stimulates the immune system to induce a specific cytotoxic T-lymphocyte (CTL) response against CD133-expressing tumor cells and leads to tumor cell lysis. CD133 is overexpressed on various types of cancer cells; its overexpression is correlated with increased resistance to chemotherapy.	ICT-121 Dendritic Cell Vaccine		Cell|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C124653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124653>	C177177|C177176	Telratolimod|3M 052|3M-052|MEDI 9197|MEDI-9197|MEDI9197|TELRATOLIMOD|TLR7/TLR8 Dual Agonist MEDI9197|Toll-like Receptor 7/8 Agonist MEDI9197	A toll-like receptor type 7 and 8 (TLR7/8) agonist with potential immunostimulating and antitumor activities. Upon intratumoral administration, telratolimod binds to and activates TLR7 and 8, thereby stimulating antigen-presenting cells (APCs), including dendritic cells (DCs). Activation of DCs results in the production of proinflammatory cytokines, and the activation of cytotoxic T-lymphocyte (CTL) and B-lymphocyte immune responses. This may cause tumor cell lysis. TLR7 and 8, members of the TLR family, play fundamental roles in the activation of the immune system.	Telratolimod		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124654>	C146993	Ralaniten Acetate|1,2-Propanediol, 3-(4-(1-(4-((2S)-2-(acetyloxy)-3-chloropropoxy)phenyl)-1-methylethyl)phenoxy)-, 1,2-Diacetate, (2S)-|AR Inhibitor EPI-506|EPI-506|RALANITEN ACETATE	An orally bioavailable, small molecule inhibitor of the acetate form of ralaniten, a N-terminal domain (NTD) of the androgen receptor (AR), with potential antineoplastic activity. Upon oral administration of ralaniten acetate, ralaniten specifically binds to the NTD of AR, thereby inhibiting both AR activation and the AR-mediated signaling pathway. This inhibits cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in proliferation, survival and chemoresistance of tumor cells.	Ralaniten Acetate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124655>	C28681|C138180|C129826	Autologous T-lymphocytes-expressing NY-ESO-1-C259-specific Enhanced T-cell Receptors|NY-ESO-1/C259T|NY-ESO-1C259T|NY-ESOc259T	Human autologous lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the cancer/testis antigen NY-ESO-1, with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the autologous T-lymphocytes expressing NY-ESO-1-C259-specific enhanced T-cell receptors bind to NY-ESO-1-overexpressing tumor cells. This may result in the specific cytotoxic T-lymphocyte (CTL) killing of NY-ESO-1-positive cancer cells. NY-ESO-1, a tumor-associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types; the TCR is specific for SLLMWITQC, an NY-ESO-1-derived peptide, in a complex with human leukocyte antigen (HLA) A2 peptide.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124656>	C201173|C200766	Anti-CD22 scFv TCRz:41BB-CAR Lentiviral Vector-transduced Autologous T-lymphocytes|Autologous T-lymphocytes-expressing CD22 CARs-expressing Tandem TCR-zeta/4-1BB|TCRzeta/4-1BB CART22 Cells	Autologous human T-lymphocytes transduced with a recombinant lentiviral vector encoding a chimeric T-cell receptor consisting of an anti-CD22 single chain variable fragment (scFv) and the co-stimulatory domain 4-1BB (CD137) coupled to the zeta chain of the TCR/CD3 complex (CD3-zeta), with potential immunostimulating and antineoplastic activities. Autologous peripheral blood lymphocytes (PBLs) from a patient with CD22-positive cancer are transduced with this lentiviral vector that encodes the CAR gene specific for CD22. After isolation, transduction, expansion in culture and reintroduction into the patient, the anti-CD22 scFv TCRz:41BB-CAR lentiviral vector-transduced autologous T-lymphocytes express anti-CD22-CAR on their cell surfaces and bind to the CD22 antigen on tumor cell surfaces. Subsequently, CD22-expressing tumor cells are lysed. CD22, a B-lineage-restricted, transmembrane phosphoglycoprotein, is expressed on malignant B-cells.	Anti-CD22 scFv TCRz:41BB-CAR Lentiviral Vector-transduced Autologous T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124657>	C201818|C199456	Ravulizumab|ALXN 1210|ALXN-1210|ALXN1210|RAVULIZUMAB|Ravulizumab-cwvz|Ultomiris	A longer-acting antibody directed against terminal complement protein C5, with potential anti-inflammatory activity. Upon administration, ravulizumab binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and preventing the complement-mediated destruction of red blood cells (RBCs) as seen in paroxysmal nocturnal hemoglobinuria (PNH). Compared to other anti-C5 antibodies, ALXN1210 is longer-acting and allows for monthly dosing. C5, a complement pathway protein, is expressed at high levels by the liver.	Ravulizumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C124658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124658>	C210691	Concentrated Fortified Collagen Protein Hydrolysate Liquid Supplement|Pro-Stat 101	A liquid-based nutritional supplement containing enzyme-hydrolyzed concentrated protein derived from collagen, and fortified with L-tryptophan, with potential anti-cachexic and wound-healing activities. The concentrated, fortified, collagen protein hydrolysate liquid supplement contains all essential and non-essential amino acids. Upon oral administration, this supplement may improve both gastric functioning and gastrointestinal (GI) health, thereby reducing vomiting and diarrhea. The hydrolyzed protein helps to alleviate the digestive burden and allows for fast and efficient absorption and utilization of the protein. This may prevent both malnutrition and weight loss.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C124659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124659>	C263|C258	Nitroglycerin/Sodium Citrate/Ethanol Solution|GTN-Citrate-Ethanol|Glyceryl Trinitrate-Citrate-Ethanol|NiCE|Nitroglycerin - Citrate - Ethanol	An antimicrobial lock solution (ALS) containing the nitrate nitroglycerin, sodium citrate and ethanol, with potential antimicrobial and anticoagulant activities. Upon application to the catheter as an ALS, the nitroglycerin is converted into nitric oxide (NO), which exerts antimicrobial activity. The citrate exerts anticoagulant activity, thereby preventing blood clotting and occlusion and maintaining the fluidity of the administered solution. In addition, both citrate and ethanol exert antimicrobial activity. This may prevent bacterial colonization on the surface of the catheter, biofilm formation and prevents catheter-associated infections.			Antibiotic|Pharmacologic Substance	NCI Drug Dictionary Terminology
C12465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12465>	C13040	Peripheral Nervous System|Peripheral nervous system|peripheral nervous system	That part of the nervous system consisting of the nerves and neurons that reside or extend outside the central nervous system.	Peripheral Nervous System		Body System	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C124660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124660>	C2080	Cobiprostone Spray|Cobiprostone Oral Spray|SPI-8811 Spray	A topical spray formulation containing the prostone cobiprostone, a type 2 chloride channel (ClC-2) agonist, with potential mucosal protective and anti-mucositis activities. Upon administration of cobiprostine via a spray into the oral cavity, cobiprostone specifically binds to and activates the ClC2 channel located on the mucosal membrane. This activates the epithelial ClC2 channel, enhances secretion of chloride, and promotes epithelial barrier repair.  This prevents or reduces mucosal injury and reduces mucositis. ClC2 plays a key role in the protection of mucosal barrier function.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C124661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124661>	C118970	CDISC Clinical Classification Tanner Scale-Boy Test Name Terminology|CC-Tanner Scale-Boy TEST|TANN02TN|Tanner Scale Boy Clinical Classification Test Name	Test names of clinical classification questions associated with the Tanner Scale Boy Version (Tanner Scale-Boy) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124662>	C118970	CDISC Clinical Classification Tanner Scale-Boy Test Code Terminology|CC-Tanner Scale-Boy TESTCD|TANN02TC|Tanner Scale Boy Clinical Classification Test Code	Test codes of clinical classification questions associated with the Tanner Scale Boy Version (Tanner Scale-Boy) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124663>	C118970	CDISC Clinical Classification Tanner Scale-Girl Test Name Terminology|CC-Tanner Scale-Girl TEST|TANN01TN|Tanner Scale Girl Clinical Classification Test Name	Test names of clinical classification questions associated with the Tanner Scale Girl Version (Tanner Scale-Girl) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124664>	C118970	CDISC Clinical Classification Tanner Scale-Girl Test Code Terminology|CC-Tanner Scale-Girl TESTCD|TANN01TC|Tanner Scale Girl Clinical Classification Test Code	Test codes of clinical classification questions associated with the Tanner Scale Girl Version (Tanner Scale-Girl) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124665>	C118970	CDISC Clinical Classification Atherosclerotic Cardiovascular Disease 10-Year Risk Estimator Test Name Terminology|ASCVD1TN|Atherosclerotic Cardiovascular Disease 10-Year Risk Estimator Clinical Classification Test Name|CC-ASCVD 10-Year Risk Estimator TEST	Test names of clinical classification questions associated with the Atherosclerotic Cardiovascular Disease 10-Year Risk Estimator (ASCVD 10-Year Risk Estimator) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124666>	C118970	CDISC Clinical Classification Atherosclerotic Cardiovascular Disease 10-Year Risk Estimator Test Code Terminology|ASCVD1TC|Atherosclerotic Cardiovascular Disease 10-Year Risk Estimator Clinical Classification Test Code|CC-ASCVD 10-Year Risk Estimator TESTCD	Test codes of clinical classification questions associated with the Atherosclerotic Cardiovascular Disease 10-Year Risk Estimator (ASCVD 10-Year Risk Estimator) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124667>	C118970	CDISC Clinical Classification ASSIGN Score Test Name Terminology|ASSG01TN|ASSIGN Cardiovascular Disease 10-Year Risk Score Clinical Classification Test Name|CC-ASSIGN Score TEST	Test names of clinical classification questions associated with the ASSIGN Cardiovascular Disease 10-Year Risk Score (ASSIGN Score) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124668>	C118970	CDISC Clinical Classification ASSIGN Score Test Code Terminology|ASSG01TC|ASSIGN Cardiovascular Disease 10-Year Risk Score Clinical Classification Test Code|CC-ASSIGN Score TESTCD	Test codes of clinical classification questions associated with the ASSIGN Cardiovascular Disease 10-Year Risk Score (ASSIGN Score) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124669>	C118970	CDISC Clinical Classification FHS CVD 10-Year Risk Score Test Name Terminology|CC-FHS CVD 10-Year Risk Score TEST|FCVD1TN|Framingham Heart Study Cardiovascular Disease 10-Year Risk Score Clinical Classification Test Name	Test names of clinical classification questions associated with the Framingham Heart Study Cardiovascular Disease 10-Year Risk Score (FHS CVD 10-Year Risk Score) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12466>	C13040	Nerve|NERVE|nerve	Part of the peripheral nervous system composed of bundles of nerve fibers running to various organs and tissues of the body using chemical and electrical signals to transmit sensory and motor information from one body part to another.	Nerve		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C124670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124670>	C118970	CDISC Clinical Classification FHS CVD 10-Year Risk Score Test Code Terminology|CC-FHS CVD 10-Year Risk Score TESTCD|FCVD1TC|Framingham Heart Study Cardiovascular Disease 10-Year Risk Score Clinical Classification Test Code	Test codes of clinical classification questions associated with the Framingham Heart Study Cardiovascular Disease 10-Year Risk Score (FHS CVD 10-Year Risk Score) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124671>	C118970	CDISC Clinical Classification Reynolds CVD 10-Year Risk Score Test Name Terminology|CC-Reynolds CVD 10-Year Risk Score TEST|RCVD01TN|Reynolds Cardiovascular Disease 10-Year Risk Score Clinical Classification Test Name	Test names of clinical classification questions associated with the Reynolds Cardiovascular Disease 10-Year Risk Score (Reynolds CVD 10-Year Risk Score) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124672>	C118970	CDISC Clinical Classification Reynolds CVD 10-Year Risk Score Test Code Terminology|CC-Reynolds CVD 10-Year Risk Score TESTCD|RCVD01TC|Reynolds Cardiovascular Disease 10-Year Risk Score Clinical Classification Test Code	Test codes of clinical classification questions associated with the Reynolds Cardiovascular Disease 10-Year Risk Score (Reynolds CVD 10-Year Risk Score) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124673>	C118970	CDISC Clinical Classification WHO Clinical Staging of HIV/AIDS for Adults and Adolescents Test Name Terminology|CC-WHO Clinical Staging of HIV/AIDS for Adults and Adolescents TEST|WHIVS1TN|WHO Clinical Staging of HIV/AIDS for Adults and Adolescents Clinical Classification Test Name	Test names of clinical classification questions associated with the World Health Organization Clinical Staging of HIV/AIDS for Adults and Adolescents (WHO Clinical Staging of HIV/AIDS for Adults and Adolescents) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124674>	C118970	CDISC Clinical Classification WHO Clinical Staging of HIV/AIDS for Adults and Adolescents Test Code Terminology|CC-WHO Clinical Staging of HIV/AIDS for Adults and Adolescents TESTCD|WHIVS1TC|WHO Clinical Staging of HIV/AIDS for Adults and Adolescents Clinical Classification Test Code	Test codes of clinical classification questions associated with the World Health Organization Clinical Staging of HIV/AIDS for Adults and Adolescents (WHO Clinical Staging of HIV/AIDS for Adults and Adolescents) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124675>	C118970	CDISC Clinical Classification WHO Clinical Staging of HIV/AIDS for Children Test Name Terminology|CC-WHO Clinical Staging of HIV/AIDS for Children TEST|WHIVS2TN|WHO Clinical Staging of HIV/AIDS for Children Clinical Classification Test Name	Test names of clinical classification questions associated with the World Health Organization Clinical Staging of HIV/AIDS for Children (WHO Clinical Staging of HIV/AIDS for Children) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124676>	C118970	CDISC Clinical Classification WHO Clinical Staging of HIV/AIDS for Children Test Code Terminology|CC-WHO Clinical Staging of HIV/AIDS for Children TESTCD|WHIVS2TC|WHO Clinical Staging of HIV/AIDS for Children Clinical Classification Test Code	Test codes of clinical classification questions associated with the World Health Organization Clinical Staging of HIV/AIDS for Children (WHO Clinical Staging of HIV/AIDS for Children) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124677>	C118970	CDISC Clinical Classification CDC Classification System for HIV-Infected Adults and Adolescents Test Name Terminology|CC-CDC Classification System for HIV-Infected Adults and Adolescents TEST|CDC Classification System for HIV-Infected Adults and Adolescents Clinical Classification Test Name|CHIVC1TN	Test names of clinical classification questions associated with the Center for Disease Control and Prevention Classification System for HIV-Infected Adults and Adolescents (CDC Classification System for HIV-Infected Adults and Adolescents) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124678>	C118970	CDISC Clinical Classification CDC Classification System for HIV-Infected Adults and Adolescents Test Code Terminology|CC-CDC Classification System for HIV-Infected Adults and Adolescents TESTCD|CDC Classification System for HIV-Infected Adults and Adolescents Clinical Classification Test Code|CHIVC1TC	Test codes of clinical classification questions associated with the Center for Disease Control and Prevention Classification System for HIV-Infected Adults and Adolescents (CDC Classification System for HIV-Infected Adults and Adolescents) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124679>	C118970	CDISC Clinical Classification West Haven Criteria Test Name Terminology|CC-West Haven Criteria TEST|WHEG01TN|West Haven Hepatic Encephalopathy Grade Clinical Classification Test Name	Test names of clinical classification questions associated with the West Haven Hepatic Encephalopathy Grade (West Haven Criteria) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12467>	C12720	Sympathetic Ganglion|SYMPATHETIC GANGLIA	A cluster of nerve cell bodies located within one of two paravertebral columns comprised of bundled nerve fibers that extend from the base of the skull to the first coccygeal vertebrae, or in a subsidiary location within the sympathetic nervous system. Sympathetic ganglia play a major role in the fight or flight and other stress-mediated responses.	Sympathetic Ganglion		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124680>	C118970	CDISC Clinical Classification West Haven Criteria Test Code Terminology|CC-West Haven Criteria TESTCD|WHEG01TC|West Haven Hepatic Encephalopathy Grade Clinical Classification Test Code	Test codes of clinical classification questions associated with the West Haven Hepatic Encephalopathy Grade (West Haven Criteria) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124681>	C118970	CDISC Clinical Classification Glasgow Coma Scale-NINDS Version 1.0 Test Name Terminology|CC-GCS NINDS Version TEST|GCS01TN|Glasgow Coma Scale NINDS Version 1.0 Clinical Classification Test Name	Test names of clinical classification questions associated with the Glasgow Coma Scale-NINDS Version 1.0 (GCS NINDS Version 1.0) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124682>	C118970	CDISC Clinical Classification Glasgow Coma Scale-NINDS Version 1.0 Test Code Terminology|CC-GCS NINDS Version TESTCD|GCS01TC|Glasgow Coma Scale NINDS Version 1.0 Clinical Classification Test Code	Test codes of clinical classification questions associated with the Glasgow Coma Scale-NINDS Version 1.0 (GCS NINDS Version 1.0) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124683>	C118970	CDISC Clinical Classification CRS-R Test Name Terminology|CC-CRS-R TEST|CRSR01TN|JFK Coma Recovery Scale-Revised Clinical Classification Test Name	Test names of clinical classification questions associated with the JFK Coma Recovery Scale-Revised (CRS-R) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124684>	C118970	CDISC Clinical Classification CRS-R Test Code Terminology|CC-CRS-R TESTCD|CRSR01TC|JFK Coma Recovery Scale-Revised Clinical Classification Test Code	Test codes of clinical classification questions associated with the JFK Coma Recovery Scale-Revised (CRS-R) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124685>	C118970	CDISC Clinical Classification PANSS Test Name Terminology|CC-PANSS TEST|PANSS1TN|Positive and Negative Syndrome Scale Clinical Classification Test Name	Test names of clinical classification questions associated with the Positive and Negative Syndrome Scale (PANSS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124686>	C118970	CDISC Clinical Classification PANSS Test Code Terminology|CC-PANSS TESTCD|PANSS1TC|Positive and Negative Syndrome Scale Clinical Classification Test Code	Test codes of clinical classification questions associated with the Positive and Negative Syndrome Scale (PANSS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124687>	C115302	CDISC Functional Test TMT Test Name Terminology|FT-TMT TEST|TMT01TN|Trail Making Test Functional Test Test Name	Test names of functional test questions associated with the Trail Making Test (TMT) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124688>	C115302	CDISC Functional Test TMT Test Code Terminology|FT-TMT TESTCD|TMT01TC|Trail Making Test Functional Test Test Code	Test codes of functional test questions associated with the Trail Making Test (TMT) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124689>	C211913	Tanner Scale-Boy Clinical Classification Question	A question associated with the Tanner Scale-Boy clinical classification.			Intellectual Product	
C12468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12468>	C13018	Lung|LUNG|Lung structure (body structure)|Lung, NOS|Lungs|Respiratory System, Lung|lung|lung|pulmo	One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.	Lung		Body Part, Organ, or Organ Component	AML Adverse Events Table|AML Authorized Value Terminology|CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CTDC Value Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|GCT Authorized Value Terminology|GCT Tumor Assessment Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Biopsy/Surgical Procedures Table|HL Lesion Characteristics Table|HL Radiation Therapy Table|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C124690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124690>	C211913	Tanner Scale-Girl Clinical Classification Question	A question associated with the Tanner Scale-Girl clinical classification.			Intellectual Product	
C124691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124691>	C211913	ASCVD 10-Year Risk Estimator Clinical Classification Question	A question associated with the ASCVD 10-Year Risk Estimator clinical classification.			Intellectual Product	
C124692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124692>	C211913	ASSIGN Score Clinical Classification Question	A question associated with the ASSIGN Score clinical classification.			Intellectual Product	
C124693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124693>	C211913	FHS CVD 10-Year Risk Score Clinical Classification Question	A question associated with the FHS CVD 10-Year Risk Score clinical classification.			Intellectual Product	
C124694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124694>	C211913	Reynolds CVD 10-Year Risk Score Clinical Classification Question	A question associated with the Reynolds CVD 10-Year Risk Score clinical classification.			Intellectual Product	
C124695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124695>	C211913	West Haven Criteria Clinical Classification Question	A question associated with the West Haven Criteria clinical classification.			Intellectual Product	
C124696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124696>	C211913	GCS NINDS Version 1.0 Clinical Classification Question	A question associated with the GCS NINDS Version 1.0 clinical classification.			Intellectual Product	
C124697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124697>	C211913	CRS-R Clinical Classification Question	A question associated with the CRS-R clinical classification.			Intellectual Product	
C124698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124698>	C211913	PANSS Clinical Classification Question	A question associated with the PANSS clinical classification.			Intellectual Product	
C124699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124699>	C211913	WHO Clinical Staging of HIV/AIDS for Adults and Adolescents Clinical Classification Question	A question associated with the WHO Clinical Staging of HIV/AIDS for Adults and Adolescents clinical classification.			Intellectual Product	
C12469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12469>	C12749	Pleura|PLEURA|PLEURA|PLEURA|PLEURAL TISSUE|Pleura, NOS|Pleural|Pleural Tissue|pleura|pleura|wall of pleural sac	The tissue that lines the wall of the thoracic cavity and the surface of the lungs.			Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTDC Value Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C1246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1246>	C862	Testosterone Cypionate|17Beta-Cyclopentanepropionate|Depo-Testosterone|Depo-testosterone|Depotest|Depovirin|Depovirin|Pertestis|Pertestis|TESTOSTERONE CYPIONATE|Testosterone cypionate|Testosterone cypionate|Virilon|depAndro	An eight-carbon ester form of Testosterone. The number of ester carbon atoms correlate with the half-life of the prodrug.  Testosterone inhibits gonadotropin secretion from the pituitary gland and ablates estrogen production in the ovaries, thereby decreasing endogenous estrogen levels.  In addition, this agent promotes the maintenance of male sex characteristics and is indicated for testosterone replacement in hypogonadal males. (NCI04)	Testosterone Cypionate		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C124700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124700>	C211913	WHO Clinical Staging of HIV/AIDS for Children Clinical Classification Question	A question associated with the WHO Clinical Staging of HIV/AIDS for Children clinical classification.			Intellectual Product	
C124701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124701>	C211913	CDC Classification System for HIV-Infected Adults and Adolescents Clinical Classification Question	A question associated with the CDC Classification System for HIV-Infected Adults and Adolescents clinical classification.			Intellectual Product	
C124702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124702>	C211913	TMT Functional Test Question	A question associated with the TMT functional test.			Intellectual Product	
C124703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124703>	C82394	Tanner Scale Boy Version|TANN02|TANNER SCALE BOY|Tanner Scale-Boy	A standardized rating scale developed by Marshal and Tanner in 1970, which is a classification system used to measure physical development in children, adolescents and adults. The boy version of the tanner scale assesses the different stages of physical maturity based on testicular volume, genitalia growth and the development of pubic hair. This instrument has 5 stages.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124704>	C82394	Tanner Scale Girl Version|TANN01|TANNER SCALE GIRL|Tanner Scale-Girl	A standardized rating scale developed by Marshal and Tanner in 1969, which is a classification system used to measure physical development in children, adolescents and adults. The girl version of the tanner scale assesses the different stages of physical maturity based on breast development and the growth of pubic hair. This instrument has 5 stages.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124705>	C118969	Atherosclerotic Cardiovascular Disease 10-Year Risk Estimator Clinical Classification|ASCVD 10-YEAR RISK|ASCVD 10-Year Risk Estimator|ASCVD1	A standardized rating scale developed by Goff et al in 2013, which is a classification system used to estimate 10-year and lifetime risks for atherosclerotic cardiovascular disease (ASCVD). This estimation takes into consideration of an individual's sex, age, race, diabetes and smoking histories, treatment for hypertension, as well as systolic blood pressure, total cholesterol and high-density lipoprotein (HDL) cholesterol levels.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124706>	C118969	ASSIGN Cardiovascular Disease 10-Year Risk Score Clinical Classification|ASSG01|ASSIGN CVD 10-YEAR RISK|ASSIGN Score	A standardized rating scale developed by Woodward et al and the Scottish Intercollegiate Guidelines Network (SIGN) in 2007, which is a classification system used to predict 10-year risk of cardiovascular disease.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124707>	C118969	Framingham Heart Study Cardiovascular Disease 10-Year Risk Score Clinical Classification|FCVD1|FHS CVD 10-YEAR RISK|FHS CVD 10-Year Risk Score	A standardized rating scale developed by D'Agostino et al in 2008 used to estimate the 10-year risk of cardiovascular disease (CVD). This estimation takes into consideration of an individual's sex, age, smoking history, treatment for blood pressure, as well as systolic blood pressure, total cholesterol and high-density lipoprotein (HDL) cholesterol levels.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124708>	C118969	Reynolds Cardiovascular Disease 10-Year Risk Score Clinical Classification|RCVD01|REYNOLDS CVD 10-YEAR RISK|Reynolds CVD 10-Year Risk Score	A standardized rating scale developed and modified by Ridker et al in 2007 and 2008, which is a classification system used to estimate the 10-year risk of cardiovascular disease (CVD). This estimation takes into consideration of an individual's sex, age, smoking and CVD family histories, as well as systolic blood pressure, high sensitivity C-reactive protein (hsCRP), total cholesterol and high-density lipoprotein (HDL) cholesterol levels.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124709>	C118969	West Haven Hepatic Encephalopathy Grade Clinical Classification|WEST HAVEN HEPATIC ENCEPHALOPATHY GRADE|WHEG01|West Haven Criteria	A standardized rating scale developed by Blei and Cordoba in 2001, which is a classification system used to describe the severity of hepatic encephalopathy based on the level of mental status and intellectual function. This instrument has 4 grades.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12470>	C13018	Skin|Human Skin|Integument|Integument|SKIN|Skin structure (body structure)|Skin, NOS|Skin, total|entire skin|skin of body|skin organ	An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages.	Skin		Body Part, Organ, or Organ Component	AML Adverse Events Table|AML Authorized Value Terminology|AML Myeloid Sarcoma Involvement Table|CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTDC Value Terminology|FDA Structured Product Labeling Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Genomic Specimen Type Value Set|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|SPL Tissue Form Product Type Terminology|UBERON Terminology
C124710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124710>	C118969	Glasgow Coma Scale-NINDS Version 1.0 Clinical Classification|GCS NINDS V1.0|GCS NINDS Version 1.0|GCS01	A standardized rating scale developed by Teasdale and Jennett in 1974, which is a classification system used to assess the level of consciousness. The NINDS version measures eye opening, motor and verbal responses.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124711>	C118969	JFK Coma Recovery Scale-Revised Clinical Classification|CRS-R|CRS-R|CRSR01	A standardized rating scale developed by Giacino et al in 1991, and modified and further characterized by Giacino et al in 2004, which is a classification system used to assist with differential diagnosis, prognostic assessment and treatment planning in patients with disorders of consciousness. This instrument contains 6 subscales addressing auditory, visual, motor, oromotor, communication, and arousal processes.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124712>	C118969	Positive and Negative Syndrome Scale Clinical Classification|PANSS|PANSS|PANSS1	A standardized rating scale developed by Kay et al in 1987, which is a classification system used to measure severity of patients with schizophrenia. This instrument rates a patient on a scale of 1 (absent) to 7 (extreme) on 30 different symptoms.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124713>	C118969	World Health Organization Clinical Staging of HIV/AIDS for Adults and Adolescents Clinical Classification|WHIVS1|WHO Clinical Staging of HIV/AIDS for Adults and Adolescents|WHO HIV STAGING FOR ADULTS AND ADOLESCENTS	A standardized rating scale developed by the World Health Organization (WHO) in 2007, which is a classification system used for immunological staging of HIV/AIDS in adults and adolescents with established HIV infection. This instrument classifies HIV disease on the basis of clinical manifestations.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124714>	C118969	World Health Organization Clinical Staging of HIV/AIDS for Children Clinical Classification|WHIVS2|WHO Clinical Staging of HIV/AIDS for Children|WHO HIV STAGING FOR CHILDREN	A standardized rating scale developed by the World Health Organization (WHO) in 2007, which is a classification system used for immunological staging of HIV/AIDS in children with established HIV infection. This instrument classifies HIV disease on the basis of clinical manifestations.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124715>	C118969	Center for Disease Control and Prevention Classification System for HIV-Infected Adults and Adolescents Clinical Classification|CDC Classification System for HIV-Infected Adults and Adolescents|CDC HIV CLASSIFICATION FOR ADULTS AND ADOLESCENTS|CHIVC1	A standardized rating scale developed and revised by the Centers for Disease Control and Prevention (CDC) in 1993, which is a classification system used to assess the severity of HIV disease based on CD4 cell counts and the presence of specific HIV-related conditions.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124716>	C124689	Tanner Scale-Boy - Genitalia Stages|TANN02-Genitalia Stages|TANN02-Genitalia Stages|TANN0201	Tanner Scale Boy Version (Tanner Scale-Boy) Genitalia stages.			Intellectual Product	CDISC Clinical Classification Tanner Scale-Boy Test Code Terminology|CDISC Clinical Classification Tanner Scale-Boy Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124717>	C124689	Tanner Scale-Boy - Pubic Hair Stages|TANN02-Pubic Hair Stages|TANN02-Pubic Hair Stages|TANN0202	Tanner Scale Boy Version (Tanner Scale-Boy) Pubic hair stages.			Intellectual Product	CDISC Clinical Classification Tanner Scale-Boy Test Code Terminology|CDISC Clinical Classification Tanner Scale-Boy Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124718>	C124690	Tanner Scale-Girl - Breast Stages|TANN01-Breast Stages|TANN01-Breast Stages|TANN0101	Tanner Scale Girl Version (Tanner Scale-Girl) Breast stages.			Intellectual Product	CDISC Clinical Classification Tanner Scale-Girl Test Code Terminology|CDISC Clinical Classification Tanner Scale-Girl Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124719>	C124690	Tanner Scale-Girl - Pubic Hair Stages|TANN01-Pubic Hair Stages|TANN01-Pubic Hair Stages|TANN0102	Tanner Scale Girl Version (Tanner Scale-Girl) Pubic hair stages.			Intellectual Product	CDISC Clinical Classification Tanner Scale-Girl Test Code Terminology|CDISC Clinical Classification Tanner Scale-Girl Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12471>	C12964	Soft Tissue|SOFT TISSUE|soft tissue	A general term comprising tissue that is not hardened or calcified; including muscle, fat, blood vessels, nerves, tendons, ligaments and fascia.	Soft Tissue		Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Radiation Therapy Table|EWS Tumor Assessment Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Lesion Characteristics Table|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table
C124720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124720>	C124691	ASCVD 10-Year Risk Estimator - Risk Score|ASCVD1-ASCVD 10-Year Risk Score|ASCVD1-ASCVD 10-Year Risk Score|ASCVD101	Atherosclerotic Cardiovascular Disease 10-Year Risk Estimator (ASCVD 10-Year Risk Estimator) Risk score.			Intellectual Product	CDISC Clinical Classification Atherosclerotic Cardiovascular Disease 10-Year Risk Estimator Test Code Terminology|CDISC Clinical Classification Atherosclerotic Cardiovascular Disease 10-Year Risk Estimator Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124721>	C124692	ASSIGN Score - Risk Score|ASSG01-ASSIGN Score|ASSG01-ASSIGN Score|ASSG0101	ASSIGN Cardiovascular Disease 10-Year Risk Score (ASSIGN Score) Risk score.			Intellectual Product	CDISC Clinical Classification ASSIGN Score Test Code Terminology|CDISC Clinical Classification ASSIGN Score Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124722>	C124693	FHS CVD 10-Year Risk Score - Risk Score|FCVD1-Framingham CVD 10-Year Risk Score|FCVD1-Framingham CVD 10-Year Risk Score|FCVD101	Framingham Heart Study Cardiovascular Disease 10-Year Risk Score (FCVD1-Framingham CVD 10-Year Risk Score) Risk score.			Intellectual Product	CDISC Clinical Classification FHS CVD 10-Year Risk Score Test Code Terminology|CDISC Clinical Classification FHS CVD 10-Year Risk Score Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124723>	C124694	Reynolds CVD 10-Year Risk Score - Risk Score|RCVD01-Reynolds CVD 10-Year Risk Score|RCVD01-Reynolds CVD 10-Year Risk Score|RCVD0101	Reynolds Cardiovascular Disease 10-Year Risk Score (Reynolds CVD 10-Year Risk Score) Risk score.			Intellectual Product	CDISC Clinical Classification Reynolds CVD 10-Year Risk Score Test Code Terminology|CDISC Clinical Classification Reynolds CVD 10-Year Risk Score Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124724>	C124696	Glasgow Coma Scale-NINDS Version 1.0 - Best Eye Response|GCS01-Best Eye Response|GCS01-Best Eye Response|GCS0101	Glasgow Coma Scale-NINDS Version 1.0 (GCS NINDS Version 1.0) Best eye response.			Intellectual Product	CDISC Clinical Classification Glasgow Coma Scale-NINDS Version 1.0 Test Code Terminology|CDISC Clinical Classification Glasgow Coma Scale-NINDS Version 1.0 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124725>	C124696	Glasgow Coma Scale-NINDS Version 1.0 - Motor Response|GCS01-Motor Response|GCS01-Motor Response|GCS0102	Glasgow Coma Scale-NINDS Version 1.0 (GCS NINDS Version 1.0) Motor response.			Intellectual Product	CDISC Clinical Classification Glasgow Coma Scale-NINDS Version 1.0 Test Code Terminology|CDISC Clinical Classification Glasgow Coma Scale-NINDS Version 1.0 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124726>	C124696	Glasgow Coma Scale-NINDS Version 1.0 - Verbal Response|GCS01-Verbal Response|GCS01-Verbal Response|GCS0103	Glasgow Coma Scale-NINDS Version 1.0 (GCS NINDS Version 1.0) Verbal response.			Intellectual Product	CDISC Clinical Classification Glasgow Coma Scale-NINDS Version 1.0 Test Code Terminology|CDISC Clinical Classification Glasgow Coma Scale-NINDS Version 1.0 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124727>	C124696	Glasgow Coma Scale-NINDS Version 1.0 - Total Score|GCS01-Total Score|GCS01-Total Score|GCS0104	Glasgow Coma Scale-NINDS Version 1.0 (GCS NINDS Version 1.0) Total score.			Intellectual Product	CDISC Clinical Classification Glasgow Coma Scale-NINDS Version 1.0 Test Code Terminology|CDISC Clinical Classification Glasgow Coma Scale-NINDS Version 1.0 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124728>	C124696	Glasgow Coma Scale-NINDS Version 1.0 - Confounder: GCS Accurate|GCS01-Confounder: GCS Accurate|GCS01-Confounder: GCS Accurate|GCS0105A	Glasgow Coma Scale-NINDS Version 1.0 (GCS NINDS Version 1.0) GCS Confounder Type: GCS accurate.			Intellectual Product	CDISC Clinical Classification Glasgow Coma Scale-NINDS Version 1.0 Test Code Terminology|CDISC Clinical Classification Glasgow Coma Scale-NINDS Version 1.0 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124729>	C124696	Glasgow Coma Scale-NINDS Version 1.0 - Confounder: Paralytic|GCS01-Confounder: Paralytic|GCS01-Confounder: Paralytic|GCS0105B	Glasgow Coma Scale-NINDS Version 1.0 (GCS NINDS Version 1.0) GCS Confounder Type: paralytic.			Intellectual Product	CDISC Clinical Classification Glasgow Coma Scale-NINDS Version 1.0 Test Code Terminology|CDISC Clinical Classification Glasgow Coma Scale-NINDS Version 1.0 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12472>	C12471	Adipose Tissue|ADIPOSE TISSUE|ADIPOSE TISSUE|Adipose|Body Fat|Body Fat|Fat Tissue|Human Adipose Tissue|adipose tissue|fat|fat tissue|fatty tissue	A specialized form of connective tissue consisting primarily of adipocytes (fat cells), surrounded by a meshwork of collagen fibers.	Adipose Tissue		Tissue	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Structured Product Labeling Terminology|GDC Terminology|GDC Value Terminology|SPL Tissue Form Product Type Terminology|UBERON Terminology
C124730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124730>	C124696	Glasgow Coma Scale-NINDS Version 1.0 - Confounder: Alcohol or Drug of Abuse|GCS01-Confounder: Alcohol/Drug of Abuse|GCS01-Confounder: Alcohol/Drug of Abuse|GCS0105C	Glasgow Coma Scale-NINDS Version 1.0 (GCS NINDS Version 1.0) GCS Confounder Type: alcohol or drugs of abuse.			Intellectual Product	CDISC Clinical Classification Glasgow Coma Scale-NINDS Version 1.0 Test Code Terminology|CDISC Clinical Classification Glasgow Coma Scale-NINDS Version 1.0 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124731>	C124696	Glasgow Coma Scale-NINDS Version 1.0 - Confounder: C-Spine Injury|GCS01-Confounder: C-Spine Injury|GCS01-Confounder: C-Spine Injury|GCS0105D	Glasgow Coma Scale-NINDS Version 1.0 (GCS NINDS Version 1.0) GCS Confounder Type: C-spine injury.			Intellectual Product	CDISC Clinical Classification Glasgow Coma Scale-NINDS Version 1.0 Test Code Terminology|CDISC Clinical Classification Glasgow Coma Scale-NINDS Version 1.0 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124732>	C124696	Glasgow Coma Scale-NINDS Version 1.0 - Confounder: Hypoxia or Hypotension|GCS01-Confounder: Hypoxia/Hypotension|GCS01-Confounder: Hypoxia/Hypotension|GCS0105E	Glasgow Coma Scale-NINDS Version 1.0 (GCS NINDS Version 1.0) GCS Confounder Type: hypoxia or hypotension.			Intellectual Product	CDISC Clinical Classification Glasgow Coma Scale-NINDS Version 1.0 Test Code Terminology|CDISC Clinical Classification Glasgow Coma Scale-NINDS Version 1.0 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124733>	C124696	Glasgow Coma Scale-NINDS Version 1.0 - Confounder: Hypothermia|GCS01-Confounder: Hypothermia|GCS01-Confounder: Hypothermia|GCS0105F	Glasgow Coma Scale-NINDS Version 1.0 (GCS NINDS Version 1.0) GCS Confounder Type: hypothermia.			Intellectual Product	CDISC Clinical Classification Glasgow Coma Scale-NINDS Version 1.0 Test Code Terminology|CDISC Clinical Classification Glasgow Coma Scale-NINDS Version 1.0 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124734>	C124696	Glasgow Coma Scale-NINDS Version 1.0 - Confounder: Sedation|GCS01-Confounder: Sedation|GCS01-Confounder: Sedation|GCS0105G	Glasgow Coma Scale-NINDS Version 1.0 (GCS NINDS Version 1.0) GCS Confounder Type: sedation.			Intellectual Product	CDISC Clinical Classification Glasgow Coma Scale-NINDS Version 1.0 Test Code Terminology|CDISC Clinical Classification Glasgow Coma Scale-NINDS Version 1.0 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124735>	C124696	Glasgow Coma Scale-NINDS Version 1.0 - Confounder: Unknown|GCS01-Confounder: Unknown|GCS01-Confounder: Unknown|GCS0105H	Glasgow Coma Scale-NINDS Version 1.0 (GCS NINDS Version 1.0) GCS Confounder Type: unknown.			Intellectual Product	CDISC Clinical Classification Glasgow Coma Scale-NINDS Version 1.0 Test Code Terminology|CDISC Clinical Classification Glasgow Coma Scale-NINDS Version 1.0 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124736>	C124697	CRS-R - Diagnosis|CRSR01-Diagnosis|CRSR01-Diagnosis|CRSR0101	JFK Coma Recovery Scale-Revised (CRS-R) Diagnosis.			Intellectual Product	CDISC Clinical Classification CRS-R Test Code Terminology|CDISC Clinical Classification CRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124737>	C124697	CRS-R - Etiology|CRSR01-Etiology|CRSR01-Etiology|CRSR0102	JFK Coma Recovery Scale-Revised (CRS-R) Etiology.			Intellectual Product	CDISC Clinical Classification CRS-R Test Code Terminology|CDISC Clinical Classification CRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124738>	C124697	CRS-R - Date of Onset|CRSR01-Date of Onset|CRSR01-Date of Onset|CRSR0103	JFK Coma Recovery Scale-Revised (CRS-R) Date of onset.			Intellectual Product	CDISC Clinical Classification CRS-R Test Code Terminology|CDISC Clinical Classification CRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124739>	C124697	CRS-R - Date of Admission|CRSR01-Date of Admission|CRSR01-Date of Admission|CRSR0104	JFK Coma Recovery Scale-Revised (CRS-R) Date of admission.			Intellectual Product	CDISC Clinical Classification CRS-R Test Code Terminology|CDISC Clinical Classification CRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12473>	C12749|C12471	Synovial Membrane|SYNOVIAL MEMBRANE|SYNOVIUM|Synovial Stratum|Synovium|Synovium|membrana synovialis (capsula articularis)|membrana synovialis capsulae articularis|stratum synoviale|stratum synoviale (capsula articularis)|synovial membrane|synovial membrane of synovial joint	The inner layer of the connective tissue that seals the joint.	Synovium		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|UBERON Terminology
C124740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124740>	C124697	CRS-R - Auditory Function Scale|CRSR01-Auditory Function Scale|CRSR01-Auditory Function Scale|CRSR0105	JFK Coma Recovery Scale-Revised (CRS-R) Auditory function scale.			Intellectual Product	CDISC Clinical Classification CRS-R Test Code Terminology|CDISC Clinical Classification CRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124741>	C124697	CRS-R - Visual Function Scale|CRSR01-Visual Function Scale|CRSR01-Visual Function Scale|CRSR0106	JFK Coma Recovery Scale-Revised (CRS-R) Visual function scale.			Intellectual Product	CDISC Clinical Classification CRS-R Test Code Terminology|CDISC Clinical Classification CRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124742>	C124697	CRS-R - Motor Function Scale|CRSR01-Motor Function Scale|CRSR01-Motor Function Scale|CRSR0107	JFK Coma Recovery Scale-Revised (CRS-R) Motor function scale.			Intellectual Product	CDISC Clinical Classification CRS-R Test Code Terminology|CDISC Clinical Classification CRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124743>	C124697	CRS-R - Oromotor/Verbal Function|CRSR01-Oromotor/Verbal Function|CRSR01-Oromotor/Verbal Function|CRSR0108	JFK Coma Recovery Scale-Revised (CRS-R) Oromotor/verbal function scale.			Intellectual Product	CDISC Clinical Classification CRS-R Test Code Terminology|CDISC Clinical Classification CRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124744>	C124697	CRS-R - Communication Scale|CRSR01-Communication Scale|CRSR01-Communication Scale|CRSR0109	JFK Coma Recovery Scale-Revised (CRS-R) Communication scale.			Intellectual Product	CDISC Clinical Classification CRS-R Test Code Terminology|CDISC Clinical Classification CRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124745>	C124697	CRS-R - Arousal Scale|CRSR01-Arousal Scale|CRSR01-Arousal Scale|CRSR0110	JFK Coma Recovery Scale-Revised (CRS-R) Arousal scale.			Intellectual Product	CDISC Clinical Classification CRS-R Test Code Terminology|CDISC Clinical Classification CRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124746>	C124697	CRS-R - Total Score|CRSR01-Total Score|CRSR01-Total Score|CRSR0111	JFK Coma Recovery Scale-Revised (CRS-R) Total score.			Intellectual Product	CDISC Clinical Classification CRS-R Test Code Terminology|CDISC Clinical Classification CRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124747>	C124698	PANSS - Delusions|PANSS1-Delusions|PANSS1-Delusions|PANSS101	Positive and Negative Syndrome Scale (PANSS) Temperature - Delusions.			Intellectual Product	CDISC Clinical Classification PANSS Test Code Terminology|CDISC Clinical Classification PANSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124748>	C124698	PANSS - Conceptual Disorganization|PANSS1-Conceptual Disorganization|PANSS1-Conceptual Disorganization|PANSS102	Positive and Negative Syndrome Scale (PANSS) Temperature - Conceptual disorganization.			Intellectual Product	CDISC Clinical Classification PANSS Test Code Terminology|CDISC Clinical Classification PANSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124749>	C124698	PANSS - Hallucinatory Behavior|PANSS1-Hallucinatory Behavior|PANSS1-Hallucinatory Behavior|PANSS103	Positive and Negative Syndrome Scale (PANSS) Temperature - Hallucinatory behavior.			Intellectual Product	CDISC Clinical Classification PANSS Test Code Terminology|CDISC Clinical Classification PANSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12474>	C12535	B-Lymphocyte|B Cell|B Cells|B Lymphocytes|B cell|B lymphocyte|B-Cell|B-Cells|B-Lymphocytes|Bursa-Dependent Lymphocyte|Bursa-Equivalent Lymphocyte	Immunologically important lymphocyte that is not thymus-dependent, is either short-lived and naive or long-lived and of memory phenotype, and resembles the bursa-derived lymphocyte of birds in that it is responsible for the production of immunoglobulins.	B-Lymphocyte		Cell	CTRP Biomarker Terminology|CTRP Terminology
C124750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124750>	C124698	PANSS - Excitement|PANSS1-Excitement|PANSS1-Excitement|PANSS104	Positive and Negative Syndrome Scale (PANSS) Temperature - Excitement.			Intellectual Product	CDISC Clinical Classification PANSS Test Code Terminology|CDISC Clinical Classification PANSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124751>	C124698	PANSS - Grandiosity|PANSS1-Grandiosity|PANSS1-Grandiosity|PANSS105	Positive and Negative Syndrome Scale (PANSS) Temperature - Grandiosity.			Intellectual Product	CDISC Clinical Classification PANSS Test Code Terminology|CDISC Clinical Classification PANSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124752>	C124698	PANSS - Suspiciousness or Persecution|PANSS1-Suspiciousness/Persecution|PANSS1-Suspiciousness/Persecution|PANSS106	Positive and Negative Syndrome Scale (PANSS) Temperature - Suspiciousness or persecution.			Intellectual Product	CDISC Clinical Classification PANSS Test Code Terminology|CDISC Clinical Classification PANSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124753>	C124698	PANSS - Hostility|PANSS1-Hostility|PANSS1-Hostility|PANSS107	Positive and Negative Syndrome Scale (PANSS) Temperature - Hostility.			Intellectual Product	CDISC Clinical Classification PANSS Test Code Terminology|CDISC Clinical Classification PANSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124754>	C124698	PANSS - Blunted Affect|PANSS1-Blunted Affect|PANSS1-Blunted Affect|PANSS108	Positive and Negative Syndrome Scale (PANSS) Temperature - Blunted affect.			Intellectual Product	CDISC Clinical Classification PANSS Test Code Terminology|CDISC Clinical Classification PANSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124755>	C124698	PANSS - Emotional Withdrawal|PANSS1-Emotional Withdrawal|PANSS1-Emotional Withdrawal|PANSS109	Positive and Negative Syndrome Scale (PANSS) Temperature - Emotional withdrawal.			Intellectual Product	CDISC Clinical Classification PANSS Test Code Terminology|CDISC Clinical Classification PANSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124756>	C124698	PANSS - Poor Rapport|PANSS1-Poor Rapport|PANSS1-Poor Rapport|PANSS110	Positive and Negative Syndrome Scale (PANSS) Temperature - Poor rapport.			Intellectual Product	CDISC Clinical Classification PANSS Test Code Terminology|CDISC Clinical Classification PANSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124757>	C124698	PANSS - Passive or Apathetic Social Withdrawal|PANSS1-Passive/Apathetic Social Withdraw|PANSS1-Passive/Apathetic Social Withdraw|PANSS111	Positive and Negative Syndrome Scale (PANSS) Temperature - Passive or apathetic social withdrawal.			Intellectual Product	CDISC Clinical Classification PANSS Test Code Terminology|CDISC Clinical Classification PANSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124758>	C124698	PANSS - Difficulty in Abstract Thinking|PANSS1-Difficulty in Abstract Thinking|PANSS1-Difficulty in Abstract Thinking|PANSS112	Positive and Negative Syndrome Scale (PANSS) Temperature - Difficulty in abstract thinking.			Intellectual Product	CDISC Clinical Classification PANSS Test Code Terminology|CDISC Clinical Classification PANSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124759>	C124698	PANSS - Lack of Spontaneity|PANSS1-Lack of Spontaneity|PANSS1-Lack of Spontaneity|PANSS113	Positive and Negative Syndrome Scale (PANSS) Temperature - Lack of spontaneity and flow of conversation.			Intellectual Product	CDISC Clinical Classification PANSS Test Code Terminology|CDISC Clinical Classification PANSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12475>	C32271|C12578	Skin Basal Cell|Basal Cells|basal cell	A cuboidal or low columnar cell in the deepest epidermal layer, stratum basale (stratum germinativum), adjacent to the basal lamina.	Basal Cell		Cell	
C124760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124760>	C124698	PANSS - Stereotyped Thinking|PANSS1-Stereotyped Thinking|PANSS1-Stereotyped Thinking|PANSS114	Positive and Negative Syndrome Scale (PANSS) Temperature - Stereotyped thinking.			Intellectual Product	CDISC Clinical Classification PANSS Test Code Terminology|CDISC Clinical Classification PANSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124761>	C124698	PANSS - Somatic Concern|PANSS1-Somatic Concern|PANSS1-Somatic Concern|PANSS115	Positive and Negative Syndrome Scale (PANSS) Temperature - Somatic concern.			Intellectual Product	CDISC Clinical Classification PANSS Test Code Terminology|CDISC Clinical Classification PANSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124762>	C124698	PANSS - Anxiety|PANSS1-Anxiety|PANSS1-Anxiety|PANSS116	Positive and Negative Syndrome Scale (PANSS) Temperature - Anxiety.			Intellectual Product	CDISC Clinical Classification PANSS Test Code Terminology|CDISC Clinical Classification PANSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124763>	C124698	PANSS - Guilt Feelings|PANSS1-Guilt Feelings|PANSS1-Guilt Feelings|PANSS117	Positive and Negative Syndrome Scale (PANSS) Temperature - Guilt feelings.			Intellectual Product	CDISC Clinical Classification PANSS Test Code Terminology|CDISC Clinical Classification PANSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124764>	C124698	PANSS - Tension|PANSS1-Tension|PANSS1-Tension|PANSS118	Positive and Negative Syndrome Scale (PANSS) Temperature - Tension.			Intellectual Product	CDISC Clinical Classification PANSS Test Code Terminology|CDISC Clinical Classification PANSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124765>	C124698	PANSS - Mannerisms and Posturing|PANSS1-Mannerisms and Posturing|PANSS1-Mannerisms and Posturing|PANSS119	Positive and Negative Syndrome Scale (PANSS) Temperature - Mannerisms and posturing.			Intellectual Product	CDISC Clinical Classification PANSS Test Code Terminology|CDISC Clinical Classification PANSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124766>	C124698	PANSS - Depression|PANSS1-Depression|PANSS1-Depression|PANSS120	Positive and Negative Syndrome Scale (PANSS) Temperature - Depression.			Intellectual Product	CDISC Clinical Classification PANSS Test Code Terminology|CDISC Clinical Classification PANSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124767>	C124698	PANSS - Motor Retardation|PANSS1-Motor Retardation|PANSS1-Motor Retardation|PANSS121	Positive and Negative Syndrome Scale (PANSS) Temperature - Motor retardation.			Intellectual Product	CDISC Clinical Classification PANSS Test Code Terminology|CDISC Clinical Classification PANSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124768>	C124698	PANSS - Uncooperativeness|PANSS1-Uncooperativeness|PANSS1-Uncooperativeness|PANSS122	Positive and Negative Syndrome Scale (PANSS) Temperature - Uncooperativeness.			Intellectual Product	CDISC Clinical Classification PANSS Test Code Terminology|CDISC Clinical Classification PANSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124769>	C124698	PANSS - Unusual Thought Content|PANSS1-Unusual Thought Content|PANSS1-Unusual Thought Content|PANSS123	Positive and Negative Syndrome Scale (PANSS) Temperature - Unusual thought content.			Intellectual Product	CDISC Clinical Classification PANSS Test Code Terminology|CDISC Clinical Classification PANSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12476>	C39567	T-Lymphocyte|T Cell|T Cells|T cell|T lymphocyte|T-Cell|T-Cells|T-Lymphocytes|Thymus Derived Lymphocyte|Thymus-Dependent Lymphocytes	A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc.	T-Lymphocyte		Cell	CTRP Biomarker Terminology|CTRP Terminology
C124770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124770>	C124698	PANSS - Disorientation|PANSS1-Disorientation|PANSS1-Disorientation|PANSS124	Positive and Negative Syndrome Scale (PANSS) Temperature - Disorientation.			Intellectual Product	CDISC Clinical Classification PANSS Test Code Terminology|CDISC Clinical Classification PANSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124771>	C124698	PANSS - Poor Attention|PANSS1-Poor Attention|PANSS1-Poor Attention|PANSS125	Positive and Negative Syndrome Scale (PANSS) Temperature - Poor attention.			Intellectual Product	CDISC Clinical Classification PANSS Test Code Terminology|CDISC Clinical Classification PANSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124772>	C124698	PANSS - Lack of Judgement|PANSS1-Lack of Judgment and Insight|PANSS1-Lack of Judgment and Insight|PANSS126	Positive and Negative Syndrome Scale (PANSS) Temperature - Lack of judgement and insight.			Intellectual Product	CDISC Clinical Classification PANSS Test Code Terminology|CDISC Clinical Classification PANSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124773>	C124698	PANSS - Disturbance of Volition|PANSS1-Disturbance of Volition|PANSS1-Disturbance of Volition|PANSS127	Positive and Negative Syndrome Scale (PANSS) Temperature - Disturbance of volition.			Intellectual Product	CDISC Clinical Classification PANSS Test Code Terminology|CDISC Clinical Classification PANSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124774>	C124698	PANSS - Poor Impulse Control|PANSS1-Poor Impulse Control|PANSS1-Poor Impulse Control|PANSS128	Positive and Negative Syndrome Scale (PANSS) Temperature - Poor impulse control.			Intellectual Product	CDISC Clinical Classification PANSS Test Code Terminology|CDISC Clinical Classification PANSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124775>	C124698	PANSS - Preoccupation|PANSS1-Preoccupation|PANSS1-Preoccupation|PANSS129	Positive and Negative Syndrome Scale (PANSS) Temperature - Preoccupation.			Intellectual Product	CDISC Clinical Classification PANSS Test Code Terminology|CDISC Clinical Classification PANSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124776>	C124698	PANSS - Active Social Avoidance|PANSS1-Active Social Avoidance|PANSS1-Active Social Avoidance|PANSS130	Positive and Negative Syndrome Scale (PANSS) Temperature - Active social avoidance.			Intellectual Product	CDISC Clinical Classification PANSS Test Code Terminology|CDISC Clinical Classification PANSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124777>	C124699	WHO Clinical Staging of HIV/AIDS for Adults and Adolescents - WHO Clinical Stage of HIV/AIDS|WHIVS1-WHO Clinical Stage of HIV/AIDS|WHIVS1-WHO Clinical Stage of HIV/AIDS|WHIVS101	World Health Organization Clinical Staging of HIV/AIDS for Adults and Adolescents (WHO Clinical Staging of HIV/AIDS for Adults and Adolescents) WHO clinical stage of HIV/AIDS.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification WHO Clinical Staging of HIV/AIDS for Adults and Adolescents Test Code Terminology|CDISC Clinical Classification WHO Clinical Staging of HIV/AIDS for Adults and Adolescents Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124778>	C124700	WHO Clinical Staging of HIV/AIDS for Children - WHO Clinical Stage of HIV/AIDS|WHIVS2-WHO Clinical Stage of HIV/AIDS|WHIVS2-WHO Clinical Stage of HIV/AIDS|WHIVS201	World Health Organization Clinical Staging of HIV/AIDS for Children (WHO Clinical Staging of HIV/AIDS for Children) WHO clinical stage of HIV/AIDS.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification WHO Clinical Staging of HIV/AIDS for Children Test Code Terminology|CDISC Clinical Classification WHO Clinical Staging of HIV/AIDS for Children Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124779>	C124701	CDC Classification System for HIV-Infected Adults and Adolescents - CDC HIV Infection Category|CHIVC1-CDC HIV Infection Category|CHIVC1-CDC HIV Infection Category|CHIVC101	Center for Disease Control and Prevention Classification System for HIV-Infected Adults and Adolescents (CDC Classification System for HIV-Infected Adults and Adolescents) CDC HIV infection category.			Intellectual Product	CDISC Clinical Classification CDC Classification System for HIV-Infected Adults and Adolescents Test Code Terminology|CDISC Clinical Classification CDC Classification System for HIV-Infected Adults and Adolescents Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12477>	C12615	Astrocyte|Astrocytes|Astroglia|astrocyte	A heterogeneous group of specialized neuroglial cells with many diverse supporting roles in the structure, function, and homeostasis of the central nervous system.	Astrocyte		Cell	
C124780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124780>	C124702	TMT - Time to Complete Trails A|TMT01-Time to Complete Trails A|TMT01-Time to Complete Trails A|TMT0101	Trail Making Test (TMT) Time (in seconds) to complete Trails A.			Intellectual Product	CDISC Functional Test Terminology|CDISC Functional Test TMT Test Code Terminology|CDISC Functional Test TMT Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124781>	C124702	TMT - Time to Complete Trails B|TMT01-Time to Complete Trails B|TMT01-Time to Complete Trails B|TMT0102	Trail Making Test (TMT) Time (in seconds) to complete Trails B.			Intellectual Product	CDISC Functional Test Terminology|CDISC Functional Test TMT Test Code Terminology|CDISC Functional Test TMT Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124782>	C103502	PHQ-15 - Total Score|PHQ02-Total Score|PHQ02-Total Score|PHQ0216	Patient Health Questionnaire - 15 (PHQ-15) Total score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ-15 Test Code Terminology|CDISC Questionnaire PHQ-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C124783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124783>	C96040	Anti-OX40 Monoclonal Antibody GSK3174998|GSK-3174998|GSK3174998	An agonistic humanized immunoglobulin G1 (IgG1) monoclonal antibody against the cell surface receptor OX40 (CD134; TNFRSF4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-OX40 monoclonal antibody GSK3174998 selectively binds to and activates OX40. Receptor activation induces proliferation of memory and effector T-lymphocytes and results in a T-cell-mediated immune response against tumor cells, which leads to tumor cell lysis. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and provides a co-stimulatory signal that promotes both the proliferation and survival of activated T-cells.	Anti-OX40 Monoclonal Antibody GSK3174998		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C124784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124784>	C71470	Refusal to Participate|Decline to Participate|Declined to Participate|Refused to Participate	Declining to take part in activities or procedures that are available to, or requested or expected of, an individual.			Qualitative Concept	
C124785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124785>	C28076	Oral Mucositis WHO Grading Scale|OMGS|Oral Mucositis Grading Scale|WHO OMGS|WHO Oral Mucositis Grading Scale	A grading system for mucositis based on clinical appearance and functional status.			Classification	
C124786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124786>	C124785	Oral Mucositis WHO Grade 0|Oral Mucositis Grade 0|WHO Oral Mucositis Grade 0	None; no oral mucositis.			Classification	Oral Mucositis WHO Grading Scale
C124787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124787>	C124785	Oral Mucositis WHO Grade I|Oral Mucositis Grade I|Oral Mucositis WHO Grade 1|WHO Oral Mucositis Grade 1|WHO Oral Mucositis Grade I	Mild mucositis with oral soreness and erythema.	Oral Mucositis WHO Grade I		Classification	CTRP Disease Terminology|CTRP Terminology|Oral Mucositis WHO Grading Scale
C124788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124788>	C124785	Oral Mucositis WHO Grade II|Oral Mucositis Grade II|Oral Mucositis WHO Grade 2|WHO Oral Mucositis Grade 2|WHO Oral Mucositis Grade II	Moderate mucositis with oral erythema and ulcers; solid diet tolerated.	Oral Mucositis WHO Grade II		Classification	CTRP Disease Terminology|CTRP Terminology|Oral Mucositis WHO Grading Scale
C124789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124789>	C124785	Oral Mucositis WHO Grade III|Oral Mucositis Grade III|Oral Mucositis WHO Grade 3|WHO Oral Mucositis Grade 3|WHO Oral Mucositis Grade III	Severe mucositis with oral ulcers; liquid diet only.			Classification	Oral Mucositis WHO Grading Scale
C12478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12478>	C33923	Clear Cell|Clear Cells|clear cell	A cell with empty-appearing cytoplasm when viewed with a light microscope.	Clear Cell		Cell	
C124790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124790>	C124785	Oral Mucositis WHO Grade IV|Oral Mucositis Grade IV|Oral Mucositis WHO Grade 4|WHO Oral Mucositis Grade 4|WHO Oral Mucositis Grade IV	Life-threatening mucositis with oral ulcers; oral alimentation impossible.			Classification	Oral Mucositis WHO Grading Scale
C124791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124791>	C1708	Antipneumocystis Agent|Anti-pneumocystis Agent	Any agent used in the treatment of Pneumocystis jiroveci pneumonia (PJP), formerly known as Pneumocystis carinii pneumonia (PCP).			Chemical Viewed Functionally	
C124792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124792>	C1708	Amphotericin Product	Any formulation containing amphotericin B as the active agent for the treatment of fungal infections.			Chemical Viewed Functionally	
C124793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124793>	C97927|C148101	SMO Gene Mutation|FZD11 Gene Mutation|Frizzled Family Member 11 Gene Mutation|SMOH Gene Mutation|Smoothened Homolog (Drosophila) Gene Mutation|Smoothened Homolog Gene Mutation|Smoothened, Frizzled Class Receptor Gene Mutation	A molecular genetic abnormality that refers to the mutation of the SMO gene located on chromosome 7q32.3.	SMO Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C124794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124794>	C43243|C42713	Extended Release Chewable Tablet Dosage Form|CHEWABLE EXTENDED RELEASE TABLET|Extended Release Chewable Tablet|Extended Release Chewable Tablet Dose Form|Prolonged-release chewable tablet|TABLET, CHEWABLE, EXTENDED RELEASE	A tablet that must be chewed in order to release active and/or inert ingredient(s) at a controlled, prolonged rate so as to reduce dosing frequency.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology|FDA Structured Product Labeling Terminology|SPL Pharmaceutical Dosage Form Terminology
C124795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124795>	C200766|C176018	Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|CD19R(EQ)28zetaEGFRt+ Tn/Tmem|CD19R(EQ)28zetaEGFRt+ Tn/mem Cells	A preparation of genetically modified autologous lymphocytes comprised of CD62L-positive naïve and memory T-cells (Tn/mem), that are transduced ex vivo with a self-inactivating (SIN) lentiviral vector expressing a hinge-optimized chimeric antigen receptor (CAR) specific for the CD19 antigen and containing CD28 and CD3 zeta signaling domains, and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon isolation of peripheral blood lymphocytes (PBLs), transduction of the CD62L-positive T-lymphocytes, expansion ex vivo and reintroduction of the cells into the patient, the autologous CD19R(EQ)-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-cells target CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.  Devoid of both ligand binding domains and tyrosine kinase activity, EGFRt both facilitates in vivo detection of the administered T-cells and can promote elimination of those cells upon a cetuximab-induced antibody dependent cellular cytotoxicity response. Tn/mem T-cells include naïve T-cells, central memory T-cells (Tcm) and stem cell memory T-cells (Tscm). CD19R(EQ) contains two point mutations in the immunoglobulin (Ig) G4 spacer region, thereby preventing recognition of the CAR by Fc receptors (FcRs).	Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCIt Antineoplastic Agent Terminology
C124796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124796>	C2089	Darovasertib|DAROVASERTIB|IDE 196|IDE-196|IDE196|LXS196|PKC Inhibitor IDE196|Protein Kinase C Inhibitor IDE196|Protein Kinase C Inhibitor LXS196	An orally available protein kinase C (PKC) inhibitor with potential immunosuppressive and antineoplastic activities. Upon oral administration, darovasertib inds to and inhibits PKC, which prevents the activation of PKC-mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells. PKC, a serine/threonine protein kinase overexpressed in certain types of cancer cells, is involved in tumor cell differentiation, proliferation, invasion and survival.	Darovasertib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124797>	C2124	Carbon C 14 Lenvatinib Mesylate|14C Lenvatinib Mesylate|14C-lenvatinib Mesylate	A radioconjugate composed of the orally bioavailable mesylate salt form of lenvatinib, a receptor tyrosine kinase (RTK) inhibitor, labeled with the radioisotope carbon C 14, with potential use for evaluating the pharmacokinetic profile of lenvatinib. Upon administration of carbon C14 lenvatinib mesylate, lenvatinib targets and binds strongly to multiple RTKs, including vascular endothelial growth factor receptor 1 (VEGFR1;FLT1), VEGFR2 (KDR), VEGFR3 (FLT4), fibroblast growth factor receptor 1 (FGFR1), FGFR2, FGFR3, and FGFR4, platelet derived growth factor receptor alpha (PDGFRa), KIT, and RET. This inhibits growth of tumor cells that overexpress these RTKs. Labeling of lenvatinib with the radioactive tracer carbon C 14 permits the evaluation of lenvatinib's pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME).			Pharmacologic Substance	NCI Drug Dictionary Terminology
C124799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124799>	C2124	Technetium Tc 99m-labeled Rhenium Sulfide Nanocolloid|99mTc-labeled Rhenium Sulfide Nanocolloid|Nanocis	A colloid formulation of rhenium sulfide that is labeled with the gamma-emitting epitope technetium Tc 99m (Tc-99m) with diagnostic imaging activity. Upon administration, the 99mTc-colloidal rhenium sulfide is taken up by the lymph nodes. This allows imaging of the lymphatic drainage pattern during lymphoscintigraphic or sentinel lymph node mapping procedures.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C12479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12479>	C33923	Ductal Epithelial Cell	A stratified columnar epithelial cell that surrounds a lumen in a gland such as the breast, pancreas or prostate. These cells are uniform in appearance and have uniformly sized and shaped nuclei.	Ductal Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C1247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1247>	C862	Testosterone Enanthate|Andro LA|Androtardyl|Androtardyl|Delatestryl|Everone|Everone|Primosteston|TESTOSTERONE ENANTHATE|Testate|Testate|Testinon|Testinon|Testo-Enant|Testosterone enanthate	A long-acting intramuscular form of the androgen testosterone. Testosterone inhibits gonadotropin secretion from the pituitary gland and ablates estrogen production in the ovaries, thereby decreasing endogenous estrogen levels. In addition, this agent promotes the maintenance of male sex characteristics and is indicated for testosterone replacement in hypogonadal males, delayed puberty, and metastatic mammary cancer. (NCI04)	Testosterone Enanthate		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology
C124800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124800>	C1967|C163790	FLT3 Inhibitor|Receptor-Type Tyrosine-Protein Kinase FLT3 Protein Inhibitor	Any drug or substance that inhibits the activity of receptor-type tyrosine-protein kinase FLT3 protein.			Chemical Viewed Functionally	
C124801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124801>	C1967|C163774	BTK Inhibitor|Tyrosine-Protein Kinase BTK Protein	Any drug or substance that inhibits the activity of tyrosine-protein kinase BTK protein.			Chemical Viewed Functionally	
C124802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124802>	C24010	Mouse Kidney Carcinoma	A carcinoma arising from the epithelium of the renal parenchyma or the renal pelvis of a mouse.			Neoplastic Process	Cellosaurus Disease Terminology
C124803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124803>	C17048	Knowledge, Understanding and Judgment Scale|KUJ|KUJ Scale|Knowledge, Understanding and Judgement (KUJ) Scale	A questionnaire developed to assess a patient's knowledge of prostate cancer, understanding of treatment choices, and judgment of survival with and without treatment.			Intellectual Product	
C124804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124804>	C91102	Stage of Your Cancer Question|Stage of Your Cancer|The stage of your cancer is|Your Cancer Stage	A question about the self-reported stage of an individual's cancer.			Intellectual Product	Knowledge, Understanding and Judgment Scale
C124805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124805>	C91102	Grade of Your Cancer Question|Grade of Your Cancer|The grade, or aggressiveness, of your cancer is|Your Cancer Grade	A question about the self-reported grade of an individual's cancer.			Intellectual Product	Knowledge, Understanding and Judgment Scale
C124806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124806>	C91102	Most Recent PSA Level Question|Most Recent PSA Level|Your Most Recent PSA Level|Your most recent PSA level is	A question about an individual's most recent self-reported PSA level.			Intellectual Product	Knowledge, Understanding and Judgment Scale
C124807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124807>	C173896	Most Common Complication After Surgery for Prostate Cancer Question|After surgery, the most common complication is|Most Common Complication After Surgery for Prostate Cancer	A question about an individual's knowledge of the most common complication after surgery for prostate cancer.			Intellectual Product	Knowledge, Understanding and Judgment Scale
C124808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124808>	C173896	Most Common Complication After Radiotherapy for Prostate Cancer Question|After radiotherapy, the most common complication is|Most Common Complication After Radiotherapy for Prostate Cancer	A question about an individual's knowledge of the most common complication after radiotherapy for prostate cancer.			Intellectual Product	Knowledge, Understanding and Judgment Scale
C124809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124809>	C173896|C173812	Most Common Complication Without Treatment for Prostate Cancer Question|After no treatment, the most common complication is|Most Common Complication Without Treatment for Prostate Cancer	A question about an individual's knowledge of the most common complication without treatment for prostate cancer.			Intellectual Product	Knowledge, Understanding and Judgment Scale
C12480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12480>	C43370|C12370	Terminal Ductal Lobular Unit|TDLU|Terminal Ductal Lobular Units	The epithelial structures within the breast that produce milk during lactation.	Terminal Ductal Lobular Unit		Tissue	
C124810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124810>	C173896|C173812|C173803	More Than Half of Patients Will Have Sexual or Urinary Symptoms Within Five Years Without Treatment for Prostate Cancer Question|More Than Half of Patients Will Have Sexual or Urinary Symptoms Within Five Years Without Treatment for Prostate Cancer|Without treatment, more than half of patients will have sexual or urinary symptoms in 5 years	A question about whether an individual thinks that, without treatment, more than half of patients will have sexual or urinary symptoms in 5 years.			Intellectual Product	Knowledge, Understanding and Judgment Scale
C124811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124811>	C173896|C173803	One of Three Patients Will Have Urine Control Problem After Surgery for Prostate Cancer Question|One of Three Patients Will Have Urine Control Problem After Surgery for Prostate Cancer|One of three patients who has surgery will have some problem with control of urine after surgery	A question about whether an individual thinks that one of three patients who has surgery will have some problem with control of urine after surgery.			Intellectual Product	Knowledge, Understanding and Judgment Scale
C124812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124812>	C173896|C173803	One of Three Patients Will Need Diapers Due to Very Poor Urine Control After Surgery for Prostate Cancer Question|One of Three Patients Will Need Diapers Due to Very Poor Urine Control After Surgery for Prostate Cancer|One of three patients who has surgery will need diapers due to very poor control of urine after surgery	A question about whether an individual thinks that one of three patients who has surgery will need diapers due to very poor control of urine after surgery.			Intellectual Product	
C124813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124813>	C173896|C173803	One of Ten Patients Will Need Diapers Due to Very Poor Urine Control After Surgery for Prostate Cancer Question|One of 10 patients who has surgery will need diapers due to very poor control of urine after surgery|One of Ten Patients Will Need Diapers Due to Very Poor Urine Control After Surgery for Prostate Cancer	A question about whether an individual thinks that one of ten patients who has surgery will need diapers due to very poor control of urine after surgery.			Intellectual Product	Knowledge, Understanding and Judgment Scale
C124814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124814>	C173896	Three of Four Patients Will Have Penile Erections Firm Enough to Have Sexual Intercourse After Surgery for Prostate Cancer Question|Three of Four Patients Will Have Penile Erections Firm Enough to Have Sexual Intercourse After Surgery for Prostate Cancer|Three of four patients who have surgery will have penile erections firm enough to have sexual intercourse after surgery	A question about whether an individual thinks that three of four patients who have surgery will have penile erections firm enough to have sexual intercourse after surgery.			Intellectual Product	Knowledge, Understanding and Judgment Scale
C124815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124815>	C173896	Four of Five Patients Are Able to Have Erections Firm Enough to Have Sexual Intercourse After External Radiation Therapy for Prostate Cancer Question|Four of Five Patients Are Able to Have Erections Firm Enough to Have Sexual Intercourse After External Radiation Therapy for Prostate Cancer|Four of five patients who get radiation rays (not seeds) are able to have erections firm enough to have intercourse after radiation	A question about whether an individual thinks that four of five patients who get external radiation therapy are able to have erections firm enough to have intercourse after treatment.			Intellectual Product	Knowledge, Understanding and Judgment Scale
C124816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124816>	C173896	Four of Five Patients Are Able to Have Erections Firm Enough to Have Sexual Intercourse After Radiation Seeds for Prostate Cancer Question|Four of Five Patients Are Able to Have Erections Firm Enough to Have Sexual Intercourse After Radiation Seeds for Prostate Cancer|Four of five patients who get radiation seeds are able to have erections firm enough to have intercourse after radiation seeds	A question about whether an individual thinks that four of five patients who get radiation seeds are able to have erections firm enough to have intercourse after treatment.			Intellectual Product	Knowledge, Understanding and Judgment Scale
C124817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124817>	C173896|C173812	One of Three Patients Will Die Within Ten Years Due to Prostate Cancer Without Treatment Question|One of Three Patients Will Die Within Ten Years Due to Prostate Cancer Without Treatment|Without treatment, one out of three patients will die within 10 years due to prostate cancer	A question about whether an individual thinks that, without treatment, one out of three patients will die within ten years due to prostate cancer.			Intellectual Product	Knowledge, Understanding and Judgment Scale
C124818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124818>	C174127|C173896|C173812	Treatment Decisions Should be Made Within Six Months or Prostate Cancer Can Spread Beyond Cure Question|Treatment Decisions Should be Made Within Six Months or Prostate Cancer Can Spread Beyond Cure|You should make your decision about which kind of treatment within 6 months, or the cancer can spread beyond cure	A question about whether an individual thinks that you should make your decision within six months about which kind of treatment to receive, or the cancer can spread beyond curable.			Intellectual Product	Knowledge, Understanding and Judgment Scale
C124819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124819>	C173896|C173812	Prostate Cancer Will Spread in One of Three Patients Within Ten Years Without Treatment Question|Prostate Cancer Will Spread in One of Three Patients Within Ten Years Without Treatment|Without treatment, cancer will spread in one of three patients within 10 years	A question about whether an individual thinks that, without treatment, cancer will spread in one of three patients within ten years.			Intellectual Product	Knowledge, Understanding and Judgment Scale
C12481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12481>	C12471	Endothelium|Endothelial	The layer of cells that lines the cavities of the heart and of the blood vessels (Endothelium, Vascular) and lymph vessels (Endothelium, Lymphatic), and the serous cavities of the body, originating from the mesoderm.	Endothelium		Tissue	
C124820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124820>	C173896|C173812	How Long Do You Expect to Live Without Any Treatment for Prostate Cancer Question|How Long Do You Expect to Live Without Any Treatment for Prostate Cancer|Keeping in mind your age and health at present, how long do you expect you will live without any treatment for prostate cancer	A question about how long an individual expects to live without any treatment for prostate cancer, keeping in mind their age and health at present.			Intellectual Product	Knowledge, Understanding and Judgment Scale
C124821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124821>	C173896|C173812	How Long Do You Expect to Live After Treatment for Prostate Cancer Question|How Long Do You Expect to Live After Treatment for Prostate Cancer|Keeping in mind your age and health at present, how long do you expect you will live after the treatment of your choice for prostate cancer	A question about how long an individual expects to live after the treatment of their choice for prostate cancer, keeping in mind their age and health at present.			Intellectual Product	Knowledge, Understanding and Judgment Scale
C124822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124822>	C171083	Very Slow Growing|Very Slow Growth Rate|Very slow growing	An indication that something is growing at a very slow rate.			Conceptual Entity	Knowledge, Understanding and Judgment Scale
C124823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124823>	C171083	Slow Growing|Slow Growth Rate|Slow growing	An indication that something is growing at a slow rate.			Conceptual Entity	Knowledge, Understanding and Judgment Scale
C124824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124824>	C171083	Medium Growth Rate|Medium	An indication that something is growing at an intermediate rate.			Conceptual Entity	Knowledge, Understanding and Judgment Scale
C124825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124825>	C171083	Fast Growing|Fast Growth Rate|Fast growing	An indication that something is growing at a fast rate.			Conceptual Entity	Knowledge, Understanding and Judgment Scale
C124826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124826>	C171083	Very Fast Growing|Very Fast Growth Rate|Very fast growing	An indication that something is growing at a very fast rate.			Conceptual Entity	Knowledge, Understanding and Judgment Scale
C124827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124827>	C41185	PSA Level|PSA Value	The concentration of prostate specific antigen in a sample.	PSA Level		Quantitative Concept	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C124828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124828>	C138961	PSA Level Less than Five|<5|Less than Five|PSA Level Less than 5	A blood concentration of prostate specific antigen below 5 ng/mL.	PSA Level Less than Five		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Knowledge, Understanding and Judgment Scale
C124829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124829>	C138961	PSA Level Five to Ten|5-10|Five to Ten|PSA Level 5 to 10	A blood concentration of prostate specific antigen between 5 and 10 ng/mL.	PSA Level Five to Ten		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Knowledge, Understanding and Judgment Scale
C12482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12482>	C12555	Fibroblast|FIBROBLAST|Fibroblasts|Fibroblasts|fibroblast		Fibroblast		Cell	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C124830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124830>	C138961	PSA Level Ten to Fifty|10-50|PSA Level 10 to 50|Ten to Fifty	A blood concentration of prostate specific antigen between 10 and 50 ng/mL.	PSA Level Ten to Fifty		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Knowledge, Understanding and Judgment Scale
C124831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124831>	C138961	PSA Level Greater than Fifty|>50|Greater than Fifty|PSA Level Greater than 50	A blood concentration of prostate specific antigen above 50 ng/mL.	PSA Level Greater than Fifty		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Knowledge, Understanding and Judgment Scale
C124832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124832>	C77140	No Complication|No complication	An indication that no complication occurred.			Finding	Knowledge, Understanding and Judgment Scale
C124833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124833>	C99547	Life Expectancy Less than Five Years|< 5 years|Less Than Five Years	A response indicating that an individual expects to, or is expected to, live less than five years.			Intellectual Product	Knowledge, Understanding and Judgment Scale
C124834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124834>	C99547	Life Expectancy Less than Ten Years|< 10 years|Less Than Ten Years	A response indicating that an individual expects to, or is expected to, live less than ten years.			Intellectual Product	Knowledge, Understanding and Judgment Scale
C124835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124835>	C99547	Life Expectancy Less than Twenty Years|< 20 years|Less Than Twenty Years	A response indicating that an individual expects to, or is expected to, live less than twenty years.			Intellectual Product	Knowledge, Understanding and Judgment Scale
C124836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124836>	C99547	Life Expectancy Greater than Twenty Years|> 20 years|Greater Than Twenty Years	A response indicating that an individual expects to, or is expected to, live greater than twenty years.			Intellectual Product	Knowledge, Understanding and Judgment Scale
C124837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124837>	C53543|C28193	Kabuki Syndrome|KMS|Kabuki Make-Up Syndrome|Kabuki Make-up Syndrome|Niikawa-Kuroki Syndrome	A rare, autosomal dominant or X-linked dominant inherited syndrome caused by mutations in the KMT2D gene (also known as MLL2) or the KDM6A gene. It is characterized by distinctive facial features including arched eyebrows, long eyelashes, long palpebral fissures with the lower lids turned out at the outside edges, a flat nose, and large protruding earlobes, developmental delay and intellectual disability.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C124838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124838>	C53543|C28193	Orofacial Cleft 1	Cleft lip with or without cleft palate mapped to chromosome 6p24.			Disease or Syndrome	Cellosaurus Disease Terminology
C124839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124839>	C85865|C53543|C28193	Pettigrew Syndrome|PGS	A rare, X-linked inherited syndrome characterized by mental retardation and additional features, which include choreoathetosis, hydrocephalus, Dandy-Walker malformation, seizures, and iron or calcium deposition in the brain.			Disease or Syndrome	Cellosaurus Disease Terminology
C124840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124840>	C53543|C28193	Shprintzen-Goldberg Craniosynostosis Syndrome	A rare, autosomal dominant inherited syndrome often caused by mutations in the SKI gene. It is characterized by premature fusion of skull bones and distinctive facial features, including a long, narrow head, hypertelorism, exophthalmos, downslanting palpebral fissures, a high, narrow palate, micrognathia, and low-set ears. The bodies of affected individuals resemble those of people with Marfan syndrome.			Disease or Syndrome	Cellosaurus Disease Terminology
C124841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124841>	C53543|C28193	Orofaciodigital Syndrome Type 6|Varadi-Papp Syndrome	A rare, autosomal recessive syndrome characterized by orofacial anomalies, metacarpal abnormalities with central polydactyly, and cerebellar dysgenesis.			Disease or Syndrome	Cellosaurus Disease Terminology
C124842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124842>	C85222	Waardenburg Syndrome Type 4|Waardenburg Syndrome Type IV|Waardenburg-Shah Syndrome	A rare, autosomal dominant or autosomal recessive syndrome caused by mutations in the SOX10, EDN3, or EDNRB genes. It is characterized by pigmentary abnormalities of the hair, skin, and eyes, congenital sensorineural hearing loss, and Hirschsprung disease.			Disease or Syndrome	Cellosaurus Disease Terminology
C124843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124843>	C62761|C1663	Pemlimogene Merolisbac|ADU-214|JNJ-64041757|LADD Listeria monocytogenes JNJ-64041757|PEMLIMOGENE MEROLISBAC	A proprietary, live-attenuated, double-deleted (LADD) strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding the tumor-associated antigens (TAAs) epidermal growth factor receptor mutant form EGFRvIII and human mesothelin, with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, the live-attenuated Listeria monocytogenes encoding EGFRvIII-mesothelin vaccine Pemlimogene merolisbac is taken up by antigen-presenting cells (APCs), including dendritic cells (DCs). EGFRvIII and mesothelin are subsequently expressed by the APCs and then processed and presented to the immune system by both major histocompatibility complex (MHC) class I and II molecules. This activates the immune system and leads to the recruitment and activation of cytotoxic T-lymphocytes (CTLs) against EGFRvIII- and mesothelin-expressing tumor cells, eventually resulting in tumor cell lysis. EGFRvIII and mesothelin are overexpressed in many types of cancer. Two genes contributing to the virulence of Lm have been removed to minimize the risk of infection.	Pemlimogene Merolisbac		Bacterium|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124844>	C53543|C28193	Dyggve-Melchior-Clausen Syndrome|DMC|Dyggve-Melchior-Clausen Disease	A rare, autosomal recessive inherited syndrome caused by mutations in the DYM gene. It is characterized by abnormal skeletal development, microcephaly, and intellectual disability.			Disease or Syndrome	Cellosaurus Disease Terminology
C124845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124845>	C53543	Hyperglycerolemia|GKD|Glycerol Kinase Deficiency	A rare, X-linked recessive genetic disorder of glycerol metabolism caused by mutations or deletion in the GK gene. It results in deficiency of the enzyme glycerol kinase.  It is characterized by elevated plasma and urine glycerol levels and neurometabolic manifestations which can cause life-threatening metabolic crisis in children.			Disease or Syndrome	Cellosaurus Disease Terminology
C124846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124846>	C53543|C28193	Potocki-Lupski Syndrome|17p11.2 Duplication Syndrome|PTLS	A rare genetic disorder characterized by hypotonia, failure to thrive, mental retardation, developmental disorders, congenital anomalies, and autism spectrum disorders. The majority of patients harbor a microduplication of chromosome 17p11.			Disease or Syndrome	Cellosaurus Disease Terminology
C124847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124847>	C21295	DAZ1 Gene|DAZ1|DAZ1|Deleted in Azoospermia 1 Gene	This gene is involved in spermatogenesis.			Gene or Genome	
C124848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124848>	C124847	DAZ1 wt Allele|DAZ|Deleted in Azoospermia 1 wt Allele|Deleted in Azoospermia Gene|SPGY	Human DAZ1 wild-type allele is located in the vicinity of Yq11.223 and is approximately 70 kb in length. This allele, which encodes deleted in azoospermia protein 1, is a candidate for the human Y-chromosomal azoospermia factor (AZF) and plays a role in germ-cell progression to meiosis and the formation of haploid germ cells.			Gene or Genome	
C124849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124849>	C21298	Deleted in Azoospermia Protein 1	Deleted in azoospermia protein 1 (744 aa, ~83 kDa) is encoded by the human DAZ1 gene. This protein is involved in spermatogenesis.			Amino Acid, Peptide, or Protein	
C124850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124850>	C141146|C129820	Sabatolimab|Anti-TIM-3 Monoclonal Antibody MBG453|Anti-TIM3 Checkpoint Inhibitor MBG453|MBG 453|MBG453|SABATOLIMAB	An inhibitor of the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sabatolimab binds to TIM-3 expressed on certain immune cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis resulting in a reduction in tumor growth. TIM-3, a transmembrane protein expressed on certain T-cells, is associated with tumor-mediated immune suppression.	Sabatolimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124851>	C53543	Analbuminemia	A rare, autosomal recessive inherited disorder characterized by the absence or severe reduction of circulating human serum albumin.			Disease or Syndrome	Cellosaurus Disease Terminology
C124852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124852>	C28193|C103921	Miller-Dieker Syndrome|Miller-Dieker Lissencephaly Syndrome	A rare syndrome caused by deletion of genetic material in the short arm of chromosome 17. It is characterized by an abnormally smooth brain with fewer folds and grooves. It results in intellectual disability, developmental delay, seizures, spasticity, hypotonia, and feeding difficulties. Affected individuals have distinctive facial features that include a prominent forehead, midface hypoplasia, small, upturned nose, low-set ears, small jaw, and thick upper lip.			Disease or Syndrome	Cellosaurus Disease Terminology
C124853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124853>	C53543|C28193	Mayer-Rokitansky-Kuster-Hauser Syndrome|MRKH|MRKH Syndrome|Mullerian Aplasia/Dysgenesis	A rare syndrome of unknown cause that occurs in females. It is characterized by underdeveloped or absent vagina and uterus in an otherwise phenotypically normal female with a normal 46,XX karyotype. Other abnormalities include unilateral renal agenesis, skeletal abnormalities, hearing loss, and heart defects.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C124854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124854>	C16447	COL18A1 Gene Product	A protein encoded by the COL18A1 gene.			Amino Acid, Peptide, or Protein	
C124855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124855>	C686	TAC1 Gene Product	A protein encoded by the TAC1 gene.			Amino Acid, Peptide, or Protein	
C124856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124856>	C124855	Protachykinin-1|PPT|Preprotachykinin|Protachykinin|Protachykinin 1	Protachykinin-1 (129 aa, ~15 kDa) is encoded by the human TAC1 gene. This protein is involved in neuronal excitation, behavioral responses, and smooth muscle contraction.	Protachykinin-1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124857>	C173938|C173737|C173358	Past Seven Days Frequency of Loss of Control of Bowel Movements Question|Frequency of Loss of Control of Bowel Movements Past Seven Days|Past Seven Days Frequency of Loss of Control of Bowel Movements|Past Seven Days Frequency of Loss of Control of Bowel Movements	A question about the frequency of an individual's loss of control of bowel movements over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C124858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124858>	C173938|C173787|C173584	Past Seven Days Loss of Control of Bowel Movements Interferes with Usual or Daily Activities Question|Loss of Control of Bowel Movements Interferes with Usual or Daily Activities Past Seven Days|Past Seven Days Loss of Control of Bowel Movements Interferes with Usual or Daily Activities|Past Seven Days Loss of Control of Bowel Movements Interferes with Usual or Daily Activities	A question about how much an individual's loss of control of bowel movements interfered with usual or daily activities over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C124859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124859>	C91105	Contemplation Ladder for Smoking Cessation	A self-administered questionnaire that measures a person's readiness to consider smoking cessation.			Intellectual Product	
C12485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12485>	C32506	Neuroendocrine Cell|Neuroendocrine Cells	An endocrine cell that produces and releases hormones and regulatory proteins such as neurotransmitters and neuropeptide hormones. This type of cell enables autocrine communication with paracrine and endocrine cells throughout the body.	Neuroendocrine Cell		Body Part, Organ, or Organ Component	
C124860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124860>	C173060	Readiness to Quit Smoking Question|Please complete the following concerning your readiness to quit smoking|Readiness to Quit Smoking	A question about a person's readiness to quit smoking.			Intellectual Product	Contemplation Ladder for Smoking Cessation
C124861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124861>	C85429	Contemplation Ladder Readiness to Quit Smoking Likert Scale	A scale for the subjective scoring of readiness to quit smoking that ranges from 0: I am not ready to quit to 10: I am ready to quit now.			Intellectual Product	Contemplation Ladder for Smoking Cessation
C124862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124862>	C175277	Readiness to Quit Smoking Score 10|I am ready to quit now|Readiness Score 10	A subjective score of 10 on a scale that ranges from 0: I am not ready to quit to 10: I am ready to quit now.			Intellectual Product	Contemplation Ladder Readiness to Quit Smoking Likert Scale
C124863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124863>	C175277	Readiness to Quit Smoking Score 9|Readiness Score 9	A subjective score of 9 on a scale that ranges from 0: I am not ready to quit to 10: I am ready to quit now.			Intellectual Product	Contemplation Ladder Readiness to Quit Smoking Likert Scale
C124864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124864>	C175277	Readiness to Quit Smoking Score 8|I have cut down or am seriously thinking of quitting|Readiness Score 8	A subjective score of 8: I have cut down or am seriously thinking of quitting on a scale that ranges from 0: I am not ready to quit to 10: I am ready to quit now.			Intellectual Product	Contemplation Ladder Readiness to Quit Smoking Likert Scale
C124865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124865>	C175277	Readiness to Quit Smoking Score 7|Readiness Score 7	A subjective score of 7 on a scale that ranges from 0: I am not ready to quit to 10: I am ready to quit now.			Intellectual Product	Contemplation Ladder Readiness to Quit Smoking Likert Scale
C124866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124866>	C175277	Readiness to Quit Smoking Score 6|I am thinking about cutting down or quitting|Readiness Score 6	A subjective score of 6: I am thinking about cutting down or quitting on a scale that ranges from 0: I am not ready to quit to 10: I am ready to quit now.			Intellectual Product	Contemplation Ladder Readiness to Quit Smoking Likert Scale
C124867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124867>	C175277	Readiness to Quit Smoking Score 5|Readiness Score 5	A subjective score of 5 on a scale that ranges from 0: I am not ready to quit to 10: I am ready to quit now.			Intellectual Product	Contemplation Ladder Readiness to Quit Smoking Likert Scale
C124868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124868>	C175277	Readiness to Quit Smoking Score 4|I think I should quit but I'm not quite ready|Readiness Score 4	A subjective score of 4: I think I should quit but I'm not quite ready on a scale that ranges from 0: I am not ready to quit to 10: I am ready to quit now.			Intellectual Product	Contemplation Ladder Readiness to Quit Smoking Likert Scale
C124869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124869>	C175277	Readiness to Quit Smoking Score 3|Readiness Score 3	A subjective score of 3 on a scale that ranges from 0: I am not ready to quit to 10: I am ready to quit now.			Intellectual Product	Contemplation Ladder Readiness to Quit Smoking Likert Scale
C12486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12486>	C33058	Plasma Cell|Plasma Cells|Plasmacytes|Plasmocyte|plasma cell|plasmacyte|plasmacytic	A fully mature B-Cell that produces a specific antibody.	Plasma Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C124870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124870>	C175277	Readiness to Quit Smoking Score 2|I think I need to consider quitting some day|Readiness Score 2	A subjective score of 2: I think I need to consider quitting some day on a scale that ranges from 0: I am not ready to quit to 10: I am ready to quit now.			Intellectual Product	Contemplation Ladder Readiness to Quit Smoking Likert Scale
C124871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124871>	C175277	Readiness to Quit Smoking Score 1|Readiness Score 1	A subjective score of 1 on a scale that ranges from 0: I am not ready to quit to 10: I am ready to quit now.			Intellectual Product	Contemplation Ladder Readiness to Quit Smoking Likert Scale
C124872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124872>	C175277	Readiness to Quit Smoking Score 0|I am not ready to quit|Readiness Score 0	A subjective score of 0 on a scale that ranges from 0: I am not ready to quit to 10: I am ready to quit now.			Intellectual Product	Contemplation Ladder Readiness to Quit Smoking Likert Scale
C124873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124873>	C80336	Hyperdiploid with Status of Chromosomes 4 and 10 Unknown|Hyperdiploid with Status of 4 and 10 Unknown|Hyperdiploid; Status of 4 and 10 Unknown	Having a chromosomal number greater than the normal diploid number, with the status of chromosomes 4 and 10 unknown.			Cell or Molecular Dysfunction	
C124874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124874>	C36527	Intrachromosomal Amplification of Chromosome 21|iAMP21|iAMP21|iAMP21	A cytogenetic abnormality that refers to the allelic gain of an internal part of chromosome 21. It is a rare high-risk chromosomal abnormality that occurs in approximately 2-5% of pediatric patients with B-cell precursor Acute Lymphoblastic Leukemia. This abnormality has been associated with a poor outcome in patients treated by standard protocols.	Intrachromosomal Amplification of Chromosome 21		Cell or Molecular Dysfunction	ALL Authorized Value Terminology|ALL Molecular Analysis Table|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C124875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124875>	C20194	HFE Gene|HFE|HFE|Hemochromatosis Gene	This gene plays a role in the modulation of iron transport.			Gene or Genome	
C124876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124876>	C124875	HFE wt Allele|HFE1|HH|HLA-H|HLAH|Hemochromatosis wt Allele|High Fe Gene|MVCD7|TFQTL2	Human HFE wild-type allele is located in the vicinity of 6p21.3 and is approximately 11 kb in length. This allele, which encodes hereditary hemochromatosis protein, is involved in iron homeostasis. Mutation of the gene is associated with hemochromatosis and microvascular complications of diabetes 7.			Gene or Genome	
C124877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124877>	C18466	Hereditary Hemochromatosis Protein|HFE|HLA-H|Hereditary Hemochromatosis Protein HLA-H|MHC Class I-Like Protein HFE	Hereditary hemochromatosis protein (348 aa, ~40 kDa) is encoded by the human HFE gene. This protein plays a role in the regulation of transport of iron.			Amino Acid, Peptide, or Protein	
C124878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124878>	C21344	PDGFD Gene|PDGFD|PDGFD|Platelet Derived Growth Factor D Gene	This gene is involved in growth factor signaling.			Gene or Genome	
C124879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124879>	C124878	PDGFD wt Allele|IEGF|MSTP036|Platelet Derived Growth Factor D wt Allele|SCDGF-B|SCDGFB|UNQ1899/PRO4345	Human PDGFD wild-type allele is located in the vicinity of 11q22.3 and is approximately 257 kb in length. This allele, which encodes platelet-derived growth factor D protein, plays a role in growth factor signaling, embryonic development, cell proliferation, wound healing and angiogenesis.			Gene or Genome	
C12487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12487>	C12913	Signet Ring Cell|Signet-Ring Cell	A neoplastic cell containing cytoplasmic mucin. The presence of mucin pushes the nucleus of the cell to the periphery, assuming a configuration resembling a signet ring.			Cell	
C124880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124880>	C20424	Platelet-Derived Growth Factor D|Iris-Expressed Growth Factor|PDGF-D|SCDGF-B|Spinal Cord Derived Growth Factor B|Spinal Cord-Derived Growth Factor B|Spinal Cord-Derived Growth Factor-B	Platelet-derived growth factor D (370 aa, ~43 kDa) is encoded by the human PDGFD gene. This protein is involved in growth factor signaling that modulates many developmental and cellular processes.			Amino Acid, Peptide, or Protein	
C124881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124881>	C21518	CFHR1 Gene|CFHR1|CFHR1|Complement Factor H-Related 1 Gene	This gene plays a role in complement regulation.			Gene or Genome	
C124882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124882>	C124881	CFHR1 wt Allele|CFHL|CFHL1|CFHL1P|CFHR1P|Complement Factor H-Related 1 Pseudogene|Complement Factor H-Related 1 wt Allele|FHR1|Factor H-Related Gene 1|H Factor (Complement)-Like 1 Gene|H Factor (Complement)-Like 2 Gene|H36-1|H36-2|HFL1|HFL2	Human CFHR1 wild-type allele is located in the vicinity of 1q32 and is approximately 12 kb in length. This allele, which encodes complement factor H-related protein 1, is involved in the modulation of complement activity. Mutation of the gene is associated with atypical hemolytic-uremic syndrome and age-related macular degeneration.			Gene or Genome	
C124883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124883>	C21523	Complement Factor H-Related Protein 1|CFHR1|Complement Factor H-Related 1|FHR-1|H Factor-Like Protein 1|H-Factor-Like 1|H36	Complement factor H-related protein 1 (330 aa, ~38 kDa) is encoded by the human CFHR1 gene. This protein plays a role in the regulation of complement activation.			Amino Acid, Peptide, or Protein	
C124884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124884>	C91105	Smoking Self-Efficacy Questionnaire|SEQ12|Smoking Self-Efficacy Questionnaire (SEQ-12)	A questionnaire measuring the confidence of current and former smokers in their ability to abstain from smoking in high-risk situations. Two six-item subscales measure confidence in ability to refrain from smoking when facing internal and external stimuli.			Intellectual Product	
C124885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124885>	C173160|C173060	Refrain from Smoking when Nervous Question|Refrain from Smoking when Nervous|When I feel nervous	A question about an individual's certainty that they can avoid smoking when they are feeling nervous.			Intellectual Product	Smoking Self-Efficacy Questionnaire
C124886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124886>	C173160|C173060	Refrain from Smoking when Depressed Question|Refrain from Smoking when Depressed|When I feel depressed	A question about an individual's certainty that they can avoid smoking when they are feeling depressed.			Intellectual Product	Smoking Self-Efficacy Questionnaire
C124887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124887>	C173060	Refrain from Smoking when Angry Question|Refrain from Smoking when Angry|When I am angry	A question about an individual's certainty that they can avoid smoking when they are feeling angry.			Intellectual Product	Smoking Self-Efficacy Questionnaire
C124888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124888>	C173386|C173060	Can Refrain from Smoking when Very Anxious Question|Refrain from Smoking when Very Anxious|When I Feel Very Anxious	A question about an individual's certainty that they can avoid smoking when they are feeling very anxious.			Intellectual Product	Smoking Self-Efficacy Questionnaire
C124889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124889>	C173597|C173060	Refrain from Smoking when Thinking about a Difficult Problem Question|Refrain from Smoking when Thinking about a Difficult Problem|When I want to think about a difficult problem	A question about an individual's certainty that they can avoid smoking when they are thinking about a difficult problem.			Intellectual Product	Smoking Self-Efficacy Questionnaire
C124890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124890>	C16617	HLA-F Gene|HLA-F|HLA-F|Major Histocompatibility Complex, Class I, F Gene	This gene is involved in the presentation of cytoplasmic protein fragments to cytotoxic lymphocytes.			Gene or Genome	
C124891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124891>	C124890	HLA-F wt Allele|CDA12|HLA-5.4|HLA-CDA12|HLA-F Histocompatibility Type Gene|HLAF|Major Histocompatibility Complex, Class I, F wt Allele|cda12 Class I Gene	Human HLA-F wild-type allele is located in the vicinity of 6p21.3 and is approximately 16 kb in length. This allele, which encodes HLA class I histocompatibility antigen, alpha chain F protein, plays a role in antigen presentation.			Gene or Genome	
C124892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124892>	C20706	HLA Class I Histocompatibility Antigen, Alpha Chain F|HLA F Antigen|HLA-F|Leukocyte Antigen F|MHC Class I Antigen F	HLA class I histocompatibility antigen, alpha chain F (346 aa, ~39 kDa) is encoded by the human HLA-F gene. This protein is involved in antigen presentation.			Amino Acid, Peptide, or Protein	
C124893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124893>	C173160|C173060	Refrain from Smoking when Feeling the Urge to Smoke Question|Refrain from Smoking when Feeling the Urge to Smoke|When I feel the urge to smoke	A question about an individual's certainty that they can avoid smoking when they are feeling the urge to smoke.			Intellectual Product	Smoking Self-Efficacy Questionnaire
C124894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124894>	C173060	Refrain from Smoking when Having a Drink with Friends Question|Refrain from Smoking when Having a Drink with Friends|When having a drink with friends	A question about an individual's certainty that they can avoid smoking when having a drink with friends.			Intellectual Product	Smoking Self-Efficacy Questionnaire
C124895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124895>	C173060	Refrain from Smoking when Celebrating Something Question|Refrain from Smoking when Celebrating Something|When celebrating something	A question about an individual's certainty that they can avoid smoking when celebrating something.			Intellectual Product	Smoking Self-Efficacy Questionnaire
C124896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124896>	C173060	Refrain from Smoking when Drinking Alcohol Question|When drinking beer, wine or other spirits	A question about an individual's certainty that they can avoid smoking when drinking alcohol.			Intellectual Product	Smoking Self-Efficacy Questionnaire
C124897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124897>	C173060	Refrain from Smoking when with Other Smokers Question|Refrain from Smoking when with Other Smokers|When I am with smokers	A question about an individual's certainty that they can avoid smoking when they are with other smokers.			Intellectual Product	Smoking Self-Efficacy Questionnaire
C124898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124898>	C173060	Refrain from Smoking After a Meal Question|After a meal|Refrain from Smoking After a Meal	A question about an individual's certainty that they can avoid smoking after a meal.			Intellectual Product	Smoking Self-Efficacy Questionnaire
C124899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124899>	C173060	Refrain from Smoking When Having Coffee or Tea Question|Refrain from Smoking When Having Coffee or Tea|When having coffee or tea	A question about an individual's certainty that they can avoid smoking when having coffee or tea.			Intellectual Product	Smoking Self-Efficacy Questionnaire
C1248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1248>	C862	Testosterone Isobutyrate|Agovirin-Depot|Perandren M|TESTOSTERONE ISOBUTYRATE|Testocryst	An four-carbon ester form of Testosterone. The number of ester carbon atoms correlate with the half-life of the prodrug.  Testosterone inhibits gonadotropin secretion from the pituitary gland and ablates estrogen production in the ovaries, thereby decreasing endogenous estrogen levels.  In addition, this agent promotes the maintenance of male sex characteristics and is indicated for testosterone replacement in hypogonadal males. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C124900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124900>	C91213|C226734	Not At All Sure|Not at All Certain|Not at all sure	A subjective answer of non-agreement regarding the certainty of something.			Intellectual Product	Smoking Self-Efficacy Questionnaire
C124901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124901>	C226734	Not Very Sure|Not Very Certain|Not very sure	A subjective answer of weak agreement regarding the certainty of something.			Intellectual Product	Smoking Self-Efficacy Questionnaire
C124902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124902>	C16616	HLA-DOB Gene|HLA-DOB|HLA-DOB|Major Histocompatibility Complex, Class II, DO Beta Gene	This gene plays a role in the presentation of exogenous peptide antigens.			Gene or Genome	
C124903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124903>	C124902	HLA-DOB wt Allele|DOB|Major Histocompatibility Complex, Class II, DO Beta wt Allele	Human HLA-DOB wild-type allele is located in the vicinity of 6p21.3 and is approximately 4 kb in length. This allele, which encodes HLA class II histocompatibility antigen, DO beta chain protein, is involved in the regulation of presentation of exogenous peptides.			Gene or Genome	
C124904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124904>	C226734	More or Less Sure|More or Less Certain|More or less sure	A subjective answer of partial agreement regarding the certainty of something.			Intellectual Product	Smoking Self-Efficacy Questionnaire
C124905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124905>	C226734	Fairly Sure|Fairly Certain|Fairly sure|Relatively Certain|relatively certain	A subjective answer of agreement regarding the certainty of something.			Intellectual Product	Smoking Self-Efficacy Questionnaire|Work Ability Index
C124906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124906>	C226734	Absolutely Sure|Absolutely Certain|Absolutely sure	A subjective answer of strong agreement regarding the certainty of something.			Intellectual Product	Smoking Self-Efficacy Questionnaire
C124907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124907>	C20705	HLA Class II Histocompatibility Antigen, DO Beta Chain|HLA-DO Histocompatibility Type, Beta Chain|MHC Class II Antigen DOB	HLA class II histocompatibility antigen, DO beta chain (273 aa, ~31 kDa) is encoded by the human HLA-DOB gene. This protein plays a role in the modulation of exogenous antigen presentation.			Amino Acid, Peptide, or Protein	
C124908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124908>	C20134	Refrain from Smoking|Abstain from Smoking|Abstinence from Cigarette Smoking|Abstinence from Cigarettes|Smoking Abstinence	To abstain or keep oneself from smoking.			Individual Behavior	
C124909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124909>	C25993	TRPM3 Gene|TRPM3|TRPM3|Transient Receptor Potential Cation Channel, Subfamily M, Member 3 Gene	This gene is involved in calcium homeostasis.			Gene or Genome	
C124910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124910>	C124909	TRPM3 wt Allele|GON-2|KIAA1616|LTRPC3|MLSN2|Transient Receptor Potential Cation Channel, Subfamily M, Member 3 wt Allele	Human TRPM3 wild-type allele is located in the vicinity of 9q21.12 and is approximately 918 kb in length. This allele, which encodes transient receptor potential cation channel subfamily M member 3 protein, plays a role in calcium transport.			Gene or Genome	
C124911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124911>	C28505	Transient Receptor Potential Cation Channel Subfamily M Member 3|LTrpC-3|LTrpC3|Long Transient Receptor Potential Channel 3|MLSN2|Melastatin 2|Melastatin-2|TRPM3	Transient receptor potential cation channel subfamily M member 3 (1732 aa, ~198 kDa) is encoded by the human TRPM3 gene. This protein is involved in calcium internalization.			Amino Acid, Peptide, or Protein	
C124912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124912>	C20988	NRXN2 Gene|NRXN2|NRXN2|Neurexin 2 Gene	This gene may play a role in cell adhesion.			Gene or Genome	
C124913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124913>	C124912	NRXN2 wt Allele|KIAA0921|Neurexin 2 wt Allele	Human NRXN2 wild-type allele is located in the vicinity of 11q13 and is approximately 117 kb in length. This allele, which encodes neurexin-2 protein and neurixin-2-beta protein, may be involved in neuronal cell adhesion.			Gene or Genome	
C124914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124914>	C16393	NRXN2 Gene Product	A protein encoded by the NRXN2 gene.			Amino Acid, Peptide, or Protein	
C124915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124915>	C124914	Neurexin-2|Neurexin II|Neurexin II-Alpha|Neurexin-2 Isoform 1a|Neurexin-2-Alpha	Neurexin-2 (1712 aa, ~185 kDa) is encoded by the human NRXN2 gene. This protein may play a role in adhesion and signaling in neuronal cells.			Amino Acid, Peptide, or Protein	
C124916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124916>	C124914	Neurexin-2-Beta|Neurexin II-Beta|Neurexin-2 Isoform 1b	Neurexin-2-beta (666 aa, ~71 kDa) is encoded by the human NRXN2 gene. This protein is involved in cell-cell adhesion in neurons.			Amino Acid, Peptide, or Protein	
C124917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124917>	C20194	COPS6 Gene|COP9 Signalosome Subunit 6 Gene|COPS6|COPS6	This gene is involved in signalosome function.			Gene or Genome	
C124918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124918>	C124917	COPS6 wt Allele|COP9 Constitutive Photomorphogenic Homolog Subunit 6 (Arabidopsis) Gene|COP9 Signalosome Subunit 6 wt Allele|COP9 Signalosome, Subunit 6 Gene|COP9 Subunit 6 (MOV34 Homolog, 34 kD) Gene|CSN6|HVIP|MOV34 Family, 34-kD Member Gene|MOV34 Homolog, 34 kD Gene|MOV34-34KD	Human COPS6 wild-type allele is located in the vicinity of 7q22.1 and is approximately 3 kb in length. This allele, which encodes COP9 signalosome complex subunit 6 protein, plays a role in the modulation of signalosome function.			Gene or Genome	
C124919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124919>	C18466	COP9 Signalosome Complex Subunit 6|COP9 Constitutive Photomorphogenic Homolog Subunit 6|COPS6|JAB1-Containing Signalosome Subunit 6|MOV34 Homolog|SGN6|Signalosome Subunit 6|Vpr-Interacting Protein|hVIP	COP9 signalosome complex subunit 6 (327 aa, ~36 kDa) is encoded by the human COPS6 gene. This protein is involved in the mediation of signalosome-dependent cellular processes.			Amino Acid, Peptide, or Protein	
C12491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12491>	C225418	Intrathoracal	Within the thorax.	Intrathoracal		Spatial Concept	
C124920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124920>	C20744	ACTN1 Gene|ACTN1|ACTN1|Actinin, Alpha 1 Gene	This gene plays a role in actin crosslink formation.			Gene or Genome	
C124921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124921>	C124920	ACTN1 wt Allele|Actinin, Alpha 1 wt Allele|Actinin, Alpha-1 Gene|BDPLT15	Human ACTN1 wild-type allele is located in the vicinity of 14q24 or within 14q22-q24 and is approximately 105 kb in length. This allele, which encodes alpha-actinin-1 protein, is involved in the formation of F-actin crosslinks. Mutation of the gene is associated with autosomal dominant platelet-type bleeding disorder-15.			Gene or Genome	
C124922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124922>	C18073	Alpha-Actinin-1|ACTN1|Actinin 1 Smooth Muscle|Alpha-Actinin Cytoskeletal Isoform|F-Actin Cross-Linking Protein|Non-Muscle Alpha-Actinin-1	Alpha-actinin-1 (892 aa, ~103 kDa) is encoded by the human ACTN1 gene. This protein plays a role in F-actin crosslinking.			Amino Acid, Peptide, or Protein	
C124923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124923>	C106409	PTPRS Gene|PTPRS|PTPRS|Protein Tyrosine Phosphatase, Receptor Type, S Gene	This gene is involved in protein dephosphorylation.			Gene or Genome	
C124924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124924>	C124923	PTPRS wt Allele|PTPSIGMA|Protein Tyrosine Phosphatase, Receptor Type, S wt Allele|Protein-Tyrosine Phosphatase, Receptor-Type, Sigma Gene	Human PTPRS wild-type allele is located in the vicinity of 19p13.3 and is approximately 182 kb in length. This allele, which encodes receptor-type tyrosine-protein phosphatase S protein, plays a role in tyrosine dephosphorylation.			Gene or Genome	
C124925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124925>	C17444	Receptor-Type Tyrosine-Protein Phosphatase S|EC 3.1.3.48|PTPRS|Protein Tyrosine Phosphatase PTPsigma|R-PTP-S|R-PTP-Sigma|RPTP-Sigma	Receptor-type tyrosine-protein phosphatase S (1948 aa, ~217 kDa) is encoded by the human PTPRS gene. This protein is involved in the dephosphorylation of tyrosine residues.			Amino Acid, Peptide, or Protein|Enzyme	
C124926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124926>	C26006	ATXN2 Gene|ATXN2|ATXN2|Ataxin 2 Gene	This gene plays a role in receptor trafficking.			Gene or Genome	
C124927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124927>	C124926	ATXN2 wt Allele|ASL13|ATX2|Ataxin 2 wt Allele|SCA2|Spinocerebellar Ataxia 2 (Olivopontocerebellar Ataxia 2, Autosomal Dominant, Ataxin 2) Gene|TNRC13|Trinucleotide Repeat-Containing Gene 13	Human ATXN2 wild-type allele is located in the vicinity of 12q24.1 and is approximately 147 kb in length. This allele, which encodes ataxin-2 protein, is involved in the regulation of endocytosis of the epidermal growth factor receptor. Mutation of the gene is associated with spinocerebellar ataxia type 2, susceptibility to amyotrophic lateral sclerosis 13 and increased susceptibility for late-onset Parkinson disease.			Gene or Genome	
C124928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124928>	C16386	Ataxin-2|ATXN2|Spinocerebellar Ataxia Type 2 Protein|Trinucleotide Repeat Containing 13|Trinucleotide Repeat-Containing Gene 13 Protein	Ataxin-2 (1313 aa, ~140 kDa) is encoded by the human ATXN2 gene. This protein plays a role in the modulation of epidermal growth factor receptor internalization.			Amino Acid, Peptide, or Protein	
C124929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124929>	C2124|C129819	Lutetium Lu 177 Satoreotide Tetraxetan|177Lu-DOTA-Cpa-c[d-Cys-Aph(Hor)-d-Aph(Cbm)-Lys-Thr-Cys]-d-Tyr-NH2|177Lu-DOTA-JR11|177Lu-DOTA-[Cpa-c(DCys-Aph(Hor)-DAph(Cbm)-Lys-Thr-Cys)-DTyr-NH2]|Lu-177 OPS-201|SATOREOTIDE TETRAXETAN LUTETIUM LU-177|SOMther|Satoreotide Tetraxetan Lutetium Lu-177|Satoreotide Tetraxetan Lutetium-177	A radioconjugate consisting of the somatostatin antagonistic peptide satoreotide tetraxetan (JR11) that is linked, via the chelating agent dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and imaging activity during positron emission tomography/computed tomography (PET/CT). Upon administration, lutetium Lu 177-DOTA-JR11 binds to somatostatin receptors (SSTRs), with high affinity for SSTR2, present on the cell membranes of many types of neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. SSTRs have been shown to be present in large numbers on NETs and their metastases, while most normal tissues express low levels of SSTRs.	Lutetium Lu 177 DOTA-JR11		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12492>	C225418	Intra-abdominal|Intra-Abdominal	Within the abdomen.	Intra-abdominal		Body Location or Region	EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table
C124930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124930>	C2124	Gallium Ga 68 Satoreotide Tetraxetan|68Ga-DOTA-Cpa-c[d-Cys-Aph(Hor)-d-Aph(Cbm)-Lys-Thr-Cys]-d-Tyr-NH2|68Ga-DOTA-JR11|68Ga-DOTA-[Cpa-c(DCys-Aph(Hor)-DAph(Cbm)-Lys-Thr-Cys)-DTyr-NH2]|Gallium Ga 68 DOTA-JR11|SATOREOTIDE TETRAXETAN GALLIUM GA-68	A radioconjugate consisting of the somatostatin antagonistic peptide satoreotide that is linked via the chelating agent tetraxetan (dodecanetetraacetic acid; DOTA), to the beta-emitting radioisotope gallium Ga 68, with potential imaging activity during positron emission topography/computed tomography (PET/CT). Upon administration, gallium Ga 68 satoreotide tetraxetan binds to somatostatin receptors (SSTRs), with high affinity for SSTR2, present on the cell membranes of many types of neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate can be used to quantify tumor uptake of satoreotide using PET/CT. SSTRs have been shown to be present in large numbers on NETs and their metastases, while most normal tissues express low levels of SSTRs.	Gallium Ga 68 Satoreotide Tetraxetan		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C124931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124931>	C155727	pan FGFR Inhibitor PRN1371|FGFR 1-4 Inhibitor PRN1371|PRN 1371|PRN-1371|PRN1371|Pan-FGFR Tyrosine Kinase Inhibitor PRN1371	A highly specific covalent inhibitor of human fibroblast growth factor receptor types 1, 2, 3 and 4 (FGFR1-4) with potential antiangiogenic and antineoplastic activities. FGFR1-4 tyrosine kinase inhibitor PRN1371 specifically binds to a conserved cysteine residue in the glycine-rich loop in FGFRs and inhibits their tyrosine kinase activity, which may result in the inhibition of both tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. FGFRs are a family of receptor tyrosine kinases, which may be upregulated in various tumor cell types and may be involved in tumor cell differentiation, proliferation and survival, and in tumor angiogenesis. This agent potently inhibits FGFR1-4 but does not inhibit other tyrosine kinases, even those that share the conserved cysteine, which may improve therapeutic responses and decrease toxicity when compared with less selective inhibitors.	pan FGFR Inhibitor PRN1371		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124932>	C25952	VCP Gene|VCP|VCP|Valosin Containing Protein Gene	This gene is involved in the formation of the transitional endoplasmic reticulum and Golgi apparatus maintenance during mitosis.			Gene or Genome	
C124933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124933>	C124932	VCP wt Allele|ALS14|CDC48, Yeast, Homolog of Gene|IBMPFD|TERA|Valosin Containing Protein wt Allele|Yeast Cdc48p Homolog Gene|p97	Human VCP wild-type allele is located in the vicinity of 9p13.3 and is approximately 17 kb in length. This allele, which encodes transitional endoplasmic reticulum ATPase protein, plays a role in maintenance of both the transitional endoplasmic reticulum and the Golgi apparatus. Mutation of the gene is associated with amyotrophic lateral sclerosis 14 and inclusion body myopathy with early-onset Paget disease and frontotemporal dementia 1 (IBMPFD1).			Gene or Genome	
C124934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124934>	C16561	Transitional Endoplasmic Reticulum ATPase|15S Mg(2+)-ATPase P97 Subunit|ATPase p97|EC 3.6.4.6|Epididymis Luminal Protein 220|Epididymis Secretory Protein Li 70|TER ATPase|VCP|Valosin Containing Protein|Valosin-Containing Protein|p97 ATPase	Transitional endoplasmic reticulum ATPase (806 aa, ~89 kDa) is encoded by the human VCP gene. This protein is involved in maintaining the Golgi during and after mitosis and the the formation of the transitional endoplasmic reticulum.			Amino Acid, Peptide, or Protein|Enzyme	
C124935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124935>	C26006	VAPB Gene|VAMP (Vesicle-Associated Membrane Protein)-Associated Protein B and C Gene|VAPB|VAPB	This gene plays a role in the endoplasmic reticulum unfolded protein response.			Gene or Genome	
C124936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124936>	C124935	VAPB wt Allele|ALS8|DVAP33A, Drosophila, Homolog of Gene|UNQ484/PRO983|VAMP (Vesicle-Associated Membrane Protein)-Associated Protein B and C wt Allele|VAMP-B|VAMP-B/VAMP-C|VAMP-C|VAP-B|VAP-B/VAP-C|VAP-C|VAPC	Human VAPB wild-type allele is located in the vicinity of 20q13.33 and is approximately 62 kb in length. This allele, which encodes vesicle-associated membrane protein-associated protein B and vesicle-associated membrane protein-associated protein C, is involved in the mediation of the response to unfolded proteins. Mutation of the gene is associated with amyotrophic lateral sclerosis 8 and autosomal dominant adult proximal spinal muscular atrophy (SMAPAD).			Gene or Genome	
C124937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124937>	C16386	VAPB Gene Product|VAMP-Associated Protein B/C|VAMP-B/C|VAP-B/C|Vesicle-Associated Membrane Protein-Associated Protein B/C	A protein encoded by the VAPB gene.			Amino Acid, Peptide, or Protein	
C124938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124938>	C124937	Vesicle-Associated Membrane Protein-Associated Protein B|VAMP-Associated 33 kDa Protein|VAMP-Associated Protein B|VAMP-B|VAP-B	Vesicle-associated membrane protein-associated protein B (243 aa, ~27 kDa) is encoded by the human VAPB gene. This protein plays a role in the regulation of the unfolded protein response.			Amino Acid, Peptide, or Protein	
C124939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124939>	C124937	Vesicle-Associated Membrane Protein-Associated Protein C|VAMP-Associated Protein C|VAMP-C|VAP-C	Vesicle-associated membrane protein-associated protein C (99 aa, ~11 kDa) is encoded by the human VAPB gene. This protein plays a role in the unfolded protein response.			Amino Acid, Peptide, or Protein	
C12493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12493>	C34076	Base of the Skull|Base of Skull|SKULL, BASE	The portion of the skull that forms the floor on which the brain lies. The internal surface of the cranial base has three large depressions that lie on different levels known as the anterior, middle, and posterior cranial fossae.	Base of Skull		Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124940>	C25939	DAO Gene|D-Amino-Acid Oxidase Gene|DAO|DAO	This gene is involved in the modification of amino acids.			Gene or Genome	
C124941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124941>	C124940	DAO wt Allele|D-Amino-Acid Oxidase wt Allele|DAAO|DAMOX|OXDA	Human DAO wild-type allele is located in the vicinity of 12q24 and is approximately 42 kb in length. This allele, which encodes D-amino-acid oxidase protein, plays a role in amino acid modification. Mutation of the gene is associated with schizophrenia and may be associated with familial amyotrophic lateral sclerosis.			Gene or Genome	
C124942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124942>	C16946	D-Amino-Acid Oxidase|D-Amino Acid Oxidase|DAAO|DAMOX|DAO|EC 1.4.3.3	D-amino-acid oxidase (347 aa, ~39 kDa) is encoded by the human DAO gene. This protein is involved in amino acid metabolism.			Amino Acid, Peptide, or Protein|Enzyme	
C124943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124943>	C26070	FIG4 Gene|FIG4|FIG4|FIG4 Phosphoinositide 5-Phosphatase Gene	This gene plays a role in the metabolism of polyphosphoinositides.			Gene or Genome	
C124944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124944>	C124943	FIG4 wt Allele|ALS11|BTOP|CMT4J|FIG4 Homolog (S. cerevisiae) Gene|FIG4 Homolog, SAC Domain Containing Lipid Phosphatase Gene|FIG4 Homolog, SAC1 Domain Containing Lipid Phosphatase 3 Gene|FIG4 Homolog, SAC1 Lipid Phosphatase Domain Containing (S. cerevisiae) Gene|FIG4 Homolog, SAC1 Lipid Phosphatase Domain Containing 3 Gene|FIG4 Phosphoinositide 5-Phosphatase wt Allele|FIG4, S. cerevisiae, Homolog of Gene|KIAA0274|SAC3|YVS|dJ249I4.1|hSac3	Human FIG4 wild-type allele is located in the vicinity of 6q21 and is approximately 134 kb in length. This allele, which encodes polyphosphoinositide phosphatase protein, is involved in polyphosphoinositide metabolism. Mutation of the gene is associated with amyotrophic lateral sclerosis 11, Yunis-Varon syndrome, Yunis-Varon syndrome, bilateral temporooccipital polymicrogyria, and Charcot-Marie-Tooth disease, type 4J.			Gene or Genome	
C124945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124945>	C16981	Polyphosphoinositide Phosphatase|EC 3.1.3.-|FIG4|Phosphatidylinositol 3,5-Bisphosphate 5-Phosphatase|SAC Domain-Containing Protein 3|Sac Domain-Containing Inositol Phosphatase 3	Polyphosphoinositide phosphatase (907 aa, ~104 kDa) is encoded by the human FIG4 gene. This protein plays a role in the mediation of polyphosphoinositide metabolism.			Amino Acid, Peptide, or Protein|Enzyme	
C124946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124946>	C143250	PD1 Inhibitor|Anti-PD-1 Agent|PD-1 Inhibitor|PD-1-targeting Agent|Programmed Cell Death Protein 1 Inhibitor|Protein PD-1 Inhibitor	An agent designed to interfere with the activity of programmed cell death protein 1 (PD1). PD1 inhibitors block T-cell apoptosis and act as non-specific activators of the immune system.	PD1 Inhibitor		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology
C124947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124947>	C26868	Noncardiogenic Pulmonary Edema|Non-Cardiogenic Pulmonary Edema	Pulmonary edema that is not a result of cardiac dysfunction.			Disease or Syndrome	
C124948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124948>	C110937	Joint Contracture	Permanent shortening of a joint, usually resulting from prolonged spasticity in a muscle area.	Joint Contracture		Finding	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|CTRP Disease Terminology|CTRP Terminology
C124949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124949>	C26057	SETX Gene|SETX|SETX|Senataxin Gene	This gene is involved in DNA and RNA metabolism			Gene or Genome	
C12494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12494>	C34076	Clivus|CLIVUS	A sloped depression between the dorsum sellae and foramen magnum at the base of the skull.	Clivus		Body Space or Junction	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C124950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124950>	C124949	SETX wt Allele|ALS4|AOA2|Amyotrophic Lateral Sclerosis 4 Gene|KIAA0625|SCAR1|Senataxin wt Allele|Spinocerebellar Ataxia, Recessive, Non-Friedreich Type 1 Gene|bA479K20.2	Human SETX wild-type allele is located in the vicinity of 9q34.13 and is approximately 95 kb in length. This allele, which encodes probable helicase senataxin protein, plays a role in the metabolism of both DNA and RNA. Mutation of the gene is associated with juvenile amyotrophic lateral sclerosis 4 and autosomal recessive spinocerebellar ataxia 1.			Gene or Genome	
C124951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124951>	C20423	Probable Helicase Senataxin|Amyotrophic Lateral Sclerosis 4 Protein|EC 3.6.4.-|SEN1 Homolog|SETX|Senataxin	Probable helicase senataxin (2677 aa, ~303 kDa) is encoded by the human SETX gene. This protein is involved in nucleic acid processing.			Amino Acid, Peptide, or Protein|Enzyme	
C124952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124952>	C28404	OTUD5 Gene|OTU Deubiquitinase 5 Gene|OTUD5|OTUD5	This gene plays a role in both protein deubiquitination and immune system regulation.			Gene or Genome	
C124953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124953>	C124952	OTUD5 wt Allele|DKFZp761A052|DUBA|OTU Deubiquitinase 5 wt Allele|OTU Domain Containing 5 Gene	Human OTUD5 wild-type allele is located in the vicinity of Xp11.23 and is approximately 37 kb in length. This allele, which encodes OTU domain-containing protein 5, is involved in protein deubiquitination, modulation of interferon expression and immune system regulation.			Gene or Genome	
C124954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124954>	C16481	OTU Domain-Containing Protein 5|DUBA|Deubiquinating Enzyme A|Deubiquitinating Enzyme A|EC 3.4.19.12|OTUD5	OTU domain-containing protein 5 (571 aa, ~61 kDa) is encoded by the human OTUD5 gene. This protein plays a role in protein deubiquitination that modulates inate immunity.			Amino Acid, Peptide, or Protein|Enzyme	
C124955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124955>	C21295	ANXA8L1 Gene|ANXA8L1|ANXA8L1|Annexin A8-Like 1 Gene	This gene is involved in binding to calcium and phospholipids.			Gene or Genome	
C124956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124956>	C124955	ANXA8L1 wt Allele|ANXA8|ANXA8L2|Annexin A8-Like 1 wt Allele|Annexin A8-Like 2 Gene|VAC-beta|bA145E20.2|bA301J7.3	Human ANXA8L1 wild-type allele is located in the vicinity of 10q11.22 and is approximately 162 kb in length. This allele, which encodes annexin A8-like protein 1, plays a role in calcium-mediated phospholipid binding.			Gene or Genome	
C124957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124957>	C17728	Annexin A8-Like Protein 1|ANXA8L1|Annexin A8-Like Protein 2|Annexin A8L2|Vascular Anticoagulant-Beta	Annexin A8-like protein 1 (327 aa, ~37 kDa) is encoded by the human ANXA8L1 gene. This protein is involved in calcium-dependent binding to phospholipids.			Amino Acid, Peptide, or Protein	
C124958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124958>	C20923	MRGPRX2 Gene|MAS-Related GPR, Member X2 Gene|MRGPRX2|MRGPRX2	This gene plays a role in both G protein-coupled receptor signaling and mast cell activation.			Gene or Genome	
C124959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124959>	C91105	Modified 18-Item Memorial Anxiety Scale for Prostate Cancer|MODMAX-PC|Modified 18-Item MAX-PC|Modified 18-Item Memorial Anxiety Scale for Prostate Cancer (Modified 18-item MAX-PC)|Modified Memorial Anxiety Scale for Prostate Cancer	An 18-item questionnaire designed to facilitate the identification and assessment of men with prostate cancer-related anxiety.			Intellectual Product	
C12495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12495>	C34076	Foramen Magnum	A large orifice in the occipital bone through which the spinal cord enters the cranial cavity.	Foramen Magnum		Body Space or Junction	
C124960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124960>	C173896|C173160	Reference to Prostate Cancer Brought Up Strong Feelings Question|Any reference to prostate cancer brought up strong feelings in me|Reference to Prostate Cancer Brought Up Strong Feelings	A question about how frequently a reference to prostate cancer brings up or brought up strong feelings in an individual.			Intellectual Product	Modified 18-Item Memorial Anxiety Scale for Prostate Cancer
C124961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124961>	C91102	Getting a PSA Test Scared Me Question|Even though it's a good idea, I found that getting a PSA test scared me|Getting a PSA Test Scared Me	A question about how frequently an individual finds or found that the idea of getting a PSA test scared them.			Intellectual Product	Modified 18-Item Memorial Anxiety Scale for Prostate Cancer
C124962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124962>	C173896|C173386	More Anxious about Having Prostate Cancer Whenever Hearing about Friend or Public Figure with Prostate Cancer Question|More Anxious about Having Prostate Cancer Whenever Hearing about Friend or Public Figure with Prostate Cancer|Whenever I heard about a friend or public figure with prostate cancer, I got more anxious about my having prostate cancer	A question about how frequently an individual is or was more anxious about having prostate cancer whenever they heard about a friend or public figure with prostate cancer.			Intellectual Product	Modified 18-Item Memorial Anxiety Scale for Prostate Cancer
C124963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124963>	C124958	MRGPRX2 wt Allele|MAS-Related G Protein-Coupled Receptor, Member X2 Gene|MAS-Related GPR, Member X2 wt Allele|MGRG3|MRGX2	Human MRGPRX2 wild-type allele is located in the vicinity of 11p15.1 and is approximately 6 kb in length. This allele, which encodes Mas-related G-protein coupled receptor member X2 protein, is involved in both mast cell activation and receptor signaling.			Gene or Genome	
C124964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124964>	C173896|C173597|C173386	More Anxious About Having Prostate Cancer When Thinking about Having a PSA Test Question|More Anxious About Having Prostate Cancer When Thinking about Having a PSA Test|When I thought about having a PSA test, I got more anxious about my having prostate cancer	A question about how frequently an individual is or was more anxious about having prostate cancer when thinking about having a PSA test.			Intellectual Product	Modified 18-Item Memorial Anxiety Scale for Prostate Cancer
C124965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124965>	C18239	Mas-Related G-Protein Coupled Receptor Member X2|G Protein-Coupled Receptor MRGX2|G-Protein Coupled Receptor MRGX2|Mas-Related G Protein-Coupled Receptor G3|Mas-Related G Protein-Coupled Receptor Member X2|Mas-Related G-Protein Coupled Receptor G3	Mas-related G-protein coupled receptor member X2 (330 aa, ~37 kDa) is encoded by the human MRGPRX2 gene. This protein plays a role in G protein-coupled receptor signaling and mast cell activation.			Amino Acid, Peptide, or Protein|Receptor	
C124966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124966>	C173896|C173597	Other Things Made Me Think about Prostate Cancer Question|Other Things Made Me Think about Prostate Cancer|Other things kept making me think about prostate cancer	A question about how frequently other things make or made an individual think about prostate cancer.			Intellectual Product	Modified 18-Item Memorial Anxiety Scale for Prostate Cancer
C124967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124967>	C173896|C173597|C173160	Felt Numb When Thinking about Prostate Cancer Question|Felt Numb When Thinking about Prostate Cancer|I felt kind of numb when I thought about prostate cancer	A question about how frequently an individual feels of felt numb when they thought about prostate cancer.			Intellectual Product	Modified 18-Item Memorial Anxiety Scale for Prostate Cancer
C124968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124968>	C173896|C173597	Thought about Prostate Cancer Even Though Didn't Mean To Question|I thought about prostate cancer even though I didn't mean to|Thought about Prostate Cancer Even Though Didn't Mean To	A question about how frequently an individual thinks or thought about prostate cancer even when they didn't mean to.			Intellectual Product	Modified 18-Item Memorial Anxiety Scale for Prostate Cancer
C124969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124969>	C173896|C173160	Have Feelings about Prostate Cancer but Don't Want to Deal with Them Question|Have Feelings about Prostate Cancer but Don't Want to Deal with Them|I had a lot of feelings about prostate cancer, but I didn't want to deal with them	A question about how frequently an individual has or had feelings about prostate cancer but they didn't want to deal with them.			Intellectual Product	Modified 18-Item Memorial Anxiety Scale for Prostate Cancer
C12496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12496>	C34076	Jugular Foramen|Posterior Lacerate Foramen	An orifice in the base of the skull between the temporal and occipital bone through which cranial nerves IX, X, and XI, the inferior petrosal sinus, and the internal jugular vein pass.	Jugular Foramen		Body Space or Junction	
C124970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124970>	C173896|C173597|C104294	Had More Trouble Falling Asleep Because of Thoughts of Prostate Cancer Question|Had More Trouble Falling Asleep Because of Thoughts of Prostate Cancer|I had more trouble falling asleep because I couldn't get thoughts of prostate cancer out of my mind	A question about how frequently an individual has or had more trouble falling asleep because they couldn't get thoughts of prostate cancer out of their mind.			Intellectual Product	Modified 18-Item Memorial Anxiety Scale for Prostate Cancer
C124971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124971>	C173047	Afraid That Results from PSA Test Would Show That Disease was Getting Worse Question|Afraid That Results from PSA Test Would Show That Disease was Getting Worse|I was afraid that the results from my PSA test would show that my disease was getting worse	A question about how frequently an individual is or was afraid that results from a PSA test would show that their disease is getting worse.			Intellectual Product	Modified 18-Item Memorial Anxiety Scale for Prostate Cancer
C124972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124972>	C173896	Hearing the Words Prostate Cancer Scared Me Question|Hearing the Words Prostate Cancer Scared Me|Just hearing the words "prostate cancer" scared me	A question about how frequently an individual is or was scared just hearing the words "prostate cancer".			Intellectual Product	Modified 18-Item Memorial Anxiety Scale for Prostate Cancer
C124973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124973>	C173597|C173386	Have Been so Anxious about PSA Test Have Thought About Delaying It Question|Have Been so Anxious about PSA Test Have Thought About Delaying It|I have been so anxious about my PSA test that I have thought about delaying it	A question about how frequently an individual is or was so anxious about their PSA test that they have thought about delaying it.			Intellectual Product	Modified 18-Item Memorial Anxiety Scale for Prostate Cancer
C124974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124974>	C173934|C173597	Have Been so Worried about PSA Test Result Have Thought about Asking Doctor To Repeat It Question|Have Been so Worried about PSA Test Result Have Thought about Asking Doctor To Repeat It|I have been so worried about my PSA test result that I have thought about asking my doctor to repeat it	A question about how frequently an individual is or was so worried about their PSA test result that they have thought about asking their doctor to repeat it.			Intellectual Product	Modified 18-Item Memorial Anxiety Scale for Prostate Cancer
C124975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124975>	C173597	Have Been so Concerned about PSA Test Result Have Thought about Having Test Repeated at Another Lab Question|Have Been so Concerned about PSA Test Result Have Thought about Having Test Repeated at Another Lab|I have been so concerned about my PSA test result that I have thought about having the test repeated at another lab to make sure they were accurate	A question about how frequently an individual is or was so concerned about their PSA test result that they have thought about having the test repeated at another lab to make sure it was accurate.			Intellectual Product	Modified 18-Item Memorial Anxiety Scale for Prostate Cancer
C124976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124976>	C91102	Cannot Plan for the Future Because Cancer is Unpredictable Question|Because cancer is unpredictable, I feel I cannot plan for the future|Cannot Plan for the Future Because Cancer is Unpredictable	A question about an individual's agreement concerning not being able to plan for the future because cancer is unpredictable.			Intellectual Product	Modified 18-Item Memorial Anxiety Scale for Prostate Cancer
C124977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124977>	C124978	Fear of Cancer Getting Worse Gets in Way of Enjoying Life Question|Fear of Cancer Getting Worse Gets in Way of Enjoying Life|My fear of having my cancer getting worse gets in the way of my enjoying life	A question about an individual's agreement concerning fear of their cancer getting worse getting in the way of enjoying their life.			Intellectual Product	Modified 18-Item Memorial Anxiety Scale for Prostate Cancer
C124978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124978>	C173047	Afraid of Cancer Getting Worse Question|Afraid of Cancer Getting Worse|I am afraid of my cancer getting worse	A question about an individual's agreement concerning being afraid of their cancer getting worse.			Intellectual Product	Modified 18-Item Memorial Anxiety Scale for Prostate Cancer
C124979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124979>	C173896	More Nervous Since Prostate Cancer Diagnosis Question|I am more nervous since I was diagnosed with prostate cancer|More Nervous Since Prostate Cancer Diagnosis	A question about an individual's agreement concerning being more nervous since they were diagnosed with prostate cancer.			Intellectual Product	Modified 18-Item Memorial Anxiety Scale for Prostate Cancer
C12497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12497>	C34076	Sella Turcica|sella turcica|sella turcica	A bony prominence situated on the upper surface of the body of the sphenoid bone housing the pituitary gland.	Sella Turcica		Body Location or Region	Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C124980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124980>	C26003	DPP9 Gene|DPP9|DPP9|Dipeptidyl-Peptidase 9 Gene	This gene is involved in dipeptidyl aminopeptidase activity.			Gene or Genome	
C124981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124981>	C124980	DPP9 wt Allele|DP9|DPLP9|DPRP-2|DPRP2|Dipeptidyl-Peptidase 9 wt Allele|Dipeptidylpeptidase 9 Gene	Human DPP9 wild-type allele is located in the vicinity of 19p13.3 and is approximately 50 kb in length. This allele, which encodes dipeptidyl peptidase 9 protein, plays a role in post-translational protein cleavage.			Gene or Genome	
C124982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124982>	C17123	Dipeptidyl Peptidase 9|DP9|DPLP9|DPP IX|DPP9|DPRP-2|Dipeptidyl Peptidase IV-Related Protein 2|Dipeptidyl Peptidase IV-Related Protein-2|Dipeptidyl Peptidase IX|Dipeptidyl Peptidase-Like Protein 9|EC 3.4.14.5	Dipeptidyl peptidase 9 (863 aa, ~98 kDa) is encoded by the human DPP9 gene. This protein is involved in the removal of dipeptides from the amino-termini of substrates.			Amino Acid, Peptide, or Protein|Enzyme	
C124983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124983>	C25939	MDH2 Gene|MDH2|MDH2|Malate Dehydrogenase 2 Gene	This gene plays a role in the metabolism of both carbohydrates and oxoacids.			Gene or Genome	
C124984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124984>	C124983	MDH2 wt Allele|M-MDH|MDH|MGC:3559|MOR1|Malate Dehydrogenase 2 wt Allele|Malate Dehydrogenase 2, NAD (Mitochondrial) Gene	Human MDH2 wild-type allele is located within 7cen-q22 and is approximately 19 kb in length. This allele, which encodes malate dehydrogenase, mitochondrial protein, is involved in the metabolism of malate and the synthesis of oxaloacetate.			Gene or Genome	
C124985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124985>	C16946	Malate Dehydrogenase, Mitochondrial|EC 1.1.1.37|MDH2	Malate dehydrogenase, mitochondrial (338 aa, ~36 kDa) is encoded by the human MDH2 gene. This protein plays a role in the conversion of malate to oxaloacetate.			Amino Acid, Peptide, or Protein|Enzyme	
C124986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124986>	C20673	IRF5 Gene|IRF5|IRF5|Interferon Regulatory Factor 5 Gene	This gene is involved in the transcriptional regulation of genes encoding interferons and inflammatory cytokines.			Gene or Genome	
C124987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124987>	C124986	IRF5 wt Allele|IBD14|Interferon Regulatory Factor 5 wt Allele|SLEB10	Human IRF5 wild-type allele is located in the vicinity of 7q32 and is approximately 12 kb in length. This allele, which encodes interferon regulatory factor 5 protein, plays a role in the regulation of interferon and inflammatory cytokine expression. Mutation of the gene is associated with inflammatory bowel disease 14 and susceptibility to systemic lupus erythematosus 10.			Gene or Genome	
C124988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124988>	C17207	Interferon Regulatory Factor 5|IRF-5|IRF5	Interferon regulatory factor 5 (498 aa, ~56 kDa) is encoded by the human IRF5 gene. This protein is involved in the modulation of pro-inflammatory gene expression.			Amino Acid, Peptide, or Protein	NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C124989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124989>	C28533	SLC12A7 Gene|SLC12A7|SLC12A7|Solute Carrier Family 12 (Potassium/Chloride Transporter), Member 7 Gene	This gene plays a role in the transport of calcium and potassium ions across cell membranes.			Gene or Genome	
C12498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12498>	C13043	External Acoustic Meatus|Auditory Canal|Auditory Canal|EAR CANAL|EXTERNAL ACOUSTIC MEATUS|Ear Canal|Ear Canal|External Auditory Canal|External Auditory Canal|External Auditory Meatus|auditory canal|ear canal|external acoustic meatus|external acoustic tube|external auditory canal|external auditory tube	A part of the ear canal that is external to the ear drum.	External Auditory Canal		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C124990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124990>	C124989	SLC12A7 wt Allele|DKFZP434F076|KCC4|Solute Carrier Family 12 (Potassium/Chloride Transporter), Member 7 wt Allele|Solute Carrier Family 12 (Potassium/Chloride Transporters), Member 7 Gene	Human SLC12A7 wild-type allele is located in the vicinity of 5p15 and is approximately 62 kb in length. This allele, which encodes solute carrier family 12 member 7 protein, is involved in cellular homeostasis.			Gene or Genome	
C124991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124991>	C16386	Solute Carrier Family 12 Member 7|Electroneutral Potassium-Chloride Cotransporter 4|K-Cl Cotransporter 4|Potassium-Chloride Coransporter 4|Potassium/Chloride Transporter KCC4|SLC12A7	Solute carrier family 12 member 7 (1083 aa, ~119 kDa) is encoded by the human SLC12A7 gene. This protein plays a role in transmembrane transport of both potassium and calcium ions.			Amino Acid, Peptide, or Protein	
C124992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124992>	C142078	Adipose-derived Stromal Vascular Fraction Cells|Adipose-derived SVF Cells	A population of stromal vascular fraction (SVF) cells derived from autologous adipose tissue, with potential tissue regenerative activity. SVF cells are obtained through liposuction and contain multiple cell types, including adipose-derived stem cells (ADSCs), mesenchymal and endothelial progenitor cells, leukocyte subtypes, lymphatic cells, pericytes, and vascular smooth muscle cells. The SVF cells are processed in such a way as to contain a reproducible and consistent composition of heterogeneous cells. Upon processing and administration, the adipose-derived SVF cells can differentiate into different tissue types, support neovascularization, replace cells and repair injured issue.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology
C124993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124993>	C28227|C164001|C133878|C129822	Amivantamab|AMIVANTAMAB|Amivantamab-vmjw|Anti-EGFR/c-Met Bispecific Antibody JNJ-61186372|CNTO-4424|JNJ 61186372|JNJ-611|JNJ-61186372|JNJ61186372|Rybrevant	A human bispecific antibody targeting both epidermal growth factor receptor EGFR and hepatocyte growth factor receptor (HGFR; cMet), with potential antineoplastic activity. Upon administration, amivantamab simultaneously targets and binds to wild-type or certain mutant forms of both EGFR and cMet expressed on cancer cells, thereby preventing receptor phosphorylation. This prevents the activation of both EGFR- and cMet-mediated signaling pathways. In addition, binding results in receptor degradation, which further inhibits EGFR- and cMet-mediated signaling. JNJ-61186372 also causes antibody-dependent cellular cytotoxicity (ADCC). Altogether, this results in the inhibition of tumor cell proliferation. EGFR and cMet, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation.	Amivantamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124994>	C73913	Salvia hispanica Seed|CHIA SEED|Chia|Chia Seed|SH Seed	The edible seed of the flowering plant Salvia hispanica (chia) used as a nutritional supplement, with potential immunomodulating activity. Upon ingestion, chia seed supplies essential fatty acids, including alpha linolenic acid (an omega-3) and linoleic acid (an omega-6), B vitamins, especially niacin (B3) and thiamine (B1), and several minerals, including calcium, zinc, manganese, magnesium, phosphorus and iron; it also contains high levels of antioxidants and dietary soluble fiber. When used as a dietary supplement, this agent may improve a patient's nutrient intake and may balance their intestinal microbiome.	Salvia hispanica Seed		Plant	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C124995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124995>	C2167|C155322	Lifirafenib|BGB 283|BGB-283|Begeine-283|LIFIRAFENIB	An inhibitor of the serine/threonine protein kinase B-raf (BRAF) and epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Lifirafenib selectively binds to and inhibits the activity of BRAF and certain BRAF mutant forms, and EGFR. This prevents BRAF- and EGFR-mediated signaling and inhibits the proliferation of tumor cells that either contain a mutated BRAF gene or express over-activated EGFR. In addition, BGB-283 inhibits mutant forms of the Ras proteins K-RAS and N-RAS. BRAF and EGFR are mutated or upregulated in many tumor cell types.	Lifirafenib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124996>	C1511|C129819	Iodine I 131 Tenatumomab|131I-Tenatumomab	A radioimmunoconjugate of tenatumomab, a murine monoclonal antibody targeting the tumor-associated antigen (TAA) tenascin-C (TNC), labeled with iodine I 131, with potential antineoplastic activity. The antibody moiety of iodine I 131 tenatumomab binds to TNC, thereby delivering a cytotoxic dose of iodine I 131 specifically to tumors expressing TNC. TNC, an extracellular matrix protein, is upregulated in a variety of tumor cell types; it plays a key role in invasion, tumor cell proliferation and immune evasion.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124997>	C28681|C129826	Autologous Cytotoxic T-lymphocytes Induced with MUC1 Gene-transfected Dendritic Cells|MUC1-DC-CTL|MUC1-Gene-DC-CTL	A preparation of autologous cytotoxic T-lymphocytes (CTL), specifically reactive to the tumor-associated antigen (TAA) mucin-1 (MUC1), with potential antineoplastic activity. Peripheral blood mononuclear cells (PBMCs) are collected from the patient with MUC1-positive tumors and are exposed ex vivo to dendritic cells (DCs) transfected with a replication-deficient adenovirus encoding MUC1 to generate MUC1-specific CTLs, which are subsequently expanded in vitro. Upon re-infusion of autologous CTLs induced with MUC1 gene-transfected DCs to the patient, the CTLs target and lyse the MUC1-expressing tumor cells. This inhibits tumor cell proliferation. MUC1 is expressed by a variety of tumor cell types.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124998>	C28681|C129826	Autologous Cytotoxic T-lymphocytes Induced with MUC1 Peptide-pulsed Dendritic Cells|MUC1-Peptide-DC-CTL	A preparation of autologous cytotoxic T-lymphocytes (CTL), specifically reactive to the tumor-associated antigen (TAA) mucin-1 (MUC1), with potential antineoplastic activity. Peripheral blood mononuclear cells (PBMCs) are collected from the patient with MUC1-positive tumors and are exposed ex vivo to dendritic cells (DCs) that are pulsed with a MUC1 peptide to generate MUC1-specific CTLs, which are subsequently expanded in vitro. Upon re-infusion of autologous CTLs induced with MUC1 peptide-pulsed DCs to the patient, the CTLs target and lyse the MUC1-expressing tumor cells. This inhibits tumor cell proliferation. MUC1 is expressed by a variety of tumor cell types.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C124999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C124999>	C20401|C129822	Lacutamab|Anti-KIR3DL2 Monoclonal Antibody IPH4102|Anti-KIR3DL2 mAb IPH4102|IPH-4102|IPH4102|LACUTAMAB	A humanized monoclonal antibody against the immune receptor human killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2 (KIR3DL2), with potential immunomodulating and antineoplastic activities. Upon administration, lacutamab binds to KIR3DL2 expressed on certain tumor cells. This recruits natural killer (NK) cells and leads to lysis of KIR3DL2-expressing tumor cells. In addition, lacutamab induces antibody-dependent cellular cytotoxicity (ADCC), thereby further eliminating tumor cells. KIR3DL2, a tumor-associated antigen (TAA) and inhibitory receptor of the KIR family, is specifically expressed in most subtypes of cutaneous T-cell lymphomas (CTCL) and expressed only on a fraction of normal NK cells.	Lacutamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12499>	C13043	Inner Ear|EAR, INNER|INNER EAR|Internal Ear|Internal Ear|Labyrinth|Labyrinth	The portion of the ear located within the temporal bone that is involved in both hearing and balance and includes the semicircular canals, vestibule, and cochlea. (from American Heritage Dictionary online)	Inner Ear		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C1249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1249>	C862	Testosterone Undecanoate|Andriol|Nebido|Pantestone|Restandol|TESTOSTERONE UNDECANOATE|Testosterone 17Beta-Undecylate	The undecanoate ester form of the androgen testosterone, with gonadotropin-secretory inhibiting and hormone replacement activity. As testosterone inhibits the secretion of gonadotropins from the pituitary gland, administration of testosterone decreases the secretion of luteinizing hormone (LH). By inhibiting LH secretion, the growth of Leydig cells, which are normally stimulated by LH to produce testosterone, may be suppressed. In addition, this agent promotes the maintenance of male sex characteristics and can be used for testosterone replacement in hypogonadal males.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C125000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125000>	C275|C1892	Ginseng Compound	A compound containing the traditional Chinese medicine (TCM) ginseng, a herb belonging to the Araliaceae family, with potential antioxidant, chemopreventive, anti-inflammatory and antineoplastic activities. Upon administration of the ginseng compound, the active ingredients, mainly ginsenosides, inhibit various signal transduction pathways that play key roles in carcinogenesis and inflammation. This leads to the induction of apoptosis in and inhibits proliferation of tumor cells. In addition, ginsenosides enhance the activity of various antioxidant enzymes, induce nitric oxide (NO) formation, inhibit the formation of reactive oxygen species (ROS) and protect against free radical-induced DNA damage. Ginseng also modulates various components of the immune system, including the activation of dendritic cells (DCs).			Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125001>	C2189|C1742	Huaier Extract Granule|Huaier Granule|Trametes robiniophila murr Extract Granule	An orally bioavailable traditional Chinese medicine (TCM) composed of a granule containing an aqueous extract of Trametes robiniophila murr (Huaier), a mushroom found on hardwood tree trunks, with potential antineoplastic and anti-angiogenic activities. Although the exact mechanism of action through which Huaier exerts its effects is largely unknown, upon administration, this agent induces cell cycle arrest and apoptosis, and inhibits proliferation and migration of susceptible cancer cells through the modulation of various signal transduction pathways involved in carcinogenesis and angiogenesis.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C125002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125002>	C281|C226473	Topical Trichloroacetic Acid|Topical TCA	A topical solution containing the caustic agent trichloroacetic acid (TCA), with potential keratolytic, anti-viral and antineoplastic activities. Upon topical application to the affected area, TCA causes tissue necrosis through coagulation of proteins, leads to the destruction of human papilloma virus (HPV)-associated warts and inhibits HPV-driven proliferation of cancer cells.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125003>	C2336	Naporafenib|LXH 254|LXH-254|LXH254|NAPORAFENIB|Raf Family Kinase Inhibitor LXH254|pan-RAF Inhibitor LXH254|pan-RAF Kinase Inhibitor LXH254	An orally available inhibitor of all members of the serine/threonine protein kinase Raf family, with potential antineoplastic activity. Upon administration, naporafenib binds to Raf proteins and inhibits Raf-mediated signal transduction pathways. This inhibits proliferation of Raf-overexpressing tumor cells. Raf protein kinases are critical enzymes in the Ras/Raf/MEK/ERK signaling pathway and are upregulated in a variety of cancer cell types. They play key roles in tumor cell proliferation and survival.	Naporafenib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125004>	C25473	Once Daily|Once a day|Once per Day|One Time Daily	Scheduled or occurring at a frequency of once per day.			Quantitative Concept	Operational Ontology for Radiation Oncology Prostate Cancer Terminology|Revised Dyadic Adjustment Scale
C125005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125005>	C25404	Reversal	A change in something from one state to the opposite state.			Activity	
C125006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125006>	C124351	Pathologic Examination|PATHOLOGICAL EVALUATION|Pathologic Review|Pathology Examination	The evaluation of a disease process by a pathologist.	Pathologic Examination		Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C125008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125008>	C125581	Gross Pathology Result|Gross Pathologic Result	The outcome of a gross, or macroscopic, pathologic examination.			Finding	
C125009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125009>	C41255	Clinical Interpretation	The determination of the meaning of a clinical result.			Activity	
C12500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12500>	C13043	Eustachian Tube|Auditory Tube|Auditory Tube|EUSTACHIAN TUBE|Pharyngotympanic Tube|Pharyngotympanic Tube|Tuba Auditoria|Tuba Auditoria	A tubular structure that runs from the middle ear to the nasopharynx and is approximately 3-4 cm length. Its lumen is roughly triangular and has average diameter of 2-3 mm. The lumen is lined by ciliated pseudostratified, columnar epithelium, which sweeps material from the middle ear to the nasopharynx. It is functionally collapsed at rest, with slight negative pressure present in the middle ear, and opens during swallowing, sneezing, and yawning.  It serves to ventilate pressure differences between the middle ear and nasopharynx. This tube also allows middle ear secretions to drain into the nasopharynx.	Eustachian Tube		Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C125010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125010>	C70950	Quantitation Range|ROQ|Range of Quantitation	A set of values that demarcate the detection limits for a specific assay.			Intellectual Product	
C125011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125011>	C173803|C118873	How Often Have You Leaked Urine Question|How Often Have You Leaked Urine|How often do you leak urine|How often have you leaked urine|Urine Leak Frequency	A question about how often an individual has leaked urine.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125012>	C118873	How Often Have You Urinated Blood Question|How Often Have You Urinated Blood|How often have you urinated blood	A question about how often an individual has urinated blood.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125013>	C173803|C173346|C118873	How Often Have You Had Pain or Burning with Urination Question|How Often Have You Had Pain or Burning with Urination|How often have you had pain or burning with urination	A question about how often an individual has had pain or burning with urination.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125014>	C173803|C173045	Ability to Control Urination Question|Ability to Control Urination|Urinary Control|Which of the following best describes your urinary control	A question about an individual's ability to control their urination.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125015>	C178809	How Many Pads or Adult Diapers per Day Did You Use to Control Leakage Question|How Many Pads or Adult Diapers per Day Did You Use to Control Leakage|How many pads or adult diapers per day did you usually use to control leakage	A question about how many pads or adult diapers an individual used each day to control leakage.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125016>	C173803|C173516	How Big a Problem is Dripping or Leaking Urine Question|Dripping or leaking urine|How Big a Problem is Dripping or Leaking Urine	A question about an individual's assessment of how big a problem dripping or leaking urine has been.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125017>	C173803|C173346	How Big a Problem is Pain or Burning on Urination Question|How Big a Problem is Pain or Burning on Urination|Pain or burning on urination	A question about an individual's assessment of how big a problem pain or burning urination has been.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125018>	C179032|C173803|C173516	How Big a Problem is Bleeding with Urination Question|Bleeding with urination|How Big a Problem is Bleeding with Urination	A question about an individual's assessment of how big a problem bleeding with urination has been.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125019>	C173803|C173516	How Big a Problem is Weak Urine Stream or Incomplete Emptying Question|How Big a Problem is Weak Urine Stream or Incomplete Emptying|Weak urine stream or incomplete emptying	A question about an individual's assessment of how big a problem a weak urine stream or incompletely emptying has been.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125020>	C173516	How Big a Problem is Waking Up to Urinate Question|How Big a Problem is Waking Up to Urinate|Waking up to urinate	A question about an individual's assessment of how big a problem waking up to urinate has been.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125021>	C173516	How Big a Problem is the Need to Urinate Frequently During the Day Question|How Big a Problem is the Need to Urinate Frequently During the Day|Need to urinate frequently during the day	A question about an individual's assessment of how big a problem the need to urinate frequently during the day has been.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125022>	C173803|C173516	Overall How Big a Problem is Urinary Function Question|Overall How Big a Problem is Urinary Function|Overall, how big a problem has your urinary function been for you	A question about an individual's overall assessment of how big a problem their urinary function has been.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125023>	C118873	How Often had Rectal Urgency Question|How Often had Rectal Urgency|How often have you had rectal urgency (felt like I had to pass stool, but did not)	A question about how often an individual had rectal urgency.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125024>	C118873	How Often had Uncontrolled Leakage of Stool or Feces Question|How Often had Uncontrolled Leakage of Stool or Feces|How often have you had uncontrolled leakage of stool or feces	A question about how often an individual had uncontrolled leakage of stool or feces.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125025>	C173938|C118873	How Often had Stools That Were Loose or Liquid Question|How Often had Stools That Were Loose or Liquid|How often have you had stools (bowel movements) that were loose or liquid (no form, watery, mushy)	A question about how often an individual had stools that were loose or liquid.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125026>	C118873	How Often had Bloody Stools Question|How Often had Bloody Stools|How often have you had bloody stools	A question about how often an individual had bloody stools.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125027>	C173938|C173346|C118873	How Often Have Your Bowel Movements Been Painful Question|How Often Have Your Bowel Movements Been Painful|How often have your bowel movements been painful	A question about how often an individual had bowel movements that were painful.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125028>	C173938	How Many Bowel Movements on a Typical Day Question|How Many Bowel Movements on a Typical Day|How many bowel movements have you had on a typical day	A question about how many bowel movements an individual had on a typical day.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125029>	C173346|C118873	How Often had Crampy Pain in Abdomen, Pelvis, or Rectum Question|How Often had Crampy Pain in Abdomen, Pelvis, or Rectum|How often have you had crampy pain in your abdomen, pelvis or rectum	A question about how often an individual had crampy pain in their abdomen, pelvis or rectum.			Intellectual Product	Expanded Prostate Cancer Index Composite
C12502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12502>	C13166	Tympanic Membrane|Ear Drum|Eardrum|Membrana Tympanica|Membrane, Tympanic|TM|TYMPANIC MEMBRANE	A thin membrane that separates the external auditory canal from the middle ear. The movement of the tympanic membrane in response to air pressure changes in the external ear facilitates the transmission of sound energy by causing vibration of the ossicular chain.	Tympanic Membrane		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C125030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125030>	C173938|C173516	How Big a Problem is Urgency to Have Bowel Movement Question|How Big a Problem is Urgency to Have Bowel Movement|Urgency to have a bowel movement	A question about an individual's assessment of how big a problem urgency to have bowel movements has been.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125031>	C173938|C173516	How Big a Problem is Increased Frequency of Bowel Movements Question|How Big a Problem is Increased Frequency of Bowel Movements|Increased frequency of bowel movements	A question about an individual's assessment of how big a problem increased frequency of bowel movements has been.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125032>	C173938|C173516	How Big a Problem is Watery Bowel Movements Question|How Big a Problem is Watery Bowel Movements|Watery bowel movements	A question about an individual's assessment of how big a problem watery bowel movements have been.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125033>	C173516	How Big a Problem is Losing Control of Stools Question|How Big a Problem is Losing Control of Stools|Losing control of your stools	A question about an individual's assessment of how big a problem losing control of their stools has been.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125034>	C173516	How Big a Problem is Bloody Stools Question|Bloody stools|How Big a Problem is Bloody Stools	A question about an individual's assessment of how big a problem bloody stools have been.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125035>	C173346	How Big a Problem is Abdominal, Pelvic, or Rectal Pain Question|Abdominal/Pelvic/Rectal pain|How Big a Problem is Abdominal, Pelvic, or Rectal Pain	A question about an individual's assessment of how big a problem abdominal, pelvic, or rectal pain has been.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125036>	C173938|C173516	Overall How Big a Problem Have Your Bowel Habits Been Question|Overall How Big a Problem Have Your Bowel Habits Been|Overall how big a problem have your bowel habits been for you	A question about an individual's overall assessment of how big a problem their bowel habits have been.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125037>	C173704	Level of Sexual Desire Question|Desire for Sexual Intimacy|Level of Sexual Desire|My desire for sexual intimacy|Your level of sexual desire	A question about an individual's level of sexual desire.			Intellectual Product	Clinical Global Impression Original Version Questionnaire|Expanded Prostate Cancer Index Composite
C125038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125038>	C173704|C173045	Ability to Have An Erection Question|Ability to Have An Erection|Your ability to have an erection	A question about an individual's ability to have an erection.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125039>	C173704|C173045	Ability to Reach Orgasm Question|Ability to Reach Orgasm|Have you reached orgasm|Your ability to reach orgasm (climax)	A question about an individual's ability to reach orgasm.			Intellectual Product	Expanded Prostate Cancer Index Composite|Rectal Cancer Female Sexuality Score
C12503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12503>	C34076	Mastoid Process|MASTOID PROCESS|Mastoid|Mastoid structure (body structure)|Process Mastoideus	A honeycombed section of bone located near the base of the skull, protruding behind the outer ear. It is connected to the middle ear.	Mastoid		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C125040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125040>	C91102	Usual Quality of Erections Question|How would you describe the usual QUALITY of your erections|Usual Quality of Erections	A question about the usual quality of an individual's erections.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125041>	C173358	Frequency of Erections Question|Frequency of Erections|How would you describe the FREQUENCY of your erections	A question about the frequency of an individual's erections.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125042>	C118873	How Often Awakened in the Morning or Night with an Erection Question|How Often Awakened in the Morning or Night with an Erection|How often have you awakened in the morning or night with an erection	A question about how often an individual awoke in the morning or night with an erection.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125043>	C173704|C118873	How Often had Any Sexual Activity Question|How Often had Any Sexual Activity|How often did you have any sexual activity	A question about how often an individual had any sexual activity.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125044>	C118873	How Often had Sexual Intercourse Question|How Often had Sexual Intercourse|How often did you have sexual intercourse	A question about often an individual had sexual intercourse.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125045>	C173704	Overall Ability to Function Sexually Question|Overall Ability to Function Sexually|Overall, how would you rate your ability to function sexually	A question about an individual's overall assessment of their ability to function sexually.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125046>	C173704|C173516	How Big a Problem is Your Level of Sexual Desire Question|How Big a Problem is Your Level of Sexual Desire|Your level of sexual desire	A question about an individual's assessment of how big a problem their level of sexual desire has been.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125047>	C173516	How Big a Problem is Your Ability to Have an Erection Question|How Big a Problem is Your Ability to Have an Erection|Your ability to have an erection	A question about an individual's assessment of how big a problem their ability to have an erection has been.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125048>	C173516	How Big a Problem is Your Ability to Reach an Orgasm Question|How Big a Problem is Your Ability to Reach an Orgasm|How Big a Problem is Your Ability to Reach an Orgasm	A question about an individual's assessment of how big a problem their ability to reach an orgasm has been.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125049>	C173516	Overall How Big a Problem is Your Sexual Function or Lack of Sexual Function Question|Overall , how big a problem has your sexual function or lack of sexual function been for you|Overall How Big a Problem is Your Sexual Function or Lack of Sexual Function	A question about an individual's overall assessment of how big a problem their sexual function or lack of sexual function has been.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125050>	C175990|C118873	How Often Experienced Hot Flashes Question|How Often Experienced Hot Flashes|How often have you experienced hot flashes	A question about how often an individual experienced hot flashes.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125051>	C173791|C118873	How Often had Breast Tenderness Question|How Often had Breast Tenderness|How often have you had breast tenderness	A question about often an individual had breast tenderness.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125052>	C173160|C118873	How Often Felt Depressed Question|How Often Felt Depressed|How often have you felt depressed	A question about how often an individual felt depressed.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125053>	C173160|C118873	How Often Felt a Lack of Energy Question|How Often Felt a Lack of Energy|How Often Lack of Energy|How often have you felt a lack of energy|Lack of Energy Frequency|Lack of energy	A question about how often an individual feels or felt a lack of energy.			Intellectual Product	Expanded Prostate Cancer Index Composite|Memorial Symptom Assessment Scale
C125054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125054>	C175990	How Much Change in Weight Have You Experienced Question|How Much Change in Weight Have You Experienced|How much change in your weight have you experienced, if any	A question about how much weight change an individual has experienced.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125055>	C173516	How Big a Problem Are Hot Flashes Question|Hot flashes|How Big a Problem Are Hot Flashes	A question about an individual's assessment of how big a problem hot flashes have been.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125056>	C173791|C173516	How Big a Problem is Breast Tenderness or Enlargement Question|Breast tenderness/enlargement|How Big a Problem is Breast Tenderness or Enlargement	A question about an individual's assessment of how big a problem breast tenderness or enlargement has been.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125057>	C173516	How Big a Problem is Loss of Body Hair Question|How Big a Problem is Loss of Body Hair|Loss of Body Hair	A question about an individual's assessment of how big a problem loss of body hair has been.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125058>	C173160	How Big a Problem is Feeling Depressed Question|Feeling depressed|How Big a Problem is Feeling Depressed	A question about an individual's assessment of how big a problem feeling depressed has been.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125059>	C173516	How Big a Problem is Lack of Energy Question|How Big a Problem is Lack of Energy|Lack of energy	A question about an individual's assessment of how big a problem lack of energy has been.			Intellectual Product	Expanded Prostate Cancer Index Composite
C12505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12505>	C77637	Buccal Mucosa|BUCCAL MUCOSA|Buccal mucosa|Buccal mucosa|Cheek mucosa|MUCOSA, BUCCAL|buccal mucosa|buccal mucosa	The mucosal membranes located on the inside of the cheek, in the buccal cavity.	Buccal Mucosa		Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C125060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125060>	C173516	How Big a Problem is Your Change in Body Weight Question|Change in body weight|How Big a Problem is Your Change in Body Weight	A question about an individual's assessment of how big a problem their body weight change has been.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125061>	C173896|C173812|C173792	Overall Satisfaction with Treatment Received for Prostate Cancer Question|Overall Satisfaction|Overall Satisfaction with Treatment Received for Prostate Cancer|Overall, how satisfied are you with the treatment you received for your prostate cancer	A question about an individual's overall satisfaction with the treatment they received for their prostate cancer.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125062>	C61074	Tomivosertib|EFT-508|Spiro(cyclohexane-1,3'(2'H)-imidazo(1,5-a)pyridine)-1',5'-dione, 6'-((6-Amino-4-pyrimidinyl)amino)-8'-methyl-|TOMIVOSERTIB|eFT508	An orally bioavailable inhibitor of mitogen-activated protein kinase (MAPK)-interacting serine/threonine-protein kinase 1 (MNK1) and 2 (MNK2), with potential antineoplastic activity. Upon oral administration, tomivosertib binds to and inhibits the activity of MNK1 and 2. This prevents MNK1/2-mediated signaling, and inhibits the phosphorylation of certain regulatory proteins, including eukaryotic translation initiation factor 4E (eIF4E), that regulate the translation of messenger RNAs (mRNAs) involved in tumor cell proliferation, angiogenesis, survival and immune signaling. This inhibits tumor cell proliferation in MNK1/2-overexpressing tumor cells. MNK1/2 are overexpressed in a variety of tumor cell types and promote phosphorylation of eIF4E; eIF4E is overexpressed in many tumor cell types and contributes to tumor development, maintenance and resistance.	Tomivosertib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125063>	C78284|C29639	Botanical Lotion CG428|CG428	A proprietary lotion containing a blend of the four botanicals Allium cepa L. (Onion), Citrus limon L. (Citrus), Theobroma cacao L. (Cocoa), Paullinia cupana (Guarana), with potential activity against chemotherapy-induced alopecia (CIA). Upon administration to the scalp, botanical lotion CG428 may normalize the apoptotic process of hair follicular cells and reduce inflammation in the scalp. This may reverse chemotherapy-induced alopecia (CIA), restore the natural hair cycle, improve hair regrowth, and improve the psychosocial well-being of the affected patient.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C125064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125064>	C477	Pegol-sihematide Injection|EPO 018B|EPO-018B	A synthetic peptide derived from erythropoietin (EPO) linked to polyethylene glycol (PEG), with erythropoietic stimulating activity. Upon administration, pegol sihematide binds to and activates EPO receptors on the surface of erythroid progenitor cells in the bone marrow resulting in their differentiation and proliferation. This increases the production of red blood cells and prevents anemia. Pegylation increases this agent's blood circulation time.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C125065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125065>	C178366	Body Weight Gain Exceeding 10 Pounds|Gained 10 pounds or more|Weight Gain Exceeding 10 Pounds	A subjective response indicating that an individual has gained 10 pounds or more.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125066>	C178366	Body Weight Gain Less Than 10 Pounds|Gained less than 10 pounds|Weight Gain Less Than 10 Pounds	A subjective response indicating that an individual has gained less than 10 pounds.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125067>	C178366	No Change in Body Weight|No Change in Weight|No change in weight	A subjective response indicating that an individual has had no change in weight.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125068>	C178366	Body Weight Loss Less Than 10 Pounds|Lost less than 10 pounds|Weight Loss Less Than 10 Pounds	A subjective response indicating that an individual has lost less than 10 pounds.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125069>	C178366	Body Weight Loss Exceeding 10 Pounds|Lost 10 pounds or more|Weight Loss Exceeding 10 Pounds	A subjective response indicating that an individual has lost 10 pounds or more.			Intellectual Product	Expanded Prostate Cancer Index Composite
C12506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12506>	C38617	Tooth|TOOTH|Teeth	The hard bonelike structures in the jaws of vertebrates; primarily used for eating.	Tooth		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C125070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125070>	C176250	Dissatisfied	A subjective response indicating that an individual is displeased and discontent.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125071>	C176250	Uncertain if Satisfied or Dissatisfied|Uncertain	A subjective response indicating that an individual is unsure if they are satisfied or dissatisfied.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125072>	C176250	Satisfied	A subjective response indicating that an individual is pleased and content.			Intellectual Product	Expanded Prostate Cancer Index Composite
C125073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125073>	C172982	Bothered by Chills Question|Bothered by Chills|I am bothered by the chills	A question about whether an individual is or was bothered by the chills.			Intellectual Product	FACT-BRM Questionnaire
C125074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125074>	C173593|C172982	Bothered by Lumps or Swelling in Certain Parts of My Body Question|Bothered by Lumps or Swelling in Certain Parts of My Body|I am bothered by lumps or swelling in certain parts of my body (e.g., neck, armpits, or groin)	A question about whether an individual is or was bothered by lumps or swelling in certain parts of their body.			Intellectual Product	FACT-BRM Questionnaire
C125075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125075>	C173160	Feel Uncertain About My Future Health Question|Feel Uncertain About My Future Health|I feel uncertain about my future health	A question about whether an individual feels or felt uncertain about their future health.			Intellectual Product	FACT-BRM Questionnaire
C125076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125076>	C173812|C111736	Feel Isolated from Others Because of My Illness or Treatment Question|Feel Isolated from Others Because of My Illness or Treatment|I feel isolated from others because of my illness or treatment	A question about whether an individual feels or felt isolated from others because of their illness or treatment.			Intellectual Product	Clinical or Research Assessment Question
C125077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125077>	C179032	Bleed Easily Question|Bleed Easily|I bleed easily	A question about whether an individual bleeds or bled easily.			Intellectual Product	FACT-Th11 Questionnaire
C125078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125078>	C173981	Bruise Easily Question|Bruise Easily|I bruise easily	A question about whether an individual bruises or bruised easily.			Intellectual Product	FACT-Th11 Questionnaire
C125079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125079>	C91105	FACT-Th11 Questionnaire|FACT-Th11|Functional Assessment of Cancer Therapy - Thrombocytopenia|Functional Assessment of Cancer Therapy Thrombocytopenia Questionnaire	A subscale complement to the FACT-G developed specifically for evaluating the quality of life of cancer patients with thrombocytopenia.			Intellectual Product	
C12507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12507>	C54648	Mantle Field|mantle field	A type of extended radiation field that includes lymph node areas in the neck, chest, and axilla.	Mantle Field		Body Location or Region	GDC Terminology|GDC Value Terminology
C125080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125080>	C177175	Tilsotolimod Sodium|IMO 2125|IMO-2125|TILSOTOLIMOD SODIUM|TLR9 Agonist IMO-2125	The sodium salt form of tilsotolimod, a proprietary synthetic oligonucleotide-based agonist of toll-like receptor 9 (TLR9), with potential immunostimulating activity. Upon administration, tilsotolimod binds to and activates TLR9 expressed by plasmacytoid dendritic cells (pDCs) and B-cells. This initiates immune signaling pathways, activates B-cells and pDCs, and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.	Tilsotolimod Sodium		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125081>	C172641|C129822	Lenzilumab|Immunoglobulin G1-kappa, Anti-(Homo sapiens CSF2 (Colony Stimulating Factor 2 (Granulocyte-Macrophage), Granulocyte Macrophage Colony Stimulating Factor, GM-CSF)), Homo sapiens Monoclonal Antibody|KB 003|KB003|LENZILUMAB	A recombinant monoclonal antibody against the cytokine granulocyte macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating activity. Upon administration, lenzilumab binds to and neutralizes GM-CSF. This prevents GM-CSF binding to the GM-CSF receptor, which is a heterodimeric protein expressed on myeloid progenitor cells, and prevents GM-CSF-mediated signaling. This may induce apoptosis in and inhibit proliferation of cancer cells that overproduce GM-CSF. GM-CSF plays a key role in the differentiation and proliferation of monocytes, macrophages and granulocytes; elevated levels of GM-CSF are associated with certain autoimmune diseases, inflammatory diseases, and cancers.	Lenzilumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C125082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125082>	C217121	Decisional Conflict Scale|DCS	A questionnaire that measures health-care consumers' uncertainty in making a health-related decisions, the modifiable factors contributing to the uncertainty, and health-care consumers' perceived effective decision making.			Intellectual Product	
C125083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125083>	C177743	Know Which Options Are Available Question|I know which options are available to me|Know Which Options Are Available	A question about an individual's assessment of whether they know or knew which options were available to them.			Intellectual Product	Decisional Conflict Scale
C125084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125084>	C177743	Know the Benefits of Each Option Question|I know the benefits of each option|Know the Benefits of Each Option	A question about an individual's assessment of whether they know or knew the benefits of each option.			Intellectual Product	Decisional Conflict Scale
C125085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125085>	C173933	Know the Risks and Side Effects of Each Option Question|I know the risks and side effects of each option|Know the Risks and Side Effects of Each Option	A question about an individual's assessment of whether they know or knew the risks and side effects of each option.			Intellectual Product	Decisional Conflict Scale
C125086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125086>	C173081	Clear About Which Benefits Matter Most Question|Clear About Which Benefits Matter Most|I am clear about which benefits matter most to me	A question about an individual's assessment of whether they are or were clear about which benefits matter most to them.			Intellectual Product	Decisional Conflict Scale
C125087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125087>	C173933|C173081	Clear About Which Risks and Side Effects Matter Most Question|Clear About Which Risks and Side Effects Matter Most|I am clear about which risks and side effects matter most	A question about an individual's assessment of whether they are or were clear about which risks and side effects matter most.			Intellectual Product	Decisional Conflict Scale
C125088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125088>	C173081	Clear About Whether Benefits or Risks are More Important Question|Clear About Whether Benefits or Risks are More Important|I am clear about which is more important to me (the benefits or the risks and side effects)	A question about an individual's assessment of whether they are or were clear about whether the benefits or the risks and side effects were more important to them.			Intellectual Product	Decisional Conflict Scale
C125089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125089>	C91102	Have Enough Support from Others to Make a Choice Question|Have Enough Support from Others to Make a Choice|I have enough support from others to make a choice	A question about an individual's assessment of whether they have or had enough support from others to make a choice.			Intellectual Product	Decisional Conflict Scale
C12508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12508>	C21599	Cell|Cell Type|Cell Types|Cells|Cellular|Normal Cell|cell|{Cells}	The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid.	Cell Types		Cell	GDC Terminology|GDC Value Terminology
C125090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125090>	C91102	Choosing Without Pressure from Others Question|Choosing Without Pressure from Others|I am choosing without pressure from others	A question about an individual's assessment of whether they are choosing or chose without pressure from others.			Intellectual Product	Decisional Conflict Scale
C125091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125091>	C91102	Have Enough Advice to Make a Choice Question|Have Enough Advice to Make a Choice|I have enough advice to make a choice	A question about an individual's assessment of whether they have or had enough advice to make a choice.			Intellectual Product	Decisional Conflict Scale
C125092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125092>	C173081	Clear About the Best Choice Question|Clear About the Best Choice|I am clear about the best choice for me	A question about an individual's assessment of whether they are or were clear about the best choice for them.			Intellectual Product	Decisional Conflict Scale
C125093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125093>	C173160	Sure About What to Choose Question|I feel sure about what to choose|Sure About What to Choose	A question about an individual's assessment of whether they are or were sure about what to choose.			Intellectual Product	Decisional Conflict Scale
C125094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125094>	C174127	Decision is Easy to Make Question|Decision is Easy to Make|This decision is easy for me to make	A question about an individual's assessment of whether the decision is or was easy for them.			Intellectual Product	Decisional Conflict Scale
C125095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125095>	C173160	Have Made an Informed Choice Question|Have Made an Informed Choice|I feel I have made an informed choice	A question about an individual's assessment of whether they feel or felt they made an informed choice.			Intellectual Product	Decisional Conflict Scale
C125096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125096>	C174127	Decision Shows What is Important Question|Decision Shows What is Important|My decision shows what is important to me	A question about an individual's assessment of whether the decision shows or showed what is important to them.			Intellectual Product	Decisional Conflict Scale
C125097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125097>	C174127	Expect to Stick With Decision Question|Expect to Stick With Decision|I expect to stick with my decision	A question about an individual's assessment of whether they expect or expected to stick with their decision.			Intellectual Product	Decisional Conflict Scale
C125098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125098>	C174127|C173792	Satisfied With Decision Question|I am satisfied with my decision|Satisfied With Decision	A question about an individual's assessment of whether they are or were satisfied with their decision.			Intellectual Product	Decisional Conflict Scale
C125099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125099>	C25871	IP6K1 Gene|IP6K1|IP6K1|Inositol Hexakisphosphate Kinase 1 Gene	This gene is involved in the synthesis of inositol pyrophosphates.			Gene or Genome	
C12509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12509>	C13031	Infratentorial Brain|INFRATENTORIAL BRAIN|Infratentorial Anatomy|Infratentorial Nervous System	A region in the brain that is located below the tentorium cerebelli and contains the cerebellum.	Infratentorial Brain|Infratentorial Nervous System		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C1250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1250>	C1450	Ormaplatin|ORMAPLATIN|Platinum, tetrachloro(1,2-cyclohexanediamine-N,N')-, (OC-6-22-(trans))-|Tetraplatin|Tetraplatin|tetrachloro(1,2-cyclohexanediamine-N,N')-, (OC-6-22-(trans))Platinum	A platinum(IV) analogue with antineoplastic activity. Ormaplatin alkylates DNA, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity.			Inorganic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125100>	C125099	IP6K1 wt Allele|IHPK1|Inositol Hexakisphosphate Kinase 1 wt Allele|KIAA0263|PiUS	Human IP6K1 wild-type allele is located in the vicinity of 3p21.31 and is approximately 62 kb in length. This allele, which encodes inositol hexakisphosphate kinase 1 protein, plays a role in inositol phosphate metabolism.			Gene or Genome	
C125101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125101>	C201493|C200766	Autologous Anti-CD123 CAR TCR/4-1BB-expressing T-lymphocytes|Anti-CD123 CAR mRNA-electroporated Autologous T-lymphocytes|Autologous Anti-CD123 CAR TCR/4-1BB-expressing T Lymphocytes|Autologous RNA CART123 Cells|RNA Anti-CD123 CAR T Cells|RNA CART123 Cells	Autologous, genetically engineered T-lymphocytes that have been electroporated with a messenger RNA (mRNA) encoding a chimeric antigen receptor (CAR) consisting of an anti-human interleukin-3 receptor alpha chain (IL3RA; CD123) single chain variable fragment (scFv) coupled to the co-stimulatory signaling domains of 4-1BB (CD137) and the zeta chain of the T-cell receptor (TCR) CD3 complex (CD3-zeta), with potential immunomodulating and antineoplastic activities.  Upon transfusion, the mRNA-electroporated autologous anti-CD123 CAR TCR/4-1BB expressing T-lymphocytes attach to cancer cells expressing CD123. This induces selective toxicity in and causes lysis of CD123-expressing tumor cells. The 4-1BB co-stimulatory molecule signaling domain enhances T-cell activation and signaling after recognition of CD123. CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with both increased leukemic cell proliferation and aggressiveness.	Autologous Anti-CD123 CAR TCR/4-1BB-expressing T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125102>	C16984	Inositol Hexakisphosphate Kinase 1|ATP:1D-Myo-Inositol-Hexakisphosphate Phosphotransferase|EC 2.7.4.21|IP6K1|Inositol Hexaphosphate Kinase 1|InsP6 Kinase 1|Pi Uptake Stimulator	Inositol hexakisphosphate kinase 1 (441 aa, ~50 kDa) is encoded by the human IP6K1 gene. This protein is involved in the metabolism of second messenger molecules.			Amino Acid, Peptide, or Protein|Enzyme	
C125103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125103>	C16830	NovoTTF-100A Device|NovoTTF-100A|NovoTTF-100A System|NovoTTF-100A system (Optune)|NovoTTFields|NovoTumor Treatment Fields|Optune|Optune Device	A portable, battery-operated device that is used to apply low intensity, alternating electric fields, also called tumor treatment fields (TTFs; TTFields), that can potentially be used to kill cancer cells. Upon placement of the insulated electrodes of the NovoTTF-100A device on the skin's surface encircling the tumor area, electrical charges are delivered, and the resulting electrical fields interfere with cell division. This induces cell death in and inhibits proliferation of tumor cells.	NovoTTF-100A Device		Medical Device	CTRP Intervention Terminology|CTRP Terminology|HemOnc Agent Terminology
C125104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125104>	C25616	Past 3 Months|Last 3 Months|Last 3 months|Past Three Months	A period of time consisting of the 3 months before the present.			Temporal Concept	Adherence Starts With Knowledge 12 Questionnaire|TAPS Tool - Interviewer Version
C125105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125105>	C91105	TAPS Tool - Interviewer Version|TAPS|TAPS Tool|TAPS Tool Part 1 - Interviewer Version (QSC)|The Tobacco, Alcohol, Prescription Medication and Other Substances Tool - Interviewer Version	An instrument designed to screen and assess adult primary care patients for tobacco, alcohol, prescription drug, and drug use and problems related to their use.			Intellectual Product	
C125106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125106>	C133710	TRAIP Gene|TRAF Interacting Protein Gene|TRAIP|TRAIP	This gene plays a role in protein ubiquitination and signal pathway regulation.			Gene or Genome	
C125107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125107>	C125106	TRAIP wt Allele|RNF206|TRAF Interacting Protein wt Allele|TRIP	Human TRAIP wild-type allele is located in the vicinity of 3p21.31 and is approximately 28 kb in length. This allele, which encodes E3 ubiquitin-protein ligase TRAIP protein, is involved in the ubiquitination of protein substrates.			Gene or Genome	
C125108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125108>	C21254	E3 Ubiquitin-Protein Ligase TRAIP|EC 2.3.2.27|EC 6.3.2.-, Formerly|Ring Finger Protein 206|TRAF-Interacting Protein	E3 ubiquitin-protein ligase TRAIP (469 aa, ~53 kDa) is encoded by the human TRAIP gene. This protein plays a role in ubiquitination.			Amino Acid, Peptide, or Protein|Enzyme	
C125109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125109>	C25997	WASF2 Gene|WASF2|WASF2|WASP Family Member 2 Gene	This gene is involved in both the mediation of signal transduction and the regulation of cytoskeletal reorganization.			Gene or Genome	
C12510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12510>	C13031	Mesencephalon|BRAIN, MIDBRAIN|MIDBRAIN|Mid-brain|Midbrain|Midbrain|midbrain	The uppermost portion of the brainstem located between the pons and the diencephalon. The midbrain contains the cerebral peduncles, oculomotor, trochlear and red nuclei, substantia nigra and various other nuclei and tracts.	Midbrain		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF6 DIPG Imaging Assessment Table|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C125110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125110>	C125109	WASF2 wt Allele|IMD2|Putative Wiskott-Aldrich Syndrome Protein Family Member 4 Gene|SCAR, Dictyostelium, Homolog of, 2 Gene|SCAR2|Suppressor of Cyclic-AMP Receptor (WASP-Family) Gene|WAS Protein Family Member 2 Gene|WAS Protein Family, Member 2 Gene|WASF4|WASP Family Member 2 wt Allele|WASP Family Protein Member 4 Gene|WASP Family Verprolin-Homologous Protein 2 Gene|WASP Family, Member 2 Gene|WASP Family, Verprolin Homology Domain-Containing Protein 2 Gene|WASP Protein Family, Member 2 Gene|WAVE2|dJ393P12.2	Human WASF2 wild-type allele is located in the vicinity of 1p36.11 and is approximately 86 kb in length. This allele, which encodes actin-binding protein WASF2 protein, plays a role in signal transduction that regulates actin filament organization.			Gene or Genome	
C125111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125111>	C26231	Actin-Binding Protein WASF2|Protein WAVE-2|Verprolin Homology Domain-Containing Protein 2|WASF2|WASP Family Protein Member 2|WASP Family Verprolin-Homologous Protein 2|Wiskott-Aldrich Syndrome Protein Family Member 2	Actin-binding protein WASF2 (498 aa, ~54 kDa) is encoded by the human WASF2 gene. This protein is involved in signaling that mediates actin cytoskeleton morphology.			Amino Acid, Peptide, or Protein	
C125112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125112>	C25873	MAP3K3 Gene|MAP3K3|MAP3K3|Mitogen-Activated Protein Kinase Kinase Kinase 3 Gene	This gene plays a role in mitogen-activated kinase signaling pathways.			Gene or Genome	
C125113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125113>	C125112	MAP3K3 wt Allele|MAPKKK3|MEKK3|Mitogen-Activated Protein Kinase Kinase Kinase 3 wt Allele	Human MAP3K3 wild-type allele is located in the vicinity of 17q23.3 and is approximately 74 kb in length. This allele, which encodes mitogen-activated protein kinase kinase kinase 3 protein, is involved in protein phosphorylation and signal transduction.			Gene or Genome	
C125114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125114>	C17325	Mitogen-Activated Protein Kinase Kinase Kinase 3|EC 2.7.11.25|MAP/ERK Kinase Kinase 3|MAP3K3|MAPK/ERK Kinase Kinase 3|MEK Kinase 3|MEKK 3	Mitogen-activated protein kinase kinase kinase 3 (626 aa, ~71 kDa) is encoded by the human MAP3K3 gene. This protein plays a role in the propagation of signaling pathways.			Amino Acid, Peptide, or Protein|Enzyme	
C125115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125115>	C172730	Smoke Cigarette Containing Tobacco Question|Did you smoke a cigarette containing tobacco|Smoke Cigarette Containing Tobacco|Smoked Cigarette Containing Tobacco	A question about whether an individual smokes or smoked a cigarette containing tobacco.			Intellectual Product	TAPS Tool - Interviewer Version
C125116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125116>	C173060	Usually Smoke More Than 10 Cigarettes Each Day Question|Did you usually smoke more than 10 cigarettes each day|Usually Smoke More Than 10 Cigarettes Each Day	A question about whether an individual usually smokes or smoked more than 10 cigarettes each day.			Intellectual Product	TAPS Tool - Interviewer Version
C125117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125117>	C173060	Usually Smoke Within 30 Minutes After Waking Question|Did you usually smoke within 30 minutes after waking|Usually Smoke Within 30 Minutes After Waking	A question about whether an individual usually smokes or smoked within 30 minutes after waking.			Intellectual Product	TAPS Tool - Interviewer Version
C125118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125118>	C173703	Have Drink Containing Alcohol Question|Did you have a drink containing alcohol|Do You Drink|Do You Drink Alcohol|Have Alcoholic Drink|Have Drink Containing Alcohol	A question about whether an individual has or had a drink containing alcohol.			Intellectual Product	TAPS Tool - Interviewer Version
C125119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125119>	C173703	On Occasion Drink More Than 4 Standard Drinks of Alcohol Question|On Occasion Drink More Than 4 Alcoholic Drinks|On Occasion Drink More Than 4 Standard Alcoholic Drinks|On Occasion Drink More Than 4 Standard Drinks of Alcohol|On any occasion, did you drink more than 4 standard drinks of alcohol	A question about whether an individual drinks or drank more than 4 standard drinks of alcohol on any occasion.			Intellectual Product	TAPS Tool - Interviewer Version
C12511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12511>	C13031	Pons Varolii|BRAIN, PONS|PONS VAROLII|Pons|Pons|Pons Cerebelli|Pontine structure (body structure)|pons|pons	The middle portion of the brainstem located between the midbrain and the medulla oblongata. The fourth ventricle lies dorsal to the pons which also contains the motor trigeminal nuclei and the abducens nuclei. The cerebellum contributes a large number of afferent fibers to the pons.	Pons		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C125120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125120>	C173703	On Occasion Drink More Than 5 Standard Drinks of Alcohol Question|On Occasion Drink More Than 5 Alcoholic Drinks|On Occasion Drink More Than 5 Standard Alcoholic Drinks|On Occasion Drink More Than 5 Standard Drinks of Alcohol|On any occasion, did you drink more than 5 standard drinks of alcohol	A question about whether an individual drinks or drank more than 5 standard drinks of alcohol on any occasion.			Intellectual Product	TAPS Tool - Interviewer Version
C125121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125121>	C173703	Tried and Failed to Control, Cut Down, or Stop Drinking Question|Have Tried and Failed to Control, Cut Down or Stop Drinking|Have you tried and failed to control, cut down or stop drinking|Tried and Failed to Control, Cut Down, or Stop Drinking	A question about whether an individual tried and failed to control, cut down, or stop drinking alcohol.			Intellectual Product	TAPS Tool - Interviewer Version
C125122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125122>	C173703|C173084	Concern About Your Drinking Question|Concern About Your Drinking|Has anyone expressed concern about your drinking	A question about whether anyone has expressed concern about an individual's drinking.			Intellectual Product	TAPS Tool - Interviewer Version
C125123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125123>	C212876	Use Marijuana Question|Did you use marijuana (cannabis, weed)|Use Marijuana	A question about whether an individual uses or used marijuana.			Intellectual Product	TAPS Tool - Interviewer Version
C125124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125124>	C91102	Strong Desire to Use Marijuana at Least Once a Week Question|Have you had a strong desire or urge to use marijuana at least once a week or more often|Strong Desire to Use Marijuana Once a Week or More Often|Strong Desire to Use Marijuana at Least Once a Week	A question about whether an individual has or had a strong desire or urge to use marijuana at least once a week or more often.			Intellectual Product	TAPS Tool - Interviewer Version
C125125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125125>	C173084	Concern About Your Use of Marijuana Question|Concern About Your Use of Marijuana|Has anyone expressed concern about your use of marijuana	A question about whether anyone has expressed concern about an individual's use of marijuana.			Intellectual Product	TAPS Tool - Interviewer Version
C125126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125126>	C212876	Use of Stimulant Medication Not as Prescribed or Without a Prescription Question|Did you use a stimulant medication (e.g., amphetamine, Ritalin) not as prescribed or without a prescription|Use of Stimulant|Use of Stimulant Medication Not as Prescribed or Without a Prescription	A question about whether an individual uses or used a stimulant medication not as prescribed or without a prescription.			Intellectual Product	TAPS Tool - Interviewer Version
C125127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125127>	C212876	Use Stimulant at Least Once a Week Question|Did you use a stimulant at least once a week or more often|Use Stimulant Once a Week or More Often|Use Stimulant at Least Once a Week	A question about whether an individual uses or used a stimulant at least once a week or more often.			Intellectual Product	TAPS Tool - Interviewer Version
C125128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125128>	C173084	Concern About Your Use of a Stimulant Question|Concern About Your Use of a Stimulant|Has anyone expressed concern about your use of a stimulant	A question about whether anyone has expressed concern about an individual's use of a stimulant.			Intellectual Product	TAPS Tool - Interviewer Version
C125129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125129>	C212876	Use Cocaine or Methamphetamine Question|Did you use cocaine or methamphetamine|Use Cocaine or Methamphetamine	A question about whether an individual uses or used cocaine or methamphetamine.			Intellectual Product	TAPS Tool - Interviewer Version
C12512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12512>	C49346	Supratentorial Brain|SUPRATENTORIAL BRAIN|Supratentorial Anatomy|Supratentorial Nervous System	The part of the brain that is located superior to the tentorium cerebelli.	Supratentorial Brain		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C125130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125130>	C212876	Use Cocaine or Methamphetamine at Least Once a Week Question|Did you use cocaine or methamphetamine at least once a week or more often|Use Cocaine or Methamphetamine Once a Week or More Often|Use Cocaine or Methamphetamine at Least Once a Week	A question about whether an individual uses or used cocaine or methamphetamine at least once a week or more often.			Intellectual Product	TAPS Tool - Interviewer Version
C125131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125131>	C173084	Concern About Your Use of Cocaine or Methamphetamine Question|Concern About Your Use of Cocaine or Methamphetamine|Has anyone expressed concern about your use of cocaine or methamphetamine	A question about whether anyone has expressed concern about an individual's use of cocaine or methamphetamine.			Intellectual Product	TAPS Tool - Interviewer Version
C125132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125132>	C173925	Use Sedative or Sleeping Medication Not as Prescribed or Without a Prescription Question|Did you use a sedative or sleeping medication (e.g., benzodiazepine, Xanax, Klonopin) not as prescribed or without a prescription|Use Sedative or Sleeping Medication Not as Prescribed or Without a Prescription	A question about whether an individual uses or used a sedative or sleeping medication not as prescribed or without a prescription.			Intellectual Product	TAPS Tool - Interviewer Version
C125133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125133>	C212876	Use Opioid-Containing Medication Not as Prescribed or Without a Prescription Question|Did you use an opioid-containing medication (e.g., OxyContin, Vicodin, Percocet, Suboxone or Buprenorphine, methadone) not as prescribed or without a prescription|Use Opioid-Containing Medication Not as Prescribed or Without a Prescription	A question about whether an individual use an opioid-containing medication not as prescribed or without a prescription.			Intellectual Product	TAPS Tool - Interviewer Version
C125134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125134>	C173925	Strong Desire to Use Sedative or Sleeping Medication at Least Once a Week Question|Have you had a strong desire or urge to use such a medication at least once a week or more often|Strong Desire to Use Sedative or Sleeping Medication Once a Week or More Often|Strong Desire to Use Sedative or Sleeping Medication at Least Once a Week	A question about whether an individual has or had a strong desire or urge to use a sedative or sleeping medication at least once a week or more often.			Intellectual Product	TAPS Tool - Interviewer Version
C125135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125135>	C173925|C173084	Concern About Your Use of Sedative or Sleeping Medication Question|Concern About Your Use of Sedative or Sleeping Medication|Has anyone expressed concern about your use of a sedative or sleeping medication	A question about whether anyone has expressed concern about an individual's use of a sedative or sleeping medication.			Intellectual Product	TAPS Tool - Interviewer Version
C125136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125136>	C91102	Tried and Failed to Control, Cut Down, or Stop Using an Opioid Medication Question|Have you tried and failed to control, cut down or stop using an opioid medication|Tried and Failed to Control, Cut Down, or Stop Using an Opioid Medication	A question about whether an individual tried and failed to control, cut down, or stop using an opioid medication.			Intellectual Product	TAPS Tool - Interviewer Version
C125137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125137>	C173084	Concern About Your Use of an Opioid Medication Question|Concern About Your Use of an Opioid Medication|Has anyone expressed concern about your use of an opioid medication	A question about whether anyone has expressed concern about an individual's use of an opioid medication.			Intellectual Product	TAPS Tool - Interviewer Version
C125138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125138>	C212876	Use Heroin Question|Did you use heroin|Use Heroin	A question about whether an individual uses or used heroin.			Intellectual Product	TAPS Tool - Interviewer Version
C125139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125139>	C91102	Tried and Failed to Control, Cut Down, or Stop Using Heroin Question|Have you tried and failed to control, cut down or stop using heroin|Tried and Failed to Control, Cut Down, or Stop Using Heroin	A question about whether an individual tried and failed to control, cut down, or stop using heroin.			Intellectual Product	TAPS Tool - Interviewer Version
C12513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12513>	C12877	Sagittal Sinus	A space between the endosteal and meningeal layer of the dura mater, which traverses through the midline along the superior and inferior borders of the falx cerebri, ultimately dividing into two parts: the superior and inferior sagittal sinus.	Sagittal Sinus		Body Space or Junction	
C125140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125140>	C173084	Concern About Your Use of Heroin Question|Concern About Your Use of Heroin|Has anyone expressed concern about your use of heroin	A question about whether anyone has expressed concern about an individual's use of heroin.			Intellectual Product	TAPS Tool - Interviewer Version
C125141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125141>	C212876	Use Any Other Drug Question|Did you use any other drug|Use Another Drug|Use Any Other Drug|Use Other Drug	A question about whether an individual uses or used any other drug.			Intellectual Product	TAPS Tool - Interviewer Version
C125142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125142>	C173984	Other Drug Taken Question|Other Drug Taken|What did you take	A question about what other drug an individual is taking or took.			Intellectual Product	TAPS Tool - Interviewer Version
C125143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125143>	C214995	Pegzilarginase|AEB-1102|AEB1102|Co-ArgI-PEG|PEGZILARGINASE|Pegylated Recombinant Arginase AEB1102	A recombinant modified form of the human enzyme arginase 1 (ARG1), in which cobalt is substituted for manganese as a cofactor, covalently attached to polyethylene glycol (PEG), with potential arginine degrading and antineoplastic activities. Upon intravenous administration of pegzilarginase, ARG1 metabolizes the amino acid arginine to ornithine and urea, thereby lowering blood arginine levels. This normalizes blood arginine levels in patients with ARG1 deficiency and prevents hyperargininemia. This also inhibits the proliferation of cancer cells that are dependent on extracellular arginine uptake for their proliferation. In normal, healthy cells, arginine is synthesized intracellularly by the enzymes ornithine transcarbamylase (OTC), argininosuccinate synthase (ASS), and argininosuccinate lyase (ASL); thus they are not dependent on extracellular arginine for survival. In cancer cells these enzymes are disabled; therefore, this agent may inhibit proliferation and survival of these cells by depleting extracellular arginine. Pegylation improves blood circulation times and cobalt substitution increases the catalytic activity of ARG1.	Pegzilarginase		Amino Acid, Peptide, or Protein|Enzyme|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125144>	C91105	FACT-M Questionnaire|FACT-M|Functional Assessment of Cancer Therapy - Melanoma|Functional Assessment of Cancer Therapy Melanoma Questionnaire	A subscale complement to the FACT-G developed specifically for evaluating the quality of life of melanoma patients.			Intellectual Product	
C125145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125145>	C91126	Have Pain at Melanoma Site Question|Have Pain at Melanoma Site|I have pain at my melanoma site or surgical site	A question about whether an individual has or had pain at their melanoma site or surgical site.			Intellectual Product	FACT-M Questionnaire
C125146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125146>	C173981	Have Noticed New Changes in Skin Question|Changes in skin|Have Changes in Skin|Have Noticed New Changes in Skin|I have noticed new changes in my skin (lumps, bumps, color)	A question about whether an individual has or had noticed changes in their skin.			Intellectual Product	FACT-M Questionnaire|Memorial Symptom Assessment Scale - Short Form
C125147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125147>	C173934	Worry About Appearance of Surgical Scars Question|I worry about the appearance of surgical scars|Worry About Appearance of Surgical Scars	A question about whether an individual worries or worried about the appearance of surgical scars.			Intellectual Product	FACT-M Questionnaire
C125148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125148>	C173981	Have Noticed Blood in Stool Question|Have Noticed Blood in Stool|I have noticed blood in my stool	A question about whether an individual has or had noticed blood in their stool.			Intellectual Product	FACT-M Questionnaire
C125149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125149>	C91102	Isolate Myself from Others Because of Condition Question|I isolate myself from others because of my condition|Isolate Myself from Others Because of Condition	A question about whether an individual isolates or isolated themselves from others because of their condition.			Intellectual Product	FACT-M Questionnaire
C12514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12514>	C12513	Inferior Sagittal Sinus|Lesser Sagittal Sinus|Sagittal Sinus, Inferior|Sagittal Sinus, Lesser	An intracranial venous sinus that lies in a midline location along the lower free border of the falx cerebri of the brain. The sinus receives blood from the great cerebral vein and joins the superior sagittal sinus posteriorly.	Inferior Sagittal Sinus		Body Space or Junction	
C125150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125150>	C173597|C173398	Have Difficulty Thinking Clearly Question|Have Difficulty Thinking Clearly|I have difficulty thinking clearly (remembering, concentrating)	A question about whether an individual has or had difficulty thinking clearly.			Intellectual Product	FACT-M Questionnaire
C125151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125151>	C105770	Have Swelling at Melanoma Site Question|Have Swelling at Melanoma Site|I have swelling at my melanoma site	A question about whether an individual has or had swelling at their melanoma site.			Intellectual Product	FACT-M Questionnaire
C125152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125152>	C105770	Have Swelling as Result of Surgery Question|Have Swelling as Result of Surgery|I have swelling as a result of surgery	A question about whether an individual has or had swelling as a result of surgery.			Intellectual Product	FACT-M Questionnaire
C125153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125153>	C173593|C172982	Bothered by Amount of Swelling Question|Bothered by Amount of Swelling|I am bothered by the amount of swelling	A question about whether an individual is or was bothered by the amount of swelling.			Intellectual Product	FACT-M Questionnaire
C125154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125154>	C173593|C173346	Movement of Swollen Area is Painful Question|Movement of Swollen Area is Painful|Movement of my swollen area is painful	A question about whether the movement of an individual's swollen area is or was painful.			Intellectual Product	FACT-M Questionnaire
C125155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125155>	C173593	Swelling Keeps Me from Doing Things I Want to Do Question|Swelling Keeps Me from Doing Things I Want to Do|Swelling keeps me from doing the things I want to do	A question about whether an individual's swelling keeps or kept them from doing the things they want to do.			Intellectual Product	FACT-M Questionnaire
C125156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125156>	C173593	Swelling Keeps Me From Wearing What I Want to Wear Question|Swelling Keeps Me From Wearing What I Want to Wear|Swelling keeps me from wearing clothes or shoes I want to wear	A question about whether an individual's swelling keeps or kept them from wearing clothes or shoes they want or wanted to wear.			Intellectual Product	FACT-M Questionnaire
C125157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125157>	C105777	Feel Numbness at Surgical Site Question|Feel Numbness at Surgical Site|Feel Surgical Site Numbness|I feel numbness at my surgical site	A question about whether an individual feels or felt numbness at their surgical site.			Intellectual Product	FACT-M Questionnaire
C125158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125158>	C173981	Have Good Range of Movement in My Arm or Leg Question|Have Good Range of Movement in My Arm or Leg|I have good range of movement in my arm or leg	A question about whether an individual has or had good range of movement in their arm or leg.			Intellectual Product	FACT-M Questionnaire
C125159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125159>	C91105	FAIT-U Questionnaire|FAIT-U|Functional Assessment of Incontinence Therapy - Urinary	A symptom-specific subscale of the FACIT scales that is used to assess how urinary incontinence affects an individual's life.			Intellectual Product	
C12515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12515>	C12513	Superior Sagittal Sinus|Greater Sagittal Sinus|SUPERIOR SAGITTAL SINUS|Sagittal Sinus, Greater|Sagittal Sinus, Superior|Supratentorial Localization	An intracranial venous sinus that lies in a superior and midline location above the interhemispheric fissure along the superior border of the falx cerebri of the brain. The sinus receives blood from the cerebral veins and drains posteriorly into the lateral sinuses of the brain, which in turn drain into the internal jugular veins.	Superior Sagittal Sinus		Body Space or Junction	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology
C125160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125160>	C173695|C173458	Have to Limit Physical Activity Because of Condition Question|Have to Limit Physical Activity Because of Condition|I have to limit my physical activity because of my condition	A question about whether an individual has or had to limit their physical activity because of their condition.			Intellectual Product	FAIT-U Questionnaire
C125161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125161>	C176021|C173695	Have to Limit Social Activity Because of Condition Question|Have to Limit Social Activity Because of Condition|I have to limit my social activity because of my condition	A question about whether an individual has or had to limit their social activity because of their condition.			Intellectual Product	FAIT-U Questionnaire
C125163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125163>	C173160	Feel Overwhelmed by Condition Question|Feel Overwhelmed by Condition|I feel overwhelmed by my condition	A question about whether an individual feels or felt overwhelmed by their condition.			Intellectual Product	Functional Assessment of Multiple Sclerosis Questionnaire
C125164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125164>	C25872	MAP2K3 Gene|MAP2K3|MAP2K3|Mitogen-Activated Protein Kinase Kinase 3 Gene	This gene is involved in stress-mediated signaling.			Gene or Genome	
C125165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125165>	C125164	MAP2K3 wt Allele|MAPKK3|MEK3|MKK3|Mitogen-Activated Protein Kinase Kinase 3 wt Allele|PRKMK3|Protein Kinase, Mitogen-Activated, Kinase 3 Gene|SAPKK-2|SAPKK2|SKK2	Human MAP2K3 wild-type allele is located in the vicinity of 17q11.2 and is approximately 31 kb in length. This allele, which encodes dual specificity mitogen-activated protein kinase kinase 3 protein, plays a role in signal transduction.			Gene or Genome	
C125166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125166>	C18152	Dual Specificity Mitogen-Activated Protein Kinase Kinase 3|Dual Specificity Mitogen Activated Protein Kinase Kinase 3|MAP Kinase Kinase 3|MAP2K3|MAPK/ERK Kinase 3|MAPKK 3|MEK 3|MKK3|SAPK Kinase 2|SAPKK-2|SAPKK2|Stress-Activated Protein Kinase Kinase 2	Dual specificity mitogen-activated protein kinase kinase 3 (347 aa, ~39 kDa) is encoded by the human MAP2K3 gene. This protein is involved in signaling induced by environmental stress.			Amino Acid, Peptide, or Protein|Enzyme	
C125167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125167>	C20673	WWC1 Gene|WW and C2 Domain Containing 1 Gene|WWC1|WWC1	This gene plays a role in both transcriptional regulation and signal transduction.			Gene or Genome	
C125168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125168>	C125167	WWC1 wt Allele|HBEBP3|HBEBP36|KIAA0869|KIBRA|MEMRYQTL|PPP1R168|Protein Phosphatase 1, Regulatory Subunit 168 Gene|WW and C2 Domain Containing 1 wt Allele|WW, C2 and Coiled-Coil Domain Containing 1 Gene|WW, C2, and Coiled-Coil Domain-Containing 1 Gene	Human WWC1 wild-type allele is located in the vicinity of 5q34 and is approximately 181 kb in length. This allele, which encodes protein KIBRA, is involved in the hippo signaling pathway and as a transcriptional coactivator for estrogen receptor.			Gene or Genome	
C125169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125169>	C26199	Protein KIBRA|HBeAg-Binding Protein 3|KIBRA|Kidney and Brain Expressed Protein|Kidney and Brain Protein|Protein WWC1|WW Domain-Containing Protein 1	Protein KIBRA (1113 aa, ~125 kDa) is encoded by the human WWC1 gene. This protein plays a role in transcription coactivation and signaling.			Amino Acid, Peptide, or Protein	
C125170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125170>	C20988	DCHS2 Gene|DCHS2|DCHS2|Dachsous Cadherin-Related 2 Gene	This gene is involved in calcium-dependent cell adhesion.			Gene or Genome	
C125171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125171>	C125170	DCHS2 wt Allele|CDH27|CDHJ|CDHR7|Dachsous 2 (Drosophila) Gene|Dachsous Cadherin-Related 2 wt Allele|Dachsous, Drosophila, Homolog of, 2 Gene|FLJ20047|PCDH23|PCDHJ	Human DCHS2 wild-type allele is located in the vicinity of 4q31.3 and is approximately 260 kb in length. This allele, which encodes protocadherin-23 protein, plays a role in cell-cell adhesion.			Gene or Genome	
C125172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125172>	C16393	Protocadherin-23|Cadherin J|Cadherin-27|Cadherin-Like 27|Cadherin-Like Protein CDHJ|Cadherin-Like Protein VR8|Cadherin-Related Family Member 7|Protein Dachsous Homolog 2|Protocadherin 23|Protocadherin J|Protocadherin PCDHJ	Protocadherin-23 (2916 aa, ~322 kDa) is encoded by the human DCHS2 gene. This protein is involved in calcium-dependent cell-cell adhesion.			Amino Acid, Peptide, or Protein	
C125173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125173>	C25873	TAOK1 Gene|TAO Kinase 1 Gene|TAOK1|TAOK1	This gene plays a role in both serine/threonine phosphorylation and mitogen-activated kinase pathways.			Gene or Genome	
C125174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125174>	C125173	TAOK1 wt Allele|FLJ14314|KFC-B|KIAA1361|MAP3K16|MARKK|PSK-2|PSK2|TAO Kinase 1 wt Allele|TAO1|hKFC-B|hTAOK1	Human TAOK1 wild-type allele is located in the vicinity of 17q11.2 and is approximately 161 kb in length. This allele, which encodes serine/threonine-protein kinase TAO1 protein, is involved in the mediation of protein kinase activity and the modulation of signaling.			Gene or Genome	
C125175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125175>	C17325	Serine/Threonine-Protein Kinase TAO1|EC 2.7.11.1|Kinase From Chicken Homolog B|MARK Kinase 3|MARKK|Microtubule Affinity Regulating Kinase Kinase|PSK-2|PSK2|Prostate-Derived STE20-Like Kinase 2|Prostate-Derived Sterile 20-Like Kinase 2|STE20-Like Kinase PSK2|Serine/Threonine Protein Kinase TAO1 Homolog|TAOK1|Thousand and One Amino Acid Protein 1|Thousand and One Amino Acid Protein Kinase 1|hKFC-B|hTAOK1	Serine/threonine-protein kinase TAO1 (1001 aa, ~116 kDa) is encoded by the human TAOK1 gene. This protein plays a role in protein phosphorylation and the propagation of intracellular signals.			Amino Acid, Peptide, or Protein|Enzyme	
C125176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125176>	C25404	Escalation|Escalate	An increase in extent or intensity; to become more serious.			Activity	
C125177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125177>	C19464	Financial Disclosure Form|FDF	An official legal document to disclose any financial arrangement between the parties involved in a business arrangement.			Manufactured Object	
C125178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125178>	C82547	Mass Effect	The pressure and/or displacement of adjacent tissues that results from the growth of a mass.			Finding	
C125179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125179>	C35869	Midline Shift	A radiologic finding that describes the movement of the brain beyond the center line.			Finding	
C125180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125180>	C20673	RBPMS Gene|RBPMS|RBPMS|RNA Binding Protein With Multiple Splicing Gene	This gene is involved in both RNA binding and transcriptional activation.			Gene or Genome	
C125181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125181>	C125180	RBPMS wt Allele|HERMES|RNA Binding Protein With Multiple Splicing wt Allele|RNA-Binding Protein Gene With Multiple Splicing Gene	Human RBPMS wild-type allele is located in the vicinity of 8p12 and is approximately 188 kb in length. This allele, which encodes RNA-binding protein with multiple splicing, plays a role in transcription coactivator activity.			Gene or Genome	
C125182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125182>	C26199	RNA-Binding Protein With Multiple Splicing|Heart and RRM Expressed Sequence|Hermes|RBP-MS|RBPMS	RNA-binding protein with multiple splicing (196 aa, ~22 kDa) is encoded by the human RBPMS gene. This protein is involved in poly(A) RNA binding and transcriptional coactivation.			Amino Acid, Peptide, or Protein	
C125183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125183>	C21295	CHI3L1 Gene|CHI3L1|CHI3L1|Chitinase 3-Like 1 Gene	This gene plays a role in carbohydrate binding, inflammation and tissue remodeling.			Gene or Genome	
C125184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125184>	C125183	CHI3L1 wt Allele|ASRT7|CGP-39|Chitinase 3-Like 1 (Cartilage Glycoprotein-39) Gene|Chitinase 3-Like 1 wt Allele|GP-39|GP39|HC-gp39|HCGP-3P|YKL-40|YKL40|YYL-40|hCGP-39	Human CHI3L1 wild-type allele is located in the vicinity of 1q32.1 and is approximately 8 kb in length. This allele, which encodes chitinase-3-like protein 1, is involved in inflammation, chitin binding and tissue remodeling. Mutation of the gene is associated with increased susceptibility to asthma or schizophrenia.			Gene or Genome	
C125185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125185>	C28681|C129826	Anti-CD3/Anti-EGFR-bispecific Monoclonal Antibody-armed Activated Autologous T-lymphocytes|Anti-CD3 x Anti-EGFR AATCs|Anti-CD3 x Anti-EGFR BATs|Anti-CD3 x Anti-EGFR-bispecific Antibody Armed Activated Autologous T-cells	Autologous activated T-cells that have been coated with bispecific antibodies (BiAb) comprised of an anti-CD3 monoclonal antibody heteroconjugated to an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, with potential antineoplastic and immunomodulating activities. Upon administration, anti-CD3 x anti-EGFR bispecific antibody-armed activated T-cells (AATC) attach to and selectively cross-link CD3-expressing T-cells and EGFR-expressing tumor cells. This results in the activation of cytotoxic T-lymphocytes (CTLs) and selective cytotoxicity towards the EGFR-expressing tumor cells. In addition, cytokine and chemokine secretion by the T-cells further activates the immune system, which leads to the recruitment and activation of CTLs, and additional CTL-mediated tumor-specific cell lysis. CD3 is part of the functional T-cell receptor (TCR) complex, which is necessary for antigen recognition by T-cells, and is required for signal transduction. EGFR, a receptor tyrosine kinase, is overexpressed on the surfaces of various tumor cell types.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125186>	C1595	Doxycycline Hyclate Injection	An injectable formulation composed of the hyclate salt form of doxycycline, a synthetic, broad-spectrum tetracycline antibiotic, with antimicrobial activity. Upon injection, doxycycline reversibly binds to the bacterial 30S ribosomal subunit, and blocks the binding of aminoacyl-tRNA to the mRNA-ribosome complex. This leads to an inhibition of bacterial protein synthesis and abrogates bacterial infections.			Antibiotic|Pharmacologic Substance	NCI Drug Dictionary Terminology
C125189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125189>	C13321	Alimentary Bolus|Bolus|Bolus of Food|Bolus of Ingested Food	A soft mass or lump of chewed food that is passed from the mouth into the esophagus and the stomach.			Body Substance	
C12518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12518>	C13054|C12978	Blastomere|Blastomeres	A cell formed by cleavage division during embryogenesis.	Blastomere		Cell	
C125192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125192>	C200766|C176018	Lisocabtagene Maraleucel|Anti-CD19-CAR Genetically Engineered Autologous T Lymphocytes JCAR017|Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes JCAR017|Autologous Anti-CD19-EGFRt-4-1BB-zeta-modified CAR CD8+ and CD4+ T-lymphocytes JCAR017|Breyanzi|JCAR 017|JCAR-017|JCAR017|LISOCABTAGENE MARALEUCEL|Liso-cel|Lisocabtagene maraleucel	A preparation of a defined ratio of CD4+ and CD8+ autologous T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-CD19 single chain variable fragment (scFv) fused to the signaling domain of 4-1BB (CD137), the zeta chain of the TCR/CD3 complex (CD3-zeta), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, lisocabtagene maraleucel is directed to and induces selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a cetuximab-induced antibody dependent cellular cytotoxicity (ADCC) response. The 4-1BB costimulatory signaling domain enhances both proliferation of T-cells and antitumor activity.	Lisocabtagene Maraleucel		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125193>	C198515	Eltanexor|(2E)-3-(3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)prop-2-enamide|ATG 016|ATG-016|ATG016|ELTANEXOR|Exportin 1 Inhibitor KPT-8602|KPT-8602|Selective Inhibitor of Nuclear Export KPT-8602|XPO1-inhibiting SINE Compound KPT-8602	An orally bioavailable inhibitor of exportin-1 (XPO1; chromosome region maintenance 1 protein homolog; CRM1), with potential antineoplastic activity. Upon administration, eltanexor binds to the XPO1 cargo binding site, which prevents the XPO1-mediated nuclear export of cargo proteins such as tumor suppressor proteins (TSPs), including p53, p73, BRCA1/2, pRB, FOXO, and other growth regulatory proteins and leads to their selective accumulation in the nuclei of tumor cells. As a selective inhibitor of nuclear export (SINE), KPT-8602 restores the nuclear localization and function of tumor suppressing proteins which leads to the induction of apoptosis in tumor cells. XPO1, the major export factor that transports proteins from the nucleus to the cytoplasm, is overexpressed in a variety of cancer cell types while minimally expressed in normal, healthy cells. The export of tumor suppressor proteins into the cytoplasm prevents them from initiating apoptosis and leads to uncontrolled tumor cell proliferation.	Eltanexor		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125194>	C2021|C1557	Topical Fluorouracil|Actino-Hermal|Arumel|Arumel|Carac|Cytosafe|Efudex|Efudex|Efurix|Fiverocil|Fluoroplex|Fluoroplex|Flurox|Timazin|Timazin|Tolak	A topical formulation containing the antimetabolite 5-fluorouracil (5-FU), with antineoplastic activity. Upon topical administration, 5-FU is converted into the active metabolite 5-fluoroxyuridine monophosphate (F-UMP), which competes with uracil during RNA synthesis and inhibits RNA processing. Conversion of 5-FU into another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase; this results in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in DNA synthesis, and thus inhibits DNA synthesis. Altogether, this prevents the proliferation of tumor cells locally.	Topical Fluorouracil		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125195>	C25364	Previous Device Identifier	The identifier previously used to specify a medical device, prior to a change of the identifier.			Intellectual Product	FDA CDRH GUDID Terminology
C125196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125196>	C54131	Previous Labeling Company|Previous Company Name	The company that was formerly responsible for labeling a medical device.			Organization	FDA CDRH GUDID Terminology
C125197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125197>	C25873	PKN1 Gene|PKN1|PKN1|Protein Kinase N1 Gene	This gene is involved in the phosphorylation of cytoskeletal intermediate filaments, cell migration and histone modification.			Gene or Genome	
C125198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125198>	C125197	PKN1 wt Allele|DBK|MGC46204|PAK-1|PAK1|PAK1, Rat, Homolog of Gene|PKN|PKN-ALPHA|PRK1|PRKCL1|Protein Kinase N1 wt Allele	Human PKN1 wild-type allele is located in the vicinity of 19p13.12 and is approximately 39 kb in length. This allele, which encodes serine/threonine-protein kinase N1 protein, plays a role in the phosphorylation of intermediate filaments and histone H3.			Gene or Genome	
C125199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125199>	C17325	Serine/Threonine-Protein Kinase N1|EC 2.7.11.13|PAK-1|PKN1|Protease-Activated Kinase 1|Protein Kinase C-Like 1|Protein Kinase C-Like PKN|Protein Kinase C-Related Kinase 1|Protein Kinase PKN-Alpha|Protein-Kinase C-Related Kinase 1|Serine-Threonine Kinase N|Serine-Threonine Protein Kinase N|Serine/Threonine Protein Kinase N	Serine/threonine-protein kinase N1 (942 aa, ~104 kDa) is encoded by the human PKN1 gene. This protein is involved in post-translational protein phosphorylation.			Amino Acid, Peptide, or Protein|Enzyme	
C12519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12519>	C32725	Peripheral Blood Cell	A general term describing the three cellular components of blood (white blood cells, red blood cells, and platelets), all which are made in the bone marrow. (Lymphoma Information Network Glossary)	Blood Cells		Cell	
C1251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1251>	C1556	Thiamiprine|THIAMIPRINE	A cytotoxic purine antagonist that has both immunosuppressive and antiarthritic activity. (NCI)			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C125200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125200>	C25616	Post-Allogeneic Bone Marrow Transplant|Post-Allogeneic BMT	The time subsequent to an allogeneic bone marrow transplant.			Temporal Concept	
C125201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125201>	C17177	Overall Survival	A measure of the time until death from any cause.			Conceptual Entity	
C125202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125202>	C38155	Relapse of Prior Malignancy	Clinical and/or laboratory evidence of reemergence of a malignancy after a period of remission.			Finding	
C125203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125203>	C166165	Transplant-Related Mortality|TRM|Transplant Related Death|Transplant Related Mortality|Transplant-Related Death	Death due to complications following an organ transplant.			Qualitative Concept	
C125204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125204>	C16977	Disease Phenotype	Measurable developmental, cognitive, behavioral, morphological, or biological traits or characteristics more often found in patients with a condition or disease than in those without.			Organism Attribute	
C125205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125205>	C36291	Reversal of Disease Phenotype	Lack of the prior infectious complications or malignancy that preceded a transplant			Finding	
C125206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125206>	C49131	Cell Cycle Profile|Cell Cycle Analysis|Cell-Cycle Analysis	The identification and quantitation of cells found in each phase of the cell cycle.	Cell Cycle Profile		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C125207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125207>	C107495	Anti-Chimeric Antigen Receptor Antibody|Anti-CAR Antibody	Any antibody that recognizes a chimeric antigen receptor complex.	Anti-Chimeric Antigen Receptor Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C125208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125208>	C68564	Oral Microbiome|OMC Profile|Oral Flora|Oral Microbial Community Profile|Oral Microbiota|Oral Microflora	The collection of microorganisms existing in the oral cavity of an organism.	Oral Microbiome		Organism	CTRP Biomarker Terminology|CTRP Terminology
C125209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125209>	C222543|C180953	EGFR NM_005228.3:c.2303G>T|EGFR c.2303G>T|ERBB c.2303G>T|ERBB1 c.2303G>T|Epidermal Growth Factor Receptor Gene c.2303G>T|HER1 c.2303G>T|NM_005228.3:c.2303G>T	A nucleotide substitution at position 2303 of the coding sequence of the EGFR gene where guanine has been mutated to thymine.	EGFR NM_005228.3:c.2303G>T		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12520>	C12519	Platelet|Bizzozero Corpuscle|Deetjen Body|PLATELET|Platelets|Reticuloendothelial System, Platelets|Thrombocyte|Thrombocyte|Thrombocytes|platelet|thrombocyte	An irregular, disc-shaped element in the blood that assists in blood clotting. Platelets are not blood cells, they are fragments of large bone marrow cells called megakaryocytes.	Blood Platelet|Platelet		Cell	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C125210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125210>	C180970	EGFR NP_005219.2:p.S768I|Activating S768I Mutation|EGFR Exon 20 S768I|EGFR NP_005219.2:p.Ser768Ile|EGFR S768I|EGFR S768I Mutation|EGFR Ser768Ile|EGFR p.S768I|EGFR p.Ser768Ile|Epidermal Growth Factor Receptor S768I|NP_005219.2:p.Ser768Ile|Proto-Oncogene c-ErbB-1 S768I|Receptor Tyrosine-Protein Kinase erbB-1 S768I	A change in the amino acid residue at position 768 in the epidermal growth factor receptor protein where serine has been replaced by isoleucine.	EGFR NP_005219.2:p.S768I		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C125211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125211>	C25869|C20194	TMEM37 Gene|TMEM37|TMEM37|Transmembrane Protein 37 Gene	This gene may be involved in the regulation of voltage-gated calcium transport.	TMEM37 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C125212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125212>	C125211	TMEM37 wt Allele|PR|PR1|Transmembrane Protein 37 wt Allele	Human TMEM37 wild-type allele is located in the vicinity of 2q14.2 and is approximately 8 kb in length. This allele, which encodes voltage-dependent calcium channel gamma-like subunit protein, may play a role in the modulation of calcium channel activity.	TMEM37 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C125213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125213>	C18466	Voltage-Dependent Calcium Channel Gamma-Like Subunit|Neuronal Voltage-Gated Calcium Channel Gamma-Like Subunit|Transmembrane Protein 37|Voltage-Dependent Calcium Channel Gamma Subunit-Like Protein	Voltage-dependent calcium channel gamma-like subunit (190 aa, ~21 kDa) is encoded by the human TMEM37 gene. This protein may be involved in the regulation of voltage-gated calcium ion channel activity.	Voltage-Dependent Calcium Channel Gamma-Like Subunit		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C125214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125214>	C20745	MAP2 Gene|MAP2|MAP2|Microtubule Associated Protein 2 Gene	This gene may play a role in maintaining microtubules.	MAP2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C125215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125215>	C125214	MAP2 wt Allele|MAP, Dendrite-Specific Gene|MAP2A|MAP2B|MAP2C|Microtubule Associated Protein 2 wt Allele	Human MAP2 wild-type allele is located within 2q34-q35 and is approximately 310 kb in length. This allele, which encodes microtubule-associated protein 2, may be involved in the stabilization of microtubules.	MAP2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C125216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125216>	C16861	Microtubule-Associated Protein 2|MAP-2|MAP2|Microtubule Associated Protein 2	Microtubule-associated protein 2 (1827 aa, ~200 kDa) is encoded by the human MAP2 gene. This protein may play a role in microtubule stability.	Microtubule-Associated Protein 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C125217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125217>	C25616	Past Year	A period of time consisting of the 12 months before the present.			Temporal Concept	TAPS Tool - Interviewer Version
C125218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125218>	C173358|C173060	Frequency Any Tobacco Use Question|Frequency Any Tobacco Use|How Often Use Any Tobacco Product|Used any tobacco product (cigarettes, e-cigarettes, cigars, pipes, or smokeless tobacco)	A question about how often an individual uses or used any tobacco product.			Intellectual Product	TAPS Tool - Interviewer Version
C125219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125219>	C173703	Have 5 or More Drinks in One Day Question|Had 5 or more drinks in one day|Have 5 or More Alcoholic Drinks in One Day|Have 5 or More Drinks in One Day	A question about how often an individual has or had five or more alcoholic drinks in one day.			Intellectual Product	TAPS Tool - Interviewer Version
C12521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12521>	C12519	Erythrocyte|Blood Corpuscles|Blood Erythrocyte|ERYTHROCYTES|Erythrocytes|Erythrocytic|Normocyte|RBC|RBC|RBC|RBCs|Red Blood Cells|Red Blood Cells|Red Blood Corpuscule|Red Cell|Red blood cells|Red cells|Reticuloendothelial System, Erythrocytes|erythrocyte|red blood cell	A blood cell specialized for oxygen transport, having a high concentration of hemoglobin in the cytoplasm. They are biconcave, anucleate discs, with a 6-8um diameter in humans.	Erythrocyte		Cell	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology|HemOnc Agent Terminology
C125220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125220>	C173703	Have 4 or More Drinks in One Day Question|Had 4 or more drinks in one day|Have 4 or More Alcoholic Drinks in One Day|Have 4 or More Drinks in One Day	A question about how often an individual has or had four or more alcoholic drinks in one day.			Intellectual Product	TAPS Tool - Interviewer Version
C125221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125221>	C91105|C21154	Profile of Mood States Questionnaire|POMS Questionnaire|Profile of Mood States	A 65-item self-report questionnaire that utilizes a 5-point Likert Scale rating system to assess an individual's mood state.			Intellectual Product	
C125222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125222>	C173358	Frequency Medication Use For the Feeling, To Get High, More Often, or in Larger Doses than Prescribed Question|Frequency Medication Use For the Feeling, To Get High, More Often, or in Larger Doses than Prescribed|How Often Use Medication For the Feeling, To Get High, More Often, or in Larger Doses than Prescribed|Used any of the following medications just for the feeling, to get high, or more often or in larger doses than prescribed	A question about how often an individual uses or used any medication just for the feeling, to get high, or more often or in larger doses than prescribed.			Intellectual Product	TAPS Tool - Interviewer Version
C125223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125223>	C173358	Frequency Any Illegal Drug Use Question|Frequency Any Illegal Drug Use|Frequency Any Illegal Drug Use|How Often Use Any Illegal Drugs|Used any illegal drugs including marijuana, cocaine or crack, heroin, methamphetamine, hallucinogens, ecstasy/MDMA	A question about how often an individual uses or used any illegal drugs.			Intellectual Product	TAPS Tool - Interviewer Version
C125224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125224>	C175311	Daily or Almost Daily Response|Daily or Almost Daily	A subjective response that something happens daily or almost daily.			Intellectual Product	TAPS Tool - Interviewer Version
C125225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125225>	C91781	How True Feel Exhausted Right Now Question|Exhausted|How Exhausted at Present|How True Feel Exhausted Right Now	A question about the degree to which an individual feels exhausted right now.			Intellectual Product	Profile of Mood States Questionnaire
C125226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125226>	C226671	Once or Twice Response|Once or Twice	An indication that something occurs or occurred once or twice.			Intellectual Product	TAPS Tool - Interviewer Version
C125227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125227>	C91781	How True Feel Ready to Fight Right Now Question|How Ready to Fight at Present|How True Feel Ready to Fight Right Now|Ready to Fight	A question about the degree to which an individual feels ready to fight right now.			Intellectual Product	Profile of Mood States Questionnaire
C125228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125228>	C47933	Lead Pb-207|Lead 207|Lead Pb 207|Lead-207|Pb-207|Pb207	A stable isotope of lead (Pb) and the final non-radioactive product of radioactive decay in the actinium series (uranium-235) or plutonium cascade (plutonium-239), which both include the daughter radionuclide radium-223 (Ra-223). As Ra-223 is used to treat metastatic bone disease and Ra-223 decays to the stable isotope Pb-207, the concentration of Pb-207 found in bone metastases may be used to estimate the amount of Ra-223 that accumulated in the bone during treatment.	Lead Pb-207		Element, Ion, or Isotope	CTRP Biomarker Terminology|CTRP Terminology
C125229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125229>	C91781	How True Feel Good-natured Right Now Question|Good-natured|How Good-natured at Present|How True Feel Good-natured Right Now	A question about the degree to which an individual feels good-natured right now.			Intellectual Product	Profile of Mood States Questionnaire
C12522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12522>	C36987	Abnormal Red Blood Cell|Abnormal Erythrocyte				Cell	
C125230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125230>	C125231	Hydroxylated Polybrominated Diphenyl Ether|OH-PBDE	Hydroxylated metabolites of polybrominated diphenyl ether (PBDE)-based flame retardants. PBDEs are being phased out of use because of their environmental persistence and potential hormone-disrupting effects in humans. In addition to the potential toxicity of OH-PBDEs in humans, OH-PBDE exposure may also disrupt oxidative phosphorylation.	Hydroxylated Polybrominated Diphenyl Ether		Hazardous or Poisonous Substance|Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C125231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125231>	C45388	Polybrominated Diphenyl Ether|PBDE	A mixture of synthetic solids, containing aromatic rings connected by an ether bond and containing one or more bromine atoms, that is virtually insoluble in water but is soluble in fat and various organic solvents and have been used in industrial applications as flame retardants. These compounds are being phased out of industrial use because of their environmental persistence and potential hormone-disrupting effects in humans. The primary routes of potential human exposure to polybrominated diphenyl ethers (PBDEs) are ingestion, inhalation, and dermal contact either for personnel associated with the manufacture or recycling of PDBEs or for people exposed to domestic products containing these chemicals.	Polybrominated Diphenyl Ether		Hazardous or Poisonous Substance|Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C125232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125232>	C91781	How True Feel Gloomy Right Now Question|Gloomy|How Gloomy at Present|How True Feel Gloomy Right Now	A question about the degree to which an individual feels gloomy right now.			Intellectual Product	Profile of Mood States Questionnaire
C125233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125233>	C91781	How True Feel Desperate Right Now Question|Desperate|How Desperate at Present|How True Feel Desperate Right Now	A question about the degree to which an individual feels desperate right now.			Intellectual Product	Profile of Mood States Questionnaire
C125234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125234>	C91781	How True Feel Sluggish Right Now Question|How Sluggish at Present|How True Feel Sluggish Right Now|Sluggish	A question about the degree to which an individual feels sluggish right now.			Intellectual Product	Profile of Mood States Questionnaire
C125235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125235>	C91781	How True Feel Rebellious Right Now Question|How Rebellious at Present|How True Feel Rebellious Right Now|Rebellious	A question about the degree to which an individual feels rebellious right now.			Intellectual Product	Profile of Mood States Questionnaire
C125236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125236>	C91781	How True Feel Weary Right Now Question|How True Feel Weary Right Now|How Weary at Present|Weary	A question about the degree to which an individual feels weary right now.			Intellectual Product	Profile of Mood States Questionnaire
C125237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125237>	C91781	How True Feel Bewildered Right Now Question|Bewildered|How Bewildered at Present|How True Feel Bewildered Right Now	A question about the degree to which an individual feels bewildered right now.			Intellectual Product	Profile of Mood States Questionnaire
C125238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125238>	C217121	Memorial Symptom Assessment Scale|MSAS|Memorial Symptom Assessment Scale - MSAS	A patient-rated instrument developed to provide multidimensional information about a diverse group of common symptoms. This 32-question, self-rated questionnaire evaluates the prevalence, characteristics, and distress associated with each of the symptoms.			Intellectual Product	
C125239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125239>	C125238	Memorial Symptom Assessment Scale - Short Form|MSAS-SF|Memorial Symptom Assessment Scale - Short Form - MSAS-SF	An abbreviated version of the Memorial Symptom Assessment Scale designed to evaluate the burden of physical and psychological symptoms in advanced cancer patients.			Intellectual Product	Memorial Symptom Assessment Scale
C12523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12523>	C12522	Acanthocyte|Acanthocytes|Crenated Red Blood Cell|Spur Cell	An abnormal red blood cell, characterized by an irregularly spiculated cell membrane, that is typically associated with abetalipoproteinemia or liver disease.	Acanthocytes		Cell	
C125240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125240>	C91781	How True Feel Alert Right Now Question|Alert|How Alert at Present|How True Feel Alert Right Now	A question about the degree to which an individual feels alert right now.			Intellectual Product	Profile of Mood States Questionnaire
C125241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125241>	C173398|C118873	How Often Difficulty Concentrating Question|Difficulty Concentrating Frequency|Difficulty concentrating|How Often Difficulty Concentrating	A question about how often an individual has or had difficulty concentrating.			Intellectual Product	Memorial Symptom Assessment Scale
C125242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125242>	C91781	How True Feel Deceived Right Now Question|Deceived|How Deceived at Present|How True Feel Deceived Right Now	A question about the degree to which an individual feels deceived right now.			Intellectual Product	Profile of Mood States Questionnaire
C125243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125243>	C203332|C1904	Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin DFP-13318|DFP-13318|DFP-13318|PEG SN38 DFP-13318|PL 0264|PL-0264|PLX-0264|Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin|Ultra-Long-Acting-PEG-SN-38|Ultra-long Acting PEG-SN38	A long-acting formulation composed of 7-ethyl-10-hydroxycamptothecin (SN38), a camptothecin derivative and active metabolite of irinotecan conjugated to polyethylene glycol (PEG), via a proprietary, cleavable linker, with potential antineoplastic activity. Upon administration, the proprietary linkage system allows for very slow release of SN38 from the formulation. Upon release, SN38 selectively stabilizes covalent topoisomerase I-DNA complexes, and results in single-stranded and double-stranded DNA breaks, the inhibition of DNA replication, and the induction of apoptosis. This agent is designed to deliver the active metabolite to tumor cells without the need for conversion as is the case with irinotecan. Compared to other PEG-SN38-based formulations, the linker system in DFP-13318 increases its half-life and the exposure time for tumor cells, while decreasing both blood plasma concentrations and exposure to off-target organs; this results in increased efficacy.	Polyethyleneglycol-7-ethyl-10-hydroxycamptothecin DFP-13318		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125244>	C91781	How True Feel Furious Right Now Question|Furious|How Furious at Present|How True Feel Furious Right Now	A question about the degree to which an individual feels furious right now.			Intellectual Product	Profile of Mood States Questionnaire
C125245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125245>	C91781	How True Feel Effacious Right Now Question|Effacious|How Effacious at Present|How True Feel Effacious Right Now	A question about the degree to which an individual feels effacious right now.			Intellectual Product	Profile of Mood States Questionnaire
C125246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125246>	C91781	How True Feel Trusting Right Now Question|How True Feel Trusting Right Now|How Trusting at Present|Trusting	A question about the degree to which an individual feels trusting right now.			Intellectual Product	Profile of Mood States Questionnaire
C125247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125247>	C91781	How True Feel Full of Pep Right Now Question|Full of pep|How Full of Pep at Present|How True Feel Full of Pep Right Now	A question about the degree to which an individual feels full of pep right now.			Intellectual Product	Profile of Mood States Questionnaire
C125248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125248>	C91781	How True Feel Bad-tempered Right Now Question|Bad-tempered|How Bad-tempered at Present|How True Feel Bad-tempered Right Now	A question about the degree to which an individual feels bad-tempered right now.			Intellectual Product	Profile of Mood States Questionnaire
C125249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125249>	C91781|C176020	How True Feel Forgetful Right Now Question|Forgetful|How Forgetful at Present|How True Feel Forgetful Right Now	A question about the degree to which an individual feels forgetful right now.			Intellectual Product	Profile of Mood States Questionnaire
C12524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12524>	C37054	Megaloblast				Cell	
C125250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125250>	C91781	How True Feel Carefree Right Now Question|Carefree|How Carefree at Present|How True Feel Carefree Right Now	A question about the degree to which an individual feels carefree right now.			Intellectual Product	Profile of Mood States Questionnaire
C125251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125251>	C91781	How True Feel Terrified Right Now Question|How Terrified at Present|How True Feel Terrified Right Now|Terrified	A question about the degree to which an individual feels terrified right now.			Intellectual Product	Profile of Mood States Questionnaire
C125252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125252>	C91781	How True Feel Guilty Right Now Question|Guilty|How Guilty at Present|How True Feel Guilty Right Now	A question about the degree to which an individual feels guilty right now.			Intellectual Product	Profile of Mood States Questionnaire
C125253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125253>	C91781	How True Feel Vigorous Right Now Question|How True Feel Vigorous Right Now|How Vigorous at Present|Vigorous	A question about the degree to which an individual feels vigorous right now.			Intellectual Product	Profile of Mood States Questionnaire
C125254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125254>	C91781	How True Feel Uncertain About Things Right Now Question|How True Feel Uncertain About Things Right Now|How Uncertain About Things at Present|Uncertain about things	A question about the degree to which an individual feels uncertain about things right now.			Intellectual Product	Profile of Mood States Questionnaire
C125255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125255>	C91781|C173219	How True Feel Bushed Right Now Question|Bushed|How Bushed at Present|How True Feel Bushed Right Now	A question about the degree to which an individual feels bushed right now.			Intellectual Product	Profile of Mood States Questionnaire
C125256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125256>	C226651	Moderate Response|Moderate|Moderately	A subjective answer of a degree of agreement that is approximately halfway between the highest and lowest degrees of agreement.			Intellectual Product	Profile of Mood States Questionnaire
C125257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125257>	C226651	Extreme Response|Extreme|Extremely	A subjective answer of the highest degree of agreement.			Intellectual Product	Profile of Mood States Questionnaire
C125258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125258>	C20194	INO80D Gene|INO80 Complex Subunit D Gene|INO80D|INO80D|INO80D	This gene plays a role in ATP-dependent chromatin remodeling.			Gene or Genome	GDC Terminology|GDC Value Terminology
C125259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125259>	C125258	INO80D wt Allele|FLJ20309|INO80 Complex Subunit D wt Allele	Human INO80D wild-type allele is located in the vicinity of 2q33.3 and is approximately 93 kb in length. This allele, which encodes INO80 complex subunit D protein, is involved in chromatin remodeling.			Gene or Genome	
C12525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12525>	C12522	Spherocyte|Spherocytes	An abnormally small appearing red blood cell that is sphere-shaped and lacks the characteristic central pallor due to cell membrane loss with preservation of cellular contents.	Spherocyte		Cell	
C125260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125260>	C18466	INO80 Complex Subunit D|INO80D	INO80 complex subunit D (878 aa, ~98 kDa) is encoded by the human INO80D gene. This protein plays a role in chromatin remodeling.			Amino Acid, Peptide, or Protein	
C125261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125261>	C20420	TRIM29 Gene|TRIM29|TRIM29|Tripartite Motif Containing 29 Gene	This gene may be involved in cellular stress signaling.			Gene or Genome	
C125262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125262>	C125261	TRIM29 wt Allele|ATDC|FLJ36085|Tripartite Motif Containing 29 wt Allele	Human TRIM29 wild-type allele is located in the vicinity of 11q23.3 and is approximately 74 kb in length. This allele, which encodes tripartite motif-containing protein 29, may play a role in the modulation of cellular stress responses. Mutation of the gene may be associated with ataxia-telangiectasia.			Gene or Genome	
C125263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125263>	C17207	Tripartite Motif-Containing Protein 29|Ataxia Telangiectasia Group D-Associated Protein|Ataxia-Telangiectasia Group D-Associated Protein|Tripartite Motif Protein TRIM29|Tripartite Motif-Containing 29	Tripartite motif-containing protein 29 (588 aa, ~66 kDa) is encoded by the human TRIM29 gene. This protein may be involved in the cellular stress response.			Amino Acid, Peptide, or Protein	
C125264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125264>	C20420	E2F4 Gene|E2F Transcription Factor 4 Gene|E2F4|E2F4	This gene plays a role in tumor suppressor-dependent transcriptional regulation.			Gene or Genome	
C125265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125265>	C125264	E2F4 wt Allele|E2F Transcription Factor 4 wt Allele|E2F Transcription Factor 4, p107/p130-Binding Gene|E2F-4	Human E2F4 wild-type allele is located in the vicinity of 16q22.1 and is approximately 7 kb in length. This allele, which encodes transcription factor E2F4 protein, is involved in the regulation of gene expression.			Gene or Genome	
C125266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125266>	C17207	Transcription Factor E2F4|E2F Transcription Factor 4|E2F-4|p107/p130-Binding Protein	Transcription factor E2F4 (413 aa, ~44 kDa) is encoded by the human E2F4 gene. This protein plays a role in the modulation of tumor suppressor-dependent gene expression.			Amino Acid, Peptide, or Protein	
C125267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125267>	C28533	SLC9A9 Gene|SLC9A9|SLC9A9|Solute Carrier Family 9, Subfamily A (NHE9, Cation Proton Antiporter 9), Member 9 Gene	This gene is involved in intracellular organelle ion homeostasis.			Gene or Genome	
C125268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125268>	C173160|C118873	How Often Feeling Nervous Question|Feeling nervous|Frequency of Feeling Nervous|Frequency of Nervous Feelings|How Often Feeling Nervous|How Often Nervous Feelings	A question about how often an individual feels or felt nervous.			Intellectual Product	Memorial Symptom Assessment Scale
C125269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125269>	C125267	SLC9A9 wt Allele|AUTS16|FLJ35613|NHE9|Nbla00118|Solute Carrier Family 9 (Sodium/Hydrogen Exchanger), Isoform 9 Gene|Solute Carrier Family 9 (Sodium/Hydrogen Exchanger), Member 9 Gene|Solute Carrier Family 9, Subfamily A (NHE9, Cation Proton Antiporter 9), Member 9 wt Allele	Human SLC9A9 wild-type allele is located in the vicinity of 3q24 and is approximately 583 kb in length. This allele, which encodes sodium/hydrogen exchanger 9 protein, plays a role in the regulation of ion exchange in the Golgi. Mutations in the gene are associated with autism susceptibility 16 and a pericentric inversion of inv(3)(p14;q21), which disrupts the gene, is associated with attention-deficit/hyperactivity disorder.			Gene or Genome	
C12526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12526>	C12552	Erythroid Stem Cell|EPC|Erythroid Precursor Cell|Erythroid Precursor Cells|Erythroid Progenitor Cell|Erythroid Progenitor Cells|Erythroid Stem Cells|Erythropoietic Progenitor Cell|Erythropoietic Progenitor Cells|Erythropoietic Stem Cells	A unipotent hematopoietic progenitor cell derived from myeloid stem cells that is committed to the erythrocyte cell lineage.	Erythroid Progenitor Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C125270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125270>	C118873	How Often Dry Mouth Question|Dry Mouth Frequency|Dry mouth|Frequency of Dry Mouth|How Often Dry Mouth	A question about how often an individual has or had dry mouth.			Intellectual Product	Memorial Symptom Assessment Scale
C125271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125271>	C16386	Sodium/Hydrogen Exchanger 9|NHE-9|Na(+)/H(+) Exchanger 9|Putative Protein Product Of Nbla00118|SLC9A9|Sodium/Proton Exchanger NHE9|Solute Carrier Family 9 Member 9	Sodium/hydrogen exchanger 9 (645 aa, ~73 kDa) is encoded by the human SLC9A9 gene. This protein is involved in both cation exchange and pH homeostasis.			Amino Acid, Peptide, or Protein	
C125272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125272>	C173130|C118873	How Often Nausea Question|Frequency of Nausea|How Often Have Nausea|How Often Nausea|Nausea|Nausea Frequency	A question about how often an individual has or had nausea.			Intellectual Product	Memorial Symptom Assessment Scale
C125273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125273>	C173219|C118873	How Often Feeling Drowsy Question|Drowsiness Frequency|Feeling drowsy|Frequency Feeling Drowsy|How Often Feeling Drowsy	A question about how often an individual feels or felt drowsy.			Intellectual Product	Memorial Symptom Assessment Scale
C125274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125274>	C173734|C118873	How Often Have Numbness or Tingling in Hands or Feet Question|Frequency of Numbness or Tingling in Hands or Feet|How Often Have Numbness or Tingling in Hands or Feet|Numbness/tingling in hands/feet	A question about how often an individual has or had numbness or tingling in their hands or feet.			Intellectual Product	Memorial Symptom Assessment Scale
C125275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125275>	C173925|C173398|C118873	How Often Difficulty Sleeping Question|Difficulty Sleeping Frequency|Difficulty sleeping|Frequency of Difficulty Sleeping|How Often Difficulty Sleeping	A question about how often an individual has or had difficulty sleeping.			Intellectual Product	Memorial Symptom Assessment Scale
C125276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125276>	C173219|C118873	How Often Feeling Bloated Question|Feeling Bloated Frequency|Feeling bloated|Frequency Feeling Bloated|How Often Feeling Bloated	A question about how often an individual feels or felt bloated.			Intellectual Product	Memorial Symptom Assessment Scale
C125277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125277>	C173803|C118873	How Often Problems with Urination Question|Frequency Problem with Urination|Frequency Urination Problem|How Often Problems with Urination|How Often Urination Problem|Problems with urination	A question about how often an individual has or had problems with urination.			Intellectual Product	Memorial Symptom Assessment Scale
C125278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125278>	C173604|C118873	How Often Vomiting Question|Frequency of Vomiting|How Often Vomited|How Often Vomiting|Vomiting|Vomiting Frequency	A question about how often an individual vomits or vomited.			Intellectual Product	Memorial Symptom Assessment Scale
C125279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125279>	C118873	How Often Shortness of Breath Question|Frequency of Shortness of Breath|How Often Shortness of Breath|Shortness of Breath Frequency|Shortness of breath	A question about how often an individual has or had shortness or breath.			Intellectual Product	Memorial Symptom Assessment Scale
C12527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12527>	C12918|C12549	Erythroblast|Erythroblasts|Nucleated Erythrocyte|Nucleated Erythrocytes|Nucleated RBC|Nucleated Red Blood Cell|Nucleated Red Blood Cells|Nucleated Red Cell|Nucleated Red Cells	An immature, nucleated erythrocyte occupying the stage of erythropoiesis that follows formation of erythroid progenitor cells and precedes formation of reticulocytes.	Erythroblast		Cell	
C125280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125280>	C173936|C118873	How Often Diarrhea Question|Diarrhea|Diarrhea Frequency|Frequency of Diarrhea|How Often Diarrhea	A question about how often an individual has or had diarrhea.			Intellectual Product	Memorial Symptom Assessment Scale
C125281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125281>	C173160|C118873	How Often Feel Sad Question|Feeling sad|Frequency Feeling Sad|Frequency of Sadness|How Often Feel Sad|Sadness Frequency	A question about how often an individual feels or felt sad.			Intellectual Product	Memorial Symptom Assessment Scale
C125282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125282>	C118873	How Often Sweats Question|Frequency of Sweats|How Often Sweats|Sweats	A question about how often an individual has or had sweats.			Intellectual Product	Memorial Symptom Assessment Scale
C125283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125283>	C173934|C118873	How Often Worry Question|Frequency of Worrying|How Often Worry|Worry Frequency|Worrying	A question about how often an individual worries or worried.			Intellectual Product	Memorial Symptom Assessment Scale
C125284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125284>	C173704|C118873	How Often Problems with Sexual Interest or Activity Question|Frequency of Problems with Sexual Interest or Activity|How Often Problems with Sexual Interest or Activity|Problems with sexual interest or activity	A question about how often an individual has or had problems with sexual interest or activity.			Intellectual Product	Memorial Symptom Assessment Scale
C125285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125285>	C172828|C118873	How Often Itching Question|Frequency of Itching|How Often Itching|Itching|Itching Frequency	A question about how often an individual has or had itching.			Intellectual Product	Memorial Symptom Assessment Scale
C125286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125286>	C118873	How Often Lack of Appetite Question|Frequency of Lack of Appetite|How Often Lack of Appetite|Lack of Appetite Frequency|Lack of appetite	A question about how often an individual has or had a lack of appetite.			Intellectual Product	Memorial Symptom Assessment Scale
C125287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125287>	C173600|C118873	How Often Dizzy Question|Dizziness|Dizzy Frequency|Frequency of Dizziness|How Often Dizzy	A question about how often an individual feels or felt dizzy.			Intellectual Product	Memorial Symptom Assessment Scale
C125288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125288>	C125410|C118873	How Often Difficulty Swallowing Question|Difficulty Swallowing Frequency|Difficulty swallowing|Frequency of Difficulty Swallowing|How Often Difficulty Swallowing	A question about how often an individual has or had difficulty swallowing.			Intellectual Product	Memorial Symptom Assessment Scale
C125289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125289>	C173160|C118873	How Often Feel Irritable Question|Feeling irritable|Frequency of Feeling Irritable|How Often Feel Irritable|How Often Felt Irritable	A question about how often an individual feels or felt irritable.			Intellectual Product	Memorial Symptom Assessment Scale
C12528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12528>	C12521	Reticulocyte|RETICULOCYTES|Reticulocytes	Immature erythrocytes that have just undergone extrusion of their cell nucleus. They still contain some organelles that gradually decrease in number as the cells mature.	Reticulocytes		Cell	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C125290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125290>	C118873	How Often Mouth Sores Question|Frequency of Mouth Sores|How Often Mouth Sores|Mouth Sores Frequency|Mouth sores	A question about how often an individual has or had mouth sores.			Intellectual Product	Memorial Symptom Assessment Scale
C125291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125291>	C173063|C118873	How Often Change in Food Tastes Question|Change in the way food tastes|Frequency of Change in Food Tastes|How Often Change in Food Tastes	A question about how often an individual has or had a change in how food tastes.			Intellectual Product	Memorial Symptom Assessment Scale
C125292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125292>	C118873	How Often Weight Loss Question|Frequency of Weight Loss|How Often Weight Loss|Weight Loss Frequency|Weight loss	A question about how often an individual has or had weight loss.			Intellectual Product	Memorial Symptom Assessment Scale
C125293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125293>	C118873	How Often Hair Loss Question|Frequency of Hair Loss|Hair Loss Frequency|Hair loss|How Often Hair Loss	A question about how often an individual has or had hair loss.			Intellectual Product	Memorial Symptom Assessment Scale
C125294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125294>	C118873	How Often Constipation Question|Constipation|Constipation Frequency|Frequency of Constipation|How Often Constipation	A question about how often an individual has or had constipation.			Intellectual Product	Memorial Symptom Assessment Scale
C125295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125295>	C173593|C118873	How Often Swelling of Arms or Legs Question|Frequency of Swelling of Arms or Legs|How Often Swelling of Arms or Legs|Swelling of Arms or Legs Frequency|Swelling of arms or legs	A question about how often an individual has or had swelling of their arms or legs.			Intellectual Product	Memorial Symptom Assessment Scale
C125296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125296>	C118873	How Often Don't Look Like Myself Question|Frequency Don't Look Like Myself|How Often Don't Look Like Myself|I don't look like myself	A question about how often an individual feels or felt that they don't look like themselves.			Intellectual Product	Memorial Symptom Assessment Scale
C125297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125297>	C118873	How Often Changes in Skin Question|Changes in skin|Frequency of Changes in Skin|How Often Changes in Skin	A question about how often an individual has or had skin changes.			Intellectual Product	Memorial Symptom Assessment Scale
C125298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125298>	C212877|C173398	Usual Severity Difficulty Concentrating Question|Difficulty concentrating|Usual Severity Difficulty Concentrating	A question about the usual severity of an individual's difficulty concentrating.			Intellectual Product	Memorial Symptom Assessment Scale
C125299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125299>	C212877|C173346	Usual Severity Pain Question|Pain|Usual Severity Pain	A question about the usual severity of an individual's pain.			Intellectual Product	Memorial Symptom Assessment Scale
C12529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12529>	C12519	Leukocyte|LEUKOCYTE|Leukocytes|Leukocytes|Reticuloendothelial System, Leukocytes|WBC|WBCs|White Blood Cell|White Blood Cells|White Blood Cells|White Blood Corpuscle|White Cell|leukocyte|white blood cell	Blood cells that are devoid of hemoglobin, capable of ameboid motion and phagocytosis, and act as the principal components of the immune system.	Leukocytes		Cell	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C1252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1252>	C67421	Thiocolchicine|THIOCOLCHICINE	An antimitotic alkaloid that binds to microtubules and inhibits tubulin polymerization and induces apoptosis. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C125300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125300>	C212877	Usual Severity Lack of Energy Question|Lack of energy|Usual Severity Lack of Energy	A question about the usual severity of an individual's lack of energy.			Intellectual Product	Memorial Symptom Assessment Scale
C125301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125301>	C212877|C173134	Usual Severity Cough Question|Cough|Usual Severity Cough	A question about the usual severity of an individual's cough.			Intellectual Product	Memorial Symptom Assessment Scale
C125302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125302>	C212877|C173160	Usual Severity Feeling Nervous Question|Feeling nervous|Usual Severity Feeling Nervous	A question about the usual severity of an individual's feeling of nervousness.			Intellectual Product	Memorial Symptom Assessment Scale
C125303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125303>	C212877	Usual Severity Dry Mouth Question|Dry mouth|Usual Severity Dry Mouth	A question about the usual severity of an individual's dry mouth.			Intellectual Product	Memorial Symptom Assessment Scale
C125304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125304>	C212877|C173130	Usual Severity Nausea Question|Nausea|Usual Severity Nausea	A question about the usual severity of an individual's nausea.			Intellectual Product	Memorial Symptom Assessment Scale
C125305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125305>	C212877|C173219	Usual Severity Feeling of Drowsiness Question|Feeling drowsy|Usual Severity Feeling of Drowsiness	A question about the usual severity of an individual's drowsiness.			Intellectual Product	Memorial Symptom Assessment Scale
C125306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125306>	C212877|C173734	Usual Severity Numbness or Tingling in Hands or Feet Question|Numbness/tingling in hands/feet|Usual Severity Numbness or Tingling in Hands or Feet	A question about the usual severity of an individual's numbness or tingling in their hands or feet.			Intellectual Product	Memorial Symptom Assessment Scale
C125307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125307>	C212877|C173925	Usual Severity Difficulty Sleeping Question|Difficulty sleeping|Usual Severity Difficulty Sleeping	A question about the usual severity of an individual's difficulty sleeping.			Intellectual Product	Memorial Symptom Assessment Scale
C125308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125308>	C212877|C173219	Usual Severity Feeling of Bloatedness Question|Feeling bloated|Usual Severity Feeling of Bloatedness	A question about the usual severity of an individual's feeling of bloatedness			Intellectual Product	Memorial Symptom Assessment Scale
C125309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125309>	C212877|C173803	Usual Severity Problems with Urination Question|Problems with urination|Usual Severity Problems with Urination	A question about the usual severity of an individual's problems with urination.			Intellectual Product	Memorial Symptom Assessment Scale
C12530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12530>	C12549	Granulocyte|GRANULOCYTE|Granular Leukocyte|Granular Leukocytes|Granulocytes|Granulocytes|Granulocytic|Granulocytic Cell|PMN|Polymorphonuclear Cell|Polymorphonuclear Leukocytes|granular leukocyte|granulocyte|polymorphonuclear leukocyte	A type of leukocyte with a multilobed nucleus and cytoplasmic granules. The unique morphology of the nucleus has led to their also being known as polymorphonuclear leukocytes (PMLs or PMNs). Granulocytes are subdivided according to the staining properties of their granules into eosinophils (red with acidic dye), basophils (blue with basic dye), and neutrophils (not amenable to staining with either acidic or basic dyes).	Granulocyte		Cell	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C125310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125310>	C212877|C173604	Usual Severity Vomiting Question|Usual Severity Vomiting|Vomiting	A question about the usual severity of an individual's vomiting.			Intellectual Product	Memorial Symptom Assessment Scale
C125311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125311>	C212877	Usual Severity Shortness of Breath Question|Shortness of breath|Usual Severity Shortness of Breath	A question about the usual severity of an individual's shortness of breath.			Intellectual Product	Memorial Symptom Assessment Scale
C125312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125312>	C212877|C173936	Usual Severity Diarrhea Question|Diarrhea	A question about the usual severity of an individual's diarrhea.			Intellectual Product	Memorial Symptom Assessment Scale
C125313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125313>	C212877|C173160	Usual Severity Feeling of Sadness Question|Feeling sad|Usual Severity Feeling of Sadness	A question about the usual severity of an individual's feeling of sadness.			Intellectual Product	Memorial Symptom Assessment Scale
C125314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125314>	C212877	Usual Severity Sweats Question|Sweats|Usual Severity Sweats	A question about the usual severity of an individual's sweats.			Intellectual Product	Memorial Symptom Assessment Scale
C125315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125315>	C212877|C173934	Usual Severity Worry Question|Usual Severity Worry|Worrying	A question about the usual severity of an individual's worry.			Intellectual Product	Memorial Symptom Assessment Scale
C125316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125316>	C212877|C173704	Usual Severity Problems with Sexual Interest or Activity Question|Problems with sexual interest or activity|Usual Severity Problems with Sexual Interest or Activity	A question about the usual severity of an individual's problems with sexual interest or activity.			Intellectual Product	Memorial Symptom Assessment Scale
C125317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125317>	C212877|C172828	Usual Severity Itching Question|Itching|Usual Severity Itching	A question about the usual severity of an individual's itching.			Intellectual Product	Memorial Symptom Assessment Scale
C125318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125318>	C212877	Usual Severity Lack of Appetite Question|Lack of appetite|Usual Severity Lack of Appetite	A question about the usual severity of an individual's appetite.			Intellectual Product	Memorial Symptom Assessment Scale
C125319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125319>	C212877|C173600	Usual Severity Dizziness Question|Dizziness|Usual Severity Dizziness	A question about the usual severity of an individual's dizziness.			Intellectual Product	Memorial Symptom Assessment Scale
C12531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12531>	C12530|C12529	Basophil|Basophilic Granulocyte|Basophilic Leukocyte|Basophils|basophil		Basophil		Cell	CTRP Biomarker Terminology|CTRP Terminology
C125320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125320>	C212877|C125410	Usual Severity Difficulty Swallowing Question|Difficulty swallowing|Usual Severity Difficulty Swallowing	A question about the usual severity of an individual's difficulty swallowing.			Intellectual Product	Memorial Symptom Assessment Scale
C125321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125321>	C212877|C173160	Usual Severity Feeling Irritable Question|Feeling irritable|Usual Severity Feeling Irritable	A question about the usual severity of an individual's feeling irritable.			Intellectual Product	Memorial Symptom Assessment Scale
C125322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125322>	C212877	Usual Severity Mouth Sores Question|Mouth sores|Usual Severity Mouth Sores	A question about the usual severity of an individual's mouth sores.			Intellectual Product	Memorial Symptom Assessment Scale
C125323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125323>	C212877|C173063	Usual Severity Change in the Way Food Tastes Question|Change in the way food tastes|Usual Severity Change in the Way Food Tastes	A question about the usual severity of an individual's change in the way food tastes.			Intellectual Product	Memorial Symptom Assessment Scale
C125324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125324>	C212877	Usual Severity Weight Loss Question|Usual Severity Weight Loss|Weight loss	A question about the usual severity of an individual's weight loss.			Intellectual Product	Memorial Symptom Assessment Scale
C125325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125325>	C212877	Usual Severity Hair Loss Question|Hair loss|Usual Severity Hair Loss	A question about the usual severity of an individual's hair loss.			Intellectual Product	Memorial Symptom Assessment Scale
C125326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125326>	C212877	Usual Severity Constipation Question|Constipation|Usual Severity Constipation	A question about the usual severity of an individual's constipation.			Intellectual Product	Memorial Symptom Assessment Scale
C125327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125327>	C212877|C173593	Usual Severity Swelling of Arms or Legs Question|Swelling of arms or legs|Usual Severity Swelling of Arms or Legs	A question about the usual severity of an individual's swelling of arms or legs.			Intellectual Product	Memorial Symptom Assessment Scale
C125328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125328>	C212877|C176022|C173160	Usual Severity Feeling of I Don't Look Like Myself Question|I don't look like myself|Usual Severity Feeling of I Don't Look Like Myself	A question about the usual severity of an individual's feeling of not looking like themselves.			Intellectual Product	Memorial Symptom Assessment Scale
C125329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125329>	C212877	Usual Severity Changes in Skin Question|Changes in skin|Usual Severity Changes in Skin	A question about the usual severity of an individual's changes in skin.			Intellectual Product	Memorial Symptom Assessment Scale
C12532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12532>	C12530|C12529	Eosinophil|Acidophilic Leukocyte|Blood Eosinophil|Eosinocyte|Eosinophilic Granulocyte|Eosinophilic Leukocyte|Eosinophils|eosinophil	Granular leukocytes with a nucleus that usually has two lobes connected by a slender thread of chromatin, and cytoplasm containing coarse, round granules that are uniform in size and stainable by eosin.	Eosinophil		Cell	CTRP Biomarker Terminology|CTRP Terminology
C125330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125330>	C173398|C173393	How Much Distress Difficulty Concentrating Question|Difficulty concentrating|How Much Distress Difficulty Concentrating	A question about an individual's distress from their difficulty concentrating.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|Memorial Symptom Assessment Scale
C125331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125331>	C173393|C173346	How Much Distress Pain Question|How Much Distress Pain|Pain	A question about an individual's distress from their pain.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|Memorial Symptom Assessment Scale
C125332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125332>	C173393	How Much Distress Lack of Energy Question|How Much Distress Lack of Energy|Lack of energy	A question about an individual's distress from their lack of energy.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|Memorial Symptom Assessment Scale
C125333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125333>	C173393|C173134	How Much Distress Cough Question|Cough|How Much Distress Cough	A question about an individual's distress from their cough.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|Memorial Symptom Assessment Scale
C125334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125334>	C173393	How Much Distress Feeling Nervous Question|Feeling nervous|How Much Distress Feeling Nervous	A question about an individual's distress from their feeling of nervousness.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|Memorial Symptom Assessment Scale
C125335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125335>	C173393	How Much Distress Dry Mouth Question|Dry mouth|How Much Distress Dry Mouth	A question about an individual's distress from their dry mouth.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|Memorial Symptom Assessment Scale
C125336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125336>	C173393|C173130	How Much Distress Nausea Question|How Much Distress Nausea|Nausea	A question about an individual's distress from their nausea.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|Memorial Symptom Assessment Scale
C125337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125337>	C173393|C173219	How Much Distress Feeling Drowsy Question|Feeling drowsy|How Much Distress Feeling Drowsy	A question about an individual's distress from feeling of drowsy.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|Memorial Symptom Assessment Scale
C125338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125338>	C173734|C173393	How Much Distress Numbness or Tingling in Hands or Feet Question|How Much Distress Numbness or Tingling in Hands or Feet|Numbness/tingling in hands/feet	A question about an individual's distress from their numbness or tingling in hands or feet.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|Memorial Symptom Assessment Scale
C125339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125339>	C173925|C173398|C173393	How Much Distress Difficulty Sleeping Question|Difficulty sleeping|How Much Distress Difficulty Sleeping	A question about an individual's distress from their difficulty sleeping.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|Memorial Symptom Assessment Scale
C12533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12533>	C12530|C12529	Neutrophil|Blood Segmented Neutrophil|Neutrophilic Granulocyte|Neutrophilic Leukocyte|Polymorphonuclear Neutrophils|neutrophil	Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes.	Neutrophil		Cell	CTRP Biomarker Terminology|CTRP Terminology
C125340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125340>	C173393|C173219	How Much Distress Feeling Bloated Question|Feeling bloated|How Much Distress Feeling Bloated	A question about an individual's distress from feeling bloated.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|Memorial Symptom Assessment Scale
C125341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125341>	C173803|C173393	How Much Distress Problems with Urination Question|How Much Distress Problems with Urination|Problems with urination	A question about an individual's distress from their problems with urination.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|Memorial Symptom Assessment Scale
C125342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125342>	C173604|C173393	How Much Distress Vomiting Question|How Much Distress Vomiting|Vomiting	A question about an individual's distress from their vomiting.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|Memorial Symptom Assessment Scale
C125343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125343>	C173393	How Much Distress Shortness of Breath Question|How Much Distress Shortness of Breath|Shortness of breath	A question about an individual's distress from their shortness of breath.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|Memorial Symptom Assessment Scale
C125344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125344>	C173936|C173393	How Much Distress Diarrhea Question|Diarrhea|How Much Distress Diarrhea	A question about an individual's distress from their diarrhea.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|Memorial Symptom Assessment Scale
C125345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125345>	C173393	How Much Distress Feeling Sad Question|Feeling sad|How Much Distress Feeling Sad	A question about an individual's distress from their feeling of sadness.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|Memorial Symptom Assessment Scale
C125346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125346>	C173393	How Much Distress Sweats Question|How Much Distress Sweats|Sweats	A question about an individual's distress from their sweats.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|Memorial Symptom Assessment Scale
C125347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125347>	C173934|C173393	How Much Distress Worrying Question|How Much Distress Worrying|Worrying	A question about an individual's distress from their worrying.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|Memorial Symptom Assessment Scale
C125348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125348>	C173704|C173393	How Much Distress Problems with Sexual Interest or Activity Question|How Much Distress Problems with Sexual Interest or Activity|Problems with sexual interest or activity	A question about an individual's distress from their problems with sexual interest or activity.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|Memorial Symptom Assessment Scale
C125349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125349>	C173393|C172828	How Much Distress Itching Question|How Much Distress Itching|Itching	A question about an individual's distress from their itching.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|Memorial Symptom Assessment Scale
C12534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12534>	C33904	Non-Granular Leukocyte|Agranulocyte|Mononuclear Leukocyte|Non-Granular Leukocytes|agranulocyte	A white blood cell that lacks cytoplasmic granules with an affinity for specific biological stains; typically, a lymphocyte, monocyte, or plasma cell.	Leukocyte, Mononuclear		Cell	
C125350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125350>	C173393	How Much Distress Lack of Appetite Question|How Much Distress Lack of Appetite|Lack of appetite	A question about an individual's distress from their lack of appetite.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|Memorial Symptom Assessment Scale
C125351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125351>	C173600|C173393	How Much Distress Dizziness Question|Dizziness|How Much Distress Dizziness	A question about an individual's distress from their dizziness.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|Memorial Symptom Assessment Scale
C125352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125352>	C173393|C125410	How Much Distress Difficulty Swallowing Question|Difficulty swallowing|How Much Distress Difficulty Swallowing	A question about an individual's distress from their difficulty swallowing.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|Memorial Symptom Assessment Scale
C125353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125353>	C173393	How Much Distress Feeling Irritable Question|Feeling irritable|How Much Distress Feeling Irritable	A question about an individual's distress from feeling irritable.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|Memorial Symptom Assessment Scale
C125354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125354>	C173393	How Much Distress Mouth Sores Question|How Much Distress Mouth Sores|Mouth sores	A question about an individual's distress from their mouth sores.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|Memorial Symptom Assessment Scale
C125355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125355>	C173393|C173063	How Much Distress Change in the Way Food Tastes Question|Change in the way food tastes|How Much Distress Change in the Way Food Tastes	A question about an individual's distress from a change in the way food tastes.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|Memorial Symptom Assessment Scale
C125356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125356>	C173393	How Much Distress Weight Loss Question|How Much Distress Weight Loss|Weight loss	A question about an individual's distress from their weight loss.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|Memorial Symptom Assessment Scale
C125357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125357>	C173393	How Much Distress Hair Loss Question|Hair loss|How Much Distress Hair Loss	A question about an individual's distress from their hair loss.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|Memorial Symptom Assessment Scale
C125358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125358>	C173393	How Much Distress Constipation Question|Constipation|How Much Distress Constipation	A question about an individual's distress from their constipation.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|Memorial Symptom Assessment Scale
C125359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125359>	C173593|C173393	How Much Distress Swelling of Arms or Legs Question|How Much Distress Swelling of Arms or Legs|Swelling of arms or legs	A question about an individual's distress from their swelling of arms or legs.			Intellectual Product	Clinical or Research Assessment Question|Memorial Symptom Assessment Scale - Short Form
C12535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12535>	C32725	Lymphocyte|LYMPHOCYTE|Lymph Cell|Lymphocytes|Lymphocytes|lymphocyte	White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each); those with characteristics of neither major class are called null cells.	Lymphocyte		Cell	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C125360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125360>	C173393	How Much Distress I Don't Look Like Myself Question|How Much Distress I Don't Look Like Myself|I don't look like myself	A question about an individual's distress from their not looking like themselves.			Intellectual Product	Clinical or Research Assessment Question|Memorial Symptom Assessment Scale - Short Form
C125361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125361>	C173393	How Much Distress Changes in Skin Question|Changes in skin|How Much Distress Changes in Skin	A question about an individual's distress from their changes in skin.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|Memorial Symptom Assessment Scale
C125362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125362>	C217122	MSAS Global Distress Index|MSAS-GDI	A subscale of the Memorial Symptom Assessment Scale that measures overall symptom distress.			Intellectual Product	Memorial Symptom Assessment Scale
C125363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125363>	C222045	MSAS Physical Symptom Subscale|MSAS-PHYS	A subscale of the Memorial Symptom Assessment Scale that is the average of the frequency, severity, and distress associated with the symptoms of lack of appetite, lack of energy, pain, feeling drowsy, constipation, dry mouth, nausea, vomiting, change in taste, weight loss, feeling bloated, and dizziness.			Intellectual Product	Memorial Symptom Assessment Scale
C125364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125364>	C222045	MSAS Psychological Symptom Subscale|MSAS-PSYCH	A subscale of the Memorial Symptom Assessment Scale that is the average of the frequency, severity, and distress associated with worrying, feeling sad, feeling nervous, difficulty sleeping, feeling irritable, and difficulty concentrating.			Intellectual Product	Memorial Symptom Assessment Scale
C125365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125365>	C217122	Total MSAS Score|TMSAS	A subscale of the Memorial Symptom Assessment Scale that is the average of the symptom scores of all 32 symptoms in the full MSAS instrument.			Intellectual Product	Memorial Symptom Assessment Scale
C125366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125366>	C175311	Rarely or None of the Time|Rarely or none of the time	A response indicating that something happens or happened never or almost never.			Intellectual Product	Center for Epidemiologic Studies Depression Scale
C125367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125367>	C175311	Some or a Little of the Time|Some or a little of the time	A response indicating that something happens or happened a small amount of the time but not often.			Intellectual Product	Center for Epidemiologic Studies Depression Scale
C125368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125368>	C175311	Occasionally or a Moderate Amount of Time|Occasionally or a moderate amount of time	A response indicating that something happens or happened from time to time but not excessively.			Intellectual Product	Center for Epidemiologic Studies Depression Scale
C125369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125369>	C172982	Bothered by Things That Usually Don't Bother Me Question|Bothered by Things That Usually Don't Bother Me|I was bothered by things that usually don't bother me	A question about whether an individual is or was bothered by things that aren't usually bothersome.			Intellectual Product	Center for Epidemiologic Studies Depression Scale
C12536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12536>	C39568	Natural Killer Cell|Killer Cell|Killer Cells|NATURAL KILLER CELL|NK|NK Cell|NK Cells|NK cell|NK-Cell|NK-LGL|killer cell|natural killer cell	Natural killer cells are cells that resemble large granular lymphocytes.  They do not express markers of either T or B cell lineage. They are positive for CD16, CD56, and CD 94.  These cells do possess Fc receptors for IgG and can kill target cells using antibody-dependent cell-mediated cytotoxicity. They can also use perforin to kill cells in the absence of antibody and killing may occur without previous sensitization.	Natural Killer Cell		Cell	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C125370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125370>	C173160	Did Not Feel Like Eating, Appetite Poor Question|Did Not Feel Like Eating, Appetite Poor|I did not feel like eating; my appetite was poor	A question about whether an individual does or did not feel like eating and their appetite was poor.			Intellectual Product	Center for Epidemiologic Studies Depression Scale
C125371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125371>	C173160|C173151	Could Not Shake Off the Blues Even with Help from Family Question|Could Not Shake Off the Blues Even with Help from Family|I felt that I could not shake off the blues even with help from my family	A question about whether an individual feels or felt that they could not shake off the blues even with the help from family.			Intellectual Product	Center for Epidemiologic Studies Depression Scale
C125372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125372>	C173160	Felt Just as Good as Other People Question|Felt Just as Good as Other People|I felt that I was just as good as other people	A question about whether an individual feels or felt that they were just as good as other people.			Intellectual Product	Center for Epidemiologic Studies Depression Scale
C125373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125373>	C173981|C173398	Had Trouble Keeping My Mind on What I was Doing Question|Had Trouble Keeping My Mind on What I was Doing|I had trouble keeping my mind on what I was doing	A question about whether an individual has or had trouble keeping their mind on what they were doing.			Intellectual Product	Center for Epidemiologic Studies Depression Scale
C125374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125374>	C173160	Felt Everything was an Effort Question|Felt Everything was an Effort|I felt that everything I did was an effort	A question about whether an individual feels or felt that everything they did was an effort.			Intellectual Product	Center for Epidemiologic Studies Depression Scale
C125375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125375>	C173597	Life Has Been a Failure Question|I thought my life had been a failure|Life Has Been a Failure	A question about whether an individual thinks or thought their life has been a failure.			Intellectual Product	Center for Epidemiologic Studies Depression Scale
C125376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125376>	C173160	Felt Happy Question|Feel Happy|Felt Happy|I was happy|Was Happy	A question about whether an individual is or was happy.			Intellectual Product	Center for Epidemiologic Studies Depression Scale
C125377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125377>	C91102	Talked Less Than Usual Question|I talked less than usual|Talked Less|Talked Less Than Usual	A question about whether an individual talks or talked less than usual.			Intellectual Product	Center for Epidemiologic Studies Depression Scale
C125378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125378>	C173160	Felt Lonely Question|Feel Lonely|Felt Lonely|I felt lonely	A question about whether an individual feels or felt lonely.			Intellectual Product	Center for Epidemiologic Studies Depression Scale
C125379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125379>	C91102	People Were Unfriendly Question|People Were Unfriendly|People were unfriendly	A question about whether an individual feels or felt people were unfriendly.			Intellectual Product	Center for Epidemiologic Studies Depression Scale
C12537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12537>	C33061	CD4-Positive T-Lymphocyte|CD4 Lymphocyte|CD4 Lymphocytes|CD4+ T Cell|CD4+ T Lymphocyte|CD4+ T Lymphocytes|CD4+ T-Lymphocyte|CD4-Positive Lymphocyte|CD4-Positive Lymphocytes|CD4-Positive T-Lymphocytes|CD4-positive T lymphocyte|T4 Cell|T4 Cells|T4 Lymphocyte|T4 Lymphocytes		CD4-Positive T-Lymphocyte		Cell	CTRP Biomarker Terminology|CTRP Terminology
C125380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125380>	C173981	Had Crying Spells Question|Cried|Had Crying Spells|I had crying spells	A question about whether an individual has or had crying spells.			Intellectual Product	Center for Epidemiologic Studies Depression Scale
C125381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125381>	C173160	People Disliked Me Question|I felt that people disliked me|People Disliked Me	A question about whether an individual feels or felt that people disliked them.			Intellectual Product	Center for Epidemiologic Studies Depression Scale
C125382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125382>	C173160	Could Not Get Going Question|Could Not Get Going|I could not get going	A question about whether an individual can or could not get going.			Intellectual Product	Center for Epidemiologic Studies Depression Scale
C125383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125383>	C34593	Primary Erythromelalgia|PERYTHM|Primary Erythermalgia	An autosomal dominant condition caused by mutation(s) in the SCN9A gene, encoding sodium channel protein type 9 subunit alpha. It is characterized by episodes of recurrent warmth, redness, and burning sensations in the extremities.			Disease or Syndrome	Cellosaurus Disease Terminology
C125384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125384>	C26760	Rasmussen Subacute Encephalitis|CFE|Chronic Focal Encephalitis|Rasmussen Encephalitis	A rare, progressive chronic inflammation of a single cerebral hemisphere that usually affects children. It is characterized by severe seizures, loss of motor skills and speech, hemiparesis, and dementia.			Disease or Syndrome	Cellosaurus Disease Terminology
C125385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125385>	C53543	Paroxysmal Extreme Pain Disorder	A very rare, autosomal dominant inherited disorder caused by mutations in the SCN9A gene. It is characterized by skin redness and flushing and attacks of severe pain. The pain attacks usually last seconds to minutes.			Disease or Syndrome	Cellosaurus Disease Terminology
C125386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125386>	C53543	Indifference to Pain, Congenital, Autosomal Recessive|CIP|Congenital Insensitivity to Pain|Congenital Pain Insensitivity	A very rare, autosomal recessive inherited condition caused by mutations in the SCN9A gene. It is characterized by a lack of the ability to perceive physical pain.			Disease or Syndrome	
C125387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125387>	C53543	Migrating Partial Seizures in Infancy|MMPSI|MPSI|Malignant Migrating Partial Seizures in Infancy	A very rare severe form of epilepsy with poor prognosis that usually begins within a few weeks of birth. The seizure activity can appear in multiple locations in the brain or migrate from one region to another during an episode. It results in severe developmental delay.			Disease or Syndrome	
C125388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125388>	C53543|C3501	Neuropathy, Hereditary Sensory and Autonomic, Type VII|HSAN7|Hereditary Sensory and Autonomic Neuropathy Type VII	A very rare disorder caused by mutation in the SCN11A gene.  Affected individuals are unable to experience pain since birth resulting in self-inflicted injuries.			Disease or Syndrome	Cellosaurus Disease Terminology
C125389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125389>	C4731	Small Fiber Neuropathy|Painful Peripheral Neuropathy Small Nerve Fiber Neuropathy	Neuropathy caused by damage to the small myelinated (A-delta) fibers or unmyelinated C fibers in the peripheral nerves. It manifests with burning pain, shooting pain, allodynia, and hyperesthesia.			Disease or Syndrome	Cellosaurus Disease Terminology
C12538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12538>	C12537	Helper-Inducer T-Lymphocyte|Helper T-Cell|Helper T-Cells|Helper T-Lymphocyte|Helper T-Lymphocytes|Inducer T-Lymphocyte|Inducer T-Lymphocytes|T-Lymphocyte, Helper-Inducer|helper T cell	A subtype of CD4+ T lymphocyte that triggers differentiation of nearby immune cells, and initiates a variety of other immune functions, including the induction of humoral and cellular inflammatory immune responses by B and other T lymphocytes, respectively.	T-Lymphocyte, Helper-Inducer		Cell	CTRP Biomarker Terminology|CTRP Terminology
C125390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125390>	C53543|C28193	Episodic Pain Syndrome, Familial, 3|FEPS3	A rare, autosomal dominant disorder caused by mutation in the SCN11A gene. It is characterized by intense episodic pain mainly affecting the distal lower extremities in early childhood. The pain diminishes with age.			Disease or Syndrome	
C125391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125391>	C128462	BET Inhibitor GSK2820151|GSK 2820151|GSK2820151	An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, the BET inhibitor GSK2820151 binds to the acetylated lysine recognition motifs in the bromodomains of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.	BET Inhibitor GSK2820151		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125392>	C266	Crofelemer|CROFELEMER|Fulyzaq|SP 303|SP-303|Virend	An oligomeric proanthocyanidin extracted from the latex produced by the tree Croton lechleri (Euphorbiaceae), with antidiarrheal, and potential antiviral and antimicrobial activities. Upon oral administration, crofelemer acts locally within the gastrointestinal (GI) tract by inhibiting both the cystic fibrosis transmembrane conductance regulator (CFTR) chloride ion (Cl-) channel and the calcium-activated Cl- channel (CaCC) expressed on the luminal surface of enterocytes. This inhibits the secretion of chloride ions into the intestinal lumen and prevents high volume water loss. By normalizing Cl- and water balance in the intestines, crofelemer relieves secretory diarrhea.	Crofelemer		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C125393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125393>	C217121	Bristol Stool Scale|BSF|BSF Scale|BSFS|BSFS|BSFS01|Bristol Stool Chart|Bristol Stool Form Scale	A medical scale designed to classify human feces into seven categories by form.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125394>	C221033	Bristol Stool Type 1|Type 1	Separate hard lumps, hard to pass; indicative of severe constipation.			Intellectual Product	Bowel Function Diary for Assessing Opioid-Induced Constipation|Bristol Stool Scale
C125395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125395>	C221033	Bristol Stool Type 2|Type 2	Lumpy and sausage-like; indicative of constipation.			Intellectual Product	Bowel Function Diary for Assessing Opioid-Induced Constipation|Bristol Stool Scale
C125396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125396>	C221033	Bristol Stool Type 3|Type 3|Type 3	A sausage shape with cracks in the surface; normal stool.			Intellectual Product	Bowel Function Diary for Assessing Opioid-Induced Constipation|Bristol Stool Scale
C125397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125397>	C221033	Bristol Stool Type 4|Type 4|Type 4	Like a smooth, soft sausage or snake; normal stool.			Intellectual Product	Bowel Function Diary for Assessing Opioid-Induced Constipation|Bristol Stool Scale
C125398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125398>	C221033	Bristol Stool Type 5|Type 5|Type 5	Soft blobs with clear-cut edges, passed easily.			Intellectual Product	Bowel Function Diary for Assessing Opioid-Induced Constipation|Bristol Stool Scale
C125399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125399>	C221033	Bristol Stool Type 6|Type 6|Type 6	Mushy pieces with ragged edges.			Intellectual Product	Bowel Function Diary for Assessing Opioid-Induced Constipation|Bristol Stool Scale
C12539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12539>	C12538	Type 1 Helper Cell|Th-1 Cell|Th1 Cell|Th1 Cell|Th1 Cells	Type 1 Helper Cells are a subset of helper-inducer T-lymphocytes which synthesize and secrete interleukin-2, gamma-interferon, and interleukin-12. Due to their ability to kill antigen-presenting cells and their lymphokine-mediated effector activity, these cells are associated with delayed-type hypersensitivity reactions.	Th1 Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C1253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1253>	C548|C308	Thymalfasin|THYMALFASIN|Thymosin Alpha 1|Thymosin Alpha 1|Zadaxin	A synthetic analogue of thymosin-alpha-1, a 28-amino acid protein derived from the precursor protein prothymosin-alpha.  Exhibiting a variety of immunoregulating properties, thymosin-alpha-1 induces differentiation of murine T-cell precursors and human thymocytes and the terminal differentiation of functionally immature cord blood lymphocytes and induces production of IL-2, high affinity IL-2 receptors, and B-cell growth factors by peripheral blood mononuclear cells. T-helper and cytotoxic/suppressor T-cell populations are targets of thymosin activity. Thymosin-alpha-1 has been shown to increase the efficiency of antigen presentation by macrophages and to be an endogenous modulator of alpha-thrombin activity. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C125400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125400>	C221033	Bristol Stool Type 7|Type 7|Type 7	Liquid consistency with no solid pieces; indicative of diarrhea.			Intellectual Product	Bowel Function Diary for Assessing Opioid-Induced Constipation|Bristol Stool Scale
C125401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125401>	C173457|C173393	How Much Distress Other Symptom 1 Question|How Much Distress Other Symptom 1|Other 1|Other Symptom 1	A question about an individual's distress from the first of their other symptoms.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form
C125402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125402>	C173457|C173393	How Much Distress Other Symptom 2 Question|How Much Distress Other Symptom 2|Other 2|Other Symptom 2	A question about an individual's distress from the second of their other symptoms.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form
C125403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125403>	C173457|C173393	How Much Distress Other Symptom 3 Question|How Much Distress Other Symptom 3|Other 3|Other Symptom 3	A question about an individual's distress from the third of their other symptoms.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form
C125404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125404>	C226671	Almost Constantly|Almost constantly	A response indicating that something was occurring or recurring nearly continually without interruption.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form|PRO-CTCAE Attribute Value Terminology|PRO-CTCAE Version 1.0 Questionnaire Terminology
C125405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125405>	C173398	Have Difficulty Concentrating Question|Difficulty concentrating|Had Difficulty Concentrating|Have Difficulty Concentrating|I have difficulty concentrating	A question about whether an individual has or had difficulty concentrating.			Intellectual Product	ANCHOR Health-Related Symptom Index|Memorial Symptom Assessment Scale - Short Form
C125406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125406>	C173803	Problem with Urination Question|Problem with Urination	A question about whether an individual has or had a problem with urination.			Intellectual Product	
C125407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125407>	C173981	Have Sweats Question|Have Sweats|Sweats	A question about whether an individual has or had sweats.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form
C125408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125408>	C173704	Problem with Sexual Interest or Activity Question|Problem with Sexual Interest or Activity|Problems with sexual interest or activity	A question about whether an individual has or had problems with sexual interest or activity.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form
C125409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125409>	C173600	Have Dizziness Question|Dizziness|Have Been Dizzy|Have Dizziness	A question about whether an individual has or had dizziness.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form
C12540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12540>	C12538	Type 2 Helper Cell|Th-2 Cell|Th2 Cell|Th2 Cell|Th2 Cells	Type 2 Helper Cells are a subset of helper-inducer T-lymphocytes which synthesize and secrete the interleukins IL-4, IL-5, IL-6, and IL-10. These cytokines influence B-cell development and antibody production as well as augmenting humoral responses.	Th2 Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C125410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125410>	C173454|C173398	Have Difficulty Swallowing Question|Difficulty swallowing|Had Trouble Swallowing|Have Difficulty Swallowing|Have you had trouble swallowing|Trouble Swallowing	A question about whether an individual has or had difficulty in swallowing.			Intellectual Product	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 Items|Memorial Symptom Assessment Scale - Short Form
C125413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125413>	C105770	Have Swelling of Arms and/or Legs Question|Have Swelling of Arms and/or Legs|Swelling of arms or legs	A question about whether an individual has or had swelling of their arms or legs.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form
C125414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125414>	C176022	Don't Look Like Myself Question|Don't Look Like Myself|I don't look like myself	A question about whether an individual feels or felt like they don't look like themselves.			Intellectual Product	Memorial Symptom Assessment Scale - Short Form
C125415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125415>	C60695	Rat Malignant Peripheral Nerve Sheath Tumor	A malignant peripheral nerve sheath tumor occurring in a rat.			Neoplastic Process	Cellosaurus Disease Terminology
C125416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125416>	C60695	Rat Multiple Myeloma|Rat Plasma Cell Myeloma	Plasma cell myeloma occurring in a rat.			Neoplastic Process	Cellosaurus Disease Terminology
C125417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125417>	C21628	Mouse Multiple Myeloma|Mouse Plasma Cell Myeloma	Plasma cell myeloma occurring in a mouse.			Neoplastic Process	Cellosaurus Disease Terminology
C125418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125418>	C53543|C28193	Pseudotrisomy 13 Syndrome|Holoprosencephaly-Polydactyly Syndrome	A rare syndrome likely inherited in an autosomal recessive pattern. It is characterized by holoprosencephaly, polydactyly, phenotypic features reminiscent of trisomy 13, and normal karyotype.			Disease or Syndrome	Cellosaurus Disease Terminology
C125419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125419>	C53543	Spondyloepimetaphyseal Dysplasia with Joint Laxity Type 2|SEMDJL2	A rare disorder caused by mutation in the KIF22 gene. It is characterized by short stature, midface retrusion, progressive knee malalignment, generalized ligamentous laxity, and mild spinal deformity.			Disease or Syndrome	Cellosaurus Disease Terminology
C12541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12541>	C12537	Suppressor-Inducer T-Lymphocyte|Suppressor-Inducer T-Cell|Suppressor-Inducer T-Cells|Suppressor-Inducer T-Lymphocytes	A subtype of CD4+ T lymphocyte that triggers CD8+ T lymphocytes to inhibit the production of antibodies.	T-Lymphocyte, Suppressor-Inducer		Cell	
C125420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125420>	C201493|C200765	Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes|Allogeneic CD123R(EQ)28zeta/EGFRt+ T Cells	A preparation of genetically modified allogeneic T-cells transduced with a replication-incompetent, self-inactivating lentiviral vector expressing a hinge-optimized, chimeric antigen receptor (CAR), comprised of a CD28 co-stimulatory signaling domain fused to CD3 zeta, the single-chain variable fragment of CD123 antigen (interleukin-3 receptor alpha chain or IL3RA), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes are directed to and induce selective toxicity in CD123-expressing tumor cells. CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with increased leukemic cell proliferation and aggressiveness. Devoid of both ligand binding domains and tyrosine kinase activity, EGFRt both facilitates detection of the administered T-cells in vivo and can promote elimination of those cells following a cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) response. The costimulatory signaling domain enhances both proliferation of T-cells and antitumor activity. Hinge optimization prevents recognition of the CAR by Fc receptors (FcRs).	Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125421>	C207067	Clinical Trial Operational Oversight Documentation|Clinical Trial Operational Oversight|Operational Oversight|Operational Oversight	Documentation describing clinical trial operations oversight by a sponsor.			Activity	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Trial Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C125422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125422>	C207067	Clinical Trial Committee Member Financial Disclosure Form Documentation|Committee Member Financial Disclosure Form|Committee Member Financial Disclosure Form	A document pertaining to the financial interests and arrangements of the committee members for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Trial Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C125423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125423>	C207067	Clinical Trial Committee Member Contract Documentation|Committee Member Contract|Committee Member Contract	Documentation describing the contractual responsibilities between a sponsor or vendor and a member from a committee established for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Trial Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C125424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125424>	C207067	Clinical Trial Committee Member Confidentiality Disclosure Agreement Documentation|Committee Member Confidentiality Disclosure Agreement|Committee Member Confidentiality Disclosure Agreement	Documentation describing the provisions governing the nondisclosure requirements between a sponsor or vendor and a member from a committee established for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Trial Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C125425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125425>	C207067	Clinical Trial Team Evidence of Training Documentation|Clinical Trial Team Training Documents|Trial Team Evidence of Training|Trial Team Evidence of Training	Documentation verifying clinical trial team training completion.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Trial Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C125426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125426>	C207067	Clinical Trial Coordinating Investigator Documentation|Coordinating Investigator Documentation|Coordinating Investigator Documentation	Documentation pertaining to a coordinating investigator in the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C125427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125427>	C207067	Clinical Trial Subject Eligibility Verification Form and Worksheet Documentation|Clinical Trial Eligibility Forms|Subject Eligibility Verification Forms and Worksheets|Subject Eligibility Verification Forms and Worksheets	Documentation verifying a subject is an appropriate candidate to participate in the clinical trial, as outlined by the clinical study protocol.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C125428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125428>	C207067	Clinical Trial Ongoing Vendor Oversight Documentation|Clinical Trial Third Party Compliance|Ongoing Third Party Oversight|Ongoing Third Party Oversight	Documentation confirming that a vendor continues to meet all relevant criteria to fulfill a contractual obligation for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Vendor Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C125429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125429>	C207067	Clinical Trial Roles and Responsibilities Matrix Documentation|Roles and Responsibilities Matrix|Roles and Responsibility Matrix|Task Ownership Matrix|Technical Agreement|Third Party Roles and Responsibilities|Transfer of Obligations|Transfer of Regulatory Obligation	Documentation describing the range and distribution of tasks and responsibilities.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Trial Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C12542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12542>	C33061	CD8-Positive T-Lymphocyte|CD8 Cell|CD8 Lymphocyte|CD8 Lymphocytes|CD8+ T Cell|CD8+ T Lymphocyte|CD8+ T Lymphocytes|CD8+ T-Lymphocyte|CD8-Positive Lymphocyte|CD8-Positive Lymphocytes|CD8-Positive T-Lymphocytes|T8 Cell|T8 Cells|T8 Lymphocyte|T8 Lymphocytes	A subset of T-lymphocytes that express the CD8 surface glycoprotein and bind epitopes that are part of class I histocompatibility molecules. CD8-positive T-lymphocytes include cytotoxic T-lymphocytes and CD8+ suppressor T-lymphocytes.	CD8-Positive T-Lymphocyte		Cell	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C125430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125430>	C78508	Clinical Trial Device Review Committee|Device Review Committee|Device Review Committee	Committee established by the sponsor to assess, at intervals, the functioning of device; or review of specified features in relationship to study objectives or safety and efficacy of device.			Population Group	CareLex eTMF Terminology
C125431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125431>	C207067	Medical Device Report of Prior Investigations Documentation|Report of Prior Investigations|Report of Prior Investigations	Documentation reporting all prior clinical, animal, and laboratory testing of a medical device.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Central Trial Documents Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C125432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125432>	C207067	Clinical Trial Medical Device Investigators Agreement Documentation|Device Investigators Agreement|Investigators Agreement (Device)|Investigators Agreement - Device	Documentation pertaining to the non-financial agreement for medical devices between the sponsor and the clinical trial investigator(s) documenting various responsibilities.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C125433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125433>	C207067	Clinical Trial Source Data Verification Documentation|Source Data Verification|Source Data Verification	Documentation describing source data and associated verification activities for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C125434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125434>	C207067	Clinical Trial Subject Identification Log Documentation|Subject Identification Log|Subject Identification Log	Documentation identifying all the subjects screened, screen failed and enrolled for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C125435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125435>	C207074	Clinical Trial Investigational Product Retest and Expiry Documentation|IP Retest and Expiry Document|IP Retest and Expiry Documentation	Documentation describing the batch retesting of the investigational product(s) for the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IP and Trial Supplies Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C125436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125436>	C45279	Investigational Product Device Maintenance Log|IP Device Maintenance Log	A record or log of activities documenting the quality and condition of medical devices used in clinical trials.			Intellectual Product	CareLex eTMF Terminology
C125437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125437>	C19498	Electronic Case Report Form Technical Design Document|Technical Design Document	Document containing the design elements of the electronic case report form (eCRF) system used in a clinical trial.			Intellectual Product	CareLex eTMF Terminology
C125438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125438>	C207067	Clinical Trial Database Change Control Documentation|Database Change Control|Database Change Control	Documentation detailing the changes made to the clinical trial database.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Data Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C125439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125439>	C54631	Independent Review Committee Member Curriculum Vitae|Committee Member Curriculum Vitae	A summary of the qualifications of independent review committee members, including educational and work experience.			Intellectual Product	CareLex eTMF Terminology
C12543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12543>	C12542|C104083	Cytotoxic T-Lymphocyte|CTL|Cytolytic T-Cell|Cytotoxic T Cell|Cytotoxic T Cells|Cytotoxic T lymphocyte|Cytotoxic T-Lymphocytes|T-Lymphocyte, Cytotoxic|T-Lymphocytes, Cytotoxic|cytotoxic T cell|cytotoxic T lymphocyte|killer T cell	Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. These cells are distinct from natural killer cells and from killer cells mediating antibody-dependent cell cytotoxicity.	Cytotoxic T-Lymphocyte		Cell	CTRP Biomarker Terminology|CTRP Terminology
C125440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125440>	C207067	Clinical Trials Vendor Curriculum Vitae Documentation|Third Party Curriculum Vitae|Third Party Curriculum Vitae	Documentation detailing the education, qualification and work experience of the vendor team members participating in the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Vendor Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C125441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125441>	C54631	Clinical Trial Team Curriculum Vitae|Other Curriculum Vitae|Study Team Curriculum Vitae	A summary of educational and work experience qualifications and eligibility of study team members and Trial Team Members affiliated with the Site, Sponsor and Sponsor partner(s). Excludes Principal Investigator or Sub-Investigator.			Intellectual Product	CareLex eTMF Terminology
C125442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125442>	C207067	Clinical Trial Source Data Documentation|Source Data|Source Data	Documentation pertaining to the original records or certified copies of data collected from the clinical trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C125443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125443>	C207073	Clinical Trial Site Monitoring Visit Follow-up Documentation|MVR FU|MVR Follow-up|Monitoring Visit Follow-up Documentation|Monitoring Visit Follow-up Letter	Documentation pertaining to the follow-up of a monitoring visit of the clinical trial site.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Site Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C125444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125444>	C21295	PFN1 Gene|PFN1|PFN1|Profilin 1 Gene	This gene plays a role in the regulation of actin polymerization.			Gene or Genome	
C125445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125445>	C125444	PFN1 wt Allele|ALS18|Profilin 1 wt Allele	Human PFN1 wild-type allele is located in the vicinity of 17p13.3 and is approximately 3 kb in length. This allele, which encodes profilin-1 protein, is involved in cytoskeleton regulation. Deletion of the gene may be associated with Miller-Dieker syndrome and mutation of the gene is associated with amyotrophic lateral sclerosis 18.			Gene or Genome	
C125446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125446>	C16492	Profilin-1|Epididymis Tissue Protein Li 184a|Profilin I|Profilin-I	Profilin-1 (140 aa, ~15 kDa) is encoded by the human PFN1 gene. This protein plays a role in the modulation of actin polymerization.			Amino Acid, Peptide, or Protein	
C125447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125447>	C25972	PTPN14 Gene|PTPN14|PTPN14|Protein Tyrosine Phosphatase, Non-Receptor Type 14 Gene	This gene is involved in protein dephosphorylation, cell migration, cell adhesion and lymphangiogenesis.			Gene or Genome	
C125448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125448>	C125447	PTPN14 wt Allele|PEZ|PTP36|PTPD2|Protein Tyrosine Phosphatase, Non-Receptor Type 14 wt Allele|Protein Tyrosine Phosphatase, Nonreceptor-Type, 14 Gene	Human PTPN14 wild-type allele is located in the vicinity of 1q32.2 and is approximately 204 kb in length. This allele, which encodes tyrosine-protein phosphatase non-receptor type 14 protein, plays a role in the regulation of cellular processes that are mediated by tyrosine dephosphorylation. Deletion of the gene may be associated with choanal atresia and lymphedema (CHATLY).			Gene or Genome	
C125449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125449>	C106408	Tyrosine-Protein Phosphatase Non-Receptor Type 14|Cytoskeletal-Associated Protein Tyrosine Phosphatase|EC 3.1.3.48|PTPN14|Phosphatase with Ezrin Domain|Protein-Tyrosine Phosphatase Pez	Tyrosine-protein phosphatase non-receptor type 14 (1187 aa, ~135 kDa) is encoded by the human PTPN14 gene. This protein is involved in lymphangiogenesis, cell migration, cell adhesion and protein dephosphorylation.			Amino Acid, Peptide, or Protein|Enzyme	
C12544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12544>	C12542	Suppressor-Effector T-Lymphocyte|Suppressor T Lymphocyte|Suppressor-Effector T-Cells|Suppressor-Effector T-Lymphocytes|T Suppressor Cell	T-lymphocytes that respond to signals from suppressor-inducer T-cells by inhibiting either cell-mediated immunity or antibody production by B-cells.	T-Lymphocytes, Suppressor-Effector		Cell	
C125450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125450>	C172200	JAK2 Inhibitor	Any substance that inhibits JAK2 tyrosine protein kinase, an enzyme that phosphorylates the hydroxyl group of tyrosine on various proteins in various signaling cascades.			Chemical Viewed Functionally	
C125451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125451>	C91105	Was It Worth It Questionnaire|WIWI|Was It Worth It (WIWI) Questionnaire	A questionnaire designed to measure a patient's opinion of their participation in a phase II or III treatment trial and their decision making regarding treatment.			Intellectual Product	
C125452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125452>	C91102	Worthwhile to Participate in Research Study Question|Was it worthwhile for you to participate in this research study|Worthwhile to Participate in Research Study	A question about whether an individual thinks it was worthwhile to participate in a research study.			Intellectual Product	Was It Worth It Questionnaire
C125453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125453>	C91102	Would Participate in Research Study Again Question|If you had it to do over, would you participate in this research study again|Would Participate in Research Study Again	A question about whether an individual would participate in a research study again.			Intellectual Product	Was It Worth It Questionnaire
C125454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125454>	C91102	Recommend Participating in Research Study to Others Question|Recommend Participating in Research Study to Others|Would you recommend participating in this research study to others	A question about whether an individual would recommend participation in a research study.			Intellectual Product	Was It Worth It Questionnaire
C125455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125455>	C173504	Overall Quality of Life Change by Participating in Research Study Question|Overall Quality of Life Change by Participating in Research Study|Overall, did your quality of life change by participating in this research study	A question about how an individual's quality of life is or was changed by participation in a research study.			Intellectual Product	Was It Worth It Questionnaire
C125456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125456>	C91102	Overall Experience Participating in Research Study Question|Overall Experience Participating in Research Study|Overall how was your experience of participating in this research study	A question about an individual's experience while participating in a research study.			Intellectual Product	Was It Worth It Questionnaire
C125457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125457>	C91102	One Thing to Improve Experience Participating in Research Study Question|If there was one thing that could have been done to improve your experience in this research study, what would it be|One Thing to Improve Experience Participating in Research Study	A question about the one thing an individual would recommend to improve their experience participating in a research study.			Intellectual Product	Was It Worth It Questionnaire
C125458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125458>	C91102	Talk with Someone about Concerns Question|Takes a Lot of Effort to Concentrate on Things|Would you like to talk with someone about your concerns	A question about whether an individual would like to talk to someone about their concerns.			Intellectual Product	Was It Worth It Questionnaire
C125459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125459>	C175309	Improved|Better|IMPROVED|It improved	A subjective response indicating that something improved.			Intellectual Product	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology|Sexual Adjustment and Body Image Scale for Gynecologic Cancer|Was It Worth It Questionnaire
C125460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125460>	C226723	Stayed the Same|It stayed the same	A subjective response indicating that something is unchanged.			Intellectual Product	Was It Worth It Questionnaire
C125461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125461>	C226723	Got Worse|It got worse|Worsened	A subjective response indicating that something got worse.			Intellectual Product	Was It Worth It Questionnaire
C125462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125462>	C20923	GPR158 Gene|G Protein-Coupled Receptor 158 Gene|GPR158|GPR158	This gene plays a role in the mediation of G protein-coupled receptor signaling.			Gene or Genome	
C125463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125463>	C125462	GPR158 wt Allele|G Protein-Coupled Receptor 158 wt Allele|KIAA1136	Human GPR158 wild-type allele is located in the vicinity of 10p12.31 and is approximately 427 kb in length. This allele, which encodes probable G-protein coupled receptor 158 protein, is involved in G protein-coupled receptor signal transduction.			Gene or Genome	
C125464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125464>	C18239	Probable G-Protein Coupled Receptor 158|G Protein-Coupled Receptor 158|G-Protein Coupled Receptor 158|GPR158|Probable G Protein-Coupled Receptor 158	Probable G-protein coupled receptor 158 (1215 aa, ~135 kDa) is encoded by the human GPR158 gene. This protein plays a role in G protein-coupled receptor activity.			Amino Acid, Peptide, or Protein|Receptor	
C125465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125465>	C20921	ARHGAP11B Gene|ARHGAP11B|ARHGAP11B|Rho GTPase-Activating Protein 11B Gene	This gene is involved in corticogenesis.			Gene or Genome	
C125466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125466>	C125465	ARHGAP11B wt Allele|B'-T|FAM7B1|Family With Sequence Similarity 7, Member B1 Gene|GAP (1-8) Gene|Rho GTPase-Activating Protein 11B wt Allele	Human ARHGAP11B wild-type allele is located in the vicinity of 15q13.2 and is approximately 149 kb in length. This allele, which encodes Rho GTPase-activating protein 11B, plays a role in both signal transduction and brain cortex development.			Gene or Genome	
C125467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125467>	C17298	Rho GTPase-Activating Protein 11B|ARHGAP11B|Protein FAM7B1|Rho-Type GTPase-Activating Protein 11B	Rho GTPase-activating protein 11B (267 aa, ~30 kDa) is encoded by the human ARHGAP11B gene. This protein is involved in corticogenesis.			Amino Acid, Peptide, or Protein	
C125468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125468>	C20103	TREM2 Gene|TREM2|TREM2|Triggering Receptor Expressed On Myeloid Cells 2 Gene	This gene plays a role in the activation of immune responses.	TREM2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C125469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125469>	C125468	TREM2 wt Allele|TREM-2|Trem2a|Trem2b|Trem2c|Triggering Receptor Expressed On Myeloid Cells 2 wt Allele|Triggering Receptor Expressed On Myeloid Cells 2a Gene	Human TREM2 wild-type allele is located in the vicinity of 6p21.1 and is approximately 5 kb in length. This allele, which encodes triggering receptor expressed on myeloid cells 2 protein, is involved in inflammation. Expression of the gene may be associated with chronic inflammation and mutation of the gene is associated with polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (Nasu-Hakola disease).	TREM2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12546>	C12535	Tumor Infiltrating Lymphocyte|Lymphocytes, Tumor-Infiltrating|Lymphocytes, Tumor-Infiltrating|TIL|TILs|Tumor Infiltrating Lymphocytes|tumor infiltrating lymphocyte	Lymphocytes that show specificity for autologous tumor cells and can infiltrate a tumor.	Lymphocytes, Tumor-Infiltrating		Cell	CTRP Biomarker Terminology|CTRP Terminology
C125470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125470>	C18106	Triggering Receptor Expressed On Myeloid Cells 2|TREM-2|TREM2|Triggering Receptor Expressed On Monocytes 2	Triggering receptor expressed on myeloid cells 2 (230 aa, ~25 kDa) is encoded by the human TREM2 gene. This protein plays a role in macrophage and dendritic cell immune responses.	Triggering Receptor Expressed On Myeloid Cells 2		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C125471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125471>	C2152|C129825	Eganelisib|EGANELISIB|IPI 549|IPI-549	An orally bioavailable, highly selective small molecule inhibitor of the gamma isoform of phosphoinositide-3 kinase (PI3K-gamma) with potential immunomodulating and antineoplastic activities. Upon administration, eganelisib prevents the activation of the PI3K-gamma-mediated signaling pathways, which may lead to a reduction in cellular proliferation in PI3K-gamma-expressing tumor cells. In addition, this agent is able to modulate anti-tumor immune responses and inhibit tumor-mediated immunosuppression. Unlike other isoforms of PI3K, the gamma isoform is overexpressed in certain tumor cell types and immune cells; its expression increases tumor cell proliferation and survival. By selectively targeting the gamma isoform, PI3K signaling in normal, non-neoplastic cells is minimally or not affected, which results in a reduced side effect profile.	Eganelisib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125472>	C54179	Ann Arbor Clinical Stage I|Stage I	A clinical stage that refers to lymphoma involving a single lymph node region or a single extranodal organ (Ie).	Ann Arbor Clinical Stage I		Classification	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C125473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125473>	C54179	Ann Arbor Pathologic Stage I|Stage I	A pathologic stage that refers to lymphoma involving a single lymph node region or a single extranodal organ (Ie).			Classification	GDC Terminology|GDC Value Terminology
C125474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125474>	C54179	Ann Arbor Clinical Stage II|Stage II	A clinical stage that refers to lymphoma involving two or more node regions on the same side of the diaphragm or a single extranodal organ plus its regional lymph nodes with or without other nodes on the same side of the diaphragm (IIe).	Ann Arbor Clinical Stage II		Classification	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C125475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125475>	C54179	Ann Arbor Pathologic Stage II|Stage II	A pathologic stage that refers to lymphoma involving two or more node regions on the same side of the diaphragm or a single extranodal organ plus its regional lymph nodes with or without other nodes on the same side of the diaphragm (IIe).			Classification	GDC Terminology|GDC Value Terminology
C125476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125476>	C54179	Ann Arbor Clinical Stage III|Stage III	A clinical stage that refers to lymphoma involving node regions on both sides of the diaphragm, or an extralymphatic organ or site plus nodes on both sides of the diaphragm (IIIe), or lymph nodes on both sides of the diaphragm plus spleen (IIIs).	Ann Arbor Clinical Stage III		Classification	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C125477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125477>	C54179	Ann Arbor Pathologic Stage III|Stage III	A pathologic stage that refers to lymphoma involving node regions on both sides of the diaphragm, or an extralymphatic organ or site plus nodes on both sides of the diaphragm (IIIe), or lymph nodes on both sides of the diaphragm plus spleen (IIIs).			Classification	GDC Terminology|GDC Value Terminology
C125478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125478>	C54179	Ann Arbor Clinical Stage IV|Stage IV	A clinical stage that refers to diffuse extralymphatic involvement by lymphoma.	Ann Arbor Clinical Stage IV		Classification	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C125479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125479>	C54179	Ann Arbor Pathologic Stage IV|Stage IV	A pathologic stage that refers to diffuse extralymphatic involvement by lymphoma.			Classification	GDC Terminology|GDC Value Terminology
C12547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12547>	C12529	Monocyte|MONOCYTE|Monocytes|monocyte	Large, phagocytic mononuclear leukocytes produced in the vertebrate bone marrow and released into the blood; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles.	Monocyte		Cell	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C125480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125480>	C1892	Curcuminoid|CURCUMINOIDS|Curcuminoids|Curcuminoids				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C125481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125481>	C54443	GAIA Terminology|Global Alignment of Immunization safety Assessment in pregnancy Terminology	A subset of terms developed in collaboration with NICHD that focuses on developing common standards, guidance, and tools to strengthen programs of immunization in pregnancy.			Intellectual Product	
C125482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125482>	C133710	RNF5 Gene|RNF5|RNF5|Ring Finger Protein 5 Gene	This gene is involved in both mono- and polyubiqutination of protein substrates.			Gene or Genome	
C125483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125483>	C125482	RNF5 wt Allele|G16|NG2|RING5|RMA1|Ring Finger Protein 5, E3 Ubiquitin Protein Ligase wt Allele	Human RNF5 wild-type allele is located in the vicinity of 6p21.3 and is approximately 2 kb in length. This allele, which encodes E3 ubiquitin-protein ligase RNF5 protein, plays a role in protein ubiquitination and protein catabolism.			Gene or Genome	
C125484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125484>	C26812	Ectopia Lentis	Partial or complete displacement of the crystalline lens from its normal position in the eye.			Disease or Syndrome	Cellosaurus Disease Terminology
C125485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125485>	C27608	Microcornea	A congenital abnormality characterized by an abnormally small cornea. The horizontal corneal diameter is less than 10mm or less than 9mm in newborns. It is associated with an increased risk of glaucoma.			Disease or Syndrome	Cellosaurus Disease Terminology
C125486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125486>	C21254	E3 Ubiquitin-Protein Ligase RNF5|EC 2.3.2.27|EC 6.3.2.-, Formerly|HsRma1|Protein G16|RING Finger Protein 5|Ram1 Homolog|Ring Finger Protein 5	E3 ubiquitin-protein ligase RNF5 (180 aa, ~20 kDa) is encoded by the human RNF5 gene. This protein is involved in the regulation of protein catabolism.			Amino Acid, Peptide, or Protein|Enzyme	
C125487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125487>	C85865|C28193	Opitz G/BBB Syndrome|Opitz G Syndrome|Opitz GBBB Syndrome|Opitz-G Syndrome	An X-linked syndrome caused by mutations in the MID1 gene or autosomal dominant syndrome caused by changes in chromosome 22. It is characterized by ocular hypertelorism, and defects of the larynx, trachea, or esophagus. Most males have hypospadias, cryptorchidism, underdeveloped scrotum, or a scrotum divided into two lobes. Mild intellectual disability and developmental delays occur in approximately half of the affected individuals.			Disease or Syndrome	Cellosaurus Disease Terminology
C125488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125488>	C53543|C28193	Seckel Syndrome|Bird-Headed Dwarfism|Microcephalic Primordial Dwarfism|Nanocephalic Dwarfism|SCKL|Seckel-Type Dwarfism	A rare autosomal recessive inherited syndrome caused by mutations in the ATR gene, RBBP8 gene, CENPJ gene, CEP152 gene, CEP63 gene, NIN gene, DNA2 gene, or TRAIP gene. It is characterized by intrauterine growth retardation, dwarfism, microcephaly, mental retardation, and a "bird-headed" facial appearance.			Disease or Syndrome	Cellosaurus Disease Terminology
C125489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125489>	C25952	PDE9A Gene|PDE9A|PDE9A|Phosphodiesterase 9A Gene	This gene plays a role in the metabolism of cyclic nucleotide monophosphates.			Gene or Genome	
C12548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12548>	C28676	Monocyte, Activated Killer|Monocytes, Activated Killer	A monocyte that has been activated for cytotoxicity by gamma interferon.			Cell|Pharmacologic Substance	
C125490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125490>	C125489	PDE9A wt Allele|HSPDE9A2|Phosphodiesterase 9A wt Allele	Human PDE9A wild-type allele is located in the vicinity of 21q22.3 and is approximately 122 kb in length. This allele, which encodes high affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A protein, is involved in the metabolism of both cyclic GMP and cyclic AMP.			Gene or Genome	
C125491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125491>	C16561	High Affinity cGMP-Specific 3',5'-Cyclic Phosphodiesterase 9A|EC 3.1.4.35|High Affinity cGMP-Specific 3,5-Cyclic Phosphodiesterase 9A|Homo sapiens Phosphodiesterase PDE9A2|PDE9A|Phosphodiesterase PDE9A21|cGMP-Specific 3',5'-Cyclic Phosphodiesterase Type 9|cGMP-Specific 3,5-Cyclic Phosphodiesterase Type 9	High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A (593 aa, ~68 kDa) is encoded by the human PDE9A gene. This protein plays a role in the conversion of cyclic nucleotide monophosphates to non-cyclic monophosphates.			Amino Acid, Peptide, or Protein|Enzyme	
C125492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125492>	C114371	First Trimester Antepartum Hemorrhage|Antepartum Hemorrhage, First Trimester	Excessive blood loss within the first trimester but prior to onset of labor.			Finding	NICHD Terminology|Perinatal Terminology
C125493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125493>	C114371	Second Trimester Antepartum Hemorrhage|Antepartum Hemorrhage, Second Trimester	Excessive blood loss within the second trimester but prior to onset of labor.			Finding	NICHD Terminology|Perinatal Terminology
C125494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125494>	C114371	Third Trimester Antepartum Hemorrhage|Antepartum Hemorrhage, Third Trimester	Excessive blood loss within the third trimester but prior to onset of labor.			Finding	NICHD Terminology|Perinatal Terminology
C125495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125495>	C25873	PRKG1 Gene|PRKG1|PRKG1|Protein Kinase, cGMP-Dependent, Type I Gene	This gene is involved in the modulation of the nitric oxide/cyclic GMP signaling pathway.			Gene or Genome	
C125496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125496>	C125495	PRKG1 wt Allele|AAT8|PGK|PKG|PRKG1B|PRKGR1B|Protein Kinase, cGMP-Dependent, Regulatory, Type I Gene|Protein Kinase, cGMP-Dependent, Regulatory, Type I, Alpha Gene|Protein Kinase, cGMP-Dependent, Regulatory, Type I, Beta Gene|Protein Kinase, cGMP-Dependent, Type I wt Allele|cGK|cGK 1|cGK1|cGKI|cGKI-Alpha|cGKI-BETA|cGMP-Dependent Protein Kinase, Type I, Alpha Gene|cGMP-Dependent Protein Kinase, Type I, Beta Gene	Human PRKG1 wild-type allele is located in the vicinity of 10q11.2 and is approximately 1307 kb in length. This allele, which encodes cGMP-dependent protein kinase 1 protein, plays a role in both protein phosphorylation and nitric oxide signaling. Mutation of the gene is associated with familial thoracic aortic aneurysm type 8.			Gene or Genome	
C125497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125497>	C17325	cGMP-Dependent Protein Kinase 1|EC 2.7.11.12|cGK 1|cGK1|cGKI|cGKI-Alpha|cGKI-BETA|cGMP-Dependent Protein Kinase I	cGMP-dependent protein kinase 1 (671 aa, ~76 kDa) is encoded by the human PRKG1 gene. This protein is involved in nitric oxide/cyclic GMP-dependent signal transduction.			Amino Acid, Peptide, or Protein|Enzyme	
C125498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125498>	C20703	ID4 Gene|ID4|ID4|Inhibitor of DNA Binding 4, Dominant Negative Helix-Loop-Helix Protein Gene	This gene plays a role in the negative regulation of gene expression.			Gene or Genome	
C125499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125499>	C125498	ID4 wt Allele|IDB4|Inhibitor of DNA Binding 4, Dominant Negative Helix-Loop-Helix Protein wt Allele|bHLHb27	Human ID4 wild-type allele is located in the vicinity of 6p22.3 and is approximately 5 kb in length. This allele, which encodes DNA-binding protein inhibitor ID-4 protein, is involved in the inhibition of basic helix-loop-helix transcription factors.			Gene or Genome	
C12549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12549>	C32725	Myeloid Cell|Myeloid Cells	Cells which include the monocytes and the granulocytes.	Myeloid Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C1254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1254>	C2087|C1556	Tiazofurin|2-.beta.-D-Ribofuranosyl-4-thiazolecarboxamide|2-.beta.-D-Ribofuranosylthiazole-4-carboxamide|2-Beta-D-ribofuranosyl-4-thiazolecarboxamide|2-Beta-D-ribofuranosylthiazole-4-carboxamide|4-Thiazolecarboxamide, 2-.beta.-D-ribofuranosyl- (9CI)|4-Thiazolecarboxamide, 2-Beta-D-ribofuranosyl- (9CI)|Riboxamide|TCAR|TIAZOFURIN|Tiazofurine|tiazofurin	A synthetic nucleoside analogue with antineoplastic activity. Tiazofurin (TR) is anabolized intracellularly to an analogue of NAD, tiazole-4-carboxamide adenine dinucleotide (TAD), a potent inhibitor of IMP dehydrogenase (IMPDH); IMPDH is the rate-limiting enzyme for de novo purine synthesis. Inhibition of IMPDH results in reduced levels of guanylates, resulting in the inhibition tumor cell growth in vitro and in vivo. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125500>	C26199	DNA-Binding Protein Inhibitor ID-4|Class B Basic Helix-Loop-Helix Protein 27|ID4|Inhibitor of DNA Binding 4|Inhibitor of Differentiation 4|bHLHb27	DNA-binding protein inhibitor ID-4 (161 aa, ~17 kDa) is encoded by the human ID4 gene. This protein plays a role in transcriptional repression.			Amino Acid, Peptide, or Protein	
C125501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125501>	C91105	Patient Satisfaction Questionnaire Short Form|PSQ-18|Short-Form Patient Satisfaction Questionnaire (PSQ-18)	A short-form version of the 50-item Patient Satisfaction Questionnaire III designed to evaluate patient satisfaction with seven aspects of medical care.			Intellectual Product	
C125502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125502>	C25939	MAOB Gene|MAOB|MAOB|Monoamine Oxidase B Gene	This gene is involved in the oxidation of amines.			Gene or Genome	
C125503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125503>	C173145	Doctors are Good About Explaining the Reasons for Medical Tests Question|Doctors are Good About Explaining the Reasons for Medical Tests|Doctors are good about explaining the reasons for medical tests	A question about whether an individual feels their doctors are good about explaining the reasons for medical tests.			Intellectual Product	Patient Satisfaction Questionnaire Short Form
C125504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125504>	C125502	MAOB wt Allele|MAO, Brain Gene|MAO, Platelet Gene|MAO-B|Monoamine Oxidase B wt Allele	Human MAOB wild-type allele is located in the vicinity of Xp11.23 and is approximately 116 kb in length. This allele, which encodes amine oxidase [flavin-containing] B protein, plays a role in the metabolism of amines.			Gene or Genome	
C125505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125505>	C16946	Amine Oxidase [Flavin-Containing] B|Adrenalin Oxidase|Amine Oxidase (Flavin-Containing) B|EC 1.4.3.4|MAO-B|MAOB|Monoamine Oxidase Type B|Tyramine Oxidase	Amine oxidase [flavin-containing] B (520 aa, ~59 kDa) is encoded by the human MAOB gene. This protein is involved in the deamination of amines.			Amino Acid, Peptide, or Protein|Enzyme	
C125506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125506>	C176545|C173597|C173145	Doctor's Office Has Everything Needed to Provide Complete Medical Care Question|Doctor's Office Has Everything Needed to Provide Complete Medical Care|I think my doctor's office has everything needed to provide complete medical care	A question about whether an individual feels their doctor's office has everything it needs to provide complete medical care.			Intellectual Product	Patient Satisfaction Questionnaire Short Form
C125507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125507>	C176545	Medical Care I Have Been Receiving is Just About Perfect Question|Medical Care I Have Been Receiving is Just About Perfect|The medical care I have been receiving is just about perfect	A question about whether an individual feels the medical care they have received is just about perfect.			Intellectual Product	Patient Satisfaction Questionnaire Short Form
C125508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125508>	C173145	Sometimes Doctors Make Me Wonder if Their Diagnosis is Correct Question|Sometimes Doctors Make Me Wonder if Their Diagnosis is Correct|Sometimes doctors make me wonder if their diagnosis is correct	A question about whether an individual sometimes wonders if their doctor's diagnosis is correct.			Intellectual Product	Patient Satisfaction Questionnaire Short Form
C125509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125509>	C187306|C176545|C173086	Confident That I Can Get the Medical Care I Need Without Being Set Back Financially Question|Confident That I Can Get the Medical Care I Need Without Being Set Back Financially|I feel confident that I can get the medical care I need without being set back financially	A question about whether an individual feels confident they can get the medical care they need without being set back financially.			Intellectual Product	Patient Satisfaction Questionnaire Short Form
C125510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125510>	C173145	Doctors are Careful to Check Everything When Treating and Examining Me Question|Doctors are Careful to Check Everything When Treating and Examining Me|When I go for medical care, they are careful to check everything when treating and examining me	A question about whether an individual feels their doctors are careful to check everything when treating and examining them.			Intellectual Product	Patient Satisfaction Questionnaire Short Form
C125511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125511>	C176545	Have to Pay More of My Medical Care Than I Can Afford Question|Have to Pay More of My Medical Care Than I Can Afford|I have to pay for more of my medical care than I can afford	A question about whether an individual feels they have to pay for more of their medical care than they can afford.			Intellectual Product	Patient Satisfaction Questionnaire Short Form
C125512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125512>	C91102	Have Easy Access to the Medical Specialists I Need Question|Have Easy Access to the Medical Specialists I Need|I have easy access to the medical specialists I need	A question about whether an individual feels they have easy access to the medical specialists they need.			Intellectual Product	Patient Satisfaction Questionnaire Short Form
C125513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125513>	C176545|C173812	Wait for Emergency Treatment is Too Long Where I Get Medical Care Question|Wait for Emergency Treatment is Too Long Where I Get Medical Care|Where I get medical care, people have to wait too long for emergency treatment	A question about whether an individual feels that the wait is too long for emergency treatment where they get their medical care.			Intellectual Product	Patient Satisfaction Questionnaire Short Form
C125514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125514>	C173145	Doctors Act Too Businesslike and Impersonal Toward Me Question|Doctors Act Too Businesslike and Impersonal Toward Me|Doctors act too businesslike and impersonal toward me	A question about whether an individual feels doctors act too businesslike and impersonal toward them.			Intellectual Product	Patient Satisfaction Questionnaire Short Form
C125515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125515>	C173145	Doctors Treat Me In a Very Friendly and Courteous Manner Question|Doctors Treat Me In a Very Friendly and Courteous Manner|My doctors treat me in a very friendly and courteous manner	A question about whether an individual feels doctors treat them in a very friendly and courteous manner.			Intellectual Product	Patient Satisfaction Questionnaire Short Form
C125516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125516>	C176545	Those Providing Medical Care Sometimes Hurry Too Much When They Treat Me Question|Those Providing Medical Care Sometimes Hurry Too Much When They Treat Me|Those who provide my medical care sometimes hurry too much when they treat me	A question about whether an individual feels those providing medical care sometimes hurry too much when they are being treated.			Intellectual Product	Patient Satisfaction Questionnaire Short Form
C125517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125517>	C173145	Doctors Sometimes Ignore What I Tell Them Question|Doctors Sometimes Ignore What I Tell Them|Doctors sometimes ignore what I tell them	A question about whether an individual feels doctors sometimes ignore what they tell them.			Intellectual Product	Patient Satisfaction Questionnaire Short Form
C125518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125518>	C173145	Have Some Doubts About the Ability of the Doctors Who Treat Me Question|Have Some Doubts About the Ability of the Doctors Who Treat Me|I have some doubts about the ability of the doctors who treat me	A question about whether an individual has some doubts about the ability of the doctors who treat them.			Intellectual Product	Patient Satisfaction Questionnaire Short Form
C125519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125519>	C173145	Doctors Usually Spend Plenty of Time With Me Question|Doctors Usually Spend Plenty of Time With Me|Doctors usually spend plenty of time with me	A question about whether an individual feels doctors usually spend plenty of time with them.			Intellectual Product	Patient Satisfaction Questionnaire Short Form
C12551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12551>	C32725|C12662	Hematopoietic Stem Cell|Ferrata cell|HPC|HSC|HSCs|Hematohistioblast|Hematopoietic Progenitor Cell|Hematopoietic Progenitor Cells|Hematopoietic Stem Cells|Hemohistioblast	Primitive blood cells derived from embryonic mesenchyme capable of differentiating into any of the blood cell line progenitor cells (erythroblasts, young granulocytic series cells, megakaryocytes, etc.)	Hematopoietic Stem Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C125520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125520>	C176545|C173398	Find it Hard to Get an Appointment for Medical Care Right Away Question|Find it Hard to Get an Appointment for Medical Care Right Away|I find it hard to get an appointment for medical care right away	A question about whether an individual finds it hard to get an appointment for medical care right away.			Intellectual Product	Patient Satisfaction Questionnaire Short Form
C125521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125521>	C176545|C173792	Dissatisfied With Some Things About the Medical Care I Receive Question|Dissatisfied With Some Things About the Medical Care I Receive|I am dissatisfied with some things about the medical care I receive	A question about whether an individual is dissatisfied with some things about the medical care they receive.			Intellectual Product	Patient Satisfaction Questionnaire Short Form
C125522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125522>	C176545|C173045	Able to Get Medical Care Whenever I Need It Question|Able to Get Medical Care Whenever I Need It|I am able to get medical care whenever I need it	A question about whether an individual feels they are able to get medical care whenever they need it.			Intellectual Product	Patient Satisfaction Questionnaire Short Form
C125523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125523>	C28533	SLC39A6 Gene|SLC39A6|SLC39A6|Solute Carrier Family 39 (Zinc Transporter), Member 6 Gene	This gene plays a role in zinc transport.	SLC39A6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C125524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125524>	C125523	SLC39A6 wt Allele|LIV-1|LIV-1 Protein, Estrogen Regulated Gene|LIV1|Solute Carrier Family 39 (Metal Ion Transporter), Member 6 Gene|Solute Carrier Family 39 (Zinc Transporter), Member 6 wt Allele|ZIP6	Human SLC39A6 wild-type allele is located in the vicinity of 18q12.2 and is approximately 21 kb in length. This allele, which encodes zinc transporter ZIP6 protein, is involved in the transport of zinc ions. Aberrant expression of the gene is associated with luminal A breast cancer.	SLC39A6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C125525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125525>	C16386	Zinc Transporter ZIP6|Estrogen-Regulated Protein LIV-1|SLC39A6|Solute Carrier Family 39 Member 6|ZIP-6|Zrt- And Irt-Like Protein 6	Zinc transporter ZIP6 (755 aa, ~85 kDa) is encoded by the human SLC39A6 gene. This protein plays a role in zinc ion transport.	Zinc Transporter ZIP6		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C125526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125526>	C25997	PARD3 Gene|PARD3|PARD3|Par-3 Family Cell Polarity Regulator Gene	This gene is involved in asymmetric cell division, signal transduction, and tight junction formation.			Gene or Genome	
C125527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125527>	C125526	PARD3 wt Allele|ASIP|Baz|Bazooka Gene|PAR3|PAR3A|PAR3alpha|PARD-3|PARD3A|PPP1R118|Par-3 (Partitioning Defective 3, C.elegans) Homolog Gene|Par-3 Family Cell Polarity Regulator Alpha Gene|Par-3 Family Cell Polarity Regulator wt Allele|Par-3 Partitioning Defective 3 Homolog (C. elegans) Gene|Partitioning-Defective Protein 3, C. elegans, Homolog of Gene|Protein Phosphatase 1, Regulatory Subunit 118 Gene|SE2-5L16|SE2-5LT1|SE2-5T2	Human PARD3 wild-type allele is located in the vicinity of 10p11.21 and is approximately 706 kb in length. This allele, which encodes partitioning defective 3 homolog protein, plays a role in signaling processes involved in both cell division and cell-cell adhesion.			Gene or Genome	
C125528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125528>	C91105	Attitudes and Preferences Questionnaire|APQ	A questionnaire designed to assess a patient's attitudes toward the goals and benefits of personalized treatment and conventional treatment.			Intellectual Product	
C125529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125529>	C26231	Partitioning Defective 3 Homolog|ASIP|Atypical PKC Isotype-Specific Interacting Protein|Atypical PKC Isotype-Specific-Interacting Protein|CTCL Tumor Antigen Se2-5|PAR3-Alpha|PARD3|Par-3 Partitioning Defective 3 Homolog	Partitioning defective 3 homolog (1356 aa, ~151 kDa) is encoded by the human PARD3 gene. This protein is involved in signal transduction, tight junction formation and asymmetric cell division.			Amino Acid, Peptide, or Protein	
C12552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12552>	C13456	Bone Marrow Myeloid Stem Cell|CFU-GEMM|CFU-M|CMP|Common Myeloid Progenitor|Common Myeloid Progenitor Cell|Common Myeloid Progenitor Cell|Multipotent Bone Marrow Stem Cell with Wide Myeloid Potential|Myeloid Colony Forming Unit|Myeloid Progenitor Cell|Myeloid Progenitor Cells|Myeloid Stem Cell|Myeloid Stem Cells|Primitive Bone Marrow Myeloid Stem Cell	A hematopoietic stem cell found in the bone marrow that is committed to form erythrocytes, megakaryocytes, and all leukocytes except lymphocytes.	Common Myeloid Progenitor Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C125530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125530>	C173812|C173564	How Important that Treatment Based on Tumor Molecular Profile Extends Survival Question|Extends Survival|How Important Treatment Based on Tumor Molecular Profile Extends Survival|How Important that Treatment Based on Tumor Molecular Profile Extends Survival	A question about how an individual rates the importance that treatment based on the molecular profile of their specific tumor extends survival.			Intellectual Product	Attitudes and Preferences Questionnaire
C125531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125531>	C173812|C173564|C173457	How Important that Treatment Based on Tumor Molecular Profile Improves Symptoms Question|How Important Treatment Based on Tumor Molecular Profile Improves Symptoms|How Important that Treatment Based on Tumor Molecular Profile Improves Symptoms|Improves symptoms (e.g., reduces pain, increases appetite)	A question about how an individual rates the importance that treatment based on the molecular profile of their specific tumor improves symptoms.			Intellectual Product	Attitudes and Preferences Questionnaire
C125532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125532>	C173933|C173812|C173564	How Important that Treatment Based on Tumor Molecular Profile Avoids Side Effects from Treatment Question|Avoids side effects from treatment|How Important that Treatment Based on Tumor Molecular Profile Avoids Side Effects from Treatment	A question about how an individual rates the importance that treatment based on the molecular profile of their specific tumor avoids side effects from treatment.			Intellectual Product	Attitudes and Preferences Questionnaire
C125533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125533>	C20194	PSMD11 Gene|PSMD11|PSMD11|Proteasome 26S Subunit, Non-ATPase 11 Gene	This gene plays a role in the assembly and activity of the proteasome.			Gene or Genome	
C125534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125534>	C173812|C173564|C173504	How Important that Treatment Based on Tumor Molecular Profile Improves Quality of Life Question|How Important Treatment Based on Tumor Molecular Profile Improves Quality of Life|How Important that Treatment Based on Tumor Molecular Profile Improves Quality of Life|Improves quality of life	A question about how an individual rates the importance that treatment based on the molecular profile of their specific tumor improves quality of life.			Intellectual Product	Attitudes and Preferences Questionnaire
C125535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125535>	C125533	PSMD11 wt Allele|MGC3844|Proteasome (Prosome, Macropain) 26S Subunit, Non-ATPase, 11 Gene|Proteasome 26S Subunit, Non-ATPase 11 wt Allele|Proteasome 26S Subunit, Non-ATPase, 11 Gene|Rpn6|S9|p44.5	Human PSMD11 wild-type allele is located in the vicinity of 17q11.2 and is approximately 39 kb in length. This allele, which encodes 26S proteasome non-ATPase regulatory subunit 11 protein, is involved in proteasome assembly and activity.			Gene or Genome	
C125536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125536>	C18466	26S Proteasome Non-ATPase Regulatory Subunit 11|26S Proteasome Regulatory Subunit 9|26S Proteasome Regulatory Subunit P44.5|26S Proteasome Regulatory Subunit RPN6|26S Proteasome Regulatory Subunit S9|PSMD11	26S proteasome non-ATPase regulatory subunit 11 (422 aa, ~47 kDa) is encoded by the human PSMD11 gene. This protein plays a role in the assembly of the proteasome.			Amino Acid, Peptide, or Protein	
C125537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125537>	C173812|C173564	How Important that Standard Treatment Extends Survival Question|Extends Survival|How Important Standard Treatment Extends Survival|How Important that Standard Treatment Extends Survival	A question about how an individual rates the importance that standard treatment extends survival.			Intellectual Product	Attitudes and Preferences Questionnaire
C125538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125538>	C173812|C173564|C173457	How Important that Standard Treatment Improves Symptoms Question|How Important Standard Treatment Improves Symptoms|How Important that Standard Treatment Improves Symptoms|Improves symptoms (e.g., reduces pain, increases appetite)	A question about how an individual rates the importance that standard treatment improves symptoms.			Intellectual Product	Attitudes and Preferences Questionnaire
C125539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125539>	C173933|C173812|C173564	How Important that Standard Treatment Avoids Side Effects from Treatment Question|Avoids side effects from treatment|How Important Standard Treatment Avoids Side Effects from Treatment|How Important that Standard Treatment Avoids Side Effects from Treatment	A question about how an individual rates the importance that standard treatment avoids side effects from treatment.			Intellectual Product	Attitudes and Preferences Questionnaire
C12553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12553>	C12549	Megakaryocyte|Megakaryocytes|Megakaryocytic|Megalokaryocyte	Very large bone marrow cells which release mature blood platelets.	Megakaryocyte		Cell	CTRP Biomarker Terminology|CTRP Terminology
C125540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125540>	C173812|C173564|C173504	How Important that Standard Treatment Improves Quality of Life Question|How Important that Standard Treatment Improves Quality of Life|Improves quality of life	A question about how an individual rates the importance that standard treatment improves quality of life.			Intellectual Product	Attitudes and Preferences Questionnaire
C125541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125541>	C173812	Overall Value Treatment Based on Tumor Molecular Profile Question|How would you rate the overall value of a treatment that is based on your own tumor's molecular profile|Overall Value Treatment Based on Tumor Molecular Profile	A question about how an individual rates the overall value of a treatment based on their tumor's molecular profile.			Intellectual Product	Attitudes and Preferences Questionnaire
C125542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125542>	C85429	Importance Rating Likert Scale	A scale for the subjective scoring of importance that ranges from 0: Not at all important to 4: Extremely important.			Intellectual Product	Attitudes and Preferences Questionnaire
C125543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125543>	C221035	Importance Rating Score 0|Importance 0|Importance Score 0|Important	A subjective score of 0 on a scale that ranges from 0: Not at all important to 4: Extremely important.			Intellectual Product	Attitudes and Preferences Questionnaire
C125544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125544>	C221035	Importance Rating Score 1|Importance 1|Importance Score 1	A subjective score of 1 on a scale that ranges from 0: Not at all important to 4: Extremely important.			Intellectual Product	Attitudes and Preferences Questionnaire
C125545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125545>	C221035	Importance Rating Score 2|Importance 2|Importance Score 2	A subjective score of 2 on a scale that ranges from 0: Not at all important to 4: Extremely important.			Intellectual Product	Attitudes and Preferences Questionnaire
C125546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125546>	C221035	Importance Rating Score 3|Importance 3|Importance Score 3	A subjective score of 3 on a scale that ranges from 0: Not at all important to 4: Extremely important.			Intellectual Product	Attitudes and Preferences Questionnaire
C125547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125547>	C221035	Importance Rating Score 4|Extremely Important|Importance 4|Importance Score 4	A subjective score of 4 on a scale that ranges from 0: Not at all important to 4: Extremely important.			Intellectual Product	Attitudes and Preferences Questionnaire
C125548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125548>	C198645	Emactuzumab|EMACTUZUMAB|RG-7155|RG7155|RO-5509554|RO5509554	A humanized monoclonal antibody directed against the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R; CSF-1R; CD115), also known as macrophage colony-stimulating factor receptor (M-CSFR), with potential antineoplastic and immunomodulating activities. Upon administration, emactuzumab binds to CSF1R expressed on macrophages and inhibits the binding of colony-stimulating factor-1 (CSF-1) to CSF1R. This prevents CSF1R activation and CSF1R-mediated signaling in these cells, which blocks the production of inflammatory mediators by macrophages and reduces inflammation. By blocking both the activity of CSF1R-dependent tumor-associated macrophages (TAMs) and the recruitment of TAMs to the tumor microenvironment, emactuzumab enhances T-cell infiltration and antitumor T-cell immune responses, which inhibits the proliferation of tumor cells. TAMs play key roles in immune suppression and promoting inflammation, tumor cell proliferation and survival.	Emactuzumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125549>	C198859	Loncastuximab Tesirine|ADC ADCT-402|ADCT 402|ADCT-402|ADCT402|Anti-CD19 PBD-conjugate ADCT-402|LONCASTUXIMAB TESIRINE|Loncastuximab Tesirine-lpyl|Loncastuximab tesirine|MT 2111|MT-2111|MT2111|Zynlonta	An antibody-drug conjugate (ADC) consisting of an anti-CD19 humanized monoclonal antibody conjugated, via a cleavable linker comprised of valine-alanine and maleimide, to a cytotoxic, cross-linking agent pyrrolobenzodiazepine (PBD) dimer, which targets DNA minor grooves, with potential antineoplastic activity. Upon administration, the monoclonal antibody portion of loncastuximab tesirine targets the cell surface antigen CD19 on various cancer cells. Upon antibody/antigen binding and internalization, the cytotoxic PBD moiety is released. The imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces interstrand cross-links in the minor groove of DNA and inhibits DNA replication, which inhibits the proliferation of CD19-overexpressing tumor cells. CD19, a transmembrane receptor and tumor-associated antigen (TAA), is expressed on a number of B-cell-derived cancers.	Loncastuximab Tesirine		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12554>	C48431	Chromaffin Cell|Chromaffin Cells|chromaffin cell	Neuroendocrine cells, found in the medulla of the adrenal gland and other sympathetic nervous system ganglia, that release catecholamines into circulation.	Chromaffin Cell		Cell	
C125550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125550>	C174127|C173812|C173507	Preference for Decision About Choosing a Treatment Question|Preference for Decision About Choosing a Treatment|Which of the following best describes what you prefer for choosing a treatment	A question about an individual's preference for ways to decide about choosing a treatment.			Intellectual Product	Attitudes and Preferences Questionnaire
C125551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125551>	C21295	DRG2 Gene|DRG2|DRG2|Developmentally Regulated GTP Binding Protein 2 Gene	This gene is involved in the modulation of cell proliferation and differentiation.			Gene or Genome	
C125552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125552>	C125551	DRG2 wt Allele|Developmentally Regulated GTP Binding Protein 2 wt Allele	Human DRG2 wild-type allele is located in the vicinity of 17p11.2 and is approximately 20 kb in length. This allele, which encodes developmentally-regulated GTP-binding protein 2, plays a role in the regulation of cell growth and differentiation. Deletion of the region that the gene is located in is associated with Smith-Magenis syndrome.			Gene or Genome	
C125553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125553>	C17728	Developmentally-Regulated GTP-Binding Protein 2|DRG-2|DRG2|Developmentally Regulated GTP-Binding Protein 2	Developmentally-regulated GTP-binding protein 2 (364 aa, ~41 kDa) is encoded by the human DRG2 gene. This protein is involved in cell proliferation and cell differentiation.			Amino Acid, Peptide, or Protein	
C125554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125554>	C226911|C226709	Prefer to Make Final Selection About Which Treatment I Will Receive|I prefer to make the decision about which treatment I will receive|I prefer to make the final selection about which treatment I will receive	A response indicating that an individual prefers to make the final selection about which treatment they will receive.			Intellectual Product	Attitudes and Preferences Questionnaire|Control Preference Scale
C125555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125555>	C226911|C226709	Prefer to Make Final Selection of My Treatment After Seriously Considering My Doctor's Opinion|I prefer to make the final decision about my treatment after seriously considering my doctor's opinion|I prefer to make the final selection of my treatment after seriously considering my doctor's opinion	A response indicating that an individual prefers to make the final selection of their treatment after seriously considering their doctor's opinion.			Intellectual Product	Attitudes and Preferences Questionnaire|Control Preference Scale
C125556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125556>	C226911|C226709	Prefer My Doctor and I Share Responsibility for Deciding Which Treatment is Best|I prefer that my doctor and I share responsibility for deciding which treatment is best for me	A response indicating that an individual prefers that they and their doctor share responsibility for deciding which treatment is best for them.			Intellectual Product	Attitudes and Preferences Questionnaire|Control Preference Scale
C125557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125557>	C226911|C226709	Prefer My Doctor Makes Final Decision About Which Treatment is Used but Seriously Considers My Opinion|I prefer that my doctor makes the final decision about which treatment will be used but seriously considers my opinion	A response indicating that an individual prefers that their doctor makes the final decision about which treatment will be used but seriously considers their opinion.			Intellectual Product	Attitudes and Preferences Questionnaire|Control Preference Scale
C125558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125558>	C226911|C226709	Prefer to Leave All Decisions Regarding Treatment to My Doctor|I prefer leaving all decisions regarding treatment to my doctors|I prefer to leave all decisions regarding my treatment to my doctor	A response indicating that an individual prefers to leave all decisions regarding treatment to their doctor.			Intellectual Product	Attitudes and Preferences Questionnaire|Control Preference Scale
C125559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125559>	C174127|C173812|C173145	You and Your Doctor's Cancer Treatment Decision Question|How did you and your doctor(s) decide about your cancer treatment|You and Your Doctor's Cancer Treatment Decision	A question about how an individual and their doctor(s) decided their cancer treatment.			Intellectual Product	Attitudes and Preferences Questionnaire
C12555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12555>	C12508	Connective and Soft Tissue Cell	A non-epithelial cell of mesodermal origin that is found in mesenchymal tissue and functions to support, surround, or protect other structures or organs in the body.	Connective Tissue Cell		Cell	
C125560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125560>	C226911	Made Final Selection About Which Treatment I Will Receive|I made the final selection about which treatment I will receive	A response indicating that an individual made the final selection about which treatment they will receive.			Intellectual Product	Attitudes and Preferences Questionnaire
C125561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125561>	C226911	Made Final Selection of My Treatment After Seriously Considering Doctor's Opinion|I made the final selection of my treatment after seriously considering my doctor's opinion	A response indicating that an individual made the final selection of their treatment after seriously considering their doctor's opinion.			Intellectual Product	Attitudes and Preferences Questionnaire
C125562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125562>	C226911	Doctor and I Shared Responsibility for Deciding Which Treatment is Best for Me|My doctor and I shared responsibility for deciding which treatment is best for me	A response indicating that an individual and their doctor shared responsibility for deciding which treatment is best for them.			Intellectual Product	Attitudes and Preferences Questionnaire
C125563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125563>	C226911	Doctor Made Final Decision About Which Treatment Will Be Used but Seriously Considered My Opinion|My doctor made the final decision about which treatment will be used but seriously considered my opinion	A response indicating that an individual's doctor made the final decision about which treatment will be used but seriously considered their opinion.			Intellectual Product	Attitudes and Preferences Questionnaire
C125564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125564>	C173812	Conflicting Expert Opinions About a Medical Test or Treatment Would Lower My Trust in the Experts Question|Conflicting Expert Opinions About a Medical Test or Treatment Would Lower My Trust in the Experts|Conflicting expert opinions about a medical test or treatment would lower my trust in the experts	A question about an individual's agreement that expert opinions about a medical test or treatment would lower their trust in the experts.			Intellectual Product	Attitudes and Preferences Questionnaire
C125565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125565>	C173812	Would Not Have Confidence in a Medical Test or Treatment if Experts Had Conflicting Opinions Question|I would not have confidence in a medical test or treatment if experts had conflicting opinions about it|Would Not Have Confidence in a Medical Test or Treatment if Experts Had Conflicting Opinions	A question about an individual's agreement that they would not have confidence in a medical test or treatment if experts had conflicting opinions about it.			Intellectual Product	Attitudes and Preferences Questionnaire
C125566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125566>	C173812	Conflicting Expert Opinions About a Medical Test or Treatment Would Make Me Upset Question|Conflicting Expert Opinions About a Medical Test or Treatment Would Make Me Upset|Conflicting expert opinions about a medical test or treatment would make me upset	A question about an individual's agreement that conflicting expert opinions about a medical test or treatment would make them upset.			Intellectual Product	Attitudes and Preferences Questionnaire
C125567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125567>	C173812	Not Afraid of Trying a Medical Test or Treatment Even If Experts Had Conflicting Opinions Question|I would not be afraid of trying a medical test or treatment even if experts had conflicting opinions about it|Not Afraid of Trying a Medical Test or Treatment Even If Experts Had Conflicting Opinions	A question about an individual's agreement that they would not be afraid of trying a medical test or treatment even if experts had conflicting opinions about it.			Intellectual Product	Attitudes and Preferences Questionnaire
C125568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125568>	C173812	Willing to Try Medical Test or Treatment if Experts Had Conflicting Opinions Question|If experts had conflicting opinions about a medical test or treatment, I would still be willing to try it|Willing to Try Medical Test or Treatment if Experts Had Conflicting Opinions	A question about an individual's agreement that if experts had conflicting opinions about a medical test or treatment, they would still be willing to try it.			Intellectual Product	Attitudes and Preferences Questionnaire
C125569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125569>	C175989|C174127|C173812	Would Avoid Making Decisions About A Medical Test or Treatment if Experts Had Conflicting Opinions Question|I would avoid making a decision about a medical test or treatment if experts had conflicting opinions about it|Would Avoid Making Decisions About A Medical Test or Treatment if Experts Had Conflicting Opinions	A question about an individual's agreement that they would avoid making a decision about a medical test or treatment if experts had conflicting opinions about it.			Intellectual Product	Attitudes and Preferences Questionnaire
C12556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12556>	C12555	Adipocyte|Adipose Cell|Fat Cell|Lipocyte	A connective tissue cell that is specialized to synthesize and store fat.	Adipocyte		Cell	
C125570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125570>	C226653	Slightly Disagree|Disagree Slightly|Disagree Somewhat|Somewhat Disagree	A response indicating that an individual is in slight disagreement with something.			Intellectual Product	Attitudes and Preferences Questionnaire|BREAST-Q
C125571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125571>	C176244	Slightly Agree|Agree Slightly|Agree Somewhat|Slightly|Somewhat Agree	A response indicating that an individual is in slight agreement with something.			Intellectual Product	Attitudes and Preferences Questionnaire|Breast Cancer Prevention Trial Symptom Scales|BREAST-Q
C125572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125572>	C20745	MYO15A Gene|MYO15A|MYO15A|Myosin XVA Gene	This gene plays a role in the structure of stereocilia.			Gene or Genome	
C125573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125573>	C125572	MYO15A wt Allele|DFNB3|MYO15|Myosin XV Gene|Myosin XVA wt Allele	Human MYO15A wild-type allele is located in the vicinity of 17p11.2 and is approximately 71 kb in length. This allele, which encodes unconventional myosin-XV protein, is involved in the formation of stereocilia. Mutation of the gene is associated with autosomal recessive deafness 3.			Gene or Genome	
C125574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125574>	C16492	Unconventional Myosin-XV|MYO15A|Myosin XV|Myosin-15|Myosin-XV|Unconventional Myosin-15	Unconventional myosin-XV (3530 aa, ~395 kDa) is encoded by the human MYO15A gene. This protein plays a role in stereocilia organization.			Amino Acid, Peptide, or Protein	
C125575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125575>	C21295	MORC2 Gene|MORC Family CW-Type Zinc Finger 2 Gene|MORC2|MORC2	This gene may be involved in the regulation of fatty acid metabolism.			Gene or Genome	
C125576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125576>	C125575	MORC2 wt Allele|AC004542.C22.1|KIAA0852|MORC Family CW-Type Zinc Finger 2 wt Allele|Microrchidia, Mouse, Homolog of, 2 Gene|ZCW3|ZCWCC1|Zinc Finger, CW Type With Coiled-Coil Domain 1 Gene|Zinc Finger, CW-Type With Coiled-Coil Domain 1 Gene	Human MORC2 wild-type allele is located in the vicinity of 22q12.2 and is approximately 43 kb in length. This allele, which encodes MORC family CW-type zinc finger protein 2, may play a role in lipid metabolism. Variation of the gene is associated with autosomal dominant axonal Charcot-Marie-Tooth disease type 2Z.			Gene or Genome	
C125577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125577>	C17728	MORC Family CW-Type Zinc Finger Protein 2|MORC2|Zinc Finger CW Domain Protein 3|Zinc Finger CW Domain- And Coiled-Coil Domain-Containing Protein 1|Zinc Finger CW-Type Coiled-Coil Domain Protein 1	MORC family CW-type zinc finger protein 2 (1032 aa, ~118 kDa) is encoded by the human MORC2 gene. This protein may be involved in fatty acid metabolism.			Amino Acid, Peptide, or Protein	
C125578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125578>	C21295	OSBP2 Gene|OSBP2|OSBP2|Oxysterol Binding Protein 2 Gene	This gene plays a role in binding to oxysterols.			Gene or Genome	
C125579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125579>	C125578	OSBP2 wt Allele|HLM|KIAA1664|ORP-4|ORP4|OSBPL1|OSBPL4|Oxysterol Binding Protein 2 wt Allele	Human OSBP2 wild-type allele is located in the vicinity of 22q12.2 and is approximately 214 kb in length. This allele, which encodes oxysterol-binding protein 2, is involved in 7-ketocholesterol binding.			Gene or Genome	
C12557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12557>	C48695	Chondrocyte|Chondrocytes|chondrocyte	A cell arising from mesenchymal stem cells that produces and is surrounded by the extracellular matrix of cartilage.	Chondrocyte		Cell	
C125580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125580>	C17728	Oxysterol-Binding Protein 2|ORP-4|OSBP-Related Protein 4|OSPB2|Oxysterol Binding Protein-Like 1|Oxysterol-Binding Protein-Related Protein 4	Oxysterol-binding protein 2 (916 aa, ~101 kDa) is encoded by the human OSBP2 gene. This protein plays a role in binding to oxidized forms of cholesterol.			Amino Acid, Peptide, or Protein	
C125581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125581>	C36292	Pathology Result|Pathologic Examination Result|Pathologic Result	The outcome of a pathologic examination.			Finding	
C125582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125582>	C20744	SCRIB Gene|SCRIB|SCRIB|Scribbled Planar Cell Polarity Protein Gene	This gene is involved in the establishment of cell polarity.			Gene or Genome	
C125583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125583>	C125582	SCRIB wt Allele|CRIB1|Circletail, Mouse, Homolog of Gene|KIAA0147|LAP4|SCRB1|SCRIB1|Scribble 1 Gene|Scribble, Drosophila, Homolog of Gene|Scribbled Homolog (Drosophila) Gene|Scribbled Homolog Gene|Scribbled Planar Cell Polarity Protein wt Allele|VARTUL|Vartul	Human SCRIB wild-type allele is located in the vicinity of 8q24.3 and is approximately 24 kb in length. This allele, which encodes protein scribble homolog, plays a role in the differentiation of polarized cells.			Gene or Genome	
C125584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125584>	C18073	Protein Scribble Homolog|Protein LAP4|Scribble|hScrib	Protein scribble homolog (1630 aa, ~175 kDa) is encoded by the human SCRIB gene. This protein is involved in cell polarization.			Amino Acid, Peptide, or Protein	
C125585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125585>	C20194	ANP32A Gene|ANP32A|ANP32A|Acidic Nuclear Phosphoprotein 32 Family Member A Gene	This gene plays a role in tumor suppression, cell proliferation, transcriptional repression and many other cellular processes.			Gene or Genome	
C125586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125586>	C125585	ANP32A wt Allele|Acidic (Leucine-Rich) Nuclear Phosphoprotein 32 Family, Member A Gene|Acidic Leucine-Rich Nuclear Phosphoprotein 32 Family, Member A Gene|Acidic Nuclear Phosphoprotein 32 Family Member A wt Allele|C15orf1|HPPCn|I1PP2A|LANP|MAPM|PHAP1|PHAPI|PP32	Human ANP32A wild-type allele is located in the vicinity of 15q23 and is approximately 42 kb in length. This allele, which encodes acidic leucine-rich nuclear phosphoprotein 32 family member A protein, is involved in number of cellular processes, including cellular proliferation and differentiation, apoptosis, tumor suppression, inhibition of protein phosphatase 2A and acetyltransferases, regulation of mRNA trafficking and stability, and transcriptional repression.			Gene or Genome	
C125587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125587>	C18466	Acidic Leucine-Rich Nuclear Phosphoprotein 32 Family Member A|ANP32A|Acidic Nuclear Phosphoprotein Pp32|Cerebellar Leucine Rich Acidic Nuclear Protein|Hepatopoietin Cn|Inhibitor-1 of Protein Phosphatase-2A|LANP|Leucine-Rich Acidic Nuclear Protein|Mapmodulin|PHAP I|PHAPI|Potent Heat-Stable Protein Phosphatase 2A Inhibitor I1PP2A|Putative HLA-DR-Associated Protein I|Putative Human HLA Class II Associated Protein I|Putative Human HLA Class II-Associated Protein I|pp32	Acidic leucine-rich nuclear phosphoprotein 32 family member A (249 aa, ~29 kDa) is encoded by the human ANP32A gene. This protein plays a role in enzyme inhibition, transcriptional regulation, apoptosis, mRNA localization and stability, cell proliferation and differentiation, and tumor suppression.			Amino Acid, Peptide, or Protein	
C125588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125588>	C212945	CSNK1D Gene|CSNK1D|CSNK1D|Casein Kinase 1, Delta Gene	This gene is involved in cellular growth and survival processes.			Gene or Genome	
C125589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125589>	C125588	CSNK1D wt Allele|ASPS|CKIdelta|Casein Kinase 1, Delta wt Allele|FASPS2|HCKID	Human CSNK1D wild-type allele is located in the vicinity of 17q25 and is approximately 35 kb in length. This allele, which encodes casein kinase I isoform delta protein, plays a role in protein phosphorylation, cellular growth and cellular survival. Mutation of the gene is associated with familial advanced sleep phase syndrome-2.			Gene or Genome	
C12558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12558>	C12657	Macrophage|Macrophages|macrophage	A cell that arises from stem cells and/or bone marrow-derived monocytes that function in different aspects of host defense and tissue repair; such as phagocytosis, cytotoxic activity, and regulation of the immune response (antigen presentation and T-cell activation).	Macrophage		Cell	CTRP Biomarker Terminology|CTRP Terminology
C125590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125590>	C17325	Casein Kinase I Isoform Delta|CKI-Delta|CKId|CSNK1D|Casein Kinase 1 Isoform Delta|EC 2.7.11.1|EC 2.7.11.26|Tau-Protein Kinase CSNK1D	Casein kinase I isoform delta (415 aa, ~47 kDa) is encoded by the human CSNK1D gene. This protein is involved in protein phosphorylation, cell survival and cellular growth.			Amino Acid, Peptide, or Protein|Enzyme	
C125591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125591>	C53543|C28193	Dubowitz Syndrome	A rare, autosomal recessive inherited syndrome characterized by microcephaly, growth retardation, and a small, round, triangular shaped face with a pointed, receding chin, a broad, wide-tipped nose, and wide-set eyes with drooping eyelids.			Disease or Syndrome	Cellosaurus Disease Terminology
C125592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125592>	C53543|C28193	Holt-Oram Syndrome	A rare, autosomal dominant inherited syndrome caused by mutations in the TBX5 gene. It is characterized by skeletal abnormalities in the upper limbs and heart abnormalities.			Disease or Syndrome	Cellosaurus Disease Terminology
C125593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125593>	C53543|C3235	Hyperpipecolatemia|Pipecolic Acidemia	A rare, autosomal recessive inherited metabolic disorder characterized by high levels of pipecolic acid in the blood, leading to neuropathy and hepatomegaly.			Disease or Syndrome	Cellosaurus Disease Terminology
C125594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125594>	C53543	Kniest Dysplasia	A rare, autosomal dominant inherited bone growth disorder caused by mutations in the COL2A1gene. It is characterized by short stature (dwarfism) and other skeletal abnormalities, round, flat face with bulging and wide-set eyes, myopia and retinal detachment that can lead to blindness.			Disease or Syndrome	Cellosaurus Disease Terminology
C125595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125595>	C61267	Mucolipidosis Type IIIA	A lysosomal storage disease characterized by multiple bone formation abnormalities, progressive joint stiffness, developmental abnormalities, hearing loss, hepatosplenomegaly, increased acne, enlarged tongue, and cornea clouding due to accumulation of lipid substances.			Disease or Syndrome	Cellosaurus Disease Terminology
C125596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125596>	C61267	Neuraminidase Deficiency|Mucolipidosis I|Sialidosis Type II	An autosomal recessive inherited lysosomal storage disease characterized by excessive intracellular accumulation and urinary excretion of sialic acid associated with neuraminidase deficiency.			Disease or Syndrome	Cellosaurus Disease Terminology
C125597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125597>	C87125|C3235	Polysyndactyly	A rare anatomical malformation characterized by polydactyly (extra fingers or toes) and syndactyly (webbed fingers or toes).			Disease or Syndrome	Cellosaurus Disease Terminology
C125598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125598>	C34560	Spondylocostal Dysostosis	A rare disorder caused by mutations in the DLL3, MESP2, FNG, or HES7 gene and characterized by abnormal development of bones in the spine and ribs.			Disease or Syndrome	Cellosaurus Disease Terminology
C125599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125599>	C53543|C28193	Weaver Syndrome|WVS|Weaver-Smith Syndrome	A rare syndrome caused by mutations in the EZH2 gene, and rarely mutations in the NSD1 gene. It is characterized by advanced bone age, foot deformities, permanently bent joints, macrocephaly, flattened back of the head, a broad forehead, hypertelorism, large, low-set ears, micrognathia, delayed development of motor skills, and mild intellectual disability.			Disease or Syndrome	CCPS Disease Terminology|Cellosaurus Disease Terminology|Childhood Cancer Predisposition Study Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C12559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12559>	C12657	Epithelioid Cell|Epithelioid Cells	A cell of mononuclear phagocyte system origin that resembles an epithelial cell and is involved in immune granuloma formation.	Epithelioid Cell		Cell	
C1255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1255>	C1420	Tin Ethyl Etiopurpurin|DRG-0268|SnET2|SnET2|Tin, (ethyl tetramethyl-20-phorbinecarboxylato(2-)-N23,N24,N25,N26)-, (SP-4-2)-|tin ethyl etiopurpurin	A synthetic purpurin with photosensitizing activity.  Tin ethyl etiopurpurin preferentially accumulates in tumor cells due to an increased rate of metabolism. Upon exposure to a light source, this agent absorbs light, forming an extended high energy conformational state that produces high quantum yields of singlet oxygen with local cytotoxic effects. (NCI04)			Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125600>	C116518	Off-Label Treatment|Off-Label|Off-Label Use|off-label	The use of an FDA-approved device, drug, or treatment for a purpose other than that for which it was approved.			Health Care Activity	CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C125601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125601>	C156290	Carboplatin/Etoposide/Melphalan Regimen|CEM|CEM Regimen	A regimen containing carboplatin, etoposide and melphalan used for the treatment of childhood neuroblastoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|NCI Drug Dictionary Terminology|Pharmacotherapy Regimens
C125602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125602>	C226911	Left All Decisions Regarding My Treatment to My Doctor|I left all decisions regarding my treatment to my doctor.	A response indicating that an individual left all decisions about treatment to their doctor.			Intellectual Product	Attitudes and Preferences Questionnaire
C125603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125603>	C159200	Bcl-2 Inhibitor BCL201|BCL-201|BCL201|S-55746|S-55746|S55746|Servier 1|Servier-1	A selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon administration, Bcl-2 inhibitor BCL201 binds to and inhibits the activity of Bcl-2. This restores apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in many cancers and plays an important role in the negative regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival.	Bcl-2 Inhibitor BCL201		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125604>	C29731	Conjugated Estrogens/Bazedoxifene|CE/BZA|CE/BZA Formulation|Duavee	A combination preparation of conjugated estrogens and the selective estrogen receptor modulator (SERM) bazedoxifene that can be used for hormone replacement purposes. The conjugated estrogens increase the diminishing levels of estrogen in menopausal and postmenopausal women by binding to and activating estrogen receptors (ERs), which, in turn, bind to estrogen response elements (EREs) in target genes; this results in the transcription of estrogen-regulated genes. Maintaining adequate estrogen levels decreases symptoms such as hot flashes, night sweats, irregular menstruation, fat redistribution, mood swings, sleep disorders, vaginal dryness and osteoporosis. Bazedoxifene specifically binds to and activates ERs in certain tissues, including liver, bone, breast, and endometrium, and also promotes the transcription of estrogen-regulated genes in these tissues. However, bazedoxifene acts as an estrogen antagonist in uterine and breast tissue, thereby blocking the proliferative effects of estrogen-binding to ER-positive cells in these tissues.	Conjugated Estrogens/Bazedoxifene		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C125605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125605>	C128663	EGFR Exon 20 Insertion Mutation|Exon 20 Insertion	Mutation located after the C-helix of the tyrosine kinase domain of EGFR.	EGFR Exon 20 Insertion Mutation		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C125606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125606>	C15222	BRAT Diet	A bland-food diet consisting of bananas, rice, applesauce, and toast. It may be recommended for recovery from an upset stomach or diarrhea.			Food	
C125607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125607>	C177279	P-cadherin-targeting Agent PF-06671008|PF-06671008|PF-06671008	An agent that targets p-cadherin (CDH3), with potential antineoplastic activity. Upon administration, PF-06671008 binds to and inhibits the activity of p-cadherin; this may inhibit both invasion and proliferation of p-cadherin expressing tumor cells. P-cadherin, a cell-surface protein and member of the cadherin family, is overexpressed in a variety of tumors and plays a role in cell adhesion, motility, invasion, and proliferation.	P-cadherin-targeting Agent PF-06671008		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125608>	C20401	Begelomab|BEGELOMAB|BT 5/9|Begedina|SAND-26	A monoclonal antibody against the human dipeptidyl peptidase 4 (dipeptidylpeptidase IV, DPPIV, DPP4; CD26), with potential activity against graft-versus-host disease (GvHD). Upon administration, begelomab binds to CD26 expressed on T-cells. This inhibits the stimulation of T-cells and may prevent GvHD. CD26, a membrane-bound glycoprotein with dipeptidyl peptidase activity, plays a key role in T-cell activation and immune regulation.	Begelomab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C125609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125609>	C17007|C116441	4D PET Scan|4D Gated PET|4D Gated PET Scan|4D PET	Positron emission tomography imaging collected over time. It is designed to capture the internal movement of organs and the metabolism of the tumor.  It creates the most complete and accurate information on the tumor and provides information how the tumor moves with breathing and other body motions.	4D PET Scan		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C12560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12560>	C36832	Foam Cell|Foam Cells|Foamy Macrophage	A type of macrophage that ingests low-density lipoproteins found in fatty deposits on blood vessel walls, resulting in a foamy appearance.	Foam Cell		Cell	
C125610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125610>	C84514	Formalin-Fixed Paraffin-Embedded B-Cell (CD20) Slide|Physical Slide-FFPE B-Cell (CD20) Slide	A biospecimen consisting of formalin-fixed, paraffin embedded CD20-positive B-cells affixed to a slide for light microscopy			Body Substance	
C125611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125611>	C84514	Formalin-Fixed Paraffin-Embedded T-Cell (CD3) Slide|Physical Slide-FFPE T-Cell (CD3) Slide	A biospecimen consisting of formalin-fixed, paraffin embedded CD3-positive B-cells affixed to a slide for light microscopy.			Body Substance	
C125612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125612>	C19477	Formalin-Fixed Paraffin-Embedded B-Cell (CD20) Digital Image|Digital Image-FFPE B-Cell (CD20) Slide	A digital image obtained from a formalin-fixed, paraffin embedded CD20-positive B-cell specimen.			Laboratory or Test Result	
C125613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125613>	C19477	Formalin-Fixed Paraffin-Embedded T-Cell (CD3) Digital Image|Digital Image-FFPE T-Cell (CD3) Slide	A digital image obtained from a formalin-fixed, paraffin embedded CD3-positive T-cell specimen.			Laboratory or Test Result	
C125614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125614>	C25638	Inconsistency Due to Macrodissection|Macrodissection Performed	The inconsistency was caused because macrodissection was performed at the tissue source site to select a region containing an acceptable diagnosis, and the sample histological subtype of the resulting sample was different from the original pathology report.			Finding	
C125615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125615>	C40998	Histological Subtype Different, Other Pathology Review|Other Pathology Review	Pathology analysis not related to the pathologic prescreen review determined a specific histological subtype that is different from the original pathology report.			Finding	
C125616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125616>	C40998	Histological Subtype Different, Pathology Review for this Project|Pathology Review for this Project	The pathologic prescreen review for this project determined that the histologic subtype is different from the pathology report.			Finding	
C125617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125617>	C62289	Depression Subordinate Domain|Depression	The collection of PROMIS item scales that assess negative mood, negative views of the self, negative social cognition, and decreased positive affect and engagement.			Functional Concept	Patient Reported Outcomes Measurement Information System
C125618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125618>	C62289	Sleep Disturbance Subordinate Domain|Sleep Disturbance	The collection of PROMIS item scales that assess perceptions of sleep quality, sleep depth, and restoration associated with sleep; perceived difficulties and concerns with getting to sleep or staying asleep; and perceptions of the adequacy of and satisfaction with sleep.			Functional Concept	Patient Reported Outcomes Measurement Information System
C125619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125619>	C62289	Pain Interference Subordinate Domain|Pain Interference	The collection of PROMIS item scales that assess the consequences of pain on relevant aspects of a person's life, including the impact of pain on social, cognitive, emotional, physical, and recreational activities as well as sleep and enjoyment in life.			Functional Concept	Patient Reported Outcomes Measurement Information System
C12561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12561>	C12607	Foreign Body Giant Cell|Giant Cell, Foreign Body	An assemblage of macrophages that become fused in an inflammatory response to the presence of exogenous material.			Cell	
C125620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125620>	C20401|C163999|C129822	Anti-c-KIT Monoclonal Antibody CDX 0158|Anti-c-KIT Monoclonal Antibody KTN0158|CDX 0158|CDX-0158|CDX-0158|CDX0158|KTN 0158|KTN-0158|KTN0158	A humanized immunoglobulin (Ig) G1 monoclonal antibody against the stem cell factor receptor c-Kit (SCFR; KIT; CD117), with potential antineoplastic and anti-allergic activities. Upon administration, the anti-c-KIT monoclonal antibody CDX 0158 binds to and inhibits the activation of the cell surface antigen c-Kit. This leads to an inhibition of the activation of c-KIT-mediated signal transduction pathways and inhibits cell proliferation in cancer cells expressing c-Kit. In mast cells, inhibition of c-KIT and c-KIT-mediated signaling prevents mast cell activation, degranulation and subsequent cytokine release. c-Kit, a transmembrane protein and receptor tyrosine kinase, is overexpressed in various cell types, including certain cancer cells and mast cells; it plays a key role in the regulation of cell differentiation and proliferation.	Anti-c-KIT Monoclonal Antibody CDX 0158		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125621>	C91105	Global Rating of Change in Joint Pain and Stiffness Questionnaire|GRC-JPS|Global Rating of Change - Joint Pain and Stiffness	A questionnaire designed to measure joint pain and stiffness over a 36 month period.			Intellectual Product	
C125622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125622>	C91102	Change Since Last Time Questionnaire Filled Out Question|Change Since Last Time Questionnaire Filled Out|Change in Joint Pain and Stiffness Since Last Time Questionnaire Filled Out|Change since the last time you filled out a questionnaire	A question about whether an individual has experienced a change in joint pain and stiffness since the last time they filled out a questionnaire.			Intellectual Product	Global Rating of Change in Joint Pain and Stiffness Questionnaire
C125623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125623>	C173346	Level of Joint Pain Question|Joint Pain|Level of Joint Pain|Your level of joint pain is	A question about the level of joint pain experienced by an individual.			Intellectual Product	Global Rating of Change in Joint Pain and Stiffness Questionnaire
C125624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125624>	C2124	Carbon C 14 Anlotinib Hydrochloride|14C-labeled Anlotinib Hydrochloride|[14C] Anlotinib Hydrochloride	A radioconjugate composed of the orally bioavailable hydrochloride salt form of anlotinib, a receptor tyrosine kinase (RTK) inhibitor, labeled with the radioisotope carbon C 14, with potential use for evaluating the pharmacokinetic profile of anlotinib. Upon administration of carbon C 14 anlotinib hydrochloride, anlotinib targets multiple RTKs, including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt cell growth in tumor cells that overexpress these RTKs. Labeling of anlotinib with the radioactive tracer carbon C 14 permits the evaluation of this agent's pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME).			Pharmacologic Substance	NCI Drug Dictionary Terminology
C125625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125625>	C173981	Level of Joint Stiffness Question|Joint Stiffness|Level of Joint Stiffness|Your level of joint stiffness is	A question about the level of joint stiffness experienced by an individual.			Intellectual Product	Global Rating of Change in Joint Pain and Stiffness Questionnaire
C125626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125626>	C175309	Very Much Better|Very much better	A subjective response indicating that something is very much better.			Intellectual Product	Global Rating of Change in Joint Pain and Stiffness Questionnaire
C125627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125627>	C175309	Moderately Better|Moderately better	A subjective response indicating that something is moderately better.			Intellectual Product	Global Rating of Change in Joint Pain and Stiffness Questionnaire
C125628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125628>	C226692	About the Same Response|About the same	A subjective response indicating that something is about the same.			Intellectual Product	Global Rating of Change in Joint Pain and Stiffness Questionnaire
C125629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125629>	C175310	Moderately Worse|Moderately worse	A subjective response indicating that something is moderately worse.			Intellectual Product	Global Rating of Change in Joint Pain and Stiffness Questionnaire
C12562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12562>	C12607	Langhans Cell|Langhans' - Type Giant Cell				Cell	
C125630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125630>	C175310	Very Much Worse|Very Much Worsened|Very much worse|Very much worsened	A subjective response indicating that something is very much worse.			Intellectual Product	Global Rating of Change in Joint Pain and Stiffness Questionnaire|Sexual Adjustment and Body Image Scale for Gynecologic Cancer
C125631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125631>	C62761	Opolimogene Capmilisbac|ADU-741|JNJ-64041809|JNJ-809|OPOLIMOGENE CAPMILISBAC	A proprietary, live-attenuated, double-deleted (LADD) strain of the Gram-positive bacterium Listeria monocytogenes (Lm) encoding multiple, as of yet undisclosed, tumor-associated antigens (TAAs), with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, opolimogene capmilisbac is taken up by antigen-presenting cells (APCs), including dendritic cells (DCs). The TAAs are subsequently expressed by the APCs and then processed and presented to the immune system by both major histocompatibility complex (MHC) class I and II molecules. This activates the immune system and leads to the recruitment and activation of cytotoxic T-lymphocytes (CTLs) against the TAA-expressing tumor cells, eventually resulting in tumor cell lysis. Two genes contributing to the virulence of Lm have been removed to minimize the risk of infection.	Opolimogene Capmilisbac		Bacterium|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125632>	C448	Shi Pi Yin Herbal Decoction|Shi Pi Decoction|Shi Pi TCM Herbal Decoction|Shi Pi Traditional Chinese Medicine Herbal Decoction|Shi Pi Yin|Shi-pi-yin	A traditional Chinese medicine (TCM) decoction containing a mixture of Aconiti lateral root, Zingiberis (ginger) root, Fu Ling (Poria), Atractylodis macrocephalae, Chaenomelis fruit (flowering quince fruit), magnolia bark, Aucklandia costus root, Arecae pericarpium, Tsao-Ko (cardamon) fruit, and licorice root, and may also contain Arecae seeds and Ziziphus jujuba fruit (red date), which may be used to treat edema. Although the exact mechanism(s) of action through which Shi Pi Yin decoction exerts its effect has yet to be fully elucidated, upon oral administration, this TCM may reduce edema.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C125633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125633>	C129826	Anti-Epidermal Growth Factor Receptor 2 Antibody Expressing Pluripotent Killer T-Lymphocytes|Anti-ERBB2 Antibody Expressing Pluripotent Killer T-Cells|Anti-ERBB2 Antibody Expressing Pluripotent Killer T-Lymphocytes|Anti-Epidermal Growth Factor Receptor 2 Antibody Expressing Pluripotent Killer T-Cells|Anti-HER2 Antibody Expressing Pluripotent Killer T-Cells|Anti-HER2 Antibody Expressing Pluripotent Killer T-Lymphocytes|PIK-HER2	A specific population of pluripotent killer (PIK) T-cells that have been induced to express high levels of antibodies against human epidermal growth factor receptor 2 (ERBB2; HER2), with potential antitumor activity. Although the exact mechanism(s) of action through which PIK-HER2 cells exert their effects has yet to be elucidated, upon infusion, these cells secrete antibodies targeting HER2 expressed on the surface of tumor cells. This may inhibit HER2-dependent signaling, which may lead to inhibition of cellular proliferation and differentiation. Additionally, these cells may stimulate the host immune system to mount both a highly-specific cytotoxic T-lymphocyte (CTL) response and antibody-dependent cell cytotoxicity (ADCC) directed against HER2-overexpressing tumors, which leads to tumor cell lysis. HER2 is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases and is frequently overexpressed in solid tumors.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125634>	C129826	Dendritic Cell-Precision Multiple Antigen T-Lymphocytes|DC-PMAT|Dendritic Cell-Precision Multiple Antigen T-Cells	A preparation of dendritic cell-precision multiple antigen T-cells (DC-PMAT) that have been induced to specifically target multiple undisclosed tumor-associated antigens (TAAs), with potential antitumor activity. Although the exact mechanism(s) of action through which DC-PMAT cells exert their effects has yet to be elucidated, upon infusion, these cells may stimulate the host immune system to mount a highly-specific cytotoxic T-lymphocyte (CTL) response against tumors expressing common TAAs, which leads to tumor cell lysis.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125635>	C91105	Breast Cancer Prevention Trial Symptom Scales|BCPT|BCPTSS|Breast Cancer Prevention Trial Symptom Scales (BCPT)	A questionnaire designed to assess side effects, and to examine correlates, of the derived symptom dimensions among patient populations who had previously been diagnosed with breast cancer or were at risk for the disease.			Intellectual Product	
C125636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125636>	C76369	Mycobacterium mucogenicum|MYCOLICIBACTERIUM MUCOGENICUM|Mycolicibacterium mucogenicum	A species of nonpigmented, nonmotile, and weakly Gram-positive bacteria in the family Mycobacteriaceae. M. mucogenicum has been identified as a water contaminant in hospitals and infection is associated with clinical diseases in both immunocompromised and immunocompetent individuals. The species is tolerant to disinfection by chlorination and extreme temperatures, and to traditional antimycobacterial agents, but is susceptible to amikacin, imipenem, cefoxitin, clarithromycin, ciprofloxacin, the new fluoroquinolones, and trimethoprim/sulfamethoxazole.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125637>	C120539	Mucorales|MUCORALES|Mucoromycotan Fungi|Pin Molds	An order of fungi in the subdivision Mucoromycotina. Mucorales species are typically fast-growing, with wide hyphae lacking septa; the hyphae may be simple or ramified and support sac-like sporangia filled with asexual sporangiospores. Many species are known to damage stored food, but others can cause mycosis, generally in patients already infected with other diseases.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125638>	C112030	Chikungunya Virus|CHIKUNGUNYA VIRUS	A species of alpha virus in the Togaviridae family. The virus is transmitted to people by mosquitoes. The most common symptoms of chikungunya virus infection are fever and joint pain.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125639>	C14203	Enterovirus D68|ENTEROVIRUS D68|EV-D68|EV-D68|Enterovirus 68|Enterovirus D68 (EV-D68)|Human Enterovirus 68|Human Enterovirus D68|Human Enterovirus D68|Human Enterovirus EV68|Human enterovirus 68	A species of enterovirus in the family Picornaviridae. EV-D68 can cause respiratory illness with symptoms ranging from runny nose, sneezing, cough, and body and muscle aches to wheezing and difficulty breathing.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12563>	C43251|C12558|C12555	Histiocyte|Fixed Macrophage|Mature Tissue Histiocyte	A macrophage present in connective tissue.	Histiocyte		Cell	
C125640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125640>	C125956	Human Metapneumovirus|HMPV|HUMAN METAPNEUMOVIRUS|hMPV	A species of nonsegmented, negative-strand ssRNA viruses in the family Paramyxoviridae. Infections with human metapneumovirus can cause upper and lower respiratory tract infections in patients of all ages. This virus is second only to respiratory syncytial virus as the most commonly identified cause of pediatric lower respiratory illness.	Human Metapneumovirus		Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Disease Terminology|CTRP Terminology
C125641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125641>	C75532	Human Parainfluenza Virus|HPIV|HUMAN PARAINFLUENZA VIRUS	A non-taxonomic group of paramyxoviruses that are cause of respiratory tract infections in humans. Infection is most common in infants and young children and symptoms may include fever, runny nose, and cough. Infection is usually self-limiting but can also cause more severe illness, such as croup or pneumonia.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125642>	C14376	Helminth|Helminths	A non-taxonomic group of parasitic worms. The term may be used to describe flatworms (Platyhelminthes), namely cestodes (tapeworms) and trematodes (flukes), and roundworms (Nematoda). These are common infectious agents of humans in developing countries.			Classification	
C125643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125643>	C125924	Strongyloides stercoralis|STRONGYLOIDES STERCORALIS	A species of human pathogenic parasitic roundworm in the family Strongyloididae. The species alternates between free-living and parasitic cycles, with the potential for autoinfection and multiplication within the host. Infection with S. stercoralis usually results in asymptomatic chronic infestation of the gut, but may also cause a severe, persistent diarrhea.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125644>	C75538	Toxoplasma gondii|TOXOPLASMA GONDII	A species of obligate intracellular, parasitic protozoa in the family Sarcocystidae. Birds and rodents act as intermediate hosts with wild and domestic cats acting as the definitive hosts. Animals bred for human consumption may also become infected with tissue cysts after ingestion of sporulated oocysts in the environment. Humans may become infected by ingestion of contaminated meat or water or through contact with feline feces. More rarely, infection may occur by congenital transmission or by receiving infected infected blood or organs.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125645>	C172982	Bothered by Hot Flashes Question|Bothered by Hot Flashes|Hot flashes|Hot flushes or flashes	A question about whether an individual is or was bothered by hot flashes.			Intellectual Product	Breast Cancer Prevention Trial Symptom Scales|Menopause-specific Quality of Life Questionnaire
C125646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125646>	C173130|C172982	Bothered by Nausea Question|Bothered by Nausea|Nausea	A question about whether an individual is or was bothered by nausea.			Intellectual Product	Breast Cancer Prevention Trial Symptom Scales
C125647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125647>	C173604|C172982	Bothered by Vomiting Question|Bothered by Vomiting|Vomiting	A question about whether an individual is or was bothered by vomiting.			Intellectual Product	Breast Cancer Prevention Trial Symptom Scales
C125648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125648>	C173398|C172982	Bothered by Difficulty with Bladder Control when Laughing or Crying Question|Bothered by Difficulty with Bladder Control when Laughing or Crying|Difficulty with bladder control when laughing or crying	A question about whether an individual is or was bothered by difficulty with bladder control when laughing or crying.			Intellectual Product	Breast Cancer Prevention Trial Symptom Scales
C125649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125649>	C173398|C172982	Bothered by Difficulty with Bladder Control at Other Times Question|Bothered by Difficulty with Bladder Control at Other Times|Difficulty with bladder control at other times	A question about whether an individual is or was bothered by difficulty with bladder control at other times.			Intellectual Product	Breast Cancer Prevention Trial Symptom Scales
C12564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12564>	C12558	Kupffer Cell|Kupffer Cells|Kupffer's Cell|Stellate Sinusoidal Macrophage	Large star-shaped or pyramidal cells with a large oval nucleus and a small prominent nucleolus. These intensely phagocytic cells line the walls of the sinusoids of the liver and form a part of the reticuloendothelial system.	Kupffer Cell		Cell	
C125650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125650>	C172982	Bothered by Vaginal Dryness Question|Bothered by Vaginal Dryness|Vaginal dryness	A question about whether an individual is or was bothered by vaginal dryness.			Intellectual Product	Breast Cancer Prevention Trial Symptom Scales
C125652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125652>	C245	Liposomal Bupivacaine|Bupivacaine Liposome Injectable Suspension|Exparel	A liposome-encapsulated formulation of bupivacaine, which is an amide-type, long-acting local anesthetic. Upon administration, bupivacaine reversibly binds to specific sodium ion channels in the neuronal membrane, resulting in both a decrease in the voltage-dependent membrane permeability to sodium ions and membrane stabilization. This leads to inhibition of both depolarization and nerve impulse conduction, and a reversible loss of sensation. Compared to bupivacaine alone, liposomal delivery increases the duration of local anesthetic action and delays the peak plasma concentration of bupivacaine due to its slow release from the liposome.	Liposomal Bupivacaine		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C125653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125653>	C265	Vortioxetine Hydrobromide|1-(2-((2,4-Dimethylphenyl)sulfanyl)phenyl)piperazine Monohydrobromide|Brintellix|Piperazine, 1-(2-((2,4-dimethylphenyl)thio)phenyl)-, Hydrobromide (1:1)|Trintellix|VORTIOXETINE HYDROBROMIDE	A hydrobromide salt form of vortioxetine, a serotonin (5-HT) modulator and stimulator (SMS), with antidepressant activity. Vortioxetine inhibits the reuptake of serotonin and norepinephrine from the synaptic cleft and acts variably as a serotonin receptor agonist (5-HT1A), partial agonist (5-HT1B) or antagonist (5-HT3, 5-HT1D and 5-HT7). It is not clear how this agent's purported multimodal mechanism of action contributes to its antidepressant effect; however, it is presumed to increase the synaptic availability of serotonin and norepinephrine.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C125654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125654>	C129826	Anti-Programmed Cell Death Protein 1 Antibody Expressing Pluripotent Killer T-Lymphocytes|Anti-PD-1 Antibody Expressing Pluripotent Killer T-Cells|Anti-PD-1 Antibody Expressing Pluripotent Killer T-Lymphocytes|Anti-PDCD1 Antibody Expressing Pluripotent Killer T-Cells|Anti-PDCD1 Antibody Expressing Pluripotent Killer T-Lymphocytes|Anti-Programmed Cell Death Protein 1 Antibody Expressing Pluripotent Killer T-Cells|PIK-PD-1	A specific population of pluripotent killer (PIK) T-cells that have been induced to express high levels of antibodies against the negative immunoregulatory human cell surface receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential antitumor activity. Although the exact mechanism(s) of action through which PIK-PD-1 cells exert their effects has yet to be elucidated, upon infusion, these cells secrete antibodies that target PD-1 expressed on the surface of activated T-cells and tumor cells. This may block the interaction of PD-1 with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1; CD274) and PD-1 ligand 2 (PD-L2, PD-1L2; CD273). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation; PD-L1 is overexpressed on certain cancer cells, and PD-L2 is primarily expressed on antigen presenting cells (APCs).			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125655>	C71972	Smoked Plum|Black Plum|Chinese Plum|Japanese Apricot|Mume Fruit|PRUNUS MUME FRUIT|Wu Mei	The fruit of the Prunus mume tree that is used as a traditional Chinese medicine (TCM) called Wu Mei, which may be used to promote hydration and improve bowel function. Although the exact mechanism(s) of action through which this TCM exerts its effect has yet to be fully elucidated, upon oral administration, this TCM may reduce dehydration and improve peristalsis in the bowel.			Food	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C125656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125656>	C511	Methotrexate-Encapsulating Autologous Tumor-Derived Microparticles|MTX-ATMP	A suspension of autologous tumor-derived microparticles (ATMP), that are harvested from a patient with malignant pleural effusion, encapsulating the antimetabolic drug methotrexate (MTX), with potential anticancer activity. Although the exact mechanism(s) of action through which this agent exerts its effect has yet to be fully elucidated, upon administration of MTX-ATMP, the MTX moiety is released and internalized by tumor cells. It then binds to and inhibits the enzyme dihydrofolate reductase. This results in the inhibition of purine nucleotide synthesis and leads to decreased synthesis of both DNA and RNA, which induces cell death. Presumably, the encapsulation of MTX by the ATMP improves its bioavailability and decreases its toxicity.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125657>	C129824	Ets-family Transcription Factor Inhibitor TK216|TK-216|TK216	A proprietary biologic that inhibits the transcriptional-promoting activity of E26 transformation-specific (Ets, E-twenty-six) family transcription factors, with potential antineoplastic activity. Although the exact mechanism(s) of action through which this agent exerts its effect has yet to be fully elucidated, upon administration, Ets-family transcription factor inhibitor TK216 inhibits transcriptional activation mediated by Ets family proteins, including the oncogenic Ewing sarcoma breakpoint region 1/Friend leukemia virus integration 1 (EWSR1/FLI1; EWS/FLI1) fusion protein. This agent may both inhibit the malignant downstream effects mediated by genomic rearrangements that result in the overexpression of Ets family transcription factors and decrease tumor cell growth and proliferation. A chromosomal translocation t(11;22)(q24;q12) fuses the EWSR1 gene and the FLI1 gene and encodes the EWSR1/FLI1 fusion protein, which is an oncoprotein expressed by peripheral primitive neuroectodermal (pPNET) tumors.	Ets-family Transcription Factor Inhibitor TK216		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125658>	C93144	Fructooligosaccharide/Lactobacillus paracasei/Lactobacillus rhamnosus/Lactobacillus acidophilus/Bifidobacterium lactis Probiotic Supplement|Fructooligosaccharide/L. paracasei/L. rhamnosus/L. acidophilus/B. lactis Probiotic Supplement|LactoFos	A synbiotic nutritional supplement containing fructooligosaccharides (FOS), which are linear chains of fructose units that are linked by beta (2-1) bonds, and probiotic cultures of Lactobacillus paracasei (L. paracasei), L. rhamnosus, L. acidophilus and Bifidobacterium lactis (B. lactis), with gastrointestinal (GI) protective and immunomodulating activities. Upon oral administration, the bacteria in this probiotic supplement help maintain adequate colonization of the GI tract and modulate the composition of the normal microflora. Upon colonization of the GI tract, the probiotic bacteria form a protective barrier that helps maintain the integrity of the epithelial barrier. This will interfere with the attachment of pathogenic bacteria and other harmful substances, prevent inflammation and improve GI function. Additionally, the reconstituted microflora may metabolize FOS, which may promote calcium mobilization into the bloodstream by maintaining a neutral pH in the lower gut.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C125659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125659>	C2139	Ciforadenant|3H-1,2,3-Triazolo(4,5-d)pyrimidin-5-amine, 7-(5-Methyl-2-furanyl)-3-((6-((((3S)-tetrahydro-3-furanyl)oxy)methyl)-2-pyridinyl)methyl)-|Adenosine-A2A Receptor-Targeting Agent CPI-444|CIFORADENANT|CPI-444|V81444	A small molecule immune checkpoint inhibitor of the adenosine A2A receptor (ADORA2A) with potential antineoplastic activity. Upon oral administration, ciforadenant binds to adenosine A2A receptors expressed on the surface of immune cells, including T-lymphocytes, natural killer (NK) cells, macrophages and dendritic cells (DCs). This prevents tumor-released adenosine from interacting with the A2A receptors on these key immune surveillance cells, thereby abrogating adenosine-induced immunosuppression in the tumor microenvironment. This may stimulate anti-tumor immune responses, resulting in tumor regression.	Ciforadenant		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12565>	C12558	Alveolar Macrophage|Pulmonary Macrophage|Pulmonary Macrophages	Phagocytic macrophages on the surface of the pulmonary alveoli.  They ingest foreign substances inhaled into the alveoli.	Alveolar Macrophage		Cell	
C125660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125660>	C21637	Mouse Trisomy 16	A mouse chromosomal abnormality consisting of the presence of a third copy of chromosome 16 in somatic cells. Mice that are trisomic for chromosome 16 offer a genetic model for studies relevant to Down syndrome.			Cell or Molecular Dysfunction	Cellosaurus Disease Terminology
C125661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125661>	C53543|C3235	Carnosinemia|Carnosinase Deficiency	A rare autosomal recessive metabolic disorder caused by mutation in CNDP1 gene. It is characterized by deficiency of carnosinase and manifests with severe mental defects and myoclonic seizures.			Disease or Syndrome	Cellosaurus Disease Terminology
C125662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125662>	C84476	Carotid Artery Dissection|Dissection of carotid artery	Spontaneous or traumatic separation of the layers of the carotid artery wall. It manifests with headache, neck pain, temporary vision loss, and/or ischemic stroke.			Disease or Syndrome	Cellosaurus Disease Terminology|mCode Elixhauser Peripheral Vascular Disease Value Set|mCode Terminology
C125663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125663>	C3235	Combined Oxidative Phosphorylation Deficiency 1|COXPD1	A progressive, fatal autosomal recessive disorder. It results from a defect in the mitochondrial oxidative phosphorylation system. It manifests with growth retardation, microcephaly, hypertonicity, axial hypotonia, encephalopathy, cardiomyopathy, and liver dysfunction.			Disease or Syndrome	Cellosaurus Disease Terminology
C125664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125664>	C53543	Pain Agnosia|Analgesia	Loss of the ability to perceive and process pain.			Disease or Syndrome	
C125665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125665>	C85865|C28193	Cerebral Creatine Deficiency Syndrome 1|CCDS1|X-Linked Creatine Transporter Deficiency	A rare X-linked inherited disorder. It is caused by mutations in the SLC6A8 gene resulting in the absence of a compound needed to transport creatine into cells. It manifests with intellectual disability, seizures, short stature, and midface hypoplasia.			Disease or Syndrome	Cellosaurus Disease Terminology
C125666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125666>	C275	MnSOD Mimetic BMX-001|BMX-001|BMX-001|Manganese (III) ortho N-Butoxyethylpyridylporphyrin|Manganese Butoxyethyl Pyridyl Porphyrin|Manganese(5+), ((2,2',2'',2'''-(21H,23H-porphine-5,10,15,20-tetrayl-kappaN21,kappaN22,kappaN23,kappaN24)tetrakis(1-(2-butoxyethyl)pyridiniumato))(2-))-, Chloride (1:5), (sp-4-1)-|Mitochondrial Manganese Superoxide Dismutatse Mimetic BMX-001|Mn(III) meso-tetrakis(N-n-butoxyethylpyridinium-2-yl)porphyrin|MnTnBuOE-3-PyP 5+	A third generation, cationic, lipophilic, manganese (Mn) and porphyrin-based mimetic of the human mitochondrial manganese superoxide dismutase (MnSOD), with antioxidant and potential chemoprotective activities. Upon administration, MnSOD mimetic BMX-001 is internalized by cells and mimics the activity of MnSOD by scavenging reactive oxygen species (ROS), such as superoxide anion, hydrogen peroxide, and hydroxyl radical. This prevents oxidative damage to macromolecules such as DNA and minimizes oxygen free radical-related chemotoxicity in normal tissues. This agent was designed to be more lipophilic and less toxic than first and second generation Mn-porphyrin mimetics.	MnSOD Mimetic BMX-001		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C125667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125667>	C129826	Autologous Interferon-producing Killer Dendritic Cells|Autologous IKDC|Autologous IKDC-like Cells	A preparation of autologous dendritic cells (DC) with a molecular expression profile similar to both natural killer (NK) cells and DCs, with potential antineoplastic activity. Autologous interferon-producing killer dendritic cells (IKDCs) are characterized by double-negative expression of CD3 and CD19; these cells also express low levels of CD11 and are positive for B220. They are distinguished from plasmacytoid DCs (pDCs) by the absence of lymphocyte antigen 6C (Ly6C, Gr-1) expression. IKDCs produce interferon gamma (IFN-gamma) and interleukin (IL) -12, and are able to kill typical NK target cells using NK receptors while retaining DC-like antigen-presenting activity. Upon administration of the autologous IKDCs, these cells secrete high levels of IFN-gamma and, when in contact with tumor cells, mediate TNF-related apoptosis-inducing ligand (TRAIL)-dependent direct lysis of tumor cells. The resulting apoptotic tumor antigens may be presented by the IKDCs, thus activating the immune system to exert a cytotoxic T-lymphocyte (CTL) response to further eliminate tumor cells.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125668>	C19928	BCL2L1 Gene Product	A protein encoded by the human BCL2L1 gene.			Amino Acid, Peptide, or Protein	
C125669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125669>	C173346|C172982	Bothered by Pain with Intercourse Question|Bothered by Pain with Intercourse|Pain with intercourse	A question about whether an individual is or was bothered by pain with intercourse.			Intellectual Product	Breast Cancer Prevention Trial Symptom Scales
C12566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12566>	C12558	Peritoneal Macrophage|Peritoneal Macrophages	A differentiated macrophage that resides in the serosal peritoneal membrane and plays an important role in the defense against peritoneal cavity infections.	Peritoneal Macrophage		Cell	
C125670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125670>	C173346|C172982	Bothered by General Aches and Pains Question|Bothered by General Aches and Pains|General aches and pains	A question about whether an individual is or was bothered by general aches and pains.			Intellectual Product	Breast Cancer Prevention Trial Symptom Scales
C125671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125671>	C173346|C172982	Bothered by Joint Pains Question|Bothered by Joint Pains|Joint pains	A question about whether an individual is or was bothered by joint pains.			Intellectual Product	Breast Cancer Prevention Trial Symptom Scales
C125672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125672>	C172982	Bothered by Muscle Stiffness Question|Bothered by Muscle Stiffness|Muscle stiffness	A question about whether an individual is or was bothered by muscle stiffness.			Intellectual Product	Breast Cancer Prevention Trial Symptom Scales
C125673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125673>	C172982	Bothered by Weight Gain Question|Bothered by Weight Gain|Weight gain	A question about whether an individual is or was bothered by weight gain.			Intellectual Product	Breast Cancer Prevention Trial Symptom Scales
C125674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125674>	C176020|C172982	Bothered by Forgetfulness Question|Bothered by Forgetfulness|Forgetfulness	A question about whether an individual is or was bothered by forgetfulness.			Intellectual Product	Breast Cancer Prevention Trial Symptom Scales
C125675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125675>	C176022|C172982	Bothered by the Appearance of My Body Question|Bothered by Unhappiness with the Appearance of My Body|Bothered by the Appearance of My Body|Unhappy with the appearance of my body	A question about whether an individual is or was bothered by unhappiness with the appearance of their body.			Intellectual Product	Breast Cancer Prevention Trial Symptom Scales
C125676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125676>	C172982	Bothered by Night Sweats Question|Bothered by Night Sweats|Night sweats	A question about whether an individual is or was bothered by night sweats.			Intellectual Product	Breast Cancer Prevention Trial Symptom Scales
C125677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125677>	C173398|C172982	Bothered by Difficulty Concentrating Question|Bothered by Difficulty Concentrating|Difficulty concentrating	A question about whether an individual is or was bothered by difficulty concentrating.			Intellectual Product	Breast Cancer Prevention Trial Symptom Scales
C125678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125678>	C172982	Bothered by Being Easily Distracted Question|Bothered by Being Easily Distracted|Easily distracted	A question about whether an individual is or was bothered by being easily distracted.			Intellectual Product	Breast Cancer Prevention Trial Symptom Scales
C125679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125679>	C173593|C172982	Bothered by Arm Swelling Question|Arm swelling (lymphedema)|Bothered by Arm Swelling	A question about whether an individual is or was bothered by arm swelling.			Intellectual Product	Breast Cancer Prevention Trial Symptom Scales
C12567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12567>	C33793	Odontoblast|Odontoblasts	A cell derived from a preodontoblast that secretes predentin. Each odontoblast has a cytoplasmic extension, an odontoblastic process that traverses the thickness of the dentin and helps to maintain the dentin.	Odontoblast		Cell	
C125680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125680>	C172982	Bothered by Decreased Range of Motion in Arm on Surgery Side Question|Bothered by Decreased Range of Motion in Arm on Surgery Side|Decreased range of motion in arm on surgery side	A question about whether an individual is or was bothered by decreased range of motion in arm on surgery side.			Intellectual Product	Breast Cancer Prevention Trial Symptom Scales
C125681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125681>	C176244	Extremely Agree|Extreme Agreement|Extremely	A response indicating that an individual is in extreme agreement with something.			Intellectual Product	Breast Cancer Prevention Trial Symptom Scales
C125683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125683>	C175303	Somewhat Bothered|Somewhat bothered	A response indicating that an individual is or was somewhat bothered.			Intellectual Product	PhenX
C125684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125684>	C226655	A Little Disrupted|Disrupted a little	A response indicating that an individual is or was a little disrupted.			Intellectual Product	PhenX
C125685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125685>	C226655	Quite a Bit Disrupted|Disrupted quite a bit|Quite Disrupted	A response indicating that an individual is or was quite a bit disrupted.			Intellectual Product	PhenX
C125686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125686>	C226655	Somewhat Disrupted|Disrupted somewhat	A response indicating that an individual is or was somewhat disrupted.			Intellectual Product	PhenX
C125687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125687>	C226655	Totally Disrupted|Disrupted totally	A response indicating that an individual is or was totally disrupted.			Intellectual Product	PhenX
C125688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125688>	C91213|C226655	Not at All Disrupted|Not Disrupted|Not disrupted at all	A response indicating that an individual is or was not at all disrupted.			Intellectual Product	PhenX
C125689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125689>	C213308	PhenX|Consensus Measures for Phenotypes and Exposures	A project supported by the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH) with the goal to provide the scientific community with recommended, standard high-priority measures of phenotypes and exposures for use in Genome-wide Association Studies (GWAS) and more generally, epidemiological and biomedical research.			Research Activity	
C12568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12568>	C48762	Osteoblast|Osteoblasts	Cells which secrete an extracellular matrix into which hydroxyapaetite crystals are deposited to form bone.	Osteoblast		Cell	CTRP Biomarker Terminology|CTRP Terminology
C125690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125690>	C272	Antimetabolite FF-10502|FF-10502|FF-10502-01	An antimetabolite with potential antineoplastic activity. Upon administration, FF-10502 is able to enter the nucleus where it inhibits DNA polymerases, thereby preventing DNA synthesis and halting tumor cell proliferation.	Antimetabolite FF-10502		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125691>	C200766|C176018	Autologous Anti-CD19 CAR-expressing T Lymphocytes|Autologous Anti-CD19-CAR T Cells	A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) that targets the human tumor associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR-expressing T lymphocytes bind to and induce selective toxicity against CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.	Autologous Anti-CD19 CAR-expressing T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125692>	C1752|C1663	Multipeptide Vaccine S-588210|S-488210/S-488211|S-588210	A cancer vaccine composed of a combination of the injectable formulations S-488210, which contains the three HLA-A*02:01-restricted peptides up-regulated lung cancer 10 (lymphocyte antigen 6K; LY6K; URLC10), cell division cycle-associated protein 1 (kinetochore protein Nuf2; NUF2; CDCA1) and insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3; KOC1) and S-488211, which contains the two HLA-A*02:01-restricted peptides DEP domain-containing protein 1A (DEPDC1) and M-phase phosphoprotein 1 (kinesin-like protein KIF20B; MPHOSPH1), with potential immunostimulatory and antitumor activities. Upon administration, multipeptide vaccine S-588210 may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing KOC1, CDCA1, URLC10, DEPDC1 or MPHOSPH1 peptides, resulting in tumor cell lysis and decreased tumor growth.	Multipeptide Vaccine S-588210		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125693>	C53543	Atransferrinemia|Congenital Atransferrinemia|Familial Hypotransferrinemia|Hereditary Atransferrinemia	An extremely rare iron overload disorder caused by mutation in the structural gene for transferrin (TF gene). It is characterized by hypochromic microcytic anemia and hemosiderosis.			Disease or Syndrome	Cellosaurus Disease Terminology
C125694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125694>	C53543	Sitosterolemia	An extremely rare autosomal recessive inherited disorder caused by mutations in the ABCG5 or ABCG8 genes. It is characterized by a defective sterolin transporter that impairs the elimination of plant sterols and, to a lesser degree, cholesterol from the body. These fatty substances build up in the tissues including arteries and skin, resulting in atherosclerosis and xanthomas.			Disease or Syndrome	Cellosaurus Disease Terminology
C125695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125695>	C84909|C4802	Striatonigral Degeneration|Striatonigral degeneration	A progressive neurodegenerative disorder caused by a disruption in the connection between the striatum and the substantia nigra. It is a type of multiple system atrophy (MSA). Signs and symptoms include rigidity, instability, impaired speech, and slow movements.			Disease or Syndrome	Cellosaurus Disease Terminology|mCode Elixhauser Neurological Movement Disorder Value Set|mCode Terminology
C125696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125696>	C34568	Ehlers-Danlos Syndrome, Type I	A classic type of Ehlers-Danlos syndrome resulting from autosomal dominant mutation(s) in the COL5A1 gene, encoding collagen alpha-1(V) chain.			Disease or Syndrome	Cellosaurus Disease Terminology
C125697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125697>	C34568	Ehlers-Danlos Syndrome, Type II	A classic type of Ehlers-Danlos syndrome resulting from autosomal dominant mutation(s) in the COL5A2 gene, encoding collagen alpha-2(V) chain.			Disease or Syndrome	Cellosaurus Disease Terminology
C125698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125698>	C34568	Ehlers-Danlos Syndrome, Type III	Ehlers-Danlos syndrome, type III is the hypermobility type Ehlers-Danlos syndrome. In most cases, the cause is unknown. Mutations in the TNXB gene have been found in a very small percentage of cases.			Disease or Syndrome	Cellosaurus Disease Terminology
C125699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125699>	C34568	Ehlers-Danlos Syndrome, Type IV	Ehlers-Danlos syndrome, type IV is the vascular type Ehlers-Danlos syndrome. It results from mutations in the COL3A1 gene.			Disease or Syndrome	Cellosaurus Disease Terminology
C12569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12569>	C48762	Osteocyte|Osteocytes	A cell that is formed when an osteoblast becomes embedded within the bone matrix that it has secreted. Osteoclasts reside in chambers called lacunae that are found in mature bone.	Osteocyte		Cell	
C1256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1256>	C1821	Toremifene|(Z)-2-[4-(4-Chloro-1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine|(Z)-4-Chloro-1,2-diphenyl-1[4-[2-(N,N-dimethylamino)ethoxy]phenyl]-1-butene|Farestone|TOREMIFENE|toremifene	A nonsteroidal triphenylethylene antiestrogen.  Chemically related to tamoxifen, toremifene is a selective estrogen receptor modulator (SERM).  This agent binds competitively to estrogen receptors, thereby interfering with estrogen activity.  Toremifene also has intrinsic estrogenic properties, which are manifested according to tissue type or species. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C125700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125700>	C34568	Ehlers-Danlos Syndrome, Type VI|Ehlers-Danlos Syndrome, Kyphoscoliotic Type, 1	Ehlers-Danlos syndrome, type VI is the kyphoscoliosis type Ehlers-Danlos syndrome. It results from mutations in the PLOD1 gene.			Disease or Syndrome	Cellosaurus Disease Terminology
C125701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125701>	C34568	Ehlers-Danlos Syndrome, Type VII	Ehlers-Danlos syndrome, type VII includes the arthrochalasia type (types VIIA and VIIB) Ehlers-Danlos syndrome, and the dermatosparaxis type (type VIIC) Ehlers-Danlos syndrome. The arthrochalasia type Ehlers-Danlos syndrome is caused by mutations in the COL1A1 gene or the COL1A2 gene. The dermatosparaxis type Ehlers-Danlos syndrome is caused by mutations in the ADAMTS2 gene.			Disease or Syndrome	Cellosaurus Disease Terminology
C125702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125702>	C62505	Fanconi Anemia, Complementation Group A	Fanconi anemia caused by mutations of the FANCA gene. FANCA gene mutations are the most common cause of Fanconi anemia. This gene provides instructions for making a protein that is involved in the Fanconi anemia (FA) pathway.			Disease or Syndrome	Cellosaurus Disease Terminology
C125703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125703>	C62505	Fanconi Anemia, Complementation Group B	Fanconi anemia caused by mutations of the FANCB gene. This gene encodes the protein for complementation group B.			Disease or Syndrome	Cellosaurus Disease Terminology
C125704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125704>	C62505	Fanconi Anemia, Complementation Group C	Fanconi anemia caused by mutations of the FANCC gene. This gene provides instructions for making a protein that delays the onset of apoptosis and promotes homologous recombination repair of damaged DNA.			Disease or Syndrome	Cellosaurus Disease Terminology
C125705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125705>	C62505	Fanconi Anemia, Complementation Group D1	Fanconi anemia caused by mutations of the BRCA2 gene.			Disease or Syndrome	Cellosaurus Disease Terminology
C125706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125706>	C62505	Fanconi Anemia, Complementation Group D2	Fanconi anemia caused by mutations of the FANCD2 gene. This gene is involved in the repair of DNA double-strand breaks, both by homologous recombination and single-strand annealing.			Disease or Syndrome	Cellosaurus Disease Terminology
C125707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125707>	C62505	Fanconi Anemia, Complementation Group F	Fanconi anemia caused by mutations of the FANCF gene. This gene encodes a polypeptide with homology to the prokaryotic RNA-binding protein ROM.			Disease or Syndrome	Cellosaurus Disease Terminology
C125708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125708>	C62505	Fanconi Anemia, Complementation Group G	Fanconi anemia caused by mutations of the FANCG gene.			Disease or Syndrome	Cellosaurus Disease Terminology
C125709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125709>	C62505	Fanconi Anemia, Complementation Group E	Fanconi anemia caused by mutations of the FANCE gene. This is a protein coding gene. It is required for the nuclear accumulation of FANCC and provides a critical bridge between the FA complex and FANCD2.			Disease or Syndrome	Cellosaurus Disease Terminology
C12570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12570>	C48762	Osteoclast|Osteoclasts	A large, multinucleated cell that secretes bone-degrading enzymes in the processes of normal bone remodeling and pathological bone loss. Osteoclasts are derived from macrophages.	Osteoclast		Cell	CTRP Biomarker Terminology|CTRP Terminology
C125710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125710>	C25404	Transfill	The transfer of gas, either in a liquid or gaseous state, from a larger container, or from permanently mounted tanks, into smaller high-pressure cylinders or cryogenic vessels, in a process known as "cascading".  During the transfer, different gases may be mixed together.			Activity	FDA Structured Product Labeling Terminology|SPL Business Operation Terminology
C125711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125711>	C93210|C53543|C28193	KSHV Inflammatory Cytokine Syndrome|KICS|Kaposi-sarcoma Associated Herpesvirus (KSHV) Inflammatory Cytokine Syndrome	A syndrome caused by Kaposi sarcoma-associated herpesvirus (KSHV) infection. It manifests with fever, weight loss, and fluid retention in the legs or abdomen. Patients are at risk of developing KSHV-related cancers including Kaposi sarcoma and lymphoma.	KSHV Inflammatory Cytokine Syndrome		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C125712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125712>	C28193	Immune Reconstitution Inflammatory Syndrome Associated with Kaposi Sarcoma|IRIS-Associated KS|IRIS-KS|KS-Associated IRIS|KS-IRIS|Kaposi Sarcoma Immune Reconstitution Syndrome|Kaposi Sarcoma-Associated Immune Reconstitution Syndrome	A syndrome that occurs in a proportion of patients with HIV infection and Kaposi sarcoma after initiation of highly active antiretroviral therapy. It is characterized by a deterioration in their clinical status, despite control of virologic and immunologic parameters.	Immune Reconstitution Inflammatory Syndrome Associated with Kaposi Sarcoma		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C125714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125714>	C214840	Alvelestat|6-Methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-((5-(methylsulfonyl)pyridin-2-yl)methyl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide|ALVELESTAT|AZD 9668|AZD-9668|AZD9668	An orally bioavailable, selective and reversible inhibitor of human neutrophil elastase (NE), with potential anti-inflammatory activity. Upon administration, alvelestat binds to and inhibits the activity of human NE. This inhibits NE-mediated inflammatory responses, which may prevent lung inflammation and injury, and may improve lung function associated with NE-induced respiratory diseases. NE, a serine protease released by neutrophils during inflammation, is upregulated in a number of respiratory diseases.	Alvelestat		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C125715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125715>	C7600|C148427	Recurrent Acute Myeloid Leukemia, Myelodysplasia-Related|Recurrent Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes|Recurrent Acute Myeloid Leukemia with Myelodysplasia-Related Changes|Recurrent HRMDS|Recurrent Myelodysplastic Syndrome|Relapsed or Refractory HRMDS|Relapsed or Refractory High-Risk Myelodysplastic Syndrome	The reemergence of acute myeloid leukemia, myelodysplasia-related after a period of remission.	Recurrent Acute Myeloid Leukemia with Myelodysplasia-Related Changes		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C125716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125716>	C15322	Expiratory Muscle Strength Training|EMST	High-intensity, low-repetition expiratory exercises designed to promote strength in the expiratory muscles. Expiratory muscle strength training typically uses a pressure threshold device with a regimented treatment protocol. This treatment may benefit individuals with spinal cord injury, chronic obstructive pulmonary disease, multiple sclerosis, Parkinson's disease, voice disorders, and the sedentary elderly.	Expiratory Muscle Strength Training		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C125717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125717>	C2333	Anti-CD33 Antibody-drug Conjugate IMGN779|ADC IMGN779|Anti-CD33 ADC IMGN779|IMGN-779|IMGN779	An antibody-drug conjugate (ADC) consisting of the humanized monoclonal antibody Z4681A conjugated, via a cleavable disulfide linker, to the cytotoxic DNA alkylating agent DGN462, which is an indolino-benzodiazepine dimer containing a mono-imine moiety, with potential antineoplastic activity. The monoclonal antibody portion of anti-CD33 monoclonal antibody-DGN462 conjugate IMGN779 specifically binds to the cell surface antigen CD33 expressed on myeloid leukemia cells; upon internalization, the DGN462 moiety is released, and covalently binds to and alkylates DNA, thereby causing cell cycle arrest, apoptosis and inhibition of cell growth in myeloid leukemia cells that express CD33. CD33 is expressed on normal non-pluripotent hematopoietic stem cells and myeloid leukemia cells.	Anti-CD33 Antibody-drug Conjugate IMGN779		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125718>	C208255|C192655|C141144|C129820	Ontorpacept|ONTORPACEPT|SIRPa-Fc Fusion Protein TTI-621|SIRPaFc|TTI 621|TTI-621|TTI-621	A soluble recombinant antibody-like fusion protein composed of the N-terminal CD47 binding domain of human signal-regulatory protein alpha (SIRPa) linked to the Fc domain of human immunoglobulin G1 (IgG1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, ontorpacept selectively targets and binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with endogenous SIRPa, a cell surface protein expressed on macrophages. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis of cancer cells. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, thereby allowing cancer cells to proliferate.	Ontorpacept		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C125719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125719>	C91105|C21154	Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20 Items|CIPN20 Questionnaire|EOR25|EORTC QLQ-CIPN20|EORTC QLQ-CIPN20	A questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) consisting of 20 questions designed to assess quality of life related to symptoms and functional limitations in patients with Chemotherapy-Induced Peripheral Neuropathy (CIPN).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12571>	C12555	Stromal Cell|Stromal Cells|stromal cell	Connective tissue cells found in the tissue stroma of any organ.	Stromal Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C125720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125720>	C173734	Have Tingling Fingers or Hands Question|Did you have tingling fingers or hands|Have Tingling Fingers or Hands	A question about whether an individual has or had tingling in their fingers or hands.			Intellectual Product	Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20 Items
C125721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125721>	C173734	Have Tingling Toes or Feet Question|Did you have tingling toes or feet|Have Tingling Toes or Feet	A question about whether an individual has or had tingling in their toes or feet.			Intellectual Product	Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20 Items
C125722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125722>	C105777	Have Numbness in Fingers or Hands Question|Did you have numbness in your fingers or hands|Have Numbness in Fingers or Hands	A question about whether an individual has or had numbness in their fingers or hands.			Intellectual Product	Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20 Items
C125723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125723>	C105777	Have Numbness in Toes or Feet Question|Did you have numbness in your toes or feet|Have Numbness in Toes or Feet	A question about whether an individual has or had numbness in their toes or feet.			Intellectual Product	Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20 Items
C125724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125724>	C91126	Have Shooting or Burning Pain in Fingers or Hands Question|Did you have shooting or burning pain in your fingers or hands|Have Shooting or Burning Pain in Fingers or Hands	A question about whether an individual has or had shooting or burning pain in their fingers or hands.			Intellectual Product	Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20 Items
C125725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125725>	C91126	Have Shooting or Burning Pain in Toes or Feet Question|Did you have shooting or burning pain in your toes or feet|Have Shooting or Burning Pain in Toes or Feet	A question about whether an individual has or had shooting or burning pain in their toes or feet.			Intellectual Product	Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20 Items
C125726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125726>	C173981	Have Cramps in Hands Question|Did you have cramps in your hands|Have Cramps in Hands	A question about whether an individual has or had cramps in their hands.			Intellectual Product	Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20 Items
C125727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125727>	C173981	Have Cramps in Feet Question|Did you have cramps in your feet|Have Cramps in Feet	A question about whether an individual has or had cramps in their feet.			Intellectual Product	Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20 Items
C125728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125728>	C173398|C173219	Have Problems Standing or Walking Because of Difficulty Feeling the Ground Under Feet Question|Did you have problems standing or walking because of difficulty feeling the ground under your feet|Have Problems Standing or Walking Because of Difficulty Feeling the Ground Under Feet	A question about whether an individual has or had problems standing or walking because of difficulty feeling the ground under their feet.			Intellectual Product	Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20 Items
C125729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125729>	C173398	Have Difficulty Distinguishing Between Hot and Cold Water Question|Did you have difficulty distinguishing between hot and cold water|Have Difficulty Distinguishing Between Hot and Cold Water	A question about whether an individual has or had difficulty distinguishing between hot and cold water.			Intellectual Product	Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20 Items
C12572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12572>	C41608|C12555	Theca Cell|Ovarian Interstitial Cell|Ovarian Interstitial Cells|Theca Cells	An endocrine cell located in the ovary that functions to produce androgens for estrogen biosynthesis and provide structural support during oocyte maturation.	Theca Cell		Cell	
C125730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125730>	C173981	Have Problem Holding a Pen Which Makes Writing Difficult Question|Did you have a problem holding a pen, which made writing difficult|Have Problem Holding a Pen Which Makes Writing Difficult	A question about whether an individual has or had a problem holding a pen, which makes or made writing difficult.			Intellectual Product	Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20 Items
C125731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125731>	C173398	Have Difficulty Manipulating Small Objects with Fingers Question|Did you have difficulty manipulating small objects with your fingers (for example, fastening small buttons)|Have Difficulty Manipulating Small Objects with Fingers	A question about whether an individual has or had difficulty manipulating small objects with their fingers.			Intellectual Product	Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20 Items
C125732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125732>	C173398	Have Difficulty Opening a Jar or Bottle Because of Weakness in Hands Question|Did you have difficulty opening a jar or bottle because of weakness in your hands|Have Difficulty Opening a Jar or Bottle Because of Weakness in Hands	A question about whether an individual has or had difficulty opening a jar or bottle because of weakness in their hands.			Intellectual Product	Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20 Items
C125733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125733>	C173398|C173135	Have Difficulty Walking Because Feet Drop Downwards Question|Did you have difficulty walking because your feet dropped downwards|Have Difficulty Walking Because Feet Drop Downwards	A question about whether an individual has or had difficulty walking because their feet drop downwards.			Intellectual Product	Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20 Items
C125734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125734>	C173398	Have Difficulty Climbing Stairs or Getting Out of Chair Because of Weakness in Legs Question|Did you have difficulty climbing stairs or getting up out of a chair because of weakness in your legs|Have Difficulty Climbing Stairs or Getting Out of Chair Because of Weakness in Legs	A question about whether an individual has or had difficulty climbing stairs or getting up out of a chair because of weakness in their legs.			Intellectual Product	Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20 Items
C125735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125735>	C173600	Dizzy When Standing Up from a Sitting or Lying Position Question|Dizzy When Standing Up from a Sitting or Lying Position|Were you dizzy when standing up from a sitting or lying position	A question about whether an individual is or was dizzy when standing up from a sitting or lying position.			Intellectual Product	Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20 Items
C125737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125737>	C173398	Have Difficulty Using Car Pedals Question|Did you have difficulty using the pedals|Have Difficulty Using Car Pedals	A question about whether an individual has or had difficulty using the pedals of a car.			Intellectual Product	Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy 20 Items
C125738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125738>	C28108	FIGO Stage|figo stage|figo_stage	A set of staging terms for gynecologic cancers developed by the International Federation of Gynecology and Obstetrics (FIGO).			Classification	GDC Property Terminology|GDC Terminology
C125739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125739>	C128462	BRD4 Inhibitor PLX51107|PLX 51107|PLX-51107|PLX-51107|PLX51107	An inhibitor of the bromodomain-containing protein 4 (BRD4), with potential antineoplastic activity. Upon administration, the BRD4 inhibitor PLX51107 binds to the acetylated lysine recognition motifs in the bromodomains of the BRD4 protein, thereby preventing the binding of BRD4 to acetylated lysines on histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an induction of apoptosis and an inhibition of proliferation in BRD4-overexpressing tumor cells. BRD4, a member of the human bromodomain and extra-terminal (BET) family of proteins, is a transcriptional regulator that is overexpressed in certain tumor cells and plays an important role in cellular proliferation.	BRD4 Inhibitor PLX51107		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12573>	C12485	Endocrine Cell of the Digestive System|Endocrine Cell of Gut|Endocrine Cells of Gut|Gastrointestinal Endocrine Cell|Gastrointestinal Endocrine Cells		Endocrine Cell of Gut		Cell	
C125740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125740>	C100110	CDISC Questionnaire ASEX-Female Version Test Name Terminology|ASEX01TN|Arizona Sexual Experiences Scale - Female Questionnaire Test Name|QS-ASEX-Female Version TEST	Test names of questionnaire questions associated with the Arizona Sexual Experiences Scale-Female Version (ASEX-Female Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125741>	C100110	CDISC Questionnaire ASEX-Female Version Test Code Terminology|ASEX01TC|Arizona Sexual Experiences Scale - Female Questionnaire Test Code|QS-ASEX-Female Version TESTCD	Test codes of questionnaire questions associated with the Arizona Sexual Experiences Scale-Female Version (ASEX-Female Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125742>	C100110	CDISC Questionnaire ASEX-Male Version Test Name Terminology|ASEX02TN|Arizona Sexual Experiences Scale - Male Questionnaire Test Name|QS-ASEX-Male Version TEST	Test names of questionnaire questions associated with the Arizona Sexual Experiences Scale-Male Version (ASEX-Male Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125743>	C100110	CDISC Questionnaire ASEX-Male Version Test Code Terminology|ASEX02TC|Arizona Sexual Experiences Scale - Male Questionnaire Test Code|QS-ASEX-Male Version TESTCD	Test codes of questionnaire questions associated with the Arizona Sexual Experiences Scale-Male Version (ASEX-Male Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125744>	C100110	CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|ED1TN|Expanded Disability Rating Scale - Postacute Interview Caregiver Version Questionnaire Test Name|QS-Expanded DRS-PI Caregiver Version TEST	Test names of questionnaire questions associated with the Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125745>	C100110	CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|ED1TC|Expanded Disability Rating Scale - Postacute Interview Caregiver Version Questionnaire Test Code|QS-Expanded DRS-PI Caregiver Version TESTCD	Test codes of questionnaire questions associated with the Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125746>	C100110	CDISC Questionnaire Expanded DRS-PI Survivor Version Test Name Terminology|ED2TN|Expanded Disability Rating Scale - Postacute Interview Survivor Version Questionnaire Test Name|QS-Expanded DRS-PI Survivor Version TEST	Test names of questionnaire questions associated with the Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125747>	C100110	CDISC Questionnaire Expanded DRS-PI Survivor Version Test Code Terminology|ED2TC|Expanded Disability Rating Scale - Postacute Interview Survivor Version Questionnaire Test Code|QS-Expanded DRS-PI Survivor Version TESTCD	Test codes of questionnaire questions associated with the Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125748>	C100110	CDISC Questionnaire PHQ Screener Version Test Name Terminology|PHQ03TN|Patient Health Questionnaire Screener Version Questionnaire Test Name|QS-PHQ Screener Version TEST	Test names of questionnaire questions associated with the Patient Health Questionnaire Screener Version (PHQ Screener Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125749>	C100110	CDISC Questionnaire PHQ Screener Version Test Code Terminology|PHQ03TC|Patient Health Questionnaire Screener Version Questionnaire Test Code|QS-PHQ Screener Version TESTCD	Test codes of questionnaire questions associated with the Patient Health Questionnaire Screener Version (PHQ Screener Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12574>	C12573	Delta Cell|D Cell|D Cells|Somatostatin Cell|Somatostatin Cells|Somatostatin Secreting Cell	A somatostatin-producing cell found in the stomach, intestines, or pancreas.	D Cell		Cell	
C125750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125750>	C211913	ASEX-Female Version Questionnaire Question	A question associated with the ASEX-Female Version questionnaire.			Intellectual Product	
C125751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125751>	C211913	ASEX-Male Version Questionnaire Question	A question associated with the ASEX-Male Version questionnaire.			Intellectual Product	
C125752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125752>	C211913	Expanded DRS-PI Caregiver Version Questionnaire Question	A question associated with the Expanded DRS-PI Caregiver Version questionnaire.			Intellectual Product	
C125753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125753>	C211913	Expanded DRS-PI Survivor Version Questionnaire Question	A question associated with the Expanded DRS-PI Survivor Version questionnaire.			Intellectual Product	
C125754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125754>	C211913	PHQ Screener Version Questionnaire Question	A question associated with the PHQ Screener Version questionnaire.			Intellectual Product	
C125755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125755>	C177561	AJCC Cancer Staging Manual 7th Edition|7th|AJCC V7|AJCC v7|AJCC1|AJCC7|Seventh Edition (2010)	The 7th edition of the criteria developed by the American Joint Committee on Cancer (AJCC) in 2010, used for the classification and staging of neoplastic diseases.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C125756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125756>	C91105	COPD Assessment Test Questionnaire|CAT|CAT01|COPD ASSESSMENT TEST	A standardized rating scale developed by Jones et al in 2009, which is a self-administered instrument used to measure the health status of patients with COPD. This instrument contains 8 items; each item is scored on a scale from 0 to 5.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125757>	C91105	Arizona Sexual Experiences Scale-Female Version Questionnaire|ASEX-FEMALE|ASEX-Female Version|ASEX01	A standardized rating scale developed by McGahuey et al in 2000, which is used to measure sexual dysfunction. The female version of the instrument contains 5 items and quantifies sex drive, arousal, vaginal lubrication, ability to reach orgasm, and satisfaction from orgasm.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125758>	C91105	Arizona Sexual Experiences Scale-Male Version Questionnaire|ASEX-MALE|ASEX-Male Version|ASEX02	A standardized rating scale developed by McGahuey et al in 2000, which is used to measure sexual dysfunction. The male version of the instrument contains 5 items and quantifies sex drive, arousal, penile erection, ability to reach orgasm, and satisfaction from orgasm.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125759>	C91105	Expanded Disability Rating Scale - Postacute Interview Caregiver Version Questionnaire|ED1|EXPANDED DRS-PI CAREGIVER VERSION|Expanded DRS-PI Caregiver Version	A standardized rating scale developed by Rappaport et al in 1982, which is used to track recovery of an individual from coma to community and to capture functional changes over the course of recovery for individuals with moderate to severe TBI. The caregiver version of this instrument has 30 items.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12575>	C12573	Enterochromaffin Cell|EC Cell|Enterochromaffin|Enterochromaffin Cells	The most abundant and widely distributed type of enteroendocrine cell found in the gastrointestinal tract. It is characterized by serotonin production and an affinity to binding silver and chromium salts.	Enterochromaffin Cell		Cell	
C125760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125760>	C91105	Expanded Disability Rating Scale - Postacute Interview Survivor Version Questionnaire|ED2|EXPANDED DRS-PI SURVIVOR VERSION|Expanded DRS-PI Survivor Version	A standardized rating scale developed by Rappaport et al in 1982, which is used to track recovery of an individual from coma to community and to capture functional changes over the course of recovery for individuals with moderate to severe TBI. The survivor version of this instrument has 26 items.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125761>	C91105	Patient Health Questionnaire Screener Version|PHQ SCREENER VERSION|PHQ Screener Version|PHQ03	A standardized rating scale developed by Spitzer et al in 1999, which is used to screen and diagnose mental health disorders of depression, anxiety, alcohol, eating, and somatoform. The screener version of this instrument contains 59 items.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125762>	C103500	ODI v2.1a - Oswestry Disability Index|ODI01-Oswestry Disability Index|ODI01-Oswestry Disability Index|ODI0111	The Oswestry Disability Index Version 2.1a (ODI v2.1a) Your ODI.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ODI v2.1a Test Code Terminology|CDISC Questionnaire ODI v2.1a Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125763>	C125750	ASEX-Female Version - Sex Drive|ASEX01-Sex Drive|ASEX01-Sex Drive|ASEX0101	Arizona Sexual Experiences Scale-Female Version (ASEX-Female Version) How strong is your sex drive?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ASEX-Female Version Test Code Terminology|CDISC Questionnaire ASEX-Female Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125764>	C125750	ASEX-Female Version - Sexually Aroused|ASEX01-Sexually Aroused|ASEX01-Sexually Aroused|ASEX0102	Arizona Sexual Experiences Scale-Female Version (ASEX-Female Version) How easily are you sexually aroused (turned on)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ASEX-Female Version Test Code Terminology|CDISC Questionnaire ASEX-Female Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125765>	C125750	ASEX-Female Version - Vagina Become Moist|ASEX01-Vagina Become Moist|ASEX01-Vagina Become Moist|ASEX0103	Arizona Sexual Experiences Scale-Female Version (ASEX-Female Version) How easily does your vagina become moist or wet during sex?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ASEX-Female Version Test Code Terminology|CDISC Questionnaire ASEX-Female Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125766>	C125750	ASEX-Female Version - Reach Orgasm|ASEX01-Reach Orgasm|ASEX01-Reach Orgasm|ASEX0104	Arizona Sexual Experiences Scale-Female Version (ASEX-Female Version) How easily can you reach an orgasm?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ASEX-Female Version Test Code Terminology|CDISC Questionnaire ASEX-Female Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125767>	C125750	ASEX-Female Version - Orgasms Satisfying|ASEX01-Orgasms Satisfying|ASEX01-Orgasms Satisfying|ASEX0105	Arizona Sexual Experiences Scale-Female Version (ASEX-Female Version) Are your orgasms satisfying?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ASEX-Female Version Test Code Terminology|CDISC Questionnaire ASEX-Female Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125768>	C125751	ASEX-Male Version - Sex Drive|ASEX02-Sex Drive|ASEX02-Sex Drive|ASEX0201	Arizona Sexual Experiences Scale-Male Version (ASEX-Male Version) How strong is your sex drive?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ASEX-Male Version Test Code Terminology|CDISC Questionnaire ASEX-Male Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125769>	C125751	ASEX-Male Version - Sexually Aroused|ASEX02-Sexually Aroused|ASEX02-Sexually Aroused|ASEX0202	Arizona Sexual Experiences Scale-Male Version (ASEX-Male Version) How easily are you sexually aroused (turned on)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ASEX-Male Version Test Code Terminology|CDISC Questionnaire ASEX-Male Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12576>	C12573	Enterochromaffin-Like Cell|ECL Cell|ECL Cells|Enterochromaffin-like Cells	A type of enteroendocrine cell located in the oxyntic glands of the stomach that releases histamine in regulation of acid secretion. It is morphologically similar to enterochromaffin cells, but lacks an affinity to binding silver salts.	Enterochromaffin-like Cell		Cell	
C125770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125770>	C125751	ASEX-Male Version - Keep Erection|ASEX02-Keep Erection|ASEX02-Keep Erection|ASEX0203	Arizona Sexual Experiences Scale-Male Version (ASEX-Male Version) Can you easily get and keep an erection?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ASEX-Male Version Test Code Terminology|CDISC Questionnaire ASEX-Male Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125771>	C125751	ASEX-Male Version - Reach Orgasm|ASEX02-Reach Orgasm|ASEX02-Reach Orgasm|ASEX0204	Arizona Sexual Experiences Scale-Male Version (ASEX-Male Version) How easily can you reach an orgasm?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ASEX-Male Version Test Code Terminology|CDISC Questionnaire ASEX-Male Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125772>	C125751	ASEX-Male Version - Orgasms Satisfying|ASEX02-Orgasms Satisfying|ASEX02-Orgasms Satisfying|ASEX0205	Arizona Sexual Experiences Scale-Male Version (ASEX-Male Version) Are your orgasms satisfying?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ASEX-Male Version Test Code Terminology|CDISC Questionnaire ASEX-Male Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125773>	C125752	Expanded DRS-PI Caregiver Version - Able to Communicate Clearly|ED1-Able to Communicate Clearly|ED1-Able to Communicate Clearly|ED102_1	Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Is [name] able to communicate with you in a way that you and others clearly understand?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125774>	C125752	Expanded DRS-PI Caregiver Version - How They Communicate Primarily|ED1-How They Communicate Primarily|ED1-How They Communicate Primarily|ED102_2	Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) How do they communicate primarily?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125775>	C125752	Expanded DRS-PI Caregiver Version - Give Correct Date and Time When Asked|ED1-Correct Date and Time|ED1-Correct Date and Time|ED102_3	Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Is [name] able to give the correct date and time within a few seconds of being asked?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125776>	C125752	Expanded DRS-PI Caregiver Version - Use Few Words or Random Shouting|ED1-Few Words or Random Answers/Shouting|ED1-Few Words or Random Answers/Shouting|ED102_4	Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [name] have only a few words that [s/he] uses over and over or does [s/he] express him/herself only through random answers, shouting or swearing?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125777>	C125752	Expanded DRS-PI Caregiver Version - Make Sounds Not Understandable|ED1-Moan/Groan/Sounds Not Understandable|ED1-Moan/Groan/Sounds Not Understandable|ED102_5	Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [name] only moan, groan or make other sounds that are not understandable?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125778>	C125752	Expanded DRS-PI Caregiver Version - Feed Independently Without Help|ED1-Feed Independently Without Help|ED1-Feed Independently Without Help|ED104_1	Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Can [name] feed him/herself independently or manage tube feedings appropriately without help or reminders?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125779>	C125752	Expanded DRS-PI Caregiver Version - Understand Feeding Utensils|ED1-Understand Feeding Utensils|ED1-Understand Feeding Utensils|ED104_2	Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [name] understand what eating or feeding utensils or equipment are for and how they should be used?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12577>	C12573	G-Cell|G Cell|G Cells|Gastrin Cell|Gastrin Cells|Gastrin Secreting Cell	A gastrin-producing enteroendocrine cell that is located in the gastric antrum.	G Cells		Cell	
C125780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125780>	C125752	Expanded DRS-PI Caregiver Version - Know Meal Times|ED1-Know Meal Times|ED1-Know Meal Times|ED104_3	Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [name] know when meal or feeding times are?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125781>	C125752	Expanded DRS-PI Caregiver Version - Use Toilet Independently|ED1-Use Toilet Independently|ED1-Use Toilet Independently|ED105_1	Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Can [name] use the toilet or manage their bowel and bladder routine independently and appropriately without help or reminders?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125782>	C125752	Expanded DRS-PI Caregiver Version - Manage Clothing When Toileting|ED1-Manage Clothing When Toileting|ED1-Manage Clothing When Toileting|ED105_2	Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [name] understand how to manage their clothing or special equipment when toileting or in bowel and bladder management?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125783>	C125752	Expanded DRS-PI Caregiver Version - Know When to Use Toilet|ED1-Know When to Use Toilet|ED1-Know When to Use Toilet|ED105_3	Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [name] know when to use the toilet or to conduct bowel and bladder management?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125784>	C125752	Expanded DRS-PI Caregiver Version - Can Dress and Groom Self Independently|ED1-Can Dress/Groom Independently|ED1-Can Dress/Groom Independently|ED106_1	Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Can [name] dress and groom him/herself independently and appropriately or direct someone else in these activities without help or reminders?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125785>	C125752	Expanded DRS-PI Caregiver Version - Know How to Bathe and Wash|ED1-Know How to Bathe/Wash|ED1-Know How to Bathe/Wash|ED106_2	Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [s/he] know how to bathe and wash?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125786>	C125752	Expanded DRS-PI Caregiver Version - Understand How to Get Dressed|ED1-Understand How to Get Dressed|ED1-Understand How to Get Dressed|ED106_3	Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [s/he] understand how to get dressed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125787>	C125752	Expanded DRS-PI Caregiver Version - Start and Finish Grooming Activities|ED1-Start/Finish Grooming Activities|ED1-Start/Finish Grooming Activities|ED106_4	Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Can [s/he] start and finish these grooming activities without prompting?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125788>	C125752	Expanded DRS-PI Caregiver Version - Function Completely Independently|ED1-Function Completely Independently|ED1-Function Completely Independently|ED107_1	Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [name] function completely independently? That is, [s/he] does not require any physical assistance, supervision, equipment, devices or reminders for cognitive, social, behavioral, emotional, and physical function?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125789>	C125752	Expanded DRS-PI Caregiver Version - Require Special Aids or Equipment|ED1-Require Specific Aids/Equipment|ED1-Require Specific Aids/Equipment|ED107_2	Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [name] REQUIRE special aids or equipment such as a brace, walker, wheelchair, memory notebook, day planner, verbal reminders, prompts, cues, or alarm watch because of a disability?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12578>	C12508	Epithelial Cell|EPITHELIAL CELL|Epithelial Cells	Any of the cells of the epithelium, which covers the body and lines its cavities and glands.	Epithelial Cell		Cell	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125790>	C125752	Expanded DRS-PI Caregiver Version - Require Physical Assistance|ED1-Require Physical Assistance|ED1-Require Physical Assistance|ED107_3	Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [name] require physical assistance from another person to meet daily needs?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125791>	C125752	Expanded DRS-PI Caregiver Version - Require Assistance Thinking Tasks|ED1-Require Assistance Thinking Tasks|ED1-Require Assistance Thinking Tasks|ED107_4	Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [s/he] require assistance from another person in tasks that require thinking abilities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125792>	C125752	Expanded DRS-PI Caregiver Version - Require Assistance Managing Emotions|ED1-Require Assistance Managing Emotions|ED1-Require Assistance Managing Emotions|ED107_5	Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [s/he] require assistance from another person to manage emotions and behavior?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125793>	C125752	Expanded DRS-PI Caregiver Version - Need a Helper Always Close By|ED1-Need a Helper Always Close By|ED1-Need a Helper Always Close By|ED107_6A	Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [s/he] take care of some of their needs but also need a helper who is always close by?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125794>	C125752	Expanded DRS-PI Caregiver Version - Need Help With All Major Activities|ED1-Need Help With All Major Activities|ED1-Need Help With All Major Activities|ED107_6B	Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [s/he] need help with all major activities and the assistance of another person all the time?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125795>	C125752	Expanded DRS-PI Caregiver Version - Need 24-Hour Care|ED1-Need 24-Hour Care|ED1-Need 24-Hour Care|ED107_6C	Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Does [s/he] need 24-hour care and is not able to help with their own care at all?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125796>	C125752	Expanded DRS-PI Caregiver Version - Function With Independent Work or Social Situations|ED1-Independent Work/Social Situations|ED1-Independent Work/Social Situations|ED108_1	Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Can [name] function with complete independence in work or social situations?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125797>	C125752	Expanded DRS-PI Caregiver Version - Understand and Follow Directions|ED1-Understand/Follow Directions|ED1-Understand/Follow Directions|ED108_2	Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Can [name] understand, remember, and follow directions?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125798>	C125752	Expanded DRS-PI Caregiver Version - Keep Track of Time|ED1-Keep Track of Time/Schedules|ED1-Keep Track of Time/Schedules|ED108_3	Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) Can [name] keep track of time, schedules and appointments?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125799>	C125752	Expanded DRS-PI Caregiver Version - Perform Jobs or Manage a Home Independently|ED1-Perform Jobs, Manage Home/School|ED1-Perform Jobs, Manage Home/School|ED108_4	Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) How certain are you that [name] can perform in a wide variety of jobs of [his/her] choosing or manage a home independently or participate in school full-time?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12579>	C33793|C12578	Ameloblast|Ameloblasts	A columnar epithelial cell located in the inner layer of the enamel organ of a developing tooth that plays a role in calcium transport and the synthesis and resorption of enamel matrix proteins.	Ameloblast		Cell	
C1257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1257>	C222	Treosulfan|(S-(R*,R*))-1,2,3,4-butanetetrol,1,4-dimethanesulfonate|1,2,3, 4-Butanetetrol, 1,4-dimethanesulfonate, [R-(R*,S*)]-|Dihydroxybusulfan|Dihydroxybusulfan|Grafapex|L-Threitol 1,4-dimethanesulfonate|Ovastat|TREOSULFAN|Trecondi|Treosulphan|Tresulfon|treosulfan	The prodrug of a bifunctional sulfonate alkylating agent with myeloablative, immunosuppressive, and antineoplastic activities. Under physiological conditions, treosulfan converts nonenzymatically to L-diepoxybutane via a monoepoxide intermediate. The monoepoxide intermediate and L-diepoxybutane alkylate DNA at guanine residues and produce DNA interstrand crosslinks, resulting in DNA fragmentation and apoptosis. In escalated doses, this agent also exhibits myeloablative and immunosuppressive activities.	Treosulfan		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125800>	C125752	Expanded DRS-PI Caregiver Version - Successful With Accommodations|ED1-Successful With Accommodations|ED1-Successful With Accommodations|ED108_5	Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) How certain are you that [name] can be successful at work, school or in home management with some reduction in the work load or with other accommodations due to disabilities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125801>	C125752	Expanded DRS-PI Caregiver Version - Successful With Limited Choices|ED1-Successful With Limited Choices|ED1-Successful With Limited Choices|ED108_6	Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) How certain are you that [name] can be successful at work, school or in home management but with limited choices in jobs or school courses due to disabilities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125802>	C125752	Expanded DRS-PI Caregiver Version - Work With Frequent Supervision and Support|ED1-Work With Frequent Support|ED1-Work With Frequent Support|ED108_7	Expanded Disability Rating Scale - Postacute Interview Caregiver Version (Expanded DRS-PI Caregiver Version) How certain are you that [name] can be able to work at home or in a special setting like a sheltered workshop in which the work is very routine and there is very frequent supervision and support?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Caregiver Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125803>	C125753	Expanded DRS-PI Survivor Version - Give Correct Date and Time When Asked|ED2-Correct Date and Time|ED2-Correct Date and Time|ED202_3	Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Are you able to give the correct date and time within a few seconds of being asked?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125804>	C125753	Expanded DRS-PI Survivor Version - Feed Yourself Independently Without Help|ED2-Feed Independently Without Help|ED2-Feed Independently Without Help|ED204_1	Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Can you feed yourself independently or manage tube feedings appropriately without help or reminders?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125805>	C125753	Expanded DRS-PI Survivor Version - Understand Feeding Utensils|ED2-Understand Feeding Utensils|ED2-Understand Feeding Utensils|ED204_2	Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Do you understand what eating or feeding utensils or equipment are for and how they should be used?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125806>	C125753	Expanded DRS-PI Survivor Version - Know Meal Times|ED2-Know Meal Times|ED2-Know Meal Times|ED204_3	Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Do you know when meal or feeding times are?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125807>	C125753	Expanded DRS-PI Survivor Version - Use Toilet Independently|ED2-Use Toilet Independently|ED2-Use Toilet Independently|ED205_1	Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Can you use the toilet or manage your bowel and bladder routine independently and appropriately without help or reminders?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125808>	C125753	Expanded DRS-PI Survivor Version - Manage Clothing When Toileting|ED2-Manage Clothing When Toileting|ED2-Manage Clothing When Toileting|ED205_2	Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Do you understand how to manage your clothing or special equipment when toileting or in bowel and bladder management?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125809>	C125753	Expanded DRS-PI Survivor Version - Know When to Use Toilet|ED2-Know When to Use Toilet|ED2-Know When to Use Toilet|ED205_3	Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Do you know when to use the toilet or to conduct bowel and bladder management?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12580>	C13006	Chief Cell|Chief Cells	One of three cell types that are found in the gastric or parathyroid glands, or in the carotid body. Gastric chief cells secrete pepsinogen and chymosin. Parathyroid chief cells secrete parathyroid hormone. Type 1 (chief) cells in the carotid body contain neurosecretory vesicles that may play a role in chemoreception.	Chief Cell		Cell	
C125810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125810>	C125753	Expanded DRS-PI Survivor Version - Can Dress and Groom Self Independently|ED2-Can Dress/Groom Independently|ED2-Can Dress/Groom Independently|ED206_1	Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Can you dress and groom yourself independently and appropriately or direct someone else in these activities without help or reminders?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125811>	C125753	Expanded DRS-PI Survivor Version - Know How to Bathe and Wash|ED2-Know How to Bathe/Wash|ED2-Know How to Bathe/Wash|ED206_2	Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Do you know how to bathe and wash?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125812>	C125753	Expanded DRS-PI Survivor Version - Understand How to Get Dressed|ED2-Understand How to Get Dressed|ED2-Understand How to Get Dressed|ED206_3	Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Do you understand how to get dressed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125813>	C125753	Expanded DRS-PI Survivor Version - Start and Finish Grooming Activities|ED2-Start/Finish Grooming Activities|ED2-Start/Finish Grooming Activities|ED206_4	Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Can you start and finish these grooming activities without prompting?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125814>	C125753	Expanded DRS-PI Survivor Version - Function Completely Independently|ED2-Function Completely Independently|ED2-Function Completely Independently|ED207_1	Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Do you function completely independently? That is, you do not require any physical assistance, supervision, equipment, devices, or reminders for cognitive, social, behavioral, emotional, and physical function?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125815>	C125753	Expanded DRS-PI Survivor Version - Require Special Aids or Equipment|ED2-Require Specific Aids/Equipment|ED2-Require Specific Aids/Equipment|ED207_2	Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Do you REQUIRE special aids or equipment, such as, a brace, walker, wheelchair, memory notebook, day planner, verbal reminders, prompts, cues, or alarm watch because of a disability?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125816>	C125753	Expanded DRS-PI Survivor Version - Require Physical Assistance|ED2-Require Physical Assistance|ED2-Require Physical Assistance|ED207_3	Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Do you require physical assistance from another person to meet daily needs?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125817>	C125753	Expanded DRS-PI Survivor Version - Require Assistance Thinking Tasks|ED2-Require Assistance Thinking Tasks|ED2-Require Assistance Thinking Tasks|ED207_4	Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Do you require assistance from another person in tasks that require thinking abilities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125818>	C125753	Expanded DRS-PI Survivor Version - Require Assistance Managing Emotions|ED2-Require Assistance Managing Emotions|ED2-Require Assistance Managing Emotions|ED207_5	Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Do you require assistance from another person to manage emotions and behavior?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125819>	C125753	Expanded DRS-PI Survivor Version - Need a Helper Always Close By|ED2-Need a Helper Always Close By|ED2-Need a Helper Always Close By|ED207_6A	Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Do you take care of some of your needs but also need a helper who is always close by?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12581>	C22188	Chromatophore|Chromatophores	A pigment-producing cell located in the deeper layers of the skin.	Chromatophore		Cell	
C125820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125820>	C125753	Expanded DRS-PI Survivor Version - Need Help With All Major Activities|ED2-Need Help With All Major Activities|ED2-Need Help With All Major Activities|ED207_6B	Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Do you need help with all major activities and the assistance of another person all the time?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125821>	C125753	Expanded DRS-PI Survivor Version - Need 24-Hour Care|ED2-Need 24-Hour Care|ED2-Need 24-Hour Care|ED207_6C	Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Do you need 24-hour care and are not able to help with your own care at all?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125822>	C125753	Expanded DRS-PI Survivor Version - Function With Independent Work or Social Situations|ED2-Independent Work/Social Situations|ED2-Independent Work/Social Situations|ED208_1	Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Can you function with complete independence in work or social situations?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125823>	C125753	Expanded DRS-PI Survivor Version - Understand and Follow Directions|ED2-Understand/Follow Directions|ED2-Understand/Follow Directions|ED208_2	Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Can you understand, remember, and follow directions?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125824>	C125753	Expanded DRS-PI Survivor Version - Keep Track of Time|ED2-Keep Track of Time/Schedules|ED2-Keep Track of Time/Schedules|ED208_3	Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) Can you keep track of time, schedules and appointments?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125825>	C125753	Expanded DRS-PI Survivor Version - Perform Jobs or Manage a Home Independently|ED2-Perform Jobs, Manage Home/School|ED2-Perform Jobs, Manage Home/School|ED208_4	Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) How certain are you that you can perform in a wide variety of jobs of your choosing or manage a home independently or participate in school full-time?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125826>	C125753	Expanded DRS-PI Survivor Version - Successful With Accommodations|ED2-Successful With Accommodations|ED2-Successful With Accommodations|ED208_5	Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) How certain are you that you can be successful at work, school or in home management with some reduction in the work load or with other accommodations due to disabilities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125827>	C125753	Expanded DRS-PI Survivor Version - Successful With Limited Choices|ED2-Successful With Limited Choices|ED2-Successful With Limited Choices|ED208_6	Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) How certain are you that you can be successful at work, school or in home management but with limited choices in jobs or school courses due to disabilities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125828>	C125753	Expanded DRS-PI Survivor Version - Work With Frequent Supervision and Support|ED2-Work With Frequent Support|ED2-Work With Frequent Support|ED208_7	Expanded Disability Rating Scale - Postacute Interview Survivor Version (Expanded DRS-PI Survivor Version) How certain are you that you can be able to work at home or in a special setting like a sheltered workshop in which the work is very routine and there is very frequent supervision and support?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Code Terminology|CDISC Questionnaire Expanded DRS-PI Survivor Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125829>	C125754	PHQ Screener Version - Stomach Pain|PHQ03-Stomach Pain|PHQ03-Stomach Pain|PHQ0301A	Patient Health Questionnaire Screener Version (PHQ Screener Version) During the last 4 weeks, how much have you been bothered by stomach pain?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12582>	C12581	Melanophore|Melanophores	A specialized cell, derived from the neural crest, that contains melanin and regulates changes in pigment.	Melanophore		Cell	
C125830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125830>	C125754	PHQ Screener Version - Back Pain|PHQ03-Back Pain|PHQ03-Back Pain|PHQ0301B	Patient Health Questionnaire Screener Version (PHQ Screener Version) During the last 4 weeks, how much have you been bothered by back pain?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125831>	C125754	PHQ Screener Version - Pain in Arms, Legs, Joints|PHQ03-Pain in Your Arms/Legs/Joints|PHQ03-Pain in Your Arms/Legs/Joints|PHQ0301C	Patient Health Questionnaire Screener Version (PHQ Screener Version) During the last 4 weeks, how much have you been bothered by pain in your arms, legs, or joints (knees, hips, etc.)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125832>	C125754	PHQ Screener Version - Menstrual Cramp or Other Problem|PHQ03-Menstrual Cramp/Problem|PHQ03-Menstrual Cramp/Problem|PHQ0301D	Patient Health Questionnaire Screener Version (PHQ Screener Version) During the last 4 weeks, how much have you been bothered by menstrual cramps or other problems with your periods?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125833>	C125754	PHQ Screener Version - Pain During Intercourse|PHQ03-Pain/Problems During Intercourse|PHQ03-Pain/Problems During Intercourse|PHQ0301E	Patient Health Questionnaire Screener Version (PHQ Screener Version) During the last 4 weeks, how much have you been bothered by pain or problems during sexual intercourse?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125834>	C125754	PHQ Screener Version - Headaches|PHQ03-Headaches|PHQ03-Headaches|PHQ0301F	Patient Health Questionnaire Screener Version (PHQ Screener Version) During the last 4 weeks, how much have you been bothered by headaches?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125835>	C125754	PHQ Screener Version - Chest Pain|PHQ03-Chest Pain|PHQ03-Chest Pain|PHQ0301G	Patient Health Questionnaire Screener Version (PHQ Screener Version) During the last 4 weeks, how much have you been bothered by chest pain?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125836>	C125754	PHQ Screener Version - Dizziness|PHQ03-Dizziness|PHQ03-Dizziness|PHQ0301H	Patient Health Questionnaire Screener Version (PHQ Screener Version) During the last 4 weeks, how much have you been bothered by dizziness?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125837>	C125754	PHQ Screener Version - Fainting Spells|PHQ03-Fainting Spells|PHQ03-Fainting Spells|PHQ0301I	Patient Health Questionnaire Screener Version (PHQ Screener Version) During the last 4 weeks, how much have you been bothered by fainting spells?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125838>	C125754	PHQ Screener Version - Feeling Your Heart Pound or Race|PHQ03-Feeling Your Heart Pound/Race|PHQ03-Feeling Your Heart Pound/Race|PHQ0301J	Patient Health Questionnaire Screener Version (PHQ Screener Version) During the last 4 weeks, how much have you been bothered by feeling your heart pound/race?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125839>	C125754	PHQ Screener Version - Shortness of Breath|PHQ03-Shortness of Breath|PHQ03-Shortness of Breath|PHQ0301K	Patient Health Questionnaire Screener Version (PHQ Screener Version) During the last 4 weeks, how much have you been bothered by shortness of breath?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12583>	C43251|C12621	Dendritic Cell|Dendritic Cells|dendritic cell	Immunocompetent cells of the lymphoid and hemopoietic systems and skin. They function morphologically and phenotypically by presenting or processing antigens, thereby stimulating cellular immunity. They represent the most potent antigen-presenting cells and, therefore, play a critical role in the primary T cell immune response.	Dendritic Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C125840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125840>	C125754	PHQ Screener Version - Constipation or Diarrhea|PHQ03-Constipation/Diarrhea|PHQ03-Constipation/Diarrhea|PHQ0301L	Patient Health Questionnaire Screener Version (PHQ Screener Version) During the last 4 weeks, how much have you been bothered by constipation, loose bowels, or diarrhea?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125841>	C125754	PHQ Screener Version - Nausea, Gas or Indigestion|PHQ03-Nausea/Gas/Indigestion|PHQ03-Nausea/Gas/Indigestion|PHQ0301M	Patient Health Questionnaire Screener Version (PHQ Screener Version) During the last 4 weeks, how much have you been bothered by nausea, gas, indigestion?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125842>	C125754	PHQ Screener Version - Little Interest in Doing Things|PHQ03-Little Interest in Doing Things|PHQ03-Little Interest in Doing Things|PHQ0302A	Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 2 weeks, how often have you been bothered by little interest or pleasure in doing things?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125843>	C125754	PHQ Screener Version - Feeling Down or Depressed|PHQ03-Feeling Down/Depressed|PHQ03-Feeling Down/Depressed|PHQ0302B	Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 2 weeks, how often have you been bothered by feeling down, depressed, or hopeless?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125844>	C125754	PHQ Screener Version - Last 2 Weeks, Trouble Falling or Staying Asleep|PHQ03-Last 2 Week Trouble Falling Asleep|PHQ03-Last 2 Week Trouble Falling Asleep|PHQ0302C	Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 2 weeks, how often have you been bothered by trouble falling or staying asleep, or sleeping too much?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125845>	C125754	PHQ Screener Version - Feeling Tired or Little Energy|PHQ03-Feeling Tired/Little Energy|PHQ03-Feeling Tired/Little Energy|PHQ0302D	Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 2 weeks, how often have you been bothered by feeling tired or having little energy?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125846>	C125754	PHQ Screener Version - Poor Appetite or Overeating|PHQ03-Poor Appetite or Overeating|PHQ03-Poor Appetite or Overeating|PHQ0302E	Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 2 weeks, how often have you been bothered by poor appetite or overeating?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125847>	C125754	PHQ Screener Version - Feeling Bad About Yourself|PHQ03-Feeling Bad About Yourself|PHQ03-Feeling Bad About Yourself|PHQ0302F	Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 2 weeks, how often have you been bothered by feeling bad about yourself - or that you are a failure or have let yourself or your family down?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125848>	C125754	PHQ Screener Version - Last 2 Weeks, Trouble Concentrating|PHQ03-Last 2 Week Trouble Concentrating|PHQ03-Last 2 Week Trouble Concentrating|PHQ0302G	Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 2 weeks, how often have you been bothered by trouble concentrating on things, such as reading the newspaper or watching television?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125849>	C125754	PHQ Screener Version - Moving Slowly or Moving More|PHQ03-Moving Slowly/Fidgety/Restless|PHQ03-Moving Slowly/Fidgety/Restless|PHQ0302H	Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 2 weeks, how often have you been bothered by moving or speaking so slowly that other people could have noticed? Or the opposite - being so fidgety or restless that you have been moving around a lot more than usual?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12584>	C32271|C12583	Langerhans Cell|Langerhans Cells	Dendritic clear cells in the epidermis, containing distinctive granules that appear rod- or racket-shaped in section, but lacking tonofilaments, melanosomes, and desmosomes; they carry surface receptors for immunoglobulin (Fc) and complement (C3), and are believed to be antigen fixing and processing cells of monocytic origin; active participants in cutaneous delayed hypersensitivity.	Langerhans Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C125850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125850>	C125754	PHQ Screener Version - Thoughts Be Better Off Dead|PHQ03-Thoughts Be Better Off Dead|PHQ03-Thoughts Be Better Off Dead|PHQ0302I	Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 2 weeks, how often have you been bothered by thoughts that you would be better off dead or of hurting yourself in some way?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125851>	C125754	PHQ Screener Version - Anxiety Attack|PHQ03-Anxiety Attack|PHQ03-Anxiety Attack|PHQ0303A	Patient Health Questionnaire Screener Version (PHQ Screener Version) In the last 4 weeks, have you had an anxiety attack - suddenly feeling fear or panic?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125852>	C125754	PHQ Screener Version - Anxiety Attack Happened Before|PHQ03-Anxiety Attack Happened Before|PHQ03-Anxiety Attack Happened Before|PHQ0303B	Patient Health Questionnaire Screener Version (PHQ Screener Version) Has this ever happened before?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125853>	C125754	PHQ Screener Version - Anxiety Attacks Come Suddenly|PHQ03-Anxiety Attacks Come Suddenly|PHQ03-Anxiety Attacks Come Suddenly|PHQ0303C	Patient Health Questionnaire Screener Version (PHQ Screener Version) Do some of these attacks come suddenly out of the blue - that is, in situations where you don't expect to be nervous or uncomfortable?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125854>	C125754	PHQ Screener Version - Anxiety Attacks Bother a Lot|PHQ03-Anxiety Attacks Bother a Lot|PHQ03-Anxiety Attacks Bother a Lot|PHQ0303D	Patient Health Questionnaire Screener Version (PHQ Screener Version) Do these attacks bother you a lot or are you worried about having another attack?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125855>	C125754	PHQ Screener Version - Anxiety Attack Short of Breath|PHQ03-Anxiety Attack Short of Breath|PHQ03-Anxiety Attack Short of Breath|PHQ0304A	Patient Health Questionnaire Screener Version (PHQ Screener Version) Think about your last bad anxiety attack. Were you short of breath?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125856>	C125754	PHQ Screener Version - Anxiety Attack Heart Race or Pound|PHQ03-Anxiety Attack Heart Race/Pound|PHQ03-Anxiety Attack Heart Race/Pound|PHQ0304B	Patient Health Questionnaire Screener Version (PHQ Screener Version) Think about your last bad anxiety attack. Did your heart race, pound, or skip?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125857>	C125754	PHQ Screener Version - Anxiety Attack Chest Pain|PHQ03-Anxiety Attack Chest Pain|PHQ03-Anxiety Attack Chest Pain|PHQ0304C	Patient Health Questionnaire Screener Version (PHQ Screener Version) Think about your last bad anxiety attack. Did you have chest pain or pressure?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125858>	C125754	PHQ Screener Version - Anxiety Attack Sweat|PHQ03-Anxiety Attack Sweat|PHQ03-Anxiety Attack Sweat|PHQ0304D	Patient Health Questionnaire Screener Version (PHQ Screener Version) Think about your last bad anxiety attack. Did you sweat?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125859>	C125754	PHQ Screener Version - Anxiety Attack Choking|PHQ03-Anxiety Attack Choking|PHQ03-Anxiety Attack Choking|PHQ0304E	Patient Health Questionnaire Screener Version (PHQ Screener Version) Think about your last bad anxiety attack. Did you feel as if you were choking?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12585>	C33923	Enterocyte|Enterocytes	A type of epithelial cell that lines the intestines and colon. It participates in the absorption of water and nutrients from the intestinal lumen, and in the secretion of digestive enzymes.	Enterocyte		Cell	
C125860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125860>	C125754	PHQ Screener Version - Anxiety Attack Hot Flash or Chill|PHQ03-Anxiety Attack Hot Flash/Chill|PHQ03-Anxiety Attack Hot Flash/Chill|PHQ0304F	Patient Health Questionnaire Screener Version (PHQ Screener Version) Think about your last bad anxiety attack. Did you have hot flashes or chills?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125861>	C125754	PHQ Screener Version - Anxiety Attack Nausea or Diarrhea|PHQ03-Anxiety Attack Nausea/Diarrhea|PHQ03-Anxiety Attack Nausea/Diarrhea|PHQ0304G	Patient Health Questionnaire Screener Version (PHQ Screener Version) Think about your last bad anxiety attack. Did you have nausea or an upset stomach, or the feeling that you were going to have diarrhea?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125862>	C125754	PHQ Screener Version - Anxiety Attack Dizzy or Faint|PHQ03-Anxiety Attack Dizzy/Faint|PHQ03-Anxiety Attack Dizzy/Faint|PHQ0304H	Patient Health Questionnaire Screener Version (PHQ Screener Version) Think about your last bad anxiety attack. Did you feel dizzy, unsteady, or faint?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125863>	C125754	PHQ Screener Version - Anxiety Attack Tingling or Numbness|PHQ03-Anxiety Attack Tingling/Numbness|PHQ03-Anxiety Attack Tingling/Numbness|PHQ0304I	Patient Health Questionnaire Screener Version (PHQ Screener Version) Think about your last bad anxiety attack. Did you have tingling or numbness in parts of your body?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125864>	C125754	PHQ Screener Version - Anxiety Attack Tremble or Shake|PHQ03-Anxiety Attack Tremble/Shake|PHQ03-Anxiety Attack Tremble/Shake|PHQ0304J	Patient Health Questionnaire Screener Version (PHQ Screener Version) Think about your last bad anxiety attack. Did you tremble or shake?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125865>	C125754	PHQ Screener Version - Anxiety Attack Afraid You Were Dying|PHQ03-Anxiety Attack Afraid You Dying|PHQ03-Anxiety Attack Afraid You Dying|PHQ0304K	Patient Health Questionnaire Screener Version (PHQ Screener Version) Think about your last bad anxiety attack. Were you afraid you were dying?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125866>	C125754	PHQ Screener Version - Feeling Nervous or Anxious|PHQ03-Feeling Nervous/Anxious|PHQ03-Feeling Nervous/Anxious|PHQ0305A	Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 4 weeks, how often have you been bothered by feeling nervous, anxious, on edge, or worrying a lot about different things?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125867>	C125754	PHQ Screener Version - Feeling Restless|PHQ03-Feeling Restless|PHQ03-Feeling Restless|PHQ0305B	Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 4 weeks, how often have you been bothered by feeling restless so that it is hard to sit still?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125868>	C125754	PHQ Screener Version - Getting Tired Easily|PHQ03-Getting Tired Easily|PHQ03-Getting Tired Easily|PHQ0305C	Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 4 weeks, how often have you been bothered by getting tired very easily?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125869>	C125754	PHQ Screener Version - Muscle Tension|PHQ03-Muscle Tension/Aches/Soreness|PHQ03-Muscle Tension/Aches/Soreness|PHQ0305D	Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 4 weeks, how often have you been bothered by muscle tension, aches, or soreness?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12586>	C33923|C13055	Goblet Cell|Goblet Cells|Goblet Cells	A mucin-producing and -secreting epithelial cell found mainly in the intestinal and respiratory tracts.	Goblet Cell		Cell	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology
C125870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125870>	C125754	PHQ Screener Version - Last 4 Weeks, Trouble Falling or Staying Asleep|PHQ03-Last 4 Week Trouble Falling Asleep|PHQ03-Last 4 Week Trouble Falling Asleep|PHQ0305E	Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 4 weeks, how often have you been bothered by trouble falling asleep or staying asleep?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125871>	C125754	PHQ Screener Version - Last 4 Weeks, Trouble Concentrating|PHQ03-Last 4 Week Trouble Concentrating|PHQ03-Last 4 Week Trouble Concentrating|PHQ0305F	Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 4 weeks, how often have you been bothered by trouble concentrating on things, such as reading a book or watching TV?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125872>	C125754	PHQ Screener Version - Becoming Easily Annoyed|PHQ03-Becoming Easily Annoyed|PHQ03-Becoming Easily Annoyed|PHQ0305G	Patient Health Questionnaire Screener Version (PHQ Screener Version) Over the last 4 weeks, how often have you been bothered by becoming easily annoyed or irritable?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125873>	C125754	PHQ Screener Version - No Control What or How Much Eat|PHQ03-No Control What/How Much Eat|PHQ03-No Control What/How Much Eat|PHQ0306A	Patient Health Questionnaire Screener Version (PHQ Screener Version) Do you often feel that you can't control what or how much you eat?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125874>	C125754	PHQ Screener Version - Often Eat Large Amount Food|PHQ03-Eat 2-Hours Large Amount Food|PHQ03-Eat 2-Hours Large Amount Food|PHQ0306B	Patient Health Questionnaire Screener Version (PHQ Screener Version) Do you often eat, within any 2 - hour period, what most people would regard as an unusually large amount of food?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125875>	C125754	PHQ Screener Version - Eat a Lot Twice Week|PHQ03-Eat a Lot Twice Week|PHQ03-Eat a Lot Twice Week|PHQ0306C	Patient Health Questionnaire Screener Version (PHQ Screener Version) Has this been as often, on average, as twice a week for the last 3 months?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125876>	C125754	PHQ Screener Version - Avoid Gaining Weight, Made Yourself Vomit|PHQ03-Made Yourself Vomit|PHQ03-Made Yourself Vomit|PHQ0307A	Patient Health Questionnaire Screener Version (PHQ Screener Version) In the last 3 months have you often done any of the following in order to avoid gaining weight: Made yourself vomit?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125877>	C125754	PHQ Screener Version - Avoid Gaining Weight, Took Twice Dose of Laxatives|PHQ03-Took Twice Dose of Laxatives|PHQ03-Took Twice Dose of Laxatives|PHQ0307B	Patient Health Questionnaire Screener Version (PHQ Screener Version) In the last 3 months have you often done any of the following in order to avoid gaining weight: Took more than twice the recommended dose of laxatives to avoid gaining weight?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125878>	C125754	PHQ Screener Version - Avoid Gaining Weight, Fasted at Least 24 Hours|PHQ03-Fasted at Least 24 Hours|PHQ03-Fasted at Least 24 Hours|PHQ0307C	Patient Health Questionnaire Screener Version (PHQ Screener Version) In the last 3 months have you often done any of the following in order to avoid gaining weight: Fasted - not eaten anything at all for at least 24 hours to avoid gaining weight?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125879>	C125754	PHQ Screener Version - Avoid Gaining Weight, Exercise|PHQ03-Exercised Avoid Gaining Weight|PHQ03-Exercised Avoid Gaining Weight|PHQ0307D	Patient Health Questionnaire Screener Version (PHQ Screener Version) In the last 3 months have you often done any of the following in order to avoid gaining weight: Exercised for more than an hour specifically to avoid gaining weight after binge eating?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12587>	C41608	Granulosa Cell|Granulosa Cells		Granulosa Cell		Cell	
C125880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125880>	C125754	PHQ Screener Version - Avoid Gaining Weight Twice Week|PHQ03-Avoid Gaining Weight Twice Week|PHQ03-Avoid Gaining Weight Twice Week|PHQ0308	Patient Health Questionnaire Screener Version (PHQ Screener Version) If you checked "YES" to any of these ways of avoiding gaining weight, were any as often, on average, as twice a week?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125881>	C125754	PHQ Screener Version - Drink Alcohol|PHQ03-Drink Alcohol|PHQ03-Drink Alcohol|PHQ0309	Patient Health Questionnaire Screener Version (PHQ Screener Version) Do you ever drink alcohol (including beer or wine)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125882>	C125754	PHQ Screener Version - Drank Alcohol With Health Problem|PHQ03-Drank Alcohol With Health Problem|PHQ03-Drank Alcohol With Health Problem|PHQ0310A	Patient Health Questionnaire Screener Version (PHQ Screener Version) Have any of the following happened to you more than once in the last 6 months: You drank alcohol even though a doctor suggested that you stop drinking because of a problem with your health?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125883>	C125754	PHQ Screener Version - Drank Alcohol at Work or School|PHQ03-Alcohol at Work/School|PHQ03-Alcohol at Work/School|PHQ0310B	Patient Health Questionnaire Screener Version (PHQ Screener Version) Have any of the following happened to you more than once in the last 6 months: You drank alcohol, were high from alcohol, or hung over while you were working, or going to school, or taking care of children or other responsibilities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125884>	C125754	PHQ Screener Version - Missed Work Because of Drinking|PHQ03-Missed Work Because of Drinking|PHQ03-Missed Work Because of Drinking|PHQ0310C	Patient Health Questionnaire Screener Version (PHQ Screener Version) Have any of the following happened to you more than once in the last 6 months: You missed or were late for work, school, or other activities because you were drinking or hung over?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125885>	C125754	PHQ Screener Version - Problem Getting Along With People While Drinking|PHQ03-Problem With People While Drinking|PHQ03-Problem With People While Drinking|PHQ0310D	Patient Health Questionnaire Screener Version (PHQ Screener Version) Have any of the following happened to you more than once in the last 6 months: You had a problem getting along with other people while you were drinking?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125886>	C125754	PHQ Screener Version - Drove Car After Several Drinks|PHQ03-Drove After Several Drinks|PHQ03-Drove After Several Drinks|PHQ0310E	Patient Health Questionnaire Screener Version (PHQ Screener Version) Have any of the following happened to you more than once in the last 6 months: You drove a car after having several drinks or after drinking too much?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125887>	C125754	PHQ Screener Version - Problems Made It Difficult to Work|PHQ03-Problems Made It Difficult to Work|PHQ03-Problems Made It Difficult to Work|PHQ0311	Patient Health Questionnaire Screener Version (PHQ Screener Version) If you checked off any problems on this questionnaire, how difficult have these problems made it for you to do your work, take care of things at home, or get along with other people?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ Screener Version Test Code Terminology|CDISC Questionnaire PHQ Screener Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125888>	C118396	Disruptive TP53 Mutation	Any mutation of the TP53 gene that results in a nonconservative mutation within the key DNA-binding domain (L2-L3 region) of the p53 protein, or a stop codon in any region.			Cell or Molecular Dysfunction	
C125889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125889>	C118396	Non-Disruptive TP53 Mutation	Any conservative mutation in the coding region of the TP53 gene that maintains the structure and function of the p53 protein.			Cell or Molecular Dysfunction	
C12588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12588>	C33923	Hepatocyte|Hepatic Cells|Hepatic Parenchymal Cell|Hepatocytes|hepatocyte	A parenchymal liver cell.	Hepatocyte		Cell	
C125890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125890>	C39750	Small Cell Glioblastoma	A morphologic variant of glioblastoma characterized by the presence of a highly proliferative and monotonous population of malignant small glial cells.			Neoplastic Process	NCIt Neoplasm Core Terminology
C125891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125891>	C27993	Signed By|Signatory|Signer	Indicates the person who has signed a document, physically or electronically (digital signature).			Qualitative Concept	
C125892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125892>	C175311	Most or Almost All of the Time|Most or almost all of the time	An indication that something happens or happened most or almost most of the time.			Intellectual Product	Center for Epidemiologic Studies Depression Scale
C125893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125893>	C175311	Moderately or Much of the Time|Moderately or much of the time	An indication that something happens or happened moderately or much of the time.			Intellectual Product	Center for Epidemiologic Studies Depression Scale
C125894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125894>	C153598	Ion Semiconductor Sequencing|Ion Torrent|Ion Torrent Sequencing|Ion Torrent Sequencing Technology|Semiconductor Sequencing|Silicon Sequencing|pH-Mediated Sequencing	A method of DNA sequencing based on the detection of hydrogen ions that are released during synthesis of a complementary strand polymerized on a template strand. This technology differs from other sequencing technologies in that no modified nucleotides or optics are used. It claims to be simpler, faster, and more cost effective and scalable than any other technology available.			Molecular Biology Research Technique	GDC Terminology|GDC Value Terminology
C125895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125895>	C22188	Experimental Organism Anal Sac Gland|GLAND, ANAL SAC	Apocrine gland of the anal sac.			Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C125896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125896>	C12712	Anal Sac|SAC, ANAL	One of two pouches located on either side of the anus that contain the secretions of the anal glands.			Anatomical Structure	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C125897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125897>	C13236	Thoracic Fluid|FLUID, THORAX	Fluid that is present in the thoracic cavity.			Body Substance	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C125898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125898>	C78284	Evaux Thermal Spring Water-based Solution|EvoNail	A topical solution containing Evaux thermal spring water, with potential moisturizing and skin protecting activities. Upon application to the nails and surrounding skin, Evaux spring water-based solution forms a film on the nails that serves as a protective barrier. This prevents water loss from, provides moisture to, and strengthens the nails, and protects them from damage. The solution also relieves pain caused by cracked, peeled, thinning or soft nails. Evaux thermal spring water contains the elements lithium, manganese and strontium which may help heal the nails and prevent onycholysis. It also contains chlorphenesin and piroctone olamine, both of which have antifungal activity. Some chemotherapy and/or radiation therapy can induce damage to the nails.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C125899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125899>	C192742|C192741	Dalpiciclib|CDK4/6 Inhibitor SHR6390|DALPICICLIB|SHR 6390|SHR-6390|SHR6390	A cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Upon administration, dalpiciclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6). This inhibits retinoblastoma (Rb) protein phosphorylation early in the G1 phase, which prevents CDK-mediated G1-S phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12589>	C33562	Keratinocyte|KERATINOCYTE|Keratinocytes	The keratin-producing cells of the epidermis.  They are the predominant cells of the epidermis that form in the deep basal layer of the stratified epithelium of the epidermis.  They gradually migrate upward to the cornified layer of the epidermis undergoing characteristic changes.	Keratinocyte		Cell	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C1258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1258>	C511|C2153	Triazinate|BAF|Baker's Antifol|Baker's Antifol|Baker's Antifol soluble|Baker's Antifolate|Bakers Antifol|Bakers Antifolate|Benzenesulfonyl fluoride, 3-chloro-4-[4-[2-chloro-4-(4, 6-diamino-2,2-dimethyl-1,3,5-triazin-1(2H)-yl)phenyl]butyl]-, monoethanesulfonate (9CI)|Ethanesulfonic Acid Compound|Ethanesulfonic acid, compd. with 3-chloro-4-[4-[2-chloro-4-(4, 6-diamino-2, 2-dimethyl-s-triazin-1(2H)-yl)phenyl]butyl]benzenesulfonyl fluoride (1:1) (8CI)|Ethanesulfonic acid, compd. with 3-chloro-4-[4-[2-chloro-4-(4,6-diamino-2, 2-dimethyl-s-triazin-1(2H)-yl)phenyl]butyl]benzenesulfonyl fluoride|Ethanesulfonic acid, compd. with 3-chloro-4-[4-[2-chloro-4-(4,6-diamino-2,2-dimethyl-1,3, 5-triazin-1(2H)-yl)phenyl]butyl]benzenesulfonyl fluoride (1:1) (9CI)|Soluble Baker's Antifol|TRIAZINATE|TZT|alpha-(2-chloro-4-(4,6-diamino-2,2-dimethyl-s-trizin-1(2H)-yl)phenoxy)-N,N-dimethyl-m-toluamide ethanesulfonic acid|benzenesulfonyl fluoride, 3-chloro-4-[4-[2-chloro-4-(4, 6-diamino-2,2-dimethyl-1,3,5-triazin-1(2H)-yl)phenyl]butyl]-, monoethanesulfonate (9CI)|ethanesulfonic acid compound with 3-((2-chloro-4-(4,6-diamino-2,2-dimethyl-1,3,5-triazin-1(2H)-yl)phenoxy)methyl)-N,N-dimethylben zamide (1:1)|ethanesulfonic acid, compd. with 3-chloro-4-[4-[2-chloro-4-(4, 6-diamino-2, 2-dimethyl-s-triazin-1(2H)-yl)phenyl]butyl]benzenesulfonyl fluoride (1:1)(8CI)|ethanesulfonic acid, compd. with 3-chloro-4-[4-[2-chloro-4-(4,6-diamino-2, 2-dimethyl-s-triazin-1(2H)-yl)phenyl]butyl]benzenesulfonyl fluoride|ethanesulfonic acid, compd. with 3-chloro-4-[4-[2-chloro-4-(4,6-diamino-2,2-dimethyl-1,3, 5-triazin-1(2H)-yl)phenyl]butyl]benzenesulfonyl fluoride (1:1)(9CI)	A synthetic dihydrotriazine derivative with antineoplastic properties.  As an antifolate agent related to methotrexate (MTX), triazinate inhibits the enzyme dihydrofolate reductase (DHFR), resulting in decreased tetrahydrofolate production and interference with thymidylate synthesis.  Unlike MTX, this agent is not converted to polyglutamate forms. Triazinate also inhibits the transport of folates and may be selectively toxic to MTX-resistant tumor cells. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125900>	C20401|C129822	Anti-CA19-9 Monoclonal Antibody BNT321|5B1|Anti-CA19-9 Monoclonal Antibody 5B1|BNT 321|BNT-321|BNT321|HuMab 5B1|HuMab-5B1|MVT-5873|MVT-5873	A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the carbohydrate antigen sialyl Lewis A (carbohydrate antigen 19-9; CA19-9), with potential antineoplastic activity. Upon administration, anti-CA19-9 monoclonal antibody BNT321 targets and binds to CA19-9, and kills CA19-9-expressing tumor cells through the induction of both complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). CA19-9 is overexpressed on a number of different tumor cell types, and plays a key role in tumor cell survival and metastasis.	Anti-CA19-9 Monoclonal Antibody BNT321		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125901>	C67439|C1557	Etidronate-Cytarabine Conjugate MBC-11|Etidronate-ara-C Conjugate MBC-11|MBC-11|MBC-11	A synthetic conjugate composed of the bisphosphonate etidronate linked to the cytostatic agent and antimetabolite cytarabine, with potential antineoplastic and antiresorptive activities. Upon intravenous administration of the etidronate-cytarabine conjugate MBC-11, the etidronate moiety targets bone and the two moieties are released upon hydrolysis. Etidronate binds to hydroxyapatite crystals in bone tissues and prevents its resorption. This prevents bone destruction and induces bone cell mineralization. In addition, the bone-targeting nature of this agent allows for the accumulation of cytarabine in bone tissue, where it is able to exert its antitumor effect locally by competing with cytidine for incorporation into DNA, thereby inhibiting DNA synthesis, while reducing systemic exposure. This leads to a destruction of bone-associated tumor cells, an inhibition of tumor cell proliferation and bone metastasis, and prevents tumor-mediated bone destruction.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125902>	C176586	STING-activating Cyclic Dinucleotide Agonist MIW815|ADU-S100|ADU-S100|CDN Agonist ADU-S100|MIW815	A synthetic, cyclic dinucleotide (CDN) and agonist of stimulator of interferon genes protein (STING; transmembrane protein 173; TMEM173), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration, the STING agonist MIW815 binds to STING and stimulates STING-mediated pathways. This activates the immune response through the activation of certain immune cells, including dendritic cells (DCs), which induces the expression of cytokines and chemokines, and leads to an antigen-specific T-cell mediated immune response against cancer cells. STING, a transmembrane protein that activates immune cells in the tumor microenvironment, plays a key role in the activation of the innate immune system.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C125903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125903>	C208255|C141144	Efprezimod Alfa|CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc|CD24Fc|CD24Fc CD24IgG|EFPREZIMOD ALFA|MK-7110|SACCOVID	A recombinant fusion protein composed of the extracellular domain of the mature human glycoprotein CD24 linked to a human immunoglobulin G1 (IgG1) Fc domain, with potential immune checkpoint inhibitory, anti-inflammatory and antineoplastic activities. Upon administration, efprezimod alfa binds to injured cell components, also called DAMPs (Danger-Associated Molecular Patterns), thereby preventing the interaction of DAMPs with toll-like receptors (TLRs) and inhibiting both nuclear factor-kappa B (NFkB) activation and secretion of inflammatory cytokines. In addition, efprezimod alfa binds to and activates Siglec G/10, a sialic acid-binding immunoglobulin-type lectin, and stimulates SHP-1-mediated inhibitory signaling, while also preventing NFkB activation and secretion of inflammatory mediators, which further prevents inflammatory responses. DAMPs activate the innate immune system. CD24 binds to both DAMPs and Siglec G/10 to regulate immune responses.CD24/Siglec G/10 interaction plays a key role in a number of immune-mediated diseases including graft-versus-host disease (GvHD), multiple sclerosis and rheumatoid arthritis.	Efprezimod Alfa		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C125904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125904>	C138195	High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements|DH Lymphoma|DHL|Double Hit Lymphoma|Double-Hit Lymphoma|Double-Hit Lymphoma|HGBCL-DH|High-Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements|double hit lymphoma|double_hit_lymphoma	High-grade B-cell lymphoma characterized by the abnormal rearrangement of two genes, MYC gene and either BCL2 or BCL6 genes. Patients with this type of lymphoma usually respond poorly to standard treatments and have a poor prognosis.	Double-Hit Lymphoma		Neoplastic Process	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology|GDC Property Terminology|GDC Terminology|NCIt Neoplasm Core Terminology
C125905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125905>	C12801	Non-Cellular Component|Non-Cellular Component of Tissue|Non-Cellular Tissue Component	A term that refers to the non-cellular component of the innate immune system which includes cytokines, chemokines, complements, and other mediators of inflammation, to the non-cellular component of blood (plasma), or the non-cellular component of body fluids and broncoalveolar lavage fluid.			Tissue	
C125906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125906>	C91105|C21154	Quality of Life Questionnaire - Pancreatic Cancer 26|EORTC QLQ-PAN26|PAN26 Questionnaire	A questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) consisting of 26 questions designed to assess pain, dietary changes, jaundice, altered bowel habit, emotional problems related to pancreatic cancer, and other symptoms (cachexia, indigestion, flatulence, dry mouth, taste changes).			Intellectual Product	
C125907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125907>	C91126	Have Pain During the Night Question|Did you have pain during the night|Have Pain During the Night	A question about whether an individual has or had pain during the night.			Intellectual Product	Quality of Life Questionnaire - Pancreatic Cancer 26
C125908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125908>	C91102	Uncomfortable in Certain Positions Question|Did you find it uncomfortable in certain positions (e.g. lying down)|Uncomfortable in Certain Positions	A question about whether an individual is or was uncomfortable in certain positions.			Intellectual Product	Quality of Life Questionnaire - Pancreatic Cancer 26
C125909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125909>	C16588	Modified Barium Swallow|MBS|VFSS|Videofluoroscopic Swallowing Study	A fluoroscopic procedure that examines a person's swallowing pattern. Liquid and solid food that contains barium sulfate is digested to determine if it is entering a person's larynx and trachea.	Modified Barium Swallow		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C12590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12590>	C33704	Supporting Cell of Organ of Corti|Labyrinth Supporting Cell|Labyrinth Supporting Cells	One of the non-sensory cells that compose the supporting structures of the Organ of Corti.	Labyrinth Supporting Cell		Cell	
C125910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125910>	C173812	Restricted in the Types of Food You Can Eat as a Result of Disease or Treatment Question|Restricted in the Types of Food You Can Eat as a Result of Disease or Treatment|Were you restricted in the types of food you can eat as a result of your disease or treatment	A question about whether an individual is or was restricted in the types of food they can eat as a result of their disease or treatment.			Intellectual Product	Quality of Life Questionnaire - Pancreatic Cancer 26
C125911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125911>	C173812	Restricted in the Amount of Food You Can Eat as a Result of Disease or Treatment Question|Restricted in the Amount of Food You Can Eat as a Result of Disease or Treatment|Were you restricted in the amounts of food you could eat as a result of your disease or treatment	A question about whether an individual is or was restricted in the amounts of food they could eat as a result of their disease or treatment.			Intellectual Product	Quality of Life Questionnaire - Pancreatic Cancer 26
C125912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125912>	C173063	Food and Drink Taste Different from Usual Question|Did food and drink taste different from usual|Food and Drink Taste Different from Usual	A question about whether food or drink tastes or tasted different from usual.			Intellectual Product	Quality of Life Questionnaire - Pancreatic Cancer 26
C125913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125913>	C173981	Have Indigestion Question|Have Indigestion|Have you had indigestion	A question about whether an individual has or had indigestion.			Intellectual Product	Quality of Life Questionnaire - Pancreatic Cancer 26
C125914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125914>	C115340	Worried About Weight Being Too Low Question|Have you worried about your weight being too low|Worried About Weight Being Too Low	A question about whether an individual worries or worried about their weight being too low.			Intellectual Product	Quality of Life Questionnaire - Pancreatic Cancer 26
C125915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125915>	C173150	Extent Have Yellow Skin Question|Extent of Yellow Skin|Have Yellow Skin|To what extent was your skin yellow	A question about the extent to which an individual has or had yellow skin.			Intellectual Product	Quality of Life Questionnaire - Pancreatic Cancer 26
C125916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125916>	C173938|C173358	Have Frequent Bowel Movements Question|Did you have frequent bowel movements|Have Frequent Bowel Movements	A question about whether an individual has or had frequent bowel movements.			Intellectual Product	Quality of Life Questionnaire - Pancreatic Cancer 26
C125917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125917>	C173938|C173160	Feel Urge to Move Bowels Quickly Question|Did you feel the urge to move your bowels quickly|Feel Urge to Move Bowels Quickly	A question about whether an individual feels or felt the urge to move their bowels quickly.			Intellectual Product	Quality of Life Questionnaire - Pancreatic Cancer 26
C125918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125918>	C173933|C173812|C173150	Extent Troubled with Side Effects from Treatment Question|Extent Troubled with Side Effects from Treatment|To what extent have you been troubled with side-effects from your treatment|Troubled with Side Effects from Treatment	A question about the extent to which an individual is or was troubled with side effects from their treatment.			Intellectual Product	Quality of Life Questionnaire - Pancreatic Cancer 26
C125919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125919>	C173695	Limited in Planning Activities in Advance Question|Limited in Planning Activities in Advance|Were you limited in planning activities in advance (e.g. meeting friends)	A question about whether an individual is or was limited in planning activities in advance.			Intellectual Product	Quality of Life Questionnaire - Pancreatic Cancer 26
C12591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12591>	C32271	Melanocyte|Melanocytes|melanocyte		Melanocyte		Cell	
C125920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125920>	C176545	Receive Adequate Support from Health Care Professionals Question|Have you received adequate support from your health care professionals|Receive Adequate Support from Health Care Professionals	A question about whether an individual receives or received adequate support from their health care professionals.			Intellectual Product	Quality of Life Questionnaire - Pancreatic Cancer 26
C125921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125921>	C176537|C173812	Adequate Information Given About Physical Condition and Treatment Question|Adequate Information Given About Physical Condition and Treatment|Has the information given about your physical condition and treatment been adequate|Information Given About Physical Condition and Treatment is Adequate	A question about whether the information given to an individual about their physical condition and treatment is or was adequate.			Intellectual Product	Quality of Life Questionnaire - Pancreatic Cancer 26
C125922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125922>	C66830	CDISC SDTM Microscopic Findings Test Detail Terminology|MIFTSDTL|Microscopic Findings Test Details|SDTM-MIFTSDTL	Terminology associated with the microscopic findings test detail codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125923>	C66830	CDISC SDTM BRIDG Activity Mood Terminology|BRDGMOOD|BRIDG Activity Mood|SDTM-BRDGMOOD	Terminology associated with the biomedical research integrated domain group (BRIDG) activity mood codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125924>	C14248	Strongyloides|STRONGYLOIDES	A genus of parasitic nematodes in the family Strongyloididae that infects the gastrointestinal tract of mammals, birds, reptiles and amphibians, and has an unusual life cycle that includes free-living dioecious adult generations. Infection in immunocompromised individuals can result in potentially fatal disseminated strongyloidiasis.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125925>	C122045	Taenia|TAENIA	A genus of parasitic cestodes in the family Taeniidae that infect mammals and are characterized by ribbon-like bodies.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125926>	C77167	Torulaspora	A genus of ascomycetous yeasts in the family Saccharomycetaceae. Species in this genus reproduce vegetatively by multilateral budding. Cells are globose or ellipsoid and pseudohyphae may be formed. Members of this genus are vigorous fermenters but will not grow on nitrate as a sole source of nitrogen.			Fungus	
C125927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125927>	C14248	Toxocara|TOXOCARA	A genus of parasitic nematodes in the family Toxocaridae that is commonly found in the digestive tracts of carnivorous animals, with the final host being domestic animals. The typical route of infection is through ingestion of larvae contaminated soil. Human infections more frequently occur in children.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125928>	C14248	Trichinella|TRICHINELLA	A genus of parasitic nematodes in the family Trichinellidae that is found in the digestive tract of a broad spectrum of both wild and domestic mammals. The typical route of infection is through oral ingestion of larvae contaminated tissue.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125929>	C14248	Trichuris|TRICHURIS	A genus of parasitic nematodes in the family Trichuridae that is found in the mucosa of the lower intestines of humans and domestic animals. The typical route of infection is through oral ingestion of egg contaminated food, water, or soil.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12592>	C32271|C12485	Merkel Cell|Merkel Cells|Merkel cell	An epidermal cell, primarily located in the basal layer, that is thought to function in tactile sensory perception.	Merkel Cells		Cell	
C125930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125930>	C14248	Trichostrongylus|TRICHOSTRONGYLUS	A genus of parasitic nematodes in the family Strongylidae that affect domestic and wild ruminants, pigs, horses, and poultry. All Trichostrongylus species have a direct life cycle with no intermediate host. The typical route of infection is through oral ingestion of larvae-contaminated water or vegetation.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125931>	C77916	Trypanosoma|Trypanosome	A genus of kinetoplastid, unicellular, parasitic flagellate protozoa in the phylum Euglenozoa. Most trypanosomes are heteroxenous, requiring more than one obligatory host to complete its life cycle.			Eukaryote	
C125932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125932>	C211406	Tumor Response System|RESPONSE_SYSTEM|RESPONSE_SYSTEM|RESPONSE_SYSTEM|Tumor Response Criteria	A standard from which a judgment concerning tumor response to therapy can be established.			Intellectual Product	EWS Subject Response Table|EWS Variable Terminology|GCT Subject Response Table|GCT Variable Terminology|OS Subject Response Table|OS Variable Terminology
C125933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125933>	C173704|C173160	Feel Less Interest in Sex Question|Feel Less Interest in Sex|Have you felt less interest in sex	A question about whether an individual feels or felt less interest in sex.			Intellectual Product	Quality of Life Questionnaire - Pancreatic Cancer 26
C125934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125934>	C173704|C173160	Feel Less Sexual Enjoyment Question|Feel Less Sexual Enjoyment|Have you felt less sexual enjoyment	A question about whether an individual feels or felt less sexual enjoyment.			Intellectual Product	Quality of Life Questionnaire - Pancreatic Cancer 26
C125935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125935>	C49236	Protein Interaction Domain Inhibitor Therapy|Protein-Protein Interaction Inhibitor Therapy	A form of treatment that uses substances which inhibit protein-protein interactions.	Protein Interaction Domain Inhibitor Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C125936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125936>	C25180	Time Matched Derivation Indicator	An indication that data points gathered at the same timepoint will be used in the statistical analysis.			Conceptual Entity	
C125937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125937>	C20189	Scheduled|SCHEDULED	To order a planned list of activities or events.			Qualitative Concept	CDISC SDTM BRIDG Activity Mood Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125938>	C71738	Baseline Epoch|BASELINE	A period in a clinical study during which a subject's base standard measurements are collected and recorded for use in future comparisons and analyses.			Research Activity	CDISC SDTM Epoch Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125939>	C210738	ABO Blood Group Determination|ABO|ABO Blood Group|ABO Blood Group	The determination of the blood type of an individual by testing for the presence or absence of A antigen and/or B antigen on the surface of red blood cells.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12593>	C33923	Paneth Cell|Paneth Cells	A granule-rich columnar epithelial cell found in the mucous membrane lining at the base of the small intestine crypts of Lieberkühn. Paneth Cells secrete antimicrobial peptides that contribute to microbial density in the lumen of the small intestine and in the maintenance of the gastrointestinal barrier.	Paneth Cell		Cell	
C125940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125940>	C64430	Amyloid A Measurement|AMYLOIDA|Amyloid A|Amyloid A	The determination of the amount of amyloid A present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C125941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125941>	C64488	Ionized pH Adjusted Calcium Measurement|CAIONPH|Calcium, Ionized pH Adjusted|Calcium, Ionized pH Adjusted	The determination of the amount of ionized pH adjusted calcium present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C125942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125942>	C64430	Calbindin Measurement|CALB|Calbindin|Calbindin	The determination of the amount of calbindin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C125943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125943>	C82037	Carbohydrate-Deficient Transferrin to Transferrin Ratio Measurement|CDTTFRN|Carb-Deficient Transferrin/Transferrin|Carb-Deficient Transferrin/Transferrin	The determination of the ratio of carbohydrate-deficient transferrin to total transferrin present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C125944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125944>	C210012|C210010	Hepatitis B Virus Antibody Measurement	The determination of the amount of hepatitis B virus antibody present in a sample.			Laboratory Procedure	
C125945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125945>	C49237	Inulin Measurement|INULIN|Inulin|Inulin	The determination of the amount of inulin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C125946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125946>	C49237	Iohexol Measurement|IOHEXOL|Iohexol|Iohexol	The determination of the amount of iohexol present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C125947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125947>	C49188	Lipoarabinomannan Measurement|LAM|Lipoarabinomannan|Lipoarabinomannan	The determination of the amount of lipoarabinomannan present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C125948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125948>	C210738	RhD Factor Measurement|RHD|RhD Factor|RhD Factor	The determination of the amount of Rhesus factor type D present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C125949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125949>	C74760	Urea Nitrogen Measurement|UREAN|Urea Nitrogen|Urea Nitrogen	The determination of the amount of urea nitrogen present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12594>	C32655	Parietal Cell|Gastric Parietal Cells|Oxyntic Cells|Parietal Cells	A large epithelial cell located in the mucous membrane of the stomach that secretes gastric intrinsic factor and hydrochloric acid.	Parietal Cell		Cell	
C125950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125950>	C74760	Urea Nitrogen to Creatinine Ratio Measurement|UREANCRT|Urea Nitrogen/Creatinine|Urea Nitrogen/Creatinine	The determination of the ratio of urea-nitrogen to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C125951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125951>	C73456	Cardiologist|CARDIOLOGIST	A physician who specializes in the diagnosis and treatment of heart disorders.			Professional or Occupational Group	CDISC SDTM Evaluator Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125952>	C111328|C111281	Particle-Enhanced Nephelometric Immunoassay|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|PENIA	A method to quantify the concentration of immunoaggregates suspended in a liquid or gas using a nephelometer. The immunoaggregates are target antigens agglutinated to antigen-specific antibody-coated polystyrene latex-enhanced particles.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C125953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125953>	C111328	Particle-Enhanced Turbidimetric Immunoassay|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|PETIA	A method to quantify the opaqueness of a liquid using a turbidimeter, by measuring the decrease in light intensity due to the scattering effect of suspended immunoaggregates in a liquid sample. The immunoaggregates are target antigens agglutinated to antigen-specific antibody-coated polystyrene latex-enhanced particles.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C125954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125954>	C122319	Aerobic Gram-Negative Coccobacillus|AEROBIC GRAM-NEGATIVE COCCOBACILLUS	Any bacteria with a shape between that of a sphere and a rod that requires oxygen to grow or respirate and has a cell wall that contains low levels of peptidoglycan and stains pink with the Gram staining technique.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125955>	C122319|C119323	Anaerobic Gram-Negative Coccobacillus|ANAEROBIC GRAM-NEGATIVE COCCOBACILLUS	Any bacteria with a shape between that of a sphere and a rod that does not require oxygen to grow or respirate and has a cell wall that contains low levels of peptidoglycan and stains pink with the Gram staining technique.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125956>	C14308	Metapneumovirus|METAPNEUMOVIRUS	A genus of nonsegmented, negative-strand ssRNA viruses in the Pneumovirinae subfamily that uniquely accomplishes cell fusion without the help of an attachment protein. This virus has a genome of about 13 kb, encoding eight proteins. The virion is enveloped and spherical with a diameter of about 150 nm			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125957>	C68564	Normal Flora|NORMAL FLORA	Harmless or beneficial population of microorganisms or plant life that normally occur in specific areas of the body or the environment.			Classification	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125958>	C14278	Streptomyces paraguayensis|STREPTOMYCES PARAGUAYENSIS	A species of gram-positive, aerobic actinomycetes bacteria in the genus Streptomyces that has a branching, filamentous growth pattern and is associated with black grained mycetoma disease in humans.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125959>	C77194	Syncephalastrum|SYNCEPHALASTRUM	The only fungal genus in the Syncephalastraceae family within the Mucorales order. Sporangiospores are produced asexually through the development of cylindrical merosporangia; however, syncephalastrum also undergoes a sexual cycle that produces zygospores. It is primarily isolated from animal excrement, plant material, and soil in tropical or subtropical regions.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12595>	C41608	Sertoli Cell|Sertoli Cells|Sustentacular Cell of Testis	Elongated cells in the seminiferous tubules to which spermatids are attached during spermiogenesis; they secrete androgen-binding protein and establish the blood-testis barrier by forming tight junctions with adjacent Sertoli's cells.	Sertoli Cell		Cell	
C125960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125960>	C125925	Taenia saginata|Beef Tapeworm|TAENIA SAGINATA	A species of parasitic cestodes in the genus Taenia that is acquired through the ingestion of infected bovine tissue. Humans are the definitive host of the adult cestodes, resulting in taeniasis.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125961>	C125925	Taenia solium|Cysticercus cellulosae|Pork Tapeworm|TAENIA SOLIUM	A species of parasitic cestodes in the genus Taenia that is acquired through the ingestion of infected porcine tissue. Humans are the definitive host of the adult cestodes, resulting in taeniasis. Taenia solium also causes cysticercosis, a tissue infection caused by larval cysts, which results when humans serve as an intermediate host.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125962>	C125926	Torulaspora delbrueckii|TORULASPORA DELBRUECKII	A species of ascomycetous yeast in the Torulaspora genus that has the ability to ferment and assimilate carbon compounds.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125963>	C125927	Toxocara canis|Dog Roundworm|TOXOCARA CANIS	A species of parasitic nematodes in the genus Toxocara where canids are the definitive host.  Human infection occurs through the accidental ingestion of infective larvae in the tissues of other terrestrial mammals, which serve as paratenic hosts. Toxocara canis is the most common cause of toxocariasis in humans.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125964>	C125927	Toxocara cati|Cat Roundworm|Feline Roundworm|TOXOCARA CATI	A species of parasitic nematodes in the genus Toxocara where felids are the definitive host.  Paratenic hosts include invertebrates, birds, and rodents. Human infection most commonly occurs in children through accidental ingestion of larvated eggs from a contaminated environment.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125965>	C125928	Trichinella spiralis|TRICHINELLA SPIRALIS	A species of parasitic nematodes in the genus Trichinella that is found worldwide. There are four region-specific subspecies that have different carnivorous animal hosts. Trichinosis infection may occur through the ingestion of raw or undercooked animal tissue that contains encysted larvae. The larvae invade intestinal mucosa, where sexual maturation occurs. Female nematodes penetrate the mucosa and larvae travel through the bloodstream to penetrate and encyst in muscle tissue.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125966>	C77167	Trichoderma|TRICHODERMA	A genus of green-spored ascomycetes fungi in the family Hypocreaceae where nonseptate conidia are produced on two- or three-branched conidiophores. Trichoderma is present in all soil.  Some species are pathogenic to other fungi and others have reportedly caused opportunistic infection in immune-compromised humans, particularly children.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125967>	C89825	Trichomonas vaginalis|TRICHOMONAS VAGINALIS	A species of flagellated protozoan parasite in the genus Trichomonas that resides in the genitourinary tract of both male and female humans, which are the only natural hosts. Transmission occurs through sexual intercourse, and results in trichomonal vaginitis in females or urethral infection in males.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125968>	C125930	Trichostrongylus axei|TRICHOSTRONGYLUS AXEI	A species of parasitic roundworms in the family Trichostrongylidae that infest horses and ruminants, causing anorexia, persistent diarrhea, and weight loss. Adult T. axei are slender, measuring up to 8 mm long, and are usually found in the stomach of infected animals. Humans are rarely infected.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125969>	C125930	Trichostrongylus colubriformis|Bankrupt Worm|Black Scour Worm|TRICHOSTRONGYLUS COLUBRIFORMIS	A species of parasitic roundworms in the family Trichostrongylidae that causes black scour disease in sheep, cattle, and goats.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12596>	C12508	Eukaryotic Cell|Eukaryotic Cells	A cell with a membrane-bound nucleus.	Eukaryotic Cells		Cell	
C125970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125970>	C125930	Trichostrongylus orientalis|TRICHOSTRONGYLUS ORIENTALIS	A species of parasitic roundworms in the family Trichostrongylidae that is most prevalent in Asian countries.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125971>	C125930	Trichostrongylus probolurus|TRICHOSTRONGYLUS PROBOLURUS	A species of parasitic roundworms in the family Trichostrongylidae that most often infests sheep, goats, and camels.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125972>	C125930	Trichostrongylus vitrinus|TRICHOSTRONGYLUS VITRINUS	A species of parasitic roundworms in the family Trichostrongylidae that most often infests sheep, goats, camel, deer, and rabbits and are mostly found in the proximal third of the small intestine.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125973>	C125929	Trichuris trichiura|Human Whipworm|TRICHURIS TRICHIURA	A species of parasitic roundworms in the family Trichuridae most commonly found in tropical Asia and, to a lesser degree, in Africa and South America. Infestation with T. trichiura is generally confined to the cecum and colon but can be present in more distal segments of the GI tract in heavily infected individuals.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125974>	C77169	Tritirachium|TRITIRACHIUM	A genus of anamorphic molds in the phylum Basidiomycota characterized by the zig-zag shape of the fertile portions of the conidiogenous cells and the absence of distinct denticles. Tritirachium species are hyphal in culture and the colonies are colored in shades ranging from pale pinkish or lilac to brown.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125975>	C125931	Trypanosoma brucei gambiense|TRYPANOSOMA BRUCEI GAMBIENSE	A species of parasitic flagellate protozoa in the order Kinetoplastida. T. b. gambiense is transmitted by the tsetse fly and causes West African trypanosomiasis. Humans are the main reservoir for T. b. gambiense, but this species can also be found in animals.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125976>	C125931	Trypanosoma brucei rhodesiense|TRYPANOSOMA BRUCEI RHODESIENSE	A species of parasitic flagellate protozoa in the order Kinetoplastida. T. b. rhodesiense is transmitted by the tsetse fly and causes East African trypanosomiasis. Wild game animals are the main reservoir of T. b. rhodesiense.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125977>	C125931	Trypanosoma cruzi|TRYPANOSOMA CRUZI	A species of parasitic euglenoid protozoan in the family Trypanosomatidae. T. cruzi is passed between mammalian hosts through the feces of a triatomine insect vector. Infection in humans causes Chagas disease.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125978>	C77167	Ulocladium|ULOCLADIUM	A genus of saprophytic fungi in the family Pleosporaceae with numerous, usually solitary, multicelled conidia that are typically obovoid, dark brown, and often rough-walled. Ulocladium species are commonly found in the soil and on decaying herbaceous plants but they also grown indoors on cellulose containing materials.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125979>	C77169	Ustilago|USTILAGO	A genus of smut fungi in the phylum Basidiomycota with a branched, septate, hyaline, intercellular mycellium, with or without haustoria. Species in this genus infect the floral parts of wheat, barley, oat, maize, sugarcane, rye and wild grasses.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12597>	C12508	Germ Cell|Gamete|Gametes|Germ Cells|Reproductive Cells|Sex Cell|Sexual Cell|germ cell|reproductive cell	Gametes, also known as sex cells or germ cells, are the cells that come together during fertilization or conception in organisms that reproduce sexually.  Their genetic complement consists of a single set of unpaired chromosomes.	Germ Cells		Cell	
C125980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125980>	C50921	Vancomycin Resistant Staphylococcus Aureus|STAPHYLOCOCCUS AUREUS, VANCOMYCIN RESISTANT|VRSA|Vancomycin-Resistant Staphylococcus Aureus|Vancomycin-resistant Staphylococcus aureus	Strains of Staphylococcus aureus that are not readily killed by vancomycin antibiotics. Vancomycin resistance is acquired by mutation and thickening of the cell wall due to accumulation of excess amounts of peptidoglycan.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125981>	C76311	Vancomycin Susceptible Enterococcus|VANCOMYCIN SUSCEPTIBLE ENTEROCOCCUS|VSE|Vancomycin-Susceptible Enterococcus	A non-taxonomic grouping of enterococcus species that are sensitive to vancomycin antibiotics.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125982>	C86837	Veillonella atypica|VEILLONELLA ATYPICA|Veillonella parvula subsp. atypica	A species of nonmotile, non-spore-forming, anaerobic, Gram negative, cocci shaped bacteria in the family Veillonellaceae. This species is a normal part of human oral microbiota.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125983>	C77167	Verticillium|VERTICILLIUM	A genus of fungi in the phylum Ascomycota. Species in this genus cause verticillium wilt in eudicot plants.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125984>	C77916	Vorticella|VORTICELLA	A genus of stalked, inverted bell-shaped, ciliated protozoa in the phylum Ciliophora.			Eukaryote	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125985>	C25338	Allred Proportion Positive Score|ALLRED PROPORTION POSITIVE SCORE	A score developed by Allred et al. (1998) for the proportion of tumor cells that are positive for a given biomarker. The proportion score is assigned based on the biomarker positivity measurement.			Finding	CDISC SDTM Microscopic Findings Test Detail Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125986>	C25338	Allred Average Staining Intensity Score|ALLRED STAINING INTENSITY SCORE	A score developed by Allred et al. (1998) for the average staining intensity for all stained protein-positive cells.			Finding	CDISC SDTM Microscopic Findings Test Detail Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125987>	C25338	Allred Total Score|ALLRED TOTAL SCORE|Allred Score	A score for the semi-quantitative staining of estrogen-positive (ER+) or progesterone-positive (PR+) cells in breast cancer tissue samples. It combines a score of 0 through 5 for percentage of stained cells and a score of 0-3 for the intensity of staining. A score of 0-2 is considered negative and 3-8 qualify as positive.			Finding	CDISC SDTM Microscopic Findings Test Detail Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125988>	C25338	H Score Total Score|H SCORE TOTAL SCORE|H Score	The histopathological evaluation of staining in tissue based on the H Score scoring system (McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716-721).			Finding	CDISC SDTM Microscopic Findings Test Detail Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125989>	C94299	Receptor Overall Status|RECEPTOR OVERALL STATUS	A qualitative assessment of the status of a biological specimen with regards to a cellular receptor.			Laboratory or Test Result	CDISC SDTM Microscopic Findings Test Detail Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12598>	C12597	Oocyte|Egg|Human Oocyte (Egg)|Oocytes|Ovocyte|Ovum|Unfertilized Egg	The female gamete, germ cells in stages between the prophase of the first maturation division and the completion of the second maturation division.	Ovum		Cell	FDA Structured Product Labeling Terminology|SPL Tissue Form Product Type Terminology
C125990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125990>	C125932	Blazer Colorectal Cancer 2008 Oncology Response Criteria|BLAZER COLORECTAL CANCER 2008				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125991>	C125932	Boonsirikamchai Colorectal Cancer 2011 Oncology Response Criteria|BOONSIRIKAMCHAI COLORECTAL CANCER 2011				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125992>	C125932	Bruggemann MRD 2010 Oncology Response Criteria|BRUGGEMANN MRD 2010				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125993>	C125932	Burcombe Breast Cancer 2005 Oncology Response Criteria|BURCOMBE BREAST CANCER 2005				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125994>	C125932	Cheson CLL 2006 Oncology Response Criteria|CHESON CLL 2006				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125995>	C125932	Cheson CLL 2012 Oncology Response Criteria|CHESON CLL 2012				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125996>	C125932	Cheson Hodgkins Non-Hodgkins Lymphoma 2008 Oncology Response Criteria|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125997>	C125932	Cheson Lymphoma 2008 Oncology Response Criteria|CHESON LYMPHOMA 2008				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125998>	C125932	Cheson Malignant Lymphoma 2007 Oncology Response Criteria|CHESON MALIGNANT LYMPHOMA 2007				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C125999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C125999>	C125932	Cheson Non-Hodgkins Hodgkins Lymphoma 1993 Oncology Response Criteria|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C1259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1259>	C1911	Tri-N-butyl Phosphate|TRI-N-BUTYL PHOSPHATE|Tributyl Phosphate|Tributyl phosphate	Tri-n-butyl phosphate, Bu3-P, TBP.  Industrial chemical; used as a plasticizer, in hydraulic fluid, as a solvent and extractant for metal ions, and as a heat exchange agent.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C126000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126000>	C125932	Cheson Non-Hodgkins Lymphoma 1999 Oncology Response Criteria|CHESON NON-HODGKINS LYMPHOMA 1999				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126001>	C125932	Chollet Breast Cancer 2002 Oncology Response Criteria|CHOLLET BREAST CANCER 2002				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126002>	C125932	Dohner AML 2010 Oncology Response Criteria|DOHNER AML 2010				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126003>	C125932	Durie Multiple Myeloma 2006 Oncology Response Criteria|DURIE MULTIPLE MYELOMA 2006				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126004>	C125932	EASL Bruix Liver Cancer 2001 Oncology Response Criteria|EASL BRUIX LIVER CANCER 2001				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126005>	C125932	EBMT Blade Myeloma 1998 Oncology Response Criteria|EBMT BLADE MYELOMA 1998				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126006>	C125932	EORTC Olsen Mycosis Fungoides And Sezary Syndrome 2011 Oncology Response Criteria|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126007>	C125932	European Leukemianet Baccarani CML 2006 Oncology Response Criteria|EUROPEAN LEUKEMIANET BACCARANI CML 2006				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126008>	C125932	GCIG Rustin Ovarian Cancer 2011 Oncology Response Criteria|GCIG RUSTIN OVARIAN CANCER 2011				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126009>	C125932	Guilhot CML 2007 Oncology Response Criteria|GUILHOT CML 2007				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12600>	C12598	Primary Oocyte|Oogonia|Oogonium|Primordial Ovum	An oocyte that is arrested in the diplotene stage of meiosis prophase 1.	Oogonium		Cell	
C126010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126010>	C125932	Guppy Ovarian Cancer 2002 Oncology Response Criteria|GUPPY OVARIAN CANCER 2002				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126011>	C125932	Hamaoka Breast Cancer 2010 Oncology Response Criteria|HAMAOKA BREAST CANCER 2010				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126012>	C125932	Hartmann Germ Cell Cancer 2002 Oncology Response Criteria|HARTMANN GERM CELL CANCER 2002				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126013>	C125932	Hartman Pancreatic Cancer 2012 Oncology Response Criteria|HARTMAN PANCREATIC CANCER 2012				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126014>	C125932	IWC Hallek CLL 2008 Oncology Response Criteria|IWC HALLEK CLL 2008				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126015>	C125932	IWG Cheson AML 2003 Oncology Response Criteria|IWG CHESON AML 2003				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126016>	C125932	IWG Cheson MDS 2000 Oncology Response Criteria|IWG CHESON MDS 2000				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126017>	C125932	IWG Cheson MDS 2006 Oncology Response Criteria|IWG CHESON MDS 2006				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126018>	C125932	Jacinto Cervical Cancer 2007 Oncology Response Criteria|JACINTO CERVICAL CANCER 2007				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126019>	C125932	Japanese Classification Gastric Cancer 2011 Oncology Response Criteria|JAPANESE CLASSIFICATION GASTRIC CANCER 2011				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12601>	C12508	Zygote|Egg, Fertilized|Fertilized Egg|Fertilized Ovums|Ovum, Fertilized	The cell formed by the union of two gametes, especially a fertilized ovum before cleavage. (Online Medical Dictionary)	Zygote		Embryonic Structure	
C126020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126020>	C125932	Juweid Non-Hodgkins Lymphoma 2005 Oncology Response Criteria|JUWEID NON-HODGKINS LYMPHOMA 2005				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126021>	C125932	Keam Breast Cancer 2013 Oncology Response Criteria|KEAM BREAST CANCER 2013				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126022>	C125932	Kimby Waldenstroms Macroglobulinemia 2006 Oncology Response Criteria|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126023>	C125932	Kuker Lymphoma 2005 Oncology Response Criteria|KUKER LYMPHOMA 2005				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126024>	C125932	Lee Lung Cancer 2011 Oncology Response Criteria|LEE LUNG CANCER 2011				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126025>	C125932	Lugano Classification Oncology Response Criteria|LUGANO CLASSIFICATION				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126026>	C125932	Macdonald Glioma 1990 Oncology Response Criteria|MACDONALD GLIOMA 1990				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126027>	C125932	Morphology, Attenuation, Size, and Structure Criteria|MASS|MASS				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126028>	C125932	Minkov Langerhans Cell Histiocytosis 2009 Oncology Response Criteria|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126029>	C125932	Montserrat CLL 1989 Oncology Response Criteria|MONTSERRAT CLL 1989				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12602>	C33582	Spermatozoon|SPERMATOZOON|Sperm|Sperm Cell|Spermatic|Spermatozoa|Zoosperm|sperm	The male reproductive cell that is formed in the testicle. A sperm consists of a head, a body, and a tail that provides propulsion.	Spermatozoa		Cell	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126030>	C125932	Modified RANO Van Den Bent Glioma 2011 Oncology Response Criteria|MRANO VAN DEN BENT GLIOMA 2011				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126031>	C125932	Modified RECIST Byrne Mesothelioma 2004 Oncology Response Criteria|MRECIST BYRNE MESOTHELIOMA 2004|mRECIST	Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. (Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004 Feb;15(2):257-60.)			Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GCT Authorized Value Terminology|GCT Subject Response Table
C126032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126032>	C125932	Modified RECIST Lencioni Liver Cancer 2010 Oncology Response Criteria|MRECIST LENCIONI LIVER CANCER 2010				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126033>	C125932	Murphy Prostate Cancer 1980 Oncology Response Criteria|MURPHY PROSTATE CANCER 1980				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126034>	C125932	NCCN ALL MRD 2014 Oncology Response Criteria|NCCN ALL MRD 2014				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126035>	C125932	NCIWG Cheson CLL 1996 Oncology Response Criteria|NCIWG CHESON CLL 1996				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126036>	C125932	Palumbo Multiple Myeloma 2009 Oncology Response Criteria|PALUMBO MULTIPLE MYELOMA 2009|Palumbo IMWG 2009				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126037>	C125932	PCWG Bubley Prostate Cancer 1999 Oncology Response Criteria|PCWG BUBLEY PROSTATE CANCER 1999|PCWG1				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126038>	C125932	PCWG Scher Prostate Cancer 2008 Oncology Response Criteria|PCWG SCHER PROSTATE CANCER 2008|PCWG2				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126039>	C125932	PET Response Criteria in Solid Tumors|PERCIST|PERCIST|PERCIST	A set of rules that define when tumors in cancer patients respond, stabilize, or progress during treatment with respect to positron emission tomography.			Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GCT Authorized Value Terminology|GCT Subject Response Table
C12603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12603>	C13038	Head of the Spermatozoon|Sperm Head	The anterior, often oval-shaped, part of a mature spermatozoon, which contains haploid male nuclear material.	Sperm Head		Cell Component	
C126040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126040>	C125932	Petit Breast Cancer 2001 Oncology Response Criteria|PETIT BREAST CANCER 2001				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126041>	C125932	Prince T Cell Lymphoma 2010 Oncology Response Criteria|PRINCE TCELL LYMPHOMA 2010				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126042>	C117960	Protocol Defined Response Criteria|PROTOCOL DEFINED RESPONSE CRITERIA	A description of the disease response to treatment as characterized by the clinical trial protocol.			Idea or Concept	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126043>	C125932	Rajkumar Myeloma 2011 Oncology Response Criteria|RAJKUMAR MYELOMA 2011				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126044>	C125932	Response Evaluation Criteria in Cancer of the Liver|RECICL|RECICL				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126045>	C125932	Size and Attenuation CT Criteria|SACT|SACT Criteria				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126046>	C125932	Scher Prostate Cancer 2011 Oncology Response Criteria|SCHER PROSTATE CANCER 2011				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126047>	C125932	Schwarz Cervical Cancer 2009 Oncology Response Criteria|SCHWARZ CERVICAL CANCER 2009				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126048>	C125932	Shindoh Colorectal Cancer 2013 Oncology Response Criteria|SHINDOH COLORECTAL CANCER 2013				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126049>	C125932	Tsukasaki Leukemia Lymphoma 2009 Oncology Response Criteria|TSUKASAKI LEUKEMIA LYMPHOMA 2009				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12604>	C33582	Spermatid|Spermatids|Spermatoblast|Spermatoblasts|Spermoblast	An immature male germ cell that is formed by meiotic division of a secondary spermatocyte. Spermatids develop into spermatozoa.	Spermatid		Cell	
C126050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126050>	C125932	Guidelines for Management of Breast Cancer WHO 2006|WHO BREAST CANCER 2006				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126051>	C125932	Wolchok Solid Tumors 2009 Oncology Response Criteria|Modified Overall Immune Related Response Criterion|Modified irRC|WOLCHOK SOLID TUMORS 2009|irRC|irRECIST	A measure proposed by Wolchok et al. (Clin Cancer Res 2009;15:7412-7420) to determine the extent of an antitumor response to a particular immunotherapeutic agent.			Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126052>	C38081	Percent Predicted Functional Residual Capacity|FRCPP|Percent Predicted FRC|Percent Predicted FRC	The volume of air remaining in the lungs after a normal exhalation as a proportion of the predicted normal value. (CDISC)			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126053>	C78741	Exhaled Breath Condensate|EXHALED BREATH CONDENSATE	Expired air that has been condensed.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126054>	C27992	Non-Pathological|NON-PATHOLOGICAL	The absence of disease or pathology.			Qualitative Concept	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C126055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126055>	C50995	Present Without Unequivocal Progression	There is evidence of disease without evidence of unequivocal progression.			Finding	
C126056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126056>	C119241	Calcification Indicator|CALCFIND	A textual indication as to whether calcification is present.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C126057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126057>	C96622	Percent Change From Nadir in Sum of Area	The most recently recorded sum of areas minus the lowest sum of diameters previously recorded divided by the lowest sum of areas previously recorded, multiplied by 100.			Quantitative Concept	
C126058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126058>	C164620	Biospecimen Retained and/or Contains DNA Indicator	An indication as to whether biospecimens have been retained and/or whether those retained biospecimens contain DNA.			Conceptual Entity	
C126059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126059>	C25337	EMA Decision Number for Pediatric Investigation Plan|EMA Decision Number for PIP|EMA Decision Number for PIP|EMPIPDCN	An alphnumeric code assigned by the European Medicines Agency (EMA) to an EMA regulatory decision.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C12605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12605>	C33582	Spermatocyte|Spermatocytes|Spermiocyte|Spermiocytes	An immature male germ cell that is formed during the spermatocytogenesis phase of spermatogenesis. Spermatocytes are derived from spermatogonia and develop into spermatids.	Spermatocyte		Cell	
C126060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126060>	C25180	EudraCT Resubmission Indicator|EURSBIND	An indication as to whether the trial being submitted to the EudraCT is a trial that has been previously submitted to the EudraCT system and withdrawn.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C126061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126061>	C25364	EudraVigilance Sender Identifier|EVSNDID|EudraVigilance Sender ID|EudraVigilance Sender ID	A unique identifier assigned to the organization that is transmitting an adverse drug reaction report to the EudraVigilance system.			Intellectual Product	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C126062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126062>	C43513	Protocol Keyword|KEYWORD|Keyword	A word or small set of words designed to convey the subject of a clinical study.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology|SeroNet Study Descriptors|SeroNet Variables
C126063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126063>	C25337	Number of Groups or Cohorts|NCOHORT|Number of Groups/Cohorts|Number of Groups/Cohorts	The number of groups or cohorts that are part of the study.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C126064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126064>	C15787	Observational Model|OBSMODEL	The trial design developed to compare biomedical and/or health outcomes in pre-defined and non-assigned groups of individuals.			Research Activity	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C126065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126065>	C21514	Observational Time Perspective of Study|OBSTIMP|Observational Time Perspective|Observational Time Perspective|Observational Time Perspective	The temporal relationship between the observation period and time of subject enrollment. (ClinicalTrials.gov)			Temporal Concept	CDISC DDF Observational Study Design Attribute Terminology|CDISC DDF Terminology|CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C126066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126066>	C70834	Observational Study Population Description|OBSTPOPD|Obs Study Population Description|Obs Study Population Description	A textual description of the population group from which the group or cohort will be selected for observational studies.			Intellectual Product	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C126067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126067>	C71492	Observational Study Sampling Method|OBSTSMM	The process by which subjects are selected to participate in observational studies.			Activity	CDISC DDF Observational Study Design Attribute Terminology|CDISC DDF Terminology|CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C126068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126068>	C25365	Observational Study Sampling Method Description|OBSTSMMD|Obs Study Sampling Method Description|Obs Study Sampling Method Description	A textual description of the sampling method used to assign study participants into groups or cohorts within an observational study.			Intellectual Product	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C126069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126069>	C25180	Pediatric Investigation Plan Indicator|PIPIND	An indication as to whether the trial is part of the pediatric investigation plan.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C12606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12606>	C33582	Spermatogonium|Spermatogonia	An undeveloped male germ cell. Spermatogonia develop into primary spermatocytes.	Spermatogonium		Cell	
C126070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126070>	C25180	Rare Disease Indicator|RDIND	An indication as to whether the condition under study is considered a rare or orphan disease.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C126071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126071>	C68805	Resubmission Letter|RESUBLTR	An alphabetic character that describes the incremental order of trial submissions or resubmissions.			Functional Concept	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C126072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126072>	C25365	Retained Biospecimen Description|RTSPCDES	A textual description of the specimen types, which are collected during the course of the study.			Intellectual Product	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C126073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126073>	C25180	SUSAR Reporting to EudraVigiliance Clinical Trial Module Indicator|SREVIND|SUSAR Reporting to EVCTM Indicator|SUSAR Reporting to EVCTM Indicator	An indication as to whether suspected unexpected serious adverse reactions will be reported to a EudraVigiliance clinical trial module.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C126074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126074>	C25180	SUSAR Reporting to National Competent Authority Indicator|SRNCAIND|SUSAR Reporting to NCA Indicator|SUSAR Reporting to NCA Indicator	An indication as to whether suspected unexpected serious adverse reactions will be reported to national competent authorities.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C126075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126075>	C25365	Substudy Details|SSTDYDTL	A textual description of the substudy.			Intellectual Product	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C126076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126076>	C25180	Substudy Planned Indicator|SSTDYIND	An indication as to whether a study performed on a subgroup of subjects included in the original trial is planned to be included as part of the current study.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C126077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126077>	C93625	Planned Follow-Up Duration|TRGFUDUR|Target Follow-Up Duration|Target Follow-Up Duration	The anticipated time period over which each study participant is to be followed. (clinicaltrials.gov)			Temporal Concept	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C126078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126078>	C73681	Absorbance Unit per Milliliter|AU/mL|Absorbance U/mL|{Absorbance U}/mL|{Absorbance U}/mL|{Absorbance U}/ml|{Absorbance U}/ml	A unit of optical density expressed as the absorbance of light transmitted through the medium on the logarithmic scale per unit of volume equal to one milliliter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C126079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126079>	C67442	Copies per Microgram|copies/ug|{copies}/ug|{copies}/ug	A unit of concentration expressed as a number of copies per unit mass equal to one microgram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12607>	C12913	Giant Cell|MULTINUCLEATED GIANT CELL|Multinucleated Giant Cell|syncytium	An abnormally large cell that contains multiple nuclei and an abundant amount of cytoplasm.			Cell	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C126080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126080>	C48568	Cubic Millimeter per Square Millimeter per Year|mm3/mm2/a|mm3/mm2/a|mm3/mm2/year	A rate unit defined as the number of cubic millimeters of substance per area equal to one square millimeter per unit of time equal to one year.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C126081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126081>	C48564	Micrometer per Day|um/d|um/d|um/day	A unit of volumetric flow rate defined as the rate at which one micrometer of matter crosses a given surface during the period of time equal to one day.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C126082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126082>	C67395	Micromole per Kilogram per Minute|umol/kg/min|umol/kg/min|umol/kg/min	A unit of concentration (molarity unit) equal to one millionth of a mole (10E-6 mole) per kilogram of a substance per period of time equal to sixty seconds.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C126083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126083>	C171083	Basal Metabolic Rate|BMR	A patient's energy expenditure at rest.			Clinical Attribute	CDISC SDTM Terminology|CDISC SDTM Vital Sign Test Code Terminology|CDISC SDTM Vital Sign Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C126084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126084>	C134576	Experimental Organism Benign Mixed Sertoli-Leydig Cell Tumor|SERTOLI-LEYDIG CELL TUMOR, MIXED, BENIGN	A benign neoplasm composed of Sertoli cells arranged in tubules intermixed with pleomorphic Leydig cells.			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C126085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126085>	C134576	Experimental Organism Benign Mixed Mullerian Tumor|MULLERIAN TUMOR, MIXED, BENIGN	A benign neoplasm arising from pluripotent mesodermal cells of the Mullerian ducts. (INHAND)			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C126086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126086>	C134576	Experimental Organism Benign Neuroendocrine Cell Tumor|NEUROENDOCRINE CELL TUMOR, BENIGN	A benign neoplasm arising from neuroendocrine cells.			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C126087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126087>	C134576	Experimental Organism Malignant Neuroendocrine Cell Tumor|NEUROENDOCRINE CELL TUMOR, MALIGNANT	A malignant neoplasm arising from neuroendocrine cells with evidence of invasion.			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C126088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126088>	C134576	Experimental Organism Malignant Renal Mesenchymal Tumor|RENAL MESENCHYMAL TUMOR, MALIGNANT	A malignant neoplasm arising from foci of atypical fibroblast-like cells in the interstitium of the outer stripe of the outer medulla of the kidney. (INHAND)			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C126089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126089>	C3824	Needle Tract Lesion|NEEDLE TRACT LESION	A localized pathological or traumatic structural change due to insertion and/or withdrawal of a needle.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12608>	C45714	Islet of Langerhans|Endocrine Pancreas|Endocrine Pancreas|Human Pancreatic Islet Cells|Islands of Langerhans|Islet Cells|Islets of Langerhans|Islets of Langerhans|Langerhans Islets|PANCREAS, ENDOCRINE|Pancreatic Islets|Pars Endocrina Pancreatis	A specialized region of tissue located within the parenchyma of the pancreas that contains a mixed population of distinct endocrine cells, including beta, alpha, pancreatic polypeptide, delta, and epsilon cells, which respectively produce and secrete insulin, glucagon, pancreatic polypeptide, somatostatin, and ghrelin.	Islets of Langerhans		Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Structured Product Labeling Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|SPL Tissue Form Product Group Terminology|SPL Tissue Form Product Type Terminology
C126090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126090>	C93874	EudraVigilance Sender Organization Name|EVSNDORG|EudraVigilance Sender Organization|EudraVigilance Sender Organization|EudraVigilance Sender Organization	The name of the group or institution that is transmitting an adverse drug reaction report to the EudraVigilance system.			Intellectual Product	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C126091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126091>	C16847	Transfills Medical Gas	The process of transfilling in order to produce a medical gas product.			Activity	FDA Structured Product Labeling Terminology|SPL Business Operation Qualifier Terminology
C126092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126092>	C207072	Institutional Review Board Independent Ethics Committee Progress Report Documentation|IRB or IEC Progress Report|IRB-IEC Progress Report|IRB-IEC Progress Report|IRB/IEC Progress Report|Spon IRB Prog Rpt	Documentation containing regular reports of the clinical trial conduct, other than safety reports, submitted to the Institutional Review Board or Independent Ethics Committee.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IRB or IEC and Other Approvals Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C126093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126093>	C207067	Clinical Trial Submission to Other Committees Documentation|Other Submissions|Other Submissions|Spon Othr IRB Subm	Documentation submitted to other committee(s) for approval of the clinical trial, and those related to any changes or updates made to that trial.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM IRB or IEC and Other Approvals Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C126094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126094>	C207067	Clinical Trial Vendor Management Plan Documentation|Vendor Management Plan|Vendor Management Plan|Vendor Mgmt Pln	Documentation describing the overall management strategy for vendors used to conduct clinical trial-related activities.			Intellectual Product	CareLex eTMF Terminology|CDISC TMF Terminology|CDISC TMF-RM Trial Management Zone Terminology|Clinical Data Interchange Standards Consortium Terminology
C126095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126095>	C91105|C21154	Perceived Stress Scale - 14 Questionnaire|PSS-14|PSS-14 Questionnaire	A 14 item self-report questionnaire that utilizes a 5-point Likert Scale rating system to assess an individual's perception of the stressfulness of life situations in the past month.			Intellectual Product	
C126096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126096>	C118873	How Often Dealt Successfully with Day to Day Problems and Annoyances in the Last Month Question|How Often Dealt Successfully with Day to Day Problems and Annoyances in the Last Month|In the last month, how often have you dealt successfully with day to day problems and annoyances	A question about the frequency an individual dealt successfully with day to day problems and annoyances in the last month.			Intellectual Product	Perceived Stress Scale - 14 Questionnaire
C126097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126097>	C173160|C118873	How Often Felt You Were Effectively Coping with Important Changes Occurring in Life Question|How Often Felt You Were Effectively Coping with Important Changes Occurring in Life in the Last Month|In the last month, how often have you felt that you were effectively coping with important changes that were occurring in your life	A question about the frequency an individual felt that they were effectively coping with important changes occurring in their life in the last month.			Intellectual Product	Perceived Stress Scale - 14 Questionnaire
C126098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126098>	C173597|C118873	How Often Found Yourself Thinking About Things That You Have to Accomplish in the Last Month Question|How Often Found Yourself Thinking About Things That You Have to Accomplish in the Last Month|In the last month, how often have you found yourself thinking about things that you have to accomplish	A question about the frequency an individual found themself thinking about things that they had to accomplish in the last month.			Intellectual Product	Perceived Stress Scale - 14 Questionnaire
C126099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126099>	C173045|C118873	How Often Able to Control the Way You Spend Your Time in the Last Month Question|How Often Able to Control the Way You Spend Your Time in the Last Month|In the last month, how often have you been able to control the way you spend your time	A question about the frequency an individual has been able to control the way they spent their time in the last month.			Intellectual Product	Perceived Stress Scale - 14 Questionnaire
C12609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12609>	C41608	Leydig Cell|Interstitial Cell of Testis|Interstitial Cell of the Testis|Interstitial cell of Leydig|Leydig Cells	Testosterone-secreting interstitial cells located between the seminiferous tubules of the testes.	Leydig Cell		Cell	
C1260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1260>	C1934	Tributyrin|1,2,3-Propanetriyl Butanoate|1,2,3-Tributyrylglycerol|1,2,3-Tributyrylglycerol|Butanoic Acid 1,2,3-Propanetriyl Ester|Butanoic Acid, 1,2,3-Propanetriyl Ester|Butyryl Triglyceride|Glyceryl Tributyrate|Glyceryl tributyrate|TB|TRIBUTYRIN|tributyrin	A triglyceride prodrug of butyric acid with potential antineoplastic activity. Butyrate, the active metabolite of tributyrin, inhibits histone deacetylase, resulting in increased differentiation, decreased proliferation, cell cycle arrest, and apoptosis in some tumor cell lines. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126100>	C45597	Scopoletin|2H-1-Benzopyran-2-One, 7-Hydroxy-6-Methoxy-|2H-1-Benzopyran-2-One, 7-Hydroxy-6-Methoxy- (9CI)|6-Methoxyumbelliferone|6-Methylesculetin|6-O-Methylesculetin|7-Hydroxy-5-Methoxycoumarin|7-Hydroxy-6-Methoxychromen-2-One|7-Hydroxy-6-Methoxycoumarin|Chrysatropic Acid|Coumarin, 7-Hydroxy-6-Methoxy-|Escopoletin|Esculetin-6-Methyl Ether|Gelseminic Acid|Methylesculetin|Murrayetin|SCOPOLETIN|Scopoletine|Scopoletol	A coumarin compound found in several plants including those in the genus Scopolia and the genus Brunfelsia, as well as chicory (Cichorium), redstem wormwood (Artemisia scoparia), stinging nettle (Urtica dioica), passion flower (Passiflora), noni (Morinda citrifolia fruit) and European black nightshade (Solanum nigrum) that is comprised of umbelliferone with a methoxy group substituent at position 6. Scopoletin is used to standardize and establish pharmacokinetic properties for products derived from the plants that produce it, such as noni extract. Although the mechanism(s) of action have not yet been established, this agent has potential antineoplastic, antidopaminergic, antioxidant, anti-inflammatory and anticholinesterase effects.	Scopoletin		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C126101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126101>	C48655	Not Available|Unavailable	The desired information is not available.			Qualitative Concept	CDISC Define-XML Origin Type Terminology|CDISC Define-XML Terminology|Clinical Data Interchange Standards Consortium Terminology
C126102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126102>	C201285	Chimeric Antigen Receptor T-Cell Therapy|CAR T Infusion|CAR T Therapy|CAR T-cell Therapy|CAR T-cell therapy|Chimeric Antigen Receptor T-cell Infusion|Chimeric Antigen Receptor T-cell Therapy|Chimeric Antigen Receptor T-cell Therapy|chimeric antigen receptor T-cell therapy	Treatment that uses T-cells that have been engineered to contain a chimeric antigen receptor (CAR) that specifically targets a particular antigen.	Chimeric Antigen Receptor T-Cell Therapy|Chimeric Antigen Receptor T-cell Therapy		Therapeutic or Preventive Procedure	AML Authorized Value Terminology|AML Cellular Immunotherapy Table|CTRP Intervention Terminology|CTRP Terminology
C126103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126103>	C113745	Urine Pellet	The cells, crystals, casts, bacteria, yeast, or other particles collected by centrifugation of a urine sample.			Body Substance	
C126104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126104>	C19235	Gene Modification|Gene Editing|Genetic Modification	Any gene manipulation method used to generate a product with an altered sequence, structure, or conformation.			Molecular Biology Research Technique	
C126105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126105>	C1946|C1590	Tinostamustine|1H-Benzimidazole-2-heptanamide, 5-(Bis(2-chloroethyl)amino)-N-hydroxy-1-methyl-|7-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)-N-hydroxyheptanamide|EDO-S 101|EDO-S-101|EDO-S101|TINOSTAMUSTINE	An alkylating histone-deacetylase inhibitor (HDACi) fusion molecule composed of the alkylating agent bendamustine fused to the pan-HDACi vorinostat, with potential bi-functional antineoplastic activity. Upon administration of tinostamustine the vorinostat moiety targets and binds to HDACs. This leads to an accumulation of highly acetylated histones, which results in an induction of chromatin remodeling, a modulation of gene expression, an inhibition of tumor cell division and the induction of tumor cell apoptosis. The bendamustine moiety binds to, alkylates and crosslinks macromolecules, inhibiting DNA, RNA and protein synthesis, which also results in tumor cell apoptosis. Thus, tinostamustine shows superior efficacy compared to the activity of either agent alone. In addition, the inhibition of HDAC6 activity by tinostamustine induces the activation of inositol-requiring enzyme 1 (IRE-1), the key regulatory protein for the unfolded protein response (UPR). Induction of the UPR increases the sensitivity of certain cancer cell types to certain chemotherapeutic agents, such as proteasome inhibitors. Therefore, tinostamustine may work synergistically with proteasome inhibitors. HDACs, enzymes that deacetylate chromatin histone proteins, are overexpressed in various cancers and play a key role in proliferation and resistance of tumor cells.	Tinostamustine		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126106>	C2124	Fluorine F 18 Clofarabine|18F-CA|18F-Clofarabine|2-Chloro-9-(2'-deoxy-2'-18F-fluoro-beta-D-arabinofuranosyl)adenine|Cl-18F-ara-A|[18F]-Clofarabine	A radioconjugate composed of the nucleoside analog and deoxycytidine kinase (DCK)-dependent pro-drug clofarabine (Cl-F-ara-A) linked to the radioisotope fluorine F 18, with potential imaging activity using positron emission tomography/computed tomography (PET/CT). Upon administration of fluorine F 18 clofarabine, the clofarabine moiety is preferentially taken up by and accumulates in cells with dysregulated nucleoside metabolism, including tumor cells expressing high levels of DCK. The clofarabine moiety is phosphorylated by DCK into its active triphosphate form, Cl-F-ara-ATP. The 18F moiety can be visualized by PET imaging.  As many nucleoside analog prodrugs are chemotherapeutic agents that require DCK for their phosphorylation and activation, fluorine F 18 clofarabine can potentially be used as a marker to measure DCK activity and to predict the chemotherapeutic efficacy of DCK-dependent prodrugs. DCK, a rate-limiting enzyme in the deoxyribonucleoside salvage pathway for DNA synthesis, is overexpressed in certain solid tumors, lymphoid and myeloid malignancies and certain immune cells, such as proliferating T-lymphocytes. Compared to other nucleoside analogs, clofarabine is not susceptible to deamination by cytidine deaminase (CDA).	Fluorine F 18 Clofarabine		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C126107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126107>	C17067	Antigen Receptor|Native Antigen Receptor	A cell-surface receptor found on T-cells or B-cells that recognize specific antigenic peptides. Each cell naturally produces a unique receptor that binds to a unique epitope on a target cell.			Receptor	
C126108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126108>	C17081|C126107	Chimeric Antigen Receptor|Artificial Antigen Receptor|CAR|Non-Native Antigen Receptor	A cell-surface receptor that has been engineered to combine novel features and specificities from various sources in order to enhance its antigen specificity. Engineered T-cells or B-cells will produce the specialized receptor that will be capable of binding to an epitope on its target cell.			Receptor	
C126109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126109>	C4030|C213705|C129828	Metastatic Urothelial Carcinoma|Metastatic Transitional Cell Carcinoma of the Urinary Tract|Metastatic Urothelial Cancer	A carcinoma that arises from the urothelium and has spread from its original site of growth to another anatomic site.	Metastatic Urothelial Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C12610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12610>	C41608	Lutein Cell|Luteal Cell|Lutein Cells	A cell located in the corpus luteum of the ovary that is derived from theca or granulosa cells and secretes progesterone and estrogen or androgens.	Lutein Cell		Cell	
C126110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126110>	C9298|C209281|C122603	Infant Acute Undifferentiated Leukemia|Acute Undifferentiated Leukemia	An acute undifferentiated leukemia that occurs in infancy.	Infant Acute Undifferentiated Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C126111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126111>	C4673|C212201|C122603	Infant Acute Biphenotypic Leukemia|Acute Biphenotypic Leukemia	An acute biphenotypic leukemia that occurs in infancy.	Infant Acute Biphenotypic Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C126112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126112>	C7953|C122614	Infant T Acute Lymphoblastic Leukemia|Infant Precursor T Lymphoblastic Leukemia|Infant Precursor T-Lymphoblastic Leukemia|Infant T-ALL|Infant T-Acute Lymphoblastic Leukemia|T Acute Lymphoblastic Leukemia	A T acute lymphoblastic leukemia that occurs in infancy.	Infant T Acute Lymphoblastic Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C126113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126113>	C129822|C128036	Zalifrelimab|AGEN-1884|AGEN1884|UGN 301|UGN-301|UGN301|ZALIFRELIMAB	A recombinant human monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, zalifrelimab binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.	Zalifrelimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126114>	C20130	Phospholipase C Gamma|1-Phosphatidylinositol-4,5-Bisphosphate Phosphodiesterase Gamma|PLC-Gamma|PLCG|PLCgamma|Phosphoinositide Phospholipase C-Gamma|Phospholipase C-Gamma	A family of phospholipases that are activated by receptor tyrosine kinases, bind to the non-catalytic domains of src-family protein tyrosine kinases, and catalyze the biosynthesis of second messenger signaling molecules.	Phospholipase C Gamma		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126115>	C18520	Kinase Inhibitor Sensitivity	A metabolic marker that predicts which kinase inhibitor agent could be an effective treatment for a patient's tumor based on the in vitro treatment response for cells extracted from the tumor.	Kinase Inhibitor Sensitivity		Functional Concept	CTRP Biomarker Terminology|CTRP Terminology
C126116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126116>	C20424	PGF Gene Product	A protein encoded by the PGF gene.	PGF Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126117>	C126116	Placenta Growth Factor Isoform 1|Isoform PlGF-1|PLGF-1|PLGF1|PlGF-131|Placental Growth Factor 1 Isoform|Placental Growth Factor Isoform 1	Placenta growth factor isoform 1 (149 aa, ~17 kDa) is encoded by the human PGF gene. This protein may be involved in the positive regulation of endothelial cell growth.	Placenta Growth Factor Isoform 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126118>	C48181	HLA-Cw Serotype|HLA-Cw	A subset of serotypes for the HLA class I histocompatibility antigen, C alpha chain protein (HLA-C) found in the human population. Expression of Cw1 is associated with multinodular goiters, Cw6 is associated with susceptibility to psoriasis and alleles of Cw7 are associated with increased risk of age-related macular degeneration. Expression of Cw5 may be associated with increased risk of rheumatoid arthritis (RA) and expression of Cw4 may protect patients from RA, while Cw3 expression may be associated with increased risk of developing vascular complications for patients with RA. Expression of Cw4 may also be associated with reduced susceptibility to HIV-1 viremia.	HLA-Cw Serotype		Functional Concept	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126119>	C36331|C159455	Polysomy 7|Chromosome 7 Polysomy	A numerical chromosomal abnormality characterized by the presence of more than two copies of chromosome 7 in a cell.	Polysomy 7		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12611>	C33058	Antibody-Producing Cell|Antibody Producing Cell|Antibody-Producing Cells|Immunoglobulin-Producing Cell|Immunoglobulin-Producing Cells	A type of B lymphocyte that reacts with antigens to produce immune proteins called antibodies.	Antibody-Producing Cell		Cell	
C126120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126120>	C16676	Oxygenated Hemoglobin|HbO2|Oxyhemoglobin	Hemoglobin where the heme group has formed a reversible complex with oxygen (O2) in the lungs. This molecule is found in the systemic arteries and transports O2 from the lungs to the tissues where it is readily released.	Oxygenated Hemoglobin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126121>	C16676	Deoxygenated Hemoglobin|Deoxyhemoglobin	Hemoglobin containing a heme group that is not bound to oxygen (O2). This molecule is normally found in the systemic veins following transit through capillaries and release of O2 into the tissues. Excess deoxyhemoglobin can be associated with hypoxia.	Deoxygenated Hemoglobin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126122>	C21176	CD42 Complex|CD42|CD42 Antigen|CD42a-d Complex|GPIb-V-IX|GPIb/V/IX|Glycoprotein Ib-V-IX|Glycoprotein Ib/V/IX Complex|Platelet Glycoprotein Ib-V-IX|Platelet Glycoprotein Ib/V/IX Complex	A heterotetrameric protein complex expressed on the surface of platelets that is involved in promoting platelet adhesion to von Willebrand factor during wound healing. This non-covalent complex is comprised of glycoprotein 5 (GPV; CD42d), glycoprotein 9 (GPIX; CD42a), and glycoprotein Ib (GPIb). GPIb is a heterodimer comprised of platelet glycoprotein Ib alpha chain (GPIba; CD42b) covalently bound to platelet glycoprotein Ib beta chain (GPIbb; CD42c).	CD42 Complex		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126123>	C20988	TIGIT Gene|T-Cell Immunoreceptor with Ig and ITIM Domains Gene|TIGIT|TIGIT	This gene is involved in cell-cell adhesion and the regulation of T-cell and dendritic cell activity.	TIGIT Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126124>	C126123	TIGIT wt Allele|DKFZp667A205|FLJ39873|T Cell Immunoreceptor with Ig and ITIM Domains Gene|T-Cell Immunoreceptor with Ig and ITIM Domains wt Allele|V-Set and Immunoglobulin Domain Containing 9 Gene|V-Set and Transmembrane Domain Containing 3 Gene|VSIG9|VSTM3|WUCAM|Washington University Cell Adhesion Molecule Gene	Human TIGIT wild-type allele is located in the vicinity of 3q13.31 and is approximately 33 kb in length. This allele, which encodes T-cell immunoreceptor with Ig and ITIM domains protein, plays a role in dendritic cell maturation, the inhibition of T-cell activation and cell adhesion.	TIGIT wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126125>	C16393	T-Cell Immunoreceptor with Ig and ITIM Domains|T-Cell Immunoreceptor with Immunoglobulin and ITIM Domains|TIGIT|V-Set and Immunoglobulin Domain-Containing Protein 9|V-Set and Transmembrane Domain-Containing Protein 3	T-cell immunoreceptor with Ig and ITIM domains (244 aa, ~26 kDa) is encoded by the human TIGIT gene. This protein is involved in immunomodulation and cell-cell adhesion.	T-Cell Immunoreceptor with Ig and ITIM Domains		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126126>	C28533|C20917	KIF20B Gene|KIF20B|KIF20B|Kinesin Family Member 20B Gene	This gene plays a role in microtubule-based transport, cytokinesis and cell polarity.	KIF20B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126127>	C126126	KIF20B wt Allele|CT90|KRMP1|Kinesin Family Member 20B wt Allele|MPHOSPH1|MPP-1|MPP1	Human KIF20B wild-type allele is located in the vicinity of 10q23.31 and is approximately 73 kb in length. This allele, which encodes kinesin-like protein KIF20B, is involved in cytokinesis, cell polarity and microtubule-based transport.	KIF20B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126128>	C17761|C16386	Kinesin-Like Protein KIF20B|CT90|Cancer/Testis Antigen 90|Kinesin-Related Motor Interacting with PIN1|M-Phase Phosphoprotein 1|MPP1|Mitotic Kinesin-Like Protein|Mitotic Kinesin-Related Protein	Kinesin-like protein KIF20B (1820 aa, ~211 kDa) is encoded by the human KIF20B gene. This protein plays a role in cell polarity, microtubule-based transport and cytokinesis.	Kinesin-Like Protein KIF20B		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126129>	C54362	DEPDC1 Gene|DEP Domain Containing 1 Gene|DEPDC1|DEPDC1	This gene is involved in the negative regulation of gene transcription.	DEPDC1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C12612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12612>	C12555	Muscle Cell|Muscle Cells|Myocyte	A connective tissue cell with the ability to convert chemical energy into mechanical energy via a contractile apparatus. As part of the contractile apparatus, the proteins actin and myosin form parallel myofilaments. The interaction of actin and myosin mediates muscle cell contraction in response to stimulation of the excitable cell membrane.	Muscle Cell		Cell	
C126130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126130>	C126129	DEPDC1 wt Allele|DEP Domain Containing 1 wt Allele|DEP.8|DEPDC1-V2|DEPDC1A|FLJ20354|SDP35	Human DEPDC1 wild-type allele is located in the vicinity of 1p31.2 and is approximately 23 kb in length. This allele, which encodes DEP domain-containing protein 1A, plays a role in transcriptional regulation. Aberrant expression of this gene is associated with bladder cancer.	DEPDC1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126131>	C26199	DEP Domain-Containing Protein 1A|Cell Cycle Control Protein SDP35|DEPDC1	DEP domain-containing protein 1A (811 aa, ~93 kDa) is encoded by the human DEPDC1 gene. This protein is involved in the negative regulation of transcription.	DEP Domain-Containing Protein 1A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126132>	C20194	LY6K Gene|LY6K|LY6K|Lymphocyte Antigen 6 Complex, Locus K Gene	This gene may be involved in cell growth regulation.	LY6K Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126133>	C126132	LY6K wt Allele|CO16|CT97|FLJ35226|HSJ001348|Lymphocyte Antigen 6 Complex, Locus K wt Allele|URLC10|ly-6K	Human LY6K wild-type allele is located in the vicinity of 8q24.3 and is approximately 5 kb in length. This allele, which encodes lymphocyte antigen 6K protein, may play a role in the regulation of cell growth.	LY6K wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126134>	C18466	Lymphocyte Antigen 6K|Cancer/Testis Antigen 97|LY6K|Ly-6K|Up-Regulated In Lung Cancer 10	Lymphocyte antigen 6K (165 aa, ~19 kDa) is encoded by the human LY6K gene. This protein may be involved in cell growth.	Lymphocyte Antigen 6K		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126135>	C20194	ATG13 Gene|ATG13|ATG13|Autophagy Related 13 Gene	This gene plays a role in both autophagosome formation and mitophagy.	ATG13 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126136>	C126135	ATG13 wt Allele|ATG13 Autophagy Related 13 Homolog (S. cerevisiae) Gene|ATG13 Autophagy Related 13 Homolog Gene|Autophagy 13, S. cerevisiae, Homolog of Gene|Autophagy Related 13 wt Allele|KIAA0652|PARATARG8	Human ATG13 wild-type allele is located in the vicinity of 11p11.2 and is approximately 59 kb in length. This allele, which encodes autophagy-related protein 13, is involved in both mitophagy and autophagy.	ATG13 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126137>	C18466	Autophagy-Related Protein 13|ATG13|PARATARG 8|Paraprotein Target 8|Paratarg-8	Autophagy-related protein 13 (517 aa, ~57 kDa) is encoded by the human ATG13 gene. This protein plays a role in the modulation of autophagy.	Autophagy-Related Protein 13		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126138>	C173045	Getting In and Out of Chairs or Bed Without Assistance Question|Getting In and Out of Chairs or Bed Without Assistance|Getting In and Out of Chairs or Bed Without Help|Getting in and out of chairs or bed (without assistance)	A question about an individual's ability to get in and out of chairs or bed without assistance.			Intellectual Product	Human Activity Profile
C126139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126139>	C91102	Listening to the Radio Question|Listening to the Radio|Listening to the radio	A question about an individual's ability to listen to the radio.			Intellectual Product	Human Activity Profile
C12613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12613>	C33904	Fast-Twitch Muscle Fiber|Muscle Fibers, Fast-Twitch|Type II Muscle Fiber|Type II Skeletal Muscle Fiber	A large-diameter skeletal muscle fiber that uses glycogen reserves rather than oxygen-rich blood for quick energy and a more rapid production of force. Fast twitch muscle fibers have a low oxidative capacity and can produce ATP without the need for oxygen, resulting in a higher activation threshold and a higher velocity signal conduction.	Muscle Fibers, Fast-Twitch		Cell	
C126140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126140>	C176426|C173045	Reading Ability Question|Reading|Reading Ability|Reading books, magazines, or newspapers	A question about an individual's ability to read books, magazines, or newspapers.			Intellectual Product	Human Activity Profile
C126141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126141>	C173045	Writing Ability Question|Writing|Writing (letters, notes)|Writing Ability	A question about an individual's ability to write letters or notes.			Intellectual Product	Human Activity Profile
C126142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126142>	C173924|C173045	Working at a Desk or Table Question|Working at a Desk or Table|Working at a desk or table	A question about an individual's ability to work at a desk or table.			Intellectual Product	Human Activity Profile
C126143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126143>	C173458	Standing for More Than 1 Minute Question|Standing (for more than 1 minute)|Standing for More Than 1 Minute	A question about an individual's ability to stand for more than 1 minute.			Intellectual Product	Human Activity Profile
C126144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126144>	C173458	Standing for More Than 5 Minutes Question|Standing (more than 5 minutes)|Standing for More Than 5 Minutes	A question about an individual's ability to stand more than 5 minutes.			Intellectual Product	Human Activity Profile
C126145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126145>	C131923	Dressing or Undressing Without Assistance Question|Dressing or Undressing Without Assistance|Dressing or Undressing Without Help|Dressing or undressing (without assistance)	A question about an individual's ability to dress or undress without assistance.			Intellectual Product	Human Activity Profile
C126146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126146>	C131923	Getting Clothes from Drawers or Closets Question|Getting Clothes from Drawers or Closets|Getting clothes from drawers or closets	A question about an individual's ability to get clothes from drawers or closets.			Intellectual Product	Human Activity Profile
C126147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126147>	C173045	Getting In or Out of a Car Without Assistance Question|Getting In or Out of a Car Without Assistance|Getting In or Out of a Car Without Help|Getting in or out of a car (without assistance)	A question about an individual's ability to get in or out of a car without assistance.			Intellectual Product	Human Activity Profile
C126148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126148>	C173045	Dining at a Restaurant Question|Dining at a Restaurant|Dining at a restaurant|Eating at a Restaurant	A question about an individual's ability to dine at a restaurant.			Intellectual Product	Human Activity Profile
C126149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126149>	C173458	Playing Cards or Table Games Question|Playing Cards or Table Games|Playing cards/table games	A question about an individual's ability to play cards or table games.			Intellectual Product	Human Activity Profile
C12614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12614>	C33904	Slow-Twitch Muscle Fiber|Muscle Fiber, Slow-Twitch|Type I Muscle Fiber|Type I Skeletal Muscle Fiber	A skeletal muscle fiber that utilizes aerobic respiration to fuel muscle contraction.  Slow twitch muscle fibers, which have a high concentration of myoglobin and mitochondrial oxidative enzymes, are resistant to fatigue.	Muscle Fibers, Slow-Twitch		Cell	
C126150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126150>	C131925	Bathing Without Assistance Question|Bathing Without Assistance|Bathing Without Help|Bathing with No Assistance Needed|Taking a Bath Without Assistance|Taking a Bath Without Help|Taking a Bath with No Assistance Needed|Taking a bath (no assistance needed)	A question about an individual's ability to take a bath with no assistance needed.			Intellectual Product	Human Activity Profile
C126151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126151>	C131923	Putting on Shoes, Stockings, or Socks Without Rest or a Break Question|Putting on Shoes, Stockings, or Socks Without Rest or a Break|Putting on Shoes, Stockings, or Socks with No Rest or Break Needed|Putting on shoes, stockings, or socks (no rest or break needed)	A question about an individual's ability to put on shoes, stockings, or socks with no rest or break needed.			Intellectual Product	Human Activity Profile
C126152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126152>	C173058	Attending a Movie, Play, Church Event, or Sports Activity Question|Attending a Movie, Play, Church Event, or Sports Activity|Attending a movie, play, church event or sports activity	A question about an individual's ability to attend a movie, play, church event or sports activity.			Intellectual Product	Human Activity Profile
C126153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126153>	C156133	Walking 30 Yards Question|Walking 27 Meters|Walking 30 Yards|Walking 30 yards (27 meters)	A question about an individual's ability to walk 30 yards (27 meters).			Intellectual Product	Human Activity Profile
C126154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126154>	C131923	Dressing or Undressing Without Rest or a Break Question|Dressing or Undressing Without Rest or a Break|Dressing or Undressing with No Rest or Break Needed|Dressing/undressing (no rest break needed)	A question about an individual's ability to dress or undress with no rest break needed.			Intellectual Product	Human Activity Profile
C126155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126155>	C126153	Walking 30 Yards Nonstop Question|Walking 30 Yards Nonstop|Walking 30 yards (nonstop)	A question about an individual's ability to walk 30 yards nonstop.			Intellectual Product	Human Activity Profile
C126156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126156>	C198102	Using Public Transport or Driving a Car, 99 Miles or Less Question|Using Public Transport or Driving a Car, 99 Miles or Less|Using public transport or driving a car (99 miles or less)	A question about an individual's ability to use public transport or drive a car for 99 miles or less.			Intellectual Product	Human Activity Profile
C126157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126157>	C198102	Using Public Transport or Driving a Car, 100 Miles or More Question|Using Public Transport or Driving a Car, 100 Miles or More|Using public transport or driving a car (100 miles or more)	A question about an individual's ability to use public transport or driving a car for 100 miles or more.			Intellectual Product	Human Activity Profile
C126158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126158>	C110952	Cooking Your Own Meals Question|Cooking Your Own Meals|Cooking your own meals	A question about an individual's ability to cook their own meals.			Intellectual Product	Human Activity Profile
C126159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126159>	C173458	Washing or Drying Dishes Question|Washing or Drying Dishes|Washing or drying dishes	A question about an individual's ability to wash or dry dishes.			Intellectual Product	Human Activity Profile
C12615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12615>	C41410|C33704	Glial Cell|Glia|Glial Cells|Kolliker Reticulum|Neuroglia|Neuroglial Cell|Neuroglial Cells|glial cell|neuroglia	A non-neuronal cell of the nervous system. Glial cells have diverse roles, including in regulation of neuronal survival and differentiation, maintenance of ion and neurotransmitter concentrations in the neuronal environment, synapse formation, and support of synaptic interactions and electrical signal propagation.	Neuroglia		Cell	
C126160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126160>	C173458	Putting Groceries on Shelves Question|Putting Groceries on Shelves|Putting groceries on shelves	A question about an individual's ability to put groceries on shelves.			Intellectual Product	Human Activity Profile
C126161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126161>	C173458	Ironing or Folding Clothes Question|Ironing or Folding Clothes|Ironing or folding clothes	A question about an individual's ability to iron or fold clothes.			Intellectual Product	Human Activity Profile
C126162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126162>	C173458	Dusting or Polishing Furniture or a Polishing Car Question|Dusting or Polishing Furniture or a Polishing Car|Dusting/polishing furniture or polishing car	A question about an individual's ability to dust or polish furniture or polish a car.			Intellectual Product	Human Activity Profile
C126163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126163>	C173082	Climbing 6 Steps Question|Climbing 6 Steps|Climbing 6 steps	A question about an individual's ability to climb 6 steps.			Intellectual Product	Human Activity Profile
C126164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126164>	C126163	Climbing 6 Steps Nonstop Question|Climbing 6 Steps Nonstop|Climbing 6 steps (nonstop)	A question about an individual's ability to climb 6 steps nonstop.			Intellectual Product	Human Activity Profile
C126165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126165>	C173082	Climbing 9 Steps Question|Climbing 9 Steps|Climbing 9 steps	A question about an individual's ability to climb 9 steps.			Intellectual Product	Human Activity Profile
C126166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126166>	C173082	Climbing 12 Steps Question|Climbing 12 Steps|Climbing 12 steps	A question about an individual's ability to climb 12 steps.			Intellectual Product	Human Activity Profile
C126167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126167>	C164300	Walking Half a Block on Level Ground Question|Walking 1/2 Block on Level Ground|Walking 1/2 block on level ground|Walking Half a Block on Level Ground	A question about an individual's ability to walk 1/2 block on level ground.			Intellectual Product	Human Activity Profile
C126168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126168>	C126167	Walking Half Block on Level Ground Nonstop Question|Walking 1/2 Block on Level Ground Nonstop|Walking 1/2 block on level ground (nonstop)|Walking Half Block on Level Ground Nonstop	A question about an individual's ability to walk 1/2 block on level ground nonstop.			Intellectual Product	Human Activity Profile
C126169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126169>	C173045	Ability to Make a Bed Question|Ability to Make a Bed|Make a Bed|Making a Bed|Making a Bed, Not Changing Sheets|Making a bed (not changing sheets)	A question about an individual's ability to make a bed, not changing sheets.			Intellectual Product	Human Activity Profile
C12616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12616>	C12657	Microglia|Hortega cell|Microglial Cell|Microgliocyte	A type of glial cell that mediates immune responses by clearing cellular debris and dead neurons from nervous tissue through phagocytosis.	Microglia		Cell	CTRP Biomarker Terminology|CTRP Terminology
C126170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126170>	C173458	Cleaning Windows Question|Cleaning Windows|Cleaning windows	A question about an individual's ability to clean windows.			Intellectual Product	Human Activity Profile
C126171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126171>	C173458	Kneeling or Squatting to Do Light Work Question|Kneeling or Squatting to Do Light Work|Kneeling or squatting to do light work	A question about an individual's ability to kneel or squat to do light work.			Intellectual Product	Human Activity Profile
C126172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126172>	C173061	Carrying a Light Load of Groceries Question|Carrying a Light Load of Groceries|Carrying a light load of groceries	A question about an individual's ability to carry a light load of groceries.			Intellectual Product	Human Activity Profile
C126173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126173>	C126165	Climbing 9 Steps Nonstop Question|Climbing 9 Steps Nonstop|Climbing 9 steps (nonstop)	A question about an individual's ability to climb 9 steps nonstop.			Intellectual Product	Human Activity Profile
C126174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126174>	C126166	Climbing 12 Steps Nonstop Question|Climbing 12 Steps Nonstop|Climbing 12 steps (nonstop)	A question about an individual's ability to climb 12 steps nonstop.			Intellectual Product	Human Activity Profile
C126175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126175>	C156133	Walking Half Block Uphill Question|Walking 1/2 Block Uphill|Walking 1/2 block uphill|Walking Half Block Uphill	A question about an individual's ability to walk 1/2 block uphill.			Intellectual Product	Human Activity Profile
C126176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126176>	C126175	Walking Half Block Uphill Nonstop Question|Walking 1/2 Block Uphill Nonstop|Walking 1/2 block uphill (nonstop)|Walking Half Block Uphill Nonstop	A question about an individual's ability to walk 1/2 block uphill nonstop.			Intellectual Product	Human Activity Profile
C126177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126177>	C121254	Shopping by Yourself Question|Shopping (by yourself)|Shopping by Yourself	A question about an individual's ability to shop alone.			Intellectual Product	Human Activity Profile
C126178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126178>	C173458	Washing Clothes by Yourself Question|Washing Clothes by Yourself|Washing clothes (by yourself)	A question about an individual's ability to wash clothes alone.			Intellectual Product	Human Activity Profile
C126179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126179>	C164300	Walking 1 Block on Level Ground Question|Walking 1 Block on Level Ground|Walking 1 block on level ground	A question about an individual's ability to walk 1 block on level ground.			Intellectual Product	Human Activity Profile
C12617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12617>	C32695	Neuropil	An area of dense, interwoven nerve cell fibers and synapses, glial processes, and dendrites that is located within the central or peripheral nervous system and contains very few cell bodies.	Neuropil		Tissue	CTRP Biomarker Terminology|CTRP Terminology
C126180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126180>	C164300	Walking 2 Blocks on Level Ground Question|Walking 2 Blocks on Level Ground|Walking 2 blocks on level ground	A question about an individual's ability to walk 2 blocks on level ground.			Intellectual Product	Human Activity Profile
C126181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126181>	C126179	Walking 1 Block on Level Ground Nonstop Question|Walking 1 Block on Level Ground Nonstop|Walking 1 block on level ground (nonstop)	A question about an individual's ability to walk 1 block on level ground nonstop.			Intellectual Product	Human Activity Profile
C126182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126182>	C126180	Walking 2 Blocks on Level Ground Nonstop Question|Walking 2 Blocks on Level Ground Nonstop|Walking 2 blocks on level ground (nonstop)	A question about an individual's ability to walk 2 blocks on level ground nonstop.			Intellectual Product	Human Activity Profile
C126183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126183>	C173458	Scrubbing Doors, Walls, or Cars Question|Scrubbing (doors, walls, or cars)|Scrubbing Doors, Walls, or Cars	A question about an individual's ability to scrub doors, walls, or cars.			Intellectual Product	Human Activity Profile
C126184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126184>	C173045	Making a Bed and Changing Sheets Question|Making a Bed and Changing Sheets|Making a Bed, Changing Sheets|Making a bed (changing sheets)	A question about an individual's ability to make a bed, changing sheets.			Intellectual Product	Human Activity Profile
C126185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126185>	C173458	Sweeping Ability Question|Sweeping|Sweeping Ability	A question about an individual's ability to sweep.			Intellectual Product	Human Activity Profile
C126186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126186>	C126185	Sweeping 5 Minutes Nonstop Question|Sweeping (5 minutes nonstop)|Sweeping 5 Minutes Nonstop	A question about an individual's ability to sweep 5 minutes nonstop.			Intellectual Product	Human Activity Profile
C126187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126187>	C173061	Carrying a Large Suitcase or Bowling 1 Game Question|Carrying a Large Suitcase or Bowling 1 Game|Carrying a large suitcase or bowling (1 game)	A question about an individual's ability to carry a large suitcase or bowl 1 game.			Intellectual Product	Human Activity Profile
C126188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126188>	C173458	Vacuuming Carpets Ability Question|Vacuuming Carpets|Vacuuming Carpets Ability|Vacuuming carpets	A question about an individual's ability to vacuum carpets.			Intellectual Product	Human Activity Profile
C126189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126189>	C126188	Vacuuming Carpets 5 Minutes Nonstop Ability Question|Vacuuming Carpets 5 Minutes Nonstop|Vacuuming Carpets 5 Minutes Nonstop Ability|Vacuuming carpets (5 minutes nonstop)	A question about an individual's ability to vacuum carpets 5 minutes nonstop.			Intellectual Product	Human Activity Profile
C12618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12618>	C12615	Oligodendrocyte|Oligodendrocytes|Oligodendroglia|Oligodendroglia Cell|oligodendrocyte	A type of large glial cell located in the central nervous system that produces myelin as its main function.	Oligodendroglia		Cell	
C126190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126190>	C173458	House Painting Ability Question|House Painting|House Painting Ability|Painting (interior/exterior)|Painting, Interior or Exterior	A question about an individual's ability to paint interior/exterior.			Intellectual Product	Human Activity Profile
C126191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126191>	C164300	Walking 6 Blocks on Level Ground Question|Walking 6 Blocks on Level Ground|Walking 6 blocks on level ground	A question about an individual's ability to walk 6 blocks on level ground.			Intellectual Product	Human Activity Profile
C126192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126192>	C126191	Walking 6 Blocks on Level Ground Nonstop Question|Walking 6 Blocks on Level Ground Nonstop|Walking 6 blocks on level ground (nonstop)	A question about an individual's ability to walk 6 blocks on level ground nonstop.			Intellectual Product	Human Activity Profile
C126193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126193>	C173061	Carrying Out the Garbage Question|Carrying Out the Garbage|Carrying out the garbage|Taking Out the Garbage	A question about an individual's ability to carry out the garbage.			Intellectual Product	Human Activity Profile
C126194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126194>	C173061	Carrying a Heavy Load of Groceries Question|Carrying a Heavy Load of Groceries|Carrying a Heavy Load of Groceries	A question about an individual's ability to carry a heavy load of groceries.			Intellectual Product	Human Activity Profile
C126195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126195>	C173082	Climbing 24 Steps Question|Climbing 24 Steps|Climbing 24 steps	A question about an individual's ability to climb 24 steps.			Intellectual Product	Human Activity Profile
C126196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126196>	C173082	Climbing 36 Steps Question|Climbing 36 Steps|Climbing 36 steps	A question about an individual's ability to climb 36 steps.			Intellectual Product	Human Activity Profile
C126197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126197>	C126195	Climbing 24 Steps Nonstop Question|Climbing 24 Steps Nonstop|Climbing 24 steps (nonstop)	A question about an individual's ability to climb 24 steps nonstop.			Intellectual Product	Human Activity Profile
C126198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126198>	C126196	Climbing 36 Steps Nonstop Question|Climbing 36 Steps Nonstop|Climbing 36 steps (nonstop)	A question about an individual's ability to climb 36 steps nonstop.			Intellectual Product	Human Activity Profile
C126199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126199>	C156133	Walking 1 Mile Question|Walking 1 Mile|Walking 1 mile	A question about an individual's ability to walk 1 mile.			Intellectual Product	Human Activity Profile
C12619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12619>	C33516	Perineuronal Satellite Cell	A flattened non-neuronal cell surrounding a ganglion cell.	Perineuronal Satellite Cell		Cell	
C1261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1261>	C514|C1946	Trichostatin A|(2E,4E,6R)-7-[4-(Dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide|(2E,4E,6R)-7-[4-(Dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide|TRICHOSTATIN A	A natural derivative of dienohydroxamic acid isolated from species of the bacterial genus Streptomyces.  Trichostatin A (TSA) reversibly and specifically inhibits histone deacetylases, resulting in hyperacetylation of core histones which modulate chromatin structure.  The increase in histone acetylation promotes selective gene transcription and the inhibition of tumor growth.  This agent is a potent inducer of tumor cell growth arrest, differentiation and apoptosis in a variety of transformed cells in culture and in tumor-bearing animals. (NCI04)			Antibiotic|Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C126200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126200>	C126199	Walking 1 Mile Nonstop Question|Walking 1 Mile Nonstop|Walking 1 mile (nonstop)	A question about an individual's ability to walk 1 mile nonstop.			Intellectual Product	Human Activity Profile
C126201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126201>	C173458	Running 110 Yards or Playing Softball or Baseball Question|Running 100 Meters or Playing Softball or Baseball|Running 110 Yards or Playing Softball or Baseball|Running 110 yards (100 meters) or playing softball/baseball	A question about an individual's ability to run 110 yards or 100 meters or play softball or baseball.			Intellectual Product	Human Activity Profile
C126202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126202>	C173458	Social Dancing Ability Question|Dancing (social)|Social Dancing|Social Dancing Ability	A question about an individual's ability to do social dancing.			Intellectual Product	Human Activity Profile
C126203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126203>	C173458	Doing Calisthenics or Aerobic Dancing 5 Minutes Nonstop Question|Doing Calisthenics or Aerobic Dancing 5 Minutes Nonstop|Doing calisthenics or aerobic dancing (5 minutes nonstop)	A question about an individual's ability to do calisthenics or aerobic dancing 5 minutes nonstop.			Intellectual Product	Human Activity Profile
C126204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126204>	C173458	Mowing The Lawn with a Power Mower Question|Mowing The Lawn with a Power Mower|Mowing The Lawn with a Power Mower, Not a Riding Mower|Mowing the lawn (power mower, not a riding mower)	A question about an individual's ability to mow the lawn using a power mower, not a riding mower.			Intellectual Product	Human Activity Profile
C126205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126205>	C156133	Walking 2 Miles Question|Walking 2 Miles|Walking 2 miles	A question about an individual's ability to walk 2 miles.			Intellectual Product	Human Activity Profile
C126206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126206>	C126205	Walking 2 Miles Nonstop Question|Walking 2 Miles Nonstop|Walking 2 miles (nonstop)	A question about an individual's ability to walk 2 miles nonstop.			Intellectual Product	Human Activity Profile
C126207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126207>	C173082	Climbing 50 Steps or 2 1/2 Floors Question|Climbing 50 Steps or 2 1/2 Floors|Climbing 50 steps (2 1/2 floors)	A question about an individual's ability to climb 50 steps 2 1/2 floors.			Intellectual Product	Human Activity Profile
C126208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126208>	C173458	Shoveling, Digging, or Spading Question|Shoveling, Digging, or Spading|Shoveling, digging, or spading	A question about an individual's ability to shovel, dig, or spade.			Intellectual Product	Human Activity Profile
C126209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126209>	C126208	Shoveling, Digging, or Spading 5 Minutes Nonstop Question|Shoveling, Digging, or Spading 5 Minutes Nonstop|Shoveling, digging, or spading (5 minutes nonstop)	A question about an individual's ability to shovel, dig, or spade 5 minutes nonstop.			Intellectual Product	Human Activity Profile
C12620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12620>	C41416|C12555	Schwann Cell|Neurilemma Cell|Neurilemmal Cell|Schwann Cells|Schwann cell	A supporting cell of the peripheral nervous system that aids the growth, development, function, maintenance and repair of peripheral nerves. Myelinating Schwann cells form the myelin sheath around large diameter axons while non-myelinating Schwann cells bundle together portions of several unmyelinated smaller diameter axons and may also play a role in the formation and maintenance of synaptic connections in the neuromuscular junction.	Schwann Cells		Cell	
C126210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126210>	C126207	Climbing 50 Steps Nonstop Question|Climbing 50 Steps Nonstop|Climbing 50 steps (nonstop)	A question about an individual's ability to climb 50 steps nonstop.			Intellectual Product	Human Activity Profile
C126211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126211>	C156133	Walking 3 Miles or Golfing 18 Holes Without a Riding Cart Question|Walking 3 Miles or Golfing 18 Holes Without a Riding Cart|Walking 3 miles or golfing 18 holes without a riding cart	A question about an individual's ability to walk 3 miles or golf 18 holes without a riding cart.			Intellectual Product	Human Activity Profile
C126212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126212>	C156133	Walking 3 Miles Nonstop Question|Walking 3 Miles Nonstop|Walking 3 miles (nonstop)	A question about an individual's ability to walk 3 miles nonstop.			Intellectual Product	Human Activity Profile
C126213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126213>	C173594	Swimming 25 Yards Ability Question|Swimming 25 Yards|Swimming 25 Yards Ability|Swimming 25 yards	A question about an individual's ability to swim 25 yards.			Intellectual Product	Human Activity Profile
C126214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126214>	C126213	Swimming 25 Yards Nonstop Ability Question|Swimming 25 Yards Nonstop|Swimming 25 Yards Nonstop Ability|Swimming 25 yards (nonstop)	A question about an individual's ability to swim 25 yards nonstop.			Intellectual Product	Human Activity Profile
C126215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126215>	C173049	Bicycling 1 Mile Question|Bicycling 1 Mile|Bicycling 1 mile	A question about an individual's ability to bicycle 1 mile.			Intellectual Product	Human Activity Profile
C126216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126216>	C173049	Bicycling 2 Miles Question|Bicycling 2 Miles|Bicycling 2 miles	A question about an individual's ability to bicycle 2 miles.			Intellectual Product	Human Activity Profile
C126217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126217>	C126215	Bicycling 1 Mile Nonstop Question|Bicycling 1 Mile Nonstop|Bicycling 1 mile (nonstop)	A question about an individual's ability to bicycle 1 mile nonstop.			Intellectual Product	Human Activity Profile
C126218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126218>	C126216	Bicycling 2 Miles Nonstop Question|Bicycling 2 Miles Nonstop|Bicycling 2 miles (nonstop)	A question about an individual's ability to bicycle 2 miles nonstop.			Intellectual Product	Human Activity Profile
C126219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126219>	C173458	Running or Jogging 1/4 Mile Question|Running or Jogging 1/4 Mile|Running or jogging 1/4 mile	A question about an individual's ability to run or jog 1/4 mile.			Intellectual Product	Human Activity Profile
C12621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12621>	C12508	Antigen Presenting Cell|APC|APC|Accessory Cell|Antigen Presenting Cells|Antigen Processing Cell|Antigen-Presenting Cell|Antigen-Presenting Cell|Antigen-Presenting Cells|antigen-presenting cell	A cell that enables a T-lymphocyte to recognize an antigen by engulfing the antigen, breaking down the antigen into smaller fragments which bind to MHC molecules on the surface of the antigen presenting cell. The T-lymphocyte can now recognize and bind with the MHC-linked antigen.	Antigen-Presenting Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C126220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126220>	C173458	Running or Jogging 1/2 Mile Question|Running or Jogging 1/2 Mile|Running or jogging 1/2 mile	A question about an individual's ability to run or jog 1/2 mile.			Intellectual Product	Human Activity Profile
C126221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126221>	C173458	Playing Tennis or Racquetball Question|Playing Tennis or Racquetball|Playing tennis or racquetball	A question about an individual's ability to play tennis or racquetball.			Intellectual Product	Human Activity Profile
C126222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126222>	C173458	Playing a Basketball or Soccer Game Question|Playing a Basketball or Soccer Game|Playing basketball/soccer (game play)	A question about an individual's ability to play basketball or soccer.			Intellectual Product	Human Activity Profile
C126223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126223>	C126219	Running or Jogging 1/4 Mile Nonstop Question|Running or Jogging 1/4 Mile Nonstop|Running or jogging 1/4 mile (nonstop)	A question about an individual's ability to run or jog 1/4 mile nonstop.			Intellectual Product	Human Activity Profile
C126224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126224>	C126220	Running or Jogging 1/2 Mile Nonstop Question|Running or Jogging 1/2 Mile Nonstop|Running or jogging 1/2 mile (nonstop)	A question about an individual's ability to run or jog 1/2 mile nonstop.			Intellectual Product	Human Activity Profile
C126225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126225>	C173458	Running or Jogging 1 Mile Question|Running or Jogging 1 Mile|Running or jogging 1 mile	A question about an individual's ability to run or jog 1 mile.			Intellectual Product	Human Activity Profile
C126226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126226>	C173458	Running or Jogging 2 Miles Question|Running or Jogging 2 Miles|Running or jogging 2 miles	A question about an individual's ability to run or jog 2 miles.			Intellectual Product	Human Activity Profile
C126227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126227>	C173458	Running or Jogging 3 Miles Question|Running or Jogging 3 Miles|Running or jogging 3 miles	A question about an individual's ability to run or jog 3 miles.			Intellectual Product	Human Activity Profile
C126228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126228>	C126225	Running or Jogging 1 Mile in 12 Minutes or Less Question|Running or Jogging 1 Mile in 12 Minutes or Less|Running or jogging 1 mile in 12 minutes or less	A question about an individual's ability to run or jog 1 mile in 12 minutes or less.			Intellectual Product	Human Activity Profile
C126229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126229>	C126226	Running or Jogging 2 Miles in 20 Minutes or Less Question|Running or Jogging 2 Miles in 20 Minutes or Less|Running or jogging 2 miles in 20 minutes or less	A question about an individual's ability to run or jog 2 miles in 20 minutes or less.			Intellectual Product	Human Activity Profile
C12622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12622>	C12583	Follicular Dendritic Cell|Follicular Dendritic Cells	Antigen Presenting Cells (APCs) located in the follicles of secondary lymphoid organs.  These dendritic cells are unique because of their location, primarily in lymphoid follicles, and because of their function in retaining antigen molecules for extended periods of time and serving as APCs for B cells.	Follicular Dendritic Cell		Cell	
C126230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126230>	C126227	Running or Jogging 3 Miles in 30 Minutes or Less Question|Running or Jogging 3 Miles in 30 Minutes or Less|Running or jogging 3 miles in 30 minutes or less	A question about an individual's ability to run or jog 3 miles in 30 minutes or less.			Intellectual Product	Human Activity Profile
C126231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126231>	C226611	Still Doing This Activity	A response indicating that an individual is still doing an activity.			Intellectual Product	Human Activity Profile
C126232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126232>	C226611	Have Stopped Doing This Activity	A response indicating that an individual has stopped doing an activity.			Intellectual Product	Human Activity Profile
C126233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126233>	C226611|C176245	Never Did This Activity	A response indicating that an individual is never did an activity.			Intellectual Product	Human Activity Profile
C126234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126234>	C1802	Very Low Nicotine Content Cigarette|VLNCC	A tobacco cigarette with a nicotine yield of less than 0.1 mg.	Very Low Nicotine Content Cigarette		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C126235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126235>	C91105	Nurses' Health Study II Activity and Inactivity Questionnaire|NHS II-PAQ|Nurses' Health Study II Physical Activity Questionnaire|Nurses' Health Study II: Activity and Inactivity Questionnaire (NHS II)	A self-reported questionnaire designed to measure physical activity and inactivity in a cohort of nurses who were recruited in 1989 and were between the ages of 25 and 42 at recruitment.			Intellectual Product	
C126236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126236>	C176021	Average Time Per Week Spent on Activity Question|Activity Average Time Per Week Spent|Average Time Per Week Spent on Activity|During the past year, what was your average time per week spent at each of the following recreational activities	A question about the average time per week that an individual spent on a specific activity.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126237>	C173924	Time Spent Walking or Hiking Outdoors Question|Time Spent Walking or Hiking Outdoors|Walking or hiking outdoors (include walking to work)	A question about time spent walking or hiking outdoors.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126238>	C173458	Time Spent Jogging Slower than 10 Minutes per Mile Question|Jogging (slower than 10 minutes/mile)|Time Spent Jogging Slower than 10 Minutes per Mile	A question about time spent jogging slower than 10 minutes per mile.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126239>	C173458	Time Spent Running 10 Minutes per Mile or Faster Question|Running (10 minutes/mile or faster)|Time Spent Running 10 Minutes per Mile or Faster	A question about time spent running 10 minutes per mile or faster.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C12623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12623>	C41405	Neuron|Nerve Cell|Nerve Cells|Neural Cell|Neurocyte|Neurons|nerve cell|neuron	Any of the conducting cells of the nervous system. A typical neuron consists of a cell body, containing the nucleus and the surrounding cytoplasm (perikaryon); several short radiating processes (dendrites); and one long process (the axon), which terminates in twiglike branches (telodendrons) and may have branches (collaterals) projecting along its course.	Neuron		Cell	
C126240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126240>	C198122|C173049	Time Spent Bicycling Question|Bicycling (include stationary machine)|Time Spent Bicycling	A question about time spent bicycling.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126241>	C173458	Time Spent Doing Calisthenics, Aerobics, Aerobic Dance, Rowing Machine Question|Calisthenics/aerobics/aerobic dance/rowing machine|Time Spent Doing Calisthenics, Aerobics, Aerobic Dance, Rowing Machine	A question about time spent doing calisthenics, aerobics, aerobic dance, or rowing machine use.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126242>	C173458	Time Spent Playing Tennis, Squash, or Racquetball Question|Tennis, squash, or racquetball|Time Spent Playing Tennis, Squash, or Racquetball	A question about time spent playing tennis, squash or racquetball.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126243>	C173594	Time Spent Lap Swimming Question|Lap swimming|Time Spent Lap Swimming	A question about time spent lap swimming.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126244>	C173458	Time Spent on Other Aerobic Recreation Question|Other aerobic recreation (e.g. lawn mowing)|Time Spent on Other Aerobic Recreation	A question about time spent on other aerobic recreation.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126245>	C176021	Average Hours Per Week Spent on Activity Question|Average Hours Per Week Spent on Activity|On average, how many hours per week do you spend	A question about the average hours per week that an individual spent on a specific activity.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126246>	C173924	Time Spent Standing or Walking at Work Question|Standing or walking around at work|Time Spent Standing or Walking Around at Work|Time Spent Standing or Walking at Work	A question about time spent standing or walking around at work.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126247>	C173458	Time Spent Standing or Walking at Home Question|Standing or walking around at home|Time Spent Standing or Walking Around at Home|Time Spent Standing or Walking at Home	A question about time spent standing or walking around at home.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126248>	C173924	Time Spent Sitting at Work or While Driving Question|Sitting at work or while driving|Time Spent Sitting at Work or While Driving	A question about time spent sitting at work or while driving.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126249>	C91102	Time Spent Sitting at Home Question|Sitting at home|Time Spent Sitting at Home	A question about time spent sitting at home.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C12624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12624>	C32177	Preganglionic Autonomic Fiber|Autonomic Fibers, Preganglionic|Preganglionic Fiber	An axon that projects from a nerve cell body within the central nervous system and innervates a cell within an autonomic ganglia. Preganglionic sympathetic fibers use acetylcholine as transmitters, sometimes with peptide cotransmitters.	Autonomic Fibers, Preganglionic		Body Part, Organ, or Organ Component	
C126250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126250>	C173135	Usual Walking Pace Outdoors Question|Usual Walking Pace Outdoors|What is your usual walking pace outdoors	A question about an individual's usual walking pace outdoors.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126251>	C173082	Flights of Stairs Climbed Daily Question|Flights of Stairs Climbed Daily|How many flights of stairs (not individual steps) do you climb daily	A question about how many flights of stairs an individual climbs daily.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126252>	C176256	Zero Activity Time|No Active Time|No Activity Time|Zero|Zero Active Time	A response indicating that no time was spent on an activity.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126253>	C176256	One to Four Activity Minutes|1-4 min.|One to Four Active Minutes	A response indicating that 1 to 4 minutes were spent on an activity.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126254>	C176256	Five to Nineteen Activity Minutes|5-19 min.|Five to Nineteen Active Minutes	A response indicating that 5 to 19 minutes were spent on an activity.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126255>	C176256	Twenty to Fifty-Nine Activity Minutes|20-59 min.|Twenty to Fifty-Nine Active Minutes	A response indicating that 20 to 59 minutes were spent on an activity.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126256>	C176256	One Activity Hour|One Active Hour|One hour	A response indicating that one hour (60 minutes) was spent on an activity.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126257>	C176256	One to One and One Half Activity Hours|1-1.5 hr|One to One and One Half Active Hours	A response indicating that 1 to 1 1/2 hours were spent on an activity.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126258>	C176256	Two to Three Activity Hours|2-3 hr|Two to Three Active Hours	A response indicating that 2 to 3 hours were spent on an activity.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126259>	C176256	Four to Six Activity Hours|4-6 hr|Four to Six Active Hours	A response indicating that 4 to 6 hours were spent on an activity.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C12625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12625>	C12623	Interneuron|Connector Neuron|Intercalary Neuron|Intercalated Neuron|Intercalated Neurons|Interneurons|Internuncial Cell|Internuncial Neuron	A type of neuron in the central nervous system that conducts impulses between other neurons.	Interneuron		Cell	
C126260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126260>	C176256	Seven to Ten Activity Hours|7-10 hr|Seven to Ten Active Hours	A response indicating that 7 to 10 hours were spent on an activity.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126261>	C176256	Eleven or More Activity Hours|11+ hr|Eleven or More Active Hours	A response indicating that 11 or more hours were spent on an activity.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126262>	C176256	Two to Five Activity Hours|2-5 hr|Two to Five Active Hours	A response indicating that 2 to 5 hours were spent on an activity.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126263>	C176256	Six to Ten Activity Hours|6-10 hr|Six to Ten Active Hours	A response indicating that 6 to 10 hours were spent on an activity.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126264>	C176256	Eleven to Twenty Activity Hours|11-20 hr|Eleven to Twenty Active Hours	A response indicating that 11 to 20 hours were spent on an activity.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126265>	C176256	Twenty-One to Forty Activity Hours|21-40 hr|Twenty-One to Forty Active Hours	A response indicating that 21 to 40 hours were spent on an activity.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126266>	C176256	Forty-One to Sixty Activity Hours|41-60 hr|Forty-One to Sixty Active Hours	A response indicating that 41 to 60 hours were spent on an activity.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126267>	C176256	Sixty-One to Ninety Activity Hours|61-90 hr|Sixty-One to Ninety Active Hours	A response indicating that 61 to 90 hours were spent on an activity.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126268>	C176256	Over Ninety Activity Hours|Over 90 hr|Over Ninety Active Hours	A response indicating that over 90 hours were spent on an activity.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126269>	C1511	Iodine I 131 SGMIB-Anti-HER2 CAM-H2|I-131-CAM H2|I-131-CAM-H2|I-131-CAMH2|I-131-VHH1|Iodine I 131 N-succinimidyl 4-guanidinomethyl-3-iodobenzoate-Anti-HER2 VHH1|Iodine I 131 SGMIB-Anti-HER2 VHH1|Iodine I 131 SGMIB-Anti-HER2 sdAb 2Rs 15d|[131I]-SGMIB Anti-HER2 VHH1	A radioconjugate composed of a camelid single domain antibody (sdAb) CAM-H2 (VHH1; sdAb 2Rs 15d) directed against human epidermal growth factor receptor 2 (HER2, EGFR2, ERBB2) that is covalently linked via N-succinimidyl 4-guanidinomethyl-3-iodobenzoate (SGMIB) to the radionuclide iodine I 131, with radioimaging and antineoplastic activities. Upon administration of iodine I 131 SGMIB-anti-HER2 CAM-H2, the anti-HER2 antibody moiety targets and binds to HER2-expressing cells. This facilitates both the detection of HER2-expressing tumor cells and the targeted destruction of HER2-positive tumors. HER2, a tyrosine kinase is overexpressed on the cell surfaces of various tumor cell types. CAM-H2 is composed of small (15 kDa), heavy chain-only anti-HER2 antibody fragments that are able to cross the blood-brain barrier (BBB) and are thus potentially useful in the treatment of central nervous system (CNS) metastases.	Iodine I 131 SGMIB-Anti-HER2 CAM-H2		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12626>	C33834|C12625	Amacrine Cell|Amacrine Cell of Retina|Amacrine Cells|Amacrine Cells of Retina	A retinal neuron that lacks large axons, having only processes that resemble dendrites.	Amacrine Cell		Cell	
C126270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126270>	C28681|C138180|C129826	Autologous HBV-specific TCR-redirected T-Lymphocytes|Autologous HBV Antigen-specific TCR-redirected T-Cells|Autologous HBV/TCR-T-Cells	A preparation of human autologous T-lymphocytes transduced with a viral vector encoding for a T-cell receptor (TCR) specific for a human hepatitis B virus (HBV) surface antigen (HBsAg), with potential antineoplastic activity. Following administration, the autologous HBV antigen specific TCR-redirected autologous T-lymphocytes recognize and bind to the HBV antigen-positive cells, which induces cytotoxic T-lymphocyte (CTL)-mediated elimination of HBV antigen-positive cancer cells. HBV antigens are found on HBV-positive cells and HPV-induced hepatocellular carcinoma (HCC).			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126271>	C2152|C129825	PI3K p110beta/delta Inhibitor CVL237|CVL 237|CVL-237|CVL237|KA 2237|KA2237|PI3 Kinase b/d Inhibitor KA2237|PI3K p110beta/delta Inhibitor KA2237	A dual selective inhibitor of the beta and delta isoforms of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K-beta/delta), with potential antineoplastic activity. PI3K-beta/delta inhibitor CVL237 selectively inhibits the PI3K-beta and -delta isoforms and prevents their activation, which inhibits PI3K-beta/delta-mediated signal transduction pathways. This decreases proliferation and induces cell death in susceptible tumor cells. Unlike other isoforms of PI3K, PI3K-beta and -delta are overexpressed primarily in solid and hematological tumor cells and play crucial roles in tumor cell survival, and immunoregulation. The targeted inhibition of these PI3Ks allows this agent to potentially be more efficacious and less toxic than pan PI3K inhibitors, which also affect normal, healthy cells.	PI3K p110beta/delta Inhibitor CVL237		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126272>	C1966	Fluorescence Imaging Agent EMI-137|EMI-137|EMI-137	A water-soluble compound composed of a 26-amino acid cyclic peptide targeting the human hepatocyte growth factor receptor (c-MET) conjugated to a cyanine-based fluorescent dye, with potential fluorescent imaging activity. Upon administration of EMI-137, the peptide moiety specifically targets and binds to the human tyrosine kinase receptor c-Met, which is often overexpressed on cancer cells. Upon imaging, the cancer cells can be visualized.			Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C126274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126274>	C62554	Fuzuloparib|4-((3-((5,6-Dihydro-2-(trifluoromethyl)(1,2,4)triazolo(1,5-a)pyrazin-7(8H)-yl)carbonyl)-4-fluorophenyl)methyl)-1(2H)-phthalazinone|AiRuiYi|FUZULOPARIB|Fluzoparib|SHR-3162|SHR3162	An orally available inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2, with potential antineoplastic activity. Upon oral administration, fuzuloparib inhibits PARP 1 and 2 activity, which inhibits PARP-mediated repair of damaged DNA via the base excision repair (BER) pathway, enhances the accumulation of DNA strand breaks, promotes genomic instability, and leads to an induction of apoptosis. The PARP family of proteins catalyze post-translational ADP-ribosylation of nuclear proteins, which then transduce signals to recruit other proteins to repair damaged DNA. PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126275>	C214993	Anti-LAMP1 Antibody-drug Conjugate SAR428926|ADC SAR428926|Anti-LAMP1 ADC SAR428926|SAR428926	An antibody-drug conjugate (ADC) consisting of a monoclonal antibody against lysosome-associated membrane protein 1 (LAMP1) conjugated, via the disulfide-containing cleavable linker N-succinimidyl-4-(2-pyridyldithio)butyrate (SPDB), to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. Upon administration of anti-LAMP1 ADC SAR428926, the anti-LAMP1 monoclonal antibody moiety targets and binds to the cell surface antigen LAMP1. After antibody-antigen interaction and internalization, the SPDB linker is selectively cleaved by proteases in the cytosol and the DM4 moiety is released. DM4 binds to tubulin and disrupts microtubule assembly/disassembly dynamics, thereby inhibiting both cell division and cell growth of LAMP1-expressing tumor cells. LAMP1, overexpressed on a variety of cancer cells, plays a key role in cell-cell adhesion and migration. The SPDB linker is resistant to cleavage in the bloodstream, which may increase stability and reduce toxicity.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126276>	C574	PE/HPV16 E7/KDEL Fusion Protein/GPI-0100 TVGV-1|PE-E7-KDEL/GPI-0100 TVGV-1|PEK Fusion Protein/GPI-0100 Vaccine|TVGV-1|TVGV-1 Vaccine	A fusion protein consisting of a peptide sequence of human papillomavirus (HPV) type 16 E7 nuclear protein and fused to the Pseudomonas aeruginosa exotoxin A (PE) and a endoplasmic reticulum (ER) retention signal (KDEL), with potential antineoplastic activity. Upon administration of PE/HPV16 E7/KDEL fusion protein TVGV-1, the PE moiety binds to CD91 (LRP1) expressed on a variety of cells, including antigen-presenting cells such as dendritic cells (DCs), which facilitates the internalization, through endocytosis, of TVGV-1. Following endocytosis, this agent is proteolytically cleaved by the proteasome and the epitopes from the HPV E7 protein become bound to MHC-I molecules and are presented on the DC-cell surface. This facilitates a cytotoxic T-cell- mediated immune response against HPV16 E7 expressing-tumor cells. KDEL targets the fusion protein to the ER, which increases this agent's potential to be bound by MHC-I molecules; this increases the immune response against HPV16 E7-expressing cancer cells.	PE/HPV16 E7/KDEL Fusion Protein/GPI-0100 TVGV-1		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126277>	C1966	Neutrophil Activation Probe Imaging Agent|NAP|NAP Imaging Agent	A fluorescence imaging agent composed of a fluorescent agent linked, via a human neutrophil elastase (HNE) cleavable peptide, to a dequencher molecule, with imaging activity for diagnostic purposes. Upon local administration, the neutrophil activation probe (NAP) imaging agent, initially quenched, is quickly taken up by activated neutrophils. In turn, the HNE expressed by these cells, specifically cleaves the linker and dequenches the fluorescent agent. The activated fluorescent moiety allows for visualization of activated neutrophils and HNE activity upon using a fluorescence imaging device. Activated neutrophils are upregulated at sites of inflammation and in inflammation-induced cancers, and express high levels of HNE.			Indicator, Reagent, or Diagnostic Aid	NCI Drug Dictionary Terminology
C126278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126278>	C91105	Cancer Rehabilitation Evaluation System for Research|CARES|CAncer Rehabilitation Evaluation System for Research (CARES)	A self-reported, clinically relevant instrument designed to assess the rehabilitation needs and daily problems of patients with cancer.			Intellectual Product	
C126279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126279>	C142985	Autologous Fat Graft|Autologous Fat Cell Transplantation|Autologous Fat Injection|Autologous Fat Transfer	The transfer of an individual's own body fat from one location to another.	Autologous Fat Graft		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C12627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12627>	C32177	Myelinated Nerve Fiber|Myelinated Nerve Fibers	A nerve axon that is surrounded by a layer of myelin.	Myelinated Nerve Fiber		Cell Component	
C126280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126280>	C176022	Clothes Do Not Look Good Question|Clothes Do Not Look Good|Clothes Do Not Look Good on Me|I find that my clothes do not look good on me	A question about whether an individual finds that clothes do not look good on them.			Intellectual Product	Cancer Rehabilitation Evaluation System for Research
C126281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126281>	C176022	Clothes Do Not Fit Question|Clothes Do Not Fit|I find that my clothes do not fit|My Clothes Do Not Fit	A question about whether an individual finds that their clothes do not fit.			Intellectual Product	Cancer Rehabilitation Evaluation System for Research
C126282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126282>	C173398	Difficulty Finding Clothes to Fit Question|Difficult to Find Clothes to Fit|Difficulty Finding Clothes to Fit|I have difficulty finding clothes to fit	A question about whether an individual has difficulty finding clothes to fit.			Intellectual Product	Cancer Rehabilitation Evaluation System for Research
C126283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126283>	C173601	Embarrassed to Show Body Because of Illness Question|Embarrassed to Show Body Because of Illness|I am embarrassed to show my body to others because of my illness	A question about whether an individual is embarrassed to show their body to others because of their illness.			Intellectual Product	Cancer Rehabilitation Evaluation System for Research
C126284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126284>	C173160	Uncomfortable Showing Scars Question|I am uncomfortable showing my scars to others|Uncomfortable Showing Scars	A question about whether an individual is uncomfortable showing their scars to others.			Intellectual Product	Cancer Rehabilitation Evaluation System for Research
C126285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126285>	C173160	Uncomfortable with Changes in Body Question|I am uncomfortable with the changes in my body|Uncomfortable with Changes in Body	A question about whether an individual is uncomfortable with changes in their body.			Intellectual Product	Cancer Rehabilitation Evaluation System for Research
C126286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126286>	C226692	A Fair Amount|A fair amount	A subjective response indicating that something is or was a fair amount.			Intellectual Product	Cancer Rehabilitation Evaluation System for Research
C126287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126287>	C226692	Much	A subjective response indicating that something is or was a large amount.			Intellectual Product	Cancer Rehabilitation Evaluation System for Research
C126288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126288>	C63334	Transjugular Intrahepatic Portosystemic Shunt|TIPS|TIPS Placement|TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT PLACEMENT	An interventional radiologic procedure in which a shunt is created in the liver that establishes communication between the portal vein and hepatic vein for the treatment of portal hypertension. The shunt is created using an image-guided endovascular approach, with the jugular vein as the entry site.			Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126289>	C16546	Variceal Banding|Endoscopic Variceal Banding	An endoscopic procedure in which an elastic ring is placed around an enlarged esophageal vein to cut off the blood flow through the vein. It is used to prevent bleeding from esophageal varices.			Diagnostic Procedure	
C12628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12628>	C13154	Sensory Neuron|Afferent Neuron|Afferent Neurons|Sensory Cell Afferent Neuron|Sensory Neurons	An afferent neuron that converts environmental stimuli into electrical impulses that are transmitted to the central nervous system.	Afferent Neuron		Cell	
C126290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126290>	C3131	TERC Deficiency	A condition of decreased or absent presence of telomerase RNA component. Deficiency of telomerase RNA component is associated with autosomal dominant dyskeratosis congenita 1, telomere-related pulmonary fibrosis, and bone marrow failure 2.			Disease or Syndrome	
C126291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126291>	C3131	TERT Deficiency	A condition of decreased or absent presence of telomerase reverse transcriptase. Deficiency of this protein is associated with autosomal dominant dyskeratosis congenital 2, autosomal recessive dyskeratosis congenita 4, telomere-related pulmonary fibrosis, and bone marrow failure 1.			Disease or Syndrome	
C126292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126292>	C3131	Perforin Deficiency	A condition of decreased or absent presence of perforin. Deficiency of this protein is associated with T-cell lymphoblastic lymphoma, aplastic anemia, hemophagocytic lymphohistiocytosis familial type 2, autoimmune lymphoproliferative syndrome and other lymphoproliferative disorders, including various forms of lymphoma.			Disease or Syndrome	
C126293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126293>	C3131	UNC13D Deficiency|MUNC13-4 Deficiency|MUNC13-4 Deficiency/UNC13D	A condition of decreased or absent presence of protein unc-13 homolog D. Deficiency of this protein is associated with familial hemophagocytic lymphohistiocytosis 3.			Disease or Syndrome	
C126294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126294>	C3131	STXBP2 Deficiency|MUNC18-2 Deficiency|MUNC18-2 Deficiency/STXBP2	A condition of decreased or absent presence of syntaxin-binding protein 2. Deficiency of this protein is associated with familial hemophagocytic lymphohistiocytosis type 5.			Disease or Syndrome	
C126295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126295>	C61246	X-linked Lymphoproliferative Syndrome 2|XIAP Deficiency|XIAP Deficiency/XLPs|XLP2|XLP2/XIAP	An X-linked lymphoproliferative disorder caused by mutations in the XIAP gene. Clinical manifestations include hemophagocytic lymphohistiocytosis (often associated with EBV), dysgammaglobulinemia, and inflammatory bowel disease. Patients are at an increased risk of developing lymphoma, typically B-cell non-Hodgkin lymphoma.			Disease or Syndrome	
C126296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126296>	C3131	Immunodeficiency of Unknown Origin|Unidentified Immunodeficiency	A condition of compromised immune function resulting from an uncharacterized defect.			Disease or Syndrome	
C126297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126297>	C19896	Vector of Transplantation Incompatibility|Vector of HLA Allele Mismatch|Vector of Incompatibility	Refers to the direction of allorecognition between donor and recipient.			Classification	
C126298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126298>	C169009	HLA Mismatch|HLA Allele Mismatch|HLA Locus Mismatch|HLA Serotype Mismatch|Mismatch|Non-match|Non-match	The state when a recipient of a hematopoietic stem cell transplant is not fully matched with their donor for HLA-A, HLA-B, HLA-C, and HLA-DRB1.			Laboratory or Test Result	ALL Authorized Value Terminology|ALL Stem Cell Transplant Table|AML Authorized Value Terminology|AML Stem Cell Transplant Table
C126299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126299>	C126298	Unidirectional HLA Mismatch|Unidirectional HLA Allele Mismatch|Unidirectional HLA Locus Mismatch	The state when a recipient of a hematopoietic stem cell transplantation is not fully matched with their unrelated adult volunteer donor for HLA-A, HLA-B, HLA-C, and HLA-DRB1 and either the recipient or donor is heterozygous at one locus. Occurs when only the donor or recipient is homozygous.			Classification	
C12629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12629>	C33063	Cochlear Hair Cell|Corti Cell	A type of sensory epithelial cell, located in the inner ear, that use hair-like projections called stereocilia to detect sound waves and transform them into neural signals that can be interpreted by the brain.	Hair Cell		Cell	
C1262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1262>	C155764	Triciribine Phosphate|1, 5-Dihydro-5-methyl-1-(5-O-phosphono-.beta.-D-ribofuranosyl)-1,4,5, 6,8-pentaazaacenaphthylen-3-amine|1, 5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)-1,4,5, 6,8-pentaazaacenaphthylen-3-amine|1,4, 5,6,8-Pentaazaacenaphthylen-3-amine, 1, 5-dihydro-5-methyl-1-(5-O-phosphono-.beta.-D-ribofuranosyl)- (9CI)|1,4, 5,6,8-pentaazaacenaphthylen-3-amine, 1, 5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)- (9CI)|1,4,5,6, 8-Pentaazaacenaphthalen-3-amine, 1, 5-dihydro-5-methyl-1-(5-O-phosphono-.beta.-D-ribofuranosyl)-|1,4,5,6, 8-pentaazaacenaphthalen-3-amine, 1, 5-dihydro-5-methyl-1-(5-O-phosphono-beta-D-ribofuranosyl)|3-Amino-1, 5-dihydro-5-methyl-1-.beta.-D-ribofuranosyl-1,4,5,6, 8-pentaazaacenaphthylene 5'-(dihydrogen phosphate)|3-amino-1, 5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6, 8-pentaazaacenaphthylene 5'-(dihydrogen phosphate)|TCN|TRICIRIBINE PHOSPHATE|Triciribine|Triciribine|Triciribine|Tricyclic Nucleoside 5'-Phosphate|Tricycloside Phosphate	The phosphate salt of the synthetic, cell-permeable tricyclic nucleoside triciribine with potential antineoplastic activity. Triciribine inhibits the phosphorylation, activation, and signalling of Akt-1, -2, and -3, which may result in the inhibition of Akt-expressing tumor cell proliferation. Akts are anti-apoptotic serine/threonine-specific protein kinases that phosphorylate and inactivate components of the apoptotic machinery, including Bcl-xL/Bcl-2-associated death promoter (BAD) and caspase 9.	Triciribine Phosphate		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126300>	C126298	Bidirectional HLA Mismatch|Bidirectional HLA Allele Mismatch|Bidirectional HLA Locus Mismatch	The state when a recipient of a hematopoietic stem cell transplantation is not fully matched with their unrelated adult volunteer donor for HLA-A, HLA-B, HLA-C, and HLA-DRB1 and both are heterozygous for different alleles at one locus.			Classification	
C126301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126301>	C126299	Graft-versus-Host Unidirectional Mismatch|GVH Unidirectional Mismatch|Graft-versus-Host Unidirectional HLA Allele Mismatch|Graft-versus-Host Unidirectional HLA Locus Mismatch|Graft-versus-Host Unidirectional HLA Mismatch	The state when a recipient of a hematopoietic stem cell transplantation is not fully matched with their unrelated adult volunteer donor for HLA-A, HLA-B, HLA-C, and HLA-DRB1 and the heterozygous recipient is receiving a graft from a homozygous donor.			Classification	
C126302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126302>	C126299	Host-versus-Graft Unidirectional Mismatch|HVG Unidirectional Mismatch|Host-versus-Graft Unidirectional HLA Allele Mismatch|Host-versus-Graft Unidirectional HLA Locus Mismatch|Host-versus-Graft Unidirectional HLA Mismatch	The state when recipients of hematopoietic stem cell transplantations are not fully matched with their unrelated adult volunteer donors for HLA-A, HLA-B, HLA-C, and HLA-DRB1 and the homozygous recipient is receiving a graft from a heterozygous donor.			Classification	
C126303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126303>	C202497	Tubulocystic Renal Cell Carcinoma|TcRCC|Tubulocystic renal cell carcinoma	A rare, cytologically high grade carcinoma that arises from the renal parenchyma. It is characterized by the presence of prominently dilated cystic spaces in a bland, fibrotic stroma. The lining cells have large irregular nuclei with prominent nucleoli and abundant eosinophilic cytoplasm. Necrosis and mitotic figures are not present. It rarely metastasizes.	Tubulocystic Renal Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C126304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126304>	C553|C45678	Xylene|Benzene, Dimethyl-|Dimethylbenzene|Methyl Toluene|Methyltoluene|XYLENE (MIXED ISOMERS)|Xylol	An aromatic hydrocarbon composed of a benzene ring linked to two methyl groups and that exists in three isoforms depending on the sites where the methyl groups are attached. Xylene is used for various industrial applications.	Xylene		Hazardous or Poisonous Substance|Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C126305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126305>	C42075	Dilated Cystic Spaces Present	A morphologic finding indicating the presence of dilated cystic spaces in the stroma of a neoplasm.			Finding	
C126306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126306>	C3058|C203285|C203274|C200759	Recurrent Glioblastoma	The reemergence of glioblastoma after a period of remission.	Recurrent Glioblastoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C126307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126307>	C7899|C39851|C157631	Recurrent Bladder Urothelial Carcinoma|Recurrent Bladder Transitional Cell Carcinoma|Recurrent Bladder Urothelial Cancer	The reemergence of bladder urothelial carcinoma after a period of remission.	Recurrent Bladder Urothelial Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C126308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126308>	C40081	Borderline Ovarian Clear Cell Tumor/Atypical Proliferative Ovarian Clear Cell Tumor	A non-invasive clear cell adenofibromatous neoplasm that arises from the ovary. It is characterized by the presence of atypia in the glandular epithelium.			Neoplastic Process	
C126309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126309>	C4967|C136488	Refractory Adult Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia (ALL)	An acute lymphoblastic leukemia that occurs in adulthood and does not respond to treatment.	Refractory Adult Acute Lymphoblastic Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C12630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12630>	C12632	Type I Hair Cell|Inner Hair Cell|Inner Hair Cells	A flask-shaped mechanoreceptor cell that detects and transduces head movements into neural impulses and is located within the vestibular systems of mammals, birds, and reptiles.	Inner Hair Cell		Cell	
C126310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126310>	C7282|C4060	Ovarian Seromucinous Cystadenoma	A non-metastasizing cystic mixed epithelial neoplasm that arises from the ovary. It is characterized by the presence of more than one epithelial cell type, most often serous and endocervical-type mucinous.			Neoplastic Process	Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C126311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126311>	C8984|C7282	Ovarian Seromucinous Adenofibroma	A non-metastasizing mixed epithelial neoplasm that arises from the ovary. It is characterized by the presence of more than one epithelial cell type, most often serous and endocervical-type mucinous and prominent fibrous stroma..			Neoplastic Process	
C126312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126312>	C176254	Easy or Casual Walking Pace|Easy, casual (less than 2 mph)|Less than 2 mph Pace	A response indicating a usual walking pace that is easy or casual, less than 2 mph.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126313>	C176254	Normal or Average Walking Pace|2-2.9 mpg Pace|Normal, average (2-2.9 mph)	A response indicating a usual walking pace that is normal or average, 2-2.9 mph.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126314>	C176254	Brisk Walking Pace|3-3.9 mph Pace|Brisk pace (3-3.9 mph)	A response indicating a usual walking pace that is brisk, 3-3.9 mph.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126315>	C176254	Very Brisk or Striding Pace|4 mph or Faster Pace|Very brisk/striding (4 mph or faster)	A response indicating a usual walking pace that is very brisk or striding, 4 mph or faster.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126316>	C226669	Two or Less Flights of Steps Daily|2 flights or less|Two or Less Flights Daily	A response that indicates climbing two or less flights of stairs daily.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126317>	C226669	Three to Four Flights of Steps Daily|3-4 flights|Three to Four Flights Daily	A response that indicates climbing three to four flights of stairs daily.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126318>	C226669	Five to Nine Flights of Steps Daily|5-9 flights|Five to Nine Flights Daily	A response that indicates climbing five to nine flights of stairs daily.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126319>	C226669	Ten to Fourteen Flights of Steps Daily|10-14 flights|Ten to Fourteen Flights Daily	A response that indicates climbing ten to 14 flights of stairs daily.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C12631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12631>	C12632	Type II Hair Cell|Outer Hair Cell|Outer Hair Cells|Type II Hair Cells	A cylinder-shaped mechanoreceptor cell that detects and transduces head movements into neural impulses and is located within the vestibular systems of all vertebrates.	Outer Hair Cell		Cell	
C126320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126320>	C226669	Fifteen or More Flights of Steps Daily|15 or more flights|Fifteen or More Flights Daily	A response that indicates climbing 15 or more flights of stairs daily.			Intellectual Product	Nurses' Health Study II Activity and Inactivity Questionnaire
C126321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126321>	C6264	Ovarian Luteinized Thecoma Associated with Sclerosing Peritonitis	A rare usually bilateral luteinized thecoma that arises from the ovary and is associated with sclerosing peritonitis. It occurs mostly in premenopausal women. The ovarian tumor is benign but patients may develop intestinal obstruction due to the sclerosing peritonitis.			Neoplastic Process	
C126322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126322>	C39971|C39970	Ovarian Retiform Sertoli-Leydig Cell Tumor, Variant with Heterologous Elements	A retiform Sertoli-Leydig cell tumor that arises from the ovary. It is characterized by the presence of an epithelial and/or mesenchymal heterologous component.			Neoplastic Process	
C126323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126323>	C154617|C126324	Gastroesophageal Junction Large Cell Neuroendocrine Carcinoma	An aggressive high-grade carcinoma with neuroendocrine differentiation that arises from the gastroesophageal junction and is composed of malignant large cells. The mitotic count is more than 20 per 2 mm2 and/or the Ki-67 index is more than 20%.			Neoplastic Process	Cellosaurus Disease Terminology
C126324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126324>	C95405|C223236|C203675	Gastroesophageal Junction Neuroendocrine Carcinoma|Gastroesophageal Junction NEC	An aggressive high-grade carcinoma with neuroendocrine differentiation that arises from the gastroesophageal junction. It is composed of malignant small or large cells. The mitotic count is more than 20 per 2 mm2 and/or the Ki-67 index is more than 20%.			Neoplastic Process	
C126325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126325>	C154641|C126324	Gastroesophageal Junction Small Cell Neuroendocrine Carcinoma|Gastroesophageal Junction Small Cell Carcinoma	An aggressive high-grade carcinoma with neuroendocrine differentiation that arises from the gastroesophageal junction and is composed of malignant small cells. The mitotic count is more than 20 per 2 mm2 and/or the Ki-67 index is more than 20%.			Neoplastic Process	
C126326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126326>	C53543|C28193	Roberts Syndrome	A rare, autosomal recessive inherited syndrome caused by mutations in the ESCO2 gene. It is characterized by limb and facial abnormalities and slow growth. Intellectual impairment occurs in approximately half of the affected individuals.			Disease or Syndrome	Cellosaurus Disease Terminology
C126327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126327>	C85217	Usher Syndrome Type 1	A syndrome characterized by congenital, bilateral, severe sensorineural hearing loss, abnormalities in the vestibular system, and adolescent-onset retinitis pigmentosa.			Disease or Syndrome	Cellosaurus Disease Terminology
C126328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126328>	C85217	Usher Syndrome Type 2	A syndrome characterized by congenital, bilateral sensorineural hearing loss that is mild to moderate in the low frequencies and severe to profound in the higher frequencies, no abnormalities in the vestibular system, and retinitis pigmentosa.			Disease or Syndrome	Cellosaurus Disease Terminology
C126329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126329>	C85217	Usher Syndrome Type 3	A syndrome characterized by postlingual progressive hearing loss, abnormalities in the vestibular system, and onset of retinitis pigmentosa symptoms usually by the second decade of life.			Disease or Syndrome	
C12632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12632>	C33063	Vestibular Hair Cell|Vestibular Hair Cells	A sensory receptor cell, located within the vestibular system, that detects and transduces head movements into neural impulses that are transmitted by vestibular afferent nerves to the brain.	Vestibular Hair Cell		Cell	
C126330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126330>	C85865|C116757	X-Linked Dystonia Parkinsonism|DYT3|Dystonia 3|X-Linked Dystonia-Parkinsonism|XDP	An X-linked recessive inherited movement disorder caused by mutations in and near the TAF1 gene. It is found only in people of Filipino descent. It is characterized by parkinsonism and later in life the development of involuntary, sustained muscle contractions.			Disease or Syndrome	Cellosaurus Disease Terminology
C126331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126331>	C3762|C2895	Ovarian Adenomatoid Tumor|Benign Ovarian Mesothelioma	A rare benign mesothelial tumor that arises from the ovary. It is characterized by the presence of gland-like structures.			Neoplastic Process	
C126332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126332>	C1511	Zirconium Zr 89-labeled Anti-CA19-9 Monoclonal Antibody 5B1|89Zr-DFO-HuMab-5B1|MVT-2163	A radioimmunoconjugate comprised of the recombinant human monoclonal antibody against the carbohydrate antigen sialyl-Lewis a (carbohydrate antigen 19-9; CA19-9) conjugated to the chelator desferrioxamine (DFO) and labeled with the radioisotope zirconium Zr 89 (Zr 89), with radioisotopic activity and potential use as an imaging agent in positron emission tomography (PET). The antibody moiety of zirconium Zr 89 anti-CA19-9 monoclonal antibody 5B1 targets and binds to CA19-9 expressing-tumor cells. Upon binding, internalization and proteolysis, the radioisotope moiety may be detected using PET, thus allowing imaging and quantification of CA19-9-expressing tumor cells. CA19-9, overexpressed on a number of different tumor cell types, plays a key role in tumor cell survival and metastasis.	Zirconium Zr 89-labeled Anti-CA19-9 Monoclonal Antibody 5B1		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C126333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126333>	C797	Lamellar Body Mimetic Mouth Spray LMS-611|LMS-611|OXB/1-20|RIX-LMS-611x-20|Visco-ease	A suspension-based oral spray containing multilamellar lipid vesicles in which the lipids mimic the lipidic composition of endogenous extra-alveolar lamellar bodies, with muco-restorative and protective activity against radiotherapy (RT)-induced xerostomia (RIX). Upon sublingual administration of the lamellar body mimetic LMS-611 using a spray, the lipids in this agent mimic the natural secretions of endogenous lamellar bodies. This makes mucus more fluid and may prevent dryness of the mouth. This restores saliva functions and makes it easier to chew, swallow and talk, and also prevents xerostomia-induced infections, tooth decay and tooth enamel decay. RT decreases saliva secretion by causing the destruction of the parotid and submandibular serous salivary glands and lamellar bodies. This results in thicker and more visco-adhesive saliva, which causes various xerostomia-induced symptoms; intact lamellar bodies maintain the fluidity of mucus and lubricate the mouth.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C126334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126334>	C133879|C129822	Anti-FGFR4 Monoclonal Antibody U3-1784|U3 1784|U3-1784	A human monoclonal antibody against human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon administration, U3-1784 specifically binds to and blocks FGFR4. This prevents the activation of FGFR4, inhibits FGFR4-mediated signaling and leads to an inhibition of cell proliferation in FGFR4-overexpressing tumor cells. FGFR4, a receptor tyrosine kinase overexpressed by certain tumor cell types, is involved in tumor cell proliferation, differentiation, angiogenesis, and survival.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126336>	C85865|C3131	X-Linked Immunodeficiency with Magnesium Defect, Epstein-Barr Virus Infection and Neoplasia|MAGT1 Deficiency|X-Linked Immunodeficiency with Magnesium Defect Epstein-Barr Virus Infection and Neoplasia|XMEN|XMEN	An X-linked recessive condition caused by mutation(s) in the MAGT1 gene, encoding magnesium transporter protein 1. It is characterized by CD4 lymphopenia, defective T-cell activation and susceptibility to severe chronic viral infections, particularly Epstein-Barr virus (EBV), which may lead to the development of EBV-associated B-cell lymphoproliferative disorders.			Disease or Syndrome	
C126337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126337>	C3131	IFN-gamma Receptor 1 Deficiency|IFN-gamma receptor 1 deficiency	A condition of decreased or absent presence or activity of interferon gamma receptor 1. Deficiency of this protein is associated with immunodeficiency 27A and immunodeficiency 27B.			Disease or Syndrome	
C126338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126338>	C3131	Hypomorphic RAG1 Deficiency|Hypomorphic Rag1 deficiency	A condition of decreased or absent presence or activity of V(D)J recombination-activating protein 1. Deficiency of this protein is associated with Omenn syndrome, severe combined immunodeficiency, b cell-negative, combined cellular and humoral immune defects with granulomas, and alpha/beta T-cell lymphopenia with gamma/delta T-cell expansion, severe cytomegalovirus infection, and autoimmunity.			Disease or Syndrome	
C126339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126339>	C3131	PGM3-Associated Immunodeficiency|IMD 23|Immunodeficiency 23|PGM3 Deficiency|PGM3 Phosphoglucomutase Deficiency|PGM3 deficiency	A condition of decreased or absent presence or activity of phosphoglucomutase 3. Deficiency of this protein is associated with immunodeficiency 23.			Disease or Syndrome	
C12633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12633>	C12628	Olfactory Receptor Neuron|Olfactory Receptor Cell|Olfactory Receptor Cells|Olfactory Receptor Neurons	A bipolar neuron located in the sensory epithelium within the nasal cavity that detects odor signal molecules and transmits olfactory information to the central nervous system.	Olfactory Receptor Neuron		Cell	
C126340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126340>	C178120|C157554	Activating PI3K Gene Mutation|Activating 1-Phosphatidylinositol 3-Kinase Gene Mutation|Activating PI3 Kinase Gene Mutation|Activating PI3-Kinase Gene Mutation|Activating PI3K Family Gene Mutation|Activating PI3K Mutation|Activating PI3K Mutation|Activating PIK3 Gene Mutation|Activating Phosphatidylinositide 3-Kinase Gene Mutation|Activating Phosphatidylinositol 3 Kinase Gene Mutation|Activating Phosphatidylinositol 3-Kinase Gene Mutation|Activating Phosphatidylinositol-3-Kinase Gene Mutation|Activating Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Gene Mutation	A change in the nucleotide sequence of any one of the genes encoding proteins in the phosphatidylinositol 3-kinase (PI3K) family that results in constitutive PI3K activity and aberrant activation of PI3K-dependent signaling pathways.	Activating PI3K Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126341>	C2889	CTLA4 Deficiency|CHAI|CTLA4 Haploinsufficiency|CTLA4 haploinsufficiency	A genetic condition caused by mutation(s) in the CTLA4 gene, encoding cytotoxic T-lymphocyte protein 4. Cytotoxic T-lymphocyte protein 4 is an inhibitory receptor acting as a negative regulator of T-cells, and two functional copies of the gene are required for normal immune function. Clinically, it may be characterized by gastrointestinal symptoms, lymphadenopathy, hepatomegaly, and splenomegaly, and autoimmune disorders. Mutations(s) in CTLA4 are also associated with autoimmune lymphoproliferative syndrome, type V.			Disease or Syndrome	
C126342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126342>	C3144	STAT3 Deficiency|Autosomal dominant hyper-IgE syndrome|Hyper-IgE Recurrent Infection Syndrome|Job Syndrome|Job's syndrome|STAT3 deficiency	A condition of decreased or absent presence or activity of signal transducer and activator of transcription 3 protein. Deficiency of this protein is associated with hyper-IgE syndrome.			Disease or Syndrome	
C126343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126343>	C3144	DOCK8 Deficiency|Autosomal Recessive hyper IgE syndrome|DOCK8 deficiency|Dedicator of Cytokinesis 8 Deficiency	A condition of decreased or absent presence or activity of dedicator of cytokinesis protein 8. Deficiency of this protein is associated with autosomal recessive hyper-IgE recurrent infection syndrome.	DOCK8 Deficiency		Disease or Syndrome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126344>	C3131	Lymphoproliferative Syndrome 1|IL-2 Inducible T-cell Kinase Deficiency|ITK Deficiency|LPFS1|Lymphoproliferative Syndrome 1/ITK Deficiency	An autosomal recessive immunodeficiency caused but mutation(s) in the ITK gene, encoding tyrosine-protein kinase ITK/TSK. It is characterized by the early childhood onset of Epstein-Barr virus (EBV)-associated immune dysregulation leading to lymphoma, lymphomatoid granulomatosis, hemophagocytic lymphohistiocytosis, and/or hypogammaglobulinemia.			Disease or Syndrome	CCPS Disease Terminology|Childhood Cancer Predisposition Study Terminology
C126345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126345>	C178120|C153514	Activating STAT3 Gene Mutation|Activating STAT3 Mutation|STAT-3 GOF|STAT3 Activating Gene Mutation|STAT3 Activating Mutation|STAT3 Gain of Function|STAT3 Gain of Function Gene Mutation|STAT3 Gain of Function Mutation|STAT3 gain of function	A mutation in the STAT3 gene that results in an increase in cytokine-related function. STAT3 mutations of this type are associated with infantile-onset multisystem autoimmune disease.	Activating STAT3 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126346>	C178120|C176672	Activating STAT1 Gene Mutation|Activating STAT1 Mutation|STAT-1 GOF|STAT1 Activating Gene Mutation|STAT1 Activating Mutation|STAT1 Gain of Function|STAT1 Gain of Function Gene Mutation|STAT1 Gain of Function Mutation|STAT1 gain of function	A mutation in the STAT1 gene that results in an increase in cytokine-related functions associated with IFN-alpha/beta, IFN-gamma, IFN-delta, and IL-27. STAT1 mutations of this type are associated with autosomal dominant immunodeficiency 31C.			Cell or Molecular Dysfunction	
C126347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126347>	C26847	Adenosine Deaminase 2 Deficiency|Adenosine deaminase 2 deficiency/DAD2|DADA2|VAIHS	A disorder characterized by abnormal inflammation of various tissues, particularly the blood vessels, with intermittent. fevers, areas of net-like, mottled skin discoloration (livedo racemosa), hepatosplenomegaly, and recurrent strokes.	Adenosine Deaminase 2 Deficiency		Disease or Syndrome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126348>	C190402	Chronic Active EBV Disease|CAEBV|CAEBV Infection|Chronic Active EBV Infection|Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form|Chronic Active Epstein-Barr Virus Disease|Chronic active Epstein-Barr virus (without identified mutation)|Systemic CAEBV of T-and NK-Cell Type|Systemic Chronic Active EBV Disease|Systemic Chronic Active EBV Infection of T-Cell and NK-Cell Type	An EBV-positive T-cell/NK-cell lymphoproliferative disorder characterized by repeated infectious mononucleosis-like symptoms, a very high titer of anti-EBV antibodies, and high levels of Epstein-Barr virus nucleic acids. Patients often develop progressive cellular and humoral immunodeficiency with pancytopenia and hypogammaglobulinemia.			Neoplastic Process	Cellosaurus Disease Terminology
C126349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126349>	C3131	GATA2 Deficiency|GATA2 deficiency/MonoMac syndrome|Immunodeficiency 21|MonoMAC Syndrome|Monocytopenia and Mycobacterial Infection Syndrome	A condition of decreased or absent presence or activity of endothelial transcription factor GATA-2 protein. Deficiency of this protein is associated with immunodeficiency 21 and autosomal dominant and sporadic monocytopenia and mycobacterial infection syndrome (MonoMAC).	GATA2 Deficiency		Disease or Syndrome	CCPS Disease Terminology|Childhood Cancer Predisposition Study Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12634>	C12628	Photoreceptor Cell|Photosensitive Cell	A sensory neuron, located in the retina of the eye, that converts light signals into nerve impulses.	Photoreceptor		Cell	
C126351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126351>	C84275|C3483	Chronic Eosinophilic Leukemia with FIP1L1-PDGFRA|Chronic Eosinophilic Leukemia with FIP1L1::PDGFRA	Chronic eosinophilic leukemia characterized by the rearrangement of the PDGFRA gene, most often resulting in the formation of FIP1L1-PDGFRA fusion transcripts.			Neoplastic Process	
C126352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126352>	C85865|C111802	X-Linked Dyskeratosis Congenita|Hoyeraal Hreidarsson Syndrome	Dyskeratosis congenita inherited in an X-linked recessive pattern. It is caused by mutations in the DKC1 gene.			Disease or Syndrome	
C126353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126353>	C40023|C213446	Primary Peritoneal High Grade Serous Adenocarcinoma|Primary Peritoneal High-Grade Serous Adenocarcinoma	A serous adenocarcinoma that arises from the lining of the peritoneum. It is characterized by high-grade histopathologic features.	Primary Peritoneal High Grade Serous Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C126354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126354>	C40023|C213448	Primary Peritoneal Low Grade Serous Adenocarcinoma|Invasive Micropapillary Serous Carcinoma of the Peritoneum|Invasive Micropapillary Serous Carcinoma of the Peritoneum|Primary Peritoneal Low-Grade Serous Adenocarcinoma	A serous adenocarcinoma that arises from the lining of the peritoneum. It is characterized by low-grade histopathologic features.	Invasive Micropapillary Serous Carcinoma of the Peritoneum		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C126355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126355>	C213143|C155712	Anti-HER2 Antibody-drug Conjugate MEDI4276|ADC MEDI4276|MEDI-4276|MEDI-4276|MEDI4276	An antibody-drug conjugate (ADC) composed of a bispecific antibody against the extracellular domain of human epidermal growth factor receptor 2 (HER2; ERBB2) comprised of the single-chain variable fragment (scFv) of the anti- HER2 monoclonal antibody trastuzumab, which binds to domain IV of HER2, fused to the heavy chains of the anti-HER2 monoclonal antibody 39S, which binds to domain II of HER2, and conjugated, via a cleavable linker, to the cytotoxic anti-microtubule agent tubulysin, with potential antineoplastic activity. Upon administration of ADC MEDI4276, the anti-HER2 bispecific antibody specifically targets and binds to HER2 on the surface of certain cancer cells. Upon binding, crosslinking and internalization of antibody-HER2 complexes occurs and MEDI4276 is transported to the lysosome where the linker is cleaved, thereby delivering tubulysin inside HER2-expressing cancer cells. Tubulysin binds to tubulin and inhibits microtubule polymerization, which blocks cell division. This results in G2/M phase arrest, tumor cell apoptosis, and decreased proliferation of HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.	Anti-HER2 Antibody-drug Conjugate MEDI4276		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126356>	C8300|C3538	Peritoneal Desmoplastic Small Round Cell Tumor|Peritoneal DSRCT	A desmoplastic small round cell tumor that occurs in the abdominal and/or pelvic peritoneum.			Neoplastic Process	
C126357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126357>	C7634|C3322	Peritoneal Solitary Fibrous Tumor|Peritoneal SFT	A rare, usually benign fibroblastic neoplasm that arises from the peritoneum. It is characterized by the presence of prominent hemangiopericytoma-like vessels.			Neoplastic Process	
C126358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126358>	C9182	Pelvic Fibromatosis|Pelvic Desmoid Tumor	Fibromatosis that occurs in the pelvis. It affects almost always females. It is characterized by the presence of elongated spindle-shaped fibroblasts, collagenous stroma formation, and an infiltrative growth pattern. It recurs if incompletely resected but lacks metastatic potential.			Neoplastic Process	
C126359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126359>	C6481	Abdominal Inflammatory Myofibroblastic Tumor	An inflammatory myofibroblastic tumor that arises from the abdominal cavity.			Neoplastic Process	
C12635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12635>	C33904	Photoreceptors, Invertebrate	Specialized cells in invertebrate animals that convert light signals into nerve impulses.	Photoreceptors, Invertebrate		Cell	
C126360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126360>	C27666	Peritoneal Gliomatosis|Gliomatosis Peritonei	A benign condition characterized by the presence of peritoneal implants composed of mature glial tissue. It is usually accompanied by an ovarian teratoma.			Disease or Syndrome	
C126361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126361>	C2959	Disease Sequela|Pathologic Sequela|Sequela|Sequelae|Sequelae	A pathologic condition that results from a disease, treatment, or injury.			Finding	
C126362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126362>	C25150	Age of Majority	The age at which a minor assumes legal control over their person, actions, and decisions.			Organism Attribute	
C126363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126363>	C17610	Packed Red Blood Cells|PRBCs|Packed Cells|Packed Red Cells	The red blood cells from a unit of whole blood following removal of most of the plasma, leaving a unit with a hematocrit of about 60%.			Body Substance	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C126364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126364>	C25245	Face	A flat surface of an object.			Classification	
C126365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126365>	C54707	Blood Pressure Excursion	Instances where blood pressure is outside of established parameters.			Finding	
C126366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126366>	C25404	Placement|Place|Placed	The act of putting something into a position or location.			Activity	
C126367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126367>	C50236	Centrifugation Tube	A high-strength tube of glass or plastic designed for spinning in a centrifuge.			Manufactured Object	
C126368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126368>	C25404	Witness	To attest to the genuineness of a document or signature.			Activity	
C126369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126369>	C172299	Dehydration|Dehydration Procedure|Dehydration Technique	Any procedure designed to remove the water from a substance or sample.			Laboratory Procedure	
C126370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126370>	C19238	Cover Slip	A thin flat piece of transparent material that is placed over a specimen for viewing with a microscope.			Manufactured Object	
C126371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126371>	C42729	Local Pathology Review|LPR	Microscopic examination of tissue specimen(s) by a pathologist in the local institution where a patient had a procedure performed, using local standardized methods and criteria.			Activity	
C126372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126372>	C19238	Blade	The thin, sharp part of a knife, tool, or weapon designed to cut things.			Manufactured Object	
C126373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126373>	C16742	Microtome	An instrument that cuts thin slices of something for microscopic examination.			Manufactured Object	
C126374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126374>	C20189	Notable|Noted	When something is worthy of attention or notice.			Conceptual Entity	
C126375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126375>	C220782	Pathology Ink|Marking Ink	Medical grade dye or pigment that is applied to surgically removed tissue specimens to maintain orientation and indicate tumor resection margins.			Indicator, Reagent, or Diagnostic Aid	
C126376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126376>	C20189	Unusable|Not Usable|Not Useable|Unuseable	Not fit for the intended purpose.			Conceptual Entity	
C126377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126377>	C198859	Anti-CD19 Antibody-drug Conjugate SGN-CD19B|ADC SGN-CD19B|SGN CD19B|SGN-CD19B	An antibody-drug conjugate (ADC) consisting of an anti-CD19 humanized monoclonal antibody (hBU12ec) with engineered cysteines (EC-mAb) conjugated, via a maleimidocaproyl-valine-alanine dipeptide protease-cleavable linker, to the cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer (SGD-1882), with potential antineoplastic activity. Upon administration of anti-CD19 ADC SGN-CD19B, the antibody moiety targets the cell surface antigen CD19, which is found on B-cell-derived cancers. Upon antibody/antigen binding, internalization and lysosome uptake, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of CD19-overexpressing tumor cells. CD19, a transmembrane receptor belonging to the immunoglobulin superfamily and a B-cell specific antigen, is expressed on B-cell-derived cancers. The cysteine engineering of the EC-mAb allows for a site-specific and stable conjugation of PBD to the antibody.	Anti-CD19 Antibody-drug Conjugate SGN-CD19B		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126378>	C171086	Drinking Status|alcohol intensity|alcohol_intensity	The current status of a person with regard to the amount of alcoholic beverages they consume.			Qualitative Concept	GDC Property Terminology|GDC Terminology
C126379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126379>	C126378	Non-Drinker|Abstainer|Nondrinker	An individual who does not drink at the present time. This is a heterogeneous group comprising both lifelong teetotallers and ex-drinkers.			Qualitative Concept	GDC Terminology|GDC Value Terminology
C12637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12637>	C12634	Retinal Cone|Cone|Cone Cell|Cones	A photoreceptor cell located in the retina of the eye that allows high spatial acuity and color sensitivity.	Cone		Cell	
C126380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126380>	C126379	Lifelong Non-Drinker|Lifelong non-drinker|Teetotaller	An individual who does not drink at the present time and who claims that they have never been a drinker.			Qualitative Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C126381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126381>	C126379	Ex-Drinker	An individual who used to drink regularly, but does not drink at the present time.			Qualitative Concept	
C126382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126382>	C126378	Occasional Drinker	An individual who drinks from time to time, but generally less than once per week.			Qualitative Concept	GDC Terminology|GDC Value Terminology
C126383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126383>	C126378	Drinker|Alcohol user|Regular Drinker	An individual who drinks at least once per week with regularity.			Qualitative Concept	GDC Terminology|GDC Value Terminology
C126384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126384>	C126383	Heavy Drinker	A man who drinks more than 14 standard drinks per week or a woman who drinks more than 7 standard drinks per week.			Qualitative Concept	GDC Terminology|GDC Value Terminology
C126385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126385>	C54131	Fisher Scientific	A commercial provider of laboratory equipment, chemicals, supplies, and services used in scientific research, safety, healthcare, and education.			Organization	
C126386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126386>	C20189	In-House|In-house	Created, done, or existing within a company or organization.			Conceptual Entity	SeroNet Assay Metadata|SeroNet Assay Target Metadata|SeroNet Authorized Values
C126387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126387>	C15256	Laparoscopically Assisted Vaginal Hysterectomy|LAVH|Laparoscopically Assisted Vaginal Hysterectomy (LAVH)	A surgical procedure that uses a laparoscope to guide the removal of the uterus and/or Fallopian tubes and ovaries through the vagina.			Therapeutic or Preventive Procedure	
C126388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126388>	C62219	Leico Peloris Rapid Tissue Processor	A proprietary automated tissue processor designed to do fast, high quality tissue processing for histology laboratories.			Manufactured Object	
C126389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126389>	C126373	Microm Ergostar HM200 Microtome|Microm Ergostar HM200	A multi-purpose, proprietary specimen preparation system that integrates rotary and sliding microtomes.			Manufactured Object	
C12638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12638>	C12634	Retinal Rod|Rod|Rod Cell|Rods	A photoreceptor cell located in the retina of the eye that allows low light vision.	Rod		Cell	
C126390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126390>	C27993	Neither	Not either one; not the one or the other.			Qualitative Concept	
C126391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126391>	C16079	Open Surgical Procedure|Open|Open Surgery|Surgery, Open	Traditional surgery using a long incision for visualization and for the insertion of instruments.			Therapeutic or Preventive Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uveal Melanoma Baseline Form|GDC Terminology|GDC Value Terminology
C126392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126392>	C19238	PAXgene Blood Tissue System|PAXgene	A system of proprietary reagents and supplies utilizing formalin-free solutions for the simultaneous preservation of histomorphology and biomolecules and the purification of RNA, DNA, miRNA, proteins, and phosphoproteins from the same sample.			Manufactured Object	
C126393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126393>	C113124	PAXgene Blood DNA Tube|PAXgene DNA Vacutainer	A blood collection tube that uses proprietary reagents for whole blood collection and stabilization prior to genomic DNA isolation.			Manufactured Object	
C126394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126394>	C113124	PAXgene Blood RNA Tube|PAXgene RNA Vacutainer	A blood collection tube that uses proprietary reagents for whole blood collection and stabilization prior to isolation of cellular RNA.			Manufactured Object	
C126395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126395>	C25404	Recycle|Recycled	To use again following processing.			Activity	
C126396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126396>	C126372	Sakura Low Profile Accu-Edge Blade|Sakura Finetek Low Profile Microtome Blade|Sakura Low Profile Accu-Edge|Tissue-Tek Accu-Edge Disposable Low Profile Microtome Blade	A proprietary disposable microtome blade with an 8-mm height.			Manufactured Object	
C126397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126397>	C40961	Supracervical Hysterectomy|SCH|Supracervical	A hysterectomy that removes the uterus and leaves the cervix in place.			Therapeutic or Preventive Procedure	GDC Terminology|GDC Value Terminology
C126398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126398>	C48050	Uncharged	Not carrying an electric charge.			Qualitative Concept	
C12639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12639>	C33239	Rod Outer Segment|Rod Outer Segment of the Retina|Rod Outer Segments	A portion of the retinal rod cell largely consisting of a stack of discs (membrane infoldings that are incompletely separated in cones) that are continually replenished near the inner segment and that are shed from the distal end and phagocytosed by the pigmented epithelium.	Rod Outer Segments		Cell Component	
C1263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1263>	C2355|C2184|C2017	Trilostane|(4Alpha,5alpha,17beta)-4,5-epoxy-3,17-dihydroxyandrost-2-ene-2-carbonitrile|2Alpha-cyano-4alpha,5alpha-epoxyandrostan-17beta-ol-3-one|4,5-Epoxy-17-hydroxy-3-oxoandrostane-2-carbonitrile|Desopan|Modrastane|Modrenal|TRILOSTANE|WIN 24,540|WIN 24540	A synthetic derivative of androstane with adrenocortical suppressive properties.  Trilostane reversibly inhibits 3 beta-hydroxysteroid dehydrogenase delta 5-4 isomerase in the adrenal cortex, resulting in the decreased synthesis of mineralocorticoids and glucocorticoids and the decreased conversion of pregnenolone to progesterone. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C126400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126400>	C49236	Renal Replacement Therapy|RENAL REPLACEMENT THERAPY|RRT|RRT|Renal replacement therapy	Treatments that substitute for the blood-filtering function of the kidneys. It includes dialysis (hemodialysis or peritoneal dialysis), hemofiltration, and hemodiafiltration. Kidney transplant may also be considered a renal replacement therapy.			Therapeutic or Preventive Procedure	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|Appendix 8: Pharmacological Therapy Terminology|CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|Therapies for Supportive Care During COVID-19 Infection Terminology
C126401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126401>	C4086	Bronchial Epithelial Dysplasia|Endobronchial Dysplasia	A non-invasive precancerous lesion in the bronchial epithelium. Depending on the morphologic features it is classified as columnar cell dysplasia, basal cell dysplasia, squamous dysplasia, or bronchial epithelial dysplasia with transitional differentiation.	Bronchial Epithelial Dysplasia		Finding	CTRP Disease Terminology|CTRP Terminology
C126402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126402>	C116489	Near-Infrared Fluorescence Imaging|NIR Fluorescence Imaging|NIR Optical Imaging|NIRF|Near Infrared Fluoroscopy	Fluorescence imaging using dyes that fluoresce in the near-infrared range. NIR optical imaging permits relatively deep photon penetration into tissue, minimal tissue auto-fluorescence, less scatter, and high optical contrast.	Near-Infrared Fluorescence Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C126403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126403>	C54131	Novartis	A Swiss multinational pharmaceutical company that is engaged in the development, manufacturing, and marketing of healthcare products.			Organization	
C126404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126404>	C54131	Juno Therapeutics	A clinical-stage company developing cellular immunotherapies based on Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies.			Organization	
C126405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126405>	C54131	Celgene	An American biotechnology company that manufactures drug therapies for cancer and inflammatory disorders.			Organization	
C126406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126406>	C54131	Kite Pharma	A clinical-stage biopharmaceutical company engaged in the development of cancer immunotherapy products with a primary focus on engineered autologous T cell therapy designed to restore the immune system's ability to recognize and eliminate tumors.			Organization	
C126407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126407>	C54131	Bluebird Bio|Blue Bird Biotec	A clinical-stage biotechnology company using gene therapy, cancer immunotherapy, and gene editing to treat and cure genetic diseases and cancer.			Organization	
C126408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126408>	C4815	Thyroid Gland Cribriform Morular Carcinoma|CMTC|Cribriform Morular Thyroid Gland Carcinoma|Cribriform-Morular Variant Thyroid Gland Papillary Cancer|Cribriform-Morular Variant Thyroid Gland Papillary Carcinoma	A thyroid gland carcinoma characterized by the presence of cribriform, trabecular, follicular, papillary, and solid growth patterns and squamoid morulae formation. It may occur with familial adenomatous polyposis or sporadically.	Cribriform-Morular Variant Thyroid Gland Papillary Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C126409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126409>	C46068|C4035|C3679	Warthin-Like Variant Thyroid Gland Papillary Carcinoma|Warthin Tumor-Like Variant Thyroid Gland Papillary Cancer|Warthin Tumor-Like Variant Thyroid Gland Papillary Carcinoma	A rare variant of papillary thyroid gland carcinoma characterized by the presence of eosinophilic large cells lining the papillae and a brisk lymphoplasmacytic infiltrate in the papillary stalks.	Warthin Tumor-Like Variant Thyroid Gland Papillary Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C12640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12640>	C12625	Posterior Horn Cell|Dorsal Horn Cells|Neurons, Dorsal Horn|Neurons, Posterior Horn|Posterior Horn Cells	Neurons in the posterior (dorsal) horn of the spinal cord whose cell bodies and processes are confined entirely to the central nervous system. They receive collateral or direct terminations of dorsal root fibers. They send their axons either directly to anterior horn cells or to the white matter ascending and descending longitudinal fibers.	Posterior Horn Cell		Body Part, Organ, or Organ Component	
C126410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126410>	C4035	Thyroid Gland Papillary Carcinoma with Fibromatosis/Fasciitis-Like/Desmoid-Type Stroma|Nodular Fasciitis-Like Stroma Variant Thyroid Gland Papillary Carcinoma|Nodular Fasciitis-like Stroma Variant Thyroid Gland Papillary Cancer|Thyroid Gland Papillary Carcinoma with Fibromatosis/Fasciitis-Like Stroma	A rare morphologic variant of papillary thyroid gland carcinoma characterized by the presence of abundant and cellular stroma resembling nodular fasciitis, fibromatosis, or other proliferative myofibroblastic processes. (WHO)	Nodular Fasciitis-like Stroma Variant Thyroid Gland Papillary Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C126411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126411>	C35996	Prominent Stromal Reaction	A morphologic finding indicating the presence of an exuberant proliferation of fibroblasts and myofibroblasts in the stroma of a tumor sample.			Finding	
C126412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126412>	C20424	VEGFA Gene Product	A protein encoded by the VEGFA gene.	VEGFA Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126413>	C126412	Vascular Endothelial Growth Factor A 165 Isoform|VEGF 164|VEGF 165|VEGF(164)|VEGF-164|VEGF-164 Isoform|VEGF-165|VEGF164|VEGF164(165)|VEGF165|Vascular Endothelial Growth Factor A 164 Isoform	Vascular endothelial growth factor A 165 isoform (191 aa, ~22 kDa) is encoded by the human VEGFA gene. This protein plays a role in the positive regulation of both cell proliferation and angiogenesis.	Vascular Endothelial Growth Factor A 165 Isoform		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126414>	C20130	APOBEC Family Protein|APOBEC Family|APOBEC Protein|Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like|Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like Family|Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like Protein|Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like Protein Family	A family of enzymes involved in cytidine deamination, which converts cytidine into uracil, in DNA or RNA. These enzymes play a role in mRNA editing and retroviral host defenses.	APOBEC Family Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126415>	C16631	HLA-KIR Compound Genotype|HLA/KIR Compound Genotype|Human Leukocyte Antigens - Killer-Cell Immunoglobulin-Like Receptors Compound Genotype|Human Leukocyte Antigens/Killer-Cell Immunoglobulin-Like Receptors Compound Genotype|KIR-HLA Compound Genotype|KIR/HLA Compound Genotype|KIR/HLA Genotype	The combination of polymorphisms in the DNA encoding human leukocyte antigens (HLA) and killer-cell immunoglobulin-like receptors (KIR) found in an individual's genome. Certain combinations may indicate that the subject is more likely to develop certain diseases such as autoimmune disorders, viral infections, and cancer.	HLA-KIR Compound Genotype		Organism Attribute	CTRP Biomarker Terminology|CTRP Terminology
C126416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126416>	C16295	Human Papillomavirus Antibody|Anti-HPV Antibody|Anti-Human Papilloma Virus Antibody|Anti-Human Papillomavirus Antibody|HPV Antibody|Human Papilloma Virus Antibody	Any immunoglobulin that recognizes antigens expressed by human papillomaviruses.	Human Papillomavirus Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C126417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126417>	C119321	Butyrate-Producing Bacteria|BPB|Butyrate-Producing Microbe	Any anaerobic bacteria that metabolizes complex carbohydrates to produce butyrate. These microorganisms may form colonies in the intestines of mammals; their presence may aid the host by catabolizing undigested fiber and starch. Additionally, butyrate is metabolized by colonic epithelial cells and may protect the host against ulcerative colitis and cancer.	Butyrate-Producing Bacteria		Organism	CTRP Biomarker Terminology|CTRP Terminology
C126418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126418>	C16295	Immunizing Neoantigen Peptide Antibody|Anti-Immunizing Neoantigen Peptide Antibody|Anti-Immunizing Peptide Antibody|Anti-Neoantigen Peptide Antibody|Immunizing Peptide Antibody|Neoantigen Peptide Antibody	Any antibody that recognizes tumor-associated peptide antigens that are in neoantigen peptide-based vaccines.	Immunizing Neoantigen Peptide Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C126419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126419>	C201812|C122731|C104083	Effector Memory T-Lymphocyte|Effector Memory T Cell|Effector Memory T Lymphocyte|Effector Memory T-Cell	Long-lived antigen-specific T-lymphocytes, which express CD8 and effector cytokines. Upon subsequent exposure to their target antigen, these cells rapidly become effector cells.	Effector Memory T-Lymphocyte		Cell	CTRP Biomarker Terminology|CTRP Terminology
C12641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12641>	C33969	Substantia Gelatinosa	A collection of gelatinous-appearing grey matter cells in the dorsal horn of the spinal cord that receives direct input from the dorsal nerve roots and plays a role in regulating pain impulses at the spinal cord level.	Substantia Gelatinosa		Body Part, Organ, or Organ Component	
C126420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126420>	C122730|C104082	Central Memory T-Lymphocyte|Central Memory T Cell|Central Memory T Lymphocyte|Central Memory T-Cell|Tcm	Long-lived antigen-specific T-lymphocytes, which express CD45RO, L-selectin and CCR7. Upon subsequent exposure to their target antigen, these cells rapidly proliferate and differentiate into effector cells.	Central Memory T-Lymphocyte		Cell	CTRP Biomarker Terminology|CTRP Terminology
C126421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126421>	C214440	Lysine-specific Demethylase 1 Inhibitor INCB059872|INCB-059872|INCB059872|LSD1 Inhibitor INCB059872	An orally available inhibitor of lysine-specific demethylase 1 (LSD1), with potential antineoplastic activity. Upon administration, INCB059872 binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4, respectively, through amine oxidation. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor-suppressor genes. In addition, LSD1 demethylates mono- or di-methylated H3K9 which increases gene expression of tumor promoting genes; inhibition of LSD1 promotes H3K9 methylation and decreases transcription of these genes. Altogether, this may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. LSD1, an enzyme belonging to the flavin adenine dinucleotide (FAD)-dependent amine oxidase family, is overexpressed in certain tumor cells and plays a key role in the regulation of gene expression and in tumor cell growth and survival.	Lysine-specific Demethylase 1 Inhibitor INCB059872		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126423>	C154267	H1-1 Gene|H1-1|H1-1|H1.1 Linker Histone, Cluster Member Gene|HIST1H1A|HIST1H1A Gene	This gene is involved in both DNA binding and nucleosome formation.	HIST1H1A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126424>	C126423	H1-1 wt Allele|H1 Histone Family, Member 1 Gene|H1 Histone Family, Member A Gene|H1.1|H1.1 Linker Histone, Cluster Member wt Allele|H1A|H1F1|HIST1|HIST1 Cluster, H1A Gene|HIST1H1A|HIST1H1A wt Allele|Histone 1, H1A Gene|Histone Cluster 1, H1a Gene|Histone Gene Cluster 1, H1 Gene|Histone Gene Cluster 1, H1 Histone Family, Member A Gene|Histone Gene Cluster 1, H1A Gene	Human H1-1 wild-type allele is located in the vicinity of 6p21.3 and is approximately 1 kb in length. This allele, which encodes histone H1.1 protein, plays a role in the formation of nucleosomes and higher-order chromatin structures.	HIST1H1A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126425>	C16683	Histone H1.1|H1-1|HIST1H1A|Histone H1a	Histone H1.1 (215 aa, ~22 kDa) is encoded by the human H1-1 gene. This protein is involved in both DNA binding and chromatin compaction into higher order structures.	Histone H1.1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126426>	C16353	Hepatopetal Portal Venous Flow	The normal pattern of blood flow towards the liver through the portal vein.			Organ or Tissue Function	
C126427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126427>	C492	Protectin|Protectins	Fatty acids belonging to a group of specialized pro-resolving mediators (SPM) that are either endogenously-derived from the fatty acid docosahexaenoic acid (DHA) or chemically synthesized, with potential anti-inflammatory and protective activities. Protectins promote the resolution of inflammatory responses in various tissues and may prevent tissue damage.	Protectin		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C126428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126428>	C492	Resolvin|Resolution-Phase Interaction Products|Resolvins	Dihydroxy or trihydroxy polyunsaturated fatty acids (PUFAs) belonging to a group of specialized pro-resolving mediators (SPM) that are either endogenously-derived from polyunsaturated omega-3 fatty acids or chemically synthesized, with potential anti-inflammatory and protective activities. Resolvins may promote the resolution of inflammatory responses by interacting with specific G protein-coupled receptors on inflammatory cells in various tissues and may prevent tissue damage.	Resolvin		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C126429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126429>	C91105	Center for Epidemiologic Studies Depression Scale Revised|CESD-R|Center for Epidemiologic Studies Depression Scale - Revised|Center for Epidemiologic Studies Depression Scale - Revised (CESD-R)	A self-report screening test for depression and depressive disorder measuring symptoms defined by the American Psychiatric Association Diagnostic and Statistical Manual (DSM-V) for a major depressive episode.			Intellectual Product	
C12642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12642>	C13155	Retinal Ganglion Cell|Retinal Ganglion Cells	An output neuron in the retina that receives visual signals from photoreceptors via interneurons, and transmits the information to the thalamus, hypothalamus, and superior colliculus of the brain through the optic nerve.	Retinal Ganglion Cell		Cell	
C126430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126430>	C173981	Poor Appetite Question|Appetite Poor|My appetite was poor|Poor Appetite	A question about whether an individual's appetite is or was poor.			Intellectual Product	Center for Epidemiologic Studies Depression Scale Revised
C126431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126431>	C173160	Could not Shake Off the Blues Question|Could not Shake Off the Blues|I could not shake off the blues	A question about whether an individual could or could not shake off the blues.			Intellectual Product	Center for Epidemiologic Studies Depression Scale Revised
C126432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126432>	C173160	Nothing Made Me Happy Question|Nothing Made Me Happy|Nothing made me happy	A question about whether nothing makes or made an individual happy.			Intellectual Product	Center for Epidemiologic Studies Depression Scale Revised
C126433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126433>	C20673	CITED2 Gene|CITED2|CITED2|Cbp/p300 Interacting Transactivator, With Glu/Asp-Rich Carboxy-Terminal Domain 2 Gene	This gene plays a role in transcription coactivation.	CITED2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126434>	C126433	CITED2 wt Allele|ASD8|Cbp/p300 Interacting Transactivator, With Glu/Asp-Rich Carboxy-Terminal Domain 2 wt Allele|Cbp/p300-Interacting Transactivator, With Glu/Asp Rich Carboxy-Terminal Domain, 2 Gene|Cbp/p300-Interacting Transactivator, With Glu/Asp-Rich C-Terminal Domain, 2 Gene|Cbp/p300-Interacting Transactivator, With Glu/Asp-Rich Carboxy-Terminal Domain, 2 Gene|MRG-1|MRG1|MSG1-Related Gene 1 Gene|Melanocyte-Specific Gene 1-Related Gene 1|P35SRJ|VSD2	Human CITED2 wild-type allele is located in the vicinity of 6q23.3 and is approximately 3 kb in length. This allele, which encodes Cbp/p300-interacting transactivator 2 protein, is involved in transcriptional coactivation. Mutation of the gene is associated with cardiac septal defects.	CITED2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126435>	C26199	Cbp/p300-Interacting Transactivator 2|CITED2|MRG-1|MSG-Related Protein 1|p35SRJ	Cbp/p300-interacting transactivator 2 (270 aa, ~28 kDa) is encoded by the human CITED2 gene. This protein plays a role in the positive regulation of gene expression.	Cbp/p300-Interacting Transactivator 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126436>	C173160	Feel Like a Bad Person Question|Feel Like a Bad Person|I felt like a bad person	A question about whether an individual feels or felt like a bad person.			Intellectual Product	Center for Epidemiologic Studies Depression Scale Revised
C126437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126437>	C91102	Lost Interest in Usual Activities Question|I lost interest in my usual activities|Lost Interest in Usual Activities	A question about whether an individual loses or lost interest in their usual activities.			Intellectual Product	Center for Epidemiologic Studies Depression Scale Revised
C126438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126438>	C173925	Slept Much More than Usual Question|I slept much more than usual|Sleeping Much More than Usual|Slept Much More than Usual	A question about whether an individual sleeps or slept much more than usual.			Intellectual Product	Center for Epidemiologic Studies Depression Scale Revised
C126439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126439>	C173160	Feel Like Moving too Slowly Question|Feel Like I'm Moving too Slowly|Feel Like Moving too Slowly|I felt like I was moving too slowly	A question about whether an individual feels or felt like they are moving too slowly.			Intellectual Product	Center for Epidemiologic Studies Depression Scale Revised
C12643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12643>	C12623	Efferent Neuron|Efferent Nerve|Efferent Neurons	A neuron that sends impulses from the central nervous system to skeletal muscles, glands, and visceral organs.	Efferent Neuron		Cell	
C126440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126440>	C173160	Feel Fidgety Question|Feel Fidgety|I felt fidgety	A question about whether an individual feels or felt fidgety.			Intellectual Product	Center for Epidemiologic Studies Depression Scale Revised
C126441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126441>	C173160	Wish I Were Dead Question|I wished I were dead|Wish I Were Dead|Wished I Were Dead	A question about whether an individual wishes or wished they were dead.			Intellectual Product	Center for Epidemiologic Studies Depression Scale Revised
C126442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126442>	C91102	Want to Hurt Myself Question|I wanted to hurt myself|Want to Hurt Myself|Wanted to Hurt Myself	A question about whether an individual wants or wanted to hurt themself.			Intellectual Product	Center for Epidemiologic Studies Depression Scale Revised
C126443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126443>	C173935	Tired All the Time Question|I was tired all the time|Tired All the Time	A question about whether an individual is or was tired all the time.			Intellectual Product	Center for Epidemiologic Studies Depression Scale Revised
C126444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126444>	C173160	Do Not Like Myself Question|Do Not Like Myself|I did not like myself|I don't like myself	A question about whether an individual does not like themself.			Intellectual Product	Center for Epidemiologic Studies Depression Scale Revised|Impact of Weight on Quality of Life-Lite
C126445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126445>	C91102	Lost a Lot of Weight Without Trying Question|I lost a lot of weight without trying to|Lost a Lot of Weight Without Trying	A question about whether an individual lost a lot of weight without trying to.			Intellectual Product	Center for Epidemiologic Studies Depression Scale Revised
C126446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126446>	C173981|C104294	Have a Lot of Trouble Getting to Sleep Question|Have a Lot of Trouble Getting to Sleep|I had a lot of trouble getting to sleep	A question about whether an individual has or had a lot of trouble getting to sleep.			Intellectual Product	Center for Epidemiologic Studies Depression Scale Revised
C126447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126447>	C173160	Could Not Focus on Important Things Question|Could Not Focus on Important Things|I could not focus on the important things	A question about whether an individual could or could not focus on the important things.			Intellectual Product	Center for Epidemiologic Studies Depression Scale Revised
C126448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126448>	C176242	One or Two Days|1 - 2 days	A response indicating that something happens or happened on one or two days.			Intellectual Product	Center for Epidemiologic Studies Depression Scale Revised
C126449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126449>	C4123|C40099	Serous Tubal Intraepithelial Carcinoma|Fallopian Tube Carcinoma in Situ|STIC|Serous tubal intraepithelial carcinoma|Serous tubal intraepithelial carcinoma (STIC)|Tubal Intraepithelial Carcinoma	A non-invasive serous carcinoma arising from the fallopian tube.			Neoplastic Process	GDC Terminology|GDC Value Terminology
C12644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12644>	C33533|C33143|C12643	Motor Neuron|Efferent Neuron|Motoneuron|Motor Neurons	An efferent neuron that sends impulses from the central nervous system to skeletal muscles.	Motor Neuron		Cell	
C126450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126450>	C176242	Three or Four Days|3 - 4 days	A response indicating that something happens or happened on three or four days.			Intellectual Product	Center for Epidemiologic Studies Depression Scale Revised
C126451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126451>	C176242	Five to Seven Days|5 - 7 days	A response indicating that something happens or happened between five and seven days.			Intellectual Product	Center for Epidemiologic Studies Depression Scale Revised
C126452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126452>	C175311	Nearly Every Day for 2 Weeks|Nearly every day for 2 weeks	A response indicating that something happens or happened nearly every day for two weeks.			Intellectual Product	Center for Epidemiologic Studies Depression Scale Revised
C126453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126453>	C21295	CABIN1 Gene|CABIN1|CABIN1|Calcineurin Binding Protein 1 Gene	This gene may be involved in both chromatin assembly and the inhibition of calcineurin-dependent signaling.	CABIN1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126454>	C126453	CABIN1 wt Allele|CAIN|Calcineurin Binding Protein 1 wt Allele|KB-318B8.7|KIAA0330|PPP3IN	Human CABIN1 wild-type allele is located in the vicinity of 22q11.23 and is approximately 167 kb in length. This allele, which encodes calcineurin-binding protein cabin-1, may play a role in the negative regulation of calcineurin-mediated signaling.	CABIN1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126455>	C17728	Calcineurin-Binding Protein Cabin-1|CAIN|Calcineurin Binding Protein Cabin 1|Calcineurin Inhibitor|Calcineurin-Binding Protein 1	Calcineurin-binding protein cabin-1 (2220 aa, ~246 kDa) is encoded by the human CABIN1 gene. This protein may be involved in both calcineurin binding and chromatin assembly.	Calcineurin-Binding Protein Cabin-1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126456>	C40099|C213446	Fallopian Tube High Grade Serous Adenocarcinoma|Fallopian Tube High-Grade Serous Adenocarcinoma|High Grade Fallopian Tube Serous Adenocarcinoma|High Grade Fallopian Tube Serous Adenocarcinoma|High Grade Fallopian Tube Serous Carcinoma	A rapidly growing serous adenocarcinoma that arises from the fallopian tube. It is characterized by the presence of high-grade cytologic features and frequent mitotic figures.	High Grade Fallopian Tube Serous Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C126457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126457>	C62241	Low Grade Fallopian Tube Serous Adenocarcinoma	A slow-growing serous adenocarcinoma that arises from the fallopian tube. It is characterized by the presence of low grade cytologic features and infrequent mitotic figures.			Neoplastic Process	
C126458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126458>	C25972	PTPN21 Gene|PTPN21|PTPN21|Protein Tyrosine Phosphatase, Non-Receptor Type 21 Gene	This gene plays a role in peptidyl-tyrosine dephosphorylation.	PTPN21 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126459>	C126458	PTPN21 wt Allele|DJ1175B15.2 (Protein Tyrosine Phosphatase, Non-Receptor Type 21) Gene|PTPD1|PTPRL10|Protein Tyrosine Phosphatase, Non-Receptor Type 21 wt Allele|Protein-Tyrosine Phosphatase, Nonreceptor-Type, 21 Gene	Human PTPN21 wild-type allele is located in the vicinity of 14q31.3 and is approximately 89 kb in length. This allele, which encodes tyrosine-protein phosphatase non-receptor type 21 protein, is involved in protein dephosphorylation.	PTPN21 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12645>	C12644	Anterior Horn Cell|Anterior Horn Cells|Anterior Horn Neuron|Anterior Horn Neurons|Ventral Horn Cell|Ventral Horn Cells|Ventral Horn Neuron|Ventral Horn Neurons	A motor neuron that is located in one of the ventral horns of the spinal cord and innervates skeletal muscles of the trunk or head.	Anterior Horn Cell		Cell	
C126460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126460>	C106408	Tyrosine-Protein Phosphatase Non-Receptor Type 21|EC 3.1.3.48|PTPN21|Protein Tyrosine Phosphatase D1|Protein-Tyrosine Phosphatase D1	Tyrosine-protein phosphatase non-receptor type 21 (1174 aa, ~133 kDa) is encoded by the human PTPN21 gene. This protein plays a role in dephosphorylation of phosphotyrosines.	Tyrosine-Protein Phosphatase Non-Receptor Type 21		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126461>	C82995	Tubal Hyperplasia|Tubal Epithelial Hyperplasia	Benign proliferation of the fallopian tube epithelium.			Disease or Syndrome	
C126462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126462>	C26686	Tubo-Ovarian Abscess	An abscess involving the distal fallopian tube and ovary. It is caused by pelvic inflammatory disease or other infections.			Disease or Syndrome	
C126463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126463>	C96363	Fallopian Tube Mucinous Metaplasia	Metaplastic mucinous changes in the fallopian tube epithelium. It may be seen in association with gynecological, appendiceal, or colonic mucinous tumors, or chronic inflammation.			Finding	
C126464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126464>	C7480|C213738	Fallopian Tube Lymphoma|Primary Fallopian Tube Lymphoma	An exceedingly rare lymphoma that arises from the fallopian tube.			Neoplastic Process	
C126465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126465>	C35850|C3482|C170467	Metastatic Head and Neck Carcinoma|Metastatic Head and Neck Cancer	A carcinoma that arises from the head and neck and has spread from the original site of growth to another anatomic site.	Metastatic Head and Neck Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C126466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126466>	C26006	NAPA Gene|NAPA|NAPA|NSF Attachment Protein Alpha Gene	This gene is involved in vesicular transport between the endoplasmic reticulum and the Golgi.	NAPA Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126467>	C126466	NAPA wt Allele|N-Ethylmaleimide-Sensitive Factor Attachment Protein, Alpha Gene|NSF Attachment Protein Alpha wt Allele|SNAP, Alpha Gene|SNAPA|Soluble NSF-Attachment Protein, Alpha Gene	Human NAPA wild-type allele is located in the vicinity of 19q13.33 and is approximately 28 kb in length. This allele, which encodes alpha-soluble NSF attachment protein, plays a role in intracellular vesicle transport.	NAPA wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126468>	C16386	Alpha-Soluble NSF Attachment Protein|Alpha SNAP|Alpha-SNAP|N-Ethylmaleimide-Sensitive Factor Attachment Protein Alpha|NAPA|SNAP-Alpha	Alpha-soluble NSF attachment protein (295 aa, ~33 kDa) is encoded by the human NAPA gene. This protein is involved in the transport of vesicles between the endoplasmic reticulum and Golgi.	Alpha-Soluble NSF Attachment Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126469>	C7074|C3646|C27788|C179931	Borderline Broad Ligament Serous Tumor|Serous Borderline Broad Ligament Tumor/Atypical Proliferative Serous Broad Ligament Tumor	A rare non-invasive tumor that arises from the broad ligament. It is characterized by the presence of serous epithelial cell proliferation and cytological atypia.			Neoplastic Process	
C12646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12646>	C12644	Gamma Motor Neuron|Fusimotor Neuron|Fusimotor Neurons|Gamma Motor Neurons|Gamma-Efferent Motor Neuron|Gamma-Efferent Motor Neurons	A type of motor neuron, found in the ventral horn of the spinal cord, that innervates intrafusal muscle fibers of neuromuscular spindles to help regulate skeletal muscle tone.	Gamma Motor Neuron		Cell	
C126470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126470>	C25873	MARK2 Gene|MAP/Microtubule Affinity-Regulating Kinase 2 Gene|MARK2|MARK2	This gene plays a role in microtubule dynamics.	MARK2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126471>	C126470	MARK2 wt Allele|EMK-1|EMK1|MAP/Microtubule Affinity-Regulating Kinase 2 wt Allele|PAR-1|PAR1. C. elegans, Homolog of, B Gene|Par-1b|Par1b	Human MARK2 wild-type allele is located in the vicinity of 11q13.1 and is approximately 72 kb in length. This allele, which encodes serine/threonine-protein kinase MARK2 protein, is involved in both protein phosphorylation and microtubule dynamics.	MARK2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126472>	C17325	Serine/Threonine-Protein Kinase MARK2|EC 2.7.11.1|EC 2.7.11.26|ELKL Motif Kinase|ELKL Motif Kinase 1|EMK-1|MAP/Microtubule Affinity-Regulating Kinase 2|MARK2|PAR1 Homolog|PAR1 Homolog B|Par-1b|Par1b|Ser/Thr Protein Kinase PAR-1B|Serine/Threonine Protein Kinase EMK	Serine/threonine-protein kinase MARK2 (788 aa, ~88 kDa) is encoded by the human MARK2 gene. This protein plays a role in both microtubule dynamics and serine/threonine phosphorylation.	Serine/Threonine-Protein Kinase MARK2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126473>	C26006	EHD1 Gene|EH Domain Containing 1 Gene|EHD1|EHD1	This gene is involved in endocytosis and recycling of the plasma membrane.	EHD1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126474>	C126473	EHD1 wt Allele|CDABP0131|EH Domain Containing 1 wt Allele|EH Domain-Containing 1 Gene|EH-Domain Containing 1 Gene|FLJ42622|FLJ44618|H-PAST|HPAST1|PAST|PAST1	Human EHD1 wild-type allele is located in the vicinity of 11q13 and is approximately 37 kb in length. This allele, which encodes EH domain-containing protein 1, plays a role in endocytic recycling.	EHD1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126475>	C16386	EH Domain-Containing Protein 1|PAST Homolog 1|Testilin|hPAST1	EH domain-containing protein 1 (534 aa, ~61 kDa) is encoded by the human EHD1 gene. This protein is involved in plasma membrane endocytosis and recycling.	EH Domain-Containing Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126476>	C3783|C179933	Broad Ligament Serous Cystadenoma	A rare serous cystadenoma arising from the broad ligament.			Neoplastic Process	
C126477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126477>	C126478	Broad Ligament Serous Cystadenofibroma	A rare serous cystadenofibroma arising from the broad ligament.			Neoplastic Process	
C126478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126478>	C62241	Broad Ligament Serous Adenofibroma	A rare serous adenofibroma arising from the broad ligament.			Neoplastic Process	
C126479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126479>	C40135|C40101	Broad Ligament Serous Adenocarcinoma|High-Grade Broad Ligament Serous Adenocarcinoma	A rare serous adenocarcinoma that arises from the broad ligament.			Neoplastic Process	
C12647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12647>	C12623	Nitrergic Neuron|Nitrergic Neurons|Nitroxidergic Neurons	A nerve cell that uses nitric oxide as its neurotransmitter.	Nitrergic Neuron		Cell	
C126480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126480>	C62241	Low Grade Broad Ligament Serous Adenocarcinoma|Low-Grade Broad Ligament Serous Adenocarcinoma	A slow-growing serous adenocarcinoma that arises from the broad ligament. It is characterized by the presence of low grade cytologic features and infrequent mitotic figures.			Neoplastic Process	
C126482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126482>	C62695	Meat	The flesh of animals used as food.			Food	
C126483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126483>	C126482	Processed Meat|Processed meat	Meat that has been modified to either extend its shelf life or change its taste.			Food	
C126484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126484>	C38187	NTS Gene|NTS|NTS|Neurotensin Gene	This gene may play a role in both fat digestion and antimicrobial activity.	NTS Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126485>	C15863	The Cancer Human Biobank|caHUB	A derived program of the National Cancer Institute's Biorepositories and Biospecimen Research Branch (NCI BBRB) that carries out specialized biospecimen and data procurements to support biospecimen science activities. The caHUB network consists of Biospecimen Source Sites (BSSs), The Comprehensive Biospecimen Resource (CBR), The Comprehensive Data Resource (CDR), The Pathology Resource Center (PRC), and Molecular Analysis Facilities (MAFs).			Research Activity	
C126486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126486>	C126484	NTS wt Allele|NMN-125|NN|NT|NT/N|NTS1|Neurotensin wt Allele	Human NTS wild-type allele is located in the vicinity of 12q21 and is approximately 9 kb in length. This allele, which encodes neurotensin/neuromedin N protein, may be involved in both antimicrobial activity and fat digestion.	NTS wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126487>	C686	NTS Gene Product	A protein encoded by the NTS gene.	NTS Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126488>	C126487	Neurotensin/Neuromedin N|Neurotensin/Neuromedin|Pro-NT|Pro-NT/N|Pro-NTS|Pro-Neurotensin|Pro-Neurotensin/Neuromedin	Neurotensin/neuromedin N (170 aa, ~20 kDa) is encoded by the human NTS gene. This protein may play a role in both the digestion of fat in the gut and anti-bacterial/fungal activity.	Neurotensin/Neuromedin N		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126489>	C52647	Biospecimen Pre-analytical Variables Program|BPV|Biospecimen Pre-Analytical Variables|Biospecimen Pre-analytical Variables	A program designed to systematically investigate the effects of individual pre-analytical factors on the molecular profiles of biospecimens. The results of this study will be used to develop evidence-based protocols and best practices for optimal collection, processing, and storage of biospecimens.			Research Activity	
C12648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12648>	C32177	Postganglionic Autonomic Fiber|Autonomic Fibers, Postganglionic|Postganglionic Fiber	An axon that projects from a nerve cell body within an autonomic ganglion and innervates an effector cell within a target organ.	Autonomic Fibers, Postganglionic		Body Part, Organ, or Organ Component	
C126490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126490>	C126487	Neurotensin|Gln-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu|NT|NTS|QLYENKPRRPYIL	Neurotensin (13 aa, ~2 kDa) is encoded by the human NTS gene. This protein may be involved in the regulation of fat metabolism in the gut.	Neurotensin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126491>	C126487	Neuromedin N|IPYIL|Ile-Pro-Tyr-Ile-Leu|NN|NmN	Neuromedin N (5 aa, ~1 kDa) is encoded by the human NTS gene. This protein may play a role in antimicrobial activity.	Neuromedin N		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126492>	C38187	PENK Gene|PENK|PENK|Proenkephalin Gene	This gene is involved in neuropeptide signaling.	PENK Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126493>	C4934|C40133	Benign Uterine Ligament Neoplasm	A neoplasm that arises from the broad or other uterine ligaments and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.			Neoplastic Process	
C126494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126494>	C126492	PENK wt Allele|Enkephalin A Gene|PE|PENK-A|Proenkephalin wt Allele	Human PENK wild-type allele is located in the vicinity of 8q12.1 and is approximately 10 kb in length. This allele, which encodes proenkephalin-A protein, plays a role in opioid receptor signaling.	PENK wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126495>	C686	PENK Gene Product	A protein encoded by the PENK gene.	PENK Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126496>	C126495	Proenkephalin-A|Preproenkephalin|Preproenkephalin A|Preproenkephalin-A|Proenkephalin|Proenkephalin A	Proenkephalin-A (267 aa, ~31 kDa) is encoded by the human PENK gene. This protein is involved in opioid receptor signaling.	Proenkephalin-A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126497>	C126495|C114795	Met-Enkephalin|OGF|Opioid Growth Factor|Tyr-Gly-Gly-Phe-Met|YGGPM|[Met(5)]-Enkephalin	Met-enkephalin (5 aa, ~1 kDa) is encoded by the human PENK and POMC genes. This protein plays a role in the activation of delta opioid receptors.	Met-Enkephalin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126498>	C4913|C40133	Malignant Uterine Ligament Neoplasm	A primary or metastatic malignant neoplasm that affects the broad or other uterine ligaments.			Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology
C126499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126499>	C126495	Leu-Enkephalin|Tyr-Gly-Gly-Phe-Leu|YGGPL	Leu-enkephalin (5 aa, ~1 kDa) is encoded by the human PENK gene. This protein is involved in the activation of mu and delta opioid receptors.	Leu-Enkephalin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12649>	C12648	Postganglionic Parasympathetic Fiber|Parasympathetic Fibers, Postganglionic	An axon that projects from a nerve cell body within a parasympathetic ganglion and innervates an effector cell within a target organ. Postganglionic parasympathetic fibers use acetylcholine as transmitters, sometimes with peptide cotransmitters.	Parasympathetic Fibers, Postganglionic		Body Part, Organ, or Organ Component	
C1264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1264>	C67421	Trimethylcolchicinic Acid|Colchicinic Acid, Trimethyl-|Desacetyl Colchicine D-tartrate|Desacetylcholchiceine|N-Deacetylcolchiceine|SKF 284|TMCA|TRIMETHYLCOLCHICINIC ACID|Trimethylcolchicinic Acid Methyl Ether d-tartrate|Trimethylcolchicinic acid	A colchicine analog with potential antineoplastic activity.  Trimethylcolchicinic acid binds to tubulin, inhibiting its polymerization into microtubules and preventing cell division. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126500>	C21295	CD2BP2 Gene|CD2 (Cytoplasmic Tail) Binding Protein 2 Gene|CD2BP2|CD2BP2	This gene plays a role in both spliceosome assembly and T-cell activation.	CD2BP2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126501>	C126500	CD2BP2 wt Allele|CD2 (Cytoplasmic Tail) Binding Protein 2 wt Allele|CD2 Antigen (Cytoplasmic Tail) Binding Protein 2 Gene|CD2 Antigen (Cytoplasmic Tail)-Binding Protein 2 Gene|FWP010|KIAA1178|LIN1|PPP1R59|Protein Phosphatase 1, Regulatory Subunit 59 Gene|Snu40|U5-52K	Human CD2BP2 wild-type allele is located in the vicinity of 16p11.2 and is approximately 5 kb in length. This allele, which encodes CD2 antigen cytoplasmic tail-binding protein 2, is involved in T-cell activation and RNA splicing.	CD2BP2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126502>	C17728	CD2 Antigen Cytoplasmic Tail-Binding Protein 2|CD2 Antigen-Binding Protein 2|CD2 Cytoplasmic Domain-Binding Protein 2|CD2 Tail-Binding Protein 2|CD2BP2|U5 SnRNP 52K Protein|U5-52K	CD2 antigen cytoplasmic tail-binding protein 2 (341 aa, ~38 kDa) is encoded by the human CD2BP2 gene. This protein plays a role in mRNA splicing and T-cell activation.	CD2 Antigen Cytoplasmic Tail-Binding Protein 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126503>	C20744	NUSAP1 Gene|NUSAP1|NUSAP1|Nucleolar and Spindle Associated Protein 1 Gene	This gene is involved in microtubule stabilization and mitosis.	NUSAP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126504>	C126503	NUSAP1 wt Allele|ANKT|BM-037|BM037|FLJ13421|LNP|NUSAP|Nucleolar and Spindle Associated Protein 1 wt Allele|PRO0310|PRO0310p1|Q0310|SAPL	Human NUSAP1 wild-type allele is located in the vicinity of 15q15.1 and is approximately 48 kb in length. This allele, which encodes nucleolar and spindle-associated protein 1, plays a role in cell division.	NUSAP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126505>	C16861	Nucleolar and Spindle-Associated Protein 1|NuSAP|Nucleolar Protein ANKT	Nucleolar and spindle-associated protein 1 (441 aa, ~49 kDa) is encoded by the human NUSAP1 gene. This protein is involved in mitotic spindle stabilization.	Nucleolar and Spindle-Associated Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126506>	C20917	CDCA8 Gene|CDCA8|CDCA8|Cell Division Cycle Associated 8 Gene	This gene plays a role in the regulation of mitosis.	CDCA8 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126507>	C126506	CDCA8 wt Allele|BOR|BOREALIN|Cell Division Cycle Associated 8 wt Allele|DasraB|FLJ12042|MESRGP|PESCRG3	Human CDCA8 wild-type allele is located in the vicinity of 1p34.3 and is approximately 17 kb in length. This allele, which encodes borealin protein, is involved in the modulation of cell division.	CDCA8 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126508>	C17761	Borealin|CDCA8|Cell Division Cycle-Associated Protein 8|Dasra B|Dasra-B|Pluripotent Embryonic Stem Cell-Related Gene 3 Protein|hDasra-B	Borealin (280 aa, ~31 kDa) is encoded by the human CDCA8 gene. This protein plays a role in mitosis.	Borealin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126509>	C20103	SORL1 Gene|SORL1|SORL1|Sortilin-Related Receptor, L(DLR Class) A Repeats Containing Gene	This gene is involved in both endocytosis and protein sorting.			Gene or Genome	
C12650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12650>	C12648	Postganglionic Sympathetic Fiber|Sympathetic Fibers, Postganglionic	An axon that projects from a nerve cell body within a sympathetic ganglion and innervates an effector cell within a target organ. Postganglionic sympathetic fibers use norepinephrine and acetylcholine as transmitters, sometimes with peptide cotransmitters.	Sympathetic Fibers, Postganglionic		Body Part, Organ, or Organ Component	
C126510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126510>	C126509	SORL1 wt Allele|C11orf32|Chromosome 11 Open Reading Frame 32 Gene|LR11|LRP9|SORLA|SorLA-1|Sortilin-Related Receptor, L(DLR Class) A Repeats Containing wt Allele|Sortilin-Related Receptor, L(DLR Class) A Repeats-Containing Gene|gp250	Human SORL1 wild-type allele is located within 11q23.2-q24.2 and is approximately 182 kb in length. This allele, which encodes sortilin-related receptor protein, plays a role in both intracellular protein sorting and endocytosis of lipoproteins and enzymes. Mutation of the gene may be associated with Alzheimer disease.			Gene or Genome	
C126511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126511>	C18106	Sortilin-Related Receptor|LDLR Relative With 11 Ligand-Binding Repeats|LR11|Low-Density Lipoprotein Receptor Relative With 11 Ligand-Binding Repeats|Mosaic Protein LR11|SorLA|SorLA-1|Sorting Protein-Related Receptor Containing LDLR Class A Repeats	Sortilin-related receptor (2214 aa, ~248 kDa) is encoded by the human SORL1 gene. This protein is involved in both endocytosis and protein trafficking.			Amino Acid, Peptide, or Protein|Receptor	
C126512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126512>	C54362	ZFTA Gene|C11orf95|ZFTA|ZFTA|Zinc Finger Translocation Associated Gene	This gene may be involved in the repression of transcription.			Gene or Genome	
C126513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126513>	C126512	ZFTA wt Allele|C11orf95|Chromosome 11 Open Reading Frame 95 Gene|MGC3032|Zinc Finger Translocation Associated wt Allele	Human ZFTA wild-type allele is located in the vicinity of 11q13.1 and is approximately 9 kb in length. This allele, which encodes zinc finger translocation-associated protein, may play a role in transcriptional regulation. A chromosomal aberration, t(11;16)(q13;p13), involving this gene and the MRTFB (MKL2) gene may be associated with chondroid lipomas. A chromosomal aberration involving chromothripsis of the long arm of chromosome 11 causes fusions of this gene and the RELA gene and is associated with more than two-thirds of supratentorial ependymomas.			Gene or Genome	
C126514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126514>	C26199	Zinc Finger Translocation-Associated Protein|Uncharacterized Protein C11orf95|ZFTA	Zinc finger translocation-associated protein (678 aa, ~73 kDa) is encoded by the human ZFTA gene. This protein may be involved in the downregulation of gene transcription.			Amino Acid, Peptide, or Protein	
C126515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126515>	C25994	GUCA2A Gene|GUCA2A|GUCA2A|Guanylate Cyclase Activator 2A Gene	This gene plays a role in the positive regulation of intestinal guanylate cyclase.	GUCA2A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126516>	C126515	GUCA2A wt Allele|GCAP-I|GUCA2|Guanylate Cyclase Activator 2A (Guanylin 2, Intestinal, Heat-Stable) Gene|Guanylate Cyclase Activator 2A (Guanylin) Gene|Guanylate Cyclase Activator 2A wt Allele|Guanylin 2, Intestinal Gene|STARA	Human GUCA2A wild-type allele is located within 1p35-p34 and is approximately 2 kb in length. This allele, which encodes guanylin protein, is involved in the regulation of intestinal guanylate cyclase activity.	GUCA2A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126517>	C1746	Guanylin|GCAP-I|GUCA2A|Guanylate Cyclase Activator 2A|Guanylate Cyclase-Activating Protein 1|Guanylate Cyclase-Activating Protein I|Prepro-Guanylin	Guanylin (115 aa, ~12 kDa) is encoded by the human GUCA2A gene. This protein plays a role in the activation of intestinal guanylate cyclase.	Guanylin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126518>	C18515	GNAS Gene Product	A protein encoded by the GNAS gene.			Amino Acid, Peptide, or Protein	
C126519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126519>	C19273|C126518	Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short|Adenylate Cyclase-Stimulating G Alpha Protein|G(s) Alpha|GNAS	Guanine nucleotide-binding protein G(s) subunit alpha isoforms short (394 aa, ~46 kDa) is encoded by the human GNAS gene. This protein plays a role in the activation of adenylate cyclase activity.	Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12651>	C33143	Purkinje Cell|Cerebellar Purkinje Cell|Purkinje Cells|Purkinje's Cell|Purkinje's Corpuscle|Purkinje's Corpuscles	A large neuron that transmits signals from the cerebellar cortex and play a major role in controlling motor movement.	Purkinje Cell		Cell	
C126520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126520>	C126518	Neuroendocrine Secretory Protein 55|NESP55|Secretogranin VI	Neuroendocrine secretory protein 55 (245 aa, ~28 kDa) is encoded by the human GNAS gene. This protein is involved in the response to parathyroid hormone.	Neuroendocrine Secretory Protein 55		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126521>	C126518	Protein ALEX|Alternative Gene Product Encoded by XL-Exon	Protein ALEX (626 aa, ~68 kDa) is encoded by the human GNAS gene. This protein plays a role in the inhibition of adenylate cyclase-stimulating G alpha proteins.	Protein ALEX		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126522>	C28533|C20917	KIF20A Gene|KIF20A|KIF20A|Kinesin Family Member 20A Gene	This gene is involved in both protein trafficking and cytokinesis.			Gene or Genome	
C126523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126523>	C126522	KIF20A wt Allele|Kinesin Family Member 20A wt Allele|MKLP2|RAB6 Interacting, Kinesin-Like (Rabkinesin6) Gene|RAB6-Interacting Protein, Kinesin-Like Gene|RAB6KIFL	Human KIF20A wild-type allele is located in the vicinity of 5q31 and is approximately 9 kb in length. This allele, which encodes kinesin-like protein KIF20A, plays a role in both cytokinesis and intracellular protein transport.			Gene or Genome	
C126524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126524>	C17761|C16386	Kinesin-Like Protein KIF20A|GG10_2|KIF20A|MKlp2|Mitotic Kinesin-Like Protein 2|Rab6-Interacting Kinesin-Like Protein|Rabkinesin 6|Rabkinesin-6	Kinesin-like protein KIF20A (890 aa, ~100 kDa) is encoded by the human KIF20A gene. This protein is involved in both intracellular protein transport and cell division.			Amino Acid, Peptide, or Protein	
C126525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126525>	C25952	DFFB Gene|DFFB|DFFB|DNA Fragmentation Factor Subunit Beta Gene	This gene is involved in apoptosis.			Gene or Genome	
C126526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126526>	C126525	DFFB wt Allele|CAD|CPAN|DFF-40|DFF2|DFF40|DNA Fragmentation Factor Subunit Beta wt Allele|DNA Fragmentation Factor, 40-kD, Beta Subunit Gene|DNA Fragmentation Factor, 40kDa, Beta Polypeptide (Caspase-Activated DNase) Gene|Deoxyribonuclease III, Caspase-Activated Gene	Human DFFB wild-type allele is located in the vicinity of 1p36.3 and is approximately 28 kb in length. This allele, which encodes DNA fragmentation factor subunit beta protein, plays a role in the regulation of DNA fragmentation and chromosome condensation during apoptosis.			Gene or Genome	
C126527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126527>	C16499	DNA Fragmentation Factor Subunit Beta|CAD|CPAN|Caspase-Activated DNase|Caspase-Activated Deoxyribonuclease|Caspase-Activated Nuclease|DFF-40|DFFB|DNA Fragmentation Factor 40 kDa Subunit|EC 3.-.-.-	DNA fragmentation factor subunit beta (338 aa, ~39 kDa) is encoded by the human DFFB gene. This protein is involved in the modulation of DNA fragmentation and chromosome condensation during apoptosis.			Amino Acid, Peptide, or Protein|Enzyme	
C126528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126528>	C42331	Central African	Denotes a person whose ancestry is in any of the countries of the central part of the African continent: Burundi, the Central African Republic, Chad, the Democratic Republic of the Congo, and Rwanda.			Population Group	
C126529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126529>	C42331	North African	Denotes a person whose ancestry is in any of the countries of the northern part of the African continent: Algeria, Egypt, Libya, Morocco, Sudan, Tunisia, and Western Sahara.			Population Group	
C12652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12652>	C33143	Pyramidal Cell|Pyramidal Cells	A neuron located in the cerebral cortex, hippocampus, and amygdala that is characterized by a pyramidal-shaped cell body and apical and basal dendritic trees. Pyramidal cells are involved in complex cortical functions.	Pyramidal Cell		Cell	
C126530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126530>	C42331	South African	Denotes a person whose ancestry is in the country of South Africa.			Population Group	
C126531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126531>	C17049	Latin American|LATIN AMERICAN	Denotes a person whose ancestry is in any of the countries of the Americas or the Caribbean where Spanish or Portuguese is spoken.			Population Group	CDISC CDASH Terminology|CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Collected Race Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126532>	C17459	South American|SOUTH AMERICAN	Denotes a person whose ancestry is in any of the countries of South America.			Population Group	CDISC CDASH Terminology|CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126533>	C41260	Southeast Asian|SOUTHEAST ASIAN	Denotes a person whose ancestry is in any of the Asian countries south of China, east of India, west of New Guinea and north of Australia.			Population Group	CDISC CDASH Terminology|CDISC SDTM Collected Race Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126534>	C41260	Central Asian|CENTRAL ASIAN	Denotes a person whose ancestry is in any of the Asian countries between the Caspian Sea in the west, China in the east, Afghanistan in the south, and Russia in the north.			Population Group	CDISC CDASH Terminology|CDISC SDTM Collected Race Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C126535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126535>	C17049	Australian	Denotes a person whose ancestry is in the country or continent of Australia.			Population Group	
C126536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126536>	C17049	New Zealander	Denotes a person whose ancestry is in the country of New Zealand.			Population Group	
C126537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126537>	C43851	Icelander|Icelandic	Denotes a person whose ancestry is in the country of Iceland.			Population Group	
C126538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126538>	C43851	Scandinavian	Denotes a person whose ancestry is in the countries of Scandinavia: Denmark, Norway and Sweden. Finland and Iceland are generally included as part of the Scandinavian region.			Population Group	
C126540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126540>	C25870	DLST Gene|DLST|DLST|Dihydrolipoamide S-Succinyltransferase (E2 Component of 2-Oxo-Glutarate Complex) Gene	This gene plays a role in both the citric acid cycle and lysine degradation.			Gene or Genome	
C126541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126541>	C126540	DLST wt Allele|Alpha-Ketoglutarate Dehydrogenase Complex, E2 Component of Gene|DLTS|Dihydrolipoamide S-Succinyltransferase (E2 Component of 2-Oxo-Glutarate Complex) wt Allele	Human DLST wild-type allele is located in the vicinity of 14q24.3 and is approximately 22 kb in length. This allele, which encodes dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial protein, is involved in both lysine degradation and the tricarboxylic acid cycle.			Gene or Genome	
C126542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126542>	C16259	Dihydrolipoyllysine-Residue Succinyltransferase Component of 2-Oxoglutarate Dehydrogenase Complex, Mitochondrial|2-Oxoglutarate Dehydrogenase Complex Component E2|Dihydrolipoamide S-Succinyltransferase|Dihydrolipoamide Succinyltransferase Component of 2-Oxoglutarate Dehydrogenase Complex|E2K|EC 2.3.1.61|OGDC-E2	Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial (453 aa, ~49 kDa) is encoded by the human DLST gene. This protein plays a role in both the Krebs cycle and lysine catabolism.			Amino Acid, Peptide, or Protein|Enzyme	
C126543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126543>	C25993|C20103	GABRA3 Gene|GABRA3|GABRA3|Gamma-Aminobutyric Acid Type A Receptor Alpha3 Subunit Gene	This gene is involved in neurotransmission and ligand-gated ion transport.			Gene or Genome	
C126544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126544>	C126543	GABRA3 wt Allele|GABA(A) Receptor, Alpha 3 Gene|Gaba-A Receptor, Alpha-3 Polypeptide Gene|Gamma-Aminobutyric Acid (GABA) A Receptor, Alpha 3 Gene|Gamma-Aminobutyric Acid Receptor, Alpha-3 Gene|Gamma-Aminobutyric Acid Type A Receptor Alpha3 Subunit wt Allele	Human GABRA3 wild-type allele is located in the vicinity of Xq28 and is approximately 285 kb in length. This allele, which encodes gamma-aminobutyric acid receptor subunit alpha-3 protein, plays a role in both the inhibition of neurotransmission and chloride transport.			Gene or Genome	
C126545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126545>	C28505|C18106	Gamma-Aminobutyric Acid Receptor Subunit Alpha-3|GABA(A) Receptor Subunit Alpha-3|GABA(A) Receptor, Alpha 3|GABRA3	Gamma-aminobutyric acid receptor subunit alpha-3 (492 aa, ~55 kDa) is encoded by the human GABRA3 gene. This protein is involved in both ligand-gated chloride transport and the inhibition of neurotransmission.			Amino Acid, Peptide, or Protein|Receptor	
C126546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126546>	C21295	GP1BA Gene|GP1BA|GP1BA|Glycoprotein Ib Platelet Alpha Subunit Gene	This gene plays a role in platelet aggregation.	GP1BA Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126547>	C126546	GP1BA wt Allele|BDPLT1|BDPLT3|BSS|CD42B|CD42b-alpha|DBPLT3|GP Ib, Alpha Subunit Gene|GP1B|GPIbA|GPIbalpha|Glycoprotein Ib (Platelet), Alpha Polypeptide Gene|Glycoprotein Ib Platelet Alpha Subunit wt Allele|Glycoprotein Ib, Platelet, Alpha Polypeptide Gene|Platelet Glycoprotein Ib, Alpha Polypeptide Gene|VWDP	Human GP1BA wild-type allele is located in the vicinity of 17p13.2 and is approximately 3 kb in length. This allele, which encodes platelet glycoprotein Ib alpha chain protein, is involved in the regulation of blood coagulation. Mutation of the gene is associated with Bernard-Soulier syndrome type A1 and platelet-type von Willebrand disease and with increased susceptibility to nonarteritic anterior ischemic optic neuropathy.	GP1BA wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126548>	C17728	Platelet Membrane Glycoprotein 1b Alpha Chain|Antigen CD42b-Alpha|CD42b Antigen|CD42b-Alpha|GP-Ib Alpha|GPIb-Alpha|GPIbA|Glycoprotein Ibalpha|Platelet Membrane Glycoprotein 1b-Alpha Subunit	Platelet glycoprotein Ib alpha chain (652 aa, ~72 kDa) is encoded by the human GP1BA gene. This protein plays a role in von Willebrand factor binding.	Platelet Membrane Glycoprotein 1b Alpha Chain		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126549>	C21295	GP1BB Gene|GP1BB|GP1BB|Glycoprotein Ib Platelet Beta Subunit Gene	This gene is involved in the regulation of blood coagulation.			Gene or Genome	
C12654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12654>	C33923	Oxyphil Cell|Askenazy Cells|Oncocyte|Oncocytes|Oxyphil Cells|Oxyphilic Cell	A glandular cell with acidophilic cytoplasm that contains tightly packed mitochondria. Oxyphil cells are found in the thyroid gland (Hurthle cells) and parathyroid gland.	Oxyphil Cell		Cell	
C126550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126550>	C126549	GP1BB wt Allele|BDPLT1|CD42C|GP Ib, Beta Subunit Gene|GPIBB|GPIbbeta|Glycoprotein Ib (Platelet), Beta Polypeptide Gene|Glycoprotein Ib Platelet Beta Subunit wt Allele|Glycoprotein Ib, Platelet, Beta Polypeptide Gene|Nuclear Localization Signal Deleted In Velocardiofacial Syndrome Gene|Platelet Glycoprotein Ib, Beta Polypeptide Gene	Human GP1BB wild-type allele is located in the vicinity of 22q11.21 and is approximately 2 kb in length. This allele, which encodes platelet glycoprotein Ib beta chain protein, plays a role in platelet aggregation. Mutation of the gene is associated with Bernard-Soulier syndrome type B.			Gene or Genome	
C126551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126551>	C17728	Platelet Membrane Glycoprotein 1b Beta Chain|Antigen CD42b-Beta|CD42c Antigen|GP-Ib Beta|GPIb-Beta|GPIbB|Glycoprotein Ibbeta	Platelet glycoprotein Ib beta chain (206 aa, ~22 kDa) is encoded by the human GP1BB gene. This protein is involved in the modulation of platelet aggregation.			Amino Acid, Peptide, or Protein	
C126552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126552>	C21295	GP9 Gene|GP9|GP9|Glycoprotein IX Platelet Gene	This gene plays a role in von Willebrand factor binding.			Gene or Genome	
C126553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126553>	C126552	GP9 wt Allele|CD42a|GPIX|Glycoprotein IX (Platelet) Gene|Glycoprotein IX Platelet wt Allele|Glycoprotein IX, Platelet Gene	Human GP9 wild-type allele is located in the vicinity of 3q21.3 and is approximately 7 kb in length. This allele, which encodes platelet glycoprotein IX protein, is involved in the regulation of platelet aggregation. Mutation of the gene is associated with Bernard-Soulier syndrome type C.			Gene or Genome	
C126554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126554>	C17728	Platelet Glycoprotein IX|CD42a|CD42a Antigen|GP IX|GP-IX|GPIX|Glycoprotein 9|Platelet Glycoprotein 9	Platelet glycoprotein IX (177 aa, ~19 kDa) is encoded by the human GP9 gene. This protein plays a role in blood coagulation.			Amino Acid, Peptide, or Protein	
C126555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126555>	C21295	GP5 Gene|GP5|GP5|Glycoprotein V Platelet Gene	This gene is involved in blood coagulation.			Gene or Genome	
C126556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126556>	C126555	GP5 wt Allele|CD42d|GPV|Glycoprotein V (Platelet) Gene|Glycoprotein V Platelet wt Allele|Glycoprotein V, Platelet Gene	Human GP5 wild-type allele is located in the vicinity of 3q29 and is approximately 4 kb in length. This allele, which encodes platelet glycoprotein V protein, plays a role in von Willebrand factor-dependent platelet aggregation.			Gene or Genome	
C126557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126557>	C17728	Platelet Glycoprotein V|CD42d|CD42d Antigen|GP V|GP-V|GPV|Glycoprotein 5|Platelet Glycoprotein 5	Platelet glycoprotein V (560 aa, ~61 kDa) is encoded by the human GP5 gene. This protein is involved in von Willebrand factor binding.			Amino Acid, Peptide, or Protein	
C126558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126558>	C53543	Combined Lipase Deficiency	A rare disorder caused by mutation in the LMF1 gene resulting in combined lipase deficiency with concomitant hypertriglyceridemia and associated disorders.			Disease or Syndrome	Cellosaurus Disease Terminology
C126559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126559>	C53543|C28193|C27555	Hard Skin Syndrome Parana Type|Parana Hard-Skin Syndrome	A rare disorder characterized by rigid, thick skin that covers the entire body and affects movements. The movement of the chest and abdomen is severely restricted. Affected individuals develop respiratory insufficiency which may lead to death.			Disease or Syndrome	Cellosaurus Disease Terminology
C12655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12655>	C48431	APUD Cell|APUD Cells	An endocrine cell that has the capabilities of amine precursor uptake and decarboxylation, and low molecular weight polypeptide hormone secretion.	APUD Cell		Cell	
C126560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126560>	C53543	Leri-Weill Dyschondrosteosis|Dyschondrosteosis|Leri-Weill Syndrome	A bone growth disorder inherited in a pseudoautosomal dominant pattern caused by mutations in the SHOX gene. It is characterized by short long bones in the arms and legs, short stature, and abnormalities of the wrist and forearm bones which may cause pain and limit wrist movement.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C126561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126561>	C61269	Niemann-Pick Disease, Type A	An autosomal recessive inherited lysosomal storage disease caused by mutations in the SMPD1 gene. It manifests with hepatosplenomegaly, failure to thrive, psychomotor regression, and interstitial lung disease.			Disease or Syndrome	Cellosaurus Disease Terminology
C126562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126562>	C82341|C176696	Spinocerebellar Ataxia Type 7	An autosomal dominant inherited neurodegenerative disorder caused by mutations in the ATXN7 gene. It is characterized by progressive cerebellar ataxia, including dysarthria and dysphagia, cone-rod and retinal dystrophy, and progressive central visual loss resulting in blindness.			Disease or Syndrome	Cellosaurus Disease Terminology
C126563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126563>	C54362	ZNF224 Gene|ZNF224|ZNF224|Zinc Finger Protein 224 Gene	This gene plays a role in the negative regulation of gene transcription.			Gene or Genome	
C126564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126564>	C126563	ZNF224 wt Allele|BMZF-2|BMZF2|KOX22|ZNF255|ZNF27|Zinc Finger 2, Bone Marrow Gene|Zinc Finger Protein 224 wt Allele	Human ZNF224 wild-type allele is located in the vicinity of 19q13.2 and is approximately 16 kb in length. This allele, which encodes zinc finger protein 224, is involved in transcriptional repression.			Gene or Genome	
C126565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126565>	C26199	Zinc Finger Protein 224|Bone Marrow Zinc Finger 2|Bone Marrow Zinc Finger Protein 2|ZNF224|Zinc Finger Protein 233|Zinc Finger Protein 255|Zinc Finger Protein 27|Zinc Finger Protein KOX22|Zinc Finger Protein ZNF255	Zinc finger protein 224 (707 aa, ~82 kDa) is encoded by the human ZNF224 gene. This protein plays a role in the regulation of gene transcription.			Amino Acid, Peptide, or Protein	
C126566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126566>	C85865|C28193|C176696	Fragile X Tremor/Ataxia Syndrome|FXTAS	An X-linked dominant inherited syndrome caused by mutations in the FMR1 gene. It is a late onset disorder, usually occurring after age 50. It affects males more frequently than females. It is characterized by abnormalities in the cerebellum and white matter. It manifests with intention tremor, ataxia, and cognitive disabilities. The symptoms worsen with age.			Disease or Syndrome	Cellosaurus Disease Terminology
C126567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126567>	C78274	Vasopressor|Anti-hypotensive Agent|Antihypotensive Agent|IV vasopressors	Any substance used in the treatment of hypotension. A vasopressor agent increases reduced blood pressure.			Chemical Viewed Functionally	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|Appendix 8: Pharmacological Therapy Terminology|Therapies for Supportive Care During COVID-19 Infection Terminology
C126568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126568>	C26147	GCNT3 Gene|GCNT3|GCNT3|Glucosaminyl (N-Acetyl) Transferase 3, Mucin Type Gene	This gene is involved in the glycosylation of mucins.			Gene or Genome	
C126569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126569>	C126568	GCNT3 wt Allele|C2/4GnT|C24GNT|C2GNT2|C2GNTM|GNTM|Glucosaminyl (N-Acetyl) Transferase 3, Mucin Type wt Allele|Glucosaminyl (N-Acetyl) Transferase 3, Mucin-Type Gene	Human GCNT3 wild-type allele is located in the vicinity of 15q21.3 and is approximately 45 kb in length. This allele, which encodes beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 3 protein, plays a role in mucin glycosylation.			Gene or Genome	
C12656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12656>	C12555	Pericyte|Adventitial Cell|Pericapillary Cell|Pericytes|Perivascular Cell|Rouget Cell|Rouget Cells	A multipotent perivascular cell that is embedded in the basement membrane of capillaries and contributes to tissue repair in response to injury.	Pericyte		Cell	CTRP Biomarker Terminology|CTRP Terminology
C126570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126570>	C17434	Beta-1,3-Galactosyl-O-Glycosyl-Glycoprotein Beta-1,6-N-Acetylglucosaminyltransferase 3|Beta-1,6-N-Acetylglucosaminyltransferase-3|Beta1,6-N-Acetylglucosaminyltransferase-M|Beta1,6GlcNAc-Transferase|C2/4GnT|C2GnT-M|C2GnT-Mucin Type|Core 2/Core 4 Beta-1,6-N-Acetylglucosaminyltransferase|EC 2.4.1.102|EC 2.4.1.150|GCNT3|Mucus-Type Core 2 Beta-1,6-N-Acetylglucosaminyltransferase|hC2GnT-M	Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 3 (438 aa, ~51 kDa) is encoded by the human GCNT3 gene. This protein is involved in O-linked glycosylation of mucin proteins.			Amino Acid, Peptide, or Protein|Enzyme	
C126571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126571>	C25873	NUAK1 Gene|NUAK Family Kinase 1 Gene|NUAK1|NUAK1	This gene plays a role in DNA damage response, apoptosis inhibition, cell adhesion, cellular senescence, and cell proliferation.	NUAK1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126572>	C126571	NUAK1 wt Allele|ARK5|KIAA0537|NUAK Family Kinase 1 wt Allele|NUAK Family, SNF1-Like Kinase, 1 Gene|OMPHK1	Human NUAK1 wild-type allele is located in the vicinity of 12q23.3 and is approximately 77 kb in length. This allele, which encodes NUAK family SNF1-like kinase 1 protein, is involved in serine/threonine phosphorylation.	NUAK1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126573>	C17325	NUAK Family SNF1-Like Kinase 1|AMP-Activated Protein Kinase Family Member 5|AMPK-Related Protein Kinase 5|ARK5|EC 2.7.11.1|Omphalocele Kinase 1	NUAK family SNF1-like kinase 1 (661 aa, ~74 kDa) is encoded by the human NUAK1 gene. This protein plays a role in protein phosphorylation, which regulates DNA damage response, apoptosis, cell adhesion, cellular senescence, and cell proliferation.	NUAK Family SNF1-Like Kinase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126574>	C54362	NELFB Gene|NELFB|NELFB|Negative Elongation Factor Complex Member B Gene	This gene is involved in pausing transcriptional elongation.			Gene or Genome	
C126575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126575>	C126574	NELFB wt Allele|COBRA1|KIAA1182|NELF-B|Negative Elongation Factor Complex Member B wt Allele	Human NELFB wild-type allele is located in the vicinity of 9q34 and is approximately 18 kb in length. This allele, which encodes negative elongation factor B protein, plays a role in the modulation of transcriptional elongation.			Gene or Genome	
C126576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126576>	C26199	Negative Elongation Factor B|Cofactor of BRCA1|NELF-B|NELFB|Negative Elongation Factor Polypeptide B|Negative Elongation Factor Protein B	Negative elongation factor B (580 aa, ~66 kDa) is encoded by the human NELFB gene. This protein is involved in the negative regulation of transcript elongation.			Amino Acid, Peptide, or Protein	
C126577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126577>	C20348	BOK Gene|BCL2-Related Ovarian Killer Gene|BOK|BOK	This gene plays a role in the activation of apoptosis.			Gene or Genome	
C126578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126578>	C126577	BOK wt Allele|BCL2-Like 9 Gene|BCL2-Related Ovarian Killer wt Allele|BCL2L9|BOKL|MGC4631	Human BOK wild-type allele is located in the vicinity of 2q37.3 and is approximately 16 kb in length. This allele, which encodes Bcl-2-related ovarian killer protein, is involved in the induction of apoptosis.			Gene or Genome	
C126579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126579>	C19928	Bcl-2-Related Ovarian Killer Protein|Bcl-2-Like Protein 9|Bcl2-L-9|hBOK	Bcl-2-related ovarian killer protein (212 aa, ~23 kDa) is encoded by the human BOK gene. This protein plays a role in the positive regulation of apoptosis.			Amino Acid, Peptide, or Protein	
C12657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12657>	C12621	Phagocytic Cell|Phagocyte|Phagocytes|phagocyte		Phagocyte		Cell	
C126580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126580>	C20917	GMNC Gene|GMNC|GMNC|Geminin Coiled-Coil Domain Containing Gene	This gene is involved in the modulation of DNA replication.			Gene or Genome	
C126581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126581>	C126580	GMNC wt Allele|GEMC1|Geminin Coiled-Coil Domain Containing wt Allele	Human GMNC wild-type allele is located in the vicinity of 3q28 and is approximately 49 kb in length. This allele, which encodes geminin coiled-coil domain-containing protein 1, plays a role in the positive regulation of DNA replication.			Gene or Genome	
C126582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126582>	C17761	Geminin Coiled-Coil Domain-Containing Protein 1|GMNC|Geminin Coiled-Coil Domain-Containing Protein	Geminin coiled-coil domain-containing protein 1 (334 aa, ~38 kDa) is encoded by the human GMNC gene. This protein is involved in the promotion of DNA replication.			Amino Acid, Peptide, or Protein	
C126583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126583>	C25804	NIT1 Gene|NIT1|NIT1|Nitrilase 1 Gene	This gene plays a role in apoptosis and the catabolism of nitrogen compounds.			Gene or Genome	
C126584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126584>	C126583	NIT1 wt Allele|Nitrilase 1 wt Allele	Human NIT1 wild-type allele is located within 1q21-q22 and is approximately 7 kb in length. This allele, which encodes deaminated glutathione amidase protein, is involved in both the catabolism of nitrogen compounds and the regulation of apoptosis.			Gene or Genome	
C126585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126585>	C16701	Deaminated Glutathione Amidase|EC 3.5.1.128|NIT1|Nitrilase Homolog 1|dGSH amidase	Deaminated glutathione amidase (327 aa, ~38 kDa) is encoded by the human NIT1 gene. This protein plays a role in both nitrogen compound metabolism and the positive regulation of apoptosis.			Amino Acid, Peptide, or Protein|Enzyme	
C126586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126586>	C20189	Eligible|Eligibility|Eligibility	Satisfying the appropriate conditions for inclusion.			Conceptual Entity	
C126587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126587>	C62439	Forty Three|43|Forty-Three|Forty-three	A natural number greater than forty-two and less than forty-four and the quantity that it denotes.			Quantitative Concept	
C126588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126588>	C20103	ROBO1 Gene|ROBO1|ROBO1|Roundabout Guidance Receptor 1 Gene	This gene is involved in neuroblast migration and axon guidance.			Gene or Genome	
C126589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126589>	C126588	ROBO1 wt Allele|CPHD8|DUTT1|Deleted in U Twenty Twenty Gene|FLJ21882|NORS|NYS8|Roundabout (Axon Guidance Receptor, Drosophila) Homolog 1 Gene|Roundabout Guidance Receptor 1 wt Allele|Roundabout, Axon Guidance Receptor, Homolog 1 (Drosophila) Gene|Roundabout, Axon Guidance Receptor, Homolog 1 Gene|Roundabout, Drosophila, Homolog of, 1 Gene|SAX3|SAX3, C. elegans, Homolog of, 1 Gene	Human ROBO1 wild-type allele is located in the vicinity of 3p12 and is approximately 1170 kb in length. This allele, which encodes roundabout homolog 1 protein, plays a role in both axon guidance and neuroblast migration.			Gene or Genome	
C126590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126590>	C18106	Roundabout Homolog 1|Deleted in U Twenty Twenty|H-Robo-1|ROBO1	Roundabout homolog 1 (1651 aa, ~181 kDa) is encoded by the human ROBO1 gene. This protein is involved in neuronal development.			Amino Acid, Peptide, or Protein|Receptor	
C126591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126591>	C20194	NLRX1 Gene|NLR Family Member X1 Gene|NLRX1|NLRX1	This gene plays a role in the response to virus.			Gene or Genome	
C126592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126592>	C126591	NLRX1 wt Allele|CLR11.3|DLNB26|NLR Family Member X1 wt Allele|NLR Family, X1 Gene|NOD-Like Receptor X1 Gene|NOD26|NOD5|NOD9|Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat Containing X1 Gene	Human NLRX1 wild-type allele is located in the vicinity of 11q23.3 and is approximately 17 kb in length. This allele, which encodes NLR family member X1 protein, is involved in antiviral signaling.			Gene or Genome	
C126593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126593>	C18466	NLR Family Member X1|CLR11.3|Caterpiller Protein 11.3|Nucleotide-Binding Oligomerization Domain Protein 26|Nucleotide-Binding Oligomerization Domain Protein 5|Nucleotide-Binding Oligomerization Domain Protein 9	NLR family member X1 (975 aa, ~108 kDa) is encoded by the human NLRX1 gene. This protein plays a role in the modulation of antiviral signaling pathways.			Amino Acid, Peptide, or Protein	
C126594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126594>	C4035	Follicular Variant Thyroid Gland Papillary Carcinoma|FVPTC|Papillary Thyroid Carcinoma, Follicular Variant|Papillary carcinoma, follicular variant	An encapsulated or nonencapsulated variant of papillary carcinoma of the thyroid gland characterized by the predominance of follicular structures. The malignant follicular cells display the nuclear features that characterize the papillary adenocarcinomas of the thyroid gland.			Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Morphology PT Terminology|Mapped ICDO3.1 Morphology Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C126595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126595>	C20917	PSMC3IP Gene|PSMC3 Interacting Protein Gene|PSMC3IP|PSMC3IP	This gene is involved in meiotic recombination and nuclear receptor-dependent gene regulation.			Gene or Genome	
C126596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126596>	C126595	PSMC3IP wt Allele|26S Proteasome Regulatory Subunit, ATPase 3, Interacting Protein Gene|GT198|HOP2|HOP2, S. cerevisiae, Homolog of Gene|HUMGT198A|ODG3|PSMC3 Interacting Protein wt Allele|TBPIP	Human PSMC3IP wild-type allele is located in the vicinity of 17q21.2 and is approximately 6 kb in length. This allele, which encodes homologous-pairing protein 2 homolog protein, plays a role in both meiosis and transcriptional activation.			Gene or Genome	
C126597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126597>	C17761	Homologous-Pairing Protein 2 Homolog|DBD-Interacting|Nuclear Receptor Coactivator GT198|PSMC3-Interacting Protein|Proteasome 26S ATPase Subunit 3-Interacting Protein|TBP-1 Interacting Protein|TBP-1-Interacting Protein|TBP1-Interacting Protein|Tat-Binding Protein 1-Interacting Protein	Homologous-pairing protein 2 homolog (217 aa, ~25 kDa) is encoded by the human PSMC3IP gene. This protein is involved in the pairing of homologous chromosomes during meiosis and coactivation of hormone-dependent transcription.			Amino Acid, Peptide, or Protein	
C126598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126598>	C36035|C187273	Thyroid Gland Noninvasive Follicular Neoplasm with Papillary-Like Nuclear Features|Follicular Thyroid Tumor|NIEFVPTC|NIFTP|Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)|Noninvasive Encapsulated Follicular Variant Papillary Thyroid Gland Carcinoma|Noninvasive Encapsulated Follicular Variant Thyroid Gland Papillary Carcinoma|Noninvasive Follicular Thyroid Gland Neoplasm with Papillary-Like Nuclear Features|Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features|Thyroid Gland Noninvasive Follicular Tumor with Papillary-Like Nuclear Features	A non-invasive neoplasm of thyroid follicular cells with a follicular growth pattern and nuclear features of papillary thyroid carcinoma that has an extremely low malignant potential. These tumors were formerly classified as non-invasive encapsulated follicular variant of papillary thyroid carcinoma or well-differentiated tumor of uncertain malignant potential. (WHO)			Neoplastic Process	GDC Terminology|GDC Value Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C126599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126599>	C129433	CT45A2 Gene|CT45A2|CT45A2|Cancer/Testis Antigen Family 45, Member A2 Gene	This gene may be involved in testis development and tumorigenesis.			Gene or Genome	
C12659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12659>	C70699	Protoplast|Protoplasts	A bacterial cell deprived of its cell wall, for example by growth in an isotonic medium in the presence of antibiotics that block synthesis of the wall peptidoglycan. Alternatively, a plant cell similarly deprived by enzymic treatment.	Protoplasts		Cell	
C1265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1265>	C2153	Trimetrexate Glucuronate|2,4-Diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline mono-D-glucuronate|Neutrexin|TMTX|TRIMETREXATE GLUCURONATE|TRIMETREXATE GLUCURONATE|trimetrexate glucuronate	A lipid soluble methotrexate derivative with potential antineoplastic activity.  Trimetrexate glucuronate inhibits the enzyme dihydrofolate reductase, thereby preventing the synthesis of purine nucleotides and thymidylate, with subsequent inhibition of DNA and RNA synthesis.  Trimetrexate glucuronate also exhibits antiviral activity. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126600>	C126599	CT45A2 wt Allele|CT45-2|CT45.2|Cancer/Testis Antigen Family 45, Member 2 Gene|Cancer/Testis Antigen Family 45, Member A2 wt Allele	Human CT45A2 wild-type allele is located in the vicinity of Xq26.3 and is approximately 18 kb in length. This allele, which encodes cancer/testis antigen family 45 member A2 protein, may play a role in tumorigenesis.			Gene or Genome	
C126601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126601>	C54672	Cancer/Testis Antigen Family 45 Member A2|Cancer/Testis Antigen 45-2|Cancer/Testis Antigen 45A2|Cancer/Testis Antigen CT45-2	Cancer/testis antigen family 45 member A2 (189 aa, ~21 kDa) is encoded by the human CT45A2 gene. This protein may be involved in tumorigenesis and testis development.			Amino Acid, Peptide, or Protein	
C126602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126602>	C25997	SORBS2 Gene|SORBS2|SORBS2|Sorbin and SH3 Domain Containing 2 Gene	This gene plays a role in the formation of signaling protein complexes.			Gene or Genome	
C126603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126603>	C126602	SORBS2 wt Allele|ARGBP2|KIAA0777|PRO0618|Sorbin and SH3 Domain Containing 2 wt Allele	Human SORBS2 wild-type allele is located in the vicinity of 4q35.1 and is approximately 371 kb in length. This allele, which encodes sorbin and SH3 domain-containing protein 2, is involved in the positive regulation of signaling.			Gene or Genome	
C126604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126604>	C26231	Sorbin and SH3 Domain-Containing Protein 2|Arg Binding Protein 2|Arg-Binding Protein 2|Arg/Abl Interacting Protein 2|Arg/Abl-Interacting Protein 2|ArgBP2|Sorbin|Sorbin and SH3 Domains-Containing Protein 2	Sorbin and SH3 domain-containing protein 2 (1100 aa, ~124 kDa) is encoded by the human SORBS2 gene. This protein plays a role in linking signaling proteins to the cytoskeleton.			Amino Acid, Peptide, or Protein	
C126605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126605>	C29938	CIP2A Gene|CIP2A|CIP2A|Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A Gene|KIAA1524	This gene is involved in phosphatase inhibition and anchorage-independent cell growth.			Gene or Genome	
C126606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126606>	C126605	CIP2A wt Allele|Autoantigen, 90-kD Gene|Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A wt Allele|KIAA1524|p90	Human CIP2A wild-type allele is located in the vicinity of 3q13.13 and is approximately 44 kb in length. This allele, which encodes protein CIP2A, plays a role in both tumorigenesis and the inhibition of protein phosphatase 2A.			Gene or Genome	
C126607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126607>	C18072	Protein CIP2A|Cancerous Inhibitor of PP2A|Cancerous Inhibitor of Protein Phosphatase 2A|p90 Autoantigen	Protein CIP2A (905 aa, ~102 kDa) is encoded by the human CIP2A gene. This protein is involved in the positive regulation of cell growth.			Amino Acid, Peptide, or Protein	
C126608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126608>	C20917	PDS5A Gene|PDS5 Cohesin Associated Factor A Gene|PDS5A|PDS5A	This gene plays a role in the regulation of both mitosis and cell proliferation.			Gene or Genome	
C126609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126609>	C126608	PDS5A wt Allele|KIAA0648|PDS5 Cohesin Associated Factor A wt Allele|PDS5, Regulator of Cohesion Maintenance, Homolog A (S. cerevisiae) Gene|PDS5, Regulator of Cohesion Maintenance, Homolog A Gene|PDS5, Regulator of Cohesion Maintenance, S. cerevisiae, Homolog of, A Gene|PIG54|SCC-112|SCC112	Human PDS5A wild-type allele is located in the vicinity of 4p14 and is approximately 155 kb in length. This allele, which encodes sister chromatid cohesion protein PDS5 homolog A protein, is involved in cell division.			Gene or Genome	
C12660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12660>	C37008	Reed-Sternberg Cell|R-S Cell|Reed-Sternberg cell				Cell	
C126610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126610>	C17761	Sister Chromatid Cohesion Protein PDS5 Homolog A|Cell Proliferation-Inducing Gene 54 Protein|PDS5A|SCC-112|Sister Chromatid Cohesion Protein 112	Sister chromatid cohesion protein PDS5 homolog A (1337 aa, ~151 kDa) is encoded by the human PDS5A gene. This protein plays a role in sister chromatid cohesion in mitosis.			Amino Acid, Peptide, or Protein	
C126611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126611>	C20745	CEP170B Gene|CEP170B|CEP170B|CEP170B|Centrosomal Protein 170B Gene	This gene may be involved in microtubule organization.			Gene or Genome	GDC Terminology|GDC Value Terminology
C126612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126612>	C126611	CEP170B wt Allele|CEP170R|Centrosomal Protein 170B wt Allele|FAM68C|KIAA0284	Human CEP170B wild-type allele is located in the vicinity of 14q32.33 and is approximately 31 kb in length. This allele, which encodes centrosomal protein of 170 kDa protein B, may play a role in microtubule organization.			Gene or Genome	
C126613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126613>	C16492	Centrosomal Protein of 170 kDa Protein B|Centrosomal Protein 170B|Cep170-Related|Cep170B	Centrosomal protein of 170 kDa protein B (1589 aa, ~172 kDa) is encoded by the human CEP170B gene. This protein may be involved in microtubule dynamics.			Amino Acid, Peptide, or Protein	
C126614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126614>	C20194	NRIP3 Gene|NRIP3|NRIP3|Nuclear Receptor Interacting Protein 3 Gene	This gene may play a role in proteolysis or nuclear receptor activity.			Gene or Genome	
C126615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126615>	C126614	NRIP3 wt Allele|C11orf14|Chromosome 11 Open Reading Frame 14 Gene|NY-SAR-105|Nuclear Receptor Interacting Protein 3 wt Allele	Human NRIP3 wild-type allele is located in the vicinity of 11p15.3 and is approximately 23 kb in length. This allele, which encodes nuclear receptor-interacting protein 3, may be involved in the modulation of nuclear receptor activity.			Gene or Genome	
C126616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126616>	C18466	Nuclear Receptor-Interacting Protein 3|NRIP3|Sarcoma Antigen NY-SAR-105	Nuclear receptor-interacting protein 3 (241 aa, ~27 kDa) is encoded by the human NRIP3 gene. This protein may play a role in nuclear receptor activity or proteolysis.			Amino Acid, Peptide, or Protein	
C126617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126617>	C20462	CASP8AP2 Gene|CASP8AP2|CASP8AP2|Caspase 8 Associated Protein 2 Gene	This gene is involved in apoptotic signaling.			Gene or Genome	
C126618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126618>	C126617	CASP8AP2 wt Allele|CED-4|Caspase 8 Associated Protein 2 wt Allele|FLASH|FLJ11208|KIAA1315|RIP25	Human CASP8AP2 wild-type allele is located in the vicinity of 6q15 and is approximately 45 kb in length. This allele, which encodes CASP8-associated protein 2, plays a role in the regulation of apoptosis.			Gene or Genome	
C126619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126619>	C19928	CASP8-Associated Protein 2|CASP8 Associated Protein 2|Caspase 8-Associated Protein 2|FLASH Homolog RIP25|FLICE-Associated Huge Protein|Human FLASH	CASP8-associated protein 2 (1982 aa, ~223 kDa) is encoded by the human CASP8AP2 gene. This protein is involved in the positive regulation of caspase-dependent apoptosis.			Amino Acid, Peptide, or Protein	
C12661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12661>	C70699	Spheroplast|Spheroplasts	A cell that has lost it's typical shape and becomes spherical due to partial loss of the cell wall.	Spheroplasts		Cell	
C126620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126620>	C20745	MYO1F Gene|MYO1F|MYO1F|Myosin IF Gene	This gene plays a role in the movement of intracellular components.			Gene or Genome	
C126621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126621>	C126620	MYO1F wt Allele|MYO1F|Myosin IF wt Allele	Human MYO1F wild-type allele is located within 19p13.3-p13.2 and is approximately 57 kb in length. This allele, which encodes unconventional myosin-If, is involved in intracellular movement.			Gene or Genome	
C126622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126622>	C16492	Unconventional Myosin-If|MYO1F|Myosin ID|Myosin-ID|Myosin-Ie	Unconventional myosin-If (1098 aa, ~125 kDa) is encoded by the human MYO1F gene. This protein plays a role in the transport of intracellular components.			Amino Acid, Peptide, or Protein	
C126623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126623>	C20194	FRYL Gene|FRY-Like Gene|FRYL|FRYL|FRYL	This gene is involved in the regulation of cell shape and polarity.			Gene or Genome	GDC Terminology|GDC Value Terminology
C126624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126624>	C126623	FRYL wt Allele|AF4p12|DKFZp686E205|FRY-Like wt Allele|Furry Homolog-Like (Drosophila) Gene|Furry-Like Gene|KIAA0826|MOR2|Mor2 Cell Polarity Protein Homolog (S. pombe) Gene	Human FRYL wild-type allele is located in the vicinity of 4p11 and is approximately 283 kb in length. This allele, which encodes protein furry homolog-like, plays a role in the modulation of both cell polarity and cell shape.			Gene or Genome	
C126625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126625>	C18466	Protein Furry Homolog-Like|ALL1-Fused Gene From Chromosome 4p12 Protein|FRYL	Protein furry homolog-like (3013 aa, ~340 kDa) is encoded by the human FRYL gene. This protein is involved in the regulation of cell shape in polarized cells.			Amino Acid, Peptide, or Protein	
C126626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126626>	C21240	EEFSEC Gene|EEFSEC|EEFSEC|Eukaryotic Elongation Factor, Selenocysteine-tRNA-Specific Gene	This gene plays a role in protein translation.			Gene or Genome	
C126627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126627>	C126626	EEFSEC wt Allele|EFSEC|Eukaryotic Elongation Factor, Selenocysteine-tRNA-Specific wt Allele|SELB	Human EEFSEC wild-type allele is located in the vicinity of 3q21.3 and is approximately 273 kb in length. This allele, which encodes selenocysteine-specific elongation factor protein, is involved in the translation of selenocysteine-containing proteins.			Gene or Genome	
C126628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126628>	C38576	Selenocysteine-Specific Elongation Factor|EEFSEC|Elongation Factor Sec|Elongation Factor for Selenoprotein Translation|Selenoprotein Translation Factor SELB	Selenocysteine-specific elongation factor (596 aa, ~65 kDa) is encoded by the human EEFSEC gene. This protein plays a role in the synthesis of selenocysteine-containing proteins.			Amino Acid, Peptide, or Protein	
C126629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126629>	C20194	BTBD18 Gene|BTB Domain Containing 18 Gene|BTBD18|BTBD18|BTBD18	This gene may be involved in protein ubiquitination.			Gene or Genome	GDC Terminology|GDC Value Terminology
C12662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12662>	C12508	Stem Cell|Mother Cells|Progenitor Cell|Progenitor Cells|Stem Cells|stem cell	An unspecialized cell that has the capacity for reproduction through cell division and can be induced to differentiate into a tissue or organ specific cell.	Stem Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C126630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126630>	C126629	BTBD18 wt Allele|BTB (POZ) Domain Containing 18 Gene|BTB Domain Containing 18 wt Allele|HCG1730474	Human BTBD18 wild-type allele is located in the vicinity of 11q12.1 and is approximately 9 kb in length. This allele, which encodes BTB/POZ domain-containing protein 18, may play a role in the ubiquitination of proteins.			Gene or Genome	
C126631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126631>	C95242	BTB/POZ Domain-Containing Protein 18|BTB Domain-Containing 18|BTBD18	BTB/POZ domain-containing protein 18 (712 aa, ~78 kDa) is encoded by the human BTBD18 gene. This protein may be involved in the regulation of ubiquitination.			Amino Acid, Peptide, or Protein	
C126632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126632>	C20744	ACTN4 Gene|ACTN4|ACTN4|Actinin Alpha 4 Gene	This gene plays a role in the binding of actin to other cellular structures.			Gene or Genome	
C126633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126633>	C126632	ACTN4 wt Allele|ACTININ-4|Actinin Alpha 4 wt Allele|Actinin, Alpha 4 Gene|Actinin, Alpha-4 Gene|FSGS|FSGS1|Focal Segmental Glomerulosclerosis 1 Gene	Human ACTN4 wild-type allele is located in the vicinity of 19q13 and is approximately 84 kb in length. This allele, which encodes alpha-actinin-4 protein, is involved in crosslinking actin to other cellular proteins. Mutations in this gene are associated with focal segmental glomerulosclerosis.			Gene or Genome	
C126634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126634>	C18073	Alpha-Actinin-4|ACTN4|Actinin Alpha4 Isoform|Non-Muscle Alpha-Actinin 4	Alpha-actinin-4 (911 aa, ~105 kDa) is encoded by the human ACTN4 gene. This protein plays a role in actin crosslinking.			Amino Acid, Peptide, or Protein	
C126635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126635>	C20194	PRRC1 Gene|PRRC1|PRRC1|Proline Rich Coiled-Coil 1 Gene	This gene has no known function.			Gene or Genome	
C126636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126636>	C126635	PRRC1 wt Allele|FLJ32875|Proline Rich Coiled-Coil 1 wt Allele	Human PRRC1 wild-type allele is located in the vicinity of 5q23.2 and is approximately 37 kb in length. This allele, which encodes protein PRRC1, has no known function. Mutation or deletion of the gene may be associated with leukemogenesis.			Gene or Genome	
C126637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126637>	C18466	Protein PRRC1|Proline-Rich Coiled-Coil 1|Proline-Rich and Coiled-Coil-Containing Protein 1	Protein PRRC1 (445 aa, ~47 kDa) is encoded by the human PRRC1 gene. The function of this protein is unknown.			Amino Acid, Peptide, or Protein	
C126638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126638>	C471	Imipramine Blue|IB	A triphenylmethane-based dye and an inhibitor of nicotinamide adenine dinucleotide phosphate (NADP+) oxidase 4 (NOX4), with potential anti-invasive and anti-oxidative activities. Upon administration, imipramine blue (IB) inhibits the activity of NOX4 and prevents NOX4-mediated cell signaling. This prevents the formation of NOX4-mediated reactive oxygen species (ROS), abrogates the ROS-induced inhibition of protein tyrosine phosphatase (PTP) activation, and induces both G2/M cell cycle arrest and apoptosis. NOX4, an enzyme belonging to the NOX family of proteins, promotes the production of ROS and plays a key role in the suppression of PTP activation; it is upregulated in a variety of cancers.	Imipramine Blue		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C126639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126639>	C200766|C176018	Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014|Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ CM T-lymphocytes JCAR014|JCAR014	A defined preparation of CD4+ and CD8+ central memory (CM) autologous T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-CD19 single chain variable fragment (scFv) fused to the signaling domains of CD28, 4-1BB (CD137), the zeta chain of the TCR/CD3 complex (CD3-zeta), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+CM T-lymphocytes JCAR014 are directed to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a cetuximab-induced antibody dependent cellular cytotoxicity (ADCC) response. The 4-1BB costimulatory signaling domain enhances both proliferation of T-cells and antitumor activity.	Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126640>	C128462	Alobresib|(2-Cyclopropyl-6-(3,5-dimethyl-1,2-oxazol-4-yl)-1hbenzimidazol-4-yl)(dipyridin-2-yl)methanol|ALOBRESIB|GS 5829|GS-5829|GS5829	An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, alobresib binds to the acetylated lysine recognition motifs in the bromodomains of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of proliferation in BET-overexpressing tumor cells. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.	Alobresib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126641>	C210988	Simurosertib|Cell Division Cycle 7 Inhibitor TAK-931|SIMUROSERTIB|TAK 931|TAK-931|Thieno(3,2-d)pyrimidin-4(3H)-one, 2-(2S)-1-Azabicyclo(2.2.2)oct-2-yl-6-(3-methyl-1H-pyrazol-4-yl)-	An orally bioavailable inhibitor of cell division cycle 7 (cell division cycle 7-related protein kinase; CDC7), with potential antineoplastic activity. Upon administration, simurosertib binds to and inhibits CDC7; this prevents the initiation of DNA replication during mitosis, which causes cell cycle arrest and induces apoptosis. This inhibits cell growth in CDC7-overexpressing tumor cells. CDC7, a serine/threonine kinase and cell division cycle protein, is overexpressed in a variety of cancers and plays a key role in the activation of DNA replication and the regulation of cell cycle progression.	Simurosertib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126642>	C663	Sustained-release Mitomycin C Hydrogel Formulation UGN-101|MP77-08|Mitogel|RTGel with MMC|RTGel with Mitomycin C|SR Mitomycin C|Sustained-release Mitomycin C Gel Formulation|UGN-101	A sustained-release (SR) hydrogel polymer-based formulation containing the antineoplastic antibiotic mitomycin C (MMC), with potential antineoplastic activity. Upon local administration of the SR MMC hydrogel formulation to the upper urinary tract via a ureteral catheter, the gel solidifies and deposits MMC locally to prevent the excretion of this chemotherapeutic agent via urinary flow. In turn, MMC alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis. Due to its reverse thermal-gelation properties, this gel is able to stay in a liquid state at cold temperatures and solidifies at body temperature. This allows for increased accumulation of MMC locally in the upper urinary tract which leads to increased efficacy compared to standard intravesical delivery of MMC for upper tract urothelial carcinoma (UTUC).	Sustained-release Mitomycin C Hydrogel Formulation UGN-101		Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126643>	C129822|C128058	Ragifilimab|Anti-GITR Agonistic Monoclonal Antibody INCAGN01876|INCAGN 01876|INCAGN 1876|INCAGN-1876|INCAGN01876|RAGIFILIMAB	An anti-human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor superfamily, member 18; TNFRSF18; GITR; CD357) agonistic humanized monoclonal antibody, with potential immune checkpoint modulating activity. Ragifilimab binds to and activates GITRs found on multiple types of T-cells. This stimulates the immune system, induces both the activation and proliferation of tumor-antigen-specific T effector cells (Teff), and suppresses the function of activated T regulatory cells (Tregs). This leads to tumor cell eradication. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B-cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress Teffs and suppress T-cell receptor (TCR) signaling.	Ragifilimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126644>	C198860|C1742	Anti-VEGF/ANG2 Nanobody BI 836880|Anti-VEGF/ANG2 BI 836880|BI 836880|BI-836880|Bi-specific Anti-VEGF/Ang2 Nanobody BI 836880	A nanobody directed against angiopoietin-2 (Ang2; ANGPT2)- and vascular endothelial growth factor (VEGF)-derived peptides, with potential antiangiogenic and antineoplastic activities. Anti-VEGF/ANG2 nanobody BI 836880 binds to Ang2 and VEGF and inhibits receptor binding; this prevents Ang2- and VEGF-mediated signaling and inhibits both tumor angiogenesis and tumor cell proliferation. Both VEGF and Ang2 are upregulated in a variety of cancer cell types and play a crucial role in angiogenesis. The nanobody is based on functional fragments of single-chain antibodies.	Anti-VEGF/ANG2 Nanobody BI 836880		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126645>	C307	Dehydrated Human Amnion/Chorion Membrane|AmnioFix|dHACM	Tissue derived from portions of the placenta donated by the patient during a C-section, with potential regenerative activity. Upon placement of the tissue around or on the affected area, dehydrated human amnion/chorion membrane (dHCAM), which contains regenerative cytokines, promotes wound angiogenesis and may help heal the wound, restore tissue function and reduce risk of inflammation.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C126646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126646>	C225455|C129825	Padnarsertib|ATG 019|ATG-019|ATG019|KCP-9274|KPT-9274|PADNARSERTIB|PAK4/NAMPT Inhibitor ATG-019|PAK4/NAMPT Inhibitor KPT-9274	An orally bioavailable inhibitor of both the serine/threonine kinase P21-activated kinase 4 (PAK4) and the nicotinamide adenine dinucleotide (NAD)-synthesizing enzyme nicotinamide phosphoribosyltransferase (NAMPT; NAMPRTase), with potential antineoplastic activity. Upon administration, padnarsertib allosterically binds to, destabilizes and causes degradation of PAK4. This inhibits PAK4-mediated signaling, induces cell death in, and inhibits the proliferation of PAK4-overexpressing tumor cells. In addition, padnarsertib binds to and inhibits the activity of NAMPT. This depletes cellular NAD and inhibits NAD-dependent enzymes, both of which are needed for rapid cell proliferation; this results in tumor cell death in NAMPT-overexpressing cancer cells. PAK4, a serine/threonine kinase and member of the PAK family of proteins upregulated in various cancer cell types, regulates cell motility, proliferation and survival. NAMPT, an enzyme that is responsible for maintaining the intracellular NAD pool, plays a key role in the regulation of cellular metabolism and has cytokine-like activities. NAMPT is often overexpressed in a variety of cancers and metabolic disorders and tumor cells rely on NAMPT activity for their NAD supply.	Padnarsertib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126647>	C281|C2459	Imidazolyl Ethanamide Pentandioic Acid|6-(2-(1H-Imidazol-4-yl)ethylamino)-5-oxohexanoic Acid|Dicarbamin|IEPA|INGAVIRIN|Ingavirin|Myelo 001|Myelo001|Pentanedioic Acid Imidazolyl Ethanamide|Vitaglutam	An orally bioavailable small molecule, with potential hematopoiesis inducing and antiviral activities. Upon oral administration, myelo001 stimulates the differentiation of bone marrow cells of the leukocytic, lymphocytic, and erythrocytic lineages, and prevents apoptosis of hematopoietic cells. This prevents chemotherapy-induced neutropenia (CIN), inhibits the risk of infections, increases tolerance and allows for the continuation of the neutropenia-inducing chemotherapeutic agent. In addition, myelo 001 has antiviral properties.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C126649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126649>	C178192	White Carrot	A vegetable, also known as Arracacha, with potential chemoprevenitve, anti-oxidant and protective activities. White carrot contains a variety of nutrients, including minerals and vitamins. Polyacetylenes, including falcarinol, falcarindiol and falcarindiol-3-acetate are mainly responsible for its potential anti-cancer activity.			Food	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12664>	C25444	Abdomen|ABDOMINAL CAVITY|Abdomen, NOS|Abdomen, total|Abdominal Cavity|Abdominal Cavity|BODY CAVITY, ABDOMINAL|abdomen|abdomen|abdominopelvic region|abdominopelvis	The cavity located between the lungs and pelvis. It contains the lower esophagus, stomach, pancreas, intestines, liver, gallbladder and spleen.	Abdomen		Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Radiation Therapy Table|EWS Tumor Assessment Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Radiation Therapy Table|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C126650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126650>	C28193	Infantile Convulsions and Paroxysmal Choreoathetosis, Familial|ICCA|ICCA Syndrome|PKD/IC|Paroxysmal Kinesigenic Dyskinesia with Infantile Convulsions	An autosomal dominant inherited disorder caused by mutation(s) in the PRRT2 gene, encoding proline-rich transmembrane protein 2. It is characterized by epileptic seizures and paroxysmal kinesigenic choreoathetosis. It shares features with episodic kinesigenic dyskinesia-1, which is an allelic disorder.			Disease or Syndrome	
C126651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126651>	C78245	Progressive Familial Heart Block, Type Ia|Lenegre's Disease|Lenegre-Lev Disease|PFHB1A|Progressive Familial Heart Block 1A	An autosomal dominant inherited cardiac bundle branch disorder which can progress to complete heart block.			Disease or Syndrome	Cellosaurus Disease Terminology
C126652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126652>	C62695	Oat Biscuit	A biscuit containing oats.			Food	NCI Drug Dictionary Terminology
C126653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126653>	C2124	Fluorine F 18 Dabrafenib|DABRAFENIB F-18|[F18]dabrafenib	A radioconjugate containing dabrafenib, a tyrosine kinase inhibitor of the V600 mutated version of the B-raf (BRAF) protein and labeled with the positron-emitting isotope fluorine F 18 with potential prostate tumor imaging upon positron emission tomography (PET). Upon administration, the dabrafenib moiety of fluorine F 18 dabrafenib specifically targets and binds to the BRAF V600-mutated form, expressed on tumor cells, thereby allowing the visualization of tumor cells expressing BRAF V600 upon PET. BRAF is constitutively activated in a variety of cancers due to BRAF gene mutations.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C126654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126654>	C52647	Genotype-Tissue Expression Program|GTEx|Genotype-Tissue Expression	A program sponsored by the National Institutes of Health's Common Fund, designed to provide insights into the mechanisms of gene regulation by studying human gene expression and regulation in multiple tissues from healthy individuals, exploring disease-related perturbations in a variety of human diseases, and examining sexual dimorphisms in gene expression and regulation in multiple tissues. Genetic variation between individuals will be examined for correlation with differences in gene expression level to identify regions of the genome that influence whether and how much a gene is expressed.			Research Activity	
C126655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126655>	C20189	Unexplained	Having a reason or cause that is not known.			Conceptual Entity	
C126656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126656>	C5036	Track Marks|Needle Track Marks|Needle track	Visible marks on the skin caused by puncture wounds, most commonly associated with intravenous drug use.			Finding	
C126657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126657>	C19683	Body Piercing|Piercing	The practice of puncturing a part of the human body to create an opening in which jewelry, or other objects, may be worn.			Individual Behavior	
C126658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126658>	C199143	National Disease Research Interchange|NDRI	A federally-funded non-profit organization that acts as a liaison between tissue and organ donors and the scientific community.			Group	
C126659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126659>	C143048	NCIt Neoplasm Core Terminology	A core reference set of NCIt neoplasm classification concepts to facilitate consistent coding, analysis, and data sharing across a broad range of NCI and related resources.			Intellectual Product	National Cancer Institute Terminology
C12665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12665>	C12700	Abducens Nerve|ABDUCENS NERVE|Abducens nerve structure (body structure)|Cranial Nerve VI|Nervus Abducens|Sixth Cranial Nerve	A cranial nerve that supplies motor impulses to the lateral rectus muscle of the eye.	Abducens Nerve		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C126660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126660>	C107589	Mavorixafor|(S)-N1-((1H-benzo[d]imidazol-2-yl)methyl)-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine|AMD-070|AMD-11070|AMD11070|MAVORIXAFOR|X4P 001|X4P-001|X4P001|Xolremdi	An orally bioavailable inhibitor of C-X-C chemokine receptor type 4 (CXCR4), with potential antineoplastic and immune checkpoint inhibitory activities. Upon administration, mavorixafor selectively binds to CXCR4 and prevents the binding of CXCR4 to its ligand, stromal cell-derived factor 1 (SDF-1 or CXCL12). This inhibits receptor activation and results in decreased proliferation and migration of CXCR4-overexpressing tumor cells. In addition, inhibition of CXCR4 prevents the recruitment of regulatory T-cells and myeloid-derived suppressor cells (MDSCs) to the tumor microenvironment, thereby abrogating CXCR4-mediated immunosuppression and enabling the activation of a cytotoxic T-lymphocyte-mediated immune response against cancer cells. The G protein-coupled receptor CXCR4, which is upregulated in several tumor cell types, induces the recruitment of immunosuppressive cells in the tumor microenvironment, suppresses immune surveillance, and promotes tumor angiogenesis and tumor cell proliferation. It is also a co-receptor for HIV entry into T-cells.	Mavorixafor		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126661>	C129820	Apilimod Dimesylate Capsule|LAM 002A|LAM-002A	A capsule containing the dimesylate salt form of apilimod, an inhibitor of the class III PI kinase phosphatidylinositol-3-phosphate 5-kinase (PIKfyve), with potential antineoplastic and immunomodulatory activities. Upon oral administration of apilimod dimesylate capsule, apilimod selectively binds to and inhibits PIKfyve. The inhibition leads to disruption of PIKfyve-mediated signal transduction pathways and eventually inhibits tumor cell growth in PIKfyve-overexpressing tumor cells. Also, PIKfyve inhibition by apilimod inhibits the toll-like receptor (TLR)-induced production of various cytokines, including interleukin-12 (IL-12) and IL-23, thereby preventing IL-12/IL-23-mediated immune responses. PIKfyve, a lipid kinase dysregulated in various tumor types, plays a key role in TLR signaling and tumor cell migration, proliferation and survival.	Apilimod Dimesylate Capsule		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C126662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126662>	C172828|C107401	Skin Itching at its Worst Question|Skin Itching at its Worst|Your skin itching at its worst	A question about an individual's skin itching at its worst.			Intellectual Product	
C126663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126663>	C107401	Skin and/or Joint Tightening at its Worst Question|Skin and/or Joint Tightening at its Worst|Your skin and/or joint tightening at their worst	A question about an individual's skin and/or joint tightening at its worst.			Intellectual Product	
C126664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126664>	C107401	Mouth Sensitivity at its Worst Question|Mouth Sensitivity at its Worst|Your mouth sensitivity at its worst	A question about an individual's mouth sensitivity at its worst.			Intellectual Product	
C126665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126665>	C173518|C107401	Genital Discomfort at its Worst Question|Genital Discomfort at its Worst|Your genital discomfort at its worst	A question about an individual's genital discomfort at its worst.			Intellectual Product	
C126666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126666>	C91102	Global Rating Question|Global Rating|Global Rating	A question relating to the overall ranking of something based on a comparative assessment.			Intellectual Product	
C126667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126667>	C175280	Severity Score 0	A subjective score of 0 on a severity scale that ranges from 0: Not at all severe to 10: most severe.			Intellectual Product	
C126668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126668>	C175280	Severity Score 1	A subjective score of 1 on a severity scale that ranges from 0: Not at all severe to 10: most severe.			Intellectual Product	
C126669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126669>	C175280	Severity Score 2	A subjective score of 2 on a severity scale that ranges from 0: Not at all severe to 10: most severe.			Intellectual Product	
C12666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12666>	C12704	Adrenal Gland|ADRENAL GLAND|Adrenal|Adrenal|Adrenal Glands|Adrenal gland|Adrenal gland, NOS|Adrenal structure (body structure)|Adrenals|Adrenals|GLAND, ADRENAL|adrenal gland|adrenal gland|glandula adrenalis|glandula suprarenalis|suprarenal gland	A flattened, roughly triangular body resting upon the upper end of each kidney; it is one of the ductless glands furnishing internal secretions (epinephrine and norepinephrine from the medulla and steroid hormones from the cortex).	Adrenal Gland		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTDC Value Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C126670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126670>	C175280	Severity Score 3	A subjective score of 3 on a severity scale that ranges from 0: Not at all severe to 10: most severe.			Intellectual Product	
C126671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126671>	C175280	Severity Score 4	A subjective score of 4 on a severity scale that ranges from 0: Not at all severe to 10: most severe.			Intellectual Product	
C126672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126672>	C175280	Severity Score 5	A subjective score of 5 on a severity scale that ranges from 0: Not at all severe to 10: most severe.			Intellectual Product	
C126673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126673>	C175280	Severity Score 6	A subjective score of 6 on a severity scale that ranges from 0: Not at all severe to 10: most severe.			Intellectual Product	
C126674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126674>	C175280	Severity Score 7	A subjective score of 7 on a severity scale that ranges from 0: Not at all severe to 10: most severe.			Intellectual Product	
C126675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126675>	C175280	Severity Score 8	A subjective score of 8 on a severity scale that ranges from 0: Not at all severe to 10: most severe.			Intellectual Product	
C126676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126676>	C175280	Severity Score 9	A subjective score of 9 on a severity scale that ranges from 0: Not at all severe to 10: most severe.			Intellectual Product	
C126677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126677>	C175280	Severity Score 10	A subjective score of 10 on a severity scale that ranges from 0: Not at all severe to 10: most severe.			Intellectual Product	
C126678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126678>	C175270	Comparative Score 3+	A score of 3+ on a comparative scale that ranges from 3+: Very much better to -3: Very much worse.			Intellectual Product	
C126679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126679>	C175270	Comparative Score 2+	A score of 2+ on a comparative scale that ranges from 3+: Very much better to -3: Very much worse.			Intellectual Product	
C12667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12667>	C32301	Anterior Chamber of the Eye|Anterior Chamber|Anterior Chamber (Eye)|Anterior Chamber of Eye|Chamber, Anterior|EYE, ANTERIOR CHAMBER	The space in the eye, filled with aqueous humor, bounded anteriorly by the cornea and a small portion of the sclera and posteriorly by a small portion of the ciliary body, the iris, and that part of the crystalline lens which presents through the pupil. (Cline et al., Dictionary of Visual Science, 4th ed, p109)	Anterior Chamber of Eye		Body Space or Junction	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C126680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126680>	C175270	Comparative Score 1+	A score of 1+ on a comparative scale that ranges from 3+: Very much better to -3: Very much worse.			Intellectual Product	
C126681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126681>	C175270	Comparative Score 0	A score of 0 on a comparative scale that ranges from 3+: Very much better to -3: Very much worse.			Intellectual Product	
C126682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126682>	C175270	Comparative Score -1	A score of -1 on a comparative scale that ranges from 3+: Very much better to -3: Very much worse.			Intellectual Product	
C126683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126683>	C175270	Comparative Score -2	A score of -2 on a comparative scale that ranges from 3+: Very much better to -3: Very much worse.			Intellectual Product	
C126684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126684>	C175270	Comparative Score -3	A score of -3 on a comparative scale that ranges from 3+: Very much better to -3: Very much worse.			Intellectual Product	
C126685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126685>	C20993	Behavior Assessment System for Children, Third Edition|BASC-3	A comprehensive set of rating scales designed to facilitate the differential diagnosis and classification of a variety of emotional and behavioral disorders of children, aid in the design of treatment plans, and provide insight into an individual's thoughts and feelings. Version three incorporates additional questionnaires, scales and forms.			Intellectual Product	
C126686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126686>	C28681|C138180|C129826	Autologous MAGE-A10-specific HLA-A2-restricted TCR c796 Gene-engineered Lymphocytes|Autologous Genetically-modified T-cells MAGEA10c796|Autologous MAGE A10c796 T-Cells|MAGEA10c796 T	Human autologous T-lymphocytes transduced with a retroviral vector encoding a high-affinity T-cell receptor (TCR) specific for human leukocyte antigen (HLA)-A2-restricted, human melanoma-associated antigen A10 (MAGE-A10), clone 796 (c796), with potential antineoplastic activity. Peripheral blood mononuclear cells (PBMCs) are isolated from a patient, transduced with an anti-MAGE-A10(c796)-HLA-A2 restricted TCR, expanded ex vivo, and reintroduced into the HLA-A2-positive patient. Upon reintroduction, the autologous MAGE-A10-specific, HLA-A2-restricted TCR c796 gene-engineered lymphocytes bind to tumor cells expressing the MAGE-A10 antigen, which may induce cell death in and halt the growth of MAGE-A10-expressing cancer cells. The tumor-associated antigen MAGE-A10, a member of the MAGE-A family of cancer/testis tumor-associated antigens (CT-TAAs), is overexpressed by a variety of cancer cell types.	Autologous MAGE-A10-specific HLA-A2-restricted TCR c796 Gene-engineered Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126687>	C174048	Rineterkib|ERK Inhibitor LTT462|LTT 462|LTT462|RINETERKIB	An orally available inhibitor of extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon oral administration, rineterkib binds to and inhibits ERK, thereby preventing the activation of ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is upregulated in numerous tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.	Rineterkib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126688>	C101216	Bethlem Myopathy 1|BTHLM1	A usually autosomal dominant inherited movement disorder caused by mutations in the COL6A1, COL6A2, and COL6A3 genes. It is characterized by progressive muscle weakness and joint stiffness in the fingers, wrists, elbows, and ankles.			Disease or Syndrome	Cellosaurus Disease Terminology
C126689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126689>	C84648	Centronuclear Myopathy 1|CNM1	A myopathy inherited in an autosomal dominant or recessive pattern, caused by mutations in the DNM2, BIN1, and TTN genes. Microscopically there is central displacement of the nucleus in muscle cells. It is characterized by muscle weakness and atrophy in the skeletal muscles.			Disease or Syndrome	Cellosaurus Disease Terminology
C12668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12668>	C33525	Anterior Eye Segment|EYE, ANTERIOR SEGMENT	The part of the eye anterior to the lens, including but not limited to the anterior chamber, cornea and related structures.	Anterior Eye Segment		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C126690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126690>	C84910|C84392	Congenital Muscular Dystrophy-Dystroglycanopathy with Intellectual Developmental Disorder Type B2|Congenital Muscular Dystrophy-Dystroglycanopathy with Mental Retardation Type B2|MDDGB2	An autosomal recessive inherited congenital muscular dystrophy caused by mutations in the POMT2 gene. It is characterized by mental retardation and mild structural brain abnormalities resulting from defective glycosylation of alpha-dystroglycan.			Disease or Syndrome	Cellosaurus Disease Terminology
C126691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126691>	C84910	Rigid Spine Muscular Dystrophy 1|RSMD1|RSS|Rigid Spine Syndrome	An inherited muscular dystrophy caused by mutations in the SEPN1 gene. It is characterized by severe limitation in flexion of the dorsolumbar and cervical spine, due to contracture of the spinal extensors. It leads to loss of movement of the spine and the thoracic cage.			Disease or Syndrome	Cellosaurus Disease Terminology
C126692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126692>	C28193	Chromosome 15q11-q13 Duplication Syndrome	A syndrome caused by duplication of chromosome 15q11-q13. It is characterized by autism, mental retardation, ataxia, seizures, developmental delays, and behavioral problems.			Disease or Syndrome	Cellosaurus Disease Terminology
C126693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126693>	C62761	BCG Tokyo-172 Strain Vaccine|Bacillus Calmette-Guerin Tokyo-172 Strain Vaccine	A vaccine containing bacillus Calmette-Guerin (BCG), a live, attenuated strain of Mycobacterium bovis obtained from the Pasteur Institute in 1924, with non-specific immunoadjuvant and immunotherapeutic activities. Upon intradermal administration, BCG Tokyo-172 strain vaccine activates the immune system and enhances a specific, systemic BCG antigen immune response. This results in active immunization against tuberculosis and primes the immune system against future administered BCG antigens.	BCG Tokyo-172 Strain Vaccine		Bacterium|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C126694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126694>	C62761	BCG Tokyo-172 Strain Solution|BACILLUS CALMETTE-GUERIN SUBSTRAIN TOKYO 172-1 LIVE ANTIGEN|BCG Tokyo-172 Strain Vaccine|Bacillus Calmette-Guerin Tokyo-172 Strain Solution|Immunobladder	A solution containing an attenuated, live culture preparation of the bacillus Calmette-Guerin (BCG) strain of Mycobacterium bovis obtained from the Pasteur Institute in 1924, with potential immunostimulating and antineoplastic activities. Although the precise mechanism of action is unknown, upon intravesical instillation through a catheter, the attenuated, live BCG bacteria in the BCG Tokyo-172 strain solution come into direct contact with the bladder wall and elicits a local, multifaceted immune response against the BCG antigens, which kills the bladder cancer cells. Previous vaccination with a systemic BCG vaccine may enhance the immune system's response against the BCG antigens.	BCG Tokyo-172 Strain Vaccine		Bacterium|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126695>	C38101	Digital Tomosynthesis|DT	An imaging technique in which multiple X-rays of an object are take from a discrete number of angles. These cross-sectional images are used to reconstruct 3-D images of the object being scanned. Tomosynthesis differs from computed tomography because the range of angles used is less than 360 degrees, as used in computed tomography.			Diagnostic Procedure	
C126696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126696>	C126695	Stationary Digital Tomosynthesis|s-DT	Digital tomosynthesis that uses an array of x-ray sources to obtain cross-sectional images of an object for 3-D image construction. Stationary digital tomosynthesis eliminates the blur associated with a moving x-ray source and also decreases the time needed to obtain the images.	Stationary Digital Tomosynthesis		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C126697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126697>	C126695	Digital Chest Tomosynthesis|Digital Tomosynthesis of Chest|Digital Tomosynthesis of Thorax	Digital tomosynthesis used to image structures in the thoracic cavity.	Digital Chest Tomosynthesis		Diagnostic Procedure	
C126698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126698>	C126697|C126696	Stationary Digital Chest Tomosynthesis|s-DCT	Stationary digital tomography used to image structures in the thoracic cavity.	Stationary Digital Chest Tomosynthesis		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C126699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126699>	C4870	Complete Response in GvHD	Complete resolution of all signs and symptoms in all affected organs or tissues in graft versus host disease.			Finding	
C12669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12669>	C12679	Aorta|AORTA|ARTERY, AORTA|Aortic|Aortic structure (body structure)|aorta|aorta|trunk of aortic tree|trunk of systemic arterial tree	The major arterial trunk that carries oxygenated blood from the left ventricle into the ascending aorta behind the heart, the aortic arch, through the thorax as the descending aorta and through the abdomen as the abdominal aorta; it bifurcates into the left and right common iliac arteries.	Aorta		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C1266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1266>	C1821	Trioxifene|(3,4-Dihydro-2-(4-methoxyphenyl)-1-naphthalenyl)(4-(2-(1-pyrrolidinyl)ethoxy)phenyl) Methanone|TRIOXIFENE	A nonsteroidal selective estrogen receptor modulator (SERM) with potential antineoplastic activity.  Trioxifene competes with estradiol in binding to estrogen receptor alpha (ER alpha), thereby inhibiting ER alpha-mediated signal transduction and gene expression. In addition, trioxifene exerts intrinsic estrogenic activity depending on the tissue. Clinical development of trioxifene has not been preceded due to its side effect profile and lack of increased efficacy over tamoxifen.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126700>	C126699	Skin Complete Response GvHD|Skin Complete GvHD Response|Skin Complete Response	An NIH skin score of 0 after previous GvHD involvement.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C126701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126701>	C126699	Eyes Complete Response GvHD|Eyes Complete GvHD Response|Eyes Complete Response	An NIH eye score of 0 after previous GvHD involvement.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C126702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126702>	C126699	Mouth Complete Response GvHD|Mouth Complete GvHD Response|Mouth Complete Response	An NIH modified Oral Mucosa Rating Scale (OMRS) score of 0 following previous GvHD involvement.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C126703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126703>	C126699	Esophagus Complete Response GvHD|Esophagus Complete GvHD Response|Esophagus Complete Response	An NIH esophagus score of 0 after previous GvHD involvement.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C126704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126704>	C126699	Upper GI Complete Response GvHD|Upper GI Complete GvHD Response|Upper GI Complete Response	An NIH upper GI score of 0 after previous GvHD involvement.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C126705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126705>	C126699	Lower GI Complete Response GvHD|Lower GI Complete GvHD Response|Lower GI Complete Response	An NIH lower GI score of 0 after previous GvHD involvement.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C126706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126706>	C126699	Liver Complete Response GvHD|Liver Complete GvHD Response|Liver Complete Response	Normal ALT, alkaline phosphatase, and total bilirubin after previous elevation of 1 or more following GvHD involvement.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C126707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126707>	C126699	Lungs Complete Response GvHD|Lungs Complete GvHD Response|Lungs Complete Response	Either normal %FEV1, alkaline phosphatase, and total bilirubin after previous elevation of 1 or more or an NIH lung symptom score of 0 following GvHD involvement.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C126708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126708>	C126699	Joints and Fascia Complete Response GvHD|Joints and Fascia Complete GvHD Response|Joints and Fascia Complete Response	Both an NIH joint and fascia score of 0 and a P-ROM score of 25 after previous GvHD involvement by at least 1 measure.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C126709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126709>	C126699	Global Complete Response GvHD|Global Complete GvHD Response|Global Complete Response	A clinician overall severity score 0 following GvHD response.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C12670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12670>	C12729	Aortic Valve|AORTIC VALVE|Aortic valve structure (body structure)|VALVE, AORTIC	A valve that is located between and controls the flow of blood from the left ventricle of the heart and the aorta.	Aortic Valve		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C126710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126710>	C16393	NRXN3 Gene Product	A protein encoded by the NRXN3 gene.			Amino Acid, Peptide, or Protein	
C126711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126711>	C126710	Neurexin-3-Beta|Neurexin III-Beta	Neurexin-3-beta (637 aa, ~69 kDa) is encoded by the human NRXN3 gene. This protein plays a role in cell adhesion.	Neurexin-3-Beta		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126712>	C795	Fluoroquinolone Antibiotic|Fluoroquinolone|Fluoroquinolones	Any quinolone antibiotic with a fluorine (F) atom attached to the quinolone structure, with broad-spectrum antibacterial activity. Fluoroquinolones diffuse through the bacterial cell wall and act by inhibiting bacterial topoisomerase II, DNA gyrase and/or bacterial topoisomerase IV, which are enzymes involved in bacterial DNA replication. This prevents DNA replication and leads to a blockage of bacterial cell proliferation.	Fluoroquinolone Antibiotic		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C126713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126713>	C18058	Partial Response in GvHD	An improvement in one or more organs without complete resolution in all affected organs or progression of graft versus host disease.			Finding	
C126714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126714>	C126713	Skin Partial Response GvHD|Skin Partial GvHD Response|Skin Partial Response	An NIH skin score that has decreased by 1 or more points.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C126715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126715>	C126713	Eyes Partial Response GvHD|Eyes Partial GvHD Response|Eyes Partial Response	An NIH eye score that has decreased by 1 or more points.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C126716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126716>	C126713	Mouth Partial Response GvHD|Mouth Partial GvHD Response|Mouth Partial Response	An NIH modified Oral Mucosa Rating Scale (OMRS) score that has decreased by 2 or more points.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C126717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126717>	C126713	Esophagus Partial Response GvHD|Esophagus Partial GvHD Response|Esophagus Partial Response	An NIH esophagus score that has decreased by 1 or more points.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C126718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126718>	C126713	Upper GI Partial Response GvHD|Upper GI Partial GvHD Response|Upper GI Partial Response	An NIH upper GI score that has decreased by 1 or more points.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C126719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126719>	C126713	Lower GI Partial Response GvHD|Lower GI Partial GvHD Response|Lower GI Partial Response	An NIH lower GI score that has decreased by 1 or more points.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C12671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12671>	C12429	Upper Extremity|LIMB, UPPER|Upper Body Extremity|Upper Limb|Upper Limb|Upper extremity|Upper limb, NOS|arm	The region of the body that includes the arm, the forearm, and hand.	Upper Extremity		Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Radiation Therapy Table|EWS Tumor Assessment Table|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C126720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126720>	C126713	Liver Partial Response GvHD|Liver Partial GvHD Response|Liver Partial Response	A decrease by 50% for ALT, alkaline phosphatase, and total bilirubin.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C126721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126721>	C126713	Lungs Partial Response GvHD|Lungs Partial GvHD Response|Lungs Partial Response	Either an increase by 10% predicted absolute value of %FEV1 or an NIH lung symptom score that has decreased by 1 or more points.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C126722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126722>	C126713	Joints and Fascia Partial Response GvHD|Joints and Fascia Partial GvHD Response|Joints and Fascia Partial Response	A NIH Joint and Fascia score that has decreased by 1 or more points or an increase in P-ROM score by 1 point for any site.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C126723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126723>	C126713	Global Partial Response GvHD|Global Partial GvHD Response|Global Partial Response	A clinician overall severity score that has decreased by 2 or more points on a 0-10 scale.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C126724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126724>	C50995	Progression in GvHD	Worsening of graft versus host disease (GvHD) in a previously affected organ or development of GvHD in an organ that was previously unaffected.			Finding	
C126725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126725>	C126724	Skin Progression GvHD|GvHD Skin Progression|Skin Progression	An NIH skin score that has increased by 1 or more points, except 0 to 1.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C126726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126726>	C126724	Eyes Progression GvHD|Eyes Progression|GvHD Eyes Progression	An NIH eye score that has increased by 1 or more points, except 0 to 1.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C126727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126727>	C126724	Mouth Progression GvHD|GvHD Mouth Progression|Mouth Progression	An NIH modified Oral Mucosa Rating Scale (OMRS) score that has increased by 2 or more points.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C126728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126728>	C126724	Esophagus Progression GvHD|Esophagus Progression|GvHD Esophagus Progression	An NIH esophagus score that has increased by 1 or more points, except 0 to 1.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C126729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126729>	C126724	Upper GI Progression GvHD|GvHD Upper GI Progression|Upper GI Progression	An NIH upper GI score that has increased by 1 or more points, except 0 to 1.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C12672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12672>	C12679	Arteriole	A small, terminal branch in the arterial system. Arterioles often connect to capillaries.	Arteriole		Body Part, Organ, or Organ Component	
C126730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126730>	C126724	Lower GI Progression GvHD|GvHD Lower GI Progression|Lower GI Progression	An NIH lower GI score that has increased by 1 or more points, except 0 to 1.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C126731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126731>	C2124	Iodine I 123 RISAD-P|(123) IRISAD-P|123IRISAD-P|5-[123I]iodo-3'-O-(17b-succinyl-5a-androstan-3-one)-2'-deoxyuridin-5'-yl Monophosphate|I 123 RISAD-P|RISAD-P I-123|[123]I-5-Radioiodo-3'-O-(17beta-succinyl-5alpha-androstan-3-one)-2'-deoxyuridin-5'-yl Phosphate|[123]I-RISAD-P	A radioconjugate containing an androgen receptor (AR) targeting agent, 5-radioiodo-3'-O-(17beta-succinyl-5alpha-androstan-3-one)-2'-deoxyuridin-5'-yl phosphate (RISAD-P), labeled with the radioisotope iodine I 123 ([123]I-RISAD-P), with potential use as an imaging agent for single photon emission computed tomography (SPECT) imaging. Upon administration, iodine I 123 RISAD-P selectively binds to and is taken up by AR. Upon SPECT imaging, AR-expressing tumor cells can be imaged and AR expression levels can be assessed. AR, which is overexpressed on certain tumor cells, plays key roles in tumor cell growth and survival.	Iodine I 123 RISAD-P		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C126732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126732>	C126724	Liver Progression GvHD|GvHD Liver Progression|Liver Progression	An increase by two times the upper limit of normal for ALT, alkaline phosphatase, and total bilirubin.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C126733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126733>	C126724	Lung Progression GvHD|GvHD Lung Progression|Lung Progression	Either a decrease by 10% predicted absolute value of %FEV1 or an NIH lung symptom score that has increased by 1 or more points, except 0 to 1.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C126734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126734>	C126724	Joints and Fascia Progression GvHD|GvHD Joints and Fascia Progression|Joints and Fascia Progression	A NIH joint and fascia score that has increased by 1 or more points or a decrease in P-ROM score by 1 point for any site.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C126735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126735>	C126724	Global Progression GvHD|Global Progression|GvHD Global Progression	A clinician overall severity score that has increased by 2 or more points on a 0-10 scale.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C126736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126736>	C12470	Suprapubic Skin|Suprapubic skin	The skin above the pubic area.			Anatomical Structure	
C126737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126737>	C13031	Frontal Pole|Frontal pole	The anterior pointed end of a cerebral hemisphere.			Body Part, Organ, or Organ Component	Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C126738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126738>	C85865|C34816	Phosphoglycerate Kinase 1 Deficiency	An X-linked recessive inherited disorder caused by mutations in the PGK1 gene. Clinical manifestations include hemolytic anemia, myopathy, and neurologic involvement.			Disease or Syndrome	Cellosaurus Disease Terminology
C126739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126739>	C84828	Muscular Dystrophy-Dystroglycanopathy (Limb-Girdle) Type C, 5|LGMD2I|Limb-Girdle Muscular Dystrophy Type 2I|MDDGC5	An autosomal recessive inherited limb-girdle muscular dystrophy caused by mutations in the gene encoding fukutin-related protein (FKRP). It is characterized by variable age at onset, normal cognition, and no structural brain changes.			Disease or Syndrome	Cellosaurus Disease Terminology
C12673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12673>	C33968	Autonomic Nervous System|ANS|Autonomic|Autonomic nervous system, NOS|autonomic division of peripheral nervous system|autonomic nervous system|autonomic nervous system|autonomic part of peripheral nervous system|divisio autonomica systematis nervosi peripherici|involuntary nervous system|pars autonomica systematis nervosi peripherici|peripheral autonomic nervous system|visceral nervous system	The part of the nervous system of vertebrates that controls involuntary actions of the smooth muscles and heart and glands.	Autonomic Nervous System		Body System	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C126740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126740>	C99109	Muscular Dystrophy-Dystroglycanopathy (Congenital with Brain and Eye Anomalies) Type A, 3|MDDGA3	An autosomal recessive muscular dystrophy caused by mutations in the POMGNT1 gene. It is associated with characteristic brain and eye malformations, profound mental retardation, and death usually in the first years of life.			Disease or Syndrome	Cellosaurus Disease Terminology
C126741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126741>	C99109	Muscular Dystrophy-Dystroglycanopathy (Congenital with Brain and Eye Anomalies) Type A, 4|MDDGA4	An autosomal recessive muscular dystrophy caused by mutations in the gene encoding fukutin (FKTN).  It is associated with characteristic brain and eye malformations, seizures, and mental retardation.			Disease or Syndrome	Cellosaurus Disease Terminology
C126742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126742>	C99109	Muscular Dystrophy-Dystroglycanopathy (Congenital with Brain and Eye Anomalies) Type A, 2|MDDGA2	An autosomal recessive muscular dystrophy caused by mutations in the POMT2 gene. It is associated with characteristic brain and eye malformations and profound mental retardation.			Disease or Syndrome	Cellosaurus Disease Terminology
C126743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126743>	C99109	Muscular Dystrophy-Dystroglycanopathy (Congenital with Brain and Eye Anomalies) Type A, 6|MDDGA6	An autosomal recessive muscular dystrophy caused by mutations in the LARGE gene. It is associated with characteristic brain and eye malformations, profound mental retardation, and death usually in the first years of life.			Disease or Syndrome	Cellosaurus Disease Terminology
C126744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126744>	C53543|C28193	Codas Syndrome	A rare syndrome caused by mutations in the LONP1 gene. It is characterized by developmental delay, cerebral, ocular, dental, auricular, and skeletal abnormalities.			Disease or Syndrome	Cellosaurus Disease Terminology
C126745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126745>	C84685	Emery-Dreifuss Muscular Dystrophy 2, Autosomal Dominant|EDMD2	Emery-Dreifuss muscular dystrophy inherited in an autosomal dominant pattern and caused by mutations in the LMNA gene.			Disease or Syndrome	Cellosaurus Disease Terminology
C126746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126746>	C53543|C34816	Congenital Disorder of Deglycosylation|CDDG	A rare autosomal recessive inherited disorder caused by mutations in the NGLY1 gene. It is characterized by developmental delay, hypotonia, abnormal involuntary movements, poor tear production, microcephaly, intractable seizures, abnormal eye movements, and liver abnormalities.			Disease or Syndrome	Cellosaurus Disease Terminology
C126747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126747>	C85865|C84392|C28193	Lubs X-Linked Intellectual Disability Syndrome|Lubs X-Linked Mental Retardation Syndrome|MECP2 Duplication Syndrome|MRXSL	An X-linked inherited syndrome caused by duplication or triplication of the gene encoding methyl-CpG-binding protein-2 (MECP2). It is characterized by mental retardation, infantile hypotonia, mild dysmorphic features, poor speech development, autistic features, seizures, progressive spasticity, and recurrent infections.			Disease or Syndrome	Cellosaurus Disease Terminology
C126748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126748>	C224902	Acute Myeloid Leukemia with FLT3/ITD Mutation|Acute Myeloid Leukemia (AML) with FLT3/ITD	Acute myeloid leukemia characterized by the presence of a FLT3-internal tandem duplication (ITD) mutation. Patients with this mutation usually present with more aggressive disease and have higher rates of relapse after remission.	Acute Myeloid Leukemia with FLT3/ITD		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C12674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12674>	C12680	Axilla|AXILLA|Armpit|Armpit|Underarm|arm pit|armpit|axilla|axilla|axillary region|regio axillaris	The underside concavity where the arm and the shoulder are joined.	Axilla		Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Radiation Therapy Table|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C126750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126750>	C8181	Oropharyngeal Poorly Differentiated Carcinoma|Poorly Differentiated Oropharyngeal Throat Cancer	A high-grade carcinoma that arises from the oropharynx. It is characterized by the presence of malignant cells which bear minimal resemblance to the cells from which they arose.	Oropharyngeal Poorly Differentiated Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C126751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126751>	C8181|C37290	Oropharyngeal Basaloid Squamous Cell Carcinoma|Oropharyngeal Basaloid Carcinoma|Oropharyngeal Basaloid Carcinoma	A high-grade variant of squamous cell carcinoma that arises from the oropharynx. It is characterized by the presence of small malignant cells with hyperchromatic nuclei and scant amount of cytoplasm forming lobules with peripheral palisading.	Oropharyngeal Basaloid Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C126752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126752>	C199379	Mobocertinib|AP 32788|AP-32788|AP32788|EGFR/HER2 Inhibitor TAK-788|MOBOCERTINIB|TAK 788|TAK-788|TAK788	An orally available inhibitor of human epidermal growth factor receptor (EGFR) exon 20 insertion mutations, with antineoplastic activity. Upon oral administration, mobocertinib, and its active metabolites, specifically and irreversibly binds to and inhibits exon 20 insertion mutations of EGFR. This prevents EGFR-mediated signaling and leads to cell death in tumor cells expressing exon 20 insertion mutations. In addition, mobocertinib may inhibit the activity of other EGFR family members, such as human epidermal growth factor receptor 2 (HER2; ERBB2) and HER4. EGFR, HER-2 and -4 are receptor tyrosine kinases often mutated in numerous tumor cell types. They play key roles in tumor cell proliferation and tumor vascularization.	Mobocertinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126753>	C37927	Aqua	A light bluish-green to light greenish-blue color.			Qualitative Concept	
C126754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126754>	C796	2,6-Dimethoxyquinone|2,5-Cyclohexadiene-1,4-Dione, 2,6-Dimethoxy-|2,5-Cyclohexadiene-1,4-Dione, 2,6-Dimethoxy- (9CI)|2,6-DIMETHOXYQUINONE|2,6-DMBQ|2,6-Dimethoxy-1,4-Benzoquinone|2,6-Dimethoxy-p-Benzoquinone|2,6-Dimethoxy-p-Quinone|2,6-Dimethoxybenzoquinone|2,6-Dimethoxycyclohexa-2,5-Diene-1,4-Dione|p-Benzoquinone, 2,6-Dimethoxy-	A methoxy-substituted benzoquinone and bioactive compound found in fermented wheat germ extracts, with potential antineoplastic and immune-enhancing activity. 2,6-Dimethoxyquinone (2,6-DMBQ) inhibits anaerobic glycolysis thereby preventing cellular metabolism and inducing apoptosis. As cancer cells use the anaerobic glycolysis pathway to metabolize glucose and cancer cells proliferate at an increased rate as compared to normal, healthy cells, this agent is specifically cytotoxic towards cancer cells. In addition, 2,6-DMBQ exerts immune-enhancing effects by increasing natural killer (NK) cell and T-cell activity against cancer cells.	2,6-Dimethoxyquinone		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C126755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126755>	C12537	Type 1 Regulatory T-Cell|T Regulatory Cell 1|Tr1|Tr1 Cell|Type 1 Regulatory T Cell|Type 1 Regulatory T Lymphocyte|Type 1 Regulatory T-Lymphocyte|Type 1 T reg|Type 1 Treg|Type-1 T Regulatory Cell	A population of CD4+, CD25-, and FoxP3- T-lymphocytes that are involved in immunotolerance. These cells secrete the immunosuppressive cytokines, tumor growth factor-beta (TGF-B) and interleukin-10, and may induce cell cycle arrest or apoptosis in effector T-cells.	Type 1 Regulatory T-Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C126756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126756>	C12470	Peristomal Skin|Healthy Peristomal Skin	The skin surrounding a stoma and on which the pouching system is placed.	Peristomal Skin		Anatomical Structure	CTRP Terminology
C126757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126757>	C16830	Double-Walled Airbag Breast Immobilization Device	A device that utilizes an inflatable double-walled airbag to establish and maintain the breast in a fixed and well-defined position during radiotherapy.	Double-Walled Airbag Breast Immobilization Device		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C126758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126758>	C20921	PRICKLE1 Gene|PRICKLE1|PRICKLE1|Prickle Planar Cell Polarity Protein 1 Gene	This gene is involved in gastrulation and the regulation of Wnt signaling.	PRICKLE1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126759>	C126758	PRICKLE1 wt Allele|EPM1B|FLJ31937|Prickle Homolog 1 (Drosophila) Gene|Prickle Planar Cell Polarity Protein 1 wt Allele|Prickle, Drosophila, Homolog of, 1 Gene|Prickle-Like 1 (Drosophila) Gene|RILP	Human PRICKLE1 wild-type allele is located in the vicinity of 12q12 and is approximately 134 kb in length. This allele, which encodes prickle-like protein 1, plays a role in the negative regulation of Wnt signaling and in embryonic development. Mutation of the gene is associated with progressive myoclonic epilepsy 1B.	PRICKLE1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12675>	C12712	Bartholin Gland|Bartholin's Gland	The two mucous secreting glands on either side of the vaginal opening.	Bartholin's Gland		Body Part, Organ, or Organ Component	Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C126760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126760>	C18515	Prickle-Like Protein 1|Prickle-Like 1|REST (RE-1 Silencing Transcription Factor)/NRSF (Neuron-Restrictive Silencer Factor)-Interacting LIM Domain Protein|REST-Interacting LIM Domain Protein|REST/NRSF Interacting LIM Domain Protein|REST/NRSF-Interacting LIM Domain Protein 1	Prickle-like protein 1 (831 aa, ~94 kDa) is encoded by the human PRICKLE1 gene. This protein is involved in embryonic morphology.	Prickle-Like Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126761>	C16615	CDX4 Gene|CDX4|CDX4|Caudal Type Homeobox 4 Gene	This gene plays a role in the modulation of gene expression during development.	CDX4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126762>	C126761	CDX4 wt Allele|Caudal Type Homeobox 4 wt Allele	Human CDX4 wild-type allele is located in the vicinity of Xq13.2 and is approximately 8 kb in length. This allele, which encodes homeobox protein CDX-4, is involved in the regulation of gene expression.	CDX4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126763>	C17207	Homeobox Protein CDX-4|Caudal Type Homeo Box Transcription Factor 4|Caudal-Type Homeo Box Transcription Factor 4|Caudal-Type Homeobox Protein 4	Homeobox protein CDX-4 (284 aa, ~30 kDa) is encoded by the human CDX4 gene. This protein plays a role in the regulation of embryonic development.	Homeobox Protein CDX-4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126764>	C154299	H2AZ1 Gene|H2A.Z Variant Histone Gene|H2AFZ|H2AFZ Gene|H2AZ1	This gene is involved in nucleosome formation.	H2AFZ Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126765>	C126764	H2AZ1 wt Allele|H2A Histone Family Member Z Gene|H2A Histone Family, Member Z Gene|H2A.Z Variant Histone wt Allele|H2A.Z-1|H2A.z|H2A/z|H2AFZ|H2AFZ wt Allele|H2AZ	Human H2AZ1 wild-type allele is located in the vicinity of 4q24 and is approximately 2 kb in length. This allele, which encodes histone H2A.Z protein, plays a role in chromatin packaging.	H2AFZ wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126766>	C16684	Histone H2A.Z|H2A.Z-1|H2A.Z.1|H2A.Z.1|H2A/z|H2AZ Histone|H2AZ1	Histone H2A.Z (128 aa, ~14 kDa) is encoded by the human H2AZ1 gene. This protein is involved in nucleosome and heterochromatin formation.	Histone H2A.Z		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C126767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126767>	C19851	GTF2A1 Gene Product	A protein encoded by the GTF2A1 gene.			Amino Acid, Peptide, or Protein	
C126768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126768>	C16830	Anesthesia Probe|Anesthesia probe|Ultrasound Probe for Anesthesia Procedure	An ultrasound probe suitable for use during an anesthesia procedure to facilitate the placement of local or regional anesthetics.			Medical Device	
C126769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126769>	C7558	Endometrial Dedifferentiated Carcinoma	A carcinoma that arises from the endometrium and is characterized by the presence of an undifferentiated carcinomatous component and a second component of either FIGO grade 1 or 2 endometrioid carcinoma.			Neoplastic Process	
C12676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12676>	C33353	Basilar Artery|BA|BASILAR ARTERY	An artery formed by the union of the two vertebral arteries at the posterior border of the pons then diverges at the anterior border forming the two superior and two posterior cerebral arteries.	Basilar Artery		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C126770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126770>	C42075	Dedifferentiated Malignant Infiltrate	A morphologic finding indicating the presence of a high grade undifferentiated malignant cellular infiltrate and a second component of a low grade malignant cellular infiltrate in a tissue sample.			Finding	
C126771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126771>	C6300|C3809	Uterine Corpus Neuroendocrine Neoplasm|Uterine Corpus Neuroendocrine Tumor	An epithelial neoplasm with neuroendocrine differentiation that arises from the uterine corpus. It includes neuroendocrine tumor G1 (carcinoid tumor), small cell carcinoma pulmonary type, and large cell neuroendocrine carcinoma.			Neoplastic Process	
C126772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126772>	C215422|C171033	Endometrial Large Cell Neuroendocrine Carcinoma	A high grade neuroendocrine carcinoma that arises from the endometrium. It is composed of large polygonal cells arranged in well-demarcated nests, trabeculae or cords with peripheral palisading.			Neoplastic Process	
C126773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126773>	C203250|C126771	Uterine Corpus Neuroendocrine Tumor G1|Uterine Corpus Carcinoid Tumor|Uterine Corpus Neuroendocrine Tumor Grade 1|Uterine Corpus Well Differentiated Neuroendocrine Tumor, Grade 1	A very rare, well-differentiated, low-grade neuroendocrine neoplasm that arises from the uterine corpus.			Neoplastic Process	
C126774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126774>	C20103	ROBO2 Gene|ROBO2|ROBO2|ROBO2|Roundabout Guidance Receptor 2 Gene	This gene plays a role in ligand binding, axon guidance and cell migration.	ROBO2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C126775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126775>	C126774	ROBO2 wt Allele|KIAA1568|Roundabout (Axon Guidance Receptor, Drosophila) Homolog 2 Gene|Roundabout Guidance Receptor 2 wt Allele|Roundabout, Axon Guidance Receptor, Homolog 2 (Drosophila) Gene|Roundabout, Axon Guidance Receptor, Homolog 2 Gene|Roundabout, Drosophila, Homolog of, 2 Gene|SAX3|SAX3, C. elegans, Homolog of, 2 Gene	Human ROBO2 wild-type allele is located in the vicinity of 3p12.3 and is approximately 1743 kb in length. This allele, which encodes roundabout homolog 2 protein, is involved in axon guidance, cell migration and ligand binding. Chromosomal anomalies, including t(Y;3)(p11;p12), that cause dominant-negative mutations in this gene are associated with vesicoureteral reflux.	ROBO2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126776>	C18106	Roundabout Homolog 2|ROBO2	Roundabout homolog 2 (1378 aa, ~151 kDa) is encoded by the human ROBO2 gene. This protein plays a role in cell migration, axon guidance and ligand binding.	Roundabout Homolog 2		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126777>	C20103	ROBO3 Gene|ROBO3|ROBO3|Roundabout Guidance Receptor 3 Gene	This gene is involved in neuronal cell shape.	ROBO3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126778>	C126777	ROBO3 wt Allele|FLJ21044|HGPPS|HGPS|Horizontal Gaze Palsy With Progressive Scoliosis Gene|RB-Inhibiting Gene 1|RBIG1|RIG1|Retinoblastoma Inhibiting Gene 1|Roundabout (Axon Guidance Receptor, Drosophila) Homolog 3 Gene|Roundabout Guidance Receptor 3 wt Allele|Roundabout, Axon Guidance Receptor, Homolog 3 (Drosophila) Gene|Roundabout, Axon Guidance Receptor, Homolog 3 Gene|Roundabout, Drosophila, Homolog of, 3 Gene|Scoliosis Gene	Human ROBO3 wild-type allele is located in the vicinity of 11q24.2 and is approximately 16 kb in length. This allele, which encodes roundabout homolog 3 protein, plays a role in axon guidance and neurite outgrowth. Mutation of the gene is associated with horizontal gaze palsy with progressive scoliosis.	ROBO3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126779>	C18106	Roundabout Homolog 3|ROBO3|Roundabout-Like Protein 3	Roundabout homolog 3 (1386 aa, ~148 kDa) is encoded by the human ROBO3 gene. This protein is involved in the modulation of neurite outgrowth and axon guidance.	Roundabout Homolog 3		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12677>	C12376	Intrahepatic Bile Duct|INTRAHEPATIC BILE DUCT|Intrahepatic bile duct|intrahepatic bile duct|intrahepatic bile duct	The bile ducts which are located within the liver. They include the small interlobular bile ducts, intrahepatic large bile ducts, and the intrahepatic portions of the left and right hepatic ducts.	Intrahepatic Bile Duct		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C126780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126780>	C96363	Endometrial Metaplasia	A morphologic finding indicating the alteration of the mature endometrial glandular epithelium to another that differs from that of normal endometrioid glands.			Finding	
C126781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126781>	C3824	Endometrial Lymphoma-Like Lesion|Endometrial Pseudolymphoma	Dense diffuse and superficial infiltration of the endometrium by lymphoid cells. It is typically seen in association with chronic endometritis.			Finding	
C126782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126782>	C20194	SLIT1 Gene|SLIT1|SLIT1|Slit Guidance Ligand 1 Gene	This gene plays a role in axon guidance and angiogenesis.	SLIT1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126783>	C126782	SLIT1 wt Allele|KIAA0813|MEGF4|SLIL1|SLIT-1|SLIT3|Slit (Drosophila) Homolog 1 Gene|Slit Guidance Ligand 1 wt Allele|Slit Homolog 1 (Drosophila) Gene|Slit, Drosophila, Homolog of, 1 Gene	Human SLIT1 wild-type allele is located within 10q23.3-q24 and is approximately 188 kb in length. This allele, which encodes slit homolog 1 protein, is involved in both angiogenesis and axon guidance.	SLIT1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126784>	C18466	Slit Homolog 1 Protein|Multiple EGF-Like Domains Protein 4|Multiple Epidermal Growth Factor-Like Domains Protein 4|Slit Homolog 1|Slit-1	Slit homolog 1 protein (1534 aa, ~168 kDa) is encoded by the human SLIT1 gene. This protein plays a role in the development of blood vessels and the differentiation of neurons.	Slit Homolog 1 Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126785>	C20194	SLIT2 Gene|SLIT2|SLIT2|Slit Guidance Ligand 2 Gene	This gene is involved in cell migration and nervous system development.	SLIT2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126786>	C126785	SLIT2 wt Allele|SLIL3|Slit (Drosophila) Homolog 2 Gene|Slit Guidance Ligand 2 wt Allele|Slit Homolog 2 (Drosophila) Gene|Slit, Drosophila, Homolog of, 2 Gene|Slit-2	Human SLIT2 wild-type allele is located in the vicinity of 4p15.2 and is approximately 369 kb in length. This allele, which encodes slit homolog 2 protein, plays a role in both nervous system development and cell migration.	SLIT2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126787>	C18466	Slit Homolog 2 Protein|Slit Homolog 2|Slit-2	Slit homolog 2 protein (1529 aa, ~170 kDa) is encoded by the human SLIT2 gene. This protein is involved in the modulation of cell migration and the development of the nervous system.	Slit Homolog 2 Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126788>	C20194	SLIT3 Gene|SLIT3|SLIT3|Slit Guidance Ligand 3 Gene	This gene plays a role in the regulation of cell migration.	SLIT3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126789>	C126788	SLIT3 wt Allele|KIAA0814|MEGF5|SLIL2|SLIT1|Slit (Drosophila) Homolog 3 Gene|Slit Guidance Ligand 3 wt Allele|Slit Homolog 3 (Drosophila) Gene|Slit, Drosophila, Homolog of, 3 Gene|Slit-3|UNQ691/PRO1336|slit2	Human SLIT3 wild-type allele is located in the vicinity of 5q35 and is approximately 640 kb in length. This allele, which encodes slit homolog 3 protein, is involved in cell migration.	SLIT3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12678>	C13018	Biliary Tract|BILIARY TRACT|Bile Tract|Biliary System|Biliary tract, NOS|Tract, Biliary|biliary system|biliary tract	The system that transports bile from the hepatocytes in the liver to the small intestine. It is comprised of the intrahepatic bile ducts, hepatic ducts, common bile duct, cystic duct, and the gallbladder.	Biliary Tract		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C126790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126790>	C18466	Slit Homolog 3 Protein|Multiple EGF-Like Domains Protein 5|Multiple Epidermal Growth Factor-Like Domains Protein 5|Slit Homolog 3|Slit-3	Slit homolog 3 protein (1523 aa, ~168 kDa) is encoded by the human SLIT3 gene. This protein plays a role in the modulation of cell migration.	Slit Homolog 3 Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126791>	C172200	Ruxolitinib Phosphate Cream|INCB018424 Phosphate Cream	A topical cream formulation containing the phosphate salt form of ruxolitinib, a bioavailable Janus-associated kinase (JAK) inhibitor, with potential immunomodulating activity. Upon topical administration of the ruxolitinib phosphate cream, ruxolitinib specifically binds to and inhibits the protein tyrosine kinases JAK 1 and 2; this inhibits signal transduction pathways of various cytokines and reduces inflammation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling pathways initiated by many cytokines and growth factors; JAK kinases are upregulated in various inflammatory and autoimmune diseases, including alopecia areata.	Ruxolitinib Phosphate Cream		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology
C126792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126792>	C168794	Busulfan/Melphalan Regimen|BuMel|BuMel Regimen|Busulfan and Melphalan|Busulfan-Melphalan Regimen	A regimen composed of busulfan and melphalan used as a conditioning regimen for stem cell transplantation (SCT).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|NCI Drug Dictionary Terminology|Pharmacotherapy Regimens
C126793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126793>	C93221	Kava-based Supplement|AB-free Kava|Flavokavain A/Flavokavain B-free Kava Supplement|Flavokavains A and B-free Kava Supplement|Flavokavains A/B-free Kava Supplement|Kava Supplement|Kavalactones-based Supplement	A Kava supplement derived from Piper methysticum and containing high amounts of kavalactones, with potential cancer preventative and anxiolytic activities and that may be used to facilitate tobacco cessation. Upon oral administration, the kava-based supplement may affect the metabolism of certain carcinogens, presumably because of the kavalactones present in this product. This increases detoxification of the carcinogens and may suppress carcinogen-induced DNA damage and may lower the risk of carcinogenesis. Intake of the kava-based supplement may also suppress stress-mediated protein kinase A (PKA) activation, and reduces plasma cortisol levels. This may induce relaxation, may relief stress and anxiety, improve sleep, and may help reduce tobacco use and tobacco dependence, and may ultimately decrease the risk of tobacco-associated lung carcinogenesis. The Kava-based supplement is free of flavokavains A and B, which are potential hepatotoxic ingredients in kava.	Kava-based Supplement		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C126794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126794>	C20401|C129822	Anti-LGR5 Monoclonal Antibody BNC101|BNC-101|BNC101|ET-101	A humanized monoclonal antibody targeting leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), with potential antineoplastic activity. Upon administration, the anti-LGR5 humanized monoclonal antibody BNC101 targets and binds to LGR5, thereby inhibiting LRG5-mediated signal transduction pathways. This prevents proliferation of LRG5-expressing tumor cells. LGR5, a member of the Wnt signaling pathway, is a cancer stem cell (CSC) receptor overexpressed on certain cancer cells; it plays a key role in CSC proliferation and survival.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126795>	C78275|C129986	Wu-ling-San|Hoelen Five Herb Formula|Poria Five Powder|Powder of Five Drugs with Poria|WLS|WLS Formula|Wu Ling Pian|Wu Ling San|Wu Ling Wan|Wuling San	A traditional Chinese medicine (TCM) composed of Polyporus sclerotium (Sclerotium polypori Umbrellati; Zhu Ling), Sclerotium Poriae Cocos (Poria; Fu Ling), Alismatis rhizome (Alisma; Rhizoma Alismatis Orientalis; Ze Xie), Cinnamomi cortex (Ramulus Cinnamomi Cassiae; Gui Zhi) and Atractylodis macrocephalae rhizome (Rhizoma Atractylodis Macrocephalae; Bai Zhu) with potential diuresis-inducing and kidney protective activities. Upon oral administration, wu-ling san may increase the removal of excess fluid, prevent the retention of water, maintain healthy water metabolism by promoting diuresis, and protect kidney function.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C126796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126796>	C29730	Balanced Crystalloid Solution|PLASMALYTE A|Plasma-Lyte A|PlasmaLyte-A|Sodium Chloride/Sodium Gluconate/Sodium Acetate/Potassium Chloride/Magnesium Chloride Solution	A multiple electrolyte, isotonic, crystalloid solution for intravenous infusion containing sodium chloride, sodium gluconate, sodium acetate, potassium chloride and magnesium chloride, which can restore electrolyte balance, normalize pH, and provide hydration. Upon intravenous administration, the balanced crystalloid solution will replace lost body fluids and electrolytes thereby providing hydration, normalizing electrolyte concentrations and regulating acid-base balance.			Inorganic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C126797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126797>	C28310	Autologous Tumor-associated Peptide Antigen-pulsed Dendritic Cell Vaccine|Autologous TAPA loaded DC Vaccine|Autologous TAPA-pulsed DC Vaccine KiroVAX|Autologous Tumor Associated Peptide Antigen-pulsed DC Vaccine KiroVAX|KiroVAX	A dendritic cell (DC)-based cancer vaccine composed of autologous DCs pulsed with specific tumor-associated peptide antigens (TAPA), with potential immunostimulatory and antineoplastic activities. Upon administration, autologous TAPA-pulsed DC vaccine exposes the immune system to the specific TAPAs, which may result in cytotoxic T-lymphocyte (CTL)-mediated immune responses against the TAPA-expressing cancer cells. This leads to cancer cell lysis. This vaccine is specific towards peptides derived from the following proteins: sperm autoantigenic protein 17 (SP17), ropporin, A-kinase anchor protein 4 (AKAP4), pituitary tumor-transforming 1 (PTTG1) and SPANX family member B (SPANX-B).			Cell|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126798>	C25995|C129825	Pidnarulex|2-(4-Methyl-1,4-diazepan-1-yl)-N-((5-methylpyrazin-2-yl)methyl)-5-oxo-5H-benzo[4,5]thiazolo[3,2-a][1,8]naphthyridine-6-carboxamide|2-(4-Methyl-1,4-diazepan-1-yl)-N-[(5-methylpyrazin-2-yl)methyl]-5-oxo-[1,3]benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide|5H-Benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide, 2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-N-[(5-methyl-2-pyrazinyl)methyl]-5-oxo-|CX-5461|CX5461|PIDNARULEX|Pol I Inhibitor CX5461|RNA Pol I Inhibitor CX5461	An orally bioavailable inhibitor of RNA polymerase I (Pol I), with potential antineoplastic activity. Upon oral administration, pidnarulex selectively binds to and inhibits Pol I, prevents Pol I-mediated ribosomal RNA (rRNA) synthesis, induces apoptosis, and inhibits tumor cell growth. Pol I, the multiprotein complex that synthesizes rRNA, is upregulated in cancer cells and plays a key role in cell proliferation and survival. Hyperactivated rRNA transcription is associated with uncontrolled cancer cell proliferation.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126799>	C129822|C128037	Dostarlimab|ANB011|DOSTARLIMAB|Dostarlimab-gxly|Immunoglobulin G4, Anti-programmed Cell Death Protein 1 (PDCD1) (Humanized Clone ABT1 Gamma4-chain), Disulfide with Humanized Clone ABT1 Kappa-chain, Dimer|Jemperli|TSR 042|TSR-042|TSR042	A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, dostarlimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells. PD-1, a transmembrane protein in the Ig superfamily expressed on T-cells, functions as an immune checkpoint protein that negatively regulates T-cell activation and T-cell-mediated immune responses when activated by its ligands programmed cell death receptor ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.	Dostarlimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12679>	C25762	Blood Vessel|BLOOD VESSEL|Human Blood Vessel|VESSEL, BLOOD|Vessel|blood vessel|blood vessel	A tubular structure through which the blood circulates in the body. Blood vessels constitute a network composed of arteries, arterioles, capillaries, venules, and veins.	Blood Vessel		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology|FDA Structured Product Labeling Terminology|GDC Terminology|GDC Value Terminology|SPL Tissue Form Product Type Terminology|UBERON Terminology
C1267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1267>	C1910	Triptorelin|6-D-Tryptophan-LH-RH|6-D-Tryptophanluteinizing Hormone-releasing Factor|AY 25650|AY-25650|AY25650|CL 118532|CL-118,532|CL-118532|CL118532|Detryptoreline|TRIPTORELIN|triptorelin	A synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH).  Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men. (NCI04)	Triptorelin		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C126800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126800>	C129821	CEBPA-targeting saRNA MTL-CEBPA Liposome|MTL-501|MTL-CEBPA	A lipid-based nanoparticle formulation composed of liposomes encapsulating a small oligonucleotide encoding a small activating RNA (saRNA) targeting the CCAAT enhancer binding protein alpha (CEBPA; C/EBP-a) gene, with potential antineoplastic activity. Although the exact mechanism of action through which saRNAs exert their effect(s) is still largely being investigated, it appears that, upon administration, the CEBPA-targeting saRNA MTL-CEBPA liposome targets and binds to a specific DNA regulatory target region, most likely the promoter region, for the CEBPA gene. This restores CEBPA gene transcription, and increases both CEBPA mRNA levels and protein expression. This in turn activates the expression of tumor suppressor genes and may halt proliferation of susceptible tumor cells. Specifically, upregulation of CEBPA in liver cells abrogates liver cancer cell proliferation, thereby prevents liver failure and normalizes liver function. CEBPA, a transcription factor that plays a key role in the regulation of the expression of genes with many functions, including those involved in cellular proliferation, metastasis and normal hepatocyte function, is found in many tissues, including liver cells, adipose tissue and myeloid cells. CEBPA is downregulated in certain types of cancer cells, such as liver cancer cells. saRNA is a short, double-stranded RNA that is structurally related to siRNAs; saRNA is most likely to bind to a target site on the promoter of the CEBPA gene and upregulates its gene expression.	CEBPA-targeting saRNA MTL-CEBPA Liposome		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126801>	C200766	EpCAM-specific CAR-expressing Autologous T-lymphocytes|EpCAM-specific CAR Autologous T-cells	A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the antigen epithelial cell adhesion molecule (EpCAM), with potential immunostimulating and antineoplastic activities. Upon administration, the EpCAM-specific CAR-expressing autologous T-lymphocytes specifically recognize and bind to EpCAM-expressing tumor cells, resulting in tumor cell lysis. EpCAM, a cell surface protein, is expressed by a variety of tumor cells.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126802>	C1420	Phytochlorin Sodium-Polyvinylpyrrolidone Complex|BLC-1013|Chlorin E6-PVP|Chlorin E6-polyvinylpyrrolidone|Chlorin E6/PVP|Fotolon|Photolon	A photosensitizer composed of the sodium salt form of chlorin e6 and its derivatives complexed with a low-molecular weight polyvinylpyrrolidone (PVP) polymer component, with diagnostic and antineoplastic activities upon photodynamic therapy (PDT). Upon intravenous administration, the photosensitizer phytochlorin-PVP sodium complex preferentially accumulates in hyperproliferative tissues, such as tumors. Local application of light with a certain wavelength to the tumor site results in the absorption of light by this agent leading to its photoactivation. This results in a photodynamic reaction between phytochlorin and oxygen, which causes the production of reactive oxygen species (ROS), including singlet oxygen molecules, the superoxide ion, and other cytotoxic free radicals. The formation of ROS induces free radical-mediated oxidative DNA damage followed by apoptosis of tumor cells. Chlorin e6-PVP is able to penetrate deeply into tissues and is therefore able to treat hard-to-reach tumors.	Phytochlorin Sodium-Polyvinylpyrrolidone Complex		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126803>	C82130	Tris-acryl Gelatin Microspheres|Embospheres|TAGM|Trisacryl Gelatin Microspheres	An embolic particle composed of water-soluble, compressible, nonabsorbable microspheres composed of tris-acryl gelatin, with potential use for embolization. Upon administration, the tris-acryl gelatin microspheres (TAGM) serve as an embolic agent before surgery for highly vascularized areas, such as those seen in certain tumors, by penetrating into the blood vessel system and blocking blood flow. These microspheres may be used to encapsulate various therapeutic agents; drug-loaded microspheres can then be used as drug delivery vehicles during embolization of tumor vasculature.	Tris-acryl Gelatin Microspheres		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126804>	C141145	Feladilimab|Anti-ICOS Agonist Antibody GSK3359609|FELADILIMAB|GSK3359609	An agonistic antibody for the inducible T-cell co-stimulator (ICOS; CD278), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, feladilimab targets and binds to ICOS expressed on tumor infiltrating CD4-positive T-cells. This stimulates ICOS-positive T-cell proliferation, enhances cytotoxic T-lymphocyte (CTL) survival and increases CTL-mediated immune responses against tumor cells. ICOS, a T-cell specific, CD28-superfamily costimulatory molecule and immune checkpoint protein, is normally expressed on certain activated T-cells and plays a key role in the proliferation and activation of T-cells.	Feladilimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126805>	C128462	BET Bromodomain Inhibitor ZEN-3694|BETi ZEN-3694|ZEN 3694|ZEN-3694|ZEN-3694|ZEN003694	An orally bioavailable inhibitor of the bromodomain and extra-terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, the BET inhibitor ZEN-3694 binds to the acetylated lysine recognition motifs in the bromodomains of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of proliferation in BET-overexpressing tumor cells. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.	BET Bromodomain Inhibitor ZEN-3694		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126806>	C27701	Post-Essential Thrombocythemia Myelofibrosis|Myelofibrosis Transformation in Essential Thrombocythemia|Myelofibrosis Transformation in Essential Thrombocythemia|Post-ET MF|Post-ET Myelofibrosis	Myelofibrosis that develops in a patient with history of essential thrombocythemia.	Myelofibrosis Transformation in Essential Thrombocythemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C126807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126807>	C19254	Coroner	An appointed public official whose job is to identify and certify an individual's death.			Biomedical Occupation or Discipline	
C126808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126808>	C19254	Medical Examiner|ME	A physician, usually a forensic pathologist by training, whose job is to determine the cause of an individual's death and perform autopsies.			Biomedical Occupation or Discipline	
C126809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126809>	C92809	Glucocorticoid Resistance|Chrousos Syndrome|Generalized Glucocorticoid Resistance	An autosomal dominant condition due to mutation(s) in the NR3C1 gene, encoding the glucocorticoid receptor, resulting in decreased receptor affinity to glucocorticoids. Compensatory activation of the hypothalamic- pituitary-adrenal (HPA) axis results in increased mineralocorticoid and androgen production; clinical manifestations of glucocorticoid deficiency are rare.			Finding	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C12680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12680>	C12219	Body Region|Anatomic Region	Named areas of the body.	Body Region		Body Location or Region	
C126810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126810>	C92809	Hyponatremic Mineralocorticoid Resistance due to Mineralocorticoid Receptor Defect|PHA1AD|Pseudohypoaldosteronism Type I Autosomal Dominant	An autosomal dominant condition presenting with hyponatremia and hyperkalemia, mimicking low concentrations of aldosterone, associated with loss-of-function mutation(s) in the NR3C2 gene, encoding the mineralocorticoid receptor.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C126811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126811>	C92809	Hyponatremic Mineralocorticoid Resistance due to Urinary Tract Infection|Mineralocorticoid Resistance due to UTI|Secondary PHA due to UTI	A transient condition associated with urinary tract infections in infants presenting with hyponatremia and hyperkalemia, mimicking low concentrations of aldosterone.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C126812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126812>	C92809	Hyperkalemic Mineralocorticoid Resistance|Chloride Shunt Syndrome|Familial Hyperkalemic Hypertension|Gordon Hyperkalemia|Mineralocorticoid Resistant Hyperkalemia|PHA Type 2|Pseudohypoaldosteronism, Type II|Spitzer-Weinstein Syndrome	A genetically heterogenous condition characterized by hyperkalemia, hyperchloremic acidosis, low or suppressed renin activity, and normal to high concentrations of aldosterone. Mutations in genes (for example WNK1 or WNK4), regulating Na-Cl cotransporters (NCC), Na-K-Cl cotransporters (NKCC2), or the renal outer medullary potassium (ROMK) channel have been identified as causative in this condition. The primary abnormality is thought to be a specific defect of the renal secretory mechanism for potassium, which limits the kaliuretic response to, but not the sodium and chloride reabsorptive effect of, mineralocorticoid.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C126813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126813>	C113206	Aldosterone Synthase Deficiency|Corticosterone Methyl Oxidase Deficiency	An autosomal recessive condition due to mutation(s) in the CYP11B2 gene that results in decreased activity of mitochondrial cytochrome P450 11B2 with reduced aldosterone synthesis and salt wasting.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C126814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126814>	C126813	Aldosterone Synthase Deficiency Type 1|CMO Type 1|Corticosterone Methyl Oxidase Deficiency Type 1	Aldosterone synthase deficiency characterized by decreased conversion of corticosterone to 18-hydroxycorticosterone.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C126815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126815>	C126813	Aldosterone Synthase Deficiency Type 2|CMO Type 2|Corticosterone Methyl Oxidase Deficiency Type 2	Aldosterone synthase deficiency characterized by decreased conversion of 18-hydroxycorticosterone to aldosterone.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C126816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126816>	C113206	Hyporeninenmic Hypoaldosteronism|Hyporeninemic Hypoaldosteronism	Hypoaldosteronism characterized by hyperkalemia and inappropriately low renin activity. This condition may be caused by a primary renal disorder, drugs or autoimmune processes.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C126817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126817>	C113206	Hyperreninemic Hypoaldosteronism	Hypoaldosteronism characterized by impaired secretion of aldosterone, despite increased renin activity. This condition may be caused by chronic or critical illness, aldosterone synthase deficiency or other genetic conditions.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C126818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126818>	C136635|C116396	KIT NM_000222.2:c.2447A>T|CD117 c.2447A>T|KIT Proto-Oncogene Tyrosine Protein Kinase c.2447A>T|KIT c.2447A>T|NM_000222.2:c.2447A>T|V-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.2447A>T|c-KIT c.2447A>T	A nucleotide substitution at position 2447 of the coding sequence of the KIT gene where adenine has been mutated to thymine.	KIT NM_000222.2:c.2447A>T		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126819>	C97928	KIT Protein Variant|CD117 Antigen Protein Variant|Mast/Stem Cell Growth Factor Receptor Kit Protein Variant|Proto-Oncogene Tyrosine-Protein Kinase Kit Protein Variant|Proto-Oncogene c-Kit Protein Variant|Stem Cell Factor Receptor Protein Variant|Tyrosine-Protein Kinase Kit Protein Variant|c-KIT Protein Variant	A variation in the amino acid sequence for the mast/stem cell growth factor receptor Kit protein.	KIT Protein Variant		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C12681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12681>	C12372	Brachial Artery|ARTERY, BRACHIAL|BRACHIAL ARTERY|Brachial|Brachial artery	An artery originating at the axillary artery and branching into the radial and ulnar arteries.	Brachial Artery		Body Part, Organ, or Organ Component	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|Appendix 9: Therapeutic and Supportive Procedures for COVID-19 Terminology|CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Invasive Coronary/Vascular/Neurovascular Revascularization Treatment Terminology
C126820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126820>	C126819	KIT NP_000213.1:p.D816V|CD117 Antigen Asp816Val|CD117 Antigen D816V|KIT Asp816Val|KIT D816V|KIT NP_000213.1:p.Asp816Val|KIT p.Asp816Val|KIT p.D816V|Mast/Stem Cell Growth Factor Receptor Kit Asp816Val|Mast/Stem Cell Growth Factor Receptor Kit D816V|NP_000213.1:p.Asp816Val|NP_000213.1:p.D816V|Proto-Oncogene Tyrosine-Protein Kinase Kit Asp816Val|Proto-Oncogene Tyrosine-Protein Kinase Kit D816V|Proto-Oncogene c-Kit Asp816Val|Proto-Oncogene c-Kit D816V|Stem Cell Factor Receptor Asp816Val|Stem Cell Factor Receptor D816V|Tyrosine-Protein Kinase Kit Asp816Val|Tyrosine-Protein Kinase Kit D816V|c-KIT Asp816Val|c-KIT D816V|c-KIT p.Asp816Val|c-KIT p.D816V|cKIT D816V Mutation	A change in the amino acid residue at position 816 in the mast/stem cell growth factor receptor Kit protein where aspartic acid has been replaced by valine.	KIT NP_000213.1:p.D816V		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126821>	C97927	MPL Gene Mutation|CD110 Gene Mutation|MPL|MPL Proto-Oncogene, Thrombopoietin Receptor Gene Mutation|Myeloproliferative Leukemia Virus Oncogene Gene Mutation|TPOR Gene Mutation|c-MPL Gene Mutation	A change in the nucleotide sequence of the MPL gene.	MPL Gene Mutation		Cell or Molecular Dysfunction	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126822>	C126821	MPL NM_005373.2:c.1544G>T|CD110 c.1544G>T|MPL Proto-Oncogene, Thrombopoietin Receptor c.1544G>T|MPL c.1544G>T|Myeloproliferative Leukemia Virus Oncogene c.1544G>T|NM_005373.2:c.1544G>T|TPOR c.1544G>T|c-MPL c.1544G>T	A nucleotide substitution at position 1544 of the coding sequence of the MPL gene where guanine has been mutated to thymine.	MPL NM_005373.2:c.1544G>T		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126823>	C97928	MPL Protein Variant|CD110 Antigen Protein Variant|Myeloproliferative Leukemia Protein Protein Variant|Proto-Oncogene c-Mpl Protein Variant|TPO-R Protein Variant|Thrombopoietin Receptor Protein Variant|c-MPL Protein Variant	A variation in the amino acid sequence for the thrombopoietin receptor protein.	MPL Protein Variant		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126824>	C126823	MPL NP_005364.1:p.W515L|CD110 Antigen Trp515Leu|CD110 Antigen W515L|MPL NP_005364.1:p.Trp515Leu|MPL Trp515Leu|MPL W515L|MPL p.Trp515Leu|MPL p.W515L|Myeloproliferative Leukemia Protein Trp515Leu|Myeloproliferative Leukemia Protein W515L|NP_005364.1:p.Trp515Leu|NP_005364.1:p.W515L|Proto-Oncogene c-Mpl Trp515Leu|Proto-Oncogene c-Mpl W515L|TPO-R Trp515Leu|TPO-R W515L|Thrombopoietin Receptor Trp515Leu|Thrombopoietin Receptor W515L|c-MPL Trp515Leu|c-MPL W515L|c-MPL p.Trp515Leu|c-MPL p.W515L	A change in the amino acid residue at position 515 in the thrombopoietin receptor protein where tryptophan has been replaced by leucine.	MPL NP_005364.1:p.W515L		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126825>	C126823	MPL NP_005364.1:p.W515K|CD110 Antigen Trp515Lys|CD110 Antigen W515K|MPL NP_005364.1:p.Trp515Lys|MPL Trp515Lys|MPL W515K|MPL p.Trp515Lys|MPL p.W515K|Myeloproliferative Leukemia Protein Trp515Lys|Myeloproliferative Leukemia Protein W515K|NP_005364.1:p.Trp515Lys|NP_005364.1:p.W515K|Proto-Oncogene c-Mpl Trp515Lys|Proto-Oncogene c-Mpl W515K|TPO-R Trp515Lys|TPO-R W515K|Thrombopoietin Receptor Trp515Lys|Thrombopoietin Receptor W515K|c-MPL Trp515Lys|c-MPL W515K|c-MPL p.Trp515Lys|c-MPL p.W515K	A change in the amino acid residue at position 515 in the thrombopoietin receptor protein where tryptophan has been replaced by lysine.	MPL NP_005364.1:p.W515K		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126826>	C126821	MPL NM_005373.2:c.1543_1544delinsAA|CD110 c.1543_1544TG>AA|MPL NM_005373.2:c.1543_1544TG>AA|MPL NM_005373.2:c.1543_1544delTGinsAA|MPL NM_005373.2:c.1543_1544delTGinsAA|MPL Proto-Oncogene, Thrombopoietin Receptor c.1543_1544TG>AA|MPL c.1543_1544TG>AA|Myeloproliferative Leukemia Virus Oncogene c.1543_1544TG>AA|NM_005373.2:c.1543_1544TG>AA|NM_005373.2:c.1543_1544delTGinsAA|NM_005373.2:c.1543_1544delinsAA|TPOR c.1543_1544TG>AA|c-MPL c.1543_1544TG>AA	A complex substitution where the nucleotide sequence at positions 1543 and 1544 of the coding sequence of the MPL gene has changed from thymine-guanine to adenine-adenine.	MPL NM_005373.2:c.1543_1544delTGinsAA		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126827>	C126821	MPL NM_005373.2:c.1543_1545delinsAAA|CD110 c.1543_1544TGG>AAA|MPL NM_005373.2:c.1543_1545TGG>AAA|MPL NM_005373.2:c.1543_1545delTGG>insAAA|MPL NM_005373.2:c.1543_1545delTGGinsAAA|MPL Proto-Oncogene, Thrombopoietin Receptor c.1543_1544TGG>AAA|MPL c.1543_1545TGG>AAA|Myeloproliferative Leukemia Virus Oncogene c.1543_1544TGG>AAA|NM_005373.2: c.1543_1544TGG>AAA|NM_005373.2:c.1543_1545delTGG>insAAA|NM_005373.2:c.1543_1545delinsAAA|TPOR c.1543_1544TGG>AAA|c-MPL c.1543_1544TGG>AAA	A complex substitution where the nucleotide sequence at positions 1543 and 1545 of the coding sequence of the MPL gene has changed from thymine-guanine-guanine to adenine-adenine-adenine.	MPL NM_005373.2:c.1543_1545delTGG>insAAA		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126828>	C25161	GAIA Level of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Level of Diagnostic Certainty	A classification of maternal and fetal outcomes developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C126829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126829>	C97927|C48301	SDHA Gene Mutation|Succinate Dehydrogenase Complex Flavoprotein Subunit A Gene Mutation|Succinate Dehydrogenase Complex, Subunit A, Flavoprotein (Fp) Gene Mutation	A change in the nucleotide sequence of the SDHA gene.	SDHA Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12682>	C49601	Brachial Plexus|BRACHIAL PLEXUS|Brachial plexus structure (body structure)|NERVE, BRACHIAL PLEXUS|brachial plexus	A nerve network originating from C5 to T1 that supplies cutaneous and muscular innervation to the arm and hand.	Brachial Plexus		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C126830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126830>	C126828	GAIA Neonatal Case Definitions|Global Alignment of Immunization safety Assessment in pregnancy Neonatal Case Definitions	A set of terms and defintions created by the Global Alignment of Immunization safety Assessment in pregnancy that are related to the neonatal effects of immunizations.			Classification	
C126831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126831>	C126829	SDHA NM_004168.3:c.1660C>T|NM_004168.3:c.1660C>T|SDHA c.1660C>T|Succinate Dehydrogenase Complex Flavoprotein Subunit A c.1660C>T|Succinate Dehydrogenase Complex, Subunit A, Flavoprotein (Fp) c.1660C>T	A nucleotide substitution at position 1660 of the coding sequence of the SDHA gene where cytosine has been mutated to thymine.	SDHA NM_004168.3:c.1660C>T		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126832>	C97928	SDHA Protein Variant|Succinate Dehydrogenase [Ubiquinone] Flavoprotein Subunit, Mitochondrial Protein Variant	A variation in the amino acid sequence for the succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial protein.	SDHA Protein Variant		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126833>	C126832	SDHA NP_004159.2:p.R554W|NP_004159.2:p.Arg554Trp|NP_004159.2:p.R554W|SDHA Arg554Trp|SDHA NP_004159.2:p.Arg554Trp|SDHA R554W|SDHA p.Arg554Trp|SDHA p.R554W|Succinate Dehydrogenase [Ubiquinone] Flavoprotein Subunit, Mitochondrial Arg554Trp|Succinate Dehydrogenase [Ubiquinone] Flavoprotein Subunit, Mitochondrial R554W	A change in the amino acid sequence at position 544 of the the succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial protein where arginine has been replaced by tryptophan.	SDHA NP_004159.2:p.R554W		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126834>	C126828	GAIA Obstetric Case Definitions|Global Alignment of Immunization safety Assessment in pregnancy Obstetric Case Definitions	A set of terms and defintions created by the Global Alignment of Immunization safety Assessment in pregnancy that are related to the maternal effects of immunizations.			Classification	
C126835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126835>	C97927	DRD2 Gene Mutation|Dopamine Receptor D2 Gene Mutation	A change in the nucleotide sequence of the DRD2 gene.	DRD2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126836>	C159659	Hematopoietic Cell Transplant Recipient|Hematopoietic Cell Transplantation Recipient|Hematopoietic Cell Transplantation Recipient	An individual receiving a hematopoietic cell transplant.	Hematopoietic Cell Transplantation Recipient		Human	CTRP Intervention Terminology|CTRP Terminology
C126837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126837>	C126835	DRD2 NM_000795.3:c.957C>T|DRD2 957T Indel Mutation|DRD2 C957T Indel Mutation|DRD2 c.957C>T|Dopamine Receptor D2 c.957C>T|NM_000795.3:c.957C>T	A nucleotide substitution at position 957 of the coding sequence of the DRD2 gene where cytosine has been mutated to thymine.	DRD2 NM_000795.3:c.957C>T		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126838>	C190205|C126835	DRD2 NM_000795.3:c.-486_-485insC|DRD2 -141 indel|DRD2 -141C Ins/Del|DRD2 -141insC Mutation|DRD2 c.-486_-485insC|Dopamine Receptor D2 c.-486_-485insC|NM_000795.3:c.-486_-485insC	A nucleotide insertion of a cytosine between positions -486 and -485 in the 5' promoter region of the DRD2 gene.	DRD2 NM_000795.3:c.-486_-485insC		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126839>	C70785	Study Site Temporarily Closed to Accrual and Intervention|Suspended	Trial is temporarily not accruing and patients are not receiving therapy/intervention.			Qualitative Concept	
C12683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12683>	C13037	Bronchus|BRONCHUS|Bronchi|Bronchi|Bronchial structure (body structure)|bronchi|bronchi|bronchial trunk|bronchus|bronchus	Tubular structure in continuation with the trachea, serving as air passage. It terminates in the lung (terminal bronchiole).	Bronchus		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C126840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126840>	C308	IL-10 Immunomodulator MK-1966|MK 1966|MK-1966	An agent that downregulates the activity of the anti-inflammatory cytokine human interleukin-10 (IL-10), with potential immunomodulating and antineoplastic activities. Upon administration, IL-10 immunomodulator MK-1966 blocks the activity of IL-10 and may abrogate the IL-10-induced immunosuppressive tumor microenvironment. This activates cell-mediated immunity against cancer cells, increases cytokine production, including interferon-gamma (IFN-g), decreases T regulatory cell (Treg) activity, and induces a tumor-specific cytotoxic CD8+ T-cell-mediated immune response, which enhances tumor cell death.	IL-10 Immunomodulator MK-1966		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126841>	C20401|C129822	Ordesekimab|AMG 714|AMG714|Anti-IL-15 Monoclonal Antibody AMG 714|HUMAX-IL 15|HuMab-IL15 AMG 714|ORDESEKIMAB	A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human pro-inflammatory cytokine interleukin-15 (IL-15), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon administration, ordesekimab binds to and neutralizes IL-15, thereby preventing IL-15-mediated pro-inflammatory signaling. By inhibiting IL-15-mediated immune responses, ordesekimab decreases natural killer (NK) cell activation and proliferation, reduces T-cell infiltration, increases T-cell apoptosis, and may prevent the growth of IL-15-driven cancer cells. IL-15 plays a key role in inflammation and is associated with a variety of autoimmune and inflammatory disorders as well as with cell proliferation in certain cancer types, such as T-cell lymphomas. IL-15 is required for the proliferation of certain T-cells and NK cells.	Ordesekimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126842>	C126830	GAIA Major Congenital Anomalies Level of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Major Congenital Anomalies Level of Diagnostic Certainty|Major Congenital Anomalies Level of Diagnostic Certainty	A classification of maternal and fetal outcomes relating to major congenital anomalies, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C126843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126843>	C126830	GAIA Neonatal Death Level of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Neonatal Death Level of Diagnostic Certainty|Neonatal Death Level of Diagnostic Certainty	A classification of maternal and fetal outcomes relating to neonatal death, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C126844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126844>	C126830	GAIA Neonatal Infections Level of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Neonatal Infections Level of Diagnostic Certainty|Neonatal Infections Level of Diagnostic Certainty	A classification of maternal and fetal outcomes relating to neonatal infections, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C126845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126845>	C126830	GAIA Preterm Birth Level of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Preterm Birth Level of Diagnostic Certainty|Preterm Birth Level of Diagnostic Certainty	A classification of maternal and fetal outcomes relating to preterm birth, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C126846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126846>	C126830	GAIA Stillbirth Level of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Stillbirth Level of Diagnostic Certainty|Stillbirth Level of Diagnostic Certainty	A classification of maternal and fetal outcomes relating to stillbirth, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C126847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126847>	C126834	GAIA Non-Reassuring Fetal Status Level of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Non-Reassuring Fetal Status Level of Diagnostic Certainty|Non-Reassuring Fetal Status Level of Diagnostic Certainty	A classification of maternal and fetal outcomes relating to non-reassuring fetal status, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C126848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126848>	C126834	GAIA Maternal Death Level of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Maternal Death Level of Diagnostic Certainty|Maternal Death Level of Diagnostic Certainty	A classification of maternal and fetal outcomes relating to maternal death, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C126849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126849>	C126834	GAIA Postpartum Hemorrhage Level of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Postpartum Hemorrhage Level of Diagnostic Certainty|Postpartum Hemorrhage Level of Diagnostic Certainty	A classification of maternal and fetal outcomes relating to postpartum hemorrhage, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C12684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12684>	C13037	Bronchiole|BRONCHIOLE|Bronchioles|Bronchiolus|bronchiole|bronchiole|lobular bronchiole	The smallest subdivisions of the bronchial tree, which are both acartilagenous and aglandular.	Bronchiole		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C126850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126850>	C126834	GAIA Preeclampsia Level of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Preeclampsia Level of Diagnostic Certainty|Preeclampsia Level of Diagnostic Certainty	A classification of maternal and fetal outcomes relating to preeclampsia, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C126851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126851>	C126834	GAIA Pathways to Preterm Birth Level of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Pathways to Preterm Birth Level of Diagnostic Certainty|Pathways to Preterm Birth Level of Diagnostic Certainty	A classification of maternal and fetal outcomes relating to pathways to preterm birth, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C126852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126852>	C125481	GAIA Major Congenital Anomalies Level of Diagnostic Certainty Terminology|Global Alignment of Immunization safety Assessment in pregnancy Major Congenital Anomalies Level of Diagnostic Certainty Terminology	A subset of terminology related to major congenital anomalies, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.			Intellectual Product	
C126853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126853>	C125481	GAIA Neonatal Death Level of Diagnostic Certainty Terminology|Global Alignment of Immunization safety Assessment in pregnancy Neonatal Death Level of Diagnostic Certainty Terminology	A subset of terminology related to neonatal death, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.			Intellectual Product	
C126854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126854>	C125481	GAIA Neonatal Infections Level of Diagnostic Certainty Terminology|Global Alignment of Immunization safety Assessment in pregnancy Neonatal Infections Level of Diagnostic Certainty Terminology	A subset of terminology related to neonatal infections, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.			Intellectual Product	
C126855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126855>	C125481	GAIA Preterm Birth Level of Diagnostic Certainty Terminology|Global Alignment of Immunization safety Assessment in pregnancy Preterm Birth Level of Diagnostic Certainty Terminology	A subset of terminology related to preterm birth, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.			Intellectual Product	
C126856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126856>	C125481	GAIA Stillbirth Level of Diagnostic Certainty Terminology|Global Alignment of Immunization safety Assessment in pregnancy Stillbirth Level of Diagnostic Certainty Terminology	A subset of terminology related to stillbirth, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.			Intellectual Product	
C126857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126857>	C125481	GAIA Non-Reassuring Fetal Status Level of Diagnostic Certainty Terminology|Global Alignment of Immunization safety Assessment in pregnancy Non-Reassuring Fetal Status Level of Diagnostic Certainty Terminology	A subset of terminology related to non-reassuring fetal status, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.			Intellectual Product	
C126858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126858>	C125481	GAIA Maternal Death Level of Diagnostic Certainty Terminology|Global Alignment of Immunization safety Assessment in pregnancy Maternal Death Level of Diagnostic Certainty Terminology	A subset of terminology related to maternal death, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.			Intellectual Product	
C126859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126859>	C125481	GAIA Postpartum Hemorrhage Level of Diagnostic Certainty Terminology|Global Alignment of Immunization safety Assessment in pregnancy Postpartum Hemorrhage Level of Diagnostic Certainty Terminology	A subset of terminology related to postpartum hemorrhage, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.			Intellectual Product	
C12685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12685>	C25762	Capillary	A tiny vessel that can be either a blood capillary or a lymphatic capillary.	Capillary		Body Part, Organ, or Organ Component	GDC Terminology|GDC Value Terminology
C126860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126860>	C125481	GAIA Preeclampsia Level of Diagnostic Certainty Terminology|Global Alignment of Immunization safety Assessment in pregnancy Preeclampsia Level of Diagnostic Certainty Terminology	A subset of terminology related to preeclampsia, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.			Intellectual Product	
C126861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126861>	C125481	GAIA Pathways to Preterm Birth Level of Diagnostic Certainty Terminology|Global Alignment of Immunization safety Assessment in pregnancy Pathways to Preterm Birth Level of Diagnostic Certainty Terminology	A subset of terminology related to pathways to preterm birth, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.			Intellectual Product	
C126862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126862>	C27993	Unsatisfactory|Inadequate|Insufficient	Failing to meet the quantitative or qualitative measures for the needs of a situation.			Qualitative Concept	GDC Terminology|GDC Value Terminology
C126863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126863>	C62439	Thirty One|31|31|Thirty-One	A natural number greater than thirty and less than thirty-two and the quantity that it denotes.			Quantitative Concept	
C126864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126864>	C85214	Niemann-Pick Disease, Type C1|Type C1 Niemann-Pick Disease	Type C Niemann-Pick disease associated with a mutation in the gene NPC1, encoding Niemann-Pick C1 protein.			Disease or Syndrome	Cellosaurus Disease Terminology
C126865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126865>	C85214	Niemann-Pick Disease, Type C2|Type C2 Niemann-Pick Disease	Type C Niemann-Pick disease associated with a mutation in the gene NPC2, encoding Niemann-Pick C2 protein.			Disease or Syndrome	Cellosaurus Disease Terminology
C126866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126866>	C61269	Niemann-Pick Disease, Type B|Type B Niemann-Pick Disease	An autosomal recessive lysosomal storage disease caused by mutations in the SMPD1 gene, encoding sphingomyelin phosphodiesterase. The condition is characterized by hepatosplenomegaly and interstitial lung disease, but with little neurological involvement. It is part of a continuum of disease resulting from decrease activity of sphingomyelin phosphodiesterase, with Type B being the milder form.			Disease or Syndrome	Cellosaurus Disease Terminology
C126867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126867>	C126830	GAIA Maternal Immunization Level of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Maternal Immunization Level of Diagnostic Certainty|Maternal Immunisation Level of Diagnostic Certainty	A classification of maternal and fetal outcomes relating to maternal immunization, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C126868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126868>	C84615	Congenital Disorder of Glycosylation Type Ia|CDGIa	A congenital disorder of glycosylation subtype caused by mutation(s) in the PMM2 gene, encoding phosphomannomutase 2.			Disease or Syndrome	Cellosaurus Disease Terminology
C126869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126869>	C84615	Congenital Disorder of Glycosylation Type Ic|CDGIc	A congenital disorder of glycosylation sub-type caused by mutation(s) in the ALG6 gene, encoding dolichyl pyrophosphate Man9GlcNAc2 alpha-1,3-glucosyltransferase.			Disease or Syndrome	Cellosaurus Disease Terminology
C12686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12686>	C12919	Cardiovascular System|Body System, Cardiovascular|CARDIOVASCULAR SYSTEM|Cardiovascular|Cardiovascular|Cardiovascular Body System|Cardiovascular Organ System|Circulatory System|Organ System, Cardiovascular|Vascular, Heart|circulatory system	Relating to the heart and the blood vessels or the circulation.	Cardiovascular System		Body System	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|ICDC Terminology|ICDC Value Terminology
C126870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126870>	C84615	Congenital Disorder of Glycosylation Type Id|CDGId	A congenital disorder of glycosylation subtype caused by mutation(s) in the ALG3 gene, encoding dol-P-Man:Man(5)GlcNAc(2)-PP-Dol alpha-1,3-mannosyltransferase.			Disease or Syndrome	Cellosaurus Disease Terminology
C126871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126871>	C84615	Congenital Disorder of Glycosylation Type Ie|CDGIe	A congenital disorder of glycosylation sub-type caused by mutation(s) in the DPM1 gene, encoding dolichol-phosphate mannosyltransferase subunit 1.			Disease or Syndrome	Cellosaurus Disease Terminology
C126872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126872>	C84615	Congenital Disorder of Glycosylation Type If|CDGIf	A congenital disorder of glycosylation sub-type caused by mutation(s) in the MPDU1 gene, encoding mannose-P-dolichol utilization defect 1 protein.			Disease or Syndrome	Cellosaurus Disease Terminology
C126873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126873>	C84615	Congenital Disorder of Glycosylation Type Ig|CDGIg	A congenital disorder of glycosylation sub-type caused by mutation(s) in the ALG12 gene, dol-P-Man:Man(7)GlcNAc(2)-PP-Dol alpha-1,6-mannosyltransferase.			Disease or Syndrome	Cellosaurus Disease Terminology
C126874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126874>	C84615	Congenital Disorder of Glycosylation Type Ij|CDGIj	A congenital disorder of glycosylation sub-type caused by mutation(s) in the DPAGT1 gene, encoding UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferase.			Disease or Syndrome	Cellosaurus Disease Terminology
C126875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126875>	C61272	Glycogen Storage Disease Type VI	An autosomal recessive sub-type of glycogen storage disease caused by mutation(s) in the PYGL gene, encoding glycogen phosphorylase, liver form. The condition is characterized by mild-moderate hypoglycemia, growth retardation and hepatomegaly.			Disease or Syndrome	Cellosaurus Disease Terminology
C126876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126876>	C121156	Langer Mesomelic Dysplasia|Langer Syndrome|Langer Type Mesomelic Dysplasia	An autosomal recessive condition caused by mutation (s) in the SHOX gene, encoding short stature homeobox protein. The condition is characterized by shortening of the bones of the middle segments of the limbs.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C126877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126877>	C8957|C3131	Epidermodysplasia Verruciformis|EV|Lewandowsky-Lutz Dysplasia	An extremely rare skin disorder usually inherited in an autosomal recessive pattern and caused by mutation(s) in the TMC6 or TMC8 gene, encoding transmembrane channel-like protein 6 and transmembrane channel-like protein 8, respectively. It is characterized by chronic human papillomavirus infection. Patients develop papillomatous wart-like lesions and pigmented plaques on the skin. It predisposes to cutaneous carcinomas, especially in situ and invasive squamous cell carcinomas.			Disease or Syndrome	Cellosaurus Disease Terminology
C126879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126879>	C15747	Psychosocial Assessment|Psychosocial Studies	The act of determining, usually through interviews and observation, the state of an individual's psychological state and social environment.	Psychosocial Assessment		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C12687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12687>	C12372	Common Carotid Artery|ARTERY, CAROTID|CAROTID ARTERY|Carotid|Carotid Artery|Carotid Artery|Carotid Artery|Carotid artery structure (body structure)|carotid artery	One of two arteries that supply oxygenated blood to the head and neck; the left common carotid branches from the aorta and the right common carotid from the innominate (brachiocephalic artery).	Carotid Artery		Body Part, Organ, or Organ Component	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C126880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126880>	C15747	Psychosocial Care|Psychosocial Support	The act of providing psychological assistance or support to an individual based on their needs.	Psychosocial Care		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C126881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126881>	C217122	Inattention/Hyperactivity Composite Score	A composite score of the Behavior Assessment System for Children that combines the Attention Problems scale and the Hyperactivity scale.			Intellectual Product	
C126882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126882>	C20993	Zoo Locations Subtest	A subtest of the Wechsler Preschool and Primary Scale of Intelligence, that measures visual as well as spatial dimension skills. Working within a specified time limit, the child views pictures of animals placed on a zoo layout and them must place the proper animal in the correct location.			Intellectual Product	Wechsler Preschool and Primary Scale of Intelligence
C126883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126883>	C217122	Digit Span Total Score	The sum of the scores for the Digit Span Forward, Digit Span Backward, and Digit Span Sequencing scales of the Wechsler Intelligence Scale for Children.			Intellectual Product	Wechsler Intelligence Scale for Children
C126884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126884>	C62439	Twenty Two|22|Twenty-Two	A natural number greater than twenty-one and less than twenty-three and the quantity that it denotes.			Quantitative Concept	
C126885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126885>	C62439	Twenty Three|23|Twenty-Three	A natural number greater than twenty-two and less than twenty-four and the quantity that it denotes.			Quantitative Concept	
C126886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126886>	C62439	Twenty Six|26|Twenty-Six	A natural number greater than twenty-five and less than twenty-seven and the quantity that it denotes.			Quantitative Concept	
C126887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126887>	C62439	Twenty Seven|27|Twenty-Seven	A natural number greater than twenty-six and less than twenty-eight and the quantity that it denotes.			Quantitative Concept	
C126888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126888>	C62439	Twenty Eight|28|Twenty-Eight	A natural number greater than twenty-seven and less than twenty-nine and the quantity that it denotes.			Quantitative Concept	
C126889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126889>	C1708	Personal Care Product	A consumer product used for personal hygiene or for beautification.			Chemical Viewed Functionally	
C12688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12688>	C33545|C199635	Carpal Bone|BONE, CARPAL|CARPAL BONE|Carpus|Carpus Bone	Any of the small bones of the wrist joint, located between the radius and the ulna and the metacarpus.	Carpal Bone		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C126890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126890>	C25616	Past 2 Weeks|Last 2 Weeks|Last 2 weeks|Last Two Weeks|Past Two Weeks	A period of time consisting of the 14 days before the present.			Temporal Concept	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126891>	C91105	Chronic Respiratory Questionnaire Self-Administered Standardized Format|CRQ-SAS|Chronic Respiratory Questionnaire Self-Administered Standardized Format (CRQ-SAS)	A standardized rating scale developed by Schunemann et al in 2003, which is a self-administered instrument used to measure the health-related quality of life (HRQL) in patients with chronic airflow limitation.			Intellectual Product	
C126892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126892>	C128662	EGFR Exon 19 Deletion Mutation|EGFR DEL19|EGFR DEL19 Mutation|EGFR Ex19Del|EGFR Exon 19 Gene Deletion Mutation|EGFR del19|ERBB Exon 19 Deletion Mutation|ERBB1 Exon 19 Deletion Mutation|Epidermal Growth Factor Receptor Gene Exon 19 Deletion Mutation|Ex19Del|Exon 19 Deletion|HER1 Exon 19 Deletion Mutation	In-frame deletions occurring within the exon 19-encoded part of the epidermal growth factor receptor (EGFR) kinase domain. These mutations are commonly seen in non-small cell lung cancer and are associated with increased sensitivity to EGFR tyrosine kinase inhibitors.	EGFR Exon 19 Deletion Mutation		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126893>	C70561	Globohexaosylceramide|Globo H|Globo-H	A hexasaccharide glycosphingolipid and human cancer antigen expressed on the surface of many types of tumor cells. Globohexaosylceramide (Globo H) is minimally or not expressed on healthy, normal cells; its expression on cancer cells is associated with increased proliferation and poor prognosis.	Globohexaosylceramide		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C126894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126894>	C518	Fucosyl Monosialotetrahexosylganglioside|Fuc-GM1|Fucosyl GM1|Fucosyl-GM1	A fucosylated derivative of monosialotetrahexosylganglioside (GM1) and tumor antigen associated with small-cell lung cancer (SCLC). Fucosyl-GM1 is specifically expressed in SCLC while minimally or not expressed on healthy, normal cells; it plays a key role in tumor cell proliferation and may be a biomarker to detect the presence of these cancer cells.	Fucosyl Monosialotetrahexosylganglioside		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C126895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126895>	C20401	Monoclonal Antibody M30|M30|Mouse Anti-Human Caspase Cleaved Keratin 18 Monoclonal Antibody|Mouse Anti-Human K18Asp396 Monoclonal Antibody|Mouse Anti-Human K18Asp396 Neo-Epitope Monoclonal Antibody|Mouse Anti-Human K18Asp396-NE Monoclonal Antibody|Mouse Anti-Human ccK18 Monoclonal Antibody|Mouse Monoclonal Antibody M30	A mouse monoclonal antibody that recognizes the soluble caspase-cleaved (cc) form of human keratin, type I cytoskeletal 18 (cytokeratin 18, K18, KRT18, CK18). Monoclonal antibody M30 binds to a neo-epitope (NE) exposed after caspase cleavage after the aspartic acid residue at position 396 of K18 (K18Asp396). This neo-epitope results from the proteolytic activity of caspase-3, -7 or -9, which are active during apoptosis. Thus, M30 can be used to indirectly identify caspase activation and to determine if the cell death in a sample is due to apoptosis rather than necrosis.	Monoclonal Antibody M30		Amino Acid, Peptide, or Protein|Immunologic Factor|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126896>	C709	Cytidine Triphosphate|5'-CTP|CTP|CYTIDINE TRIPHOSPHATE|Cytidine 3'-Triphosphate|Cytidine 5'-(Tetrahydrogen Triphosphate)|Cytidine 5'-Triphosphoric Acid|Cytidine-5'-Triphosphate|Deoxycytidine Triphosphate	A cytosine derived nucleotide comprised of three phosphate groups esterified to the deoxyribose sugar moiety. Nucleotide metabolism is upregulated in cancer cells; therefore, this nucleotide could be used as a biomarker to detect the presence of cancer cells.	Cytidine Triphosphate		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C126897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126897>	C542	Deoxypyridinoline|D-PYR|D-Pyrilinks|DPD|DPYD|DeoxyPYD|Deoxypyridinium|Lysylpyridinoline|N-(5-Amino-5-Carboxypentyl)-3-Hydroxy-4-(2-Amino-2-Carboxyethyl)-5-(3-Amino-3-Carboxypropyl)Pyridine|Pyridinium, 4-((2S)-2-Amino-2-Carboxyethyl)-1-((5S)-5-Amino-5-Carboxypentyl)-3-((3S)-3-Amino-3-Carboxypropyl)-5-Hydroxy-, Inner Salt|Pyridinium, 4-(2-Amino-2-Carboxyethyl)-1-(5-Amino-5-Carboxypentyl)-3-(3-Amino-3-Carboxypropyl)-5-Hydroxy-, Hydroxide, Inner Salt, Stereoisomer|Pyrilinks-D	A pyridinium-derived moiety that forms crosslinks in type I collagen in bone. Urine levels of deoxypyridinoline are used as a correlative marker for bone resorption and osteoclast activity; both of these activities may be increased in certain diseases.	Deoxypyridinoline		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C126898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126898>	C782	2,3-Dinor-6-Ketoprostaglandin F1alpha|2,3-Dinor-6-Keto-Pgf1alpha|2,3-Dinor-6-Oxo-Pgf1alpha|2,3-Dinor-6-Oxoprostaglandin F1alpha|2,3-Dkpgf1alpha|2,3d-6K-PGF1alpha|Cyclopentanepentanoic Acid, 3,5-Dihydroxy-2-((1E,3S)-3-Hydroxy-1-Octenyl)-Gamma-Oxo-, (1R,2R,3R,5S)-|Cyclopentanepentanoic Acid, 3,5-Dihydroxy-2-(3-Hydroxy-1-Octenyl)-Gamma-Oxo-, (1R-(1alpha,2beta(1E,3S*),3alpha,5alpha))-|PGI2-M|Pgi2-M	A beta-oxidation product of 6-keto prostaglandin F1 alpha (PGF1a) and the major urinary metabolite of prostaglandin I2 (prostacyclin, PGI2). 2,3-dinor-6-ketoprostaglandin F1alpha in urine is often used as a correlative marker to indirectly measure prostacyclin production.	2,3-Dinor-6-Ketoprostaglandin F1alpha		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C126899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126899>	C20401	Anti-Hairy Cell Leukemia Antibody DBA.44|Anti-Hairy Cell Leukemia Antibody (Clone DBA.44)|Anti-Hairy Cell Leukemia Antibody (DBA.44)|Anti-Hairy Cell Leukemia Antibody [DBA.44]|DBA.44|DBA44	A mouse monoclonal antibody directed against an epitope expressed by the DEAU B-lymphoma cell line, with potential diagnostic applications ex vivo. Anti-hairy cell leukemia antibody DBA.44 detects an antigen expressed on a subpopulation of B-lymphocytes in the mantle zone of lymphoid follicles. DBA.44 reacts with the majority of lymphocytes of hairy cell leukemia (HCL).	Anti-Hairy Cell Leukemia Antibody DBA.44		Amino Acid, Peptide, or Protein|Immunologic Factor|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Biomarker Terminology|CTRP Terminology
C12689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12689>	C12791	Cauda Equina|Cauda Equina Spinal Cord|Cauda equina|Cauda equina structure (body structure)|cauda equina	The collection of spinal nerve roots, arising from lumbar pairs two through five, sacral pairs one through five, and the coccygeal nerve, that branch off the conus medullaris at the termination of the spinal cord, and float freely within the lumbar cistern before exiting the spinal column at the appropriate vertebra.	Cauda Equina		Body Part, Organ, or Organ Component	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C1268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1268>	C697	Trofosfamide|2-[bis(2-chloroethyl)amino]-3-(2-chloroethyl)tetrahydro-2H-1,3,2-oxaphosphorine 2-oxide|2H-1,3,2-Oxazaphosphorin-2-amine, N,N, 3-tris(2-chloroethyl)tetrahydro-, 2-oxide, (+)-|2H-1,3,2-Oxazaphosphorin-2-amine, N,N, 3-tris(2-chloroethyl)tetrahydro-, 2-oxide, (-)-|A-4828|A-4828|Genoxal Trofosfamida|Ixoten|Ixoten|N,N,3-tris(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide|N,N,N'-tris(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide|TROFOSFAMIDE|Trilophosphamide|Trilophosphamide|Trofosfamid|Trofosfamid|Trophosphamide|Trophosphamide|Z 4828|Z-4828|Z-4828	An orally bioavailable oxazaphosphorine prodrug with antineoplastic activity. Trofosfamide (TFF) is metabolized predominantly to the cyclophosphamide analogue ifosfamide (IFO), which is then metabolized by liver cytochrome P450s to the active isophosphoramide mustard (IPM). IPM alkylates DNA to form DNA-DNA cross-links, which may result in inhibition of DNA, RNA and protein synthesis, and ultimately lead to tumor cell apoptosis.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C126900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126900>	C268	HLA-DR Antigen 1D10|1D10 Antigen	A polymorphic epitope on the HLA-DR beta chain that is expressed on normal and neoplastic B-cells.	HLA-DR Antigen 1D10		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126901>	C67038	Phytoene|(6E,10E,14E,16E,18E,22E,26E)-2,6,10,14,19,23,27,31-Octamethyldotriaconta-2,6,10,14,16,18,22,26,30-Nonaene|7,7',8,8',11,11',12,12'-Octahydro-Psi,Psi-Carotene|All-Trans-Phytoene|PHYTOENE|Psi,Psi-Carotene, 7,7',8,8',11,11',12,12'-Octahydro-	A 40 carbon dietary fatty acid produced by the conversion of two molecules of geranylgeranyl pyrophosphate by the enzyme phytoene synthase that is an intermediate in carotenoid biosynthesis in plants with potential to absorb ultraviolet radiation (UV), and potential antioxidant, chemopreventive, and anti-inflammatory activities in skin. Following ingestion and digestion, phytoene may accumulate in the epidermis where it may prevent UV-mediated sun damage and carcinogenesis. In addition, phytofluene may prevent carcinogenesis by protecting cells against DNA damage through its free radical scavenger effects.	Phytoene		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C126902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126902>	C176021	How Much Shortness of Breath During Activity Question|How Much Shortness of Breath|How Much Shortness of Breath During Activity|How much shortness of breath you have had while doing that activity	A question about how much shortness of breath an individual had or has while doing a specific activity.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126903>	C67038	Phytofluene|(6E,10E,12E,14E,16Z,18E,22E,26E)-2,6,10,14,19,23,27,31-Octamethyldotriaconta- 2,6,10,12,14,16,18,22,26,30-Decaene|15-Cis-7,8,11,12,7',8'-Hexahydro-Psi,Psi-Carotene|15-Cis-Phytofluene (SY)|All-Trans-Phytofluene|PHYTOFLUENE, ALL-TRANS-	A 40 carbon dietary fatty acid that is an intermediate in carotenoid biosynthesis in plants and is derived from the desaturation of double bonds in phytoene with potential to absorb ultraviolet radiation (UV), and potential antioxidant, chemopreventive and anti-inflammatory activities. Following ingestion and digestion, phytofluene may accumulate in the skin where it may prevent UV-mediated sun damage and carcinogenesis. In addition, phytofluene may prevent carcinogenesis by protecting cells against DNA damage through its free radical scavenger effects.	Phytofluene		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C126904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126904>	C173160	Feel Emotional Question|Feel Emotional|Feeling emotional such as angry or upset	A question about an individual feeling emotional, such as angry or upset.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126905>	C91102	Take Care of Basic Needs Question|Take Care of Basic Needs|Taking care of your basic needs (bathing, showering, eating or dressing)	A question about an individual taking care of their basic needs including bathing, showering, eating or dressing.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126906>	C173458	Perform Chores Question|Perform Chores|Performing Chores|Performing chores (such as housework, shopping groceries)	A question about an individual performing chores such as housework, shopping groceries.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126907>	C68425	Sphingosine 1-Phosphate|(2-Amino-3-Hydroxy-Octadec-4-Enoxy)Phosphonic Acid|(2S,3R,4E)-2-Amino-3-Hydroxyoctadec-4-En-1-Yl Dihydrogen Phosphate|(2S,3R,4E)-2-Amino-4-Octadecene-1,3-Diol 1-(Dihydrogen Phosphate)|4-Octadecene-1,3-Diol, 2-Amino-, 1-(Dihydrogen Phosphate), (2S,3R,4E)|4-Octadecene-1,3-Diol, 2-Amino-, 1-(Dihydrogen Phosphate), (R-(R*,S*-(E)))-|D-Erythro-Sphingosine 1-Phosphate|S1P|SPHINGOSINE 1-PHOSPHATE|SPP|Sphing-4-Enine 1-Phosphate|Sphingosine 1-Phosphic Acid|Sphingosine-1-Phosphate	A bioactive sphingolipid comprised of a sphingosine with a phosphate group attached to the carbon at position 1. Sphingosine 1-phosphate (S1P) binds to G protein-coupled S1P receptors (S1PRs) and initiates signaling pathways involved in the regulation of angiogenesis, the proliferation of skin cells, vascular stability and permeability, and T- and B-cell trafficking.	Sphingosine 1-Phosphate		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C126908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126908>	C463	Epoxyeicosatrienoic Acid|EET|EETs|Epoxyicosatrienoic Acid|Epoxyicosatrienoic Acids	A class of eicosanoids produced by the epoxidation of one of the double bonds of arachidonic acid by some of the members of the cytochrome P450 family of epoxygenases. Epoxides in the epoxyeicosatrienoic acid (EET) family act locally to stimulate signaling pathways involved in the regulation of blood pressure, vascular maintenance, inflammation, and pain responses. EETs may promote the proliferation and survival of certain types of cancer cells.	Epoxyeicosatrienoic Acid		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C126909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126909>	C173045	Participate in Social Activities Question|Participate in Social Activities|Participating in social activities	A question about an individual participating in social activities.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C12690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12690>	C12877	Cavernous Sinus	One of a pair of dural venous sinuses located on either side of the pituitary fossa and lateral to the sella turcica. It receives blood from the superior and inferior ophthalmic veins, and drains via the superior and inferior petrosal sinuses, as well as into the emissary vein.	Cavernous Sinus		Body Space or Junction	
C126910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126910>	C713	2'-5'-Oligoadenylate|2'-5' Oligoadenylate|2-5-Oligoadenylate|2-5A	An oligonucleotide synthesized from adenosine triphosphate (ATP) by enzymes in the 2'-5'-oligoadenylate synthase family. The production of 2'-5'-oligoadenylate is stimulated by the presence of double stranded RNA (dsRNA) and binds to inactive monomeric forms of ribonuclease L (RNase L), thereby promoting RNase L dimerization and activation. Active RNase L degrades both cellular and viral RNAs, which inhibits protein translation and leads to the abrogation of viral replication. 2'-5'-oligoadenylates play a key role in the innate immunity against viruses.	2-5-Oligoadenylate		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology
C126911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126911>	C73539	3-Nitrotyrosine|3-Mononitrotyrosine|3-NITRO-L-TYROSINE|3-NT|Tyrosine, 3-Nitro-	A tyrosine derivative with a nitro group attached to carbon 3 on the phenyl ring that is a product of tyrosine nitration mediated by reactive nitrogen species, including peroxynitrite anion and nitrogen dioxide. 3-nitrotyrosine is a biomarker of cell damage, inflammation, and NO (nitric oxide) production; it is overproduced in many diseases where oxidative stress plays a key role.	3-Nitrotyrosine		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C126912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126912>	C173160	Feel Frustrated or Impatient Question|Feel Frustrated or Impatient|How much of the time have you felt frustrated or impatient	A question about an individual feeling frustrated or impatient.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126913>	C942	Tocopherylquinone|2,5-Cyclohexadiene-1,4-Dione, 2-(3-Hydroxy-3,7,11,15-Tetramethylhexadecyl)-3,5,6-Trimethyl-, (3R-(3R*,7R*,11R*))-|2-(3-Hydroxy-3,7,11,15-Tetramethylhexadecyl)-3,5,6-Trimethyl-p-Benzoquinone|Alpha-TQ|Alpha-Tocopherol Quinone|Alpha-Tocopherolquinone|Alpha-Tocopheroquinone|Alpha-Tocoquinone|TOCOQUINONE|TQ|Tocoquinone|VEQ|Vitamin E Quinone|p-Benzoquinone, 2-(3-Hydroxy-3,7,11,15-Tetramethylhexadecyl)-3,5,6-Trimethyl-	An oxidized form of alpha-tocopherol with potent anticoagulant activity. Although the mechanism of action has not been fully elucidated, dietary supplementation with tocopherylquinone may lead to the inhibition of the vitamin K-dependent gamma-carboxylase (gamma-glutamyl carboxylase). This prevents the carboxylation of glutamyl residues in coagulation factor proteins and inhibits platelet aggregation and clotting.	Tocopherylquinone		Pharmacologic Substance|Vitamin	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C126914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126914>	C173398|C173160|C118873	Feel Fear or Panic When Difficult to Get Breath Question|Feel Fear or Panic When Difficult to Get Breath|How often did you have a feeling of fear or panic when you had difficulty getting your breath	A question about an individual feeling fear or panic when they had difficulty getting their breath.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126915>	C173601|C173134|C118873	Feel Embarrassed by Coughing or Heavy Breathing Question|Feel Embarrassed by Coughing or Heavy Breathing|How often have you felt embarrassed by your coughing or heavy breathing	A question about an individual feeling embarrassed by their coughing or heavy breathing.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126916>	C173086	Feel Very Confident Can Deal with Illness Question|Feel Very Confident Can Deal with Illness|How much of the time did you feel very confident and sure that you could deal with your illness	A question about an individual feeling very confident and sure that you could deal with your illness.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126917>	C173160	Feel Upset, Worried, or Depressed Question|Feel Upset, Worried, or Depressed|How much of the time did you feel upset, worried, or depressed	A question about an individual feeling upset, worried, or depressed.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126918>	C173160|C118873	Feel in Complete Control of Breathing Problems Question|Feel in Complete Control of Breathing Problems|How often did you feel you had complete control of your breathing problems	A question about an individual feeling they had complete control of their breathing problems.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126919>	C173160	Feel Relaxed and Free of Tension Question|Feel Relaxed and Free of Tension|How much of the time did you feel relaxed and free of tension	A question about an individual feeling relaxed and free of tension.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C12691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12691>	C12980	Cerebral Artery|CEREBRAL ARTERY|Cerebral Arteries	An artery which directly supplies the cerebral cortex and which has deeper branches that supply the underlying white matter.	Cerebral Artery		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C126920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126920>	C173458|C173160|C118873	Feel Low in Energy Question|Do you ever feel too tired to play|Feel Low in Energy|Have Low Energy|How often have you felt low in energy|I have low energy|Low Energy|Low energy level	A question about whether an individual feels or felt low in energy.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126921>	C173160|C118873	Feel Discouraged or Down in Dumps Question|Feel Discouraged or Down in Dumps|How often have you felt discouraged or down in the dumps	A question about an individual feeling discouraged or down in the dumps.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126922>	C173219|C118873	Feel Worn Out or Sluggish Question|Feel Sluggish|Feel Worn Out or Sluggish|How often have you felt worn out or sluggish|I feel sluggish	A question about an individual feeling worn out or sluggish.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format|Multidimensional Fatigue Symptom Inventory-Short Form
C126923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126923>	C173792	Happy, Satisfied, or Pleased with Personal Life Question|Happy, Satisfied, or Pleased with Personal Life|How happy, satisfied, or pleased have you been with your personal life	A question about an individual feeling happy, satisfied, or pleased with their personal life.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126924>	C173398|C173160|C118873	Feel Upset or Scared When Having Difficulty Getting Breath Question|Feel Upset or Scared When Having Difficulty Getting Breath|How often did you feel upset or scared when you had difficulty getting your breath	A question about an individual feeling upset or scared when they had difficulty getting their breath.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126925>	C173160|C118873	Feel Restless, Tense, or Uptight Question|Feel Restless, Tense, or Uptight|How often have you felt restless, tense, or uptight	A question about an individual feeling restless, tense, or uptight.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126926>	C175457	Extremely Short of Breath|Extremely short of breath	A response indicating that an individual is or was extremely short of breath.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126927>	C175457	Very Short of Breath|Very short of breath	A response indicating that an individual is or was very short of breath.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126928>	C175457	Quite a Bit Short of Breath|Quite a bit short of breath	A response indicating that an individual is or was quite a bit short of breath.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126929>	C175457	Some Shortness of Breath|Some shortness of breath	A response indicating that an individual experiences or experienced some shortness of breath.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C12692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12692>	C13236	Cerebrospinal Fluid|CEREBROSPINAL FLUID|CSF|CSF|CSF|CSF|CSF|CSF|Cerebral Spinal Fluid|Cerebral spinal fluid|Cerebrospinal fluid|FLUID, CEREBROSPINAL|cerebral spinal fluid|cerebrospinal fluid|cerebrospinal fluid	The fluid that is contained within the brain ventricles, the subarachnoid space and the central canal of the spinal cord.	Cerebrospinal Fluid		Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GCT Authorized Value Terminology|GCT Tumor Assessment Table|GDC Terminology|GDC Value Terminology|mCode Genomic Specimen Type Value Set|mCode Terminology|UBERON Terminology
C126930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126930>	C175457	A Little Short of Breath|A Little Shortness of Breath|A little shortness of breath	A response indicating that an individual is or was a little short of breath.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126931>	C941	24,25-Dihydroxycholecalciferol|(3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-Triene-3,24,25-Triol|24,25(OH)(2)D|24,25(OH)2 D3|24,25-DIHYDROXYCHOLECALCIFEROL|24,25-Dihydroxyvitamin D|24,25-Dihydroxyvitamin D 3|24,25-Dihydroxyvitamin D3|24,25-Hydroxy Vitamin D3|9,10-Secocholesta-5,7,10(19)-Triene-3,24,25-Triol, (3-beta,5Z,7E)-	A vitamin D derivative that is produced by the conversion of calcifediol by 1,25-dihydroxyvitamin D3 24-hydroxylase (CYP24A1). 24,25-dihydroxycholecalciferol is a marker for calcifediol catabolism because it is the major metabolite of calcifediol, and its urine levels are increased in certain diseases, such as chronic kidney disease (CKD).	24,25-Dihydroxycholecalciferol		Vitamin	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C126932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126932>	C175457	Not at All Short of Breath|Not at all short of breath	A response indicating that an individual is or was not at all short of breath.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126933>	C226740	Extremely Tired|Extremely tired	A response indicating that an individual is or was extremely tired.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126934>	C226740	Very Tired|Very tired	A response indicating that an individual is or was very tired.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126935>	C226740	Quite a Bit of Tiredness|Quite a Bit Tired|Quite a bit of tiredness	A response indicating that an individual is or was quite a bit of tired.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126936>	C226740	Moderately Tired|Moderately tired	A response indicating that an individual is or was moderately tired.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126937>	C226740	Somewhat Tired|Somewhat tired	A response indicating that an individual is or was somewhat tired.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126938>	C226740	A Little Tired|A little tired	A response indicating that an individual is or was a little tired.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126939>	C91213|C226740	Not at All Tired|Not at all tired	A response indicating that an individual is or was not at all tired.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C12693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12693>	C12933	Cervical Vertebra|CERVICAL VERTEBRA|Cervical Vertebrae	Any one of the seven vertebrae that are caudal to the skull, denoted as C1, C2, C3, C4, C5, C6 or C7.	Cervical Vertebrae		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table
C126940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126940>	C226663	No Energy at All|No energy at all	A response indicating that an individual has or had no energy at all.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126941>	C226663	A Little Energy|A little energy	A response indicating that an individual has or had a little energy.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126942>	C226663	Some Energy|Some energy	A response indicating that an individual has or had some energy.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126943>	C226663	Moderately Energetic|Moderately energetic	A response indicating that an individual is or was moderately energetic.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126944>	C226663	Quite a Bit of Energy|Quite a bit of energy	A response indicating that an individual has or had quite a bit of energy.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126945>	C226663	Very Energetic|Very energetic	A response indicating that an individual is or was very energetic.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126946>	C226663	Full of Energy|Full of energy	A response indicating that an individual is or was full of energy.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126947>	C176250	Somewhat Dissatisfied, Unhappy|Somewhat dissatisfied, unhappy	A response indicating that an individual is or has been somewhat dissatisfied or unhappy.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C126949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126949>	C226674	Happy Most of the Time|Happy most of the time	A response indicating that an individual is or has been happy most of the time.			Intellectual Product	Chronic Respiratory Questionnaire Self-Administered Standardized Format
C12694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12694>	C13031	Choroid Plexus|BRAIN, CHOROID PLEXUS|CHOROID PLEXUS	Blood vessels forming villous structures in the third, fourth, and lateral ventricles of the brain.	Choroid Plexus		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C126950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126950>	C20923	ADGRE1 Gene|ADGRE1|ADGRE1|Adhesion G Protein-Coupled Receptor E1 Gene	This gene is involved in immunity, cell adhesion and G protein-coupled receptor signaling.	ADGRE1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126951>	C126950	ADGRE1 wt Allele|Adhesion G Protein-Coupled Receptor E1 wt Allele|EGF-Like Module-Containing, Mucin-Like, Hormone Receptor 1 Gene|EMR1|Egf-Like Module Containing, Mucin-Like, Hormone Receptor-Like 1 Gene|Egf-Like Module Containing, Mucin-Like, Hormone Receptor-Like Sequence 1 Gene|F4/80|F4/80 Homolog Gene|TM7LN3	Human ADGRE1 wild-type allele is located in the vicinity of 19p13.3 and is approximately 53 kb in length. This allele, which encodes adhesion G protein-coupled receptor E1 protein, plays a role in cell-cell adhesion of immune cells.	ADGRE1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126952>	C18239	Adhesion G Protein-Coupled Receptor E1|ADGRE1|EGF-Like Module Receptor 1|EGF-Like Module-Containing Mucin-Like Hormone Receptor-Like 1|EMR1 Hormone Receptor|F4/80 Transmembrane Protein Homolog	Adhesion G protein-coupled receptor E1 (886 aa, ~98 kDa) is encoded by the human ADGRE1 gene. This protein is involved in cell adhesion, signaling and immunity.	Adhesion G Protein-Coupled Receptor E1		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126953>	C21295	SELENOF Gene|SELENOF|SELENOF|SEP15|Selenoprotein F Gene	This gene plays a role in selenium binding.	SELENOF Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126954>	C126953	SELENOF wt Allele|15 kDa Selenoprotein Gene|SEP15|Selenoprotein F (15kDa) Gene|Selenoprotein F wt Allele|Selenoprotein, 15-kD Gene	Human SELENOF wild-type allele is located in the vicinity of 1p22.3 and is approximately 52 kb in length. This allele, which encodes selenoprotein F, may be involved in protein folding.	SELENOF wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126955>	C20315	Selenoprotein F|15 kDa Selenoprotein|SELENOF	Selenoprotein F (162 aa, ~18 kDa) is encoded by the human SELENOF gene. This protein binds selenium and may play a role in protein folding.	Selenoprotein F		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126956>	C21518	C2 Gene|C2|C2|Complement Component 2 Gene	This gene is involved in the classical pathway of the complement system.	C2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126957>	C126956	C2 wt Allele|ARMD14|CO2|Complement Component 2 wt Allele	Human C2 wild-type allele is located in the vicinity of 6p21.3 and is approximately 48 kb in length. This allele, which encodes complement C2 protein, plays a role in proteolysis and complement activation. Mutation of the gene is associated with C2 deficiency and increased susceptibility for age-related macular degeneration.	C2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126958>	C21523|C17123	Complement C2|C2|C3/C5 Convertase|Complement Component 2|EC 3.4.21.43	Complement C2 (752 aa, ~83 kDa) is encoded by the human C2 gene. This protein is involved in post-translational protein processing and complement activity.	Complement C2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126959>	C25790	MICA Gene|MHC Class I Polypeptide-Related Sequence A Gene|MICA|MICA	This gene plays a role in the immune response to stress.	MICA Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C12695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12695>	C33003	Clavicle|BONE, CLAVICLE|Bone structure of clavicle (body structure)|CLAVICLE|Collar Bone|clavicle|clavicle|clavicle bone|clavicula|collar bone|collarbone|collarbone	One of a pair of bones linking the scapula and the sternum. The clavicle is part of the pectoral girdle.	Clavicle		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|GDC Terminology|GDC Value Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C126960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126960>	C126959	MICA wt Allele|MHC Class I Polypeptide-Related Sequence A wt Allele|MIC-A|Major Histocompatibility Class I Chain-Related Gene A|PERB11.1	Human MICA wild-type allele is located in the vicinity of 6p21.3 and is approximately 16 kb in length. This allele, which encodes MHC class I polypeptide-related sequence A protein, is involved in natural killer cell inhibition. Variation of the gene may be associated with increased susceptibility to psoriasis 1 and psoriatic arthritis.	MICA wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126961>	C16725	MHC Class I Polypeptide-Related Sequence A|MIC-A|MICA|Stress Inducible Class I Homolog	MHC class I polypeptide-related sequence A (383 aa, ~43 kDa) is encoded by the human MICA gene. This protein plays a role in the negative regulation of natural killer cells.	MHC Class I Polypeptide-Related Sequence A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126962>	C30073	KRT8 Gene|KRT8|KRT8|Keratin 8 Gene	This gene is involved in muscle and epithelial structures.	KRT8 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126963>	C126962	KRT8 wt Allele|CARD2|CK-8|CK8|CYK8|K2C8|K8|KO|Keratin 8 wt Allele|Keratin 8, Type II Gene	Human KRT8 wild-type allele is located in the vicinity of 12q13 and is approximately 53 kb in length. This allele, which encodes keratin, type II cytoskeletal 8 protein, plays a role in the structure of striated muscle and simple epithelia. Mutation of the gene is associated with cryptogenic cirrhosis.	KRT8 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126964>	C20694	Keratin, Type II Cytoskeletal 8|CK-8|Cytokeratin 8|Cytokeratin-8|K8|KRT8|Keratin 8|Keratin-8|Type-II Keratin Kb8	Keratin, type II cytoskeletal 8 (483 aa, ~54 kDa) is encoded by the human KRT8 gene. This protein is involved in maintaining the structure of striated muscles and simple epithelia.	Keratin, Type II Cytoskeletal 8		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126965>	C25790	ORM1 Gene|ORM1|ORM1|Orosomucoid 1 Gene	This gene plays a role in immune modulation and transport.	ORM1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126966>	C126965	ORM1 wt Allele|AGP|AGP-A|AGP1|ALPHA-1-AGP|Glycoprotein, Alpha-1-Acid, of Serum Gene|HEL-S-153w|ORM|Orosomucoid 1 wt Allele	Human ORM1 wild-type allele is located in the vicinity of 9q32 and is approximately 3 kb in length. This allele, which encodes alpha-1-acid glycoprotein 1, is involved in immunity and small molecule binding.	ORM1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126967>	C16725	Alpha-1-Acid Glycoprotein 1|AGP 1|Alpha-1 Acid Glycoprotein|Alpha-1-Acid Glycoprotein|Epididymis Secretory Sperm Binding Protein Li 153w|OMD 1|ORM1|Orosomucoid 1|Orosomucoid-1	Alpha-1-acid glycoprotein 1 (201 aa, ~24 kDa) is encoded by the human ORM1 gene. This protein may play a role in immunosuppression and small molecule transport.	Alpha-1-Acid Glycoprotein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126968>	C20912	IL15RA Gene|IL15RA|IL15RA|Interleukin 15 Receptor Subunit Alpha Gene	This gene is involved in interleukin binding and signaling.	IL15RA Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126969>	C126968	IL15RA wt Allele|CD215|Interleukin 15 Receptor Subunit Alpha wt Allele|Interleukin 15 Receptor, Alpha Gene	Human IL15RA wild-type allele is located in the vicinity of 10p15.1 and is approximately 41 kb in length. This allele, which encodes interleukin-15 receptor subunit alpha protein, plays a role in interleukin-mediated signaling.	IL15RA wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12696>	C32881|C168690	Coccyx|COCCYX|coccygeal skeleton|coccygeal vertebrae I-IV|coccyx|coccyx|fused caudal vertebrae|fused caudal vertebral column|os coccygis|tailbone|vertebrae coccygeae I-IV	A small bone located at the bottom of the spine. The coccyx is a result of 3-5 fused rudimentary vertebrae.	Coccyx		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C126970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126970>	C17667	Interleukin-15 Receptor Subunit Alpha|CD215 Antigen|IL-15 Receptor Subunit Alpha|IL-15R-Alpha|IL-15RA	Interleukin-15 receptor subunit alpha (267 aa, ~28 kDa) is encoded by the human IL15RA gene. This protein is involved in interleukin-dependent signaling.	Interleukin-15 Receptor Subunit Alpha		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126971>	C21292	ADRB3 Gene|ADRB3|ADRB3|Adrenoceptor Beta 3 Gene	This gene plays a role in the modulation of the physiological effects of catecholamines.	ADRB3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126972>	C126971	ADRB3 wt Allele|ADRB3R|Adrenergic, Beta-3-, Receptor Gene|Adrenoceptor Beta 3 wt Allele|B3AR|BETA3AR	Human ADRB3 wild-type allele is located in the vicinity of 8p11.23 and is approximately 4 kb in length. This allele, which encodes beta-3 adrenergic receptor protein, is involved in catecholamine-dependent G protein-coupled receptor signaling. Mutation and variation in the gene is associated with increased susceptibility to obesity.	ADRB3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126973>	C17062	Beta-3 Adrenergic Receptor|Beta 3 Adrenergic Receptor|Beta 3 Adrenoceptor|Beta-3 Adrenoceptor|Beta-3 Adrenoreceptor|Beta-3-Adrenergic Receptor|Beta-3-Adrenoceptor|Beta-3-Adrenoreceptor	Beta-3 adrenergic receptor (408 aa, ~44 kDa) is encoded by the human ADRB3 gene. This protein plays a role in G protein-coupled receptor signaling, lipolysis, and thermogenesis.	Beta-3 Adrenergic Receptor		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126974>	C192998	Sorted Cells	Cells separated and collected from a heterogeneous population based on physical, phenotypic, biochemical, and/or molecular properties, regardless of technique.			Body Substance	GDC Terminology|GDC Value Terminology
C126975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126975>	C3434	Uterine Corpus Hydropic Leiomyoma	A variant of leiomyoma arising from the uterine corpus. It is characterized by conspicuous zonal edema. Hyalinization may also be present.			Neoplastic Process	
C126976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126976>	C19747	Piezoelectric Elastic Modulus Scanner	A device that maps the elasticity modulus of a material surface using a piezoresonance probe during scanning microscopy.	Piezoelectric Elastic Modulus Scanner		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C126977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126977>	C21295	CD46 Gene|CD46|CD46|CD46 Molecule Gene	This gene is involved in fertilization, pathogen binding, complement activation and T-regulatory cell differentiation.	CD46 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126978>	C126977	CD46 wt Allele|AHUS2|CD46 Antigen, Complement Regulatory Protein Gene|CD46 Molecule wt Allele|CD46 Molecule, Complement Regulatory Protein Gene|MCP|MGC26544|MIC10|Membrane Cofactor Protein (CD46, Trophoblast-Lymphocyte Cross-Reactive Antigen) Gene|TLX|TRA2.10	Human CD46 wild-type allele is located in the vicinity of 1q32 and is approximately 43 kb in length. This allele, which encodes membrane cofactor protein, plays a role in the stimulation of T-regulatory cell differentiation, oocyte fertilization, the classical complement pathway and pathogen binding. Mutation of the gene is associated with increased susceptibility to hemolytic uremic syndrome.	CD46 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126979>	C17728	Membrane Cofactor Protein|Antigen Defined By Monoclonal Antibody TRA-2-10|Antigen Identified By Monoclonal Antibody TRA-2-10|CD46 Antigen|Complement Membrane Cofactor Protein|Measles Virus Receptor|TLX|Trophoblast Leucocyte Common Antigen|Trophoblast Leukocyte Common Antigen|Trophoblast-Lymphocyte Cross-Reactive Antigen	Membrane cofactor protein (392 aa, ~44 kDa) is encoded by the human CD46 gene. This protein is involved in the classical complementation pathway, pathogen binding, fertilization and T-cell differentiation.	Membrane Cofactor Protein		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12697>	C12700	Cochlear Nerve|Acoustic Nerve|Acoustic Nerve|Acoustic nerve|Auditory Nerve|Cochlear Root of Acoustic Nerve|Cochlear Root of Eighth Cranial Nerve|NERVE, COCHLEAR	The cochlear portion of cranial nerve VIII (the vestibulocochlear nerve), which transmits auditory sensory impulses to the cochlear nucleus in the brainstem.	Cochlear Nerve		Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C126980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126980>	C25839	CDK9 Gene|CDK9|CDK9|Cyclin-Dependent Kinase 9 Gene	This gene plays a role in cyclin-dependent phosphorylation of protein substrates.	CDK9 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|Pediatric Oncology Biomarkers/Targets Associated with Other Relevant Evidence
C126981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126981>	C126980	CDK9 wt Allele|C-2k|CDC2L4|CTK1|CTK1, Yeast, Homolog of Gene|Cyclin-Dependent Kinase 9 (CDC2-Related Kinase) Gene|Cyclin-Dependent Kinase 9 wt Allele|PITALRE|TAK	Human CDK9 wild-type allele is located in the vicinity of 9q34.1 and is approximately 5 kb in length. This allele, which encodes cyclin-dependent kinase 9 protein, is involved in protein phosphorylation and the regulation of transcription.	CDK9 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126982>	C17767	Cyclin-Dependent Kinase 9|C-2K|CDK9|Cell Division Cycle 2-Like Protein Kinase 4|Cell Division Protein Kinase 9|EC 2.7.11.22|EC 2.7.11.23|Serine/Threonine Protein Kinase PITALRE|Serine/Threonine-Protein Kinase PITALRE|Tat-Associated Kinase Complex Catalytic Subunit	Cyclin-dependent kinase 9 (372 aa, ~43 kDa) is encoded by the human CDK9 gene. This protein plays a role in the positive regulation of transcriptional elongation.	Cyclin-Dependent Kinase 9		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Biomarkers/Targets Associated with Other Relevant Evidence
C126983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126983>	C26511	CYP26A1 Gene|CYP26A1|CYP26A1|Cytochrome P450 Family 26 Subfamily A Member 1 Gene	This gene is involved in retinoic acid metabolism.	CYP26A1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126984>	C126983	CYP26A1 wt Allele|CP26|CYP26|Cytochrome P450 Family 26 Subfamily A Member 1 wt Allele|Cytochrome P450, Family 26, Subfamily A, Polypeptide 1 Gene|Cytochrome P450, Subfamily XXVIA, Polypeptide 1 Gene|P450, Retinoic Acid-Inactivating, 1 Gene|P450RAI|P450RAI1	Human CYP26A1 wild-type allele is located within 10q23-q24 and is approximately 4 kb in length. This allele, which encodes cytochrome P450 26A1 protein, plays a role in the metabolism of retinoids.	CYP26A1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126985>	C16484	Cytochrome P450 26A1|CYP26A1|Cytochrome P450 Retinoic Acid-Inactivating 1|Cytochrome P450RAI|EC 1.14.-.-|Retinoic Acid 4-Hydroxylase|Retinoic Acid-Metabolizing Cytochrome|hP450RAI	Cytochrome P450 26A1 (497 aa, ~56 kDa) is encoded by the human CYP26A1 gene. This protein is involved in the hydroxylation of retinoic acid.	Cytochrome P450 26A1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126986>	C25802	DNAJA1 Gene|DNAJA1|DNAJA1|DnaJ Heat Shock Protein Family (Hsp40) Member A1 Gene	This gene plays a role in both folding and intracellular trafficking of proteins.	DNAJA1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126987>	C126986	DNAJA1 wt Allele|DJ-2|DNAJ2|DjA1|DnaJ (Hsp40) Homolog, Subfamily A, Member 1 Gene|DnaJ Heat Shock Protein Family (Hsp40) Member A1 wt Allele|DnaJ/Hsp40 Homolog, Subfamily A, Member 1 Gene|HDJ2|HSDJ|HSJ-2|HSJ2|HSPF4|Heat Shock Protein, DNAJ-Like 2 Gene|NEDD7|Neural Precursor Cell Expressed, Developmentally Down-Regulated 7 Gene|hDJ-2	Human DNAJA1 wild-type allele is located in the vicinity of 9p13.3 and is approximately 15 kb in length. This allele, which encodes DnaJ homolog subfamily A member 1 protein, is involved in both protein folding and protein trafficking.	DNAJA1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126988>	C17764	DnaJ Homolog Subfamily A Member 1|DNAJA1|DnaJ Protein Homolog 2|HSDJ|HSJ-2|Heat Shock 40 kDa Protein 4|Heat Shock Protein J2|Human DnaJ Protein 2|hDj-2	DnaJ homolog subfamily A member 1 (397 aa, ~45 kDa) is encoded by the human DNAJA1 gene. This protein plays a role in both protein trafficking and protein folding.	DnaJ Homolog Subfamily A Member 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126989>	C21295	DRG1 Gene|DRG1|DRG1|Developmentally Regulated GTP Binding Protein 1 Gene	This gene is involved in both GTP binding and cell growth regulation.	DRG1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C12698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12698>	C32573	Common Bile Duct|COMMON BILE DUCT|Common Duct|Common Duct|Common bile duct structure (body structure)|DUCT, COMMON BILE|Ductus Communis Choledochus|common bile duct|common bile duct|ductus choledochus (biliaris)	Bile ducts are passageways that carry bile. Two major bile ducts come together into a "trunk"-the common bile duct which empties into the upper part of the small intestine (the part next to the stomach).	Common Bile Duct		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C126990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126990>	C126989	DRG1 wt Allele|DRG|Developmentally Regulated GTP Binding Protein 1 wt Allele|NEDD3|Neural Precursor Cell Expressed, Developmentally Down-Regulated 3 Gene|Neural Precursor Cell Expressed, Developmentally Downregulated 3 Gene	Human DRG1 wild-type allele is located in the vicinity of 22q12.2 and is approximately 129 kb in length. This allele, which encodes developmentally-regulated GTP-binding protein 1, plays a role in both cell growth regulation and GTP binding.	DRG1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126991>	C17728	Developmentally-Regulated GTP-Binding Protein 1|DRG-1|DRG1|Developmentally Regulated GTP-Binding Protein|Developmentally Regulated GTP-Binding Protein 1|NEDD-3|Neural Precursor Cell Expressed Developmentally Down-Regulated Protein 3	Developmentally-regulated GTP-binding protein 1 (367 aa, ~41 kDa) is encoded by the human DRG1 gene. This protein is involved in both GTP binding and the regulation of cell growth.	Developmentally-Regulated GTP-Binding Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126992>	C20921	GCSAM Gene|GCSAM|GCSAM|Germinal Center Associated Signaling and Motility Gene	This gene plays a role in both signaling and cell motility	GCSAM Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126993>	C126992	GCSAM wt Allele|GCAT2|GCET2|Germinal Center Associated Signaling and Motility wt Allele|Germinal Center B-Cell-Expressed Transcript 2 Gene|Germinal Center Expressed Transcript 2 Gene|Germinal Center-Associated, Signaling and Motility Gene|Germinal Center-Expressed Transcript 2 Gene|HGAL|Human Germinal Center-Associated Lymphoma Gene|MGC40441	Human GCSAM wild-type allele is located in the vicinity of 3q13.2 and is approximately 16 kb in length. This allele, which encodes germinal center-associated signaling and motility protein, is involved in signaling pathways and the negative regulation of lymphocyte migration.	GCSAM wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126994>	C18515	Germinal Center-Associated Signaling and Motility Protein|Germinal Center B-Cell-Expressed Transcript 2 Protein|Germinal Center-Associated Lymphoma Protein|hGAL	Germinal center-associated signaling and motility protein (178 aa, ~21 kDa) is encoded by the human GCSAM gene. This protein plays a role in both the negative regulation of lymphocyte motility and the modulation of signaling.	Germinal Center-Associated Signaling and Motility Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126995>	C26068	GDF2 Gene|GDF2|GDF2|Growth Differentiation Factor 2 Gene	This gene is involved in the inhibition of angiogenesis.	GDF2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C126996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126996>	C126995	GDF2 wt Allele|BMP-9|BMP9|Growth Differentiation Factor 2 wt Allele|HHT5	Human GDF2 wild-type allele is located in the vicinity of 10q11.22 and is approximately 5 kb in length. This allele, which encodes growth/differentiation factor 2 protein, plays a role in angiogenesis regulation. Mutation of the gene is associated with hereditary hemorrhagic telangiectasia type 5.	GDF2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126997>	C17274	Growth/Differentiation Factor 2|BMP-9|Bone Morphogenetic Protein 9|GDF-2	Growth/differentiation factor 2 (429 aa, ~47 kDa) is encoded by the human GDF2 gene. This protein is involved in the negative regulation of angiogenesis.	Growth/Differentiation Factor 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C126998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126998>	C40219	Uterine Corpus High Grade Endometrial Stromal Sarcoma|Endometrial Stromal Sarcoma, High Grade|High Grade ESS|High Grade Endometrial Stromal Sarcoma|High-Grade ESS|High-Grade Endometrial Stromal Sarcoma|Uterine Corpus High Grade ESS|Uterine Corpus High-Grade Endometrial Stromal Sarcoma|YWHAE-FAM22 ESS|YWHAE-FAM22 Endometrial Stromal Sarcoma|YWHAE::FAM22 Endometrial Stromal Sarcoma	A rare, high-grade sarcoma that arises from the endometrial stroma. It is characterized by round cell morphology. It was previously also known as undifferentiated uterine sarcoma. In 2014, high grade endometrial stromal sarcoma was reclassified and is currently considered a distinct and rare neoplasm. It appears to have a prognosis that falls between low grade endometrial stromal sarcoma and undifferentiated sarcoma.			Neoplastic Process	GDC Terminology|GDC Value Terminology|NCIt Neoplasm Core Terminology
C126999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C126999>	C28533	GJB2 Gene|GJB2|GJB2|Gap Junction Protein Beta 2 Gene	This gene plays a role in gap junction function.	GJB2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C12699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12699>	C13019	Corneal Stroma|CORNEAL STROMA	The thickest layer of corneal tissue, composed of collagen fibrils, that is located between the epithelium and the inner endothelium, and extends from behind Bowman's layer to in front of Descement's membrane.	Corneal Stroma		Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C1269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1269>	C912	TAG-72 Antigen|Antitumor-Associated Glycoprotein 72|CA 72-4|CA-72-4|CA72-4|Cancer Antigen 72-4|TAG-72|TAG-72|TAG-72 antigen	Tumor-associated oncofetal glycoprotein 72 (TAG-72) is a high molecular weight (220-400 kD) complex expressed by a wide variety of human adenocarcinomas. This antigen is expressed by a majority of invasive ductal breast carcinomas, and most colon, pancreatic, gastric, esophageal, lung (non-small cell), ovarian and endometrial adenocarcinomas, and on normal secretory endometrium, but not on other normal tissues. It is not expressed by leukemias, lymphomas, sarcomas, mesotheliomas, melanomas or benign tumors. The monoclonal antibodies against TAG-72 have been widely employed for the immunohistochemical analysis of adenocarcinomas as well as for radioimmunoscintigraphy and radioimmunoguided surgery.	TAG-72 Antigen		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C127000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127000>	C126999	GJB2 wt Allele|CX26|DFNA3|DFNA3A|DFNB1|DFNB1A|Gap Junction Protein Beta 2 wt Allele|Gap Junction Protein, 26kD Gene|Gap Junction Protein, Beta 2, 26kD (Connexin 26) Gene|Gap Junction Protein, Beta 2, 26kDa (Connexin 26) Gene|Gap Junction Protein, Beta 2, 26kDa Gene|Gap Junction Protein, Beta-2 Gene|HID|KID|NSRD1|PPK	Human GJB2 wild-type allele is located within 13q11-q12 and is approximately 6 kb in length. This allele, which encodes gap junction beta-2 protein, is involved in the assembly and function of gap junctions. Mutation in the gene is associated with syndromic deafness.	GJB2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127001>	C16386	Gap Junction Beta-2 Protein|Connexin 26|Connexin-26|Cx26|GJB2|Gap Junction Protein Beta 2	Gap junction beta-2 protein (226 aa, ~26 kDa) is encoded by the human GJB2 gene. This protein plays a role in gap junction-mediated facilitated diffusion.	Gap Junction Beta-2 Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127002>	C25939	GPX3 Gene|GPX3|GPX3|Glutathione Peroxidase 3 Gene	This gene is involved in the metabolism of hydrogen peroxide and lipid peroxides.	GPX3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C127003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127003>	C127002	GPX3 wt Allele|GPXP|GPx-P|GSHPx-3|GSHPx-P|Glutathione Peroxidase 3 (Plasma) Gene|Glutathione Peroxidase 3 wt Allele|Glutathione Peroxidase 3, Plasma Gene	Human GPX3 wild-type allele is located 5q33.1 and is approximately 9 kb in length. This allele, which encodes glutathione peroxidase 3 protein, plays a role in hydrogen peroxide and lipid peroxide metabolism.	GPX3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127004>	C16946	Glutathione Peroxidase 3|EC 1.11.1.9|Extracellular Glutathione Peroxidase|GPX3|GPx-3|GPx-P|GSHPx-3|GSHPx-P|Plasma Glutathione Peroxidase	Glutathione peroxidase 3 (226 aa, ~26 kDa) is encoded by the human GPX3 gene. This protein is involved in hydrogen peroxide and lipid peroxide detoxification.	Glutathione Peroxidase 3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127005>	C40217	Uterine Corpus Tumor Resembling Ovarian Sex Cord Tumor	A usually benign neoplasm that arises from the uterine corpus. It resembles ovarian sex cord tumors. It lacks a component of recognizable endometrial stroma and the JAZF1-SUZ12 fusion which is characteristic of the endometrial stromal neoplasms.			Neoplastic Process	
C127006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127006>	C26003	HGFAC Gene|HGF Activator Gene|HGFAC|HGFAC	This gene is involved in growth factor processing.	HGFAC Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C127007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127007>	C127006	HGFAC wt Allele|HGF Activator wt Allele|HGFA|HGFAP	Human HGFAC wild-type allele is located in the vicinity of 4p16 and is approximately 8 kb in length. This allele, which encodes hepatocyte growth factor activator protein, plays a role in the activation of hepatocyte growth factor.	HGFAC wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127008>	C17123	Hepatocyte Growth Factor Activator|EC 3.4.21.-|HGF Activator|HGFA|HGFAC	Hepatocyte growth factor activator (655 aa, ~71 kDa) is encoded by the human HGFAC gene. This protein is involved in the proteolysis of single-chain hepatocyte growth factor.	Hepatocyte Growth Factor Activator		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127009>	C20921	HHIP Gene|HHIP|HHIP|Hedgehog Interacting Protein Gene	This gene plays a role in hedgehog signaling pathways.	HHIP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C12700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12700>	C12466	Cranial Nerve|CRANIAL NERVE|Cranial nerve, NOS|NERVE, CRANIAL|Nerve(s) Cranial|cranial nerve|cranial neural tree organ	Any of the 12 paired nerves that originate in the brain stem.	Cranial Nerve		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C127010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127010>	C127009	HHIP wt Allele|FLJ20992|HIP|Hedgehog Interacting Protein wt Allele|UNQ5825/PRO19644	Human HHIP wild-type allele is located within 4q28-q32 and is approximately 99 kb in length. This allele, which encodes hedgehog-interacting protein, is involved in the modulation of hedgehog-mediated signaling.	HHIP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127011>	C18515	Hedgehog-Interacting Protein|HHIP|HIP	Hedgehog-interacting protein (700 aa, ~79 kDa) is encoded by the human HHIP gene. This protein plays a role in the regulation of hedgehog signaling pathways.	Hedgehog-Interacting Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127012>	C129825|C129650|C125450	Baricitinib|3-Azetidineacetonitrile, 1-(Ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)-|BARICITINIB|INCB 028050|INCB028050|JAK inhibitors: baricitinib|LY 3009104|LY-3009104|LY3009104|Olumiant	An orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon administration, baricitinib binds to JAK1/2, which inhibits JAK1/2 activation and leads to the inhibition of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This decreases the production of inflammatory cytokines and may prevent an inflammatory response. In addition, baricitinib may induce apoptosis and reduce proliferation of JAK1/2-expressing tumor cells. JAK kinases are intracellular enzymes involved in cytokine signaling, inflammation, immune function and hematopoiesis; they are also upregulated and/or mutated in various tumor cell types.	Baricitinib		Pharmacologic Substance	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|Appendix 8: Pharmacological Therapy Terminology|CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology|Therapies for COVID-19 Terminology
C127013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127013>	C210660	IGHV3-21 Gene|IGHV3-21|IGHV3-21|Immunoglobulin Heavy Variable 3-21 Gene	This gene is involved in immunoglobulin heavy chain structure.	IGHV3-21 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C127014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127014>	C127013	IGHV3-21 wt Allele|Homo sapiens Immunoglobulin Heavy Variable 3-21 Gene|IGHV321|Immunogloblin Heavy Chain Variable Region 3-21 Gene|Immunoglobulin Heavy Variable 3-21 wt Allele|VH	Human IGHV3-21 wild-type allele is located in the vicinity of 14q32.33 and is approximately 1 kb in length. This allele, which encodes the immunoglobulin heavy variable 3-21 protein, plays a role in the structure of immunoglobulin heavy chains. Expression of mutated IGHV3-21 in chronic lymphocytic leukemia may be associated with a poor prognosis.	IGHV3-21 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127015>	C210663	Immunoglobulin Heavy Variable 3-21|Homo sapiens Immunoglobulin Heavy Variable 3-21|IGHV3-21|Immunogloblin Heavy Chain Variable Region 3-21|Protein IGHV3-21	Immunoglobulin heavy variable 3-21 (117 aa, ~13 kDa) is encoded by the human IGHV3-21 gene. This protein is involved in immunoglobulin heavy chain variability.	Immunoglobulin Heavy Variable 3-21		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127016>	C25871	ITPKC Gene|ITPKC|ITPKC|Inositol-Trisphosphate 3-Kinase C Gene	This gene plays a role in both second messenger metabolism and calcium homeostasis.	ITPKC Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C127017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127017>	C127016	ITPKC wt Allele|IP3-3KC|IP3KC|Inositol-Trisphosphate 3-Kinase C wt Allele	Human ITPKC wild-type allele is located in the vicinity of 19q13.1 and is approximately 24 kb in length. This allele, which encodes inositol-trisphosphate 3-kinase C protein, is involved in calcium homeostasis and inositol phosphate metabolism.	ITPKC wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127018>	C16984	Inositol-Trisphosphate 3-Kinase C|EC 2.7.1.127|IP3 3-Kinase C|IP3K C|ITPKC|Inositol 1,4,5-Trisphosphate 3-Kinase C|InsP 3 Kinase C|InsP 3-Kinase C	Inositol-trisphosphate 3-kinase C (683 aa, ~75 kDa) is encoded by the human ITPKC gene. This protein plays a role in the phosphorylation of inositol phosphate.	Inositol-Trisphosphate 3-Kinase C		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127019>	C21295	ELAPOR1 Gene|ELAPOR1|ELAPOR1|Endosome-Lysosome Associated Apoptosis and Autophagy Regulator 1 Gene|KIAA1324|KIAA1324 Gene	This gene is involved in autophagy and RNA binding.	KIAA1324 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C12701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12701>	C33563	Dermis|Corium|Cutis|DERMAL TISSUE|dermis|dermis|vertebrate dermis	The lower layer of the skin containing connective tissue, blood vessels, oil and sweat glands, nerves, hair follicles and other structures.	Dermis		Tissue	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|OS Authorized Value Terminology|OS Tumor Assessment Table|UBERON Terminology
C127020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127020>	C127019	ELAPOR1 wt Allele|EIG121|Endosome-Lysosome Associated Apoptosis and Autophagy Regulator 1 wt Allele|Endosome-Lysosome-Associated Apoptosis and Autophagy Regulator 1 Gene|Estrogen Induced Gene 121|Estrogen-Induced Gene 121|KIAA1324|KIAA1324 wt Allele|Maba1|UNQ2426/PRO4985	Human ELAPOR1 wild-type allele is located in the vicinity of 1p13.3 and is approximately 93 kb in length. This allele, which encodes endosome/lysosome-associated apoptosis and autophagy regulator 1 protein, plays a role in poly(A) RNA binding and autophagosome assembly.	KIAA1324 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127021>	C21298	Endosome/Lysosome-Associated Apoptosis and Autophagy Regulator 1|ELAPOR1|Estrogen-Induced Gene 121 Protein|UPF0577 Protein KIAA1324|UPF0577 Protein KIAA1324	Endosome/lysosome-associated apoptosis and autophagy regulator 1 (1013 aa, ~111 kDa) is encoded by the human ELAPOR1 gene. This protein is involved in promoting autophagy and binding to RNA.	UPF0577 Protein KIAA1324		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127022>	C20744	MBP Gene|MBP|MBP|Myelin Basic Protein Gene	This gene plays a role in myelin sheath formation.	MBP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C127023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127023>	C127022	MBP wt Allele|Myelin A1 Protein, Basic Gene|Myelin Basic Protein wt Allele	Human MBP wild-type allele is located in the vicinity of 18q23 and is approximately 155 kb in length. This allele, which encodes myelin basic protein, is involved in neuronal development and myelination.	MBP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127024>	C91105	Cancer Patient Tobacco Use Questionnaire|C-TUQ|Cancer Patient Tobacco Use Questionnaire (C-TUQ)	A questionnaire developed for the baseline and longitudinal assessment of tobacco use in the cancer setting. Domains include cigarette smoking history and current use, use relative to cancer diagnosis and treatment, other tobacco product use, cessation, and second-hand exposure.			Intellectual Product	
C127025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127025>	C18073	Myelin Basic Protein|MBP|Myelin A1 Protein|Myelin Membrane Encephalitogenic Protein	Myelin basic protein (304 aa, ~33 kDa) is encoded by the human MBP gene. This protein plays a role in myelination and neuronal development.	Myelin Basic Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127026>	C175313	Smoked a Cigarette Today|I smoked a cigarette today (at least one puff)	A response indicating that an individual smoked at least one puff of a cigarette today.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127027>	C175313	Last Smoked a Cigarette Between One and Seven Days Ago|1-7 days	A response indicating that it has been between one and seven days since an individual smoked a cigarette.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127028>	C175313	Last Smoked a Cigarette Less than One Month Ago|Less than 1 month	A response indicating that it has been less than one month since an individual smoked a cigarette.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127029>	C175313	Last Smoked a Cigarette Less than One Year Ago|Less than 1 year	A response indicating that it has been less than one year since an individual smoked a cigarette.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C12702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12702>	C13056	Diaphragm|DIAPHRAGM|Diaphragm structure (body structure)|MUSCLE, DIAPHRAGM|diaphragm|diaphragm|diaphragm muscle|diaphragm of thorax|thoracic diaphragm	Fibromuscular tissue that separates the thoracic from the abdominal cavity. It increases the volume of the thoracic cavity through contractions, thus facilitating respiration.	Diaphragm		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C127030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127030>	C175313	Last Smoked a Cigarette More than One Year Ago|More than 1 year	A response indicating that it has been more than one year since an individual smoked a cigarette.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127031>	C175313	Don't Know or Remember When Last Smoked a Cigarette|Don't know/don't remember	A response indicating that an individual doesn't know and/or remember how long it has been since they last smoked a cigarette.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127032>	C175313	Smoked a Cigarette Every Day|Smoked every day	A response indicating that an individual smoked a cigarette every day.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127033>	C175313	Smoked a Cigarette Some Days|Smoked some days	A response indicating that an individual smoked a cigarette some days.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127034>	C175313	Did Not Smoke at All|Didn't smoke at all	A response indicating that an individual didn't smoke a cigarette at all.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127035>	C175313	Don't Know or Not Sure When Smoked a Cigarette	A response indicating that an individual doesn't know or is not sure whether they smoked a cigarette.			Intellectual Product	
C127036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127036>	C175313	Have Not Smoked Since Diagnosis|Not applicable; I have not smoked cigarettes since my diagnosis	A response indicating that an individual has not smoked since they have been diagnosed with cancer.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127037>	C226724	Have Not Been Diagnosed|I have not been diagnosed	A response indicating that an individual has not been diagnosed with cancer.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127038>	C226700	Have Not Had Cancer Surgery|I have not had cancer surgery	A response indicating that an individual has not had surgery for cancer.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127039>	C226700	Have Not Received Treatment|I have not received treatment	A response indicating that an individual has not been treated for cancer.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C12703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12703>	C54105	Ectoderm|Ectodermal	The outer of the three germ layers of the embryo; it gives rise to epidermis and neural tissue.	Ectoderm		Embryonic Structure	
C127040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127040>	C226700	Have Not Completed Treatment|I have not completed treatment	A response indicating that an individual has not completed treatment for cancer.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127041>	C91106	First Visit to This Clinic|This is my first visit to this clinic	A response indicating that this is an individual's first visit to the clinic.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127042>	C175282	Stayed Off Cigarettes Entire Time Since Diagnosis|Stayed off cigarettes entire time since diagnosis	A response indicating that an individual stayed off cigarettes the entire time since their diagnosis.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127043>	C175282	Stayed Off Cigarettes Less than One Day Since Diagnosis|Stayed off cigarettes less than one day	A response indicating that an individual stayed off cigarettes less than one day since their diagnosis.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127044>	C175282	Stayed Off Cigarettes Less than One Month Since Diagnosis|Less than 1 month	A response indicating that an individual stayed off cigarettes less than one month since their diagnosis.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127045>	C175282	Stayed Off Cigarettes Less than One Year Since Diagnosis|Less than 1 year	A response indicating that an individual stayed off cigarettes less than one year since their diagnosis.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127046>	C175282	Stayed Off Cigarettes More than One Year Since Diagnosis|More than 1 year	A response indicating that an individual stayed off cigarettes more than one year since their diagnosis.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127047>	C175282	Don't Know or Remember if Stayed Off Cigarettes Since Diagnosis|Don't know/Don't remember	A response indicating that an individual doesn't know or remember if they stayed off cigarettes since their diagnosis.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127048>	C3014|C27788	Atypical Endometriosis	A precancerous lesion characterized by the presence of atypical glandular epithelial features in foci of endometriosis. Atypical endometriosis has been observed in contiguity with carcinomas.			Disease or Syndrome	
C127049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127049>	C226398|C219858	t(10;17)(q22;p13)	A cytogenetic abnormality that refers to the translocation of the long arm (q22) of chromosome 10 and the short arm (p13) of chromosome 17. It results in an YWHAE-FAM22 fusion. It has been described in high grade endometrial stromal sarcomas and a subset of clear cell sarcomas of the kidney.			Cell or Molecular Dysfunction	
C12704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12704>	C13319	Endocrine Gland|Endocrine Organs|Endocrine gland, NOS|ductless gland|endocrine gland|glandula endocrina	Ductless glands that secrete substances which are released directly into the circulation and which influence metabolism and other body functions.	Endocrine Gland		Body Part, Organ, or Organ Component	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C127050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127050>	C36346	YWHAE-FAM22 Fusion Protein Expression	Expression of fusion protein YWHAE-FAM22 transcripts resulting from a t(10;17)(q22;p13). The translocation results in rearrangement of the YWHAE gene on chromosome 17 and FAM22 gene on chromosome 10. It has been described in high grade endometrial stromal sarcomas and a subset of clear cell sarcomas of the kidney.			Cell or Molecular Dysfunction	
C127051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127051>	C1813	Filtered Cigar	A smaller cigar that is combined with a filter intended to reduce the amount of smoke, tar, and fine particles inhaled.			Manufactured Object	Cancer Patient Tobacco Use Questionnaire
C127052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127052>	C892	Snus	A moist powder tobacco product that is used by placing it under the upper lip for extended periods.			Hazardous or Poisonous Substance	Cancer Patient Tobacco Use Questionnaire
C127053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127053>	C47795	Paan with Tobacco|Paan Tobacco|Paan with tobacco	A combination of betel leaf, areca nut, and tobacco. It is chewed for its stimulant and psychoactive effects.			Pharmacologic Substance	Cancer Patient Tobacco Use Questionnaire
C127054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127054>	C47795	Gutka|Gutka Tobacco	A combination of crushed areca nut, tobacco, catechu, paraffin wax, slaked lime, and sweet or savory flavorings. It is placed between the cheek and gum and is a mild stimulant.			Pharmacologic Substance	Cancer Patient Tobacco Use Questionnaire
C127055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127055>	C47795	Zarda|Zarda Tobacco	A combination of tobacco, lime, spices, vegetable dyes, and areca nut. It is typically chewed for its stimulant effects.			Pharmacologic Substance	Cancer Patient Tobacco Use Questionnaire
C127056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127056>	C47795	Khaini|Khaini Tobacco	A combination of tobacco and slaked lime paste with or without areca nut. It is placed between the cheek and gum and is a mild stimulant.			Pharmacologic Substance	Cancer Patient Tobacco Use Questionnaire
C127057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127057>	C28510	YWHAE/FAM22 Fusion Gene|YWHAE-FAM22 Fusion Gene|YWHAE-FAM22A-B-E Fusion Gene|YWHAE-NUTM2 Fusion Gene|YWHAE-NUTM2A-B-E Fusion Gene|YWHAE/FAM22A-B-E Fusion Gene|YWHAE/NUTM2 Fusion Gene|YWHAE/NUTM2A-B-E Fusion Gene|YWHAE::FAM22 Fusion Gene|YWHAE::NUTM2 Fusion Gene|YWHAE::NUTM2A-B-E Fusion Gene|YWHAE::NUTM2A/B/E Fusion Gene	A fusion gene that results from a chromosomal translocation t(10;17)(q22;p13) which fuses exon 5 the YWHAE gene with exon 2 of the FAM22A (NUTM2A), FAM22B (NUTM2B), or FAM22E (NUTM2E) gene. These fusions are associated with high grade endometrial stromal sarcomas and clear cell sarcomas of the kidney.			Gene or Genome	
C127058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127058>	C6339|C214845	Uterine Corpus Rhabdomyosarcoma	A rare malignant heterologous neoplasm with skeletal muscle differentiation arising from the uterine corpus. It usually manifests with vaginal bleeding. The prognosis is poor.			Neoplastic Process	
C127059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127059>	C172730	Smoked at Least 100 Cigarettes in Entire Life Question|Have you smoked at least 100 cigarettes (5 packs=100 cigarettes) in your entire life|Smoked at Least 100 Cigarettes in Entire Life	A question about whether an individual has smoked at least 100 cigarettes in their entire lifetime.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C12705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12705>	C12919	Endocrine System|Body System, Endocrine/Metabolic|Endocrine|Endocrine/Metabolic Body System|Endocrine/Metabolic Organ System|Hormonal System|Metabolic/Endocrine Body System|Organ System, Endocrine/Metabolic|endocrine system|endocrine system	The body system that comprises the organs and glands that produce hormones that are secreted into the blood and control physiological functions that include reproduction, growth and development, metabolism, and stress responses.	Endocrine System		Body System	ICDC Terminology|ICDC Value Terminology|UBERON Terminology
C127060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127060>	C173060	Age When First Smoked a Cigarette Question|AGESTSMK|AGESTSMK|Age Started Smoking|Age Started Smoking|Age Started Smoking|Age When First Smoked a Cigarette|Enter age at which the participant started smoking|How old were you when you first smoked a cigarette (even one or two puffs)	A question about how old an individual was when they first smoked a cigarette.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire|CDISC SDTM Subject Characteristic Test Code Terminology|CDISC SDTM Subject Characteristic Test Name Terminology|CDISC SDTM Terminology|CDISC SDTM Tobacco Findings About Test Code Terminology|CDISC SDTM Tobacco Findings About Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C127061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127061>	C173060	How Old When First Began Smoking Cigarettes Regularly Question|How Old When First Began Smoking Cigarettes Regularly|How old were you when you first began smoking cigarettes regularly	A question about how old an individual was when they first began smoking cigarettes regularly.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127062>	C176245|C175313	Never Smoked Cigarettes Regularly|Check here if you have never smoked cigarettes regularly	A response indicating that an individual never smoked cigarettes regularly.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127063>	C173060	Total Years Have Smoked Cigarettes Question|How many total years have you smoked (or did you smoke) cigarettes|Total Years Have Smoked Cigarettes|Total Years of Cigarette Smoking|years smoked|years_smoked	A question about the total years an individual smoked or currently smokes cigarettes.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire|GDC Property Terminology|GDC Terminology
C127064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127064>	C173060	Average Number Cigarettes Smoked a Day Question|Average Number Cigarettes Smoked a Day|On average when you have smoked, about how many cigarettes do you (or did you) smoke a day|cigarettes per day|cigarettes_per_day	A question about the average number of cigarettes an individual smoked or smokes in one day.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire|GDC Property Terminology|GDC Terminology
C127065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127065>	C173060	How Long Since Last Cigarette Question|How Long Since Last Cigarette|How Long Since Last Smoked Cigarette|How long has it been since you last smoked a cigarette (even one or two puffs)	A question about how long it has been since an individual last smoked a cigarette.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127066>	C173060	Number of Days Since Last Cigarette Question|Number of Days Since Last Cigarette|Number of days since last cigarette	A question about the number of days since an individual last smoked a cigarette.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127067>	C173060	Number of Weeks Since Last Cigarette Question|Number of Weeks Since Last Cigarette|Number of weeks since last cigarette	A question about the number of weeks since an individual last smoked a cigarette.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127068>	C173060	Number of Months Since Last Cigarette Question|Number of Months Since Last Cigarette|Number of months since last cigarette	A question about the number of months since an individual last smoked a cigarette.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127069>	C173060	Number of Years Since Last Cigarette Question|Number of Years Since Last Cigarette|Number of years since last cigarette	A question about the number of years since an individual last smoked a cigarette.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C12706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12706>	C54105	Endoderm	The deepest of the three primary germ layers (ectoderm, mesoderm and endoderm) found in the early trilaminar embryo, which forms the epithelial linings of the respiratory and digestive tracts.	Endoderm		Embryonic Structure	
C127070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127070>	C172730	Smoked Cigarettes During Year Before First Diagnosed with Cancer Question|Smoked Cigarettes During Year Before First Diagnosed with Cancer|Smoked Cigarettes Year Before First Told You Had Cancer|The year before you were first told you had cancer	A question about whether an individual smoked cigarettes the year before they were first told they had cancer.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127071>	C40180|C3608|C121791	Benign Uterine Corpus PEComa|Benign Uterine Corpus Perivascular Epithelioid Cell Tumor|Uterine Corpus Benign PEComa|Uterine Corpus Benign Perivascular Epithelioid Cell Tumor	A benign neoplasm with perivascular epithelioid cell differentiation arising from the uterine corpus. It is characterized by the absence of pleomorphism and scarcity or absence of mitotic figures. It usually affects perimenopausal women. Patients present with a pelvic mass or abnormal bleeding.			Neoplastic Process	
C127072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127072>	C61574|C40180|C121792	Uterine Corpus Malignant PEComa|Malignant Uterine Corpus PEComa|Malignant Uterine Corpus Perivascular Epithelioid Cell Tumor|Uterine Corpus Malignant Perivascular Epithelioid Cell Tumor	A malignant neoplasm with perivascular epithelioid cell differentiation arising from the uterine corpus. The neoplasm is usually a large size, and charcaterized by the presence of marked nuclear atypia, pleomorphism, increased mitotic activity, necrosis, and infiltrative margins.  The most common metastatic sites are lungs, lymph nodes, and bone. Patients present with a pelvic mass or abnormal bleeding.			Neoplastic Process	
C127073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127073>	C173812|C172730	Smoked Cigarettes After Diagnosis and Before Treatment Start Question|After diagnosis, and before treatment started|Smoked Cigarettes After Diagnosis and Before Treatment Start	A question about whether an individual smoked cigarettes after diagnosis and before treatment started.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127074>	C172730	Smoked Cigarettes From Two Days Before Last Cancer Surgery to Two Days After Question|From 2 days before your last cancer surgery to 2 days after|Smoked Cigarettes From Two Days Before Last Cancer Surgery to Two Days After	A question about whether an individual smoked cigarettes from two days before to two days after their last cancer surgery.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127075>	C173812|C172730	Smoked Cigarettes During the Course of Treatment Question|During the course of treatment|Smoked Cigarettes During the Course of Treatment	A question about whether an individual smoked cigarettes during the course of treatment.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127076>	C173812|C172730	Smoked Cigarettes After Treatment End Question|After treatment ended|Smoked Cigarettes After Treatment End	A question about whether an individual smoked cigarettes after treatment ended.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127077>	C6300|C3918	Uterine Corpus Germ Cell Tumor	A benign or malignant germ cell tumor that arises from the uterine corpus. Representative examples include teratoma and yolk sac tumor.			Neoplastic Process	
C127078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127078>	C172730	Smoked Cigarettes Since Last Visit to This Clinic Question|Since your last visit to this clinic|Smoked Cigarettes Since Last Visit to This Clinic	A question about whether an individual smoked cigarettes since their last visit to this clinic.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127079>	C173060	Tobacco Products Used Regularly Since Cancer Diagnosis Question|Products Used Regularly Since Cancer Diagnosis|Products Used Regularly Since First Told You Had Cancer|Since you were first told you had cancer, which of the following products have you used regularly|Tobacco Products Used Regularly Since Cancer Diagnosis	A question about the tobacco-containing products an individual has used regularly since they were first told they had cancer.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C12707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12707>	C12481	Corneal Endothelium|CORNEAL ENDOTHELIUM	A single layer of specialized, flat, mitochondria-rich cells that line the posterior surface of the cornea, which govern fluid and solute transport across the posterior surface of the cornea.	Corneal Endothelium		Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127080>	C91102	Other Products Used Regularly Since Cancer Diagnosis Question|Other Products Used Regularly Since Cancer Diagnosis|Other Products Used Regularly Since First Told You Had Cancer|Other Tobacco Products Used Regularly Since Cancer Diagnosis|What other product have you used regularly	A question about the use of tobacco-containing products not previously mentioned or specified that an individual has used regularly since they were first told they had cancer.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127081>	C173060	Longest Time Stayed off Cigarettes Since Cancer Diagnosis Question|Longest Time Stayed off Cigarettes Since Cancer Diagnosis|Longest Time Stayed off Cigarettes Since First Told You Had Cancer|Since you were first told you had cancer, what was the longest time you stayed (or have stayed) off cigarettes	A question about the longest time an individual has stayed off cigarettes since they were first told they had cancer.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127082>	C173060	Number of Days Stayed Off Cigarettes Question|Number of Days Stayed Off Cigarettes|Number of days stayed off cigarettes	A question about the number of days an individual stayed off cigarettes.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127083>	C173060	Number of Weeks Stayed Off Cigarettes Question|Number of Weeks Stayed Off Cigarettes|Number of weeks stayed off cigarettes	A question about the number of weeks an individual stayed off cigarettes.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127084>	C173060	Number of Months Stayed Off Cigarettes Question|Number of Months Stayed Off Cigarettes|Number of months stayed off cigarettes	A question about the number of months an individual stayed off cigarettes.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127085>	C173060	Number of Years Stayed Off Cigarettes Question|Number of Years Stayed Off Cigarettes|Number of years stayed off cigarettes	A question about the number of years an individual stayed off cigarettes.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127086>	C172730	Smoked Any Cigarettes Past 30 Days Question|In the past 30 days, have you smoked any cigarettes, even one or two puffs|Past 30 Days Smoked Any Cigarettes|Smoked Any Cigarettes Past 30 Days	A question about whether an individual has smoked any cigarettes in the past 30 days.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127087>	C173060	Number of Days Smoked Cigarettes Past 30 Days Question|In the past 30 days, on how many days did you smoke cigarettes|Number of Days Smoked Cigarettes Past 30 Days|Past 30 Days Number of Days Smoked Cigarettes	A question about how many days an individual has smoked in the past 30 days.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127088>	C173060	Products Used to Quit or Stay Off Smoking Cigarettes Since Diagnosis Question|Products Used to Quit or Stay Off Smoking Cigarettes Since Diagnosis|Products Used to Quit or Stay Off Smoking Cigarettes Since First Told You Had Cancer|Since you were first told you had cancer, which of the following products have you used to quit (or to stay off) smoking cigarettes	A question about the products an individual has used to quit or stay off smoking cigarettes since they were first told they had cancer.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127089>	C173060	Other Products Used to Quit or Stay Off Smoking Cigarettes Since Diagnosis Question|Other Products Used to Quit or Stay Off Smoking Cigarettes Since Diagnosis|Other Products Used to Quit or Stay Off Smoking Cigarettes Since First Told You Had Cancer|What other products have you used to quit (or to stay off) smoking cigarettes	A question about the use of products not previously mentioned or specified that an individual has used since they were first told they had cancer.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C12708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12708>	C33563	Epidermis|EPIDERMAL TISSUE|Epidermal|epidermis	The epithelial portion of the skin (cutis). It consists of the following layers: stratum corneum (horny layer), stratum granulosum (granular layer), stratum spinosum (prickle cell layer), and stratum basale (basal cell layer).	Epidermis		Tissue	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127090>	C173060	Assistance Used to Quit or Stay Off Smoking Cigarettes Since Diagnosis Question|Assistance Used to Quit or Stay Off Smoking Cigarettes Since Diagnosis|Assistance Used to Quit or Stay Off Smoking Cigarettes Since First Told You Had Cancer|Since you were first told you had cancer, what assistance have you used to quit (or to stay off) smoking cigarettes	A question about what assistance an individual has used to quit or stay off smoking cigarettes since they were first told they first had cancer.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127091>	C173060	Other Assistance Used to Quit or Stay Off Smoking Cigarettes Since Diagnosis Question|Other Assistance Used to Quit or Stay Off Smoking Cigarettes Since Diagnosis|Other Assistance Used to Quit or Stay Off Smoking Cigarettes Since First Told You Had Cancer|What other assistance have you used to quit (or to stay off) smoking cigarettes	A question about the use of assistance not previously mentioned or specified that an individual has used to quit or stay off smoking cigarettes since they were first told they had cancer.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127092>	C173145|C173060	Cancer Doctor Advised to Quit Smoking Cigarettes Question|Cancer Doctor Advised Quit Cigarette Smoking|Cancer Doctor Advised to Quit Smoking Cigarettes|Have your cancer doctors advised you to quit smoking cigarettes	A question about whether an individual's cancer doctor has advised them to quit smoking cigarettes.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127093>	C173060	Trying to Quit or Stay Off Smoking Cigarettes Past 30 Days Question|In the past 30 days, have you been trying to quit (or trying to stay off) smoking cigarettes|Past 30 Days Trying to Quit or Stay Off Smoking Cigarettes|Trying to Quit or Stay Off Smoking Cigarettes Past 30 Days	A question about whether an individual has tried or has been trying to quit or stay off smoking cigarettes.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127094>	C173060	Products Used to Quit or Stay Off Smoking Cigarettes Past 30 Days Question|In the past 30 days, what, if any, products have you used to quit (or to stay off) smoking cigarettes|Past 30 Days Products Used to Quit or Stay Off Smoking Cigarettes|Products Used to Quit or Stay Off Smoking Cigarettes Past 30 Days	A question about the products an individual used in the past 30 days to quit or stay off smoking cigarettes.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127095>	C173060	Other Products Used to Quit or Stay Off Smoking Cigarettes Past 30 Days Question|Other Products Used to Quit or Stay Off Smoking Cigarettes Past 30 Days|Past 30 Days Other Products Used to Quit or Stay Off Smoking Cigarettes|What other products have you used to quit (or to stay off) smoking cigarettes	A question about products not previously mentioned or specified that an individual used in the past 30 days to quit or stay off smoking cigarettes.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127096>	C173060	Assistance Used to Quit or Stay Off Smoking Cigarettes Past 30 Days Question|Assistance Used to Quit or Stay Off Smoking Cigarettes Past 30 Days|In the past 30 days, what assistance have you used to quit (or to stay off) smoking cigarettes|Past 30 Days Assistance Used to Quit or Stay Off Smoking Cigarettes	A question about the assistance an individual used in the past 30 days to quit or stay off smoking cigarettes.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127097>	C173060	Other Assistance Used to Quit or Stay Off Smoking Cigarettes Past 30 Days Question|Other Assistance Used to Quit or Stay Off Smoking Cigarettes Past 30 Days|Past 30 Days Other Assistance Used to Quit or Stay Off Smoking Cigarettes|What other assistance have you used to quit (or to stay off) smoking cigarettes	A question about assistance not previously mentioned or specified that an individual used in the past 30 days to quit or stay off smoking cigarettes.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127098>	C173060	Smoking Products Ever Used Regularly Question|Products Ever Used Regularly|Smoking Products Ever Used Regularly|Which of the following products have you ever used regularly	A question about the smoking products an individual has ever used regularly.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127099>	C173060	Other Smoking Products Ever Used Regularly Question|Other Products Ever Used Regularly|Other Smoking Products Ever Used Regularly|Which other products have you ever used regularly	A question about smoking products not previously mentioned or specified that an individual has ever used regularly.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C12709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12709>	C38617	Epiglottis|EPIGLOTTIS|Epiglottic|epiglottis	A small cartilagenous flap-like valve that closes over the larynx during swallowing to prevent food entering the lungs.	Epiglottis		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C1270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1270>	C2156	Adozelesin|(7bR,8aS)-N-(2-((4,5,8,8a-Tetrahydro-7-methyl-4-oxocyclopropa(c)pyrrolo(3,2-e)indol-2(1H)-yl)carbonyl)indol-5-yl)-2-benzofurancarboxamide|ADOZELESIN|U-73,975|U-73975	An alkylating agent that bind to the DNA minor groove in a sequence-specific manner and form covalent adducts with adenines, resulting in the inhibition of DNA replication and induction of apoptosis. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C127100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127100>	C173060	Smoking Products Used Past 30 Days Question|In the past 30 days, which of the following products have you used|Past 30 Days Smoking Products Used|Smoking Products Used Past 30 Days	A question about which smoking products an individual has used in the past 30 days.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127101>	C173060	Other Smoking Products Used Past 30 Days Question|In the past 30 days, which other products have you used|Other Smoking Products Used Past 30 Days|Past 30 Days Other Smoking Products Used	A question about which smoking products not previously mentioned or specified that an individual has used in the past 30 days.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127102>	C173509|C173060	Currently Living with Smoker Question|Are you currently living with a smoker|Currently Living with Smoker|Living with Smoker	A question about whether an individual is currently living with a smoker.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127103>	C173060	Lived in Place Where Other People Smoked Cigarettes Indoors Past 30 Days Question|Lived in Place Where Other People Smoked Cigarettes Indoors Past 30 Days|Lived in a place where other people smoked cigarettes indoors|Past 30 Days Lived in Place Where Other People Smoked Cigarettes Indoors	A question about whether an individual has lived in a place where other people smoked cigarettes indoors in the past 30 days.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127104>	C173924|C173060	Worked in Place Where Other People Smoked Cigarettes Indoors Past 30 Days Question|Past 30 Days Worked in Place Where Other People Smoked Cigarettes Indoors|Worked in Place Where Other People Smoked Cigarettes Indoors Past 30 Days|Worked in a place where other people smoked cigarettes indoors	A question about whether an individual has worked in a place where other people smoked cigarettes indoors in the past 30 days.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127105>	C173060	Ever Lived in Place Where Other People Smoked Cigarettes Indoors Question|Childhood or Adult Life Ever Lived in Place Where Other People Smoked Cigarettes Indoors|Ever Lived in Place Where Other People Smoked Cigarettes Indoors|Thinking of all your childhood and adult years, have you ever lived in a place where other people smoked cigarettes indoors	A question about whether a person, over all their childhood and adult years, has ever lived in a place where other people smoked cigarettes indoors.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127106>	C173060	Total Years Lived in Place Where Other People Smoked Cigarettes Indoors Question|In total, for about how many years|Total Years Lived in Place Where Other People Smoked Cigarettes Indoors|Total Years Lived in Place Where Other People Smoked Cigarettes Indoors Childhood or Adult Life	A question about the total number of years a person, over all their childhood and adult years, has ever lived in a place where other people smoked cigarettes indoors.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127107>	C173924|C173060	Ever Worked in Place Where Other People Smoked Cigarettes Indoors Question|All Work Years Have Ever Worked in Place Where Other People Smoked Cigarettes Indoors|Ever Worked in Place Where Other People Smoked Cigarettes Indoors|Thinking of all the years you have worked, have you ever worked in a place where other people smoked cigarettes indoors	A question about whether a person, over all the years they have worked, has ever worked in a place where other people smoked cigarettes indoors.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127108>	C173924|C173060	Total Years Worked in Place Where Other People Smoked Cigarettes Indoors Question|All Work Years How Many Total Years Worked in Place Where Other People Smoked Cigarettes Indoors|In total, for about how many years|Total Years Worked in Place Where Other People Smoked Cigarettes Indoors	A question about the total number of years a person, over all the years they have worked, has ever worked in a place where other people smoked cigarettes indoors.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127109>	C25638	Invalid Reason|Reason Invalid	Why something is not recognized or acceptable for a purpose.			Idea or Concept	Observational Medical Outcomes Partnership
C12710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12710>	C45714	Epithelium|epithelium	The avascular cellular layers that cover body surfaces and cavities and may form glands.	Epithelium		Tissue	
C127110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127110>	C199144	Drug Enforcement Administration|DEA|United States Drug Enforcement Administration	The federal law enforcement agency, under the U.S. Department of Justice, tasked with enforcing the controlled substances laws and regulations of the United States.			Professional or Occupational Group	Observational Medical Outcomes Partnership
C127111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127111>	C25337	Drug Refills|Number of Refills	The number of refills permitted for a prescribed medication.			Quantitative Concept	Observational Medical Outcomes Partnership
C127112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127112>	C48298	RxNorm	A system that provides normalized names for generic and branded drugs and that functions as a tool to support interoperability between terminologies. RxNorm is produced by the National Library of Medicine.			Intellectual Product	Observational Medical Outcomes Partnership
C127113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127113>	C199143	Observational Medical Outcomes Partnership|OMOP	A public-private partnership established to inform the appropriate use of observational healthcare databases for studying the effects of medical products. Its goals were: 1) conduct methodological research to empirically evaluate the performance of various analytical methods on their ability to identify true associations and avoid false findings, 2) develop tools and capabilities for transforming, characterizing, and analyzing disparate data sources across the health care delivery spectrum, and 3) establish a shared resource so that the broader research community can collaboratively advance the science.			Professional or Occupational Group	
C127114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127114>	C156804	Valemetostat|DS 3201|DS-3201|DS3201|VALEMETOSTAT	An orally available selective inhibitor of the histone lysine methyltransferases enhancer of zeste homolog 1 (EZH1) and 2 (EZH2), with potential antineoplastic activity. Upon oral administration, valemetostat selectively inhibits the activity of both wild-type and mutated forms of EZH1 and EZH2. Inhibition of EZH1/2 specifically prevents the methylation of lysine 27 on histone H3 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways, enhances transcription of certain target genes, and results in decreased proliferation of EZH1/2-expressing cancer cells. EZH1/2, histone lysine methyltransferase (HMT) class enzymes and catalytic subunits of the polycomb repressive complex 2 (PRC2), are overexpressed or mutated in a variety of cancer cells and play key roles in tumor cell proliferation, progression, stem cell self-renewal and migration.	Valemetostat		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C127115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127115>	C28310	Autologous Neuroblastoma Lysate/KLH-pulsed Dendritic Cell Vaccine|Autologous Neuroblastoma Lysate/KLH-pulsed DC Vaccine|Keyhole Limpet Hemocyanin-pulsed Dendritic Cell Vaccine	A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with a cell lysate from an autologous neuroblastoma containing tumor-associated antigens (TAAs) and the immunostimulant keyhole limpet hemocyanin (KLH), with potential immunostimulatory and antineoplastic activities. Upon administration, autologous neuroblastoma lysate/KLH-pulsed DC vaccine may stimulate the immune system to mount an anti-tumoral cytotoxic T-lymphocyte (CTL) response against neuroblastoma cells, which may result in tumor cell lysis. KLH is an immunogenic carrier and serves as an immunostimulant to improve antigenic immune recognition and T-cell responses.	Autologous Neuroblastoma Lysate/KLH-pulsed Dendritic Cell Vaccine		Cell|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C127116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127116>	C200418	Dubermatinib|2-((5-Chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide|DUBERMATINIB|TP 0903|TP-0903|TP0903	An orally available and selective inhibitor of the receptor tyrosine kinase AXL (UFO), with potential antineoplastic activity. Upon administration, dubermatinib targets and binds to AXL and prevents its activity. This blocks AXL-mediated signal transduction pathways and inhibits the epithelial-mesenchymal transition (EMT), which, in turn, inhibits tumor cell proliferation and migration. In addition, TP-0903 enhances chemo-sensitivity to certain other chemotherapeutic agents. AXL, a member of the Tyro3, AXL and Mer (TAM) family of receptor tyrosine kinases and overexpressed by many tumor cell types, plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance and poor prognosis.	Dubermatinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C127117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127117>	C226455	Mucoadhesive Hydrogel Gargle|FORRAD|Oral Ulcer Gargle|Oral Viscous Mucoadhesive Hydrogel Gargle	An oral rinse composed of a viscous, mucoadhesive hydrogel, with potential protective and antimucositis activities. Upon gargling with the oral viscous mucoadhesive hydrogel formulation in the oral cavity, the hydrogel forms a protective barrier over the oral mucosa, which prevents inflammation of the mucosal membranes and may decrease chemotherapy- and/or radiation-induced oral mucositis.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C127118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127118>	C29639|C226455	Cyanocobalamin/Dexamethasone/Gentamicin/Procaine Formulation|Cyanocobalamin/Dexamethasone/Gentamicin/Procaine Oral Formulation|Quadruple Mixture	A quadruple mixture composed of the corticosteroid dexamethasone, the aminoglycoside antibiotic gentamicin, the vitamin cyanocobalamin (vitamin B12), and the local anesthetic agent procaine, with antimucositic activity. Upon oral administration of the cyanocobalamin/dexamethasone/gentamicin/procaine formulation, the active ingredients prevent or inhibit inflammation and infection of the oral mucosa and reduce the associated pain. This may prevent or treat radiation-induced oral mucositis (OM).			Pharmacologic Substance	NCI Drug Dictionary Terminology
C127119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127119>	C208191	Omidubicel|Ex Vivo-expanded Umbilical Cord Blood-derived Hematopoietic CD34-positive Progenitor Cells|NiCord|OMIDUBICEL|Omidubicel-onlv|Omisirge|UCB-derived CD34+ HPCs	A population of cryopreserved, ex vivo expanded and nicotinamide (NAM)-treated, CD34-positive hematopoietic progenitor cells (HPCs) derived from allogeneic, CD34+ cells isolated from human umbilical cord blood (UCB) that can be used during transplantation. CD34+ HPCs were isolated from human UCB mononuclear cells, and expanded ex vivo. Upon transplantation with omidubicel, these cells can differentiate into a variety of cell types including fibroblasts, osteoblasts, chondrocytes, myocytes, adipocytes, and endothelial cells. Compared to bone marrow transplants, these HPCs have decreased risk of causing graft-versus host disease (GvHD), increased survival, and enhanced transplant and engraftment potential for any given patient as there is no need for a matched donor. Compared to untreated HPCs, treating the cells ex vivo with NAM increases the number of HPCs from UCB, enhances migration, bone marrow (BM) homing, engraftment and increases neutrophil and platelet recovery.	Omidubicel		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C12711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12711>	C32881	Ethmoid Bone|ETHMOID BONE|Ethmoid|Ethmoid bone structure (body structure)	A light and spongy bone that is cubical in shape. This bone is positioned at the anterior part of the cranium, sitting between the two orbits, at the roof of the nose. It consists of four parts: a horizontal or cribriform plate; a perpendicular plate; and two lateral masses or labyrinths.	Ethmoid Bone		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table
C127120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127120>	C201511|C201282|C129822	Vibecotamab|Anti-CD123/Anti-CD3 Bispecific Antibody XmAb14045|VIBECOTAMAB|XmAb14045	An anti-CD123/anti-CD3 bispecific monoclonal antibody, in which most of the naturally-occurring Fc domain is maintained, with potential immunostimulatory and antineoplastic activities. Vibecotamab possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD123, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of vibecotamab, this bispecific antibody simultaneously binds to both CD3-expressing T-cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated cell lysis of CD123-expressing tumor cells. CD123, the interleukin-3 receptor alpha chain, is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells. The Fc domain on the antibody prolongs the half-life of the bispecific antibody and enhances T-cell mediated tumor cell killing through its binding to the Fc receptors.	Vibecotamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C127121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127121>	C129821	Bifunctional Expression Vector Plasmid DNA-bi-shRNA EWS/FLI1 Type 1 Lipoplex|Pbi-functional Short Hairpin RNA EWS/FLI1 Type 1 Lipoplex|Pbi-functional shRNA EWS-FLI1 Type 1 Lipoplex|Pbi-shRNA EWS/FLI1 Type 1 Lipoplex|pbi-shRNA EWS/FLI1 Type 1 LP|pbi-shRNA EWS/FLI1 Type 1 LPX	A proprietary plasmid DNA expression vector encoding bi-functional short hairpin RNAs (bi-shRNAs) targeting the identical type 1 translocation junction region of the human fusion oncogene Ewing sarcoma (EWS)/Ets family transcription factor Friend leukemia virus integration 1 (FLI1) and are encapsulated in liposomal delivery vehicle (lipoplex; LPX), with potential antineoplastic activity. pbi-shRNA EWS/FLI1 type 1 contains 2 stem-loop structures encoded by a plasmid vector: one cleavage-dependent unit with perfectly matched passenger- and guide-strand, which is the small interfering RNA (siRNA)-like component, and one cleavage-independent unit composed of a strategically mismatched double strand, which is the microRNA (miRNA)-like component. Upon intratumoral administration and transcription into tumor cells, one shRNA unit with an imperfectly matched sequence causes inhibition of EWS/FLI1 messenger RNA (mRNA) translation (through mRNA sequestration and cleavage-independent degradation) while the other unit with a perfectly matched sequence promotes EWS/FLI1 mRNA degradation (through cleavage-dependent mRNA silencing). This prevents EWS/FLI1 expression in tumor cells, which results in a reduction of tumor cell proliferation. The EWS/FLI1 type 1 fusion gene product is overexpressed in type 1 Ewing's sarcoma and correlates with increased tumor proliferation and poor prognosis.	Bifunctional Expression Vector Plasmid DNA-bi-shRNA EWS/FLI1 Type 1 Lipoplex		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C127122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127122>	C78311	Absorbable Modified Polymer Hemostatic Powder|AMP|AMP Hemostatic Powder|Endo-Clot|Endoclot	A hemostatic powder composed of hydrophilic, absorbable modified polymers (AMPs) derived from plant starch, with potential anti-hemorrhagic activity. Upon local administration of the AMP hemostatic powder directly sprayed over the bleeding surface, this powder adheres to the bleeding area, and the AMPs are able to absorb fluid and therefore soak up blood at the bleeding site. This leads to the formation of a gelled matrix that seals the affected site, and allows platelets, red blood cells and clotting factors in the blood to concentrate at the wound. In turn, this promotes the coagulation cascade, helps to stop or control bleeding, and prevents further blood loss. The AMP particles are naturally degraded by human enzymes over time.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C127123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127123>	C20401	Emapalumab|Anti-IFN gamma Monoclonal Antibody NI-0501|Anti-IFNg mAb NI-0501|Anti-interferon gamma Monoclonal Antibody NI-0501|EMAPALUMAB|Emapalumab-lzsg|Gamifant|NI 0501|NI-0501|NI0501	A human monoclonal antibody against the cytokine interferon-gamma (IFN-gamma; IFNg), with potential immunomodulating activity. Upon administration, emapalumab binds to and neutralizes IFNg. This inhibits IFNg-mediated signaling pathways and suppresses the activation of the immune system. IFNg, a cell-signaling protein, plays a key role in the regulation and activation of the immune system; its upregulation is associated with certain auto-immune and auto-inflammatory diseases in which the immune system is abnormally activated.	Emapalumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C127124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127124>	C199656|C129822	Onvatilimab|CI 8993|CI-8993|CI8993|Immunoglobulin G1, Anti-(Human Protein Vista (v-domain Immunoglobulin Suppressor of T Cell Activation)) (Human Clone JNJ 61610588 gamma1-chain), Disulfide with Human Clone JNJ|JNJ 61610588|JNJ-61610588|ONVATILIMAB|WHO 10758	A human monoclonal antibody against the protein V-domain immunoglobulin (Ig) suppressor of T-cell activation (VISTA; programmed death 1 homolog; PD1H; PD-1H), with potential negative checkpoint regulatory and antineoplastic activities. Upon administration, onvatilimab targets and binds to VISTA. This inhibits VISTA signaling, abrogates the VISTA-induced suppression of T-lymphocyte-mediated immune responses, enhances cytotoxic T-cell responses against tumor cells and inhibits tumor cell growth. VISTA, mainly expressed on hematopoietic cells, plays a key role in immunosuppression.	Onvatilimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C127125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127125>	C1752	NY-ESO-1/PRAME/MAGE-A3/WT-1 Peptide Vaccine|NPMW-peptide Vaccine	A peptide-based cancer vaccine comprised of synthetic peptides derived from the cancer-testis antigen NY-ESO-1, preferentially expressed antigen in melanoma (PRAME), human melanoma antigen A3 (MAGE-A3) and the human Wilms tumor protein-1 (WT-1), with potential immunostimulating and antineoplastic activities. Upon administration, NY-ESO-1/PRAME/MAGE-A3/WT-1 peptide vaccine may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing NY-ESO-1, PRAME, MAGE-A3 and WT-1, resulting in tumor cell lysis. The NY-ESO-1, PRAME, MAGE-A3 and WT-1 peptides, tumor-associated antigens (TAAs) overexpressed in a variety of cancer cell types, play a key role in tumor cell proliferation.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C127126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127126>	C16830	Ostomy Skin Barrier|Skin Barrier	A device designed to adhere to the peristomal skin to protect it from the output of the stoma. It may be incorporated into a system for attaching an ostomy pouch.	Ostomy Skin Barrier		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C127127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127127>	C45398	4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol|3-Pyridinemethanol, Alpha-(3-(Methylnitrosoamino)Propyl)-|4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANOL|4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butan-1-Ol|4-(Methylnitrosoamino)-1-(3-Pyridyl)-1-Butanol|4-[Methyl(Nitroso)Amino]-1-(Pyridin-3-Yl)Butan-1-Ol|Alpha-(3-(Methylnitrosoamino)Propyl)-3-Pyridinemethanol|NNAL|Nicotine-Derived Nitrosamine Alcohol	The major metabolite of the potentially carcinogenic nitrosamine 4-methylnitrosamino-1,3-pyridyl-1-butanone (nicotine-derived nitrosamine ketone; NNK) that is detected in the urine of subjects exposed to tobacco products. 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (nicotine-derived nitrosamine alcohol; NNAL) is produced by carbonyl reduction of NNK and may also be a carcinogen.	4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol		Hazardous or Poisonous Substance|Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C127128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127128>	C45398	4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol Glucuronide|4-(Methylnitrosamino)-1-(3-Pyridyl)-1-(Beta-D-Glucopyranuronosyl)Butanol|4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol Beta-D-Glucuronide|4-(Methylnitrosoamino)-1-(3-Pyridyl)-1-Butanol Beta-D-Glucuronide|Glucuronidated-NNAL|NNAL-Gluc|NNAL-Glucuronide	A non-carcinogenic and detoxified glucuronidated form of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (nicotine-derived nitrosamine alcohol; NNAL), which is the primary metabolite of the potentially carcinogenic nitrosamine 4-methylnitrosamino-1,3-pyridyl-1-butanone (nicotine-derived nitrosamine ketone; NNK). NNAL-gluconuronide is detected in the urine of subjects exposed to tobacco products.	4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol Glucuronide		Hazardous or Poisonous Substance|Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C127129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127129>	C39788	MET Exon 14 Mutation|HGFR Exon 14 Mutation|MET Proto-Oncogene, Receptor Tyrosine Kinase Exon 14 Mutation|Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Exon 14 Mutation|c-Met Exon 14 Mutation	A molecular genetic abnormality indicating the presence of a mutation in exon 14 of the MET gene located in the vicinity of 7q31.	MET Exon 14 Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12712>	C13319	Exocrine Gland|Apocrine|Apocrine Gland|apocrine gland	A gland from which secretions reach a free surface of the body by ducts.	Exocrine Gland		Body Part, Organ, or Organ Component	
C127130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127130>	C80699	MIR574 Gene|MIR574|MIR574|MicroRNA 574 Gene	This gene may play a role in the modulation of target gene expression.	MIR574 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C127131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127131>	C127130	MIR574 wt Allele|MIRN574|Micro RNA 574 Gene|MicroRNA 574 wt Allele|hsa-mir-574|mir-574	Human MIR574 wild-type allele is located within chromosome 4 and is approximately 1 kb in length. This allele, which encodes MIR574 pre-miRNA, may be involved in the regulation of gene expression.	MIR574 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127132>	C25968	MIR574 Pre-miRNA	MIR574 pre-miRNA (96 bp) is encoded by the human MIR574 gene. This oligoribonucleotide may play a role in the regulation of protein synthesis.	MIR574 Pre-miRNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127133>	C25966	MicroRNA 574-3p|MIR574-3p|Micro RNA 574-3p|hsa-miR-574-3p|hsa-mir-574|miR-574-3p	A 22 ribonucleotide sequence that is a final product of the processing of the human MIR574 pre-miRNA. This oligonucleotide may be involved in the negative regulation of gene expression.	MicroRNA 574-3p		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127134>	C25966	MicroRNA 335-5p|MIR335-5p|Micro RNA 335-5p|hsa-miR-335|hsa-miR-335-5p|miR-335-5p	A 23 ribonucleotide sequence that is a final product of the processing of MIR335 pre-miRNA. This oligonucleotide may be involved in the negative regulation of gene expression.	MicroRNA 335-5p		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127135>	C25966	MicroRNA 205-5p|MIR205-5p|Micro RNA 205-5p|hsa-miR-205|hsa-miR-205-5p|miR-205-5p	A 22 ribonucleotide sequence that is a final product of the processing of MIR205 pre-miRNA. This oligonucleotide may be involved in the negative regulation of gene expression.	MicroRNA 205-5p		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127136>	C26006	RAMP1 Gene|RAMP1|RAMP1|Receptor Activity Modifying Protein 1 Gene	This gene is involved in the localization of calcitonin gene-related peptide type 1 receptor.			Gene or Genome	
C127137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127137>	C127136	RAMP1 wt Allele|Receptor (Calcitonin) Activity Modifying Protein 1 Gene|Receptor (G Protein-Coupled) Activity Modifying Protein 1 Gene|Receptor Activity Modifying Protein 1 wt Allele	Human RAMP1 wild-type allele is located within 2q36-q37.1 and is approximately 53 kb in length. This allele, which encodes receptor activity-modifying protein 1, plays a role in the modulation of ligand-dependent signaling.			Gene or Genome	
C127138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127138>	C16386	Receptor Activity-Modifying Protein 1|CRLR Activity-Modifying Protein 1|Calcitonin-Receptor-Like Receptor Activity-Modifying Protein 1|RAMP1	Receptor activity-modifying protein 1 (148 aa, ~17 kDa) is encoded by the human RAMP1 gene. This protein is involved in the transport of calcitonin gene-related peptide type 1 receptor to the plasma membrane.			Amino Acid, Peptide, or Protein	
C127139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127139>	C25939	ME1 Gene|ME1|ME1|Malic Enzyme 1 Gene	This gene plays a role in the metabolism of malate, pyruvate and oxaloacetate.	ME1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C12713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12713>	C32574	Eyelid|EYELID|Palpebra|Palpebra|eyelid	A thin membrane of skin with the purpose of covering and protecting an eye.	Eyelid		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C127140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127140>	C127139	ME1 wt Allele|HUMNDME|MES|Malate Dehydrogenase (Oxaloacetate-Decarboxylating) (NADP(+)) Gene|Malate Dehydrogenase, NADP(+)-Dependent, Soluble Gene|Malic Enzyme 1 wt Allele|Malic Enzyme 1, NADP(+)-Dependent, Cytosolic Gene|Malic Enzyme 1, Soluble Gene|Malic Enzyme, Cytoplasmic Gene|Malic Enzyme, NADP(+)-Dependent, Cytosolic Gene	Human ME1 wild-type allele is located in the vicinity of 6q12 and is approximately 221 kb in length. This allele, which encodes NADP-dependent malic enzyme protein, is involved in glycolysis, the citric acid cycle and fatty acid biogenesis.	ME1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127141>	C16946	NADP-Dependent Malic Enzyme|EC 1.1.1.40|ME1|Malate Dehydrogenase|Malic Enzyme 1|NADP-ME|Pyruvic-Malic Carboxylase	NADP-dependent malic enzyme (572 aa, ~64 kDa) is encoded by the human ME1 gene. This protein plays a role in the oxidative decarboxylation of malate.	NADP-Dependent Malic Enzyme		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127142>	C18520	DNA Repair Capacity	A cellular metabolic marker that may indicate an increased risk for neoplastic disease that is based on a semi-quantitative determination of the ability of cells in a biological sample to maintain the integrity of its genome.	DNA Repair Capacity		Functional Concept	CTRP Biomarker Terminology|CTRP Terminology
C127143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127143>	C91105	Medical Research Council Breathlessness Score|MRC Dyspnea Scale|MRC-BS|Medical Research Council Breathlessness Score (MRC)	A self-administered questionnaire designed to rate an individual's respiratory disability from none to almost complete incapacity.			Intellectual Product	
C127144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127144>	C175903|C173398	Troubled By Breathlessness Other Than on Strenuous Exertion Question|Are you ever troubled by breathlessness except on strenuous exertion|Troubled By Breathlessness Except on Strenuous Exertion|Troubled By Breathlessness Other Than on Strenuous Exertion	A question about whether an individual is or was ever troubled by breathlessness other than during strenuous exertion.			Intellectual Product	Medical Research Council Breathlessness Score
C127145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127145>	C175903|C173135	Short of Breath When Hurrying on Level Ground or Walking Up a Slight Hill Question|Are you short of breath when hurrying on the level or walking up a slight hill|Short of Breath When Hurrying on Level Ground or Walking Up a Slight Hill	A question about whether an individual is or was short of breath when hurrying on level ground or walking up a slight hill.			Intellectual Product	Medical Research Council Breathlessness Score
C127146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127146>	C173135	Have to Walk Slower Than Most People on Level Ground Question|Do you have to walk slower than most people on the level|Have to Walk Slower Than Most People on Level Ground	A question about whether an individual has or had to walk slower than most people on level ground.			Intellectual Product	Medical Research Council Breathlessness Score
C127147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127147>	C173135	Have to Stop After Walking a Mile, or After One Quarter Hour, on Level Ground at Own Pace Question|Do you have to stop after a mile or so (or after one quarter hour) on the level at your own pace|Have to Stop After Walking a Mile, or After One Quarter Hour, on Level Ground at Own Pace	A question about whether an individual has or had to stop after walking a mile, or after a quarter of an hour, on level ground at their own pace.			Intellectual Product	Medical Research Council Breathlessness Score
C127148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127148>	C173135	Have to Stop for Breath After Walking About 100 Yards on Level Ground Question|Do you have to stop for breath after walking about 100 yds. (or after a few minutes) on the level|Have to Stop for Breath After Walking About 100 Yards on Level Ground	A question about whether an individual has or had to stop for breath after walking about 100 yards, or after a few minutes, on level ground.			Intellectual Product	Medical Research Council Breathlessness Score
C127149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127149>	C91102	Too Breathless to Leave the House or Breathless After Undressing Question|Are you too breathless to leave the house, or breathless after undressing|Too Breathless to Leave the House or Breathless After Undressing	A question about whether an individual is or was too breathless to leave the house, or breathless after undressing.			Intellectual Product	Medical Research Council Breathlessness Score
C12714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12714>	C12700	Facial Nerve|FACIAL NERVE|Facial nerve structure (body structure)|NERVE, FACIAL|Seventh Cranial Nerve|Seventh Cranial Nerve	Cranial nerve VII, which originates in the brainstem between the pons and the medulla. It controls the facial expression muscles and transports taste and sensation from the tongue and mouth.	Facial Nerve		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C127150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127150>	C26006	RAMP2 Gene|RAMP2|RAMP2|Receptor Activity Modifying Protein 2 Gene	This gene is involved in adrenomedullin binding and signaling.	RAMP2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C127151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127151>	C127150	RAMP2 wt Allele|Receptor (Calcitonin) Activity Modifying Protein 2 Gene|Receptor (G Protein-Coupled) Activity Modifying Protein 2 Gene|Receptor Activity Modifying Protein 2 wt Allele	Human RAMP2 wild-type allele is located within 17q12-q21.1 and is approximately 5 kb in length. This allele, which encodes receptor activity-modifying protein 2, plays a role in the regulation of calcitonin gene-related peptide type 1 receptor activity.	RAMP2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127152>	C16386	Receptor Activity-Modifying Protein 2|CRLR Activity-Modifying Protein 2|Calcitonin-Receptor-Like Receptor Activity-Modifying Protein 2|RAMP2	Receptor activity-modifying protein 2 (175 aa, ~20 kDa) is encoded by the human RAMP2 gene. This protein is involved in the membrane localization of calcitonin gene-related peptide type 1 receptor.	Receptor Activity-Modifying Protein 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127153>	C4813|C132146	Recurrent Malignant Solid Neoplasm|Recurrent Malignant Solid Tumor|Recurrent Malignant Solid Tumor|Recurrent Solid Neoplasm|Recurrent Solid Tumor|Relapsed Malignant Solid Neoplasm|Relapsed Solid Neoplasm	A malignant solid neoplasm that has recurred after a period of remission.	Relapsed Solid Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C127154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127154>	C49146|C129820	Ad-ISF35|Ad-CD154 ISF35|Ad-CD40L ISF35	A replication-defective adenovirus vector (Ad-ISF35), which encodes a membrane-stabilized, chimeric human-mouse CD40 binding protein (CD40 ligand; CD40L; CD154), with potential immunomodulatory and antineoplastic activities. Upon intratumoral administration, Ad-ISF135 preferentially transduces tumor cells and immunoregulatory cells in the tumor microenvironment. This increases the expression of CD154 in tumor cells, activates CD40 and stimulates signaling and immunoactivation, which are both mediated by CD40. This increases the expression of co-stimulatory molecules on these cells, which enhances their ability to function as antigen presenting cells (APCs) and increases their apoptotic potential. This leads to an increase in the infiltration of macrophages and neutrophils, which promote direct cytotoxicity, enhances the production of pro-inflammatory cytokines in the tumor microenvironment, and induces a specific cytotoxic T-lymphocyte (CTL) response against the tumor cells. In addition, transduction with Ad-ISF35 induces direct tumor cell death, probably through an anti-viral immune response. Ad-ISF35 also exerts a strong bystander effect in non-transduced cells thereby further inducing tumor cell death. Altogether, this will eradicate tumor cells. CD154, the main ligand for CD40, plays a key role in the activation of APCs, promotes immunoactivation, and increases apoptotic potential. The protein encoded by Ad-ISF35 does not contain the mouse antibody binding domains and does not induce human neutralizing antibodies. The metalloprotease cleavage site is deleted in this chimeric CD154 and thus it resists cleavage; the encoded protein also contains amino acid substitutions within the carboxy-terminal. Both sets of engineered mutations promote cell surface expression.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C127155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127155>	C36263|C132146	Metastatic Malignant Solid Neoplasm|Metastatic Malignant Solid Tumor|Metastatic Malignant Solid Tumor|Metastatic Solid Neoplasm|Metastatic Solid Tumor	A malignant solid neoplasm that has spread from its original site of growth to another anatomic site.	Metastatic Malignant Solid Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C127156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127156>	C9292	Unresectable Solid Neoplasm|Unresectable Solid Tumor	A solid neoplasm that is not amenable to surgical resection.	Unresectable Solid Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C127157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127157>	C92809	Corticotropin-Releasing Hormone Deficiency|CRH Deficiency|Tertiary Adrenal Insufficiency	Diminished production of adrenocortical hormones due to presumed insufficient secretion of corticotropin-releasing hormone from the hypothalamus.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C127158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127158>	C92809	Primary Adrenal Glucocorticoid Excess	Supranormal glucocorticoid concentrations resulting from a condition originating within the adrenal gland.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C127159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127159>	C2969	Exogenous Cushing Syndrome|Iatrogenic Cushing Syndrome|Iatrogenic Cushing Syndrome	Cushing syndrome as a result of increased glucocorticoids due to medical therapy.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C12715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12715>	C12372	Femoral Artery|ARTERY, FEMORAL|FEMORAL ARTERY|Femoral|Femoral artery|Structure of femoral artery (body structure)|femoral artery	An artery that starts within the inguinal region and extends to the lower extremities.	Femoral Artery		Body Part, Organ, or Organ Component	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|Appendix 9: Therapeutic and Supportive Procedures for COVID-19 Terminology|CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Invasive Coronary/Vascular/Neurovascular Revascularization Treatment Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C127160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127160>	C113213	Familial Hyperaldosteronism	A heritable form of hyperaldosteronism.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C127161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127161>	C127160	Familial Hyperaldosteronism Type 1|CYP11B1/CYP11B2 Chimerism|Glucocorticoid Remediable Aldosteronism|Glucocorticoid Suppressible Hypertension|Glucocorticoid-responsive primary hyperaldosteronism	Familial hyperaldosteronism caused by a chimeric gene containing regions of CYP11B1 and CYP11B2. This condition is responsive to exogenous glucocorticoids.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C127162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127162>	C127160	Familial Hyperaldosteronism Type 2	Familial hyperaldosteronism unresponsive to glucocorticoid therapy. The molecular basis for this condition has not been fully elucidated.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C127163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127163>	C127160	Familial Hyperaldosteronism Type 3	Familial hyperaldosteronism caused by a mutation in the KCNJ5 gene, which encodes the inwardly rectifying potassium channel. This condition, characterized by hypokalemia and severe hypertension, presents during early childhood, and is unresponsive to glucocorticoid therapy.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C127164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127164>	C34360	Multinodular Adrenal Hyperplasia	A subtype of adrenal hyperplasia, based on histopathologic features, in which there are multiple nodules.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C127165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127165>	C34360	Micronodular Adrenal Hyperplasia|Micronodular Adrenal Disease	Adrenal hyperfunction associated with multiple bilateral adrenal nodules, usually less than one centimeter in diameter.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C127166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127166>	C34360	Macronodular Adrenal Hyperplasia|Macronodular Adrenal Disease	Adrenal hyperfunction associated with multiple bilateral adrenal nodules, usually more than one centimeter in diameter.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C127167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127167>	C103186	Ovotesticular Differences of Sex Development|Ovotesticular DSD|Ovotesticular Disorders of Sex Development|True Hermaphroditism	Difference of sex development characterized by the presence of ovarian and testicular tissue in the same individual. The clinical manifestations of the condition, which can be associated with 46,XX, 46,XY or 46,XX/46,XY mosaic karyotype, are variable.			Congenital Abnormality|Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C127168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127168>	C103186	Sex Chromosome Differences of Sex Development	A condition affecting gonadal and/or internal and/or external reproductive/genital development in which there is an atypical number of sex chromosomes (i.e. fewer or greater than the typical 2 X chromosomes or 1 X and 1 Y chromosome).			Congenital Abnormality|Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C127169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127169>	C103186	46,XX Differences of Sex Development|46,XX DSD|46,XX Disorders of Sex Development	Conditions affecting individuals with 46,XX karyotype characterized by atypical development of one or more of the following: the gonads, the internal reproductive structures, the external reproductive/genital structures.			Congenital Abnormality|Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C12716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12716>	C12814	Femoral Vein|FEMORAL VEIN|VEIN, FEMORAL|femoral vein	A vein that starts within the inguinal region and extends to the lower extremities.	Femoral Vein		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|UBERON Terminology
C127170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127170>	C127169	46,XX Testicular Differences of Sex Development|46,XX Testicular DSD|46,XX Testicular Disorders of Sex Development	Presence of testes in an individual with a 46,XX karyotype, typically associated with translocation of the SRY gene, encoding the transcription factor sex-determining region Y protein, from the paternal Y chromosome to the paternal X chromosome during gametogenesis (SRY-positive). Approximately 15-20% of individuals with 46,XX testicular DSD are SRY-negative. These individuals may have other genetic variations affecting testis determination, such as duplication of the SOX9 gene, which encodes the transcription factor SOX-9.			Congenital Abnormality|Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C127171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127171>	C103186	46,XY Differences of Sex Development|46,XY DSD|46,XY Disorders of Sex Development	Differences of sex development in individuals with 46,XY karyotype.			Congenital Abnormality|Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C127172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127172>	C127169|C127167	46,XX Ovotesticular Difference of Sex Development|46,XX True Hermaphroditism	The presence of ovarian and testicular tissue in the an individual with 46,XX karyotype. The anatomical expression of this condition is variable.			Congenital Abnormality|Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C127173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127173>	C127167	46,XY Ovotesticular Differences of Sex Development|46,XY True Hermaphroditism	The presence of ovarian and testicular tissue in the an individual with 46,XY karyotype. The anatomical expression of this condition is variable.			Congenital Abnormality|Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C127174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127174>	C127167	46,XX/46,XY Ovotesticular Differences of Sex Development|46,XX/46,XY Disorders of Sex Development	Ovotesticular differences of sex development in individuals with 46,XY/46,XX mosaic karyotype.			Congenital Abnormality|Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C127175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127175>	C91841	Continent Urinary Diversion	A surgical procedure in which segments of the both small and large intestine are incorporated into the urinary tract to create a pouch that collects the urine.			Therapeutic or Preventive Procedure	
C127176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127176>	C127175	Continent Catheterizable Diversion|Continent Non-Orthotopic Catheterizable Diversion	Continent urinary diversion procedure in which the surgically-created pouch requires a catheter to be inserted to drain the urine.			Therapeutic or Preventive Procedure	
C127177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127177>	C127175	Continent Orthotopic Diversion	Continent urinary diversion procedure in which the ureters are connected to a surgically-created neo-bladder that is also connected to the urethra so that the patient can empty the bladder normally.			Therapeutic or Preventive Procedure	
C127178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127178>	C222260	Modified Barium Swallow Impairment Profile|MBSImP|Modified Barium Swallow Impairment Profile (MBSImP)	An evidence-based, standardization of the Modified Barium Swallow Study in adults. The protocol assesses 17 critical components of swallowing and provides an objective profile of the physiologic impairment affecting adult swallowing function.			Intellectual Product	
C127179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127179>	C36279	Oral Impairment During Swallowing|Oral Impairment	An assessment of an individual's oral impairment during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C12717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12717>	C33003|C12982	Femur|BONE, FEMUR|Bone structure of femur (body structure)|Bone, Femoral|FEMUR|Femoral|femur|thigh bone	The upper leg bone positioned between the pelvis and the knee.	Femur		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C127180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127180>	C36279	Pharyngeal Impairment During Swallowing|Pharyngeal Impairment	An assessment of an individual's pharyngeal impairment during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127181>	C36279	Esophageal Impairment During Swallowing|Esophageal Impairment	An assessment of an individual's esophageal impairment during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127182>	C127179	Impairment of Lip Closure|Lip Closure	An observation of an individual's lip closure during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127183>	C127182	No Labial Escape|No labial escape	A finding of no labial escape during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127184>	C127182	Interlabial Escape; No Progression to Anterior Lip|Interlabial escape; no progression to anterior lip	A finding of interlabial escape during swallowing, but no progression to anterior lip.			Finding	Modified Barium Swallow Impairment Profile
C127185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127185>	C127182	Escape From Interlabial Space or Lateral Juncture; No Extension	A finding of escape from interlabial space or lateral juncture during swallowing, but no extension.			Finding	
C127186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127186>	C127182	Escape Beyond Vermilion Border|Beyond vermilion border	A finding of escape beyond the vermilion border during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127187>	C127182	Escape Progressing to Mid-Chin|Escape progressing to mid-chin	A finding of escape progressing to mid-chin during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127188>	C127182	Escape Beyond Mid-Chin|Escape beyond mid-chin	A finding of escape beyond mid-chin during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127189>	C127179	Impairment of Tongue Control During Bolus Hold|Tongue Control During Bolus Hold	An observation of an individual's tongue control during bolus hold.			Finding	Modified Barium Swallow Impairment Profile
C12718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12718>	C33003|C12982	Fibula|BONE, FIBULA|Bone structure of fibula (body structure)|FIBULA|fibula	The small, lateral calf bone extending from the knee to the ankle.	Fibula		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C127190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127190>	C127189	Cohesive Bolus Between Tongue to Palatal Seal|Cohesive bolus between tongue to palatal seal	A finding of cohesive bolus between tongue to palatal seal during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127191>	C127189	Escape to Lateral Buccal Cavity/Floor of Mouth|Escape to lateral buccal cavity/floor of mouth (FOM)	A finding of escape to lateral buccal cavity/floor of mouth during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127192>	C127189	Posterior Escape of Less Than Half of Bolus|Posterior escape of less than half of bolus	A finding of posterior escape of less than half of bolus during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127193>	C127189	Posterior Escape of Greater Than Half of Bolus|Posterior escape of greater than half of bolus	A finding of posterior escape of greater than half of bolus during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127194>	C187086	Somatotroph-Lactotroph Pituitary Neuroendocrine Tumor|Growth Hormone and Prolactin-Producing Adenoma|Growth Hormone and Prolactin-Producing Adenoma|Somatotroph-Lactotroph PitNET/Adenoma|Somatotroph-Lactotroph Pituitary Neuroendocrine Tumor/Adenoma|Somatotroph/Lactotroph Adenoma	A pituitary neuroendocrine tumor that produces both growth hormone and prolactin.			Neoplastic Process	NICHD Terminology|Pediatric Endocrinology Terminology
C127195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127195>	C21637	Mouse Urological Syndrome|MURINE OBSTRUCTIVE UROPATHY|Mouse Urological Syndrome (MUS)	A constellation of findings in male mice characterized by ulceration and/or inflammation of the penis and prepuce, proteinaceous material with inflammatory cells, spermatozoa or desquamated urothelial cells forming a plug in the urethra and generally dilatation of the bladder, hydroureter and hydronephrosis.			Disease or Syndrome	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127196>	C40998	Growth Hormone and Prolactin-Producing Neoplastic Cells Present	An immunohistochemical finding indicating the presence of growth hormone and prolactin producing cells in a tumor.			Finding	
C127197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127197>	C127179	Impairment of Bolus Preparation or Mastication|Bolus Preparation/Mastication	An observation of an individual's bolus preparation and/or mastication prior to swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127198>	C127197	Timely and Efficient Chewing and Mashing|Timely and efficient chewing and mashing	A finding of timely and efficient chewing and mashing prior to swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127199>	C127197	Slow Prolonged Chewing or Mashing with Complete Re-Collection|Slow prolonged chewing/mashing with complete re-collection	A finding of slow prolonged chewing or mashing with complete re-collection prior to swallowing.			Finding	Modified Barium Swallow Impairment Profile
C12719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12719>	C33968	Ganglion|GANGLION|Ganglia|Ganglia|Ganglia|Ganglionic|Neural Ganglion|Neural Ganglion|ganglion	A cluster of nervous tissue principally composed of neuronal cell bodies external to the central nervous system (CNS).	Ganglion		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|UBERON Terminology
C1271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1271>	C1404	7-Hydroxystaurosporine|(+)-UCN-01|2,3,9,10,11,12-Hexahydro-3-hydroxy-9-methoxy-8-methyl-10-(methylamino)-8,12-epoxy-1H,8H-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)triinden-1-one|7-HYDROXYSTAUROSPORINE|7-Hydroxy-staurosporine|8,12-Epoxy-1H,8H-2,7b,12a-triazadibenzo[a, g]cyclonona[cde] Trinden-1-one, 2,3,9,10,11, 12-hexahydro-3-hydroxy-9-methoxy-8-methyl-10-(methylamino)|UCN-01|UCN-01|UCN-01	A synthetic derivative of staurosporine with antineoplastic activity. 7-hydroxystaurosporine inhibits many phosphokinases, including the serine/threonine kinase AKT, calcium-dependent protein kinase C, and cyclin-dependent kinases. This agent arrests tumor cells in the G1/S of the cell cycle and prevents nucleotide excision repair by inhibiting the G2 checkpoint kinase chk1, resulting in apoptosis. (NCI04)	7-Hydroxystaurosporine		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C127200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127200>	C127197	Disorganized Chewing or Mashing with Solid Pieces of Bolus Unchewed|Disorganized chewing/mashing with solid pieces of bolus unchewed	A finding of disorganized chewing or mashing with solid pieces of bolus unchewed prior to swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127201>	C127197	Minimal Chewing or Mashing with Majority of Bolus Unchewed|Minimal chewing/mashing with majority of bolus unchewed	A finding of minimal chewing or mashing with majority of bolus unchewed prior to swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127202>	C127179	Impairment of Bolus Transport or Lingual Motion|Bolus Transport/Lingual Motion	An observation of an individual's bolus transport and lingual motion during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127203>	C127202	Brisk Tongue Motion|Brisk tongue motion	A finding of brisk tongue motion during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127204>	C127202	Delayed Initiation of Tongue Motion|Delayed initiation of tongue motion	A finding of delayed initiation of tongue motion during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127205>	C127202	Slowed Tongue Motion|Slowed tongue motion	A finding of slowed tongue motion during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127206>	C127202	Repetitive or Disorganized Tongue Motion|Repetitive/disorganized tongue motion	A finding of repetitive or disorganized tongue motion during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127207>	C127202	Minimal to No Tongue Motion|Minimal to no tongue motion	A finding of minimal to no tongue motion during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127208>	C127179	Oral Residue Following Swallowing|Oral Residue	An observation of oral residue remaining after an individual swallows.			Finding	Modified Barium Swallow Impairment Profile
C127209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127209>	C127208	Complete Oral Clearance|A finding of complete oral clearance after swallowing.	A finding of complete oral clearance after swallowing.			Finding	Modified Barium Swallow Impairment Profile
C12720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12720>	C12719	Autonomic Ganglion|Autonomic Ganglia	A cluster of nerve cell bodies in the peripheral nervous system, which consists of large, multipolar, motor neurons. There are two types of autonomic ganglia: sympathetic ganglia lie close to the CNS in sympathetic chain, or in clusters called prevertebral ganglia, and parasympathetic ganglia occur farther from CNS, often in target organs.	Autonomic Ganglion		Body Part, Organ, or Organ Component	
C127210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127210>	C127208	Trace Residue Lining Oral Structures|Trace residue lining oral structures	A finding of trace residue lining oral structures after swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127211>	C127208	Residue Collection on Oral Structures|Residue collection on oral structures	A finding of residue collection on oral structures after swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127212>	C127208	Majority of Bolus Remaining|Majority of bolus remaining	A finding of the majority of bolus remaining after swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127213>	C127208	Minimal to No Bolus Clearance|Minimal to no clearance	A finding of minimal to no clearance of bolus after swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127214>	C25341	Location of Oral Residue Following Swallowing|Location	An observation of the location of oral residue remaining after an individual swallows.			Finding	Modified Barium Swallow Impairment Profile
C127215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127215>	C127214	Residue on Floor of Mouth|Floor of mouth (FOM)	A finding of oral residue remaining on floor of mouth after an individual swallows.			Finding	Modified Barium Swallow Impairment Profile
C127216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127216>	C127214	Residue on Palate|Palate	A finding of oral residue remaining on palate after an individual swallows.			Finding	Modified Barium Swallow Impairment Profile
C127217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127217>	C127214	Residue on Tongue|Tongue	A finding of oral residue remaining on tongue after an individual swallows.			Finding	Modified Barium Swallow Impairment Profile
C127218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127218>	C127214	Residue on Lateral Sulci|Lateral sulci	A finding of oral residue remaining on lateral sulci after an individual swallows.			Finding	Modified Barium Swallow Impairment Profile
C127219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127219>	C36279	Initiation of Pharyngeal Swallow	An observation of an individual's initiation of pharyngeal swallow.			Finding	Modified Barium Swallow Impairment Profile
C12721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12721>	C13060	Geniculate Ganglion|Facial Nerve Ganglion|Genicular Ganglia|Genicular Ganglion	A cluster of cranial nerve VII cell bodies located within the petrous temporal bone at the facial genu; it contains sensory nerve cell bodies for taste (from chorda tympani) and external ear sensation (from sensory auricular branch).	Geniculate Ganglion		Body Part, Organ, or Organ Component	
C127220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127220>	C127219	Initiation of Pharyngeal Swallow with Bolus Head at Posterior Angle of Ramus|Bolus head at posterior angle of ramus (first hyoid excursion)	A finding of pharyngeal swallow initiated with bolus head at posterior angle of ramus.			Finding	Modified Barium Swallow Impairment Profile
C127221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127221>	C127219	Initiation of Pharyngeal Swallow with Bolus Head in Valleculae|Bolus head in valleculae	A finding of pharyngeal swallow initiated with bolus head in valleculae.			Finding	Modified Barium Swallow Impairment Profile
C127222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127222>	C127219	Initiation of Pharyngeal Swallow with Bolus Head at Posterior Laryngeal Surface of Epiglottis|Bolus head at posterior laryngeal surface of epiglottis	A finding of pharyngeal swallow initiated with bolus head at posterior laryngeal surface of epiglottis.			Finding	Modified Barium Swallow Impairment Profile
C127223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127223>	C127219	Initiation of Pharyngeal Swallow with Bolus Head in Pyriform Sinus|Bolus head in pyriforms	A finding of pharyngeal swallow initiated with bolus head in the pyriform sinus.			Finding	Modified Barium Swallow Impairment Profile
C127224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127224>	C127219	No Visible Initiation of Pharyngeal Swallow at Any Location|No visible initiation at any location	A finding of no visible initiation of pharyngeal swallow at any location.			Finding	Modified Barium Swallow Impairment Profile
C127225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127225>	C127180	Impairment of Soft Palate Elevation|Soft Palate Elevation	An observation of an individual's soft palate elevation during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127226>	C127225	No Bolus Between Soft Palate/Pharyngeal Wall During Swallowing|No bolus between soft palate (SP)/pharyngeal wall (PW)	A finding of no bolus between soft palate/pharyngeal wall during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127227>	C127225	Trace Column of Contrast or Air Between Soft Palate and Pharyngeal Wall During Swallowing|Trace column of contrast or air between SP and PW	A finding of a trace column of contrast or air between soft palate and pharyngeal wall during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127228>	C127225	Escape to Nasopharynx During Swallowing|Escape to nasopharynx	A finding of escape to nasopharynx during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127229>	C127225	Escape to Nasal Cavity During Swallowing|Escape to nasal cavity	A finding of escape to nasal cavity during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C12722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12722>	C12841	Male Reproductive System|Body System, Reproductive, Male|Genital System, Male|MALE REPRODUCTIVE SYSTEM|Male Genital Tract|Male Reproductive Body System|Male Reproductive Organ System|Male Reproductive Tract|Organ System, Male Reproductive|Penis and Other Genital|Reproductive System, Male	The sex organs of the male.	Male Reproductive System		Body System	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C127230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127230>	C127225	Escape to Nostril with or without Emission During Swallowing|Escape to nostril with/without emission	A finding of escape to nostril with or without emission during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127231>	C127180	Impairment of Laryngeal Elevation|Laryngeal Elevation	An observation of an individual's larygeal elevation during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127232>	C127231	Complete Superior Movement of Thyroid Cartilage During Swallowing|Complete superior movement of thyroid cartilage with complete approximation of arytenoids to epiglottic petiole	A finding of complete superior movement of thyroid cartilage with complete approximation of arytenoids to epiglottic petiole during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127233>	C127231	Partial Superior Movement of Thyroid Cartilage During Swallowing|Partial superior movement of thyroid cartilage/partial approximation of arytenoids to epiglottic petiole	A finding of partial superior movement of thyroid cartilage/partial approximation of arytenoids to epiglottic petiole during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127234>	C127231	Partial Superior Movement of Thyroid Cartilage with Minimal Approximation of Arytenoids to Epiglottic Petiole During Swallowing|Partial superior movement of thyroid cartilage with minimal approximation of arytenoids to epiglottic petiole	A finding of minimal superior movement of thyroid cartilage with minimal approximation of arytenoids to epiglottic petiole during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127235>	C127231	No Superior Movement of Thyroid Cartilage During Swallowing|No superior movement of thyroid cartilage	A finding of no superior movement of thyroid cartilage during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127236>	C127180	Impairment of Anterior Hyoid Excursion|Anterior Hyoid Excursion	An observation of an individual's anterior hyoid excursion during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127237>	C127236	Complete Anterior Movement of Hyoid During Swallowing|Complete anterior movement	A finding of complete anterior movement of hyoid during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127238>	C127236	Partial Anterior Movement of Hyoid During Swallowing|Partial anterior movement	A finding of partial anterior movement of hyoid during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127239>	C127236	No Anterior Movement of Hyoid During Swallowing|No anterior movement	A finding of no anterior movement of hyoid during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C12723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12723>	C12700	Glossopharyngeal Nerve|Cranial Nerve IX|GLOSSOPHARYNGEAL NERVE|Glossopharyngeal nerve structure (body structure)|Nervus Glossopharyngeus|Ninth Cranial Nerve	The ninth cranial nerve. It originates in the brainstem and passes through the jugular foramen. It has motor and sensory functions that relate to the tongue, pharynx and middle ear.	Glossopharyngeal Nerve		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C127240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127240>	C127180	Impairment of Epiglottic Movement|Epiglottic Movement	An observation of an individual's epiglottic movement during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127241>	C127240	Complete Inversion of Epiglottis During Swallowing|Complete inversion	A finding of complete inversion of epiglottis during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127242>	C127240	Partial Inversion of Epiglottis During Swallowing|Partial inversion	A finding of partial inversion of epiglottis during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127243>	C127240	No Inversion of Epiglottis During Swallowing|No inversion	A finding of no inversion of epiglottis during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127244>	C175282	Stayed Off Cigarettes Between One and Seven Days|1-7 days	A response indicating that an individual stayed off cigarettes between one and seven days since their diagnosis.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127245>	C175314	Used Individual or Group Counseling to Quit Cigarette Smoking|Individual or group counseling	A response indicating that an individual used individual or group counseling to quit smoking cigarettes.	Used Individual or Group Counseling to Quit Cigarette Smoking		Intellectual Product	Cancer Patient Tobacco Use Questionnaire|CTRP Intervention Terminology|CTRP Terminology
C127246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127246>	C175314	Used Telephone Help Line or Quit Cigarette Smoking Line|A telephone help line or quit line	A response indicating that an individual used a telephone help line or quit line to quit smoking cigarettes.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127247>	C175314	Used Quit Cigarette Smoking Books and/or Pamphlets|Books, pamphlets	A response indicating that an individual used books and/or pamphlets to quit smoking cigarettes.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127248>	C175314	Used Quit Cigarette Smoking Videos|Videos	A response indicating that an individual used videos to quit smoking cigarettes.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127249>	C175314	Used Quit Tobacco Clinic, Class, or Support Group|A quit tobacco clinic, class, or support group	A response indicating that an individual used a quit tobacco clinic, class, or support group to quit smoking cigarettes.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C12724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12724>	C38617	Glottis|GLOTTIS|Glottis structure (body structure)|glottis|glottis	The space in which the vocal cords are located.	Glottis		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C127250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127250>	C175314	Used Quit Cigarette Smoking Internet or Web-Based Program|An internet or web-based program	A response indicating that an individual used an internet or web-based program to quit smoking cigarettes.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127251>	C175314	Used Text Message-Based Smoking Cessation Program|A text-message based smoking cessation program	A response indicating that an individual used a text message-based smoking cessation program to quit smoking cigarettes.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127252>	C175314	Used Support of Friends and Family to Quit Cigarette Smoking|Support of friends and family	A response indicating that an individual used the support of friends and family to quit smoking cigarettes.			Intellectual Product	Cancer Patient Tobacco Use Questionnaire
C127253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127253>	C127180	Impairment of Laryngeal Vestibular Closure, Height of Swallow|Laryngeal Vestibular Closure - Height of Swallow	An observation of an individual's laryngeal vestibular closing and height of swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127254>	C127253	Complete Laryngeal Vestibular Closure|Complete; no air/contrast in laryngeal vestibule	A finding of complete laryngeal vestibular closure; no air/contrast in laryngeal vestibule.			Finding	Modified Barium Swallow Impairment Profile
C127255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127255>	C127253	Incomplete Laryngeal Vestibular Closure|Incomplete; narrow column air/contrast in laryngeal vestibule	A finding of incomplete laryngeal vestibular closure; narrow column air/contrast in laryngeal vestibule.			Finding	Modified Barium Swallow Impairment Profile
C127256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127256>	C127253	No Laryngeal Vestibular Closure|None; wide column air/contrast in laryngeal vestibule	A finding of no laryngeal vestibular closure; wide column air/contrast in laryngeal vestibule.			Finding	Modified Barium Swallow Impairment Profile
C127257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127257>	C66830	CDISC SDTM Contact Role for Clinical Study Terminology|CONROL|Contact Role for Clinical Study|SDTM-CONROL	Terminology associated with the contact role for clinical study codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127258>	C103175	CDISC SDTM Observational Study Biospecimen Retention Terminology|SDTM-OBSSBSR	Terminology associated with the observational study biospecimen retention codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	
C127259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127259>	C66830	CDISC SDTM Observational Study Model Terminology|OBSSMO|Observational Study Model|SDTM-OBSSMO	Terminology associated with the observation study model codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12725>	C13018	Gonad|GONAD|Gonadal|Gonads|gonad	A reproductive system organ that produces and releases either sperm (testis) or eggs (ovary).	Gonad		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127260>	C66830	CDISC SDTM Observational Study Sampling Method Terminology|OBSSSM|Observational Study Sampling Method|SDTM-OBSSSM	Terminology associated with the observation study sampling method codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127261>	C66830	CDISC SDTM Observational Study Time Perspective Terminology|OBSSTP|Observational Study Time Perspective|SDTM-OBSSTP	Terminology associated with the observation study time perspective codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127262>	C66830	CDISC SDTM Environmental Setting Terminology|Environmental Setting|SDTM-SETTING|SETTING	Terminology associated with the environmental setting codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127263>	C66830	CDISC SDTM Case Finding Terminology|CASEFIND|Case Finding|SDTM-CASEFIND	Terminology associated with the case finding codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127264>	C66830	CDISC SDTM Culture Medium Type Terminology|CLTMDTYP|Culture Medium Type|SDTM-CLTMDTYP	Terminology associated with the culture medium type codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127265>	C66830	CDISC SDTM Mode of Disease Transmission Terminology|MODTRN|Mode of Disease Transmission|SDTM-MODTRN	Terminology associated with the mode of disease transmission codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127266>	C66830	CDISC SDTM Tuberculosis Findings About Test Code Terminology|SDTM-TBFATSCD|TBFATSCD|Tuberculosis Findings About Test Code	Terminology associated with the tuberculosis findings about test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127267>	C66830	CDISC SDTM Tuberculosis Findings About Test Name Terminology|SDTM-TBFATS|TBFATS|Tuberculosis Findings About Test Name	Terminology associated with the tuberculosis findings about test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127268>	C66830	CDISC SDTM Disease Presentation Type Terminology|DSPRTYP|Disease Presentation Type|SDTM-DSPRTYP	Terminology associated with the disease presentation type codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127269>	C66830	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|MUSCTSCD|Musculoskeletal System Finding Test Code|SDTM-MUSCTSCD	Terminology associated with the musculoskeletal system finding test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12726>	C12680	Inguinal Region|Groin|Groin|Groin|Groin|INGUINAL REGION|Inguinal|groin|groin|groin area|groin region|iliac region|inguen|inguinal part of abdomen|inguinal region	The lower region of the anterior abdominal wall located laterally to the pubic region.	Groin		Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Microscopic Findings Result Modifier Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C127270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127270>	C66830	CDISC SDTM Musculoskeletal System Finding Test Name Terminology|MUSCTS|Musculoskeletal System Finding Test Name|SDTM-MUSCTS	Terminology associated with the musculoskeletal system finding test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127271>	C125637	Apophysomyces	A genus of filamentous fungi that are found in soil and on decaying vegetation in tropical and subtropical regions. The genus can be identified by its sporangiophores, having a distinctive funnel or bell-shaped apophyses and hemispherical-shaped columellae. Species in this genus are resistant to cycloheximide.			Fungus	
C127272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127272>	C77167	Arthrinium|Apiospora	A genus of fungi in the phylum Ascomycota that are found as saprobes on plant materials. Several species in the genus synthesize compounds of pharmacologic interest.			Fungus	
C127273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127273>	C77167	Arthroderma	A genus of fungi in the phylum Ascomycota that are causative agents of dermatophytosis.			Fungus	
C127274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127274>	C77169	Asterotremella|Vanrija	A genus of yeast-like fungi in the phylum Basidiomycota.			Fungus	
C127275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127275>	C77167	Aureobasidium	A genus of yeast-like fungi in the phylum Ascomycota with colonies that start cream to pink, becoming dark brown with age.			Fungus	
C127276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127276>	C77167	Byssochlamys|Paecilomyces	A genus of heat resistant fungi in the phylum Ascomycota and the family Trichocomaceae.			Fungus	
C127277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127277>	C54117|C15721	Case Search	The activity of looking for individuals with a shared characteristic such as a disease.			Research Activity	
C127278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127278>	C77169	Coprinellus	A genus of mushroom-forming fungi in the phylum Basidiomycota and the family Psathyrellaceae.			Fungus	
C127279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127279>	C77169	Cystobasidium	A genus of yeast in the phylum Basidiomycota and the family Cystobasidiaceae.			Fungus	
C12727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12727>	C13018	Heart|Cardiac|HEART|Heart structure (body structure)|chambered heart|heart|vertebrate heart	A hollow organ located slightly to the left of the middle portion of the chest. It is composed of muscle and it is divided by a septum into two sides: the right side which receives de-oxygenated blood from the body and the left side which sends newly oxygenated blood to the body. Each side is composed of two chambers: the atrium (receiving blood) and ventricle (ejecting blood).	Heart		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Lesion Characteristics Table|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C127280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127280>	C85932	Dickeya|Erwinia	A genus of gram-negative facultatively anaerobic bacillus bacteria in the family Enterobacteriaceae comprising mainly pathogens from herbaceous plants.			Bacterium	
C127281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127281>	C77167	Epidermophyton	A genus of filamentous fungi in the phylum Ascomycota. Species in this genus are causative agents of superficial and cutaneous mycoses in humans.			Fungus	
C127282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127282>	C77167	Eurotium	A genus of filamentous fungi in the phylum Ascomycota that are the sexual states of Aspergillus species.			Fungus	
C127283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127283>	C77167	Exophiala	A genus of anamorphic fungi in the phylum Ascomycota.			Fungus	
C127284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127284>	C77169	Hannaella	A genus of fungi in the phylum Basidiomycota.			Fungus	
C127285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127285>	C77167	Hanseniaspora|Kloeckera	A genus of apiculate yeast in the phylum Ascomycota that are frequently present in fruit juices and fermenting musts.			Fungus	
C127286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127286>	C76196	Herbaspirillum	A genus of Gram-negative, motile, spirillum-shaped bacteria in the Proteobacteria phylum and Betaproteobacteria class that colonize diverse plants. Many species within Herbaspirillum are able to fix nitrogen. Sugars are oxidized, but not fermented.			Bacterium	
C127287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127287>	C77167	Hortaea	A genus of dematiaceous melanized fungi in the phylum Ascomycota comprising plant-infecting pathogens and free-living saprobes.			Fungus	
C127288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127288>	C85914	Kerstersia	A genus of Gram-negative, catalase-positive, oxidase-negative bacteria in the in phylum Proteobacteria that occur as single cells, in pairs, or in short chains.			Bacterium	
C127289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127289>	C77167	Kodamaea	A genus of yeast-like fungi in the phylum Ascomycota that are part of the normal or transient flora of the human throat and alimentary tract.			Fungus	
C12728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12728>	C13023	Cardiac Atrium|Atria of Heart|Atria, Cardiac|Atrial structure (body structure)|Atrium|Atrium of Heart|Auricle of Heart|Cardiac Atria|HEART, ATRIUM|Heart Atria|Heart Atrium	The paired upper chambers of the heart. The left atrium receives oxygenated blood from the pulmonary vein and pumps blood into the left ventricle. The right atrium receives venous deoxygenated blood from the entire body via the superior and inferior vena cavae and pumps blood into the right ventricle.	Cardiac Atrium		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C127290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127290>	C77167	Lomentospora	A genus of filamentous fungi in the phylum Ascomycota which is isolated from soils, polluted water, composts, and manure of cattle and fowl.			Fungus	
C127291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127291>	C77167	Madurella	A genus of fungi in the phylum Ascomycota Species in this genus are causative agents of mycetoma.			Fungus	
C127292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127292>	C77169	Malassezia|MALASSEZIA	A genus of obligatory lipophilic yeast in the phylum Basidiomycota naturally found on the skin of many warm-blooded animals. Species in this genus are associated with superficial infections of the skin and associated structures.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127293>	C77167	Metschnikowia	A genus of yeast in the phylum Ascomycota characterized by the formation of needle-shaped ascospores.			Fungus	
C127294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127294>	C77167	Microsporum	A genus of fungi in the phylum Ascomycota that forms both macroconidia and microconidia on short conidiophores. Species in this genus are causative agents of tinea capitis, tinea corpus, ringworm, and other types of dermatophytoses.			Fungus	
C127295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127295>	C77167	Monascus	A genus of saprobic mold in the phylum Ascomycota. Species in this genus are used in the production of various fermented food products, pigments, and food supplements.			Fungus	
C127296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127296>	C77167	Purpureocillium	A genus of fungi in the phylum Ascomycota characterized by purple conidia.			Fungus	
C127297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127297>	C77167	Scedosporium	A genus of filamentous fungi in the phylum Ascomycota which is isolated from soils, polluted water, composts, and manure of cattle and fowl.			Fungus	
C127298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127298>	C77167	Scolecobasidium	A genus of mitosporic fungi in the phylum Ascomycota characterized by short conidiospores with thread-like sterigmata bearing a terminal conidium.			Fungus	
C127299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127299>	C77167	Setosphaeria	A genus of fungi in the phylum Ascomycota.			Fungus	
C12729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12729>	C13023	Cardiac Valve|CARDIAC VALVE|Cardiac Valves|Cardiac valve structure (body structure)|VALVE, CARDIAC	Any of the four heart valves, including the two atrioventricular valves and the two semilunar valves, which regulate the flow of blood through the chambers of the heart.	Cardiac Valve		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C1272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1272>	C755	Recombinant Vascular Endothelial Growth Factor|VEGF|VPF|Vascular Endothelial Growth Factor|Vascular Permeability Factor|rhuVEGF|vascular endothelial growth factor	A recombinant therapeutic agent which is chemically identical to or similar to endogenous vascular endothelial growth factor (VEGF).  Produced by a wide variety of cell types, endogenous VEGF is a homodimeric, glycosylated protein that is a highly specific mitogen for vascular endothelial cells; significantly influences vascular permeability; appears to play a role in neovascularisation under physiological conditions; is a potent chemoattractant; has pro-coagulatory activities; and is hypoxia-inducible.  Therapeutic VEGF may be used to induce angiogenesis in the treatment of ischemic conditions and may have a role in stimulating nerve regeneration. (NCI04)			Chemical Viewed Functionally	
C127300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127300>	C77169	Sporidiobolus	A genus of anamorphic fungi in the phylum Basidiomycota that produce bilaterally symmetrical ballistoconidia and have CoQ 10 or CoQ 10(H2) as their major ubiquinone.			Fungus	
C127301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127301>	C77167	Sporothrix	A genus of thermally dimorphic fungi in the phylum Ascomycota that is found growing as filamentous hyphae at lower temperatures and as a yeast at 37C. Species in this genus are characterized by brown, thick-walled conidia attached along the hyphae.			Fungus	
C127302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127302>	C77169	Tausonia|Guehomyces	A genus of yeast-like fungi in the phylum Basidiomycota with arthroconidia developing from disarticulate hyphae. Species in this genus are positive for urease and diazonium blue B. Sexual reproduction is not observed.			Fungus	
C127303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127303>	C77167	Trematosphaeria	A genus of mostly saprobic or hemibiotrophic fungi in the phylum Ascomycota with additional species inhabiting marine and freshwater environments. Species in this genus are characterized by medium to large sized ascomata with peridia composed of small compressed cells, clavate to cylindrical bitunicate asci, a trabeculate hamathecium in a gelatinous matrix and reddish-brown ellipsoid to fusoid transversely septate ascospores sometimes with paler end cells.			Fungus	
C127304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127304>	C77167	Trichomonascus	A genus of endomycete-like fungi in the phylum Ascomycota. Species in this genus may or may not be mycoparasitic.			Fungus	
C127305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127305>	C77167	Trichophyton	A genus of fungi in the phylum Ascomycota that includes those that cause tinea, athlete's foot, ringworm, and jock itch. Species in this genus are molds, characterized by the development of smooth-walled macro- and microconidia.			Fungus	
C127306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127306>	C13023	Mitral Valve Annulus|MITRAL VALVE ANNULUS	A saddle-shaped, fibrous structure that provides support to the mitral valve leaflets, and functions to contract during ventricular systole, thereby providing complete closure of the mitral valve and preventing regurgitant blood flow into the left atrium.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127307>	C86467	Kocuria rhizophila|KOCURIA RHIZOPHILA				Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127308>	C124358	Pneumocystis carinii|PNEUMOCYSTIS CARINII	A species of yeast-like fungi in the family Pneumocystidaceae. P. carinii typically infects the lungs of rats.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127309>	C150873	Quantitative Ultrasound Spectroscopy|QUS	An application of conventional frequency spectroscopic ultrasound data that uses ultrasound backscattered radiofrequency (RF) signals to determine the bioacoustic properties of the underlying tissue for characterizing its microstructure.	Quantitative Ultrasound Spectroscopy		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C12730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12730>	C13023	Cardiac Ventricle|Cardiac Ventricles|Cardiac ventricular structure (body structure)|HEART, VENTRICLE|Heart Ventricle|Ventricle|Ventricles, Heart	One of the two lower chambers of the heart that receives blood from an atrium and pumps blood to the arteries.	Cardiac Ventricle		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C127310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127310>	C127180	Impairment of Pharyngeal Stripping Wave|Pharyngeal Stripping Wave	An observation of an individual's pharyngeal stripping wave during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127311>	C127310	Pharyngeal Stripping Wave Present and Complete|Present - complete	A finding of a pharyngeal stripping wave present and complete.			Finding	Modified Barium Swallow Impairment Profile
C127312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127312>	C127310	Pharyngeal Stripping Wave Present but Diminished|Present - diminished	A finding of a pharyngeal stripping wave present but diminished.			Finding	Modified Barium Swallow Impairment Profile
C127313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127313>	C127310	Pharyngeal Stripping Wave Absent|Absent	A finding of an absent pharyngeal stripping wave.			Finding	Modified Barium Swallow Impairment Profile
C127314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127314>	C127180	Impairment of Pharyngeal Contraction|Pharyngeal Contraction - Anterior Posterior View Only	An observation of an individual's pharyngeal contraction during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127315>	C127314	Complete Pharyngeal Contraction|Complete	A finding of complete pharyngeal contraction during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127316>	C127314	Incomplete Pharyngeal Contraction|Incomplete (Pseudodiverticulae)	A finding of incomplete pharyngeal contraction during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127317>	C127314	Unilateral Bulging on Pharyngeal Contraction|Unilateral Bulging	A finding of unilateral bulging on pharyngeal contraction during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127318>	C127314	Bilateral Bulging on Pharyngeal Contraction|Bilateral Bulging	A finding of bilateral bulging on pharyngeal contraction during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127319>	C127180	Impairment of Pharyngoesophageal Segment Opening|Pharyngoesophageal Segment Opening	An observation of an individual's pharyngoesophageal segment opening during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C12731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12731>	C33003|C12983	Humerus|BONE, HUMERUS|Bone structure of humerus (body structure)|Bone, Humeral|HUMERUS|humeri|humerus|humerus bone	The upper arm bone between the shoulder and elbow.	Humerus		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C127320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127320>	C127319	Complete Distension and Complete Duration of Pharyngoesophageal Segment Opening During Swallowing|Complete distension and complete duration; no obstruction of flow	A finding of complete distension and complete duration of pharyngoesophageal segment opening during swallowing; no obstruction of flow.			Finding	Modified Barium Swallow Impairment Profile
C127321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127321>	C127319	Partial Distension or Partial Duration of Pharyngoesophageal Segment Opening During Swallowing|Partial distension/partial duration; partial obstruction of flow	A finding of partial distension or partial duration of pharyngoesophageal segment opening during swallowing; partial obstruction of flow.			Finding	Modified Barium Swallow Impairment Profile
C127322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127322>	C127319	Minimal Distension or Minimal Duration of Pharyngoesophageal Segment Opening During Swallowing|Minimal distension/minimal duration; marked obstruction of flow	A finding of minimal distension or minimal duration of pharyngoesophageal segment opening during swallowing; marked obstruction of flow.			Finding	Modified Barium Swallow Impairment Profile
C127323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127323>	C127319	No Distension of Pharyngoesophageal Segment Opening During Swallowing|No distension with total obstruction of flow	A finding of no distension of pharyngoesophageal segment opening during swallowing with total obstruction of flow.			Finding	Modified Barium Swallow Impairment Profile
C127324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127324>	C127180	Impairment of Tongue Base Retraction|Tongue Base (TB) Retraction	An observation of an individual's tongue base retraction during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127325>	C127324	No Contrast Between Tongue Base and Posterior Pharyngeal Wall During Swallowing|No contrast between TB and posterior pharyngeal wall (PW)	A finding of no contrast between tongue base and posterior pharyngeal wall during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127326>	C127324	Trace Column of Contrast or Air Between Tongue Base and Posterior Pharyngeal Wall During Swallowing|Trace column of contrast or air between TB and PW	A finding of a trace column of contrast or air between tongue base and posterior pharyngeal wall during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127327>	C127324	Narrow Column of Contrast or Air Between Tongue Base and Posterior Pharyngeal Wall During Swallowing|Narrow column of contrast or air between TB and PW	A finding of a narrow column of contrast or air between tongue base and posterior pharyngeal wall during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127328>	C127324	Wide Column of Contrast or Air Between Tongue Base and Posterior Pharyngeal Wall During Swallowing|Wide column of contrast or air between TB and PW	A finding of a wide column of contrast or air between tongue base and posterior pharyngeal wall during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127329>	C127324	No Visible Posterior Motion of Tongue Base During Swallowing|No visible posterior motion of TB	A finding of no visible posterior motion of tongue base during swallowing.			Finding	Modified Barium Swallow Impairment Profile
C12732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12732>	C12700	Hypoglossal Nerve|HYPOGLOSSAL NERVE|Hypoglossal nerve structure (body structure)|Twelfth Cranial Nerve	The twelfth cranial nerve. It arises from the hypoglossal nucleus and leads to the tongue.	Hypoglossal Nerve		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C127330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127330>	C127180	Pharyngeal Residue Following Swallowing|Pharyngeal Residue	An observation of the pharyngeal residue remaining after an individual swallows.			Finding	Modified Barium Swallow Impairment Profile
C127331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127331>	C127330	Complete Pharyngeal Clearance Following Swallowing|Complete pharyngeal clearance	A finding of complete pharyngeal clearance following swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127332>	C127330	Trace Residue Within or On Pharyngeal Structures Following Swallowing|Trace residue within or on pharyngeal structures	A finding of trace residue within or on pharyngeal structures following swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127333>	C127330	Collection of Residue Within or On Pharyngeal Structures Following Swallowing|Collection of residue within or on pharyngeal structures	A finding of collection of residue within or on pharyngeal structures following swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127334>	C127330	Majority of Contrast Within or On Pharyngeal Structures Following Swallowing|Majority of contrast within or on pharyngeal structures	A finding of the majority of contrast within or on pharyngeal structures following swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127335>	C127330	Minimal to No Pharyngeal Clearance Following Swallowing|Minimal to no pharyngeal clearance	A finding of minimal to no pharyngeal clearance following swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127336>	C25341	Location of Pharyngeal Residue Following Swallowing|Location	An observation of the location of pharyngeal residue remaining after an individual swallows.			Finding	Modified Barium Swallow Impairment Profile
C127337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127337>	C127336	Residue on Tongue Base Following Swallowing|Tongue Base	A finding of residue on tongue base following swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127338>	C127336	Residue on Valleculae Following Swallowing|Valleculae	A finding of residue on valleculae following swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127339>	C127336	Residue on Pharyngeal Wall Following Swallowing|Pharyngeal wall	A finding of residue on pharyngeal wall following swallowing.			Finding	Modified Barium Swallow Impairment Profile
C12733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12733>	C32039	Iliac Artery|ARTERY, ILIAC	A branch of the abdominal aorta that supplies blood to the lower trunk and the legs.	Iliac Artery		Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C127340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127340>	C127336	Residue on Aryepiglottic Folds Following Swallowing|Aryepiglottic folds	A finding of residue on aryepiglottic folds following swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127341>	C127336	Residue on Pyriform Sinuses Following Swallowing|Pyriform sinuses	A finding of residue on pyriform sinuses following swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127342>	C127330	Diffuse Residue Following Swallowing|Diffuse (>3 areas)	A finding of diffuse residue following swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127343>	C127181	Impairment of Esophageal Clearance Following Swallowing in Upright Position|Esophageal Clearance Upright Position	An observation of an individual's esophageal clearance after swallowing in an upright position.			Finding	Modified Barium Swallow Impairment Profile
C127344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127344>	C127343	Complete Esophageal Clearance Following Swallowing|Complete clearance; esophageal coating	A finding of complete esophageal clearance following swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127345>	C127343	Esophageal Retention Following Swallowing|Esophageal retention	A finding of esophageal retention following swallowing.			Finding	Modified Barium Swallow Impairment Profile
C127346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127346>	C127343	Esophageal Retention with Retrograde Flow Below Pharyngoesophageal Segment Following Swallowing|Esophageal retention with retrograde flow below pharyngoesophageal segment (PES)	A finding of esophageal retention with retrograde flow below the pharyngoesophageal segment.			Finding	Modified Barium Swallow Impairment Profile
C127347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127347>	C127343	Esophageal Retention with Retrograde Flow Through Pharyngoesophageal Segment Following Swallowing|Esophageal retention with retrograde flow through PES	A finding of esophageal retention with retrograde flow through the pharyngoesophageal segment.			Finding	Modified Barium Swallow Impairment Profile
C127348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127348>	C127343	Minimal to No Esophageal Clearance Following Swallowing|Minimal to no esophageal clearance	A finding of minimal to no esophageal clearance.			Finding	Modified Barium Swallow Impairment Profile
C127349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127349>	C100110	CDISC Questionnaire EPIC-26 Test Name Terminology|EPIC1TN|QS-EPIC-26 TEST|The Expanded Prostate Cancer Index Composite Short Form Questionnaire Test Name	Test names of questionnaire questions associated with the Expanded Prostate Cancer Index Composite Short Form (EPIC-26) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12734>	C12814	Iliac Vein|ILIAC VEIN	Any of the three veins including the common, external and internal iliac veins.	Iliac Vein		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C127350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127350>	C100110	CDISC Questionnaire EPIC-26 Test Code Terminology|EPIC1TC|QS-EPIC-26 TESTCD|The Expanded Prostate Cancer Index Composite Short Form Questionnaire Test Code	Test codes of questionnaire questions associated with the Expanded Prostate Cancer Index Composite Short Form (EPIC-26) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127351>	C100110	CDISC Questionnaire EPIC-CP Test Name Terminology|EPIC2TN|QS-EPIC-CP TEST|The Expanded Prostate Cancer Index Composite for Clinical Practice Questionnaire Test Name	Test names of questionnaire questions associated with the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127352>	C100110	CDISC Questionnaire EPIC-CP Test Code Terminology|EPIC2TC|QS-EPIC-CP TESTCD|The Expanded Prostate Cancer Index Composite for Clinical Practice Questionnaire Test Code	Test codes of questionnaire questions associated with the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127353>	C100110	CDISC Questionnaire FACT-G Version 4 Test Name Terminology|FAC001TN|QS-FACT-G Version 4 TEST|The Functional Assessment of Cancer Therapy-General Version 4 Questionnaire Test Name	Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127354>	C100110	CDISC Questionnaire FACT-G Version 4 Test Code Terminology|FAC001TC|QS-FACT-G Version 4 TESTCD|The Functional Assessment of Cancer Therapy-General Version 4 Questionnaire Test Code	Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127355>	C100110	CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Name Terminology|FAC052TN|QS-NCCN-FACT-FPSI 17 Version 2 TEST|The National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 Questionnaire Test Name	Test names of questionnaire questions associated with the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127356>	C100110	CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Code Terminology|FAC052TC|QS-NCCN-FACT-FPSI 17 Version 2 TESTCD|The National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 Questionnaire Test Code	Test codes of questionnaire questions associated with the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127357>	C100110	CDISC Questionnaire FACT-P Version 4 Test Name Terminology|FAC023TN|QS-FACT-P Version 4 TEST|The Functional Assessment of Cancer Therapy-Prostate Version 4 Questionnaire Test Name	Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127358>	C100110	CDISC Questionnaire FACT-P Version 4 Test Code Terminology|FAC023TC|QS-FACT-P Version 4 TESTCD|The Functional Assessment of Cancer Therapy-Prostate Version 4 Questionnaire Test Code	Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127359>	C100110	CDISC Questionnaire PROSQOLI Test Name Terminology|PROS01TN|QS-PROSQOLI TEST|The Prostate Cancer Specific Quality of Life Instrument Questionnaire Test Name	Test names of questionnaire questions associated with the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12735>	C12919	Immune System|allergic/immunologic body system|allergic/immunologic organ system|body system, allergic/immunologic|immune system|immune system|immunologic/allergic organ system|organ system, allergic/immunologic	The complex group of organs like thymus, spleen, tonsils, lymphatic system, hematopoetic system and cells like lymphocytes, granulocytes, monocytes and macrophages that defends the body against infection or disease. It consists of a complex interrelated cellular, molecular and genetic component.	Immune System		Body System	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C127360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127360>	C100110	CDISC Questionnaire PROSQOLI Test Code Terminology|PROS01TC|QS-PROSQOLI TESTCD|The Prostate Cancer Specific Quality of Life Instrument Questionnaire Test Code	Test codes of questionnaire questions associated with the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127361>	C211913	EPIC-26 Questionnaire Question	A question associated with the EPIC-26 questionnaire.			Intellectual Product	
C127362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127362>	C211913	EPIC-CP Questionnaire Question	A question associated with the EPIC-CP questionnaire.			Intellectual Product	
C127363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127363>	C211913	FACT-G Version 4 Questionnaire Question	A question associated with the FACT-G Version 4 questionnaire.			Intellectual Product	
C127364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127364>	C211913	NCCN-FACT-FPSI 17 Version 2 Questionnaire Question	A question associated with the NCCN-FACT-FPSI 17 Version 2 questionnaire.			Intellectual Product	
C127365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127365>	C211913	FACT-P Version 4 Questionnaire Question	A question associated with the FACT-P Version 4 questionnaire.			Intellectual Product	
C127366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127366>	C211913	PROSQOLI Questionnaire Question	A question associated with the PROSQOLI questionnaire.			Intellectual Product	
C127367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127367>	C91105	The Expanded Prostate Cancer Index Composite Short Form Questionnaire|EPIC-26|EPIC-26|EPIC-26 (Priority 1)|EPIC1	A standardized rating scale developed by Szymanski et al in 2010, which is used to monitor health-related quality of life outcomes in patients with prostate cancer. This instrument contains five symptom domains (urinary incontinence, urinary irritative/obstructive, sexual, bowel, hormonal) and 26 items, scored from 0 (worst) to 100 (best).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C127368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127368>	C91105	Expanded Prostate Cancer Index Composite for Clinical Practice Questionnaire|EPIC-CP|EPIC-CP|EPIC2	A standardized rating scale developed by Chang et al in 2011, which is used to measure urinary incontinence, urinary irritation, and the bowel, sexual and hormonal health related quality of life in patients with prostate cancer. This instrument contains 16 items.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127369>	C91105	Functional Assessment of Cancer Therapy-General Version 4 Questionnaire|FAC001|FACT-G V4|FACT-G Version 4	A standardized rating scale originally developed by Cella et al in 1993, which is used for general measurements of quality of life in patients with any form of cancer, or other chronic illness condition. The version 4 of this instrument contains 27 items which are divided into four domains: physical well-being, social/family well-being, emotional well-being, and functional well-being.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12736>	C13018	Intestine|Bowel|Bowel|INTESTINE|Intestinal structure (body structure)|Intestinal tract, NOS|Intestines|bowel|intestine|intestine	The portion of the gastrointestinal tract between the stomach and the anus. It includes the small intestine and large intestine.	Intestine		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C127370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127370>	C91105	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 Questionnaire|FAC052|NCCN-FACT FPSI-17 V2|NCCN-FACT-FPSI 17 Version 2	A standardized rating scale modified from FACT-G and FACT-P and developed by Victorson et al in 2011, based on the recommendations of the National Comprehensive Cancer Network (NCCN). This instrument contains 17 items, and is used to examine the effectiveness of noncurative treatments in patients with advanced prostate cancer.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127371>	C91105	Functional Assessment of Cancer Therapy-Prostate Version 4 Questionnaire|FAC023|FACT-P V4|FACT-P Version 4	A standardized rating scale originally developed by Cella et al in 1993 and modified by Esper et al in 1997, which includes a 12-item prostate cancer subscale (PCS) in addition to the original 27 items from FACT-G. FACT-P contains 39 items and measures both general health-related quality of life as well as prostate cancer-specific quality of life; the total score is based on both FACT-G and PCS.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127372>	C91105	Prostate Cancer Specific Quality of Life Instrument Questionnaire|PROS01|PROSQOLI|PROSQOLI	A standardized rating scale developed by Stockler et al in 1999 which is used to assess health-related quality of life in patients with advanced hormone-resistant prostate cancer. The instrument contains 9 linear analogue self-assessment scales measuring symptoms, function, and overall well-being, and a six-point ordinal adjectival scale of present pain intensity from the McGill Pain Questionnaire.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127373>	C127361	EPIC-26 - How Often Have You Leaked Urine|EPIC1-How Often Have You Leaked Urine|EPIC1-How Often Have You Leaked Urine|EPIC101	The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) Over the past 4 weeks, how often have you leaked urine?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-26 Test Code Terminology|CDISC Questionnaire EPIC-26 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127374>	C127361	EPIC-26 - Best Describes Urinary Control|EPIC1-Best Describes Urinary Control|EPIC1-Best Describes Urinary Control|EPIC102	The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) Which of the following best describes your urinary control during the last 4 weeks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-26 Test Code Terminology|CDISC Questionnaire EPIC-26 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127375>	C127361	EPIC-26 - Pads or Adult Diapers per Day|EPIC1-Pads or Adult Diapers per Day|EPIC1-Pads or Adult Diapers per Day|EPIC103	The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How many pads or adult diapers per day did you usually use to control leakage during the last 4 weeks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-26 Test Code Terminology|CDISC Questionnaire EPIC-26 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127376>	C127361	EPIC-26 - Dripping or Leaking Urine|EPIC1-Problem Dripping or Leaking Urine|EPIC1-Problem Dripping or Leaking Urine|EPIC104A	The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How big a problem, if any, has each of the following been for you during the last 4 weeks? Dripping or leaking urine.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-26 Test Code Terminology|CDISC Questionnaire EPIC-26 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127377>	C127361	EPIC-26 - Pain or Burning on Urination|EPIC1-Problem Pain/Burning on Urination|EPIC1-Problem Pain/Burning on Urination|EPIC104B	The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How big a problem, if any, has each of the following been for you during the last 4 weeks? Pain or burning on urination.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-26 Test Code Terminology|CDISC Questionnaire EPIC-26 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127378>	C127361	EPIC-26 - Bleeding With Urination|EPIC1-Problem Bleeding With Urination|EPIC1-Problem Bleeding With Urination|EPIC104C	The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How big a problem, if any, has each of the following been for you during the last 4 weeks? Bleeding with urination.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-26 Test Code Terminology|CDISC Questionnaire EPIC-26 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127379>	C127361	EPIC-26 - Weak Urine Stream or Incomplete Emptying|EPIC1-Problem Weak Urine Stream/Emptying|EPIC1-Problem Weak Urine Stream/Emptying|EPIC104D	The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How big a problem, if any, has each of the following been for you during the last 4 weeks? Weak urine stream or incomplete emptying.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-26 Test Code Terminology|CDISC Questionnaire EPIC-26 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12737>	C13019	Iris|EYE, IRIS|Eye, Iris|IRIS|iris	The colored disc of the eye composed of connective tissue, epithelium, and endothelium. It separates the anterior chamber from the posterior chamber.	Iris		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C127380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127380>	C127361	EPIC-26 - Urinate Frequently During the Day|EPIC1-Problem Need to Urinate Frequently|EPIC1-Problem Need to Urinate Frequently|EPIC104E	The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How big a problem, if any, has each of the following been for you during the last 4 weeks? Need to urinate frequently during the day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-26 Test Code Terminology|CDISC Questionnaire EPIC-26 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127381>	C127361	EPIC-26 - Overall Problem Urinary Function|EPIC1-Overall Problem Urinary Function|EPIC1-Overall Problem Urinary Function|EPIC105	The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) Overall, how big a problem has your urinary function been for you during the last 4 weeks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-26 Test Code Terminology|CDISC Questionnaire EPIC-26 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127382>	C127361	EPIC-26 - Urgency to Have a Bowel Movement|EPIC1-Problem Urgency of Bowel Movement|EPIC1-Problem Urgency of Bowel Movement|EPIC106A	The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How big a problem, if any, has each of the following been for you? Urgency to have a bowel movement.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-26 Test Code Terminology|CDISC Questionnaire EPIC-26 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127383>	C127361	EPIC-26 - Increased Frequency of Bowel Movements|EPIC1-Problem Increased Freq Bowel Move|EPIC1-Problem Increased Freq Bowel Move|EPIC106B	The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How big a problem, if any, has each of the following been for you? Increased frequency of bowel movements.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-26 Test Code Terminology|CDISC Questionnaire EPIC-26 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127384>	C127361	EPIC-26 - Losing Control of Stools|EPIC1-Problem Losing Control of Stools|EPIC1-Problem Losing Control of Stools|EPIC106C	The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How big a problem, if any, has each of the following been for you? Losing control of your stools.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-26 Test Code Terminology|CDISC Questionnaire EPIC-26 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127385>	C127361	EPIC-26 - Bloody Stools|EPIC1-Problem Bloody Stools|EPIC1-Problem Bloody Stools|EPIC106D	The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How big a problem, if any, has each of the following been for you? Bloody stools.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-26 Test Code Terminology|CDISC Questionnaire EPIC-26 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127386>	C127361	EPIC-26 - Abdominal or Pelvic or Rectal Pain|EPIC1-Problem Abdom/Pelvic/Rectal Pain|EPIC1-Problem Abdom/Pelvic/Rectal Pain|EPIC106E	The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How big a problem, if any, has each of the following been for you? Abdominal/pelvic/rectal pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-26 Test Code Terminology|CDISC Questionnaire EPIC-26 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127387>	C127361	EPIC-26 - Overall Problem Bowel Habits|EPIC1-Overall Problem Bowel Habits|EPIC1-Overall Problem Bowel Habits|EPIC107	The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) Overall, how big a problem have your bowel habits been for you during the last 4 weeks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-26 Test Code Terminology|CDISC Questionnaire EPIC-26 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127388>	C127361	EPIC-26 - Ability to Have an Erection|EPIC1-Rate Ability to Have an Erection|EPIC1-Rate Ability to Have an Erection|EPIC108A	The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How would you rate each of the following during the last 4 weeks? Your ability to have an erection?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-26 Test Code Terminology|CDISC Questionnaire EPIC-26 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127389>	C127361	EPIC-26 - Ability to Reach Orgasm|EPIC1-Rate Ability to Reach Orgasm|EPIC1-Rate Ability to Reach Orgasm|EPIC108B	The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How would you rate each of the following during the last 4 weeks? Your ability to reach orgasm (climax)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-26 Test Code Terminology|CDISC Questionnaire EPIC-26 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12738>	C12814	Jugular Vein|JUGULAR VEIN|Structure of jugular vein (body structure)|VEIN, JUGULAR|Vena Jugularis	Veins in the neck which drain the brain, face, and neck into the brachiocephalic or subclavian veins.	Jugular Vein		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C127390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127390>	C127361	EPIC-26 - Quality of Erections|EPIC1-Quality of Your Erections|EPIC1-Quality of Your Erections|EPIC109	The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How would you describe the usual quality of your erections during the last 4 weeks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-26 Test Code Terminology|CDISC Questionnaire EPIC-26 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127391>	C127361	EPIC-26 - Frequency of Erections|EPIC1-Frequency of Your Erections|EPIC1-Frequency of Your Erections|EPIC110	The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How would you describe the frequency of your erections during the last 4 weeks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-26 Test Code Terminology|CDISC Questionnaire EPIC-26 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127392>	C127361	EPIC-26 - Ability to Function Sexually|EPIC1-Rate Ability to Function Sexually|EPIC1-Rate Ability to Function Sexually|EPIC111	The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) Overall, how would you rate your ability to function sexually during the last 4 weeks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-26 Test Code Terminology|CDISC Questionnaire EPIC-26 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127393>	C127361	EPIC-26 - Overall Problem Sexual Function|EPIC1-Overall Problem Sexual Function|EPIC1-Overall Problem Sexual Function|EPIC112	The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) Overall, how big a problem has your sexual function or lack of sexual function been for you during the last 4 weeks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-26 Test Code Terminology|CDISC Questionnaire EPIC-26 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127394>	C127361	EPIC-26 - Hot Flashes|EPIC1-Problem Hot Flashes|EPIC1-Problem Hot Flashes|EPIC113A	The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How big a problem during the last 4 weeks, if any, has each of the following been for you? Hot flashes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-26 Test Code Terminology|CDISC Questionnaire EPIC-26 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127395>	C127361	EPIC-26 - Breast Tender or Enlargement|EPIC1-Problem Breast Tender/Enlargement|EPIC1-Problem Breast Tender/Enlargement|EPIC113B	The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How big a problem during the last 4 weeks, if any, has each of the following been for you? Breast tenderness/enlargement.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-26 Test Code Terminology|CDISC Questionnaire EPIC-26 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127396>	C127361	EPIC-26 - Feeling Depressed|EPIC1-Problem Feeling Depressed|EPIC1-Problem Feeling Depressed|EPIC113C	The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How big a problem during the last 4 weeks, if any, has each of the following been for you? Feeling depressed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-26 Test Code Terminology|CDISC Questionnaire EPIC-26 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127397>	C127361	EPIC-26 - Lack of Energy|EPIC1-Problem Lack of Energy|EPIC1-Problem Lack of Energy|EPIC113D	The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How big a problem during the last 4 weeks, if any, has each of the following been for you? Lack of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-26 Test Code Terminology|CDISC Questionnaire EPIC-26 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127398>	C127361	EPIC-26 - Change in Body Weight|EPIC1-Problem Change in Body Weight|EPIC1-Problem Change in Body Weight|EPIC113E	The Expanded Prostate Cancer Index Composite Short Form (EPIC-26) How big a problem during the last 4 weeks, if any, has each of the following been for you? Change in body weight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-26 Test Code Terminology|CDISC Questionnaire EPIC-26 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127399>	C127362	EPIC-CP - Overall Problem Urinary Function|EPIC2-Overall Problem Urinary Function|EPIC2-Overall Problem Urinary Function|EPIC201	Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) Overall, how much of a problem has your urinary function been for you?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-CP Test Code Terminology|CDISC Questionnaire EPIC-CP Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12739>	C33461	Renal Cortex|Cortical|Cortical Portion of Kidney|Cortical Portion of the Kidney|KIDNEY, CORTEX|Structure of cortex of kidney (body structure)	The outer part of the renal parenchyma beneath the renal capsule. It contains glomeruli and tubules.	Renal Cortex		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C1273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1273>	C1744	Vindoline|(2beta,3beta,4beta,5alpha,12beta,19alpha)-4-(Acetyloxy)-6,7-didehydro-3-hydroxy-16-methoxy-1-methylaspidospermidine-3-carboxylic acid|VINDOLINE|VINDOLINE	An indole alkaloid that exhibits antimitotic activity by inhibiting microtubule assembly. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C127400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127400>	C127362	EPIC-CP - Best Describes Urinary Control|EPIC2-Best Describes Urinary Control|EPIC2-Best Describes Urinary Control|EPIC202	Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) Which of the following best describes your urinary control?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-CP Test Code Terminology|CDISC Questionnaire EPIC-CP Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127401>	C127362	EPIC-CP - Adult Diapers Used per Day|EPIC2-Pads or Adult Diapers per Day|EPIC2-Pads or Adult Diapers per Day|EPIC203	Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) How many pads or adult diapers per day have you been using for urinary leakage?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-CP Test Code Terminology|CDISC Questionnaire EPIC-CP Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127402>	C127362	EPIC-CP - Problem Urinary Dripping/Leakage|EPIC2-Problem Urinary Dripping/Leakage|EPIC2-Problem Urinary Dripping/Leakage|EPIC204	Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) How big a problem, if any, has urinary dripping or leakage been for you?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-CP Test Code Terminology|CDISC Questionnaire EPIC-CP Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127403>	C127362	EPIC-CP - Pain or Burning With Urination|EPIC2-Problem Pain/Burning w/Urination|EPIC2-Problem Pain/Burning w/Urination|EPIC205A	Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) How big a problem, if any, has each of the following been for you? Pain or burning with urination.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-CP Test Code Terminology|CDISC Questionnaire EPIC-CP Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127404>	C127362	EPIC-CP - Weak Urine Stream or Incomplete Bladder Emptying|EPIC2-Problem Weak Stream/Incompl Empty|EPIC2-Problem Weak Stream/Incompl Empty|EPIC205B	Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) How big a problem, if any, has each of the following been for you? Weak urine stream/incomplete bladder emptying.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-CP Test Code Terminology|CDISC Questionnaire EPIC-CP Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127405>	C127362	EPIC-CP - Need to Urinate Frequently|EPIC2-Problem Need to Urinate Frequently|EPIC2-Problem Need to Urinate Frequently|EPIC205C	Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) How big a problem, if any, has each of the following been for you? Need to urinate frequently. How big a problem, if any, has each of the following been for you? Need to urinate frequently.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-CP Test Code Terminology|CDISC Questionnaire EPIC-CP Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127406>	C127362	EPIC-CP - Rectal Pain or Urgency of Bowel Movements|EPIC2-Problem Rectal Pain/Urgent Bowel|EPIC2-Problem Rectal Pain/Urgent Bowel|EPIC206A	Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) How big a problem, if any, has each of the following been for you? Rectal pain or urgency of bowel movements.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-CP Test Code Terminology|CDISC Questionnaire EPIC-CP Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127407>	C127362	EPIC-CP - Increased Frequency of Bowel Movements|EPIC2-Problem Increased Freq Bowel Move|EPIC2-Problem Increased Freq Bowel Move|EPIC206B	Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) How big a problem, if any, has each of the following been for you? Increased frequency of your bowel movements.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-CP Test Code Terminology|CDISC Questionnaire EPIC-CP Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127408>	C127362	EPIC-CP - Overall Problems With Bowel Habits|EPIC2-Overall Problem Bowel Habits|EPIC2-Overall Problem Bowel Habits|EPIC206C	Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) How big a problem, if any, has each of the following been for you? Overall problems with your bowel habits.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-CP Test Code Terminology|CDISC Questionnaire EPIC-CP Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127409>	C127362	EPIC-CP - Rate Ability to Reach Orgasm|EPIC2-Rate Ability to Reach Orgasm|EPIC2-Rate Ability to Reach Orgasm|EPIC207	Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) How would you rate your ability to reach orgasm (climax)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-CP Test Code Terminology|CDISC Questionnaire EPIC-CP Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12740>	C33461	Renal Medulla|KIDNEY, MEDULLA|Medullary Portion of Kidney|Medullary Portion of the Kidney	The inner part of the renal parenchyma. It consists mostly of collecting tubules and is organized in sections called pyramids.	Renal Medulla		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127410>	C127362	EPIC-CP - Quality of Erections|EPIC2-Quality of Your Erections|EPIC2-Quality of Your Erections|EPIC208	Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) How would you describe the usual quality of your erections?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-CP Test Code Terminology|CDISC Questionnaire EPIC-CP Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127411>	C127362	EPIC-CP - Problem Lack of Sexual Function|EPIC2-Overall Problem Sexual Function|EPIC2-Overall Problem Sexual Function|EPIC209	Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) Overall, how much of a problem has your sexual function or lack of sexual function been for you?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-CP Test Code Terminology|CDISC Questionnaire EPIC-CP Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127412>	C127362	EPIC-CP - Hot Flashes or Breast Tenderness|EPIC2-Problem Hot Flash/Breast Tender|EPIC2-Problem Hot Flash/Breast Tender|EPIC210A	Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) How big a problem, if any, has each of the following been for you? Hot flashes or breast tenderness/enlargement.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-CP Test Code Terminology|CDISC Questionnaire EPIC-CP Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127413>	C127362	EPIC-CP - Feeling Depressed|EPIC2-Problem Feeling Depressed|EPIC2-Problem Feeling Depressed|EPIC210B	Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) How big a problem, if any, has each of the following been for you? Feeling depressed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-CP Test Code Terminology|CDISC Questionnaire EPIC-CP Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127414>	C127362	EPIC-CP - Lack of Energy|EPIC2-Problem Lack of Energy|EPIC2-Problem Lack of Energy|EPIC210C	Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) How big a problem, if any, has each of the following been for you? Lack of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-CP Test Code Terminology|CDISC Questionnaire EPIC-CP Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127415>	C127362	EPIC-CP - Urinary Incontinence Symptom Score|EPIC2-Urinary Incontinence Symptom Score|EPIC2-Urinary Incontinence Symptom Score|EPIC211	Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) Urinary incontinence symptom score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-CP Test Code Terminology|CDISC Questionnaire EPIC-CP Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127416>	C127362	EPIC-CP - Urinary Irritation/Obstruction Symptom Score|EPIC2-Urinary Irrit/Obstr Symptom Score|EPIC2-Urinary Irrit/Obstr Symptom Score|EPIC212	Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) Urinary irritation/obstruction symptom score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-CP Test Code Terminology|CDISC Questionnaire EPIC-CP Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127417>	C127362	EPIC-CP - Bowel Symptom Score|EPIC2-Bowel Symptom Score|EPIC2-Bowel Symptom Score|EPIC213	Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) Bowel symptom score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-CP Test Code Terminology|CDISC Questionnaire EPIC-CP Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127418>	C127362	EPIC-CP - Sexual Symptom Score|EPIC2-Sexual Symptom Score|EPIC2-Sexual Symptom Score|EPIC214	Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) Sexual symptom score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-CP Test Code Terminology|CDISC Questionnaire EPIC-CP Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127419>	C127362	EPIC-CP - Vitality/Hormonal Symptom Score|EPIC2-Vitality/Hormonal Symptom Score|EPIC2-Vitality/Hormonal Symptom Score|EPIC215	Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) Vitality/hormonal symptom score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-CP Test Code Terminology|CDISC Questionnaire EPIC-CP Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127420>	C127362	EPIC-CP - Overall Score|EPIC2-Overall Prostate Cancer QOL Score|EPIC2-Overall Prostate Cancer QOL Score|EPIC216	Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) Overall prostate cancer QOL score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPIC-CP Test Code Terminology|CDISC Questionnaire EPIC-CP Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127421>	C127363	FACT-G Version 4 - I Have a Lack of Energy|FAC001-I Have a Lack of Energy|FAC001-I Have a Lack of Energy|FAC00101	Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Physical Well-Being: I have a lack of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-G Version 4 Test Code Terminology|CDISC Questionnaire FACT-G Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127422>	C127363	FACT-G Version 4 - I Have Nausea|FAC001-I Have Nausea|FAC001-I Have Nausea|FAC00102	Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Physical Well-Being: I have nausea.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-G Version 4 Test Code Terminology|CDISC Questionnaire FACT-G Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127423>	C127363	FACT-G Version 4 - Trouble Meeting Needs of Family|FAC001-Trouble Meeting Needs of Family|FAC001-Trouble Meeting Needs of Family|FAC00103	Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Physical Well-Being: Because of my physical condition, I have trouble meeting the needs of my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-G Version 4 Test Code Terminology|CDISC Questionnaire FACT-G Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127424>	C127363	FACT-G Version 4 - I have pain|FAC001-I Have Pain|FAC001-I Have Pain|FAC00104	Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Physical Well-Being: I have pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-G Version 4 Test Code Terminology|CDISC Questionnaire FACT-G Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127425>	C127363	FACT-G Version 4 - Bothered by Treatment Side Effect|FAC001-Bothered by Treatment Side Effect|FAC001-Bothered by Treatment Side Effect|FAC00105	Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Physical Well-Being: I am bothered by side effects of treatment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-G Version 4 Test Code Terminology|CDISC Questionnaire FACT-G Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127426>	C127363	FACT-G Version 4 - I Feel Ill|FAC001-I Feel Ill|FAC001-I Feel Ill|FAC00106	Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Physical Well-Being: I feel ill.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-G Version 4 Test Code Terminology|CDISC Questionnaire FACT-G Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127427>	C127363	FACT-G Version 4 - I Am Forced to Spend Time in Bed|FAC001-I Am Forced to Spend Time in Bed|FAC001-I Am Forced to Spend Time in Bed|FAC00107	Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Physical Well-Being: I am forced to spend time in bed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-G Version 4 Test Code Terminology|CDISC Questionnaire FACT-G Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127428>	C127363	FACT-G Version 4 - I Feel Close to My Friends|FAC001-I Feel Close to My Friends|FAC001-I Feel Close to My Friends|FAC00108	Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Social/Family Well-Being: I feel close to my friends.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-G Version 4 Test Code Terminology|CDISC Questionnaire FACT-G Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127429>	C127363	FACT-G Version 4 - I Get Emotional Support From My Family|FAC001-Get Emotional Support From Family|FAC001-Get Emotional Support From Family|FAC00109	Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Social/Family Well-Being: I get emotional support from my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-G Version 4 Test Code Terminology|CDISC Questionnaire FACT-G Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12742>	C12429	Lower Extremity|LIMB, LOWER|Lower Body Extremity|Lower Limb|Lower extremity|Lower limb, NOS	The limb that is composed of the hip, thigh, leg and foot.	Lower Extremity		Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Radiation Therapy Table|EWS Tumor Assessment Table|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table
C127430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127430>	C127363	FACT-G Version 4 - I Get Support From My Friends|FAC001-I Get Support From My Friends|FAC001-I Get Support From My Friends|FAC00110	Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Social/Family Well-Being: I get support from my friends.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-G Version 4 Test Code Terminology|CDISC Questionnaire FACT-G Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127431>	C127363	FACT-G Version 4 - My Family Has Accepted My Illness|FAC001-My Family Has Accepted My Illness|FAC001-My Family Has Accepted My Illness|FAC00111	Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Social/Family Well-Being: My family has accepted my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-G Version 4 Test Code Terminology|CDISC Questionnaire FACT-G Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127432>	C127363	FACT-G Version 4 - Satisfied With Family Communication|FAC001-Satisfied Communication Illness|FAC001-Satisfied Communication Illness|FAC00112	Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Social/Family Well-Being: I am satisfied with family communication about my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-G Version 4 Test Code Terminology|CDISC Questionnaire FACT-G Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127433>	C127363	FACT-G Version 4 - I Feel Close to My Partner|FAC001-I Feel Close to My Partner|FAC001-I Feel Close to My Partner|FAC00113	Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Social/Family Well-Being: I feel close to my partner (or the person who is my main support).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-G Version 4 Test Code Terminology|CDISC Questionnaire FACT-G Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127434>	C127363	FACT-G Version 4 - I Am Satisfied With My Sex Life|FAC001-I Am Satisfied With My Sex Life|FAC001-I Am Satisfied With My Sex Life|FAC00114	Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Social/Family Well-Being: I am satisfied with my sex life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-G Version 4 Test Code Terminology|CDISC Questionnaire FACT-G Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127435>	C127363	FACT-G Version 4 - I Feel Sad|FAC001-I Feel Sad|FAC001-I Feel Sad|FAC00115	Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Emotional Well-Being: I feel sad.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-G Version 4 Test Code Terminology|CDISC Questionnaire FACT-G Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127436>	C127363	FACT-G Version 4 - Satisfied With How I Am Coping With Illness|FAC001-Satisfied With How I Am Coping|FAC001-Satisfied With How I Am Coping|FAC00116	Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Emotional Well-Being: I am satisfied with how I am coping with my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-G Version 4 Test Code Terminology|CDISC Questionnaire FACT-G Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127437>	C127363	FACT-G Version 4 - Losing Hope Against Illness|FAC001-Losing Hope Against Illness|FAC001-Losing Hope Against Illness|FAC00117	Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Emotional Well-Being: I am losing hope in the fight against my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-G Version 4 Test Code Terminology|CDISC Questionnaire FACT-G Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127438>	C127363	FACT-G Version 4 - I Feel Nervous|FAC001-I Feel Nervous|FAC001-I Feel Nervous|FAC00118	Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Emotional Well-Being: I feel nervous.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-G Version 4 Test Code Terminology|CDISC Questionnaire FACT-G Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127439>	C127363	FACT-G Version 4 - I Worry About Dying|FAC001-I Worry About Dying|FAC001-I Worry About Dying|FAC00119	Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Emotional Well-Being: I worry about dying.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-G Version 4 Test Code Terminology|CDISC Questionnaire FACT-G Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12743>	C13019	Lens|Crystalline Lens|Crystalline Lens|EYE, LENS|LENS|Lens of Eye|Ocular Lens|Ocular Lens|Structure of lens of eye (body structure)|lens	A biconvex transparent structure of the eye through which light is focused on the retina. The lens sits behind the iris and is supported by the zonule, which connects it to the ciliary body. The lens is an avascular structure.	Lens		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C127440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127440>	C127363	FACT-G Version 4 - Worry My Condition Will Get Worse|FAC001-Worry My Condition Will Get Worse|FAC001-Worry My Condition Will Get Worse|FAC00120	Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Emotional Well-Being: I worry that my condition will get worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-G Version 4 Test Code Terminology|CDISC Questionnaire FACT-G Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127441>	C127363	FACT-G Version 4 - I Am Able to Work|FAC001-I Am Able to Work|FAC001-I Am Able to Work|FAC00121	Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Functional Well-Being: I am able to work (include work at home).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-G Version 4 Test Code Terminology|CDISC Questionnaire FACT-G Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127442>	C127363	FACT-G Version 4 - My Work Is Fulfilling|FAC001-My Work Is Fulfilling|FAC001-My Work Is Fulfilling|FAC00122	Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Functional Well-Being: My work (include work at home) is fulfilling.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-G Version 4 Test Code Terminology|CDISC Questionnaire FACT-G Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127443>	C127363	FACT-G Version 4 - I Am Able to Enjoy Life|FAC001-I Am Able to Enjoy Life|FAC001-I Am Able to Enjoy Life|FAC00123	Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Functional Well-Being: I am able to enjoy life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-G Version 4 Test Code Terminology|CDISC Questionnaire FACT-G Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127444>	C127363	FACT-G Version 4 - I Have Accepted My Illness|FAC001-I Have Accepted My Illness|FAC001-I Have Accepted My Illness|FAC00124	Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Functional Well-Being: I have accepted my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-G Version 4 Test Code Terminology|CDISC Questionnaire FACT-G Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127445>	C127363	FACT-G Version 4 - I Am Sleeping Well|FAC001-I Am Sleeping Well|FAC001-I Am Sleeping Well|FAC00125	Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Functional Well-Being: I am sleeping well.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-G Version 4 Test Code Terminology|CDISC Questionnaire FACT-G Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127446>	C127363	FACT-G Version 4 - Enjoy Things I Usually Do for Fun|FAC001-Enjoy Things I Usually Do for Fun|FAC001-Enjoy Things I Usually Do for Fun|FAC00126	Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Functional Well-Being: I am enjoying the things I usually do for fun.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-G Version 4 Test Code Terminology|CDISC Questionnaire FACT-G Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127447>	C127363	FACT-G Version 4 - Content With Quality of My Life|FAC001-Content With Quality of My Life|FAC001-Content With Quality of My Life|FAC00127	Functional Assessment of Cancer Therapy-General Version 4 (FACT-G Version 4) Functional Well-Being: I am content with the quality of my life right now.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-G Version 4 Test Code Terminology|CDISC Questionnaire FACT-G Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127448>	C127364	NCCN-FACT-FPSI 17 Version 2 - I Have a Lack of Energy|FAC052-I Have a Lack of Energy|FAC052-I Have a Lack of Energy|FAC05201	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I have a lack of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127449>	C127364	NCCN-FACT-FPSI 17 Version 2 - I Have Pain|FAC052-I Have Pain|FAC052-I Have Pain|FAC05202	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I have pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12744>	C12933	Lumbar Vertebra|Bone structure of lumbar vertebra (body structure)|LUMBAR VERTEBRA|Lumbar Vertebrae	One of the five bones situated between the thoracic vertebrae and the sacrum in the lower part of the spine.	Lumbar Vertebrae		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C127450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127450>	C127364	NCCN-FACT-FPSI 17 Version 2 - I Have Difficulty Urinating|FAC052-I Have Difficulty Urinating|FAC052-I Have Difficulty Urinating|FAC05203	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I have difficulty urinating.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127451>	C127364	NCCN-FACT-FPSI 17 Version 2 - I Am Losing Weight|FAC052-I Am Losing Weight|FAC052-I Am Losing Weight|FAC05204	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I am losing weight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127452>	C127364	NCCN-FACT-FPSI 17 Version 2 - I Have Bone Pain|FAC052-I Have Bone Pain|FAC052-I Have Bone Pain|FAC05205	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I have bone pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127453>	C127364	NCCN-FACT-FPSI 17 Version 2 - I Feel Fatigued|FAC052-I Feel Fatigued|FAC052-I Feel Fatigued|FAC05206	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I feel fatigued.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127454>	C127364	NCCN-FACT-FPSI 17 Version 2 - I Have Weakness in My Legs|FAC052-I Have Weakness in My Legs|FAC052-I Have Weakness in My Legs|FAC05207	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I have weakness in my legs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127455>	C127364	NCCN-FACT-FPSI 17 Version 2 - Pain Keeps Me From Doing Things|FAC052-Pain Keeps Me From Doing Things|FAC052-Pain Keeps Me From Doing Things|FAC05208	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) My pain keeps me from doing things I want to do.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127456>	C127364	NCCN-FACT-FPSI 17 Version 2 - I Have a Good Appetite|FAC052-I Have a Good Appetite|FAC052-I Have a Good Appetite|FAC05209	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I have a good appetite.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127457>	C127364	NCCN-FACT-FPSI 17 Version 2 - I Am Sleeping Well|FAC052-I Am Sleeping Well|FAC052-I Am Sleeping Well|FAC05210	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I am sleeping well.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127458>	C127364	NCCN-FACT-FPSI 17 Version 2 - Worry My Condition Will Get Worse|FAC052-Worry My Condition Will Get Worse|FAC052-Worry My Condition Will Get Worse|FAC05211	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I worry that my condition will get worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127459>	C127364	NCCN-FACT-FPSI 17 Version 2 - I Have Nausea|FAC052-I Have Nausea|FAC052-I Have Nausea|FAC05212	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I have nausea.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12745>	C13018	Lymph Node|LYMPH NODE|Lymph Gland|Lymph Node(s)|Lymph Node, NOS|Lymph Nodes|Lymph Nodes|Lymph Nodes|Lymph node, NOS|Lymph nodes|Lymphatic Gland|Reticuloendothelial System, Lymph Node|Structure of lymph node (body structure)|lymph gland|lymph node|lymph node	A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection.	Lymph Node		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Terminology|CTDC Value Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C127460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127460>	C127364	NCCN-FACT-FPSI 17 Version 2 - I Have Trouble Moving My Bowels|FAC052-I Have Trouble Moving My Bowels|FAC052-I Have Trouble Moving My Bowels|FAC05213	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I have trouble moving my bowels.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127461>	C127364	NCCN-FACT-FPSI 17 Version 2 - I Am Satisfied With My Sex Life|FAC052-I Am Satisfied With My Sex Life|FAC052-I Am Satisfied With My Sex Life|FAC05214	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I am satisfied with my sex life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127462>	C127364	NCCN-FACT-FPSI 17 Version 2 - Bothered by Treatment Side Effect|FAC052-Bothered by Treatment Side Effect|FAC052-Bothered by Treatment Side Effect|FAC05215	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I am bothered by side effects of treatment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127463>	C127364	NCCN-FACT-FPSI 17 Version 2 - I Am Able to Enjoy Life|FAC052-I Am Able to Enjoy Life|FAC052-I Am Able to Enjoy Life|FAC05216	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I am able to enjoy life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127464>	C127364	NCCN-FACT-FPSI 17 Version 2 - Content With Quality of My Life|FAC052-Content With Quality of My Life|FAC052-Content With Quality of My Life|FAC05217	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Prostate Symptom Index 17 Version 2 (NCCN-FACT-FPSI 17 Version 2) I am content with the quality of my life right now.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT-FPSI 17 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127465>	C127365	FACT-P Version 4 - I Have a Lack of Energy|FAC023-I Have a Lack of Energy|FAC023-I Have a Lack of Energy|FAC02301	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Physical Well-Being: I have a lack of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127466>	C127365	FACT-P Version 4 - I Have Nausea|FAC023-I Have Nausea|FAC023-I Have Nausea|FAC02302	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Physical Well-Being: I have nausea.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127467>	C127365	FACT-P Version 4 - Trouble Meeting Needs of Family|FAC023-Trouble Meeting Needs of Family|FAC023-Trouble Meeting Needs of Family|FAC02303	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Physical Well-Being: Because of my physical condition, I have trouble meeting the needs of my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127468>	C127365	FACT-P Version 4 - I Have Pain|FAC023-I Have Pain|FAC023-I Have Pain|FAC02304	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Physical Well-Being: I have pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127469>	C127365	FACT-P Version 4 - Bothered by Treatment Side Effect|FAC023-Bothered by Treatment Side Effect|FAC023-Bothered by Treatment Side Effect|FAC02305	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Physical Well-Being: I am bothered by side effects of treatment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12746>	C41166	Lymphatic System|Lymphatic|Lymphatics|Lymphoid System|Reticuloendothelial System, Lymphatic System|lymphatic system	The anatomic system that includes the lymph nodes, lymphoid tissues in various organs (spleen, thymus, tonsils, gastrointestinal tract), and lymphatic vessels.  It is part of the immune system that offers protection against infections.	Lymphatic System		Body System	ICDC Terminology|ICDC Value Terminology
C127470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127470>	C127365	FACT-P Version 4 - I Feel Ill|FAC023-I Feel Ill|FAC023-I Feel Ill|FAC02306	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Physical Well-Being: I feel ill.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127471>	C127365	FACT-P Version 4 - I Am Forced to Spend Time in Bed|FAC023-I Am Forced to Spend Time in Bed|FAC023-I Am Forced to Spend Time in Bed|FAC02307	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Physical Well-Being: I am forced to spend time in bed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127472>	C127365	FACT-P Version 4 - I Feel Close to My Friends|FAC023-I Feel Close to My Friends|FAC023-I Feel Close to My Friends|FAC02308	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Social/Family Well-Being: I feel close to my friends.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127473>	C127365	FACT-P Version 4 - Get Emotional Support From Family|FAC023-Get Emotional Support From Family|FAC023-Get Emotional Support From Family|FAC02309	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Social/Family Well-Being: I get emotional support from my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127474>	C127365	FACT-P Version 4 - I Get Support From My Friends|FAC023-I Get Support From My Friends|FAC023-I Get Support From My Friends|FAC02310	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Social/Family Well-Being: I get support from my friends.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127475>	C127365	FACT-P Version 4 - My Family Has Accepted My Illness|FAC023-My Family Has Accepted My Illness|FAC023-My Family Has Accepted My Illness|FAC02311	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Social/Family Well-Being: My family has accepted my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127476>	C127365	FACT-P Version 4 - Satisfied With Family Communication|FAC023-Satisfied Communication Illness|FAC023-Satisfied Communication Illness|FAC02312	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Social/Family Well-Being: I am satisfied with family communication about my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127477>	C127365	FACT-P Version 4 - I Feel Close to My Partner|FAC023-I Feel Close to My Partner|FAC023-I Feel Close to My Partner|FAC02313	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Social/Family Well-Being: I feel close to my partner (or the person who is my main support).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127478>	C127365	FACT-P Version 4 - I Am Satisfied With My Sex Life|FAC023-I Am Satisfied With My Sex Life|FAC023-I Am Satisfied With My Sex Life|FAC02314	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Social/Family Well-Being: I am satisfied with my sex life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127479>	C127365	FACT-P Version 4 - I Feel Sad|FAC023-I Feel Sad|FAC023-I Feel Sad|FAC02315	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Emotional Well-Being: I feel sad.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12747>	C32725	Mast Cell|Mast Cells|Mastocyte|mast cell	Mast cells are hematopoietic tissue cells that contain coarse, basophilic, metachromatic granules.  They are believed to contain heparin and histamine and derive from hematopoietic progenitor cells.	Mast Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C127480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127480>	C127365	FACT-P Version 4 - Satisfied With How I Am Coping|FAC023-Satisfied With How I Am Coping|FAC023-Satisfied With How I Am Coping|FAC02316	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Emotional Well-Being: I am satisfied with how I am coping with my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127481>	C127365	FACT-P Version 4 - Losing Hope Against Illness|FAC023-Losing Hope Against Illness|FAC023-Losing Hope Against Illness|FAC02317	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Emotional Well-Being: I am losing hope in the fight against my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127482>	C127365	FACT-P Version 4 - I Feel Nervous|FAC023-I Feel Nervous|FAC023-I Feel Nervous|FAC02318	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Emotional Well-Being: I feel nervous.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127483>	C127365	FACT-P Version 4 - I Worry About Dying|FAC023-I Worry About Dying|FAC023-I Worry About Dying|FAC02319	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Emotional Well-Being: I worry about dying.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127484>	C127365	FACT-P Version 4 - Worry My Condition Will Get Worse|FAC023-Worry My Condition Will Get Worse|FAC023-Worry My Condition Will Get Worse|FAC02320	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Emotional Well-Being: I worry that my condition will get worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127485>	C127365	FACT-P Version 4 - I Am Able to Work|FAC023-I Am Able to Work|FAC023-I Am Able to Work|FAC02321	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Functional Well-Being: I am able to work (include work at home).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127486>	C127365	FACT-P Version 4 - My Work Is Fulfilling|FAC023-My Work Is Fulfilling|FAC023-My Work Is Fulfilling|FAC02322	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Functional Well-Being: My work (include work at home) is fulfilling.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127487>	C127365	FACT-P Version 4 - I Am Able to Enjoy Life|FAC023-I Am Able to Enjoy Life|FAC023-I Am Able to Enjoy Life|FAC02323	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Functional Well-Being: I am able to enjoy life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127488>	C127365	FACT-P Version 4 - I Have Accepted My Illness|FAC023-I Have Accepted My Illness|FAC023-I Have Accepted My Illness|FAC02324	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Functional Well-Being: I have accepted my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127489>	C127365	FACT-P Version 4 - I Am Sleeping Well|FAC023-I Am Sleeping Well|FAC023-I Am Sleeping Well|FAC02325	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Functional Well-Being: I am sleeping well.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12748>	C12680	Mediastinum|MEDIASTINUM|Mediastinal structure (body structure)|Mediastinum, NOS|mediastinal part of chest|mediastinum|mediastinum	An anatomic site along the midline and under the sternum that contains the heart and pericardium, the bases of the great vessels, the trachea and bronchi, esophagus, thymus, lymph nodes, thoracic duct, phrenic and vagus nerves, and other structures and tissues.	Mediastinum		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|GCT Authorized Value Terminology|GCT Biopsy/Surgical Procedures Table|GCT Radiation Therapy Table|GCT Tumor Assessment Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Biopsy/Surgical Procedures Table|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C127490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127490>	C127365	FACT-P Version 4 - Enjoy Things I Usually Do for Fun|FAC023-Enjoy Things I Usually Do for Fun|FAC023-Enjoy Things I Usually Do for Fun|FAC02326	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Functional Well-Being: I am enjoying the things I usually do for fun.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127491>	C127365	FACT-P Version 4 - Content With Quality of My Life|FAC023-Content With Quality of My Life|FAC023-Content With Quality of My Life|FAC02327	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Functional Well-Being: I am content with the quality of my life right now.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127492>	C127365	FACT-P Version 4 - I Am Losing Weight|FAC023-I Am Losing Weight|FAC023-I Am Losing Weight|FAC02328	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Additional Concerns: I am losing weight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127493>	C127365	FACT-P Version 4 - I Have a Good Appetite|FAC023-I Have a Good Appetite|FAC023-I Have a Good Appetite|FAC02329	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Additional Concerns: I have a good appetite.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127494>	C127365	FACT-P Version 4 - Have Aches and Pains That Bother Me|FAC023-Have Aches/Pains That Bother Me|FAC023-Have Aches/Pains That Bother Me|FAC02330	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Additional Concerns: I have aches and pains that bother me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127495>	C127365	FACT-P Version 4 - Certain Parts of Body Experience Pain|FAC023-Certain Parts of Body Have Pain|FAC023-Certain Parts of Body Have Pain|FAC02331	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Additional Concerns: I have certain parts of my body where I experience pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127496>	C127365	FACT-P Version 4 - Pain Keeps Me From Doing Things|FAC023-Pain Keeps Me From Doing Things|FAC023-Pain Keeps Me From Doing Things|FAC02332	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Additional Concerns: My pain keeps me from doing things I want to do.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127497>	C127365	FACT-P Version 4 - Satisfied With Comfort Level|FAC023-Satisfied With Comfort Level|FAC023-Satisfied With Comfort Level|FAC02333	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Additional Concerns: I am satisfied with my present comfort level.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127498>	C127365	FACT-P Version 4 - I Am Able to Feel Like a Man|FAC023-I Am Able to Feel Like a Man|FAC023-I Am Able to Feel Like a Man|FAC02334	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Additional Concerns: I am able to feel like a man.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127499>	C127365	FACT-P Version 4 - I Have Trouble Moving My Bowels|FAC023-I Have Trouble Moving My Bowels|FAC023-I Have Trouble Moving My Bowels|FAC02335	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Additional Concerns: I have trouble moving my bowels.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12749>	C12801	Membrane|Membranous|membrane	A thin sheet or layer of pliable tissue, serving as a covering or envelope of a part, as the lining of a cavity, as a partition or septum, or to connect two structures.	Membrane		Tissue	
C1274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1274>	C932|C67422	Vinepidine|4'-Deoxyepivincristine|VINEPIDINE	A vinca alkaloid compound and semi-synthetic vincristine derivative with antineoplastic activity. Vinepidine binds to and stabilizes tubulin, thereby preventing tubulin polymerization and depolymerization, which result in microtubule assembly and disassembly, respectively. Treated cells are unable to complete mitosis process and are arrested in the metaphase, thereby leading to an inhibition of cell growth.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C127500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127500>	C127365	FACT-P Version 4 - I Have Difficulty Urinating|FAC023-I Have Difficulty Urinating|FAC023-I Have Difficulty Urinating|FAC02336	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Additional Concerns: I have difficulty urinating.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127501>	C127365	FACT-P Version 4 - I Urinate More Frequently|FAC023-I Urinate More Frequently|FAC023-I Urinate More Frequently|FAC02337	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Additional Concerns: I urinate more frequently than usual.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127502>	C127365	FACT-P Version 4 - Problem Urinating Limits Activity|FAC023-Problem Urinating Limits Activity|FAC023-Problem Urinating Limits Activity|FAC02338	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Additional Concerns: My problems with urinating limit my activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127503>	C127365	FACT-P Version 4 - Able to Have and Maintain an Erection|FAC023-Able to Have/Maintain Erection|FAC023-Able to Have/Maintain Erection|FAC02339	Functional Assessment of Cancer Therapy-Prostate Version 4 (FACT-P Version 4) Additional Concerns: I am able to have and maintain an erection.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-P Version 4 Test Code Terminology|CDISC Questionnaire FACT-P Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127504>	C127366	PROSQOLI - Pain|PROS01-Pain|PROS01-Pain|PROS0101	Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) Pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PROSQOLI Test Code Terminology|CDISC Questionnaire PROSQOLI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127505>	C127366	PROSQOLI - Physical Activity|PROS01-Physical Activity|PROS01-Physical Activity|PROS0102	Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) Physical activity.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PROSQOLI Test Code Terminology|CDISC Questionnaire PROSQOLI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127506>	C127366	PROSQOLI - Fatigue|PROS01-Fatigue|PROS01-Fatigue|PROS0103	Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) Fatigue.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PROSQOLI Test Code Terminology|CDISC Questionnaire PROSQOLI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127507>	C127366	PROSQOLI - Appetite|PROS01-Appetite|PROS01-Appetite|PROS0104	Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) Appetite.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PROSQOLI Test Code Terminology|CDISC Questionnaire PROSQOLI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127508>	C127366	PROSQOLI - Constipation|PROS01-Constipation|PROS01-Constipation|PROS0105	Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) Constipation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PROSQOLI Test Code Terminology|CDISC Questionnaire PROSQOLI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127509>	C127366	PROSQOLI - Urinary Problems|PROS01-Urinary Problems|PROS01-Urinary Problems|PROS0106	Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) Urinary problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PROSQOLI Test Code Terminology|CDISC Questionnaire PROSQOLI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12750>	C54105	Mesoderm	The middle of the three germ layers found in the trilaminar embryo (endo-, meso-, ecto-).	Mesoderm		Embryonic Structure	
C127510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127510>	C127366	PROSQOLI - Enjoying Time with Friends and Family|PROS01-Enjoying Time Friends/Family|PROS01-Enjoying Time Friends/Family|PROS0107	Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) Enjoying time with friends and family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PROSQOLI Test Code Terminology|CDISC Questionnaire PROSQOLI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127511>	C127366	PROSQOLI - Mood|PROS01-Mood|PROS01-Mood|PROS0108	Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) Mood.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PROSQOLI Test Code Terminology|CDISC Questionnaire PROSQOLI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127512>	C127366	PROSQOLI - Overall Well-Being|PROS01-Overall Well-Being|PROS01-Overall Well-Being|PROS0109	Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) Overall well-being (how do you feel?).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PROSQOLI Test Code Terminology|CDISC Questionnaire PROSQOLI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127513>	C127366	PROSQOLI - Present Pain Intensity|PROS01-Present Pain Intensity|PROS01-Present Pain Intensity|PROS0110	Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) Present pain intensity: please circle the appropriate number according to how much pain you felt on average during the past 24 hours.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PROSQOLI Test Code Terminology|CDISC Questionnaire PROSQOLI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127514>	C118849	Nuclear Radiology Imaging Procedure|NUCLEAR RADIOLOGY	Any type of imaging method that uses radioactive materials.	Nuclear Radiology Imaging Procedure		Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C127515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127515>	C127277	Active Case Search|ACTIVE CASE SEARCH	Purposefully looking for subjects with a particular characteristic or disease.			Activity	CDISC SDTM Case Finding Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127516>	C127277	Passive Case Search|PASSIVE CASE SEARCH	Finding subjects with a particular characteristic or disease without actively searching.			Activity	CDISC SDTM Case Finding Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127517>	C85504	Blood Agar Growth Medium|BLOOD AGAR|Blood Agar	A solid and selective growth medium containing agar and blood; it allows for the cultivation and differentiation of microorganisms based on hemolytic activity.			Indicator, Reagent, or Diagnostic Aid	CDISC SDTM Culture Medium Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127518>	C85504	Middlebrook 7H10S Growth Medium|MIDDLEBROOK 7H10S AGAR|Middlebrook 7H10 Selective Agar	A solid and selective growth medium modified from the Middlebrook 7H10 agar by the addition of four antimicrobial agents: polymyxin B, carbenicillin, amphotericin B, and trimethoprim lactate.			Indicator, Reagent, or Diagnostic Aid	CDISC SDTM Culture Medium Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127519>	C85504	Middlebrook 7H11S Growth Medium|MIDDLEBROOK 7H11S AGAR|Middlebrook 7H11 Selective Agar	A solid and selective growth medium modified from the Middlebrook 7H11 agar by the addition of four antimicrobial agents: polymyxin B, carbenicillin, amphotericin B, and trimethoprim lactate.			Indicator, Reagent, or Diagnostic Aid	CDISC SDTM Culture Medium Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12751>	C33003|C199635	Metacarpal Bone|BONE, METACARPAL|METACARPAL BONE|Metacarpal|Metacarpal Bones|Metacarpals|Metacarpus|Os Metacarpale	Any of the five bones between the wrist and the fingers that form the skeleton of the palm.	Metacarpal Bones		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table
C127520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127520>	C85504	Middlebrook 7H12 Growth Medium|MIDDLEBROOK 7H12 BROTH	A liquid growth medium modified from the Middlebrook 7H9 broth by the addition of the following: bovine serum albumin, casein hydrolysate, catalase, and 14C-labelled palmitic acid.			Indicator, Reagent, or Diagnostic Aid	CDISC SDTM Culture Medium Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127521>	C85504	Middlebrook 7H9 Growth Medium|MIDDLEBROOK 7H9 BROTH	A liquid growth medium developed specifically for the primary and secondary cultivation of mycobacterium, which comprises albumin, glycerol, dextrose, and inorganic compounds.			Indicator, Reagent, or Diagnostic Aid	CDISC SDTM Culture Medium Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127522>	C25461	Competent Authority Applicant|CA APPLICANT|CA Applicant	The person responsible for the competent authority application.			Human	CDISC SDTM Contact Role for Clinical Study Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127523>	C25461	Central Contact for Recruitment|CENTRAL CONTACT FOR RECRUITMENT	The main or principle contact person responsible for coordinating recruitment information for a study.			Human	CDISC SDTM Contact Role for Clinical Study Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127524>	C25461	Central Contact for Recruitment Backup|CENTRAL CONTACT FOR RECRUITMENT BACKUP	The secondary contact person responsible for coordinating recruitment information for a study.			Human	CDISC SDTM Contact Role for Clinical Study Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127525>	C25461	Clinical Investigator Network Contact|CLINICAL NETWORK CONTACT	The main or principle contact person for a clinical investigator network.			Human	CDISC SDTM Contact Role for Clinical Study Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127526>	C25461	Public Queries Study Contact|CONTACT FOR PUBLIC QUERIES	The study contact person who is responsible for questions from the public.			Human	CDISC SDTM Contact Role for Clinical Study Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127527>	C25461	Scientific Queries Study Contact|CONTACT FOR SCIENTIFIC QUERIES	The study contact person who is responsible for questions from the scientific community.			Human	CDISC SDTM Contact Role for Clinical Study Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127528>	C25461	Facility Contact|FACILITY CONTACT	The main or principle contact person at a facility.			Human	CDISC SDTM Contact Role for Clinical Study Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127529>	C25461	Facility Contact Backup|FACILITY CONTACT BACKUP	The secondary contact person at a facility.			Human	CDISC SDTM Contact Role for Clinical Study Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12752>	C33003|C13068	Metatarsal Bone|BONE, METATARSAL|METATARSAL BONE|Metatarsal Bones|Metatarsals|Metatarsus	A bone belonging to the middle part of the foot located between toes and ankle. There are 5 metatarsal bones and they are numbered from the medial side.	Metatarsal Bones		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table
C127530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127530>	C25461	Study Further Information Contact|FURTHER INFORMATION CONTACT	The contact person responsible for disseminating additional information about a study.			Human	CDISC SDTM Contact Role for Clinical Study Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127531>	C25461	Independent Ethics Committee Applicant|IEC APPLICANT|IEC Applicant	The person responsible for the independent ethics committee application.			Human	CDISC SDTM Contact Role for Clinical Study Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127532>	C25461	Legal Representative for the Study|LEGAL REPRESENTATIVE FOR THE STUDY	An individual with expertise in the law who provides legal counsel and representation for a study.			Human	CDISC SDTM Contact Role for Clinical Study Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127533>	C25461	Primary Study Contact|PRIMARY CONTACT	The main or principle contact person for a study.			Human	CDISC SDTM Contact Role for Clinical Study Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127534>	C25461	Subcontractor Contact|SUBCONTRACTOR CONTACT	The main or principle contact person for a subcontractor or subcontracting organization.			Human	CDISC SDTM Contact Role for Clinical Study Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127535>	C35552	Annular a' Velocity|ANNAVEL	The maximum rate of the annular motion during late diastole (active ventricular filling).			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127536>	C35552	Annular e' Velocity|ANNEVEL	The maximum rate of the annular motion during early diastole (passive ventricular filling).			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127537>	C35552	Area at End Ventricular Diastole|AREAEVD|Area, End Ventricular Diastole|Area, End Ventricular Diastole	The 2-dimensional surface enclosed within a boundary and measured at end ventricular diastole.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127538>	C35552	Area at End Ventricular Systole|AREAEVS|Area, End Ventricular Systole|Area, End Ventricular Systole	The 2-dimensional surface enclosed within a boundary and measured at end ventricular systole.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127539>	C35552	Aortic Regurgitant Jet Width to Left Ventricular Outflow Tract Diameter Ratio|ARGJWLVD|Aortic Regur Jet Width LVOT Diam Rt|Aortic Regur Jet Width LVOT Diam Rt	A relative measurement (ratio or percentage) of the aortic regurgitant jet width to left ventricular outflow tract diameter.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12753>	C176322	Mitral Valve|Left Atrioventricular Valve|MITRAL VALVE|Mitral valve structure (body structure)|VALVE, LEFT ATRIOVENTRICULAR	A dual-flap valve of the heart that regulates the flow of blood between the left atrium and the left ventricle of the heart.	Mitral Valve		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C127540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127540>	C35552	Aortic Valve Regurgitant Fraction|AVRGF	A quantitative measurement of the amount of retrograde blood flow across the orifice of the aortic valve expressed as a percentage of the anterograde flow.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127541>	C35552	Aortic Valve Regurgitant Jet Width|AVRGJW	The measured width of the backflow of blood into the left ventricular outflow tract.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127542>	C35552	Aortic Valve Regurgitant Volume|AVRGVOL	A quantitative measurement of the amount of retrograde blood flow across the orifice of the aortic valve.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127543>	C35552	Aortic Valve Vena Contracta Area|AVVCA	The area of the vena contracta of the aortic valve.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127544>	C35552	Aortic Valve Vena Contracta Width|AVVCW	The width of the vena contracta of the aortic valve.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127545>	C35552	Cross-sectional Diameter at End Ventricular Diastole|CSDIAEVD|Cross-sec Diameter, EVD|Cross-sec Diameter, EVD|Cross-sectional Diameter, End Ventricular Diastole	The cross sectional diameter measured at end ventricular diastole.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127546>	C35552	Cross-sectional Diameter at End Ventricular Systole|CSDIAEVS|Cross-sec Diameter, EVS|Cross-sec Diameter, EVS|Cross-sectional Diameter, End Ventricular Systole	The cross sectional diameter measured at end ventricular systole.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127547>	C35552	Cross-sectional Diameter at Mid Ventricular Systole|CSDIAMVS|Cross-sec Diameter, MVS|Cross-sec Diameter, MVS|Cross-sectional Diameter, Mid Ventricular Systole	The cross sectional diameter measured at mid ventricular systole.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127548>	C181043	Cusp Doming Indicator|CSPDIND	An indication as to whether there is doming of a cardiac cusp.			Conceptual Entity	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127549>	C35552	Cusp Doming Severity|CSPDSEV	The qualitative measurement of the severity of doming of a cardiac cusp.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12754>	C12919	Musculoskeletal System|MUSCULOSKELETAL SYSTEM|Musculoskeletal	The system of muscles, tendons, ligaments, bones, joints and associated tissues that move the body and maintain its form.	Musculoskeletal System		Body System	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|ICDC Terminology|ICDC Value Terminology
C127550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127550>	C181043	Cusp Flail Indicator|CSPFIND	An indication as to whether there is a flailing cardiac valve cusp.			Conceptual Entity	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127551>	C35552	Cusp Flail Severity|CSPFSEV	The qualitative measurement of the severity of a flailing cardiac valve cusp.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127552>	C35552	Cusp Flail Timing|CSPFT	The time point during the cardiac cycle when the flail of one or more cusps occurs.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127553>	C181043	Cusp Prolapse Indicator|CSPPIND	An indication as to whether there is a prolapsed cardiac valve cusp.			Conceptual Entity	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127554>	C35552	Cusp Prolapse Severity|CSPPSEV	The qualitative measurement of the severity of a prolapsing cardiac valve cusp.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127555>	C35552	Cusp Prolapse Timing|CSPPT	The time point during the cardiac cycle when the prolapse of of one or more cusps occurs.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127556>	C181043	Cusp Restricted Motion Indicator|CSPRMIND	An indication as to whether there is restricted motion of a cardiac valve cusp.			Conceptual Entity	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127557>	C35552	Cusp Restricted Motion Severity|CSPRMSEV	The qualitative measurement of the severity of restricted motion of a cardiac valve cusp.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127558>	C181043	Cusp Tethering Indicator|CSPTEIND	An indication as to whether there is tethering of a cardiac valve cusp.			Conceptual Entity	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127559>	C35552	Cusp Tethering Severity|CSPTESEV	The qualitative measurement of the severity of tethering of a cardiac valve cusp.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12755>	C12919	Nervous System|Body System, Neurologic|Nervous system, NOS|Neurologic|Neurologic Body System|Neurologic Organ System|Organ System, Neurologic|nervous system|nervous system	The entire nerve apparatus, composed of a central part, the brain and spinal cord, and a peripheral part, the cranial and spinal nerves, autonomic ganglia, and plexuses.	Nervous System		Body System	GDC Terminology|GDC Value Terminology|ICDC Terminology|ICDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C127560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127560>	C181043	Cusp Thickening Indicator|CSPTIND	An indication as to whether there is a thickened cardiac valve cusp.			Conceptual Entity	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127561>	C35552	Cusp Thickening Severity|CSPTSEV	The qualitative measurement of the severity of a thickening cardiac valve cusp.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127562>	C181043	Chordae Tendineae Prolapse Indicator|CTPIND	An indication as to whether there is a prolapsed cardiac valve chordae tendineae.			Conceptual Entity	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127563>	C35552	Cardiac Valve Regurgitant Jet Direction|CVRGJDR|Cardiac Valve Regur Jet Direction|Cardiac Valve Regur Jet Direction|Cardiac Valve Regurgitation Jet Direction	The anatomic trajectory of the retrograde blood flow from a cardiac valve.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127564>	C35552	Cardiac Wall Motion Type|CWMTYP	A qualitative assesment of the movement of the cardiac muscle, either as a whole or at one or more specific anatomical locations.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127565>	C35552	Effective Regurgitant Orifice Area|EFFRGOA	The quantitative measurement of the effective regurgitant orifice area of a cardiac valve.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127566>	C35552	Largest Cross-sectional Diameter at End Ventricular Diastole|LCDIAEVD|Largest Cross-sec Diameter, EVD|Largest Cross-sec Diameter, EVD|Largest Cross-sectional Diameter, End Ventricular Diastole	The largest cross sectional diameter measured at end ventricular diastole.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127567>	C35552	Largest Cross-sectional Thickness|LGTHCK|Largest Cross-sec Thickness|Largest Cross-sec Thickness	The assessment of the largest cross-sectional thickness of a tissue.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127568>	C35552	Left Ventricular Outflow Tract Peak Velocity|LVOT Peak Velocity|LVOT Peak Velocity|LVOTPVEL	The measurement of the maximum rate of blood flow measured in the left ventricular outflow tract during systole.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127569>	C35552	Left Ventricular Outflow Tract Velocity Time Integral|LVOT Velocity Time Integral|LVOT Velocity Time Integral|LVOTVTI	The integral of all of the flow velocities within the left ventricular outflow tract during ventricular systole.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12756>	C33224	Nose|NOSE|Nasal structure (body structure)	A structure of special sense serving as an organ of the sense of smell and as an entrance to the respiratory tract.	Nose		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C127570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127570>	C35552	Mean Blood Flow Velocity|MBFVEL	The measurement of the average rate of blood flow across an area or tissue.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127571>	C35552	Mitral E/A Ratio|MITRALEA	The ratio of the rate of blood flow during early diastole to the rate of blood flow during late diastole.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127572>	C35552	Mitral E/e' Ratio|MITRALEE	The ratio of the peak early diastolic transmitral velocity to the peak mitral annular motion velocity.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127573>	C35552	Major Axis Cross-sectional Diameter at End Ventricular Diastole|MJDIAEVD|Major Axis Cross-sec Diameter, EVD|Major Axis Cross-sec Diameter, EVD|Major Axis Cross-sectional Diameter, End Ventricular Diastole	The cross sectional diameter of a cardiovascular structure measured along the major axis at end ventricular diastole.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127574>	C35552	Major Axis Cross-sectional Diameter at End Ventricular Systole|MJDIAEVS|Major Axis Cross-sec Diameter, EVS|Major Axis Cross-sec Diameter, EVS|Major Axis Cross-sectional Diameter, End Ventricular Systole	The cross sectional diameter of a cardiovascular structure measured along the major axis at end ventricular systole.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127575>	C35552	Minor Axis Cross-sectional Diameter at End Ventricular Diastole|MNDIAEVD|Minor Axis Cross-sec Diameter, EVD|Minor Axis Cross-sec Diameter, EVD|Minor Axis Cross-sectional Diameter, End Ventricular Diastole	The cross sectional diameter a cardiovascular structure measured in the minor axis at end ventricular diastole.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127576>	C35552	Minor Axis Cross-sectional Diameter at End Ventricular Systole|MNDIAEVS|Minor Axis Cross-sec Diameter, EVS|Minor Axis Cross-sec Diameter, EVS|Minor Axis Cross-sectional Diameter, End Ventricular Systole	The cross sectional diameter a cardiovascular structure measured in the minor axis at end ventricular systole.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127577>	C35552	Mitral Regurgitant Jet Area to Left Atrial Area Ratio|MRGJALA|Mitral Regur Jet Area L Atrial Area Rt|Mitral Regur Jet Area L Atrial Area Rt	A relative measurement (ratio or percentage) of the mitral regurgitant jet area to left atrial area.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127578>	C35552	Mitral Valve Regurgitant Fraction|MVRGF	A quantitative measurement of the amount of retrograde blood flow across the orifice of the mitral valve expressed as a percentage of the anterograde flow.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127579>	C35552	Mitral Valve Regurgitant Jet Area|MVRGJA	The measured area of the backflow of blood into the left atrium.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12757>	C32616	Occipital Bone|OCCIPITAL BONE|Occipital bone structure (body structure)	The trapezoidal-shaped bone that forms the back and part of the base of the skull.	Occipital Bone		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C127580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127580>	C35552	Mitral Valve Regurgitant Volume|MVRGVOL	A quantitative measurement of the amount of retrograde blood flow across the orifice of the mitral valve.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127581>	C35552	Mitral Valve Vena Contracta Area|MVVCA	The area of the vena contracta of the mitral valve.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127582>	C35552	Mitral Valve Vena Contracta Width|MVVCW	The width of the vena contracta of the mitral valve.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127583>	C35552	Peak Blood Flow Velocity|PBFVEL	The measurement of the maximum rate of blood flow across an area or tissue.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127584>	C35552	Peak A Velocity|PKAVEL	The maximum rate of blood flow across a cardiac valve during late diastole (active ventricular filling).			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127585>	C35552	Peak E Velocity|PKEVEL	The maximum rate of blood flow across a cardiac valve during early diastole (passive ventricular filling).			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127586>	C35552	Pulmonic Regurgitant Jet Width to Right Ventricular Outflow Tract Diameter Ratio|PRGJWRVD|Pulmonic Regur Jet Width RVOT Diam Rt|Pulmonic Regur Jet Width RVOT Diam Rt	A relative measurement (ratio or percentage) of the pulmonic regurgitant jet width to the right ventricular outflow tract diameter.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127587>	C35552	Pulmonary Vein Dominance|PVEINDOM	The determination of whether blood flow in the pulmonary veins is greater during ventricular systole or diastole.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127588>	C35552	Pulmonary Valve Regurgitant Fraction|PVRGF	A quantitative measurement of the amount of retrograde blood flow across the orifice of the pulmonic valve expressed as a percentage of the anterograde flow.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127589>	C35552	Pulmonic Valve Regurgitant Jet Width|PVRGJW	The measured width of the backflow of blood into the right ventricular outflow tract.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12758>	C12700	Oculomotor Nerve|Cranial Nerve III|NERVE, OCULOMOTOR|OCULOMOTOR NERVE|Oculomotor nerve structure (body structure)|Third Cranial Nerve|Third Cranial Nerve	The third cranial nerve that originates originating at the oculomotor nerve nucleus at the level of the superior colliculus in the midbrain, provides motor innervation to the levator palpebrae superioris, the superior, inferior, and medial rectus muscles, and the inferior oblique muscles, and provides parasympathetic innervation to the ciliary ganglion.	Oculomotor Nerve		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C127590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127590>	C35552	Pulmonary Valve Regurgitant Volume|PVRGVOL	A quantitative measurement of the amount of retrograde blood flow across the orifice of the pulmonic valve.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127591>	C35552	Pulmonary Valve Vena Contracta Area|PVVCA	The area of the vena contracta of the pulmonic valve.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127592>	C35552	Pulmonary Valve Vena Contracta Width|PVVCW	The width of the vena contracta of the pulmonic valve.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127593>	C181043	Systolic Anterior Motion Indicator|SAM Indicator|SAMIND	An indication as to whether there is systolic anterior motion of a cardiac cusp.			Conceptual Entity	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127594>	C35552	Systolic Anterior Motion Severity|SAM Severity|SAMSEV	The qualitative measurement of the severity of the systolic anterior motion of a cardiac cusp.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127595>	C35552	Cross-sectional Thickness at End Ventricular Diastole|Cross-sec Thickness, EVD|Cross-sec Thickness, EVD|Cross-sectional Thickness, End Ventricular Diastole|THCKEVD	The cross-sectional thickness of a tissue measured at end ventricular diastole.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127596>	C35552	Cross-sectional Thickness at End Ventricular Systole|Cross-sec Thickness, EVS|Cross-sec Thickness, EVS|Cross-sectional Thickness, End Ventricular Systole|THCKEVS	The cross-sectional thickness of a tissue measured at end ventricular systole.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127597>	C35552	Tricuspid Regurgitant Jet Area to Right Atrial Area Ratio|TRGJARA|Tricus Regur Jet Area R Atrial Area Rt|Tricus Regur Jet Area R Atrial Area Rt	A relative measurement (ratio or percentage) the tricuspid regurgitant jet area to the right atrial area.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127598>	C35552	Tricuspid Valve Regurgitant Fraction|TVRGF	A quantitative measurement of the amount of retrograde blood flow across the orifice of the tricuspid valve expressed as a percentage of the anterograde flow.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127599>	C35552	Tricuspid Valve Regurgitant Jet Area|TVRGJA	The measured area of the backflow of blood into the right atrium.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12759>	C12700	Olfactory Nerve|Cranial Nerve I|First Cranial Nerve|OLFACTORY NERVE|Olfactory nerve	The first cranial nerve. It is the shortest cranial nerve and of paramount importance in the sense of smell. Its neurons are in the olfactory mucosa in the nasal cavity.	Olfactory Nerve		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C1275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1275>	C932|C67422	Vinorelbine|3',4'-Didehydro-4'-deoxy-C'-norvincaleukoblastine|5'-Nor-Anhydrovinblastine|Dihydroxydeoxynorvinkaleukoblastine|VINORELBINE|nor-5'-Anhydrovinblastine|vinorelbine	A semisynthetic vinca alkaloid. Vinorelbine binds to tubulin and prevents formation of the mitotic spindle, resulting in the arrest of tumor cell growth in metaphase. This agent may also interfere with amino acid, cyclic AMP. and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.	Vinorelbine		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|HL Authorized Value Terminology|HL Protocol Treatment Modifications Table|HL Total Dose Table|NCIt Antineoplastic Agent Terminology
C127600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127600>	C35552	Tricuspid Valve Regurgitant Volume|TVRGVOL	A quantitative measurement of the amount of retrograde blood flow across the orifice of the tricuspid valve.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127601>	C35552	Tricuspid Valve Vena Contracta Area|TVVCA	The area of the vena contracta of the tricuspid valve.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127602>	C35552	Tricuspid Valve Vena Contracta Width|TVVCW	The width of the vena contracta of the tricuspid valve.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127603>	C35552	Blood Flow Velocity Time Integral|VELTI|Velocity Time Integral, Blood Flow|Velocity Time Integral, Blood Flow	The integral of all of the flow velocities during the time of blood flow across or within a specified area.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127604>	C35552	Volume at End Ventricular Diastole	The volume of blood remaining in a receptacle chamber at end ventricular diastole.			Finding	
C127605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127605>	C35552	Volume at End Ventricular Systole	The volume of blood remaining in a receptacle chamber at end ventricular systole.			Finding	
C127606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127606>	C41421	Complex Cystic Lesion|COMPLEX CYSTIC LESION|Complex Cystic and Solid	A lesion that demonstrates both cystic and solid components; the solid components can range from thin walls (septae) to a solid tissue mass.			Finding	CDISC SDTM Disease Presentation Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127607>	C64430	Beta-1B Glycoprotein Measurement|B1BGLP|Beta-1B Glycoprotein|Beta-1B Glycoprotein|Beta-1B-Glycoprotein Measurement|HPX|Hemopexin|Hemopexin Measurement	The determination of the amount of beta-1B glycoprotein present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127608>	C74760	Beta-2 Microglobulin to Creatinine Ratio Measurement|B2MCREAT|Beta-2 Microglobulin/Creatinine|Beta-2 Microglobulin/Creatinine	The determination of the ratio of beta-2 microglobulin compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127609>	C48938	Blister Cell Count|BLISTCE|Blister Cell|Blister Cell	The determination of the number of blister cells in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12760>	C13019	Optic Disc|OPTIC DISC|Optic Disk|Optic Nerve Head|Optic Nerve Head|Optic Papilla	A portion of the retina at which the axons of the ganglion cells exit the eyeball to form the optic nerve. No light-sensitive photoreceptors are contained within this portion of the retina.	Optic Disc		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127610>	C80160	Complement C4d Measurement|C4D|Complement C4d|Complement C4d	The determination of the amount of complement C4d present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127611>	C210735	Circulating Immune Complex Measurement|CIC|Circulating Immune Complexes|Circulating Immune Complexes	The determination of the amount of circulating immune complexes present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127612>	C64430	Copeptin Measurement|COPEP|Copeptin|Copeptin	The determination of the amount of copeptin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127613>	C74760	Type I Collagen C-Telopeptide to Creatinine Ratio Measurement|CTXICRT|Type I Collagen C-Telopeptides/Creat|Type I Collagen C-Telopeptides/Creat|Type I Collagen X-Linked C-Telopeptides/Creatinine	The determination of the ratio of type I collagen c-telopeptides compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127614>	C110935	Estimated Glomeluar Filtration Rate from Cystatin C and Creatinine Adjusted for Standard BSA|GFR from Cystatin C and Creat Adj BSA|GFR from Cystatin C and Creat Adj BSA|GFRBSCCC	The determination of the glomerular filtration rate by measurement of creatinine and cystatin C clearance and whose result is adjusted for body surface area.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127615>	C67208	Band Form Granulocyte to Total Cell Ratio Measurement|Band Form Granulocytes to Total Cells Ratio Measurement|GRANBCE|Granulocytes Band Form/Total Cells|Granulocytes Band Form/Total Cells	The determination of the ratio of band form granulocytes compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127616>	C67208	Segmented Granulocyte to Total Cell Ratio Measurement|GRANSGCE|GRANSGCE|Granulocytes Segmented/Total Cells|Granulocytes Segmented/Total Cells|Granulocytes Segmented/Total Cells|Segmented Granulocytes to Total Cells Ratio Measurement|Segmented Granulocytes/Total Cells	The determination of the ratio of segmented granulocytes compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127617>	C64848	Free Hemoglobin Measurement|HGBFR|Hemoglobin, Free|Hemoglobin, Free	The determination of the amount of free hemoglobin present in a sample.	Free Hemoglobin Measurement		Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C127618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127618>	C210012|C210010|C171145	Human Papillomavirus 11 Antibody Measurement	The determination of the amount of human papillomavirus 11 antiboy present in a sample.			Laboratory Procedure	
C127619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127619>	C210012|C210010|C171145	Human Papillomavirus 16 Antibody Measurement	The determination of the amount of human papillomavirus 16 antiboy present in a sample.			Laboratory Procedure	
C12761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12761>	C12700	Optic Nerve|NERVE, OPTIC|OPTIC NERVE|Optic nerve|Optic nerve structure (body structure)|Second Cranial Nerve|Second Cranial Nerve|optic nerve	The second cranial nerve.	Optic Nerve		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C127620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127620>	C210012|C210010|C171145	Human Papillomavirus 18 Antibody Measurement	The determination of the amount of human papillomavirus 18 antiboy present in a sample.			Laboratory Procedure	
C127621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127621>	C210012|C210010|C171145	Human Papillomavirus 6 Antibody Measurement	The determination of the amount of human papillomavirus 6 antiboy present in a sample.			Laboratory Procedure	
C127622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127622>	C64430	Islet Amyloid Polypeptide Measurement|Amylin|IAPP|Islet Amyloid Polypeptide|Islet Amyloid Polypeptide	The determination of the amount of islet amyloid polypeptide present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127623>	C74804	Interleukin 12 Beta Measurement|INTLK12B|Interleukin 12 Beta|Interleukin 12 Beta|Interleukin 12 Beta Subunit|Interleukin 12 p40|Interleukin 12 p40 Subunit	The determination of the amount of interleukin 12 beta present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127624>	C64430	Klotho Protein Measurement|KLOTHO|Klotho|Klotho	The determination of the amount of klotho protein present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127625>	C96672|C51948	Immature Leukocyte Count|Immature Leukocytes|Immature Leukocytes|LEIM	The determination of the number of immature leukocytes in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127626>	C67208	Immature Leukocyte to Leukocytes Ratio Measurement|Immature Leukocytes/Leukocytes|Immature Leukocytes/Leukocytes|LEIMLE	The determination of the ratio of immature leukocytes compared to total leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127627>	C67208	Vacuolated Lymphocyte to Leukocyte Ratio Measurement|LYMVACLE|Vacuolated Lymphocytes/Leukocytes|Vacuolated Lymphocytes/Leukocytes	The determination of the ratio of vacuolated lymphocytes compared to total leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127628>	C67208	Maturing Erythroid Cell to Total Cell Ratio Measurement|Erythroid Precursors/Total Cells|MERCECE|MERCECE|Maturing Erythroid Cells to Total Cells Ratio Measurement|Maturing Erythroid Cells/Total Cells|Maturing Erythroid Cells/Total Cells|Maturing Erythroid/Total Cells|Maturing Erythroid/Total Cells|Total Erythroid Precursors/Total Cells	The determination of the ratio of maturing erythroid cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127629>	C67208	Maturing Myeloid Cell to Total Cell Ratio Measurement|MMYCECE|Maturing Myeloid Cells to Total Cells Ratio Measurement|Maturing Myeloid Cells/Total Cells|Maturing Myeloid/Total Cells	The determination of the ratio of maturing myeloid cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12762>	C38617	Oropharynx|OROPHARYNX|Oropharyngeal structure (body structure)|Oropharynx, NOS|oral part of pharynx|oropharynx|oropharynx	The part of the pharynx between the soft palate and the upper portion of the epiglottis.	Oropharynx		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C127630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127630>	C74738	Murinoglobulin Measurement|MUG|Murinoglobulin|Murinoglobulin	The determination of the amount of murinoglobulin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127631>	C74972	Para-Aminohippurate Sodium Measurement	The determination of the amount of para-aminohippurate sodium present in a sample.			Laboratory Procedure	
C127632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127632>	C67208	Proliferating Erythroid Cell to Total Cell Ratio Measurement|PERCECE|Proliferating Erythroid Cells to Total Cells Ratio Measurement|Proliferating Erythroid/Total Cells|Proliferating Erythroid/Total Cells	The determination of the ratio of proliferating erythroid cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127633>	C64430	Plasminogen Measurement|PLG|Plasminogen|Plasminogen	The determination of the amount of plasminogen present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127634>	C67208	Proliferating Myeloid Cell to Total Cell Ratio Measurement|PMYCECE|PMYCECE|Proliferating Myeloid Cells to Total Cells Ratio Measurement|Proliferating Myeloid Cells/Total Cells|Proliferating Myeloid Cells/Total Cells|Proliferating Myeloid Cells/Total Cells	The determination of the ratio of proliferating myeloid cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127635>	C202425	S100 Calcium-Binding Protein B Measurement|S100 Calcium-Binding Protein B|S100 Calcium-Binding Protein B|S100 Calcium-Binding Protein B|S100B|S100B	The determination of the amount of S100 calcium-binding protein B present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127636>	C135443	Troponin I Type 2 Measurement|Fast-Twitch Skeletal Muscle Troponin I|TROPONI2|Troponin I Type 2|Troponin I Type 2|fsTnI	The determination of the amount of toponin I type 2 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127637>	C64430	WD Repeat-Containing Protein 26 Measurement|CDW2|MIP2|Macrophage Inflammatory Protein-2|WD Repeat-Containing Protein 26|WD Repeat-Containing Protein 26|WDR26	The determination of the amount of WD-repeat containing protein 26 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127638>	C33849	Left Coronary Cusp of the Aortic Valve|AORTIC VALVE, LEFT CORONARY CUSP|Aortic Valve, Left Semilunar Cusp	The cusp of the aortic valve that overlies the left coronary ostium.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127639>	C33849	Non-Coronary Cusp of the Aortic Valve|AORTIC VALVE, NON-CORONARY CUSP|Aortic Valve, Posterior Semilunar Cusp	The cusp of the aortic valve that is positioned posteriorly relative to the other two aortic cusps.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12763>	C38617|C33556	Paranasal Sinus|Accessory Sinus|Accessory Sinuses|Accessory sinus, NOS|Accessory sinuses|Nasal Sinus|Nasal Sinuses|Nasal and Sinuses|PARANASAL SINUS|Paranasal Sinuses|Paranasal Sinuses|Paranasal sinuses|Sinuses, Nasal|Sinuses, Paranasal|paranasal sinus|paranasal sinus	Any one of the air-filled spaces within the ethmoid, frontal, maxillary, or sphenoid bones, which communicate with the nasal cavity.	Nasal Sinus		Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Tumor Assessment Table|UBERON Terminology
C127640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127640>	C33849	Right Coronary Cusp of the Aortic Valve|AORTIC VALVE, RIGHT CORONARY CUSP|Aortic Valve, Right Semilunar Cusp	The cusp of the aortic valve that overlies the right coronary ostium.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127641>	C25762	Aortic Root|ASCENDING AORTA, AORTIC ROOT	The portion of the ascending aorta between the aortic annulus and the sinotubular junction.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127642>	C25762	Sinotubular Junction|ASCENDING AORTA, SINOTUBULAR JUNCTION	The terminus of the aortic root; the point at which the aorta attains a tubular configuration.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127643>	C13023	Left Atrial Appendage|HEART, LEFT ATRIAL APPENDAGE	The ear-shaped, muscular pouch of the left atrium.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127644>	C13023	Left Ventricular Outflow Tract|HEART, LEFT VENTRICULAR OUTFLOW TRACT	The funnel-shaped structure through which blood flows from the left ventricle into the aortic root.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127645>	C13023	Left Ventricular Wall|HEART, LEFT VENTRICULAR WALL	The wall of the left ventricle, comprising anterior, inferior, lateral, apical, basal wall; and excluding the interventricular septum.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127646>	C13023	Right Atrial Appendage|HEART, RIGHT ATRIAL APPENDAGE	The ear-shaped, muscular pouch of the right atrium.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127647>	C13023	Right Ventricular Free Wall|HEART, RIGHT VENTRICULAR FREE WALL	The lateral segment of the right ventricular wall, excluding the anterior and inferior right ventricular wall.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127648>	C13023	Right Ventricular Outflow Tract|HEART, RIGHT VENTRICULAR OUTFLOW TRACT	The funnel-shaped structure through which blood flows from the right ventricle into the pulmonary trunk.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127649>	C13023	Right Ventricular Wall|HEART, RIGHT VENTRICULAR WALL	The wall of the right ventricle, comprising anterior, inferior, and lateral walls; and excluding the interventricular septum.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12764>	C34060	Parasympathetic Nervous System	The division of the autonomic nervous system responsible for conserving and restoring energy (opposing the sympathetic nervous system), which arises from preganglionic cell bodies in the gray matter of the brain stem and the middle three segments of the sacral cord.	Parasympathetic Nervous System		Body System	
C127650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127650>	C13023	Left Ventricular Apex Segment|LEFT VENTRICULAR APEX SEGMENT	The apical cap division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127651>	C13023	Left Ventricular Apical Anterior Segment|LEFT VENTRICULAR APICAL ANTERIOR SEGMENT	The anterior portion of the apical division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127652>	C13023	Left Ventricular Apical Inferior Segment|LEFT VENTRICULAR APICAL INFERIOR SEGMENT	The inferior portion of the apical division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127653>	C13023	Left Ventricular Apical Lateral Segment|LEFT VENTRICULAR APICAL LATERAL SEGMENT	The lateral portion of the apical division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127654>	C13023	Left Ventricular Apical Septal Segment|LEFT VENTRICULAR APICAL SEPTAL SEGMENT	The septal portion of the apical division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127655>	C13023	Left Ventricular Basal Anterior Segment|LEFT VENTRICULAR BASAL ANTERIOR SEGMENT	The anterior portion of the basal division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127656>	C13023	Left Ventricular Basal Anterolateral Segment|LEFT VENTRICULAR BASAL ANTEROLATERAL SEGMENT	The anterolateral portion of the basal division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127657>	C13023	Left Ventricular Basal Anteroseptal Segment|LEFT VENTRICULAR BASAL ANTEROSEPTAL SEGMENT	The anteroseptal portion of the basal division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127658>	C13023	Left Ventricular Basal Inferior Segment|LEFT VENTRICULAR BASAL INFERIOR SEGMENT	The inferior portion of the basal division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127659>	C13023	Left Ventricular Basal Inferolateral Segment|LEFT VENTRICULAR BASAL INFEROLATERAL SEGMENT	The inferolateral portion of the basal division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12765>	C12704	Parathyroid Gland|GLAND, PARATHYROID|Head and Neck, Parathyroid|PARATHYROID GLAND|Parathyroid|Parathyroid|Parathyroid gland|Parathyroid structure (body structure)|parathyroid|parathyroid gland|parathyroid gland	One of two small paired endocrine glands, superior and inferior, usually found embedded in the connective tissue capsule on the posterior surface of the thyroid gland; these glands secrete parathyroid hormone that regulates the metabolism of calcium and phosphorus. The parenchyma is composed of chief and oxyphilic cells arranged in anastomosing cords.	Parathyroid Gland		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C127660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127660>	C13023	Left Ventricular Basal Inferoseptal Segment|LEFT VENTRICULAR BASAL INFEROSEPTAL SEGMENT	The inferoseptal portion of the basal division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127661>	C13023	Left Ventricular Mid Anterior Segment|LEFT VENTRICULAR MID ANTERIOR SEGMENT	The anterior portion of the mid-cavity division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127662>	C13023	Left Ventricular Mid Anterolateral Segment|LEFT VENTRICULAR MID ANTEROLATERAL SEGMENT	The anterolateral portion of the mid-cavity division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127663>	C13023	Left Ventricular Mid Anteroseptal Segment|LEFT VENTRICULAR MID ANTEROSEPTAL SEGMENT	The anteroseptal portion of the mid-cavity division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127664>	C13023	Left Ventricular Mid Inferior Segment|LEFT VENTRICULAR MID INFERIOR SEGMENT	The inferior portion of the mid-cavity division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127665>	C13023	Left Ventricular Mid Inferolateral Segment|LEFT VENTRICULAR MID INFEROLATERAL SEGMENT	The inferolateral portion of the mid-cavity division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127666>	C13023	Left Ventricular Mid Inferoseptal Segment|LEFT VENTRICULAR MID INFEROSEPTAL SEGMENT	The inferoseptal portion of the mid-cavity division of the left ventricular myocardium as determined using the AHA 17-Segment Model (Cerqueira et al., 2002).			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127667>	C32889	Metacarpal 1 Base|METACARPAL 1 BASE	The proximal end of the first metacarpal bone.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127668>	C127306	Anterior Annulus of the Mitral Valve|MITRAL VALVE, ANTERIOR ANNULUS|Mitral Valve, Anteroseptal Annulus	The portion of the mitral valve annulus that attaches to the anterior mitral valve leaflet, and also forms the mitral portion of the aortic-mitral curtain.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127669>	C127306	Anterior Cusp of the Mitral Valve|MITRAL VALVE, ANTERIOR CUSP	The cusp of the mitral valve that is anchored to the aortic-mitral curtain.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12766>	C32616	Parietal Bone|PARIETAL BONE|Parietal bone structure (body structure)	One of two cranial bones that by their union form the sides and roof of the skull.	Parietal Bone		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C127670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127670>	C127306	Posterior Annulus of the Mitral Valve|MITRAL VALVE, POSTERIOR ANNULUS|Mitral Valve, Posterolateral Annulus	The portion of the mitral valve annulus that attaches to the posterior mitral valve leaflet.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127671>	C127306	Posterior Cusp of the Mitral Valve|MITRAL VALVE, POSTERIOR CUSP	The cusp of the mitral valave that is located posterior to the two commissures, and which has no attachement to the aortic root.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127672>	C13023	Pericardial Wall|PERICARDIAL WALL	The wall of the pericardium, comprising the following tissue layers: the fibrous pericardium; the parietal and visceral layers of the serous pericardium.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127673>	C33849	Anterior Cusp of the Pulmonary Valve|PULMONARY VALVE, ANTERIOR CUSP|Pulmonary Valve, Anterior Semilunar Cusp	The cusp of the pulmonic valve that has no attachment to the cardiac septum.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127674>	C33849	Left Cusp of the Pulmonary Valve|PULMONARY VALVE, LEFT CUSP|Pulmonary Valve, Left Semilunar Cusp	The cusp of the pulmonic valve attached to the left side of the cardiac septum.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127675>	C33849	Right Cusp of the Pulmonary Valve|PULMONARY VALVE, RIGHT CUSP|Pulmonary Valve, Right Semilunar Cusp	The cusp of the pulmonic valve attached to the right side of the cardiac septum.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127676>	C33894	Scaphoid-Capitate Joint|SCAPHOID-CAPITATE JOINT	A condyloid synovial joint within the wrist connecting the scaphoid bone to the capitate bone.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127677>	C33894	Scaphoid-Lunate-Capitate Joint|SCAPHOID-LUNATE-CAPITATE JOINT	A condyloid synovial joint within the wrist connecting the scaphoid, lunate, and capitate bones.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127678>	C33894	Scaphoid-Trapezium Joint|SCAPHOID-TRAPEZIUM JOINT	A condyloid synovial joint within the wrist connecting the scaphoid bone to the trapezium bone.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127679>	C190556	Cineangiography|CINEANGIOGRAPHY|Cineradiograph|Diagnostic Cineradiograph Service Type|Diagnostic Cineradiography|XRC	A type of angiography in which motion picture camera technology is used to record the passage of dye (usually fluorescent) through blood vessels and the heart.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12767>	C25444	Pelvis|BODY CAVITY, PELVIC|PELVIS|Pelvic|Pelvic Cavity|Pelvic Region|Pelvis, NOS|lesser pelvis|pelvic|pelvic region|pelvic region of trunk|pelvis|pelvis|pelvis region|true pelvis	The bony, basin-shaped structure formed by the hipbones and the base of the backbone supporting the lower limbs in humans.	Pelvis		Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Radiation Therapy Table|EWS Tumor Assessment Table|GCT Authorized Value Terminology|GCT Tumor Assessment Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Radiation Therapy Table|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C127680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127680>	C86083	Acidaminococcus intestini|ACIDAMINOCOCCUS INTESTINI	A species of anaerobic, Gram negative, non-spore-forming and non-motile coccobacilli shaped bacterium in the family Veillonellaceae isolated from the human gastrointestinal tract. A. intestini is oxidase- and catalase-negative and negative for gelatinase and nitrate-reduction tests.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127681>	C127271	Apophysomyces elegans|APOPHYSOMYCES ELEGANS	A species of filamentous fungi in the order Mucorales that is one of the causative agents of mucormycosis in humans.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127682>	C127272	Arthrinium phaeospermum|ARTHRINIUM PHAEOSPERMUM	A species of dematiaceous anamorphic fungi in the phylum Ascomycota with smooth, hyaline, branched, septate hyphae.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127683>	C127273	Arthroderma fulvum|ARTHRODERMA FULVUM|Microsporum fulvum	A species of geophilic fungi in the phylum Ascomycota with thin-walled, elongate, ellipsoidal macroconidia having 3 to 6 septa.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127684>	C127273	Arthroderma obtusum|ARTHRODERMA OBTUSUM|Microsporum nanum	A species of heterothallic fungi in the phylum Ascomycota with small, clavate, thick-walled conidia and usually one septa.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127685>	C127273	Arthroderma otae|ARTHRODERMA OTAE|Microsporum canis|Nannizzia otae	A species of zoophilic dermatophyte fungi in the phylum Ascomycota. This species causes superficial infections of the scalp (tinea capitis) in humans.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127686>	C127273	Arthroderma persicolor|ARTHRODERMA PERSICOLOR|Trichophyton persicolor	A species of dermatophyte fungi in the genus Arthroderma.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127687>	C127273	Arthroderma simii|ARTHRODERMA SIMII|Trichophyton simii	A species of dermatophyte fungi in the phylum Ascomycota with smooth, thin-walled, cylindrical to fusiform macroconidia. This species causes skin infections in monkeys, chickens, and humans.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127688>	C77180	Aspergillus versicolor|ASPERGILLUS VERSICOLOR|Sterigmatocystis versicolor	A species of slow-growing filamentous fungi in the phylum Ascomycota with long, septate hyphae and conidiophores that terminate in small vesicles. This species is commonly isolated from soil and plant debris and is among the most common of indoor molds.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127689>	C127274	Asterotremella humicola|ASTEROTREMELLA HUMICOLA|Apiotrichum humicola|Azymoprocandida humicola|Candida humicola|Cryptococcus humicola|Mycotorula humicola|Torula humicola|Vanrija humicola|Vanrijia humicola	A species of psychrotrophic, dimorphic yeast-like fungi in the phylum Basidiomycota and genus Asterotremella found in soil and water. This species has no sexual form.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12768>	C33968|C12466	Peripheral Nerve|NERVE, PERIPHERAL|PERIPHERAL NERVE|Peripheral Nerves|Peripheral nerve structure (body structure)|nerve|nerves|peripheral nerve	Any nerve outside the brain or spinal cord that connects with peripheral receptors or effectors.	Peripheral Nerve		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C127690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127690>	C127275	Aureobasidium pullulans|AUREOBASIDIUM PULLULANS|Aureobasidium pullulans var. pullulans	A species of yeast-like saprophytic fungi in the phylum Ascomycota with slimy masses of conidia and chains of one to two-celled, thick-walled, darkly pigmented arthroconidia.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127691>	C14299	Bocaparvovirus|BOCAPARVOVIRUS|Bocavirus	A genus of non-enveloped single-stranded DNA viruses in the family Parvoviridae with a 21-22 nm diameter capsid and a genome of about 5.5kb. Bocaparvoviruses encode a novel protein called NP1 that is not present in parvoviruses from other genera.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127692>	C86202	Bordetella hinzii|BORDETELLA HINZII	A species of Gram-negative, oxidase- and catalase-positive, nonsporulating, short motile rod-shaped bacteria in the family Alcaligenaceae. Poultry species act as a reservoir for B. hinzii. Transmission to humans is rare, mostly occurring through occupational exposure.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127693>	C86202	Bordetella petrii|BORDETELLA PETRII	A species of Gram-negative, coccobacillus-shaped, non-spore-forming, non-motile, facultatively anaerobic bacteria in the family Alcaligenaceae that is able to reduce selenate to elemental selenium. B. petrii is unable to utilize carbohydrates as a carbon source.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127694>	C127276	Byssochlamys spectabilis|BYSSOCHLAMYS SPECTABILIS|Paecilomyces spectabilis|Paecilomyces variotii|Talaromyces spectabilis	A species of fungi in the family Trichocomacae characterized by broadly ellipsoidal to lemon-shaped conidia, loosely branched conidiophores and phialides with pointed tips. B. spectabilis is strongly heat-resistant and is a common contaminant of heat-treated foods and juices.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127695>	C77163	Candida boidinii|CANDIDA BOIDINII|Hansenula alcolica	A species of yeast in the family Trichocomacae that is capable of utilizing methanol as a carbon source.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127696>	C77163	Candida famata|CANDIDA FAMATA|Debaryomyces hansenii|Torulopsis candida	A species of commensal yeast in the family Trichocomaca that are found in cheese, dairy products and the environment. It is rarely recovered from clinical specimens, usually associated with skin. C. famata is negative for fermentation on lactose and galactose.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127697>	C77163	Candida inconspicua|CANDIDA INCONSPICUA|Torulopsis inconspicua	A species of yeast in the family Trichocomaceae. Clinical isolates of C. inconspicua has been obtained from human immunodeficiency virus-infected patients with either oral or esophageal infections, women with vaginal infections, and patients with diabetes mellitus.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127698>	C77163	Candida sake|CANDIDA SAKE	A species of yeast in the family Trichocomaceae. C. sake is rarely pathogenic but has been identified as a causative agent of spondylodiscitis, fungal endocarditis, peritonitis, and bloodstream infection.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127699>	C127278	Coprinellus radians|COPRINELLUS RADIANS|Coprinus radians	A species of saprobic mushroom-forming fungi in the family Psathyrellaceae.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12769>	C25444	Peritoneal Cavity|BODY CAVITY, PERITONEAL|PERITONEAL CAVITY|peritoneal cavity|peritoneal cavity	The potential space located between the parietal and visceral layers of the peritoneum.	Peritoneal Cavity		Body Space or Junction	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C1276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1276>	C932|C67422	Vinzolidine|2H-3,7-Methanoazacycloundecino(5,4-b)indole-9-carboxylic acid, 9-((2-beta,3-beta,4-beta,5-alpha,12-beta,19-alpha)-4-(acetyloxy)-3'-(2-chloroethyl)-6,7-didehydro-16-methoxy-1-methyl-2',4'-dioxospiro(aspidospermidine-3,5'-oxazolidin)-15-yl)-5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-, methyl ester, (3R-(3R*,5S*,7R*,9S*))-|VINZOLIDINE	An orally active semisynthetic vinca alkaloid with potential antineoplastic activity. Like other vinca alkaloid compounds, vinzolidine binds to and stabilizes tubulin molecules, thereby interfering with microtubule assembly/disassembly dynamics. As a result, vinzolidine prevents mitotic spindle formation and leads to cell cycle arrest in metaphase.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C127700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127700>	C76308	Corynebacterium aurimucosum|CORYNEBACTERIUM AURIMUCOSUM|Corynebacterium nigricans	A species of non-motile, catalase-positive, non-lipophilic, pleomorphic coryneform bacteria in the family Corynebacteriaceae that are aerobic or facultatively anaerobic. The species is positive for utilization of fructose, glucose, maltose, and sucrose. C. aurimucosum is positive for alkaline phosphatase but negative for acid phosphatase, lipase, alpha- and beta-glucosidase, and alpha- and beta-galactosidase.	Corynebacterium aurimucosum		Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C127701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127701>	C114267	Cryptococcus albidus Var. albidus|CRYPTOCOCCUS ALBIDUS VAR. ALBIDUS|Torulopsis albida var. albida	A variety of Cryptococcus albidus that is characterized by its ability to assimilate lactose, but not galactose.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127702>	C77184	Cryptococcus diffluens|CRYPTOCOCCUS DIFFLUENS|Cryptococcus albidus var. diffluens|Cryptococcus diffluens var. diffluens|Naganishia diffluens|Torulopsis diffluens	A species of yeast in the phylum Basidiomycota. Colonies white to cream, and fluid to mucoid. C.diffluens is associated with rare cases of skin, nail, and subcutaneous infection.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127703>	C77184	Cryptococcus terreus|CRYPTOCOCCUS TERREUS|Cryptococcus elinovii|Cryptococcus himalayensis|Solicoccozyma terreus	A species of yeast in the phylum Basidiomycota. This species is characterized by its ability to utilize glucose, lactose, galactose, and potassium nitrate and its inability to ferment sucrose.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127704>	C127279	Cystobasidium minutum|CYSTOBASIDIUM MINUTUM|Cystobasidium minuta|Rhodotorula minuta|Torula minuta	A species of saprobic yeast in the phylum Basidiomycota and the family Cystobasidiaceae.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127705>	C127280	Dickeya dadantii|DICKEYA DADANTII|Erwinia chrysanthemi	A species of gram-negative, motile, nonsporulating bacillus bacteria in the family Enterobacteriaceae. D. dadantii causes necrosis, blight and soft rot on a wide range of ornamental and horticultural host plants.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127706>	C14329	Enteric Bacteria|ENTERIC BACTERIA	Any of the bacteria that normally or pathogenically reside in the intestinal tracts of animals.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127707>	C127281	Epidermophyton floccosum|Acrothecium floccosum|EPIDERMOPHYTON FLOCCOSUM|Epidermophyton floccosum var. nigricans	A species of dermatophylic and anthropophilic fungi in the phylum Ascomycota. E. floccosum is the causative agent of various cutaneous mycoses, but is restricted to the cornified layers of the epidermis.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127708>	C127282	Eurotium herbariorum|Aspergillus glaucus|Aspergillus herbariorum|EUROTIUM HERBARIORUM	A species of filamentous fungi in the phylum Ascomycota with conidial heads and characterized by smooth ascospores. E. herbariorum is the source for aspergiolide A, an anthraquinone derivative.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127709>	C127283	Exophiala dermatitidis|EXOPHIALA DERMATITIDIS|Wangiella dermatitidis	A species of anamorphic, thermophilic black yeast in the phylum Ascomycota that is commonly isolated from saunas, steam baths, and dish washers. E. dermatitidis is considered a human opportunistic pathogen.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12770>	C13169	Peritoneum|Human Peritoneal Membrane|PERITONEUM|Peritoneum, NOS|peritoneum|peritoneum	The tissue that lines the wall of the abdominal cavity, intestine, mesentery, and pelvic organs. It consists of the parietal peritoneum and the visceral peritoneum.	Peritoneum		Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Structured Product Labeling Terminology|GCT Authorized Value Terminology|GCT Tumor Assessment Table|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|SPL Tissue Form Product Type Terminology|UBERON Terminology
C127710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127710>	C127283	Exophiala jeanselmei|EXOPHIALA JEANSELMEI|Phialophora jeanselmei|Pullularia jeanselmei|Torula jeanselmei	A species of saprobic fungi in the phylum Ascomycota. E. jeanselmei is the causative agent of maduromycosis, an asymptomatic disease which presents with black or brown macular lesions.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127711>	C77185	Fusarium chlamydosporum|FUSARIUM CHLAMYDOSPORUM	A species of filamentous fungi in the phylum Ascomycota. Infection with F. chlamydosporum is associated with superficial mycoses and keratitis in immunocompetent individuals and with invasive and disseminated infection in immunocompromised individuals.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127712>	C77185	Fusarium incarnatum|FUSARIUM INCARNATUM|Fusarium pallidoroseum|Fusarium semitectum	A fungal plant pathogen in the phylum Ascomycota.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127713>	C122315	Geotrichum klebahnii|GEOTRICHUM KLEBAHNII|Geotrichum penicillatum|Trichosporon penicillatum	A species of filamentous yeast-like fungi in the family Endomycetaceae normally found in plant tissues, silage and soil. It is also a component of the natural flora of the human mouth, skin and gastrointestinal tract.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127714>	C127302	Guehomyces pullulans|Basidiotrichosporon pullulans|GUEHOMYCES PULLULANS|Monilia pullulans|Oidium pullulans|Oospora pullulans|Tausonia pullulans|Trichosporon pullulans	A species of yeast-like fungi in the phylum Basidiomycota having cell walls containing xylose and lacking septal pores. It is characterized by an optimum growth temperature of 17 C, assimilation of nitrate, and an absence of growth with lactate.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127715>	C76324	Haemophilus paraphrohaemolyticus|HAEMOPHILUS PARAPHROHAEMOLYTICUS	A species of Gram-negative, pleomorphic, coccobacilli bacteria in the phylum Proteobacteria that is positive for nitrate reduction and for growth with glucose, fructose, maltose, and sucrose.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127716>	C127284	Hannaella luteola|Chromotorula luteola|Cryptococcus luteolus|HANNAELLA LUTEOLA|Hannaella luteolus|Rhodotorula luteola|Torula luteola|Torulopsis luteola	A species of fungi in the phylum Basidiomycota. This species is positive for assimilation of arabinose, sucrose, maltose, galactose, and others. It is generally non-fermenting.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127717>	C127285	Hanseniaspora guilliermondii|Acaromyces laviae|HANSENIASPORA GUILLIERMONDII|Hanseniaspora apuliensis|Hanseniaspora melligeri|Kloeckera apiculata|Kloeckera apis|Willia guilliermondii	A species of apiculate yeast in the phylum Ascomycota that are found on dates, grapes, tomatoes, figs, and in soil. This species is only able to ferment glucose.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127718>	C127285	Hanseniaspora uvarum|HANSENIASPORA UVARUM|Hanseniaspora apiculata|Kloeckera apiculata|Kloeckeraspora uvarum	A species of apiculate yeast in the phylum Ascomycota frequently found on mature fruits and particularly on grapes where it forms part of the grape and fermentation microbiome.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127719>	C127285	Hanseniaspora valbyensis|HANSENIASPORA VALBYENSIS	A species of apiculate yeast in the phylum Ascomycota with hat or bell-shaped spores.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12771>	C12936	Peyer Patch|PEYER'S PATCH|Peyer's Patch|Peyer's Patches	Lymphoid cell tissue in the small intestinal mucosa.	Peyer's Patch		Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127720>	C127286	Herbaspirillum huttiense|HERBASPIRILLUM HUTTIENSE|Pseudomonas huttiensis	A species of Gram-negative, motile, spirillum-shaped bacteria in the phylum Proteobacteria that is unable to grow in N2-free medium and lacks the nitrogen-fixing genes nifH and nifD. H. huttiense is oxidase- and catalase-positive, nitrate reduction negative, and able to hydrolyse urea.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127721>	C127287	Hortaea werneckii|Exophiala werneckii|HORTAEA WERNECKII	A species of saprophytic fungi in the phylum Ascomycota with two-celled yeast-like cells producing annelloconidia. H. werneckii is the causative agent of tinea nigra in humans.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127722>	C127288	Kerstersia gyiorum|KERSTERSIA GYIORUM	A species of Gram-negative, catalase-positive, oxidase-negative bacteria in the in phylum Proteobacteria that is positive for assimilation of caprylate and the absence of assimilation of isobutyrate, isovalerate, or glutarate.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127723>	C127285	Kloeckera japonica|KLOECKERA JAPONICA	A species of apiculate yeast in the phylum Ascomycota with polar budding and evanescent asci containing 1 to 4 hat-shaped ascospores.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127724>	C114123	Kluyveromyces lactis|Candida sphaerica|KLUYVEROMYCES LACTIS|Kluyveromyces drosophilarum|Kluyveromyces lactis var. drosophilarum|Kluyveromyces lactis var. lactis|Kluyveromyces marxianus lactis|Kluyveromyces marxianus var. drosophilarum|Kluyveromyces marxianus var. lactis|Saccharomyces lactis	A species of yeasts in the family Saccharomycetaceae and phylum Ascomycota with the ability to utilize lactose and convert it into lactic acid. The species is heterothallic, with a predominantly haploid life cycle. K. lactis has emerged as an important yeast species for research and industrial biotechnology.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127725>	C127289	Kodamaea ohmeri|Candida guilliermondii var. membranifaciens|KODAMAEA OHMERI|Pichia ohmeri|Yamadazyma ohmeri	A species of yeast-like fungi in the phylum Ascomycota. K. ohmeri is a causative agent of fungemia in immunocompromised patients. This species is widely used in the food industry for fermentation of fruits, pickles and rinds.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127727>	C76197	Lysinibacillus|LYSINIBACILLUS	A genus of gram-positive, rod-shaped, non-motile bacteria in the phylum Firmicutes.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127728>	C127291	Madurella mycetomatis|MADURELLA MYCETOMATIS|Madurella ikedae|Madurella mycetomi|Streptotrix mycetomatis	A species of fungi in the phylum ascomycota characterized by brown diffusible pigment that is produced in primary cultures and the occasional presence of phialides. This species is a causative agent of eumycetoma.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127729>	C127292	Malassezia furfur|MALASSEZIA FURFUR|Pityrosporum orbiculare|Pityrosporum ovale|Saccharomyces ovalis	A species of obligatory lipophilic, anthropophilic yeast in the phylum Basidiomycota that is part of the normal human skin flora. This species is the causative agent of pityriasis versicolor.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12772>	C13029	Anterior Lobe of the Pituitary Gland|Adenohypophysis|Anterior Lobe of Pituitary|Anterior Lobe of Pituitary Gland|Anterior Pituitary Gland|Gland, Anterior Pituitary|Glands, Anterior Pituitary|Pars Anterior Pituitary Gland|Pituitary Anterior Lobe|Pituitary Gland, Anterior	The glandular or anterior lobe of the pituitary gland which secretes several hormones.	Anterior Pituitary Gland		Body Part, Organ, or Organ Component	
C127730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127730>	C127292	Malassezia pachydermatis|MALASSEZIA PACHYDERMATIS|Pityrosporum pachydermatis	A zoophilic species of lipophilic yeast in the phylum Basidiomycota that can be found within the microflora of healthy mammals. M. pachydermatis can be distinguished from other species in the genus by its ability to grow on Sabouraud agar.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127731>	C127293	Metschnikowia pulcherrima|Candida pulcherrima|METSCHNIKOWIA PULCHERRIMA	A species of yeast in the phylum Ascomycota commonly found on grapes, cherries, flowers, and spoiled fruit. Each cell of M. pulcherrima contains a single globule of oil and the species is being investigated as a source for a palm oil alternative.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127732>	C127294	Microsporum audouinii|MICROSPORUM AUDOUINII	A species of anthropophilic fungi in the phylum Ascomycota that is characterized by spindle shaped macroconidia, clavate microconidia, and pitted or spiny external walls. This species is a causative agent of tinea capitis and tinea corporis.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127733>	C127294	Microsporum distortum|MICROSPORUM DISTORTUM|Microsporum canis var. distortum	A species of fungi in the phylum Ascomycota characterized by thick-walled, roughened macroconidia with a distorted shape. This species is a causative agent of tinea capitis and tinea corporis.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127734>	C127294	Microsporum equinum|MICROSPORUM EQUINUM	A species of fungi in the phylum Ascomycota with macroconidia that are small, broad, irregular, and spindle-shaped with rough thick walls and few septa. This species is a causative agent of ringworm in horses and humans.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127735>	C127294	Microsporum ferrugineum|MICROSPORUM FERRUGINEUM	A species of anthropophilic fungi in the phylum Ascomycota characterized by "bamboo hyphae". This species is a causative agent of juvenile tinea capitis in humans.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127736>	C127294	Microsporum gypseum|Arthroderma gypseum|Gymnoascus gypseus|MICROSPORUM GYPSEUM|Nannizzia gypsea	A species of soil-associated keratinophilic fungi in the phylum Ascomycota with a world-wide distribution. This species is known for causing diseases on human skin, particularly associated with rural and agricultural workers.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127737>	C127295	Monascus ruber|MONASCUS RUBER	A genus of salt- and acid-tolerant fungi in the phylum Ascomycota. This species is used in the production of pigments.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127738>	C120708	Mucor ramosissimus|MUCOR RAMOSISSIMUS	A species of saprobic fungi in the phylum Zygomycota with sporangiophores that are hyaline, slightly roughened, tapering towards the apex, and erect with repeated sympodial branching.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127739>	C123543	Phialophora verrucosa|PHIALOPHORA VERRUCOSA	A species of dematiaceous fungi in the phylum Ascomycota that produces conidia from phialides with conspicuous darkened collarettes. This species is a causative agent of chromoblastomycosis.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12773>	C13029	Posterior Lobe of the Pituitary Gland|Neurohypophysis|Posterior Lobe of Pituitary|Posterior Lobe of Pituitary Gland|Posterior Pituitary Gland	The neural or post-neural lobe of the pituitary gland which stores and releases vasopressin, oxytocin, and neurophysins.	Posterior Pituitary Gland		Body Part, Organ, or Organ Component	
C127740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127740>	C123544	Pichia fermentans|Candida fimetaria|Candida lambica|Mycoderma lambica|PICHIA FERMENTANS	A species of yeast in the phylum Ascomycota that occurs singly, in pairs, or in short chains and that produces 2-4 hat-shaped ascospores per ascus. This species is a normal member of the flora of skin, mouth, and vagina, and is also found in the environment.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127741>	C123545	Piedraia hortae|PIEDRAIA HORTAE	A species of dermatophytic fungi in the phylum Ascomycota. This species is a causative agent of black piedra.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127742>	C127296	Purpureocillium lilacinum|PURPUREOCILLIUM LILACINUM|Paecilomyces lilacinus|Penicillium lilacinum|Purpureocillium lilacinus	A species of saprobic, filamentous fungi in the phylum Ascomycota. Depending upon available nutrients in the environment P. lilacinum may be entomopathogenic, mycoparasitic, saprophytic, or nematophagous. Human infections are rare, but may occur in patients with compromised immune systems or intraocular lens implants.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127743>	C77196	Rhizopus oryzae|RHIZOPUS ORYZAE|Rhizopus arrhizus|Rhizopus chiuniang|Rhizopus formosaensis|Rhizopus hangchow|Rhizopus javanicus Y. Takeda|Rhizopus liquefaciens|Rhizopus peka|Rhizopus pseudochinensis|Rhizopus suinus|Rhizopus tamarii|Rhizopus thermosus|Rhizopus tritici	A species of filamentous fungi in the phylum Zygomycota characterized by sporangiophores that arise from nodes at the point where the rhizoids are formed. R. oryzae is a causative agent of mucormycosis in immunocompromised individuals. This species is used in the fermentation of tempeh.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127744>	C127297	Scedosporium boydii|Allescheria boydii|Petriellidium boydii|Pseudallescheria boydii|SCEDOSPORIUM BOYDII	A species of saprophytic fungi in the phylum frequently isolated from agricultural soil and polluted water. It is the causative agent of human scedosporiosis.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127745>	C127298	Scolecobasidium terreum|SCOLECOBASIDIUM TERREUM	A species of soil-borne, saprotrophic fungi in the phylum Ascomycota. S. terreum is the type species for Scolecobasidium.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127746>	C124394	Scopulariopsis brevicaulis|Microascus brevicaulis|SCOPULARIOPSIS BREVICAULIS	A genus of anamorphic fungi in the family Microascaceae. This species is a causative agent of human nail infections and deep fungal infections.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127747>	C127299	Setosphaeria rostrata|Exserohilum rostratum|SETOSPHAERIA ROSTRATA	A species of fungi in the phylum Ascomycota characterized by mature conidia with a distinct protruding hilum. This species is commonly found in soils, but is an opportunistic agent of sinusitis, keratitis, and CNS vasculitis as well as cutaneous and subcutaneous mycoses.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127748>	C127300	Sporidiobolus salmonicolor|Aessosporon salmonicolor|SPORIDIOBOLUS SALMONICOLOR|Sporobolomyces salmonicolor	A species of yeast-like fungus in the phylum Basidiomycota. The asexual form of S. salmonicolor is characterized by pink, ballistosporic yeast that are forcibly ejected into the air upon maturity. This species is considered an opportunistic fungal pathogen of immunocompromised individuals.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127749>	C127301	Sporothrix schenckii|SPOROTHRIX SCHENCKII	A species of thermally dimorphic fungi in the phylum Ascomycota. In the environment S. schenckii is found growing as filamentous hyphae; in host tissue it is found as a yeast. This species is the causative agent of sporotrichosis.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12774>	C12372	Pulmonary Artery|ARTERY, PULMONARY|PULMONARY ARTERY BRANCH|Pulmonary artery structure (body structure)	Either one of two arteries arising from the pulmonary trunk that carry deoxygenated blood to the lungs.	Pulmonary Artery		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C127750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127750>	C127303	Trematosphaeria grisea|Madurella grisea|TREMATOSPHAERIA GRISEA	A species of fungi in the phylum Ascomycota. T. grisea is a causative agent of black-grain mycetoma.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127751>	C127304	Trichomonascus ciferrii|Candida ciferrii|Stephanoascus ciferrii|TRICHOMONASCUS CIFERRII	A species of yeast-like fungi in the phylum Ascomycota that is associated with otitis externa in humans and animals.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127752>	C127305	Trichophyton equinum|TRICHOPHYTON EQUINUM	A species of zoophilic fungi in the phylum Ascomycota that causes ringworm in horses, but rare infections in humans.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127753>	C127305	Trichophyton mentagrophytes|Microsporum mentagrophytes|TRICHOPHYTON MENTAGROPHYTES	A species of zoophilic fungi in the phylum Ascomycota with a worldwide distribution and a wide range of animal hosts. This species causes inflammatory skin or scalp lesions in humans.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127754>	C127305	Trichophyton rubrum|Epidermophyton rubrum|TRICHOPHYTON RUBRUM|Trichophyton fischeri|Trichophyton kanei|Trichophyton megninii|Trichophyton raubitschekii	A species of anthropophilic and dermatophytic fungi in the phylum Ascomycota. This species causes chronic infections of skin, nails, and rarely scalp.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127755>	C127305	Trichophyton schoenleinii|TRICHOPHYTON SCHOENLEINII	A species of anthropophilic fungi in the phylum Ascomycota with a geographic distribution limited to certain areas of Africa. This species causes favus in humans.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127756>	C127305	Trichophyton soudanense|TRICHOPHYTON SOUDANENSE	A species of anthropophilic and dermatophytic fungi in the phylum Ascomycota with a geographic distribution limited to areas of Africa. This species causes tinea of the scalp.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127757>	C127305	Trichophyton tonsurans|TRICHOPHYTON TONSURANS	A species of anthropophilic fungi in the phylum Ascomycota with a worldwide distribution. This species causes inflammatory, or chronic non-inflammatory, finely scaling lesions of skin, nails and scalp.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127758>	C127305	Trichophyton verrucosum|TRICHOPHYTON VERRUCOSUM	A species of zoophilic and dermatophytic fungi in the phylum Ascomycota. This species causes ringworm in cattle.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127759>	C127305	Trichophyton violaceum|TRICHOPHYTON VIOLACEUM	A species of anthropophilic fungi in the phylum Ascomycota with a worldwide distribution. This species causes inflammatory, or chronic non-inflammatory, finely scaling lesions of skin, nails, beard and scalp, producing black dot tinea capitis.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12775>	C12729	Pulmonary Valve|PULMONARY VALVE|Pulmonary valve structure (body structure)|Pulmonic Valve|VALVE, PULMONARY	A valve that is located between and controls the flow of blood from the right ventricle of the heart and the pulmonary artery.	Pulmonic Valve		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C127760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127760>	C127305	Trichophyton yaoundei|TRICHOPHYTON YAOUNDEI	A species of anthropophilic and dermatophytic fungi in the phylum Ascomycota that is endemic to equatorial Africa. This species causes tinea of the scalp, but is capable of infecting the glabrous skin, nails, and the soles of the feet.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127761>	C114129	Trichosporon beigelii|TRICHOSPORON BEIGELII	A species of urease-positive, non-encapsulated yeasts in the phylum Basidiomycota characterized by the development of hyaline, septate hyphae that fragment into oval or rectangular arthroconidia.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127762>	C83490	Staining Intensity|STAINING INTENSITY|staining intensity value|staining_intensity_value	The degree or magnitude of staining by a dye or reagent within a microscopic specimen.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Detail Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Property Terminology|GDC Terminology
C127763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127763>	C64430	Cytokeratin 16 Measurement|CY16|Cytokeratin 16|Cytokeratin 16	The determination of the amount of cytokeratin 16 present in a sample.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127764>	C64430	Dendritic Cell Lysosomal-Associated Membrane Protein Measurement|DC LAMP Protein Measurement|DCLAMP|DCLAMP Protein Measurement|Dendritic Cell-Lysosomal-Assoc Memb Prot|Dendritic Cell-Lysosomal-Assoc Memb Prot|LAMP3 Protein Measurement|Lysosome-Associated Membrane Glycoprotein 3 Measurement	The determination of the amount of dendritic cell lysosomal-associated membrane protein present in a sample.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127765>	C18190	Fibrosis Assessment|FIBROSIS|Fibrosis|Fibrosis	An evaluation of the presence or degree of fibrosis present in a sample.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127766>	C18190	Lymphatic Invasion Assessment|LYMPHINV|Lymphatic Invasion|Lymphatic Invasion	An evaluation of the presence or degree of lymphatic invasion present in a sample.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127767>	C48938	Normal Cell to Total Cell Ratio Measurement|NORMCECE|Normal Cells to Total Cells Ratio Measurement|Normal Cells/Total Cells|Normal Cells/Total Cells	The determination of the ratio of normal cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127768>	C18190	Perineural Invasion Assessment|PNLINV|Perineural Invasion|Perineural Invasion|Perineural Invasion|perineural invasion present|perineural_invasion_present	An evaluation of the presence or degree of perineural invasion present in a sample.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Terminology|GDC Property Terminology|GDC Terminology
C127769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127769>	C202425	S100 Calcium Binding Protein A7 Measurement|S100 Calcium Binding Protein A7|S100 Calcium Binding Protein A7|S100-A7 Protein Measurement|S100A7	The determination of the amount of S100 calcium binding protein A7 protein present in a sample.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12776>	C12814	Pulmonary Vein|PULMONARY VEIN|VEIN, PULMONARY	One of four veins that carries oxygen-rich blood from the lungs to the cardiac left atrium.	Pulmonary Vein		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127770>	C48938	Stromal Cell to Total Cell Ratio Measurement|STRMCECE|Stromal Cells to Total Cells Ratio Measurement|Stromal Cells/Total Cells|Stromal Cells/Total Cells	The determination of the ratio of stromal cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127772>	C18190	Vascular Invasion Assessment|VASINV|Vascular Invasion|Vascular Invasion|vascular invasion present|vascular_invasion_present	An evaluation of the presence or degree of vascular invasion present in a sample.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Property Terminology|GDC Terminology
C127773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127773>	C17214	Horizontal Transmission|HORIZONTAL TRANSMISSION|Horizontal Disease Transmission	The transmission of a disease from one individual to another.			Pathologic Function	CDISC SDTM Mode of Disease Transmission Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127774>	C119241	Swollen Indicator|SWLLIND	An indicator as to whether the subject has symptoms of swelling.			Conceptual Entity	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127775>	C119241	Tenderness Indicator|TNDRIND|TNDRIND	An indicator as to whether the subject has symptoms of tenderness.			Conceptual Entity	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127776>	C164620	Biospecimens Not Retained	An indication that no biospecimen samples were retained as reserve samples.			Conceptual Entity	
C127777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127777>	C126058	Retained Biospecimen Contains DNA Indicator|BRDNAIND|Biospecimen Retention Contains DNA Ind|Biospecimen Retention Contains DNA Ind|Biospecimen Retention Includes DNA Indicator	An indication as to whether retained biospecimens contain DNA.			Conceptual Entity	CDISC DDF Biospecimen Retention Attribute Terminology|CDISC DDF Terminology|CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C127778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127778>	C126058	Retained Specimens Do Not Contain DNA	An indication that the retained biospecimens do not contain DNA.			Conceptual Entity	
C127779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127779>	C70821|C16084	Observational Case-Crossover Study|CASE CROSSOVER	A study in which the subject with the condition under study (the case) at the timepoint of disease onset is compared against an earlier, pre-disease timepoint in that subject's life (the control).			Research Activity	CDISC SDTM Observational Study Model Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12777>	C33003|C12983	Radius Bone|BONE, RADIUS|Bone structure of radius (body structure)|RADIUS|Radial Bone|Radius|Radius|radius bone	The long bone of the forearm that extends from the lateral aspect of the elbow to the thumb-side of the wrist.	Radius		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C127780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127780>	C16084	Ecologic or Community Based Study|ECOLOGIC OR COMMUNITY|Ecological Study|Ecological Study	A study in which participants within a certain population or community are observed to determine whether there might be a correlation between a disease and an exposure or suspected cause.			Research Activity	CDISC SDTM Observational Study Model Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|SeroNet Authorized Values|SeroNet Study Descriptors
C127781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127781>	C71492	Non-Probability Sampling Method|NON-PROBABILITY SAMPLE	A non-random process used to select a study population in which the participants have been selected based on convenience or with a particular purpose in mind.			Activity	CDISC SDTM Observational Study Sampling Method Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127782>	C21480|C199000	Household Relative|RELATIVE, HOUSEHOLD	Any individual who is related biologically or legally to another individual, and who resides in the same residence.			Human	CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127783>	C21480	Non-household Relative|RELATIVE, NON-HOUSEHOLD	Any individual who is related biologically or legally to another individual, but who does not reside in the same residence.			Human	CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127784>	C198997|C198996	Schoolmate|SCHOOLMATE	Any individual with whom the subject attends or attended the same school.			Human	CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127785>	C19696	Childcare Center|CHILD CARE CENTER|Child Day Care Center	Daytime supervision, which may include recreational or medical facilities, for infants and children.			Functional Concept	CDISC SDTM Environmental Setting Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C127786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127786>	C25180	Occurrence Indicator|OCCUR|OCCUR|OCCUR|OCCUR|OCCUR|OCCUR|OCCUR|OCCUR|OCCUR|OCCUR|OCCUR	An indication as to whether something has happened, such as an event or intervention.			Conceptual Entity	CDISC SDTM Asthma Findings About Test Code Terminology|CDISC SDTM Asthma Findings About Test Name Terminology|CDISC SDTM COVID-19 Findings About Test Code Terminology|CDISC SDTM COVID-19 Findings About Test Name Terminology|CDISC SDTM Ebola Virus Findings About Test Code Terminology|CDISC SDTM Ebola Virus Findings About Test Name Terminology|CDISC SDTM Findings About Adjudicated Event Test Code Terminology|CDISC SDTM Findings About Adjudicated Event Test Name Terminology|CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Malaria Findings About Test Code Terminology|CDISC SDTM Malaria Findings About Test Name Terminology|CDISC SDTM Nutrition Findings About Test Code Terminology|CDISC SDTM Nutrition Findings About Test Name Terminology|CDISC SDTM Pediatric Findings About Test Code Terminology|CDISC SDTM Pediatric Findings About Test Name Terminology|CDISC SDTM Schizophrenia Findings About Test Code Terminology|CDISC SDTM Schizophrenia Findings About Test Name Terminology|CDISC SDTM Terminology|CDISC SDTM Tuberculosis Findings About Test Code Terminology|CDISC SDTM Tuberculosis Findings About Test Name Terminology|CDISC SDTM Vaccines Findings About Test Code Terminology|CDISC SDTM Vaccines Findings About Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C127787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127787>	C25337|C25256	Total Number|TOTNUM|TOTNUM	The determination of the amount of total number of entities.			Quantitative Concept	CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|CDISC SDTM Tuberculosis Findings About Test Code Terminology|CDISC SDTM Tuberculosis Findings About Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C127788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127788>	C93531	Clinical Study Citation|CITNSTDY|Citation Used in Study|Citation Used in Study	A bibliographical reference to a particular study.			Intellectual Product	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C127789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127789>	C25688	Sponsor Commercial Status|CMSPSTAT|Commercial Sponsor Status|Commercial Sponsor Status	The state or condition of the sponsor as it pertains to whether the sponsor is considered a commercial entity.			Qualitative Concept	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C12778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12778>	C32039	Renal Artery|ARTERY, RENAL|RENAL ARTERY|renal artery	Either of two arteries (right or left) that arise from the aorta to supply the kidneys.	Renal Artery		Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C127790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127790>	C25180	Data Monitoring Committee Indicator|DMCIND|dataMonitoringCommitteeIndicator	An indication as to whether a clinical trial has an appointed data monitoring committee.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology|CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C127791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127791>	C42775	E-mail Address for XML File Feedback|EMAILXML|Email Address for XML File|Email Address for XML File	The E-mail address to which copies of the XML format of the CT application should be sent.			Intellectual Product	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C127792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127792>	C172240	Clinicaltrials.gov NCT Number for the Expanded Access Record|EXPARECN|Expanded Access Record NCT Number|Expanded Access Record NCT Number	The unique alphanumeric identifier for a study with associated expanded access record, as assigned by the clinicaltrials.gov PRS system.			Intellectual Product	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C127793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127793>	C171103	Trial Expanded Access Status|EXPASTAT|Expanded Access Status|Expanded Access Status	The state or condition of an experimental drug or device as it pertains to its availability for use in expanded access studies.			Qualitative Concept	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C127794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127794>	C25180	Multiple Site European Union State Trial Indicator|MSEUTIND|Multiple Site EU State Trial Indicator|Multiple Site EU State Trial Indicator	An indication as to whether the clinical study is being conducted at multiple sites within the European Union member state concerned by the application.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C127795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127795>	C25337	Number of Trial Sites within European Union State|NUMSEUST|Number of Trial Sites EU State|Number of Trial Sites EU State	The number of trial sites within a European Union state.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C127796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127796>	C93625	Planned Trial Duration|PLNTRDUR	The approximate period of time over which a clinical trial is planned to occur.			Temporal Concept	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C127797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127797>	C93638|C70663	PubMed Unique Identifier|PMID_REF|PUBMEDID|PubMed ID|PubMed ID|PubMed ID|PubMed ID for Citation Used in Study|PubMed ID for Citation Used in Study|PubMed Identifier|PubMed Indexing Number|pubmed id|pubmed id|pubmed_id|pubmed_id	A globally unique identifier for a biomedical article, as assigned by PubMed.			Intellectual Product	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology|CTDC Property Terminology|GCT Lab Table|GCT Variable Terminology|ICDC Property Terminology|ICDC Terminology|SeroNet Study Descriptors|SeroNet Variables
C127798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127798>	C25180	Study Saved as XML Indicator|RXMLCIND|Request for XML Copy of Study Indicator|Request for XML Copy of Study Indicator	An indication as to whether the data submitted to EudraCT should be saved to EudraCT as an XML file.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C127799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127799>	C25180	Requires Secure Email Delivery of XML Indicator|SDXMLIND|Secure Delivery XML Required Indicator|Secure Delivery XML Required Indicator	An indication as to whether the XML copy of the CT application requires secure E-mail delivery.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C12779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12779>	C12919	Respiratory System|Body System, Pulmonary|Organ System, Pulmonary|Pulmonary Body System|Pulmonary Organ System|RESPIRATORY SYSTEM|Respiratory|respiratory system|respiratory system|respiratory tract	The organs involved in the exchange of carbon dioxide and oxygen including the trachea, bronchi, and lung parenchyma.	Respiratory System		Body System	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|ICDC Terminology|ICDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C1277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1277>	C2152	Wortmannin|(1 Alpha,11 alpha)-11-(acetyloxy)-1-(methoxymethyl)-2-oxaandrosta-5,8-dieno(6,5,4-bc)furan- 3,7,17-trione|(1S,6bR,9aS,11R,11bR)-11-(Acetyloxy)-1,6b,7,8,9a,10,11,11b-octahydro-1-(methoxymethyl)-9a,11b-dimethyl-3H-furo[4,3,2-de]indeno[4,5-h]-2-benzopyran-3,6,9-trione|(1S,6bR,9aS,11R,11bR)-11-(Acetyloxy)-1,6b,7,8,9a,10,11,11b-octahydro-1-(methoxymethyl)-9a,11b-dimethyl-3H-furo[4,3,2-de]indeno[4,5-h]-2-benzopyran-3,6,9-trione|2-Oxaandrosta-5,8-dieno[6,5,4-bc]furan-3,7,17-trione, 11-(acetyloxy)-1-(methoxymethyl)-, (1.alpha.,11.alpha.)-|SL-2052|WORTMANNIN|WORTMANNIN	A potent fungal metabolite isolated from Penicillium wortmannin that selectively inhibits phosphatidylinositol 3-kinase and affects the signal transduction pathway. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C127800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127800>	C25180	Single Site European Union State Trial Indicator|SSEUTIND|Single Site EU State Trial Indicator|Single Site EU State Trial Indicator	An indication as to whether the clinical study is being conducted at only one site within the European Union member state concerned by the application.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C127801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127801>	C42743	Study Protocol Uniform Resource Locator|URL Related to Study|URL Related to Study|URLSTDY	The uniform resource locator for a clinical study protocol.			Intellectual Product	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C127802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127802>	C25365	Study Protocol Uniform Resource Locator Description|URL Related to Study Description|URL Related to Study Description|URLSTDYD	A textual description for the uniform resource locator of a clinical study protocol.			Intellectual Product	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C127803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127803>	C49660	Dose Response Study|DOSE RESPONSE	A study of the effect of dose changes on the efficacy of a drug in order to determine the dose-response relationship and optimal dose of a therapy.			Research Activity	CDISC SDTM Terminology|CDISC SDTM Trial Type Terminology|Clinical Data Interchange Standards Consortium Terminology
C127804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127804>	C67416	One per Second Times Kilopascal|/(s*kPa)|1/(s*kPa)|1/(s*kPa)|1/(s.kPa)|1/(s.kPa)	A unit of resistance equal to the inverse of one kilopascal multiplied by a unit of time equal to one second.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127805>	C67275	Metabolic Equivalent of Task Unit|MET|MET|MET|Metabolic Equivalent of Task|[MET]|[MET]|[MET]|[MET]|metabolic equivalent|metabolic equivalent	A unit of energy expenditure equal to the ratio of the metabolic rate during physical activity in comparison to a reference metabolic rate.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit for Vital Sign Result Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology|UCUM Terminology
C127806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127806>	C67275	Metabolic Equivalent of Task Hours|MET*h|MET*h|[MET].h|[MET].h	A unit of energy expenditure equal to the number of metabolic equivalent of task units multiplied by the number of hours of performed activity.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127807>	C67275	Metabolic Equivalent of Task Minute|MET*min|MET*min|[MET].min|[MET].min	A unit of energy expenditure equal to the number of metabolic equivalent units multiplied by the number of minutes of performed activity.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127808>	C67415	Milliliter per Heartbeat|mL/beat|mL/beat|mL/{beat}|mL/{beat}|ml/{beat}|ml/{beat}	A unit of measure expressed as the number of milliliter(s) per heart beat.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127809>	C69180	Millinewton|mN|mN|mN	An SI derived unit of force equal to one thousandth of a Newton.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12780>	C33904	Reticuloendothelial System|RE System|Reticuloendothelial system, NOS|reticuloendothelial system	A network of phagocytic cells, primarily monocytes and macrophages, located in the connective tissue of the bone marrow, spleen, and liver that are involved in the clearance of bacteria, toxins, exogenous antigens, and immune complexes from the blood and tissues, as well as cytotoxicity against tumor cells.	Reticuloendothelial System		Body System	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C127810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127810>	C48207	Pheresis Unit|PHERESIS UNIT|{PHERESIS UNIT}|{PHERESIS UNIT}	An arbitrary unit of substance concentration equal to the yield from a blood pheresis procedure.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127811>	C134576	Experimental Organism Benign Endometrial Adenoma|ADENOMA, ENDOMETRIAL, BENIGN	A benign epithelial neoplasm arising from the endometrium.			Neoplastic Process	CDISC SDTM Terminology|CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C127812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127812>	C49165	Flap Surgical Reconstruction	The surgical transfer of tissue from one site to another while maintaining its own blood supply.	Flap Surgical Reconstruction		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C127813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127813>	C18190	Toxic Vacuolation Assessment|TOXVAC|Toxic Vacuolation|Toxic Vacuolation	An evaluation of the presence or degree of toxic vacuolation present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127814>	C12981	Flap|Flap Graft|Flap Transplant|Reconstructive Flap	A unit of tissue that is transferred from one site to another while maintaining its own blood supply.			Body Part, Organ, or Organ Component	
C127815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127815>	C2124	Iodine I 125 RISAD-P|(125) IRISAD-P|125IRISAD-P|5-[125I]iodo-3'-O-(17b-succinyl-5a-androstan-3-one)-2'-deoxyuridin-5'-yl Monophosphate|I 125 RISAD-P|RISAD-P I-125|[125]I-5-Radioiodo-3'-O-(17beta-succinyl-5alpha-androstan-3-one)-2'-deoxyuridin-5'-yl Phosphate|[125]I-RISAD-P	A radioconjugate containing an androgen receptor (AR) targeting agent, 5-radioiodo-3'-O-(17beta-succinyl-5alpha-androstan-3-one)-2'-deoxyuridin-5'-yl phosphate (RISAD-P), labeled with the radioisotope iodine I 125 ([125]I-RISAD-P), with potential use as an imaging agent for single photon emission computed tomography (SPECT) imaging. Upon administration, iodine I 125 RISAD-P selectively binds to and is taken up by AR. Upon SPECT imaging, AR-expressing tumor cells can be imaged and AR expression levels can be assessed. AR, which is overexpressed on certain tumor cells, plays key roles in tumor cell growth and survival.	Iodine I 125 RISAD-P		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C127816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127816>	C4822	WHO Grade 3 Glioma|Anaplastic Glioma|WHO Grade III Glioma|WHO Grade III Glioma	A group of malignant gliomas that includes anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and anaplastic ependymoma.	WHO Grade III Glioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C127817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127817>	C137990	Tapotoclax|AMG 176|TAPOTOCLAX	An inhibitor of induced myeloid leukemia cell differentiation protein MCL-1 (myeloid cell leukemia-1), with potential pro-apoptotic and antineoplastic activities. Upon administration, tapotoclax binds to and inhibits the activity of MCL-1. This disrupts the formation of MCL-1/Bcl-2-like protein 11 (BCL2L11; BIM) complexes and induces apoptosis in tumor cells. MCL-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival.	Tapotoclax		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C127818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127818>	C15215	Cryoballoon Ablation Therapy	An image-guided, minimally invasive surgical technique that uses a balloon-tipped catheter to deliver cryogenic energy to targeted tissue, resulting in cell death secondary to cryogenic injury.	Cryoballoon Ablation Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C127819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127819>	C122785	Subcutaneous Emphysema	The presence of air or gas in subcutaneous tissue.			Finding	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology
C127820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127820>	C127819	Orbital Emphysema	The presence of air or gas in the subcutaneous tissue of the orbit of the eye.			Finding	
C127821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127821>	C35552	Arterial Insufficiency	A condition in which there is inadequate blood flow through an artery.			Finding	
C127822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127822>	C35552	Venous Insufficiency	A condition in which there is inadequate blood flow through a vein.			Finding	
C127823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127823>	C78551	Pharyngocutaneous Fistula	An abnormal communication between the skin and the pharynx.			Anatomical Abnormality	
C127824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127824>	C78506	Orocutaneous Fistula	An abnormal communication between the skin and the oral cavity.			Disease or Syndrome	
C127825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127825>	C78641	Tracheoarterial Fistula	An erosion through the tracheal wall into an artery.			Disease or Syndrome	
C127826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127826>	C49236	Decannulation|Tracheostomy Tube Removal	The process of removing a tracheostomy tube.			Therapeutic or Preventive Procedure	
C127827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127827>	C164158	Loss of Stoma|Loss of Puncture	The unplanned closing of a stoma.			Finding	
C127828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127828>	C36291	Sialocele	A fluid-filled cavity containing saliva.			Finding	
C127829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127829>	C122785	Pneumocephalus	The presence of air or gas within the cranial cavity.			Finding	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology
C12782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12782>	C32616	Rib|BONE, RIB|Bone structure of rib (body structure)|RIB|rib	Any one of the paired bones, 12 on either side, extending from the thoracic vertebrae toward the median line on the ventral aspect of the trunk. The long curved bones which form the rib cage. Generally, ribs 1 to 7 are connected to the sternum by their costal cartilages and are called true ribs, whereas ribs 8 to 12 are termed false ribs.	Rib		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|GDC Terminology|GDC Value Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C127831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127831>	C225418	Subdural	Beneath the dura mater.			Spatial Concept	
C127832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127832>	C27993	Unexpected	Something that is not planned or anticipated.			Qualitative Concept	
C127833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127833>	C27993	Unrecognized	Not identified from previous encounters or knowledge.			Qualitative Concept	
C127834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127834>	C12768	Marginal Mandibular Branch of the Facial Nerve	A branch of the facial nerve that innervates the musculature of the lower lip.			Body Part, Organ, or Organ Component	
C127835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127835>	C12768	Lingual Nerve	A branch of the mandibular division of the trigeminal nerve that supplies sensory innervation to the tongue.			Body Part, Organ, or Organ Component	
C127836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127836>	C357	Ceftazidime/Avibactam Sodium|Avycaz|CAZ-AVI|Ceftazidime-Avibactam Sodium	A combination preparation containing the third-generation cephalosporin ceftazidime and the sodium salt form of avibactam, a non-beta-lactam beta-lactamase inhibitor, with antibiotic and beta-lactamase inhibiting activity, respectively. Upon administration, ceftazidime binds to essential penicillin-binding proteins (PBPs) and inhibits cell wall synthesis in certain bacteria. Avibactam binds to and inactivates beta-lactamases, thereby protecting ceftazidime from degradation and increasing ceftazidime's efficacy.	Ceftazidime/Avibactam Sodium		Antibiotic|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C127837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127837>	C18485|C17558	Three-Dimensional Echo-Planar Spectroscopic Imaging|3D-EPSI|Volumetric Echo-Planar Spectroscopic Imaging	A three-dimensional application of magnetic resonance spectroscopic imaging that uses an alternating gradient applied along one of the spatial readout directions to simultaneously encode the space and chemical shift, thereby reducing the phase-encoding dimension by one and increasing speed.	Three-Dimensional Echo-Planar Spectroscopic Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C127838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127838>	C183052|C129818	Relacorilant|((4aR)-1-(4-Fluorophenyl)-6-(1-methyl-1H-pyrazole-4-sulfonyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone|CORT-125134|CORT125134|Lifyorli|Methanone, ((4aR)-1-(4-Fluorophenyl)-1,4,5,6,7,8-hexahydro-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4aH-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)-2-pyridinyl)-|RELACORILANT	An orally available antagonist of the glucocorticoid receptor (GR), with potential antineoplastic activity. Upon administration,  relacorilant competitively binds to and blocks GRs. This inhibits the activity of GRs, and prevents both the translocation of the ligand-GR complexes to the nucleus and gene expression of GR-associated genes. This decreases the negative effects that result from excess levels of endogenous glucocorticoids, like those seen when tumors overproduce glucocorticoids. In addition, by binding to GRs and preventing their activity, inhibition with CORT125134 also inhibits the proliferation of GR-overexpressing cancer cells. GRs are overexpressed in certain tumor cell types and promote tumor cell proliferation.	Relacorilant		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C127839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127839>	C308	Bevifimod|BEVIFIMOD|Highly Purified Staphylococcal Protein A PRTX-100|PRTX-100|SpA PRTX-100	A proprietary formulation containing a highly purified form of Staphylococcal protein A (SpA; protein A), with potential immunomodulating activity. Upon administration of bevifimod, this protein is able to specifically bind to both the subset of B-lymphocytes that express the heavy chain variable region 3 (VH3)-encoded immunoglobulin (Ig) (VH3-B-cells) and macrophages. This prevents B-cell activation, induces apoptosis, prevents VH3-derived antibody formation, antibody-mediated immune responses, and destruction by macrophages. This may modulate specific immune signaling pathways and restore normal immune system functions caused by certain immune-mediated inflammatory diseases.  In patients with the autoimmune-mediated disease immune thrombocytopenia (ITP), PRTX-100 prevents destruction of platelets, increases platelet production and platelet blood levels, and decreases the risk of bleeding. SpA, a 42 kDa bacterial membrane protein produced by Staphylococcus aureus bacteria, consists of five nearly identical Ig binding domains; each SpA domain binds with high affinity to the Igs containing regions encoded by the VH3 gene family. B-lymphocytes that express VH3-encoded Igs are specifically involved in various auto-immune diseases.	Bevifimod		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C12783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12783>	C32616	Scapula|BONE, SCAPULA|Bone structure of scapula (body structure)|SCAPULA|Shoulder Blade|Shoulder Blade|scapula|scapula|scapulae|shoulder blade	The flat triangle-shaped bone that connects the humerus with the clavicle in the back of the shoulder.	Scapula		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C127840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127840>	C8604|C80307	Recurrent Waldenstrom Macroglobulinemia	The reemergence of Waldenstrom macroglobulinemia after a period of remission.	Recurrent Waldenstrom Macroglobulinemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C127841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127841>	C26683	Abnormal PAP Smear|Abnormal PAP Test	A finding indicating the presence of abnormal cervical cells in a Pap smear.	Abnormal PAP Smear		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C127842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127842>	C20709	NR1I2 Gene|NR1I2|NR1I2|Nuclear Receptor Subfamily 1 Group I Member 2 Gene	This gene is involved in the regulation of genes that affect steroid and xenobiotic metabolism.	NR1I2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C127843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127843>	C127842	NR1I2 wt Allele|BXR|Nuclear Receptor Subfamily 1 Group I Member 2 wt Allele|Nuclear Receptor Subfamily 1, Group I, Member 2 Gene|ONR1|PAR|PAR1|PAR2|PARq|PRR|PXR|SAR|SXR	Human NR1I2 wild-type allele is located within 3q12-q13.3 and is approximately 38 kb in length. This allele, which encodes nuclear receptor subfamily 1 group I member 2 protein, plays a role in the regulation of both gene expression and steroid metabolism.	NR1I2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127844>	C17671	Nuclear Receptor Subfamily 1 Group I Member 2|NR1I2|Orphan Nuclear Receptor PAR1|Orphan Nuclear Receptor PXR|Pregnane X Nuclear Receptor|Pregnane X Receptor|Steroid and Xenobiotic Receptor	Nuclear receptor subfamily 1 group I member 2 (434 aa, ~50 kDa) is encoded by the human NR1I2 gene. This protein is involved in the metabolism of xenobiotics and steroids.	Nuclear Receptor Subfamily 1 Group I Member 2		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127845>	C20921	OPHN1 Gene|OPHN1|OPHN1|Oligophrenin 1 Gene	This gene plays a role in the mediation of GTP hydrolysis of Rho subfamily members.	OPHN1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C127846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127846>	C127845	OPHN1 wt Allele|ARHGAP41|MRX60|Mental Retardation, X-Linked 60 Gene|OPN1|Oligophrenin 1 wt Allele|Oligophrenin-1, Rho-GTPase Activating Protein Gene	Human OPHN1 wild-type allele is located in the vicinity of Xq12 and is approximately 392 kb in length. This allele, which encodes oligophrenin-1 protein, is involved in the regulation of small GTPase mediated signal transduction. Mutation of the gene is associated with X-linked mental retardation with cerebellar hypoplasia and distinctive facial dysmorhphism.	OPHN1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127848>	C17298	Oligophrenin-1|ARHGAP41|Oligophrenin 1|Rho GTPase-Activating Protein 41	Oligophrenin-1 (802 aa, ~92 kDa) is encoded by the human OPHN1 gene. This protein plays a role in GTP hydrolysis.	Oligophrenin-1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127849>	C25873	PAK3 Gene|PAK3|PAK3|p21 (RAC1) Activated Kinase 3 Gene	This gene is involved in signal transduction and the modulation of cell shape and cellular migration.	PAK3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C12784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12784>	C13019	Sclera|EYE, SCLERA|Human Sclera|SCLERA|White of Eye|sclera	The white, opaque, fibrous, outer tunic of the eyeball, covering it entirely excepting the segment covered anteriorly by the cornea. It is essentially avascular but contains apertures for vessels, lymphatics, and nerves. It receives the tendons of insertion of the extraocular muscles and at the corneoscleral junction contains the canal of Schlemm. (From Cline et al., Dictionary of Visual Science, 4th ed)	Sclera		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Structured Product Labeling Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|SPL Tissue Form Product Type Terminology
C127850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127850>	C127849	PAK3 wt Allele|ARA|MRX30|MRX47|Mental Retardation, X-Linked 47 Gene|OPHN3|PAK-3|PAK3beta|bPAK|beta-PAK|p21 (CDKN1A)-Activated Kinase 3 Gene|p21 (RAC1) Activated Kinase 3 wt Allele|p21 Protein (Cdc42/Rac)-Activated Kinase 3 Gene	Human PAK3 wild-type allele is located in the vicinity of Xq23 and is approximately 283 kb in length. This allele, which encodes serine/threonine-protein kinase PAK 3 protein, plays a role in small G protein-mediated signaling. Mutation of the gene is associated with X-linked mental retardation type 30/47.	PAK3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127851>	C17325	Serine/Threonine-Protein Kinase PAK 3|Beta-PAK|EC 2.7.11.1|Oligophrenin 3|Oligophrenin-3|PAK-3|PAK3|PAK3beta|p21 CDC42/RAC1-Activated Kinase 3|p21-Activated Kinase 3|p21-Activated Kinase-3|p21-Activated Protein Kinase 3	Serine/threonine-protein kinase PAK 3 (559 aa, ~62 kDa) is encoded by the human PAK3 gene. This protein is involved in the phosphorylation-dependent modulation of signal transduction.	Serine/Threonine-Protein Kinase PAK 3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127852>	C26003	PCSK1 Gene|PCSK1|PCSK1|Proprotein Convertase Subtilisin/Kexin Type 1 Gene	This gene plays a role in the metabolism of prohormones and neuropeptides.	PCSK1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C127853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127853>	C127852	PCSK1 wt Allele|BMIQ12|NEC1|PC1|PC3|Proprotein Convertase Subtilisin/Kexin Type 1 wt Allele|SPC3	Human PCSK1 wild-type allele is located within 5q15-q21 and is approximately 44 kb in length. This allele, which encodes neuroendocrine convertase 1 protein, is involved in the activation of neuropeptides and protein hormones. Mutation of the gene is associated with proprotein convertase 1/3 deficiency and increased susceptibility to obesity.	PCSK1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127854>	C17123	Neuroendocrine Convertase 1|EC 3.4.21.93|NEC 1|PC1|PCSK1|Prohormone Convertase 1|Proprotein Convertase 1|Proprotein Convertase Subtilisin/Kexin Type 1|Proprotein Convertase Subtilisin/Kexin-Type 1	Neuroendocrine convertase 1 (753 aa, ~84 kDa) is encoded by the human PCSK1 gene. This protein plays a role in the proteolytic activation of protein hormones and neuropeptides.	Neuroendocrine Convertase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127855>	C26110	PRMT5 Gene|PRMT5|PRMT5|Protein Arginine Methyltransferase 5 Gene	This gene is involved in both histone methylation and the formation of omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA).	PRMT5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|Pediatric Oncology Biomarkers/Targets Associated with Other Relevant Evidence
C127856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127856>	C127855	PRMT5 wt Allele|HRMT1L5|Histone Synthetic Lethal 7, S. cerevisiae, Homolog of Gene|IBP72|ICLN-Binding Protein, 72-kD Gene|JBP1|Protein Arginine Methyltransferase 5 wt Allele|SHK1 Kinase-Binding Protein 1, S. pombe, Homolog of Gene|SKB1|SKB1 Homolog (S. pombe) Gene|SKB1Hs|Skb1 (S. pombe) Homolog Gene	Human PRMT5 wild-type allele is located in the vicinity of 14q11.2 and is approximately 9 kb in length. This allele, which encodes protein arginine N-methyltransferase 5 protein, plays a role in arginine metabolism.	PRMT5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127857>	C16849	Protein Arginine N-Methyltransferase 5|72 kDa ICln-Binding Protein|EC 2.1.1.125|EC 2.1.1.320|HMT1 HnRNP Methyltransferase-Like 5|Histone-Arginine N-Methyltransferase PRMT5|Jak-Binding Protein 1|Protein Arginine Methyltransferase 5|SKB1 Homolog|SKB1Hs|Shk1 Kinase-Binding Protein 1 Homolog	Protein arginine N-methyltransferase 5 (637 aa, ~73 kDa) is encoded by the human PRMT5 gene. This protein is involved in the methylation of arginine.	Protein Arginine N-Methyltransferase 5		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Biomarkers/Targets Associated with Other Relevant Evidence
C127858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127858>	C28533	SLC31A1 Gene|SLC31A1|SLC31A1|Solute Carrier Family 31 Member 1 Gene	This gene plays a role in copper transport.	SLC31A1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C127859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127859>	C127858	SLC31A1 wt Allele|COPT1|CTR1|Copper Transport 1 Homolog (S. cerevisiae) Gene|Solute Carrier Family 31 (Copper Transporter), Member 1 Gene|Solute Carrier Family 31 (Copper Transporters), Member 1 Gene|Solute Carrier Family 31 Member 1 wt Allele	Human SLC31A1 wild-type allele is located in the vicinity of 9q32 and is approximately 43 kb in length. This allele, which encodes high affinity copper uptake protein 1, is involved in transmembrane copper ion transport.	SLC31A1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12785>	C12470	Scrotum|SCROTUM|Scrotal structure (body structure)|Scrotum, NOS|scrotum|scrotum	The musculocutaneous pouch that encloses the testicles.	Scrotum		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C127860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127860>	C16386	High Affinity Copper Uptake Protein 1|Copper Transport 1 Homolog|Copper Transporter 1|Solute Carrier Family 31 Member 1|hCTR1	High affinity copper uptake protein 1 (190 aa, ~21 kDa) is encoded by the human SLC31A1 gene. This protein plays a role in copper ion transport.	High Affinity Copper Uptake Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127861>	C217122	Combs Prognostic Index	A prognostic index developed to predict the outcome of reirradiation for recurrent glioma. The index accounts for histology, patient age, and time between initial radiation and re-irradiation.			Intellectual Product	
C127862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127862>	C20194	SMN1 Gene|SMN1|SMN1|Survival of Motor Neuron 1, Telomeric Gene	This gene plays a role in assembly of small nuclear ribonucleoproteins.	SMN1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C127863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127863>	C127861	Excellent Survival after Reirradiation|Combs Score 0	A score of 0 on the Combs Prognostic Index scale.			Intellectual Product	Combs Prognostic Index
C127864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127864>	C127862	SMN1 wt Allele|BCD541|GEMIN1|SMA|SMA1|SMA2|SMA3|SMA4|SMN|SMNT|Spinal Muscular Atrophy (Werdnig-Hoffmann Disease, Kugelberg-Welander Disease) Gene|Survival Motor Neuron 1 Protein Gene|Survival of Motor Neuron 1 Gene|Survival of Motor Neuron 1, Telomeric wt Allele|Survival of Motor Neuron, Telomeric Copy Gene|T-BCD541|TDRD16A|Tudor Domain Containing 16A Gene	Human SMN1 wild-type allele is located in the vicinity of 5q13.2 and is approximately 29 kb in length. This allele, which encodes survival motor neuron protein, is involved in the modulation of spliceosome assembly. Mutation of the gene is associated with spinal muscular atrophy types 1 through 4.	SMN1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127865>	C127861	Good Survival after Reirradiation|Combs Score 1	A score of 1 on the Combs Prognostic Index scale.			Intellectual Product	Combs Prognostic Index
C127866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127866>	C127861	Moderate Survival after Reirradiation|Combs Score 2	A score of 2 on the Combs Prognostic Index scale.			Intellectual Product	Combs Prognostic Index
C127867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127867>	C20194	SMN2 Gene|SMN2|SMN2|Survival of Motor Neuron 2, Centromeric Gene	This gene plays a role in the modulation of spliceosome formation.	SMN2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C127868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127868>	C127861	Poor Survival after Reirradiation|Combs Score 3	A score of 3 on the Combs Prognostic Index scale.			Intellectual Product	Combs Prognostic Index
C127869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127869>	C127867	SMN2 wt Allele|BCD541|C-BCD541|GEMIN1|SMNC|Survival of Motor Neuron 2, Centromeric wt Allele|Survival of Motor Neuron, Centromeric Copy Gene|TDRD16B|Tudor Domain Containing 16B Gene	Human SMN2 wild-type allele is located in the vicinity of 5q13.2 and is approximately 29 kb in length. This allele, which encodes survival motor neuron protein, is involved in the assembly of small nuclear ribonucleoproteins. Mutation of the gene is associated with sporadic adult-onset lower motor neuron disease (LMND) and a modified form of spinal muscular atrophy type 3.	SMN2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12786>	C12688	Lunate Bone|LUNATE BONE|Lunate|Semilunar Bone	The bone in the proximal row of carpal bones that lies between the scaphoid and triquetral bones.	Lunate Bone		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127870>	C127861	Very Poor Survival after Reirradiation|Combs Score 4	A score of 4 on the Combs Prognostic Index scale.			Intellectual Product	Combs Prognostic Index
C127871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127871>	C18466	Survival Motor Neuron Protein|Component of Gems 1|Gemin-1	Survival motor neuron protein (294 aa, ~32 kDa) is encoded by the human SMN1 and SMN2 genes. This protein plays a role in the assembly of small nuclear ribonucleoproteins.	Survival Motor Neuron Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127872>	C217122	European Treatment Outcome Study Score|EUTOS|European Treatment Outcome Study (EUTOS) Score	A method for assessing prognosis for patients with chronic myeloid leukemia. Patients are classified as a high or low risk on the basis of the percentage of basophils in the peripheral blood and spleen size at diagnosis.			Intellectual Product	
C127873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127873>	C217122	Hasford Score|Hasford	A method for assessing prognosis for patients with chronic myeloid leukemia. Patients are classified as a high, medium, or low risk on the basis of age, spleen size, and eosinophil, basophil, and platelet counts.			Intellectual Product	
C127874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127874>	C20194	MSLNL Gene|MSLNL|MSLNL|Mesothelin-Like Gene	This gene may be involved in cell-matrix adhesion.	MSLNL Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C127875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127875>	C217122	Sokal Score|Sokal	A method for assessing prognosis for patients with chronic myeloid leukemia. The numerical value is calculated at diagnosis from the percentage of blast cells in peripheral blood, the platelet count, the spleen size, and the age of the patient.			Intellectual Product	
C127876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127876>	C127874	MSLNL wt Allele|C16orf37|Chromosome 16 Open Reading Frame 37 Gene|MPFL|Mesothelin-Like wt Allele	Human MSLNL wild-type allele is located in the vicinity of 16p13.3 and is approximately 14 kb in length. This allele, which encodes mesothelin-like protein, may play a role in cell adhesion.	MSLNL wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127877>	C217121	International Scale for BCR-ABL1 Measurement|IS|International Scale|International Scale for Quantitative BCR-ABL1 Result Reporting	A scale established in 2005 to standardize quantitative BCR-ABL1 measurements across tests and laboratories, so as to facilitate interlaboratory studies, patient portability, and a harmonized definition of treatment response.			Intellectual Product	
C127878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127878>	C18466	Mesothelin-Like Protein|MPF-Like|Pre-Pro-Megakaryocyte-Potentiating-Factor-Like	Mesothelin-like protein (702 aa, ~75 kDa) is encoded by the human MSLNL gene. This protein may be involved in cell adhesion.	Mesothelin-Like Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127879>	C17003	Consensus PCR|Consensus Polymerase Chain Reaction	Polymerase chain reaction that uses primers designed to amplify sequences from a group of genetically related targets, using specific or degenerate primer sets.			Laboratory Procedure	
C12787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12787>	C13018	Seminal Vesicle|GLAND, SEMINAL VESICLE|SEMINAL VESICLE|Seminal Sacs|Seminal Sacs|Seminal Vesicles|Seminal vesicle structure (body structure)|seminal vesicle|seminal vesicle	One of the two paired glands in the male genitourinary system, posterior to the bladder and superior to the prostate gland, that produces fructose-rich seminal fluid which is a component of semen. These glands join the ipsilateral ductus deferens to form the ejaculatory duct.	Seminal Vesicle		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C127880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127880>	C17003	Nested PCR|NESTED POLYMERASE CHAIN REACTION|Nested Polymerase Chain Reaction	Polymerase chain reaction that uses two sets of primers, in two sequential runs of amplification, with the second set intended to amplify a target within the first run product.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127881>	C713	Allele-Specific Oligonucleotide|ASO|Allele-specific oligonucleotide	An oligonucleotide designed to be specific for only one allele of a gene.			Nucleic Acid, Nucleoside, or Nucleotide	
C127882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127882>	C26006	SNAP25 Gene|SNAP25|SNAP25|Synaptosomal Associated Protein 25kDa Gene	This gene plays a role in neurotransmitter release and plasma membrane recycling.	SNAP25 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C127883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127883>	C127882	SNAP25 wt Allele|CMS18|RIC-4|RIC4|Resistance To Inhibitors of Cholinesterase 4 Homolog Gene|SEC9|SNAP|SNAP-25|SUP|Synaptosomal Associated Protein 25kDa wt Allele|Synaptosomal-Associated Protein, 25-kD Gene|Synaptosomal-Associated Protein, 25kD Gene|Synaptosomal-Associated Protein, 25kDa Gene|bA416N4.2|dJ1068F16.2	Human SNAP25 wild-type allele is located within 20p12-p11.2 and is approximately 89 kb in length. This allele, which encodes synaptosomal-associated protein 25, is involved in vesicular trafficking, neurotransmitter release and plasma membrane recycling. Mutation of the gene may be associated with congenital myasthenic syndrome-18 and certain polymorphisms may be linked to attention deficit-hyperactivity disorder.	SNAP25 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127884>	C16386	Synaptosomal-Associated Protein 25|SNAP-25|SUP|Super Protein|Synaptosomal-Associated 25 kDa Protein	Synaptosomal-associated protein 25 (206 aa, ~23 kDa) is encoded by the human SNAP25 gene. This protein plays a role in vesicular transport.	Synaptosomal-Associated Protein 25		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127885>	C25997	SPHKAP Gene|SPHK1 Interactor, AKAP Domain Containing Gene|SPHKAP|SPHKAP	This gene is involved in the modulation of cAMP- and sphingosine-mediated signaling.	SPHKAP Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C127886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127886>	C127885	SPHKAP wt Allele|KIAA1678|SKIP|SPHK1 (Sphingosine Kinase Type 1) Interacting Protein Gene|SPHK1 Interactor, AKAP Domain Containing wt Allele|SPHK1 Interactor, AKAP Domain-Containing Gene	Human SPHKAP wild-type allele is located in the vicinity of 2q36 and is approximately 202 kb in length. This allele, which encodes A-kinase anchor protein SPHKAP, plays a role in the regulation of protein kinase A-dependent signaling.	SPHKAP wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127887>	C26231	A-Kinase Anchor Protein SPHKAP|SPHK1-Interacting Protein|SPHK1-Interactor and AKAP Domain-Containing Protein|Sphingosine Kinase Type 1-Interacting Protein	A-kinase anchor protein SPHKAP (1700 aa, ~186 kDa) is encoded by the human SPHKAP gene. This protein is involved in the regulation of signaling mediated by protein kinase A and by sphingosine kinase 1.	A-Kinase Anchor Protein SPHKAP		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127888>	C25870	SPTLC1 Gene|SPTLC1|SPTLC1|Serine Palmitoyltransferase, Long Chain Base Subunit 1 Gene	This gene plays a role in lipid modification.	SPTLC1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C127889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127889>	C127888	SPTLC1 wt Allele|HSAN1|HSN1|Hereditary Sensory Neuropathy, Type 1 Gene|LBC1|LCB1|SPT1|SPTI|Serine Palmitoyltransferase, Long Chain Base Subunit 1 wt Allele|Serine Palmitoyltransferase, Long-Chain Base Subunit 1 Gene	Human SPTLC1 wild-type allele is located in the vicinity of 9q22.2 and is approximately 84 kb in length. This allele, which encodes serine palmitoyltransferase 1 protein, is involved in the metabolism of lipids. Mutation of the gene is associated with hereditary sensory neuropathy type IA.	SPTLC1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12788>	C25769	Skeletal System|Skeleton|skeletal|skeleton	The collection of bones and tissues, including ligaments and cartilage, that compose the rigid internal framework of the human body, and which serves a multitude of functions, including structural support, movement, protection, production of blood cells, storage of ions, and endocrine regulation.	Skeletal System		Body System	
C127890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127890>	C16259	Serine Palmitoyltransferase 1|EC 2.3.1.50|LCB 1|Long Chain Base Biosynthesis Protein 1|SPT 1|SPT1|Serine C-Palmitoyltransferase|Serine-Palmitoyl-CoA Transferase 1	Serine palmitoyltransferase 1 (473 aa, ~53 kDa) is encoded by the human SPTLC1 gene. This protein plays a role in the biosynthesis of sphingolipids.	Serine Palmitoyltransferase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127891>	C25939	SUMF1 Gene|SUMF1|SUMF1|Sulfatase Modifying Factor 1 Gene	This gene is involved in the activation of sulfatase.	SUMF1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C127892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127892>	C127891	SUMF1 wt Allele|AAPA3037|FGE|PSEC0152|Sulfatase Modifying Factor 1 wt Allele|UNQ3037|UNQ3037/PRO9852	Human SUMF1 wild-type allele is located in the vicinity of 3p26.1 and is approximately 766 kb in length. This allele, which encodes sulfatase-modifying factor 1 protein, plays a role in the positive regulation of sulfatase activity. Mutation of the gene is associated with multiple sulfatase deficiency.	SUMF1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127893>	C16946	Sulfatase-Modifying Factor 1|C-Alpha-Formylglycine-Generating Enzyme 1|EC 1.8.99.-|FGly-Generating Enzyme|Sulfatase Modifying Factor 1	Sulfatase-modifying factor 1 (374 aa, ~41 kDa) is encoded by the human SUMF1 gene. This protein is involved in sulfatase oxidation.	Sulfatase-Modifying Factor 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127894>	C25939	TH Gene|TH|TH|Tyrosine Hydroxylase Gene	This gene plays a role in dopamine biosynthesis.	TH Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C127895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127895>	C127894	TH wt Allele|DYT14|DYT5b|Dystonia 14 Gene|TYH|Tyrosine Hydroxylase wt Allele	Human TH wild-type allele is located in the vicinity of 11p15.5 and is approximately 8 kb in length. This allele, which encodes tyrosine 3-monooxygenase protein, is involved in tyrosine metabolism. Mutation of the gene is associated with autosomal recessive Segawa syndrome.	TH wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127896>	C16865	Tyrosine 3-Monooxygenase|EC 1.14.16.2|TH|Tyrosine 3-Hydroxylase	Tyrosine 3-monooxygenase (528 aa, ~59 kDa) is encoded by the human TH gene. This protein plays a role in the synthesis of dopamine from L-tyrosine.	Tyrosine 3-Monooxygenase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127897>	C21295	TIA1 Gene|TIA1|TIA1|TIA1 Cytotoxic Granule-Associated RNA Binding Protein Gene	This gene is involved in nucleolysis, RNA binding and alternative splicing.	TIA1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C127898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127898>	C127897	TIA1 wt Allele|P40-TIA-1 (Containing P15-TIA-1) Gene|TIA-1|TIA1 Cytotoxic Granule-Associated RNA Binding Protein wt Allele|TIA1 Cytotoxic Granule-Associated RNA-Binding Protein Gene|WDM	Human TIA1 wild-type allele is located in the vicinity of 2p13 and is approximately 39 kb in length. This allele, which encodes nucleolysin TIA-1 isoform p40, plays a role in both RNA binding and splicing. Mutation of the gene is associated with Welander distal myopathy.	TIA1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127899>	C21298	Nucleolysin TIA-1 Isoform p40|P40-TIA-1|RNA-Binding Protein TIA-1|T-Cell-Restricted Intracellular Antigen-1|TIA-1	Nucleolysin TIA-1 isoform p40 (386 aa, ~43 kDa) is encoded by the human TIA1 gene. This protein is involved in RNA binding, alternative splicing, translational regulation and nucleolysis.	Nucleolysin TIA-1 Isoform p40		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12789>	C34076	Skull|BONE, SKULL|Bone structure of cranium (body structure)|Bone, Skull|Cranium|Cranium|Cranium|Cranium|Cranium|SKULL|Skull Bone|skull	The bones that form the head, made up of the bones of the braincase and face.	Skull		Body Part, Organ, or Organ Component	ALL Authorized Value Terminology|ALL Radiation Therapy Table|AML Authorized Value Terminology|AML Radiation Therapy Table|CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|GDC Terminology|GDC Value Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C1278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1278>	C265	Venlafaxine|VENLAFAXINE|venlafaxine	A synthetic phenethylamine bicyclic derivative with antidepressant activity. Venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV), are potent inhibitors of neuronal serotonin and norepinephrine reuptake and weak dopamine reuptake inhibitors.  This agent may reduce hormone-related vasomotor symptoms. (NCI04)	Venlafaxine		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C127900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127900>	C1904	Topoisomerase-1 Inhibitor LMP744|5H-(1,3)Dioxolo(5,6)indeno(1,2-C)isoquinoline-5,12(6H)-dione, 6-(3-((2-Hydroxyethyl)amino)propyl)-2,3-dimethoxy-|Indenoisoquinoline LMP744|LMP-744|LMP-744|LMP744	An indenoisoquinoline derivative and topoisomerase 1 (Top1) inhibitor, with potential antineoplastic activity. Upon administration, LMP744 binds to and stabilizes cleaved DNA-Top1 complexes, which prevents DNA re-ligation, induces stable, irreversible DNA strand breaks, prevents DNA repair, and leads to cell cycle arrest and apoptosis. As tumor cells proliferate at a much higher rate than normal cells, LMP744 specifically targets cancer cells. Top1, a DNA modifying enzyme essential for transcription, replication, and repair of double-strand DNA breaks, is overexpressed in tumor cells.	Topoisomerase-1 Inhibitor LMP744		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C127901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127901>	C21165	TNFRSF13B Gene|TNFRSF13B|TNFRSF13B|Tumor Necrosis Factor Receptor Superfamily Member 13B Gene	This gene plays a role in cytokine-dependent signaling and lymphocyte activation.	TNFRSF13B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C127902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127902>	C127901	TNFRSF13B wt Allele|CD267|CVID|CVID2|IGAD2|RYZN|TACI|TNFRSF14B|Tumor Necrosis Factor Receptor Superfamily Member 13B wt Allele|Tumor Necrosis Factor Receptor Superfamily, Member 13B Gene	Human TNFRSF13B wild-type allele is located in the vicinity of 17p11.2 and is approximately 42 kb in length. This allele, which encodes tumor necrosis factor receptor superfamily member 13B protein, is involved in ligand-mediated signaling and immunity.	TNFRSF13B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127903>	C19285	Tumor Necrosis Factor Receptor Superfamily Member 13B|CD267 Antigen|TACI|TNFRSF13B|Transmembrane Activator and CAML Interactor|Tumor Necrosis Factor Receptor 13B	Tumor necrosis factor receptor superfamily member 13B (293 aa, ~32 kDa) is encoded by the human TNFRSF13B gene. This protein plays a role in cytokine binding and lymphocyte activation.	Tumor Necrosis Factor Receptor Superfamily Member 13B		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127904>	C4056	Cervical Transitional Metaplasia	Cervical metaplasia in which the cervical squamous epithelium resembles benign urothelium as a result of a lack of cellular maturation.			Finding	
C127906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127906>	C164001|C129822	Anti-Met Monoclonal Antibody Mixture Sym015|Hu9006-Hu9338|Hu9006/Hu9338|Sym 015|Sym-015|Sym015	A mixture of two humanized immunoglobulin G1 (IgG1) monoclonal antibodies, Hu9006 and Hu9338, which recognize non-overlapping epitopes in the extracellular domain of the human hepatocyte growth factor receptor (MET; HGFR; c-Met), with potential antineoplastic activity. Upon administration, anti-MET monoclonal antibody mixture Sym015 targets and binds to the extracellular domain of MET, thereby preventing the binding of its ligand, hepatocyte growth factor (HGF). This may prevent activation of the receptor and MET-mediated signal transduction pathways. This inhibits MET-dependent tumor cell proliferation. MET, a receptor tyrosine kinase, is overexpressed on the cell surfaces of various solid tumor cell types; it plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.	Anti-Met Monoclonal Antibody Mixture Sym015		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C127907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127907>	C27677	Endocervical Adenocarcinoma, Usual-Type|Adenocarcinoma, Endocervical Type|Adenocarcinoma, endocervical type|Cervical Adenocarcinoma, Usual Type|Cervical Adenocarcinoma, Usual-Type|Cervical Mucinous Adenocarcinoma, Endocervical Type|Cervical Mucinous Adenocarcinoma, Endocervical-Type|Endocervical Adenocarcinoma, Usual Type|Endocervical adenocarcinoma usual type|Mucinous adenocarcinoma, endocervical type|UEA	A cervical adenocarcinoma in which 0-50% of malignant cells contain intracytoplasmic mucin. It is the most common subtype of cervical adenocarcinoma and represents 75% of all invasive cervical adenocarcinomas. The neoplastic epithelium shows a pseudostratified architecture and the malignant cells have enlarged, elongated, and hyperchromatic nuclei. Historically, usual-type cervical adenocarcinomas were termed "endocervical-type".	Endocervical Adenocarcinoma, Usual-Type		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Morphology PT Terminology|Mapped ICDO3.1 Morphology Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C127908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127908>	C210691	Alanylglutamine|AG|ALANYL GLUTAMINE|Ala-Gln|Alanyl-glutamine|L-alanyl-L-glutamine|L-alanyl/L-glutamine|N(2)-L-Alanyl-L-glutamine|Sustamine	A nutritional supplement containing a stable, water-soluble dipeptide comprised of the amino acids L-glutamine and L-alanine, with potential protective and absorption enhancing activities. Upon oral or enteral administration, alanylglutamine works locally in the gastrointestinal (GI) tract to both protect the integrity of the intestinal mucosa and maintain intestinal barrier functions. This reduces bacterial translocation, the risk of infection, infection-induced inflammatory damage and infection-associated symptoms, such as diarrhea, dehydration, malabsorption and electrolyte imbalances. Alanylglutamine also increases absorption of other chemicals, enhances epithelial repair, and inhibits apoptosis due to cellular damage, and stimulates cellular proliferation. Altogether, this improves absorption of nutrients, decreases weight loss, reduces diarrhea, decreases the risk of GI-associated infections and improves recovery. Upon absorption, alanylglutamine may also help inhibit muscle protein catabolism.	Alanylglutamine		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C127909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127909>	C25802	TRAP1 Gene|TNF Receptor Associated Protein 1 Gene|TRAP1|TRAP1	This gene is involved in protein folding and ATPase activity.	TRAP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C12790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12790>	C32881	Sphenoid Bone|SPHENOID BONE|Spheniod Bone|Sphenoid bone structure (body structure)	The butterfly-shaped bone located at the base of the skull that helps to form the orbit of the eye.	Sphenoid Bone		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C127910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127910>	C39619	pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine|WOKVAC|WOKVAC Vaccine|pUMVC3-IGFBP2-HER2-IGF1R|pUMVC3-IGFBP2-HER2-IGF1R Vaccine	A polyepitope plasmid DNA vaccine containing the mammalian expression vector pUMVC3 encoding epitopes derived from three tumor-associated antigens (TAAs): human insulin-like growth factor-binding protein 2 (IGFBP2), human epidermal growth factor receptor 2 (HER2; ERBB2) and insulin-like growth factor 1 receptor (IGF1R), with potential immunostimulating and antineoplastic activities. Upon intradermal vaccination, pUMVC3-IGFBP2-HER2-IGF1R plasmid DNA vaccine transfects local keratinocytes, which process the plasmid, express the epitopes and present them to antigen-presenting cells (APCs). This activates the immune system to mount a combined response from specific T helper type 1 (Th1) cells, memory T-cells and cytotoxic T-lymphocytes (CTL) against IGFBP2-, HER2-, and IGF1R-expressing tumor cells. IGFBP2, HER2, and IGF1R are tumor-associated proteins overexpressed in certain tumor cell types, and play key roles in cellular proliferation and survival.	pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine		Immunologic Factor|Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C127911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127911>	C127909	TRAP1 wt Allele|HSP 75|HSP75|HSP90L|TNF Receptor Associated Protein 1 wt Allele|TNFR-Associated Protein 1 Heat-Shock Protein, 75-kD Gene|TRAP-1	Human TRAP1 wild-type allele is located in the vicinity of 16p13.3 and is approximately 66 kb in length. This allele, which encodes heat shock protein 75 kDa, mitochondrial, plays a role in both ATPase activity and protein folding.	TRAP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127912>	C17764	Heat Shock Protein 75 kDa, Mitochondrial|HSP 75|HSP90-Like Protein|TNF Receptor-Associated Protein 1|TNFR-Associated Protein 1|TRAP-1|TRAP1|Tumor Necrosis Factor Type 1 Receptor-Associated Protein	Heat shock protein 75 kDa, mitochondrial (704 aa, ~80 kDa) is encoded by the human TRAP1 gene. This protein is involved in mitochondrial protein folding.	Heat Shock Protein 75 kDa, Mitochondrial		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127913>	C20420	TWIST2 Gene|TWIST2|TWIST2|Twist Family bHLH Transcription Factor 2 Gene	This gene plays a role in the negative regulation of both gene transcription and osteoblast differentiation.	TWIST2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C127914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127914>	C127913	TWIST2 wt Allele|AMS|BBRSAY|BHLHA39|DERMO1|Dermis-Expressed Protein 1, Mouse, Homolog of Gene|FFDD3|SETLSS|Twist Family bHLH Transcription Factor 2 wt Allele|Twist Homolog 2 (Drosophila) Gene|Twist, Drosophila, Homolog of, 2 Gene|bHLHa39	Human TWIST2 wild-type allele is located in the vicinity of 2q37.3 and is approximately 63 kb in length. This allele, which encodes twist-related protein 2, is involved in the modulation of osteogenesis. Mutation of the gene is associated with Ablepharon-macrostomia syndrome, Barber-Say syndrome, and Setleis type focal facial dermal dysplasia 3.	TWIST2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127915>	C66745|C4029	Cervical Adenocarcinoma Admixed with Neuroendocrine Carcinoma	A carcinoma that arises from the cervix and is characterized by the presence of a cervical adenocarcinoma variant and a neuroendocrine carcinoma component.			Neoplastic Process	GDC Terminology|GDC Value Terminology
C127916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127916>	C17207	Twist-Related Protein 2|Class A Basic Helix-Loop-Helix Protein 39|Dermis-Expressed Protein 1|Dermo-1|Twist Basic Helix-Loop-Helix Transcription Factor 2|Twist Homolog 2|Twist Related Protein 2|Twist-Related bHLH Protein Dermo1|bHLHa39	Twist-related protein 2 (160 aa, ~18 kDa) is encoded by the human TWIST2 gene. This protein plays a role in transcriptional regulation and osteogenesis.	Twist-Related Protein 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127917>	C26147	UGCG Gene|UDP-Glucose Ceramide Glucosyltransferase Gene|UGCG|UGCG	This gene is involved in glucosylceramide synthesis.	UGCG Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C127918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127918>	C127917	UGCG wt Allele|GCS|GLCT1|UDP-Glucose Ceramide Glucosyltransferase wt Allele	Human UGCG wild-type allele is located in the vicinity of 9q31 and is approximately 39 kb in length. This allele, which encodes ceramide glucosyltransferase protein, plays a role in glycosphingolipid synthesis.	UGCG wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127919>	C17434	Ceramide Glucosyltransferase|CERAMIDE GLUCOSYLTRANSFERASE|EC 2.4.1.80|GCS|GLCT-1|Glucosylceramide Synthase|UDP-Glucose Ceramide Glucosyltransferase|UDP-Glucose:N-Acylsphingosine D-Glucosyltransferase|UGCG	Ceramide glucosyltransferase (394 aa, ~45 kDa) is encoded by the human UGCG gene. This protein is involved in the glycosylation of N-acylsphingosine.	Ceramide Glucosyltransferase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C12791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12791>	C54024	Spinal Nerve Root|Spinal Nerve Roots|Spinal Roots	Either of the two initial segments of a spinal nerve, the dorsal sensory nerve root or the ventral motor nerve root; once emerged, the two fuse to form a single spinal nerve.	Spinal Nerve Root		Body Part, Organ, or Organ Component	
C127920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127920>	C117720	Tunnel Clusters	A benign lesion characterized by the presence of rounded, lobular aggregates of endocervical glands in the cervical wall.			Finding	
C127921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127921>	C20100	WNT5B Gene|WNT5B|WNT5B|Wnt family member 5B Gene	This gene plays a role in the modulation of Wnt-frizzled signaling pathways.	WNT5B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C127922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127922>	C127921	WNT5B wt Allele|Wingless-Type MMTV Integration Site Family, Member 5B Gene|Wnt family member 5B wt Allele	Human WNT5B wild-type allele is located in the vicinity of 12p13.3 and is approximately 117 kb in length. This allele, which encodes protein Wnt-5b, is involved in G protein-coupled receptor signaling.	WNT5B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127923>	C20394	Protein Wnt-5b|Wnt-5b|Wnt5b	Protein Wnt-5b (359 aa, ~40 kDa) is encoded by the human WNT5B gene. This protein plays a role in the initiation of G protein-coupled receptor signaling.	Protein Wnt-5b		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127924>	C25982	IL32 Gene|IL32|IL32|Interleukin 32 Gene	This gene is involved in cytokine-mediated immunity.	IL32 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C127925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127925>	C127924	IL32 wt Allele|IL-32alpha|IL-32beta|IL-32delta|IL-32gamma|Interleukin 32 wt Allele|NK4|Natural Killer Cell Transcript 4 Gene|TAIF|TAIFa|TAIFb|TAIFc|TAIFd	Human IL32 wild-type allele is located in the vicinity of 16p13.3 and is approximately 17 kb in length. This allele, which encodes interleukin-32 protein, plays a role in cytokine signaling.	IL32 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127926>	C20497	Interleukin-32|IL-32|IL32|Interleukin 32|Natural Killer Cells Protein 4|Tumor Necrosis Factor Alpha-Inducing Factor	Interleukin-32 (234 aa, ~27 kDa) is encoded by the human IL32 gene. This protein is involved in interleukin-dependent signaling.	Interleukin-32		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127927>	C26147	UGT1A Locus|GNT1|UDP Glucuronosyltransferase 1 Family, Polypeptide A Cluster|UDP Glucuronosyltransferase 1 Family, Polypeptide A Complex Locus|UDP Glucuronosyltransferase Family 1 Member A Complex Locus|UDP Glycosyltransferase 1 Family, Polypeptide A Cluster|UGT|UGT1|UGT1A|UGT1A|Uridine Phosphate Glycosyltransferase Family 1 Member A Locus	Human UGT1A gene locus is located in the vicinity of 2q37 and is approximately 188 kb in length. This locus includes nine protein-encoding genes and four pseudogenes. The protein-encoding genes are involved in glucuronidation of toxins, drugs and xenobiotics.	UGT1A Locus		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C127928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127928>	C54362	PRAME Gene|PRAME|PRAME|Preferentially Expressed Antigen in Melanoma Gene	This gene plays a role in the repression of retinoic acid receptor signaling.	PRAME Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|Pediatric Oncology Target Cell Lineage Determinant Terminology
C127929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127929>	C127928	PRAME wt Allele|CT130|MAPE|OIP-4|OIP4|Preferentially Expressed Antigen in Melanoma wt Allele	Human PRAME wild-type allele is located in the vicinity of 22q11.22 and is approximately 12 kb in length. This allele, which encodes melanoma antigen preferentially expressed in tumors protein, is involved in transcriptional repression. Aberrant expression of the gene is associated with melanoma and some acute leukemias.	PRAME wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12792>	C12466	Spinal Nerve|NERVE, SPINAL|Spinal Nerves|Spinal Roots	Paired nerves that arise from the spinal cord. In all, there are 31 pairs of spinal nerves located in the human body.	Spinal Nerve		Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C127930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127930>	C26199	Melanoma Antigen Preferentially Expressed in Tumors|Cancer/Testis Antigen 130|OIP-4|Opa-Interacting Protein 4|Opa-Interacting Protein OIP4|PRAME|Preferentially Expressed Antigen in Melanoma|Preferentially Expressed Antigen of Melanoma	Melanoma antigen preferentially expressed in tumors (509 aa, ~58 kDa) is encoded by the human PRAME gene. This protein plays a role in the repression of retinoic acid receptor-dependent gene expression.	Melanoma Antigen Preferentially Expressed in Tumors		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Cell Lineage Determinant Terminology
C127931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127931>	C82995	Cervical Microglandular Hyperplasia	A benign endocervical gland proliferation characterized by the presence of closely packed glands composed of columnar to cuboidal cells with subnuclear mucin vacuoles. It is associated with progestins or pregnancy.			Disease or Syndrome	
C127932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127932>	C82995	Lobular Endocervical Glandular Hyperplasia|Pyloric Gland Metaplasia	Lobular proliferations of benign-appearing small to moderate sized endocervical glands in the inner half of the cervical stroma. The glands are lined by columnar epithelial cells which contain pyloric gland-type mucin. There is minimal atypia and mitotic figures are rare. Some cases have been associated with adenocarcinoma in situ/high grade cervical glandular intraepithelial neoplasia and gastric-type adenocarcinomas.			Disease or Syndrome	
C127933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127933>	C82995	Diffuse Laminar Endocervical Hyperplasia	A benign band-like proliferation of tightly-packed, small to medium sized endocervical glands below the surface of the endocervical canal.			Disease or Syndrome	
C127934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127934>	C308	Microparticle MDP/Bacterial DNA-containing MIS416|MIS 416|MIS-416|MIS416|Microparticle MIS416	A microparticle combining two immune-modifying components derived from the bacterium Propionibacterium acnes, a bacterial cell wall component that is rich in muramyl dipeptide (MDP) and single-stranded bacteria-derived DNA fragments, with potential immunomodulating and immunoadjuvant activities. Upon administration of MIS416, this agent localizes in and is taken up mainly by the liver, thereby forming a liver depot. MIS416 is then taken up by immune cells, such as monocytes and dendritic cells (DCs), where MDP and the bacterial DNA target and bind to the cytosolic innate pattern recognition receptors (PRRs) nucleotide-binding oligomerization domain-containing protein 2 (NOD2), and toll-like receptor 9 (TLR9), respectively. The simultaneous binding and activation of both NOD2 and TLR9, leads to activation of both NOD2 and TLR9 signaling. This stimulates the innate immune system, induces secretion of cytokines, particularly interferon (IFN), and modulates the activation of various immune cells.  In the presence of tumor-associated antigens (TAAs), through simultaneous administration of a TAA-based vaccine, MIS416 modulates T-cell subsets and enhances the cytotoxic T lymphocyte (CTL)-mediated immune response against TAAs, resulting in an increased anti-tumor immune response. The combination of NOD2 and TLR9 agonists in MIS416 appears to activate different signaling pathways as compared to the administration of NOD2 and TLR9 agonists alone.	Microparticle MDP/Bacterial DNA-containing MIS416		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology
C127935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127935>	C117720	Cervical Mesonephric Remnants and Hyperplasia	The presence of embryonic remnants of mesonephric ducts in the cervix and their benign hyperplastic proliferations.			Finding	
C127936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127936>	C117720	Cervical Endocervicosis	A benign lesion characterized by the presence of endocervical-type glands in the outer half of the cervical wall.			Finding	
C127937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127937>	C4056	Tuboendometrioid Metaplasia	Replacement of the endocervical-type epithelium of the cervix by benign tubal or endometrioid epithelium.			Finding	
C127938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127938>	C132486|C117720	Ectopic Prostate Tissue in the Cervix|Ectopic Prostatic Tissue in the Cervix	Replacement of the endocervical epithelium with benign-appearing prostatic glands.			Finding	
C127939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127939>	C28676	NK Cell-enriched Donor Lymphocytes|NK Cell-enriched Allogeneic Lymphocytes	A preparation of donor-derived lymphocytes that are enriched for donor-derived natural killer (NK) cells, with direct tumor cytotoxic activity. Following allogeneic stem cell transplantation and subsequent infusion of the NK cell-enriched donor lymphocytes, these cells recognize and bind to tumor cells, upon which they secrete and release perforins, granzymes, and cytokines, which results in cancer cell lysis. Infusion of donor lymphocytes is limited by the risk of graft-versus-host disease (GVHD) and NK cells normally constitute only a small portion of circulating lymphocytes. Therefore, NK cell-enrichment may result in higher amounts of NK cells per infusion and improved anti-tumor immunity without increasing the risk of GVHD.	NK Cell-enriched Donor Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCIt Antineoplastic Agent Terminology
C12793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12793>	C32616	Sternum|BONE, STERNUM|STERNUM|Sterna|breastbone|sternum|sternum|vertebrate sternum	The long, flat bone connecting with the cartilages of the first seven ribs and the clavicle.	Sternum		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|GDC Terminology|GDC Value Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C127940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127940>	C126851	GAIA Premature Preterm Rupture of Membranes Levels of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Premature Preterm Rupture of Membranes Levels of Diagnostic Certainty	A classification of maternal and fetal outcomes relating to the assessment of premature preterm rupture of membranes, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C127941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127941>	C126851	GAIA Preterm Labor Levels of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Preterm Labor Levels of Diagnostic Certainty	A classification of maternal and fetal outcomes relating to the assessment of preterm labor, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C127942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127942>	C126851	GAIA Insufficient Cervix Levels of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Insufficient Cervix Levels of Diagnostic Certainty	A classification of maternal and fetal outcomes relating to the assessment of an insufficient cervix, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C127943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127943>	C126851	GAIA Provider Initiated Preterm Delivery Levels of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Provider Initiated Preterm Delivery Levels of Diagnostic Certainty	A classification of maternal and fetal outcomes relating to the assessment of provider initiated preterm delivery, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C127944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127944>	C127940	GAIA Level 1 Assessment of Premature Preterm Rupture of Membranes|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Assessment of Premature Preterm Rupture of Membranes|Level 1 Assessment of Premature Preterm Rupture of Membranes	GAIA Level 1 Assessment of Premature Preterm Rupture of Membranes is defined by five criteria: first, presentation between 24 0/7 and 36 6/7 weeks gestation with a clinical history of rupture of membranes, the fluid from which may be any color, including clear, blood-tinged, meconium-tinged (fetal stool), or purulent-tinged (yellowish, suggesting infection); second, the patient is determined to not be in preterm labor (having less than or equal to 4 contractions per hour documented clinically or on tocodynometer, with less than 2cm cervical dilation); third, visible leakage of fluid on vaginal speculum exam; fourth, one of the two following requirements must be met: a) Visible arborization (ferning) on microscopy of amniotic fluid; OR b) Ultrasound with oligohydramnios (amniotic fluid index (AFI) less than 5, or maximum vertical pocket (MVP) less than 2); fifth, documentation of the membrane rupture by one of the following diagnostic tests: a) Positive intra-amniotic dye-injection method; b) Positive result on amniotic fluid alpha-fetoprotein test kit; c) Amniotic fluid pH measurement (nitrazine paper test); d) Amniotic fluid placental alpha macroglobulin-1 protein assay (PAMG-1) test (AmniSure test); e) Amniotic fluid insulin-like growth factor binding protein (IGFBP-1) test (Actim PROM test).			Classification	GAIA Pathways to Preterm Birth Level of Diagnostic Certainty Terminology|GAIA Terminology
C127945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127945>	C127940	GAIA Level 2 Assessment of Premature Preterm Rupture of Membranes|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Assessment of Premature Preterm Rupture of Membranes|Level 2 Assessment of Premature Preterm Rupture of Membranes	GAIA Level 2 Assessment of Premature Preterm Rupture of Membranes is defined by four criteria: first, presentation between 24 0/7 and 36 6/7 weeks gestation with a clinical history of rupture of membranes, the fluid from which may be any color, including clear, blood-tinged, meconium-tinged (fetal stool), or purulent-tinged (yellowish, suggesting infection); second, the patient is determined to not be in preterm labor (having less than or equal to 4 contractions per hour documented clinically or on tocodynometer, with less than 2cm cervical dilation); third, visible leakage of fluid on vaginal speculum exam; fourth, one of the three following requirements must be met: a) Visible arborization (ferning) on microscopy of amniotic fluid; OR b) Ultrasound with oligohydramnios (amniotic fluid index (AFI) less than 5, or maximum vertical pocket (MVP) less than; OR c) documentation of the membrane rupture by one of the following diagnostic tests: 1) Positive intra-amniotic dye-injection method; 2) Positive result on amniotic fluid alpha-fetoprotein test kit; 3) Amniotic fluid pH measurement (nitrazine paper test); 4) Amniotic fluid placental alpha macroglobulin-1 protein assay (PAMG-1) test (AmniSure test); 5) Amniotic fluid insulin-like growth factor binding protein (IGFBP-1) test (Actim PROM test).			Classification	GAIA Pathways to Preterm Birth Level of Diagnostic Certainty Terminology|GAIA Terminology
C127946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127946>	C127940	GAIA Level 3 Assessment of Premature Preterm Rupture of Membranes|Global Alignment of Immunization safety Assessment in pregnancy Level 3 Assessment of Premature Preterm Rupture of Membranes|Level 3 Assessment of Premature Preterm Rupture of Membranes	GAIA Level 3 Assessment of Premature Preterm Rupture of Membranes is defined by three criteria: first, presentation between 24 0/7 and 36 6/7 weeks gestation with a clinical history of rupture of membranes, the fluid from which may be any color, including clear, blood-tinged, meconium-tinged (fetal stool), or purulent-tinged (yellowish, suggesting infection); second, the patient is determined to not be in preterm labor (having less than or equal to 4 contractions per hour documented clinically or on tocodynometer, with less than 2cm cervical dilation); third, visible leakage of presumed amniotic fluid, which may be on vaginal speculum examination (pooling in the vagina), on inspection of the perineum (wet perineum due to leakage of fluid from the vagina), or fluid soaked cloth/clothes/sanitary pad.			Classification	GAIA Pathways to Preterm Birth Level of Diagnostic Certainty Terminology|GAIA Terminology
C127947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127947>	C127941	GAIA Level 1 Assessment of Preterm Labor|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Assessment of Preterm Labor|Level 1 Assessment of Preterm Labor	GAIA Level 1 Assessment of Preterm Labor is defined by three criteria: first, confirmed delivery of a fetus between 24 0/7 and 36 6/7 weeks gestation; second, greater than four uterine contractions per hour as determined by a tocodynometer OR transvaginal ultrasound during a two hour period; third, documented change in length or dilation of the cervix by physical examination, with clinical criteria obtained by digital examination, including: a) Cervical dilation of two centimeters or more at the internal os; b) Cervical length of one centimeter or less; c) greater than or equal to 50% effacement of the cervix.			Classification	GAIA Pathways to Preterm Birth Level of Diagnostic Certainty Terminology|GAIA Terminology
C127948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127948>	C127941	GAIA Level 2 Assessment of Preterm Labor|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Assessment of Preterm Labor|Level 2 Assessment of Preterm Labor	GAIA Level 2 Assessment of Preterm Labor is defined by three criteria: first, confirmed delivery of a fetus between 24 0/7 and 36 6/7 weeks gestation; second, greater than four uterine contractions per hour as determined by a tocodynometer OR by clinical assessment; third, documented change in length or dilation of the cervix by physical examination, with clinical criteria obtained by digital examination, including: a) Cervical dilation of two centimeters or more at the internal os; b) Cervical length of one centimeter or less; c) greater than or equal to 50% effacement of the cervix.			Classification	GAIA Pathways to Preterm Birth Level of Diagnostic Certainty Terminology|GAIA Terminology
C127949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127949>	C127941	GAIA Level 3 Assessment of Preterm Labor|Global Alignment of Immunization safety Assessment in pregnancy Level 3 Assessment of Preterm Labor|Level 3 Assessment of Preterm Labor	GAIA Level 3 Assessment of Preterm Labor is defined by three criteria: first, confirmed delivery of a fetus between 24 0/7 and 36 6/7 weeks gestation; second, greater than four uterine contractions per hour as determined by clinical assessment; third, documented changes in cervical dilation or effacement during a two hour period.			Classification	GAIA Pathways to Preterm Birth Level of Diagnostic Certainty Terminology|GAIA Terminology
C12794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12794>	C12814	Subclavian Vein|SUBCLAVIAN VEIN|Structure of subclavian vein (body structure)	The vein that drains the axillary vein and joins the internal jugular vein to form the brachiocephalic vein. The subclavian vein runs parallel to the subclavian artery.	Subclavian Vein		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C127950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127950>	C127943	GAIA Level 1 Assessment of Provider Initiated Preterm Delivery|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Assessment of Provider-Initiated Preterm Delivery|Level 1 Assessment of Provider-Initiated Preterm Delivery	GAIA Level 1 Assessment of Provider-Initiated Preterm Delivery is defined by three criteria: first, the patient is determined to be between 24 0/7 and 36 6/7 weeks gestation; second, documentation in the healthcare record as noted by the delivering provider of the absence of any signs or symptoms of spontaneous onset of preterm labor; third, additional documentation of the need to induce labor or to perform a cesarean delivery, resulting in a preterm delivery.			Classification	GAIA Pathways to Preterm Birth Level of Diagnostic Certainty Terminology|GAIA Terminology
C127951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127951>	C127943	GAIA Level 2 Assessment of Provider Initiated Preterm Delivery|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Assessment of Provider-Initiated Preterm Delivery|Level 2 Assessment of Provider-Initiated Preterm Delivery	GAIA Level 2 Assessment of Provider-Initiated Preterm Delivery is defined by three criteria: first, the patient is determined to be between 24 0/7 and 36 6/7 weeks gestation; second, a report from the delivering provider, based on recall, that there were no signs or symptoms of the spontaneous onset of preterm labor; third, additional documentation of the need to induce labor or to perform a cesarean delivery, resulting in a preterm delivery.			Classification	GAIA Pathways to Preterm Birth Level of Diagnostic Certainty Terminology|GAIA Terminology
C127952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127952>	C127943	GAIA Level 3 Assessment of Provider Initiated Preterm Delivery|Global Alignment of Immunization safety Assessment in pregnancy Level 3 Assessment of Provider-Initiated Preterm Delivery|Level 3 Assessment of Provider-Initiated Preterm Delivery	GAIA Level 3 Assessment of Provider-Initiated Preterm Delivery is defined by three criteria: first, the patient is determined to be between 24 0/7 and 36 6/7 weeks gestation; second, from recall, the patient reports that there were no signs or symptoms of spontaneous onset of preterm labor; third, from recall, the patient reports that the healthcare provider indicated the need to induce labor or to perform a cesarean delivery between, resulting in preterm delivery.			Classification	GAIA Pathways to Preterm Birth Level of Diagnostic Certainty Terminology|GAIA Terminology
C127953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127953>	C127942	GAIA Level 1 Assessment of Insufficient Cervix|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Assessment of Insufficient Cervix|Level 1 Assessment of Insufficient Cervix	GAIA Level 1 Assessment of Insufficient Cervix is defined by two criteria: first, the following three requirements must all be met: a) Presentation between 16 and 23 6/7 weeks gestation; b) Advanced cervical dilation greater than two centimeters, resulting in either treatment with a cerclage (cervical stitch) or with preterm delivery; c) Less than or equal to four contractions per hour as documented by a tocodynometer, meaning the patient is not in preterm labor; second, dilation of the internal cervical os greater than two centimeters as determined by transvaginal ultrasound or digital examination.			Classification	GAIA Pathways to Preterm Birth Level of Diagnostic Certainty Terminology|GAIA Terminology
C127954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127954>	C127942	GAIA Level 2 Assessment of Insufficient Cervix|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Assessment of Insufficient Cervix|Level 2 Assessment of Insufficient Cervix	GAIA Level 2 Assessment of Insufficient Cervix is defined by two criteria: first, the following three requirements must be met: a) Presentation between 16 and 23 6/7 weeks gestation; b) Advanced cervical dilation greater than two centimeters, resulting in either treatment with a cerclage (cervical stitch) or preterm delivery; c) less than or equal to four contractions per hour as documented by a tocodynometer, meaning the patient is not in preterm labor; second, dilation of the internal cervical os greater than two centimeters as determined by digital examination.			Classification	GAIA Pathways to Preterm Birth Level of Diagnostic Certainty Terminology|GAIA Terminology
C127955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127955>	C127942	GAIA Level 3 Assessment of Insufficient Cervix|Global Alignment of Immunization safety Assessment in pregnancy Level 3 Assessment of Insufficient Cervix|Level 3 Assessment of Insufficient Cervix	GAIA Level 3 Assessment of Insufficient Cervix is defined by three criteria: first, the following three requirements must be met: a) Presentation between 16 and 23 6/7 weeks gestation; b) Advanced cervical dilation greater than two centimeters, resulting in either treatment with a cerclage (cervical stitch) or preterm delivery; c) less than or equal to four contractions per hour as documented by a tocodynometer, meaning the patient is not in preterm labor; second, patient reported fetal delivery without painful contractions; third, the patient's history excludes other causes of mid-second trimester delivery.			Classification	GAIA Pathways to Preterm Birth Level of Diagnostic Certainty Terminology|GAIA Terminology
C127956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127956>	C2849	Major Congenital Anomaly	A major congenital anomaly is a structural or functional defect with the following three characteristics: 1) Of prenatal origin; 2) Present at the time of live birth or fetal demise, or in utero; 3) Affecting (or has the propensity to affect) the health, survival, or physical or cognitive functioning of the individual.			Congenital Abnormality	GAIA Major Congenital Anomalies Level of Diagnostic Certainty Terminology|GAIA Terminology
C127957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127957>	C126842	GAIA Level 1 Major External Structural Defect|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Major External Structural Defect|Level 1 Major External Structural Defect	GAIA Level 1 Major External Structural Defect is defined by four criteria: first, the defects are of a prenatal origin; second, at least one of the following requirements must be met: a) Alterations in the external anatomy that are present and visible at the time of live birth, and that persist beyond the immediate peripartum period unless surgically repaired OR b) Alterations in the external anatomy that are present and visible in a stillbirth or in the products of conception of a spontaneous or therapeutic abortion; third, the defect(s) affect (or have the propensity to affect) the health, survival, or physical or cognitive functioning of the individual; fourth, there must be documented confirmation of a diagnosis made by a clinician who is both experienced in diagnosing congenital anomalies and who has the highest level of morphology training for the specific setting.			Classification	GAIA Major Congenital Anomalies Level of Diagnostic Certainty Terminology|GAIA Terminology
C127958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127958>	C126842	GAIA Level 2 Major External Structural Defect|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Major External Structural Defect|Level 2 Major External Structural Defect	GAIA Level 2 Major External Structural Defect is defined by four criteria: first, the defects are of a prenatal origin; second, at least one of the following requirements must be met: a) Alterations in the external anatomy that are present and visible at the time of live birth, and that persist beyond the immediate peripartum period unless surgically repaired OR b) Alterations in the external anatomy that are present and visible in a stillbirth or in the products of conception of a spontaneous or therapeutic abortion; third, the defect(s) affect (or have the propensity to affect) the health, survival, or physical or cognitive functioning of the individual; fourth,  there must be documented confirmation of a diagnosis made by a clinician with some experience diagnosing congenital anomalies.			Classification	GAIA Major Congenital Anomalies Level of Diagnostic Certainty Terminology|GAIA Terminology
C127959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127959>	C126842	GAIA Level 3 Major External Structural Defect|Global Alignment of Immunization safety Assessment in pregnancy Level 3 Major External Structural Defect|Level 3 Major External Structural Defect	GAIA Level 3 Major External Structural Defect is defined by four criteria: first, the defects are of a prenatal origin; second, at least one of the following requirements must be met: a) Alterations in the external anatomy that are present and visible at the time of live birth, and that persist beyond the immediate peripartum period unless surgically repaired OR b) Alterations in the external anatomy that are present and visible in a stillbirth or in the products of conception of a spontaneous or therapeutic abortion; third, the defect(s) affect (or have the propensity to affect) the health, survival, or physical or cognitive functioning of the individual; fourth, at least one of the following requirements must be met: a) Documented confirmation of a diagnosis made by a trained maternal or child health care provider with at least minimal experience diagnosing congenital anomalies; OR b) For live births, the diagnosis is confirmed using individual (ICD-9/ICD-10) codes or as part of an ICD-9/ICD-10 code based algorithm, for which the outcome (individual code or algorithm) has been validated.			Classification	GAIA Major Congenital Anomalies Level of Diagnostic Certainty Terminology|GAIA Terminology
C12795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12795>	C34060	Sympathetic Nervous System|SNS|sympathetic nervous system	The part of the autonomic nervous system comprising paired, paraspinal sympathetic trunks together with their branches, plexi, and subsidiary ganglia; it functions to mobilize the body for activity and opposes the physiological effects of the parasympathetic nervous system.	Sympathetic Nervous System		Body System	
C127960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127960>	C126842	GAIA Level 4 Major External Structural Defect|Global Alignment of Immunization safety Assessment in pregnancy Level 4 Major External Structural Defect|Level 4 Major External Structural Defect	GAIA Level 4 Major External Structural Defect is defined by four criteria: first, the defects are of a prenatal origin; second, at least one of the following requirements must be met: a) Alterations in the external anatomy that are present and visible at the time of live birth, and that persist beyond the immediate peripartum period unless surgically repaired OR b) Alterations in the external anatomy that are present and visible in a stillbirth or in the products of conception of a spontaneous or therapeutic abortion; third, the defect(s) affect (or have the propensity to affect) the health, survival, or physical or cognitive functioning of the individual; fourth, at least one of the following requirements must be met: a) Confirmation by medical record review; OR b) Confirmed in claims data (ICD-9/ICD-10 diagnoses).			Classification	GAIA Major Congenital Anomalies Level of Diagnostic Certainty Terminology|GAIA Terminology
C127961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127961>	C126842	GAIA Level 1 Major Internal Structural Defect|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Major Internal Structural Defect|Level 1 Major Internal Structural Defect	GAIA Level 1 Major Internal Structural Defect is defined by three criteria: first, the defects are prenatal in origin; second, the defect(s) affect (or have the propensity to affect) the health, survival, or physical or cognitive functioning of the individual; third, one of the following requirements must be met: a) For a live birth, alterations in the internal anatomy must be present at the time of live birth, must persist beyond the immediate peripartum period unless surgically repaired, and require confirmation of the diagnosis by definitive imaging study or intraoperative diagnosis; OR b) For a stillbirth, or for a spontaneous or therapeutic abortion, alterations in the internal anatomy must be detected during an autopsy, which are subsequently confirmed by documentation by a pathologist or other relevant subspecialist.			Classification	GAIA Major Congenital Anomalies Level of Diagnostic Certainty Terminology|GAIA Terminology
C127962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127962>	C126842	GAIA Level 2 Major Internal Structural Defect|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Major Internal Structural Defect|Level 2 Major Internal Structural Defect	GAIA Level 2 Major Internal Structural Defect is defined by three criteria: first, the defects are prenatal in origin; second, the defect(s) affect (or have the propensity to affect) the health, survival, or physical or cognitive functioning of the individual; third, one of the following requirements must be met: a) For a live birth, alterations in the internal anatomy must be present at the time of live birth, must persist beyond the immediate peripartum period unless surgically repaired, and require documented confirmation of a diagnosis made by a clinician who is experienced in diagnosing congenital anomalies, and who has the highest level of morphology training for the specific setting without using definitive imaging or intraoperative evaluation; OR b) For a stillbirth, or for a spontaneous or therapeutic abortion, an internal structural defect is visible prenatally either by ultrasound or by other imaging modality.			Classification	GAIA Major Congenital Anomalies Level of Diagnostic Certainty Terminology|GAIA Terminology
C127963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127963>	C126842	GAIA Level 3 Major Internal Structural Defect|Global Alignment of Immunization safety Assessment in pregnancy Level 3 Major Internal Structural Defect|Level 3 Major Internal Structural Defect	GAIA Level 3 Major Internal Structural Defect is defined by three criteria: first, the defects are prenatal in origin; second, the defect(s) affect (or have the propensity to affect) the health, survival, or physical or cognitive functioning of the individual; third, for a live birth, alterations in the internal anatomy must be present at the time of live birth, must persist beyond the immediate peripartum period unless surgically repaired, and must either a) Require documented confirmation of a diagnosis made by a clinician with some experience diagnosing congenital anomalies; OR b) Confirmation of a diagnosis using either individual (ICD-9/ICD-10) codes or as part of an ICD-9/ICD-10 code based algorithm, for which the outcome (individual code or algorithm) has been validated.			Classification	GAIA Major Congenital Anomalies Level of Diagnostic Certainty Terminology|GAIA Terminology
C127964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127964>	C126842	GAIA Level 4 Major Internal Structural Defect|Global Alignment of Immunization safety Assessment in pregnancy Level 4 Major Internal Structural Defect|Level 4 Major Internal Structural Defect	GAIA Level 4 Major Internal Structural Defect is defined by three criteria: first, the defects are prenatal in origin; second, the defect(s) affect (or have the propensity to affect) the health, survival, or physical or cognitive functioning of the individual; third, at least one of the following requirements must be met: a) Alterations in the internal anatomy that are present at the time of live birth, and that persist beyond the immediate peripartum period unless surgically repaired; OR b) Alterations in the internal anatomy that are present at the time of the stillbirth or of the spontaneous or therapeutic abortion; fourth, at least one of the following requirements must be met: a) Documented confirmation in the medical record that the anomaly was present at the time of live birth or at the time of fetal demise, and that the anomaly was diagnosed by a trained maternal or a child health care provider who has minimal experience diagnosing congenital anomalies; OR b) Confirmed by claims data (ICD-9/ICD-10 diagnoses).			Classification	GAIA Major Congenital Anomalies Level of Diagnostic Certainty Terminology|GAIA Terminology
C127965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127965>	C126842	GAIA Level 1 Major Functional Defect|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Major Functional Defect|Level 1 Major Functional Defect	GAIA Level 1 Major Functional Defect is defined by two criteria. first, at least one of the following requirements must be met: a) For live births, there must be alterations in functioning of one or more organs or body parts that are not due to a structural defect, that are present at the time of birth (or propensity to develop alteration present at live birth), and that persist beyond the immediate peripartum period unless treated through gene therapy or stem cell transplantation; OR b) For stillbirths or for spontaneous or therapeutic abortions, there must be alterations in the function of one or more organs or body parts that are not due to a structural defect; second, there must be confirmation of the defect(s) by definitive diagnostic study.			Classification	GAIA Major Congenital Anomalies Level of Diagnostic Certainty Terminology|GAIA Terminology
C127966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127966>	C126842	GAIA Level 2 Major Functional Defect|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Major Functional Defect|Level 2 Major Functional Defect	GAIA Level 2 Major Functional Defect is defined by two criteria: first, at least one of the following requirements must be met: a) For live births, there must be alterations in the functioning of one or more organs or body parts that are not due to a structural defect, that are present at live birth (or propensity to develop alteration present at live birth), and that persist beyond the immediate peripartum period, unless treated through gene therapy or stem cell transplantation; OR b) For stillbirths or for spontaneous or therapeutic abortions, there must be alterations in the function of one or more organs or body parts that are not due to a structural defect; second, there must be documented confirmation of a diagnosis made by a clinician who is experienced in diagnosing congenital anomalies, and who has the highest level of training in the diagnosis of functional defects for the specific setting.			Classification	GAIA Major Congenital Anomalies Level of Diagnostic Certainty Terminology|GAIA Terminology
C127967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127967>	C126842	GAIA Level 3 Major Functional Defect|Global Alignment of Immunization safety Assessment in pregnancy Level 3 Major Functional Defect|Level 3 Major Functional Defect	GAIA Level 3 Major Functional Defect is defined by two criteria: first, at least one of the following requirements must be met: a) For live births, there must be alterations in the functioning of one or more organs or body parts that are not due to a structural defect, that are present at live birth (or propensity to develop alteration present at live birth), and that persist beyond the immediate peripartum period, unless treated through gene therapy or stem cell transplantation; OR b) For stillbirths or spontaneous or therapeutic abortions, there must be alterations in the functioning of one or more organs or body parts that are not due to a structural defect; second, at least one of the following requirements must be met: a) Documented confirmation of a diagnosis made by a clinician who has some experience diagnosing functional defects; OR b) Confirmation of a diagnosis using either individual (ICD-9/ICD-10) codes or as part of an ICD-9/ICD-10 code based algorithm, for which the outcome (individual code or algorithm) has been validated.			Classification	GAIA Major Congenital Anomalies Level of Diagnostic Certainty Terminology|GAIA Terminology
C127968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127968>	C126842	GAIA Level 4 Major Functional Defect|Global Alignment of Immunization safety Assessment in pregnancy Level 4 Major Functional Defect|Level 4 Major Functional Defect	GAIA Level 4 Major Functional Defect is defined by two criteria: first, at least one of the following requirements must be met: a) For live births, there must be alterations in the functioning of one or more organs or body parts that are not due to a structural defect, that are present at the time of live birth (or propensity to develop alteration present at live birth), and that persist beyond the immediate peripartum period, unless treated through gene therapy or stem cell transplantation; OR b) For stillbirths or spontaneous or therapeutic abortions, there must be alterations in the function of one or more organs or body parts that are not due to a structural defect; second, at least one of the following requirements must be met: a) Documented confirmation in the medical record that the anomaly was present at the time of live birth or at the time of fetal demise, and that the anomaly was diagnosed by a trained maternal or child health care provider who is not a qualified geneticist, neonatologist, pathologist, subspecialist, pediatrician, obstetrician, or family medicine practitioner; OR b) Confirmation by claims data (ICD-9/ICD-10 diagnoses).			Classification	GAIA Major Congenital Anomalies Level of Diagnostic Certainty Terminology|GAIA Terminology
C127969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127969>	C126843	GAIA Level 1 Neonatal Death in a Non-viable Live Birth|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Neonatal Death in a Non-viable Live Birth|Level 1 Neonatal Death in a Non-viable Live Birth	GAIA Level 1 Neonatal Death in a Non-viable Live Birth is defined by three criteria: first, the infant must be live born; second, at least one of the following requirements must be met: a) Gestational age less than 22 weeks (a GA level of certainty of one); OR b) Birth weight less than 500g; third, the death of the infant within the first 28 days of life must be documented.			Classification	GAIA Neonatal Death Level of Diagnostic Certainty Terminology|GAIA Terminology
C12796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12796>	C33545|C13068	Tarsal Bone|BONE, TARSUS|Bone, Tarsal|TARSUS BONE|Tarsal Bones|Tarsals|Tarsus Bone	Any one of the seven bones forming the instep of the foot.	Tarsal Bones		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table
C127970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127970>	C126843	GAIA Level 2 Neonatal Death in a Non-viable Live Birth|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Neonatal Death in a Non-viable Live Birth|Level 2 Neonatal Death in a Non-viable Live Birth	GAIA Level 2 Neonatal Death in a Non-viable Live Birth is defined by three criteria: first, the infant must be live born; second, at least one of the following requirements must be met: a) Gestational age less than 22 weeks (where the GA level of certainty is either level one or level two) OR b) Birth weight less than 500g; third, the death of the infant within the first 28 days of life must be documented.			Classification	GAIA Neonatal Death Level of Diagnostic Certainty Terminology|GAIA Terminology
C127971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127971>	C126843	GAIA Level 3 Neonatal Death in a Non-viable Live Birth|Global Alignment of Immunization safety Assessment in pregnancy Level 3 Neonatal Death in a Non-viable Live Birth|Level 3 Neonatal Death in a Non-viable Live Birth	GAIA Level 3 Neonatal Death in a Non-viable Live Birth is defined by three criteria: first, the infant must be live born; second, the gestational age must be less than 5 months according to parent/family member/delivery attendant (a GA level of certainty of either level two or three); third, the death of the infant within the first 28 days of life must be documented.			Classification	GAIA Neonatal Death Level of Diagnostic Certainty Terminology|GAIA Terminology
C127972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127972>	C126843	GAIA Level 1 Neonatal Death in an Extremely Preterm Live Birth|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Neonatal Death in an Extremely Preterm Live Birth|Level 1 Neonatal Death in an Extremely Preterm Live Birth	GAIA Level 1 Neonatal Death in an Extremely Preterm Live Birth is defined by three criteria: first, the infant must be live born; second, at least one of the following requirements must be met: a) Gestational age greater than or equal to 22 weeks and less than 28 weeks (where the GA level of certainty is one); OR b) Birth weight greater than or equal to 500g but less than 1000g. Third, the death of the infant within the first 28 days of life must be documented.			Classification	GAIA Neonatal Death Level of Diagnostic Certainty Terminology|GAIA Terminology
C127973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127973>	C126843	GAIA Level 2 Neonatal Death in an Extremely Preterm Live Birth|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Neonatal Death in an Extremely Preterm Live Birth|Level 2 Neonatal Death in an Extremely Preterm Live Birth	GAIA Level 2 Neonatal Death in an Extremely Preterm Live Birth is defined by three criteria: first, the infant must be live born; second, at least one of the following requirements must be met: a) Gestational age greater than or equal to 22 and less than 28 weeks (where the GA level of certainty is either level one or level two) OR b) Birth weight greater than or equal to 500g but less than 1000g; third, the death of the infant within the first 28 days of life must be documented.			Classification	GAIA Neonatal Death Level of Diagnostic Certainty Terminology|GAIA Terminology
C127974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127974>	C126843	GAIA Level 3 Neonatal Death in an Extremely Preterm Live Birth|Global Alignment of Immunization safety Assessment in pregnancy Level 3 Neonatal Death in an Extremely Preterm Live Birth|Level 3 Neonatal Death in an Extremely Preterm Live Birth	GAIA Level 3 Neonatal Death in an Extremely Preterm Live Birth is defined by three criteria: first, the infant must be live born; second, the gestational age must be greater than or equal to 5 months but less than 7 months according to parent/family member/delivery attendant (a GA level of certainty of either level two or three); third, the death of the infant within the first 28 days of life must be documented.			Classification	GAIA Neonatal Death Level of Diagnostic Certainty Terminology|GAIA Terminology
C127975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127975>	C126843	GAIA Level 1 Neonatal Death in a Preterm Live Birth|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Neonatal Death in a Preterm Live Birth|Level 1 Neonatal Death in a Preterm Live Birth	GAIA Level 1 Neonatal Death in a Preterm Live Birth is defined by three criteria: first, the infant must be live born; second, at least one of the following requirements must be met: a) Gestational age greater than or equal to 28 weeks and less than 37 weeks (where the GA level of certainty is one); OR b) Birth weight greater than or equal to 1000g but less than 2500g; third, the death of the infant within the first 28 days of life must be documented.			Classification	GAIA Neonatal Death Level of Diagnostic Certainty Terminology|GAIA Terminology
C127976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127976>	C126843	GAIA Level 2 Neonatal Death in a Preterm Live Birth|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Neonatal Death in a Preterm Live Birth|Level 2 Neonatal Death in a Preterm Live Birth	GAIA Level 2 Neonatal Death in a Preterm Live Birth is defined by three criteria: first, the infant must be live born; second, at least one of the following requirements must be met: a) Gestational age greater than or equal to 28 and less than 37 weeks (where the GA level of certainty is either level one or level two); OR b) Birth weight greater than or equal to 1000g but less than 2500g; third, the death of the infant within the first 28 days of life must be documented.			Classification	GAIA Neonatal Death Level of Diagnostic Certainty Terminology|GAIA Terminology
C127977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127977>	C126843	GAIA Level 3 Neonatal Death in a Preterm Live Birth|Global Alignment of Immunization safety Assessment in pregnancy Level 3 Neonatal Death in a Preterm Live Birth|Level 3 Neonatal Death in a Preterm Live Birth	GAIA Level 3 Neonatal Death in a Preterm Live Birth is defined by three criteria: first, the infant must be live born; second, the gestational age must be greater than or equal to 7 months but less than 9 months according to parent/family member/delivery attendant (a GA level of certainty of either level two or three); third, the death of the infant within the first 28 days of life must be documented.			Classification	GAIA Neonatal Death Level of Diagnostic Certainty Terminology|GAIA Terminology
C127978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127978>	C126843	GAIA Level 1 Neonatal Death in a Term Live Birth|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Neonatal Death in a Term Live Birth|Level 1 Neonatal Death in a Term Live Birth	GAIA Level 1 Neonatal Death in a Term Live Birth is defined by four criteria: first, the infant must be live born; second, the gestational age must be greater than or equal to 37 weeks (a GA level of certainty of one); third, at least one of the following requirements must be met: a) Birth weight greater than 2500g; OR b) Documented intra-uterine growth retardation if weight is less than or equal to 2500g; fourth, the death of the infant within the first 28 days of life must be documented.			Classification	GAIA Neonatal Death Level of Diagnostic Certainty Terminology|GAIA Terminology
C127979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127979>	C126843	GAIA Level 2 Neonatal Death in a Term Live Birth|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Neonatal Death in a Term Live Birth|Level 2 Neonatal Death in a Term Live Birth	GAIA Level 2 Neonatal Death in a Term Live Birth is defined by three criteria: first, the infant must be live born; second, at least one of the following requirements must be met: a) Gestational age greater than or equal to 37 weeks (where the GA level of certainty is either level one or level two) OR b) Birth weight greater than or equal to 2500g; third, the death of the infant within the first 28 days of life must be documented.			Classification	GAIA Neonatal Death Level of Diagnostic Certainty Terminology|GAIA Terminology
C12797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12797>	C32881	Temporal Bone|TEMPORAL BONE|Temporal bone structure (body structure)	A large irregular bone situated at the base and side of the skull, connected with the mandible via the temporomandibular joint. The temporal bone consists of the squamous, tympanic and petrous parts. The petrous portion of the temporal bone contains the vestibulocochlear organ of the inner ear.	Temporal Bone		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table
C127980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127980>	C126843	GAIA Level 3 Neonatal Death in a Term Live Birth|Global Alignment of Immunization safety Assessment in pregnancy Level 3 Neonatal Death in a Term Live Birth|Level 3 Neonatal Death in a Term Live Birth	GAIA Level 3 Neonatal Death in a Term Live Birth is defined by three criteria: first, the infant must be live born; second, the gestational age must be greater than or equal to 9 months according to parent/ family member/delivery attendant (a GA level of certainty of either level two or three); third, the death of the infant within the first 28 days of life must be documented.			Classification	GAIA Neonatal Death Level of Diagnostic Certainty Terminology|GAIA Terminology
C127981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127981>	C126867	GAIA Level 1 Maternal Immunization|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Maternal Immunization|Level 1 Maternal Immunisation	GAIA Level 1 Maternal immunization is defined by three criteria: first, the pregnancy must be confirmed by either a positive pregnancy test or by ultrasound confirmation; second, the date/time of the immunization of the pregnant woman must be recorded in the medical records by the health care worker who administered/witnessed administration of vaccine; third, the details of vaccine must include the lot number and the date of immunization.			Classification	GAIA Neonatal Death Level of Diagnostic Certainty Terminology|GAIA Terminology
C127982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127982>	C126867	GAIA Level 2 Maternal Immunization|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Maternal Immunization|Level 2 Maternal Immunisation	GAIA Level 2 Maternal immunization is defined by three criteria: first, pregnancy must be confirmed by both the patient's report of cessation of menstrual period and by physical exam revealing a gravid uterus; second, the date (at least month and year) of the immunization of the pregnant woman must be recorded in the medical records by the health care worker who administered/witnessed administration of vaccine; third, the medical record must contain details of the disease against which the individual was vaccinated.			Classification	GAIA Neonatal Death Level of Diagnostic Certainty Terminology|GAIA Terminology
C127983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127983>	C126867	GAIA Level 3 Maternal Immunization|Global Alignment of Immunization safety Assessment in pregnancy Level 3 Maternal Immunization|Level 3 Maternal Immunisation	GAIA Level 3 Maternal immunization is defined by two criteria: first, the woman/medical attendant reports the pregnancy; second, the woman reports receipt of vaccination during pregnancy, but no formal recording of the immunization is available.			Classification	GAIA Neonatal Death Level of Diagnostic Certainty Terminology|GAIA Terminology
C127984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127984>	C126844	GAIA Level 1 Neonatal Invasive Bloodstream Infection|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Neonatal Invasive Blood Stream Infection|Level 1 Neonatal Blood Stream Infection	GAIA Level 1 Neonatal Invasive Bloodstream Infection is defined by two criteria: first, identification of a recognized pathogen from a normally sterile site using a validated method; second, if a normally non-pathogenic organism is isolated from blood cultures the following two requirements must be met: a) The cultures must be obtained from two different sites OR taken at two different times; b) One or more of the level 2 criteria must be present.			Classification	GAIA Neonatal Infections Level of Diagnostic Certainty Terminology|GAIA Terminology
C127985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127985>	C126844	GAIA Level 2 Neonatal Invasive Bloodstream Infection|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Neonatal Invasive Blood Stream Infection|Level 2 Neonatal Blood Stream Infection	GAIA Level 2 Neonatal Invasive Bloodstream Infection is defined by two criteria: first, the criteria does not meet the requirements for level 1 diagnostic certainty; second, three or more of the following requirements must be met: a) Temperature greater than or equal to 37.5 degrees C or less than 35.5 degrees C; b) Tachycardia or new or more frequent episodes of bradycardia; c) New or more frequent episodes of apnea or increased oxygen requirement or increased requirement for ventilatory support; d) Lethargy or moving only when stimulated or hypotonia or irritability; e) Difficulty in feeding or abdominal distention; f) Pallor or poor perfusion or hypotension; g) Abnormal white cell count or I/T (immature/total neutrophil) ratio greater than 0.2; h) Abnormal platelet count; i) Increased number of inflammatory markers (CRP, procalcitonin); j) Metabolic acidosis as defined by a base excess.			Classification	GAIA Neonatal Infections Level of Diagnostic Certainty Terminology|GAIA Terminology
C127986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127986>	C126844	GAIA Level 3 Neonatal Invasive Bloodstream Infection|Global Alignment of Immunization safety Assessment in pregnancy Level 3 Neonatal Invasive Blood Stream Infection|Level 3 Neonatal Blood Stream Infection	GAIA Level 3 Neonatal Invasive Bloodstream Infection is defined by two criteria: first, the criteria does not meet the requirements for level 1 or 2 diagnostic certainty; second, two or more of the following requirements must be met: a) Temperature greater than or equal to 37.5 degrees C or less than 35.5 degrees C; b) Tachypnea or severe chest indrawing or grunting or cyanosis; c) Change in level of activity; d) History of feeding difficulty; e) History of convulsions.			Classification	GAIA Neonatal Infections Level of Diagnostic Certainty Terminology|GAIA Terminology
C127987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127987>	C126844	GAIA Level 1 Neonatal Infectious Meningitis|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Neonatal Infectious Meningitis|Level 1 Neonatal Meningitis	GAIA Level 1 Neonatal Infectious Meningitis is defined by two criteria: first, the recognized pathogen must be identified, using a validated method, from cerebrospinal fluid (CSF); second, if an organism normally considered to be non-pathogenic is identified from the CSF, level 1 of diagnostic certainty additionally requires all level 2 criteria: i.e. CSF pleocytosis AND temperature criteria AND one or more clinical criteria.			Classification	GAIA Neonatal Infections Level of Diagnostic Certainty Terminology|GAIA Terminology
C127988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127988>	C126844	GAIA Level 2 Neonatal Infectious Meningitis|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Neonatal Infectious Meningitis|Level 2 Neonatal Meningitis	GAIA Level 2 Neonatal Infectious Meningitis is defined by four criteria: first, CSF pleocytosis OR positive IgM antibodies to a specific pathogen in the CSF; second, a recognized pathogen is identified, using a validated method from a normally sterile site other than the CSF; third, a temperature greater than or equal to 37.5 degrees C or less than 35.5 degrees C; fourth, one or more of the following requirements must be met: a) History of convulsions; b) Lethargy or irritability; c) Coma; d) Apnea; e) Bulging fontanel; f) Neck stiffness.			Classification	GAIA Neonatal Infections Level of Diagnostic Certainty Terminology|GAIA Terminology
C127989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127989>	C126844	GAIA Level 3a Neonatal Infectious Meningitis|Global Alignment of Immunization safety Assessment in pregnancy Level 3a Neonatal Infectious Meningitis|Level 3a Neonatal Bacterial/Fungal/Viral Meningitis	GAIA Level 3a Neonatal Infectious Meningitis is defined by four criteria: first, CSF pleocytosis; second, NO recognized pathogen is identified, using a validated method, from a normally sterile site; third, temperature greater than or equal to 37.5 degrees C or less than 35.5 degrees C; fourth, three or more of the following requirements must be met: a) History of convulsions; b) Lethargy or irritability; c) Coma; d) Apnea; e) Bulging fontanel; f) Neck stiffness.			Classification	GAIA Neonatal Infections Level of Diagnostic Certainty Terminology|GAIA Terminology
C12798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12798>	C12933	Thoracic Vertebra|Bone structure of thoracic vertebra (body structure)|THORACIC VERTEBRA|Thoracic Vertebrae	One of 12 vertebrae in the human vertebral column. The thoracic vertebrae are situated between the seventh cervical vertebra down to the first lumbar vertebra.	Thoracic Vertebrae		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C127990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127990>	C126844	GAIA Level 3b Neonatal Infectious Meningitis|Global Alignment of Immunization safety Assessment in pregnancy Level 3b Neonatal Infectious Meningitis|Level 3b Neonatal Meningitis	GAIA Level 3b Neonatal Infectious Meningitis is defined by three criteria: first, no lumbar puncture is done or no sample is available; second, temperature greater than or equal to 37.5 degrees C or less than 35.5 degrees C; third, four or more of the following requirements must be met: a) History of convulsions; b) Lethargy or irritability; c) Coma; d) Apnea; e) Bulging fontanel; f) Neck stiffness.			Classification	GAIA Neonatal Infections Level of Diagnostic Certainty Terminology|GAIA Terminology
C127991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127991>	C126844	GAIA Level 1 Neonatal Respiratory Tract Infection|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Neonatal Respiratory Tract Infection|Level 1 Neonatal Respiratory Tract Infection	GAIA Level 1 Neonatal Respiratory Tract Infection is defined by two criteria: first, a new or progressive or persistent infiltrate or shadowing or fluid in the intrapleural cavity or interlobar fissure on chest X-ray OR a recognized virus identified using a validated assay from an upper respiratory sample OR a recognized pathogen identified, using a validated method, from a normally sterile site; second, three or more of the following requirements must be met: a) Temperature greater than or equal to 37.5 degrees C or less than 35.5 degrees C; b) Tachypnea or nasal flaring or chest indrawing or grunting; c) Desaturations or increased oxygen requirements or increased ventilator requirements or oxygen saturation less than 95%; d) Apnea; e) Increased respiratory secretions or increased suctioning requirements; f) Cough, wheeze, or crepitations; g) Increased CRP or procalcitonin.			Classification	GAIA Neonatal Infections Level of Diagnostic Certainty Terminology|GAIA Terminology
C127992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127992>	C126844	GAIA Level 2 Neonatal Respiratory Tract Infection|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Neonatal Respiratory Tract Infection|Level 2 Neonatal Respiratory Tract Infection	GAIA Level 2 Neonatal Respiratory Tract Infection is defined by two criteria: first, new or progressive or persistent infiltrate or shadowing or fluid in the intrapleural cavity or interlobar fissure on chest X-ray; second, four or more of the following requirements must be met: a) Temperature greater than or equal to 37.5 degrees C or less than 35.5 degrees C; b) Tachypnea or nasal flaring or chest indrawing or grunting; c) Desaturations or increased oxygen requirements or increased ventilator requirements or oxygen saturation less than 95%; d) Apnea; e) Increased respiratory secretions or increased suctioning requirements; f) Cough, wheeze, or crepitations; g) Increased CRP or procalcitonin.			Classification	GAIA Neonatal Infections Level of Diagnostic Certainty Terminology|GAIA Terminology
C127993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127993>	C126844	GAIA Level 3 Neonatal Respiratory Tract Infection|Global Alignment of Immunization safety Assessment in pregnancy Level 3 Neonatal Respiratory Tract Infection|Level 3 Neonatal Respiratory Tract Infection	GAIA Level 3 Neonatal Respiratory Tract Infection is defined by the presence of two or more of the following criteria: a) Difficulty in breathing/tachypnea; b) Severe chest indrawing; c) Nasal flaring; d) Grunting; e) Wheeze; f) Stridor.			Classification	GAIA Neonatal Infections Level of Diagnostic Certainty Terminology|GAIA Terminology
C127994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127994>	C126847	GAIA Level 1 Non-reassuring Fetal Status|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Non-reassuring Fetal Status|Level 1 Non-reassuring Fetal Status	GAIA Level 1 Non-reassuring Fetal Status is defined by two criteria: first, a Category III fetal heart rate tracing detected via continuous cardiotocography as defined by the NICHD; second, one of the following two conditions must be met: a) an absent baseline fetal heart rate variability AND any of the following: recurrent late decelerations, recurrent variable deceleration, bradycardia (less than 110 bpm); OR b) a sinusoidal pattern; third, umbilical cord blood analysis that is consistent with metabolic acidosis (pH less than 7.0 and a base deficit greater than 12mmol/L).			Classification	GAIA Non-Reassuring Fetal Status Level of Diagnostic Certainty Terminology|GAIA Terminology
C127995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127995>	C126847	GAIA Level 2 Non-reassuring Fetal Status|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Non-reassuring Fetal Status|Level 2 Non-reassuring Fetal Status	GAIA Level 2 Non-reassuring Fetal Status is defined by the presence of at least one of the following two criteria: first, a category III fetal heart rate tracing detected via continuous cardiotocography as defined by NICHD; second, one of the following two conditions must be met: a) an absent baseline fetal heart rate variability AND any of the following: recurrent late decelerations, recurrent variable deceleration, bradycardia (less than 110 bpm); OR b) a sinusoidal pattern.			Classification	GAIA Non-Reassuring Fetal Status Level of Diagnostic Certainty Terminology|GAIA Terminology
C127996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127996>	C126847	GAIA Level 3 Non-reassuring Fetal Status|Global Alignment of Immunization safety Assessment in pregnancy Level 3 Non-reassuring Fetal Status|Level 3 Non-reassuring Fetal Status	GAIA Level 3 Non-reassuring Fetal Status is defined by the presence of the following criteria: A fetal heart pattern that is detected via intermittent auscultation, and that is suggestive of fetal hypoxia, including the following requirements that must be met: a) Baseline fetal heart rate less than 110 bpm or greater than 160 bpm; b) Presence of repetitive or prolonged (greater than 3 minutes) decelerations; c) More than five contractions in a ten minute period.			Classification	GAIA Non-Reassuring Fetal Status Level of Diagnostic Certainty Terminology|GAIA Terminology
C127997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127997>	C126848	GAIA Level 1 Maternal Death|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Maternal Death|Level 1 Maternal Death	GAIA Level 1 Maternal Death is defined by three criteria: first, diagnosis of a pregnancy as established by any one of the following documented requirements: a) Ultrasound examination; b) Fetal heart tones; c) Positive serum or urine human chorionic gonadotropin pregnancy test; d) Delivery of a neonate or other products of conception (abortus, stillborn); second, the death of the mother while pregnant or within 42 days of the termination of a pregnancy, irrespective of the duration and the site of the pregnancy; third, documentation of the maternal cause of death as one of the following: a) Direct: abortive outcome, hypertensive disorder, obstetric hemorrhage, pregnancy related infection, other obstetric complications, unanticipated complications; b) Indirect: non obstetric complications; c) Death during pregnancy, childbirth, and the puerperium: other or coincidental.			Classification	GAIA Maternal Death Level of Diagnostic Certainty Terminology|GAIA Terminology
C127998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127998>	C126848	GAIA Level 2 Maternal Death|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Maternal Death|Level 2 Maternal Death	GAIA Level 2 Maternal Death is defined by three criteria: first, diagnosis of a pregnancy, in the absence of level 1 criteria, as established by either of the following requirements: a) last menstrual period date; b) Serial symphysio fundal height examinations; second, death of the mother while pregnant or within 42 days of termination of pregnancy, irrespective of the duration and the site of the pregnancy; third, documentation of the maternal cause of death wherein one of the following requirements must be met: a) Direct: abortive outcome, hypertensive disorder, obstetric hemorrhage, pregnancy related infection, other obstetric complications, unanticipated complications; b) Indirect: non obstetric complications; c) Death during pregnancy, childbirth, and the puerperium: other or coincidental; d) Unspecified: unknown or undetermined.			Classification	GAIA Maternal Death Level of Diagnostic Certainty Terminology|GAIA Terminology
C127999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C127999>	C126848	GAIA Level 3 Maternal Death|Global Alignment of Immunization safety Assessment in pregnancy Level 3 Maternal Death|Level 3 Maternal Death	GAIA Level 3 Maternal Death is defined by three criteria: first, the absence of level 1 or level 2 criteria for establishing diagnosis of pregnancy, and both the uncertainty of the individual's last menstrual period date and no documented clinical examination; second, death of the mother temporal to pregnancy, childbirth, or the postpartum period when exact timing of death is unknown; third, documentation of the maternal cause of death wherein one of the following requirements must be met: a) Direct: abortive outcome, hypertensive disorder, obstetric hemorrhage, pregnancy related infection, other obstetric complications, unanticipated complications; b) Indirect: non-obstetric complications; c) Death during pregnancy, childbirth, and the puerperium: other or coincidental; d) Unspecified: unknown or undetermined.			Classification	GAIA Maternal Death Level of Diagnostic Certainty Terminology|GAIA Terminology
C12799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12799>	C12680	Thorax|THORAX|Thorax, NOS|anterolateral part of thorax|chest|front of thorax|pectus|ventral part of thoracic region	The division of the body lying between the neck and the abdomen.	Thorax		Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C1279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1279>	C2311|C2143	Pingyangmycin|BLEOMYCIN A5|Bleomycetin|Bleomycin A5|N1-(3-((4-Aminobutyl)amino)propyl)bleomycinamide|Zhengguangmycin A5	The naturally-occurring bleomycin antineoplastic antibiotic isolated from the bacterium Streptomyces pingyangensisn.  Pingyangmycin induces tumor cell apoptosis, possibly via a mechanism mediated by the mitogen-activated protein kinase (MAPK) pathway. (NCI04)			Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C128000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128000>	C126849	GAIA Level 1 Postpartum Hemorrhage|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Postpartum Hemorrhage|Level 1 Postpartum Haemorrhage	GAIA Level 1 Postpartum Hemorrhage is the presence of genital bleeding after delivery, leading to severe maternal outcome (maternal death or maternal near miss) as defined by WHO.			Classification	GAIA Postpartum Hemorrhage Level of Diagnostic Certainty Terminology|GAIA Terminology
C128001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128001>	C126849	GAIA Level 2 Postpartum Hemorrhage|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Postpartum Hemorrhage|Level 2 Postpartum Haemorrhage	GAIA Level 2 Postpartum Hemorrhage is defined by the presence of the following criteria: genital bleeding after delivery with at least one of the following: a) Measured abnormal bleeding (1000ml or more); or b) Any bleeding leading to hypotension or blood transfusion.			Classification	GAIA Postpartum Hemorrhage Level of Diagnostic Certainty Terminology|GAIA Terminology
C128002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128002>	C126849	GAIA Level 3 Postpartum Hemorrhage|Global Alignment of Immunization safety Assessment in pregnancy Level 3 Postpartum Hemorrhage|Level 3 Postpartum Haemorrhage	GAIA Level 3 Postpartum Hemorrhage is defined by the presence of genital bleeding after delivery that is estimated at 1000ml or more.			Classification	GAIA Postpartum Hemorrhage Level of Diagnostic Certainty Terminology|GAIA Terminology
C128003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128003>	C126850	GAIA Level 1 Preeclampsia|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Preeclampsia|Level 1 Preeclampsia	GAIA Level 1 Preeclampsia is defined by three criteria: first, the gestational age of the pregnancy must be greater than or equal to 20 weeks; second, a diagnosis of new onset maternal hypertension (systolic blood pressure greater than or equal to 140mmHg and/or diastolic blood pressure greater than or equal to 90mmHg) that is sustained on two measurements over a minimum of one hour; third, a diagnosis of new onset proteinuria that is a level one diagnostic certainty (proteinuria diagnosed with greater than or equal to 300 mg of protein during 24 hour urine collection OR greater than or equal to 0.3 for spot protein:creatinine ratio.)			Classification	GAIA Preeclampsia Level of Diagnostic Certainty Terminology|GAIA Terminology
C128004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128004>	C126850	GAIA Level 2 Preeclampsia|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Preeclampsia|Level 2 Preeclampsia	GAIA Level 2 Preeclampsia is defined by three criteria: first, the gestational age of the pregnancy must be greater than or equal to 20 weeks; second, a diagnosis of new onset maternal hypertension (systolic blood pressure greater than or equal to 140mmHg and/or diastolic blood pressure greater than or equal to 90mmHg) that is sustained on two measurements for a minimum of one hour; third, a diagnosis of new onset proteinuria that is a level 2 diagnostic certainty (proteinuria diagnosed with greater than or equal to 1+ protein on urine dipstick).			Classification	GAIA Preeclampsia Level of Diagnostic Certainty Terminology|GAIA Terminology
C128005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128005>	C126850	GAIA Insufficient Evidence for Diagnosis of Preeclampsia|Global Alignment of Immunization safety Assessment in pregnancy Insufficient Evidence for Diagnosis of Preeclampsia|Insufficient Evidence for Preeclampsia	GAIA Insufficient Evidence for Diagnosis of Preeclampsia is defined as a pregnancy with gestational age greater than or equal to 20 weeks and either a) The inability to measure blood pressure OR b) The inability to evaluate for proteinuria.			Classification	GAIA Preeclampsia Level of Diagnostic Certainty Terminology|GAIA Terminology
C128006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128006>	C126850	GAIA Level 1 Preeclampsia with Severe Features|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Preeclampsia with Severe Features|Level 1 Preeclampsia with Severe Features	GAIA Level 1 Preeclampsia with Severe Features is defined by three criteria: first, the gestational age of the pregnancy must be greater than or equal to 20 weeks; second, a diagnosis of new onset maternal hypertension (systolic blood pressure greater than or equal to 140mmHg and/or diastolic blood pressure greater than or equal to 90mmHg) that is sustained on two measurements over a minimum of one hour); third, the presence of one or more of the following requirements: a) Systolic blood pressure greater than or equal to 160mmHg and/or diastolic blood pressure greater than or equal to 110mmHg, which is confirmed after only minutes; b) Development of severe, persistent headache; c) Development of visual changes; d) Eclampsia; e) New onset thrombocytopenia (platelets less than 100,000/microliter); f) New onset unremitting epigastric pain; g) AST and ALT elevated to twice the upper limit of normal; h) Evidence of liver capsular hematoma or liver rupture (diagnosed on clinical exam or with imaging); i) Worsening renal function, as evidenced by serum creatinine level greater than 1.1 mg/dL, a doubling of the serum creatinine (absent other renal disease), or oliguria (less than 500 cc/24 hours); j) Pulmonary edema (confirmed on either imaging with chest x-ray or on clinical exam).			Classification	GAIA Preeclampsia Level of Diagnostic Certainty Terminology|GAIA Terminology
C128007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128007>	C126850	GAIA Level 2 Preeclampsia with Severe Features|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Preeclampsia with Severe Features|Level 2 Preeclampsia with Severe Features	GAIA Level 2 Preeclampsia with Severe Features is defined by three criteria: first, the gestational age of the pregnancy must be greater than or equal to 20 weeks; second, a diagnosis of new onset maternal hypertension (systolic blood pressure greater than or equal to 140mmHg and/or diastolic blood pressure greater than or equal to 90mmHg) that is sustained on two measurements for a minimum of one hour; third, the diagnosis of new onset nausea and vomiting.			Classification	GAIA Preeclampsia Level of Diagnostic Certainty Terminology|GAIA Terminology
C128008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128008>	C126850	GAIA Insufficient Evidence for Diagnosis of Preeclampsia with Severe Features|Global Alignment of Immunization safety Assessment in pregnancy Insufficient Evidence for Diagnosis of Preeclampsia with Severe Features|Insufficient Evidence for Preeclampsia with Severe Features	GAIA Insufficient Evidence for Diagnosis of Preeclampsia with Severe Features is a pregnancy with a gestational age greater than or equal to 20 weeks and the inability to measure blood pressure.			Classification	GAIA Preeclampsia Level of Diagnostic Certainty Terminology|GAIA Terminology
C128009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128009>	C126850	GAIA Level 1 Gestational Hypertension|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Gestational Hypertension|Level 1 Gestational Hypertension	GAIA Level 1 Gestational Hypertension is defined by four criteria: first, the gestational age of the pregnancy must be greater than or equal to 20 weeks; second, a diagnosis of new onset maternal hypertension (systolic blood pressure greater than or equal to 140mmHg and/or diastolic blood pressure greater than or equal to 90mmHg) that is sustained on two measurements over a minimum of one hour; third, the absence of any severe features (see preeclampsia with severe features category); fourth, the absence of proteinuria (as defined by 24 hour urine collection less than 300 mg, and spot protein:creatinine ratio less than 0.3).			Classification	GAIA Preeclampsia Level of Diagnostic Certainty Terminology|GAIA Terminology
C12800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12800>	C33003|C12982	Tibia|BONE, TIBIA|TIBIA|shankbone|shinbone|shinbone|tibia|tibia	A bone located between the femur and the tarsus, being part of the lower leg.	Tibia		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C128010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128010>	C126850	GAIA Level 2 Gestational Hypertension|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Gestational Hypertension|Level 2 Gestational Hypertension	GAIA Level 2 Gestational Hypertension is defined by four criteria: first, the gestational age of the pregnancy must be greater than or equal to 20 weeks; second, a diagnosis of new onset maternal hypertension (systolic blood pressure greater than or equal to 140mmHg and/or diastolic blood pressure greater than or equal to 90mmHg) that is sustained on two measurements for a minimum of one hour; third, the absence of any severe features (see preeclampsia with severe features category); fourth, the absence of proteinuria (as defined by urine dipstick result of negative or trace).			Classification	GAIA Preeclampsia Level of Diagnostic Certainty Terminology|GAIA Terminology
C128011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128011>	C126850	GAIA Insufficient Evidence for Diagnosis of Gestational Hypertension|Global Alignment of Immunization safety Assessment in pregnancy Insufficient Evidence for Diagnosis of Gestational Hypertension|Insufficient Evidence for Gestational Hypertension	GAIA Insufficient Evidence for Diagnosis of Gestational Hypertension is defined by two criteria: first, a pregnancy with gestational age greater than or equal to 20 weeks; second, one or more of the following requirements: a) The inability to measure blood pressure; b) The inability to evaluate for proteinuria.			Classification	GAIA Preeclampsia Level of Diagnostic Certainty Terminology|GAIA Terminology
C128012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128012>	C126845	GAIA Gestational Age Levels of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Gestational Age Levels of Diagnostic Certainty	A classification of gestational age levels developed by the Global Alignment of Immunization safety Assessment in pregnancy.			Classification	
C128013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128013>	C128012	GAIA Level 1 Assessment of Gestational Age|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Assessment of Gestational Age|Level 1 Assessment of Prematurity and Gestational Age	GAIA Level 1 Assessment of Gestational Age is defined by the presence of at least one of the following criteria: a) the last menstrual period (LMP) or intrauterine insemination (IUI) date or embryo transfer (ET) date with confirmatory first trimester scan (less than or equal to 13 6/7 weeks); OR b) first trimester scan (less than or equal to 13 6/7 weeks).			Classification	GAIA Preterm Birth Level of Diagnostic Certainty Terminology|GAIA Terminology
C128014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128014>	C128012	GAIA Level 2a Assessment of Gestational Age|Global Alignment of Immunization safety Assessment in pregnancy Level 2a Assessment of Gestational Age|Level 2a Assessment of Prematurity and Gestational Age	GAIA Level 2a Assessment of Gestational Age is defined by the presence of at least one of the following criteria: a) Certain last menstrual period (LMP) date with second trimester scan (14 0/7 weeks to 27 6/7 weeks), (If LMP and ultrasound (U/S) do not correlate, default to U/S GA assessment); OR b) Certain LMP date with first trimester physical examination.			Classification	GAIA Preterm Birth Level of Diagnostic Certainty Terminology|GAIA Terminology
C128015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128015>	C128012	GAIA Level 2b Assessment of Gestational Age|Global Alignment of Immunization safety Assessment in pregnancy Level 2b Assessment of Gestational Age|Level 2b Assessment of Prematurity and Gestational Age	GAIA Level 2b Assessment of Gestational Age is defined by the following criteria: uncertain last menstrual period (LMP) date with second trimester scan (14 0/7 weeks to 27 6/7 weeks).			Classification	GAIA Preterm Birth Level of Diagnostic Certainty Terminology|GAIA Terminology
C128016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128016>	C128012	GAIA Level 3a Assessment of Gestational Age|Global Alignment of Immunization safety Assessment in pregnancy Level 3a Assessment of Gestational Age|Level 3a Assessment of Prematurity and Gestational Age	GAIA Level 3a Assessment of Gestational Age is defined by the presence at least one of the following criteria: a) Certain last menstrual period (LMP) date with third trimester scan (28 0/7 weeks or more); OR b) Certain LMP date with confirmatory second trimester fundal height (FH); OR c) Certain LMP date with birth weight; OR d) Uncertain LMP date with first trimester physical examination.			Classification	GAIA Preterm Birth Level of Diagnostic Certainty Terminology|GAIA Terminology
C128017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128017>	C128012	GAIA Level 3b Assessment of Gestational Age|Global Alignment of Immunization safety Assessment in pregnancy Level 3b Assessment of Gestational Age|Level 3b Assessment of Prematurity and Gestational Age	GAIA Level 3b Assessment of Gestational Age is defined by the presence of at least one of the following criteria: a) Uncertain last menstrual period (LMP) date with fundal height (FH); OR b) Uncertain LMP date with newborn physical assessment; OR c) Uncertain LMP date with birth weight.			Classification	GAIA Preterm Birth Level of Diagnostic Certainty Terminology|GAIA Terminology
C128018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128018>	C126846	GAIA Level 1 Antepartum Stillbirth|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Antepartum Stillbirth|Level 1 Antepartum Stillbirth	GAIA Level 1 Antepartum Stillbirth is defined by four criteria: first, one or more of the following three requirements must be met: a) Prenatal ultrasound examination (e.g. basic ultrasound or special ultrasound with Doppler) documenting an absence of fetal cardiac activity or movement before the onset of labor; b) Radiology findings consistent with intrauterine fetal death; c) Delivery of an infant with no of signs of life at birth, including no spontaneous movements, no umbilical cord pulse, no heartbeat, no respirations, and Apgar scores of 0 at both 1 and 5 minutes. The determination of the absence of signs of life is made by physical examination after delivery, with or without electronic monitoring of heart rate, respiratory rate, and pulse oximetry; second, the following three criteria must be met: a) Maternal report of the absence of fetal movement for 24 hours or more; b) Maternal physical examination confirming the absence of fetal movement; c) Auscultation for fetal heart tones using electronic devices (e.g. handheld Doppler or fetal heart rate monitor) OR non-electronic devices (e.g. stethoscope, fetoscope, or Pinard horn) that documents the absence of a fetal heartbeat; third, one of the following two requirements must be met: a) Attended delivery, followed by a post-delivery physical examination of the fetus by an obstetrician, a neonatologist, a pediatrician, a maternal-fetal medicine specialist, or a pathologist that is consistent with antepartum death. In a setting where access to a specialist is not feasible, diagnosis by a health care provider trained or experienced to make the diagnosis is acceptable (e.g. general practice physician, mid-wife, nurse practitioner, a physician's assistant, or other qualified trained practitioner); OR b) fetal/placental pathology report that is consistent with antepartum death; fourth, gestational age within the pre-defined range for selected stillbirth definition, as assessed by maternal and/or fetal parameters (level 1 in GA assessment algorithm).			Classification	GAIA Stillbirth Level of Diagnostic Certainty Terminology|GAIA Terminology
C128019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128019>	C126846	GAIA Level 2 Antepartum Stillbirth|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Antepartum Stillbirth|Level 2 Antepartum Stillbirth	GAIA Level 2 Antepartum Stillbirth is defined by four criteria: first, delivery of an infant with no of signs of life at birth, including the following: no spontaneous movements, no umbilical cord pulse, no heartbeat, no respirations, and an Apgar score of 0 at both 1 and 5 minutes. Determination of the absence of signs of life is made by physical examination after delivery, with or without electronic monitoring of heart rate, respiratory rate, and pulse oximetry; second, one or more of the following three requirements must be met: a) Maternal report of the absence of fetal movement for 24 hours or more; b) Maternal physical examination confirming the absence of fetal movement; c) Auscultation for fetal heart tones using electronic devices (e.g. handheld Doppler or fetal heart rate monitor) or non-electronic devices (e.g. stethoscope, fetoscope or Pinard horn) that documents the absence of a fetal heartbeat; third, one or more of the following two requirements must be met: a) Attended delivery followed by a post-delivery physical examination of the fetus that is performed by specialist or qualified trained practitioner appropriate to the health care setting, and that is consistent with antepartum death; b) fetal/placental pathology report that is consistent with antepartum death; fourth, gestational age within the pre-defined range for selected stillbirth definition, as assessed by maternal and/or fetal parameters (level 1-2 in GA assessment algorithm).			Classification	GAIA Stillbirth Level of Diagnostic Certainty Terminology|GAIA Terminology
C12801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12801>	C12219	Tissue|Normal|Normal|Normal Tissue|TISSUE|Tissue, NOS|Tissues|tissue	An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function.	Tissue		Tissue	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTDC Value Terminology|GDC Terminology|GDC Value Terminology|ICDC Terminology|ICDC Value Terminology|mCode Genomic Specimen Type Value Set|mCode Terminology
C128020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128020>	C126846	GAIA Level 3 Antepartum Stillbirth|Global Alignment of Immunization safety Assessment in pregnancy Level 3 Antepartum Stillbirth|Level 3 Antepartum Stillbirth	GAIA Level 3 Antepartum Stillbirth is defined by three criteria: first, delivery of an infant with no signs of life at birth, including the following: no spontaneous movements, no umbilical cord pulse, no heartbeat, no crying, no spontaneous respirations or chest movement, and full body cyanosis; second, one or more of the following three requirements must be met: a) Maternal report of the absence of fetal movement for 24 hours or more prior to delivery; b) Report of auscultation for fetal heart tones using electronic devices (e.g. handheld Doppler or fetal heart rate monitor) or non-electronic devices (e.g. stethoscope, fetoscope or Pinard horn) that documents the absence of a fetal heartbeat; c) Non-attended delivery followed by a post-delivery physical examination of the fetus that is performed by a health care professional who meets the standard of care in the immediate health care setting, and that is consistent with antepartum death; d) a verbal history provided by a trained health care provider, non-medical witness, or the mother of the fetus documenting that the fetus was born with no signs of life, was unresponsive to resuscitation efforts immediately after delivery, and had physical features consistent with antepartum death; third, gestational age within the pre-defined range for selected stillbirth definition as assessed by maternal and/or fetal parameters.			Classification	GAIA Stillbirth Level of Diagnostic Certainty Terminology|GAIA Terminology
C128021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128021>	C126846	GAIA Level 4 Antepartum Stillbirth|Global Alignment of Immunization safety Assessment in pregnancy Level 4 Antepartum Stillbirth|Level 4 Antepartum Stillbirth	GAIA Level 4 Antepartum Stillbirth is defined by two criteria: first, a report of a stillbirth, but the fetus is unavailable for physical examination after birth so no objective assessment can be made; second, maternal information is insufficient to assess gestational age.			Classification	GAIA Stillbirth Level of Diagnostic Certainty Terminology|GAIA Terminology
C128022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128022>	C126846	GAIA Level 1 Intrapartum Stillbirth|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Intrapartum Stillbirth|Level 1 Intrapartum Stillbirth	GAIA Level 1 Intrapartum Stillbirth is defined by four criteria: first, delivery of an infant with no of signs of life at birth, including the following: no spontaneous movements, no umbilical cord pulse, no heartbeat, no respirations, and an Apgar score of 0 at both 1 and 5 minutes. Determination of the absence of signs of life is made by physical examination after delivery, with or without electronic monitoring of heart rate, respiratory rate, and pulse oximetry; second, evidence of a live fetus prior to the onset of labor (confirmed by documentation of fetal movement and of fetal heart tones by ultrasound prior to onset of labor). NOTE: In the absence of evidence of a live fetus prior to the onset of labor, the fetal death should be reported as a stillbirth or an antepartum stillbirth; third, attended delivery followed by post-delivery physical examination by an obstetrician, a neonatologist, a pediatrician, a maternal-fetal medicine specialist, or a pathologist that is consistent with intrapartum death. In a setting where access to a specialist is not feasible, diagnosis by a health care provider trained or experienced to make the diagnosis is acceptable (e.g. general practice physician, mid-wife, or other qualified trained practitioner); fourth, gestational age within the pre-defined range for selected stillbirth definition as assessed by maternal and/or fetal-neonatal parameters (level 1 in GA assessment algorithm).			Classification	GAIA Stillbirth Level of Diagnostic Certainty Terminology|GAIA Terminology
C128023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128023>	C126846	GAIA Level 2 Intrapartum Stillbirth|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Intrapartum Stillbirth|Level 2 Intrapartum Stillbirth	GAIA Level 2 Intrapartum Stillbirth is defined by four criteria: first, the delivery of an infant with no signs of life at birth, including the following: no spontaneous movements, no umbilical cord pulse, no heartbeat, no respirations, and an Apgar score of 0 at both 1 and 5 minutes. Determination of the absence of signs of life is made by physical examination after delivery, with or without electronic monitoring of heart rate, respiratory rate, and pulse oximetry OR documentation of lack of response to resuscitation efforts; second, evidence of a live fetus prior to the onset of labor (maternal report of fetal movement prior to the onset of labor and documentation of fetal heart tones by auscultation or hand held Doppler). NOTE: In the absence of evidence of a live fetus prior to the onset of labor, the fetal death should be reported as a stillbirth or an antepartum stillbirth; third, attended delivery followed by post-delivery physical examination that is performed by a health care professional who meets the standard of care in the immediate health care setting, and which is consistent with intrapartum death; fourth, gestational age within the pre-defined range for selected stillbirth definition as assessed by maternal and/or fetal parameters (level 1-2 in GA assessment algorithm).			Classification	GAIA Stillbirth Level of Diagnostic Certainty Terminology|GAIA Terminology
C128024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128024>	C126846	GAIA Level 3 Intrapartum Stillbirth|Global Alignment of Immunization safety Assessment in pregnancy Level 3 Intrapartum Stillbirth|Level 3 Intrapartum Stillbirth	GAIA Level 3 Intrapartum Stillbirth is defined by four criteria: first, delivery of an infant who is reported to have no of signs of life at birth, including the following: no spontaneous movements, no umbilical cord pulse, no heartbeat, no crying, no spontaneous respirations or chest movement, and full body cyanosis; second, evidence of a live fetus prior to the onset of labor (maternal report of fetal movement prior to the onset of labor OR auscultation of fetal heart tones). NOTE: in the absence of evidence of a live fetus prior to the onset of labor, the fetal death should be reported as a stillbirth or an antepartum stillbirth; third, a non-attended delivery followed by a post-delivery physical examination that is performed by a health care professional who meets the standard of care in the immediate health care setting, and that is consistent with intrapartum death, or a verbal history that is provided by a trained health care provider, a non-medical witness, or the mother of the fetus that documents a fetus born with no signs of life and who was unresponsive to resuscitation efforts immediately after birth; fourth, gestational age within the pre-defined range for selected stillbirth definition as assessed by maternal and/or fetal parameters (level 2-3 in GA assessment algorithm).			Classification	GAIA Stillbirth Level of Diagnostic Certainty Terminology|GAIA Terminology
C128025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128025>	C126846	GAIA Level 4 Intrapartum Stillbirth|Global Alignment of Immunization safety Assessment in pregnancy Level 4 Intrapartum Stillbirth|Level 4 Intrapartum Stillbirth	GAIA Level 4 Intrapartum Stillbirth is defined by two criteria: first, a report of stillbirth, but the fetus is unavailable for physical examination after birth so no objective assessment can be made; second, maternal information is insufficient to assess gestational age.			Classification	GAIA Stillbirth Level of Diagnostic Certainty Terminology|GAIA Terminology
C128026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128026>	C96040	Anti-OX40 Antibody BMS 986178|BMS 986178|BMS-986178|BMS-986178	An agonistic monoclonal antibody against the co-stimulatory receptor OX40 (CD134; TNFRSF4), with potential immunostimulatory activity. Upon administration, anti-OX40 monoclonal antibody BMS 986178 selectively binds to and activates the OX40 receptor, by mimicking the action of the endogenous OX40 ligand (OX40L). OX40 receptor activation induces proliferation of memory and effector T-lymphocytes. In the presence of tumor-associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor family (TNFRSF), is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T-cells.	Anti-OX40 Antibody BMS 986178		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C128027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128027>	C210746	Gluten-free DHA/EPA/GLA/Antioxidant-rich Nutritional Liquid|Oxepa	A gluten- and lactose-free, energy-rich, calorie-dense, non-complete liquid nutritional supplement enriched with eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), gamma-linolenic acid (GLA) and antioxidants, with potential anti-cachexic and anti-inflammatory activities. The nutritional liquid also contains protein, in the form of sodium and calcium caseinates, carbohydrates, as maltodextrin and sucrose, fat, as canola, borage, and marine oils, L-carnitine, taurine, and several other vitamins and minerals. Upon oral intake of the gluten-free DHA/EPA/GLA/antioxidant-rich nutritional liquid, the essential omega-3 polyunsaturated fatty acids EPA and DHA, derived from refined marine oil, and GLA, derived from borage oil, are incorporated into cell membranes and affect the production of pro-inflammatory mediators, which elicits an anti-inflammatory effect and may also prevent infections. The antioxidants, including ascorbic acid, beta-carotene, and tocopherols, neutralize free radicals, thereby protecting tissues and organs from oxidative damage. Medium chain triglycerides (MCT) and large chain triglycerides (LCT) in this supplement enhance fat absorption and increase calorie intake. Additionally, this nutritional supplement may prevent malnutrition and weight loss.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C128028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128028>	C129822|C128058	Anti-GITR Monoclonal Antibody GWN 323|GWN 323|GWN-323|GWN323	An anti-human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor superfamily, member 18; TNFRSF18; GITR; CD357) agonistic monoclonal antibody, with potential immune checkpoint modulating activity. Anti-GITR antibody GWN 323 binds to and activates GITRs found on multiple types of T-cells. This stimulates the immune system, induces both the activation and proliferation of tumor-antigen-specific T effector cells (Teff), and suppresses the function of activated T regulatory cells (Tregs). This leads to tumor cell eradication. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B-cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress both Teffs and T-cell receptor (TCR) signaling.	Anti-GITR Monoclonal Antibody GWN 323		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C128029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128029>	C28676|C138180|C129826	PRAME-targeting T-cell Receptor/Inducible Caspase 9 BPX-701|BPX-701|CaspaCID-based PRAME-TCR Allogeneic T-lymphocytes BPX-701	Human allogeneic T-lymphocytes transduced with a retroviral vector encoding a high-affinity T-cell receptor (TCR) specific for human leukocyte antigen (HLA)-A2-01-restricted, preferentially-expressed antigen in melanoma (PRAME) and containing the chemical induction of dimerization (CID) suicide/safety switch, composed of a drug binding domain coupled to the signaling domain of the suicide enzyme caspase-9, with potential antineoplastic activity. Peripheral blood mononuclear cells (PBMCs) are isolated from a patient, transduced with an anti-PRAME-HLA-A2 restricted TCR, expanded ex vivo, and reintroduced into the HLA-A2-positive patient. Upon reintroduction, PRAME-targeting T-cell receptor-based therapy BPX-701 binds to tumor cells expressing PRAME, which may induce cell death in and halt the growth of PRAME-expressing cancer cells. The tumor-associated antigen PRAME is overexpressed by a variety of cancer cell types. If potential T-cell toxicity due to graft-versus-host disease (GvHD) occurs, the chemical dimerizer rimiducid (AP1903) can be adminstered. Rimiducid binds to the drug binding domain expressed by the BPX-701 T-cells, and triggers activation of the caspase-9 domain, which leads to caspase 9-mediated signaling, the induction of apoptosis and to selective and complete elimination of BPX-701 cells.			Cell|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12802>	C13018	Tonsil|TONSIL|Tonsillar structure (palatine) (body structure)|Tonsils|tonsil|tonsil	The two organs situated in the throat on either side of the narrow passage from the mouth to the pharynx. They are composed of lymphoid tissues.	Tonsil		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C128030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128030>	C217486	Evexomostat|EVEXOMOSTAT|MetAP2 Inhibitor SDX-7320|Methionine aminopeptidase type II Inhibitor SDX-7320|SDX-7320	A synthetic copolymer-drug conjugate of a fumagillin-derived methionine aminopeptidase 2 (MetAP2) inhibitor conjugated to the bio-compatible polymer poly(N-(hydroxypropyl)methacrylamide) (HPMA), with potential antineoplastic activity. Upon administration of SDX-7320, the active moiety SDX7539 is released inside the tumor cells. SDX7539 binds to and inhibits MetAP2, which prevents MetAP2-mediated signal transduction pathways and results in tumor cell death. MetAP2, a member of the dimetallohydrolase family upregulated in certain tumor cell types, plays a key role in angiogenesis, proliferation and survival. Polymer conjugation reduces systemic drug exposure and increases this agent's efficacy as compared to non-polymer conjugates.	Evexomostat		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C128031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128031>	C200766	Autologous Prostate Stem Cell Antigen-specific CAR T Cells BPX-601|Autologous PSCA-Specific Chimeric Antigen Receptor Engineered T Cells BPX-601|Autologous PSCA-specific CAR T Cells BPX-601|BPX-601|GoCART BPX-601|iMC/PSCA-zeta CAR BPX-601	A preparation of autologous T-lymphocytes expressing a chimeric antigen receptor (CAR) consisting of an anti-human prostate stem cell antigen (PSCA) scFv (single chain variable fragment) coupled to the zeta chain of the T-cell receptor (TCRzeta) and a drug-induced co-stimulatory molecule, composed of an inducible, chimeric MyD88/CD40 (inducible MC; iMC) co-stimulatory domain, in which both the MyD88 and CD40 lack their extracellular domains, with potential antineoplastic activity. Upon administration of BPX-601, the T-cells target and bind to PSCA-expressing cancer cells. Upon subsequent administration of the chemical inducer of dimerization (CID) agent rimiducid, this agent targets and binds to the drug binding domain, which leads to iMC expression, activation of both CD40- and MyD88-mediated signal transduction pathways, and an induction of selective cytotoxicity in, and eradication of PSCA-expressing cancer cells. iMC activation by rimiducid increases T-cell survival and anti-tumor activity of the administered T-cells, compared to T-cells without the drug iMC activation-switch. As these T-cells are engineered to only be fully activated by binding to both antigen and rimiducid, T-cell proliferation, activity and toxicity can be controlled by adjusting the dose of rimiducid, thereby preventing uncontrolled T-cell activation which increases the safety of the administered T-cells. PSCA is a glycosylphosphatidylinositol (GPI)-anchored cell surface antigen overexpressed in many cancer cell types.			Cell|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C128033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128033>	C1966	Hyperpolarized Helium 3|HP3He|Hyperpolarized He-3|Hyperpolarized He3|Hyperpolarized Helium-3	A contrast agent composed of hyperpolarized helium He 3 gas (HP3He), with potential usage in diagnostic nuclear magnetic resonance (NMR)-based imaging (MRI). Upon inhalation, the hyperpolarized helium He 3 gas is distributed throughout the lungs. MRI, immediately following HP3He administration, allows for the visualization of lung structures based on the distribution pattern of the gas. This may aid in the diagnosis of certain lung abnormalities. Hyperpolarization of He 3 enhances NMR signals and thus improves imaging and assessment of lung function.			Indicator, Reagent, or Diagnostic Aid	NCI Drug Dictionary Terminology
C128034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128034>	C1966	Hyperpolarized Xenon 129|HP 129Xe|Hyperpolarized Xe-129|Hyperpolarized Xe129|Hyperpolarized Xenon-129|XENON XE-129, HYPERPOLARIZED	A contrast agent composed of hyperpolarized xenon Xe 129 gas (HP129Xe), with potential usage in diagnostic nuclear magnetic resonance (NMR)-based imaging (MRI). Upon inhalation, the hyperpolarized xenon 129 gas is distributed throughout the lungs. MRI, immediately following HP129Xe administration, allows for the visualization of lung structures based on the distribution pattern of the gas. This may aid in the diagnosis of certain lung abnormalities. Hyperpolarization of Xe 129 enhances NMR signals and thus improves imaging and assessment of lung function.			Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C128035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128035>	C2124	Gallium Ga 68-NOTA-BBN(7-14)-RGD|68Ga-NOTA-BBN(7-14)-RGD|68Ga-NOTA-BBN-RGD|Gallium Ga 68-NOTA-BBN-RGD	A radioconjugate containing the bombesin (BBN) fragment BBN(7-14) comprised of the amino acid sequence Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2, which targets the gastrin-releasing peptide receptor (GRPR), and linked, via a glutamate linker, to the cyclic arginine-glycine-aspartic acid (RGD) sequence-based peptide cyclo[Arg-Gly-Asp-D-Tyr-Lys] (c(RGDyK)), which targets integrin alphaVbeta3 (aVb3), and labeled with the radionuclide gallium (Ga) 68 through the macrocyclic chelating agent, 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA), with potential use in diagnostic imaging using positron emission tomography/computed tomography (PET/CT). Upon administration of gallium Ga 68-NOTA-BBN(7-14)-RGD, the BBN peptide moiety of the RGD-BBN heterodimer specifically targets and binds to GRPR while the RGD moiety specifically binds to the aVb3. Upon PET/CT, GRPR- and/or aVb3-expressing tumor cells can be visualized and expression levels can be quantified. GRPR, also called bombesin receptor 2 (BB2), is a seven-transmembrane G protein-coupled receptor belonging to the bombesin receptor family. aVb3, an integrin receptor, plays a key role in angiogenesis, tumor proliferation and survival. Both are overexpressed in certain types of cancers.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C128036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128036>	C20401|C191738	Anti-CTLA-4 Monoclonal Antibody|Anti-CTLA4 Monoclonal Antibody	Any monoclonal antibody against the antigen cytotoxic T-lymphocyte associated protein 4 (CTLA-4; CTLA4; CD152).	Anti-CTLA-4 Monoclonal Antibody		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C128037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128037>	C20401|C124946	Anti-PD1 Monoclonal Antibody|Anti-PD-1 Monoclonal Antibody	A monoclonal antibody directed against programmed cell death protein 1 (PD-1; PD1; CD279).			Chemical Viewed Functionally	
C128038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128038>	C681	Naloxegol Oxalate|4,5Alpha-epoxy-6alpha-((3,6,7,12,15,18,21-Heptaoxadocosyl)oxy)-17-(prop-2-enyl)morphinan-3,14-diol Hydrogen Ethanedioate|Morphinan-3,14-diol, 4,5-Epoxy-6-(3,6,9,12,15,18,21-heptaoxadocos-1-yloxy)-17-(2-propen-1-yl)-, (5alpha,6alpha)-, Ethanedioate (1:1)|NALOXEGOL OXALATE|NKTR-118 Oxalate				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C128039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128039>	C199169	Defactinib Hydrochloride|Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, Hydrochloride (1:1)|DEFACTINIB HYDROCHLORIDE	The hydrochloride salt form of defactinib, an orally bioavailable, small-molecule focal adhesion kinase (FAK) inhibitor with potential antiangiogenic and antineoplastic activities. Defactinib inhibits FAK, which may prevent the integrin-mediated activation of several downstream signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, thus inhibiting tumor cell migration, proliferation, survival, and tumor angiogenesis. The tyrosine kinase FAK, a signal transducer for integrins, is normally activated by binding to integrins in the extracellular matrix (ECM) but may be upregulated and constitutively activated in various tumor cell types.	Defactinib Hydrochloride		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12803>	C33904	Trabecular Meshwork	Mesh-like tissue responsible for draining the aqueous humor from the eye that is located at the iridocorneal angle of the eye, between the anterior chamber and the venous sinus of the sclera.	Trabecular Meshwork		Body Part, Organ, or Organ Component	
C128040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128040>	C446|C2115	Brostacillin Hydrochloride|4-(2-Bromoacrylamido)-N'''-(2-guanidinoethyl)-1,1',1',1'''-tetramethyl-N,4':N',4':N',4'''-quater(pyrrole-2-carboxamide) Hydrochloride|BROSTALLICIN HYDROCHLORIDE|PNU-166196 Hydrochloride|brostallicin hydrochloride	The hydrochloride salt form of brostacillin, a synthetic, alpha-bromoacrylic, second-generation minor groove binder (MGB), related to distamycin A, with potential antineoplastic activity. Brostallicin binds to DNA minor groove DNA, after having formed a highly reactive glutathione (GSH)-brostallicin complex in the presence of the enzyme glutathione S-transferase (GST), which is overexpressed in cancer cells; DNA replication and cell division are inhibited, resulting in tumor cell death. Compared to typical MGBs, this agent appears to bind covalently to DNA in a different manner and its activity does not depend on a functional DNA mismatch repair (MMR) mechanism. Accordingly, brostallicin may be effective against MMR-defective tumors that are refractory to various anticancer agents.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C128041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128041>	C3809|C2940	Cervical Neuroendocrine Neoplasm	A neuroendocrine neoplasm that arises from the cervix. This category includes neuroendocrine tumor grade 1, neuroendocrine tumor grade 2, and neuroendocrine carcinoma (small cell and large cell neuroendocrine carcinoma).			Neoplastic Process	
C128042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128042>	C16731	Moderate to Late Preterm Infant	An age group comprised of infants born alive with a gestational age between 32 to less than 37 weeks.			Age Group	GAIA Preterm Birth Level of Diagnostic Certainty Terminology|GAIA Terminology
C128043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128043>	C203250|C188221	Cervical Neuroendocrine Tumor G1|Cervical Carcinoid Tumor|Cervical Low Grade Neuroendocrine Tumor, Grade 1	A well-differentiated, low-grade neuroendocrine neoplasm that arises from the cervix.			Neoplastic Process	
C128044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128044>	C72074|C188221	Cervical Neuroendocrine Tumor G2|Cervical Low Grade Neuroendocrine Tumor, Grade 2	A well-differentiated, intermediate-grade neuroendocrine neoplasm arising from the cervix.			Neoplastic Process	
C128045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128045>	C215420|C206192|C128041	Cervical Neuroendocrine Carcinoma|Cervical High Grade Neuroendocrine Neoplasm|Cervical Neuroendocrine Cancer	An aggressive high-grade carcinoma with neuroendocrine differentiation that arises from the cervix. This category includes small cell and large cell neuroendocrine carcinoma.	Cervical Neuroendocrine Carcinoma		Neoplastic Process	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology
C128046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128046>	C6510|C128053	Cervical Leiomyoma	An uncommon benign smooth muscle neoplasm that arises from the cervix.			Neoplastic Process	
C128047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128047>	C3158|C128054	Cervical Leiomyosarcoma	A malignant neoplasm with smooth muscle differentiation arising from the cervix.			Neoplastic Process	
C128048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128048>	C214845|C128054	Cervical Rhabdomyosarcoma	A rare malignant neoplasm with skeletal muscle differentiation arising from the cervix.			Neoplastic Process	
C128049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128049>	C5385|C128054	Cervical Angiosarcoma	A highly aggressive malignant vascular neoplasm that arises from the cervix and shows endothelial cell differentiation.			Neoplastic Process	
C128050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128050>	C3798|C128054	Cervical Malignant Peripheral Nerve Sheath Tumor	A rare malignant neoplasm with nerve sheath differentiation arising from the cervix.			Neoplastic Process	
C128051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128051>	C6948	Postoperative Spindle Cell Nodule of the Cervix|Cervical Postoperative Spindle Cell Nodule	A rare, benign, non-neoplastic reactive lesion that develops in the cervix at the site of a prior operative procedure. It is composed of spindle cells, small blood vessels, and chronic inflammation.			Disease or Syndrome	
C128052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128052>	C574	Gusperimus|(+/-)-15-Deoxyspergualin|15-Deoxyspergualin|GUSPERIMUS|Heptanamide, 7-((Aminoiminomethyl)amino)-N-(2-((4-((3-aminopropyl)amino)butyl)amino)-1-hydroxy-2-oxoethyl)-				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C128053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128053>	C40216|C3607	Benign Cervical Soft Tissue Neoplasm	A rare benign mesenchymal neoplasm that arises from the cervix.			Neoplastic Process	
C128054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128054>	C9311|C9306|C40216	Cervical Sarcoma|Primary Cervical Sarcoma	A rare sarcoma that arises from the cervix.			Neoplastic Process	
C128055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128055>	C9311|C3011|C180879	Cervical Yolk Sac Tumor|Cervical Endodermal Sinus Tumor	A yolk sac tumor that arises from the cervix. Patients present with abnormal vaginal bleeding and a polypoid, friable mass, protruding into the vagina.			Neoplastic Process	
C128056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128056>	C93243	Perfusion-Weighted Magnetic Resonance Imaging|PWI|Perfusion-Weighted MR|Perfusion-Weighted MRI	A magnetic resonance imaging modality used to quantify the blood supply to an organ or tissue using signal measurement as detected from a parenterally administered contrast agent.	Perfusion-Weighted Magnetic Resonance Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C128057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128057>	C20401|C191689	Anti-PD-L1 Monoclonal Antibody	A monoclonal antibody directed against programmed death-ligand 1 (PD-L1; CD274).	Anti-PD-L1 Monoclonal Antibody		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C128058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128058>	C20401|C201119|C141144	Anti-GITR Monoclonal Antibody	Any monoclonal antibody directed against the antigen glucocorticoid-induced TNFR-related protein (GITR; tumor necrosis factor receptor superfamily member 18 (TNFRSF18).			Chemical Viewed Functionally	
C128059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128059>	C155322	Dabrafenib Mesylate|DABRAFENIB MESYLATE|Dabrafenib Methanesulfonate|GSK2118436 Methane Sulfonate Salt|GSK2118436B|Tafinlar	The mesylate salt form of dabrafenib, an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.	Dabrafenib Mesylate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12805>	C176322	Tricuspid Valve|Right Atrioventricular Valve|TRICUSPID VALVE|Tricuspid valve structure (body structure)|VALVE, RIGHT ATRIOVENTRICULAR	A three-cusp valve of the heart that regulates the flow of blood between the right atrium and the right ventricle of the heart.	Tricuspid Valve		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C128060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128060>	C4102|C180915	Vaginal Papillary Carcinoma|Vaginal Squamotransitional Carcinoma|Vaginal Squamotransitional Cell Carcinoma	A rare squamous cell carcinoma that arises from the vagina resembling transitional cell carcinoma of the urinary tract.			Neoplastic Process	
C128061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128061>	C3664	Vaginal Tubulosquamous Polyp|Skene Duct Cyst|Vaginal Ectopic Prostatic Tissue	A rare benign lesion that arises from the vagina. It is characterized by the presence of squamous epithelial and tubular structures in a fibrovascular stroma.			Disease or Syndrome	
C128062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128062>	C179634	Vaginal Transitional Cell Metaplasia	Vaginal metaplasia in which the vaginal surface squamous epithelium resembles benign transitional urothelium.			Finding	
C128063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128063>	C120861|C117720	Vaginal Adenosis	The presence of glandular structures in the vagina.			Finding	
C128064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128064>	C3014|C27621	Vaginal Endometriosis	Endometriosis that affects the vagina. It is characterized by the presence of endometrial stroma with or without endometrial-type glands in the vagina.			Disease or Syndrome	
C128065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128065>	C222045	Voice Handicap Index Functional Subscale	A subscale of the Voice Handicap Index that measures an individual's perception of the effect of their voice handicap on their daily activity.			Intellectual Product	Voice Handicap Index
C128066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128066>	C117720	Vaginal Endocervicosis	A rare benign lesion characterized by the presence of endocervical-type glands in the vaginal wall.			Finding	
C128067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128067>	C222045	Voice Handicap Index Physical Subscale	A subscale of the Voice Handicap Index that measures an individual's perception of the characteristics of their vocal production and laryngeal discomfort.			Intellectual Product	Voice Handicap Index
C128068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128068>	C222045	Voice Handicap Index Emotional Subscale	A subscale of the Voice Handicap Index that measures an individual's perception of the emotional impact of their voice handicap.			Intellectual Product	Voice Handicap Index
C128069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128069>	C19477	Actigraph|Actigram	A continuous record of body movement obtained from a monitor worn by an individual and that is used to measure rest-activity (sleep-wake) cycles.	Actigraph		Laboratory or Test Result	CTRP Intervention Terminology|CTRP Terminology
C12806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12806>	C12700	Trigeminal Nerve|Cranial Nerve V|Fifth Cranial Nerve|Fifth Cranial Nerve|NERVE, TRIGEMINAL|Nervus Trigeminus|TRIGEMINAL NERVE|Trigeminal nerve structure (body structure)|fifth cranial nerve|trigeminal nerve	The fifth set of paired nerves of the face that emerge from the brain steam. These nerves have sensory and motor functions in the face, oral cavity, and nasal cavity.	Trigeminal Nerve		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C128070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128070>	C173937	Voice Difficulties Restrict Personal and Social Life Question|My voice difficulties restrict my personal and social life|Voice Difficulties Restrict Personal and Social Life	A question about how frequently an individual's voice difficulties restrict their personal and social life.			Intellectual Product	Voice Handicap Index
C128071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128071>	C173937|C111717	Feel Left Out of Conversation Because of Voice Question|Feel Left Out of Conversation Because of Voice|I feel left out of conversation because of my voice	A question about how frequently an individual feels left out of conversation because of their voice.			Intellectual Product	Voice Handicap Index
C128072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128072>	C173937	Voice Problem Causes Loss of Income Question|My voice problem causes me to lose income|Voice Problem Causes Loss of Income	A question about how frequently an individual's voice problem causes them to lose income.			Intellectual Product	Voice Handicap Index
C128073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128073>	C3917|C215420	Vaginal Neuroendocrine Carcinoma|Vaginal High Grade Neuroendocrine Carcinoma|Vaginal High Grade Neuroendocrine Neoplasm|Vaginal Neuroendocrine Cancer	A rare neuroendocrine carcinoma that arises from the vagina. This category includes small cell and large cell neuroendocrine carcinoma.	Vaginal Neuroendocrine Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C128074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128074>	C173937|C173219	Feel Like Have to Strain to Produce Voice Question|Feel Like Have to Strain to Produce Voice|I feel as though I have to strain to produce voice	A question about how frequently an individual feels as though they have to strain to produce voice.			Intellectual Product	Voice Handicap Index
C128075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128075>	C215422|C128073	Vaginal Large Cell Neuroendocrine Carcinoma	A rare aggressive neuroendocrine carcinoma that arises from the vagina and is characterized by the presence of malignant cells with abundant cytoplasm, large nuclei, and prominent nucleoli.			Neoplastic Process	
C128076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128076>	C173937	Clarity of Voice is Unpredictable Question|Clarity of Voice is Unpredictable|The clarity of my voice is unpredictable	A question about how frequently the clarity of an individual's voice is unpredictable.			Intellectual Product	Voice Handicap Index
C128077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128077>	C173937	Voice Problem Upsets Me Question|My voice problem upsets me|Voice Problem Upsets Me	A question about how frequently an individual's voice problem upsets them.			Intellectual Product	Voice Handicap Index
C128078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128078>	C173937|C173160	Voice Makes Me Feel Handicapped Question|My voice makes me feel handicapped|Voice Makes Me Feel Handicapped	A question about how frequently an individual's voice makes them feel handicapped.			Intellectual Product	Voice Handicap Index
C128079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128079>	C40265|C3610|C121181	Vaginal Superficial Myofibroblastoma|Superficial Myofibroblastoma of the Lower Female Genital Tract|Vaginal Myofibroblastoma	An uncommon, benign, well circumscribed mesenchymal neoplasm that grows beneath the vaginal epithelium. It is characterized by the presence of cells containing bland ovoid, spindle, or stellate-shaped nuclei in a collagenous stroma.			Neoplastic Process	
C12807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12807>	C33904	Trigeminal Nucleus|Nucleus of Fifth Nerve|Nucleus of the Fifth Nerve|Trigeminal Nuclei	Any one of the four nuclei of the fifth cranial nerve located in the brain stem, which includes the principal sensory nucleus, the mesencephalic nucleus, the spinal trigeminal tract, and the motor nucleus.	Trigeminal Nucleus		Body Part, Organ, or Organ Component	
C128080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128080>	C7737|C214845	Vaginal Rhabdomyosarcoma	A malignant mesenchymal neoplasm with skeletal muscle differentiation arising from the vagina.			Neoplastic Process	
C128081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128081>	C4908	Ovarian Cancer by FIGO Stage 2014|Ovarian Carcinoma by FIGO Stage 2014	A category of staging terms for ovarian cancer according to the International Federation of Gynecology and Obstetrics (FIGO), 2014. AJCC ovarian cancer stage terms from the 6th and 7th editions that are synonymous to the FIGO ovarian cancer staging classification of 2014 are included as preferred terms.			Neoplastic Process	
C128082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128082>	C206249	FIGO Stage IC1 Ovarian Cancer 2014|FIGO Stage IC1 Ovarian Cancer|FIGO Stage IC1 Ovarian Carcinoma 2014	Stage IC ovarian cancer with surgical spill. (FIGO 2014)	FIGO Stage IC1 Ovarian Cancer		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C128083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128083>	C206249	FIGO Stage IC2 Ovarian Cancer 2014|FIGO Stage IC2 Ovarian Cancer|FIGO Stage IC2 Ovarian Carcinoma 2014	Stage IC ovarian cancer with capsule rupture before surgery or tumor on ovarian surface. (FIGO 2014)	FIGO Stage IC2 Ovarian Cancer		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C128084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128084>	C206249	FIGO Stage IC3 Ovarian Cancer 2014|FIGO Stage IC3 Ovarian Cancer|FIGO Stage IC3 Ovarian Carcinoma 2014	Stage IC ovarian cancer with malignant cells in the ascites or peritoneal washings. (FIGO 2014)	FIGO Stage IC3 Ovarian Cancer		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C128085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128085>	C128081	FIGO Stage II Ovarian Cancer 2014|FIGO Stage II Ovarian Cancer|FIGO Stage II Ovarian Carcinoma 2014	Ovarian cancer involving one or both ovaries with pelvic extension (below the pelvic brim) or primary peritoneal cancer. (FIGO 2014)	FIGO Stage II Ovarian Cancer		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C128086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128086>	C128081	FIGO Stage III Ovarian Cancer 2014|FIGO Stage III Ovarian Cancer|FIGO Stage III Ovarian Carcinoma 2014	Ovarian cancer involving 1 or both ovaries with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes. (FIGO 2014)	FIGO Stage III Ovarian Cancer		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C128087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128087>	C128086	FIGO Stage IIIA Ovarian Cancer 2014|FIGO Stage IIIA Ovarian Cancer|FIGO Stage IIIA Ovarian Carcinoma 2014	Ovarian cancer with positive retroperitoneal lymph nodes and/or microscopic metastasis beyond the pelvis. (FIGO 2014)	FIGO Stage IIIA Ovarian Cancer		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C128088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128088>	C128087	FIGO Stage IIIA1 Ovarian Cancer|FIGO Stage IIIA1 Ovarian Carcinoma	Ovarian cancer with positive retroperitoneal lymph nodes only. (FIGO 2014)	FIGO Stage IIIA1 Ovarian Cancer		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C128089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128089>	C128088	FIGO Stage IIIA1(i) Ovarian Cancer|FIGO Stage IIIA1(i) Ovarian Carcinoma	Ovarian cancer with positive retroperitoneal lymph nodes only. Metastasis equal or less than 10 mm. (FIGO 2014)	FIGO Stage IIIA1(i) Ovarian Cancer		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C12808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12808>	C12700	Trochlear Nerve|Cranial Nerve IV|Fourth Cranial Nerve|TROCHLEAR NERVE	The cranial nerve that controls the superior oblique muscle of the eye.	Trochlear Nerve		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C128090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128090>	C128088	FIGO Stage IIIA1(ii) Ovarian Cancer|FIGO Stage IIIA1(ii) Ovarian Carcinoma	Ovarian cancer with positive retroperitoneal lymph nodes only. Metastasis greater than 10 mm. (FIGO 2014)	FIGO Stage IIIA1(ii) Ovarian Cancer		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C128091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128091>	C128087	FIGO Stage IIIA2 Ovarian Cancer|FIGO Stage IIIA2 Ovarian Carcinoma	Ovarian cancer with microscopic, extrapelvic (above the brim) peritoneal involvement +/- positive retroperitoneal lymph nodes. (FIGO 2014)	FIGO Stage IIIA2 Ovarian Cancer		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C128092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128092>	C128086	FIGO Stage IIIB Ovarian Cancer 2014|FIGO Stage IIIB Ovarian Cancer|FIGO Stage IIIB Ovarian Carcinoma 2014	Ovarian cancer with macroscopic, extrapelvic, peritoneal metastasis equal or less than 2 cm +/- positive retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen. (FIGO 2014)	FIGO Stage IIIB Ovarian Cancer		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C128093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128093>	C128086	FIGO Stage IIIC Ovarian Cancer 2014|FIGO Stage IIIC Ovarian Cancer|FIGO Stage IIIC Ovarian Carcinoma 2014	Ovarian cancer with macroscopic, extrapelvic, peritoneal metastasis greater than 2 cm +/- positive retroperitoneal lymph nodes. Includes extension to capsule of liver/spleen. (FIGO 2014)	FIGO Stage IIIC Ovarian Cancer		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C128094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128094>	C206216	FIGO Stage IVA Ovarian Cancer 2014|FIGO Stage IVA Ovarian Cancer|FIGO Stage IVA Ovarian Carcinoma 2014|Stage IVA Ovarian Epithelial Cancer	Ovarian cancer with pleural effusion with positive cytology. (FIGO 2014)	FIGO Stage IVA Ovarian Cancer		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C128095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128095>	C206216	FIGO Stage IVB Ovarian Cancer 2014|FIGO Stage IVB Ovarian Cancer|FIGO Stage IVB Ovarian Carcinoma 2014|Stage IVB Ovarian Epithelial Cancer	Ovarian cancer with hepatic and/or splenic parenchymal metastasis, metastasis to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside of the abdominal cavity). (FIGO 2014)	FIGO Stage IVB Ovarian Cancer		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C128096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128096>	C15749	Optimal Debulking	Visible residual tumor less than or equal to one centimeter in diameter after cytoreductive surgery.			Therapeutic or Preventive Procedure	
C128097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128097>	C15749	Suboptimal Debulking	Residual tumor greater than one centimeter in diameter after cytoreductive surgery.			Therapeutic or Preventive Procedure	
C128098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128098>	C15749	Maximal Debulking	No macroscopic residual tumor after cytoreductive surgery.			Therapeutic or Preventive Procedure	
C128099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128099>	C96251	FIGO Stage IC1|Stage IC1	A FIGO stage term that applies to ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It refers to cancer with surgical spill.			Classification	GDC Terminology|GDC Value Terminology
C12809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12809>	C33003|C12983	Ulna|BONE, ULNA|ULNA	One of the bones that comprise the forearm. The largest aspect articulates with the humerus at the elbow joint and the smallest portion of the ulna articulates with the carpal bones in the wrist.	Ulna		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table
C1280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1280>	C210653	Zinc Sulfate|ZINC SULFATE, UNSPECIFIED FORM|Zinc sulfate|zinc sulfate	A salt of the essential trace metal zinc. Zinc is involved in tissue repair and is an important constituent of some proteins, including those involved in taste and smell. Zinc sulfate supplementation may prevent radiation-induced aguesia. (NCI04)	Zinc Sulfate		Inorganic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C128100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128100>	C96251	FIGO Stage IC2|Stage IC2	A FIGO stage term that applies to ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It refers to cancer with capsule rupture before surgery or tumor on ovarian surface.			Classification	GDC Terminology|GDC Value Terminology
C128101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128101>	C96251	FIGO Stage IC3|Stage IC3	A FIGO stage term that applies to ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It refers to cancer with malignant cells in the ascites or peritoneal washings.			Classification	GDC Terminology|GDC Value Terminology
C128102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128102>	C96256	FIGO Stage IIIA1|Stage IIIA1	A FIGO stage term that applies to ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It refers to cancer with positive retroperitoneal lymph nodes only.			Classification	GDC Terminology|GDC Value Terminology
C128103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128103>	C128102	FIGO Stage IIIA1i|FIGO Stage IIIA1(i)|Stage IIIA1(i)	A FIGO stage term that applies to ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It refers to cancer with positive retroperitoneal lymph nodes only. Metastasis equal or less than 10 mm.			Classification	GDC Terminology|GDC Value Terminology
C128104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128104>	C128102	FIGO Stage IIIA1ii|FIGO Stage IIIA1(ii)|Stage IIIA1(ii)	A FIGO stage term that applies to ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It refers to cancer with positive retroperitoneal lymph nodes only. Metastasis greater than 10 mm.			Classification	GDC Terminology|GDC Value Terminology
C128105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128105>	C96256	FIGO Stage IIIA2|Stage IIIA2	A FIGO stage term that applies to ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It refers to cancer with microscopic, extrapelvic (above the brim) peritoneal involvement +/- positive retroperitoneal lymph nodes.			Classification	GDC Terminology|GDC Value Terminology
C128106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128106>	C4908	Ovarian Cancer by AJCC v6 and v7 Stage|Ovarian Carcinoma by AJCC v6 and v7 Stage	A category of staging terms for ovarian cancer according to the American Joint Committee on cancer (AJCC) 6th and 7th editions. International Federation of Gynecology and Obstetrics (FIGO) ovarian cancer staging terms prior to 2014 are included in this category if synonymous with the AJCC terms.			Neoplastic Process	
C128107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128107>	C222318|C2139	Nemvaleukin Alfa|ALKS 4230|Intermediate-affinity IL-2R Agonist ALKS 4230|Intermediate-affinity Interleukin-2 Receptor Agonist ALKS 4230|NEMVALEUKIN ALFA|RDB 1450|RDB-1450	A selective effector cell activator protein and agonist of the intermediate-affinity interleukin-2 (IL-2) receptor with potential immunostimulating and antineoplastic activity. Upon administration, nemvaleukin alfa binds to and signals through the intermediate-affinity IL-2 receptor complex; this may selectively stimulate and activate natural killer (NK) cells and memory CD8 T-cells, leading to tumor cell elimination, while circumventing the activation of immunosuppressive cells that may prevent the anti-tumor response. IL-2 is a cytokine signaling molecule that plays a critical role in the immune response.	Nemvaleukin Alfa		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C128108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128108>	C120887	Idiopathic Membranous Glomerulopathy	Chronic degenerative changes in the kidney characterized by thickened and inflamed glomeruli and proteinurea, the cause of which is unknown.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C12810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12810>	C12919	Genitourinary System|GENITOURINARY SYSTEM|Genitourinary|Genitourinary Tract|Urogenital System|Urogenital Tract|genitourinary system|genitourinary system	The body system that includes all organs involved in reproduction and in the formation and voidance of urine.	Genitourinary System		Body System	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|ICDC Terminology|ICDC Value Terminology|UBERON Terminology
C128110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128110>	C34845	Nephrotic Syndrome - Infrequently Relapsing	Nephrotic syndrome in which there is a relapse occurring less than twice in the first six months, or less than four times in a year.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C128111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128111>	C6948	Postoperative Spindle Cell Nodule of the Vagina	A rare, benign, non-neoplastic reactive lesion that develops in the vagina at the site of a prior operative procedure. It is composed of spindle cells, small blood vessels, and chronic inflammation.			Disease or Syndrome	
C128112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128112>	C3708|C3437	Vaginal Germ Cell Tumor	A germ tumor that arises from the vagina.			Neoplastic Process	
C128113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128113>	C9011|C3610|C128112	Vaginal Dermoid Cyst|Vaginal Mature Cystic Teratoma|Vaginal Teratoma	A rare benign cystic teratoma that arises from the vagina. It presents as a slow growing cyst in the vaginal wall that contains sebaceous material and hair. The cyst is lined by squamous epithelium. Skin adnexal structures and sometimes smooth and skeletal muscle are present.			Neoplastic Process	
C128114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128114>	C34709	Hypercholesterolemia, Familial, 4|Autosomal Recessive Hypercholesterolemia|FCHL4	An autosomal recessive condition caused by mutation(s) in the LDLRAP1 gene, encoding low density lipoprotein receptor adaptor protein 1. The phenotype is similar to that of familial hypercholesterolemia, but generally considered to be a milder form of hypercholesterolemia.			Disease or Syndrome	Cellosaurus Disease Terminology
C128115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128115>	C53543|C28193	Marshall Syndrome	An autosomal dominant condition caused by mutation(s) in the COL11A1 gene, encoding collagen alpha-1(XI) chain. The syndrome may be characterized by facial dysmorphism, cataracts, myopia, hearing loss, and short stature. Mutation(s) in the COL11A1 gene are causative in Stickler syndrome, but the phenotype of Marshall syndrome is more mild.			Disease or Syndrome	Cellosaurus Disease Terminology
C128116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128116>	C61257	Neuronal Ceroid Lipofuscinosis Type 4B|Autosomal Dominant Kufs Disease|CLN4B|Neuronal Ceroid Lipofuscinosis, Parry Type	A condition associated with mutation(s) in the DNAJC5 gene, encoding dnaJ homolog subfamily C member 5. The condition is one of a group of genetically heterogeneous neurodegenerative disorders, characterized by accumulation of intracellular lipopigments.			Disease or Syndrome	Cellosaurus Disease Terminology
C128117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128117>	C84638	Primary Ciliary Dyskinesia 1|CILD1	An autosomal recessive primary ciliary motility defect caused by mutation(s) in the DNAI1 gene, encoding dynein intermediate chain 1, axonemal.			Disease or Syndrome	Cellosaurus Disease Terminology
C128118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128118>	C99109	Muscular Dystrophy-Dystroglycanopathy (Congenital with Brain and Eye Anomalies) Type A, 1|MDDGA1	An autosomal recessive muscular dystrophy caused by mutations in the POMT1 gene, encoding protein O-mannosyl-transferase 1. It is associated with characteristic brain and eye malformations, profound mental retardation, and early death.			Disease or Syndrome	Cellosaurus Disease Terminology
C128119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128119>	C97089|C34816	Fructose-1,6-Bisphosphatase Deficiency	A rare autosomal recessive metabolic disorder caused by a lack of fructose-1,6-bisphosphatase that is characterized by recurrent episodes of fasting hypoglycemia and lactic acidosis.			Disease or Syndrome	Cellosaurus Disease Terminology
C12811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12811>	C13019	Uvea|EYE, UVEA|Iris, Ciliary Body and Choroid|Tunica Vasculosa of Eyeball|UVEA|Uveal Tract|uvea|uveal tract	The pigmented layer of the eyeball between the tough, white outer coat of the eye and the retina.	Uveal Tract		Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C128120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128120>	C134526	Canine Leukemia	An acute or chronic malignant (clonal) hematologic disorder, arising from hematopoietic stem cells in dogs. It is characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.			Neoplastic Process	Cellosaurus Disease Terminology
C128121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128121>	C134526	Canine Lymphoma	A malignant lymphoproliferative disorder that affects dogs. It is characterized by the clonal proliferation of B- or T-lymphocytes in the lymph nodes, bone marrow, and/or extranodal sites.			Neoplastic Process	Cellosaurus Disease Terminology
C128122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128122>	C134526	Canine Prostate Carcinoma	A malignant epithelial neoplasm arising from the prostate gland of a dog.			Neoplastic Process	Cellosaurus Disease Terminology
C128123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128123>	C21637	Mouse Testicular Teratoma	A non-seminomatous germ cell tumor arising from the testis of a mouse, characterized by the presence of various tissues corresponding to the different germinal layers (endoderm, mesoderm, and ectoderm).			Neoplastic Process	Cellosaurus Disease Terminology
C128124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128124>	C20117	Diffusion Spectrum Imaging|DSI	A high angular resolution diffusion MRI technique that maps complex tissue structures at the scale of single MRI voxels.	Diffusion Spectrum Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C128125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128125>	C134526	Canine Histiocytic Sarcoma	A malignant neoplasm that affects dogs, characterized by the presence of malignant cells with morphologic and immunophenotypic characteristics similar to those seen in mature histiocytes.			Neoplastic Process	Cellosaurus Disease Terminology
C128126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128126>	C134526	Canine Transitional Cell Carcinoma	A malignant neoplasm that affects dogs, arising from transitional epithelium.			Neoplastic Process	Cellosaurus Disease Terminology
C128127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128127>	C173603	Worst Severity Past Seven Days Dry Mouth Question|In the last 7 days, what was the severity of your dry mouth at its worst|Worst Severity Past Seven Days Dry Mouth|Worst Severity of Dry Mouth Past Seven Days	A question about the worst severity of an individual's dry mouth during the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C128128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128128>	C173603	Worst Severity Past Seven Days Problems with Tasting Food or Drink Question|In the last 7 days, what was the severity of your problems with tasting food or drink at their worst|Worst Severity Past Seven Days Problems with Tasting Food or Drink|Worst Severity of Problems with Tasting Food or Drink Past Seven Days	A question about the worst severity of an individual's problems with tasting food or drink during the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C128129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128129>	C173737|C173358	Past Seven Days Frequency of Heartburn Question|Frequency of Heartburn Past Seven Days|In the last 7 days, how often did you have heartburn|Past Seven Days Frequency of Heartburn	A question about the frequency of an individual's heartburn during the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C12812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12812>	C12700	Vagus Nerve|Cranial Nerve X|NERVE, VAGUS|Pneumogastric Nerve|Tenth Cranial Nerve|Tenth Cranial Nerve|VAGUS NERVE	The tenth cranial nerve. It is the longest cranial nerve. It originates in the medulla and exits the cranium through the jugular foramen. It supplies various muscles, including muscles of the pharynx and soft palate.	Vagus Nerve		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C128130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128130>	C173603	Worst Severity Past Seven Days Heartburn Question|In the last 7 days, what was the severity of your heartburn at its worst|Worst Severity Past Seven Days Heartburn|Worst Severity of Heartburn Past Seven Days	A question about the worst severity of an individual's heartburn during the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C128131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128131>	C173737|C173358	Past Seven Days Frequency of Bloating of the Abdomen Question|Frequency of Bloating of the Abdomen Past Seven Days|In the last 7 days, how often did you have bloating of the abdomen (belly)|Past Seven Days Frequency of Bloating of the Abdomen	A question about the frequency of an individual's bloating of the abdomen during the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C128132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128132>	C2124	Iodine I 124-cRGDY-PEG-C Dots|124I-cRGDY-PEG-C Dots|124I-cRGDY-PEG-dots|124I-cRGDY-PEG-ylated Dots|124I-cRGDY-PEG-ylated-C Dots|I-124 cRGDY-PEG-C Dots|I-124 cRGDY-PEG-dots|Iodine I 124-cRGDY-PEG-dots	An imaging agent composed of silica-based nanoparticles labeled with a near-infrared (NIR) fluorophore, Cyanine 5.5 (Cy5.5) and surrounded by polyethylene glycol (PEG) chains attached to cyclo-[Arg-Gly-Asp-Tyr] (cRGDY) peptides labeled with the positron-emitting radioisotope iodine I 124 via a tyrosine linker, with potential use in positron emission tomography (PET)/spiral computed tomography (CT) imaging. Upon intravenous administration of the radiolabeled iodine I 124-cRGDY-PEG-C dots, the cRGD moiety selectively binds to alphaVbeta3 integrin expressed on tumor cells. Upon PET/CT imaging, alphaVbeta3 integrin-expressing tumor cells can be visualized and the degree of both tumor metastasis and sentinel lymph node (SLN) trafficking can be assessed. Integrins are transmembrane glycoproteins upregulated on proliferating tumor vessel endothelial cells and various cancer cells; their overexpression has been associated with neovascularization, differentiation, proliferation of tumor cells, metastasis and an overall poor prognosis.	Iodine I 124-cRGDY-PEG-C Dots		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology
C128133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128133>	C173603	Worst Severity Past Seven Days Bloating of the Abdomen Question|In the last 7 days, what was the severity of your bloating of the abdomen (belly) at its worst|Worst Severity Past Seven Days Bloating of the Abdomen|Worst Severity of Bloating of the Abdomen Past Seven Days	A question about the worst severity of an individual's bloating of the abdomen during the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C128134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128134>	C173737|C173386|C173358	Past Seven Days Frequency of Anxiety Question|Frequency of Anxiety Past Seven Days|In the last 7 days, how often did you feel anxiety|Past Seven Days Frequency of Anxiety	A question about the frequency of an individual's anxiety during the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C128135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128135>	C173603|C173386	Worst Severity Past Seven Days Anxiety Question|In the last 7 days, what was the severity of your anxiety at its worst|Worst Severity Past Seven Days Anxiety|Worst Severity of Anxiety Past Seven Days	A question about the worst severity of an individual's anxiety during the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C128136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128136>	C173787|C173737|C173584|C173386	Past Seven Days Anxiety Interfering with Usual or Daily Activities Question|Anxiety Interfering with Usual or Daily Activities Past Seven Days|In the last 7 days, how much did anxiety interfere with your usual or daily activities|Past Seven Days Anxiety Interfering with Usual or Daily Activities	A question about how much an individual's anxiety interfered with their usual or daily activities during the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C128137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128137>	C173737|C173358|C173160	Past Seven Days Frequency of Sad or Unhappy Feelings Question|Frequency of Sad or Unhappy Feelings Past Seven Days|In the last 7 days, how often did you have sad or unhappy feelings|Past Seven Days Frequency of Sad or Unhappy Feelings	A question about the frequency of an individual's sad or unhappy feelings during the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C128138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128138>	C129822|C128057	Lodapolimab|Anti-PD-L1 Checkpoint Antibody LY3300054|Anti-PD-L1 Monoclonal Antibody LY3300054|Anti-Programmed Cell Death Ligand 1 Checkpoint Antibody LY3300054|LODAPOLIMAB|LY3300054|WHO 11185	A monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1) with immune checkpoint inhibitory and potential antineoplastic activities. Upon administration, lodapolimab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T-cells.	Lodapolimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C128139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128139>	C173603|C173160	Worst Severity Past Seven Days Sad or Unhappy Feelings Question|In the last 7 days, what was the severity of your sad or unhappy feelings at their worst|Worst Severity Past Seven Days Sad or Unhappy Feelings|Worst Severity of Sad or Unhappy Feelings Past Seven Days	A question about the worst severity of an individual's sad or unhappy feelings during the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C12813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12813>	C12948	Vas Deferens|Ductus Deferens|VAS DEFERENS|deferent duct|ductus deferens|vas deferen|vas deferens|vas deferens	Duct carrying spermatozoa.	Vas Deferens		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C128140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128140>	C173787|C173737|C173584|C173160	Past Seven Days Sad or Unhappy Feelings Interfering with Usual or Daily Activities Question|In the last 7 days, how much did sad or unhappy feelings interfere with your usual or daily activities|Past Seven Days Sad or Unhappy Feelings Interfering with Usual or Daily Activities|Sad or Unhappy Feelings Interfering with Usual or Daily Activities Past Seven Days	A question about how much an individual's sad or unhappy feelings interfered with their usual or daily activities during the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C128141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128141>	C16830	Swallowable Sponge Cell Sampling Device|Cytosponge|Swallowable Sponge|Swallowable Sponge Device	A minimally invasive cell sampling device comprising a sponge-like material that is compressed into a swallowable and dissolvable capsule, and a cord for retrieval.	Swallowable Sponge Cell Sampling Device		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C128142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128142>	C4756	Vulvar Squamous Intraepithelial Lesion, HPV-Associated|Classical VIN|Usual Type VIN|VIN of Usual Type|Vulvar Intraepithelial Neoplasia of Usual Type|Vulvar Intraepithelial Neoplasia, HPV-Associated|Vulvar SIL|Vulvar Squamous Intraepithelial Lesion	An intraepithelial lesion of the vulvar squamous epithelium associated with HPV infection. It is characterized by maturation abnormalities and nuclear hyperchromasia that are confined to the basement membrane.			Neoplastic Process	
C128143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128143>	C35444	Idiopathic Crescentic Glomerulonephritis	Crescentic glomerulonephritis, the cause of which is unknown.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C128144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128144>	C34645|C120887	Membranous Nephropathy - Secondary|Secondary Membranous Glomerulopathy|Secondary Membranous Glomerulopathy	Membranous nephropathy due to another medical condition.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C128145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128145>	C35337	Pierson Syndrome	An autosomal recessive disorder caused by mutation(s) in the LAMB2 gene, encoding laminin subunit beta-2. It is characterized by congenital nephrotic syndrome with diffuse mesangial sclerosis and distinct ocular abnormalities.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C128146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128146>	C27600	Renal Infarct|Kidney Infarct|Kidney Infarct	Ischemic necrosis of the kidney caused by interruption of the blood supply to the area.			Disease or Syndrome	NICHD Terminology|Pediatric Nephrology Terminology
C128147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128147>	C36286	Acquired Solitary Kidney	A finding of one kidney after the loss of the second, whether due to injury, disease or surgery.			Finding	NICHD Terminology|Pediatric Nephrology Terminology
C128148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128148>	C173509	Spiritual Well-being Question|Spiritual Well Being|Spiritual Well-being|Spiritual Well-being	A question regarding the status of one's sense of meaning and purpose in life and ability to relate to their religious beliefs.			Intellectual Product	Linear Analogue Self-Assessment
C128149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128149>	C91102	Intellectual Well-being Question|Intellectual Well Being|Intellectual Well-being|Intellectual Well-being	A question regarding the status of one's mental capacity and ability to think clearly, concentrate, and remember things.			Intellectual Product	Linear Analogue Self-Assessment
C12814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12814>	C12679	Vein|VEIN|Venous|vein|vein|venous tree organ part	A blood vessel that carries blood toward the heart.	Vein		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|UBERON Terminology
C128150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128150>	C217121	Quality of Life Linear Analogue Scale|Quality Rating Linear Analogue Scale|Quality Rating Scale|Quality of Life Rating Scale	A linear analogue scale for the subjective scoring of quality of life with anchor point descriptions of 0: As bad as it can be and 10: As good as it can be.			Intellectual Product	Linear Analogue Self-Assessment
C128151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128151>	C221045	Quality Rating Score 0|Quality of Life Rating Score 0	A subjective rating score of 0 on a linear analogue scale with anchor point descriptions of 0: As bad as it can be and 10: As good as it can be.			Intellectual Product	Linear Analogue Self-Assessment
C128152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128152>	C221045	Quality Rating Score 1|Quality of Life Rating Score 1	A subjective rating score of 1 on a linear analogue scale with anchor point descriptions of 0: As bad as it can be and 10: As good as it can be.			Intellectual Product	Linear Analogue Self-Assessment
C128153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128153>	C221045	Quality Rating Score 2|Quality of Life Rating Score 2	A subjective rating score of 2 on a linear analogue scale with anchor point descriptions of 0:As bad as it can be and 10: As good as it can be.			Intellectual Product	Linear Analogue Self-Assessment
C128154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128154>	C221045	Quality Rating Score 3|Quality of Life Rating Score 3	A subjective rating score of 3 on a linear analogue scale with anchor point descriptions of 0: As bad as it can be and 10: As good as it can be.			Intellectual Product	Linear Analogue Self-Assessment
C128155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128155>	C221045	Quality Rating Score 4|Quality of Life Rating Score 4	A subjective rating score of 4 on a linear analogue scale with anchor point descriptions of 0: As bad as it can be and 10: As good as it can be.			Intellectual Product	Linear Analogue Self-Assessment
C128156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128156>	C221045	Quality Rating Score 5|Quality of Life Rating Score 5	A subjective rating score of 5 on a linear analogue scale with anchor point descriptions of 0: As bad as it can be and 10: As good as it can be.			Intellectual Product	Linear Analogue Self-Assessment
C128157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128157>	C221045	Quality Rating Score 6|Quality of Life Rating Score 6	A subjective rating score of 6 on a linear analogue scale with anchor point descriptions of 0: As bad as it can be and 10: As good as it can be.			Intellectual Product	Linear Analogue Self-Assessment
C128158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128158>	C221045	Quality Rating Score 7|Quality of Life Rating Score 7	A subjective rating score of 7 on a linear analogue scale with anchor point descriptions of 0: As bad as it can be and 10: As good as it can be.			Intellectual Product	Linear Analogue Self-Assessment
C128159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128159>	C221045	Quality Rating Score 8|Quality of Life Rating Score 8	A subjective rating score of 8 on a linear analogue scale with anchor point descriptions of 0: As bad as it can be and 10: As good as it can be.			Intellectual Product	Linear Analogue Self-Assessment
C12815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12815>	C12814	Inferior Vena Cava|Caudal Vena Cava|INFERIOR VENA CAVA|Posterior Vena Cava|inferior vena cava	A large vein that returns blood from the lower half of the body to the heart.	Inferior Vena Cava		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C128160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128160>	C221045	Quality Rating Score 9|Quality of Life Rating Score 9	A subjective rating score of 9 on a linear analogue scale with anchor point descriptions of 0: As bad as it can be and 10: As good as it can be.			Intellectual Product	Linear Analogue Self-Assessment
C128161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128161>	C221045	Quality Rating Score 10|Quality of Life Rating Score 10	A subjective rating score of 10 on a linear analogue scale with anchor point descriptions of 0: As bad as it can be and 10: As good as it can be.			Intellectual Product	Linear Analogue Self-Assessment
C128162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128162>	C6380	Vulvar Adenocarcinoma of Mammary Gland Type|AGMLGs|Adenocarcinoma of Anogenital Mammary-Like Glands|Adenocarcinoma of Anogenital Mammary-Type Glands|Adenocarcinoma of Mammary Gland Type|Adenocarcinoma of Mammary Gland-Type|Adenocarcinoma of the Vulva with Breast Carcinoma Features|Vulvar Adenocarcinoma of Mammary Gland-Type	A rare adenocarcinoma that arises from the vulva and is characterized by the presence of morphological features identical to those seen in breast adenocarcinomas.			Neoplastic Process	
C128163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128163>	C42075	Mammary Gland Type Features Present	A microscopic finding indicating the presence of mammary gland type morphological features in a tumor sample.			Finding	
C128164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128164>	C6938|C6380|C40304	Vulvar Adenocarcinoma of Sweat Gland Origin|Vulvar Adenocarcinoma of Sweat Gland Type	A rare adenocarcinoma arising from vulvar skin sweat glands.			Neoplastic Process	
C128165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128165>	C7502|C4275|C181905	Malignant Vulvar Phyllodes Tumor	A rare malignant phyllodes tumor arising from the vulva.			Neoplastic Process	
C128166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128166>	C6380|C4126|C26712	Vulvar Mucinous Adenocarcinoma, Intestinal-Type|Primary Villoglandular Mucinous Adenocarcinoma Arising in the Surface Epithelium of the Vulva|Vulvar Adenocarcinoma of Intestinal Type|Vulvar Adenocarcinoma, Intestinal-Type|Vulvar Cloacogenic Adenocarcinoma|Vulvar Cloacogenic Carcinoma	A rare vulvar mucinous adenocarcinoma that resembles a large intestinal adenocarcinoma.			Neoplastic Process	
C128167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128167>	C4052|C212871	Vulvar Keratoacanthoma	A keratoacanthoma that arises from the vulva. It grows rapidly and may regress spontaneously. It is considered a variant of well-differentiated squamous cell carcinoma with distinct clinical behavior.			Neoplastic Process	
C128168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128168>	C17214	Contact Transmission|Contact Pathogen Transmission	The transmission of an infectious agent via touch.			Pathologic Function	NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology|NICHD Terminology|Pediatric Infectious Disease Terminology
C128169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128169>	C128168	Direct Transmission|Direct Contact Transmission	The transmission of an infectious agent from a source (e.g., person, animal, or surface) to a host without an intermediary.			Pathologic Function	NICHD Terminology|Pediatric Infectious Disease Terminology
C12816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12816>	C12814	Superior Vena Cava|Anterior Vena Cava|Cranial Vena Cava|SUPERIOR VENA CAVA|superior vena cava	The large vein that terminates in the right atrium and transports deoxygenated blood from the head, neck, arms, and chest to the heart.	Superior Vena Cava		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C128170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128170>	C128168	Indirect Transmission|Indirect Contact Transmission	The transmission of an infectious agent from a source to a host through an intermediary such as inanimate objects (vehicles) or living organisms (vectors).			Pathologic Function	NICHD Terminology|Pediatric Infectious Disease Terminology
C128171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128171>	C5685|C172682	Colon Conventional Adenoma with Severe Dysplasia	A colon conventional adenoma characterized by the presence of severe epithelial dysplasia.			Neoplastic Process	NCIt Neoplasm Core Terminology
C128172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128172>	C97927|C136417	PDGFRB Gene Mutation|CD140b Gene Mutation|JTK12 Gene Mutation|PDGFR1 Gene Mutation|Platelet Derived Growth Factor Receptor Beta Gene Mutation	A change in the nucleotide sequence of the PDGRFB gene.	PDGFRB Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128173>	C97928	PDGFRB Protein Variant|Beta Platelet-Derived Growth Factor Receptor Protein Variant|Beta-Type Platelet-Derived Growth Factor Receptor Protein Variant|CD140 Antigen-Like Family Member B Protein Variant|CD140b Protein Variant|PDGF-R-Beta Protein Variant|PDGFR-1 Protein Variant|PDGFR-Beta Protein Variant|Platelet-Derived Growth Factor Receptor 1 Protein Variant|Platelet-Derived Growth Factor Receptor Beta Protein Variant	A variation in the amino acid sequence of the platelet-derived growth factor receptor beta protein.	PDGFRB Protein Variant		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128174>	C128173	PDGFRB NP_002600.1:p.T681I|Beta Platelet-Derived Growth Factor Receptor T681I|Beta Platelet-Derived Growth Factor Receptor Thr681Ile|Beta-Type Platelet-Derived Growth Factor Receptor T681I|Beta-Type Platelet-Derived Growth Factor Receptor Thr681Ile|CD140 Antigen-Like Family Member B T681I|CD140 Antigen-Like Family Member B Thr681Ile|CD140b T681I|CD140b Thr681Ile|NP_002600.1:pT681I|NP_002600.1:pThr681Ile|PDGF-R-Beta T681I|PDGF-R-Beta Thr681Ile|PDGFR-1 T681I|PDGFR-1 Thr681Ile|PDGFR-Beta T681I|PDGFR-Beta Thr681Ile|PDGFRB NP_002600.1:pThr681Ile|PDGFRB T681I|PDGFRB Thr681Ile|PDGFRB p.T681I|PDGFRB p.Thr681Ile|Platelet-Derived Growth Factor Receptor 1 T681I|Platelet-Derived Growth Factor Receptor 1 Thr681Ile|Platelet-Derived Growth Factor Receptor Beta T681I|Platelet-Derived Growth Factor Receptor Beta Thr681Ile	A change in the amino acid residue at position 681 in the platelet-derived growth factor receptor beta protein where threonine has been replaced by isoleucine.	PDGFRB NP_002600.1:p.T681I		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128175>	C97927	MYD88 Gene Mutation|Myeloid Differentiation Primary Response 88 Gene Mutation	A change in the nucleotide sequence of the MYD88 gene.	MYD88 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128176>	C157594	MYD88 NM_002468.4:c.794T>C|MYD88 c.794T>C|Myeloid Differentiation Primary Response 88 c.794T>C|NM_002468.4:c.794T>C	A nucleotide substitution at position 794 of the coding sequence of the MYD88 gene where thymine has been mutated to cytosine.	MYD88 NM_002468.4:c.794T>C		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128177>	C97928	MYD88 Protein Variant|Myeloid Differentiation Primary Response Protein MyD88 Protein Variant	A variation in the amino acid sequence of the myeloid differentiation primary response protein MyD88.	MYD88 Protein Variant		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128178>	C128177	MYD88 NP_002459.2:p.L265P|MYD88 L265P|MYD88 Leu265Pro|MYD88 NP_002459.2:p.Leu265Pro|MYD88 p.L265P|MYD88 p.Leu265Pro|Myeloid Differentiation Primary Response Protein MyD88 L265P|Myeloid Differentiation Primary Response Protein MyD88 Leu265Pro|NP_002459.2:p.L265P|NP_002459.2:p.Leu265Pro	A change in the amino acid residue at position 265 in the myeloid differentiation primary response protein MyD88 where leucine has been replaced by proline.	MYD88 NP_002459.2:p.L265P		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128179>	C20130	Glutaminase Family|EC 3.5.1.2|Glutaminase|Glutaminase I|Glutaminase I Family|Glutamine Aminohydrolase|Glutamine Aminohydrolase Family|L-Glutaminase|L-Glutaminase Family|L-Glutamine Amidohydrolase|L-Glutamine Amidohydrolase Family	An enzyme family that cleaves amide bonds to generate glutamate from glutamine. There are two human glutaminase genes that are expressed in a tissue specific pattern.	Glutaminase Family		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12817>	C12814	Vena Cava|VEIN, VENA CAVA|VENA CAVA|Vena caval structure (body structure)	A large vein which returns blood from the head, neck and extremities to the heart.	Vena Cava		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C128180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128180>	C68564	Mycobiome|Mycobiome Profile	The microbial fungi that are present in an environment or in a biological sample.	Mycobiome		Organism	CTRP Biomarker Terminology|CTRP Terminology
C128181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128181>	C19967	Decipher Prostate Cancer Test|DECIPHER|Decipher|Decipher Metastasis Test|Decipher Test	A proprietary genetic test that evaluates a prostate cancer tumor for its potential for metastasis. Decipher measures the expression levels of 22 RNA biomarkers involved in multiple biological pathways that are associated with metastasis and aggressive prostate cancer to classify tumors as high, average, or low risk of metastasis.	Decipher Prostate Cancer Test		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C128182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128182>	C20194	GREB1 Gene|GREB1|GREB1|Growth Regulation By Estrogen In Breast Cancer 1 Gene	This gene may be involved in hormone-dependent cell proliferation.	GREB1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C128183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128183>	C128182	GREB1 wt Allele|Gene Regulated By Estrogen In Breast Cancer|Growth Regulation By Estrogen In Breast Cancer 1 wt Allele|KIAA0575	Human GREB1 wild-type allele is located in the vicinity of 2p25.1 and is approximately 160 kb in length. This allele, which encodes protein GREB1, may plays a role in tissue responses to estrogen. Aberrant expression may be associated with estrogen receptor-positive breast carcinoma and other hormone-responsive neoplasms.	GREB1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128184>	C18466	Protein GREB1|Gene Regulated In Breast Cancer 1 Protein	Protein GREB1 (1949 aa, ~216 kDa) is encoded by the human GREB1 gene. This protein may be involved in estrogen-stimulated cell proliferation.	Protein GREB1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128185>	C20923	PTGER4 Gene|PTGER4|PTGER4|Prostaglandin E Receptor 4 Gene	This gene plays a role in prostaglandin-dependent signaling.	PTGER4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C128186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128186>	C128185	PTGER4 wt Allele|EP4|EP4R|PGE Receptor, EP4 Subtype Gene|Prostaglandin E Receptor 4 (Subtype EP4) Gene|Prostaglandin E Receptor 4 wt Allele|Prostaglandin E Receptor 4, EP4 Subtype Gene	Human PTGER4 wild-type allele is located in the vicinity of 5p13.1 and is approximately 62 kb in length. This allele, which encodes prostaglandin E2 receptor EP4 subtype protein, is involved in prostaglandin-mediated G protein-coupled receptor signaling.	PTGER4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128187>	C34816	2-Hydroxyglutaric Aciduria	A group of genetic disorders characterized by elevated urinary concentrations of 2-hydroxyglutaric acid. Three different types have been identified based on the steroisomeric composition of the elevated alpha-hydroxyglutaric acid metabolites. Additionally, the disease may be categorized by the genetic mutation that is causative. Genes associated with 2-hydroxyglutaric aciduria are L2HGDH, D2HGDH, IDH2, and/or SLC25A1. Generally, there is nervous system involvement, but the clinical manifestations are variable and are dependent on the specific type of defect present.			Disease or Syndrome	Cellosaurus Disease Terminology
C128188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128188>	C127171	46,XY Sex Reversal 1|SRXY1	Sex reversal in an individual with 46,XY karyotype caused by point mutations or deletions in the SRY gene, encoding sex-determining region Y protein.			Disease or Syndrome	Cellosaurus Disease Terminology
C128189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128189>	C3023	Childhood Absence Epilepsy	A common generalized epilepsy syndrome occurring in children, characterized by absence seizures of short duration. The cause of the syndrome is presumed to be genetic. Genes which are associated with the condition include GABRB3, GABRG2, GABRA1, CACNA1H, and ECA1.			Disease or Syndrome	Cellosaurus Disease Terminology
C12818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12818>	C12679	Venule	The part of the microvasculature that receives blood from the capillaries, and which then converges to form veins.	Venule		Body Part, Organ, or Organ Component	
C128190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128190>	C34816	Congenital Sucrase-Isomaltase Deficiency|Disaccharide Intolerance 1	An autosomal recessive genetic disorder caused by mutations in the SI gene, encoding sucrase-isomaltase, intestinal. The condition is characterized by malabsorption and osmotic diarrhea.			Disease or Syndrome	Cellosaurus Disease Terminology
C128191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128191>	C28193	Lymphedema-Distichiasis Syndrome	An autosomal dominant genetic disorder caused by mutation(s) in the FOXC2 gene, encoding forkhead box protein C2. The condition is characterized by lymphedema and distichiasis.			Disease or Syndrome	Cellosaurus Disease Terminology
C128192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128192>	C222065	Mosaic Variegated Aneuploidy Syndrome 1|MVA1	A mosaic variegated aneuploidy syndrome caused by mutations in the BUB1B gene. Clinical manifestations include growth retardation and an increased risk of developing malignant neoplasms, usually acute lymphoblastic leukemia, rhabdomyosarcoma, and Wilms tumor.			Disease or Syndrome	CCPS Disease Terminology|Cellosaurus Disease Terminology|Childhood Cancer Predisposition Study Terminology
C128193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128193>	C34816	Glutathione Synthetase Deficiency|5-Oxoprolinuria|GSSD|Pyroglutamic Aciduria	An autosomal recessive genetic disorder caused by mutation(s) in the GSS gene, encoding glutathione synthetase. Mutation(s) in the same gene is causative in hemolytic anemia due to glutathione synthetase deficiency, with the more severe condition causing elevated urinary concentrations of 5-oxoproline and central nervous system damage in addition to hemolytic anemia.			Disease or Syndrome	Cellosaurus Disease Terminology
C128194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128194>	C18239	Prostaglandin E2 Receptor EP4 Subtype|E-Type Prostanoid Receptor 4|EP4|EP4 Receptor|PGE Receptor EP4 Subtype|PGE2 Receptor EP(4)|PGE2 Receptor EP4 Subtype|PTGER4|Prostanoid EP4 Receptor	Prostaglandin E2 receptor EP4 subtype (488 aa, ~53 kDa) is encoded by the human PTGER4 gene. This protein plays a role in the regulation of prostaglandin E2-dependent signaling.	Prostaglandin E2 Receptor EP4 Subtype		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128195>	C134526	Canine Sarcoma	A malignant mesenchymal neoplasm that affects dogs. It arises from muscle, fat, fibrous tissue, bone, cartilage, and blood vessels.			Neoplastic Process	Cellosaurus Disease Terminology
C128196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128196>	C16275	Coexpression Extrapolation|COXEN|Coexpression Extrapolation (COXEN)	A measure of drug sensitivity and resistance predictions for bladder cancers based on the COXEN gene expression profile method.			Intellectual Product	
C128197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128197>	C217121	COXEN Sensitivity Scale	A scale that represents drug sensitivity and resistance predictions for bladder tumors, ranging from 1 for the most drug-resistant to 40 for the most drug-sensitive.			Intellectual Product	Coexpression Extrapolation
C128198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128198>	C221046	COXEN Score 1	A score of 1 on the COXEN Sensitivity Scale.			Intellectual Product	
C128199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128199>	C221046	COXEN Score 2	A score of 2 on the COXEN Sensitivity Scale.			Intellectual Product	
C12819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12819>	C33353	Vertebral Artery|Structure of vertebral artery (body structure)|VA|VERTEBRAL ARTERY	The first branch of the subclavian artery that ascends both sides of the neck and merges at the middle line to from the basilar artery at the level of the pons.	Vertebral Artery		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C1281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1281>	C577	Biohazardous Substance|Biohazard|Biohazard Substance	A biological or chemical substance that exerts toxic or pathologic effects on living entities.			Hazardous or Poisonous Substance	
C128200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128200>	C221046	COXEN Score 3	A score of 3 on the COXEN Sensitivity Scale.			Intellectual Product	
C128201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128201>	C221046	COXEN Score 4	A score of 4 on the COXEN Sensitivity Scale.			Intellectual Product	
C128202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128202>	C221046	COXEN Score 5	A score of 5 on the COXEN Sensitivity Scale.			Intellectual Product	
C128203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128203>	C221046	COXEN Score 6	A score of 6 on the COXEN Sensitivity Scale.			Intellectual Product	
C128204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128204>	C221046	COXEN Score 7	A score of 7 on the COXEN Sensitivity Scale.			Intellectual Product	
C128205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128205>	C221046	COXEN Score 8	A score of 8 on the COXEN Sensitivity Scale.			Intellectual Product	
C128206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128206>	C221046	COXEN Score 9	A score of 9 on the COXEN Sensitivity Scale.			Intellectual Product	
C128207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128207>	C221046	COXEN Score 10	A score of 10 on the COXEN Sensitivity Scale.			Intellectual Product	
C128208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128208>	C221046	COXEN Score 11	A score of 11 on the COXEN Sensitivity Scale.			Intellectual Product	
C128209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128209>	C221046	COXEN Score 12	A score of 12 on the COXEN Sensitivity Scale.			Intellectual Product	
C12820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12820>	C12700	Vestibular Nerve|Vestibular Nerve (VIII)|Vestibular Root of Eighth Cranial Nerve	One of the two branches of cranial nerve VIII (vestibulocochlear nerve), which transmits sensory information transmitted from vestibular hair cells located in the utricle, the saccule, and the three semicircular canals.	Vestibular Nerve		Body Part, Organ, or Organ Component	
C128210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128210>	C221046	COXEN Score 13	A score of 13 on the COXEN Sensitivity Scale.			Intellectual Product	
C128211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128211>	C221046	COXEN Score 14	A score of 14 on the COXEN Sensitivity Scale.			Intellectual Product	
C128212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128212>	C221046	COXEN Score 15	A score of 15 on the COXEN Sensitivity Scale.			Intellectual Product	
C128213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128213>	C221046	COXEN Score 16	A score of 16 on the COXEN Sensitivity Scale.			Intellectual Product	
C128214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128214>	C221046	COXEN Score 17	A score of 17 on the COXEN Sensitivity Scale.			Intellectual Product	
C128215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128215>	C221046	COXEN Score 18	A score of 18 on the COXEN Sensitivity Scale.			Intellectual Product	
C128216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128216>	C221046	COXEN Score 19	A score of 19 on the COXEN Sensitivity Scale.			Intellectual Product	
C128217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128217>	C221046	COXEN Score 20	A score of 20 on the COXEN Sensitivity Scale.			Intellectual Product	
C128218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128218>	C221046	COXEN Score 21	A score of 21 on the COXEN Sensitivity Scale.			Intellectual Product	
C128219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128219>	C221046	COXEN Score 22	A score of 22 on the COXEN Sensitivity Scale.			Intellectual Product	
C12821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12821>	C49346	Vestibular Nucleus|Vestibular Nuclei	The cranial nuclei, located in both the pons and the medulla, for the vestibular nerve.	Vestibular Nuclei		Anatomical Structure	
C128220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128220>	C221046	COXEN Score 23	A score of 23 on the COXEN Sensitivity Scale.			Intellectual Product	
C128221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128221>	C221046	COXEN Score 24	A score of 24 on the COXEN Sensitivity Scale.			Intellectual Product	
C128222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128222>	C221046	COXEN Score 25	A score of 25 on the COXEN Sensitivity Scale.			Intellectual Product	
C128223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128223>	C221046	COXEN Score 26	A score of 26 on the COXEN Sensitivity Scale.			Intellectual Product	
C128224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128224>	C221046	COXEN Score 27	A score of 27 on the COXEN Sensitivity Scale.			Intellectual Product	
C128225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128225>	C221046	COXEN Score 28	A score of 28 on the COXEN Sensitivity Scale.			Intellectual Product	
C128226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128226>	C221046	COXEN Score 29	A score of 29 on the COXEN Sensitivity Scale.			Intellectual Product	
C128227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128227>	C221046	COXEN Score 30	A score of 30 on the COXEN Sensitivity Scale.			Intellectual Product	
C128228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128228>	C221046	COXEN Score 31	A score of 31 on the COXEN Sensitivity Scale.			Intellectual Product	
C128229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128229>	C221046	COXEN Score 32	A score of 32 on the COXEN Sensitivity Scale.			Intellectual Product	
C12822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12822>	C38617	Vocal Cord|VOCAL CORD|Vocal Cords|Vocal cord structure (body structure)|vocal cord	A pair of small bands of muscle that stretch from the thyroid cartilage in front to the arytenoid cartilage in back of the larynx. The vocal cords help prevent food entering the lungs and produce sound through vibration.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C128230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128230>	C221046	COXEN Score 33	A score of 33 on the COXEN Sensitivity Scale.			Intellectual Product	
C128231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128231>	C221046	COXEN Score 34	A score of 34 on the COXEN Sensitivity Scale.			Intellectual Product	
C128232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128232>	C221046	COXEN Score 35	A score of 35 on the COXEN Sensitivity Scale.			Intellectual Product	
C128233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128233>	C221046	COXEN Score 36	A score of 36 on the COXEN Sensitivity Scale.			Intellectual Product	
C128234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128234>	C221046	COXEN Score 37	A score of 37 on the COXEN Sensitivity Scale.			Intellectual Product	
C128235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128235>	C221046	COXEN Score 38	A score of 38 on the COXEN Sensitivity Scale.			Intellectual Product	
C128236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128236>	C221046	COXEN Score 39	A score of 39 on the COXEN Sensitivity Scale.			Intellectual Product	
C128237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128237>	C221046	COXEN Score 40	A score of 40 on the COXEN Sensitivity Scale.			Intellectual Product	
C128238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128238>	C1708	Sensitive Anticancer Agent	An FDA-approved anticancer agent that an NCI-60 cell line is predicted to be sensitive to.			Chemical Viewed Functionally	Coexpression Extrapolation
C128239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128239>	C463	Isofuran|IsoF	A group of eicosanoids that contain a substituted tetrahydrofuran ring formed by free radical mediated peroxidation of arachidonic acid. Isofuran production is favored over isoprostane production when elevated levels of oxygen are present. As isofurans are stable byproducts of lipid peroxidation, they can be used as biomarkers for oxidative stress.	Isofuran		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C12823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12823>	C13019	Corneoscleral Limbus|Corneal Limbus	The transitional zone where the cornea becomes continuous with the sclera.	Corneal Limbus		Body Part, Organ, or Organ Component	Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C128240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128240>	C4171|C40303|C40292|C3611	Vulvar Hidradenoma Papilliferum|Vulvar Papillary Hidradenoma	A benign glandular neoplasm that arises from the vulva. It presents as a mass or cystic lesion in or adjacent to the interlabial sulcus. It is characterized by the presence of complex branching papillae with fibrovascular stalks, lined by uniform columnar epithelial secretory cells and myoepithelial cells.			Neoplastic Process	
C128241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128241>	C82995	Bartholin Gland Hyperplasia|Bartholin Gland Nodular Hyperplasia	Nodular/lobular proliferation of normal Bartholin gland tissue and ducts.			Disease or Syndrome	
C128242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128242>	C3611|C139547	Vulvar Fibroadenoma|Vulvar Ectopic Fibroadenoma	A benign epithelial-stromal neoplasm that arises from the vulva and resembles the breast fibroadenoma.			Neoplastic Process	
C128243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128243>	C4866|C215420	Vulvar Neuroendocrine Carcinoma|Vulvar High Grade Neuroendocrine Carcinoma|Vulvar High Grade Neuroendocrine Neoplasm|Vulvar Neuroendocrine Cancer	A neuroendocrine carcinoma that arises from the vulva. This category includes small cell and large cell neuroendocrine carcinoma. Most small cell neuroendocrine carcinomas of the vulva are Merkel cell carcinomas.	Vulvar Neuroendocrine Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C128244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128244>	C215421|C128243	Vulvar Small Cell Neuroendocrine Carcinoma|Vulvar Small Cell Carcinoma	A rare small cell neuroendocrine carcinoma that arises from the vulva.			Neoplastic Process	
C128245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128245>	C215422|C128243	Vulvar Large Cell Neuroendocrine Carcinoma	A high-grade carcinoma with neuroendocrine differentiation that arises from the vulva and is characterized by the presence of malignant large cells.			Neoplastic Process	
C128247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128247>	C173586|C128243	Vulvar Merkel Cell Carcinoma	A Merkel cell carcinoma that arises from the vulva. It usually presents as a cutaneous nodular lesion. Most small cell neuroendocrine carcinomas of the vulva are Merkel cell carcinomas.			Neoplastic Process	
C128248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128248>	C63522|C63487	PEB Regimen|Cisplatin-Etoposide-Bleomycin Regimen|Cisplatin/Etoposide/Bleomycin|PEB|Pediatric BEP Regimen|Pediatric PEB|Pediatric PEB Regimen|Platinol-Etoposide-Bleomycin Regimen	A regimen consisting of bleomycin, etoposide and cisplatin used for the treatment of pediatric germ cell tumors (GCT). In the PEB regimen, the pediatric patients receive bleomycin once per cycle and do not receive weekly bleomycin during the weeks between cycles (every 21 days); in the adult BEP regimen, patients receive weekly bleomycin.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|NCI Drug Dictionary Terminology|Pharmacotherapy Regimens
C128249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128249>	C203001	Autologous CD34-positive Hematopoietic Progenitor Cells|Autologous CD34-positive HPCs	A population of autologous CD34-positive hematopoietic progenitor cells (HPCs) that can be used for autotransplantation. CD34+ HPCs are isolated from human blood stem cells upon apheresis. Upon transplantation with the CD34+ HPCs, these cells can differentiate into a variety of cell types including fibroblasts, osteoblasts, chondrocytes, myocytes, adipocytes, and endothelial cells.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology
C12824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12824>	C12372	Tibial Artery|Tibial Arteries	Any of the tibial arteries including the anterior and posterior tibial arteries and the anterior and posterior recurrent tibial arteries.	Tibial Artery		Body Part, Organ, or Organ Component	
C128251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128251>	C26057	CHD4 Gene|CHD4|CHD4|CHD4|Chromodomain Helicase DNA Binding Protein 4 Gene	This gene is involved in ATP-dependent chromatin remodeling.	CHD4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C128252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128252>	C128251	CHD4 wt Allele|CHD-4|Chromodomain Helicase DNA Binding Protein 4 wt Allele|Mi-2b|Mi2-BETA|SIHIWES	Human CHD4 wild-type allele is located in the vicinity of 12p13 and is approximately 37 kb in length. This allele, which encodes chromodomain-helicase-DNA-binding protein 4, plays a role in DNA unwinding.	CHD4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128253>	C16517	Chromodomain-Helicase-DNA-Binding Protein 4|ATP-Dependent Helicase CHD4|CHD-4|CHD4|Chromodomain Helicase DNA-Binding Protein 4|Dermatomyositis Autoantigen Mi-2 Beta|EC 3.6.4.12|MI-2 BETA ANTIGEN|MI-2 Beta|MI-2b|Mi-2 Autoantigen 218 kDa Protein|Mi-2 Beta|Mi2-Beta	Chromodomain-helicase-DNA-binding protein 4 (1912 aa, ~218 kDa) is encoded by the human CHD4 gene. This protein is involved in chromatin remodeling.	Chromodomain-Helicase-DNA-Binding Protein 4		Amino Acid, Peptide, or Protein|Enzyme	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128254>	C20988	FAT4 Gene|FAT Atypical Cadherin 4 Gene|FAT4|FAT4|FAT4	This gene plays a role in planar cell polarity.	FAT4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C128255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128255>	C128254	FAT4 wt Allele|CDHF14|CDHR11|FAT Atypical Cadherin 4 wt Allele|FAT Tumor Suppressor Homolog 4 (Drosophila) Gene|FAT Tumor Suppressor, Drosophila, Homolog of, 4 Gene|FAT-J|FATJ|HKLLS2|NBLA00548|VMLDS2	Human FAT4 wild-type allele is located in the vicinity of 4q28.1 and is approximately 177 kb in length. This allele, which encodes protocadherin Fat 4 protein, is involved in cell polarity. Mutation of the gene is associated with Hennekam lymphangiectasia-lymphedema syndrome 2 and Van Maldergem syndrome 2.	FAT4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128256>	C16393	Protocadherin Fat 4|Cadherin Family Member 14|Cadherin-Related Family Member 11|FAT Tumor Suppressor Homolog 4|Fat-Like Cadherin Protein FAT-J|hFat4	Protocadherin Fat 4 (4981 aa, ~543 kDa) is encoded by the human FAT4 gene. This protein plays a role in cell polarity.	Protocadherin Fat 4		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128257>	C20420	LZTR1 Gene|LZTR1|LZTR1|LZTR1|LZTR1|Leucine Zipper Like Transcription Regulator 1 Gene	This gene may be involved in Golgi stabilization, embryogenesis or transcriptional regulation.	LZTR1 Gene		Gene or Genome	CCPS Genetics Terminology|Childhood Cancer Predisposition Study Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C128258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128258>	C128257	LZTR1 wt Allele|BTBD29|LZTR-1|Leucine Zipper Like Transcription Regulator 1 wt Allele|Leucine-Zipper-Like Transcription Regulator 1 Gene|NS10|SWNTS2|TCFL2	Human LZTR1 wild-type allele is located in the vicinity of 22q11.21 or within 22q11.1-q11.2 and is approximately 20 kb in length. This allele, which encodes leucine-zipper-like transcriptional regulator 1 protein, may play a role in transcriptional regulation or Golgi functions. Mutation of the gene is associated with Noonan syndrome 10 and increased susceptibility to schwannomatosis 2. Deletion of the gene may be associated with DiGeorge syndrome.	LZTR1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128259>	C17207	Leucine-Zipper-Like Transcriptional Regulator 1|LZTR-1|Leucine Zipper-Like Transcriptional Regulator 1|Leucine-Zipper-Like Transcription Regulator 1	Leucine-zipper-like transcriptional regulator 1 (840 aa, ~95 kDa) is encoded by the human LZTR1 gene. This protein may be involved in embryogenesis.	Leucine-Zipper-Like Transcriptional Regulator 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12825>	C12372	Anterior Tibial Artery|ANTERIOR TIBIAL ARTERY	An artery of the lower extremity that supplies blood to the anterior part of the leg and the foot.	Anterior Tibial Artery		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128260>	C95943	MT-RNR1 Gene|12S Mitochondrial Ribosomal RNA Gene|MT-RNR1|MT-RNR1	This gene is involved in the translation of mitochondrial proteins and cellular metabolic processes.	MT-RNR1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C128261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128261>	C128260	MT-RNR1 wt Allele|12S Mitochondrial Ribosomal RNA wt Allele|MTRNR1|RNR1|Ribosomal RNA, Mitochondrial, 12S Gene|rRNA, 12S, Mitochondrial Gene|s-rRNA	Human MT-RNR1 wild-type allele is located within the circular mitochondrial (MT) chromosome and is approximately 1 kb in length. This allele, which encodes both 12S mitochondrial ribosomal RNA and mitochondrial-derived peptide MOTS-c protein, plays a role in cellular metabolism and the translation of mitochondrial proteins.	MT-RNR1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128262>	C18466	Mitochondrial-Derived Peptide MOTS-c|MOTS-c|Mitochondrial Open Reading Frame of the 12S rRNA-c	Mitochondrial-derived peptide MOTS-c (16 aa, ~2 kDa) is encoded by the human MT-RNR1 gene. This protein may be involved in cellular homeostasis.	Mitochondrial-Derived Peptide MOTS-c		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128263>	C814	12S Mitochondrial Ribosomal RNA|12S Mitochondrial rRNA|12S RNA|Mitochondrially Encoded 12S RNA|s-rRNA	12S mitochondrial ribosomal RNA is encoded by the human MT-RNR1 gene. This ribonucleotide is involved in mitochondrial protein translation.	12S Mitochondrial Ribosomal RNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology
C128264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128264>	C185631	Pulmonary Function Test Reference Value|PFT Reference Value	A standardized value that allows for the comparison of an individual's pulmonary function test results to those same results obtained from a reference population, which establishes a context through which individual results can be interpreted.			Laboratory or Test Result	
C128265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128265>	C114830	Vitamin D3 Deficiency	Abnormally low concentration of vitamin D3 (cholecalciferol) in the blood.	Vitamin D3 Deficiency		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C128266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128266>	C200258	Enitociclib|BAY 1251152|BAY1251152|ENITOCICLIB|PTEF-b/CDK9 Inhibitor BAY1251152|PTEF-b/CDK9 Inhibitor VIP152|VIP 152|VIP-152|VIP152	An inhibitor of cyclin-dependent kinase 9 (CDK9), the catalytic subunit of the RNA polymerase II (RNA Pol II) elongation factor positive transcription elongation factor b (PTEF- b; PTEFb), with potential antineoplastic activity. Upon administration, enitociclib binds to and blocks the phosphorylation and kinase activity of CDK9, thereby preventing PTEFb-mediated activation of RNA Pol II and leading to the inhibition of gene transcription of various anti-apoptotic proteins. This may cause cell cycle arrest and induce apoptosis, which may lead to a reduction in tumor cell proliferation. The protein complex PTEF-b, a heterodimer consisting of CDK9 and a regulatory cyclin subunit of the T family, is over-activated in various tumor cell types; it plays a key role in the regulation of Pol II-mediated transcription of anti-apoptotic proteins. Tumor cells are dependent on anti-apoptotic proteins for their survival.	Enitociclib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C128267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128267>	C21295	TMSB15A Gene|TMSB15A|TMSB15A|Thymosin Beta 15a Gene	This gene plays a role in both actin binding and cytoskeletal remodeling.			Gene or Genome	
C128268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128268>	C128267	TMSB15A wt Allele|TMSB15|TMSB15B|TMSL8|TMSNB|Tb15|TbNB|Thymosin Beta 15a wt Allele|Thymosin, Beta, Identified In Neuroblastoma Cells Gene|Thymosin, Beta-15A Gene	Human TMSB15A wild-type allele is located within Xq21.33-q22.3 and is approximately 3 kb in length. This allele, which encodes thymosin beta-15A protein, is involved in binding to and the modulation of polymerization of actin. The expression of this gene may be directly correlated with the metastatic potential of a neoplastic disease or with prostate tumor Gleason scoring.			Gene or Genome	
C128269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128269>	C18068	Cobalt Gray Equivalent|CGE|CGE|CGE|cGE|{CGE}|{CGE}	A unit of relative biological effectiveness of protons equivalent to 60 cobalt gamma rays.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C12826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12826>	C12372	Posterior Tibial Artery|POSTERIOR TIBIAL ARTERY|Posterior tibial	A terminal branch of the popliteal artery that runs along the tibia from the lower portion of the popliteus muscle to the lower ankle with numerous branches supplying the lower leg and foot.	Posterior Tibial Artery		Body Part, Organ, or Organ Component	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128270>	C4242|C40316|C3611|C3192	Vulvar Lipoma	An uncommon benign neoplasm of the vulva, composed of lobules of mature adipocytes.			Neoplastic Process	
C128271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128271>	C4249|C128270	Vulvar Fibrolipoma	A lipoma of the vulva with a predominant fibrous component.			Neoplastic Process	
C128272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128272>	C40316|C3611|C121181	Vulvar Superficial Myofibroblastoma	An uncommon benign polypoid or nodular mesenchymal neoplasm that arises in the vulvar region. It is characterized by the presence of oval or spindle-shaped cells in a collagenous stroma and is separated from the epidermis by a variably thick Grenz zone.			Neoplastic Process	
C128273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128273>	C3749|C181944	Vulvar Alveolar Rhabdomyosarcoma	An extremely rare malignant mesenchymal neoplasm of the vulva exhibiting skeletal muscle differentiation with an alveolar pattern.			Neoplastic Process	
C128274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128274>	C449	Circulating Cell-Free DNA|Cell Free Circulating DNA|Cell Free DNA|Circulating Cell Free DNA|Circulating DNA|cfDNA|cfDNA|cfDNA	DNA found in blood plasma and other bodily fluids that is not associated with cells.	Circulating Cell-Free DNA		Nucleic Acid, Nucleoside, or Nucleotide	CDISC SDTM Genetic Sample Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C128275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128275>	C17671	Liver X Receptor-Like Family|LXR|LXR Family|NR1H|Nuclear Receptor Subfamily 1 Group H	A nuclear receptor family that binds oxysterols or bile acids and, after forming a heterodimer with a member of the retinoid X receptor (RXR) family, modulates the expression of genes that are involved in cholesterol, fatty acid, and glucose homeostasis. The members of this family include oxysterols receptor LXR-alpha (NR1H3), oxysterols receptor LXR-beta (NR1H2) and bile acid receptor (NR1H4).	Liver X Receptor-Like Family		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128276>	C18153	CASP3 Gene Product	A protein encoded by the CASP3 gene.	CASP3 Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128277>	C128276	Activated Caspase-3|Activated CASP-3|Activated CASP3|Activated Caspase 3|CC3|Cleaved CASP-3|Cleaved CASP3|Cleaved Caspase 3|Cleaved Caspase-3	Activated caspase-3 (249 aa, ~29 kDa) is encoded by the human CASP3 gene. This protein plays a role in the promotion of apoptosis.	Activated Caspase-3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128278>	C48182	Interferon-Related DNA Damage Resistance Gene Signature|IFN-Related DNA Damage Resistance Signature|IRDS	An experimental therapy-predictive system used to assess if patient's tumor may be resistant to chemotherapy. This system is based on the expression profile of a panel of genes that are associated with both interferon signaling pathways and resistance to radiation-induced DNA damage.	Interferon-Related DNA Damage Resistance Gene Signature		Functional Concept	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128279>	C16620	Human Adenovirus Type 5 Early Region 1|Ad5E1	A region of the adenovirus type 5 genome that contains the transforming early genes E1A and E1B.	Human Adenovirus Type 5 Early Region 1		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12827>	C12356	Third Ventricle|BRAIN, THIRD VENTRICLE|Third Cerebral Ventricle|Third Ventricle of Brain|Ventricle, Third	A centrally placed component of the ventricular system of the brain located in the diencephalon. Cerebrospinal fluid from the lateral ventricles flows into the third ventricle via the foramina of Monroe and exits the third ventricle via the aqueduct of Sylvius. The thalamus and hypothalamus border the lateral walls of the third ventricle.	Third Ventricle of Brain		Body Space or Junction	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128280>	C2116	Selective Estrogen Receptor Degrader LSZ102|LSZ 102|LSZ-102|LSZ102|SERD LSZ 102|SERD LSZ102	An selective estrogen receptor (ER) degrader (SERD), with potential antineoplastic activity. Upon administration of LSZ102, this agent binds to the ER and induces the degradation of the receptor. This prevents ER activation and ER-mediated signaling, and inhibits the growth and survival of ER-expressing cancer cells.	Selective Estrogen Receptor Degrader LSZ102		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C128281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128281>	C28681|C129826	PDCD-1 Knockout Autologous T-lymphocytes|PD-1 Knockout Autologous T-cells|PD-1-disrupted Autologous T-lymphocytes|PDCD-1 Knockout Autologous T Lymphocytes|PDCD1 Gene Knockout Autologous T-cells	A population of engineered autologous T-lymphocytes in which the gene encoding for the programmed cell death protein 1 (PDCD-1) is deleted, with potential immunomodulating activity. Following collection of peripheral blood lymphocytes and selection of T-cells, the PDCD-1 gene was knocked out and the T-cells were expanded. Upon reinfusion of the PDCD-1 knockout T-lymphocytes, these T-cells target and lyse cancer cells. The PDCD-1 protein, found on activated T-cells and often overexpressed on T-cells in cancer patients, negatively regulates T-cell activity; it plays a key role in immune evasion and prevents tumor cell lysis. PDCD-1 knockout enhances cytotoxicity and T-cell-mediated anti-tumor immune responses.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C128282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128282>	C21176	Eukaryotic Translation Initiation Factor 4F|eIF-4F|eIF4F	A protein complex comprised of a heterotetrameric core, eukaryotic initiation factor 4A, 4E, and 4 gamma, bound to other factors; the exact composition of varies with the cellular environmental conditions. This complex recognizes the 5' cap of mRNA and promotes the initiation of translation.	Eukaryotic Translation Initiation Factor 4F		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128283>	C1752	HER-2-positive B-cell Peptide Antigen P467-DT-CRM197/Montanide Vaccine IMU-131|HER-Vaxx|HER-Vaxx Peptide Vaccine|IMU-131|IMU-131 HER2/Neu Peptide Vaccine|IMU-131 Vaccine|P467-CRM197/Montanide Vaccine IMU-131	A cancer vaccine consisting of a fusion peptide, composed of three peptides derived from the extracellular domain (ECD) of the HER2 peptide antigen found on B-cells (P4, P6 and P7; P467), conjugated to the carrier protein DT-CRM197, a non-toxic, mutated form of diphtheria toxin (DT), and combined with the immunoadjuvant montanide ISA 51, with potential immunostimulatory and antineoplastic activities. Upon administration, IMU-131 vaccine induces the production of polyclonal antibodies against the HER2 protein. In turn, the antibodies bind to three separate binding sites on HER2 expressed on tumor cells and inhibit HER2 dimerization and activity, which leads to the inhibition of HER2-mediated signal transduction pathways. This induces apoptosis in and reduces cellular proliferation of HER2-overexpressing tumor cells. In addition, IMU-131 induces a cytotoxic T-lymphocyte (CTL) response against the HER2-expressing tumor cells. The tumor-associated antigen (TAA) HER2, also called Neu or ErbB2, is a tyrosine kinase receptor for epidermal growth factor (EGF) and is often overexpressed by a variety of tumor cell types. Montanide ISA 51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil (w/o) emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens. DT-CRM197 is used to increase the immunogenicity of the HER2/neu peptide antigen. In P467, the three B-cell epitopes were combined in a specific order into a single 49 amino acid peptide antigen.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C128284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128284>	C17220	Low Molecular Weight Cyclin E|LMW-E|Low Molecular Weight Cyclin-E	Proteolytically processed forms of cyclin E proteins, which are specifically generated in tumors that overexpress cyclin E proteins.	Low Molecular Weight Cyclin E		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128285>	C21176	Platelet-Derived Growth Factor-AA|PDGF-AA	A disulfide-linked homodimeric protein complex comprised of 2 platelet-derived growth factor subunit A proteins. This dimeric growth factor binds to a homodimeric receptor comprised of two platelet-derived growth factor receptor alpha proteins. Ligand binding activates the intrinsic tyrosine-protein kinase activity of the receptor complex and initiates signal transduction pathways.	Platelet-Derived Growth Factor-AA		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128286>	C21176	Platelet-Derived Growth Factor-AB|PDGF-AB	A disulfide-linked heterodimeric protein complex comprised of one platelet-derived growth factor subunit A and one platelet-derived growth factor subunit B. This dimeric growth factor binds to a heterodimeric receptor comprised of one platelet-derived growth factor receptor alpha and one platelet-derived growth factor receptor beta. Ligand binding activates the intrinsic tyrosine-protein kinase activity of the receptor complex and initiates signal transduction pathways.	Platelet-Derived Growth Factor-AB		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128287>	C21176	Platelet-Derived Growth Factor-BB|PDGF-BB	A disulfide-linked homodimeric protein complex comprised of 2 platelet-derived growth factor subunit B proteins. This dimeric growth factor binds to a homodimeric receptor comprised of two platelet-derived growth factor receptor beta proteins. Ligand binding activates the intrinsic tyrosine-protein kinase activity of the receptor complex and initiates signal transduction pathways.	Platelet-Derived Growth Factor-BB		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128288>	C200085	Luvixasertib|CFI-402257|LUVIXASERTIB|MSP1 Inhibitor CFI-402257|N-cyclopropyl-4-(7-((((1s,3s)-3-hydroxy-3-methylcyclobutyl)methyl)amino)-5-(pyridin-2-yloxy)pyrazolo[1,5-a]pyridin-3-yl)-2-methylbenzamide|TTK Inhibitor CFI-402257|Threonine Tyrosine Kinase Inhibitor CFI-402257	An orally bioavailable, selective inhibitor of the dual specificity protein kinase TTK (monopolar spindle 1 kinase, Mps1), with potential antineoplastic activity. Upon administration, luvixasertib selectively binds to and inhibits the activity of Mps1. This inactivates the spindle assembly checkpoint (SAC) and accelerates mitosis, which results in chromosomal misalignment and missegregation, and mitotic checkpoint complex destabilization. This induces cell death in Mps1-overexpressing cancer cells. Mps1, a tyrosine and serine/threonine kinase expressed in proliferating normal tissues, is essential for proper SAC functioning and chromosome alignment. Overexpressed in various human tumors, Mps1 plays a key role in uncontrolled tumor cell growth.	Luvixasertib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C128289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128289>	C7578|C40335	Vulvar Nevus|Vulvar Melanocytic Nevus	A benign, atypical, or dysplastic melanocytic nevus that arises from the vulva.			Neoplastic Process	
C12828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12828>	C12356	Fourth Ventricle|BRAIN, FOURTH VENTRICLE|Fourth Ventricle of Brain|Fourth Ventricle of the Brain	A diamond-shaped cavity filled with cerebrospinal fluid within the pons extending between the obex in the caudal medulla and the aqueduct of Sylvius in the cerebellum.	Fourth Ventricle of Brain		Body Space or Junction	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128290>	C18108	AR Gene Product	A protein encoded by the AR gene.	AR Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128291>	C128290	Androgen Receptor Splice Variant 5,6,7es|ARv567es|Androgen Receptor Splice Variant 12|Arv-12	Androgen receptor protein that is missing the amino acids encoded by exons 5-7 and part of the 5' end of exon 8 of the human AR gene. This variant protein contains nuclear receptor transcriptional activation and DNA binding domains and is missing the nuclear receptor ligand binding and activation function-2 domains. Expression of this variant is associated with a gain-of-function phenotype and may be associated with prostate cancer.	Androgen Receptor Splice Variant 5,6,7es		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128292>	C128290	Androgen Receptor Splice Variant 3|AR-v7|AR3|Androgen Receptor Splice Variant 7	Androgen receptor protein that is comprised of the amino acids encoded by exons 1-3 and those encoded by cryptic exon 3 (CE3) of the human AR gene. This variant protein contains nuclear receptor transcriptional activation and DNA binding domains and is missing the hinge region and the nuclear receptor ligand binding and activation function-2 domains. Expression of this variant is associated with both a constitutively active, gain-of-function phenotype and prostate cancer.	Androgen Receptor Splice Variant 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128293>	C275	Broccoli Sprout/Broccoli Seed Extract Supplement|Avmacol	A tablet-based nutritional supplement composed of a mixture of sprout and seed extracts of the cruciferous vegetable broccoli, with potential chemopreventive and antioxidant activities. Broccoli sprout/broccoli seed extract contains a high amount of both the glycosinolate glucoraphanin and the enzyme myrosinase, which catalyzes the production of glucoraphanin to sulforaphane. Upon administration of the broccoli sprout/broccoli seed extract, sulforaphane activates the transcription factor NF-E2-related factor 2 (Nrf2), a member of the basic leucine zipper family, which binds to and activates antioxidant-response elements (AREs). Subsequently, activated AREs promote the transcription of antioxidant and detoxifying enzymes, particularly glutathione-S-transferase and NAD(P)H dehydrogenase [quinone] 1 (NAD(P)H:quinone oxidoreductase; NQO1), resulting in the detoxification of highly reactive carcinogens. This accelerates the elimination of carcinogens, may protect against cellular damage, and prevents cancer formation. AREs are cis-acting regulatory enhancer elements found in the 5' flanking region of many phase II detoxification enzymes.	Broccoli Sprout/Broccoli Seed Extract Supplement		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C128294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128294>	C3708|C3443	Vulvar Germ Cell Tumor	A rare germ cell tumor that arises from the vulva.			Neoplastic Process	
C128295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128295>	C7502|C3011|C128294	Vulvar Yolk Sac Tumor|Vulvar Endodermal Sinus Tumor	A rare yolk sac tumor that arises from the vulva.			Neoplastic Process	
C128296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128296>	C187760	Epstein-Barr Nuclear Antigen 1|EBNA-1|EBNA1|EBV Nuclear Antigen 1|EBV Nuclear Antigen 1|EPSTEIN-BARR VIRUS NUCLEAR ANTIGEN 1|Epstein Barr Nuclear Antigen 1	Epstein-Barr nuclear antigen 1 (641 aa, ~56 kDa) is encoded by the Epstein-Barr virus EBNA1 gene. This protein is involved in the replication of viral DNA during the latent phase.	Epstein-Barr Nuclear Antigen 1		Amino Acid, Peptide, or Protein	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128297>	C17207	TP63 Gene Product	A protein encoded by the TP63 gene.	TP63 Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128298>	C128297	Tumor Protein 63 Isoform 2|Delta Np63 Alpha|Delta-N p63-Alpha|DeltaN-Alpha|DeltaNp63 Alpha|P51delNalpha|p51	Tumor protein 63 isoform 2 (586 aa, ~66 kDa) is encoded by the human TP63 gene. This protein plays a role in the mediation of both transcription and skin development.	Tumor Protein 63 Isoform 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128299>	C20130	UBE2E Family|Ubiquitin-Conjugating Enzyme E2 E Family|Ubiquitin-Conjugating Enzyme E2E Family	A family of E2 ubiquitin-conjugating enzymes (UBE2) that transfer ubiquitin from E1 ubiquitin-activating enzyme to the active site cysteine of the E2 enzyme. Then the ubiquitin is transferred from the E2 enzyme to the target protein by E3 ubiquitin ligases. The N-terminal extension found in UBE2E proteins may confer a strong preference for the monoubiquitination of substrates rather than polyubiquitination.	UBE2E Family		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12829>	C32837	Anterior Cerebral Artery|ACA|ACA|ANTERIOR CEREBRAL ARTERY|Anterior Cerebral Arteries	One of the two arteries arising from the internal carotid artery and being part of the Circle of Willis. Both left and right anterior cerebral arteries are connected by the anterior communicating artery.	Anterior Cerebral Artery		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C1282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1282>	C1450	Carboplatin|(SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum|1,1-cyclobutanedicarboxylic acid platinum complex|Blastocarb|CARBOPLATIN|CBDCA|CBDCA|Carboplat|Carboplatin Hexal|Carboplatino|Carboplatinum|Carbosin|Carbosol|Carbotec|Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinum|Displata|Ercar|JM-8|JM8|Nealorin|Novoplatinum|Paraplat|Paraplatin|Paraplatin|Paraplatin AQ|Paraplatine|Platinwas|Ribocarbo|carboplatin|cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II)|cis-diammine(cyclobutanedicarboxylato)platinum II|platinum, diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)	A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)	Carboplatin		Inorganic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GCT Authorized Value Terminology|GCT Total Dose Table|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|HL Authorized Value Terminology|HL Protocol Treatment Modifications Table|HL Total Dose Table|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology|OS Authorized Value Terminology|OS Total Dose Table
C128300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128300>	C13228	Chromosome 1 Satellite 2|C1S2	A satellite DNA located in the large heterochromatin regions of chromosome 1.	Chromosome 1 Satellite 2		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128301>	C75333	ELN Allele with Mm Haplotype for INT20/INT23|ELN with Major Allele for Intron-20 and Minor Allele for Intron-23|Mm INT20/INT23 Haplotype	Human ELN allele containing a pair of single nucleotide polymorphisms with a major allele of intron-20 (INT20), where nucleotide position +17 is a thymine, and the minor allele for intron-23 (INT23), where nucleotide position +24 is a cytosine. This haplotype may be associated with increased susceptibility for intracranial aneurysms.	ELN Allele with Mm Haplotype for INT20/INT23		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128302>	C16620	Human Herpesvirus-8 Immediate-Early Region-4 Gene Locus|HHV-8 Immediate-Early Region-4 Gene Locus|KIE-4|KIE-4 Transcription Region|KSHV Immediate-Early Region-4 Gene Locus|Kaposi Sarcoma-Associated Herpesvirus Immediate-Early Region-4 Gene Locus|Kaposi's Sarcoma-Associated Herpesvirus Immediate-Early Region-4 Gene Locus	A leftward transcribed region of the human herpesvirus-8 genome containing the immediate early genes ORF48 and ORF29b.	Human Herpesvirus-8 Immediate-Early Region-4 Gene Locus		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128303>	C21176	Interleukin-15 Receptor|High-Affinity Interleukin-15 Receptor|IL-15 Receptor|IL-15R|IL15 Receptor|IL15R|Interleukin 15 Receptor	A heterotrimeric complex comprised of interleukin-15 receptor subunit alpha, interleukin-2 receptor subunit beta, and cytokine receptor common subunit gamma. This receptor complex has high affinity for interleukin-15 and modulates interleukin signaling.	Interleukin-15 Receptor		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128304>	C2873	Hypoploidy|Hypoploid	A chromosomal abnormality in which a somatic cell is missing a single member of one or more pairs of homologous chromosomes.	Hypoploidy		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Terminology
C128305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128305>	C14334	HERV-K|Endogenous Retroviral Sequence K|Endogenous Retrovirus Group K|HERV-K Provirus|HERVK|Human Endogenous Retroviral Sequence K|Human Endogenous Retrovirus Group K	A biologically active family of human endogenous retroviral elements that are found in human and primate genomes and resemble or are derived from retroviral genomic material. Aberrant expression of these elements may be associated with testicular germ cell tumors, breast cancer, type 1 diabetes mellitus, motor neuron disease.	HERV-K		Virus	CTRP Biomarker Terminology|CTRP Terminology
C128306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128306>	C16691	HLA Class I Histocompatibility Antigen, A-0201 Alpha Chain|HLA-A Class I Antigen 0201|HLA-A Histocompatibility Type Antigen 0201|HLA-A*0201|HLA-A*02:01|MHC Class I Antigen A*0201|Major Histocompatibility Complex, Class I, A0201 Antigen	HLA class I histocompatibility antigen, A-0201 alpha chain (365 aa, ~41 kDa) is encoded by the human HLA-A gene. This protein plays a role in the presentation of foreign antigens to the immune system.	HLA Class I Histocompatibility Antigen, A-0201 Alpha Chain		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128307>	C113513	HLA Class I Histocompatibility Antigen, A-11 Alpha Chain|HLA Class I Histocompatibility Antigen, A*11 Alpha Chain|HLA-A Class I Antigen 11|HLA-A Histocompatibility Type Antigen 11|HLA-A*11|HLA-A11|HLA-A11|HLA-A11 ANTIGEN|HLA-A11 Antigen|MHC Class I Antigen A*11|Major Histocompatibility Complex, Class I, A11 Antigen	HLA class I histocompatibility antigen, A-11 alpha chain (365 aa, ~41 kDa) is encoded by the human HLA-A gene. This protein is involved in the presentation of foreign antigens to the immune system. Expression of this serotype may be associated with increased susceptibility to papillomavirus infection.	HLA Class I Histocompatibility Antigen, A-11 Alpha Chain		Amino Acid, Peptide, or Protein|Immunologic Factor	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128308>	C20706	HLA-B Gene Product	A protein encoded by the HLA-B gene.	HLA-B Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128309>	C128308	HLA Class I Histocompatibility Antigen, B-44 Alpha Chain|Bw-44|HLA Class I Histocompatibility Antigen, B*44 Alpha Chain|HLA-B44|HLA-B44 Antigen|MHC Class I Antigen B*44	HLA class I histocompatibility antigen, B-44 alpha chain (362 aa, ~40 kDa) is encoded by the human HLA-B gene. This protein plays a role in the presentation of foreign antigens to the immune system. Expression of this serotype may be associated with recurrent sinopulmonary infections and ankylosing spondylitis.	HLA Class I Histocompatibility Antigen, B-44 Alpha Chain		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C12830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12830>	C32837	Middle Cerebral Artery|MCA|MCA|MIDDLE CEREBRAL ARTERY|Middle Cerebral Arteries	The largest terminal branch of the internal carotid artery that runs along the fissure of Sylvius with branches supplying parts of the fontal, parietal and temporal lobes as well as the basal ganglia and internal capsule.	Middle Cerebral Artery		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128310>	C71274	HLA-DP4 Antigen|HLA-DP4	HLA-DP4 antigen is a protein complex of the major histocompatibility complex, class II DP protein in which the alpha subunit is encoded by the HLA-DPA1*0103 allele and the beta subunit serotype is encoded by either the *0401 allele or the *0402 allele of the HLA-DPB1 gene. This antigen represents the most common haplotype.	HLA-DP4 Antigen		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128311>	C16692	HLA-DR13 Antigen|DR13|HLA-DR13	HLA-DR13 antigen is a protein complex of the major histocompatibility complex, class II DR protein in which the alpha subunit encoded by the HLA-DRA*01 allele and the beta subunit serotype is encoded by certain alleles in the HLA-DRB1*13 group.	HLA-DR13 Antigen		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128312>	C16383	HPV Major Capsid Protein L1|HPV L1|Human Papillomavirus Major Capsid Protein L1	HPV major capsid protein L1 is encoded by the human papillomavirus L1 gene. This protein plays a role in viral capsid formation.	HPV Major Capsid Protein L1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128313>	C16295	Isohemagglutinin|Isoagglutinin|Isoagglutinins|Isohemagglutinins	The antibodies produced by an individual that target the antigens (A or B or both) found on the red blood cells (RBC) of individuals with incompatible blood groups.	Isohemagglutinin		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C128314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128314>	C18108	PGR Gene Product	A protein encoded by the PGR gene.	PGR Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128315>	C128314	Progesterone Receptor Isoform A|PRA|Progesterone Receptor A	Progesterone receptor isoform A (769 aa, ~82 kDa) is encoded by the human PGR gene. This protein plays a role in the regulation of gene transcription.	Progesterone Receptor Isoform A		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128316>	C16725	MSLN Gene Product	A protein encoded by the MSLN gene.	MSLN Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128317>	C128316	Megakaryocyte-Potentiating Factor|MPF|Megakaryocyte Potentiating Factor|OV569 Antigen|SMR|SMRP|Soluble MPF Mesothelin Related Protein|Soluble MPF/Mesothelin Related Protein|Soluble MPF/Mesothelin-Related Protein|Soluble Mesothelin Related Protein|Soluble Mesothelin/MPF-Related Protein|Soluble Mpf/Mesothelin-Related Protein	Megakaryocyte-potentiating factor (250 aa, ~27 kDa) is encoded by the human MSLN gene. This protein plays a role in megakaryocyte colony formation.	Megakaryocyte-Potentiating Factor		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128318>	C20588	Viral Protease p15|15gag Proteinase	An aspartyl protease that is a portion of the polyprotein encoded by the gag gene found in the retrovirus myeloblastosis-associated virus (MAV; avian myeloblastosis virus).	Viral Protease p15		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128319>	C118480	Delta Catenin|Catenin Delta|Delta-Catenin	A catenin protein with 10 armadillo repeats involved in the regulation of cell adhesion and tissue morphogenesis. Catenin delta-1 (CTNND1) is expressed in vascular endothelium, keratinocytes and melanocytes, and catenin delta-2 (CTNND2) is expressed in brain.	Delta Catenin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12831>	C32195	Posterior Cerebral Artery|PCA|PCA|POSTERIOR CEREBRAL ARTERY|Posterior Cerebral Arteries	The posterior cerebral artery is formed by the bifurcation of the basilar artery; it divides into three branches.	Posterior Cerebral Artery		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128320>	C36291	Infection Finding|Infection|Infection|Infection|Infection|Infection, NOS	The invasion of an organism's body tissues by disease-causing agents and their multiplication, as well as the reaction by the host to these organisms and/or toxins that the organisms produce.			Finding	ALL Authorized Value Terminology|ALL Survival Characteristics Table|AML Adverse Events Table|AML Authorized Value Terminology|AML Survival Characteristics Table|HL Adverse Events Table|HL Authorized Value Terminology|HL Protocol Treatment Modifications Table|HL Survival Characteristics Table|NICHD Terminology|Pediatric Infectious Disease Terminology
C128321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128321>	C117984	Childhood Infectious Disorder	An infectious disorder that occurs in childhood.			Disease or Syndrome	
C128322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128322>	C26686	Peritonsillar Abscess|Quinsy	An abscess that develops in the space surrounding one or both palatine tonsils.			Finding	NICHD Terminology|Pediatric Infectious Disease Terminology
C128323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128323>	C26686	Parapharyngeal Abscess|Lateral Pharyngeal Abscess	An abscess that develops in the soft tissues of the lateral pharyngeal space.			Finding	NICHD Terminology|Pediatric Infectious Disease Terminology
C128324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128324>	C26686	Retropharyngeal Abscess	An abscess that develops in the soft tissues behind the posterior pharyngeal wall.			Finding	NICHD Terminology|Pediatric Infectious Disease Terminology
C128325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128325>	C26686	Prevertebral Abscess	An abscess that develops in the tissues within the prevertebral fascia.			Finding	NICHD Terminology|Pediatric Infectious Disease Terminology
C128326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128326>	C26686	Intra-abdominal Abscess	An abscess within the abdomen.			Finding	NICHD Terminology|Pediatric Infectious Disease Terminology
C128327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128327>	C26686	Subdiaphragmatic Abscess|Subphrenic Abscess	An abscess that is located in the anatomical space between the diaphragm and the liver and/or spleen.			Finding	NICHD Terminology|Pediatric Infectious Disease Terminology
C128328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128328>	C26686	Mesenteric Abscess	An abscess that is located in any part of the tissue composing the mesentery, and that generally arises from an infection in an adjacent area of the intestine.			Finding	NICHD Terminology|Pediatric Infectious Disease Terminology
C128329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128329>	C26686	Perihepatic Abscess	An abscess that is located in the anatomical space surrounding the liver, but which is outside of the liver capsule itself.			Finding	NICHD Terminology|Pediatric Infectious Disease Terminology
C12832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12832>	C33969	Conus Medullaris	The terminal, cone-shaped end of the spinal cord.	Conus Medullaris		Body Part, Organ, or Organ Component	Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C128330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128330>	C26686	Retroperitoneal Abscess	An abscess that is located in the abdominal cavity posterior to the peritoneum.			Finding	NICHD Terminology|Pediatric Infectious Disease Terminology
C128331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128331>	C26686	Pelvic Abscess	An abscess that is located in the pelvic cavity.			Finding	NICHD Terminology|Pediatric Infectious Disease Terminology
C128332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128332>	C2883	Reactive Arthritis	A form of inflammatory arthritis that results as a reaction to a bacterial infection outside the joint.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128333>	C2883	Migratory Arthritis	A form of reactive arthritis in which the inflammation moves between joints.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128334>	C2890	Legionellosis	Any disease caused by Legionella bacteria.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128335>	C128334	Pontiac Fever	A self-limited, febrile illness without pneumonia that occurs in epidemics, and that is caused by Legionella species.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128336>	C2890	Melioidosis|Whitmore Disease	An infection that is caused by Burkholderia pseudomallei, which is found in soil and water; symptoms vary widely, but most commonly include fever, cough, pneumonia, arthralgia, myalgia, and skin ulceration.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128337>	C2890	Yersiniosis	An infection that is caused by Yersinia enterocolitica or Yersinia pseudotuberculosis, and that is usually acquired by consumption of contaminated meat, water, or unpasteurized milk. It can also be transmitted vertically, pre- or perinatally, from mother to infant. Manifestation of symptoms depends on the infecting species and mode of acquisition, and can range from gastrointestinal syndromes to septicemia.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128338>	C26704	Atypical Pneumonia|Walking Pneumonia	Historical term that references a form of pneumonia caused by Mycoplasma pneumoniae, Chlamydophila pneumoniae, or Legionella species.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128339>	C26704	Legionella Pneumonia|Legionnaires' Disease	A pneumonia caused by Legionella pneumophila and other Legionella species, which is characterized by fever, cough, progressive respiratory distress, and which is often accompanied by extrapulmonary manifestations.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C12833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12833>	C33587	Anterior Spinal Artery	The artery that delivers blood to the anterior portion of the spinal cord.	Anterior Spinal Artery		Body Part, Organ, or Organ Component	
C128340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128340>	C84586	Bacillary Peliosis	An infection that is caused by Bartonella henselae, which occurs primarily in immunocompromised persons; it is characterized by blood-filled cysts in the liver and spleen.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128341>	C84599|C128351	Foodborne Botulism	Botulism that is caused by consuming food or beverage that contains the botulinum toxin.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128342>	C84599	Wound Botulism	Botulism that is caused by toxin that is produced in a wound contaminated with Clostridium botulinum.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128343>	C84599	Infant Botulism	Botulism that is caused by contact with spores of Clostridial bacteria, which subsequently grow in the intestine and release toxin.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128344>	C84599	Adult Intestinal Botulism|Adult Intestinal Toxemia Botulism	A rare form of botulism that occurs among adults by the same mechanism as infant botulism.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128345>	C84599	Iatrogenic Botulism|Accidental Botulism	Botulism that occurs following injection of botulinum toxin.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128346>	C27582|C26920	Transmissible Spongiform Encephalopathy|Prion Disease|Prion Disease|Spongiform Encephalopathy|Transmissible Spongiform Encephalopathy(TSE)	A transmissible, infectious disease that is caused by a protein that is able to induce abnormal folding of normal cellular proteins, leading to characteristic spongiform brain changes, which are associated with neuronal loss without an inflammatory response. Such disorders have typically long incubation periods, but are then generally rapidly progressive and are uniformly fatal.			Disease or Syndrome	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|NICHD Terminology|Pediatric Infectious Disease Terminology
C128347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128347>	C26723	Antibiotic-Associated Colitis	Inflammation of the colon that is caused by an alteration in intestinal flora by antibiotic use.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128348>	C128168	Fecal-Oral Transmission	The transmission of an infectious agent to a host's oral cavity via the fecal particles of another living organism.			Pathologic Function	NICHD Terminology|Pediatric Infectious Disease Terminology
C128349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128349>	C2983	Cercarial Dermatitis|Duck Itch|Lake Itch|Swimmer's Itch	A pruritic rash that occurs as consequence of cercariae penetration of the skin after aquatic exposure to animal (usually avian) schistosomes, often in countries non-endemic to human schistosomiasis. The condition is non-invasive and responsive to symptomatic treatment.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C12834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12834>	C12356	Lateral Ventricle|BRAIN VENTRICLE, LATERAL|Lateral Ventricle of Brain|Lateral Ventricles|Ventricle, Lateral|Ventricles, Lateral	The rostral extensions of the ventricular system of the brain consisting of two cavities, one on each side of the brain within the central regions of each cerebral hemisphere.  Cerebrospinal fluid flows from the lateral ventricles into the centrally third ventricle via the foramen of Monroe.	Lateral Ventricle of Brain		Body Space or Junction	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128350>	C2987	Antibiotic-Associated Diarrhea	Diarrhea that is associated with current or recent antibiotic use.			Finding	NICHD Terminology|Pediatric Infectious Disease Terminology
C128351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128351>	C93210	Foodborne Illness|Food Poisoning	Any disorder that results from the consumption of food contaminated with an infectious agent or toxin.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128352>	C128169	Droplet Transmission|Droplet Pathogen Transmission|Droplet Spread	The direct transmission of an infectious agent to a host by a spray of a relatively large (greater than five microns), short range respiratory aerosol.			Pathologic Function	NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology|NICHD Terminology|Pediatric Infectious Disease Terminology
C128353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128353>	C128169	Airborne Transmission|Airborne Pathogen Transmission	The direct transmission of an infectious agent to a host via droplet nuclei (less than or equal to five microns) or dust suspended in the air.			Pathologic Function	NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology|NICHD Terminology|Pediatric Infectious Disease Terminology
C128354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128354>	C14198	Arthropod Vector	An animal within the phylum Arthropoda that transmits an infectious agent to a vertebrate animal.			Eukaryote	NICHD Terminology|Pediatric Infectious Disease Terminology
C128355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128355>	C34582	Native Valve Endocarditis	Endocarditis affecting a native valve of the heart.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128356>	C34582	Prosthetic Valve Endocarditis	Endocarditis occurring on parts of a valve prosthesis or a reconstructed heart valve; it can be classified into early and late prosthetic valve endocarditis.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128357>	C34582	Early Prosthetic Valve Endocarditis	Prosthetic valve endocarditis that occurs days to weeks after surgery.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128358>	C34582	Late Prosthetic Valve Endocarditis	Prosthetic valve endocarditis that occurs several months to years following valve replacement.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128359>	C78265	Bacterial Endocarditis	Endocarditis that is caused by an infection with a bacterial agent.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C12835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12835>	C49346	Nucleus Ambiguus	A very slender, longitudinal column of motor neurons in the ventrolateral medulla oblongata; its efferent fibres leave with the vagus and glossopharyngeal nerve and innervate the striated muscle fibres of the pharynx (including the musculus levator veli palatini) and the vocal cord muscles of the larynx.	Nucleus Ambiguus		Body Part, Organ, or Organ Component	
C128360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128360>	C34611	Lymphatic Filariasis|Elephantiasis	A clinical disorder that is caused by obstruction of the lymphatic system years after filarial infection. It is characterized by painful and profound lymphedema, resulting in significant swelling (elephantiasis) of extremities and genitals.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128361>	C36291	Colonization	The presence of microorganisms (not contamination) on a body surface, including the skin and mucosal surfaces (e.g., respiratory, gastrointestinal, and urogenital tracts). Colonization implies the lack of signs or symptoms of infection but often precedes infection.			Finding	NICHD Terminology|Pediatric Infectious Disease Terminology
C128362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128362>	C14209	Dimorphic Fungus	A fungus that grows as either a yeast or a mold.			Eukaryote	NICHD Terminology|Pediatric Infectious Disease Terminology
C128363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128363>	C81996|C73490	Interferon Gamma Release Assay|IGRA|IGRA|IGRA|INTERFERON GAMMA RELEASE ASSAY|Interferon-Gamma Release Assay|Interferon-Gamma Release Assay	A blood test that exposes a person's T-lymphocytes ex vivo to specific microbial antigen(s) to stimulate the production and release of interferon gamma, which provides an indication that the person has been exposed to a specific microbe.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|NICHD Terminology|Pediatric Infectious Disease Terminology
C128364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128364>	C128170	Vehicle Transmission	The indirect transmission of an infectious agent to a host via inanimate objects such as food, water, biologic products, or fomites.			Pathologic Function	NICHD Terminology|Pediatric Infectious Disease Terminology
C128365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128365>	C128170	Vector Transmission	The indirect transmission of an infectious agent to a host via another living organism, either through purely mechanical means (e.g., insect bite) or by that organism supporting the growth or changes in the agent that make it infectious to the host.			Pathologic Function	NICHD Terminology|Pediatric Infectious Disease Terminology
C128366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128366>	C26726	Clinical Infection	An infection that exhibits features or characteristics that exceed an agreed-upon threshold among subject matter experts, which warrants attention or treatment.			Disease or Syndrome	
C128367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128367>	C26726	Endogenous Infection|Auto-Infection	An infection caused by an infectious agent that is present on or in the host prior to the start of the infection.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128368>	C93210	Mastoiditis	Inflammation of the mucosal lining of the mastoid antrum and mastoid air cell system of the mastoid process.			Disease or Syndrome	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|NICHD Terminology|Pediatric Infectious Disease Terminology
C128369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128369>	C27193|C188277	Labyrinthitis|Infectious Otitis Interna|Inner Ear Infection|Internal Ear Infection	Inflammation of the anatomical structures of the inner ear secondary to an infectious process. Symptoms include severe vertigo, nausea, vomiting, anxiety, and pain. Viral etiology is most common, and recent history of an upper respiratory infection is common.			Disease or Syndrome	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|NICHD Terminology|Pediatric Infectious Disease Terminology
C12836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12836>	C49346	Abducens Nucleus|Sixth Cranial Nerve Nucleus	The cranial nerve nucleus from which the abducens nerve originates from. It is located in the middle portion of the brain stem.	Abducens Nucleus		Body Part, Organ, or Organ Component	
C128370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128370>	C26805	Fungal Keratitis	Keratitis caused by fungi.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128371>	C35056	Late Latent Syphilis	Latent syphilis when infection was acquired more than twelve months previously.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128372>	C34797	Severe Malaria|Complicated Malaria	Acute malaria with signs of organ dysfunction, severe anemia (hemoglobin less than 5 g/dL or hematocrit less than 15%) and/or hyperparasitemia (greater than 5% of red blood cells infected).			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128373>	C34797	Cerebral Malaria	A sequestration of Plasmodium falciparum in the brain, which can cause coma and/or seizures.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128374>	C26828	Eosinophilic Meningitis	Meningitis in which eosinophils predominate in the cerebrospinal fluid.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128375>	C34813|C27582	Infectious Meningoencephalitis	Inflammation of the meninges and brain caused by an infectious agent.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128376>	C25571	Mode of Transmission	The process by which an infection is transmitted to a person.			Phenomenon or Process	NICHD Terminology|Pediatric Infectious Disease Terminology
C128377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128377>	C26831	Tuberculosis Infection|LTBI|Latent Tuberculosis Infection|Mycobacterium tuberculosis	The asymptomatic presence of Mycobacterium tuberculosis in the body, which is determined by a positive result to a tuberculin skin test or interferon-gamma release assay.			Disease or Syndrome	GDC Terminology|GDC Value Terminology|NICHD Terminology|Pediatric Infectious Disease Terminology
C128378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128378>	C26832	Acute Transverse Myelitis	A neurologic disorder that is caused by inflammation across both sides of one level, or segment, of the spinal cord. (from NINDS)			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128379>	C26832	Acute Flaccid Myelitis	An acute onset of focal limb weakness that is associated mainly with gray matter abnormalities or CSF pleocytosis, but which is without an apparent cause.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C12837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12837>	C33966	Cochlear Nucleus|BRAIN, COCHLEAR NUCLEI|Cochlear Nuclei	Located at the brainstem, this sensory organ receives auditory signals from the cochlear auditory nerve fibers. It is composed of the dorsal cochlear nucleus located on the dorsolateral surface of the inferior peduncle and the ventral (or accessory) cochlear nucleus located on the ventral aspect of the inferior peduncle.	Cochlear Nuclei		Anatomical Structure	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128380>	C34831	Bacterial Myocarditis	Myocarditis that is caused by an infection with a bacterial agent.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128381>	C34831	Viral Myocarditis	Myocarditis that is caused by an infection with a viral agent.			Disease or Syndrome	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 7: Diagnostic Procedures Terminology|NICHD Terminology|Pediatric Infectious Disease Terminology
C128382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128382>	C27578	Pyomyositis|Tropical Pyomyositis	A suppurative infection of muscle.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128384>	C27557	Collapsed Lung	Atelectasis of an entire lung.			Finding	NICHD Terminology|Pediatric Infectious Disease Terminology
C128385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128385>	C27651	Uvulitis	Inflammation of the uvula.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128386>	C34885	Chronic Suppurative Otitis Media|CSOM	Otitis media that persists for at least six weeks, and that is associated with otorrhea through a perforated tympanic membrane.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128387>	C27864|C193412	Fasciolosis|Fascioliasis	A parasitic infection that is caused by liver flukes, usually Fasciola hepatica, of sheep, goats, and cattle. Humans become infected by eating uncooked, infested aquatic vegetation (classically watercress). Adult flukes inhabit the bile ducts, gallbladder, and occasionally ectopic sites. Symptoms arise secondary to inflammatory response or obstruction.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128388>	C27864|C193412	Fasciolopsiasis	A small bowel infection that is caused by Fasciolopsis buski, which is endemic in the Far East and Southeast Asia, and which is transmitted via the consumption of raw or undercooked aquatic plants. The spectrum of manifestations range from  asymptomatic to intestinal symptoms from local invasion or allergic response.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128389>	C27864|C193412	Heterophyiasis	An infection that is caused by the intestinal fluke Heterophyes heterophyes, which is most commonly found in Asia, the Middle East, and Africa, and which is transmitted via consumption of contaminated raw or undercooked fish. Symptoms typically range from asymptomatic to intermittent abdominal pain and diarrhea, with occasional ectopic infection.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C12838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12838>	C12372	Radial Artery|RADIAL ARTERY|Radial|Radial artery	The branch of the brachial artery that passes down the forearm.	Radial Artery		Body Part, Organ, or Organ Component	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|Appendix 9: Therapeutic and Supportive Procedures for COVID-19 Terminology|CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Invasive Coronary/Vascular/Neurovascular Revascularization Treatment Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C128390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128390>	C27864|C193412	Metagonimiasis	An infection that is most commonly caused by the intestinal fluke Metagonimus yokogawai, which is most commonly found in the Far East, and which is transmitted via consumption of contaminated raw or undercooked fish. Symptoms typically range from asymptomatic to intermittent abdominal pain and diarrhea, with occasional ectopic infection.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128391>	C27864|C193412	Diphyllobothriasis	An infection that is caused by the tapeworm Diphyllobothrium latum and related species; it is transmitted via consumption of raw or undercooked fish, and symptoms include abdominal discomfort, diarrhea, vomiting, fatigue, weight loss, and vitamin B12 deficiency.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128392>	C27864|C193412	Ascariasis|Ascaridiasis	An infection that is caused by the roundworm Ascaris lumbricoides, many cases of which remain asymptomatic. During the transient larval migratory phase, shortness of breath, fever, and eosinophilia can occur. Depending on the intestinal worm burden, a spectrum of gastrointestinal tract symptoms can occur.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology|NICHD Terminology|Pediatric Infectious Disease Terminology
C128393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128393>	C27864|C193412	Anisakiasis	An infection that is caused by nematodes of the genus Anisakis, which is most commonly transmitted via ingestion of infective larvae from consumption of raw or undercooked fish or squid; it is characterized by invasion of the stomach wall or intestines, resulting in the death of the worm, and triggering an inflammatory response that surrounds the worm and that can result in intestinal obstruction.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128394>	C27864|C193412	Angiostrongyliasis	An infection that is caused by nematodes of the genus Angiostrongylus; signs and symptoms are dependent on the invading species, but generally include gastrointestinal symptoms and fever, and can have extraintestinal manifestations (e.g., central nervous system, anterior and posterior eye).			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128395>	C27864|C193412	Gnathostomiasis	An infection that is caused by nematodes of the genus Gnathostoma, which is commonly found in Southeast Asia, and which is transmitted via the consumption of contaminated raw/undercooked birds, eels, fish, frogs, or reptiles. The pattern of symptoms is species-dependent, and extraintestinal manifestations are due to larval migration (e.g., pulmonary infiltrates, eosinophilic meningitis, or painful, pruritic subcutaneous swellings, and peripheral blood eosinophilia).			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128396>	C27864|C193412	Enterobiasis|Pinworm Infection|Threadworm Infection	An infection that is caused by the nematode Enterobius vermicularis; it is characterized predominantly by perianal pruritus.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128397>	C27864|C193412	Baylisascariasis|Raccoon Roundworm Infection	An infection that is caused by the raccoon nematode Baylisascaris procyonis, which is transmitted by the ingestion of embryonated eggs in contaminated soil; symptoms depend on larval migration sites (visceral organs, eye, or brain) provoking severe inflammatory responses.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128398>	C27864|C193412	Strongyloidiasis	An infection that is caused by nematodes of the genus Strongyloides, most commonly Strongyloides stercoralis, which is a soil-transmitted helminth, and which is characterized by a variety of gastrointestinal, dermatologic, and, occasionally, pulmonary manifestations. The worm's autoinfective life cycle can lead to hyper-infection and life-threatening dissemination in immunocompromised hosts decades after initial infection.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128399>	C27864|C193412	Trichuriasis|Whipworm Infection	An infection that is caused by the nematode Trichuris trichiura, a soil-transmitted helminth, which is transmitted via food and/or water contaminated with the eggs of the worm. Symptoms are usually mild and include abdominal pain, diarrhea, fatigue, and possibly anemia secondary to blood loss in diarrhea.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C12839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12839>	C12372	Ulnar Artery|ULNAR ARTERY|Ulnar	A terminal branch of the brachial artery arising just below the elbow that runs along the ulna into the wrist with numerous branches supplying the forearm, wrist and hand.	Ulnar Artery		Body Part, Organ, or Organ Component	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C1283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1283>	C308|C307	Therapeutic Cytokine|Cytokines				Chemical Viewed Functionally	
C128400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128400>	C27864|C193412	Myiasis	The infection of a fly larva (maggot) in human tissue, which most commonly occurs in tropical climates. Affected tissues most commonly include skin, especially if open wounds are present, nasal passages, ears, and eyes.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128401>	C27864|C193412	Pediculosis|Lice Infestation	A contagious infestation of parasitic insects found on the head (Pediculus humanus capitis), body (Pediculus humanus corporis), or pubic area (Pthirus pubis) that typically cause itching and rash.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128402>	C79702	Herpetic Whitlow	A painful blister of the periungual skin that is caused by herpes simplex virus type 1 or 2.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128403>	C114281	Suppurative Parotitis	Parotitis that is caused by a bacterial agent.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128404>	C34915	Bacterial Pericarditis	Pericarditis that is caused by an infection with a bacterial agent.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128405>	C34915	Viral Pericarditis	Pericarditis that is caused by an infection with a viral agent.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128406>	C34915	Fungal Pericarditis	Pericarditis that is caused by an infection with a fungal agent.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128407>	C26849	Bacterial Peritonitis	Peritonitis that is caused by a bacterial infection.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128408>	C34953	Cryptosporidiosis|Cryptosporidium Infection	An infection that is caused by Cryptosporidium parvum or hominis, which is acquired by inhalation or ingestion of infectious spores, and which typically manifests as acute enteritis.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology|NICHD Terminology|Pediatric Infectious Disease Terminology
C128409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128409>	C34953	Cyclosporiasis	A protozoan infection that is caused by Cyclospora cayetanensis, which is most commonly acquired from contaminated food or water, and which is characterized by watery diarrhea and abdominal pain.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C12840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12840>	C25444	Pleural Cavity|BODY CAVITY, PLEURAL|PLEURAL CAVITY|Pleural Space|pleural cavity|pleural cavity	The potential space between parietal and visceral pleurae. There is a separate pleural cavity for each lung.	Pleural Cavity		Body Space or Junction	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|UBERON Terminology
C128410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128410>	C35373|C34991	Rocky Mountain Spotted Fever	An infection that is caused by Rickettsia rickettsii, which is transmitted to humans from infected ticks; it is characterized by the sudden onset of fever, headache, and myalgia, followed by rash that usually begins peripherally.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128411>	C35024	Acute Sinusitis	Sinusitis lasting less than or equal to thirty days.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128412>	C35055	Primary Syphilis	The subclinical or symptomatic stage of syphilis, occurring at an average of three weeks after contact with an infected individual. It manifests with one or more painless, indurated ulcers (chancres) of the skin or mucous membranes at the site of inoculation. These lesions heal spontaneously within a few weeks.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128413>	C35055	Secondary Syphilis	The secondary stage of syphilis typically that is characterized by generalized rash (including palms and soles), mucocutaneous lesions, and lymphadenopathy. It usually begins one to two months after the primary stage.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128414>	C35055	Tertiary Syphilis|Late Syphilis	A stage of syphilis that occurs fifteen to thirty years after the initial infection; it can include gumma formation and cardiovascular or central nervous system involvement (neurosyphilis).			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128415>	C3423	Multidrug-Resistant Tuberculosis|MDR-TB|Multidrug-Resistant TB	Tuberculosis disease that is caused by a multidrug-resistant strain of Mycobacterium tuberculosis.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128416>	C3423	Pre-Extensively Drug-Resistant Tuberculosis|Pre-Extensively Drug-Resistant TB|Pre-XDR-TB	Tuberculosis disease that is caused by a pre-extensively drug-resistant strain of Mycobacterium tuberculosis.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128417>	C3423	Extensively Drug-Resistant Tuberculosis|Extensively Drug-Resistant TB|XDR-TB	Tuberculosis disease that is caused by an extensively drug-resistant strain of Mycobacterium tuberculosis.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128418>	C35412	Lassa Fever	A viral hemorrhagic fever that is caused by the Lassa virus, which is transmitted by contact with infected rodents; it is characterized by fever, headache, malaise, myalgia, and hearing loss.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128419>	C35174	Rift Valley Fever|RVF	A viral hemorrhagic fever that is caused by the Rift Valley fever virus, which is transmitted by mosquitoes and infected animals. The infection is typically asymptomatic or causes only mild illness, but can be associated with retinitis.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C12841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12841>	C12919	Reproductive System|Genital tract|Reproductive Body System|Reproductive Organ System|Reproductive Tract|reproductive system	The organs and tissues involved in the production and maturation of gametes and in their union and subsequent development as offspring.	Reproductive System		Body System	
C128420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128420>	C172342	Roseola Infantum|Exanthem Subitum|Roseola	An infection that is due to human herpesvirus (HHV) types 6 or 7; it is characterized by 3-5 days of high fever followed by the acute onset of a rosy, pink, non-pruritic, macular rash that is predominantly on the neck and trunk.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128421>	C3439	Monkeypox|Monkeypox Infection|Monkeypox Infection|Mpox	An infection that is caused by an Orthopoxvirus, which is transmitted by primates or rodents, and which is characterized by a prodromal syndrome of fever, chills, headache, myalgia, and lymphedema; initial symptoms are followed by a generalized papular rash that typically progresses from vesiculation through crusting over the course of two weeks.	Monkeypox Infection		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Infectious Disease Terminology
C128422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128422>	C3439	Chikungunya	An infection that is caused by the Chikungunya virus, which is transmitted by mosquitoes; it is characterized by fever and severe arthralgia.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128423>	C3439	Zika Virus Infection|Zika	An infection that is caused by the Zika virus, which is primarily transmitted via mosquitoes; it is characterized by fever, skin rash, arthralgia, and conjunctivitis.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128424>	C181757	Middle East Respiratory Syndrome|MERS	A viral respiratory infection that is caused by the MERS coronavirus (MERS-CoV), which most often manifests with moderate to severe respiratory symptoms, including productive cough and shortness of breath, which can progress to pneumonia and acute respiratory distress syndrome.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128425>	C35373	Anaplasmosis	An infection that is caused by Anaplasma phagocytophilum, which is transmitted to humans by infected ticks; it is characterized by fever, headache, chills, and myalgia.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128426>	C35373	Louse-Borne Relapsing Fever	An infection that is caused by certain species of Rickettsia or Borrelia, which are transmitted to humans from infected lice; it is characterized by sudden fever, chills, headaches, myalgia, arthralgia, nausea, and possibly a rash. Symptoms usually persist for two to nine days, then disappear, with recurrence after several weeks if the patient remains untreated.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128427>	C35373	Southern Tick-Associated Rash Illness|Masters Disease|STARI	A putative Borrelia infection causing acute manifestations similar to Lyme disease, particularly erythema migrans, following the bite of the lone star tick, Amblyomma americanum.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128428>	C112190	Infectious Hidradenitis	Hidradenitis that is caused by an infectious agent, usually a bacterium.			Finding	NICHD Terminology|Pediatric Infectious Disease Terminology
C128429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128429>	C112190	Hidradenitis Suppurativa	A chronic, suppurative inflammation of the apocrine sweat glands, that is characterized by clusters of bumps or sores.			Finding	NICHD Terminology|Pediatric Infectious Disease Terminology
C12842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12842>	C122940	Skin Graft|skin graft		Skin Graft		Tissue	
C128430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128430>	C35056	Early Latent Syphilis	Latent syphilis when infection was acquired less than twelve months previously.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128431>	C76370	Multidrug-Resistant Mycobacterium tuberculosis	A strain of Mycobacterium tuberculosis that is resistant to isoniazid and rifampin.			Bacterium	NICHD Terminology|Pediatric Infectious Disease Terminology
C128432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128432>	C76370	Pre-Extensively Drug-Resistant Mycobacterium tuberculosis	A strain of Mycobacterium tuberculosis that is characterized by resistance to isoniazid, rifampin, and one of the following: a) any of the fluoroquinolone antibiotics or b) one or more of three injectable drugs (kanamycin, capreomycin, amikacin).			Bacterium	NICHD Terminology|Pediatric Infectious Disease Terminology
C128433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128433>	C76370	Extensively Drug-Resistant Mycobacterium tuberculosis	A strain of Mycobacterium tuberculosis that is resistant to all of the following: isoniazid, rifampin, any of the fluoroquinolone antibiotics, and at least one of three injectable drugs (kanamycin, capreomycin, amikacin).			Bacterium	NICHD Terminology|Pediatric Infectious Disease Terminology
C128434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128434>	C35024	Rhinosinusitis	Inflammation of the mucous membranes lining the nose and paranasal sinuses.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128435>	C118969	Bayer Classification for Corneal Epitheliopathy|Bayer Classification for Cornea Morphology|Bayer Corneal Morphology	A grading system for changes in corneal morphology following treatment with anetumab ravtansine (BAY 94-9343).			Intellectual Product	
C128436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128436>	C26851	Tonsillopharyngitis	Inflammation of the palatine tonsils and the posterior pharynx (throat).			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128437>	C222039	Bayer Corneal Epitheliopathy Grade 0|Grade 0	No pathologic changes.			Intellectual Product	Bayer Classification for Corneal Epitheliopathy
C128438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128438>	C128346	Variant Creutzfeldt-Jakob Disease|vCJD	A form of Creutzfeldt-Jakob disease that is most commonly contracted after consuming meat from an animal suffering from bovine spongiform encephalopathy.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128439>	C3439	Hand Foot and Mouth Disease|HFMD|Hand, Foot, and Mouth Disease	A clinical syndrome that is usually caused by enterovirus infection, and that is characterized by fever, anorexia, and painful sores in the mouth, distal extremities, and/or other sites, including the buttocks.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C12843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12843>	C12372	Coronary Artery|ARTERY, CORONARY|CORONARY ARTERY|Coronary artery structure (body structure)	One of two arteries that arise from the aortic sinuses of the ascending aorta and supply blood to the myocardium	Coronary Artery		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C128440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128440>	C222039	Bayer Corneal Epitheliopathy Grade 1|Grade 1	Any stage of superficial punctate keratitis.			Intellectual Product	Bayer Classification for Corneal Epitheliopathy
C128441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128441>	C84586	Carrión Disease|Carrion Disease	An infection that is caused by Bartonella bacilliformis, which is transmitted to humans from infected sandflies. The acute phase (Oroya Fever) is characterized by fever, headache, myalgia, enlargement of the lymph nodes, and anemia. The chronic phase (verruga peruana/Peruvian wart) is characterized by benign, eruptive lesions that are bleeding and pruritic, arthralgia, and malaise.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C128442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128442>	C222039	Bayer Corneal Epitheliopathy Grade 2|Grade 2	Epithelial opacities; micro-cysts; micro-deposits; corneal erosion; non-central stromal opacity.			Intellectual Product	Bayer Classification for Corneal Epitheliopathy
C128443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128443>	C222039	Bayer Corneal Epitheliopathy Grade 3|Grade 3	Corneal ulcer without risk of acute rupture; central stromal opacity.			Intellectual Product	Bayer Classification for Corneal Epitheliopathy
C128444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128444>	C222039	Bayer Corneal Epitheliopathy Grade 4|Grade 4	Corneal ulcer more severe than grade 3.			Intellectual Product	Bayer Classification for Corneal Epitheliopathy
C128445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128445>	C118969	Bayer Classification of Visual Acuity Changes|Bayer Visual Acuity	A grading system for best corrected visual acuity following treatment with anetumab ravtansine (BAY 94-9343).			Intellectual Product	
C128446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128446>	C222040	Bayer Visual Acuity Changes Grade 0|Grade 0	No findings, no reporting from the patient.			Intellectual Product	Bayer Classification of Visual Acuity Changes
C128447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128447>	C222040	Bayer Visual Acuity Changes Grade 1|Grade 1	Symptomatic visual acuity loss of less than 3 lines. (ETDRS equivalent: each loss of 3 lines corresponds to halving the visual acuity)			Intellectual Product	Bayer Classification of Visual Acuity Changes
C128448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128448>	C222040	Bayer Visual Acuity Changes Grade 2|Grade 2	Visual acuity loss greater than or equal to 3 lines, but less than 6 lines. (ETDRS equivalent: each loss of 3 lines corresponds to halving the visual acuity)			Intellectual Product	Bayer Classification of Visual Acuity Changes
C128449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128449>	C222040	Bayer Visual Acuity Changes Grade 3|Grade 3	Visual acuity loss greater than or equal to 6 lines. (ETDRS equivalent: each loss of 3 lines corresponds to halving the visual acuity)			Intellectual Product	Bayer Classification of Visual Acuity Changes
C12844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12844>	C13442	Cervical|CERVICAL|cervical	Relating to a neck, or cervix, in any sense.			Spatial Concept	CDISC SEND Microscopic Findings Result Modifier Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128450>	C222040	Bayer Visual Acuity Changes Grade 4|Grade 4	Visual acuity loss greater than or equal to 6 lines, leading to blindness. (ETDRS equivalent: each loss of 3 lines corresponds to halving the visual acuity)			Intellectual Product	Bayer Classification of Visual Acuity Changes
C128451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128451>	C7158|C4479|C3272	Skin Neurofibroma|Cutaneous (Skin) Neurofibroma|Cutaneous Neurofibroma|Cutaneous Neurofibroma|Dermal Neurofibroma	A neurofibroma that grows along small branches of nerves in the dermis in patients with neurofibromatosis. It presents as a solid cutaneous tumor.	Cutaneous Neurofibroma		Neoplastic Process	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology
C128453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128453>	C90259	Pediatric Infectious Disease Terminology	Terminology developed by a collaborative effort of the National Cancer Institute's Enterprise Vocabulary Services, the National Institute of Child Health and Human Development, and an international group of clinicians and informaticists to support the reporting of events in the pediatric population with issues pertaining to infectious diseases.			Intellectual Product	
C128454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128454>	C99208	Lisch Nodule|Iris Hamartoma	A clear, yellow, or brown, well-defined, dome-shaped elevation projecting from the surface of the iris. It is composed of hamartomatous melanocytic aggregates and is the most common ocular manifestation of neurofibromatosis type 1.	Lisch Nodule		Finding	CTRP Disease Terminology|CTRP Terminology
C128455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128455>	C2848|C178427	Quadrivalent Inactivated Influenza Vaccine|Flucelvax Quadrivalent|Flucelvax Quadrivalent Influenza Vaccine|Fluzone Quadrivalent|Fluzone Quadrivalent Influenza Vaccine|QIV|Quadrivalent Influenza Vaccine	A synthetic vaccine consisting of hemagglutinin (HA) antigens derived from four inactivated influenza viruses, two different influenza type A strains and two different influenza type B strains, with protective immunizing activity. Quadrivalent influenza vaccine (QIV) is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season. Upon administration, the QIV provides active immunization against the four influenza virus strains, thereby protecting against influenza infection.	Quadrivalent Inactivated Influenza Vaccine		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C128456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128456>	C19498	Voucher	A document that can be exchanged for particular goods or services or one serving as a record of money paid.	Voucher		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C128457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128457>	C16564	American Ethnicity|American|Americas	A collection of ethnic geographical categories including African American, North American, Latin American, Caribbean, and South American.			Population Group	
C128458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128458>	C16564	Australian/New Zealand Ethnicity|Australian/New Zealand	A collection of ethnic geographical categories including Australian and New Zealander.			Population Group	
C128459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128459>	C16564	Intercontinental Ethnicity|Intercontinental	A collection of ethnic geographical categories including Middle Eastern and Hispanic.			Population Group	
C12845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12845>	C49601	Lumbar Plexus	A network of nerves lying within the substance of the psoas muscle that is formed by the ventral rami of L1-L4, and which provides motor and sensory contributions to the anterior and medial compartments of the leg, abdominal wall, and pelvic areas.	Lumbar Plexus		Body Part, Organ, or Organ Component	
C128460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128460>	C4798|C3868	Recurrent Gastrointestinal Stromal Tumor|Recurrent Gastrointestinal Stromal Tumor (GIST)	The reemergence of a gastrointestinal stromal tumor after a period of remission.	Recurrent Gastrointestinal Stromal Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C128461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128461>	C67332	Inch of Mercury|Inches of Mercury|[in_i'Hg]|[in_i'Hg]|in_i'h/i'Hg]|inch of mercury column|inch of mercury column	A measurement of the pressure exerted by a column of mercury of 1 inch in height at the standard acceleration of gravity. This measurement is used for barometric pressure in aviation, refrigeration, and weather reports. The conversion to metric units is dependent upon the temperature of the mercury.			Quantitative Concept	FDA CDRH GUDID Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology|UCUM Terminology
C128462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128462>	C129824	BET Inhibitor|BET Bromodomain Inhibitor	Any agent that inhibits one or more member of the bromodomain and extra-terminal domain (BET) family of proteins.	BET Inhibitor		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C128463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128463>	C752	OXT Gene Product	A protein encoded by the OXT gene.	OXT Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128464>	C128463	Oxytocin-Neurophysin 1|OT-NPI|OXT|Oxytocin, Prepropeptide|Oxytocin--Neurophysin I|Oxytocin-Neurophysin I|Oxytocin-Neurophysin I, Preproprotein|Preprooxytocin	Oxytocin-neurophysin 1 (125 aa, ~13kDa) is encoded by the human OXT gene. This protein plays a role in hormonal signaling involved in smooth muscle contraction in both the mammary gland and uterus, and many other psychological and physiological processes.	Oxytocin-Neurophysin 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128465>	C32049	CD16+ CD56+ CD69+ Lymphocyte|CD16, CD56, CD69 Triple-Positive Activated Lymphocyte|TrPAL|Triple-Positive Activated Lymphocyte	A population of activated lymphocytes that express CD16 (Fc-gamma receptor III), CD56 (neural cell adhesion molecule 1) and CD69 (early activation antigen CD69), which is mainly comprised of natural killer cells with an activated phenotype.	CD16+ CD56+ CD69+ Lymphocyte		Cell	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128466>	C97927	F2 Gene Mutation|Coagulation Factor II (Thrombin) Gene Mutation|Coagulation Factor II, Thrombin Gene Mutation	A change in the nucleotide sequence of the F2 gene.	F2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128467>	C128466	F2 NM_000506.4:c.*97G>A|Coagulation Factor II (Thrombin) 20210G>A|Coagulation Factor II, Thrombin 20210G>A|F2 20210G-A|F2 20210G>A|F2 G20210A|F2 c.*97G>A|F2 c.20210G>A|F2 g.25313G>A|F2, 20210G-A|Factor II 20210G-A Mutation|NG_008953.1:g.25313G>A|NM_000506.4:c.*97G>A|Prothrombin 20210G>A|Prothrombin G20210A	A nucleotide substitution at position *97 in the 3' untranslated region of the F2 gene where guanine has been mutated to adenine.	F2 NM_000506.4:c.*97G>A		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128468>	C16295	Modified Vaccinia Virus Ankara Antibody|Anti-MVA Antibody|Anti-Modified Vaccinia Ankara Virus Antibody|Anti-Modified Vaccinia Virus Ankara Antibody|MVA Antibody|Modified Vaccinia Ankara Virus Antibody	Any antibody that recognizes modified vaccinia Ankara virus.	Modified Vaccinia Virus Ankara Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C128469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128469>	C48181	Glycan Profile|Glycan Analysis|Glycan Characterization	A set of data that both identifies and quantifies all the polysaccharides and the protein or lipid conjugated polysaccharides in a biological sample or specimen.	Glycan Profile		Functional Concept	CTRP Biomarker Terminology|CTRP Terminology
C12846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12846>	C49601	Sacral Plexus|Sacral plexus structure (body structure)	A network of nerve fibers that are derived from the anterior rami of spinal nerves L4-L5 and S1-S4, and which are part of the larger lumbosacral plexus, providing motor and sensory innervation for the posterior thigh, most of the lower leg, the entire foot, and part of the pelvis.	Sacral Plexus		Body Part, Organ, or Organ Component	Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C128470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128470>	C25871	SPHK2 Gene|SPHK2|SPHK2|Sphingosine Kinase 2 Gene	This gene is involved in the biosynthesis of sphingosine 1- phosphate.	SPHK2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C128471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128471>	C128470	SPHK2 wt Allele|SK 2|SK-2|SK2|SPK 2|SPK-2|Sphingosine Kinase 2 wt Allele	Human SPHK2 wild-type allele is located in the vicinity of 19q13.33 and is approximately 11 kb in length. This allele, which encodes sphingosine kinase 2 protein, plays a role in lipid phosphorylation.	SPHK2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128472>	C16984	Sphingosine Kinase 2|EC 2.7.1.91|SK 2|SPHK2|SPK 2|Sphingosine Kinase Type 2	Sphingosine kinase 2 (654 aa, ~69 kDa) is encoded by the human SPHK2 gene. This protein is involved in phosphosphingolipid synthesis.	Sphingosine Kinase 2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128473>	C21295	PGRMC1 Gene|PGRMC1|PGRMC1|Progesterone Receptor Membrane Component 1 Gene	This gene plays a role in progesterone binding.	PGRMC1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C128474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128474>	C128473	PGRMC1 wt Allele|HPR6.6|MPR|PGRMC|Progesterone Receptor Membrane Component 1 wt Allele	Human PGRMC1 wild-type allele is located within Xq22-q24 and is approximately 8 kb in length. This allele, which encodes membrane-associated progesterone receptor component 1 protein, is involved in steroid binding.	PGRMC1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128475>	C17728	Membrane-Associated Progesterone Receptor Component 1|PGRMC1|Progesterone Binding Protein|mPR	Membrane-associated progesterone receptor component 1 (195 aa, ~22 kDa) is encoded by the human PGRMC1 gene. This protein may play a role in progesterone uptake.	Membrane-Associated Progesterone Receptor Component 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128476>	C20988	SELPLG Gene|SELPLG|SELPLG|Selectin P Ligand Gene	This gene is involved in the mediation of leukocyte rolling and cell adhesion.	SELPLG Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C128477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128477>	C128476	SELPLG wt Allele|CD162|CLA|PSGL-1|PSGL1|Selectin P Ligand wt Allele	Human SELPLG wild-type allele is located in the vicinity of 12q24 and is approximately 12 kb in length. This allele, which encodes P-selectin glycoprotein ligand 1 protein, plays a role in the regulation of migration and cell adhesion for leukocytes.	SELPLG wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128478>	C16393	P-Selectin Glycoprotein Ligand 1|CD162|CD162 Antigen|CLA|Cutaneous Lymphocyte Antigen|Cutaneous Lymphocyte-Associated Associated Antigen|P-Selectin Glycoprotein Ligand|PSGL-1|Selectin P Ligand	P-selectin glycoprotein ligand 1 (412 aa, ~43 kDa) is encoded by the human SELPLG gene. This protein is involved in the modulation of rolling and cell adhesion in circulating leukocytes.	P-Selectin Glycoprotein Ligand 1		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128479>	C25941	PDIA6 Gene|PDIA6|PDIA6|Protein Disulfide Isomerase Family A Member 6 Gene	This gene plays a role in protein folding and platelet aggregation.	PDIA6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C12847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12847>	C36725	Reactive Lymphocyte	A type of white blood cell that enlarges in response to antigenic stimulation.			Cell	
C128480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128480>	C128479	PDIA6 wt Allele|ERP5|P5|Protein Disulfide Isomerase Family A Member 6 wt Allele|Protein Disulfide Isomerase Family A, Member 6 Gene|TXNDC7|Thioredoxin Domain Containing 7 (Protein Disulfide Isomerase) Gene	Human PDIA6 wild-type allele is located in the vicinity of 2p25.1 and is approximately 55 kb in length. This allele, which encodes protein disulfide-isomerase A6 protein, is involved in both platelet aggregation and protein folding.	PDIA6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128481>	C16759	Protein Disulfide-Isomerase A6|EC 5.3.4.1|ER Protein 5|ERp5|Endoplasmic Reticulum Protein 5|PDIA6|Protein Disulfide Isomerase P5|Protein Disulfide Isomerase-Associated 6|Thioredoxin Domain-Containing Protein 7	Protein disulfide-isomerase A6 (440 aa, ~48 kDa) is encoded by the human PDIA6 gene. This protein plays a role in the inhibition of aggregation of misfolded proteins and the positive regulation of platelet activation.	Protein Disulfide-Isomerase A6		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128482>	C26147	B4GALNT1 Gene|B4GALNT1|B4GALNT1|Beta-1,4-N-Acetyl-Galactosaminyltransferase 1 Gene	This gene is involved in ganglioside biosynthesis.	B4GALNT1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C128483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128483>	C128482	B4GALNT1 wt Allele|Beta-1,4-N-Acetyl-Galactosaminyltransferase 1 wt Allele|GALGT|GALNACT|GalNAc-T|SIAT2|SPG26|Spastic Paraplegia 26 Gene|UDP-Gal:BetaGlcNAc Beta-1,4-N-Acetylgalactosaminyltransferase Transferase 1 Gene|UDP-N-Acetyl-Alpha-D-Galactosamine:(N-Acetylneuraminyl)-Galactosylglucosylceramide N-Acetylgalactosaminyltransferase (GalNAc-T) Gene	Human B4GALNT1 wild-type allele is located in the vicinity of 12q13.3 and is approximately 10 kb in length. This allele, which encodes beta-1,4 N-acetylgalactosaminyltransferase 1 protein, plays a role in the synthesis of glycosphingolipids. Mutation of the gene is associated with autosomal recessive spastic paraplegia 26.	B4GALNT1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128484>	C17434	Beta-1,4 N-Acetylgalactosaminyltransferase 1|(N-Acetylneuraminyl)-Galactosylglucosylceramide|B4GALNT1|Beta-1,4-N-Acetyl-Galactosaminyl Transferase 1|Beta-1,4-N-Acetyl-Galactosaminyltransferase 1|Beta-1,4-N-Acetylgalactosaminyltransferase|Beta1,4GalNAc-T|EC 2.4.1.92|G(M2)/G(D2) Synthase|GD2 Synthase|GD2 Synthase, GM2 Synthase|GM2 Synthase|GM2/GD2 Synthase|GalNAc-T|GalNAcT	Beta-1,4 N-acetylgalactosaminyltransferase 1 (533 aa, ~59 kDa) is encoded by the human B4GALNT1 gene. This protein is involved in ganglioside synthesis.	Beta-1,4 N-Acetylgalactosaminyltransferase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128485>	C28676|C138180|C129826	HPV-16 E7 TCR Expressing T-cells|HPV-16 E7 TCR Expressing T-lymphocytes|HPV-16 E7 TCR-expressing T Lymphocytes|Human Papillomavirus Type 16 E7 TCR Expressing T-cells	A preparation of allogeneic, genetically engineered T-lymphocytes transduced with a retroviral vector MSGV1 that encodes a T-cell receptor (TCR) targeting a specific epitope of the human papillomavirus (HPV) type 16 oncoprotein E7 (HPV-16 E7 TCR), with potential antineoplastic activity. The TCR especially recognizes and binds with high affinity to the HPV 16 E7 11-19 epitope. Upon administration, HPV-16 E7 expressing T-cells target and bind to tumor cells expressing the HPV-16 E7 antigen leading to selective cytotoxicity in HLA-A2-positive, HPV-16 E7-expressing tumor cells. HPV16 E7, a tumor-associated antigen (TAA), overexpressed in a variety of tumor cell types while not expressed in normal, healthy cells, plays a key role in tumor cell proliferation. E7 11-19 is a naturally processed epitope of HPV-16 E7 that binds specifically to human leukocyte antigen (HLA)-A*02:01 and that has been isolated from the surface of HPV-16 positive, HLA-A*02:01-positive tumor cells.	HPV-16 E7 TCR Expressing T-cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C128486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128486>	C201511|C201282|C129822	Anti-CD123/CD3 Bispecific Antibody JNJ-63709178|Humanized CD123 x CD3 DuoBody JNJ-63709178|JNJ-63709178	A humanized anti-CD123/anti-CD3 bispecific monoclonal antibody, with potential immunostimulating and antineoplastic activities. Anti-CD123/CD3 bispecific antibody JNJ-63709178 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD123, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of JNJ-63709178, this bispecific antibody simultaneously binds to both CD3-expressing T-cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated cell lysis of CD123-expressing tumor cells. CD123, the interleukin-3 receptor alpha chain, is overexpressed in a variety of cancers; its expression is low or absent in normal, healthy cells.	Anti-CD123/CD3 Bispecific Antibody JNJ-63709178		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C128487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128487>	C2124	Iodine I 124 Icapamespib|124I-PU-AD|ICAPAMESPIB I-124|Iodine I 124 PU-AD|[124I]-PU-AD	A radioconjugate composed of icapamespib, a synthetic purine-scaffold inhibitor of the molecular chaperone heat shock protein 90 (Hsp90), conjugated to the radioisotope iodine I 124, with potential imaging activity upon positron emission tomography (PET). Upon administration of iodine I 124 icapamespib, the icapamespib moiety selectively binds to cancer cells expressing stress-induced Hsp90 (stress Hsp90). Upon PET, Hsp90-overexpressing cancer cells can be visualized and patients who may benefit from icapamespib therapy can be identified. This radioconjugate may also be used to determine the pharmacokinetics of icapamespib. Icapamespib is able to cross the blood-brain-barrier (BBB) and specifically targets stress Hsp90, as seen in certain conditions, such as cancer and neurodegenerative diseases, while normal housekeeping Hsp90 complexes are not targeted by icapamespib at dose levels administered for imaging.  Additionally, housekeeping Hsp90 complexes are only targeted at doses that are much larger than that are needed to exert an anticancer effect.	Iodine I 124 Icapamespib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C128488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128488>	C390	Perflubutane Microbubble|Microbubble Ultrasound Contrast Agent PFB|PFB Microbubble|Perflubutane Microsphere|Sonazoid	A phospholipid-stabilized suspension composed of microbubbles containing the gas perfluorobutane (perflubutane, PFB) with an outer layer of hydrogenated egg phosphatidylserine (HEPS), which can be used as an ultrasound imaging contrast agent. Upon administration, the PFB microbubbles enhance echo differences between various tissues, which enhances the visualization of images during ultrasound. In particular, the PFB microbubbles seem to preferentially target the reticuloendothelial system (RES); they are taken up by macrophages in the spleen and liver (Kupffer cells), and are taken up in lymph nodes. This may aid in the detection and diagnosis of cancer and liver disease, and may improve imaging of the lymphatic and vascular systems. The microbubbles provide increased stability during ultrasound imaging.	Perflubutane Microbubble		Indicator, Reagent, or Diagnostic Aid|Organic Chemical	CTRP Agent Terminology|CTRP Terminology
C128489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128489>	C1663	HLA-A2-restricted Melanoma-specific Peptides Vaccine GRN-1201|Cancer Vaccine GRN-1201|GRN-1201|Peptide Cancer Vaccine GRN-1201|Peptide Vaccine GRN-1201	A cancer peptide vaccine composed of four human leukocyte antigen (HLA)-A2 (HLA-A*02)-restricted peptides derived from four specific and separate tumor-associated antigens (TAAs) expressed by melanoma cells, with potential antineoplastic activity. Upon administration of the HLA-A2-restricted melanoma-specific peptides vaccine, the melanoma specific antigens in the vaccine activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against the HLA-A2-positive melanoma cells.	HLA-A2-restricted Melanoma-specific Peptides Vaccine GRN-1201		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12848>	C12710	Squamous Epithelium	A simple or stratified flat epithelium.	Squamous Epithelium		Tissue	
C128490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128490>	C103175	Risk Evaluation and Mitigation Strategies Terminology|REMS Terminology	Risk Evaluation and Mitigation Strategies (REMS) are programs required by FDA and put in place by drug manufacturers to help ensure that the benefits of certain drugs outweigh their risks.	Risk Evaluation and Mitigation Strategies Terminology		Intellectual Product	
C128491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128491>	C54452	SPL REMS Requirement Terminology|Structured Product Labeling REMS Requirement Terminology	Terminology used in the framework of REMS SPL data to represent the clinical or administrative activities that a REMS program may require participants to perform.	SPL REMS Requirement Terminology		Intellectual Product	FDA Structured Product Labeling Terminology
C128492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128492>	C54452	SPL REMS Protocol Terminology|Structured Product Labeling REMS Protocol Terminology	Terminology used in the framework of REMS SPL data used to specify when REMS requirements must be carried out.	SPL REMS Protocol Terminology		Intellectual Product	FDA Structured Product Labeling Terminology
C128493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128493>	C54452	SPL REMS Stakeholder Terminology|Structured Product Labeling REMS Stakeholder Terminology	Terminology used in the framework of REMS SPL data to represent stakeholders who participate in the REMS based on the role they play in the medication use and distribution process.	SPL REMS Stakeholder Terminology		Intellectual Product	FDA Structured Product Labeling Terminology
C128494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128494>	C49235	Risk Evaluation and Mitigation Strategies Requirement|REMS Requirement|Requirement	Data elements that represent the clinical or administrative activities that a REMS program participant may be required to perform.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C128495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128495>	C70887|C128494	Designate a Healthcare Setting Representative	The healthcare setting must designate an authorized representative to act on that setting's behalf.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C128496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128496>	C70887|C128494	Be Able To Perform a Clinical Activity	The healthcare provider or setting must have the ability to carry out a particular clinical activity, such as administer a particular treatment, diagnose a particular disease, or recognize a particular adverse event.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C128497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128497>	C70887|C128494	Have Necessary Healthcare Personnel or Equipment	The healthcare provider or setting must have particular medical equipment or personnel with particular training on-site.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C128498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128498>	C192109|C128494	Review Prescribing Information	The healthcare provider or setting must review the drug's Prescribing Information.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C128499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128499>	C15931|C128494	Review Healthcare Training or Educational Materials|Review Training or Educational Materials	The healthcare provider or patient must review certain training or educational materials.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C12849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12849>	C12578	Squamous Cell|Squamous Cells|squamous cell		Squamous Cell		Cell	
C1284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1284>	C82130	Dextran Sulfate Sodium|DEXTRAN SULFATE SODIUM (5000 MW)|Dextran Sulfate	A long chain polymer of sulfated glucose with strong hydrophilic properties that binds to various membranes. Dextran sulfate has been shown to inhibit the binding of HIV-1 to CD4+ T lymphocytes by specific binding of virion-associated gp120.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C128500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128500>	C70887|C128494	Complete Healthcare Knowledge Assessment|Complete Knowledge Assessment	The healthcare provider or setting must complete a knowledge assessment. This applies to knowledge assessments that are standalone questionnaires as well as those that are incorporated into training/educational materials.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C128501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128501>	C15931|C128494	Train Staff about Medication Use Process|Train Staff	The healthcare setting must train staff who are involved in the medication use process (e.g. prescribing, dispensing, or administering the drug).			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C128502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128502>	C128494	REMS Participate in Training Session|Participate in Training Session|Risk Evaluation and Mitigation Strategies Participate in Training Session	In the context of REMS, the healthcare provider or setting must participate in a training session administered by a specified trainer, such as a REMS program or continuing education provider.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C128503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128503>	C128494	Establish Processes and Procedures to Verify REMS Safe Use Conditions|Establish Processes and Procedures to Verify Risk Evaluation and Mitigation Strategies Safe Use Conditions	In the context of REMS, the healthcare provider or setting must establish a system to verify that safe use conditions required by the REMS are in place. For purposes of this definition, "safe use condition" refers to any activity that must be completed before the drug is dispensed (e.g., enrollment or completion of a lab test).			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C128504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128504>	C128494	Enroll in the REMS|Enroll in The Risk Evaluation and Mitigation Strategies	The healthcare provider or patient must enroll in the REMS Program. Enrollment is the process by which REMS participants provide basic identifying and demographic information to the REMS Program (e.g. through a paper form or a website), allowing the application holder to track participants and communicate with them.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C128505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128505>	C128494	REMS Counsel Patient|Counsel Patient|Risk Evaluation and Mitigation Strategies Counsel Patient	In the context of REMS, the healthcare provider or setting must counsel the patient. The REMS may require that the counseling cover a specific topic, that the counseling use a specific REMS material (such as a Patient-Prescriber Agreement Form or Medication Guide), or both.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C128506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128506>	C15931|C128494	Provide Patient with Materials	The healthcare provider or setting must provide certain materials to a patient, such as patient education materials, or a Medication Guide.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C128507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128507>	C70887|C128494	Assess Patient Condition, Health Status, or Adverse Event	The healthcare provider or setting must screen or monitor the patient's condition, health status, or any adverse event.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C128508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128508>	C70887|C128494	Complete Patient Form	The healthcare provider, healthcare setting, and/or patient must complete a form such as a patient agreement or patient-prescriber agreement form.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C128509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128509>	C128494	Enroll Patient in the REMS	The healthcare provider or setting must enroll the patient in the REMS Program. Enrollment is the process by which REMS participants provide basic identifying and demographic information to the REMS Program (e.g. through a paper form or a website), allowing the application holder to track participants and communicate with them.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C12850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12850>	C13022	Stratum Spinosum|Spiny Layer	The part of the epidermis layer of the skin containing Langerhans cells, which are dendritic, MHC class II-expressing antigen presenting cells.	Stratum Spinosum		Tissue	
C128510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128510>	C192109|C128494	Do Not Prescribe Refills	The prescriber must not prescribe refills of the drug.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C128511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128511>	C192109|C128494	Do Not Dispense Refills	The dispenser must not dispense refills of the drug.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C128512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128512>	C192109|C128494	Prescribe Limited Days Supply|Prescribe limited days' supply	The prescriber must prescribe only a limited days supply of the drug.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C128513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128513>	C192109|C128494	Dispense Limited Days Supply|Dispense limited days' supply	The dispenser must dispense only a limited days supply of the drug.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C128514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128514>	C128494	Use REMS Prescription Ordering Form|Use Risk Evaluation and Mitigation Strategies Prescription Ordering Form	The prescriber must order the prescription using a special prescription ordering form provided by the REMS program. These forms are used to order product from a pharmacy and, may also remind prescribers of counseling, screening, and dosing requirements.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C128515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128515>	C15931|C128494	Verify Safe Use Conditions	The healthcare provider or setting must verify that required safe use conditions are in place before the drug is dispensed using established processes and procedures. For purposes of this definition, "safe use conditions" refers to any activity that must be completed before the drug is dispensed (e.g., enrollment or completion of a lab test).			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C128516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128516>	C128494	Obtain REMS Dispensing Authorization|Obtain Risk Evaluation and Mitigation Strategies Dispensing Authorization	The dispenser must obtain authorization to dispense the drug from the REMS Program (e.g. over the phone, through a website, or electronically through a pharmacy management system).			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C128517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128517>	C49235|C128494	Return Unused Product	The healthcare provider or setting must return unused product to the manufacturer.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C128518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128518>	C192109|C128494	Do Not Distribute, Transfer, Loan, or Sell Product	The healthcare provider or setting must not distribute, transfer, loan, or sell the product.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C128519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128519>	C70887|C128494	Maintain Healthcare Records|Maintain Records	The healthcare provider or setting must maintain records of certain activities which may be provided to the sponsor or requested in audits. This may include records of dispensing or distribution of a drug.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C12851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12851>	C12971	Female Breast|Breast, Female	The organ of milk secretion; one of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest of the mature female; it is rudimentary in the male.	Breast, Female		Body Part, Organ, or Organ Component	
C128520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128520>	C128494	Report Adverse Events	The healthcare provider or setting must report adverse events of interest to the Manufacturer, MedWatch, and/or a REMS Program.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C128521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128521>	C128494	Cooperate with REMS Audits|Cooperate with Risk Evaluation and Mitigation Strategies Audits	The healthcare provider or setting must cooperate with audits of their activities conducted by the REMS program.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C128523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128523>	C15931|C128494	Get Lab Test or Monitoring	The patient must be monitored or have a lab test completed.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C128524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128524>	C15931|C128494	Receive Counseling	The patient must receive counseling from a healthcare provider. The counseling may cover a specific topic, use a specific material, or both.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C128525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128525>	C70887|C128494	Complete Patient Questionnaire	The patient must complete a questionnaire.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C128526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128526>	C128494	Adhere to REMS Patient Safe Use Conditions|Adhere to Risk Evaluation and Mitigation Strategies Patient Safe Use Conditions	The patient must adhere to certain safe use conditions, such as using contraception or following the safe use conditions described in REMS materials.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C128527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128527>	C15931|C128494	Inform Prescriber	The patient must inform the prescriber of certain conditions, such as adverse events or changes in health status.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C128528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128528>	C25320	REMS Protocol|Protocol|Risk Evaluation and Mitigation Strategies Protocol	The "Protocol" data element is used to specify when REMS requirements must be carried out: either at a specific point in the medication use process (e.g. prescribing, dispensing, administering), or based on the receipt of REMS certification.			Intellectual Product	FDA Structured Product Labeling Terminology|SPL REMS Protocol Terminology
C128529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128529>	C43610	REMS Certification|Risk Evaluation and Mitigation Strategies Certification	The receipt of certification by a healthcare provider or setting, allowing them to prescribe, dispense, and/or administer a drug under a REMS program.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Protocol Terminology
C12852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12852>	C34076	Vertebral Body|Body of Vertebra|Body of the Vertebra|Structure of body of vertebra (body structure)	The largest part of a vertebra, which is the primary weight-bearing component of the vertebrae.	Vertebral Body		Body Part, Organ, or Organ Component	mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C128530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128530>	C21090	Pharmacotherapy Initiation|Medication Initiation	The start of treatment with a drug; the first prescription or order for a drug associated with a given course of treatment.			Therapeutic or Preventive Procedure	FDA Structured Product Labeling Terminology|SPL REMS Protocol Terminology
C128531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128531>	C21090	Pharmacotherapy Continuation|Medication Continuation	The continuation of an existing prescription or order for a given course of treatment.			Therapeutic or Preventive Procedure	FDA Structured Product Labeling Terminology|SPL REMS Protocol Terminology
C128532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128532>	C28180	All Pharmacotherapy Prescriptions	Any prescription or order associated with a given course of treatment; a new prescription or order or the continuation of an existing prescription or order.			Intellectual Product	FDA Structured Product Labeling Terminology|SPL REMS Protocol Terminology
C128533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128533>	C21090	Medication Dispensing	The dispensing of a drug to be self-administered by a patient or to be administered by a healthcare provider.			Therapeutic or Preventive Procedure	FDA Structured Product Labeling Terminology|SPL REMS Protocol Terminology
C128534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128534>	C21090	Medication Administration	The administration of a drug to a patient.	Medication Administration		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|FDA Structured Product Labeling Terminology|SPL REMS Protocol Terminology
C128535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128535>	C21090	Pharmacotherapy Discontinuation|Medication Discontinuation	The discontinuation of treatment with a drug.	Pharmacotherapy Discontinuation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|FDA Structured Product Labeling Terminology|SPL REMS Protocol Terminology
C128536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128536>	C21090	Medication Distribution	The distribution, sale, or transfer of a drug not pursuant to a specific prescription.			Therapeutic or Preventive Procedure	FDA Structured Product Labeling Terminology|SPL REMS Protocol Terminology
C128537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128537>	C113644	REMS Stakeholder|Risk Evaluation and Mitigation Strategies Stakeholder|Stakeholder	The "Stakeholder" data element represents stakeholders who participate in the REMS based on the role they play in the medication use and distribution process (e.g., whether they prescribe, dispense, or distribute the drug).			Population Group	FDA Structured Product Labeling Terminology|SPL REMS Stakeholder Terminology
C128538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128538>	C113644	Medication Prescriber	Healthcare providers who prescribe the drug.			Population Group	FDA Structured Product Labeling Terminology|SPL REMS Stakeholder Terminology
C128539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128539>	C113644	Medication Dispenser	Healthcare providers who dispense or administer the drug, settings in which the drug is dispensed or administered, or authorized representatives of the setting in which the drug is dispensed or administered. This encompasses a wide range of settings, including outpatient pharmacies, chain pharmacies, independent pharmacies, mail-order pharmacies, clinics, infusion centers, hospitals, health systems, and closed health systems.			Population Group	FDA Structured Product Labeling Terminology|SPL REMS Stakeholder Terminology
C12853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12853>	C12933	Sacral Vertebra|SACRAL VERTEBRA|Sacral Vertebrae|Sacral vertebra structure (body structure)	One of the usually five fused vertebrae forming the triangular bone just below the lumbar vertebrae.	Sacral Vertebrae		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C128540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128540>	C93394	Non-Prescribing Non-Dispensing Healthcare Provider	Healthcare providers or healthcare settings that treat patients who take the drug but neither prescribe or dispense the drug.			Population Group	FDA Structured Product Labeling Terminology|SPL REMS Stakeholder Terminology
C128541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128541>	C16960	Medication-Taking Patient	Patients who use the drug.			Population Group	FDA Structured Product Labeling Terminology|SPL REMS Stakeholder Terminology
C128542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128542>	C48289	Non-Manufacturing Medication Distributor	Parties other than the drug's manufacturer who distribute, sell, or transfer the drug for reasons other than filling a specific prescription.			Population Group	FDA Structured Product Labeling Terminology|SPL REMS Stakeholder Terminology
C128543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128543>	C76372	Nocardia cyriacigeorgica|NOCARDIA CYRIACIGEORGICA	A species of Gram-positive, catalase-positive, rod-shaped bacteria in the phylum Actinobacteria. This species is positive for use of acetate, gluconate, and sucrose as sole carbon sources and acetamide as a sole source of carbon and nitrogen. It was isolated from the bronchial secretion of a patient with chronic bronchitis and is seen as an emerging human pathogen.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128544>	C123336	Paenibacillus phoenicis|PAENIBACILLUS PHOENICIS	A species of Gram-positive, aerobic, bacillus-shaped, endospore-forming bacteria in the phylum Firmicutes. This species is negative for urease, tryptophan deaminase, and hydrolysis of gelatin. It is positive for sole carbon use with glucose, mannitol, sucrose, glycogen, and several others. The type strain was isolated from surfaces of the Payload Hazardous Servicing Facility located at the Kennedy Space Center where the Phoenix lander was assembled.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128545>	C86660	Prevotella histicola|PREVOTELLA HISTICOLA	A species of obligately anaerobic, non-motile, Gram-negative bacillus-shaped bacteria in the phylum Bacteroidetes. This species is considered a normal part of the human oral microbiota. P. histicola is considered to be commensal.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128546>	C86653	Porphyromonas bennonis|PORPHYROMONAS BENNONIS	A species of obligately-anaerobic, non-spore-forming, Gram-negative bacillus-shaped bacteria in the phylum Bacteroidetes. This species is part of the indigenous bacterial flora in the oral cavity of humans and animals.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128547>	C76375	Pseudomonas otitidis|PSEUDOMONAS OTITIDIS	A species of Gram-negative, motile, bacillus-shaped bacteria in the phylum Proteobacteria. The species was isolated from patients with otic infections.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128548>	C62583	Staphylococcus pettenkoferi|STAPHYLOCOCCUS PETTENKOFERI	A species of facultative anaerobic, Gram-positive, nonmotile, nonspore-forming, coccus-shaped bacteria in the phylum Firmicutes. This species is coagulase-negative and is a commensal organism on the skin of healthy humans but may cause infections in immunocompromised individuals.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128549>	C76383	Streptococcus urinalis|STREPTOCOCCUS URINALIS	A species of facultatively anaerobic, non-motile, non-spore forming, Gram-positive, catalase-negative, chain-forming, coccus-shaped bacteria in the phylum Firmicutes first isolated from human urine.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12854>	C12688	Scaphoid Bone|Navicular Bone of Hand|Os Scaphoideum|SCAPHOID BONE|Scaphoid	A nut-shaped bone of the wrist located in the radial site of the hand. It is one of the eight carpal bones.	Scaphoid Bone		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128550>	C114129	Trichosporon mucoides|TRICHOSPORON MUCOIDES	A species of yeast-like fungi in the phylum Basidiomycota characterized by growth with galactitol and at 37C. This species was first isolated from human clinical samples. It is known to cause deep invasive infections.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128551>	C77185	Fusarium solani|FUSARIUM SOLANI|Neocosmospora solani	A species of non-dermatophytic hyaline mold in the phylum Ascomycota. The species is a ubiquitous soil borne pathogen causing several diseases on a broad range of plants.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128552>	C86807	Streptococcus suis serotype 2|S. suis 2|STREPTOCOCCUS SUIS SEROTYPE 2|Streptococcus Group R	A serotype of Streptococcus suis that is considered the most virulent serotype and the serotype most frequently isolated from diseased animals.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128553>	C14208	Zika Virus|ZIKA VIRUS|ZIKV	A species of positive sense ssRNA viruses in the family Flaviviridae that is carried and spread by Aedes mosquitoes. This virus causes zika fever and infection in pregnant women can pass to the fetus and is associated with microcephaly and other birth defects. Zika virus infection can also trigger Guillain-Barre paralysis.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128554>	C177692|C122807	PD-L1 Positive|B7 Homolog 1 Positive|B7-H Positive|B7H1 Positive|CD274 Antigen Positive|CD274 Molecule Positive|CD274 Positive|Expression of PD-L1|PD-L1+|PDCD1L1 Positive|PDCD1LG1 Positive|PDL1 Positive|Positive|Programmed Cell Death 1 Ligand 1 Positive	An immunohistochemical test result that indicates expression of PD-L1 in a tissue sample of a primary or metastatic malignant neoplasm.	PD-L1 Positive		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128555>	C156862	Frameless Fractionated Stereotactic Radiation Therapy|FFSRT|FSRS|Frameless SRT	A type of fractionated stereotactic radiotherapy that does not involve the use of a frame to hold the patient's head still or provide external reference points.	Frameless Fractionated Stereotactic Radiation Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C128556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128556>	C201173	Anti-CD22 CAR-expressing T Lymphocytes|Anti-CD22 CAR-expressing T-cells|CD22 CAR-T	A preparation of human T-lymphocytes transduced with a recombinant viral vector encoding a chimeric T-cell receptor (chimeric antigen receptor or CAR) consisting of one or more binding domains targeting the tumor-associated antigen (TAA) CD22 and fused to one or more co-stimulatory, TCR-signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD22 CAR-expressing T-lymphocytes, express anti-CD22-CAR on their cell surfaces and bind to the CD22 antigen on tumor cell surfaces. Subsequently, CD22-expressing B-cells are lysed. CD22, a B-lineage-restricted, transmembrane phosphoglycoprotein, is expressed on malignant B-cells.	Anti-CD22 CAR-expressing T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C128557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128557>	C1748	Topoisomerase I/II Inhibitor NEV-801|NEV-801|NEV-801|NEV801|TopI/II NEV-801	A multi-targeted agent with potential antineoplastic activity. Upon administration, NEV-801 appears to selectively inhibit topoisomerase (Topo) I and II, and activates hypoxia-inducible factor 1 (HIF-1) transcription and the expression of vascular endothelial growth factor (VEGF) mRNA. NEV-801 is also able to overcome multidrug resistance (MDR) 1-mediated resistance.	Topoisomerase I/II Inhibitor NEV-801		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C128558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128558>	C2554|C177174	TLR4 Agonist GSK1795091|GSK-1795091|GSK1795091|TLR 4 Agonist GSK1795091|Toll-like Receptor 4 Agonist GSK1795091	A toll-like receptor 4 (TLR4) agonist, with potential immunoadjuvant activity. Upon administration, GSK1795091 binds to and activates TLR4, thereby stimulating dendritic cells (DCs), monocytes and macrophages. This activation results in the production of pro-inflammatory cytokines, including interferon gamma (IFN-g), tumor necrosis factor-alpha (TNF-a) and the interleukins (IL), IL-1 beta, -6 and -12. This may induce a T helper cell-1 (Th1) immune response and, upon co-administration of a vaccine containing tumor-associated antigens (TAAs), activates a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing those TAAs. TLR4, a member of the TLR family, plays a key role in the activation of innate immunity.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C128559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128559>	C267	Sumac/Black Cumin Powder|Persumac|Rhus coriaria L./Bunium persicum Boiss Powder|Sumac/Black Zira Powder	An Iranian traditional herbal medicine composed of powder derived from sumac and Bunium persicum (black cumin, black zira), with potential anti-emetic activity. Upon oral administration, sumac/black cumin powder may inhibit chemotherapy-induced nausea and vomiting (CINV). The powder may also have some anti-oxidant activities.			Organic Chemical|Pharmacologic Substance	NCI Drug Dictionary Terminology
C12855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12855>	C12688	Pisiform Bone|PISIFORM BONE|Pisiform|Pisiform Bone of Hand	The medial bone of the proximal row of carpal bones.	Pisiform Bone		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128561>	C1505	Fructooligosaccharide Supplement|FOS Supplement|Fructo-oligosaccharide Supplement|Fructo-oligosaccharides Supplement|Oligofructan Supplement|Oligofructose Supplement	A supplement containing oligosaccharide fructans, with gastrointestinal (GI) protective and immumopotentiating activities. Upon oral administration of the supplement, the oligosaccharides stimulate the growth of certain GI bacteria and activate the immune system. This improves the intestinal microflora, strengthens the immune system and increases the protective function of the GI barrier.	Fructooligosaccharide Supplement		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C128562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128562>	C1663	HLA-A2-restricted IL-13Ra2/EphA2/Survivin/Tetanus Toxoid T-helper Epitopes-Montanide 51 Vaccine|HLA-A2-restricted IL-13Ra2/EphA2/Survivin/Tetanus Toxoid T-helper Peptides-Montanide 51 Vaccine	A peptide vaccine comprised of synthetic human leukocyte antigen (HLA)-A2-restricted peptides derived from the tumor-associated antigens (TAAs) interleukin-13 receptor alpha-2 (IL-13Ra2), the tyrosine kinase receptor Ephrin receptor A2 (EphA2), and the apoptosis inhibitor protein survivin, combined with the adjuvant tetanus toxoid (TT)-derived helper T-cell peptide, and emulsified in the immunoadjuvant Montanide ISA-51, with potential immunostimulating and antineoplastic activities. Specifically, this vaccine contains the epitopes: IL-13Ralpha2 345-353:1A9V, which is an engineered peptide based on amino acids 345-353 of IL-13Ra2 where the amino acids at the first and ninth positions of the peptide have been replaced with alanine and valine, respectively, EphA2 883-891, and survivin 96-104. Upon administration, the HLA-A2-restricted IL-13Ra2/EphA2/survivin/TT T-helper epitopes-Montanide 51 vaccine may stimulate a HLA-A2-restricted cytotoxic T-lymphocyte (CTL) response against tumor cells that overexpress IL-13Ra2, EphA2, or survivin, and results in tumor cell lysis. TT T-helper peptide binds to class II major histocompatibility molecules (MHC) molecules as a nonspecific vaccine helper epitope, resulting in long-term immunopotentiation by increasing the helper T-cell response. Montanide ISA-51, a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide monooleate added as a surfactant, non-specifically stimulates cell-mediated immune responses to antigens. IL-13Ra2, EphA2 and survivin, TAAs that are overexpressed in certain tumor cell types, play key roles in tumor cell proliferation. HLA-A2 presents antigenic peptides to CD8+ T-cells; epitope design restricted to epitopes that bind most efficiently to HLA-A2 may improve peptide immunogenicity.	HLA-A2-restricted IL-13Ra2/EphA2/Survivin/Tetanus Toxoid T-helper Epitopes-Montanide 51 Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCIt Antineoplastic Agent Terminology
C128563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128563>	C3513|C155903	Unresectable Esophageal Carcinoma|Esophageal Cancer Unresectable|Esophageal Carcinoma Unresectable|Unresectable Cancer of Esophagus|Unresectable Cancer of the Esophagus|Unresectable Esophageal Cancer|Unresectable Esophageal Cancer	A carcinoma that arises from the esophagus and is not amenable to surgical resection.	Unresectable Esophageal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C128564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128564>	C118425	Plant Glycan|PLANT TYPE GLYCAN	An oligosaccharide modifying a protein in plant cells.			Chemical Viewed Structurally	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C128567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128567>	C35869	Anatomic Imaging Concept	Concepts created to assist in identifying anatomic areas on radiographic images.			Body Location or Region	
C128568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128568>	C128567	Prostate Imaging Area	The region(s) of the prostate being visualized through one or more radiologic techniques, including ultrasound (U/S), computed tomography (CT), and magnetic resonance imaging (MRI).			Body Location or Region	
C128569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128569>	C128568	Fibromuscular Stroma of Prostate	The portion of the prostate comprising both fibrous and muscle tissue that fills the spaces between the glandular tissue.			Body Location or Region	
C12856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12856>	C12688	Capitate Bone|CAPITATE BONE|Capitate	The largest of eight carpal bones, located in the center of the hand.	Capitate Bone		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128570>	C128568	Peripheral Zone of Prostate|Peripheral Zone|Peripheral zone	The region of the prostate that is located most superficial and posterior as compared to the other prostate zones. It is located closest to the rectum, and is easily palpated on digital rectal exam. This zone of the prostate surrounds the distal urethra, and is the zone of origin for the vast majority of prostatic cancers.			Body Location or Region	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C128571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128571>	C128568	Transition Zone of Prostate|Transition zone	The region of the prostate gland that is located deep to both the central and peripheral zones; it surrounds the proximal urethra, and is the zone of the prostate gland that grows throughout life, most often causing a condition called benign prostatic hypertrophy.			Conceptual Entity	GDC Terminology|GDC Value Terminology
C128572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128572>	C128568	Central Zone of Prostate|Central Zone|Central zone	This region of the prostate gland that is located between the peripheral and transition zones, surrounding the ejaculatory ducts. It gives rise to a very small percentage of prostate cancers, though these cancers are frequently more aggressive, often resulting in invasion of the seminal vesicles.			Body Location or Region	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C128573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128573>	C28381|C13035	Urethral Sphincter|URETHRAL SPHINCTER	One or both of the muscles that surround the urethra and contract to control the flow of urine, either involuntarily (the internal sphincter) or voluntarily (the external sphincter).			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128574>	C128569	Left Apical Anterior Fibromuscular Stroma of Prostate|Apex L AS	The portion of the fibromuscular stroma of the prostate that is located on the anatomical left side of the apical division of the anterior lobe.			Body Location or Region	PI-RADS Terminology
C128575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128575>	C128570	Left Anterior Apical Peripheral Zone of Prostate|Apex L PZa	The region of the prostate that is located on the anatomical left side of the anterior portion of the apical division of the peripheral zone.			Body Location or Region	PI-RADS Terminology
C128576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128576>	C128570	Left Posterolateral Apical Peripheral Zone of Prostate|Apex L PZpl	The region of the prostate that is located on the anatomical left side of the posterolateral portion of the apical division of the peripheral zone.			Body Location or Region	PI-RADS Terminology
C128577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128577>	C128570	Left Posteromedial Apical Peripheral Zone of Prostate|Apex L PZpm	The region of the prostate that is located on the anatomical left side of the posteromedial portion of the apical division of the peripheral zone.			Body Location or Region	PI-RADS Terminology
C128578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128578>	C128571	Left Anterior Apical Transition Zone of Prostate|Apex L TZa	The region of the prostate that is located on the anatomical left side of the anterior portion of the apical division of the transition zone.			Body Location or Region	PI-RADS Terminology
C128579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128579>	C128571	Left Posterior Apical Transition Zone of Prostate|Apex L TZp	The region of the prostate that is located on the anatomical left side of the posterior portion of the apical division of the transition zone.			Body Location or Region	PI-RADS Terminology
C12857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12857>	C12688	Trapezial Bone|Greater Multiangular Bone|TRAPEZIAL BONE|Trapezium|Trapezium	A carpal bone on the thumb side of the hand that articulates with the 1st and 2nd metacarpals.	Trapezial Bone		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128580>	C128569	Right Apical Anterior Fibromuscular Stroma of Prostate|Apex R AS	The portion of the fibromuscular stroma of the prostate that is located on the anatomical right side of the apical division of the anterior lobe.			Body Location or Region	PI-RADS Terminology
C128581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128581>	C128570	Right Anterior Apical Peripheral Zone of Prostate|Apex R PZa	The region of the prostate that is located on the anatomical right side of the anterior portion of the apical division of the peripheral zone.			Body Location or Region	PI-RADS Terminology
C128582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128582>	C128570	Right Posterolateral Apical Peripheral Zone of Prostate|Apex R PZpl	The region of the prostate that is located on the anatomical right side of the posterolateral portion of the apical division of the peripheral zone.			Body Location or Region	PI-RADS Terminology
C128583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128583>	C128570	Right Posteromedial Apical Peripheral Zone of Prostate|Apex R PZpm	The region of the prostate that is located on the anatomical right side of the posteromedial portion of the apical division of the peripheral zone.			Body Location or Region	PI-RADS Terminology
C128584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128584>	C128571	Right Anterior Apical Transition Zone of Prostate|Apex R TZa	The region of the prostate that is located on the anatomical right side of the anterior portion of the apical division of the transition zone.			Body Location or Region	PI-RADS Terminology
C128585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128585>	C128571	Right Posterior Apical Transition Zone of Prostate|Apex R TZp	The region of the prostate that is located on the anatomical right side of the posterior portion of the apical division of the transition zone.			Body Location or Region	PI-RADS Terminology
C128586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128586>	C128569	Left Basal Anterior Fibromuscular Stroma of Prostate|Base L AS	The portion of the fibromuscular stroma of the prostate that is located on the anatomical left side of the basal division of the anterior lobe.			Body Location or Region	PI-RADS Terminology
C128587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128587>	C128572	Central Zone of Left Half Prostate|Base L CZ	The portion of the central zone of the prostate that is located to the anatomical left of center.			Body Location or Region	PI-RADS Terminology
C128588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128588>	C128570	Left Anterior Basal Peripheral Zone of Prostate|Base L PZa	The region of the prostate that is located on the anatomical left side of the anterior portion of the basal division of the peripheral zone.			Body Location or Region	PI-RADS Terminology
C128589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128589>	C128571	Left Anterior Basal Transition Zone of Prostate|Base L TZa	The region of the prostate that is located on the anatomical left side of the anterior portion of the basal division of the transition zone.			Body Location or Region	PI-RADS Terminology
C12858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12858>	C12688	Triangular Bone|TRIANGULAR BONE|Triquetral Bone	A carpal bone located between the lunate and pisiform bones.	Triangular Bone		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128590>	C128571	Left Posterior Basal Transition Zone of Prostate|Base L TZp	The region of the prostate that is located on the anatomical left side of the posterior portion of the basal division of the transition zone.			Body Location or Region	PI-RADS Terminology
C128591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128591>	C128570	Left Posterolateral Basal Peripheral Zone of Prostate|Base L PZpl	The region of the prostate that is located on the anatomical left side of the posterolateral portion of the basal division of the peripheral zone.			Body Location or Region	PI-RADS Terminology
C128592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128592>	C128569	Right Basal Anterior Fibromuscular Stroma of Prostate|Base R AS	The portion of the fibromuscular stroma of the prostate that is located on the anatomical right side of the basal division of the anterior lobe.			Body Location or Region	PI-RADS Terminology
C128593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128593>	C128572	Central Zone of Right Half Prostate|Base R CZ	The portion of the central zone of the prostate that is located to the anatomical right of center.			Body Location or Region	PI-RADS Terminology
C128594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128594>	C128570	Right Anterior Basal Peripheral Zone of Prostate|Base R PZa	The region of the prostate that is located on the anatomical right side of the anterior portion of the basal division of the peripheral zone.			Body Location or Region	PI-RADS Terminology
C128595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128595>	C128570	Right Posterolateral Basal Peripheral Zone of Prostate|Base R PZpl	The region of the prostate that is located on the anatomical right side of the posterolateral portion of the basal division of the peripheral zone.			Body Location or Region	PI-RADS Terminology
C128596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128596>	C128571	Right Anterior Basal Transition Zone of Prostate|Base R TZa	The region of the prostate that is located on the anatomical right side of the anterior portion of the basal division of the transition zone.			Body Location or Region	PI-RADS Terminology
C128597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128597>	C128571	Right Posterior Basal Transition Zone of Prostate|Base R TZp	The region of the prostate that is located on the anatomical right side of the posterior portion of the basal division of the transition zone.			Body Location or Region	PI-RADS Terminology
C128598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128598>	C12787	Left Seminal Vesicle|L SV	The seminal gland that is located to the anatomical left of the bladder.			Body Part, Organ, or Organ Component	PI-RADS Terminology
C128599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128599>	C128569	Left Middle Anterior Fibromuscular Stroma of Prostate|Mid L AS	The portion of the fibromuscular stroma of the prostate that is located on the anatomical left side of the middle division of the anterior lobe.			Body Location or Region	PI-RADS Terminology
C12859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12859>	C12688	Trapezoid Bone|Lesser Multiangular Bone|TRAPEZOID BONE|Trapezoid	A carpal bone located between the trapezium and capitate bones.	Trapezoid Bone		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C1285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1285>	C1746	Endothelin-1|EDN1|ET-1|Endothelin 1|PPET1|Preproendothelin 1|Preproendothelin-1	Endothelin-1 (212 aa, ~24 kDa) is encoded by the human EDN1 gene. This protein is involved in vasoconstriction.	Endothelin-1		Amino Acid, Peptide, or Protein|Hormone	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128600>	C128570	Left Anterior Middle Peripheral Zone of Prostate|Mid L PZa	The region of the prostate that is located on the anatomical left side of the anterior portion of the middle division of the peripheral zone.			Body Location or Region	PI-RADS Terminology
C128601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128601>	C128570	Left Posterolateral Middle Peripheral Zone of Prostate|Mid L PZpl	The region of the prostate that is located on the anatomical left side of the posterolateral portion of the middle division of the peripheral zone.			Body Location or Region	PI-RADS Terminology
C128602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128602>	C128570	Left Posteromedial Middle Peripheral Zone of Prostate|Mid L PZpm	The region of the prostate that is located on the anatomical left side of the posteromedial portion of the middle division of the peripheral zone.			Body Location or Region	PI-RADS Terminology
C128603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128603>	C128571	Left Anterior Middle Transition Zone of Prostate|Mid L TZa	The region of the prostate that is located on the anatomical left side of the anterior portion of the middle division of the transition zone.			Body Location or Region	PI-RADS Terminology
C128604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128604>	C128571	Left Posterior Middle Transition Zone of Prostate|Mid L TZp	The region of the prostate that is located on the anatomical left side of the posterior portion of the middle division of the transition zone.			Body Location or Region	PI-RADS Terminology
C128605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128605>	C128569	Right Middle Anterior Fibromuscular Stroma of Prostate|Mid R AS	The portion of the fibromuscular stroma of the prostate that is located on the anatomical right side of the middle division of the anterior lobe.			Body Location or Region	PI-RADS Terminology
C128606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128606>	C128570	Right Anterior Middle Peripheral Zone of Prostate|Mid R PZa	The region of the prostate that is located on the anatomical right side of the anterior portion of the middle division of the peripheral zone.			Body Location or Region	PI-RADS Terminology
C128607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128607>	C128570	Right Posterolateral Middle Peripheral Zone of Prostate|Mid R PZpl	The region of the prostate that is located on the anatomical right side of the posterolateral portion of the middle division of the peripheral zone.			Body Location or Region	PI-RADS Terminology
C128608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128608>	C128570	Right Posteromedial Middle Peripheral Zone of Prostate|Mid R PZpm	The region of the prostate that is located on the anatomical right side of the posteromedial portion of the middle division of the peripheral zone.			Body Location or Region	PI-RADS Terminology
C128609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128609>	C128571	Right Anterior Middle Transition Zone of Prostate|Mid R TZa	The region of the prostate that is located on the anatomical right side of the anterior portion of the middle division of the transition zone.			Body Location or Region	PI-RADS Terminology
C12860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12860>	C12688	Hamate Bone|HAMATE BONE|Hamate|Unciform Bone|Uncinate Bone	The medial bone in the distal row of carpal bones.	Hamate Bone		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128610>	C128571	Right Posterior Middle Transition Zone of Prostate|Mid R TZp	The region of the prostate that is located on the anatomical right side of the posterior portion of the middle division of the transition zone.			Body Location or Region	PI-RADS Terminology
C128611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128611>	C12787	Right Seminal Vesicle|R SV	The seminal gland that is located to the anatomical right of the bladder.			Body Part, Organ, or Organ Component	PI-RADS Terminology
C128612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128612>	C128573	Male External Urethral Sphincter|US	The muscle that surrounds the membranous urethra, functioning to control the voluntary flow of urine.			Body Part, Organ, or Organ Component	PI-RADS Terminology
C128613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128613>	C54443	PI-RADS Terminology|Prostate Imaging Reporting and Data System	Terminology created to support the work of the Prostate Imaging Reporting and Data System.			Intellectual Product	
C128614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128614>	C797	Manuka Honey Breast Pads|Breast Pads with Manuka Honey|Manuka Honey-containing Breast Pads	Breast pads containing Manuka honey, with potential healing, wound repair, antibacterial, anti-inflammatory and protective activities. Compared to other honey products, Manuka honey contains a high concentration of the 1,2-dicarbonyl compound methylglyoxal (MG), which may account for its antibacterial activity. Upon application of the Manuka honey breast pads to the nipples, the honey may decrease nipple sensitivity, such as radiation-induced nipple sensitivity. It may also decrease itching and pain, prevent inflammation and infection, and promote wound healing. The Manuka honey is produced by bees fed on the flowers of the New Zealand bush Leptospermum scoparium (Manuka, Manuka myrtle, New Zealand teatree).	Manuka Honey Breast Pads		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology
C128615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128615>	C210987	pan-PIM Kinase Inhibitor NVP-LGB-321|LGB321|NVP-LGB-321|PIM Inhibitor NVP-LGB-321|PIM Kinase Inhibitor NVP-LGB-321	An orally available, small molecule and selective ATP-competitive pan-inhibitor of proviral integration sites for Moloney murine leukemia virus (PIM) kinases, with potential antineoplastic activity. Upon oral administration, pan-PIM kinase inhibitor NVP-LGB-321 binds to and prevents the activation of the three PIM family kinases, PIM1, PIM2 and PIM3. This prevents the activation of PIM-mediated signaling pathways and inhibits proliferation in cells that overexpress PIMs. PIMs, constitutively active proto-oncogenic serine/threonine kinases upregulated in various types of cancers, play key roles in tumor cell proliferation and survival.	pan-PIM Kinase Inhibitor NVP-LGB-321		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C128616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128616>	C217121	Simpson Grading System|Simpson Grading System for Removal of Meningiomas|Simpson Grading of Meningioma Resection|Simpson Scale	A scale that defines the extent of resection involved in the removal of intracranial meningiomas.			Intellectual Product	
C128617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128617>	C222041	Simpson Grade 1|Grade 1|Grade I	Macroscopically complete removal of the tumor, with excision of its dural attachment, and of any abnormal bone. Includes resection of venous sinus if involved.			Intellectual Product	
C128618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128618>	C222041	Simpson Grade 2|Grade 2|Grade II	Macroscopically complete removal of the tumor and its visible extensions with coagulation of its dural attachment.			Intellectual Product	
C128619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128619>	C222041	Simpson Grade 3|Grade 3|Grade III	Macroscopically complete removal of the intradural tumor, without resection or coagulation of its dural attachment or its extradural extensions.			Intellectual Product	
C128620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128620>	C222041	Simpson Grade 4|Grade 4|Grade IV	Partial removal, leaving the intradural tumor in situ.			Intellectual Product	
C128621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128621>	C222041	Simpson Grade 5|Grade 5|Grade V	Simple decompression, with or without biopsy.			Intellectual Product	
C128622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128622>	C128462	BET Inhibitor INCB057643|INCB 057643|INCB-057643|INCB057643	An inhibitor of the Bromodomain (BRD) and Extra-Terminal (BET) family of BRD-containing proteins, with potential antineoplastic activity. Upon administration, the BET inhibitor INCB057643 binds to the acetylated lysine recognition motifs found in the BRD of BET proteins, thereby preventing the interaction between the BET proteins and acetylated lysines on histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes, such as c-Myc-dependent target genes, may lead to an inhibition of tumor cell growth. BET proteins are transcriptional regulators that are overexpressed in certain tumor cells and play an important role in cellular growth.	BET Inhibitor INCB057643		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C128624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128624>	C38101	Megavoltage Topographic Imaging	The generation of a topographic image using megavolt x-ray beams.	Megavoltage Topographic Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C128625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128625>	C1327	Caplacizumab|ALX 0081|ALX 0681|ALX-0081|ALX-0681|ALX0081|ALX0681|CAPLACIZUMAB|Cablivi|Caplacizumab-yhdp	A humanized, bivalent anti-von Willebrand factor (VWF) nanobody, with potential anti-platelet and anti-thrombotic activities. Upon administration, caplacizumab specifically binds, with its two identical monovalent moieties, to the A1 domain of the adhesive glycoprotein VWF, thereby inhibiting and neutralizing VWF activity. This prevents the interaction of ultra-large VWF (ULVWF) with the platelet glycoprotein (GP)Ib-IX-V receptor complex, and prevents ULVWF-mediated platelet adhesion, and aggregation, which reduces thrombus formation. VWF is a glycoprotein and plays a key role in blood coagulation. Increased VWF, which is seen in a number of diseases, is associated with an increased risk in thrombosis; in thrombotic thrombocytopenic purpura (TTP), increased levels of ULVWF and thus increased and abnormal platelet aggregation are seen due to impaired breakdown of ULVWF. The nanobody formulation allows for rapid distribution, onset of action and clearance. The nanobody is based on the smallest functional fragments of the immunoglobulin heavy-chain variable domains that occur naturally in the Camelidae family.	Caplacizumab		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C128626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128626>	C68681	MRI-Guided Transurethral Ultrasound Ablation|MRI-TULSA	The use of high-intensity ultrasound, via a transurethral approach and using MRI-guidance, to destroy tissue.	MRI-Guided Transurethral Ultrasound Ablation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C128627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128627>	C141146|C1327	Cobolimab|Anti-TIM3 Checkpoint Inhibitor TSR-022|Anti-TIM3 Monoclonal Antibody TSR-022|COBOLIMAB|Immunoglobulin G4, Anti-(Hepatitis A Virus Cellular Receptor 2 (havcr2)) (Humanized Clone ABT2 Gamma4-chain), Disulfide with Humanized Clone ABT2 Kappa-chain, Dimer|TSR-022	A monoclonal antibody against the inhibitory T-cell receptor, T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, cobolimab binds to TIM-3 expressed on certain T-cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.	Cobolimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C128628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128628>	C103223	Ph Unknown|Philadelphia Chromosome Status Unknown	Philadelphia chromosome abnormality, t(9;22)(q34;q11) was not tested; therefore it is not known whether it is present or not.	Ph Unknown		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128629>	C8644	B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative|Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative|B-Cell Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative|Ph1-Negative ALL|Ph1-Negative Acute Lymphoblastic Leukemia|Philadelphia Chromosome Negative ALL|Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia|Philadelphia-Negative ALL|Philadelphia-Negative Acute Lymphoblastic Leukemia|Precursor B Lymphoblastic Leukemia, Philadelphia Chromosome Negative|Precursor B-Lymphoblastic Leukemia, Philadelphia Chromosome Negative	A B acute lymphoblastic leukemia (B-ALL) that does not have the cytogenetic abnormality t(9;22)(q34;q11.2). Most cases of B-ALL do not have this translocation.	Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C128630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128630>	C38617	Laryngeal Anterior Commissure|Anterior Glottic Commissure|GLOTTIS, ANTERIOR COMMISSURE	The anterior-most portion of the vocal cord, located within the larynx, that constitutes the junction of the conus elasticus and the thyroepiglottic, vestibular, and vocal ligaments.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128631>	C74095|C177692	CD20 Positive|CD20 Antigen Positive|CD20 Expressing|CD20 Present|CD20+|Leu-16 Positive|MS4A1 Positive	A finding indicating that CD20 is present on cells or expressed by cells.	CD20 Positive		Laboratory or Test Result	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128632>	C2201|C129825	mTOR Kinase Inhibitor PP242|2-(4-Amino-1-isopropyl-1H-pyrazolo(3,4-d)pyrimidin-3-yl)-1H-indol-5-ol|PP-242|PP-242|PP242				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C128633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128633>	C2160	Proteasome Inhibitor MG-132|Benzyloxycarbonylleucyl-leucyl-leucine Aldehyde|MG 132|MG-132|MG-132|S)-N-((Phenylmethoxy)carbonyl)-L-leucyl-N-(1-formyl-3-methylbutyl)-L-leucinamide				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C128634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128634>	C93252	Thapsigargin|Octanoic Acid, 6-(Acetyloxy)-2,3,3a,4,5,6,6a,7,8,9b-decahydro-3,3a-dihydroxy-3,6,9-trimethyl-8-((2-methyl-1-oxo-2-butenyl)oxy)-2-oxo-4-(1-oxobutoxy)azuleno(4,5-b)furan-7-yl Ester, (3S-(3alpha,3abeta,4alpha,6beta,6abeta,7beta,8alpha(Z),9balpha))-|THAPSIGARGIN				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C128635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128635>	C25404	Cool|Cooling	To lower the temperature of something.			Activity	
C128636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128636>	C25436	Faced Block	A block that has been cut down to the desired tissue plane, with the overlaying support material removed.			Manufactured Object	
C128637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128637>	C4798|C3713	Recurrent Respiratory Papillomatosis|RRP	A rare disease caused by the human papillomavirus (HPV), most commonly types 6 and 11, that affects tissue along the respiratory tract with the majority of cases affecting the larynx. The disease has a bimodal distribution and manifests in those younger than age 5, juvenile-onset recurrent respiratory papillomatosis (JORRP), and those older than age 40, adult-onset recurrent respiratory papillomatosis (AORRP). JORRP is more common and more severe in presentation than AORRP. In a small percentage of patients, respiratory papillomas may undergo malignant transformation to squamous cell carcinomas that have a poor prognosis.	Recurrent Respiratory Papillomatosis		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C128638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128638>	C19238	Histology Cassette|Biopsy Cassette|Tissue Cassette|Tissue Processing Cassette	A device designed to hold tissue specimens during processing, embedding and storage.			Manufactured Object	
C128639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128639>	C19157	Analyte	The sample or material being subjected to analysis.			Physical Object	
C12863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12863>	C52771	Middle Phalanx of Hand|Middle Phalanx of Finger|Middle Phalanx of the Hand|hand middle phalanx|middle manual phalanx|middle phalanx of finger|middle phalanx of hand|middle phalanx of manual digit|middle phalanx of manus|phalanx media manus	One of four finger bones located between, and articulating with, a proximal phalange and a distal phalange.	Middle Phalanx of Hand		Body Part, Organ, or Organ Component	UBERON Terminology
C128640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128640>	C62358|C1937	Gadopiclenol|(alpha3,alpha6,alpha9-Tris(3-((2,3-dihydroxypropyl)amino)-3-oxopropyl)-3,6,9,15-tetraazabicyclo(9.3.1)pentadeca-1(15),11,13-triene-3,6,9-triacetato(3-)-kappaN3,kappaN6,kappaN9,kappaN15,kappaO3,kappaO6,kappaO9)gadolinium|Elucirem|GADOPICLENOL|GBCA P03277|Gadolinium-based Magnetic Resonance Contrast Agent P03277|P 03277|P03277|WHO 10744	A gadolinium-based paramagnetic contrast agent, with potential imaging enhancing activity upon magnetic resonance imaging (MRI). Upon administration of gadopiclenol and placement in a magnetic field, this agent produces a large magnetic moment and creates a large local magnetic field, which can enhance the relaxation rate of nearby protons. This change in proton relaxation dynamics, increases the MRI signal intensity of tissues in which this agent has accumulated; therefore, contrast and visualization of those tissues is enhanced compared to unenhanced MRI.	Gadopiclenol		Indicator, Reagent, or Diagnostic Aid|Organic Chemical	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C128641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128641>	C3420|C185933	t(11;14)	A cytogenetic abnormality that involves a translocation between chromosomes 11 and 14.	t(11;14)		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128642>	C3420	t(11;22)	A cytogenetic abnormality that involves a translocation between chromosomes 11 and 22.	t(11;22)		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128643>	C3420|C185933	t(14;18)	A cytogenetic abnormality that involves a translocation between chromosomes 14 and 18.	t(14;18)		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128644>	C3420	t(21;22)	A cytogenetic abnormality that involves a translocation between chromosomes 21 and 22.	t(21;22)		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128645>	C3420	t(16;16)	A cytogenetic abnormality that involves a translocation occurring within chromosome 16.	t(16;16)		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128646>	C78275|C20401	Idarucizumab|BI 655075|BI-655075|BI655075|IDARUCIZUMAB|Praxbind	A humanized monoclonal antibody fragment directed against the thrombin-binding site of dabigatran, that may be used as a specific reversal agent for dabigatran. Upon intravenous administration, idarucizumab binds to dabigatran and its acylglucuronide metabolites with a higher affinity than the binding affinity of dabigatran to thrombin, thereby neutralizing the anticoagulant effect of dabigatran.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology
C128647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128647>	C3420	t(3;3)|T(3;3)	A cytogenetic abnormality that involves a translocation occurring within chromosome 3.	t(3;3)		Cell or Molecular Dysfunction	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128648>	C179848|C165667	EWSR1 Gene Translocation|EWS Gene Translocation|EWS Translocation|EWSR1 Translocation|Ewing Sarcoma Breakpoint Region 1 Gene Translocation|Ewing's Sarcoma Gene Translocation Mutation	A cytogenetic abnormality that refers to a translocation involving the EWSR1 gene.	EWSR1 Gene Translocation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128649>	C3420|C185933	t(8;14)	A cytogenetic abnormality that involves a translocation between chromosomes 8 and 14.	t(8;14)		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128650>	C3420|C180942	t(6;9)	A cytogenetic abnormality that involves a translocation between chromosomes 6 and 9.	t(6;9)		Cell or Molecular Dysfunction	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C128651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128651>	C3420	t(6;11)	A cytogenetic abnormality that involves a translocation between chromosomes 6 and 11.	t(6;11)		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128652>	C3420	t(4;11)	A cytogenetic abnormality that involves a translocation between chromosomes 4 and 11.	t(4;11)		Cell or Molecular Dysfunction	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C128653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128653>	C3420|C141237	t(2;13)	A cytogenetic abnormality that involves a translocation between chromosomes 2 and 13.	t(2;13)		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128654>	C36386|C3420	t(1;19)	A cytogenetic abnormality that involves a translocation between chromosomes 1 and 19.	t(1;19)		Cell or Molecular Dysfunction	ALL Authorized Value Terminology|ALL Molecular Analysis Table|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128655>	C36386|C3420|C141237	t(1;13)	A cytogenetic abnormality that involves a translocation between chromosomes 1 and 13.	t(1;13)		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128656>	C3420|C129438	t(15;17)	A cytogenetic abnormality that involves a translocation between chromosomes 15 and 17.	t(15;17)		Cell or Molecular Dysfunction	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C128657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128657>	C3420|C171054	t(12;21)	A cytogenetic abnormality that involves a translocation between chromosomes 12 and 21.	t(12;21)		Cell or Molecular Dysfunction	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128658>	C95145|C188129	t(4;14)(p16;q32)	A cytogenetic abnormality that refers to the translocation of the short arm (p16) of chromosome 4 and the long arm (q32) of chromosome 14.	t(4;14)(p16;q32)		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128659>	C36664	CHFR Promoter Methylation|Checkpoint with Forkhead and Ring Finger Domains Gene Promoter Methylation|RNF196 Promoter Methylation	An epigenetic modification involving methylation of CpG islands in the promoter region of the CHFR gene.	CHFR Promoter Methylation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12865>	C12555	Endothelial Cell|Endothelial Cells|Endotheliocyte|endothelial cell	The main type of cell forming the lining of blood and lymph vessels and the inner layer of the endocardium.	Endothelial Cell		Cell	
C128660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128660>	C202673	KIT Exon 8 Mutation|CD117 Exon 8 Mutation|CKIT Mutation - Ex8|KIT Proto-Oncogene Tyrosine Protein Kinase Gene Exon 8 Mutation|c-KIT Exon 8 Mutation|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Gene Exon 8 Mutation	A molecular genetic abnormality indicating the presence of a mutation in exon 8 of the KIT gene located within 4q11-q12.	KIT Exon 8 Mutation		Cell or Molecular Dysfunction	AML Authorized Value Terminology|AML Minimal Residual Disease Table|AML Molecular Analysis Table|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128661>	C98357	EGFR Exon 18 Mutation|ERBB Exon 18 Mutation|ERBB1 Exon 18 Mutation|Epidermal Growth Factor Receptor Gene Exon 18 Mutation|HER1 Exon 18 Mutation	A molecular genetic abnormality indicating the presence of a mutation in exon 18 of the EGFR gene.	EGFR Exon 18 Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128662>	C98357	EGFR Exon 19 Mutation|EGFR Exon 19 Gene Mutation|ERBB Exon 19 Mutation|ERBB1 Exon 19 Mutation|Epidermal Growth Factor Receptor Gene Exon 19 Mutation|HER1 Exon 19 Mutation	A molecular genetic abnormality indicating the presence of a mutation in exon 19 of the EGFR gene.	EGFR Exon 19 Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128663>	C98357	EGFR Exon 20 Mutation|ERBB Exon 20 Mutation|ERBB1 Exon 20 Mutation|Epidermal Growth Factor Receptor Gene Exon 20 Mutation|HER1 Exon 20 Mutation	A molecular genetic abnormality indicating the presence of a mutation in exon 20 of the EGFR gene.	EGFR Exon 20 Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128664>	C69013	Tru-Cut Biopsy Needle|Tru-Cut	A proprietary biopsy needle designed for manual capture of high-quality tissue samples with minimal trauma to the patient.			Medical Device	
C128665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128665>	C62653	Wallet Pack Dosage Form|Blister Wallet|Blister Wallet Card|Wallet Pack|Wallet Package	A multi-panel, re-closable end-user pack for tablet blisters.			Biomedical or Dental Material	
C128666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128666>	C98357	EGFR Exon 21 Mutation|EGFR Exon 21 Gene Mutation|ERBB Exon 21 Mutation|ERBB1 Exon 21 Mutation|Epidermal Growth Factor Receptor Gene Exon 21 Mutation|HER1 Exon 21 Mutation	A molecular genetic abnormality indicating the presence of a mutation in exon 21 of the EGFR gene.	EGFR Exon 21 Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128667>	C27993	More	Greater in size, amount, extent, or degree.			Qualitative Concept	
C128668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128668>	C71390	Triplet	Any of three offspring born from the same pregnancy.			Human	
C128669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128669>	C126834	GAIA Dysfunctional Labor Level of Diagnostic Certainty|Dysfunctional Labor Level of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Dysfunctional Labor Level of Diagnostic Certainty	A classification of maternal and fetal outcomes relating to dysfunctional labor, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C12866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12866>	C12578	Transitional Cell|Transitional Cells|transitional cell		Transitional Cell		Cell	
C128670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128670>	C126834	GAIA Antenatal Bleeding Level of Diagnostic Certainty|Antenatal Bleeding Level of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Antenatal Bleeding Level of Diagnostic Certainty	A classification of maternal and fetal outcomes relating to antenatal bleeding, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C128671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128671>	C126834	GAIA Gestational Diabetes Mellitus Level of Diagnostic Certainty|Gestational Diabetes Mellitus Level of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Gestational Diabetes Mellitus Level of Diagnostic Certainty	A classification of maternal and fetal outcomes relating to gestational diabetes mellitus, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C128672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128672>	C126834	GAIA Fetal Growth Restriction Level of Diagnostic Certainty|Fetal Growth Restriction Level of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Fetal Growth Restriction Level of Diagnostic Certainty	A classification of maternal and fetal outcomes relating to fetal growth restriction, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C128673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128673>	C126830	GAIA Failure to Thrive Level of Diagnostic Certainty|Failure to Thrive Level of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Failure to Thrive Level of Diagnostic Certainty	A classification of maternal and fetal outcomes relating to failure to thrive, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C128674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128674>	C126830	GAIA Small for Gestational Age Level of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Small for Gestational Age Level of Diagnostic Certainty|Small for Gestational Age Level of Diagnostic Certainty	A classification of maternal and fetal outcomes relating to small for gestational age, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C128675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128675>	C126830	GAIA Low Birth Weight Level of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Low Birth Weight Level of Diagnostic Certainty|Low Birth Weight Level of Diagnostic Certainty	A classification of maternal and fetal outcomes relating to low birth weight, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C128676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128676>	C126830	GAIA Neonatal Respiratory Distress Level of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Neonatal Respiratory Distress Level of Diagnostic Certainty|Neonatal Respiratory Distress Level of Diagnostic Certainty	A classification of maternal and fetal outcomes relating to neonatal respiratory distress, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C128677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128677>	C126834	GAIA Spontaneous Abortion and Ectopic Pregnancy Level of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Spontaneous Abortion and Ectopic Pregnancy Level of Diagnostic Certainty|Spontaneous Abortion and Ectopic Pregnancy Level of Diagnostic Certainty	A classification of maternal and fetal outcomes relating to spontaneous abortion and ectopic pregnancy, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C128678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128678>	C126830	GAIA Congenital Microcephaly Level of Diagnostic Certainty|Congenital Microcephaly Level of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Congenital Microcephaly Level of Diagnostic Certainty	A classification of maternal and fetal outcomes relating to congenital microcephaly, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C128679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128679>	C128677	GAIA Spontaneous Abortion Level of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Spontaneous Abortion Level of Diagnostic Certainty	A classification of maternal and fetal outcomes relating to spontaneous abortions, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C12867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12867>	C12710	Alveolar Epithelium|Lung Alveolar Epithelia	Epithelia of lung alveoli. The layer of cells covering the lining of the tiny air sacs at the end of the bronchioles.	Alveolar Epithelium		Body Part, Organ, or Organ Component	
C128680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128680>	C128677	GAIA Ectopic Pregnancy Level of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Ectopic Pregnancy Level of Diagnostic Certainty	A classification of maternal and fetal outcomes relating to ectopic pregnancies, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C128681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128681>	C66830	CDISC SDTM Gastrointestinal Test Name Terminology|GASTRO|Gastrointestinal Test Name|SDTM-GASTRO	Terminology associated with the gastrointentestinal test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128682>	C66830	CDISC SDTM Gastrointestinal Test Code Terminology|GASTROCD|Gastrointestinal Test Code|SDTM-GASTROCD	Terminology associated with the gastrointentestinal test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128683>	C77526|C66830	CDISC SDTM PK Unit of Measure Kilogram Weight Terminology|PK Units of Measure - Weight kg|PKUWKG|SDTM-PKUWKG	Terminology associated with the PK unit of measure kilogram weight codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128684>	C77526|C66830	CDISC SDTM PK Unit of Measure Gram Weight Terminology|PK Units of Measure - Weight g|PKUWG|SDTM-PKUWG	Terminology associated with the PK unit of measure gram weight codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128685>	C77526|C66830	CDISC SDTM PK Unit of Measure Milligram Dose Terminology|PK Units of Measure - Dose mg|PKUDMG|SDTM-PKUDMG	Terminology associated with the PK unit of measure milligram dose codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128686>	C77526|C66830	CDISC SDTM PK Unit of Measure Microgram Dose Terminology|PK Units of Measure - Dose ug|PKUDUG|SDTM-PKUDUG	Terminology associated with the PK unit of measure microgram dose codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128687>	C66830	CDISC SDTM Microbiology Susceptibility Test Name Terminology|MSTEST|Microbiology Susceptibility Test Name|SDTM-MSTEST	Terminology associated with the microbiology susceptibility test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128688>	C66830	CDISC SDTM Microbiology Susceptibility Test Code Terminology|MSTESTCD|Microbiology Susceptibility Test Code|SDTM-MSTESTCD	Terminology associated with the microbiology susceptibility test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128689>	C77527|C66830	CDISC SDTM Collected Race Terminology|RACEC|Race As Collected|SDTM-RACEC	Terminology associated with the race collected codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC CDASH Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12868>	C12728	Right Atrium|HEART, RIGHT ATRIUM	One of the four chambers of the heart, which is located immediately superior to the right ventricle, and which receives deoxygenated venous blood from the systemic circulation.	Right Atrium		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128690>	C77527|C66830	CDISC SDTM Collected Ethnicity Terminology|ETHNICC|Ethnicity As Collected|SDTM-ETHNICC	Terminology associated with the ethnicity as collected codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC CDASH Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128691>	C49474	International Classification of Diseases, Tenth Revision, Clinical Modification|ICD-10-CM|ICD10-CM|International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM)	An extension of the ICD-10 created by the U.S. National Center for Health Statistics so that the system could be used to capture more morbidity data. This extension included a section of procedure codes.			Classification	
C128692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128692>	C126830	GAIA Neonatal Encephalopathy Level of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Neonatal Encephalopathy Level of Diagnostic Certainty|Neonatal Encephalopathy Level of Diagnostic Certainty	A classification of maternal and fetal outcomes relating to neonatal encephalopathy, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C128693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128693>	C1910	Triptorelin Acetate|TRIPTORELIN ACETATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C128694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128694>	C128678	GAIA Postnatally Diagnosed Congenital Microcephaly Level of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Postnatally Diagnosed Congenital Microcephaly Level of Diagnostic Certainty|Postnatally Diagnosed Congenital Microcephaly Level of Diagnostic Certainty	A classification of maternal and fetal outcomes relating to diagnosing congenital microcephaly postnatally, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C128695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128695>	C128678	GAIA Prenatally Diagnosed Congenital Microcephaly Level of Diagnostic Certainty|Global Alignment of Immunization safety Assessment in pregnancy Prenatally Diagnosed Congenital Microcephaly Level of Diagnostic Certainty|Prenatally Diagnosed Congenital Microcephaly Level of Diagnostic Certainty	A classification of maternal and fetal outcomes relating to diagnosing congenital microcephaly prenatally, developed by the Global Alignment of Immunization safety Assessment in pregnancy, based on the extent to which the diagnosis has been confirmed.			Classification	
C128697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128697>	C3468	NK-Cell Lymphoma, Unclassifiable	A very rare NK-cell lymphoma with pathologic and clinical features posing difficulty in its exact diagnosis and classification.	NK-Cell Lymphoma, Unclassifiable		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C128698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128698>	C3824	Not Otherwise Specified Lesion|NOS Lesion|Not Further Specified Lesion	A lesion in which further histopathological and/or molecular characterization is not possible, available, or reported.			Finding	
C128699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128699>	C125481	GAIA Neonatal Encephalopathy Level of Diagnostic Certainty Terminology|Global Alignment of Immunization safety Assessment in pregnancy Neonatal Encephalopathy Level of Diagnostic Certainty	A subset of terminology related to neonatal encephalopathy, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.			Intellectual Product	
C12869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12869>	C12728	Left Atrium|HEART, LEFT ATRIUM|Left Atrium of Heart	One of four chambers of the heart, which receives blood from the pulmonary veins and pumps blood through the mitral valve into the left ventricle.	Left Atrium		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C1286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1286>	C898	Recombinant Transforming Growth Factor-Beta-2|CETERMIN|Cartilage-Inducing Factor-B|Glioblastoma-Derived T-Cell Suppressor Factor|TGF-Beta 2|Transforming Growth Factor-Beta 2	A recombinant polypeptide chemically identical to or similar to the endogenous cytokine transforming growth factor-beta-2 (TGF-beta-2). TGF-beta-2 modulates cell growth and immune function and may promote or inhibit tumor growth, depending on the tumor cell type. TGF-beta-2 may also suppress host immune system recognition of and/or response to tumor cells.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C128700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128700>	C125481	GAIA Congenital Microcephaly Level of Diagnostic Certainty Terminology|Global Alignment of Immunization safety Assessment in pregnancy Congenital Microcephaly Level of Diagnostic Certainty Terminology	A subset of terminology related to congenital microcephaly, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.			Intellectual Product	
C128701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128701>	C125481	GAIA Low Birth Weight Level of Diagnostic Certainty Terminology|Global Alignment of Immunization safety Assessment in pregnancy Low Birth Weight Level of Diagnostic Certainty Terminology	A subset of terminology related to low birth weight, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.			Intellectual Product	
C128702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128702>	C125481	GAIA Neonatal Respiratory Distress Level of Diagnostic Certainty Terminology|Global Alignment of Immunization safety Assessment in pregnancy Neonatal Respiratory Distress Level of Diagnostic Certainty Terminology	A subset of terminology related to neonatal respiratory distress, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.			Intellectual Product	
C128703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128703>	C125481	GAIA Small for Gestational Age Level of Diagnostic Certainty Terminology|Global Alignment of Immunization safety Assessment in pregnancy Small for Gestational Age Level of Diagnostic Certainty Terminology	A subset of terminology related to small for gestational age, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.			Intellectual Product	
C128704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128704>	C125481	GAIA Failure to Thrive Level of Diagnostic Certainty Terminology|Global Alignment of Immunization safety Assessment in pregnancy Failure to Thrive Level of Diagnostic Certainty Terminology	A subset of terminology related to failure to thrive, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.			Intellectual Product	
C128705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128705>	C125481	GAIA Spontaneous Abortion and Ectopic Pregnancy Level of Diagnostic Certainty Terminology|Global Alignment of Immunization safety Assessment in pregnancy Spontaneous Abortion and Ectopic Pregnancy Level of Diagnostic Certainty Terminology	A subset of terminology related to spontaneous abortion and ectopic pregnancy, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.			Intellectual Product	
C128706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128706>	C125481	GAIA Antenatal Bleeding Level of Diagnostic Certainty Terminology|Global Alignment of Immunization safety Assessment in pregnancy Antenatal Bleeding Level of Diagnostic Certainty Terminology	A subset of terminology related to antenatal bleeding, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.			Intellectual Product	
C128707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128707>	C125481	GAIA Dysfunctional Labor Level of Diagnostic Certainty Terminology|Global Alignment of Immunization safety Assessment in pregnancy Dysfunctional Labor Level of Diagnostic Certainty Terminology	A subset of terminology related to dysfunctional labor, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.			Intellectual Product	
C128708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128708>	C125481	GAIA Fetal Growth Restriction Level of Diagnostic Certainty Terminology|Global Alignment of Immunization safety Assessment in pregnancy Fetal Growth Restriction Level of Diagnostic Certainty Terminology	A subset of terminology related to fetal growth restriction, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.			Intellectual Product	
C128709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128709>	C125481	GAIA Gestational Diabetes Mellitus Level of Diagnostic Certainty Terminology|Global Alignment of Immunization safety Assessment in pregnancy Gestational Diabetes Mellitus Level of Diagnostic Certainty Terminology	A subset of terminology related to gestational diabetes mellitus, developed by the Global Alignment of Immunization safety Assessment in pregnancy consortium to aid in monitoring and improving fetal and maternal outcomes.			Intellectual Product	
C12870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12870>	C12730	Right Ventricle|HEART, RIGHT VENTRICLE	The lower chamber of the heart located in the right side. It receives blood from the right atrium that is no longer oxygenated and it pumps it to the pulmonary artery.	Right Ventricle		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128710>	C128680	GAIA Level 1 Ectopic Pregnancy|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Ectopic Pregnancy|Level 1 Ectopic Pregnancy	GAIA Level 1 Ectopic Pregnancy is defined by either of the following two criteria: first, the following three requirements must be met: a) Gestational age is within the pre-defined range for the selected ectopic pregnancy definition as assessed by maternal and/or fetal parameters (Level 1-2) (Brighton Preterm Birth Gestational Age algorithm; b) B-HCG serum blood test greater than 2000 mIU/ml; c) Transvaginal ultrasound showing no intrauterine pregnancy; OR second, the following two criteria must be met: a) Gestational age is within the pre-defined range for the selected ectopic pregnancy definition as assessed by maternal and/or fetal parameters (Level 1-2) (Brighton Preterm Birth Gestational Age algorithm; b) Transvaginal ultrasound showing extrauterine pregnancy OR no products of conception found on endometrial curettage after dilation and curettage procedure.			Classification	GAIA Spontaneous Abortion and Ectopic Pregnancy Level of Diagnostic Certainty Terminology|GAIA Terminology
C128711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128711>	C128680	GAIA Level 2 Ectopic Pregnancy|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Ectopic Pregnancy|Level 2 Ectopic Pregnancy	GAIA Level 2 Ectopic Pregnancy is defined by three criteria: first, it does not qualify as a Level 1 Ectopic Pregnancy; second, gestational age is within the pre-defined range for the selected ectopic pregnancy definition as assessed by maternal and/or fetal parameters (Level 1-2) (Brighton Preterm Birth Gestational Age algorithm); third, at least one of the following two requirements must be met: a) Transvaginal ultrasound showing no intrauterine pregnancy; OR b) No products of conception found on endometrial curettage after dilation and curettage procedure.			Classification	GAIA Spontaneous Abortion and Ectopic Pregnancy Level of Diagnostic Certainty Terminology|GAIA Terminology
C128712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128712>	C128680	GAIA Level 3 Ectopic Pregnancy|Global Alignment of Immunization safety Assessment in pregnancy Level 3 Ectopic Pregnancy|Level 3 Ectopic Pregnancy	GAIA Level 3 Ectopic Pregnancy is defined by four criteria: first, it does not qualify as either a Level 1 or a Level 2 Ectopic Pregnancy; second, gestational age is within the pre-defined range for the selected ectopic pregnancy definition as assessed by maternal and/or fetal parameters (Level 2-3) (Brighton Preterm Birth Gestational Age algorithm); third, a positive urine pregnancy test; fourth, no products of conception are found on endometrial curettage after a dilation and curettage procedure.			Classification	GAIA Spontaneous Abortion and Ectopic Pregnancy Level of Diagnostic Certainty Terminology|GAIA Terminology
C128713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128713>	C128680	GAIA Level 4 Ectopic Pregnancy|Global Alignment of Immunization safety Assessment in pregnancy Level 4 Ectopic Pregnancy|Level 4 Ectopic Pregnancy	GAIA Level 4 Ectopic Pregnancy is defined by two criteria: first, it does not qualify as a Level 1, a Level 2, or a Level 3 Ectopic Pregnancy; second, a maternal self-report or documentation in the medical record of a pregnancy loss without sufficient ultrasound or laboratory evidence to confirm.			Classification	GAIA Spontaneous Abortion and Ectopic Pregnancy Level of Diagnostic Certainty Terminology|GAIA Terminology
C128714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128714>	C27619	Morbidly Adherent Placenta|Morbidly Adherent Placentation	A condition in which the placenta implants abnormally into the uterine myometrium, rather than implanting into the uterine decidua basalis as is normal.			Disease or Syndrome	GAIA Antenatal Bleeding Level of Diagnostic Certainty Terminology|GAIA Terminology
C128715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128715>	C34945	Cesarean Scar Pregnancy	An ectopic pregnancy implanted in a previous cesarean (hysterotomy) scar, surrounded by myometrium and connective tissue.			Disease or Syndrome	GAIA Antenatal Bleeding Level of Diagnostic Certainty Terminology|GAIA Terminology
C128716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128716>	C34941	Uterine Rupture	The complete, nonsurgical disruption of all layers of the uterus.			Finding	GAIA Antenatal Bleeding Level of Diagnostic Certainty Terminology|GAIA Terminology
C128717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128717>	C128669	GAIA Level 1 Dysfunctional First Stage of Labor|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Dysfunctional First Stage of Labor|Level 1 Dysfunctional First Stage of Labor	GAIA Level 1 Dysfunctional First Stage of Labor is defined by progress of less than 0.5 cm of cervical dilation per hour, for at least 4 hours, in women with established labor (i.e. have regular contractions and cervical dilation of at least 4 cm) and with confirmed ruptured membranes.			Classification	GAIA Dysfunctional Labor Level of Diagnostic Certainty Terminology|GAIA Terminology
C128718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128718>	C128669	GAIA Level 2 Dysfunctional First Stage of Labor|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Dysfunctional First Stage of Labor|Level 2 Dysfunctional First Stage of Labor	GAIA Level 2 Dysfunctional First Stage of Labor is defined by progress of less than 0.5 cm of cervical dilation per hour, for at least 4 hours, in women with established labor (i.e. have regular contractions and cervical dilation of at least 4 cm) without certainty of ruptured membranes.			Classification	GAIA Dysfunctional Labor Level of Diagnostic Certainty Terminology|GAIA Terminology
C128719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128719>	C128669	GAIA Level 1 Dysfunctional Second Stage of Labor|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Dysfunctional Second Stage of Labor|Level 1 Dysfunctional Second Stage of Labor	GAIA Level 1 Dysfunctional Second Stage of Labor is defined by three criteria. For nulliparous women: first, full dilation of the cervix (10 cm dilated, or no palpable cervix around the presenting part of the fetus); second, the onset of the active stage of labor (active maternal effort (i.e. pushing) or visible baby); third, at least one of the following requirements must be met: a) Greater than 2 hours of pushing; OR b) The use of an instrument (forceps or vacuum/ventouse) for the indication of dystocia; OR c) Cesarean delivery for the indication of dystocia. For multiparous women: first, full dilation of the cervix (10 cm dilated, or no palpable cervix around the presenting part of the fetus); second, the onset of the active stage of labor (active maternal effort (i.e. pushing) or visible baby); third, at least one of the following requirements must be met: a) Greater than 1 hour of pushing; OR b) The use of an instrument (forceps or vacuum/ventouse) for the indication of dystocia; OR c) Cesarean delivery for the indication of dystocia.			Classification	GAIA Dysfunctional Labor Level of Diagnostic Certainty Terminology|GAIA Terminology
C12871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12871>	C12730	Left Ventricle|HEART, LEFT VENTRICLE	The left lower chamber of the heart that receives blood from the left atrium and pumps it through the aorta to the body.	Left Ventricle		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128720>	C128669	GAIA Level 2 Dysfunctional Second Stage of Labor|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Dysfunctional Second Stage of Labor|Level 2 Dysfunctional Second Stage of Labor	GAIA Level 2 Dysfunctional Second Stage of Labor is defined by two criteria. For nulliparous and multiparous women: first, full dilation of the cervix (10 cm dilated, or no palpable cervix around the presenting part of the fetus) during any phase of the second stage of labor; second, at least one of the following requirements must be met: a) No delivery within 3 hours of full dilation; OR b) The use of an instrument (forceps or vacuum/ventouse) for the indication of dystocia; OR d) Cesarean delivery for the indication of dystocia.			Classification	GAIA Dysfunctional Labor Level of Diagnostic Certainty Terminology|GAIA Terminology
C128721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128721>	C128672	GAIA Level 1a Fetal Growth Restriction|Global Alignment of Immunization safety Assessment in pregnancy Level 1a Fetal Growth Restriction|Level 1a Fetal Growth Restriction	GAIA Level 1a Fetal Growth Restriction is defined by two criteria: first, Level 1 evidence of pregnancy dating; second, at least one of the following requirements must be met: a) Estimated fetal weight below the third percentile using locally-accepted growth curve; OR b) Estimated fetal weight below the tenth percentile using locally-accepted growth curve AND either findings of absent or reversed end-diastolic flow of the umbilical artery Doppler OR a finding of oligohydramnios.			Classification	GAIA Fetal Growth Restriction Level of Diagnostic Certainty Terminology|GAIA Terminology
C128722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128722>	C128672	GAIA Level 1b Fetal Growth Restriction|Global Alignment of Immunization safety Assessment in pregnancy Level 1b Fetal Growth Restriction|Level 1b Fetal Growth Restriction	GAIA Level 1b Fetal Growth Restriction is defined by two criteria: first, Level 1 evidence of pregnancy dating; second, an estimated fetal weight below the tenth percentile using locally-accepted growth curve AND either no findings of absent or reversed end-diastolic flow of the umbilical artery Doppler OR absence of oligohydramnios.			Classification	GAIA Fetal Growth Restriction Level of Diagnostic Certainty Terminology|GAIA Terminology
C128723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128723>	C128672	GAIA Level 2a Fetal Growth Restriction|Global Alignment of Immunization safety Assessment in pregnancy Level 2a Fetal Growth Restriction|Level 2a Fetal Growth Restriction	GAIA Level 2a Fetal Growth Restriction is defined by two criteria: first, Level 2 evidence of pregnancy dating; second, at least one of the following requirements must be met: a) Estimated fetal weight below the third percentile using locally-accepted growth curve; OR b) Estimated fetal weight below the tenth percentile using locally-accepted growth curve AND either findings of absent or reversed end-diastolic flow of the umbilical artery Doppler OR a finding of oligohydramnios.			Classification	GAIA Fetal Growth Restriction Level of Diagnostic Certainty Terminology|GAIA Terminology
C128724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128724>	C128672	GAIA Level 2b Fetal Growth Restriction|Global Alignment of Immunization safety Assessment in pregnancy Level 2b Fetal Growth Restriction|Level 2b Fetal Growth Restriction	GAIA Level 2b Fetal Growth Restriction is defined by two criteria: first, Level 2 evidence of pregnancy dating; second, at least one of the following requirements must be met: a) Estimated fetal weight below the tenth percentile using locally-accepted growth curve AND either no findings of absent or reversed end-diastolic flow of the umbilical artery Doppler OR absence of oligohydramnios. Alternatively, Level 2b may be defined by the following two criteria: first, Level 1 evidence of pregnancy dating; second, an estimated fetal weight below the tenth percentile using locally-accepted growth curve, and absence of oligohydramnios with the inability to assess umbilical artery Doppler.			Classification	GAIA Fetal Growth Restriction Level of Diagnostic Certainty Terminology|GAIA Terminology
C128725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128725>	C128675	GAIA Level 1 Low Birth Weight|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Low Birth Weight|Level 1 Low Birth Weight	GAIA Level 1 Low Birth Weight is defined by one of the two following criteria: first, a newborn infant is weighed within 24 hours of birth; an electronic scale that is graduated to 10 grams is used; the scale is calibrated at least once a year; the scale is placed on level, hard surface; the scale is tared to zero grams; AND the birth weight recorded is less than 2500 grams; OR second, a birth weight is recorded as less than 2500 grams as assessed per the health care facility's standard operating procedure, which fulfills criteria 1 to 5 of diagnostic level of certainty one.			Classification	GAIA Low Birth Weight Level of Diagnostic Certainty Terminology|GAIA Terminology
C128726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128726>	C128675	GAIA Level 2 Low Birth Weight|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Low Birth Weight|Level 2 Low Birth Weight	GAIA Level 2 Low Birth Weight is defined by either one of the following two criteria: first, a newborn infant is weighed within 24 hours of birth; either an electronic or a spring scale that is graduated to 50 grams is used; the scale is calibrated at least once a year, or more often if moved; the scale is tared to zero grams or 0.00 kg; AND the birth weight recorded is less than 2500 grams; OR second, a birth weight is recorded as less than 2500 grams as assessed per the health care facility's standard operating procedure, which fulfills criteria 1 to 4 of diagnostic level of certainty two.			Classification	GAIA Low Birth Weight Level of Diagnostic Certainty Terminology|GAIA Terminology
C128727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128727>	C128675	GAIA Level 3 Low Birth Weight|Global Alignment of Immunization safety Assessment in pregnancy Level 3 Low Birth Weight|Level 3 Low Birth Weight	GAIA Level 3 Low Birth Weight is defined by three criteria: first, a newborn infant must be weighed within the  first 48 hours of life; second, weight is measured using a dial/ spring/ color-coded scale; third, weight is assessed as less than 2500 grams.			Classification	GAIA Low Birth Weight Level of Diagnostic Certainty Terminology|GAIA Terminology
C128728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128728>	C128675	GAIA Level 4 Low Birth Weight|Global Alignment of Immunization safety Assessment in pregnancy Level 4 Low Birth Weight|Level 4 Low Birth Weight	GAIA Level 4 Low Birth Weight is defined by either one of the following two criteria: first, the newborn's weight is assessed between 1 and 2 days of age (first 48 hrs of life); AND second, a proxy measure of birth weight is used, AND the weight category is assessed as less than 2500 grams.			Classification	GAIA Low Birth Weight Level of Diagnostic Certainty Terminology|GAIA Terminology
C128729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128729>	C128692	GAIA Level 1 Neonatal Encephalopathy|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Neonatal Encephalopathy|Level 1 Neonatal Encephalopathy	GAIA Level 1 Neonatal Encephalopathy is defined by three criteria: first, a newborn infant (1-28 days of life) born at or beyond 35 weeks of gestation; second, an abnormal level of alertness or seizures; third, difficulty with initiating and maintaining respiration; fourth, depression of muscle tone.			Classification	GAIA Neonatal Encephalopathy Level of Diagnostic Certainty Terminology|GAIA Terminology
C12872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12872>	C12843	Left Coronary Artery|CORONARY ARTERY, LEFT|LM|Left Main Coronary Artery|Left Main Coronary Artery Segment	A coronary artery that arises from the aorta and bifurcates into the left anterior descending artery and the left circumflex artery.	Left Coronary Artery		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128730>	C128692	GAIA Level 2 Neonatal Encephalopathy|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Neonatal Encephalopathy|Level 2 Neonatal Encephalopathy	GAIA Level 2 Neonatal Encephalopathy is defined by three criteria: first, a newborn infant (1 to 28 days of life) born at or beyond 35 weeks of gestation; second, an abnormal level of alertness or seizures; third, either difficulty with initiating and maintaining respiration OR depression of muscle tone.			Classification	GAIA Neonatal Encephalopathy Level of Diagnostic Certainty Terminology|GAIA Terminology
C128731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128731>	C128692	GAIA Level 3 Neonatal Encephalopathy|Global Alignment of Immunization safety Assessment in pregnancy Level 3 Neonatal Encephalopathy|Level 3 Neonatal Encephalopathy	GAIA Level 3 Neonatal Encephalopathy is defined by three criteria: first, a newborn infant (1-28 days of life) born at or beyond 35 weeks of gestation; second, an abnormal level of alertness or seizures; third, none of the following: a) difficulty with initiating or maintaining respiration; b) depression of muscle tone.			Classification	GAIA Neonatal Encephalopathy Level of Diagnostic Certainty Terminology|GAIA Terminology
C128732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128732>	C85874	Congenital Microcephaly	A congenital developmental disorder in which the circumference of the head is smaller than normal for the person's age and sex.			Finding	
C128733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128733>	C128674	GAIA Level 1 Small for Gestational Age|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Small for Gestational Age|Level 1 Small for Gestational Age	GAIA Level 1 Small for Gestational Age is defined by three criteria: first, weight below the 10th percentile for gestational age; second, assessment of weight by both of the following: a) Newborn weighed within 24 hours of birth; AND b) Weight assessed using a calibrated electronic scale with 10 g resolution; third, the gestational age is assessed by confirmatory ultrasound during the first trimester, with or without certain LMP, or IUI or embryo transfer date OR by first trimester ultrasound.			Classification	GAIA Small for Gestational Age Level of Diagnostic Certainty Terminology|GAIA Terminology
C128734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128734>	C128674	GAIA Level 2a Small for Gestational Age|Global Alignment of Immunization safety Assessment in pregnancy Level 2a Small for Gestational Age|Level 2a Small for Gestational Age	GAIA Level 2a Small for Gestational Age is defined by three criteria: first, weight below the 10th percentile for gestational age; second, newborn weighed within 24 hours of birth on any scale with a less than or equal to 50 g resolution, calibrated and tared to zero; third, the gestational age is assessed by either a) Certain LMP with first or second trimester ultrasound; or b) Certain LMP with first trimester physical exam.			Classification	GAIA Small for Gestational Age Level of Diagnostic Certainty Terminology|GAIA Terminology
C128735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128735>	C128674	GAIA Level 2b Small for Gestational Age|Global Alignment of Immunization safety Assessment in pregnancy Level 2b Small for Gestational Age|Level 2b Small for Gestational Age	GAIA Level 2b Small for Gestational Age is defined by three criteria: first, weight below the 10th percentile for gestational age; second, the newborn weighed within 24 hours on any scale with a less than or equal to 50 g resolution, calibrated and tared to zero; third, gestational age determined by uncertain LMP with second trimester ultrasound.			Classification	GAIA Small for Gestational Age Level of Diagnostic Certainty Terminology|GAIA Terminology
C128736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128736>	C128674	GAIA Level 3a Small for Gestational Age|Global Alignment of Immunization safety Assessment in pregnancy Level 3a Small for Gestational Age|Level 3a Small for Gestational Age	GAIA Level 3a Small for Gestational Age is defined by three criteria: first, weight is below the 10th percentile for gestational age; second, the newborn is weighed within the first 48 hours of life on any scale with a less than or equal to 50 g resolution, calibrated and tared to zero; third, gestational age assessed by one of the following four methods: a) Certain LMP with third trimester ultrasound; b) Certain LMP with confirmatory 2nd trimester fundal height; c) Certain LMP with birthweight; or d) Uncertain LMP with first trimester physical exam.			Classification	GAIA Small for Gestational Age Level of Diagnostic Certainty Terminology|GAIA Terminology
C128737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128737>	C128674	GAIA Level 3b Small for Gestational Age|Global Alignment of Immunization safety Assessment in pregnancy Level 3b Small for Gestational Age|Level 3b Small for Gestational Age	GAIA Level 3b Small for Gestational Age is defined by three criteria: first, the weight is below the 10th percentile for gestational age; second, the infant is weighed within the first 48 hours of life, and the weight is assessed on any scale by measuring the difference between an adult holding the infant and the adult being weighed alone; third, gestational age is assessed by one of following three methods: a) Uncertain LMP with fundal height; b) Uncertain LMP with newborn physical assessment; or c) Uncertain LMP with birthweight.			Classification	GAIA Small for Gestational Age Level of Diagnostic Certainty Terminology|GAIA Terminology
C128738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128738>	C128674	GAIA Level 4 Small for Gestational Age|Global Alignment of Immunization safety Assessment in pregnancy Level 4 Small for Gestational Age|Level 4 Small for Gestational Age	GAIA Level 4 Small for Gestational Age is defined by one of the following three criteria: first, the infant is noted to be small, but has no documented weight; second, the gestational age is assessed by infant examination only; third, the diagnosis is extracted from either billing codes or a chart with no documentation of the actual birth weight or the gestational age.			Classification	GAIA Small for Gestational Age Level of Diagnostic Certainty Terminology|GAIA Terminology
C128739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128739>	C113099	Organic Failure to Thrive|Organic FTT	Failure to thrive (FTT), that occurs in less than five percent of FTT cases; it is caused by acute or chronic disorders that interfere with nutritional uptake, including cleft palate, malabsorption due to cystic fibrosis, and short gut syndrome.			Finding	GAIA Failure to Thrive Level of Diagnostic Certainty Terminology|GAIA Terminology
C128740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128740>	C113099	Non-Organic Failure to Thrive|Non-Organic FTT	Failure to thrive caused by inadequate intake due to environmental influences, stimulus deprivation- poverty, feeding techniques, or psychological reason, and without any apparent growth-inhibiting organic disorder.			Finding	GAIA Failure to Thrive Level of Diagnostic Certainty Terminology|GAIA Terminology
C128741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128741>	C113099	Mixed Failure to Thrive|Mixed FTT	Failure to thrive due to both organic and non-organic causes.			Finding	GAIA Failure to Thrive Level of Diagnostic Certainty Terminology|GAIA Terminology
C128742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128742>	C128670	GAIA Level 1 Placenta Previa|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Placenta Previa|Level 1 Placenta Previa	GAIA Level 1 Placenta Previa is defined by a second or third trimester ultrasound (and/or MRI) that demonstrates evidence of placental tissue overlying or abutting the internal cervical os.			Classification	GAIA Antenatal Bleeding Level of Diagnostic Certainty Terminology|GAIA Terminology
C128743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128743>	C128670	GAIA Level 2 Placenta Previa|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Placenta Previa|Level 2 Placenta Previa	GAIA Level 2 Placenta Previa is defined by three criteria: first, painless vaginal bleeding during the second or third trimester; second, a high presenting part or abnormal fetal lie; third, pelvic exam with fullness palpable in the fornices (avoiding digital cervical exam) OR a speculum exam with placental tissue visible through an open cervical os.			Classification	GAIA Antenatal Bleeding Level of Diagnostic Certainty Terminology|GAIA Terminology
C128744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128744>	C128670	GAIA Level 1 Morbidly Adherent Placentation|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Morbidly Adherent Placentation|Level 1 Morbidly Adherent Placentation	GAIA Level 1 Morbidly Adherent Placentation is defined by three criteria: first, evidence of placenta previa by either a second- or third-trimester ultrasound or an MRI; second, one of the following ultrasound features must be present: for Greyscale: a) Loss of the retroplacental sonolucent zone; OR b) Irregular retroplacental sonolucent zone; OR c) Thinning or disruption of the hyperechoic serosa-bladder interface; OR d) Presence of focal exophytic masses invading the urinary bladder; OR e) Abnormal placental lacunae; for Color Doppler: a) Diffuse or focal lacunar flow; OR b) Vascular lakes with turbulent flow (peak systolic velocity over 15 cm/s); OR c) Hypervascularity of serosa-bladder interface; OR d) Markedly dilated vessels over peripheral subplacental zone; for 3D Power Doppler: a) Numerous coherent vessels involving the entire uterine serosa-bladder junction (basal view); OR b) Hypervascularity (lateral view); OR c) Inseparable cotyledonal and intervillous circulations, chaotic branching, and detour vessels (lateral view); third, one of the following risk factors must be present: a) Prior cesarean delivery; OR b) Prior uterine surgery (including endometrial ablation); OR c) Cesarean scar pregnancy. Alternatively, Level 1 may be defined as morbidly adherent placentation found on histology in a hysterectomy or partial wedge resection specimen.			Classification	GAIA Antenatal Bleeding Level of Diagnostic Certainty Terminology|GAIA Terminology
C128745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128745>	C128670	GAIA Level 2 Morbidly Adherent Placentation|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Morbidly Adherent Placentation|Level 2 Morbidly Adherent Placentation	GAIA Level 2 Morbidly Adherent Placentation is defined by two criteria: first, ultrasound evidence of placenta previa; second, hypervascularity of the lower uterine segment, diagnosed during a laparotomy. Alternatively, Level 2 may be defined as difficulty with placental separation after delivery of the infant, during either a vaginal or a cesarean delivery, with resultant hemorrhage due to partial separation.			Classification	GAIA Antenatal Bleeding Level of Diagnostic Certainty Terminology|GAIA Terminology
C128746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128746>	C128670	GAIA Level 1 Vasa Previa|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Vasa Previa|Level 1 Vasa Previa	GAIA Level 1 Vasa Previa is defined by two criteria: first, second trimester ultrasound evidence of fetal vessels (vessel with fetal heart rate identified by color flow Doppler) traversing the membranes and overlying the internal cervical os; second, post-delivery examination of the placental specimen that demonstrates unsupported fetal vessels within the membranes.			Classification	GAIA Antenatal Bleeding Level of Diagnostic Certainty Terminology|GAIA Terminology
C128747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128747>	C128670	GAIA Level 2 Vasa Previa|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Vasa Previa|Level 2 Vasa Previa	GAIA Level 2 Vasa Previa is defined by four criteria: first, vaginal bleeding during the second or third trimester at the time of ruptured amniotic membranes; second, fetal heart rate changes ultimately resulting in sinusoidal rhythm/terminal bradycardia; third, delivery of one of the following: a) a pale, anemic infant; OR b) a recent stillbirth; OR c) a neonatal death; fourth, post-delivery examination of the placental specimen that demonstrates unsupported fetal vessels within the membranes.			Classification	GAIA Antenatal Bleeding Level of Diagnostic Certainty Terminology|GAIA Terminology
C128748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128748>	C128670	GAIA Level 1 Placental Abruption|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Placental Abruption|Level 1 Placental Abruption	GAIA Level 1 Placental Abruption is defined by two criteria: first, vaginal bleeding during the second or third trimester in the absence of placenta previa on ultrasound; second, one of the following two requirements must be met: a) Uterine irritability (irregular, frequent uterine activity, not coalesced into clear contractions in a regular pattern) or labor; OR b) Clinical signs of hypovolemic shock or coagulopathy. Alternatively, Level 1 may be defined as placental pathology with histologic findings of a chronic abruption.			Classification	GAIA Antenatal Bleeding Level of Diagnostic Certainty Terminology|GAIA Terminology
C128749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128749>	C128670	GAIA Level 2 Placental Abruption|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Placental Abruption|Level 2 Placental Abruption	GAIA Level 2 Placental Abruption is defined by two criteria: first, vaginal bleeding during the second or third trimester; second, uterine irritability (irregular, frequent uterine activity, not coalesced into clear contractions in a regular pattern) or labor without clinical signs of hypovolemic shock or coagulopathy. Alternatively, Level 2 may be defined as vaginal bleeding during the second or third trimester with clinical evidence of retroplacental clot or visually evident placental infarcts at the time of delivery.			Classification	GAIA Antenatal Bleeding Level of Diagnostic Certainty Terminology|GAIA Terminology
C12874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12874>	C32958	Circumflex Branch of the Left Coronary Artery|Circumflex Branch of Left Coronary Artery|LEFT CIRCUMFLEX CORONARY ARTERY	An artery arising from the bifurcation of the left coronary artery that runs along the coronary grove with branches supplying the atria and ventricles.	Circumflex Branch of Left Coronary Artery		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128750>	C128670	GAIA Level 1 Cesarean Scar Pregnancy|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Cesarean Scar Pregnancy|Level 1 Cesarean Scar Pregnancy	GAIA Level 1 Cesarean Scar Pregnancy is defined by a transvaginal ultrasound that demonstrates the following five findings: first, an empty uterine cavity; second, an empty cervical canal, without contact with the gestational sac; third, the presence of a gestational sac, with or without a fetal pole, with or without cardiac activity, in the anterior uterine segment adjacent to the cesarean scar; fourth, an absence of or a defect in the myometrium between the bladder and the gestational sac; fifth, a well-perfused gestational sac as demonstrated by Doppler ultrasound (to differentiate from an expulsing, avascular gestational sac). Alternatively, Level 1 may be defined as a hysterectomy specimen with evidence of a pregnancy implanted into the cesarean scar.			Classification	GAIA Antenatal Bleeding Level of Diagnostic Certainty Terminology|GAIA Terminology
C128751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128751>	C128670	GAIA Level 1 Intra-abdominal Pregnancy|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Intra-abdominal Pregnancy|Level 1 Intra-abdominal Pregnancy	GAIA Level 1 Intra-abdominal Pregnancy is defined by the discovery of a fetus within the abdominal cavity during laparotomy, without evidence of uterine rupture, and with placentation not within the uterine cavity.			Classification	GAIA Antenatal Bleeding Level of Diagnostic Certainty Terminology|GAIA Terminology
C128752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128752>	C128670	GAIA Level 1 Uterine Rupture|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Uterine Rupture|Level 1 Uterine Rupture	GAIA Level 1 Uterine Rupture is the complete disruption of the uterus, at the time of laparotomy, in the context of vaginal or intra-abdominal bleeding.			Classification	GAIA Antenatal Bleeding Level of Diagnostic Certainty Terminology|GAIA Terminology
C128753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128753>	C128671	GAIA Level 1 Gestational Diabetes Mellitus|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Gestational Diabetes Mellitus|Level 1 Gestational Diabetes Mellitus	GAIA Level 1 Gestational Diabetes Mellitus is defined by three criteria: first, at least one of the following requirements must be met: a) absence of pre-gestational diabetes [pre-gestational diabetes is defined as a) previous diagnosis of diabetes while not pregnant OR b) first trimester hemoglobin A1c level of greater than or equal to 6.5% (47.5 mmol/mol) OR c) first trimester fasting blood glucose greater than or equal to 126 mg/dL (7 mmol/L)]; second, gestational age with level 1 or level 2 certainty, using the GAIA definition for gestational age; third, a diagnosis of gestational diabetes as determined by a positive result from an international standard oral glucose tolerance test using venous blood samples.			Classification	GAIA Gestational Diabetes Mellitus Level of Diagnostic Certainty Terminology|GAIA Terminology
C128754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128754>	C128671	GAIA Level 2 Gestational Diabetes Mellitus|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Gestational Diabetes Mellitus|Level 2 Gestational Diabetes Mellitus	GAIA Level 2 Gestational Diabetes Mellitus is defined by three criteria: first, absence of pre-gestational diabetes [pre-gestational diabetes is defined as a) previous diagnosis of diabetes while not pregnant OR b) first trimester hemoglobin A1c level of greater than or equal to 6.5% (47.5 mmol/mol) OR c) first trimester fasting blood glucose greater than or equal to 126 mg/dL (7 mmol/L)]; second, gestational age with at least level 1-2 certainty, using the GAIA definition for gestational age; third the diagnosis of gestational diabetes as determined by a positive result from an international standard oral glucose tolerance test using capillary blood samples.			Classification	GAIA Gestational Diabetes Mellitus Level of Diagnostic Certainty Terminology|GAIA Terminology
C128755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128755>	C128671	GAIA Level 3 Gestational Diabetes Mellitus|Global Alignment of Immunization safety Assessment in pregnancy Level 3 Gestational Diabetes Mellitus|Level 3 Gestational Diabetes Mellitus	GAIA Level 3 Gestational Diabetes Mellitus is defined by three criteria: first, absence of pre-gestational diabetes [pre-gestational diabetes is defined as a) previous diagnosis of diabetes while not pregnant OR b) first trimester hemoglobin A1c level of greater than or equal to 6.5% (47.5 mmol/mol) OR c) first trimester fasting blood glucose greater than or equal to 126 mg/dL (7 mmol/L)]; second, gestational age with at least level 3 certainty, using the GAIA definition for gestational age; third, the diagnosis of gestational diabetes as determined by fasting plasma glucose of 5.1-6.9 mmol/L (92-125 mg/dL) using either venous or capillary blood samples.			Classification	GAIA Gestational Diabetes Mellitus Level of Diagnostic Certainty Terminology|GAIA Terminology
C128756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128756>	C128671	GAIA Insufficient Evidence for Diagnosis of Gestational Diabetes Mellitus|Global Alignment of Immunization safety Assessment in pregnancy Insufficient Evidence for Diagnosis of Gestational Diabetes Mellitus|Insufficient Evidence for Gestational Diabetes Mellitus	GAIA Insufficient Evidence for Diagnosis of Gestational Diabetes Mellitus (GDM) is a category of individuals for whom a diagnosis of GDM cannot be made due to one of the following: a) the blood glucose cannot be measured; b) elevated postprandial blood glucose level without confirmatory fasting venous blood or capillary glucose level; c) use of Hemoglobin A1c alone, without a diagnostic oral glucose tolerance test or elevated fasting plasma glucose level; d) clinical and laboratory findings, including glucosuria, fundal height greater than dates, obesity, prior history of GDM, or family history for the diagnosis of gestational diabetes mellitus, without a diagnostic test.			Classification	GAIA Gestational Diabetes Mellitus Level of Diagnostic Certainty Terminology|GAIA Terminology
C128757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128757>	C128694	GAIA Level 1 Postnatally Diagnosed Congenital Microcephaly|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Postnatally Diagnosed Congenital Microcephaly|Level 1 Postnatally Diagnosed Congenital Microcephaly	GAIA Level 1 Postnatally Diagnosed Congenital Microcephaly is defined by three criteria: first, a live birth, stillbirth, or spontaneous or therapeutic abortion of at least 24 weeks Gestational Age (GA), with GA assessed by either a certain last menstrual period (LMP) date with confirmatory 1st trimester (less than 14 weeks) or 2nd trimester ultrasound (US) scan OR intrauterine insemination (IUI) OR embryo transfer date; second, a head circumference (HC) measurement either 2 standard deviations (SD) below the mean or less than the third percentile as assessed by GA and gender, using appropriate, standardized reference charts for the population (e.g. WHO growth reference charts if GA greater than or equal to 37 weeks and Intergrowth-21st reference charts for GA 24 to 36 weeks); third, the measurement is taken either between 24 and 36 hours after birth or at the end of the pregnancy. IMPORTANT NOTICE: The NCI Thesaurus contains biomedical terminologies that NCI does not own or control. This concept contains gender-related content that does not comply with Executive Order 14168.			Classification	GAIA Congenital Microcephaly Level of Diagnostic Certainty Terminology|GAIA Terminology
C128758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128758>	C128694	GAIA Level 2a Postnatally Diagnosed Congenital Microcephaly|Global Alignment of Immunization safety Assessment in pregnancy Level 2a Postnatally Diagnosed Congenital Microcephaly|Level 2a Postnatally Diagnosed Congenital Microcephaly	GAIA Level 2a Postnatally Diagnosed Congenital Microcephaly is defined by three criteria: first, a live birth, stillbirth, or spontaneous or therapeutic abortion of at least 24 weeks gestational age (GA), with GA assessed by either a certain last menstrual period (LMP) date with confirmatory 1st trimester (less than 14 weeks) or 2nd trimester ultrasound (US) scan OR intrauterine insemination (IUI) OR embryo transfer date; second, a head circumference (HC) measurement either 2 standard deviations (SD) below the mean or less than the third percentile as assessed by GA and gender, using appropriate, standardized reference charts for the population (e.g. WHO growth reference charts if GA greater than or equal to 37 weeks and Intergrowth-21st reference charts for GA 24 to 36 weeks); third, one of the following requirements is met: a) the measurement is taken within the first 24 hours after birth or at the end of the pregnancy taking into consideration the molding of the head; OR b) the measurement is taken greater than 36 hours and up to 6 weeks after birth or the end of the pregnancy with no apparent post-natal insult resulting in microcephaly. IMPORTANT NOTICE: The NCI Thesaurus contains biomedical terminologies that NCI does not own or control. This concept contains gender-related content that does not comply with Executive Order 14168.			Classification	GAIA Congenital Microcephaly Level of Diagnostic Certainty Terminology|GAIA Terminology
C128759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128759>	C128694	GAIA Level 2b Postnatally Diagnosed Congenital Microcephaly|Global Alignment of Immunization safety Assessment in pregnancy Level 2b Postnatally Diagnosed Congenital Microcephaly|Level 2b Postnatally Diagnosed Congenital Microcephaly	GAIA Level 2b Postnatally Diagnosed Congenital Microcephaly is defined by three criteria: first, a live birth, stillbirth, or spontaneous or therapeutic abortion of at least 24 weeks gestational age (GA), with GA assessed based on uncertain LMP with 2nd trimester ultrasound (US) scan; second, a head circumference (HC) measurement either 2 standard deviations (SD) below the mean or less than the third percentile as assessed by GA and gender, using appropriate, standardized reference charts for the population (e.g. WHO growth reference charts if GA greater than or equal to 37 weeks and Intergrowth-21st reference charts for GA 24 to 36 weeks); third, one of the following requirements is met: a) the measurement is taken within the first 24 hours after birth or at the end of the pregnancy taking into consideration the molding of the head; OR b) the measurement is taken greater than 36 hours and up to 6 weeks after birth or the end of the pregnancy with no apparent post-natal insult resulting in microcephaly. IMPORTANT NOTICE: The NCI Thesaurus contains biomedical terminologies that NCI does not own or control. This concept contains gender-related content that does not comply with Executive Order 14168.			Classification	GAIA Congenital Microcephaly Level of Diagnostic Certainty Terminology|GAIA Terminology
C12875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12875>	C12843	Right Coronary Artery|CORONARY ARTERY, RIGHT	A coronary artery that originates above the right coronary cusp and supplies blood predominantly to the right side of the heart.	RIght Coronary Artery		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128760>	C128694	GAIA Level 3b Postnatally Diagnosed Congenital Microcephaly|Global Alignment of Immunization safety Assessment in pregnancy Level 3b Postnatally Diagnosed Congenital Microcephaly|Level 3b Postnatally Diagnosed Congenital Microcephaly	GAIA Level 3b Postnatally Diagnosed Congenital Microcephaly is defined by two criteria: first, a live birth, stillbirth, or spontaneous or therapeutic abortion, and second, the case meets criteria for microcephaly using a validated algorithm: 1 inpatient diagnosis OR 2 outpatient diagnoses OR 1 outpatient diagnosis AND death in first year using the following diagnostic codes ICD-9-CM code 742.1 or ICD-10-CM code Q02.			Classification	GAIA Congenital Microcephaly Level of Diagnostic Certainty Terminology|GAIA Terminology
C128761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128761>	C128694	GAIA Level 4 Postnatally Diagnosed Congenital Microcephaly|Global Alignment of Immunization safety Assessment in pregnancy Level 4 Postnatally Diagnosed Congenital Microcephaly|Level 4 Postnatally Diagnosed Congenital Microcephaly	GAIA Level 4 Postnatally Diagnosed Congenital Microcephaly is defined by two criteria: first, a live birth, stillbirth, or spontaneous or therapeutic abortion; second, a diagnosis of congenital microcephaly based on either a physical inspection without head circumference (HC) measurement, OR  an ICD-9-CM or ICD-10-CM code that does not meet the validated algorithm criteria used in the case definition for GAIA Level 3 Postnatally Diagnosed Congenital Microcephaly.			Classification	GAIA Congenital Microcephaly Level of Diagnostic Certainty Terminology|GAIA Terminology
C128762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128762>	C128695	GAIA Level 1a Prenatally Diagnosed Congenital Microcephaly|Global Alignment of Immunization safety Assessment in pregnancy Level 1a Prenatally Diagnosed Congenital Microcephaly|Level 1a Prenatally Diagnosed Congenital Microcephaly	GAIA Level 1a Prenatally Diagnosed Congenital Microcephaly is defined by three criteria: first, the fetus is at least 24 weeks gestational age (GA) based on certain last menstrual period (LMP) date with confirmatory 1st trimester or 2nd trimester ultrasound (US) scan OR intrauterine insemination (IUI) or embryo transfer date; second, a head circumference (HC) measurement either 2 standard deviations (SD) below the mean or less than the third percentile according to fetal US examination, using appropriate, standardized reference charts according to GA and gender for the population (e.g. WHO growth reference charts if GA greater than or equal to 37 weeks and Intergrowth-21st reference charts for GA 24-36 weeks); third, confirmation of microcephaly (i.e., HC 2 SD below the mean or less than 3%) in the fetus by either at least one additional US after 24 weeks that occurs at least one week after the first US, OR confirmation of microcephaly by HC measurement with a standard tape measure at either birth or autopsy. IMPORTANT NOTICE: The NCI Thesaurus contains biomedical terminologies that NCI does not own or control. This concept contains gender-related content that does not comply with Executive Order 14168.			Classification	GAIA Congenital Microcephaly Level of Diagnostic Certainty Terminology|GAIA Terminology
C128763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128763>	C128695	GAIA Level 1b Prenatally Diagnosed Congenital Microcephaly|Global Alignment of Immunization safety Assessment in pregnancy Level 1b Prenatally Diagnosed Congenital Microcephaly|Level 1b Prenatally Diagnosed Congenital Microcephaly	GAIA Level 1b Prenatally Diagnosed Congenital Microcephaly is defined by three criteria: first, the fetus is at least 24 weeks gestational age (GA) based on uncertain last menstrual period (LMP) date with a 2nd trimester ultrasound (US) scan; second, a head circumference (HC) measurement either 2 standard deviations (SD) below the mean or less than the third percentile according to fetal US examination, using appropriate, standardized reference charts according to GA and gender for the population (e.g. WHO growth reference charts if GA greater than or equal to 37 weeks and Intergrowth-21st reference charts for GA 24-36 weeks); third, confirmation of microcephaly (i.e., HC 2 SD below the mean or less than 3%) in the fetus by either at least one additional US after 24 weeks that occurs at least one week after the first US, OR confirmation of microcephaly by HC measurement with a standard tape measure at either birth or autopsy. IMPORTANT NOTICE: The NCI Thesaurus contains biomedical terminologies that NCI does not own or control. This concept contains gender-related content that does not comply with Executive Order 14168.			Classification	GAIA Congenital Microcephaly Level of Diagnostic Certainty Terminology|GAIA Terminology
C128764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128764>	C128695	GAIA Level 2 Prenatally Diagnosed Congenital Microcephaly|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Prenatally Diagnosed Congenital Microcephaly|Level 2 Prenatally Diagnosed Congenital Microcephaly	GAIA Level 2 Prenatally Diagnosed Congenital Microcephaly is defined by three criteria: first, the fetus is at least 24 weeks gestational age (GA) based on last menstrual period (LMP) date with fundal height and no confirmatory first or second trimester ultrasound (US) scan; second, a head circumference (HC) measurement either 2 standard deviations (SD) below the mean or less than the third percentile according to fetal US examination, using appropriate, standardized reference charts according to GA and gender for the population (e.g. WHO growth reference charts if GA greater than or equal to 37 weeks and Intergrowth-21st reference charts for GA 24 to 36 weeks) with femur length and abdominal circumference concordant with GA assessment; third, confirmation of microcephaly (i.e., HC 2 SD below the mean or less than 3%) in the fetus by either at least one additional US after 24 weeks that occurs at least one week after the first US, OR confirmation of microcephaly by HC measurement with a standard tape measure at either birth or autopsy. IMPORTANT NOTICE: The NCI Thesaurus contains biomedical terminologies that NCI does not own or control. This concept contains gender-related content that does not comply with Executive Order 14168.			Classification	GAIA Congenital Microcephaly Level of Diagnostic Certainty Terminology|GAIA Terminology
C128765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128765>	C128695	GAIA Level 3b Prenatally Diagnosed Congenital Microcephaly|Global Alignment of Immunization safety Assessment in pregnancy Level 3b Prenatally Diagnosed Congenital Microcephaly|Level 3b Prenatally Diagnosed Congenital Microcephaly	GAIA Level 3B Prenatally Diagnosed Congenital Microcephaly is defined by three criteria: first, the fetus is at least 24 weeks gestational age (GA), with GA based on certain or uncertain last menstrual period (LMP) date, with fundal height and no confirmatory first or second trimester ultrasound (US) scan, OR uncertain LMP with second trimester ultrasound, intrauterine insemination (IUI) OR embryo transfer date; second, a head circumference (HC) measurement either 2 standard deviations (SD) below the mean or less than the third percentile according to fetal US examination, using appropriate, standardized reference charts according to GA and gender for the population (e.g. WHO growth reference charts if GA greater than or equal to 37 weeks and Intergrowth-21st reference charts for GA 24 to 36 weeks); third, no confirmation of microcephaly with any additional US or by HC measurement at either birth or autopsy. IMPORTANT NOTICE: The NCI Thesaurus contains biomedical terminologies that NCI does not own or control. This concept contains gender-related content that does not comply with Executive Order 14168.			Classification	GAIA Congenital Microcephaly Level of Diagnostic Certainty Terminology|GAIA Terminology
C128766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128766>	C128695	GAIA Level 4 Prenatally Diagnosed Congenital Microcephaly|Global Alignment of Immunization safety Assessment in pregnancy Level 4 Prenatally Diagnosed Congenital Microcephaly|Level 4 Prenatally Diagnosed Congenital Microcephaly	GAIA Level 4 Prenatally Diagnosed Congenital Microcephaly is defined by three criteria: first, the fetus is at least 24 weeks gestational age (GA), with GA based on certain last menstrual period (LMP) date with confirmatory first or second trimester ultrasound (US) scan, OR uncertain LMP with second trimester ultrasound, intrauterine insemination (IUI), OR embryo transfer, OR certain or uncertain LMP with fundal height and no confirmatory first or second trimester scan; second, HC 2 SD below mean or less than 3 percentile according to fetal US scan using appropriate standardized reference charts according to GA and gender for the population (e.g., WHO growth reference charts if GA greater than or equal to 37 weeks and Intergrowth-21st reference charts for GA 24-36 weeks); third, HC at birth or autopsy is in the normal range using appropriate standardized reference charts according to GA and gender for the population, which means that this is NOT a case of prenatally diagnosed congenital microcephaly. IMPORTANT NOTICE: The NCI Thesaurus contains biomedical terminologies that NCI does not own or control. This concept contains gender-related content that does not comply with Executive Order 14168.			Classification	GAIA Congenital Microcephaly Level of Diagnostic Certainty Terminology|GAIA Terminology
C128768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128768>	C128676	GAIA Level 1 Neonatal Respiratory Distress|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Neonatal Respiratory Distress|Level 1 Neonatal Respiratory Distress	GAIA Level 1 Neonatal Respiratory Distress is defined by four criteria: first, the newborn must be between 0 and 28 days of life; second, the presence of any one of the following three symptoms that indicate an abnormal respiratory rate: a) Tachypnea (respiratory rate of 60 or more breaths per minute); b) Bradypnea (respiratory rate of less than 30 breaths per minute); c) Apnea [cessation of respiratory effort (no breaths) for at least 20 seconds]; third, one of the following five clinical symptoms that indicate labored breathing: a) Nasal flaring (dilatation of alae nasi); b) Noisy respirations in the form of expiratory grunting, stridor, or wheeze; c) Retractions or increased chest indrawings on inspiration (subcostal, intercostal, sternal, suprasternal notch); d) Central cyanosis (whole body, including lips and tongue) on room air; e) Low Apgar score (less than 7 points) at 10 minutes, with respiration score less than 2; fourth, examination and documentation by qualified, trained health care providers who are appropriate for the clinical setting.			Classification	GAIA Neonatal Respiratory Distress Level of Diagnostic Certainty Terminology|GAIA Terminology
C128769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128769>	C128676	GAIA Level 2 Neonatal Respiratory Distress|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Neonatal Respiratory Distress|Level 2 Neonatal Respiratory Distress	GAIA Level 2 Neonatal Respiratory Distress is defined by four criteria: first, the newborn must be between 0 and 28 days of life; second, an abnormal respiratory rate (not measured, but reported as "rapid breathing", "slow breathing", having periods of "no breathing", or "abnormal breathing"); third, the presence of any one of the following five clinical symptoms that indicate labored breathing: a) Nasal flaring (dilatation of alae nasi); b) Noisy respirations in the form of expiratory grunting, stridor, or wheeze; c) Retractions or increased chest indrawings on inspiration (subcostal, intercostal, sternal, suprasternal notch) or seesaw respirations; d) Central cyanosis (whole body, including lips and tongue) on room air; e) Low Apgar score (less than 7 points) at 10 minutes with a respiration score less than 2; fourth, one of the following two requirements: a) No medical record documentation, but reporting through either a non-medical observer (e.g., mother, father, community worker) or via standard census mechanisms (e.g., Demographic and Health Surveillance System), or b) Collection of information from medical review or billing codes.			Classification	GAIA Neonatal Respiratory Distress Level of Diagnostic Certainty Terminology|GAIA Terminology
C12876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12876>	C33867|C33587	Posterior Spinal Artery	An artery arising from the vertebral artery at the level of the medulla oblongata that descends along the posterior roots of the spinal nerves on each side of the spinal cord with branches supplying the spinal cord, pia mater and medulla.	Posterior Spinal Artery		Body Part, Organ, or Organ Component	
C128770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128770>	C128673	GAIA Level 1 Failure to Thrive|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Failure to Thrive|Level 1 Failure to Thrive	GAIA Level 1 Failure to Thrive is defined by four criteria: first, the infant's age is determined by a documented birth date; second, weights are obtained using an electronic scale; third, a minimum of two documented weights measured at least four weeks apart; fourth, the weight for age deceleration must pass through at least two centile spaces on a growth chart. Additionally, the following information applies to this term: a. Age: This case definition is limited to infants up to 12 months of age. b. Weight and Length: Weight should be documented on the appropriate growth chart at the time of assessment. A fall through 2 centile spaces may be demonstrated at any point in the first 12 months of life, using any two weights as long as they are taken at least 4 weeks apart. Details of use of the weight balances allowable under this case definition and use of the Infantometer for length assessment are in Appendix A. c. Growth charts: For infants born at 37 weeks gestation or above, the WHO growth charts should be applied. When using weight for age use the growth chart most accurate for the infants age. The birth to 6 months age range should be used where data is available for this range only, the birth to 2 years chart should be used where data is available beyond 6 months of life. When using weight for length, use the chart for birth to 2 years. For infants born less than 37 completed weeks gestation, the Intergrowth charts for postnatal growth standards in preterm infant should be used. All infants should be plotted on their respective growth chart using their corrected age. Links to relevant growth charts can be found in Appendix A (www.gaia-consortium.net).			Classification	GAIA Failure to Thrive Level of Diagnostic Certainty Terminology|GAIA Terminology
C128771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128771>	C128673	GAIA Level 2a Failure to Thrive|Global Alignment of Immunization safety Assessment in pregnancy Level 2a Failure to Thrive|Level 2a Failure to Thrive	GAIA Level 2a Failure to Thrive is defined by either of two criteria: first, the following four requirements must be present: a) Infant age determined by a documented birth date; b) Weights are obtained using a beam balance scale; c) A minimum of two documented weights measured at least four weeks apart; d) Weight for age deceleration must pass through at least two centile spaces on a growth chart; OR second, the following four requirements must be present: a) Infants have an undocumented birth date, where age is determined based on mother's recall to the nearest month; b) Weights are obtained using an electronic scale; c) A minimum of two weights measured at least four weeks apart; d) Weight for age deceleration must pass through at least two centile spaces on a growth chart.			Classification	GAIA Failure to Thrive Level of Diagnostic Certainty Terminology|GAIA Terminology
C128772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128772>	C128673	GAIA Level 2b Failure to Thrive|Global Alignment of Immunization safety Assessment in pregnancy Level 2b Failure to Thrive|Level 2b Failure to Thrive	GAIA Level 2b Failure to Thrive is defined by either of two criteria: first, the following four requirements must be present: a) Infant age determined by a documented birth date; b) Weights are obtained using a spring balance scale; c) A minimum of two weights measured at least four weeks apart; d) Weight for age deceleration must pass through at least two centile spaces on a growth chart; OR second, the following three requirements must be present: a) Weight is measured using an electronic scale or beam balance scale; b) Length is documented using infantometer; c) Weight for length ratio less than or equal to the third centile on an appropriate growth chart.			Classification	GAIA Failure to Thrive Level of Diagnostic Certainty Terminology|GAIA Terminology
C128773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128773>	C128673	GAIA Level 3a Failure to Thrive|Global Alignment of Immunization safety Assessment in pregnancy Level 3a Failure to Thrive|Level 3a Failure to Thrive	GAIA Level 3a Failure to Thrive is defined by four criteria: first, infants with an undocumented birth date, where age is determined based on mother's recall to the nearest month; second, weight obtained using either beam balance or spring balance scale; third, a minimum of two weights measured at least four weeks apart; fourth, weight for age deceleration must pass through at least two centile spaces on a growth chart.			Classification	GAIA Failure to Thrive Level of Diagnostic Certainty Terminology|GAIA Terminology
C128774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128774>	C128673	GAIA Level 3b Failure to Thrive|Global Alignment of Immunization safety Assessment in pregnancy Level 3b Failure to Thrive|Level 3b Failure to Thrive	GAIA Level 3b Failure to Thrive is defined by three criteria: first, infants have no weight available; second, physical examination is consistent with failure to thrive, which is defined as having at least two findings, one of which must be a major finding: reduced subcutaneous fat stores, poor muscle mass, loose skin folds, prominent ribs, and thin limbs. Less specific findings include sparse hair, rashes, pallor, irritable temperament, and lethargy/fatigue; third, a mid-upper arm circumference (MUAC) measurement, which is indicative of severe wasting, that is less than or equal to 110 mm in infants up to six months of age, and that is less than or equal to 115 mm in infants six to twelve months of age.			Classification	GAIA Failure to Thrive Level of Diagnostic Certainty Terminology|GAIA Terminology
C128775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128775>	C34336	First Trimester Spontaneous Abortion|1st Trimester Spontaneous Abortion	Pregnancy loss at less than 14 weeks 0 days gestation.			Finding	GAIA Spontaneous Abortion and Ectopic Pregnancy Level of Diagnostic Certainty Terminology|GAIA Terminology
C128776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128776>	C128679	GAIA Level 1 First Trimester Spontaneous Abortion|Global Alignment of Immunization safety Assessment in pregnancy Level 1 First Trimester Spontaneous Abortion|Level 1 First Trimester Spontaneous Abortion	GAIA Level 1 First Trimester Spontaneous Abortion is defined by two criteria: first, at least one of the following three requirements must be met: a) Crown-rump length greater than or equal to 7 mm and no visible heartbeat on transvaginal ultrasound; OR b) Crown-rump length greater than or equal to 15 mm and no visible heartbeat on abdominal ultrasound; OR c) Ultrasound examination demonstrating mean gestational sac diameter greater than or equal to 25 mm and no visible embryo or yolk sac; second, at least one of the following three requirements must be met: a) A second transvaginal ultrasound performed greater than or equal to 7 days later (or 14 days later if transabdominal) confirming the diagnosis of a non-viable pregnancy; OR b) The absence of an embryo with heartbeat 2 weeks or more after a transabdominal scan that initially showed a gestational sac without a yolk sac; OR c) The absence of an embryo with a heartbeat 11 days or more after a transvaginal scan that initially showed a gestational sac with a yolk sac. Alternatively, GAIA Level 1 First Trimester Spontaneous Abortion can be defined by the following two criteria: first, the gestational age is within the pre-defined range for the selected abortion definition as assessed by maternal and/or fetal parameters ( Level 1-2) (using the Brighton Preterm Birth Gestational Age algorithm); second, at least one of the following four requirements must be met: a) Positive urine or blood pregnancy test that becomes negative after 7 days; OR b) Products of conception found on histopathological evaluation of pregnancy tissue; OR c) Ultrasound examination demonstrating an empty uterine cavity in a woman who had clear evidence of intrauterine pregnancy on previous ultrasound examination; OR d) Vaginal bleeding, external cervical os open or closed, with visible expulsion of pregnancy tissues/products of conception.			Classification	GAIA Spontaneous Abortion and Ectopic Pregnancy Level of Diagnostic Certainty Terminology|GAIA Terminology
C128777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128777>	C128679	GAIA Level 2 First Trimester Spontaneous Abortion|Global Alignment of Immunization safety Assessment in pregnancy Level 2 First Trimester Spontaneous Abortion|Level 2 First Trimester Spontaneous Abortion	GAIA Level 2 First Trimester Spontaneous Abortion is defined by three criteria: first, it does not qualify as a Level 1 First Trimester Spontaneous Abortion; second, at least one of the following three requirements must be met: a) Crown-rump length greater than 7 mm and no visible heartbeat, confirmed by transvaginal ultrasound; OR b) Crown-rump length greater than 15 mm and no visible heartbeat, confirmed by abdominal ultrasound; OR c) Mean gestational sac diameter is 25 mm or more and no visible embryo; third, gestational age is within the pre-defined range for the selected abortion definition as assessed by maternal and/or fetal parameters (Level 1-2) (using Brighton Preterm Birth Gestational Age algorithm).			Classification	GAIA Spontaneous Abortion and Ectopic Pregnancy Level of Diagnostic Certainty Terminology|GAIA Terminology
C128778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128778>	C128679	GAIA Level 3 First Trimester Spontaneous Abortion|Global Alignment of Immunization safety Assessment in pregnancy Level 3 First Trimester Spontaneous Abortion|Level 3 First Trimester Spontaneous Abortion	GAIA Level 3 First Trimester Spontaneous Abortion is defined by three criteria: first, it does not qualify as either a Level 1 or Level 2 First Trimester Spontaneous Abortion; second, gestational age is within the pre-defined range for the selected abortion definition as assessed by maternal and/or fetal parameters (Level 3) (using Brighton Preterm Birth Gestational Age algorithm); third, a positive urine or blood pregnancy test that becomes negative after 7 days.			Classification	GAIA Spontaneous Abortion and Ectopic Pregnancy Level of Diagnostic Certainty Terminology|GAIA Terminology
C128779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128779>	C128679	GAIA Level 4 First Trimester Spontaneous Abortion|Global Alignment of Immunization safety Assessment in pregnancy Level 4 First Trimester Spontaneous Abortion|Level 4 First Trimester Spontaneous Abortion	GAIA Level 4 First Trimester Spontaneous Abortion is defined by two criteria: first, it does not qualify as a Level 1, a Level 2, or a Level 3 First Trimester Spontaneous Abortion; second, a maternal self-report or documentation in the medical record of a pregnancy loss without sufficient ultrasound or laboratory evidence to confirm.			Classification	GAIA Spontaneous Abortion and Ectopic Pregnancy Level of Diagnostic Certainty Terminology|GAIA Terminology
C12877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12877>	C33904	Venous Sinus|VENOUS SINUS	A large vein or channel for the circulation of venous blood, such as one of the sinuses of the dura mater.	Venous Sinus		Body Space or Junction	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128780>	C34336	Second Trimester Spontaneous Abortion|2nd Trimester Spontaneous Abortion	Pregnancy loss between 14 weeks 0 days and 21 weeks 6 days gestation.			Finding	GAIA Spontaneous Abortion and Ectopic Pregnancy Level of Diagnostic Certainty Terminology|GAIA Terminology
C128781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128781>	C128679	GAIA Level 1 Second Trimester Spontaneous Abortion|Global Alignment of Immunization safety Assessment in pregnancy Level 1 Second Trimester Spontaneous Abortion|Level 1 Second Trimester Spontaneous Abortion	GAIA Level 1 Second Trimester Spontaneous Abortion is defined by two criteria: first, gestational age is within the pre-defined range for the selected abortion definition as assessed by maternal and/or fetal parameters (Level 1-2) (Brighton Preterm Birth Gestational Age algorithm); second, at least one of the following requirements must be met: a) No visible heartbeat on ultrasound; OR b) Visible expulsion of pregnancy tissues/products of conception on examination of the cervix; OR c) Products of conception found on histopathological evaluation of uterine contents.			Classification	GAIA Spontaneous Abortion and Ectopic Pregnancy Level of Diagnostic Certainty Terminology|GAIA Terminology
C128782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128782>	C128679	GAIA Level 2 Second Trimester Spontaneous Abortion|Global Alignment of Immunization safety Assessment in pregnancy Level 2 Second Trimester Spontaneous Abortion|Level 2 Second Trimester Spontaneous Abortion	GAIA Level 2 Second Trimester Spontaneous Abortion is defined by three criteria: first, it does not qualify as a Level 1 Second Trimester Spontaneous Abortion; second, gestational age is within the pre-defined range for the selected abortion definition as assessed by maternal and/or fetal parameters (Level 3) (Brighton Preterm Birth Gestational Age algorithm); third, one of the following three requirements must be met: a) No visible heartbeat on ultrasound; b) Visible expulsion of pregnancy tissues/products of conception on examination of the cervix; c) Products of conception found on histopathological evaluation of uterine contents.			Classification	GAIA Spontaneous Abortion and Ectopic Pregnancy Level of Diagnostic Certainty Terminology|GAIA Terminology
C128783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128783>	C128679	GAIA Level 4 Second Trimester Spontaneous Abortion|Global Alignment of Immunization safety Assessment in pregnancy Level 4 Second Trimester Spontaneous Abortion|Level 4 Second Trimester Spontaneous Abortion	GAIA Level 4 Second Trimester Spontaneous Abortion is defined by two criteria: first, it does not qualify as either a Level 1 or a Level 2 Second Trimester Spontaneous Abortion; second, a maternal self-report or documentation in the medical record of a pregnancy loss without sufficient ultrasound or laboratory evidence to confirm.			Classification	GAIA Spontaneous Abortion and Ectopic Pregnancy Level of Diagnostic Certainty Terminology|GAIA Terminology
C128784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784>	C143048	NCIt Antineoplastic Agent Terminology	A terminology subset in NCI Thesaurus (NCIt) containing any agent that has known or potential antineoplastic activity. The subset includes FDA approved antineoplastic agents, agents that either are or once were in clinical trial (CT) specifically for their antineoplastic activity as well as some additional investigational agents that may have antineoplastic activity. Included in this list are conventional antineoplastic agents, specific tumor-targeting agents, and cancer immunotherapeutics. Excluded from this list are: agents that treat cancer-related conditions; cancer diagnostics or agents used for tumor imaging; agents that treat drug-related adverse effects; any agent that increases an antineoplastic agent's efficacy or pharmacokinetic profile but does not have an antineoplastic effect by itself, including immunoadjuvants that boost efficacy of antineoplastic vaccines; and antineoplastic agents that are conjugated with a radioisotope and are in CT for efficacy and/or ADME studies.			Intellectual Product	National Cancer Institute Terminology
C128786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128786>	C61074	Belumosudil|2-[3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy]-N-(1-methylethyl)-acetamide|BELUMOSUDIL|KD 025|KD-025|KD025|ROCK-II Inhibitor KD025|ROCK2 Inhibitor KD025|Rho-associated Coiled-coil Kinase 2 Inhibitor KD025|SLx 2119|SLx-2119|SLx2119	An orally bioavailable inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2; ROCK-II), with potential immunomodulating activity. Upon oral administration, belumosudil binds to and inhibits the serine/threonine kinase activity of ROCK2. This inhibits ROCK2-mediated signal transduction pathways and modulates various pro- and anti-inflammatory immune cell responses through the regulation of signal transducer and activator of transcription 3 and 5 (STAT3/STAT5) phosphorylation. This downregulates pro-inflammatory Th17 cells and increases regulatory T (Treg) cells. Belumosudil also inhibits ROCK2-mediated fibrotic processes, including stress fiber formation, myofibroblast activation and pro-fibrotic gene transcription. ROCK2 is upregulated in various diseases, including various fibrotic, neurodegenerative and autoimmune diseases.	Belumosudil		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C128787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128787>	C19590	GenomePlex Whole Genome Amplification|GenomePlex|GenomePlex (Rubicon)|Genomeplex	A proprietary method for whole genome amplification (WGA) from very small samples using random fragmentation of genomic DNA and conversion of the resulting small fragments to a library of PCR-amplifiable molecules flanked by universal priming sites.			Molecular Biology Research Technique	GDC Terminology|GDC Value Terminology
C128788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128788>	C19590	REPLI-g Whole Genome Amplification|Repli-G|Repli-g (Qiagen)	A proprietary method for whole genome amplification (WGA) from small samples using high-fidelity enzyme Phi 29 polymerase to amplify complex genomic DNA using Multiple Displacement Amplification (MDA) technology.			Molecular Biology Research Technique	GDC Terminology|GDC Value Terminology
C128789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128789>	C16623	RNA Isolation|RNA Extraction	Any method that extracts RNA from biological samples, which includes the proper handling of biological samples prior to nucleic acid isolation, the separation of RNA from the rest of the components in the samples, and the storage of the RNA isolates.			Laboratory Procedure	
C12878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12878>	C12882	Cardiac Vein	Any of the three cardiac veins including the small, middle and great cardiac veins.	Cardiac Vein		Body Part, Organ, or Organ Component	
C128790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128790>	C20189	Hybrid	Being comprised of mixed attributes or parts.			Conceptual Entity	
C128791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128791>	C158425	Human Origin	An indication that cells, tissues, or other material are, or are derived from, human specimens.			Conceptual Entity	
C128792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128792>	C74942|C161601	Surgical Pathology Procedure	A laboratory procedure that involves the examination of surgical resection or biopsy tissue samples for diagnostic or research purposes.			Laboratory Procedure	
C128793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128793>	C70592	Microplate Well|Plate Well|Well	Any of the individual wells on a microwell plate.			Spatial Concept	
C128794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128794>	C48938	Proliferating Cell Count|Number Proliferating Cells|Proliferating Cell|Proliferating Cell Number|number proliferating cells|number_proliferating_cells	The number of proliferating cells found during a review of a slide(s) derived from a tissue sample.			Laboratory Procedure	GDC Property Terminology|GDC Terminology
C128795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128795>	C120481	Electronic Nicotine Delivery Device|ELECTRONIC NICOTINE DELIVERY SYSTEMS (ENDS)|Electronic Nicotine Product Device	A battery-powered electronic device designed to atomize a nicotine-containing liquid solution for inhalation.	Electronic Nicotine Delivery Device		Manufactured Object	CDISC ADaM Terminology|CDISC ADaM Tobacco Product Category Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C128796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128796>	C16830	Hemoblast Bellows|Hemoblast Bellows Hemostatic Device	A proprietary investigational device that is in trials for cardiothoracic, abdominal, and orthopedic lower extremity surgeries as an adjunct to hemostasis when control of bleeding by conventional procedures is ineffective or impractical.	Hemoblast Bellows		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C128797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128797>	C7783|C135017	Recurrent Lung Non-Squamous Non-Small Cell Carcinoma|Recurrent Non-Squamous Non-Small Cell Lung Cancer|Recurrent Non-Squamous Non-Small Cell Lung Carcinoma	The reemergence of non-squamous non-small cell lung carcinoma after a period of remission.			Neoplastic Process	
C128798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128798>	C156094|C135017	Metastatic Lung Non-Squamous Non-Small Cell Carcinoma|Metastatic Non-Squamous Non-Small Cell Lung Cancer|Metastatic Non-Squamous Non-Small Cell Lung Carcinoma	A non-squamous non-small cell carcinoma that arises from the lung and has metastasized to another anatomic site.			Neoplastic Process	
C128799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128799>	C215224|C155712	Trastuzumab Deruxtecan|DS-8201|DS-8201a|Enhertu|Fam-trastuzumab Deruxtecan-nxki|T-DXd|TRASTUZUMAB DERUXTECAN|Trastuzumab deruxtecan|WHO 10516	An antibody-drug conjugate (ADC) composed of trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2) conjugated to deruxtecan, a derivative of the camptothecin analog exatecan (DXd; DX-8951 derivative), a DNA topoisomerase 1 (topoisomerase I; Top1) inhibitor, with antineoplastic activity. Upon administration of trastuzumab deruxtecan, trastuzumab targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, deruxtecan binds to and inhibits Top1-DNA complexes, which results in an inhibition of DNA replication, cell cycle arrest and tumor cell apoptosis. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. In addition, trastuzumab deruxtecan induces antibody-dependent cell-mediated cytotoxicity (ADCC) and causes a bystander killing effect.	Trastuzumab Deruxtecan		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12879>	C12878	Great Cardiac Vein	A vein originating at the apex of the heart that receives numerous tributaries as it ascends before draining into the left extremity of the coronary sinus.	Great Cardiac Vein		Body Part, Organ, or Organ Component	
C1287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1287>	C387	Recombinant Granulocyte Colony-Stimulating Factor|Recombinant Colony-Stimulating Factor 3|rhG-CSF	A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine granulocyte colony-stimulating factor (G-CSF).  Secreted by monocytes, macrophages and neutrophils and other cells after activation, G-CSF stimulates the proliferation and differentiation of hematopoietic progenitor cells committed to the neutrophil/ granulocyte lineage. (NCI04)			Chemical Viewed Functionally	NCI Drug Dictionary Terminology
C128800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128800>	C42078	Submucosal Lesion	A pathologic process that affects the loose connective tissue beneath the mucosa.			Finding	
C128801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128801>	C8498	Hereditary Melanoma with CDKN2A Mutation|CMM2|Cutaneous Malignant Melanoma 2|Familial Cutaneous Melanoma with CDKN2A Gene Mutation|Familial Cutaneous Melanoma with CDKN2A Mutation|Familial Melanoma with CDKN2A Gene Mutation|Familial Melanoma with CDKN2A Mutation|Hereditary Cutaneous Melanoma with CDKN2A Gene Mutation|Hereditary Cutaneous Melanoma with CDKN2A Mutation|Hereditary Melanoma with CDKN2A Gene Mutation	A hereditary cutaneous melanoma caused by germline mutation(s) in the CDKN2A gene.			Neoplastic Process	Cellosaurus Disease Terminology
C128802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128802>	C53543	Acrodermatitis Enteropathica	An autosomal recessive genetic disorder caused by mutations in the SLC39A4 gene, encoding zinc transporter ZIP4. The condition is characterized by zinc deficiency, periorificial and acral dermatitis, and diarrhea.			Disease or Syndrome	Cellosaurus Disease Terminology
C128803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128803>	C95834|C78650	Bicuspid Aortic Valve|Bicommissural Aortic Valve	A genetically heterogenous congenital anomaly in which the aortic valve has two leaflets. It affects 1-2 percent of the population.  It is a clinically heterogeneous condition, with a high incidence of aortic valve and ascending aortic complications requiring surgery.			Disease or Syndrome	Cellosaurus Disease Terminology
C128804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128804>	C53543	D-Glyceric Aciduria	An autosomal recessive genetic disorder caused by mutations in the GLYCTK gene, encoding glycerate kinase. The condition is characterized by excretion of D-glyceric acid in the urine. The phenotype varies from mild to severe, and may result in encephalopathy, mental retardation, microcephaly and early death.			Disease or Syndrome	Cellosaurus Disease Terminology
C128805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128805>	C53543	Generalized Arterial Calcification of Infancy 1|GACI1	An autosomal recessive genetic disorder caused by mutations in the ENPP1 gene, encoding ectonucleotide pyrophosphatase/phosphodiesterase family member 1. The condition is characterized by calcification and narrowing of medium- and large-sized arteries, resulting in cardiovascular complications.			Disease or Syndrome	Cellosaurus Disease Terminology
C128806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128806>	C34709	Hyperalphalipoproteinemia|HALP1	An autosomal dominant genetic condition caused by mutation(s) in the CETP gene, encoding cholesteryl ester transfer protein. Affected individuals may have increased longevity due to decreased risk of coronary heart disease.			Disease or Syndrome	
C128807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128807>	C7110|C35417|C27325	Recurrent Intrahepatic Cholangiocarcinoma|Recurrent Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)	The reemergence of intrahepatic cholangiocarcinoma after a period of remission.	Recurrent Intrahepatic Cholangiocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C128808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128808>	C35682	Carcinoembryonic Antigen Positive|CEA Positive	A laboratory test result indicating the presence of carcinoembryonic antigen in a sample.	Carcinoembryonic Antigen Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128809>	C171257	Blunt	Marijuana rolled in the outer leaves of a cigar or hidden in a hollowed-out cigar.			Manufactured Object	
C12880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12880>	C12878	Middle Cardiac Vein	A vein originating at the apex of the heart that ascends along the posterior interventricular sulcus and drains into the coronary sinus.	Middle Cardiac Vein		Body Part, Organ, or Organ Component	
C128810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128810>	C35548	IgG Monoclonal Gammopathy	An abnormal laboratory test result indicating the presence of IgG monoclonal immunoglobulin in the blood or urine.	IgG Monoclonal Gammopathy		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C128811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128811>	C35548	IgA Monoclonal Gammopathy	An abnormal laboratory test result indicating the presence of IgA monoclonal immunoglobulin in the blood or urine.	IgA Monoclonal Gammopathy		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C128812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128812>	C35548	IgM Monoclonal Gammopathy	An abnormal laboratory test result indicating the presence of IgM monoclonal immunoglobulin in the blood or urine.	IgM Monoclonal Gammopathy		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C128813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128813>	C97927	BAP1 Gene Mutation|BAP1 Mutation|BRCA1 Associated Protein 1 Gene Mutation|BRCA1-Associated Protein 1 Gene Mutation|Positive|UCHL2 Gene Mutation	A change in the nucleotide sequence of the BAP1 gene.	BAP1 Gene Mutation		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128814>	C19635|C141248|C141233	Deleterious BRCA1 Gene Mutation|Deleterious BROVCA1 Gene Mutation|Deleterious Breast Cancer Type 1 Susceptibility Gene Mutation	A change in the nucleotide sequence of the BRCA1 gene that is associated with increased risk of disease.	Deleterious BRCA1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C128815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128815>	C19636|C141233	Deleterious BRCA2 Gene Mutation|Deleterious Breast Cancer Type 2 Susceptibility Gene Mutation|Deleterious FANCD1 Gene Mutation|Deleterious XRCC11 Gene Mutation	A change in the nucleotide sequence of the BRCA2 gene that is associated with increased risk of disease.	Deleterious BRCA2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C128816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128816>	C97927	CALR Gene Mutation|Autoantigen Ro Gene Mutation|CALR Mutation|CRT Gene Mutation|Calreticulin Gene Mutation|RO Gene Mutation|cC1qR Gene Mutation|mutCALR	A change in the nucleotide sequence of the CALR gene.	CALR Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128817>	C97927	CDKN2A Gene Mutation|CDK4I Gene Mutation|CDKN2A|CDKN2A Mutation|Cyclin-Dependent Kinase Inhibitor 2A Gene Mutation|p14ARF Gene Mutation|p16 Gene Mutation|p16-INK4A Gene Mutation|p16INK4 Gene Mutation|p16INK4a Gene Mutation|p19ARF Gene Mutation	A change in the nucleotide sequence of the CDKN2A gene.	CDKN2A Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|EWS Authorized Value Terminology|EWS Molecular Analysis Table
C128818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128818>	C97927	CTRC Gene Mutation|CTRC Mutation|Chymotrypsin C Gene Mutation|ELA4 Gene Mutation	A change in the nucleotide sequence of the CTRC gene.	CTRC Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128819>	C97927	DOCK8 Gene Mutation|DOCK8 Mutation|Dedicator of Cytokinesis 8 Gene Mutation	A change in the nucleotide sequence of the DOCK8 gene.	DOCK8 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12881>	C12878	Small Cardiac Vein	A vein running parallel to the right coronary artery in the coronary sulcus that drains into the right extremity of the coronary sinus.	Small Cardiac Vein		Body Part, Organ, or Organ Component	
C128820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128820>	C97927	EPCAM Gene Mutation|EPCAM Mutation|Ep-CAM Gene Mutation|Epithelial Cell Adhesion Molecule Gene Mutation|HNPCC8 Gene Mutation|TACSTD1 Gene Mutation|Tumor-Associated Calcium Signal Transducer 1 Gene Mutation	A change in the nucleotide sequence of the EPCAM gene.	EPCAM Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128821>	C97927|C133706	MSH2 Gene Mutation|COCA1 Gene Mutation|HNPCC Gene Mutation|HNPCC1 Gene Mutation|MSH2 Mutation|MutS Homolog 2 Gene Mutation|MutS, E. coli, Homolog of, 2 Gene Mutation	A change in the nucleotide sequence of the MSH2 gene.	MSH2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C128822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128822>	C97927|C133706	PMS1 Gene Mutation|HNPCC3 Gene Mutation|MLH2 Gene Mutation|PMS1 Mutation|PMSL1 Gene Mutation|Postmeiotic Segregation Increased (S. cerevisiae) 1 Gene Mutation|Postmeiotic Segregation Increased 1 Gene Mutation	A change in the nucleotide sequence of the PMS1 gene.	PMS1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128823>	C97927	PRSS1 Gene Mutation|PRSS1 Mutation|Protease, Serine, 1 Gene Mutation|TRY1 Gene Mutation	A change in the nucleotide sequence of the PRSS1 gene.	PRSS1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128824>	C97927	PRSS2 Gene Mutation|PRSS2 Mutation|Protease, Serine, 2 Gene Mutation|TRY2 Gene Mutation	A change in the nucleotide sequence of the PRSS2 gene.	PRSS2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128825>	C97927	STK11 Gene Mutation|LKB1 Gene Mutation|Liver Kinase B1 Gene Mutation|STK11 Mutation|Serine/Threonine Kinase 11 Gene Mutation	A change in the nucleotide sequence of the STK11 gene.	STK11 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128826>	C219644|C172343	IDH1 NM_005896.3:c.395G>A|G395A|IDH c.395G>A|IDH1 c.395G>A|Isocitrate Dehydrogenase 1 (NADP(+)), Cytosolic c.395G>A|Isocitrate Dehydrogenase 1 (NADP+), Soluble c.395G>A|NM_005896.3:c.395G>A	A nucleotide substitution at position 395 of the coding sequence of the IDH1 gene where guanine has been mutated to adenine.	IDH1 NM_005896.3:c.395G>A		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128827>	C117280	IDH1 NP_005887.2:p.R132H|Cytosolic NADP-Isocitrate Dehydrogenase Protein Arg132His|Cytosolic NADP-Isocitrate Dehydrogenase Protein R132H|IDH1 Arg132His|IDH1 NP_005887.2:p.Arg132His|IDH1 R132H|IDH1 R132H Mutation|IDH1 p.Arg132His|IDH1 p.R132H|Isocitrate Dehydrogenase [NADP] Cytoplasmic Arg132His|Isocitrate Dehydrogenase [NADP] Cytoplasmic R132H|NP_005887.2:p.Arg132His|NP_005887.2:p.R132H	A change in the amino acid residue at position 132 in the isocitrate dehydrogenase [NADP] cytoplasmic protein where arginine has been replaced by histidine.	IDH1 NP_005887.2:p.R132H		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128829>	C172342	HHV6 Infection|HHV-6 Infection|Human Herpes Virus-6 Infection|Human Herpesvirus-6 (HHV-6)|Human Herpesvirus-6 Infection	An infection that is caused by human herpesvirus-6.	HHV6 Infection		Disease or Syndrome	CTRP Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C12882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12882>	C12814	Coronary Vein|CORONARY VEIN	A blood vessel in the heart which returns coronary blood to the chambers of the heart, most often the right atrium.	Coronary Vein		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128830>	C188271	JC Virus Infection|JC Polyomavirus Infection|JCV Infection|John Cunningham Virus Infection|Polyomavirus JC Infection	An infection that is caused by JC virus.	JC Virus Infection		Disease or Syndrome	CTRP Biomarker Terminology|CTRP Terminology
C128831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128831>	C94299|C177692	ALK Positive|ALK+|ALK-Positive|Anaplastic Lymphoma Kinase Positive	Indicates that ALK expression has been detected in a sample.	ALK Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128832>	C177692	CCND1 Positive|BCL-1 Positive|BCL1 Positive|Cyclin D1 Positive|Cyclin-D1 Positive|PRAD1 Positive	Indicates that CCND1 expression has been detected in a sample.	CCND1 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128833>	C35682	Epstein-Barr Virus Early RNA Positive|EBER Positive|Epstein-Barr Encoded RNA Positive|Epstein-Barr Virus-Associated Early RNA Positive	Indicates that Epstein-Barr virus early RNA has been detected in a sample.	Epstein-Barr Virus Early RNA Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128834>	C177684|C165233	BCR/ABL1 Fusion Negative|BCR-ABL Fusion Negative|BCR-ABL Negative|BCR-ABL1 Fusion Negative|BCR-ABL1 Negative|BCR/ABL Fusion Negative|BCR/ABL Negative|BCR/ABL1 Negative	Indicates that expression of the BCR/ABL1 fusion has not been detected in a sample.	BCR/ABL1 Fusion Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128835>	C177692	Latent Membrane Protein 1 Positive|EBV Latent Membrane Protein 1 Positive|Epstein-Barr Virus Latent Membrane Protein 1 Positive|LMP Positive|LMP1 Positive	Indicates that Epstein-Barr virus latent membrane protein 1 expression has been detected in a sample.	Latent Membrane Protein 1 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128836>	C158948	PML/RARA Fusion Positive|PML-RAR Alpha Fusion Positive|PML-RAR Alpha Positive|PML-RARA Fusion Positive|PML-RARA Positive|PML/RAR Alpha Fusion Positive|PML/RAR Alpha Positive|PML/RARA Positive	Indicates that expression of the PML/RARA fusion has been detected in a sample.	PML/RARA Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128837>	C158948	RUNX1/RUNX1T1 Fusion Positive|AML-ETO Fusion Positive|AML-ETO Positive|AML/ETO Fusion Positive|AML/ETO Positive|RUNX1-RUNX1T1 Fusion Positive|RUNX1-RUNX1T1 Positive|RUNX1/RUNX1T1 Positive	Indicates that expression of the RUNX1/RUNXT1 fusion has been detected in a sample.	RUNX1/RUNX1T1 Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128838>	C35681|C175007	Human Anti-Mouse Antibodies Negative|HAMA Negative|Human Anti-Mouse Antibodies Absent	Indicates that human anti-mouse antibodies have not been detected in a sample.	Human Anti-Mouse Antibodies Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C128839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128839>	C35682	Human Papillomavirus Positive|HPV Positive|HPV+|Human Papilloma Virus Positive	Indicates that human papillomavirus has been detected in a sample.	Human Papillomavirus Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C12883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12883>	C12814	Brachial Vein|BRACHIAL VEIN|VEIN, BRACHIAL	Deep vein of the upper arm that forms at the junction of the radial and ulnar veins and ends at the inferior border of the teres major.	Brachial Vein		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128840>	C94299|C177692	IGF1R Positive|CD221 Positive|IGF-1R Positive|IGFR Positive|Insulin Like Growth Factor 1 Receptor Positive	Indicates that IGF1R expression has been detected in a sample.	IGF1R Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128841>	C177692	Mesothelin Positive|MSLN Positive|Mesothelin-Expressing	Indicates that mesothelin expression has been detected in a sample.	Mesothelin Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128842>	C177692	RB1 Positive|RB Positive|RB+|RB1+|Retinoblastoma 1 Positive|Retinoblastoma Positive	Indicates that RB1 expression has been detected in a sample.	RB1 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128843>	C158948	Philadelphia Chromosome Positive|Ph Positive|Ph+	Indicates that the Philadelphia chromosome abnormality, t(9;22)(q34;q11), has been detected in a sample.	Philadelphia Chromosome Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128844>	C158949|C103223	Philadelphia Chromosome Negative|Ph Negative|Ph-	Indicates that the Philadelphia chromosome abnormality, t(9;22)(q34;q11), has not been detected in a sample.	Philadelphia Chromosome Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128845>	C94299|C177692	TNFRSF17 Positive|B Cell Maturation Antigen Positive|BCMA Positive|CD269 Antigen Positive|CD269 Positive|Tumor Necrosis Factor Receptor Superfamily Member 1 Positive	Indicates that TNFRSF17 expression has been detected in a sample.	TNFRSF17 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128846>	C177692	Tyrosinase Positive|TYR Positive	Indicates that tyrosinase expression has been detected in a sample.	Tyrosinase Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128847>	C3512|C226433	Lung Micropapillary Adenocarcinoma|Micropapillary adenocarcinoma|Micropapillary carcinoma, NOS	An aggressive variant of lung adenocarcinoma that exhibits a micropapillary architectural pattern. The prognosis is usually poor.			Neoplastic Process	Cellosaurus Disease Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Morphology PT Terminology|Mapped ICDO3.1 Morphology Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C128848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128848>	C25943|C25870	GART Gene|GART|GART|Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase Gene	This gene is involved in purine nucleotide biosynthesis.	GART Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C128849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128849>	C128848	GART wt Allele|AIRS|GARFT|GARS|GARTF|PAIS|PGFT|PRGS|Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase wt Allele|Phosphoribosylglycinamide Formyltransferase/Phosphoribosylglycinamide Synthetase/Phosphoribosylaminoimidazole Synthetase Gene	Human GART wild-type allele is located in the vicinity of 21q22.11 and is approximately 40 kb in length. This allele, which encodes trifunctional purine biosynthetic protein adenosine-3, plays a role in the synthesis of purines.	GART wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12884>	C13318	Urothelium|Transitional Epithelium of the Urinary Tract|urothelium	Transitional epithelium lining the renal pelvis, bladder, ureter, and part of the urethra.	Urothelium		Tissue	
C128850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128850>	C17210|C16796	Trifunctional Purine Biosynthetic Protein Adenosine-3|5'-Phosphoribosylglycinamide Transformylase|AIR Synthase|AIRS|EC 2.1.2.2|EC 6.3.3.1|EC 6.3.4.13|GAR Transformylase|GARS|GARS-AIRS-GART|GART|Glycinamide Ribonucleotide Formyltransferase|Glycinamide Ribonucleotide Synthetase|Phosphoribosyl-Aminoimidazole Synthetase|Phosphoribosylamine--Glycine Ligase|Phosphoribosylamine-Glycine Ligase|Phosphoribosylformylglycinamidine Cyclo-Ligase|Phosphoribosylglycinamide Formyltransferase|Phosphoribosylglycinamide Synthetase	Trifunctional purine biosynthetic protein adenosine-3 (1010 aa, ~108 kDa) is encoded by the human GART gene. This protein is involved in the de novo biosynthesis of purine nucleotides.	Trifunctional Purine Biosynthetic Protein Adenosine-3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128851>	C25994	CCK Gene|CCK|CCK|Cholecystokinin Gene	This gene is involved in digestion.	CCK Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C128852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128852>	C128851	CCK wt Allele|Cholecystokinin Triacontatriapeptide Gene|Cholecystokinin wt Allele	Human CCK wild-type allele is located in the vicinity of 3p22.1 and is approximately 8 kb in length. This allele, which encodes cholecystokinin protein, plays a role in the stimulation of both gallbladder contraction and pancreatic enzyme release.	CCK wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128853>	C1746	Cholecystokinin|CCK|CCK-PZ|Pancreozymin|Prepro-CCK|Prepro-Cholecystokinin|Preprocholecystokinin	Cholecystokinin (115 aa, ~13 kDa) is encoded by the human CCK gene. This protein is involved in both pancreatic enzyme release and gallbladder contraction.	Cholecystokinin		Amino Acid, Peptide, or Protein|Hormone	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128854>	C21295	MUC4 Gene|MUC4|MUC4|MUC4|Mucin 4, Cell Surface Associated Gene	This gene is involved in both cell adhesion and receptor signaling.	MUC4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C128855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128855>	C128854	MUC4 wt Allele|ASGP|HSA276359|MUC-4|Mucin 4, Cell Surface Associated wt Allele|Mucin 4, Tracheobronchial Gene	Human MUC4 wild-type allele is located in the vicinity of 3q29 and is approximately 66 kb in length. This allele, which encodes mucin-4 protein, plays a role in both cell adhesion and tumor progression.	MUC4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128856>	C17728|C16883	Mucin-4|Ascites Sialoglycoprotein|MUC-4|MUC4|Pancreatic Adenocarcinoma Mucin|Testis Mucin|Tracheobronchial Mucin	Mucin-4 (2169 aa, ~232 kDa) is encoded by the human MUC4 gene. This protein is involved in receptor signaling, the modulation of cell-matrix adhesion, and in tumor progression.	Mucin-4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128857>	C21518	C4A Gene|C4A|C4A|Complement Component 4A (Rodgers Blood Group) Gene	This gene plays a role in the progression of the classical complement pathway.	C4A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C128858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128858>	C128857	C4A wt Allele|C4|C4, Rodgers Form Gene|C4A2|C4A3|C4A4|C4A6|C4AD|C4S|CO4|CPAMD2|Complement Component 4A (Rodgers Blood Group) wt Allele|RG|SLP|SLP, Mouse, Homolog of Gene	Human C4A wild-type allele is located in the vicinity of 6p21.3 and is approximately 21 kb in length. This allele, which encodes complement C4-A protein, is involved in the innate immune response. The expression of this gene is associated with the expression of Rodgers blood group antigens. Mutation of the gene is associated with complement component C4A deficiency. Copy number variation and polymorphisms are associated with increased risk for systemic lupus erythematosus.	C4A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128859>	C21518	C4B Gene|C4B|C4B|Complement Component 4B (Chido Blood Group) Gene	This gene is involved in innate immunity.	C4B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C12885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12885>	C34030|C34028	Renal Capsule|renal capsule	A layer of dense connective tissue that covers the outer surface of each kidney.	Renal Capsule		Body Part, Organ, or Organ Component	GDC Terminology|GDC Value Terminology
C128860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128860>	C2594	Ad5-survivin-transduced Autologous Dendritic Cell Vaccine|Ad5-survivin-transduced Autologous DC Vaccine|Autologous DC:AdmS|Autologous Dendritic Cell Adenovirus Type 5-Survivin Vaccine	A cell-based cancer vaccine containing autologous dendritic cells (DCs) that are transduced with a replication-deficient adenovirus type 5 vector (Ad5) encoding a mutated form of the tumor-associated antigen (TAA) survivin, with potential immunostimulatory and antineoplastic activities. Upon administration, Ad5-survivin-transduced autologous DC vaccine may elicit an immune response against cancer cells expressing survivin by activating cytotoxic T-cells (CTLs). This leads to an induction of cell death in survivin-positive tumor cells. Survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types and plays a key role in tumor cell growth and survival.	Ad5-survivin-transduced Autologous Dendritic Cell Vaccine		Cell|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C128861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128861>	C128859	C4B wt Allele|C4, Chido Form Gene|C4B1|C4B12|C4B2|C4B3|C4B5|C4BD|C4F|CH|CO4|CPAMD3|Complement Component 4B (Chido Blood Group) wt Allele	Human C4B wild-type allele is located in the vicinity of 6p21.3 and is approximately 21 kb in length. This allele, which encodes complement C4-B protein, plays a role in both host defense and inflammation. The expression of this gene is associated with the expression of Chido blood group antigens. Mutation of the gene is associated with complement component C4B deficiency. Copy number variation and polymorphisms are associated with increased risk for systemic lupus erythematosus.	C4B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128862>	C155727	FGFR4 Inhibitor H3B-6527|Fibroblast Growth Factor Receptor 4 Inhibitor H3B-6527|H3B 6527|H3B-6527|H3B-6527|H3B6527	An orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon administration, H3B-6527 specifically binds to and blocks FGFR4. This prevents the activation of FGFR4, inhibits FGFR4-mediated signaling and leads to an inhibition of cell proliferation in FGFR4-overexpressing tumor cells. FGFR4, a receptor tyrosine kinase overexpressed by certain tumor cell types, is involved in tumor cell proliferation, differentiation, angiogenesis, and survival; FGFR4 expression is associated with poor prognosis.	FGFR4 Inhibitor H3B-6527		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C128863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128863>	C21518	C4B_2 Gene|C4B_2|C4B_2|Complement Component 4B (Chido Blood Group), Copy 2 Gene	This gene is involved in complement-mediated immunity.	C4B_2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C128864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128864>	C128863	C4B_2 wt Allele|Complement Component 4B (Chido Blood Group), Copy 2 wt Allele	Human C4B_2 wild-type allele is located in the vicinity of the 6p21.3 alternate reference locus and is approximately 21 kb in length. This allele, which encodes complement C4-B protein, plays a role in complement-dependent immune processes. The expression of this gene is associated with the expression of Chido blood group antigens. Mutation of the gene is associated with complement component C4B deficiency. Copy number variation and polymorphisms are associated with increased risk for systemic lupus erythematosus.	C4B_2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128865>	C182130	Complement C4-A|Acidic C4|Acidic Complement C4|C3 and PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 2|C4A|Complement Component 4A|Complement Component 4S|Rodgers Form of C4	Complement C4-A (1744 aa, ~193 kDa) is encoded by the human C4A gene. This protein plays a role in both host defense and inflammation.	Complement C4-A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128866>	C182130	Complement C4-B|Basic C4|Basic Complement C4|C3 and PZP-Like Alpha-2-Macroglobulin Domain-Containing Protein 2|C4B|Chido Form of C4|Complement Component 4B|Complement Component 4F	Complement C4-B (1744 aa, ~193 kDa) is encoded by the human C4B and C4B_2 genes. This protein is involved in the propagation of the classical complement pathway.	Complement C4-B		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128867>	C20729	CSTA Gene|CSTA|CSTA|Cystatin A Gene	This gene plays a role in both thiol proteinase inhibition and epidermal structure.	CSTA Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C128868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128868>	C128867	CSTA wt Allele|AREI|Cystatin A (Stefin A) Gene|Cystatin A wt Allele|PSS4|STF1|STFA	Human CSTA wild-type allele is located in the vicinity of 3q21 and is approximately 17 kb in length. This allele, which encodes cystatin-A protein, is involved in the inhibition of thiol proteinases and desmosome-mediated cell-cell adhesion. Mutation of the gene is associated with peeling skin syndrome 4.	CSTA wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128869>	C18072	Cystatin-A|Cystatin A|Cystatin AS|Cystatin-AS|Stefin A|Stefin-A	Cystatin-A (98 aa, ~11 kDa) is encoded by the human CSTA gene. This protein plays a role in both cell-cell adhesion in the epidermis and the regulation of thiol proteinase activity.	Cystatin-A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12886>	C33461	Renal Pyramid	A cone-shaped structure of the kidney. It is located in the medullary portion of the kidney (pyramid of Malpighi) or the cortical portion of the kidney (pyramid of Ferrein).	Renal Pyramid		Body Part, Organ, or Organ Component	
C128870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128870>	C20729	CSTB Gene|CSTB|CSTB|Cystatin B Gene	This gene is involved in the inhibition of cathepsins.	CSTB Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C128871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128871>	C128870	CSTB wt Allele|CPI-B|CST6|Cystatin B (Stefin B) Gene|Cystatin B wt Allele|EPM1|EPM1A|PME|STFB|ULD	Human CSTB wild-type allele is located in the vicinity of 21q22.3 and is approximately 4 kb in length. This allele, which encodes cystatin-B protein, plays a role in thiol protease inhibition. Mutation of the gene is associated with progressive myoclonic epilepsy 1A (myoclonic epilepsy of Unverricht and Lundborg).	CSTB wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128872>	C18072	Cystatin-B|CPI-B|Cystatin B|Liver Thiol Proteinase Inhibitor|Stefin B|Stefin-B	Cystatin-B (98 aa, ~11 kDa) is encoded by the human CSTB gene. This protein is involved in the regulation of cathepsins.	Cystatin-B		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128873>	C94299|C177692	Somatostatin Receptor Positive|SSTR Positive	A laboratory test result indicating the presence or expression of somatostatin receptor in a sample.	Somatostatin Receptor Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128874>	C21282	DDC Gene|DDC|DDC|Dopa Decarboxylase Gene	This gene plays a role in the synthesis of monoamine neurotransmitters.	DDC Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C128875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128875>	C128874	DDC wt Allele|AADC|Dopa Decarboxylase (Aromatic L-Amino Acid Decarboxylase) Gene|Dopa Decarboxylase wt Allele	Human DDC wild-type allele is located in the vicinity of 7p12.2 and is approximately 107 kb in length. This allele, which encodes aromatic-L-amino-acid decarboxylase protein, is involved in monoamine neurotransmitter synthesis. Mutation of the gene is associated with aromatic L-amino-acid decarboxylase deficiency (AADCD).	DDC wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128876>	C16804	Aromatic-L-Amino-Acid Decarboxylase|AADC|Aromatic L-Amino Acid Decarboxylase|DDC|DOPA Decarboxylase|EC 4.1.1.28	Aromatic-L-amino-acid decarboxylase (480 aa, ~54 kDa) is encoded by the human DDC gene. This protein plays a role in the conversion of amino acids to monoamine neurotransmitters.	Aromatic-L-Amino-Acid Decarboxylase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128877>	C20719	EPHA5 Gene|EPH Receptor A5 Gene|EPHA5|EPHA5	This gene is involved in brain development.	EPHA5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C128878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128878>	C128877	EPHA5 wt Allele|BSK|BSK, Mouse, Homolog of Gene|CEK7|EHK-1|EHK1|EHK1, Rat, Homolog of Gene|EK7|EPH Homology Kinase 1, Rat, Homolog of Gene|EPH Receptor A5 wt Allele|HEK7|Hek7|TYRO4	Human EPHA5 wild-type allele is located in the vicinity of 4q13.1 and is approximately 351 kb in length. This allele, which encodes ephrin type-A receptor 5 protein, plays a role in cell-cell signaling, hippocampus development, and neuron development.	EPHA5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128879>	C17660	Ephrin Type-A Receptor 5|Brain-Specific Kinase|EC 2.7.10.1|EHK-1|EK7|EPH Homology Kinase 1|EPH-Like Kinase 7|EPHA5|Ephrin Receptor EphA5|Receptor Protein-Tyrosine Kinase HEK7|Tyrosine-Protein Kinase Receptor EHK-1|hEK7	Ephrin type-A receptor 5 (1037 aa, ~115 kDa) is encoded by the human EPHA5 gene. This protein is involved in tyrosine phosphorylation, cell-cell signaling and central nervous system development.	Ephrin Type-A Receptor 5		Amino Acid, Peptide, or Protein|Enzyme|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12887>	C34028	Renal Pelvis|RENAL PELVIS|Renal pelvis|Renal pelvis structure (body structure)|renal pelvis|renal pelvis	The funnel-shaped proximal portion of the ureter located within the kidney into which urine is secreted from the collecting duct system of the kidney.	Renal Pelvis		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C128880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128880>	C20828|C171402|C116448	Ultrasound-Guided Near-Infrared Optical Tomography|NIR/US|Ultrasound-Guided Near-Infrared Tomography	An imaging modality that combines ultrasound imaging with diffused light imaging by near-infrared (NIR) optical tomography to obtain coregistered ultrasound and NIR diffusive light images in order to improve optical imaging reconstruction and location certainty. The use of NIR in this combination can also be used to assess functional parameters of a tissue.	Ultrasound-Guided Near-Infrared Optical Tomography		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C128881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128881>	C20673	IRF7 Gene|IRF7|IRF7|Interferon Regulatory Factor 7 Gene	This gene plays a role in the modulation of the innate immune response against DNA and RNA viruses.	IRF7 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C128882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128882>	C128881	IRF7 wt Allele|IMD39|IRF-7H|IRF7A|IRF7B|IRF7C|IRF7H|Interferon Regulatory Factor 7 wt Allele	Human IRF7 wild-type allele is located in the vicinity of 11p15.5 and is approximately 3 kb in length. This allele, which encodes interferon regulatory factor 7 protein, is involved in the regulation of antiviral gene expression.	IRF7 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128883>	C17207	Interferon Regulatory Factor 7|IRF-7|IRF7|Interferon Regulatory Factor-7	Interferon regulatory factor 7 (503 aa, ~54 kDa) is encoded by the human IRF7 gene. This protein plays a role in the cellular response to viral infection.	Interferon Regulatory Factor 7		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C128884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128884>	C25873	GSK3B Gene|GSK3B|GSK3B|Glycogen Synthase Kinase 3 Beta Gene	This gene plays a role in the inhibition of glycogen synthesis.	GSK3B Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|Pediatric Oncology Biomarkers/Targets Associated with Other Relevant Evidence
C128885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128885>	C128884	GSK3B wt Allele|Glycogen Synthase Kinase 3 Beta wt Allele	Human GSK3B wild-type allele is located in the vicinity of 3q13.3 and is approximately 273 kb in length. This allele, which encodes glycogen synthase kinase-3 beta protein, is involved in the negative regulation of glycogen synthesis.	GSK3B wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128886>	C17325	Glycogen Synthase Kinase-3 Beta|EC 2.7.11.1|EC 2.7.11.26|GSK-3 Beta|GSK3-beta|GSK3B|Glycogen Synthase Kinase 3-Beta|Serine/Threonine-Protein Kinase GSK3B	Glycogen synthase kinase-3 beta (420 aa, ~47 kDa) is encoded by the human GSK3B gene. This protein plays a role in both protein phosphorylation and the inhibition of glycogen synthesis.	Glycogen Synthase Kinase-3 Beta		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Biomarkers/Targets Associated with Other Relevant Evidence
C128887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128887>	C1752	NY-ESO-1 Protein/Microparticle MDP/Bacterial DNA-containing MIS416 Vaccine|NY-ESO-1 Protein with MIS416|NY-ESO-1 Protein/MIS416	A combination preparation composed of a protein derived from the human tumor-associated antigen (TAA) cancer-testis antigen 1 (NY-ESO-1) and a microparticle combining two immune-modifying components derived from the bacterium Propionibacterium acnes, a bacterial cell wall component that is rich in muramyl dipeptide (MDP) and bacteria-derived single-stranded DNA fragments, with potential immunomodulating, immunoadjuvant and antineoplastic activities. Upon administration of NY-ESO-1 protein/microparticle MDP/bacterial DNA-containing MIS416 vaccine, MIS416 localizes in and is taken up mainly by the liver, thereby forming a liver depot. MIS416 is then taken up by immune cells, such as monocytes and dendritic cells (DCs), where MDP and the bacterial DNA target and bind to the cytosolic innate pattern recognition receptors (PRRs) nucleotide-binding oligomerization domain-containing protein 2 (NOD2), and toll-like receptor 9 (TLR9), respectively. The simultaneous binding and activation of both NOD2 and TLR9, leads to activation of both NOD2 and TLR9 signaling pathways. This stimulates the innate immune system, induces secretion of cytokines, particularly interferon (IFN), and modulates the activation of various immune cells. In the presence of the NY-ESO-1 peptide, MIS416 enhances the cytotoxic T-lymphocyte (CTL)-mediated immune response against NY-ESO-1, resulting in an increased anti-tumor immune response. NY-ESO-1 is expressed in normal testes and on the surfaces of various tumor cells, and plays a key role in tumor cell proliferation and survival.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C128888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128888>	C1557	Cytarabine Monophosphate Prodrug MB07133|(2R,4S)-4-amino-1-[5-O-[2-oxo-4-(4-pyridyl)-1,3,2-dioxaphosphorinan-2-yl]-beta-d-arabinofuranosyl]-2(1H)-pyrimidinone|Cytarabine Prodrug MB07133|MB07133	A prodrug of the monophosphate (MP) form of the antimetabolite cytarabine (araCMP), an analogue of cytidine with a modified sugar moiety (arabinose instead of ribose), with potential antineoplastic activity. Upon administration of the cytarabine MP prodrug MB07133, the targeting moiety of this agent specifically delivers the cytarabine moiety to the liver. In turn, araCMP is selectively converted to araC triphosphate (araCTP) by a liver kinase, where it binds to and competes with cytidine for incorporation into DNA, thereby inhibiting DNA polymerase, and DNA synthesis. This leads to the inhibition of tumor cell proliferation and destruction of liver cancer cells. The liver is not able to convert araC into araCMP; araCMP is not converted into araCTP in tissues other than the liver. This enhances efficacy and minimizes systemic toxicity.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C128889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128889>	C308	French Maritime Pine Bark Extract|MARITIME PINE|PYC|Pycnogenol	A nutritional supplement containing an extract obtained from the French maritime pine bark Pinus pinaster, with potential immunomodulating and antioxidant activities. The French maritime pine bark extract contains high amounts of the phytochemicals proanthocyanidins. Proanthocyanidins are able to scavenge free radicals, and therefore may inhibit cellular damage. This extract may also ameliorate the symptoms of lymphedema and improve blood flow. It might also stimulate the immune system and have antioxidant effects.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12888>	C13058	Visual System|Visual Pathway	The part of the central nervous system that contains the organs and connections that allow for the processing of visual images as well as some non-image forming visual functions, including circadian photoentrainment. Structures comprising the visual system include the eye, the optic nerve, the optic chiasma, the optic tract, the lateral geniculate nucleus, the optic radiations, the visual cortex, and the visual association cortex.	Visual System		Body System	
C128890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128890>	C1966	Fluorescent Antibody SGM-101|Anti-CEA Fluorescent Antibody SGM-101|SGM-101	A near infrared-emitting fluorochrome-labeled anti-carcinoembryonic antigen (ACE; anti-CEA) monoclonal antibody, with potential diagnostic imaging activity. Upon administration, the fluorescent antibody SGM-101 binds CEA-overexpressing cancer cells. Upon fluorescence imaging, the fluorochrome can be visualized and CEA-overexpressing cancer cell can be imaged and detected. CEA, a tumor-associated antigen (TAA), is overexpressed on the surface of tumor cells.			Indicator, Reagent, or Diagnostic Aid	NCI Drug Dictionary Terminology
C128891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128891>	C1287	Pegteograstim|Neurapeg|PEGTEOGRASTIM	An analogue of pegfilgrastim, a recombinant, pegylated form of endogenous human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Similar to endogenous G-CSF, this agent binds to and activates specific cell surface receptors, and stimulates neutrophil progenitor proliferation, differentiation and selected neutrophil functions. Pegteograstim may prevent and shorten the duration of chemotherapy-induced neutropenia (CIN). Pegylation of teograstim increases the half-life of this agent.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C128892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128892>	C28681|C129826	Type-1 Polarized Dendritic Cell-induced Antigen-specific Autologous Cytotoxic T Lymphocytes|Autologous DC1-CTL|DC1-induced Antigen-specific Autologous CTLs|Type-1 Polarized DC-induced Antigen-specific Autologous CTLs	A preparation of autologous cytotoxic T-lymphocytes (CTL), specifically reactive to melanoma-associated antigen 3 (MAGE-3), MAGE-4, survivin, human epidermal growth factor receptor 2 (HER2; ERBB2) and cyclooxygenase-2 (COX-2), with potential immunomodulating activity. Peripheral blood mononuclear cells (PBMCs) are collected from the patient. Subsequently, autologous dendritic cells (DCs) are separated, treated with a certain combination of cytokines to produce polarized type-1 DCs (DC1), and then are loaded with MAGE-3/MAGE-4/survivin/HER2/COX-2 CTL epitope peptides. In turn, autologous CTLs are collected, exposed ex vivo to the antigen-loaded DC1s and subsequently expanded in vitro. Upon re-infusion of the DC1-induced MAGE-3/MAGE-4/survivin/HER2/COX-2-specific autologous CTLs, the CTLs target and lyse tumor cells expressing the tumor-associated antigens (TAAs). Exposure to DC1s generates more potent CTLs and thus induces a more potent CTL response against TAA-expressing tumor cells. The targeted TAAs play key roles in cellular proliferation and are overexpressed by a variety of cancer cell types.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C128893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128893>	C29639|C2459	Chinese Herbal Formulation LC09|Herba Epimedii Compound Extraction LC09|LC09|TCM Formula LC09|TCM LC09|Traditional Chinese Medicine Formula LC09	A traditional Chinese medicine (TCM) decoction containing Herba Epimedii that can be used for chemotherapy-induced hand-foot syndrome (HFS; Palmar-Plantar Erythrodysesthesia; PPE). Soaking of the affected hands and feet with TCM Formula LC09 may reduce the severity of HFS and may decrease HFS-associated pain.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C128894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128894>	C263	Thrombomodulin Alfa|1-498-Thrombomodulin (Human Clone TMP26/TMJ1 Protein Moiety Reduced)|ART 123|ART-123|Recomodulin|THROMBOMODULIN ALFA|Thrombomodulin (Human 498-Amino Acid Fragment)	A recombinant, soluble form of the human protein thrombomodulin, with potential anticoagulant activity. Upon administration, thrombomodulin binds to thrombin, which stimulates the activation of protein C. Activated protein C (APC) degrades factor Va and Factor VIIa in the presence of the cofactor protein S, inhibits thrombin formation, and prevents both thrombin-mediated coagulation and further clot formation.	Thrombomodulin Alfa		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C128895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128895>	C143099|C129825	c-Met Inhibitor HS-10241|HS-10241	An orally bioavailable small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration, HS-10241 targets and binds to the c-Met protein, prevents c-Met phosphorylation and disrupts c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C128896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128896>	C201491	4SCAR-GD2-modified T-lymphocytes|4S-GD2-CAR-T-cells|4SCAR-GD2|4SCAR-GD2 T Cells|4SCAR-GD2-modified T Cells|GD2-specific 4th Generation Chimeric Antigen Receptor-modified T Cells	Genetically modified autologous T-lymphocytes transduced with a lentiviral vector encoding a fourth generation specific chimeric antigen receptor (4SCAR) specific for the disialoganglioside GD2 and which includes the CD3zeta chain and the signaling domains of the co-stimulatory molecules CD28, CD137, and CD27 fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunomodulating and antineoplastic activities. Upon intravenous administration of 4SCAR-GD2 T-cells, these cells target the GD2 antigen on tumor cells to induce selective toxicity against GD2-expressing tumor cells. The tumor-associated antigen (TAA) GD2 is overexpressed on the surface of neuroblastoma cells and by other neuroectoderm-derived neoplasms, while it is minimally expressed on normal cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered; this binds to the drug binding FKBP12-F36V domain and activates caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology
C128897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128897>	C67502|C163952	Doxorubicin-loaded EGFR-targeting Nanocells|Doxorubicin-loaded EGFR-targeting Nanocell|EGFR (Vectibix Sequence)-Targeted EnGeneIC Dream Vectors Containing Doxorubicin|EGFR(V)-EDV-Dox|EGFR-targeted EnGeneIC Dream Vectors Containing Doxorubicin	A nanocell formulation targeting the epidermal growth factor receptor (EGFR) using bispecific antibodies (bsAb) against EGFR and containing the antineoplastic anthracycline antibiotic doxorubicin, with potential antineoplastic activity. Upon administration of doxorubicin-loaded EGFR-targeting nanocells, the nanocells are stable in the bloodstream and the anti-EGFR bsAb moiety targets and binds to EGFR-expressing tumor cells. Upon binding, the nanocell allows for specific delivery of doxorubicin to tumor cells overexpressing EGFR. Upon endocytosis by the tumor cells, the nanocell is broken down and releases doxorubicin, which intercalates into DNA and interferes with topoisomerase II activity, thereby inhibiting DNA replication and RNA synthesis. Compared to doxorubicin alone or liposomal doxorubicin, targeted delivery of doxorubicin improves efficacy while lowering the toxicity profile. EGFR, a tyrosine kinase receptor, is overexpressed in many cancer cell types. The nanocell is a bacterially derived nanosphere; the bacterial components are unlikely to induce an immune response in the immunosuppressed tumor microenvironment.	Doxorubicin-loaded EGFR-targeting Nanocells		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C128898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128898>	C1752|C1663	Multi-epitope Anti-folate Receptor Peptide Vaccine TPIV 200|TPIV 200|TPIV 200 Vaccine|TPIV-200|TPIV200|TPIV200/huFR-1	A peptide vaccine containing five immunogenic peptide epitopes of the human folate receptor 1 (FOLR1; FR-alpha), with potential immunomodulating and antineoplastic activities. Upon intradermal administration, multi-epitope anti-folate receptor peptide vaccine TPIV 200 may induce a cytotoxic T-lymphocyte (CTL) response against FR-alpha-overexpressing tumor cells. FR-alpha is a high-affinity folate-binding protein and a member of the folate receptor family; this receptor is overexpressed in various cancer cell types.	Multi-epitope Anti-folate Receptor Peptide Vaccine TPIV 200		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C128899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128899>	C70799	REMS Approval|Risk Evaluation and Mitigation Strategies Approval	The approval of a Risk Evaluation and Mitigation Strategy (REMS) Program.			Activity	FDA Structured Product Labeling Terminology
C12889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12889>	C13058	Auditory System	The organs involved with detecting and processing auditory information, including the pinna, external auditory canal, ear drum, middle ear, and inner ear (including the cochlear organ).	Auditory System		Body System	
C1288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1288>	C387	Recombinant Granulocyte-Macrophage Colony-Stimulating Factor|CSF 39300|CSF 39300/GM-CSF|CSF-GM (Hoechst)|Colony-Stimulating Factor, Granulocyte-Macrophage|GM CSF|GM-CSF|GM-CSF (Schering)|GMCSF|Recombinanr Colony-Stimulating Factor 2|Recombinant Colony-Stimulating Factor 2	A recombinant therapeutic agent which is chemically identical to or similar to the endogenous glycoprotein cytokine growth factor granulocyte-macrophage colony stimulating factor (GM-CSF). Therapeutic GM-CSF induces the clonal expansion and differentiation of progenitor blood cells and stimulates the cytotoxicity of monocytes and neutrophils, thereby restoring immune function and host antitumor immune responses and stimulating engraftment of transplanted bone marrow tissue. (NCI04)			Chemical Viewed Functionally	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology
C128900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128900>	C219644|C172343	IDH1 NM_005896.3:c.395_396inv|IDH c.395_396GT>AC|IDH1 NM_005896.3:c.395_396GT>AC|IDH1 NM_005896.3:c.395_396delGTinsAC|IDH1 NM_005896.3:c.395_396delGTinsAC|IDH1 c.395_396GT>AC|IDH1 c.395_396delGTinsAC|Isocitrate Dehydrogenase 1 (NADP(+)), Cytosolic c.395_396GT>AC|Isocitrate Dehydrogenase 1 (NADP+), Soluble c.395_396GT>AC|NM_005896.3:c.395_396GT>AC|NM_005896.3:c.395_396delGTinsAC|NM_005896.3:c.395_396inv	A complex substitution where the nucleotide sequence at positions 395 and 396 of the coding sequence of the IDH1 gene has changed from thymine-guanine to adenine-cytosine.	IDH1 NM_005896.3:c.395_396delGTinsAC		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128901>	C178120|C132229	Activating RAS Mutation|Activating RAS|Activating RAS Family Gene Mutation|Activating RAS Family Mutation|Activating RAS Gene Mutation	A mutation in a RAS family gene (HRAS, KRAS or NRAS) that causes the encoded GTPase to be resistant to GTP hydrolysis and results in constitutive activation of its activity and downstream pathways.	Activating RAS Mutation		Cell or Molecular Dysfunction	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128902>	C118489	Epstein Barr Nuclear Antigen Antibody|Anti-EBNA Antibody|Anti-Epstein Barr Nuclear Antigen Antibody|Anti-Epstein-Barr Nuclear Antigen Antibody|EBNA Antibody|Epstein-Barr Nuclear Antigen Antibody	Any immunoglobulin that recognizes Epstein-Barr nuclear antigen proteins.	Epstein Barr Nuclear Antigen Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C128903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128903>	C97928	FGFR3 Protein Variant|CD333 Antigen Protein Variant|FGFR-3 Protein Variant|Fibroblast Growth Factor Receptor 3 Protein Variant|Tyrosine Kinase JTK4 Protein Variant	A variation in the amino acid sequence for the fibroblast growth factor receptor 3 protein.	FGFR3 Protein Variant		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128904>	C142132	FGFR3 NM_000142.4:c.742C>T|CD333 c.742C>T|FGFR3 c.742C>T|Fibroblast Growth Factor Receptor 3 c.742C>T|JTK4 c.742C>T|NM_000142.4:c.742C>T	A nucleotide substitution at position 742 of the coding sequence of the FGFR3 gene where cytosine has been mutated to thymine.	FGFR3 NM_000142.4:c.742C>T		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128905>	C128903	FGFR3 NP_000133.1:p.R248C|CD333 Antigen Arg248Cys|CD333 Antigen R248C|FGFR-3 Arg248Cys|FGFR-3 R248C|FGFR-3 p.Arg248Cys|FGFR-3 p.R248C|FGFR3 Arg248Cys|FGFR3 NP_000133.1:p.Arg248Cys|FGFR3 R248C|FGFR3 p.Arg248Cys|FGFR3 p.R248C|Fibroblast Growth Factor Receptor 3 Arg248Cys|Fibroblast Growth Factor Receptor 3 R248C|NP_000133.1:p.Arg248Cys|NP_000133.1:p.R248C|Tyrosine Kinase JTK4 Arg248Cys|Tyrosine Kinase JTK4 R248C	A change in the amino acid residue at position 284 in the fibroblast growth factor receptor 3 protein where arginine has been replaced by cysteine.	FGFR3 NP_000133.1:p.R248C		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128906>	C39877	FGFR3 NM_000142.4:c.1138G>A|CD333 c.1138G>A|FGFR3 c.1138G>A|Fibroblast Growth Factor Receptor 3 c.1138G>A|JTK4 c.1138G>A|NM_000142.4:c.1138G>A	A nucleotide substitution at position 1138 of the coding sequence of the FGFR3 gene where guanine has been mutated to adenine.	FGFR3 NM_000142.4:c.1138G>A		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128907>	C128903	FGFR3 NP_000133.1:p.G380R|CD333 Antigen G380R|CD333 Antigen Gly380Arg|FGFR-3 G380R|FGFR-3 Gly380Arg|FGFR-3 p.G380R|FGFR-3 p.Gly380Arg|FGFR3 G380R|FGFR3 Gly380Arg|FGFR3 NP_000133.1:p.Gly380Arg|FGFR3 p.G380R|FGFR3 p.Gly380Arg|Fibroblast Growth Factor Receptor 3 G380R|Fibroblast Growth Factor Receptor 3 Gly380Arg|NP_000133.1:p.G380R|NP_000133.1:p.Gly380Arg|Tyrosine Kinase JTK4 G380R|Tyrosine Kinase JTK4 Gly380Arg	A change in the amino acid residue at position 380 in the fibroblast growth factor receptor 3 protein where glycine has been replaced by arginine.	FGFR3 NP_000133.1:p.G380R		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128908>	C39877	FGFR3 NM_000142.4:c.1111A>T|CD333 c.1111A>T|FGFR3 c.1111A>T|Fibroblast Growth Factor Receptor 3 c.1111A>T|JTK4 c.1111A>T|NM_000142.4:c.1111A>T	A nucleotide substitution at position 1111 of the coding sequence of the FGFR3 gene where adenine has been mutated to thymine.	FGFR3 NM_000142.4:c.1111A>T		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128909>	C128903	FGFR3 NP_000133.1:p.S371C|CD333 Antigen S371C|CD333 Antigen Ser371Cys|FGFR-3 S371C|FGFR-3 Ser371Cys|FGFR-3 p.S371C|FGFR-3 p.Ser371Cys|FGFR3 NP_000133.1:p.Ser371Cys|FGFR3 S371C|FGFR3 Ser371Cys|FGFR3 p.S371C|FGFR3 p.Ser371Cys|Fibroblast Growth Factor Receptor 3 S371C|Fibroblast Growth Factor Receptor 3 Ser371Cys|NP_000133.1:p.S371C|NP_000133.1:p.Ser371Cys|Tyrosine Kinase JTK4 S371C|Tyrosine Kinase JTK4 Ser371Cys	A change in the amino acid residue at position 371 in the fibroblast growth factor receptor 3 protein where serine has been replaced by cysteine.	FGFR3 NP_000133.1:p.S371C		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12890>	C33966	Falx Cerebri|Cerebral Falx|Falx of Cerebrum	A double-fold of dura mater that lies within the medial longitudinal fissure, and which separates the two cerebral hemispheres. It is attached rostrally to the crista galli and caudally to the surface of the tentorium cerebelli.	Cerebral Falx		Body Part, Organ, or Organ Component	Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C128910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128910>	C142132	FGFR3 NM_000142.4:c.1118A>G|CD333 c.1118A>G|FGFR3 c.1118A>G|Fibroblast Growth Factor Receptor 3 c.1118A>G|JTK4 c.1118A>G|NM_000142.4:c.1118A>G	A nucleotide substitution at position 1118 of the coding sequence of the FGFR3 gene where adenine has been mutated to guanine.	FGFR3 NM_000142.4:c.1118A>G		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128911>	C128903	FGFR3 NP_000133.1:p.Y373C|CD333 Antigen Tyr373Cys|CD333 Antigen Y373C|FGFR-3 Tyr373Cys|FGFR-3 Y373C|FGFR-3 p.Tyr373Cys|FGFR-3 p.Y373C|FGFR3 NP_000133.1:p.Tyr373Cys|FGFR3 Tyr373Cys|FGFR3 Y373C|FGFR3 p.Tyr373Cys|FGFR3 p.Y373C|Fibroblast Growth Factor Receptor 3 Tyr373Cys|Fibroblast Growth Factor Receptor 3 Y373C|NP_000133.1:p.Tyr373Cys|NP_000133.1:p.Y373C|Tyrosine Kinase JTK4 Tyr373Cys|Tyrosine Kinase JTK4 Y373C	A change in the amino acid residue at position 373 in the fibroblast growth factor receptor 3 protein where tyrosine has been replaced by cysteine.	FGFR3 NP_000133.1:p.Y373C		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128912>	C142132	FGFR3 NM_000142.4:c.1108G>T|CD333 c.1108G>T|FGFR3 c.1108G>T|Fibroblast Growth Factor Receptor 3 c.1108G>T|JTK4 c.1108G>T|NM_000142.4:c.1108G>T	A nucleotide substitution at position 1108 of the coding sequence of the FGFR3 gene where guanine has been mutated to thymine.	FGFR3 NM_000142.4:c.1108G>T		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128913>	C128903	FGFR3 NP_000133.1:p.G370C|CD333 Antigen G370C|CD333 Antigen Gly370Cys|FGFR-3 G370C|FGFR-3 Gly370Cys|FGFR-3 p.G370C|FGFR-3 p.Gly370Cys|FGFR3 G370C|FGFR3 Gly370Cys|FGFR3 NP_000133.1:p.Gly370Cys|FGFR3 p.G370C|FGFR3 p.Gly370Cys|Fibroblast Growth Factor Receptor 3 G370C|Fibroblast Growth Factor Receptor 3 Gly370Cys|NP_000133.1:p.G370C|NP_000133.1:p.Gly370Cys|Tyrosine Kinase JTK4 G370C|Tyrosine Kinase JTK4 Gly370Cys	A change in the amino acid residue at position 370 in the fibroblast growth factor receptor 3 protein where glycine has been replaced by cysteine.	FGFR3 NP_000133.1:p.G370C		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128914>	C142132	FGFR3 NM_000142.4:c.746C>G|CD333 c.746C>G|FGFR3 c.746C>G|Fibroblast Growth Factor Receptor 3 c.746C>G|JTK4 c.746C>G|NM_000142.4:c.746C>G	A nucleotide substitution at position 746 of the coding sequence of the FGFR3 gene where cytosine has been mutated to guanine.	FGFR3 NM_000142.4:c.746C>G		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128915>	C128672	GAIA Insufficient Evidence for Diagnosis of Fetal Growth Restriction|Global Alignment of Immunization safety Assessment in pregnancy Insufficient Evidence for Diagnosis of Fetal Growth Restriction|Insufficient Evidence for Fetal Growth Restriction	GAIA Insufficient Evidence for Diagnosis of Fetal Growth Restriction is defined as the absence of an ultrasound for use in the assessment of estimated fetal weight.			Classification	GAIA Fetal Growth Restriction Level of Diagnostic Certainty Terminology|GAIA Terminology
C128916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128916>	C128903	FGFR3 NP_000133.1:p.S249C|CD333 Antigen S249C|CD333 Antigen Ser249Cys|FGFR-3 S249C|FGFR-3 Ser249Cys|FGFR-3 p.S249C|FGFR-3 p.Ser249Cys|FGFR3 NP_000133.1:p.Ser249Cys|FGFR3 S249C|FGFR3 Ser249Cys|FGFR3 p.S249C|FGFR3 p.Ser249Cys|Fibroblast Growth Factor Receptor 3 S249C|Fibroblast Growth Factor Receptor 3 Ser249Cys|NP_000133.1:p.S249C|NP_000133.1:p.Ser249Cys|Tyrosine Kinase JTK4 S249C|Tyrosine Kinase JTK4 Ser249Cys	A change in the amino acid residue at position 249 in the fibroblast growth factor receptor 3 protein where serine has been replaced by cysteine.	FGFR3 NP_000133.1:p.S249C		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128917>	C20130	Annexin Family Protein|Annexin|Annexin Family	A family of proteins that are capable of binding negatively charged phospholipids in a calcium-dependent manner and contain four annexin repeats. This family has been linked with a wide variety of biological processes, including inhibition of phospholipase activity, exocytosis, endocytosis, coagulation, fibrinolysis, the regulation of inflammation and membrane organization.	Annexin Family Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128918>	C16212	Radio Frequency Energy Therapy	A procedure that uses low-level, non-thermal, non-ionizing radio frequency energy (RFE) to create an oscillating magnetic field that blocks the division of cancer cells by inhibiting cancer cell dynamics.	Radio Frequency Energy Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C128919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128919>	C97927|C141240	FLT3 Gene Mutation|CD135 Gene Mutation|FLK2 Gene Mutation|FLT3|FLT3 Gene Mutant|FLT3 Mutation|FLT3 Mutation|FMS-Related Tyrosine Kinase 3 Gene Mutation	A change in the nucleotide sequence of the FLT3 gene.	FLT3 Gene Mutation		Cell or Molecular Dysfunction	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C12891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12891>	C33969	Central Canal of Spinal Cord|Central Canal|Central Canal of the Spinal Cord|central canal of spinal cord	The hollow tube filled with cerebrospinal fluid that begins in the inferior portion of the fourth ventricle and runs the entire length of the spinal.	Central Canal of Spinal Cord		Body Space or Junction	UBERON Terminology
C128920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128920>	C97928	FLT3 Protein Variant|CD135 Antigen Protein Variant|Fetal Liver Kinase-2 Protein Variant|Flt-3 Receptor Protein Variant|Fms-Related Tyrosine Kinase 3 Protein Variant|Receptor-Type Tyrosine-Protein Kinase FLT3 Protein Variant|Stem Cell Tyrosine Kinase 1 Protein Variant	A variation in the amino acid sequence for the receptor-type tyrosine-protein kinase FLT3 protein.	FLT3 Protein Variant		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C128921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128921>	C128920	FLT3 NP_004110.2:p.D835X|CD135 Antigen Asp835Xxx|CD135 Antigen D835X|D835|D835X|FLT3 Asp835 Mutation|FLT3 Asp835Xxx|FLT3 D835 Mutation|FLT3 D835X|FLT3 NP_004110.2:p.Asp835Xxx|FLT3 p.Asp835Xxx|FLT3 p.D835X|FLT3-D835|FLT3-TKD/D835 Mutation|Fetal Liver Kinase-2 Asp835Xxx|Fetal Liver Kinase-2 D835X|Flt-3 Receptor Asp835Xxx|Flt-3 Receptor D835X|Fms-Related Tyrosine Kinase 3 Asp835Xxx|Fms-Related Tyrosine Kinase 3 D835X|NP_004110.2:p.Asp835Xxx|NP_004110.2:p.D835X|Receptor-Type Tyrosine-Protein Kinase FLT3 Asp835Xxx|Receptor-Type Tyrosine-Protein Kinase FLT3 D835X|Stem Cell Tyrosine Kinase 1 Asp835Xxx|Stem Cell Tyrosine Kinase 1 D835X	A change in the amino acid residue at position 835 in the receptor-type tyrosine-protein kinase FLT3 protein where asparagine has been replaced by another amino acid.	FLT3 NP_004110.2:p.D835X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128922>	C51678|C51586|C201559	High Resolution Anoscopy with Biopsy|High Resolution Anoscopy-Monitored Biopsy	A procedure that uses a rigid, tubular anoscope along with a high resolution colposcope to examine the anal canal for abnormalities and to recover tissue samples.	High Resolution Anoscopy with Biopsy		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C128923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128923>	C212859	EBF1/PDGFRB Fusion Gene|EBF-PDGFRB Fusion Gene|EBF/PDGFRB Fusion Gene|EBF1-PDGFRB Fusion Gene|EBF1::PDGFRB Fusion Gene|Early B-Cell Factor 1/Platelet Derived Growth Factor Receptor Beta Fusion Gene	A fusion gene resulting from a rearrangement of the q arm of chromosome 5 that fuses the first 15 exons of the EBF1 gene to exon 11 of the PDGFRB gene. This fusion may be associated with Ph-like acute lymphoblastic leukemia.	EBF1/PDGFRB Fusion Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128924>	C213261	EBF1/PDGFRB Fusion Protein|EBF1-PDGFRB Fusion Protein|EBF1::PDGFRB Fusion Protein|Transcription Factor COE1/Beta-Type Platelet-Derived Growth Factor Receptor Fusion Protein|Transcription Factor COE1/PDGFR-Beta Fusion Protein|Transcription Factor COE1/Platelet-Derived Growth Factor Receptor Beta Fusion Protein	A fusion protein encoded by the EBF1/PDGFRB fusion gene. This protein is comprised of the first 600 amino acids of transcription factor COE1, including the DNA binding domain, fused to the C-terminal transmembrane and cytoplasmic domains of the platelet-derived growth factor receptor beta protein, including the protein kinase domain.	EBF1/PDGFRB Fusion Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128925>	C78275	Ethylene-vinyl Alcohol Copolymer-based Embolic Agent|EVOH-based Embolic Agent|Onyx	A non-adhesive, non-absorbable, permanent liquid embolic agent comprised of ethylene vinyl alcohol (EVOH) copolymer dissolved in dimethyl sulfoxide (DMSO), and of micronized tantalum powder that can be used to occlude blood vessels. Upon administration of the EVOH-based embolic agent, contact with fluids, such as blood, induces the solidification of EVOH into a sponge-like material. This causes occlusion of blood vessels and prevents blood flow to the treated area.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C128926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128926>	C16615	DLX5 Gene|DLX5|DLX5|Distal-Less Homeobox 5 Gene	This gene is involved in osteoblast differentiation.	DLX5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C128927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128927>	C128926	DLX5 wt Allele|Distal-Less Homeo Box 5 Gene|Distal-Less Homeobox 5 wt Allele|SHFM1D|Split Hand/Foot Malformation Type 1 With Sensorineural Hearing Loss Gene	Human DLX5 wild-type allele is located in the vicinity of 7q21.3 and is approximately 5 kb in length. This allele, which encodes homeobox protein DLX-5, plays a role in transcriptional activation that is essential for osteoblast differentiation. Mutation of the gene is associated with split-hand/foot malformation 1 with sensorineural hearing loss.	DLX5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128928>	C17207	Homeobox Protein DLX-5|DLX5	Homeobox protein DLX-5 (289 aa, ~32 kDa) is encoded by the human DLX5 gene. This protein is involved in the positive regulation of osteoblast differentiation.	Homeobox Protein DLX-5		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128929>	C80699	MIR551A Gene|MIR551A|MIR551A|MicroRNA 551a Gene	This gene plays a role in the inhibition of target gene expression.	MIR551A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C12892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12892>	C33969	Cervical Spinal Cord|Cervical Portion of Spinal Cord|Cervical cord|Cervical spinal cord structure (body structure)|SPINAL CORD, CERVICAL|cervical spinal cord	The portion of the spinal cord located in the cervical region.	Cervical Spinal Cord		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF7 Pathology Review Table|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C128930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128930>	C128929	MIR551A wt Allele|MIRN551A|Micro RNA 551A Gene|MicroRNA 551a wt Allele|hsa-miR-551a|miR-551a|miRNA155A	Human MIR551A wild-type allele is located in the vicinity of 1p36.32 and is 96 bases in length. This allele, which encodes MIR551A pre-miRNA, is involved in the negative regulation of gene expression.	MIR551A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128931>	C25968	MIR551A Pre-miRNA	MIR551A pre-miRNA (96 bases) is encoded by the human MIR551A gene. This oligoribonucleotide may play a role in transcriptional silencing.	MIR551A Pre-miRNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128932>	C18004	Derkay Staging System	A staging system for assessment of recurrent respiratory papillomatosis (RRP). The staging system includes a functional assessment of severity as well as an anatomic assessment of disease distribution. The anatomic score can then be used in combination with the functional assessment to measure an individual patient's clinical course and response to therapy over time.			Classification	
C128933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128933>	C213867	HLA Mismatch Count|HLAMSC	The determination of the total number of mismatches between the study subject and his or her donor for the human leukocyte antigens (HLA).			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128934>	C21295	NELL1 Gene|NELL1|NELL1|Neural EGFL Like 1 Gene	This gene is involved in the positive regulation of osteoblast differentiation.	NELL1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C128935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128935>	C128934	NELL1 wt Allele|IDH3GL|NEL-Like 1 (Chicken) Gene|NEL-Like 1 Gene|NRP1|Nel (Chicken)-Like Gene|Neural EGFL Like 1 wt Allele	Human NELL1 wild-type allele is located in the vicinity of 11p15.1 and is approximately 906 kb in length. This allele, which encodes protein kinase C-binding protein NELL1, plays a role in bone mineralization.	NELL1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128936>	C17728	Protein Kinase C-Binding Protein NELL1|NEL-Like Protein 1|Nel-Related Protein 1|Neural Epidermal Growth Factor-Like 1	Protein kinase C-binding protein NELL1 (810 aa, ~90 kDa) is encoded by the human NELL1 gene. This protein is involved in the modulation of osteoblast cell growth and differentiation.	Protein Kinase C-Binding Protein NELL1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128937>	C16352	African American|AFRICAN AMERICAN|Afro American|Afro-American	Denotes a person of African ancestral origins whose family settled in America.			Population Group	CDISC CDASH Terminology|CDISC SDTM Collected Race Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128938>	C16352	Black|BLACK|Black Populations	A person having origins in the original peoples of sub-Saharan Africa or the Caribbean.			Population Group	CDISC CDASH Terminology|CDISC SDTM Collected Race Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12893>	C12791	Cervical Spinal Nerve Root|Cervical Spinal Nerve Roots	The initial segment of a nerve leaving the cervical spine. There are eight pairs of cervical roots, each consisting of two parts: the ventral (efferent motor) and the dorsal (afferent sensory) root which unite to form a single spinal nerve. All cervical nerves exit superiorly to their corresponding vertebrae with the exception of C8, which exits inferiorly to the C7 vertebra.	Cervical Spinal Nerve Root		Body Part, Organ, or Organ Component	
C128940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128940>	C16502	Radiographic Examination|RADIOGRAPHY|Radiographic Exam|Radiographic examination|Radiography	A radiographic procedure using the emission of penetrating energy waves to form an image of the structure penetrated by the radiation.	Radiographic Examination|Radiography		Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Age Estimation Method Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C128941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128941>	C158414	MT-CO1 Gene|MT-CO1|MT-CO1|Mitochondrially Encoded Cytochrome C Oxidase I Gene	This gene plays a role in oxidative phosphorylation.	MT-CO1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C128942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128942>	C128941	MT-CO1 wt Allele|COI|COX1|COXI|Complex IV, Cytochrome c Oxidase Subunit I Gene|MTCO1|Mitochondrially Encoded Cytochrome C Oxidase I wt Allele	Human MT-CO1 wild-type allele is located within the circular mitochondrial (MT) chromosome and is approximately 1 kb in length. This allele, which encodes cytochrome c oxidase subunit 1, is involved in positive regulation of the mitochondrial electron transport chain. Allelic variation of the gene is associated with Leber hereditary optic neuropathy (LHON). Mutation of the gene is associated with mitochondrial complex IV deficiency (MT-C4D), recurrent mitochondrial myoglobinuria, and mitochondrially inherited nonsyndromic sensorineural deafness. Mutations may also be associated with colorectal cancer.	MT-CO1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128943>	C158419	Cytochrome C Oxidase Subunit 1|COX Complex IV Subunit I|COX1|Cytochrome C Oxidase I|Cytochrome C Oxidase Polypeptide I|Cytochrome C Oxidase Subunit I|EC 1.9.3.1, Formerly|EC 7.1.1.9|MT-CO1	Cytochrome c oxidase subunit 1 (513 aa, ~57 kDa) is encoded by the human MT-CO1 gene. This protein plays a role in the final step of oxidative phosphorylation in the mitochondrion.	Cytochrome C Oxidase Subunit 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128944>	C20194	IFT88 Gene|IFT88|IFT88|Intraflagellar Transport 88 Gene	This gene is involved in cilium morphology and autophagy.	IFT88 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C128945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128945>	C128944	IFT88 wt Allele|D13S1056E|DAF19|DAF19, C. elegans, Homolog of Gene|Intraflagellar Transport 88 Homolog (Chlamydomonas) Gene|Intraflagellar Transport 88 Homolog Gene|Intraflagellar Transport 88 wt Allele|MGC26259|Polaris Homolog Gene|Polaris, Mouse, Homolog of Gene|Probe HTg737 (Polycystic Kidney Disease, Autosomal Recessive) Gene|TG737|TG737, Mouse, Homolog of Gene|TTC10|hTg737	Human IFT88 wild-type allele is located in the vicinity of 13q12.1 and is approximately 125 kb in length. This allele, which encodes intraflagellar transport protein 88 homolog, plays a role in the assembly of both cilia and autophagosomes.	IFT88 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128946>	C18466	Intraflagellar Transport Protein 88 Homolog|IFT88|Recessive Polycystic Kidney Disease Protein Tg737 Homolog|TPR Repeat Protein 10|Testicular Tissue Protein Li 93|Tetratricopeptide Repeat Domain 10|Tetratricopeptide Repeat Protein 10	Intraflagellar transport protein 88 homolog (833 aa, ~94 kDa) is encoded by the human IFT88 gene. This protein is involved in cilium and autophagosome assembly.	Intraflagellar Transport Protein 88 Homolog		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C128947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128947>	C41604|C25625	Specimen Isolation|ISOLATING	The act of separating a sub-component from the original collected specimen.			Laboratory Procedure	CDISC SDTM Biospecimen Events Dictionary Derived Term Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128948>	C42614	Name of Fixative|FIXNAM|Fixative Name|Fixative Name	The name of the compound that preserves tissues and cells for microscopic study.			Conceptual Entity	CDISC SDTM Biospecimen Characteristics Test Code Terminology|CDISC SDTM Biospecimen Characteristics Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128949>	C85504	Kirchner Growth Medium|KIRCHNER MEDIUM	A liquid growth medium mainly consisting of sodium dihydrogen phosphate, potassium dihydrogen phosphate, magnesium sulphate, trisodium citrate, L-asparagine and phenol red, which is developed for the culture and recovery of Mycobacteria.			Indicator, Reagent, or Diagnostic Aid	CDISC SDTM Culture Medium Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12894>	C33969	Thoracic Spinal Cord|SPINAL CORD, THORACIC|Thoracic Portion of Spinal Cord|Thoracic spinal cord structure (body structure)|thoracic spinal cord	The portion of the spinal cord located in the thoracic region.	Thoracic Spinal Cord		Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C128950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128950>	C85504	MB Redox Broth Growth Medium|MB REDOX BROTH	A liquid and selective growth medium that is modified based on the Kirchner medium by the addition of a mixture of antimicrobial agents (typically polymyxin B, amphotericin B, carbenicillin, and trimethoprim) and colorless tetrazolium salt as a growth indicator, which is developed for the cultivation of mycobacterium.			Indicator, Reagent, or Diagnostic Aid	CDISC SDTM Culture Medium Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128951>	C116210	B-lymphocyte Crossmatch Measurement|B-lymphocyte Crossmatch|B-lymphocyte Crossmatch|BLYMXM	The determination of the HLA histocompatibility between the donor and the study subject by examining the presence or absence of the subject's anti-HLA antibody reactivity towards HLA antigens expressed on the donor B-lymphocytes.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128952>	C81867|C186057	Chemokine (C-X-C Motif) Ligand 1 Measurement|CXCL1|Chemokine (C-X-C Motif) Ligand 1|Chemokine (C-X-C Motif) Ligand 1|GRO Alpha|GRO/KC|GRO1|GROA|Growth-Regulated Alpha Protein|Melanoma Growth Stimulating Activity, Alpha	The determination of the amount of chemokine (C-X-C motif) ligand 1 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128953>	C128964	HLA-A23 Antibody Measurement	The determination of the amount of HLA-A23 antibody present in a sample.			Laboratory Procedure	
C128954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128954>	C128964	HLA-A2 Antibody Measurement	The determination of the amount of HLA-A2 antibody present in a sample.			Laboratory Procedure	
C128955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128955>	C71329	HLA-A Antigen Type|HLAAAGT	The determination of the amount of human leukocyte antigen, class I, group A (HLA-A), present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128956>	C128933	HLA-A Mismatch Count|HLAAMSC	The determination of the number of mismatch between the study subject and his or her donor for the human leukocyte antigen, class I, group A (HLA-A).			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128957>	C71329	HLA-B Antigen Type|HLABAGT	The determination of the amount of human leukocyte antigen, class I, group B (HLA-B), present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128958>	C128933	HLA-B Mismatch Count|HLABMSC	The determination of the number of mismatch between the study subject and his or her donor for the human leukocyte antigen, class I, group B (HLA-B).			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128959>	C128965	HLA-DR51 Antibody Measurement	The determination of the amount of HLA-DR51 antibody present in a sample.			Laboratory Procedure	
C12895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12895>	C33969	Lumbar Spinal Cord|Lumbar Portion of Spinal Cord|Lumbar spinal cord structure (body structure)|SPINAL CORD, LUMBAR|lumbar spinal cord	The portion of the spinal cord located in the lumbar region.	Lumbar Spinal Cord		Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C128960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128960>	C128965	HLA-DR52 Antibody Measurement	The determination of the amount of HLA-DR52 antibody present in a sample.			Laboratory Procedure	
C128961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128961>	C128965	HLA-DR53 Antibody Measurement	The determination of the amount of HLA-DR53 antibody present in a sample.			Laboratory Procedure	
C128962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128962>	C71329	HLA-DR Antigen Type|HLADRAGT	The determination of the amount of human leukocyte antigen, class II, antigen-D-related (HLA-DR), present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128963>	C128933	HLA-DR Mismatch Count|HLADRMSC	The determination of the number of mismatch between the study subject and his or her donor for the human leukocyte antigen, class II, antigen-D-related (HLA-DR).			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128964>	C210735|C210010	HLA Class I Antibody Measurement	The determination of the amount of HLA class I antibody present in a sample.			Laboratory Procedure	
C128965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128965>	C210735|C210010	HLA Class II Antibody Measurement	The determination of the amount of HLA class II antibody present in a sample.			Laboratory Procedure	
C128966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128966>	C128965|C116210	HLA Class II Panel Reactive Antibody Measurement|HLA Class II Panel Reactive Antibody|HLA Class II Panel Reactive Antibody|HLAIIPRA	The determination of the amount of human leukocyte antigen (HLA) class II panel reactive antibody present in a sample.			Laboratory Procedure	CDISC SDTM Immunogenicity Specimen Assessments Test Code Terminology|CDISC SDTM Immunogenicity Specimen Assessments Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128967>	C128964|C116210	HLA Class I Panel Reactive Antibody Measurement|HLA Class I Panel Reactive Antibody|HLA Class I Panel Reactive Antibody|HLAIPRA	The determination of the amount of human leukocyte antigen (HLA) class I panel reactive antibody present in a sample.			Laboratory Procedure	CDISC SDTM Immunogenicity Specimen Assessments Test Code Terminology|CDISC SDTM Immunogenicity Specimen Assessments Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128968>	C165773	Insulin-Like Growth Factor Binding Protein 1 Measurement|IGFBP1|IGFBP1 Measurement|Insulin-Like Growth Factor Binding Prot1|Insulin-Like Growth Factor Binding Prot1|Insulin-Like Growth Factor Binding Protein 1	The determination of the amount of insulin-like growth factor binding protein 1 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128969>	C165773	Insulin-Like Growth Factor Binding Protein 2 Measurement|IGFBP2|IGFBP2 Measurement|Insulin-Like Growth Factor Binding Prot2|Insulin-Like Growth Factor Binding Prot2|Insulin-Like Growth Factor Binding Protein 2	The determination of the amount of insulin-like growth factor binding protein 2 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12896>	C33969	Sacral Spinal Cord|SPINAL CORD, SACRAL|Sacral spinal cord structure (body structure)	The portion of the spinal cord located in the sacral region.	Sacral Spinal Cord		Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C128970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128970>	C74804	Interleukin 12+23 p40 Measurement|IL122340|Interleukin 12+23 p40|Interleukin 12+23 p40	The determination of the amount of interleukin 12+23 p40 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128971>	C67208	Metarubricyte to Total Cell Ratio Measurement|METARBCE|Metarubricyte/Total Cells|Metarubricyte/Total Cells|Metarubricytes to Total Cells Ratio Measurement	The determination of the ratio of the metarubricytes compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128972>	C28133	Metarubricyte Count|Acidophilic Erythroblast|METARUB|Metarubricyte|Metarubricyte|Orthochromatophilic Normoblast|Orthochromic Erythroblast|Orthochromic Normoblast	The determination of the amount of metarubricytes present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128973>	C64430	Procollagen 3 N-Terminal Propeptide Measurement|N-Terminal Type III Collagen Propeptide|P3NP|P3NP Measurement|PIIINP|Procollagen 3 N-Terminal Propeptide|Procollagen 3 N-Terminal Propeptide	The determination of the amount of procollagen 3 N-terminal propeptide present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128974>	C28133	Plasma Cell Count|PC|PLSTCE|Plasma Cells|Total Plasma Cells|Total Plasma Cells	The determination of the amount of plasma cells present in a sample.			Laboratory Procedure	CDISC SDTM Cell Phenotyping Test Code Terminology|CDISC SDTM Cell Phenotyping Test Name Terminology|CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128975>	C67208	Plasma Cells to Leukocytes Ratio Measurement|PCLE|PLSTCELE|Plasma Cell to Leukocyte Ratio Measurement|Plasma Cells/Leuk|Plasma Cells/Leuk|Total Plasma Cells/Leukocytes|Total Plasma Cells/Leukocytes	The determination of the ratio of the plasma cells compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Cell Phenotyping Test Code Terminology|CDISC SDTM Cell Phenotyping Test Name Terminology|CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128976>	C28133	Prorubricyte Count|Basophilic Erythroblast|Basophilic Normoblast|PRORUB|Prorubricyte|Prorubricyte	The determination of the amount of prorubricytes present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128977>	C67208	Prorubricyte to Total Cell Ratio Measurement|PRORUBCE|Prorubricyte/Total Cells|Prorubricyte/Total Cells|Prorubricytes to Total Cells Ratio Measurement	The determination of the ratio of the prorubricytes compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128978>	C28133	Rubricyte Count|Polychromatophilic Erythroblast|Polychromatophilic Normoblast|RUB|Rubricyte|Rubricyte	The determination of the amount of rubricytes present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128979>	C116210	T-lymphocyte Crossmatch Measurement|T-lymphocyte Crossmatch|T-lymphocyte Crossmatch|TLYMXM	The determination of the HLA histocompatibility between the donor and the study subject by examining the presence or absence of the subject's anti-HLA antibody reactivity towards HLA antigens expressed on the donor T-lymphocytes.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C12897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12897>	C49346	Oculomotor Nucleus	A collection of neurons of cranial nerve III located in the rostral half of the midbrain at the level of the superior colliculus, which contain somatic efferent motor neurons that innervate all the extraocular muscles except the superior oblique and lateral rectus.	Oculomotor Nucleus		Body Part, Organ, or Organ Component	
C128980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128980>	C64430	Free Testosterone to Total Protein Ratio Measurement|TSTSFRPT|Testosterone, Free/Total Protein|Testosterone, Free/Total Protein	The determination of the ratio of free testosterone compared to total protein present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128981>	C198305	Acid-Fast Bacilli Measurement|AFB|Acid-Fast Bacilli|Acid-Fast Bacilli	The determination of the amount of acid-fast bacilli present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128982>	C49188	Mycobacterium Tuberculosis Measurement|MTB|Mycobacterium tuberculosis|Mycobacterium tuberculosis	The determination of the amount of mycobacterium tuberculosis present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128983>	C49188	Mycobacterium tuberculosis Complex Measurement|MTBCMPLX|Mycobacterium tuberculosis Complex|Mycobacterium tuberculosis Complex	The determination of the amount of mycobacterium tuberculosis complex present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128984>	C23044	Papanicolaou Staining Method|PAP STAIN|PAP Stain|Papanicolau Stain	A microscopy staining method that utilizes a mixture of dyes including hematoxylin, orange G (OG), and eosin azure, which contains variable portions of Eosin Y, light green SF yellowish, and Bismarck brown Y. This multichromatic staining method is used to differentially stain samples containing mixed cell populations.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C128985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128985>	C116117	Minimum Inhibitory Concentration Test|MIC|Minimum Inhibitory Concentration|Minimum Inhibitory Concentration	A laboratory test to determine the lowest concentration of a substance that will inhibit a biological or biochemical function, such as microorganism growth or enzymatic activity.			Laboratory Procedure	CDISC SDTM Microbiology Susceptibility Test Code Terminology|CDISC SDTM Microbiology Susceptibility Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128986>	C25338	Sharp Genant Bone Erosion Score|SGBESCR|Sharp/Genant Bone Erosion Score|Sharp/Genant Bone Erosion Score	The numerical value that represents the result of a clinical assessment of bone erosion based on the Genant modification of the Sharp Joint Erosion Assessment (Genant HK. Methods of assessing radiographic change in rheumatoid arthritis. Am J Med. 1983 Dec 30;75(6A):35-47).			Quantitative Concept	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128987>	C25338	Sharp Genant Joint Space Narrowing Score|SGJSNSCR|Sharp/Genant JSN Score|Sharp/Genant JSN Score	The numerical value that represents the result of a clinical assessment of joint space narrowing based on the Genant modification of the Sharp Joint Space Narrowing Assessment (Genant HK. Methods of assessing radiographic change in rheumatoid arthritis. Am J Med. 1983 Dec 30;75(6A):35-47).			Quantitative Concept	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128988>	C25338	Sharp van der Heijde Bone Erosion Score|SVBESCR|Sharp/Van der Heijde Bone Erosion Score|Sharp/Van der Heijde Bone Erosion Score	The numerical value that represents the result of a clinical assessment of bone erosion based on the Van der Heijde modification of the Sharp Joint Erosion Assessment (Van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, van de Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;1:1036-8).			Quantitative Concept	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128989>	C25338	Sharp van der Heijde Joint Space Narrowing Score|SVJSNSCR|Sharp/Van der Heijde JSN Score|Sharp/Van der Heijde JSN Score	The numerical value that represents the result of a clinical assessment of joint space narrowing based on the Van der Heijde modification of the Sharp Joint Space Narrowing Assessment (Van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, van de Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;1:1036-8).			Quantitative Concept	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12898>	C49346	Facial Nerve Nucleus|Facial Nucleus	A collection of cell bodies of cranial nerve VII found in the brainstem. There are three nuclei with distinct functions: the facial motor nucleus, which sends muscular efferent nerves to the muscles of facial expression and the stapedius; the superior salivary nucleus, which sends visceral parasympathetic efferent nerves mostly to the lacrimal and salivary glands; and the geniculate ganglion, which receives mostly afferent nerves for taste sensation.	Facial Nerve Nucleus		Body Part, Organ, or Organ Component	
C128990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128990>	C125932	Supplement to Farooqui CLL 2014 Oncology Response Criteria|FAROOQUI SUPP CLL 2014				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128991>	C16352	Black Central American|BLACK CENTRAL AMERICAN	Denotes a person of African ancestral origins whose family settled in Central America.			Population Group	CDISC CDASH Terminology|CDISC SDTM Collected Race Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128992>	C16352	Black South American|BLACK SOUTH AMERICAN	Denotes a person of African ancestral origins whose family settled in South America.			Population Group	CDISC CDASH Terminology|CDISC SDTM Collected Race Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128993>	C41261	White Central American|WHITE CENTRAL AMERICAN	A person having origins in the any of the countries of Central America who identifies as white.			Population Group	CDISC CDASH Terminology|CDISC SDTM Collected Race Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128994>	C41261	White South American|WHITE SOUTH AMERICAN	A person having origins in the any of the countries of South America who identifies as white.			Population Group	CDISC CDASH Terminology|CDISC SDTM Collected Race Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128995>	C38114	Intrathalamic Route of Administration|INTRATHALAMIC	Administration within the thalamus.			Functional Concept	CDISC SDTM Route of Administration Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128996>	C38114	Intravaginal Route of Administration|INTRAVAGINAL	Administration within the vagina.			Functional Concept	CDISC SDTM Route of Administration Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C128997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128997>	C38114	Suprachoroidal Route of Administration|SUPRACHOROIDAL|Suprachoroidal|Suprachoroidal uses	Administration above the choroid.		Concept_Pending_Approval	Functional Concept	CDISC SDTM Route of Administration Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|EDQM Health Care Terminology|EDQM-HC Routes and Methods of Administration Terminology|FDA Structured Product Labeling Terminology|SPL Drug Route of Administration Terminology
C128998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128998>	C18058	Partial Response with Lymphocytosis|PR WITH LYMPHOCYTOSIS|PR-L|PRL	A decrease in the size and extent of tissue involvement by cancer, accompanied by an increase in blood lymphocyte count above a predetermined threshold.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C128999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128999>	C70714	Concentrated Specimen|CONCENTRATED	A specimen that has been concentrated, that is whose volume has decreased and density has increased.			Qualitative Concept	CDISC SDTM Specimen Condition Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12899>	C49346	Nucleus of the Hypoglossal Nerve|Hypoglossal Nucleus	A motor nucleus within the medulla oblongata with axons projecting to the tongue muscles.	Hypoglossal Nucleus		Anatomical Structure	
C1289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1289>	C1592	Recombinant Interleukin-8|Anionic Neutrophil Activating Peptide|Anionic Neutrophil-Activating Peptide|CXCL8|GCP-IL-8|Granulocyte Chemotactic Peptide Interleukin 8|IL-8|Interleukin-8|Leukocyte Adhesion Inhibitor|MDNCF|Macrophage-Derived Chemotactic Factor|Monocyte-Derived Neutrophil Chemotactic Factor|Monocyte-Derived Neutrophil-Activating Peptide|NAP-1|Neutrophil Activation Factor|Neutrophil Activation Peptide|Neutrophil Chemotactic Factor	A member of the CXC chemokine family. This chemokine is one of the major mediators of the inflammatory response. This chemokine is secreted by several cell types including monocytes, macrophages, T-lymphocytes, fibroblasts, endothelial cells, and keratinocytes. It functions as a chemoattractant, and is also a potent angiogenic factor. (from LocusLink)			Chemical Viewed Functionally	
C129000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129000>	C16084	Patient Registry Study|PATIENT REGISTRY	Observational studies which include an organized system that uses observational methods to collect uniform data (clinical and other) prospectively for a population defined by a particular disorder/disease, condition (including susceptibility to a disorder), or exposure (including products, health care services, and/or procedures) and that serves a predetermined scientific, clinical, or policy purpose. Patient registries may be single purpose or on-going data collection programs that address one or more questions. (AHRQ)	Patient Registry Study		Research Activity	CDISC SDTM Study Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C129001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129001>	C39421	Pharmacogenetic Study|PHARMACOGENETIC	A study that assesses variation in DNA sequence, usually within a single gene, and its effect on drug response.			Research Activity	CDISC SDTM Terminology|CDISC SDTM Trial Type Terminology|Clinical Data Interchange Standards Consortium Terminology
C129002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129002>	C48572	Beam Break Unit|BEAM BREAKS|{BEAM BREAKS}|{BEAM BREAKS}	The unit of measure for the number of times in which light paths are interrupted by movement.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C129003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129003>	C90384	Qualitative Food Consumption|FCQUAL|Food Consumption, Qualitative|Food Consumption, Qualitative|QUALITATIVE FOOD CONSUMPTION	An evaluation of food consumption that is primarily descriptive and interpretative, and may or may not lend itself to quantification			Activity	CDISC SEND Category for Clinical Observation Terminology|CDISC SEND Food and Water Consumption Test Code Terminology|CDISC SEND Food and Water Consumption Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C129004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129004>	C35867	Increased Mucification Present|MUCIFICATION, INCREASED	A finding indicating an increase in the numbers of epithelial cells that have been transformed into mucus-secreting cells. This does not include the normal increase in mucification seen in the estrous cycle.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C129005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129005>	C19697	Lung/Bronchus/Trachea/Larynx|LUNG/BRONCHUS/TRACHEA/LARYNX	A laboratory specimen consisting of the lungs, bronchus, trachea, and larynx.			Tissue	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C129006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129006>	C67208	Rubricyte to Total Cell Ratio Measurement|RUBCE|Rubricyte/Total Cells|Rubricyte/Total Cells|Rubricytes to Total Cells Ratio Measurement	The determination of the ratio of the rubricytes compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C129007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129007>	C709	3-Hydroxy-3-Methylglutaryl-Coenzyme A|(3S)-3-Hydroxy-3-Methylglutaryl-CoA|(S)-3-Hydroxy-3-Methylglutaryl-Coenzyme A|3-Hydroxy-3-Methylglutaryl-CoA|HMG-CoA|HMG-Coenzyme A|Hydroxymethylglutaroyl Coenzyme A|Hydroxymethylglutaryl-CoA|S-(Hydrogen 3-Hydroxy-3-Methylglutaryl)Coenzyme A|S-(Hydrogen 3-Hydroxy-3-Methylpentanedioate) Coenzyme A	An intermediate for the synthesis of mevalonic acid, ketone bodies and cholesterol and a metabolic product for leucine; it can be formed de novo from acetyl coenzyme A (CoA) and acetoacetyl CoA by HMG-CoA (3-Hydroxy-3-Methylglutaryl-Coenzyme A) synthase.	3-Hydroxy-3-Methylglutaryl-Coenzyme A		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology
C129008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129008>	C707	5-Methylcytosine|5-METHYLCYTOSINE	A methylated form of the nucleobase cytosine occurring predominantly in cytosine-phosphate-guanine (CpG) islands that are produced by DNA methyltransferases and may regulate gene expression. Like cytosine, the DNA sequence containing 5-methylcytosine (5-mC) is able to be replicated without error and 5-mC can pair with guanine in double stranded DNA. However, DNA sequences containing a high local concentration of 5-mC may be less transcriptionally active than areas with higher ratios of unmodified cytosine.	5-Methylcytosine		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C129009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129009>	C608	Leukotriene E4|(5S,6R,7E,9E,11Z,14Z)-6-(2-Amino-2-Carboxyethyl)Sulfanyl-5-Hydroxyicosa-7,9,11,14-Tetraenoic Acid|(5S-(5R*,6S*(S*),7E,9E,11Z,14Z))-6-((2-Amino-2-Carboxyethyl)Thio)-5-Hydroxy-7,9,11,14-Eicosatetraenoic Acid|(7E,9E,11Z,14Z)-(5S,6R)-6-(Cystein-S-yl)-5-Hydroxyeicosa-7,9,11,14-Tetraenoate|(7E,9E,11Z,14Z)-(5S,6R)-6-(Cystein-S-yl)-5-Hydroxyicosa-7,9,11,14-Tetraenoate|5S-Hydroxy,6R-(S-Cysteinyl),7E,9E,11Z,14Z-Eicosatetraenoic Acid|7,9,11,14-Eicosatetraenoic Acid, 6-((2-Amino-2-Carboxyethyl)Thio)-5-Hydroxy-, (5S-(5R*,6S*(S*),7E,9E,11Z,14Z))-|LEUKOTRIENE E4|LTE4|Leukotriene E(4)|S-{(1R,2E,4E,6Z,9Z)-1-[(1S)-4-Carboxy-1-Hydroxybutyl]Pentadeca-2,4,6,9-Tetraen-1-yl}-L-Cysteine	The final and most stable product of the pathway where 5-lipoxygenase converts arachidonic acid to cysteinyl leukotrienes, with inflammatory activity. Because of its inherent stability, leukotriene E4 is used as a marker for leukotriene production.	Leukotriene E4		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C12900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12900>	C32301	Posterior Chamber of the Eye|EYE, POSTERIOR CHAMBER|Eye, Posterior Compartment|Posterior Chamber (Eye)|Posterior Chamber of Eye	A space within the eye located between the iris and the lens. It is filled with aqueous humor.	Posterior Chamber of Eye		Body Space or Junction	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C129010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129010>	C1916	Neopterin|2-Amino-6-(1,2,3-Trihydroxypropyl)-4(3H)-Pteridinone|4(1H)-Pteridinone, 2-Amino-6-(1,2,3-Trihydroxypropyl)-|NEOPTERIN	A pteridine that is a metabolite of guanine triphosphate (GTP) and a precursor for biopterin. Neopterin is released from interferon-gamma (IFNg) stimulated macrophages and dendritic cells (DCs); therefore, urine or serum levels may be used as a marker of immune system activation.	Neopterin		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C129011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129011>	C759	Putrescine|1,4-Butanediamine|1,4-Butylenediamine|1,4-Diaminobutane|1,4-Tetramethylenediamine|Butane-1,4-Diamine|PUTRESCINE|Tetramethylenediamine	A four carbon diamine produced during tissue decomposition by the decarboxylation of amino acids. Polyamines, including putrescine, may act as growth factors that promote cell division; however, putrescine is toxic at high doses.	Putrescine		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C129012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129012>	C759	Spermidine|1,4-Butanediamine, N-(3-Aminopropyl)-|1,4-Butanediamine, N1-(3-Aminopropyl)-|1,4-Diaminobutane, N-(3-Aminopropyl)-|1,5,10-Triazadecane|4-Azaoctamethylenediamine|4-Azaoctane-1,8-Diamine|N-(3-Aminopropyl)-1,4-Butane-Diamine|SPERMIDINE	A polyamine derived from putrescine that is involved in many biological processes, including the regulation of membrane potential, the inhibition of nitric oxide synthase (NOS) and the induction of autophagy.	Spermidine		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C129013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129013>	C941	1,24,25-Trihydroxyergocalciferol|(1alpha,3beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10(19),22-Tetraene-1,3,24,25-Tetrol|1,24,25(OH)3 D2|1,24,25-Trihydroxyvitamin D2|9,10-Secoergosta-5,7,10(19),22-Tetraene-1,3,24,25-Tetrol, (1alpha,3beta,5Z,7E,22E)-	A biologically inactive vitamin D derivative that is produced by the hydroxylation of 1,25-dihydroxyvitamin D2 presumably by 1,25-dihydroxyvitamin D3 24-hydroxylase (CYP24A1). 1,24,25-trihydroxyergocalciferol may be a marker for the metabolism of dietary ergocalciferol.	1,24,25-Trihydroxyergocalciferol		Vitamin	CTRP Biomarker Terminology|CTRP Terminology
C129014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129014>	C942	Tocopherylhydroquinone|.ALPHA.-TOCOPHERYLHYDROQUINONE|Alpha-TQH2|Alpha-Tocopheryl Hydroquinone|Alpha-Tocopheryl-Hydroquinone|Alpha-Tocopherylhydroquinone|AlphaTQH2|TQH2|Tocopheryl Hydroquinone	A reduced form of the vitamin E metabolite tocopherylquinone with potential antioxidant activity. Although the mechanism of action has not been fully elucidated, tocopherylhydroquinone may donate a hydrogen atom to reactive oxygen species, which could transform oxygen radicals into non-toxic compounds and block their genotoxic and carcinogenic effects.	Tocopherylhydroquinone		Pharmacologic Substance|Vitamin	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C129015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129015>	C217517	Simeprevir|HSDB 8227|N-(17-(2-(4-isopropylthiazole-2-yl)-7-methoxy-8-methylquinolin-4-yloxy)-13-methyl-2,14-dioxo-3,13-diazatricyclo(13.3.0.04,6)octadec-7-ene-4-carbonyl)(cyclopropyl)sulfonamide|Olysio|SIMEPREVIR|TMC 435|TMC-435|TMC435	An orally bioavailable inhibitor of the hepatitis C virus (HCV) protease complex comprised of non-structural protein 3 and 4A (NS3/NS4A), with activity against HCV genotype 1. Upon administration, simeprevir reversibly binds to the active center and binding site of the HCV NS3/NS4A protease and prevents NS3/NS4A protease-mediated polyprotein maturation. This disrupts both the processing of viral proteins and the formation of the viral replication complex, which inhibits viral replication in HCV genotype 1-infected host cells. NS3, a serine protease, is essential for the proteolytic cleavage of multiple sites within the HCV polyprotein and plays a key role during HCV ribonucleic acid (RNA) replication. NS4A is an activating factor for NS3. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family; HCV infection is associated with the development of hepatocellular carcinoma (HCC).			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129016>	C20103	KIR2DL1 Gene|KIR2DL1|KIR2DL1|Killer Cell Immunoglobulin Like Receptor, Two Ig Domains and Long Cytoplasmic Tail 1 Gene	This gene is involved in the regulation of natural killer cell activity.	KIR2DL1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C129018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129018>	C129016	KIR2DL1 wt Allele|47.11|CD158A|KIR-K64|KIR221|KIR2DL1/3DL2|KIR2DL3|Killer Cell Immunoglobulin Like Receptor, Two Ig Domains and Long Cytoplasmic Tail 1 wt Allele|Killer Cell Immunoglobulin-Like Receptor, Two Domains, Long Cytoplasmic Tail, 1 Gene|NKAT|NKAT-1|NKAT1|cl-42|p58.1	Human KIR2DL1 wild-type allele is located in the vicinity of 19q13.4 and is approximately 15 kb in length. This allele, which encodes killer cell immunoglobulin-like receptor 2DL1 protein, plays a role in the regulation of the immune response.	KIR2DL1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129019>	C217549	Ledipasvir|Carbamic Acid, N-((1S)-1-(((6S)-6-(5-(9,9-difluoro-7-(2-((1R,3S,4S)-2-((2S)-2-((methoxycarbonyl)amino)-3-methyl-1-oxobutyl)-2-azabicyclo(2.2.1)hept-3-yl)-1H-benzimidazol-6-yl)-9H-fluoren-2-yl)-1H-imidazol-2-yl)-5-azaspiro(2.4)hept-5-yl)carbonyl)-2-methylpropyl)-, Methyl Ester|GS 5885|GS-5885|GS5885|LEDIPASVIR|WHO 9796	An orally available inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex, with potential activity against HCV. Upon oral administration and after intracellular uptake, ledipasvir binds to and blocks the activity of the NS5A protein. This results in the disruption of the viral RNA replication complex, blockage of HCV RNA production, and inhibition of viral replication. NS5A, a zinc-binding and proline-rich hydrophilic phosphoprotein, plays a crucial role in HCV RNA replication. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family; HCV infection is associated with the development of hepatocellular carcinoma (HCC).	Ledipasvir		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C12901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12901>	C12341	Palpebral Conjunctiva|CONJUNCTIVA, PALPEBRAL|PALPEBRAL CONJUNCTIVA	The part of the conjunctiva, a thin transparent mucous membrane, that covers the posterior surface of the eyelids.	Palpebral Conjunctiva		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C129020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129020>	C18106	Killer Cell Immunoglobulin-Like Receptor 2DL1|CD158 Antigen-Like Family Member A|CD158a|CD158a Antigen|KIR2DL1|Killer Inhibitory Receptor 2-2-1|MHC Class I NK Cell Receptor|NK-Associated Transcript 1|NKAT-1|Natural Killer-Associated Transcript 1|p58 Killer Cell Inhibitory Receptor KIR-K64|p58 NK Cell Inhibitory Receptor NKR-K6|p58 NK Receptor CL-42/47.11|p58 Natural Killer Cell Receptor Clones CL-42/47.11|p58.1 MHC Class-I-Specific NK Receptor	Killer cell immunoglobulin-like receptor 2DL1 (348 aa, ~39 kDa) is encoded by the human KIR2DL1 gene. This protein is involved in the negative regulation of natural killer cell activity.	Killer Cell Immunoglobulin-Like Receptor 2DL1		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129021>	C84392|C53543|C28193	Chromosome 2q37 Deletion Syndrome|BDMR|Brachydactyly Intellectual Disability Syndrome|Brachydactyly Mental Retardation Syndrome	A syndrome of high phenotypic variability caused by contiguous gene deletions in 2q37.  The inheritance is autosomal dominant. The condition may be characterized by brachydactly type E; mental retardation; short stature; and other skeletal, cardiovascular, and neurologic manifestations.			Disease or Syndrome	Cellosaurus Disease Terminology
C129022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129022>	C84650	Deafness, Autosomal Recessive 1A|DFNB1A	An autosomal recessive disorder caused by mutations in the GJB2 gene, encoding gap junction beta-2 protein. The condition is characterized by profound sensorineural hearing loss and may be associated with vestibular dysfunction.			Disease or Syndrome	Cellosaurus Disease Terminology
C129023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129023>	C53543|C27644	Deafness, Autosomal Recessive 28|DFNB28	An autosomal recessive disorder caused by mutations in the TRIOBP gene, encoding TRIO and F-actin-binding protein. The condition is characterized by severe to profound sensorineural hearing loss.			Disease or Syndrome	Cellosaurus Disease Terminology
C129024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129024>	C53543|C27644	Deafness, Autosomal Recessive 49|DFNB49	An autosomal recessive disorder caused by mutations in the MARVELD2 gene, encoding MARVEL domain-containing protein 2. The condition is characterized  by profound prelingual deafness.			Disease or Syndrome	Cellosaurus Disease Terminology
C129025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129025>	C53543|C28193	Exfoliation Syndrome|Exfoliation Glaucoma|XFG|XFS	An autosomal dominant disorder caused by mutations in the LOXL1 gene, encoding lysyl oxidase homolog 1. The condition is characterized by abnormal fibrillar extracellular material in anterior segment tissues, and may lead to glaucoma.			Disease or Syndrome	Cellosaurus Disease Terminology
C129026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129026>	C62505	Fanconi Anemia, Complementation Group I	Fanconi anemia caused by mutations in the FANCI gene, encoding Fanconi anemia group I protein.			Disease or Syndrome	Cellosaurus Disease Terminology
C129027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129027>	C62505	Fanconi Anemia, Complementation Group J	Fanconi anemia caused by mutations in the BRIP1 gene, encoding Fanconi anemia group J protein.			Disease or Syndrome	Cellosaurus Disease Terminology
C129028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129028>	C53543	Frontonasal Dysplasia|FND1|Frontonasal Dysplasia 1	Frontonasal dysplasia caused by mutations in the ALX3 gene, encoding homeobox protein aristaless-like 3. It is inherited in an autosomal recessive fashion.			Disease or Syndrome	Cellosaurus Disease Terminology
C129029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129029>	C53543|C28193	Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome|HHH	An autosomal recessive disorder caused by mutation(s) in the SLC25A15 gene, encoding mitochondrial ornithine transporter 1. The condition is characterized by failure to thrive, liver dysfunction, psychomotor retardation, encephalopathy and seizures.			Disease or Syndrome	Cellosaurus Disease Terminology
C12902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12902>	C12341	Bulbar Conjunctiva|BULBAR CONJUNCTIVA|CONJUNCTIVA, BULBAR|Ocular Conjunctiva	The part of the conjunctiva, a thin transparent mucous membrane, that is loosely attached the orbital septum and covers the anterior surface of the sclera.	Bulbar Conjunctiva		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C129030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129030>	C53543	Pancreatic Lipase Deficiency|PNLIPD	An autosomal recessive disorder caused by mutation(s) in the PNLIP gene, encoding pancreatic triacylglycerol lipase. The condition is characterized by absent or reduced pancreatic lipase.			Disease or Syndrome	Cellosaurus Disease Terminology
C129031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129031>	C53543|C28193	Spondyloepimetaphyseal Dysplasia, Sponastrime Type|Short Limb Dwarfism-Saddle Nose-Spinal Alterations-Metaphyseal Striation Syndrome|Short-Limb Dwarfism with Saddle Nose, Spinal Alterations, and Metaphyseal Striation|Sponastrime Dysplasia	A rare disorder characterized by severe short stature, lumbar lordosis, midface hypoplasia, micromelia, frontal bossing, epiphyseal and metaphyseal abnormalities. The inheritance is autosomal recessive.			Disease or Syndrome	Cellosaurus Disease Terminology
C129032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129032>	C98640	Tyrosinemia Type II|Hereditary Tyrosinemia Type II	Tyrosinemia caused by mutation(s) in the TAT gene, encoding tyrosine aminotransferase. The inheritance is autosomal recessive.			Disease or Syndrome	Cellosaurus Disease Terminology
C129034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129034>	C137802	Canine GM1-Gangliosidosis	GM1-gangliosidosis that occurs in dogs, caused by mutation(s) in the GLB1 gene, encoding beta-galactosidase.			Disease or Syndrome	Cellosaurus Disease Terminology
C129035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129035>	C53543|C203448|C104003	Thrombocytopenia 2|THC2	An autosomal dominant disorder caused by mutation(s) in the ANKRD26 gene, encoding ANKRD26 protein. Additionally, in one family, a mutation(s) has been identified in the MASTL gene, encoding serine/threonine-protein kinase greatwall. The condition is characterized by mild to moderate bruisability.			Disease or Syndrome	Cellosaurus Disease Terminology
C129036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129036>	C20103	KIR2DL2 Gene|KIR2DL2|KIR2DL2|Killer Cell Immunoglobulin Like Receptor, Two Ig Domains and Long Cytoplasmic Tail 2 Gene	This gene plays a role in the negative regulation of natural killer cell activity.	KIR2DL2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C129037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129037>	C129036	KIR2DL2 wt Allele|CD158B1|CD158b|CD158k|Killer Cell Immunoglobulin Like Receptor, Two Ig Domains and Long Cytoplasmic Tail 2 wt Allele|Killer Cell Immunoglobulin-Like Receptor, Two Domains, Long Cytoplasmic Tail, 2 Gene|NKAT-6|NKAT6|cl-43|p58.2	Human KIR2DL2 wild-type allele is located in the vicinity of 19q13.4 and is approximately 15 kb in length. This allele, which encodes killer cell immunoglobulin-like receptor 2DL2 protein, is involved in the modulation of natural killer cell activity.	KIR2DL2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129038>	C18106	Killer Cell Immunoglobulin-Like Receptor 2DL2|CD158 Antigen-Like Family Member B1|CD158b1|CD158b1 Antigen|KIR2DL2|MHC Class I NK Cell Receptor|NK-Associated Transcript 6|NKAT-6|Natural Killer-Associated Transcript 6|p58 NK Receptor CL-43|p58 Natural Killer Cell Receptor Clone CL-43	Killer cell immunoglobulin-like receptor 2DL2 (348 aa, ~38 kDa) is encoded by the human KIR2DL2 gene. This protein plays a role in the inhibition of natural killer cell activity.	Killer Cell Immunoglobulin-Like Receptor 2DL2		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129039>	C20103	KIR2DL3 Gene|KIR2DL3|KIR2DL3|Killer Cell Immunoglobulin Like Receptor, Two Ig Domains and Long Cytoplasmic Tail 3 Gene	This gene is involved in the inhibition of natural killer cell-mediated cell lysis.	KIR2DL3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C12903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12903>	C33027	Supraclavicular Lymph Node|Lymph Node(s) Supraclavicular|SUPRACLAVICULAR LYMPH NODE|Structure of supraclavicular lymph node (body structure)|Supraclavicular Lymph Nodes|Supraclavicular Nodes|Supraclavicular lymph nodes|nodus lymphaticus supraclavicularis axillae|supraclavicular lymph node|supraclavicular lymph node|supraclavicular node	A lymph node which is located above the clavicle.	Supraclavicular Lymph Node		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Biopsy/Surgical Procedures Table|HL Lesion Characteristics Table|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C129040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129040>	C129039	KIR2DL3 wt Allele|CD158B2|CD158b|GL183|KIR-023GB|KIR-K7b|KIR-K7c|KIR2DL|KIR2DS5|KIRCL23|Killer Cell Immunoglobulin Like Receptor, Two Ig Domains and Long Cytoplasmic Tail 3 wt Allele|Killer Cell Immunoglobulin-Like Receptor, Two Domains, Long Cytoplasmic Tail, 3 Gene|Killer Cell Immunoglobulin-Like Receptor, Two Domains, Short Cytoplasmic Tail, 5 Gene|NKAT|NKAT2|NKAT2A|NKAT2B|cl-6|p58	Human KIR2DL3 wild-type allele is located in the vicinity of 19q13.4 and is approximately 15 kb in length. This allele, which encodes killer cell immunoglobulin-like receptor 2DL3 protein, plays a role in the regulation of the immune response.	KIR2DL3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129041>	C18106	Killer Cell Immunoglobulin-Like Receptor 2DL3|CD158 Antigen-Like Family Member B2|CD158b2|CD158b2 Antigen|KIR-023GB|Killer Inhibitory Receptor Cl 2-3|MHC Class I NK Cell Receptor|NK-Associated Transcript 2|NKAT-2|NKAT2a|Natural Killer Associated Transcript 2|Natural Killer Cell Inhibitory Receptor KIR2DL3|Natural Killer-Associated Transcript 2|p58 NK Receptor CL-6|p58 Natural Killer Cell Receptor Clone CL-6|p58.2 MHC Class-I Specific NK Receptor|p58.2 MHC Class-I-Specific NK Receptor	Killer cell immunoglobulin-like receptor 2DL3 (341 aa, ~38 kDa) is encoded by the human KIR2DL3 gene. This protein is involved in the modulation of natural killer cell-mediated immunity.	Killer Cell Immunoglobulin-Like Receptor 2DL3		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129042>	C20194	STMN1 Gene|STMN1|STMN1|Stathmin 1 Gene	This gene plays a role in the promotion of microtubule disassembly.	STMN1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C129043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129043>	C129042	STMN1 wt Allele|C1orf215|Chromosome 1 Open Reading Frame 215 Gene|FLJ32206|LAP18|Lag|OP18|PP17|PP19|PR22|SMN|Stathmin 1 wt Allele|Stathmin 1/Oncoprotein 18 Gene	Human STMN1 wild-type allele is located in the vicinity of 1p36.11 and is approximately 23 kb in length. This allele, which encodes stathmin protein, is involved in the disassembly of microtubules.	STMN1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129044>	C18466	Stathmin|Leukemia-Associated Phosphoprotein p18|Metablastin|Oncoprotein 18|Op18|Phosphoprotein 19|Phosphoprotein p19|Prosolin|Protein Pr22|STMN1|Testicular Tissue Protein Li 189|Transmembrane Protein C1orf215|pp17|pp19	Stathmin (149 aa, ~17 kDa) is encoded by the human STMN1 gene. This protein plays a role in the inhibition of assembly of microtubules.	Stathmin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129045>	C20921	ARRB2 Gene|ARRB2|ARRB2|Arrestin Beta 2 Gene	This gene is involved in receptor desensitization.	ARRB2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C129046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129046>	C129045	ARRB2 wt Allele|ARB2|ARR2|Arrestin 3 Gene|Arrestin Beta 2 wt Allele|Arrestin, Beta 2 Gene|Arrestin, Beta, 2 Gene|BARR2|DKFZp686L0365	Human ARRB2 wild-type allele is located in the vicinity of 17p13 and is approximately 11 kb in length. This allele, which encodes beta-arrestin-2 protein, plays a role in the downregulation of G protein-coupled receptor signaling.	ARRB2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129047>	C18515	Beta-Arrestin-2|Arrestin Beta-2|Beta-Arrestin 2	Beta-arrestin-2 (409 aa, ~46 kDa) is encoded by the human ARRB2 gene. This protein is involved in the modulation of G protein-receptor signaling.	Beta-Arrestin-2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129048>	C308	Iberdomide|(S)-3-(4-((4-(Morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione|CC 220|CC-220|IBERDOMIDE	A modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with immunomodulating and pro-apoptotic activities. Upon administration, iberdomide specifically binds to the cereblon (CRBN) part of the ligase complex, thereby affecting the ubiquitin E3 ligase activity, and targeting certain substrate proteins for ubiquitination. This induces the proteasome-mediated degradation of certain transcription factors, including Ikaros (IKZF1) and Aiolos (IKZF3) which are transcriptional repressors in T-cells. This leads to a reduction of their protein levels, and the modulation of the immune system, including activation of T-lymphocytes. In addition, this leads to a downregulation of other proteins, including interferon regulatory factor 4 (IRF4), which plays a key role in the proliferation of certain cancer cell types. CRBN, the substrate recognition component of the E3 ubiquitin ligase complex, plays a key role in the ubiquitination of certain proteins.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129049>	C21282	CBS Gene|CBS|CBS|Cystathionine-Beta-Synthase Gene	This gene plays a role in transsulfuration.	CBS Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C12904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12904>	C33027	Axillary Lymph Node|ALN|AXILLARY LYMPH NODE|Axillary Lymph Nodes|Axillary Node|Axillary Nodes|Axillary lymph node structure (body structure)|Axillary lymph nodes|LYMPH NODE, AXILLARY|Lymph Node(s) Axilla|Lymph Node, Axillary|Lymph nodes of axilla or arm|axillary lymph node|axillary lymph node	One of approximately 20-30 lymph nodes in chain formation that traverse the concavity of the underarm to the clavicle.	Axillary Lymph Node		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Biopsy/Surgical Procedures Table|HL Lesion Characteristics Table|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C129050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129050>	C129049	CBS wt Allele|Cystathionine-Beta-Synthase wt Allele|HIP4	Human CBS wild-type allele is located in the vicinity of 21q22.3 and is approximately 24 kb in length. This allele, which encodes cystathionine beta-synthase protein, is involved in the detoxification of homocysteine and the synthesis of cysteine. Mutation of the gene is associated with cystathionine beta-synthase deficiency (CBSD), which can lead to homocystinuria and an increase risk of thrombosis.	CBS wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129051>	C16804	Cystathionine Beta-Synthase|Beta-Thionase|CBS|Cystathionine-Beta-Synthase|EC 4.2.1.22|Methylcysteine Synthase|Serine Sulfhydrase	Cystathionine beta-synthase (551 aa, ~61 kDa) is encoded by the human CBS gene. This protein plays a role in homocysteine metabolism.	Cystathionine Beta-Synthase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129052>	C25939	AKR1C3 Gene|AKR1C3|AKR1C3|Aldo-Keto Reductase Family 1 Member C3 Gene	This gene is involved in the conversion of aldehydes and ketones to alcohols.	AKR1C3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|Pediatric Oncology Target Cell Lineage Determinant Terminology
C129053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129053>	C129052	AKR1C3 wt Allele|Aldo-Keto Reductase Family 1 Member C3 wt Allele|Aldo-Keto Reductase Family 1, Member C3 (3-Alpha Hydroxysteroid Dehydrogenase, Type II) Gene|Aldo-Keto Reductase Family 1, Member C3 Gene|DD3|DDH2|DDX|HA1753|HAKRB|HAKRD|HAKRe|HSD17B5|KIAA0119|PGFS|hluPGFS	Human AKR1C3 wild-type allele is located within 10p15-p14 and is approximately 72 kb in length. This allele, which encodes aldo-keto reductase family 1 member C3 protein, plays a role in the metabolism of prostaglandins and steroids.	AKR1C3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129054>	C16946	Aldo-Keto Reductase Family 1 Member C3|17-Beta-HSD 5|17-Beta-Hydroxysteroid Dehydrogenase Type 5|17-Beta-Hydroxysteroid Dehydrogenase V|3-Alpha Hydroxysteroid Dehydrogenase, Type II|3-Alpha-HSD Type 2|3-Alpha-HSD Type II, Brain|3-Alpha-Hydroxysteroid Dehydrogenase Type 2|AKR1C3|Aldo-Keto Reductase 1C3|Aldo-Keto Reductase B|Chlordecone Reductase Homolog HAKRb|DD-3|DD3|Dihydrodiol Dehydrogenase 3|Dihydrodiol Dehydrogenase Type I|Dihydrodiol Dehydrogenase X|EC 1.-.-.-|HA1753|Hydroxysteroid (17-Beta) Dehydrogenase 5|Indanol Dehydrogenase|PGFS|Testosterone 17-Beta-Dehydrogenase 5|Trans-1,2-Dihydrobenzene-1,2-Diol Dehydrogenase|Type IIb 3-Alpha Hydroxysteroid Dehydrogenase	Aldo-keto reductase family 1 member C3 (323 aa, ~37 kDa) is encoded by the human AKR1C3 gene. This protein is involved in steroid and prostaglandin metabolism.	Aldo-Keto Reductase Family 1 Member C3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Cell Lineage Determinant Terminology
C129055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129055>	C20731	DUSP10 Gene|DUSP10|DUSP10|Dual Specificity Phosphatase 10 Gene	This gene plays a role in the negative regulation of MAP kinase activity.	DUSP10 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C129056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129056>	C129055	DUSP10 wt Allele|Dual Specificity Phosphatase 10 wt Allele|MKP-5|MKP5	Human DUSP10 wild-type allele is located in the vicinity of 1q41 and is approximately 41 kb in length. This allele, which encodes dual specificity protein phosphatase 10 protein, is involved in the downregulation of mitogen-activated kinases.	DUSP10 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129057>	C25880	Dual Specificity Protein Phosphatase 10|DUSP10|Dual Specificity Phosphatase MKP-5|Dual-Specificity Phosphatase 10|EC 3.1.3.16|EC 3.1.3.48|MAP Kinase Phosphatase 5|MKP-5|Map Kinase Phosphatase 5|Mitogen-Activated Protein Kinase Phosphatase 5	Dual specificity protein phosphatase 10 (482 aa, ~53 kDa) is encoded by the human DUSP10 gene. This protein plays a role in both the dephosphorylation and inactivation of MAP kinases.	Dual Specificity Protein Phosphatase 10		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129058>	C20103	NCR1 Gene|NCR1|NCR1|Natural Cytotoxicity Triggering Receptor 1 Gene	This gene is involved in the activation of natural killer cell-mediated cytotoxicity.	NCR1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C129059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129059>	C129058	NCR1 wt Allele|CD335|LY94|Lymphocyte Antigen 94 (Mouse) Homolog (Activating NK-Receptor; NK-P46) Gene|Lymphocyte Antigen 94 Homolog (Activating NK-Receptor; NK-P46) Gene|Lymphocyte Antigen 94, Mouse, Homolog of Gene|NK-p46|NKP46|Natural Cytotoxicity Triggering Receptor 1 wt Allele	Human NCR1 wild-type allele is located in the vicinity of 19q13.42 and is approximately 32 kb in length. This allele, which encodes natural cytotoxicity triggering receptor 1 protein, plays a role in the modulation of natural killer cell-mediated cytotoxicity.	NCR1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12905>	C25444	Thoracic Cavity|BODY CAVITY, THORACIC|THORACIC CAVITY	The cavity in the vertebrate body enclosed by the ribs between the diaphragm and the neck and containing the lungs and heart.	Thoracic Cavity		Body Space or Junction	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C129060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129060>	C18106	Natural Cytotoxicity Triggering Receptor 1|Activating Natural Killer Receptor p46|CD335 Antigen|HNKp46|Lymphocyte Antigen 94 Homolog|NK Cell-Activating Receptor|NK-p46|NKp46|Natural Killer Cell p46-Related Protein	Natural cytotoxicity triggering receptor 1 (304 aa, ~34 kDa) is encoded by the human NCR1 gene. This protein is involved in the positive regulation of natural killer cell-mediated cytotoxicity.	Natural Cytotoxicity Triggering Receptor 1		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129061>	C192218	DNA-dependent Protein Kinase Inhibitor VX-984|DNA-PK Inhibitor VX-984|VX-984|VX-984|VX984	An ATP-competitive inhibitor of the catalytic subunit of DNA-dependent protein kinase (DNA-PK), with potential sensitizing and enhancing activities for both chemo- and radiotherapies. Upon administration, DNA-PK inhibitor VX-984 binds to and inhibits the catalytic subunit of DNA-PK, thereby interfering with the non-homologous end joining (NHEJ) process and preventing repair of DNA double strand breaks (DSBs) caused by ionizing radiation or chemotherapeutic treatment. This increases chemo- and radiotherapy cytotoxicity and leads to enhanced tumor cell death. The enhanced ability of tumor cells to repair DSBs plays a major role in the resistance of tumor cells to chemo- and radiotherapy; DNA-PK plays a key role in the NHEJ pathway and DSB repair.	DNA-dependent Protein Kinase Inhibitor VX-984		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129062>	C25775	CCR3 Gene|C-C Motif Chemokine Receptor 3 Gene|CCR3|CCR3	This gene plays a role in the migration of eosinophils.	CCR3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C129063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129063>	C129062	CCR3 wt Allele|C-C Motif Chemokine Receptor 3 wt Allele|CC-CKR-3|CD193|CKR3|CMKBR3|Chemokine (C-C Motif) Receptor 3 Gene|Chemokine (C-C) Receptor 3 Gene|Chemokine, CC Motif, Receptor 3 Gene	Human CCR3 wild-type allele is located in the vicinity of 3p21.3 and is approximately 103 kb in length. This allele, which encodes C-C chemokine receptor type 3 protein, is involved in eosinophil migration.	CCR3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129064>	C18018	C-C Chemokine Receptor Type 3|B-Chemokine Receptor|C-C CKR-3|CC Chemokine Receptor 3|CC-CKR-3|CCR-3|CCR3|CD193 Antigen|CKR3|Eosinophil CC Chemokine Receptor 3|Eosinophil Eotaxin Receptor|Eotaxin Receptor	C-C chemokine receptor type 3 (355 aa, ~41 kDa) is encoded by the human CCR3 gene. This protein plays a role in eosinophil chemotaxis.	C-C Chemokine Receptor Type 3		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129065>	C25775	CCR4 Gene|C-C Motif Chemokine Receptor 4 Gene|CCR4|CCR4|CCR4	This gene is involved in chemokine-dependent G protein-coupled receptor signaling.	CCR4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C129066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129066>	C129065	CCR4 wt Allele|C-C Motif Chemokine Receptor 4 wt Allele|CC-CKR-4|CD194|CKR4|CMKBR4|ChemR13|Chemokine (C-C Motif) Receptor 4 Gene|Chemokine (C-C) Receptor 4 Gene|Chemokine, CC Motif, Receptor 4 Gene|HGCN:14099|K5-5	Human CCR4 wild-type allele is located in the vicinity of 3p24 and is approximately 5 kb in length. This allele, which encodes C-C chemokine receptor type 4 protein, plays a role in leukocyte migration.	CCR4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129067>	C18018	C-C Chemokine Receptor Type 4|C-C CKR-4|CC Chemokine Receptor 4|CC-CKR-4|CCR-4|CCR4|CD194 Antigen|K5-5	C-C chemokine receptor type 4 (360 aa, ~41 kDa) is encoded by the human CCR4 gene. This protein is involved in leukocyte chemotaxis.	C-C Chemokine Receptor Type 4		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129068>	C85865|C75467	Charcot-Marie-Tooth Neuropathy X Type 1|CMTX1|Charcot-Marie-Tooth Neuropathy X-Linked Dominant Type 1	Charcot-Marie-Tooth neuropathy that is inherited in an X-linked manner, and is associated with mutation(s) in the GJB1 gene, encoding gap junction beta-1 protein. The condition is characterized by moderate to severe motor and sensory neuropathy in males, and mild to no symptoms in females.			Disease or Syndrome	Cellosaurus Disease Terminology
C129069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129069>	C97154	Corticobasal Degeneration|Cortical Basal Ganglionic Degeneration|Corticobasal degeneration	A progressive neurodegenerative condition affecting the cerebral cortex and basal ganglia. The disorder is characterized by varying degrees of cognitive and motor impairment.			Disease or Syndrome	Cellosaurus Disease Terminology|mCode Elixhauser Dementia Value Set|mCode Terminology
C12906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12906>	C33525	Posterior Eye Segment	The larger portion of the eye behind the lens containing the retina, vitreous humor, choroid, and optic nerve.	Posterior Eye Segment		Body Part, Organ, or Organ Component	
C129070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129070>	C53543	Cystathioninuria	An autosomal recessive disorder caused by mutations in the CTH gene, encoding cystathionine gamma-lyase. The condition is characterized by increased concentrations of cystathionine in the plasma and urine.			Disease or Syndrome	Cellosaurus Disease Terminology
C129071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129071>	C53543	Fetal Akinesia Deformation Sequence|FADS|Pena-Shokeir syndrome, Type 1	A condition characterized by fetal akinesia and intrauterine growth restriction, that may be associated with mutation(s) in the RAPSN or DOK7 genes, encoding 43 kDa receptor-associated protein of the synapse and protein Dok-7, respectively.			Disease or Syndrome	Cellosaurus Disease Terminology
C129072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129072>	C53543	Hereditary Persistence of Fetal Hemoglobin	The persistence of substantial fetal hemoglobin production into adulthood, usually associated with hemoglobinopathies due to mutations in the alpha and/or beta chain of hemoglobin.			Disease or Syndrome	Cellosaurus Disease Terminology
C129073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129073>	C61259	Mucopolysaccharidosis Type IX|Hyaluronidase Deficiency|MPS9	An autosomal recessive lysosomal storage disease caused by mutation(s) in the HYAL1 gene, encoding hyaluronidase-1. It is characterized by short stature and hyaluronidase deficiency.			Disease or Syndrome	Cellosaurus Disease Terminology
C129074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129074>	C84783	Immunodeficiency with Hyper-IgM Type 2|HIGM2	An autosomal recessive immunodeficiency that is caused by mutation(s) in the AICDA gene, single-stranded DNA cytosine deaminase. It is characterized by normal or elevated concentrations of IgM and decreased or absent concentrations of IgG, IgA, and IgE.			Disease or Syndrome	Cellosaurus Disease Terminology
C129075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129075>	C53543	Leber Congenital Amaurosis	A congenital retinopathy that is associated with mutation(s) in at least eighteen genes, typically characterized by severe visual impairment.			Disease or Syndrome	Cellosaurus Disease Terminology
C129076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129076>	C53543	Molybdenum Cofactor Deficiency	An autosomal recessive condition that is caused by mutation(s) in the MOCS1 gene, encoding molybdenum cofactor biosynthesis protein 1. it is characterized by poor feeding, encephalopathy, seizures and dysmorphic facial features.			Disease or Syndrome	Cellosaurus Disease Terminology
C129077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129077>	C134526	Canine Mastocytoma	A tumor composed of mast cells that occurs in dogs.			Neoplastic Process	Cellosaurus Disease Terminology
C129078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129078>	C20923	RHO Gene|RHO|RHO|Rhodopsin Gene	This gene plays a role in vision.	RHO Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C129079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129079>	C129078	RHO wt Allele|CSNBAD1|OPN2|Opsin 2, Rod Pigment Gene|RP4|Retinitis Pigmentosa 4, Autosomal Dominant Gene|Rhodopsin wt Allele	Human RHO wild-type allele is located in the vicinity of 3q22.1 and is approximately 7 kb in length. This allele, which encodes rhodopsin protein, is involved in photoreceptor cell activity and maintenance. Mutation of the gene is associated with congenital stationary night blindness, retinitis pigmentosa 4, and retinitis punctata albescens.	RHO wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12907>	C12919	Integumentary System|Body System, Dermatologic|Dermatologic Body System|Dermatologic Organ System|Integumentary|Organ System, Dermatologic	The enveloping membrane of the body; includes, in addition to the epidermis and dermis, all the derivatives of the epidermis, e.g., hairs, nails, sudoriferous and sebaceous glands.	Integumentary System		Body System	ICDC Terminology|ICDC Value Terminology
C129080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129080>	C18239	Rhodopsin|Opsin 2|Opsin-2|Rod Pigment 2	Rhodopsin (348 aa, ~39 kDa) is encoded by the human RHO gene. This protein plays a role in rod-dependent visual processes.	Rhodopsin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129081>	C21295	SART1 Gene|SART1|SART1|Squamous Cell Carcinoma Antigen Recognized By T-Cells 1 Gene	This gene is involved in spliceosome activity.	SART1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C129082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129082>	C129081	SART1 wt Allele|Ara1|HOMS1|SART1(259) Protein Gene|SART1259|SNRNP110|Small Nuclear Ribonucleoprotein 110kDa (U4/U6.U5) Gene|Snu66|Squamous Cell Carcinoma Antigen Recognised By T Cells Gene|Squamous Cell Carcinoma Antigen Recognized By T Cells 1 Gene|Squamous Cell Carcinoma Antigen Recognized By T-Cells 1 wt Allele	Human SART1 wild-type allele is located in the vicinity of 11q13.1 and is approximately 18 kb in length. This allele, which encodes U4/U6.U5 tri-snRNP-associated protein 1, plays a role in mRNA splicing.	SART1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129083>	C21298	U4/U6.U5 Tri-SnRNP-Associated Protein 1|Allergen Hom S 1|Hom s 1|SART-1|SNU66 Homolog|Squamous Cell Carcinoma Antigen Recognized By T-Cells 1|U4/U6.U5 Tri-SnRNP-Associated 110 kDa Protein|hSART-1|hSnu66	U4/U6.U5 tri-snRNP-associated protein 1 (800 aa, ~90 kDa) is encoded by the human SART1 gene. This protein is involved in RNA splicing.	U4/U6.U5 Tri-SnRNP-Associated Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129084>	C25871	CERK Gene|CERK|CERK|Ceramide Kinase Gene	This gene plays a role in ceramide metabolism.	CERK Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C129085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129085>	C129084	CERK wt Allele|Ceramide Kinase wt Allele|DKFZp434E0211|FLJ21430|FLJ23239|KIAA1646|LK4|dA59H18.2|dA59H18.3|hCERK	Human CERK wild-type allele is located in the vicinity of 22q13.31 and is approximately 54 kb in length. This allele, which encodes ceramide kinase protein, is involved in lipid phosphorylation.	CERK wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129086>	C16984	Ceramide Kinase|Acylsphingosine Kinase|EC 2.7.1.138|LK4|Lipid Kinase 4|Lipid Kinase LK4|hCERK	Ceramide kinase (537 aa, ~60 kDa) is encoded by the human CERK gene. This protein plays a role in the phosphorylation of ceramides.	Ceramide Kinase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129087>	C100110	CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|FAC071TN|Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 Questionnaire Test Name|QS-FACIT-F Version 4 TEST	Test names of questionnaire questions associated with the Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129088>	C100110	CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|FAC071TC|Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 Questionnaire Test Code|QS-FACIT-F Version 4 TESTCD	Test codes of questionnaire questions associated with the Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129089>	C100110	CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Name Terminology|FAC042TN|National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 Questionnaire Test Name|QS-NCCN-FACT FKSI-19 Version 2 TEST	Test names of questionnaire questions associated with the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129090>	C100110	CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Code Terminology|FAC042TC|National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 Questionnaire Test Code|QS-NCCN-FACT FKSI-19 Version 2 TESTCD	Test codes of questionnaire questions associated with the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129091>	C100110	CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Name Terminology|FAC028TN|National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 Questionnaire Test Name|QS-NCCN-FACT FBLSI-18 Version 2 TEST	Test names of questionnaire questions associated with the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129092>	C100110	CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Code Terminology|FAC028TC|National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 Questionnaire Test Code|QS-NCCN-FACT FBLSI-18 Version 2 TESTCD	Test codes of questionnaire questions associated with the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129093>	C100110	CDISC Questionnaire FACT-B Version 4 Test Name Terminology|FAC005TN|Functional Assessment of Cancer Therapy-Breast Version 4 Questionnaire Test Name|QS-FACT-B Version 4 TEST	Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129094>	C100110	CDISC Questionnaire FACT-B Version 4 Test Code Terminology|FAC005TC|Functional Assessment of Cancer Therapy-Breast Version 4 Questionnaire Test Code|QS-FACT-B Version 4 TESTCD	Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129095>	C100110	CDISC Questionnaire FOSI Test Name Terminology|FAC049TN|Functional Assessment of Cancer Therapy-Ovarian Symptom Index Questionnaire Test Name|QS-FOSI TEST	Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129096>	C100110	CDISC Questionnaire FOSI Test Code Terminology|FAC049TC|Functional Assessment of Cancer Therapy-Ovarian Symptom Index Questionnaire Test Code|QS-FOSI TESTCD	Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129097>	C100110	CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Name Terminology|FAC050TN|National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 Questionnaire Test Name|QS-NCCN-FACT FOSI-18 Version 2 TEST	Test names of questionnaire questions associated with the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129098>	C100110	CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Code Terminology|FAC050TC|National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 Questionnaire Test Code|QS-NCCN-FACT FOSI-18 Version 2 TESTCD	Test codes of questionnaire questions associated with the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129099>	C211913	FACIT-F Version 4 Questionnaire Question	A question associated with the FACIT-F Version 4 questionnaire.			Intellectual Product	
C12909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12909>	C41166	Hematopoietic System|Body System, Hematologic|Hematologic Body System|Hematologic Organ System|Hematopoietic Body System|Hematopoietic system, NOS|Organ System, Hematologic|hematopoietic system	The bodily system of organs and tissues, primarily the bone marrow, spleen, tonsils, and lymph nodes, involved in the production of blood.	Hematopoietic Body System		Body System	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C1290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1290>	C387	Recombinant Macrophage Colony-Stimulating Factor|Macrophage Colony Stimulating Factor|Recombinant Colony Stimulating Factor 1|rM-CSF	A recombinant therapeutic agent which is chemically identical to or similar to the endogenous protein cytokine macrophage colony-stimulating factor (M-CSF). Synthesized endogenously by mesenchymal cells, M-CSF stimulates the survival, proliferation, and differentiation of hematopoietic cells of the monocyte-macrophage series and can reverse treatment-related neutropenias. Recombinant M-CSF may also enhance antigen presentation and activate antitumoral cytotoxic T-cells.			Chemical Viewed Functionally	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129100>	C211913	NCCN-FACT FKSI-19 Version 2 Questionnaire Question	A question associated with the NCCN-FACT FKSI-19 Version 2 questionnaire.			Intellectual Product	
C129101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129101>	C211913	NCCN-FACT FBLSI-18 Version 2 Questionnaire Question	A question associated with the NCCN-FACT FBLSI-18 Version 2 questionnaire.			Intellectual Product	
C129102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129102>	C211913	FACT-B Version 4 Questionnaire Question	A question associated with the FACT-B Version 4 questionnaire.			Intellectual Product	
C129103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129103>	C211913	FOSI Questionnaire Question	A question associated with the FOSI questionnaire.			Intellectual Product	
C129104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129104>	C211913	NCCN-FACT FOSI-18 Version 2 Questionnaire Question	A question associated with the NCCN-FACT FOSI-18 Version 2 questionnaire.			Intellectual Product	
C129105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129105>	C91105	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 Questionnaire|FAC071|FACIT-F V4|FACIT-F Version 4	A standardized rating scale originally developed by Yellen et al in 1997 and modified by Cella et al in 2002, which includes a 13-item fatigue scale, as well as 13 items from the original FACT-G of the emotional and functional well-being sections. This instrument measures fatigue/tiredness and its impact on daily activities and functioning in a number of chronic diseases.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129106>	C91105	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 Questionnaire|FAC042|NCCN-FACT FKSI-19 V2|NCCN-FACT FKSI-19 Version 2	A standardized 19-item rating scale for symptoms of advanced kidney cancer that is comprised of disease-related, treatment side effects, and general function and well-being subscales. Originally developed by Rao et al. in 2006, it is a modified version of the National Comprehensive Cancer Network (NCCN) 15-item Functional Assessment of Cancer Therapy - Kidney Symptom Index (FKSI-15) that incorporates additional symptoms rated as highest priority by patients and clinicians from the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms (FKSI-DRS).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129107>	C91105	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 Questionnaire|FAC028|NCCN-FACT FBLSI-18 V2|NCCN-FACT FBLSI-18 Version 2	A standardized 18-item rating scale that assesses the symptoms of bladder cancer that are perceived as most important by patients and clinicians. Originally developed by Cella et al. in 2004, it is a modified version of the Functional Assessment of Cancer Therapy for patients with Bladder cancer (FACT-Bl), incorporating two additional items: 'I feel weak all over,' and 'I feel light-headed (dizzy)'.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129108>	C91105	Functional Assessment of Cancer Therapy-Breast Version 4 Questionnaire|FAC005|FACT-B V4|FACT-B Version 4	A standardized 37-item self-report rating scale to measure quality of life in patients with breast cancer that is divided into five subscales: physical, social/family, emotional, and functional well-being, as well as additional concerns for breast cancer. Originally developed by Cella, et al. in 1997, it combines the Functional Assessment of Cancer Therapy - General (FACT-G) and the Breast Cancer Subscale (BCS).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129109>	C91105	Functional Assessment of Cancer Therapy-Ovarian Symptom Index Questionnaire|FAC049|FOSI|FOSI	A standardized 8-item rating scale for the assessment of symptom response to treatment for advanced ovarian cancer that was originally developed by Cella, et al. in 1997 and derived from the ovarian cancer-specific subscale of the Functional Assessment of Cancer Therapy (FACT-O).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12910>	C13049	Mucosa-Associated Lymphoid Tissue|Lymphoid Tissue, Mucosa-associated|MALT	Lymphoid tissue located beneath the mucosal epithelia of those mucosal surfaces that have contact with the external environment, such as the respiratory, digestive, and urinary systems. MALT consists of a collection of predominantly small lymphocytes, fewer larger, transformed lymphocytes, and plasma cells. It protects the body from pathogens that enter via the mucosa. MALT gives rise to a distinctive type of B-cell lymphoma that usually follows an indolent clinical course.	Mucosa-Associated Lymphoid Tissue		Tissue	
C129110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129110>	C91105	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 Questionnaire|FAC050|NCCN-FACT FOSI-18 V2|NCCN-FACT FOSI-18 Version 2	A standardized 18-item rating scale for the assessment of symptom response to treatment for advanced ovarian cancer, including subscales that are specific for disease-related symptoms, treatment-related symptoms, and general function/well-being. Originally developed by Cella, et al. in 1997, it is derived from the ovarian cancer-specific subscale of the Functional Assessment of Cancer Therapy (FACT-O).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129111>	C129099	FACIT-F Version 4 - I Have a Lack of Energy|FAC071-I Have a Lack of Energy|FAC071-I Have a Lack of Energy|FAC07101	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Physical Well-Being: I have a lack of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129112>	C129099	FACIT-F Version 4 - I Have Nausea|FAC071-I Have Nausea|FAC071-I Have Nausea|FAC07102	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Physical Well-Being: I have nausea.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129113>	C129099	FACIT-F Version 4 - Trouble Meeting Needs of Family|FAC071-Trouble Meeting Needs of Family|FAC071-Trouble Meeting Needs of Family|FAC07103	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Physical Well-Being: Because of my physical condition, I have trouble meeting the needs of my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129114>	C129099	FACIT-F Version 4 - I Have Pain|FAC071-I Have Pain|FAC071-I Have Pain|FAC07104	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Physical Well-Being: I have pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129115>	C129099	FACIT-F Version 4 - Bothered by Treatment Side Effect|FAC071-Bothered by Treatment Side Effect|FAC071-Bothered by Treatment Side Effect|FAC07105	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Physical Well-Being: I am bothered by side effects of treatment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129116>	C129099	FACIT-F Version 4 - I Feel Ill|FAC071-I Feel Ill|FAC071-I Feel Ill|FAC07106	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Physical Well-Being: I feel ill.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129117>	C129099	FACIT-F Version 4 - I Am Forced to Spend Time in Bed|FAC071-I Am Forced to Spend Time in Bed|FAC071-I Am Forced to Spend Time in Bed|FAC07107	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Physical Well-Being: I am forced to spend time in bed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129118>	C129099	FACIT-F Version 4 - I Feel Close to My Friends|FAC071-I Feel Close to My Friends|FAC071-I Feel Close to My Friends|FAC07108	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Social/Family Well-Being: I feel close to my friends.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129119>	C129099	FACIT-F Version 4 - Get Emotional Support From Family|FAC071-Get Emotional Support From Family|FAC071-Get Emotional Support From Family|FAC07109	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Social/Family Well-Being: I get emotional support from my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129120>	C129099	FACIT-F Version 4 - I Get Support From My Friends|FAC071-I Get Support From My Friends|FAC071-I Get Support From My Friends|FAC07110	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Social/Family Well-Being: I get support from my friends.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129121>	C129099	FACIT-F Version 4 - My Family Has Accepted My Illness|FAC071-My Family Has Accepted My Illness|FAC071-My Family Has Accepted My Illness|FAC07111	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Social/Family Well-Being: My family has accepted my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129122>	C129099	FACIT-F Version 4 - Satisfied Family Communication of Illness|FAC071-Satisfied Communication Illness|FAC071-Satisfied Communication Illness|FAC07112	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Social/Family Well-Being: I am satisfied with family communication about my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129123>	C129099	FACIT-F Version 4 - I Feel Close to My Partner|FAC071-I Feel Close to My Partner|FAC071-I Feel Close to My Partner|FAC07113	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Social/Family Well-Being: I feel close to my partner (or the person who is my main support).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129124>	C129099	FACIT-F Version 4 - I Am Satisfied With My Sex Life|FAC071-I Am Satisfied With My Sex Life|FAC071-I Am Satisfied With My Sex Life|FAC07114	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Social/Family Well-Being: I am satisfied with my sex life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129125>	C129099	FACIT-F Version 4 - I Feel Sad|FAC071-I Feel Sad|FAC071-I Feel Sad|FAC07115	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Emotional Well-Being: I feel sad.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129126>	C129099	FACIT-F Version 4 - Satisfied With How I Am Coping|FAC071-Satisfied With How I Am Coping|FAC071-Satisfied With How I Am Coping|FAC07116	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Emotional Well-Being: I am satisfied with how I am coping with my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129127>	C129099	FACIT-F Version 4 - Losing Hope Against Illness|FAC071-Losing Hope Against Illness|FAC071-Losing Hope Against Illness|FAC07117	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Emotional Well-Being: I am losing hope in the fight against my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129128>	C129099	FACIT-F Version 4 - I Feel Nervous|FAC071-I Feel Nervous|FAC071-I Feel Nervous|FAC07118	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Emotional Well-Being: I feel nervous.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129129>	C129099	FACIT-F Version 4 - I Worry About Dying|FAC071-I Worry About Dying|FAC071-I Worry About Dying|FAC07119	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Emotional Well-Being: I worry about dying.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12912>	C36773	Caco-2 Cell	Human colonic adenocarcinoma cells that express features characteristic of mature intestinal cells, including enterocytes or mucus cells, which are used as in vitro models for studies investigating intestinal cell function and differentiation.			Cell	
C129130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129130>	C129099	FACIT-F Version 4 - Worry My Condition Will Get Worse|FAC071-Worry My Condition Will Get Worse|FAC071-Worry My Condition Will Get Worse|FAC07120	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Emotional Well-Being: I worry that my condition will get worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129131>	C129099	FACIT-F Version 4 - I Am Able to Work|FAC071-I Am Able to Work|FAC071-I Am Able to Work|FAC07121	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Functional Well-Being: I am able to work (include work at home).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129132>	C129099	FACIT-F Version 4 - My Work Is Fulfilling|FAC071-My Work Is Fulfilling|FAC071-My Work Is Fulfilling|FAC07122	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Functional Well-Being: My work (include work at home) is fulfilling.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129133>	C129099	FACIT-F Version 4 - I Am Able to Enjoy Life|FAC071-I Am Able to Enjoy Life|FAC071-I Am Able to Enjoy Life|FAC07123	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Functional Well-Being: I am able to enjoy life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129134>	C129099	FACIT-F Version 4 - I Have Accepted My Illness|FAC071-I Have Accepted My Illness|FAC071-I Have Accepted My Illness|FAC07124	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Functional Well-Being: I have accepted my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129135>	C129099	FACIT-F Version 4 - I Am Sleeping Well|FAC071-I Am Sleeping Well|FAC071-I Am Sleeping Well|FAC07125	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Functional Well-Being: I am sleeping well.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129136>	C129099	FACIT-F Version 4 - Enjoy Things I Usually Do for Fun|FAC071-Enjoy Things I Usually Do for Fun|FAC071-Enjoy Things I Usually Do for Fun|FAC07126	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Functional Well-Being: I am enjoying the things I usually do for fun.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129137>	C129099	FACIT-F Version 4 - Content With Quality of My Life|FAC071-Content With Quality of My Life|FAC071-Content With Quality of My Life|FAC07127	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Functional Well-Being: I am content with the quality of my life right now.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129138>	C129099	FACIT-F Version 4 - I Feel Fatigued|FAC071-I Feel Fatigued|FAC071-I Feel Fatigued|FAC07128	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Additional Concerns: I feel fatigued.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129139>	C129099	FACIT-F Version 4 - I Feel Weak All Over|FAC071-I Feel Weak All Over|FAC071-I Feel Weak All Over|FAC07129	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Additional Concerns: I feel weak all over.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12913>		Abnormal Cell	An abnormal human cell type which can occur in either disease states or disease models.			Cell	
C129140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129140>	C129099	FACIT-F Version 4 - I Feel Listless|FAC071-I Feel Listless|FAC071-I Feel Listless|FAC07130	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Additional Concerns: I feel listless ('washed out').			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129141>	C129099	FACIT-F Version 4 - I Feel Tired|FAC071-I Feel Tired|FAC071-I Feel Tired|FAC07131	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Additional Concerns: I feel tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129142>	C129099	FACIT-F Version 4 - Trouble Starting Things|FAC071-Trouble Starting Things|FAC071-Trouble Starting Things|FAC07132	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Additional Concerns: I have trouble starting things because I am tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129143>	C129099	FACIT-F Version 4 - Trouble Finishing Things|FAC071-Trouble Finishing Things|FAC071-Trouble Finishing Things|FAC07133	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Additional Concerns: I have trouble finishing things because I am tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129144>	C129099	FACIT-F Version 4 - I Have Energy|FAC071-I Have Energy|FAC071-I Have Energy|FAC07134	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Additional Concerns: I have energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129145>	C129099	FACIT-F Version 4 - Able to Do My Usual Activities|FAC071-Able to Do My Usual Activities|FAC071-Able to Do My Usual Activities|FAC07135	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Additional Concerns: I am able to do my usual activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129146>	C129099	FACIT-F Version 4 - I Need to Sleep During the Day|FAC071-I Need to Sleep During the Day|FAC071-I Need to Sleep During the Day|FAC07136	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Additional Concerns: I need to sleep during the day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129147>	C129099	FACIT-F Version 4 - I Am Too Tired to Eat|FAC071-I Am Too Tired to Eat|FAC071-I Am Too Tired to Eat|FAC07137	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Additional Concerns: I am too tired to eat.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129148>	C129099	FACIT-F Version 4 - Need Help Doing Usual Activities|FAC071-Need Help Doing Usual Activities|FAC071-Need Help Doing Usual Activities|FAC07138	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Additional Concerns: I need help doing my usual activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129149>	C129099	FACIT-F Version 4 - Frustrated by Being Too Tired|FAC071-Frustrated by Being Too Tired|FAC071-Frustrated by Being Too Tired|FAC07139	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Additional Concerns: I am frustrated by being too tired to do the things I want to do.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12914>	C41073|C37064	Neoplastic Lymphoblast	A neoplastic immature cell of lymphoid lineage that gives rise to acute lymphoblastic leukemias.	Atypical Lymphoblast		Cell	
C129150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129150>	C129099	FACIT-F Version 4 - Limit Social Activity, I am Tired|FAC071-Limit Social Activity, I am Tired|FAC071-Limit Social Activity, I am Tired|FAC07140	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Additional Concerns: I have to limit my social activity because I am tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129151>	C129100	NCCN-FACT FKSI-19 Version 2 - I Have a Lack of Energy|FAC042-I Have a Lack of Energy|FAC042-I Have a Lack of Energy|FAC04201	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I have a lack of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129152>	C129100	NCCN-FACT FKSI-19 Version 2 - I Have Pain|FAC042-I Have Pain|FAC042-I Have Pain|FAC04202	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I have pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129153>	C129100	NCCN-FACT FKSI-19 Version 2 - I Am Losing Weight|FAC042-I Am Losing Weight|FAC042-I Am Losing Weight|FAC04203	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I am losing weight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129154>	C129100	NCCN-FACT FKSI-19 Version 2 - I Feel Fatigued|FAC042-I Feel Fatigued|FAC042-I Feel Fatigued|FAC04204	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I feel fatigued.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129155>	C129100	NCCN-FACT FKSI-19 Version 2 - I Have Been Short of Breath|FAC042-I Have Been Short of Breath|FAC042-I Have Been Short of Breath|FAC04205	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I have been short of breath.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129156>	C129100	NCCN-FACT FKSI-19 Version 2 - I Am Bothered by Fevers|FAC042-I Am Bothered by Fevers|FAC042-I Am Bothered by Fevers|FAC04206	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I am bothered by fevers (episodes of high body temperature).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129157>	C129100	NCCN-FACT FKSI-19 Version 2 - I Have Bone Pain|FAC042-I Have Bone Pain|FAC042-I Have Bone Pain|FAC04207	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I have bone pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129158>	C129100	NCCN-FACT FKSI-19 Version 2 - I Have Been Coughing|FAC042-I Have Been Coughing|FAC042-I Have Been Coughing|FAC04208	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I have been coughing.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129159>	C129100	NCCN-FACT FKSI-19 Version 2 - I Feel Weak All Over|FAC042-I Feel Weak All Over|FAC042-I Feel Weak All Over|FAC04209	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I feel weak all over.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12915>	C38333	Small Cleaved Follicle Center Cell	A lymphoid cell of follicular center cell origin that has an irregularly shaped nucleus with clumped chromatin, absent nucleoli, and one or more clefts in the nuclear membrane.	Small Cleaved Cell		Cell	
C129160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129160>	C129100	NCCN-FACT FKSI-19 Version 2 - I Have Had Blood in My Urine|FAC042-I Have Had Blood in My Urine|FAC042-I Have Had Blood in My Urine|FAC04210	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I have had blood in my urine.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129161>	C129100	NCCN-FACT FKSI-19 Version 2 - I Have a Good Appetite|FAC042-I Have a Good Appetite|FAC042-I Have a Good Appetite|FAC04211	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I have a good appetite.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129162>	C129100	NCCN-FACT FKSI-19 Version 2 - I Am Sleeping Well|FAC042-I Am Sleeping Well|FAC042-I Am Sleeping Well|FAC04212	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I am sleeping well.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129163>	C129100	NCCN-FACT FKSI-19 Version 2 - Worry My Condition Will Get Worse|FAC042-Worry My Condition Will Get Worse|FAC042-Worry My Condition Will Get Worse|FAC04213	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I worry that my condition will get worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129164>	C129100	NCCN-FACT FKSI-19 Version 2 - I Have Nausea|FAC042-I Have Nausea|FAC042-I Have Nausea|FAC04214	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I have nausea.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129165>	C129100	NCCN-FACT FKSI-19 Version 2 - I Have Diarrhea|FAC042-I Have Diarrhea|FAC042-I Have Diarrhea|FAC04215	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I have diarrhea (diarrhoea).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129166>	C129100	NCCN-FACT FKSI-19 Version 2 - Bothered by Treatment Side Effect|FAC042-Bothered by Treatment Side Effect|FAC042-Bothered by Treatment Side Effect|FAC04216	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I am bothered by side effects of treatment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129167>	C129100	NCCN-FACT FKSI-19 Version 2 - I Am Able to Work|FAC042-I Am Able to Work|FAC042-I Am Able to Work|FAC04217	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I am able to work (include work at home).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129168>	C129100	NCCN-FACT FKSI-19 Version 2 - I Am Able to Enjoy Life|FAC042-I Am Able to Enjoy Life|FAC042-I Am Able to Enjoy Life|FAC04218	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I am able to enjoy life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129169>	C129100	NCCN-FACT FKSI-19 Version 2 - Content With Quality of My Life|FAC042-Content With Quality of My Life|FAC042-Content With Quality of My Life|FAC04219	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 Version 2 (NCCN-FACT FKSI-19 Version 2) I am content with the quality of my life right now.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FKSI-19 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12916>	C37046	Micromegakaryocyte|Atypically Small Megakaryocyte				Cell	
C129170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129170>	C129101	NCCN-FACT FBLSI-18 Version 2 - I Have Pain|FAC028-I Have Pain|FAC028-I Have Pain|FAC02801	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I have pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129171>	C129101	NCCN-FACT FBLSI-18 Version 2 - I Am Losing Weight|FAC028-I Am Losing Weight|FAC028-I Am Losing Weight|FAC02802	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I am losing weight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129172>	C129101	NCCN-FACT FBLSI-18 Version 2 - Have Trouble Controlling My Urine|FAC028-Have Trouble Controlling My Urine|FAC028-Have Trouble Controlling My Urine|FAC02803	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I have trouble controlling my urine.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129173>	C129101	NCCN-FACT FBLSI-18 Version 2 - I Feel Weak All Over|FAC028-I Feel Weak All Over|FAC028-I Feel Weak All Over|FAC02804	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I feel weak all over.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129174>	C129101	NCCN-FACT FBLSI-18 Version 2 - I Feel Light-headed|FAC028-I Feel Light-headed|FAC028-I Feel Light-headed|FAC02805	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I feel light-headed (dizzy).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129175>	C129101	NCCN-FACT FBLSI-18 Version 2 - Trouble Meeting Needs of Family|FAC028-Trouble Meeting Needs of Family|FAC028-Trouble Meeting Needs of Family|FAC02806	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) Because of my physical condition, I have trouble meeting the needs of my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129176>	C129101	NCCN-FACT FBLSI-18 Version 2 - I Have a Good Appetite|FAC028-I Have a Good Appetite|FAC028-I Have a Good Appetite|FAC02807	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I have a good appetite.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129177>	C129101	NCCN-FACT FBLSI-18 Version 2 - Able to Have, Maintain Erection|FAC028-Able to Have/Maintain Erection|FAC028-Able to Have/Maintain Erection|FAC02808	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) (For men only) I am able to have and maintain an erection.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129178>	C129101	NCCN-FACT FBLSI-18 Version 2 - I Am Sleeping Well|FAC028-I Am Sleeping Well|FAC028-I Am Sleeping Well|FAC02809	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I am sleeping well.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129179>	C129101	NCCN-FACT FBLSI-18 Version 2 - Worry My Condition Will Get Worse|FAC028-Worry My Condition Will Get Worse|FAC028-Worry My Condition Will Get Worse|FAC02810	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I worry that my condition will get worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12917>	C12922	Malignant Cell|Cancer Cell|MALIGNANT_CELLS|Tumor cells, malignant	Cells of, or derived from, a malignant tumor.			Cell	GCT Cytology Table|GCT Variable Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Morphology PT Terminology|Mapped ICDO3.1 Morphology Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C129180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129180>	C129101	NCCN-FACT FBLSI-18 Version 2 - I Feel Sad|FAC028-I Feel Sad|FAC028-I Feel Sad|FAC02811	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I feel sad.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129181>	C129101	NCCN-FACT FBLSI-18 Version 2 - I Have Nausea|FAC028-I Have Nausea|FAC028-I Have Nausea|FAC02812	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I have nausea.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129182>	C129101	NCCN-FACT FBLSI-18 Version 2 - I Have a Lack of Energy|FAC028-I Have a Lack of Energy|FAC028-I Have a Lack of Energy|FAC02813	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I have a lack of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129183>	C129101	NCCN-FACT FBLSI-18 Version 2 - I Feel Ill|FAC028-I Feel Ill|FAC028-I Feel Ill|FAC02814	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I feel ill.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129184>	C129101	NCCN-FACT FBLSI-18 Version 2 - I Have Control of My Bowels|FAC028-I Have Control of My Bowels|FAC028-I Have Control of My Bowels|FAC02815	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I have control of my bowels.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129185>	C129101	NCCN-FACT FBLSI-18 Version 2 - Bothered by Treatment Side Effect|FAC028-Bothered by Treatment Side Effect|FAC028-Bothered by Treatment Side Effect|FAC02816	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I am bothered by side effects of treatment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129186>	C129101	NCCN-FACT FBLSI-18 Version 2 - I Am Able to Enjoy Life|FAC028-I Am Able to Enjoy Life|FAC028-I Am Able to Enjoy Life|FAC02817	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I am able to enjoy life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129187>	C129101	NCCN-FACT FBLSI-18 Version 2 - Content With Quality of My Life|FAC028-Content With Quality of My Life|FAC028-Content With Quality of My Life|FAC02818	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Bladder Symptom Index-18 Version 2 (NCCN-FACT FBLSI-18 Version 2) I am content with the quality of my life right now.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBLSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129188>	C129102	FACT-B Version 4 - I Have a Lack of Energy|FAC005-I Have a Lack of Energy|FAC005-I Have a Lack of Energy|FAC00501	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Physical Well-Being: I have a lack of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129189>	C129102	FACT-B Version 4 - I Have Nausea|FAC005-I Have Nausea|FAC005-I Have Nausea|FAC00502	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Physical Well-Being: I have nausea.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12918>	C32725	Hematopoietic Blast Cell|Blast Cell|Blast Cells|Blasts|blast	A precursor cell which gives rise to a fully differentiated cell of hematopoietic lineage.	Blast Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C129190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129190>	C129102	FACT-B Version 4 - Trouble Meeting Needs of Family|FAC005-Trouble Meeting Needs of Family|FAC005-Trouble Meeting Needs of Family|FAC00503	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Physical Well-Being: Because of my physical condition, I have trouble meeting the needs of my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129191>	C129102	FACT-B Version 4 - I Have Pain|FAC005-I Have Pain|FAC005-I Have Pain|FAC00504	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Physical Well-Being: I have pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129192>	C129102	FACT-B Version 4 - Bothered by Treatment Side Effect|FAC005-Bothered by Treatment Side Effect|FAC005-Bothered by Treatment Side Effect|FAC00505	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Physical Well-Being: I am bothered by side effects of treatment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129193>	C129102	FACT-B Version 4 - I Feel Ill|FAC005-I Feel Ill|FAC005-I Feel Ill|FAC00506	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Physical Well-Being: I feel ill.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129194>	C129102	FACT-B Version 4 - I Am Forced to Spend Time in Bed|FAC005-I Am Forced to Spend Time in Bed|FAC005-I Am Forced to Spend Time in Bed|FAC00507	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Physical Well-Being: I am forced to spend time in bed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129195>	C129102	FACT-B Version 4 - I Feel Close to My Friends|FAC005-I Feel Close to My Friends|FAC005-I Feel Close to My Friends|FAC00508	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Social/Family Well-Being: I feel close to my friends.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129196>	C129102	FACT-B Version 4 - Get Emotional Support From Family|FAC005-Get Emotional Support From Family|FAC005-Get Emotional Support From Family|FAC00509	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Social/Family Well-Being: I get emotional support from my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129197>	C129102	FACT-B Version 4 - I Get Support From My Friends|FAC005-I Get Support From My Friends|FAC005-I Get Support From My Friends|FAC00510	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Social/Family Well-Being: I get support from my friends.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129198>	C129102	FACT-B Version 4 - My Family Has Accepted My Illness|FAC005-My Family Has Accepted My Illness|FAC005-My Family Has Accepted My Illness|FAC00511	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Social/Family Well-Being: My family has accepted my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129199>	C129102	FACT-B Version 4 - Satisfied Family Communication of Illness|FAC005-Satisfied Communication Illness|FAC005-Satisfied Communication Illness|FAC00512	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Social/Family Well-Being: I am satisfied with family communication about my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12919>	C12219	Organ System|Body Systems|Organ Systems|body system|body_system	An anatomical structure that consists of organs and organ subclasses responsible for certain body functions.  Representative examples are the gastrointestinal system, urinary system, and hematopoietic system.	Organ System		Body System	ICDC Property Terminology|ICDC Terminology
C1291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1291>	C1962	Antisense Oligonucleotides|AS ODNs|Antisense Agents|Gene Expression Inhibitor|antisense agent|antisense oligonucleotide	Antisense Oligonucleotides, short synthetic segments of DNA or RNA, designed with a sequence complimentary to a specific mRNA that target and bind with mRNA, causing inhibition of translation or overexpression of the protein encoded by the mRNA.			Chemical Viewed Functionally	NCI Drug Dictionary Terminology
C129200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129200>	C129102	FACT-B Version 4 - I Feel Close to My Partner|FAC005-I Feel Close to My Partner|FAC005-I Feel Close to My Partner|FAC00513	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Social/Family Well-Being: I feel close to my partner (or the person who is my main support).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129201>	C129102	FACT-B Version 4 - I Am Satisfied With My Sex Life|FAC005-I Am Satisfied With My Sex Life|FAC005-I Am Satisfied With My Sex Life|FAC00514	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Social/Family Well-Being: I am satisfied with my sex life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129202>	C129102	FACT-B Version 4 - I Feel Sad|FAC005-I Feel Sad|FAC005-I Feel Sad|FAC00515	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Emotional Well-Being: I feel sad.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129203>	C129102	FACT-B Version 4 - Satisfied With How I Am Coping|FAC005-Satisfied With How I Am Coping|FAC005-Satisfied With How I Am Coping|FAC00516	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Emotional Well-Being: I am satisfied with how I am coping with my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129204>	C129102	FACT-B Version 4 - Losing Hope Against Illness|FAC005-Losing Hope Against Illness|FAC005-Losing Hope Against Illness|FAC00517	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Emotional Well-Being: I am losing hope in the fight against my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129205>	C129102	FACT-B Version 4 - I Feel Nervous|FAC005-I Feel Nervous|FAC005-I Feel Nervous|FAC00518	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Emotional Well-Being: I feel nervous.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129206>	C129102	FACT-B Version 4 - I Worry About Dying|FAC005-I Worry About Dying|FAC005-I Worry About Dying|FAC00519	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Emotional Well-Being: I worry about dying.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129207>	C129102	FACT-B Version 4 - Worry My Condition Will Get Worse|FAC005-Worry My Condition Will Get Worse|FAC005-Worry My Condition Will Get Worse|FAC00520	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Emotional Well-Being: I worry that my condition will get worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129208>	C129102	FACT-B Version 4 - I Am Able to Work|FAC005-I Am Able to Work|FAC005-I Am Able to Work|FAC00521	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Functional Well-Being: I am able to work (include work at home).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129209>	C129102	FACT-B Version 4 - My Work Is Fulfilling|FAC005-My Work Is Fulfilling|FAC005-My Work Is Fulfilling|FAC00522	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Functional Well-Being: My work (include work at home) is fulfilling.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12920>	C12543	EBV-Specific Cytotoxic T-Lymphocyte|EBV-specific CTL|EBV-specific Cytotoxic T-lymphocytes|Epstein-Barr virus-specific cytotoxic T-lymphocytes	A white blood cell that is derived from a lymphocyte stem cell matured in the thymus and characterized by a CD8 marker on the surface and an antigen-specific Epstein Barr virus T cell receptor.	EBV-specific Cytotoxic T-lymphocyte		Cell	
C129210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129210>	C129102	FACT-B Version 4 - I Am Able to Enjoy Life|FAC005-I Am Able to Enjoy Life|FAC005-I Am Able to Enjoy Life|FAC00523	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Functional Well-Being: I am able to enjoy life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129211>	C129102	FACT-B Version 4 - I Have Accepted My Illness|FAC005-I Have Accepted My Illness|FAC005-I Have Accepted My Illness|FAC00524	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Functional Well-Being: I have accepted my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129212>	C129102	FACT-B Version 4 - I Am Sleeping Well|FAC005-I Am Sleeping Well|FAC005-I Am Sleeping Well|FAC00525	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Functional Well-Being: I am sleeping well.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129213>	C129102	FACT-B Version 4 - Enjoy Things I Usually Do for Fun|FAC005-Enjoy Things I Usually Do for Fun|FAC005-Enjoy Things I Usually Do for Fun|FAC00526	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Functional Well-Being: I am enjoying the things I usually do for fun.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129214>	C129102	FACT-B Version 4 - Content With Quality of My Life|FAC005-Content With Quality of My Life|FAC005-Content With Quality of My Life|FAC00527	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Functional Well-Being: I am content with the quality of my life right now.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129215>	C129102	FACT-B Version 4 - I Have Been Short of Breath|FAC005-I Have Been Short of Breath|FAC005-I Have Been Short of Breath|FAC00528	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Additional Concerns: I have been short of breath.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129216>	C129102	FACT-B Version 4 - Self-conscious About Way I Dress|FAC005-Self-conscious About Way I Dress|FAC005-Self-conscious About Way I Dress|FAC00529	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Additional Concerns: I am self-conscious about the way I dress.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129217>	C129102	FACT-B Version 4 - One or Both Arms Are Swollen or Tender|FAC005-One/Both Arms Are Swollen/Tender|FAC005-One/Both Arms Are Swollen/Tender|FAC00530	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Additional Concerns: One or both of my arms are swollen or tender.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129218>	C129102	FACT-B Version 4 - I Feel Sexually Attractive|FAC005-I Feel Sexually Attractive|FAC005-I Feel Sexually Attractive|FAC00531	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Additional Concerns: I feel sexually attractive.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129219>	C129102	FACT-B Version 4 - I Am Bothered by Hair Loss|FAC005-I Am Bothered by Hair Loss|FAC005-I Am Bothered by Hair Loss|FAC00532	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Additional Concerns: I am bothered by hair loss.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12921>	C12535	Large Granular Lymphocyte|LGL|Large Granular Lymphocytes|large granular lymphocyte	A population of large-sized lymphocytes found in human peripheral blood with slightly eccentric nuclei and abundant cytoplasmic azurophilic granules. This population of cells can be comprised of normal natural killer (NK) cells.	Large Granular Lymphocyte		Cell	CTRP Biomarker Terminology|CTRP Terminology
C129220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129220>	C129102	FACT-B Version 4 - Worry Family Will Get Illness|FAC005-Worry Family Will Get Illness|FAC005-Worry Family Will Get Illness|FAC00533	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Additional Concerns: I worry that other members of my family might someday get the same illness I have.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129221>	C129102	FACT-B Version 4 - Worry About the Effect of Stress|FAC005-Worry About the Effect of Stress|FAC005-Worry About the Effect of Stress|FAC00534	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Additional Concerns: I worry about the effect of stress on my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129222>	C129102	FACT-B Version 4 - I Am Bothered by Change in Weight|FAC005-I Am Bothered by Change in Weight|FAC005-I Am Bothered by Change in Weight|FAC00535	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Additional Concerns: I am bothered by a change in weight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129223>	C129102	FACT-B Version 4 - I Am Able to Feel Like a Woman|FAC005-I Am Able to Feel Like a Woman|FAC005-I Am Able to Feel Like a Woman|FAC00536	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Additional Concerns: I am able to feel like a woman.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129224>	C129102	FACT-B Version 4 - Certain Parts of Body Have Pain|FAC005-Certain Parts of Body Have Pain|FAC005-Certain Parts of Body Have Pain|FAC00537	Functional Assessment of Cancer Therapy-Breast Version 4 (FACT-B Version 4) Additional Concerns: I have certain parts of my body where I experience pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-B Version 4 Test Code Terminology|CDISC Questionnaire FACT-B Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129225>	C129103	FOSI - I Have a Lack of Energy|FAC049-I Have a Lack of Energy|FAC049-I Have a Lack of Energy|FAC04901	Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) I have a lack of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FOSI Test Code Terminology|CDISC Questionnaire FOSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129226>	C129103	FOSI - I Have Been Vomiting|FAC049-I Have Been Vomiting|FAC049-I Have Been Vomiting|FAC04902	Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) I have been vomiting.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FOSI Test Code Terminology|CDISC Questionnaire FOSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129227>	C129103	FOSI - I Have Pain|FAC049-I Have Pain|FAC049-I Have Pain|FAC04903	Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) I have pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FOSI Test Code Terminology|CDISC Questionnaire FOSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129228>	C129103	FOSI - I Have Nausea|FAC049-I Have Nausea|FAC049-I Have Nausea|FAC04904	Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) I have nausea.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FOSI Test Code Terminology|CDISC Questionnaire FOSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129229>	C129103	FOSI - I Have Swelling in Stomach Area|FAC049-I Have Swelling in Stomach Area|FAC049-I Have Swelling in Stomach Area|FAC04905	Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) I have swelling in my stomach area.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FOSI Test Code Terminology|CDISC Questionnaire FOSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12922>	C12913	Neoplastic Cell|Tumor Cell|Tumor cells, NOS|Tumor cells, uncertain whether benign or malignant	Cells of, or derived from, a tumor.			Cell	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Morphology PT Terminology|Mapped ICDO3.1 Morphology Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C129230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129230>	C129103	FOSI - Worry My Condition Will Get Worse|FAC049-Worry My Condition Will Get Worse|FAC049-Worry My Condition Will Get Worse|FAC04906	Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) I worry that my condition will get worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FOSI Test Code Terminology|CDISC Questionnaire FOSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129231>	C129103	FOSI - Content With Quality of My Life|FAC049-Content With Quality of My Life|FAC049-Content With Quality of My Life|FAC04907	Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) I am content with the quality of my life right now.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FOSI Test Code Terminology|CDISC Questionnaire FOSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129232>	C129103	FOSI - I Have Cramps in My Stomach Area|FAC049-I Have Cramps in My Stomach Area|FAC049-I Have Cramps in My Stomach Area|FAC04908	Functional Assessment of Cancer Therapy-Ovarian Symptom Index (FOSI) I have cramps in my stomach area.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FOSI Test Code Terminology|CDISC Questionnaire FOSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129233>	C129104	NCCN-FACT FOSI-18 Version 2 - I Have a Lack of Energy|FAC050-I Have a Lack of Energy|FAC050-I Have a Lack of Energy|FAC05001	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I have a lack of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129234>	C129104	NCCN-FACT FOSI-18 Version 2 - I Have Pain|FAC050-I Have Pain|FAC050-I Have Pain|FAC05002	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I have pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129235>	C129104	NCCN-FACT FOSI-18 Version 2 - I Feel Ill|FAC050-I Feel Ill|FAC050-I Feel Ill|FAC05003	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I feel ill.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129236>	C129104	NCCN-FACT FOSI-18 Version 2 - I Have Cramps in My Stomach Area|FAC050-I Have Cramps in My Stomach Area|FAC050-I Have Cramps in My Stomach Area|FAC05004	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I have cramps in my stomach area.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129237>	C129104	NCCN-FACT FOSI-18 Version 2 - I Feel Fatigued|FAC050-I Feel Fatigued|FAC050-I Feel Fatigued|FAC05005	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I feel fatigued.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129238>	C129104	NCCN-FACT FOSI-18 Version 2 - I Am Bothered by Constipation|FAC050-I Am Bothered by Constipation|FAC050-I Am Bothered by Constipation|FAC05006	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I am bothered by constipation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129239>	C129104	NCCN-FACT FOSI-18 Version 2 - I Have Swelling in Stomach Area|FAC050-I Have Swelling in Stomach Area|FAC050-I Have Swelling in Stomach Area|FAC05007	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I have swelling in my stomach area.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12923>	C225418	Supratentorial|supratentorial		Supratentorial		Spatial Concept	
C129240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129240>	C129104	NCCN-FACT FOSI-18 Version 2 - I Have Control of My Bowels|FAC050-I Have Control of My Bowels|FAC050-I Have Control of My Bowels|FAC05008	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I have control of my bowels.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129241>	C129104	NCCN-FACT FOSI-18 Version 2 - I Am Sleeping Well|FAC050-I Am Sleeping Well|FAC050-I Am Sleeping Well|FAC05009	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I am sleeping well.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129242>	C129104	NCCN-FACT FOSI-18 Version 2 - Worry My Condition Will Get Worse|FAC050-Worry My Condition Will Get Worse|FAC050-Worry My Condition Will Get Worse|FAC05010	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I worry that my condition will get worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129243>	C129104	NCCN-FACT FOSI-18 Version 2 - I Have Nausea|FAC050-I Have Nausea|FAC050-I Have Nausea|FAC05011	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I have nausea.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129244>	C129104	NCCN-FACT FOSI-18 Version 2 - I Am Bothered by Hair Loss|FAC050-I Am Bothered by Hair Loss|FAC050-I Am Bothered by Hair Loss|FAC05012	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I am bothered by hair loss.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129245>	C129104	NCCN-FACT FOSI-18 Version 2 - Bothered by Treatment Side Effect|FAC050-Bothered by Treatment Side Effect|FAC050-Bothered by Treatment Side Effect|FAC05013	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I am bothered by side effects of treatment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129246>	C129104	NCCN-FACT FOSI-18 Version 2 - I Have Been Vomiting|FAC050-I Have Been Vomiting|FAC050-I Have Been Vomiting|FAC05014	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I have been vomiting.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129247>	C129104	NCCN-FACT FOSI-18 Version 2 - I Am Bothered by Skin Problems|FAC050-I Am Bothered by Skin Problems|FAC050-I Am Bothered by Skin Problems|FAC05015	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I am bothered by skin problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129248>	C129104	NCCN-FACT FOSI-18 Version 2 - I Am Able to Get Around by Myself|FAC050-I Am Able to Get Around by Myself|FAC050-I Am Able to Get Around by Myself|FAC05016	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I am able to get around by myself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129249>	C129104	NCCN-FACT FOSI-18 Version 2 - I Am Able to Enjoy Life|FAC050-I Am Able to Enjoy Life|FAC050-I Am Able to Enjoy Life|FAC05017	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I am able to enjoy life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12924>	C12791	Lumbar Spinal Nerve Root|Lumbar Spinal Nerve Roots	The initial portion of a lumbar spinal nerve, formed by the union of a dorsal sensory root and ventral motor root, as it originates from the spinal cord; there are five lumbar nerve roots on each side of the vertebral column, which exit the column inferior to their corresponding vertebral body level.	Lumbar Spinal Nerve Root		Body Part, Organ, or Organ Component	
C129250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129250>	C129104	NCCN-FACT FOSI-18 Version 2 - Content With Quality of My Life|FAC050-Content With Quality of My Life|FAC050-Content With Quality of My Life|FAC05018	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Ovarian Symptom Index-18 Version 2 (NCCN-FACT FOSI-18 Version 2) I am content with the quality of my life right now.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FOSI-18 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129251>	C177692	NCAM1 Positive|CD56 Antigen Positive|CD56 Positive|CD56 Positive|CD56+|NCAM1+|Neural Cell Adhesion Molecule 1 Positive	Indicates that NCAM1 expression has been detected in a sample.	NCAM1 Positive		Laboratory or Test Result	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129252>	C46005|C3420	RET Gene Translocation|RET Translocation|RET/PTC Translocation|Ret Proto-Oncogene Translocation	A cytogenetic abnormality that refers to any translocation involving the RET gene.	RET Gene Translocation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C129253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129253>	C15175	Human Immunodeficiency Virus 1 Positive|HIV-1 Positive|HIV-1+|HIV1 Positive|HIV1+	Indicates that human immunodeficiency virus 1 has been detected in a sample.	Human Immunodeficiency Virus 1 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C129254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129254>	C125750	ASEX-Female Version - Comments|ASEX01-Comments|ASEX01-Comments|ASEX0106	Arizona Sexual Experiences Scale-Female Version (ASEX-Female Version) Comments.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ASEX-Female Version Test Code Terminology|CDISC Questionnaire ASEX-Female Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129255>	C177692	CD19 Positive|B4 Positive|CD19 Antigen Positive|CD19 Molecule Positive|CD19+	Indicates that CD19 expression has been detected in a sample.	CD19 Positive		Laboratory or Test Result	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129256>	C125751	ASEX-Male Version - Comments|ASEX02-Comments|ASEX02-Comments|ASEX0206	Arizona Sexual Experiences Scale-Male Version (ASEX-Male Version) Comments.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ASEX-Male Version Test Code Terminology|CDISC Questionnaire ASEX-Male Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129257>	C94299|C177692	TNFRSF8 Positive|CD30 Antigen Positive|CD30 Positive|CD30+|Ki-1 Antigen Positive|Ki-1 Positive|TNFRSF8+|Tumor Necrosis Factor Receptor Superfamily Member 8 Positive	Indicates that TNFRSF8 expression has been detected in a sample.	TNFRSF8 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129258>	C177692|C162803	CDKN2A-p16 Positive|CDKN2A-p16(INK4a) Positive|CDKN2A-p16+|Cyclin-Dependent Kinase 4 Inhibitor A Positive|Cyclin-Dependent Kinase Inhibitor 2A Positive|p16 Positive|p16(INK4a) Positive|p16+|p16-INK4 Positive|p16-INK4+|p16INK4 Positive|p16INK4+|p16INK4a Positive	Indicates that CDKN2A-p16 expression has been detected in a sample.	CDKN2A-p16 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129259>	C157377	Castration Levels of Testosterone	A finding of low concentrations of testosterone in a subject's serum that results from the use of surgical or chemical castration procedures.	Castration Levels of Testosterone		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C12925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12925>	C12791	Sacral Spinal Nerve Root|Sacral Spinal Nerve Roots	The initial portion of any one of the five paired sacral nerves, which is formed by the union of a dorsal sensory root and ventral motor root; collectively, these roots are called the cauda equina.	Sacral Spinal Nerve Root		Body Part, Organ, or Organ Component	
C129260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129260>	C25939	IDH Gene Family|IDH|Isocitrate Dehydrogenase Gene Family	A family of genes that encode enzymes that catalyze the decarboxylation of isocitrate yielding alpha-ketoglutarate and carbon dioxide. Alpha-ketoglutarate is a precursor used in the synthesis of alanine, glutamine and pyruvate, and is an important intermediate in the citric acid cycle, which is an essential metabolic pathway used by cells to produce energy through aerobic respiration. Mutations in the IDH1 and IDH2 genes are associated with several types of brain tumors.	IDH Gene Family		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129261>	C29936	SERPINF2 Gene|SERPINF2|SERPINF2|Serpin Family F Member 2 Gene	This gene plays a role in the inhibition of serine proteinases.	SERPINF2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C129262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129262>	C129261	SERPINF2 wt Allele|A2AP|AAP|ALPHA-2-PI|API|PLI|Serine (Or Cysteine) Proteinase Inhibitor, Clade F (Alpha-2 Antiplasmin, Pigment Epithelium Derived Factor), Member 2 Gene|Serpin Family F Member 2 wt Allele|Serpin Peptidase Inhibitor, Clade F (Alpha-2 Antiplasmin, Pigment Epithelium Derived Factor), Member 2 Gene|Serpin Peptidase Inhibitor, Clade F, Member 2 Gene	Human SERPINF2 wild-type allele is located in the vicinity of 17p13 and is approximately 12 kb in length. This allele, which encodes alpha-2-antiplasmin protein, is involved in the regulation of blood coagulation. Mutation of the gene is associated with alpha-2-plasmin inhibitor deficiency.	SERPINF2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129263>	C17122	Alpha-2-Antiplasmin|ALPHA-2-PI|Alpha-2-AP|Alpha-2-Plasmin Inhibitor|SERPINF2|Serpin F2	Alpha-2-antiplasmin (491 aa, ~55 kDa) is encoded by the human SERPINF2 gene. This protein plays a role in the regulation of plasmin-mediated processes during blood coagulation.	Alpha-2-Antiplasmin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129264>	C36327	IDH Gene Family Mutation|IDH Family Mutation|IDH Gene Mutation|IDH Mutation|Positive|Yes	A change in the nucleotide sequence of an IDH family gene.	IDH Gene Family Mutation		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129265>	C20845	RPS2 Gene|RPS2|RPS2|Ribosomal Protein S2 Gene	This gene is involved in ribosomal function.	RPS2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C129266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129266>	C173603|C125410	Worst Severity Past Seven Days Difficulty Swallowing Question|In the last 7 days, what was the severity of your difficulty swallowing at its worst|Past Seven Days Worst Severity Difficulty Swallowing|Worst Severity Past Seven Days Difficulty Swallowing	A question about an individual's observation of the worst severity they have experienced related to difficulty swallowing over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C129267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129267>	C129265	RPS2 wt Allele|LLREP3|RPS4|Ribosomal Protein S2 wt Allele|S2	Human RPS2 wild-type allele is located in the vicinity of 16p13.3 and is approximately 3 kb in length. This allele, which encodes 40S ribosomal protein S2, plays a role in ribosome assembly.	RPS2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129268>	C21210	40S Ribosomal Protein S2|40S Ribosomal Protein S4|OK/KNS-Cl.6|Protein LLRep3|RPS2|Small Ribosomal Subunit Protein uS5	40S ribosomal protein S2 (293 aa, ~31 kDa) is encoded by the human RPS2 gene. This protein is involved in ribosome formation.	40S Ribosomal Protein S2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129269>	C173787|C173737|C173584	Past Seven Days Mouth or Throat Sores Interfering with Usual or Daily Activities Question|In the last 7 days, how much did mouth or throat sores interfere with your usual or daily activities|Past Seven Days How Much Mouth or Throat Sores Interfered with Usual or Daily Activities|Past Seven Days Mouth or Throat Sores Interfering with Usual or Daily Activities	A question about how much an individual's mouth or throat sores interfered with their usual or daily activities over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C12926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12926>	C12791	Thoracic Spinal Nerve Root|Thoracic Spinal Nerve Roots	The initial portion of any one of the twelve-paired thoracic nerves, formed by the union of a dorsal sensory root and ventral motor root, as it exits from the spinal cord.	Thoracic Spinal Nerve Root		Body Part, Organ, or Organ Component	
C129270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129270>	C173603	Worst Severity Past Seven Days Skin Cracking at the Corners of Mouth Question|In the last 7 days, what was the severity of skin cracking at the corners of your mouth at its worst|Past Seven Days Worst Severity Skin Cracking at the Corners of Mouth|Worst Severity Past Seven Days Skin Cracking at the Corners of Mouth	A question about an individual's observation of the worst severity they have experienced related to skin cracking at the corners of their mouth over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C129271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129271>	C7173|C185167	Astrocytoma, IDH-Mutant, Grade 2|Astrocytoma, IDH-Mutant, Grade II|Diffuse Astrocytoma, IDH Mutant|Diffuse Astrocytoma, IDH-Mutant|Diffuse astrocytoma, IDH-mutant	IDH-mutant astrocytoma characterized by the presence of well-differentiated fibrillary glial cells diffusely infiltrating the central nervous system.			Neoplastic Process	Cellosaurus Disease Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|NCIt Neoplasm Core Terminology
C129272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129272>	C4321|C129271	Gemistocytic Astrocytoma, IDH-Mutant|Gemistocytic Astrocytoma, IDH Mutant	Gemistocytic astrocytoma carrying IDH mutations.			Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology|NCIt Neoplasm Core Terminology
C129273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129273>	C173937|C173737	Past Seven Days Voice Change Question|In the last 7 days, did you have any voice changes|Past Seven Days Any Voice Change|Past Seven Days Voice Change	A question about whether or not an individual had any voice changes over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C129274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129274>	C7173|C185184	Diffuse Astrocytoma, IDH-Wildtype|Diffuse Astrocytoma, IDH Wild Type|Diffuse astrocytoma, IDH-wildtype	Diffuse astrocytoma lacking mutations in IDH1 or IDH2 genes.			Neoplastic Process	Cellosaurus Disease Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C129275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129275>	C173937|C173603	Worst Severity Past Seven Days Hoarse Voice Question|In the last 7 days, what was the severity of your hoarse voice at its worst|Past Seven Days Worst Severity Hoarse Voice|Worst Severity Past Seven Days Hoarse Voice	A question about an individual's observation of the worst severity they have experienced related to hoarse voice over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C129276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129276>	C173737	Past Seven Days Increased Passing of Gas Question|In the last 7 days, did you have any increased passing of gas (flatulence)|Past Seven Days Any Increased Passing of Gas|Past Seven Days Increased Passing of Gas	A question about whether or not an individual had any increased passing of gas (flatulence) over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C129277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129277>	C7173|C185185	Diffuse Astrocytoma, Not Otherwise Specified|Diffuse Astrocytoma, NOS|Diffuse Astrocytoma, NOS	A central nervous system tumor with morphological features of diffuse astrocytoma in which there is insufficient information on the IDH genes status.			Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology|NCIt Neoplasm Core Terminology
C129278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129278>	C173737	Past Seven Days Hives Question|In the past 7 days, did you have any hives (itchy red bumps on the skin)|Past Seven Days Any Hives|Past Seven Days Hives	A question about whether or not an individual had any hives over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C129279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129279>	C173737	Past Seven Days Loss of Fingernails or Toenails Question|In the last 7 days, did you lose any fingernails or toenails|Past Seven Days Any Loss of Fingernails or Toenails|Past Seven Days Loss of Fingernails or Toenails	A question about whether or not an individual lost any fingernails or toenails over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C12927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12927>	C34028	Renal Calyx|Renal Calix|Renal Calyces	An intrarenal space located in the renal medulla that serves to collect and transport urine.	Renal Calix		Body Part, Organ, or Organ Component	Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C129280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129280>	C173737	Past Seven Days Ridges or Bumps on Fingernails or Toenails Question|In the last 7 days, did you have any ridges or bumps on your fingernails or toenails|Past Seven Days Any Ridges or Bumps on Fingernails or Toenails|Past Seven Days Ridges or Bumps on Fingernails or Toenails	A question about whether or not an individual had any ridges or bumps on their fingernails or toenails over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C129281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129281>	C173737	Past Seven Days Color Change of Fingernails or Toenails Question|In the last 7 days, did you have any change in the color of your fingernails or toenails|Past Seven Days Any Color Change of Fingernails or Toenails|Past Seven Days Color Change of Fingernails or Toenails	A question about whether or not an individual had any change in color of their fingernails or toenails over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C129282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129282>	C173737	Past Seven Days Increased Skin Sensitivity to Sunlight Question|In the last 7 days, did you have any increased skin sensitivity to sunlight|Past Seven Days Any Increased Skin Sensitivity to Sunlight|Past Seven Days Increased Skin Sensitivity to Sunlight	A question about whether or not an individual had any increased skin sensitivity to sunlight over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C129283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129283>	C176020|C173603	Worst Severity Past Seven Days Problems with Memory Question|In the past 7 days, what was the severity of your problems with memory at their worst|Past Seven Days Worst Severity Problems with Memory|Worst Severity Past Seven Days Problems with Memory	A question about an individual's observation of the worst severity they have experienced related to problems with memory over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C129284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129284>	C176020|C173787|C173737|C173584	Past Seven Days Problems with Memory Interfering with Usual or Daily Activities Question|In the past 7 days, how much did problems with memory interfere with your usual or daily activities|Past Seven Days How Much Problems with Memory Interfered with Usual or Daily Activities|Past Seven Days Problems with Memory Interfering with Usual or Daily Activities	A question about how much an individual's problems with memory interfered with their usual or daily activities over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C129285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129285>	C173737|C173358|C173160	Past Seven Days Frequency of Feeling Nothing Could Cheer You Up Question|In the past 7 days, how often did you feel that nothing could cheer you up|Past Seven Days Frequency of Feeling Nothing Could Cheer You Up	A question about the frequency of an individual's feelings that nothing could cheer them up over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C129286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129286>	C173603|C173160	Worst Severity Past Seven Days Feeling Nothing Could Cheer You Up Question|In the past 7 days, what was the severity of your feelings that nothing could cheer you up at their worst|Past Seven Days Worst Severity Feeling Nothing Could Cheer You Up|Worst Severity Past Seven Days Feeling Nothing Could Cheer You Up	A question about an individual's observation of the worst severity they have experienced related to feeling that nothing could cheer them up over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C129287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129287>	C173787|C173737|C173584|C173160	Past Seven Days Feeling Nothing Could Cheer You Up Interfering with Usual or Daily Activities Question|In the past 7 days, how much did feeling that nothing could cheer you up interfere with your usual or daily activities|Past Seven Days Feeling Nothing Could Cheer You Up Interfering with Usual or Daily Activities|Past Seven Days How Much Feeling Nothing Could Cheer You Up Interfered with Usual or Daily Activities	A question about how much an individual's feeling that nothing could cheer them up interfered with their usual or daily activities over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C129288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129288>	C103223	IDH Gene Family Mutation Status Unknown|Cannot be determined|Unknown: Could not be determined or unsure	A finding indicating that there is no information regarding the presence or absence of IDH1 or IDH2 gene mutations in a tumor sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C129289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129289>	C27084|C129857	Gingival Spindle Cell Carcinoma	A poorly differentiated squamous cell carcinoma that arises from the gingiva. It is characterized by the presence of malignant pleomorphic spindle cells.			Neoplastic Process	Cellosaurus Disease Terminology|NCIt Neoplasm Core Terminology
C12928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12928>	C33622	Corneal Epithelium|CORNEAL EPITHELIUM	Stratified squamous cell tissue that covers the outer surface of the cornea.	Corneal Epithelium		Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C129290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129290>	C9477|C185167	Astrocytoma, IDH-Mutant, Grade 3|Anaplastic Astrocytoma, IDH Mutant|Anaplastic Astrocytoma, IDH-Mutant|Anaplastic astrocytoma, IDH-mutant|Astrocytoma, IDH-Mutant, Grade III	IDH-mutant astrocytoma characterized by the presence of increased mitotic activity and anaplastic features.			Neoplastic Process	Cellosaurus Disease Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|NCIt Neoplasm Core Terminology
C129291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129291>	C9477|C185184	Anaplastic Astrocytoma, IDH-Wildtype|Anaplastic Astrocytoma, IDH Wild Type|Anaplastic astrocytoma, IDH-wildtype	Anaplastic astrocytoma lacking mutations in IDH1 or IDH2 genes.			Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C129292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129292>	C9477|C185185	Anaplastic Astrocytoma, Not Otherwise Specified|Anaplastic Astrocytoma, NOS|Anaplastic Astrocytoma, NOS	A central nervous system tumor with morphological features of anaplastic astrocytoma in which there is insufficient information on the IDH genes status.			Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology|NCIt Neoplasm Core Terminology
C129293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129293>	C39750	Epithelioid Glioblastoma|E-GB|E-GBM|Epithelioid glioblastoma|e-GB|e-GBM	An IDH-wildtype glioblastoma characterized by the presence of large epithelioid cells with abundant eosinophilic cytoplasm, vesicular chromatin, and prominent nucleoli.			Neoplastic Process	GDC Terminology|GDC Value Terminology
C129294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129294>	C173885	Semmes Weinstein Monofilament Examination|SWME	A noninvasive screening tool for peripheral neuropathy. A monofilament strand is pressed on a test site perpendicularly until it bends. If a patient fails to sense the monofilament after it bends, the test site is considered to be insensate.	Semmes Weinstein Monofilament Examination		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C129295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129295>	C3058	Glioblastoma, Not Otherwise Specified|Glioblastoma, NOS	A central nervous system tumor with morphological features of glioblastoma in which there is insufficient information on the IDH genes status.			Neoplastic Process	NCIt Neoplasm Core Terminology
C129296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129296>	C39750	Glioblastoma with Primitive Neuronal Component|Glioblastoma with PNET-Like Component	A glioblastoma characterized by the presence of well-demarcated nodules which contain primitive cells exhibiting neuronal differentiation.			Neoplastic Process	
C129297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129297>	C134526	Canine Glioma	A brain or spinal cord tumor arising from glial cells that occurs in dogs.			Neoplastic Process	Cellosaurus Disease Terminology
C129298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129298>	C134526	Canine Hepatocellular Carcinoma	A malignant tumor arising from hepatocytes that occurs in dogs.			Neoplastic Process	Cellosaurus Disease Terminology
C129299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129299>	C134526	Canine Lung Adenocarcinoma	A carcinoma that arises from the lung in dogs and is characterized by the presence of malignant glandular epithelial cells.			Neoplastic Process	Cellosaurus Disease Terminology
C12929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12929>	C33968	Nerve Plexus|Nerve Plexi	A network of intersecting nerve fibers that link peripheral nerves with specific areas of the body.	Nerve Plexus		Anatomical Structure	
C1292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1292>	C26549	Ribozyme|Catalytic RNA|Catalytic RNA|RIBOZYME|RNA, Catalytic|Ribonucleic Enzyme	RNA that contains an intron sequence which has an enzyme-like catalytic activity. This intron sequence has been shown to fold up to form a complex surface that can function like an enzyme in reactions with other RNA molecules and thus synthesize new molecules even in the absence of protein. Synthetic ribozymes can be engineered to specifically cleave a target RNA sequence causing expression down regulation.			Enzyme|Nucleic Acid, Nucleoside, or Nucleotide	CDISC SDTM Genetic Sample Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129300>	C134526	Canine Rhabdomyosarcoma	A malignant mesenchymal neoplasm arising from skeletal muscle that occurs in dogs.			Neoplastic Process	Cellosaurus Disease Terminology
C129301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129301>	C34360	Adrenal Gland Hyperplasia II|3-Beta-Hydroxysteroid Dehydrogenase Deficiency|Adrenal Gland Hyperplasia, Congenital, due to 3-Beta-Hydroxysteroid Dehydrogenase 2 Deficiency|HSDB	Decreased activity of the enzyme 3-beta-hydroxysteroid dehydrogenase, associated with mutation(s) in the HSD3B2 gene. The lack of activity of this enzyme produces a type of congenital adrenal hyperplasia.			Disease or Syndrome	Cellosaurus Disease Terminology
C129302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129302>	C34360	Adrenal Gland Hyperplasia III|21-Hydroxylase Deficieny|Adrenal Gland Hyperplasia, Congenital, due to 21-Hydroxylase Deficiency|CAH1|CYP21 Deficiency|Congenital Adrenal Hyperplasia 1	Decreased activity of the enzyme 21-hydroxylase, associated with mutation(s) in the CYP21A2 gene. The lack of activity of this enzyme produces a type of congenital adrenal hyperplasia (CAH) and is the cause of approximately 95% of CAH.			Disease or Syndrome	Cellosaurus Disease Terminology
C129303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129303>	C53543	Congenital Bilateral Aplasia of the Vas Deferens|CAVD	An autosomal recessive disorder that is associated with mutation(s) in the CFTR gene, encoding cystic fibrosis transmembrane conductance regulator. Mutation(s) in the same gene are associated with cystic fibrosis.			Disease or Syndrome	Cellosaurus Disease Terminology
C129304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129304>	C84647	Congenital Myasthenic Syndrome 5|CMS5|EAD|Endplate Acetylcholinesterase Deficiency	Congenital myasthenic syndrome caused by mutation(s) in the COLQ gene, encoding acetylcholinesterase collagenic tail peptide. It is inherited in an autosomal recessive manner.			Disease or Syndrome	Cellosaurus Disease Terminology
C129305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129305>	C53543	Cranioectodermal Dysplasia|Sensenbrenner Syndrome	An autosomal recessive disorder associated with mutation(s) in at least one of four genes (WDR35, IFT122, WDR19, or IFT43). It is characterized by distinctive abnormalities of the face and skull, in association with developmental abnormalities of the structures derived from ectodermal tissues.			Disease or Syndrome	Cellosaurus Disease Terminology
C129306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129306>	C53543	Microcephaly and Chorioretinopathy, Autosomal Recessive, Type 1|MCCRP1	An autosomal recessive disorder caused by mutation(s) in the TUBGCP6 gene, encoding gamma-tubulin complex component 6. It is characterized by microcephaly and chorioretinopathy.			Disease or Syndrome	Cellosaurus Disease Terminology
C129307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129307>	C53543	N-Acetylglutamate Synthase Deficiency|NAGSD	An autosomal recessive disorder caused by mutation(s) in the NAGS gene, encoding N-acetylglutamate synthase, mitochondrial. It may be characterized by failure to thrive, hyperammonemia, lethargy, seizures, and coma.			Disease or Syndrome	Cellosaurus Disease Terminology
C129308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129308>	C53543|C28193	Schinzel-Giedion Midface-Retraction Syndrome|Schinzel-Giedion Syndrome	An autosomal dominant disorder associated with mutation(s) in the SETBP1 gene, encoding SET-binding protein. It is characterized by unique facial features, including midface hypoplasia, skeletal abnormalities, and mental retardation.			Disease or Syndrome	CCPS Disease Terminology|Cellosaurus Disease Terminology|Childhood Cancer Predisposition Study Terminology
C129309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129309>	C185368	Diffuse Midline Glioma, H3 K27M-Mutant|Diffuse Midline Glioma H3 K27M|Diffuse midline glioma, H3 K27M-mutant|Non-DIPG	A diffuse midline glioma characterized by the presence of histone H3 K27M mutation.	Diffuse Midline Glioma, H3 K27M-Mutant		Neoplastic Process	CRF1 Registration Table|CRF3 Diagnosis Biopsy Table|CRF3 Diagnosis Re-Biopsy Table|CRF7 Pathology Review Table|CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C12930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12930>	C12683	Intrapulmonary Bronchus	A bronchial branch that is located within the lung tissue.	Intrapulmonary Bronchus		Body Part, Organ, or Organ Component	
C129310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129310>	C185375	H3 K27M Variant|Activating H3 K27M Mutation|H3 K27M|H3 K27M Mutation|H3 K27M Mutation|H3 K28M|H3 K28M Mutation|H3 K28M Variant|H3 Lys27Met|H3 Lys28Met|H3 p.K28M|H3 p.Lys28Met|H3K27M|H3K27M Mutation|Histone 3 K27M Mutation|Histone 3 K28M Mutation|Histone H3 K27M|Histone H3 K28M|Histone H3 Lys27Met|Histone H3 Lys28Met	A change in the amino acid residue at position 27 in histone H3 where lysine has been replaced by methionine.	H3 K27M Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C129311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129311>	C97928	H3 Protein Variant|Histone H3 Protein Variant	A variation in the amino acid sequence for the histone h3 protein.	H3 Protein Variant		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129312>	C1505	Chitin Oligosaccharides Supplement T-ChOS|Benecta|T-ChOs|Therapeutic CHOS	A proprietary, nutritional supplement comprised of chitooligosaccharides extracted from deproteinized and demineralized crustacean shell. Upon administration, chitin oligosaccharides supplement T-ChOS may increase stamina and boost energy. In addition, the chitooligosaccharides may stimulate chondrocyte growth.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C129313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129313>	C574|C208255	Factor VII-targeting Immunoconjugate Protein ICON-1|FVII Modified Conjugate ICON-1|FVII-targeting Immunoconjugate Protein ICON-1|Human Immuno-conjugate 1|ICON-1|VII-Fc Fusion Protein ICON-1	A human immunoconjugate (ICON) fusion protein composed of a modified version of human factor VII (FVII) which targets tissue factor (TF) that is fused to the Fc domain of the human immunoglobulin G1, with potential anti-thrombotic and antineoplastic activities. Acting in a similar manner as plasma FVII, the natural ligand of TF, ICON-1 targets and binds to TF expressed on neovascular endothelia, thereby preventing TF-mediated signaling pathways, and leading to the initiation of an immune response and the destruction of neovascular tissue. This prevents angiogenesis, inflammation and blood coagulation. Upon intravitreal administration, ICON-1 may block TF-induced angiogenesis and treat wet age-related macular degeneration (AMD) and ocular melanoma. TF, a naturally occurring glycoprotein in humans, regulates blood clotting, angiogenesis, and inflammation.	Factor VII-targeting Immunoconjugate Protein ICON-1		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129314>	C143099|C129825	Vilzemetkib|AL 2846|AL-2846|AL2846|VILZEMETKIB|c-Met Inhibitor AL2846	An orally bioavailable small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration vilzemetkib targets and binds to the c-Met protein, prevents c-Met phosphorylation and disrupts c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129315>	C201818	Tesidolumab|LFG-316|LFG316|NOV-4|TESIDOLUMAB	A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the complement pathway protein C5, with complement pathway inhibitory activity and potential immunomodulating activity. Upon administration, tesidolumab targets and binds to C5, thereby preventing both C5 convertase-mediated cleavage of C5 and the formation of C5a and C5b. This inhibits C5-mediated signal transduction, the formation of the membrane attack complex (MAC) and the activation of the terminal complement pathway, and results in the prevention and/or inhibition of both complement-mediated inflammation and cell destruction. C5 plays a key role in the activation of the complement cascade.	Tesidolumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129316>	C98241|C98234	Metformin Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet|ACTOplus Met XR|Metformin HCl/Pioglitazone HCl ER Tablet	An extended-release (ER) tablet composed of the hydrochloride salt form of the biguanide metformin and the hydrochloride salt form of the thiazolidinedione pioglitazone, with antihyperglycemic activity. Upon oral administration and although the exact mechanism of action has yet to be fully elucidated, metformin inhibits complex I (NADPH:ubiquinone oxidoreductase) of the mitochondrial respiratory chain and increases the cellular AMP to ATP ratio leading to activation of AMP-activated protein kinase (AMPK). This modulates AMPK-mediated transcription of target genes, which prevents hepatic gluconeogenesis, decreases intestinal absorption of glucose, enhances insulin sensitivity and fatty acid oxidation, and increases glucose uptake and utilization in target tissues. Pioglitazone binds to and activates the transcription factor peroxisome proliferator-activated receptor gamma (PPAR-gamma), thereby increasing the transcription of insulin-responsive genes. This enhances insulin sensitivity of insulin-dependent tissues, decreases insulin resistance, enhances peripheral glucose utilization, and decreases hepatic glucose output. Altogether, this lowers blood glucose levels.	Metformin Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C129318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129318>	C3288	Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted|Oligodendroglioma, IDH Mutant and 1p/19q Codeleted|Oligodendroglioma, IDH-mutant and 1p/19q-codeleted	An oligodendroglioma carrying IDH gene family mutation and combined whole-arm losses of 1p and 19q (1p/19q codeletion).	Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted		Neoplastic Process	Cellosaurus Disease Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|NCIt Neoplasm Core Terminology
C129319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129319>	C3288	Oligodendroglioma, Not Otherwise Specified|Oligodendroglioma, NOS|Oligodendroglioma, NOS|Oligodendroglioma, NOS	A central nervous system tumor with morphological features of oligodendroglioma in which there is insufficient information on the IDH genes and 1p/19q codeletion status.			Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Morphology PT Terminology|Mapped ICDO3.1 Morphology Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology|NCIt Neoplasm Core Terminology
C12931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12931>	C13442	Meningeal|MENINGEAL|meningeal		Meningeal		Spatial Concept	CDISC SEND Microscopic Findings Result Modifier Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Terminology
C129320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129320>	C103223	1p/19q Codeletion Status Unknown|Unknown	A finding indicating that there is no information regarding the presence or absence of 1p/19q codeletion in a tumor sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology
C129321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129321>	C4326	Anaplastic Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted|Anaplastic Oligodendroglioma, IDH mutant and 1p/19q Codeleted|Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted	An anaplastic oligodendroglioma carrying IDH gene family mutation and combined whole-arm losses of 1p and 19q (1p/19q codeletion).			Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology|NCIt Neoplasm Core Terminology
C129322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129322>	C4326	Anaplastic Oligodendroglioma, Not Otherwise Specified|Anaplastic Oligodendroglioma, NOS|Anaplastic Oligodendroglioma, NOS	A central nervous system tumor with morphological features of anaplastic oligodendroglioma in which there is insufficient information on the IDH genes and 1p/19q codeletion status.			Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology|NCIt Neoplasm Core Terminology
C129323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129323>	C4050	Oligoastrocytoma, Not Otherwise Specified|Oligoastrocytoma, NOS|Oligoastrocytoma, NOS	A central nervous system tumor with morphological features of oligoastrocytoma in which there is insufficient information on the IDH genes status.			Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology
C129324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129324>	C6959	Anaplastic Oligoastrocytoma, Not Otherwise Specified|Anaplastic Oligoastrocytoma, NOS|Anaplastic Oligoastrocytoma, NOS	A central nervous system tumor with morphological features of anaplastic oligoastrocytoma in which there is insufficient information on the IDH genes status.			Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology
C129325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129325>	C3059	Diffuse Glioma	A glioma that has diffusely infiltrated the surrounding central nervous system tissues.			Neoplastic Process	NCIt Neoplasm Core Terminology
C129326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129326>	C116454	Resting State Functional Connectivity Magnetic Resonance Imaging|RS-fcMRI|Resting State Functional Connectivity MRI|Resting fcMRI	A technique that monitors blood oxygen level dependent (BOLD) signals to map brain regions that active while not performing any specific task.	Resting State Functional Connectivity Magnetic Resonance Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C129327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129327>	C60781|C36025|C127816	Anaplastic Pleomorphic Xanthoastrocytoma|APX|Anaplastic pleomorphic xanthroastrocytoma|WHO Grade 3 Pleomorphic Xanthoastrocytoma|WHO Grade III Pleomorphic Xanthoastrocytoma	A WHO grade 3 pleomorphic xanthoastrocytoma characterized by the presence of five or more mitoses per 10 high-power fields. Necrosis may be present. Patients have shorter survival rates when compared to those with WHO grade 2 pleomorphic xanthoastrocytoma.	Anaplastic Pleomorphic Xanthoastrocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|NCIt Neoplasm Core Terminology
C129328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129328>	C91105	Female Sexual Function Index|FSFI|Female Sexual Function Index (FSFI)	A 19-item self-report questionnaire designed to measure sexual function in women. It was developed for assessing domains of sexual functioning (e.g. sexual arousal, orgasm, satisfaction, pain) in women participating in clinical trials for arousal disorders.			Intellectual Product	
C129329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129329>	C173704	Frequency of Sexual Desire or Interest Question|Frequency of Sexual Desire or Interest|How often did you feel sexual desire or interest	A question about how often an individual felt sexual desire or interest.			Intellectual Product	Female Sexual Function Index
C12932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12932>	C12981	Xenograft|Heterograft|Xenotransplant	Cells, tissues, or organs from a donor that are transplanted into a recipient of another species.	Xenograft		Biomedical or Dental Material	GDC Terminology|GDC Value Terminology
C129330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129330>	C173704	Level of Sexual Desire or Interest Question|How would you rate your level (degree) of sexual desire or interest|Level of Sexual Desire or Interest|Sexual Interest / Drive	A question about an individual's level or degree of sexual desire or interest.			Intellectual Product	Female Sexual Function Index|Patient Oriented Prostate Utility Scale
C129331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129331>	C173704	Frequency of Sexual Arousal During Sexual Activity or Intercourse Question|Frequency of Sexual Arousal During Sexual Activity or Intercourse|How often did you feel sexually aroused ("turned on") during sexual activity or intercourse	A question about how often an individual felt sexually aroused during sexual activity or intercourse.			Intellectual Product	Female Sexual Function Index
C129332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129332>	C173704	Level of Sexual Arousal During Sexual Activity or Intercourse Question|How would you rate your level of sexual arousal ("turn on") during sexual activity or intercourse|Level of Sexual Arousal During Sexual Activity or Intercourse	A question about an individual's level or degree of sexual arousal during sexual activity or intercourse.			Intellectual Product	Female Sexual Function Index
C129333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129333>	C173704|C173086	Confidence of Becoming Sexually Aroused During Sexual Activity or Intercourse Question|Confidence of Becoming Sexually Aroused During Sexual Activity or Intercourse|How confident were you about becoming sexually aroused during sexual activity or intercourse	A question about how confident an individual is or was to become sexually aroused during sexual activity or intercourse.			Intellectual Product	Female Sexual Function Index
C129334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129334>	C173792|C173704|C173358	Frequency of Satisfaction with Arousal During Sexual Activity or Intercourse Question|Frequency of Satisfaction with Arousal During Sexual Activity or Intercourse|How often have you been satisfied with your arousal (excitement) during sexual activity or intercourse	A question about how often an individual is or was satisfied with sexual arousal or excitement during sexual activity or intercourse.			Intellectual Product	Female Sexual Function Index
C129335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129335>	C173704|C173358	Frequency of Lubrication During Sexual Activity or Intercourse Question|Frequency of Lubrication During Sexual Activity or Intercourse|How often did you become lubricated ("wet") during sexual activity or intercourse	A question about how often an individual became lubricated during sexual activity or intercourse.			Intellectual Product	Female Sexual Function Index
C129336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129336>	C173704|C173398	Difficulty Becoming Lubricated During Sexual Activity or Intercourse Question|Difficulty Becoming Lubricated During Sexual Activity or Intercourse|How difficult was it to become lubricated ("wet") during sexual activity or intercourse	A question about how difficult it is or was for an individual to become lubricated during sexual activity or intercourse.			Intellectual Product	Female Sexual Function Index
C129337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129337>	C173704|C173358	Frequency in Maintenance of Lubrication Until Completion of Sexual Activity or Intercourse Question|Frequency in Maintenance of Lubrication Until Completion of Sexual Activity or Intercourse|How often did you maintain your lubrication ("wetness") until completion of sexual activity of intercourse	A question about how often an individual is or was able to maintain lubrication until completion of sexual activity or intercourse.			Intellectual Product	Female Sexual Function Index
C129338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129338>	C173704|C173398	Difficulty in Maintenance of Lubrication Until Completion of Sexual Activity or Intercourse Question|Difficulty in Maintenance of Lubrication Until Completion of Sexual Activity or Intercourse|How difficult was it to maintain your lubrication ("wetness") until completion of sexual activity or intercourse	A question about how difficult it is or was for an individual to maintain lubrication until completion of sexual activity or intercourse.			Intellectual Product	Female Sexual Function Index
C129339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129339>	C173704|C173358	Frequency of Reaching Orgasm with Sexual Stimulation or Intercourse Question|Frequency of Reaching Orgasm with Sexual Stimulation or Intercourse|When you had sexual stimulation or intercourse, how often did you reach orgasm (climax)	A question about how often orgasm or climax is or was reached when an individual had sexual stimulation or intercourse.			Intellectual Product	Female Sexual Function Index
C12933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12933>	C12366	Vertebra|Vertebrae	Any of thirty-three ring-shaped structures that form the vertebral column which surrounds and protects the spinal cord. Each vertebra consists of a bony body with its superior and inferior articular surfaces covered by hyaline cartilage. The body includes the centrum anteriorly and vertebral arch posteriorly. The articular surfaces of the vertebrae are connected by a fibrocartilaginous intervertebral disc.	Vertebrae		Body Part, Organ, or Organ Component	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C129340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129340>	C173704|C173398	Difficulty of Reaching Orgasm with Sexual Stimulation or Intercourse Question|Difficulty of Reaching Orgasm with Sexual Stimulation or Intercourse|When you had sexual stimulation or intercourse, how difficult was it for you reach orgasm (climax)	A question about how difficult it is or was to reach orgasm or climax when an individual had sexual stimulation or intercourse.			Intellectual Product	Female Sexual Function Index
C129341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129341>	C173792|C173704	Satisfaction of Ability to Reach Orgasm During Sexual Activity or Intercourse Question|How satisfied were you with your ability to reach orgasm (climax) during sexual activity or intercourse|Satisfaction of Ability to Reach Orgasm During Sexual Activity or Intercourse	A question about how satisfied an individual is or was with the ability to reach orgasm or climax during sexual activity or intercourse.			Intellectual Product	Female Sexual Function Index
C129342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129342>	C173792|C173704	Satisfaction of Emotional Closeness During Sexual Activity with Partner Question|How satisfied have you been with the amount of emotional closeness during sexual activity between you and your partner|Satisfaction of Emotional Closeness During Sexual Activity with Partner	A question about how satisfied an individual is or has been with the amount of emotional closeness during sexual activity with their partner.			Intellectual Product	Female Sexual Function Index
C129343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129343>	C173792|C173704	Satisfaction of Sexual Relationship with Partner Question|How satisfied have you been with your sexual relationship with your partner|Satisfaction of Sexual Relationship with Partner	A question about how satisfied an individual is or has been with the sexual relationship with their partner.			Intellectual Product	Female Sexual Function Index
C129344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129344>	C173792|C173704	Satisfaction with Overall Sexual Life Question|How satisfied have you been with your overall sexual life|Satisfaction with Overall Sexual Life	A question about how satisfied an individual is or has been with their overall sexual life.			Intellectual Product	Female Sexual Function Index
C129345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129345>	C175990|C156140|C104600	Frequency of Experiencing Discomfort or Pain During Vaginal Penetration Question|Frequency of Experiencing Discomfort or Pain During Vaginal Penetration|How often did you experience discomfort or pain during vaginal penetration	A question about how often an individual has experienced discomfort or pain during vaginal penetration.			Intellectual Product	Female Sexual Function Index
C129346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129346>	C175990|C156140|C104600	Frequency of Experiencing Discomfort or Pain Following Vaginal Penetration Question|Frequency of Experiencing Discomfort or Pain Following Vaginal Penetration|How often did you experience discomfort or pain following vaginal penetration	A question about how often an individual has experienced discomfort or pain following vaginal penetration.			Intellectual Product	Female Sexual Function Index
C129347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129347>	C156140	Level of Discomfort or Pain During or Following Vaginal Penetration Question|How would you rate your level (degree) of discomfort or pain during or following vaginal penetration|Level of Discomfort or Pain During or Following Vaginal Penetration	A question about the level or degree of discomfort or pain an individual has experienced during or following vaginal penetration.			Intellectual Product	Female Sexual Function Index
C129348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129348>	C175311	Always or Almost Always|Almost always or always	A response indicating that something happened always or almost always.			Intellectual Product	Female Sexual Function Index
C129349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129349>	C175311	A Few Times|A Few Times (Much Less Than Half the Time)|A few times (less than half the time)|Less Than Half the Time|Much Less than Half the Time	A response indicating that something happened less than half the time.			Intellectual Product	Female Sexual Function Index
C12934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12934>	C49346	Dorsal Motor Nucleus|DMN|DORSAL MOTOR NUCLEUS|Dorsal Motor Nucleus of the Vagus	A brain nucleus located in the medulla oblongata.	Dorsal Motor Nucleus of the Vagus		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C129350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129350>	C176245	Never or Almost Never|Almost never or never	A response indicating that something happened never or almost never.			Intellectual Product	Female Sexual Function Index
C129351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129351>	C186350	Supratentorial Ependymoma, ZFTA-RELA Fusion-Positive|Ependymoma, RELA Fusion-Positive|Ependymoma, RELA fusion-positive|Ependymoma, ZFTA-RELA Fusion-Positive|Supratentorial Ependymoma, RELA Fusion-Positive|Supratentorial Ependymoma, ZFTA::RELA Fusion-Positive	A supratentorial ependymoma characterized by a gene fusion involving ZFTA and RELA genes. It accounts for the majority of supratentorial ependymomas in children. It has an unfavorable outcome when compared to other ependymoma subtypes.			Neoplastic Process	GDC Terminology|GDC Value Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology|NCIt Neoplasm Core Terminology
C129352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129352>	C36346	ZFTA-RELA Fusion Protein Expression|C11orf95-RELA Fusion Protein Expression	Expression of a fusion protein that results from the fusion of RELA and ZFTA genes. It is present in the majority of supratentorial ependymomas in children.			Cell or Molecular Dysfunction	
C129353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129353>	C212860	ZFTA/RELA Fusion Gene|C11orf95-RELA Fusion Gene|C11orf95/RELA Fusion Gene|ZFTA-RELA Fusion Gene|ZFTA::RELA Fusion Gene	A fusion gene that results from chromothripsis involving chromosome 11q13.1, which fuses the first 2, 3 or 4 exons of the ZFTA gene to sequences that are located 5' of either exon 2 or 3 of the RELA gene. This rearrangement is associated with supratentorial ependymoma.			Gene or Genome	
C129354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129354>	C213262	ZFTA/RELA Fusion Protein|C11orf95-RELA Fusion Protein|C11orf95/RELA Fusion Protein|Uncharacterized Protein C11orf95/NF-Kappa B p65 Fusion Protein|Uncharacterized Protein C11orf95/Transcription Factor p65 Fusion Protein|ZFTA-RELA Fusion Protein|ZFTA::RELA Fusion Protein|Zinc Finger Translocation-Associated Protein-NF-Kappa B p65 Fusion Protein|Zinc Finger Translocation-Associated Protein/NF-Kappa B p65 Fusion Protein	A fusion protein encoded by the ZFTA/RELA fusion gene. This protein is comprised of the N-terminal domain of uncharacterized protein C11orf95 fused to most of the transcription factor p65 protein, including the transactivation domain.			Amino Acid, Peptide, or Protein	
C129355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129355>	C2950	Chromothripsis	A cytogenetic abnormality characterized by the occurrence of a large number of chromosomal rearrangements that are restricted to sites in one or a few chromosomes. Chromothripsis may result from a single catastrophic event that causes multiple double-strand breaks, which are subsequently repaired or reassembled by error-prone DNA repair pathways or through aberrant DNA replication mechanisms.			Cell or Molecular Dysfunction	
C129356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129356>	C176021|C173584|C173457	Symptoms Interfered with General Activity Question|General activity|Symptoms Interfered with General Activity	A question about how much an individual's symptoms interfere or interfered with their general activity.			Intellectual Product	MD Anderson Symptom Inventory - Brain Tumor
C129357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129357>	C173584|C173457	Symptoms Interfered with Mood Question|Mood|Symptoms Interfered with Mood	A question about how much an individual's symptoms interfere or interfered with their mood.			Intellectual Product	MD Anderson Symptom Inventory - Brain Tumor
C129358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129358>	C173924|C173584|C173457	Symptoms Interfered with Work Question|Symptoms Interfered with Work|Work (including work around the house)	A question about how much an individual's symptoms interfere or interfered with their work.			Intellectual Product	MD Anderson Symptom Inventory - Brain Tumor
C129359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129359>	C173584|C173457	Symptoms Interfered with Relations with Other People Question|Relations with other people|Symptoms Interfered with Relations with Other People	A question about how much an individual's symptoms interfere or interfered with their relations with other people.			Intellectual Product	MD Anderson Symptom Inventory - Brain Tumor
C12935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12935>	C13054|C12977	Embryonic Stem Cell|Embryonic Stem Cells	Embryonic stem (ES) cells are cells derived from the inner cell mass of the early embryo that can be propagated indefinitely in the primitive undifferentiated state while remaining pluripotent.	Embryonic Stem Cell		Cell	
C129360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129360>	C173584|C173457|C173135	Symptoms Interfered with Walking Question|Symptoms Interfered with Walking|Walking	A question about how much an individual's symptoms interfere or interfered with their walking.			Intellectual Product	MD Anderson Symptom Inventory - Brain Tumor
C129361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129361>	C173584|C173457	Symptoms Interfered with Enjoyment of Life Question|Enjoyment of life|Symptoms Interfered with Enjoyment of Life	A question about how much an individual's symptoms interfere or interfered with their enjoyment of life.			Intellectual Product	MD Anderson Symptom Inventory - Brain Tumor
C129362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129362>	C85429	Symptom Interference Likert Scale	A scale for the subjective scoring of a symptom's interference that ranges from 0: Did Not Interfere to 10: Interfered Completely.			Intellectual Product	MD Anderson Symptom Inventory - Brain Tumor
C129363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129363>	C221036	Symptom Interference Score 0|Symptoms Did Not Interfere	A subjective score of 0 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.			Intellectual Product	MD Anderson Symptom Inventory - Brain Tumor
C129364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129364>	C221036	Symptom Interference Score 1	A subjective score of 1 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.			Intellectual Product	MD Anderson Symptom Inventory - Brain Tumor
C129365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129365>	C221036	Symptom Interference Score 2	A subjective score of 2 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.			Intellectual Product	MD Anderson Symptom Inventory - Brain Tumor
C129366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129366>	C221036	Symptom Interference Score 3	A subjective score of 3 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.			Intellectual Product	MD Anderson Symptom Inventory - Brain Tumor
C129367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129367>	C221036	Symptom Interference Score 4	A subjective score of 4 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.			Intellectual Product	MD Anderson Symptom Inventory - Brain Tumor
C129368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129368>	C221036	Symptom Interference Score 5	A subjective score of 5 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.			Intellectual Product	MD Anderson Symptom Inventory - Brain Tumor
C129369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129369>	C221036	Symptom Interference Score 6	A subjective score of 6 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.			Intellectual Product	MD Anderson Symptom Inventory - Brain Tumor
C12936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12936>	C12910	Gut-Associated Lymphoid Tissue|GALT|GALT|GUT-ASSOCIATED LYMPHOID TISSUE|Gut Associated Lymphoid Tissue	Non-encapsulated accumulations of lymphoid tissue in the alimentary tract that form a secretory immune system containing cells committed to IgA or IgE synthesis; It includes Peyer's patches and the lymphoid tissue which is present throughout the gastrointestinal mucosa.	Gut Associated Lymphoid Tissue		Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C129370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129370>	C221036	Symptom Interference Score 7	A subjective score of 7 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.			Intellectual Product	MD Anderson Symptom Inventory - Brain Tumor
C129371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129371>	C221036	Symptom Interference Score 8	A subjective score of 8 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.			Intellectual Product	MD Anderson Symptom Inventory - Brain Tumor
C129372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129372>	C221036	Symptom Interference Score 9	A subjective score of 9 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.			Intellectual Product	MD Anderson Symptom Inventory - Brain Tumor
C129373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129373>	C221036	Symptom Interference Score 10|Symptoms Interfered Completely	A subjective score of 10 on a scale that ranges from 0: Did Not Interfere to 10: Interfered Completely.			Intellectual Product	MD Anderson Symptom Inventory - Brain Tumor
C129374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129374>	C28681	Baltaleucel-T|BALTALEUCEL-T|Baltaleucel T|CMD-003|Epstein Barr Virus-specific LMP1/LMP2/EBNABARF1-targeting Autologous Cytotoxic T-lymphocytes	A preparation of autologous Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes (CTLs), which have specific reactivity to the EBV antigens, latent membrane proteins (LMP) 1 (LMP1) and 2 (LMP2), EBV nuclear antigen (EBNA) and BamHI-A rightward frame-1 (BARF1), with potential immunomodulating and antineoplastic activities. Upon administration, baltaleucel-T targets and binds to EBV-expressing cancer cells specifically expressing the targeted antigens. This may kill LMP1/LMP2/EBNA/BARF1-expressing EBV-associated cancer cells. LMP1, LMP2, EBNA and BARF1 are tumor-associated antigens (TAAs) that are specifically associated with EBV infection, and play key roles in the proliferation of a variety of tumors.	Baltaleucel-T		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129375>	C141137|C129820	IDO1 Inhibitor PF-06840003|IDO-1 Inhibitor PF-06840003|Indoleamine 2,3-Dioxygenase Inhibitor PF-06840003|PF 06840003|PF-06840003|PF-06840003	An orally available hydroxyamidine and inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1 inhibitor PF-06840003 targets and binds to IDO1, an enzyme responsible for the oxidation of tryptophan into kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, PF-06840003 increases and restores the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes; PF-06840003 also induces increased interferon (IFN) production, and causes a reduction in tumor-associated regulatory T cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may inhibit the growth of IDO1-expressing tumor cells. IDO1, a cytosolic enzyme responsible for tryptophan catabolism and the conversion of tryptophan into kynurenine, is overexpressed by a variety of tumor cell types and antigen presenting cells (APCs); it plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system.	IDO1 Inhibitor PF-06840003		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129376>	C213866	Anti-FLT3 Monoclonal Antibody 4G8-SDIEM|4G8-SDIEM|FLYSYN	A human, Fc-optimized, immunoglobulin G1 (IgG1) monoclonal antibody directed against the FLT3 tyrosine kinase receptor (CD135), with potential antineoplastic activity. Upon binding to FLT3, anti-FLT3 monoclonal antibody 4G8-SDIEM blocks FLT3 ligand binding to FLT3 and subsequent phosphorylation of FLT3, which may result in the inhibition of FLT3-mediated signal transduction pathways. In addition, this agent may stimulate an anti-FLT3 antibody-dependent cell-mediated cytotoxicity (ADCC) against FLT3-expressing tumor cells, which may lead to the inhibition of cellular proliferation and decreased survival in FLT3-expressing cells. FLT3 (FLK2), a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129377>	C129764	TNFd3 Repeat|TNFd3 Allele|TNFd3 Haplotype|TNFd3 Microsatellite	One of 6 forms of the TNFd microsatellite repeat, which consists of three regions containing the repetitive dinucleotide sequence, (GA)n, each separated by a single diguanine repeat and is located 15 kb downstream of the TNF gene in intron 3 of the LST1 gene. TNFd3 three repeat regions contain 13 GA repeats, 9 GA repeats and 3 GA repeats, respectively. The TNFd3 polymorphism may influence tumor necrosis factor protein expression and may be associated with increased susceptibility to either inflammatory diseases or post-transplant complications.	TNFd3 Repeat		Nucleotide Sequence	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129378>	C97849	hTM5 Allele|TM-5|TM30|TM30nm|TM5|TPM3 hTM5 Allele|Tropomyosin 3 hTM5 Allele|hTM5	Human hTM5 allele is a variant form of the human TPM3 gene located 1q21.2 and is approximately 39 kb in length. This allele, which encodes tropomyosin alpha-3 chain low isoform 2, is involved in maintenance of the cytoskeleton.	hTM5 Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12937>	C12710|C12370	Mammary Epithelium	The epithelium that lines the lactiferous ducts and the secretory alveoli. The mammary epithelium in the lactiferous duct is a two layered epithelium. The basal cells are cuboidal and the superficial cells are columnar. Branches of the lactiferous duct are lined with a simple cuboidal epithelium. The secretory alveoli are lined by a cuboidal or columnar epithelium. During the first half of pregnancy, the epithelium undergoes considerable growth leading to the formation of new terminal branches of ducts and of alveoli. The mammary glands continue to grow during the second half of pregnancy due to increases in the height of epithelial cells and an expansion of the lumen of the alveoli.	Mammary Epithelium		Tissue	
C129380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129380>	C97849	TC22 Allele|TC22|TPM3 TC22 Allele|Tropomyosin 3 TC22 Allele	Human TC22 allele is a variant form of the human TPM3 gene located 1q21.2 and is approximately 39 kb in length. This allele, which encodes tropomyosin alpha-3 chain isoform 3, may be involved in carcinogenesis in the colon.	TC22 Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129381>	C16492	TPM3 Gene Product	A protein encoded by the TPM3 gene.	TPM3 Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129382>	C129381	Tropomyosin Alpha-3 Chain Isoform 2|Cytoskeletal Tropomyosin TM30|Heat-Stable Cytoskeletal Protein 30 kDa|Human Tropomyosin Isoform 5|TM30nm|Tropomyosin Alpha-3 Chain Cytoskeletal Isoform|Tropomyosin Alpha-3 Chain Low Molecular Weight Isoform hTM5|Tropomyosin Alpha-3 Chain Non-Muscle Isoform|Tropomyosin-5|hTM5	Tropomyosin alpha-3 chain isoform 2 (248 aa, ~30 kDa) is encoded by the hTM5 allele of the human TPM3 gene. This protein plays a role in the stabilization of the actin cytoskeleton.	Tropomyosin Alpha-3 Chain Isoform 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129383>	C222318|C210686	Simlukafusp Alfa|Anti-FAP/Interleukin-2 Fusion Protein RO6874281|FAP-IL2v FP RO6874281|FAP-IL2v RO6874281|RG 7461|RG-7461|RG7461|RO 6874281|RO-6874281|RO6874281|SIMLUKAFUSP ALFA|aFAP-IL2v RO6874281	A recombinant fusion protein comprised of a human monoclonal antibody directed against fibroblast activation protein-alpha (FAP) linked to an engineered, variant form of interleukin-2 (IL-2v), with potential immunostimulating and antineoplastic activities. Upon administration of simlukafusp alfa, the monoclonal antibody moiety recognizes and binds to FAP, thereby concentrating IL-2 in FAP-expressing tumor tissue. Subsequently, the IL-2 moiety of this fusion protein may stimulate a local immune response and activate natural killer (NK) cells and cytotoxic T-cells. FAP is a cell surface protein that is expressed on a wide variety of cancer cells. IL-2v cannot bind to IL-2 receptor-alpha (CD25, IL2Ra) and does not activate regulatory T-cells (Tregs).	Simlukafusp Alfa		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129384>	C129381	Tropomyosin Alpha-3 Chain Isoform 3|Tropomyosin Alpha-3 Chain Low Molecular Weight Isoform TC22|hTM Isoform TC22|hTM5 Isoform TC22	Tropomyosin alpha-3 chain isoform 3 (247 aa, ~92 kDa) is encoded by the TC22 allele of the human TPM3 gene. This protein may play a role in tumorigenesis.	Tropomyosin Alpha-3 Chain Isoform 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129385>	C798	Hydrogen Peroxide-hyaluronic Acid Tumor Injectable Formulation|H2O2-HA Tumor Injectable Formulation|Hydrogen Peroxide-hyaluronic Acid Intratumoral Injectable Formulation	A gel-based formulation composed of a very dilute solution of hydrogen peroxide (H2O2) combined with hyaluronic acid (HA), with potential radiosensitizing activity. Upon intratumoral injection and slow-release (SR) of H2O2 from the gel, H2O2 releases oxygen and inactivates anti-oxidative enzymes, thereby increasing the oxygen concentration in the tumor environment, which increases the efficacy of radiotherapeutic treatment. HA increases viscosity of the formulation and allows for the SR of H2O2; as compared to the injection of H2O2 alone, the addition of HA decreases diffusion of H2O2 to surrounding areas and enhances intratumoral H2O2 concentration over an increased period of time. Hypoxic tumors show a decreased response to radiotherapy; thus, increasing oxygen content increases tumor response to radiotherapy.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C129386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129386>	C17219	Alpha Tubulin|Alpha-Tubulin|TUBA|Tubulin Alpha	A family of globular proteins that form dimers with beta tubulins. The alpha-beta tubulin dimers polymerize in a guanosine triphosphate (GTP)-dependent fashion to form microtubules.	Alpha Tubulin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129387>	C28597	Janus Kinase Family|JAK|JAK Family|Janus Kinase	A family of intracellular, non-receptor tyrosine-protein kinases. These enzymes transduce signals from certain cytokine receptors by phosphorylating and activating members of the Signal Transducer and Activator of Transcription (STAT) family of transcription factor proteins.	Janus Kinase Family		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129388>	C28597	Phosphofructokinase|PFK	A family of enzymes that synthesize fructose bisphosphate by phosphorylating fructose 6-phosphate during glycolysis.	Phosphofructokinase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129389>	C20130	Phosphoglucomutase|Alpha-D-Glucose 1,6-Phosphomutase|EC 5.4.2.2|Glucose Phosphomutase|PGM|Phosphoglucose Mutase	A family of enzymes that catalyzes the interconversion of glucose 1-phosphate and glucose 6-phosphate.			Amino Acid, Peptide, or Protein|Enzyme	
C12938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12938>	C38439|C12529	Peripheral Blood Lymphocyte|PBL	A lymphocyte circulating in the peripheral blood.	Peripheral Blood Lymphocyte		Cell	
C129390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129390>	C28597	Phosphoglycerate Kinase|3-PGK|3-Phosphoglycerate Kinase|3-Phosphoglycerate Phosphokinase|3-Phosphoglyceric Acid Kinase|3-Phosphoglyceric Acid Phosphokinase|3-Phosphoglyceric Kinase|ATP-3-Phospho-D-Glycerate-1-Phosphotransferase|ATP:3-Phospho-D-Glycerate 1-Phosphotransferase|ATP:D-3-Phosphoglycerate 1-Phosphotransferase|EC 2.7.2.3|Glycerate 3-Phosphate Kinase|Glycerophosphate Kinase|PGK|Phosphoglyceric Acid Kinase|Phosphoglyceric Kinase|Phosphoglycerokinase	A family of enzymes that catalyzes the transfer of a phosphate group from 1,3-bisphosphoglycerate (1,3-BPG) to adenosine diphosphate (ADP) yielding 3-phosphoglycerate (3-PG) and adenosine triphosphate (ATP) and also catalyzes the reverse reaction that transfers a phosphate group from ATP to 3-PG yielding 1,3-BPG and ADP.	Phosphoglycerate Kinase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129391>	C28597	Hexokinase|ATP-Dependent Hexokinase|ATP:D-Hexose 6-Phosphotransferase|Glucose ATP Phosphotransferase|HK	A family of enzymes that transfers phosphate groups to six-carbon sugars (hexoses).	Hexokinase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129392>	C28597	Pyruvate Kinase|ATP:Pyruvate 2-O-Phosphotransferase|EC 2.7.1.40|Fluorokinase|Fluorokinase (Phosphorylating)|PK|Phosphoenol Transphosphorylase|Phosphoenolpyruvate Kinase|Pyruvate Kinase (Phosphorylating)|Pyruvate Phosphotransferase|Pyruvic Kinase	A family of enzymes that catalyzes the transfer of a phosphate group from phosphoenolpyruvate (PEP) to adenosine diphosphate (ADP), yielding one molecule of pyruvate and one molecule of adenosine triphosphate (ATP). This reaction is the final step of the glycolysis pathway.	Pyruvate Kinase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129393>	C20130	Aldolase|Aldehyde-Lyase|EC 4.1.2	A family of enzymes that either create or cleave aldols (aldehyde alcohols).	Aldolase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129394>	C129393	Fructose-Bisphosphate Aldolase|1,6-Diphosphofructose Aldolase|ALDO|Aldolase|D-Fructose-1,6-Bisphosphate D-Glyceraldehyde-3-Phosphate-Lyase|D-Fructose-1,6-Bisphosphate D-Glyceraldehyde-3-Phosphate-Lyase (Glycerone-Phosphate-Forming)|Diphosphofructose Aldolase|EC 4.1.2.13|Fructoaldolase|Fructose 1,6-Diphosphate Aldolase|Fructose 1-Monophosphate Aldolase|Fructose 1-Phosphate Aldolase|Fructose Diphosphate Aldolase|Fructose-1,6-Bisphosphate Triosephosphate-Lyase|Ketose 1-Phosphate Aldolase|Phosphofructoaldolase|SMALDO|Zymohexase	A family of enzymes that catalyzes interconversion between aldol phosphates and triose phosphates, the primary reaction for these enzymes is the reversible conversion of fructose 1,6-bisphosphate into dihydroxyacetone phosphate (DHAP) and glyceraldehyde 3-phosphate (G3P). Glycolysis uses the forward reaction while gluconeogenesis uses the reverse reaction.	Fructose-Bisphosphate Aldolase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129395>	C20130	Inosine Monophosphate Dehydrogenase|EC 1.1.1.205|IMP Dehydrogenase|IMP Oxidoreductase|IMP:NAD+ Oxidoreductase|IMPDH|Inosinate Dehydrogenase|Inosine 5'-Monophosphate Dehydrogenase|Inosine Monophosphate Oxidoreductase|Inosine-5'-Phosphate Dehydrogenase|Inosinic Acid Dehydrogenase	A family of enzymes that converts inosine monophosphate to xanthosine monophosphate. This reaction is the rate limiting step in de novo guanosine triphosphate (GTP) synthesis.	Inosine Monophosphate Dehydrogenase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129396>	C20130	Transcobalamin|TC|TCN|Vitamin B12 Binding Protein	A family of proteins that bind cobalamin (vitamin B12).	Transcobalamin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129397>	C20056	Adenovirus E4 Protein|E4 Protein	A group of proteins encoded by the adenovirus early transcription locus 4 (E4). These proteins are required for viral replication.			Amino Acid, Peptide, or Protein	
C129398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129398>	C41515	Mitotic Catastrophe	Programmed cell death that occurs during mitosis caused by various types of cellular damage that lead to the failure of cell cycle checkpoint(s). Micronucleation and multinuceation can occur in cells undergoing this process.	Mitotic Catastrophe		Phenomenon or Process	CTRP Biomarker Terminology|CTRP Terminology
C129399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129399>	C48966|C107495	Human Anti-Chimeric Antibody|HACA	An autoantibody that recognizes engineered antibodies that contain human and non-human domains.	Human Anti-Chimeric Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C12939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12939>	C12535	Autologous Lymphocyte|Autologous Lymphocytes|autologous lymphocyte		Autologous Lymphocyte		Cell	CTRP Agent Terminology|CTRP Terminology
C1293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1293>	C898	Recombinant Transforming Growth Factor-Beta 1|HUMAN TRANSFORMING GROWTH FACTOR .BETA.-1|TGFbeta1|Transforming Growth Factor Beta-1|Transforming Growth Factor-Beta 1	A recombinant form of the endogenous Transforming Growth Factor-Beta 1, a protein involved with the regulation of cell proliferation and differentiation.			Chemical Viewed Functionally	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C129400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129400>	C48966	Antineutrophil Cytoplasmic Antibody|ANCA|Anti-Neutrophil Cytoplasmic Antibody	An autoantibody that recognizes antigens found in the cytoplasm of neutrophils.	Antineutrophil Cytoplasmic Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C129401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129401>	C211912	Antibody-drug Conjugate Anti-TIM-1-vcMMAE CDX-014|ADC Anti-TIM-1-vcMMAE CDX-014|ADC CDX-014|Antibody-drug Conjugate CDX-014|CDX-014|CDX-014|CR014-vc-MMAE|CR014-vcMMAE	A monoclonal antibody-drug conjugate (ADC) comprised of human immunoglobulin G1 (IgG1) clone CR014, which targets the extracellular domain of T-cell immunoglobulin mucin-1 (TIM-1; HAVCR1), that is linked, via a valine-citrulline (VC) peptide linker, to the potent cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of ADC anti-TIM-1-vcMMAE CDX-014, the monoclonal antibody moiety targets and binds to TIM-1. Upon internalization and proteolytic cleavage, MMAE is released into the cytosol of TIM-1-expressing tumor cells, binds to tubulin, and inhibits microtubule polymerization, which induces both G2/M phase arrest and tumor cell apoptosis. TIM-1 is upregulated in a variety of cancer cell types while only minimally expressed in healthy tissue. The linkage system in CDX-014 is highly stable in plasma, resulting in increased specificity and cytotoxic efficacy towards TIM-1-positive cells.	Antibody-drug Conjugate Anti-TIM-1-vcMMAE CDX-014		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129402>	C209976	BTA Stat Assay|BTA Stat|Bladder Tumor Antigen Stat	An immunoassay that detects bladder cancer antigen, which is comprised of various members of the complement factor H-related protein (CFHrp) family, in urine.	BTA Stat		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129403>	C51944	NMP22 Assay|NMP-22 Assay|Nuclear Matrix Protein 22 Assay|Nuclear Matrix Protein-22 Assay	An immunoassay that detects the head domain of nuclear mitotic apparatus protein 1 (NuMA) in urine.	NMP22 Assay		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129404>	C13804	Alu Element|Alu Repeat|Alu Sequence	A family of short interspersed nuclear elements found in the human genome that are substrates for the Arthrobacter luteus restriction endonuclease. Alu elements are highly conserved within primate genomes and have been used in the investigation of human population genetics, primate and human evolution, and human diseases, including cancer.	Alu Element		Nucleotide Sequence	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129405>	C14306	Tacaribe Complex Virus|New World Arenavirus Complex|TACV Complex|TCRV|Tacaribe Complex|Tacaribe Complex Arenavirus|Tacaribe Serocomplex Virus	A family of arenaviruses predominantly found in North and South America with family Muridae, subfamily Sigmodontinae as the most common reservoir. Several of these viruses are known to cause severe hemorrhagic disease in humans.	Tacaribe Complex Virus		Virus	CTRP Biomarker Terminology|CTRP Terminology
C129406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129406>	C20130	Cyclin B|CCNB|Cyclin-B|G2/Mitotic-Specific Cyclin-B	A protein family whose members form complexes with cyclin-dependent kinase 1 to form maturation promoting factor (mitosis promoting factor; MPF), which is essential for the progression through the G2/M and DNA damage cell cycle checkpoints.	Cyclin B		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129407>	C94598	Human Placenta-derived Stem Cell Transplantation|HPDSC Transplantation|Human Placental-derived Stem Cell Transplantation	An adjunctive therapy to umbilical cord blood (UCB) transplantation that is used to augment stem cell engraftment in hematopoietic reconstitution. The process to extract human placenta-derived stem cells (HPDSCs) yields an enriched population of CD34-positive hematopoietic stem cells that, when transplanted in conjunction with UCB stem cells, may provide a novel source for natural killer (NK) cells.	Human Placenta-derived Stem Cell Transplantation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C129408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129408>	C912	CA27-29|CA 27-29|CA 27.29|CA27.29|Cancer Antigen 27-29|Cancer Antigen 27.29	An antigenic epitope that is a 20 amino acid sequence from the extracellular portion of the transmembrane protein mucin-1 (MUC1). Overexpression of MUC1 induces the shedding of its extracellular domain into the bloodstream. Increased MUC1 in the blood may be a marker for breast cancer.	CA27-29		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129409>	C36327	Core Binding Factor Complex Mutation|CBF Mutation|Core Binding Factor Mutation	Mutations in the genes that encode proteins found in the core binding factor (CBF) complex. These genes may be involved in chromosomal rearrangements that are associated with acute myeloid leukemia.	Core Binding Factor Complex Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12940>	C12922	Autologous Tumor Cell|Autologous Tumor Cells|autologous tumor cell		Autologous Tumor Cells		Cell	
C129410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129410>	C21176	Plasmin-Antiplasmin Complex|PAP|Plasmin/Alpha-2-Antiplasmin Complex|Plasmin/Antiplasmin Complex	A protein complex comprised of the serine proteinase plasmin irreversibly bound to its corresponding serine proteinase inhibitor protein (SERPIN) alpha-2-antiplasmin.	Plasmin-Antiplasmin Complex		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129411>	C14329	Clostridium Cluster	A set of non-taxonomic groups of bacterial species in either the Clostridium genus or another related genus. The members of the groups were chosen based on comparative sequence analysis of their 16S ribosomal RNA gene sequences.	Clostridium Cluster		Organism	CTRP Biomarker Terminology|CTRP Terminology
C129412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129412>	C129411	Clostridium Cluster IV	A group of at least 8 bacterial species, four in the Clostridium genus and 4 that are classified outside the Clostridium genus. This cluster is based on comparative sequence analysis of their 16S ribosomal RNA gene sequences. These species are commensal in humans.	Clostridium Cluster IV		Organism	CTRP Biomarker Terminology|CTRP Terminology
C129413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129413>	C129411	Clostridium Cluster XIV	A group comprised of more than 20 bacterial species, most are in the Clostridium genus but a few are outside the Clostridium genus. This cluster is based on comparative sequence analysis of their 16S ribosomal RNA gene sequences. Some of these species are commensal in humans.	Clostridium Cluster XIV		Organism	CTRP Biomarker Terminology|CTRP Terminology
C129414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129414>	C129411	Clostridium Cluster XVI	A group that includes Clostridium innocuum, Eubacterium biforme and Streptococcus pleomorphus, which are within the mycoplasma supercluster. This grouping is based on comparative sequence analysis of their 16S ribosomal RNA gene sequences. Some of these species are commensal in humans.	Clostridium Cluster XVI		Organism	CTRP Biomarker Terminology|CTRP Terminology
C129415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129415>	C116021	MicroRNA 181b|MIR181B|MIRN181b|MiR-181b|MiRNA181b|hsa-miR-181b|hsa-miR-181b-5p	A 23 ribonucleotide sequence that is a final product of the processing of either MIR181B1 pre-miRNA or MIR181B2 pre-miRNA. This oligonucleotide may be involved in the negative regulation of gene expression.	MicroRNA 181b		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129416>	C25966	MicroRNA 16|MIR16|MIRN16|MiR-16|MiRNA16|hsa-miR-16|hsa-miR-16-5p	A 22 ribonucleotide sequence that is a final product of the processing of either MIR16-1 pre-miRNA or MIR16-2 pre-miRNA. This oligonucleotide may be involved in the negative regulation of gene expression.			Nucleic Acid, Nucleoside, or Nucleotide	
C129417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129417>	C20401	Monoclonal Antibody CAM 5.2|Anti-Cytokeratin (CAM 5.2)|Anti-Cytokeratin Monoclonal Antibody CAM 5.2|CAM 5.2	A mouse monoclonal antibody that reacts with cytokeratin 8 and to a lesser extent with cytokeratin 7. Monoclonal antibody CAM 5.2 can be used in immunohistochemistry to determine the epithelial nature of tissue, tumors or components of tumors found in a sample.	Monoclonal Antibody CAM 5.2		Amino Acid, Peptide, or Protein|Immunologic Factor|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Biomarker Terminology|CTRP Terminology
C129418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129418>	C13334	KDR Intron 2 VNTR|KDR Intron 2VNTR|VEGFR2 Intron 2 VNTR|VEGFR2 Intron 2VNTR	A repetitive sequence found in intron 2 of the KDR gene.	KDR Intron 2 VNTR		Nucleotide Sequence	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129419>	C13334	NOS3 Intron 4 VNTR|NOS3 Intron 4VNTR|eNOS Intron 4 VNTR|eNOS Intron 4VNTR	A repetitive sequence found in intron 4 of the NOS3 gene.	NOS3 Intron 4 VNTR		Nucleotide Sequence	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12941>	C28676	Coactivated T Cell|Coactivated T Cells|coactivated T cell				Cell|Pharmacologic Substance	
C129420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129420>	C20130	Mismatch Repair Protein|DNA Mismatch Repair Protein|MMR Protein|Mut|Mut Family|Mut Protein	A DNA repair protein family that is comprised of the active components of the DNA mismatch repair system.	Mismatch Repair Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129421>	C13245	Immunoglobulin Heavy Chain Variable Domain|IgH Variable Domain|IgH Variable Region|IgHV|Immunoglobulin Heavy Chain Variable Region	The portion of an antibody molecule that contains the three hypervariable regions in the heavy chains. It is comprised of at most a third of the heavy chains from the amino termini.	Immunoglobulin Heavy Chain Variable Domain		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129422>	C17019	Histone Modification|Post-Translational Histone Modification	Post-translational processing of amino acids within a histone protein.	Histone Modification		Molecular Function	CTRP Biomarker Terminology|CTRP Terminology
C129423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129423>	C21198	ADP Ribosylation|ADP-Ribosylation|Adenosine Diphosphate Ribosylation	The transfer of ADP-ribose to amino acids within proteins or to the amino group at N2 of a 2'-deoxyguanosine residue in double-stranded DNA.	ADP Ribosylation		Phenomenon or Process	CTRP Biomarker Terminology|CTRP Terminology
C129424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129424>	C4747	Diffuse Leptomeningeal Glioneuronal Tumor|DLGNT|Diffuse leptomeningeal glioneuronal tumor|Disseminated Oligodendroglial-Like Leptomeningeal Tumor of Childhood	A relatively slow growing diffuse leptomeningeal neoplasm usually affecting children and adolescents. It is characterized by the presence of clear glial neoplastic cells reminiscent of oligodendroglioma. A neuronal component may be present. The prognosis is variable.			Neoplastic Process	GDC Terminology|GDC Value Terminology
C129425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129425>	C156880	Onalespib Lactate|AT-13387 Lactate|ATI-13387A|ATI-13387AU|ONALESPIB LACTATE|Propanoic Acid, 2-Hydroxy-, (2S)-, Compound with (1,3-Dihydro-5-((4-methyl-1-piperazinyl)methyl)-2H-isoindol-2-yl)(2,4-dihydroxy-5-(1-methylethyl)phenyl)methanone (1:1)	The lactate form of onalespib, a synthetic, orally bioavailable, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. Onalespib selectively binds to Hsp90, thereby inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability and degradation of many oncogenic signaling proteins.	Onalespib Lactate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C129426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129426>	C35886	Multinodular and Vacuolated Pattern	An architectural pattern characterized by the presence of neoplastic cells forming multiple nodules with prominent vacuolation.			Finding	
C129427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129427>	C4874|C4747|C170814	Multinodular and Vacuolated Neuronal Tumor|MVNT|Multinodular and Vacuolated Neuronal Tumor of the Cerebrum|Multinodular and Vacuolated Tumor of the Cerebrum|Multinodular and Vacuolated Tumor of the Cerebrum|Multinodular and Vacuolating Neuronal Tumor	A low-grade tumor affecting the cerebral hemispheres. It is composed of cells with glial and/or neuronal differentiation forming multiple nodules with prominent vacuolation.	Multinodular and Vacuolated Tumor of the Cerebrum		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C129428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129428>	C13031	Cerebral Convexity|Convexity	Area within the sulci of the brain, usually anterior to the rolandic fissure.			Body Part, Organ, or Organ Component	
C129429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129429>	C13031	Olfactory Groove	Cranial cavity between the brow and nose in the frontal area of the brain.			Body Part, Organ, or Organ Component	
C12942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12942>	C225418	Intracarotid	The inside of the common, external, or internal carotid arteries.	Intracarotid		Body Location or Region	
C129430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129430>	C32881	Sphenoid Wing|ALISPHENOID PROCESS|Alisphenoid Process|Greater Wing of the Sphenoid Bone	One of two strong processes of the sphenoid bone, which arise from the sides of the body, and are curved upward, laterally, and backward. The superior or cerebral surface of each greater wing forms part of the middle cranial fossa.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C129431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129431>	C4747	Rosette-Forming Glioneuronal Tumor|RGNT|Rosette-forming glioneuronal tumor	A central nervous system neoplasm mostly occurring in the fourth ventricle region. It is characterized by the presence of neurocytes forming pseudorosettes and astrocytes which contain Rosenthal fibers. Cytologic atypia is minimal.			Neoplastic Process	GDC Terminology|GDC Value Terminology
C129432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129432>	C192768	mRNA Sequencing|Messenger RNA Sequencing|Poly(A) RNA Sequencing|Poly-A RNA Sequencing|mRNA-Seq	A procedure that can determine the RNA sequences for all or part of the poly-A tail-containing messenger RNA transcripts in an individual.	mRNA Sequencing		Molecular Biology Research Technique	CTRP Biomarker Terminology|CTRP Terminology
C129433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129433>	C54306	Cancer-Testis Antigen Family 45 Gene|CT45|CT45A|Cancer/Testis Antigen 45|Cancer/Testis Antigen Family 45	A family of genes that is comprised of nine protein coding genes and one pseudogene, which are nearly identical in sequence and are clustered in the vicinity of Xq26.3.	Cancer-Testis Antigen Family 45 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129434>	C118481	Aldehyde Dehydrogenase 1 Family|ALDH1|ALDH1 Family|Aldehyde Dehydrogenase 1|Aldehyde Dehydrogenase Class 1|Aldehyde Dehydrogenase Family	A polymorphic family of intracellular enzymes that catalyze the oxidation of aldehydes and yield carboxylic acids. High aldehyde dehydrogenase 1 activity may indicate the presence of stem cells or cancer stem cells (CSC) in a sample.	Aldehyde Dehydrogenase 1 Family		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129435>	C20130	Microsomal Prostaglandin E Synthase Family|Membrane-Associated PGE Synthase|Microsomal PGES Family|mPGES	A family of membrane bound enzymes that catalyze the biosynthesis of prostaglandin E2 from prostaglandin H2.	Microsomal Prostaglandin E Synthase Family		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129436>	C3222	Large Cell/Anaplastic Medulloblastoma	A medulloblastoma composed of sheets of large cells mixed with cells characterized by marked nuclear pleomorphism and high mitotic activity.			Neoplastic Process	NCIt Neoplasm Core Terminology
C129437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129437>	C82325|C35682	WNT Pathway Activated|WNT Pathway Activation Positive	A finding indicating that the WNT signaling pathway is activated.	WNT Pathway Activated		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129438>	C2950	Chromosome 17 Abnormality	An irregularity in the structure of chromosome 17.			Cell or Molecular Dysfunction	
C129439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129439>	C3222	Medulloblastoma Molecular Subtypes|Medulloblastoma, Genetically Defined|Medulloblastoma, Molecularly Defined|Molecular Subtypes of Medulloblastoma|medulloblastoma molecular classification|medulloblastoma_molecular_classification	A term that refers to the classification of medulloblastomas based on their molecular characteristics.			Neoplastic Process	GDC Property Terminology|GDC Terminology
C12943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12943>	C33904	Intrathecal Space|Intrathecal|Intrathecal|intrathecal	The fluid-filled space between the thin layers of tissue that cover the brain and spinal cord.	Intrathecal		Spatial Concept	AML Authorized Value Terminology|AML Total Dose Table
C129440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129440>	C129439	Medulloblastoma, WNT-Activated|Medulloblastoma, WNT-activated|WNT Signaling Pathway Aberrant Medulloblastoma|WNT-Activated	A molecular subtype of medulloblastoma associated with activation of the WNT pathway. TP53 mutations may be present or absent. WNT pathway activation in medulloblastomas is associated with good outcome.			Neoplastic Process	Cellosaurus Disease Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology|NCIt Neoplasm Core Terminology
C129441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129441>	C129439	Medulloblastoma, SHH-Activated|SHH-Activated	A molecular subtype of medulloblastoma associated with activation of the sonic hedgehog (SHH) pathway. TP53 mutations may be present or absent. Patients in this group are young children and adults. Overall survival is variable and depends on the presence or absence of metastatic disease, histology, and the age at diagnosis.			Neoplastic Process	GDC Terminology|GDC Value Terminology|NCIt Neoplasm Core Terminology
C129442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129442>	C129441	Medulloblastoma, SHH-Activated, TP53-Mutant|Medulloblastoma, SHH-activated and TP53-mutant	Medulloblastoma associated with activation of the sonic hedgehog (SHH) pathway and the presence of TP53 mutations.			Neoplastic Process	Cellosaurus Disease Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology|NCIt Neoplasm Core Terminology
C129443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129443>	C129441	Medulloblastoma, SHH-Activated, TP53-Wildtype|Medulloblastoma, SHH-activated and TP53-wildtype	Medulloblastoma associated with activation of the sonic hedgehog (SHH) pathway and the absence of TP53 mutations.			Neoplastic Process	Cellosaurus Disease Terminology|GDC Terminology|GDC Value Terminology|NCIt Neoplasm Core Terminology
C129444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129444>	C129439	Medulloblastoma, Non-WNT/Non-SHH|Medulloblastoma, non-WNT/non-SHH|Non-WNT/Non-SHH Medulloblastoma|Non-WNT/non-SHH Activated	Medulloblastoma not associated with activation of the WNT pathway or sonic hedgehog (SHH) pathway. TP53 mutations are absent. This molecular subtype includes medulloblastomas numerically designated as "group 3" and "group 4".			Neoplastic Process	GDC Terminology|GDC Value Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology|NCIt Neoplasm Core Terminology
C129445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129445>	C129444	Medulloblastoma, Non-WNT/Non-SHH, Group 3|Medulloblastoma, group 3	Medulloblastoma not associated with activation of the WNT pathway or sonic hedgehog (SHH) pathway. MYC amplifications may be present. TP53 mutations are absent. Patients in this group are usually young children. The overall survival is the worst among all the molecular groups.			Neoplastic Process	Cellosaurus Disease Terminology|GDC Terminology|GDC Value Terminology
C129446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129446>	C129444	Medulloblastoma, Non-WNT/Non-SHH, Group 4|Medulloblastoma, group 4	Medulloblastoma not associated with activation of the WNT pathway or sonic hedgehog (SHH) pathway. MYC amplifications are absent. TP53 mutations are absent. Chromosome 17 abnormalities may be present.			Neoplastic Process	Cellosaurus Disease Terminology|GDC Terminology|GDC Value Terminology
C129447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129447>	C3222	Medulloblastoma, Not Otherwise Specified|Medulloblastoma, NOS|Medulloblastoma, NOS|Not Determined	A medulloblastoma which has not been further characterized.	Medulloblastoma, Not Otherwise Specified		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Morphology PT Terminology|Mapped ICDO3.1 Morphology Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C129448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129448>	C128037	Cetrelimab|CETRELIMAB|JNJ 63723283|JNJ-63723283|JNJ63723283|WHO 10757	A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 protein (PD-1, PCDC-1), with potential immune checkpoint inhibitory and antineoplastic activity. Upon administration, cetrelimab binds to PD-1, and inhibits the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation.	Cetrelimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129449>	C2852	Small Cell Adenocarcinoma	An adenocarcinoma composed of small malignant cells.			Neoplastic Process	
C12944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12944>	C12903	Medial Supraclavicular Lymph Node|Medial Supraclavicular Lymph Nodes|medial supraclavicular lymph node	A cervical lymph node located above the medial region of the clavicle.	Medial Supraclavicular Lymph Nodes		Body Part, Organ, or Organ Component	
C129450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129450>	C177692	HLA Class I Histocompatibility Antigen, A-0201 Alpha Chain Positive|HLA-A*0201 Positive	Indicates that HLA class I histocompatibility antigen, A-0201 alpha chain expression has been detected in a sample.	HLA Class I Histocompatibility Antigen, A-0201 Alpha Chain Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129451>	C177692	Wnt Positive|Wingless-Type MMTV Integration Site Family Positive|Wnt Family Positive	Indicates that expression of one or more Wnt family members has been detected in a sample.	Wnt Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129452>	C35682	Hepatitis C Virus Positive|HCV Positive|Hep C Positive	Indicates that hepatitis C virus has been detected in a sample.	Hepatitis C Virus Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C129453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129453>	C177692	WT1 Positive|Wilms Tumor 1 Positive	Indicates that WT1 expression has been detected in a sample.	WT1 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129454>	C35682	Epstein-Barr Virus Positive|EBV Positive|EBV-Positive|Epstein Barr Virus Positive|Epstein-Barr Virus-Positive|HHV-4 Positive|HHV4 Positive|Human Herpesvirus 4 Positive|Human Herpesvirus-4 Positive	Indicates that Epstein-Barr virus has been detected in a sample.	Epstein-Barr Virus Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C129455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129455>	C128839	Human Papillomavirus-16 Positive|HPV-16 Positive|HPV16 Positive|Human Papilloma Virus 16 Positive|Human Papilloma Virus-16 Positive|Human Papillomavirus 16 Positive	Indicates that human papillomavirus-16 has been detected in a sample.	Human Papillomavirus-16 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C129456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129456>	C199143	European LeukemiaNet	A publicly funded research network of excellence with a goal of curing leukemia. The European LeukemiaNet aims to strengthen and develop scientific and technological excellence in research and therapy of leukemia (CML, AML, ALL, CLL, MDS, CMPD) by integration of the leading national leukemia networks and their interdisciplinary partner groups in Europe.			Professional or Occupational Group	
C129457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129457>	C203518	Anti-CD123-Pyrrolobenzodiazepine Dimer Antibody Drug Conjugate SGN-CD123A|ADC SGN-CD123A|Anti-CD123 ADC SGN-CD123A|Anti-CD123-PBD ADC SGN-CD123A|Antibody-drug Conjugate SGN-CD123A|SGN CD123A|SGN-CD123A|SGN-CD123A	An antibody-drug conjugate (ADC) consisting of an anti-CD123 humanized monoclonal antibody conjugated, via a stable maleimidocaproyl-valine-alanine dipeptide protease-cleavable linker, to the cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of anti-CD123 ADC SGN-CD123A, the antibody moiety targets the cell surface antigen CD123. Upon antibody/antigen binding, internalization, and lysosome uptake, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of CD123-overexpressing tumor cells. CD123, the alpha subunit of the IL-3 receptor, regulates the proliferation, survival and differentiation of hematopoietic cells. CD123 is overexpressed on a variety of cancers, including myeloid leukemia, and increased expression of CD123 on leukemic stem cells is associated with poor prognosis. Cysteine engineering of the monoclonal antibody (EC-mAb) allows for a site-specific, stable conjugation and uniform loading of the PBD agent to the antibody.	Anti-CD123-Pyrrolobenzodiazepine Dimer Antibody Drug Conjugate SGN-CD123A		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129458>	C13442	Temporooccipital	Pertaining to the temporal and occipital bones of the skull or lobes of the brain.			Spatial Concept	
C129459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129459>	C13442	Frontotemporal	Pertaining to the frontal and temporal bones of the skull or lobes of the brain.			Spatial Concept	
C12945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12945>	C33904	Neuroendocrine System|Neuroendocrine|Neurosecretory System|neuroendocrine	A system of neurosecretory neurons that release hormones to the circulatory system.	Neurosecretory System		Body System	
C129460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129460>	C225418	Subungual	Pertaining to the area underneath a finger nail or toe nail.			Spatial Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C129461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129461>	C225418	Paraspinal	Pertaining to muscles and/or tissue adjacent to the spinal column.			Spatial Concept	
C129462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129462>	C225418	Submandibular|SUBMANDIBULAR	Pertaining to the area below the lower jaw or mandible.			Spatial Concept	CDISC SEND Microscopic Findings Result Modifier Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C129463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129463>	C225418	Submaxillary	Pertaining to the area underneath the upper jaw or maxilla.			Spatial Concept	
C129464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129464>	C13442	Anorectal|Anorectum	Pertaining to the anus and rectum.			Spatial Concept	GDC Terminology|GDC Value Terminology
C129465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129465>	C33904	Sun-exposed Site|Sun exposed site	An area of the body exposed to sunlight.			Conceptual Entity	
C129466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129466>	C129465	Chronically Sun-exposed Site|Chronically sun exposed site	An area of the body subjected to consistent and repetitive sun exposure.			Conceptual Entity	
C129467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129467>	C129465	Nonchronically Sun-exposed Site|Intermittently Sun-exposed Site|Nonchronically sun exposed site	An area of the body subjected to inconsistent sun exposure.			Conceptual Entity	
C129468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129468>	C99208	Pinguecula|Pingueculum	Yellowish deposits on the conjunctiva close to the edge of the cornea.			Finding	
C129469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129469>	C35867	Cellular Dedifferentiation	A morphologic finding indicating the presence of a high-grade cellular component adjacent to or admixed with a low-grade cellular infiltrate.			Finding	
C12946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12946>	C12551|C12519	Peripheral Blood Stem Cell|PBSC|PBSC|PERIPHERAL BLOOD STEM CELL|Peripheral Blood Stem Cells|Peripheral Stem Cells|peripheral stem cell	An immature (progenitor) cell circulating in the peripheral blood.  It has the capacity for replication and differentiation to mature blood cells.	Peripheral Blood Stem Cell		Cell	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Agent Terminology|CTRP Terminology
C129470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129470>	C28099	Classic Histology|Classic	A term that refers to the histologic image of a lesion which carries all the characteristic morphologic findings which are necessary to define this lesion.			Classification	
C129471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129471>	C176252	Did Not Attempt Intercourse|Did not attempt intercourse	A response indicating that sexual intercourse was not attempted.			Intellectual Product	Female Sexual Function Index
C129472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129472>	C176252	No Sexual Activity|No sexual activity	A response indicating the absence of sexual activity.			Intellectual Product	Female Sexual Function Index
C129473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129473>	C226694	Very High Level|Very high	A response indicating a very high level.			Intellectual Product	Female Sexual Function Index
C129474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129474>	C226694	High Level|High	A response indicating a high level.			Intellectual Product	Female Sexual Function Index
C129475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129475>	C226694	Moderate Level|Moderate	A response indicating a moderate level.			Intellectual Product	Female Sexual Function Index
C129476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129476>	C226694	Low Level|Low	A response indicating a low level.			Intellectual Product	Female Sexual Function Index
C129477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129477>	C226694	Very Low Level or None at All|Very low or none at all	A response indicating a very low level or an absence.			Intellectual Product	Female Sexual Function Index
C129478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129478>	C213556	Very High Confidence|Very high confidence	A response indicating a very high level of confidence.			Intellectual Product	Female Sexual Function Index
C129479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129479>	C213556	High Confidence|High confidence	A response indicating a high level of confidence.			Intellectual Product	Female Sexual Function Index
C12947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12947>	C12745	Sentinel Lymph Node|SLN|Sentinel Node|sentinel lymph node	The first lymph node that is affected by cancer spread from the primary site.  Sentinel lymph node biopsy is part of the staging work-up to determine early metastasis to regional lymph nodes in patients with breast carcinoma or melanoma.	Sentinel Lymph Node		Body Part, Organ, or Organ Component	
C129480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129480>	C213556	Moderate Confidence|Moderate confidence	A response indicating a moderate level of confidence.			Intellectual Product	Female Sexual Function Index
C129481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129481>	C213556	Low Confidence|Low confidence	A response indicating a low level of confidence.			Intellectual Product	Female Sexual Function Index
C129482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129482>	C213556	Very Low Confidence or No Confidence|Very low or no confidence	A response indicating a very low level of confidence or an absence.			Intellectual Product	Female Sexual Function Index
C129483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129483>	C176243	Extremely Difficult or Impossible|Extremely difficult or impossible	A response indicating that something is or was extremely difficult or impossible.			Intellectual Product	Female Sexual Function Index
C129484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129484>	C176243	Very Difficult|Very difficult	A response indicating that something is or was very difficult.			Intellectual Product	Female Sexual Function Index
C129485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129485>	C176243	Difficult	A response indicating that something is or was difficult.			Intellectual Product	Female Sexual Function Index
C129486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129486>	C176243	Slightly Difficult|Slightly difficult	A response indicating that something is or was slightly difficult.			Intellectual Product	Female Sexual Function Index
C129487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129487>	C176243	Not Difficult|Not difficult|Not hard	A response indicating that something is or was not difficult.			Intellectual Product	Female Sexual Function Index
C129488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129488>	C176250	Very Satisfied|Very satisfied	A response indicating a high level of satisfaction.			Intellectual Product	Female Sexual Function Index
C129489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129489>	C176250	Moderately Satisfied|Moderately satisfied	A response indicating a moderate level of satisfaction.			Intellectual Product	Female Sexual Function Index
C12948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12948>	C13018	Duct|DUCT|duct	A tube that carries various secretions from one part of the body to another.			Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C129490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129490>	C176250	About Equally Satisfied and Dissatisfied|About equally satisfied and dissatisfied|Equally Satisfied and Dissatisfied|Mixed Satisfaction	A response indicating an equal level of satisfaction and dissatisfaction.			Intellectual Product	American Urological Association Symptom Score|Female Sexual Function Index
C129491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129491>	C176250	Moderately Dissatisfied|Moderately dissatisfied	A response indicating a moderate level of dissatisfaction.			Intellectual Product	Female Sexual Function Index
C129492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129492>	C176250	Very Dissatisfied|Very dissatisfied	A response indicating a high level of dissatisfaction.			Intellectual Product	Female Sexual Function Index
C129493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129493>	C20993	PROMIS Short Form v1.0 - Fatigue 8a|PROMIS Fatigue Short Form|PROMIS Item Bank v1.0 - Fatigue - Short Form 8a|Promis Fatigue Item Bank Short Form	A self-report tool that evaluates fatigue over a range of symptoms, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. The fatigue short form is generic rather than disease specific and assesses fatigue over the past seven days.			Intellectual Product	HL Authorized Value Terminology|HL Patient Reported Outcomes Metadata Table
C129494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129494>	C173561|C173347	How Much Bothered by Fatigue on Average Question|How Much Bothered by Fatigue on Average|How much were you bothered by your fatigue on average	A question about how much an individual is or was bothered by fatigue on average.			Intellectual Product	PROMIS Short Form v1.0 - Fatigue 8a
C129496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129496>	C173347|C118873	How Often Have to Push to Get Things Done Because of Fatigue Question|How Often Have to Push to Get Things Done Because of Fatigue|How often did you have to push yourself to get things done because of your fatigue	A question about how often an individual has or had to push to get things done because of their fatigue.			Intellectual Product	PROMIS Short Form v1.0 - Fatigue 8a
C129497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129497>	C173398|C173347|C118873	How Often Have Trouble Finishing Things Because of Fatigue Question|How Often Have Trouble Finishing Things Because of Fatigue|How often did you have trouble finishing things because of your fatigue	A question about how often an individual has or had trouble finishing things because of their fatigue.			Intellectual Product	PROMIS Short Form v1.0 - Fatigue 8a
C129498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129498>	C158948|C103223	C19MC Amplification	A genetic finding indicating the presence of amplification of the C19MC region on chromosome 19 (19q13.42).			Laboratory or Test Result	
C129499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129499>	C186534	Embryonal Tumor with Multilayered Rosettes without C19MC Alteration	An embryonal tumor with multilayered rosettes characterized by the absence of C19MC amplification. Approximately half of embryonal tumors with multilayered rosettes that lack a C19MC alteration carry DICER1 mutations.			Neoplastic Process	
C12949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12949>	C12596	Somatic Cell|Somatic Cells|somatic cell		Somatic Cells		Cell	
C1294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1294>	C2266|C2139	Thymopentin|Immunox|Mepentil|Mepentil|N-(N-(N-(N(2)-L-Arginyl-L-Lysyl)-L-alpha-Aspartyl)-L-Valyl)-L-Tyrosine|N-[N-[N-(N{2}-L-Arginyl-L-lysyl)-L-alpha-aspartyl]-L-valyl]-L-tyrosine|ORF-15244|Sintomodulina|THYMOPENTIN|Timunox	A synthetic pentapeptide which is the active site of the naturally occurring hormone thymopoietin with immunomodulating properties. Thymopentin enhances the production of thymic T cells and may help restore immunocompetence in immunosuppressed subjects. This agent also augments the effects of ionizing radiation by arresting cancer cells in the G2/M phase of the cell cycle. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129500>	C38440|C177694	Loss of BRG1 Protein Expression|Loss of ATP-Dependent Helicase SMARCA4 Protein Expression|Loss of BAF190A Protein Expression|Loss of BRG-1 Protein Expression|Loss of Brahma Protein Homolog 1 Protein Expression|Loss of Possible Global Transcription Activator SNF2L4 Protein Expression|Loss of Protein Brahma Homolog 1 Protein Expression|Loss of SMARCA4 Protein Expression|Loss of SNF2-Beta Protein Expression|Loss of SWI/SNF-Related Matrix-Associated Actin-Dependent Regulator of Chromatin Subfamily A Member 4 Protein Expression	An immunohistochemical finding indicating negative staining of tumor cells for BRG1 protein, resulting from the mutation of the SMARCA4 gene.	Loss of BRG1 Protein Expression		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129501>	C6990	Central Nervous System Embryonal Tumor with Rhabdoid Features|CNS Embryonal Tumor with Rhabdoid Features|CNS Embryonal tumor with rhabdoid features	A central nervous system embryonal neoplasm characterized by the presence of histological features consistent with atypical teratoid/rhabdoid tumor and absence of mutations of the INI1 gene or SMARCA4 (BRG1) gene.			Neoplastic Process	GDC Terminology|GDC Value Terminology
C129502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129502>	C36282|C3303	Odynophagia	Pain upon swallowing.			Sign or Symptom	
C129503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129503>	C97927	PRKAR1A Gene Mutation|PKR1 Gene Mutation|PRKAR1 Gene Mutation|Protein Kinase cAMP-Dependent Type I Regulatory Subunit Alpha Gene Mutation|TSE1 Gene Mutation	A change in the nucleotide sequence of the PRKAR1A gene.			Cell or Molecular Dysfunction	
C129504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129504>	C12471	Fibrous Tissue	A tissue composed of bundles of collagenous white fibers between which are rows of connective tissue cells.			Tissue	
C129505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129505>	C91105	Patient Health Questionnaire-4|PHQ-4|Patient Health Questionnaire - 4 Item	An ultra-brief self-report questionnaire that consists of a 2-item depression scale that uses the first 2 questions from the Patient Health Questionnaire-9 (PHQ-9) and a 2-item anxiety scale that uses the first two questions from the Generalized Anxiety Disorder 7-item scale (GAD-7).			Intellectual Product	
C129506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129506>	C201922	Placement of Surgical Mesh	A surgical procedure in which a surgical mesh is implanted, usually for repair of abdominal wall hernias or pelvic organ prolapse.	Placement of Surgical Mesh		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C129507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129507>	C41075	Surgical Mesh Implant|Surgical Mesh	A surgically implanted medical device composed of woven material, often used for support of weakened or damaged organs or tissues. A surgical mesh can be used for either permanent or temporary support.	Surgical Mesh Implant		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C129508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129508>	C173603	Worst Severity Past Seven Days Wheezing Question|What was the severity of your wheezing (whistling noise in the chest with breathing) at its worst|Worst Severity Past Seven Days Wheezing|Worst Severity of Wheezing	A question about an individual's observation of the worst severity they have experienced related to wheezing (whistling noise in the chest with breathing) over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C129509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129509>	C173737|C173358|C173219	Past Seven Days Frequency of Pounding or Racing Heartbeat Question|Frequency of Pounding or Racing Heartbeat|How often did you feel a pounding or racing heartbeat (palpitations)|Past Seven Days Frequency of Pounding or Racing Heartbeat	A question about the frequency of an individual's pounding or racing heartbeat (palpitations) over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C12950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12950>	C13229|C12801	Embryonic Tissue	Tissue that is formed during the embryonic stage of life of an organism.	Embryonic Tissue		Embryonic Structure	GDC Terminology|GDC Value Terminology
C129510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129510>	C173603	Worst Severity Past Seven Days Pounding or Racing Heartbeat Question|What was the severity of your pounding or racing heartbeat (palpitations) at its worst|Worst Severity Past Seven Days Pounding or Racing Heartbeat|Worst Severity Pounding or Racing Heartbeat	A question about an individual's observation of the worst severity they have experienced related to pounding or racing heartbeat (palpitations) over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C129511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129511>	C173603	Worst Severity Past Seven Days Dry Skin Question|What was the severity of your dry skin at its worst|Worst Severity Dry Skin|Worst Severity Past Seven Days Dry Skin	A question about an individual's observation of the worst severity they have experienced related to dry skin over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C129512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129512>	C173603	Worst Severity Past Seven Days Acne or Pimples on the Face or Chest Question|What was the severity of your acne or pimples on the face or chest at its worst|Worst Severity Acne or Pimples on the Face or Chest|Worst Severity Past Seven Days Acne or Pimples on the Face or Chest	A question about an individual's observation of the worst severity they have experienced related to acne or pimples on the face or chest over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C129513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129513>	C173737	Past Seven Days Any Hair Loss Question|Any Hair Loss|Did you have any hair loss|Did you have any hair loss over the past 7 days|Past Seven Days Any Hair Loss	A question about whether or not an individual had any hair loss over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C129515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129515>	C173737	Past Seven Days Any Bed Sores Question|Any Bed Sores|Did you have any bed sores|Did you have any bed sores over the past 7 days|Past Seven Days Any Bed Sores	A question about whether or not an individual had any bed sores over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C129516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129516>	C173603	Worst Severity Past Seven Days Skin Burns from Radiation Question|What was the severity of your skin burns from radiation at their worst|Worst Severity Past Seven Days Skin Burns from Radiation|Worst Severity Skin Burns from Radiation	A question about an individual's observation of the worst severity they have experienced related to skin burns from radiation over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C129517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129517>	C173737	Past Seven Days Any Unusual Darkening of the Skin Question|Any Unusual Darkening of the Skin|Did you have any unusual darkening of the skin|Did you have any unusual darkening of the skin over the past 7 days|Past Seven Days Any Unusual Darkening of the Skin	A question about whether or not an individual had any unusual darkening of the skin over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C129518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129518>	C173737	Past Seven Days Any Stretch Marks Question|Any Stretch Marks|Did you have any stretch marks|Did you have any stretch marks over the past 7 days|Past Seven Days Any Stretch Marks	A question about whether or not an individual had any stretch marks over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C129519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129519>	C173603|C173600	Worst Severity Past Seven Days Dizziness Question|What was the severity of your dizziness at its worst|Worst Severity Dizziness|Worst Severity Past Seven Days Dizziness	A question about an individual's observation of the worst severity they have experienced related to dizziness over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C12951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12951>	C33904	Splenocyte|Splenocytes	A vague term that usually refers to the phagocytic cells (macrophages) of the spleen.	Splenocyte		Cell	
C129520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129520>	C173787|C173737|C173600|C173584	Past Seven Days How Much Dizziness Interfered with Usual or Daily Activities Question|How Much Dizziness Interfered with Usual or Daily Activities|How much did dizziness interfere with your usual or daily activities|Past Seven Days How Much Dizziness Interfered with Usual or Daily Activities	A question about how much an individual's dizziness interfered with their usual or daily activities over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C129522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129522>	C28310|C181141	Autologous Bladder Cell Carcinoma RNAs/CD40L RNA Electroporated Autologous Matured Dendritic Cells|AGS-003-BLD|Autologous DCs Electroporated with Autologous Tumor-derived IVT RNAs/CD40L IVT RNA|Autologous DCs Electroporated with Autologous Tumor-derived RNAs/CD40L RNA|Bladder Cell Carcinoma RNAs/CD40L RNA-transfected Autologous Dendritic Cells	A cell-based preparation in which autologous, mature dendritic cells (DCs) are electroporated with in vitro transcribed (IVT) RNAs encoding for a synthetic form of T-cell protein CD40 ligand (CD40L) and IVT RNA encoding for autologous tumor-associated antigens (TAAs) derived from patient-specific bladder cell carcinoma (BCC) cells, with potential immunostimulatory and antineoplastic activities. Upon electroporation into autologous DCs, the RNA is translated and processed. BCC-specific antigenic peptides are subsequently presented via major histocompatibility complex (MHC) Class I molecules on the DCs surface. When AGS-003-BLD is reintroduced to the patient, the MHC-presented peptides interact with and activate CD8-positive T-cells, which elicits a highly specific cytotoxic T-cell (CTL) response against tumor cells expressing the patient-specific BCC TAAs. The signal cascade initiated by expression of the co-stimulatory molecule CD40L results in the secretion of the inflammatory cytokine IL-12, which further stimulates CTLs.	Autologous Bladder Cell Carcinoma RNAs/CD40L RNA Electroporated Autologous Matured Dendritic Cells		Cell|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCIt Antineoplastic Agent Terminology
C129523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129523>	C180939|C135717	KRAS NM_004985.3:c.436G>A|C-K-RAS c.436G>A|KI-RAS c.436G>A|KRAS c.436G>A|KRAS1 c.436G>A|KRAS2 c.436G>A|NM_004985.3:c.436G>A|v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog c.436G>A	A nucleotide substitution at position 436 of the coding sequence of the KRAS gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C129524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129524>	C107479	KRAS NP_004976.2:p.A146T|GTPase KRas A146T|GTPase KRas Ala146Thr|K-Ras 2 A146T|K-Ras 2 Ala146Thr|KRAS A146T|KRAS Ala146Thr|KRAS NP_004976.2:p.Ala146Thr|KRAS p.A146T|KRAS p.Ala146Thr|Ki-Ras A146T|Ki-Ras Ala146Thr|NP_004976.2:p.A146T|NP_004976.2:p.Ala146Thr|c-K-ras A146T|c-K-ras Ala146Thr	A change in the amino acid residue at position 146 in the GTPase Kras protein where alanine has been replaced by threonine.			Cell or Molecular Dysfunction	
C129525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129525>	C38440	Nuclear Expression of STAT6 Protein|Gain of Nuclear STAT6	A finding indicating the presence of STAT6 nuclear signal in tumor cells by immunohistochemistry. It results from the fusion of the NAB2 and STAT6 genes.			Laboratory or Test Result	
C129526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129526>	C7634|C5449	Central Nervous System Solitary Fibrous Tumor|CNS Solitary Fibrous Tumor|CNS Solitary Fibrous Tumor/Hemangiopericytoma|Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma	A mesenchymal, non-meningothelial neoplasm arising from the central nervous system. It is characterized by a collagenous and low cellularity spindle cell and/or hemangiopericytomatous histopathological pattern, recurrent intrachromosomal rearrangement on chromosome 12q that results in the fusion of the NAB2 and STAT6 genes, high recurrence rates, and long-term risk of systemic metastasis.			Neoplastic Process	NCIt Neoplasm Core Terminology
C129527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129527>	C6894|C6758|C129526	Central Nervous System Solitary Fibrous Tumor, Grade 3|CNS Solitary Fibrous Tumor, Grade 3|CNS Solitary Fibrous Tumor/Hemangiopericytoma, Grade 3|Central Nervous System Anaplastic Hemangiopericytoma|Central Nervous System Malignant Hemangiopericytoma|Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 3|Solitary fibrous tumor/hemangiopericytoma Grade 3 (CNS)	A solitary fibrous tumor that arises from the central nervous system. It most often corresponds to the tumor previously diagnosed as anaplastic hemangiopericytoma.			Neoplastic Process	GDC Terminology|GDC Value Terminology|NCIt Neoplasm Core Terminology
C129528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129528>	C129526	Central Nervous System Solitary Fibrous Tumor, Grade 2|CNS Solitary Fibrous Tumor, Grade 2|CNS Solitary Fibrous Tumor/Hemangiopericytoma, Grade 2|Central Nervous System Hemangiopericytoma|Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 2|Solitary fibrous tumor/hemangiopericytoma Grade 2 (CNS)	A solitary fibrous tumor that arises from the central nervous system. It corresponds to the more cellular, less collagenous tumor with plump cells and staghorn vasculature which was diagnosed as central nervous system hemangiopericytoma in the past.			Neoplastic Process	GDC Terminology|GDC Value Terminology|NCIt Neoplasm Core Terminology
C129529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129529>	C123620	Major Cytogenetic Response in Chronic Myelogenous Leukemia, BCR-ABL1 Positive|MCyR in Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Major Cytogenetic Response	A cytogenetic finding indicating Philadelphia chromosome positivity less than or equal to 35% in a patient treated for chronic myelogenous leukemia, BCR-ABL1 positive.			Finding	
C129530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129530>	C129526	Central Nervous System Solitary Fibrous Tumor, Grade 1|CNS Solitary Fibrous Tumor, Grade 1|CNS Solitary Fibrous Tumor/Hemangiopericytoma, Grade 1|Central Nervous System Solitary Fibrous Tumor|Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma, Grade 1|Solitary fibrous tumor/hemangiopericytoma Grade 1 (CNS)	A solitary fibrous tumor that arises from the central nervous system. It corresponds most often to the collagenous and low cellularity spindle cell tumor which was diagnosed as central nervous system solitary fibrous tumor in the past.			Neoplastic Process	GDC Terminology|GDC Value Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology|NCIt Neoplasm Core Terminology
C129531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129531>	C25193	Retailer	A merchant who sells goods directly to consumers.			Occupation or Discipline	
C129532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129532>	C62439	One Hundred Fifty|150	A natural number greater than 149 and less than 151 and the quantity that it denotes.			Quantitative Concept	
C129533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129533>	C78254	Needle Tract Seeding|Needle Seeding|Needle Track Seeding|Neoplastic Seeding|Track Seeding|Tract Seeding	The implantation of tumor cells to surrounding tissue along the course of a contaminated instrument such as a biopsy needle or laparoscope.			Finding	
C129534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129534>	C5153|C3737	Central Nervous System Mesenchymal Chondrosarcoma	A mesenchymal chondrosarcoma that arises from the central nervous system.			Neoplastic Process	
C129535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129535>	C62727	Surface Guided Radiation Therapy|SGRT|SURF|VisionRT-Mediated Radiation Therapy|VisionRT-assisted Deep Inspiration Breath-hold Beam Delivery|VisionRT-based Deep Inspiration Breath-hold Beam Delivery	A form of image-guided radiation therapy for high-accuracy patient positioning and motion monitoring. SGRT tracks the patient's skin surface in 3 dimensions; motion that exceeds clinically acceptable tolerances can be detected and the beam can be held automatically or gated according to the patient's breathing cycle.	Surface Guided Radiation Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C129536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129536>	C6758|C3800	Central Nervous System Epithelioid Hemangioendothelioma	A low-grade malignant blood vessel neoplasm that arises from the central nervous system. It is characterized by the presence of epithelioid endothelial cells.			Neoplastic Process	
C129537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129537>	C6990|C27291	Central Nervous System Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor	A rare Ewing sarcoma/peripheral primitive neuroectodermal tumor that affects the central nervous system either as a primary dural neoplasm or by direct extension from adjacent soft tissues or bone.			Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology
C129538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129538>	C5451|C3733	Central Nervous System Angiolipoma	An angiolipoma that arises from the central nervous system.			Neoplastic Process	
C129539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129539>	C217121	Revised Dyadic Adjustment Scale|RDAS|Revised Dyadic Adjustment Scale (RDAS)	A 14 item self report questionnaire that assess seven dimensions of couple relationship satisfaction. This revised version of the Dyadic Adjustment Scale is shorter and offers improved psychometric properties.			Intellectual Product	
C12953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12953>	C33904	Nervous System Fluids and Secretions|Nervous System-Fluids, Secretions	Fluids and secretions related to the nervous system. The entire nerve apparatus, composed of a central part, the brain and spinal cord, and a peripheral part, the cranial and spinal nerves, autonomic ganglia, and plexuses.	Nervous System Fluids and Secretions		Body Substance	
C129540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129540>	C173150	Extent of Agreement or Disagreement on Religious Matters Question|Extent of Agreement or Disagreement on Religious Matters|Religious matters	A question about the extent of agreement or disagreement between an individual and their partner regarding religious matters.			Intellectual Product	Revised Dyadic Adjustment Scale
C129541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129541>	C173150	Extent of Agreement or Disagreement on Demonstrations of Affection Question|Demonstrations of affection|Extent of Agreement or Disagreement on Demonstrations of Affection	A question about the extent of agreement or disagreement between an individual and their partner regarding demonstrations of affection.			Intellectual Product	Revised Dyadic Adjustment Scale
C129542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129542>	C174127|C173150	Extent of Agreement or Disagreement on Making Major Decisions Question|Extent of Agreement or Disagreement on Making Major Decisions|Making major decisions	A question about the extent of agreement or disagreement between an individual and their partner regarding making major decisions.			Intellectual Product	Revised Dyadic Adjustment Scale
C129543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129543>	C173704|C173150	Extent of Agreement or Disagreement on Sex Relations Question|Extent of Agreement or Disagreement on Sex Relations|Sex relations	A question about the extent of agreement or disagreement between an individual and their partner regarding sex relations.			Intellectual Product	Revised Dyadic Adjustment Scale
C129544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129544>	C173150	Extent of Agreement or Disagreement on Conventionality Question|Conventionality (correct or proper behavior)|Extent of Agreement or Disagreement on Conventionality	A question about the extent of agreement or disagreement between an individual and their partner regarding conventionality of behavior.			Intellectual Product	Revised Dyadic Adjustment Scale
C129545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129545>	C174127|C173150	Extent of Agreement or Disagreement on Career Decisions Question|Career decisions|Extent of Agreement or Disagreement on Career Decisions	A question about the extent of agreement or disagreement between an individual and their partner regarding career decisions.			Intellectual Product	Revised Dyadic Adjustment Scale
C129546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129546>	C129824	Splicing Inhibitor H3B-8800|H3B 8800|H3B-8800|H3B-8800|Splicing Factor Inhibitor H3B-8800|Splicing Modulator H3B-8800	An orally bioavailable inhibitor of the splicing factor 3B subunit 1 (SF3B1), with potential antineoplastic activity. Upon administration, H3B-8800 binds to and blocks the activity of SF3B1, a core spliceosome protein that is mutated in various cancer cells. This modulates RNA splicing by preventing aberrant mRNA splicing by the spliceosome, blocks RNA mis-splicing, enhances proper RNA splicing and prevents the expression of certain tumor-associated genes. This leads to an induction of apoptosis and prevents tumor cell proliferation. In many cancer cells, core spliceosome proteins, including SF3B1, U2 small nuclear ribonucleoprotein auxiliary factor 1 (U2AF1), serine/arginine-rich splicing factor 2 (SRSF2) and U2 small nuclear ribonucleoprotein auxiliary factor subunit-related protein 2 (ZRSR2), are mutated and aberrantly activated leading to a dysregulation of mRNA splicing.	Splicing Inhibitor H3B-8800		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129547>	C118873	How Often Discuss or Consider Divorce, Separation or Terminating Relationship Question|How Often Discuss or Consider Divorce, Separation or Terminating Relationship|How often do you discuss or have you considered divorce, separation, or terminating your relationship	A question about how often an individual has discussed or considered divorce, separation, or termination of their relationship.			Intellectual Product	Revised Dyadic Adjustment Scale
C129548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129548>	C6489|C5449	Central Nervous System Desmoid Fibromatosis|Central Nervous System Desmoid-Type Fibromatosis	Intracranial and/or spinal involvement by desmoid fibromatosis.			Neoplastic Process	
C129549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129549>	C6757|C5111|C3739	Intracranial Fibrous Histiocytoma|Intracranial Benign Fibrous Histiocytoma	A benign fibrous histiocytoma involving the dura or cranial bone.			Neoplastic Process	
C12954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12954>	C12529	Peripheral Blood Mononuclear Cell|PBMC|PBMC|PERIPHERAL BLOOD MONONUCLEAR CELL	A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.	Peripheral Blood Mononuclear Cell		Cell	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C129550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129550>	C118873	How Often Quarrel with Partner Question|How Often Quarrel with Partner|How often do you and your partner quarrel	A question about how often an individual quarrels with their partner.			Intellectual Product	Revised Dyadic Adjustment Scale
C129551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129551>	C6757|C49012	Central Nervous System Myofibroblastoma	A rare myofibroblastoma affecting the central nervous system.			Neoplastic Process	
C129552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129552>	C91102	Regret Marriage or Living Together Question|Do you ever regret that you married (or lived together)|Regret Marriage or Living Together	A question about whether an individual regrets having married or lived together.			Intellectual Product	Revised Dyadic Adjustment Scale
C129553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129553>	C118873	How Often Get on Each Other's Nerves Question|How Often Get on Each Other's Nerves|How often do you and your mate "get on each other's nerves"	A question about how often an individual and their partner get on each other's nerves.			Intellectual Product	Revised Dyadic Adjustment Scale
C129554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129554>	C118873	How Often Engage in Outside Interests Together Question|Do you and your mate engage in outside interests together|How Often Engage in Outside Interests Together	A question about how often an individual and their partner engage in outside interests together.			Intellectual Product	Revised Dyadic Adjustment Scale
C129555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129555>	C73539	Kynurenine|(2S)-2-Amino-4-(2-Aminophenyl)-4-Oxobutanoic Acid|(S)-Kynurenine|3-Anthraniloyl-L-Alanine|KYN|KYNURENINE|Kynurenine, L-|L-Kynurenine	A ketone and an amino acid derivative that is synthesized by either tryptophan 2,3-dioxygenase (TDO)- or indoleamine 2,3-dioxygenase (IDO)-mediated oxidation of tryptophan with diverse biological functions, including vasodilatory, immunoregulatory and neuromodulatory activities. Kynurenine is a precursor for niacin. Additionally, kynurenine can be further metabolized into anthranilic acid, kynurenic acid, and 3-hydroxykynurenine; aberrant production of kynurenine is associated with neurological disease-related cognitive deficits and depressive symptoms. Overexpressed in certain cancer cell types, kynurenine could potentially be used as a biomarker to assess cancer risk.	Kynurenine		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C129556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129556>	C118873	How Often Have Stimulating Exchange of Ideas Question|Have a stimulating exchange of ideas|How Often Have Stimulating Exchange of Ideas	A question about how often an individual and their partner have stimulating exchange of ideas.			Intellectual Product	Revised Dyadic Adjustment Scale
C129557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129557>	C173924|C118873	How Often Work Together on Projects Question|How Often Work Together on Projects|Work together on a project	A question about how often an individual and their partner work together on a project.			Intellectual Product	Revised Dyadic Adjustment Scale
C129558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129558>	C118873	How Often Calmly Discuss Something Question|Calmly discuss something|How Often Calmly Discuss Something	A question about how often an individual and their partner calmly discuss something.			Intellectual Product	Revised Dyadic Adjustment Scale
C129559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129559>	C176244	Always Agree	A response indicating agreement at all times.			Intellectual Product	Revised Dyadic Adjustment Scale
C12955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12955>	C33904	Nervous System, Ear	Of or related to the peripheral or central auditory system.	Nervous System, Ear		Body Part, Organ, or Organ Component	
C129560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129560>	C176244	Almost Always Agree	A response indicating agreement at almost all times.			Intellectual Product	Revised Dyadic Adjustment Scale
C129561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129561>	C176244	Occasionally Agree	A response indicating occasional agreement.			Intellectual Product	Revised Dyadic Adjustment Scale
C129562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129562>	C226653	Frequently Disagree	A response indicating frequent disagreement.			Intellectual Product	Revised Dyadic Adjustment Scale
C129563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129563>	C226653	Almost Always Disagree	A response indicating disagreement at almost all times.			Intellectual Product	Revised Dyadic Adjustment Scale
C129564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129564>	C226653	Always Disagree	A response indicating disagreement at all times.			Intellectual Product	Revised Dyadic Adjustment Scale
C129565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129565>	C226671	More Often than Not|More often than not	A response indicating that something occurs more than half the time.			Intellectual Product	Revised Dyadic Adjustment Scale
C129566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129566>	C5153|C4247	Central Nervous System Undifferentiated Pleomorphic Sarcoma|Central Nervous System Malignant Fibrous Histiocytoma	A rare undifferentiated pleomorphic sarcoma (formerly known as malignant fibrous histiocytoma) involving the central nervous system.			Neoplastic Process	
C129567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129567>	C64493	Less than Once a Month|Less than monthly|Less than once a month	An indication that something is scheduled, or occurs, less than once a month.			Quantitative Concept	Revised Dyadic Adjustment Scale
C129568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129568>	C64493	Once or Twice a Month|Once or twice a month	An indication that something is scheduled, or occurs, once or twice a month.			Quantitative Concept	Revised Dyadic Adjustment Scale
C129569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129569>	C3296|C155792	Skull Osteoma	A benign, well-circumscribed bone-forming neoplasm that is predominantly composed of lamellar bone and arises in the skull.			Neoplastic Process	
C12956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12956>	C33904	Neuro-Ocular System|Nervous System, Eye	The components of the eye that are also part of the nervous system, including the retina and optic nerve.	Neuro-Ocular System		Body System	
C129570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129570>	C64493	More Often than Once a Day|More often	An indication that something is scheduled, or occurs, more than once a day.			Quantitative Concept	Revised Dyadic Adjustment Scale
C129571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129571>	C36438|C36386	Gain of Chromosome 1q21|1q21 Amplification	A cytogenetic abnormality that refers to allelic gain within the chromosomal region 1q21.	Gain of Chromosome 1q21		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129572>	C36345	EGFR Protein Translocation|EGFR Translocation|ERBB1 Translocation|Epidermal Growth Factor Receptor Protein Translocation|HER1 Translocation	A molecular abnormality indicating that the epidermal growth factor receptor protein has been localized to the membrane of an internal cellular compartment.	EGFR Protein Translocation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C129573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129573>	C177692	Ganglioside GD2 Positive|GD2 Ganglioside Positive|GD2 Positive	Indicates that expression of ganglioside GD2 has been detected in a sample.	Ganglioside GD2 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C129574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129574>	C37208|C156028	ALK Gene Rearrangement|ALK Rearrangement|ALK rearranged|Anaplastic Lymphoma Kinase Gene Rearrangement|Anaplastic Lymphoma Receptor Tyrosine Kinase Gene Rearrangement|CD246 Gene Rearrangement|Rearrangement identified	A molecular abnormality indicating rearrangement of the ALK gene.	ALK Gene Rearrangement		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C129575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129575>	C190823|C177687	EGFR Driver Mutation Negative|Deleterious EGFR Gene Mutation Negative|ERBB1 Driver Mutation Negative|Epidermal Growth Factor Receptor Driver Mutation Negative|HER1 Driver Mutation Negative|c-erbB1 Driver Mutation Negative	A genetic finding indicating that disease-causing (driver) mutations in the EGFR gene are not present in a sample.	EGFR Driver Mutation Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129576>	C177684|C165233	EML4/ALK Fusion Negative|EML4-ALK Fusion Negative|EML4-ALK Negative|EML4/ALK Negative	Indicates that expression of the EML4/ALK fusion has not been detected in a sample.	EML4/ALK Fusion Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129577>	C16691	HLA Class I Histocompatibility Antigen, A-0205 Alpha Chain|HLA-A Class I Antigen 0205|HLA-A Histocompatibility Type Antigen 0205|HLA-A*0205|HLA-A*02:05|MHC Class I Antigen A*0205|Major Histocompatibility Complex, Class I, A0205 Antigen	HLA class I histocompatibility antigen, A-0205 alpha chain (365 aa, ~41 kDa) is encoded by the human HLA-A gene. This protein plays a role in the presentation of foreign antigens to the immune system.	HLA Class I Histocompatibility Antigen, A-0205 Alpha Chain		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129578>	C16691	HLA Class I Histocompatibility Antigen, A-0206 Alpha Chain|HLA-A Class I Antigen 0206|HLA-A Histocompatibility Type Antigen 0206|HLA-A*0206|HLA-A*02:06|MHC Class I Antigen A*0206|Major Histocompatibility Complex, Class I, A0206 Antigen	HLA class I histocompatibility antigen, A-0206 alpha chain (365 aa, ~41 kDa) is encoded by the human HLA-A gene. This protein is involved in the presentation of foreign antigens to the immune system.	HLA Class I Histocompatibility Antigen, A-0206 Alpha Chain		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129579>	C136826	CEV Regimen|CEV|CEV (Carboplatin/Etoposide)|Carboplatin-Etoposide-Vincristine|Carboplatin-Etoposide-Vincristine Regimen|Carboplatin/Etoposide/Vincristine|Carboplatin/Etoposide/Vincristine Regimen	A regimen containing carboplatin, etoposide, and vincristine which may be used in the treatment of pediatric retinoblastoma (RB).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|NCI Drug Dictionary Terminology|Pharmacotherapy Regimens
C12957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12957>	C12919	Exocrine System	A system of glands that secrete fluids delivered via ducts and tubes directly to organs including the skin. Examples include the exocrine pancreas and the prostate gland.	Exocrine System		Body System	
C129580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129580>	C155927	Chk1 Inhibitor SRA737|(R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile|CCT245737|Checkpoint Kinase 1 Inhibitor CCT245737|Chk1 Inhibitor CCT245737|PNT-737|SRA 737|SRA-737|SRA-737|SRA737	An orally bioavailable inhibitor of checkpoint kinase 1 (chk1), with potential antineoplastic and chemosensitization activities. Upon oral administration, chk1 inhibitor SRA737 selectively binds to chk1, thereby preventing chk1 activity and abrogating the repair of damaged DNA. This may lead to an accumulation of damaged DNA, inhibition of cell cycle arrest, and induction of apoptosis. SRA737 may potentiate the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapeutic agents. Chk1, an adenosine triphosphate (ATP)-dependent serine/threonine kinase overexpressed in a variety of cancer cell types, mediates cell cycle checkpoint control and is essential for DNA repair; it plays a key role in resistance to chemotherapeutic agents by repairing DNA damage.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129581>	C129986	Ma Zi Ren Wan|Hemp Seed Formula|MZRW|MaZiRenWan	A proprietary, traditional Chinese herbal (TCH) formula composed of six different herbs: Semen Cannabis Sativae (Huo Ma Ren, cannabis seed), Semen Pruni Armeniacae (Xing Ren, apricot seed), Radix Paeoniae Alba (Bai Shao, white peony root), Fructus Immaturus Citri Aurantii (Zhi Shi, immature bitter orange), Cortex Magnoliae Officinalis (Hou Po, magnolia bark and Radix et Rhizoma Rhei (Da Huang, rhubarb root and rhizome). Ma Zi Ren Wan (MZRW) may help with intestinal dryness and constipation by lubricating and moistening the intestines and the stool. MZRW may also stimulate intestinal movement; it is believed to drain heat, promote the movement of Qi and unblock the bowels.	Ma Zi Ren Wan		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C129582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129582>	C129986	Huang Qi|ASTRAGALUS MONGHOLICUS ROOT|Astragalus Root|HuangQi|Milk Vetch Root|Milkvetch Root|Radix Astragali	A Chinese herbal medicine (CHM) containing the root of the perennial herbaceous plant Astragalus (Radix Astragali) belonging to the family Leguminosae. Huang Qi is believed to tonify Qi, induce diuresis, relieve edema and nourish blood. It may also replenish body fluids and help relieve pain.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C129583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129583>	C129986	Shu Di Huang|Cooked Rehmannia Root|Processed Rehmannia Glutinosa Libosch Root|Processed Rehmannia Root|Radix Rehmanniae Preparata|ShuDiHuang|Steamed Chinese Foxglove Root	A Chinese herbal medicine (CHM) containing the cooked or steamed root of the herbaceous plant Rehmannia glutinosa Libosch of the Scrophulariaceae family. Shu Di Huang is believed to treat deficiency of yin and body fluid by nourishing yin. It may tonify and nourish blood.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C129584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129584>	C129986	Mai Dong|Mai Men Dong|Maidong|OPHIOPOGON JAPONICUS ROOT|Ophiopogon|Radix Ophiopogonis	The root of the perennial herbaceous plant Ophiopogon belonging to the Liliaceae family. Mai Dong is believed to tonify yin. This traditional Chinese medicine (TCM) may replenish fluids, moisten the intestines and thereby help relieve constipation. It may also have antipyretic and antitussive effects; it may be used as an expectorant and may moisten the lungs, throat and nose.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C129585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129585>	C129986	Sheng Di Huang|Radix Rehmanniae Glutinosae|Rehmannia Glutinosa|ShengDiHuang	A Chinese herbal medicine (CHM) derived from the root tuber of perennial herbaceous plant Rehmannia glutinosa Libosch (Chinese foxglove root, Radix Rehmanniae Glutinosae) belonging to the Scrophulariaceae family. This traditional Chinese medicine (TCM) is believed to nourish yin and may help relieve any symptoms due to yin deficiency. It may replenish fluids and help with constipation and fever.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C129586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129586>	C129986	Rou Cong Rong|CISTANCHE DESERTICOLA STEM|Herba Cistanche|Rou Cong-Rong|RouCongRong	A Chinese herbal medicine (CHM) derived from the stems of the herbaceous plant Cistanche deserticola Y. C. Ma (Ginseng of the desert) belonging to the Orobanchaceae family. Rou Cong Rong may have antioxidative and neuroprotective activities. This traditional Chinese medicine (TCM) is used to help with pain, deficiency of kidney yang and may relieve constipation by moistening and smoothing stool.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C129587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129587>	C129986	Niu Xi|ACHYRANTHES BIDENTATA ROOT|Achyranthes Root|Huai Niu Xi|Niuxi|Ox-Knee Root|Radix Achyranthis Bidentatae	A Chinese herbal medicine (CHM) composed of the dried root from the herbaceous plant Ox-Knee (Achyranthes bidentata Blume) belonging to the Amaranthaceae family. Niu Xi may regulate the blood, may help relieve certain pains, and it may tonify the liver and kidneys.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C129588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129588>	C1962	Zinc Finger Nuclease ZFN-603|ZFN ZFN-603|ZFN-603|ZFN603	A zinc finger nuclease (ZFN) targeting the human papillomavirus (HPV) type 16 (HPV16) oncoprotein E7, with potential antineoplastic activity. Upon transfection of ZFN-603 into HPV16-positive cells, ZFN-603 targets, binds to and cleaves the HPV16 E7 oncogene in HPV16-infected cells. By cleaving the HPV16 E7 DNA, the E7 oncoprotein is not expressed. This results in an inhibition of E7-mediated signaling, an induction of apoptosis, and inhibition of tumor cell proliferation in HPV16-expressing cells. In addition, preventing E7 expression induces the expression of tumor suppressor genes, thereby further preventing HPV-induced cancer cell formation and proliferation. E7 plays a key role in promoting both viral infection and carcinogenesis. ZFN, an engineered endonuclease in which a DNA-binding zinc finger protein is fused to a DNA-cleavable domain, cleaves specific DNA sites.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129589>	C1962	Zinc Finger Nuclease ZFN-758|ZFN ZFN-758|ZFN-758|ZFN758	A zinc finger nuclease (ZFN) targeting the human papillomavirus (HPV) type 18 (HPV18) oncoprotein E7, with potential antineoplastic activity. Upon transfection of ZFN-758 into HPV18-positive cells, ZFN-758 targets, binds to and cleaves the HPV18 E7 oncogene in HPV18-infected cells. By cleaving the HPV18 E7 DNA, the E7 oncoprotein is not expressed. This results in an inhibition of E7-mediated signaling, an induction of apoptosis, and an inhibition of tumor cell proliferation in HPV18-expressing cells. In addition, preventing E7 expression induces the expression of tumor suppressor genes, thereby further preventing HPV-induced cancer cell formation and proliferation. E7 plays a key role in promoting both viral infection and carcinogenesis. ZFN, an engineered endonuclease in which a DNA-binding zinc finger protein is fused to a DNA-cleavable domain, cleaves specific DNA sites.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12958>	C192998	Mammalian Cell Specimen|Mammalian Cell	A biospecimen consisting of cells originating from or isolated from an animal of class Mammalia.	Mammalian Cell		Cell	
C129590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129590>	C1966	Cronexitide Lanocianine|CRONEXITIDE LANOCIANINE|Cypate-cyclo (D-Cys-Gly-Arg--Asp-Ser-Pro-Cys)-Lys-OH|Fluorescent Dye LS301|LS 301|LS-301|LS301|NIR Fluorescent Probe LS301	A hydrophobic near-infrared (NIR) fluorescent probe composed of a NIR fluorescent dye cypate linked to an unnatural D-cysteine-containing cyclic octapeptide (D-Cys-Gly-Arg--Asp-Ser-Pro-Cys)-Lys-OH, with potential cancer imaging activity. Upon administration of cronexitide lanocianine during tumor resection, the peptide component specifically targets and binds integrin receptors expressed on tumor cells, which are not expressed on normal, healthy cells. Upon receptor-mediated endocytosis and fluorescence imaging using infrared light that is visualized by the surgeon with special Cancer Vision Goggles (CVG), tumor cells can be detected, identified, and removed accordingly. This enhances the accuracy of cancer cell removal during surgery. The D-cysteine on the peptide prevents degradation by endogenous proteases.	Cronexitide Lanocianine		Indicator, Reagent, or Diagnostic Aid	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C129591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129591>	C20401|C129822	Lirentelimab|AK 002|AK002|LIRENTELIMAB|Monoclonal Antibody AK 002	A humanized, nonfucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against the inhibitory receptor sialic acid-binding immunoglobulin-like lectin 8 (Siglec-8) expressed on human mast cells and eosinophils, with potential anti-inflammatory activity. Upon administration, lirentelimab targets and binds to Siglec-8 expressed on the surface of mast cells and eosinophils. This may inhibit mast cell activation and deplete eosinophils through antibody-dependent cell-mediated cytotoxicity (ADCC) and apoptosis. This may reduce abnormal proliferation of mast cells and eosinophils, which plays a key role in allergic and inflammatory responses.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129592>	C681	Topical Naloxone Hydrochloride|E-0316|Naloxone Hydrochloride Dehydrate Lotio	A topical lotion formulation of the dehydrated, hydrochloride salt form of naloxone, an opiate antagonist, with potential anti-pruritic activity. Upon topical application of the naloxone lotion, naloxone binds to and blocks epidermal mu-opiate receptors. This may suppress or diminish pruritus.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C129593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129593>	C200766	Anti-hCD70-CAR Retroviral Vector-transduced Autologous PBLs|Anti-hCD70 Autologous CAR-transduced T Cells|Anti-hCD70 CAR autologous PBLs|Anti-hCD70-CAR Retroviral Vector-transduced Autologous Peripheral Blood Lymphocytes	A preparation of autologous human peripheral blood lymphocytes (PBLs) transduced with a retroviral vector encoding for a T-cell chimeric antigen receptor (CAR) gene specific for the human cluster of differentiation 70 (CD70), with potential immunostimulatory and antineoplastic activities. Autologous PBLs from a patient with CD70-positive cancer are transduced with a retroviral vector that encodes the CAR gene specific for CD70. After expansion in culture and reintroduction into the patient, anti-hCD70-CAR retroviral vector-transduced autologous PBLs bind to the CD70 antigen on tumor cell surfaces; subsequently, CD70-expressing tumor cells are lysed. CD70, the ligand for the costimulatory receptor CD27, is overexpressed on the surfaces of various cancer cell types.	Anti-hCD70-CAR Retroviral Vector-transduced Autologous PBLs		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129594>	C199655|C191691|C191689	PD-L1/PD-L2/VISTA Antagonist CA-170|AUPM 170|Aurigene 1|CA-170|CA-170|PD-L1/PD-L2/VISTA Checkpoint Antagonist CA-170	An orally bioavailable small molecule inhibitor of the immune checkpoint regulatory proteins programmed cell death ligand-1 (PD-L1; B7-H1; CD274), PD-L2, and V-domain immunoglobulin (Ig) suppressor of T-cell activation (VISTA; programmed death 1 homolog; PD1H; PD-1H), with potential negative immune checkpoint regulatory and antineoplastic activities. Upon oral administration, PD-L1/PD-L2/VISTA antagonist CA-170 targets and binds to PD-L1, PD-L2 and VISTA. This inhibits PD-L1/PD-L2/VISTA-mediated signaling, abrogates the PD-L1-, PD-L2- and VISTA-induced suppression of T-lymphocyte immune responses, enhances cytotoxic T-cell proliferation and activation against tumor cells, increases cytokine production by T-cells, and inhibits tumor cell growth. PD-L1, PD-L2 and VISTA, negative checkpoint molecules of immune activation, play key roles in the suppression of T-cell functions.	PD-L1/PD-L2/VISTA Antagonist CA-170		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129595>	C1505	Polypodium leucotomos Extract|Fernblock|PL Extract|PLE	A nutritional supplement composed of an aqueous extract derived from the leaves of the tropical fern belonging to the Polypodiaceae family, Polypodium leucotomos (PL; Phlebodium aureum), with potential photoprotective, skin protective, anti-inflammatory, immunomodulating and antioxidant activities. This extract contains many phenolic compounds, such as ferulic, caffeic, coumaric and vanillic acid, which are mainly responsible for this extract's effects. Upon administration, Polypodium leucotomos extract (PLE) exerts antioxidant activity by scavenging free radicals and inhibiting the generation and release of reactive oxygen species (ROS), thereby preventing ultraviolet (UV)-induced as well as ROS-induced DNA damage. In addition, the chemicals in this extract protect antioxidant enzymes and modulate expression of cancer and inflammation-related genes, including the induction of the expression of tumor suppressor genes and the inhibition of the expression of pro-inflammatory cytokines and inflammatory enzymes, thereby inhibiting the activation of signal transduction pathways involved in carcinogenesis and inflammation, respectively. PLE also stimulates tissue inhibitors of metalloproteinases (TIMPs) and inhibits matrix metalloproteinases (MMPs).			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129596>	C1752	CD4-specific Telomerase Peptide Vaccine UCPVax|UCP2/UCP4 CD4-specific Telomerase Peptide Vaccine UCPVax|UCPVax	A therapeutic peptide vaccine containing the human telomerase reverse transcriptase catalytic subunit (hTERT)-derived universal cancer peptides 2 (UCP2) and 4 (UCP4), and combined with the immunoadjuvant Montanide ISA 51 VG, with potential immunostimulating and antineoplastic activities. Vaccination with the CD4-specific telomerase peptide vaccine UCPVax activates the immune system to mount a T-helper 1 (TH1) CD4-positive T-lymphocyte immune response against and ultimately killing telomerase-expressing cells. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation.			Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129597>	C43643	Gene_Product_Variant_Of_Gene_Product	A role used to indicate that a gene product sequence variation is related to a wild-type gene product. The domain and range for this role are 'Gene Product Sequence Variation' and 'Gene Product', respectively.			Conceptual Entity	
C129598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129598>	C5322|C37193	Primary Central Nervous System Anaplastic Large Cell Lymphoma, ALK-Positive	An anaplastic large cell lymphoma, ALK-positive, arising from the central nervous system.			Neoplastic Process	
C129599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129599>	C5322|C37194	Primary Central Nervous System Anaplastic Large Cell Lymphoma, ALK-Negative	An anaplastic large cell lymphoma, ALK-negative, arising from the central nervous system.			Neoplastic Process	
C12959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12959>	C36779	Breast Cancer Cell|Human Breast Cancer Cell|Human Breast Cancer Cells	Cells found in human breast cancers or extracted from cancers as established cell lines	Human Breast Cancer Cell		Cell	
C1295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1295>	C1976	Streptogramin A|OSTREOGRYCIN A|VERNAMYCIN A|VIRGINIAMYCIN M1|Virginiamycin M1|mikamycin A|ostreogrycin A|pristinamycin IIA|staphylomycin M1|vernamycin A|virginiamycin factor M1	A streptomycin A-related cyclic depsipeptide isolated from the bacterium Streptomyces virginiae and other Streptomyces bacterial species.  Virginiamycin M1 binds to and inhibits assembly of 50S and 30S ribosomes, thereby preventing protein synthesis. (NCI04)			Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C129600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129600>	C5409|C3468	Primary Central Nervous System Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Primary Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma of the Central Nervous System	A primary central nervous system non-Hodgkin lymphoma derived from mature or post-thymic T-cells or NK-cells.			Neoplastic Process	
C129601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129601>	C43646	Related_To_Genetic_Biomarker	Indicates that a finding or lab test is related to a gene, possibly through a variant or product.			Conceptual Entity	
C129602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129602>	C71720|C4342	Central Nervous System Intravascular Large B-Cell Lymphoma	A rare extranodal B-cell non-Hodgkin lymphoma that affects the central nervous system.  It is characterized by the presence of lymphoma cells exclusively in the lumina of small vessels, particularly capillaries.			Neoplastic Process	
C129603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129603>	C225418	Superoinferior|Supero-Inferior	Pertaining to the relationship between superior and inferior.			Spatial Concept	
C129604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129604>	C128694	GAIA Level 3a Postnatally Diagnosed Congenital Microcephaly|Global Alignment of Immunization safety Assessment in pregnancy Level 3a Postnatally Diagnosed Congenital Microcephaly|Level 3a Postnatally Diagnosed Congenital Microcephaly	GAIA Level 3a Postnatally Diagnosed Congenital Microcephaly is defined by three criteria: first, a live birth, stillbirth, or spontaneous or therapeutic abortion of at least 24 weeks GA based on LMP without confirmatory 1st or 2nd trimester ultrasound; second, a head circumference (HC) measurement either 2 standard deviations (SD) below the mean or less than the third percentile as assessed by GA and gender, using appropriate, standardized reference charts for the population (e.g. WHO growth reference charts if GA greater than or equal to 37 weeks and Intergrowth-21st reference charts for GA 24 to 36 weeks); third, the measurement is taken up to 6 weeks after birth or end of pregnancy, with no apparent post-natal insult resulting in microcephaly. IMPORTANT NOTICE: The NCI Thesaurus contains biomedical terminologies that NCI does not own or control. This concept contains gender-related content that does not comply with Executive Order 14168.			Classification	GAIA Congenital Microcephaly Level of Diagnostic Certainty Terminology|GAIA Terminology
C129605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129605>	C128695	GAIA Level 3a Prenatally Diagnosed Congenital Microcephaly|Global Alignment of Immunization safety Assessment in pregnancy Level 3a Prenatally Diagnosed Congenital Microcephaly|Level 3a Prenatally Diagnosed Congenital Microcephaly	GAIA Level 3A Prenatally Diagnosed Congenital Microcephaly is defined by three criteria: first, the fetus is at least 24 weeks gestational age (GA), with GA based on certain last menstrual period (LMP) date, with confirmatory first or second trimester ultrasound (US) scan, OR uncertain LMP with second trimester ultrasound, intrauterine insemination (IUI) OR embryo transfer date; second, a head circumference (HC) measurement either 2 standard deviations (SD) below the mean or less than the third percentile according to fetal US examination, using appropriate, standardized reference charts according to GA and gender for the population (e.g. WHO growth reference charts if GA greater than or equal to 37 weeks and Intergrowth-21st reference charts for GA 24 to 36 weeks); third, no confirmation of microcephaly with any additional US or by HC measurement at either birth or autopsy. IMPORTANT NOTICE: The NCI Thesaurus contains biomedical terminologies that NCI does not own or control. This concept contains gender-related content that does not comply with Executive Order 14168.			Classification	GAIA Congenital Microcephaly Level of Diagnostic Certainty Terminology|GAIA Terminology
C129606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129606>	C128674	GAIA Level 5 Small for Gestational Age|Global Alignment of Immunization safety Assessment in pregnancy Level 5 Small for Gestational Age|Level 5 Small for Gestational Age	GAIA Level 5 Small for Gestational Age is defined by either no evidence of Small for Gestational Age (SGA) or a confirmed diagnosis other than SGA.			Classification	GAIA Small for Gestational Age Level of Diagnostic Certainty Terminology|GAIA Terminology
C129607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129607>	C217121	Breast-Impact of Treatment Scale|BIT|Breast Impact of Treatment Scale|The Breast-Impact of Treatment Scale (BIT)	A 13-item self-report questionnaire that uses a 4-point rating scale to assess body change stress for women with breast cancer.			Intellectual Product	
C129608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129608>	C173597|C118873	How Often Think About How Body Has Changed Question|How Body Has Changed Pops Into Mind|How Often Think About How Body Has Changed|How my body has changed pops into my mind	A question about how often an individual's body changes pops into their mind.			Intellectual Product	Breast-Impact of Treatment Scale
C129609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129609>	C173160|C118873	How Often Have Waves of Strong Feelings About the Way Body Looks Question|Have Waves of Strong Feelings About the Way Body Looks|How Often Have Waves of Strong Feelings About the Way Body Looks|I have waves of strong feeling about the way my body looks	A question about how often an individual has strong feelings about the way their body looks.			Intellectual Product	Breast-Impact of Treatment Scale
C12960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12960>	C12662	Liver Stem Cell|Liver Stem Cells	An undifferentiated cell found in the liver.	Liver Stem Cell		Cell	
C129610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129610>	C173597|C118873	How Often Think About How Body Used to Look Question|How Often Think About How Body Used to Look|I think about how my body used to look|Think About How Body Used to Look	A question about how often an individual thinks about how their body used to look.			Intellectual Product	Breast-Impact of Treatment Scale
C129611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129611>	C156029	FLT1 Gene Amplification|FLT Gene Amplification|FLT-1 Gene Amplification|FMS-Related Tyrosine Kinase 1 Gene Amplification|FRT Gene Amplification|Fms Related Tyrosine Kinase 1 Gene Amplification|VEGFR-1 Gene Amplification|VEGFR1 Amplification|VEGFR1 Gene Amplification|Vascular Endothelial Growth Factor Receptor 1 Gene Amplification|Vascular Endothelial Growth Factor/Vascular Permeability Factor Receptor Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the FLT1 gene.	FLT1 Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129612>	C118873	How Often Reminded by Things That are Seen or Heard that Body is Different Now Question|How Often Reminded by Things That are Seen or Heard that Body is Different Now|Reminded That Body is Different Now by Things That are Seen or Heard|Things I see or hear remind me that my body is different now	A question about how often an individual sees or hears things that remind them that their body is different now.			Intellectual Product	Breast-Impact of Treatment Scale
C129613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129613>	C156029	KDR Gene Amplification|CD309 Gene Amplification|FLK1 Gene Amplification|Kinase Insert Domain Receptor Gene Amplification|VEGFR-2 Gene Amplification|VEGFR2 Amplification|VEGFR2 Gene Amplification|Vascular Endothelial Growth Factor Receptor 2 Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the KDR gene.	KDR Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129614>	C173597|C118873	How Often Think That Body Appears Different Than Other Women Question|How Often Think That Body Appears Different Than Other Women|Think That Body Appears Different Than Other Women|When I see other women, I think that my body appears different from theirs|When I see other women, I think that my body appears different than theirs	A question about how often an individual sees other women's bodies and thinks that their body appears different.			Intellectual Product	Breast-Impact of Treatment Scale
C129616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129616>	C173160|C118873	How Often Feel Uncomfortable About Being Seen Naked Question|Feel Uncomfortable About Being Seen Naked|How Often Feel Uncomfortable About Being Seen Naked|I feel uncomfortable about being seen naked	A question about how often an individual feels uncomfortable about being seen naked.			Intellectual Product	Breast-Impact of Treatment Scale
C129617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129617>	C173597|C173160|C172982|C118873	How Often Bothered by Feelings or Thoughts About Body Changes Question|How Often Bothered by Feelings or Thoughts About Body Changes|How Often Bothered by Feelings or Thoughts About Body Disfigurement|I am bothered by feelings or thoughts about changes to my body|I am bothered by feelings or thoughts of body disfigurement	A question about how often an individual is bothered by feelings or thoughts about changes to their body.			Intellectual Product	Breast-Impact of Treatment Scale
C129618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129618>	C156029	FLT4 Gene Amplification|FMS Related Tyrosine Kinase 4 Gene Amplification|PCL Gene Amplification|VEGFR-3 Gene Amplification|VEGFR3 Amplification|VEGFR3 Gene Amplification|VGR3 Gene Amplification|Vascular Endothelial Growth Factor Receptor 3 Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the FLT4 gene.	FLT4 Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129619>	C148404	PDGFRB Gene Amplification|CD140b Gene Amplification|JTK12 Gene Amplification|PDGFR-1 Gene Amplification|PDGFR1 Gene Amplification|PDGFRB Amplification|PDGFRbeta Gene Amplification|Platelet-Derived Growth Factor Receptor Beta Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the PDGFRB gene.	PDGFRB Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12961>	C33904	Trachea and Bronchus|Respiratory System, Trachea, Bronchus|Trachea / Major Bronchi|Trachea, Bronchus	Trachea -The cartilaginous and membranous tube descending from the larynx and branching into the right and left main bronchi. Bronchi-The larger air passages of the lungs arising from the terminal bifurcation of the trachea.	Trachea and Bronchus		Body Location or Region	GDC Terminology|GDC Value Terminology
C129620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129620>	C173791|C118873	How Often Reminded of Breasts When Picking Clothes to Wear Question|How Often Reminded of Breasts When Picking Clothes to Wear|I am reminded of my breasts when I pick out clothes to wear	A question about how often an individual is reminded of their breasts when picking out clothes to wear.			Intellectual Product	Breast-Impact of Treatment Scale
C129621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129621>	C118378	FGFR3 Gene Amplification|CD333 Gene Amplification|FGFR-3 Gene Amplification|FGFR3 Amplification|Fibroblast Growth Factor Receptor 3 Gene Amplification|JTK4 Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the FGFR3 gene.	FGFR3 Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129622>	C45581	TP53 Gene Amplification|LFS1 Gene Amplification|Li-Fraumeni Syndrome Gene Amplification|P53 Gene Amplification|TP53 Amplification|Tumor Protein p53 Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the TP53 gene.	TP53 Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C129623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129623>	C118873	How Often Don't Want to Deal with How Body Looks Question|Doesn't Want to Deal with How Body Looks|How Often Don't Want to Deal with How Body Looks|I don't want to deal with how my body looks	A question about how often an individual does not want to deal with how their body looks.			Intellectual Product	Breast-Impact of Treatment Scale
C129624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129624>	C175989|C173597|C118873	How Often Avoid Getting Emotional When Thinking of How Body Has Changed Question|Avoid Getting Emotional When Thinking of How Body Has Changed|How Often Avoid Getting Emotional When Thinking of How Body Has Changed|I avoid letting myself get emotional when I think of how my body has changed	A question about how often an individual avoids getting emotional when they think of how their body has changed.			Intellectual Product	Breast-Impact of Treatment Scale
C129625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129625>	C97927|C136419	FLT1 Gene Mutation|FLT Gene Mutation|FLT-1 Gene Mutation|FMS-Related Tyrosine Kinase 1 Gene Mutation|FRT Gene Mutation|Fms Related Tyrosine Kinase 1 Gene Mutation|VEGFR-1 Gene Mutation|VEGFR1 Gene Mutation|Vascular Endothelial Growth Factor Receptor 1 Gene Mutation|Vascular Endothelial Growth Factor/Vascular Permeability Factor Receptor Gene Mutation	A change in the nucleotide sequence of the FLT1 gene.	FLT1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129626>	C173791|C173597|C118873	How Often Try Not to Think About Size and Shape of Breasts Question|How Often Try Not to Think About Size and Shape of Breasts|I try not to think about the size and shape of my breasts	A question about how often an individual tries not to think about the size and shape of their breasts.			Intellectual Product	Breast-Impact of Treatment Scale
C129627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129627>	C175989|C173791|C118873	How Often Avoid Looking at or Touching Body Question|Avoid Looking at or Touching Body|How Often Avoid Looking at or Touching Body|I avoid looking at and/or touching my body|I avoid looking at and/or touching my breasts.	A question about how often an individual avoids looking at or touching their body.			Intellectual Product	Breast-Impact of Treatment Scale
C129628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129628>	C97927|C136419	KDR Gene Mutation|CD309 Gene Mutation|FLK1 Gene Mutation|Kinase Insert Domain Receptor Gene Mutation|VEGFR-2 Gene Mutation|VEGFR2 Gene Mutation|Vascular Endothelial Growth Factor Receptor 2 Gene Mutation	A change in the nucleotide sequence of the KDR gene.	KDR Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129629>	C97927|C136419	FLT4 Gene Mutation|FMS Related Tyrosine Kinase 4 Gene Mutation|PCL Gene Mutation|VEGFR-3 Gene Mutation|VEGFR3 Gene Mutation|VGR3 Gene Mutation|Vascular Endothelial Growth Factor Receptor 3 Gene Mutation	A change in the nucleotide sequence of the FLT4 gene.	FLT4 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129630>	C173791|C173160|C118873	How Often Turn Away When Undressing In Front of Partner Question|How Often Turn Away When Undressing In Front of Partner|I feel self-conscious about letting my partner see my breast|I turn away when I have to undress in front of my partner|Turn Away When Undressing In Front of Partner	A question about how often an individual turns away when they have to undress in front of their partner.			Intellectual Product	Breast-Impact of Treatment Scale
C129631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129631>	C173597|C118873	How Often Think About How Health May Affect Sex Life Question|How Often Think About How Health May Affect Sex Life|I think about how my health may affect my sex life|Think About How Health May Affect Sex Life	A question about how often an individual thinks about how their health may affect their sex life.			Intellectual Product	Breast-Impact of Treatment Scale
C129632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129632>	C97927|C146713	FGFR1 Gene Mutation|BFGFR Gene Mutation|CD331 Gene Mutation|CEK Gene Mutation|FGFBR Gene Mutation|FGFR-1 Gene Mutation|FLG Gene Mutation|FLT-2 Gene Mutation|FLT2 Gene Mutation|FMS-Like Tyrosine Kinase 2 Gene Mutation|Fibroblast Growth Factor Receptor 1 Gene Mutation|KAL2 Gene Mutation|N-SAM Gene Mutation|OGD Gene Mutation|Positive	A change in the nucleotide sequence of the FGFR1 gene.	FGFR1 Gene Mutation		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129633>	C173597|C118873	How Often Try Not to Think About Body Being Different Question|How Often Try Not to Think About Body Being Different|I try not to think about my body being different|Try Not to Think About Body Being Different	A question about how often an individual tries not to think about their body being different.			Intellectual Product	Breast-Impact of Treatment Scale
C129634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129634>	C41278	FloTrac System|Edwards FloTrac Monitoring Device|FloTrac|FloTrac Sensor	A proprietary device system comprising a sensor and a monitor for continuous determination of a patient's fluid status and cardiac output directly from the arterial line.	FloTrac System		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C129635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129635>	C3123	Acquired Hyperthyroidism	Hyperthyroidism, the cause of which is not present from birth.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C129636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129636>	C78350	Acquired Hypoparathyroidism	Hypoparathyroidism, the cause of which is not present at birth.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C129637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129637>	C43263	Adipsic Diabetes Insipidus	Diabetes insipidus complicated by a deficient or absent thirst response to hyperosmolality, usually as a result of hypothalamic damage or dysfunction.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C129638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129638>	C16279	Astatine-211 Alpha Radiation	Alpha rays produced by the decay of astatine-211.			Natural Phenomenon or Process	Cellosaurus Resistance and Transformant Physical Factor Terminology
C129639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129639>	C16535	Cerium-144 Beta Radiation	Beta radiation produced by the decay of cerium-144.			Natural Phenomenon or Process	Cellosaurus Resistance and Transformant Physical Factor Terminology
C12963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12963>	C12710	Gut Epithelium	The epithelium that lines the gastrointestinal tract.	Gut Epithelium		Tissue	
C129640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129640>	C44386	Cobalt-60 Gamma Radiation	Gamma rays produced by the decay of cobalt-60.			Natural Phenomenon or Process	Cellosaurus Resistance and Transformant Physical Factor Terminology
C129641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129641>	C15458	Iron-56 Ion Irradiation	Irradiation with heavy, charged nuclei of iron-56.	Iron-56 Ion Irradiation		Therapeutic or Preventive Procedure	Cellosaurus Resistance and Transformant Physical Factor Terminology|CTRP Intervention Terminology|CTRP Terminology
C129642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129642>	C16279	Plutonium-238 Alpha Particle Radiation	Alpha rays produced by the decay of plutonium-238.			Natural Phenomenon or Process	Cellosaurus Resistance and Transformant Physical Factor Terminology
C129643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129643>	C44386	Cesium-137 Gamma Radiation	Gamma rays produced by the decay of cesium-137.			Natural Phenomenon or Process	Cellosaurus Resistance and Transformant Physical Factor Terminology
C129644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129644>	C26800	Acquired Hypothyroidism	Hypothyroidism, the cause of which is not present at birth.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C129645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129645>	C18520	Phosphorylated Histone H2AX|Gamma H2AX|Gamma-H2AX|Phospho-H2AX|Phosphorylated Histone H2A.X|Phosphorylated Histone H2a/x|Phosphorylated-H2A.X|Phosphorylated-H2a/x	A post-translationally modified form of variant histone H2AX where the serine residue at position 139 and/or the tyrosine residue at 142 is phosphorylated. Phosphorylation of serine-139 may be a marker for DNA damage. While phosphorylation or dephosphorylation of tyrosine-142 appears to affect the recruitment of pro-apoptotic factors or DNA repair proteins, respectively.	Phosphorylated Histone H2AX		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129646>	C20448	Vascular Endothelial Growth Factor Family|VEGF|VEGF Family|Vascular Endothelial Growth Factor	A sub-family of the cysteine knot platelet-derived growth factor family. Members of the vascular endothelial growth factor (VEGF) family play a role in the promotion of embryonic vasculogenesis and the stimulation of angiogenesis during physiologic and pathologic processes.	Vascular Endothelial Growth Factor Family		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Immunotherapeutic Target Terminology
C129647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129647>	C20130	E2F Transcription Factor Family|E2F|E2F Family|E2F Transcription Factor	A family of transcription factors that bind to the consensus sequence 5'-TTTC[CG]CGC-3' and regulate the transcription of genes involved in cell cycle regulation, DNA repair and DNA replication.	E2F Transcription Factor Family		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129648>	C70603|C123575	Continued Complete Hematologic Response|Continued CHR|Durable Complete Hematologic Response	Durable or long-term complete hematologic response. Time frames that define durability of complete hematologic response vary for different hematologic malignancies.			Finding	
C129649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129649>	C93144	Bifidobacterium animalis/Lactobacillus rhamnosus Probiotic Supplement|BB-12/LGG|Bifidobacterium animalis/Lactobacillus rhamnosus Probiotic|Lactobacillus rhamnosus GG/ Bifidobacterium animalis subsp. lactis BB-12|Lactobacillus rhamnosus/Bifidobacterium animalis subsp. lactis|PROBIO-FIX INUM	An orally bioavailable, probiotic supplement containing the non-pathogenic microorganisms Bifidobacterium animalis and Lactobacillus rhamnosus subspecies lactis with potential immunomodulating, anti-diarrheal and mucosal protective activities. Upon oral ingestion, the naturally-occurring bacterial components in Bifidobacterium animalis/Lactobacillus rhamnosus subspecies lactis probiotic supplement may improve digestion and help to maintain adequate colonization of the gastrointestinal (GI) tract by modulating the composition of the normal microflora. They produce lactic acid, hydrogen peroxide and other substances during fermentation, thereby creating an acidic environment that is unfavorable for pathogens. During colonization in the GI tract, the bacteria may also form a protective intestinal barrier, which may prevent damage to the mucosal epithelium, maintains the integrity of the epithelial barrier from potential damage by toxins and certain chemicals, and reduces the potential for attachment of pathogens. This further protects against bacterial translocation and infection. In addition, this agent may reduce the secretion of pro-inflammatory cytokines and may potentiate natural and acquired immunity. Altogether, this may increase immunity, prevent GI mucosal damage, malabsorption, inflammation, and reduce diarrhea, such as diarrhea induced by inflammation and GI mucosa-damaging agents.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C12964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12964>	C12801	Connective and Soft Tissue	The supporting connective tissue of an organ.	Connective And Soft Tissue		Tissue	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C129650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129650>	C172200	JAK1 Inhibitor|Janus Kinase 1 Inhibitor|Tyrosine-Protein Kinase JAK1 Inhibitor	Any substance that inhibits the biological action of tyrosine-protein kinase JAK1, an enzyme that plays a key role in certain types of cancer and cytokine signaling.			Chemical Viewed Functionally	
C129651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129651>	C62358|C224703	Polysiloxane/Gadolinium Chelates-based Nanoparticles|AGuIX|AGuIX-NP|Gadolinium-Based Nanoparticle|Polysiloxane Matrix-gadolinium Chelates-based Nanoparticles|Polysiloxane/Gadolinium-DOTA Chelates-based Nanoparticles	A nanoparticle formulation composed of a polysiloxane-based inorganic matrix bound to cyclic chelates composed of the chelating agent DOTA (1,4,7,10-tetra-azacyclododecane-1-glutaric anhydride-4,7,10-triacetic acid) covalently bound to the paramagnetic contrast enhancer gadolinium (Gd), a high-Z material, with potential use in enhancing diagnostic images upon magnetic resonance imaging (MRI) and potential radiosensitizing activity. Upon intravenous administration of polysiloxane matrix-gadolinium chelates-based nanoparticles, the nanoparticles extravasate to tumor sites due to the unique, hyperpermeable environment of the tumor vasculature. In addition, the small nanoparticles allow for deep penetration into the tumor, where they subsequently accumulate. Upon placement in a magnetic field, this agent produces a large magnetic moment and creates a large local magnetic field, which can enhance the relaxation rate of nearby protons. This change in proton relaxation dynamics increases the MRI signal intensity of tissues in which this agent has accumulated; therefore, contrast and visualization of those tissues are enhanced compared to unenhanced MRI. The ultra-small nanoparticles, less than 5 nm in diameter, allow for rapid renal clearance and reduced toxicity. Due to their magnetic properties, these nanoparticles make tumor cells more sensitive to radiation therapy.	Polysiloxane/Gadolinium Chelates-based Nanoparticles		Indicator, Reagent, or Diagnostic Aid|Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C129652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129652>	C1752|C1663	Synthetic Long E6 Peptide-Toll-like Receptor Ligand Conjugate Vaccine ISA201|HPV E Six Peptide Conjugated to Amplivant|HPV16 peptides AMPLIVANT Vaccine|Hespecta|ISA201|PV E6 Peptides-Amplivant|PV16 E6 Peptide Conjugated to Amplivant|SLP HPV16 E6/Amplivant Vaccine ISA201|SLP-Amplivant ISA201	A therapeutic peptide vaccine consisting of two highly immunogenic synthetic long peptides (SLPs), which are 25-35 amino acids in size, derived from the human papillomavirus (HPV) type 16 oncoprotein E6, and conjugated to a proprietary toll-like receptor 2 (TLR2) ligand (TLR2-L) immunoadjuvant, with potential immunostimulating and antitumor activities. Upon administration, the TLR2-L moiety of the synthetic long E6 peptides TLR ligand conjugate vaccine targets and binds to TLRs expressed on antigen-presenting cells (APCs), particularly dendritic cells (DCs). This increases the direct targeting of, binding to, uptake by, and processing of the SLPs into small pieces by the DCs. The processed viral epitopes are presented by DCs, which activate and stimulate the host immune system to mount specific cytotoxic T-lymphocyte (CTL) and helper T (Th) cell responses against HPV E6-expressing tumor cells. This results in the destruction of tumor cells and leads to decreased growth of HPV E6-expressing tumor cells. The E6 oncoprotein is implicated in tumorigenesis in a variety of cancers. The TLR2-L improves antigen processing and presentation by, and activation of APCs, thereby improving the immunostimulatory effect of the vaccine. The two peptides cover the most immunodominant regions of the HPV16 E6 oncogenic protein and contain both Th and CTL epitopes.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129653>	C198646	Sotuletinib|4-((2-(((1R,2R)-2-hydroxycyclohexyl)amino)benzo[d]thiazol-6-yl)oxy)-N-methylpicolinamide|4-[2((1R,2R)-2-Hydroxycyclohexylamino)-benzothiazol-6-yloxyl]-pyridine- 2-carboxylic Acid Methylamide|BLZ 945|BLZ-945|BLZ945|CSF-1R Inhibitor BLZ945|SOTULETINIB	An orally bioavailable inhibitor of colony stimulating factor 1 receptor (CSF-1R; CSF1R), with potential antineoplastic activity. CSF1R inhibitor BLZ945 selectively binds to CSF1R expressed on tumor-associated macrophages (TAMs), blocks the activity of CSF1R, and inhibits CSF1R-mediated signal transduction pathways. This inhibits the activity and proliferation of TAMs, and reprograms the immunosuppressive nature of existing TAMs. Altogether, this reduces TAM-mediated immune suppression in the tumor microenvironment, re-activates the immune system, and improves anti-tumor cell responses mediated by T-cells.  CSF1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), is a cell-surface receptor for its ligand, colony stimulating factor 1 (CSF1); this receptor is overexpressed by TAMs in the tumor microenvironment, and plays a major role in both immune suppression and the induction of tumor cell proliferation.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129654>	C224629|C210140|C155903	Unresectable Digestive System Adenocarcinoma|Unresectable Gastrointestinal System Adenocarcinoma	An adenocarcinoma that arises from the gastrointestinal system and is not amenable to surgical resection.	Unresectable Digestive System Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C129655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129655>	C17219	Beta Tubulin|Beta-Tubulin|Tubulin Beta	A family of globular proteins that form dimers with alpha tubulins. The alpha-beta tubulin dimers polymerize in a guanosine triphosphate (GTP)-dependent fashion to form microtubules.	Beta Tubulin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129656>	C20130	Eukaryotic Translation Initiation Factor 4 Gamma Family|Eukaryotic Translation Initiation Factor 4 Gamma|eIF-4-gamma|eIF-4G|eIF4G|eIF4G Family	A family of proteins that are part of the eukaryotic translation initiation factor 4F complex (eIF4F). The members of the family play a role in recognition of the 5' cap on messenger RNA and the initiation of translation.	Eukaryotic Translation Initiation Factor 4 Gamma Family		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129657>	C97139	T-Cell Receptor Profile|T Cell Receptor Clone Assessment|T Cell Receptor Profile|T Cell Receptor Repertoire|T-Cell Receptor Repertoire|TCR	A data set that both identifies and quantifies the alpha/beta or gamma/delta T-cell receptors in a biological sample or specimen.	T-Cell Receptor Profile		Qualitative Concept	CTRP Biomarker Terminology|CTRP Terminology
C129658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129658>	C97139	B-Cell Receptor Complex Profile|B Cell Receptor Complex Profile|B Cell Receptor Profile|B Cell Receptor Repertoire|B-Cell Antigen Receptor Complex Profile|B-Cell Receptor Profile|B-Cell Receptor Repertoire|BCR Profile|BCR Repertoire	A data set that both identifies the isotype of the immunoglobulin within B-cell receptor complexes and quantifies the level of expression of each isotype-specific complex in a biological sample or specimen.	B-Cell Receptor Complex Profile		Qualitative Concept	CTRP Biomarker Terminology|CTRP Terminology
C129659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129659>	C16295	Asparaginase Antibody|Anti-Asparaginase Antibody	Any immunoglobulin that recognizes asparaginase.	Asparaginase Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129660>	C449	Microbial DNA|Microbe DNA	DNA that originates from a microbe.	Microbial DNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology
C129661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129661>	C129660	Epstein-Barr Virus DNA|EBV DNA|HHV-4 DNA|HHV4 DNA|Human Herpesvirus 4 DNA|Human Herpesvirus-4 DNA	The viral DNA that originates from Epstein-Barr virus.	Epstein-Barr Virus DNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology
C129662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129662>	C129660	Human Immunodeficiency Virus DNA|HIV DNA	DNA that is reverse transcribed from human immunodeficiency virus RNA.	Human Immunodeficiency Virus DNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology
C129663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129663>	C204811	Human Immunodeficiency Virus RNA|HIV RNA	The viral RNA that originates from a human immunodeficiency virus.	Human Immunodeficiency Virus RNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology
C129664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129664>	C129660	Human Papillomavirus DNA|HPV DNA|Human Papilloma Virus DNA	The viral DNA that originates from a human papillomavirus.	Human Papillomavirus DNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C129665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129665>	C449	Tumor DNA|Tumor-Derived DNA	DNA that originates from neoplastic cells.	Tumor DNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology
C129666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129666>	C812	Tumor RNA|Tumor-Derived RNA	RNA transcribed from tumor DNA.	Tumor RNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology
C129667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129667>	C126416	HPV Transforming Protein E6 Antibody|Anti-HPV E6 Antibody|Anti-HPV Transforming Protein E6 Antibody|Anti-Human Papillomavirus Transforming Protein E6 Antibody|HPV E6 Antibody|Human Papillomavirus Transforming Protein E6 Antibody	Any immunoglobulin that recognizes HPV transforming protein E6.	HPV Transforming Protein E6 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129668>	C126416	HPV Transforming Protein E7 Antibody|Anti-HPV E7 Antibody|Anti-HPV Transforming Protein E7 Antibody|Anti-Human Papillomavirus Virus Transforming Protein E7 Antibody|HPV E7 Antibody|Human Papillomavirus Virus Transforming Protein E7 Antibody	Any immunoglobulin that recognizes HPV transforming protein E7.	HPV Transforming Protein E7 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129669>	C204811	Reovirus RNA|Reoviral RNA	The viral RNA that originates from a reovirus.	Reovirus RNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology
C129670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129670>	C16295	ERBB2 Antibody|Anti-HER-2 Antibody|Anti-HER2 Antibody|Anti-HER2/Neu Antibody|Anti-NEU Antibody|Anti-Proto-Oncogene Neu Antibody|Anti-Receptor Tyrosine-Protein Kinase erbB-2 Antibody|Anti-Tyrosine Kinase-Type Cell Surface Receptor HER2 Antibody|Anti-c-erbB2 Antibody|HER-2 Antibody|HER2 Antibody|HER2/Neu Antibody|NEU Antibody|Receptor Tyrosine-Protein Kinase erbB-2 Antibody|Tyrosine Kinase-Type Cell Surface Receptor HER2 Antibody|c-erbB2 Antibody	Any immunoglobulin that recognizes receptor tyrosine-protein kinase erbB-2 protein.	ERBB2 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129671>	C16295	MUC1 Antibody|Anti-CD227 Antibody|Anti-Epithelial Membrane Antigen Antibody|Anti-MUC1 Antibody|Anti-Mucin 1 Antibody|Anti-Mucin-1 Antibody|CD227 Antibody|Epithelial Membrane Antigen Antibody|Mucin 1 Antibody|Mucin-1 Antibody	Any immunoglobulin that recognizes mucin-1 protein.	MUC1 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129672>	C118487	ppUL38 Antibody|Anti-Phospho-UL38 Antibody|Anti-Phosphorylated Apoptosis Inhibitor UL38 Antibody|Anti-Phosphorylated UL38 Antibody|Anti-ppUL38 Antibody|Phospho-UL38 Antibody|Phosphorylated Apoptosis Inhibitor UL38 Antibody|Phosphorylated UL38 Antibody	Any immunoglobulin that recognizes phosphorylated forms of CMV apoptosis inhibitor UL38 protein.	ppUL38 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129673>	C16620	CMV UL38 Gene|CMV Involved in Apoptosis Gene|CMV UL38|HHV-5 Involved in Apoptosis Gene|HHV-5 UL38|HHV-5 UL38 Gene|HHV5 Involved in Apoptosis Gene|HHV5 UL38|HHV5 UL38 Gene|Human Cytomegalovirus Involved in Apoptosis Gene|Human Cytomegalovirus UL38|Human Cytomegalovirus UL38 Gene|Human Herpesvirus 5 Involved in Apoptosis Gene|Human Herpesvirus 5 UL38|Human Herpesvirus 5 UL38 Gene|Human Herpesvirus-5 Involved in Apoptosis Gene|Human Herpesvirus-5 UL38|Human Herpesvirus-5 UL38 Gene|Involved in Apoptosis Gene|UL38|UL38 Gene	CMV UL38, which encodes apoptosis inhibitor UL38 protein, plays a role in the modulation of host cell apoptosis.	CMV UL38 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C129674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129674>	C17254	Apoptosis Inhibitor UL38|CMV UL38|HHV-5 UL38|HHV5 UL38|Human Cytomegalovirus UL38|Human Herpesvirus 5 UL38|Human Herpesvirus-5 UL38|Protein UL38|pUL38	Apoptosis inhibitor UL38 (331 aa, ~37 kDa) is encoded by the cytomegalovirus UL38 gene. This protein plays a role in the inhibition of host cell apoptosis.	Apoptosis Inhibitor UL38		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129675>	C70766	Apoptotic Index	The percentage or fraction of cells in a biological specimen that are undergoing apoptosis.	Apoptotic Index		Conceptual Entity	CTRP Biomarker Terminology|CTRP Terminology
C129676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129676>	C41145	Basement Membrane Thickness	The dimension between the two surfaces of a basement membrane.	Basement Membrane Thickness		Quantitative Concept	CTRP Biomarker Terminology|CTRP Terminology
C129677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129677>	C18491	DNA Repair Kinetics|Repair Kinetics	The rate at which a cell can repair DNA.	DNA Repair Kinetics		Temporal Concept	CTRP Biomarker Terminology|CTRP Terminology
C129678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129678>	C118489	Epstein-Barr Virus Capsid Antigen Antibody|Anti-EBV VCA|Anti-EBV VCA-Ig|Anti-Epstein-Barr Virus Capsid Antibody|Anti-Epstein-Barr Virus Capsid Antigen Antibody|EBV VCA Antibody|EBV VCA-Ig|Epstein-Barr Virus Capsid Antibody	Any immunoglobulin that recognizes Epstein-Barr virus capsid protein.	Epstein-Barr Virus Capsid Antigen Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C129679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129679>	C68742	Colony Forming Unit-Endothelial Cells|CFU-EC|EC-CFU|Endothelial Cell-Colony Corming Unit	A population of adherent cells in fibronectin-coated culture that resemble endothelial cells.	Colony Forming Unit-Endothelial Cells		Quantitative Concept	CTRP Biomarker Terminology|CTRP Terminology
C12967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12967>	C12995	Ascending Spinal Cord Tract|Ascending Spinal Cord Tracts|Ascending Spinal Tracts|Ascending Tracts of Spinal Cord	A nervous tract that transmits pain, temperature, and touch sensations and position and vibratory sense to the brain.	Ascending Spinal Cord Tract		Body Part, Organ, or Organ Component	
C129680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129680>	C16295	IL15 Antibody|Anti-IL-15 Antibody|Anti-IL15 Antibody|Anti-Interleukin 15 Antibody|Anti-Interleukin-15 Antibody|IL-15 Antibody|Interleukin 15 Antibody|Interleukin-15 Antibody	Any immunoglobulin that recognizes interleukin-15 protein.	IL15 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129681>	C16295	MSLN Antibody|Anti-CAK1 Antibody|Anti-MSLN Antibody|Anti-Mesothelin Antibody|Anti-Pre-Pro-Megakaryocyte-Potentiating Factor Antibody|CAK1 Antibody|Mesothelin Antibody|Pre-Pro-Megakaryocyte-Potentiating Factor Antibody	Any immunoglobulin that recognizes mesothelin protein.	MSLN Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129682>	C16295	CTAG1 Antibody|Anti-CTAG1 Antibody|Anti-Cancer/Testis Antigen 1 Antibody|Anti-NY-ESO-1 Antibody|Cancer/Testis Antigen 1 Antibody|NY-ESO-1 Antibody	Any immunoglobulin that recognizes cancer/testis antigen 1 protein.	CTAG1 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129683>	C20993	Dynamic International Prognostic Scoring System|DIPSS	A time-dependent risk evaluation system for primary myelofibrosis that evaluates disease progression over time. This model includes age older than 65 years, hemoglobin level lower than 10 g/dL, white blood cell count more than 25x10^9/L, peripheral blood blasts equal to or higher than 1%, and constitutional symptoms in order to assign a patient to one of 4 risk categories.			Classification	
C129684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129684>	C97927	NFE2L2 Gene Mutation|NRF2 Gene Mutation|Nuclear Factor (Erythroid-Derived 2)-Like 2 Gene Mutation|Nuclear Factor, Erythroid 2 Like 2 Gene Mutation	A change in the nucleotide sequence of the NFE2L2 gene.	NFE2L2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129685>	C97927	KEAP1 Gene Mutation|INRF2 Gene Mutation|KLHL19 Gene Mutation|Kelch-Like ECH-Associated Protein 1 Gene Mutation	A change in the nucleotide sequence of the KEAP1 gene.	KEAP1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129686>	C158948	Xp11.2 Translocations/TFE3 Gene Fusions Present	A genetic finding indicating the presence of translocations involving the chromosome Xp11.2. These translocations result in the creation of gene fusions involving the TFE3 gene.			Laboratory or Test Result	
C129687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129687>	C168618	Olutasidenib|2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-|FT 2102|FT-2102|FT2102|IDH1-R132 Inhibitor FT-2102|OLUTASIDENIB|Rezlidhia	An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1; IDH-1; IDH1 [NADP+] soluble) with a mutation at arginine (R) 132, IDH1(R132), with potential antineoplastic activity. Upon administration, olutasidenib specifically inhibits IDH1(R132), thereby inhibiting the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing IDH(R132). IDH1(R132) mutations are highly expressed in certain malignancies, including gliomas; they initiate and drive cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.	Olutasidenib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129688>	C198646	CSF1R Inhibitor PLX73086|AC-708|AC708|PLX7 3086|PLX73086	An inhibitor of colony stimulating factor 1 receptor (CSF1R; CSF-1R), with potential antineoplastic activity. Upon administration, CSF1R inhibitor PLX73086 targets and binds to CSF1R, thereby blocking CSF1R activation and CSF1R-mediated signaling. This inhibits the activity of tumor-associated macrophages (TAMs) in the tumor tissue and prevents TAM-related tumor cell growth. CSF1R, also known as macrophage colony-stimulating factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), is a cell-surface receptor for its ligand colony stimulating factor 1 (CSF1) and plays major roles in tumor cell proliferation and metastasis.	CSF1R Inhibitor PLX73086		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C129689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129689>	C192825	Palupiprant|AN 0025|AN-0025|AN0025|E 7046|E-7046|E7046|EP4 Antagonist E7046|EP4 Inhibitor E7046|ER-886046|PALUPIPRANT|Prostaglandin E EP4 Receptor Antagonist E7046|Prostaglandin E2 EP4 Receptor Inhibitor AN0025	An orally bioavailable antagonist of the prostaglandin E2 (PGE2) receptor type 4 (EP4; EP-4), with potential immunomodulating and antineoplastic activities. Upon oral administration, palupiprant selectively targets, binds to and blocks the activity of immunosuppressive tumor-associated myeloid cells (TAMCs) in the microenvironment. This abolishes TAMC-dependent immunosuppression and reduces tumor cell proliferation. The presence of immunosuppressive myeloid cells in certain tumors is associated with a poor prognosis.	Palupiprant		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C12968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12968>	C33904	Tumor-Associated Vasculature|Neovasculature	New blood vessels formed by solid tumors.	Tumor-Associated Vasculature		Acquired Abnormality	
C129690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129690>	C112934	Ficoll-Hypaque Method|Ficoll WBC|Ficoll WBC Isolation|Ficolled WBC	A centrifugation procedure that utilizes a density-gradient medium to separate mononuclear and polymorphonuclear leukocytes from other formed elements in the blood.			Laboratory Procedure	
C129691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129691>	C200711	Mosunetuzumab|Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A|BTCT 4465A|BTCT-4465A|BTCT4465A|CD20/CD3 BiMAb BTCT4465A|Lunsumio|MOSUNETUZUMAB|Mosunetuzumab-axgb|RG 7828|RG-7828|RG7828|RO7030816	A bispecific, humanized monoclonal antibody with potential antineoplastic activity. Mosunetuzumab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, mosunetuzumab binds to both T-cells and CD20-expressing tumor B-cells; this cross-links T-cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B-cells.	Mosunetuzumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129692>	C61553	White Blood Cell Lysis|Lysed WBC	Disruption and destruction of the white blood cell membrane.			Phenomenon or Process	
C129693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129693>	C155926	Gartisertib|ATR Kinase Inhibitor VX-803|GARTISERTIB|M 4344|M-4344|M4344|VX 803|VX-803|VX803	An orally available inhibitor of ataxia telangiectasia and Rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration,gartisertib selectively inhibits ATR activity and blocks the downstream phosphorylation of the serine/threonine protein kinase CHK1. This prevents ATR-mediated signaling, which results in the inhibition of DNA damage checkpoint activation, the disruption of DNA damage repair, and the induction of tumor cell apoptosis. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression and survival; it is activated by DNA damage caused during DNA replication-associated stress.	Gartisertib		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129694>	C129822|C128058	Anti-human GITR Monoclonal Antibody AMG 228|AMG 228|AMG-228|AMG228|Agonistic GITR Antibody AMG 228	An agonistic anti-human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor receptor superfamily, member 18; TNFRSF18; GITR; CD357) humanized monoclonal antibody, with potential immune checkpoint modulating activity. Anti-human GITR monoclonal antibody AMG 228 binds to and activates GITRs found on multiple types of T-cells. This stimulates the immune system, induces both the activation and proliferation of tumor-antigen-specific T effector cells (Teffs), and suppresses the function of activated T regulatory cells (Tregs). This leads to immune-mediated tumor cell eradication though a cytotoxic T-lymphocyte (CTL) response. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B-cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress Teffs and suppress T-cell receptor (TCR) signaling.	Anti-human GITR Monoclonal Antibody AMG 228		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C129696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129696>	C49637	Since Beginning Study Agent|Since beginning the study agent	The study-associated time period following the first timepoint where the study agent was administered and continuing through the present.			Temporal Concept	Clinical Global Impression Original Version Questionnaire
C129697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129697>	C173704|C173160	Feelings About Own Sexuality Question|Feelings About Own Sexuality|My feelings about my own sexuality	A question about an individual's feelings about their own sexuality.			Intellectual Product	Clinical Global Impression Original Version Questionnaire
C129698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129698>	C91102	Overall Energy Level Question|Energy|My overall energy level|Overall Energy Level	A question about an individual's overall energy level.			Intellectual Product	Clinical Global Impression Original Version Questionnaire|Patient Oriented Prostate Utility Scale
C129699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129699>	C34375	Beta Thalassemia Major|Cooley Anemia|Cooley's Anemia	The most severe form of beta thalassemia that is characterized by the lack of functional beta-globin chain production resulting in the absence of hemoglobin A.			Disease or Syndrome	
C12969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12969>	C12995	Descending Spinal Cord Tract|Descending Spinal Cord Tracts|Descending Spinal Tracts	Neural fibers of the spinal cord, that are grouped into tracts or fasciculi, and send motor signals from the brain to lower motor neurons. These tracts function to control muscle tone, posture, precise motor movements, spinal reflexes, and spinal autonomic functions.	Descending Spinal Cord Tract		Body Part, Organ, or Organ Component	
C1296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1296>	C1976	Virginiamycin S1|Staphylomycin S|VIRGINIAMYCIN S1|Virginiamycin Factor S	A streptomycin B-related cyclic depsipeptide isolated from the bacterium Streptomyces virginiae and other Streptomyces bacterial species.  Virginiamycin S1 binds to and inhibits the formation of 50S ribosomes, thereby preventing protein synthesis. (NCI04)			Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C129700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129700>	C96866|C178120	Activating ERBB2 Mutation|Activating ERBB2 Gene Mutation|Activating HER2 Mutation|CD340 Activating Mutation|ERBB2 Activating Mutation|HER-2 Activating Mutation|HER2/Neu Activating Mutation|c-erbB2 Activating Mutation|c-erbB2 Gene Activation	A change in the nucleotide sequence of the ERBB2 gene that results in constitutive receptor tyrosine-protein kinase erbB-2-dependent signal transduction and activation of downstream signaling pathways.	Activating ERBB2 Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129701>	C39788|C178120	Activating MET Gene Mutation|Activating HGFR Mutation|Activating Hepatocyte Growth Factor Receptor Mutation|Activating MET Mutation|Activating MET Mutation|Activating MET Proto-Oncogene, Receptor Tyrosine Kinase Gene Mutation|Activating Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Mutation|Activating c-Met Mutation|MET Activating Mutation	A change in the nucleotide sequence of the MET gene that results in constitutive hepatocyte growth factor receptor-dependent signal transduction and activation of downstream signaling pathways.	Activating MET Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129702>	C43293|C178120	Activating RET Gene Mutation|Activating RET Mutation|Activating RET Mutation|Activating Ret Proto-Oncogene Mutation|RET Activating Mutation	A change in the nucleotide sequence of the RET gene that results in constitutive proto-oncogene tyrosine-protein kinase receptor Ret-dependent signal transduction and activation of downstream signaling pathways.	Activating RET Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129703>	C212093|C129574	ALK Gene Translocation|ALK Translocation|Anaplastic Lymphoma Kinase Gene Translocation|Anaplastic Lymphoma Receptor Tyrosine Kinase Gene Translocation|CD246 Gene Translocation	A cytogenetic abnormality that refers to any translocation involving the ALK gene.	ALK Gene Translocation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C129704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129704>	C3420|C130236	ROS1 Gene Translocation|MCF3 Gene Translocation|ROS Gene Translocation|ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene Translocation|ROS1 Translocation|c-ros-1 Gene Translocation	A cytogenetic abnormality that refers to any translocation involving the ROS1 gene.	ROS1 Gene Translocation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C129705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129705>	C97927	GATA2 Gene Mutation|GATA Binding Protein 2 Gene Mutation|NFE1B Gene Mutation	A change in the nucleotide sequence of the GATA2 gene.	GATA2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129706>	C94299|C177692	IL2RA Positive|CD25 Positive|CD25 Positive|IL-2 Receptor Positive|IL-2 Receptor Subunit Alpha Positive|IL-2-RA Positive|IL-2R Positive|IL-2R Subunit Alpha Positive|IL2-RA Positive|Interleukin 2 Receptor Subunit Alpha Positive|Interleukin-2 Receptor Subunit Alpha Positive	Indicates that IL2RA expression has been detected in a sample.	IL2RA Positive		Laboratory or Test Result	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129707>	C9270|C127155	Advanced Malignant Solid Neoplasm|Advanced Malignant Solid Tumor|Advanced Malignant Solid Tumor|Advanced Non-Hematologic Malignancy|Advanced Solid Neoplasm|Advanced Solid Tumor	A malignant solid neoplasm that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Malignant Solid Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C129708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129708>	C173791|C173160	Feel Self-Conscious About Letting Partner See My Breasts Question|Feel Self-Conscious About Letting Partner See My Breasts|I feel self-conscious about letting my partner see my breasts	A question about how often an individual feels self-conscious about letting their breasts be seen by their partner.			Intellectual Product	Breast-Impact of Treatment Scale
C129709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129709>	C36291	Liquid Component Present|Liquid Change	A finding indicating the formation of liquid areas in a tissue sample.			Finding	
C12970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12970>	C13031	Pontine Base|Base of Pons|Basis Pontis	The portion of the pons, located ventral to the medial lemnisci, that contains the pontine nuclei and the cortocobulbar, corticospinal, corticopontine, and transverse pontocerebellar fibers.	Pontine Base		Body Part, Organ, or Organ Component	
C129710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129710>	C213665|C129825	BTK Inhibitor TL-895|Bruton's Tyrosine Kinase Inhibitor M7583|M 7583|M-7583|M7583|TL 895|TL-895|TL-895|TL895	An orally bioavailable, selective inhibitor of Bruton's tyrosine kinase (BTK), with potential antineoplastic activity. Upon oral administration, BTK inhibitor TL-895 targets and covalently binds to BTK, thereby preventing its activity. This leads to an inhibition of B cell receptor (BCR) signaling and inhibits cell proliferation of B-cell malignancies. BTK, a cytoplasmic tyrosine kinase and member of the Tec family of kinases, plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.	BTK Inhibitor TL-895		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C129711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129711>	C1931	Botanical Agent LEAC-102|LEAC 102|LEAC-102|TAIWANOFUNGUS CAMPHORATUS FRUITING BODY	A botanical-based formulation derived from the Taiwanese mushroom Antrodia cinnamomea, with potential antineoplastic activity, Upon administration, the components in LEAC-102 may exert cytotoxic effects against cancer cells.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129712>	C78275	Etelcalcetide|AMG 416|AMG416|ETELCALCETIDE|KAI 4169|KAI-4169|KAI4169|N-acetyl-D-cysteinyl-S-(L-cysteine disulfide)-D-alanyl-D-arginyl-D-arginyl-D-arginyl-D-alanyl-D-argininamide|Parsabiv|Velcalcetide	A calcimimetic and calcium-sensing receptor (CaSR) agonist composed of a synthetic peptide comprised of seven D-amino acids that can be used to treat secondary hyperparathyroidism (sHPT) in hemodialysis patients with chronic kidney disease (CKD). Upon intravenous administration, etelcalcetide mimics calcium and allosterically binds to and activates the CaSR expressed by the parathyroid gland. This suppresses the synthesis and secretion of parathyroid hormone (PTH), thereby reducing PTH levels and lowering serum calcium and phosphorus levels. Elevated PTH is often observed in patients with CKD and is associated with dysregulated calcium-phosphate homeostasis.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C129713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129713>	C2124	Gallium Ga 68 P15-041|Gallium Ga 68 P15 041|[68Ga]P15-041	A radiotracer composed of a bone targeting agent P15-041 linked to the radioisotope gallium Ga 68, with potential imaging activity upon positron emission tomography (PET)/computed tomography (CT). Upon administration, the P15-041 moiety targets, through an as of yet unknown mechanism of action, a certain target expressed by bone and, upon PET/CT, bone metastases can be imaged.	Gallium Ga 68 P15-041		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C129714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129714>	C129822|C128057	Envafolimab|Anti-PD-L1 MoAb KN035|ENVAFOLIMAB|Enweida|KN 035|KN-035|KN035	An injectable formulation of a monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with immune checkpoint inhibitory and potential antineoplastic activities. Upon subcutaneous administration, envafolimab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells.	Envafolimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129715>	C28681|C138180|C129826	Anti-ACTR/4-1BB/CD3zeta-Viral Vector-transduced Autologous T-Lymphocytes ACTR087|ACTR-087|ACTR087|Anti-ACTR Viral Vector-transduced Autologous T-lymphocytes ACTR087|CD16-41BB-CD3zeta ACTR Autologous T-cells|Virally-delivered Antibody-coupled TCR ACTR087	Autologous T-lymphocytes that are genetically modified and transfected with a viral vector expressing the ACTR gene, a proprietary gene encoding for an antibody-coupled T-cell receptor (ATCR), with potential antineoplastic activity. The ACTR contains the extracellular Fc receptor CD16 domain, normally found on certain immune cells, such as natural killer (NK) cells, coupled to the co-immunostimulatory signaling domain 4-1BB, normally expressed on T-cells, and linked to the intracellular CD3 zeta domain (CD3z), which is needed for TCR signaling. Upon reintroduction into the patient and co-administration of a cancer-specific antibody, the co-administered antibody targets and binds to the tumor-associated antigen (TAA) expressed on the tumor cell. In turn, this induces the activation of the ACTR087 cells and destruction of the tumor cells by a) releasing cytotoxins that directly kill cancer cells; b) releasing cytokines that trigger an immune response and recruit other immune-mediated killer cells to kill the tumor cells; b) targeting and killing adjacent tumor cells that are not bound to the antibody; c) inducing T-cell proliferation and thereby further enhancing the T-cell mediated tumor cell attack. CD3 zeta is one of several membrane-bound polypeptides found in the TCR/CD3 complex; it enhances the survival and persistence of T-lymphocytes. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of the TAA.	Anti-ACTR/4-1BB/CD3zeta-Viral Vector-transduced Autologous T-Lymphocytes ACTR087		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129716>	C210691	Amino Acid/Electrolyte Mixture-based Dietary Supplement|Amino Acid/electrolyte-Coupled Transport Supplement|Enterade|Proprietary Amino Acid Mixture	A nutritional supplement containing a proprietary mix of amino acids and electrolytes, with potential rehydrating and gastrointestinal (GI) supportive activities. Upon oral administration of the amino acid-electrolyte dietary supplement, the electrolytes are transported by amino acid-coupled transporters across the intestinal epithelial barriers. This helps rehydrate the intestinal epithelial cells, helps restore normal bowel function, prevents fluid loss and improves symptoms of diarrhea. In addition, the supplement helps restore the size and functioning of the damaged villi and facilitates the restoration of the intestinal cells, thereby helping to restore and increase nutrient absorption, restoring normal bowel function and supporting healthy immune function.	Amino Acid/Electrolyte Mixture-based Dietary Supplement		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C129717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129717>	C143099|C129825	Vebreltinib|6-(1-Cyclopropyl-1h-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5-yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine|APL-101|APL101|Bozitinib|CBI-3103|CBT-101|PLB-1001|PLB1001|VEBRELTINIB	An orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) with potential antineoplastic activity. Upon administration, vebreltinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.	Vebreltinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129718>	C28193	47,XXX Syndrome|47,XXX|Triple X Syndrome|Trisomy X	A condition caused by the presence of an extra X chromosome resulting in 47,XXX karyotype in an individual with female phenotype. The condition is characterized by tall stature, increased risk of learning disabilities, and delayed development of speech and language.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C12971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12971>	C13018	Breast|BREAST|Breast structure (body structure)|Breast, NOS|Breasts|breast	One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest.	Breast		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table
C129720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129720>	C85865|C28193	Aarskog Syndrome|Aarskog-Scott Syndrome|FGD|Faciogenital Dysplasia	An X-linked condition associated in a subset of cases with mutation(s) in the FGD1 gene, encoding a complex signaling protein containing FYVE, RhoGEF, and PH domains. The condition is usually characterized by distinctive facial features, short stature, skeletal anomalies, shawl scrotum (altered anatomical relationship between the penis and the scrotum) cryptorchidism, and developmental delay.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C129721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129721>	C118434	Albright Hereditary Osteodystrophy with Multiple Hormone Resistance|PHP1a|Pseudohypoparathyroidism Type 1a	Parathyroid hormone (PTH) resistance caused by heterozygous inactivating mutation(s) of the maternal allele of the GNAS gene encoding Gs-alpha, resulting in expression of PTH from only the paternal allele. Clinical manifestations include Albright hereditary osteodystrophy, early-onset obesity, and, in some cases, resistance to thyroid-stimulating hormone, gonadotropins, and growth hormone-releasing hormone, reflecting additional manifestations of Gs-alpha deficiency.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C129722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129722>	C118434	Albright Hereditary Osteodystrophy without Multiple Hormone Resistance|Albright Hereditary Osteodystrophy with Multiple Hormone Resistance|PPHP|Pseudopseudohypoparathyroidism	A condition caused by inactivating mutation(s) in the paternal allele of the GNAS gene, encoding Gs-alpha, resulting in expression of the Gs-alpha protein from only the maternal allele. Affected individuals have the clinical phenotype of Albright hereditary osteodystrophy without hormone resistance.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C129723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129723>	C131296	Acquired Partial Lipodystrophy	Partial lipodystrophy, the cause of which is not present at birth. Examples include lipodystrophy associated with human immunodeficiency virus (HIV) therapy, and Barraquer-Simons syndrome, associated with C3 nephritic factor.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C129724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129724>	C197831	Acute Suppurative Thyroiditis	Thyroiditis due to a bacterial infection.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C129725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129725>	C34388	Anovulatory Cycle|Anovulation	A menstrual cycle in which no ovulation occurs.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C129726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129726>	C28193	Autoimmune Polyglandular Syndrome|Autoimmune Polyendocrine Syndrome|Autoimmune Polyglandular Syndrome(s)|Polyglandular Autoimmune Syndrome	A group of diverse conditions that are characterized by spontaneous, multi-organ autoimmunity, which target both endocrine (adrenal, gonad, pancreatic islet cells, parathyroid, pituitary, thyroid) and non-endocrine (gastrointestinal, integumentary, lymphatic) tissues.	Autoimmune Polyglandular Syndrome		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C129727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129727>	C129726	Autoimmune Polyglandular Syndrome Type 1|APECED Syndrome|APS1|Autoimmune Polyendocrine Syndrome Type 1|Autoimmune Polyendocrinopathy-candidiasis-ectodermal Dystrophy Syndrome|Polyglandular Autoimmune Syndrome Type 1	Autoimmune polyglandular syndrome caused by homozygous, compound heterozygous, or heterozygous mutation(s) in the AIRE gene, encoding autoimmune regulator protein. Diagnosis requires at least 2 of the 3 major clinical features: chronic mucocutaneous candidiasis, primary adrenal insufficiency, or primary hypoparathyroidism. Antibodies against type 1 interferons and interleukin 17 cytokines are almost always present. Heterozygous AIRE mutation(s) typically result in a narrower disease spectrum.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C129728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129728>	C129726	Autoimmune Polyglandular Syndrome Type 2|APS2|Schmidt Syndrome	Autoimmune polyglandular syndrome of likely polygenic etiology characterized by the presence of primary adrenal insufficiency in association with autoimmune thyroiditis and/or type 1 diabetes mellitus; this condition is not associated with mucocutaneous candidiasis.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C129729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129729>	C34617	Autonomous Ovarian Follicular Cyst	A cyst arising from an ovarian follicle that produces hormones independent of gonadotropin stimulation.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C12972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12972>	C41439	Peripheral Nerve Sheath	The protective covering surrounding the axon of neurons in the peripheral nervous system.	Peripheral Nerve Sheath		Body Part, Organ, or Organ Component	
C129730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129730>	C78350	Autosomal Dominant Hypoparathyroidism	Hypoparathyroidism associated with heterozygous mutation(s) in the PTH gene, which encodes parathyroid hormone, or in the GCM2 gene, which encodes chorion-specific transcription factor GCMb.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C129731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129731>	C78350	Autosomal Recessive Hypoparathyroidism	Hypoparathyroidism associated with homozygous mutation(s) in the PTH gene, which encodes parathyroid hormone, or in the GCM2 gene, which encodes chorion-specific transcription factor GCMb.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C129732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129732>	C26840	Autosomal Dominant Osteopetrosis|Albers-Schonberg Disease|Autosomal Dominant Osteopetrosis Type 2|Benign Osteopetrosis|Marble Bone Disease	An autosomal dominant form of osteopetrosis due to mutation(s) in the CLCN7 gene, encoding H(+)/Cl(-) exchange transporter 7. Clinical features include sclerosis involving the spine, the pelvis, and the base of the skull. Complications can include optic nerve compression, dental abscesses, anemia, and bone fragility. One third of individuals who carry a CLCN7 mutation have a normal skeletal phenotype.			Congenital Abnormality	NICHD Terminology|Pediatric Endocrinology Terminology
C129733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129733>	C26840	Autosomal Recessive Osteopetrosis|Malignant Osteopetrosis	An autosomal recessive form of osteopetrosis caused by mutation(s) in at least 8 genes related to osteoclast function. This condition is characterized by the failure of osteoclasts to resorb bone, resulting in impaired bone modeling/remodeling, and skeletal fragility despite increased bone mass; it is also associated with hematopoietic insufficiency, hypocalcemia, disturbed tooth eruption, nerve entrapment syndromes, and growth impairment. Some cases are also associated with progressive neurological deterioration.			Congenital Abnormality	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C129734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129734>	C3101	Autosomal Recessive Infantile Hypercalcemia|Idiopathic Infantile Hypercalcemia	A condition caused by autosomal recessive loss-of-function mutation(s) in the CYP24A1 or SLC34A1 gene, encoding mitochondrial 1,25-dihydroxyvitamin D(3) 24-hydroxylase, and sodium-dependent phosphate transport protein 2A, respectively. This condition is characterized by vomiting, polyuria, dehydration, and failure to thrive, accompanied by hypercalcemia, suppressed parathyroid hormone, and nephrocalcinosis.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C129735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129735>	C43263	Dipsogenic Diabetes Insipidus|Primary Polydipsia	Diabetes insipidus caused by excessive intake of water due to psychological factors or damage to the thirst-regulating mechanism.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C129736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129736>	C84933	Autosomal Dominant Neurohypophyseal Diabetes Insipidus|ADNDI	An autosomal dominant form of diabetes insipidus caused by mutation(s) in the AVP gene encoding arginine vasopressin.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C129737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129737>	C21154	Bowel Function Diary for Assessing Opioid-Induced Constipation|BF-Diary|BFD-OIC|Bowel Function Diary	A questionnaire designed to capture relevant patient information regarding opioid-induced constipation in a clinical trial setting. Three modules record information on bowel movements, symptoms experienced, and treatments used to relieve constipation.			Intellectual Product	
C129739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129739>	C2985	Monogenic Diabetes|MODY|Maturity Onset Diabetes of the Young	Diabetes mellitus caused by mutation(s) in a single gene, usually presenting in childhood or early adulthood.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C12973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12973>	C33969	Cervicomedullary Junction|Cervico-medullary Junction	The point at the base of the skull where the brainstem and cervical spine intersect.	Cervicomedullary Junction		Anatomical Structure	
C129740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129740>	C173938|C173160|C173045	How Able to Fully Empty Bowels Question|How Able to Fully Empty Bowels|How much did you feel that you were able to fully empty your bowels	A question about how much an individual feels they were able to fully empty their bowels.			Intellectual Product	Bowel Function Diary for Assessing Opioid-Induced Constipation
C129741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129741>	C129739|C114769	Glucokinase-Associated Diabetes Mellitus|GCK-Associated Diabetes Mellitus|MODY2|Maturity-Onset Diabetes of the Young, Type 2	Monogenic diabetes caused by inactivating mutation(s) in the GCK gene, encoding glucokinase. Heterozygous GCK mutations may manifest as mild hyperglycemia, which is not progressive, and usually requires no treatment. Homozygous GCK mutations result in permanent neonatal diabetes.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C129742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129742>	C129748|C114769	Hepatocyte Nuclear Factor 1-Alpha-Associated Monogenic Diabetes|HNF1A-Associated Monogenic Diabetes|MODY3|Maturity-Onset Diabetes of the Young, Type 3	Monogenic diabetes caused by inactivating mutation(s) in the gene HNF1A, encoding hepatocyte nuclear factor 1-alpha.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C129744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129744>	C129748|C114769	Hepatocyte Nuclear Factor 4-Alpha Associated Monogenic Diabetes|HNF4a-Associated Monogenic Diabetes|MODY1|Maturity-Onset Diabetes of the Young, Type 1	Monogenic diabetes caused by inactivating mutation(s) in the gene HNF4A, encoding hepatocyte nuclear factor 4-alpha.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C129745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129745>	C129748|C114769	Neurogenic Differentiation Factor 1-Associated Monogenic Diabetes|MODY6|Maturity Onset Diabetes of the Young, Type 6|NEUROD1-Associated Monogenic Diabetes	Monogenic diabetes caused by inactivating mutation(s) in the gene NEUROD1, encoding neurogenic differentiation 1. In addition to diabetes, this condition may be associated with neurogenic anomalies. Homozygous NEUROD1 mutations result in permanent neonatal diabetes.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C129746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129746>	C129748|C114769	PDX1-Associated Monogenic Diabetes|MODY4|Maturity Onset Diabetes of the Young, Type 4	Monogenic diabetes caused by inactivating mutation(s) in the PDX1 gene, encoding pancreas/duodenum homeobox protein 1. Homozygous PDX1 mutations result in permanent neonatal diabetes.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C129747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129747>	C131847	SUR1-Associated Diabetes Mellitus	Diabetes mellitus caused by activating mutation(s) in the ABCC8 gene, encoding the sulfonylurea receptor 1 (SUR1) subunit of the pancreatic beta cell adenosine triphosphate-sensitive potassium channel. Note: Inactivating mutation(s) in the ABCC8 gene result in hyperinsulinism.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C129748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129748>	C129739	Transcription Factor-Associated Monogenic Diabetes	Monogenic diabetes caused by inactivating mutation(s) in transcription factors regulating expression of pancreatic beta cell genes.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C129750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129750>	C91102	Shape and Consistency of Stool Question|Describe Shape and Consistency of Stool|How would you describe the shape and consistency of your stool|Shape and Consistency of Stool	A question about how an individual would describe the shape and consistency of their stool.			Intellectual Product	Bowel Function Diary for Assessing Opioid-Induced Constipation
C129751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129751>	C173938|C173045|C118873	How Often Unable to Have Bowel Movement Even Though Felt Had to Question|How Often Unable to Have Bowel Movement|How Often Unable to Have Bowel Movement Even Though Felt Had to|How often were you unable to have a bowel movement even though you felt like you had to	A question about how often an individual was unable to have a bowel movement even though they felt like they had to.			Intellectual Product	Bowel Function Diary for Assessing Opioid-Induced Constipation
C129752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129752>	C173219	How Much Bloating Felt Because of Constipation Question|How Much Bloating Felt Because of Constipation|How much bloating did you feel because of constipation	A question about how much bloating an individual felt because of constipation.			Intellectual Product	Bowel Function Diary for Assessing Opioid-Induced Constipation
C129753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129753>	C173346	Pain Felt in Abdomen Because of Constipation Question|How Much Pain Felt in Abdomen Because of Constipation|How much pain did you feel in your abdomen because of constipation|Pain Felt in Abdomen Because of Constipation	A question about how much pain an individual felt in their abdomen because of constipation.			Intellectual Product	Bowel Function Diary for Assessing Opioid-Induced Constipation
C129754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129754>	C173561	How Much Bothered by Gas Question|Bothered by Gas|How Much Bothered by Gas|How much were you bothered by gas	A question about how much an individual was bothered by gas.			Intellectual Product	Bowel Function Diary for Assessing Opioid-Induced Constipation
C129755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129755>	C173561	How Much Bothered by Lack of Appetite Because of Constipation Question|How Much Bothered by Lack of Appetite Because of Constipation|How much were you bothered by a lack of appetite because of constipation|Lack of Appetite Because of Constipation	A question about how much an individual was bothered by a lack of appetite because of constipation.			Intellectual Product	Bowel Function Diary for Assessing Opioid-Induced Constipation
C129756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129756>	C25616	During this Bowel Movement|This Bowel Movement|While in the process of this bowel movement	Occurring in the course of the current bowel movement.			Temporal Concept	Bowel Function Diary for Assessing Opioid-Induced Constipation
C129757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129757>	C17137	Phytohemagglutinin Skin Test|PHA Skin Test|PHA Test	A test used to evaluate patient cell-mediated immune responsiveness. A small amount of the purified plant lectin phytohemagglutinin protein is placed under the skin. For subjects with normal immunity, non-specific lymphocyte proliferation and infiltration is induced at the injection site.	Phytohemagglutinin Skin Test		Diagnostic Procedure	CTRP Biomarker Terminology|CTRP Terminology
C129758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129758>	C97139	Phosphoprotein Profile|Phospho-Protein Profile	A data set that both identifies phosphoproteins and quantifies their concentration in a biological sample or specimen.	Phosphoprotein Profile		Qualitative Concept	CTRP Biomarker Terminology|CTRP Terminology
C129759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129759>	C17019|C129423	Poly-ADP-Ribosylation|PARsylation|PARylation|Poly-ADP Ribosylation	The transfer of multiple ADP-ribose molecules to amino acids within target proteins.	Poly-ADP-Ribosylation		Phenomenon or Process	CTRP Biomarker Terminology|CTRP Terminology
C129760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129760>	C131847	Kir6.2-Associated Diabetes Mellitus	Diabetes mellitus caused by activating mutation(s) in the KCNJ11 gene, encoding the inwardly rectifying Kir6.2 subunit of the pancreatic beta cell adenosine triphosphate-sensitive potassium channel. Note: Inactivating mutation(s) in the KCNJ11 gene result in hyperinsulinism.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C129761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129761>	C97139	RAS Family Transcriptional Profile|RAS Transcriptional Profile	A data set that both identifies the RAS family proteins that are present and quantifies their concentration in a biological sample or specimen.	RAS Family Transcriptional Profile		Qualitative Concept	CTRP Biomarker Terminology|CTRP Terminology
C129762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129762>	C176244	Complete Agreement|Agree Completely|Completely|Completely Agree|Full Agreement|Fully Agree	A subjective answer of complete agreement.			Intellectual Product	Bowel Function Diary for Assessing Opioid-Induced Constipation
C129763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129763>	C16536	Serum Protein Electrophoresis|SPE|SPEP	An electrophoretic laboratory test performed to determine the concentrations of globulin proteins in the blood.	Serum Protein Electrophoresis		Molecular Biology Research Technique	CTRP Biomarker Terminology|CTRP Terminology
C129764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129764>	C13338	TNF Repeat|TNF Allele|TNF Haplotype|TNF Microsatellite	A group of five microsatellite repeats that are either upstream of the LTA gene or downstream of the TNF gene. TNF repeat polymorphism may influence either lymphotoxin-alpha or tumor necrosis factor protein expression, may be associated with certain diseases, or may be used to facilitate population genetics studies.	TNF Repeat		Nucleotide Sequence	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129765>	C25334	Telomere Length	The number of nucleotide base pairs located in the telomere of a chromosome. Telomere length decreases during each cell division and can be a marker for aging. Additionally, aberrant length can be an indicator of cell transformation.	Telomere Length		Quantitative Concept	CTRP Biomarker Terminology|CTRP Terminology
C129766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129766>	C19771	Total RNA Expression Profile|Total RNA|Total RNA Expression	An analysis of all of the RNA molecules expressed in a biological sample.	Total RNA Expression Profile		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Terminology
C129767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129767>	C19771	MicroRNA Expression Profile|MicroRNA Expression|MicroRNA Profile|miRNA Expression Profile|miRNA Profile|miRNA Profiling	An analysis of all of the microRNA molecules expressed in a biological sample.	MicroRNA Expression Profile		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129768>	C16383	Reovirus Capsid Protein|Reoviral Capsid Protein	A protein encoded by the reoviral genome that forms a three-layered icosahedral protein capsid for the virus.	Reovirus Capsid Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129769>	C48182	TGF-Beta Responsive Gene Signature|TGF-Beta Responsive Signature|Transforming Growth Factor Beta Responsive Gene Signature	A data set that determines the expression of genes that are modulated by transforming growth factor beta-dependent signaling pathways.	TGF-Beta Responsive Gene Signature		Functional Concept	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12976>	C12922	Premalignant Cell|Precancerous Cells	Cells which show sign/s, that they can become cancerous.			Cell	
C129770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129770>	C129758	Total Phosphotyrosine|Total p-Tyr|Total pY	A data set that quantifies the concentration of all of the tyrosine phosphorylated proteins in a biological sample or specimen.			Qualitative Concept	
C129771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129771>	C18687	Tumor cDNA Expression Profile|Tumor cDNA Expression	An analysis of all of the complementary DNA molecules expressed in by a tumor.	Tumor cDNA Expression Profile		Molecular Biology Research Technique	CTRP Biomarker Terminology|CTRP Terminology
C129772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129772>	C28510	MYB/NFIB Fusion Gene|MYB-NF-IB Fusion Gene|MYB-NF1-B Fusion Gene|MYB-NFI-B Fusion Gene|MYB-NFIB Fusion Gene|MYB/NF-IB Fusion Gene|MYB/NF1-B Fusion Gene|MYB/NFI-B Fusion Gene|MYB::NFIB Fusion Gene	A fusion gene that results from a translocation t(6;9)(q22-23;p23-24) that fuses the first 8, 12 or 14 exons of the MYB gene upstream of exon 8 or 9 of the NFIB gene. This fusion is associated with adenoid cystic carcinomas.	MYB/NFIB Fusion Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129773>	C17561	MYB/NFIB Fusion Protein|MYB-NF-IB Fusion Protein|MYB-NF1-B Fusion Protein|MYB-NFI-B Fusion Protein|MYB-NFIB Fusion Protein|MYB/NF-IB Fusion Protein|MYB/NF1-B Fusion Protein|MYB/NFI-B Fusion Protein|MYB::NFIB Fusion Protein|Transcriptional Activator Myb/Nuclear Factor 1 B-Type Fusion Protein	A fusion protein encoded by the MYB/NFIB fusion gene. This protein is comprised of most of transcriptional activator Myb protein fused to the amino acids comprising the extreme C-terminus of nuclear factor 1 B-type protein.	MYB/NFIB Fusion Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129774>	C2950	Telomeric Allelic Imbalance Region|N(tAI)|NtAI	A chromosomal aberration where the telomeric and subtelomeric regions of a chromosome does not have the expected 1:1 ratio for the alleles and telomeric sequences inherited from the two parental chromosomes.	Telomeric Allelic Imbalance Region		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Terminology
C129775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129775>	C67208	Th1 Cell/Th2 Cell Ratio Measurement|Th1/Th2|Th1/Th2 Ratio Measurement|Type 1 T Helper Cell/Type 2 T Helper Cell Ratio Measurement	The determination of the ratio of type 1 T helper cells (Th1) compared to type 2 T helper cells (Th2) present in a sample.	Th1 Cell/Th2 Cell Ratio Measurement		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Terminology
C129776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129776>	C20130	Natural Cytotoxicity Receptor Family|NCR|NCR Family|NK Cell-Activating Receptor|Natural Cytotoxicity Receptor|Natural Cytotoxicity Triggering Receptor	A family of receptors belonging to the immunoglobulin superfamily that are mainly expressed on natural killer (NK) cells. Natural cytotoxicity receptors (NCR) bind to a broad range of ligands derived from microbes, tumors, and endogenous sources. Predominantly, ligand binding leads to the activation of NK cells, which stimulates cell-mediated cytotoxic immune responses, but some ligands may inhibit NK cell activation.	Natural Cytotoxicity Receptor Family		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129777>	C70922|C157164	Serum-Ascites Albumin Gradient|SAAG|Serum-Ascites Albumin Gap	A value determined by subtracting the concentration of albumin in ascites fluid from its concentration in the serum where both samples come from one subject. High values indicate portal hypertension and a non-peritoneal cause for ascites; while low values indicate non-portal hypertension and a peritoneal origin of ascites.	Serum-Ascites Albumin Gradient		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C129778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129778>	C189078	2-Hour Postprandial Glucose|2 Hour Glucose|2 Hour Postprandial Glucose|2 hr Glucose|2 hr Postprandial Glucose|2-Hour Glucose|2h Glucose|2h Postprandial Glucose	The amount of glucose present in a sample two hours after a subject has eaten a meal.	2-Hour Postprandial Glucose		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C129779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129779>	C70922	2-Hour Postprandial Insulin|2 Hour Postprandial Insulin|2 hr Postprandial Insulin|2h Postprandial Insulin	The amount of insulin present in a sample two hours after a subject has eaten a meal.	2-Hour Postprandial Insulin		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C12977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12977>	C12662	Pluripotent Stem Cell|pluripotent stem cell	A cell that can differentiate to cells derived from any of the three germ layers. --2005	Pluripotent Stem Cell		Cell	
C129780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129780>	C48966	Thyroid Stimulating Immunoglobulin|TSI	An immunoglobulin that can bind to thyrotropin receptors expressed on thyroid gland cells and stimulates excess secretion of the thyroid hormones thyroxine (T4) and triiodothyronine (T3).	Thyroid Stimulating Immunoglobulin		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129781>	C912	Glioma-Associated Antigen|GAA|Glioma TAA|Glioma-type Tumor Associated Antigen	A tumor associated antigen derived from the cell surface antigens expressed on glioma cells.	Glioma-Associated Antigen		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129782>	C82433	Acute Myeloid Leukemia with Biallelic CEBPA Mutation|AML with biallelic mutations of CEBPA|Acute Myeloid Leukemia with Biallelic Mutations of CEBPA	An acute myeloid leukemia with double mutations of the CEBPA gene.			Neoplastic Process	AML Authorized Value Terminology|AML Disease Characteristics Table|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C129783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129783>	C82433	Acute Myeloid Leukemia with Monoallelic CEBPA Mutation|Acute Myeloid Leukemia with Monoallelic Mutations of CEBPA	An acute myeloid leukemia with single mutations of the CEBPA gene.			Neoplastic Process	
C129784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129784>	C4815|C165174	Unresectable Thyroid Gland Carcinoma|Unresectable Thyroid Gland Cancer	A carcinoma that arises from the thyroid gland and is not amenable to surgical resection.	Unresectable Thyroid Gland Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C129785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129785>	C7175	Acute Myeloid Leukemia with BCR-ABL1|Acute Myeloid Leukemia with BCR-ABL1 Fusion|Acute Myeloid Leukemia with BCR::ABL1|Acute Myeloid Leukemia with BCR::ABL1 Fusion|Provisional Entity: AML with BCR-ABL1	A rare, de novo acute myeloid leukemia in which the blasts harbor BCR-ABL1 translocation in the absence of a history and clinical and laboratory features of chronic myelogenous leukemia.			Neoplastic Process	AML Authorized Value Terminology|AML Disease Characteristics Table|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C129786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129786>	C82430	Acute Myeloid Leukemia with RUNX1 Mutation|Acute Myeloid Leukemia with Mutated RUNX1|Acute Myeloid Leukemia with Non-Germline Mutated RUNX1|Acute Myeloid Leukemia with RUNX1 Gene Mutation|Provisional entity: AML with mutated RUNX1	Acute myeloid leukemia characterized by the presence of RUNX1 gene mutation.			Neoplastic Process	AML Authorized Value Terminology|AML Disease Characteristics Table|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C129787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129787>	C80328	B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like|B Lymphoblastic Leukemia/Lymphoma with BCR-ABL1-Like Features|B Lymphoblastic Leukemia/Lymphoma with BCR::ABL1-Like Features|B Lymphoblastic Leukemia/Lymphoma with Translocations Involving Tyrosine Kinases or Cytokine Receptors|B Lymphoblastic Leukemia/Lymphoma, BCR::ABL1-Like|B Lymphoblastic Leukemia/Lymphoma, Philadelphia-like|B-Lymphoblastic Leukemia/Lymphoma with BCR-ABL1-Like Features|B-Lymphoblastic Leukemia/Lymphoma with BCR::ABL1-Like Features|B-Lymphoblastic Leukemia/Lymphoma, Philadelphia-like	B lymphoblastic leukemia/lymphoma characterized by a gene-expression profile similar to that of BCR-ABL1-positive B lymphoblastic leukemia/lymphoma, absence of the pathognomonic BCR-ABL1 rearrangement, alterations of lymphoid transcription factor genes, and a poor outcome.			Neoplastic Process	Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C129789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129789>	C158948	Translocations Involving Tyrosine Kinases or Cytokine Receptors Present	A cytogenetic finding indicating the presence of translocations involving either tyrosine kinases or cytokine receptors.			Laboratory or Test Result	
C12978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12978>	C12662	Totipotent Stem Cell	Totipotent stem cells, such as the product of fertilization of an ovum and its progeny, are stem cells that have total potency to form an entire mature organism, e.g., a human being, although only if placed in a woman's uterus.	Totipotent Stem Cell		Cell	
C129790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129790>	C141137|C129820	IDO1 Inhibitor KHK2455|IDO-1 Inhibitor KHK2455|KHK 2455|KHK2455	An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1 inhibitor KHK2455 targets and binds to IDO1, an enzyme responsible for the oxidation of tryptophan into kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, KHK2455 increases and restores the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes. KHK2455 also induces increased interferon (IFN) production, and causes a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may inhibit the growth of IDO1-expressing tumor cells. IDO1, a cytosolic enzyme responsible for tryptophan catabolism and the conversion of tryptophan into kynurenine, is overexpressed by a variety of tumor cell types and antigen presenting cells (APCs); it plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system.	IDO1 Inhibitor KHK2455		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129791>	C91105	Bladder Cancer Muscle-Invasive 30 Questionnaire|BLM30|EORTC QLQ-BLM30|QLQ-BLM30|Quality of Life Questionnaire-Bladder Cancer Muscle Invasive 30	A questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) consisting of 30 questions designed to assess quality of life in patients with muscle-invasive bladder cancer (BLM).			Intellectual Product	
C129792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129792>	C173150	Extent Have to Urinate Frequently During Day Question|Extent Have to Urinate Frequently During Day|Have to Urinate Frequently During Day|Have you had to urinate frequently during the day	A question about the extent to which an individual has or had to urinate frequently during the day.			Intellectual Product	Bladder Cancer Muscle-Invasive 30 Questionnaire
C129793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129793>	C173150	Extent Have to Urinate Frequently at Night Question|Extent Have to Urinate Frequently at Night|Have to Urinate Frequently at Night|Have you had to urinate frequently at night	A question about the extent to which an individual has or had to urinate frequently at night.			Intellectual Product	Bladder Cancer Muscle-Invasive 30 Questionnaire
C129794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129794>	C173803|C173219|C173150	Extent When Feel Urge to Pass Urine Have to Hurry to Get to Toilet Question|Extent Feel Urge to Pass Urine and Have to Hurry to Get to Toilet|When Feel Urge to Pass Urine Have to Hurry to Get to Toilet|When you felt the urge to pass urine, did you have to hurry to get to the toilet	A question about the extent to which an individual has or had to hurry to get to the toilet when they feel or felt the urge to pass urine.			Intellectual Product	Bladder Cancer Muscle-Invasive 30 Questionnaire
C129795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129795>	C173925|C173398|C173150	Difficult Getting Enough Sleep Because of Need to Get Up Frequently at Night to Urinate Question|Difficult Getting Enough Sleep Because of Need to Get Up Frequently at Night to Urinate|Extent of Difficulty Getting Enough Sleep Because of Need to Get Up Frequently at Night to Urinate|Was it difficult for you to get enough sleep, because you needed to get up frequently at night to urinate	A question about the extent to which an individual has or had difficulty getting enough sleep because they need to get up frequently at night to urinate.			Intellectual Product	Bladder Cancer Muscle-Invasive 30 Questionnaire
C129796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129796>	C173398|C173150	Extent of Difficulty Going Out of House Because of Need to be Close to Toilet Question|Extent Difficulty Going Out of House Because of Need to be Close to Toilet|Have Difficulty Going Out of House Because of Need to be Close to Toilet|Have you had difficulty going out of the house, because you needed to be close to a toilet	A question about the extent to which an individual has or had difficulty going out of the house because they need to be close to a toilet.			Intellectual Product	Bladder Cancer Muscle-Invasive 30 Questionnaire
C129797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129797>	C178809|C173803|C173150	Degree of Urinary Incontinence Question|Degree of Urinary Incontinence|Extent of Urinary Incontinence|Have Unintentional Release of Urine|Have Urinary Incontinence|Have you had any unintentional release (leakage) of urine	A question about the extent to which an individual has or had unintentional release or leakage of urine.			Intellectual Product	Bladder Cancer Muscle-Invasive 30 Questionnaire
C129798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129798>	C91126|C173803|C173150	Extent Have Pain or Burning with Urination Question|Extent of Pain or Burning with Urination|Have Pain or Burning Feeling When Urinating|Have Pain or Burning on Urination|Have Pain or Burning with Urination|Have you had pain or a burning feeling when urinating	A question about the extent to which an individual has or had pain or a burning feeling when urinating.			Intellectual Product	Bladder Cancer Muscle-Invasive 30 Questionnaire
C129799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129799>	C173803|C173150	Extent Have Urine Leak from Urostomy Bag Question|Extent of Urine Leakage from Urostomy Bag|Has urine leaked from your urostomy bag|Have Urine Leak from Urostomy Bag|Urine Leakage from Urostomy Bag	A question about the extent to which an individual has or had urine leak from their urostomy bag.			Intellectual Product	Bladder Cancer Muscle-Invasive 30 Questionnaire
C12979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12979>	C12913	Atypical Mononuclear Cell				Cell	
C1297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1297>	C707	8-Hydroxy-2'-deoxyguanosine|2'-Deoxy-7,8-dihydro-8-oxoguanosine|2'-Deoxy-8-Hydroxyguanosine|2'-Deoxy-8-oxoguanosine|2-Amino-9-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3,7-dihydropurine-6,8-dione|7,8-Dihydro-2'-deoxy-8-oxoguanosine|8-HYDROXY-2'-DEOXYGUANOSINE|8-Hydroxy-2-Deoxyguanosine|8-Hydroxydeoxyguanosine|8-OH-dG|8-OHdG|8-Oxo-2'-Deoxyguanosine|8-Oxo-2-Deoxyguanosine|8-Oxo-7,8-dihydro-2'-deoxyguanosine|8-Oxo-7-hydrodeoxyguanosine|8-Oxo-dG|8-OxodG	A major spontaneous oxidized derivative of 2'-deoxyguanosine and a biomarker of oxidative DNA damage. 8-hydroxy-2'-deoxyguanosine (8-oxo-dG) is formed through the reaction of guanine with reactive oxygen species. Although normally repaired and removed by the base excision repair mechanism, 8-oxo-dG can potentially mispair with deoxyadenine leading to G-to-T transversion mutations, which cause frequent recombinations and single nucleotide polymorphisms (SNPs) in the human genome. The concentration of 8-oxo-dG within a cell is a measurement of oxidative stress and may thus be used to assess the extent of physiological and environmental damage to DNA.	8-Hydroxy-2'-deoxyguanosine		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C129800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129800>	C173150	Extent Have Problem Caring for Urostomy Question|Did you have problems with caring for your urostomy|Extent of Problem Caring for Urostomy|Have Problem Caring for Urostomy	A question about the extent to which an individual has or had problems caring for their urostomy.			Intellectual Product	Bladder Cancer Muscle-Invasive 30 Questionnaire
C129801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129801>	C173150	Extent Have Irritated Skin Around Urostomy Question|Extent of Irritated Skin Around Urostomy|Have Irritated Skin Around Urostomy|Was your skin around the urostomy irritated	A question about the extent to which an individual has or had irritated skin around their urostomy.			Intellectual Product	Bladder Cancer Muscle-Invasive 30 Questionnaire
C129802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129802>	C173601|C173150	Extent Feel Embarrassed Because of Urostomy Question|Extent Feel Embarrassed Because of Urostomy|Feel Embarrassed Because of Urostomy|Have you felt embarrassed because of your urostomy	A question about the extent to which an individual feels or felt embarrassed because of their urostomy.			Intellectual Product	Bladder Cancer Muscle-Invasive 30 Questionnaire
C129803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129803>	C173150	Dependent on Others for Urostomy Care Question|Dependent on Others for Urostomy Care|Extent Dependent on Others for Urostomy Care|Have you been dependent on others for caring for your urostomy	A question about the extent to which an individual is or was dependent on others for caring for their urostomy.			Intellectual Product	Bladder Cancer Muscle-Invasive 30 Questionnaire
C129804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129804>	C91102	Have to Change Urostomy Bag Frequently Question|Did you frequently have to change the urostomy bag|Frequently Have to Change Urostomy Bag|Have to Change Urostomy Bag Frequently	A question about the frequency that an individual has or had to change their urostomy bag.			Intellectual Product	Bladder Cancer Muscle-Invasive 30 Questionnaire
C129805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129805>	C173150	Extent Have Problems with Self-Catherization Question|Extent of Problems with Self-Catherization|Have Problems with Self-Catherization|Have you had problems with self-catheterization (inserting a tube in the bladder to pass urine)	A question about the extent to which an individual has or had problems with inserting a tube in the bladder to pass urine.			Intellectual Product	Bladder Cancer Muscle-Invasive 30 Questionnaire
C129806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129806>	C92944|C3107	Central Nervous System Langerhans Cell Histiocytosis	Rare involvement of the central nervous system by Langerhans cell histiocytosis.			Neoplastic Process	
C129807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129807>	C92944|C4627|C27349	Central Nervous System Histiocytic Sarcoma	Rare involvement of the central nervous system by histiocytic sarcoma.			Neoplastic Process	
C129808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129808>	C92944|C53972	Central Nervous System Erdheim-Chester Disease	Erdheim-Chester disease that affects the central nervous system.			Neoplastic Process	
C129809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129809>	C173934|C173812	Worry About Possible Future Treatments Question|Did you worry about possible future treatments|Extent of Worry About Possible Future Treatments|Worry About Future Treatment|Worry About Possible Future Treatments	A question about the extent to which an individual worries or worried about possible treatments in the future.			Intellectual Product	Bladder Cancer Muscle-Invasive 30 Questionnaire
C12980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12980>	C12372	Intracranial Artery|INTRACRANIAL ARTERY	Arteries which have their origins within the intracranial cavity.	Intracranial Artery		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C129810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129810>	C173981|C173150	Extent Have Flatulence or Gas Question|Extent Have Flatulence or Gas|Have Flatulence or Gas|Have you had flatulence or gas	A question about the extent to which an individual has or had flatulence or gas.			Intellectual Product	Bladder Cancer Muscle-Invasive 30 Questionnaire
C129811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129811>	C173812|C173160	Feel Less Feminine or Masculine as a Result of Illness or Treatment Question|Feel Less Feminine or Masculine as a Result of Illness or Treatment|Have you felt less feminine/masculine as a result of your illness or treatment	A question about whether an individual feels or felt less feminine or masculine as a result of their illness or treatment.			Intellectual Product	Bladder Cancer Muscle-Invasive 30 Questionnaire
C129812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129812>	C173704|C173160|C173150	Extent Feel Uncomfortable About Sexual Intimacy Question|Extent Feel Uncomfortable About Sexual Intimacy|Feel Uncomfortable About Being Sexually Intimate|Feel Uncomfortable About Sexual Intimacy|Have you felt uncomfortable about being sexually intimate	A question about the extent to which an individual feels or felt uncomfortable about being sexually intimate.			Intellectual Product	Bladder Cancer Muscle-Invasive 30 Questionnaire
C129813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129813>	C173934|C173812|C173150	Extent of Worry About Contaminating Partner During Sexual Contact Due to Bladder Treatment Question|Extent of Worry About Contaminating Partner During Sexual Contact Due to Bladder Treatment|Have you worried that you may contaminate your partner during sexual contact with the bladder treatment you have been receiving|Worry About Contaminating Partner During Sexual Contact Due to Bladder Treatment	A question about the extent to which an individual worries or worried that they may contaminate their partner during sexual contact with the bladder treatment they have been receiving.			Intellectual Product	Bladder Cancer Muscle-Invasive 30 Questionnaire
C129814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129814>	C173150	Extent Have Vaginal Dryness or Other Problem During Intercourse Question|Did you have a dry vagina or other problems during intercourse|Extent of Vaginal Dryness or Other Problem During Intercourse|Have Dry Vagina or Other Problem During Intercourse	A question about the extent to which a woman experiences a dry vagina or other problems during intercourse.			Intellectual Product	Bladder Cancer Muscle-Invasive 30 Questionnaire
C129815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129815>	C38617	Glossotonsillar Sulcus	The bottom part of the palatine tonsil where it blends into the lingual tonsil tissue.			Body Part, Organ, or Organ Component	
C129816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129816>	C38617	Wall of the Pharynx|Pharyngeal Wall	The walls of the swallowing passage.			Body Part, Organ, or Organ Component	Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C129817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129817>	C129816	Lateral Wall of the Pharynx|Lateral Pharyngeal Wall	The walls on either side of the swallowing passage.			Body Part, Organ, or Organ Component	
C129818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129818>	C274|C147908	Antineoplastic Hormonal/Endocrine Agent|Antineoplastic Endocrinal Agent|Antineoplastic Hormonal Agent|Antineoplastic Hormonal Therapeutic	Any agent that affects hormone levels and exerts antineoplastic effects. Antineoplastic hormonal/endocrine agents treat either hormone-dependent or hormone-sensitive cancers by modulating hormone levels and manipulating the endocrine system.			Chemical Viewed Functionally	NCIt Antineoplastic Agent Terminology
C129819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129819>	C274|C1446	Antineoplastic Radiopharmaceutical Agent|Anti-cancer Radiopharmaceutical|Antineoplastic Radiopharmaceutical	Any radiopharmaceutical agent that targets cancer cells and exerts an antineoplastic effect through radiotoxicity.	Antineoplastic Radiopharmaceutical Agent		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology|NCIt Antineoplastic Agent Terminology
C12981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12981>	C33904	Graft|Transplant|graft	Tissue or organ transplanted from a donor to a recipient.	Graft		Body Part, Organ, or Organ Component	CTRP Intervention Terminology|CTRP Terminology
C129820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129820>	C308|C274	Antineoplastic Immunomodulating Agent|Anti-cancer Immunotherapeutic|Antineoplastic BRM|Antineoplastic Biological Response Modifier|Antineoplastic Immunotherapeutic	Any agent that is capable of modulating the immune system in order to exert antineoplastic effects. Antineoplastic immunomodulating agents either activate the immune system, restore certain immune system activators or abrogate immunosuppression.	Antineoplastic Immunomodulating Agent		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology|NCIt Antineoplastic Agent Terminology
C129821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129821>	C307|C274	Antineoplastic Biological Agent|Anti-cancer Biological Agent|Anticancer Biological|Antineoplastic Biological|Antineoplastic Biotherapeutic	Any agent that has a biological nature, such as agents containing living organisms, derived from living organisms, or comprised of ex vivo synthesized analogs of substances derived from living organisms, and that exerts antineoplastic activity.	Antineoplastic Biological Agent		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology|NCIt Antineoplastic Agent Terminology
C129822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129822>	C129821	Antineoplastic Antibody|Anti-cancer Antibody|Anticancer Antibody|Antineoplastic Ab	Any type of antibody that exerts antineoplastic activity.			Chemical Viewed Functionally	
C129823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129823>	C1512|C129821	Antineoplastic Antibody-Drug Conjugate|ADC|Antibody-Drug Conjugate|Antineoplastic ADC|Antineoplastic Antibody-drug Conjugate|Cancer-targeted Antibody Drug Conjugate|Drug-conjugated Antibody	Any tumor-targeting antibody conjugated to a cytotoxic agent that exerts an antineoplastic effect.			Chemical Viewed Functionally	
C129824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129824>	C2189	Antineoplastic Protein Inhibitor|Anti-cancer Protein Inhibitor|Antineoplastic Protein Antagonist	Any agent that inhibits the activity of any protein that is involved in cancer-specific pathways. An antineoplastic protein inhibitor is a specific cancer cell-targeting agent.			Chemical Viewed Functionally	
C129825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129825>	C471|C129824	Antineoplastic Enzyme Inhibitor|Anti-cancer Enzyme Inhibitor	Any agent that specifically inhibits a particular enzyme that is overexpressed and/or mutated in cancer cell pathways. Antineoplastic enzyme inhibitors specifically target tumor cells by targeting enzymes that are not normally expressed or are minimally expressed in normal, healthy tissues.			Chemical Viewed Functionally	
C129826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129826>	C142078|C129821|C129820	Antineoplastic Immune Cell|Anti-cancer Immune Cell|Antineoplastic Immune Cells	Any immune cell-based preparation that can be used or may potentially be used for its cytotoxic activity against cancer cells.			Chemical Viewed Functionally	
C129827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129827>	C2930|C148124	Unresectable Transitional Cell Carcinoma|Unresectable Transitional Cell Cancer	A transitional cell carcinoma which is not amenable to surgical resection.	Unresectable Transitional Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C129828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129828>	C3482|C2930	Metastatic Transitional Cell Carcinoma|Metastatic Transitional Cell Cancer	A carcinoma that arises from transitional cells and has spread from its original site of growth to another anatomic site.	Metastatic Transitional Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C129829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129829>	C18093	Biallelic Mutation	A mutation that occurs on both alleles of a single gene.			Cell or Molecular Dysfunction	
C12982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12982>	C32223	Bone of the Lower Extremity|Bone of Lower Extremity|Bones of Lower Extremity|Inferior Limb	A bone of the leg (lower extremity).	Bone of Lower Extremity		Body Part, Organ, or Organ Component	OS Authorized Value Terminology|OS Tumor Assessment Table
C129830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129830>	C18093	Monoallelic Mutation	A mutation that occurs on one allele of a gene.			Cell or Molecular Dysfunction	
C129831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129831>	C128816	CALR Exon 9 Mutation|Autoantigen Ro Gene Exon 9 Mutation|CALR Exon 9 Gene Mutation|CRT Exon 9 Mutation|Calreticulin Gene Exon 9 Mutation|RO Exon 9 Mutation|cC1qR Exon 9 Mutation	A molecular genetic abnormality indicating the presence of a mutation in exon 9 of the CALR gene.	CALR Exon 9 Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129832>	C129831	CALR Exon 9 Deletion Mutation|Autoantigen Ro Gene Exon 9 Deletion Mutation|CRT Exon 9 Deletion Mutation|Calreticulin Gene Exon 9 Deletion Mutation|RO Exon 9 Deletion Mutation|cC1qR Exon 9 Deletion Mutation	A molecular genetic abnormality indicating the presence of a deletion mutation in exon 9 of the CALR gene. These deletion mutations are associated with primary myelofibrosis and may be predicative of a favorable survival prognosis.			Cell or Molecular Dysfunction	
C129833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129833>	C129831	CALR Exon 9 Insertion Mutation|Autoantigen Ro Gene Exon 9 Insertion Mutation|CRT Exon 9 Insertion Mutation|Calreticulin Gene Exon 9 Insertion Mutation|RO Exon 9 Insertion Mutation|cC1qR Exon 9 Insertion Mutation	A molecular genetic abnormality indicating the presence of an insertion mutation in exon 9 of the CALR gene. These insertion mutations are associated with primary myelofibrosis and may be predicative of shortened survival.			Cell or Molecular Dysfunction	
C129834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129834>	C17354|C129832	CALR NM_004343.3:c.1092_1143del52|Autoantigen Ro Gene c.1092_1143del52|CALR Type 1 Gene Mutation|CALR c.1092_1143del52|CALR1|CALR1 Gene Mutation|CRT c.1092_1143del52|Calreticulin Gene c.1092_1143del52|NM_004343.3:c.1092_1143del52|RO c.1092_1143del52|Type 1 CALR Gene Variant|cC1qR c.1092_1143del52	A deletion of 52 nucleotides from the coding sequence of the CALR gene from positions 1092 through 1143.			Cell or Molecular Dysfunction	
C129835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129835>	C17354|C129833	CALR NM_004343.3:c.1154_1155insTTGTC|Autoantigen Ro Gene c.1154_1155ins5|Autoantigen Ro Gene c.1154_1155insTTGTC|CALR NM_004343.3:c.1154_1155ins5|CALR Type 2 Gene Mutation|CALR c.1154_1155ins5|CALR c.1154_1155insTTGTC|CALR2|CALR2 Gene Mutation|CRT c.1154_1155ins5|CRT c.1154_1155insTTGTC|Calreticulin Gene c.1154_1155ins5|Calreticulin Gene c.1154_1155insTTGTC|NM_004343.3:c.1154_1155ins5|NM_004343.3:c.1154_1155insTTGTC|RO c.1154_1155ins5|RO c.1154_1155insTTGTC|Type 2 CALR Gene Variant|cC1qR c.1154_1155ins5|cC1qR c.1154_1155insTTGTC	An insertion of five nucleotides, TTGTC, between positions 1154 and 1155 of the coding sequence of the CALR gene.			Cell or Molecular Dysfunction	
C129836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129836>	C97928	CALR Protein Variant|CRP55 Protein Variant|Calregulin Protein Variant|Calreticulin Protein Variant|ERp60 Protein Variant|Endoplasmic Reticulum Resident Protein 60 Protein Variant|HACBP Protein Variant|grp60 Protein Variant	A variation in the amino acid sequence for the calreticulin protein.			Cell or Molecular Dysfunction	
C129837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129837>	C129836	CALR NP_004334.1:p.L367fs*46|CALR L367fs*46|CALR Leu367fs*46|CALR NP_004334.1:p.Leu367fs*46|CALR Type 1 Protein Variant|CALR p.L367fs*46|CALR p.Leu367fs*46|CALR1 Protein Variant|CRP55 L367fs*46|CRP55 Leu367fs*46|Calregulin L367fs*46|Calregulin Leu367fs*46|Calreticulin L367fs*46|Calreticulin Leu367fs*46|ERp60 L367fs*46|ERp60 Leu367fs*46|Endoplasmic Reticulum Resident Protein 60 L367fs*46|Endoplasmic Reticulum Resident Protein 60 Leu367fs*46|HACBP L367fs*46|HACBP Leu367fs*46|NP_004334.1:p.L367fs*46|NP_004334.1:p.Leu367fs*46|NP_004334.1p.Leu367Thrfs*46|Type 1 CALR Protein Variant|grp60 L367fs*46|grp60 Leu367fs*46	A change in the amino acid composition of the calreticulin protein where a frameshift mutation results in the insertion of 45 non-canonic amino acids followed by a stop codon immediately after the leucine residue at position 367.			Cell or Molecular Dysfunction	
C129838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129838>	C129836	CALR NP_004334.1:p.K385fs*47|CALR K385fs*47|CALR Lys385fs*47|CALR NP_004334.1:p.Lys385fs*47|CALR Type 2 Protein Variant|CALR p.K385fs*47|CALR p.Lys385fs*47|CALR2 Protein Variant|CRP55 K385fs*47|CRP55 Lys385fs*47|Calregulin K385fs*47|Calregulin Lys385fs*47|Calreticulin K385fs*47|Calreticulin Lys385fs*47|ERp60 K385fs*47|ERp60 Lys385fs*47|Endoplasmic Reticulum Resident Protein 60 K385fs*47|Endoplasmic Reticulum Resident Protein 60 Lys385fs*47|HACBP K385fs*47|HACBP Lys385fs*47|NP_004334.1:p.K385fs*47|NP_004334.1:p.Lys385fs*47|Type 2 CALR Protein Variant|grp60 K385fs*47|grp60 Lys385fs*47	A change in the amino acid composition of the calreticulin protein where a frameshift mutation results in the insertion of 46 non-canonic amino acids followed by a stop codon immediately after the lysine residue at position 385.			Cell or Molecular Dysfunction	
C129839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129839>	C274	Apoptotic Pathway-targeting Antineoplastic Agent|Apoptotic Pathway-targeting Cancer Therapeutic	Any agent that directly targets the apoptotic pathway and has an antineoplastic effect.			Chemical Viewed Functionally	
C12983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12983>	C32223	Bone of the Upper Extremity|Bone of Upper Extremity|Bones of Upper Extremity	A bone of the arm (upper extremity).	Bone of Upper Extremity		Body Part, Organ, or Organ Component	
C129840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129840>	C25994	CGA Gene|CGA|CGA|Glycoprotein Hormones, Alpha Polypeptide Gene	This gene plays a role in protein hormone signaling.	CGA Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C129841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129841>	C129840	CGA wt Allele|CG-ALPHA|FSHA|GPHA1|GPHa|Glycoprotein Hormones, Alpha Polypeptide wt Allele|HCG|LHA|TSHA	Human CGA wild-type allele is located in the vicinity of 6q14.3 and is approximately 10 kb in length. This allele, which encodes glycoprotein hormones alpha chain protein, is involved in protein hormone-dependent signaling.	CGA wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129842>	C1746	Glycoprotein Hormones Alpha Chain Protein|Anterior Pituitary Glycoprotein Hormones Common Subunit Alpha|CG-ALPHA|CGA|Choriogonadotropin Alpha Chain|Chorionic Gonadotrophin Subunit Alpha|Chorionic Gonadotropin, Alpha Polypeptide|FSH-Alpha|Follicle-Stimulating Hormone Alpha Chain|Follicle-Stimulating Hormone Alpha Subunit|Follicle-Stimulating Hormone, Alpha Chain|Follitropin Alpha Chain|Glycoprotein Hormones Alpha Chain|Glycoprotein Hormones Alpha Polypeptide|Glycoprotein Hormones, Alpha Chain|Glycoprotein Hormones, Alpha Polypeptide|LSH-Alpha|Luteinizing Hormone Alpha Chain|Luteinizing Hormone, Alpha Chain|Lutropin Alpha Chain|TSH-Alpha|Thyroid-Stimulating Hormone Alpha Chain|Thyroid-Stimulating Hormone, Alpha Chain|Thyrotropin Alpha Chain|Thyrotropin, Alpha Chain	Glycoprotein hormones alpha chain (116 aa, ~13 kDa) is encoded by the human CGA gene. This protein plays a role in hormone signaling.	Glycoprotein Hormones Alpha Chain Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129843>	C25870	NAT1 Gene|N-Acetyltransferase 1 Gene|NAT1|NAT1	This gene is involved in detoxification of arylamine-containing compounds.	NAT1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C129844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129844>	C129843	NAT1 wt Allele|AAC1|MNAT|N-Acetyltransferase 1 (Arylamine N-Acetyltransferase) Gene|N-Acetyltransferase 1 wt Allele|NAT-1|NATI	Human NAT1 wild-type allele is located in the vicinity of 8p22 and is approximately 53 kb in length. This allele, which encodes arylamine N-acetyltransferase 1 protein, plays a role in the metabolism of arylamines.	NAT1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129845>	C16259	Arylamine N-Acetyltransferase 1|Acetyl-CoA:Arylamine N-Acetyltransferase|Arylamide Acetylase 1|Arylamine N-Acetyltransferase|EC 2.3.1.5|Monomorphic Arylamine N-Acetyltransferase|N-Acetyltransferase 1|N-Acetyltransferase Type 1|NAT1	Arylamine N-acetyltransferase 1 (290 aa, ~34 kDa) is encoded by the human NAT1 gene. This protein is involved in arylamine detoxification.	Arylamine N-Acetyltransferase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129846>	C26016	INHBE Gene|INHBE|INHBE|Inhibin Beta E Subunit Gene	This gene plays a role in the regulation of hormone signaling.	INHBE Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C129847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129847>	C129846	INHBE wt Allele|Inhibin Beta E Subunit wt Allele|Inhibin, Beta E Gene|MGC4638	Human INHBE wild-type allele is located in the vicinity of 12q13.3 and is approximately 7 kb in length. This allele, which encodes inhibin beta E chain protein, is involved in the modulation of hormone secretion.	INHBE wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129848>	C20424	Inhibin Beta E Chain|Activin Beta-E|Activin Beta-E Chain|INHBE|Inhibin Beta E	Inhibin beta E chain (350 aa, ~39 kDa) is encoded by the human INHBE gene. This protein plays a role in the secretion of hormones.	Inhibin Beta E Chain		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129849>	C28533	CYCS Gene|CYCS|CYCS|Cytochrome C, Somatic Gene	This gene is involved in electron transport.	CYCS Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C12984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12984>	C12745	Interval Lymph Node	One of the nodes that lie along the course of a lymphatic vessel between a primary melanoma site and a recognized node field. (from Medscape)	Interval Lymph Node		Body Part, Organ, or Organ Component	
C129850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129850>	C129849	CYCS wt Allele|CYC|Cytochrome C, Somatic wt Allele|HCS|THC4	Human CYCS wild-type allele is located in the vicinity of 7p15.3 and is approximately 7 kb in length. This allele, which encodes cytochrome c protein, plays a role in the mitochondrial electron transport chain. Mutation of the gene is associated with thrombocytopenia 4.	CYCS wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129851>	C16386	Cytochrome C|Cyt C	Cytochrome c (105 aa, ~12 kDa) is encoded by the human CYCS gene. This protein is involved in the transfer of electrons between complex III and complex IV of the mitochondrial electron transport chain.	Cytochrome C		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129852>	C84276	Chronic Myelomonocytic Leukemia with Eosinophilia Associated with t(5;12)(q31;p12)|Chronic Myelomonocytic Leukemia with Eosinophilia Associated with t(5;12)	Chronic myelomonocytic leukemia characterized by the presence of eosinophilia, PDGFRB gene rearrangement, and t(5;12)(q31;p12).			Neoplastic Process	Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C129853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129853>	C84270	Myeloid/Lymphoid Neoplasms with JAK2 Rearrangement|M/LN-eo with t(8;9)(p22;p24.1)/PCM1/JAK2|M/LN-eo with t(8;9)(p22;p24.1)/PCM1::JAK2|Myeloid and Lymphoid Neoplasms with t(8;9)(p22;p24.1);PCM1-JAK2|Myeloid and Lymphoid Neoplasms with t(8;9)(p22;p24.1);PCM1::JAK2|Myeloid/Lymphoid Neoplasm with JAK2 Rearrangement|Myeloid/Lymphoid Neoplasm with JAK2-PCM1 Fusion|Myeloid/Lymphoid Neoplasm with PCM1- JAK2 Fusion|Myeloid/Lymphoid Neoplasms with PCM1-JAK2|Myeloid/Lymphoid Neoplasms with PCM1-JAK2|Myeloid/Lymphoid Neoplasms with PCM1::JAK2	Hematologic neoplasms characterized by the presence of t(8;9)(p22;p24.1) that results in PCM1-JAK2 fusion gene expression. It is associated with eosinophilia, bone marrow findings of left-shifted erythroid predominance, lymphoid aggregates, and often myelofibrosis. Rare cases present as T- or B-acute lymphoblastic leukemia.	Myeloid/Lymphoid Neoplasms with PCM1-JAK2		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C129854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129854>	C3420|C186942|C157572	t(8;9)(p22;p24.1)	A cytogenetic abnormality that refers to the translocation of 8p22 and 9p24.1. This translocation results in the fusion of the PCM1 gene and the JAK2 gene.			Cell or Molecular Dysfunction	
C129855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129855>	C28510	PCM1/JAK2 Fusion Gene|PCM1-JAK2 Fusion Gene|PCM1::JAK2 Fusion Gene	A fusion gene that results from a chromosomal translocation t(8;9)(p22;p24.1) which fuses most of the PCM1 gene to the upstream side of the exons of the JAK2 gene encoding the tyrosine kinase domain. This fusion is associated with myeloproliferative disorders and some rare myeloid and lymphoid neoplastic diseases.	PCM1/JAK2 Fusion Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129856>	C17561	PCM1/JAK2 Fusion Protein|PCM-1/JAK-2 Fusion Protein|PCM1-JAK2 Fusion Protein|PCM1::JAK2 Fusion Protein|Pericentriolar Material 1 Protein/Tyrosine-Protein Kinase JAK2 Fusion Protein	A fusion protein that is encoded by the PCM1/JAK2 fusion gene. This protein contains the predicted coiled-coil domains and the ATP/GTP binding domain from pericentriolar material 1 protein and the entire tyrosine kinase domain of the tyrosine-protein kinase JAK2 protein.	PCM1/JAK2 Fusion Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129857>	C7721|C4833	Gingival Squamous Cell Carcinoma|Gingival SCC	A squamous cell carcinoma that arises from the gingival mucosa. It presents as an ulcerated lesion or exophytic mass. The prognosis is usually poor.			Neoplastic Process	Cellosaurus Disease Terminology|NCIt Neoplasm Core Terminology
C129858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129858>	C60679	Rat Ovarian Adenocarcinoma	Adenocarcinoma that arises from the ovary of a rat.			Neoplastic Process	Cellosaurus Disease Terminology
C129859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129859>	C21637	Mouse Teratocarcinoma	A malignant germ-cell neoplasm arising from pluripotent cells, including components from the epithelial germ-cell layer, which occurs in a mouse.			Neoplastic Process	Cellosaurus Disease Terminology
C12985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12985>	C12662	Neural Stem Cell|Neural Stem Cells	A stem cell derived from embryonic sources or found in adult neural tissue. It has the capacity to generate all the multiple cell types found in the brain and spinal cord.	Neural Stem Cell		Cell	
C129860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129860>	C173938	Time of Bowel Movement Question|Time of Bowel Movement|Time of This Bowel Movement|Time when this bowel movement occurred.	A question about the time of day when a bowel movement occurred.			Intellectual Product	Bowel Function Diary for Assessing Opioid-Induced Constipation
C129861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129861>	C170469|C153171|C126465	Advanced Head and Neck Carcinoma|Advanced Head and Neck Cancer	A head and neck carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Head and Neck Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C129862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129862>	C49236	Transcranial Direct Current Stimulation|tDCS	A noninvasive technique to alter cortical brain activity by direct current polarization. This technique is being applied in human for modification of perceptual, cognitive, and behavioral functions.	Transcranial Direct Current Stimulation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C129863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129863>	C4086	Oral Epithelial Dysplasia|OED|Oral Dysplasia	A morphologic finding of dysplastic epithelial cells in the oral cavity.			Finding	Cellosaurus Disease Terminology
C129864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129864>	C75467	Charcot-Marie-Tooth Disease Type 4C|CMT4C	An autosomal recessive form of demyelinating Charcot-Marie-Tooth disease caused by mutations in the SH3TC2 gene, encoding SH3 domain and tetratricopeptide repeat-containing protein 2.			Disease or Syndrome	Cellosaurus Disease Terminology
C129865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129865>	C84572	Congenital Contractural Arachnodactyly|Arthrogryposis, Distal, Type 9|Beals Syndrome|CCA	An autosomal dominant connective tissue disorder caused by mutation(s) in the FBN2 gene, encoding fibrillin-2. It is characterized by contractures, arachnodactyly, scoliosis, micrognathia, and crumpled ears.			Disease or Syndrome	Cellosaurus Disease Terminology
C129866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129866>	C28193	Dopamine Transporter Deficiency Syndrome|PKDYS|Parkinsonism-Dystonia, Infantile	An autosomal recessive condition caused by mutation(s) in the SLC6A3 gene, encoding sodium-dependent dopamine transporter. It is characterized by Parkinsonian features and has an onset in early infancy.			Disease or Syndrome	Cellosaurus Disease Terminology
C129867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129867>	C28193	Growth Hormone Insensitivity Syndrome|Growth Hormone Insensitivity Syndromes|Growth Hormone Insensitivity Syndromes	A group of inherited syndromes in which there is impaired growth hormone signaling, despite normal or increased growth hormone concentrations. The syndromes are characterized by some or all of the following: prenatal and/or postnatal growth failure, immature facial features, microcephaly, neurocognitive deficiencies, sensorineural hearing loss, immune dysregulation, and delayed puberty.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C129868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129868>	C3021	Juvenile Absence Epilepsy	A subtype of idiopathic generalized epilepsy, whose manifestations occur around puberty, associated with mutation(s) in the EFHC1 gene, encoding EF-hand domain-containing protein 1.			Disease or Syndrome	Cellosaurus Disease Terminology
C129869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129869>	C28193	Multiple Vascular Disruption Syndrome	A rare syndrome that refers to a constellation of anomalies resulting from multiple vascular disruption.			Disease or Syndrome	Cellosaurus Disease Terminology
C12986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12986>	C13037	Alveolus|ALVEOLUS|Alveoli|Alveoli|Bronchial Alveolus|Pulmonary Alveolus|alveoli	Any of the terminal sacs in the lungs through which gas exchange takes place with the pulmonary capillary blood.	Alveolus		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C129870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129870>	C101216	Nemaline Myopathy 3|NEM3	An inherited myopathy caused by mutations in the ACTA1 gene, encoding actin, alpha skeletal muscle. The phenotype is highly variable, and as such attempts at classification by clinical features is not optimal. Generally, affected individuals have generalized muscle weakness, typically involving proximal muscles, the face, bulbar and respiratory muscles.			Disease or Syndrome	Cellosaurus Disease Terminology
C129871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129871>	C101216	Nemaline Myopathy 8|NEM8	An autosomal recessive myopathy caused by mutations in the KLHL40 gene, encoding Kelch-like protein 40. The phenotype is highly variable, and as such attempts at classification by clinical features is not optimal. Generally, affected individuals have generalized muscle weakness, and typically involves proximal muscles, the face, bulbar and respiratory muscles.			Disease or Syndrome	Cellosaurus Disease Terminology
C129872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129872>	C28193	Pitt-Hopkins Syndrome|PTHS	An autosomal dominant condition caused by mutation(s) on the TCF4 gene, encoding transcription factor 4. It is characterized by intellectual disability, developmental delay, breathing problems and seizures.			Disease or Syndrome	Cellosaurus Disease Terminology
C129873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129873>	C4041|C37290	Floor of Mouth Basaloid Squamous Cell Carcinoma|Floor of Mouth BSCC	An aggressive variant of squamous cell carcinoma that arises from the floor of the mouth. It is characterized by the presence of small malignant cells with hyperchromatic nuclei and scant amount of cytoplasm forming lobules with peripheral palisading.			Neoplastic Process	Cellosaurus Disease Terminology
C129874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129874>	C53543|C27644	Deafness, Autosomal Recessive 39|DFNB39	An autosomal recessive disorder caused by mutations in the HGF gene, encoding hepatocyte growth factor. It is characterized by profound deafness.			Disease or Syndrome	Cellosaurus Disease Terminology
C129875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129875>	C28193	Chromosome 16p12.1 Deletion Syndrome|Chromosome 16p12.1 Deletion Syndrome, 520-KB	A condition caused by a 520 kb deletion at 16p12.1. It is characterized by developmental delay, craniofacial dysmorphology and congenital heart defects.			Disease or Syndrome	Cellosaurus Disease Terminology
C129876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129876>	C141145|C129822	Vopratelimab|Anti-ICOS Agonist MAb JTX-2011|ICOS Agonist Monoclonal Antibody JTX-2011|JTX-2011|VOPRATELIMAB	An agonistic humanized monoclonal antibody that recognizes inducible T-cell co-stimulator (ICOS; CD278), with potential antineoplastic activity. Upon administration, vopratelimab targets and binds to ICOS expressed on certain T-cells. This stimulates ICOS-mediated signaling, induces proliferation of ICOS-positive T-cells, enhances cytotoxic T-lymphocyte (CTL) survival and augments the CTL-mediated immune response against tumor cells. ICOS, a T-cell specific, CD28-superfamily co-stimulatory molecule and immune checkpoint protein, is normally expressed on certain activated T-cells and plays a key role in the proliferation and activation of T-cells.	Vopratelimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129877>	C142078	Autologous Monocytes|Therapeutic Autologous Monocytes	A preparation of autologous monocytes, with potential immunomodulating activity. Following isolation and administration, the autologous monocytes may differentiate into classic M1 macrophages, which are able to directly attack and kill tumor cells. The stimulated monocytes also promote natural killer (NK) cell differentiation, which further enhances tumor cell killing through NK-mediated cytotoxicity.	Autologous Monocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology
C129878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129878>	C226559	Completely Able|Completely	A response indicating that an individual is completely able to do something.			Intellectual Product	Bowel Function Diary for Assessing Opioid-Induced Constipation
C129879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129879>	C91102	How Much Strain Question|How Much Strain|How much did you have to strain	A question about how much an individual had to strain.			Intellectual Product	Bowel Function Diary for Assessing Opioid-Induced Constipation
C129880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129880>	C173346	Pain Felt Around Rectum Question|How Much Pain Felt Around Rectum|How much pain did you have around your rectum|Pain Felt Around Rectum	A question about how much pain an individual had around their rectum.			Intellectual Product	Bowel Function Diary for Assessing Opioid-Induced Constipation
C129881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129881>	C45822	TRAF1-C5 Locus|TRAF1-C5|TRAF1/C5|TRAF1C5|Tumor Necrosis Factor-Receptor Associated Factor 1/Complement Component 5 Gene Locus	An intergenic gene locus on the short arm of human chromosome 9 located between the TRAF1 and C5 genes. Polymorphism in this region may be associated with increased susceptibility for rheumatoid arthritis.	TRAF1-C5 Locus		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129882>	C18520	Catecholamine Metabolite	Molecules created during the catabolism of catecholamine hormones. Increased concentrations of these metabolic products in plasma and urine may indicate the presence of hormone-producing pheochromocytomas or paragangliomas.	Catecholamine Metabolite		Functional Concept	CTRP Biomarker Terminology|CTRP Terminology
C129883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129883>	C18520	Choline Metabolite	Molecules used during the synthesis or created during the catabolism of choline. The presence of these metabolic products in urine can be correlated with the amount of dietary choline or total choline-containing compounds in a subject.	Choline Metabolite		Functional Concept	CTRP Biomarker Terminology|CTRP Terminology
C129884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129884>	C18520	NNK Metabolite|4-Methylnitrosamino-1,3-Pyridyl-1-Butanone Metabolite|Nicotine-Derived Nitrosamine Ketone Metabolite	Molecules created during the catabolism of the nitrosamine 4-methylnitrosamino-1,3-pyridyl-1-butanone (nicotine-derived nitrosamine ketone; NNK). The presence of these metabolic products may be correlated with the exposure of the subject to tobacco products.	NNK Metabolite		Functional Concept	CTRP Biomarker Terminology|CTRP Terminology
C129885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129885>	C18520	Tryptophan Metabolite	Molecules created during the catabolism of the amino acid tryptophan. Increased concentrations of tryptophan metabolites are associated with neurological disease-related cognitive deficits and depressive symptoms and may be used as biomarkers for cancer risk.	Tryptophan Metabolite		Functional Concept	CTRP Biomarker Terminology|CTRP Terminology
C129886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129886>	C97139	Cytokine Expression Profile|Cytokine Profile	The identification and quantitation of all of the cytokines expressed in a biological sample.	Cytokine Expression Profile		Qualitative Concept	CTRP Biomarker Terminology|CTRP Terminology
C129887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129887>	C17632	Epigenetic Profile|Epigenetic Analysis	The analysis of all of the epigenetic DNA modifications in the genome a biological sample.	Epigenetic Profile		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Terminology
C129888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129888>	C17632	Single Nucleotide Polymorphism Profile|SNP Profile|SNP genotyping	The analysis of all of the single nucleotide polymorphisms in the genome of a biological sample.	Single Nucleotide Polymorphism Profile		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Terminology|pFDA Bioinformatics/Genomics Terminology|precisionFDA Terminology
C129889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129889>	C17632	Short Tandem Repeat Profile|STR Profile	The analysis of all of the short tandem repeats in the genome of a biological sample.	Short Tandem Repeat Profile		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Terminology
C129890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129890>	C63328	Promoter-specific Methylation Profile	The analysis of all of the methylation of all promoter sequences in the genome in a biological sample	Promoter-specific Methylation Profile		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Terminology
C129891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129891>	C48182	DDRD Signature|DDRD Gene Signature|DNA Damage Response Deficiency Gene Signature|DNA Damage Response Deficiency Signature	A gene expression profile that indicates that the cells in a sample have decreased ability to respond to and repair DNA damage.	DDRD Signature		Qualitative Concept	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129892>	C63328	Hypermethylation Profile	The identification and quantitation of sites for DNA hypermethylation in the genome of a biological sample.	Hypermethylation Profile		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Terminology
C129893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129893>	C63328	Hypomethylation Profile	The identification and quantitation of sites for DNA hypomethylation in the genome of a biological sample.	Hypomethylation Profile		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Terminology
C129894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129894>	C129886	Chemokine Expression Profile|Chemokine Profile	The identification and quantitation of all of the chemokines expressed in a biological sample.	Chemokine Expression Profile		Qualitative Concept	CTRP Biomarker Terminology|CTRP Terminology
C129895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129895>	C19770	Red Cell Fatty Acid Profile|RBC FA Profile|Red Blood Cell Fatty Acid Profile|Red Cell Fatty Acid Analysis	The identification and quantitation of all of the fatty acids expressed in the red blood cells isolated from a subject.	Red Cell Fatty Acid Profile		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Terminology
C129896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129896>	C18520	Prostaglandin E2 Metabolite|PGE Metabolite|PGE-M|PGE2 Metabolite|PGE2-M|Prostaglandin E Metabolite	Molecules created during the catabolism of prostaglandin E2 (PGE2). The presence of these metabolic products in urine can be correlated with the amount of PGE2 synthesis.	Prostaglandin E2 Metabolite		Functional Concept	CTRP Biomarker Terminology|CTRP Terminology
C129897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129897>	C18520	Prostaglandin I2 Metabolite|PGI-M|PGI2 Metabolite|PGI2-M|PGI2-Metabolite|PGIM|Prostacyclin (PGI2)-Metabolite|Prostacyclin Metabolite|Prostaglandin I Metabolite	Molecules created during the catabolism of prostaglandin I2 (PGI2). The presence of these metabolic products in plasma and urine can be correlated with the amount of PGI2 synthesis.	Prostaglandin I2 Metabolite		Functional Concept	CTRP Biomarker Terminology|CTRP Terminology
C129898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129898>	C45842|C17660	Receptor Tyrosine-Protein Kinase erbB-2 Carboxyl Terminal Fragment|ERBB2 C-Terminal Fragment|ERBB2 CTF|ERBB2 Carboxyl Terminal Fragment|ERBB2-p95|HER2 C-Terminal Fragment|HER2 CTF|HER2-p95|HER2/neu CTF|HER2/neu-p95|Receptor Tyrosine-Protein Kinase erbB-2 C-Terminal Fragment|Receptor Tyrosine-Protein Kinase erbB-2 CTF|p95 HER2|p95HER2	Receptor tyrosine-protein kinase erbB-2 carboxyl terminal fragment is encoded by the human ERBB2 gene. This protein may be involved in tyrosine kinase activity and may be associated with increased cancer severity.	Receptor Tyrosine-Protein Kinase erbB-2 Carboxyl Terminal Fragment		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129899>	C18520	LDL-C Oxidation|Oxidized LDL Cholesterol	The presence of oxidized elements in cholesterol-bearing low-density lipoprotein (LDL) particles in the blood. Oxidation may be associated with increased risk for atherosclerosis.	LDL-C Oxidation		Functional Concept	CTRP Biomarker Terminology|CTRP Terminology
C12989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12989>	C12749	Episclera|Episcleral Layer	A thin fibrous membrane that covers the outer surface of the anteriors sclera and contains blood vessels which supply the sclera.	Episclera		Body Part, Organ, or Organ Component	
C1298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1298>	C783|C2143	O-Chloroacetylcarbamoylfumagillol|(3R,4S,5S,6R)-5-Methoxy-4- [(2R,3R)-2-methyl-3-(3-methyl-2-butenyl) -oxiranyl]-1-oxaspiro [2,5] oct-6-yl(chloroacetyl) Carbamate|5-methoxy-4-(2-methyl-3-(3-methyl-2-butenyl)oxiranyl)-1-oxaspiro(2,5)oct-6-yl(chloroacetyl) carbamate|AGM-1470|AGM-1470|TNP-470|TNP-470|TNP-470|TNP-470|[3R-[3alpha,4alpha(2R*,3R*),5beta,6beta]]-5-Methoxy-4-[2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2.5]oct-6-yl (chloroacetyl)carbamate	A synthetic analog of fumagillin, an antibiotic isolated from the fungus Aspergillus fumigatus fresenius with antineoplastic activity.  TNP-470 binds to and irreversibly inactivates methionine aminopeptidase-2 (MetAP2), resulting in endothelial cell cycle arrest late in the G1 phase and inhibition of tumor angiogenesis.  This agent may also induce the p53 pathway, thereby stimulating the production of cyclin-dependent kinase inhibitor p21 and inhibiting angiogenesis. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129900>	C18520	VLDL-C Oxidation|Oxidized VLDL Cholesterol	The presence of oxidized elements in cholesterol-bearing very low-density lipoprotein (VLDL) particles in the blood. Oxidation may be associated with increased risk for atherosclerosis.	VLDL-C Oxidation		Functional Concept	CTRP Biomarker Terminology|CTRP Terminology
C129901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129901>	C212901	Retinol Binding Protein Family|RBP|RBP Family|Retinol Binding Protein|Retinol-Binding Protein	A family of proteins that bind and transport retinol and/or retinoids.			Amino Acid, Peptide, or Protein	
C129902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129902>	C17632	Genome-Wide Allelic Status|Allelic Status	The analysis of all of the alleles present in the genome in a biological sample.	Genome-Wide Allelic Status		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Terminology
C129903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129903>	C63328	Global DNA Methylation Profile|DNA MI|DNA Methylation Index|DNA Methylation Profile	The analysis of all of the methylated nucleotides present in the genome in a biological sample.	Global DNA Methylation Profile		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Terminology
C129904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129904>	C42076	Persistent Neuroblastic Cells|Persistent Neuroblastic Cells Present	A morphologic finding indicating the continuing presence of neuroblastic cells in a set of tissue samples collected over time.	Persistent Neuroblastic Cells		Finding	CTRP Biomarker Terminology|CTRP Terminology
C129905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129905>	C42076	Hematogenous CSF Blasts|CSF Blasts|Hematogenous Cerebrospinal Fluid Blasts	A morphologic finding indicating the presence of blasts in a sample of cerebrospinal fluid.	Hematogenous CSF Blasts		Finding	CTRP Biomarker Terminology|CTRP Terminology
C129906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129906>	C12476	Natural Killer T-Cell|NK T-Cell|NKT Cell|Natural Killer T Cell	A subset of T-lymphocytes that coexpress an alpha/beta T-cell receptor, and variety of molecular markers that are typically associated with natural killer (NK) cells, which may include CD161, CD16, CD68, and granzyme. NK T-cells recognize glycolipids presented by antigen-presenting glycoprotein CD1d on antigen presenting cells; antigen recognition stimulates a rapid release of various cytokines from the NK T-cells.	Natural Killer T-Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C129907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129907>	C37042	Circulating Myeloid Cell	A myeloid-derived cell found in the peripheral blood.	Circulating Myeloid Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C129908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129908>	C12549	Myeloid-Derived Suppressor Cell|MDSC	A population of myeloid cells, mainly dendritic cells, macrophages and neutrophils, that have immunosuppressive activity. During inflammation, chronic infection or cancer, these cells may promote angiogenesis or tumor cell invasion.	Myeloid-Derived Suppressor Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C129909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129909>	C25994	PPY Gene|PPY|PPY|Pancreatic Polypeptide Gene	This gene plays a role in the modulation of gastrointestinal functions and appetite.	PPY Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C12990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12990>	C33904	Lobule|lobule	A subdivision of a lobe.	Lobule		Body Part, Organ, or Organ Component	
C129910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129910>	C129909	PPY wt Allele|PNP|PP|Pancreatic Polypeptide Y Gene|Pancreatic Polypeptide wt Allele|Pancreatic Polypeptide/Pancreatic Icosapeptide Gene|Prepro-PP (Prepropancreatic Polypeptide) Gene	Human PPY wild-type allele is located in the vicinity of 17q21.31 and is approximately 3 kb in length. This allele, which encodes pancreatic prohormone protein, is involved in the regulation of pancreatic and gastrointestinal functions.	PPY wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129911>	C1746	PPY Gene Product	A protein encoded by the PPY gene.			Amino Acid, Peptide, or Protein	
C129912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129912>	C129911	Pancreatic Prohormone|PP|PPY|Pancreatic Polypeptide|Prepro-PP|Prepropancreatic Polypeptide	Pancreatic prohormone (95 aa, ~10 kDa) is encoded by the human PPY gene. This protein plays a role in the regulation of appetite, food intake and digestion.	Pancreatic Prohormone		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129913>	C129911	Pancreatic Hormone|PH	Pancreatic hormone (36 aa, ~4 kDa) is encoded by the human PPY gene. This protein plays a role in the modulation of appetite and digestion.	Pancreatic Hormone		Amino Acid, Peptide, or Protein|Hormone	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129914>	C129911	Pancreatic Icosapeptide|PI	Pancreatic icosapeptide (20 aa, ~2 kDa) is encoded by the human PPY gene. The function for this protein is not known.	Pancreatic Icosapeptide		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129915>	C21295	ATXN1 Gene|ATXN1|ATXN1|Ataxin 1 Gene	This gene is involved in both RNA metabolism and chromatin binding.	ATXN1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C129916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129916>	C129915	ATXN1 wt Allele|ATX1|Ataxin 1 wt Allele|D6S504E|SCA1|Spinocerebellar Ataxia 1 (Olivopontocerebellar Ataxia 1, Autosomal Dominant, Ataxin 1) Gene	Human ATXN1 wild-type allele is located in the vicinity of 6p22.3 and is approximately 462 kb in length. This allele, which encodes ataxin-1 protein, plays a role in Notch signaling, chromatin binding and RNA metabolism. CGA repeat expansion within the coding region of the gene is associated with spinocerebellar ataxia 1.	ATXN1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129917>	C17728	Ataxin-1|ATXN1|Ataxin 1|Spinocerebellar Ataxia Type 1 Protein	Ataxin-1 (815 aa, ~87 kDa) is encoded by the human ATXN1 gene. This protein is involved in chromatin binding, RNA metabolism and Notch signaling.	Ataxin-1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129918>	C18062	Human Anti-Idiotype Antibody|Ab2|Anti-Id|Anti-Idiotype Antibody	A human anti-mouse antibody that binds to the antigen-combining site of another antibody.	Human Anti-Idiotype Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C129919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129919>	C16296|C103990	Human Anti-Anti-Idiotype Antibody|Ab3|Anti-Anti-Id|Anti-Anti-Idiotype Antibody	A human antibody that recognizes human anti-mouse anti-idiotype antibodies.	Human Anti-Anti-Idiotype Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C12991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12991>	C42050	Neuroblast	An embryonic nerve cell capable of differentiating into a neuron.	Neuroblast		Cell	CTRP Biomarker Terminology|CTRP Terminology
C129920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129920>	C124128	Induced Anti-Tumor Antigen-specific Antibody|Ab3 Prime|Ab3'|Induced Anti-TAA Antibody|Induced Anti-Tumor-Associated Antigen Antibody|Induced Tumor Antigen-specific Antibody|Induced Tumor-Associated Antigen Antibody	An antibody that recognizes a tumor-associated antigen (TAA) and is induced and expressed following immunization by a therapeutic antibody targeting the same TAA.	Induced Anti-Tumor Antigen-specific Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C129921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129921>	C16295	GD2 Antibody|Anti-GD2 Antibody|Anti-Ganglioside GD2 Antibody|Ganglioside GD2 Antibody	Any immunoglobulin that recognizes ganglioside GD2.	GD2 Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C129922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129922>	C17207	NFKB2 Gene Product	A protein encoded by the NFKB2 gene.			Amino Acid, Peptide, or Protein	
C129923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129923>	C129922	Nuclear Factor NF-kappa-B p52 Subunit|NF-Kappa B p52|NF-kB Subunit 2 p52|NF-kappaB(p52)|NFKB p52 Subunit|Nuclear Factor Kappa-B Subunit 2 p52	Nuclear factor NF-kappa-B p52 subunit (454 aa, ~49 kDa) is encoded by the human NFKB2 gene. This protein is involved in both transcriptional regulation and signal transduction.	Nuclear Factor NF-kappa-B p52 Subunit		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129924>	C18153	CASP9 Gene Product	A protein encoded by the CASP9 gene.	CASP9 Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129925>	C129924	Activated Caspase-9|Activated CASP-9|Activated CASP9|Activated Caspase 9|EC 3.4.22.62	Activated caspase-9 (~400 aa, ~45 kDa) is encoded by the human CASP9 gene. This protein is involved in the induction of caspase-dependent apoptosis.	Activated Caspase-9		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C129926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129926>	C36281	Hidebound	Skin that is abnormally dry and stiff, lacking pliancy and closely adhered to the underlying flesh.			Finding	NIH Consensus Response Criteria for Chronic GVHD
C129927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129927>	C5156|C217295	Sacral Chordoma	A chordoma that arises from the sacral area.			Neoplastic Process	Cellosaurus Disease Terminology
C129928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129928>	C61250	Galactosialidosis|GSL|Goldberg Syndrome|Neuraminidase Deficiency with Beta-Galactosidase Deficiency	An autosomal recessive lysosomal storage disease caused by mutation(s) in the CTSA gene, encoding lysosomal protective protein. It is characterized by a combined deficiency of neuraminidase and beta-galactosidase.			Disease or Syndrome	Cellosaurus Disease Terminology
C129929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129929>	C53543	Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency|LCHAD Deficiency	An inherited condition caused by mutation(s) in the HADHA gene, encoding trifunctional enzyme subunit alpha, mitochondrial. It is characterized by hypoglycemia, hypotonia, neuropathy, cardiomyopathy, pigmentary retinopathy and may be associated with sudden death.			Disease or Syndrome	Cellosaurus Disease Terminology
C12992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12992>	C33603	Splenic Red Pulp|Red Pulp	Splenic pulp seen grossly as a reddish brown substance, due to its abundance of red blood cells, consisting of splenic sinuses and the tissue intervening between them (splenic cords).	Red Pulp		Body Part, Organ, or Organ Component	
C129930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129930>	C85865|C53543	MASA Syndrome|CRASH Syndrome|Gareis-Mason Syndrome|Intellectual Disability, Aphasia, Shuffling Gait, and Adducted Thumbs|Mental Retardation, Aphasia, Shuffling Gait, and Adducted Thumbs|SPG1|Spastic Paraplegia, X-linked	An X-linked recessive condition caused by mutation(s) in the L1CAM gene, encoding neural cell adhesion molecule L1. It is characterized by mental retardation, aphasia, shuffling gait and adducted thumbs.			Disease or Syndrome	Cellosaurus Disease Terminology
C129931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129931>	C85865|C84392|C53543	Intellectual Developmental Disorder, X-linked 102|Mental Retardation, X-linked 102	An inherited condition caused by mutation(s) in the DDX3X gene, encoding ATP-dependent RNA helicase DDX3X. It is characterized by severe intellectual disability and variable neurologic features.			Disease or Syndrome	Cellosaurus Disease Terminology
C129932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129932>	C2976	Nephropathic Cystinosis	An autosomal recessive condition caused by mutation(s) in the CTNS gene, encoding cystinosin. It is a sub-type of cystinosis, in which accumulation of cystine in the kidney results in renal dysfunction.			Disease or Syndrome	Cellosaurus Disease Terminology
C129933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129933>	C53543|C197818	Primary Lateral Sclerosis|Primary lateral sclerosis	A progressive neurodegenerative disorder affecting upper motor neurons, characterized by progressive muscle weakness.			Disease or Syndrome	Cellosaurus Disease Terminology|mCode Elixhauser Neurological Movement Disorder Value Set|mCode Terminology
C129934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129934>	C26733	Pseudobulbar Palsy	A condition affecting cranial nerves IX-XII resulting from upper motor neuron damage arising from a variety of causes.			Disease or Syndrome	Cellosaurus Disease Terminology
C129935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129935>	C1663	Personalized Peptide Cancer Vaccine NEO-PV-01|NEO PV 01|NEO-PV 01|NEO-PV-01|Neoantigen-based Anticancer Vaccine NEO-PV-01|Neoantigen-based Peptide Vaccine NEO-PV-01	A synthetic peptide-based, personalized cancer vaccine consisting of patient-specific mutated peptide epitopes, which are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-based anti-cancer vaccine NEO-PV-01 stimulates the host immune system to mount a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis.	Personalized Peptide Cancer Vaccine NEO-PV-01		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C129936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129936>	C210454|C201282|C129822	Anti-Glypican 3/CD3 Bispecific Antibody ERY974|Anti-GPC3/CD3 BiAb ERY974|Anti-GPC3/CD3 Bispecific Antibody ERY974|ERY-974|ERY974	An anti-glypican 3 (GPC3; GPC-3)/anti-CD3 bispecific monoclonal antibody, with potential immunostimulating and antineoplastic activities. Anti-GPC3/CD3 bispecific antibody ERY974 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for GPC3, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of ERY974, this bispecific antibody simultaneously binds to both CD3-expressing and GPC3-expressing cells, thereby crosslinking GPC3-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated lysis of GPC3-expressing tumor cells. GPC3, a heparan sulfate proteoglycan and an oncofetal antigen protein, is overexpressed in a variety of cancers; it plays a role in cell division and growth regulation.	Anti-Glypican 3/CD3 Bispecific Antibody ERY974		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129937>	C213143|C163790	Anti-FLT3 Antibody-drug Conjugate AGS62P1|ADC AGS62P1|AGS62P1|AGS62P1	An antibody-drug conjugate (ADC) composed of a human monoclonal antibody directed against the extracellular domain of receptor-type tyrosine-protein kinase FLT3 (FLT-3; FMS-like tyrosine kinase 3; CD135; fetal-liver kinase 2; FLK2) and conjugated, via an oxime linker and the site-directed non-natural amino acid linker para-acetyl-phenylalanine (pAcF), to a microtubule-disrupting cytotoxic agent, with potential antineoplastic activity. Upon administration of ADC AGS62P1, the antibody moiety targets and binds to FLT3. Upon antibody/antigen binding and internalization, the microtubule-targeting agent binds to and inhibits tubulin polymerization, which results in G2/M phase arrest and tumor cell apoptosis. The site-specific conjugation of the cytotoxic agent to the antibody, through pAcF, improves the biophysical properties of AGS62P1, increases payload distribution and stability, and optimizes its efficacy. FLT3, a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage, acute lymphoblastic leukemias and acute myeloid leukemias.	Anti-FLT3 Antibody-drug Conjugate AGS62P1		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129938>	C66830	CDISC SDTM Device-In-Use Response Terminology|DURS|Device-In-Use Response|SDTM-DURS	Terminology associated with the device-in-use response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129939>	C66830	CDISC SDTM Diabetic Kidney Findings About Test Name Terminology|DKFATS|Diabetic Kidney Disease Findings About Test Name|SDTM-DKFATS	Terminology associated with the diabetic kidney disease findings about test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C12993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12993>	C33603|C13049	Splenic White Pulp|White Pulp	The part of the spleen that consists of nodules and other lymphatic concentrations.	White Pulp		Body Part, Organ, or Organ Component	
C129940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129940>	C66830	CDISC SDTM Diabetic Kidney Findings About Test Code Terminology|DKFATSCD|Diabetic Kidney Disease Findings About Test Code|SDTM-DKFATSCD	Terminology associated with the diabetic kidney disease findings about test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129941>	C66830	CDISC SDTM Urinary System Test Name Terminology|SDTM-URNSTS|URNSTS|Urinary System Test Name	Terminology associated with the urinary system test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129942>	C66830	CDISC SDTM Urinary System Test Code Terminology|SDTM-URNSTSCD|URNSTSCD|Urinary System Test Code	Terminology associated with the urinary system test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C129943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129943>	C42614	Non-Clinical Principal Investigator Name|PINV|Principal Investigator|Principal Investigator	The name of the investigator who is responsible for defined aspects of a nonclinical study, as specified in the study protocol.			Conceptual Entity	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C129944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129944>	C42614	Study Chair Name|STDIR|Study Director|Study Director	The name of the person who has overall responsibility for the technical conduct of a study, as well as for the interpretation, analysis, documentation and reporting of results, and represents the single point of study control. (FDA)			Conceptual Entity	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C129945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129945>	C42614	Study Sponsor Monitor Name|STMON|Sponsor's Monitor|Sponsor's Monitor	The name of the individual working for the sponsor responsible for overseeing the activities of the study.			Conceptual Entity	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C129946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129946>	C42614	Nonclinical Study Sponsor Name|SSPONSOR|Sponsoring Organization|Sponsoring Organization	The name of the entity that is responsible for the initiation, management, and/or financing of a nonclinical study. (NCI)			Conceptual Entity	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C129947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129947>	C45233	Untreated Extensive Stage Small Cell Lung Carcinoma	A finding of small cell carcinoma which has spread beyond one hemi-thorax and the regional lymph nodes and has not been treated.			Finding	
C129948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129948>	C18492	CDKN2A Gene Product	A protein encoded by the CDKN2A gene.			Amino Acid, Peptide, or Protein	
C129949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129949>	C97927|C136420	JAK1 Gene Mutation|JAK1 Mutation|JTK3 Gene Mutation|Janus Kinase 1 (A Protein Tyrosine Kinase) Gene Mutation|Janus Kinase 1 Gene Mutation	A change in the nucleotide sequence of the JAK1 gene.	JAK1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C12994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12994>	C12476	Thymocyte|Thymocytes|thymocyte	A cell that develops in the thymus, seemingly from a stem cell of bone marrow and of fetal liver, and is the precursor of the thymus-derived lymphocyte (T lymphocyte) that effects cell-mediated (delayed type) sensitivity.	Thymocyte		Cell	
C129950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129950>	C226559	Slightly Able|Slightly	A response indicating that an individual is somewhat able to do something.			Intellectual Product	Bowel Function Diary for Assessing Opioid-Induced Constipation
C129951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129951>	C226559	Moderately Able|Moderately	A response indicating that an individual is moderately able to do something.			Intellectual Product	Bowel Function Diary for Assessing Opioid-Induced Constipation
C129952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129952>	C226559	Quite Able|Quite a Bit Able|Quite a bit	A response indicating that an individual is quite able to do something.			Intellectual Product	Bowel Function Diary for Assessing Opioid-Induced Constipation
C129953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129953>	C25298	Right Ventricular Systolic Pressure|RVSP	The maximum pressure exerted into the systemic arterial circulation during the contraction of the right ventricle of the heart.			Quantitative Concept	
C129954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129954>	C41185	Lung Tissue Drug Concentration|Lung Tissue Drug Volume|Lung Tissue Volume	The level of drug in lung tissue, expressed as a concentration.			Quantitative Concept	
C129955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129955>	C35552	Pulmonary Artery Wedge Pressure|Mean pulmonary capillary wedge pressure|PAOP|PAWP|PCWP|Pulmonary Arterial Wedge Pressure|Pulmonary Artery Occlusion Pressure|Pulmonary Capillary Wedge Pressure	The pressure measured by wedging a pulmonary catheter with an inflated balloon into a small pulmonary arterial branch.			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|Appendix 7: Diagnostic Procedures Terminology
C129956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129956>	C120942	Dynamic Compliance|Cdyn|Pulmonary Dynamic Compliance	Pulmonary compliance measured during the movement of air, such as during active inspiration.			Diagnostic Procedure	
C129957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129957>	C120942	Static Compliance|Cstat|Pulmonary Static Compliance	Pulmonary compliance measured without air flow, such as during an inspiratory pause.			Diagnostic Procedure	
C129958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129958>	C54706	Pulmonary Artery Pressure|PAP	Blood pressure in the pulmonary artery.			Clinical Attribute	
C129959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129959>	C54706	Left Atrial Pressure|LAP|PLA	Blood pressure within the left atrium. It is commonly measured indirectly by a pulmonary capillary wedge pressure.			Clinical Attribute	
C12995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12995>	C33893	Spinal Cord Tract|Ascending and Descending Tracts of Spinal Cord|Spinal Cord Tracts|Tracts of Spinal Cord	White matter in the spinal cord comprising longitudinally oriented nerve fibers (axons) that transmit impulses in both directions: ascending tracts transmit sensory information to the brain from the body, and descending tracts transmit impulses from the brain to the muscles.	Spinal Cord Tract		Body Part, Organ, or Organ Component	
C129960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129960>	C71251	Mixed Venous Oxygen Tension|PvO2	The partial pressure of oxygen in venous blood, representing the balance between oxygen consumption and oxygen delivery.			Laboratory Procedure	
C129961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129961>	C19157	Precipitate	The solid that can be caused to settle out of a solution.			Physical Object	
C129962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129962>	C68780	Solid Phase Microextraction|SPME|Solid Phase Micro Extraction	A sampling technique that uses a polymer-coated fiber to absorb to directly extract and concentrate an analyte from a fluid.			Activity	
C129963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129963>	C112825	Red/Gray Tiger Top Serum Separator Tube	A blood collection tube with a coagulant and a gel, used for serum determinations in chemistry.			Manufactured Object	
C129964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129964>	C113122	Green/Gray Tiger Top Plasma Separation Tube	A blood collection tube with lithium heparin and a gel, used for plasma determinations in chemistry.			Manufactured Object	
C129965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129965>	C113122	Red/Light Gray Tiger Top Secondary Collection Tube|Red/Light Gray Tiger Top Secondary Tube|Red/Light Gray Tiger Top Tube|Tiger Top Secondary Tube	A blood collection tube with no additives, used as a discard tube or secondary specimen tube.			Manufactured Object	
C129966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129966>	C113122	Tiger Top Discard Tube|Discard Tube	A blood collection tube designed to be filled and then thrown away.			Manufactured Object	
C129967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129967>	C96040	Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949|Anti-OX40 Agonist Antibody INCAGN01949|Anti-OX40 Monoclonal Antibody INCAGN0194|INCAGN 1949|INCAGN-1949|INCAGN1949|Monoclonal Antibody INCAGN01949|NCAGN01949	An agonistic human immunoglobulin G1 (IgG1) monoclonal antibody that recognizes the co-stimulatory receptor OX40 (CD134; TNFRSF4), with potential immunostimulatory and antineoplastic activities. Upon administration, agonistic anti-OX40 monoclonal antibody INCAGN01949 selectively binds to and activates OX40 on activated T-cells, thereby potentiating T-cell receptor (TCR) signaling. OX40 activation inhibits regulatory T-cell (Treg)-mediated suppression of effector T-cells, induces the proliferation of memory and effector T-lymphocytes and modulates cytokine production. In the presence of tumor-associated antigens (TAAs), this may promote an immune response against the TAA-expressing tumor cells. In addition, the IgG1 Fc region of INCAGN01949 binds to and co-engages with the IgG Fc-gamma receptor III (FcgammaRIII; CD16) expressed by immune effector cells; thus, binding activates FcgammaRIII-mediated signaling and facilitates the selective depletion of intratumoral Tregs, thereby further enhancing the cytotoxic T-lymphocyte (CTL)-mediated tumor cell response. OX40, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on T-lymphocytes and provides a co-stimulatory signal for the proliferation and survival of activated T-cells; OX40 stimulation abrogates the immunosuppressive tumor microenvironment.	Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C129969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129969>	C133155	CRLF2 Gene Rearrangement|CRLF2 Rearrangement|Cytokine Receptor Crl2 Gene Rearrangement|Cytokine Receptor Like Factor 2 Gene Rearrangement|Cytokine Receptor-Like Factor 2 Gene Rearrangement|TSLPR Gene Rearrangement|Thymic Stromal-Derived Lymphopoietin Receptor Gene Rearrangement	A molecular abnormality indicating rearrangement of the CRLF2 gene.	CRLF2 Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C12996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12996>	C12700	Vestibulocochlear Nerve|Cranial Nerve Eight|Cranial Nerve VIII|Eighth Cranial Nerve|Eighth Cranial Nerve|NERVE, VESTIBULOCOCHLEAR|VESTIBULOCOCHLEAR NERVE|VIIIth Cranial Nerve|Vestibulocochlear nerve structure (body structure)	The eighth cranial nerve composed of the acoustic nerve and the vestibular nerve. The nerve travels from the inner ear, enters the cranial cavity through the internal auditory foramen and joins the brainstem. The auditory nerve conveys impulses from the cochlea of the inner ear to the auditory nuclei of the brainstem. The vestibular nerve carries information from the labyrinths of the inner ear to the vestibular nuclei of the brainstem.	Vestibulocochlear Nerve		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C129970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129970>	C20189	Intrinsic	Relating to the essential qualities or features of something.			Conceptual Entity	
C129971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129971>	C20189	Universal	Present or occurring everywhere or in all things; applicable to all within a particular group.			Conceptual Entity	
C129972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129972>	C169009	HLA Match|HLA Allele Match|HLA Locus Match|HLA Serotype Match|Match|Match	The state when a recipient and their donor have the same alleles for tissue markers. A full match includes HLA-A, HLA-B, HLA-C, and HLA-DRB1. HLA match typing may also include alleles in the HLA-DQ serogroup.			Laboratory or Test Result	ALL Authorized Value Terminology|ALL Stem Cell Transplant Table|AML Authorized Value Terminology|AML Stem Cell Transplant Table
C129973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129973>	C179297	Idiopathic Basal Ganglia Calcification 1|BSPDC|Bilateral Striopallidodentate Calcinosis|IBGC1	An autosomal dominant condition caused by mutation(s) in the SLC20A2 gene, encoding sodium-dependent phosphate transporter 2. It is characterized by calcification of the basal ganglia.			Disease or Syndrome	Cellosaurus Disease Terminology
C129974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129974>	C53543	Inosine Triphosphatase Deficiency	An inherited condition caused by mutation(s) in the ITPA gene, encoding inosine triphosphate pyrophosphatase. It is characterized by elevated concentrations of inosine triphosphate in erythrocytes.			Disease or Syndrome	Cellosaurus Disease Terminology
C129975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129975>	C53543|C34816	Isobutyryl-CoA Dehydrogenase Deficiency	An inherited condition caused by mutation(s) in the ACAD8 gene, encoding isobutyryl-CoA dehydrogenase, mitochondrial. It is characterized by decreased concentrations of carnitine in the blood, encephalopathy, dilated cardiomyopathy, and anemia.			Disease or Syndrome	Cellosaurus Disease Terminology
C129976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129976>	C53543	Kleefstra Syndrome|Chromosome 9q34.3 Deletion Syndrome	A condition caused by mutation or deletion of the EHMT1 gene, encoding histone-lysine N-methyltransferase EHMT1. It is characterized by severe intellectual disability, hypotonia, cardiac defects, and characteristic facial features.			Disease or Syndrome	Cellosaurus Disease Terminology
C129977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129977>	C185235	Mitochondrial DNA Depletion Syndrome 12|MTDPS12	An inherited condition caused by mutation(s) in the SLC25A4 gene, encoding ADP/ATP translocase 1. It is characterized by hypertrophic cardiomyopathy.			Disease or Syndrome	Cellosaurus Disease Terminology
C129978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129978>	C61267	Mucolipidosis Type III Gamma|Mucolipidosis III Gamma	An autosomal recessive condition caused by mutation(s) in the GNPTAG gene, encoding N-acetylglucosamine-1-phosphotransferase subunit gamma. It is characterized by a slowing of the growth rate in childhood, joint stiffness, mild cognitive impairment, and cardiorespiratory insufficiency.			Disease or Syndrome	Cellosaurus Disease Terminology
C129980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129980>	C82892	Neonatal Hemochromatosis	An idiopathic form of neonatal hemochromatosis, characterized by liver failure and iron accumulation in the tissues.			Disease or Syndrome	Cellosaurus Disease Terminology
C129981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129981>	C140267	Spastic Paraplegia 4	An autosomal dominant condition caused by mutation(s) in the SPAST gene, encoding spastin. It is characterized by progressive lower extremity spasticity and weakness.			Disease or Syndrome	Cellosaurus Disease Terminology
C129982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129982>	C82341|C176696	Spinocerebellar Ataxia Type 1|SCA1	An autosomal dominant neurodegenerative disorder caused by mutations in the ATXN1 gene, encoding ataxin-1. It is characterized by progressive cerebellar ataxia, dysarthria and saccadic abnormalities.			Disease or Syndrome	Cellosaurus Disease Terminology
C129983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129983>	C1966	Anti-EGFR Fluorescence Imaging Agent ABY-029|ABY-029|ABY-029 Trifluoroacetate Salt|Fluorescently-labeled Anti-EGFR Affibody Molecule ABY-029|IRDye 800CW Maleimide-labeled Affibody Peptide	A fluorescence imaging and contrast agent composed of an epidermal growth factor receptor (EGFR)-targeting affibody tracer molecule and labeled, through maleimide, with a near-infrared (NIR) fluorescent probe, IRDye 800CW, with potential use in the imaging of EGFR-overexpressing cells. Upon administration, ABY-029 targets and binds to EGFR-overexpressing tumor cells. Upon fluorescent imaging, the fluorescent dye can be visualized and EGFR-positive tumor cells can be detected.			Indicator, Reagent, or Diagnostic Aid	NCI Drug Dictionary Terminology
C129984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129984>	C78275	Truncated Tissue Factor/NGR Peptide|tTF-NGR	A vascular-targeting agent composed of the extracellular domain of the trunctated form of issue factor (tTF) conjugated to the C-terminal peptide GNGRAHA (NGR), with potential procoagulatory and antineoplastic activities. Upon administration, the NGR peptide moiety of tTF-NGR targets and binds to the surface protein aminopeptidase N (CD13) expressed on endothelial cells in tumor vessels. Upon deamidation of the NGR peptide moiety, this agent also binds to integrin alphaVbeta3 (aVb3; CD51/CD61) in the tumor vasculature. In turn, the tTF causes occlusion of the tumor blood vessels, which causes an inhibition of blood supply and flow in the tumor, nutrition and induced tumor cell death and an inhibition of tumor cell proliferation. TF plays a key role in the coagulation cascade. NGR is a asparagine-glycine-arginine containing peptide and ligand of CD13. Both aVb3 and CD13 are surface proteins that are upregulated on endothelial cells of tumor vessels.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C129985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129985>	C222260	Activity Card Sort|ACS|Activity Card Sort (ACS)	An assessment tool developed to measure levels of activity engagement in older adults. Participants sort cards depicting people engaged in various activities into categories representing whether the activity is part of the individual's routine.			Intellectual Product	
C129986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129986>	C1907	Traditional Chinese Medicine Formulation|Chinese Medicinal Formulation|Pharmaceutical TCM Preparation|TCM Formula|TCM Formulation|TCM Preparation|TCM Product|TCM-based Pharmaceutical Preparation	Any pharmaceutical formulation that contains agents used in traditional Chinese medicine (TCM).			Chemical Viewed Functionally	
C129987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129987>	C62289	Instrumental Activities Domain|Instrumental|Instrumental Activities	A domain of the Activity Card Sort (ACS) related to crucial activities that may be part of an individual's routine such as driving, paying bills, and child care.			Functional Concept	Activity Card Sort
C129988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129988>	C129986	Yi Qi Fang|TCM YiQiFang|Traditional Chinese Medicine Yi Qi Fang|Traditional Chinese Medicine YiQiFang|Yi-Qi-Fang|YiQiFang	A traditional Chinese medicine (TCM) based that may benefit Qi and Yin, and may help with the detoxification process.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C129989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129989>	C62289	Low-Demand Leisure Activities Domain|Low-Demand Leisure Activities	A domain of the Activity Card Sort (ACS) related to low-physical-demand leisure activities that may be part of an individual's routine such as puzzles, quilting, and photography.			Functional Concept	Activity Card Sort
C12998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12998>	C34076	Vertebral Column|SPINAL COLUMN|Spinal Column|Spinal Column|Spine|Spine|Spine|Spine|Spine|VERTEBRAL COLUMN|Vertebral column|backbone|spinal column|spine|vertebral column|vertebral column	A series of bones, muscles, tendons, and other tissues reaching from the base of the skull to the tailbone. The vertebral column forms the axis of the skeleton and encloses as well as protects the spinal cord and the fluid surrounding the spinal cord.	Spine		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF5 Response Evaluation Image Evaluation Table|CRF6 DMG Imaging Assessment Table|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Radiation Therapy Table|EWS Tumor Assessment Table|GCT Authorized Value Terminology|GCT Tumor Assessment Table|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C129990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129990>	C62289	High-Demand Leisure Activities Domain|High-Demand Leisure Activities	A domain of the Activity Card Sort (ACS) related to high physical demand leisure activities that may be part of an individual's routine such as bicycling, woodworking, and hiking.			Functional Concept	Activity Card Sort
C129991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129991>	C62289	Social Activities Domain|Social Activities	A domain of the Activity Card Sort (ACS) related to social activities that may be part of an individual's routine such as volunteer work, visiting with friends, and traveling.			Functional Concept	Activity Card Sort
C129993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129993>	C129986	Yang Yin Fang|TCM Yang Yin Fang|Traditional Chinese Medicine Yang Yin Fang|Yang-Yin-Fang	A traditional Chinese medicine (TCM) based formulated may benefit Qi and Yin, and may help with the detoxification process.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C129994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129994>	C173045	Ability to Get In and Out of Bed Question|Ability to Get In and Out of Bed|Get in and out of bed	A question about the ability of an individual to get in and out of bed.			Intellectual Product	Health Assessment Questionnaire Disability Index
C129995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129995>	C173045	Ability to Cut Meat Question|Ability to Cut Meat|Cut your own meat	A question about the ability of an individual to cut their own meat.			Intellectual Product	Health Assessment Questionnaire Disability Index
C129996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129996>	C129986	Yi Qi Yang Yin Fang|TCM Yi-qi-yang-yin Fang|Traditional Chinese Medicine Yi-qi-yang-yin Fang|Yi-qi-yang-yin Fang|YiQiYangYinFang	A traditional Chinese medicine (TCM)-based formulation that may benefit Qi, and boost Yin.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C129997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129997>	C173045	Ability to Lift a Full Cup or Glass to Mouth Question|Ability to Lift a Full Cup or Glass to Mouth|Lift a full cup or glass to your mouth	A question about the ability of an individual to lift a full cup or glass to their mouth.			Intellectual Product	Health Assessment Questionnaire Disability Index
C129998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129998>	C173045	Ability to Open New Milk Carton Question|Ability to Open New Milk Carton|Open a new milk carton	A question about the ability of an individual to open a new milk carton.			Intellectual Product	Health Assessment Questionnaire Disability Index
C129999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129999>	C173082	Ability to Climb 5 Steps Question|Ability to Climb 5 Steps|Climb up five steps	A question about the ability of an individual to climb five steps.			Intellectual Product	Health Assessment Questionnaire Disability Index
C12999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C12999>	C12426	Major Salivary Gland|Major salivary gland, NOS|major salivary gland	One of the three larger salivary glands including the parotid, submandibular and sublingual glands.	Major Salivary Gland, NOS		Body Part, Organ, or Organ Component	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C1299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1299>	C1420	Disulfonated Aluminum Phthalocyanine|AlS2Pc|Aluminum Phthalocyanine Disulfonate	An amphiphilic compound that exhibits a direct phototoxic effect, thereby inducing tumor necrosis. (NCI)			Organic Chemical|Pharmacologic Substance	
C130000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130000>	C176021	Use Aid or Device for Activity Question|Aids or devices that you usually use for activities|Use Aid or Device for Activity	A question about an individual's use of equipment to assist with activities.			Intellectual Product	Health Assessment Questionnaire Disability Index
C130001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130001>	C213665|C129825	BTK Inhibitor DTRMWXHS-12|DTRMWXHS 12|DTRMWXHS-12	An orally available inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), with potential antineoplastic activity. Upon administration, DTRMWXHS-12 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.	BTK Inhibitor DTRMWXHS-12		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C130002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130002>	C178350	Need Help from Another Person Question|Categories for which you usually need help from another person|Need Help from Another Person	A question about an individual's need of help from another person to assist with activities.			Intellectual Product	Health Assessment Questionnaire Disability Index
C130003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130003>	C131925	Ability to Take a Tub Bath Question|Ability to Take a Tub Bath|Take a tub bath	A question about the ability of an individual to take a bath in a tub.			Intellectual Product	Health Assessment Questionnaire Disability Index
C130004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130004>	C173045	Ability to Reach and Get Down 5 Pound Object From Above Head Question|Ability to Reach and Get Down 5 Pound Object From Above Head|Reach and get down a 5 pound object (such as a bag of sugar) from above your head	A question about the ability of an individual to reach and get down a 5 pound object (such as a bag of sugar) from above their head.			Intellectual Product	Health Assessment Questionnaire Disability Index
C130005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130005>	C173045	Ability to Bend Down to Pick up Clothing from the Floor Question|Ability to Bend Down to Pick up Clothing from the Floor|Bend down to pick up clothing from the floor	A question about the ability of an individual to bend down to pick up clothing from the floor.			Intellectual Product	Health Assessment Questionnaire Disability Index
C130006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130006>	C173045	Ability to Open Car Door Question|Ability to Open Car Door|Open car doors	A question about the ability of an individual to open a car door.			Intellectual Product	Health Assessment Questionnaire Disability Index
C130007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130007>	C173045	Ability to Open Previously Opened Jar Question|Ability to Open Previously Opened Jar|Open previously opened jars	A question about the ability of an individual to open a jar that was previously opened.			Intellectual Product	Health Assessment Questionnaire Disability Index
C130008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130008>	C173045	Ability to Turn Faucets On and Off Question|Ability to Turn Faucets On and Off|Turn faucets on and off	A question about the ability of an individual to turn faucets on and off.			Intellectual Product	Health Assessment Questionnaire Disability Index
C130009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130009>	C91102	How Well Doing Health Rating Question|How Well Doing Health Rating|Rate how well you are doing regarding your health	A question about how well an individual is doing as related to their health.			Intellectual Product	Health Assessment Questionnaire Disability Index
C13000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13000>	C12612	Rhabdomyocyte	A large cylindrical- or prismatic-shaped cell that is the basic unit of striated muscle tissue.	Rhabdomyocyte		Cell	
C130010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130010>	C28227|C155711	Zanidatamab|Anti-HER2/HER2 Bispecific Antibody ZW25|HER2 x HER2 Bispecific Antibody ZW25|ZANIDATAMAB|ZW-25|ZW25|Zanidatamab-hrii|Ziihera	An engineered immunoglobulin G1 (IgG1) bi-specific monoclonal antibody that targets two different non-overlapping epitopes of the human tumor-associated antigen (TAA) epidermal growth factor receptor 2 (HER2), ECD2 and ECD4, with potential immunomodulating and antineoplastic activities. Upon administration, zanidatamab targets and binds to the two distinct HER2 domains on the tumor cell surface. This results in dual HER2 signal blockade, HER2 clustering, receptor internalization and downregulation. This also induces a cytotoxic T-lymphocyte (CTL) response and antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER2. Antibody-dependent cellular phagocytosis (ADCP) is also induced and further stimulates the immune system to kill HER2-overexpressing tumor cells. The HER2 receptor internalization also further inhibits HER2 activation, HER2-mediated signaling and HER2-mediated tumor cell growth. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.	Zanidatamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C130012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130012>	C471	Oxidative Phosphorylation Inhibitor IACS-010759|IACS-010759|IACS-010759|OXPHOS Inhibitor IACS-010759	An orally bioavailable oxidative phosphorylation (OxPhos) inhibitor, with potential antineoplastic activity. Upon administration of the OxPhos inhibitor IACS-010759, this agent binds to and inhibits complex I of the electron transport chain (NADH ubiquinone oxidoreductase), thereby selectively depriving tumor cells of nutrients, and energy, and inhibiting nucleotide and amino acid production, which induces autophagy, causes tumor cell death and inhibits cell proliferation. Mitochondrial complex I, which is hyperactivated in cancer cells to meet their increased demands for energy, plays a key role in the promotion of cancer cell proliferation.	Oxidative Phosphorylation Inhibitor IACS-010759		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C130013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130013>	C173160	Feel Fit Question|Feel Fit|I feel fit	A question about whether an individual feels or felt fit.			Intellectual Product	Multidimensional Fatigue Inventory
C130014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130014>	C2124	Carbon C 11 Metformin|11C-metformin|Carbon-11 Metformin|METFORMIN C-11|[11C]-metformin	A radiopharmaceutical tracer containing the anti-diabetic agent metformin, a biguanide and hydrophilic organic cation, and labeled with carbon 11 (11C), used to measure metformin uptake by cancer cells using positron emission tomography (PET). Upon administration of carbon C 11 metformin, the metformin moiety targets and binds to cancer cells; in turn, the compound is taken up by cancer cells. Upon PET, metformin distribution into cancer cells can be visualized, which allows for a prediction of the anti-cancer efficacy of metformin, based on tumor cell uptake. Metformin transport, such as uptake into cancer cells, appears to be correlated with the expression of organic cation transporters (OCT) 1-3, multidrug and toxin extrusion (MATE) 1 and 2, and plasma membrane monoamine transporter (PMAT). OCTs, MATEs and PMAT play a key role in the distribution and excretion of organic cationic compounds.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C130015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130015>	C173219|C173045	Feel Physically Able to Only Do a Little Question|Feel Physically Able to Only Do a Little|Physically I feel only able to do a little	A question about whether an individual physically feels or felt able to do a little.			Intellectual Product	Multidimensional Fatigue Inventory
C130016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130016>	C173219	Feel Very Active Question|Feel Very Active|I feel very active	A question about whether an individual feels or felt very active.			Intellectual Product	Multidimensional Fatigue Inventory
C130017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130017>	C173160	Feel Like Doing All Sorts of Nice Things Question|Feel Like Doing All Sorts of Nice Things|I feel like doing all sorts of nice things	A question about whether an individual feels or felt like doing all sorts of nice things.			Intellectual Product	Multidimensional Fatigue Inventory
C130018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130018>	C173597	Do a Lot in a Day Question|Do a Lot in a Day|I think I do a lot in a day	A question about whether an individual thinks or thought they do a lot in a day.			Intellectual Product	Multidimensional Fatigue Inventory
C130019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130019>	C173597	When Doing Something Can Keep Thoughts on It Question|When Doing Something Can Keep Thoughts on It|When I am doing something, I can keep my thoughts on it	A question about whether an individual, when they are doing something, can keep their thoughts on it.			Intellectual Product	Multidimensional Fatigue Inventory
C13001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13001>	C12612	Smooth Muscle Cell|Leiomyocyte|Smooth Muscle Tissue Cell	An elongated spindle-shaped contractile cell, peculiar to an involuntary muscle, containing a single nucleus and longitudinally arranged myofibrils.	Leiomyocyte		Cell	
C130020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130020>	C2124	Carbon C 13 Idasanutlin|C13 Idasanutlin|[13C]-radiolabeled Idasanutlin	A radiopharmaceutical agent composed of an orally available, small-molecule antagonist of MDM2 (mouse double minute 2; Mdm2 p53 binding protein homolog), and labeled with the radioisotope carbon C 13, with potential use for evaluating the distribution patterns, metabolism and excretion of idasanutlin using nuclear magnetic resonance (NMR) spectroscopy. Upon administration, idasanutlin binds to MDM2 blocking the interaction between the MDM2 protein and the transcriptional activation domain of the tumor suppressor protein p53. By preventing the MDM2-p53 interaction, p53 is not enzymatically degraded and the transcriptional activity of p53 is restored. This may lead to p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger nuclear phosphoprotein and negative regulator of the p53 pathway, is often overexpressed in cancer cells and has been implicated in cancer cell proliferation and survival. . Labeling of idasanutlin with the radioactive tracer carbon C 13 permits the evaluation of idasanutlin's distribution patterns, including binding to and uptake by tumors, metabolism and excretion. This may aid in the understanding of the bioactivity of this agent.			Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	NCI Drug Dictionary Terminology
C130021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130021>	C91102	Physically Can Take on a Lot Question|Can Take on a Lot Physically|Physically Can Take on a Lot|Physically I can take on a lot	A question about whether an individual physically can take on a lot.			Intellectual Product	Multidimensional Fatigue Inventory
C130022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130022>	C91102	Dread Having to do Things Question|Dread Having to do Things|I dread having to do things	A question about whether an individual dreads or dreaded having to do things.			Intellectual Product	Multidimensional Fatigue Inventory
C130023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130023>	C173597	Do Very Little in a Day Question|Do Very Little in a Day|I think I do very little in a day	A question about whether an individual thinks or thought they do very little in a day.			Intellectual Product	Multidimensional Fatigue Inventory
C130024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130024>	C2124	Carbon C 14 Idasanutlin|C14 Idasanutlin|[14C]-radiolabeled Idasanutlin	A radiopharmaceutical agent composed of an orally available, small-molecule antagonist of MDM2 (mouse double minute 2; Mdm2 p53 binding protein homolog), and labeled with the radioisotope carbon C 14, with potential use for evaluating the pharmacokinetics of idasanutlin. Upon oral administration, idasanutlin binds to MDM2 blocking the interaction between the MDM2 protein and the transcriptional activation domain of the tumor suppressor protein p53. By preventing the MDM2-p53 interaction, p53 is not enzymatically degraded and the transcriptional activity of p53 is restored. This may lead to p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger nuclear phosphoprotein and negative regulator of the p53 pathway, is often overexpressed in cancer cells and has been implicated in cancer cell proliferation and survival. . Labeling of idasanutlin with the radioactive tracer carbon C 14 permits the evaluation of idasanutlin's pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME).			Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	NCI Drug Dictionary Terminology
C130025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130025>	C91102	Am Rested Question|Am Rested|I am rested	A question about whether an individual is or was rested.			Intellectual Product	Multidimensional Fatigue Inventory
C130026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130026>	C91102	Takes a Lot of Effort to Concentrate on Things Question|It takes a lot of effort to concentrate on things|Takes a Lot of Effort to Concentrate on Things	A question about whether an individual takes a lot of effort to concentrate on things.			Intellectual Product	Multidimensional Fatigue Inventory
C130027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130027>	C173219	Physically Feel in Bad Condition Question|Feel in Bad Condition Physically|Physically Feel in Bad Condition|Physically I feel I am in a bad condition	A question about whether an individual physically feels or felt in bad condition.			Intellectual Product	Multidimensional Fatigue Inventory
C130028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130028>	C91102	Have Lots of Plans Question|Have Lots of Plans|I have a lot of plans	A question about whether an individual has or had lots of plans.			Intellectual Product	Multidimensional Fatigue Inventory
C130029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130029>	C308	Anti-inflammatory/Antimicrobial/Analgesic Aqueous Mouth Rinse|Dentoxol|Dentoxol Mouthrinse	A water-based proprietary mouthwash with anti-inflammatory, antimicrobial and analgesic activities. Upon rinsing with this mouthwash, the unspecified ingredients may help prevent or reduce the symptoms and severity of mucositis.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C13002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13002>	C33637	Cardiomyocyte|Cardiocyte|Heart Muscle Cell	A muscle cell in heart tissue (myocardium).	Cardiomyocyte		Cell	
C130030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130030>	C91102	Get Little Done Question|Get Little Done|I get little done	A question about whether an individual gets or got little done.			Intellectual Product	Multidimensional Fatigue Inventory
C130031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130031>	C173160	Don't Feel Like Doing Anything Question|Don't Feel Like Doing Anything|I don't feel like doing anything	A question about whether an individual doesn't feel like doing anything.			Intellectual Product	Multidimensional Fatigue Inventory
C130032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130032>	C173597	Thoughts Easily Wander Question|My thoughts easily wander|Thoughts Easily Wander|Thoughts Wander Easily	A question about whether an individual's thoughts easily wander.			Intellectual Product	Multidimensional Fatigue Inventory
C130033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130033>	C155700	Vamotinib|Bcr-Abl Inhibitor PF-114|Bcr-Abl Kinase Inhibitor PF-114|PF-114|VAMOTINIB	An orally bioavailable, Bcr-Abl tyrosine kinase inhibitor, with potential antineoplastic activity. Designed to overcome resistance of tumor cells to second generation Bcr-Abl inhibitors, vamotinib targets and binds to the Bcr-Abl fusion oncoprotein, including those fusion proteins with the 'gatekeeper' resistance mutation T315I, an amino acid substitution at position 315 in Bcr-Abl from a threonine (T) to an isoleucine (I). This inhibits Bcr-Abl-mediated proliferation of, and enhances apoptosis in, Philadelphia chromosome-positive (Ph+) hematologic malignancies. The Bcr-Abl fusion protein is an aberrantly activated tyrosine kinase produced by leukemia cells that contain the Philadelphia chromosome.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C130034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130034>	C173219	Physically Feel in Excellent Condition Question|Feel in Excellent Condition Physically|Physically Feel in Excellent Condition|Physically I feel I am in an excellent condition	A question about whether an individual physically feels or felt in excellent condition.			Intellectual Product	Multidimensional Fatigue Inventory
C130035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130035>	C3178	Chronic Myelomonocytic Leukemia-0|CMML-0	A chronic myelomonocytic leukemia characterized by the presence of less than 5 percent blasts in the bone marrow and less than 2 percent blasts in the peripheral blood.			Neoplastic Process	
C130036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130036>	C146993	Proxalutamide|GT-0918|GT0918|PRUXELUTAMIDE	An orally bioavailable androgen receptor (AR) antagonist with potential antineoplastic activity. Upon oral administration, proxalutamide binds to AR in target tissues, inhibits androgen-induced receptor activation, and facilitates the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes that regulate prostate cancer cell proliferation. In addition, proxalutamide induces AR downregulation, thereby further preventing AR-mediated signaling. This ultimately leads to an inhibition of growth in AR-expressing prostate cancer cells. AR is overexpressed in prostate cancer and plays a key role in prostate cancer cell proliferation.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C130037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130037>	C4036	Myelodysplastic Syndrome with Ring Sideroblasts and Single Lineage Dysplasia|MDS-RS-SLD	A myelodysplastic syndrome with ring sideroblasts and dysplastic changes involving only one myeloid cell lineage in the bone marrow.			Neoplastic Process	Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C130038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130038>	C9479|C198663	Hematologic Neoplasm with Germline Predisposition|Myeloid Neoplasm Associated with Germline Predisposition|Myeloid Neoplasm with Germline Predisposition	A term that refers to myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms, and acute myeloid leukemias that are associated with germline mutations and are familial.			Neoplastic Process	
C130039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130039>	C80328	B Lymphoblastic Leukemia/Lymphoma with Intrachromosomal Amplification of Chromosome 21|B Lymphoblastic Leukemia/Lymphoma with iAMP21|B-Lymphoblastic Leukemia/Lymphoma with Intrachromosomal Amplification of Chromosome 21|B-Lymphoblastic Leukemia/Lymphoma with iAMP21	B lymphoblastic leukemia/lymphoma characterized by amplification of a portion of chromosome 21. It usually occurs in children and is associated with an adverse prognosis.			Neoplastic Process	
C13003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13003>	C12615	Ependymal Cell|Ependymal Cells|Ependymocyte|ependymal cell	A cell that lines cavities in the central nervous system.  It is considered to be a type of glial cell.	Ependymocyte		Cell	
C130040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130040>	C199202|C130039	B Acute Lymphoblastic Leukemia with Intrachromosomal Amplification of Chromosome 21|B Acute Lymphoblastic Leukemia with iAMP21|B-ALL with iAMP21|B-Acute Lymphoblastic Leukemia with Intrachromosomal Amplification of Chromosome 21	B acute lymphoblastic leukemia characterized by amplification of a portion of chromosome 21. It usually occurs in children and is associated with an adverse prognosis.			Neoplastic Process	
C130041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130041>	C7764|C179053	Indolent T-Lymphoblastic Proliferation	A non-neoplastic T-cell lymphoproliferation that may mimic T-lymphoblastic lymphoma. It usually involves the lymphoid tissues of the upper aerodigestive tract. It recurs locally, but systemic dissemination is rare.			Disease or Syndrome	
C130042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130042>	C18467	Contrast Enhanced Digital Mammography|CEDM|Contrast Enhanced Spectral Mammography|Contrast-Enhanced Digital Mammography	A digital mammography technique that incorporates the administration of an iodinated contrast agent to enhance lesions that are not visible on standard mammograms.	Contrast Enhanced Digital Mammography		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C130043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130043>	C3183|C199170	Early T Precursor Acute Lymphoblastic Leukemia|ETP ALL|ETP-ALL|Early T Acute Lymphoblastic Leukemia|Early T Acute Lymphoblastic Leukemia|Early T-Acute Lymphoblastic Leukemia|Early T-Cell Precursor Acute Lymphoblastic Leukemia|Early T-Cell Precursor Lymphoblastic Leukemia|Early T-Precursor Acute Lymphoblastic Leukemia	A T acute lymphoblastic leukemia in which the blasts have unique immunophenotypic and genetic characteristics suggesting only limited early T-cell differentiation.			Neoplastic Process	Cellosaurus Disease Terminology
C130044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130044>	C40998	Limited Early T-Cell Differentiation	A finding indicating the presence of neoplastic cells with immunophenotypic and genetic characteristics suggesting limited early T-cell differentiation.			Laboratory or Test Result	
C130045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130045>	C25571	Ultrasound Mode|ULTRMODE	The type of ultrasound image that is being recorded on any ultrasound-based device. Examples include 2-dimensional mode, tissue Doppler mode, or motion mode.			Phenomenon or Process	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130046>	C48572	Ejaculate Unit|Ejaculate U|{Ejaculate U}|{Ejaculate U}	A unit of volume equal to the amount of seminal fluid produced by a single ejaculation event.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130047>	C13023	Tricuspid Valve Annulus|TRICUSPID VALVE ANNULUS	A fibrous membrane that attaches to, and provides support for, the tricuspid valve leaflets.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130048>	C36235	Multilineage Dysplasia Present	A hematologic test result indicating dysplastic changes in two or more of the myeloid cell lineages in the bone marrow.			Laboratory or Test Result	
C130049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130049>	C107589	Burixafor Hydrobromide|Burixafor HBr|TG-0054 HBr|TG-0054 Hydrobromide	The hydrobromide salt form of burixafor, an orally bioavailable inhibitor of CXC chemokine receptor 4 (CXCR4) with hematopoietic stem cell (HSC)-mobilization and chemosensitizing activities. Upon administration, burixafor binds to the chemokine receptor CXCR4, thereby preventing the binding of stromal cell-derived factor-1 (SDF-1 or CXCL12) to the CXCR4 receptor and subsequent receptor activation. This may induce the mobilization of hematopoietic stem and progenitor cells from the bone marrow into the peripheral circulation. Additionally, burixafor-mediated mobilization of disseminated tumor cells (DTCs) from the bone marrow into the blood may make these metastatic tumor cells more susceptible to the actions of chemotherapeutic agents. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types. CXCL12/CXCR4 interaction induces retention of hematopoietic cells in the bone marrow.	Burixafor Hydrobromide		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C13004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13004>	C13023	Endocardium|ENDOCARDIUM|Endocardial	The layer of endothelial cells and connective tissue lining the chambers of the heart.	Endocardium		Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C130050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130050>	C200711	Plamotamab|PLAMOTAMAB|XmAb13676	A bispecific, Fc domain-containing, monoclonal antibody with potential antineoplastic activity. Plamotamab contains two antigen-recognition sites: one for human CD3, a T cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, plamotamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells. Inclusion of an Fc domain on the antibody prolongs the half-life of the bispecific antibody and enhances T-cell-mediated tumor cell killing because the agent is able to bind to Fc receptors.	Plamotamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C130051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130051>	C38081	Airway Plateau Pressure|Inspiratory Pause Pressure|Plateau Pressure|Pplat	The static pressure of the entire respiratory system during inspiratory pause. It reflects the elastic retraction of the entire respiratory system.			Diagnostic Procedure	
C130052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130052>	C198996	Accidental Association|ACCIDENTAL ASSOCIATE	A person whose association to an individual is unintentional.			Human	CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130053>	C198996	Biologically Unrelated|BIOLOGICALLY UNRELATED	A person who is biologically unrelated to another individual.			Human	ALL Authorized Value Terminology|ALL Stem Cell Transplant Table|AML Authorized Value Terminology|AML Stem Cell Transplant Table|CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|HL Authorized Value Terminology|HL Stem Cell Transplant Table
C130054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130054>	C48284	Kidney Donor|DONOR, KIDNEY	Someone from whom one or more kidneys are removed for transplantation or other purpose.			Organism	CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130055>	C181043	Inferior Vena Cava Collapse Due to Sniff Test Indicator|IVCCSIND|Inferior Vena Cava Collapse Indicator|Inferior Vena Cava Collapse Sniff Ind|Inferior Vena Cava Collapse Sniff Ind	An indication as to whether resting inferior vena cava diameter is reduced with sniff, which is defined as a sharp inhalation.			Qualitative Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130056>	C54706	Estimated Mean Atrial Pressure	The estimated arithmetic average of atrial pressure.			Quantitative Concept	
C130057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130057>	C25337	Number of Events|EVENTNUM|EVENTNUM	A measurement of the total number of events that have occurred.			Quantitative Concept	CDISC SDTM Diabetic Kidney Findings About Test Code Terminology|CDISC SDTM Diabetic Kidney Findings About Test Name Terminology|CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|HL Authorized Value Terminology|HL Immunohistochemistry Table
C130058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130058>	C130045	2-Dimensional Biplane Ultrasound Mode|2-DIMENSIONAL BIPLANE MODE	A method of ultrasound imaging that uses a probe with two 2D planes set perpendicularly to each other, allowing for better detection and localization of objects/structures.	2-Dimensional Biplane Ultrasound Mode		Functional Concept	CDISC SDTM Device-In-Use Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C130059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130059>	C130045	2-Dimensional Single Plane Ultrasound Mode|2-DIMENSIONAL SINGLE PLANE MODE	A method of ultrasound imaging that uses a linear pattern of beams to produce a standard, two dimensional image.			Functional Concept	CDISC SDTM Device-In-Use Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13005>	C13169	Pericardium|Human Pericardium|PERICARDIUM|Pericardial structure (body structure)|pericardium	A conical membranous sac filled with serous fluid in which the heart as well as the roots of the aorta and other large blood vessels are contained.	Pericardium		Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTDC Value Terminology|FDA Structured Product Labeling Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|SPL Tissue Form Product Type Terminology|UBERON Terminology
C130060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130060>	C130045	3-Dimensional Ultrasound Mode|3-DIMENSIONAL MODE	A method of ultrasound imaging that allows for the construction of three dimensional images of a given object/structure.			Functional Concept	CDISC SDTM Device-In-Use Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130061>	C130045	Color Tissue Doppler Ultrasound Mode|COLOR TISSUE DOPPLER MODE|Color Flow Tissue Doppler Mode	A method of ultrasound imaging that uses pulsed wave Doppler signals to depict tissue motion direction and velocity in color images that are superimposed over normal, 2D images.			Functional Concept	CDISC SDTM Device-In-Use Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130062>	C130045	Continuous-Wave Doppler Ultrasound Mode|CONTINUOUS-WAVE DOPPLER MODE|CW Doppler|Continuous Doppler Mode	A method of ultrasound imaging that uses Doppler signals that are continuously sent and received along a single line to measure both direction and velocity of blood flow.			Functional Concept	CDISC SDTM Device-In-Use Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130063>	C130045	M-Mode Ultrasound Mode|M-MODE|Motion Mode	A method of ultrasound imaging that uses a single ultrasound beam to provide high temporal resolution of tissue motion.			Functional Concept	CDISC SDTM Device-In-Use Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130064>	C130045	Pulsed-Wave Doppler Ultrasound Mode|PULSED-WAVE DOPPLER MODE|PW Doppler|Pulsed Doppler Mode	A method of ultrasound imaging that uses intermittent Doppler signals to measure both direction and velocity of blood flow.			Functional Concept	CDISC SDTM Device-In-Use Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130065>	C130045	Pulsed-Wave Tissue Doppler Ultrasound Mode|PULSED-WAVE TISSUE DOPPLER MODE|Pulsed Tissue Doppler Mode	A method of ultrasound imaging that uses pulsed wave Doppler signals to measure velocities of tissue movement.			Functional Concept	CDISC SDTM Device-In-Use Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130066>	C130045	Tissue Doppler Ultrasound Mode|TISSUE DOPPLER MODE	A method of ultrasound imaging that uses intermittent Doppler signals to measure velocities of tissue movement.			Functional Concept	CDISC SDTM Device-In-Use Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130067>	C71076	Voltage Criteria Suggesting Left Ventricular Hypertrophy, Without Secondary ECG Findings|VOLTAGE CRITERIA SUGGESTING LEFT VENTRICULAR HYPERTROPHY, WITHOUT SECONDARY ECG FINDINGS	An electrocardiographic finding of large QRS amplitudes that may indicate left ventricular hypertrophy, but is without any of the secondary findings that are typically seen with this diagnosis: left atrial enlargement, left axis deviation, or typical pattern of ST depression and T wave inversion.			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130068>	C181398	Bermuda Grass Pollen IgE Measurement	A measurement of the Bermuda grass (Cynodon dactylon) pollen IgE in a biological specimen.			Laboratory Procedure	
C130069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130069>	C81969|C182150	Bermuda Grass Pollen IgA Measurement	A measurement of the Bermuda grass (Cynodon dactylon) pollen IgA in a biological specimen.			Laboratory Procedure	
C13006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13006>	C12578	Specialized Epithelial Cell|Specialized Epithelial Cells	A cell that covers the surface of the body and lines its cavities that has a specific function to perform.	Specialized Epithelial Cell		Cell	
C130070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130070>	C81971|C182150	Bermuda Grass Pollen IgG Measurement	A measurement of the Bermuda grass (Cynodon dactylon) pollen IgG in a biological specimen.			Laboratory Procedure	
C130071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130071>	C130070|C122130	Bermuda Grass Pollen IgG4 Measurement	A measurement of the Bermuda grass (Cynodon dactylon) pollen IgG4 in a biological specimen.			Laboratory Procedure	
C130072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130072>	C181398	Birch Pollen IgE Measurement	A measurement of the birch pollen IgE in a biological specimen.			Laboratory Procedure	
C130073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130073>	C81969|C182150	Birch Pollen IgA Measurement	A measurement of the birch pollen IgA in a biological specimen.			Laboratory Procedure	
C130074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130074>	C81971|C182150	Birch Pollen IgG Measurement	A measurement of the birch pollen IgG in a biological specimen.			Laboratory Procedure	
C130075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130075>	C130074|C122130	Birch Pollen IgG4 Measurement	A measurement of the birch pollen IgG4 in a biological specimen.			Laboratory Procedure	
C130076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130076>	C181398	Silver Birch Pollen IgE Measurement	A measurement of the silver birch pollen IgE in a biological specimen.			Laboratory Procedure	
C130077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130077>	C81969|C182150	Silver Birch Pollen IgA Measurement	A measurement of the silver birch pollen IgA in a biological specimen.			Laboratory Procedure	
C130078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130078>	C81971|C182150	Silver Birch Pollen IgG Measurement	A measurement of the silver birch pollen IgG in a biological specimen.			Laboratory Procedure	
C130079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130079>	C130078|C122130	Silver Birch Pollen IgG4 Measurement	A measurement of the silver birch pollen IgG4 in a biological specimen.			Laboratory Procedure	
C130080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130080>	C181398	Orchard Grass Pollen IgE Measurement	A measurement of the orchard grass (Dactylis glomerata) pollen IgE in a biological specimen.			Laboratory Procedure	
C130081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130081>	C81969|C182150	Orchard Grass Pollen IgA Measurement	A measurement of the orchard grass (Dactylis glomerata) pollen IgA in a biological specimen.			Laboratory Procedure	
C130082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130082>	C81971|C182150	Orchard Grass Pollen IgG Measurement	A measurement of the orchard grass (Dactylis glomerata) pollen IgG in a biological specimen.			Laboratory Procedure	
C130083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130083>	C130082|C122130	Orchard Grass Pollen IgG4 Measurement	A measurement of the orchard grass (Dactylis glomerata) pollen IgG4 in a biological specimen.			Laboratory Procedure	
C130084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130084>	C181398	English Plantain Pollen IgE Measurement	A measurement of the English plantain (Plantago lanceolata) pollen IgE in a biological specimen.			Laboratory Procedure	
C130085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130085>	C81969|C182150	English Plantain Pollen IgA Measurement	A measurement of the English plantain (Plantago lanceolata) pollen IgA in a biological specimen.			Laboratory Procedure	
C130086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130086>	C81971|C182150	English Plantain Pollen IgG Measurement	A measurement of the English plantain (Plantago lanceolata) pollen IgG in a biological specimen.			Laboratory Procedure	
C130087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130087>	C130086|C122130	English Plantain Pollen IgG4 Measurement	A measurement of the English plantain (Plantago lanceolata) pollen IgG4 in a biological specimen.			Laboratory Procedure	
C130088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130088>	C181398	Timothy Grass Pollen IgE Measurement	A measurement of the Timothy grass (Phleum pretense) pollen IgE in a biological specimen.			Laboratory Procedure	
C130089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130089>	C81969|C182150	Timothy Grass Pollen IgA Measurement	A measurement of the Timothy grass (Phleum pretense) pollen IgA in a biological specimen.			Laboratory Procedure	
C13008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13008>	C28676	Lymphokine-Activated Killer Cells|Cells, LAK|LAK Cells|LAK cell|Lymphokine Activated Killer Cell|Therapeutic Lymphokine-Activated Killer Cells|lymphokine-activated killer cell	Killer cell lymphocytes activated in the presence of interleukin-2 (IL-2).  Lymphokine-activated killer cells (LAKs) are cytotoxic effector cells with an exceptionally wide target cell spectrum including normal and malignant cells of different origins.  LAK cells exhibit a profound heterogeneity with regard to phenotype surface marker expression; it remains to be determined if they represent a unique cell lineage.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology
C130090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130090>	C81971|C182150	Timothy Grass Pollen IgG Measurement	A measurement of the Timothy grass (Phleum pretense) pollen IgG in a biological specimen.			Laboratory Procedure	
C130091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130091>	C130090|C122130	Timothy Grass Pollen IgG4 Measurement	A measurement of the Timothy grass (Phleum pretense) pollen IgG4 in a biological specimen.			Laboratory Procedure	
C130092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130092>	C181398	Western Ragweed Pollen IgE Measurement	A measurement of the western ragweed (Ambrosia psilostachya) pollen IgE in a biological specimen.			Laboratory Procedure	
C130093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130093>	C81969|C182150	Western Ragweed Pollen IgA Measurement	A measurement of the western ragweed (Ambrosia psilostachya) pollen IgA in a biological specimen.			Laboratory Procedure	
C130094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130094>	C81971|C182150	Western Ragweed Pollen IgG Measurement	A measurement of the western ragweed (Ambrosia psilostachya) pollen IgG in a biological specimen.			Laboratory Procedure	
C130095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130095>	C130094|C122130	Western Ragweed Pollen IgG4 Measurement	A measurement of the western ragweed (Ambrosia psilostachya) pollen IgG4 in a biological specimen.			Laboratory Procedure	
C130096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130096>	C181398	Mucor racemosus IgE Measurement	A measurement of the Mucor racemosus IgE in a biological specimen.			Laboratory Procedure	
C130097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130097>	C81969|C182150	Mucor racemosus IgA Measurement	A measurement of the Mucor racemosus IgA in a biological specimen.			Laboratory Procedure	
C130098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130098>	C81971|C182150	Mucor racemosus IgG Measurement	A measurement of the Mucor racemosus IgG in a biological specimen.			Laboratory Procedure	
C130099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130099>	C130098|C122130	Mucor racemosus IgG4 Measurement	A measurement of the Mucor racemosus IgG4 in a biological specimen.			Laboratory Procedure	
C1300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1300>	C67422|C1893	Dolastatin 10|B720389K560|B720389K560|DOLASTATIN 10|Dolastatin-10|L-Valinamide, N,N-dimethyl-L-valyl-N-[2-methoxy-4-[2-[1- methoxy-2-methyl-3-oxo-3-[[2-phenyl-1-(2-thiazolyl)ethyl]amino]propyl]-1-pyrrolidinyl]-1-(1-methylpropyl)-4-oxobutyl]-N-methyl-, [2S-[1[1R*(R*),2S*],2R*[1S*,2S*,3(R*)]]]|dolastatin 10	A pentapeptide originally isolated from the marine mollusk Dolabella auricularia with potential antineoplastic activity.  Binding to tubulin, Dolastatin 10 inhibits microtubule assembly, resulting in the formation of tubulin aggregates and inhibition of mitosis.  This agent also induces tumor cell apoptosis through a mechanism involving bcl-2, an oncoprotein that is overexpressed in some cancers. (NCI04)	Dolastatin 10		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C130100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130100>	C181398	Mixed Antigen IgE Antibody Measurement	A measurement of the mixed antigen IgE antibody in a biological specimen.			Laboratory Procedure	
C130101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130101>	C181398	Tree Mix Pollen Antigen IgE Antibody Measurement	A measurement of the tree mix pollen antigen IgE antibody in a biological specimen.			Laboratory Procedure	
C130102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130102>	C81971|C182150	Tree Mix Pollen Antigen IgG Antibody Measurement	A measurement of the tree mix pollen antigen IgG antibody in a biological specimen.			Laboratory Procedure	
C130103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130103>	C181398	Grass Mix Pollen Antigen IgE Antibody Measurement	A measurement of the grass mix pollen antigen IgE antibody in a biological specimen.			Laboratory Procedure	
C130104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130104>	C81971|C182150	Grass Mix Pollen Antigen IgG Antibody Measurement	A measurement of the grass mix pollen antigen IgG antibody in a biological specimen.			Laboratory Procedure	
C130105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130105>	C81969|C182150	Grass Mix Pollen Antigen IgA Antibody Measurement	A measurement of the grass mix pollen antigen IgA antibody in a biological specimen.			Laboratory Procedure	
C130106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130106>	C181398	Weed Mix Pollen Antigen IgE Antibody Measurement	A measurement of the weed mix pollen antigen IgE antibody in a biological specimen.			Laboratory Procedure	
C130107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130107>	C81971|C182150	Weed Mix Pollen Antigen IgG Antibody Measurement	A measurement of the weed mix pollen antigen IgG antibody in a biological specimen.			Laboratory Procedure	
C130108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130108>	C81969|C182150	Weed Mix Pollen Antigen IgA Antibody Measurement	A measurement of the weed mix pollen antigen IgA antibody in a biological specimen.			Laboratory Procedure	
C130109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130109>	C181398	Mold Mix Antigen IgE Antibody Measurement	A measurement of the mold mix antigen IgE antibody in a biological specimen.			Laboratory Procedure	
C13010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13010>	C12712	Brunner's Gland|Brunner's Glands|GLAND, BRUNNER'S	Compound, tubular, submucosal glands located in the duodenum proximal to the sphincter of Oddi; these glands produce alkaline-rich secretions that function to both protect the duodenum from the acidic content of the stomach and to enable intestinal enzymes to activate, thus enabling absorption to start.	Brunner's Gland		Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130110>	C81971|C182150	Mold Mix Antigen IgG Antibody Measurement	A measurement of the mold mix antigen IgG antibody in a biological specimen.			Laboratory Procedure	
C130111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130111>	C81969|C182150	Mold Mix Antigen IgA Antibody Measurement	A measurement of the mold mix antigen IgA antibody in a biological specimen.			Laboratory Procedure	
C130112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130112>	C181398	Animal Mix Antigen IgE Antibody Measurement	A measurement of the animal mix antigen IgE antibody in a biological specimen.			Laboratory Procedure	
C130113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130113>	C81971|C182150	Animal Mix Antigen IgG Antibody Measurement	A measurement of the animal mix antigen IgG antibody in a biological specimen.			Laboratory Procedure	
C130114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130114>	C181398	Industrial Mix Antigen IgE Antibody Measurement	A measurement of the industrial mix antigen IgE antibody in a biological specimen.			Laboratory Procedure	
C130115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130115>	C81971|C182150	Industrial Mix Antigen IgG Antibody Measurement	A measurement of the industrial mix antigen IgG antibody in a biological specimen.			Laboratory Procedure	
C130116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130116>	C181398	Bee Mix Antigen IgE Antibody Measurement	A measurement of the bee mix antigen IgE antibody in a biological specimen.			Laboratory Procedure	
C130117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130117>	C81971|C182150	Bee Mix Antigen IgG Antibody Measurement	A measurement of the bee mix antigen IgG antibody in a biological specimen.			Laboratory Procedure	
C130118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130118>	C130117|C122130	Bee Mix Antigen IgG4 Antibody Measurement	A measurement of the bee mix antigen IgG4 antibody in a biological specimen.			Laboratory Procedure	
C130119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130119>	C81971|C182150	Dairy Mix Antigen IgG Antibody Measurement	A measurement of the dairy mix antigen IgG antibody in a biological specimen.			Laboratory Procedure	
C13011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13011>	C25763	Ampulla of Vater|AMPULLA OF VATER|Ampulla|Ampulla Of Vater|Hepatopancreatic Ampulla|Vater's Ampulla|Vater's ampulla|ampulla biliaropancreatica|ampulla of Vater|ampulla of Vater|ampulla of bile duct|biliaropancreatic ampulla|hepatopancreatic ampulla|papilla Vateri	The junction of the common bile and main pancreatic ducts, which protrudes into the medial aspect of the descending duodenum at the major duodenal papilla. The flow of bile and pancreatic juices into the duodenum through the Ampulla of Vater is controlled by the sphincter of Oddi.	Vater's Ampulla		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|UBERON Terminology
C130120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130120>	C181398	Shellfish Mix Antigen IgE Antibody Measurement	A measurement of the shellfish mix antigen IgE antibody in a biological specimen.			Laboratory Procedure	
C130121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130121>	C81971|C182150	Shellfish Mix Antigen IgG Antibody Measurement	A measurement of the shellfish mix antigen IgG antibody in a biological specimen.			Laboratory Procedure	
C130122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130122>	C181398	Nut Mix Antigen IgE Antibody Measurement	A measurement of the nut mix antigen IgE antibody in a biological specimen.			Laboratory Procedure	
C130123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130123>	C81971|C182150	Nut Mix Antigen IgG Antibody Measurement	A measurement of the nut mix antigen IgG antibody in a biological specimen.			Laboratory Procedure	
C130124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130124>	C181398	Cat Dander Antigen IgE Antibody Measurement	A measurement of the cat dander antigen IgE antibody in a biological specimen.			Laboratory Procedure	
C130125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130125>	C81971|C182150	Cat Dander Antigen IgG Antibody Measurement	A measurement of the cat dander antigen IgG antibody in a biological specimen.			Laboratory Procedure	
C130126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130126>	C81969|C182150	Cat Dander Antigen IgA Antibody Measurement	A measurement of the cat dander antigen IgA antibody in a biological specimen.			Laboratory Procedure	
C130127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130127>	C130125|C122130	Cat Dander Antigen IgG4 Antibody Measurement	A measurement of the cat dander antigen IgG4 antibody in a biological specimen.			Laboratory Procedure	
C130128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130128>	C181398	Dog Dander Antigen IgE Antibody Measurement	A measurement of the dog dander antigen IgE antibody in a biological specimen.			Laboratory Procedure	
C130129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130129>	C81971|C182150	Dog Dander Antigen IgG Antibody Measurement	A measurement of the dog dander antigen IgG antibody in a biological specimen.			Laboratory Procedure	
C13012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13012>	C13456	Lymphoid Progenitor Cell|CFU-L|CLP|Colony Forming Units - Lymphoid|Common Lymphoid Progenitor|Common Lymphoid Progenitor Cell|Common Lymphoid Progenitor Cell|Lymphoid Blood-Forming Cell|Lymphoid Blood-Forming Cells	A hematopoietic stem cell that is committed to differentiate into T-, B- and natural killer (NK) cells.	Common Lymphoid Progenitor Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C130130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130130>	C81969|C182150	Dog Dander Antigen IgA Antibody Measurement	A measurement of the dog dander antigen IgA antibody in a biological specimen.			Laboratory Procedure	
C130131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130131>	C130129|C122130	Dog Dander Antigen IgG4 Antibody Measurement	A measurement of the dog dander antigen IgG4 antibody in a biological specimen.			Laboratory Procedure	
C130132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130132>	C181398	Dermatophagoides farinae Antigen IgE Antibody Measurement	A measurement of the Dermatophagoides farinae antigen IgE antibody in a biological specimen.			Laboratory Procedure	
C130133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130133>	C81971|C182150	Dermatophagoides farinae Antigen IgG Antibody Measurement	A measurement of the Dermatophagoides farinae antigen IgG antibody in a biological specimen.			Laboratory Procedure	
C130134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130134>	C181398	Dermatophagoides pteronyssinus Antigen IgE Antibody Measurement	A measurement of the Dermatophagoides pteronyssinus antigen IgE antibody in a biological specimen.			Laboratory Procedure	
C130135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130135>	C81971|C182150	Dermatophagoides pteronyssinus Antigen IgG Antibody Measurement	A measurement of the Dermatophagoides pteronyssinus antigen IgG antibody in a biological specimen.			Laboratory Procedure	
C130136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130136>	C181398	American Cockroach Antigen IgE Antibody Measurement	A measurement of the American cockroach (Periplaneta americana) antigen IgE antibody in a biological specimen.			Laboratory Procedure	
C130137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130137>	C81969|C182150	American Cockroach Antigen IgA Antibody Measurement	A measurement of the American cockroach (Periplaneta americana) antigen IgA antibody in a biological specimen.			Laboratory Procedure	
C130138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130138>	C81971|C182150	American Cockroach Antigen IgG Antibody Measurement	A measurement of the American cockroach (Periplaneta americana) antigen IgG antibody in a biological specimen.			Laboratory Procedure	
C130139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130139>	C130138|C122130	American Cockroach Antigen IgG4 Antibody Measurement	A measurement of the American cockroach (Periplaneta americana) antigen IgG4 antibody in a biological specimen.			Laboratory Procedure	
C13013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13013>	C13118|C12918	Lymphoblast|lymphoblast|lymphoblastic	An immature lymphocyte that has enlarged in response to antigenic stimulation.	Lymphoblast		Cell	CTRP Biomarker Terminology|CTRP Terminology
C130140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130140>	C181398	German Cockroach Antigen IgE Antibody Measurement	A measurement of the German cockroach (Blattella germanica) antigen IgE antibody in a biological specimen.			Laboratory Procedure	
C130141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130141>	C81969|C182150	German Cockroach Antigen IgA Antibody Measurement	A measurement of the German cockroach (Blattella germanica) antigen IgA antibody in a biological specimen.			Laboratory Procedure	
C130142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130142>	C81971|C182150	German Cockroach Antigen IgG Antibody Measurement	A measurement of the German cockroach (Blattella germanica) antigen IgG antibody in a biological specimen.			Laboratory Procedure	
C130143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130143>	C130142|C122130	German Cockroach Antigen IgG4 Antibody Measurement	A measurement of the German cockroach (Blattella germanica) antigen IgG4 antibody in a biological specimen.			Laboratory Procedure	
C130144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130144>	C181398	Aspergillus fumigatus Antigen IgE Antibody Measurement	A measurement of the Aspergillus fumigatus antigen IgE antibody in a biological specimen.			Laboratory Procedure	
C130145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130145>	C81971|C182150	Aspergillus fumigatus Antigen IgG Antibody Measurement	A measurement of the Aspergillus fumigatus antigen IgG antibody in a biological specimen.			Laboratory Procedure	
C130146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130146>	C181398	Penicillium notatum Antigen IgE Antibody Measurement	A measurement of the Penicillium notatum antigen IgE antibody in a biological specimen.			Laboratory Procedure	
C130147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130147>	C81969|C182150	Penicillium notatum Antigen IgA Antibody Measurement	A measurement of the Penicillium notatum antigen IgA antibody in a biological specimen.			Laboratory Procedure	
C130148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130148>	C81971|C182150	Penicillium notatum Antigen IgG Antibody Measurement	A measurement of the Penicillium notatum antigen IgG antibody in a biological specimen.			Laboratory Procedure	
C130149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130149>	C130148|C122130	Penicillium notatum Antigen IgG4 Antibody Measurement	A measurement of the Penicillium notatum antigen IgG4 antibody in a biological specimen.			Laboratory Procedure	
C13014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13014>	C12918|C12549	Monoblast	A cell derived from a myeloid progenitor cell. It differentiates into a promonocyte. It is about 12 to 20 micrometer in diameter, has a round to oval nucleus with fine, lightly dispersed chromatin and one to four nucleoli. The cytoplasm is agranular, stains moderately to lightly basophilic, and often has an intensely stained periphery and a prominent perinuclear zone. Monoblasts are found in bone marrow and never appear in the normal peripheral blood.	Monoblast		Cell	
C130150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130150>	C181398	Alternaria tenuis alternata Antigen IgE Antibody Measurement	A measurement of the Alternaria tenuis alternata antigen IgE antibody in a biological specimen.			Laboratory Procedure	
C130151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130151>	C81969|C182150	Alternaria tenuis alternata Antigen IgA Antibody Measurement	A measurement of the Alternaria tenuis alternata antigen IgA antibody in a biological specimen.			Laboratory Procedure	
C130152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130152>	C81971|C182150	Alternaria tenuis alternata Antigen IgG Antibody Measurement	A measurement of the Alternaria tenuis alternata antigen IgG antibody in a biological specimen.			Laboratory Procedure	
C130153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130153>	C130152|C122130	Alternaria tenuis alternata Antigen IgG4 Antibody Measurement	A measurement of the Alternaria tenuis alternata antigen IgG4 antibody in a biological specimen.			Laboratory Procedure	
C130154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130154>	C51948	Basophil Band Form Count|BASOB|Basophils Band Form|Basophils Band Form	The determination of the number of band basophils in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130155>	C51948	Basophil Band Form to Leukocytes Ratio Measurement|BASOBLE|Basophils Band Form/Leukocytes|Basophils Band Form/Leukocytes	The determination of the ratio of band basophils compared to leukocytes in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130156>	C81867	Chemokine (C-C Motif) Ligand 12 Measurement|CCL12|CCL12 Measurement|Chemokine (C-C Motif) Ligand 12|Chemokine (C-C Motif) Ligand 12|Monocyte Chemotactic Protein 5	The determination of the amount of chemokine (C-C Motif) ligand 12 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130157>	C81867	Chemokine (C-C Motif) Ligand 19 Measurement|CCL19|CCL19 Measurement|Chemokine (C-C Motif) Ligand 19|Chemokine (C-C Motif) Ligand 19|MIP3B|Macrophage Inflammatory Protein 3 Beta	The determination of the amount of chemokine (C-C Motif) ligand 19 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130158>	C81867	Chemokine (C-C Motif) Ligand 7 Measurement|CCL7|CCL7 Measurement|Chemokine (C-C Motif) Ligand 7|Chemokine (C-C Motif) Ligand 7|MCP3|Monocyte Chemotactic Protein 3	The determination of the amount of chemokine (C-C Motif) ligand 7 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130159>	C81867	Chemokine (C-X-C Motif) Ligand 6 Measurement|CXCL6|CXCL6 Measurement|Chemokine (C-X-C Motif) Ligand 6|Chemokine (C-X-C Motif) Ligand 6|GCP2|Granulocyte Chemotactic Protein 2	The determination of the amount of chemokine (C-X-C Motif) ligand 6 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C13015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13015>	C12918|C12549	Myeloblast|myeloblastic	An immature cell that represents the first stage in the granulocytic series of hematopoiesis. It is found in bone marrow and differentiates into a promyelocyte. Its nucleus is composed of very fine, evenly distributed chromatin with 2-5 nucleoli. The cytoplasm is basophilic and non-granular.	Myeloblast		Cell	
C130160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130160>	C64430	Cytokeratin 18 Fragment Measurement|CYFRA18|Cytokeratin 18 Fragment|Cytokeratin 18 Fragment|KRT18 Measurement	The determination of the amount of cytokeratin 18 fragment present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130161>	C48938	Epithelial Cells to Total Cells Ratio Measurement|EPICCE|EPICCE|Epithelial Cells/Total Cells|Epithelial Cells/Total Cells|Epithelial Cells/Total Cells	The determination of the ratio of epithelial cells compared to total cells in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Cell Phenotyping Test Code Terminology|CDISC SDTM Cell Phenotyping Test Name Terminology|CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130162>	C64430	Fibroblast Growth Factor 9 Measurement|FGF 9|FGF9|FGF9 Measurement|Fibroblast Growth Factor 9|Fibroblast Growth Factor 9	The determination of the amount of fibroblast growth factor 9 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130163>	C74804	Leukemia Inhibitory Factor Measurement|LIF|LIF Measurement|Leukemia Inhibitory Factor|Leukemia Inhibitory Factor	The determination of the amount of leukemia inhibitory factor present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130164>	C163464	Macrophage Inflammatory Protein 1 Gamma Measurement|C-C Motif Chemokine 9 Measurement|CCL9 Measurement|MIP1G|MIP1G Measurement|Macrophage Inflammatory Protein 1 Gamma|Macrophage Inflammatory Protein 1 Gamma	The determination of the amount of macrophage inflammatory protein 1 gamma present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130165>	C28133	Myeloid Progenitor Cell Count|MYPC|Myeloid Progenitor Cells|Myeloid Progenitor Cells	The determination of the number of myeloid progenitor cells in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130166>	C48938	Viable Cell Count|Live Cells|VBCE|VBCE|Viable Cells|Viable Cells|Viable Cells	The determination of the number of viable cells in a sample.			Laboratory Procedure	CDISC SDTM Cell Phenotyping Test Code Terminology|CDISC SDTM Cell Phenotyping Test Name Terminology|CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130167>	C13023	Aortic Valve Annulus|AORTIC VALVE ANNULUS	A fibrous membrane that attaches to, and provides support for, the aortic valve leaflets.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130168>	C34027	Suprarenal Aorta|SUPRARENAL AORTA	The portion of the abdominal aorta superior to the renal arteries.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130169>	C130047	Posterior Annulus of the Tricuspid Valve|TRICUSPID VALVE, POSTERIOR ANNULUS	The portion of the tricuspid valve annulus that attaches to both the posterior and lateral tricuspid valve leaflets.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130170>	C130171	AHG-enhanced Complement-dependent Lymphocytotoxicity Assay|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY	A form of complement-dependent lymphocytotoxicity assay with the addition of anti-human globulin (AHG), which is a complement fixing antibody to human immunoglobulin. The AHG binds to both complement proteins and alloantibodies bound to donor lymphocytes, thereby increasing the antibody density and the likelihood of activating complement, resulting in increased sensitivity of the assy.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130171>	C150876	Complement-dependent Lymphocytotoxicity Assay|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY	A method that detects the presence and reaction of alloantibodies to donor lymphocytes in pre-transplant patients via the addition of complement proteins and lysis of the lymphocytes.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130172>	C38060	Farnsworth-Munsell 100 Hue Test|FARNSWORTH-MUNSELL 100 HUE TEST	A diagrammatic method to test color blindness or deficiencies, which uses 100 colors from the Munsell color system arranged in rows of four color families, containing 25 hues for each color. The subject must put the hues in order based on the anchor colors at the ends of each row.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130173>	C18640	Hemagglutination Assay|HEMAGGLUTINATION ASSAY	An in vitro assay used to measure the relative concentration of viruses, bacteria, or antibodies in which serial dilutions of solution containing virus, bacteria, or antibody are applied to red blood cells in culture to look for the presence of hemagglutination.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130174>	C17632|C17003	High Resolution Melt Analysis|HIGH RESOLUTION MELT ANALYSIS	A reverse, real-time, polymerase chain reaction technique in which fluroescently labeled double-stranded DNA is slowly melted apart by increasing temperature. Genetic mutations and polymorphisms can be detected by analyzing the melt curves, which correspond to the rate at which double-stranded DNA become single-stranded.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130175>	C38060	Jaeger Eye Chart|JAEGER EYE CHART	A diagrammatic method to test visual acuity that uses paragraphs of text in differing font sizes to assess near vision.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130176>	C38081	Multiple Breath Washout|MULTIPLE BREATH WASHOUT	A test of lung function in which changes in exhaled tracer gas concentration is analyzed for a specified number of tidal expirations, a defined period of time, or a defined index of expired gas volume.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130177>	C101293	Next Generation Targeted Sequencing|NEXT GENERATION TARGETED SEQUENCING|Targeted NGS|Targeted NGS (sequencing of selected regions of the genome either via targeted capture or amplification)|Targeted Sequencing|Targeted Sequencing|Targeted Sequencing	A technique that determines the nucleotide sequence of a pre-specified region of DNA or RNA by using primers that are specific for that region.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTDC Value Terminology|GDC Terminology|GDC Value Terminology
C130178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130178>	C135455	Phenotypic Multiple Antigen Bead-based Multiplex Assay|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY	A type of solid-phase multiplex assay that uses microbeads coated with recombinant or infinity purified antigens from multiple alleles for the detection and identification of antibodies that would bind and react to these antigens.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130179>	C17003	Allele Specific Primer Polymerase Chain Reaction|PCR-SSP|SEQUENCE SPECIFIC PRIMER POLYMERASE CHAIN REACTION	A modified polymerase chain reaction (PCR) technique in which a specific primer can amplify its corresponding allele only; this allows for the determination of the presence or absence of a single, specific allele during genotype testing.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130180>	C153598	Sequence-based Typing|SBT|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION	A method that provides the entirety of the nucleotide sequence of a specific DNA strand, allowing for reliable and thorough genotyping of the allele in question.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130181>	C17003	Sequence-specific Oligonucleotide Probe Polymerase Chain Reaction|PCR-SSOP|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION	A modified polymerase chain reaction (PCR) technique that uses distinct probes, specifically synthesized according to the polymorphic region sequence of the gene of interest, to detect nucleotide differences during genotype testing.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130182>	C135455	Single Antigen Bead-based Multiplex Assay|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY	A type of solid-phase multiplex assay that uses microbeads coated with recombinant or infinity purified antigens from a single allele for the detection and identification of an antibody that would bind and react to this antigen.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130183>	C17003	Single-strand Conformation Polymerase Chain Reaction|PCR-SSCP|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION	A modified polymerase chain reaction (PCR) technique that uses differences in molecular weights and three-dimensional structures to identify mutations in DNA configurations.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130184>	C16809	Triple Phase MRI|TRIPLE-PHASE MRI SCAN	A form of magnetic resonance imaging (MRI) in which images are taken during three distinct timing points (phases) following the injection of contrast material: arterial, venous, and delayed.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130185>	C38060	N75 Latency|N1 Latency|N75LAT	An assessment of the latency of the N75 or N1 wave of the visual evoked potential assessment waveform.			Diagnostic Procedure	CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130186>	C125009	Wheal Diameter Interpretation|WHLINT|WHLINT	A further, qualitative assessment based on the diameter of a wheal on the skin.			Research Activity	CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Skin Response Test Code Terminology|CDISC SDTM Skin Response Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130187>	C105516	Per Large Square Neubauer Chamber|/LSQN|/Large Square Neubauer|/{LSQN}|/{LSQN}	A unit of measure equal to the instances of an entity per large square (with a 1mm x 1mm area) in a Neubauer chamber.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130188>	C66973	Per Millimeter|/mm|/mm|/mm|/mm|mm|per millimeter	A unit of length equal to one millimeter that is used as a denominator to build a derived unit expressed as a ratio.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C130189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130189>	C130046	Million Per Ejaculate Unit|10*6/{Ejaculate U}|10*6/{Ejaculate U}|10^6/Ejaculate U|10^6/{Ejaculate U}|10^6/{Ejaculate U}	A unit of measurement equal to 10 to the sixth power of entities per unit equal to one ejaculation.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C13018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13018>	C12219	Organ|Organs|organ	A unique macroscopic (gross) anatomic structure that performs specific functions. It is composed of various tissues.  An organ is part of an anatomic system or a body region. Representative examples include the heart, lung, liver, spleen, and uterus.	Organ		Body Part, Organ, or Organ Component	
C130190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130190>	C68877	Glycoprotein-ELISA Unit Per Milliliter|gpELISA unit/mL|{gpELISA unit}/mL|{gpELISA unit}/mL|{gpELISA unit}/ml|{gpELISA unit}/ml	A unit for measuring potency of immunologically active substance in a product determined as reactivity in a glycoprotein enzyme-linked immunosorbent assay for particular antigen or antibody and expressed per unit volume equal to one milliliter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130191>	C48568	Milliliter Per Minute Times One Hundred Milliliters|mL/(min*100mL)|mL/min.10*2.mL|mL/min.10*2.mL|mL/min.10*2.ml|mL/min.10*2.ml|ml/min.10*2.mL|ml/min.10*2.mL|ml/min.10*2.ml|ml/min.10*2.ml	A unit of flow rate expressed as the number of milliliters per number of minutes times a unit of volume equal to 100 milliliters.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130192>	C67375	Nanogram Equivalents Per Liter|ng.eq/L|ng.eq/L|ng.eq/l|ng.eq/l|ngEq/L|pgEq/mL	A concentration unit measured as a number of nanogram equivalent of solute per liter of solution.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130193>	C48470	Opsonization Index 50%|OI50|{OI50}|{OI50}	A potency unit equal to the dilution of serum that causes opsonization and phagocytosis of 50% of the bacteria in a sample.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130194>	C48572	Reciprocal of Seconds Times Percent O2 Concentration|s-1.(%{O2})-1|s-1.(%{O2})-1|s^-1(%O2)^-1	A unit of oxygen transfer function expressed as the reciprocal of time in seconds divided by the oxygen concentration.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130195>	C25337	Number of Renal Arteries|RNLANUM	The determination of the total number of renal arteries.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Urinary System Test Code Terminology|CDISC SDTM Urinary System Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C130196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130196>	C25337	Number of Renal Veins|RNLVNUM	The determination of the total number of renal veins.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Urinary System Test Code Terminology|CDISC SDTM Urinary System Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C130197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130197>	C134576	Experimental Organism Benign Plasma Cell Tumor|PLASMA CELL TUMOR, BENIGN	A benign neoplasm of the epithelium originating from plasma cells.			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C130198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130198>	C127787	Total Number of Study Animals Purchased|TOTANPCH	The absolute count of all animals bought for an intended purpose within a study.			Quantitative Concept	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C130199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130199>	C16441	Myelodysplastic Syndrome Clone|MDS Clone|MDS Malignant Clone	A clonal population of dysplastic hematopoietic cells found in a patient with myelodysplastic syndrome.	Myelodysplastic Syndrome Clone		Cell	CTRP Biomarker Terminology|CTRP Terminology
C13019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13019>	C38626	Eye Part	Any component associated with the organ for sight or vision.	Eye Part		Body Part, Organ, or Organ Component	
C1301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1301>	C148123	Esperamicin A1|ESPERAMICIN A1	An enediyne antineoplastic antibiotic hybrid containing an anthranilate moiety.  Esperamicin A1 is isolated from the bacterium Actinomadura verrucosospora.  The anthranilate component of esperamicin A1 intercalates DNA and the benzene diradical intermediate of the enediyne core binds to the minor groove of DNA, resulting in single- and double-stranded breaks in DNA and apoptosis. (NCI04)			Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C130200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130200>	C159659	Solid Organ Transplant Recipient|Solid Organ Transplantation Recipient|Solid Organ Transplantation Recipient	An individual who is receiving a transplant of a solid organ.	Solid Organ Transplantation Recipient		Human	CTRP Intervention Terminology|CTRP Terminology
C130201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130201>	C94600	BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.742C>G Mutation|BCR/ABL Fusion Gene with NM_005157.4:c.742C>G|BCR/ABL Fusion Gene with NM_005157.5:c.742C>G|BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.742C>G|BCR/ABL1 Fusion Gene with NM_005157.4:c.742C>G|BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.742C>G Mutation	A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where cytosine has been substituted with guanine at nucleotide position 742 of the ABL1 gene.			Gene or Genome	
C130202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130202>	C3266	Constitutional Mismatch Repair Deficiency Syndrome|BMMRD|Biallelic Mismatch Repair Deficiency|Biallelic Mismatch Repair Deficiency Syndrome|CMMR-D|CMMRD|Constitutional MMR Deficiency|Constitutional Mis-Match Repair Deficiency Syndrome|Constitutional Mismatch Repair Deficiency	A rare childhood cancer predisposition syndrome caused by biallelic inheritance of mutations in MLH1, MSH2, MSH6, or PMS2 genes. It is characterized by the development of childhood cancers, usually hematological malignancies and/or brain tumors, and colorectal cancers with multiple intestinal polyps. The majority of patients show signs of neurofibromatosis type 1.	Constitutional Mismatch Repair Deficiency Syndrome		Disease or Syndrome	CCPS Disease Terminology|Childhood Cancer Predisposition Study Terminology|CTRP Disease Terminology|CTRP Terminology
C130203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130203>	C16325	BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.L248V|BCR-ABL L248V Mutation|BCR-ABL Leu248Val Mutation|BCR-ABL1 L248V Mutation|BCR-ABL1 Leu248Val Mutation|BCR/ABL Fusion Protein with L248V|BCR/ABL Fusion Protein with Leu248Val|BCR/ABL L248V Mutation|BCR/ABL Leu248Val Mutation|BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Leu248Val|BCR/ABL1 Fusion Protein with NP_005148.2:p.L248V|BCR/ABL1 Fusion Protein with NP_005148.2:p.Leu248Val|BCR/ABL1 L248V Mutation|BCR/ABL1 Leu248Val Mutation|BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.L248V|L248V	A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.742C>G mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the leucine at position 248 of the ABL1 protein has been replaced by valine.			Amino Acid, Peptide, or Protein	
C130204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130204>	C94600	BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.749G>A Mutation|BCR/ABL Fusion Gene with NM_005157.4:c.749G>A|BCR/ABL Fusion Gene with NM_005157.5:c.749G>A|BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.749G>A|BCR/ABL1 Fusion Gene with NM_005157.4:c.749G>A|BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.749G>A Mutation	A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where guanine has been substituted with adenine at nucleotide position 749 of the ABL1 gene.			Gene or Genome	
C130205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130205>	C16325	BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.G250E|BCR-ABL G250E Mutation|BCR-ABL Gly250Glu Mutation|BCR-ABL1 G250E Mutation|BCR-ABL1 Gly250Glu Mutation|BCR/ABL Fusion Protein with G250E|BCR/ABL Fusion Protein with Gly250Glu|BCR/ABL G250E Mutation|BCR/ABL Gly250Glu Mutation|BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Gly250Glu|BCR/ABL1 Fusion Protein with NP_005148.2:p.G250E|BCR/ABL1 Fusion Protein with NP_005148.2:p.Gly250Glu|BCR/ABL1 G250E Mutation|BCR/ABL1 Gly250Glu Mutation|BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.G250E|G250E	A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.749G>A mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the glycine at position 250 of the ABL1 protein has been replaced by glutamic acid.			Amino Acid, Peptide, or Protein	
C130206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130206>	C94600	BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.756G>T Mutation|BCR/ABL Fusion Gene with NM_005157.4:c.756G>T|BCR/ABL Fusion Gene with NM_005157.5:c.756G>T|BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.756G>T|BCR/ABL1 Fusion Gene with NM_005157.4:c.756G>T|BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.756G>T Mutation	A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where guanine has been substituted with thymine at nucleotide position 756 of the ABL1 gene.			Gene or Genome	
C130207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130207>	C94600	BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.756G>C Mutation|BCR/ABL Fusion Gene with NM_005157.4:c.756G>C|BCR/ABL Fusion Gene with NM_005157.5:c.756G>C|BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.756G>C|BCR/ABL1 Fusion Gene with NM_005157.4:c.756G>C|BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.756G>C Mutation	A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where guanine has been substituted with cytosine at nucleotide position 756 of the ABL1 gene.			Gene or Genome	
C130208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130208>	C16325	BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Q252H|BCR-ABL Gln252His Mutation|BCR-ABL Q252H Mutation|BCR-ABL1 Gln252His Mutation|BCR-ABL1 Q252H Mutation|BCR/ABL Fusion Protein with Gln252His|BCR/ABL Fusion Protein with Q252H|BCR/ABL Gln252His Mutation|BCR/ABL Q252H Mutation|BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Gln252His|BCR/ABL1 Fusion Protein with NP_005148.2:p.Gln252His|BCR/ABL1 Fusion Protein with NP_005148.2:p.Q252H|BCR/ABL1 Gln252His Mutation|BCR/ABL1 Q252H Mutation|BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.Q252H|Q252H	A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.756G>T or c.756G>C mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the glutamine at position 252 of the ABL1 protein has been replaced by histidine.			Amino Acid, Peptide, or Protein	
C130209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130209>	C94600	BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.758A>T Mutation|BCR/ABL Fusion Gene with NM_005157.4:c.758A>T|BCR/ABL Fusion Gene with NM_005157.5:c.758A>T|BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.758A>T|BCR/ABL1 Fusion Gene with NM_005157.4:c.758A>T|BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.758A>T Mutation	A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where adenine has been substituted with thymine at nucleotide position 758 of the ABL1 gene.			Gene or Genome	
C13020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13020>	C32221	Breast Part|Breast-Related Entity	Any anatomic component of one or both breasts.	Breast Part		Body Part, Organ, or Organ Component	
C130210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130210>	C16325	BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Y253F|BCR-ABL Tyr253Phe Mutation|BCR-ABL Y253F Mutation|BCR-ABL1 Tyr253Phe Mutation|BCR-ABL1 Y253F Mutation|BCR/ABL Fusion Protein with Tyr253Phe|BCR/ABL Fusion Protein with Y253F|BCR/ABL Tyr253Phe Mutation|BCR/ABL Y253F Mutation|BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Tyr253Phe|BCR/ABL1 Fusion Protein with NP_005148.2:p.Tyr253Phe|BCR/ABL1 Fusion Protein with NP_005148.2:p.Y253F|BCR/ABL1 Tyr253Phe Mutation|BCR/ABL1 Y253F Mutation|BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.Y253F|Y253F	A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.758A>T mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the tyrosine at position 253 of the ABL1 protein has been replaced by phenylalanine.			Amino Acid, Peptide, or Protein	
C130211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130211>	C94600	BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.763G>A Mutation|BCR/ABL Fusion Gene with NM_005157.4:c.763G>A|BCR/ABL Fusion Gene with NM_005157.5:c.763G>A|BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.763G>A|BCR/ABL1 Fusion Gene with NM_005157.4:c.763G>A|BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.763G>A Mutation	A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where guanine has been substituted with adenine at nucleotide position 763 of the ABL1 gene. This mutation is associated with imatinib- and nilotinib-resistant leukemias.			Gene or Genome	
C130212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130212>	C16325	BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.E255K|BCR-ABL E255K Mutation|BCR-ABL Glu255Lys Mutation|BCR-ABL1 E255K Mutation|BCR-ABL1 Glu255Lys Mutation|BCR/ABL E255K Mutation|BCR/ABL Fusion Protein with E255K|BCR/ABL Fusion Protein with Glu255Lys|BCR/ABL Glu255Lys Mutation|BCR/ABL1 E255K Mutation|BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Glu255Lys|BCR/ABL1 Fusion Protein with NP_005148.2:p.E255K|BCR/ABL1 Fusion Protein with NP_005148.2:p.Glu255Lys|BCR/ABL1 Glu255Lys Mutation|BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.E255K|E255K	A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.763G>A mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the glutamic acid at position 255 of the ABL1 protein has been replaced by lysine.			Amino Acid, Peptide, or Protein	
C130213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130213>	C94600	BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.895G>C Mutation|BCR/ABL Fusion Gene with NM_005157.4:c.895G>C|BCR/ABL Fusion Gene with NM_005157.5:c.895G>C|BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.895G>C|BCR/ABL1 Fusion Gene with NM_005157.4:c.895G>C|BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.895G>C Mutation	A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where guanine has been substituted with cytosine at nucleotide position 895 of the ABL1 gene. This mutation is associated with imatinib- and dasatinib-resistant leukemias.	BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.895G>C Mutation		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C130214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130214>	C94600	BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.895G>T Mutation|BCR/ABL Fusion Gene with NM_005157.4:c.895G>T|BCR/ABL Fusion Gene with NM_005157.5:c.895G>T|BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.895G>T|BCR/ABL1 Fusion Gene with NM_005157.4:c.895G>T|BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.895G>T Mutation	A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where guanine has been substituted with thymine at nucleotide position 895 of the ABL1 gene. This mutation is associated with imatinib- and dasatinib-resistant leukemias.	BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.895G>T Mutation		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C130215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130215>	C16325	BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.V299L|BCR-ABL V299L Mutation|BCR-ABL Val299Leu Mutation|BCR-ABL1 V299L Mutation|BCR-ABL1 Val299Leu Mutation|BCR/ABL Fusion Protein with V299L|BCR/ABL Fusion Protein with Val299Leu|BCR/ABL V299L Mutation|BCR/ABL Val299Leu Mutation|BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Val299Leu|BCR/ABL1 Fusion Protein with NP_005148.2:p.V299L|BCR/ABL1 Fusion Protein with NP_005148.2:p.Val299Leu|BCR/ABL1 V299L Mutation|BCR/ABL1 Val299Leu Mutation|BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.V299L|V299L	A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.895G>C or c.895G>T mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the valine at position 299 of the ABL1 protein has been replaced by leucine.	BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.V299L		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C130216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130216>	C94600	BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.951C>A Mutation|BCR/ABL Fusion Gene with NM_005157.4:c.951C>A|BCR/ABL Fusion Gene with NM_005157.5:c.951C>A|BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.951C>A|BCR/ABL1 Fusion Gene with NM_005157.4:c.951C>A|BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.951C>A Mutation	A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where cytosine has been substituted with adenine at nucleotide position 951 of the ABL1 gene. This mutation is associated with imatinib- and dasatinib-resistant leukemias.			Gene or Genome	
C130217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130217>	C94600	BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.949T>C Mutation|BCR/ABL Fusion Gene with NM_005157.4:c.949T>C|BCR/ABL Fusion Gene with NM_005157.5:c.949T>C|BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.949T>C|BCR/ABL1 Fusion Gene with NM_005157.4:c.949T>C|BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.949T>C Mutation	A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where thymine has been substituted with cytosine at nucleotide position 949 of the ABL1 gene. This mutation is associated with imatinib- and dasatinib-resistant leukemias.			Gene or Genome	
C130218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130218>	C94600	BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.951C>G Mutation|BCR/ABL Fusion Gene with NM_005157.4:c.951C>G|BCR/ABL Fusion Gene with NM_005157.5:c.951C>G|BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.951C>G|BCR/ABL1 Fusion Gene with NM_005157.4:c.951C>G|BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.951C>G Mutation	A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where cytosine has been substituted with guanine at nucleotide position 951 of the ABL1 gene. This mutation is associated with imatinib- and dasatinib-resistant leukemias.			Gene or Genome	
C130219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130219>	C16325	BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.F317L|BCR-ABL F317L Mutation|BCR-ABL Phe317Leu Mutation|BCR-ABL1 F317L Mutation|BCR-ABL1 Phe317Leu Mutation|BCR/ABL F317L Mutation|BCR/ABL Fusion Protein with F317L|BCR/ABL Fusion Protein with Phe317Leu|BCR/ABL Phe317Leu Mutation|BCR/ABL1 F317L Mutation|BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Phe317Leu|BCR/ABL1 Fusion Protein with NP_005148.2:p.Phe317Leu|BCR/ABL1 Fusion Protein with NP_005148.2:pF317L|BCR/ABL1 Phe317Leu Mutation|BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.F317L|F317L	A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.951C>A, c.951C>G or c.949T>C mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the phenylalanine at position 317 of the ABL1 protein has been replaced by leucine.			Amino Acid, Peptide, or Protein	
C130220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130220>	C94600	BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.1052T>C Mutation|BCR/ABL Fusion Gene with NM_005157.4:c.1052T>C|BCR/ABL Fusion Gene with NM_005157.5:c.1052T>C|BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.1052T>C|BCR/ABL1 Fusion Gene with NM_005157.4:c.1052T>C|BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.1052T>C Mutation	A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where thymine has been substituted with cytosine at nucleotide position 1052 of the ABL1 gene.			Gene or Genome	
C130221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130221>	C16325	BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.M351T|BCR-ABL M351T Mutation|BCR-ABL Met351Thr Mutation|BCR-ABL1 M351T Mutation|BCR-ABL1 Met351Thr Mutation|BCR/ABL Fusion Protein with M351T|BCR/ABL Fusion Protein with Met351Thr|BCR/ABL M351T Mutation|BCR/ABL Met351Thr Mutation|BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Met351Thr|BCR/ABL1 Fusion Protein with NP_005148.2:p.M351T|BCR/ABL1 Fusion Protein with NP_005148.2:p.Met351Thr|BCR/ABL1 M351T Mutation|BCR/ABL1 Met351Thr Mutation|BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.M351T|M351T	A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.1052T>C mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the methionine at position 351 of the ABL1 protein has been replaced by threonine.			Amino Acid, Peptide, or Protein	
C130222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130222>	C94600	BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.1075T>G Mutation|BCR/ABL Fusion Gene with NM_005157.4:c.1075T>G|BCR/ABL Fusion Gene with NM_005157.5:c.1075T>G|BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.1075T>G|BCR/ABL1 Fusion Gene with NM_005157.4:c.1075T>G|BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.1075T>G Mutation	A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where thymine has been substituted with guanine at nucleotide position 1075 of the ABL1 gene. This mutation is associated with imatinib- and nilotinib-resistant leukemias.			Gene or Genome	
C130223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130223>	C16325	BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.F359V|BCR-ABL F359V Mutation|BCR-ABL Phe359Val Mutation|BCR-ABL1 F359V Mutation|BCR-ABL1 Phe359Val Mutation|BCR/ABL F359V Mutation|BCR/ABL Fusion Protein with F359V|BCR/ABL Fusion Protein with Phe359Val|BCR/ABL Phe359Val Mutation|BCR/ABL1 F359V Mutation|BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Phe359Val|BCR/ABL1 Fusion Protein with NP_005148.2:p.F359V|BCR/ABL1 Fusion Protein with NP_005148.2:p.Phe359Val|BCR/ABL1 Phe359Val Mutation|BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.F359V|F359V	A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.1075T>G mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the phenylalanine at position 359 of the ABL1 protein has been replaced by valine.			Amino Acid, Peptide, or Protein	
C130224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130224>	C94600	BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.1150C>A Mutation|BCR/ABL Fusion Gene with NM_005157.4:c.1150C>A|BCR/ABL Fusion Gene with NM_005157.5:c.1150C>A|BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.1150C>A|BCR/ABL1 Fusion Gene with NM_005157.4:c.1150C>A|BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.1150C>A Mutation	A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where cytosine has been substituted with adenine at nucleotide position 1150 of the ABL1 gene.			Gene or Genome	
C130225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130225>	C16325	BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.L384M|BCR-ABL L384M Mutation|BCR-ABL Leu384Met Mutation|BCR-ABL1 L384M Mutation|BCR-ABL1 Leu384Met Mutation|BCR/ABL Fusion Protein with L384M|BCR/ABL Fusion Protein with Leu384Met|BCR/ABL L384M Mutation|BCR/ABL Leu384Met Mutation|BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Leu384Met|BCR/ABL1 Fusion Protein with NP_005148.2:p.L384M|BCR/ABL1 Fusion Protein with NP_005148.2:p.Leu384Met|BCR/ABL1 L384M Mutation|BCR/ABL1 Leu384Met Mutation|BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.L384M|L384M	A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.1150C>A mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the leucine at position 384 of the ABL1 protein has been replaced by methionine.			Amino Acid, Peptide, or Protein	
C130226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130226>	C94600	BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.1187A>C Mutation|BCR/ABL Fusion Gene with NM_005157.4:c.1187A>C|BCR/ABL Fusion Gene with NM_005157.5:c.1187A>C|BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.1187A>C|BCR/ABL1 Fusion Gene with NM_005157.4:c.1187A>C|BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.1187A>C Mutation	A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where adenine has been substituted with cytosine at nucleotide position 1187 of the ABL1 gene.			Gene or Genome	
C130228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130228>	C16325	BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.H396P|BCR-ABL H396P Mutation|BCR-ABL His396Pro Mutation|BCR-ABL1 H396P Mutation|BCR-ABL1 His396Pro Mutation|BCR/ABL Fusion Protein with H396P|BCR/ABL Fusion Protein with His396Pro|BCR/ABL H396P Mutation|BCR/ABL His396Pro Mutation|BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.His396Pro|BCR/ABL1 Fusion Protein with NP_005148.2:p.H396P|BCR/ABL1 Fusion Protein with NP_005148.2:p.His396Pro|BCR/ABL1 H396P Mutation|BCR/ABL1 His396Pro Mutation|BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.H396P|H396P	A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.1187A>C mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the histidine at position 396 of the ABL1 protein has been replaced by proline.			Amino Acid, Peptide, or Protein	
C130229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130229>	C94600	BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.1187A>G Mutation|BCR/ABL Fusion Gene with NM_005157.4:c.1187A>G|BCR/ABL Fusion Gene with NM_005157.5:c.1187A>G|BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.1187A>G|BCR/ABL1 Fusion Gene with NM_005157.4:c.1187A>G|BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.1187A>G Mutation	A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where adenine has been substituted with guanine at nucleotide position 1187 of the ABL1 gene.			Gene or Genome	
C13022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13022>	C38620	Skin Part	Any component of the organ that constitutes the external surface of the body, including the epidermis, dermis, and skin appendages.	Skin Part		Body Part, Organ, or Organ Component	
C130230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130230>	C16325	BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.H396R|BCR-ABL H396R Mutation|BCR-ABL His396Arg Mutation|BCR-ABL1 H396R Mutation|BCR-ABL1 His396Arg Mutation|BCR/ABL Fusion Protein with H396R|BCR/ABL Fusion Protein with His396Arg|BCR/ABL H396R Mutation|BCR/ABL His396Arg Mutation|BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.His396Arg|BCR/ABL1 Fusion Protein with NP_005148.2:p.H396R|BCR/ABL1 Fusion Protein with NP_005148.2:p.His396Arg|BCR/ABL1 H396R Mutation|BCR/ABL1 His396Arg Mutation|BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.H396R|H396R	A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.1187A>G mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the histidine at position 396 of the ABL1 protein has been replaced by arginine.			Amino Acid, Peptide, or Protein	
C130231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130231>	C16325	BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.G398R|BCR-ABL G398R Mutation|BCR-ABL Gly398Arg Mutation|BCR-ABL1 G398R Mutation|BCR-ABL1 Gly398Arg Mutation|BCR/ABL Fusion Protein with G398R|BCR/ABL Fusion Protein with Gly398Arg|BCR/ABL G398R Mutation|BCR/ABL Gly398Arg Mutation|BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Gly398Arg|BCR/ABL1 Fusion Protein with NP_005148.2:p.G398R|BCR/ABL1 Fusion Protein with NP_005148.2:p.Gly398Arg|BCR/ABL1 G398R Mutation|BCR/ABL1 Gly398Arg Mutation|BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.G398R|G398R	A fusion protein encoded by the BCR/ABL1 fusion gene with a mutation located in exon 7 of the ABL1 gene. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the glycine at position 398 of the ABL1 protein has been replaced by arginine.			Amino Acid, Peptide, or Protein	
C130232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130232>	C94600	BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.1457T>C Mutation|BCR/ABL Fusion Gene with NM_005157.4:c.1457T>C|BCR/ABL Fusion Gene with NM_005157.5:c.1457T>C|BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.1457T>C|BCR/ABL1 Fusion Gene with NM_005157.4:c.1457T>C|BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.1457T>C Mutation	A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where thymine has been substituted with cytosine at nucleotide position 1457 of the ABL1 gene.			Gene or Genome	
C130233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130233>	C16325	BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.F486S|BCR-ABL F486S Mutation|BCR-ABL Phe486Ser Mutation|BCR-ABL1 F486S Mutation|BCR-ABL1 Phe486Ser Mutation|BCR/ABL F486S Mutation|BCR/ABL Fusion Protein with F486S|BCR/ABL Fusion Protein with Phe486Ser|BCR/ABL Phe486Ser Mutation|BCR/ABL1 F486S Mutation|BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Phe486Ser|BCR/ABL1 Fusion Protein with NP_005148.2:p.F486S|BCR/ABL1 Fusion Protein with NP_005148.2:p.Phe486Ser|BCR/ABL1 Phe486Ser Mutation|BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.F486S|F486S	A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.1457T>C mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the phenylalanine at position 486 of the ABL1 protein has been replaced by serine.			Amino Acid, Peptide, or Protein	
C130234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130234>	C167255	Castration-Resistant Prostate Carcinoma|CRPC|Castration-Resistant Prostate Cancer|Castration-Resistant Prostate Cancer	A prostate carcinoma that grows and continues to spread despite the surgical removal of the testes or medical intervention to block androgen production.	Castration-Resistant Prostate Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C130235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130235>	C117719	Castration Resistance	A finding indicating that a prostate carcinoma continues to grow despite the surgical removal of the testes or medical intervention to block androgen production.			Finding	
C130236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130236>	C156028	ROS1 Gene Rearrangement|MCF3 Gene Rearrangement|ROS Gene Rearrangement|ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene Rearrangement|ROS1 Rearrangement|ROS1 rearranged|Rearrangement identified|c-ros-1 Gene Rearrangement	A molecular abnormality indicating rearrangement of the ROS1 gene.	ROS1 Gene Rearrangement		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C130237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130237>	C88152|C7796	Stage IB Mycosis Fungoides AJCC v7|Stage IB Mycosis Fungoides|Stage IB Mycosis Fungoides	Stage IB includes: T2, N0, M0, B0-1. T2: Patches, papules, or plaques covering 10% or more of the skin surface.  May further stratify into T2a (patch only) vs. T2b (plaque +/- patch).  N0: No clinically abnormal peripheral lymph nodes; biopsy not required.  M0: No visceral organ involvement.  B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells).  B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2.  (AJCC 7th ed.)	Stage IB Mycosis Fungoides		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C130238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130238>	C118970	CDISC Clinical Classification BUERS Test Name Terminology|BUERS1TN|Brooke Upper Extremity Rating Scale Clinical Classification Test Name|CC-BUERS TEST	Test names of clinical classification questions associated with the Brooke Upper Extremity Rating Scale (BUERS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130239>	C118970	CDISC Clinical Classification BUERS Test Code Terminology|BUERS1TC|Brooke Upper Extremity Rating Scale Clinical Classification Test Code|CC-BUERS TESTCD	Test codes of clinical classification questions associated with the Brooke Upper Extremity Rating Scale (BUERS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13023>	C25762	Heart Part	Any component of the organ which receives blood from the veins and ejects it into the arteries.	Heart Part		Body Part, Organ, or Organ Component	
C130240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130240>	C118970	CDISC Clinical Classification VLERS Test Name Terminology|CC-VLERS TEST|VLERS1TN|Vignos Lower Extremity Rating Scale Clinical Classification Test Name	Test names of clinical classification questions associated with the Vignos Lower Extremity Rating Scale (VLERS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130241>	C118970	CDISC Clinical Classification VLERS Test Code Terminology|CC-VLERS TESTCD|VLERS1TC|Vignos Lower Extremity Rating Scale Clinical Classification Test Code	Test codes of clinical classification questions associated with the Vignos Lower Extremity Rating Scale (VLERS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130242>	C118970	CDISC Clinical Classification HAM-D6 Clinician Version Test Name Terminology|CC-HAM-D6 Clinician Version TEST|HAMD4TN|Hamilton Depression Rating Scale - 6 Clinician Version Clinical Classification Test Name	Test names of clinical classification questions associated with the Hamilton Depression Rating Scale 6 Clinician Version (HAM-D6 Clinician Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130243>	C118970	CDISC Clinical Classification HAM-D6 Clinician Version Test Code Terminology|CC-HAM-D6 Clinician Version TESTCD|HAMD4TC|Hamilton Depression Rating Scale - 6 Clinician Version Clinical Classification Test Code	Test codes of clinical classification questions associated with the Hamilton Depression Rating Scale 6 Clinician Version (HAM-D6 Clinician Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130244>	C118970	CDISC Clinical Classification HAMD 24 Test Name Terminology|CC-HAMD 24 TEST|HAMD3TN|Hamilton Depression Rating Scale - 24 Item Clinical Classification Test Name	Test names of clinical classification questions associated with the Hamilton Depression Rating Scale-24 Item (HAMD 24) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130245>	C118970	CDISC Clinical Classification HAMD 24 Test Code Terminology|CC-HAMD 24 TESTCD|HAMD3TC|Hamilton Depression Rating Scale - 24 Item Clinical Classification Test Code	Test codes of clinical classification questions associated with the Hamilton Depression Rating Scale-24 Item (HAMD 24) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130246>	C118970	CDISC Clinical Classification IDS-C Test Name Terminology|CC-IDS-C TEST|IDSC1TN|Inventory of Depressive Symptomatology Clinician-Rated Version Clinical Classification Test Name	Test names of clinical classification questions associated with the Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130247>	C118970	CDISC Clinical Classification IDS-C Test Code Terminology|CC-IDS-C TESTCD|IDSC1TC|Inventory of Depressive Symptomatology Clinician-Rated Version Clinical Classification Test Code	Test codes of clinical classification questions associated with the Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130248>	C118970	CDISC Clinical Classification QIDS-C Test Name Terminology|CC-QIDS-C TEST|QIDSC1TN|Quick Inventory of Depressive Symptomatology Clinician-Rated Version Clinical Classification Test Name	Test names of clinical classification questions associated with the Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130249>	C118970	CDISC Clinical Classification QIDS-C Test Code Terminology|CC-QIDS-C TESTCD|QIDSC1TC|Quick Inventory of Depressive Symptomatology Clinician-Rated Version Clinical Classification Test Code	Test codes of clinical classification questions associated with the Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13024>	C25763	Pancreas Part	Any component of the organ behind the lower part of the stomach that is fish-shaped and is a compound gland composed of both exocrine and endocrine tissues that make and secrete insulin and enzymes that help the body digest food.	Pancreas Part		Body Part, Organ, or Organ Component	
C130250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130250>	C118970	CDISC Clinical Classification KDPI Test Name Terminology|CC-KDPI TEST|KDPI01TN|Kidney Donor Profile Index Clinical Classification Test Name	Test names of clinical classification questions associated with the Kidney Donor Profile Index (KDPI) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130251>	C118970	CDISC Clinical Classification KDPI Test Code Terminology|CC-KDPI TESTCD|KDPI01TC|Kidney Donor Profile Index Clinical Classification Test Code	Test codes of clinical classification questions associated with the Kidney Donor Profile Index (KDPI) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130252>	C100110	CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|FAC017TN|Functional Assessment of Cancer Therapy-Leukemia Version 4 Questionnaire Test Name|QS-FACT-LEU Version 4 TEST	Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130253>	C100110	CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|FAC017TC|Functional Assessment of Cancer Therapy-Leukemia Version 4 Questionnaire Test Code|QS-FACT-LEU Version 4 TESTCD	Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130254>	C100110	CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|FAC015TN|Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 Questionnaire Test Name|QS-FACT-HEP Version 4 TEST	Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130255>	C100110	CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|FAC015TC|Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 Questionnaire Test Code|QS-FACT-HEP Version 4 TESTCD	Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130256>	C100110	CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|FAC018TN|Functional Assessment of Cancer Therapy-Lymphoma Version 4 Questionnaire Test Name|QS-FACT-LYM Version 4 TEST	Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130257>	C100110	CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|FAC018TC|Functional Assessment of Cancer Therapy-Lymphoma Version 4 Questionnaire Test Code|QS-FACT-LYM Version 4 TESTCD	Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130258>	C100110	CDISC Questionnaire HAM-D6 Self-Report Version Test Name Terminology|HAMDS1TN|Hamilton Depression Rating Scale - 6 Self-Report Questionnaire Test Name|QS-HAM-D6 Self-Report Version TEST	Test names of questionnaire questions associated with the Hamilton Depression Rating Scale 6 Self-Report Version (HAM-D6 Self-Report Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130259>	C100110	CDISC Questionnaire HAM-D6 Self-Report Version Test Code Terminology|HAMDS1TC|Hamilton Depression Rating Scale - 6 Self-Report Questionnaire Test Code|QS-HAM-D6 Self-Report Version TESTCD	Test codes of questionnaire questions associated with the Hamilton Depression Rating Scale 6 Self-Report Version (HAM-D6 Self-Report Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130260>	C100110	CDISC Questionnaire IDS-SR Test Name Terminology|IDSR1TN|Inventory of Depressive Symptomatology Self-Report Version Questionnaire Test Name|QS-IDS-SR TEST	Test names of questionnaire questions associated with the Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130261>	C100110	CDISC Questionnaire IDS-SR Test Code Terminology|IDSR1TC|Inventory of Depressive Symptomatology Self-Report Version Questionnaire Test Code|QS-IDS-SR TESTCD	Test codes of questionnaire questions associated with the Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130262>	C100110	CDISC Questionnaire QIDS-SR Test Name Terminology|QIDSR1TN|QS-QIDS-SR TEST|Quick Inventory of Depressive Symptomatology Self-Report Version Questionnaire Test Name	Test names of questionnaire questions associated with the Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130263>	C100110	CDISC Questionnaire QIDS-SR Test Code Terminology|QIDSR1TC|QS-QIDS-SR TESTCD|Quick Inventory of Depressive Symptomatology Self-Report Version Questionnaire Test Code	Test codes of questionnaire questions associated with the Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130264>	C100110	CDISC Questionnaire Q-LES-Q Test Name Terminology|QLES1TN|QS-Q-LES-Q TEST|Quality Of Life Enjoyment And Satisfaction Questionnaire Test Name	Test names of questionnaire questions associated with the Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130265>	C100110	CDISC Questionnaire Q-LES-Q Test Code Terminology|QLES1TC|QS-Q-LES-Q TESTCD|Quality Of Life Enjoyment And Satisfaction Questionnaire Test Code	Test codes of questionnaire questions associated with the Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130266>	C100110	CDISC Questionnaire Q-LES-Q-SF Test Name Terminology|QLES2TN|QS-Q-LES-Q-SF TEST|Quality Of Life Enjoyment And Satisfaction Questionnaire - Short Form Test Name	Test names of questionnaire questions associated with the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130267>	C100110	CDISC Questionnaire Q-LES-Q-SF Test Code Terminology|QLES2TC|QS-Q-LES-Q-SF TESTCD|Quality Of Life Enjoyment And Satisfaction Questionnaire - Short Form Test Code	Test codes of questionnaire questions associated with the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130268>	C100110	CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|QS-WHODAS 2.0 36-item Version Interviewer-administered TEST|WD5TN|World Health Organization Disability Assessment Schedule 2.0 - 36-Item Interviewer Questionnaire Test Name	Test names of questionnaire questions associated with the World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130269>	C100110	CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|QS-WHODAS 2.0 36-item Version Interviewer-administered TESTCD|WD5TC|World Health Organization Disability Assessment Schedule 2.0 - 36-Item Interviewer Questionnaire Test Code	Test codes of questionnaire questions associated with the World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130270>	C100110	CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|QS-WHODAS 2.0 36-item Version Proxy-administered TEST|WD6TN|World Health Organization Disability Assessment Schedule 2.0 - 36-Item Proxy Questionnaire Test Name	Test names of questionnaire questions associated with the World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130271>	C100110	CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|QS-WHODAS 2.0 36-item Version Proxy-administered TESTCD|WD6TC|World Health Organization Disability Assessment Schedule 2.0 - 36-Item Proxy Questionnaire Test Code	Test codes of questionnaire questions associated with the World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130272>	C100110	CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|QS-WHODAS 2.0 36-item Version Self-administered TEST|WD7TN|World Health Organization Disability Assessment Schedule 2.0 - 36-Item Self Questionnaire Test Name	Test names of questionnaire questions associated with the World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130273>	C100110	CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|QS-WHODAS 2.0 36-item Version Self-administered TESTCD|WD7TC|World Health Organization Disability Assessment Schedule 2.0 - 36-Item Self Questionnaire Test Code	Test codes of questionnaire questions associated with the World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130274>	C100110	CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Name Terminology|QS-WHODAS 2.0 12-item Version Interviewer-administered TEST|WD1TN|World Health Organization Disability Assessment Schedule 2.0 - 12-Item Interviewer Questionnaire Test Name	Test names of questionnaire questions associated with the World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130275>	C100110	CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Code Terminology|QS-WHODAS 2.0 12-item Version Interviewer-administered TESTCD|WD1TC|World Health Organization Disability Assessment Schedule 2.0 - 12-Item Interviewer Questionnaire Test Code	Test codes of questionnaire questions associated with the World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130276>	C100110	CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Name Terminology|QS-WHODAS 2.0 12-item Version Proxy-administered TEST|WD2TN|World Health Organization Disability Assessment Schedule 2.0 - 12-Item Proxy Questionnaire Test Name	Test names of questionnaire questions associated with the World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130277>	C100110	CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Code Terminology|QS-WHODAS 2.0 12-item Version Proxy-administered TESTCD|WD2TC|World Health Organization Disability Assessment Schedule 2.0 - 12-Item Proxy Questionnaire Test Code	Test codes of questionnaire questions associated with the World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130278>	C100110	CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Name Terminology|QS-WHODAS 2.0 12-item Version Self-administered TEST|WD3TN|World Health Organization Disability Assessment Schedule 2.0 - 12-Item Self Questionnaire Test Name	Test names of questionnaire questions associated with the World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130279>	C100110	CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Code Terminology|QS-WHODAS 2.0 12-item Version Self-administered TESTCD|WD3TC|World Health Organization Disability Assessment Schedule 2.0 - 12-Item Self Questionnaire Test Code	Test codes of questionnaire questions associated with the World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130280>	C100110	CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|QS-WHODAS 2.0 12+24-item Version Interviewer-administered TEST|WD4TN|World Health Organization Disability Assessment Schedule 2.0 - 12 + 24-Item Interviewer Questionnaire Test Name	Test names of questionnaire questions associated with the World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130281>	C100110	CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|QS-WHODAS 2.0 12+24-item Version Interviewer-administered TESTCD|WD4TC|World Health Organization Disability Assessment Schedule 2.0 - 12 + 24-Item Interviewer Questionnaire Test Code	Test codes of questionnaire questions associated with the World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130282>	C211913	BUERS Clinical Classification Question	A question associated with the BUERS clinical classification.			Intellectual Product	
C130283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130283>	C211913	VLERS Clinical Classification Question	A question associated with the VLERS clinical classification.			Intellectual Product	
C130284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130284>	C211913	HAM-D6 Clinician Version Clinical Classification Question	A question associated with the HAM-D6 Clinician Version clinical classification.			Intellectual Product	
C130285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130285>	C211913	HAMD 24 Clinical Classification Question	A question associated with the HAMD 24 clinical classification.			Intellectual Product	
C130286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130286>	C211913	IDS-C Clinical Classification Question	A question associated with the IDS-C clinical classification.			Intellectual Product	
C130287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130287>	C211913	QIDS-C Clinical Classification Question	A question associated with the QIDS-C clinical classification.			Intellectual Product	
C130288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130288>	C211913	KDPI Clinical Classification Question	A question associated with the KDPI clinical classification.			Intellectual Product	
C130289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130289>	C211913	FACT-LEU Version 4 Questionnaire Question	A question associated with the FACT-LEU Version 4 questionnaire.			Intellectual Product	
C130290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130290>	C211913	FACT-HEP Version 4 Questionnaire Question	A question associated with the FACT-HEP Version 4 questionnaire.			Intellectual Product	
C130291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130291>	C211913	FACT-LYM Version 4 Questionnaire Question	A question associated with the FACT-LYM Version 4 questionnaire.			Intellectual Product	
C130292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130292>	C211913	HAM-D6 Self-Report Version Questionnaire Question	A question associated with the HAM-D6 Self-Report Version questionnaire.			Intellectual Product	
C130293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130293>	C211913	IDS-SR Questionnaire Question	A question associated with the IDS-SR questionnaire.			Intellectual Product	
C130294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130294>	C211913	QIDS-SR Questionnaire Question	A question associated with the QIDS-SR questionnaire.			Intellectual Product	
C130295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130295>	C211913	Q-LES-Q Questionnaire Question	A question associated with the Q-LES-Q questionnaire.			Intellectual Product	
C130296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130296>	C211913	Q-LES-Q-SF Questionnaire Question	A question associated with the Q-LES-Q-SF questionnaire.			Intellectual Product	
C130297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130297>	C211913	WHODAS 2.0 36-item Version Interviewer-administered Questionnaire Question	A question associated with the WHODAS 2.0 36-item Version Interviewer-administered questionnaire.			Intellectual Product	
C130298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130298>	C211913	WHODAS 2.0 36-item Version Proxy-administered Questionnaire Question	A question associated with the WHODAS 2.0 36-item Version Proxy-administered questionnaire.			Intellectual Product	
C130299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130299>	C211913	WHODAS 2.0 36-item Version Self-administered Questionnaire Question	A question associated with the WHODAS 2.0 36-item Version Self-administered questionnaire.			Intellectual Product	
C13029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13029>	C32221	Endocrine System Part	Any component of the tissues capable of secreting hormones.	Endocrine System Part		Body Part, Organ, or Organ Component	
C1302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1302>	C1591	Recombinant I309|CCL1|I309	A recombinant form of human I-309, an inflammatory CXC cytokine secreted by activated T lymphocytes that appears to be an inducer of angiogenesis.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C130300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130300>	C211913	WHODAS 2.0 12-item Version Interviewer-administered Questionnaire Question	A question associated with the WHODAS 2.0 12-item Version Interviewer-administered questionnaire.			Intellectual Product	
C130301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130301>	C211913	WHODAS 2.0 12-item Version Proxy-administered Questionnaire Question	A question associated with the WHODAS 2.0 12-item Version Proxy-administered questionnaire.			Intellectual Product	
C130302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130302>	C211913	WHODAS 2.0 12-item Version Self-administered Questionnaire Question	A question associated with the WHODAS 2.0 12-item Version Self-administered questionnaire.			Intellectual Product	
C130303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130303>	C211913	WHODAS 2.0 12 24-item Version Interviewer-administered Questionnaire Question	A question associated with the WHODAS 2.0 12+24-item Version Interviewer-administered questionnaire.			Intellectual Product	
C130304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130304>	C118969	Brooke Upper Extremity Rating Scale Clinical Classification|BUERS|BUERS|BUERS1	A standardized 6-item clinician rating scale for the assessment of upper extremity function in patients diagnosed with neuromuscular disease. The scale was developed by Brooke, et al. in 1981 to evaluate disease severity in patients with Duchenne muscular dystrophy.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130305>	C118969	Vignos Lower Extremity Rating Scale Clinical Classification|VLERS|VLERS|VLERS1	A standardized 10-item clinician rating scale for the assessment of lower extremity function in patients diagnosed with neuromuscular disease. The scale was developed by Vignos, et al. in 1963 to evaluate ability and methods used for elevation and ambulation in patients with childhood progressive muscular dystrophy.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130306>	C118969	Hamilton Depression Rating Scale 6 Clinician Version Clinical Classification|HAM-D6 Clinician Version|HAMD 6 CLINICIAN VERSION|HAMD4	A standardized 6-item clinician rating scale for the assessment of symptoms in patients diagnosed with depression. The original 17-item Hamilton Depression Scale, developed by Max Hamilton at the University of Leeds in 1960, was independently modified by Bech, et al. in 1975, using Rasch models, to create a subscale that contains six variables.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130307>	C118969	Hamilton Depression Rating Scale-24 Item Clinical Classification|HAMD 24|HAMD 24|HAMD3	A standardized 24-item rating scale for the assessment of symptoms in patients diagnosed with depression. The original 17-item Hamilton Depression Scale, developed by Max Hamilton at the University of Leeds in 1960, was later modified to include 24 variables.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130308>	C118969	Inventory of Depressive Symptomatology Clinician-Rated Version Clinical Classification|IDS-C|IDS-C|IDSC1	A standardized 30-item clinician-scored questionnaire that utilizes a 5-point rating scale for the assessment of the severity of depressive symptoms over the seven day period prior to evaluation. The questionnaire, which was created by Rush, et al. in 1986, originally consisted of 28 items including the nine diagnostic DSM-IV symptom domains used to characterize a major depressive episode, as well as items to address melancholic and atypical features. Two additional items were later added to address leaden paralysis and interpersonal rejection sensitivity.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130309>	C118969	Quick Inventory of Depressive Symptomatology Clinician-Rated Version Clinical Classification|QIDS-C|QIDS-C|QIDSC1	A standardized 16-item clinician-scored questionnaire, derived from the 30-item Inventory of Depressive Symptomatology (IDS), that utilizes a 5-point rating scale for the assessment of the severity of depressive symptoms over the seven day period prior to evaluation. The original questionnaire, created by Rush et al. in 1986, includes the nine diagnostic DSM-IV symptom domains that are used to characterize a major depressive episode, as well as items to address melancholic and atypical features. The shortened, 16-item version was initially developed by Rush et al. in 2000 by selecting only items from the original scale that assessed DSM-IV criterion diagnostic symptoms.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130310>	C118969	Kidney Donor Profile Index Clinical Classification|KDPI|KDPI|KDPI01	A standardized clinician scored index created by Rao et al. in 2009 that combines ten donor factors, including demographics and medical history, to calculate the likelihood of graft failure after deceased donor kidney transplant.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130311>	C91105	Functional Assessment of Cancer Therapy-Leukemia Version 4 Questionnaire|FAC017|FACT-LEU V4|FACT-LEU Version 4	A standardized 44-item self-report questionnaire that utilizes a 5-point rating scale to evaluate quality of life in patients with acute and chronic leukemia. The questionnaire, composed of the 27-item Functional Assessment of Cancer Therapy-General (FACT-G) and 17 additional leukemia specific items, was developed by Cella et al. in 2012 and is divided into five subscales: physical well-being, social/family well-being, emotional well-being, functional well-being, and additional concerns.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130312>	C91105	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 Questionnaire|FAC015|FACT-HEP V4|FACT-HEP Version 4	A standardized 45-item self-report questionnaire that utilizes a 5-point rating scale to evaluate quality of life in patients with hepatobiliary cancers. The questionnaire, composed of the 27-item Functional Assessment of Cancer Therapy-General (FACT-G) and 18 additional hepatobiliary specific items, was developed by Heffernan and Cella et al. in 2002 and is divided into five subscales: physical well-being, social/family well-being, emotional well-being, functional well-being, and additional concerns.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130313>	C91105	Functional Assessment of Cancer Therapy-Lymphoma Version 4 Questionnaire|FAC018|FACT-LYM V4|FACT-LYM Version 4	A standardized 49-item self-report questionnaire that utilizes a 5-point rating scale to evaluate quality of life in patients with Non-Hodgkin lymphoma. The questionnaire, composed of the 27-item Functional Assessment of Cancer Therapy-General (FACT-G) and 22 additional Non-Hodgkin lymphoma specific items, was developed by Cella et al. in 2005 and is divided into five subscales: physical well-being, social/family well-being, emotional well-being, functional well-being, and additional concerns.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130314>	C91105	Hamilton Depression Rating Scale 6 Self-Report Version Questionnaire|HAM-D6 Self-Report Version|HAMD 6 SELF-REPORT VERSION|HAMDS1	A standardized 6-item self-report rating scale for the assessment of symptoms in patients diagnosed with depression. The original 17-item Hamilton Depression Scale, developed by Max Hamilton at the University of Leeds in 1960, was independently modified by Bech et al in 1975, using Rasch models, to create a melancholia subscale that contains six variables.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130315>	C91105	Inventory of Depressive Symptomatology Self-Report Version Questionnaire|IDS-SR|IDS-SR|IDSR1	A standardized 30-item self-report questionnaire that utilizes a 5-point rating scale for the assessment of the severity of depressive symptoms over the seven day period prior to evaluation. The questionnaire, which was created by Rush, et al. in 1986, originally consisted of 28 items including the nine diagnostic DSM-IV symptom domains used to characterize a major depressive episode, as well as items to address melancholic and atypical features. Two additional items were later added to address leaden paralysis and interpersonal rejection sensitivity.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130316>	C91105	Quick Inventory of Depressive Symptomatology Self-Report Version Questionnaire|QIDS-SR|QIDS-SR|QIDSR1	A standardized 16-item self-report questionnaire, derived from the 30-item Inventory of Depressive Symptomatology (IDS), that utilizes a 5-point rating scale for the assessment of the severity of depressive symptoms over the seven day period prior to evaluation. The original questionnaire, created by Rush et al. in 1986, includes the nine diagnostic DSM-IV symptom domains that are used to characterize a major depressive episode, as well as items to address melancholic and atypical features. The shortened, 16-item version was initially developed by Rush et al. in 2000 by selecting only items from the original scale that assessed DSM-IV criterion diagnostic symptoms.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130317>	C91105	Quality Of Life Enjoyment And Satisfaction Questionnaire|Q-LES-Q|Q-LES-Q|QLES1	A standardized self-report questionnaire, available as a 16-item short form for adults and 93-item long form for children, adolescents, and adults, that utilizes a 5-point rating scale to assess the degree of enjoyment and satisfaction experienced by individuals in various areas of daily functioning. The questionnaire was developed by Endicot et al. in 1993 to assess broad functional impairment in research and treatment settings.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130318>	C91105	Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form|Q-LES-Q-SF|Q-LES-Q-SF|QLES2	A standardized 16-item self-report questionnaire that utilizes a 5-point rating scale to assess the degree of enjoyment and satisfaction experienced by adults in various areas of daily functioning. The questionnaire was developed by Endicot et al. in 1993 to assess broad functional impairment in research and treatment settings.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130319>	C91105	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered Questionnaire|WD5|WHODAS 2.0 - 36-ITEM INTERVIEWER|WHODAS 2.0 36-item Version Interviewer-administered	A standardized 36-item interviewer-administered questionnaire that utilizes a 5-point rating scale to assess an individual's ability to perform activities in six domains of functioning over the 30 days prior to evaluation in order to calculate a global disability score. The questionnaire was developed in 2010 by the World Health Organization (WHO) Classification, Terminology and Standards team, within the framework of the WHO/National Institutes of Health (NIH) Joint Project on Assessment and Classification of Disability.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13031>	C33966	Brain Part	Any component of the central nervous system that is contained within the cranium.	Brain Part		Body Part, Organ, or Organ Component	
C130320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130320>	C91105	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered Questionnaire|WD6|WHODAS 2.0 - 36-ITEM PROXY|WHODAS 2.0 36-item Version Proxy-administered	A standardized 36-item questionnaire, administered by a friend, relative, or caretaker, that utilizes a 5-point rating scale to assess an individual's ability to perform activities in six domains of functioning over the 30 days prior to evaluation in order to calculate a global disability score. The questionnaire was developed in 2010 by the World Health Organization (WHO) Classification, Terminology and Standards team, within the framework of the WHO/National Institutes of Health (NIH) Joint Project on Assessment and Classification of Disability.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130321>	C91105	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered Questionnaire|WD7|WHODAS 2.0 - 36-ITEM SELF|WHODAS 2.0 36-item Version Self-administered	A standardized 36-item self-report questionnaire that utilizes a 5-point rating scale to assess an individual's ability to perform activities in six domains of functioning over the 30 days prior to evaluation in order to calculate a global disability score. The questionnaire was developed in 2010 by the World Health Organization (WHO) Classification, Terminology and Standards team, within the framework of the WHO/National Institutes of Health (NIH) Joint Project on Assessment and Classification of Disability.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130322>	C91105	World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered Questionnaire|WD1|WHODAS 2.0 - 12-ITEM INTERVIEWER|WHODAS 2.0 12-item Version Interviewer-administered	A standardized 12-item interviewer-administered questionnaire that utilizes a 5-point rating scale to provide a brief assessment of an individual's ability to perform activities in six domains of functioning over the 30 days prior to evaluation in order to calculate a global disability score. The questionnaire was developed in 2010 by the World Health Organization (WHO) Classification, Terminology and Standards team, within the framework of the WHO/National Institutes of Health (NIH) Joint Project on Assessment and Classification of Disability.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130323>	C91105	World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered Questionnaire|WD2|WHODAS 2.0 - 12-ITEM PROXY|WHODAS 2.0 12-item Version Proxy-administered	A standardized 12-item questionnaire, administered by a friend, relative, or caretaker, that utilizes a 5-point rating scale to provide a brief assessment of an individual's ability to perform activities in six domains of functioning over the 30 days prior to evaluation in order to calculate a global disability score. The questionnaire was developed in 2010 by the World Health Organization (WHO) Classification, Terminology and Standards team, within the framework of the WHO/National Institutes of Health (NIH) Joint Project on Assessment and Classification of Disability.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130324>	C91105	World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered Questionnaire|WD3|WHODAS 2.0 - 12-ITEM SELF|WHODAS 2.0 12-item Version Self-administered	A standardized 12-item self-report questionnaire that utilizes a 5-point rating scale to provide a brief assessment of an individual's ability to perform activities in six domains of functioning over the 30 days prior to evaluation in order to calculate a global disability score. The questionnaire was developed in 2010 by the World Health Organization (WHO) Classification, Terminology and Standards team, within the framework of the WHO/National Institutes of Health (NIH) Joint Project on Assessment and Classification of Disability.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130325>	C91105	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered Questionnaire|WD4|WHODAS 2.0 - 12 + 24-ITEM INTERVIEWER|WHODAS 2.0 12+24-item Version Interviewer-administered	A standardized interviewer-administered or computer-adaptive testing (CAT) questionnaire that utilizes a 5-point rating scale to assess an individual's ability to perform activities in six domains of functioning over the 30 days prior to evaluation in order to calculate a global disability score. The questionnaire is initially administered as 12 items to screen for problematic domains of functioning. Up to 24 items are then added based on the initial responses. The questionnaire was developed in 2010 by the World Health Organization (WHO) Classification, Terminology and Standards team, within the framework of the WHO/National Institutes of Health (NIH) Joint Project on Assessment and Classification of Disability.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130326>	C130282	BUERS - Brooke Upper Extremity Rating Scale|BUERS1-Brooke Upper Extremity Rating|BUERS1-Brooke Upper Extremity Rating|BUERS101	Brooke Upper Extremity Rating Scale (BUERS) Brooke upper extremity rating scale.			Intellectual Product	CDISC Clinical Classification BUERS Test Code Terminology|CDISC Clinical Classification BUERS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130327>	C130283	VLERS - Vignos Lower Extremity Rating|VLERS1-Vignos Lower Extremity Rating|VLERS1-Vignos Lower Extremity Rating|VLERS101	Vignos Lower Extremity Rating Scale (VLERS) Vignos rating scale.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification VLERS Test Code Terminology|CDISC Clinical Classification VLERS Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130328>	C130284	HAM-D6 - Clinician Version - Depressed Mood|HAMD4-Depressed Mood|HAMD4-Depressed Mood|HAMD401	Hamilton Depression Rating Scale 6 Clinician Version (HAM-D6 Clinician Version) Depressed mood.			Intellectual Product	CDISC Clinical Classification HAM-D6 Clinician Version Test Code Terminology|CDISC Clinical Classification HAM-D6 Clinician Version Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130329>	C130284	HAM-D6 - Clinician Version - Low Self-esteem and Guilt|HAMD4-Low Self-esteem and Guilt|HAMD4-Low Self-esteem and Guilt|HAMD402	Hamilton Depression Rating Scale 6 Clinician Version (HAM-D6 Clinician Version) Low self-esteem and guilt.			Intellectual Product	CDISC Clinical Classification HAM-D6 Clinician Version Test Code Terminology|CDISC Clinical Classification HAM-D6 Clinician Version Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130330>	C130284	HAM-D6 - Clinician Version - Social Life Activities or Interests|HAMD4-Social Life Activities/Interests|HAMD4-Social Life Activities/Interests|HAMD403	Hamilton Depression Rating Scale 6 Clinician Version (HAM-D6 Clinician Version) Social life activities and interests.			Intellectual Product	CDISC Clinical Classification HAM-D6 Clinician Version Test Code Terminology|CDISC Clinical Classification HAM-D6 Clinician Version Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130331>	C130284	HAM-D6 - Clinician Version - Psychomotor Retardation, General|HAMD4-Psychomotor Retardation, General|HAMD4-Psychomotor Retardation, General|HAMD404	Hamilton Depression Rating Scale 6 Clinician Version (HAM-D6 Clinician Version) Psychomotor retardation, general.			Intellectual Product	CDISC Clinical Classification HAM-D6 Clinician Version Test Code Terminology|CDISC Clinical Classification HAM-D6 Clinician Version Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130332>	C130284	HAM-D6 - Clinician Version - Psychic Anxiety|HAMD4-Psychic Anxiety|HAMD4-Psychic Anxiety|HAMD405	Hamilton Depression Rating Scale 6 Clinician Version (HAM-D6 Clinician Version) Psychic anxiety.			Intellectual Product	CDISC Clinical Classification HAM-D6 Clinician Version Test Code Terminology|CDISC Clinical Classification HAM-D6 Clinician Version Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130333>	C130284	HAM-D6 - Clinician Version - Tiredness and Pains|HAMD4-Tiredness and Pains|HAMD4-Tiredness and Pains|HAMD406	Hamilton Depression Rating Scale 6 Clinician Version (HAM-D6 Clinician Version) Tiredness and pains.			Intellectual Product	CDISC Clinical Classification HAM-D6 Clinician Version Test Code Terminology|CDISC Clinical Classification HAM-D6 Clinician Version Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130334>	C130284	HAM-D6 - Clinician Version - Total Score|HAMD4-Total Score|HAMD4-Total Score|HAMD407	Hamilton Depression Rating Scale 6 Clinician Version (HAM-D6 Clinician Version) Total score.			Intellectual Product	CDISC Clinical Classification HAM-D6 Clinician Version Test Code Terminology|CDISC Clinical Classification HAM-D6 Clinician Version Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130335>	C130285	HAMD 24 - Depressed Mood|HAMD3-Depressed Mood|HAMD3-Depressed Mood|HAMD301	Hamilton Depression Rating Scale-24 Item (HAMD 24) Depressed mood.			Intellectual Product	CDISC Clinical Classification HAMD 24 Test Code Terminology|CDISC Clinical Classification HAMD 24 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130336>	C130285	HAMD 24 - Low Self-esteem, Guilt|HAMD3-Low Self-Esteem, Guilt|HAMD3-Low Self-Esteem, Guilt|HAMD302	Hamilton Depression Rating Scale-24 Item (HAMD 24) Low self-esteem, guilt.			Intellectual Product	CDISC Clinical Classification HAMD 24 Test Code Terminology|CDISC Clinical Classification HAMD 24 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130337>	C130285	HAMD 24 - Suicidal Thoughts|HAMD3-Suicidal Thoughts|HAMD3-Suicidal Thoughts|HAMD303	Hamilton Depression Rating Scale-24 Item (HAMD 24) Suicidal thoughts.			Intellectual Product	CDISC Clinical Classification HAMD 24 Test Code Terminology|CDISC Clinical Classification HAMD 24 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130338>	C130285	HAMD 24 - Insomnia - Initial|HAMD3-Insomnia - Initial|HAMD3-Insomnia - Initial|HAMD304	Hamilton Depression Rating Scale-24 Item (HAMD 24) Insomnia: initial.			Intellectual Product	CDISC Clinical Classification HAMD 24 Test Code Terminology|CDISC Clinical Classification HAMD 24 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130339>	C130285	HAMD 24 - Insomnia - Middle|HAMD3-Insomnia - Middle|HAMD3-Insomnia - Middle|HAMD305	Hamilton Depression Rating Scale-24 Item (HAMD 24) Insomnia: middle.			Intellectual Product	CDISC Clinical Classification HAMD 24 Test Code Terminology|CDISC Clinical Classification HAMD 24 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13033>	C32221	Immune System Part	Any component of the complex group of organs including the thymus, spleen, tonsils, lymphatic system, hematopoietic system and cells like lymphocytes, granulocytes, monocytes and macrophages that defends the body against infection or disease.	Immune System Part		Body Part, Organ, or Organ Component	
C130340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130340>	C130285	HAMD 24 - Insomnia - Late|HAMD3-Insomnia - Late|HAMD3-Insomnia - Late|HAMD306	Hamilton Depression Rating Scale-24 Item (HAMD 24) Insomnia: late.			Intellectual Product	CDISC Clinical Classification HAMD 24 Test Code Terminology|CDISC Clinical Classification HAMD 24 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130341>	C130285	HAMD 24 - Work and Interests|HAMD3-Work and Interests|HAMD3-Work and Interests|HAMD307	Hamilton Depression Rating Scale-24 Item (HAMD 24) Work and interests.			Intellectual Product	CDISC Clinical Classification HAMD 24 Test Code Terminology|CDISC Clinical Classification HAMD 24 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130342>	C130285	HAMD 24 - Psychomotor Retardation|HAMD3-Psychomotor Retardation|HAMD3-Psychomotor Retardation|HAMD308	Hamilton Depression Rating Scale-24 Item (HAMD 24) Psychomotor retardation.			Intellectual Product	CDISC Clinical Classification HAMD 24 Test Code Terminology|CDISC Clinical Classification HAMD 24 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130343>	C130285	HAMD 24 - Psychomotor Agitation|HAMD3-Psychomotor Agitation|HAMD3-Psychomotor Agitation|HAMD309	Hamilton Depression Rating Scale-24 Item (HAMD 24) Psychomotor agitation.			Intellectual Product	CDISC Clinical Classification HAMD 24 Test Code Terminology|CDISC Clinical Classification HAMD 24 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130344>	C130285	HAMD 24 - Anxiety, Psychic|HAMD3-Anxiety - Psychic|HAMD3-Anxiety - Psychic|HAMD310	Hamilton Depression Rating Scale-24 Item (HAMD 24) Anxiety, psychic.			Intellectual Product	CDISC Clinical Classification HAMD 24 Test Code Terminology|CDISC Clinical Classification HAMD 24 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130345>	C130285	HAMD 24 - Anxiety, Somatic|HAMD3-Anxiety - Somatic|HAMD3-Anxiety - Somatic|HAMD311	Hamilton Depression Rating Scale-24 Item (HAMD 24) Anxiety, somatic.			Intellectual Product	CDISC Clinical Classification HAMD 24 Test Code Terminology|CDISC Clinical Classification HAMD 24 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130346>	C130285	HAMD 24 - Gastrointestinal Symptoms (Appetite)|HAMD3-GI Symptoms (Appetite)|HAMD3-GI Symptoms (Appetite)|HAMD312	Hamilton Depression Rating Scale-24 Item (HAMD 24) Gastrointestinal symptoms (appetite).			Intellectual Product	CDISC Clinical Classification HAMD 24 Test Code Terminology|CDISC Clinical Classification HAMD 24 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130347>	C130285	HAMD 24 - Somatic Symptoms, General|HAMD3-Somatic Symptoms - General|HAMD3-Somatic Symptoms - General|HAMD313	Hamilton Depression Rating Scale-24 Item (HAMD 24) Somatic symptoms, general.			Intellectual Product	CDISC Clinical Classification HAMD 24 Test Code Terminology|CDISC Clinical Classification HAMD 24 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130348>	C130285	HAMD 24 - Sexual Disturbances|HAMD3-Sexual Disturbances|HAMD3-Sexual Disturbances|HAMD314	Hamilton Depression Rating Scale-24 Item (HAMD 24) Sexual disturbances.			Intellectual Product	CDISC Clinical Classification HAMD 24 Test Code Terminology|CDISC Clinical Classification HAMD 24 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130349>	C130285	HAMD 24 - Hypochondriasis (Somatisation)|HAMD3-Hypochondriasis (Somatisation)|HAMD3-Hypochondriasis (Somatisation)|HAMD315	Hamilton Depression Rating Scale-24 Item (HAMD 24) Hypochondriasis (somatisation).			Intellectual Product	CDISC Clinical Classification HAMD 24 Test Code Terminology|CDISC Clinical Classification HAMD 24 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130350>	C130285	HAMD 24 - Insight|HAMD3-Insight|HAMD3-Insight|HAMD316	Hamilton Depression Rating Scale-24 Item (HAMD 24) Insight.			Intellectual Product	CDISC Clinical Classification HAMD 24 Test Code Terminology|CDISC Clinical Classification HAMD 24 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130351>	C130285	HAMD 24 - Weight Loss|HAMD3-Weight Loss|HAMD3-Weight Loss|HAMD317	Hamilton Depression Rating Scale-24 Item (HAMD 24) Weight loss.			Intellectual Product	CDISC Clinical Classification HAMD 24 Test Code Terminology|CDISC Clinical Classification HAMD 24 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130352>	C130285	HAMD 24 - Diurnal Variation|HAMD3-Diurnal Variation|HAMD3-Diurnal Variation|HAMD318	Hamilton Depression Rating Scale-24 Item (HAMD 24) Diurnal variation.			Intellectual Product	CDISC Clinical Classification HAMD 24 Test Code Terminology|CDISC Clinical Classification HAMD 24 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130353>	C130285	HAMD 24 - Depersonalization and Derealisation|HAMD3-Depersonalization/Derealization|HAMD3-Depersonalization/Derealization|HAMD319	Hamilton Depression Rating Scale-24 Item (HAMD 24) Depersonalization and derealisation.			Intellectual Product	CDISC Clinical Classification HAMD 24 Test Code Terminology|CDISC Clinical Classification HAMD 24 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130354>	C130285	HAMD 24 - Paranoid Symptoms|HAMD3-Paranoid Symptoms|HAMD3-Paranoid Symptoms|HAMD320	Hamilton Depression Rating Scale-24 Item (HAMD 24) Paranoid symptoms.			Intellectual Product	CDISC Clinical Classification HAMD 24 Test Code Terminology|CDISC Clinical Classification HAMD 24 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130355>	C130285	HAMD 24 - Obsessional and Compulsive Symptoms|HAMD3-Observational/Compulsive Symptoms|HAMD3-Observational/Compulsive Symptoms|HAMD321	Hamilton Depression Rating Scale-24 Item (HAMD 24) Obsessional and compulsive symptoms.			Intellectual Product	CDISC Clinical Classification HAMD 24 Test Code Terminology|CDISC Clinical Classification HAMD 24 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130356>	C130285	HAMD 24 - Helplessness|HAMD3-Helplessness|HAMD3-Helplessness|HAMD322	Hamilton Depression Rating Scale-24 Item (HAMD 24) Helplessness.			Intellectual Product	CDISC Clinical Classification HAMD 24 Test Code Terminology|CDISC Clinical Classification HAMD 24 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130357>	C130285	HAMD 24 - Hopelessness|HAMD3-Hopelessness|HAMD3-Hopelessness|HAMD323	Hamilton Depression Rating Scale-24 Item (HAMD 24) Hopelessness.			Intellectual Product	CDISC Clinical Classification HAMD 24 Test Code Terminology|CDISC Clinical Classification HAMD 24 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130358>	C130285	HAMD 24 - Worthlessness|HAMD3-Worthlessness|HAMD3-Worthlessness|HAMD324	Hamilton Depression Rating Scale-24 Item (HAMD 24) Worthlessness.			Intellectual Product	CDISC Clinical Classification HAMD 24 Test Code Terminology|CDISC Clinical Classification HAMD 24 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130359>	C130285	HAMD 24 - Total Score|HAMD3-Total Score|HAMD3-Total Score|HAMD325	Hamilton Depression Rating Scale-24 Item (HAMD 24) Total score.			Intellectual Product	CDISC Clinical Classification HAMD 24 Test Code Terminology|CDISC Clinical Classification HAMD 24 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13035>	C32221	Urinary System Part	Any component of the organs involved in the creation and excretion of urine.	Urinary System Part		Body Part, Organ, or Organ Component	
C130360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130360>	C130286	IDS-C - Sleep Onset Insomnia|IDSC1-Sleep Onset Insomnia|IDSC1-Sleep Onset Insomnia|IDSC101	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Sleep onset insomnia.			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130361>	C130286	IDS-C - Mid-Nocturnal Insomnia|IDSC1-Mid-Nocturnal Insomnia|IDSC1-Mid-Nocturnal Insomnia|IDSC102	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Mid-nocturnal insomnia.			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130362>	C130286	IDS-C - Early Morning Insomnia|IDSC1-Early Morning Insomnia|IDSC1-Early Morning Insomnia|IDSC103	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Early morning insomnia.			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130363>	C130286	IDS-C - Hypersomnia|IDSC1-Hypersomnia|IDSC1-Hypersomnia|IDSC104	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Hypersomnia.			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130364>	C130286	IDS-C - Mood (Sad)|IDSC1-Mood (Sad)|IDSC1-Mood (Sad)|IDSC105	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Mood (sad).			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130365>	C130286	IDS-C - Mood (Irritable)|IDSC1-Mood (Irritable)|IDSC1-Mood (Irritable)|IDSC106	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Mood (irritable).			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130366>	C130286	IDS-C - Mood (Anxious)|IDSC1-Mood (Anxious)|IDSC1-Mood (Anxious)|IDSC107	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Mood (anxious).			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130367>	C130286	IDS-C - Reactivity of Mood|IDSC1-Reactivity of Mood|IDSC1-Reactivity of Mood|IDSC108	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Reactivity of mood.			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130368>	C130286	IDS-C - Mood Variation|IDSC1-Mood Variation|IDSC1-Mood Variation|IDSC109	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Mood variation.			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130369>	C130286	IDS-C - Mood Worse in Morning, Afternoon, or Night|IDSC1-Mood Worse Morn/Afternoon/Night|IDSC1-Mood Worse Morn/Afternoon/Night|IDSC109A	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Is mood typically worse in morning, afternoon, or night.			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130370>	C130286	IDS-C - Mood Variation Attributed to Environment|IDSC1-Mood Attributed to Environment|IDSC1-Mood Attributed to Environment|IDSC109B	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Is mood variation attributed to environment by the patient?			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130371>	C130286	IDS-C - Quality of Mood|IDSC1-Quality of Mood|IDSC1-Quality of Mood|IDSC110	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Quality of mood.			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130372>	C130286	IDS-C - Appetite (Decreased)|IDSC1-Appetite (Decreased)|IDSC1-Appetite (Decreased)|IDSC111	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Appetite (decreased).			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130373>	C130286	IDS-C - Appetite (Increased)|IDSC1-Appetite (Increased)|IDSC1-Appetite (Increased)|IDSC112	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Appetite (increased).			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130374>	C130286	IDS-C - Weight (Decrease)|IDSC1-Weight (Decrease)|IDSC1-Weight (Decrease)|IDSC113	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Weight (decrease) within the last two weeks.			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130375>	C130286	IDS-C - Weight (Increase)|IDSC1-Weight (Increase)|IDSC1-Weight (Increase)|IDSC114	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Weight (increase) within the last two weeks.			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130376>	C130286	IDS-C - Concentration or Decision Making|IDSC1-Concentration/Decision Making|IDSC1-Concentration/Decision Making|IDSC115	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Concentration/decision making.			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130377>	C130286	IDS-C - Outlook (Self)|IDSC1-Outlook (Self)|IDSC1-Outlook (Self)|IDSC116	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Outlook (self).			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130378>	C130286	IDS-C - Outlook (Future)|IDSC1-Outlook (Future)|IDSC1-Outlook (Future)|IDSC117	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Outlook (future).			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130379>	C130286	IDS-C - Suicidal Ideation|IDSC1-Suicidal Ideation|IDSC1-Suicidal Ideation|IDSC118	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Suicidal ideation.			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13037>	C32221	Respiratory System Part	Any component of the organs involved in the exchange of carbon dioxide and oxygen including the trachea, bronchi, bronchial tubes, lungs, and alveoli.	Respiratory System Part	Header_Concept	Body Part, Organ, or Organ Component	
C130380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130380>	C130286	IDS-C - Involvement|IDSC1-Involvement|IDSC1-Involvement|IDSC119	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Involvement.			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130381>	C130286	IDS-C - Energy or Fatiguability|IDSC1-Energy/Fatiguability|IDSC1-Energy/Fatiguability|IDSC120	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Energy/fatiguability.			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130382>	C130286	IDS-C - Pleasure or Enjoyment|IDSC1-Pleasure/Enjoyment (Exclude Sex)|IDSC1-Pleasure/Enjoyment (Exclude Sex)|IDSC121	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Pleasure/enjoyment (exclude sexual activities).			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130383>	C130286	IDS-C - Sexual Interest|IDSC1-Sexual Interest|IDSC1-Sexual Interest|IDSC122	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Sexual interest.			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130384>	C130286	IDS-C - Psychomotor Slowing|IDSC1-Psychomotor Slowing|IDSC1-Psychomotor Slowing|IDSC123	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Psychomotor slowing.			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130385>	C130286	IDS-C - Psychomotor Agitation|IDSC1-Psychomotor Agitation|IDSC1-Psychomotor Agitation|IDSC124	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Psychomotor agitation.			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130386>	C130286	IDS-C - Somatic Complaints|IDSC1-Somatic Complaints|IDSC1-Somatic Complaints|IDSC125	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Somatic complaints.			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130387>	C130286	IDS-C - Sympathetic Arousal|IDSC1-Sympathetic Arousal|IDSC1-Sympathetic Arousal|IDSC126	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Sympathetic arousal.			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130388>	C130286	IDS-C - Panic or Phobic Symptoms|IDSC1-Panic/Phobic Symptoms|IDSC1-Panic/Phobic Symptoms|IDSC127	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Panic/phobic symptoms.			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130389>	C130286	IDS-C - Gastrointestinal|IDSC1-Gastrointestinal|IDSC1-Gastrointestinal|IDSC128	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Gastrointestinal.			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13038>	C34061	Male Reproductive System Part	Any component of the male organs and tissues involved in the production and maturation of gametes and in their union and subsequent development as offspring.	Male Reproductive System Part		Body Part, Organ, or Organ Component	
C130390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130390>	C130286	IDS-C - Interpersonal Sensitivity|IDSC1-Interpersonal Sensitivity|IDSC1-Interpersonal Sensitivity|IDSC129	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Interpersonal sensitivity.			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130391>	C130286	IDS-C - Leaden Paralysis or Physical Energy|IDSC1-Leaden Paralysis/Physical Energy|IDSC1-Leaden Paralysis/Physical Energy|IDSC130	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Please circle one response to each item that best describes the patient for the last seven days: Leaden paralysis/physical energy.			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130392>	C130286	IDS-C - Score|IDSC1-Score|IDSC1-Score|IDSC131	Inventory of Depressive Symptomatology Clinician-Rated Version (IDS-C) Score.			Intellectual Product	CDISC Clinical Classification IDS-C Test Code Terminology|CDISC Clinical Classification IDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130393>	C130288	KDPI - KDPI Score|KDPI01-KDPI Score|KDPI01-KDPI Score|KDPI0101	Kidney Donor Profile Index (KDPI) KDPI score.			Intellectual Product	CDISC Clinical Classification KDPI Test Code Terminology|CDISC Clinical Classification KDPI Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130394>	C130287	QIDS-C - Sleep Onset Insomnia|QIDSC1-Sleep Onset Insomnia|QIDSC1-Sleep Onset Insomnia|QIDSC101	Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Sleep onset insomnia.			Intellectual Product	CDISC Clinical Classification QIDS-C Test Code Terminology|CDISC Clinical Classification QIDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130395>	C130287	QIDS-C - Mid-Nocturnal Insomnia|QIDSC1-Mid-Nocturnal Insomnia|QIDSC1-Mid-Nocturnal Insomnia|QIDSC102	Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Mid-nocturnal insomnia.			Intellectual Product	CDISC Clinical Classification QIDS-C Test Code Terminology|CDISC Clinical Classification QIDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130396>	C130287	QIDS-C - Early Morning Insomnia|QIDSC1-Early Morning Insomnia|QIDSC1-Early Morning Insomnia|QIDSC103	Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Early morning insomnia.			Intellectual Product	CDISC Clinical Classification QIDS-C Test Code Terminology|CDISC Clinical Classification QIDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130397>	C130287	QIDS-C - Hypersomnia|QIDSC1-Hypersomnia|QIDSC1-Hypersomnia|QIDSC104	Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Hypersomnia.			Intellectual Product	CDISC Clinical Classification QIDS-C Test Code Terminology|CDISC Clinical Classification QIDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130398>	C130287	QIDS-C - Mood (Sad)|QIDSC1-Mood (Sad)|QIDSC1-Mood (Sad)|QIDSC105	Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Mood (sad).			Intellectual Product	CDISC Clinical Classification QIDS-C Test Code Terminology|CDISC Clinical Classification QIDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130399>	C130287	QIDS-C - Appetite (Decreased)|QIDSC1-Appetite (Decreased)|QIDSC1-Appetite (Decreased)|QIDSC106	Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Appetite (decreased).			Intellectual Product	CDISC Clinical Classification QIDS-C Test Code Terminology|CDISC Clinical Classification QIDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13039>	C34061	Female Reproductive System Part	Any component of the female organs and tissues involved in the production and maturation of gametes and in their union and subsequent development as offspring.	Female Reproductive System Part		Body Part, Organ, or Organ Component	OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table
C1303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1303>	C593	Oprelvekin|Adipogenesis Inhibitory Factor|IL-11|Interleukin 11|Interleukin-11|Interleukin-11-Recombinant|Neumega|Neumega|OPRELVEKIN|Recombinant Human Interleukin-11|Recombinant Interleukin-11|oprelvekin|recombinant human interleukin-11|rhIL-11|rhIL-11	A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin 11 (IL-11). Secreted by bone marrow stromal cells and a number of mesenchymal cells, IL-11 binds to and activates its cell-surface receptor, promoting primary and secondary immune responses, modulating antigen-specific antibody reactions, and preventing apoptotic cell death.  This agent also stimulates the T-cell-dependent development of IgG-secreting B-cells in spleen cell cultures and may be an important regulator of megakaryocytopoiesis. (NCI04)	Oprelvekin		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C130400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130400>	C130287	QIDS-C - Appetite (Increased)|QIDSC1-Appetite (Increased)|QIDSC1-Appetite (Increased)|QIDSC107	Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Appetite (increased).			Intellectual Product	CDISC Clinical Classification QIDS-C Test Code Terminology|CDISC Clinical Classification QIDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130401>	C130287	QIDS-C - Weight (Decrease)|QIDSC1-Weight (Decrease)|QIDSC1-Weight (Decrease)|QIDSC108	Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Weight (decrease) within the last two weeks.			Intellectual Product	CDISC Clinical Classification QIDS-C Test Code Terminology|CDISC Clinical Classification QIDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130402>	C130287	QIDS-C - Weight (Increase)|QIDSC1-Weight (Increase)|QIDSC1-Weight (Increase)|QIDSC109	Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Weight (increase) within the last two weeks.			Intellectual Product	CDISC Clinical Classification QIDS-C Test Code Terminology|CDISC Clinical Classification QIDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130403>	C130287	QIDS-C - Concentration or Decision Making|QIDSC1-Concentration/Decision Making|QIDSC1-Concentration/Decision Making|QIDSC110	Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Concentration/decision making.			Intellectual Product	CDISC Clinical Classification QIDS-C Test Code Terminology|CDISC Clinical Classification QIDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130404>	C130287	QIDS-C - Outlook (Self)|QIDSC1-Outlook (Self)|QIDSC1-Outlook (Self)|QIDSC111	Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Outlook (self).			Intellectual Product	CDISC Clinical Classification QIDS-C Test Code Terminology|CDISC Clinical Classification QIDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130405>	C130287	QIDS-C - Suicidal Ideation|QIDSC1-Suicidal Ideation|QIDSC1-Suicidal Ideation|QIDSC112	Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Suicidal ideation.			Intellectual Product	CDISC Clinical Classification QIDS-C Test Code Terminology|CDISC Clinical Classification QIDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130406>	C130287	QIDS-C - Involvement|QIDSC1-Involvement|QIDSC1-Involvement|QIDSC113	Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Involvement.			Intellectual Product	CDISC Clinical Classification QIDS-C Test Code Terminology|CDISC Clinical Classification QIDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130407>	C130287	QIDS-C - Energy or Fatiguability|QIDSC1-Energy/Fatiguability|QIDSC1-Energy/Fatiguability|QIDSC114	Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Energy/fatiguability.			Intellectual Product	CDISC Clinical Classification QIDS-C Test Code Terminology|CDISC Clinical Classification QIDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130408>	C130287	QIDS-C - Psychomotor Slowing|QIDSC1-Psychomotor Slowing|QIDSC1-Psychomotor Slowing|QIDSC115	Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Psychomotor slowing.			Intellectual Product	CDISC Clinical Classification QIDS-C Test Code Terminology|CDISC Clinical Classification QIDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130409>	C130287	QIDS-C - Psychomotor Agitation|QIDSC1-Psychomotor Agitation|QIDSC1-Psychomotor Agitation|QIDSC116	Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Please circle one response to each item that best describes the patient for the last seven days: Psychomotor agitation.			Intellectual Product	CDISC Clinical Classification QIDS-C Test Code Terminology|CDISC Clinical Classification QIDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13040>	C32221	Nervous System Part	Any component of the entire nerve apparatus, including the brain, spinal cord, spinal nerves, autonomic ganglia, and plexuses.	Nervous System Part		Body Part, Organ, or Organ Component	
C130410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130410>	C130287	QIDS-C - Highest Score Sleep Items|QIDSC1-Highest Score Sleep Items|QIDSC1-Highest Score Sleep Items|QIDSC117	Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Enter the highest score on any 1 of the 4 sleep items.			Intellectual Product	CDISC Clinical Classification QIDS-C Test Code Terminology|CDISC Clinical Classification QIDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130411>	C130287	QIDS-C - High Score Appetite or Weight Items|QIDSC1-High Score Appetite/Weight Items|QIDSC1-High Score Appetite/Weight Items|QIDSC118	Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Enter the highest score on any 1 of the 4 appetite/weight change items.			Intellectual Product	CDISC Clinical Classification QIDS-C Test Code Terminology|CDISC Clinical Classification QIDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130412>	C130287	QIDS-C - Highest Score Psychomotor Items|QIDSC1-Highest Score Psychomotor Items|QIDSC1-Highest Score Psychomotor Items|QIDSC119	Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Enter the highest score on either of the 2 psychomotor items.			Intellectual Product	CDISC Clinical Classification QIDS-C Test Code Terminology|CDISC Clinical Classification QIDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130413>	C130287	QIDS-C - Total Score|QIDSC1-Total Score|QIDSC1-Total Score|QIDSC120	Quick Inventory of Depressive Symptomatology Clinician-Rated Version (QIDS-C) Total score.			Intellectual Product	CDISC Clinical Classification QIDS-C Test Code Terminology|CDISC Clinical Classification QIDS-C Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130414>	C130289	FACT-LEU Version 4 - I Have a Lack of Energy|FAC017-I Have a Lack of Energy|FAC017-I Have a Lack of Energy|FAC01701	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Physical Well-Being: I have a lack of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130415>	C130289	FACT-LEU Version 4 - I Have Nausea|FAC017-I Have Nausea|FAC017-I Have Nausea|FAC01702	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Physical Well-Being: I have nausea.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130416>	C130289	FACT-LEU Version 4 - Trouble Meeting Needs of Family|FAC017-Trouble Meeting Needs of Family|FAC017-Trouble Meeting Needs of Family|FAC01703	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Physical Well-Being: Because of my physical condition, I have trouble meeting the needs of my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130417>	C130289	FACT-LEU Version 4 - I Have Pain|FAC017-I Have Pain|FAC017-I Have Pain|FAC01704	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Physical Well-Being: I have pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130418>	C130289	FACT-LEU Version 4 - Bothered by Treatment Side Effect|FAC017-Bothered by Treatment Side Effect|FAC017-Bothered by Treatment Side Effect|FAC01705	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Physical Well-Being: I am bothered by side effects of treatment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130419>	C130289	FACT-LEU Version 4 - I Feel Ill|FAC017-I Feel Ill|FAC017-I Feel Ill|FAC01706	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Physical Well-Being: I feel ill.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13041>	C33904	Body|BODY|Body structure (body structure)|Entire body as a whole (body structure)|Whole Body|Whole Body	The entire physical structure of an organism. It is composed of anatomic systems, regions, cavities, and spaces.	Body		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C130420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130420>	C130289	FACT-LEU Version 4 - I Am Forced to Spend Time in Bed|FAC017-I Am Forced to Spend Time in Bed|FAC017-I Am Forced to Spend Time in Bed|FAC01707	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Physical Well-Being: I am forced to spend time in bed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130421>	C130289	FACT-LEU Version 4 - I Feel Close to My Friends|FAC017-I Feel Close to My Friends|FAC017-I Feel Close to My Friends|FAC01708	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Social/Family Well-Being: I feel close to my friends.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130422>	C130289	FACT-LEU Version 4 - Get Emotional Support From Family|FAC017-Get Emotional Support From Family|FAC017-Get Emotional Support From Family|FAC01709	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Social/Family Well-Being: I get emotional support from my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130423>	C130289	FACT-LEU Version 4 - I Get Support From My Friends|FAC017-I Get Support From My Friends|FAC017-I Get Support From My Friends|FAC01710	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Social/Family Well-Being: I get support from my friends.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130424>	C130289	FACT-LEU Version 4 - My Family Has Accepted My Illness|FAC017-My Family Has Accepted My Illness|FAC017-My Family Has Accepted My Illness|FAC01711	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Social/Family Well-Being: My family has accepted my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130425>	C130289	FACT-LEU Version 4 - Satisfied Communication Illness|FAC017-Satisfied Communication Illness|FAC017-Satisfied Communication Illness|FAC01712	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Social/Family Well-Being: I am satisfied with family communication about my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130426>	C130289	FACT-LEU Version 4 - I Feel Close to My Partner|FAC017-I Feel Close to My Partner|FAC017-I Feel Close to My Partner|FAC01713	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Social/Family Well-Being: I feel close to my partner (or the person who is my main support).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130427>	C130289	FACT-LEU Version 4 - I Am Satisfied With My Sex Life|FAC017-I Am Satisfied With My Sex Life|FAC017-I Am Satisfied With My Sex Life|FAC01714	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Social/Family Well-Being: I am satisfied with my sex life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130428>	C130289	FACT-LEU Version 4 - I Feel Sad|FAC017-I Feel Sad|FAC017-I Feel Sad|FAC01715	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Emotional Well-Being: I feel sad.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130429>	C130289	FACT-LEU Version 4 - Satisfied With How I Am Coping|FAC017-Satisfied With How I Am Coping|FAC017-Satisfied With How I Am Coping|FAC01716	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Emotional Well-Being: I am satisfied with how I am coping with my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130430>	C130289	FACT-LEU Version 4 - Losing Hope Against Illness|FAC017-Losing Hope Against Illness|FAC017-Losing Hope Against Illness|FAC01717	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Emotional Well-Being: I am losing hope in the fight against my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130431>	C130289	FACT-LEU Version 4 - I Feel Nervous|FAC017-I Feel Nervous|FAC017-I Feel Nervous|FAC01718	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Emotional Well-Being: I feel nervous.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130432>	C130289	FACT-LEU Version 4 - I Worry About Dying|FAC017-I Worry About Dying|FAC017-I Worry About Dying|FAC01719	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Emotional Well-Being: I worry about dying.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130433>	C130289	FACT-LEU Version 4 - Worry My Condition Will Get Worse|FAC017-Worry My Condition Will Get Worse|FAC017-Worry My Condition Will Get Worse|FAC01720	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Emotional Well-Being: I worry that my condition will get worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130434>	C130289	FACT-LEU Version 4 - I Am Able to Work|FAC017-I Am Able to Work|FAC017-I Am Able to Work|FAC01721	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Functional Well-Being: I am able to work (include work at home).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130435>	C130289	FACT-LEU Version 4 - My Work Is Fulfilling|FAC017-My Work Is Fulfilling|FAC017-My Work Is Fulfilling|FAC01722	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Functional Well-Being: My work (include work at home) is fulfilling.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130436>	C130289	FACT-LEU Version 4 - I Am Able to Enjoy Life|FAC017-I Am Able to Enjoy Life|FAC017-I Am Able to Enjoy Life|FAC01723	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Functional Well-Being: I am able to enjoy life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130437>	C130289	FACT-LEU Version 4 - I Have Accepted My Illness|FAC017-I Have Accepted My Illness|FAC017-I Have Accepted My Illness|FAC01724	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Functional Well-Being: I have accepted my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130438>	C130289	FACT-LEU Version 4 - I Am Sleeping Well|FAC017-I Am Sleeping Well|FAC017-I Am Sleeping Well|FAC01725	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Functional Well-Being: I am sleeping well.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130439>	C130289	FACT-LEU Version 4 - Enjoy Things I Usually Do for Fun|FAC017-Enjoy Things I Usually Do for Fun|FAC017-Enjoy Things I Usually Do for Fun|FAC01726	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Functional Well-Being: I am enjoying the things I usually do for fun.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13043>	C38626	Ear Part	Any component pertaining to the organ for hearing including the external, middle, and inner ear.	Ear Part		Body Part, Organ, or Organ Component	
C130440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130440>	C130289	FACT-LEU Version 4 - Content With Quality of My Life|FAC017-Content With Quality of My Life|FAC017-Content With Quality of My Life|FAC01727	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Functional Well-Being: I am content with the quality of my life right now.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130441>	C130289	FACT-LEU Version 4 - I Am Bothered by Fevers|FAC017-I Am Bothered by Fevers|FAC017-I Am Bothered by Fevers|FAC01728	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I am bothered by fevers (episodes of high body temperature).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130442>	C130289	FACT-LEU Version 4 - Certain Parts of Body Have Pain|FAC017-Certain Parts of Body Have Pain|FAC017-Certain Parts of Body Have Pain|FAC01729	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I have certain parts of my body where I experience pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130443>	C130289	FACT-LEU Version 4 - I Am Bothered by the Chills|FAC017-I Am Bothered by the Chills|FAC017-I Am Bothered by the Chills|FAC01730	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I am bothered by the chills.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130444>	C130289	FACT-LEU Version 4 - I Have Night Sweats|FAC017-I Have Night Sweats|FAC017-I Have Night Sweats|FAC01731	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I have night sweats.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130445>	C130289	FACT-LEU Version 4 - Bothered by Lumps or Swelling|FAC017-Bothered by Lumps or Swelling|FAC017-Bothered by Lumps or Swelling|FAC01732	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I am bothered by lumps or swelling in certain parts of my body (e.g., neck, armpits, or groin).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130446>	C130289	FACT-LEU Version 4 - I Bleed Easily|FAC017-I Bleed Easily|FAC017-I Bleed Easily|FAC01733	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I bleed easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130447>	C130289	FACT-LEU Version 4 - I Bruise Easily|FAC017-I Bruise Easily|FAC017-I Bruise Easily|FAC01734	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I bruise easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130448>	C130289	FACT-LEU Version 4 - I Feel Weak All Over|FAC017-I Feel Weak All Over|FAC017-I Feel Weak All Over|FAC01735	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I feel weak all over.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130449>	C130289	FACT-LEU Version 4 - I Get Tired Easily|FAC017-I Get Tired Easily|FAC017-I Get Tired Easily|FAC01736	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I get tired easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13044>	C34076	Joint|Articular|Articulation|Articulation|JOINT|Joint structure (body structure)|Joints|joint|skeletal joint	The connection point between two bones or skeletal elements. The joint may be fixed or movable.	Joint		Body Space or Junction	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C130450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130450>	C130289	FACT-LEU Version 4 - I Am Losing Weight|FAC017-I Am Losing Weight|FAC017-I Am Losing Weight|FAC01737	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I am losing weight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130451>	C130289	FACT-LEU Version 4 - I Have a Good Appetite|FAC017-I Have a Good Appetite|FAC017-I Have a Good Appetite|FAC01738	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I have a good appetite.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130452>	C130289	FACT-LEU Version 4 - Able to Do My Usual Activities|FAC017-Able to Do My Usual Activities|FAC017-Able to Do My Usual Activities|FAC01739	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I am able to do my usual activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130453>	C130289	FACT-LEU Version 4 - I Worry About Getting Infections|FAC017-I Worry About Getting Infections|FAC017-I Worry About Getting Infections|FAC01740	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I worry about getting infections.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130454>	C130289	FACT-LEU Version 4 - Uncertain About My Future Health|FAC017-Uncertain About My Future Health|FAC017-Uncertain About My Future Health|FAC01741	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I feel uncertain about my future health.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130455>	C130289	FACT-LEU Version 4 - Worry I Might Get New Symptoms|FAC017-Worry I Might Get New Symptoms|FAC017-Worry I Might Get New Symptoms|FAC01742	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I worry that I might get new symptoms of my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130456>	C130289	FACT-LEU Version 4 - I Have Emotional Ups and Downs|FAC017-I Have Emotional Ups and Downs|FAC017-I Have Emotional Ups and Downs|FAC01743	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I have emotional ups and downs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130457>	C130289	FACT-LEU Version 4 - Feel Isolated Because of Illness|FAC017-Feel Isolated Because of Illness|FAC017-Feel Isolated Because of Illness|FAC01744	Functional Assessment of Cancer Therapy-Leukemia Version 4 (FACT-LEU Version 4) Additional Concerns: I feel isolated from others because of my illness or treatment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Code Terminology|CDISC Questionnaire FACT-LEU Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130458>	C130290	FACT-HEP Version 4 - I Have a Lack of Energy|FAC015-I Have a Lack of Energy|FAC015-I Have a Lack of Energy|FAC01501	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Physical Well-Being: I have a lack of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130459>	C130290	FACT-HEP Version 4 - I Have Nausea|FAC015-I Have Nausea|FAC015-I Have Nausea|FAC01502	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Physical Well-Being: I have nausea.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13045>	C32133	Tendon|Human Tendon|TENDON|Tendon structure (body structure)|Tendons|tendon|tendon	A band of fibrous connective tissue that joins bone to muscle.	Tendon		Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Structured Product Labeling Terminology|GDC Terminology|GDC Value Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|SPL Tissue Form Product Type Terminology|UBERON Terminology
C130460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130460>	C130290	FACT-HEP Version 4 - Trouble Meeting Needs of Family|FAC015-Trouble Meeting Needs of Family|FAC015-Trouble Meeting Needs of Family|FAC01503	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Physical Well-Being: Because of my physical condition, I have trouble meeting the needs of my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130461>	C130290	FACT-HEP Version 4 - I Have Pain|FAC015-I Have Pain|FAC015-I Have Pain|FAC01504	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Physical Well-Being: I have pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130462>	C130290	FACT-HEP Version 4 - Bothered by Treatment Side Effect|FAC015-Bothered by Treatment Side Effect|FAC015-Bothered by Treatment Side Effect|FAC01505	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Physical Well-Being: I am bothered by side effects of treatment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130463>	C130290	FACT-HEP Version 4 - I Feel Ill|FAC015-I Feel Ill|FAC015-I Feel Ill|FAC01506	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Physical Well-Being: I feel ill.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130464>	C130290	FACT-HEP Version 4 - I Am Forced to Spend Time in Bed|FAC015-I Am Forced to Spend Time in Bed|FAC015-I Am Forced to Spend Time in Bed|FAC01507	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Physical Well-Being: I am forced to spend time in bed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130465>	C130290	FACT-HEP Version 4 - I Feel Close to My Friends|FAC015-I Feel Close to My Friends|FAC015-I Feel Close to My Friends|FAC01508	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Social/Family Well-Being: I feel close to my friends.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130466>	C130290	FACT-HEP Version 4 - Get Emotional Support From Family|FAC015-Get Emotional Support From Family|FAC015-Get Emotional Support From Family|FAC01509	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Social/Family Well-Being: I get emotional support from my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130467>	C130290	FACT-HEP Version 4 - I Get Support From My Friends|FAC015-I Get Support From My Friends|FAC015-I Get Support From My Friends|FAC01510	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Social/Family Well-Being: I get support from my friends.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130468>	C130290	FACT-HEP Version 4 - My Family Has Accepted My Illness|FAC015-My Family Has Accepted My Illness|FAC015-My Family Has Accepted My Illness|FAC01511	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Social/Family Well-Being: My family has accepted my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130469>	C130290	FACT-HEP Version 4 - Satisfied With Communication About Illness|FAC015-Satisfied Communication Illness|FAC015-Satisfied Communication Illness|FAC01512	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Social/Family Well-Being: I am satisfied with family communication about my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13046>	C25769	Ligament|Human Ligament|LIGAMENT|Ligaments|ligament|ligament organ	Band of fibrous tissue connecting bone to bone or cartilage to bone thereby supporting or strengthening a joint.	Ligaments		Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Structured Product Labeling Terminology|GDC Terminology|GDC Value Terminology|SPL Tissue Form Product Type Terminology|UBERON Terminology
C130470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130470>	C130290	FACT-HEP Version 4 - I Feel Close to My Partner|FAC015-I Feel Close to My Partner|FAC015-I Feel Close to My Partner|FAC01513	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Social/Family Well-Being: I feel close to my partner (or the person who is my main support).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130471>	C130290	FACT-HEP Version 4 - I Am Satisfied With My Sex Life|FAC015-I Am Satisfied With My Sex Life|FAC015-I Am Satisfied With My Sex Life|FAC01514	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Social/Family Well-Being: I am satisfied with my sex life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130472>	C130290	FACT-HEP Version 4 - I Feel Sad|FAC015-I Feel Sad|FAC015-I Feel Sad|FAC01515	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Emotional Well-Being: I feel sad.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130473>	C130290	FACT-HEP Version 4 - Satisfied With How I Am Coping|FAC015-Satisfied With How I Am Coping|FAC015-Satisfied With How I Am Coping|FAC01516	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Emotional Well-Being: I am satisfied with how I am coping with my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130474>	C130290	FACT-HEP Version 4 - Losing Hope Against Illness|FAC015-Losing Hope Against Illness|FAC015-Losing Hope Against Illness|FAC01517	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Emotional Well-Being: I am losing hope in the fight against my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130475>	C130290	FACT-HEP Version 4 - I Feel Nervous|FAC015-I Feel Nervous|FAC015-I Feel Nervous|FAC01518	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Emotional Well-Being: I feel nervous.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130476>	C130290	FACT-HEP Version 4 - I Worry About Dying|FAC015-I Worry About Dying|FAC015-I Worry About Dying|FAC01519	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Emotional Well-Being: I worry about dying.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130477>	C130290	FACT-HEP Version 4 - Worry My Condition Will Get Worse|FAC015-Worry My Condition Will Get Worse|FAC015-Worry My Condition Will Get Worse|FAC01520	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Emotional Well-Being: I worry that my condition will get worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130478>	C130290	FACT-HEP Version 4 - I Am Able to Work|FAC015-I Am Able to Work|FAC015-I Am Able to Work|FAC01521	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Functional Well-Being: I am able to work (include work at home).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130479>	C130290	FACT-HEP Version 4 - My Work Is Fulfilling|FAC015-My Work Is Fulfilling|FAC015-My Work Is Fulfilling|FAC01522	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Functional Well-Being: My work (include work at home) is fulfilling.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13047>	C33758	Seminiferous Tubule|Seminiferous Tubules	A hollow tube located in the testes, which is the site of germination, maturation, and transportation of the sperm cells in a sexually mature male.	Seminiferous Tubule		Body Part, Organ, or Organ Component	
C130480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130480>	C130290	FACT-HEP Version 4 - I Am Able to Enjoy Life|FAC015-I Am Able to Enjoy Life|FAC015-I Am Able to Enjoy Life|FAC01523	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Functional Well-Being: I am able to enjoy life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130481>	C130290	FACT-HEP Version 4 - I Have Accepted My Illness|FAC015-I Have Accepted My Illness|FAC015-I Have Accepted My Illness|FAC01524	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Functional Well-Being: I have accepted my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130482>	C130290	FACT-HEP Version 4 - I Am Sleeping Well|FAC015-I Am Sleeping Well|FAC015-I Am Sleeping Well|FAC01525	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Functional Well-Being: I am sleeping well.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130483>	C130290	FACT-HEP Version 4 - Enjoy Things I Usually Do for Fun|FAC015-Enjoy Things I Usually Do for Fun|FAC015-Enjoy Things I Usually Do for Fun|FAC01526	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Functional Well-Being: I am enjoying the things I usually do for fun.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130484>	C130290	FACT-HEP Version 4 - Content With Quality of My Life|FAC015-Content With Quality of My Life|FAC015-Content With Quality of My Life|FAC01527	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Functional Well-Being: I am content with the quality of my life right now.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130485>	C130290	FACT-HEP Version 4 - Swelling or Cramps in Stomach Area|FAC015-Swelling/Cramps in Stomach Area|FAC015-Swelling/Cramps in Stomach Area|FAC01528	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I have swelling or cramps in my stomach area.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130486>	C130290	FACT-HEP Version 4 - I Am Losing Weight|FAC015-I Am Losing Weight|FAC015-I Am Losing Weight|FAC01529	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I am losing weight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130487>	C130290	FACT-HEP Version 4 - I Have Control of My Bowels|FAC015-I Have Control of My Bowels|FAC015-I Have Control of My Bowels|FAC01530	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I have control of my bowels.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130488>	C130290	FACT-HEP Version 4 - I Can Digest My Food Well|FAC015-I Can Digest My Food Well|FAC015-I Can Digest My Food Well|FAC01531	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I can digest my food well.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130489>	C130290	FACT-HEP Version 4 - I Have Diarrhea|FAC015-I Have Diarrhea|FAC015-I Have Diarrhea|FAC01532	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I have diarrhea (diarrhoea).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13048>	C33461	Nephron|Uriniferous Tube	The basic structural and functioning unit of the kidney. It is composed of the glomerulus, where waste products are filtered from the blood, the proximal and distal tubules, the loop of Henle, and the collecting ducts, where urine is produced for excretion from the body.	Nephron		Body Part, Organ, or Organ Component	
C130490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130490>	C130290	FACT-HEP Version 4 - I Have a Good Appetite|FAC015-I Have a Good Appetite|FAC015-I Have a Good Appetite|FAC01533	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I have a good appetite.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130491>	C130290	FACT-HEP Version 4 - Unhappy About Change in My Appearance|FAC015-Unhappy About Change in My Appear|FAC015-Unhappy About Change in My Appear|FAC01534	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I am unhappy about a change in my appearance.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130492>	C130290	FACT-HEP Version 4 - I Have Pain in My Back|FAC015-I Have Pain in My Back|FAC015-I Have Pain in My Back|FAC01535	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I have pain in my back.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130493>	C130290	FACT-HEP Version 4 - I Am Bothered by Constipation|FAC015-I Am Bothered by Constipation|FAC015-I Am Bothered by Constipation|FAC01536	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I am bothered by constipation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130494>	C130290	FACT-HEP Version 4 - I Feel Fatigued|FAC015-I Feel Fatigued|FAC015-I Feel Fatigued|FAC01537	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I feel fatigued.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130495>	C130290	FACT-HEP Version 4 - Able to Do My Usual Activities|FAC015-Able to Do My Usual Activities|FAC015-Able to Do My Usual Activities|FAC01538	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I am able to do my usual activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130496>	C130290	FACT-HEP Version 4 - Bothered by Jaundice or Yellow Skin|FAC015-Bothered by Jaundice/Yellow Skin|FAC015-Bothered by Jaundice/Yellow Skin|FAC01539	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I am bothered by jaundice or yellow color to my skin.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130497>	C130290	FACT-HEP Version 4 - I Have Had Fevers|FAC015-I Have Had Fevers|FAC015-I Have Had Fevers|FAC01540	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I have had fevers (episodes of high body temperature).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130498>	C130290	FACT-HEP Version 4 - I Have Had Itching|FAC015-I Have Had Itching|FAC015-I Have Had Itching|FAC01541	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I have had itching.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130499>	C130290	FACT-HEP Version 4 - Had Change in the Way Food Tastes|FAC015-Had Change in the Way Food Tastes|FAC015-Had Change in the Way Food Tastes|FAC01542	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I have had a change in the way food tastes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13049>	C41168	Lymphoid Tissue|Lymphoid Normal	Tissue characterized by the presence of large numbers of lymphocytes in different stages of transformation. Connective tissue cells including fibroblasts and macrophages may be present. Lymphoid tissue is framed by a network of reticular fibers and may be diffuse, or densely aggregated.	Lymphoid Tissue		Tissue	GDC Terminology|GDC Value Terminology
C1304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1304>	C587	PEG-interleukin-2|PEG-IL-2|Polyethylene Glycol-Modified Recombinant Interleukin-2	A complex of polyethylene glycol conjugated with human recombinant cytokine interleukin-2 (IL-2) with antineoplastic activity. PEG-interleukin-2 induces natural killer (NK) cell activity and the production of interferon-gamma (IFN-gamma), and enhances T cell-mediated cytotoxicity. Pegylation of IL-2 protects the cytokine from degradation. (NCI04)			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C130500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130500>	C130290	FACT-HEP Version 4 - I Have Had Chills|FAC015-I Have Had Chills|FAC015-I Have Had Chills|FAC01543	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I have had chills.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130501>	C130290	FACT-HEP Version 4 - My Mouth Is Dry|FAC015-My Mouth Is Dry|FAC015-My Mouth Is Dry|FAC01544	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: My mouth is dry.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130502>	C130290	FACT-HEP Version 4 - Discomfort or Pain in Stomach Area|FAC015-Discomfort/Pain in Stomach Area|FAC015-Discomfort/Pain in Stomach Area|FAC01545	Functional Assessment of Cancer Therapy-Hepatobiliary Version 4 (FACT-HEP Version 4) Additional Concerns: I have discomfort or pain in my stomach area.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Code Terminology|CDISC Questionnaire FACT-HEP Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130503>	C130291	FACT-LYM Version 4 - I Have a Lack of Energy|FAC018-I Have a Lack of Energy|FAC018-I Have a Lack of Energy|FAC01801	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Physical Well-Being: I have a lack of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130504>	C130291	FACT-LYM Version 4 - I Have Nausea|FAC018-I Have Nausea|FAC018-I Have Nausea|FAC01802	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Physical Well-Being: I have nausea.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130505>	C130291	FACT-LYM Version 4 - Trouble Meeting Needs of Family|FAC018-Trouble Meeting Needs of Family|FAC018-Trouble Meeting Needs of Family|FAC01803	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Physical Well-Being: Because of my physical condition, I have trouble meeting the needs of my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130506>	C130291	FACT-LYM Version 4 - I Have Pain|FAC018-I Have Pain|FAC018-I Have Pain|FAC01804	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Physical Well-Being: I have pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130507>	C130291	FACT-LYM Version 4 - Bothered by Treatment Side Effect|FAC018-Bothered by Treatment Side Effect|FAC018-Bothered by Treatment Side Effect|FAC01805	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Physical Well-Being: I am bothered by side effects of treatment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130508>	C130291	FACT-LYM Version 4 - I Feel Ill|FAC018-I Feel Ill|FAC018-I Feel Ill|FAC01806	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Physical Well-Being: I feel ill.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130509>	C130291	FACT-LYM Version 4 - I Am Forced to Spend Time in Bed|FAC018-I Am Forced to Spend Time in Bed|FAC018-I Am Forced to Spend Time in Bed|FAC01807	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Physical Well-Being: I am forced to spend time in bed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13050>	C12436	Skeletal Muscle Tissue|MUSCLE, SKELETAL|SKELETAL MUSCLE TISSUE|Skeletal Muscle|Skeletal Muscle|skeletal muscle tissue	Striated muscles that are under voluntary control of the organism.  They are connected at either or both ends to a bone and are utilized for locomotion and other movements.	Skeletal Muscle		Tissue	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|UBERON Terminology
C130510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130510>	C130291	FACT-LYM Version 4 - I Feel Close to My Friends|FAC018-I Feel Close to My Friends|FAC018-I Feel Close to My Friends|FAC01808	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Social/Family Well-Being: I feel close to my friends.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130511>	C130291	FACT-LYM Version 4 - Get Emotional Support From Family|FAC018-Get Emotional Support From Family|FAC018-Get Emotional Support From Family|FAC01809	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Social/Family Well-Being: I get emotional support from my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130512>	C130291	FACT-LYM Version 4 - I Get Support From My Friends|FAC018-I Get Support From My Friends|FAC018-I Get Support From My Friends|FAC01810	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Social/Family Well-Being: I get support from my friends.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130513>	C130291	FACT-LYM Version 4 - My Family Has Accepted My Illness|FAC018-My Family Has Accepted My Illness|FAC018-My Family Has Accepted My Illness|FAC01811	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Social/Family Well-Being: My family has accepted my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130514>	C130291	FACT-LYM Version 4 - Satisfied With Communication About Illness|FAC018-Satisfied Communication Illness|FAC018-Satisfied Communication Illness|FAC01812	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Social/Family Well-Being: I am satisfied with family communication about my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130515>	C130291	FACT-LYM Version 4 - I Feel Close to My Partner|FAC018-I Feel Close to My Partner|FAC018-I Feel Close to My Partner|FAC01813	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Social/Family Well-Being: I feel close to my partner (or the person who is my main support).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130516>	C130291	FACT-LYM Version 4 - I Am Satisfied With My Sex Life|FAC018-I Am Satisfied With My Sex Life|FAC018-I Am Satisfied With My Sex Life|FAC01814	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Social/Family Well-Being: I am satisfied with my sex life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130517>	C130291	FACT-LYM Version 4 - I Feel Sad|FAC018-I Feel Sad|FAC018-I Feel Sad|FAC01815	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Emotional Well-Being: I feel sad.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130518>	C130291	FACT-LYM Version 4 - Satisfied With How I Am Coping|FAC018-Satisfied With How I Am Coping|FAC018-Satisfied With How I Am Coping|FAC01816	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Emotional Well-Being: I am satisfied with how I am coping with my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130519>	C130291	FACT-LYM Version 4 - Losing Hope Against Illness|FAC018-Losing Hope Against Illness|FAC018-Losing Hope Against Illness|FAC01817	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Emotional Well-Being: I am losing hope in the fight against my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13051>	C41168	Hematopoietic Tissue|hematopoietic tissue		Hematopoietic Tissue		Tissue	
C130520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130520>	C130291	FACT-LYM Version 4 - I Feel Nervous|FAC018-I Feel Nervous|FAC018-I Feel Nervous|FAC01818	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Emotional Well-Being: I feel nervous.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130521>	C130291	FACT-LYM Version 4 - I Worry About Dying|FAC018-I Worry About Dying|FAC018-I Worry About Dying|FAC01819	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Emotional Well-Being: I worry about dying.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130522>	C130291	FACT-LYM Version 4 - Worry My Condition Will Get Worse|FAC018-Worry My Condition Will Get Worse|FAC018-Worry My Condition Will Get Worse|FAC01820	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Emotional Well-Being: I worry that my condition will get worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130523>	C130291	FACT-LYM Version 4 - I Am Able to Work|FAC018-I Am Able to Work|FAC018-I Am Able to Work|FAC01821	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Functional Well-Being: I am able to work (include work at home).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130524>	C130291	FACT-LYM Version 4 - My Work Is Fulfilling|FAC018-My Work Is Fulfilling|FAC018-My Work Is Fulfilling|FAC01822	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Functional Well-Being: My work (include work at home) is fulfilling.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130525>	C130291	FACT-LYM Version 4 - I Am Able to Enjoy Life|FAC018-I Am Able to Enjoy Life|FAC018-I Am Able to Enjoy Life|FAC01823	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Functional Well-Being: I am able to enjoy life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130526>	C130291	FACT-LYM Version 4 - I Have Accepted My Illness|FAC018-I Have Accepted My Illness|FAC018-I Have Accepted My Illness|FAC01824	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Functional Well-Being: I have accepted my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130527>	C130291	FACT-LYM Version 4 - I Am Sleeping Well|FAC018-I Am Sleeping Well|FAC018-I Am Sleeping Well|FAC01825	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Functional Well-Being: I am sleeping well.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130528>	C130291	FACT-LYM Version 4 - Enjoy Things I Usually Do for Fun|FAC018-Enjoy Things I Usually Do for Fun|FAC018-Enjoy Things I Usually Do for Fun|FAC01826	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Functional Well-Being: I am enjoying the things I usually do for fun.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130529>	C130291	FACT-LYM Version 4 - Content With Quality of My Life|FAC018-Content With Quality of My Life|FAC018-Content With Quality of My Life|FAC01827	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Functional Well-Being: I am content with the quality of my life right now.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13052>	C41443	Nerve Tissue|Human Nerve Tissue|Nervous Tissue	The tissue that generates and conducts electrical signals in the body.  It contains the neurons.	Nerve Tissue		Tissue	FDA Structured Product Labeling Terminology|GDC Terminology|GDC Value Terminology|SPL Tissue Form Product Type Terminology
C130530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130530>	C130291	FACT-LYM Version 4 - Certain Parts of Body Have Pain|FAC018-Certain Parts of Body Have Pain|FAC018-Certain Parts of Body Have Pain|FAC01828	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Additional Concerns: I have certain parts of my body where I experience pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130531>	C130291	FACT-LYM Version 4 - Bothered by Lumps or Swelling|FAC018-Bothered by Lumps or Swelling|FAC018-Bothered by Lumps or Swelling|FAC01829	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Additional Concerns: I am bothered by lumps or swelling in certain parts of my body (e.g., neck, armpits, or groin).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130532>	C130291	FACT-LYM Version 4 - I Am Bothered by Fevers|FAC018-I Am Bothered by Fevers|FAC018-I Am Bothered by Fevers|FAC01830	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Additional Concerns: I am bothered by fevers (episodes of high body temperature).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130533>	C130291	FACT-LYM Version 4 - I Have Night Sweats|FAC018-I Have Night Sweats|FAC018-I Have Night Sweats|FAC01831	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Additional Concerns: I have night sweats.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130534>	C130291	FACT-LYM Version 4 - I Am Bothered by Itching|FAC018-I Am Bothered by Itching|FAC018-I Am Bothered by Itching|FAC01832	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Additional Concerns: I am bothered by itching.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130535>	C130291	FACT-LYM Version 4 - I Have Trouble Sleeping at Night|FAC018-I Have Trouble Sleeping at Night|FAC018-I Have Trouble Sleeping at Night|FAC01833	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Additional Concerns: I have trouble sleeping at night.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130536>	C130291	FACT-LYM Version 4 - I Get Tired Easily|FAC018-I Get Tired Easily|FAC018-I Get Tired Easily|FAC01834	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Additional Concerns: I get tired easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130537>	C130291	FACT-LYM Version 4 - I Am Losing Weight|FAC018-I Am Losing Weight|FAC018-I Am Losing Weight|FAC01835	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Additional Concerns: I am losing weight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130538>	C130291	FACT-LYM Version 4 - I Have a Loss of Appetite|FAC018-I Have a Loss of Appetite|FAC018-I Have a Loss of Appetite|FAC01836	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Additional Concerns: I have a loss of appetite.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130539>	C130291	FACT-LYM Version 4 - I Have Trouble Concentrating|FAC018-I Have Trouble Concentrating|FAC018-I Have Trouble Concentrating|FAC01837	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Additional Concerns: I have trouble concentrating.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13053>	C12481	Vascular Endothelium	The layer of simple squamous epithelial tissue that lines the luminal surface of the entire circulatory system.	Vascular Endothelium		Tissue	
C130540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130540>	C130291	FACT-LYM Version 4 - I Worry About Getting Infections|FAC018-I Worry About Getting Infections|FAC018-I Worry About Getting Infections|FAC01838	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Additional Concerns: I worry about getting infections.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130541>	C130291	FACT-LYM Version 4 - Worry I Might Get New Symptoms|FAC018-Worry I Might Get New Symptoms|FAC018-Worry I Might Get New Symptoms|FAC01839	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Additional Concerns: I worry that I might get new symptoms of my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130542>	C130291	FACT-LYM Version 4 - Feel Isolated Because of Illness|FAC018-Feel Isolated Because of Illness|FAC018-Feel Isolated Because of Illness|FAC01840	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Additional Concerns: I feel isolated from others because of my illness or treatment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130543>	C130291	FACT-LYM Version 4 - I Have Emotional Ups and Downs|FAC018-I Have Emotional Ups and Downs|FAC018-I Have Emotional Ups and Downs|FAC01841	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Additional Concerns: I have emotional ups and downs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130544>	C130291	FACT-LYM Version 4 - Difficulty Planning for Future|FAC018-Difficulty Planning for Future|FAC018-Difficulty Planning for Future|FAC01842	Functional Assessment of Cancer Therapy-Lymphoma Version 4 (FACT-LYM Version 4) Additional Concerns: Because of my illness, I have difficulty planning for the future.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Code Terminology|CDISC Questionnaire FACT-LYM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130545>	C130292	HAM-D6 Self-Report Version - Depressed Mood|HAMDS1-Depressed Mood|HAMDS1-Depressed Mood|HAMDS101	Hamilton Depression Rating Scale 6 Self-Report Version (HAM-D6 Self-Report Version) (1)=Depressed mood per clinician version: How you have been feeling over the past three days, including today.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAM-D6 Self-Report Version Test Code Terminology|CDISC Questionnaire HAM-D6 Self-Report Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130546>	C130292	HAM-D6 Self-Report Version - Low Self-esteem and Guilt|HAMDS1-Low Self-esteem and Guilt|HAMDS1-Low Self-esteem and Guilt|HAMDS102	Hamilton Depression Rating Scale 6 Self-Report Version (HAM-D6 Self-Report Version) (2)=Low self-esteem and guilt per clinician version: How you have been feeling over the past three days, including today.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAM-D6 Self-Report Version Test Code Terminology|CDISC Questionnaire HAM-D6 Self-Report Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130547>	C130292	HAM-D6 Self-Report Version - Social Life Activities or Interests|HAMDS1-Social Life Activities/Interests|HAMDS1-Social Life Activities/Interests|HAMDS103	Hamilton Depression Rating Scale 6 Self-Report Version (HAM-D6 Self-Report Version) (3)=Social life activities and interests per clinician version: How you have been feeling over the past three days, including today.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAM-D6 Self-Report Version Test Code Terminology|CDISC Questionnaire HAM-D6 Self-Report Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130548>	C130292	HAM-D6 Self-Report Version - Psychomotor Retardation|HAMDS1-Psychomotor Retardation, General|HAMDS1-Psychomotor Retardation, General|HAMDS104	Hamilton Depression Rating Scale 6 Self-Report Version (HAM-D6 Self-Report Version) (4)=Psychomotor retardation, general per clinician version: How you have been feeling over the past three days, including today.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAM-D6 Self-Report Version Test Code Terminology|CDISC Questionnaire HAM-D6 Self-Report Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130549>	C130292	HAM-D6 Self-Report Version - Psychic Anxiety|HAMDS1-Psychic Anxiety|HAMDS1-Psychic Anxiety|HAMDS105	Hamilton Depression Rating Scale 6 Self-Report Version (HAM-D6 Self-Report Version) (5)=Psychic anxiety per clinician version: How you have been feeling over the past three days, including today.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAM-D6 Self-Report Version Test Code Terminology|CDISC Questionnaire HAM-D6 Self-Report Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13054>	C13229|C12508	Embryonic Cell|Blastomere|Embryonic Cells	A cell formed in the initial stages of embryonic development, after zygote formation.	Embryonic Cell		Cell	
C130550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130550>	C130292	HAM-D6 Self-Report Version - Tiredness and Pains|HAMDS1-Tiredness and Pains|HAMDS1-Tiredness and Pains|HAMDS106	Hamilton Depression Rating Scale 6 Self-Report Version (HAM-D6 Self-Report Version) (6)=Tiredness and pains per clinician version: How you have been feeling over the past three days, including today.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAM-D6 Self-Report Version Test Code Terminology|CDISC Questionnaire HAM-D6 Self-Report Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130551>	C130293	IDS-SR - Falling Asleep|IDSR1-Falling Asleep|IDSR1-Falling Asleep|IDSR101	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Falling asleep.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130552>	C130293	IDS-SR - Sleep During the Night|IDSR1-Sleep During the Night|IDSR1-Sleep During the Night|IDSR102	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Sleep during the night.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130553>	C130293	IDS-SR - Waking Up Too Early|IDSR1-Waking Up Too Early|IDSR1-Waking Up Too Early|IDSR103	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Waking up too early.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130554>	C130293	IDS-SR - Sleeping Too Much|IDSR1-Sleeping Too Much|IDSR1-Sleeping Too Much|IDSR104	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Sleeping too much.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130555>	C130293	IDS-SR - Feeling Sad|IDSR1-Feeling Sad|IDSR1-Feeling Sad|IDSR105	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Feeling sad.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130556>	C130293	IDS-SR - Feeling Irritable|IDSR1-Feeling Irritable|IDSR1-Feeling Irritable|IDSR106	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Feeling irritable.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130557>	C130293	IDS-SR - Feeling Anxious or Tense|IDSR1-Feeling Anxious or Tense|IDSR1-Feeling Anxious or Tense|IDSR107	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Feeling anxious or tense.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130558>	C130293	IDS-SR - Response of Your Mood to Good or Desired Events|IDSR1-Your Mood to Good/Desired Events|IDSR1-Your Mood to Good/Desired Events|IDSR108	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Response of your mood to good or desired events.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130559>	C130293	IDS-SR - Mood in Relation to the Time of Day|IDSR1-Mood in Relation to Time of Day|IDSR1-Mood in Relation to Time of Day|IDSR109	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Mood in relation to the time of day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13055>	C12508	Secretory Cell	One of several types of cells that generate and secrete a substance to be used by the organism.	Secretory Cell		Body Part, Organ, or Organ Component	
C130560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130560>	C130293	IDS-SR - Mood Worse in Morning, Afternoon, or Night|IDSR1-Mood Worse Morn/Afternoon/Night|IDSR1-Mood Worse Morn/Afternoon/Night|IDSR109A	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Is your mood typically worse in the morning, afternoon or night?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130561>	C130293	IDS-SR - Mood Variation Attributed to Environment|IDSR1-Mood Attributed to Environment|IDSR1-Mood Attributed to Environment|IDSR109B	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Is your mood variation attributed to the environment?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130562>	C130293	IDS-SR - The Quality of Your Mood|IDSR1-Quality of Your Mood|IDSR1-Quality of Your Mood|IDSR110	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: The quality of your mood.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130563>	C130293	IDS-SR - Decreased Appetite|IDSR1-Decreased Appetite|IDSR1-Decreased Appetite|IDSR111	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Decreased appetite.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130564>	C130293	IDS-SR - Increased Appetite|IDSR1-Increased Appetite|IDSR1-Increased Appetite|IDSR112	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Increased appetite.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130565>	C130293	IDS-SR - Weight (Decrease)|IDSR1-Weight (Decrease)|IDSR1-Weight (Decrease)|IDSR113	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: within the last two weeks: Weight (decrease).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130566>	C130293	IDS-SR - Weight (Increase)|IDSR1-Weight (Increase)|IDSR1-Weight (Increase)|IDSR114	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: within the last two weeks: Weight (increase).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130567>	C130293	IDS-SR - Concentration or Decision Making|IDSR1-Concentration/Decision Making|IDSR1-Concentration/Decision Making|IDSR115	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Concentration/decision making.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130568>	C130293	IDS-SR - View of Myself|IDSR1-View of Myself|IDSR1-View of Myself|IDSR116	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: View of myself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130569>	C130293	IDS-SR - View of My Future|IDSR1-View of My Future|IDSR1-View of My Future|IDSR117	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: View of my future.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13056>	C25769	Muscle|MUSCLE|Muscular|Skeletal and/or smooth muscle structure (body structure)	One of the contractile organs of the body.	Muscle		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology|OS Authorized Value Terminology|OS Tumor Assessment Table
C130570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130570>	C130293	IDS-SR - Thoughts of Death or Suicide|IDSR1-Thoughts of Death or Suicide|IDSR1-Thoughts of Death or Suicide|IDSR118	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Thoughts of death or suicide.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130571>	C130293	IDS-SR - General Interest|IDSR1-General Interest|IDSR1-General Interest|IDSR119	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: General interest.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130572>	C130293	IDS-SR - Energy Level|IDSR1-Energy Level|IDSR1-Energy Level|IDSR120	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Energy level.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130573>	C130293	IDS-SR - Capacity for Pleasure or Enjoyment|IDSR1-Pleasure/Enjoyment (Exclude Sex)|IDSR1-Pleasure/Enjoyment (Exclude Sex)|IDSR121	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Capacity for pleasure or enjoyment (excluding sex).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130574>	C130293	IDS-SR - Interest in Sex|IDSR1-Interest in Sex|IDSR1-Interest in Sex|IDSR122	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Interest in sex.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130575>	C130293	IDS-SR - Feeling Slowed Down|IDSR1-Feeling Slowed Down|IDSR1-Feeling Slowed Down|IDSR123	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Feeling slowed down.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130576>	C130293	IDS-SR - Feeling Restless|IDSR1-Feeling Restless|IDSR1-Feeling Restless|IDSR124	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Feeling restless.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130577>	C130293	IDS-SR - Aches and Pains|IDSR1-Aches and Pains|IDSR1-Aches and Pains|IDSR125	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Aches and pains.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130578>	C130293	IDS-SR - Other Bodily Symptoms|IDSR1-Other Bodily Symptoms|IDSR1-Other Bodily Symptoms|IDSR126	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Other bodily symptoms.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130579>	C130293	IDS-SR - Panic or Phobic Symptoms|IDSR1-Panic/Phobic Symptoms|IDSR1-Panic/Phobic Symptoms|IDSR127	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Panic/phobic symptoms.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13057>	C12555	Fibroblastic Reticular Cell|FRC|Fibroblastic Reticular Cells	A cell with processes making contact with those of other similar cells to form a cellular sheath for a network of reticular fibers, which constitutes the stroma of all secondary lymphoid organs.	Reticular Cell		Body Part, Organ, or Organ Component	
C130580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130580>	C130293	IDS-SR - Constipation or Diarrhea|IDSR1-Constipation/Diarrhea|IDSR1-Constipation/Diarrhea|IDSR128	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Constipation/diarrhea.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130581>	C130293	IDS-SR - Interpersonal Sensitivity|IDSR1-Interpersonal Sensitivity|IDSR1-Interpersonal Sensitivity|IDSR129	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Interpersonal sensitivity.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130582>	C130293	IDS-SR - Leaden Paralysis or Physical Energy|IDSR1-Leaden Paralysis/Physical Energy|IDSR1-Leaden Paralysis/Physical Energy|IDSR130	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Please circle the one response to each item that best describes you for the past seven days: Leaden paralysis/physical energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130583>	C130293	IDS-SR - Score|IDSR1-Score|IDSR1-Score|IDSR131	Inventory of Depressive Symptomatology Self-Report Version (IDS-SR) Score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IDS-SR Test Code Terminology|CDISC Questionnaire IDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130584>	C130294	QIDS-SR - Falling Asleep|QIDSR1-Falling Asleep|QIDSR1-Falling Asleep|QIDSR101	Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: Falling asleep.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire QIDS-SR Test Code Terminology|CDISC Questionnaire QIDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130585>	C130294	QIDS-SR - Sleep During the Night|QIDSR1-Sleep During the Night|QIDSR1-Sleep During the Night|QIDSR102	Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: Sleep during the night.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire QIDS-SR Test Code Terminology|CDISC Questionnaire QIDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130586>	C130294	QIDS-SR - Waking Up Too Early|QIDSR1-Waking Up Too Early|QIDSR1-Waking Up Too Early|QIDSR103	Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: Waking up too early.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire QIDS-SR Test Code Terminology|CDISC Questionnaire QIDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130587>	C130294	QIDS-SR - Sleeping Too Much|QIDSR1-Sleeping Too Much|QIDSR1-Sleeping Too Much|QIDSR104	Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: Sleeping too much.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire QIDS-SR Test Code Terminology|CDISC Questionnaire QIDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130588>	C130294	QIDS-SR - Feeling Sad|QIDSR1-Feeling Sad|QIDSR1-Feeling Sad|QIDSR105	Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: Feeling sad.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire QIDS-SR Test Code Terminology|CDISC Questionnaire QIDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130589>	C130294	QIDS-SR - Decreased Appetite|QIDSR1-Decreased Appetite|QIDSR1-Decreased Appetite|QIDSR106	Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: Decreased appetite.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire QIDS-SR Test Code Terminology|CDISC Questionnaire QIDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13058>	C33904	Special Sense Organ System	Any one of the specialized organ systems, including the auditory, gustatory, olfactory, vestibular, and visual systems, which transmit signals from their respective organs to the brain via specialized somatic and visceral afferent fibers.	Special Sense Organ System		Body System	
C130590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130590>	C130294	QIDS-SR - Increased Appetite|QIDSR1-Increased Appetite|QIDSR1-Increased Appetite|QIDSR107	Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: Increased appetite.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire QIDS-SR Test Code Terminology|CDISC Questionnaire QIDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130591>	C130294	QIDS-SR - Decreased Weight|QIDSR1-Decreased Weight|QIDSR1-Decreased Weight|QIDSR108	Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: within the last two weeks: Decreased weight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire QIDS-SR Test Code Terminology|CDISC Questionnaire QIDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130592>	C130294	QIDS-SR - Increased Weight|QIDSR1-Increased Weight|QIDSR1-Increased Weight|QIDSR109	Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: within the last two weeks: Increased weight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire QIDS-SR Test Code Terminology|CDISC Questionnaire QIDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130593>	C130294	QIDS-SR - Concentration or Decision Making|QIDSR1-Concentration/Decision Making|QIDSR1-Concentration/Decision Making|QIDSR110	Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: Concentration/decision making.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire QIDS-SR Test Code Terminology|CDISC Questionnaire QIDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130594>	C130294	QIDS-SR - View of Myself|QIDSR1-View of Myself|QIDSR1-View of Myself|QIDSR111	Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: View of myself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire QIDS-SR Test Code Terminology|CDISC Questionnaire QIDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130595>	C130294	QIDS-SR - Thoughts of Death or Suicide|QIDSR1-Thoughts of Death or Suicide|QIDSR1-Thoughts of Death or Suicide|QIDSR112	Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: Thoughts of death or suicide.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire QIDS-SR Test Code Terminology|CDISC Questionnaire QIDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130596>	C130294	QIDS-SR - General Interest|QIDSR1-General Interest|QIDSR1-General Interest|QIDSR113	Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: General interest.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire QIDS-SR Test Code Terminology|CDISC Questionnaire QIDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130597>	C130294	QIDS-SR - Energy Level|QIDSR1-Energy Level|QIDSR1-Energy Level|QIDSR114	Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: Energy level.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire QIDS-SR Test Code Terminology|CDISC Questionnaire QIDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130598>	C130294	QIDS-SR - Feeling Slowed Down|QIDSR1-Feeling Slowed Down|QIDSR1-Feeling Slowed Down|QIDSR115	Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: Feeling slowed down.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire QIDS-SR Test Code Terminology|CDISC Questionnaire QIDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130599>	C130294	QIDS-SR - Feeling Restless|QIDSR1-Feeling Restless|QIDSR1-Feeling Restless|QIDSR116	Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Please circle the one response to each item that best describes you for the past seven days: Feeling restless.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire QIDS-SR Test Code Terminology|CDISC Questionnaire QIDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13059>	C12555	Synovial Cell|Synovial Cells	A fibroblast that lies between the cartilaginous fibers in the synovial membrane of joints.	Synovial Cells		Cell	
C1305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1305>	C1967	Methyl 2,5-dihydroxycinnamate|2,4-Dihydroxymethylcinnamate|2,5-Dihydroxycinnamic Acid Methyl Ester|3-(2,5-Dihydroxyphenyl)-2-propenoic Acid Methyl Ester|ALX-270-098|BML-EI146|Methyl 3-(2,5-dihydroxyphenyl)-2-propenoate|Methyl-2,5-dihydroxycinnamate	A cell-permeable analog of erbstatin, a compound isolated from Streptomyces that inhibits the autophosphorylation of epidermal growth factor receptor.  Erbstatin analogue competitively inhibits epidermal growth factor receptor-associated tyrosine kinase, inhibiting the activation of v-abl tyrosine kinase.  In addition, this agent has induced apoptosis in mouse thymocytes and inhibits the G2/M phase of the cell cycle. (NCI)			Organic Chemical|Pharmacologic Substance	
C130600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130600>	C130294	QIDS-SR - Highest Score Sleep Items|QIDSR1-Highest Score Sleep Items|QIDSR1-Highest Score Sleep Items|QIDSR117	Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Enter the highest score on any 1 of the 4 sleep items.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire QIDS-SR Test Code Terminology|CDISC Questionnaire QIDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130601>	C130294	QIDS-SR - High Score Appetite or Weight Items|QIDSR1-High Score Appetite/Weight Items|QIDSR1-High Score Appetite/Weight Items|QIDSR118	Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Enter the highest score on any 1 of the 4 appetite/weight change items.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire QIDS-SR Test Code Terminology|CDISC Questionnaire QIDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130602>	C130294	QIDS-SR - Highest Score Psychomotor Items|QIDSR1-Highest Score Psychomotor Items|QIDSR1-Highest Score Psychomotor Items|QIDSR119	Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Enter the highest score on either of the 2 psychomotor items.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire QIDS-SR Test Code Terminology|CDISC Questionnaire QIDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130603>	C130294	QIDS-SR - Total Score|QIDSR1-Total Score|QIDSR1-Total Score|QIDSR120	Quick Inventory of Depressive Symptomatology Self-Report Version (QIDS-SR) Total score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire QIDS-SR Test Code Terminology|CDISC Questionnaire QIDS-SR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130604>	C130295	Q-LES-Q - Free of Aches, Pains, Discomfort|QLES1-Free of Aches, Pains, Discomfort|QLES1-Free of Aches, Pains, Discomfort|QLES101	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) With regard to your physical health, during the past week how much of the time have you: been completely free of aches, pains, or discomfort?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130605>	C130295	Q-LES-Q - Felt Rested|QLES1-Felt Rested|QLES1-Felt Rested|QLES102	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) With regard to your physical health, during the past week how much of the time have you: felt rested?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130606>	C130295	Q-LES-Q - Felt Energetic|QLES1-Felt Energetic|QLES1-Felt Energetic|QLES103	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) With regard to your physical health, during the past week how much of the time have you: felt energetic?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130607>	C130295	Q-LES-Q - Felt in Excellent Physical Health|QLES1-Felt in Excellent Physical Health|QLES1-Felt in Excellent Physical Health|QLES104	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) With regard to your physical health, during the past week how much of the time have you: felt in excellent physical health?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130608>	C130295	Q-LES-Q - At Least Very Good Physical Health|QLES1-At Least Very Good Physical Health|QLES1-At Least Very Good Physical Health|QLES105	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) With regard to your physical health, during the past week how much of the time have you: felt in at least very good physical health?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130609>	C130295	Q-LES-Q - Free of Worry of Physical Health|QLES1-Free of Worry of Physical Health|QLES1-Free of Worry of Physical Health|QLES106	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) With regard to your physical health, during the past week how much of the time have you: been free of worry about your physical health?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13060>	C12719	Sensory Ganglion|Sensory Ganglia	A cluster of nerve cell bodies that transmit sensory impulses and are located on either the dorsal root of a spinal nerve or on certain cranial nerves.	Sensory Ganglion		Body Part, Organ, or Organ Component	
C130610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130610>	C130295	Q-LES-Q - Felt You Got Enough Sleep|QLES1-Felt You Got Enough Sleep|QLES1-Felt You Got Enough Sleep|QLES107	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) With regard to your physical health, during the past week how much of the time have you: felt you got enough sleep?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130611>	C130295	Q-LES-Q - Be as Physically Active as Needed|QLES1-Be as Physically Active as Needed|QLES1-Be as Physically Active as Needed|QLES108	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) With regard to your physical health, during the past week how much of the time have you: felt able to be as physically active as needed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130612>	C130295	Q-LES-Q - Felt Well Coordinated|QLES1-Felt Well Coordinated|QLES1-Felt Well Coordinated|QLES109	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) With regard to your physical health, during the past week how much of the time have you: felt well coordinated?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130613>	C130295	Q-LES-Q - Felt Memory Was Functioning Well|QLES1-Felt Memory Was Functioning Well|QLES1-Felt Memory Was Functioning Well|QLES110	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) With regard to your physical health, during the past week how much of the time have you: felt your memory was functioning well?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130614>	C130295	Q-LES-Q - Felt Good Physically|QLES1-Felt Good Physically|QLES1-Felt Good Physically|QLES111	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) With regard to your physical health, during the past week how much of the time have you: felt good physically?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130615>	C130295	Q-LES-Q - Felt Full of Pep and Vitality|QLES1-Felt Full of Pep and Vitality|QLES1-Felt Full of Pep and Vitality|QLES112	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) With regard to your physical health, during the past week how much of the time have you: felt full of pep and vitality?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130616>	C130295	Q-LES-Q - Free of Visual Problems|QLES1-Free of Visual Problems|QLES1-Free of Visual Problems|QLES113	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) With regard to your physical health, during the past week how much of the time have you: been free of visual problems?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130617>	C130295	Q-LES-Q - Felt Clearheaded|QLES1-Felt Clearheaded|QLES1-Felt Clearheaded|QLES114	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: felt clearheaded?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130618>	C130295	Q-LES-Q - Felt Satisfied With Your Life|QLES1-Felt Satisfied With Your Life|QLES1-Felt Satisfied With Your Life|QLES115	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: felt satisfied with your life?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130619>	C130295	Q-LES-Q - Felt Good About Your Appearance|QLES1-Felt Good About Your Appearance|QLES1-Felt Good About Your Appearance|QLES116	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: felt good about your appearance?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130620>	C130295	Q-LES-Q - Felt Happy or Cheerful|QLES1-Felt Happy or Cheerful|QLES1-Felt Happy or Cheerful|QLES117	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: felt happy or cheerful?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130621>	C130295	Q-LES-Q - Felt Independent|QLES1-Felt Independent|QLES1-Felt Independent|QLES118	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: felt independent?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130622>	C130295	Q-LES-Q - Felt Content|QLES1-Felt Content|QLES1-Felt Content|QLES119	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: felt content?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130623>	C130295	Q-LES-Q - Able to Communicate With Others|QLES1-Able to Communicate With Others|QLES1-Able to Communicate With Others|QLES120	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: felt able to communicate with others?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130624>	C130295	Q-LES-Q - Taking Care of Your Appearance|QLES1-Taking Care of Your Appearance|QLES1-Taking Care of Your Appearance|QLES121	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: felt interested in taking care of your appearance (hair, clothing) and personal hygiene (bathing, dressing)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130625>	C130295	Q-LES-Q - Felt Able to Make Decisions|QLES1-Felt Able to Make Decisions|QLES1-Felt Able to Make Decisions|QLES122	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: felt able to make decisions?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130626>	C130295	Q-LES-Q - Felt Relaxed|QLES1-Felt Relaxed|QLES1-Felt Relaxed|QLES123	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: felt relaxed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130627>	C130295	Q-LES-Q - Felt Good About Your Life|QLES1-Felt Good About Your Life|QLES1-Felt Good About Your Life|QLES124	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: felt good about your life?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130628>	C130295	Q-LES-Q - Able to Travel About to Get Things Done When Needed|QLES1-Able to Travel About When Needed|QLES1-Able to Travel About When Needed|QLES125	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: felt able to travel about to get things done when needed (walk, use car, bus, train, or whatever is available as needed)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130629>	C130295	Q-LES-Q - Able to Deal With Life's Problems|QLES1-Able to Deal With Life's Problems|QLES1-Able to Deal With Life's Problems|QLES126	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: felt able to deal with life's problems?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13062>	C12680	Back|BACK|back|back of body proper|dorsal part of organism|dorsum	The dorsal area between the base of the neck and the sacrum.	Back		Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|UBERON Terminology
C130630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130630>	C130295	Q-LES-Q - Able to Take Care of Yourself|QLES1-Able to Take Care of Yourself|QLES1-Able to Take Care of Yourself|QLES127	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: felt able to take care of yourself?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130631>	C130295	Q-LES-Q - Have a Job|QLES1-Have a Job|QLES1-Have a Job|QLES128A	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Do you have a job?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130632>	C130295	Q-LES-Q - Work for Yourself|QLES1-Work for Yourself|QLES1-Work for Yourself|QLES128B	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Do you work for yourself?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130633>	C130295	Q-LES-Q - Do Volunteer Work|QLES1-Do Volunteer Work|QLES1-Do Volunteer Work|QLES128C	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Do you do volunteer work?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130634>	C130295	Q-LES-Q - Reason for Not Working|QLES1-Reason for Not Working|QLES1-Reason for Not Working|QLES128D	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Reason not having a job, working for yourself, and not doing volunteer work?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130635>	C130295	Q-LES-Q - Enjoyed Your Work|QLES1-Enjoyed Your Work|QLES1-Enjoyed Your Work|QLES129	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: enjoyed your work?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130636>	C130295	Q-LES-Q - Solved Work Problem Without Stress|QLES1-Solved Work Problem Without Stress|QLES1-Solved Work Problem Without Stress|QLES130	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: solved work problems or dealt with them without undue stress?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130637>	C130295	Q-LES-Q - Thought Clearly About Work|QLES1-Thought Clearly About Work|QLES1-Thought Clearly About Work|QLES131	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: thought clearly about work?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130638>	C130295	Q-LES-Q - Decisive About Work or Made Decisions|QLES1-Decisive About Work/Made Decisions|QLES1-Decisive About Work/Made Decisions|QLES132	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: been decisive about work, or made decisions when needed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130639>	C130295	Q-LES-Q - Accomplished What You Wanted to Do|QLES1-Accomplished What You Wanted to Do|QLES1-Accomplished What You Wanted to Do|QLES133	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: accomplished what you wanted to do?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13063>	C12680	Neck|Cervical|NECK|Neck, NOS|neck	The region that connects the head to the rest of the body.	Neck		Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Radiation Therapy Table|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table|UBERON Terminology
C130640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130640>	C130295	Q-LES-Q - Pleased With Work Accomplishments|QLES1-Pleased With Work Accomplishments|QLES1-Pleased With Work Accomplishments|QLES134	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: been pleased with your work accomplishments?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130641>	C130295	Q-LES-Q - Worked Well|QLES1-Worked Well|QLES1-Worked Well|QLES135	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: worked well?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130642>	C130295	Q-LES-Q - Been Interested in Your Work|QLES1-Been Interested in Your Work|QLES1-Been Interested in Your Work|QLES136	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: been interested in your work?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130643>	C130295	Q-LES-Q - Concentrated on Work|QLES1-Concentrated on Work|QLES1-Concentrated on Work|QLES137	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: concentrated on work?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130644>	C130295	Q-LES-Q - Worked Carefully|QLES1-Worked Carefully|QLES1-Worked Carefully|QLES138	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: worked carefully?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130645>	C130295	Q-LES-Q - Kept Up With Expected Work|QLES1-Kept Up With Expected Work|QLES1-Kept Up With Expected Work|QLES139	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: kept up with expected work?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130646>	C130295	Q-LES-Q - Taken Care of Work by Yourself|QLES1-Taken Care of Work by Yourself|QLES1-Taken Care of Work by Yourself|QLES140	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: taken care of work by yourself when it was necessary?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130647>	C130295	Q-LES-Q - Communicated and Interacted With Ease|QLES1-Communicated/Interacted With Ease|QLES1-Communicated/Interacted With Ease|QLES141	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: communicated and interacted with ease with others while working?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130648>	C130295	Q-LES-Q - Responsible for Household|QLES1-Responsible for Household|QLES1-Responsible for Household|QLES142	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Are you responsible for any household duties/housework/homemaker activities (e.g., cleaning, shopping, doing dishes, food shopping or preparation) for your-self or for other people?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130649>	C130295	Q-LES-Q - Reason for No Household Activities|QLES1-Reason for No Household Activities|QLES1-Reason for No Household Activities|QLES142A	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Reason for no household duties/housework/homemaker activities (e.g., cleaning, shopping doing dishes, food shopping or preparation) for your-self or for other people?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130650>	C130295	Q-LES-Q - Kept Room Clean to Satisfaction|QLES1-Kept Room Clean to Satisfaction|QLES1-Kept Room Clean to Satisfaction|QLES143	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: kept your room/apartment/house cleaned to your satisfaction?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130651>	C130295	Q-LES-Q - Paid Bills, Done Banking|QLES1-Paid Bills, Done Banking|QLES1-Paid Bills, Done Banking|QLES144	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: paid the bills, done the banking to your satisfaction?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130652>	C130295	Q-LES-Q - Shopped for Food or Household Items|QLES1-Shopped for Food/Household Items|QLES1-Shopped for Food/Household Items|QLES145	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: shopped for food or other household items to your satisfaction?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130653>	C130295	Q-LES-Q - Prepared Food or Obtained Food|QLES1-Prepared Food or Obtained Food|QLES1-Prepared Food or Obtained Food|QLES146	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: prepared food or obtained food to your satisfaction?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130654>	C130295	Q-LES-Q - Taken Care of Laundry or Cleaning|QLES1-Taken Care of Laundry/Cleaning|QLES1-Taken Care of Laundry/Cleaning|QLES147	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: taken care of the laundry/cleaning to your satisfaction?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130655>	C130295	Q-LES-Q - Accomplish Household Activities|QLES1-Accomplish Household Activities|QLES1-Accomplish Household Activities|QLES148	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: had a feeling of accomplishment with regard to household activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130656>	C130295	Q-LES-Q - Thought Clearly Household Activities to be Done|QLES1-Thought Clearly Household Activ|QLES1-Thought Clearly Household Activ|QLES149	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: concentrated and thought clearly about what household activities needed to be done?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130657>	C130295	Q-LES-Q - Solved House Problems Without Stress|QLES1-Solved House Problems w/o Stress|QLES1-Solved House Problems w/o Stress|QLES150	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: solved household problems or dealt with them without undue stress?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130658>	C130295	Q-LES-Q - Decisive With Regard to Household Activities|QLES1-Decisive Household Activities|QLES1-Decisive Household Activities|QLES151	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: been decisive or made decisions when needed with regard to household activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130659>	C130295	Q-LES-Q - Made Repairs or Household Maintenance|QLES1-Made Repairs Household Maintenance|QLES1-Made Repairs Household Maintenance|QLES152	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week, how often have you: made repairs or taken care of household maintenance as needed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13065>	C32669	Sphincter of Oddi|Glisson's Sphincter|Oddi's Sphincter	The muscle fibres around the opening of the common bile duct (ductus choledochus) into the duodenum at the papilla of Vater.	Oddi's Sphincter		Body Part, Organ, or Organ Component	Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C130660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130660>	C130295	Q-LES-Q - Taken Courses or Going to Class|QLES1-Taken Courses/Going to Class|QLES1-Taken Courses/Going to Class|QLES153	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Have you been taking any courses, going to class, or been involved in any type of course work, school or college studies during the past week?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130661>	C130295	Q-LES-Q - Reason for No Courses|QLES1-Reason for No Courses|QLES1-Reason for No Courses|QLES153A	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Reason not taking any courses, going to class, or been involved in any type of course work, school or college studies during the past week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130662>	C130295	Q-LES-Q - Enjoyed Course or Class Work|QLES1-Enjoyed Course/Class Work|QLES1-Enjoyed Course/Class Work|QLES154	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: enjoyed the course/class work?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130663>	C130295	Q-LES-Q - Looked Forward to Course Work|QLES1-Looked Forward to Course Work|QLES1-Looked Forward to Course Work|QLES155	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: looked forward to getting to work on the course/class work?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130664>	C130295	Q-LES-Q - Dealt With Course or Class Work Without Stress|QLES1-Course/Class Work Without Stress|QLES1-Course/Class Work Without Stress|QLES156	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: dealt with the course/class work without undue stress?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130665>	C130295	Q-LES-Q - Thought Clearly About Course Work|QLES1-Thought Clearly About Course Work|QLES1-Thought Clearly About Course Work|QLES157	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: thought clearly about the course/class work?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130666>	C130295	Q-LES-Q - Decisive About Course Work|QLES1-Decisive About Course Work|QLES1-Decisive About Course Work|QLES158	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: been decisive about the course/class work when needed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130667>	C130295	Q-LES-Q - Pleased With Course Accomplishment|QLES1-Pleased With Course Accomplishment|QLES1-Pleased With Course Accomplishment|QLES159	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: been pleased with your course/class work accomplishments?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130668>	C130295	Q-LES-Q - Interested in Your Course Work|QLES1-Interested in Your Course Work|QLES1-Interested in Your Course Work|QLES160	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: been interested in your course/class work?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130669>	C130295	Q-LES-Q - Concentrated on Course Work|QLES1-Concentrated on Course Work|QLES1-Concentrated on Course Work|QLES161	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: concentrated on the course/class work?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13066>	C25763	Ileocecal Valve	The valve between the ileum of the small intestine and the cecum of the large intestine.	Ileocecal Valve		Body Part, Organ, or Organ Component	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C130670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130670>	C130295	Q-LES-Q - Felt Good Doing Course Work|QLES1-Felt Good Doing Course Work|QLES1-Felt Good Doing Course Work|QLES162	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: felt good while doing your course/class work?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130671>	C130295	Q-LES-Q - Communicated With Ease at Course|QLES1-Communicated With Ease at Course|QLES1-Communicated With Ease at Course|QLES163	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how much of the time have you: communicated and interacted with ease with others at your course/class?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130672>	C130295	Q-LES-Q - Use Time for a Leisure Activity|QLES1-Use Time for a Leisure Activity|QLES1-Use Time for a Leisure Activity|QLES164	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) When you had time, how often did you use that time for a leisure time activity?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130673>	C130295	Q-LES-Q - Enjoy the Leisure Activities|QLES1-Enjoy the Leisure Activities|QLES1-Enjoy the Leisure Activities|QLES165	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) How often did you enjoy the leisure activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130674>	C130295	Q-LES-Q - Look Forward to Leisure Activities|QLES1-Look Forward to Leisure Activities|QLES1-Look Forward to Leisure Activities|QLES166	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) How often did you look forward to the leisure activities before spending time at them?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130675>	C130295	Q-LES-Q - Concentrate on Leisure Activities|QLES1-Concentrate on Leisure Activities|QLES1-Concentrate on Leisure Activities|QLES167	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) How often did you concentrate on the leisure activities and pay attention to them?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130676>	C130295	Q-LES-Q - Solve or Deal Without Undue Stress|QLES1-Solve or Deal Without Undue Stress|QLES1-Solve or Deal Without Undue Stress|QLES168	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) If a problem arose in your leisure activities, how often did you solve it or deal with it without undue stress?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130677>	C130295	Q-LES-Q - Leisure Activity Sustain Interest|QLES1-Leisure Activity Sustain Interest|QLES1-Leisure Activity Sustain Interest|QLES169	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) How often did the leisure activities sustain your interest?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130678>	C130295	Q-LES-Q - Enjoyed Being With Friends|QLES1-Enjoyed Being With Friends|QLES1-Enjoyed Being With Friends|QLES170	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how often have you: enjoyed talking with or being with friends or relatives?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130679>	C130295	Q-LES-Q - Getting Together With Friends|QLES1-Getting Together With Friends|QLES1-Getting Together With Friends|QLES171	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how often have you: looked forward to getting together with friends or relatives?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13067>	C49346	Solitary Nucleus|Nucleus Tractus Solitarius|Nucleus of the Solitary Tract|Nucleus of the Tractus Solitarius	A cluster of nerve cell bodies that form a column of gray matter in the dorsomedial region of the medulla oblongata. The solitary nucleus comprises the gustatory and visceral sensory nuclei of the brainstem, processing impulses from the taste buds, pharynx, larynx, intestinal and respiratory tracts, heart, and large blood vessels.	Solitary Nucleus		Body Part, Organ, or Organ Component	
C130680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130680>	C130295	Q-LES-Q - Made Social Plans With Friends|QLES1-Made Social Plans With Friends|QLES1-Made Social Plans With Friends|QLES172	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how often have you: made social plans with friends or relatives for future activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130681>	C130295	Q-LES-Q - Enjoyed Talking With Co-workers|QLES1-Enjoyed Talking With Co-workers|QLES1-Enjoyed Talking With Co-workers|QLES173	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how often have you: enjoyed talking with co-workers or neighbors?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130682>	C130295	Q-LES-Q - Patient With Others|QLES1-Patient With Others|QLES1-Patient With Others|QLES174	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how often have you: been patient with others when others were irritating in their actions or words?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130683>	C130295	Q-LES-Q - Interested in Problems of People|QLES1-Interested in Problems of People|QLES1-Interested in Problems of People|QLES175	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how often have you: been interested in the problems of other people?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130684>	C130295	Q-LES-Q - Felt Affection Toward People|QLES1-Felt Affection Toward People|QLES1-Felt Affection Toward People|QLES176	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how often have you: felt affection toward one or more people?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130685>	C130295	Q-LES-Q - Gotten Along Well With People|QLES1-Gotten Along Well With People|QLES1-Gotten Along Well With People|QLES177	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how often have you: gotten along well with other people?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130686>	C130295	Q-LES-Q - Joked or Laughed With Other People|QLES1-Joked or Laughed With Other People|QLES1-Joked or Laughed With Other People|QLES178	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how often have you: joked or laughed with other people?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130687>	C130295	Q-LES-Q - Met Needs of Friends or Relatives|QLES1-Met Needs of Friends or Relatives|QLES1-Met Needs of Friends or Relatives|QLES179	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how often have you: felt you met the needs of friends or relatives?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130688>	C130295	Q-LES-Q - Relationships Without Problems|QLES1-Relationships Without Problems|QLES1-Relationships Without Problems|QLES180	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) During the past week how often have you: felt your relationships with your friends or relatives were without major problems or conflicts?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130689>	C130295	Q-LES-Q - Physical Health|QLES1-Physical Health|QLES1-Physical Health|QLES181	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Taking everything into consideration, during the past week how satisfied have you been with your: physical health?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13068>	C12982	Foot Bone|Foot Bones	One of the seven tarsal, five metatarsal, or 14 phalangeal bones in the foot.	Foot Bone		Body Part, Organ, or Organ Component	Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table
C130690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130690>	C130295	Q-LES-Q - Mood|QLES1-Mood|QLES1-Mood|QLES182	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Taking everything into consideration, during the past week how satisfied have you been with your: mood?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130691>	C130295	Q-LES-Q - Work|QLES1-Work|QLES1-Work|QLES183	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Taking everything into consideration, during the past week how satisfied have you been with your: work?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130692>	C130295	Q-LES-Q - Household Activities|QLES1-Household Activities|QLES1-Household Activities|QLES184	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Taking everything into consideration, during the past week how satisfied have you been with your: household activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130693>	C130295	Q-LES-Q - Social Relationships|QLES1-Social Relationships|QLES1-Social Relationships|QLES185	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Taking everything into consideration, during the past week how satisfied have you been with your: social relationships?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130694>	C130295	Q-LES-Q - Family Relationships|QLES1-Family Relationships|QLES1-Family Relationships|QLES186	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Taking everything into consideration, during the past week how satisfied have you been with your: family relationships?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130695>	C130295	Q-LES-Q - Leisure Time Activities|QLES1-Leisure Time Activities|QLES1-Leisure Time Activities|QLES187	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Taking everything into consideration, during the past week how satisfied have you been with your: leisure time activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130696>	C130295	Q-LES-Q - Ability to Function in Daily Life|QLES1-Ability to Function in Daily Life|QLES1-Ability to Function in Daily Life|QLES188	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Taking everything into consideration, during the past week how satisfied have you been with your: ability to function in daily life?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130697>	C130295	Q-LES-Q - Sex Drive, Interest, Performance|QLES1-Sex Drive, Interest, Performance|QLES1-Sex Drive, Interest, Performance|QLES189	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Taking everything into consideration, during the past week how satisfied have you been with your: sexual drive, interest and/or performance?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130698>	C130295	Q-LES-Q - Economic Status|QLES1-Economic Status|QLES1-Economic Status|QLES190	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Taking everything into consideration, during the past week how satisfied have you been with your: economic status?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130699>	C130295	Q-LES-Q - Living or Housing Situation|QLES1-Living/Housing Situation|QLES1-Living/Housing Situation|QLES191	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Taking everything into consideration, during the past week how satisfied have you been with your: living/housing situation?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13069>	C33904	Stomatognathic System	The mouth, jaws, and other related structures that are involved in speech, mastication, and deglutition.	Stomatognathic System		Body System	
C1306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1306>	C2134	O6-Benzylguanine|2-amino-6-(benzyloxy)purine|2-amino-6-(phenylmethoxy)-9h-purine|6-O-BENZYLGUANINE|6-O-Benzylguanine|O(6)-Benzylguanine|O(6)-benzylguanine|O-6-Benzylguanine|O6-BG	A guanine analogue with antineoplastic activity. O6-benzylguanine binds the DNA repair enzyme O(6)-alkylguanine DNA alkyltransferase (AGT), transferring the benzyl moiety to the active-site cysteine and resulting in inhibition of AGT-mediated DNA repair. Co-administration of this agent potentiates the effects of other chemotherapeutic agents that damage DNA. (NCI04)	O6-Benzylguanine		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C130700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130700>	C130295	Q-LES-Q - Ability to Get Around Physically|QLES1-Ability to Get Around Physically|QLES1-Ability to Get Around Physically|QLES192	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Taking everything into consideration, during the past week how satisfied have you been with your: ability to get around physically without feeling dizzy or unsteady or falling?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130701>	C130295	Q-LES-Q - Vision Ability to Do Work or Hobbies|QLES1-Vision Ability to Do Work/Hobbies|QLES1-Vision Ability to Do Work/Hobbies|QLES193	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Taking everything into consideration, during the past week how satisfied have you been with your: your vision in terms of ability to do work or hobbies?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130702>	C130295	Q-LES-Q - Overall Sense of Well Being|QLES1-Overall Sense of Well Being|QLES1-Overall Sense of Well Being|QLES194	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Taking everything into consideration, during the past week how satisfied have you been with your: overall sense of well being?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130703>	C130295	Q-LES-Q - Medication|QLES1-Medication|QLES1-Medication|QLES195	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) Taking everything into consideration, during the past week how satisfied have you been with your: medication?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130704>	C130295	Q-LES-Q - Rate Overall Life Satisfaction|QLES1-Rate Overall Life Satisfaction|QLES1-Rate Overall Life Satisfaction|QLES196	Quality Of Life Enjoyment And Satisfaction Questionnaire (Q-LES-Q) How would you rate your overall life satisfaction and contentment during the past week?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q Test Code Terminology|CDISC Questionnaire Q-LES-Q Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130705>	C130296	Q-LES-Q-SF - Physical Health|QLES2-Physical Health|QLES2-Physical Health|QLES201	Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Taking everything into consideration, during the past week how satisfied have you been with your: physical health?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q-SF Test Code Terminology|CDISC Questionnaire Q-LES-Q-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130706>	C130296	Q-LES-Q-SF - Mood|QLES2-Mood|QLES2-Mood|QLES202	Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Taking everything into consideration, during the past week how satisfied have you been with your: mood?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q-SF Test Code Terminology|CDISC Questionnaire Q-LES-Q-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130707>	C130296	Q-LES-Q-SF - Work|QLES2-Work|QLES2-Work|QLES203	Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Taking everything into consideration, during the past week how satisfied have you been with your: work?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q-SF Test Code Terminology|CDISC Questionnaire Q-LES-Q-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130708>	C130296	Q-LES-Q-SF - Household Activities|QLES2-Household Activities|QLES2-Household Activities|QLES204	Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Taking everything into consideration, during the past week how satisfied have you been with your: household activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q-SF Test Code Terminology|CDISC Questionnaire Q-LES-Q-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130709>	C130296	Q-LES-Q-SF - Social Relationships|QLES2-Social Relationships|QLES2-Social Relationships|QLES205	Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Taking everything into consideration, during the past week how satisfied have you been with your: social relationships?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q-SF Test Code Terminology|CDISC Questionnaire Q-LES-Q-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13070>	C38617	Cheek|CHEEK|cheek	The fleshy part of the face bounded by the eyes, nose, ear, and jaw line.	Cheek		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|UBERON Terminology
C130710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130710>	C130296	Q-LES-Q-SF - Family Relationships|QLES2-Family Relationships|QLES2-Family Relationships|QLES206	Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Taking everything into consideration, during the past week how satisfied have you been with your: family relationships?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q-SF Test Code Terminology|CDISC Questionnaire Q-LES-Q-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130711>	C130296	Q-LES-Q-SF - Leisure Time Activities|QLES2-Leisure Time Activities|QLES2-Leisure Time Activities|QLES207	Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Taking everything into consideration, during the past week how satisfied have you been with your: leisure time activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q-SF Test Code Terminology|CDISC Questionnaire Q-LES-Q-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130712>	C130296	Q-LES-Q-SF - Ability to Function in Daily Life|QLES2-Ability to Function in Daily Life|QLES2-Ability to Function in Daily Life|QLES208	Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Taking everything into consideration, during the past week how satisfied have you been with your: ability to function in daily life?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q-SF Test Code Terminology|CDISC Questionnaire Q-LES-Q-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130713>	C130296	Q-LES-Q-SF - Sex Drive, Interest, Performance|QLES2-Sex Drive, Interest, Performance|QLES2-Sex Drive, Interest, Performance|QLES209	Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Taking everything into consideration, during the past week how satisfied have you been with your: sexual drive, interest and/or performance?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q-SF Test Code Terminology|CDISC Questionnaire Q-LES-Q-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130714>	C130296	Q-LES-Q-SF - Economic Status|QLES2-Economic Status|QLES2-Economic Status|QLES210	Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Taking everything into consideration, during the past week how satisfied have you been with your: economic status?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q-SF Test Code Terminology|CDISC Questionnaire Q-LES-Q-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130715>	C130296	Q-LES-Q-SF - Living or Housing Situation|QLES2-Living/Housing Situation|QLES2-Living/Housing Situation|QLES211	Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Taking everything into consideration, during the past week how satisfied have you been with your: living/housing situation?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q-SF Test Code Terminology|CDISC Questionnaire Q-LES-Q-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130716>	C130296	Q-LES-Q-SF - Ability to Get Around Physically|QLES2-Ability to Get Around Physically|QLES2-Ability to Get Around Physically|QLES212	Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Taking everything into consideration, during the past week how satisfied have you been with your: ability to get around physically without feeling dizzy or unsteady or falling?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q-SF Test Code Terminology|CDISC Questionnaire Q-LES-Q-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130717>	C130296	Q-LES-Q-SF - Vision Ability to Do Work or Hobbies|QLES2-Vision Ability to Do Work/Hobbies|QLES2-Vision Ability to Do Work/Hobbies|QLES213	Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Taking everything into consideration, during the past week how satisfied have you been with your: your vision in terms of ability to do work or hobbies?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q-SF Test Code Terminology|CDISC Questionnaire Q-LES-Q-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130718>	C130296	Q-LES-Q-SF - Overall Sense of Well Being|QLES2-Overall Sense of Well Being|QLES2-Overall Sense of Well Being|QLES214	Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Taking everything into consideration, during the past week how satisfied have you been with your: overall sense of well being?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q-SF Test Code Terminology|CDISC Questionnaire Q-LES-Q-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130719>	C130296	Q-LES-Q-SF - Medication|QLES2-Medication|QLES2-Medication|QLES215	Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) Taking everything into consideration, during the past week how satisfied have you been with your: medication?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q-SF Test Code Terminology|CDISC Questionnaire Q-LES-Q-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13071>	C38617	Face|FACE|Facial|Facial region	The anterior portion of the head extending from the forehead to the chin and ear to ear. The facial structures contain the eyes, nose and mouth, cheeks and jaws.	Face		Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Tumor Assessment Table|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table
C130720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130720>	C130296	Q-LES-Q-SF - Rate Overall Life Satisfaction|QLES2-Rate Overall Life Satisfaction|QLES2-Rate Overall Life Satisfaction|QLES216	Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) How would you rate your overall life satisfaction and contentment during the past week?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Q-LES-Q-SF Test Code Terminology|CDISC Questionnaire Q-LES-Q-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130721>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Living Situation at Interview|WD5-Living Situation at Interview|WD5-Living Situation at Interview|WD5F5	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) Living situation at time of interview.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130722>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Sex as Observed|WD5-Sex as Observed|WD5-Sex as Observed|WD5A1	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) Record sex as observed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130723>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - How Old Are You Now|WD5-How Old Are You Now|WD5-How Old Are You Now|WD5A2	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) How old are you now?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130724>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Years Studying in School or College|WD5-Years Studying in School/College|WD5-Years Studying in School/College|WD5A3	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) How many years in all did you spend studying in school, college or university?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130725>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Current Marital Status|WD5-Current Marital Status|WD5-Current Marital Status|WD5A4	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) What is your current marital status?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130726>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Describes Main Work Status Best|WD5-Describes Main Work Status Best|WD5-Describes Main Work Status Best|WD5A5	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) Which describes your main work status best?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130727>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Concentrating for Ten Minutes|WD5-Concentrating for Ten Minutes|WD5-Concentrating for Ten Minutes|WD5D1_1	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Concentrating on doing something for ten minutes?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130728>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Remembering to Do Important Things|WD5-Remembering to Do Important Things|WD5-Remembering to Do Important Things|WD5D1_2	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Remembering to do important things?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130729>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Finding Solutions to Problems|WD5-Finding Solutions to Problems|WD5-Finding Solutions to Problems|WD5D1_3	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Analysing and finding solutions to problems in day-to-day life?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13072>	C38617	Dentition	The development and arrangement of teeth in the mouth.	Dentition		Body Part, Organ, or Organ Component	
C130730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130730>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Learning a New Task|WD5-Learning a New Task|WD5-Learning a New Task|WD5D1_4	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Learning a new task, for example, learning how to get to a new place?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130731>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Understanding What People Say|WD5-Understanding What People Say|WD5-Understanding What People Say|WD5D1_5	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Generally understanding what people say?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130732>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Starting or Maintaining Conversation|WD5-Starting/Maintaining Conversation|WD5-Starting/Maintaining Conversation|WD5D1_6	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Starting and maintaining a conversation?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130733>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Standing for Long Periods|WD5-Standing for Long Periods|WD5-Standing for Long Periods|WD5D2_1	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Standing for long periods such as 30 minutes?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130734>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Standing Up From Sitting Down|WD5-Standing Up From Sitting Down|WD5-Standing Up From Sitting Down|WD5D2_2	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Standing up from sitting down?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130735>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Moving Around Inside Your Home|WD5-Moving Around Inside Your Home|WD5-Moving Around Inside Your Home|WD5D2_3	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Moving around inside your home?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130736>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Getting Out of Your Home|WD5-Getting Out of Your Home|WD5-Getting Out of Your Home|WD5SD2_4	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Getting out of your home?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130737>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Walking a Long Distance|WD5-Walking a Long Distance|WD5-Walking a Long Distance|WD5SD2_5	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Walking a long distance such as a kilometre [or equivalent]?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130738>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Washing Your Whole Body|WD5-Washing Your Whole Body|WD5-Washing Your Whole Body|WD5D3_1	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Washing your whole body?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130739>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Getting Dressed|WD5-Getting Dressed|WD5-Getting Dressed|WD5D3_2	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Getting dressed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13073>	C32716	Facial Muscle|FACIAL MUSCLE|Facial Muscles|Mimetic Muscles	A skeletal muscle located under the skin of the face that is supplied by the facial nerve and controls facial expression.	Facial Muscle		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130740>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Eating|WD5-Eating|WD5-Eating|WD5D3_3	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Eating?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130741>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Staying by Yourself for a Few Days|WD5-Staying by Yourself for a Few Days|WD5-Staying by Yourself for a Few Days|WD5D3_4	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Staying by yourself for a few days?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130742>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Dealing With People You Do Not Know|WD5-Dealing With People You Do Not Know|WD5-Dealing With People You Do Not Know|WD5D4_1	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Dealing with people you do not know?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130743>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Maintaining a Friendship|WD5-Maintaining a Friendship|WD5-Maintaining a Friendship|WD5D4_2	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Maintaining a friendship?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130744>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Get Along With People Close to You|WD5-Get Along With People Close to You|WD5-Get Along With People Close to You|WD5D4_3	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Getting along with people who are close to you?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130745>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Making New Friends|WD5-Making New Friends|WD5-Making New Friends|WD5D4_4	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Making new friends?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130746>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Sexual Activities|WD5-Sexual Activities|WD5-Sexual Activities|WD5D4_5	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Sexual activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130747>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Care of Household Responsibilities|WD5-Care of Household Responsibilities|WD5-Care of Household Responsibilities|WD5D5_1	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) Because of your health condition, in the past 30 days, how much difficulty did you have in: Taking care of your household responsibilities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130748>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Doing Important Household Tasks|WD5-Doing Important Household Tasks|WD5-Doing Important Household Tasks|WD5D5_2	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) Because of your health condition, in the past 30 days, how much difficulty did you have in: Doing your most important household tasks well?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130749>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Getting Household Work Done Needed|WD5-Getting Household Work Done Needed|WD5-Getting Household Work Done Needed|WD5D5_3	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) Because of your health condition, in the past 30 days, how much difficulty did you have in: Getting all the household work done that you needed to do?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13074>	C33147	Masseter Muscle|MASSETER MUSCLE|MUSCLE, MASSETER|Masseter muscle structure (body structure)|Masticatory Muscle	A muscle of mastication originating from the zygomatic arch.	Masticatory Muscle		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C130750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130750>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Getting Household Work Done Quickly|WD5-Getting Household Work Done Quickly|WD5-Getting Household Work Done Quickly|WD5D5_4	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) Because of your health condition, in the past 30 days, how much difficulty did you have in: Getting your household work done as quickly as needed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130751>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Days Reduce or Miss Household Work|WD5-Days Reduce or Miss Household Work|WD5-Days Reduce or Miss Household Work|WD5D5_01	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, on how many days did you reduce or completely miss household work because of your health condition?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130752>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Your Day-to-Day Work or School|WD5-Your Day-to-Day Work/School|WD5-Your Day-to-Day Work/School|WD5D5_5	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) Because of your health condition, in the past 30 days how much difficulty did you have in: Your day-to-day work/school?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130753>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Doing Important Work or School Tasks|WD5-Doing Important Work/School Tasks|WD5-Doing Important Work/School Tasks|WD5D5_6	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) Because of your health condition, in the past 30 days how much difficulty did you have in: Doing your most important work/school tasks well?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130754>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Getting All Work Done You Need to Do|WD5-Getting All Work Done You Need|WD5-Getting All Work Done You Need|WD5D5_7	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) Because of your health condition, in the past 30 days how much difficulty did you have in: Getting all the work done that you need to do?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130755>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Getting Work Done Quickly as Needed|WD5-Getting Work Done Quickly as Needed|WD5-Getting Work Done Quickly as Needed|WD5D5_8	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) Because of your health condition, in the past 30 days how much difficulty did you have in: Getting your work done as quickly as needed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130756>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Had to Work at a Lower Level|WD5-Had to Work at a Lower Level|WD5-Had to Work at a Lower Level|WD5D5_9	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) Because of your health condition, in the past 30 days how much difficulty did you have in: Have you had to work at a lower level because of a health condition?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130757>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Earn Less Money|WD5-Earn Less Money|WD5-Earn Less Money|WD5D5_10	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) Because of your health condition, in the past 30 days how much difficulty did you have in: Did you earn less money as the result of a health condition?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130758>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - How Many Days Did You Miss Work|WD5-How Many Days Did You Miss Work|WD5-How Many Days Did You Miss Work|WD5D5_02	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, on how many days did you miss work for half a day or more because of your health condition?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130759>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Problem Joining Community Activities|WD5-Problem Joining Community Activities|WD5-Problem Joining Community Activities|WD5D6_1	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days: How much of a problem did you have joining in community activities (for example, festivities, religious or other activities) in the same way as anyone else can?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13075>	C32716	Pharyngeal Muscles	The muscles that form the walls of the pharynx, including the inferior, middle, and superior constrictors, salpingopharyngeus, and stylopharyngeus.	Pharyngeal Muscle		Body Part, Organ, or Organ Component	
C130760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130760>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Problem Because of Barriers in World|WD5-Problem Because of Barriers in World|WD5-Problem Because of Barriers in World|WD5D6_2	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days: How much of a problem did you have because of barriers or hindrances in the world around you?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130761>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Problem Living with Dignity|WD5-Problem Living with Dignity|WD5-Problem Living with Dignity|WD5D6_3	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days: How much of a problem did you have living with dignity because of the attitudes and actions of others?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130762>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Time Spend on Your Health Condition|WD5-Time Spend on Your Health Condition|WD5-Time Spend on Your Health Condition|WD5D6_4	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days: How much time did you spend on your health condition or its consequences?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130763>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Emotionally Affected by Health|WD5-Emotionally Affected by Health|WD5-Emotionally Affected by Health|WD5D6_5	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days: How much have you been emotionally affected by your health condition?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130764>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Drain on Financial Resources|WD5-Drain on Financial Resources|WD5-Drain on Financial Resources|WD5D6_6	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days: How much has your health been a drain on the financial resources of you or your family?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130765>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - How Much Problem Did Your Family Have|WD5-Problem Did Your Family Have|WD5-Problem Did Your Family Have|WD5D6_7	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days: How much of a problem did your family have because of your health problems?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130766>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Problem Doing Things for Relaxation|WD5-Problem Doing Things for Relaxation|WD5-Problem Doing Things for Relaxation|WD5D6_8	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days: How much of a problem did you have in doing things by yourself for relaxation or pleasure?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130767>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - How Many Days Difficulties Present|WD5-How Many Days Difficulties Present|WD5-How Many Days Difficulties Present|WD5H1	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) Overall, in the past 30 days, how many days were these difficulties present?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130768>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - Days Unable to Carry Out Activities|WD5-Days Unable to Carry Out Activities|WD5-Days Unable to Carry Out Activities|WD5H2	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, for how many days were you totally unable to carry out your usual activities or work because of any health condition?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130769>	C130297	WHODAS 2.0 36-item Version Interviewer-administered - How Many Days Reduce Activities|WD5-How Many Days Reduce Activities|WD5-How Many Days Reduce Activities|WD5H3	World Health Organization Disability Assessment Schedule 2.0 36-item Version Interviewer-administered (WHODAS 2.0 36-item Version Interviewer-administered) In the past 30 days, not counting the days that you were totally unable, for how many days did you cut back or reduce your usual activities or work because of any health condition?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13076>	C12374	Bone Tissue|Human Bone|Osseous|Osseous Tissue	The mineralized osseous tissue that gives rigidity to the bones and forms its honeycomb-like three-dimensional internal structure.	Bone Tissue		Tissue	FDA Structured Product Labeling Terminology|SPL Tissue Form Product Type Terminology
C130770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130770>	C130298	WHODAS 2.0 36-item Version Proxy-administered - I Am (Fill in the Blank) of this Person|WD6-I Am (Fill in Blank) of This Person|WD6-I Am (Fill in Blank) of This Person|WD6H4	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) I am the (Fill in the Blank) of this person.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130771>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Concentrating for Ten Minutes|WD6-Concentrating for Ten Minutes|WD6-Concentrating for Ten Minutes|WD6D1_1	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Concentrating on doing something for ten minutes?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130772>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Remembering to Do Important Things|WD6-Remembering to Do Important Things|WD6-Remembering to Do Important Things|WD6D1_2	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Remembering to do important things?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130773>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Finding Solutions to Problems|WD6-Finding Solutions to Problems|WD6-Finding Solutions to Problems|WD6D1_3	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Analysing and finding solutions to problems in day-to-day life?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130774>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Learning a New Task|WD6-Learning a New Task|WD6-Learning a New Task|WD6D1_4	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Learning a new task, for example, learning how to get to a new place?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130775>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Understanding What People Say|WD6-Understanding What People Say|WD6-Understanding What People Say|WD6D1_5	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Generally understanding what people say?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130776>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Starting or Maintaining Conversation|WD6-Starting/Maintaining Conversation|WD6-Starting/Maintaining Conversation|WD6D1_6	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Starting and maintaining a conversation?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130777>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Standing for Long Periods|WD6-Standing for Long Periods|WD6-Standing for Long Periods|WD6D2_1	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Standing for long periods such as 30 minutes?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130778>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Standing Up From Sitting Down|WD6-Standing Up From Sitting Down|WD6-Standing Up From Sitting Down|WD6D2_2	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Standing up from sitting down?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130779>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Moving Around Inside Their Home|WD6-Moving Around Inside Their Home|WD6-Moving Around Inside Their Home|WD6D2_3	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Moving around inside their home?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13077>	C33923|C13055	Acinar Cell	A secreting cell that lines an acinus (i.e. a small sac or sac-like structure).  A representative example is the acinar cell located in the pancreas that produces pancreatic enzymes and juices.	Acinar Cell		Cell	
C130780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130780>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Getting Out of Their Home|WD6-Getting Out of Their Home|WD6-Getting Out of Their Home|WD6SD2_4	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Getting out of their home?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130781>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Walking a Long Distance|WD6-Walking a Long Distance|WD6-Walking a Long Distance|WD6SD2_5	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Walking a long distance such as a kilometre [or equivalent]?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130782>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Washing His or Her Whole Body|WD6-Washing His/Her Whole Body|WD6-Washing His/Her Whole Body|WD6D3_1	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Because of their health condition, in the past 30 days, how much difficulty did your relative have in: Washing his or her whole body?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130783>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Getting Dressed|WD6-Getting Dressed|WD6-Getting Dressed|WD6D3_2	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Because of their health condition, in the past 30 days, how much difficulty did your relative have in: Getting dressed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130784>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Eating|WD6-Eating|WD6-Eating|WD6D3_3	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Because of their health condition, in the past 30 days, how much difficulty did your relative have in: Eating?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130785>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Staying by Him or Herself a Few Days|WD6-Staying by Him/Herself a Few Days|WD6-Staying by Him/Herself a Few Days|WD6D3_4	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Because of their health condition, in the past 30 days, how much difficulty did your relative have in: Staying by himself or herself for a few days?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130786>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Dealing With People Does Not Know|WD6-Dealing With People Does Not Know|WD6-Dealing With People Does Not Know|WD6D4_1	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Because of their health condition, in the past 30 days, how much difficulty did your relative have in: Dealing with people he or she does not know?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130787>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Maintaining a Friendship|WD6-Maintaining a Friendship|WD6-Maintaining a Friendship|WD6D4_2	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Because of their health condition, in the past 30 days, how much difficulty did your relative have in: Maintaining a friendship?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130788>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Get Along With People Close to Him|WD6-Get Along With People Close to Him|WD6-Get Along With People Close to Him|WD6D4_3	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Because of their health condition, in the past 30 days, how much difficulty did your relative have in: Getting along with people who are close to him or her?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130789>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Making New Friends|WD6-Making New Friends|WD6-Making New Friends|WD6D4_4	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Because of their health condition, in the past 30 days, how much difficulty did your relative have in: Making new friends?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13078>	C41623	Ependyma|Ependymal Tissue|ependyma	A thin membrane that lines the ventricles of the brain and the central canal of the spinal cord.	Ependyma		Tissue	Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C130790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130790>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Sexual Activities|WD6-Sexual Activities|WD6-Sexual Activities|WD6D4_5	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Because of their health condition, in the past 30 days, how much difficulty did your relative have in: Sexual activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130791>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Care of Household Responsibilities|WD6-Care of Household Responsibilities|WD6-Care of Household Responsibilities|WD6D5_1	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Because of their health condition, in the past 30 days, how much difficulty did your relative have in: Taking care of his or her household responsibilities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130792>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Doing Important Household Tasks|WD6-Doing Important Household Tasks|WD6-Doing Important Household Tasks|WD6D5_2	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Because of their health condition, in the past 30 days, how much difficulty did your relative have in: Doing his or her most important household tasks well?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130793>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Getting Household Work Done Needed|WD6-Getting Household Work Done Needed|WD6-Getting Household Work Done Needed|WD6D5_3	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Because of their health condition, in the past 30 days, how much difficulty did your relative have in: Getting all the household work done that is needed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130794>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Getting Household Work Done Quickly|WD6-Getting Household Work Done Quickly|WD6-Getting Household Work Done Quickly|WD6D5_4	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Because of their health condition, in the past 30 days, how much difficulty did your relative have in: Getting the household work done as quickly as needed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130795>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Their Day-to-Day Work or School|WD6-Their Day-to-Day Work/School|WD6-Their Day-to-Day Work/School|WD6D5_5	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: His or her day-to-day work/school?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130796>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Doing Important Work or School Tasks|WD6-Doing Important Work/School Tasks|WD6-Doing Important Work/School Tasks|WD6D5_6	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Doing his or her most important work/school tasks well?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130797>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Getting All Work Done You Need|WD6-Getting All Work Done You Need|WD6-Getting All Work Done You Need|WD6D5_7	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Getting all the work done that is needed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130798>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Getting Work Done Quickly as Needed|WD6-Getting Work Done Quickly as Needed|WD6-Getting Work Done Quickly as Needed|WD6D5_8	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Getting the work done as quickly as needed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130799>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Problem Joining Community Activities|WD6-Problem Joining Community Activities|WD6-Problem Joining Community Activities|WD6D6_1	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Participation in society in the past 30 days: How much of a problem did your relative have in joining in community activities (for example, festivities, religious or other activities) in the same way as anyone else can?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13079>	C33968	Neural Pathway|Neural Pathways	The route in which a nerve impulse travels through a series of linked axons to connect different regions within the central nervous system or to convey information from the peripheral nervous system to the brain.	Neural Pathway		Body Part, Organ, or Organ Component	
C1307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1307>	C2261	Recombinant Pleiotrophin|HARP|HBGF-8|HBNF|Heparin Affin Regulatory Peptide|Heparin-Binding Growth Factor-8|Heparin-Binding Neurotrophic Factor|OSF-1|Osteoblast Specific Factor 1|Pleiotrophin|Recombinant Heparin-Binding Neurotrophic Factor	A recombinant form of the heparin-binding cytokine pleiotrophin.  Developmentally regulated, pleiotrophin functions as a growth factor during embryogenesis and the neonatal period, contributing to trophoblast formation, organ development, bone formation, and early brain development by inducing the differentiation and proliferation of neuronal tissue.  Expressed in certain tumor cell types, this agent may stimulate tumor cell growth, angiogenesis, and metastasis. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C130800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130800>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Problem Because of Barriers in World|WD6-Problem Because of Barriers in World|WD6-Problem Because of Barriers in World|WD6D6_2	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Participation in society in the past 30 days: How much of a problem did your relative have because of barriers or hindrances in the world around him or her?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130801>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Problem Living with Dignity|WD6-Problem Living with Dignity|WD6-Problem Living with Dignity|WD6D6_3	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Participation in society in the past 30 days: How much of a problem did your relative have living with dignity because of the attitudes and actions of others?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130802>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Time Spend on Your Health Condition|WD6-Time Spend on Your Health Condition|WD6-Time Spend on Your Health Condition|WD6D6_4	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Participation in society in the past 30 days: How much time did your relative spend on his or her health condition, or its consequences?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130803>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Emotionally Affected by Health|WD6-Emotionally Affected by Health|WD6-Emotionally Affected by Health|WD6D6_5	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Participation in society in the past 30 days: How much has your relative been emotionally affected by his or her health condition?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130804>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Drain on Financial Resources|WD6-Drain on Financial Resources|WD6-Drain on Financial Resources|WD6D6_6	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Participation in society in the past 30 days: How much has his or her health been a drain on his or her financial resources or on the financial resources of other relatives?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130805>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Problem Did Your Family Have|WD6-Problem Did Your Family Have|WD6-Problem Did Your Family Have|WD6D6_7	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Participation in society in the past 30 days: How much of a problem did you or the rest of his or her family have because of his or her health problems?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130806>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Problem Doing Things for Relaxation|WD6-Problem Doing Things for Relaxation|WD6-Problem Doing Things for Relaxation|WD6D6_8	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Participation in society in the past 30 days: How much of a problem did your relative have in doing things by himself or herself for relaxation or pleasure?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130807>	C130298	WHODAS 2.0 36-item Version Proxy-administered - How Many Days Difficulties Present|WD6-How Many Days Difficulties Present|WD6-How Many Days Difficulties Present|WD6H1	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) Overall, in the past 30 days, how many days were these difficulties present?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130808>	C130298	WHODAS 2.0 36-item Version Proxy-administered - Days Unable to Carry Out Activities|WD6-Days Unable to Carry Out Activities|WD6-Days Unable to Carry Out Activities|WD6H2	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, for how many days was your relative totally unable to carry out his or her usual activities or work because of any health condition?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130809>	C130298	WHODAS 2.0 36-item Version Proxy-administered - How Many Days Reduce Activities|WD6-How Many Days Reduce Activities|WD6-How Many Days Reduce Activities|WD6H3	World Health Organization Disability Assessment Schedule 2.0 36-item Version Proxy-administered (WHODAS 2.0 36-item Version Proxy-administered) In the past 30 days, not counting the days that your relative was totally unable, for how many days did your relative cut back or reduce his or her usual activities or work because of any health condition?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13080>	C13079	Afferent Pathway|Afferent Pathways	A sensory pathway that conducts impulses toward the central nervous system.	Afferent Pathway		Body Part, Organ, or Organ Component	
C130810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130810>	C130299	WHODAS 2.0 36-item Version Self-administered - Concentrating for Ten Minutes|WD7-Concentrating for Ten Minutes|WD7-Concentrating for Ten Minutes|WD7D1_1	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Concentrating on doing something for ten minutes?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130811>	C130299	WHODAS 2.0 36-item Version Self-administered - Remembering to Do Important Things|WD7-Remembering to Do Important Things|WD7-Remembering to Do Important Things|WD7D1_2	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Remembering to do important things?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130812>	C130299	WHODAS 2.0 36-item Version Self-administered - Finding Solutions to Problems|WD7-Finding Solutions to Problems|WD7-Finding Solutions to Problems|WD7D1_3	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Analysing and finding solutions to problems in day-to-day life?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130813>	C130299	WHODAS 2.0 36-item Version Self-administered - Learning a New Task|WD7-Learning a New Task|WD7-Learning a New Task|WD7D1_4	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Learning a new task, for example, learning how to get to a new place?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130814>	C130299	WHODAS 2.0 36-item Version Self-administered - Understanding What People Say|WD7-Understanding What People Say|WD7-Understanding What People Say|WD7D1_5	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Generally understanding what people say?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130815>	C130299	WHODAS 2.0 36-item Version Self-administered - Starting or Maintaining Conversation|WD7-Starting/Maintaining Conversation|WD7-Starting/Maintaining Conversation|WD7D1_6	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Starting and maintaining a conversation?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130816>	C130299	WHODAS 2.0 36-item Version Self-administered - Standing for Long Periods|WD7-Standing for Long Periods|WD7-Standing for Long Periods|WD7D2_1	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Standing for long periods such as 30 minutes?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130817>	C130299	WHODAS 2.0 36-item Version Self-administered - Standing Up From Sitting Down|WD7-Standing Up From Sitting Down|WD7-Standing Up From Sitting Down|WD7D2_2	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Standing up from sitting down?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130818>	C130299	WHODAS 2.0 36-item Version Self-administered - Moving Around Inside Your Home|WD7-Moving Around Inside Your Home|WD7-Moving Around Inside Your Home|WD7D2_3	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Moving around inside your home?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130819>	C130299	WHODAS 2.0 36-item Version Self-administered - Getting Out of Your Home|WD7-Getting Out of Your Home|WD7-Getting Out of Your Home|WD7D2_4	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Getting out of your home?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13081>	C13079	Efferent Pathway|Efferent Pathways	A sensory pathway that conducts impulses away from the central nervous system.	Efferent Pathway		Body Part, Organ, or Organ Component	
C130820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130820>	C130299	WHODAS 2.0 36-item Version Self-administered - Walking a Long Distance|WD7-Walking a Long Distance|WD7-Walking a Long Distance|WD7D2_5	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Walking a long distance such as a kilometre [or equivalent]?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130821>	C130299	WHODAS 2.0 36-item Version Self-administered - Washing Your Whole Body|WD7-Washing Your Whole Body|WD7-Washing Your Whole Body|WD7D3_1	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Washing your whole body?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130822>	C130299	WHODAS 2.0 36-item Version Self-administered - Getting Dressed|WD7-Getting Dressed|WD7-Getting Dressed|WD7D3_2	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Getting dressed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130823>	C130299	WHODAS 2.0 36-item Version Self-administered - Eating|WD7-Eating|WD7-Eating|WD7D3_3	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Eating?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130824>	C130299	WHODAS 2.0 36-item Version Self-administered - Staying by Yourself for a Few Days|WD7-Staying by Yourself for a Few Days|WD7-Staying by Yourself for a Few Days|WD7D3_4	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Staying by yourself for a few days?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130825>	C130299	WHODAS 2.0 36-item Version Self-administered - Dealing With People You Do Not Know|WD7-Dealing With People You Do Not Know|WD7-Dealing With People You Do Not Know|WD7D4_1	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Dealing with people you do not know?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130826>	C130299	WHODAS 2.0 36-item Version Self-administered - Maintaining a Friendship|WD7-Maintaining a Friendship|WD7-Maintaining a Friendship|WD7D4_2	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Maintaining a friendship?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130827>	C130299	WHODAS 2.0 36-item Version Self-administered - Get Along With People Close to You|WD7-Get Along With People Close to You|WD7-Get Along With People Close to You|WD7D4_3	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Getting along with people who are close to you?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130828>	C130299	WHODAS 2.0 36-item Version Self-administered - Making New Friends|WD7-Making New Friends|WD7-Making New Friends|WD7D4_4	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Making new friends?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130829>	C130299	WHODAS 2.0 36-item Version Self-administered - Sexual Activities|WD7-Sexual Activities|WD7-Sexual Activities|WD7D4_5	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Sexual activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13082>	C34030|C13031	Internal Capsule|BRAIN, INTERNAL CAPSULE|Internal capsule	A white matter structure in the subcortical region of the brain that contains a high concentration of motor and sensory projection nerve fibers. It consists of the anterior limb, genu, posterior limb, and the retrolentiform and sublentiform parts.	Internal Capsule		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF6 DIPG Imaging Assessment Table|CRF6 DMG Imaging Assessment Table|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C130830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130830>	C130299	WHODAS 2.0 36-item Version Self-administered - Care of Household Responsibilities|WD7-Care of Household Responsibilities|WD7-Care of Household Responsibilities|WD7D5_1	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Taking care of your household responsibilities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130831>	C130299	WHODAS 2.0 36-item Version Self-administered - Doing Important Household Tasks|WD7-Doing Important Household Tasks|WD7-Doing Important Household Tasks|WD7D5_2	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Doing most important household tasks well?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130832>	C130299	WHODAS 2.0 36-item Version Self-administered - Getting Household Work Done Needed|WD7-Getting Household Work Done Needed|WD7-Getting Household Work Done Needed|WD7D5_3	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Getting all the household work done that you needed to do?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130833>	C130299	WHODAS 2.0 36-item Version Self-administered - Getting Household Work Done Quickly|WD7-Getting Household Work Done Quickly|WD7-Getting Household Work Done Quickly|WD7D5_4	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Getting your household work done as quickly as needed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130834>	C130299	WHODAS 2.0 36-item Version Self-administered - Your Day-to-Day Work or School|WD7-Your Day-to-Day Work/School|WD7-Your Day-to-Day Work/School|WD7D5_5	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) Because of your health condition, in the past 30 days, how much difficulty did you have in: Your day-to-day work/school?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130835>	C130299	WHODAS 2.0 36-item Version Self-administered - Doing Important Work or School Tasks|WD7-Doing Important Work/School Tasks|WD7-Doing Important Work/School Tasks|WD7D5_6	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) Because of your health condition, in the past 30 days, how much difficulty did you have in: Doing your most important work/school tasks well?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130836>	C130299	WHODAS 2.0 36-item Version Self-administered - Getting All Work Done You Need|WD7-Getting All Work Done You Need|WD7-Getting All Work Done You Need|WD7D5_7	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) Because of your health condition, in the past 30 days, how much difficulty did you have in: Getting all the work done that you need to do?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130837>	C130299	WHODAS 2.0 36-item Version Self-administered - Getting Work Done Quickly as Needed|WD7-Getting Work Done Quickly as Needed|WD7-Getting Work Done Quickly as Needed|WD7D5_8	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) Because of your health condition, in the past 30 days, how much difficulty did you have in: Getting your work done as quickly as needed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130838>	C130299	WHODAS 2.0 36-item Version Self-administered - Problem Joining Community Activities|WD7-Problem Joining Community Activities|WD7-Problem Joining Community Activities|WD7D6_1	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days: How much of a problem did you have in joining in community activities (for example, festivities, religious or other activities) in the same way as anyone else can?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130839>	C130299	WHODAS 2.0 36-item Version Self-administered - Problem Because of Barriers in World|WD7-Problem Because of Barriers in World|WD7-Problem Because of Barriers in World|WD7D6_2	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days: How much of a problem did you have because of barriers or hindrances in the world around you?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13083>	C13079	Medial Forebrain Bundle	A complex tract of nerve fibers that connects the basal telencephalon, the hypothalamus, and the midbrain reticular formation. The medial forebrain bundle contains fibers involved in the reward pathway of the brain.	Medial Forebrain Bundle		Body Part, Organ, or Organ Component	
C130840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130840>	C130299	WHODAS 2.0 36-item Version Self-administered - Problem Living with Dignity|WD7-Problem Living with Dignity|WD7-Problem Living with Dignity|WD7D6_3	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days: How much of a problem did you have living with dignity because of the attitudes and actions of others?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130841>	C130299	WHODAS 2.0 36-item Version Self-administered - Time Spend on Your Health Condition|WD7-Time Spend on Your Health Condition|WD7-Time Spend on Your Health Condition|WD7D6_4	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days: How much time did you spend on your health condition, or its consequences?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130842>	C130299	WHODAS 2.0 36-item Version Self-administered - Emotionally Affected by Health|WD7-Emotionally Affected by Health|WD7-Emotionally Affected by Health|WD7D6_5	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days: How much have you been emotionally affected by your health condition?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130843>	C130299	WHODAS 2.0 36-item Version Self-administered - Drain on Financial Resources|WD7-Drain on Financial Resources|WD7-Drain on Financial Resources|WD7D6_6	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days: How much has your health been a drain on the financial resources of you or your family?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130844>	C130299	WHODAS 2.0 36-item Version Self-administered - Problem Did Your Family Have|WD7-Problem Did Your Family Have|WD7-Problem Did Your Family Have|WD7D6_7	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days: How much of a problem did your family have because of your health problems?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130845>	C130299	WHODAS 2.0 36-item Version Self-administered - Problem Doing Things for Relaxation|WD7-Problem Doing Things for Relaxation|WD7-Problem Doing Things for Relaxation|WD7D6_8	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days: How much of a problem did you have in doing things by yourself for relaxation or pleasure?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130846>	C130299	WHODAS 2.0 36-item Version Self-administered - How Many Days Difficulties Present|WD7-How Many Days Difficulties Present|WD7-How Many Days Difficulties Present|WD7H1	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) Overall, in the past 30 days, how many days were these difficulties present?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130847>	C130299	WHODAS 2.0 36-item Version Self-administered - Days Unable to Carry Out Activities|WD7-Days Unable to Carry Out Activities|WD7-Days Unable to Carry Out Activities|WD7H2	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, for how many days were you totally unable to carry out your usual activities or work because of any health condition?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130848>	C130299	WHODAS 2.0 36-item Version Self-administered - How Many Days Reduce Activities|WD7-How Many Days Reduce Activities|WD7-How Many Days Reduce Activities|WD7H3	World Health Organization Disability Assessment Schedule 2.0 36-item Version Self-administered (WHODAS 2.0 36-item Version Self-administered) In the past 30 days, not counting the days that you were totally unable, for how many days did you cut back or reduce your usual activities or work because of any health condition?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 36-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130849>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Living Situation at Interview|WD4-Living Situation at Interview|WD4-Living Situation at Interview|WD4F5	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) Living situation at time of interview.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13084>	C13079	Perforant Pathway|Perforating Fasciculus	The route of neural fibers originating in the entorhinal cortex that project through the hippocampal formation to granule cells of the dentate gyrus, providing the major input to the hippocampus.	Perforant Pathway		Body Part, Organ, or Organ Component	
C130850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130850>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Observed Sex|WD4-Sex as Observed|WD4-Sex as Observed|WD4A1	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) Record sex as observed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130851>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - How Old Are You Now|WD4-How Old Are You Now|WD4-How Old Are You Now|WD4A2	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) How old are you now?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130852>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Years Studying in School or College|WD4-Years Studying in School/College|WD4-Years Studying in School/College|WD4A3	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) How many years in all did you spend studying in school, college or university?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130853>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Current Marital Status|WD4-Current Marital Status|WD4-Current Marital Status|WD4A4	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) What is your current marital status?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130854>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Describes Main Work Status Best|WD4-Describes Main Work Status Best|WD4-Describes Main Work Status Best|WD4A5	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) Which describes your main work status best?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130855>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Standing for Long Periods|WD4-Standing for Long Periods|WD4-Standing for Long Periods|WD4S1	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Standing for long periods such as 30 minutes?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130856>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Care of Household Responsibilities|WD4-Care of Household Responsibilities|WD4-Care of Household Responsibilities|WD4S2	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Taking care of your household responsibilities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130857>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Learning a New Task|WD4-Learning a New Task|WD4-Learning a New Task|WD4S3	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Learning a new task, for example, learning how to get to a new place?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130858>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Problem Joining Community Activities|WD4-Problem Joining Community Activities|WD4-Problem Joining Community Activities|WD4S4	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Joining in community activities (for example, festivities, religious or other activities) in the same way as anyone else can?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130859>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Emotionally Affected by Health|WD4-Emotionally Affected by Health|WD4-Emotionally Affected by Health|WD4S5	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: How much have you been emotionally affected by your health problems?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13085>	C13037	Alveolar Wall	The alveolar structure that contains alveolar cells type I and II and macrophages.	Alveolar Wall		Body Part, Organ, or Organ Component	
C130860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130860>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Concentrating for Ten Minutes|WD4-Concentrating for Ten Minutes|WD4-Concentrating for Ten Minutes|WD4S6	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Concentrating on doing something for ten minutes?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130861>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Walking a Long Distance|WD4-Walking a Long Distance|WD4-Walking a Long Distance|WD4S7	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Walking a long distance such as a kilometre [or equivalent]?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130862>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Washing Your Whole Body|WD4-Washing Your Whole Body|WD4-Washing Your Whole Body|WD4S8	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Washing your whole body?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130863>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Getting Dressed|WD4-Getting Dressed|WD4-Getting Dressed|WD4S9	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Getting dressed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130864>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Dealing With People You Do Not Know|WD4-Dealing With People You Do Not Know|WD4-Dealing With People You Do Not Know|WD4S10	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Dealing with people you do not know?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130865>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Maintaining a Fiendship|WD4-Maintaining a Fiendship|WD4-Maintaining a Fiendship|WD4S11	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Maintaining a friendship?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130866>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Your Day-to-Day Work|WD4-Your Day-to-Day Work|WD4-Your Day-to-Day Work|WD4S12	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Your day-to-day work?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130867>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Remembering to Do Important Things|WD4-Remembering to Do Important Things|WD4-Remembering to Do Important Things|WD4D1_2	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Remembering to do important things?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130868>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Finding Solutions to Problems|WD4-Finding Solutions to Problems|WD4-Finding Solutions to Problems|WD4D1_3	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Analysing and finding solutions to problems in day-to-day life?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130869>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Understanding What People Say|WD4-Understanding What People Say|WD4-Understanding What People Say|WD4D1_5	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Generally understanding what people say?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13086>	C34030|C13038	Prostate Capsule|Capsule of the Prostate	The membrane the surrounds the prostate gland.	Capsule of Human Prostate		Anatomical Structure	
C130870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130870>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Starting or Maintaining Conversation|WD4-Starting/Maintaining Conversation|WD4-Starting/Maintaining Conversation|WD4D1_6	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Starting and maintaining a conversation?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130871>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Standing Up From Sitting Down|WD4-Standing Up From Sitting Down|WD4-Standing Up From Sitting Down|WD4D2_2	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Standing up from sitting down?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130872>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Moving Around Inside Your Home|WD4-Moving Around Inside Your Home|WD4-Moving Around Inside Your Home|WD4D2_3	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Moving around inside your home?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130873>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Getting Out of Your Home|WD4-Getting Out of Your Home|WD4-Getting Out of Your Home|WD4D2_4	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Getting out of your home?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130874>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Eating|WD4-Eating|WD4-Eating|WD4D3_3	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Eating?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130875>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Staying By Yourself for a Few Days|WD4-Staying By Yourself for a Few Days|WD4-Staying By Yourself for a Few Days|WD4D3_4	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Staying by yourself for a few days?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130876>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Get Along with People Close to You|WD4-Get Along with People Close to You|WD4-Get Along with People Close to You|WD4D4_3	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Getting along with people who are close to you?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130877>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Making New Friends|WD4-Making New Friends|WD4-Making New Friends|WD4D4_4	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Making new friends?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130878>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Sexual Activities|WD4-Sexual Activities|WD4-Sexual Activities|WD4D4_5	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Sexual activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130879>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Doing Important Household Tasks|WD4-Doing Important Household Tasks|WD4-Doing Important Household Tasks|WD4D5_2	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) Because of your health condition, in the past 30 days, how much difficulty did you have in: Doing your most important household tasks well?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13087>	C13038	Apex of the Prostate|Apex|Apex|Apex of Prostate|Apical Prostate|Prostatic apex	The lowest part of the prostate gland adjacent to the superior fascia of the urogenital diaphragm.	Apex of Human Prostate		Anatomical Structure	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C130880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130880>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Getting Household Work Done Needed|WD4-Getting Household Work Done Needed|WD4-Getting Household Work Done Needed|WD4D5_3	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) Because of your health condition, in the past 30 days, how much difficulty did you have in: Getting all the household work done that you needed to do?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130881>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Getting Household Work Done Quickly|WD4-Getting Household Work Done Quickly|WD4-Getting Household Work Done Quickly|WD4D5_4	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) Because of your health condition, in the past 30 days, how much difficulty did you have in: Getting your household work done as quickly as needed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130882>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Reduce or Miss Household Work|WD4-Reduce or Miss Household Work|WD4-Reduce or Miss Household Work|WD4D5_01	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, on how many days did you reduce or completely miss household work because of your health condition?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130883>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Doing Important Work or School Tasks|WD4-Doing Important Work/School Tasks|WD4-Doing Important Work/School Tasks|WD4D5_6	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) Because of your health condition, in the past 30 days how much difficulty did you have in: Doing your most important work/school tasks well?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130884>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Getting All Work Done You Need|WD4-Getting All Work Done You Need|WD4-Getting All Work Done You Need|WD4D5_7	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) Because of your health condition, in the past 30 days how much difficulty did you have in: Getting all the work done that you need to do?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130885>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Getting Work Done Quickly as Needed|WD4-Getting Work Done Quickly as Needed|WD4-Getting Work Done Quickly as Needed|WD4D5_8	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) Because of your health condition, in the past 30 days how much difficulty did you have in: Getting your work done as quickly as needed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130886>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Had to Work at a Lower Level|WD4-Had to Work at a Lower Level|WD4-Had to Work at a Lower Level|WD4D5_9	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) Because of your health condition, in the past 30 days how much difficulty did you have in: Have you had to work at a lower level because of a health condition?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130887>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Earn Less Money|WD4-Earn Less Money|WD4-Earn Less Money|WD4D5_10	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) Because of your health condition, in the past 30 days how much difficulty did you have in: Did you earn less money as the result of a health condition?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130888>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Miss Work Half Day or More|WD4-Miss Work Half Day or More|WD4-Miss Work Half Day or More|WD4D5_02	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, on how many days did you miss work for half a day or more because of your health condition?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130889>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Problem Because of Barriers in World|WD4-Problem Because of Barriers in World|WD4-Problem Because of Barriers in World|WD4D6_2	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days: How much of a problem did you have because of barriers or hindrances in the world around you?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13088>	C13038	Base of the Prostate|Base|Base	The uppermost part of the prostate gland adjacent to the bladder wall.	Base of Human Prostate		Anatomical Structure	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C130890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130890>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Problem Living With Dignity|WD4-Problem Living With Dignity|WD4-Problem Living With Dignity|WD4D6_3	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days: How much of a problem did you have living with dignity because of the attitudes and actions of others?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130891>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Time Spend on Your Health Condition|WD4-Time Spend on Your Health Condition|WD4-Time Spend on Your Health Condition|WD4D6_4	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days: How much time did you spend on your health condition, or its consequences?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130892>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Drain on Financial Resources|WD4-Drain on Financial Resources|WD4-Drain on Financial Resources|WD4D6_6	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days: How much has your health been a drain on the financial resources of you or your family?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130893>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Problem Did Your Family Have|WD4-Problem Did Your Family Have|WD4-Problem Did Your Family Have|WD4D6_7	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days: How much of a problem did your family have because of your health problems?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130894>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Problem Doing Things for Relaxation|WD4-Problem Doing Things for Relaxation|WD4-Problem Doing Things for Relaxation|WD4D6_8	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days: How much of a problem did you have in doing things by yourself for relaxation or pleasure?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130895>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - How Many Days Difficulties Present|WD4-How Many Days Difficulties Present|WD4-How Many Days Difficulties Present|WD4H1	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) Overall, in the past 30 days, how many days were these difficulties present?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130896>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - Days Unable to Carry Out Activities|WD4-Days Unable to Carry Out Activities|WD4-Days Unable to Carry Out Activities|WD4H2	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, for how many days were you totally unable to carry out your usual activities or work because of any health condition?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130897>	C130303	WHODAS 2.0 12+24-item Version Interviewer-administered - How Many Days Reduce Activities|WD4-How Many Days Reduce Activities|WD4-How Many Days Reduce Activities|WD4H3	World Health Organization Disability Assessment Schedule 2.0 12+24-item Version Interviewer-administered (WHODAS 2.0 12+24-item Version Interviewer-administered) In the past 30 days, not counting the days that you were totally unable, for how many days did you cut back or reduce your usual activities or work because of any health condition?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12+24-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130898>	C130300	WHODAS 2.0 12-item Version Interviewer-administered - Living Situation at Interview|WD1-Living Situation at Interview|WD1-Living Situation at Interview|WD1F5	World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) Living situation at time of interview.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130899>	C130300	WHODAS 2.0 12-item Version Interviewer-administered - Observed Sex|WD1-Sex as Observed|WD1-Sex as Observed|WD1A1	World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) Record sex as observed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13089>	C13091	Anterior Surface of the Prostate	The aspect of the prostate facing the pubic symphysis.	Anterior Surface of Human Prostate		Anatomical Structure	
C1308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1308>	C2197	Poly (RGD)	A synthetic polypeptide based on the arg-gly-asp (RGD) sequence present in some cell adhesion molecules.  Displays antimetastatic activity in model systems.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C130900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130900>	C130300	WHODAS 2.0 12-item Version Interviewer-administered - How Old Are You Now|WD1-How Old Are You Now|WD1-How Old Are You Now|WD1A2	World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) How old are you now?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130901>	C130300	WHODAS 2.0 12-item Version Interviewer-administered - Years Studying in School or College|WD1-Years Studying in School/College|WD1-Years Studying in School/College|WD1A3	World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) How many years in all did you spend studying in school, college or university?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130902>	C130300	WHODAS 2.0 12-item Version Interviewer-administered - Current Marital Status|WD1-Current Marital Status|WD1-Current Marital Status|WD1A4	World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) What is your current marital status?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130903>	C130300	WHODAS 2.0 12-item Version Interviewer-administered - Describes Main Work Status Best|WD1-Describes Main Work Status Best|WD1-Describes Main Work Status Best|WD1A5	World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) Which describes your main work status best?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130904>	C130300	WHODAS 2.0 12-item Version Interviewer-administered - Standing for Long Periods|WD1-Standing for Long Periods|WD1-Standing for Long Periods|WD1S1	World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Standing for long periods such as 30 minutes?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130905>	C130300	WHODAS 2.0 12-item Version Interviewer-administered - Care of Household Responsibilities|WD1-Care of Household Responsibilities|WD1-Care of Household Responsibilities|WD1S2	World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Taking care of your household responsibilities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130906>	C130300	WHODAS 2.0 12-item Version Interviewer-administered - Learning a New Task|WD1-Learning a New Task|WD1-Learning a New Task|WD1S3	World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Learning a new task, for example, learning how to get to a new place?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130907>	C130300	WHODAS 2.0 12-item Version Interviewer-administered - Problem Joining Community Activities|WD1-Problem Joining Community Activities|WD1-Problem Joining Community Activities|WD1S4	World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: How much of a problem did you have joining in community activities (for example, festivities, religious or other activities) in the same way as anyone else can?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130908>	C130300	WHODAS 2.0 12-item Version Interviewer-administered - Emotionally Affected by Health|WD1-Emotionally Affected by Health|WD1-Emotionally Affected by Health|WD1S5	World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: How much have you been emotionally affected by your health problems?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130909>	C130300	WHODAS 2.0 12-item Version Interviewer-administered - Concentrating for Ten Minutes|WD1-Concentrating for Ten Minutes|WD1-Concentrating for Ten Minutes|WD1S6	World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Concentrating on doing something for ten minutes?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13090>	C13091	Inferolateral Surface of the Prostate	The aspect of the prostate facing the pelvic diaphragm and pubis.	Inferolateral Surface of Human Prostate		Anatomical Structure	
C130910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130910>	C130300	WHODAS 2.0 12-item Version Interviewer-administered - Walking a Long Distance|WD1-Walking a Long Distance|WD1-Walking a Long Distance|WD1S7	World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Walking a long distance such as a kilometre [or equivalent]?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130911>	C130300	WHODAS 2.0 12-item Version Interviewer-administered - Washing Your Whole Body|WD1-Washing Your Whole Body|WD1-Washing Your Whole Body|WD1S8	World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Washing your whole body?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130912>	C130300	WHODAS 2.0 12-item Version Interviewer-administered - Getting Dressed|WD1-Getting Dressed|WD1-Getting Dressed|WD1S9	World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Getting dressed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130913>	C130300	WHODAS 2.0 12-item Version Interviewer-administered - Dealing With People You Do Not Know|WD1-Dealing With People You Do Not Know|WD1-Dealing With People You Do Not Know|WD1S10	World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Dealing with people you do not know?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130914>	C130300	WHODAS 2.0 12-item Version Interviewer-administered - Maintaining a Friendship|WD1-Maintaining a Friendship|WD1-Maintaining a Friendship|WD1S11	World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Maintaining a friendship?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130915>	C130300	WHODAS 2.0 12-item Version Interviewer-administered - Your Day-to-Day Work or School|WD1-Your Day-to-Day Work/School|WD1-Your Day-to-Day Work/School|WD1S12	World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) In the past 30 days, how much difficulty did you have in: Your day-to-day work/school?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130916>	C130300	WHODAS 2.0 12-item Version Interviewer-administered - How Many Days Difficulties Present|WD1-How Many Days Difficulties Present|WD1-How Many Days Difficulties Present|WD1H1	World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) Overall, in the past 30 days, how many days were these difficulties present?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130917>	C130300	WHODAS 2.0 12-item Version Interviewer-administered - Days Unable to Carry Out Activities|WD1-Days Unable to Carry Out Activities|WD1-Days Unable to Carry Out Activities|WD1H2	World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) In the past 30 days, for how many days were you totally unable to carry out your usual activities or work because of any health condition?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130918>	C130300	WHODAS 2.0 12-item Version Interviewer-administered - How Many Days Reduce Activities|WD1-How Many Days Reduce Activities|WD1-How Many Days Reduce Activities|WD1H3	World Health Organization Disability Assessment Schedule 2.0 12-item Version Interviewer-administered (WHODAS 2.0 12-item Version Interviewer-administered) In the past 30 days, not counting the days that you were totally unable, for how many days did you cut back or reduce your usual activities or work because of any health condition?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Interviewer-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130919>	C130301	WHODAS 2.0 12-item Version Proxy-administered - I Am the (Fill in the Blank) of This Person|WD2-I Am (Fill in Blank) of This Person|WD2-I Am (Fill in Blank) of This Person|WD2H4	World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) I am the (Fill in the Blank) of this person.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13091>	C34022|C13038	Surface of the Prostate	The external portion of the prostate including the anterior, inferolateral, lateral and posterior surfaces.	Surface of Human Prostate		Anatomical Structure	
C130920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130920>	C130301	WHODAS 2.0 12-item Version Proxy-administered - Standing for Long Periods|WD2-Standing for Long Periods|WD2-Standing for Long Periods|WD2S1	World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Standing for long periods such as 30 minutes?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130921>	C130301	WHODAS 2.0 12-item Version Proxy-administered - Care of Household Responsibilities|WD2-Care of Household Responsibilities|WD2-Care of Household Responsibilities|WD2S2	World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Taking care of his or her household responsibilities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130922>	C130301	WHODAS 2.0 12-item Version Proxy-administered - Learning a New Task|WD2-Learning a New Task|WD2-Learning a New Task|WD2S3	World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Learning a new task, for example, learning how to get to a new place?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130923>	C130301	WHODAS 2.0 12-item Version Proxy-administered - Problem Joining Community Activities|WD2-Problem Joining Community Activities|WD2-Problem Joining Community Activities|WD2S4	World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: How much of a problem did your relative have joining in community activities (for example, festivities, religious or other activities) in the same way as anyone else can?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130924>	C130301	WHODAS 2.0 12-item Version Proxy-administered - Emotionally Affected by Health|WD2-Emotionally Affected by Health|WD2-Emotionally Affected by Health|WD2S5	World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: How much has your relative been emotionally affected by his or her health condition?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130925>	C130301	WHODAS 2.0 12-item Version Proxy-administered - Concentrating for Ten Minutes|WD2-Concentrating for Ten Minutes|WD2-Concentrating for Ten Minutes|WD2S6	World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Concentrating on doing something for ten minutes?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130926>	C130301	WHODAS 2.0 12-item Version Proxy-administered - Walking a Long Distance|WD2-Walking a Long Distance|WD2-Walking a Long Distance|WD2S7	World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Walking a long distance such as a kilometre [or equivalent]?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130927>	C130301	WHODAS 2.0 12-item Version Proxy-administered - Washing His or Her Whole Body|WD2-Washing His/Her Whole Body|WD2-Washing His/Her Whole Body|WD2S8	World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Washing his or her whole body?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130928>	C130301	WHODAS 2.0 12-item Version Proxy-administered - Getting Dressed|WD2-Getting Dressed|WD2-Getting Dressed|WD2S9	World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Getting dressed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130929>	C130301	WHODAS 2.0 12-item Version Proxy-administered - Dealing With People Does Not Know|WD2-Dealing With People Does Not Know|WD2-Dealing With People Does Not Know|WD2S10	World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Dealing with people he or she does not know?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13092>	C52726	Lateral Lobe of the Prostate|PROSTATE GLAND, LATERAL LOBE	The prostate gland lobe that is located on the lateral side of the organ.	Lateral Lobes of Human Prostate		Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130930>	C130301	WHODAS 2.0 12-item Version Proxy-administered - Maintaining a Friendship|WD2-Maintaining a Friendship|WD2-Maintaining a Friendship|WD2S11	World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: Maintaining a friendship?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130931>	C130301	WHODAS 2.0 12-item Version Proxy-administered - Your Day-to-Day Work or School|WD2-Your Day-to-Day Work/School|WD2-Your Day-to-Day Work/School|WD2S12	World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) In the past 30 days, how much difficulty did your relative have in: His or her day-to-day work?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130932>	C130301	WHODAS 2.0 12-item Version Proxy-administered - How Many Days Difficulties Present|WD2-How Many Days Difficulties Present|WD2-How Many Days Difficulties Present|WD2H1	World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) Overall, in the past 30 days, how many days were these difficulties present?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130933>	C130301	WHODAS 2.0 12-item Version Proxy-administered - Days Unable to Carry Out Activities|WD2-Days Unable to Carry Out Activities|WD2-Days Unable to Carry Out Activities|WD2H2	World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) In the past 30 days, for how many days were you totally unable to carry out your usual activities or work because of any health condition?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130934>	C130301	WHODAS 2.0 12-item Version Proxy-administered - How Many Days Reduce Activities|WD2-How Many Days Reduce Activities|WD2-How Many Days Reduce Activities|WD2H3	World Health Organization Disability Assessment Schedule 2.0 12-item Version Proxy-administered (WHODAS 2.0 12-item Version Proxy-administered) In the past 30 days, not counting the days that you were totally unable, for how many days did you cut back or reduce your usual activities or work because of any health condition?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Proxy-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130935>	C130302	WHODAS 2.0 12-item Version Self-administered - Standing for Long Periods|WD3-Standing for Long Periods|WD3-Standing for Long Periods|WD3S1	World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Standing for long periods such as 30 minutes?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130936>	C130302	WHODAS 2.0 12-item Version Self-administered - Care of Household Responsibilities|WD3-Care of Household Responsibilities|WD3-Care of Household Responsibilities|WD3S2	World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Taking care of your household responsibilities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130937>	C130302	WHODAS 2.0 12-item Version Self-administered - Learning a New Task|WD3-Learning a New Task|WD3-Learning a New Task|WD3S3	World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Learning a new task, for example, learning how to get to a new place?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130938>	C130302	WHODAS 2.0 12-item Version Self-administered - Problem Joining Community Activities|WD3-Problem Joining Community Activities|WD3-Problem Joining Community Activities|WD3S4	World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) In the past 30 days, how much difficulty did you have in: How much of a problem did you have joining in community activities (for example, festivities, religious or other activities) in the same way as anyone else can?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130939>	C130302	WHODAS 2.0 12-item Version Self-administered - Emotionally Affected by Health|WD3-Emotionally Affected by Health|WD3-Emotionally Affected by Health|WD3S5	World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) In the past 30 days, how much difficulty did you have in: How much have you been emotionally affected by your health problems?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13093>	C52726	Posterior Lobe of the Prostate|PROSTATE GLAND, POSTERIOR LOBE	The prostate gland lobe that is located on the posterior side of the organ.	Posterior Lobe of Human Prostate		Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C130940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130940>	C130302	WHODAS 2.0 12-item Version Self-administered - Concentrating for Ten Minutes|WD3-Concentrating for Ten Minutes|WD3-Concentrating for Ten Minutes|WD3S6	World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Concentrating on doing something for ten minutes?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130941>	C130302	WHODAS 2.0 12-item Version Self-administered - Walking a Long Distance|WD3-Walking a Long Distance|WD3-Walking a Long Distance|WD3S7	World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Walking a long distance such as a kilometre [or equivalent]?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130942>	C130302	WHODAS 2.0 12-item Version Self-administered - Washing Your Whole Body|WD3-Washing Your Whole Body|WD3-Washing Your Whole Body|WD3S8	World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Washing your whole body?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130943>	C130302	WHODAS 2.0 12-item Version Self-administered - Getting Dressed|WD3-Getting Dressed|WD3-Getting Dressed|WD3S9	World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Getting dressed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130944>	C130302	WHODAS 2.0 12-item Version Self-administered - Dealing With People You Do Not Know|WD3-Dealing With People You Do Not Know|WD3-Dealing With People You Do Not Know|WD3S10	World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Dealing with people you do not know?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130945>	C130302	WHODAS 2.0 12-item Version Self-administered - Maintaining a Friendship|WD3-Maintaining a Friendship|WD3-Maintaining a Friendship|WD3S11	World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Maintaining a friendship?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130946>	C130302	WHODAS 2.0 12-item Version Self-administered - Your Day-to-Day Work or School|WD3-Your Day-to-Day Work/School|WD3-Your Day-to-Day Work/School|WD3S12	World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) In the past 30 days, how much difficulty did you have in: Your day-to-day work?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130947>	C130302	WHODAS 2.0 12-item Version Self-administered - How Many Days Difficulties Present|WD3-How Many Days Difficulties Present|WD3-How Many Days Difficulties Present|WD3H1	World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) Overall, in the past 30 days, how many days were these difficulties present?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130948>	C130302	WHODAS 2.0 12-item Version Self-administered - Days Unable to Carry Out Activities|WD3-Days Unable to Carry Out Activities|WD3-Days Unable to Carry Out Activities|WD3H2	World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) In the past 30 days, for how many days were you totally unable to carry out your usual activities or work because of any health condition?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C130949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130949>	C130302	WHODAS 2.0 12-item Version Self-administered - How Many Days Reduce Activities|WD3-How Many Days Reduce Activities|WD3-How Many Days Reduce Activities|WD3H3	World Health Organization Disability Assessment Schedule 2.0 12-item Version Self-administered (WHODAS 2.0 12-item Version Self-administered) In the past 30 days, not counting the days that you were totally unable, for how many days did you cut back or reduce your usual activities or work because of any health condition?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Code Terminology|CDISC Questionnaire WHODAS 2.0 12-item Version Self-administered Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13094>	C52726	Middle Lobe of the Prostate|Middle|Middle|PROSTATE GLAND, MIDDLE LOBE	The upper, smaller part of the prostate between the ejaculatory ducts and the urethra.	Median Lobe of Human Prostate		Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C130950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130950>	C4953|C102871	Posterior Fossa Neoplasm|Posterior Cranial Fossa Neoplasm|Posterior Cranial Fossa Tumor|Posterior Cranial Fossa Tumor|Posterior Fossa Tumor	A neoplasm that arises from the posterior cranial fossa. Examples include meningiomas and medulloblastomas.	Posterior Cranial Fossa Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C130951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130951>	C88151|C7796	Stage IA Mycosis Fungoides AJCC v7|Stage IA Mycosis Fungoides|Stage IA Mycosis Fungoides	Stage IA includes: T1, N0, M0, B0-1.  T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface.  May further stratify into T1a (patch only) vs. T1b (plaque +/- patch).  N0: No clinically abnormal peripheral lymph nodes; biopsy not required.  M0: No visceral organ involvement.  B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells).  B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2.  (AJCC 7th ed.)	Stage IA Mycosis Fungoides AJCC v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C130952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130952>	C97927|C141240	ROS1 Gene Mutation|MCF3 Gene Mutation|ROS Gene Mutation|ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene Mutation|ROS1 Mutation|c-ros-1 Gene Mutation	A change in the nucleotide sequence of the ROS1 gene.	ROS1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C130953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130953>	C20993	Truth Agreement Scale	A subjective scale for the scoring of truth agreement that ranges from 1: yes, that is true to 5: no, that is not true.			Intellectual Product	
C130954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130954>	C221047	Truth Agreement Score 1	A subjective score of 1 on a scale that ranges from 1: yes, that is true to 5: no, that is not true.			Intellectual Product	Multidimensional Fatigue Inventory
C130955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130955>	C221047	Truth Agreement Score 2	A subjective score of 2 on a scale that ranges from 1: yes, that is true to 5: no, that is not true.			Intellectual Product	Multidimensional Fatigue Inventory
C130956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130956>	C221047	Truth Agreement Score 3	A subjective score of 3 on a scale that ranges from 1: yes, that is true to 5: no, that is not true.			Intellectual Product	Multidimensional Fatigue Inventory
C130957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130957>	C221047	Truth Agreement Score 4	A subjective score of 4 on a scale that ranges from 1: yes, that is true to 5: no, that is not true.			Intellectual Product	Multidimensional Fatigue Inventory
C130958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130958>	C221047	Truth Agreement Score 5	A subjective score of 5 on a scale that ranges from 1: yes, that is true to 5: no, that is not true.			Intellectual Product	Multidimensional Fatigue Inventory
C130959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130959>	C226701	Device for Dressing Usually Used|Devices used for Dressing (button hook, zipper pull, etc.)	A response indicating that an individual usually uses an aid or device for dressing, such as a button hook or zipper pull.			Intellectual Product	Multidimensional Fatigue Inventory
C13095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13095>	C13091	Posterior Surface of the Prostate	The flattened aspect of the prostate with a slight furrow facing the rectum and anus.	Posterior Surface of Human Prostate		Anatomical Structure	
C130960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130960>	C226701	Special or Built Up Chair Usually Used|Special or built up chair	A response indicating that an individual usually uses a special or built up chair.			Intellectual Product	Multidimensional Fatigue Inventory
C130961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130961>	C226701	Special or Built Up Utensils Usually Used|Built up or special utensils	A response indicating that an individual usually uses special or built up utensils.			Intellectual Product	Multidimensional Fatigue Inventory
C130962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130962>	C226701	Cane Usually Used|Cane	A response indicating that an individual usually uses a cane.			Intellectual Product	Multidimensional Fatigue Inventory
C130963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130963>	C226701|C176254	Walker Usually Used|Walker	A response indicating that an individual usually uses a walker.			Intellectual Product	Multidimensional Fatigue Inventory
C130964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130964>	C226701	Crutches Usually Used|Crutches	A response indicating that an individual usually uses crutches.			Intellectual Product	Multidimensional Fatigue Inventory
C130965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130965>	C226576	Wheelchair Usually Used|Wheelchair	A response indicating that an individual usually uses a wheelchair.			Intellectual Product	Multidimensional Fatigue Inventory
C130966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130966>	C226701	Raised Toilet Seat Usually Used|Raised toilet seat	A response indicating that an individual usually uses a raised toilet seat.			Intellectual Product	Multidimensional Fatigue Inventory
C130967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130967>	C226701	Bathtub Seat Usually Used|Bathtub seat	A response indicating that an individual usually uses a bathtub seat.			Intellectual Product	Multidimensional Fatigue Inventory
C130968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130968>	C226701	Bathtub Bar Usually Used|Bathtub bar	A response indicating that an individual usually uses a bathtub bar.			Intellectual Product	Multidimensional Fatigue Inventory
C130969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130969>	C226701	Long-handled Appliances in Bathroom Usually Used|Long-handled appliances in bathroom	A response indicating that an individual usually uses a long-handled appliance in the bathroom.			Intellectual Product	Multidimensional Fatigue Inventory
C13096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13096>	C33904	Prostatic Glandular Tissue		Human Prostatic Glandular Tissue		Tissue	
C130970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130970>	C226701	Long-handled Appliances for Reach Usually Used|Long-handled appliances for reach	A response indicating that an individual usually uses a long-handled appliance for reach.			Intellectual Product	Multidimensional Fatigue Inventory
C130971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130971>	C226701	Jar Opener Usually Used|Jar opener (for jars previously opened)	A response indicating that an individual usually uses a jar opener for jars that were previously opened.			Intellectual Product	Multidimensional Fatigue Inventory
C130972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130972>	C175285	Usually Need Help from Another Person for Dressing and Grooming|Dressing and grooming	A response indicating that an individual needs help from another person for dressing and grooming.			Intellectual Product	Multidimensional Fatigue Inventory
C130973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130973>	C202280|C175285	Usually Need Help from Another Person for Eating|Eating	A response indicating that an individual needs help from another person for eating.			Intellectual Product	Multidimensional Fatigue Inventory
C130974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130974>	C175285	Usually Need Help from Another Person for Arising|Arising|Getting Up|Usually Need Help from Another Person for Getting Up	A response indicating that an individual needs help from another person for getting up.			Intellectual Product	Multidimensional Fatigue Inventory
C130975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130975>	C226710|C226575|C175285	Usually Need Help from Another Person for Walking|Walking	A response indicating that an individual needs help from another person for walking.			Intellectual Product	Multidimensional Fatigue Inventory
C130976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130976>	C175285	Usually Need Help from Another Person for Hygiene|Hygiene	A response indicating that an individual needs help from another person for hygiene.			Intellectual Product	Multidimensional Fatigue Inventory
C130977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130977>	C175285	Usually Need Help from Another Person for Reach|Reach	A response indicating that an individual needs help from another person for reach.			Intellectual Product	Multidimensional Fatigue Inventory
C130978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130978>	C175285	Usually Need Help from Another Person for Gripping and Opening Things|Gripping and opening things	A response indicating that an individual needs help from another person for gripping and opening things.			Intellectual Product	Multidimensional Fatigue Inventory
C130979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130979>	C175285	Usually Need Help from Another Person for Errands and Chores|Errands and chores	A response indicating that an individual needs help from another person for errands and chores.			Intellectual Product	Multidimensional Fatigue Inventory
C130980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130980>	C19442	Surface Mail	Mail that is transported by land or sea, rather than by air.			Manufactured Object	
C130981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130981>	C226641	Have Very Mild Bloating|Very Mild Bloating	A response indicating that when an individual has or had bloating, it was very mild.			Intellectual Product	Bowel Function Diary for Assessing Opioid-Induced Constipation
C130982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130982>	C28193	10p13-p14 Deletion Syndrome|DGS2|DiGeorge Syndrome Type 2	A congenital condition caused by a deletion on the short arm of chromosome 10p13-p14. The NEBL gene, encoding nebulette, a heart-specific component of the sarcomere, may be responsible for the clinical findings. The condition is characterized by immunodeficiency, unusual facies, congenital heart anomalies (tetralogy of Fallot, pulmonary atresia with ventricular septal defect, truncus arteriosus, interrupted aortic arch, isolated anomalies of the aortic arch, and ventricular septal defect), hypoparathyroidism, and increased susceptibility to infections.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C130983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130983>	C28193	Barakat Syndrome|Hypoparathyroidism, Deafness, and Renal Anomalies Syndrome	A condition characterized by hypoparathyroidism, sensorineural deafness, and renal failure. It is related to autosomal dominant inactivating mutation(s) in GATA3, encoding a transcription factor important for the embryonic development of the parathyroid gland, the auditory stem, and the kidneys.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C130985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130985>	C28193	Cole-Carpenter Syndrome	Bone dysplasia due to autosomal dominant mutation(s) in the P4HB gene, encoding prolyl 4-hydroxylase subunit beta, or autosomal recessive mutation(s) in the SEC24D gene, encoding SEC24 homolog D, COPII coat complex component. This condition is characterized by bone fragility, growth failure, craniosynostosis, hydrocephalus, and distinctive facial features, including marked frontal bossing, blue sclerae, ocular proptosis, midface hypoplasia, and micrognathia.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C130986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130986>	C28193	Distal 18q Deletion Syndrome|18q partial monosomy syndrome	A contiguous gene deletion syndrome involving deletion of the distal portion of the long arm of chromosome 18. The clinically heterogenous condition is characterized by some or all of the following: growth hormone deficiency with resulting short stature; hand, foot, skull, facial, and genital anomalies; hypotonia; and developmental delay.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C130988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130988>	C28193	IMAGe Syndrome	A condition caused by heterozygous mutation(s) in the CDKN1C gene, encoding cyclin-dependent kinase inhibitor 1C, and characterized by intrauterine growth restriction, metaphyseal dysplasia, congenital adrenal hypoplasia, and genital anomalies.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C130989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130989>	C85865|C28193	Immunoglobulin Superfamily Member 1 Deficiency Syndrome|Hypothyroidism Central and Testicular Enlargement	An X-linked recessive syndrome caused by loss-of-function mutation(s) in IGSF1, encoding immunoglobulin superfamily member 1. This condition can result in central hypothyroidism, macroorchidism, delayed puberty, and variable prolactin deficiency.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C13098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13098>	C33904	Orifice of Human Prostatic Duct	The opening of a prostatic duct into the floor of the prostatic portion of the urethra.	Orifice of Human Prostatic Duct		Body Part, Organ, or Organ Component	
C130990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130990>	C28193	Insulin Receptor Mutation - Associated Insulin Resistance Syndromes	Insulin resistance caused by inactivating mutation(s) in the INSR gene encoding the insulin receptor.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C130991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130991>	C28193	Kenny-Caffey Syndrome	A genetic condition characterized by long bone sclerosis and thickening, short stature, and head and eye anomalies. Many affected individuals have hypoparathyroidism with hypocalcemia.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C130992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130992>	C130991	Kenny-Caffey Syndrome Type 1	An autosomal recessive form of Kenny-Caffey syndrome due to mutation(s) in the TBCE gene, encoding tubulin-specific chaperone E. This condition is characterized by hypoparathyroidism with hypocalcemia, marked growth retardation, craniofacial anomalies, absent diploic space in the skull, cortical thickening of long bones with medullary stenosis, and small hands and feet.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C130993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130993>	C130991	Kenny-Caffey Syndrome Type 2	An autosomal dominant form of Kenny-Caffey Syndrome due to mutation(s) in the FAM111A gene, encoding protein FAM111A. This condition is characterized by transient hypocalcemia, delayed closure of the anterior fontanel, eye anomalies, including microphthalmia, proportionate short stature, and cortical thickening and medullary stenosis of the tubular bones.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C130994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130994>	C28193	Laron Syndrome|Growth Hormone Receptor Deficiency	Growth hormone insensitivity syndrome caused by mutation(s) and/or deletion(s) in the GHR gene, encoding the growth hormone receptor.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C130995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130995>	C28193	Low T3 Syndrome|Low Triiodothyronine Syndrome	Reduced serum concentration of tri-iodothyronine caused by a variety of non-thyroidal conditions in which there is no dysfunction in the thyroid gland or the hypothalamic-pituitary axis.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C130996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130996>	C28193	Maternal Diabetes and Deafness Syndrome|MIDD Syndrome|Maternally Inherited Diabetes and Deafness|Maternally Transmitted Diabetes with Deafness	A maternally inherited condition characterized by diabetes and sensorineural deafness with onset after the age of 20, caused by mutation(s) in one of several mitochondrial genes, most frequently the MT-TL1 gene, which encodes the mitochondrial transfer RNA for leucine. Some patients may have additional features observed in mitochondrial disorders, including pigmentary retinopathy, ptosis, cardiomyopathy, myopathy, renal problems, and neuropsychiatric symptoms.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C130997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130997>	C28193	Mauriac Syndrome	A complication of poorly controlled type 1 diabetes mellitus in children characterized by linear growth impairment, glycogenic hepatopathy, and Cushingoid features.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C130998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C130998>	C28193	Osteoporosis Pseudoglioma Syndrome	An autosomal recessive condition caused by homozygous or compound heterozygous inactivating mutation(s) in the gene LRP5, encoding low-density lipoprotein receptor-related protein 5. This condition is characterized by severe juvenile-onset osteoporosis and congenital or juvenile-onset blindness due to a vascularized retinal mass that resembles a glioma.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C1309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1309>	C496	Recombinant Fibroblast Growth Factor 4|FGF4|Fibroblast Growth Factor 4|HBGF-4|Transforming Protein KS3	A recombinant therapeutic agent which is chemically identical to or similar to endogenous fibroblast growth factor 4 (FGF-4). Therapeutic FGF-4 induces vascular permeability, angiogenesis, and arteriogenesis and has potential uses in the treatment of peripheral vascular disease. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C131000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131000>	C28193	Rabson-Mendenhall Syndrome	An autosomal recessive condition caused by mutation(s) in the INSR gene, encoding the insulin receptor, and characterized by insulin resistance, intrauterine growth restriction (IUGR) and/or failure to thrive, muscle atrophy, hypertrichosis, and distinctive facial features; the condition is typically diagnosed early in life, with death usually occurring before the third decade of life. The symptoms and course of this syndrome are moderately severe as compared to the other two syndromes on the spectrum: Insulin Resistant Diabetes Mellitus with Acanthosis Nigricans and Hyperandrogenism, and Donohue Syndrome.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131001>	C28193	Rieger Syndrome|Axenfeldt-Rieger Syndrome	A congenital condition associated with mutation(s) in the PITX2 and/or FOXC1 genes, encoding pituitary homeobox 2 and forkhead box protein C1, respectively. The condition is characterized by anterior segment dysgenesis of the eye(s), iris and corneal anomalies, glaucoma, craniofacial anomalies, hypodontia, and pituitary hypoplasia with hypopituitarism, and hypospadius.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C131002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131002>	C28193	Simpson-Golabi-Behmel Syndrome|Simpson Dysmorphia Syndrome	An X-linked recessive syndrome caused by mutation(s) in the GPC3, OFD1, or rarely the GPC4 gene, encoding glypican 3, oral-facial-digital syndrome 1 protein, and glypican 4, respectively. The condition is characterized by macrosomia, coarse facies, cryptorchidism, congenital heart, kidney, liver, spleen, and musculoskeletal abnormalities.			Disease or Syndrome	CCPS Disease Terminology|Childhood Cancer Predisposition Study Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C131003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131003>	C28193	Single Central Incisor Syndrome|Single Central Maxillary Incisor Syndrome|Solitary Central Maxillary Incisor Syndrome	An autosomal dominant condition usually caused by mutation(s) in the SHH gene, encoding sonic hedgehog, a secreted protein involved in the organization and morphology of the developing embryo. This condition is characterized by multiple, mainly midline, developmental variations, including the presence of a tooth in the center of the maxillary dental arch in both primary and permanent dentition, and any combination of the following: holoprosencephaly, congenital nasal malformation (choanal atresia, midnasal stenosis, or congenital pyriform aperture stenosis), cleft lip and/or palate, hypopituitarism (including hypothyroidism and hypogonadism, resulting in variations in genital development including small penis or incomplete masculinization in male infants), congenital heart anomalies, and developmental delay.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131006>	C28193	Wilms Tumor 1 Gene Syndromes|WT1 Gene Syndromes|WT1 Gene Syndromes|WT1 Syndromes	A group of syndromes caused by autosomal dominant mutation(s) in the WT1 gene, encoding Wilms tumor protein. Patients with this mutation may have a predisposition to developing Wilms tumors.			Disease or Syndrome	CCPS Disease Terminology|Childhood Cancer Predisposition Study Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C131007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131007>	C28193	Wolcott-Rallison Syndrome	A rare, autosomal recessive condition caused by mutation(s) in the EIF2AK3 gene, which encodes translation initiation factor 2-alpha kinase-3. The condition is characterized by the following: permanent insulin-dependent diabetes, with onset in the neonatal period or infancy; epiphyseal dysplasia; deficient bone mineralization, diagnosed in the first year or two of life; and liver dysfunction, occurring in early childhood. Other features may include intellectual deficit, hypothyroidism, renal dysfunction, neutropenia, and thyroid dysfunction. The manifestations and clinical course are variable.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131008>	C28193	Hyperandrogenism, Insulin Resistance, Acanthosis Nigricans Syndrome|HAIR-AN Syndrome	A condition characterized by hyperandrogenism, insulin resistance, and acanthosis nigricans, typically associated with obesity in teenage girls. It is considered to be a subtype of polycystic ovarian syndrome, but may occur in male individuals. Etiology is unclear, but some cases may be associated with mutations affecting the tyrosine kinase domain of the insulin receptor.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131009>	C85865|C28193	Immune Dysregulation, Polyendocrinopathy, and Enteropathy X-Linked Syndrome|IPEX|Immune Dysfunction and Diarrhea Syndrome|Immune Dysregulation, Polyendocrinopathy, and Enteropathy X-linked Syndrome|X linked Polyendocrinopathy|XLAAD|XPID	An X-linked recessive autoimmune condition caused by mutation(s) in the FOXP3 gene, encoding the forkhead box P3 transcription factor. The condition is characterized by infantile onset of severe diarrhea due to enteropathy, type 1 diabetes mellitus, and dermatitis. Associated features may include hypothyroidism, autoimmune hemolytic anemia, thrombocytopenia, lymphadenopathy, hepatitis, and nephritis. The condition is usually fatal before age 2 years if not treated with bone marrow transplantation.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C13100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13100>	C12437	Prostatic Muscular Tissue	The supporting structure for the prostate. A dense layer of smooth muscle tissue lies directly underneath the fibrous capsule and another dense layer of circular fibers surrounds the urethra (striated and smooth). In between these two layers is a mesh of smooth muscle tissue in which the prostatic glands are embedded.	Human Prostatic Muscular Tissue		Tissue	
C131010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131010>	C28193	Mullerian-Renal-Cervical Spine Syndrome|MRKH Type 2|MURCS Syndrome|Mullerian Duct Aplasia|Unilateral Renal Dysplasia and Cervicothoracic Somite Anomalies	A condition characterized by Mullerian duct aplasia, unilateral renal dysplasia, and cervicothoracic anomalies. Other associated findings may include skeletal abnormalities (scoliosis, vertebral anomalies, rib malformations, spina bifida), and face and limb malformations (brachymesophalangy, ectrodactyly). Heart malformations may include valvular pulmonary stenosis, aortopulmonary window, atrial septal defect, and/or tetralogy of Fallot. Putative candidate genes such as HNF1B (17q12), LHX1 (17q12), SHOX (Xp22.33 and Yp11.32), TBX6 (16p11.2), and ITIH5 (10p14) may be implicated.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131012>	C94600	BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.764A>T Mutation|BCR/ABL Fusion Gene with NM_005157.4:c.764A>T|BCR/ABL Fusion Gene with NM_005157.5:c.764A>T|BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.764A>T|BCR/ABL1 Fusion Gene with NM_005157.4:c.764A>T|BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.764A>T Mutation	A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where adenine has been substituted with thymine at nucleotide position 764 of the ABL1 gene. This mutation is associated with imatinib- and nilotinib-resistant leukemias.			Gene or Genome	
C131013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131013>	C94600	BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.827A>G Mutation|BCR/ABL Fusion Gene with NM_005157.4:c.827A>G|BCR/ABL Fusion Gene with NM_005157.5:c.827A>G|BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.827A>G|BCR/ABL1 Fusion Gene with NM_005157.4:c.827A>G|BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.827A>G Mutation	A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where adenine has been substituted with guanine at nucleotide position 827 of the ABL1 gene.			Gene or Genome	
C131014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131014>	C94600	BCR/ABL1 Fusion Gene with ABL1 NM_005157.4:c.835G>A Mutation|BCR/ABL Fusion Gene with NM_005157.4:c.835G>A|BCR/ABL Fusion Gene with NM_005157.5:c.835G>A|BCR/ABL1 Fusion Gene with ABL1 NM_005157.5:c.835G>A|BCR/ABL1 Fusion Gene with NM_005157.4:c.835G>A|BCR::ABL1 Fusion Gene with ABL1 NM_005157.4:c.835G>A Mutation	A fusion gene that results from a translocation t(9;22)(q34;q11) that fuses the 5' part of the BCR gene to the 5' side of exon 2 of a mutated form of the ABL1 gene. In this fusion gene there is a point mutation where guanine has been substituted with adenine at nucleotide position 835 of the ABL1 gene.			Gene or Genome	
C131015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131015>	C16325	BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.E255V|BCR-ABL E255V Mutation|BCR-ABL Glu255Val Mutation|BCR-ABL1 E255V Mutation|BCR-ABL1 Glu255Val Mutation|BCR/ABL E255V Mutation|BCR/ABL Fusion Protein with E255V|BCR/ABL Fusion Protein with Glu255Val|BCR/ABL Glu255Val Mutation|BCR/ABL1 E255V Mutation|BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Glu255Val|BCR/ABL1 Fusion Protein with NP_005148.2:p.E255V|BCR/ABL1 Fusion Protein with NP_005148.2:p.Glu255Val|BCR/ABL1 Glu255Val Mutation|BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.E255V|E255V	A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.764A>T mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the glutamic acid at position 255 of the ABL1 protein has been replaced by valine.			Amino Acid, Peptide, or Protein	
C131016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131016>	C16325	BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.D276G|BCR-ABL Asp276Gly Mutation|BCR-ABL D276G Mutation|BCR-ABL1 Asp276Gly Mutation|BCR-ABL1 D276G Mutation|BCR/ABL Asp276Gly Mutation|BCR/ABL D276G Mutation|BCR/ABL Fusion Protein with Asp276Gly|BCR/ABL Fusion Protein with D276G|BCR/ABL1 Asp276Gly Mutation|BCR/ABL1 D276G Mutation|BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Asp276Gly|BCR/ABL1 Fusion Protein with NP_005148.2:p.Asp276Gly|BCR/ABL1 Fusion Protein with NP_005148.2:p.D276G|BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.D276G|D276G	A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.827A>G mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the aspartic acid at position 276 of the ABL1 protein has been replaced by glycine.			Amino Acid, Peptide, or Protein	
C131017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131017>	C16325	BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.E279K|BCR-ABL E279K Mutation|BCR-ABL Glu279Lys Mutation|BCR-ABL1 E279K Mutation|BCR-ABL1 Glu279Lys Mutation|BCR/ABL E279K Mutation|BCR/ABL Fusion Protein with E279K|BCR/ABL Fusion Protein with Glu279Lys|BCR/ABL Glu279Lys Mutation|BCR/ABL1 E279K Mutation|BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Glu279Lys|BCR/ABL1 Fusion Protein with NP_005148.2:p.E279K|BCR/ABL1 Fusion Protein with NP_005148.2:p.Glu279Lys|BCR/ABL1 Glu279Lys Mutation|BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.E279K|E279K	A fusion protein encoded by the BCR/ABL1 fusion gene with ABL1 NM_005157.4:c.835G>A mutation. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the glutamic acid at position 279 of the ABL1 protein has been replaced by lysine.			Amino Acid, Peptide, or Protein	
C131018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131018>	C129821	Recombinant Human Bone Morphogenetic Protein 4|HUMAN RECOMBINANT BONE MORPHOGENETIC PROTEIN 4|Recombinant Human BMP4|hrBMP-4|hrBMP4	A recombinant form of human bone morphogenetic protein 4 (rhBMP4; rhBMP-4), with potential antineoplastic activity. Upon administration, rhBMP4 binds to BMP receptors (BMPRs) and activates BMP-mediated signal transduction pathways. This may lead to the transcription of BMP4-target genes and to inhibition of the proliferation of certain tumor cell types. Additionally, rhBMP4 binding promotes the differentiation of normal stem cells and decreases both differentiation and renewal of cancer stem cells (CSCs). BMP4, an extracellular signaling molecule belonging to the transforming growth factor beta (TGFb) superfamily, plays a key role in bone formation. It also plays a role in the pathogenesis of certain cancers; BMP4 suppresses growth of certain types of cancer cells, and is also able to induce migration, invasion, and epithelial-mesenchymal transition (EMT), which may promote cancer metastasis and progression.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C131019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131019>	C587	Bempegaldesleukin|Aldesleukin Prodrug NKTR-214|BEMPEGALDESLEUKIN|NKTR-214	A recombinant form of the endogenous cytokine interleukin-2 (IL-2) conjugated to six releasable polyethylene glycol (PEG) chains, with potential immunostimulating activity. Upon administration of bempegaldesleukin, the IL-2 moiety binds to the IL-2 receptor beta subunit (IL2Rb; IL2Rbeta; CD122). The binding of IL-2 to IL2Rb activates IL2Rb-mediated signaling, which activates cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells, and induces expression of certain cytotoxic cytokines, such as interferon-gamma (IFNg) and transforming growth factor-beta (TGFb). The specific induction of T-cell-mediated cytotoxic immune responses against tumor cells primarily causes tumor cell destruction. IL2Rb plays a key role in the proliferation and activation of effector T-cells. PEG conjugation prevents IL-2 binding to the IL2Ralpha subunit (IL2Ra) because signaling through IL2Ra activates CD4-positive regulatory, immunosuppressive T-cells (Tregs), which would suppress tumor cell killing.	Bempegaldesleukin		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C13101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13101>	C160608	Prostatic Urethra|Prostatic Portion of the Male Urethra|Prostatic urethra structure (body structure)|URETHRA, PROSTATIC	That part of the male urethra that passes through the prostate gland.	Prostatic Urethra		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C131020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131020>	C93221	Arugula Seed Powder|Eruca sativa Seed Powder	A dietary supplement containing an extract powder derived from the seeds of the cruciferous vegetable arugula (Eruca sativa), with potential chemopreventive and antioxidant activities. Arugula seed powder contains numerous vitamins and minerals, and is rich in phytonutrients, such as sulforaphane and indole-3-carbinol. Although the exact mechanism of action through which arugula seed powder may exert its anti-tumor effect has yet to be fully elucidated, the effects of this powder on cancer cells may be attributable to the antioxidant and pro-apoptotic activities of the phytonutrients.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131021>	C97927	TSHR Gene Mutation|TSH Receptor Defect|Thyroid Simulating Hormone Receptor Gene Mutation|Thyroid Stimulating Hormone Receptor Gene Mutation|Thyrotropin Receptor Defect	A change in the nucleotide sequence of the TSHR gene.			Cell or Molecular Dysfunction	NICHD Terminology|Pediatric Endocrinology Terminology
C131022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131022>	C187275|C177694	Thyroid-Binding Globulin Deficiency|TBG Deficiency|TBG Deficiency	Subnormal concentration of thyroid-binding globulin.			Laboratory or Test Result	NICHD Terminology|Pediatric Endocrinology Terminology
C131023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131023>	C81326|C187275	Thyroid-Binding Globulin Excess|TBG Excess|TBG Excess	Supranormal concentration of thyroid-binding globulin.			Laboratory or Test Result	NICHD Terminology|Pediatric Endocrinology Terminology
C131024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131024>	C217122	GvHD Final Skin Score|Final GVHD Skin Score|Graft versus Host Disease Final Skin Score	A scoring system for graft versus host disease that combines a score for percentage of body surface area (BSA) involved with a score for disease signs and cutaneous features.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131026>	C131024	GvHD Final Skin Score 0|Graft versus Host Disease Final Skin Score 0|Score 0	Body surface area involvement is 0 percent and there are no sclerotic features.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131027>	C131024	GvHD Final Skin Score 1|Graft versus Host Disease Final Skin Score 1|Score 1	Body surface area involvement is 1-18 percent.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131028>	C131024	GvHD Final Skin Score 2|Graft versus Host Disease Final Skin Score 2|Score 2	Body surface area involvement is 19-50 percent and there are superficial sclerotic features.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131029>	C131024	GvHD Final Skin Score 3|Graft versus Host Disease Final Skin Score 3|Score 3	Body surface area involvement is greater than 50 percent and there are any skin features that are Score 3. This score is also used when superficial sclerotic features are present (Score 2), but there is impaired mobility or ulceration (Score 3).			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C13102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13102>	C12948	Prostatic Duct	A small canal that receives prostatic secretions from the glandular tubules and discharges it through the prostatic portion of the urethra.	Human Prostatic Duct		Body Part, Organ, or Organ Component	
C131030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131030>	C171128	Transient Hyperinsulinism	Hyperinsulinism that resolves spontaneously. This is the most common cause of neonatal hypoglycemia.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131031>	C26800	Transient Hypothyroxinemia	Reduced concentration of thyroid hormone(s), usually associated with a non-thyroidal illness, that resolves spontaneously.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131032>	C48259	Transient Neonatal Hyperparathyroidism	Hyperparathyroidism in an infant less than one month of age that resolves spontaneously.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131033>	C217122	GvHD Body Surface Area Involvement Score|Graft versus Host Disease Body Surface Area Involvement Score	A score for graft versus host disease based on the percentage of of body surface area (BSA) involved.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131034>	C113145	Transient Primary Hypothyroidism	Primary hypothyroidism that resolves spontaneously.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131035>	C131033	BSA Involvement Score 0|Body Surface Area Involvement Score 0|Score 0	No body surface area involved.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131036>	C131033	BSA Involvement Score 1|Body Surface Area Involvement Score 1|Score 1	1-18% of body surface area involved.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131037>	C131033	BSA Involvement Score 2|Body Surface Area Involvement Score 2|Score 2	19-50% of body surface area involved.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131038>	C131033	BSA Involvement Score 3|Body Surface Area Involvement Score 3|Score 3	Greater than 50% of body surface area involved.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131039>	C217122	GvHD Skin Features Score|Graft versus Host Disease Skin Features Score	A score for graft versus host disease based on features of skin involvement.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C13103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13103>	C12710	Prostatic Epithelium	Tissue composed of one or more layers of epithelial cells and a basement membrane. It lines the secretory alveoli and secretory ducts of the prostate. The secretory epithelium consists mostly of pseudostratified columnar cells and basal cells with areas of cuboidal and squamous epithelial cells. The walls of the prostatic urethra and the distal regions of the longer ducts are lined with transitional epithelium.	Epithelium of Human Prostate Gland		Tissue	
C131040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131040>	C131039	Skin Features Score 0|Score 0	No sclerotic features.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131041>	C131039	Skin Features Score 2|Score 2	Superficial sclerotic features; not hidebound (able to pinch).			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131042>	C131039	Skin Features Score 3|Score 3	One or more of: deep sclerotic features; hidebound; impaired mobility; ulceration.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131043>	C217122	GvHD Final Lung Score|Final GVHD Lung Score|Graft versus Host Disease Final Lung Score	A scoring system for graft versus host disease that combines a symptoms score with a score for FEV1.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131044>	C131043	GvHD Final Lung Score 0|Graft versus Host Disease GvHD Final Lung Score 0|Score 0	FEV1 is greater than or equal to 80 percent with or without lung symptoms.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131045>	C131043	GvHD Final Lung Score 1|Graft versus Host Disease GvHD Final Lung Score 1|Score 1	FEV1 is 60 to 79 percent and lung symptoms are none or mild.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131046>	C147564	Thyroid Stimulating Hormone Resistance|TSH Resistance|TSH Resistance|TSH Unresponsiveness|TSH Unresponsiveness	Reduced response to thyroid stimulating hormone resulting in low thyroid hormone production despite elevated thyroid stimulating hormone, associated with mutation(s) in the TSHR gene.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C131047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131047>	C131043	GvHD Final Lung Score 2|Graft versus Host Disease GvHD Final Lung Score 2|Score 2	FEV1 is 40 to 59 percent and lung symptoms are none to moderate.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131048>	C131043	GvHD Final Lung Score 3|Graft versus Host Disease GvHD Final Lung Score 3|Score 3	FEV1 is less than or equal to 39 percent and lung symptoms are none to severe.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131049>	C217122	GvHD Lung Symptom Score|Graft versus Host Disease Lung Symptom Score	A score for graft versus host disease based on the severity of lung symptoms.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C13104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13104>	C33414	Prostatic Stroma|Stroma of the Prostate Gland	The non-glandular tissue of the prostate gland, consisting of two major cell types, smooth muscle cells and fibroblasts. Stromal cells are key regulators of growth and differentiation in the prostate.	Stroma of Human Prostate Gland		Body Part, Organ, or Organ Component	
C131050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131050>	C131049	GvHD Lung Symptom Score 0|Graft versus Host Disease Lung Symptom Score 0|Score 0	No symptoms.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131051>	C131049	GvHD Lung Symptom Score 1|Graft versus Host Disease Lung Symptom Score 1|Score 1	Mild symptoms (shortness of breath after climbing one flight of steps).			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131052>	C131049	GvHD Lung Symptom Score 2|Graft versus Host Disease Lung Symptom Score 2|Score 2	Moderate symptoms (shortness of breath after walking on flat ground).			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131053>	C131049	GvHD Lung Symptom Score 3|Graft versus Host Disease Lung Symptom Score 3|Score 3	Severe symptoms (shortness of breath at rest; requiring O2).			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131054>	C217122	GvHD Lung Obstructive Function Score|Graft versus Host Disease Lung Obstructive Function Score	A score for graft versus host disease based on FEV1.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131055>	C131054	Lung Obstructive Function Score 0|Score 0	FEV1 greater than or equal to 80%.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131056>	C131054	Lung Obstructive Function Score 1|Score 1	FEV1 60-79%.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131057>	C131054	Lung Obstructive Function Score 2|Score 2	FEV1 40-59%.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131058>	C131054	Lung Obstructive Function Score 3|Score 3	FEV1 less than or equal to 39%.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131059>	C120446	TXNRD2-Associated Familial Glucocorticoid Deficiency|Glucocorticoid Deficiency 5|TXNRD2-Associated FGD|TXNRD2-Associated FGD	Familial glucocorticoid deficiency caused by mutation(s) in the TXNRD2 gene encoding thioredoxin reductase 2.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C131060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131060>	C15438	Checkpoint Blockade Immunotherapy|ICB Therapy|Immune Checkpoint Blockade Therapy	Any type of immunotherapy that targets and blocks the immune checkpoint pathways to activate immune responses against tumor cells.	Checkpoint Blockade Immunotherapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C131061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131061>	C177692	MYC Positive|MYC Expression|Myc Proto-Oncogene Positive|Proto-Oncogene c-Myc Positive|c-MYC Positive|v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog Positive	Indicates that MYC expression has been detected in a sample.	MYC Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131062>	C177692	MYCN Positive|N-Myc Positive|N-Myc Proto-Oncogene Positive|NMYC Positive|Neuroblastoma MYC Positive|v-myc Avian Myelocytomatosis Viral Oncogene Neuroblastoma Derived Homolog Positive	Indicates that MYCN expression has been detected in a sample.	MYCN Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131063>	C177692	CD5 Positive|CD5 Antigen Positive|CD5 Molecule Positive|LEU1 Positive|Lymphocyte Antigen CD5 Positive|Lymphocyte Antigen T1/Leu-1 Positive|T-Cell Surface Glycoprotein CD5 Positive	Indicates that CD5 expression has been detected in a sample.	CD5 Positive		Laboratory or Test Result	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131064>	C158949|C103223	t(11;14) Negative	A cytogenetic finding indicating that the translocation t(11;14) has not been detected in a sample.	t(11;14) Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131065>	C36345	EPHA2 Protein Overexpression|EPH Receptor A2 Protein Overexpression|EphA2 Overexpression|Ephrin Type-A Receptor 2 Protein Overexpression	A molecular abnormality indicating the presence of an abnormally high level of the ephrin type-A receptor 2 protein.	EPHA2 Protein Overexpression		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131066>	C177692	CD22 Positive|B-Cell Antigen CD22 Positive|B-Cell Receptor CD22 Positive|B-Lymphocyte Cell Adhesion Molecule Positive|BL-CAM Positive|CD22 Antigen Positive|CD22 Molecule Positive|SIGLEC-2 Positive|SIGLEC2 Positive|Sialic Acid-Binding Ig-Like Lectin 2 Positive|Sialic Acid-Binding Immunoglobulin-Like Lectin 2 Positive|T-Cell Surface Antigen Leu-14 Positive	Indicates that CD22 expression has been detected in a sample.	CD22 Positive		Laboratory or Test Result	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131067>	C128834	BCR/ABL1 Fusion Protein Negative|BCR ABL Fusion Protein Negative|BCR-ABL1 Fusion Protein Negative|BCR-ABL1 Protein Negative|BCR/ABL Chimeric Protein Negative|BCR/ABL Fusion Protein Negative|BCR/ABL Oncoprotein Negative|BCR/ABL1 Protein Negative|Breakpoint Cluster Region/Tyrosine-Protein Kinase ABL1 Fusion Protein Negative	Indicates that expression of the BCR/ABL1 fusion protein has not been detected in a sample.	BCR/ABL1 Fusion Protein Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131068>	C94299|C177692	MET Positive|HGFR Positive|Hepatocyte Growth Factor Receptor Positive|MET Proto-Oncogene, Receptor Tyrosine Kinase Positive|Met Proto-Oncogene Positive|c-met Positive	Indicates that MET expression has been detected in a sample.	MET Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131069>	C158948	RET Fusion Positive|Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret Fusion Positive|Proto-Oncogene c-Ret Fusion Positive|RET Fusion|RET/PTC Fusion Positive|Ret Proto-Oncogene Fusion Positive|Tyrosine-Protein Kinase Receptor RET Fusion Positive	Indicates that the expression of a RET fusion has been detected in a sample.	RET Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13106>	C33904	Verumontanum|Colliculus Seminalis|Human Verumontanum	A ridge of urothelium in the prostatic urethra that serves as an important anatomical landmark that is important in the classification of several urethral disorders, including posterior urethral valves, urethral carcinoid tumors, and hypospadias.	Human Veru Montanum		Body Part, Organ, or Organ Component	
C131070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131070>	C138156	NTRK1 Fusion Positive|High Affinity Nerve Growth Factor Receptor Fusion Positive|NTRK1 Fusion|NTRK1 fusion|Neurotrophic Receptor Tyrosine Kinase 1 Fusion Positive|TRK1 Fusion Positive|TRKA Fusion Positive|Trk-A Fusion Positive|Tropomyosin-Related Kinase A Fusion Positive	Indicates that the expression of a NTRK1 fusion has been detected in a sample.	NTRK1 Fusion Positive		Laboratory or Test Result	CRF8 Pathology Review Targeted Genomics Table|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131071>	C158948	ROS1 Fusion Positive|MCF3 Fusion Positive|Proto-Oncogene Tyrosine-Protein Kinase ROS Fusion Positive|Proto-Oncogene c-Ros Fusion Positive|Proto-Oncogene c-Ros-1 Fusion Positive|ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Fusion Positive|ROS1 Fusion|Receptor Tyrosine Kinase c-Ros Oncogene 1 Fusion Positive|c-Ros-1 Fusion Positive	Indicates that the expression of a ROS1 fusion has been detected in a sample.	ROS1 Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131072>	C131437	Uninodular Goiter	Nodular goiter characterized by one discrete tissue mass.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131073>	C26878|C114830	Vitamin D 1 Alpha-Hydroxylase Deficiency|1 Alpha-hydroxylase Deficiency|Pseudo Vitamin-D Deficient Rickets|Selective 1-alpha, 25-hydroxyvitamin D3 deficiency|VDDR1|Vitamin D Hydroxylation-deficient Rickets type 1a|Vitamin D-Dependent Rickets Type 1|Vitamin D-dependent Rickets Type 1	An autosomal recessive form of rickets caused by inactivating mutation(s) in the CYP27B1 gene, encoding 25-hydroxyvitamin D-1 alpha hydroxylase, the renal enzyme that converts 25-hydroxyvitamin D to 1 alpha,25-dihydroxyvitamin D (calcitriol), the active metabolite of vitamin D (cholecalciferol). The condition is characterized by reduced serum concentrations of 1 alpha,25-hydroxyvitamin D, normal concentrations of 25-hydroxyvitamin D, increased serum alkaline phosphatase, hypocalcemia due to reduced intestinal calcium absorption, hypophosphatemia due to renal phosphate wasting, secondary hyperparathyroidism, rickets, seizures, muscle weakness and failure to thrive.	Vitamin D 1 Alpha-Hydroxylase Deficiency		Disease or Syndrome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C131074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131074>	C26878|C114830	Vitamin D 25-Hydroxylase Deficiency|Vitam D Hydroxylation-Deficient Rickets Type 1b|Vitamin D Hydroxylation-deficient Rickets Type 1b	An autosomal recessive form of rickets caused by inactivating mutation(s) in the CYP2R1 gene, encoding vitamin D 25-hydroxylase, the hepatic enzyme that converts vitamin D to 25-hydroxyvitamin D, the precursor of 1,25-dihydroxyvitamin D (calcitriol). The condition is characterized by reduced serum concentrations of 25-hydroxyvitamin D, hypophosphatemia, hypocalcemia with secondary hyperparathyroidism and elevated serum alkaline phosphatase, and by failure to thrive, seizures, muscle weakness, and rickets.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131075>	C131077	Vitamin D Dependent Rickets 2a|Hereditary 1,25 Dihydroxyvitamin D-Resistant Rickets with Abnormal Vitamin D Receptor with Alopecia|VDDR2a|Vitamin D Receptor Deficiency Rickets	Rickets caused by a defect in the VDR gene, encoding the vitamin D receptor. This form of rickets is characterized by hypocalcemia, elevated 1,25-dihydroxyvitamin D (calcitriol) concentrations and may also manifest with alopecia.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131076>	C131077	Vitamin D Dependent Rickets 2b|Hereditary 1,25 Dihydroxyvitamin D-Resistant Rickets with Abnormal Vitamin D Receptor without Alopecia|Vitamin D Receptor Signaling Defect Rickets|Vitamin D Resistant Rickets	Rickets caused by a post-receptor defect in the vitamin D signaling pathway producing vitamin D resistance due to constitutive overexpression of a nuclear ribonucleoprotein that competes with the vitamin D receptor-retinoid X receptor dimer binding with DNA vitamin D response elements. This condition has a similar phenotype to vitamin D receptor deficiency rickets including elevated 1,25-dihydroxyvitamin D (calcitriol) concentrations.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131077>	C26878	Vitamin D Dependent Rickets 2|Hereditary 1,25 Dihydroxyvitamin D-resistant Rickets with Abnormal Vitamin D Receptor|VDDR2|Vitamin D Receptor Deficiency	An autosomal recessive form of rickets caused by mutation(s) in the VDR gene, encoding the vitamin D receptor. The condition is characterized by hypocalcemia, increased concentrations of calcitriol, secondary hyperparathyroidism, early-onset rickets and alopecia.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131078>	C26800	Wolff-Chaikoff Phenomenon|Wolff-Chaikoff|Wolff-Chaikoff Syndrome/Phenomenon	Hypothyroidism induced by excessive levels of iodine in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131079>	C85865|C78350	X-Linked Hypoparathyroidism|X-linked Hypoparathyroidism	Hypoparathyroidism in which the inheritance is recessive and linked to the q26-q27 region of the X chromosome. The parathyroid glands are usually incompletely developed (parathyroid dysgenesis) or absent (parathyroid agenesis).			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C13107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13107>	C13038	Wall of Prostatic Duct	A layer of epithelium comprising both columnar and small cuboidal cells.			Body Part, Organ, or Organ Component	
C131080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131080>	C117719	Testicular Failure	The failure of testicular hormone production and spermatogenesis.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C131081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131081>	C3492	Steroidogenic Acute Regulatory Protein Deficiency|StAR Deficiency|StAR Deficiency	Congenital lipoid adrenal hyperplasia (CLAH) due to loss-of-function mutations in the STAR gene, resulting in decreased or absent production of steroidogenic acute regulatory protein (StAR), which leads to deficient transport of cholesterol from the outer to the inner mitochondrial membrane.			Laboratory or Test Result	NICHD Terminology|Pediatric Endocrinology Terminology
C131082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131082>	C16840	Impression|IMPRESSION|Imp|Mental Impression	An effect produced upon the mind or senses as a consequence of experience.			Mental Process	CDISC SDTM Result Type Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C131083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131083>	C27565	11 Beta-Hydroxysteroid Dehydrogenase Type 2 Deficiency|Apparent Mineralocorticoid Excess	Decreased activity of 11-beta-hydroxysteroid dehydrogenase type 2, which catalyzes the conversion of cortisol to cortisone due to autosomal recessive deactivating mutation(s) in the HSD11B2 gene. Resultant elevated cortisol concentrations in the kidney activate the mineralocorticoid receptor, resulting in hypertension, hypokalemia, and hypernatremia.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131084>	C34816|C27565	11-Beta-Hydroxysteroid Dehydrogenase Type 1 Deficiency|Cortisone Reductase Deficiency Type 2	Decreased activity of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 due to inactivating mutation(s) in the HSD11B1 gene. The condition is characterized by hyperandrogenism as a result of increased adrenocorticotropic hormone stimulation of the adrenal gland due to failure of cortisol-mediated down-regulation, and is clinically indistinguishable from H6PD deficiency.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131085>	C27565	11-Beta-Hydroxylase Deficiency	Decreased or absent activity of the enzyme 11-beta-hydroxylase caused by loss-of-function mutations in the CYP11B1 gene, resulting in congenital adrenal hyperplasia. Clinical manifestations of this condition include virilization in 46XX infants and hypertension.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131086>	C27565	17-Alpha-Hydroxylase/17,20 Lyase Deficiency	Decreased or absent activity of the enzyme 17-alpha-hydroxylase/17,20 lyase due to loss-of-function mutation(s) in the CYP17A1 gene. The clinical manifestations of the deficiency are dependent on whether one or both activities of the enzyme are affected, and may include hypertension due to reduced 17-hydroxylase activity and incomplete genital masculinization in 46,XY infants due to reduced 17,20 lyase activity.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131087>	C27565	21-Hydroxylase Deficiency|21-OHD	A classic form of congenital adrenal hyperplasia that is characterized by severe 21-hydroxylase deficiency, resulting in glucocorticoid and mineralocorticoid deficiency, without clinically significant salt wasting, and androgen excess, which causes virilization in female infants.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131088>	C27565	3-Beta-Hydroxysteroid Dehydrogenase Deficiency|3-beta HSD Deficiency	Congenital adrenal hyperplasia due to presumed mutation(s) in the HSD3B2 gene, which results in decreased activity of the enzyme 3-beta-hydroxysteroid dehydrogenase. The clinical manifestations of the deficiency are dependent on the degree of reduction in enzymatic activity: 46,XY infants may have incomplete development of the genitalia, while 46,XX infants may have virilization.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131089>	C131815	Acquired Generalized Lipodystrophy	Generalized lipodystrophy, the cause of which is not present at birth.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C13108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13108>	C25769	Fascia|FASCIA|Human Fascia	A sheet or band of fibrous connective tissue enveloping, separating, or binding together muscles, organs, and other soft structures of the body.	Fascia		Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Structured Product Labeling Terminology|SPL Tissue Form Product Type Terminology
C131090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131090>	C113351	Acquired Ovarian Failure	Ovarian failure, the cause of which is not present at birth.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131091>	C131080	Acquired Testicular Failure	Testicular failure, the cause of which is not present at birth.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C131092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131092>	C103223	3-Log Reduction in Ph+ Cells|3-Log Reduction|3-Log Reduction in Philadelphia Chromosome Positive Cells	A 1000 times reduction in the Philadelphia Chromosome positive cells.			Finding	
C131093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131093>	C219644|C172343	IDH1 NM_005896.3:c.394C>A|C394A|IDH c.394C>A|IDH1 c.394C>A|Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic c.394C>A|Isocitrate Dehydrogenase 1 (NADP+), Soluble c.394C>A|NM_005896.3:c.394C>A	A nucleotide substitution at position 394 of the coding sequence of the IDH1 gene where cytosine has been mutated to adenine.			Cell or Molecular Dysfunction	
C131094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131094>	C219644	IDH1 NM_005896.3:c.394_395delinsTC|IDH c.394_395CG>TC|IDH c.394_395delCGinsTC|IDH1 NM_005896.3:c.394_395delCGinsTC|IDH1 c.394_395CG>TC|IDH1 c.394_395delCGinsTC|Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic c.394_395CG>TC|Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic c.394_395delCGinsTC|Isocitrate Dehydrogenase 1 (NADP+), Soluble c.394_395CG>TC|Isocitrate Dehydrogenase 1 (NADP+), Soluble c.394_395delCGinsTC|NM_005896.3:c.394_395CG>TC|NM_005896.3:c.394_395delCGinsTC|NM_005896.3:c.394_395delinsTC	A complex substitution where the nucleotide sequence at positions 394 and 395 of the coding sequence of the IDH1 gene has changed from cytosine-guanine to thymine-cytosine.			Cell or Molecular Dysfunction	
C131095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131095>	C117280	IDH1 NP_005887.2:p.R132S|Cytosolic NADP-Isocitrate Dehydrogenase Protein Arg132Ser|Cytosolic NADP-Isocitrate Dehydrogenase Protein R132S|IDH1 Arg132Ser|IDH1 NP_005887.2:p.Arg132Ser|IDH1 R132S|IDH1 R132S Mutation|IDH1 p.Arg132Ser|IDH1 p.R132S|Isocitrate Dehydrogenase [NADP] Cytoplasmic Arg132Ser|Isocitrate Dehydrogenase [NADP] Cytoplasmic R132S|NP_005887.2:p.Arg132Ser|NP_005887.2:p.R132S	A change in the amino acid residue at position 132 in the isocitrate dehydrogenase [NADP] cytoplasmic protein where arginine has been replaced by serine.	IDH1 NP_005887.2:p.R132S		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131096>	C219644	IDH1 NM_005896.3:c.394C>G|C394G|IDH c.394C>G|IDH1 c.394C>G|Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic c.394C>G|Isocitrate Dehydrogenase 1 (NADP+), Soluble c.394C>G|NM_005896.3:c.394C>G	A nucleotide substitution at position 394 of the coding sequence of the IDH1 gene where cytosine has been mutated to guanine.			Cell or Molecular Dysfunction	
C131097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131097>	C117280	IDH1 NP_005887.2:p.R132G|Cytosolic NADP-Isocitrate Dehydrogenase Protein Arg132Gly|Cytosolic NADP-Isocitrate Dehydrogenase Protein R132G|IDH1 Arg132Gly|IDH1 NP_005887.2:p.Arg132Gly|IDH1 R132G|IDH1 R132G Mutation|IDH1 p.Arg132Gly|IDH1 p.R132G|Isocitrate Dehydrogenase [NADP] Cytoplasmic Arg132Gly|Isocitrate Dehydrogenase [NADP] Cytoplasmic R132G|NP_005887.2:p.Arg132Gly|NP_005887.2:p.R132G	A change in the amino acid residue at position 132 in the isocitrate dehydrogenase [NADP] cytoplasmic protein where arginine has been replaced by glycine.	IDH1 NP_005887.2:p.R132G		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131098>	C219644|C172343	IDH1 NM_005896.3:c.394C>T|C394T|IDH c.394C>T|IDH1 c.394C>T|Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic c.394C>T|Isocitrate Dehydrogenase 1 (NADP+), Soluble c.394C>T|NM_005896.3:c.394C>T	A nucleotide substitution at position 394 of the coding sequence of the IDH1 gene where cytosine has been mutated to thymine.			Cell or Molecular Dysfunction	
C131099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131099>	C117280	IDH1 NP_005887.2:p.R132C|Cytosolic NADP-Isocitrate Dehydrogenase Protein Arg132Cys|Cytosolic NADP-Isocitrate Dehydrogenase Protein R132C|IDH1 Arg132Cys|IDH1 NP_005887.2:p.Arg132Cys|IDH1 R132C|IDH1 R132C Mutation|IDH1 p.Arg132Cys|IDH1 p.R132C|Isocitrate Dehydrogenase [NADP] Cytoplasmic Arg132Cys|Isocitrate Dehydrogenase [NADP] Cytoplasmic R132C|NP_005887.2:p.Arg132Cys|NP_005887.2:p.R132C	A change in the amino acid residue at position 132 in the isocitrate dehydrogenase [NADP] cytoplasmic protein where arginine has been replaced by cysteine.	IDH1 NP_005887.2:p.R132C		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C1310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1310>	C2089	Ro 31-8220|Bisindolylmaleimide IX Methanesulfonate|RO-31-8220|Ro-31-8220	A methanesulfonate salt form, a staurosporine analog that inhibits protein kinase C and induces apoptosis. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C131100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131100>	C219644|C172343	IDH1 NM_005896.3:c.395G>T|G395T|IDH c.395G>T|IDH1 c.395G>T|Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic c.395G>T|Isocitrate Dehydrogenase 1 (NADP+), Soluble c.395G>T|NM_005896.3:c.395G>T	A nucleotide substitution at position 395 of the coding sequence of the IDH1 gene where guanine has been mutated to thymine.			Cell or Molecular Dysfunction	
C131101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131101>	C117280	IDH1 NP_005887.2:p.R132L|Cytosolic NADP-Isocitrate Dehydrogenase Protein Arg132Leu|Cytosolic NADP-Isocitrate Dehydrogenase Protein R132L|IDH1 Arg132Leu|IDH1 NP_005887.2:p.Arg132Leu|IDH1 R132L|IDH1 R132L Mutation|IDH1 p.Arg132Leu|IDH1 p.R132L|Isocitrate Dehydrogenase [NADP] Cytoplasmic Arg132Leu|Isocitrate Dehydrogenase [NADP] Cytoplasmic R132L|NP_005887.2:p.Arg132Leu|NP_005887.2:p.R132L	A change in the amino acid residue at position 132 in the isocitrate dehydrogenase [NADP] cytoplasmic protein where arginine has been replaced by leucine.	IDH1 NP_005887.2:p.R132L		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131102>	C118389	IDH1 NM_005896.3:c.356G>A|G356A|IDH c.356G>A|IDH1 c.356G>A|Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic c.356G>A|Isocitrate Dehydrogenase 1 (NADP+), Soluble c.356G>A|NM_005896.3:c.356G>A	A nucleotide substitution at position 356 of the coding sequence of the IDH1 gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C131103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131103>	C117278	IDH1 NP_005887.2:p.R119Q|Cytosolic NADP-Isocitrate Dehydrogenase Protein Arg119Gln|Cytosolic NADP-Isocitrate Dehydrogenase Protein R119Q|IDH1 Arg119Gln|IDH1 NP_005887.2:p.Arg119Gln|IDH1 R119Q|IDH1 p.Arg119Gln|IDH1 p.R119Q|Isocitrate Dehydrogenase [NADP] Cytoplasmic Arg119Gln|Isocitrate Dehydrogenase [NADP] Cytoplasmic R119Q|NP_005887.2:p.Arg119Gln|NP_005887.2:p.R119Q	A change in the amino acid residue at position 119 in the isocitrate dehydrogenase [NADP] cytoplasmic protein where arginine has been replaced by glutamine.			Cell or Molecular Dysfunction	
C131104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131104>	C97927|C151919	TERT Gene Mutation|DKCA2 Gene Mutation|DKCB4 Gene Mutation|EST2 Gene Mutation|TCS1 Gene Mutation|TERT mutation|TP2 Gene Mutation|TRT Gene Mutation|Telomerase Reverse Transcriptase Gene Mutation	A change in the nucleotide sequence of the TERT gene.	TERT Gene Mutation		Cell or Molecular Dysfunction	CRF8 Pathology Review Targeted Genomics Table|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C131105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131105>	C177913	Quite a Bit of Strain|Quite a Bit	A response indicating that an individual needed quite a bit of strain to do something.			Intellectual Product	Bowel Function Diary for Assessing Opioid-Induced Constipation
C131106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131106>	C160585	TERT NM_198253.2:c.1-146C>T|1 295 250 C>T|C250T|NM_198253.2:c.1-146C>T|TERT 1 295 250 C>T|TERT C250T|TERT:c.1-146C>T|Telomerase Reverse Transcriptase c.1-146C>T	A nucleotide substitution in the 5' promoter region of the TERT gene at a position that is 146 nucleotides upstream of the translation start site where cytosine has been mutated to thymine.			Cell or Molecular Dysfunction	
C131107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131107>	C160585	TERT NM_198253.2:c.1-124C>T|1 295 228 C>T|C228T|NM_198253.2:c.1-124C>T|TERT 1 295 228 C>T|TERT C228T|TERT:c.1-124C>T|Telomerase Reverse Transcriptase c.1-124C>T	A nucleotide substitution in the 5' promoter region of the TERT gene at a position that is 124 nucleotides upstream of the translation start site where cytosine has been mutated to thymine.			Cell or Molecular Dysfunction	
C131108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131108>	C219645|C172344	IDH2 NM_002168.3:c.514A>G|A514G|IDH c.514A>G|IDH2 c.514A>G|Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial c.514A>G|Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial c.514A>G|NM_002168.3:c.514A>G	A nucleotide substitution at position 514 of the coding sequence of the IDH2 gene where adenine has been mutated to guanine.			Cell or Molecular Dysfunction	
C131109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131109>	C117282	IDH2 NP_002159.2:p.R172G|IDH2 Arg172Gly|IDH2 NP_002159.2:p.Arg172Gly|IDH2 R172G|IDH2 R172G Mutation|IDH2 p.Arg172Gly|Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial Arg172Gly|Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial R172G|Isocitrate Dehydrogenase [NADP], Mitochondrial Arg172Gly|Isocitrate Dehydrogenase [NADP], Mitochondrial R172G|NP_002159.2:p.Arg172Gly|NP_002159.2:p.R172G|R172G	A change in the amino acid residue at position 172 in the isocitrate dehydrogenase [NADP], mitochondrial protein where arginine has been replaced by glycine.	IDH2 NP_002159.2:p.R172G		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131110>	C219645	IDH2 NM_002168.3:c.515G>A|G515A|IDH c.515G>A|IDH2 c.515G>A|Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial c.515G>A|Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial c.515G>A|NM_002168.3:c.515G>A	A nucleotide substitution at position 515 of the coding sequence of the IDH2 gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C131111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131111>	C219645	IDH2 NM_002168.3:c.515_516delinsAA|IDH c.515_516GG>AA|IDH c.515_516delGGinsAA|IDH2 NM_002168.3:c.515_516GG>AA|IDH2 NM_002168.3:c.515_516delGGinsAA|IDH2 c.515_516GG>AA|IDH2 c.515_516delGGinsAA|Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial c.515_516GG>AA|Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial c.515_516delGGinsAA|Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial c.515_516GG>AA|Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial c.515_516delGGinsAA|NM_002168.3:c.515_516GG>AA|NM_002168.3:c.515_516delGGinsAA|NM_002168.3:c.515_516delinsAA	A complex substitution where the nucleotide sequence at positions 515 and 516 of the coding sequence of the IDH1 gene has changed from guanine-guanine to adenine-adenine.			Cell or Molecular Dysfunction	
C131112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131112>	C117282	IDH2 NP_002159.2:p.R172K|IDH2 Arg172Lys|IDH2 NP_002159.2:p.Arg172Lys|IDH2 R172K|IDH2 R172K Mutation|IDH2 p.Arg172Lys|Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial Arg172Lys|Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial R172K|Isocitrate Dehydrogenase [NADP], Mitochondrial Arg172Lys|Isocitrate Dehydrogenase [NADP], Mitochondrial R172K|NP_002159.2:p.Arg172Lys|NP_002159.2:p.R172K|R172K	A change in the amino acid residue at position 172 in the isocitrate dehydrogenase [NADP], mitochondrial protein where arginine has been replaced by lysine.	IDH2 NP_002159.2:p.R172K		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131113>	C219645	IDH2 NM_002168.3:c.515G>T|G515T|IDH c.515G>T|IDH2 c.515G>T|Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial c.515G>T|Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial c.515G>T|NM_002168.3:c.515G>T	A nucleotide substitution at position 515 of the coding sequence of the IDH2 gene where guanine has been mutated to thymine.			Cell or Molecular Dysfunction	
C131114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131114>	C117282	IDH2 NP_002159.2:p.R172M|IDH2 Arg172Met|IDH2 NP_002159.2:p.Arg172Met|IDH2 R172M|IDH2 R172M Mutation|IDH2 p.Arg172Met|Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial Arg172Met|Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial R172M|Isocitrate Dehydrogenase [NADP], Mitochondrial Arg172Met|Isocitrate Dehydrogenase [NADP], Mitochondrial R172M|NP_002159.2:p.Arg172Met|NP_002159.2:p.R172M|R172M	A change in the amino acid residue at position 172 in the isocitrate dehydrogenase [NADP], mitochondrial protein where arginine has been replaced by methionine.	IDH2 NP_002159.2:p.R172M		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131115>	C94299	Poliovirus Receptor Staining Finding	The results of staining for poliovirus receptor in a sample.			Laboratory or Test Result	
C131116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131116>	C131115	Poliovirus Receptor 3+ Staining Finding|3+ PVR Staining|Poliovirus Receptor 3+ Staining	A finding of 3+ staining for poliovirus receptor in a sample.			Laboratory or Test Result	
C131117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131117>	C131115	Poliovirus Receptor 2+ Staining Finding|2+ PVR Staining|Poliovirus Receptor 2+ Staining	A finding of 2+ staining for poliovirus receptor in a sample.			Laboratory or Test Result	
C131118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131118>	C131115	Poliovirus Receptor 1+ Staining Finding|1+ PVR Staining|Poliovirus Receptor 1+ Staining	A finding of 1+ staining for poliovirus receptor in a sample.			Laboratory or Test Result	
C131119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131119>	C226696	Test Not Ordered	An indication that a test was not ordered.			Intellectual Product	
C131120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131120>	C226656	Unable to Perform	An indication that an action, task, or function was not done due to a lack of skill, means, or opportunity.			Intellectual Product	
C131121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131121>	C226716	Insufficient Sample Volume|Insufficient Sample	An indication that there was not enough sample available.			Intellectual Product	CDRH Cause Investigation - Investigation Findings Terminology
C131122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131122>	C226716	Block Depleted	An indication that a sample block has been depleted by testing.			Intellectual Product	
C131123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131123>	C54443	FDA Terminology|Food and Drug Administration Terminology	Terminology subsets associated with the Food and Drug Administration.			Intellectual Product	
C131124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131124>	C50304	Continuous Temperature Monitoring Device	A device designed to take a temperature reading at preset intervals over an extended period of time.	Continuous Temperature Monitoring Device		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C131125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131125>	C171083	Glucocorticoid Sensitivity	The ability of a biological specimen to respond to glucocorticoid-glucocorticoid receptor-dependent signaling.			Conceptual Entity	
C131126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131126>	C17207	NFKB1 Gene Product	A protein encoded by the NFKB1 gene.			Amino Acid, Peptide, or Protein	
C131127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131127>	C131126	Nuclear Factor NF-kappa-B p50 Subunit|NF-Kappa B p50|NF-kB Subunit 1 p50|NF-kappaB(p50)|NFKB p50 Subunit|Nuclear Factor Kappa-B Subunit 1 p50	Nuclear factor NF-kappa-B p50 subunit (433 aa, ~48 kDa) is encoded by the human NFKB1 gene. This protein is involved in both transcriptional regulation and signal transduction.	Nuclear Factor NF-kappa-B p50 Subunit		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131128>	C12542	Circulating Tumor-Reactive T-Cell|Circulating Tumor Reactive T Cell|Circulating Tumor Reactive T-Cell|Circulating Tumor-Reactive CD8-Positive T-Cell|Circulating Tumor-Reactive T Cell	A population of T-lymphocytes that can mount an immune response against circulating tumor cells. These cells may spontaneously arise as a response to the presence of either endogenous tumor antigens or exogenous tumor antigens administered as a cancer vaccine.	Circulating Tumor-Reactive T-Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C131129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131129>	C2667	CEA-MUC-1-TRICOM Vaccine CV301|CV-301|CV301|CV301-V/F|CVAC-301|MVA-BN/Fowlpox-CEA-MUC-1-TRICOM Vaccine CV301|PANVAC	A cancer prime/boost vaccine-based immunotherapeutic consisting of a prime, which is comprised of a proprietary version of the recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN) and a recombinant fowlpox viral vector, used for the boosts, encoding both the two tumor-associated antigens (TAA), carcinoembryonic antigen (CEA) and mucin-1 (MUC-1), and TRICOM, which is comprised of three immune-enhancing co-stimulatory molecules, B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. The administration of the vaccinia priming dose is followed by multiple boosting doses of the fowlpox vector. CEA-MUC-1-TRICOM Vaccine CV301 may enhance presentation of CEA and MUC-1 to antigen-presenting cells (APCs) and may activate a cytotoxic T-lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells. In addition, CV301 upregulates the expression of PD-L1 due to CTL-mediated tumor attack; additionally, when combined with a PD-1 immune checkpoint inhibitor, the antitumor effect may be increased. CEA and MUC-1 are overexpressed in certain cancers.	CEA-MUC-1-TRICOM Vaccine CV301		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C13112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13112>	C12522	Macrocytic Red Blood Cell|Macrocyte|Macrocytes	An abnormally large red blood cell occurring mainly in anemias (as pernicious anemia), also called megalocyte.  Lack of vitamin B12 and folic acid could also cause macrocytes. (NCI)			Cell	
C131130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131130>	C129867	STAT5B Deficiency	Growth hormone insensitivity syndrome caused by mutation(s) in the STAT5B gene, encoding signal transducer and activator of transcription 5B, a protein critical for the transcription of growth hormone-dependent genes.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131131>	C125932	Immunotherapy Response Assessment in Neuro-Oncology Criteria|Immunotherapy Response Assessment for Neuro-Oncology|iRANO|iRANO Criteria	Response assessment criteria for the evaluation of patients undergoing immunotherapy for the treatment of malignant glioma. These recommendations integrate guidance for the determination and confirmation of tumor progression based on the response assessment in neuro-oncology (RANO) working group and the immune-related response criteria (irRC).			Intellectual Product	
C131132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131132>	C131298	Secondary Parathyroid Hormone Resistance|Acquired Parathyroid Hormone Resistance|Acquired Parathyroid Hormone Resistance|Pseudohypoparathyroidism, Type 2|Pseudohypoparathyroidism, Type 2	Parathyroid hormone (PTH) resistance caused by vitamin D deficiency and characterized by clinically increased PTH concentrations with relative hyperphosphatemia. The diagnosis can be confirmed by finding of a normal cyclic adenosine monophosphate (cAMP) response to PTH infusion, but deficient phosphaturic response, indicating a defect distal to cAMP generation in renal cells.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C131133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131133>	C53543	Sclerosteosis|Cortical Hyperostosis with Syndactyly|Cortical Hyperostosis with Syndactyly	An autosomal recessive form of craniotubular hyperostosis due to loss-of-function mutation(s) in the SOST gene, encoding sclerostin. Clinical features include tall stature, enlarged jaw and facial bones, and cranial nerve compression leading to hearing loss and facial palsy. About two-thirds of patients have syndactyly and/or nail malformations. Increased intracranial pressure due to the thickened calvaria and skull base can occur.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131134>	C131087	Salt-Wasting 21-Hydroxylase Deficiency|Salt-wasting 21-OHD|Salt-wasting 21-OHD	A classic form of congenital adrenal hyperplasia characterized by complete absence of 21-hydroxylase activity resulting in deficiency of glucocorticoids and mineralocorticoids accompanied by androgen excess causing virilization in female infants. Mineralocorticoid deficiency results in renal salt-wasting, and if untreated, hyponatremia, hyperkalemia, and shock.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131135>	C131298	Renal Parathyroid Hormone Resistance|Pseudohypoparathyroidism Type 1b	Parathyroid hormone resistance caused by defects in methylation in the GNAS gene that cause loss of expression of Gs-alpha from the maternal allele in renal tissue, resulting in decreased phosphate excretion and increased calcium excretion. Individuals with this condition may also have brachydactyly and partial resistance to thyroid-stimulating hormone.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C131136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131136>	C36344|C156029	ALK Gene Amplification|ALK Amplification|ALK Amplification|ALK Copy Number Gain|ALK Copy Number Gain|Anaplastic Lymphoma Kinase Receptor Gene Amplification|Anaplastic Lymphoma Receptor Tyrosine Kinase Gene Amplification|CD246 Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the ALK gene.	ALK Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C131137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131137>	C41332	Immune-Mediated Adverse Reaction|Immune Related Side Effect|Immune-Mediated Adverse Event|Immune-Related Adverse Event|Immune-Related Adverse Event|irAE	An adverse event resulting from an immune system reaction to a drug or device. It can affect any organ or system.			Finding	
C131138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131138>	C20051	Renal Bed|Kidney Bed|Kidney Bed|RENAL BED	The cavity evident following excision of a kidney. The renal bed is a potential site of recurrent disease post-nephrectomy.			Body Space or Junction	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C131139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131139>	C20921	ARHGAP32 Gene|ARHGAP32|ARHGAP32|Rho GTPase Activating Protein 32 Gene	This gene is involved in both small GTPase activity and NMDA receptor signaling.			Gene or Genome	
C13113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13113>	C12530	Immature Granulocyte	A not-yet-mature white blood cell with staining granules in its cytoplasm. The staining granules may be neutrophilic, acidophilic, or basophilic in character. There are indications that an immature granulocyte count is a better measure of infection and sepsis than a total white blood cell count and comparable to absolute neutrophil count.			Body Part, Organ, or Organ Component	
C131140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131140>	C131139	ARHGAP32 wt Allele|GC-GAP|GRIT|KIAA0712|MGC1892|PX-RICS|RICS|Rho GTPase Activating Protein 32 wt Allele|p200RhoGAP|p250GAP	Human ARHGAP32 wild-type allele is located in the vicinity of 11q24.3 and is approximately 314 kb in length. This allele, which encodes Rho GTPase-activating protein 32, plays a role in the modulation of both NMDA receptor signaling and small GTPase activity. Deletion of the chromosomal region containing the gene is associated with a subset of Jacobsen syndrome patients that exhibit autism spectrum disorder.			Gene or Genome	
C131141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131141>	C17298	Rho GTPase-Activating Protein 32|ARHGAP32|Brain-Specific Rho GTP-Ase-Activating Protein|Brain-Specific Rho GTPase-Activating Protein|GAB-Associated CDC42|GAB-Associated Cdc42/Rac GTPase-Activating Protein|GC-GAP|GTPase Interacting With TrkA|GTPase Regulator Interacting With TrkA|GTPase-Activating Protein For Cdc42 and Rac1|PX-RICS|Rho GTPase Involved In Beta-Catenin, N-Cadherin, and NMDA Receptor Signaling|Rho-Type GTPase-Activating Protein 32|Rho/Cdc42/Rac GTPase-Activating Protein RICS|RhoGAP Involved in the Beta-Catenin-N-Cadherin and NMDA Receptor Signaling|p200RhoGAP|p250GAP	Rho GTPase-activating protein 32 (2087 aa, ~231 kDa) is encoded by the human ARHGAP32 gene. This protein is involved in the regulation of signaling mediated by both Rho family GTPases and the NMDA receptor.			Amino Acid, Peptide, or Protein	
C131142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131142>	C35869	Pseudoresponse|PSEUDORESPONSE|PSR-Pseudoresponse|PsR	A marked decrease in contrast enhancement that is not due to actual tumor shrinkage, but that may be due to anti-angiogenic therapy or an increase in steroid dosage.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C131143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131143>	C35869	Immunoprogression|IPD-Immunoprogression	A marked increase in contrast enhancement that is not due to actual tumor growth, but that may be due to a reaction to immunotherapy.			Finding	GDC Terminology|GDC Value Terminology
C131144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131144>	C35869	Immunoresponse|IMR-Immunoresponse	A marked decrease in contrast enhancement that is not due to actual tumor shrinkage, but that may be due to immunotherapy.			Finding	GDC Terminology|GDC Value Terminology
C131145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131145>	C20194	TNP2 Gene|TNP2|TNP2|Transition Protein 2 Gene	This gene plays a role in spermatid differentiation.			Gene or Genome	
C131146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131146>	C131145	TNP2 wt Allele|TP2|Transition Protein 2 (During Histone To Protamine Replacement) Gene|Transition Protein 2 wt Allele	Human TNP2 wild-type allele is located in the vicinity of 16p13.13 and is approximately 2 kb in length. This allele, which encodes nuclear transition protein 2, is involved in chromatin packaging during spermatogenesis.			Gene or Genome	
C131147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131147>	C18466	Nuclear Transition Protein 2|TP-2|TP2|Transition Protein 2	Nuclear transition protein 2 (138 aa, ~16 kDa) is encoded by the human TNP2 gene. This protein plays a role in chromatid packaging during spermatid differentiation.			Amino Acid, Peptide, or Protein	
C131148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131148>	C20462	CARD9 Gene|CARD9|CARD9|Caspase Recruitment Domain Family Member 9 Gene	This gene is involved in both innate immunity and apoptosis regulation.			Gene or Genome	
C131149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131149>	C131148	CARD9 wt Allele|CANDF2|Caspase Recruitment Domain Family Member 9 wt Allele|Caspase Recruitment Domain Family, Member 9 Gene|hCARD9	Human CARD9 wild-type allele is located in the vicinity of 9q34 and is approximately 12 kb in length. This allele, which encodes caspase recruitment domain-containing protein 9, plays a role in both the regulation of apoptosis and innate immune responses..			Gene or Genome	
C13114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13114>	C12530	Promyelocyte	A cell of the bone marrow that is derived from myeloblasts and will give rise to myelocytes, precursors of myeloid cells and neutrophil granulocytes.			Cell	
C131150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131150>	C19928	Caspase Recruitment Domain-Containing Protein 9|CARD9|hCARD9	Caspase recruitment domain-containing protein 9 (536 aa, ~62 kDa) is encoded by the human CARD9 gene. This protein is involved in both the modulation of pathogen-triggered signaling pathways and the regulation of apoptosis.			Amino Acid, Peptide, or Protein	
C131151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131151>	C21344	MST1 Gene|MST1|MST1|Macrophage Stimulating 1 Gene	This gene plays a role in both macrophage activation and ciliary motility.			Gene or Genome	
C131152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131152>	C131151	MST1 wt Allele|D3F15S2|DNF15S2|HGFL|MSP|Macrophage Stimulating 1 (Hepatocyte Growth Factor-Like) Gene|Macrophage Stimulating 1 wt Allele|NF15S2	Human MST1 wild-type allele is located in the vicinity of 3p21 and is approximately 6 kb in length. This allele, which encodes hepatocyte growth factor-like protein, is involved in the regulation of both ciliary motility and macrophage activation. Variation in the gene may be associated with inflammatory bowel disease.			Gene or Genome	
C131153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131153>	C20424	Hepatocyte Growth Factor-Like Protein|Hepatocyte Growth Factor-Like|Hepatocyte Growth Factor-Like Protein Homolog|MSP|Macrophage Stimulating Protein|Macrophage Stimulatory Protein|Macrophage-Stimulating Protein	Hepatocyte growth factor-like protein (711 aa, ~80 kDa) is encoded by the human MST1 gene. This protein plays a role in the positive regulation of both macrophage activation and ciliary motility.			Amino Acid, Peptide, or Protein	
C131154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131154>	C20993	PROMIS Sexual Function and Satisfaction Measures|PROMIS SexFS|PROMIS Sexual Function and Satisfaction|SexFS	A questionnaire for self-reported satisfaction with sexual function that includes 79 items in 11 domains: interest in sexual activity, lubrication, vaginal discomfort, erectile function, global satisfaction with sex life, orgasm, anal discomfort, therapeutic aids, sexual activities, interfering factors, and screener questions.			Intellectual Product	
C131155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131155>	C62289	Global Satisfaction with Sex Life Subordinate Domain|Global Satisfaction with Sex Life|Global Satisfaction with Sex Life Domain	The collection of PROMIS item scales that assess self-reported perceptions of overall sexual satisfaction in men and women.			Functional Concept	PROMIS Sexual Function and Satisfaction Measures
C131156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131156>	C62289	Interest in Sexual Activity Subordinate Domain|Interest in Sexual Activity|Interest in Sexual Activity Domain	The collection of PROMIS item scales that assess self-reported perceptions of interest in sexual activity in men and women.			Functional Concept	PROMIS Sexual Function and Satisfaction Measures
C131157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131157>	C62289	Sexual Function and Satisfaction Interfering Factors Subordinate Domain	A subgroup of PROMIS Sexual Function and Satisfaction item scales that assess self-reported perceptions of the degree to which various factors affect satisfaction with sex life in men and women.			Functional Concept	
C131158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131158>	C173792|C173704	How Satisfied with Sex Life Question|How Satisfied with Sex Life|How satisfied have you been with your sex life	A question about how satisfied an individual is or was with their sex life.			Intellectual Product	Global Satisfaction with Sex Life Subordinate Domain
C131159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131159>	C173704	How Much Pleasure Sex Life Gives Question|How Much Pleasure Sex Life Gives|How much pleasure has your sex life given you	A question about how much pleasure an individual gets from their sex.			Intellectual Product	Global Satisfaction with Sex Life Subordinate Domain
C13115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13115>	C12530	Myelocyte	A cell derived from a promyelocyte. It differentiates into a metamyelocyte. It has a diameter of 10-18 micrometer, and an oval or round nucleus with finely granulated chromatin.			Cell	
C131160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131160>	C173597|C118873	How Often Thought Sex Life is Wonderful Question|How Often Thought Sex Life is Wonderful|How often have you thought that your sex life is wonderful	A question about how often an individual thinks or thought their sex life was wonderful.			Intellectual Product	Global Satisfaction with Sex Life Subordinate Domain
C131161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131161>	C173792|C173704	How Satisfied with Sexual Relationship with Partner Question|How Satisfied with Sexual Relationship with Partner|How satisfied have you been with your sexual relationship with a partner	A question about how satisfied an individual is or was with their sexual relationship with their partner.			Intellectual Product	Global Satisfaction with Sex Life Subordinate Domain
C131162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131162>	C173704	How Much Enjoyment from Sexual Activity Question|How Much Enjoyment from Sexual Activity|When you have had sexual activity, how much have you enjoyed it	A question about how much an individual enjoys or enjoyed sexual activity.			Intellectual Product	Global Satisfaction with Sex Life Subordinate Domain
C131163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131163>	C173792|C173704	How Satisfied with Sexual Activity Question|How Satisfied with Sexual Activity|When you have had sexual activity, how satisfying has it been	A question about how satisfied an individual is or was with their sexual activity.			Intellectual Product	Global Satisfaction with Sex Life Subordinate Domain
C131164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131164>	C173704	How Interested in Sexual Activity Question|How Interested in Sexual Activity|How interested have you been in sexual activity	A question about how interested an individual is or was in sexual activity.			Intellectual Product	Interest in Sexual Activity Subordinate Domain
C131165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131165>	C173704|C173160|C118873	How Often Feel Like Want to Have Sex Question|How Often Feel Like Having Sex|How Often Feel Like Want to Have Sex|How Often Feel Want to Have Sex|How often have you felt like you wanted to have sex	A question about how often an individual feels or felt like they wanted to have sex.			Intellectual Product	Interest in Sexual Activity Subordinate Domain
C131166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131166>	C173597|C118873	How Often Have Sexual Thoughts or Fantasies While Awake Question|How Often Have Sexual Thoughts or Fantasies While Awake|How often have you had sexual thoughts or fantasies while you were awake	A question about how often an individual has or had sexual fantasies while awake.			Intellectual Product	Interest in Sexual Activity Subordinate Domain
C131167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131167>	C118873	How Often Interested Enough to Start Sexual Activity Question|How Often Interested Enough to Start Sexual Activity|How often were you interested enough to start a sexual activity	A question about how often an individual is or was interested enough to start a sexual activity.			Intellectual Product	Interest in Sexual Activity Subordinate Domain
C131168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131168>	C173792|C173704|C173347	How Much Fatigue or Lack of Energy Affects Satisfaction with Sex Life Question|How Much Fatigue or Lack of Energy Affects Satisfaction with Sex Life|How much has fatigue or lack of energy affected your satisfaction with your sex life	A question about how much an individual's fatigue or lack of energy affects or affected satisfaction with their sex life.			Intellectual Product	Sexual Function and Satisfaction Interfering Factors Subordinate Domain
C131169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131169>	C178374	Past 30 Days No Partner|Have not had a partner in the past 30 days|No Partner Past 30 Days	A response indicating that an individual has not had a partner in the past 30 days.			Intellectual Product	PROMIS Sexual Function and Satisfaction Measures
C13116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13116>	C12530	Metamyelocyte	A cell derived from a promyelocyte and differentiates into a neutrophil. It is nonproliferative and is usually found in bone marrow. Its nucleus is indented and the chromatin clumped and dense.			Cell	
C131170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131170>	C226663	Past 30 Days No Fatigue or Lack of Energy|Have not had fatigue or lack of energy in the past 30 days|No Fatigue or Lack of Energy Past 30 Days	A response indicating that an individual has not had fatigue or lack of energy in the past 30 days.			Intellectual Product	PROMIS Sexual Function and Satisfaction Measures
C131171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131171>	C20194	UBASH3A Gene|UBASH3A|UBASH3A|Ubiquitin Associated and SH3 Domain Containing A Gene	This gene may be involved in the negative regulation of T-cell receptor signaling.			Gene or Genome	
C131172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131172>	C131171	UBASH3A wt Allele|CLIP4|STS-2|STS2|TULA|TULA-1|Ubiquitin Associated and SH3 Domain Containing A wt Allele	Human UBASH3A wild-type allele is located in the vicinity of 21q22.3 and is approximately 44 kb in length. This allele, which encodes ubiquitin-associated and SH3 domain-containing protein A, may play a role in the modulation of T-cell receptor signaling pathways.			Gene or Genome	
C131173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131173>	C18466	Ubiquitin-Associated and SH3 Domain-Containing Protein A|CLIP4|Cbl-Interacting Protein 4|STS-2|Suppressor of T-Cell Receptor Signaling|T-Cell Ubiquitin Ligand 1|T-Cell Ubiquitin Ligand Protein|TULA-1	Ubiquitin-associated and SH3 domain-containing protein A (661 aa, ~74 kDa) is encoded by the human UBASH3A gene. This protein may be involved in the inhibition of T-cell receptor signaling.			Amino Acid, Peptide, or Protein	
C131174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131174>	C129823	Anti-CD352 Antibody-drug Conjugate SGN-CD352A|ADC SGN-CD352A|PBD Dimer ADC SGN-CD352A|PBD-based Anti-CD352 ADC SGN-CD352A|PBD-based Anti-CD352 Antibody-drug Conjugate SGN-CD352A|SGN-CD352A|SGN-CD352A	An antibody-drug conjugate (ADC) consisting of an engineered cysteine humanized monoclonal antibody (EC-mAb) targeting CD352 (SLAM family member 6; SLAM6) that is conjugated to the cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of anti-CD352 ADC SGN-CD352A, the antibody moiety targets the cell surface antigen CD352. Upon antibody/antigen binding, internalization, and lysosome uptake, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of CD352-overexpressing tumor cells. CD352, a tumor-associated antigen (TAA), is overexpressed on a variety of cancers. Cysteine engineering of the monoclonal antibody allows for a site-specific, stable conjugation and uniform loading of the PBD agent to the antibody.	Anti-CD352 Antibody-drug Conjugate SGN-CD352A		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131175>	C199386	Anti-EGFR/HER2/HER3 Monoclonal Antibody Mixture Sym013|Pan-HER mAb Mixture Sym013|Sym-013|Sym013|pan-HER Antibody Mixture Sym013	An antibody mixture composed of six humanized, immunoglobulin G1 (IgG1) monoclonal antibodies directed against three members of the human epidermal growth factor receptor (EGFR; HER) family: EGFR (HER1; ErbB1), HER2 (ErbB2) and HER3 (ErbB3), with potential antineoplastic activity. Upon administration of anti-EGFR/HER2/HER3 monoclonal antibody mixture Sym013, the six antibodies bind to non-overlapping epitopes on EGFR, HER2 and HER3, which prevents both ligand binding and receptor activation, and induce simultaneous down-modulation of EGFR, HER2 and HER3.  This inhibits the activation of HER-dependent signaling pathways and HER-dependent tumor cell proliferation. Overexpression of the HER family plays a key role in many cancers; targeting multiple HER family members simultaneously may increase therapeutic efficacy.	Anti-EGFR/HER2/HER3 Monoclonal Antibody Mixture Sym013		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131176>	C27992	Immune-mediated	Resulting from the activity of the immune system.			Qualitative Concept	
C131177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131177>	C308	Eragidomide|CC 90009|CC-90009|Cereblon Modulator CC-90009|ERAGIDOMIDE	A modulator of cereblon (CRBN), which is part of the cullin 4-RING E3 ubiquitin ligase complex (CRL4-CRBN E3 ubiquitin ligase; CUL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and pro-apoptotic activities. Upon administration, eragidomide specifically binds to CRBN, thereby affecting the activity of the ubiquitin E3 ligase complex. This leads to the ubiquitination of certain substrate proteins and induces the proteasome-mediated degradation of certain transcription factors, including Ikaros (IKZF1) and Aiolos (IKZF3), which are transcriptional repressors in T-cells. This reduces the levels of these transcription factors, and modulates the activity of the immune system, which may include the activation of T-lymphocytes. In addition, this downregulates the expression of other proteins, including interferon regulatory factor 4 (IRF4) and c-myc, which plays a key role in the proliferation of certain cancer cell types. CRBN, the substrate recognition component of the E3 ubiquitin ligase complex, plays a key role in the ubiquitination of certain proteins.	Eragidomide		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131178>	C62554	Rucaparib Camsylate|8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-pyrrolo(4,3,2-ef)(2)benzazepin-6-one (7,7-dimethyl-2-oxobicyclo(2.2.1)heptan-1-yl)methanesulfonate (1:1)|8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic Acid Salt|Bicyclo(2.2.1)heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (1S,4R)-, Compound with 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-6H-pyrrolo(4,3,2-ef)(2)benzazepin-6-one (1:1)|CO 338|CO-338|CO338|RUCAPARIB CAMSYLATE|Rubraca	The camsylate salt form of rucaparib, an orally bioavailable tricyclic indole and inhibitor of poly(ADP-ribose) polymerases (PARPs) 1 (PARP1), 2 (PARP2) and 3 (PARP3), with potential chemo/radiosensitizing and antineoplastic activities. Upon administration, rucaparib selectively binds to PARP1, 2 and 3 and inhibits PARP-mediated DNA repair. This enhances the accumulation of DNA strand breaks, promotes genomic instability and induces cell cycle arrest and apoptosis. This may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy. PARPs are enzymes activated by single-strand DNA breaks that catalyze the post-translational ADP-ribosylation of nuclear proteins, which induces signaling and the recruitment of other proteins to repair damaged DNA. The PARP-mediated repair pathway plays a key role in DNA repair and is dysregulated in a variety of cancer cell types.	Rucaparib Camsylate		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131179>	C189956|C127129	MET Exon 14 Skipping Mutation|Deletion of MET Exon 14|Deletion of c-MET Exon 14|HGFR Exon 14 Skipping Alteration|HGFR Exon 14 Skipping Mutation|HGFR Exon 14 Splice Mutation|Loss of MET Exon 14|Loss of c-MET Exon 14|MET Exon 14 Deletion Mutation|MET Exon 14 Skipping Alteration|MET Exon 14 Splice Mutation|MET Proto-Oncogene, Receptor Tyrosine Kinase Exon 14 Skipping Alteration|MET Proto-Oncogene, Receptor Tyrosine Kinase Exon 14 Skipping Mutation|MET exon 14 deletion detected|Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Exon 14 Skipping Alteration|Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Exon 14 Skipping Mutation|Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Exon 14 Splice Mutation|c-MET Exon 14 Deletion Mutation|c-MET Exon 14 Splice Mutation|c-Met Exon 14 Skipping Alteration|c-Met Exon 14 Skipping Mutation	A molecular genetic abnormality indicating the presence of a splice site mutation that results in a loss of transcription of exon 14 of the MET gene.	MET Exon 14 Skipping Mutation		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13117>	C12530	Band Cell	A late precursor of a granulocyte in which the nucleus is in the form of a curved or coiled band, not having acquired the typical multilobar shape of the mature polymorphonuclear neutrophil.			Body Part, Organ, or Organ Component	
C131180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131180>	C20923	GPR35 Gene|G Protein-Coupled Receptor 35 Gene|GPR35|GPR35	This gene plays a role in kynurenic acid-dependent signaling.			Gene or Genome	
C131181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131181>	C21514	a.m.|Anti Meridiem	The time period between midnight and noon.			Qualitative Concept	
C131182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131182>	C131180	GPR35 wt Allele|CXCR8|Chemokine, CXC Motif, Receptor 8 Gene|G Protein-Coupled Receptor 35 wt Allele	Human GPR35 wild-type allele is located in the vicinity of 2q37.3 and is approximately 26 kb in length. This allele, which encodes G-protein coupled receptor 35 protein, is involved in kynurenic acid binding.			Gene or Genome	
C131183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131183>	C21514	p.m.|Post Meridiem	The time period between noon and midnight.			Qualitative Concept	
C131184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131184>	C18239	G-Protein Coupled Receptor 35|G Protein-Coupled Receptor 35|KYNA Receptor|Kynurenic Acid Receptor	G-protein coupled receptor 35 (309 aa, ~34 kDa) is encoded by the human GPR35 gene. This protein plays a role in kynurenic acid-dependent G protein-coupled receptor signaling.			Amino Acid, Peptide, or Protein	
C131185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131185>	C21295	RAVER1 Gene|RAVER1|RAVER1|Ribonucleoprotein, PTB Binding 1 Gene	This gene is involved in alternative splicing.			Gene or Genome	
C131186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131186>	C131185	RAVER1 wt Allele|KIAA1978|RAVER1, Mouse, Homolog of Gene|Ribonucleoprotein, PTB Binding 1 wt Allele|Ribonucleoprotein, PTB-Binding 1 Gene	Human RAVER1 wild-type allele is located in the vicinity of 19p13.2 and is approximately 17 kb in length. This allele, which encodes ribonucleoprotein PTB-binding 1 protein, plays a role in the regulation of alternative splicing.			Gene or Genome	
C131187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131187>	C27565	Pycnodysostosis	An autosomal recessive disorder caused by loss-of-function mutation(s) in the CTSK gene, encoding cathepsin K, an enzyme involved in bone resorption by osteoclasts. This condition is characterized by some or all of the following: osteosclerosis, short stature, pituitary hypoplasia with growth hormone deficiency, and cerebral demyelination.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131188>	C21298	Ribonucleoprotein PTB-Binding 1|Protein Raver-1|RAVER1	Ribonucleoprotein PTB-binding 1 (606 aa, ~64 kDa) is encoded by the human RAVER1 gene. This protein is involved in RNA binding and alternative splicing.			Amino Acid, Peptide, or Protein	
C131189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131189>	C20194	ZNF365 Gene|ZNF365|ZNF365|Zinc Finger Protein 365 Gene	This gene may play a role in uric acid excretion and gamma-tubulin localization.			Gene or Genome	
C13118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13118>	C12535	Immature Lymphocyte	A cell that develops from hematopoietic stem cells. An immature lymphocyte represents of one of five stages of lymphocyte maturation. It is estimated 90% of immature lymphocytes die in the thymus and bone marrow.			Cell	
C131190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131190>	C131189	ZNF365 wt Allele|KIAA0844|Su48|TALN|UAN|ZNF365A|ZNF365B|ZNF365C|ZNF365D|Zinc Finger Protein 365 wt Allele	Human ZNF365 wild-type allele is located in the vicinity of 10q21.2 and is approximately 298 kb in length. This allele, which encodes both protein ZNF365 and talanin protein, may be involved in gamma-tubulin localization and uric acid secretion. Mutation of the gene is associated with increased susceptibility to uric acid nephrolithiasis.			Gene or Genome	
C131191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131191>	C18466	ZNF365 Gene Product	A protein encoded by the ZNF365 gene.			Amino Acid, Peptide, or Protein	
C131192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131192>	C131191	Talanin|ZNF365D|Zinc Finger Protein 365 Isoform 4|Zinc Finger Protein 365 Isoform D	Talanin (216 aa, ~24 kDa) is encoded by the human ZNF365 gene. This protein may play a role in the excretion of uric acid and the localization of gamma-tubulin.			Amino Acid, Peptide, or Protein	
C131193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131193>	C50680	Progressive Heterotopic Heteroplasia|Osteoma Cutis|Progressive Osseous Heteroplasia	Loss of function mutation(s) in the paternal allele of the GNAS gene, encoding guanine nucleotide-binding protein G(s) subunit alpha isoforms short resulting in dermal ossification beginning in infancy, followed by increasing and extensive heterotopic bone formation in deep muscle and fascia.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C131194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131194>	C131191	Protein ZNF365|Protein Su48|ZNF365A|Zinc Finger Protein 365|Zinc Finger Protein 365 Isoform 1|Zinc Finger Protein 365 Isoform A	Protein ZNF365 (407 aa, ~47 kDa) is encoded by the human ZNF365 gene. This protein may be involved in the localization of gamma-tubulin.			Amino Acid, Peptide, or Protein	
C131195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131195>	C131080	Primary Testicular Failure|Hypergonadotropic Hypogonadism (Male)|Male Hypergonadotropic Hypogonadism	Testicular failure due to a condition directly affecting the testes.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C131196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131196>	C127165	Primary Pigmented Nodular Adrenal Dysplasia|PPNAD|PPNAD	A subtype of micronodular adrenal hyperplasia, characterized by multiple pigmented nodules, which may occur in isolation or as part of the Carney complex.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C131197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131197>	C20744	LCE3B Gene|LCE3B|LCE3B|Late Cornified Envelope 3B Gene	This gene is involved in epidermal keratinization.			Gene or Genome	
C131198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131198>	C131197	LCE3B wt Allele|LEP14|Late Cornified Envelope 3B wt Allele	Human LCE3B wild-type allele is located in the vicinity of 1q21.3 and is approximately 1 kb in length. This allele, which encodes late cornified envelope protein 3B, plays a role in the keratinization of the epidermis. Variation of the gene may be associated with psoriatic arthritis.			Gene or Genome	
C131199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131199>	C18073	Late Cornified Envelope Protein 3B|Late Envelope Protein 14	Late cornified envelope protein 3B (95 aa, ~10 kDa) is encoded by the human LCE3B gene. This protein is involved in keratin formation in the epidermis.			Amino Acid, Peptide, or Protein	
C13119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13119>	C12535	Prolymphocyte	A medium-sized round lymphocyte of B or T-cell lineage with prominent nucleoli.  It is an intermediate cell between the lymphoblast and the small, mature lymphocyte.			Cell	
C1311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1311>	C146638	Tacrolimus|FK 506|FK-506|FK506|Fujimycin|Hecoria|Hexadecahydro-5,19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone|Hexadecahydro-5,19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone|Prograf|Protopic|TACROLIMUS|Tacforius|tacrolimus	A macrolide isolated from Streptomyces tsukubaensis. Tacrolimus binds to the FKBP-12 protein and forms a complex with calcium-dependent proteins, thereby inhibiting calcineurin phosphatase activity and resulting in decreased cytokine production. This agent exhibits potent immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation. Tacrolimus possesses similar immunosuppressive properties to cyclosporine, but is more potent.	Tacrolimus		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C131200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131200>	C20194	NXPE1 Gene|NXPE1|NXPE1|Neurexophilin and PC-Esterase Domain Family Member 1 Gene	This gene may play a role in lipid metabolism.			Gene or Genome	
C131201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131201>	C131200	NXPE1 wt Allele|FAM55A|Family With Sequence Similarity 55, Member A Gene|Neurexophilin and PC-Esterase Domain Family Member 1 wt Allele|Neurexophilin and PC-Esterase Domain Family, Member 1 Gene	Human NXPE1 wild-type allele is located in the vicinity of 11q23.2 and is approximately 42 kb in length. This allele, which encodes NXPE family member 1 protein, may be involved in lipid metabolism.			Gene or Genome	
C131202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131202>	C18466	NXPE Family Member 1|Protein FAM55A	NXPE family member 1 (547 aa, ~63 kDa) is encoded by the human NXPE1 gene. This protein may play a role in the metabolism of lipids.			Amino Acid, Peptide, or Protein	
C131203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131203>	C20462	BECN2 Gene|BECN2|BECN2|Beclin 2 Gene	This gene is involved in autophagy and G protein-coupled receptor turnover.			Gene or Genome	
C131204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131204>	C131203	BECN2 wt Allele|BECN1L1|BECN1P1|Beclin 1, Autophagy Related, Pseudogene 1 Gene|Beclin 2 wt Allele|Beclin-1 Autophagy-Related Pseudogene 1 Gene	Human BECN2 wild-type allele is located in the vicinity of 1q43 and is approximately 1 kb in length. This allele, which encodes beclin-2 protein, plays a role in the regulation of both G protein-coupled receptor catabolism and autophagy.			Gene or Genome	
C131205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131205>	C19928	Beclin-2|Beclin 1-Like Protein 1|Beclin 2|Beclin-1 Autophagy-Related Pseudogene 1 Protein|Beclin-1-Like Protein 1	Beclin-2 (431 aa, ~48 kDa) is encoded by the human BECN2 gene. This protein is involved in both autophagy and the catabolism of G protein-coupled receptors.			Amino Acid, Peptide, or Protein	
C131206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131206>	C20194	SAMMSON Gene|SAMMSON|SAMMSON|Survival Associated Mitochondrial Melanoma Specific Oncogenic Non-Coding RNA Gene	This gene plays a role in melanoma cell survival.			Gene or Genome	
C131207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131207>	C131206	SAMMSON wt Allele|LINC01212|LincRNA 1212|Long Intergenic Non-Protein Coding RNA 1212 Gene|Long Intergenic Noncoding RNA 1212 Gene|Survival Associated Mitochondrial Melanoma Specific Oncogenic Non-Coding RNA (Sammson), Long Non-Coding RNA Gene|Survival Associated Mitochondrial Melanoma Specific Oncogenic Non-Coding RNA wt Allele|Survival-Associated Mitochondrial Melanoma-Specific Oncogenic Noncoding RNA Gene	Human SAMMSON wild-type allele is located in the vicinity of 3p13 and is approximately 16 kb in length. This allele, which encodes survival associated mitochondrial melanoma specific oncogenic non-coding RNA, is involved in the positive regulation of melanoma cell survival.			Gene or Genome	
C131208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131208>	C88924	Survival Associated Mitochondrial Melanoma Specific Oncogenic Non-Coding RNA|LINC01212|LincRNA 1212|Long Intergenic Non-Protein Coding RNA 1212|Long Intergenic Noncoding RNA 1212|SAMMSON|Survival-Associated Mitochondrial Melanoma-Specific Oncogenic Noncoding RNA	Survival associated mitochondrial melanoma specific oncogenic non-coding RNA (~2 kb) is encoded by the human SAMMSON gene. This plays a role in the maintenance of mitochondria in melanoma cells.			Nucleic Acid, Nucleoside, or Nucleotide	
C131209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131209>	C3796|C182019	Recurrent Gliosarcoma	The reemergence of gliosarcoma after a period of remission.	Recurrent Gliosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13120>	C12547	Immature Monocyte	A cell derived from a myeloid stem cell. It is the representation of one stage of monocyte development.			Cell	
C131211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131211>	C2124	Carbon C 11 Pittsburgh Compound B|11 Carbon Pittsburgh Compound B|11C-PIB|11C-PiB|C11 Pittsburgh Compound B|C11-PiB|PIB C-11|[11C]PiB|[N-methyl-11C]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole	A radioconjugate composed of the beta-amyloid binding agent Pittsburgh compound B (PiB), a derivative of the amyloid-binding dye thioflavin T (ThT), that is conjugated to the radioisotope carbon C11, with potential amyloid imaging activity upon positron emission tomography (PET). Upon administration of carbon C 11 PiB, the PiB moiety targets and binds to beta-amyloid plaques in the brain, which can then be detected and analyzed using PET imaging. Increased production and concentration of amyloid beta protein and the deposition of amyloid plaques in the brain are correlated with the cognitive decline seen in neurodegenerative diseases, such as dementia, Alzheimer's disease (AD) and chemotherapy-induced cognitive impairment (CICI).	Carbon C 11 Pittsburgh Compound B		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C131213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131213>	C61078	Nab-paclitaxel/Rituximab-coated Nanoparticle AR160|AR160|Abraxane Coated with Rituximab 160nm Nanoparticle|Abraxane coated with Rituximab|Abraxane/Rituxan 160 Complex	A formulation composed of nanoparticle albumin-bound (nab) paclitaxel, which is an albumin-stabilized nanoparticle containing the natural taxane paclitaxel, non-covalently coated with rituximab, a recombinant chimeric murine/human antibody directed against the CD20 antigen found on B-lymphocytes, with potential antineoplastic activity. Upon administration of nab-paclitaxel/rituximab nanoparticle AR160, the rituximab moiety specifically binds to CD20 and targets this formulation to CD20-positive tumor cells. Paclitaxel binds to and stabilizes microtubules, which prevents depolymerization and inhibits cellular motility, mitosis, and replication. This leads to cell death of the CD20-expressing tumor cells that were targeted by this agent. The combination of albumin-stabilization and rituximab-targeting allows for higher efficacy and decreased paclitaxel-induced toxicity as it specifically targets CD20-expressing tumor cells. Rituximab may also induce complement-dependent cytotoxicity and antibody-dependent cellular toxicity.	Nab-paclitaxel/Rituximab-coated Nanoparticle AR160		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131214>	C200766|C176018	Autologous iCasp9-deltaNGFR-CD19CAR-expressing T Cells|Autologous ICASP9-deltaNGFR-CD19CAR-expressing T-Lymphocytes|Autologous iC9.2A.deltaNGFR.2A.CAR.CD19 T Cells	A preparation of autologous T-lymphocytes that are transduced with a retroviral vector encoding a chimeric antigen receptor (CAR) specific for the CD19 antigen, the suicide gene, inducible human caspase 9 (iCasp9 or iC9), and a truncated low-affinity nerve growth factor receptor (deltaNGFR), with potential immunomodulating and antineoplastic activities. The iCasp9 construct consists of the entire coding sequence for the human FK506-drug binding protein (FKBP12) with an F36V mutation (FKBP12-F36V) that is linked to the gene encoding human caspase 9, which is deleted of its endogenous caspase activation and recruitment domains. Upon intravenous administration, autologous iCasp9-deltaNGFR-CD19CAR-expressing T cells are selectively toxic to CD19-expressing tumor cells. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered, which binds to the FKBP12-F36V drug binding domain, activates caspase 9, and results in apoptosis of the administered CAR19 T-cells. The CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Prior to administration, deltaNGFR, is used to select the CAR19-transduced T-cells for further enrichment by flow cytometry using an anti-NGFR antibody.	Autologous iCasp9-deltaNGFR-CD19CAR-expressing T Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131215>	C2848|C1455	Montanide ISA-51 VG/KLH/NY-ESO-1/MART-1 Peptide Vaccine|Montanide ISA-51 VG/KLH/NY-ESO-1/MART-1 Vaccine|NY-ESO-1/MART-1/KLH/Montanide ISA-51 VG Vaccine	A cancer vaccine consisting of two immunogenic peptides derived from the cancer-testis antigen NY-ESO-1 and the melanoma differentiation antigen Melan-A (MART-1; Melanoma Antigen Recognized by T-cells 1), which are conjugated with the immunostimulant keyhole limpet hemocyanin (KLH) and emulsified in the immunoadjuvant Montanide ISA-51 VG, with potential immunomodulating and antineoplastic activities. Upon subcutaneous vaccination, the Montanide ISA-51 VG/KLH/NY-ESO-1/MART-1 peptide vaccine stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the NY-ESO-1 and Melan-A antigens, resulting in tumor cell lysis. NY-ESO-1 and Melan-A are overexpressed in a variety of tumor cell types. The surfactant mannide monooleate in Montanide ISA 51 VG is derived from vegetable-grade (VG) oleic acid that was purified from olive oil. KLH is a hapten carrier and serves as an immunostimulant to improve immune recognition.	Montanide ISA-51 VG/KLH/NY-ESO-1/MART-1 Peptide Vaccine		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCIt Antineoplastic Agent Terminology
C131216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131216>	C147564	Pituitary Resistance to Thyroid Hormone|PitRTH|PitRTH	Decreased response to thyroid hormones in the pituitary gland with normal response in peripheral tissues.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C131217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131217>	C94299|C177692	CRLF2 Positive|Cytokine Receptor-Like Factor 2 Positive|TSLPR Positive|Thymic Stromal-Derived Lymphopoietin Receptor Positive	An indication that CRLF2 expression has been detected in a sample.	CRLF2 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131218>	C7508|C6166|C157631	Recurrent Urethral Urothelial Carcinoma|Recurrent Urethral Urothelial Cancer|Recurrent Urothelial Carcinoma of the Urethra	The reemergence of urethral urothelial carcinoma after a period of remission.	Recurrent Urethral Urothelial Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C131219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131219>	C25873	SLK Gene|SLK|SLK|STE20 Like Kinase Gene	This gene is involved in protein phosphorylation and apoptosis.			Gene or Genome	
C13121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13121>	C13120	Promonocyte|Premonocyte	An immature cell of the mononuclear phagocytic system. It is the representation of one stage of monocyte development.			Cell	
C131220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131220>	C131219	SLK wt Allele|KIAA0204|LOSK|SNF1 (Sucrose Nonfermenting, Yeast, Homolog)-Like Kinase Gene|SNF1 (Sucrose Nonfermenting, Yeast, Homolog)-Like Kinase, SNF1 Sucrose Nonfermenting Like Kinase (Yeast) Gene|SNF1 (Sucrose Nonfermenting, Yeast, Homolog)-Like Kinase, SNF1 Sucrose Nonfermenting Like Kinase Gene|SNF1 Sucrose Nonfermenting Like Kinase (Yeast) Gene|SNF1 Sucrose Nonfermenting Like Kinase Gene|STE20 Like Kinase wt Allele|STE20-Like Kinase (Yeast) Gene|STK2|bA16H23.1|se20-9	Human SLK wild-type allele is located in the vicinity of 10q25.1 and is approximately 62 kb in length. This allele, which encodes STE20-like serine/threonine-protein kinase protein, plays a role in both apoptosis and protein phosphorylation.			Gene or Genome	
C131221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131221>	C17325	STE20-Like Serine/Threonine-Protein Kinase|CTCL Tumor Antigen Se20-9|EC 2.7.11.1|Long Ste20-Like Kinase|SNF1 Sucrose Nonfermenting Like Kinase|STE20-Like Kinase|STE20-Like Protein Kinase|STE20-Related Kinase|STE20-Related Serine/Threonine-Protein Kinase|Serine/Threonine-Protein Kinase 2|Ste20-Related Serine/Threonine Kinase|hSLK	STE20-like serine/threonine-protein kinase (1235 aa, ~143 kDa) is encoded by the human SLK gene. This protein is involved in both serine/threonine phosphorylation and apoptosis regulation.			Amino Acid, Peptide, or Protein|Enzyme	
C131222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131222>	C82556	Reason Form Not Complete|Reason parent did not complete	A question about why a form or questionnaire was not completed.			Idea or Concept	
C131223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131223>	C173398|C173135	Hard to Walk More Than One Block Question|Hard to Walk More Than One Block|Is it hard for you to walk|It is hard for me to walk more than one block|Walking|Walking more than one block	A question about whether it is or was hard for an individual to walk more than one block.			Intellectual Product	
C131224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131224>	C20917	STAG1 Gene|STAG1|STAG1|STAG1|Stromal Antigen 1 Gene	This gene plays a role in sister chromatid binding.			Gene or Genome	GDC Terminology|GDC Value Terminology
C131225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131225>	C173458|C173398	Hard to Run Question|Hard to Run|Is it hard for you to run|It is hard for me to run|Running	A question about whether it is or was hard for an individual to run.			Intellectual Product	
C131226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131226>	C131224	STAG1 wt Allele|SA-1|SA1|SCC3A|Stromal Antigen 1 wt Allele	Human STAG1 wild-type allele is located in the vicinity of 3q22.3 and is approximately 416 kb in length. This allele, which encodes cohesin subunit SA-1 protein, is involved in sister chromatid cohesion.			Gene or Genome	
C131227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131227>	C173458|C173398	Hard to do Sports Activity or Exercise Question|Hard to do Sports Activity or Exercise|Is it hard for you to play sports or exercise|It is hard for me to do sports activity or exercise|Participating in active play or exercise|Participating in sports activity or exercise	A question about whether it is or was hard for an individual to do sports activities or exercise.			Intellectual Product	
C131228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131228>	C17761	Cohesin Subunit SA-1|Nuclear Protein Stromal Antigen 1|SCC3 Homolog 1|STAG1|Stromal Antigen 1	Cohesin subunit SA-1 (1258 aa, ~144 kDa) is encoded by the human STAG1 gene. This protein plays a role in the cohesion of sister chromatids.			Amino Acid, Peptide, or Protein	
C131229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131229>	C173398	Hard to Lift Something Heavy Question|Hard to Lift Something Heavy|Is it hard for you to pick up big things|It is hard for me to lift something heavy|Lifting something heavy	A question about whether it is or was hard for an individual to lift something heavy.			Intellectual Product	
C13122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13122>	C12918|C12549	Megakaryoblast|Megacaryoblast	The precursor of a megakaryocyte.			Cell	
C131230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131230>	C173398|C131925	Hard to Bathe or Shower Question|Bathing|Hard to Bathe or Shower|Is it hard for you to take a bath or shower|It is hard for me to take a bath or shower by myself|Taking a bath or shower by him or herself	A question about whether it is or was hard for an individual to bathe or shower.			Intellectual Product	
C131231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131231>	C173398	Hard to do Chores Question|Doing chores around the house|Doing chores, like picking up his or her toys|Hard to do Chores|Helping to pick up his or her toys|Is it hard for you to do chores (like pick up your toys)|It is hard for me to do chores around the house	A question about whether it is or was hard for an individual to do chores.			Intellectual Product	
C131232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131232>	C173219	Hurt or Ache Question|Do you have hurts or aches (Where?)|Having hurts or aches|Hurt or Ache|Hurting or Aching|I hurt or ache	A question about whether an individual has or had hurts or aches.			Intellectual Product	
C131233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131233>	C173160	Feel Afraid or Scared Question|Do you feel scared|Feel Afraid or Scared|Feeling afraid or scared|I feel afraid or scared	A question about whether an individual feels or felt afraid or scared.			Intellectual Product	
C131234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131234>	C173160	Feel Sad or Blue Question|Do you feel sad|Feel Sad or Blue|Feeling sad or blue|I feel sad or blue	A question about whether an individual feels or felt sad or blue.			Intellectual Product	
C131235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131235>	C173160	Feel Angry Question|Do you feel mad|Feel Angry|Feel mad|Feeling angry|I feel angry	A question about whether an individual feels or felt angry.			Intellectual Product	
C131236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131236>	C173934	Worry About What Will Happen Question|Do you worry about what will happen to you|I worry about what will happen to me|Worry About What Will Happen|Worrying|Worrying about what will happen to him or her	A question about whether an individual worries or worried about what will happen.			Intellectual Product	
C131237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131237>	C21275	PITRM1 Gene|PITRM1|PITRM1|Pitrilysin Metallopeptidase 1 Gene	This gene is involved in mitochondrial peptide degradation.			Gene or Genome	
C131238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131238>	C131237	PITRM1 wt Allele|KIAA1104|MP1|Metalloprotease 1 (Pitrilysin Family) Gene|Pitrilysin Metallopeptidase 1 wt Allele|PreP	Human PITRM1 wild-type allele is located in the vicinity of 10p15.2 and is approximately 35 kb in length. This allele, which encodes presequence protease, mitochondrial protein, plays a role in peptide degradation.			Gene or Genome	
C131239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131239>	C173398	Trouble Getting Along with Others Question|Getting along with other children|Getting along with other teens|I have trouble getting along with other kids|I have trouble getting along with other teens|Is it hard for you to get long with other kids|Playing with other children|Trouble Getting Along with Others	A question about whether an individual has or had trouble getting along with others.			Intellectual Product	
C13123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13123>	C33058	Memory B-Lymphocyte|Memory B Cell|Memory B Lymphocyte|Memory B-Cell	A subset of mature B-lymphocytes that are formed during primary antigen exposure, survive for many years after the infection has resolved and maintain specificity toward the primary antigen. These cells can quickly produce a large amount of antigen-specific antibodies in response to a subsequent exposure.	Memory B-Lymphocyte		Cell	CTRP Biomarker Terminology|CTRP Terminology
C131240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131240>	C16843	Presequence Protease, Mitochondrial|EC 3.4.24.-|Metalloendoprotease 1|Metalloprotease 1|PITRM1|Pitrilysin Metallopeptidase 1|Pitrilysin Metalloproteinase 1|PreP Peptidasome|Presequence Protease|hMP1|hPreP	Presequence protease, mitochondrial (1037 aa, ~117 kDa) is encoded by the human PITRM1 gene. This protein is involved in the catabolism of mitochondrial peptides.			Amino Acid, Peptide, or Protein|Enzyme	
C131241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131241>	C91102	Others Not Want to be Friends Question|Do other kids say they do not want to play with you|Other kids do not want to be my friend|Other kids not wanting to be his or her friend|Other kids not wanting to play with him or her|Other teens do not want to be my friend|Other teens not wanting to be his or her friend|Others Not Want to be Friends	A question about whether others do not want to be friends with an individual.			Intellectual Product	
C131242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131242>	C91102	Others Tease Me Question|Do other kids tease you|Getting teased by other children|Getting teased by other teens|Other kids tease me|Other teens tease me|Others Tease Me	A question about whether others tease an individual.			Intellectual Product	
C131243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131243>	C173890	Cannot Do Things Others Same Age Can Question|Can other kids do things that you cannot do|Cannot Do Things Others Same Age Can|I cannot do things that other kids my age can do|I cannot do things that other teens my age can do|Not able to do things that other children his or her age can do|Not able to do things that other teens his or her age can do	A question about whether an individual can do the same things as others their age.			Intellectual Product	
C131244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131244>	C173890|C173458|C173398	Hard to Keep up with Peers Question|Hard to Keep up with Peers|Is it hard for you to keep up when you play with other kids|It is hard to keep up when I play with other kids|It is hard to keep up with my peers|Keeping up when playing with other children|Keeping up with other teens	A question about whether it is hard for an individual to keep up with peers.			Intellectual Product	
C131245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131245>	C173398	Hard to Pay Attention in Class Question|Hard to Pay Attention in Class|Is it hard for you to pay attention in school|It is hard to pay attention in class|Paying attention in class	A question about whether it is hard for an individual to pay attention in class.			Intellectual Product	
C131246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131246>	C176020	Forget Things Question|Do you forget things|Forget Things|Forgetting things|I forget things	A question about whether an individual forgets things.			Intellectual Product	
C131247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131247>	C173398	Have Trouble Keeping Up with Schoolwork Question|Doing the same school activities as peers|Have Trouble Keeping Up with Schoolwork|I have trouble keeping up with my schoolwork|Is it hard to keep up with schoolwork|Keeping up with school activities|Keeping up with schoolwork	A question about whether an individual has trouble keeping up with schoolwork.			Intellectual Product	
C131248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131248>	C173160	Miss School Because of Not Feeling Well Question|Do you miss school because of not feeling good|I miss school because of not feeling well|Miss School Because of Not Feeling Well|Missing school because of not feeling well|Missing school/daycare because of not feeling well	A question about whether an individual misses school because of not feeling well.			Intellectual Product	
C131249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131249>	C173145	Miss School to go to Doctor or Hospital Question|Do you miss school because you have to go to the doctors or hospital|I miss school to go to the doctor or hospital|Miss School to go to Doctor or Hospital|Missing school to go to the doctor or hospital|Missing school/daycare to go to the doctor or hospital	A question about whether an individual misses school because of doctor or hospital visits.			Intellectual Product	
C13124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13124>	C12578	Epithelial Reticular Cell|Epithelial Reticular Cells	A branched epithelial cell that supports epithelial structures.			Body Part, Organ, or Organ Component	
C131250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131250>	C227071	Form Not Presented or Mailed to Parent|Form not presented or mailed to parent	A response indicating that a form was not presented or mail to a parent.			Intellectual Product	
C131251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131251>	C227071	Parental Refusal for Current Questionnaire|Parental refusal for current questionnaire	A response indicating that a parent refused the current questionnaire.			Intellectual Product	
C131252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131252>	C227071	Parent Given Form and Form not Returned|Parent Given Form but Form not Returned|Parent given form and form not returned	A response indicating that a form was given to a parent, but that it was not returned.			Intellectual Product	
C131253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131253>	C91106	Parent Wishes to Withdraw From Further Participation in the Study|Parent Wishes to Withdraw From Further Participation|Parent wishes to withdraw from further participation in the quality of life study	A response indicating that a parent wishes to withdraw from further participation.			Intellectual Product	
C131254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131254>	C227071	Parent Did Not Come to Clinic and Mailed Form Not Returned|Patient did not come to clinic and mailed form was not returned	A response indicating that a parent did not come to a clinic and that a mailed form was not returned.			Intellectual Product	
C131255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131255>	C227071	Patient Too Ill to Complete Form at this Assessment|Patient felt too ill to complete the quality of life form at this assessment	A response indicating that a patient was too ill to complete a form at this assessment.			Intellectual Product	
C131256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131256>	C227075	Parent or Guardian Does Not Speak English|Parent/guardian does not speak English	A response indicating that a parent or guardian did not speak English.			Intellectual Product	
C131257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131257>	C226654	Severe Cognitive Impairments|Severe cognitive impairments	A response indicating that a patient has or had severe cognitive impairments.			Intellectual Product	
C131258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131258>	C95943	MT-RNR2 Gene|MT-RNR2|MT-RNR2|Mitochondrially Encoded 16S RNA Gene	This gene plays a role in both mitochondrial protein translation and apoptosis regulation.			Gene or Genome	
C131259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131259>	C131258	MT-RNR2 wt Allele|HN|HNM|Humanin, Mitochondrial Gene|MTRNR2|Mitochondrially Encoded 16S RNA wt Allele|RNR2|Ribosomal RNA, Mitochondrial, 16S Gene|l-rRNA|rRNA, 16S, Mitochondrial Gene	Human MT-RNR2 wild-type allele is located within the circular mitochondrial (MT) chromosome and is approximately 2 kb in length. This allele, which encodes both 16S mitochondrial ribosomal RNA and humanin protein, is involved in mitochondrial protein translation and the negative regulation of apoptosis.			Gene or Genome	
C131260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131260>	C19928	Humanin|Formyl-Humanin|HNM|Humanin Mitochondrial	Humanin (24 aa, ~3 kDa) is encoded by the human MT-RNR2 gene. This protein plays a role in the inhibition of apoptosis.			Amino Acid, Peptide, or Protein	
C131261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131261>	C814	16S Mitochondrial Ribosomal RNA|16S Mitochondrial rRNA|l-rRNA	16S mitochondrial ribosomal RNA is encoded by the human MT-RNR2 gene. This ribonucleotide is involved in mitochondrial protein translation.			Nucleic Acid, Nucleoside, or Nucleotide	
C131262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131262>	C26000	COMP Gene|COMP|COMP|Cartilage Oligomeric Matrix Protein Gene	This gene plays a role in the structure of cartilage.			Gene or Genome	
C131263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131263>	C131262	COMP wt Allele|Cartilage Oligomeric Matrix Protein (Pseudoachondroplasia, Epiphyseal Dysplasia 1, Multiple) Gene|Cartilage Oligomeric Matrix Protein wt Allele|Cartilage Oligomeric Matrix Protein(Pseudoachondroplasia, Epiphyseal Dysplasia 1, Multiple) Gene|EDM1|EPD1|MED|PSACH|Pseudoachondroplasia (Epiphyseal Dysplasia 1, Multiple) Gene|THBS5	Human COMP wild-type allele is located in the vicinity of 19p13.1 and is approximately 9 kb in length. This allele, which encodes cartilage oligomeric matrix protein, is involved in cartilage structural integrity. Mutation of the gene is associated with pseudoachondroplasia and multiple epiphyseal dysplasia 1.			Gene or Genome	
C131264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131264>	C17351	Cartilage Oligomeric Matrix Protein|COMP|TSP5|Thrombospondin 5|Thrombospondin V|Thrombospondin-5|Thrombospondin-V	Cartilage oligomeric matrix protein (757 aa, ~83 kDa) is encoded by the human COMP gene. This protein plays a role in the formation and maintenance of cartilage.			Amino Acid, Peptide, or Protein	
C131265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131265>	C28533|C20735	PMP2 Gene|PMP2|PMP2|Peripheral Myelin Protein 2 Gene	This gene is involved in myelin formation.			Gene or Genome	
C131266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131266>	C131265	PMP2 wt Allele|FABP8|M-FABP|MP2|P2|Peripheral Myelin Protein 2 wt Allele	Human PMP2 wild-type allele is located within 8q21.3-q22.1 and is approximately 7 kb in length. This allele, which encodes myelin P2 protein, plays a role in lipid transport.			Gene or Genome	
C131267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131267>	C16386	Myelin P2 Protein|PMP2|Peripheral Myelin Protein 2|Peripheral Myelin Protein-2	Myelin P2 protein (132 aa, ~15 kDa) is encoded by the human PMP2 gene. This protein is involved in lipid transport and myelin formation.			Amino Acid, Peptide, or Protein	
C131268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131268>	C20703	BCORL1 Gene|BCL6 Corepressor-Like 1 Gene|BCORL1|BCORL1|BCORL1	This gene plays a role in the inhibition of gene expression.	BCORL1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C131269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131269>	C131268	BCORL1 wt Allele|BCL6 Corepressor-Like 1 wt Allele|BCoR-L1|CXorf10|Chromosome X Open Reading Frame 10 Gene	Human BCORL1 wild-type allele is located in the vicinity of Xq26.1 and is approximately 78 kb in length. This allele, which encodes BCL-6 corepressor-like protein 1, is involved in the inhibition of transcription. Mutation of the gene may be associated with acute myeloid leukemia and head and neck squamous cell carcinoma	BCORL1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13126>	C12520	Immature Platelet	A young platelet that contains residual mRNA and rRNA when released from the bone marrow into the peripheral circulation as a result of thrombopoiesis. Immature platelets normally make up a small percentage of the total circulating platelets (1.1-6.1%, with a mean of 3.4%.). An increased proportion of immature platelets in blood indicates increased thrombopoiesis. The relationship between the percent of immature platelets and the platelet count can be used to determine the rate of platelet turnover.			Body Part, Organ, or Organ Component	
C131270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131270>	C26199	BCL-6 Corepressor-Like Protein 1|BCL6 Co-Repressor-Like 1|BCL6 Corepressor-Like 1|BCORL1|BCoR-L1|BCoR-Like Protein 1	BCL-6 corepressor-like protein 1 (78 aa, ~183 kDa) is encoded by the human BCORL1 gene. This protein plays a role in the repression of gene transcription.	BCL-6 Corepressor-Like Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131271>	C27993	Suspicious	Of a questionable or potentially dangerous nature.			Qualitative Concept	
C131272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131272>	C20745	CEP350 Gene|CEP350|CEP350|Centrosomal Protein 350 Gene	This gene is involved in anchoring microtubules to the centrosome.			Gene or Genome	
C131273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131273>	C131272	CEP350 wt Allele|CAP350|Centrosomal Protein 350 wt Allele|Centrosomal Protein 350kDa Gene|Centrosome-Associated Protein, 350-kDa Gene|GM133|KIAA0480	Human CEP350 wild-type allele is located in the vicinity of 1q25.2 and is approximately 160 kb in length. This allele, which encodes centrosome-associated protein 350, plays a role in centriole assembly.			Gene or Genome	
C131274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131274>	C16492	Centrosome-Associated Protein 350|Centrosomal Protein 350|Centrosomal Protein of 350 kDa|Centrosome Associated Protein 350|Centrosome-Associated Protein of 350 kDa|Cep350	Centrosome-associated protein 350 (3117 aa, ~351 kDa) is encoded by the human CEP350 gene. This protein is involved in centriole growth.			Amino Acid, Peptide, or Protein	
C131275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131275>	C147564	Peripheral Resistance to Thyroid Hormone|PRTH|PRTH	Decreased response to thyroid hormones in peripheral tissues, with normal response in the pituitary gland.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C131276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131276>	C25869|C20921	TSPAN3 Gene|TSPAN3|TSPAN3|Tetraspanin 3 Gene	This gene plays a role in receptor signaling pathways.			Gene or Genome	
C131277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131277>	C171128	Perinatal-Stress Induced Hyperinsulinism	Transient hyperinsulinism that occurs in response to neonatal stress resulting in prolonged neonatal hypoglycemia, which is distinct from transitional hypoglycemia of typical infants.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131278>	C131276	TSPAN3 wt Allele|TM4-A|TM4SF8|TSPAN-3|Tetraspanin 3 wt Allele	Human TSPAN3 wild-type allele is located in the vicinity of 15q24.3 and is approximately 43 kb in length. This allele, which encodes tetraspanin-3 protein, is involved in signal transduction.			Gene or Genome	
C131279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131279>	C18515	Tetraspanin-3|TSPAN-3|Tetraspan 3|Tetraspan TM4SF8|Tetraspanin TM4-A|Transmembrane 4 Superfamily Member 8	Tetraspanin-3 (253 aa, ~28 kDa) is encoded by the human TSPAN3 gene. This protein plays a role in the modulation of signal transduction.			Amino Acid, Peptide, or Protein	
C13127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13127>	C13432	7p15-p14	A chromosome band present on 7p			Gene or Genome	
C131280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131280>	C25790	FGL2 Gene|FGL2|FGL2|Fibrinogen Like 2 Gene	This gene may be involved in memory T-cell function.			Gene or Genome	
C131281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131281>	C131280	FGL2 wt Allele|Fibrinogen Like 2 wt Allele|Fibrinogen-Like 2 Gene|T49|pT49	Human FGL2 wild-type allele is located in the vicinity of 7q11.23 and is approximately 6 kb in length. This allele, which encodes fibroleukin protein, may play a role in the activity of memory T-cells.			Gene or Genome	
C131282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131282>	C16725	Fibroleukin|FGL2|Fibrinogen-Like Protein 2|pT49	Fibroleukin (439 aa, ~50 kDa) is encoded by the human FGL2 gene. This protein may be involved in memory T-cell functionality.			Amino Acid, Peptide, or Protein	
C131283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131283>	C15176	Battlefield Acupuncture|BFA|Battle Field Acupuncture	A form of acupuncture that uses needles placed in the ear as a protocol for pain management.	Battlefield Acupuncture		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C131284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131284>	C20194	TRPC4AP Gene|TRPC4AP|TRPC4AP|Transient Receptor Potential Cation Channel Subfamily C Member 4 Associated Protein Gene	This gene may play a role in the regulation of both ion channels and ubiquitination.			Gene or Genome	
C131285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131285>	C131284	TRPC4AP wt Allele|C20orf188|Chromosome 20 Open Reading Frame 188 Gene|DKFZP727M231|DKFZp586C1223|PPP1R158|Protein Phosphatase 1, Regulatory Subunit 158 Gene|TRRP4AP|TRUSS|Transient Receptor Potential Cation Channel, Subfamily C, Member 4 Associated Protein Gene|Transient Receptor Potential Cation Channel, Subfamily C, Member 4 Associated Protein wt Allele|dJ756N5.2	Human TRPC4AP wild-type allele is located in the vicinity of 20q11.22 and is approximately 90 kb in length. This allele, which encodes short transient receptor potential channel 4-associated protein, may be involved in the modulation of both protein ubiquitination and ion transport.			Gene or Genome	
C131286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131286>	C95242	Short Transient Receptor Potential Channel 4-Associated Protein|Protein TAP1|Protein TRUSS|Short Transient Receptor Potential Channel 4 Associated Protein|TNF-Receptor Ubiquitous Scaffolding/Signaling Protein|TNFR1-Associated Ubiquitous Scaffolding and Signaling Protein|Transient Receptor Potential Channel 4-Associated Protein|Trp4-Associated Protein|Trpc4-Associated Protein|Tumor Necrosis Factor Receptor-Associated Ubiquitous Scaffolding and Signaling Protein	Short transient receptor potential channel 4-associated protein (797 aa, ~91 kDa) is encoded by the human TRPC4AP gene. This protein may play a role in both ion channel-dependent transport and protein ubiquitination.			Amino Acid, Peptide, or Protein	
C131287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131287>	C28310	KLH/NY-ESO-1/MART-1 Peptide-pulsed Dendritic Cell Vaccine|KLH/NY-ESO-1/MART-1 Peptide-pulsed DC Vaccine|KLH/NY-ESO-1/Melan-A Peptide-pulsed DC Vaccine|NY-ESO-1/MART-1 Peptide/KLH-pulsed Dendritic Cell Vaccine	A cell-based cancer vaccine composed dendritic cells (DC) that were matured in the presence of a synthetic complex comprised of polyinosinic-polycytidylic acid, poly-L-lysine double-stranded RNA, and carboxymethylcellulose (poly-ICLC), and then pulsed with peptides derived from the tumor-associated antigens (TAAs) cancer/testis antigen NY-ESO-1 and melanoma antigen recognized by T-cells (MART-1/Melan-A), which are linked to the immunostimulant and carrier protein keyhole limpet hemocyanin (KLH), with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, the KLH/NY-ESO-1/MART-1 peptide-pulsed DC vaccine stimulates the immune system to mount an anti-tumor cytotoxic T-lymphocyte (CTL) response against NY-ESO-1/MART-1-expressing tumor cells, which may result in tumor cell lysis. NY-ESO-1 is expressed both in normal testes and on the surfaces of various tumor cells. MART-1 is expressed by melanoma cells. The adjuvant poly-ICLC, a ligand for toll-like receptor-3 (TLR-3), induces the release of cytokines that may help boost the immune response against the TAAs. KLH boosts the immune response against the TAA-expressing tumor cells.	KLH/NY-ESO-1/MART-1 Peptide-pulsed Dendritic Cell Vaccine		Cell|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCIt Antineoplastic Agent Terminology
C131288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131288>	C2124	Carbon C14 EGFR Inhibitor ASP8273|14C ASP8273|14C EGFR Inhibitor ASP8273|[14C] EGFR Inhibitor ASP8273|[14C]ASP8273	A radioconjugate composed of ASP8273, an orally available, third-generation, mutant-selective, irreversible epidermal growth factor receptor (EGFR) inhibitor, labeled with the radioisotope carbon C 14, with potential use for evaluating the pharmacokinetic profile of ASP8273 during positron emission tomography (PET). Upon administration of carbon C 14 ASP8273, ASP8273 targets, covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M mutant form. Labeling of ASP8273 with the radioactive tracer carbon C 14 permits the evaluation of this agent's pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME) using PET.	Carbon C14 EGFR Inhibitor ASP8273		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C131289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131289>	C129820	2-Fluorofucose|2-FF Containing SGN-2FF|2-FLUOROFUCOSE|2FF-containing SGN-2FF|SGN-2FF	An orally bioavailable fluorinated analog of fucose that is a protein fucosylation inhibitor, with potential antineoplastic and immunomodulating activities. Upon administration, 2-fluorofucose (2-FF) mimics fucose and is converted to guanosine diphosphate (GDP)-2FF, which prevents the formation of the fucosylation substrate GDP-fucose, and the incorporation of fucose into glycoproteins by fucosyltransferase. As fucosylation of glycoproteins plays a key role in many biological processes, such as protein function, receptor binding, cell signaling and cellular adhesion, and is essential for tumor progression, blocking fucosylation decreases tumor cell growth. In addition, blocking fucosylation of monoclonal antibodies generates fucose-deficient antibodies that exert enhanced antibody-dependent cell-mediated cytotoxicity (ADCC).	2-Fluorofucose		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C13128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13128>	C13432	7q35	A chromosome band present on 7q			Gene or Genome	
C131290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131290>	C21295	GPC1 Gene|GPC1|GPC1|Glypican 1 Gene	This gene is involved in heparan sulfate binding and metabolism.			Gene or Genome	
C131291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131291>	C134787|C129822	Tiragolumab|MTIG7192A|RG6058|TIRAGOLUMAB	A human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, tiragolumab binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells, and leads to CD226 dimerization and CD226-mediated signaling. This activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family and immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.	Tiragolumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131292>	C131290	GPC1 wt Allele|Glypican 1 wt Allele|Glypican Gene	Human GPC1 wild-type allele is located in the vicinity of 2q37.3 and is approximately 32 kb in length. This allele, which encodes glypican-1 protein, plays a role in the mediation of heparan sulfate binding.			Gene or Genome	
C131293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131293>	C17728	Glypican-1|GPC1|Glypican 1|Glypican Proteoglycan 1	Glypican-1 (558 aa, ~62 kDa) is encoded by the human GPC1 gene. This protein is involved in the regulation of heparan sulfate metabolism.			Amino Acid, Peptide, or Protein	
C131294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131294>	C129820	Cintirorgon|CINTIRORGON|LYC-55716|LYC55716|RORg Agonist LYC-55716	An orally bioavailable agonist of retinoic acid-related orphan receptor gamma (RORg), with potential immunomodulatory and antineoplastic activities. Upon oral administration of cintirorgon, this agent selectively binds to the nuclear receptor transcription factor RORg, forming a receptor complex that translocates to the nucleus, and binds to ROR response elements (ROREs), enhancing the function, proliferation and survival of type 17 T-cells, including Th17 (helper T-cells) and Tc17 (cytotoxic T-cells). This may increase the expression of co-stimulatory molecules and decrease the expression of co-inhibitory molecules on T-cells leading to increased production of cytokines and chemokines by T-cells, decreased proliferation of regulatory T-cells (Tregs), and abrogation of tumor-induced immunosuppression. This ultimately induces a T-cell-mediated immune response against cancer cells and leads to a reduction in tumor cell growth. RORg, the nuclear receptor transcription factor that is involved in Th17/Tc17 differentiation, plays a key role in immune activation.	Cintirorgon		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131295>	C20401|C129822	Anti-HA Epitope Monoclonal Antibody MEDI8852|Anti-Influenza A Hemagglutinin Epitope mAb MEDI8852|MEDI 8852|MEDI-8852|MEDI-8852|MEDI8852|pan-Influenza A mAb MEDI8852	A human immunoglobulin (Ig) G1 kappa monoclonal antibody (mAb) targeting a unique epitope in the stalk of the influenza A hemagglutinin (HA) protein, with broad influenza A virus neutralization activity. MEDI8852 was derived from an antibody isolated from human memory B-cells from patients previously infected with influenza caused by type A strains that was further optimized to increase neutralization potential. Upon infusion, MEDI8852 targets and binds to a region within the stalk of the HA protein that is highly conserved amongst all influenza A virus subtypes. This neutralizes and prevents essential steps of the viral lifecycle, thereby blocking infectivity of all influenza A virus subtypes. HA, a glycoprotein found on the surface of the influenza virus, plays a key role in viral attachment and cell entry.	Anti-HA Epitope Monoclonal Antibody MEDI8852		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131296>	C97093	Partial Lipodystrophy	Loss and redistribution of subcutaneous and/or visceral adipose tissue from specific regions of the body.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131297>	C20923	MC4R Gene|MC4R|MC4R|Melanocortin 4 Receptor Gene	This gene plays a role in neuropeptide-dependent G protein-coupled receptor signaling.			Gene or Genome	
C131298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131298>	C147564	Parathyroid Hormone Resistance|Pseudohypoparathyroidism|Pseudoparathyroidism	A finding indicating decreased tissue sensitivity to parathyroid hormone.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C131299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131299>	C131297	MC4R wt Allele|Melanocortin 4 Receptor wt Allele	Human MC4R wild-type allele is located in the vicinity of 18q22 and is approximately 2 kb in length. This allele, which encodes melanocortin receptor 4 protein, is involved in ligand-stimulated signaling. Mutation of the gene is associated with autosomal dominant obesity.			Gene or Genome	
C13129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13129>	C12549	Proerythroblast	The earliest of four stages in development of the normoblast.			Cell	
C1312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1312>	C1708	Generic Drug|Generic|generic	A pharmaceutical product equivalent to the brand name drug in dosage, safety, strength, how it is taken, quality, performance, and intended use. The FDA bases evaluations of substitutability, or therapeutic equivalence of a generic drug on scientific evaluation. A generic drug product must contain the identical amounts of the same active ingredient(s) as the brand name product and is expected to have equal effect when substituted for the brand name product.			Pharmacologic Substance	
C131300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131300>	C18239	Melanocortin Receptor 4|MC4-R|MC4R|MCR Receptor|Melanocortin 4 Receptor	Melanocortin receptor 4 (332 aa, ~37 kDa) is encoded by the human MC4R gene. This protein plays a role in G protein-coupled receptor signaling.			Amino Acid, Peptide, or Protein|Receptor	
C131301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131301>	C20401|C198644|C129822	Anti-CSF1 Monoclonal Antibody PD-0360324|Anti-M-CSF mAb PD-0360324|PD 0360324|PD 360324|PD-0360324|PD-0360324|PD-360,324	A humanized immunoglobulin (Ig) G2 monoclonal antibody (mAb) directed against the cytokine colony stimulating factor 1 (CSF1; CSF-1; macrophage colony-stimulating factor; M-CSF), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CSF1 monoclonal antibody PD-0360324 targets, binds to and neutralizes CSF1. This prevents the binding of CSF1 to its receptor CSF1R (CD115; M-CSFR), which is expressed on various immune cells, such as monocytes and macrophages. This prevents CSF1R activation and CSF1R-mediated signaling in these cells; this inhibits monocyte differentiation, blocks the activity of macrophages, and reduces their production of inflammatory mediators, which reduces inflammation. By blocking the activity and proliferation of CSF1R-dependent tumor-associated macrophages (TAMs) in the tumor microenvironment, PD-0360324 reduces TAM-mediated immune suppression, decreases regulatory T-cells (Tregs), re-activates the immune system, and improves anti-tumor cell responses mediated by increasing infiltration by cytotoxic T-cells. TAMs play key roles in immune suppression, and tumor cell proliferation and survival. CSF-1 plays a key role in the regulation of the proliferation, differentiation and survival of monocytes and macrophages.	Anti-CSF1 Monoclonal Antibody PD-0360324		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131302>	C120206	P450 Oxidoreductase Deficiency	Decreased or absent activity of P450 oxidoreductase due to mutation(s) in the POR gene.			Laboratory or Test Result	NICHD Terminology|Pediatric Endocrinology Terminology
C131303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131303>	C214440	Pulrodemstat|CC 90011|CC-90011|CC90011|LSD1 Inhibitor CC-90011|Lysine-specific Demethylase 1 Inhibitor CC-90011|PULRODEMSTAT	An orally available inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity. Upon administration, pulrodemstat binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4, respectively. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor (remove hyphen) suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. In addition, LSD1 demethylates mono- or di-methylated H3K9 which increases gene expression of tumor promoting genes; inhibition of LSD1 promotes H3K9 methylation and decreases transcription of these genes. LSD1, an enzyme belonging to the flavin adenine dinucleotide (FAD)-dependent amine oxidase family that is overexpressed in certain tumor cells, plays a key role in tumor cell growth and survival.	Pulrodemstat		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131304>	C21176	Interleukin-35|IL-35|IL35|Interleukin 35	A heterodimeric cytokine that is comprised of interleukin-12 subunit alpha and interleukin-27 subunit beta. This protein complex is reported to be secreted by regulatory T-cells and may suppress inflammation.			Amino Acid, Peptide, or Protein	
C131305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131305>	C28681|C129826	Ex Vivo-expanded Autologous T Cells IMA101|ACTolog IMA101|IMA101|IMA101 T-Cells|IMA101 T-cell Product	A preparation of autologous cytotoxic T-lymphocytes, specifically recognizing certain tumor-associated antigens (TAAs), with potential antineoplastic activity. The endogenous T-cells are isolated, expanded ex vivo, and reintroduced back into the patient. Upon administration, the ex vivo-expanded autologous T-cells IMA101 target and kill tumor cells. The T-cells are analyzed beforehand for their ability to specifically recognize certain TAAs, based on a proprietary antigen warehouse.	Ex Vivo-expanded Autologous T Cells IMA101		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131306>	C129824	Risperidone Formulation in Rumenic Acid|Risperidone Lipid Formulation VAL401|VAL-401|VAL401	An orally bioavailable capsule formulation containing the antipsychotic agent risperidone suspended in the lipid rumenic acid, with potential antineoplastic activity. Upon administration of VAL401, risperidone may, through an as of yet not elucidated mechanism of action, reduce cellular activity and tumor cell proliferation in multiple cancers.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131307>	C253	Pegylated Liposomal Mitoxantrone Hydrochloride|PLM60	A pegylated liposomal mitoxantrone formulation composed of the hydrochloride salt form of the anthracenedione antibiotic mitoxantrone encapsulated within pegylated small unilamellar vesicles (SUVs), with potential antineoplastic activity. Upon intravenous administration, mitoxantrone intercalates into and forms crosslinks with DNA, thereby disrupting DNA and RNA replication. This agent also binds to topoisomerase II, which both results in DNA strand breaks and prevents DNA synthesis. This leads to the induction of apoptosis in rapidly dividing cancer cells. The pegylated liposomal formulation improves drug penetration into tumors and decreases drug clearance, thereby increasing drug circulation and therapeutic efficacy while lowering toxic effects.			Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131308>	C26840	Osteoclast-Rich Osteopetrosis	A form of osteopetrosis in which osteoclasts are abundant but have severely impaired resorptive function.			Congenital Abnormality	NICHD Terminology|Pediatric Endocrinology Terminology
C131309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131309>	C26798	Odontohypophosphatasia	Hypophosphastasia characterized by the premature loss of deciduous teeth, but without accompanying bony abnormalities.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C13130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13130>	C12527	Basophilic Erythroblast	A nucleated red blood cell that stains readily with basic dye.			Cell	
C131310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131310>	C28681|C129826	Autologous Cytokine-induced Killer Cells|Immuncell-LC	A proprietary formulation of autologous cytokine-induced killer (CIK) T-lymphocytes, with immunopotentiating and antineoplastic activities. These CIK cells are generated by ex vivo incubation of autologous peripheral blood lymphocytes with an undisclosed mixture of compounds to stimulate killer T-cell differentiation; this is followed by expansion of the cells. Upon reintroduction into the patient, the autologous CIK cells are able to target and kill tumor cells.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131311>	C1907	Sipjeondaebo-tang|Deciten Granule|Juzen-taiho-to|SJDBT|Shi-Quan-Da-Bu-Tang	An orally bioavailable east Asian herbal supplement, with potential gastro- and neuro-protective, immunostimulatory, anti-inflammatory, anti-cancer, anti-cachexic and antioxidant activities. Sipjeondaebo-tang is comprised of various components, including Angelica root (Angelicae Gigantis Radix), the rhizome of Cnidium officinale Makino (Cnidii Rhizoma), Radix Paeoniae, Rehmannia glutinosa root (Rehmanniae Radix Preparata), Ginseng root (Ginseng Radix Alba), Atractylodes lancea root (Atractylodis Rhizoma Alba), the dried sclerotia of Poria cocos (Poria cocos Sclerotium), Licorice root (Glycyrrhizae Radix), Astragalus root (Astragali Radix), and the dried bark of Cinnamomum verum (Cinnamomi Cortex). Upon administration, and although the exact mechanism of action has yet to be fully elucidated, sipjeondaebo-tang may exert its effect through the various mechanism of actions that may be attributed to the different herbs.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C131312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131312>	C25870|C20420	EGR2 Gene|EGR2|EGR2|Early Growth Response 2 Gene	This gene plays a role in both transcriptional regulation and protein sumoylation.			Gene or Genome	
C131313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131313>	C131312	EGR2 wt Allele|AT591|CMT1D|CMT4E|Early Growth Response 2 (Krox-20 Homolog, Drosophila) Gene|Early Growth Response 2 wt Allele|KROX-20, Drosophila, Homolog (Early Growth Response-2) Gene|KROX20	Human EGR2 wild-type allele is located in the vicinity of 10q21.1 and is approximately 108 kb in length. This allele, which encodes E3 SUMO-protein ligase EGR2 protein, is involved in the regulation of both gene transcription and protein modification. Mutation of the gene is associated with Charcot-Marie-Tooth disease type 1D (CMT1D), Charcot-Marie-Tooth disease type 4E (CMT4E), and with Dejerine-Sottas syndrome (DSS).			Gene or Genome	
C131314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131314>	C17207|C16259	E3 SUMO-Protein Ligase EGR2|AT591|E3 SUMO-Protein Transferase ERG2|EC 2.3.2.-|EC 6.3.2.-, Formerly|EGR-2|EGR2|Early Growth Response Protein 2|Krox-20 Homolog|Zinc Finger Protein Krox-20	E3 SUMO-protein ligase EGR2 (476 aa, ~50 kDa) is encoded by the human EGR2 gene. This protein plays a role in both protein sumoylation and sequence-specific DNA binding.			Amino Acid, Peptide, or Protein|Enzyme	
C131315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131315>	C21240	EIF1AX Gene|EIF1AX|EIF1AX|EIF1AX|Eukaryotic Translation Initiation Factor 1A X-Linked Gene	This gene is involved in translation initiation and efficiency.			Gene or Genome	GDC Terminology|GDC Value Terminology
C131316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131316>	C131315	EIF1AX wt Allele|EIF1A|EIF1AP1|EIF4C|Eukaryotic Translation Initiation Factor 1A X-Linked wt Allele|Eukaryotic Translation Initiation Factor 1A, X Chromosome Gene|Eukaryotic Translation Initiation Factor 1A, X-Linked Gene|eIF-1A|eIF-4C	Human EIF1AX wild-type allele is located in the vicinity of Xp22.13 and is approximately 17 kb in length. This allele, which encodes eukaryotic translation initiation factor 1A, X-chromosomal protein, plays a role in regulating the efficiency of the translation machinery.			Gene or Genome	
C131317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131317>	C17461	Eukaryotic Translation Initiation Factor 1A, X-Chromosomal|EIF1AX|Eukaryotic Translation Initiation Factor 1A|Eukaryotic Translation Initiation Factor 4C|Putative Eukaryotic Translation Initiation Factor 1A|eIF-1A X Isoform|eIF-4C	Eukaryotic translation initiation factor 1A, X-chromosomal (144 aa, ~16 kDa) is encoded by the human EIF1AX gene. This protein is involved in the modulation of translation.			Amino Acid, Peptide, or Protein	
C131318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131318>	C20917|C20745	CEP20 Gene|CEP20|CEP20|Centrosomal Protein 20 Gene|FOPNL	This gene plays a role in the formation of cilia and in S phase progression.			Gene or Genome	
C131319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131319>	C131318	CEP20 wt Allele|C16orf63|Centrosomal Protein 20 wt Allele|Chromosome 16 Open Reading Frame 63 Gene|DKFZp686N1651|FGFR1OP N-Terminal Like Gene|FLJ31153|FOP-Related Protein, 20-kD Gene|FOPNL|FOR20|PHSECRG2	Human CEP20 wild-type allele is located in the vicinity of 16p13.11 and is approximately 23 kb in length. This allele, which encodes centrosomal protein 20, is involved in S phase progression and cilia formation.			Gene or Genome	
C13131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13131>	C12527	Polychromatic Erythroblast|Polychromatophilic Erythroblast				Cell	
C131320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131320>	C17761|C16492	Centrosomal Protein 20|CEP20|FGFR1OP N-Terminal Domain-Like Protein|FGFR1OP N-Terminal-Like Protein|FOP-Related Protein of 20 kDa|LisH Domain-Containing Protein C16orf63|LisH Domain-Containing Protein FOPNL|Pluripotent Embryonic Stem Cell-Related Protein	Centrosomal protein 20 (174 aa, ~20 kDa) is encoded by the human CEP20 gene. This protein plays a role in ciliogenesis and progression of the S phase of the cell cycle.			Amino Acid, Peptide, or Protein	
C131321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131321>	C180942|C171043	NTRK2 Gene Rearrangement|NTRK2 Rearrangement|Neurotrophic Tyrosine Kinase Receptor 2 Gene Rearrangement|Neurotrophic Tyrosine Kinase Receptor Type 2 Gene Rearrangement|TRKB Tyrosine Kinase Gene Rearrangement|Tropomyosin-Related Kinase B Gene Rearrangement	A molecular abnormality indicating rearrangement of the NTRK2 gene.	NTRK2 Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131322>	C20194	REG1A Gene|REG1A|REG1A|Regenerating Family Member 1 Alpha Gene	This gene may be involved in cell proliferation in the brain and pancreas.			Gene or Genome	
C131323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131323>	C131322	REG1A wt Allele|ICRF|P19|PSP|PSPS|PSPS1|PTP|Pancreatic Stone Protein, Secretory Gene|REG|Regenerating Family Member 1 Alpha wt Allele|Regenerating Islet-Derived 1 Alpha (Pancreatic Stone Protein, Pancreatic Thread Protein) Gene|Regenerating Islet-Derived, Rat, Homolog of Gene	Human REG1A wild-type allele is located in the vicinity of 2p12 and is approximately 3 kb in length. This allele, which encodes lithostathine-1-alpha protein, may play a role in the modulation of the proliferation of both islet cells and neurons. Gene expression may be associated with both diabetogenesis and pancreatic lithogenesis.			Gene or Genome	
C131324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131324>	C18466	Lithostathine-1-Alpha|ICRF|Islet Cells Regeneration Factor|Islet of Langerhans Regenerating Protein|Lithostathine|Lithostathine 1 Alpha|PSP|PTP|Pancreatic Stone Protein|Pancreatic Thread Protein|Protein-X|REG|REG1A|Reg-1-Alpha|Regenerating Islet-Derived 1 Alpha|Regenerating Islet-Derived 1-Alpha|Regenerating Islet-Derived Protein 1-Alpha|Regenerating Protein I Alpha	Lithostathine-1-alpha (166 aa, ~19 kDa) is encoded by the human REG1A gene. This protein may be involved in the modulation of neuronal and pancreatic cell proliferation.			Amino Acid, Peptide, or Protein	
C131325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131325>	C171043	NTRK3 Gene Rearrangement|NTRK3 Rearrangement|Neurotrophic Tyrosine Kinase Receptor 3 Gene Rearrangement|Neurotrophic Tyrosine Kinase Receptor Type 3 Gene Rearrangement|Neurotrophic Tyrosine Kinase, Receptor, Type 3 Gene Rearrangement|TRKC Gene Rearrangement	A molecular abnormality indicating rearrangement of the NTRK3 gene.	NTRK3 Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131326>	C165233	EGFR T790M Mutation Negative|EGFR NP_005219.2:p.T790M Negative|EGFR NP_005219.2:p.Thr790Met Negative|EGFR Thr790Met Mutation Negative|EGFR p.T790M Mutation Negative|Epidermal Growth Factor Receptor T790M Negative|Proto-Oncogene c-ErbB-1 T790M Negative|Receptor Tyrosine-Protein Kinase erbB-1 T790M Negative	Indicates that the T790M mutation of the epidermal growth factor receptor gene has not been detected in a sample.	EGFR T790M Mutation Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131327>	C153242	Folate Receptor Alpha Positive|FBP Positive|FOLR Positive|FOLR1 Positive|FR-Alpha Positive|Folate Receptor 1 Positive|Folate-Binding Protein, Adult Positive	An indication that folate receptor alpha has been detected in a sample.	Folate Receptor Alpha Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131328>	C35682	Cytomegalovirus Positive|CMV Positive|HHV-5 Positive|Human Herpesvirus 5 Positive	An indication that cytomegalovirus has been detected in a sample.	Cytomegalovirus Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C131329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131329>	C131797	POLE Exonuclease Domain Mutation|DNA Polymerase Epsilon Catalytic Subunit A Exonuclease Domain Mutation|DNA Polymerase Epsilon, Catalytic Subunit Exonuclease Domain Mutation|POLE1 Exonuclease Domain Mutation	A missense mutation in the POLE gene located in the region that encodes the exonuclease domain of the DNA polymerase epsilon catalytic subunit A protein (POLE protein). These mutations lead to defective DNA proof-reading by POLE protein during DNA replication and have been reported in patients with colorectal carcinoma and certain subtypes of endometrial carcinoma.	POLE Exonuclease Domain Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13132>	C12527	Orthochromatic Erythroblast|Acidophilic Erythroblast|Orthochromatophilic Erythroblast|Oxyphilic Erythroblast	A cell derived from a polychromatophilic erythroblast in bone marrow. It has a dense nucleus and its cytoplasm is approaching the color of a mature erythrocyte. It differentiates into a reticulocyte when it extrudes its nucleus.			Cell	
C131330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131330>	C25616	Past 30 days|In the last month|Last 30 Days|Last Month|Past Month	A period of time consisting of the 30 days before the present.			Temporal Concept	Adherence Starts With Knowledge 12 Questionnaire
C131331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131331>	C49236|C49165	Ischemia Procedure|Ischemia|Therapeutic Ischemia	A surgical procedure during which the blood supply to an organ or tissue is interrupted and then later reestablished.			Therapeutic or Preventive Procedure	
C131332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131332>	C225418	Transperitoneal	Passing through the peritoneum.			Spatial Concept	
C131333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131333>	C275	Oligomeric Procyanidin Complex|OPC|Oligomeric Flavanols|Oligomeric Proanthocyanidins|Oligomeric Procyanidolic Complex	A preparation containing plant-derived polyphenolic bioflavonoids composed of multimers (dimers, trimers, or higher order polymers) of the flavan-3-ol-based monomers catechin and epicatechin, which are extracted from sources rich in these chemicals, such as grape seeds, grape skin and pine bark, with potential anti-oxidant, anti-inflammatory, anti-microbial, anti-cancer and protective activities. Upon oral administration of oligomeric procyanidin complex (OPC), the polyphenols exert anti-oxidant activity by scavenging free radicals, which prevents both the formation of reactive oxygen species (ROS), particularly nitrous oxide (NO), and DNA damage. OPC also inhibits chemical-induced lipid peroxidation. In addition, OPC reduces the production advanced glycation end-products (AGE), decreases AGE accumulation in tissues, and inhibits the progression of AGE/receptor for AGE (RAGE)-mediated inflammatory transduction pathways, which inhibits the activation of pro-inflammatory transcriptional regulators and prevents the secretion of pro-inflammatory cytokines/chemokines. This ultimately prevents inflammatory-driven damage to end organs and may reduce inflammation-induced cancer formation and progression. In addition, OPC inhibits the activity of a variety of enzymes, including xanthine oxidase, collagenase, elastase hyaluronidase and beta-glucuronidase.	Oligomeric Procyanidin Complex		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131334>	C128037	Toripalimab|Anti-PD-1 Monoclonal Antibody JS001|JS 001|JS-001|JS001|Loqtorzi|TAB 001|TAB-001|TORIPALIMAB|Toripalimab-tpzi|Tuoyi	A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (programmed death-1; PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, toripalimab binds to PD-1 and inhibits the binding of PD-1 to its ligands, programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the Ig superfamily that is expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.	Toripalimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131335>	C174048	Temuterkib|ERK1/2 Inhibitor LY3214996|LY 3214996|LY-3214996|LY3214996|TEMUTERKIB	An orally available inhibitor of extracellular signal-regulated kinase (ERK) 1 and 2, with potential antineoplastic activity. Upon oral administration, temuterkib inhibits both ERK 1 and 2, thereby preventing the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The MAPK/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.	Temuterkib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131336>	C2594	Multiple TAA-loaded Dendritic Cell Vaccine|Antigen-pulsed DCs MASCT-I|MASCT-I|Multiple TAA-loaded DC Vaccine|Multiple Target Antigen-stimulating Cells-I	A dendritic cell (DC) vaccine in which autologous DCs are loaded with multiple tumor-associated antigens (TAAs), with potential immunostimulating and antineoplastic activities. Upon re-infusion into the patient, the antigen-pulsed DCs stimulate the immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against the TAA-expressing tumor cells.			Cell|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131337>	C20744	DIAPH3 Gene|DIAPH3|DIAPH3|Diaphanous-Related Formin 3 Gene	This gene plays a role in actin dynamics, Rho and Src localization, and cytokinesis.			Gene or Genome	
C131338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131338>	C131337	DIAPH3 wt Allele|AN|AUNA1|Auditory Neuropathy, Autosomal Dominant 1 Gene|DIA2|DIAP3|DRF3|Diaphanous (Drosophila, Homolog) 3 Gene|Diaphanous Homolog 3 (Drosophila) Gene|Diaphanous Homolog 3 Gene|Diaphanous, Drosophila, Homolog of, 3 Gene|Diaphanous-Related Formin 3 wt Allele|FLJ34705|NSDAN|diap3|mDia2	Human DIAPH3 wild-type allele is located in the vicinity of 13q21.2 and is approximately 498 kb in length. This allele, which encodes protein diaphanous homolog 3, is involved in cytoskeletal dynamics, signaling molecule localization and cell division. Mutation of the gene is associated with autosomal dominant auditory neuropathy 1.			Gene or Genome	
C131339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131339>	C18073	Protein Diaphanous Homolog 3|DIAP3|DRF3|Diaphanous-Related Formin-3|MDia2	Protein diaphanous homolog 3 (1193 aa, ~137 kDa) is encoded by the human DIAPH3 gene. This protein plays a role in Rho and Src coupling, cytokinesis and actin polymerization.			Amino Acid, Peptide, or Protein	
C131340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131340>	C179032|C173737|C173358	Past Seven Days Frequency of Nosebleeds Question|In the past 7 days, how often did you have nosebleeds|Past Seven Days Frequency of Nosebleeds	A question about the frequency of an individual's nose bleeds over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C131341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131341>	C25994	ASIP Gene|ASIP|ASIP|Agouti Signaling Protein Gene	This gene is involved in the modulation of melanogenesis.			Gene or Genome	
C131342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131342>	C131341	ASIP wt Allele|AGSW|AGTI|AGTIL|ASP|Agouti (Mouse)-Signaling Protein Gene|Agouti Signaling Protein wt Allele|Agouti Signaling Protein, Nonagouti Homolog (Mouse) Gene|Agouti Signaling Protein, Nonagouti Homolog Gene|Agouti, Mouse, Homolog of Gene|SHEP9	Human ASIP wild-type allele is located within 20q11.2-q12 and is approximately 75 kb in length. This allele, which encodes agouti-signaling protein, plays a role in the regulation of melanogenesis. Homozygous polymorphism in the 3' untranslated region of the gene is associated with an increased likelihood of having dark hair and brown eyes.			Gene or Genome	
C131343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131343>	C1746	Agouti-Signaling Protein|ASIP|ASP|Agouti Switch Protein	Agouti-signaling protein (132 aa, ~15 kDa) is encoded by the human ASIP gene. This protein is involved in the inhibition of melanin synthesis and the promotion of pheomelanin synthesis.			Amino Acid, Peptide, or Protein|Hormone	
C131344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131344>	C179032|C173603	Worst Severity Past Seven Days Nosebleeds Question|In the past 7 days, what was the severity of your nosebleeds at their worst|Worst Severity Past Seven Days Nosebleeds	A question about an individual's observation of the worst severity they have experienced related to nosebleeds over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C131345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131345>	C173737	Past Seven Days Any Flashing Lights in Front of Your Eyes Question|In the past 7 days, did you have any flashing lights in front of your eyes|Past Seven Days Any Flashing Lights in Front of Your Eyes	A question about whether or not an individual had any flashing lights in front of their eyes over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C131346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131346>	C173737	Past Seven Days Any Spots or Lines that Drift in Front of Your Eyes Question|In the past 7 days, did you have any spots or lines (floaters) that drift in front of your eyes|Past Seven Days Any Spots or Lines that Drift in Front of Your Eyes	A question about whether or not an individual had any spots or drifting lines in front of their eyes over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C131347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131347>	C173737	Past Seven Days Any Urine Color Change Question|In the past 7 days, did you have any urine color change|Past Seven Days Any Urine Color Change	A question about whether an individual had any color change in their urine over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C131348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131348>	C173737	Past Seven Days Unexpected Decrease in Sweating Question|In the past 7 days, did you have an unexpected decrease in sweating|Past Seven Days Unexpected Decrease in Sweating	A question about whether an individual had any unexpected decrease in sweating over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C131349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131349>	C28533	OCA2 Gene|OCA2|OCA2|OCA2|OCA2 Melanosomal Transmembrane Protein Gene	This gene plays a role in transport and melanin synthesis.			Gene or Genome	CCPS Genetics Terminology|Childhood Cancer Predisposition Study Terminology
C13134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13134>	C13432	2q37	A chromosome band present on 2q			Gene or Genome	
C131350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131350>	C173737|C173593|C173346	Past Seven Days Any Pain, Swelling, or Redness at Site of Drug Injection or IV Question|In the past 7 days, did you have any pain, swelling, or redness at a site of drug injection or IV|Past Seven Days Any Pain, Swelling, or Redness at Site of Drug Injection or IV	A question about whether an individual had any pain, swelling, or redness at the site of a drug injection or IV over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C131351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131351>	C173737|C173358	Past Seven Days Frequency of Shivering or Shaking Chills Question|In the past 7 days, how often did you have shivering or shaking chills|Past Seven Days Frequency of Shivering or Shaking Chills	A question about the frequency of an individual's shivering or shaking chills over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C131352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131352>	C173603	Worst Severity Past Seven Days Shivering or Shaking Chills Question|In the past 7 days, what was the severity of your shivering or shaking chills at their worst|Worst Severity Past Seven Days Shivering or Shaking Chills	A question about the worst severity of an individual's shivering or shaking chills over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C131353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131353>	C173737|C173358	Past Seven Days Frequency of Hot Flashes Question|In the past 7 days, how often did you have hot flashes|Past Seven Days Frequency of Hot Flashes	A question about the frequency of an individual's hot flashes over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C131354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131354>	C131349	OCA2 wt Allele|BEY|BEY1|BEY2|BOCA|D15S12|EYCL|EYCL2|EYCL3|Eye Color 2 (Central Brown) Gene|Eye Color 3 (Brown) Gene|HCL3|Hair Color 3 (Brown) Gene|OCA2 Melanosomal Transmembrane Protein wt Allele|Oculocutaneous Albinism II (Pink-Eye Dilution Homolog, Mouse) Gene|Oculocutaneous Albinism II Gene|P|P Gene|PED|Pink-Eyed Dilution Gene|SHEP1|Total Brown Iris Pigmentation Gene	Human OCA2 wild-type allele is located within 15q12-q13.1 and is approximately 344 kb in length. This allele, which encodes P protein, is involved in eye and skin color. Mutations in this gene are associated with type 2 oculocutaneous albinism.			Gene or Genome	
C131355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131355>	C173603	Worst Severity Past Seven Days Hot Flashes Question|In the past 7 days, what was the severity of your hot flashes at their worst|Worst Severity Past Seven Days Hot Flashes	A question about an individual's observation of the worst severity they have experienced related to hot flashes over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C131356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131356>	C16386	P Protein|Melanocyte-Specific Transporter Protein|OCA2|P-Protein|Pink-Eyed Dilution Protein Homolog	P protein (838 aa, ~93 kDa) is encoded by the human OCA2 gene. This protein plays a role in melanogenesis and transmembrane transport of tyrosine and hydrogen ions.			Amino Acid, Peptide, or Protein	
C131357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131357>	C173737|C173358	Past Seven Days Frequency of Unexpected or Excessive Sweating During the Day or Nighttime Question|In the past 7 days, how often did you have unexpected or excessive sweating during the day or nighttime (not related to hot flashes)|Past Seven Days Frequency of Unexpected or Excessive Daytime or Nighttime Sweating|Past Seven Days Frequency of Unexpected or Excessive Sweating During the Day or Nighttime	A question about the frequency of an individual's unexpected or excessive daytime or nighttime sweating over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C131358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131358>	C173603	Worst Severity Past Seven Days Unexpected or Excessive Sweating During the Day or Nighttime Question|In the past 7 days, what was the severity of your unexpected or excessive sweating during the day or nighttime (not related to hot flashes) at its worst|Worst Severity Past Seven Days Unexpected or Excessive Daytime or Nighttime Sweating|Worst Severity Past Seven Days Unexpected or Excessive Sweating During the Day or Nighttime	A question about an individual's observation of the worst severity they have experienced related to unexpected or excessive daytime or nighttime sweating over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C131359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131359>	C21295	STN1 Gene|OBFC1|STN1|STN1|STN1 Subunit of CST Complex Gene	This gene is involved in DNA replication and telomere maintenance.			Gene or Genome	
C13135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13135>	C13432	Xp11.23	A chromosome band present on Xp			Gene or Genome	
C131360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131360>	C131359	STN1 wt Allele|AAF-44|AAF44|Alpha Accessory Factor, 44-kD Subunit Gene|FLJ22559|OBFC1|Oligonucleotide/Oligosaccharide-Binding Fold Containing 1 Gene|RPA-32|STN1 Subunit of CST Complex wt Allele|STN1, CST Complex Subunit Gene|STN1, S. pombe, Homolog of Gene|bA541N10.2	Human STN1 wild-type allele is located in the vicinity of 10q24.33 and is approximately 48 kb in length. This allele, which encodes CST complex subunit STN1 protein, plays a role in both telomere maintenance and DNA replication.			Gene or Genome	
C131361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131361>	C16518	CST Complex Subunit STN1|Alpha Accessory Factor 44|Oligonucleotide/Oligosaccharide-Binding Fold-Containing Protein 1|Replication Protein A 32 kDa Subunit|STN1|Suppressor of cdc Thirteen Homolog	CST complex subunit STN1 (368 aa, ~42 kDa) is encoded by the human STN1 gene. This protein is involved in DNA binding, telomere homeostasis and DNA replication.			Amino Acid, Peptide, or Protein	
C131362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131362>	C25870|C21240	CDKAL1 Gene|CDK5 Regulatory Subunit Associated Protein 1 Like 1 Gene|CDKAL1|CDKAL1	This gene plays a role in transfer RNA methylthiolation.			Gene or Genome	
C131363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131363>	C131362	CDKAL1 wt Allele|CDK5 Regulatory Subunit Associated Protein 1 Like 1 wt Allele|CDK5 Regulatory Subunit Associated Protein 1-Like 1 Gene|FLJ20342	Human CDKAL1 wild-type allele is located in the vicinity of 6p22.3 and is approximately 698 kb in length. This allele, which encodes threonylcarbamoyladenosine tRNA methylthiotransferase protein, is involved in tRNA modification. Mutation of the gene is associated with increased susceptibility to type 2 diabetes.			Gene or Genome	
C131364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131364>	C38576|C17210	Threonylcarbamoyladenosine tRNA Methylthiotransferase|CDK5 Regulatory Subunit-Associated Protein 1-Like 1|CDKAL1|EC 2.8.4.5|tRNA-t(6)A37 Methylthiotransferase	Threonylcarbamoyladenosine tRNA methylthiotransferase (579 aa, ~65 kDa) is encoded by the human CDKAL1 gene. This protein plays a role in the methylthiolation of transfer RNA.			Amino Acid, Peptide, or Protein|Enzyme	
C131365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131365>	C20194	AGR3 Gene|AGR3|AGR3|Anterior Gradient 3, Protein Disulphide Isomerase Family Member Gene	This gene may be involved in cilia movement.			Gene or Genome	
C131366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131366>	C131365	AGR3 wt Allele|AG-3|AG3|Anterior Gradient 3 Homolog (Xenopus laevis) Gene|Anterior Gradient 3, Protein Disulphide Isomerase Family Member wt Allele|Anterior Gradient 3, Xenopus, Homolog of Gene|BCMP11|HAG3|PDIA18|UNQ642/PRO1272|hAG-3	Human AGR3 wild-type allele is located in the vicinity of 7p21.1 and is approximately 23 kb in length. This allele, which encodes anterior gradient protein 3 homolog, plays a role in the rate of cilia movement.			Gene or Genome	
C131367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131367>	C18466	Anterior Gradient Protein 3 Homolog|AG-3|AG3|AGR3|Anterior Gradient 3|Anterior Gradient Homolog 3|Breast Cancer Membrane Protein 11|Protein Disulfide Isomerase Family A, Member 18|hAG-3	Anterior gradient protein 3 homolog (166 aa, ~19 kDa) is encoded by the human AGR3 gene. This protein may involved in the regulation of cilia motion.			Amino Acid, Peptide, or Protein	
C131368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131368>	C129821	Spherical Nucleic Acid Nanoparticle NU-0129|NU-0129|SNA Gold Nanoparticle NU-0129|SNA NU-0129	A spherical nucleic acid (SNA) gold nanoparticle formulation composed of small interfering RNAs (siRNAs) targeting the Bcl-2-like protein 12 (BCL2L12) sequence and conjugated to gold nanoparticles, with potential antineoplastic activity. Upon administration of SNA NU-0129, the siRNA prevents the translation of the BCL2L12 gene. Inhibiting the expression of BCL2L12 by NU-0129 induces tumor cell apoptosis. Bcl2L12, a protein belonging to the Bcl-2 protein family, is overexpressed in glioblastoma multiforme (GBM) and plays a role in tumor cell progression and tumor cell resistance to apoptosis. NU-0129 is able to cross the blood brain barrier (BBB).	Spherical Nucleic Acid Nanoparticle NU-0129		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131369>	C217121	Pediatric Quality of Life Inventory-Multidimensional Fatigue Scale|PedsQL Multi-Dimensional Fatigue Scale|PedsQL Multidimensional Fatigue Scale|PedsQL-Fatigue|PedsQL-Fatigue Scale|PedsQL-MFS	An 18 item component of the Pediatric Quality of Life Inventory is a generic symptom-specific instrument to measure fatigue in pediatric patients ages 2-18 comprised of General Fatigue, Sleep/Rest Fatigue, and Cognitive Fatigue domains.			Intellectual Product	GCT Authorized Value Terminology|GCT Patient Reported Outcomes Metadata Table|Pediatric Quality of Life Inventory
C13136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13136>	C13432	19q13.2-q13.3	A chromosome band present on 19q			Gene or Genome	
C131370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131370>	C104301	Feel Too Tired to do Things I Like to Do Question|Do you feel too tired to do the things you like to do|Feel Too Tired to do Things I Like to Do|Feeling too tired to do the things that he/she likes to do|I feel too tired to do the things I like to do|Too Tired to do Things I Like to Do	A question about whether an individual feels or felt too tired to do the things they like to do.			Intellectual Product	Pediatric Quality of Life Inventory
C131371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131371>	C104301	Feel Too Tired to Spend Time with Friends Question|Do you feel too tired to spend time with your friends|Feel Too Tired to Spend Time with Friends|Feeling too tired to spend time with his/her friends|I feel too tired to spend time with my friends|Too Tired to Spend Time with Friends	A question about whether an individual feels or felt too tired to spend time with friends.			Intellectual Product	Pediatric Quality of Life Inventory
C131372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131372>	C173398	Have Trouble Finishing Things Question|Do you have trouble finishing things|Have Trouble Finishing Things|I have trouble finishing things|Trouble Finishing Things|Trouble finishing things	A question about whether an individual has or had trouble finishing things.			Intellectual Product	Pediatric Quality of Life Inventory
C131373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131373>	C173398	Have Trouble Starting Things Question|Do you have trouble starting things|Have Trouble Starting Things|I have trouble starting things|Trouble Starting Things|Trouble starting things	A question about whether an individual has or had trouble starting things.			Intellectual Product	Pediatric Quality of Life Inventory
C131374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131374>	C173925	Sleep a Lot Question|Do you sleep a lot|I sleep a lot|Sleep a Lot|Sleeping a lot	A question about whether an individual sleeps or slept a lot.			Intellectual Product	Pediatric Quality of Life Inventory
C131375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131375>	C173925|C173398	Hard to Sleep Through Night Question|Difficulty sleeping through the night|Hard to Sleep Through Night|Is it hard for you to sleep through the night|It is hard for me to sleep through the night	A question about whether an individual finds or found it hard to sleep through the night.			Intellectual Product	Pediatric Quality of Life Inventory
C131376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131376>	C104301	Feel Tired When Wake Up Question|Do you feel tired when you wake up in the morning|Feel Tired When Wake Up|Feeling tired when he/she wakes up in the morning|I feel tired when I wake up in the morning|Tired When Wake Up	A question about whether an individual feels or felt tired upon waking up in the morning.			Intellectual Product	Pediatric Quality of Life Inventory
C131377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131377>	C91102	Rest a Lot Question|Do you rest a lot|I rest a lot|Rest a Lot|Resting a lot	A question about whether an individual rests or rested a lot.			Intellectual Product	Pediatric Quality of Life Inventory
C131378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131378>	C91102	Take Lots of Naps Question|Do you take a lot of naps|I take a lot of naps|Take Lots of Naps|Taking a lot of naps	A question about whether an individual takes or took a lot of naps.			Intellectual Product	Pediatric Quality of Life Inventory
C131379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131379>	C91102	Spend a Lot of Time in Bed Question|Do you spend a lot of time in bed|I spend a lot of time in bed|Spend a Lot of Time in Bed|Spending a lot of time in bed	A question about whether an individual spends or spent a lot of time in bed.			Intellectual Product	Pediatric Quality of Life Inventory
C13137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13137>	C13432	13q33	A chromosome band present on 13q			Gene or Genome	
C131380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131380>	C173398	Hard to Keep Attention on Things Question|Difficulty keeping his/her attention on things|Hard to Keep Attention on Things|Is it hard for you to keep your attention on things|It is hard for me to keep my attention on things	A question about whether an individual finds or found it hard to keep their attention on things.			Intellectual Product	Pediatric Quality of Life Inventory
C131381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131381>	C173398	Hard to Remember What People Tell Me Question|Difficulty remembering what people tell him/her|Hard to Remember What People Tell Me|Is it hard for you to remember what people tell you|It is hard for me to remember what people tell me	A question about whether an individual finds or found it hard to remember what people told them.			Intellectual Product	Pediatric Quality of Life Inventory
C131382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131382>	C173398	Hard to Remember What I Just Heard Question|Difficulty remembering what he/she just heard|Hard to Remember What I Just Heard|Is it hard for you to remember what you just heard|It is hard for me to remember what I just heard	A question about whether an individual finds or found it hard to remember what they just heard.			Intellectual Product	Pediatric Quality of Life Inventory
C131383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131383>	C173597|C173398	Hard to Think Quickly Question|Difficulty thinking quickly|Hard to Think Quickly|Is it hard for you to think quickly|It is hard for me to think quickly	A question about whether an individual finds or found it hard to think quickly.			Intellectual Product	Pediatric Quality of Life Inventory
C131384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131384>	C173597|C173398	Have Trouble Remembering What I Was Just Thinking Question|Do you have trouble remembering what you were just thinking|Have Trouble Remembering What I Was Just Thinking|I have trouble remembering what I was just thinking|Trouble remembering what he/she was just thinking	A question about whether an individual has or had trouble remembering what they were just thinking.			Intellectual Product	Pediatric Quality of Life Inventory
C131385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131385>	C173398	Have Trouble Remembering More Than One Thing at a Time Question|Do you have trouble remembering more than one thing at a time|Have Trouble Remembering More Than One Thing at a Time|I have trouble remembering more than one thing at a time|Trouble remembering more than one thing at a time	A question about whether an individual has or had trouble remembering more than one thing at a time.			Intellectual Product	Pediatric Quality of Life Inventory
C131386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131386>	C177692	CD3 Positive|CD3 Antigen Positive|CD3 Complex Positive|T-Cell Surface Glycoprotein CD3 Positive|T3 Complex Positive	An indication that the CD3 complex has been detected in a sample.	CD3 Positive		Laboratory or Test Result	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131387>	C91105|C21154	Rotterdam Symptom Checklist|RSCL|Rotterdam Symptom Checklist (RSCL)	A questionnaire designed to measure both physical and psychological aspects of quality of life as an outcome measure of symptom control.			Intellectual Product	
C131388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131388>	C172982	Bothered by Lack of Appetite Question|Bothered by Lack of Appetite|Have you, during the past week, been bothered by lack of appetite	A question about whether an individual is or was bothered by lack of appetite.			Intellectual Product	Rotterdam Symptom Checklist
C131389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131389>	C172982	Bothered by Irritability Question|Bothered by Irritability|Have you, during the past week, been bothered by irritability	A question about whether an individual is or was bothered by irritability.			Intellectual Product	Rotterdam Symptom Checklist
C13138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13138>	C13432	16p13.3-p13.11	A chromosome band present on 16p			Gene or Genome	
C131390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131390>	C173935|C172982	Bothered by Tiredness Question|Bothered by Tiredness|Have you, during the past week, been bothered by tiredness|Tiredness	A question about whether an individual is or was bothered by tiredness.			Intellectual Product	Breast Cancer Prevention Trial Symptom Scales|Rotterdam Symptom Checklist
C131391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131391>	C173934|C172982	Bothered by Worrying Question|Bothered by Worrying|Have you, during the past week, been bothered by worrying	A question about whether an individual is or was bothered by worrying.			Intellectual Product	Rotterdam Symptom Checklist
C131392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131392>	C172982	Bothered by Sore Muscles Question|Bothered by Muscle Soreness|Bothered by Sore Muscles|Have you, during the past week, been bothered by sore muscles	A question about whether an individual is or was bothered by sore muscles.			Intellectual Product	Rotterdam Symptom Checklist
C131393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131393>	C172982	Bothered by Depressed Mood Question|Bothered by Depressed Mood|Bothered by Depression|Feeling depressed, down or blue|Have you, during the past week, been bothered by depressed mood	A question about whether an individual is or was bothered by depressed mood.			Intellectual Product	Menopause-specific Quality of Life Questionnaire|Rotterdam Symptom Checklist
C131394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131394>	C172982	Bothered by Lack of Energy Question|Bothered by Feeling a Lack of Energy|Bothered by Lack of Energy|Have you, during the past week, been bothered by lack of energy|Lack of energy	A question about whether an individual is or was bothered by lack of energy.			Intellectual Product	Breast Cancer Prevention Trial Symptom Scales|Menopause-specific Quality of Life Questionnaire|Rotterdam Symptom Checklist
C131395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131395>	C173346|C172982	Bothered by Low Back Pain Question|Bothered by Low Back Pain|Have you, during the past week, been bothered by low back pain|Low backache	A question about whether an individual is or was bothered by low back pain.			Intellectual Product	Menopause-specific Quality of Life Questionnaire|Rotterdam Symptom Checklist
C131396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131396>	C172982	Bothered by Nervousness Question|Bothered by Nervousness|Have you, during the past week, been bothered by nervousness	A question about whether an individual is or was bothered by nervousness.			Intellectual Product	Rotterdam Symptom Checklist
C131397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131397>	C172982	Bothered by Despairing About the Future Question|Bothered by Despair About the Future|Bothered by Despairing About the Future|Despair About the Future|Have you, during the past week, been bothered by despairing about the future	A question about whether an individual is or was bothered by despairing about the future.			Intellectual Product	Rotterdam Symptom Checklist
C131398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131398>	C173925|C173398|C172982	Bothered by Difficulty Sleeping Question|Bothered by Difficulty Sleeping|Have you, during the past week, been bothered by difficulty sleeping	A question about whether an individual is or was bothered by difficulty sleeping.			Intellectual Product	Rotterdam Symptom Checklist
C131399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131399>	C172982	Bothered by Headaches Question|Bothered by Headaches|Have you, during the past week, been bothered by headaches	A question about whether an individual is or was bothered by headaches.			Intellectual Product	Rotterdam Symptom Checklist
C13139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13139>	C13432	3q22-q24	A chromosome band present on 3q			Gene or Genome	
C1313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1313>	C78568|C29701|C2080	Misoprostol|(11alpha,13E)-(+-)-11,16-Dihydroxy-16-methyl-9-oxo-prost-13-en-1-oic Acid Methyl Ester|Cytotec|MISOPROSTOL|Methyl (11alpha,13E)-11,16-Dihydroxy-16-methyl-9-oxoprost-13-en-1-oate|SC-29333|misoprostol				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C131400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131400>	C173600|C172982	Bothered by Dizziness Question|Bothered by Dizziness|Have you, during the past week, been bothered by dizziness	A question about whether an individual is or was bothered by dizziness.			Intellectual Product	Rotterdam Symptom Checklist
C131401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131401>	C206503	Bothered by Decreased Sexual Interest Question|Bothered by Decreased Sexual Interest|Have you, during the past week, been bothered by decreased sexual interest	A question about whether an individual is or was bothered by decreased sexual interest.			Intellectual Product	Rotterdam Symptom Checklist
C131402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131402>	C172982	Bothered by Tension Question|Bothered by Tension|Have you, during the past week, been bothered by tension	A question about whether an individual is or was bothered by tension.			Intellectual Product	Rotterdam Symptom Checklist
C131403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131403>	C172982	Bothered by Abdominal Aches Question|Bothered by Abdominal Aches|Have you, during the past week, been bothered by abdominal (stomach) aches	A question about whether an individual is or was bothered by abdominal (stomach) aches.			Intellectual Product	Rotterdam Symptom Checklist
C131404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131404>	C173386|C172982	Bothered by Anxiety Question|Bothered by Anxiety|Have you, during the past week, been bothered by anxiety	A question about whether an individual is or was bothered by anxiety.			Intellectual Product	Rotterdam Symptom Checklist
C131405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131405>	C173936|C172982	Bothered by Diarrhea Question|Bothered by Diarrhea|Have you, during the past week, been bothered by diarrhoea	A question about whether an individual is or was bothered by diarrhea.			Intellectual Product	Rotterdam Symptom Checklist
C131406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131406>	C172982	Bothered by Shivering Question|Bothered by Shivering|Have you, during the past week, been bothered by shivering	A question about whether an individual is or was bothered by shivering.			Intellectual Product	Rotterdam Symptom Checklist
C131407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131407>	C173734|C172982	Bothered by Tingling Hands or Feet Question|Bothered by Tingling Hands or Feet|Have you, during the past week, been bothered by tingling hands or feet	A question about whether an individual is or was bothered by tingling hands or feet.			Intellectual Product	Rotterdam Symptom Checklist
C131408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131408>	C173454|C173346|C172982	Bothered by Sore Mouth and/or Pain When Swallowing Question|Bothered by Sore Mouth and/or Pain When Swallowing|Have you, during the past week, been bothered by sore mouth/pain when swallowing	A question about whether an individual is or was bothered by sore mouth/pain when swallowing.			Intellectual Product	Rotterdam Symptom Checklist
C131409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131409>	C172982	Bothered by Burning and/or Sore Eyes Question|Bothered by Burning and/or Sore Eyes|Have you, during the past week, been bothered by burning/sore eyes	A question about whether an individual is or was bothered by burning/sore eyes.			Intellectual Product	Rotterdam Symptom Checklist
C13140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13140>	C13432	7q11-q22	A chromosome band present on 7q			Gene or Genome	
C131410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131410>	C172982	Bothered by Shortness of Breath Question|Bothered by Shortness of Breath|Have you, during the past week, been bothered by shortness of breath	A question about whether an individual is or was bothered by shortness of breath.			Intellectual Product	Rotterdam Symptom Checklist
C131411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131411>	C172982	Bothered by Dry Mouth Question|Bothered by Dry Mouth|Have you, during the past week, been bothered by dry mouth	A question about whether an individual is or was bothered by dry mouth.			Intellectual Product	Rotterdam Symptom Checklist
C131412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131412>	C173045	Ability to Care for Myself Question|Ability to Care for Myself|care for myself	A question about the ability of an individual to care for themself.			Intellectual Product	Rotterdam Symptom Checklist
C131413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131413>	C173924|C173045	Ability to Go to Work Question|Ability to Go to Work|go to work	A question about the ability of an individual to go to work.			Intellectual Product	Rotterdam Symptom Checklist
C131414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131414>	C226656|C178389	Only with Help|only with help	A response indicating that an individual is only able to do an activity with help.			Intellectual Product	Rotterdam Symptom Checklist
C131415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131415>	C226656|C178389	Without Help, With Difficulty|without help, with difficulty	A response indicating that an individual is able to do an activity without help but it is difficult.			Intellectual Product	Rotterdam Symptom Checklist
C131416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131416>	C226673	Moderately Good|moderately good	A subjective response indicating that something is moderately good.			Intellectual Product	Rotterdam Symptom Checklist
C131417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131417>	C226673|C226633	Neither Good nor Bad|neither good or bad	A subjective response indicating that something is neither good nor bad.			Intellectual Product	Rotterdam Symptom Checklist
C131418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131418>	C226694	Rather Poor|rather poor	A subjective response indicating that something is rather poor.			Intellectual Product	Rotterdam Symptom Checklist
C131419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131419>	C226694	Extremely Poor|extremely poor	A subjective response indicating that something is extremely poor.			Intellectual Product	Rotterdam Symptom Checklist
C131420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131420>	C84978	Blomstrand Type Chondrodysplasia	An autosomal recessive lethal condition caused by inactivating mutation(s) in the PTH1R gene, encoding parathyroid hormone/parathyroid hormone-related peptide receptor. This condition is characterized by short limbs, polyhydramnios, hydrops fetalis, facial anomalies, increased bone density, and advanced skeletal maturation.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131421>	C26878	Calcium Deficiency Rickets|Calciopenic Rickets	Rickets due to low calcium concentrations, the cause of which can be nutritional or genetic.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131422>	C118675	Cholesterol Side-Chain Cleavage Deficiency|P450scc Deficiency	CLAH due to loss-of-function mutations in the CYP11A1 gene, resulting in decreased or absent activity of the enzyme P450scc, which leads to reduced conversion of cholesterol to pregnenolone, the first step in steroidogenesis.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131423>	C34360	Classic Congenital Adrenal Hyperplasia	A severe form of congenital adrenal hyperplasia characterized by very low or absent activity of an enzyme in the steroidogenic pathway typically presenting early in life, and requiring life-long cortisol replacement.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131425>	C171128	Congenital Hyperinsulinism|HHI|Hyperinsulinemia of Infancy|Hyperinsulinemic Hypoglycemia|Neonatal Hyperinsulinism|Nesidioblastosis	An etiologically heterogenous condition resulting in dysregulated insulin secretion whose cause is present from birth. It is the most common cause of persistent hypoglycemia in neonates, infants and children.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C131426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131426>	C34360	Congenital Lipoid Adrenal Hyperplasia|CLAH	Congenital adrenal hyperplasia resulting from the deposition of lipid in the adrenal glands due to a defect of intracellular cholesterol transport or metabolism. The condition is characterized by deficiencies of glucocorticoids, mineralocorticoids, and sex steroids: 46,XY infants are undervirilized, whereas 46,XX infants have no genital manifestations.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131427>	C113351	Congenital Ovarian Failure	Ovarian failure, the cause of which is present at birth.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C131428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131428>	C131080	Congenital Testicular Failure	Testicular failure, the cause of which is present at birth.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C131429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131429>	C34712	Craniodiaphyseal Dysplasia|CDD|Lionitis	An autosomal dominant or recessive form of craniotubular hyperostosis due to mutation(s) in the SOST gene, encoding sclerostin. This condition is characterized by massive generalized hyperostosis and sclerosis, especially involving the skull and facial bones, which is so severe that the resulting facial distortion is referred to as 'leontiasis ossea'; the bone deposition results in progressive stenosis of craniofacial foramina and can lead to severe neurologic impairment in childhood.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C13142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13142>	C33923|C13055	Mucus-Secreting Cell	It is the epithelium cell that produces mucin gel adherent to the mucosal surface. Mucus-secreting cells are widely distributed through the body. (NCI)			Cell	
C131430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131430>	C34712	Craniotubular Hyperostosis	A group of sclerosing bone dysplasias characterized by pronounced sclerosis of the cranial vault and the long bones, resulting in increased cortical bone density. Most cases are caused by mutation(s) in the SOST or LRP5 genes, encoding sclerostin and low-density lipoprotein receptor-related protein 5, respectively. Other genes have been implicated, and some cases have been described, but do not yet have identified genetic mutations.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131431>	C121749	Defective Thyroglobulin Synthesis	Impairment in the intracellular synthesis of thyroglobulin.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131432>	C121749	Defective Thyroglobulin Transport	Impairment in the intracellular transport of thyroglobulin.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131433>	C3071	Neonatal Graves Disease	Graves disease in the neonate resulting from transplacental passage of thyrotropin receptor antibody.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131434>	C129839	Ceramide Nanoliposome|CNL|KN 001|KN-001|KN-01|Nanoliposomal Ceramide	A lipid-based nanoparticle formulation composed of the apoptosis-inducing sphingolipid ceramide encapsulated within nanoliposomes, with potential apoptotic and antineoplastic activities. Upon administration, ceramide nanoliposomes accumulate in the tumor environment, due to the unique properties of the tumor vasculature, and easily enter tumor cells. This delivers ceramide inside the tumor cells, where ceramide induces apoptosis. Although the process is not completely understood, ceramide-dependent apoptosis most likely results from the downregulation of nutrient transporter proteins, which prevents cellular access to extracellular nutrients and causes tumor cell starvation. This selectively destroys tumor cells. Ceramide alone is insoluble and has a very short half-life; therefore, the nanoliposome formulation increases its solubility and half-life. Ceramide plays a key role in the regulation of autophagy, apoptosis, survival and proliferation. Serving as a tumor suppressor lipid, the expression of ceramide is inversely correlated with tumor cell growth, survival and metastasis.	Ceramide Nanoliposome		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131435>	C3492	Deiodinase Deficiency|Dehalogenase Deficiency	Presumed loss-of-function mutation(s) in the IYD gene, resulting in reduced activity of the enzyme iodotyrosine deiodinase.			Laboratory or Test Result	NICHD Terminology|Pediatric Endocrinology Terminology
C131436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131436>	C26785	Diffuse Goiter	Enlargement of the entire thyroid gland without discrete mass(es).			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131437>	C26785	Nodular Goiter|Nodular Hyperplasia|Thyroid Nodular Hyperplasia	Goiter characterized by discrete tissue mass(es) that may or may not produce thyroid hormones.			Disease or Syndrome	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|GDC Terminology|GDC Value Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C131438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131438>	C131437	Multinodular Goiter	Nodular goiter characterized by more than one discrete tissue mass.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131439>	C215221|C213143	Anti-CDH6 Antibody-drug Conjugate HKT288|Anti-CDH6 ADC HKT288|HKT 288|HKT-288|HKT-288|HKT288|Maytansine-based ADC HKT-288	An immunoconjugate consisting of a human monoclonal antibody directed against the tumor-associated antigen (TAA) cadherin-6 (CDH6; CDH-6) conjugated to a maytansine-based cytotoxic agent, with potential antineoplastic activity. The monoclonal antibody moiety of HKT288 targets and binds to CDH6 located on tumor cell surfaces. After internalization, the maytansine moiety binds to tubulin, which disrupts microtubule assembly/disassembly dynamics and inhibits both division and proliferation of CDH6-expressing tumor cells. CDH6, a member of the cadherin family and overexpressed by a variety of cancers, plays a key role in tumor cell proliferation.	Anti-CDH6 Antibody-drug Conjugate HKT288		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C13143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13143>	C33923	Club Cell|Clara Cell|Nonciliated Bronchiolar Epithelial Cell	A rounded, club-shaped, nonciliated cell found in between ciliated cells in the epithelium of respiratory and terminal bronchioles. It has a secretory function.			Body Part, Organ, or Organ Component	
C131440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131440>	C26785	Hypothyroid Goiter	Goiter associated with reduced thyroid hormone secretion.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131442>	C34360	Non-Classic Congenital Adrenal Hyperplasia|Late-onset Congenital Adrenal Hyperplasia	A milder form of congenital adrenal hyperplasia characterized by decreased activity of an enzyme in the steroidogenic pathway, typically presenting later in life, that does not require life-long cortisol replacement.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131443>	C69408	HLA-A*0205 Positive Cells Present|HLA-A*0205 Positive|HLA-A*02:05 Positive|HLA-A*02:05 Positive Cells Present|HLA-A0205 Positive	An indication that cells expressing HLA-A*0205 have been detected in a sample.	HLA-A*0205 Positive Cells Present		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131444>	C69408	HLA-A*0206 Positive Cells Present|HLA-A*0206 Positive|HLA-A*02:06 Positive|HLA-A*02:06 Positive Cells Present|HLA-A0206 Positive	An indication that cells expressing HLA-A*0206 have been detected in a sample.	HLA-A*0206 Positive Cells Present		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131445>	C131447|C131421	Nutritional Calcium Deficient Rickets|Nutritional Calciopenic Rickets	Nutritional rickets due to dietary deficiency of calcium.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131446>	C131447	Nutritional Hypophosphatemic Rickets	Hypophosphatemic rickets due to insufficient dietary phosphate intake or absorption.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131447>	C26878	Nutritional Rickets	Rickets due to dietary deficiency of calcium, phosphate, or vitamin D.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131448>	C131447|C114830	Nutritional Vitamin D Deficiency Rickets	Nutritional rickets due to dietary deficiency of vitamin D.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131449>	C26878	Hypophosphatemic Rickets|Phosphopenic Rickets	Rickets due to low serum phosphate concentrations, the cause of which can be nutritional or genetic. This condition is characterized by normal parathyroid hormone concentrations, usually caused by renal phosphate wasting occurring in isolation or as part of a renal tubular disorder, and characterized by resistance to treatment with ultraviolet radiation or vitamin D.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C13144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13144>	C32053|C12849	Alveolar Cell Type I|Squamous Alveolar Lining Cell|Type I Pneumocyte	A squamous cell that forms the inner lining of the alveoli and is distinguished by its greatly attenuated cytoplasm and paucity of organelles.			Cell	
C131450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131450>	C131449	Hereditary Hypophosphatemic Rickets with Hypercalciuria|HHRH|Hypercalciuric Hypophosphatemic Rickets|Hypophosphatemic Hypercalciuric Rickets	An autosomal recessive form of hypophosphatemic rickets caused by inactivating mutation(s) in the SLC34A3 gene, encoding sodium-dependent phosphate transport protein 2C, a protein involved in maintenance of inorganic phosphate concentration in the kidney. The condition is characterized by elevated 1,25-dihydroxyvitamin D (calcitriol) concentrations, resulting in increased intestinal calcium absorption and hypercalciuria. This form of hypophosphatemic rickets is also distinguished by the lack of elevated fibroblast growth factor 23 (FGF23) concentrations.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131451>	C120446	Familial Glucocorticoid Deficiency Type 3|GCCD3|Non-classic CLAH (FGD variant)	A variant of familial glucocorticoid deficiency caused by a defect in the steroidogenic acute regulatory protein; it may mimic lipoid congenital adrenal hyperplasia.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C131452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131452>	C120446	Familial Glucocorticoid Deficiency Type 4|GCCD4	Familial glucocorticoid deficiency caused by mutation(s) in the NNT gene encoding nicotinamide nucleotide transhydrogenase.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C131453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131453>	C45581	EMSY Gene Amplification|C11orf30 Gene Amplification|EMSY, BRCA2 Interacting Transcriptional Repressor Gene Amplification|EMSY, BRCA2-Interacting Transcriptional Repressor Gene Amplification|GL002 Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the EMSY gene.	EMSY Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131454>	C45581	FANCD2 Gene Amplification|FA-D2 Gene Amplification|FA4 Gene Amplification|FACD Gene Amplification|FAD Gene Amplification|FAD2 Gene Amplification|FANCD Gene Amplification|Fanconi Anemia Complementation Group D2 Gene Amplification|Fanconi Anemia, Complementation Group D2 Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the FANCD2 gene.	FANCD2 Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131455>	C45581	FANCE Gene Amplification|FACE Gene Amplification|FAE Gene Amplification|Fanconi Anemia Complementation Group E Gene Amplification|Fanconi Anemia, Complementation Group E Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the FANCE gene.	FANCE Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131456>	C45581	FANCC Gene Amplification|FA3 Gene Amplification|FAC Gene Amplification|FACC Gene Amplification|Fanconi Anemia Complementation Group C Gene Amplification|Fanconi Anemia, Complementation Group C Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the FANCC gene.	FANCC Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131457>	C45581	FANCA Gene Amplification|FA Gene Amplification|FA-H Gene Amplification|FA1 Gene Amplification|FAA Gene Amplification|FACA Gene Amplification|FAH Gene Amplification|FANCH Gene Amplification|Fanconi Anemia Complementation Group A Gene Amplification|Fanconi Anemia, Complementation Group A Gene Amplification|Fanconi Anemia, Complementation Group H Gene Amplification|Fanconi Anemia, Type 1 Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the FANCA gene.	FANCA Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131458>	C157646	Mismatch Repair Protein Proficient|MMR-P|MMRP|Mismatch Repair Protein-Proficient|pMMR	Indicates that normal concentrations of unmutated mismatch repair proteins have been detected in a sample.	Mismatch Repair Protein Proficient		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131459>	C103223	Microsatellite Stable|MSI Stable|MSI stable|MSS|MSS|Stable	Indicates that no positive loci have been detected in the microsatellite instability (MSI) biomarkers in a sample.	Microsatellite Stable		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C13145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13145>	C12578	Epithelial Receptor Cell	A cell on the surface of the body or lining a body cavity that responds to physical and chemical stimuli by sending information to the central nervous system.			Body Part, Organ, or Organ Component	
C131460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131460>	C138941	PDGFRA Positive|CD140A Positive|PDGFR-2 Positive|PDGFR2 Positive|PDGFRalpha Positive|Platelet Derived Growth Factor Receptor Alpha Positive|Platelet-Derived Growth Factor Receptor Alpha Positive|RHEPDGFRA Positive	Indicates that PDGFRA expression has been detected in a sample.	PDGFRA Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131461>	C128821	MSH2 NM_000251.2:c.1906G>C|HNPCC c.1906G>C|HNPCC1 c.1906G>C|MSH2 c.1906G>C|MutS Homolog 2 c.1906G>C|NM_000251.2:c.1906G>C|Postmeiotic Segregation Increased 1 c.1906G>C	A nucleotide substitution at position 1906 of the coding sequence of the MSH2 gene where guanine has been mutated to cytosine.	MSH2 NM_000251.2:c.1906G>C		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131462>	C97928	MSH2 Protein Variant|DNA Mismatch Repair Protein Msh2 Protein Variant|MutS Homolog 2 Protein Variant|MutS Protein Homolog 2 Protein Variant	A variation in the amino acid sequence for DNA mismatch repair protein Msh2.	MSH2 Protein Variant		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C131463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131463>	C131462	MSH2 NP_000242.1:p.A636P|DNA Mismatch Repair Protein Msh2 A636P|DNA Mismatch Repair Protein Msh2 Ala636Pro|MSH2 A636P|MSH2 Ala636Pro|MSH2 NP_000242.1:p.Ala636Pro|MSH2 p.A636P|MSH2 p.Ala636Pro|MutS Homolog 2 A636P|MutS Homolog 2 Ala636Pro|MutS Protein Homolog 2 A636P|MutS Protein Homolog 2 Ala636Pro|NP_000242.1:p.A636P|NP_000242.1:p.Ala636Pro	A change in the amino acid residue at position 636 in DNA mismatch repair protein Msh2 where alanine has been replaced by proline.	MSH2 NP_000242.1:p.A636P		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131464>	C43287|C17354	BLM NM_000057.3:c.2207_2212delinsTAGATTC|BLM NM_000057.3:c.2207_2212delATCTGAins7|BLM NM_000057.3:c.2207_2212delATCTGAinsTAGATTC|BLM NM_000057.3:c.2207_2212delATCTGAinsTAGATTC|BLM c.2207-2212delATCTGAinsTAGATTC|BLM c.2207_2212delATCTGAins7|BLM c.2207_2212delATCTGAinsTAGATTC|BLM c2281delATCTGAinsTAGATTC|BLM(Ash) Mutation|BS c.2207_2212delATCTGAinsTAGATTC|Bloom Syndrome c.2207_2212delATCTGAinsTAGATTC|NM_000057.3:c.2207_2212delATCTGAins7|NM_000057.3:c.2207_2212delATCTGAinsTAGATTC|NM_000057.3:c.2207_2212delinsTAGATTC|RECQ2 c.2207_2212elATCTGAinsTAGATTC|RECQL2 c.2207_2212delATCTGAinsTAGATTC|RECQL3 c.2207_2212delATCTGAinsTAGATTC|blmAsh Mutation	A complex mutation in the BLM gene consisting of a 6 base pair deletion of the nucleotide sequence ATCTGA encompassing nucleic acid positions 2207 through 2212 accompanied by an insertion of 7 base pairs with the sequence TAGATTC.	BLM NM_000057.3:c.2207_2212delATCTGAinsTAGATTC		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131465>	C97928	BLM Protein Variant|Bloom Syndrome Protein Variant|DNA Helicase, RecQ-Like Type 2 Protein Variant|RecQ Protein-Like 3 Protein Variant|RecQ2 Protein Variant	A variation in the amino acid sequence for Bloom syndrome protein.	BLM Protein Variant		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131466>	C131465	BLM NP_000048.1:p.Y736fs*4|BLM NP_000048.1:p.Tyr736fs*4|BLM Tyr736fs*4|BLM Y736fs*4|BLM p.Tyr736fs*4|BLM p.Y736fs*4|BLM(Ash) Protein|Bloom Syndrome Protein Tyr736fs*4|Bloom Syndrome Protein Y736fs*4|DNA Helicase, RecQ-Like Type 2 Tyr736fs*4|DNA Helicase, RecQ-Like Type 2 Y736fs*4|NP_000048.1:p.Tyr736fs*4|NP_000048.1:p.Y736fs*4|RecQ Protein-Like 3 Tyr736fs*4|RecQ Protein-Like 3 Y736fs*4|RecQ2 Tyr736fs*4|RecQ2 Y736fs*4|blmAsh Protein	A change in the amino acid sequence of Bloom syndrome protein where a frameshift mutation results in the replacement of a tyrosine residue at position 736 with 3 non-canonic amino acids followed by a stop codon.	BLM NP_000048.1:p.Y736fs*4		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131467>	C97928	BRCA1 Protein Variant|BRCA1/BRCA2-Containing Complex, Subunit 1 Protein Variant|Breast Cancer Type 1 Susceptibility Protein Variant|Breast and Ovarian Cancer Susceptibility Protein 1 Protein Variant|Breast-Ovarian Cancer Protein Variant|Fanconi Anemia, Complementation Group S Protein Variant	A variation in the amino acid sequence for breast cancer type 1 susceptibility protein.	BRCA1 Protein Variant		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131468>	C97928	BRCA2 Protein Variant|BRCA1/BRCA2-Containing Complex, Subunit 2 Protein Variant|Breast Cancer 2 Tumor Suppressor Protein Variant|Breast Cancer 2, Early Onset Protein Variant|Breast Cancer Type 2 Susceptibility Protein Variant|Breast and Ovarian Cancer Susceptibility Protein 2 Protein Variant|Fanconi Anemia Group D1 Protein Variant	A variation in the amino acid sequence for breast cancer type 2 susceptibility protein.	BRCA2 Protein Variant		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131469>	C134527	Bovine Leukemia	A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood which occurs in cattle			Neoplastic Process	Cellosaurus Disease Terminology
C13146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13146>	C12578	Intercalated Cell|Dark Cell|Intercalated Cells	The intercalated cell is an epithelial cell of the renal collecting tubule that is specialized for H+ and HCO3 transport. These cells exist in two types, [alpha] and [beta]. The [alpha] cell secretes H+ into the lumen by an apical H+ ATPase and a basolateral Cl:HCO3. The [beta] cell secretes HCO3- into the lumen by an apical Cl:HCO3 and a basolateral H+ ATPase.			Cell	
C131470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131470>	C137802	Bovine Congenital Erythropoietic Porphyria	A congenital metabolic disorder characterized by a deficiency in the enzyme uroporphyrinogen III synthase, which occurs in cattle.			Disease or Syndrome	Cellosaurus Disease Terminology
C131472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131472>	C134527	Bovine Protoporphyria	A congenital metabolic disorder characterized by a deficiency in the enzyme ferrochelatase, which occurs in cattle.			Neoplastic Process	Cellosaurus Disease Terminology
C131473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131473>	C19635|C17354	BRCA1 NM_007294.3:c.68_69delAG|BRCA-1 c.68_69delAG|BRCA1 185delAG|BRCA1 187delAG|BRCA1 c.68_69delAG|BROVCA1 c.68_69delAG|Breast Cancer 1 c.68_69delAG|Breast Cancer 1, Early Onset c.68_69delAG|Breast Cancer Type 1 Susceptibility c.68_69delAG|NM_007294.3:c.68_69delAG	A deletion of the two nucleotides in positions 68 and 69 from the coding sequence of the BRCA1 gene.	BRCA1 NM_007294.3:c.68_69delAG		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131474>	C131467	BRCA1 NP_009225.1:p.E23Vfs*17|BRCA1 E23Vfs*17|BRCA1 Glu23Valfs|BRCA1 NP_009225.1:p.E23Vfs|BRCA1 NP_009225.1:p.Glu23Valfs|BRCA1 NP_009225.1:p.Glu23ValfsTer17|BRCA1 p.(Glu23ValfsTer17)|BRCA1 p.Glu23Valfs|BRCA1/BRCA2-Containing Complex, Subunit 1 Protein E23Vfs|BRCA1/BRCA2-Containing Complex, Subunit 1 Protein Glu23Valfs|Breast Cancer Type 1 Susceptibility Protein E23Vfs|Breast Cancer Type 1 Susceptibility Protein Glu23Valfs|Breast and Ovarian Cancer Susceptibility Protein 1 Protein E23Vfs|Breast and Ovarian Cancer Susceptibility Protein 1 Protein Glu23Valfs|Breast-Ovarian Cancer Protein E23Vfs|Breast-Ovarian Cancer Protein Glu23Valfs|Fanconi Anemia, Complementation Group S E23Vfs|Fanconi Anemia, Complementation Group S Glu23Valfs|NP_009225.1:p.E23Vfs|NP_009225.1:p.Glu23Valfs	A change in the amino acid sequence of breast cancer type 1 susceptibility protein where a deletion mutation results in the replacement of the glutamic acid at position 23 with a valine immediately by 16 non-canonical amino acids and a stop codon.	BRCA1 NP_009225.1:p.E23Vfs		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131475>	C19635	BRCA1 NM_007294.3:c.5265_5266insC|BRCA-1 c.5265_5266insC|BRCA1 5382_5383insC,5382insC|BRCA1 5382insC|BRCA1 c.5265_5266insC|BRCA1 c.5266dup|BRCA1 c.5266dupC|BROVCA1 c.5265_5266insC|Breast Cancer 1 c.5265_5266insC|Breast Cancer 1, Early Onset c.5265_5266insC|Breast Cancer Type 1 Susceptibility c.5265_5266insC|NM_007294.3:c.5265_5266insC|NM_007294.3:c.5266dup|NM_007294.3c.5266dupC	An insertion of a single cytosine nucleotide between positions 5265 and 5266 of the coding sequence of the BRCA1 gene.	BRCA1 NM_007294.3:c.5265_5266insC		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131476>	C131467	BRCA1 NP_009225.1:p.Q1756Pfs|BRCA1 Gln1756Profs|BRCA1 NP_009225.1:p.Gln1756Profs|BRCA1 Q1756Pfs|BRCA1 Q1756Pfs*74|BRCA1 p.(Gln1756ProfsTer74)|BRCA1 p.Gln1756Profs|BRCA1 p.Q1756Pfs|BRCA1/BRCA2-Containing Complex, Subunit 1 Protein Gln1756Profs|BRCA1/BRCA2-Containing Complex, Subunit 1 Protein Q1756Pfs|Breast Cancer Type 1 Susceptibility Protein Gln1756Profs|Breast Cancer Type 1 Susceptibility Protein Q1756Pfs|Breast and Ovarian Cancer Susceptibility Protein 1 Protein Gln1756Profs|Breast and Ovarian Cancer Susceptibility Protein 1 Protein Q1756Pfs|Breast-Ovarian Cancer Protein Gln1756Profs|Breast-Ovarian Cancer Protein Q1756Pfs|Fanconi Anemia, Complementation Group S Gln1756Profs|Fanconi Anemia, Complementation Group S Q1756Pfs|NP_009225.1:p.Gln1756Profs|NP_009225.1:p.Q1756Pfs	A change in the amino acid sequence of breast cancer type 1 susceptibility protein where an insertion mutation results in the replacement of the glutamine at position 1756 with a proline immediately followed by a stop codon.	BRCA1 NP_009225.1:p.Q1756Pfs		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131477>	C19636|C17354	BRCA2 NM_000059.3:c.5946delT|BRCA2 6174delT|BRCA2 NM_000059.3:c.5946_5946delT|BRCA2 c.5946_5946delT|BRCA2 c.5946delT|BRCC2 c.5946delT|BROVCA2 c.5946delT|Breast Cancer 2 c.5946delT|Breast Cancer 2, Early Onset Gene c.5946delT|Breast Cancer Type 2 Susceptibility Gene c.5946delT|FANCD1 c.5946delT|NM_000059.3:c.5946_5946delT|NM_000059.3:c.5946delT|XRCC11 c.5946delT	A deletion of the thymine nucleotide at position 5946 of the coding sequence of the BRCA2 gene.	BRCA2 NM_000059.3:c.5946delT		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131478>	C131468	BRCA2 NP_000050.2:p.S1982Rfs*22|BRCA1/BRCA2-Containing Complex, Subunit 2 S1982Rfs|BRCA1/BRCA2-Containing Complex, Subunit 2 Ser1982Argfs|BRCA2 NP_000050.2:p.S1982Rfs|BRCA2 NP_000050.2:p.Ser1982ArgfsTer22|BRCA2 S1982Rfs|BRCA2 Ser1982Argfs|BRCA2 p.S1982Rfs|BRCA2 p.Ser1982Argfs|Breast Cancer 2 Tumor Suppressor S1982Rfs|Breast Cancer 2 Tumor Suppressor Ser1982Argfs|Breast Cancer 2, Early Onset Protein S1982Rfs|Breast Cancer 2, Early Onset Protein Ser1982Argfs|Breast Cancer Type 2 Susceptibility Protein S1982Rfs|Breast Cancer Type 2 Susceptibility Protein Ser1982Argfs|Breast and Ovarian Cancer Susceptibility Protein 2 S1982Rfs|Breast and Ovarian Cancer Susceptibility Protein 2 Ser1982Argfs|Fanconi Anemia Group D1 Protein S1982Rfs|Fanconi Anemia Group D1 Protein Ser1982Argfs|NP_000050.2:p.S1982Rfs|NP_000050.2:p.Ser1982Argfs	A change in the amino acid sequence of breast cancer type 2 susceptibility protein where a deletion mutation results in the replacement of the serine at position 1982 with an arginine followed by 21 non-canonical amino acids and a stop codon.	BRCA2 NP_000050.2:p.S1982Rfs		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131479>	C97927|C131783	ATR Gene Mutation|ATR Serine/Threonine Kinase Gene Mutation|Ataxia Telangiectasia and Rad3 Related Gene Mutation|FRP1 Gene Mutation|MEC1 Gene Mutation	A change in the nucleotide sequence of the ATR gene.	ATR Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13147>	C13145	Taste Bud Cell|Taste Bud Cells	Any of the three types of the cells that constitute the taste bud. They are classified as neuroepithelial (sensory) cells, supporting cells, and basal cells.			Cell	
C131480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131480>	C97927|C159204|C133695	RAD51C Gene Mutation|BROVCA3 Gene Mutation|FANCO Gene Mutation|RAD51 Homolog C Gene Mutation|RAD51 Paralog C Gene Mutation|RAD51L2 Gene Mutation	A change in the nucleotide sequence of the RAD51C gene.	RAD51C Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131481>	C97927|C133695	RAD51D Gene Mutation|BROVCA4 Gene Mutation|R51H3 Gene Mutation|RAD51 Homolog D Gene Mutation|RAD51 Paralog D Gene Mutation|RAD51-Like 3 Gene Mutation|RAD51L3 Gene Mutation|TRAD Gene Mutation	A change in the nucleotide sequence of the RAD51D gene.	RAD51D Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131482>	C165233	RB1 Negative|RB Negative|RB1 Loss|Rb Loss|Retinoblastoma 1 Negative|Retinoblastoma Negative	Indicates that expression of RB1 has not been detected in a sample.	RB1 Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131483>	C20985	Irreversible Electroporation|IRE	A non-thermal ablation modality that is used in the treatment of locally advanced soft tissue tumors. This technique uses ultra-short, but strong, electrical fields to create permanent, lethal nanopores in cell membranes, disrupting cellular homeostasis and causing cell death. The technique may be performed intraoperatively, laparoscopically, or percutaneously.			Therapeutic or Preventive Procedure	
C131484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131484>	C97927	FBXW7 Gene Mutation|AGO Gene Mutation|Archipelago Homolog Gene Mutation|Archipelago Homolog, Drosophila Gene Mutation|CDC4 Gene Mutation|F-Box and WD Repeat Domain Containing 7 Gene Mutation|F-box and WD-40 Domain Protein 7 (Archipelago Homolog, Drosophila) Gene Mutation|FBW6 Gene Mutation|FBW7 Gene Mutation|FBX30 Gene Mutation|FBXW6 Gene Mutation|FBXW7 mutation|SEL-10 Gene Mutation|SEL10 Gene Mutation	A change in the nucleotide sequence of the FBXW7 gene.	FBXW7 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C131485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131485>	C94299|C177694	TNFRSF8 Low|CD30 Antigen Low|CD30 Low|Ki-1 Antigen Low|Ki-1 Low|Low Expression of CD30|Low Expression of TNFRSF8|Tumor Necrosis Factor Receptor Superfamily Member 8 Low	Indicates that low expression of TNFRSF8 has been detected in a sample.	TNFRSF8 Low		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131486>	C158948	JAK2 Fusion Positive|JAK-2 Fusion Positive|JTK10 Fusion Positive|Janus Kinase 2 Fusion Positive|Tyrosine-Protein Kinase JAK2 Fusion Positive	Indicates that expression of a fusion containing sequences from JAK2 has been detected in a sample.	JAK2 Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131487>	C94299|C165233	FCER2 Negative|CD23 Antigen Negative|CD23 Negative|CD23 Negative|Fc Fragment of IgE Receptor I Negative|Fc-Epsilon-RII Negative|Immunoglobulin E-Binding Factor Negative|Low Affinity Immunoglobulin Epsilon Fc Receptor Negative	Indicates that expression of FCER2 has not been detected in a sample.	FCER2 Negative		Laboratory or Test Result	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131488>	C35681	Human Papillomavirus Negative|HPV Negative|Human Papilloma Virus Negative|None	Indicates that human papillomavirus has not been detected in a sample.	Human Papillomavirus Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C131489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131489>	C36386|C133155	ABL2 Gene Rearrangement|ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase Gene Rearrangement|ABLL Gene Rearrangement|ARG Gene Rearrangement|Abelson-Related Gene Rearrangement|v-Abl Abelson Murine Leukemia Viral Oncogene Homolog 2 Gene Rearrangement	A molecular abnormality indicating rearrangement of the ABL2 gene.	ABL2 Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C13148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13148>	C12578	Light Cell	A cell located in the collecting tube of the nephron..			Cell	
C131490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131490>	C180942|C133155	ABL1 Gene Rearrangement|ABL Proto-Oncogene 1, Non-Receptor Tyrosine Kinase Gene Rearrangement|JTK7 Gene Rearrangement|c-ABL1 Gene Rearrangement|v-Abl Abelson Murine Leukemia Viral Oncogene Homolog 1 Gene Rearrangement	A molecular abnormality indicating rearrangement of the ABL1 gene.	ABL1 Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C131491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131491>	C129839	BXQ-350 Nanovesicle Formulation|BXQ-350|SAPOSIN C (NON-GLYCOSYLATED)|SapC-DOPS Nanovesicles|Saposin C-Dioleoylphosphatidylserine Complexes|Saposin C-Dioleoylphosphatidylserine Nanovesicles	A stable, nanovesicle formulation composed of a synthetic form of the human glycoprotein saposin C (SapC) linked to the phospholipid dioleoylphosphatidylserine (DOPS), with potential antineoplastic activity. Upon intravenous administration, the BXQ-350 nanovesicle formulation selectively targets and preferentially accumulates in tumor vessels and cells, due to the leaky nature of tumor vasculature and the presence of phosphatidylserine (PS) lipids in tumor cell membranes. Upon binding to the phospholipids in the tumor cell membrane, SapC fuses with the membrane and is internalized leading to its accumulation within the internal membrane. SapC becomes active in the acidic tumor microenvironment and as a lysosomal sphingolipid activator protein, activates lysosomal enzymes, such as beta-glucosidase, acid sphingomyelinase, and beta-galactosylceramidase. This leads to the degradation of glucosylceramide and sphingomyelin, and the conversion of galactosylceramide to ceramide, respectively. This elevates intracellular ceramide levels, activates caspases and induces ceramide-mediated apoptosis, which together lead to an inhibition of tumor cell growth. SapC plays key roles in lipid transport and organization of biological membranes and has strong lipid membrane binding activity.	BXQ-350 Nanovesicle Formulation		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131492>	C2167|C124800	Ruserontinib|9-Isopropyl-N2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-(pyridin-3-yl)-9H-purine-2,8-diamine|9H-Purine-2,8-diamine, 9-(1-Methylethyl)-N2-[4-(4-methyl-1-piperazinyl)phenyl]-N8-3-pyridinyl-|EGFR/FLT3/Abl Inhibitor SKLB1028|Multikinase Inhibitor SKLB1028|RUSERONTINIB|SKLB 1028|SKLB-1028|SKLB1028	An orally available inhibitor of epidermal growth factor receptor (EGFR), FMS-related tyrosine kinase 3 (FLT3, STK1, CD135 or FLK2), and the non-receptor tyrosine kinase ABL (Abl), with potential antineoplastic activity. Upon administration, ruserontinib specifically binds to and inhibits EGFR, FLT3 and Abl, which interferes with the activation of EGFR-, FLT3- and Abl-mediated signal transduction pathways and reduces cell proliferation in cancer cells that overexpress EGFR, FLT3 and/or Abl. EGFR, EGFR and Abl are all overexpressed in a variety of cancers and play key roles in tumor cell proliferation.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131493>	C200766	Autologous Anti-MG7-CAR T-Lymphocytes|Autologous Anti-MG7 CAR-T Cells|Autologous Anti-MG7-CAR T Lymphocytes|Autologous MG7-CART|Autologous MG7-CART Cells|MG7-targeted Chimeric Antigen Receptor T Cells	A preparation of autologous, engineered T-lymphocytes that express both a second-generation chimeric antigen receptor (CAR) specific for the human gastric carcinoma-associated antigen MG7, and the co-stimulatory molecule 4-1BB (CD137), with potential antineoplastic activity. Upon intratumoral injection, the autologous anti-MG7-CAR T-lymphocytes target and attach to cancer cells expressing MG7. This induces selective toxicity in and causes lysis of MG7-expressing tumor cells. MG7, a glycosylated protein sequence from the tumor-associated antigen (TAA) carcinoembryonic antigen (CEA), plays a key role in the development of certain tumor cell types. 4-1BB enhances T-cell activation and signaling after recognition of MG7.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131494>	C1951|C1663	DPX-E7 HPV Vaccine|DPX E7|DPX-E7|DPX-E7 Vaccine|HPV16-E7 11-19 Nanomer Vaccine DPX-E7|HPV16-E7 11-19 Vaccine|HPV16-E711-19 Peptide Vaccine DPX-E7	A therapeutic vaccine composed of a synthetic peptide consisting of amino acids 11 through 19 of the viral oncoprotein human papillomavirus (HPV) subtype 16 E7 (HPV16-E7 11-19), with potential antineoplastic and immunostimulating activities. Immunization with the DPX-E7 HPV vaccine may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the HPV16-E7 protein. HPV type 16 plays a key role in the carcinogenesis of certain cancers.	HPV16-E711-19 Peptide Vaccine DPX-E7		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131495>	C1951|C1663	HPV Types 16/18 E6/E7-Adenoviral Transduced Autologous Lymphocytes/alpha-Galactosylceramide Vaccine BVAC-C|Autologous Lymphocyte/Tumor Antigen Gene Vaccine BVAC-C|BVAC-C	An immunotherapeutic vaccine composed of the immunoadjuvant alpha-galactosylceramide (a-GC) and autologous antigen presenting cells (APCs), specifically B-lymphocytes and monocytes transfected with an adenoviral vector that expresses the tumor-associated antigens (TAAs) E6 and E7 derived from human papillomavirus (HPV) types 16 and 18 (HPV-16/18 E6/E7), with potential immunostimulating and antineoplastic activities. Upon administration of BVAC-C, the APCs stimulate the immune system to mount a TAA-specific cytotoxic T-lymphocyte (CTL) response, as well as natural killer (NK) cell, NK T-cell (NKT), helper T-cell and antibody-mediated immune responses, against the tumor cells. This directly or indirectly kills the TAA-expressing tumor cells. HPV-16/18 E6/E7 are overexpressed on certain tumor cell types and play key roles in tumor cell proliferation. a-GC, an NKT cell ligand, is used to specifically stimulate NKT cells and to further stimulate an anti-tumor immune response.			Cell|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131496>	C201688	Anti-androgen siRNA SXL01|SXL 01|SXL-01|SXL01	A small-interfering RNA (siRNA) directed against androgen receptor (AR), with potential antineoplastic activity. Upon administration of anti-AR siRNA SXL01, the siRNAs bind to AR mRNAs, which may result in the inhibition of translation of the AR protein. By preventing AR expression, AR-mediated signaling is decreased, which leads to growth inhibition for AR-expressing tumor cells. AR, overexpressed in a variety of cancers, is involved in cellular proliferation and survival.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C131497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131497>	C2124	Fluorine F 18 ODS2004436|18F-ODS2004436|[18F]-ODS2004436	A radioconjugate containing the epidermal growth factor receptor (EGFR) kinase tracer ODS2004436 labeled with fluorine F 18 for potential tumor imaging using positron emission tomography (PET). Upon administration of fluorine F 18 ODS2004436, the ODS2004436 moiety selectively targets and binds to forms of EGFR that contain activating mutations. This allows the visualization of tumor cells expressing activating EGFR mutations using PET. This agent can also be utilized in the prediction of responsiveness to EGFR tyrosine kinase inhibitors (TKIs) and the selection of patients that respond well to those kinase inhibitors that specifically target forms of EGFR with activating mutations. EGFR-activating mutations play a key role in the development of certain tumors and in tumor resistance to a variety of antineoplastic agents.			Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	NCI Drug Dictionary Terminology
C131498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131498>	C2124	Zirconium Zr 89 Nanocolloidal Albumin|89-Zirconium-Nanocoll|89Zr Nanocolloidal Albumin|89Zr-Colloidal Albumin|89Zr-labeled Albumin Nanocolloid|89Zr-labeled Nanocolloid Human Serum Albumin|89Zr-nanocoll	A radioimmunoconjugate composed of a nanoformulation of colloidal human serum albumin (HSA) labeled with zirconium Zr 89 (Zr89), via the bifunctional chelate p-isothiocyanatobenzyldesferrioxamine B, with potential imaging activity using positron emission tomography (PET). Upon administration, the zirconium Zr 89 nanocolloidal albumin travels through the bloodstream and into the lymphatic system. Using PET, the draining pattern of the lymph nodes can be visualized and lymph node status, including that of the sentinel lymph node (SLN), can be detected and analyzed. Compared to some other formulations, the smaller particle size of nanocolloidal albumin allows for enhanced imaging of the lymphatic system.			Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	NCI Drug Dictionary Terminology
C131499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131499>	C16830	Artificial Pancreas|Artificial Pancreas Device System|Automated Insulin Delivery System|Autonomous System for Glycemic Control	A system that connects an insulin pump with a continuous glucose monitor via a software control algorithm to automate insulin delivery.			Manufactured Object	
C13149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13149>	C13147	Type III Epithelial Receptor Cell|Type III Cell	A light cell found in taste buds, characterized by afferent synaptic specializations to intragemminal nerve endings including increased density of the plasma membrane along the nerve and aggregations of synaptic vesicles, and by the presence of cored vesicles of 80-150 nm in diameter. The core is dense and the cell is immunoreactive for 5-hydroxytryptamine, neural cell adhesion molecule, and PGP 9.5.			Body Part, Organ, or Organ Component	
C1314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1314>	C511|C2153	Trimetrexate|2,4-Quinazolinediamine, 5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-|5-Methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediamine|CI-898|TMQ|TRIMETREXATE|Trimexate	A methotrexate derivative with potential antineoplastic activity.  Trimetrexate inhibits the enzyme dihydrofolate reductase, thereby preventing the synthesis of purine nucleotides and thymidylate, with subsequent inhibition of DNA and RNA synthesis.  Trimetrexate also exhibits antiviral activity. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCIt Antineoplastic Agent Terminology
C131500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131500>	C4813	Recurrent Primary Malignant Neoplasm|Recurrent Primary Malignancy	The reemergence of a primary malignant neoplasm after a period of remission.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131501>	C4813	Recurrent Subsequent Malignant Neoplasm|Recurrent Secondary Malignancy|Recurrent Secondary Malignant Neoplasm|Recurrent Subsequent Malignancy	The reemergence of a malignant neoplasm other than the original one, after a period of remission.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131502>	C122691	Childhood Acute Myeloid Leukemia with t(5;11)(q35;p15); NUP98-NSD1|AML with t(5;11)(q35;p15); NUP98-NSD1|Acute Myeloid Leukemia with t(5;11)(q35.3;p15.5); NUP98-NSD1|Acute Myeloid Leukemia with t(5;11)(q35.3;p15.5); NUP98::NSD1|Acute Myeloid Leukemia with t(5;11)(q35;p15); NUP98-NSD1|Childhood AML with t(5;11)(q35;p15); NUP98-NSD1|Childhood AML with t(5;11)(q35;p15); NUP98::NSD1|Childhood Acute Myeloid Leukemia with t(5;11)(q35.3;p15.5); NUP98-NSD1|Childhood Acute Myeloid Leukemia with t(5;11)(q35.3;p15.5); NUP98::NSD1|Childhood Acute Myeloid Leukemia with t(5;11)(q35;p15); NUP98-NSD1 Fusion|Childhood Acute Myeloid Leukemia with t(5;11)(q35;p15); NUP98::NSD1 Fusion	An acute myeloid leukemia that occurs in childhood and is associated with t(5;11)(q35;p15) resulting in the formation of NUP98-NSD1 fusion gene.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131503>	C226530|C186930	t(5;11)(q35;p15)	A cytogenetic abnormality that refers to the translocation of chromosome 11p15 with chromosome 5q35. It results in the formation of NUP98/NSD1 fusion gene. It is associated with the development of acute myeloid leukemia with t(5;11)(q35;p15); NUP98-NSD1.			Cell or Molecular Dysfunction	AML Authorized Value Terminology|AML Minimal Residual Disease Table|AML Molecular Analysis Table
C131504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131504>	C122691	Childhood Acute Myeloid Leukemia with t(11;15)(p15;q35); NUP98-JARID1A|AML with t(11;15)(p15;q35); NUP98-JARID1A|Acute Myeloid Leukemia with t(11;15)(p15;q35); NUP98-JARID1A|Childhood AML with t(11;15)(p15;q35); NUP98-JARID1A|Childhood AML with t(11;15)(p15;q35); NUP98::JARID1A|Childhood Acute Myeloid Leukemia with t(11;15)(p15;q35); NUP98-JARID1A Fusion|Childhood Acute Myeloid Leukemia with t(11;15)(p15;q35); NUP98::JARID1A Fusion	Acute myeloid leukemia with a cytogenetically cryptic fusion of NUP98 to JARID1A, t(11;15)(p15;q35). It typically has a megakaryocytic phenotype and occurs in 10% of pediatric, non-Down syndrome-related acute megakaryoblastic leukemia cases.			Neoplastic Process	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131505>	C226530	t(11;15)(p15;q35)	A cytogenetic abnormality that refers to the translocation of chromosome 11p15 with chromosome 15q35. It results in the formation of NUP98/JARID1A fusion gene. It is associated with the development of acute myeloid leukemia with t(11;15)(p15;q35); NUP98-JARID1A.			Cell or Molecular Dysfunction	AML Authorized Value Terminology|AML Minimal Residual Disease Table|AML Molecular Analysis Table
C131506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131506>	C3224|C208332|C114451	Childhood Melanoma	A melanoma that occurs during childhood.			Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131507>	C20988	DCHS1 Gene|DCHS1|DCHS1|Dachsous Cadherin-Related 1 Gene	This gene plays a role in neuroprogenitor cell proliferation and differentiation.			Gene or Genome	
C131508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131508>	C131507	DCHS1 wt Allele|CDH19|CDH25|CDHR6|Cadherin, Fibroblast, 1 Gene|Dachsous 1 (Drosophila) Gene|Dachsous Cadherin-Related 1 wt Allele|Dachsous, Drosophila, Homolog of, 1 Gene|FIB1|FLJ11790|KIAA1773|PCDH16|VMLDS1	Human DCHS1 wild-type allele is located in the vicinity of 11p15.4 and is approximately 43 kb in length. This allele, which encodes protocadherin-16 protein, is involved in calcium-mediated cell-cell adhesion and neuroprogenitor cell proliferation and differentiation. Mutation of the gene is associated with mitral valve prolapse 2 and Van Maldergem syndrome 1.			Gene or Genome	
C131509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131509>	C16393	Protocadherin-16|Cadherin 19|Cadherin 25|Cadherin-19|Cadherin-25|Cadherin-Related Family Member 6|DCHS1|Fibroblast Cadherin 1|Fibroblast Cadherin FIB1|Fibroblast Cadherin-1|Protein Dachsous Homolog 1|Protocadherin 16	Protocadherin-16 (3298 aa, ~346 kDa) is encoded by the human DCHS1 gene. This protein plays a role in both neurogenesis and cell-cell adhesion.			Amino Acid, Peptide, or Protein	
C13150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13150>	C12578	Olfactory Epithelial Cell|Olfactory Epithelial Cells	A cell found in the pseudostratified epithelium lining the olfactory region of the nasal cavity. The olfactory epithelium has three major cell types - olfactory receptor cells, basal cell and sustentacular cells.			Cell	
C131510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131510>	C25870	ZDHHC2 Gene|ZDHHC2|ZDHHC2|Zinc Finger DHHC-Type Palmitoyltransferase 2 Gene	This gene is involved in protein palmitoylation.			Gene or Genome	
C131511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131511>	C131510	ZDHHC2 wt Allele|DHHC2|ZNF372|Zinc Finger DHHC-Type Containing 2 Gene|Zinc Finger DHHC-Type Palmitolytransferase 2 wt Allele|Zinc Finger, DHHC Domain Containing 2 Gene|Zinc Finger, DHHC-Type Containing 2 Gene	Human ZDHHC2 wild-type allele is located in the vicinity of 8p22 and is approximately 69 kb in length. This allele, which encodes palmitoyltransferase ZDHHC2 protein, plays a role in post-translational protein modification.			Gene or Genome	
C131512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131512>	C16259	Palmitoyltransferase ZDHHC2|DHHC Domain-Containing Protein 2|DHHC-2|EC 2.3.1.225|Ream|Rec|Reduced Expression Associated with Metastasis Protein|Reduced Expression in Cancer Protein|Zinc Finger DHHC Domain-Containing Protein 2|Zinc Finger DHHC-Type Palmitoyltransferase 2|Zinc Finger Protein 372	Palmitoyltransferase ZDHHC2 (367 aa, ~42 kDa) is encoded by the human ZDHHC2 gene. This protein is involved in the palmitoylation of protein substrates.			Amino Acid, Peptide, or Protein|Enzyme	
C131513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131513>	C20194	SEMA3D Gene|SEMA3D|SEMA3D|Semaphorin 3D Gene	This gene plays a role in the inhibition of axonal growth.			Gene or Genome	
C131514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131514>	C131513	SEMA3D wt Allele|Sema Domain, Immunoglobulin Domain (Ig), Short Basic Domain, Secreted, (Semaphorin) 3D Gene|Sema-Z2|Semaphorin 3D wt Allele|UNQ760/PRO1491|coll-2	Semaphorin-3D (777 aa, ~90 kDa) is encoded by the human SEMA3D gene. This protein plays a role in the negative regulation of axon migration.			Gene or Genome	
C131515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131515>	C18466	Semaphorin-3D|Collapsin 2|Collapsin-2|Sema3D	Semaphorin-3D (777 aa, ~90 kDa) is encoded by the human SEMA3D gene. This protein plays a role in the negative regulation of axon migration.			Amino Acid, Peptide, or Protein	
C131516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131516>	C80699	MIR483 Gene|MIR483|MIR483|MicroRNA 483 Gene	This gene may be involved in the negative regulation of translation.			Gene or Genome	
C131517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131517>	C131516	MIR483 wt Allele|MIRN483|MIRNA438|Micro RNA 483 Gene|MicroRNA 483 wt Allele|hsa-mir-483|mir-483	Human MIR483 wild-type allele is located in the vicinity of 11p15.5 and is approximately 80 bases in length. This allele, which encodes MIR483 pre-miRNA, may play a role in the negative regulation of mRNA translation. Alteration in the expression of this gene may be associated with development of non small lung cell carcinoma.			Gene or Genome	
C131518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131518>	C25968	MIR483 Pre-miRNA	MIR483 pre-miRNA (76 bases) is encoded by the human MIR483 gene. This oligoribonucleotide may be involved in the negative regulation of gene expression.			Nucleic Acid, Nucleoside, or Nucleotide	
C131519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131519>	C25966	MicroRNA 483-5p|hsa-miR-483-5p|miR-483-5p	A 22 ribonucleotide sequence that is a final product of the processing of MIR483 pre-miRNA. This oligonucleotide may be involved in the negative regulation of gene expression.			Nucleic Acid, Nucleoside, or Nucleotide	
C131520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131520>	C25966	MicroRNA 193a-5p|hsa-miR-193a-5p	A 22 ribonucleotide sequence that is a final product of the processing of MIR193A pre-miRNA. This oligonucleotide may be involved in the negative regulation of gene expression.			Nucleic Acid, Nucleoside, or Nucleotide	
C131521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131521>	C25966	MicroRNA 7|hsa-miR-7|hsa-miR-7-5p|miR-7|miR-7-5p	A 23 ribonucleotide sequence that is a final product of the processing of MIR7-1, MIR7-2 or MIR7-3 pre-miRNA. This oligonucleotide may be involved in the negative regulation of gene expression.			Nucleic Acid, Nucleoside, or Nucleotide	
C131522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131522>	C159207|C133708	UBE2T Gene|UBE2T|UBE2T|Ubiquitin-Conjugating Enzyme E2T Gene	This gene plays a role in monoubiquitination of the Fanconi anemia complex.			Gene or Genome	
C131523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131523>	C131522	UBE2T wt Allele|Cell Proliferation-Inducing Gene 50|FANCT|HSPC150|PIG50|Ubiquitin Conjugating Enzyme E2T wt Allele	Human UBE2T wild-type allele is located in the vicinity of 1q32.1 and is approximately 10 kb in length. This allele, which encodes ubiquitin-conjugating enzyme E2 T protein, is involved in both protein ubiquitination and DNA repair. Mutation of the gene is associated with Fanconi anemia complementation group T.			Gene or Genome	
C131524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131524>	C21170|C133711	Ubiquitin-Conjugating Enzyme E2 T|Cell Proliferation-Inducing Gene 50 Protein|E2 Ubiquitin-Conjugating Enzyme T|EC 2.3.2.23|EC 6.3.2.19, Formerly|HSPC150 Protein Similar To Ubiquitin-Conjugating Enzyme|UBE2T|Ubiquitin Carrier Protein T|Ubiquitin-Conjugating Enzyme E2T|Ubiquitin-Protein Ligase T	Ubiquitin-conjugating enzyme E2 T (197 aa, ~23 kDa) is encoded by the human UBE2T gene. This protein plays a role in the modulation of Fanconi anemia complex DNA repair activity.			Amino Acid, Peptide, or Protein|Enzyme	
C131525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131525>	C91105	Premorbid Adjustment Scale|PAS|Premorbid	A 26-item, retrospective questionnaire designed to assess the degree of an individual's achievement of developmental goals from childhood through adulthood, prior to the onset of schizophrenia. This rating scale includes measures for sociability and social withdrawal, peer relationships, scholastic performance, adaptation to school, and ability to form socio-sexual relationships. Performance is scored on a 7-point scale ranging from 0 (healthiest adjustment) to 6 (lowest adjustment).			Intellectual Product	
C131526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131526>	C186359	Ependymal Tumor of Spinal Cord	A finding indicating the presence of an ependymal tumor in the spinal cord.			Finding	
C131527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131527>	C217121	Brief Psychiatric Rating Scale - version 4|BPRS-4|BPRS-v4|Brief Psychiatric Rating Scale Expanded Version (4.0)|Brief Psychiatric Rating Scale v4	A clinician-administered rating scale for assessing the severity of psychopathology in individuals diagnosed with psychotic disorders, especially schizophrenia. The measure consists of 18 symptom constructs covering positive symptoms, negative symptoms, and mood with each item rated from 1 (not present) to 7 (extremely severe).			Intellectual Product	
C131528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131528>	C222259	Computerized Neurocognitive Battery|CNB|Computerized Neurocognitive Battery (CNB)	A series of tests designed to measure performance accuracy and speed on specific neurobehavioral tasks. The included tests measure: abstraction and mental flexibility, attention, working memory, episodic memory (word, face, and spatial recognition memory), language reasoning, spatial processing, sensorimotor, motor speed, and emotion identification. Accuracy is scored as the total number of correct responses and speed is scored as the median response time (RT) for correct items.	Computerized Neurocognitive Battery		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C131529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131529>	C20993	Auditory Continuous Performance Test|ACPT	A test designed to identify auditory attention deficits. The test requires that a subject listen to a list of single words and respond when hearing the targeted word. The test can aid in the diagnosis of ADD or ADHD in children 6 through 11.			Intellectual Product	
C13152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13152>	C13150	Olfactory Supporting Cell	A cell that serves to provide support and protection to the olfactory epithelium.			Cell	
C131530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131530>	C20993	AX-Continuous Performance Test|A-X CPT|AX Continuous Performance Test|AX-CPT|AX-type CPT|Continuous Performance Test - AX version	A measure of sustained attention where the subject is instructed to respond one way whenever the stimulus is an X that was preceded by an A and another way for all other stimuli, including an A, an X that was not preceded by an A, and any other letter.			Intellectual Product	
C131531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131531>	C20993	Structured Clinical Interview for DSM-5|SCID-5|Structured Clinical Interview for DSM-5 (SCID-5)|Structured Clinical Interview for DSM-5 Disorders	A semi-structured interview designed to guide a clinician or trained mental health professional through the DSM-5 diagnostic process. The included interview questions correspond to specific DSM-5 criteria and aids in rating each as either present or absent.			Intellectual Product	
C131532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131532>	C18485	Three-Dimensional Magnetization-Prepared Rapid Gradient Echo Imaging|3-Dimensional Magnetization-Prepared Rapid Gradient Echo Imaging|3D MP RAGE	A 3-dimensional imaging technique that combines the power of magnetization-prepared imaging and rapid 3-D gradient echo acquisition techniques to provide excellent tissue contrasts, high spatial resolution, and full tissue coverage in a short scan time. This technique is applicable for 3D imaging throughout the body.			Diagnostic Procedure	
C131533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131533>	C28193	Bohring-Opitz Syndrome	An autosomal dominant condition caused by mutation(s) in the ASXL1 gene, encoding putative polycomb group protein ASXL1. It is characterized by severe intrauterine growth retardation, profound mental retardation, craniofacial dysmorphisms, and flexion deformities of the upper limbs.			Disease or Syndrome	CCPS Disease Terminology|Childhood Cancer Predisposition Study Terminology
C131534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131534>	C107589	CXCR4 Antagonist USL311|CXCR4 Inhibitor USL311|USL 311|USL-311|USL311	An orally bioavailable inhibitor of C-X-C chemokine receptor type 4 (CXCR4), with potential antineoplastic activity. Upon administration, USL311 binds to CXCR4, thereby preventing the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4 and inhibiting CXCR4 activation, which may result in decreased proliferation and migration of CXCR4-expressing tumor cells. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) family, plays an important role in chemotaxis and angiogenesis, and is upregulated in several tumor cell types.	CXCR4 Antagonist USL311		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131535>	C210973	Osilodrostat|(R)-4-(6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluorobenzonitrile|LCI 699|LCI-699|LCI699|OSILODROSTAT	An orally bioavailable inhibitor of both steroid 11beta-hydroxylase (cytochrome P450 (CYP) 11B1) and aldosterone synthase (CYP11B2; steroid 18-hydroxylase), with potential anti-adrenal activity and ability to treat Cushing disease (CD). Upon administration, osilodrostat binds to and inhibits the activity of CYP11B1, the enzyme that catalyzes the final step of cortisol synthesis from the precursor 11-deoxycortisol, and CYP11B2, the enzyme that catalyzes aldosterone synthesis from corticosterone and 11-deoxycorticosterone in the adrenal gland. The inhibition of CYP11B1 prevents the production of excess cortisol, thereby decreasing and normalizing the levels of cortisol. CD is most often caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary tumor.	Osilodrostat		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131536>	C28676	Non-Fucosylated Umbilical Cord Blood Regulatory T-cells|Non-Fucosylated UCB Regulatory T-cells|Non-Fucosylated UCB Tregs|Non-Fucosylated Umbilical Cord Blood Tregs	A preparation of non-fucosylated regulatory T-lymphocytes (Tregs) allogeneically derived from umbilical cord blood (UCB), with potential immunomodulating activity. Tregs are essential in maintaining immunologic homeostasis, preventing autoimmunity, through the suppression of self-reactive T-cells, and they may induce tolerance to allogeneic organ transplants, including hematopoetic stem cell transplants (HSCTs). Administration of the non-fucosylated UCB Tregs upon HSCT may prevent or reduce graft-versus host disease (GVHD).	Non-Fucosylated Umbilical Cord Blood Regulatory T-cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology
C131537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131537>	C129822|C128057	Anti-PD-L1 Monoclonal Antibody FAZ053|FAZ 053|FAZ-053|FAZ-053|FAZ053	A monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1), with immune checkpoint inhibitory and potential antineoplastic activities. Upon administration, anti-PD-L1 monoclonal antibody FAZ053 binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated anti-tumor immune response and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T-cells.	Anti-PD-L1 Monoclonal Antibody FAZ053		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131538>	C25939	EGLN2 Gene|EGLN2|EGLN2|Egl-9 Family Hypoxia-Inducible Factor 2 Gene	This gene is involved in the response to hypoxia.			Gene or Genome	
C131539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131539>	C131538	EGLN2 wt Allele|EGL Nine (C.elegans) Homolog 2 Gene|EGL9, C. elegans, Homolog of, 2 Gene|EIT6|Egl Nine Homolog 2 (C. elegans) Gene|Egl-9 Family Hypoxia-Inducible Factor 2 wt Allele|HIF-PH1|HIFP4H1|HIFPH1|HPH-1|HPH-3|PHD1	Human EGLN2 wild-type allele is located in the vicinity of 19q13.2 and is approximately 9 kb in length. This allele, which encodes egl nine homolog 2 protein, plays a role in the cellular response to hypoxia.			Gene or Genome	
C13153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13153>	C13150	Olfactory Basal Cell|Olfactory Basal Cells	A cell found in the pseudostratified epithelium lining the olfactory region of the nasal cavity. It gives rise to olfactory receptor cells and sustentacular cells.			Cell	
C131540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131540>	C16946	Egl Nine Homolog 2|EC 1.14.11.29|EGLN2|Estrogen-Induced Tag 6|HIF Prolyl 4-Hydroxylase 1|HIF Prolyl Hydroxylase 1|HIF-PH1|HIF-Prolyl Hydroxylase 1|HPH-1|HPH-3|Hypoxia-Inducible Factor Prolyl 4-Hydroxylase 1|Hypoxia-Inducible Factor Prolyl Hydroxylase 1|PHD1|Prolyl Hydroxylase Domain-Containing Protein 1	Egl nine homolog 2 (407 aa, ~44 kDa) is encoded by the human EGLN2 gene. This protein is involved in the hydroxylation of hypoxia-inducible factor alpha proteins.			Amino Acid, Peptide, or Protein|Enzyme	
C131541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131541>	C20401	Timolumab|BTT 1023|BTT-1023|SI-3106|TIMOLUMAB		Utomilumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C131542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131542>	C20420	FOXC1 Gene|FOXC1|FOXC1|Forkhead Box C1 Gene	This gene plays a role in the regulation of both embryonic and ocular development.			Gene or Genome	
C131543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131543>	C131542	FOXC1 wt Allele|ARA|FKHL7|FREAC-3|FREAC3|Forkhead Box C1 wt Allele|Forkhead, Drosophila, Homolog-Like 7 Gene|IGDA|IHG1|IRID1|RIEG3	Human FOXC1 wild-type allele is located in the vicinity of 6p25 and is approximately 4 kb in length. This allele, which encodes forkhead box protein C1, is involved in both embryogenesis and eye development. Mutations in this gene are associated with Peters anomaly, primary congenital glaucoma, autosomal dominant iridogoniodysgenesis type 1, and Axenfeld Rieger syndrome 3.			Gene or Genome	
C131544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131544>	C17207	Forkhead Box Protein C1|FOXC1|FREAC-3|Forkhead Box C1 Protein|Forkhead-Related Activator 3|Forkhead-Related Protein FKHL|Forkhead-Related Transcription Factor 3|Forkhead/Winged Helix-Like Transcription Factor 7|Myeloid Factor-Delta	Forkhead box protein C1 (553 aa, ~57 kDa) is encoded by the human FOXC1 gene. This protein plays a role in transcriptional regulation during both embryonic development and ocular development.			Amino Acid, Peptide, or Protein	
C131545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131545>	C21295	FSTL1 Gene|FSTL1|FSTL1|Follistatin Like 1 Gene	This gene is involved in both heparin binding and signaling.			Gene or Genome	
C131546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131546>	C131545	FSTL1 wt Allele|FRP|FSL1|Follistatin Like 1 wt Allele|Follistatin-Like 1 Gene	Human FSTL1 wild-type allele is located in the vicinity of 3q13.33 and is approximately 59 kb in length. This allele, which encodes follistatin-related protein 1, plays a role in both signal transduction and heparin binding.			Gene or Genome	
C131547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131547>	C17728	Follistatin-Related Protein 1|FSTL1|Follistatin-Like Protein 1	Follistatin-related protein 1 (308 aa, ~35 kDa) is encoded by the human FSTL1 gene. This protein is involved in both signaling pathways and binding to heparin.			Amino Acid, Peptide, or Protein	
C131548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131548>	C25939	WWOX Gene|WW Domain Containing Oxidoreductase Gene|WWOX|WWOX	This gene plays a role in oxidation/reduction, tumor suppression and the regulation of apoptosis.			Gene or Genome	
C131549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131549>	C131548	WWOX wt Allele|D16S432E|EIEE28|FOR|FRA16D|HHCMA56|PRO0128|SCAR12|SDR41C1|Short Chain Dehydrogenase/Reductase Family 41C, Member 1 Gene|WOX1|WW Domain Containing Oxidoreductase wt Allele	Human WWOX wild-type allele is located in the vicinity of 16q23 and is approximately 1113 kb in length. This allele, which encodes WW domain-containing oxidoreductase protein, is involved in tumor suppression, apoptosis and oxidation/reduction. Mutation of the gene is associated with early infantile epileptic encephalopathy 28, somatic esophageal squamous cell carcinoma, and autosomal recessive spinocerebellar ataxia 12.			Gene or Genome	
C13154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13154>	C12623	Bipolar Neuron|Bipolar Neurons	A nerve cell with two processes.			Cell	
C131550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131550>	C16946	WW Domain-Containing Oxidoreductase|EC 1.1.1.-|Fragile Site FRA16D Oxidoreductase|Short Chain Dehydrogenase/Reductase Family 41C Member 1|WW Domain-Containing Protein WWOX|WWOX	WW domain-containing oxidoreductase (414 aa, ~47 kDa) is encoded by the human WWOX gene. This protein plays a role in apoptosis, oxidation/reduction and tumor suppression.			Amino Acid, Peptide, or Protein|Enzyme	
C131551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131551>	C26057|C19676	MCM8 Gene|MCM8|MCM8|Minichromosome Maintenance 8 Homologous Recombination Repair Factor Gene	This gene is involved in the repair of DNA interstrand cross-links.			Gene or Genome	
C131552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131552>	C131551	MCM8 wt Allele|C20orf154|Chromosome 20 Open Reading Frame 154 Gene|MGC119522|MGC119523|MGC12866|MGC4816|Minichromosome Maintenance 8 Homologous Recombination Repair Factor wt Allele|POF10|REC Homolog (Drosophila) Gene|REC Homolog Gene|dJ967N21.5	Human MCM8 wild-type allele is located in the vicinity of 20p12.3 and is approximately 45 kb in length. This allele, which encodes DNA helicase MCM8 protein, plays a role in homologous recombination repair. Mutation of the gene is associated with premature ovarian failure 10.			Gene or Genome	
C131553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131553>	C21170|C16517	DNA Helicase MCM8|DNA Replication Licensing Factor MCM8|EC 3.6.4.12|MCM8|MCM8 Minichromosome Maintenance Deficient 8|Minichromosome Maintenance 8|Minichromosome Maintenance Complex Component 8|Minichromosome Maintenance Protein 8	DNA helicase MCM8 (840 aa, ~94 kDa) is encoded by the human MCM8 gene. This protein is involved in DNA repair.			Amino Acid, Peptide, or Protein|Enzyme	
C131554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131554>	C26057|C19676	MCM9 Gene|MCM9|MCM9|Minichromosome Maintenance 9 Homologous Recombination Repair Factor Gene	This gene plays a role in homologous recombination repair.			Gene or Genome	
C131555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131555>	C131554	MCM9 wt Allele|C6orf61|Chromosome 6 Open Reading Frame 61 Gene|FLJ20170|MCMDC1|MGC35304|Minichromosome Maintenance 9 Homologous Recombination Repair Factor wt Allele|ODG4|dJ329L24.1|dJ329L24.3	Human MCM9 wild-type allele is located in the vicinity of 6q22.31 and is approximately 122 kb in length. This allele, which encodes DNA helicase MCM9 protein, is involved in DNA repair.			Gene or Genome	
C131556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131556>	C21170|C16517	DNA Helicase MCM9|DNA Replication Licensing Factor MCM9|EC 3.6.4.12|MCM9|Mini-Chromosome Maintenance Deficient Domain-Containing Protein 1|Minichromosome Maintenance 9|Minichromosome Maintenance Complex Component 9|Minichromosome Maintenance Deficient Domain Containing 1|Minichromosome Maintenance Protein 9|hMCM9	DNA helicase MCM9 (1143 aa, ~127 kDa) is encoded by the human MCM9 gene. This protein plays a role in homologous recombination repair of replication forks.			Amino Acid, Peptide, or Protein|Enzyme	
C131557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131557>	C177692	CTAG1 Positive|CT6.1 Positive|Cancer/Testis Antigen 1 Positive|LAGE-2 Positive|LAGE2 Positive|NY-ESO-1 Positive|NY-ESO-1 Positive	An indication that Cancer/Testis Antigen 1 expression has been detected in a sample.	NY-ESO-1 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131558>	C128873	Somatostatin Receptor 2 Positive|SSR2 Positive|SSTR2 Positive|Somatostatin Receptor Type 2 Positive	An indication that somatostatin receptor type 2 expression has been detected in a sample.	Somatostatin Receptor 2 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131559>	C26360	MAPK15 Gene|MAPK15|MAPK15|Mitogen-Activated Protein Kinase 15 Gene	This gene is involved in both protein phosphorylation and telomere maintenance.			Gene or Genome	
C13155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13155>	C12625	Ganglion Cell|Ganglion Cells	A type of interneuron that conveys information to the brain.			Cell	
C131560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131560>	C131559	MAPK15 wt Allele|ERK7|ERK8|Mitogen-Activated Protein Kinase 15 wt Allele	Human MAPK15 wild-type allele is located in the vicinity of 8q24.3 and is approximately 6 kb in length. This allele, which encodes mitogen-activated protein kinase 15 protein, plays a role in both telomere maintenance and protein phosphorylation.			Gene or Genome	
C131561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131561>	C16376	Mitogen-Activated Protein Kinase 15|EC 2.7.11.24|ERK-7|ERK-8|Extracellular Signal Regulated Kinase 8|Extracellular Signal-Regulated Kinase 7|Extracellular Signal-Regulated Kinase 8|MAP Kinase 15|MAPK 15|MAPK15	Mitogen-activated protein kinase 15 (544 aa, ~60 kDa) is encoded by the human MAPK15 gene. This protein is involved in serine/threonine protein phosphorylation and telomere maintenance.			Amino Acid, Peptide, or Protein|Enzyme	
C131562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131562>	C575	Nendratareotide Uzatansine|NENDRATAREOTIDE UZATANSINE|PEN 221|PEN-221|PEN221|SSTR2-targeting Protein/DM1 Conjugate PEN-221|SSTR2PEN-221	A miniaturized drug conjugate composed of a peptide analog of somatostatin that targets the somatostatin receptor 2 (SSTR2) and is conjugated, through a cleavable linker, to the microtubule-binding cytotoxic maytansinoid DM1 (mertansine), with potential anti-tumor activity. Upon administration, the peptide ligand moiety of nendratareotide uzatansine targets and binds to SSTR2, which is overexpressed on certain tumor cell types. Binding stimulates SSTR2-mediated endocytosis of the agent; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics. This inhibits both cell division and the proliferation of SSTR2-expressing cancer cells. Compared to antibody-drug conjugates (ADCs), miniaturized drug conjugates are much smaller and can more easily penetrate and distribute in dense tumor tissue.	Nendratareotide Uzatansine		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131563>	C25870	NSMCE2 Gene|NSE2/MMS21 Homolog, SMC5-SMC6 Complex SUMO Ligase Gene|NSMCE2|NSMCE2	This gene plays a role in protein sumoylation, DNA repair and the inhibition of apoptosis.			Gene or Genome	
C131564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131564>	C131563	NSMCE2 wt Allele|C8orf36|Chromosome 8 Open Reading Frame 36 Gene|FLJ32440|MMS21|MMS21, S. cerevisiae, Homolog of Gene|Methyl Methanesulfonate Sensitivity Gene 21|NSE2|NSE2/MMS21 Homolog, SMC5-SMC6 Complex SUMO Ligase wt Allele|Non-SMC Element 2 Homolog (MMS21, S. cerevisiae) Gene|Non-SMC Element 2, MMS21 Homolog (S. cerevisiae) Gene|Non-SMC Element 2, S. cerevisiae, Homolog of Gene|ZMIZ7|Zinc Finger, MIZ-Type Containing 7 Gene	Human NSMCE2 wild-type allele is located in the vicinity of 8q24.13 and is approximately 275 kb in length. This allele, which encodes E3 SUMO-protein ligase NSE2 protein, is involved in the negative regulation of apoptosis, protein sumoylation, and the promotion of DNA repair. Mutation of the gene is associated with Seckel syndrome 10.			Gene or Genome	
C131565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131565>	C16259	E3 SUMO-Protein Ligase NSE2|E3 SUMO-Protein Transferase NSE2|EC 2.3.2.-|EC 6.3.2.-, Formerly|MMS21 Homolog|NSMCE2|Non-SMC Element 2 Homolog|Non-Structural Maintenance Of Chromosomes Element 2 Homolog|SMC5/SMC6 Complex SUMO Ligase NSMCE2|hMMS21	E3 SUMO-protein ligase NSE2 (247 aa, ~28 kDa) is encoded by the human NSMCE2 gene. This protein plays a role in DNA double-strand break repair by homologous recombination, the prevention of DNA damage-induced apoptosis, and the sumolyation of protein substrates.			Amino Acid, Peptide, or Protein|Enzyme	
C131566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131566>	C25993	SCN5A Gene|SCN5A|SCN5A|Sodium Voltage-Gated Channel Alpha Subunit 5 Gene	This gene is involved in voltage-dependent sodium ion transport.			Gene or Genome	
C131567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131567>	C131566	SCN5A wt Allele|CDCD2|CMD1E|CMPD2|HB1|HB2|HBBD|HH1|ICCD|IVF|LQT3|Nav1.5|PFHB1|SSS1|Sodium Channel, Voltage Gated, Type V Alpha Subunit Gene|Sodium Channel, Voltage-Gated, Type V, Alpha (Long QT Syndrome 3) Gene|Sodium Channel, Voltage-Gated, Type V, Alpha Subunit Gene|Sodium Voltage-Gated Channel Alpha Subunit 5 wt Allele|VF1	Human SCN5A wild-type allele is located in the vicinity of 3p21 and is approximately 102 kb in length. This allele, which encodes sodium channel protein type 5 subunit alpha protein, plays a role in voltage-dependent sodium transport. Mutation of the gene is associated with long QT syndrome-3, sick sinus syndrome 1, Brugada syndrome 1, familial atrial fibrillation 10, familial ventricular fibrillation 1, dialated cardiomyopathy 1E, progressive heart block type 1A and non-progressive heart block.			Gene or Genome	
C131568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131568>	C28505	Sodium Channel Protein Type 5 Subunit Alpha|Cardiac Tetrodotoxin-Insensitive Voltage-Dependent Sodium Channel Alpha Subunit|HH1|SCN5A|Sodium Channel Protein Cardiac Muscle Subunit Alpha|Sodium Channel Protein Type V Subunit Alpha|Voltage-Gated Sodium Channel Alpha Subunit Nav1.5|Voltage-Gated Sodium Channel Subunit Alpha Nav1.5	Sodium channel protein type 5 subunit alpha (2016 aa, ~227 kDa) is encoded by the human SCN5A gene. This protein is involved in voltage-gated transport of sodium ions.			Amino Acid, Peptide, or Protein	
C131569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131569>	C28533	ETFA Gene|ETFA|ETFA|Electron Transfer Flavoprotein Alpha Subunit Gene	This gene plays a role in the electron transport chain.			Gene or Genome	
C13156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13156>	C12508	Receptor Cell	Specialized cells located in sense organs that respond to physical and chemical stimuli by sending information to the central nervous system.			Body Part, Organ, or Organ Component	
C131570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131570>	C131569	ETFA wt Allele|EMA|Electron Transfer Flavoprotein Alpha Subunit wt Allele|Electron Transfer Flavoprotein, Alpha Polypeptide Gene|Electron-Transfer-Flavoprotein, Alpha Polypeptide Gene|GA2|MADD	Human ETFA wild-type allele is located within 15q24.2-q24.3 and is approximately 96 kb in length. This allele, which encodes electron transfer flavoprotein subunit alpha, mitochondrial protein, is involved in cellular respiration. Mutation of the gene is associated with glutaric aciduria 2A.			Gene or Genome	
C131571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131571>	C16386	Electron Transfer Flavoprotein Subunit Alpha, Mitochondrial|Alpha-ETF|ETFA|Electron Transfer Flavoprotein Alpha-Subunit|Electron Transfer Flavoprotein, Alpha Polypeptide	Electron transfer flavoprotein subunit alpha, mitochondrial (333 aa, ~35 kDa) is encoded by the human ETFA gene. This protein plays a role in electron transport.			Amino Acid, Peptide, or Protein	
C131572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131572>	C215099|C20401|C129822	Anti-CXCR4 Monoclonal Antibody PF-06747143|Anti-CXCR4 IgG1 Antibody PF-06747143|PF 06747143|PF-06747143|PF-06747143	A humanized immunoglobulin (Ig) G1 monoclonal antibody (mAb) against C-X-C chemokine receptor type 4 (CXCR4), with potential antineoplastic activity. Upon administration, anti-CXCR4 mAb PF-06747143 binds to CXCR4, thereby preventing the binding of stromal cell-derived factor-1 (SDF-1 or CXCL12) to CXCR4 and inhibiting CXCR4 activation. This results in decreased proliferation and migration of CXCR4-expressing tumor cells. In addition, PF-06747143 promotes cell death through the induction of both complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) family, is upregulated in several tumor cell types and plays an important role in cancer cell proliferation, survival, and chemotaxis, and in tumor angiogenesis.	Anti-CXCR4 Monoclonal Antibody PF-06747143		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131573>	C186359	Frontal Lobe Ependymal Tumor	A finding indicating the presence of an ependymal tumor in the frontal lobe of the brain.			Finding	
C131574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131574>	C186359	Temporal Lobe Ependymal Tumor	A finding indicating the presence of an ependymal tumor in the temporal lobe of the brain.			Finding	
C131575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131575>	C186359	Parietal Lobe Ependymal Tumor	A finding indicating the presence of an ependymal tumor in the parietal lobe of the brain.			Finding	
C131576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131576>	C186359	Cerebellar Ependymal Tumor	A finding indicating the presence of an ependymal tumor in the cerebellum.			Finding	
C131577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131577>	C186359	Ventricular Ependymal Tumor	A finding indicating the presence of an ependymal tumor in a brain ventricle.			Finding	
C131578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131578>	C186359	Ventricular and Brain Stem Ependymal Tumor	A finding indicating the presence of an ependymal tumor in a brain ventricle and the brain stem.			Finding	
C131579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131579>	C16186	Joint Replacement|Arthroplasty (Total Joint Replacement Surgery)|Joint Replacement Surgery|Replacement Arthroplasty|Total Joint Replacement Surgery	A surgical procedure to replace part, or all structures, of a joint with an orthopedic prosthesis.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|GDC Terminology|GDC Value Terminology
C13157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13157>	C33923	Cuboidal Cell|Cuboidal Cells	A cube-shaped epithelial cell. Because a cuboidal cell has a relatively large cytoplasmic volume, it can undertake more complex functions such as absorption and secretion. Most glandular secretory cells are cuboidal epithelial cells and the ducts of most exocrine glands and kidney tubules are lined by cuboidal cells.			Cell	
C131580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131580>	C717|C204441	Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|Oncolytic VSV-hIFNbeta-NIS|VSV-IFNb-NIS|VSV-expressing hIFNb and NIS|VSV-hIFNb-NIS|VSV-hIFNbeta-NIS|VV1|Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|Voyager-V1	A recombinant, replication competent form of the oncolytic RNA virus vesicular stomatitis virus (VSV), based on the Indiana strain of VSV, that is genetically engineered to express the genes for the human cytokine interferon beta (IFNbeta) and the human thyroidal sodium-iodide symporter (NIS), with potential oncolytic and imaging activities. Upon intravenous administration, VSV-hIFNbeta-NIS is preferentially taken up by tumor cells, resulting in tumor cell infection, viral replication and a direct virus-mediated cytolytic effect against the infected tumor cells. IFN-mediated signaling is defective in tumor cells and tumor cells are unable to exert an anti-viral response against VSV. As normal, healthy cells secrete and respond normally to IFNbeta and are able to activate IFN-mediated anti-viral pathways, the expressed IFNbeta from the VSV-infected tumor cells helps protect normal cells from VSV infection. Upon subsequent administration of certain isotope-containing imaging agents, NIS expression by the infected tumor cells allows visualization and tracking of VSV biodistribution, and analysis and quantification of VSV-infected tumor cells by positron emission tomography (PET). Also, upon subsequent administration of the radioisotope iodine I 131 (I131), I131 can be taken up by NIS and allows for a cytotoxic dose of radiation to accumulate in the NIS-expressing VSV-infected tumor cells, which also leads to tumor cell death.	Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter		Pharmacologic Substance|Virus	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131581>	C186359	Parietal Lobe and Occipital Lobe Ependymal Tumor	A finding indicating the presence of an ependymal tumor in the parietal and occipital lobes of the brain.			Finding	
C131582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131582>	C186359	Temporal Lobe and Parietal Lobe Ependymal Tumor	A finding indicating the presence of an ependymal tumor in the temporal and parietal lobes of the brain.			Finding	
C131583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131583>	C186359	Cerebellar and Ventricular Ependymal Tumor	A finding indicating the presence of an ependymal tumor in the cerebellum and a brain ventricle.			Finding	
C131584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131584>	C186359	Frontal Lobe and Parietal Lobe Ependymal Tumor	A finding indicating the presence of an ependymal tumor in the frontal and parietal lobes of the brain.			Finding	
C131585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131585>	C186359	Cerebellar and Brain Stem Ependymal Tumor	A finding indicating the presence of an ependymal tumor in the cerebellum and brain stem.			Finding	
C131586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131586>	C186359	Cerebellar, Fourth Ventricle, and Brain Stem Ependymal Tumor	A finding indicating the presence of an ependymal tumor in the cerebellum, fourth ventricle, and brain stem.			Finding	
C131587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131587>	C186359	Posterior Fossa Ependymal Tumor|Posterior Cranial Fossa Ependymal Tumor	A finding indicating the presence of an ependymal tumor in the posterior cranial fossa.			Finding	
C131588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131588>	C25942	POLR3B Gene|POLR3B|POLR3B|RNA Polymerase III Subunit B Gene	This gene is involved in the synthesis of small RNAs.			Gene or Genome	
C131589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131589>	C186359	Occipital Lobe, Parietal Lobe, and Ventricular Ependymal Tumor	A finding indicating the presence of an ependymal tumor in the occipital and parietal lobes and a brain ventricle.			Finding	
C13158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13158>	C33923	Columnar Cell|Columnar Cells	An epithelial cell that is taller than it is wide. The nucleus is oval, usually situated at the base of the cell. These cells line large glands and ducts.			Cell	
C131590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131590>	C131588	POLR3B wt Allele|C128|C128, S. cerevisiae, Homolog of Gene|FLJ10388|HLD8|INMAP|Polymerase (RNA) III (DNA Directed) Polypeptide B Gene|Polymerase III, RNA, Subunit B Gene|RNA Polymerase III Subunit B wt Allele|RPC2	Human POLR3B wild-type allele is located in the vicinity of 12q23.3 and is approximately 153 kb in length. This allele, which encodes DNA-directed RNA polymerase III subunit RPC2 protein, plays a role in the synthesis of ribosomal and transfer RNAs. Mutation of the gene is associated with hypomyelinating leukodystrophy-8.			Gene or Genome	
C131591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131591>	C17104	DNA-Directed RNA Polymerase III Subunit RPC2|DNA-Directed RNA Polymerase III 127.6 kDa Polypeptide|DNA-Directed RNA Polymerase III Subunit B|EC 2.7.7.6|Interphase Nucleus and Mitotic Apparatus Associated Protein|POLR3B|RNA Polymerase III Subunit C2	DNA-directed RNA polymerase III subunit RPC2 (1133 aa, ~128 kDa) is encoded by the human POLR3B gene. This protein is involved in small RNA synthesis.			Amino Acid, Peptide, or Protein|Enzyme	
C131592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131592>	C131610	Cerebellar, Brain Stem, and Cervical Spinal Cord Ependymal Tumor	A finding indicating the presence of an ependymal tumor in the cerebellum, brain stem, and the cervical region of spinal cord.			Finding	
C131593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131593>	C131577	Fourth Ventricle Ependymal Tumor	A finding indicating the presence of an ependymal tumor in the fourth ventricle of the brain.			Finding	
C131594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131594>	C131577	Lateral Ventricle Ependymal Tumor	A finding indicating the presence of an ependymal tumor in a lateral ventricle of the brain.			Finding	
C131595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131595>	C131577	Third Ventricle Ependymal Tumor	A finding indicating the presence of an ependymal tumor in the third ventricle of the brain.			Finding	
C131596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131596>	C131578	Fourth Ventricle and Brain Stem Ependymal Tumor	A finding indicating the presence of an ependymal tumor in the fourth ventricle and the brain stem.			Finding	
C131597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131597>	C131583	Cerebellar and Fourth Ventricle Ependymal Tumor	A finding indicating the presence of an  ependymal tumor in the cerebellum and fourth ventricle.			Finding	
C131598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131598>	C186359	Temporal Lobe, Parietal Lobe, and Lateral Ventricle Ependymal Tumor	A finding indicating the presence of an ependymal tumor in the temporal and parietal lobes, and a lateral ventricle of the brain.			Finding	
C131599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131599>	C20921	SRGAP2 Gene|SLIT-ROBO Rho GTPase Activating Protein 2 Gene|SRGAP2|SRGAP2	This gene is involved in remodeling of the actin cytoskeleton.			Gene or Genome	
C13159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13159>	C12657	Mesangial Cell	Cell found within the glomerular lobules of mammalian kidney. Mesangial cells serve as structural supports, may regulate blood flow, are phagocytic and may act as accessory cells, presenting antigen in immune responses.			Cell	
C1315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1315>	C213	Aflatoxin B1|(6AR-cis)-2,3,6a,9a-tetrahydro-4-methoxycyclopenta(c)furo(3',2':4,5)furo(2,3-h)(1)benzopyran-1,11-dione|AFB1|AFLATOXIN B1	A member of a group of mycotoxins produced by Aspergillus flavus and A. parasiticus. Alflatoxin B1 is the most hepatotoxic and hepatocarcinogenic of the aflatoxins and occurs as a contaminant in a variety of foods.	Aflatoxin B1		Hazardous or Poisonous Substance|Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C131600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131600>	C131599	SRGAP2 wt Allele|ARHGAP34|FNBP2|KIAA0456|SLIT-ROBO GAP 2|SLIT-ROBO GTPase Activating Protein 2, Rho, 2 Gene|SLIT-ROBO Rho GTPase Activating Protein 2 wt Allele|SRGAP2A|SRGAP3	Human SRGAP2 wild-type allele is located in the vicinity of 1q32.1 and is approximately 261 kb in length. This allele, which encodes SLIT-ROBO Rho GTPase-activating protein 2, plays a role in cytoskeletal remodeling in cell differentiation, cell migration and neuronal morphogenesis.			Gene or Genome	
C131601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131601>	C131526	Cervical Spinal Cord Ependymal Tumor	A finding indicating the presence of an ependymal tumor in the cervical region of spinal cord.			Finding	
C131602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131602>	C17298	SLIT-ROBO Rho GTPase-Activating Protein 2|Formin Binding Protein 2|Formin-Binding Protein 2|Rho GTPase-Activating Protein 34|srGAP2	SLIT-ROBO Rho GTPase-activating protein 2 (1071 aa, ~121 kDa) is encoded by the human SRGAP2 gene. This protein is involved in cell differentiation, cell migration and neuronal morphogenesis.			Amino Acid, Peptide, or Protein	
C131603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131603>	C131526	Thoracic Spinal Cord Ependymal Tumor	A finding indicating the presence of an ependymal tumor in the thoracic region of spinal cord.			Neoplastic Process	
C131604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131604>	C131526	Lumbosacral Spinal Cord Ependymal Tumor	A finding indicating the presence of an ependymal tumor in the lumbosacral region of spinal cord.			Finding	
C131605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131605>	C131526	Cervical and Thoracic Spinal Cord Ependymal Tumor	A finding indicating the presence of an ependymal tumor in the cervical and thoracic regions of spinal cord.			Finding	
C131606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131606>	C131526	Thoracic and Lumbosacral Spinal Cord Ependymal Tumor	A finding indicating the presence of an ependymal tumor in the thoracic and lumbosacral regions of spinal cord.			Finding	
C131607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131607>	C1450	Albumin-binding Cisplatin Prodrug BTP-114|Albumin-conjugating Platinum-prodrug BTP-114|BTP 114|BTP-114|Cisplatin Prodrug BTP-114|Cisplatin/Maleimide-based Complex BTP-114|Platinum-Prodrug BTP-114|Prodrug BTP 114	A proprietary, albumin-binding platinum (Pt)-based complex containing a prodrug form of the platinum compound cisplatin and a maleimide moiety, with an ability to strongly and selectively bind human serum albumin (HSA), and with potential antineoplastic activity.  Upon intravenous administration, the maleimide group of BTP-114 rapidly conjugates with HSA in the bloodstream; this prolongs the blood circulation, enhances the half-life, and alters the biodistribution of BTP-114, as compared to cisplatin alone. Thus, BTP-114 demonstrates enhanced extravasation to the tumor, an increased accumulation in the tumor tissue and enhanced uptake by cancer cells. The prodrug form is reduced in the hypoxic tumor cell environment, which releases the highly cytotoxic active metabolite cisplatin. Once inside the tumor cell, cisplatin binds to nucleophilic groups, such as GC-rich sites, in DNA and induces intrastrand and interstrand DNA cross-links, resulting in apoptosis and cell growth inhibition. Compared to cisplatin alone, BTP-114 has improved selectivity towards tumor tissue, thereby enhancing efficacy while reducing systemic toxicities.	Albumin-binding Cisplatin Prodrug BTP-114		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131608>	C131526	Cervical and Lumbosacral Spinal Cord Ependymal Tumor	A finding indicating the presence of an ependymal tumor in the cervical and lumbosacral regions of spinal cord.			Finding	
C131609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131609>	C131526	Cervical, Thoracic, and Lumbosacral Spinal Cord Ependymal Tumor	A finding indicating the presence of an ependymal tumor in the cervical, thoracic, and lumbosacral regions of spinal cord.			Finding	
C131610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131610>	C186359	Ependymal Tumor of Brain and Spinal Cord	A finding indicating the presence of an ependymal tumor in the brain and spinal cord.			Finding	
C131611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131611>	C186359	Supratentorial Ependymal Tumor	A finding indicating the presence of an ependymal tumor in the supratentorial region of the brain.			Finding	
C131612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131612>	C186359	Infratentorial Ependymal Tumor	A finding indicating the presence of an ependymal tumor in the infratentorial region of the brain.			Finding	
C131613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131613>	C131610	Infratentorial and Spinal Cord Ependymal Tumor	A finding indicating the presence of an ependymal tumor in the infratentorial region of the brain and spinal cord.			Finding	
C131614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131614>	C20194	GOLM2 Gene|CASC4|GOLM2|GOLM2|Golgi Membrane Protein 2 Gene	This gene may play a role in Golgi apparatus activity and tumor growth.			Gene or Genome	
C131615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131615>	C131614	GOLM2 wt Allele|CASC4|Cancer Susceptibility 4 Gene|Cancer Susceptibility Candidate 4 Gene|Cancer Susceptibility Candidate Gene 4|DKFZp459F1927|GOLM2|Gene Associated With HER-2/Neu Overexpression|Golgi Membrane Protein 2 wt Allele|H63|UNQ2573/PRO6308	Human GOLM2 wild-type allele is located in the vicinity of 15q15.3 and is approximately 127 kb in length. This allele, which encodes protein GOLM2, may be involved in tumor progression and Golgi activity. Aberrant expression of the gene is seen in tumors that overexpress the ERBB2 gene.			Gene or Genome	
C131616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131616>	C18466	Protein GOLM2|Cancer Susceptibility Candidate Gene 4 Protein|GOLM2|Golgi Membrane Protein 2|Protein CASC4	Protein GOLM2 (436 aa, ~49 kDa) is encoded by the human GOLM2 gene. This protein may play a role in protein maturation and tumorigenesis.			Amino Acid, Peptide, or Protein	
C131617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131617>	C6770|C132506	Recurrent Ependymal Tumor	The reemergence of an ependymal tumor after a period of remission.			Neoplastic Process	
C131618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131618>	C36280	Ventricular Involvement Only	A finding indicating that a neoplasm affects exclusively a brain ventricle.			Finding	
C131619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131619>	C177692	MAGEA10 Positive|CT1.10 Positive|Cancer/Testis Antigen 1.10 Positive|MAGE-10 Antigen Positive|Melanoma Antigen 10 Positive|Melanoma-Associated Antigen 10 Positive	An indication that melanoma-associated antigen 10 expression has been detected in a sample.	MAGEA10 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13161>	C13055	Juxtaglomerular Cell	Any of a group of cells that are situated in the wall of each afferent arteriole of a kidney glomerulus near its point of entry adjacent to a macula densa and that produce and secrete renin.			Cell	
C131620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131620>	C93102|C17666	Deleterious Germline Mutation	A mutation that appears in the genome of the germ cells and is associated with increased risk of disease.	Deleterious Germline Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131621>	C34347|C26692	Acquired Factor I Deficiency	An acquired coagulation disorder characterized by the partial or complete absence of fibrinogen (factor I) activity in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131622>	C34347|C131737	Acquired Factor II Deficiency|Acquired hypoprothrombinemia	An acquired coagulation disorder characterized by the partial or complete absence of prothrombin (factor II) activity in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131623>	C34347|C131635	Acquired Factor III Deficiency|Acquired Tissue Factor Deficiency	An acquired coagulation disorder characterized by the partial or complete absence of tissue factor (factor III) activity in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131624>	C34347|C131738	Acquired Factor V Deficiency	An acquired coagulation disorder characterized by the partial or complete absence of factor V activity in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131625>	C34347|C131631	Acquired Factor VII Deficiency	An acquired coagulation disorder characterized by the partial or complete absence of factor VII activity in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131626>	C34347|C131632	Acquired Factor X Deficiency	An acquired coagulation disorder characterized by the partial or complete absence of factor X activity in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131627>	C34347|C131739	Acquired Factor XI Deficiency	An acquired coagulation disorder characterized by the partial or complete absence of factor XI activity in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131628>	C34347|C131740	Acquired Factor XII Deficiency	An acquired coagulation disorder characterized by the partial or complete absence of factor XII activity in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131629>	C34347|C131633	Acquired Factor XIII Deficiency	An acquired coagulation disorder characterized by the partial or complete absence of factor XIII activity in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131630>	C35472	Anemia due to Erythrocyte Enzyme Disorder	Any form of anemia that results from the absence of, or the defective action of, any enzyme involved in erythropoiesis.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131631>	C27215	Factor VII Deficiency	A coagulation disorder characterized by the partial or complete absence of factor VII activity in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131632>	C27215	Factor X Deficiency	A coagulation disorder characterized by the partial or complete absence of factor X activity in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131633>	C27215	Factor XIII Deficiency	A coagulation disorder characterized by the partial or complete absence of factor XIII activity in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131634>	C26324	Platelet Disorder|Platelet Abnormality|Platelet Abnormality	A disorder of platelet function or platelet production that may cause increased bleeding.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131635>	C27215	Tissue Factor Deficiency|Factor III Deficiency|Factor III Deficiency	A coagulation disorder characterized by the partial or complete absence of tissue factor (factor III) activity in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131636>	C173398	Have Difficulty Breathing When Exposed to Cold Temperatures Question|Have Difficulty Breathing When Exposed to Cold Temperatures|I have difficulty breathing when I am exposed to cold temperatures	A question about whether an individual has or had difficulty breathing when exposed to cold temperatures			Intellectual Product	
C131637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131637>	C49188	Beta-D-Glucan Assay|Fungitell Assay|Fungitell beta-D Glucan Assay	A laboratory assay designed to detect elevated levels of (1,3)-beta-D-glucan in serum as an indication of infection by certain fungi species.			Laboratory Procedure	
C131638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131638>	C34816|C131630	Bisphosphoglycerate Mutase Deficiency|Diphosphoglycerate Phosphatase Deficiency	A rare, autosomal recessive, inherited disorder caused by mutation of the BPGM gene. It is characterized by hemolytic anemia and splenomegaly.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131639>	C28193|C158788	Epstein Syndrome	An autosomal dominant disorder characterized by thrombocytopenia, giant platelets, nephritis, and deafness; it is associated with mutation of the MYH9 gene.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131640>	C34816|C131630	Erythrocyte Adenylate Kinase Deficiency|Red Cell Adenylate Kinase Deficiency	An autosomal recessive disorder caused by mutation of the AK1 gene. It is associated with moderate to severe non-spherocytic hemolytic anemia and, in some cases, with intellectual disability and psychomotor impairment.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131641>	C34816|C131630	Erythrocyte Enolase Deficiency|Alpha-Enolase Deficiency|Phosphopyruvate Hydratase Deficiency	A rare, autosomal dominant, inherited disorder caused by mutation of the ENO1 gene. It is associated with spherocytic hemolytic anemia, exercise-induced myalgia and weakness.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131642>	C28193|C158788	Fechtner Syndrome	An autosomal dominant disorder characterized by the triad of thrombocytopenia, giant platelets, and characteristic inclusions in peripheral blood leukocytes, with the additional features of nephritis, hearing loss, and eye abnormalities, mostly cataracts; it is associated with mutation of the MYH9 gene.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131643>	C34816|C131630	Glucose Phosphate Isomerase Deficiency|Glucose-6-Phosphate Isomerase Deficiency	A rare, autosomal recessive, inherited disorder caused by mutation of the GPI gene. It is characterized by chronic, non-spherocytic hemolytic anemia.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131644>	C98942|C131635	Hereditary Factor III Deficiency|Hereditary Tissue Factor Deficiency	An autosomal recessive, inherited coagulation disorder characterized by the partial or complete absence of tissue factor (factor III) activity in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131645>	C97089|C34816|C131630	Hexokinase Deficiency|Erythrocyte Hexokinase Deficiency|HK1 Deficiency	A rare, autosomal recessive, inherited disorder caused by mutation of the HK1 gene. It is characterized by the early-onset of severe, non-spherocytic hemolytic anemia.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131646>	C28193|C158788	May-Hegglin Anomaly	An autosomal dominant disorder characterized by the triad of thrombocytopenia, giant platelets, and characteristic inclusions in peripheral blood leukocytes. It is characterized by varying degrees of thrombocytopenia that may be associated with purpura and bleeding; it is associated with mutation of the MYH9 gene.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131647>	C61272|C131630	Phosphoglycerate Mutase Deficiency|Glycogen Storage Disease X|Muscle Phosphoglycerate Mutase Deficiency	A rare, autosomal recessive, inherited disorder caused by mutation of the PGAM2 gene. It is characterized by non-spherocytic hemolytic anemia, exercise-induced cramping, myoglobinuria, and presence of tubular aggregates on muscle biopsy.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131648>	C53543|C2902	Plasma Kallikrein Deficiency	A coagulation disorder characterized by the partial or complete absence of plasma-type kallikrein activity in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131649>	C35469|C34816|C34379|C131630	Pyrimidine-5'-Nucleotidase Deficiency	An autosomal recessive disorder caused by mutation of the NT5C3A gene. It is the most frequent abnormality of red cell nucleotide metabolism, causing chronic, non-spherocytic hemolytic anemia. Most affected individuals have Mediterranean, Jewish, or African ancestry. Basophilic stippling and accumulation of pyrimidines within erythrocytes are hallmarks of this disorder.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C13164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13164>	C13023	Epicardium|EPICARDIUM	The outer membranous connective tissue layer of the heart tissue.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C131650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131650>	C28193|C158788	Sebastian Syndrome|Sebastian Platelet Syndrome	An autosomal dominant disorder characterized by the triad of thrombocytopenia, giant platelets, and characteristic inclusions in peripheral blood leukocytes, without other organ dysfunction; it is associated with mutation of the MYH9 gene.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131651>	C53543|C2902	Tissue Kallikrein Deficiency	A disorder characterized by the partial or complete absence of tissue-type kallikrein activity in the tissues and glandular secretions where it is normally present.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131652>	C34816|C34379|C131630	Triosephosphate Isomerase Deficiency|TP1 Deficiency|Triosephosphate-Isomerase Deficiency	An autosomal recessive condition caused by mutation(s) in the TPI1 gene, encoding triosephosphate isomerase. It is characterized by congenital hemolytic anemia and progressive neuromuscular dysfunction.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131653>	C78797	Acquired Thrombotic Thrombocytopenic Purpura|Acquired ADAMTS13 Deficiency|Acquired TTP	Thrombotic thrombocytopenic purpura for which the cause is not present at birth.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131654>	C15699	Alpha-Beta T-Cell Depletion	Restriction of the T-cell population in stem cell transplants to those expressing only the gamma-delta receptor. Alpha-beta receptors are expressed on the majority of peripheral blood T-cells and are the primary mediators of graft versus host disease.	Alpha-Beta T-Cell Depletion		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131655>	C2869	Anemia due to Decreased Production	Anemia that results from a decreased rate of erythropoiesis.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131656>	C2869	Anemia due to Increased Destruction	Anemia that results from an increased rate of erythrocyte destruction.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131657>	C78797	Congenital Thrombotic Thrombocytopenic Purpura|Congenital ADAMTS-13 Deficiency|Congenital ADAMTS13 Deficiency|Congenital TTP	Thrombotic thrombocytopenic purpura for which the cause is present from birth.	Congenital Thrombotic Thrombocytopenic Purpura		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131658>	C2902	Consumptive Coagulopathy|Consumption Coagulopathy	Disorders of coagulation caused by the depletion of coagulation factors in the peripheral blood.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131659>	C2902	Dysfibrinogenemia	A coagulation disorder caused by abnormalities in fibrin that result in defective clot formation. This disorder may be inherited or acquired.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131660>	C131621	Factor I Inactivation|Factor I Inhibitor Present	Presence of inactivating antibodies to fibrinogen (factor I) in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131661>	C131622	Factor II Inactivation|Factor II Inhibitor Present	Presence of inactivating antibodies to prothrombin (factor II) in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131662>	C131623	Factor III Inactivation|Factor III Inhibitor Present|Tissue Factor Inhibitor Present	Presence of inactivating antibodies to tissue factor (factor III) in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131663>	C35440	Factor IX Inactivation|Factor IX Inhibitor Present	Presence of inactivating antibodies to factor IX in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131664>	C131624	Factor V Inactivation|Factor V Inhibitor Present	Presence of inactivating antibodies to factor V in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131665>	C131625	Factor VII Inactivation|Factor VII Inhibitor Present	Presence of inactivating antibodies to factor VII in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131666>	C35345	Factor VIII Inactivation|Factor VIII Inhibitor Present	Presence of inactivating antibodies to factor VIII in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131667>	C131626	Factor X Inactivation|Factor X Inhibitor Present	Presence of inactivating antibodies to factor X in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131668>	C131627	Factor XI Inactivation|Factor XI Inhibitor Present	Presence of inactivating antibodies to factor XI in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131669>	C131628	Factor XII Inactivation|Factor XII Inhibitor Present	Presence of inactivating antibodies to factor XII in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C13166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13166>	C12749	Mucosa|MUCOSA|Mucosal|Mucous Membrane|Mucous Membrane|mucosa|mucous membrane	Mucous membrane.			Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C131670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131670>	C131629	Factor XIII Inactivation|Factor XIII Inhibitor Present	Presence of inactivating antibodies to factor XIII in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131671>	C15699	Gamma-Delta T-Cell Depletion	Restriction of the T-cell population in stem cell transplants to those expressing only the alpha-beta receptor.			Therapeutic or Preventive Procedure	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131672>	C158758	Gross Total Resection|Gross Total|Gross Total|Gross Total	Surgical removal of an entire visible lesion, with no obvious lesion detected on post-operative evaluation; microscopic residual disease may be present.			Therapeutic or Preventive Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|GCT Authorized Value Terminology|GCT Biopsy/Surgical Procedures Table|GDC Terminology|GDC Value Terminology|NICHD Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|Pediatric Hematology-Oncology Terminology
C131673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131673>	C2902	Immune-Mediated Coagulopathy|IMC|Immune-Mediated Coagulation Disorder	Disorders of coagulation caused by autoantibodies generated against native coagulation factors or therapeutically-administered hemostatic agents.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131674>	C101218	Infantile Pyknocytosis|Hereditary Pyknocytosis	A rare, neonatal syndrome characterized by early jaundice that becomes rapidly associated with severe hemolytic anemia. The peripheral blood smear is remarkable for small irregular, contracted red blood cells with hyper-dense spikes (pyknocytes), that progressively increase in number and then spontaneously disappear.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131675>	C48284	Matched Related Donor	A donor who is related to the transplant recipient, and who is a human leukocyte antigen (HLA) tissue type match.			Qualitative Concept	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131676>	C48284	Matched Unrelated Donor|MUD|Matched Non-Related Donor	A donor who is not related to the transplant recipient, but who is a human leukocyte antigen (HLA) tissue type match.			Qualitative Concept	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131677>	C34382	Megaloblastic Anemia 1|Imerslund-Gräsbeck Syndrome|Juvenile Megaloblastic Anemia|MGA-1	An autosomal recessive disorder caused by mutations in the CUBN or AMN genes. It is characterized by vitamin B12 deficiency due to selective malabsorption of the vitamin, and usually results in megaloblastic anemia appearing in childhood (but not immediately after birth).			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131678>	C48284	Mismatched Unrelated Donor|MMUD|Mismatched Non-Related Donor, Mismatched Donor	A donor who is not related to the transplant recipient, and who is not a human leukocyte antigen (HLA) tissue type match at one or more of the following loci: HLA-A, HLA-B, HLA-C, and HLA-DRB1.			Qualitative Concept	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131679>	C64468	Myeloablative Conditioning|Myeloablation|Myeloablative|Myeloablative|Myeloablative|Myeloablative Cytoreduction	A conditioning regimen with high doses of chemotherapy or radiation to eliminate host hematopoietic stem cells prior to restitution via transplantation.			Therapeutic or Preventive Procedure	ALL Authorized Value Terminology|ALL Stem Cell Transplant Table|AML Authorized Value Terminology|AML Stem Cell Transplant Table|HL Authorized Value Terminology|HL Stem Cell Transplant Table|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C13167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13167>	C12801	Submucosa|submucosa	A layer of areolar tissue beneath the mucous membrane			Tissue	
C131680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131680>	C158758	Partial Resection|Incomplete Resection|Subtotal Resection|Subtotal Resection|Subtotal Resection	Resection of part of an organ or tissue structure.			Therapeutic or Preventive Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|GCT Authorized Value Terminology|GCT Biopsy/Surgical Procedures Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Biopsy/Surgical Procedures Table|NICHD Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|Pediatric Hematology-Oncology Terminology
C131681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131681>	C68677	Platelet-Type von Willebrand Disease|Pseudo-von Willebrand Disease	A rare autosomal dominant bleeding disorder characterized by abnormally enhanced binding of von Willebrand factor (VWF) by the platelet glycoprotein Ib receptor complex. Hemostatic function is impaired due to the removal of VWF multimers from the circulation. It is due to a mutation in the gene encoding for platelet glycoprotein Ib alpha, resulting in enhanced affinity for VWF. It is often misdiagnosed as type 2B von Willebrand disease due to similarities between these two conditions. Patients present with a mild thrombocytopenia with large platelets. Platelet aggregates are often visible in blood smears.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131682>	C34383	Sickle Cell-SS Disease|Hb SS|Hemoglobin SS|Hemoglobin SS Disease|Hemoglobin SS Disease|Sickle Cell (SS only)	A variant of sickle cell disease due to homozygosity of the E6V mutation, amino acid substitution of valine for glutamic acid in the sixth position of the beta chain, resulting in the production of hemoglobin S from both alleles.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131683>	C70548	Transient Erythroblastopenia of Childhood|TEC	An acquired pure red cell aplasia that is self-limited. It is the most common cause of decreased red blood cell production in the pediatric population, and typically presents as a normocytic anemia with reticulocytopenia in an otherwise asymptomatic and normal child with no evidence of other causes for anemia, including blood loss, hemolysis, nutritional deficiency, or malignancy.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131684>	C35129	Vitamin B12 Deficiency|Hypocobalaminemia	Low serum levels of vitamin B12 (cobalamin) due to poor intestinal absorption, decreased dietary intake, or increased physiologic requirement.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131685>	C68677	von Willebrand Disease, Type 1	An autosomally inherited (generally dominant) coagulation disorder characterized by quantitative partial deficiency of circulating von Willebrand factor (VWF) which account for 60 to 80% of cases of von Willebrand disease. It is characterized by mild to moderate quantitative deficiencies of VWF and factor VIII, which are coordinately reduced from normal plasma levels.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131686>	C68677	von Willebrand Disease, Type 2A	An autosomally inherited (generally dominant) coagulation disorder characterized by qualitative abnormalities of the von Willebrand factor (VWF). The mutant VWF causes decreased platelet adhesion due to a selective deficiency of high molecular weight multimers. The decrease in large multimers can be due to a failure to synthesize the multimers ('group 1') or enhanced ADAMTS13-mediated proteolysis of the secreted high molecular weight protein ('group 2').			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131687>	C68677	von Willebrand Disease, Type 2B	An autosomally inherited (generally dominant) coagulation disorder characterized by qualitative abnormalities of the von Willebrand factor (VWF). The mutant VWF shows increased affinity to platelet glycoprotein Ib alpha, resulting in increased platelet aggregation, and increased proteolysis of VWF subunits causing a decrease of large VWF multimers; patients often have secondary thrombocytopenia due to platelet consumption.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131688>	C68677	von Willebrand Disease, Type 2M	An autosomally inherited (generally dominant) coagulation disorder characterized by qualitative abnormalities of the von Willebrand factor (VWF). The mutant VWF shows decreased platelet adhesion without a deficiency of high molecular weight multimers; this functional defect is caused by mutations that disrupt VWF binding to platelets or to subendothelium.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131689>	C68677	von Willebrand Disease, Type 2N|von Willebrand Disease Normandy Variant	An autosomally inherited (generally recessive) coagulation disorder characterized by qualitative abnormalities of the von Willebrand factor (VWF). The mutant VWF shows markedly decreased binding affinity for factor VIII, which can be confused with mild hemophilia A. The phenotype is characterized by a disproportionate decrease in factor VIII compared to VWF.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131690>	C168618	Pan-Mutant-IDH1 Inhibitor Bay-1436032|3-(2-((4-(Trifluoromethoxy)phenyl)amino)-1-((1R,5R)-3,3,5-trimethylcyclohexyl)-1H-benzo[d]imidazol-5-yl)propanoic Acid|BAY 1436032|BAY-1436032|BAY1436032	An orally available pan-inhibitor of mutant forms of the metabolic enzyme isocitrate dehydrogenase type 1 (IDH1; IDH-1; IDH1 [NADP+] soluble), including forms with mutations of arginine 132 (IDH1(R132)), with potential antineoplastic activity. Upon administration, pan-mutant-IDH-1 inhibitor BAY-1436032 specifically inhibits the activity of IDH1 mutant forms, which prevents the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing IDH1 mutant forms. IDH1 mutations, including IDH1(R132) mutations, are highly expressed in certain malignancies; they initiate and drive cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.	Pan-Mutant-IDH1 Inhibitor Bay-1436032		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131691>	C173219	Have Skin Tightness Question|Does any part of your skin feel tight|Have Skin Tightness|Skin Tightness	A question about whether an individual's skin feels or felt tight.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131692>	C173219	Have Raw or Sore Skin Question|Does any part of your skin feel raw or sore|Have Raw or Sore Skin|Skin Raw or Sore	A question about whether an individual's skin feels or felt raw or sore.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131693>	C173981|C172828	Have Dry or Itchy Skin Question|Does any part of your skin feel dry or itchy|Have Dry or Itchy Skin|Skin Dry or Itchy	A question about whether an individual's skin feels or felt dry or itchy.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131694>	C173981	Have a Skin Rash Question|Does any part of your skin have a rash|Have a Skin Rash|Skin Rash	A question about whether an individual has or had a skin rash.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131695>	C173981	Have Shiny Skin Scar Question|Does any part of your skin look like a shiny scar|Have Shiny Scar|Have Shiny Skin Scar|Shiny Skin Scar|Skin Shiny Scar	A question about whether an individual has or had a shiny scar.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131696>	C173981	Have Scaly or Flaky Skin Question|Does any part of your skin look scaly or flaky|Have Scaly or Flaky Skin|Skin Scaly or Flaky	A question about whether an individual's skin looks or looked scaly or flaky.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131697>	C176022|C173981	Have Darker or Lighter Skin than Normal Question|Does any part of your skin look darker or lighter than normal|Have Darker or Lighter Skin than Normal|Skin Darker or Lighter than Normal	A question about whether an individual's skin looks or looked darker or lighter than normal.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131698>	C173981	Hair Thinning or Falling Out Question|Hair Thinning or Falling Out|Is your hair thinning or falling out	A question about whether an individual's hair is thinning or falling out.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131699>	C176022	Nails Look Unusual Question|Do your nails look unusual|Nails Look Unusual	A question about whether an individual's nails look or looked unusual.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C13169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13169>	C12749	Serosa|Serous Membrane|serosa|serous membrane	A membrane lining the external walls of the body cavities and reflected over the surfaces of protruding organs. It consists of mesothelium lying on a connective tissue layer, and secretes a watery exudate.			Tissue	
C1316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1316>	C66883	Oxidopamine|2,4,5-Trihydroxyphenethylamine|5-(2-Aminoethyl)-1,2,4-benzenetriol|5-(2-Aminoethyl)-1,2,4-benzenetriol|6-Hydroxydopamine|6-OHDA|OXIDOPAMINE	An antagonist of the neurotransmitter dopamine with potential antineoplastic activity. 6-Hydroxydopamine (6-HOD) can be taken up by selective adrenergic terminals, thereby causing acute degeneration of adrenergic terminals that leads to depletion of norepinephrine, and of dopamine in the dopamine-sensitive sites. This agent is auto-oxidated at physiological pH that leads to the formation of reactive free radicals, thereby leading to cytotoxicity in neural cells.  6-Hydroxydopamine is often used to induce CNS and sympathetic neural lesions that model aging and various nervous disorders in animal systems.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131700>	C173219	Eyes Feel Dry or Gritty Question|Do your eyes feel dry or gritty|Eyes Dry or Gritty|Eyes Feel Dry or Gritty	A question about whether an individual's eyes feel or felt dry or gritty.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131701>	C173981	Have Excessive Tearing Question|Do your eyes have excessive tearing|Excessive Tearing|Have Excessive Tearing	A question about whether an individual's eyes have or had excessive tearing.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131702>	C91126	Have Eye Pain in Wind Question|Do your eyes hurt because of wind|Eye Pain in Wind|Eyes Hurt Because of Wind|Have Eye Pain in Wind	A question about whether an individual's eyes hurt because of the wind.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131703>	C173398	Have Difficulty Opening Eyes on Waking Question|Difficulty Opening Eyes on Waking|Do your eyes have difficulty opening on waking|Have Difficulty Opening Eyes on Waking	A question about whether an individual's eyes are difficult to open on waking.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131704>	C91102	Use Artificial Tears Question|Do you use artificial tears|Use Artificial Tears|Use Artificial Tears	A question about whether an individual uses artificial tears.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131705>	C173812	Have Tear Ducts Plugged or Cauterized Question|Have Tear Ducts Plugged or Cauterized|Have you had your tear ducts plugged or cauterized|Tear Ducts Plugged or Cauterized	A question about whether an individual has had their tear ducts plugged or cauterized.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131706>	C173346	Wear Special Eyewear or Scleral Lenses to Relieve Eye Pain Question|Do you wear special eyewear or scleral lenses to relieve eye pain|Wear Special Eyewear or Scleral Lenses to Relieve Eye Pain	A question about whether an individual wears special eyewear or scleral lenses to relieve eye pain.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131707>	C173924|C173790	Eye Dryness Affects Vision or Prevents Working Question|Does your eye dryness affect your vision or prevent you from working|Eye Dryness Affects Vision or Prevents Working	A question about whether an individual's eye dryness affects their vision or prevents them from working.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131708>	C106645	Manufactures Human Over-the-Counter Drug Products Produced Under a Monograph	The process of manufacturing non-prescription medications under a monograph (as opposed to under an approved drug application), for humans by a pharmaceutical company.			Activity	FDA Structured Product Labeling Terminology|SPL Business Operation Qualifier Terminology
C131709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131709>	C106645	Manufactures Human Over-the-Counter Drug Products Produced Under an Approved Drug Application	The process of manufacturing non-prescription medications under an approved drug application (as opposed to under a monograph), for humans by a pharmaceutical company.			Activity	FDA Structured Product Labeling Terminology|SPL Business Operation Qualifier Terminology
C13170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13170>	C33952	Hassall's Corpuscle|Hassall's Body|Hassall's Concentric Corpuscle|Thymic Corpuscle|Virchow-Hassall Body	A small spherical body composed of keratinized squamous epithelial cells arranged in a concentric pattern in the medullary portion of the thymus.			Body Part, Organ, or Organ Component	
C131710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131710>	C106645	Manufactures Human Over-the-Counter Drug Products Neither Produced Under an Approved Application nor Under a Monograph	The process of manufacturing non-prescription medications under neither a monograph nor an approved drug application, for humans by a pharmaceutical company.			Activity	FDA Structured Product Labeling Terminology|SPL Business Operation Qualifier Terminology
C131711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131711>	C128839	Human Papillomavirus-18 Positive|HPV-18 Positive|HPV18 Positive|Human Papilloma Virus 18 Positive|Human Papilloma Virus-18 Positive|Human Papillomavirus 18 Positive	An indication that human papillomavirus-18 has been detected in a sample.	Human Papillomavirus-18 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C131712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131712>	C173457	Using Narcotics to Relieve Mouth Symptoms Question|Using Narcotics to Relieve Mouth Symptoms|Using narcotics to relieve mouth symptoms	A question about whether an individual uses narcotic products to relieve mouth symptoms.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131713>	C173981	Have Mouth or Lip Sores or Ulcers Question|Any mouth (or lip) sores or ulcers|Have Mouth or Lip Sores or Ulcers	A question about whether an individual has or had mouth or lip sores or ulcers.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131714>	C188083|C173346|C173045	Unable to Eat Because of Mouth Pain Question|Unable to Eat Because of Mouth Pain|Unable to eat because of pain	A question about whether an individual is or was unable to eat because of mouth pain.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131715>	C173518	Have Mouth Discomfort with Hot or Cold Question|Any mouth discomfort with hot/cold|Have Mouth Discomfort with Hot or Cold	A question about whether an individual has or had mouth discomfort with hot or cold.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131716>	C173518	Have Mouth Discomfort with Toothpaste Question|Any mouth discomfort with toothpaste|Have Mouth Discomfort from Toothpaste|Have Mouth Discomfort with Toothpaste	A question about whether an individual has or had mouth discomfort with toothpaste.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131717>	C173518	Have Mouth Discomfort with Spicy Food Question|Any mouth discomfort with spicy food|Have Mouth Discomfort from Spicy Food|Have Mouth Discomfort with Spicy Food	A question about whether an individual has or had mouth discomfort with spicy food.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131718>	C173518	Have Mouth Discomfort with Carbonated Beverage Question|Any mouth discomfort with soda/pop|Have Mouth Discomfort from Carbonated Beverage|Have Mouth Discomfort with Carbonated Beverage	A question about whether an individual has or had mouth discomfort with carbonated beverages.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131719>	C173219	Mouth Feels Dry Most of the Time Question|Does your mouth feel dry most of the time|Mouth Feels Dry Most of the Time	A question about whether an individual's feels or felt dry most of the time.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C13171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13171>	C13821|C13022	Meissner Corpuscle|Corpusculum Tactus|Meissner's Corpuscle|Oval Corpuscle|Tactile Corpuscle|Touch Corpuscle	One of numerous oval bodies found in the papillae of the skin, especially those of the fingers and toes; they consist of a connective tissue capsule in which the axon fibrils terminate around and between a pile of wedge-shaped epithelioid cells. SYN corpusculum tactus, oval corpuscle, touch corpuscle.			Anatomical Structure	
C131720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131720>	C173398	Difficult to Open Mouth Wide Question|Difficult to Open Mouth Wide|Difficulty Opening Mouth Wide|Is it difficult to open your mouth wide	A question about whether an individual has or had difficulty opening their mouth wide.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131721>	C173695|C173457	Mouth Symptoms Limit Oral Intake Question|Do mouth symptoms limit your oral intake|Mouth Symptoms Limit Oral Intake	A question about whether an individual limits their oral intake due to mouth symptoms.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131722>	C131721	Mouth Symptoms Partially Limit Oral Intake Question|Do mouth symptoms partially limit your oral intake|Mouth Symptoms Partially Limit Oral Intake	A question about whether an individual partially limits their oral intake due to mouth symptoms.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131723>	C131721	Mouth Symptoms Cause Major Limit to Oral Intake Question|Do mouth symptoms cause major limit to your oral intake|Mouth Symptoms Cause Major Limit to Oral Intake	A question about whether an individual majorly limits their oral intake due to mouth symptoms.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131724>	C91102	Sinus Draining of Liquid Into Throat Question|Any draining of liquid into your throat|Sinus Draining of Liquid Into Throat	A question about whether an individual has or had sinus fluids draining into their throat.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131725>	C173346	Have Sinus Congestion or Pain Question|Any sinus congestion or pain|Have Sinus Congestion or Pain	A question about whether an individual has or had sinus congestion or pain.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131726>	C173981	Had Recent Sinus Infection Question|Any recent sinus infections|Had Recent Sinus Infection	A question about whether an individual has or had recent sinus infections.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131727>	C173812	Had Sinus Drainage Surgery Question|Any sinus drainage surgery|Had Sinus Drainage Surgery	A question about whether an individual has or had sinus drainage surgery.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131728>	C173981	Have Poor or Reduced Appetite Question|Have Poor or Reduced Appetite|Is your appetite poor or reduced from normal	A question about whether an individual's appetite is or was reduced from normal.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131729>	C91102	Easily Full Question|Are you easily full|Easily Full|Easily Satiated	A question about whether an individual gets or got easily full.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C13172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13172>	C13821|C13022	Vater-Pacini Corpuscle|Corpuscula Lamellosa|Lamellated Corpuscle|Pacinian Corpuscle|Vater's Corpuscle	A specialized bulblike nerve ending located in the subcutaneous tissue of the skin; occurs abundantly in the skin of palms and soles and joints and genitals.			Body Part, Organ, or Organ Component	
C131730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131730>	C173454	Foods or Pills Get Stuck Question|Do foods or pills get stuck|Foods or Pills Get Stuck	A question about whether an individual experiences or experienced having food or pills get stuck in their throat.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131731>	C173454	Can Easily Swallow Liquid or Soft Food Question|Can Easily Swallow Liquid or Soft Food|Can you easily swallow liquid/soft foods	A question about whether an individual can easily swallow liquids or soft foods.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131732>	C173981	Have Tightness in Arms, Legs, or Joints Question|Are your arms, legs, or joints tight|Have Tightness in Arms, Legs, or Joints	A question about whether an individual has or had tight arms, legs, or joints.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131733>	C173346	Have Muscle Cramps or Pain Question|Do you have muscle cramps or pains|Have Muscle Cramps or Pain	A question about whether an individual has or had muscle cramps or pains.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131734>	C173593	Have Swollen Feet, Ankles, or Joints Question|Do you have swollen feet, ankles, or joints|Have Swollen Feet, Ankles, or Joints	A question about whether an individual has or had swollen feet, ankles, or joints.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131735>	C176242	Some Days|Some days	A response indicating that an individual experiences or experienced something on some days.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131736>	C176254	Walking on Flat Ground|When walking on flat	A response indicating that an individual experiences or experienced something when walking on flat ground.			Intellectual Product	NIH Consensus Response Criteria for Chronic GVHD
C131737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131737>	C27215	Factor II Deficiency	A coagulation disorder characterized by the partial or complete absence of prothrombin (factor II) activity in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131738>	C27215	Factor V Deficiency	A coagulation disorder characterized by the partial or complete absence of factor V activity in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131739>	C3093	Factor XI Deficiency	A coagulation disorder characterized by the partial or complete absence of factor XI activity in the blood.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C13173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13173>	C13821|C13022	Merkel's Corpuscle|Meniscus Tactus|Merkel's Disc|Merkel's Disk|Merkel's Tactile Cell|Tactile Disc|Tactile Disk|Tactile Meniscus	A specialized tactile sensory nerve ending in the epidermis, characterized by a terminal cuplike expansion of an intraepidermal axon in contact with the base of a single modified keratinocyte. SYN meniscus tactus, Merkel's corpuscle, Merkel's tactile cell, Merkel's tactile disk, tactile disk.			Body Part, Organ, or Organ Component	
C131740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131740>	C27215	Factor XII Deficiency	A coagulation disorder characterized by the partial or complete absence of factor XII activity in the blood. It is not associated with increased bleeding risk.			Disease or Syndrome	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C131741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131741>	C492	13-Hydroxyoctadecadienoic Acid|13-HODE|13-Hydroxy-9,11-Octadecadienoic Acid|13-Lox|9,11-Octadecadienoic Acid, 13-Hydroxy-	A monohydroxy fatty acid resulting from the oxidation of linoleic acid or 13-hydroperoxy-9,11-octadecadienoic acid (13-HpODE). 13-HODE may mediate physiological and pathological responses and is a potential biomarker of various human diseases, and could contribute to the progression of certain diseases.	13-Hydroxyoctadecadienoic Acid		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C131743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131743>	C20194	SNORD50A Gene|SNORD50A|SNORD50A|Small Nucleolar RNA, C/D Box 50A Gene	This gene is involved in methylation of preribosomal RNA.			Gene or Genome	
C131744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131744>	C131743	SNORD50A wt Allele|RNA, U50 Small Nuclear Gene|RNU50|Small Nucleolar RNA, C/D Box 50A wt Allele|Small Nucleolar RNA, C/D Box, 50A Gene|U50|snoRNA, U50 Gene	Human SNORD50A wild-type allele is located in the vicinity of 6q14.3 and is approximately 2 kb in length. This allele, which encodes U50 small nucleolar RNA, plays a role in the metabolism of preribosomal RNA. Somatic loss of the gene may be associated with several cancers.			Gene or Genome	
C131745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131745>	C111316	U50 Small Nucleolar RNA|SNORD50A|U50 snoRNA	U50 small nucleolar RNA (75 bases) is encoded by the human SNORD50A gene. This oligoribonucleotide plays a role in the methylation of ribose in preribosomal RNA.			Nucleic Acid, Nucleoside, or Nucleotide	
C131746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131746>	C20194	SNORD50B Gene|SNORD50B|SNORD50B|Small Nucleolar RNA, C/D Box 50B Gene	This gene plays a role in the methylation of 28S ribosomal RNA.			Gene or Genome	
C131747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131747>	C131746	SNORD50B wt Allele|RNA, U50' Small Nuclear Gene|RNA, U50-Prime Small Nuclear Gene|Small Nucleolar RNA, C/D Box 50B wt Allele|Small Nucleolar RNA, C/D Box, 50B Gene|U50'|U50-Prime|U50B|snoRNA, U50' Gene|snoRNA, U50-Prime Gene	Human SNORD50B wild-type allele is located in the vicinity of 6q14.3 and is approximately 2 kb in length. This allele, which encodes U50' small nucleolar RNA, is involved in the metabolism of ribosomal RNA. Somatic loss of the gene may be associated with various neoplastic diseases.			Gene or Genome	
C131748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131748>	C111316	U50' Small Nucleolar RNA|SNORD50B|U50' snoRNA|U50-Prime Small Nucleolar RNA|U50-Prime snoRNA	U50' small nucleolar RNA (75 bases) is encoded by the human SNORD50B gene. This oligoribonucleotide plays a role in ribosomal RNA methylation.			Nucleic Acid, Nucleoside, or Nucleotide	
C131749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131749>	C20194	SMIM24 Gene|SMIM24|SMIM24|Small Integral Membrane Protein 24 Gene	This gene encodes a membrane protein of unknown function.			Gene or Genome	
C13174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13174>	C33968	Free Nerve Ending|Free Nerve Endings	Free nerve endings are widely distributed throughout the body, and are found as branches of unmyelinated, or lightly myelinated fibres grouped in bundles beneath the epithelium. As they penetrate the epithelium, they lose their myelin, and branch among the epithelial cells. Branches of one nerve may cover a wide area and overlap the territories of other nerves. The free nerve endings detect pain, touch, pressure and temperature, and are associated with C fibres.			Body Part, Organ, or Organ Component	
C131750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131750>	C131749	SMIM24 wt Allele|C19orf77|Chromosome 19 Open Reading Frame 77 Gene|HSPC323|MARDI|Small Integral Membrane Protein 24 wt Allele	Human SMIM24 wild-type allele is located in the vicinity of 19p13.3 and is approximately 7 kb in length. This allele, which encodes small integral membrane protein 24, has no known function.			Gene or Genome	
C131751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131751>	C18466	Small Integral Membrane Protein 24|MAP17-Related Dimer|SMIM24|Transmembrane Protein C19orf77|Transmembrane Protein HSPC323	Small integral membrane protein 24 (130 aa, ~15 kDa) is encoded by the human SMIM24 gene. This protein has no known function.			Amino Acid, Peptide, or Protein	
C131752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131752>	C20194	CPXM1 Gene|CPXM1|CPXM1|Carboxypeptidase X, M14 Family Member 1 Gene	This gene may be involved in cell-cell interactions.			Gene or Genome	
C131753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131753>	C131752	CPXM1 wt Allele|CPX1|CPXM|Carboxypeptidase X (M14 Family), Member 1 Gene|Carboxypeptidase X, M14 Family Gene|Carboxypeptidase X, M14 Family Member 1 wt Allele|UNQ3015/PRO9782	Human CPXM1 wild-type allele is located in the vicinity of 20p13 and is approximately 7 kb in length. This allele, which encodes probable carboxypeptidase X1 protein, may play a role in cell interactions.			Gene or Genome	
C131754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131754>	C18466	Probable Carboxypeptidase X1|CPXM1|Carboxypeptidase-Like Protein X1|EC 3.4.17.-|Metallocarboxypeptidase CPX-1	Probable carboxypeptidase X1 (734 aa, ~82 kDa) is encoded by the human CPXM1 gene. This protein may be involved in the interactions between cells.			Amino Acid, Peptide, or Protein	
C131755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131755>	C20194	FAM30A Gene|FAM30A|FAM30A|Family With Sequence Similarity 30, Member A Gene	This gene may play a role in both cell migration and epithelial-mesenchymal transition.			Gene or Genome	
C131756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131756>	C131755	FAM30A wt Allele|C14orf110|Chromosome 14 Open Reading Frame 110 Gene|Family With Sequence Similarity 30, Member A wt Allele|HSPC053|KIAA0125	Human FAM30A wild-type allele is located in the vicinity of 14q32.33 and is approximately 15 kb in length. This allele, which encodes FAM30A protein and long non-coding RNA KIAA0125, may be involved in the promotion of both cell migration and cell differentiation.			Gene or Genome	
C131757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131757>	C18466	FAM30A Protein|HCG2029388, Isoform CRA_d|Putative Uncharacterized Protein KIAA0125	FAM30A protein (136 aa, ~15 kDa) is encoded by the human FAM30A gene. This protein may play a role in the regulation of both epithelial-mesenchymal transition and cell migration.			Amino Acid, Peptide, or Protein	
C131758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131758>	C88924	Long Noncoding RNA KIAA0125|FAM30A, Long Non-Coding RNA|Family With Sequence Similarity 30, Member A, Long Non-Coding RNA|Long Non-Coding RNA KIAA0125|lncRNA KIAA0125	Long noncoding RNA KIAA0125 (~10 kb) is encoded by the human FAM30A gene. This non-coding RNA may be involved in the modulation of both cell migration and epithelial-mesenchymal transition.			Nucleic Acid, Nucleoside, or Nucleotide	
C131759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131759>	C159659	Bone Marrow Transplant Recipient|Bone Marrow Transplantation Recipient|Bone Marrow Transplantation Recipient	An individual receiving a bone marrow transplant.	Bone Marrow Transplantation Recipient		Human	CTRP Intervention Terminology|CTRP Terminology
C13175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13175>	C13821|C13022	Ruffini Corpuscle|Ruffini's Corpuscle|Ruffini's Ending	Mechanoreceptors located in subcutaneous tissue, which are enlarged dendritic endings with elongated capsules, and which respond to sustained pressure.			Body Part, Organ, or Organ Component	
C131760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131760>	C7457	Anastomosing Hemangioma	An unusual variant of capillary hemangioma. It is characterized by a unique anastomosing sinusoidal-like architecture which may mimic angiosarcoma. It was originally described in the kidney but rare cases have been reported in other sites.			Neoplastic Process	
C131761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131761>	C20194	DPYSL3 Gene|DPYSL3|DPYSL3|Dihydropyrimidinase Like 3 Gene	This gene is involved in semaphorin signaling and neuronal development.			Gene or Genome	
C131762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131762>	C131761	DPYSL3 wt Allele|CRMP-4|CRMP4|DRP-3|DRP3|Dihydropyrimidinase Like 3 wt Allele|Dihydropyrimidinase-Like 3 Gene|LCRMP|ULIP|ULIP-1|ULIP1	Human DPYSL3 wild-type allele is located in the vicinity of 5q32 and is approximately 119 kb in length. This allele, which encodes dihydropyrimidinase-related protein 3, plays a role in neuronal development and semaphorin signaling.			Gene or Genome	
C131763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131763>	C18466	Dihydropyrimidinase-Related Protein 3|CRMP-4|Collapsin Response Mediator Protein 4|DPYSL3|DRP-3|Testicular Secretory Protein Li 7|ULIP-1|Unc-33 Like Phosphoprotein 1|Unc-33-Like Phosphoprotein 1	Dihydropyrimidinase-related protein 3 (570 aa, ~62 kDa) is encoded by the human DPYSL3 gene. This protein is involved in the regulation of both semaphorin signaling and the development of neurons.			Amino Acid, Peptide, or Protein	
C131764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131764>	C20921	ARHGAP22 Gene|ARHGAP22|ARHGAP22|Rho GTPase Activating Protein 22 Gene	This gene plays a role in RAC1 activation.			Gene or Genome	
C131765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131765>	C131764	ARHGAP22 wt Allele|Rho GTPase Activating Protein 22 wt Allele|RhoGAP2|RhoGap22	Human ARHGAP22 wild-type allele is located within 10q11.22-q11.23 and is approximately 226 kb in length. This allele, which encodes Rho GTPase-activating protein 22, is involved in the conversion of GTP to GDP.			Gene or Genome	
C131766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131766>	C17298	Rho GTPase-Activating Protein 22|ARHGAP22|Rho GTPase Activating Protein 22|Rho-Type GTPase-Activating Protein 22	Rho GTPase-activating protein 22 (698 aa, ~77 kDa) is encoded by the human ARHGAP22 gene. This protein plays a role in the activation of Ras-related C3 botulinum toxin substrate 1.			Amino Acid, Peptide, or Protein	
C131767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131767>	C21295	NYNRIN Gene|NYN Domain and Retroviral Integrase Containing Gene|NYNRIN|NYNRIN|NYNRIN	This gene may be involved in DNA transposition.			Gene or Genome	CCPS Genetics Terminology|Childhood Cancer Predisposition Study Terminology
C131768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131768>	C131767	NYNRIN wt Allele|CGIN1|Cousin of GIN1 Gene|FLJ11811|KIAA1305|NYN Domain and Retroviral Integrase Containing wt Allele	Human NYNRIN wild-type allele is located in the vicinity of 14q12 and is approximately 21 kb in length. This allele, which encodes protein NYNRIN, may play a role in DNA integration.			Gene or Genome	
C131769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131769>	C16518	Protein NYNRIN|NYN Domain and Retroviral Integrase Catalytic Domain-Containing Protein|Protein Cousin of GIN1	Protein NYNRIN (208 aa, ~208 kDa) is encoded by the human NYNRIN gene. This protein may be involved in the mediation of DNA transposition.			Amino Acid, Peptide, or Protein	
C13176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13176>	C13819	Nociceptor|Nociceptors|Pain Receptor	A free nerve ending that is a receptor for painful stimuli. (Kanner)			Body Part, Organ, or Organ Component	
C131770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131770>	C177692	CD276 Antigen Positive|4Ig-B7-H3 Positive|8H9 Positive|8H9 Reactive|Antigen CD276 Positive|B7 Homolog 3 Positive|B7-H3 Positive|B7H3 Positive|B7RP-2 Positive|CD276 Molecule Positive|CD276 Positive|M8H9 Antigen Positive|PSEC0249 Positive	An indication that CD276 expression has been detected in a sample.	CD276 Antigen Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131771>	C54362	ZBTB46 Gene|ZBTB46|ZBTB46|Zinc Finger and BTB Domain Containing 46 Gene	This gene plays a role in the regulation of PRDM1 gene transcription.			Gene or Genome	
C131772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131772>	C131771	ZBTB46 wt Allele|BTB (POZ) Domain Containing 4 Gene|BTBD4|BZEL|FLJ13502|RINZF|ZNF340|Zinc Finger and BTB Domain Containing 46 wt Allele|dJ583P15.7|dJ583P15.8	Human ZBTB46 wild-type allele is located in the vicinity of 20q13.33 and is approximately 89 kb in length. This allele, which encodes zinc finger and BTB domain-containing protein 46, is involved in the negative regulation of PRDM1 gene expression.			Gene or Genome	
C131773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131773>	C26199	Zinc Finger and BTB Domain-Containing Protein 46|BTB-ZF Protein Expressed In Effector Lymphocytes|BTB-Zinc Finger Protein Expressed In Effector Lymphocytes|BTB/POZ Domain-Containing Protein 4|ZBTB46|Zinc Finger Protein 340|Zinc Finger- and BTB Domain-Containing Protein 46	Zinc finger and BTB domain-containing protein 46 (589 aa, ~64 kDa) is encoded by the human ZBTB46 gene. This protein plays a role in the negative regulation of PR domain zinc finger protein 1 expression.			Amino Acid, Peptide, or Protein	
C131774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131774>	C93102|C132002	Deleterious BRIP1 Gene Mutation|Deleterious BACH1 Gene Mutation|Deleterious BRCA1 Interacting Protein C-Terminal Helicase 1 Gene Mutation|Deleterious FANCJ Gene Mutation	A change in the nucleotide sequence of the BRIP1 gene that is associated with increased risk of disease.	Deleterious BRIP1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C131775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131775>	C93102|C101641	Deleterious PALB2 Gene Mutation|Deleterious FANCN Gene Mutation|Deleterious Fanconi Anemia, Complementation Group N Gene Mutation|Deleterious PNCA3 Gene Mutation|Deleterious Partner and Localizer of BRCA2 Gene Mutation	A change in the nucleotide sequence of the PALB2 gene that is associated with increased risk of disease.	Deleterious PALB2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C131776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131776>	C93102|C131789	Deleterious BARD1 Gene Mutation|Deleterious BARD-1 Gene Mutation|Deleterious BRCA1 Associated RING Domain 1 Gene Mutation	A change in the nucleotide sequence of the BARD1 gene that is associated with increased risk of disease.	Deleterious BARD1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131777>	C93102|C128821	Deleterious MSH2 Gene Mutation|Deleterious COCA1 Gene Mutation|Deleterious HNPCC Gene Mutation|Deleterious HNPCC1 Gene Mutation|Deleterious MutS Homolog 2 Gene Mutation|Deleterious MutS, E. coli, Homolog of, 2 Gene Mutation	A change in the nucleotide sequence of the MSH2 gene that is associated with increased risk of disease.	Deleterious MSH2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C131778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131778>	C93102|C118395	Deleterious MSH6 Gene Mutation|Deleterious HNPCC5 Gene Mutation|Deleterious MutS Homolog 6 Gene Mutation|Deleterious MutS, E. coli, Homolog of, 6 Gene Mutation	A change in the nucleotide sequence of the MSH6 gene that is associated with increased risk of disease.	Deleterious MSH6 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C131779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131779>	C93102|C118394	Deleterious MLH1 Gene Mutation|Deleterious COCA2 Gene Mutation|Deleterious HNPCC2 Gene Mutation|Deleterious MutL Homolog 1 Gene Mutation|Deleterious MutL, E. coli, Homolog of, 1 Gene Mutation	A change in the nucleotide sequence of the MLH1 gene that is associated with increased risk of disease.	Deleterious MLH1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C13177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13177>	C12710	Pigment Epithelium|Pigmented Epithelium	Tissue consisting of one or more layers of epithelial cells and a basement membrane. The cells contain granules of pigment or melanin, as in the retinal or iris pigment layer.			Body Part, Organ, or Organ Component	
C131780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131780>	C93102|C118397	Deleterious PMS2 Gene Mutation|Deleterious HNPCC4 Gene Mutation|Deleterious MLH4 Gene Mutation|Deleterious PMS1 Homolog 2, Mismatch Repair System Component Gene Mutation|Deleterious PMS2CL Gene Mutation|Deleterious PMSL2 Gene Mutation|Deleterious Postmeiotic Segregation Increased (S. cerevisiae) 2 Gene Mutation|Deleterious Postmeiotic Segregation Increased 2 Gene Mutation	A change in the nucleotide sequence of the PMS2 gene that is associated with increased risk of disease.	Deleterious PMS2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C131781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131781>	C141248|C131480	Deleterious RAD51C Gene Mutation|Deleterious BROVCA3 Gene Mutation|Deleterious FANCO Gene Mutation|Deleterious RAD51 Homolog C Gene Mutation|Deleterious RAD51 Paralog C Gene Mutation|Deleterious RAD51L2 Gene Mutation	A change in the nucleotide sequence of the RAD51C gene that is associated with increased risk of disease.	Deleterious RAD51C Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131782>	C141248|C131481	Deleterious RAD51D Gene Mutation|Deleterious BROVCA4 Gene Mutation|Deleterious R51H3 Gene Mutatio|Deleterious RAD51 Homolog D Gene Mutation|Deleterious RAD51 Paralog D Gene Mutation|Deleterious RAD51-Like 3 Gene Mutation|Deleterious RAD51L3 Gene Mutation|Deleterious TRAD Gene Mutation	A change in the nucleotide sequence of the RAD51D gene that is associated with increased risk of disease.	Deleterious RAD51D Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131783>	C36327	DNA Repair Gene Mutation|DNA Repair Mutation|DNA Repair Mutation|DNA Repair Mutation Positive	A change in the nucleotide sequence of a gene involved in DNA repair.	DNA Repair Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131784>	C45581	CCND3 Gene Amplification|CCND3 Amplification|CCND3 amplification|Cyclin D3 Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the CCND3 gene.	CCND3 Gene Amplification		Cell or Molecular Dysfunction	CRF8 Pathology Review Targeted Genomics Table|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131785>	C45581	CCND2 Gene Amplification|CCND2 Amplification|CCND2 amplification|Cyclin D2 Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the CCND2 gene.	CCND2 Gene Amplification		Cell or Molecular Dysfunction	CRF8 Pathology Review Targeted Genomics Table|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C131786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131786>	C45581	CDK4 Gene Amplification|CDK4 Amplification|CDK4 amplification|Cell Division Kinase 4 Gene Amplification|Cyclin Dependent Kinase 4 Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the CDK4 gene.	CDK4 Gene Amplification		Cell or Molecular Dysfunction	CRF8 Pathology Review Targeted Genomics Table|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131787>	C165233	CDKN2A Negative|CDKN2A Loss|CDKN2A Null|Cyclin-Dependent Kinase 4 Inhibitor A Negative|Cyclin-Dependent Kinase Inhibitor 2A Negative|Cyclin-Dependent Kinase Inhibitor 2A Null	Indicates that expression of CDKN2A has not been detected in a sample.	CDKN2A Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131788>	C97927	CHEK1 Gene Mutation|CHK1 Checkpoint Homolog (S. pombe) Gene Mutation|CHK1 Gene Mutation|Checkpoint Kinase 1 Gene Mutation	A change in the nucleotide sequence of the CHEK1 gene.	CHEK1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131789>	C97927	BARD1 Gene Mutation|BARD-1 Gene Mutation|BRCA1 Associated RING Domain 1 Gene Mutation	A change in the nucleotide sequence of the BARD1 gene.	BARD1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13178>	C33554|C12848	Simple Squamous Epithelium	Epithelium composed of a single layer of flat cells wider than they are tall. This epithelium is found in anatomic sites where exchange of nutrients, wastes and gases occur.			Body Part, Organ, or Organ Component	
C131790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131790>	C97927|C159204	FANCD2 Gene Mutation|FA-D2 Gene Mutation|FA4 Gene Mutation|FACD Gene Mutation|FAD Gene Mutation|FAD2 Gene Mutation|FANCD Gene Mutation|Fanconi Anemia Complementation Group D2 Gene Mutation|Fanconi Anemia, Complementation Group D2 Gene Mutation	A change in the nucleotide sequence of the FANCD2 gene.	FANCD2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131791>	C97927|C159204	FANCE Gene Mutation|FACE Gene Mutation|FAE Gene Mutation|Fanconi Anemia Complementation Group E Gene Mutation|Fanconi Anemia, Complementation Group E Gene Mutation	A change in the nucleotide sequence of the FANCE gene.	FANCE Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131792>	C97927|C159204	FANCC Gene Mutation|FA3 Gene Mutation|FAC Gene Mutation|FACC Gene Mutation|Fanconi Anemia Complementation Group C Gene Mutation|Fanconi Anemia, Complementation Group C Gene Mutation	A change in the nucleotide sequence of the FANCC gene.	FANCC Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131793>	C97927|C133695	RAD50 Gene Mutation|NBSLD Gene Mutation|RAD50 (S. cerevisiae) Homolog Gene Mutation|RAD50 Double Strand Break Repair Protein Gene Mutation|RAD50 Homolog (S. cerevisiae) Gene Mutation|RAD50 Homolog, Double Strand Break Repair Protein Gene Mutation|RAD50, S. cerevisiae, Homolog of Gene Mutation|RAD50-2 Gene Mutation|RAD502 Gene Mutation|hRad50 Gene Mutation	A change in the nucleotide sequence of the RAD50 gene.	RAD50 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131794>	C97927|C159204	FANCA Gene Mutation|FA Gene Mutation|FA-H Gene Mutation|FA1 Gene Mutation|FAA Gene Mutation|FACA Gene Mutation|FAH Gene Mutation|FANCH Gene Mutation|Fanconi Anemia Complementation Group A Gene Mutation|Fanconi Anemia, Complementation Group A Gene Mutation|Fanconi Anemia, Complementation Group H Gene Mutation|Fanconi Anemia, Type 1 Gene Mutation	A change in the nucleotide sequence of the FANCA gene.	FANCA Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131795>	C97927|C159204|C133695	RAD51 Gene Mutation|BRCC5 Gene Mutation|FANCR Gene Mutation|HRAD51 Gene Mutation|HsRad51 Gene Mutation|RAD51 Homolog (S. cerevisiae) Gene Mutation|RAD51 Recombinase Gene Mutation|RAD51, S. cerevisiae, Homolog of A Gene Mutation|RAD51A Gene Mutation|RECA Gene Mutation	A change in the nucleotide sequence of the RAD51 gene.	RAD51 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C131796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131796>	C97927|C157553	CDK12 Gene Mutation|CDC2 Related Protein Kinase 7 Gene Mutation|CRK7 Gene Mutation|CRKR Gene Mutation|CRKRS Gene Mutation|Cdc2-Related Kinase, Arginine/Serine-Rich Gene Mutation|Cyclin Dependent Kinase 12 Gene Mutation|Cyclin-Dependent Kinase 12 Gene Mutation	A change in the nucleotide sequence of the CDK12 gene.	CDK12 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131797>	C97927|C131783	POLE Gene Mutation|DNA Polymerase Epsilon Catalytic Subunit A Exonuclease Gene Mutation|DNA Polymerase Epsilon, Catalytic Subunit Exonuclease Gene Mutation|POLE1 Gene Mutation	A change in the nucleotide sequence of the POLE gene.	POLE Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C131798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131798>	C97927|C131783	POLD1 Gene Mutation|CDC2 Gene Mutation|CDC2 Homolog (S. cerevisiae) Gene Mutation|CRCS10 Gene Mutation|DNA Polymerase Delta 1, Catalytic Subunit Gene Mutation|MDPL Gene Mutation|POLD Gene Mutation|Polymerase (DNA Directed), Delta 1, Catalytic Subunit (125kD) Gene Mutation|Polymerase (DNA Directed), Delta 1, Catalytic Subunit Gene Mutation|Polymerase (DNA) Delta 1, Catalytic Subunit Gene Mutation	A change in the nucleotide sequence of the POLD1 gene.	POLD1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C131799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131799>	C97927|C174175	PRKDC Gene Mutation|DNA-PKcs Gene Mutation|DNAPK Gene Mutation|DNPK1 Gene Mutation|HYRC Gene Mutation|HYRC1 Gene Mutation|Hyper-Radiosensitivity of Murine SCID Mutation, Complementing 1 Gene Mutation|Hyperradiosensitivity Complementing 1, Mouse, Homolog of Gene Mutation|Protein Kinase, DNA-Activated, Catalytic Polypeptide Gene Mutation|XRCC7 Gene Mutation|p350 Gene Mutation	A change in the nucleotide sequence of the PRKDC gene.	PRKDC Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13179>	C12749	Basilar Membrane	A sheet of amorphous extracellular material upon which the basal surfaces of epithelial cells rest. It is made up of two layers, the basal lamina and the reticular lamina. It is also associated with muscle cells, Schwann cells, fat cells, and capillaries; and is interposed between the cellular elements and the underlying connective tissue.			Body Part, Organ, or Organ Component	
C1317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1317>	C265	Bupropion Hydrochloride|(+-)-1-(3-Chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone Hydrochloride|Amfebutamone|BUPROPION HYDROCHLORIDE|BW 323U66|Wellbutrin	The hydrochloride salt of the aminoketone bupropion, with antidepressant activity and for potential use in promoting smoking cessation and improving sexual desire. Bupropion is a weak blocker of the neuronal uptake of serotonin, dopamine and norepinephrine and is a central nicotinic acetylcholine receptor antagonist.	Bupropion Hydrochloride		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C131800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131800>	C97927|C174168	ERCC2 Gene Mutation|CXPD Gene Mutation|EM9 Gene Mutation|ERCC Excision Repair 2, TFIIH Core Complex Helicase Subunit Gene Mutation|Excision Repair Cross-Complementing Rodent Repair Deficiency, Complementation Group 2 Gene Mutation|Excision-Repair, Complementing Defective, In Chinese Hamster, 2 Gene Mutation|MAG Gene Mutation|TTD Gene Mutation|TTD1 Gene Mutation|XP4 Gene Mutation|XPD Gene Mutation|XPDC Gene Mutation	A change in the nucleotide sequence of the ERCC2 gene.	ERCC2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131801>	C25942|C19676	POLQ Gene|DNA Polymerase Theta Gene|POLQ|POLQ|POLQ	This gene is involved in DNA synthesis and repair.	POLQ Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C131802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131802>	C131801	POLQ wt Allele|DNA Polymerase Theta wt Allele|PRO0327|Polymerase (DNA Directed), Theta Gene|Polymerase (DNA) Theta Gene|Polymerase, DNA, Theta Gene	Human POLQ wild-type allele is located in the vicinity of 3q13.33 and is approximately 115 kb in length. This allele, which encodes DNA polymerase theta protein, plays a role in both the repair and synthesis of DNA.	POLQ wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131803>	C21170|C16512	DNA Polymerase Theta|EC 2.7.7.7|POLQ	DNA polymerase theta (2590 aa, ~290 kDa) is encoded by the human POLQ gene. This protein is involved in microhomology-mediated end-joining and low-fidelity DNA synthesis.	DNA Polymerase Theta		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131804>	C97927|C131783	POLQ Gene Mutation|DNA Polymerase Theta Gene Mutation|Polymerase (DNA Directed), Theta Gene Mutation|Polymerase (DNA) Theta Gene Mutation|Polymerase, DNA, Theta Gene Mutation	A change in the nucleotide sequence of the POLQ gene.	POLQ Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131805>	C97927|C183307|C133695	MRE11 Gene Mutation|ATLD Gene Mutation|HNGS1 Gene Mutation|MRE11 Homolog A, Double Strand Break Repair Nuclease Gene Mutation|MRE11 Homolog, Double Strand Break Repair Nuclease Gene Mutation|MRE11 Meiotic Recombination 11 Homolog A (S. cerevisiae) Gene Mutation|MRE11A Gene Mutation|MRE11B Gene Mutation|Meiotic Recombination (S. cerevisiae) 11 Homolog A Gene Mutation|Meiotic Recombination 11, S. cerevisiae, Homolog of, A Gene Mutation	A change in the nucleotide sequence of the MRE11 gene.	MRE11 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131806>	C97927|C133695	NBN Gene Mutation|AT-V1 Gene Mutation|AT-V2 Gene Mutation|ATV Gene Mutation|NBS Gene Mutation|NBS1 Gene Mutation|Nibrin Gene Mutation|Nijmegen Breakage Syndrome 1 Gene Mutation|P95 Gene Mutation	A change in the nucleotide sequence of the NBN gene.	NBN Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131807>	C35681	Cytomegalovirus Negative|CMV Negative|HHV-5 Negative|HHV5 Negative|Human Herpesvirus 5 Negative	Indicates that cytomegalovirus has not been detected in a sample.	Cytomegalovirus Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C131808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131808>	C3420	t(2;8)	A cytogenetic abnormality that involves a translocation between chromosomes 2 and 8.	t(2;8)		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13180>	C33622|C12848	Stratified Squamous Epithelium	Epithelium consisting of multiple layers of cells that are flattened and more cuboidal toward the base. Its function is protection. Outer layers may be dead and hardened (keratinized) such as with skin or on top of wet, mucous surfaces such as the cornea			Body Part, Organ, or Organ Component	
C131810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131810>	C3420	t(8;22)	A cytogenetic abnormality that involves a translocation between chromosomes 8 and 22.	t(8;22)		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131811>	C53543	Eiken Type Chondrodysplasia	An autosomal recessive skeletal dysplasia caused by mutation(s) in the PTH1R gene, encoding parathyroid hormone/parathyroid hormone-related peptide receptor. This condition is characterized by severely delayed skeletal maturation, as well as by abnormal modeling of the bones in the hands and feet, abnormal persistence of cartilage in the pelvis, and mild growth retardation. Calcium and phosphate concentrations are normal.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131812>	C34712	Endosteal Hyperostosis|van Buchem Disease|van Buchem Disease Type 1	An autosomal recessive form of craniotubular hyperostosis due to a 52-kb deletion in the SOST gene, encoding sclerostin. Clinical features include normal stature, enlarged jaw and facial bones, hearing loss, and facial palsy due to cranial nerve deficits. The absence of syndactyly distinguishes this condition from sclerosteosis.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131813>	C3123	Familial Dysalbuminemic Hyperthyroidism|Familial Dysalbuminemic Hyperthyroxinemia	A genetic condition caused by a variant in the ALB gene, associated with increased affinity of albumin for thyroxine.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131814>	C97093	Focal Lipodystrophy|Localized Lipodystrophy	Loss of subcutaneous fat confined to small area(s) of the body.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131815>	C97093	Generalized Lipodystrophy	Almost complete absence of subcutaneous and/or visceral adipose tissue.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131816>	C147564	Generalized Thyroid Hormone Resistance|GTHR	Decreased response to thyroid hormones in peripheral tissues and in the pituitary gland.			Finding	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C131817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131817>	C92809	Glucagon Deficiency	Impaired pancreatic secretion of glucagon that results in severely low blood glucose.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C131818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131818>	C113144	Iatrogenic Central Hypothyroidism	Central hypothyroidism due to medical or surgical treatment.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131819>	C113143	Iatrogenic Primary Hypothyroidism	Primary hypothyroidism due to medical or surgical treatment.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C13181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13181>	C49316	Pseudostratified Columnar Ciliated Epithelium	Epithelium composed of a single layer of cells, appearing as layered because the column-shaped cells vary in height so the nuclei are at different levels. The basal portions of all the cells are in contact with the basement membrane. It lines the respiratory system and the male reproductive tract. The cilia in the respiratory tract are motile, while the stereocilia in the male reproductive tract are immobile.			Tissue	
C131820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131820>	C35553	Hypothyroxinemia	Decreased concentration of thyroxine.			Laboratory or Test Result	NICHD Terminology|Pediatric Endocrinology Terminology
C131821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131821>	C2124|C129819	Iodine I 131 MIP-1095|((S)-2-(3-((S)-1-carboxy-5-(3-(4-[(131)I]iodophenyl)ureido)pentyl)ureido)pentanedioic Acid|(131) I-MIP-1095|131I-MIP-1095|I-131 MIP-1095|MIP-1095 I-131|MIP-1095 I-131	A radioconjugate composed of MIP-1095, a urea-based ligand for the tumor-associated antigen (TAA) prostate-specific membrane antigen (PSMA) radiolabeled with iodine I 131 (I131), with potential antineoplastic activity. Upon administration of iodine I 131 MIP-1095, the MIP-1095 moiety selectively targets and binds to the extracellular domain of PSMA, thereby delivering cytotoxic iodine I 131 specifically to PSMA-expressing cancer cells. PSMA is a transmembrane glycoprotein that is highly expressed by malignant prostate epithelial cells and certain other tumor cells.	Iodine I 131 MIP-1095		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131822>	C797|C78276|C275|C2459	Malva sylvestris/Alcea digitata Herbal Compound|M. sylvestris/A. digitata Herbal Compound|Traditional Persian Medicine Preparation M. sylvestris/A. digitata	A traditional Persian medicine composed of Malva sylvestris (M. sylvestris) and Alcea digitata (A. digitata; Boiss), with potential use for the treatment of radiation- and chemotherapy-induced xerostomia, and potential immunomodulating, anti-oxidant and antimicrobial activities. Upon administration to the mouth, M. sylvestris/A. digitata herbal compound may lubricate the mouth and throat, and may improve the symptoms of dry mouth, thereby preventing tooth decay and improving chewing, eating, tasting, swallowing, and speaking. M. sylvestris/A. digitata herbal compound may also improve mucositis by modulating the immune system, thereby preventing infection, reducing inflammation and promoting wound healing.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C131823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131823>	C1505	Sodium Nitrate Supplement|Dietary Supplement Sodium Nitrate	A dietary supplement containing sodium nitrate, that can be used for nitrate supplementation purposes. Upon oral administration, nitrate is absorbed by the body and is partially converted to nitrite, which is stored and circulated in the blood, leading to an increase in nitrite levels. Nitrate, and to some extent nitrite, accumulates in saliva and may enhance salivary flow, which may help to treat dry mouth and chemo- and radiation-induced oropharyngeal problems.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C131824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131824>	C129820	Modified Vitamin D Binding Protein Macrophage Activator EF-022|EF-022|MVDP-Macrophage Activator|Modified VDBP-Macrophage Activator EF-022	A modified version of vitamin D binding protein (VDBP; Gc protein) macrophage activator, with potential antineoplastic and anti-angiogenic activities. Upon administration, modified VDBP-macrophage activator EF-022, acting in a similar manner as VDBP-macrophage activating factor (GcMAF), is able to activate tumoricidal macrophages, thereby enhancing the killing and eradication of cancer cells. In addition, EF-022 may inhibit tumor cell proliferation, migration and angiogenesis. VDBP is a glycoprotein and precursor for macrophage activating factor (MAF), which promotes macrophage activation; however VDBP can be deglycosylated by serum alpha-N-acetylgalactosaminidase, which is secreted from cancerous cells, and cannot be converted to MAF. Thus, the macrophage activation cascade is often impaired in tumor cells and plays a key role in tumor immunosuppression. Modification of VDBP stabilizes MAF.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131825>	C177174	Adenovirus-expressing TLR5/TLR5 Agonist Nanoformulation M-VM3|M-VM3|Mobilan	A nanoparticle-based formulation containing a recombinant non-replicating adenovirus (Ad) encoding toll-like receptor 5 (TLR5) and its specific ligand protein 502S, with potential antineoplastic and immunomodulating activities. Upon administration, the Ad preferentially and specifically infects cells expressing the Coxsackievirus and adenovirus receptor (CAR), which is highly expressed in certain human tumors, and expresses both TLR5 and a specific agonistic ligand in the same cell. 502S binds to and activates TLR5, thereby allowing for continuous TLR5 signaling. This stimulates dendritic cells (DCs), monocytes, macrophages and the nuclear factor-kappa B (NF-kappaB) signaling cascade. This activation results in the production of pro-inflammatory cytokines, including interferon alpha, tumor necrosis factor-alpha and the interleukins (IL), IL-1 beta, -6 and -12. This may induce a T helper cell-1 (Th1) immune response and activate a cytotoxic T-lymphocyte (CTL) response against tumor associated antigens (TAAs). TLR5, a member of the TLR family, plays a key role in the activation of innate immunity.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131826>	C2252	VDAC/HK2 Modulator Ointment VDA-110|VDA-1102|VDA-1102 Ointment|VDA-1102 Topical Dermal Ointment	A topical ointment formulation containing a voltage-dependent anion channel (VDAC)/hexokinase 2 (HK2) modulator, with potential activity against certain skin cancers. Upon topical application, VDA-1102, as a protein-protein interaction (PPI) disrupter, allosterically binds to HK2, and causes HK2 to dissociate from VDAC, which prevents glycolysis and triggers apoptosis, thereby inhibiting tumor cell growth in VDAC/HK2-expressing tumor cells without affecting the surrounding healthy skin tissue. The VDAC/HK2 system, over-activated in cancer cells, plays a key role in tumor cell proliferation. The VDAC/HK2 association protects cancer cells from apoptosis. HK2 is overexpressed in many malignant cancer tissues that rely on glycolysis, while its expression is limited in normal healthy cells.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C131827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131827>	C214440	Bomedemstat|BOMEDEMSTAT|IMG 7289|IMG-7289|LSD-1 Inhibitor IMG-7289|Lysine-specific Demethylase 1 Inhibitor IMG-7289	An orally available, irreversible inhibitor of lysine-specific demethylase 1 (LSD1), with potential antineoplastic activity. Upon administration, bomedemstat binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor suppressor genes. In addition, LSD1 demethylates mono- or di-methylated H3K9 which increases gene expression of tumor promoting genes; thus, inhibition of LSD1 also promotes H3K9 methylation and decreases transcription of these genes. Altogether, this may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. LSD1, an enzyme belonging to the flavin adenine dinucleotide (FAD)-dependent amine oxidase family is overexpressed in certain tumor cells and plays a key role in the regulation of gene expression, tumor cell growth and survival.	Bomedemstat		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131828>	C129821	Anti-CD133-PE38-KDEL Fusion Protein|Anti-CD133-Deimmunized Pseudomonas Exotoxin A-KDEL Fusion Protein|Deimmunized CD133KDEL|Deimmunized CD133KDEL Toxin|dCD133KDEL	A fusion protein consisting of an anti-single-chain variable fragment (scFv) peptide sequence targeting the extracellular domain of human CD133 (prominin-1) (anti-CD133scFV) and a deimmunized truncated form of Pseudomonas exotoxin A (38-kDa derivative of PE; PE38) where the five C-terminal amino acid residues have been replaced with the endoplasmic reticulum (ER) retention signal, KDEL, with potential antineoplastic activity. Upon administration of the anti-CD133-PE38-KDEL fusion protein, the anti-CD133 scFV moiety targets and binds to CD133, which is expressed on a variety of tumor cells. Upon internalization of the receptor-fusion protein complex, the KDEL sequence targets the fusion protein to the ER, where the PE38 exotoxin portion then inhibits protein synthesis, which results in a reduction of proliferation of CD133-expressing tumor cells. CD133, a glycoprotein expressed by a variety of cancers and especially by cancer stem cells (CSCs), plays a key role in tumor initiation, proliferation and progression.			Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C13182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13182>	C43370	Columnar Epithelium	Epithelium that is composed of columnar glandular cells.			Tissue	
C131830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131830>	C131842	Focal KATP-Associated Hyperinsulinism	KATP-associated hyperinsulinism in which there is an area of adenomatous beta-cell hyperplasia. This condition results from paternal recessive mutation(s) in either the ABCC8 or the KCNJ11 gene and paternal uniparental isodisomy of chromosome region 11p15 with loss of tumor suppressor genes expressed from the maternally inherited chromosome.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131831>	C131840	Glucokinase-Associated Hyperinsulinism|GCK-Associated Hyperinsulinism	Hyperinsulinism due to activating mutation(s) in the gene GCK, encoding glucokinase.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131832>	C131840	Glutamate Dehydrogenase 1 Hyperinsulinism|GDH Hyperinsulinism|GLUD1 Hyperinsulinism|Hyperinsulinism/Hyperammonemia Syndrome	Hyperinsulinism due to activating mutation(s) in the GLUD1 gene, encoding glutamate dehydrogenase 1. This condition is characterized by protein induced hypoglycemia and hyperammonemia, which is presumed to be due to increased ammonia production in the kidney.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131833>	C131840	Hepatocyte Nuclear Factor 1-Alpha Hyperinsulinism|HNF1A-Associated Hyperinsulinism	Hyperinsulinism due to mutation(s) in the gene HNF1A, encoding the transcription factor hepatocyte nuclear factor 1-alpha. This condition may progress to diabetes later in life.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131834>	C131840	Hepatocyte Nuclear Factor 4-Alpha Hyperinsulinism|HNF4A-Associated Hyperinsulinism	Hyperinsulinism due to mutation(s) in the gene HNF4A, encoding the transcription factor hepatocyte nuclear factor 4-alpha. This condition may progress to diabetes later in life.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131835>	C171128	Hyperinsulinism in the Infant of a Diabetic Mother	Transient hypoglycemia that occurs in the infant of a diabetic mother due to increased postnatal insulin release as a result of in utero exposure to maternal hyperglycemia.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131836>	C171128	Insulin Resistant Diabetes Mellitus with Acanthosis Nigricans and Hyperandrogenism|Type A Insulin Resistance Syndrome	A syndrome of insulin resistance caused by mutation(s) in the INSR gene, encoding the insulin receptor. This condition is characterized by a clinical triad of hyperinsulinemia, acanthosis nigricans, and hyperandrogenism without lipodystrophy. This is the least severe of a spectrum of disorders; the other two conditions are Rabson-Mendenhall Syndrome and Donohoe Syndrome.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131837>	C131840	Mitochondrial Hydroxyacyl-Coenzyme A Dehydrogenase Hyperinsulinism|HADH-Associated Hyperinsulinism|SCHAD Hyperinsulinism	Hyperinsulinism due to inactivating mutation(s) in the gene HADH, encoding mitochondrial (short-chain) hydroxyacyl-coenzyme A dehydrogenase, resulting in loss of inhibition of glutamate dehydrogenase (GDH). This condition is also characterized by protein-induced hypoglycemia, but in contrast to GLUD1-associated hyperinsulinism, hyperammonemia is absent.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131838>	C131840	Mitochondrial Uncoupling Protein 2 Hyperinsulinism|UCP2 Hyperinsulinism	Hyperinsulinism due to mutation(s) in the gene UCP2, encoding mitochondrial uncoupling protein 2, which plays a role in attenuating insulin secretion.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131839>	C131840	Monocarboxylate Transporter 1 Hyperinsulinism|Exercise-induced Hyperinsulinism|MCT1 Hyperinsulinism	Hyperinsulinism due to mutation(s) in the regulatory region of the SLC16A1 gene, encoding monocarboxylate transporter 1 (MCT1). The mutation(s) result in aberrant expression of MCT1 in the beta cell, leading to inappropriate insulin secretion and hypoglycemia triggered by anaerobic exercise.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C13183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13183>	C13076	Endosteum	A thin vascular connective tissue membrane that lines the medullary cavities of bone.			Tissue	
C131840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131840>	C171128	Monogenic Hyperinsulinism	A genetically heterogenous group of hyperinsulinemic conditions caused by mutation(s) in one of the many genes involved in the regulation of insulin secretion.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131841>	C171128	Obesity-Associated Insulin Resistance	Insulin resistance associated with obesity, which may be attributed in part to impaired insulin signaling in target tissues, or impaired insulin-stimulated glucose transport due to reduced expression of the glucose transporter protein 4.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131842>	C171128	KATP-Associated Hyperinsulinism	Hyperinsulinism caused by non-functional beta-cell ATP-sensitive potassium channels due to inactivating mutation(s) in either the ABCC8 or KCNJ11 gene.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131843>	C131842	Diffuse KATP-Associated Hyperinsulinism	KATP-associated hyperinsulinism affecting all pancreatic beta cells.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131844>	C91105	Edinburgh Postnatal Depression Scale|EPDS|Edinburgh Postnatal Depression Scale (EPDS)	A 10-item, self-rating questionnaire designed to screen postpartum women for indications of depression.			Intellectual Product	
C131845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131845>	C131847	K ATP Associated Developmental Delay, Epilepsy and Neonatal Diabetes|DEND Syndrome	A condition characterized by K ATP channel-associated permanent neonatal diabetes mellitus accompanied by neurological manifestations of developmental delay and epilepsy that may be associated with the severity of the mutation(s).			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131846>	C131847|C114899	K ATP Associated Transient Neonatal Diabetes Mellitus|TNDM	K ATP channel-associated neonatal diabetes mellitus that resolves spontaneously.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131847>	C129739	K ATP Channel-Associated Diabetes Mellitus	Diabetes mellitus caused by activating mutation(s) in genes (KNCJ11 and/or ABCC8) encoding either of the 2 proteins (Kir6.2 and/or SUR1) that make up the pancreatic beta cell adenosine triphosphate-sensitive potassium channel, which is crucial for the regulation of glucose-induced insulin secretion.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131848>	C131847|C114902	K ATP Permanent Neonatal Diabetes|PNDM	K ATP channel-associated neonatal diabetes mellitus that does not resolve spontaneously.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131849>	C34816|C27565	Hexose-6-phosphate Dehydrogenase Deficiency|Cortisone Reductase Deficiency Type 1|Hexose-6-Phosphate Dehydrogenase Deficiency	Decreased activity of hexose-6-phosphatase due to autosomal recessive mutation(s) in the H6PD gene. This enzyme is necessary to generate NADPH, a cofactor in the 11-beta-hydroxysteroid dehydrogenase pathway required for conversion of cortisone to cortisol. The condition is characterized by hyperandrogenism as a result of increased adrenocorticotropic hormone stimulation of the adrenal gland due to failure of cortisol-mediated down-regulation, and is clinically indistinguishable from 11-beta HSD type 1 deficiency.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C13184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13184>	C13076	Periosteum	The outer membrane that surrounds a bone. It contains connective tissue, capillaries, nerves, and a number of types of cell, including osteoclasts. The periosteum plays an important role in bone repair and growth.			Body Part, Organ, or Organ Component	
C131850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131850>	C35553	Hyperthyroxinemia	Supranormal concentration of thyroxine in the blood.			Laboratory or Test Result	NICHD Terminology|Pediatric Endocrinology Terminology
C131851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131851>	C34816	Hyperphosphatemic Familial Tumoral Calcinosis	An autosomal recessive disorder caused by loss-of-function mutation(s) in the GALNT3, FGF23, or KL gene, which encode polypeptide N-acetylgalactosaminyltransferase 3, fibroblast growth factor 23, and klotho, respectively. This condition, the biochemical hallmark of which is hyperphosphatemia caused by increased renal phosphate absorption, is characterized by the progressive deposition of calcium phosphate crystals in periarticular spaces, soft tissues, and/or bone.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C131852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131852>	C3123	Congenital Hyperthyroidism	Hyperthyroidism, the cause of which is present at birth.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131853>	C48280	Neonatal Severe Primary Hyperparathyroidism	A genetic condition caused by loss-of-function mutation(s) in the CASR gene, encoding extracellular calcium-sensing receptor. It is characterized by severe hypercalcemia and metabolic bone disease occurring in the first six months of life.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C131854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131854>	C3126	Ketotic Hypoglycemia	A condition in which hypoglycemia is accompanied by ketosis. This condition may be a manifestation of another condition such as glycogen storage disease, ketone utilization defects, growth hormone deficiency, or cortisol deficiency.			Laboratory or Test Result	NICHD Terminology|Pediatric Endocrinology Terminology
C131855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131855>	C131854	Idiopathic Ketotic Hypoglycemia|Accelerated Starvation	Ketotic hypoglycemia that usually occurs in young, thin children in association with infection or fasting, and which typically resolves by age 6-8 years.			Laboratory or Test Result	NICHD Terminology|Pediatric Endocrinology Terminology
C131856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131856>	C78350	Iatrogenic Hypoparathyroidism	Hypoparathyroidism resulting from medical treatment or intervention.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131857>	C113347	Hypogonadotropic Hypogonadism with Adrenal Hypoplasia Congenita	Hypogonadotropic hypogonadism with congenital adrenal hypoplasia associated with mutation(s) in the NR0B1 gene (on the X chromosome).			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131859>	C2985	Mitochondrial Diabetes	Diabetes mellitus caused by mutation(s) in mitochondrial DNA.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C13185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13185>	C13147	Taste Bud Basal Cell	A small, round cell found in the lower part of the epidermis of the taste bud. It differentiates into a new receptor cell and renewed about every 10 days.			Body Part, Organ, or Organ Component	
C131860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131860>	C3123	Iodine-Induced Hyperthyroidism|Jod-Basedow|Jod-Basedow|Jod-Basedow Phenomenon|Jod-Basedow Phenomenon|Jod-Basedow Syndrome	Iodine-induced hyperthyroidism.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131861>	C3292	Juvenile Paget Disease|Familial Hyperphosphatasia|PDB5|Paget Disease of Bone-5	A bone disorder caused by autosomal recessive mutation(s) of the gene TNFRSF11B, which encodes tumor necrosis factor receptor superfamily member 11B. This condition is characterized by excessive osteoclastic resorption of bone followed by deposition of weak, disorganized woven bone. Clinical characteristics include short stature, enlarged skull, bony deformities, bone pain, warm skin over the affected bone, joint stiffness, headaches, hearing loss, and elevated serum alkaline phosphatase.			Disease or Syndrome	Cellosaurus Disease Terminology|NICHD Terminology|Pediatric Endocrinology Terminology
C131862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131862>	C27627	Gonadotropin-Resistant Ovary Syndrome|ROS|Resistant Ovary Syndrome|Savage Syndrome	Ovarian dysfunction due to a defect at the receptor or post receptor level, or due to the presence of antibodies against gonadotropin receptors, resulting in deficient gonadotropin signaling that causes elevated concentrations of follicle stimulating hormone and/or luteinizing hormone. A distinguishing feature is the presence of normal numbers of ova.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131863>	C120187	Iatrogenic Contrasexual Pubertal Development	Contrasexual pubertal development caused by medical intervention.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131864>	C103186	Idiopathic 46,XY Differences of Sex Development|Idiopathic 46,XY Disorder of Sex Development	Conditions affecting individuals whose karyotype is 46,XY that is characterized by atypical development of the internal or external sex structures, or the gonads, and in whom no genetic, environmental, or biochemical causation can be established.			Congenital Abnormality	NICHD Terminology|Pediatric Endocrinology Terminology
C131865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131865>	C92809	Luteinizing Hormone Deficiency|LH deficiency|Lutropin Deficiency	Subnormal concentration of luteinizing hormone.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C131866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131866>	C127165	Isolated Non-Pigmented Micronodular Adrenal Hyperplasia	A subtype of micronodular adrenal hyperplasia, characterized by multiple non-pigmented nodules.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C131867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131867>	C35261	Miniature Adult Form of AHC	An autosomal recessive or sporadic form of adrenal hypoplasia congenita frequently associated with central nervous system anomalies including anencephaly and pituitary defects. Histologically the adrenal gland is distinguished by the absence of fetal adrenal cortex and the presence of a small amount of normal, permanent adult adrenal cortex.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C131868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131868>	C53543	Metaphyseal Chondrodysplasia, Jansen Type	A form of metaphyseal chondrodysplasia caused by mutation(s) in the PTH1R gene, encoding parathyroid hormone/parathyroid hormone-related peptide receptor. This condition is characterized by severe short stature, short bowed limbs, clinodactyly, prominent upper face, and a small mandible. Hypercalcemia and hypophosphatemia due to PTH resistance can appear later in childhood.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C13186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13186>	C13404	A-DNA|A-Form DNA	A-DNA is a shorter and wider helix than B-DNA. Most RNA and RNA-DNA duplex are in this form. While deep, narrow major groove is not easily accessible to proteins but wide, shallow minor groove is accessible to proteins but with lower information content than major groove. A-DNA is the favored conformation at low water concentrations. Base pairs are tilted to helix axis and displaced from axis and sugar pucker is C3'-endo (in RNA 2'-OH inhibits C2'-endo conformation). When examined from the top of the helix, there is a large hole in the middle, the sugar phosphate backbone is at the edge of the helix, and the bases are displaced towards the edge.			Nucleic Acid, Nucleoside, or Nucleotide	
C131870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131870>	C129826	Virus-specific Cytotoxic T-lymphocytes|Virus-specific CTLs	A population of cytotoxic T-lymphocytes (CTLs) specifically reactive to one or more pre-selected viruses, with potential antiviral activity. Upon infusion, after an allogeneic hematopoietic cell transplant (HCT) or in other immunodeficient states, these CTLs help reconstitute viral-specific CTL responses and kill virally infected cells, thereby inhibiting viral infection in immunocompromised patients.			Cell|Pharmacologic Substance	
C131871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131871>	C177692	HLA-A11 Positive Cells Present|HLA-A*11 Positive|HLA-A*11 Positive Cells Present|HLA-A11 Positive	A laboratory test result indicating the presence of HLA-A11 positive cells in a tissue sample.	HLA-A11 Positive Cells Present		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131872>	C177692	Survivin Positive|BIRC5 Positive|Baculoviral IAP Repeat-Containing 5 Positive|Survivin Antigen Positive	An indication that survivin expression has been detected in a sample.	Survivin Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131873>	C27911|C204124	Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	The reemergence of chronic lymphocytic leukemia/small lymphocytic lymphoma after a period of remission.			Neoplastic Process	
C131874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131874>	C146993	Androgen Receptor Antagonist TRC253|AR Antagonist TRC253|JNJ 63576253|JNJ-63576253|JNJ63576253|TRC 253|TRC-253|TRC-253|TRC253	An orally bioavailable androgen receptor (AR) antagonist, with potential antineoplastic activity. Upon oral administration, AR antagonist TRC253 specifically binds to both wild-type and certain mutant forms of AR, thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes, inhibits the expression of genes that regulate prostate cancer cell proliferation, and may lead to an inhibition of growth of tumor cells in which AR is overexpressed and/or mutated. AR is often overexpressed and/or mutated in prostate cancers and plays a key role in proliferation, survival and chemoresistance of tumor cells.	Androgen Receptor Antagonist TRC253		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131875>	C7953|C7784|C150131	Recurrent Childhood T Acute Lymphoblastic Leukemia|Recurrent Childhood T-Acute Lymphoblastic Leukemia|Recurrent T Acute Lymphoblastic Leukemia	The reemergence of T acute lymphoblastic leukemia in childhood after a period of remission.	Recurrent Childhood T Acute Lymphoblastic Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C131876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131876>	C7938	Childhood T Acute Lymphoblastic Leukemia in Remission|T Acute Lymphoblastic Leukemia in Remission	A finding of T acute lymphoblastic leukemia in childhood that is not growing and responds to treatment.	Childhood T Acute Lymphoblastic Leukemia in Remission		Finding	CTRP Disease Terminology|CTRP Terminology
C131877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131877>	C20993	Relational and Item-Specific Encoding Task|Relational and Item-Specific Encoding|Relational and Item-Specific Encoding (RiSE)|RiSE	A clinical test designed to assess episodic memory encoding and retrieval processes in individuals with cognitive impairment.			Intellectual Product	
C131878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131878>	C91105	AYA-HEARS|Adolescent and Young Adult Hearing Screen	A questionnaire designed to measure hearing loss or problems experienced by patients who have received treatment for cancer.			Intellectual Product	GCT Authorized Value Terminology|GCT Patient Reported Outcomes Metadata Table
C131879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131879>	C173059|C118873	How Often Have Problem with Hearing Question|How Often Have Problem with Hearing|How often did you have a problem with hearing	A question about how often an individual had problems with hearing.			Intellectual Product	AYA-HEARS
C13187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13187>	C13303	Amino Acid Sequence|AMINO ACID SEQUENCE|Primary Protein Structure|Protein Sequence|amino acid sequence	The sequence of amino acids along a polypeptide chain.			Amino Acid Sequence	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C131880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131880>	C173059	How Severe Were Hearing Problems Question|How Severe Were Hearing Problems|How severe were your hearing problems	A question about how severe an individual's hearing problems are or were.			Intellectual Product	AYA-HEARS
C131881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131881>	C173561|C173059	How Much Did Hearing Problems Bother You Question|How Much Did Hearing Problems Bother You|How Much Do Hearing Problems Bother You|How much did hearing problems bother you	A question about how much an individual's hearing problems bothers or bothered them.			Intellectual Product	AYA-HEARS
C131882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131882>	C173787|C173584|C173059	How Much Did Hearing Problems Interfere with Daily Activities Question|How Much Did Hearing Problems Interfere with Daily Activities|How much did hearing problems interfere with your daily activities	A question about how much an individual's hearing problems interferes or interfered with their daily activities.			Intellectual Product	AYA-HEARS
C131883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131883>	C173059	How Hard to Hear When You Talk to One Other Person in Quiet Place Question|How Hard to Hear When You Talk to One Other Person in Quiet Place|How hard was it to hear when you talked to one other person in a quiet place	A question about how hard it was for an individual to hear when they talked to one other person in a quiet place.			Intellectual Product	AYA-HEARS
C131884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131884>	C173059	How Hard to Hear When You Talk to Group of People in Quiet Place Question|How Hard to Hear When You Talk to Group of People in Quiet Place|How hard was it to hear when you talked to a group of people in a quiet place	A question about how hard it was for an individual to hear when they talked to a group of people in a quiet place.			Intellectual Product	AYA-HEARS
C131885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131885>	C173059	How Hard to Hear When You Talk to One Other Person in Noisy Place Question|How Hard to Hear When You Talk to One Other Person in Noisy Place|How hard was it to hear when you talked to one other person in a noisy place	A question about how hard it was for an individual to hear when they talked to one other person in a noisy place.			Intellectual Product	AYA-HEARS
C131886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131886>	C173059	How Hard to Hear When You Talk to Group of People in Noisy Place Question|How Hard to Hear When You Talk to Group of People in Noisy Place|How hard was it to hear when you talked to a group of people in a noisy place	A question about how hard it was for an individual to hear when they talked to a group of people in a noisy place.			Intellectual Product	AYA-HEARS
C131887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131887>	C173398	When in Group of People and Could Not See Speaker, How Hard to Know Where That Person Was Question|When in Group of People and Could Not See Speaker, How Hard to Know Where That Person Was|When you were in a group of people and couldn't see who was speaking, how hard was it to know where that person was	A question about how hard it was for an individual to know where a person was if they couldn't see them speaking.			Intellectual Product	AYA-HEARS
C131888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131888>	C118873	How Often Turn Up Volume Watching TV Question|How Often Turn Up Volume Watching TV|How often did you have to turn up the volume when you watched TV	A question about how often an individual has or had to turn up the volume when watching TV.			Intellectual Product	AYA-HEARS
C131889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131889>	C118873	How Often Turn Up Volume When Talking on Phone Question|How Often Turn Up Volume When Talking on Phone|How often did you have to turn up the volume when you talked on a phone	A question about how often an individual has or had to turn up the volume when talking on the phone.			Intellectual Product	AYA-HEARS
C13188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13188>	C13398	Amniotic Fluid|AMNIOTIC FLUID|AMNIOTIC FLUID|Amniotic fluid|Aqua Amnii|Aqua Amnii|FLUID, AMNIOTIC|Human Amniotic Fluid|Liquor Amnii|Waters (Amniotic Fluid)|amniotic fluid	The fluid within the amniotic cavity which surrounds and protects the developing embryo. It is initially produced by the amnion and then later by the lungs and kidneys. The amount at term normally varies from 500 to 2000 ml.			Body Substance	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Structured Product Labeling Terminology|GDC Terminology|GDC Value Terminology|mCode Genomic Specimen Type Value Set|mCode Terminology|SPL Tissue Form Product Type Terminology|UBERON Terminology
C131890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131890>	C173398	When You Talk on Phone, How Hard to Understand What Other Person Was Saying Question|When You Talk on Phone, How Hard to Understand What Other Person Was Saying|When you talked on a phone, how hard was it to understand what the other person was saying	A question about how hard it was for an individual to understand what the other person was saying while talking on a telephone.			Intellectual Product	AYA-HEARS
C131891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131891>	C173059|C118873	How Often Hear Ringing, Buzzing, Whistling Noises Only You Could Hear Question|How Often Hear Ringing, Buzzing, Whistling Noises Only You Could Hear|How often did you hear ringing, buzzing or whistling noises that only you could hear	A question about how often an individual heard ringing, buzzing or whistling noises that only they could hear.			Intellectual Product	AYA-HEARS
C131892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131892>	C173059	How Severe Were Ringing, Buzzing, Whistling Noises that Only You Could Hear Question|How Severe Were Ringing, Buzzing, Whistling Noises that Only You Could Hear|How severe were the ringing, buzzing, or whistling noises that only you could hear	A question about the severity of the ringing, buzzing, or whistling noises that only an individual could hear.			Intellectual Product	AYA-HEARS
C131893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131893>	C173561	How Much Did Ringing, Buzzing, Whistling Noises Bother You Question|How Much Did Ringing, Buzzing, Whistling Noises Bother You|How Much Does Ringing, Buzzing, Whistling Noises Bother You|How much did ringing, buzzing, or whistling noises bother you	A question about how much an individual was bothered by ringing, buzzing, or whistling noises.			Intellectual Product	AYA-HEARS
C131894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131894>	C173787|C173584	How Much Did Ringing, Buzzing, Whistling Noises Interfere with Your Daily Activities Question|How Much Did Ringing, Buzzing, Whistling Noises Interfere with Your Daily Activities|How much did ringing, buzzing, or whistling noises interfere with your daily activities	A question about how much an individual's daily activities were interfered with by ringing, buzzing, or whistling noises.			Intellectual Product	AYA-HEARS
C131895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131895>	C173059	How Much Did Ringing, Buzzing, Whistling Noises Make it Hard to Pay Attention to Things Question|How Much Did Ringing, Buzzing, Whistling Noises Make it Hard to Pay Attention to Things|How much did ringing, buzzing, or whistling noises make it hard to pay attention to things	A question about how hard it was for an individual to concentrate because of ringing, buzzing, or whistling noises.			Intellectual Product	AYA-HEARS
C131896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131896>	C173925|C118873	How Often Did Ringing, Buzzing, Whistling Noises Make it Hard to Fall Asleep Question|How Often Did Ringing, Buzzing, Whistling Noises Make it Hard to Fall Asleep|How often did ringing, buzzing, or whistling noises make it hard to fall asleep	A question about how often ringing, buzzing, or whistling noises make or made it hard for an individual to fall asleep.			Intellectual Product	AYA-HEARS
C131897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131897>	C173925|C118873	How Often Did Ringing, Buzzing, Whistling Noises Wake You from Sleep Question|How Often Did Ringing, Buzzing, Whistling Noises Wake You from Sleep|How often did ringing, buzzing, or whistling noises wake you up from sleep	A question about how often ringing, buzzing, or whistling noises woke an individual up from sleep.			Intellectual Product	AYA-HEARS
C131898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131898>	C177913|C176249	No Hearing Problems|Did not have hearing problems	A response indicating that an individual did not have hearing problems.			Intellectual Product	AYA-HEARS
C131899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131899>	C752	AVP Gene Product	A protein encoded by the AVP gene.			Amino Acid, Peptide, or Protein	
C13189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13189>	C13379	Epitope|Antigenic Determinant|Antigenic Determinants|Binding Determinants|epitope	The simplest form of an antigenic determinant, on a complex antigenic molecule, which can combine with antibody or T cell receptor.			Immunologic Factor|Molecular Function	
C1318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1318>	C29710	Lithium Carbonate|Escalith|Eskalith|Eskalith|LITHIUM CARBONATE|Lithane|Lithane|Lithium|Lithium carbonate|Lithobid|Lithobid|Lithonate|Lithonate|Lithotabs|Lithotabs	The carbonate salt of lithium, a soft alkali metal, with antimanic and hematopoietic activities. Lithium interferes with transmembrane sodium exchange in nerve cells by affecting sodium, potassium-stimulated adenosine triphosphatase (Na+, K+-ATPase); alters the release of neurotransmitters; affects cyclic adenosine monophosphate (cAMP) concentrations; and blocks inositol metabolism resulting in depletion of cellular inositol and inhibition of phospholipase C-mediated signal transduction. The exact mechanism through which lithium exerts its mood-stabilizing effect has not been established. In addition, lithium stimulates granulocytopoiesis and appears to increase the level of pluripotent hematopoietic stem cells by stimulating the release of hematopoietic cytokines and/or directly acting on hematopoietic stem cells.	Lithium Carbonate		Inorganic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C131900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131900>	C226878	Artificial Saliva Spray|Hypozalix Spray	A spray formulation containing a saliva substitute, composed of potassium chloride, sodium chloride, magnesium chloride, calcium chloride, dipotassium phosphate and monopotassium phosphate, that has potential anti-xerostomia activity. Upon direct oral application of the artificial saliva spray, a protective film of moisture is deposited over the mucous membranes of the mouth, which relieves dryness of the mucous membranes and increases salivary flow. In addition, artificial saliva may help prevent chemotherapy- or radiotherapy-induced oral mucositis.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C131901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131901>	C28676|C201545	Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells|(mbIL21)-expanded Haploidentical NK Cells|Donor mbIL21-expanded NK Cells|mbIL21-expanded Haploidentical NK Cells	A preparation of human cytokine interleukin-21 (IL-21) primed, tumor-activated allogeneic human leukocyte antigen (HLA) haploidentical natural killer (NK) cells, with potential cytolytic and immunoregulatory activities. Allogeneic leukemia cells are genetically modified to express membrane-bound interleukin-21 (mbIL-21) on their cell surfaces. When human peripheral blood mononuclear cells (PBMCs) from an HLA-haploidentical donor are subsequently exposed to these cells, the donor PBMC differentiate into mature, highly cytotoxic NK cells, which are subsequently expanded in ex vivo culture.  Upon infusion of the mbIL-21-expanded haploidentical NK cells, the NK cells target, lyse and destroy tumor cells. mbIL-21 promotes sustained ex vivo proliferation of human NK cells and enhances its cytotoxic activity.	Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131902>	C25404	Examination	A formal or careful inspection of an object or subject.			Activity	
C131903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131903>	C67437	Oral Docetaxel|Docetaxel-P-glycoprotein Inhibitor|Docetaxel-P-gp Inhibitor|Oradoxel	An oral proprietary P-glycoprotein (P-gp) pump inhibitor-based formulation containing the taxane docetaxel, a semisynthetic analogue of paclitaxel, and a P-gp pump inhibitor, with potential antineoplastic activity. Upon administration of oral docetaxel, the P-gp pump inhibitor moiety, which is not absorbed, binds to the P-gp pump in the gastrointestinal (GI) tract and prevents the P-gp pump-mediated efflux of docetaxel from cells the docetaxel has been internalized by back into the GI tract. This decreases P-gp-mediated excretion and enhances absorption of docetaxel. Upon absorption, docetaxel binds specifically to the beta-tubulin subunit of the microtubule, stabilizes tubulin and inhibits microtubule disassembly, which results in cell-cycle arrest at the G2/M phase and cell death. The P-gp pump inhibitor enhances the bioavailability of certain poorly bioavailable agents and thereby allows oral administration of those agents. P-gp, an efflux membrane transporter, plays a key role in active drug export, and prevents cellular uptake and accumulation of certain substances.			Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131904>	C2124	Gallium Ga 68-NOTA-3PTATE-RGD|68Ga-NOTA-3PTATE-RGD	A radiopharmaceutical agent composed of a modified form of the somatostatin analogue octreotate (TATE), linked, via a glutamate linker, to the cyclic tri-amino acid arginine-glycine-aspartic acid (RGD) motif (3PTATE-RGD), and labeled, via the macrocyclic chelating agent 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA) with the radioisotope gallium Ga 68, with potential somatostatin receptor type 2 (SSTR2) and alphaVbeta3 (aVb3) integrin imaging activity upon positron emission topography (PET) or single photon emission computed tomography (SPECT). After intravenous administration, gallium Ga 68-NOTA-3PTATE-RGD simultaneously binds to SSTR, with its TATE moiety (with a preference for SSTR2), and to the integrin receptor aVb3 with its RGD moiety. Both SSTR2 and aVb3 are expressed on the membrane of certain tumor cells while minimally or not expressed on healthy, normal cells. Upon PET imaging, SSTR2- and aVb3 integrin-expressing tumor cells can be visualized and expression levels can be quantified. SSTR2 and aVb3 play key roles in tumor proliferation and survival.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C131905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131905>	C1420	BF-200 Gel Formulation|BF-200|BF-200 ALA	A topical nanoemulsion-based gel formulation containing 5-aminolevulinic acid (ALA), a metabolic precursor of the photosensitizer protoporphyrin IX, with a potential application for enhanced photodynamic therapy (PDT) for various precancerous and malignant skin lesions. After topical administration of a thick layer of the ALA-based BF-200 gel formulation to the affected area, ALA penetrates the skin and is intracellularly converted to protoporphyrin IX (PpIX). Exposure of PpIX to the proper excitation wavelength of light generates singlet oxygen molecules, resulting in a local cytotoxic effect.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131906>	C27910|C159717	EBV-Positive Mucocutaneous Ulcer|EBVMCU|Epstein-Barr Virus-Positive Mucocutaneous Ulcer|Epstein-Barr Virus-Positive Mucocutaneous Ulcer	A rare Epstein-Barr virus-positive B-cell lymphoproliferative disorder that affects mucosal sites (including oral mucosa, palate, tonsils, and gastrointestinal tract) and skin. It presents with well-circumscribed, often painful ulcers. It is associated with immune suppression, including age-related and drug-induced immunosuppression. In the majority of cases the lesions regress either spontaneously or following withdrawal of the immunosuppression therapy.	Epstein-Barr Virus-Positive Mucocutaneous Ulcer		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C131907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131907>	C134787|C129822	Renvistobart|Anti-TIGIT Monoclonal Antibody BMS-986207|BMS-986207|RENVISTOBART	A human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, renvistobart binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells, and leads to CD226 dimerization and CD226-mediated signaling. This activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.	Renvistobart		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131908>	C214440	Iadademstat|1,4-Cyclohexanediamine, N1-((1R,2S)-2-Phenylcyclopropyl)-, trans-|IADADEMSTAT|ORY 1001|ORY-1001|RG 6016|RG6016|RO 7051790|RO7051790|trans-N1-((1R,2S)-2-Phenylcyclopropyl)-1,4-cyclohexanediamine	An orally available inhibitor of lysine specific histone demethylase 1 (KDM1A; LSD1), with potential antineoplastic activity. Upon administration, iadademstat binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4, respectively. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. In addition, LSD1 demethylates mono- or di-methylated H3K9, which increases gene expression of tumor promoting genes; inhibition of LSD1 promotes H3K9 methylation and decreases transcription of these genes. LSD1, an enzyme belonging to the flavin adenine dinucleotide (FAD)-dependent amine oxidase family, is overexpressed in certain tumor cells and plays a key role in in the regulation of gene expression, tumor cell growth and survival.	Iadademstat		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131909>	C2167|C129825	EGFR T790M Antagonist BPI-15086|BPI 15086|BPI-15086|BPI15086|EGFR T790M Inhibitor BPI-15086	An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. EGFR T790M antagonist BPI-15086 specifically binds to and inhibits EGFR T790M, a secondarily acquired resistance mutation, which prevents EGFR-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells. EGFR, a receptor tyrosine kinase that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C13190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13190>	C13236	Aqueous Humor|AQUEOUS HUMOR|AQUEOUS HUMOR|Aqueous Fluid|Aqueous Humour|EYE, AQUEOUS HUMOR|aqueous humor|aqueous humor of eyeball|aqueous humour|humor aquosus	The watery fluid which is present in the anterior and posterior chambers of the eye.			Body Substance	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|UBERON Terminology
C131910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131910>	C129820	Abequolixron|ABEQUOLIXRON|LXR-b Agonist RGX-104|Liver X Receptor beta Agonist RGX-104|RGX 104|RGX-104|RGX104|SB-742881	An orally bioavailable agonist of the nuclear receptor liver X receptor beta (LXRbeta; NR1H2; LXR-b), with potential immunomodulating and antineoplastic activities. Upon oral administration, abequolixron selectively targets and binds to LXRbeta, thereby activating LXRbeta-mediated signaling, leading to the transcription of certain tumor suppressor genes and the downregulation of certain tumor promoter genes. This particularly activates the expression of apolipoprotein E (ApoE), a tumor suppressor protein, in tumor cells and certain immune cells. This activates the innate immune system, resulting in depletion of immunosuppressive myeloid-derived suppressor cells (MDSCs), tumor cells and endothelial cells in the tumor microenvironment. This reverses immune evasion, enhances anti-tumor immune responses and inhibits proliferation of tumor cells. LXRbeta, a member of the oxysterol receptor family, which is in the nuclear receptor family of transcription factors, plays a key role in cholesterol transport, glucose metabolism and the modulation of inflammatory responses; activation of LXRbeta suppresses tumor cell invasion, angiogenesis, tumor progression, and metastasis in a variety of tumor cell types. The expression of the ApoE protein becomes silenced in human cancers as they grow, become invasive, and metastasize; ApoE silencing is related to reduced survival in cancer patients. The LXR-ApoE pathway regulates the ability of cancers to evade the immune system and recruit blood vessels.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C131911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131911>	C7056|C178541	Large B-Cell Lymphoma with 11q Aberration|B-Cell Lymphoma with 11q Aberration Resembling Burkitt Lymphoma|Burkitt-Like Lymphoma with 11q Aberration|Burkitt-Like Lymphoma with 11q Aberration|High Grade B-Cell Lymphoma with 11q Aberrations|High-Grade B-Cell Lymphoma with 11q Aberrations|MYC-Negative B-Cell Lymphoma with 11q Aberration Resembling Burkitt Lymphoma|MYC-Negative High-Grade B-Cell Lymphoma with 11q Aberration Resembling Burkitt Lymphoma	A molecularly distinct large B-cell lymphoma reminiscent of Burkitt lymphoma. It is characterized by the absence of MYC translocation and the presence of chromosome 11q aberrations.	MYC-Negative B-Cell Lymphoma with 11q Aberration Resembling Burkitt Lymphoma	Provisional_Concept	Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C131912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131912>	C2950	11q Aberration|11q Abnormality|Aberration of 11q|Chromosome 11q Abnormality|Chromosome 11q Abnormality	A cytogenetic abnormality characterized by deregulation of genes in 11q.	Chromosome 11q Abnormality		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C131913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131913>	C138195	High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements|HGBCL-TH|High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements|Triple Hit Lymphoma|Triple-Hit Lymphoma|Triple-Hit Lymphoma	High-grade B-cell lymphoma characterized by the abnormal rearrangement of MYC gene, BCL2 gene, and BCL6 gene. Patients with this type of lymphoma usually respond poorly to standard treatments and have a poor prognosis.	High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements		Neoplastic Process	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology
C131914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131914>	C217122	Barthel Index of Activities of Daily Living|Barthel ADL Index|Barthel Activities of Daily Living (ADL) Index|Barthel Index|Barthel Index of ADL	A clinical assessment tool designed to measure functional independence and need for assistance in mobility, self-care, and activities of daily living.			Intellectual Product	
C131915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131915>	C25616	Past 24 to 48 Hours|Preceding 24 to 48 Hours	The 24-48 hour period occurring just before the present time.			Temporal Concept	Barthel Index of Activities of Daily Living
C131916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131916>	C178809|C173938	Bowel Continence Question|Bowel Continence|Bowel Incontinence Question|Bowels	A question about an individual's ability to control their bowels.			Intellectual Product	Barthel Index of Activities of Daily Living
C131917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131917>	C178809|C173803	Bladder Continence Question|Bladder|Bladder Continence|Urinary Incontinence|Urinary Incontinence Question	A question about an individual's ability to control their bladder.			Intellectual Product	Barthel Index of Activities of Daily Living
C131918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131918>	C173045	Grooming Ability Question|Grooming|Grooming Ability	A question about an individual's ability to perform personal hygiene tasks.			Intellectual Product	Barthel Index of Activities of Daily Living
C131919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131919>	C173045	Toilet Use Question|Toilet Use|Toilet Use|Toilet Use Ability|Toilet Use Capacity|Using the toilet|Using toilet	A question about an individual's ability or capacity to use the toilet.			Intellectual Product	Barthel Index of Activities of Daily Living
C13191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13191>	C38622|C12749	Basement Membrane	Ubiquitous supportive tissue adjacent to epithelium and around smooth and striated muscle cells. This tissue contains intrinsic macromolecular components such as collagen, laminin, and sulfated proteoglycans. As seen by light microscopy one of its subdivisions is the basal (basement) lamina.	Basement Membrane		Tissue	CTRP Biomarker Terminology|CTRP Terminology
C131920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131920>	C173045	Feeding Ability Question|Feeding|Feeding Ability	A question about an individual's ability to self feed.			Intellectual Product	Barthel Index of Activities of Daily Living
C131921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131921>	C173045	Transfer Ability Question|Transfer|Transfer Ability	A question about an individual's ability to move from a bed to a chair and back.			Intellectual Product	Barthel Index of Activities of Daily Living
C131922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131922>	C173458	Mobility Ability Question|Mobility|Mobility Ability	A question about an individual's ability to move about the house or indoors.			Intellectual Product	Barthel Index of Activities of Daily Living
C131923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131923>	C173045	Dressing Ability Question|Dressing|Dressing Ability	A question about an individual's ability to select and put on clothes.			Intellectual Product	Barthel Index of Activities of Daily Living
C131924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131924>	C173045	Ability to Use Stairs Question|Ability to Use Stairs|Stairs	A question about an individual's ability to walk up and down stairs.			Intellectual Product	Barthel Index of Activities of Daily Living
C131925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131925>	C173045	Bathing Ability Question|Bathing|Bathing Ability	A question about an individual's ability to get in and out of a bathtub or shower and clean their body.			Intellectual Product	Barthel Index of Activities of Daily Living
C131926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131926>	C226778	Fecal Incontinence or Requires Enema|incontinent (or needs to be given enemata)	A response indicating that an individual has fecal incontinence or requires enemas.			Intellectual Product	Clinical or Research Assessment Answer
C131927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131927>	C226778	Occasional Fecal Accident, Once per Week|occasional accident (once/week)	A response indicating that an individual has a fecal accident about once per week.			Intellectual Product	Clinical or Research Assessment Answer
C131928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131928>	C226778	Fecal Continence|Continent|Controlling bowels independent|Controls Bowels without Help|Independent for Controlling Bowels	A response indicating that an individual is fecally continent.			Intellectual Product	Barthel Index of Activities of Daily Living
C131929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131929>	C226650	Urinary Incontinent, or Catheterized and Unable to Manage|incontinent, or catheterized and unable to manage	A response indicating that an individual is urinary incontinent or catheterized and unable to manage.			Intellectual Product	Barthel Index of Activities of Daily Living
C13192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13192>	C32875	Bile|BILE|Bile Fluid|Bile Juice|bile	Fluid composed of waste products, bile acids, salts, cholesterol, and electrolytes. It is secreted by the liver parenchyma and stored in the gallbladder.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|mCode Genomic Specimen Type Value Set|mCode Terminology
C131930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131930>	C226650	Occasional Urinary Accident, Maximum of Once per 24 Hours|occasional accident (max. once per 24 hours)	A response indicating that an individual has urinary accidents, but no more than once per 24 hours.			Intellectual Product	Barthel Index of Activities of Daily Living
C131931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131931>	C226650	Urinary Continent Over 7 Days|continent (for over 7 days)	A response indicating that an individual is or has been urinary continent for over 7 days.			Intellectual Product	Barthel Index of Activities of Daily Living
C131932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131932>	C226572	Needs Help with Personal Grooming|Does Personal Grooming with Help|Personal toilet (wash face, comb hair, shave, clean teeth) with help|needs help with personal care	A response indicating that an individual needs help with personal grooming care.			Intellectual Product	Barthel Index of Activities of Daily Living
C131933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131933>	C226572	Independent for Personal Grooming|Does Personal Grooming without Help|Personal toilet (wash face, comb hair, shave, clean teeth) independent|independent face/hair/teeth/shaving (implements provided)	A response indicating that an individual requires no help with their personal grooming care.			Intellectual Product	Barthel Index of Activities of Daily Living
C131934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131934>	C226577	Dependent for Toilet Use|dependent	A response indicating that an individual is dependent on others for using the toilet.			Intellectual Product	Barthel Index of Activities of Daily Living
C131935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131935>	C226577	Needs Some Help for Toilet Use|needs some help, but can do something alone	A response indicating that an individual needs some help but can do something alone.			Intellectual Product	Barthel Index of Activities of Daily Living
C131936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131936>	C226577	Independent for Toilet Use|Getting on and off toilet (handling clothes, wipe, flush) independent|Uses Toilet without Help|independent (on and off, dressing, wiping)	A response indicating that an individual can use the toilet independently of help from others.			Intellectual Product	Barthel Index of Activities of Daily Living
C131937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131937>	C226571	Unable to Feed Self|unable	A response indicating that an individual is unable to do feed themself.			Intellectual Product	Barthel Index of Activities of Daily Living
C131938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131938>	C226571	Needs Help with Eating Tasks|Feeding with help|Feeds Self with Help|needs help cutting, spreading butter, etc.	A response indicating that an individual needs help with tasks related to eating, such as cutting food, spreading butter, etc.			Intellectual Product	Barthel Index of Activities of Daily Living
C131939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131939>	C226571	Independent for Eating|independent (food provided within reach)	A response indicating that an individual can eat independently of help from others when food is provided within reach.			Intellectual Product	Barthel Index of Activities of Daily Living
C13193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13193>	C13806	Antibody Binding Site|Antibody Combining Site	The site at which an antibody makes direct physical contact with a corresponding epitope on an antigen.			Amino Acid Sequence	
C131940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131940>	C226574	Unable to Transfer|unable, no sitting balance	A response indicating that an individual lacks sitting balance and is unable to sit or transfer.			Intellectual Product	Barthel Index of Activities of Daily Living
C131941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131941>	C226574	Major Help to Transfer|major help (one or two people, physical), can sit	A response indicating that an individual can transfer and sit, but needs major, physical help from one or two people.			Intellectual Product	Barthel Index of Activities of Daily Living
C131942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131942>	C226574	Minor Help to Transfer|minor help (verbal or physical)	A response indicating that an individual needs minor verbal or physical help to transfer.			Intellectual Product	Barthel Index of Activities of Daily Living
C131943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131943>	C226574	Independent for Transfer|Independent for Transfer Between Wheelchair and Bed|Independent for Wheelchair Transfer|Moving from wheelchair to bed and return independent|independent	A response indicating that an individual can transfer independently of help from others.			Intellectual Product	Barthel Index of Activities of Daily Living
C131944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131944>	C226578|C226573	Immobile|immobile	A response indicating that an individual is not mobile.			Intellectual Product	Barthel Index of Activities of Daily Living
C131945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131945>	C226576	Wheelchair Independent|wheelchair independent, including corners, etc.	A response indicating that an individual is independent with use of a wheelchair.			Intellectual Product	Barthel Index of Activities of Daily Living
C131946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131946>	C226575|C178389	Walks with Help of One Person|walks with help of one person (verbal or physical)	A response indicating that an individual can walk with verbal or physical help of one person.			Intellectual Product	Barthel Index of Activities of Daily Living
C131947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131947>	C226701|C226575	Mobily Independent, but May Require a Walking Aid|independent (but may use any aid, e.g., stick)	A response indicating that an individual is independently mobile but may require the use of an aid, such as a cane or stick.			Intellectual Product	Barthel Index of Activities of Daily Living
C131948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131948>	C226570	Dependent Dressing|Dresses with Help|Dressing (includes tying shoes, fastening fasteners) with help|dependent	A response indicating that an individual is dependent on others for dressing.			Intellectual Product	Barthel Index of Activities of Daily Living
C131949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131949>	C226570	Needs Help with Dressing but Can Do About Half Unaided|needs help, but can do about half unaided	A response indicating that an individual needs help with dressing but can do about half unaided.			Intellectual Product	Barthel Index of Activities of Daily Living
C13194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13194>	C33966	Blood-Brain Barrier|BBB|BBB|Blood Brain Barrier|blood-brain barrier	The mechanism for restricting the passage of charged ions and large molecules from the blood into the brain and central nervous system (CNS) by employing a unique capillary bed with tight junctions between the endothelial cells.			Body Part, Organ, or Organ Component	
C131950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131950>	C226570	Independent for Dressing|Dresses without Help|Dressing (includes tying shoes, fastening fasteners) independent|Independent Dressing|independent (including buttons, zips, laces, etc.)	A response indicating that an individual can dress independently of help from others.			Intellectual Product	Barthel Index of Activities of Daily Living
C131951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131951>	C226563	Unable to Use Stairs|unable	A response indicating that an individual is unable to use stairs.			Intellectual Product	Barthel Index of Activities of Daily Living
C131952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131952>	C226563	Needs Help to Use Stairs|Ascend and descend stairs with help|Uses Stairs with Help|needs help (verbal, physical, carrying aid)	A response indicating that an individual needs verbal or physical help or a carrying aid to use stairs.			Intellectual Product	Barthel Index of Activities of Daily Living
C131953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131953>	C226563	Independent for Stairs|Ascend and descend stairs independent|Uses Stairs without Help|independent up and down	A response indicating that an individual can go up and down stairs independently of help from others.			Intellectual Product	Barthel Index of Activities of Daily Living
C131954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131954>	C226567	Dependent Bathing|Bathes with Help|Bathing self with help|dependent	A response indicating that an individual is dependent on others to bathe.			Intellectual Product	Barthel Index of Activities of Daily Living
C131955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131955>	C226567	Independent Bathing or in Shower|Bathes without Help|Bathing self independent|independent (or in shower)	A response indicating that an individual is independent of others for bathing in the tub or shower.			Intellectual Product	Barthel Index of Activities of Daily Living
C131956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131956>	C91105	Chemotherapy-induced Nausea and Vomiting Questionnaire|CINV|CINV Questionnaire	A questionnaire designed to assess the extent of nausea on vomiting in individuals undergoing chemotherapy.			Intellectual Product	
C131957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131957>	C217121	Difficulty Falling Asleep Scale	A scale for the subjective scoring of difficulty faling asleep that ranges from 0: No difficulty to 10: Didn't fall asleep.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131958>	C217121	Percentage Food Eaten Scale	A scale for the subjective scoring of percentage of food eaten that ranges from 0%: None to 100%: All of my food.			Intellectual Product	
C131959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131959>	C217121	Nausea Scale	A scale for the subjective scoring of nausea that ranges from 0: None to 10: The worst you can think of.			Intellectual Product	
C13195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13195>	C103411	Bronchoalveolar Lavage Fluid|Bronchial Lavage|Bronchial Lavage Fluid|FLUID, BRONCHOALVEOLAR LAVAGE|Fluid, Bronchial Lavage	Fluid introduced into, and collected from, the lungs by a bronchoalveolar lavage procedure.			Body Substance	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C131960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131960>	C221048	Difficulty Falling Asleep Score 0	A subjective score of 0 on a difficulty falling asleep scale that ranges from 0: No difficulty to 10: Didn't fall asleep.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131961>	C221048	Difficulty Falling Asleep Score 1	A subjective score of 1 on a difficulty falling asleep scale that ranges from 0: No difficulty to 10: Didn't fall asleep.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131962>	C221048	Difficulty Falling Asleep Score 2	A subjective score of 2 on a difficulty falling asleep scale that ranges from 0: No difficulty to 10: Didn't fall asleep.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131963>	C221048	Difficulty Falling Asleep Score 3	A subjective score of 3 on a difficulty falling asleep scale that ranges from 0: No difficulty to 10: Didn't fall asleep.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131964>	C221048	Difficulty Falling Asleep Score 4	A subjective score of 4 on a difficulty falling asleep scale that ranges from 0: No difficulty to 10: Didn't fall asleep.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131965>	C221048	Difficulty Falling Asleep Score 5	A subjective score of 5 on a difficulty falling asleep scale that ranges from 0: No difficulty to 10: Didn't fall asleep.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131966>	C221048	Difficulty Falling Asleep Score 6	A subjective score of 6 on a difficulty falling asleep scale that ranges from 0: No difficulty to 10: Didn't fall asleep.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131967>	C221048	Difficulty Falling Asleep Score 7	A subjective score of 7 on a difficulty falling asleep scale that ranges from 0: No difficulty to 10: Didn't fall asleep.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131968>	C221048	Difficulty Falling Asleep Score 8	A subjective score of 8 on a difficulty falling asleep scale that ranges from 0: No difficulty to 10: Didn't fall asleep.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131969>	C221048	Difficulty Falling Asleep Score 9	A subjective score of 9 on a difficulty falling asleep scale that ranges from 0: No difficulty to 10: Didn't fall asleep.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C13196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13196>	C34070	Nucleolus	The region within a cell nucleus where ribosomal DNA is clustered, ribosomal RNA is synthesized and ribosomes are assembled.			Cell Component	
C131970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131970>	C221048	Difficulty Falling Asleep Score 10	A subjective score of 10 on a difficulty falling asleep scale that ranges from 0: No difficulty to 10: Didn't fall asleep.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131971>	C221049	Percentage Food Eaten Score 0	A subjective score of 0% on a scale that ranges from 0%: None to 100%: All of my food.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131972>	C221049	Percentage Food Eaten Score 10	A subjective score of 10% on a scale that ranges from 0%: None to 100%: All of my food.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131973>	C221049	Percentage Food Eaten Score 20	A subjective score of 20% on a scale that ranges from 0%: None to 100%: All of my food.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131974>	C221049	Percentage Food Eaten Score 30	A subjective score of 30% on a scale that ranges from 0%: None to 100%: All of my food.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131975>	C221049	Percentage Food Eaten Score 40	A subjective score of 40% on a scale that ranges from 0%: None to 100%: All of my food.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131976>	C221049	Percentage Food Eaten Score 50	A subjective score of 50% on a scale that ranges from 0%: None to 100%: All of my food.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131977>	C221049	Percentage Food Eaten Score 60	A subjective score of 60% on a scale that ranges from 0%: None to 100%: All of my food.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131978>	C221049	Percentage Food Eaten Score 70	A subjective score of 70% on a scale that ranges from 0%: None to 100%: All of my food.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131979>	C221049	Percentage Food Eaten Score 80	A subjective score of 80% on a scale that ranges from 0%: None to 100%: All of my food.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C13197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13197>	C14135	Nucleus|Cell Nucleus|Cell Nucleus|NUCLEUS|Nuclei|Nucleic|nucleus	A body within the cell, surrounded by a membrane, within which lie the chromosomes, one or more nucleoli, combined with proteins, and exhibits mitosis.			Cell Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C131980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131980>	C221049	Percentage Food Eaten Score 90	A subjective score of 90% on a scale that ranges from 0%: None to 100%: All of my food.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131981>	C221049	Percentage Food Eaten Score 100	A subjective score of 100% on a scale that ranges from 0%: None to 100%: All of my food.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131982>	C221050	Nausea Score 0	A subjective score of 0 on a scale that ranges from 0: None to 10: The worst you can think of.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131983>	C221050	Nausea Score 1	A subjective score of 1 on a scale that ranges from 0: None to 10: The worst you can think of.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131984>	C221050	Nausea Score 2	A subjective score of 2 on a scale that ranges from 0: None to 10: The worst you can think of.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131985>	C221050	Nausea Score 3	A subjective score of 3 on a scale that ranges from 0: None to 10: The worst you can think of.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131986>	C221050	Nausea Score 4	A subjective score of 4 on a scale that ranges from 0: None to 10: The worst you can think of.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131987>	C221050	Nausea Score 5	A subjective score of 5 on a scale that ranges from 0: None to 10: The worst you can think of.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131988>	C221050	Nausea Score 6	A subjective score of 6 on a scale that ranges from 0: None to 10: The worst you can think of.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131989>	C221050	Nausea Score 7	A subjective score of 7 on a scale that ranges from 0: None to 10: The worst you can think of.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C13198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13198>	C34070	Centromere	The nonstaining primary constriction of a chromosome which is the point of attachment of the spindle fiber; provides the mechanism of chromosome movement during cell division; the centromere divides the chromosome into two arms, and its position is constant for a specific chromosome: near one end (acrocentric), near the center (metacentric), or between (submetacentric).			Cell Component	
C131990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131990>	C221050	Nausea Score 8	A subjective score of 8 on a scale that ranges from 0: None to 10: The worst you can think of.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131991>	C221050	Nausea Score 9	A subjective score of 9 on a scale that ranges from 0: None to 10: The worst you can think of.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131992>	C221050	Nausea Score 10	A subjective score of 10 on a scale that ranges from 0: None to 10: The worst you can think of.			Intellectual Product	Chemotherapy-induced Nausea and Vomiting Questionnaire
C131993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131993>	C18515	GLMN Gene Product	A protein encoded by the GLMN gene.			Amino Acid, Peptide, or Protein	
C131994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131994>	C131993	FKBP-Associated Protein 48 kDa|FAP48|FK506-Binding Protein-Associated Protein 48 kDa|FKBP-Associated Protein FAP48|GLMN|Glomulin Isoform 2	FKBP-associated protein 48 kDa (417 aa, ~48 kDa) is encoded by the human GLMN gene. This protein may play a role in the inhibition of cell proliferation and in the positive regulation of interferon-2 expression.			Amino Acid, Peptide, or Protein	
C131995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131995>	C177167|C176249	Hearing Problems Did Not Interfere with Activities|Hearing problems did not interfere with activities	A response indicating that an individual did not have hearing problems or hearing problems did not interfere with activities.			Intellectual Product	AYA-HEARS
C131996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131996>	C175286	Did Not Hear Ringing or Other Noises|Did not hear ringing or other noises	A response indicating that an individual did not hear ringing or other noises.			Intellectual Product	AYA-HEARS
C131997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131997>	C175303|C175286	Ringing or Other Noises Did Not Bother|Ringing or other noises did not bother me	A response indicating that an individual was not bothered by or ringing or other noises.			Intellectual Product	AYA-HEARS
C131998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131998>	C177167|C175286	Ringing or Other Noises Did Not Interfere with Activities|Ringing or other noises did not interfere with activities	A response indicating that ringing or other noises did not interfere with an individual's activities.			Intellectual Product	AYA-HEARS
C131999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C131999>	C175286	Ringing or Other Noises Did Not Make it Hard to Pay Attention|Ringing or other noises did not make it hard to pay attention	A response indicating that ringing or other noises did not make it hard for an individual to pay attention.			Intellectual Product	AYA-HEARS
C13199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13199>	C22188	Chloroplast	Photosynthetic organelle containing chlorophyll, the photosynthetic pigment, in cells of leaves and young stems of higher plants. Lens-shaped and rather variable in size but approximately 5 m long. Surrounded by a double membrane and contains circular DNA (though not enough to code for all proteins in the chloroplast). Like the mitochondrion, it is semi-autonomous. It resembles a cyanobacterium from which, on the endosymbiont hypothesis, it might be derived. Chlorophyll is associated with the membrane of vesicles (thylakoids) that are stacked to form grana.			Cell Component	
C1319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1319>	C1910	Leuprolide Acetate|6-D-Leucine-9-(N-ethyl-L-prolinamide)-1-9-luteinizing Hormone-releasing Factor (Pig) Monoacetate|6-D-Leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig) Monoacetate|A 43818|A-43818|A43818|Abbott 43818|Abbott-43818|Carcinil|Depo-Eligard|Eligard|Enanton|Enantone|Enantone-Gyn|Fensolvi|Ginecrin|LEUP|LEUPROLIDE ACETATE|Leuplin|Leuprorelin Acetate|Lucrin|Lucrin Depot|Luprodex Depot|Lupron|Lupron|Lupron Depot|Lupron Depot-3 Month|Lupron Depot-4 Month|Lupron Depot-Ped|Lutrate|Procren|Procrin|Prostap|TAP 144|TAP-144|TAP144|Trenantone|Uno-Enantone|Viadur|Viadur|leuprolide acetate	The acetate salt of a synthetic nonapeptide analogue of gonadotropin-releasing hormone. Leuprolide binds to and activates gonadotropin-releasing hormone (GnRH) receptors. Continuous, prolonged administration of leuprolide in males results in pituitary GnRH receptor desensitization and inhibition of pituitary secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. This agent reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.	Leuprolide Acetate		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C132000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132000>	C175286	Ringing or Other Noises Did Not Make it Hard to Fall Asleep|Ringing or other noises did not make it hard to fall asleep	A response indicating that ringing or other noises did not make it hard for an individual to fall asleep.			Intellectual Product	AYA-HEARS
C132001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132001>	C175286	Ringing or Other Noises Did Not Wake Me From Sleep|Ringing or other noises did not wake me from sleep	A response indicating that ringing or other noises did not wake an individual from sleep.			Intellectual Product	AYA-HEARS
C132002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132002>	C97927|C159204	BRIP1 Gene Mutation|BACH1 Gene Mutation|BRCA1 Interacting Protein C-Terminal Helicase 1 Gene Mutation|FANCJ Gene Mutation	A change in the nucleotide sequence of the BRIP1 gene.	BRIP1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C132003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132003>	C97927|C159204	FANCF Gene Mutation|FAF Gene Mutation|Fanconi Anemia Complementation Group F Gene Mutation|Fanconi Anemia, Complementation Group F Gene Mutation	A change in the nucleotide sequence of the FANCF gene.	FANCF Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132004>	C97927|C159204	FANCM Gene Mutation|FAAP250 Gene Mutation|Fanconi Anemia Complementation Group M Gene Mutation|Fanconi Anemia, Complementation Group M Gene Mutation	A change in the nucleotide sequence of the FANCM gene.	FANCM Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132005>	C97927|C133695	RAD51B Gene Mutation|R51H2 Gene Mutation|RAD51 Paralog B Gene Mutation|RAD51L1 Gene Mutation|REC2 Gene Mutation	A change in the nucleotide sequence of the RAD51B gene.	RAD51B Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132006>	C97927|C133695	RAD54L Gene Mutation|HR54 Gene Mutation|HRAD54 Gene Mutation|RAD54 Homolog Gene Mutation|RAD54-like (S. cerevisiae) Gene Mutation|RAD54A Gene Mutation|hHR54 Gene Mutation	A change in the nucleotide sequence of the RAD54L gene.	RAD54L Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132007>	C97927|C131783	RPA1 Gene Mutation|RF-A Gene Mutation|RP-A Gene Mutation|RPA70 Gene Mutation|Replication Protein A1 Gene Mutation|Replication Protein A1, 70kDa Gene Mutation	A change in the nucleotide sequence of the RPA1 gene.	RPA1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132008>	C15608	Restaging|RESTAGING	Staging that is performed to determine the extent of cancer that has reoccurred following treatment or how the cancer responded to treatment.			Diagnostic Procedure	CDISC SDTM Medical History Event Date Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132009>	C90259	Pediatric Hematology-Oncology Terminology|Pediatric Heme-Onc Terminology	Terminology developed by a collaborative effort of the National Cancer Institute's Enterprise Vocabulary Services, the National Institute of Child Health and Human Development, and an international group of clinicians and informaticists to support the reporting of events observed in clinical care and research in children and adolescents seen by experts in blood disorders and cancer.			Intellectual Product	
C13200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13200>	C34070	Chromatid	One of the two side by side replicas produced by chromosome replication in mitosis or meiosis. Subunit of a chromosome after replication and prior to anaphase of meiosis II or mitosis. At anaphase of meiosis II or mitosis when the centromeres divide and the sister chromatids separate each chromatid becomes a chromosome. (Biology-Text.com)			Cell Component	
C132010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132010>	C48885	T5 TNM Finding|T5 Stage Finding	An antiquated primary tumor finding term that refers to colorectal cancer which has spread by direct extension beyond the immediately adjacent organs or tissues. (AJCC 1st Ed.)			Finding	
C132011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132011>	C177692	BCL6 Positive|B-Cell CLL/Lymphoma 6 Positive|B-Cell Lymphoma 6 Positive|BCL5 Positive|LAZ-3 Positive|LAZ3 Positive|ZBTB27 Positive|ZNF51 Positive	An indication that B-cell lymphoma 6 expression has been detected in a sample.	BCL6 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132012>	C34447|C210815	Resectable Head and Neck Squamous Cell Carcinoma|Resectable Head and Neck Squamous Cell Cancer	A squamous cell carcinoma of the head and neck that is amenable to surgical resection.	Resectable Head and Neck Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132013>	C207758	TGFbeta Inhibitor LY3200882|LY 3200882|LY-3200882|LY3200882|TGFb Inhibitor LY 3200882	An orally bioavailable agent that targets transforming growth factor-beta (TGFb), with potential antineoplastic activity. Upon administration, LY3200882 specifically targets and binds to TGFb, which prevents both the binding of TGFb to its receptor TGFbR and TGFb-mediated signal transduction. This may lead to a reduction in TGFb-dependent proliferation of cancer cells. The TGFb signaling pathway is often deregulated in tumors, and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, angiogenesis, and various immune responses.	TGFbeta Inhibitor LY3200882		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C132014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132014>	C78283|C521|C2459	Sustained-Exposure Dexamethasone Formulation OTO-104|Dexamethasone Sustained-exposure Formulation OTO-104|OTO-104|SR DXM Formulation OTO-104|Sustained Release Dexamethasone Formulation OTO-104	A sustained-release (SR) poloxamer hydrogel formulation containing the glucocorticoid dexamethasone (DXM), with potential otoprotective and anti-apoptotic activities. Prior to the administration of an ototoxic drug and upon intratympanic (IT) injection of the DXM sustained-exposure formulation OTO-104, DXM is slowly released from the hydrogel over time; DMX then binds to glucocorticoid nuclear receptors, and activates cell survival pathways. This prevents ototoxic drug-induced generation of reactive oxygen species (ROS) by activating anti-oxidant enzymes, blocking the activation of inflammatory cytokines and inducing stress signaling pathways, which ultimately prevents apoptosis of auditory hair cells in the inner ear compartment. This prevents or reduces drug-induced ototoxicity caused by certain therapeutic agents, such as platinum-based anticancer agents. This may reduce or prevent hearing loss, tinnitus, and vertigo. The SR formulation provides increased concentrations of DXM in the inner ear and maintains the elevated levels for a longer time without the need of the multiple IT injections needed when using non-SR DXM formulations. This agent also reduces the symptoms of certain ear-related disorders.	Sustained-Exposure Dexamethasone Formulation OTO-104		Bacterium|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C132015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132015>	C167435|C115907	Untreated Chronic Lymphocytic Leukemia	A finding of chronic lymphocytic leukemia that has not been treated.			Finding	
C132016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132016>	C167447|C115907	Untreated Small Lymphocytic Lymphoma	A finding of small lymphocytic lymphoma that has not been treated.			Finding	
C132017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132017>	C211912|C201141	Enapotamab Vedotin|Anti-AXL/MMAE ADC|Anti-AXL/MMAE Antibody-Drug Conjugate|ENAPOTAMAB VEDOTIN|HuMax-AXL-ADC|Immunoglobulin G1, Anti-(Human Growth Factor Receptor axl)(Human Humax-axl Gamma1-chain), Disulfide with Human Humax-axl Kappa-chain, Dimer Tetrakis(thioether) with Vedotin	An antibody-drug conjugate (ADC), consisting of a human monoclonal antibody directed against AXL receptor tyrosine kinase (AXL; UFO) and conjugated, through a protease-cleavable linker, to the cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of enapotamab vedotin binds to AXL, which is expressed on the surfaces of a variety of cancer cell types. Upon endocytosis and enzymatic cleavage, MMAE is released into the tumor cell cytosol, where it binds to tubulin and inhibits tubulin polymerization; this may result in G2/M phase arrest and apoptosis. AXL, a member of the TAM (TYRO3, AXL and MER) family of receptor tyrosine kinases and overexpressed by many tumor cell types, plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance and poor prognosis.	Enapotamab Vedotin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C132018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132018>	C212833	MYC Gene Rearrangement|C-MYC Gene Rearrangement|MRTL Gene Rearrangement|MYCC Gene Rearrangement|bHLHe39 Gene Rearrangement|c-myc Gene Rearrangement|v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog Gene Rearrangement	A molecular abnormality indicating rearrangement of the MYC gene.	MYC Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C132019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132019>	C133155	BCL2 Gene Rearrangement|B-Cell CLL-Lymphoma 2 Gene Rearrangement|B-Cell CLL/Lymphoma 2 Gene Rearrangement|BCL2, Apoptosis Regulator Gene Rearrangement|Bcl-2 Gene Rearrangement	A molecular abnormality indicating rearrangement of the BCL2 gene.	BCL2 Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13201>	C34070	Chromatin|CHROMATIN	The genetic material of the nucleus, consisting of deoxyribonucleoprotein, which occurs in two forms during the phase between mitotic divisions: 1) as heterochromatin, seen as condensed, readily stainable clumps; 2) as euchromatin, dispersed lightly staining or nonstaining material. During mitotic division the chromatin condenses into chromosomes.	Chromatin		Cell Component	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C132020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132020>	C79086|C133155	BCL6 Gene Rearrangement|B-Cell CLL/Lymphoma 6 Gene Rearrangement|BCL5 Gene Rearrangement|Bcl-6 Gene Rearrangement|LAZ3 Gene Rearrangement|ZBTB27 Gene Rearrangement|ZNF51 Gene Rearrangement|Zinc Finger Protein 51 Gene Rearrangement	A molecular abnormality indicating rearrangement of the BCL6 gene.	BCL6 Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132021>	C45581	BCL2 Gene Amplification|B-Cell CLL-Lymphoma 2 Gene Amplification|B-Cell CLL/Lymphoma 2 Gene Amplification|BCL2, Apoptosis Regulator Gene Amplification|Bcl-2 Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the BCL2 gene.	BCL2 Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132022>	C45581	BCL6 Gene Amplification|B-Cell CLL/Lymphoma 6 Gene Amplification|BCL5 Gene Amplification|Bcl-6 Gene Amplification|LAZ3 Gene Amplification|ZBTB27 Gene Amplification|ZNF51 Gene Amplification|Zinc Finger Protein 51 Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the BCL6 gene.	BCL6 Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132023>	C2167|C129825	Olafertinib|CK 101|CK-101|CK101|EGFR Mutant-specific Inhibitor CK-101|OLAFERTINIB|RX-518	An orally available third-generation and selective inhibitor of certain epidermal growth factor receptor (EGFR) activating mutations, including the resistance mutation T790M, and the L858R and del 19 mutations, with potential antineoplastic activity. Upon administration, olafertinib specifically and covalently binds to and inhibits selective EGFR mutations, with particularly high selectivity against the T790M mutation, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Compared to some other EGFR inhibitors, olafertinib may have therapeutic benefits in tumors with T790M-mediated drug resistance. This agent shows minimal activity against wild-type EGFR (WT EGFR), and does not cause dose-limiting toxicities that occur during the use of non-selective EGFR inhibitors, which also inhibit WT EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.	Olafertinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C132024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132024>	C129820	Yang Yin Fu Zheng|Fu Zheng Yang Yin|Fu Zheng Yang Yin Decoction|TCM Yang Yin Fu Zheng|Yang Yin Fu Zheng Jie Du|Yangyin Fuzheng Jiedu	A traditional Chinese medicine (TCM)-based formulation, with potential immuno-enhancing, detoxifying and antineoplastic activities. Upon administration, Yang Yin Fu Zheng may activate the immune system and may help inhibit tumor cell proliferation. This TCM may also help remove toxic substances.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C132025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132025>	C213472|C200418|C143099	AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M|AXL/cMET Inhibitor BPI-9016M|BPI 9016|BPI-9016|BPI-9016M	An orally available inhibitor of the AXL receptor tyrosine kinase (AXL; UFO) and the receptor tyrosine kinase c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Upon administration, AXL receptor tyrosine kinase/cMET inhibitor BPI-9016M, binds to both AXL and cMet, thereby disrupting both AXL- and c-Met-mediated signaling pathways. Altogether, this agent inhibits growth in AXL and cMet-overexpressing tumor cells. AXL, a member of the TAM (TYRO3, AXL and MER) family of receptor tyrosine kinases, and cMet, both overexpressed by many tumor cell types, play key roles in tumor cell proliferation, survival, invasion and metastasis.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C132026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132026>	C129820	Yiqi-yangyin-jiedu Herbal Decoction|TCM Yiqi-yangyin-jiedu Decoction|YYJ Decoction|YYJD|Yiqi Yangyin Jiedu Decoction	A traditional Chinese medicine (TCM) based formulation consisting of milkvetch root, glehnia root, asparagus root, lilyturf root, grossy privet fruit, spikemoss herb, Chinese sage herb, and manyleaf paris rhizome, with potential immuno-enhancing, detoxifying and antineoplastic activities. Upon administration, yiqi-yangyin-jiedu decoction (YYJD) may activate the immune system by enhancing T-lymphocyte activity, and inhibiting tumor cell proliferation. YYJD may also ameliorate the qi-yin deficiency syndrome by strengthening qi and nourishing yin. YYJD may help remove toxic substance.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C132027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132027>	C129826	CD8+NKG2D+ AKT Cell|NKG2D/AKT-expressing CD8-positive T-cells	A preparation of human CD8-positive tumor-specific T-lymphocytes engineered to express the natural killer cell activating receptor group 2D (NKG2D) and the serine/threonine kinase AKT, with potential immunomodulating and antineoplastic activities. Upon administration of CD8+NKG2D+ AKT cells, these cells target and kill tumor cells. AKT-mediated signaling enhances the activation, differentiation, proliferation and cytokine production of tumor specific T-cells, which enhances their anti-tumor effects; AKT activity in T-cells is often downregulated in the tumor environment. NKG2D, a stimulatory lymphocyte receptor, mediates the recognition of tumors cells and promotes T-cell activation and T-cell-mediated tumor cell killing; NKG2D ligands are expressed on cancer cells, while they are minimally expressed by or absent from normal, healthy cells.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C132028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132028>	C2124	Fluorine F 18 Vidoflufolastat|18F-CTT-1057|18F-CTT1057|CTT 1057 18F|CTT 1057 F18|Fluorine F 18 CTT1057|Fluorine-18-CTT 1057|PSMA-targeted PET Imaging Agent Fluorine F 18 CTT-1057|VIDOFLUFOLASTAT F-18|Vidoflufolastat (18F)	A radioconjugate composed of the phosphoramidate agent vidoflufolastat, a human prostate specific membrane antigen (PSMA) inhibitor, and labeled with the radioisotope fluorine F 18, with potential use as a tracer for PSMA-expressing tumors during positron emission tomography (PET). Upon intravenous administration, fluorine F 18 vidoflufolastat targets and irreversibly binds to the extracellular domain of PSMA-expressing tumor cells. Upon rapid internalization, and following PET imaging, PSMA-expressing tumor cells can be detected. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.	Fluorine F 18 Vidoflufolastat		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C132029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132029>	C2124|C1937	Gallium Ga 68-NODAGA-Ac-Cys-ZEGFR:1907|68Ga-NODAGA-Ac-Cys-ZEGFR:1907|Gallium Ga 68-NODAGA-Ac-Cys-Z(EGFR:1907)|[68Ga]-labeled Anti-EGFR Affibody Molecule Ac-Cys-ZEGFR:1907	A radiolabeled recombinant EGFR-specific affibody molecule composed of an epidermal growth factor receptor (EGFR)-targeting protein, the anti-EGFR affibody ZEGFR:1907 with an acetylated cysteine (Ac-Cys) at the N terminal of the affibody, and conjugated to the radioisotope gallium Ga 68, via the chelating agent NODAGA (1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid), with potential use for imaging EGFR-expressing tumor cells upon positron emission tomography (PET). Upon administration of gallium Ga 68-NODAGA-Ac-Cys-ZEGFR:1907, the ZEGFR:1907 affibody molecule moiety targets and binds to the extracellular domain (ECD) of EGFR expressed on various tumor cell types. Upon PET, EGFR-expressing tumor cells can be visualized. EGFR, frequently overexpressed in cancers, plays important roles in cell proliferation, survival, adhesion, migration, and differentiation. The affibody protein scaffold is based on the Z-domain, which is derived from one of the immunoglobulin (Ig) G-binding domains of staphylococcal protein A.			Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	NCI Drug Dictionary Terminology
C13202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13202>	C13404	Chromosome|CHROMOSOME|CHROMOSOME|CHROMOSOME|CHROMOSOME|Chromosomal|chromosome|chromosome|chromosome	A structure found in cells that is comprised of a strand of linearized double-stranded DNA plus proteins that package the DNA in a condensed coil form and regulate chromosomal function.			Cell Component	ALL Molecular Analysis Table|ALL Variable Terminology|AML Molecular Analysis Table|AML Variable Terminology|BRIDG Class Terminology|BRIDG Terminology|CTDC Property Terminology|EWS Molecular Analysis Table|EWS Variable Terminology|GCT Molecular Analysis Table|GCT Variable Terminology|GDC Property Terminology|GDC Terminology
C132030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132030>	C2124|C1937	Gallium Ga 68-NODAGA-ZIGF-1R:4:40|68Ga-NODAGA-ZIGF-1R:4:40|[68Ga]-labeled Anti-IGF-1R Affibody Molecule ZIGF-1R:4:40	A radiolabeled recombinant insulin-like growth factor 1 receptor (IGF-1R; IGF1R)-specific affibody ligand composed of an IGF1R-targeting protein, the anti-IGF1R affibody ZIGF-1R:4:40 with an acetylated cysteine (Ac-Cys) at the N terminal of the affibody, that is site-specifically conjugated with the chelating agent NODAGA (1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid), and labeled with the radioisotope gallium Ga 68, with potential use for imaging IGF1R-expressing tumor cells upon positron emission tomography (PET). Upon administration of gallium Ga 68-NODAGA-ZIGF-1R:4:40, the ZIGF-1R:4:40 affibody molecule moiety targets and binds to IGF1R expressed on various tumor cell types. Upon PET, IGF1R-expressing tumor cells can be visualized. IGF1R, frequently overexpressed in cancers, plays important roles in cell proliferation, survival, adhesion, migration, and differentiation. The affibody protein scaffold is based on the Z-domain, which is derived from one of the immunoglobulin (Ig) G-binding domains of staphylococcal protein A.			Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	NCI Drug Dictionary Terminology
C132031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132031>	C20921	NLRC5 Gene|NLR Family CARD Domain Containing 5 Gene|NLRC5|NLRC5	This gene is involved in innate immunity and antiviral responses.			Gene or Genome	
C132032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132032>	C132031	NLRC5 wt Allele|CLR16.1|FLJ21709|NLR Family CARD Domain Containing 5 wt Allele|NLR Family, CARD Domain Containing 5 Gene|NLR Family, CARD-Containing 5 Gene|NLR Family, Caspase Recruitment Domain-Containing 5 Gene|NOD27|NOD4|Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat and CARD Domain Containing 5 Gene	Human NLRC5 wild-type allele is located in the vicinity of 16q13 and is approximately 94 kb in length. This allele, which encodes protein NLRC5, plays a role in signaling, immunity and antiviral processes.			Gene or Genome	
C132033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132033>	C18515	Protein NLRC5|CLR16.1|Caterpiller Protein 16.1|NOD-Like Receptor C5|Nucleotide-Binding Oligomerization Domain Protein 27|Nucleotide-Binding Oligomerization Domain Protein 4|Nucleotide-Binding Oligomerization Domains 27	Protein NLRC5 (1866 aa, ~205 kDa) is encoded by the human NLRC5 gene. This protein is involved in signaling pathways and antiviral responses.			Amino Acid, Peptide, or Protein	
C132034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132034>	C26110	CMTR2 Gene|CMTR2|CMTR2|Cap Methyltransferase 2 Gene	This gene plays a role in the methylation of the 5' mRNA cap.	CMTR2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C132035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132035>	C132034	CMTR2 wt Allele|AFT|Adrift Homolog (Drosophila) Gene|Cap Methyltransferase 2 wt Allele|FLJ11171|FTSJD1|HMTr2|MTr2	Human CMTR2 wild-type allele is located in the vicinity of 16q22.2 and is approximately 8 kb in length. This allele, which encodes cap-specific mRNA (nucleoside-2-O-)-methyltransferase 2 protein, is involved in modification of mRNA.	CMTR2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132036>	C16849	Cap-Specific mRNA (Nucleoside-2-O-)-Methyltransferase 2|Adrift Homolog|CMTR2|Cap2 2'O-Ribose Methyltransferase 2|EC 2.1.1.296|FtsJ Methyltransferase Domain Containing 1|FtsJ Methyltransferase Domain-Containing Protein 1|HMTr2|MTr2|Protein Adrift Homolog	Cap-specific mRNA (nucleoside-2-O-)-methyltransferase 2 (770 aa, ~88 kDa) is encoded by the human CMTR2 gene. This protein plays a role in mRNA maturation.	Cap-Specific mRNA (Nucleoside-2-O-)-Methyltransferase 2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132037>	C25952	PDE4D Gene|PDE4D|PDE4D|Phosphodiesterase 4D Gene	This gene is involved in the metabolism of the second messenger, cyclic adenosine monophosphate (cAMP).			Gene or Genome	
C132038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132038>	C132037	PDE4D wt Allele|ACRDYS2|DPDE3|HSPDE4D|PDE43|PDE4DN2|Phosphodiesterase 4D wt Allele|Phosphodiesterase 4D, cAMP-Specific (Dunce (Drosophila)-Homolog Phosphodiesterase E3) Gene|Phosphodiesterase 4D, cAMP-Specific (Phosphodiesterase E3 Dunce Homolog, Drosophila) Gene|Phosphodiesterase 4D, cAMP-Specific Gene|Phosphodiesterase E3 Dunce Homolog (Drosophila) Gene|STRK1	Human PDE4D wild-type allele is located in the vicinity of 5q12 and is approximately 1553 kb in length. This allele, which encodes cAMP-specific 3',5'-cyclic phosphodiesterase 4D protein, plays a role in the modulation of second messenger signaling. Mutation of the gene is associated with acrodysostosis 2 and increased susceptibility to stroke.			Gene or Genome	
C132039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132039>	C16561	cAMP-Specific 3',5'-Cyclic Phosphodiesterase 4D|DPDE3|Dunce-Like Phosphodiesterase E3|EC 3.1.4.53|PDE43|PDE4D|cAMP-Specific Phosphodiesterase PDE4D6	cAMP-specific 3',5'-cyclic phosphodiesterase 4D (809 aa, ~91 kDa) is encoded by the human PDE4D gene. This protein is involved in the conversion of cyclic adenosine monophosphate (cAMP) to AMP.			Amino Acid, Peptide, or Protein|Enzyme	
C13203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13203>	C13202	Human Chromosome	A structure found in the nucleus of human cells that is comprised of a strand of linearized double-stranded DNA plus proteins that package the DNA in a condensed coil form and regulate chromosomal function.			Cell Component	
C132040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132040>	C21295	SNRPD3 Gene|SNRPD3|SNRPD3|Small Nuclear Ribonucleoprotein D3 Polypeptide Gene	This gene plays a role in spliceosome formation.			Gene or Genome	
C132041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132041>	C132040	SNRPD3 wt Allele|SMD3|Sm-D3|Small Nuclear Ribonucleoprotein D3 Polypeptide (18kD) Gene|Small Nuclear Ribonucleoprotein D3 Polypeptide 18kDa Gene|Small Nuclear Ribonucleoprotein D3 Polypeptide wt Allele	Human SNRPD3 wild-type allele is located in the vicinity of 22q11.23 and is approximately 54 kb in length. This allele, which encodes small nuclear ribonucleoprotein Sm D3 protein, is involved in spliceosome activity.			Gene or Genome	
C132042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132042>	C21298	Small Nuclear Ribonucleoprotein Sm D3|Sm-D3|Small Nuclear Ribonucleoprotein Polypeptide D3|SnRNP Core Protein D3	Human SNRPD3 wild-type allele is located in the vicinity of 22q11.23 and is approximately 54 kb in length. This allele, which encodes small nuclear ribonucleoprotein Sm D3 protein, is involved in spliceosome activity.			Amino Acid, Peptide, or Protein	
C132043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132043>	C25873	PASK Gene|PAS Domain Containing Serine/Threonine Kinase Gene|PASK|PASK	This gene is involved in energy homeostasis.			Gene or Genome	
C132044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132044>	C132043	PASK wt Allele|KIAA0135|PAS Domain Containing Serine/Threonine Kinase wt Allele|PASKIN|STK37	Human PASK wild-type allele is located in the vicinity of 2q37.3 and is approximately 44 kb in length. This allele, which encodes PAS domain-containing serine/threonine-protein kinase protein, plays a role in serine/threonine protein phosphorylation.			Gene or Genome	
C132045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132045>	C17325	PAS Domain-Containing Serine/Threonine-Protein Kinase|EC 2.7.11.1|PAS Domain-Containing Serine/Threonine Kinase|PAS-Kinase|Per-Arnt-Sim (PAS) Domain Kinase|hPASK	PAS domain-containing serine/threonine-protein kinase (1323 aa, ~143 kDa) is encoded by the human PASK gene. This protein is involved in the phosphorylation of proteins that play a role in energy homeostasis.			Amino Acid, Peptide, or Protein|Enzyme	
C132046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132046>	C2180	Nelivaptan|(2S,4R)-1-((3R)-5-Chloro-1-((2,4-dimethoxybenzene)sulfonyl)-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl)-4-hydroxy-N,N-dimethylpyrrolidine-2-carboxamide|NELIVAPTAN|SSR 149415|SSR149415				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132047>	C2180	Mozavaptan Hydrochloride|MOZAVAPTAN HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132048>	C19337|C148281	Volumetric Contrast-Enhanced Ultrasound Imaging|VCEUS|VCEUS Imaging|Volumetric Contrast-Enhanced Ultrasound	A type of contrast-enhanced ultrasound imaging that captures the nonlinear second harmonic signal from microbubble contrast agents flowing in the vasculature to create a 3-dimensional image.	Volumetric Contrast-Enhanced Ultrasound Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C132049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132049>	C1509	Tramiprosate Sodium|Sodium 3-Aminopropanesulphonate|TRAMIPROSATE SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C13204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13204>	C13203	Human Chromosome 1|Chromosome 1|Chromosome 1|Chromosome 1|chr1|chr1|chr1	The designation for each member of the largest human autosomal chromosome pair. Chromosome 1 spans about 247 million nucleotide base pairs and represents about 8% of the total DNA in normal diploid cells.	Chromosome 1		Cell Component	CTDC Value Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C132050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132050>	C98079	Mitiglinide Calcium|2H-Isoindole-2-butanoic Acid, Octahydro-gamma-oxo-alpha-(phenylmethyl)-, Calcium|Calcium 2-Benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate Dihydrate|Glufast|MITIGLINIDE CALCIUM ANHYDROUS				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132051>	C27304	Ectopic Thyroid Gland|Thyroid Ectopy	Location of the thyroid gland somewhere other than at the base of the neck.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C132052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132052>	C132051	Lingual Thyroid Gland	Ectopic thyroid gland located at the base of the tongue.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C132053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132053>	C26800	Iodine Deficiency Hypothyroidism|Hypothyroidism due to Iodine Deficiency	Hypothyroidism due to insufficient intake of iodine.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C132054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132054>	C36285	Euthyroid Condition	Derangement of the thyroid gland or thyroid hormone metabolism that is unaccompanied by signs or symptoms of hypothyroidism or hyperthyroidism.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C132055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132055>	C27567	Autoimmune Hypophysitis|Lymphocytic Hypophysitis	An autoimmune condition affecting the pituitary gland, characterized by lymphocytic infiltration, commonly presenting with pituitary hormone deficiencies.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C132056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132056>	C28404	USP22 Gene|USP22|USP22|Ubiquitin Specific Peptidase 22 Gene	This gene plays a role in the deubiquitination of histone H2 proteins.			Gene or Genome	
C132057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132057>	C132056	USP22 wt Allele|KIAA1063|USP3L|Ubiquitin Specific Peptidase 22 wt Allele	Human USP22 wild-type allele is located in the vicinity of 17p11.2 and is approximately 44 kb in length. This allele, which encodes ubiquitin carboxyl-terminal hydrolase 22 protein, is involved in the removal of ubiquitin from histone H2 proteins.			Gene or Genome	
C132058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132058>	C16481	Ubiquitin Carboxyl-Terminal Hydrolase 22|Deubiquitinating Enzyme 22|EC 3.4.19.12|USP22|Ubiquitin Specific Peptidase 22|Ubiquitin Specific Peptidase 3-Like|Ubiquitin Specific Protease 22|Ubiquitin Thioesterase 22|Ubiquitin Thiolesterase 22|Ubiquitin-Specific Processing Protease 22|Ubiquitin-Specific Protease 22|Ubiquitin-Specific-Processing Protease 22	Ubiquitin carboxyl-terminal hydrolase 22 (525 aa, ~60 kDa) is encoded by the human USP22 gene. This protein plays a role in the deubiquitination of histones H2A and H2B.			Amino Acid, Peptide, or Protein|Enzyme	
C132059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132059>	C36284	Lack of Adrenarche	Absent or incomplete development of adrenal androgen-mediated secondary sexual characteristics.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C13205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13205>	C13203	Human Chromosome 10|Chromosome 10|Chromosome 10|Chromosome 10|chr10|chr10|chr10	The designation for each member of the tenth largest human autosomal chromosome pair. Chromosome 10 spans about 135 million base pairs and represents between 4 and 4.5% of the total DNA in normal diploid cells.	Chromosome 10		Cell Component	CTDC Value Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C132060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132060>	C178120|C131021	Activating TSHR Gene Mutation|Activating Thyroid Stimulating Hormone Receptor Gene Mutation	Mutation(s) in the TSHR gene resulting in increased function of the thyroid stimulating hormone receptor.			Cell or Molecular Dysfunction	NICHD Terminology|Pediatric Endocrinology Terminology
C132061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132061>	C178119|C131021	Inactivating TSHR Gene Mutation|Inactivating Thyroid Stimulating Hormone Receptor Gene Mutation	Mutation(s) in the TSHR gene, resulting in decreased function of the thyroid stimulating hormone receptor.			Cell or Molecular Dysfunction	NICHD Terminology|Pediatric Endocrinology Terminology
C132062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132062>	C124594	Osteoma Cutis	Heterotopic ossification of the skin not associated with a preexisting lesion or process, such as inflammation or neoplasia.			Finding	NICHD Terminology|Pediatric Endocrinology Terminology
C132063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132063>	C45576	Kataegis	Regions of hypermutation that are found in clusters and are localized to one or more hot spots in the genome.			Cell or Molecular Dysfunction	
C132064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132064>	C1595	Minocycline Hydrochloride Dihydrate|4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide Monohydrochloride Dihydrate|MINOCYCLINE HYDROCHLORIDE DIHYDRATE				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132065>	C258	Valnemulin Hydrochloride|((2-((R)-2-Amino-3-methylbutyramido)-1,1-dimethylethyl)thio)acetic Acid, 8-ester with (3aS,4R,5S,6S,8R,9R,9aR,10R)-octahydro-5,8- dihydroxy-4,6,9,10-tetramethyl-6-vinyl-3a,9-propano-3ah- cyclopentacycloocten-1(4H)-one Hydrochloride|VALNEMULIN HYDROCHLORIDE				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132066>	C21176	Eukaryotic Initiation Factor 3|EIF3|Eukaryotic Translation Initiation Factor 3|eIF-3 Complex|eIF3	A protein complex comprised of 13 nonidentical subunits (EIF3A-M) that is involved in translation initiation and the disassembly and recycling of post-termination ribosomal complexes.			Amino Acid, Peptide, or Protein	
C132067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132067>	C3059	Low Grade Glioma|CNS, low grade glioma (LGG)|LGG|Low Grade Glial Neoplasm|Low-Grade Glioma	A grade I or grade II glioma arising from the central nervous system. This category includes pilocytic astrocytoma, diffuse astrocytoma, subependymal giant cell astrocytoma, ependymoma, oligodendroglioma, oligoastrocytoma, and angiocentric glioma.	Low Grade Glioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C132068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132068>	C64982|C155678	Cytoreductive Surgery|Cytoreduction	A surgical procedure that refers to the removal of as many malignant cells as possible from an anatomic site affected by cancer.	Cytoreductive Surgery		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C132069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132069>	C64982	Peritonectomy|Peritoneal Stripping	A surgical procedure that refers to the removal of the peritoneal sites affected by cancer.			Therapeutic or Preventive Procedure	
C13206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13206>	C13203	Human Chromosome 11|Chromosome 11|Chromosome 11|Chromosome 11|chr11|chr11|chr11	The designation for each member of the eleventh largest human autosomal chromosome pair. Chromosome 11 spans about 134.5 million base pairs and represents between 4 and 4.5% of the total DNA in normal diploid cells.	Chromosome 11		Cell Component	CTDC Value Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C132070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132070>	C64982	Diaphragmatic Stripping|Diaphragm Stripping	A surgical procedure that refers to the removal of the diaphragmatic sites affected by cancer.			Therapeutic or Preventive Procedure	
C132071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132071>	C66885|C1327	Sarpogrelate Hydrochloride|Butanedioic Acid, Mono(2-(dimethylamino)-1-((2-(2-(3-methoxyphenyl)ethyl)phenoxy)methyl)ethyl) ester, Hydrochloride, (+-)-|SARPOGRELATE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132072>	C20745	CAPZA2 Gene|CAPZA2|CAPZA2|Capping Actin Protein of Muscle Z-Line Alpha Subunit 2 Gene	This gene is involved in the regulation of actin polymerization.			Gene or Genome	
C132073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132073>	C132072	CAPZA2 wt Allele|CAPPA2|CAPZ|Cap Protein, Actin, Alpha-2 Subunit Gene|Capping Actin Protein of Muscle Z-Line Alpha Subunit 2 wt Allele|Capping Protein (Actin Filament) Muscle Z-Line, Alpha 2 Gene|Capping Protein, Alpha-2 Gene	Human CAPZA2 wild-type allele is located in the vicinity of 7q31.2 and is approximately 111 kb in length. This allele, which encodes F-actin-capping protein subunit alpha-2 protein, plays a role in the modulation of actin polymerization.			Gene or Genome	
C132074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132074>	C16492	F-Actin-Capping Protein Subunit Alpha-2|CAPZA2|CapZ Alpha-2|F-Actin Capping Protein Alpha-2 Subunit	F-actin-capping protein subunit alpha-2 (286 aa, ~33 kDa) is encoded by the human CAPZA2 gene. This protein is involved in the inhibition of actin polymerization and depolymerization.			Amino Acid, Peptide, or Protein	
C132075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132075>	C20103	KIR2DS3 Gene|KIR2DS3|KIR2DS3|Killer Cell Immunoglobulin Like Receptor, Two Ig Domains and Short Cytoplasmic Tail 3 Gene	This gene is involved in the regulation of natural killer cell-dependent immune responses.			Gene or Genome	
C132076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132076>	C132075	KIR2DS3 wt Allele|Killer Cell Immunoglobulin Like Receptor, Two Ig Domains and Short Cytoplasmic Tail 3 wt Allele|Killer Cell Immunoglobulin-Like Receptor, Two Domains, Short Cytoplasmic Tail, 3 Gene|NK-Associated Transcript 7 Gene|NKAT-7|NKAT7	Human KIR2DS3 wild-type allele is located in the vicinity of 19q13.4 and is approximately 14 kb in length. This allele, which encodes killer cell immunoglobulin-like receptor 2DS3 protein, plays a role in HLA-C binding and immunity.			Gene or Genome	
C132077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132077>	C18106	Killer Cell Immunoglobulin-Like Receptor 2DS3|KIR2DS3|MHC Class I NK Cell Receptor|NKAT-7|Natural Killer-Associated Transcript 7	Killer cell immunoglobulin-like receptor 2DS3 (304 aa, ~34 kDa) is encoded by the human KIR2DS3 gene. This protein is involved in the positive regulation of natural killer cell-mediated immunity.			Amino Acid, Peptide, or Protein|Receptor	
C132078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132078>	C27296	Positive Para-Aortic Lymph Node	A laboratory test result indicating the presence of a pathologic process in a para-aortic lymph node.	Positive Para-Aortic Lymph Node		Finding	CTRP Biomarker Terminology|CTRP Terminology
C132079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132079>	C27296	Positive Pelvic Lymph Node	A laboratory test result indicating the presence of a pathologic process in a pelvic lymph node.	Positive Pelvic Lymph Node		Finding	CTRP Biomarker Terminology|CTRP Terminology
C13207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13207>	C13203	Human Chromosome 12|Chromosome 12|Chromosome 12|Chromosome 12|chr12|chr12|chr12	The designation for each member of the twelfth largest human autosomal chromosome pair. Chromosome 12 spans about 143 million base pairs and represents between 4 and 4.5% of the total DNA in normal diploid cells.	Chromosome 12		Cell Component	CTDC Value Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C132080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132080>	C53543|C2849|C27572	Congenital Pseudarthrosis of Tibia	A condition characterized by non-union of the tibia, which is present at birth. It is usually associated with neurofibromatosis type 1.	Congenital Pseudarthrosis of Tibia		Congenital Abnormality	CTRP Disease Terminology|CTRP Terminology
C132081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132081>	C20745	SPTBN1 Gene|SPTBN1|SPTBN1|Spectrin Beta, Non-Erythrocytic 1 Gene	This gene plays a role in actin binding, cell shape and calcium-dependent transport.			Gene or Genome	
C132082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132082>	C132081	SPTBN1 wt Allele|Beta-Spectrin, General Form Gene|ELF|Fodrin, Beta Gene|HEL102|SPTB2|Spectrin Beta, Non-Erythrocytic 1 wt Allele|Spectrin, Beta, Non-Erythrocytic 1 Gene|Spectrin, Beta, Nonerythrocytic, 1 Gene|Spectrin, Beta-II Gene|Spectrin, Nonerythroid, Beta Subunit Gene|betaSpII	Human SPTBN1 wild-type allele is located in the vicinity of 2p21 and is approximately 215 kb in length. This allele, which encodes spectrin beta chain, non-erythrocytic 1 protein, is involved in the modulation of both cell shape and calcium-dependent secretory pathways.			Gene or Genome	
C132083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132083>	C16492	Spectrin Beta Chain, Non-Erythrocytic 1|Beta-Fodrin|Beta-G Spectrin|Beta-II Spectrin|Beta-Spectrin|Beta-Spectrin II|Beta-Spectrin Non-Erythrocytic 1|Embryonic Liver Beta-Fodrin|Epididymis Luminal Protein 102|Fodrin Beta Chain|Spectrin Beta Chain, Brain 1|Spectrin, Non-Erythroid Beta Chain 1	Spectrin beta chain, non-erythrocytic 1 (2364 aa, ~275 kDa) is encoded by the human SPTBN1 gene. This protein plays a role in both calcium-dependent intercellular transport and cell morphology.			Amino Acid, Peptide, or Protein	
C132084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132084>	C16615	EMX2 Gene|EMX2|EMX2|Empty Spiracles Homeobox 2 Gene	This gene is involved in development and transcriptional regulation.			Gene or Genome	
C132085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132085>	C132084	EMX2 wt Allele|Empty Spiracles Homeobox 2 wt Allele|Empty Spiracles Homolog 2 (Drosophila) Gene|Empty Spiracles, Drosophila, Homolog of, 2 Gene	Human EMX2 wild-type allele is located in the vicinity of 10q26.11 and is approximately 7 kb in length. This allele, which encodes homeobox protein EMX2, plays a role in transcriptional regulation. Mutation of the gene may be associated with schizencephaly, endometrioid adenocarcinomas and Mullerian mesodermal tumors.			Gene or Genome	
C132086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132086>	C17207	Homeobox Protein EMX2|Empty Spiracles Homolog 2|Empty Spiracles-Like Protein 2	Homeobox protein EMX2 (252 aa, ~28 kDa) is encoded by the human EMX2 gene. This protein is involved in the development of the nervous system and the urogenital system.			Amino Acid, Peptide, or Protein	
C132087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132087>	C28533	ATP1B3 Gene|ATP1B3|ATP1B3|ATPase Na+/K+ Transporting Subunit Beta 3 Gene	This gene plays a role in ion exchange activity.			Gene or Genome	
C132088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132088>	C132087	ATP1B3 wt Allele|ATPB-3|ATPase Na+/K+ Transporting Subunit Beta 3 wt Allele|ATPase, Na+/K+ Transporting, Beta 3 Polypeptide 2 Gene|CD298|FLJ29027|Na, K-ATPase Beta-3 Polypeptide Gene|Sodium-Potassium ATPase Subunit Beta 3 (Non-Catalytic) Gene	Human ATP1B3 wild-type allele is located in the vicinity of 3q23 and is approximately 50 kb in length. This allele, which encodes sodium/potassium-transporting ATPase subunit beta-3 protein, is involved in sodium/potassium ion exchange.			Gene or Genome	
C132089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132089>	C16386	Sodium/Potassium-Transporting ATPase Subunit Beta-3|ATP1B3|ATPB-3|CD298 Antigen|Sodium Pump Subunit Beta-3|Sodium/Potassium-Dependent ATPase Beta-3 Subunit|Sodium/Potassium-Dependent ATPase Subunit Beta-3|Sodium/Potassium-Transporting ATPase Beta-3 Chain	Sodium/potassium-transporting ATPase subunit beta-3 (279 aa, ~32 kDa) is encoded by the human ATP1B3 gene. This protein plays a role in sodium ion import and potassium ion export.			Amino Acid, Peptide, or Protein	
C13208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13208>	C13203	Human Chromosome 13|Chromosome 13|Chromosome 13|Chromosome 13|chr13|chr13|chr13	The designation for each member of the thirteenth largest human autosomal chromosome pair. Chromosome 13 spans about 113 million base pairs and represents between 3.5 and 4% of the total DNA in normal diploid cells.	Chromosome 13		Cell Component	CTDC Value Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C132090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132090>	C28404	USP14 Gene|USP14|USP14|Ubiquitin Specific Peptidase 14 Gene	This gene is involved in ubiquitin recycling.	USP14 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C132091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132091>	C132090	USP14 wt Allele|TGT|TGT, 60-kD Subunit Gene|Ubiquitin Specific Peptidase 14 (tRNA-Guanine Transglycosylase) Gene|Ubiquitin Specific Peptidase 14 wt Allele|Ubiquitin Specific Protease 14 (tRNA-Guanine Transglycosylase) Gene|tRNA-Guanine Transglycosylase, 60-kD Subunit Gene	Human USP14 wild-type allele is located in the vicinity of 18p11.32 and is approximately 56 kb in length. This allele, which encodes ubiquitin carboxyl-terminal hydrolase 14 protein, plays a role in the removal of ubiquitin from protein substrates.	USP14 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132092>	C16481	Ubiquitin Carboxyl-Terminal Hydrolase 14|Deubiquitinating Enzyme 14|EC 3.4.19.12|USP14|Ubiquitin Thioesterase 14|Ubiquitin Thiolesterase 14|Ubiquitin-Specific Processing Protease 14|Ubiquitin-Specific Protease 14|Ubiquitin-Specific-Processing Protease 14	Ubiquitin carboxyl-terminal hydrolase 14 (494 aa, ~56 kDa) is encoded by the human USP14 gene. This protein is involved in the regulation of both ubiquitinated protein degradation and endoplasmic reticulum-associated degradation.	Ubiquitin Carboxyl-Terminal Hydrolase 14		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132093>	C105821	HOXA5 Gene|HOXA5|HOXA5|Homeobox A5 Gene	This gene plays a role in the regulation of gene transcription during embryogenesis.			Gene or Genome	
C132094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132094>	C132093	HOXA5 wt Allele|HOX1|HOX1.3|HOX1C|Homeo Box 1C Gene|Homeo Box A5 Gene|Homeobox 1C Gene|Homeobox A5 wt Allele|Hox-1.3, Mouse, Homolog of Gene	Human HOXA5 wild-type allele is located in the vicinity of 7p15.2 and is approximately 3 kb in length. This allele, which encodes homeobox protein Hox-A5, is involved in transcriptional regulation.			Gene or Genome	
C132095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132095>	C17207	Homeobox Protein Hox-A5|HOXA5|Homeobox Protein HOXA5|Homeobox Protein Hox-1C	Homeobox protein Hox-A5 (270 aa, ~29 kDa) is encoded by the human HOXA5 gene. This protein plays a role in the regulation of gene expression.			Amino Acid, Peptide, or Protein	
C132096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132096>	C131087	Simple Virilizing 21-Hydroxylase Deficiency|Simple Virilizing 21-OHD	A classic form of congenital adrenal hyperplasia that is characterized by severe 21-hydroxylase deficiency, resulting in glucocorticoid and mineralocorticoid deficiency, but without clinically significant salt wasting, and with androgen excess, which causes virilization in female infants.			Disease or Syndrome	NICHD Terminology|Pediatric Endocrinology Terminology
C132097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132097>	C20921	SOSTDC1 Gene|SOSTDC1|SOSTDC1|Sclerostin Domain Containing 1 Gene	This gene is involved in the negative regulation of bone morphogenic protein signaling.			Gene or Genome	
C132098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132098>	C132097	SOSTDC1 wt Allele|CDA019|DAND7|DKFZp564D206|ECTODIN|Sclerostin Domain Containing 1 wt Allele|USAG1|Uterine Sensitization-Associated Gene 1|WISE	Human SOSTDC1 wild-type allele is located in the vicinity of 7p21.2 and is approximately 69 kb in length. This allele, which encodes sclerostin domain-containing protein 1, plays a role in the modulation of bone morphogenic protein-dependent signaling pathways.			Gene or Genome	
C132099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132099>	C18515	Sclerostin Domain-Containing Protein 1|Cystine-Knot Containing Secreted Protein|Ectodermal BMP Inhibitor|Ectodin|USAG-1|Uterine Sensitization-Associated Gene 1 Protein|Uterine Sensitization-Associated Protein-1	Sclerostin domain-containing protein 1 (206 aa, ~23 kDa) is encoded by the human SOSTDC1 gene. This protein is involved in the inhibition of bone morphogenic proteins.			Amino Acid, Peptide, or Protein	
C13209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13209>	C13203	Human Chromosome 14|Chromosome 14|Chromosome 14|Chromosome 14|chr14|chr14|chr14	The designation for each member of the fourteenth largest human autosomal chromosome pair. Chromosome 14 spans about 105 million base pairs and represents between 3 and 3.5% of the total DNA in normal diploid cells.	Chromosome 14		Cell Component	CTDC Value Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C1320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1320>	C593	Recombinant Interleukin 10|B cell-derived T cell growth factor|CSIF|Cytokine Synthesis Inhibitory Factor|IL-10|Interleukin-10	A recombinant cytokine chemically identical to or similar to interleukin-10 (IL-10) secreted by certain leukocytes with immunomodulatory activities. IL-10 is an anti-inflammatory cytokine, capable of inhibiting synthesis of pro-inflammatory cytokines, such as Interferon-gamma, IL-2, IL-3, TNF-alpha, and GM-CSF. However, it also has stimulatory effects on certain T cells, mast cells, and B cells, as well as inducing expression of class II major histocompatibility complex.			Chemical Viewed Functionally	NCI Drug Dictionary Terminology
C132100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132100>	C35869	Mammographically Dense Breast	A mammographic finding of heterogeneously or extremely dense breast composition, as defined by the visually estimated content of fibroglandular-density tissue within the breast, based on updated editions of the American College of Radiology's Breast Imaging Reporting and Data System (BI-RADS).	Mammographically Dense Breast		Finding	CTRP Biomarker Terminology|CTRP Terminology
C132101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132101>	C6924	Acute Myeloid Leukemia with t(10;11)(p12.3;q23.3); MLLT10-KMT2A|Acute Myeloid Leukemia (AML) with t(10;11)(p12.3;q23.3); KMT2A::MLLT10|Acute Myeloid Leukemia (AML) with t(10;11)(p12.3;q23.3); MLL-MLLT10|Acute Myeloid Leukemia with t(10;11)(p12.3;q23.3); MLL-MLLT10|Acute Myeloid Leukemia with t(10;11)(p12.3;q23.3); MLLT10-KMT2A Fusion|Acute Myeloid Leukemia with t(10;11)(p12.3;q23.3); MLLT10-MLL|Acute Myeloid Leukemia with t(10;11)(p12.3;q23.3); MLLT10::KMT2A Fusion	An acute myeloid leukemia characterized by t(10;11)(p12.3;q23.3) resulting in MLLT10-KMT2A gene fusion. It is associated with an unfavorable prognosis.	Acute Myeloid Leukemia with t(10;11)(p12;q23); MLL-MLLT10		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132102>	C186911|C167144	t(10;11)(p12;q23)	A cytogenetic abnormality that refers to the translocation of chromosome 10p12 with chromosome 11q23. It is associated with acute myeloid leukemia in childhood.	t(10;11)(p12;q23)		Cell or Molecular Dysfunction	AML Authorized Value Terminology|AML Minimal Residual Disease Table|AML Molecular Analysis Table|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132103>	C132100	Heterogeneously Dense Breast|Heterogeneously dense|Mammographically Heterogeneously Dense Breast	A mammographic finding of heterogeneously dense breast composition, as defined by the visually estimated content of fibroglandular-density tissue within the breast, based on updated editions of the American College of Radiology's Breast Imaging Reporting and Data System (BI-RADS).	Heterogeneously Dense Breast		Finding	CTRP Biomarker Terminology|CTRP Terminology
C132104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132104>	C132100	Extremely Dense Breast|Extremely dense|Mammographically Extremely Dense Breast	A mammographic finding of extremely dense breast composition, as defined by the visually estimated content of fibroglandular-density tissue within the breast, based on updated editions of the American College of Radiology's Breast Imaging Reporting and Data System (BI-RADS).	Extremely Dense Breast		Finding	CTRP Biomarker Terminology|CTRP Terminology
C132105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132105>	C6924	Acute Myeloid Leukemia with t(6;11)(q27;q23.3); MLLT4-KMT2A|Acute Myeloid Leukemia (AML) with t(6;11)(q27;q23.3); KMT2A-MLLT4|Acute Myeloid Leukemia with t(6;11)(q27;q23); KMT2A-MLLT4|Acute Myeloid Leukemia with t(6;11)(q27;q23); MLL-MLLT4|Acute Myeloid Leukemia with t(6;11)(q27;q23.3); KMT2A-MLLT4|Acute Myeloid Leukemia with t(6;11)(q27;q23.3); KMT2A::MLLT4|Acute Myeloid Leukemia with t(6;11)(q27;q23.3); MLLT4-KMT2A Fusion|Acute Myeloid Leukemia with t(6;11)(q27;q23.3); MLLT4-MLL|Acute Myeloid Leukemia with t(6;11)(q27;q23.3); MLLT4::KMT2A Fusion	An acute myeloid leukemia characterized by t(6;11)(q27;q23.3) resulting in MLLT4-KMT2A gene fusion. It is associated with an unfavorable prognosis.	Acute Myeloid Leukemia with t(6;11)(q27;q23); KMT2A-MLLT4		Neoplastic Process	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology
C132106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132106>	C20923	OR51E2 Gene|OR51E2|OR51E2|Olfactory Receptor Family 51 Subfamily E Member 2 Gene	This gene may play a role in olfactory chemosensation.			Gene or Genome	
C132107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132107>	C132106	OR51E2 wt Allele|OR51E3P|OR52A2|Olfactory Receptor Family 51 Subfamily E Member 2 wt Allele|Olfactory Receptor Family 52 Subfamily A Member 2 Gene|Olfactory Receptor, Family 51, Subfamily E, Member 2 Gene|Olfactory Receptor, Family 51, Subfamily E, Member 3 Pseudogene Gene|Olfactory Receptor, Family 52, Subfamily A, Member 2 Gene|PSGR	Human OR51E2 wild-type allele is located in the vicinity of 11p15.4 and is approximately 18 kb in length. This allele, which encodes olfactory receptor 51E2 protein, may be involved in olfaction.			Gene or Genome	
C132108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132108>	C18239	Olfactory Receptor 51E2|HPRAJ|Olfactory Receptor OR11-16|Prostate Specific G Protein-Coupled Receptor|Prostate Specific G-Protein Coupled Receptor|Prostate-Specific G-Protein Coupled Receptor	Olfactory receptor 51E2 (320 aa, ~35 kDa) is encoded by the human OR51E2 gene. This protein may play a role in binding odorant molecules.			Amino Acid, Peptide, or Protein|Receptor	
C132109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132109>	C224907	Acute Megakaryoblastic Leukemia with CBFA2T3-GLIS2|Acute Megakaryoblastic Leukemia with CBFA2T3::GLIS2|Acute Megakaryoblastic Leukemia with inv(16)(p13.3q24.3); CBFA2T3-GLIS2|Acute Megakaryoblastic Leukemia with inv(16)(p13.3q24.3); CBFA2T3::GLIS2|Acute Myeloid Leukemia with inv(16)(p13.3q24.3); CBFA2T3-GLIS2|Acute Myeloid Leukemia with inv(16)(p13.3q24.3); CBFA2T3::GLIS2	A non-Down syndrome acute megakaryoblastic leukemia that occurs in children. It is associated with CBFA2T3-GLIS2 chimeric oncogene and has an unfavorable prognosis.	Acute Megakaryoblastic Leukemia with CBFA2T3-GLIS2		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13210>	C13203	Human Chromosome 15|Chromosome 15|Chromosome 15|Chromosome 15|chr15|chr15|chr15	The designation for each member of the fifteenth largest human autosomal chromosome pair. Chromosome 15 spans about 106 million base pairs and represents between 3 and 3.5% of the total DNA in normal diploid cells.	Chromosome 15		Cell Component	CTDC Value Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C132110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132110>	C226530|C226401	t(11;12)(p15;p13)	A cytogenetic abnormality that refers to the translocation of chromosome 11p15 with chromosome 12p13. It results in NUP98-KDM5A fusion and is associated with acute megakaryoblastic leukemia in childhood.			Cell or Molecular Dysfunction	
C132111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132111>	C122691	Childhood Acute Megakaryoblastic Leukemia with NUP98-KDM5A|Acute Megakaryoblastic Leukemia with NUP98-KDM5A|Acute Myeloid Leukemia with t(11;12)(p15.5;p13.5); NUP98-KDM5A|Acute Myeloid Leukemia with t(11;12)(p15.5;p13.5); NUP98::KDM5A|Childhood Acute Megakaryoblastic Leukemia with NUP98-KDM5A Fusion|Childhood Acute Megakaryoblastic Leukemia with NUP98::KDM5A|Childhood Acute Megakaryoblastic Leukemia with NUP98::KDM5A Fusion|Childhood Acute Myeloid Leukemia with t(11;12)(p15.5;p13.5); NUP98-KDM5A|Childhood Acute Myeloid Leukemia with t(11;12)(p15.5;p13.5); NUP98::KDM5A	A non-Down syndrome acute megakaryoblastic leukemia that occurs in childhood. It is associated with t(11;12)(p15;p13) which results in the presence of NUP98-KDM5A chimeric oncogene.	Acute Megakaryoblastic Leukemia with NUP98-KDM5A		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132112>	C213143|C155712	Anti-HER2/Auristatin Payload Antibody-drug Conjugate XMT-1522|ADC XMT-1522|Anti-HER2 ADC XMT-1522|XMT-1522	An antibody-drug conjugate (ADC) composed of HT-19, a monoclonal antibody directed against the human epidermal growth factor receptor 2 (ERBB2; HER2), conjugated, via a proprietary biodegradable, hydrophilic polymer backbone and various linkers, to proprietary auristatin-derived payload molecules (about 15 per antibody), with potential antineoplastic activity. Upon administration of anti-HER2/auristatin payload ADC XMT-1522, the antibody moiety targets and binds to a unique epitope in the extracellular domain (ECD) of HER2. Upon internalization, cleavage and release of the cytotoxic molecules, the auristatin-derived molecules bind to tubulin and inhibit its polymerization, which results in G2/M phase arrest and induces apoptosis of HER2-expressing tumor cells. The attachment of multiple auristatin molecules to the backbone enables XMT-1522 to effectively kill tumors that express relatively low amounts of the HER2 protein; therefore, this agent shows increased therapeutic potential in tumors with low HER2 expression compared to other anti-HER2 antibody-based therapies. The polymer-based proprietary platform optimizes delivery of the cytotoxic drug payload and improves drug solubility.	Anti-HER2/Auristatin Payload Antibody-drug Conjugate XMT-1522		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C132113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132113>	C20709	NR1H3 Gene|NR1H3|NR1H3|Nuclear Receptor Subfamily 1 Group H Member 3 Gene	This gene is involved in the regulation of retinoid responses and cholesterol homeostasis.			Gene or Genome	
C132114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132114>	C132113	NR1H3 wt Allele|LX Receptor, Alpha Gene|LXR-a|LXRA|Liver X Receptor, Alpha Gene|Nuclear Receptor Subfamily 1 Group H Member 3 wt Allele|Nuclear Receptor Subfamily 1, Group H, Member 3 Gene|RLD-1	Human NR1H3 wild-type allele is located in the vicinity of 11p11.2 and is approximately 21 kb in length. This allele, which encodes oxysterols receptor LXR-alpha protein, plays a role in both cholesterol homeostasis and the expression of retinoid-responsive genes.			Gene or Genome	
C132115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132115>	C128275	Oxysterols Receptor LXR-Alpha|Liver X Nuclear Receptor Alpha|Liver X Receptor Alpha|Liver X Receptor-Alpha|NR1H3|Nuclear Receptor Subfamily 1 Group H Member 3	Oxysterols receptor LXR-alpha (447 aa, ~50 kDa) is encoded by the human NR1H3 gene. This protein is involved in transcriptional regulation and cholesterol homeostasis.			Amino Acid, Peptide, or Protein|Receptor	
C132116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132116>	C25873	NEK1 Gene|NEK1|NEK1|NIMA Related Kinase 1 Gene	This gene plays a role in protein phosphorylation and the modulation of cilia assembly and cell division.			Gene or Genome	
C132117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132117>	C132116	NEK1 wt Allele|KIAA1901|NIMA (Never In Mitosis Gene A)-Related Kinase 1 Gene|NIMA Related Kinase 1 wt Allele|NY-REN-55|SRPS2|SRPS2A|SRTD6	Human NEK1 wild-type allele is located in the vicinity of 4q33 and is approximately 219 kb in length. This allele, which encodes serine/threonine-protein kinase Nek1 protein, is involved in cell division, cilia assembly and protein phosphorylation. Mutation of the gene is associated with short-rib thoracic dysplasia 6 with or without polydactyly.			Gene or Genome	
C132118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132118>	C17325	Serine/Threonine-Protein Kinase Nek1|EC 2.7.11.1|NIMA-Related Kinase 1|Never In Mitosis A-Related Kinase 1|NimA-Related Protein Kinase 1|Renal Carcinoma Antigen NY-REN-55	Serine/threonine-protein kinase Nek1 (1258 aa, ~143 kDa) is encoded by the human NEK1 gene. This protein plays a role in cilia assembly, protein phosphorylation and cell division.			Amino Acid, Peptide, or Protein|Enzyme	
C132119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132119>	C70700	Nasal Swab|Nasal Swab Test|Nasopharyngeal Swab|Nasopharyngeal Swab Test	A method used to collect biological material from within the nasal passages. A cotton swab is inserted into the nasal opening and rotated against the anterior nasal mucosa and then withdrawn.	Nasal Swab		Laboratory Procedure	
C13211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13211>	C13203	Human Chromosome 16|Chromosome 16|Chromosome 16|Chromosome 16|chr16|chr16|chr16	The designation for each member of the sixteenth largest human autosomal chromosome pair. Chromosome 16 spans about 90 million base pairs and represents just under 3% of the total DNA in normal diploid cells.	Chromosome 16		Cell Component	CTDC Value Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C132120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132120>	C54362	GON4L Gene|GON4L|GON4L|Gon-4 Like Gene	This gene may play a role in the negative regulation of gene transcription.			Gene or Genome	
C132121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132121>	C132120	GON4L wt Allele|FLJ20203|GON-4|GON4|Gon-4 Homolog (C.elegans) Gene|Gon-4 Like wt Allele|Gon-4-Like (C. elegans) Gene|KIAA1606|YARP	Human GON4L wild-type allele is located in the vicinity of 1q22 and is approximately 110 kb in length. This allele, which encodes GON-4-like protein, is involved in transcriptional repression.			Gene or Genome	
C132122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132122>	C26199	GON-4-Like Protein|GON-4 Homolog|GON4-Like Protein|GON4L|Gon-4 Homolog|YY1AP Related Protein|YY1AP-Related Protein1	GON-4-like protein (2241 aa, ~249 kDa) is encoded by the human GON4L gene. This protein plays a role in the repression of gene transcription.			Amino Acid, Peptide, or Protein	
C132123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132123>	C25942	POLE2 Gene|DNA Polymerase Epsilon 2, Accessory Subunit Gene|POLE2|POLE2	This gene is involved in both chromosomal DNA replication and DNA repair.			Gene or Genome	
C132124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132124>	C132123	POLE2 wt Allele|DNA Polymerase Epsilon 2, Accessory Subunit wt Allele|DPE2|Polymerase (DNA Directed), Epsilon 2 (p59 Subunit) Gene|Polymerase (DNA Directed), Epsilon 2, Accessory Subunit Gene|Polymerase (DNA) Epsilon 2, Accessory Subunit Gene|Polymerase, DNA, Epsilon-2 Gene	Human POLE2 wild-type allele is located in the vicinity of 14q21.3 and is approximately 45 kb in length. This allele, which encodes DNA polymerase epsilon subunit 2 protein, plays a role in DNA-dependent replication.			Gene or Genome	
C132125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132125>	C16512	DNA Polymerase Epsilon Subunit 2|DNA Polymerase Epsilon Subunit B|DNA Polymerase II Subunit 2|EC 2.7.7.7|POLE2	DNA polymerase epsilon subunit 2 (527 aa, ~60 kDa) is encoded by the human POLE2 gene. This protein is involved in the replication and repair of chromosomal DNA.			Amino Acid, Peptide, or Protein|Enzyme	
C132126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132126>	C70700	Nasal Wash and Collection|Nasal Lavage|Nasal Wash|Nasopharyngeal Lavage|Nasopharyngeal Wash	A method used to collect biological material from within the nasal passages. A saline solution is introduced into the nasal passages, retained briefly, and then expelled.	Nasal Wash and Collection		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C132127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132127>	C25943	GARS1 Gene|GARS|GARS1|GARS1|Glycyl-tRNA Synthetase 1 Gene	This gene plays a role in the attachment of glycine to the appropriate tRNA.			Gene or Genome	
C132128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132128>	C132127	GARS1 wt Allele|CMT2D|Charcot-Marie-Tooth Neuropathy 2D Gene|Charcot-Marie-Tooth Neuropathy, Neuronal Type, D Gene|DSMAV|GARS|GlyRS|Glycine tRNA Ligase Gene|Glycyl-tRNA Synthetase 1 wt Allele|Glycyl-tRNA Synthetase Gene|HMN5|SMAD1|SMAJI	Human GARS1 wild-type allele is located in the vicinity of 7p14.3 and is approximately 39 kb in length. This allele, which encodes glycine-tRNA ligase protein, is involved in the synthesis of glycyl-tRNA. Mutation of the gene is associated with type 2D Charcot-Marie-Tooth disease and distal hereditary motor neuropathy, type Va.			Gene or Genome	
C132129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132129>	C16796	Glycine-tRNA Ligase|AP-4-A Synthetase|Ap4A Synthetase|Diadenosine Tetraphosphate Synthetase|EC 6.1.1.14|EJ ANTIGEN|GARS|GARS1|GlyRS|GlyRS|Glycine tRNA Ligase|Glycine--tRNA Ligase|Glycine—tRNA Ligase|Glycyl-tRNA Synthetase|Glycyl-tRNA Synthetase|Glycyl-tRNA Synthetase 1	Glycine-tRNA ligase (739 aa, ~83 kDa) is encoded by the human GARS1 gene. This protein plays a role in tRNA aminoacylation.			Amino Acid, Peptide, or Protein|Enzyme	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C13212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13212>	C13203	Human Chromosome 17|Chromosome 17|Chromosome 17|Chromosome 17|chr17|chr17|chr17	The designation for each member of the seventeenth largest human autosomal chromosome pair. Chromosome 17 spans more than 81 million base pairs and represents between 2.5 and 3% of the total DNA in normal diploid cells.	Chromosome 17		Cell Component	CTDC Value Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C132130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132130>	C25873	LIMK2 Gene|LIM Domain Kinase 2 Gene|LIMK2|LIMK2	This gene is involved in serine/threonine phosphorylation of protein substrates.			Gene or Genome	
C132131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132131>	C132130	LIMK2 wt Allele|LIM Domain Kinase 2 wt Allele	Human LIMK2 wild-type allele is located in the vicinity of 22q12.2 and is approximately 68 kb in length. This allele, which encodes LIM domain kinase 2 protein, plays a role in serine/threonine phosphorylation.			Gene or Genome	
C132132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132132>	C17325	LIM Domain Kinase 2|EC 2.7.11.1|LIMK-2|LIMK2	LIM domain kinase 2 (638 aa, ~72 kDa) is encoded by the human LIMK2 gene. This protein is involved in the phosphorylation of serines or threonines in protein substrates.			Amino Acid, Peptide, or Protein|Enzyme	
C132133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132133>	C261	Hachimycin|HACHIMYCIN|Trichomycin				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132134>	C54362	WDR5 Gene|WD Repeat Domain 5 Gene|WDR5|WDR5	This gene plays a role in the regulation of histone modification.			Gene or Genome	Pediatric Oncology Biomarkers/Targets Associated with Other Relevant Evidence
C132135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132135>	C132134	WDR5 wt Allele|BIG-3|BIG3|BMP2-Induced 3-kb Gene|BMP2-Induced Gene|CFAP89|SWD3|SWD3, Set1c WD40 Repeat Protein, Homolog (S. cerevisiae) 2 Gene|Set1c WD40 Repeat Protein, Homolog Gene|WD Repeat Domain 5 wt Allele	Human WDR5 wild-type allele is located in the vicinity of 9q34.2 and is approximately 25 kb in length. This allele, which encodes WD repeat-containing protein 5, is involved in the acetylation and methylation of histones.			Gene or Genome	
C132136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132136>	C26199	WD Repeat-Containing Protein 5|BMP2-Induced 3-kb Gene Protein|Cilia and Flagella Associated Protein 89|WDR5	WD repeat-containing protein 5 (334 aa, ~37 kDa) is encoded by the human WDR5 gene. This protein plays a role in post-translational modification of histone proteins.			Amino Acid, Peptide, or Protein	Pediatric Oncology Biomarkers/Targets Associated with Other Relevant Evidence
C132137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132137>	C245	Tutocaine|4-(Dimethylamino)-3-methyl-2-butanol p-Aminobenzoate (Ester)|TUTOCAINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132138>	C1323	Fenoprofen Sodium|FENOPROFEN SODIUM|Fenoprofen Na|Propionic Acid, 2-(3-Phenoxyphenyl)-, Sodium Salt, (+-)-|d,l-2-(3-Phenoxyphenyl)propionic Acid, Sodium Salt				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132139>	C245	Tutocaine Hydrochloride|4-(Dimethylamino)-3-methyl-2-butanol p-Aminobenzoate (Ester) Hydrochloride|TUTOCAINE HYDROCHLORIDE|Tutocaine HCl				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C13213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13213>	C13203	Human Chromosome 18|Chromosome 18|Chromosome 18|chr18|chr18|chr18	The designation for each member of the eighteenth largest human autosomal chromosome pair. Chromosome 18 spans about 76 million base pairs and represents about 2.5% of the total DNA in normal diploid cells.			Cell Component	CTDC Value Terminology|GDC Terminology|GDC Value Terminology
C132140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132140>	C25997	SH3KBP1 Gene|SH3 Domain Containing Kinase Binding Protein 1 Gene|SH3KBP1|SH3KBP1	This gene is involved in the regulation of protein-protein interactions in signaling pathways.			Gene or Genome	
C132141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132141>	C132140	SH3KBP1 wt Allele|CD2BP3|CIN85|Cbl-Interacting Protein, 85-kD Gene|GIG10|HSB-1|HSB1|MIG18|SH3 Domain Containing Kinase Binding Protein 1 wt Allele	Human SH3KBP1 wild-type allele is located in the vicinity of Xp22.12 and is approximately 354 kb in length. This allele, which encodes SH3 domain-containing kinase-binding protein 1, plays a role in adaptor signaling protein activity.			Gene or Genome	
C132142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132142>	C261	Terdecamycin|1-Pipeprazinecarboxylic Acid, 4-Methyl-, 7-Ester with (-)-N-(1S,2R,3E,5E,7S,9E,11E,13S,15R,19R)-7,13-dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo(13.2.2)nonadeca-3,5,9,11-tetraen-2-yl)pyruvamide|TERDECAMYCIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132143>	C26231	SH3 Domain-Containing Kinase-Binding Protein 1|C-Cbl-Interacting Protein|CD2-Binding Protein 3|CD2BP3|Cbl-Interacting Protein of 85 kDa|HSB-1|Human Src Family Kinase-Binding Protein 1|SH3 Domain Containing Kinase Binding Protein 1|SH3-Domain Kinase Binding Protein 1|SH3KBP1|Src Family Kinase-Binding Protein 1|Src-Related Kinase Binding Protein-1	SH3 domain-containing kinase-binding protein 1 (665 aa, ~73 kDa) is encoded by the human SH3KBP1 gene. This protein is involved in the modulation of protein-protein interactions.			Amino Acid, Peptide, or Protein	
C132144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132144>	C66884|C47794	Roxindole Hydrochloride|1H-Indol-5-ol, 3-(4-(3,6-dihydro-4-phenyl-1(2H)-pyridinyl)butyl)-, Monohydrochloride|ROXINDOLE HYDROCHLORIDE				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132145>	C281	Pocapavir|4-Amino-1-(4-C-Azido-2',3',5'-Tri-O-(2-Methylpropanoyl)-Beta-D-Ribofuranosyl)Pyrimidin- 2(1H)-One|Benzene, 1-((2-Chloro-4-methoxyphenoxy)methyl)-4-((2,6-dichlorophenoxy)methyl)-|POCAPAVIR|Sch-48973|V-073				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132146>	C9305|C9292	Malignant Solid Neoplasm|Malignant Solid Tumor|Malignant Solid Tumor	A malignant neoplasm arising from tissues that do not include fluid areas. Representative examples include carcinomas and sarcomas. Hematopoietic and lymphoid tissue malignancies are not considered solid neoplasms.	Malignant Solid Neoplasm		Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C132147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132147>	C3158|C148331	Unresectable Leiomyosarcoma	A leiomyosarcoma which is not amenable to surgical resection.	Unresectable Leiomyosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132148>	C3194|C148331	Unresectable Liposarcoma	A liposarcoma which is not amenable to surgical resection.	Unresectable Liposarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132149>	C25804	PADI2 Gene|PADI2|PADI2|Peptidyl Arginine Deiminase 2 Gene	This gene plays a role in post-translational deimination of proteins.			Gene or Genome	
C13214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13214>	C13203	Human Chromosome 19|Chromosome 19|Chromosome 19|Chromosome 19|chr19|chr19|chr19	The designation for each member of the nineteenth largest human autosomal chromosome pair. Chromosome 19 spans more than 63 million base pairs and represents between 2 and 2.5% of the total DNA in normal diploid cells.	Chromosome 19		Cell Component	CTDC Value Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C132150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132150>	C132149	PADI2 wt Allele|KIAA0994|PAD-H19|PAD2|PDI2|Peptidyl Arginine Deiminase 2 wt Allele|Peptidyl Arginine Deiminase, Type II Gene|Peptidylarginine Deiminase, Type II Gene	Human PADI2 wild-type allele is located in the vicinity of 1p36.13 and is approximately 53 kb in length. This allele, which encodes protein-arginine deiminase type-2 protein, is involved in arginine residue metabolism.			Gene or Genome	
C132151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132151>	C16701	Protein-Arginine Deiminase Type-2|EC 3.5.3.15|PAD-H19|PADI2|Peptidyl Arginine Deiminase 2|Peptidylarginine Deiminase II|Protein-Arginine Deiminase Type II	Protein-arginine deiminase type-2 (665 aa, ~76 kDa) is encoded by the human PADI2 gene. This protein plays a role in the conversion of arginine residues to citrulline.			Amino Acid, Peptide, or Protein|Enzyme	
C132152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132152>	C25943	WARS2 Gene|Tryptophanyl tRNA Synthetase 2, Mitochondrial Gene|WARS2|WARS2	This gene is involved in tRNA maturation.			Gene or Genome	
C132153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132153>	C132152	WARS2 wt Allele|NEMMLAS|PKDYS3|TrpRS|Tryptophan tRNA Ligase 2, Mitochondrial Gene|Tryptophanyl tRNA Synthetase 2, Mitochondrial wt Allele|Tryptophanyl-tRNA Synthetase 2, Mitochondrial Gene|mtTrpRS	Human WARS2 wild-type allele is located in the vicinity of 1p12 and is approximately 40 kb in length. This allele, which encodes tryptophan-tRNA ligase, mitochondrial protein, plays a role in tRNA aminoacylation.			Gene or Genome	
C132154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132154>	C16796	Tryptophan-tRNA Ligase, Mitochondrial|(Mt)TrpRS|EC 6.1.1.2|Mitochondrial TrpRS|TrpRS|Tryptophan tRNA Ligase 2, Mitochondrial|Tryptophan--tRNA Ligase, Mitochondrial|Tryptophanyl-tRNA Synthetase|Tryptophanyl-tRNA Synthetase 2|Tryptophanyl-tRNA Synthetase, Mitochondrial|Tryptophan—tRNA Ligase, Mitochondrial|WARS2	Tryptophan-tRNA ligase, mitochondrial (360 aa, ~110 kDa) is encoded by the human WARS2 gene. This protein is involved in the synthesis of tryptophyl-tRNA.			Amino Acid, Peptide, or Protein|Enzyme	
C132155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132155>	C21295	VSIG10L Gene|V-Set and Immunoglobulin Domain Containing 10 Like Gene|VSIG10L|VSIG10L	This gene may play a role in intercellular junction formation.			Gene or Genome	
C132156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132156>	C132155	VSIG10L wt Allele|V-Set and Immunoglobulin Domain Containing 10 Like wt Allele	Human VSIG10L wild-type allele is located in the vicinity of 19q13.41 and is approximately 11 kb in length. This allele, which encodes V-set and immunoglobulin domain-containing protein 10-like, may be involved in cell-cell adhesion. Mutation or loss of expression of the gene may be associated with neoplastic or pre-neoplastic diseases.			Gene or Genome	
C132157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132157>	C17728	V-Set and Immunoglobulin Domain-Containing Protein 10-Like|V-Set and Immunoglobulin Domain Containing 10 Like|V-Set and Immunoglobulin Domains-Containing Protein 10-Like|VSIG10-Like Protein|VSIG10L	V-set and immunoglobulin domain-containing protein 10-like (867 aa, ~92 kDa) is encoded by the human VSIG10L gene. This protein may play a role in cell-cell junction formation.			Amino Acid, Peptide, or Protein	
C132158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132158>	C19540	PCAT1 Gene|PCAT1|PCAT1|Prostate Cancer Associated Transcript 1 (Non-Protein Coding) Gene	This gene may be involved in cancer progression.			Gene or Genome	
C132159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132159>	C132158	PCAT1 wt Allele|PCA1|PCAT-1|Prostate Cancer Associated Transcript 1 (Non-Protein Coding) wt Allele|Prostate Cancer Associated Transcript 1, Noncoding Gene	Human PCAT1 wild-type allele is located in the vicinity of 8q24.21 and is approximately 174 kb in length. This allele, which encodes prostate cancer associated transcript 1 non-coding RNA, may be involved in carcinogenesis.			Gene or Genome	
C13215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13215>	C13203	Human Chromosome 2|Chromosome 2|Chromosome 2|Chromosome 2|chr2|chr2|chr2	The designation for each member of the second largest human autosomal chromosome pair. Chromosome 2 spans more than 237 million base pairs and represents almost 8% of the total DNA in normal diploid cells.	Chromosome 2		Cell Component	CTDC Value Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C132160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132160>	C88924	Prostate Cancer Associated Transcript 1|Long Non-Coding RNA PCAT-1|Long Noncoding RNA PCAT-1|PCA1|PCAT-1|PCAT1	Prostate cancer associated transcript 1 (~2 kb) is encoded by the human PCAT1 gene. This non-coding RNA may play a role in tumorigenesis.			Nucleic Acid, Nucleoside, or Nucleotide	
C132161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132161>	C20194	DINOL Gene|DINO|DINOL|DINOL|Damage Induced Long Noncoding RNA Gene	This gene plays a role in p53-dependent responses to DNA damage.			Gene or Genome	
C132162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132162>	C132161	DINOL wt Allele|DINO|DNA Damage, p53 is Stabilized and p53-Responsive Gene|Damage Induced Long Noncoding RNA wt Allele|Damage Induced Noncoding RNA Gene|Damage-Induced Non-Coding RNA Gene	Human DINOL wild-type allele is located in the vicinity of 6p21.2 and is approximately 1 kb in length. This allele, which encodes damage induced long noncoding RNA, plays a role in stabilization of cellular tumor antigen p53.			Gene or Genome	
C132163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132163>	C88924	Damage Induced Long Noncoding RNA|DINO|DINOL|Damage Induced Noncoding RNA|Damage Induced Noncoding lncRNA|Damage-Induced Long Non-Coding RNA|Damage-Induced Long Noncoding RNA|Damage-Induced Non-Coding RNA|Damage-Induced Noncoding RNA|lncRNA DINO	Damage induced long noncoding RNA (~1 kb) is encoded by the human DINOL gene. This non-coding RNA is involved in p53-dependent gene expression, cell cycle arrest, and apoptosis in response to DNA damage.			Nucleic Acid, Nucleoside, or Nucleotide	
C132164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132164>	C52647	National Cancer Institute Community Oncology Research Program|NCI Community Oncology Research Program|NCORP	A national network of investigators, cancer care providers, academic institutions, and other organizations that conduct multi-site cancer clinical trials and studies in diverse populations in community-based healthcare systems across the United States and Puerto Rico.			Research Activity	
C132165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132165>	C18640	Immune Checkpoint Functional Assay|Checkpoint Signaling Assay|Immune Checkpoint Profile	Various bioassays designed to measure levels of key regulatory molecules, such as PD-1 (PDCD1), CTLA-4, GITR (TNFRSF18), 4-1BB (TNFRSF9), OX40 (TNFRSF4), and TIGIT, that mediate immune checkpoint receptor pathways or assays to measure proliferation, expression of cell surface activation markers, and cytokine expression induced by these pathways.			Laboratory Procedure	
C132166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132166>	C2152|C129825	Inavolisib|GDC 0077|GDC-0077|GDC0077|INAVOLISIB|Itovebi|PI3K Inhibitor GDC0077|RG 6114|RG-6114|RG6114|RO 7113755	An orally available inhibitor of phosphatidylinositol 3-kinase (PI3K), with potential antineoplastic activity. Upon administration, inavolisib binds to and inhibits various members of the PI3K family, including activating mutations in the catalytic alpha isoform PIK3CA. PI3K inhibition prevents the activation of the PI3K-mediated signaling pathway and results in the inhibition of growth and survival of PI3K-overexpressing tumor cells. Dysregulation of the PI3K signaling pathway is frequently associated with tumorigenesis and tumor resistance to a variety of antineoplastic agents and radiotherapy. PIK3CA, which encodes the p110-alpha catalytic subunit of the class I PI3K, is frequently mutated in a variety of cancer cell types and plays a key role in cancer cell growth and invasion.	Inavolisib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C132167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132167>	C20194	ASB2 Gene|ASB2|ASB2|Ankyrin Repeat and SOCS Box Containing 2 Gene	This gene is involved in substrate recognition of ubiquitin ligase complexes.			Gene or Genome	
C132168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132168>	C132167	ASB2 wt Allele|ASB-2|Ankyrin Repeat and SOCS Box Containing 2 wt Allele|Ankyrin Repeat and SOCS Box-Containing 2 Gene	Human ASB2 wild-type allele is located in the vicinity of 14q32.12 and is approximately 43 kb in length. This allele, which encodes ankyrin repeat and SOCS box protein 2, plays a role in promoting the ubiquitination of substrate proteins.			Gene or Genome	
C132169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132169>	C95242	Ankyrin Repeat and SOCS Box Protein 2|ASB-2|Ankyrin Repeat and SOCS Box-Containing Protein 2|Ankyrin Repeat- and SOCS Box-Containing Protein 2	Ankyrin repeat and SOCS box protein 2 (587 aa, ~65 kDa) is encoded by the human ASB2 gene. This protein is involved in the recognition of substrates by the Elongin-Cullin-SOCS-box protein (ECS) E3 ubiquitin-protein ligase complex.			Amino Acid, Peptide, or Protein	
C13216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13216>	C13203	Human Chromosome 20|Chromosome 20|Chromosome 20|Chromosome 20|chr20|chr20|chr20	The designation for each member of the third smallest human autosomal chromosome pair. Chromosome 20 spans around 63 million base pairs and represents between 2 and 2.5% of the total DNA in normal diploid cells.	Chromosome 20		Cell Component	CTDC Value Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C132170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132170>	C21295	MB21D2 Gene|MB21D2|MB21D2|MB21D2|Mab-21 Domain Containing 2 Gene	This gene plays a role in protein-protein interactions.			Gene or Genome	GDC Terminology|GDC Value Terminology
C132171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132171>	C132170	MB21D2 wt Allele|C3orf59|Chromosome 3 Open Reading Frame 59 Gene|Mab-21 Domain Containing 2 wt Allele	Human MB21D2 wild-type allele is located in the vicinity of 3q29 and is approximately 121 kb in length. This allele, which encodes protein MB21D2, may be involved in adherens junction functions.			Gene or Genome	
C132172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132172>	C17728	Protein MB21D2|Mab-21 Domain-Containing Protein 2	Protein MB21D2 (491 aa, ~56 kDa) is encoded by the human MB21D2 gene. This protein may play a role in cadherin-dependent cell-cell adhesion.			Amino Acid, Peptide, or Protein	
C132174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132174>	C28533	SPNS2 Gene|SPNS2|SPNS2|Sphingolipid Transporter 2 Gene	This gene plays a role in lipid transport.			Gene or Genome	
C132175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132175>	C132174	SPNS2 wt Allele|Sphingolipid Transporter 2 wt Allele|Spinster Homolog 2 (Drosophila) Gene|Spinster, Drosophila, Homolog of, 2 Gene	Human SPNS2 wild-type allele is located in the vicinity of 17p13.2 and is approximately 41 kb in length. This allele, which encodes protein spinster homolog 2, is involved in sphingolipid transport. Mutation of the gene may be involved in early onset progressive hearing loss.			Gene or Genome	
C132176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132176>	C16386	Protein Spinster Homolog 2|SPNS2 Protein	Protein spinster homolog 2 (549 aa, ~58 kDa) is encoded by the human SPNS2 gene. This protein plays a role in the transport of sphingosine 1-phosphate (S1P).			Amino Acid, Peptide, or Protein	
C132177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132177>	C54444	BCAR4 Gene|BCAR4|BCAR4|Breast Cancer Anti-Estrogen Resistance 4 (Non-Protein Coding) Gene	This gene may involved in breast cancer metastasis and resistance to antiestrogens.			Gene or Genome	
C132178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132178>	C132177	BCAR4 wt Allele|Breast Cancer Anti-Estrogen Resistance 4 (Non-Protein Coding) wt Allele|Breast Cancer Anti-Estrogen Resistance 4 Gene|Breast Cancer Antiestrogen Resistance 4 Gene|hCG_1814062	Human BCAR4 wild-type allele is located in the vicinity of 16p13.13 and is approximately 9 kb in length. This allele, which encodes breast cancer anti-estrogen resistance 4 long non-coding RNA, plays a role in both metastasis and antiestrogen resistance in breast carcinoma. Focal amplification and chromosomal rearrangement involving the gene may be associated with cervical cancer.			Gene or Genome	
C132179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132179>	C88924	Breast Cancer Anti-Estrogen Resistance 4 Long Non-Coding RNA|BCAR4 LincRNA|BCAR4 LncRNA|Breast Cancer Anti-Estrogen Resistance 4 Long Noncoding RNA|Breast Cancer Antiestrogen Resistance 4 Long Non-Coding RNA|Breast Cancer Antiestrogen Resistance 4 Long Noncoding RNA	Breast cancer anti-estrogen resistance 4 long non-coding RNA (~1.3 kb) is encoded by the human BCAR4 gene. This non-coding RNA is involved in both metastasis and antiestrogen resistance in breast carcinoma.			Nucleic Acid, Nucleoside, or Nucleotide	
C13217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13217>	C13203	Human Chromosome 21|Chromosome 21|Chromosome 21|Chromosome 21|chr21|chr21|chr21	The designation for each member of the second smallest human autosomal chromosome pair. Chromosome 21 spans around 47 million nucleotides and represents about 1.5% of the total DNA in normal diploid cells.	Chromosome 21		Cell Component	CTDC Value Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C132180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132180>	C20194	SNHG5 Gene|SNHG5|SNHG5|Small Nucleolar RNA Host Gene 5 Gene	This gene plays a role in small nucleolar RNA synthesis.			Gene or Genome	
C132181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132181>	C132180	SNHG5 wt Allele|C6orf160|Chromosome 6 Open Reading Frame 160 Gene|LINC00044|MGC16362|NCRNA00044|Small Nucleolar RNA Host Gene (Non-Protein Coding) 5 Gene|Small Nucleolar RNA Host Gene 5 (Non-Protein Coding) Gene|Small Nucleolar RNA Host Gene 5 wt Allele|U50 Host Gene|U50/U50B Host Gene|U50HG|bA33E24.2	Human SNHG5 wild-type allele is located in the vicinity of 6q14.3 and is approximately 18 kb in length. This allele, which encodes long intergenic non-protein coding RNA 44, is involved in the synthesis of small nucleolar RNAs U50 and U50'. Translocation t(3;6)(q27;q15) involving the SNHG5 and BCL6 genes is associated with B-cell lymphoma.			Gene or Genome	
C132182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132182>	C88924	Long Intergenic Non-Protein Coding RNA 44|LINC00044|NCRNA00044|Non-Protein Coding RNA 44|SNHG5 LincRNA|Small Nucleolar RNA Host Gene 5 LincRNA|Small Nucleolar RNA Host Gene 5 Long Non-Coding RNA|U50 Host LincRNA	Long intergenic non-protein coding RNA 44 (~0.5 kb) is encoded by the human SNHG5 gene. This non-coding RNA plays a role in the synthesis of small nucleolar RNAs U50 and U50'.			Nucleic Acid, Nucleoside, or Nucleotide	
C132183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132183>	C20194	PHLDB3 Gene|PHLDB3|PHLDB3|Pleckstrin Homology Like Domain Family B Member 3 Gene	This gene may be involved in enzyme binding.			Gene or Genome	
C132184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132184>	C132183	PHLDB3 wt Allele|FLJ40193|Pleckstrin Homology Like Domain Family B Member 3 wt Allele|Pleckstrin Homology-Like Domain, Family B, Member 3 Gene	Human PHLDB3 wild-type allele is located in the vicinity of 19q13.31 and is approximately 31 kb in length. This allele, which encodes pleckstrin homology-like domain family B member 3 protein, may play a role in protein-protein interactions.			Gene or Genome	
C132185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132185>	C18466	Pleckstrin Homology-Like Domain Family B Member 3|PHLDB3	Pleckstrin homology-like domain family B member 3 (640 aa, ~72 kDa) is encoded by the human PHLDB3 gene. This protein may be involved in interacting with enzymes.			Amino Acid, Peptide, or Protein	
C132186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132186>	C25775	ACKR5 Gene|ACKR5|ACKR5|Atypical Chemokine Receptor 5 Gene|GPR182	This gene may play a role in the modulation of chemokine-mediated signaling.			Gene or Genome	
C132187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132187>	C132186	ACKR5 wt Allele|7TMR|ADMR|AM-R|AMR|Adrenomedullin Receptor Gene|Atypical Chemokine Receptor 5 wt Allele|G Protein-Coupled Receptor 182 Gene|G10D|GPR182|L1-R|gamrh|hrhAMR	Human ACKR5 wild-type allele is located in the vicinity of 12q13.3 and is approximately 4 kb in length. This allele, which encodes G-protein coupled receptor 182 protein, may be involved in chemokine scavenger receptor activity.			Gene or Genome	
C132188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132188>	C18239	G-Protein Coupled Receptor 182|ACKR5|G Protein-Coupled Receptor 182|Gpr182	G-protein coupled receptor 182 (404 aa, ~45 kDa) is encoded by the human ACKR5 gene. This protein may play a role in chemokine homeostasis and immune regulation.			Amino Acid, Peptide, or Protein|Receptor	
C132189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132189>	C25870	PORCN Gene|PORCN|PORCN|Porcupine Homolog (Drosophila) Gene	This gene is involved in the lipidation of Wnt family proteins.	PORCN Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C13218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13218>	C13203	Human Chromosome 22|Chromosome 22|Chromosome 22|Chromosome 22|chr22|chr22|chr22	The designation for each member of the smallest human autosomal chromosome pair. Chromosome 22 spans about 49 million base pairs and represents between 1.5 and 2% of the total DNA in normal diploid cells.	Chromosome 22		Cell Component	CTDC Value Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C132190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132190>	C132189	PORCN wt Allele|DHOF|Dermal Hypoplasia, Focal Gene|FODH|MG61|PORC|PPN|Porcupine Homolog (Drosophila) wt Allele|Porcupine, Drosophila, Homolog of Gene|por	Human PORCN wild-type allele is located in the vicinity of Xp11.23 and is approximately 12 kb in length. This allele, which encodes protein-serine O-palmitoleoyltransferase porcupine protein, plays a role in post-translational modification of Wnt family proteins. Mutation of the gene is associated with focal dermal hypoplasia.	PORCN wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132191>	C16259	Protein-Serine O-Palmitoleoyltransferase Porcupine|EC 2.3.1.-|PORCN|Probable Protein-Cysteine N-Palmitoyltransferase Porcupine|Protein MG61	Protein-serine O-palmitoleoyltransferase porcupine (461 aa, ~52 kDa) is encoded by the human PORCN gene. This protein is involved in serine palmitoylation of Wnt family proteins.	Protein-Serine O-Palmitoleoyltransferase Porcupine		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132192>	C128057	Pacmilimab|CX 072|CX-072|PACMILIMAB|PD-L1 Probody Therapeutic CX-072|Probody CX-072	A recombinant antibody prodrug composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) programmed cell death 1 ligand 1 (PD-L1; B7-H1; CD274) that is linked to a proprietary masking peptide through a protease-cleavable linker on the amino terminus of the light chain domain of the antibody, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of pacmilimab, the linkage system is stable in the circulation and, upon extravasation into the tumor microenvironment, the peptide mask is cleaved by tumor-associated proteases. These proteases are present in high concentrations and aberrantly activated in the tumor microenvironment, while expressed as inactive forms, at much lower concentrations, in normal, healthy tissue. Protease cleavage of the linker enables binding of the unmasked, fully active monoclonal antibody moiety of CX-072 to PD-L1, which is over expressed on certain cancer cells. This blocks the binding to and activation of its receptor programmed cell death 1 (PD-1) on T-lymphocytes, thereby enhancing the T-cell-mediated anti-tumor immune response and reversing PD-L1/PD-1-mediated T-cell suppression. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. Compared to the unmodified PD-L1 antibody, peptide masking of CX-072 minimizes binding to PD-L1 in normal tissues, thereby decreasing autoimmune-based side effects while retaining anti-tumor activity.	Pacmilimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C132193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132193>	C134528	Feline Lymphoma	A lymphoma that occurs in cats. It is associated with exposure to feline leukemia virus and feline immunodeficiency virus.			Neoplastic Process	Cellosaurus Disease Terminology
C132194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132194>	C60679	Rat Pituitary Gland Neoplasm|Rat Pituitary Gland Tumor	A benign or malignant neoplasm that affects the pituitary gland of a rat.			Neoplastic Process	Cellosaurus Disease Terminology
C132195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132195>	C53543|C28193	Galloway-Mowat Syndrome|GAMOS	An autosomal recessive neurodegenerative condition caused by mutation(s) in the WDR73 gene, encoding WD repeat-containing protein 73. It is characterized by microcephaly and severely delayed psychomotor development.			Disease or Syndrome	Cellosaurus Disease Terminology
C132196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132196>	C53543	Carboxypeptidase N Deficiency	An autosomal recessive condition caused by mutation(s) in the CPN1 gene, encoding carboxypeptidase N catalytic chain. It may be characterized by episodic angioedema, chronic urticaria, asthma and/or allergic hypersensitivity.			Disease or Syndrome	Cellosaurus Disease Terminology
C132197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132197>	C173737|C173358|C173160	Past Seven Days Frequency of Feeling Urge to Urinate All of a Sudden Question|In the past 7 days, how often did you feel a sudden need to urinate|In the past 7 days, how often did you feel an urge to urinate all of a sudden|Past Seven Days Frequency of Feeling Urge to Urinate All of a Sudden|Sudden Need to Urinate	A question about the frequency of an individual's feeling an urge to urinate all of a sudden over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C132198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132198>	C173737	Past Seven Days How Often Times When Have to Urinate Frequently Question|In the past 7 days, were there times when you had to urinate frequently|Past Seven Days How Often Times When Have to Urinate Frequently	A question about how often an individual had times when they had to urinate frequently over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C132199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132199>	C178809|C173803|C173737|C173358	Past Seven Days Frequency of Urinary Incontinence Question|In the past 7 days, how often did you have loss of control of urine (leakage)|Past Seven Days Frequency of Loss of Control of Urine|Past Seven Days Frequency of Urinary Incontinence	A question about the frequency of an individual's loss of control of urine (leakage) over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C13219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13219>	C13203	Human Chromosome 3|Chromosome 3|Chromosome 3|Chromosome 3|chr3|chr3|chr3	The designation for each member of the third largest human autosomal chromosome pair. Chromosome 3 spans almost 200 million base pairs and represents about 6.5% of the total DNA in normal diploid cells.	Chromosome 3		Cell Component	CTDC Value Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C1321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1321>	C112883	Muromonab-CD3|Anti-CD3 Monoclonal Antibody OKT3|MUROMONAB-CD3|MoAb OKT3|Monoclonal Antibody OKT3|Orthoclone OKT3|muromonab-CD3 monoclonal antibody	A murine IgG2a monoclonal antibody with immunosuppressive activity. Muromonab-CD3 binds to and inhibits CD3 on the surface of circulating T-lymphocytes; binding of muromonab-CD3 to CD3-positive T cells results in an early activation of this T cell subset, followed by cytokine release, and subsequently inhibition of T cell functions. This agent may cause the opsonization and elimination of CD3-positive T cells from the circulation by mononuclear phagocytes in the liver and spleen. CD3 is part of the functional T cell receptor (TCR) complex, which is necessary for antigen recognition by T cells, and is required for signal transduction.	Muromonab-CD3		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C132200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132200>	C173737|C173358	Past Seven Days Frequency of Ejaculation Problems Question|In the past 7 days, how often did you have ejaculation problems|Past Seven Days Frequency of Ejaculation Problems	A question about the frequency of an individual's ejaculation problems over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C132201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132201>	C173790|C173603	Worst Severity Past Seven Days Blurry Vision Question|In the past 7 days, what was the severity of your blurry vision at its worst|Worst Severity Past Seven Days Blurred Vision|Worst Severity Past Seven Days Blurry Vision	A question about an individual's observation of the worst severity they have experienced related to blurry vision over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C132202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132202>	C173603	Worst Severity Past Seven Days Watery Eyes Question|In the past 7 days, what was the severity of your watery eyes (tearing) at their worst|Worst Severity Past Seven Days Tearing Eyes|Worst Severity Past Seven Days Watering Eyes|Worst Severity Past Seven Days Watery Eyes	A question about an individual's observation of the worst severity they have experienced related to watery eyes (tearing) over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C132203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132203>	C173603	Worst Severity Past Seven Days Ringing in Ears Question|In the past 7 days, what was the severity of ringing in your ears at its worst|Worst Severity Past Seven Days Ringing in Ears	A question about an individual's observation of the worst severity they have experienced related to ringing in their ears over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C132204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132204>	C173603	Worst Severity Past Seven Days Vaginal Dryness Question|In the past 7 days, what was the severity of your vaginal dryness at its worst|Worst Severity Past Seven Days Vaginal Dryness	A question about an individual's observation of the worst severity they have experienced related to vaginal dryness over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C132205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132205>	C173803|C107407	Worst Severity Past Seven Days Pain or Burning with Urination Question|In the past 7 days, what was the severity of your pain or burning with urination at its worst|Worst Severity Past Seven Days Pain or Burning with Urination|Worst Severity Past Seven Days Painful Urination	A question about an individual's observation of the worst severity they have experienced related to pain or burning with urination over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C132206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132206>	C173603|C173398	Worst Severity Past Seven Days Difficulty Getting or Keeping an Erection Question|In the past 7 days, what was the severity of your difficulty getting or keeping an erection at its worst|Worst Severity Past Seven Days Difficulty Getting or Keeping an Erection	A question about an individual's observation of the worst severity they have experienced related to difficulty getting or keeping an erection over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C132207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132207>	C173603	Worst Severity Past Seven Days Decreased Sexual Interest Question|In the past 7 days, what was the severity of your decreased sexual interest at its worst|Worst Severity Past Seven Days Decreased Sexual Desire|Worst Severity Past Seven Days Decreased Sexual Interest	A question about an individual's observation of the worst severity they have experienced related to decreased sexual interest over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C132208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132208>	C107407	Worst Severity Past Seven Days Pain During Vaginal Sex Question|In the past 7 days, what was the severity of your pain during vaginal sex at its worst|Worst Severity Past Seven Days Pain During Vaginal Intercourse|Worst Severity Past Seven Days Pain During Vaginal Penetration|Worst Severity Past Seven Days Pain During Vaginal Sex	A question about an individual's observation of the worst severity they have experienced related to pain during vaginal sex over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C132209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132209>	C173791|C173603	Worst Severity Past Seven Days Breast Area Enlargement or Tenderness Question|In the past 7 days, what was the severity of your breast area enlargement or tenderness at its worst|Worst Severity Past Seven Days Breast Area Enlargement or Tenderness	A question about an individual's observation of the worst severity they have experienced related to breast area enlargement or tenderness over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C13220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13220>	C13203	Human Chromosome 4|Chromosome 4|Chromosome 4|Chromosome 4|chr4|chr4|chr4	The designation for each member of the fourth largest human autosomal chromosome pair. Chromosome 4 spans more than 186 million base pairs and represents between 6 and 6.5% of the total DNA in normal diploid cells.	Chromosome 4		Cell Component	CTDC Value Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C132210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132210>	C173603	Worst Severity Past Seven Days Body Odor Question|In the past 7 days, what was the severity of your body odor at its worst|Worst Severity Past Seven Days Body Odor	A question about an individual's observation of the worst severity they have experienced related to body odor over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C132211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132211>	C173790|C173787|C173737|C173584	Past Seven Days How Much Blurry Vision Interfered with Usual or Daily Activities Question|In the past 7 days, how much did blurry vision interfere with your usual or daily activities|Past Seven Days How Much Blurry Vision Interfered with Usual or Daily Activities	A question about how much an individual's blurry vision interfered with their usual or daily activities over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C132212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132212>	C173787|C173737|C173584	Past Seven Days How Much Watery Eyes Interfered with Usual or Daily Activities Question|In the past 7 days, how much did watery eyes (tearing) interfere with your usual or daily activities|Past Seven Days How Much Watery Eyes Interfered with Usual or Daily Activities	A question about how much an individual's watery eyes (tearing) interfered with their usual or daily activities over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C132213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132213>	C173787|C173737|C173584	Past Seven Days How Much Sudden Urges to Urinate Interfered with Usual or Daily Activities Question|In the past 7 days, how much did sudden urges to urinate interfere with your usual or daily activities|Past Seven Days How Much Sudden Urges to Urinate Interfered with Usual or Daily Activities	A question about how much an individual's sudden urges to urinate interfered with their usual or daily activities over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C132214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132214>	C173803|C173787|C173737|C173584	Past Seven Days How Much Frequent Urination Interfered with Usual or Daily Activities Question|In the past 7 days, how much did frequent urination interfere with your usual or daily activities|Past Seven Days How Much Frequent Urination Interfered with Usual or Daily Activities	A question about how much an individual's frequent urination interfered with their usual or daily activities over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C132215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132215>	C178809|C173803|C173787|C173737|C173584	Past Seven Days How Much Urinary Incontinence Interfered with Usual or Daily Activities Question|In the past 7 days, how much did loss of control of urine (leakage) interfere with your usual or daily activities|Past Seven Days How Much Loss of Control of Urine Interfered with Usual or Daily Activities|Past Seven Days How Much Urinary Incontinence Interfered with Usual or Daily Activities	A question about how much an individual's loss of control of urine (leakage) interfered with their usual or daily activities over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C132216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132216>	C173737	Past Seven Days Any Unusual Vaginal Discharge Question|In the past 7 days, did you have any unusual vaginal discharge|Past Seven Days Any Unusual Vaginal Discharge	A question about whether or not an individual had any unusual vaginal discharge over the past seven days.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C132217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132217>	C173737	Past Seven Days Any Irregular Menstrual Period Question|In the past 7 days, did you have any irregular menstrual periods|Past Seven Days Any Irregular Menstrual Period	A question about whether or not an individual had any irregular menstral periods.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C132218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132218>	C173737	Past Seven Days Missed Expected Menstrual Period Question|In the past 7 days, did you miss an expected menstrual period|Past Seven Days Missed Expected Menstrual Period|Past Seven Days Missed Menstrual Period	A question about whether or not an individual missed an expected menstrual period.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C132219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132219>	C173737|C173160	Past Seven Days Took Too Long to Have Orgasm Question|In the past 7 days, did you feel that it took too long to have an orgasm or climax|Past Seven Days Took Too Long to Have Orgasm	A question about whether or not an individual felt that it took too long to have an orgasm or climax.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C13221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13221>	C13203	Human Chromosome 5|Chromosome 5|Chromosome 5|Chromosome 5|chr5|chr5|chr5	The designation for each member of the fifth largest human autosomal chromosome pair. Chromosome 5 spans about 181 million base pairs and represents almost 6% of the total DNA in normal diploid cells.	Chromosome 5		Cell Component	CTDC Value Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C132220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132220>	C173737|C173704|C173045	Past Seven Days Unable to Have Orgasm Question|In the past 7 days, were you unable to have an orgasm or climax|Past Seven Days Unable to Have Orgasm	A question about whether or not an individual was unable to have an orgasm or climax.			Intellectual Product	Patient Reported Outcomes Version of CTCAE
C132221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132221>	C176252	Not Sexually Active|Not Sexually Active At All|Not sexually active|Not sexually active	A response indicating that an individual is not or was not sexually active.			Intellectual Product	Patient Reported Outcomes Version of CTCAE|PRO-CTCAE Attribute Value Terminology|PRO-CTCAE Version 1.0 Questionnaire Terminology
C132222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132222>	C226709	Prefer Not to Answer|Choose Not to Disclose|Prefer not to answer|Prefer not to answer|Prefer not to answer	A response indicating that an individual prefers or preferred not to answer.			Intellectual Product	Patient Reported Outcomes Version of CTCAE|PRO-CTCAE Attribute Value Terminology|PRO-CTCAE Version 1.0 Questionnaire Terminology|SeroNet Authorized Values|SeroNet Study Descriptors
C132223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132223>	C15791	Supplemental Testing	Additional, or secondary, testing done to confirm a preliminary result.			Health Care Activity	
C132224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132224>	C53543	Ataxia-Telangiectasia-Like Disorder 1|ATLD|ATLD1|Ataxia-Telangiectasia-Like Disorder	An autosomal recessive condition caused by mutation(s) in the MRE11A gene, encoding double-strand break repair protein MRE11. It is characterized by progressive cerebellar degeneration resulting in ataxia and oculomotor apraxia.			Disease or Syndrome	Cellosaurus Disease Terminology
C132225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132225>	C12814	Venous Segment	A segment of a blood vessel that is part of the venous system.			Anatomical Structure	
C132226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132226>	C162803|C131787	CDKN2A-p16 Negative|CDKN2A-p16(INK4a) Negative|Cyclin-Dependent Kinase 4 Inhibitor A Negative|Cyclin-Dependent Kinase Inhibitor 2A Negative|Negative|p16 Negative|p16(INK4a) Negative|p16-INK4 Negative|p16INK4 Negative|p16INK4a Negative	Indicates that expression of the p16 form of CDKN2A has not been detected in a sample.	CDKN2A-p16 Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132227>	C97927	CREBBP Gene Mutation|CBP Gene Mutation|CREB Binding Protein Gene Mutation|CREB-Binding Protein Gene Mutation|KAT3A Gene Mutation|RSTS Gene Mutation|Rubinstein-Taybi Syndrome Gene Mutation	A change in the nucleotide sequence of the CREBBP gene.	CREBBP Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132228>	C177692	CD33 Positive|CD33 Antigen Positive|CD33 Molecule Positive|Myeloid Cell Surface Antigen CD33 Positive|SIGLEC-3 Positive|SIGLEC3 Positive|gp67 Positive|p67 Positive	Indicates that CD33 expression has been detected in a sample.	CD33 Positive		Laboratory or Test Result	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132229>	C36327	RAS Family Gene Mutation|Mutant RAS|Mutant RAS Family Gene|RAS Family Mutation|RAS Mutation	A change in the nucleotide sequence in a RAS family gene (HRAS, KRAS or NRAS).	RAS Family Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C13222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13222>	C13203	Human Chromosome 6|Chromosome 6|Chromosome 6|Chromosome 6|chr6|chr6|chr6	The designation for each member of the sixth largest human autosomal chromosome pair. Chromosome 6 spans more than 170 million base pairs and represents between 5.5 and 6% of the total DNA in normal diploid cells.	Chromosome 6		Cell Component	CTDC Value Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C132230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132230>	C177692	CD79B Positive|AGM6 Positive|B-Cell Antigen Receptor Complex-Associated Protein Beta Chain Positive|B29 Positive|CD79b Antigen Positive|CD79b Molecule Positive|IGB Positive|Ig-Beta Positive	Indicates that CD78B expression has been detected in a sample.	CD79B Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132231>	C94299|C177692	FCER2 Positive|Antigen CD23 Positive|CD23 Antigen Positive|CD23 Positive|CD23 Positive|Fc Fragment of IgE Receptor I Positive|Fc-Epsilon-RII Positive|Immunoglobulin E-Binding Factor Positive|Low Affinity Immunoglobulin Epsilon Fc Receptor Positive	Indicates that FCER2 expression has been detected in a sample.	FCER2 Positive		Laboratory or Test Result	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132232>	C82340	GATA1 Exon 3 Mutation|ERYF1 Exon 3 Mutation|GATA Binding Protein 1 Gene Exon 3 Mutation|GATA-1 Exon 3 Mutation|GF-1 Exon 3 Mutation|GF1 Exon 3 Mutation|NF-E1 Exon 3 Mutation|NFE1 Exon 3 Mutation	A molecular genetic abnormality indicating the presence of a mutation in exon 3 of the GATA1 gene.	GATA1 Exon 3 Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132233>	C82340	GATA1 Exon 2 Mutation|ERYF1 Exon 2 Mutation|GATA Binding Protein 1 Gene Exon 2 Mutation|GATA-1 Exon 2 Mutation|GF-1 Exon 2 Mutation|GF1 Exon 2 Mutation|NF-E1 Exon 2 Mutation|NFE1 Exon 2 Mutation	A molecular genetic abnormality indicating the presence of a mutation in exon 2 of the GATA1 gene.	GATA1 Exon 2 Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132234>	C177692	TFE3 Positive|RCCP2 Positive|RCCX1 Positive|TFEA Positive|Transcription Factor Binding to IGHM Enhancer 3 Positive|Transcription Factor E3 Positive|bHLHe33 Positive	Indicates that TFE3 expression has been detected in a sample.	TFE3 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132235>	C138156	NTRK2 Fusion Positive|BDNF/NT-3 Growth Factors Receptor Fusion Positive|NTRK2 Fusion|NTRK2 fusion|Neurotrophic Receptor Tyrosine Kinase 2 Fusion Positive|TRKB Tyrosine Kinase Fusion Positive|TrkB Fusion Positive|Tropomyosin-Related Kinase B Fusion Positive	Indicates that the expression of a NTRK2 fusion has been detected in a sample.	NTRK2 Fusion Positive		Laboratory or Test Result	CRF8 Pathology Review Targeted Genomics Table|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132236>	C138156	NTRK3 Fusion Positive|NT-3 Growth Factor Receptor Fusion Positive|NTRK3 Fusion|NTRK3 fusion|Neurotrophic Receptor Tyrosine Kinase 3 Fusion Positive|TRKC Tyrosine Kinase Fusion Positive|TrkC Fusion Positive	Indicates that the expression of a NTRK3 fusion has been detected in a sample.	NTRK3 Fusion Positive		Laboratory or Test Result	CRF8 Pathology Review Targeted Genomics Table|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132237>	C94299|C177692	NR3C1 Positive|GCR Positive|GR Positive|GRL Positive|Glucocorticoid Receptor Positive|Nuclear Receptor Subfamily 3 Group C Member 1 Positive	Indicates that NR3C1 expression has been detected in a sample.	NR3C1 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132238>	C18930	HLA-A*02:01/TP53aa264-272 Complex|HLA Class I Histocompatibility Antigen, A*02:01 Alpha Chain/Cellular Tumor Antigen p53 264-272 Peptide Complex|HLA-A2.1/TP53aa264-272 Complex	A protein complex comprised of the nine amino acid residues starting at position 264 and ending at position 272 of the wild-type form of cellular tumor antigen p53 bound to the cell surface antigen presenting molecule HLA class I histocompatibility antigen, A*02:01 alpha chain.	HLA-A*02:01/TP53aa264-272 Complex		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132239>	C177692	CD70 Positive|CD27 Ligand Positive|CD27L Positive|CD27LG Positive|CD70 Antigen Positive|CD70 Molecule Positive|Ki-24 Antigen Positive|TNFSF7 Positive|Tumor Necrosis Factor Ligand Superfamily, Member 7 Positive	Indicates that CD70 expression has been detected in a sample.	CD70 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13223>	C13203	Human Chromosome 7|Chromosome 7|Chromosome 7|Chromosome 7|chr7|chr7|chr7	The designation for each member of the seventh largest human autosomal chromosome pair. Chromosome 7 spans more than 158 million base pairs and represents between 5 and 5.5% of the total DNA in normal diploid cells.	Chromosome 7		Cell Component	CTDC Value Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C132240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132240>	C21295	LYPD3 Gene|LY6/PLAUR Domain Containing 3 Gene|LYPD3|LYPD3	This gene is involved in cell migration.	LYPD3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C132241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132241>	C132240	LYPD3 wt Allele|C4.4A|LY6/PLAUR Domain Containing 3 wt Allele|Matrigel-Induced Gene C4|UNQ491/PRO1007	Human LYPD3 wild-type allele is located in the vicinity of 19q13.31 and is approximately 5 kb in length. This allele, which encodes Ly6/PLAUR domain-containing protein 3, plays a role in cell-matrix interactions.	LYPD3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132242>	C17728	Ly6/PLAUR Domain-Containing Protein 3|2310061G07Rik|C4.4A|GPI-Anchored Metastasis-Associated Protein C4.4A|GPI-Anchored Metastasis-Associated Protein C4.4A Homolog|GPI-Anchored Metastasis-Associated Protein Homolog|LYPD3|MIG-C4|Matrigel-Induced Gene C4 Protein	Ly6/PLAUR domain-containing protein 3 (346 aa, ~36 kDa) is encoded by the human LYPD3 gene. This protein is involved in cell-matrix interactions during cell migration.	Ly6/PLAUR Domain-Containing Protein 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132243>	C177692	LYPD3 Positive|C4.4a Positive|LY6/PLAUR Domain Containing 3 Positive|LY6/PLAUR Domain-Containing 3 Positive	Indicates that LYPD3 expression has been detected in a sample.	LYPD3 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132244>	C177683|C133705	FGFR Gene Fusion Positive|FGF Receptor Gene Family Fusion Positive|FGF Receptor Gene Fusion Positive|FGFR Gene Family Fusion Positive|Fibroblast Growth Factor Receptor Gene Family Fusion Positive|Fibroblast Growth Factor Receptor Gene Fusion Positive	Indicates that a fusion containing FGFR family gene sequences has been detected in a sample.	FGFR Gene Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132245>	C165233	CD19 Negative|B4 Negative|CD19 Antigen Negative|CD19 Molecule Negative	Indicates that expression of CD19 has not been detected in a sample.	CD19 Negative		Laboratory or Test Result	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132246>	C18016	Chromosome Arm 3p Loss of Heterozygosity|3p LOH|3p Loss of Heterozygosity	A molecular abnormality that results in monoallelic loss of function mutations located within the short arm of chromosome 3 (3p).	Chromosome Arm 3p Loss of Heterozygosity		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132247>	C180942|C18016	Chromosome Arm 9p Loss of Heterozygosity|9p LOH|9p Loss of Heterozygosity	A molecular abnormality that results in monoallelic loss of function mutations located  within the short arm of chromosome 9 (9p).	Chromosome Arm 9p Loss of Heterozygosity		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132248>	C28108	AJCC v8 Stage	A cancer stage defined according to the AJCC 8th edition criteria.			Classification	
C132249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132249>	C78281	Dibotermin Alfa|DIBOTERMIN ALFA|Diotermin|rhBMP-2|rhBMP2	A recombinant form of human bone morphogenetic protein 2 (rhBMP-2), with potential bone remodeling and osteoinductive activities. Following administration, dibotermin alfa induces signaling cascades, which leads to osteoblast differentiation, enhancement of bone repair and formation, and improvement of re-vascularization. This promotes bone healing. BMP-2, a protein belonging to the transforming growth factor beta (TGFb) superfamily of proteins, plays a key role in bone and cartilage formation.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C13224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13224>	C13203	Human Chromosome 8|Chromosome 8|Chromosome 8|Chromosome 8|chr8|chr8|chr8	The designation for each member of the eighth largest human autosomal chromosome pair. Chromosome 8 spans about 145 million base pairs and represents between 4.5 and 5.0% of the total DNA in normal diploid cells.	Chromosome 8		Cell Component	CTDC Value Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C132250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132250>	C207757|C129822	Nisevokitug|Anti-TGF-beta Monoclonal Antibody NIS793|NIS793|NISEVOKITUG	A monoclonal antibody directed against human transforming growth factor beta (TGF-beta), with potential antineoplastic activity. Upon administration, nisevokitug targets and binds to TGF-beta, thereby preventing the activation of TGF-beta-mediated signaling pathways. TGF-beta, a pro-inflammatory mediator that is mutated and/or overexpressed in a number of cancer cell types, is involved in cancer cell proliferation and migration, and tumor progression.	Nisevokitug		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C132251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132251>	C28681|C129826	Autologous PD-1-targeted Chimeric Switch Receptor-modified T Lymphocytes|Autologous Chimeric Switch Receptor PD-1:CD28 Modified T Cells|Autologous PD-1-targeted CSR T Cells|Chimeric Switch Receptor PD1CD28 Modified T Cells|PD1CD28 CSR T Cells	Autologous human T-lymphocytes that are genetically engineered to express a chimeric switch receptor (CSR) composed of the extracellular ligand binding domain of the human inhibitory receptor programmed cell death protein 1 (PD-1; PDCD1) fused to the transmembrane and cytoplasmic co-stimulatory signaling domains of CD28 (PD1CD28; PD-1:CD28 switch receptor), with potential immunomodulating and antineoplastic activities. Upon reintroduction of autologous PD-1-targeted CSR-modified T-lymphocytes into the patient, the switch receptor expressed by the engineered T-cells targets and binds to the PD-1 ligands, programmed cell death ligand 1 (PD-L1) and 2 (PD-L2) expressed, on tumor cells. The nature of the PD-1/CD28 switch receptor fusion protein prevents the normal PD1/PD-L1-mediated T-cell suppression and, instead, promotes signaling through the CD28 domain, which results in the stimulation of T-lymphocytes. This induces enhanced toxicity against PD-L1-expressing tumor cells. PD-1 protein, found on activated T-cells, negatively regulates T-cell activity; it plays a key role in immune evasion and prevents tumor cell lysis. Exchanging the transmembrane and intracellular domain of PD-1 with that of CD28 converts PD-L1 into a co-stimulation ligand of primary human CD8+ cytotoxic T-lymphocytes (CTLs). CD28, is a molecule expressed by T-cells that stimulates increased T-lymphocyte proliferation and activity.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C132252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132252>	C129822|C128037	Ezabenlimab|Anti-PD-1 Monoclonal Antibody BI 754091|BI 754091|EZABENLIMAB	A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death protein 1 (PD-1; PDCD1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, ezabenlimab selectively binds to and blocks the activation of PD-1, an immunoglobulin (Ig) superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and T-cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.	Ezabenlimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C132253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132253>	C15426	Cooperative Donor Registry|Cooperative Registry	A formal business relationship between donor registries allowing for tissue matching against the pool of donors created by all participating registries.			Intellectual Product	
C132254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132254>	C97927	BTK Gene Mutation|AGMX1 Gene Mutation|AT Gene Mutation|ATK Gene Mutation|BPK Gene Mutation|Bruton Agammaglobulinemia Tyrosine Kinase Gene Mutation|Bruton Tyrosine Kinase Gene Mutation|IMD1 Gene Mutation|MGC126261 Gene Mutation|MGC126262 Gene Mutation|PSCTK1 Gene Mutation|XLA Gene Mutation	A change in the nucleotide sequence of the BTK gene.	BTK Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132255>	C41278	SmartPill|SmartPill Motility Monitoring System	A proprietary ingestible capsule for gastrointestinal tract functional assessment that measures pressure, pH, temperature, and transit time as it travels through the entire gastrointestinal tract.	SmartPill		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C132256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132256>	C19697	Unspecified Tissue|TISSUE, UNSPECIFIED	A tissue specimen whose anatomic origin is not known or reported.			Tissue	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132257>	C129825	Idronoxil Suppository NOX66|NOX66	A proprietary, suppository-based formulation composed of idronoxil, a synthetic flavonoid derivative, surrounded by a proprietary lipid that protects idronoxil from phase 2 degradation, with potential chemo- and radio-sensitizing activities. Upon administration, idronoxil blocks the activity of ecto-NOX disulfide-thiol exchanger 2 (ENOX2; tNOX), a tumor-specific external NADH oxidase that maintains the transmembrane electron potential across the plasma membrane and is overexpressed in certain cancer cell types while absent in normal, healthy cells. Loss of this potential directly inhibits certain pro-survival signal transduction pathways, such as the PARP1/PI3 kinase/Akt signaling pathway. The inhibition of these pathways prevents resistance to standard chemo- and radio-therapy and makes tumor cells more susceptible to the anti-tumor activity of conventional chemotherapeutic agents and radiotherapy. The formulation prevents detoxification of idronoxil to an inactive form by bypassing phase 2 metabolism; this increases idronoxil's bioavailability as compared to idronoxil alone.	Idronoxil Suppository NOX66		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C132258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132258>	C176586	Ulevostinag|MK 1454|MK-1454|STING Agonist MK-1454|ULEVOSTINAG	A synthetic cyclic dinucleotide (CDN) and agonist of stimulator of interferon genes protein (STING), with potential immunoactivating and antineoplastic activities. Upon intratumoral (IT) administration,ulevostinag binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor microenvironment; this leads to the production of pro-inflammatory cytokines, including interferons (IFNs). Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens by CD8alpha-positive and CD103-positive dendritic cells (DCs) to cytotoxic T-lymphocytes (CTLs). This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis.	Ulevostinag		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C132259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132259>	C70783	Study Site Dissolved|Dissolved|Site Dissolved	An indication that a study site has closed down and is no longer participating in a study.			Qualitative Concept	
C13225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13225>	C13203	Human Chromosome 9|Chromosome 9|Chromosome 9|Chromosome 9|chr9|chr9|chr9	The designation for each member of the ninth largest human autosomal chromosome pair. Chromosome 9 spans about 145 million base pairs of nucleic acids and represents between 4 and 4.5% of the total DNA in normal diploid cells.	Chromosome 9		Cell Component	CTDC Value Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C132260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132260>	C7523|C3520|C213901	Small Intestinal Myeloid Sarcoma|Myeloid Sarcoma of the Small Intestine	A myeloid sarcoma that affects the small intestine. It often presents with abdominal pain and obstruction.			Neoplastic Process	
C132261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132261>	C96631	Sum of Products of Perpendicular Diameters|SPD|SUMPPD|Sum of Products of Perpendicular Diam|Sum of Products of Perpendicular Diam	A calculation of the aggregated products of perpendicular diameter values.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C132262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132262>	C66830	CDISC SDTM Microscopic Findings Test Name Terminology|MITS|SDTM Microscopic Findings Test Name|SDTM-MITS	Terminology associated with the SDTM microscopic findings test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132263>	C66830	CDISC SDTM Microscopic Findings Test Code Terminology|MITSCD|SDTM Microscopic Findings Test Code|SDTM-MITSCD	Terminology associated with the SDTM microscopic findings test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132264>	C96621	Percent Change From Baseline in Sum of Products of Perpendicular Diameter|PCBSPPD|Percent Change Baseline in Sum of PPD|Percent Change Baseline in Sum of PPD|Percent Change Baseline in Sum of PPD	The most recently recorded sum of products of perpendicular diameters minus the baseline sum of products of perpendicular diameters divided by the baseline sum of products of perpendicular diameters, multiplied by 100.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C132265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132265>	C96622	Percent Change From Nadir in Sum of Products of Perpendicular Diameters|PCNSPPD|Percent Change From Nadir in Sum of Area|Percent Change Nadir in Sum of PPD|Percent Change Nadir in Sum of PPD	The most recently recorded sum of products of perpendicular diameters minus the lowest sum of diameters previously recorded divided by the lowest sum of products of perpendicular diameters previously recorded, multiplied by 100.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C132266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132266>	C176988	Anti-CD73 Monoclonal Antibody BMS-986179|BMS 986179|BMS-986179|BMS-986179	A monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD73 monoclonal antibody BMS-986179 targets and binds to CD73, leading to clustering and internalization of CD73. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine and decreases the amount of free adenosine. This prevents adenosine-mediated suppression of lymphocyte activity and increases the activity of CD8-positive effector cells. This also activates macrophages, and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes. By abrogating the inhibitory effect on the immune system and enhancing the cytotoxic T-cell-mediated immune response against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, is upregulated on a number of cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment.	Anti-CD73 Monoclonal Antibody BMS-986179		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C132267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132267>	C129822|C128058	Anti-GITR Agonistic Monoclonal Antibody BMS-986156|Anti-GITR MoAb BMS-986156|BMS 986156|BMS-986156|BMS-986156|GITR Agonist BMS-986156|TNFRSF18 Agonist BMS-986156	An anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR; tumor necrosis factor superfamily member 18; TNFRSF18; CD357) agonistic monoclonal antibody, with potential immune checkpoint modulating activity. Anti-GITR antibody BMS-986156 binds to and activates GITR, which is expressed on the cell surface of multiple types of T-cells. This stimulates the immune system, induces both the activation and proliferation of tumor antigen-specific T-effector cells (Teffs), and suppresses the function of activated T-regulatory cells (Tregs). This leads to tumor cell eradication. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B-cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress both Teffs and T-cell receptor (TCR) signaling.	Anti-GITR Agonistic Monoclonal Antibody BMS-986156		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C132268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132268>	C521	Funisolide Anhydrous|FLUNISOLIDE ANHYDROUS				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132269>	C247	Sampatrilat|Beta-Alanine, 2-((1-(((1-Carboxy-2-(4-hydroxyphenyl)ethyl)amino)carbonyl)cyclopentyl)methyl)-N-(N2-(methylsulfonyl)-L-lysyl)-, (S-(R*,R*))-|SAMPATRILAT|UK 81,252				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C13226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13226>	C14135	Cytoplasm|Cytoplasmic|cytoplasm	That portion of the cell contained within the plasma membrane but excluding the nucleus.			Cell Component	
C132270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132270>	C127171	46,XY Sex Reversal 4|SRXY4	Sex reversal in an individual associated with a 9p24.3 deletion.			Disease or Syndrome	Cellosaurus Disease Terminology
C132271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132271>	C697|C574	Oxeclosporin|Cyclo(((2S,3R,4R,6E)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl)-L-2-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-O-(2-hydroxyethyl)-D-seryl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl)|Cyclosporin A, 2-(O-(2-hydroxyethyl)-D-serine)-|OXECLOSPORIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C132272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132272>	C2124	Iometopane I 123|(123I)-RTI 55|(123I)-beta-CIT|8-Azabicyclo(3.2.1)-octane-2-carboxylic acid, 3-(4-(Iodo-I)phenyl)-8-methyl-, Methyl Ester (1R-(exo,exo))-|IOMETOPANE I-123|Iometopane (123I)|Methyl 3beta-(p-(123I)iodophenyl)-1alphaH,5alphaH-tropane-2beta- Carboxylate				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132273>	C47796	Milameline|3-Pyridinecarboxaldehyde, 1,2,5,6-Tetrahydro-1-methyl-, O-methyloxime, (E)-|E)-1,2,5,6-Tetrahydro-1-methyl-3-pyridinecarboxaldehyde O-methyloxime|MILAMELINE				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132274>	C134528	Feline Mammary Carcinoma	Mammary carcinoma occurring in a cat.			Neoplastic Process	Cellosaurus Disease Terminology
C132275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132275>	C134526	Canine Thyroid Adenocarcinoma	Adeonocarcinoma of the thyroid gland occurring in a dog.			Neoplastic Process	Cellosaurus Disease Terminology
C132276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132276>	C134526	Canine Soft Tissue Sarcoma	Soft tissue sarcoma occurring in a dog.			Neoplastic Process	Cellosaurus Disease Terminology
C132277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132277>	C2092	Teverelix|ANB019|Ac-D-Nal-D-cpa-D-pal-ser-tyr-D-hci-leu-lys(ipr)-pro-D-ala-NH2|D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-(aminocarbonyl)-D-lysyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-|EP 24332|TEVERELIX	A synthetic decapeptide and antagonist of the naturally occurring gonadotropin-releasing hormone (GnRH), with potential hormone production inhibitory and antineoplastic activities. Upon administration, teverelix directly competes with GnRH for receptor binding in the anterior pituitary gland, thereby inhibiting GnRH receptor signaling. This inhibits the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation. In females, this prevents the production of estrogen by the ovaries and may relieve symptoms from sex-hormone dependent diseases.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt Antineoplastic Agent Terminology
C132278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132278>	C263	Sothrombomodulin Alfa|SOTHROMBOMODULIN ALFA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132279>	C173066	Napsagatran Anhydrous|NAPSAGATRAN ANHYDROUS				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C13227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13227>	C33174	Cytoskeleton|Cellular Matrix|Cytoskeletal|Cytoskeletal System	The protein scaffolding (the network of filaments microfilaments, microtubules, intermediate filaments, and their associated proteins) that gives shape, structure, and organization to the cytoplasm and a cell its shape.			Cell Component	
C132281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132281>	C126712	Gatifloxacin Mesylate|3-Quinolinecarboxylic Acid, 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-, Monomethanesulfonate|GATIFLOXACIN MESYLATE|Gemifloxacin Mesilate	The mesylate salt form of gatifloxacin, a synthetic 8-methoxyfluoroquinolone with antibacterial activity against a wide range of gram-negative and gram-positive microorganisms. Gatifloxacin exerts its effect through inhibition of DNA gyrase, an enzyme involved in DNA replication, transcription and repair, and inhibition of topoisomerase IV, an enzyme involved in partitioning of chromosomal DNA during bacterial cell division.			Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132282>	C62289	General Fatigue Dimension|General Fatigue	A dimension of general fatigue in the Multidimensional Fatigue Inventory.			Functional Concept	Multidimensional Fatigue Inventory
C132283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132283>	C2124	Iodocetylic Acid I 123|16-Iodo-(sup 123)I-hexadecanoic Acid|IODOCETYLIC ACID I-123|Iodocetylic Acid (123I)				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132284>	C62289	Physical Fatigue Dimension|Physical Fatigue	A dimension of physical fatigue in the Multidimensional Fatigue Inventory.			Functional Concept	Multidimensional Fatigue Inventory
C132285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132285>	C62289	Mental Fatigue Dimension|Mental Fatigue	A dimension of mental fatigue in the Multidimensional Fatigue Inventory.			Functional Concept	Multidimensional Fatigue Inventory
C132286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132286>	C62289	Reduced Motivation Dimension|Reduced Motivation	A dimension of reduced motivation in the Multidimensional Fatigue Inventory.			Functional Concept	Multidimensional Fatigue Inventory
C132287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132287>	C62289	Reduced Activity Dimension|Reduced Activity	A dimension of reduced activity in the Multidimensional Fatigue Inventory.			Functional Concept	Multidimensional Fatigue Inventory
C132288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132288>	C91105	Health Assessment Questionnaire Disability Index|HAQ-DI|Health Assessment Questionnaire Disability Index (HAQ-DI)	A questionnaire for the assessment of rheumatoid arthritis.			Intellectual Product	
C132289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132289>	C21007	Functional Disability	An impairment that causes an individual to require assistance in order to perform an activity.			Organism Attribute	
C13228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13228>	C13298	Satellite DNA	DNA that contains many tandem highly repetitive sequences, that have a base composition (and thus density) sufficiently different from that of normal DNA that it sediments as a distinct band in cesium chloride density gradients.  Satellite DNA is located at very specific spots in the genome (on chromosomes 1, 9, 16 and the Y chromosome, the tiny short arms of chromosomes 13-15 and 21 and 22, and near the centromeres of chromosomes).			Nucleic Acid, Nucleoside, or Nucleotide|Nucleotide Sequence	
C132290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132290>	C53543	Carbonic Anhydrase I Deficiency	Decreased or absent activity of the enzyme carbonic anhydrase 1, due to loss-of-function mutation(s) in the gene CA1.			Disease or Syndrome	Cellosaurus Disease Terminology
C132291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132291>	C245	Procaine Merethoxylline|PROCAINE MERETHOXYLLINE|Procaine Merethoxylline Component of Dicurin Procaine				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132292>	C84647	Presynaptic Congenital Myasthenic Syndrome 6|CMS6	Congenital myasthenic syndrome caused by mutation(s) in the CHAT gene, encoding choline O-acetyltransferase. It is inherited in an autosomal recessive manner.			Disease or Syndrome	Cellosaurus Disease Terminology
C132293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132293>	C119758	Severe Neonatal Encephalopathy Due to MECP2 Mutations	An X-linked recessive condition caused by mutation(s) in the MECP2 gene, encoding methyl-CpG-binding protein 2. It is characterized by severe neonatal encephalopathy.			Disease or Syndrome	Cellosaurus Disease Terminology
C132294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132294>	C27838|C158437	Recurrent Endometrial Serous Adenocarcinoma|Recurrent Uterine Corpus Serous Carcinoma	The reemergence of endometrial serous adenocarcinoma after a period of remission.	Recurrent Endometrial Serous Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132295>	C159438	Pralsetinib|(cis)-N-((S)-1-(6-(4-Fluoro-1H-pyrazol-1-yl)pyridin-3-yl)ethyl)-1-methoxy-4-(4-methyl-6-(5-methyl-1H-pyrazol-3-ylamino)pyrimidin-2-yl)cyclohexanecarboxamide|BLU 667|BLU-667|BLU667|Gavreto|PRALSETINIB	An orally bioavailable selective inhibitor of mutant forms of and fusion products involving the proto-oncogene receptor tyrosine kinase RET, with potential antineoplastic activity. Upon administration, pralsetinib binds to and targets various RET mutants and RET-containing fusion product. RET gene mutations and translocations result in the upregulation and/or activation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role in the development and regression of these cancers.	Pralsetinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C132296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132296>	C3329	Atypical Pituitary Neuroendocrine Tumor|Atypical PitNET/Adenoma|Atypical Pituitary Gland Adenoma|Atypical Pituitary Neuroendocrine Tumor/Adenoma	A usually aggressive and invasive pituitary neuroendocrine tumor characterized by excessive p53 immunoreactivity, increased mitotic activity, and MIB-1 proliferative index greater than 3%.			Neoplastic Process	
C132297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132297>	C49286	Plasma Cell Enrichment	Concentration of plasma cells in a sample for the purpose of the detection of cytogenetic abnormalities.			Laboratory Procedure	
C132298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132298>	C103175	CDISC Protocol Terminology	The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) protocol group.			Intellectual Product	Clinical Data Interchange Standards Consortium Terminology
C132299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132299>	C25364	Protocol Identifier|Protocol Identifying Number|protocol identifier|protocol_identifier	A sequence of letters, numbers, or other characters that uniquely identifies a study protocol.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Property Terminology|GDC Terminology
C13229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13229>	C34144	Embryonic Structure|Embryologic Structure	A body part, organ or organ component that is formed during the embryonic stage of life of an organism.			Embryonic Structure	
C1322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1322>	C471	Lipooxygenase Inhibitor	Any substance that inhibits lipooxygenase, an enzyme that catalyses the dioxygenation of polyunsaturated fatty acids in lipids. Lipooxygenase is involved in the metabolism of eicosanoids (such as prostaglandins and leukotrienes) and its inhibition can suppress hypersensitivity reactions.			Chemical Viewed Functionally	
C132300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132300>	C42774	Protocol Title|protocol title	The name of a study protocol.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C132301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132301>	C49237|C18473	Ribonucleic Acid Measurement|RNA|RNA Measurement|Ribonucleic Acid|Ribonucleic Acid	The determination of the amount of ribonucleic acids in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132302>	C85575	Average Concentration from T1 to T2|Average Conc from T1 to T2|Average Conc from T1 to T2|CAVGINT	The area under the curve over the interval from T1 to T2 divided by the length of the interval.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132303>	C17089	Microscopist|MICROSCOPIST				Professional or Occupational Group	CDISC SDTM Evaluator Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132304>	C17089	Rater|RATER	Any individual qualified to perform an evaluation.			Professional or Occupational Group	CDISC SDTM Evaluator Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132305>	C199143	Office of Management and Budget|OMB|Office of Management and Budget (OMB)	The largest office within the Executive Office of the President of the United States. It oversees the performance of federal agencies, and administers the federal budget.			Professional or Occupational Group	
C132306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132306>	C25162	Healthcare Financing Administration Common Procedure Coding System|HCPCS|Healthcare Financing Administration Common Procedure Coding System (HCPCS)	A standardized coding system used by Medicare and other health insurance programs to ensure that claims are processed in an orderly and consistent manner. The coding system comprises the procedure codes of the American Medical Association Current Procedural Terminology (CPT) and an additional standardized coding set that is used primarily to identify products, supplies, and services not included in the CPT codes.			Intellectual Product	
C132307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132307>	C49474	ICD-10 Procedure Coding System|ICD-10 Procedure Coding System (ICD-10-PCS)|ICD-10-PCS|International Classification of Diseases Procedure Coding System, version 10|International Classification of Diseases, 10th Revision, Procedure Coding System	The International Classification of Diseases, 10th Revision, Procedure Coding System, an international system of medical classification used for procedural coding.			Classification	
C132308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132308>	C103175	CDISC Protocol Entities Physical Address Attribute Terminology|PROT-Att Physical Address|Physical Address Attribute Terminology|Physical Address Attribute Terminology	Terminology associated with the protocol entity physical address attribute codelist of the Clinical Data Interchange Standards Consortium (CDISC).			Intellectual Product	
C132309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132309>	C103175	CDISC Protocol Entities Study Protocol Attribute Terminology|PROT-Att Study Protocol|Study Protocol Attribute Terminology|Study Protocol Attribute Terminology	Terminology associated with the protocol entity study protocol attribute codelist of the Clinical Data Interchange Standards Consortium (CDISC).			Intellectual Product	
C13230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13230>	C33089	Endoplasmic Reticulum|ER	The endoplasmic reticulum is a network of tubular membranes within the cytoplasm of the cell, occurring either with a smooth surface (smooth endoplasmic reticulum) or studded with ribosomes (rough endoplasmic reticulum), involved in the transport of materials. (Infoplease Dictionary)			Cell Component	
C132310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132310>	C103175	CDISC Protocol Entities Terminology|PROT-Prot Entities|Protocol Entity Terminology|Protocol Entity Terminology	Terminology associated with the protocol entity codelist of the Clinical Data Interchange Standards Consortium (CDISC).			Intellectual Product	
C132311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132311>	C66830	CDISC SDTM Administration Technique Response Terminology|ADTNQRS|Administration Technique Response|SDTM-ADTNQRS	Terminology associated with the administration technique response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132312>	C66830	CDISC SDTM Asthma Findings About Test Name Terminology|ASFATS|Asthma Findings About Test Name|SDTM-ASFATS	Terminology associated with the asthma findings about test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132313>	C66830	CDISC SDTM Asthma Findings About Test Code Terminology|ASFATSCD|Asthma Findings About Test Code|SDTM-ASFATSCD	Terminology associated with the asthma findings about test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132314>	C66830	CDISC SDTM Specimen Collection Method Terminology|CLMETH|SDTM-CLMETH|Specimen Collection Method	Terminology associated with the specimen collection method codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132315>	C66830	CDISC SDTM Ebola Virus Findings About Test Name Terminology|EBFATS|Ebola Virus Findings About Test Name|SDTM-EBFATS	Terminology associated with the Ebola virus findings about test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132316>	C66830	CDISC SDTM Ebola Virus Findings About Test Code Terminology|EBFATSCD|Ebola Virus Findings About Test Code|SDTM-EBFATSCD	Terminology associated with the Ebola virus findings about test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132317>	C103175	CDISC SDTM Genetic Region of Interest Type Terminology|SDTM-GENRTYP	Terminology associated with the genetic region of interest type codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	
C132319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132319>	C66830	CDISC SDTM Malaria Findings About Test Name Terminology|MRFATS|Malaria Findings About Test Name|SDTM-MRFATS	Terminology associated with the malaria findings about test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13231>	C13445	Exon|exon	The sequences of a gene that are present in the final, mature, spliced messenger RNA molecule from that gene.	Exon		Gene or Genome	CTRP Biomarker Terminology|CTRP Terminology
C132320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132320>	C66830	CDISC SDTM Malaria Findings About Test Code Terminology|MRFATSCD|Malaria Findings About Test Code|SDTM-MRFATSCD	Terminology associated with the malaria findings about test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132321>	C77526	CDISC SEND Within Normal Limits Results Terminology|NORMRS|SEND-NORMRS|Within Normal Limits Results	Terminology associated with the within normal limits results codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132322>	C20194	RHBDF2 Gene|RHBDF2|RHBDF2|Rhomboid 5 Homolog 2 Gene	This gene plays a role in modulation of epidermal growth factor receptor signaling pathways.			Gene or Genome	
C132323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132323>	C132322	RHBDF2 wt Allele|FLJ22341|IRHOM2|RHBDL5|RHBDL6|Rhomboid 5 Homolog 2 (Drosophila) Gene|Rhomboid 5 Homolog 2 wt Allele|Rhomboid 5, Drosophila, Homolog of, 2 Gene|Rhomboid, Veinlet-Like 6 (Drosophila) Gene|TEC|TOC|TOCG|Tylosis With Esophageal Cancer Gene|iRhom2	Human RHBDF2 wild-type allele is located in the vicinity of 17q25.3 and is approximately 31 kb in length. This allele, which encodes inactive rhomboid protein 2, is involved in the regulation of the secretion of various ligands of the epidermal growth factor receptor. Mutation of the gene is associated with tylosis with esophageal cancer.			Gene or Genome	
C132324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132324>	C18466	Inactive Rhomboid Protein 2|Rhomboid 5 Homolog 2|Rhomboid Family Member 2|Rhomboid Veinlet-Like Protein 5|Rhomboid Veinlet-Like Protein 6|iRhom2	Inactive rhomboid protein 2 (856 aa, ~97 kDa) is encoded by the human RHBDF2 gene. This protein plays a role in the modulation of both epidermal growth factor receptor (EGFR) ligand secretion and EGFR-dependent signaling.			Amino Acid, Peptide, or Protein	
C132325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132325>	C25941	PGAM1 Gene|PGAM1|PGAM1|Phosphoglycerate Mutase 1 Gene	This gene is involved in glycolysis.			Gene or Genome	
C132326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132326>	C132325	PGAM1 wt Allele|CDABP0006|HEL-S-35|PGAM-B|PGAMA|Phosphoglycerate Mutase 1 (Brain) Gene|Phosphoglycerate Mutase 1 wt Allele|Phosphoglycerate Mutase A, Nonmuscle Form Gene|Phosphoglycerate Mutase, Brain Gene	Human PGAM1 wild-type allele is located in the vicinity of 10q24.1 and is approximately 7 kb in length. This allele, which encodes phosphoglycerate mutase 1 protein, plays a role in the glycolytic pathway.			Gene or Genome	
C132327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132327>	C16759	Phosphoglycerate Mutase 1|BPG-Dependent PGAM 1|EC 5.4.2.11|Epididymis Secretory Protein Li 35|PGAM-B|PGAM1|Phosphoglycerate Mutase A|Phosphoglycerate Mutase Isozyme B	Phosphoglycerate mutase 1 (254 aa, ~29 kDa) is encoded by the human PGAM1 gene. This protein is involved in the interconversion of 3- and 2-phosphoglycerate during glycolysis.			Amino Acid, Peptide, or Protein|Enzyme	
C132328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132328>	C54362	BCL9L Gene|B-Cell CLL/Lymphoma 9-Like Gene|BCL9L|BCL9L|BCL9L	This gene plays a role in the coactivation of gene transcription.	BCL9L Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C132329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132329>	C132328	BCL9L wt Allele|B-Cell CLL/Lymphoma 9-Like wt Allele|BCL9-2|DLNB11	Human BCL9L wild-type allele is located in the vicinity of 11q23.3 and is approximately 32 kb in length. This allele, which encodes B-cell CLL/lymphoma 9-like protein, is involved in transcriptional activation.	BCL9L wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13232>	C14136|C12374	Extracellular Matrix|Cell-Extracellular Matrix|ECM	The extracellular matrix is a network of fibers that hold cells together. It is found within the extracellular space and in association with the basement membrane of the cell surface. It promotes cellular proliferation and provides a supporting structure to which cells or cell lysates in culture dishes adhere. It is broken down during normal physiological and disease processes such as bone remodeling, embryogenesis, cancer, and arthritis.			Tissue	
C132330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132330>	C26199	B-Cell CLL/Lymphoma 9-Like Protein|B-Cell Lymphoma 9-Like Protein|BCL9-Like Protein|BCL9L|Nuclear Co-Factor of Beta-Catenin Signaling|Nuclear Co-Factor of Beta-Catenin Signalling|Protein BCL9-2	B-cell CLL/lymphoma 9-like protein (1499 aa, ~157 kDa) is encoded by the human BCL9L gene. This protein plays a role in the promotion of beta-catenin transcriptional activity.	B-Cell CLL/Lymphoma 9-Like Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132331>	C16610	Human Cytomegalovirus Envelope Glycoprotein B|CMV Envelope Glycoprotein B|CMV Glycoprotein B|CMV gB protein|Envelope Glycoprotein B|Glycoprotein B|HCMV gB|HHV5 Envelope Glycoprotein B|Human Cytomegalovirus Glycoprotein B|Human Herpesvirus 5 Glycoprotein B|gB	Envelope glycoprotein B (906 aa; ~102 kDa) is encoded by the human cytomegalovirus gB gene, which is located within the open reading frame (ORF) UL55. This protein is involved in host cell entry, cell to-cell virus transmission, and fusion of infected cells.	Human Cytomegalovirus Envelope Glycoprotein B		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132332>	C35552	Extravascular Extracellular Volume Fraction|ECV|Ve	The ratio of interstitial fluid volume to total body fluid.			Finding	
C132333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132333>	C73581	Approved Drug Product Manufactured Under Contract	A marketing category specifying that an approved drug product is manufactured by a contract manufacturer and not marketed by the contract manufacturer.			Qualitative Concept	FDA Structured Product Labeling Terminology|SPL Marketing Category Terminology
C132334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132334>	C73581	OTC Monograph Drug Product Manufactured Under Contract	A marketing category specifying that an OTC monograph drug product is manufactured by a contract manufacturer and not marketed by the contract manufacturer.			Qualitative Concept	FDA Structured Product Labeling Terminology|SPL Marketing Category Terminology
C132335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132335>	C73581	Unapproved Drug Product Manufactured Under Contract	A marketing category specifying that an unapproved drug product is manufactured by a contract manufacturer and not marketed by the contract manufacturer.			Qualitative Concept	FDA Structured Product Labeling Terminology|SPL Marketing Category Terminology
C132336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132336>	C15239	Guideline Concordant Care|GCC|Guideline-concordant Treatment	Treatment that is in compliance with established guidelines.	Guideline Concordant Care		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C132337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132337>	C17494	ARHGEF5 Gene Product	A protein encoded by the ARHGEF5 gene.			Amino Acid, Peptide, or Protein	
C132338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132338>	C132337	Oncogene TIM Protein|Oncoprotein TIM|Rho Guanine Nucleotide Exchange Factor 5 Isoform 2|Rho Guanine Nucleotide Exchange Factor 5 p60 Isoform|TIM|TIM1|Transforming Immortalized Mammary Oncogene Protein|Transforming Immortalized Mammary Protein|p60|p60 TIM	Oncogene TIM protein (519 aa, ~60 kDa) is encoded by the human ARHGEF5 gene. This protein is involved in the activation of Rho family small GTPases and may induce cellular transformation.			Amino Acid, Peptide, or Protein	
C132339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132339>	C134305	Fianlimab|Anti-LAG-3 MoAb REGN3767|FIANLIMAB|REGN 3767|REGN3767|WHO 11182	A monoclonal antibody directed against the inhibitory receptor lymphocyte activation gene-3 protein (LAG-3; LAG3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, fianlimab binds to LAG-3 expressed by tumor infiltrating lymphocytes (TILs) and blocks LAG-3 binding to tumor cells expressing major histocompatibility complex (MHC) class II molecules. This may activate antigen-specific T-lymphocytes and enhance cytotoxic T-lymphocyte (CTL)-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells; its expression on TILs is associated with tumor-mediated immune suppression and the negative regulation of both cellular proliferation and T-cell activation.	Fianlimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C13233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13233>	C70699	Exudate|EXUDATE	Material, such as purulent and nonpurulent fluid, cells, or cellular debris, which has escaped from blood vessels and has been deposited in tissues or on tissue surfaces, usually as a result of inflammation.  An exudate, in contrast to a transudate, is characterized by a relatively high protein content.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132340>	C80304	Best Observed Case Imputation Technique|BOC|Best Observed Case	A data imputation technique that populates analysis values with the best outcome recorded within a subject.			Quantitative Concept	CDISC ADaM Derivation Type Terminology|CDISC ADaM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132341>	C80304	Last Observed Value Imputation Technique|LOV|Last Observed Value	A data imputation technique that populates analysis values with the subject's last recorded nonmissing observation.			Quantitative Concept	CDISC ADaM Derivation Type Terminology|CDISC ADaM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132342>	C80304	Last Value Prior to Dosing Imputation Technique|LVPD|Last Value Prior to Dosing	A data imputation technique that populates missing values with the subject's last observed value prior to the start of study treatment.			Quantitative Concept	CDISC ADaM Derivation Type Terminology|CDISC ADaM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132343>	C80304	Worst Observed Case Imputation Technique|WOC|Worst Observed Case	A data imputation technique that populates analysis values with the worst recorded outcome within a subject.			Quantitative Concept	CDISC ADaM Derivation Type Terminology|CDISC ADaM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132344>	C90353|C132299	Alternate Protocol Identifier	A unique code that identifies a specific protocol assigned by an affiliated governing body or other organization.			Intellectual Product	
C132345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132345>	C132300	Brief Protocol Title	The short, descriptive name for the protocol.			Intellectual Product	
C132346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132346>	C132300	Official Protocol Title|Full Title|official protocol title|scientific protocol title	The formal, descriptive name of the protocol.			Intellectual Product	CDISC Glossary Terminology|ICH M11 Protocol Section Title Page Data Element Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C132347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132347>	C41200	Protocol Amendment|protocol amendment(s)	A written description of a change(s) to, or formal clarification of, a protocol. (ICH E6)			Intellectual Product	CDISC Glossary Terminology
C132348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132348>	C132299	Registry Protocol Identifier	A unique code, which is assigned by the clinical trial registry, that identifies a specific protocol.			Intellectual Product	
C132349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132349>	C25211	Schedule of Activities|Schedule of Events|SoA|schedule of activities	A planned list of clinical trial activities to include interventions, assessments, and study administrative activities.			Intellectual Product	CDISC Glossary Terminology|ICH M11 Protocol Section 1 Data Element Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C13234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13234>	C13321	Feces|FECES|Fecal|Gastrointestinal Tract, Feces|STOOL|Stool|Stool = Fecal|feces|stool	The material discharged from the bowel during defecation.  It consists of undigested food, intestinal mucus, epithelial cells, and bacteria.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|mCode Genomic Specimen Type Value Set|mCode Terminology
C132350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132350>	C132300	Scientific Protocol Title	The descriptive name of the protocol that is intended for medical professionals, and which is written using medical and scientific language.			Intellectual Product	
C132351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132351>	C132299	Sponsor Protocol Identifier	A unique code, which is assigned by the sponsor, that identifies a specific protocol.			Intellectual Product	ICH M11 Protocol Section Title Page Data Element Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C132352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132352>	C71476	Protocol Approval by Sponsor Date|Approval Date|Sponsor Approval Date|Study Protocol Version Approval Date	Date protocol that was finalized or approved internally by the sponsor.			Temporal Concept	ICH M11 Protocol Section 12 Data Element Terminology|ICH M11 Protocol Section Title Page Data Element Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C132353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132353>	C198356	Induced Expectoration Technique|INDUCED EXPECTORATION	A type of expectoration procedure in which hypotonic saline is inhaled, making lung secretions easier to cough up.			Diagnostic Procedure	CDISC SDTM Specimen Collection Method Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132354>	C117304	Associated Persons Demographics Submission Domain	An associated persons domain utilized for the submission of information encompassing and representing data, vocabulary, or records related to demographics.			Idea or Concept	
C132355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132355>	C71100	6 Lead NEHB-SPORI|6 LEAD NEHB-SPORI	An electrocardiogram (ECG) lead configuration that is primarily used to record ECGs in non-human animals, and which uses six (6) electrodes to generate eight (8) ECG leads (ECG wave forms). The six electrode configuration includes the following: four (4) limb electrodes, which are placed analogous to an Einthoven configuration in humans, and two (2) chest electrodes. The eight (8) ECG leads recorded comprise three standard limb leads (leads I, II, and III), three augmented leads (Leads aVr, aVF, and aVL), and two chest leads, which are generated using two unipolar chest leads, typically CV5RL [rV2] and CV6LL [V2] for canines, or MV1 and MV2 for primates. (CDISC)			Classification	CDISC SDTM ECG Test Method Terminology|CDISC SDTM Terminology|CDISC SEND ECG Method Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132356>	C71100	8 Lead Standard|8 LEAD STANDARD	An electrocardiogram (ECG) recorded using 6 electrodes to generate 8 ECG leads (ECG wave forms). The 6 electrode configuration includes 4 limb electrodes in an Einthoven configuration and two chest electrodes. The 8 ECG leads recorded comprise three standard limb leads (leads I, II, and III), three augmented leads (leads aVR, aVF, and aVL), and two chest leads, which are generated using two unipolar chest leads, typically CV5RL [rV2] and CV6LL [V2] for canines, or MV1 and MV2 for non-human primates. This lead configuration is typically used to record ECGs in non-human animals. (CDISC)			Classification	CDISC SDTM ECG Test Method Terminology|CDISC SDTM Terminology|CDISC SEND ECG Method Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132357>	C47824	CDISC Integrated Basic Data Structure Dataset	IBDS is the ADaM Model for the Integrated Basic Data Structure. The structure includes per pool as defined in the integrated SAP when multiple records per subject are included in integrated ADSL. (CDISC)			Idea or Concept	
C132358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132358>	C47824	CDISC Integrated Occurrence Data Structure Dataset	IOCCDS is the ADaM Model for Integrated Occurrence Data structure. The structure includes per pool as defined in the integrated SAP when multiple records per subject are included in integrated ADSL. (CDISC)			Idea or Concept	
C132359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132359>	C47824	CDISC Integrated Subject Level Dataset	IADSL is the ADaM Model for Integrated Subject Level Analysis Dataset. The structure is one record per subject per pool as defined in the integrated SAP. Multiple records per subject are required in an integrated ADSL dataset when any subject's data is used in more than one pool and the values for subject-level variables differ across pools. (CDISC)			Idea or Concept	
C13235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13235>	C34144	Fetus|FETUS|Fetal|fetus	An unborn or unhatched vertebrate in the later stages of development showing the main recognizable features of the mature being.			Embryonic Structure	CDISC SEND Implantation Findings Result Category Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Newborn Screening Terminology|NICHD Terminology
C132360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132360>	C48938	Ebola Virus Specific IgG Antibody Secreting Cell Count	The determination of the number of Ebola virus-specific IgG antibody secreting cells in a biological sample.			Laboratory Procedure	
C132361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132361>	C48938	Ebola Virus Specific IgM Antibody Secreting Cell Count	The determination of the number of Ebola virus-specific IgM antibody secreting cells in a biological sample.			Laboratory Procedure	
C132362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132362>	C181399	IgM Antibody Secreting Cell Count	The determination of the number of IgM antibody-secreting cells in a biological sample.			Laboratory Procedure	
C132363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132363>	C64430	High Molecular Weight Adiponectin Measurement|ADPNHMW|Adiponectin, High Molecular Weight|Adiponectin, High Molecular Weight	The determination of the amount of high molecular weight adiponectin in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132364>	C64430	Alpha-Methylacyl Coenzyme A Racemase Measurement|AMACR|AMACR|AMACR Measurement|Alpha-Methylacyl Coenzyme A Racemase|Alpha-Methylacyl Coenzyme A Racemase|Alpha-Methylacyl Coenzyme A Racemase	The determination of the amount of alpha-methylacyl coenzyme A racemase in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132365>	C132301	Alpha-Methylacyl Coenzyme A Racemase mRNA Measurement|AMACR mRNA|AMACR mRNA|AMACR mRNA Measurement|AMCRMRNA	The determination of the amount of alpha-methylacyl coenzyme A racemase mRNA in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132366>	C48938	Squamous Epithelial Cells to Total Cells Ratio Measurement|EPISCECE|EPISCECE|Squamous Cells/Total Cells|Squamous Epithelial Cells/Total Cells|Squamous Epithelial Cells/Total Cells|Squamous Epithelial Cells/Total Cells	The determination of the ratio of the squamous epithelial cells compared to the total cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132367>	C132301	Folate Hydrolase mRNA Measurement|FOLH1 mRNA Measurement|FOLHMRNA|Folate Hydrolase 1 mRNA Measurement|Folate Hydrolase mRNA|Folate Hydrolase mRNA	The determination of the amount of folate hydrolase mRNA in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132368>	C48938	G6PD-Deficient Erythrocytes Count|G6PD-Deficient Erythrocytes|G6PD-Deficient Erythrocytes|G6PDRBC	The determination of the amount of G6PD-deficient erythrocytes in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132369>	C48938	G6PD-Deficient Erythrocytes to Erythrocytes Ratio Measurement|G6PD-Deficient Erythrocytes/Erythrocytes|G6PD-Deficient Erythrocytes/Erythrocytes|G6PDRBRB	The determination of the ratio of the G6PD-deficient erythrocytes as compared to the total erythrocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C13236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13236>	C12219	Body Fluid or Substance|Body Fluids and Substances|Body Fluids or Substances|FLUID	Material produced by living organisms; it can be a necessary constituent of, or product of an organismal process.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|Clinical Data Interchange Standards Consortium Terminology|Newborn Screening Terminology|NICHD Terminology
C132370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132370>	C49237	1,3-Beta-D-Glucan Measurement|1,3-Beta-D-Glucan|1,3-Beta-D-Glucan|GLUBD13	The determination of the amount of 1,3-beta-D-glucan in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132371>	C49237	Glycerol Measurement|GLYCRL|GLYCRL|Glycerol|Glycerol|Glycerol	The determination of the amount of glycerol in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SDTM Tobacco Product Testing Test Code Terminology|CDISC SDTM Tobacco Product Testing Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132372>	C81971	Keyhole Limpet Hemocyanin IgG Antibody Measurement	The determination of the amount of keyhole limpet hemocyanin IgG antibody in a biological sample.			Laboratory Procedure	
C132373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132373>	C81972	Keyhole Limpet Hemocyanin IgM Antibody Measurement	The determination of the amount of keyhole limpet hemocyanin IgM antibody in a biological sample.			Laboratory Procedure	
C132374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132374>	C64430	Kallikrein-2 Measurement|KLK-2 Measurement|KLK2|KLK2 Measurement|Kallikrein-2|Kallikrein-2	The determination of the amount of kallikrein-2 in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132375>	C74804	Lymphotoxin Alpha Measurement|LTA|LTA Measurement|Lymphotoxin Alpha|Lymphotoxin Alpha|TNF-beta|TNFSF1 Measurement|Tumor Necrosis Factor Beta	The determination of the amount of lymphotoxin alpha in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132376>	C49286	Neutrophilic Toxic Change Assessment|NEUTTOXC|Neutrophilic Toxic Change|Neutrophilic Toxic Change	The determination of any type of toxic change in the neutrophilic cells within a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132377>	C74804	Oncostatin M Measurement|OSM|OSM Measurement|Oncostatin M|Oncostatin M	The determination of the amount of oncostatin M in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132378>	C132301	PCA3 mRNA to PSA mRNA Ratio Measurement|PC3MPSAM|PCA3 mRNA/PSA mRNA|PCA3 mRNA/PSA mRNA	The determination of the ratio of prostate cancer antigen 3 mRNA as compared to the total prostate specific antigen mRNA present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132379>	C132301	Prostate Cancer Antigen 3 mRNA Measurement|PCA3|PCA3 Test|PCA3 mRNA Measurement|PCA3MRNA|Prostate Cancer Antigen 3 mRNA|Prostate Cancer Antigen 3 mRNA	The determination of the amount of prostate cancer antigen 3 mRNA in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132380>	C49286	Platelet Mass Distribution Width|PMDW	The determination of the variation defined by two standard deviations of the platelet dry mass distribution in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132381>	C116210	Calculated Panel Reactive Antibody Measurement|CPRA Measurement|Calculated Panel Reactive Antibody|Calculated Panel Reactive Antibody|PRABC	The determination of the calculated panel reactive antibody (CPRA), which is based on the number/type of unacceptable HLA antigens to which an organ recipient has been sensitized, and which algorithmically estimates the level of sensitization in the recipient. The CPRA is computed from HLA antigen frequencies in a given donor population using both anti-HLA class I and class II antibody specificities; it also represents the percentage of actual organ donors that express one or more unacceptable HLA antigens to which a recipient may react adversely.			Laboratory Procedure	CDISC SDTM Immunogenicity Specimen Assessments Test Code Terminology|CDISC SDTM Immunogenicity Specimen Assessments Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132382>	C96593	Circulating Prostate Tumor Cell Count|PRCTC|PRCTC|Prostate Circulating Tumor Cells|Prostate Circulating Tumor Cells|Prostate Circulating Tumor Cells	The determination of the amount of circulating prostate tumor cells present in a sample.			Laboratory Procedure	CDISC SDTM Cell Phenotyping Test Code Terminology|CDISC SDTM Cell Phenotyping Test Name Terminology|CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132383>	C17634	Free Prostate Specific Antigen Measurement|PSAF|Prostate Specific Antigen, Free|Prostate Specific Antigen, Free	The determination of the amount of free prostate specific antigen in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132384>	C17634	Free PSA to Total PSA Ratio Measurement|PSA, Free/PSA|PSA, Free/PSA|PSAFPSAT	The determination of the ratio of free prostate specific antigen as compared to the total prostate specific antigen present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132385>	C17634|C132301	Prostate Specific Antigen mRNA Measurement|PSAMRNA|Prostate Specific Antigen mRNA|Prostate Specific Antigen mRNA	The determination of the amount of prostate specific antigen mRNA in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132386>	C124345	Soluble Intercellular Adhesion Molecule 1 Measurement|SICAM1|Soluble Intercell Adhesion Molecule 1|Soluble Intercell Adhesion Molecule 1|sICAM-1 Measurement|sICAM1 Measurement	The determination of the amount of soluble intercellular adhesion molecule 1 in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132387>	C64430	T-Kininogen Measurement|T-Kininogen|T-Kininogen|TKG	The determination of the amount of T-kininogen in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132388>	C210011|C210010	Treponema pallidum Antibody Measurement	The determination of the amount of Treponema pallidum antibody in a biological sample.			Laboratory Procedure	
C132389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132389>	C92514	Vascular Endothelial Growth Factor A Measurement|VEGFA|VEGFA Measurement|Vascular Endothelial Growth Factor A|Vascular Endothelial Growth Factor A	The determination of the amount of vascular endothelial growth factor A in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C13238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13238>	C33089	Golgi Apparatus|Golgi|Golgi Complex	A stack of flattened vesicles located between the nucleus and the secretory pole or surface of a cell. Functions in posttranslational processing and sorting of proteins, receiving them from the rough endoplasmic reticulum and directing them to secretory vesicles, lysosomes, or the cell membrane. The movement of proteins takes place by transfer vesicles that bud off from the rough endoplasmic reticulum or golgi apparatus and fuse with the golgi, lysosomes or cell membrane.			Cell Component	
C132390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132390>	C12680	Periventricular Region|BRAIN, PERIVENTRICULAR REGION	The area surrounding the ventricles of the brain.			Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132391>	C33027	Diaphragmatic Lymph Node|DIAPHRAGMATIC LYMPH NODE|Structure of diaphragmatic lymph node (body structure)	Lymph node located adjacent to the diaphragm.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C132392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132392>	C33423	Inferior Pubic Ramus|INFERIOR PUBIC RAMUS	The portion of the pubic ramus that lies between the superior pubic ramus and the inferior ramus of the ischium.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132393>	C222548	Left Lung, Inferior Lobe, Anterior Basal Segment|LUNG, LEFT, INFERIOR LOBE, ANTERIOR BASAL SEGMENT	The anterior basal segment of the inferior lobe of the left lung.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132394>	C222548	Left Lung, Inferior Lobe, Lateral Basal Segment|LUNG, LEFT, INFERIOR LOBE, LATERAL BASAL SEGMENT	The lateral basal segment of the inferior lobe of the left lung.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132395>	C222548	Left Lung, Inferior Lobe, Medial Basal Segment|LUNG, LEFT, INFERIOR LOBE, MEDIAL BASAL SEGMENT	The medial basal segment of the inferior lobe of the left lung.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132396>	C222548	Left Lung, Inferior Lobe, Posterior Basal Segment|LUNG, LEFT, INFERIOR LOBE, POSTERIOR BASAL SEGMENT	The posterior basal segment of the inferior lobe of the left lung.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132397>	C222548	Left Lung, Inferior Lobe, Superior Segment|LUNG, LEFT, INFERIOR LOBE, SUPERIOR SEGMENT	The superior segment of the inferior lobe of the left lung.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132398>	C222549	Left Lung, Superior Lobe, Anterior Segment|LUNG, LEFT, SUPERIOR LOBE, ANTERIOR SEGMENT	The anterior segment of the superior lobe of the left lung.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132399>	C222549	Left Lung, Superior Lobe, Apicoposterior Segment|LUNG, LEFT, SUPERIOR LOBE, APICOPOSTERIOR SEGMENT	The apicoposterior segment of the superior lobe of the left lung.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C13239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13239>	C13189	Hapten|Haptens	A substance that can act as an epitope for an antibody but that lacks immunogenicity unless coupled to a larger carrier molecule.			Immunologic Factor	
C1323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1323>	C471|C257	Cyclooxygenase Inhibitor|COX Inhibitor|COX inhibitor|Clyclooxygenases Inhibitor|Prostaglandin G/H Synthase Inhibitor|cyclooxygenase inhibitor	Any agent that inhibits prostaglandin G/H synthase (cyclooxygenase or COX), an enzyme that catalyzes the production of prostanoids, including prostaglandins, prostacyclin and thromboxane, from arachidonic acid. Cyclooxygenase inhibitors are a type of non-steroidal anti-inflammatory drug.			Chemical Viewed Functionally	
C132400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132400>	C222549	Left Lung, Superior Lobe, Inferior Lingular Segment|LUNG, LEFT, SUPERIOR LOBE, INFERIOR LINGULAR SEGMENT	The inferior lingular segment of the superior lobe of the left lung.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132401>	C222549	Left Lung, Superior Lobe, Superior Lingular Segment|LUNG, LEFT, SUPERIOR LOBE, SUPERIOR LINGULAR SEGMENT	The superior lingular segment of the superior lobe of the left lung.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132402>	C222551	Right Lung, Inferior Lobe, Anterior Basal Segment|LUNG, RIGHT, INFERIOR LOBE, ANTERIOR BASAL SEGMENT	The anterior basal segment of the inferior lobe of the right lung.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132403>	C222551	Right Lung, Inferior Lobe, Lateral Basal Segment|LUNG, RIGHT, INFERIOR LOBE, LATERAL BASAL SEGMENT	The lateral basal segment of the inferior lobe of the right lung.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132404>	C222551	Right Lung, Inferior Lobe, Medial Basal Segment|LUNG, RIGHT, INFERIOR LOBE, MEDIAL BASAL SEGMENT	The medial basal segment of the inferior lobe of the right lung.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132405>	C222551	Right Lung, Inferior Lobe, Posterior Basal Segment|LUNG, RIGHT, INFERIOR LOBE, POSTERIOR BASAL SEGMENT	The posterior basal segment of the inferior lobe of the right lung.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132406>	C222551	Right Lung, Inferior Lobe, Superior Segment|LUNG, RIGHT, INFERIOR LOBE, SUPERIOR SEGMENT	The superior segment of the inferior lobe of the right lung.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132407>	C222552	Right Lung, Middle Lobe, Lateral Segment|LUNG, RIGHT, MIDDLE LOBE, LATERAL SEGMENT	The lateral segment of the middle lobe of the right lung.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132408>	C222552	Right Lung, Middle Lobe, Medial Segment|LUNG, RIGHT, MIDDLE LOBE, MEDIAL SEGMENT	The medial segment of the middle lobe of the right lung.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132409>	C222553	Right Lung, Superior Lobe, Anterior Segment|LUNG, RIGHT, SUPERIOR LOBE, ANTERIOR SEGMENT	The anterior segment of the superior lobe of the right lung.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132410>	C222553	Right Lung, Superior Lobe, Apical Segment|LUNG, RIGHT, SUPERIOR LOBE, APICAL SEGMENT	The apical segment of the superior lobe of the right lung.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132411>	C222553	Right Lung, Superior Lobe, Posterior Segment|LUNG, RIGHT, SUPERIOR LOBE, POSTERIOR SEGMENT	The posterior segment of the superior lobe of the right lung.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132412>	C32674	Periureteral Region|PERIURETERAL REGION	The area surrounding the ureter.			Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132413>	C132225	Portal Vein Bifurcation|PORTAL VEIN BIFURCATION	The portion of the distal end of the main portal vein that branches into the left and right portal veins.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132414>	C12680	Presacral Space|PRESACRAL SPACE	The potential body space formed between the rectum and the sacrum.			Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132415>	C33423	Superior Pubic Ramus|SUPERIOR PUBIC RAMUS	The portion of the pubic ramus that lies between the body of the ilium and the inferior pubic ramus.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132416>	C49188	Microorganism Identification|MCORGIDN|Microbial Organism Identification|Microbial Organism Identification|Microbial identification test	The determination of the type of microorganism in a biological sample.			Diagnostic Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132417>	C221586	Asexual Plasmodium knowlesi Measurement|PKNOWLA|Plasmodium knowlesi, Asexual|Plasmodium knowlesi, Asexual	The determination of the amount of the organism assigned to the Plasmodium knowlesi species in the asexual phase in a biological sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132418>	C221587	Sexual Plasmodium knowlesi Measurement|PKNOWLS|Plasmodium knowlesi, Sexual|Plasmodium knowlesi, Sexual	The determination of the amount of the organism assigned to the Plasmodium knowlesi species in the sexual phase in a biological sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132419>	C49188	Taxonomic Identification Below Species Level	The determination of the taxonomic ranking of the microorganism that is below species level.			Diagnostic Procedure	
C13241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13241>	C13201	Heterochromatin	A tightly packed area of chromatin that may function to protect chromosome integrity and regulate gene expression.			Cell Component	
C132420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132420>	C184673	Zaire Ebolavirus Measurement|ZEBOV|Zaire Ebola Virus Measurement|Zaire Ebolavirus|Zaire Ebolavirus	The determination of the amount of the organism assigned to the Zaire ebola virus species in a biological sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132421>	C132303	Microscopist 1|MICROSCOPIST 1	The first in a series of microscopists that are performing an assessment.			Professional or Occupational Group	CDISC SDTM Medical Evaluator Identifier Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132422>	C132303	Microscopist 2|MICROSCOPIST 2	The second in a series of microscopists that are performing an assessment.			Professional or Occupational Group	CDISC SDTM Medical Evaluator Identifier Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132423>	C132303	Microscopist 3|MICROSCOPIST 3	The third in a series of microscopists that are performing an assessment.			Professional or Occupational Group	CDISC SDTM Medical Evaluator Identifier Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132424>	C73456	Optometrist|OPTOMETRIST	A physician with a Doctor of Optometry degree (or analogous) that specializes in the diagnosis and treatment of eye disorders.			Biomedical Occupation or Discipline	CDISC SDTM Evaluator Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132425>	C132304	Rater 1|RATER 1	The first in a series of raters that are performing an assessment.			Professional or Occupational Group	CDISC SDTM Medical Evaluator Identifier Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132426>	C132304	Rater 2|RATER 2	The second in a series of raters that are performing an assessment.			Professional or Occupational Group	CDISC SDTM Medical Evaluator Identifier Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132427>	C15958	Fluorescent Spot Test|FLUORESCENT SPOT TEST	A method to assess enzymatic activity in which a substrate reagent is incubated with a biological specimen and spotted on filter paper. The spots are then examined for fluorescence, which correlates with enzyme activity.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132428>	C38060	Hillmen Color Chart|HILLMEN COLOR CHART	A visual color scale created by Hillman et al in 2004 to enable standardization of urine color in the assessment of hemoglobinuria. (Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE, Cullen MJ, Richards SJ, Rollins SA, Mojcik CF, Rother RP. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004 Feb 5;350(6):552-9.)			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132429>	C28076	Enhanced Liver Fibrosis Score|ELF|ENHANCED LIVER FIBROSIS SCORE	A scoring system for liver fibrosis developed by Lichtinghagen et al, based on an algorithm that takes into account tissue inhibitor of metalloproteinases 1 (TIMP-1), amino-terminal propeptide of type III procollagen (PIIINP) and hyaluronic acid (HA) levels. (Lichtinghagen R, Pietsch D, Bantel H, Manns MP, Brand K, Bahr MJ. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. J Hepatol. 2013 Aug;59(2):236-42.)			Classification	CDISC SDTM Microscopic Findings Test Detail Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13242>	C13806	Immunoglobulin Constant Region	The portion of an antibody that is invariant within a class of immunoglobulins. It is comprised of the carboxyl terminal half of both light chains and at least three quarters of each heavy chain starting from the carboxyl terminus and excludes the variable regions of the heavy and light chains.			Amino Acid Sequence	
C132430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132430>	C49131	Cellular Differentiation Assessment|CELLDIFF|Cellular Differentiation|Cellular Differentiation	The determination of the amount of cellular differentiation in a biological sample.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132431>	C64430	Folate Hydrolase 1 Measurement|FOLH1|FOLH1 Measurement|Folate Hydrolase 1|Folate Hydrolase 1|Folate Hydrolase Measurement	The determination of the amount of folate hydrolase 1 in a biological sample.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132432>	C28076	Hyperemia Grade|HYPERGR	An evaluation of the presence and extent of hyperemia.			Classification	CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132433>	C19896	Allelic Family	A subgroup of alleles of a polymorphic gene that may form clusters (e.g., phylogenetic) based on high sequence similarity, which may include either a shared single nucleotide polymorphism or a shared set of polymorphic sites.			Classification	
C132434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132434>	C25681	Amplicon Size	The number of base pairs present in an RNA or DNA sequence, which is the product of an amplification process.			Quantitative Concept	
C132435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132435>	C102356	Accumulation Ratio AUC Over Dosing Interval Normalized by Dose|ARAUCD|Accum Ratio AUCTAU norm by dose|Accum Ratio AUCTAU norm by dose	The area under the curve (AUCtau) at steady state divided by the area under the curve (AUCtau) over the initial dosing interval, each divided by the associated dose.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132436>	C102356	Accumulation Ratio AUC T1 to T2 Normalized by Dose|ARAUCIND|Accum Ratio AUC T1 to T2 norm by dose|Accum Ratio AUC T1 to T2 norm by dose	The area under the curve from T1 to T2 at steady state divided by the area under the curve from T1 to T2 during the initial dosing interval, each divided by the associated dose. (CDISC)			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132437>	C102357	Accumulation Ratio Cmax Normalized by Dose|ARCMAXD|Accum Ratio Cmax norm by dose|Accum Ratio Cmax norm by dose	The maximum concentration at steady state divided by the maximum concentration during the initial dosing interval, each divided by the associated dose. (CDISC)			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132438>	C102358	Accumulation Ratio Cmin Normalized by Dose|ARCMIND|Accum Ratio Cmin norm by dose|Accum Ratio Cmin norm by dose	The minimum concentration at steady state divided by the minimum concentration during the initial dosing interval, each divided by the associated dose. (CDISC)			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132439>	C102426	Accumulation Ratio Ctrough Normalized by Dose|ARCTROUD|Accum Ratio Ctrough norm by dose|Accum Ratio Ctrough norm by dose	The trough concentration at steady state divided by the trough concentration during the initial dosing interval, each divided by the associated dose. (CDISC)			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C13243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13243>	C13806	Immunoglobulin Joining Region	The portion of the light and heavy chains of immunoglobulin molecules where the variable and constant regions meet.			Amino Acid, Peptide, or Protein	
C132440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132440>	C132302	Average Concentration from T1 to T2 Normalized by Body Mass Index|Average Conc from T1 to T2 Norm by BMI|Average Conc from T1 to T2 Norm by BMI|CAVGINTB	The area under the curve over the interval from T1 to T2 divided by the length of the interval and then divided by the body mass index. (CDISC)			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132441>	C132302	Average Concentration from T1 to T2 Normalized by Dose|Average Conc from T1 to T2 Norm by Dose|Average Conc from T1 to T2 Norm by Dose|CAVGINTD	The area under the curve over the interval from T1 to T2 divided by the length of the interval and then divided by the dose. (CDISC)			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132442>	C132302	Average Concentration from T1 to T2 Normalized by Surface Area|Average Conc from T1 to T2 Norm by SA|Average Conc from T1 to T2 Norm by SA|CAVGINTS	The area under the curve over the interval from T1 to T2 divided by the length of the interval and then divided by the surface area. (CDISC)			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132443>	C132302	Average Concentration from T1 to T2 Normalized by Weight|Average Conc from T1 to T2 Norm by WT|Average Conc from T1 to T2 Norm by WT|CAVGINTW	The area under the curve over the interval from T1 to T2 divided by the length of the interval and then divided by the weight. (CDISC)			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132444>	C92571	Day Times Microgram per Milliliter Times Kilogram per Milligram|d.ug/mL/(mg/kg)|d.ug/mL/(mg/kg)|d.ug/ml/(mg/kg)|d.ug/ml/(mg/kg)|day*ug/mL/(mg/kg)|day*ug/mL/(mg/kg)	Days times microgram per milliliter, divided by milligrams times kilograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132445>	C92571	Hour Times Nanomole per Liter per Milligram per Kilogram|h*nmol/L/(mg/kg)|h*nmol/L/(mg/kg)|h.nmol/L/(mg/kg)|h.nmol/L/(mg/kg)|h.nmol/l/(mg/kg)|h.nmol/l/(mg/kg)	Hours times nanomoles per liter, divided by milligrams per kilograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132446>	C92571	Hour Times Micromole per Liter per Milligram per Kilogram|h*umol/L/(mg/kg)|h*umol/L/(mg/kg)|h.umol/L/(mg/kg)|h.umol/L/(mg/kg)|h.umol/l/(mg/kg)|h.umol/l/(mg/kg)	Hours times micromoles per liter, divided by milligrams per kilograms.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM PK Unit of Measure Milligram Dose Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132447>	C70732	Eligibility Criteria Met By Subject|ELIGIBILITY CRITERIA MET	An indication that the subject has fulfilled the criteria needed to continue to the next study period.			Conceptual Entity	CDISC SDTM Protocol Milestone Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132448>	C25168	Blood Donor|DONOR, BLOOD	Someone from whom blood is removed for transplantation or other purpose.			Human	CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132449>	C25368	Household Member|HOUSEHOLD MEMBER|Household Resident	An individual who is considered part of the social unit comprising one or more individuals living together (all of whom need not be related) in the same dwelling, who aggregate and share their incomes.			Human	CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13244>	C13445	Immunoglobulin Switch Region	Nucleotide sequences found upstream of exons encoding the constant regions of immunoglobulin heavy chains where exon rearrangement can occur. The combination of exons selected in a B-cell determines the immunoglobulin isotype produced by that cell.			Nucleic Acid, Nucleoside, or Nucleotide|Nucleotide Sequence	
C132450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132450>	C25189|C166116	Stepmother|MOTHER, STEP|Step Mother	A female who is married to a spouse with children whom are not biologically related to her.			Human	CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C132451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132451>	C71384|C71382	Biological Relative, Paternal|RELATIVE, BIOLOGICAL PATERNAL	Any individual related biologically to an individual's father.			Human	CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132452>	C199001	Suspected Source Case|SUSPECTED SOURCE CASE	An individual who is believed to have likely transmitted a disease to another individual.			Human	CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132453>	C38081	Forced Expiratory Volume in 3 Seconds|FEV3	The volume exhaled during the first three seconds of a forced expiratory maneuver that is started from the level of total lung capacity.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132454>	C125932	PCWG Scher Prostate Cancer 2016 Oncology Response Criteria|PCWG SCHER PROSTATE CANCER 2016|PCWG3				Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132455>	C50995	Bone Response|BONERESP	An assessment of the bone response of a disease to a therapy.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Assessment Test Code Terminology|CDISC SDTM Tumor Response Assessment Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C132456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132456>	C181043	Metastatic Disease Indicator|METSIND|Metastatic Indicator|Metastatic Indicator	An indication as to whether a malignancy has appeared at sites distant to the primary site of disease.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Assessment Test Code Terminology|CDISC SDTM Tumor Response Assessment Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C132457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132457>	C50995	Soft Tissue Response|SFTSRESP	An evaluation of the soft tissue response of the disease to the therapy.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Assessment Test Code Terminology|CDISC SDTM Tumor Response Assessment Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C132458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132458>	C225430	Tumor Marker Response|TMRESP	An evaluation of the tumor marker response of the disease to the therapy.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Assessment Test Code Terminology|CDISC SDTM Tumor Response Assessment Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C132459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132459>	C19332	Primary Language Spoken|LNGSPP|Primary Language Spoken at Home	The main language that is spoken by the subject most frequently or dominantly.			Conceptual Entity	CDISC SDTM Subject Characteristic Test Code Terminology|CDISC SDTM Subject Characteristic Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C13245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13245>	C13806	Immunoglobulin Variable Region	The portion of an antibody molecule that contains the three hypervariable regions in both the heavy and light chains. It is comprised of the amino terminal half of the light chains and at most a third of the heavy chains from the amino termini.	Immunoglobulin Variable Region		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132460>	C19332	Secondary Language Spoken|LNGSPS	Additional language(s) that is spoken by the subject but which is not considered the primary language.			Conceptual Entity	CDISC SDTM Subject Characteristic Test Code Terminology|CDISC SDTM Subject Characteristic Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132461>	C13356	Capillary Plasma|CAPILLARY PLASMA	Plasma that has been isolated from capillary blood.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132462>	C13356	Venous Plasma|VENOUS PLASMA	Plasma that has been isolated from venous blood.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132463>	C174277	Number of Bone Lesions|BNLNUM	A measurement of the total number of bone tumors.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C132464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132464>	C132463	Number of New Bone Lesions|NBNLNUM	A measurement of the total number of bone tumors that have not been previously seen or characterized.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C132465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132465>	C181043	Two or More Persisting New Bone Lesions Indicator|PBNL2IND|Two or More Persist New Bone Lesions Ind|Two or More Persist New Bone Lesions Ind	An indication as to whether there are two or more bone tumors that have been previously seen or characterized.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C132466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132466>	C94189	Bone Lesion Identification|BONE LESION	The identification of a localized, pathological, or traumatic structural change, damage, deformity, or discontinuity of the bone.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor and Lesion Identification Test Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C132467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132467>	C94189	New Bone Lesion Lesion Identification|NEW BONE LESION	A localized, pathological, or traumatic structural change, damage, deformity, or discontinuity of the bone that has not been previously seen or characterized.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor and Lesion Identification Test Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C132468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132468>	C94189	Non-target Enhancing Lesion Identification|NON-TARGET ENHANCING	The identification of a tumor or lesion that has a well-defined area of unequivocally increased signal intensity on MRI or CT scan images compared with the normal-appearing surrounding tissues, and is not the target of the therapeutic intervention.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor and Lesion Identification Test Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C132469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132469>	C94189	Non-Target Extra Nodal Lesion Identification|NON-TARGET EXTRA NODAL	The identification of a tumor or lesion that is present at baseline, located outside of or independent of any lymph nodes, and is not the target of the therapeutic intervention.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor and Lesion Identification Test Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C13246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13246>	C13806	Fab Fragment|Antigen Binding Fragment|Fab|Immunoglobulin, F(ab) Fragment	Part of an immunoglobulin antibody that binds a specific antigen and consists of both a light chain and part of a heavy chain.  By comparison, natural antibodies consist of two heavy and two light chains.  An FAB (fragment antibody) offers the advantages of smaller size and lower cross-reactivity compared to the complete antibody. (NCI04)			Amino Acid, Peptide, or Protein|Immunologic Factor	
C132470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132470>	C94189	Non-Target Nodal Lesion Identification|NON-TARGET NODAL	The identification of a tumor or lesion located at or near the lymph node that is present at baseline, and is not the target of the therapeutic intervention.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor and Lesion Identification Test Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C132471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132471>	C94189	Non-target Non-enhancing Lesion Identification|NON-TARGET NON-ENHANCING	The identification of a tumor or lesion without a well-defined area of unequivocally increased signal intensity on MRI or CT scan images compared with the normal-appearing surrounding tissues, and is not the target of the therapeutic intervention.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor and Lesion Identification Test Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C132472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132472>	C96619	Per 200 High Powered Fields|/200 HPFs|/200 HPFs|/200.[HPF]|/200.[HPF]|Per 200HPF	A unit of measurement of the number of entities per unit of area equal to 200 high powered fields.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132473>	C67218	Per 2000 Red Blood Cells|/2000 RBC|/2000 RBC|/2000{RBC}|/2000{RBC}|/2x10^3 RBC	Natural number unit of measurement for a portion of a particular type of cell (excluding red blood cell subtypes) per 2000 red blood cells.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132474>	C67218	Per 2500 White Blood Cells|/2500 WBC|/2500 WBC|/2500{WBC}|/2500{WBC}	Natural number unit of measurement for a portion of a particular type of cell (excluding white blood cell subtypes) per 2500 white blood cells.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132475>	C96619	Per 40 High Powered Fields|/40 HPFs|/40 HPFs|/40.[HPF]|/40.[HPF]|Per 40HPF	A unit of measurement of the number of entities per unit of area equal to 40 high powered fields.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132476>	C67218	Per 500 White Blood Cells|/500 WBC|/500 WBC|/500{WBC}|/500{WBC}	Natural number unit of measurement for a portion of a particular type of cell (excluding white blood cell subtypes) per 500 white blood cells.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132477>	C48572	Base Pair Unit|BASE PAIRS|BP|BP|{BP}|{BP}	The unit of measure for the number of paired nucleotides in a DNA or RNA sequence.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132478>	C67375	Log10 50 Percent Tissue Culture Infective Dose per Milliliter|log10 TCID 50/mL|log10 TCID 50/mL|{log}.[TCID_50]/mL|{log}.[TCID_50]/mL|{log}.[TCID_50]/ml|{log}.[TCID_50]/ml	A logarithmic-scale (base 10) potency unit for measuring infectious activity of a biologic product or infectious agent preparation equal to the potency at which one milliliter of infectious material contains one 50 percent tissue culture infective dose.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132479>	C67375	Log10 50 Percent Tissue Culture Infective Dose per Microliter|log10 TCID 50/uL|log10 TCID 50/uL|{log}.[TCID_50]/uL|{log}.[TCID_50]/uL|{log}.[TCID_50]/ul|{log}.[TCID_50]/ul	A logarithmic-scale (base 10) potency unit for measuring infectious activity of a biologic product or infectious agent preparation equal to the potency at which one microliter of infectious material contains one 50 percent tissue culture infective dose.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C13247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13247>	C13806	Immunoglobulin Fc|Fc Fragment|Fragment Crystallizable Region|IGG FC	A protein product that results from the digestion of antibodies with papain and is comprised of the second and third constant regions of the antibody heavy chain.			Amino Acid, Peptide, or Protein|Immunologic Factor	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132480>	C48207	MilliMerck Unit per Milliliter|mMU/mL|mMU/mL|{mMU}/mL|{mMU}/mL|{mMU}/ml|{mMU}/ml	A unit of concentration based on the vaccine specific number of titers that are the geometric mean titer at which an individual is considered to convert from a seronegative to a seropositive response due to the vaccine.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132481>	C66973	Microliter per Kilogram per Day|(uL/day)/kg|nL/g/day|uL/kg/d|uL/kg/d|uL/kg/day|uL/kg/day|uL/kg/day|ul/kg/d|ul/kg/d	A unit of volume expressed as a number of microliters of the constituent per kilogram of weight per day.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132482>	C81328	Estimated Body Weight|EWEIGHT|Estimated Weight|Estimated Weight	An approximate determination of the weight of a body.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Vital Sign Test Code Terminology|CDISC SDTM Vital Sign Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132483>	C35867	Adipocyte Accumulation|ACCUMULATION, ADIPOCYTES	An increase of adipocytes in the extracellular space.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132484>	C45481	Hemangiectasis	Dilatation of the blood vessels.			Finding	
C132485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132485>	C35867	Apoptosis and Necrosis	A finding that generally has features of degeneration and necrosis.			Finding	
C132486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132486>	C42075	Ectopic Tissue|ECTOPIC TISSUE|Ectopia|Heterotopia	A tissue that forms in a location of the body at or in which it is not normally associated.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132487>	C35867	Eosinophilic Globules|EOSINOPHILIC GLOBULES	A cellular droplet comprising fibrin degradation products or intracytoplasmic proteinaceous accumulations that can be stained by eosin.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132488>	C35867	Helicobacter Present|HELICOBACTER	The presence of any species of Helicobacter.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132489>	C42614	Non-clinical Contributing Scientist Name|CNTRBSC|Contributing Scientist|Contributing Scientist	The name of a scientist involved in study activities, which may include but is not limited to preparation of a contributor report. This role does not imply regulatory responsibilities or oversight. (CDISC)			Conceptual Entity	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C13248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13248>	C32603	Intermediate Filament	A class of tough protein filaments (including keratin filaments, neurofilaments, desmin, and vimentin) that measure 8-10 nm in thickness and comprise part of the cytoskeleton of the cytoplasm of most eukaryotic cells; so named because they are intermediate in thickness between actin filaments and microtubules.			Cell Component	
C132490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132490>	C181043	Two or More New Bone Lesions Indicator|NBNL2IND	An indication as to whether there are two or more bone tumors that have not been previously seen or characterized.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C132491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132491>	C101510	Contract FDF Manufacturing|Contract Manufacturing	Manufacturing of a part or all of final dosage form (FDF) that takes place in a contract facility and the contract facility is not identified in an approved ANDA owned by that facility or its affiliates.			Activity	FDA Structured Product Labeling Terminology|SPL Business Operation Qualifier Terminology
C132492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132492>	C20993	NCCN Distress Thermometer and Problem List for Patients Version 2.2016|Distress Thermometer|Distress Thermometer, 2.2016	A screening tool developed by the National Comprehensive Cancer Network (NCCN) Distress Management Panel used to identify patient distress coming from any source and patient problems in five categories.			Intellectual Product	
C132493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132493>	C173350	Distress over Physical Problem with Substance Abuse Question|Distress over Physical Problem with Substance Abuse|Distress over Physical Problem with Substance Abuse	A question about an individual's distress related to their physical problems with substance abuse.			Intellectual Product	NCCN Distress Thermometer and Problem List for Patients Version 2.2016
C132494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132494>	C32298	Neck Lymph Node Boundary Levels and Sublevels	The anatomical structures that define the neck lymph node boundaries.			Finding	
C132495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132495>	C132494	Neck Lymph Node Boundary Sublevel IA	The following anatomical structures define the neck lymph node boundary for sublevel IA: Superior: symphysis of the mandible; inferior: body of the hyoid; anterior (medial): anterior belly of the contralateral digastric muscle; posterior (lateral): anterior belly of the ipsilateral digastric muscle. (AJCC 8th ed.)			Finding	
C132496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132496>	C132494	Neck Lymph Node Boundary Sublevel IB	The following anatomical structures define the neck lymph node boundary for sublevel IB: Superior: body of the mandible; inferior: posterior belly of the digastric muscle; anterior (medial): anterior belly of the digastric muscle; posterior (lateral): stylohyoid muscle. (AJCC 8th ed.)			Finding	
C132497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132497>	C202889	Neck Lymph Node Boundary Sublevel IIA	The following anatomical structures define the neck lymph node boundary for sublevel IIA: Superior: skull base; inferior: horizontal plane defined by the inferior border of the hyoid bone; anterior (medial): stylohyoid muscle; posterior (lateral): vertical plane defined by the spinal accessory nerve. (AJCC 8th ed.)			Finding	
C132498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132498>	C202889	Neck Lymph Node Boundary Sublevel IIB	The following anatomical structures define the neck lymph node boundary for sublevel IIB: Superior: skull base; inferior: horizontal plane defined by the inferior body of the hyoid bone; anterior (medial): vertical plane defined by the spinal accessory nerve; posterior (lateral): lateral border of the sternocleidomastoid muscle. (AJCC 8th ed.)			Finding	
C132499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132499>	C132494	Neck Lymph Node Boundary Level III|CERVICAL LYMPH NODE LEVEL III	The following anatomical structures define the neck lymph node boundary for level III: Superior: horizontal plane defined by the inferior body of the hyoid; inferior: horizontal plane defined by the inferior border of the cricoid cartilage; anterior (medial): lateral border of the sternohyoid muscle; posterior (lateral): lateral border of the sternocleidomastoid or sensory branches of the cervical plexus. (AJCC 8th ed.)			Finding	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C13249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13249>	C13445	Intron|Intervening Sequence|Intronic|intron	Non-coding, intervening sequences of DNA that are transcribed, but are removed from within the primary gene transcript and rapidly degraded during maturation of messenger RNA.			Gene or Genome	
C1324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1324>	C593	Therapeutic Interleukin-9|IL-9|INTERLEUKIN-9|Interleukin 9|P40 T-Cell Growth Factor	A therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin-9 (IL-9). Produced by CD4+ lymphocytes, IL-9 stimulates the proliferation of T-helper cells and the growth of mast cells and megakaryoblasts.  This agent also enhances the growth of some leukemia cell lines and may play a role in the pathogenesis of Hodgkin disease and large cell anaplastic lymphoma. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132500>	C132494	Neck Lymph Node Boundary Level IV|CERVICAL LYMPH NODE LEVEL IV	The following anatomical structures define the neck lymph node boundary for level IV: Superior: horizontal plane defined by the inferior border of the cricoid cartilage; inferior: clavicle; anterior (medial): lateral border of the sternohyoid muscle; posterior (lateral): lateral border of the sternocleidomastoid or sensory branches of the cervical plexus. (AJCC 8th ed.)			Finding	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132501>	C202890	Neck Lymph Node Boundary Sublevel VA	The following anatomical structures define the neck lymph node boundary for sublevel VA: Superior: apex of the convergence of the sternocleidomastoid and trapezius muscles; inferior: horizontal plane defined by the lower border of the cricoid cartilage; anterior (medial): posterior border of the sternocleidomastoid muscle or sensory branches of the cervical plexus; posterior (lateral): anterior border of the trapezius muscle. (AJCC 8th ed.)			Finding	
C132502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132502>	C202890	Neck Lymph Node Boundary Sublevel VB	The following anatomical structures define the neck lymph node boundary for sublevel VB: Superior: horizontal plane defined by the lower border of the cricoid cartilage; inferior: clavicle; anterior (medial): posterior border of the sternocleidomastoid muscle; posterior (lateral): anterior border of the trapezius muscle. (AJCC 8th ed.)			Finding	
C132503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132503>	C132494	Neck Lymph Node Boundary Level VI	The following anatomical structures define the neck lymph node boundary for level VI: Superior: hyoid bone; inferior: suprasternal notch; anterior (medial): common carotid artery; posterior (lateral): common carotid artery. (AJCC 8th ed.)			Finding	
C132504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132504>	C132494	Neck Lymph Node Boundary Level VII	The following anatomical structures define the neck lymph node boundary for level VII: Superior: suprasternal notch; inferior: innominate artery; anterior (medial): sternum; posterior (lateral): trachea, esophagus, and prevertebral fascia. (AJCC 8th ed.)			Finding	
C132505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132505>	C132067	WHO Grade 2 Glioma|Grade 2 Glioma|Grade II Glioma|Grade II Glioma|WHO Grade II Glioma	A category of low grade gliomas that includes diffuse astrocytoma, ependymoma, oligodendroglioma, and oligoastrocytoma.	Grade II Glioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132506>	C71700|C3059	Recurrent Glioma	The reemergence of a glioma after a period of remission.	Recurrent Glioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132507>	C12745	Neck Lymph Node Groups	Lymph node groups found within the seven levels and sublevels of the neck. (AJCC 8th ed.)			Body Part, Organ, or Organ Component	
C132508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132508>	C132507	Submental Lymph Node Group (Sublevel IA)|Lymph node level IA (qualifier value)	Lymph nodes within the triangular boundary of the anterior belly of the digastric muscles and the hyoid bone. These nodes are at greatest risk for harboring metastases from cancers arising from the floor of mouth, anterior oral tongue, anterior mandibular alveolar ridge, and lower lip. (AJCC 8th ed.)			Body Part, Organ, or Organ Component	mCode Radiotherapy Treatment Location Qualifier Value Set|mCode Terminology
C132509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132509>	C132507	Submandibular Lymph Node Group (Sublevel IB)|Lymph node level IB (qualifier value)	Lymph nodes within the boundaries of the anterior and posterior bellies of the digastric muscle, the stylohyoid muscle, and the body of the mandible. These include the preglandular and the postglandular nodes and the prevascular and postvascular nodes. The submandibular gland is included in the specimen when the lymph nodes within the triangle are removed. These nodes are at greatest risk for harboring metastases from cancers arising from the oral cavity, anterior nasal cavity, skin, and soft tissue structures of the midface, as well as from the submandibular gland. (AJCC 8th ed.)			Body Part, Organ, or Organ Component	mCode Radiotherapy Treatment Location Qualifier Value Set|mCode Terminology
C13250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13250>	C34028	Glomerulus|GLOMERULUS|Glomerular|Malpighian Tuft|Renal Glomerulus|renal glomerulus	A tuft of capillaries situated at the entrance to each nephron, within the Bowman's capsule. This tuft functions as the first stage in filtering blood in the kidney.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132510>	C132507	Upper Jugular Lymph Node Group (Sublevels IIA and IIB)	Lymph nodes located around the upper third of the internal jugular vein and adjacent spinal accessory nerve, extending from the level of the skull base (above) to the level of the inferior border of the hyoid bone (below). The anterior (medial) boundary is the stylohyoid muscle (the radiologic correlate is the vertical plane defined by the posterior surface of the submandibular gland) and the posterior (lateral) boundary is the posterior border of the sternocleidomastoid muscle. Sublevel IIA nodes are located anterior (medial) to the vertical plain defined by the spinal accessory nerve. Sublevel IIB nodes are located posterior (lateral) to the vertical plane defined by the spinal accessory nerve (the radiologic correlate is the lateral border of the internal jugular on a contrast-enhanced CT scan). The upper jugular nodes are at greatest risk for harboring metastases from cancers arising from the oral cavity, nasal cavity, nasopharynx, oropharynx, hypopharynx, larynx, and parotid gland. (AJCC 8th ed.)			Body Part, Organ, or Organ Component	
C132511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132511>	C132507	Middle Jugular Lymph Node Group (Level III)|MID-JUGULAR LYMPH NODE	Lymph nodes located around the middle third of the internal jugular vein, extending from the inferior border of the hyoid bone (above) to the inferior border of the cricoid cartilage (below). The anterior (medial) boundary is the lateral border of the sternohyoid muscle, and the posterior (lateral) boundary is the posterior border of the sternocleidomastoid muscle. These nodes are at greatest risk for harboring metastases from cancers arising from the oral cavity, nasopharynx, oropharynx, hypopharynx, and larynx. (AJCC 8th ed.)			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132512>	C132507	Lower Jugular Lymph Node Group (Level IV)|LOWER JUGULAR LYMPH NODE	Lymph nodes located around the lower third of the internal jugular vein, extending from the inferior border of the cricoid cartilage (above) to the clavicle below. The anterior (medial) boundary is the lateral border of the sternohyoid muscle and the posterior (lateral) boundary is the posterior border of the sternocleidomastoid muscle. These nodes are at greatest risk for harboring metastases from cancers arising from the hypopharynx, thyroid, cervical esophagus, and larynx. (AJCC 8th ed.)			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132513>	C132507	Posterior Triangle Lymph Node Group (Sublevels VA and VB)	This group is composed predominantly of the lymph nodes located along the lower half of the spinal accessory nerve and the transverse cervical artery. The supraclavicular nodes also are included in the posterior triangle group. The superior boundary is the apex formed by the convergence of the sternocleidomastoid and trapezius muscles; the inferior boundary is the clavicle; the anterior (medial) boundary is the posterior border of the sternocleidomastoid muscle; and the posterior (lateral) boundary is the anterior border of the trapezius muscle. Thus, sublevel VA includes the spinal accessory nodes, whereas sublevel VB includes the nodes following the transverse cervical vessels and the supraclavicular nodes, with the exception of the Virchow node, which is located in level IV. The posterior triangle nodes are at greatest risk for harboring metastases from cancers arising from the nasopharynx, oropharynx, and cutaneous structures of the posterior scalp and neck. (AJCC 8th ed.)			Body Part, Organ, or Organ Component	
C132514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132514>	C132507	Anterior Compartment Lymph Node Group (Level VI)|CERVICAL LYMPH NODE LEVEL VI|Central Compartment Lymph Nodes	Lymph nodes in this compartment include the pretracheal and paratracheal nodes, precricoid (Delphian) node, and the perithyroidal nodes, including the lymph nodes along the recurrent laryngeal nerves. The superior boundary is the hyoid bone; the inferior boundary is the suprasternal notch; and the lateral boundaries are the common carotid arteries. These nodes are at greatest risk for harboring metastases from cancers arising from the thyroid gland, glottic and subglottic larynx, apex of the piriform sinus, and cervical esophagus. (AJCC 8th ed.)			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132515>	C132507	Superior Mediastinal Lymph Node Group (Level VII)|SUPERIOR MEDIASTINAL LYMPH NODE LEVEL VII	Lymph nodes in this group include pretracheal, paratracheal, and esophageal groove lymph nodes, extending from the level of the suprasternal notch cephalad and up to the innominate artery caudad. These nodes are at greatest risk of involvement by thyroid cancer and cancer of the esophagus. (AJCC 8th ed.)			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132516>	C118970	CDISC Clinical Classification NSAA Test Name Terminology|CC-NSAA TEST|NSAA1TN|North Star Ambulatory Assessment Clinical Classification Test Name	Test names of clinical classification questions associated with the North Star Ambulatory Assessment (NSAA) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132517>	C118970	CDISC Clinical Classification NSAA Test Code Terminology|CC-NSAA TESTCD|NSAA1TC|North Star Ambulatory Assessment Clinical Classification Test Code	Test codes of clinical classification questions associated with the North Star Ambulatory Assessment (NSAA) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132518>	C100110	CDISC Questionnaire CES Test Name Terminology|CES01TN|Combat Exposure Scale Questionnaire Test Name|QS-CES TEST	Test names of questionnaire questions associated with the Combat Exposure Scale (CES) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132519>	C100110	CDISC Questionnaire CES Test Code Terminology|CES01TC|Combat Exposure Scale Questionnaire Test Code|QS-CES TESTCD	Test codes of questionnaire questions associated with the Combat Exposure Scale (CES) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13251>	C13298	Long Terminal Repeat|LTR	Identical DNA sequences found at either end of retrovirus proviral DNA, formed by reverse transcription of viral RNA.			Nucleotide Sequence	
C132520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132520>	C100110	CDISC Questionnaire EPDS Test Name Terminology|EPDS01TN|Edinburgh Postnatal Depression Scale Questionnaire Test Name|QS-EPDS TEST	Test names of questionnaire questions associated with the Edinburgh Postnatal Depression Scale (EPDS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132521>	C100110	CDISC Questionnaire EPDS Test Code Terminology|EPDS01TC|Edinburgh Postnatal Depression Scale Questionnaire Test Code|QS-EPDS TESTCD	Test codes of questionnaire questions associated with the Edinburgh Postnatal Depression Scale (EPDS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132522>	C100110	CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|HAQ02TN|Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale Questionnaire Test Name|QS-HAQ-DI Without VAS TEST	Test names of questionnaire questions associated with the Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132523>	C100110	CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|HAQ02TC|Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale Questionnaire Test Code|QS-HAQ-DI Without VAS TESTCD	Test codes of questionnaire questions associated with the Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132524>	C100110	CDISC Questionnaire TSQM Version 1.4 Test Name Terminology|QS-TSQM Version 1.4 TEST|TSQM01TN|Treatment Satisfaction Questionnaire for Medication Version 1.4 Questionnaire Test Name	Test names of questionnaire questions associated with the Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132525>	C100110	CDISC Questionnaire TSQM Version 1.4 Test Code Terminology|QS-TSQM Version 1.4 TESTCD|TSQM01TC|Treatment Satisfaction Questionnaire for Medication Version 1.4 Questionnaire Test Code	Test codes of questionnaire questions associated with the Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132526>	C211913	NSAA Clinical Classification Question	A question associated with the NSAA clinical classification.			Intellectual Product	
C132527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132527>	C211913	CES Questionnaire Question	A question associated with the CES questionnaire.			Intellectual Product	
C132528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132528>	C211913	EPDS Questionnaire Question	A question associated with the EPDS questionnaire.			Intellectual Product	
C132529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132529>	C211913	HAQ-DI Without VAS Questionnaire Question	A question associated with the HAQ-DI without VAS questionnaire.			Intellectual Product	
C13252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13252>	C13236	Lymph|LYMPH|Reticuloendothelial System, Lymph|lymph|lymphatic fluid	A clear, transparent, sometimes faintly yellow and slightly opalescent fluid that is collected from the tissues throughout the body, flows in the lymphatic vessels (through the lymph nodes), and is eventually added to the venous blood circulation. Lymph consists of a clear liquid portion, varying numbers of white blood cells (chiefly lymphocytes), and a few red blood cells.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132530>	C211913	TSQM Version 1.4 Questionnaire Question	A question associated with the TSQM Version 1.4 questionnaire.			Intellectual Product	
C132531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132531>	C118969	North Star Ambulatory Assessment Clinical Classification|NSAA|NSAA|NSAA1	A standardized 17-item scale that was developed by Elaine Scott and Michelle Eagle in 2011 to measure functional motor ability in ambulant children and adolescents with Duchenne muscular dystrophy. The instrument, which is partly based on the Hammersmith Motor Ability Scale (2003), utilizes a 3-point rating scale to grade activities ranging from standing to running, as well as abilities that are necessary for a patient to remain functionally ambulant and that are known to progressively deteriorate in untreated DMD.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132532>	C91105	Combat Exposure Scale Questionnaire|CES|CES|CES01	A standardized 7-item self-report scale that was developed by Keane et al in 1989 to measure combat exposure. The instrument is derived from Figley's combat scale (1980), with additional items included by consensus of a group of clinical psychologists with experience in the assessment and treatment of combat-related PTSD. The items are weighted according to the severity of the combat experience.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132533>	C91105	Edinburgh Postnatal Depression Scale Questionnaire|EPDS|EPDS|EPDS01	A standardized 10-item self-report scale that was developed by Cox et al 1987 to assist health professionals in identifying possible symptoms of depression in the postnatal period. The instrument utilizes a 4-point symptom rating scale to allow women to grade their experiences over the past seven days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132534>	C91105	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale|HAQ-DI WITHOUT VAS|HAQ-DI Without VAS|HAQ02	A standardized 20-item self-report component of the Health Assessment Questionnaire, developed by Fries et al 1978, that assesses a patient's level of functional ability. The disability index utilizes a 4-point symptom rating scale to allow patients to grade eight categories of ability, including dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132535>	C91105	Treatment Satisfaction Questionnaire for Medication Version 1.4|TSQM V1.4|TSQM Version 1.4|TSQM01	A standardized 14-item self-report scale developed by Atkinson et al in 2004 to assess the major dimensions of patients' satisfaction with medication. The instrument, which permits comparisons across medication types and patient conditions, provides scores on four scales: side effects, effectiveness, convenience, and global satisfaction.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132536>	C132526	NSAA - Stand|NSAA1-Stand|NSAA1-Stand|NSAA101	North Star Ambulatory Assessment (NSAA) Can you stand up tall for me for as long as you can and as still as you can.			Intellectual Product	CDISC Clinical Classification NSAA Test Code Terminology|CDISC Clinical Classification NSAA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132537>	C132526	NSAA - Walk|NSAA1-Walk|NSAA1-Walk|NSAA102	North Star Ambulatory Assessment (NSAA) Can you walk from A to B (state to and where from) for me.			Intellectual Product	CDISC Clinical Classification NSAA Test Code Terminology|CDISC Clinical Classification NSAA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132538>	C132526	NSAA - Stand Up From Chair|NSAA1-Stand Up From Chair|NSAA1-Stand Up From Chair|NSAA103	North Star Ambulatory Assessment (NSAA) Stand up from the chair keeping your arms folded if you can.			Intellectual Product	CDISC Clinical Classification NSAA Test Code Terminology|CDISC Clinical Classification NSAA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132539>	C132526	NSAA - Stand on One Leg - Right|NSAA1-Stand on One Leg - Right|NSAA1-Stand on One Leg - Right|NSAA104	North Star Ambulatory Assessment (NSAA) Can you stand on your right leg for as long as you can?			Intellectual Product	CDISC Clinical Classification NSAA Test Code Terminology|CDISC Clinical Classification NSAA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13253>	C33089	Lysosome|lysosome	A class of morphologically heterogeneous cytoplasmic membrane-bound vesicle in animal and plant tissues characterized by their content of a wide variety of glycoprotein hydrolytic enzymes active at an acid pH and the structure-linked latency of these enzymes. The intracellular functions of lysosomes depend on their lytic potential. The single unit membrane of the lysosome acts as a barrier between the enzymes enclosed in the lysosome and the external substrate. The activity of the enzymes contained in lysosomes is limited or nil unless the vesicle in which they are enclosed is ruptured. Such rupture serves to digest exogenous material, such as bacteria, as well as effete organelles of the cells and is supposed to be under metabolic (hormonal) control.			Cell Component	
C132540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132540>	C132526	NSAA - Stand on One Leg - Left|NSAA1-Stand on One Leg - Left|NSAA1-Stand on One Leg - Left|NSAA105	North Star Ambulatory Assessment (NSAA) Can you stand on your left leg for as long as you can?			Intellectual Product	CDISC Clinical Classification NSAA Test Code Terminology|CDISC Clinical Classification NSAA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132541>	C132526	NSAA - Climb Box Step - Right|NSAA1-Climb Box Step - Right|NSAA1-Climb Box Step - Right|NSAA106	North Star Ambulatory Assessment (NSAA) Can you step onto the top of the box using your right leg first?			Intellectual Product	CDISC Clinical Classification NSAA Test Code Terminology|CDISC Clinical Classification NSAA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132542>	C132526	NSAA - Climb Box Step - Left|NSAA1-Climb Box Step - Left|NSAA1-Climb Box Step - Left|NSAA107	North Star Ambulatory Assessment (NSAA) Can you step onto the top of the box using your left leg first?			Intellectual Product	CDISC Clinical Classification NSAA Test Code Terminology|CDISC Clinical Classification NSAA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132543>	C132526	NSAA - Descend Box Step - Right|NSAA1-Descend Box Step - Right|NSAA1-Descend Box Step - Right|NSAA108	North Star Ambulatory Assessment (NSAA) Can you step down from the box using your right leg first?			Intellectual Product	CDISC Clinical Classification NSAA Test Code Terminology|CDISC Clinical Classification NSAA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132544>	C132526	NSAA - Descend Box Step - Left|NSAA1-Descend Box Step - Left|NSAA1-Descend Box Step - Left|NSAA109	North Star Ambulatory Assessment (NSAA) Can you step down from the box using your left leg first?			Intellectual Product	CDISC Clinical Classification NSAA Test Code Terminology|CDISC Clinical Classification NSAA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132545>	C132526	NSAA - Gets to Sitting|NSAA1-Gets to Sitting|NSAA1-Gets to Sitting|NSAA110	North Star Ambulatory Assessment (NSAA) Can you get from lying to sitting?			Intellectual Product	CDISC Clinical Classification NSAA Test Code Terminology|CDISC Clinical Classification NSAA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132546>	C132526	NSAA - Rise From Floor|NSAA1-Rise From Floor|NSAA1-Rise From Floor|NSAA111	North Star Ambulatory Assessment (NSAA) Get up from the floor using as little support as possible and as fast as you can (from supine).			Intellectual Product	CDISC Clinical Classification NSAA Test Code Terminology|CDISC Clinical Classification NSAA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132547>	C132526	NSAA - Rise From Floor Time|NSAA1-Rise From Floor Time|NSAA1-Rise From Floor Time|NSAA111A	North Star Ambulatory Assessment (NSAA) Time to get up from the floor using as little support as possible and as fast as you can (from supine) (seconds).			Intellectual Product	CDISC Clinical Classification NSAA Test Code Terminology|CDISC Clinical Classification NSAA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132548>	C132526	NSAA - Lifts Head|NSAA1-Lifts Head|NSAA1-Lifts Head|NSAA112	North Star Ambulatory Assessment (NSAA) Lift your head to look at your toes keeping your arms folded.			Intellectual Product	CDISC Clinical Classification NSAA Test Code Terminology|CDISC Clinical Classification NSAA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132549>	C132526	NSAA - Stands on Heels|NSAA1-Stands on Heels|NSAA1-Stands on Heels|NSAA113	North Star Ambulatory Assessment (NSAA) Can you stand on your heels?			Intellectual Product	CDISC Clinical Classification NSAA Test Code Terminology|CDISC Clinical Classification NSAA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13254>	C33089	Peroxisome|Microbody	Subcellular respiratory organelles containing catalase and hydrogen peroxide-producing flavin oxidases among its enzymatic constituents, which carry out an essentially oxidative type of metabolism.			Cell Component	
C132550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132550>	C132526	NSAA - Jump|NSAA1-Jump|NSAA1-Jump|NSAA114	North Star Ambulatory Assessment (NSAA) How high can you jump?			Intellectual Product	CDISC Clinical Classification NSAA Test Code Terminology|CDISC Clinical Classification NSAA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132551>	C132526	NSAA - Hop Right Leg|NSAA1-Hop Right Leg|NSAA1-Hop Right Leg|NSAA115	North Star Ambulatory Assessment (NSAA) Can you hop on your right leg?			Intellectual Product	CDISC Clinical Classification NSAA Test Code Terminology|CDISC Clinical Classification NSAA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132552>	C132526	NSAA - Hop Left Leg|NSAA1-Hop Left Leg|NSAA1-Hop Left Leg|NSAA116	North Star Ambulatory Assessment (NSAA) Can you hop on your left leg?			Intellectual Product	CDISC Clinical Classification NSAA Test Code Terminology|CDISC Clinical Classification NSAA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132553>	C132526	NSAA - Run (10m)|NSAA1-Run (10m)|NSAA1-Run (10m)|NSAA117	North Star Ambulatory Assessment (NSAA) Run as fast as you can to...(give point).			Intellectual Product	CDISC Clinical Classification NSAA Test Code Terminology|CDISC Clinical Classification NSAA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132554>	C132526	NSAA - Run (10m) Time|NSAA1-Run (10m) Time|NSAA1-Run (10m) Time|NSAA117A	North Star Ambulatory Assessment (NSAA) Time to run as fast as you can (seconds).			Intellectual Product	CDISC Clinical Classification NSAA Test Code Terminology|CDISC Clinical Classification NSAA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132555>	C132526	NSAA - Total|NSAA1-Total|NSAA1-Total|NSAA118	North Star Ambulatory Assessment (NSAA) Total.			Intellectual Product	CDISC Clinical Classification NSAA Test Code Terminology|CDISC Clinical Classification NSAA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132556>	C132527	CES - Ever Combat Patrols or Dangerous Duty|CES01-Ever Combat Patrols/Dangerous Duty|CES01-Ever Combat Patrols/Dangerous Duty|CES0101	Combat Exposure Scale (CES) Did you ever go on combat patrols or have other dangerous duty?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CES Test Code Terminology|CDISC Questionnaire CES Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132557>	C132527	CES - Were You Ever Under Enemy Fire|CES01-Were You Ever Under Enemy Fire|CES01-Were You Ever Under Enemy Fire|CES0102	Combat Exposure Scale (CES) Were you ever under enemy fire?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CES Test Code Terminology|CDISC Questionnaire CES Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132558>	C132527	CES - Ever Surrounded by the Enemy|CES01-Ever Surrounded by the Enemy|CES01-Ever Surrounded by the Enemy|CES0103	Combat Exposure Scale (CES) Were you ever surrounded by the enemy?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CES Test Code Terminology|CDISC Questionnaire CES Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132559>	C132527	CES - Soldiers in Unit Killed (KIA), Wounded, Missing (MIA)|CES01-Soldiers in Unit KIA, Wounded, MIA|CES01-Soldiers in Unit KIA, Wounded, MIA|CES0104	Combat Exposure Scale (CES) What percentage of the soldiers in your unit were killed (KIA), wounded or missing in action (MIA)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CES Test Code Terminology|CDISC Questionnaire CES Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13255>	C32603	Actin Filament|Microfilament	The finest filamentous element of the cytoskeleton, having a diameter of about 5 nm and consisting primarily of actin.			Cell Component	
C132560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132560>	C132527	CES - How Often Fire Rounds at Enemy|CES01-How Often Fire Rounds at Enemy|CES01-How Often Fire Rounds at Enemy|CES0105	Combat Exposure Scale (CES) How often did you fire rounds at the enemy?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CES Test Code Terminology|CDISC Questionnaire CES Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132561>	C132527	CES - See Someone Hit by Rounds|CES01-See Someone Hit by Rounds|CES01-See Someone Hit by Rounds|CES0106	Combat Exposure Scale (CES) How often did you see someone hit by incoming or outgoing rounds?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CES Test Code Terminology|CDISC Questionnaire CES Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132562>	C132527	CES - In Danger of Being Injured or Killed|CES01-In Danger of Being Injured/Killed|CES01-In Danger of Being Injured/Killed|CES0107	Combat Exposure Scale (CES) How often were you in danger of being injured or killed (i.e., being pinned down, overrun, ambushed, near miss, etc.)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CES Test Code Terminology|CDISC Questionnaire CES Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132563>	C132528	EPDS - Able to Laugh and See Funny Side|EPDS01-Able to Laugh and See Funny Side|EPDS01-Able to Laugh and See Funny Side|EPDS0101	Edinburgh Postnatal Depression Scale (EPDS) I have been able to laugh and see the funny side of things.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPDS Test Code Terminology|CDISC Questionnaire EPDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132564>	C132528	EPDS - Looked Forward With Enjoyment|EPDS01-Looked Forward With Enjoyment|EPDS01-Looked Forward With Enjoyment|EPDS0102	Edinburgh Postnatal Depression Scale (EPDS) I have looked forward with enjoyment to things.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPDS Test Code Terminology|CDISC Questionnaire EPDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132565>	C132528	EPDS - Blamed Myself Unnecessarily|EPDS01-Blamed Myself Unnecessarily|EPDS01-Blamed Myself Unnecessarily|EPDS0103	Edinburgh Postnatal Depression Scale (EPDS) I have blamed myself unnecessarily when things went wrong.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPDS Test Code Terminology|CDISC Questionnaire EPDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132566>	C132528	EPDS - Anxious or Worried No Good Reason|EPDS01-Anxious/Worried No Good Reason|EPDS01-Anxious/Worried No Good Reason|EPDS0104	Edinburgh Postnatal Depression Scale (EPDS) I have been anxious or worried for no good reason.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPDS Test Code Terminology|CDISC Questionnaire EPDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132567>	C132528	EPDS - Scared or Panicky for No Good Reason|EPDS01-Scared/Panicky for No Good Reason|EPDS01-Scared/Panicky for No Good Reason|EPDS0105	Edinburgh Postnatal Depression Scale (EPDS) I have felt scared or panicky for no very good reason.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPDS Test Code Terminology|CDISC Questionnaire EPDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132568>	C132528	EPDS - Things Getting on Top of Me|EPDS01-Things Getting on Top of Me|EPDS01-Things Getting on Top of Me|EPDS0106	Edinburgh Postnatal Depression Scale (EPDS) Things have been getting on top of me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPDS Test Code Terminology|CDISC Questionnaire EPDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132569>	C132528	EPDS - Unhappy Had Difficulty Sleeping|EPDS01-Unhappy Had Difficulty Sleeping|EPDS01-Unhappy Had Difficulty Sleeping|EPDS0107	Edinburgh Postnatal Depression Scale (EPDS) I have been so unhappy that I have had difficulty sleeping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPDS Test Code Terminology|CDISC Questionnaire EPDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13256>	C32603	Microtubule|Micro Tubule|Micro-tubule	Microtubules of the eukaryotic cytoskeleton perform essential and diverse functions and are composed of a heterodimer of alpha and beta tubulin. The genes encoding these microtubule constituents are part of the tubulin superfamily, which is composed of six distinct families. Genes from the alpha, beta and gamma tubulin families are found in all eukaryotes. The alpha and beta tubulins represent the major components of microtubules, while gamma tubulin plays a critical role in the nucleation of microtubule assembly. There are multiple alpha and beta tubulin genes and they are highly conserved among and between species. (from LocusLink)			Cell Component	
C132570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132570>	C132528	EPDS - I Have Felt Sad or Miserable|EPDS01-I Have Felt Sad or Miserable|EPDS01-I Have Felt Sad or Miserable|EPDS0108	Edinburgh Postnatal Depression Scale (EPDS) I have felt sad or miserable.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPDS Test Code Terminology|CDISC Questionnaire EPDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132571>	C132528	EPDS - So Unhappy I Have Been Crying|EPDS01-So Unhappy I Have Been Crying|EPDS01-So Unhappy I Have Been Crying|EPDS0109	Edinburgh Postnatal Depression Scale (EPDS) I have been so unhappy that I have been crying.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPDS Test Code Terminology|CDISC Questionnaire EPDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132572>	C132528	EPDS - Thought of Harming Myself|EPDS01-Thought of Harming Myself|EPDS01-Thought of Harming Myself|EPDS0110	Edinburgh Postnatal Depression Scale (EPDS) The thought of harming myself has occurred to me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EPDS Test Code Terminology|CDISC Questionnaire EPDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132573>	C132529	HAQ-DI Without VAS - Dress Yourself|HAQ02-Dress Yourself|HAQ02-Dress Yourself|HAQ0201	Dressing & Grooming: Are you able to dress yourself, including tying shoelaces and doing buttons?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132574>	C132529	HAQ-DI Without VAS - Shampoo Your Hair|HAQ02-Shampoo Your Hair|HAQ02-Shampoo Your Hair|HAQ0202	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Dressing & Grooming: Are you able to shampoo your hair?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132575>	C132529	HAQ-DI Without VAS - Stand Up From a Straight Chair|HAQ02-Stand Up From a Straight Chair|HAQ02-Stand Up From a Straight Chair|HAQ0203	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Arising: Are you able to stand up from a straight chair?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132576>	C132529	HAQ-DI Without VAS - Get In and Out of Bed|HAQ02-Get In and Out of Bed|HAQ02-Get In and Out of Bed|HAQ0204	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Arising: Are you able to get in and out of bed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132577>	C132529	HAQ-DI Without VAS - Cut Your Meat|HAQ02-Cut Your Meat|HAQ02-Cut Your Meat|HAQ0205	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Eating: Are you able to cut your meat?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132578>	C132529	HAQ-DI Without VAS - Lift a Full Cup or Glass to Mouth|HAQ02-Lift a Full Cup or Glass to Mouth|HAQ02-Lift a Full Cup or Glass to Mouth|HAQ0206	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Eating: Are you able to lift a full cup or glass to your mouth?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132579>	C132529	HAQ-DI Without VAS - Open a New Milk Carton|HAQ02-Open a New Milk Carton|HAQ02-Open a New Milk Carton|HAQ0207	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Eating: Are you able to open a new milk carton?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13257>	C13401	Mammary Gland Milk|BREAST MILK|Breast Milk|Breast Milk|MILK|Milk	Milk produced by female mammals for the purpose of feeding their young.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Newborn Screening Terminology|NICHD Terminology
C132580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132580>	C132529	HAQ-DI Without VAS - Walk Outdoors on Flat Ground|HAQ02-Walk Outdoors on Flat Ground|HAQ02-Walk Outdoors on Flat Ground|HAQ0208	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Walking: Are you able to walk outdoors on flat ground?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132581>	C132529	HAQ-DI Without VAS - Climb Up Five Steps|HAQ02-Climb Up Five Steps|HAQ02-Climb Up Five Steps|HAQ0209	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Walking: Are you able to climb up five steps?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132582>	C132529	HAQ-DI Without VAS - Aid: Cane|HAQ02-Aid: Cane|HAQ02-Aid: Cane|HAQ0210	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Cane.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132583>	C132529	HAQ-DI Without VAS - Aid: Walker|HAQ02-Aid: Walker|HAQ02-Aid: Walker|HAQ0211	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Walker.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132584>	C132529	HAQ-DI Without VAS - Aid: Crutches|HAQ02-Aid: Crutches|HAQ02-Aid: Crutches|HAQ0212	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Crutches.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132585>	C132529	HAQ-DI Without VAS - Aid: Wheelchair|HAQ02-Aid: Wheelchair|HAQ02-Aid: Wheelchair|HAQ0213	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Wheelchair.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132586>	C132529	HAQ-DI Without VAS - Aid: Devices Used for Dressing|HAQ02-Aid: Devices Used for Dressing|HAQ02-Aid: Devices Used for Dressing|HAQ0214	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Devices used for Dressing (button hook, zipper pull, long-handled shoe horn, etc.).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132587>	C132529	HAQ-DI Without VAS - Aid: Built Up or Special Utensils|HAQ02-Aid: Built Up or Special Utensils|HAQ02-Aid: Built Up or Special Utensils|HAQ0215	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Built up or special utensils.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132588>	C132529	HAQ-DI Without VAS - Aid: Special or Built Up Chair|HAQ02-Aid: Special or Built Up Chair|HAQ02-Aid: Special or Built Up Chair|HAQ0216	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Special or built up chair.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132589>	C132529	HAQ-DI Without VAS - Other Aid (Dress or Arising or Eat or Walk)|HAQ02-Othr Aid (Dress/Arising/Eat/Walk)|HAQ02-Othr Aid (Dress/Arising/Eat/Walk)|HAQ0217	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Other (for dressing and grooming, arising, eating and walking).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13258>	C33089	Mitochondrion|Mitochondria|Mitochondria|Mitochondrial|mitochondria	Semiautonomous, self-reproducing organelles that occur in the cytoplasm of all cells of most, but not all, eukaryotes. Mitochondria contain distinctive ribosomes, transfer RNAs, amino acyl t-RNA synthetases, and elongation and termination factors. Mitochondria depend upon genes within the nucleus for many essential messenger RNAs. Mitochondria consist of two sets of membranes, a smooth continuous outer coat and an inner membrane arranged in tubules or more often in folds that form platelike double membranes (cristae). Mitochondria are the principal energy source of the cell and contains the cytochrome enzymes of terminal electron transport and the enzymes of the citric acid cycle, fatty acid oxidation, and oxidative phosphorylation. Mitochondria are the sites of the reactions of oxidative phosphorylation, which result in the formation of ATP.			Cell Component	GDC Terminology|GDC Value Terminology
C132590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132590>	C132529	HAQ-DI Without VAS - Special Aid (Dress or Arising or Eat or Walk)|HAQ02-Spec Aid (Dress/Arising/Eat/Walk)|HAQ02-Spec Aid (Dress/Arising/Eat/Walk)|HAQ0218	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Other (specify) - for dressing and grooming, arising, eating and walking.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132591>	C132529	HAQ-DI Without VAS - Help: Dressing and Grooming|HAQ02-Help: Dressing and Grooming|HAQ02-Help: Dressing and Grooming|HAQ0219	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Usually need help from another person: Dressing and grooming.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132592>	C132529	HAQ-DI Without VAS - Help: Arising|HAQ02-Help: Arising|HAQ02-Help: Arising|HAQ0220	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Usually need help from another person: Arising.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132593>	C132529	HAQ-DI Without VAS - Help: Eating|HAQ02-Help: Eating|HAQ02-Help: Eating|HAQ0221	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Usually need help from another person: Eating.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132594>	C132529	HAQ-DI Without VAS - Help: Walking|HAQ02-Help: Walking|HAQ02-Help: Walking|HAQ0222	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Usually need help from another person: Walking.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132595>	C132529	HAQ-DI Without VAS - Wash and Dry Your Body|HAQ02-Wash and Dry Your Body|HAQ02-Wash and Dry Your Body|HAQ0223	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Hygiene: Are you able to wash and dry your body?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132596>	C132529	HAQ-DI Without VAS - Take a Tub Bath|HAQ02-Take a Tub Bath|HAQ02-Take a Tub Bath|HAQ0224	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Hygiene: Are you able to take a tub bath?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132597>	C132529	HAQ-DI Without VAS - Get On and Off The Toilet|HAQ02-Get On and Off The Toilet|HAQ02-Get On and Off The Toilet|HAQ0225	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Hygiene: Are you able to get on and off the toilet?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132598>	C132529	HAQ-DI Without VAS - Reach-Get Down 5 Lb Object Above Head|HAQ02-Reach-Get Down 5 Lb Obj Above Head|HAQ02-Reach-Get Down 5 Lb Obj Above Head|HAQ0226	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Reach: Are you able to reach and get down a 5-pound object (such as a bag of sugar) from just above your head?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132599>	C132529	HAQ-DI Without VAS - Bend Down Pick Up Clothing - Floor|HAQ02-Bend Down Pick Up Clothing - Floor|HAQ02-Bend Down Pick Up Clothing - Floor|HAQ0227	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Reach: Are you able to bend down to pick up clothing from the floor?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13259>	C13236	Mucus|MUCUS|mucus	The thick fluid secreted by the mucus glands in the aerodigestive tract and the vagina.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C1325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1325>	C96404	HIV Vaccine|AIDS Vaccines|HIV/AIDS Vaccines	A vaccine intended to prevent or treat infections caused by human immunodeficiency viruses (HIVs).			Chemical Viewed Functionally	
C132600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132600>	C132529	HAQ-DI Without VAS - Open Car Doors|HAQ02-Open Car Doors|HAQ02-Open Car Doors|HAQ0228	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Grip: Are you able to open car doors?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132601>	C132529	HAQ-DI Without VAS - Open Jars Previously Opened|HAQ02-Open Jars Previously Opened|HAQ02-Open Jars Previously Opened|HAQ0229	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Grip: Are you able to open jars which have been previously opened?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132602>	C132529	HAQ-DI Without VAS - Turn Faucets On And Off|HAQ02-Turn Faucets On And Off|HAQ02-Turn Faucets On And Off|HAQ0230	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Grip: Are you able to turn faucets on and off?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132603>	C132529	HAQ-DI Without VAS - Run Errands and Shop|HAQ02-Run Errands and Shop|HAQ02-Run Errands and Shop|HAQ0231	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Activities: Are you able to run errands and shop?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132604>	C132529	HAQ-DI Without VAS - Get In and Out of a Car|HAQ02-Get In and Out of a Car|HAQ02-Get In and Out of a Car|HAQ0232	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Activities: Are you able to get in and out of a car?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132605>	C132529	HAQ-DI Without VAS - Able to Do Chores|HAQ02-Able to Do Chores|HAQ02-Able to Do Chores|HAQ0233	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Activities: Are you able to do chores such as vacuuming or yardwork?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132606>	C132529	HAQ-DI Without VAS - Aid: Raised Toilet Seat|HAQ02-Aid: Raised Toilet Seat|HAQ02-Aid: Raised Toilet Seat|HAQ0234	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Raised toilet seat.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132607>	C132529	HAQ-DI Without VAS - Aid: Bathtub Seat|HAQ02-Aid: Bathtub Seat|HAQ02-Aid: Bathtub Seat|HAQ0235	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Bathtub seat.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132608>	C132529	HAQ-DI Without VAS - Aid: Jar Opener (Previously Open)|HAQ02-Aid: Jar Opener (Previously Open)|HAQ02-Aid: Jar Opener (Previously Open)|HAQ0236	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Jar opener (for jars previously opened).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132609>	C132529	HAQ-DI Without VAS - Aid: Bathtub Bar|HAQ02-Aid: Bathtub Bar|HAQ02-Aid: Bathtub Bar|HAQ0237	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Bathtub bar.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13260>	C12948	Mullerian Duct|Müllerian Duct|Paramesonephric Duct	A pair of embryonic tubular structures that extend along the genital ridge and continue toward the cloaca, which in females will develop into the vagina, uterus, and fallopian tubes, and which will degenerate and be resorbed in males.			Embryonic Structure	
C132610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132610>	C132529	HAQ-DI Without VAS - Aid: Long-Handled Appliances Reach|HAQ02-Aid: Long-Handled Appl Reach|HAQ02-Aid: Long-Handled Appl Reach|HAQ0238	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Long-handled appliances for reach.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132611>	C132529	HAQ-DI Without VAS - Aid: Long-Handled Appliances Bathroom|HAQ02-Aid: Long-Handled Appl Bathroom|HAQ02-Aid: Long-Handled Appl Bathroom|HAQ0239	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Long-handled appliances in bathroom.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132612>	C132529	HAQ-DI Without VAS - Other Aid (Hygiene or Reach or Grip or Act)|HAQ02-Othr Aid (Hygiene/Reach/Grip/Act)|HAQ02-Othr Aid (Hygiene/Reach/Grip/Act)|HAQ0240	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Other (for hygiene, reach, grip and activities).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132613>	C132529	HAQ-DI Without VAS - Special Aid (Hygiene or Reach or Grip or Act)|HAQ02-Spec Aid (Hygiene/Reach/Grip/Act)|HAQ02-Spec Aid (Hygiene/Reach/Grip/Act)|HAQ0241	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Aids or devices that you usually use for any of these activities: Other (specify) - for hygiene, reach, grip and activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132614>	C132529	HAQ-DI Without VAS - Help: Hygiene|HAQ02-Help: Hygiene|HAQ02-Help: Hygiene|HAQ0242	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Usually need help from another person: Hygiene.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132615>	C132529	HAQ-DI Without VAS - Help: Reach|HAQ02-Help: Reach|HAQ02-Help: Reach|HAQ0243	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Usually need help from another person: Reach.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132616>	C132529	HAQ-DI Without VAS - Help: Gripping and Opening Things|HAQ02-Help: Gripping and Opening Things|HAQ02-Help: Gripping and Opening Things|HAQ0244	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Usually need help from another person: Gripping and opening things.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132617>	C132529	HAQ-DI Without VAS - Help: Errands and Chores|HAQ02-Help: Errands and Chores|HAQ02-Help: Errands and Chores|HAQ0245	Health Assessment Questionnaire Disability Index Without Pain Visual Analog Scale (HAQ-DI Without VAS) Usually need help from another person: Errands and chores.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Code Terminology|CDISC Questionnaire HAQ-DI Without VAS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132618>	C132530	TSQM Version 1.4 - Medication to Prevent or Treat Condition|TSQM01-Med to Prevent/Treat Condition|TSQM01-Med to Prevent/Treat Condition|TSQM0101	Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) How satisfied or dissatisfied are you with the ability of the medication to prevent or treat your condition?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSQM Version 1.4 Test Code Terminology|CDISC Questionnaire TSQM Version 1.4 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132619>	C132530	TSQM Version 1.4 - Way Medication Relieves Symptoms|TSQM01-Way Medication Relieves Symptoms|TSQM01-Way Medication Relieves Symptoms|TSQM0102	Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) How satisfied or dissatisfied are you with the way the medication relieves your symptoms?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSQM Version 1.4 Test Code Terminology|CDISC Questionnaire TSQM Version 1.4 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13261>	C41439	Myelin Sheath|Myelin|Myelinated|myelin	A layer of phospholipids and protein found on neuronal axons. This structure acts as an electrical insulator that allows nerve impulses to travel faster by increasing the resistance and decreasing the capacitance over that found in unmyelinated nerve fibers.			Cell Component	
C132620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132620>	C132530	TSQM Version 1.4 - Time Takes Medication to Start Working|TSQM01-Time Takes Med to Start Working|TSQM01-Time Takes Med to Start Working|TSQM0103	Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) How satisfied or dissatisfied are you with the amount of time it takes the medication to start working?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSQM Version 1.4 Test Code Terminology|CDISC Questionnaire TSQM Version 1.4 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132621>	C132530	TSQM Version 1.4 - Experience Any Side Effect at All|TSQM01-Experience Any Side Effect at All|TSQM01-Experience Any Side Effect at All|TSQM0104	Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) As a result of taking this medication, do you experience any side effects at all?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSQM Version 1.4 Test Code Terminology|CDISC Questionnaire TSQM Version 1.4 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132622>	C132530	TSQM Version 1.4 - How Bothersome Are Side Effects|TSQM01-How Bothersome Are Side Effects|TSQM01-How Bothersome Are Side Effects|TSQM0105	Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) How bothersome are the side effects of the medication you take to treat your condition?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSQM Version 1.4 Test Code Terminology|CDISC Questionnaire TSQM Version 1.4 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132623>	C132530	TSQM Version 1.4 - Interfere With Physical Health|TSQM01-Interfere With Physical Health|TSQM01-Interfere With Physical Health|TSQM0106	Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) To what extent do the side effects interfere with your physical health and ability to function (i.e., strength, energy levels, etc.)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSQM Version 1.4 Test Code Terminology|CDISC Questionnaire TSQM Version 1.4 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132624>	C132530	TSQM Version 1.4 - Interfere With Mental Function|TSQM01-Interfere With Mental Function|TSQM01-Interfere With Mental Function|TSQM0107	Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) To what extent do the side effects interfere with your mental function (i.e., ability to think clearly, stay awake, etc.)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSQM Version 1.4 Test Code Terminology|CDISC Questionnaire TSQM Version 1.4 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132625>	C132530	TSQM Version 1.4 - Side Effect Affect Overall Satisfaction|TSQM01-Side Effect Affect Overall Satisf|TSQM01-Side Effect Affect Overall Satisf|TSQM0108	Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) To what degree have medication side effects affected your overall satisfaction with the medication?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSQM Version 1.4 Test Code Terminology|CDISC Questionnaire TSQM Version 1.4 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132626>	C132530	TSQM Version 1.4 - Easy or Difficult Use Medication|TSQM01-Easy/Difficult Use Medication|TSQM01-Easy/Difficult Use Medication|TSQM0109	Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) How easy or difficult is it to use the medication in its current form?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSQM Version 1.4 Test Code Terminology|CDISC Questionnaire TSQM Version 1.4 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132627>	C132530	TSQM Version 1.4 - Easy or Difficult to Plan Use of Medication|TSQM01-Easy/Difficult to Plan Use of Med|TSQM01-Easy/Difficult to Plan Use of Med|TSQM0110	Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) How easy or difficult is it to plan when you will use the medication each time?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSQM Version 1.4 Test Code Terminology|CDISC Questionnaire TSQM Version 1.4 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132628>	C132530	TSQM Version 1.4 - Convenient or Inconvenient Take Medication|TSQM01-Convenient/Inconvenient Take Med|TSQM01-Convenient/Inconvenient Take Med|TSQM0111	Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) How convenient or inconvenient is it to take the medication as instructed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSQM Version 1.4 Test Code Terminology|CDISC Questionnaire TSQM Version 1.4 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132629>	C132530	TSQM Version 1.4 - Confident Medication Is Good for You|TSQM01-Confident Med Is Good for You|TSQM01-Confident Med Is Good for You|TSQM0112	Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) Overall, how confident are you that taking this medication is a good thing for you?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSQM Version 1.4 Test Code Terminology|CDISC Questionnaire TSQM Version 1.4 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132630>	C132530	TSQM Version 1.4 - Certain Good Things Outweigh Bad|TSQM01-Certain Good Things Outweigh Bad|TSQM01-Certain Good Things Outweigh Bad|TSQM0113	Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) How certain are you that the good things about your medication outweigh the bad things?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSQM Version 1.4 Test Code Terminology|CDISC Questionnaire TSQM Version 1.4 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132631>	C132530	TSQM Version 1.4 - Satisfied or Dissatisfied With Medication|TSQM01-Satisfied/Dissatisfied With Med|TSQM01-Satisfied/Dissatisfied With Med|TSQM0114	Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM Version 1.4) Taking all things into account, how satisfied or dissatisfied are you with this medication?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSQM Version 1.4 Test Code Terminology|CDISC Questionnaire TSQM Version 1.4 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132632>	C48233	Head and Neck Cancer TNM Finding v8	A finding about one or more characteristics of head and neck cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C132633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132633>	C132632	Head and Neck Cancer Clinical TNM Finding v8	A clinical finding about one or more characteristics of head and neck cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C132634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132634>	C132633	Head and Neck Cancer Clinical Regional Lymph Nodes TNM Finding v8|Pathologic Staging: Regional Lymph Nodes (pN)	A clinical finding about one or more characteristics of head and neck cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C132635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132635>	C132634	Head and Neck Cancer cN2 TNM Finding v8	Head and neck cancer with metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE (extranodal extension)(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, ENE(-). (from AJCC 8th Ed.)			Finding	
C132636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132636>	C132635	Head and Neck Cancer cN2a TNM Finding v8	Head and neck cancer with metastasis in a single ipsilateral or contralateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132637>	C132635	Head and Neck Cancer cN2b TNM Finding v8	Head and neck cancer with metastasis in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132638>	C132635	Head and Neck Cancer cN2c TNM Finding v8	Head and neck cancer with metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132639>	C132634	Head and Neck Cancer cN3 TNM Finding v8	Head and neck cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastases in a single ipsilateral lymph node ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes, any with ENE(+). (from AJCC 8th Ed.)			Finding	
C13263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13263>	C13248	Neurofilament	An intermediate filament that is found in the axons of neurons.			Cell Component	
C132640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132640>	C132639	Head and Neck Cancer cN3a TNM Finding v8	Head and neck cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132641>	C132639	Head and Neck Cancer cN3b TNM Finding v8	Head and neck cancer with metastasis in a single ipsilateral lymph node ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes, any with ENE(+). (from AJCC 8th Ed.)			Finding	
C132642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132642>	C132632	Head and Neck Cancer Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of head and neck cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C132643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132643>	C132642	Head and Neck Cancer Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of head and neck cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C132644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132644>	C132643	Head and Neck Cancer pNX TNM Finding v8|pNX	Head and neck cancer in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C132645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132645>	C132643	Head and Neck Cancer pN0 TNM Finding v8|pN0	Head and neck cancer in which no regional lymph node metastases are detected. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C132646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132646>	C132643	Head and Neck Cancer pN1 TNM Finding v8|pN1	Head and neck cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (extranodal extension)(-). (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C132647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132647>	C132643	Head and Neck Cancer pN2 TNM Finding v8|pN2	Head and neck cancer with metastasis in a single ipsilateral lymph node 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, ENE(-). (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C132648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132648>	C132647	Head and Neck Cancer pN2a TNM Finding v8|pN2a	Head and neck cancer with metastasis in a single ipsilateral lymph node 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C132649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132649>	C132647	Head and Neck Cancer pN2b TNM Finding v8|pN2b	Head and neck cancer with metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C13264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13264>	C13446	Nuclear Matrix	A network of fibrillar structures within cell nuclei that may play a role in chromatin organization and the localization of proteins within the nucleus.			Cell Component	
C132650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132650>	C132647	Head and Neck Cancer pN2c TNM Finding v8|pN2c	Head and neck cancer with metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C132651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132651>	C132643	Head and Neck Cancer pN3 TNM Finding v8|pN3	Head and neck cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastases in a single ipsilateral lymph node larger than 3 cm and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes, any with ENE(+). (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C132652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132652>	C132651	Head and Neck Cancer pN3a TNM Finding v8|pN3a	Head and neck cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C132653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132653>	C132651	Head and Neck Cancer pN3b TNM Finding v8|pN3b	Head and neck cancer with metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes, any with ENE(+). (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C132655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132655>	C94299|C177692	Interleukin-3 Receptor Subunit Alpha Positive|CD123 Antigen Positive|CD123 Positive|IL-3 Receptor Subunit Alpha Positive|IL-3R Subunit Alpha Positive|IL-3R-Alpha Positive|IL-3RA Positive|IL3R Positive|IL3R-Alpha Positive|IL3RA Positive|IL3RX Positive|Interleukin 3 Receptor Alpha Chain Positive|Interleukin 3 Receptor Alpha Positive|Interleukin 3 Receptor Positive|Low Affinity Interleukin 3 Receptor Alpha Positive	Indicates that interleukin-3 receptor subunit alpha expression has been detected in a sample.	Interleukin-3 Receptor Subunit Alpha Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132656>	C132632	Cervical Lymph Nodes and Unknown Primary Tumors TNM Finding v8	A finding about one or more characteristics of cervical lymph nodes and unknown primary tumors, following the rules of the TNM AJCC v8 classification system. It applies to squamous cell carcinoma and salivary gland carcinoma of all head and neck sites except HPV-related oropharynx cancer, nasopharynx cancer, melanoma, thyroid carcinoma, and sarcoma. Staging of the patient who presents with an occult primary tumor and EBV-unrelated and HPV-unrelated metastatic cervical lymphadenopathy is also included. (from AJCC 8th Ed.)			Finding	
C132657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132657>	C132656|C132633	Unknown Primary Tumor Clinical Cervical Lymph Nodes TNM Finding v8	A clinical finding about one or more characteristics of an unknown primary tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of cervical lymph nodes. It applies to patients who are treated with primary nonsurgical treatment without a cervical lymph node dissection. (from AJCC 8th Ed.)			Finding	
C132658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132658>	C132657	Unknown Primary Tumor cN2 TNM Finding v8	Unknown primary tumor with metastasis in a single ipsilateral cervical lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE (extranodal extension)(-); or metastases in multiple ipsilateral cervical lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral cervical lymph nodes, none larger than 6 cm in greatest dimension, ENE(-). (from AJCC 8th Ed.)			Finding	
C132659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132659>	C132658	Unknown Primary Tumor cN2a TNM Finding v8	Unknown primary tumor with metastasis in a single ipsilateral cervical lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C13265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13265>	C32876	Nuclear Membrane|Nuclear Envelope	The double-layer membrane structure enclosing the nucleus in eukaryotic cells. It separates the DNA of the cell from the cytosol. For exchange of material, for example, proteins and mRNA, it is punctured with numerous nuclear pores.			Cell Component	
C132660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132660>	C132658	Unknown Primary Tumor cN2b TNM Finding v8	Unknown primary tumor with metastases in multiple ipsilateral cervical lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132661>	C132658	Unknown Primary Tumor cN2c TNM Finding v8	Unknown primary tumor with metastases in bilateral or contralateral cervical lymph nodes, none larger than 6 cm in greatest dimension, ENE(-). (from AJCC 8th Ed.)			Finding	
C132662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132662>	C132657	Unknown Primary Tumor cN3 TNM Finding v8	Unknown primary tumor with metastasis in a cervical lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in any cervical node(s) with clinically overt ENE(+) (ENEc). ENEc is defined as invasion of skin, infiltration of musculature, dense tethering or fixation to adjacent structures, or cranial nerve, brachial plexus, sympathetic trunk, or phrenic nerve invasion with dysfunction. (from AJCC 8th Ed.)			Finding	
C132663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132663>	C132662	Unknown Primary Tumor cN3a TNM Finding v8	Unknown primary tumor with metastasis in a cervical lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132664>	C132662	Unknown Primary Tumor cN3b TNM Finding v8	Unknown primary tumor with metastasis in any cervical node(s) with clinically overt ENE(+) (ENEc). ENEc is defined as invasion of skin, infiltration of musculature, dense tethering or fixation to adjacent structures, or cranial nerve, brachial plexus, sympathetic trunk, or phrenic nerve invasion with dysfunction. (from AJCC 8th Ed.)			Finding	
C132665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132665>	C132656|C132642	Unknown Primary Tumor Pathologic Cervical Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of an unknown primary tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of cervical lymph nodes. It applies to patients who are treated surgically with a cervical lymph node dissection. (from AJCC 8th Ed.)			Finding	
C132666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132666>	C132665	Unknown Primary Tumor pNX TNM Finding v8	Unknown primary tumor in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)			Finding	
C132667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132667>	C132665	Unknown Primary Tumor pN0 TNM Finding v8	Unknown primary tumor in which no regional lymph node metastases are detected. (from AJCC 8th Ed.)			Finding	
C132668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132668>	C132665	Unknown Primary Tumor pN1 TNM Finding v8	Unknown primary tumor with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (extranodal extension)(-). (from AJCC 8th Ed.)			Finding	
C132669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132669>	C132665	Unknown Primary Tumor pN2 TNM Finding v8	Unknown primary tumor with metastasis in a single ipsilateral or contralateral cervical lymph node 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral cervical lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral cervical lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral cervical lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). ENE detected on histopathologic examination is designated as ENEmi (microscopic ENE equal or less than 2 mm) or ENEma (major ENE more than 2 mm).  (from AJCC 8th Ed.)			Finding	
C13266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13266>	C34070	Nuclear Pore	An octagonal opening, about 70 nm across, where the inner and outer membranes of the nuclear envelope are continuous.			Cell Component	
C132670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132670>	C132669	Unknown Primary Tumor pN2a TNM Finding v8	Unknown primary tumor with metastasis in a single ipsilateral or contralateral cervical lymph node 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral cervical lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132671>	C132669	Unknown Primary Tumor pN2b TNM Finding v8	Unknown primary tumor with metastases in multiple ipsilateral cervical lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132672>	C132669	Unknown Primary Tumor pN2c TNM Finding v8	Unknown primary tumor with metastases in bilateral or contralateral cervical lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132673>	C132665	Unknown Primary Tumor pN3 TNM Finding v8	Unknown primary tumor with metastasis in a cervical lymph node larger than 6 cm in greatest dimension and ENE(-); or metastases in a single ipsilateral cervical lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral cervical lymph nodes, any size and ENE(+) in any node. (from AJCC 8th Ed.)			Finding	
C132674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132674>	C132673	Unknown Primary Tumor pN3a TNM Finding v8	Unknown primary tumor with metastasis in a cervical lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132675>	C132673	Unknown Primary Tumor pN3b TNM Finding v8	Unknown primary tumor with metastases in a single ipsilateral cervical lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral cervical lymph nodes, any size and ENE(+) in any node. (from AJCC 8th Ed.)			Finding	
C132676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132676>	C8566	Unknown Primary Tumor (Except for EBV-Related and HPV-Related Tumors) and Metastatic Cervical Adenopathy by AJCC v8 Stage	A term that refers to the staging of unknown primary tumor (except for EBV-related and HPV-related tumors) and metastatic cervical adenopathy according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C132677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132677>	C132676	Stage III Unknown Primary Tumor (Except for EBV-Related and HPV-Related Tumors) and Metastatic Cervical Adenopathy AJCC v8	Stage III includes: T0, N1, M0. T0: No evidence of primary tumor. N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (extranodal extension)(-). M0: No distant metastasis. (AJCC 8th Ed.)			Neoplastic Process	
C132678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132678>	C132676	Stage IVA Unknown Primary Tumor (Except for EBV-Related and HPV-Related Tumors) and Metastatic Cervical Adenopathy AJCC v8	Stage IVA includes: T0, N2, M0. T0: No evidence of primary tumor. N2: Metastasis in a single ipsilateral or contralateral cervical lymph node 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral cervical lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral cervical lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral cervical lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). M0: No distant metastasis. (AJCC 8th Ed.)			Neoplastic Process	
C132679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132679>	C132676	Stage IVB Unknown Primary Tumor (Except for EBV-Related and HPV-Related Tumors) and Metastatic Cervical Adenopathy AJCC v8	Stage IVB includes: T0, N3, M0. T0: No evidence of primary tumor. N3: Metastasis in a cervical lymph node larger than 6 cm in greatest dimension and ENE(-); or metastases in a single ipsilateral cervical lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral cervical lymph nodes, any size and ENE(+) in any node. M0: No distant metastasis. (AJCC 8th Ed.)			Neoplastic Process	
C13267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13267>	C13377	Nucleolar Organizer Region	Nucleolar organizer regions (NORs), which are loops of DNA containing ribosomal RNA genes, have been shown to correlate with cell proliferation and malignant transformation.			Gene or Genome	
C132680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132680>	C132676	Stage IVC Unknown Primary Tumor (Except for EBV-Related and HPV-Related Tumors) and Metastatic Cervical Adenopathy AJCC v8	Stage IVC includes: T0, Any N, M1. T0: No evidence of primary tumor. M1: Distant metastasis. (AJCC 8th Ed.)			Neoplastic Process	
C132681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132681>	C28227|C201534|C133877|C129822	Anti-CD40/Anti-mesothelin Bispecific Antibody ABBV-428|ABBV 428|ABBV-428|Anti-CD40 x Anti-mesothelin Bispecific Antibody ABBV-428|Anti-CD40/Anti-MSLN Bispecific Antibody ABBV-428	A bispecific antibody directed against both the cell-surface receptor CD40 and the tumor-associated antigen (TAA) mesothelin (MSLN), with potential immunostimulatory and antineoplastic activities. Upon administration of anti-CD40/anti-MSLN bispecific antibody ABBV-428, the anti-MSLN moiety targets and binds to MSLN expressed on tumor cells. The agonistic anti-CD40 moiety targets and binds to various CD40-expressing immune cells in the tumor microenvironment (TME) and induces CD40-dependent signaling pathways, which triggers the proliferation and activation of antigen-presenting cells (APCs) and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD40, a stimulatory receptor and a member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells, such as macrophages, B-lymphocytes, and dendritic cells (DCs); it plays a key role in the activation of the immune system. MSLN, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types.	Anti-CD40/Anti-mesothelin Bispecific Antibody ABBV-428		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C132682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132682>	C245	Lidocaine Hydrochloride Ophthalmic Gel|Akten|Lidocaine HCl Ophthalmic Gel	An ophthalmic gel formulation containing the synthetic amide-type anesthetic lidocaine, with potential analgesic activity. Upon ophthalmic application, the active ingredient lidocaine binds to and blocks voltage-gated sodium channels in neuronal cell membranes. Lidocaine-mediated stabilization of neuronal membranes inhibits the initiation and conduction of nerve impulses, which numbs the nerves, prevents the trigemino-cardiac reflex and produces a reversible local anesthesia.	Lidocaine Patch		Pharmacologic Substance	NCI Drug Dictionary Terminology
C132683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132683>	C200766	Anti-LeY-CAR-transduced Autologous T-Lymphocytes|Autologous-derived LeY-targeted CAR-T Cells|LeY-targeted Autologous CAR-T Cells	Genetically modified, autologous T-lymphocytes transduced with a retroviral vector encoding a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) Lewis-Y (LeY), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, anti-LeY-CAR-transduced autologous T-lymphocytes specifically target and induce selective toxicity in LeY-expressing tumor cells. LeY, a difucosylated carbohydrate antigen, is overexpressed by a variety of cancer cell types.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology
C132684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132684>	C1663	H3.3K27M-specific Peptide Vaccine|H3.3K27M Peptide Vaccine	A vaccine composed of a peptide derived from histone H3.3 containing the amino acid substitution mutation lysine (Lys) 27-to-methionine (H3.3K27M), with potential immunoactivating and antineoplastic activities. Upon administration of the H3.3K27M-specific peptide vaccine, the immune system may exert a cytotoxic T-lymphocyte (CTL)-mediated immune response against H3.3K27M-expressing tumor cells. The H3.3K27M mutation alters the methylation and acetylation profile of the histone H3 variant H3.3 at Lys 27. Modification of H3.3 at Lys 27 regulates gene expression, and the H3.3K27M mutation occurs in a variety of cancer cell types.	H3.3K27M-specific Peptide Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C132685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132685>	C1420	Deuteporfin	A photosensitizing agent composed of four sub-porphyrin derivatives, methoxyethy-hydroxyethyl-dipropionic, di-methoxyethyl-dipropionic, hydroxyethy-vinyl-dipropionic and methoxyethy-vinyl-dipropionic, with potential photosensitizing activity upon photodynamic therapy (PDT) and potential diagnostic imaging activity. Upon intravenous administration, deuteporfin preferentially targets and accumulates in cancer cells, especially those in the lymphatic system. Following photoactivation with an appropriate wavelength, deuteporfin generates highly cytotoxic singlet oxygen species, and induces oxidative stress that results in the damage and death of cancer cells. In addition, deuteporfin could be used as a tracer in near-infrared (NIR) fluorescence lymph node mapping.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology
C132686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132686>	C274	Demethylating Agent|DNA Methylation Inhibitor	Any agent that inhibits or prevents DNA methylation or agents that promote the removal of methyl groups from DNA.			Chemical Viewed Functionally	
C132687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132687>	C2124	Florbetaben (18F)|18F-BAY94-9172|18F-Florbetaben|4-((1E)-2-(4-(2-(2-(2-((sup 18(f))fluoroethoxy)ethoxy)ethoxy)phenyl)eth-1-en-1-yl)-N-methylaniline|FLORBETABEN F-18|Florbetaben 18F|Neuraceq	A stilbene derivative labeled with the positron-emitting isotope fluorine F 18, that may be used for positron emission tomography (PET) detection of beta-amyloid neuritic plaques and other amyloid protein deposits. Upon administration, F 18-florbetaben exhibits differential retention in regions that contain certain amyloid deposits. Differences in signal intensity between tissues showing specific and non-specific uptake of F 18-florbetaben allows for the detection of amyloid neuritic plaques in patients being evaluated for Alzheimer's disease, and potentially the detection of amyloid deposits in amyloidosis.	Florbetaben (18F)		Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C132688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132688>	C132632	Lip and Oral Cavity Cancer TNM Finding v8|Lip and Oral Cavity Carcinoma TNM Finding v8	A finding about one or more characteristics of lip and oral cavity cancer, following the rules of the TNM AJCC v8 classification system.  Cutaneous squamous cell carcinoma of the vermilion lip, nonepithelial tumors such as those of lymphoid tissue, soft tissue, bone, cartilage, and mucosal melanoma are not included in this classification. (from AJCC 8th Ed.)			Finding	
C132689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132689>	C132688|C132633	Lip and Oral Cavity Cancer Clinical TNM Finding v8|Lip and Oral Cavity Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of lip and oral cavity cancer, following the rules of the TNM AJCC v8 classification system.  The assessment of the primary tumor is based on inspection and palpation of the oral cavity and neck.  Additional studies may include CT, MRI, or ultrasound.  (from AJCC 8th Ed.)			Finding	
C13268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13268>	C34070	Nucleosome|NUCLEOSOME	A DNA packaging complex comprised of approximately 200 base pairs of DNA wound around a protein core, which is formed by an octomer of histones. The histone octomer includes two dimers of histones H2A and H2B that surround a tetramer consisting of two molecules of histone H3 and two molecules of histone H4.			Amino Acid, Peptide, or Protein|Nucleic Acid, Nucleoside, or Nucleotide	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C132690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132690>	C132688|C132642	Lip and Oral Cavity Cancer Pathologic TNM Finding v8|Lip and Oral Cavity Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of lip and oral cavity cancer, following the rules of the TNM AJCC v8 classification system.  The pathologic staging is determined after the complete resection of the primary site and/or regional nodal dissection, followed by pathologic examination of the resected specimen(s).  (from AJCC 8th Ed.)			Finding	
C132691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132691>	C132690	Lip and Oral Cavity Cancer Pathologic Primary Tumor TNM Finding v8|Lip and Oral Cavity Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of lip and oral cavity cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C132692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132692>	C132691	Lip and Oral Cavity Cancer pTX TNM Finding v8|Lip and Oral Cavity Carcinoma pTX TNM Finding v8	Lip and oral cavity cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C132693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132693>	C2092	Detirelix|BRN 6564671|D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-D-tryptophyl-L-seryl-L-tyrosyl-N(sup 6)-(bis(ethylamino)methylene)-D-lysyl-L-leucyl-L-arginyl-L-prolyl-|DETIRELIX|N-Ac-D-Nal(2)1,D-pCl-Phe2,D-Trp3,D-hArg(Et2)6,D-Ala(10)-GnRH				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C132694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132694>	C132691	Lip and Oral Cavity Cancer pTis TNM Finding v8|Lip and Oral Cavity Carcinoma pTis TNM Finding v8	Lip and oral cavity cancer with a finding of carcinoma in situ. (from AJCC 8th Ed.)			Finding	
C132695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132695>	C132691	Lip and Oral Cavity Cancer pT1 TNM Finding v8|Lip and Oral Cavity Carcinoma pT1 TNM Finding v8	Lip and oral cavity cancer with tumor size 2 cm or less in greatest dimension and 5 mm or less depth of invasion (DOI). DOI is depth of invasion and not tumor thickness. (from AJCC 8th Ed.)			Finding	
C132696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132696>	C132691	Lip and Oral Cavity Cancer pT2 TNM Finding v8|Lip and Oral Cavity Carcinoma pT2 TNM Finding v8	Lip and oral cavity cancer with tumor size 2 cm or less in greatest dimension, DOI greater than 5 mm and equal or less than 10 mm or tumor greater than 2 cm but 4 cm or less in greatest dimension and 10 mm or less DOI. (from AJCC 8th Ed.)			Finding	
C132697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132697>	C132691	Lip and Oral Cavity Cancer pT3 TNM Finding v8|Lip and Oral Cavity Carcinoma pT3 TNM Finding v8	Lip and oral cavity cancer with tumor size greater than 4 cm or any tumor greater than 10 mm DOI. (from AJCC 8th Ed.)			Finding	
C132698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132698>	C132691	Lip and Oral Cavity Cancer pT4 TNM Finding v8|Lip and Oral Cavity Carcinoma pT4 TNM Finding v8	Lip and oral cavity cancer with moderately advanced or very advanced local disease. (from AJCC 8th Ed.)			Finding	
C132699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132699>	C132698	Lip and Oral Cavity Cancer pT4a TNM Finding v8|Lip and Oral Cavity Carcinoma pT4a TNM Finding v8	Lip and oral cavity cancer with moderately advanced local disease. For lip: Tumor invades through cortical bone or involves the inferior alveolar nerve, floor of mouth, or skin of face (i.e., chin or nose). For oral cavity: Tumor invades adjacent structures only (e.g., through cortical bone of the mandible or maxilla, or involves the maxillary sinus or skin of face). Note: Superficial erosion of bone/tooth socket (alone) by a gingival primary is not sufficient to classify a tumor as T4. (from AJCC 8th Ed.)			Finding	
C13269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13269>	C34070	Cytoplasmic Organelle|Organelle	A subcellular feature in the cytoplasm of a cell with a definite structure and a specific role in the function of the cell.			Cell Component	
C1326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1326>	C67502	Doxorubicin Hydrochloride|14-Hydroxydaunorubicin Hydrochloride|3-Hydroxyacetyldaunorubicin Hydrochloride|5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)|5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-,hydrochloride, (8S-cis)-(9CI)|ADM|ADRIAMYCIN, HYDROCHLORIDE|Adriacin|Adriacin|Adriamycin|Adriamycin Hydrochloride|Adriamycin PFS|Adriamycin PFS|Adriamycin RDF|Adriamycin RDF|Adriamycin hydrochloride|Adriamycine|Adriblastina|Adriblastina|Adriblastine|Adrimedac|Chloridrato de Doxorrubicina|DOX|DOX|DOXO-CELL|DOXORUBICIN HYDROCHLORIDE|Doxolem|Doxorubicin HCl|Doxorubicin hydrochloride|Doxorubicin.HCl|Doxorubin|FI 106|FI 106|FI-106|FI106|Farmiblastina|L-Lyxo-hexopyranoside, 3b-glycol-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-alpha-, hydrochloride|Rubex|Rubex|doxorubicin hydrochloride|hydroxydaunorubicin	The hydrochloride salt of doxorubicin, an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.	Doxorubicin Hydrochloride		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|OS Subject Characteristics Table
C132700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132700>	C132698	Lip and Oral Cavity Cancer pT4b TNM Finding v8|Lip and Oral Cavity Carcinoma pT4b TNM Finding v8	Lip and oral cavity cancer with very advanced local disease. Tumor invades masticator space, pterygoid plates, or skull base and/or encases the internal carotid artery. (from AJCC 8th Ed.)			Finding	
C132701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132701>	C132690	Lip and Oral Cavity Cancer Pathologic Regional Lymph Nodes TNM Finding v8|Lip and Oral Cavity Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of lip and oral cavity cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C132702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132702>	C132701	Lip and Oral Cavity Cancer pNX TNM Finding v8|Lip and Oral Cavity Carcinoma pNX TNM Finding v8	Lip and oral cavity cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C132703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132703>	C132701	Lip and Oral Cavity Cancer pN0 TNM Finding v8|Lip and Oral Cavity Carcinoma pN0 TNM Finding v8	Lip and oral cavity cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)			Finding	
C132704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132704>	C132701	Lip and Oral Cavity Cancer pN1 TNM Finding v8|Lip and Oral Cavity Carcinoma pN1 TNM Finding v8	Lip and oral cavity cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132705>	C132701	Lip and Oral Cavity Cancer pN2 TNM Finding v8|Lip and Oral Cavity Carcinoma pN2 TNM Finding v8	Lip and oral cavity cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE (-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, ENE(-). (from AJCC 8th Ed.)			Finding	
C132706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132706>	C132705	Lip and Oral Cavity Cancer pN2a TNM Finding v8|Lip and Oral Cavity Carcinoma pN2a TNM Finding v8	Lip and oral cavity cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE (-). (from AJCC 8th Ed.)			Finding	
C132707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132707>	C132705	Lip and Oral Cavity Cancer pN2b TNM Finding v8|Lip and Oral Cavity Carcinoma pN2b TNM Finding v8	Lip and oral cavity cancer with metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132708>	C132705	Lip and Oral Cavity Cancer pN2c TNM Finding v8|Lip and Oral Cavity Carcinoma pN2c TNM Finding v8	Lip and oral cavity cancer with metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132709>	C132701	Lip and Oral Cavity Cancer pN3 TNM Finding v8|Lip and Oral Cavity Carcinoma pN3 TNM Finding v8	Lip and oral cavity cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE (-); or in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral or bilateral lymph nodes any with ENE(+). (from AJCC 8th Ed.)			Finding	
C13270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13270>	C13321	Pancreatic Secretion				Body Substance	
C132710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132710>	C132709	Lip and Oral Cavity Cancer pN3a TNM Finding v8|Lip and Oral Cavity Carcinoma pN3a TNM Finding v8	Lip and oral cavity cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE (-). (from AJCC 8th Ed.)			Finding	
C132711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132711>	C132709	Lip and Oral Cavity Cancer pN3b TNM Finding v8|Lip and Oral Cavity Carcinoma pN3b TNM Finding v8	Lip and oral cavity cancer with metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral or bilateral lymph nodes any with ENE(+). (from AJCC 8th Ed.)			Finding	
C132712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132712>	C132689	Lip and Oral Cavity Cancer Clinical Regional Lymph Nodes TNM Finding v8|Lip and Oral Cavity Carcinoma Clinical Regional Lymph Nodes TNM Finding v8	A clinical finding about one or more characteristics of lip and oral cavity cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C132713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132713>	C132712	Lip and Oral Cavity Cancer cN2 TNM Finding v8|Lip and Oral Cavity Carcinoma cN2 TNM Finding v8	Lip and oral cavity cancer with metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, and ENE(-). (from AJCC 8th Ed.)			Finding	
C132714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132714>	C132713	Lip and Oral Cavity Cancer cN2a TNM Finding v8|Lip and Oral Cavity Carcinoma cN2a TNM Finding v8	Lip and oral cavity cancer with metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-).  (from AJCC 8th Ed.)			Finding	
C132715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132715>	C132713	Lip and Oral Cavity Cancer cN2b TNM Finding v8|Lip and Oral Cavity Carcinoma cN2b TNM Finding v8	Lip and oral cavity cancer with metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132716>	C132713	Lip and Oral Cavity Cancer cN2c TNM Finding v8|Lip and Oral Cavity Carcinoma cN2c TNM Finding v8	Lip and oral cavity cancer with metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, and ENE(-). (from AJCC 8th Ed.)			Finding	
C132717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132717>	C132712	Lip and Oral Cavity Cancer cN3 TNM Finding v8|Lip and Oral Cavity Carcinoma cN3 TNM Finding v8	Lip and oral cavity cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in any node(s) and clinically overt ENE(+). (from AJCC 8th Ed.)			Finding	
C132718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132718>	C132717	Lip and Oral Cavity Cancer cN3a TNM Finding v8|Lip and Oral Cavity Carcinoma cN3a TNM Finding v8	Lip and oral cavity cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132719>	C132717	Lip and Oral Cavity Cancer cN3b TNM Finding v8|Lip and Oral Cavity Carcinoma cN3b TNM Finding v8	Lip and oral cavity cancer with metastasis in any node(s) and clinically overt ENE(+). (from AJCC 8th Ed.)			Finding	
C13271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13271>	C186810|C131490|C117116	t(9;22)(q34.1;q11.2)|t(9;22)(q34;q11)|t(9;22)(q34;q11.2)|t(9;22)(q34;q11.2)	A translocation between chromosomes 9 and 22 that is associated with the Philadelphia chromosome.	t(9;22)(q34.1;q11.2)		Cell or Molecular Dysfunction	AML Authorized Value Terminology|AML Minimal Residual Disease Table|AML Molecular Analysis Table|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132720>	C132690	Lip and Oral Cavity Cancer Pathologic Distant Metastasis TNM Finding v8|Lip and Oral Cavity Carcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of lip and oral cavity cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.  There is no pathologic M0 for lip and oral cavity cancer.			Finding	
C132721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132721>	C132720	Lip and Oral Cavity Cancer pM1 TNM Finding v8|Lip and Oral Cavity Carcinoma pM1 TNM Finding v8	Lip and oral cavity cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C132722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132722>	C132689	Lip and Oral Cavity Cancer Clinical Distant Metastasis TNM Finding v8|Lip and Oral Cavity Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of lip and oral cavity cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C132723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132723>	C132722	Lip and Oral Cavity Cancer cM0 TNM Finding v8|Lip and Oral Cavity Carcinoma cM0 TNM Finding v8	Lip and oral cavity cancer without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C132724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132724>	C132722	Lip and Oral Cavity Cancer cM1 TNM Finding v8|Lip and Oral Cavity Carcinoma cM1 TNM Finding v8	Lip and oral cavity cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C132725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132725>	C47794|C29728	Vabicaserin|Cyclopenta(4,5)pyrido(3,2,1-jk)(1,4)benzodiazepine, 4,5,6,7,9,9a,10,11,12,12a-Decahydro-, (9aR,12aS)-rel-(-)-|SCA-136|VABICASERIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132726>	C15690	Myelosuppressive Chemotherapy|Myelosuppression Chemotherapy	The use of naturally occurring or synthetic chemicals for the purpose of decreasing the rate of blood cell production in the bone marrow.			Therapeutic or Preventive Procedure	
C132727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132727>	C99107	Cerebral Vein Thrombosis|Cerebral Venous Thrombosis|Cerebral venous thrombosis	The formation of a blood clot in a cerebral vein.	Cerebral Vein Thrombosis		Disease or Syndrome	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 4: COVID-19 Cardiovascular Complications Terminology|CTRP Disease Terminology|CTRP Terminology|Postacute Cardiovascular Sequelae of SARS-CoV-2 Infection or Long-Term Cardiovascular Complications of COVID-19 Terminology
C132728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132728>	C9315	Lip and Oral Cavity Cancer by AJCC v8 Stage|Lip and Oral Cavity Carcinoma by AJCC v8 Stage	A term that refers to the staging of lip and oral cavity carcinoma according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C132729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132729>	C132728	Stage I Lip and Oral Cavity Cancer AJCC v8|Stage I Lip and Oral Cavity Cancer|Stage I Lip and Oral Cavity Carcinoma AJCC v8	Stage I includes: T1, N0, M0.  T1: Tumor size 2 cm or less in greatest dimension and 5 mm or less depth of invasion (DOI).  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 8th Ed.)	Stage I Lip and Oral Cavity Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13272>	C34055	Placenta|PLACENTA|Placental|allantoic placenta|eutherian placenta|placenta|placenta	An organ present in some vertebrates during embryonic gestation that surrounds the fetus and provides it with nutrients and oxygen, facilitates gas and waste exchange between the fetus and mother, and provides parasitic cloaking from the mother's immune system by excretion of neurokinin B.			Embryonic Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology|mCode Genomic Specimen Type Value Set|mCode Terminology|UBERON Terminology
C132730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132730>	C132728	Stage II Lip and Oral Cavity Cancer AJCC v8|Stage II Lip and Oral Cavity Cancer|Stage II Lip and Oral Cavity Carcinoma AJCC v8	Stage II includes: T2, N0, M0. T2: Tumor size 2 cm or less in greatest dimension, DOI greater than 5 mm and equal or less than 10 mm or tumor greater than 2 cm but 4 cm or less in greatest dimension and 10 mm or less DOI.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 8th Ed.)	Stage II Lip and Oral Cavity Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132731>	C132728	Stage III Lip and Oral Cavity Cancer AJCC v8|Stage III Lip and Oral Cavity Cancer|Stage III Lip and Oral Cavity Carcinoma AJCC v8	Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T3: Tumor size greater than 4 cm or any tumor greater than 10 mm DOI. T1: Tumor size 2 cm or less in greatest dimension and 5 mm or less DOI. T2: Tumor size 2 cm or less in greatest dimension, DOI greater than 5 mm and equal or less than 10 mm or tumor greater than 2 cm but 4 cm or less in greatest dimension and 10 mm or less DOI N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (extranodal extension)(-). M0: No distant metastasis. (AJCC 8th Ed.)	Stage III Lip and Oral Cavity Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132732>	C132728	Stage IV Lip and Oral Cavity Cancer AJCC v8|Stage IV Lip and Oral Cavity Cancer|Stage IV Lip and Oral Cavity Carcinoma AJCC v8	Stage IV includes: IVA (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB (Any T, N3, M0); (T4b, Any N, M0); IVC (Any T, Any N, M1). T4a (lip): Tumor invades through cortical bone or involves the inferior alveolar nerve, floor of mouth, or skin of face (i.e., chin or nose).  T4a (oral cavity): Tumor invades adjacent structures only (e.g., through cortical bone of the mandible or maxilla, or involves the maxillary sinus or skin of face). Note: Superficial erosion of bone/tooth socket (alone) by a gingival primary is not sufficient to classify a tumor as T4. T1: Tumor size 2 cm or less in greatest dimension and 5 mm or less DOI. T2: Tumor size 2 cm or less in greatest dimension, DOI greater than 5 mm and equal or less than 10 mm or tumor greater than 2 cm but 4 cm or less in greatest dimension and 10 mm or less DOI. T3: Tumor size greater than 4 cm or any tumor greater than 10 mm DOI. T4b: Tumor invades masticator space, pterygoid plates, or skull base and/or encases the internal carotid artery. N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-). N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE (-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, ENE(-). N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE (-); or in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral or bilateral lymph nodes any with ENE(+). M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th Ed.)	Stage IV Lip and Oral Cavity Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132733>	C132732	Stage IVA Lip and Oral Cavity Cancer AJCC v8|Stage IVA Lip and Oral Cavity Cancer|Stage IVA Lip and Oral Cavity Carcinoma AJCC v8	Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0). T4a (lip): Tumor invades through cortical bone or involves the inferior alveolar nerve, floor of mouth, or skin of face (i.e., chin or nose).  T4a (oral cavity): Tumor invades adjacent structures only (e.g., through cortical bone of the mandible or maxilla, or involves the maxillary sinus or skin of face). Note: Superficial erosion of bone/tooth socket (alone) by a gingival primary is not sufficient to classify a tumor as T4. T1: Tumor size 2 cm or less in greatest dimension and 5 mm or less DOI. T2: Tumor size 2 cm or less in greatest dimension, DOI greater than 5 mm and equal or less than 10 mm or tumor greater than 2 cm but 4 cm or less in greatest dimension and 10 mm or less DOI. T3: Tumor size greater than 4 cm or any tumor greater than 10 mm DOI. N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-). N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE (-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, ENE(-). M0: No distant metastasis. (AJCC 8th Ed.)	Stage IVA Lip and Oral Cavity Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132734>	C132732	Stage IVB Lip and Oral Cavity Cancer AJCC v8|Stage IVB Lip and Oral Cavity Cancer|Stage IVB Lip and Oral Cavity Carcinoma AJCC v8	Stage IVB includes: (Any T, N3, M0); (T4b, Any N, M0). T4b: Tumor invades masticator space, pterygoid plates, or skull base and/or encases the internal carotid artery. N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE (-); or in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral or bilateral lymph nodes any with ENE(+). M0: No distant metastasis. (AJCC 8th Ed.)	Stage IVB Lip and Oral Cavity Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132735>	C132732	Stage IVC Lip and Oral Cavity Cancer AJCC v8|Stage IVC Lip and Oral Cavity Cancer|Stage IVC Lip and Oral Cavity Carcinoma AJCC v8	Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th Ed.)	Stage IVC Lip and Oral Cavity Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132736>	C9315	Lip and Oral Cavity Cancer by AJCC v6 and v7 Stage	A term that refers to the staging of lip and oral cavity carcinoma according to the American Joint Committee on Cancer, 6th and 7th editions.			Neoplastic Process	
C132737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132737>	C38291	Intracanalicular Route of Administration|Intracanalicular	Administration to, or situated within, a tubular passage or channel of the body.			Functional Concept	FDA Structured Product Labeling Terminology|SPL Drug Route of Administration Terminology
C132738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132738>	C48149	Abediterol|5-((1R)-2-((6-(2,2-Difluoro-2-phenylethoxy)hexyl)amino)-1-hydroxyethyl)-8- hydroxyquinolin-2(1H)-one|ABEDITEROL|LAS 100977				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132739>	C132632	Major Salivary Gland Cancer TNM Finding v8|Major Salivary Gland Carcinoma TNM Finding v8	A finding about one or more characteristics of major salivary gland cancer, following the rules of the TNM AJCC v8 classification system.  This classification does not apply to lymphomas and minor salivary gland cancers. (from AJCC 8th Ed.)			Finding	
C13273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13273>	C13722	Lung Surfactant|LUNG SURFACTANT|Surfactant|Surfactant, Lung	Pulmonary surfactant lines the lung epithelium and lowers surface tension to prevent collapse at end-expiration. Deficiency of pulmonary surfactant results in respiratory distress syndrome (RDS) in premature infants. Lung surfactant is synthesized in alveolar type II cells, stored in lamellar bodies and secreted via exocytosis.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132740>	C1967	Decernotinib|(2R)-2-Methyl-2-((2-(1H-pyrrolo(2,3-b)pyridin-3-yl)pyrimidin- 4-yl)amino)-N-(2,2,2-trifluoroethyl)butanamide|Adelatinib|DECERNOTINIB|VRT 831509|VX 509|VX-509|VX509				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132741>	C132739|C132633	Major Salivary Gland Cancer Clinical TNM Finding v8|Major Salivary Gland Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of major salivary gland cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C132742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132742>	C132739|C132642	Major Salivary Gland Cancer Pathologic TNM Finding v8|Major Salivary Gland Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of major salivary gland cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C132743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132743>	C132742	Major Salivary Gland Cancer Pathologic Primary Tumor TNM Finding v8|Major Salivary Gland Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of major salivary gland cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C132744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132744>	C132743	Major Salivary Gland Cancer pTX TNM Finding v8|Major Salivary Gland Carcinoma pTX TNM Finding v8	Major salivary gland cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C132745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132745>	C132743	Major Salivary Gland Cancer pT0 TNM Finding v8|Major Salivary Gland Carcinoma pT0 TNM Finding v8	Major salivary gland cancer with no evidence of a primary tumor. (from AJCC 8th Ed.)			Finding	
C132746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132746>	C132743	Major Salivary Gland Cancer pTis TNM Finding v8|Major Salivary Gland Carcinoma pTis TNM Finding v8	Major salivary gland cancer with a finding of carcinoma in situ. (from AJCC 8th Ed.)			Finding	
C132747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132747>	C132743	Major Salivary Gland Cancer pT1 TNM Finding v8|Major Salivary Gland Carcinoma pT1 TNM Finding v8	Major salivary gland cancer with tumor 2 cm or less in greatest dimension without extraparenchymal extension. Extraparenchymal extension is clinical or macroscopic evidence of invasion of soft tissues. Microscopic evidence alone does not constitute extraparenchymal extension for classification purposes. (from AJCC 8th Ed.)			Finding	
C132748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132748>	C132743	Major Salivary Gland Cancer pT2 TNM Finding v8|Major Salivary Gland Carcinoma pT2 TNM Finding v8	Major salivary gland cancer with tumor more than 2 cm, but not more than 4 cm in greatest dimension without extraparenchymal extension. Extraparenchymal extension is clinical or macroscopic evidence of invasion of soft tissues. Microscopic evidence alone does not constitute extraparenchymal extension for classification purposes. (from AJCC 8th Ed.)			Finding	
C132749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132749>	C132743	Major Salivary Gland Cancer pT3 TNM Finding v8|Major Salivary Gland Carcinoma pT3 TNM Finding v8	Major salivary gland cancer with tumor more than 4 cm in greatest dimension, and/or tumor having extraparenchymal extension. Extraparenchymal extension is clinical or macroscopic evidence of invasion of soft tissues. Microscopic evidence alone does not constitute extraparenchymal extension for classification purposes. (from AJCC 8th Ed.)			Finding	
C13274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13274>	C33174	Ribosome|Ribosomal|ribosome	Ribosomes are small organelles composed of ribosomal RNA (rRNA) and 80 some different proteins. rRNA is synthesized in the nucleolus and the ribosomal subunits are assembled there from rRNA and imported cytoplasmic made proteins. Once assembled, the subunits pass through the nuclear pores to the cytoplasm where they take part in protein synthesis. Some ribosomes are free in the cytoplasm and can be recruited to a polyribosomal structure when a messenger RNA (mRNA) strand is to be translated into a cytoplasmic protein. Other ribosomes are attached to the endoplasmic reticulum where the protein is formed within the interior to the endoplasmic reticulum. These proteins are destined for secretion, storage or incorporation into membranes.	Ribosome		Cell Component	CTRP Biomarker Terminology|CTRP Terminology
C132750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132750>	C132743	Major Salivary Gland Cancer pT4 TNM Finding v8|Major Salivary Gland Carcinoma pT4 TNM Finding v8	Moderately advanced or very advanced major salivary gland cancer. (from AJCC 8th Ed.)			Finding	
C132751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132751>	C132750	Major Salivary Gland Cancer pT4a TNM Finding v8|Major Salivary Gland Carcinoma pT4a TNM Finding v8	Moderately advanced major salivary gland cancer. Tumor invades skin, mandible, ear canal, and/or facial nerve. (from AJCC 8th Ed.)			Finding	
C132752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132752>	C132750	Major Salivary Gland Cancer pT4b TNM Finding v8|Major Salivary Gland Carcinoma pT4b TNM Finding v8	Very advanced major salivary gland cancer. Tumor invades skull base and/or pterygoid plates and/or encases carotid artery. (from AJCC 8th Ed.)			Finding	
C132753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132753>	C132742	Major Salivary Gland Cancer Pathologic Regional Lymph Nodes TNM Finding v8|Major Salivary Gland Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of major salivary gland cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C132754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132754>	C132753	Major Salivary Gland Cancer pNX TNM Finding v8|Major Salivary Gland Carcinoma pNX TNM Finding v8	Major salivary gland cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C132755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132755>	C132753	Major Salivary Gland Cancer pN0 TNM Finding v8|Major Salivary Gland Carcinoma pN0 TNM Finding v8	Major salivary gland cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)			Finding	
C132756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132756>	C132753	Major Salivary Gland Cancer pN1 TNM Finding v8|Major Salivary Gland Carcinoma pN1 TNM Finding v8	Major salivary gland cancer with metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132757>	C132753	Major Salivary Gland Cancer pN2 TNM Finding V8|Major Salivary Gland Carcinoma pN2 TNM Finding v8	Major salivary gland cancer with metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(+); or more than 3 cm but not more than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-), or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132758>	C132757	Major Salivary Gland Cancer pN2a TNM Finding V8|Major Salivary Gland Carcinoma pN2a TNM Finding v8	Major salivary gland cancer with metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(+); or a single ipsilateral node more than 3 cm but not more than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132759>	C132757	Major Salivary Gland Cancer pN2b TNM Finding V8|Major Salivary Gland Carcinoma pN2b TNM Finding v8	Major salivary gland cancer with metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-).  (from AJCC 8th Ed.)			Finding	
C13275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13275>	C34062	Saliva|Head and Neck, Saliva|SALIVA|saliva	The watery fluid in the mouth made by the salivary glands. Saliva moistens food to help digestion and it helps protect the mouth against infections.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|mCode Genomic Specimen Type Value Set|mCode Terminology
C132760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132760>	C132757	Major Salivary Gland Cancer pN2c TNM Finding V8|Major Salivary Gland Carcinoma pN2c TNM Finding v8	Major salivary gland cancer with metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132761>	C132753	Major Salivary Gland Cancer pN3 TNM Finding v8|Major Salivary Gland Carcinoma pN3 TNM Finding v8	Major salivary gland cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+). (from AJCC 8th Ed.)			Finding	
C132762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132762>	C132761	Major Salivary Gland Cancer pN3a TNM Finding v8|Major Salivary Gland Carcinoma pN3a TNM Finding v8	Major salivary gland cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132763>	C132761	Major Salivary Gland Cancer pN3b TNM Finding v8|Major Salivary Gland Carcinoma pN3b TNM Finding v8	Major salivary gland cancer with metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+). (from AJCC 8th Ed.)			Finding	
C132764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132764>	C132741	Major Salivary Gland Cancer Clinical Regional Lymph Nodes TNM Finding v8|Major Salivary Gland Carcinoma Clinical Regional Lymph Nodes TNM Finding v8	A clinical finding about one or more characteristics of major salivary gland cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C132765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132765>	C132764	Major Salivary Gland Cancer cN2 TNM Finding V8|Major Salivary Gland Carcinoma cN2 TNM Finding V8	Major salivary gland cancer with metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-), or in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132766>	C132765	Major Salivary Gland Cancer cN2a TNM Finding V8|Major Salivary Gland Carcinoma cN2a TNM Finding V8	Major salivary gland cancer with metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132767>	C132765	Major Salivary Gland Cancer cN2b TNM Finding V8|Major Salivary Gland Carcinoma cN2b TNM Finding V8	Major salivary gland cancer with metastasis in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132768>	C132765	Major Salivary Gland Cancer cN2c TNM Finding V8|Major Salivary Gland Carcinoma cN2c TNM Finding V8	Major salivary gland cancer with metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132769>	C132764	Major Salivary Gland Cancer cN3 TNM Finding v8|Major Salivary Gland Carcinoma cN3 TNM Finding V8	Major salivary gland cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in any node(s) with clinically overt ENE(+). (from AJCC 8th Ed.)			Finding	
C13276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13276>	C13409	Sebum|SEBUM|sebum	A thick, oily substance produced by the sebaceous glands located in the dermis.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132770>	C132769	Major Salivary Gland Cancer cN3a TNM Finding v8|Major Salivary Gland Carcinoma cN3a TNM Finding V8	Major salivary gland cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132771>	C132769	Major Salivary Gland Cancer cN3b TNM Finding v8|Major Salivary Gland Carcinoma cN3b TNM Finding V8	Major salivary gland cancer with metastasis in any node(s) with clinically overt ENE(+). (from AJCC 8th Ed.)			Finding	
C132772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132772>	C132741	Major Salivary Gland Cancer Clinical Distant Metastasis TNM Finding v8|Major Salivary Gland Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of major salivary gland cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C132773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132773>	C132772	Major Salivary Gland Cancer cM0 TNM Finding v8|Major Salivary Gland Carcinoma cM0 TNM Finding V8	Major salivary gland cancer without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C132774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132774>	C132772	Major Salivary Gland Cancer cM1 TNM Finding v8|Major Salivary Gland Carcinoma cM1 TNM Finding V8	Major salivary gland cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C132775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132775>	C132742	Major Salivary Gland Cancer Pathologic Distant Metastasis TNM Finding v8|Major Salivary Gland Carcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of major salivary gland cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C132776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132776>	C132775	Major Salivary Gland Cancer pM1 TNM Finding v8|Major Salivary Gland Carcinoma pM1 TNM Finding v8	Major salivary gland cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C132777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132777>	C2578	Parnaparin Sodium|PARNAPARIN SODIUM				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132778>	C5907	Major Salivary Gland Cancer by AJCC v7 Stage	A term that refers to the staging of major salivary gland cancer according to the American Joint Committee on Cancer, 7th edition.			Neoplastic Process	
C132779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132779>	C5907	Major Salivary Gland Cancer by AJCC v8 Stage|Major Salivary Gland Carcinoma by AJCC v8 Stage	A term that refers to the staging of major salivary gland cancer according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C13277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13277>	C13713	Semen|Human Semen (Sperm)|SEMEN|Seminal Plasma|semen	The thick, whitish secretion of the male reproductive organs. It is composed of spermatozoa in their nutrient plasma, secretions from the prostate, seminal vesicles, and various other glands, epithelial cells, and minor constituents.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Structured Product Labeling Terminology|SPL Tissue Form Product Type Terminology
C132780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132780>	C29711	Fasiglifam|((3S)-6-((3-(4-(3-Methanesulfonylpropoxy)-2,6-dimethylphenyl]phenyl}methoxy)-2,3-dihydro-1-benzofuran-3-yl)acetic Acid|FASIGLIFAM|TAK 875|TAK-875				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132781>	C132779	Stage I Major Salivary Gland Cancer AJCC v8|Stage I Major Salivary Gland Cancer|Stage I Major Salivary Gland Carcinoma AJCC v8	Stage I includes: T1, N0, M0. T1: Tumor measuring 2 cm or less in greatest dimension without extraparenchymal extension. Extraparenchymal extension is clinical or macroscopic evidence of invasion of soft tissues. Microscopic evidence alone does not constitute extraparenchymal extension for classification purposes. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Major Salivary Gland Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132782>	C15426	European Union Drug Regulating Authorities Clinical Trials Database|EudraCT|EudraCT|European Union Drug Regulating Authorities Clinical Trials|European Union Drug Regulating Authorities Clinical Trials (EudraCT)	The European Union's electronic database of clinical trials. It contains information submitted by sponsors and informs users about ongoing clinical trials in EU Member States and European Economic Area countries.			Intellectual Product	CDISC Dictionary Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C132783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132783>	C132779	Stage 0 Major Salivary Gland Cancer AJCC v8|Stage 0 Major Salivary Gland Cancer|Stage 0 Major Salivary Gland Carcinoma AJCC v8	Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0 Major Salivary Gland Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132784>	C19975	University Medical Information Network|UMIN|University Medical Information Network (UMIN)	A cooperative organization for national medical schools in Japan designed to: provide up-to-date information to healthcare professionals; promote communications between healthcare professionals; support collaborative work among university hospitals; support collaborative medical research; standardize medical data and collect hospital statistics; support education and training at hospitals.			Professional or Occupational Group	
C132785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132785>	C132779	Stage II Major Salivary Gland Cancer AJCC v8|Stage II Major Salivary Gland Cancer|Stage II Major Salivary Gland Carcinoma AJCC v8	Stage II includes: T2, N0, M0. T2: Tumor measuring more than 2 cm, but not more than 4 cm in greatest dimension without extraparenchymal extension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Major Salivary Gland Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132786>	C132779	Stage III Major Salivary Gland Cancer AJCC v8|Stage III Major Salivary Gland Cancer|Stage III Major Salivary Gland Carcinoma AJCC v8	Stage III includes: (T3, N0, M0); (T0, N1, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0).  T3: Tumor measuring more than 4 cm in greatest dimension, and/or tumor having extraparenchymal extension.  T0: No evidence of primary tumor. T1: Tumor measuring 2 cm or less in greatest dimension without extraparenchymal extension. T2: Tumor measuring more than 2 cm, but not more than 4 cm in greatest dimension without extraparenchymal extension.  N0: No regional lymph node metastasis.  N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(-). M0: No distant metastasis. (AJCC 8th ed.)	Stage III Major Salivary Gland Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132787>	C132779	Stage IV Major Salivary Gland Cancer AJCC v8|Stage IV Major Salivary Gland Cancer|Stage IV Major Salivary Gland Carcinoma AJCC v8	Stage IV includes: IVA (T4a, N0, M0); (T4a, N1, M0); (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB (T4b, Any N, M0); (Any T, N3, M0); IVC (Any T, Any N, M1). T4a: Moderately advanced disease.  Tumor invades skin, mandible, ear canal, and/or facial nerve. T0: No evidence of primary tumor. T1: Tumor measuring 2 cm or less in greatest dimension without extraparenchymal extension. T2: Tumor measuring more than 2 cm, but not more than 4 cm in greatest dimension without extraparenchymal extension. T3: Tumor measuring more than 4 cm in greatest dimension, and/or tumor having extraparenchymal extension. T4b: Very advanced disease.  Tumor invades skull base and/or pterygoid plates and/or encases carotid artery. N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. N2: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(+); or more than 3 cm but not more than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-), or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-). N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+). M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Major Salivary Gland Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132788>	C132787	Stage IVA Major Salivary Gland Cancer AJCC v8|Stage IVA Major Salivary Gland Cancer|Stage IVA Major Salivary Gland Carcinoma AJCC v8	Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0). T4a: Moderately advanced disease.  Tumor invades skin, mandible, ear canal, and/or facial nerve. T0: No evidence of primary tumor. T1: Tumor measuring 2 cm or less in greatest dimension without extraparenchymal extension. T2: Tumor measuring more than 2 cm, but not more than 4 cm in greatest dimension without extraparenchymal extension. T3: Tumor measuring more than 4 cm in greatest dimension, and/or tumor having extraparenchymal extension. N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension. N2: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(+); or more than 3 cm but not more than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-), or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-). M0: No distant metastasis. (AJCC 8th ed.)	Stage IVA Major Salivary Gland Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132789>	C132787	Stage IVB Major Salivary Gland Cancer AJCC v8|Stage IVB Major Salivary Gland Cancer|Stage IVB Major Salivary Gland Carcinoma AJCC v8	Stage IVB includes: (T4b, Any N, M0); (Any T, N3, M0). T4b: Very advanced disease.  Tumor invades skull base and/or pterygoid plates and/or encases carotid artery. N0: No regional lymph node metastasis. N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+). M0: No distant metastasis. (AJCC 8th ed.)	Stage IVB Major Salivary Gland Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13278>	C13722	Sputum|SPUTUM|sputum	Material containing mucus, cellular debris, microorganisms and sometimes blood or pus.  It is ejected through the mouth from the lungs, bronchi, and trachea.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|mCode Genomic Specimen Type Value Set|mCode Terminology
C132790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132790>	C132787	Stage IVC Major Salivary Gland Cancer AJCC v8|Stage IVC Major Salivary Gland Cancer|Stage IVC Major Salivary Gland Carcinoma AJCC v8	Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)	Stage IVC Major Salivary Gland Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132791>	C132632	Pharyngeal Cancer TNM Finding v8|Pharyngeal Carcinoma TNM Finding v8	A finding about one or more characteristics of pharyngeal cancer, following the rules of the TNM AJCC v8 classification system. (from AJCC 8th Ed.)			Finding	
C132792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132792>	C132791	Nasopharyngeal Cancer TNM Finding v8|Nasopharyngeal Carcinoma TNM Finding v8	A finding about one or more characteristics of nasopharyngeal cancer, following the rules of the TNM AJCC v8 classification system. Epithelial tumors of the nasopharynx are staged using this staging system. Mucosal melanoma, lymphoma, and sarcoma of soft tissue, bone, and cartilage are not included in this classification. (from AJCC 8th Ed.)			Finding	
C132793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132793>	C132792|C132633	Nasopharyngeal Cancer Clinical TNM Finding v8|Nasopharyngeal Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of nasopharyngeal cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C132794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132794>	C132792|C132642	Nasopharyngeal Cancer Pathologic TNM Finding v8|Nasopharyngeal Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of nasopharyngeal cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C132795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132795>	C132794	Nasopharyngeal Cancer Pathologic Primary Tumor TNM Finding v8|Nasopharyngeal Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of nasopharyngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C132796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132796>	C132795	Nasopharyngeal Cancer pTX TNM Finding v8|Nasopharyngeal Carcinoma pTX TNM Finding v8	Nasopharyngeal cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C132797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132797>	C132795	Nasopharyngeal Cancer pT0 TNM Finding v8|Nasopharyngeal Carcinoma pT0 TNM Finding v8	No tumor identified, but EBV-positive cervical node(s) involvement is present. (from AJCC 8th Ed.)			Finding	
C132798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132798>	C132795	Nasopharyngeal Cancer pT1 TNM Finding v8|Nasopharyngeal Carcinoma pT1 TNM Finding v8	Nasopharyngeal cancer with tumor confined to the nasopharynx, or tumor extending to oropharynx and/or nasal cavity without parapharyngeal involvement. (from AJCC 8th Ed.)			Finding	
C132799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132799>	C132795	Nasopharyngeal Cancer pT2 TNM Finding v8|Nasopharyngeal Carcinoma pT2 TNM Finding v8	Nasopharyngeal cancer with extension to parapharyngeal space, and/or adjacent soft tissue involvement (medial pterygoid, lateral pterygoid, prevertebral muscles). (from AJCC 8th Ed.)			Finding	
C1327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1327>	C78275	Antiplatelet Agent	An agent that inhibits platelet aggregation and reduces coagulation in the circulatory system.			Chemical Viewed Functionally	
C132800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132800>	C132795	Nasopharyngeal Cancer pT3 TNM Finding v8|Nasopharyngeal Carcinoma pT3 TNM Finding v8	Nasopharyngeal cancer with tumor infiltrating bony structures at skull base, cervical vertebrae, pterygoid structures, and/or paranasal sinuses. (from AJCC 8th Ed.)			Finding	
C132801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132801>	C132795	Nasopharyngeal Cancer pT4 TNM Finding v8|Nasopharyngeal Carcinoma pT4 TNM Finding v8	Nasopharyngeal cancer with intracranial extension, involvement of cranial nerves, hypopharynx, orbit, parotid gland, and/or extensive soft tissue infiltration beyond the lateral surface of the lateral pterygoid muscle. (from AJCC 8th Ed.)			Finding	
C132802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132802>	C132795	Nasopharyngeal Cancer pTis TNM Finding v8|Nasopharyngeal Carcinoma pTis TNM Finding v8	Nasopharyngeal cancer with a finding of carcinoma in situ. (from AJCC 8th Ed.)			Finding	
C132803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132803>	C132794	Nasopharyngeal Cancer Pathologic Regional Lymph Nodes TNM Finding v8|Nasopharyngeal Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of nasopharyngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C132804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132804>	C132803	Nasopharyngeal Cancer pNX TNM Finding v8|Nasopharyngeal Carcinoma pNX TNM Finding v8	Nasopharyngeal cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C132805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132805>	C132803	Nasopharyngeal Cancer pN0 TNM Finding v8|Nasopharyngeal Carcinoma pN0 TNM Finding v8	Nasopharyngeal cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)			Finding	
C132806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132806>	C132803	Nasopharyngeal Cancer pN1 TNM Finding v8|Nasopharyngeal Carcinoma pN1 TNM Finding v8	Nasopharyngeal cancer with unilateral metastasis in cervical lymph node(s), and/or unilateral or bilateral metastasis in retropharyngeal lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage. (from AJCC 8th Ed.)			Finding	
C132807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132807>	C132803	Nasopharyngeal Cancer pN2 TNM Finding v8|Nasopharyngeal Carcinoma pN2 TNM Finding v8	Nasopharyngeal cancer with bilateral metastasis in cervical lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage. (from AJCC 8th Ed.)			Finding	
C132808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132808>	C132803	Nasopharyngeal Cancer pN3 TNM Finding v8|Nasopharyngeal Carcinoma pN3 TNM Finding v8	Nasopharyngeal cancer with unilateral or bilateral metastasis in cervical lymph node(s), larger than 6 cm in greatest dimension, and/or extension below the caudal border of cricoid cartilage. (from AJCC 8th Ed.)			Finding	
C132809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132809>	C132794	Nasopharyngeal Cancer Pathologic Distant Metastasis TNM Finding v8|Nasopharyngeal Carcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of nasopharyngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C13280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13280>	C13409	Sweat|PERSPIRATION|Perspiration|SWEAT|Sweats	The liquid secreted by the sweat glands, having a salty taste and a pH that varies from 4.5 to 7.5. Sweat produced by the eccrine sweat glands is clear with a faint characteristic odor, and contains water, sodium chloride, and traces of albumin, urea, and other compounds. Its composition varies with many factors, e.g., fluid intake, external temperature and humidity, and some hormonal activity. Sweat produced by the larger, deeper, apocrine sweat glands of the axillae contains, in addition, organic material which on bacterial decomposition produces an offensive odor.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|NICHD Terminology|Pediatric Adverse Events Terminology Mapped to MedDRA|Pediatric Adverse Events Terminology
C132810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132810>	C132809	Nasopharyngeal Cancer pM1 TNM Finding v8|Nasopharyngeal Carcinoma pM1 TNM Finding v8	Nasopharyngeal cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C132811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132811>	C132793	Nasopharyngeal Cancer Clinical Distant Metastasis TNM Finding v8|Nasopharyngeal Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of nasopharyngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C132812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132812>	C132811	Nasopharyngeal Cancer cM0 TNM Finding v8|Nasopharyngeal Carcinoma cM0 TNM Finding v8	Nasopharyngeal cancer without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C132813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132813>	C132811	Nasopharyngeal Cancer cM1 TNM Finding v8|Nasopharyngeal Carcinoma cM1 TNM Finding v8	Nasopharyngeal cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C132814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132814>	C9466	Pharyngeal Carcinoma by AJCC v8 Stage	A term that refers to the staging of pharyngeal carcinoma according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C132816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132816>	C3871|C132814	Nasopharyngeal Carcinoma by AJCC v8 Stage	A term that refers to the staging of nasopharyngeal carcinoma according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C132817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132817>	C8768|C132816	Stage I Nasopharyngeal Carcinoma AJCC v8|Stage I Nasopharyngeal Throat Cancer	Stage I includes: T1, N0, M0. T1: Tumor confined to the nasopharynx, or tumor extending to oropharynx and/or nasal cavity without parapharyngeal involvement. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Nasopharyngeal Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132818>	C8769|C132816	Stage II Nasopharyngeal Carcinoma AJCC v8|Stage II Nasopharyngeal Throat Cancer	Stage II includes: (T1, N1, M0); (T0, N1, M0); (T2, N0, M0); (T2, N1, M0). T1: Tumor confined to the nasopharynx, or tumor extending to oropharynx and/or nasal cavity without parapharyngeal involvement. T0: No tumor identified, but EBV-positive cervical node(s) involvement is present. T2: Tumor with extension to parapharyngeal space, and/or adjacent soft tissue involvement (medial pterygoid, lateral pterygoid, prevertebral muscles). N0: No regional lymph node metastasis. N1: Tumor with unilateral metastasis in cervical lymph node(s), and/or unilateral or bilateral metastasis in retropharyngeal lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Nasopharyngeal Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132819>	C8770|C132816	Stage III Nasopharyngeal Carcinoma AJCC v8|Stage III Nasopharyngeal Throat Cancer	Stage III includes: (T1, N2, M0); (T0, N2, M0); (T2, N2, M0); (T3, N0, M0); (T3, N1, M0); (T3, N2, M0). T1: Tumor confined to the nasopharynx, or tumor extending to oropharynx and/or nasal cavity without parapharyngeal involvement. T0: No tumor identified, but EBV-positive cervical node(s) involvement is present. T2: Tumor with extension to parapharyngeal space, and/or adjacent soft tissue involvement (medial pterygoid, lateral pterygoid, prevertebral muscles). T3: Tumor infiltrating bony structures at skull base, cervical vertebrae, pterygoid structures, and/or paranasal sinuses. N0: No regional lymph node metastasis. N1: Tumor with unilateral metastasis in cervical lymph node(s), and/or unilateral or bilateral metastasis in retropharyngeal lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage. N2: Tumor with bilateral metastasis in cervical lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Nasopharyngeal Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13281>	C13983	Synapse|synapse	A cell-cell junction between a neuron and another neuron or a cell in a target organ. At this interface, the presynaptic neuron can transmit chemical (neurotransmitter) or electical signals (nerve impulses) to the postsynaptic target.			Anatomical Structure	
C132820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132820>	C8771|C132816	Stage IV Nasopharyngeal Carcinoma AJCC v8|Stage IV Nasopharyngeal Throat Cancer	Stage IV includes: IVA: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0); (Any T, N3, M0); IVB: (Any T, Any N, M1). T4: Tumor with intracranial extension, involvement of cranial nerves, hypopharynx, orbit, parotid gland, and/or extensive soft tissue infiltration beyond the lateral surface of the lateral pterygoid muscle.  N0: No regional lymph node metastasis. N1: Tumor with unilateral metastasis in cervical lymph node(s), and/or unilateral or bilateral metastasis in retropharyngeal lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage. N2: Tumor with bilateral metastasis in cervical lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage. N3: Tumor with unilateral or bilateral metastasis in cervical lymph node(s), larger than 6 cm in greatest dimension, and/or extension below the caudal border of cricoid cartilage. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Nasopharyngeal Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132821>	C6000|C132820	Stage IVA Nasopharyngeal Carcinoma AJCC v8|Stage IVA Nasopharyngeal Throat Cancer	Stage IVA includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0); (Any T, N3, M0); T4: Tumor with intracranial extension, involvement of cranial nerves, hypopharynx, orbit, parotid gland, and/or extensive soft tissue infiltration beyond the lateral surface of the lateral pterygoid muscle.  N0: No regional lymph node metastasis. N1: Tumor with unilateral metastasis in cervical lymph node(s), and/or unilateral or bilateral metastasis in retropharyngeal lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage. N2: Tumor with bilateral metastasis in cervical lymph node(s), 6 cm or smaller in greatest dimension, above the caudal border of cricoid cartilage. N3: Tumor with unilateral or bilateral metastasis in cervical lymph node(s), larger than 6 cm in greatest dimension, and/or extension below the caudal border of cricoid cartilage. M0: No distant metastasis. (AJCC 8th ed.)	Stage IVA Nasopharyngeal Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132822>	C6001|C132820	Stage IVB Nasopharyngeal Carcinoma AJCC v8|Stage IVB Nasopharyngeal Throat Cancer	Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)	Stage IVB Nasopharyngeal Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132823>	C134526	Canine Oral Squamous Cell Carcinoma	Oral squamous cell carcinoma that occurs in a dog.			Neoplastic Process	Cellosaurus Disease Terminology
C132824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132824>	C134528	Feline Oral Squamous Cell Carcinoma	Oral squamous cell carcinoma that occurs in a cat.			Neoplastic Process	Cellosaurus Disease Terminology
C132825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132825>	C134528	Feline Osteosarcoma	Osteosarcoma that occurs in a cat.			Neoplastic Process	Cellosaurus Disease Terminology
C132826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132826>	C75467	Charcot-Marie-Tooth Disease, Spinal, Type I|DHMN1|Distal HMN I|Distal Hereditary Motor Neuronopathy Type I|HMN1|Spinal CMT I	An autosomal dominant neurodegenerative disorder characterized by juvenile onset, distal motor weakness without sensory impairment, and anterior horn cell degeneration.			Disease or Syndrome	Cellosaurus Disease Terminology
C132827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132827>	C84776	Autosomal Recessive Congenital Ichthyosis 2|ARCI2	An autosomal recessive condition caused by mutation(s) in the ALOX12B gene, encoding arachidonate 12-lipoxygenase, 12R-type. It is characterized by dry, thickened, scaly skin.			Disease or Syndrome	Cellosaurus Disease Terminology
C132828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132828>	C121547	Distress Score Visual Analogue Scale|Distress Score|Distress Score Likert Scale|Distress Thermometer|NCCN Distress Thermometer	A visual analogue scale that ranges from 0: No distress to 10: Extreme distress.			Intellectual Product	NCCN Distress Thermometer and Problem List for Patients Version 2.2016
C132829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132829>	C221022	Distress Score 0	A subjective score of 0 on a visual analogue scale that ranges from 0: No distress to 10: Extreme distress.			Intellectual Product	
C13282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13282>	C14135	Subcellular Structure|Intracellular Structure	An anatomical element found within cells or tissues that are smaller than cells and are at or below the size that can be resolved by light microscopy.			Cell Component	
C132830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132830>	C221022	Distress Score 1	A subjective score of 1 on a visual analogue scale that ranges from 0: No distress to 10: Extreme distress.			Intellectual Product	
C132831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132831>	C221022	Distress Score 2	A subjective score of 2 on a visual analogue scale that ranges from 0: No distress to 10: Extreme distress.			Intellectual Product	
C132832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132832>	C221022	Distress Score 3	A subjective score of 3 on a visual analogue scale that ranges from 0: No distress to 10: Extreme distress.			Intellectual Product	
C132833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132833>	C221022	Distress Score 4	A subjective score of 4 on a visual analogue scale that ranges from 0: No distress to 10: Extreme distress.			Intellectual Product	
C132834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132834>	C221022	Distress Score 5	A subjective score of 5 on a visual analogue scale that ranges from 0: No distress to 10: Extreme distress.			Intellectual Product	
C132835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132835>	C221022	Distress Score 6	A subjective score of 6 on a visual analogue scale that ranges from 0: No distress to 10: Extreme distress.			Intellectual Product	
C132836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132836>	C221022	Distress Score 7	A subjective score of 7 on a visual analogue scale that ranges from 0: No distress to 10: Extreme distress.			Intellectual Product	
C132837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132837>	C221022	Distress Score 8	A subjective score of 8 on a visual analogue scale that ranges from 0: No distress to 10: Extreme distress.			Intellectual Product	
C132838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132838>	C221022	Distress Score 9	A subjective score of 9 on a visual analogue scale that ranges from 0: No distress to 10: Extreme distress.			Intellectual Product	
C132839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132839>	C221022	Distress Score 10	A subjective score of 10 on a visual analogue scale that ranges from 0: No distress to 10: Extreme distress.			Intellectual Product	
C13283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13283>	C13236	Urine|URINE|Urinary System, Urine|urine	The fluid that is excreted by the kidneys.  It is stored in the bladder and discharged through the urethra.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|OS Authorized Value Terminology|OS Lab Table
C132840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132840>	C19896	Suicide Gene	A gene which will cause a cell to kill itself, typically through interaction with a prodrug.			Classification	
C132841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132841>	C29711	Imeglimin|(4R)-6-(Dimethylamino)-4-methyl-4,5-dihydro-1,3,5-triazin-2-amine|IMEGLIMIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132842>	C28394	Auriclosene|1-Propanesulfonic Acid, 2-(Dichloroamino)-2-methyl-|AURICLOSENE|CD0722|NVC 422|NVC-422				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132843>	C66883|C29710	Pentiapine|PENTIAPINE				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132844>	C2124	Technetium Tc 99m Lidofenin|TECHNETIUM TC-99M LIDOFENIN|Tc-99m HIDA|Technetate(1-)-99tc, bis(N-(carboxymethyl)-N-(2-((2,6-dimethylphenyl)amino)-2-oxoethyl)glycinato(2-))-, (oc-6-11')-|Technetium tc-99m Lidofenin				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132845>	C776	6,7-Epidrospirenone|6,7-EPIDROSPIRENONE|6alpha,7alpha-Drospirenone				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132846>	C29701	Almagodrate|ALMAGODRATE|Almagodrate Hydrate				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C132847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132847>	C177696	RAS Wild Type|RAS Family Gene Mutation Negative|RAS Gene Mutation Negative|RAS Mutation Negative|RAS wt Allele|Wild Type RAS	A genetic finding indicating that RAS family gene mutations are absent in a sample.	RAS Wild Type		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132848>	C177696	RAF Wild Type|RAF Family Gene Mutation Negative|RAF Gene Mutation Negative|RAF Mutation Negative|RAF wt Allele|Rapidly Accelerated Fibrosarcoma Family Gene Mutation Negative|Rapidly Accelerated Fibrosarcoma Family Kinase Gene Mutation Negative|Wild Type RAF	A genetic finding indicating that RAF family gene mutations are absent in a sample.	RAF Wild Type		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132849>	C4817|C148331	Unresectable Ewing Sarcoma	A Ewing sarcoma which is not amenable to surgical resection.	Unresectable Ewing Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13284>	C33089	Vacuole|Vacuolar	Any membrane-enclosed spaces or cavities within a cell.			Cell Component	
C132850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132850>	C9145|C148331	Unresectable Osteosarcoma	An osteosarcoma which is not amenable to surgical resection.	Unresectable Osteosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132851>	C208255|C192655|C129824	Evorpacept|ALX 148|ALX-148|ALX148|CD47 Antagonist ALX148|CD47/SIRPa-blocking Agent ALX148|EVORPACEPT|LGGL-ALX-148|SIRPa Variant ALX148	A variant of signal regulatory protein alpha (SIRPa) that antagonizes the human cell surface antigen CD47, with potential phagocytosis-inducing, immunostimulating and antineoplastic activities. Upon administration, evorpacept binds to CD47 expressed on tumor cells and prevents the interaction of CD47 with its ligand SIRPa, a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of the pro-phagocytic signal calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor cytotoxic T-lymphocyte (CTL) immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.	Evorpacept		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C132852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132852>	C18194	Respiratory Pathogen Panel|Respiratory Pathogen PCR Panel	A diagnostic test for respiratory pathogens that uses PCR for differential diagnosis during upper or lower respiratory tract infection.			Laboratory Procedure	
C132853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132853>	C4925|C4813	Recurrent Malignant Germ Cell Tumor|Recurrent Germ Cell Neoplasm|Recurrent Germ Cell Tumor|Recurrent Germ Cell Tumor	The reemergence of a malignant germ cell tumor after a period of remission.	Recurrent Germ Cell Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132854>	C4925|C36263	Metastatic Malignant Germ Cell Tumor|Metastatic Germ Cell Neoplasm|Metastatic Germ Cell Tumor|Metastatic Germ Cell Tumor	A malignant germ cell tumor that has spread from its original site of growth to another anatomic site.	Metastatic Germ Cell Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132855>	C17003	HSV1 DNA CSF Ql Non-probe PCR|Herpes Simplex Virus 1 DNA (Presence)|Herpes simplex virus 1 DNA|Herpes simplex virus 1 DNA [Presence] in Cerebral spinal fluid by Target amplification with non-probe based detection	This assay detects the presence of nucleic acid sequences from the Herpes simplex virus 1 DNA in cerebrospinal fluid (CSF) using PCR and non-probe based detection methods, such as melt curve analysis. (LOINC)			Laboratory Procedure	
C132856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132856>	C17003	HSV2 DNA CSF Ql Non-probe PCR|Herpes Simplex Virus 2 DNA (Presence)|Herpes simplex virus 2 DNA|Herpes simplex virus 2 DNA [Presence] in Cerebral spinal fluid by Target amplification with non-probe based detection	This assay detects the presence of nucleic acid sequences from the Herpes simplex virus 2 DNA in cerebrospinal fluid (CSF) using PCR and non-probe based detection methods, such as melt curve analysis. (LOINC)			Laboratory Procedure	
C132857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132857>	C17003	HHV6 DNA CSF Ql Non-probe PCR|Herpes Virus 6 DNA (Presence)|Herpes virus 6 DNA|Herpes virus 6 DNA [Presence] in Cerebral spinal fluid by Target amplification with non-probe based detection	This assay detects the presence of nucleic acid sequences from the Herpes virus 6 DNA in cerebrospinal fluid (CSF) using PCR and non-probe based detection methods, such as melt curve analysis. (LOINC)			Laboratory Procedure	
C132858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132858>	C132791	HPV-Mediated (p16-Positive) Oropharyngeal Cancer TNM Finding v8|HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma TNM Finding v8	A finding about one or more characteristics of HPV-mediated (p16-positive) oropharyngeal cancer, following the rules of the TNM AJCC v8 classification system. Oropharyngeal cancers which are p16-negative are staged according to the classification for oropharynx (p16-negative) and hypopharynx cancers. (from AJCC 8th Ed.)			Finding	
C132859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132859>	C132858|C132642	HPV-Mediated (p16-Positive) Oropharyngeal Cancer Pathologic TNM Finding v8|HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of HPV-mediated (p16-positive) oropharyngeal cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C13285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13285>	C13203	Human Chromosome X|Chromosome X|Chromosome X|Chromosome X|Human X Chromosome|X Chromosome|chrX|chrX|chrX	The larger of the two human sex chromosomes. It is usually present singly in males and doubly in females.	Chromosome X		Cell Component	CTDC Value Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C132860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132860>	C132858|C132633	HPV-Mediated (p16-Positive) Oropharyngeal Cancer Clinical TNM Finding v8|HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of HPV-mediated (p16-positive) oropharyngeal cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C132861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132861>	C132859	HPV-Mediated (p16-Positive) Oropharyngeal Cancer Pathologic Primary Tumor TNM Finding v8|HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of HPV-mediated (p16-positive) oropharyngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C132862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132862>	C132861	HPV-Mediated (p16-Positive) Oropharyngeal Cancer pT0 TNM Finding v8|HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma pT0 TNM Finding v8	No primary identified. (from AJCC 8th Ed.)			Finding	
C132863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132863>	C132861	HPV-Mediated (p16-Positive) Oropharyngeal Cancer pT1 TNM Finding v8|HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma pT1 TNM Finding v8	HPV-mediated (p16-positive) oropharyngeal cancer with tumor 2 cm or smaller in greatest dimension. (from AJCC 8th Ed.)			Finding	
C132864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132864>	C132861	HPV-Mediated (p16-Positive) Oropharyngeal Cancer pT2 TNM Finding v8|HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma pT2 TNM Finding v8	HPV-mediated (p16-positive) oropharyngeal cancer with tumor larger than 2 cm but not larger than 4 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C132865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132865>	C132861	HPV-Mediated (p16-Positive) Oropharyngeal Cancer pT3 TNM Finding v8|HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma pT3 TNM Finding v8	HPV-mediated (p16-positive) oropharyngeal cancer with tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis. (from AJCC 8th Ed.)			Finding	
C132866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132866>	C132861	HPV-Mediated (p16-Positive) Oropharyngeal Cancer pT4 TNM Finding v8|HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma pT4 TNM Finding v8	HPV-mediated (p16-positive) oropharyngeal cancer with moderately advanced local disease. Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible or beyond. Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of the larynx. (from AJCC 8th Ed.)			Finding	
C132867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132867>	C132859	HPV-Mediated (p16-Positive) Oropharyngeal Cancer Pathologic Regional Lymph Nodes TNM Finding v8|HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of HPV-mediated (p16-positive) oropharyngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C132868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132868>	C132867	HPV-Mediated (p16-Positive) Oropharyngeal Cancer pNX TNM Finding v8|HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma pNX TNM Finding v8	HPV-mediated (p16-positive) oropharyngeal cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C132869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132869>	C132867	HPV-Mediated (p16-Positive) Oropharyngeal Cancer pN0 TNM Finding v8|HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma pN0 TNM Finding v8	HPV-mediated (p16-positive) oropharyngeal cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)			Finding	
C13286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13286>	C13203	Human Chromosome Y|Chromosome Y|Chromosome Y|Chromosome Y|Human Y Chromosome|Y Chromosome|chrY|chrY|chrY	The smaller of the two human sex chromosome. Its presence usually determines the development of a fetus as male, while its absence usually determines the development of a fetus as female.	Chromosome Y		Cell Component	CTDC Value Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C132870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132870>	C132867	HPV-Mediated (p16-Positive) Oropharyngeal Cancer pN1 TNM Finding v8|HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma pN1 TNM Finding v8	HPV-mediated (p16-positive) oropharyngeal cancer with metastasis in four or fewer lymph nodes. (from AJCC 8th Ed.)			Finding	
C132871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132871>	C132867	HPV-Mediated (p16-Positive) Oropharyngeal Cancer pN2 TNM Finding v8|HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma pN2 TNM Finding v8	HPV-mediated (p16-positive) oropharyngeal cancer with metastasis in more than four lymph nodes. (from AJCC 8th Ed.)			Finding	
C132872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132872>	C132860	HPV-Mediated (p16-Positive) Oropharyngeal Cancer Clinical Regional Lymph Nodes TNM Finding v8|HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma Clinical Regional Lymph Nodes TNM Finding v8	A clinical finding about one or more characteristics of HPV-mediated (p16-positive) oropharyngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C132873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132873>	C132872	HPV-Mediated (p16-Positive) Oropharyngeal Cancer cN1 TNM Finding v8|HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma cN1 TNM Finding v8	HPV-mediated (p16-positive) oropharyngeal cancer with metastasis in one or more ipsilateral lymph nodes, none larger than 6 cm. (from AJCC 8th Ed.)			Finding	
C132874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132874>	C132872	HPV-Mediated (p16-Positive) Oropharyngeal Cancer cN2 TNM Finding v8|HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma cN2 TNM Finding v8	HPV-mediated (p16-positive) oropharyngeal cancer with contralateral or bilateral lymph node metastasis, none larger than 6 cm. (from AJCC 8th Ed.)			Finding	
C132875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132875>	C132872	HPV-Mediated (p16-Positive) Oropharyngeal Cancer cN3 TNM Finding v8|HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma cN3 TNM Finding v8	HPV-mediated (p16-positive) oropharyngeal cancer with lymph node(s) metastasis, larger than 6 cm. (from AJCC 8th Ed.)			Finding	
C132876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132876>	C132859	HPV-Mediated (p16-Positive) Oropharyngeal Cancer Pathologic Distant Metastasis TNM Finding v8|HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of HPV-mediated (p16-positive) oropharyngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C132877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132877>	C132876	HPV-Mediated (p16-Positive) Oropharyngeal Cancer pM1 TNM Finding v8|HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma pM1 TNM Finding v8	HPV-mediated (p16-positive) oropharyngeal cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C132878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132878>	C132860	HPV-Mediated (p16-Positive) Oropharyngeal Cancer Clinical Distant Metastasis TNM Finding v8|HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of HPV-mediated (p16-positive) oropharyngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C132879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132879>	C132878	HPV-Mediated (p16-Positive) Oropharyngeal Cancer cM0 TNM Finding v8|HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma cM0 TNM Finding v8	HPV-mediated (p16-positive) oropharyngeal cancer without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C13287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13287>	C13404	Z-DNA|zDNA	Z-DNA can be obtained for certain sequences such as CGCGCG by increasing the salt concentration of the solution containing the sample to 4 molar NaCl. Z-DNA is left-handed and the thinnest & tallest with a diameter of about 18 Angstrom. The sugar pucker is both C(3')-endo and C(2')-endo. In Z-DNA, the Watson-Crick base pairs are perpendicular to the helix axis. When examined from the top of the helix, bases are present throughout the matrix of the helix with no exclusive domains for either the bases or the backbone. At times the sugar phosphate backbone travels very close to the center of the helix, and the bases to the very edge of the helix.			Nucleic Acid, Nucleoside, or Nucleotide	
C132880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132880>	C132878	HPV-Mediated (p16-Positive) Oropharyngeal Cancer cM1 TNM Finding v8|HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma cM1 TNM Finding v8	HPV-mediated (p16-positive) oropharyngeal cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C132881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132881>	C8946|C114831	Metastatic Prostate Carcinoma in the Soft Tissue|Metastatic Prostate Cancer in the Soft Tissue|Prostate Carcinoma Metastatic in the Soft Tissue	A carcinoma that arises from the prostate gland and has spread to the soft tissue.	Metastatic Prostate Carcinoma in the Soft Tissue		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132882>	C87055|C132814	HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma by AJCC v8 Stage|HPV-Mediated (p16-Positive) Oropharyngeal Squamous Cell Carcinoma by AJCC v8 Stage	A term that refers to the staging of HPV-mediated (p16-positive) oropharyngeal squamous cell carcinoma according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C132883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132883>	C132882	HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma by AJCC v8 Clinical Stage|HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma by AJCC v8 cTNM Stage|HPV-Mediated (p16-Positive) Oropharyngeal Squamous Cell Carcinoma by AJCC v8 Clinical Stage	A term that refers to the clinical staging of HPV-mediated (p16-positive) oropharyngeal squamous cell carcinoma according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C132884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132884>	C132882	HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma by AJCC v8 Pathologic Stage|HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma by AJCC v8 pTNM Stage|HPV-Mediated (p16-Positive) Oropharyngeal Squamous Cell Carcinoma by AJCC v8 Pathologic Stage	A term that refers to the pathologic staging of HPV-mediated (p16-positive) oropharyngeal squamous cell carcinoma according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C132885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132885>	C8768|C132883	Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Squamous Cell Carcinoma AJCC v8|Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer	Stage I includes: (T0, N0, M0); (T0, N1, M0); (T1, N0, M0); (T1, N1, M0); (T2, N0, M0); (T2, N1, M0). T0: No primary identified. T1: Tumor 2 cm or smaller in greatest dimension. T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or more ipsilateral lymph nodes, none larger than 6 cm. M0: No distant metastasis. (AJCC 8th ed.)	Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132886>	C8769|C132883	Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Squamous Cell Carcinoma AJCC v8|Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer	Stage II includes: (T0, N2, M0); (T1, N2, M0) ;(T2, N2, M0); (T3, N0, M0); (T3, N1, M0); (T3, N2, M0). T0: No primary identified. T1: Tumor 2 cm or smaller in greatest dimension. T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension. T3: Tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or more ipsilateral lymph nodes, none larger than 6 cm. N2: Tumor with contralateral or bilateral lymph nodes metastasis, none larger than 6 cm. M0: No distant metastasis. (AJCC 8th ed.)	Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132887>	C80699	MIR124-2 Gene|MIR124-2|MIR124-2|MicroRNA 124-2 Gene	This gene may be involved in gene expression regulation in neurons.	MIR124-2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C132888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132888>	C132887	MIR124-2 wt Allele|MIRN124-2|MIRN124A2|MicroRNA 124-2 wt Allele|MicroRNA 124a-2 Gene|hsa-mir-124-2|hsa-mir-124a-2|mir-124-2	Human MIR124-2 wild-type allele is located in the vicinity of 8q12.3 and is approximately 109 bases in length. This allele, which encodes MIR124-2 pre-miRNA, may play a role in neuronal differentiation.	MIR124-2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132889>	C25968	MIR124-2 Pre-miRNA|Pre-MIR124-2|Pre-MicroRNA 124-2|Pre-miRNA MIR124-2	MIR124-2 pre-miRNA (109 bases) is encoded by the human MIR124-2 gene. This oligonucleotide may be involved in the regulation of neuronal gene expression.	MIR124-2 Pre-miRNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13288>	C13426	RGD Motif|Arginine-Glycine-Aspartic Acid Cell Adhesion Domain|RGD|RGD Cell Adhesion Domain|RGD Domain|RGD Peptide|RGD Tripeptide Sequence	A consensus tripeptide that is recognized by and for binding to proteins of the integrin family, including many cell adhesion molecules. The one-letter codes for arginine - glycine - aspartic acid. This motif can be found in proteins of the extracellular matrix and it is recognized by different members of the integrin family. The structure of the tenth type III module of fibronectin has shown that the RGD motif lies on a flexible loop.			Amino Acid Sequence	
C132890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132890>	C32725	Immune Cell	A cell in the immune system that is involved in host defense. This category may include lymphocytes, monocytes, macrophages, neutrophils, eosinophils, basophils, mast cells, and thrombocytes. Precursor cells in these lineages may also be included.	Immune Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C132891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132891>	C8770|C132883	Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Squamous Cell Carcinoma AJCC v8|Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer	Stage III includes: (T0, N3, M0); (T1, N3, M0); (T2, N3, M0); (T3, N3, M0); (T4, N0, M0); (T4, N1, M0); (T4, N2, M0); (T4, N3, M0). T0: No primary identified. T1: Tumor 2 cm or smaller in greatest dimension. T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension. T3: Tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis. T4: Tumor with moderately advanced local disease. Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible or beyond. Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of the larynx. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or more ipsilateral lymph nodes, none larger than 6 cm. N2: Tumor with contralateral or bilateral lymph nodes metastasis, none larger than 6 cm. N3: Tumor with lymph node(s) metastasis, larger than 6 cm. M0: No distant metastasis. (AJCC 8th ed.)	Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132892>	C103223	Unmethylated MGMT Gene Promoter|Absent|MGMT Gene Promoter Methylation Negative|Negative|Unmethylated MGMT Promoter|Unmethylated MGMT Promoter|Unmethylated Methylguanine-DNA Methyltransferase Gene Promoter|Unmethylated O-6-Methylguanine-DNA Methyltransferase Gene Promoter	A genetic finding indicating the absence of DNA methylation in the promoter region of the MGMT gene. This finding is associated with a poor prognosis in patients with glioblastoma.	Unmethylated MGMT Promoter		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132893>	C8771|C132883	Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Squamous Cell Carcinoma AJCC v8|Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer	Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)	Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132894>	C97927|C157554	PIK3R1 Gene Mutation|GRB1 Gene Mutation|PIK3R1 mutation|Phosphoinositide-3-Kinase Regulatory Subunit 1 Gene Mutation|p85-ALPHA Gene Mutation	A change in the nucleotide sequence of the PIK3R1 gene.	PIK3R1 Gene Mutation		Cell or Molecular Dysfunction	CRF8 Pathology Review Targeted Genomics Table|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132895>	C45581	AKT3 Gene Amplification|AKT Serine/Threonine Kinase 3 Gene Amplification|PKB-GAMMA Gene Amplification|PKBG Gene Amplification|PRKBG Gene Amplification|RAC-Gamma Gene Amplification|RAC-PK-Gamma Gene Amplification|STK-2 Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the AKT3 gene.	AKT3 Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132896>	C45581	PIK3C2B Gene Amplification|C2-PI3K Gene Amplification|PI3K-C2beta Gene Amplification|Phosphatidylinositol-4-Phosphate 3-Kinase, Catalytic Subunit Type 2 Beta Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the PIK3C2B gene.	PIK3C2B Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132897>	C45581	CDK6 Gene Amplification|CDK6 Amplification|CDK6 amplification|Cyclin Dependent Kinase 6 Gene Amplification|Cyclin-Dependent Kinase 6 Gene Amplification|PLSTIRE Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the CDK6 gene.	CDK6 Gene Amplification		Cell or Molecular Dysfunction	CRF8 Pathology Review Targeted Genomics Table|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C132898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132898>	C8768|C132884	Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Squamous Cell Carcinoma AJCC v8|Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer	Stage I includes: (T0, N0, M0); (T0, N1, M0); (T1, N0, M0); (T1, N1, M0); (T2, N0, M0); (T2, N1, M0). T0: No primary identified. T1: Tumor 2 cm or smaller in greatest dimension. T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension. N0: No regional lymph node metastasis. N1: Tumor with metastasis in four or fewer lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132899>	C8769|C132884	Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Squamous Cell Carcinoma AJCC v8|Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer	Stage II includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N0, M0); (T3, N1, M0); (T4, N0, M0); (T4, N1, M0). T0: No primary identified. T1: Tumor 2 cm or smaller in greatest dimension. T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension. T3: Tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis. T4: Moderately advanced local disease. Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible or beyond. Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of the larynx. N0: No regional lymph node metastasis. N1: Tumor with metastasis in four or fewer lymph nodes.  N2: Tumor with metastasis in more than four lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13289>	C13201	Euchromatin	Euchromatin. The parts of chromosomes that, during interphase, are uncoiled dispersed threads and not stained by ordinary dyes; metabolically active, in contrast to the inert heterochromatin.			Amino Acid, Peptide, or Protein|Cell Component|Nucleic Acid, Nucleoside, or Nucleotide	
C132900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132900>	C8770|C132884	Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Squamous Cell Carcinoma AJCC v8|Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer	Stage III includes: (T3, N2, M0); (T4, N2, M0). T3: Tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis. T4: Moderately advanced local disease. Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible or beyond. Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of the larynx. N2: Tumor with metastasis in more than four lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132901>	C8771|C132884	Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Squamous Cell Carcinoma AJCC v8|Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer	Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)	Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132902>	C39750	MGMT-Unmethylated Glioblastoma|Unmethylated MGMT Glioblastoma	A glioblastoma characterized by the absence of DNA methylation in the promoter region of the MGMT gene. It is associated with a poor outcome.			Neoplastic Process	
C132903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132903>	C202154	PROMIS-29 Adult Profile v1.0|PROMIS-29	A 29-item multidimensional and universal measure of health intended for use across a variety of conditions. It measures an adult patient's self-reported health status in seven domains: physical function, anxiety, depression, fatigue, sleep disturbance, pain interference, and participation in social roles. The v1.0 form was copyright in 2009.			Intellectual Product	
C132904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132904>	C173924|C173792	Satisfied with How Much Work I Can Do Question|I am satisfied with how much work I can do (include work at home)|Satisfied with How Much Work I Can Do	A question about an individual's satisfaction with how much work they can do, including work at home.			Intellectual Product	PROMIS-29 Adult Profile v1.0
C132905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132905>	C173924|C173792|C173045	Satisfied with Ability to Work Question|I am satisfied with how much work I can do (include work at home)|Satisfied with Ability to Work	A question about an individual's satisfaction with their ability to work, including work at home.			Intellectual Product	PROMIS-29 Adult Profile v1.0
C132906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132906>	C173792	Satisfied with Ability to do Regular Personal and Household Responsibilities Question|I am satisfied with my ability to do regular personal and household responsibilities|Satisfied with Ability to do Regular Personal and Household Responsibilities	A question about an individual's satisfaction with their ability to do regular personal and household responsibilities.			Intellectual Product	PROMIS-29 Adult Profile v1.0
C132907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132907>	C173792	Satisfied with Ability to Perform Daily Routine Question|I am satisfied with my ability to perform my daily routine|Satisfied with Ability to Perform Daily Routine	A question about an individual's satisfaction with their ability to perform their daily routine.			Intellectual Product	PROMIS-29 Adult Profile v1.0
C132908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132908>	C132791	Oropharyngeal (p16-Negative) and Hypopharyngeal Cancer TNM Finding v8|Oropharyngeal (p16-Negative) and Hypopharyngeal Carcinoma TNM Finding v8	A finding about one or more characteristics of p16-negative oropharyngeal and hypopharyngeal cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to p16-negative squamous cell carcinomas of the oropharynx, oropharyngeal cancers without p16 immunostaining performed, and all cancers of the hypopharynx. Minor salivary gland cancers and neuroendocrine carcinomas of the oropharynx and hypopharynx are included in this classification. Oropharyngeal cancers which are p16-positive are staged according to the classification for p16-positive oropharyngeal cancers. (from AJCC 8th Ed.)			Finding	
C132909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132909>	C132908	Oropharyngeal (p16-Negative) Cancer TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma TNM Finding v8	A finding about one or more characteristics of p16-negative oropharyngeal cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to p16-negative squamous cell carcinomas of the oropharynx, oropharyngeal cancers without p16 immunostaining performed, minor salivary gland carcinomas of the oropharynx, and neuroendocrine carcinomas of the oropharynx. Oropharyngeal cancers which are p16-positive are staged according to the classification for p16-positive oropharyngeal cancers. (from AJCC 8th Ed.)			Finding	
C13290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13290>	C13426	Kringle Domain|Kringle	Kringles are autonomous structural domains, found throughout the blood clotting and fibrinolytic proteins. Kringle domains are believed to play a role in binding mediators (e.g., membranes, other proteins or phospholipids), and in the regulation of proteolytic activity. Kringle domains are characterised by a triple loop, 3-disulphide bridge structure, whose conformation is defined by a number of hydrogen bonds and small pieces of anti-parallel beta-sheet. They are found in a varying number of copies, in some serine proteases and plasma proteins.			Amino Acid Sequence	
C132910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132910>	C132908	Hypopharyngeal Cancer TNM Finding v8|Hypopharyngeal Carcinoma TNM Finding v8	A finding about one or more characteristics of hypopharyngeal cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to all cancers of the hypopharynx. Minor salivary gland carcinomas and neuroendocrine carcinomas of the hypopharynx are included in this classification. (from AJCC 8th Ed.)			Finding	
C132911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132911>	C132909|C132633	Oropharyngeal (p16-Negative) Cancer Clinical TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of p16-negative oropharyngeal cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C132912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132912>	C132909|C132642	Oropharyngeal (p16-Negative) Cancer Pathologic TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of p16-negative oropharyngeal cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C132913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132913>	C132910|C132633	Hypopharyngeal Cancer Clinical TNM Finding v8|Hypopharyngeal Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of hypopharyngeal cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C132914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132914>	C132910|C132642	Hypopharyngeal Cancer Pathologic TNM Finding v8|Hypopharyngeal Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of hypopharyngeal cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C132915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132915>	C132912	Oropharyngeal (p16-Negative) Cancer Pathologic Primary Tumor TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of p16-negative oropharyngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C132916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132916>	C132915	Oropharyngeal (p16-Negative) Cancer pTX TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma pTX TNM Finding v8	Oropharyngeal (p16-negative) cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C132917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132917>	C132915	Oropharyngeal (p16-Negative) Cancer pTis TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma pTis TNM Finding v8	Oropharyngeal (p16-negative) cancer with a finding of carcinoma in situ. (from AJCC 8th Ed.)			Finding	
C132918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132918>	C132915	Oropharyngeal (p16-Negative) Cancer pT1 TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma pT1 TNM Finding v8	Oropharyngeal (p16-negative) cancer with tumor 2 cm or smaller in greatest dimension. (from AJCC 8th Ed.)			Finding	
C132919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132919>	C132915	Oropharyngeal (p16-Negative) Cancer pT2 TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma pT2 TNM Finding v8	Oropharyngeal (p16-negative) cancer with tumor larger than 2 cm but not larger than 4 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C13291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13291>	C13426	Leucine Zipper	Domains in DNA-binding proteins that contain amino acid sequences that show periodic arrays of leucine residues. These residues exist in an alpha-helical conformation, with the leucine side chains extending from one alpha helix interdigitating with those displayed from a similar alpha helix of a second polypeptide, facilitating dimerization.			Amino Acid Sequence	
C132920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132920>	C132915	Oropharyngeal (p16-Negative) Cancer pT3 TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma pT3 TNM Finding v8	Oropharyngeal (p16-negative) cancer with tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis. (from AJCC 8th Ed.)			Finding	
C132921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132921>	C45788	Linear Structural Repeat Unit Connection Points|LINEAR STRUCTURAL REPEAT UNIT CONNECTION POINTS	The head and the tail of a repeating structural unit in a polymer.			Spatial Concept	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C132922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132922>	C132915	Oropharyngeal (p16-Negative) Cancer pT4 TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma pT4 TNM Finding v8	Oropharyngeal (p16-negative) cancer with moderately advanced or very advanced local disease. (from AJCC 8th Ed.)			Finding	
C132923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132923>	C45788	Structural Repeat Unit Substitution Point|STRUCTURAL REPEAT UNIT SUBSTITUTION POINT	The location of a substituted repeating structural unit in a polymer.			Spatial Concept	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C132924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132924>	C132922	Oropharyngeal (p16-Negative) Cancer pT4a TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma pT4a TNM Finding v8	Oropharyngeal (p16-negative) cancer with moderately advanced local disease. Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible. Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of the larynx. (from AJCC 8th Ed.)			Finding	
C132925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132925>	C132922	Oropharyngeal (p16-Negative) Cancer pT4b TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma pT4b TNM Finding v8	Oropharyngeal (p16-negative) cancer with very advanced local disease. Tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base or encases carotid artery. (from AJCC 8th Ed.)			Finding	
C132926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132926>	C132914	Hypopharyngeal Cancer Pathologic Primary Tumor TNM Finding v8|Hypopharyngeal Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of hypopharyngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C132927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132927>	C132926	Hypopharyngeal Cancer pTX TNM Finding v8|Hypopharyngeal Carcinoma pTX TNM Finding v8	Hypopharyngeal cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C132928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132928>	C132926	Hypopharyngeal Cancer pTis TNM Finding v8|Hypopharyngeal Carcinoma pTis TNM Finding v8	Hypopharyngeal cancer with a finding of carcinoma in situ. (from AJCC 8th Ed.)			Finding	
C132929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132929>	C132926	Hypopharyngeal Cancer pT1 TNM Finding v8|Hypopharyngeal Carcinoma pT1 TNM Finding v8	Hypopharyngeal cancer with tumor limited to one subsite of hypopharynx and/or 2 cm or smaller in greatest dimension. (from AJCC 8th Ed.)			Finding	
C13292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13292>	C63552	Open Reading Frame|ORF	A sequence of nucleotides in that contains no termination codons and so can potentially translate as a polypeptide chain.			Nucleotide Sequence	
C132930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132930>	C132926	Hypopharyngeal Cancer pT2 TNM Finding v8|Hypopharyngeal Carcinoma pT2 TNM Finding v8	Hypopharyngeal cancer with tumor invading more than one subsite of hypopharynx or an adjacent site, or measuring more than 2 cm but not more than 4 cm in greatest dimension without fixation of hemilarynx. (from AJCC 8th Ed.)			Finding	
C132931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132931>	C132926	Hypopharyngeal Cancer pT3 TNM Finding v8|Hypopharyngeal Carcinoma pT3 TNM Finding v8	Hypopharyngeal cancer with tumor larger than 4 cm in greatest dimension or with fixation of hemilarynx or extension to esophagus. (from AJCC 8th Ed.)			Finding	
C132932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132932>	C132926	Hypopharyngeal Cancer pT4 TNM Finding v8|Hypopharyngeal Carcinoma pT4 TNM Finding v8	Hypopharyngeal cancer with moderately advanced or very advanced local disease. (from AJCC 8th Ed.)			Finding	
C132933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132933>	C132932	Hypopharyngeal Cancer pT4a TNM Finding v8|Hypopharyngeal Carcinoma pT4a TNM Finding v8	Hypopharyngeal cancer with moderately advanced local disease. Tumor invades thyroid/cricoid cartilage, hyoid bone, thyroid gland, or central compartment soft tissue. Central compartment soft tissue includes prelaryngeal strap muscles and subcutaneous fat.  (from AJCC 8th Ed.)			Finding	
C132934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132934>	C132932	Hypopharyngeal Cancer pT4b TNM Finding v8|Hypopharyngeal Carcinoma pT4b TNM Finding v8	Hypopharyngeal cancer with very advanced local disease. Tumor invades prevertebral fascia, encases carotid artery, or involves mediastinal structures.  (from AJCC 8th Ed.)			Finding	
C132935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132935>	C132911	Oropharyngeal (p16-Negative) Cancer Clinical Regional Lymph Nodes TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma Clinical Regional Lymph Nodes TNM Finding v8	A clinical finding about one or more characteristics of oropharyngeal (p16-negative) cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C132936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132936>	C132913	Hypopharyngeal Cancer Clinical Regional Lymph Nodes TNM Finding v8|Hypopharyngeal Carcinoma Clinical Regional Lymph Nodes TNM Finding v8	A clinical finding about one or more characteristics of hypopharyngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C132937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132937>	C132912	Oropharyngeal (p16-Negative) Cancer Pathologic Regional Lymph Nodes TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of oropharyngeal (p16-negative) cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C132938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132938>	C132914	Hypopharyngeal Cancer Pathologic Regional Lymph Nodes TNM Finding v8|Hypopharyngeal Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of hypopharyngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C132939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132939>	C132935	Oropharyngeal (p16-Negative) Cancer cNX TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma cNX TNM Finding v8	Oropharyngeal (p16-negative) cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C13293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13293>	C13445	TATA Box	A consensus sequence found in the promoter region of most genes transcribed by eukaryotic RNA polymerase II. It is found about 25 nucleotides before the site of initiation of transcription and has the consensus sequence: 5' TATAAAA 3'. This sequence seems to be important in determining accurately the position at which transcription is initiated.			Nucleotide Sequence	
C132940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132940>	C132936	Hypopharyngeal Cancer cNX TNM Finding v8|Hypopharyngeal Carcinoma cNX TNM Finding v8	Hypopharyngeal cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C132941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132941>	C132935	Oropharyngeal (p16-Negative) Cancer cN0 TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma cN0 TNM Finding v8	Oropharyngeal (p16-negative) cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)			Finding	
C132942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132942>	C132936	Hypopharyngeal Cancer cN0 TNM Finding v8|Hypopharyngeal Carcinoma cN0 TNM Finding v8	Hypopharyngeal cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)			Finding	
C132943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132943>	C132935	Oropharyngeal (p16-Negative) Cancer cN1 TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma cN1 TNM Finding v8	Oropharyngeal (p16-negative) cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (-). (from AJCC 8th Ed.)			Finding	
C132944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132944>	C132936	Hypopharyngeal Cancer cN1 TNM Finding v8|Hypopharyngeal Carcinoma cN1 TNM Finding v8	Hypopharyngeal cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (-). (from AJCC 8th Ed.)			Finding	
C132945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132945>	C132935	Oropharyngeal (p16-Negative) Cancer cN2 TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma cN2 TNM Finding v8	Oropharyngeal (p16-negative) cancer with metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132946>	C132936	Hypopharyngeal Cancer cN2 TNM Finding v8|Hypopharyngeal Carcinoma cN2 TNM Finding v8	Hypopharyngeal cancer with metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132947>	C132945	Oropharyngeal (p16-Negative) Cancer cN2a TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma cN2a TNM Finding v8	Oropharyngeal (p16-negative) cancer with metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132948>	C132946	Hypopharyngeal Cancer cN2a TNM Finding v8|Hypopharyngeal Carcinoma cN2a TNM Finding v8	Hypopharyngeal cancer with metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132949>	C132945	Oropharyngeal (p16-Negative) Cancer cN2b TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma cN2b TNM Finding v8	Oropharyngeal (p16-negative) cancer with metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C13294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13294>	C13427	C2H2 Zinc Finger	One of three structural motifs observed in DNA binding domains of zinc proteins. Domains in DNA- and RNA-binding proteins that contain amino acids which are folded into a single structural unit around a zinc atom that links two cysteines and two histidines. Each finger is postulated to recognize a specific sequence of about five nucleotide pairs. Originally identified in the TFIIIA transcription factor, it is also known as the C2H2 zinc finger.			Amino Acid Sequence	
C132950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132950>	C132946	Hypopharyngeal Cancer cN2b TNM Finding v8|Hypopharyngeal Carcinoma cN2b TNM Finding v8	Hypopharyngeal cancer with metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132951>	C132945	Oropharyngeal (p16-Negative) Cancer cN2c TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma cN2c TNM Finding v8	Oropharyngeal (p16-negative) cancer with metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132952>	C132946	Hypopharyngeal Cancer cN2c TNM Finding v8|Hypopharyngeal Carcinoma cN2c TNM Finding v8	Hypopharyngeal cancer with metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132953>	C132935	Oropharyngeal (p16-Negative) Cancer cN3 TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma cN3 TNM Finding v8	Oropharyngeal (p16-negative) cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in any node(s) and clinically overt ENE(+). (from AJCC 8th Ed.)			Finding	
C132954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132954>	C132936	Hypopharyngeal Cancer cN3 TNM Finding v8|Hypopharyngeal Carcinoma cN3 TNM Finding v8	Hypopharyngeal cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in any node(s) and clinically overt ENE(+). (from AJCC 8th Ed.)			Finding	
C132955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132955>	C132953	Oropharyngeal (p16-Negative) Cancer cN3a TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma cN3a TNM Finding v8	Oropharyngeal (p16-negative) cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132956>	C132954	Hypopharyngeal Cancer cN3a TNM Finding v8|Hypopharyngeal Carcinoma cN3a TNM Finding v8	Hypopharyngeal cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132957>	C132953	Oropharyngeal (p16-Negative) Cancer cN3b TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma cN3b TNM Finding v8	Oropharyngeal (p16-negative) cancer with metastasis in any node(s) and clinically overt ENE(+). (from AJCC 8th Ed.)			Finding	
C132958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132958>	C132954	Hypopharyngeal Cancer cN3b TNM Finding v8|Hypopharyngeal Carcinoma cN3b TNM Finding v8	Hypopharyngeal cancer with metastasis in any node(s) and clinically overt ENE(+). (from AJCC 8th Ed.)			Finding	
C132959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132959>	C132937	Oropharyngeal (p16-Negative) Cancer pNX TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma pNX TNM Finding v8	Oropharyngeal (p16-negative) cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C13295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13295>	C13377	Telomere|Telomeres|telomere	A stretch of repetitive nucleotide sequences (TTAGGG repeats in humans) found at both ends of each chromatid arm that plays a role in chromosome stability during replication.			Cell Component	
C132960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132960>	C132938	Hypopharyngeal Cancer pNX TNM Finding v8|Hypopharyngeal Carcinoma pNX TNM Finding v8	Hypopharyngeal cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C132961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132961>	C132937	Oropharyngeal (p16-Negative) Cancer pN0 TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma pN0 TNM Finding v8	Oropharyngeal (p16-negative) cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)			Finding	
C132962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132962>	C132938	Hypopharyngeal Cancer pN0 TNM Finding v8|Hypopharyngeal Carcinoma pN0 TNM Finding v8	Hypopharyngeal cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)			Finding	
C132963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132963>	C132937	Oropharyngeal (p16-Negative) Cancer pN1 TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma pN1 TNM Finding v8	Oropharyngeal (p16-negative) cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (-). (from AJCC 8th Ed.)			Finding	
C132964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132964>	C132938	Hypopharyngeal Cancer pN1 TNM Finding v8|Hypopharyngeal Carcinoma pN1 TNM Finding v8	Hypopharyngeal cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (-). (from AJCC 8th Ed.)			Finding	
C132965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132965>	C132937	Oropharyngeal (p16-Negative) Cancer pN2 TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma pN2 TNM Finding v8	Oropharyngeal (p16-negative) cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132966>	C132965	Oropharyngeal (p16-Negative) Cancer pN2a TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma pN2a TNM Finding v8	Oropharyngeal (p16-negative) cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132967>	C132938	Hypopharyngeal Cancer pN2 TNM Finding v8|Hypopharyngeal Carcinoma pN2 TNM Finding v8	Hypopharyngeal cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132968>	C132967	Hypopharyngeal Cancer pN2a TNM Finding v8|Hypopharyngeal Carcinoma pN2a TNM Finding v8	Hypopharyngeal cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132969>	C132965	Oropharyngeal (p16-Negative) Cancer pN2b TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma pN2b TNM Finding v8	Oropharyngeal (p16-negative) cancer with metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C13296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13296>	C13734	Enhancer	A 50-150bp DNA sequence that increases the rate of transcription of coding sequences. It may be located at various distances and in either orientation upstream from, downstream from or within a structural gene.  When bound by a specific transcription factor it increases the levels of expression of the gene, but is not sufficient alone to cause expression. Distinguished from a promoter, that is alone sufficient to cause expression of the gene when bound.	Enhancer		Nucleotide Sequence	CTRP Biomarker Terminology|CTRP Terminology
C132970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132970>	C132967	Hypopharyngeal Cancer pN2b TNM Finding v8|Hypopharyngeal Carcinoma pN2b TNM Finding v8	Hypopharyngeal cancer with metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132971>	C132965	Oropharyngeal (p16-Negative) Cancer pN2c TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma pN2c TNM Finding v8	Oropharyngeal (p16-negative) cancer with metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132972>	C132967	Hypopharyngeal Cancer pN2c TNM Finding v8|Hypopharyngeal Carcinoma pN2c TNM Finding v8	Hypopharyngeal cancer with metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132973>	C132937	Oropharyngeal (p16-Negative) Cancer pN3 TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma pN3 TNM Finding v8	Oropharyngeal (p16-negative) cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+). (from AJCC 8th Ed.)			Finding	
C132974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132974>	C132938	Hypopharyngeal Cancer pN3 TNM Finding v8|Hypopharyngeal Carcinoma pN3 TNM Finding v8	Hypopharyngeal cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+). (from AJCC 8th Ed.)			Finding	
C132975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132975>	C132973	Oropharyngeal (p16-Negative) Cancer pN3a TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma pN3a TNM Finding v8	Oropharyngeal (p16-negative) cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132976>	C132974	Hypopharyngeal Cancer pN3a TNM Finding v8|Hypopharyngeal Carcinoma pN3a TNM Finding v8	Hypopharyngeal cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C132977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132977>	C132973	Oropharyngeal (p16-Negative) Cancer pN3b TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma pN3b TNM Finding v8	Oropharyngeal (p16-negative) cancer with metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+). (from AJCC 8th Ed.)			Finding	
C132978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132978>	C132974	Hypopharyngeal Cancer pN3b TNM Finding v8|Hypopharyngeal Carcinoma pN3b TNM Finding v8	Hypopharyngeal cancer with metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+). (from AJCC 8th Ed.)			Finding	
C132979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132979>	C132911	Oropharyngeal (p16-Negative) Cancer Clinical Distant Metastasis TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of oropharyngeal (p16-negative) cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C13297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13297>	C13734	Promoter	A DNA sequence at which RNA polymerase binds and initiates transcription.	Promoter		Nucleotide Sequence	CTRP Biomarker Terminology|CTRP Terminology
C132980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132980>	C132913	Hypopharyngeal Cancer Clinical Distant Metastasis TNM Finding v8|Hypopharyngeal Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of hypopharyngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C132981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132981>	C132912	Oropharyngeal (p16-Negative) Cancer Pathologic Distant Metastasis TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of oropharyngeal (p16-negative) cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C132982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132982>	C132914	Hypopharyngeal Cancer Pathologic Distant Metastasis TNM Finding v8|Hypopharyngeal Carcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of hypopharyngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C132983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132983>	C132979	Oropharyngeal (p16-Negative) Cancer cM0 TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma cM0 TNM Finding v8	Oropharyngeal (p16-negative) cancer without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C132984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132984>	C132979	Oropharyngeal (p16-Negative) Cancer cM1 TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma cM1 TNM Finding v8	Oropharyngeal (p16-negative) cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C132985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132985>	C132980	Hypopharyngeal Cancer cM0 TNM Finding v8|Hypopharyngeal Carcinoma cM0 TNM Finding v8	Hypopharyngeal cancer without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C132986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132986>	C132980	Hypopharyngeal Cancer cM1 TNM Finding v8|Hypopharyngeal Carcinoma cM1 TNM Finding v8	Hypopharyngeal cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C132987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132987>	C132981	Oropharyngeal (p16-Negative) Cancer pM1 TNM Finding v8|Oropharyngeal (p16-Negative) Carcinoma pM1 TNM Finding v8	Oropharyngeal (p16-negative) cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C132988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132988>	C132982	Hypopharyngeal Cancer pM1 TNM Finding v8|Hypopharyngeal Carcinoma pM1 TNM Finding v8	Hypopharyngeal cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C132989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132989>	C225034|C200766	Anti-Glypican 3-scFvGC33-CAR-expressing T Lymphocytes|Anti-GPC3-scFvGC33-CAR Autologous T Lymphocytes|Autologous GAP T Cells|Autologous GPC3-CAR T Cells|GPC3-CAR Transduced Autologous T Cells|Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells|Glypican 3-specific Chimeric Antigen Receptor-expressing Autologous T Cells	A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) derived from the anti-glypican-3 (GPC3) monoclonal antibody GC33 (scFvGC33), with potential immunostimulating and antineoplastic activities. Upon administration, anti-GPC3-scFvGC33-CAR autologous T-lymphocytes specifically target and bind to GPC3-expressing tumor cells, resulting in tumor cell lysis. GPC3, a heparan sulfate proteoglycan and a member of the glypican family, is overexpressed on certain tumor cell types while minimally expressed in normal, healthy cells.. GPC3 plays an important role in cellular proliferation and differentiation.	Anti-Glypican 3-scFvGC33-CAR-expressing T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C13298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13298>	C13299	Repetitive Sequence|Repeated Sequence|Repeated Sequences|Repetitive Element	Nucleotide sequences present in multiple copies in the genome. There are several types of repeated sequences. Interspersed (or dispersed) DNA repeats (Interspersed Repetitive Sequences) are copies of transposable elements interspersed throughout the genome.  Flanking (or terminal) repeats (Terminal Repeat Sequences) are sequences that are repeated on both ends of a sequence, for example, the long terminal repeats (LTRs) on retroviruses. Direct terminal repeats are in the same direction and inverted terminal repeats are opposite to each other in direction. Tandem repeats (Tandem Repeat Sequences) are repeated copies which lie adjacent to each other. These can also be direct or inverted. The ribosomal RNA and transfer RNA genes belong to the class of middle repetitive DNA.			Nucleotide Sequence	GDC Terminology|GDC Value Terminology
C132990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132990>	C2521|C2313	Rilimogene Galvacirepvec/Rilimogene Glafolivec|PROSTVAC|PROSTVAC-V-PROSTVAC-F|PROSTVAC-V/F|PROSTVAC-VF-TRICOM|PROSTVAC-VF/TRICOM|Recombinant Vaccinia-Fowlpox-Prostate-specific Antigen-TRICOM Vaccine|Rilimogene Galvacirepvec-Rilimogene Glafolivec	A vaccine formulation consisting of rilimogene galvacirepvec (V-PSA-TRICOM; PROSTVAC-V), a recombinant vaccinia virus, and rilimogene glafolivec (F-PSA-TRICOM; PROSTVAC-F), a recombinant fowlpox virus, with potential immunostimulating and antineoplastic activities. Both viruses encode modified forms of human prostate specific antigen (PSA) and the three co-stimulatory molecule transgenes (TRIad of COstimulatory Molecules; TRICOM), B7.1 (CD80), intercellular adhesion molecule-1 (ICAM-1), and lymphocyte function-associated antigen-3 (LFA-3). Using a prime-boost vaccine regimen, with a primary vaccination of rilimogene galvacirepvec followed by multiple booster vaccinations of rilimogene glafolivec, the PSA-TRICOM vaccines infect antigen-presenting cells (APCs), such as dendritic cells (DCs). Upon processing and expression of the PSA and TRICOM proteins on their surfaces, the DCs are able to initiate cytotoxic T-lymphocyte (CTL) responses against PSA-expressing cancer cells. The combination of PSA and TRICOM greatly enhances T-cell activation and T-cell-mediated tumor cell killing.	Rilimogene Galvacirepvec/Rilimogene Glafolivec		Pharmacologic Substance|Virus	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C132991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132991>	C162996	Alrizomadlin|AA-115|ALRIZOMADLIN|APG 115|APG-115|MDM2-p53 Inhibitor APG-115|p53-HDM2 Protein-protein Interaction Inhibitor APG-115	An orally available inhibitor of human homolog of double minute 2 (HDM2; mouse double minute 2 homolog; MDM2), with potential antineoplastic activity. Upon oral administration,alrizomadlin binds to HDM2, preventing the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This may result in the restoration of p53 signaling and lead to the p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger protein and a negative regulator of the p53 pathway, is often overexpressed in cancer cells. It has been implicated in cancer cell proliferation and survival.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C132992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132992>	C129822|C128037	Sintilimab|Anti-PD-1 Monoclonal Antibody IBI308|Anti-PDCD1 Monoclonal Antibody IBI308|Daboshu|IBI 308|IBI-308|IBI308|SINTILIMAB|Tyvyt	A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PDCD1; PD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sintilimab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.	Sintilimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C132993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132993>	C2124	Gallium Ga 68-NODAGA-E(c[RGDyK])2|68Ga-NODAGA-E(c[RGDyK])2	A radiopharmaceutical agent composed of a dimeric cyclic arginine-glycine-aspartic acid (RGD)-based peptide (c[RGDyK]) and labeled, via the chelating agent 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA), with gallium Ga 68, with potential alphaVbeta3 (aVb3) integrin imaging activity upon positron emission topography (PET) or single photon emission computed tomography (SPECT). After intravenous administration of gallium Ga 68-NODAGA-E(c[RGDyK])2, the cyclic RGD moiety targets and binds to aVb3 integrin which is expressed on the cell membrane of tumor cells and tumor-resident endothelial cells. Upon imaging, aVb3 integrin-expressing cells can be visualized and expression levels can be quantified. This can be used to assess response to anti-angiogenic treatment. aVb3 integrin is overexpressed on certain tumor cells and tumor-resident endothelial cells, while minimally or not expressed on healthy, normal cells; aVb3 integrin plays a key role in angiogenesis, tumor proliferation and survival.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C132994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132994>	C173414|C132814	Oropharyngeal (p16-Negative) Carcinoma by AJCC v8 Stage|Oropharyngeal (p16-Negative) Squamous Cell Carcinoma by AJCC v8 Stage	A term that refers to the staging of p16-negative oropharyngeal squamous cell carcinoma according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C132995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132995>	C4942|C132994	Stage 0 Oropharyngeal (p16-Negative) Carcinoma AJCC v8|Stage 0 Oropharyngeal (p16-Negative) Squamous Cell Carcinoma AJCC v8|Stage 0 Oropharyngeal (p16-Negative) Throat Cancer	Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0 Oropharyngeal (p16-Negative) Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132996>	C8768|C132994	Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8|Stage I Oropharyngeal (p16-Negative) Squamous Cell Carcinoma AJCC v8|Stage I Oropharyngeal (p16-Negative) Throat Cancer	Stage I includes: T1, N0, M0. T1: Tumor 2 cm or smaller in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132997>	C8769|C132994	Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8|Stage II Oropharyngeal (p16-Negative) Squamous Cell Carcinoma AJCC v8|Stage II Oropharyngeal (p16-Negative) Throat Cancer	Stage II includes: T2, N0, M0. T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132998>	C8770|C132994	Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8|Stage III Oropharyngeal (p16-Negative) Squamous Cell Carcinoma AJCC v8|Stage III Oropharyngeal (p16-Negative) Throat Cancer	Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T3: Tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis. T1: Tumor 2 cm or smaller in greatest dimension. T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension. N0: No regional lymph node metastasis. N1: Tumor with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (-). M0: No distant metastasis. (AJCC 8th ed.)	Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C132999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C132999>	C8771|C132994	Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8|Stage IV Oropharyngeal (p16-Negative) Squamous Cell Carcinoma AJCC v8|Stage IV Oropharyngeal (p16-Negative) Throat Cancer	Stage IV includes: IVA: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB: (Any T, N3, M0); (T4b, Any N, M0); IVC: (Any T, Any N, M1). T4a: Moderately advanced local disease. Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible. Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of the larynx. T1: Tumor 2 cm or smaller in greatest dimension. T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension. T3: Tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis. T4b: Very advanced local disease. Tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base or encases carotid artery. N0: No regional lymph node metastasis. N1: Tumor with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (-). N2: Tumor with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). N3: Tumor with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+). M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13299>	C45374	DNA Sequence|Sequence|Sequences	The sequence of nucleotide residues along a DNA chain.			Nucleotide Sequence	
C1329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1329>	C449	Cloning Vector|Vector|Vectors|Vectors [Cloning Vectors]	Any DNA molecule capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. They are or are derived from plasmids, bacteriophages, or viruses and are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain genetic markers to facilitate their selective recognition.			Nucleic Acid, Nucleoside, or Nucleotide|Research Device	
C133000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133000>	C6000|C132999	Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8|Stage IVA Oropharyngeal (p16-Negative) Squamous Cell Carcinoma AJCC v8|Stage IVA Oropharyngeal (p16-Negative) Throat Cancer	Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0). T4a: Moderately advanced local disease. Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible. Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of the larynx. T1: Tumor 2 cm or smaller in greatest dimension. T2: Tumor larger than 2 cm but not larger than 4 cm in greatest dimension. T3: Tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis. N0: No regional lymph node metastasis. N1: Tumor with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-). N2: Tumor with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). M0: No distant metastasis. (AJCC 8th ed.)	Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133001>	C6001|C132999	Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8|Stage IVB Oropharyngeal (p16-Negative) Squamous Cell Carcinoma AJCC v8|Stage IVB Oropharyngeal (p16-Negative) Throat Cancer	Stage IVB includes: (Any T, N3, M0); (T4b, Any N, M0). T4b: Very advanced local disease. Tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base or encases carotid artery. N3: Tumor with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+). M0: No distant metastasis. (AJCC 8th ed.)	Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133002>	C6002|C132999	Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8|Stage IVC Oropharyngeal (p16-Negative) Squamous Cell Carcinoma AJCC v8|Stage IVC Oropharyngeal (p16-Negative) Throat Cancer	Stage IVC includes: Any T, Any N, M1. M1: distant metastasis. (AJCC 8th ed.)	Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133003>	C9465|C132814	Hypopharyngeal Carcinoma by AJCC v8 Stage	A term that refers to the staging of hypopharyngeal carcinoma according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C133005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133005>	C8768|C133003	Stage I Hypopharyngeal Carcinoma AJCC v8|Stage I Hypopharyngeal Throat Cancer	Stage I includes: T1, N0, M0. T1: Tumor limited to one subsite of hypopharynx and/or 2 cm or smaller in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Hypopharyngeal Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133006>	C8769|C133003	Stage II Hypopharyngeal Carcinoma AJCC v8|Stage II Hypopharyngeal Throat Cancer	Stage II includes: T2, N0, M0. T2: Tumor invading more than one subsite of hypopharynx or an adjacent site, or measuring more than 2 cm but not more than 4 cm in greatest dimension without fixation of hemilarynx. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Hypopharyngeal Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133007>	C8770|C133003	Stage III Hypopharyngeal Carcinoma AJCC v8|Stage III Hypopharyngeal Throat Cancer	Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T3: Tumor larger than 4 cm in greatest dimension or with fixation of hemilarynx or extension to esophagus. T1: Tumor limited to one subsite of hypopharynx and/or 2 cm or smaller in greatest dimension. T2: Tumor invading more than one subsite of hypopharynx or an adjacent site, or measuring more than 2 cm but not more than 4 cm in greatest dimension without fixation of hemilarynx. N0: No regional lymph node metastasis. N1: Tumor with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (-). M0: No distant metastasis. (AJCC 8th ed.)	Stage III Hypopharyngeal Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133008>	C8771|C133003	Stage IV Hypopharyngeal Carcinoma AJCC v8|Stage IV Hypopharyngeal Throat Cancer	Stage IV includes: IVA: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB: (Any T, N3, M0); (T4b, Any N, M0); IVC: (Any T, Any N, M1). T4a: Moderately advanced local disease. Tumor invades thyroid/cricoid cartilage, hyoid bone, thyroid gland, or central compartment soft tissue. Central compartment soft tissue includes prelaryngeal strap muscles and subcutaneous fat. T1: Tumor limited to one subsite of hypopharynx and/or 2 cm or smaller in greatest dimension. T2: Tumor invading more than one subsite of hypopharynx or an adjacent site, or measuring more than 2 cm but not more than 4 cm in greatest dimension without fixation of hemilarynx. T3: Tumor larger than 4 cm in greatest dimension or with fixation of hemilarynx or extension to esophagus. T4b: Very advanced local disease. Tumor invades prevertebral fascia, encases carotid artery, or involves mediastinal structures.  N0: No regional lymph node metastasis. N1: Tumor with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE (-). N2: Tumor with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). N3: Tumor with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+). M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Hypopharyngeal Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133009>	C6000|C133008	Stage IVA Hypopharyngeal Carcinoma AJCC v8|Stage IVA Hypopharyngeal Throat Cancer	Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0). T4a: Moderately advanced local disease. Tumor invades thyroid/cricoid cartilage, hyoid bone, thyroid gland, or central compartment soft tissue. Central compartment soft tissue includes prelaryngeal strap muscles and subcutaneous fat. T1: Tumor limited to one subsite of hypopharynx and/or 2 cm or smaller in greatest dimension. T2: Tumor invading more than one subsite of hypopharynx or an adjacent site, or measuring more than 2 cm but not more than 4 cm in greatest dimension without fixation of hemilarynx. T3: Tumor larger than 4 cm in greatest dimension or with fixation of hemilarynx or extension to esophagus. N0: No regional lymph node metastasis. N1: Tumor with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-). N2: Tumor with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). M0: No distant metastasis. (AJCC 8th ed.)	Stage IVA Hypopharyngeal Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13300>	C17610	Umbilical Cord Blood|CORD BLOOD|Cord Blood|Cord Blood|Cord Blood|Cord blood|Unmanipulated Cord Blood|umbilical cord blood	Blood present in the umbilical vessels at the time of delivery. If cryopreserved at birth, cord blood can serve as a source of hematopoietic progenitor cells for transplantation to a patient later diagnosed and treated for a hematopoietic disorder.			Body Substance	ALL Authorized Value Terminology|ALL Stem Cell Transplant Table|AML Authorized Value Terminology|AML Stem Cell Transplant Table|CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|mCode Genomic Specimen Type Value Set|mCode Terminology
C133010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133010>	C6001|C133008	Stage IVB Hypopharyngeal Carcinoma AJCC v8|Stage IVB Hypopharyngeal Throat Cancer	Stage IVB includes: (Any T, N3, M0); (T4b, Any N, M0). T4b: Very advanced local disease. Tumor invades prevertebral fascia, encases carotid artery, or involves mediastinal structures. N3: Tumor with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+). M0: No distant metastasis. (AJCC 8th ed.)	Stage IVB Hypopharyngeal Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133011>	C6002|C133008	Stage IVC Hypopharyngeal Carcinoma AJCC v8|Stage IVC Hypopharyngeal Throat Cancer	Stage IVC includes: Any T, Any N, M1. M1: distant metastasis. (AJCC 8th ed.)	Stage IVC Hypopharyngeal Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133012>	C217121	Decision Regret Scale|DRS	A 5-item Likert scale designed to measure distress or remorse after a health care decision..			Intellectual Product	
C133013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133013>	C174127	Made Right Decision Question|It was the right decision|Made Right Decision	A question about whether an individual thinks they made the right healthcare decision.			Intellectual Product	Decision Regret Scale
C133014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133014>	C173160	Regret Choice Made Question|I regret the choice that was made|Regret Choice Made	A question about whether an individual regrets the healthcare choice that they made.			Intellectual Product	Decision Regret Scale
C133015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133015>	C91102	Would Make Same Choice Again Question|I would go for the same choice if I had to do it over again|Would Make Same Choice Again	A question about whether an individual would go for the same healthcare choice if they had to do it over again.			Intellectual Product	Decision Regret Scale
C133016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133016>	C176545	Choice Did Harm Question|Choice Did Harm|The choice did me a lot of harm	A question about whether an individual thinks their healthcare choice did them a lot of harm.			Intellectual Product	Decision Regret Scale
C133017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133017>	C174127	Decision was Wise Question|Decision was Wise|Decision was Wise|The decision was a wise one	A question about whether an individual thinks their healthcare decision was a wise one.			Intellectual Product	Decision Regret Scale
C133018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133018>	C110937	Untreated Adult Rhabdomyosarcoma	A finding of rhabdomyosarcoma in adulthood that has not been treated.	Untreated Adult Rhabdomyosarcoma		Finding	CTRP Disease Terminology|CTRP Terminology
C133019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133019>	C744|C129839	Proapoptotic Sulindac Analog CP-461|1H-Indene-3-acetamide, 5-Fluoro-2-methyl-N-(phenylmethyl)-1-(4-pyridinylmethylene)-, Monohydrochloride, (1Z)-|CEL 031|CP 461|CP-461|CP-461|CP461|OSI 461	An orally bioavailable second-generation selective apoptotic antineoplastic drug (SAAND) and analog of the nonsteroidal anti-inflammatory drug (NSAID) sulindac, with potential pro-apoptotic and antineoplastic activities. Upon administration, CP-461 specifically binds to and blocks the activity of cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway. Inhibition of cGMP-PDE permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death. cGMP-PDE is overexpressed in a variety of cancer cell types; therefore, CP-461 selectively induces apoptosis in cancer cells, with minimal or no effect in healthy cells.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C13301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13301>	C32504	Mesenchyme	Embryonic tissue of mesodermal origin.  Develops into connective tissue, blood vessels, and lymphatic tissue.			Embryonic Structure	
C133020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133020>	C67439|C2150|C2136	Gallium Maltolate|GALLIUM MALTOLATE|GaM|Tris(3-hydroxy-2-methyl-4H-pyran-4-onato)gallium(III)	An orally bioavailable form of the element gallium (Ga) composed of a trivalent gallium cation (Ga3+) coordinated to three maltolate ligands, with anti-inflammatory, anti-proliferative, antineoplastic, analgesic, antiresorptive and antibacterial activities. Upon administration of gallium maltolate, Ga3+, which is structurally similar to the ferric ion (Fe3+), competes with and replaces Fe3+ in many vital Fe 3+-mediated biological reactions.. Unlike Fe3+, Ga3+ cannot be reduced, cannot participate in redox reactions and cannot mimic Fe3+ functions. In rapidly proliferating cells, such as cancer cells, high amounts of iron are needed for DNA synthesis. The incorporation of Ga3+ inactivates the Fe3+-dependent enzyme ribonucleotide reductase (RR), an enzyme essential for DNA synthesis, leading to an inhibition of DNA synthesis and induction of cell death in rapidly proliferating cells. Gallium similarly reduces bacterial cell growth. In addition, Ga3+ is able to suppress inflammation through the down-regulation of pro-inflammatory cells and the inhibition of pro-inflammatory cytokine secretion. Gallium also exerts analgesic effects due to the inhibition of Fe3+-dependent enzymes involved in inflammation and may interfere with the activity of certain metalloproteinases and neuropeptides that are implicated in pain. Also, gallium is able to inhibit bone resorption by osteoclasts, may inhibit metastasis to bone and may prevent the destruction of bone by tumors.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C133021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133021>	C471	Gelonin|GEL Protein, Gelonium multiflorum|Ribosome-inactivating Protein Gelonin, Gelonium multiflorum|rGel	A class I ribosome-inactivating protein (RIP) and toxin derived from the seeds of the plant Gelonium multiflorum. Gelonin (rGel) exerts N-glycosidase activity on the 28S ribosomal RNA (rRNA) unit of eukaryotic ribosomes by cleaving out adenine at the 4324 site, which depurinates rRNA, inactivates ribosomes, inhibits protein synthesis, and results in cell death. Used as the toxin moiety of certain immunotoxins and linked to antibodies specific for a tumor-associated antigen (TAA), gelonin can be targeted to and induce specific cytotoxicity in tumor cells expressing the TAA.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C133022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133022>	C201523|C129822	Anti-Ep-CAM Monoclonal Antibody ING-1|ING 1|ING-1	An engineered monoclonal antibody (MAb) directed against the tumor-associated antigen (TAA) human epithelial cell adhesion molecule (Ep-CAM; EpCAM; CD326), with potential antitumor activity. Upon administration, anti-Ep-CAM monoclonal antibody ING-1 binds to Ep-CAM, which may result in a cytotoxic T-lymphocyte (CTL)-mediated immune response against Ep-CAM-expressing tumor cells. Ep-CAM, a cell surface protein upregulated on many tumor cell types, promotes the proliferation, migration and invasiveness of tumor cells.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C133023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133023>	C2124|C129819	Iodine I 131 Iodocholesterol|Cholest-5-en-3-ol, 19(Iodo-(sup 131)I)-, (3beta)-|I-131 Iodocholesterol|IODOCHOLESTEROL I-131|Iodine 131 Iodocholesterol|Iodine I-131 Iodocholesterol|Iodocholesterol (131 I)|Iodocholesterol (131I)|Iodocholesterol I 131	A radioiodine-labeled cholesterol analogue with diagnostic imaging activity upon scintigraphy. Upon administration, iodine I 131 iodocholesterol accumulates in tissues where steroid hormones are produced, including the adrenal glands and, to a lesser extent, the ovaries and the testes. After binding to low-density lipoprotein (LDL) receptors on adrenocortical cells, this agent is internalized. As cholesterol is the precursor for all adrenocortical steroid hormones, areas of hormonal hypersecretion, can be visualized using scintigraphy and the adrenocortical function can be assessed.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C133024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133024>	C132632	Nasal Cavity and Paranasal Sinuses Cancer TNM Finding v8|Nasal Cavity and Paranasal Sinuses Carcinoma TNM Finding v8	A finding about one or more characteristics of nasal cavity and paranasal sinuses cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to malignancies that arise in the epithelial lining of the nasal cavity and paranasal sinuses, with the exception of lymphoma and sarcoma. Mucosal melanoma of the nasal cavity and paranasal sinuses is staged according to the classification for mucosal melanoma of the head and neck. (from AJCC 8th Ed.)			Finding	
C133025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133025>	C133024|C132633	Nasal Cavity and Paranasal Sinuses Cancer Clinical TNM Finding v8|Nasal Cavity and Paranasal Sinuses Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of nasal cavity and paranasal sinuses cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C133026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133026>	C133024|C132642	Nasal Cavity and Paranasal Sinuses Cancer Pathologic TNM Finding v8|Nasal Cavity and Paranasal Sinuses Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of nasal cavity and paranasal sinuses cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C133027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133027>	C133026	Maxillary Sinus Cancer Pathologic Primary Tumor TNM Finding v8|Maxillary Sinus Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of maxillary sinus cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C133028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133028>	C133026	Nasal Cavity and Ethmoid Sinus Cancer Pathologic Primary Tumor TNM Finding v8|Nasal Cavity and Ethmoid Sinus Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of nasal cavity and ethmoid sinus cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C133029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133029>	C133026	Nasal Cavity and Paranasal Sinuses Cancer Pathologic Regional Lymph Nodes TNM Finding v8|Nasal Cavity and Paranasal Sinuses Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of nasal cavity and paranasal sinuses cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C13302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13302>	C13303	Secondary Protein Structure|Secondary Structure	The specific 3-dimensional folded protein structure that is determined by the hydrogen bonds formed between amino acids in the polypeptide chain.			Spatial Concept	
C133030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133030>	C133025	Nasal Cavity and Paranasal Sinuses Cancer Clinical Regional Lymph Nodes TNM Finding v8|Nasal Cavity and Paranasal Sinuses Carcinoma Clinical Regional Lymph Nodes TNM Finding v8	A clinical finding about one or more characteristics of nasal cavity and paranasal sinuses cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C133031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133031>	C133026	Nasal Cavity and Paranasal Sinuses Cancer Pathologic Distant Metastasis TNM Finding v8|Nasal Cavity and Paranasal Sinuses Carcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of nasal cavity and paranasal sinuses cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C133032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133032>	C133025	Nasal Cavity and Paranasal Sinuses Cancer Clinical Distant Metastasis TNM Finding v8|Nasal Cavity and Paranasal Sinuses Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of nasal cavity and paranasal sinuses cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C133033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133033>	C133027	Maxillary Sinus Cancer pTX TNM Finding v8|Maxillary Sinus Carcinoma pTX TNM Finding v8	Maxillary sinus cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C133034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133034>	C133027	Maxillary Sinus Cancer pTis TNM Finding v8|Maxillary Sinus Carcinoma pTis TNM Finding v8	Maxillary sinus cancer with a finding of carcinoma in situ. (from AJCC 8th Ed.)			Finding	
C133035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133035>	C133027	Maxillary Sinus Cancer pT1 TNM Finding v8|Maxillary Sinus Carcinoma pT1 TNM Finding v8	Maxillary sinus cancer with tumor limited to the maxillary sinus mucosa with no erosion or destruction of bone. (from AJCC 8th Ed.)			Finding	
C133036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133036>	C133027	Maxillary Sinus Cancer pT2 TNM Finding v8|Maxillary Sinus Carcinoma pT2 TNM Finding v8	Maxillary sinus cancer with tumor causing bone erosion or destruction including extension into the hard palate and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and pterygoid plates. (from AJCC 8th Ed.)			Finding	
C133037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133037>	C133027	Maxillary Sinus Cancer pT3 TNM Finding v8|Maxillary Sinus Carcinoma pT3 TNM Finding v8	Maxillary sinus cancer with tumor invading any of the following: bone of the posterior wall of maxillary sinus, subcutaneous tissues, floor or medial wall of orbit, pterygoid fossa, or ethmoid sinuses. (from AJCC 8th Ed.)			Finding	
C133038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133038>	C133027	Maxillary Sinus Cancer pT4 TNM Finding v8|Maxillary Sinus Carcinoma pT4 TNM Finding v8	Maxillary sinus cancer with moderately advanced or very advanced local disease. (from AJCC 8th Ed.)			Finding	
C133039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133039>	C133038	Maxillary Sinus Cancer pT4a TNM Finding v8|Maxillary Sinus Carcinoma pT4a TNM Finding v8	Maxillary sinus cancer with moderately advanced local disease. Tumor invades anterior orbital contents, skin of cheek, pterygoid plates, infratemporal fossa, cribriform plate, sphenoid or frontal sinuses. (from AJCC 8th Ed.)			Finding	
C13303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13303>	C14134	Protein Structure	The amino acids and their 3-D arrangement in constituting a protein.			Spatial Concept	
C133040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133040>	C133038	Maxillary Sinus Cancer pT4b TNM Finding v8|Maxillary Sinus Carcinoma pT4b TNM Finding v8	Maxillary sinus cancer with very advanced local disease.  Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than maxillary division of trigeminal nerve (V2), nasopharynx, or clivus. (from AJCC 8th Ed.)			Finding	
C133041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133041>	C133028	Nasal Cavity and Ethmoid Sinus Cancer pTX TNM Finding v8|Nasal Cavity and Ethmoid Sinus Carcinoma pTX TNM Finding v8	Nasal cavity and ethmoid sinus cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C133042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133042>	C133028	Nasal Cavity and Ethmoid Sinus Cancer pTis TNM Finding v8|Nasal Cavity and Ethmoid Sinus Carcinoma pTis TNM Finding v8	Nasal cavity and ethmoid sinus cancer with a finding of carcinoma in situ. (from AJCC 8th Ed.)			Finding	
C133043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133043>	C133028	Nasal Cavity and Ethmoid Sinus Cancer pT1 TNM Finding v8|Nasal Cavity and Ethmoid Sinus Carcinoma pT1 TNM Finding v8	Nasal cavity and ethmoid sinus cancer with tumor restricted to any one subsite, with or without bony invasion. (from AJCC 8th Ed.)			Finding	
C133044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133044>	C133028	Nasal Cavity and Ethmoid Sinus Cancer pT2 TNM Finding v8|Nasal Cavity and Ethmoid Sinus Carcinoma pT2 TNM Finding v8	Nasal cavity and ethmoid sinus cancer with tumor invading two subsites in a single region or extending to involve an adjacent region within the nasoethmoidal complex, with or without bony invasion. (from AJCC 8th Ed.)			Finding	
C133045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133045>	C133028	Nasal Cavity and Ethmoid Sinus Cancer pT3 TNM Finding v8|Nasal Cavity and Ethmoid Sinus Carcinoma pT3 TNM Finding v8	Nasal cavity and ethmoid sinus cancer with tumor invading the medial wall or floor of the orbit, maxillary sinus, palate, or cribriform plate. (from AJCC 8th Ed.)			Finding	
C133046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133046>	C133028	Nasal Cavity and Ethmoid Sinus Cancer pT4 TNM Finding v8|Nasal Cavity and Ethmoid Sinus Carcinoma pT4 TNM Finding v8	Nasal cavity and ethmoid sinus cancer with moderately advanced or very advanced local disease. (from AJCC 8th Ed.)			Finding	
C133047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133047>	C133046	Nasal Cavity and Ethmoid Sinus Cancer pT4a TNM Finding v8|Nasal Cavity and Ethmoid Sinus Carcinoma pT4a TNM Finding v8	Nasal cavity and ethmoid sinus cancer with moderately advanced local disease. Tumor invades any of the following: anterior orbital contents, skin of nose or cheek, minimal extension to anterior cranial fossa, pterygoid plates, sphenoid or frontal sinuses. (from AJCC 8th Ed.)			Finding	
C133048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133048>	C133046	Nasal Cavity and Ethmoid Sinus Cancer pT4b TNM Finding v8|Nasal Cavity and Ethmoid Sinus Carcinoma pT4b TNM Finding v8	Nasal cavity and ethmoid sinus cancer with very advanced local disease. Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than maxillary division of trigeminal nerve (V2), nasopharynx, or clivus. (from AJCC 8th Ed.)			Finding	
C133049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133049>	C133030	Nasal Cavity and Paranasal Sinuses Cancer cNX TNM Finding v8|Nasal Cavity and Paranasal Sinuses Carcinoma cNX TNM Finding v8	Nasal cavity and paranasal sinuses cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C13304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13304>	C13442	Pulmonary|PULMONARY|pulmonary	Relating to the lungs as the intended site of administration, where the pharmaceutical product is administered, usually by inhalation, for local action in the lower respiratory tract or for systemic action after absorption via the lower respiratory tract.			Qualitative Concept	CDISC SEND Microscopic Findings Result Modifier Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EDQM Health Care Terminology|EDQM-HC Intended Site of Administration Terminology
C133050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133050>	C133030	Nasal Cavity and Paranasal Sinuses Cancer cN0 TNM Finding v8|Nasal Cavity and Paranasal Sinuses Carcinoma cN0 TNM Finding v8	Nasal cavity and paranasal sinuses cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)			Finding	
C133051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133051>	C133030	Nasal Cavity and Paranasal Sinuses Cancer cN1 TNM Finding v8|Nasal Cavity and Paranasal Sinuses Carcinoma cN1 TNM Finding v8	Nasal cavity and paranasal sinuses cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C133052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133052>	C133030	Nasal Cavity and Paranasal Sinuses Cancer cN2 TNM Finding v8|Nasal Cavity and Paranasal Sinuses Carcinoma cN2 TNM Finding v8	Nasal cavity and paranasal sinuses cancer with metastasis in a single ipsilateral lymph node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes , none larger than 6 cm in greatest dimension and ENE(-); or in in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-) . (from AJCC 8th Ed.)			Finding	
C133053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133053>	C133052	Nasal Cavity and Paranasal Sinuses Cancer cN2a TNM Finding v8|Nasal Cavity and Paranasal Sinuses Carcinoma cN2a TNM Finding v8	Nasal cavity and paranasal sinuses cancer with metastasis in a single ipsilateral lymph node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C133054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133054>	C133052	Nasal Cavity and Paranasal Sinuses Cancer cN2b TNM Finding v8|Nasal Cavity and Paranasal Sinuses Carcinoma cN2b TNM Finding v8	Nasal cavity and paranasal sinuses cancer with metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C133055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133055>	C133052	Nasal Cavity and Paranasal Sinuses Cancer cN2c TNM Finding v8|Nasal Cavity and Paranasal Sinuses Carcinoma cN2c TNM Finding v8	Nasal cavity and paranasal sinuses cancer with metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-) . (from AJCC 8th Ed.)			Finding	
C133056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133056>	C133030	Nasal Cavity and Paranasal Sinuses Cancer cN3 TNM Finding v8|Nasal Cavity and Paranasal Sinuses Carcinoma cN3 TNM Finding v8	Nasal cavity and paranasal sinuses cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in any node(s) with clinically overt ENE(+) . (from AJCC 8th Ed.)			Finding	
C133057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133057>	C133056	Nasal Cavity and Paranasal Sinuses Cancer cN3a TNM Finding v8|Nasal Cavity and Paranasal Sinuses Carcinoma cN3a TNM Finding v8	Nasal cavity and paranasal sinuses cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C133058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133058>	C133056	Nasal Cavity and Paranasal Sinuses Cancer cN3b TNM Finding v8|Nasal Cavity and Paranasal Sinuses Carcinoma cN3b TNM Finding v8	Nasal cavity and paranasal sinuses cancer with metastasis in any node(s) with clinically overt ENE(+) (ENEc). (from AJCC 8th Ed.)			Finding	
C133059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133059>	C133029	Nasal Cavity and Paranasal Sinuses Cancer pNX TNM Finding v8|Nasal Cavity and Paranasal Sinuses Carcinoma pNX TNM Finding v8	Nasal cavity and paranasal sinuses cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C13305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13305>	C13442	Laryngeal|Laryngeal (qualifier value)|laryngeal	Referring to the larynx.			Qualitative Concept	mCode Radiotherapy Treatment Location Qualifier Value Set|mCode Terminology
C133060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133060>	C133029	Nasal Cavity and Paranasal Sinuses Cancer pN0 TNM Finding v8|Nasal Cavity and Paranasal Sinuses Carcinoma pN0 TNM Finding v8	Nasal cavity and paranasal sinuses cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)			Finding	
C133061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133061>	C133029	Nasal Cavity and Paranasal Sinuses Cancer pN1 TNM Finding v8|Nasal Cavity and Paranasal Sinuses Carcinoma pN1 TNM Finding v8	Nasal cavity and paranasal sinuses cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C133062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133062>	C133029	Nasal Cavity and Paranasal Sinuses Cancer pN2 TNM Finding v8|Nasal Cavity and Paranasal Sinuses Carcinoma pN2 TNM Finding v8	Nasal cavity and paranasal sinuses cancer with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes , none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C133063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133063>	C133062	Nasal Cavity and Paranasal Sinuses Cancer pN2a TNM Finding v8|Nasal Cavity and Paranasal Sinuses Carcinoma pN2a TNM Finding v8	Nasal cavity and paranasal sinuses cancer with metastasis in a single ipsilateral or contralateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-).  (from AJCC 8th Ed.)			Finding	
C133064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133064>	C133062	Nasal Cavity and Paranasal Sinuses Cancer pN2b TNM Finding v8|Nasal Cavity and Paranasal Sinuses Carcinoma pN2b TNM Finding v8	Nasal cavity and paranasal sinuses cancer with metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C133065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133065>	C133062	Nasal Cavity and Paranasal Sinuses Cancer pN2c TNM Finding v8|Nasal Cavity and Paranasal Sinuses Carcinoma pN2c TNM Finding v8	Nasal cavity and paranasal sinuses cancer with metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C133066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133066>	C133029	Nasal Cavity and Paranasal Sinuses Cancer pN3 TNM Finding v8|Nasal Cavity and Paranasal Sinuses Carcinoma pN3 TNM Finding v8	Nasal cavity and paranasal sinuses cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral or bilateral nodes, any with ENE(+) . (from AJCC 8th Ed.)			Finding	
C133067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133067>	C133066	Nasal Cavity and Paranasal Sinuses Cancer pN3a TNM Finding v8|Nasal Cavity and Paranasal Sinuses Carcinoma pN3a TNM Finding v8	Nasal cavity and paranasal sinuses cancer with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C133068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133068>	C133066	Nasal Cavity and Paranasal Sinuses Cancer pN3b TNM Finding v8|Nasal Cavity and Paranasal Sinuses Carcinoma pN3b TNM Finding v8	Nasal cavity and paranasal sinuses cancer with metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral or bilateral nodes, any with ENE(+) . (from AJCC 8th Ed.)			Finding	
C133069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133069>	C133032	Nasal Cavity and Paranasal Sinuses Cancer cM0 TNM Finding v8|Nasal Cavity and Paranasal Sinuses Carcinoma cM0 TNM Finding v8	Nasal cavity and paranasal sinuses cancer without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C13306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13306>	C13442	Cardiac|cardiac				Qualitative Concept	
C133070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133070>	C133032	Nasal Cavity and Paranasal Sinuses Cancer cM1 TNM Finding v8|Nasal Cavity and Paranasal Sinuses Carcinoma cM1 TNM Finding v8	Nasal cavity and paranasal sinuses cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C133071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133071>	C133031	Nasal Cavity and Paranasal Sinuses Cancer pM1 TNM Finding v8|Nasal Cavity and Paranasal Sinuses Carcinoma pM1 TNM Finding v8	Nasal cavity and paranasal sinuses cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C133072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133072>	C176018	CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes|CD19-CAR-specific/truncated EGFR Lentiviral Vector-transduced T Cells|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T Cells|CD19R(EQ)28zeta/EGFRt+ TCM|CD19R(EQ)28zeta/truncated Human EGFR+ Central Memory T Cells|CD19R:CD28:lentiviral/EGFRt+ T Cells	A preparation of genetically modified central memory (Tcm) enriched T-cells transduced with a replication incompetent lentiviral vector expressing a chimeric antigen receptor (CAR), containing a CD28 signaling domain fused to both CD3 zeta, which targets the CD19 antigen, and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells are directed to CD19-expressing tumor cells, thereby inducing a selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.  Devoid of both ligand binding domains and tyrosine kinase activity, EGFRt both facilitates in vivo detection of the administered T-cells and can promote elimination of those cells upon a cetuximab-induced antibody dependent cellular cytotoxicity response. The costimulatory signaling domain enhances proliferation of T cells and antitumor activity.	CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C133073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133073>	C176018	CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T Cells|CD19R(EQ)28zeta/EGFRt+ Naive and Memory T Cells|CD19R(EQ)28zetaEGFRt+ Tn/mem Cells	A preparation of genetically modified lymphocytes comprised of CD62L-positive naïve and memory T-cells (Tn/mem), that are transduced ex vivo with a self-inactivating (SIN) lentiviral vector expressing a hinge-optimized chimeric antigen receptor (CAR) specific for the CD19 antigen and containing CD28 and CD3 zeta signaling domains, and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon isolation of peripheral blood lymphocytes (PBLs), transduction of the CD62L-positive T-lymphocytes, expansion ex vivo and administration, the CD19R(EQ)-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-cells target CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.  Devoid of both ligand binding domains and tyrosine kinase activity, EGFRt both facilitates in vivo detection of the administered T-cells and can promote elimination of those cells upon a cetuximab-induced antibody dependent cellular cytotoxicity response. Tn/mem T-cells include naïve T-cells, central memory T-cells (Tcm) and stem cell memory T-cells (Tscm). CD19R(EQ) contains two point mutations in the immunoglobulin (Ig) G4 spacer region, thereby preventing recognition of the CAR by Fc receptors (FcRs).	CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C133074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133074>	C54293	Sinonasal Cancer by AJCC v8 Stage|Nasal Cavity and Paranasal Sinus Cancer by AJCC v8 Stage|Nasal Cavity and Paranasal Sinus Carcinoma by AJCC v8 Stage|Sinonasal Carcinoma by AJCC v8 Stage	A term that refers to the staging of nasal cavity and paranasal sinus carcinoma according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C133076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133076>	C133074	Stage I Sinonasal Cancer AJCC v8|Stage I Nasal Cavity and Paranasal Sinus Cancer|Stage I Nasal Cavity and Paranasal Sinus Cancer AJCC v8|Stage I Nasal Cavity and Paranasal Sinus Carcinoma AJCC v8|Stage I Sinonasal Carcinoma AJCC v8	Stage I includes: T1, N0, M0. T1: Maxillary sinus: Tumor limited to the maxillary sinus mucosa with no erosion or destruction of bone. Nasal cavity and ethmoid sinus: Tumor restricted to any one subsite, with or without bony invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Nasal Cavity and Paranasal Sinus Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133077>	C133074	Stage II Sinonasal Cancer AJCC v8|Stage II Nasal Cavity and Paranasal Sinus Cancer|Stage II Nasal Cavity and Paranasal Sinus Cancer AJCC v8|Stage II Nasal Cavity and Paranasal Sinus Carcinoma AJCC v8|Stage II Sinonasal Carcinoma AJCC v8	Stage II includes: T2, N0, M0. T2: Maxillary sinus: Tumor causing bone erosion or destruction including extension into the hard palate and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and pterygoid plates. Nasal cavity and ethmoid sinus: Tumor invading two subsites in a single region or extending to involve an adjacent region within the nasoethmoidal complex, with or without bony invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Nasal Cavity and Paranasal Sinus Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133078>	C133074	Stage III Sinonasal Cancer AJCC v8|Stage III Nasal Cavity and Paranasal Sinus Cancer|Stage III Nasal Cavity and Paranasal Sinus Cancer AJCC v8|Stage III Nasal Cavity and Paranasal Sinus Carcinoma AJCC v8|Stage III Sinonasal Carcinoma AJCC v8	Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T3: Maxillary sinus: Tumor invading any of the following: bone of the posterior wall of maxillary sinus, subcutaneous tissues, floor or medial wall of orbit, pterygoid fossa, or ethmoid sinuses. Nasal cavity and ethmoid sinus: Tumor invading the medial wall or floor of the orbit, maxillary sinus, palate, or cribriform plate.  T1: Maxillary sinus: Tumor limited to the maxillary sinus mucosa with no erosion or destruction of bone. Nasal cavity and ethmoid sinus: Tumor restricted to any one subsite, with or without bony invasion. T2: Maxillary sinus: Tumor causing bone erosion or destruction including extension into the hard palate and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and pterygoid plates. Nasal cavity and ethmoid sinus: Tumor invading two subsites in a single region or extending to involve an adjacent region within the nasoethmoidal complex, with or without bony invasion. N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(-). M0: No distant metastasis. (AJCC 8th ed.)	Stage III Nasal Cavity and Paranasal Sinus Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133079>	C133074	Stage IV Sinonasal Cancer AJCC v8|Stage IV Nasal Cavity and Paranasal Sinus Cancer|Stage IV Nasal Cavity and Paranasal Sinus Cancer AJCC v8|Stage IV Nasal Cavity and Paranasal Sinus Carcinoma AJCC v8|Stage IV Sinonasal Carcinoma AJCC v8	Stage IV includes: IVA: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB: (T4b, Any N, M0); (Any T, N3, M0); IVC: (Any T, Any N, M1). T4a: Maxillary sinus: Moderately advanced local disease. Tumor invades anterior orbital contents, skin of cheek, pterygoid plates, infratemporal fossa, cribriform plate, sphenoid or frontal sinuses. Nasal cavity and ethmoid sinus: Moderately advanced local disease. Tumor invades any of the following: anterior orbital contents, skin of nose or cheek, minimal extension to anterior cranial fossa, pterygoid plates, sphenoid or frontal sinuses. T4b: Very advanced local disease.  Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than maxillary division of trigeminal nerve (V2), nasopharynx, or clivus. T1: Maxillary sinus: Tumor limited to the maxillary sinus mucosa with no erosion or destruction of bone. Nasal cavity and ethmoid sinus: Tumor restricted to any one subsite, with or without bony invasion. T2: Maxillary sinus: Tumor causing bone erosion or destruction including extension into the hard palate and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and pterygoid plates. Nasal cavity and ethmoid sinus: Tumor invading two subsites in a single region or extending to involve an adjacent region within the nasoethmoidal complex, with or without bony invasion. T3: Maxillary sinus: Tumor invading any of the following: bone of the posterior wall of maxillary sinus, subcutaneous tissues, floor or medial wall of orbit, pterygoid fossa, or ethmoid sinuses. Nasal cavity and ethmoid sinus: Tumor invading the medial wall or floor of the orbit, maxillary sinus, palate, or cribriform plate. N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(-). N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes , none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral or bilateral nodes, any with ENE(+). M0: No distant metastasis. M1: Distant metastasis.  (AJCC 8th ed.)	Stage IV Nasal Cavity and Paranasal Sinus Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13307>	C13442	Gastric|gastric	Relating to the stomach.			Spatial Concept	EDQM Health Care Terminology|EDQM-HC Intended Site of Administration Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C133080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133080>	C133079	Stage IVA Sinonasal Cancer AJCC v8|Stage IVA Nasal Cavity and Paranasal Sinus Cancer|Stage IVA Nasal Cavity and Paranasal Sinus Cancer AJCC v8|Stage IVA Nasal Cavity and Paranasal Sinus Carcinoma AJCC v8|Stage IVA Sinonasal Carcinoma AJCC v8	Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0). T4a: Maxillary sinus: Moderately advanced local disease. Tumor invades anterior orbital contents, skin of cheek, pterygoid plates, infratemporal fossa, cribriform plate, sphenoid or frontal sinuses. Nasal cavity and ethmoid sinus: Moderately advanced local disease. Tumor invades any of the following: anterior orbital contents, skin of nose or cheek, minimal extension to anterior cranial fossa, pterygoid plates, sphenoid or frontal sinuses. T1: Maxillary sinus: Tumor limited to the maxillary sinus mucosa with no erosion or destruction of bone. Nasal cavity and ethmoid sinus: Tumor restricted to any one subsite, with or without bony invasion. T2: Maxillary sinus: Tumor causing bone erosion or destruction including extension into the hard palate and/or middle nasal meatus, except extension to posterior wall of maxillary sinus and pterygoid plates. Nasal cavity and ethmoid sinus: Tumor invading two subsites in a single region or extending to involve an adjacent region within the nasoethmoidal complex, with or without bony invasion. T3: Maxillary sinus: Tumor invading any of the following: bone of the posterior wall of maxillary sinus, subcutaneous tissues, floor or medial wall of orbit, pterygoid fossa, or ethmoid sinuses. Nasal cavity and ethmoid sinus: Tumor invading the medial wall or floor of the orbit, maxillary sinus, palate, or cribriform plate. N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(-). N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes , none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-). M0: No distant metastasis. (AJCC 8th ed.)	Stage IVA Nasal Cavity and Paranasal Sinus Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133081>	C133079	Stage IVB Sinonasal Cancer AJCC v8|Stage IVB Nasal Cavity and Paranasal Sinus Cancer|Stage IVB Nasal Cavity and Paranasal Sinus Cancer AJCC v8|Stage IVB Nasal Cavity and Paranasal Sinus Carcinoma AJCC v8|Stage IVB Sinonasal Carcinoma AJCC v8	Stage IVB includes: (T4b, Any N, M0); (Any T, N3, M0). T4b: Very advanced local disease. Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than maxillary division of trigeminal nerve (V2), nasopharynx, or clivus. N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral or bilateral nodes, any with ENE(+). M0: No distant metastasis. (AJCC 8th ed.)	Stage IVB Nasal Cavity and Paranasal Sinus Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133082>	C133079	Stage IVC Sinonasal Cancer AJCC v8|Stage IVC Nasal Cavity and Paranasal Sinus Cancer|Stage IVC Nasal Cavity and Paranasal Sinus Cancer AJCC v8|Stage IVC Nasal Cavity and Paranasal Sinus Carcinoma AJCC v8|Stage IVC Sinonasal Carcinoma AJCC v8	Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)	Stage IVC Nasal Cavity and Paranasal Sinus Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133083>	C93302	LORETA Neurofeedback Training|LNFB Training|LORETA Neurofeedback|LORETA Z-score NFT|LORETA Z-score Neurofeedback Training|LORETA Z-score Training|LORETA-EEG-NFB|LZNFT|Low Resolution Electromagnetic Tomography Neurofeedback Training	A type of operant conditioning that uses real-time displays of EEG to illustrate brain activity and allow a subject to self-regulate brain EEG activity. The use of low resolution electromagnetic tomography allows neurofeedback directly on deep brain areas and functions.	LORETA Neurofeedback Training		Mental Process	CTRP Intervention Terminology|CTRP Terminology
C133084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133084>	C197908	GM2-Gangliosidosis, AB Variant|Tay-Sachs Disease, AB Variant	An autosomal recessive lysosomal storage disease caused by mutation(s) in the GM2A gene, encoding ganglioside GM2 activator. It is characterized by GM2-ganglioside accumulation in tissues resulting in hypotonia, cherry-red macular spots, and neurocognitive dysfunction.			Disease or Syndrome	Cellosaurus Disease Terminology
C133085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133085>	C4802	Brachial Amyotrophic Diplegia|BAD|FAS|Flail Arm Syndrome|MIBS|Man-in-barrel Syndrome	A neurodegenerative condition characterized by asymmetric weakness in the upper extremities resulting from segmental lower motor neuron dysfunction.			Disease or Syndrome	Cellosaurus Disease Terminology
C133086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133086>	C53543	Carnitine-Acylcarnitine Translocase Deficiency	An autosomal recessive condition caused by mutation(s) in the SLC25A20 gene, encoding mitochondrial carnitine/acylcarnitine carrier protein. It is characterized by cardiomyopathy, skeletal muscle damage, and liver dysfunction that results from derangement of long-chain fatty acid oxidation.			Disease or Syndrome	Cellosaurus Disease Terminology
C133087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133087>	C75467	Charcot-Marie-Tooth Disease, Type 3|CMT3|Dejerine-Sottas Neuropathy|HMSN3|Hereditary Motor and Sensory Neuropathy Type III|Hypertrophic Neuropathy of Dejerine-Sottas	A demyelinating peripheral neuropathy characterized by delayed motor development.			Disease or Syndrome	Cellosaurus Disease Terminology
C133088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133088>	C137802	Canine Globoid Cell Leukodystrophy	Globoid cell leukodystrophy that occurs in a dog.			Classification	Cellosaurus Disease Terminology
C133089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133089>	C134988	Hamster Melanoma	Melanoma that occurs in a hamster.			Neoplastic Process	Cellosaurus Disease Terminology
C13308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13308>	C13442	Hepatic|HEPATIC|hepatic	Pertaining to, affecting, or associated with the liver.			Body Location or Region	CDISC SEND Microscopic Findings Result Modifier Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C133090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133090>	C134988	Hamster Pancreatic Ductal Adenocarcinoma	Pancreatic ductal carcinoma that occurs in a hamster.			Neoplastic Process	Cellosaurus Disease Terminology
C133091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133091>	C6930|C4454	Lung Adenofibroma|Pulmonary Adenofibroma	A very rare benign neoplasm that arises from the lung. It is characterized by the presence of a stromal and an epithelial component. It resembles the adenofibromas that arise from the organs of the female reproductive system.			Neoplastic Process	
C133092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133092>	C5384|C5184|C170727	Recurrent Breast Angiosarcoma	The reemergence of breast angiosarcoma after a period of remission.			Neoplastic Process	
C133093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133093>	C8524|C127155	Locally Advanced Malignant Solid Neoplasm|Locally Advanced Malignant Solid Tumor|Locally Advanced Malignant Solid Tumor|Locally Advanced Solid Neoplasm|Locally Advanced Solid Tumor	A malignant solid neoplasm that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Malignant Solid Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133094>	C2124	Fluorine F 18 alphaVbeta6-Binding Peptide|18F-aVb6-BP|18F-alphaVbeta6-Binding Peptide|18F-alphaVbeta6-Binding-Peptide|Fluorine F 18-alphaVbeta6-Binding-Peptide	A radiotracer composed of a 20 amino acid peptide derived from the GH loop of an envelope protein (VP1) of the foot-and-mouth disease virus (FMDV), where the N-terminal lysine has been substituted with arginine, conjugated with two polyethylene glycol units and radiolabeled with fluorine 18, for potential positron emission tomography (PET) imaging of alphaVbeta6 integrin expression. Upon administration, the arginine-glycine-aspartic acid (RGD) motif within the peptide moiety of the fluorine 18 F alphaVbeta6-binding peptide selectively binds to alphaVbeta6 integrin. During PET imaging, alphaVbeta6-expressing tumor cells can be visualized and the degree of tumor growth can be determined. AlphaVbeta6 integrin, a cell adhesion and signaling receptor, is upregulated in certain cancers and has been associated with proliferation, migration and invasion of tumor cells.	Fluorine F 18 alphaVbeta6-Binding Peptide		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C133095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133095>	C9278|C7489	AIDS-Related Anal Canal Carcinoma|AIDS-Related Anal Canal Cancer	A carcinoma arising from the anal canal and occurring in HIV-positive patients.	AIDS-Related Anal Canal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133096>	C132632	Laryngeal Cancer TNM Finding v8|Laryngeal Carcinoma TNM Finding v8	A finding about one or more characteristics of laryngeal cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to the supraglottic, glottic, and subglottic laryngeal cancers. Nonepithelial cancers such as those of lymphoid tissue, soft tissue, bone, and cartilage are not included in this classification. (from AJCC 8th Ed.)			Finding	
C133097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133097>	C133096|C132633	Laryngeal Cancer Clinical TNM Finding v8|Laryngeal Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of laryngeal cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C133098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133098>	C133096|C132642	Laryngeal Cancer Pathologic TNM Finding v8|Laryngeal Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of laryngeal cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C133099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133099>	C133098	Supraglottic Cancer Pathologic Primary Tumor TNM Finding v8|Supraglottic Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of supraglottic cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C13309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13309>	C13442	Vaginal|vaginal	Of or relating to the vagina.			Qualitative Concept	EDQM Health Care Terminology|EDQM-HC Intended Site of Administration Terminology
C133100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133100>	C133099	Supraglottic Cancer pTX TNM Finding v8|Supraglottic Carcinoma pTX TNM Finding v8	Supraglottic cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C133101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133101>	C133099	Supraglottic Cancer pTis TNM Finding v8|Supraglottic Carcinoma pTis TNM Finding v8	Supraglottic cancer with a finding of carcinoma in situ. (from AJCC 8th Ed.)			Finding	
C133102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133102>	C133099	Supraglottic Cancer pT1 TNM Finding v8|Supraglottic Carcinoma pT1 TNM Finding v8	Supraglottic cancer with tumor limited to one subsite of supraglottis with normal vocal cord mobility. (from AJCC 8th Ed.)			Finding	
C133103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133103>	C133099	Supraglottic Cancer pT2 TNM Finding v8|Supraglottic Carcinoma pT2 TNM Finding v8	Supraglottic cancer with tumor invading the mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis (e.g., mucosa of base of the tongue, vallecula, medial wall of pyriform sinus) without fixation of the larynx. (from AJCC 8th Ed.)			Finding	
C133104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133104>	C133099	Supraglottic Cancer pT3 TNM Finding v8|Supraglottic Carcinoma pT3 TNM Finding v8	Supraglottic cancer with tumor limited to larynx with vocal cord fixation and/or invading any of the following: postcricoid area, preepiglottic space, paraglottic space, and/or inner cortex of thyroid cartilage. (from AJCC 8th Ed.)			Finding	
C133105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133105>	C133099	Supraglottic Cancer pT4 TNM Finding v8|Supraglottic Carcinoma pT4 TNM Finding v8	Supraglottic cancer with moderately advanced or very advanced disease. (from AJCC 8th Ed.)			Finding	
C133106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133106>	C133105	Supraglottic Cancer pT4a TNM Finding v8|Supraglottic Carcinoma pT4a TNM Finding v8	Supraglottic cancer with moderately advanced local disease. Tumor invades through the outer cortex of the thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck including deep extrinsic muscle of the tongue, strap muscles, thyroid, or esophagus). (from AJCC 8th Ed.)			Finding	
C133107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133107>	C133105	Supraglottic Cancer pT4b TNM Finding v8|Supraglottic Carcinoma pT4b TNM Finding v8	Supraglottic cancer with very advanced local disease. Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures. (from AJCC 8th Ed.)			Finding	
C133108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133108>	C133098	Glottic Cancer Pathologic Primary Tumor TNM Finding v8|Glottic Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of glottic cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C133109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133109>	C133108	Glottic Cancer pTX TNM Finding v8|Glottic Carcinoma pTX TNM Finding v8	Glottic cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C13310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13310>	C27993	Systemic|systemic	Affecting an entire system.			Conceptual Entity	AML Authorized Value Terminology|AML Total Dose Table|HL Authorized Value Terminology|HL Total Dose Table
C133110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133110>	C133108	Glottic Cancer pTis TNM Finding v8|Glottic Carcinoma pTis TNM Finding v8	Glottic cancer with a finding of carcinoma in situ. (from AJCC 8th Ed.)			Finding	
C133111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133111>	C133108	Glottic Cancer pT1 TNM Finding v8|Glottic Carcinoma pT1 TNM Finding v8	Glottic cancer with tumor limited to the vocal cord(s) (may involve anterior or posterior commissure) with normal mobility. (from AJCC 8th Ed.)			Finding	
C133112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133112>	C133111	Glottic Cancer pT1a TNM Finding v8|Glottic Carcinoma pT1a TNM Finding v8	Glottic cancer with tumor limited to one vocal cord. (from AJCC 8th Ed.)			Finding	
C133113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133113>	C133111	Glottic Cancer pT1b TNM Finding v8|Glottic Carcinoma pT1b TNM Finding v8	Glottic cancer with tumor involving both vocal cords. (from AJCC 8th Ed.)			Finding	
C133114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133114>	C133108	Glottic Cancer pT2 TNM Finding v8|Glottic Carcinoma pT2 TNM Finding v8	Glottic cancer with tumor extending to supraglottis and/or subglottis, and/or with impaired vocal cord mobility. (from AJCC 8th Ed.)			Finding	
C133115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133115>	C133108	Glottic Cancer pT3 TNM Finding v8|Glottic Carcinoma pT3 TNM Finding v8	Glottic cancer with tumor limited to the larynx with vocal cord fixation and /or invasion of paraglottic space, and/or inner cortex of the thyroid cartilage. (from AJCC 8th Ed.)			Finding	
C133116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133116>	C133108	Glottic Cancer pT4 TNM Finding v8|Glottic Carcinoma pT4 TNM Finding v8	Glottic cancer with moderately advanced or very advanced disease. (from AJCC 8th Ed.)			Finding	
C133117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133117>	C133116	Glottic Cancer pT4a TNM Finding v8|Glottic Carcinoma pT4a TNM Finding v8	Glottic cancer with moderately advanced local disease. Tumor invades through the outer cortex of the thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, cricoid cartilage, soft tissues of neck including deep extrinsic muscle of the tongue, strap muscles, thyroid, or esophagus). (from AJCC 8th Ed.)			Finding	
C133118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133118>	C133116	Glottic Cancer pT4b TNM Finding v8|Glottic Carcinoma pT4b TNM Finding v8	Glottic cancer with very advanced local disease. Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures. (from AJCC 8th Ed.)			Finding	
C133119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133119>	C133098	Subglottic Cancer Pathologic Primary Tumor TNM Finding v8|Subglottic Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of subglottic cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C13311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13311>	C13442	Vascular|VASCULAR	Relating to or containing blood vessels.			Qualitative Concept	CDISC SEND Microscopic Findings Result Modifier Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C133120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133120>	C133119	Subglottic Cancer pTX TNM Finding v8|Subglottic Carcinoma pTX TNM Finding v8	Subglottic cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C133121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133121>	C133119	Subglottic Cancer pTis TNM Finding v8|Subglottic Carcinoma pTis TNM Finding v8	Subglottic cancer with a finding of carcinoma in situ. (from AJCC 8th Ed.)			Finding	
C133122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133122>	C133119	Subglottic Cancer pT1 TNM Finding v8|Subglottic Carcinoma pT1 TNM Finding v8	Subglottic cancer in which the tumor is limited to the subglottis. (from AJCC 8th Ed.)			Finding	
C133123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133123>	C133119	Subglottic Cancer pT2 TNM Finding v8|Subglottic Carcinoma pT2 TNM Finding v8	Subglottic cancer with tumor extending to vocal cord(s) with normal or impaired mobility. (from AJCC 8th Ed.)			Finding	
C133124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133124>	C133119	Subglottic Cancer pT3 TNM Finding v8|Subglottic Carcinoma pT3 TNM Finding v8	Subglottic cancer with tumor limited to the larynx with vocal cord fixation and/or invasion of paraglottic space and/or inner cortex of the thyroid cartilage. (from AJCC 8th Ed.)			Finding	
C133125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133125>	C133119	Subglottic Cancer pT4 TNM Finding v8|Subglottic Carcinoma pT4 TNM Finding v8	Subglottic cancer with moderately advanced or very advanced disease. (from AJCC 8th Ed.)			Finding	
C133126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133126>	C133125	Subglottic Cancer pT4a TNM Finding v8|Subglottic Carcinoma pT4a TNM Finding v8	Subglottic cancer with moderately advanced local disease. Tumor invades cricoid or thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck including deep extrinsic muscles of the tongue, strap muscles, thyroid, or esophagus). (from AJCC 8th Ed.)			Finding	
C133127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133127>	C133125	Subglottic Cancer pT4b TNM Finding v8|Subglottic Carcinoma pT4b TNM Finding v8	Subglottic cancer with very advanced local disease. Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures. (from AJCC 8th Ed.)			Finding	
C133128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133128>	C133097	Laryngeal Cancer Clinical Regional Lymph Nodes TNM Finding v8|Laryngeal Carcinoma Clinical Regional Lymph Nodes TNM Finding v8	A clinical finding about one or more characteristics of laryngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C133129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133129>	C133128	Laryngeal Cancer cNX TNM Finding v8|Laryngeal Carcinoma cNX TNM Finding v8	Laryngeal cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C13312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13312>	C32530	Gap Junction|Communicating Junction|Low-resistance Junction|Nexus|Nexus Junction	Intercellular connections comprised of complexes of connexin family proteins that permit the transfer of cytoplasmic ions and molecules between connected cells. Each cell contains a hemichannel made up of homo- or hetero-hexamers of connexins.			Cell Component	
C133130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133130>	C133128	Laryngeal Cancer cN0 TNM Finding v8|Laryngeal Carcinoma cN0 TNM Finding v8	Laryngeal cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)			Finding	
C133131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133131>	C133128	Laryngeal Cancer cN1 TNM Finding v8|Laryngeal Carcinoma cN1 TNM Finding v8	Laryngeal cancer with metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C133132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133132>	C133128	Laryngeal Cancer cN2 TNM Finding v8|Laryngeal Carcinoma cN2 TNM Finding v8	Laryngeal cancer with metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-); or metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C133133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133133>	C133132	Laryngeal Cancer cN2a TNM Finding v8|Laryngeal Carcinoma cN2a TNM Finding v8	Laryngeal cancer with metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C133134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133134>	C133132	Laryngeal Cancer cN2b TNM Finding v8|Laryngeal Carcinoma cN2b TNM Finding v8	Laryngeal cancer with metastases in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C133135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133135>	C133132	Laryngeal Cancer cN2c TNM Finding v8|Laryngeal Carcinoma cN2c TNM Finding v8	Laryngeal cancer with metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C133136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133136>	C133128	Laryngeal Cancer cN3 TNM Finding v8|Laryngeal Carcinoma cN3 TNM Finding v8	Laryngeal cancer with metastasis in a lymph node, more than 6 cm in greatest dimension and ENE(-); or metastasis in any lymph node(s) with clinically overt ENE(+). (from AJCC 8th Ed.)			Finding	
C133137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133137>	C133136	Laryngeal Cancer cN3a TNM Finding v8|Laryngeal Carcinoma cN3a TNM Finding v8	Laryngeal cancer with metastasis in a lymph node, more than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C133138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133138>	C133136	Laryngeal Cancer cN3b TNM Finding v8|Laryngeal Carcinoma cN3b TNM Finding v8	Laryngeal cancer with metastasis in any lymph node(s) with clinically overt ENE(+). (from AJCC 8th Ed.)			Finding	
C133139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133139>	C133098	Laryngeal Cancer Pathologic Regional Lymph Nodes TNM Finding v8|Laryngeal Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of laryngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C13313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13313>	C13425	Helix-Loop-Helix Domain|HLH Domain|HLH Motif|Helix-Loop-Helix Motif	In transcription regulators of cell cycle control, cell determination, and cell differentiation, the conserved HLH (Helix-Loop-Helix) Domain of 40-50 amino acids forms amphipathic helixes between a variable loop. HLHs typically mediate homo- or heterodimerization through interactions with self or other motifs to activate or inactivate trans-activating function. The N-helix often contains DNA-interacting basic residues; the C-helix typically contains characteristically spaced hydrophobic residues. An adjacent basic region of 15 amino acids in most HLH proteins binds to DNA. Basic (b)HLH proteins bind variants of the 'CANNTG' E-box. Proteins lacking the basic domain act as inhibitors, failing to bind DNA. bHLH proteins exhibit specific dimerization partner combinations. In calcium-binding proteins, certain invariant hydrophilic loop residues in the HLH motif bind calcium. (NCI)			Amino Acid Sequence	
C133140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133140>	C133139	Laryngeal Cancer pNX TNM Finding v8|Laryngeal Carcinoma pNX TNM Finding v8	Laryngeal cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C133141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133141>	C133139	Laryngeal Cancer pN0 TNM Finding v8|Laryngeal Carcinoma pN0 TNM Finding v8	Laryngeal cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)			Finding	
C133142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133142>	C133139	Laryngeal Cancer pN1 TNM Finding v8|Laryngeal Carcinoma pN1 TNM Finding v8	Laryngeal cancer with metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C133143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133143>	C133139	Laryngeal Cancer pN2 TNM Finding v8|Laryngeal Carcinoma pN2 TNM Finding v8	Laryngeal cancer with metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(+); or metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-); or metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C133144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133144>	C133143	Laryngeal Cancer pN2a TNM Finding v8|Laryngeal Carcinoma pN2a TNM Finding v8	Laryngeal cancer with metastasis in a single ipsilateral or contralateral lymph node, 3 cm or less in greatest dimension and ENE(+); or metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C133145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133145>	C133143	Laryngeal Cancer pN2b TNM Finding v8|Laryngeal Carcinoma pN2b TNM Finding v8	Laryngeal cancer with metastases in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C133146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133146>	C133143	Laryngeal Cancer pN2c TNM Finding v8|Laryngeal Carcinoma pN2c TNM Finding v8	Laryngeal cancer with metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C133147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133147>	C133139	Laryngeal Cancer pN3 TNM Finding v8|Laryngeal Carcinoma pN3 TNM Finding v8	Laryngeal cancer with metastasis in a lymph node, more than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral lymph node, more than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+). (from AJCC 8th Ed.)			Finding	
C133148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133148>	C133147	Laryngeal Cancer pN3a TNM Finding v8|Laryngeal Carcinoma pN3a TNM Finding v8	Laryngeal cancer with metastasis in a lymph node, more than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C133149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133149>	C133147	Laryngeal Cancer pN3b TNM Finding v8|Laryngeal Carcinoma pN3b TNM Finding v8	Laryngeal cancer with metastasis in a single ipsilateral lymph node, more than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+). (from AJCC 8th Ed.)			Finding	
C13314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13314>	C13282	Proteasome|Proteosome	Proteolytic complexes, proteolytic core of the proteasome system, that degrade cytosolic and nuclear proteins are implicated in ATP dependent ubiquitin protein complex degradation and in antigen processing in antigen presenting cells. The 20S proteasome (700 kD), essential in ATP ubiquitin degradation pathway, has 13-15 subunits each of which has three or four different peptidase activities. The 20S proteasome interacts with additional subunits, PA700 and PA28, to form an ATP-dependent multicatalytic proteinase complex (MPC) involved in the degradation of ubiquitinated cellular proteins and certain non-ubiquitinated proteins. 26S proteasomes may be formed in an ATP dependent fashion from a 20S proteasome and additional components, CF1 (660 kD), CF2 (250 kD) and CF3 (600 kD).			Amino Acid, Peptide, or Protein|Cell Component|Enzyme	Pediatric Oncology Biomarkers/Targets Associated with Other Relevant Evidence
C133150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133150>	C133097	Laryngeal Cancer Clinical Distant Metastasis TNM Finding v8|Laryngeal Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of laryngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C133151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133151>	C133150	Laryngeal Cancer cM0 TNM Finding v8|Laryngeal Carcinoma cM0 TNM Finding v8	Laryngeal cancer without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C133152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133152>	C133150	Laryngeal Cancer cM1 TNM Finding v8|Laryngeal Carcinoma cM1 TNM Finding v8	Laryngeal cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C133153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133153>	C133098	Laryngeal Cancer Pathologic Distant Metastasis TNM Finding v8|Laryngeal Carcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of laryngeal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C133154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133154>	C133153	Laryngeal Cancer pM1 TNM Finding v8|Laryngeal Carcinoma pM1 TNM Finding v8	Laryngeal cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C133155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133155>	C36541|C36327	Gene Rearrangement Abnormality|Abnormal Gene Rearrangement|Abnormal Rearrangement|Gene Rearrangement	A molecular abnormality characterized by rearrangement of a gene sequence that results in either aberrant gene expression or the translation of a novel protein.			Cell or Molecular Dysfunction	
C133156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133156>	C4855	Laryngeal Cancer by AJCC v8 Stage|Laryngeal Carcinoma by AJCC v8 Stage	A term that refers to the staging of laryngeal carcinoma according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C133158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133158>	C133156	Stage I Laryngeal Cancer AJCC v8|Stage I Laryngeal Carcinoma AJCC v8|Stage I Laryngeal Throat Cancer	Stage I includes: T1, N0, M0. T1: Supraglottis: Tumor is limited to one subsite of supraglottis with normal vocal cord mobility. Glottis: Tumor is limited to the vocal cord(s) (may involve anterior or posterior commissure) with normal mobility. Subglottis: Tumor is limited to the subglottis. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Laryngeal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133159>	C133156	Stage II Laryngeal Cancer AJCC v8|Stage II Laryngeal Carcinoma AJCC v8|Stage II Laryngeal Throat Cancer	Stage II includes: T2, N0, M0. T2: Supraglottis: Tumor invades the mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis (e.g., mucosa of base of the tongue, vallecula, medial wall of pyriform sinus) without fixation of the larynx. Glottis: Tumor extends to supraglottis and/or subglottis, and/or with impaired vocal cord mobility. Subglottis: Tumor extends to vocal cord(s) with normal or impaired mobility. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Laryngeal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13315>	C13442	Epithelial|EPITHELIAL|epithelial	A term that refers to the cells that make up the epithelial tissues.  They are found in the skin, and in the parenchyma, surface and lumen of internal organs.			Body System	CDISC SEND Microscopic Findings Result Modifier Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C133160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133160>	C133156	Stage III Laryngeal Cancer AJCC v8|Stage III Laryngeal Carcinoma AJCC v8|Stage III Laryngeal Throat Cancer	Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T3: Supraglottis: Tumor is limited to larynx with vocal cord fixation and/or invades any of the following: postcricoid area, preepiglottic space, paraglottic space, and/or inner cortex of thyroid cartilage. Glottis: Tumor is limited to the larynx with vocal cord fixation and /or invades the paraglottic space, and/or inner cortex of the thyroid cartilage. Subglottis: Tumor is limited to the larynx with vocal cord fixation and/or invades the paraglottic space and/or inner cortex of the thyroid cartilage. T1: Supraglottis: Tumor is limited to one subsite of supraglottis with normal vocal cord mobility. Glottis: Tumor is limited to the vocal cord(s) (may involve anterior or posterior commissure) with normal mobility. Subglottis: Tumor is limited to the subglottis. T2: Supraglottis: Tumor invades the mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis (e.g., mucosa of base of the tongue, vallecula, medial wall of pyriform sinus) without fixation of the larynx. Glottis: Tumor extends to supraglottis and/or subglottis, and/or with impaired vocal cord mobility. Subglottis: Tumor extends to vocal cord(s) with normal or impaired mobility. N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(-). M0: No distant metastasis. (AJCC 8th ed.)	Stage III Laryngeal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133161>	C133156	Stage IV Laryngeal Cancer AJCC v8|Stage IV Laryngeal Carcinoma AJCC v8|Stage IV Laryngeal Throat Cancer	Stage IV includes: IVA: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0); IVB: (Any T, N3, M0); (T4b, Any N, M0); IVC: (Any T, Any N, M1). T4a: Supraglottis: Moderately advanced local disease. Tumor invades through the outer cortex of the thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck including deep extrinsic muscle of the tongue, strap muscles, thyroid, or esophagus). Glottis: Moderately advanced local disease. Tumor invades through the outer cortex of the thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, cricoid cartilage, soft tissues of neck including deep extrinsic muscle of the tongue, strap muscles, thyroid, or esophagus). Subglottis: Moderately advanced local disease. Tumor invades cricoid or thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck including deep extrinsic muscles of the tongue, strap muscles, thyroid, or esophagus). T3: Supraglottis: Tumor is limited to larynx with vocal cord fixation and/or invades any of the following: postcricoid area, preepiglottic space, paraglottic space, and/or inner cortex of thyroid cartilage. Glottis: Tumor is limited to the larynx with vocal cord fixation and /or invades the paraglottic space, and/or inner cortex of the thyroid cartilage. Subglottis: Tumor is limited to the larynx with vocal cord fixation and/or invades the paraglottic space and/or inner cortex of the thyroid cartilage. T1: Supraglottis: Tumor is limited to one subsite of supraglottis with normal vocal cord mobility. Glottis: Tumor is limited to the vocal cord(s) (may involve anterior or posterior commissure) with normal mobility. Subglottis: Tumor is limited to the subglottis. T2: Supraglottis: Tumor invades the mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis (e.g., mucosa of base of the tongue, vallecula, medial wall of pyriform sinus) without fixation of the larynx. Glottis: Tumor extends to supraglottis and/or subglottis, and/or with impaired vocal cord mobility. Subglottis: Tumor extends to vocal cord(s) with normal or impaired mobility. T4b: Supraglottis: Very advanced local disease. Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures. Glottis: Very advanced local disease. Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures. Subglottis: Very advanced local disease. Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures. N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(-). N2: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(+); or metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-); or metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-). N3: metastasis in a lymph node, more than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral lymph node, more than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+). M0: No distant metastasis. M1: distant metastasis. (AJCC 8th ed.)	Stage IV Laryngeal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133162>	C133161	Stage IVA Laryngeal Cancer AJCC v8|Stage IVA Laryngeal Carcinoma AJCC v8|Stage IVA Laryngeal Throat Cancer	Stage IVA includes: (T4a, N0, M0); (T4a, N1, M0); (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4a, N2, M0). T4a: Supraglottis: Moderately advanced local disease. Tumor invades through the outer cortex of the thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck including deep extrinsic muscle of the tongue, strap muscles, thyroid, or esophagus). Glottis: Moderately advanced local disease. Tumor invades through the outer cortex of the thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, cricoid cartilage, soft tissues of neck including deep extrinsic muscle of the tongue, strap muscles, thyroid, or esophagus). Subglottis: Moderately advanced local disease. Tumor invades cricoid or thyroid cartilage and/or invades tissues beyond the larynx (e.g., trachea, soft tissues of neck including deep extrinsic muscles of the tongue, strap muscles, thyroid, or esophagus). T3: Supraglottis: Tumor is limited to larynx with vocal cord fixation and/or invades any of the following: postcricoid area, preepiglottic space, paraglottic space, and/or inner cortex of thyroid cartilage. Glottis: Tumor is limited to the larynx with vocal cord fixation and /or invades the paraglottic space, and/or inner cortex of the thyroid cartilage. Subglottis: Tumor is limited to the larynx with vocal cord fixation and/or invades the paraglottic space and/or inner cortex of the thyroid cartilage. T1: Supraglottis: Tumor is limited to one subsite of supraglottis with normal vocal cord mobility. Glottis: Tumor is limited to the vocal cord(s) (may involve anterior or posterior commissure) with normal mobility. Subglottis: Tumor is limited to the subglottis. T2: Supraglottis: Tumor invades the mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis (e.g., mucosa of base of the tongue, vallecula, medial wall of pyriform sinus) without fixation of the larynx. Glottis: Tumor extends to supraglottis and/or subglottis, and/or with impaired vocal cord mobility. Subglottis: Tumor extends to vocal cord(s) with normal or impaired mobility. N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(-). N2: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension and ENE(+); or metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-); or metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension and ENE(-). M0: No distant metastasis. (AJCC 8th ed.)	Stage IVA Laryngeal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133163>	C133161	Stage IVB Laryngeal Cancer AJCC v8|Stage IVB Laryngeal Carcinoma AJCC v8|Stage IVB Laryngeal Throat Cancer	Stage IVB includes: (Any T, N3, M0); (T4b, Any N, M0). T4b: Supraglottis: Very advanced local disease. Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures. Glottis: Very advanced local disease. Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures. Subglottis: Very advanced local disease. Tumor invades prevertebral space, encases carotid artery, or invades mediastinal structures. N3: Metastasis in a lymph node, more than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral lymph node, more than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+). M0: No distant metastasis. (AJCC 8th ed.)	Stage IVB Laryngeal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133164>	C133161	Stage IVC Laryngeal Cancer AJCC v8|Stage IVC Laryngeal Carcinoma AJCC v8|Stage IVC Laryngeal Throat Cancer	Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)	Stage IVC Laryngeal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133165>	C133155	Polyclonal Gene Rearrangement	DNA sequence rearrangements that result in the creation of multiple immunoglobulins or T-cell receptors being expressed in a lymphocyte population.			Cell or Molecular Dysfunction	
C133166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133166>	C36333	Clonal Rearrangement, Single Peak	DNA sequence rearrangements that are detected or characterized by presence of a single type of protein molecule in a cell population.			Cell or Molecular Dysfunction	
C133167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133167>	C133165	Clonal Rearrangement, Multiple Peaks	DNA sequence rearrangements that are detected or characterized by presence of multiple types of protein molecules in a cell population.			Cell or Molecular Dysfunction	
C133168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133168>	C132632	Head and Neck Mucosal Melanoma TNM Finding v8|Mucosal Melanoma of the Head and Neck TNM Finding v8	A finding about one or more characteristics of mucosal melanoma of the head and neck, following the rules of the TNM AJCC v8 classification system. It applies to mucosal melanomas arising in the nasal cavity, paranasal sinuses, oral cavity, oropharynx, nasopharynx, larynx, and hypopharynx. No prognostic stage grouping is proposed in AJCC 8th edition. (from AJCC 8th Ed.)			Finding	
C133169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133169>	C133168|C132633	Head and Neck Mucosal Melanoma Clinical TNM Finding v8|Mucosal Melanoma of the Head and Neck Clinical TNM Finding v8	A clinical finding about one or more characteristics of mucosal melanoma of the head and neck, following the rules of the TNM AJCC v8 classification system.			Finding	
C13316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13316>	C13442	Cutaneous|cutaneous	Involving the skin.			Spatial Concept	EDQM Health Care Terminology|EDQM-HC Intended Site of Administration Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table
C133170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133170>	C133169	Head and Neck Mucosal Melanoma Clinical Distant Metastasis TNM Finding v8|Mucosal Melanoma of the Head and Neck Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of mucosal melanoma of the head and neck, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C133171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133171>	C133170	Head and Neck Mucosal Melanoma cM0 TNM Finding v8|Mucosal Melanoma of the Head and Neck cM0 TNM Finding v8	Mucosal melanoma of the head and neck without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C133172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133172>	C133170	Head and Neck Mucosal Melanoma cM1 TNM Finding v8|Mucosal Melanoma of the Head and Neck cM1 TNM Finding v8	Mucosal melanoma of the head and neck with distant metastasis. (from AJCC 8th Ed.)			Finding	
C133173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133173>	C133168|C132642	Head and Neck Mucosal Melanoma Pathologic TNM Finding v8|Mucosal Melanoma of the Head and Neck Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of mucosal melanoma of the head and neck, following the rules of the TNM AJCC v8 classification system.			Finding	
C133174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133174>	C137990	Mcl-1 Inhibitor MIK665|MIK 665|MIK-665|MIK-665|MIK665|S 64315|S-64315|S64315	An inhibitor of induced myeloid leukemia cell differentiation protein (Mcl-1; Bcl2-L-3), with potential pro-apoptotic and antineoplastic activities. Upon administration, MIK665 binds to and inhibits the activity of Mcl-1, which promotes apoptosis of cells overexpressing Mcl-1. Mcl-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival.	Mcl-1 Inhibitor MIK665		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C133175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133175>	C133173	Head and Neck Mucosal Melanoma Pathologic Distant Metastasis TNM Finding v8|Mucosal Melanoma of the Head and Neck Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of mucosal melanoma of the head and neck, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C133176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133176>	C133175	Head and Neck Mucosal Melanoma pM1 TNM Finding v8|Mucosal Melanoma of the Head and Neck pM1 TNM Finding v8	Mucosal melanoma of the head and neck with distant metastasis. (from AJCC 8th Ed.)			Finding	
C133177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133177>	C133173	Head and Neck Mucosal Melanoma Pathologic Primary Tumor TNM Finding v8|Mucosal Melanoma of the Head and Neck Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of mucosal melanoma of the head and neck, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C133178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133178>	C133177	Head and Neck Mucosal Melanoma pT3 TNM Finding v8|Mucosal Melanoma of the Head and Neck pT3 TNM Finding v8	Mucosal melanoma of the head and neck with tumor limited to the mucosa and immediately underlying soft tissue, regardless of thickness or greatest dimension; for example, polypoid nasal disease, pigmented or nonpigmented lesions of the oral cavity, pharynx, or larynx. (from AJCC 8th Ed.)			Finding	
C133179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133179>	C133177	Head and Neck Mucosal Melanoma pT4 TNM Finding v8|Mucosal Melanoma of the Head and Neck pT4 TNM Finding v8	Mucosal melanoma of the head and neck with moderately advanced or very advanced disease. (from AJCC 8th Ed.)			Finding	
C13317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13317>	C38465	Hair Follicle|Follicles|HAIR FOLLICLE|Hair Follicles|hair follicle	A tube-like invagination of the epidermis from which the hair shaft develops and into which the sebaceous glands open; the follicle is lined by a cellular inner and outer root sheath of epidermal origin and is invested with a fibrous sheath derived from the dermis.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C133180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133180>	C133179	Head and Neck Mucosal Melanoma pT4a TNM Finding v8|Mucosal Melanoma of the Head and Neck pT4a TNM Finding v8	Mucosal melanoma of the head and neck with moderately advanced disease. Tumor involves deep soft tissue, cartilage, bone, or overlying skin. (from AJCC 8th Ed.)			Finding	
C133181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133181>	C133179	Head and Neck Mucosal Melanoma pT4b TNM Finding v8|Mucosal Melanoma of the Head and Neck pT4b TNM Finding v8	Mucosal melanoma of the head and neck with very advanced disease. Tumor involves brain, dura, skull base, lower cranial nerves (IX, X, XI, XII), masticator space, carotid artery, prevertebral space, or mediastinal structures. (from AJCC 8th Ed.)			Finding	
C133182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133182>	C133173	Head and Neck Mucosal Melanoma Pathologic Regional Lymph Nodes TNM Finding v8|Mucosal Melanoma of the Head and Neck Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of mucosal melanoma of the head and neck, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C133183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133183>	C133182	Head and Neck Mucosal Melanoma pNX TNM Finding v8|Mucosal Melanoma of the Head and Neck pNX TNM Finding v8	Mucosal melanoma of the head and neck in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)			Finding	
C133184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133184>	C133182	Head and Neck Mucosal Melanoma pN0 TNM Finding v8|Mucosal Melanoma of the Head and Neck pN0 TNM Finding v8	Mucosal melanoma of the head and neck with no metastases to regional lymph nodes. (from AJCC 8th Ed.)			Finding	
C133185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133185>	C133182	Head and Neck Mucosal Melanoma pN1 TNM Finding v8|Mucosal Melanoma of the Head and Neck pN1 TNM Finding v8	Mucosal melanoma of the head and neck with regional lymph node metastases. (from AJCC 8th Ed.)			Finding	
C133186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133186>	C133187	Head and Neck Mucosal Melanoma by AJCC v7 Stage	A term that refers to the staging of mucosal melanoma of the head and neck according to the American Joint Committee on Cancer, 7th edition. No prognostic stage grouping is proposed in the 8th edition.			Neoplastic Process	
C133187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133187>	C214952|C173488|C114828	Head and Neck Mucosal Melanoma|Mucosal Melanoma of the Head and Neck|Mucosal Melanoma of the Head and Neck	A melanoma that arises from the mucosa of the nasal cavity, paranasal sinuses, oral cavity, oropharynx, nasopharynx, hypopharynx, and larynx.	Mucosal Melanoma of the Head and Neck		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133188>	C61512	Dose Expansion Cohort|DEC	A group of subjects in a phase I trial, usually accrued after the maximum tolerated dose maximum tolerated dose has been established. These subjects, often with additional eligibility criteria, are used to: confirm that a safe level of drug exposure has been established, obtain preliminary evidence of efficacy, and identify specific patient subgroups that might derive particular benefits from the investigational treatment.			Population Group	
C133189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133189>	C200766|C176018	Autologous EGFRt/19-28z/4-1BBL CAR T-Lymphocytes|Autologous EGFRt/19-28z/4-1BBL CAR T Cells|CD19-Targeted EGFRt/19-28z/4-1BBL "Armored" CAR Modified T Cells|CD19-Targeted EGFRt/19-28z/4-1BBL "Armored" Chimeric Antigen Receptor Modified T-Cells	Genetically modified autologous T-lymphocytes transduced with a replication incompetent retroviral vector expressing both tumor necrosis factor ligand superfamily (TNFSF) member 9 (TNFSF9; 4-1BBL) and a chimeric T cell antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment), fused to the extracellular, transmembrane and intracellular signaling domains of the T-cell co-stimulatory receptor CD28, the cytoplasmic signaling domain of the zeta chain of the TCR/CD3 complex (CD3-zeta) (19-28z), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous EGFRt/19-28z/4-1BBL CAR T-lymphocytes are directed to CD19-expressing tumor cells, which induces selective toxicity in CD19-expressing tumor cells. These cells also express 4-1BBL, a secreted protein and member of the TNFSF of growth factors, that induces proliferation of T-cells and may help reverse immunosuppression in the tumor environment. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. The CD28 co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19. The inclusion of the CD28 signaling domain may increase proliferation of T-cells and antitumor activity compared to the inclusion of the CD3-zeta chain alone. Devoid of both ligand binding domains and tyrosine kinase activity, EGFRt both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a cetuximab-induced antibody dependent cellular cytotoxicity (ADCC) response.	Autologous EGFRt/19-28z/4-1BBL CAR T-Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C13318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13318>	C33622	Transitional Epithelium	Stratified epithelium that changes shape from cuboidal to squamous when stretched without losing strength or consistency. This type of epithelium is found in the urinary tract.			Tissue	
C133190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133190>	C200225|C1511	Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10|APAMISTAMAB-B10-ASTATINE AT-211|Astatine 211-Labeled Anti-CD45 Monoclonal Antibody BC8-B10|Astatine At 211 MAb BC8-B10|At 211 Anti-CD45 Monoclonal Antibody BC8-B10|At 211 MAb BC8-B10	A radioimmunoconjugate containing the murine IgG1 anti-CD45 monoclonal antibody (MAb) BC8 where the lysine side groups have been conjugated with decaborate (closo-decaborate; B10) and labeled with astatine (At) 211, with potential immunotherapeutic activity. Astatine At 211 anti-CD45 monoclonal antibody BC8-B10 binds to CD45 antigen, a receptor protein-tyrosine phosphatase expressed on the surface of both normal and malignant hematopoietic cells. After binding and internalization by CD45-expressing tumor cells, this agent may deliver a cytotoxic dose of alpha radiation. Additionally, the radiolabel can be leveraged to assay the biodistribution and/or pharmacokinetics (absorption, distribution, metabolism and excretion) for this agent. The use of B10 rather than other labeling methods increases the therapeutic efficacy while decreasing the toxicity of the radioconjugate.	Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C133191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133191>	C200766|C176018	Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes|Anti-CD19-CAR Genetically Engineered Autologous T Lymphocytes huJCAR014|Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes huJCAR014|Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes|huJCAR014	A preparation of a defined ratio of CD4+ and bulk CD8+ autologous T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing a human anti-CD19 single chain variable fragment (scFv) fused to the signaling domain of 4-1BB (CD137), the zeta chain of the TCR/CD3 complex (CD3-zeta), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous human anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes are directed to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a cetuximab-induced antibody dependent cellular cytotoxicity (ADCC) response. The 4-1BB costimulatory signaling domain enhances both proliferation of T-cells and antitumor activity.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology
C133192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133192>	C8989|C8366|C7425	Oral Intraepithelial Neoplasia	A precancerous neoplastic process affecting the oral mucosa. It is characterized by the presence of dysplasia in the mucosal epithelium.	Oral Intraepithelial Neoplasia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133193>	C4815|C126465	Metastatic Thyroid Gland Carcinoma|Metastatic Thyroid Gland Cancer	Thyroid gland carcinoma that has spread from its original site of growth to another anatomic site.	Metastatic Thyroid Gland Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133194>	C132632	Head and Neck Cutaneous Squamous Cell Carcinoma TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck TNM Finding v8	A finding about one or more characteristics of cutaneous squamous cell carcinoma of the head and neck, following the rules of the TNM AJCC v8 classification system. It applies to cutaneous squamous cell carcinoma of the head and neck and all other nonmelanoma skin carcinomas of the head and neck (except Merkel cell carcinoma). It also applies to the adenocarcinomas that develop from eccrine or sebaceous glands and to the spindle cell variant of cutaneous squamous cell carcinoma. (from AJCC 8th Ed.)			Finding	
C133195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133195>	C133194|C132633	Head and Neck Cutaneous Squamous Cell Carcinoma Clinical TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck Clinical TNM Finding v8	A clinical finding about one or more characteristics of cutaneous squamous cell carcinoma of the head and neck, following the rules of the TNM AJCC v8 classification system.			Finding	
C133196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133196>	C133194|C132642	Head and Neck Cutaneous Squamous Cell Carcinoma Pathologic TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of cutaneous squamous cell carcinoma of the head and neck, following the rules of the TNM AJCC v8 classification system.			Finding	
C133197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133197>	C86930	Post Mastectomy Recovery Jacket|Jacki Recovery Jacket	A type of functional clothing designed to be worn over the torso during the recovery period following surgical removal of the breast, typically with built-in features to manage post-surgical drains and discomfort.	Post Mastectomy Recovery Jacket		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C133198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133198>	C133195	Head and Neck Cutaneous Squamous Cell Carcinoma Clinical Distant Metastasis TNM Finding v8|Clinical Staging: Distant Metastasis (cM)|Cutaneous Squamous Cell Carcinoma of the Head and Neck Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of cutaneous squamous cell carcinoma of the head and neck, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C133199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133199>	C133198	Head and Neck Cutaneous Squamous Cell Carcinoma cM0 TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck cM0 TNM Finding v8|cM0	Cutaneous squamous cell carcinoma of the head and neck without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C13319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13319>	C13018	Gland|Glandular|gland	An organ that produces and secretes hormones (e.g. endocrine gland), saliva or sweat (e.g. exocrine gland).			Body Part, Organ, or Organ Component	
C1331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1331>	C1968|C1931	Epipodophyllotoxin Compound|epipodophyllotoxin	An alkaloid isolated or derived synthetically from Podophyllum peltatum that can bind to and inhibit topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.			Chemical Viewed Functionally	
C133200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133200>	C133198	Head and Neck Cutaneous Squamous Cell Carcinoma cM1 TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck cM1 TNM Finding v8|cM1	Cutaneous squamous cell carcinoma of the head and neck with distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C133201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133201>	C133196	Head and Neck Cutaneous Squamous Cell Carcinoma Pathologic Distant Metastasis TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck Pathologic Distant Metastasis TNM Finding v8|Pathologic Staging: Distant Metastasis (pM)	A pathologic finding about one or more characteristics of cutaneous squamous cell carcinoma of the head and neck, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C133202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133202>	C133201	Head and Neck Cutaneous Squamous Cell Carcinoma pM1 TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck pM1 TNM Finding v8	Cutaneous squamous cell carcinoma of the head and neck with distant metastasis. (from AJCC 8th Ed.)			Finding	
C133203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133203>	C133196	Head and Neck Cutaneous Squamous Cell Carcinoma Pathologic Primary Tumor TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck Pathologic Primary Tumor TNM Finding v8|Pathologic Staging: Primary Tumor (pT)	A pathologic finding about one or more characteristics of cutaneous squamous cell carcinoma of the head and neck, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C133204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133204>	C133203	Head and Neck Cutaneous Squamous Cell Carcinoma pTX TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck pTX TNM Finding v8|pTX	Cutaneous squamous cell carcinoma of the head and neck in which the primary tumor cannot be identified. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C133205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133205>	C133203	Head and Neck Cutaneous Squamous Cell Carcinoma pTis TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck pTis TNM Finding v8|pTis	Cutaneous squamous cell carcinoma of the head and neck with a finding of carcinoma in situ. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C133206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133206>	C133203	Head and Neck Cutaneous Squamous Cell Carcinoma pT1 TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck pT1 TNM Finding v8|pT1	Cutaneous squamous cell carcinoma of the head and neck with tumor smaller than 2 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C133207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133207>	C133203	Head and Neck Cutaneous Squamous Cell Carcinoma pT2 TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck pT2 TNM Finding v8|pT2	Cutaneous squamous cell carcinoma of the head and neck with tumor 2 cm or larger, but smaller than 4 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C133208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133208>	C133203	Head and Neck Cutaneous Squamous Cell Carcinoma pT3 TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck pT3 TNM Finding v8|pT3	Cutaneous squamous cell carcinoma of the head and neck with tumor 4 cm or larger in greatest dimension or minor bone erosion or perineural invasion or deep invasion. Deep invasion is defined as invasion beyond the subcutaneous fat or larger than 6 mm; perineural invasion for T3 classification is defined as tumor cells within the nerve sheath of a nerve lying deeper than the dermis or measuring 0.1 mm or larger in caliber, or presenting with clinical or radiographic involvement of named nerves without skull base invasion or transgression.  (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C133209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133209>	C133203	Head and Neck Cutaneous Squamous Cell Carcinoma pT4 TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck pT4 TNM Finding v8|pT4	Cutaneous squamous cell carcinoma of the head and neck with gross cortical bone/marrow, skull base invasion and/or skull base foramen invasion.  (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C133210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133210>	C133209	Head and Neck Cutaneous Squamous Cell Carcinoma pT4a TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck pT4a TNM Finding v8|pT4a	Cutaneous squamous cell carcinoma of the head and neck with gross cortical bone/marrow invasion.  (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C133211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133211>	C133209	Head and Neck Cutaneous Squamous Cell Carcinoma pT4b TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck pT4b TNM Finding v8|pT4b	Cutaneous squamous cell carcinoma of the head and neck with skull base invasion and/or skull base foramen involvement.  (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C133212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133212>	C133195	Head and Neck Cutaneous Squamous Cell Carcinoma Clinical Regional Lymph Nodes TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck Clinical Regional Lymph Nodes TNM Finding v8	A clinical finding about one or more characteristics of cutaneous squamous cell carcinoma of the head and neck, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C133213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133213>	C133212	Head and Neck Cutaneous Squamous Cell Carcinoma cNX TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck cNX TNM Finding v8	Cutaneous squamous cell carcinoma of the head and neck in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)			Finding	
C133214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133214>	C133212	Head and Neck Cutaneous Squamous Cell Carcinoma cN0 TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck cN0 TNM Finding v8	Cutaneous squamous cell carcinoma of the head and neck without metastasis in the regional lymph nodes.  (from AJCC 8th Ed.)			Finding	
C133215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133215>	C133212	Head and Neck Cutaneous Squamous Cell Carcinoma cN1 TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck cN1 TNM Finding v8	Cutaneous squamous cell carcinoma of the head and neck with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-).  (from AJCC 8th Ed.)			Finding	
C133216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133216>	C133212	Head and Neck Cutaneous Squamous Cell Carcinoma cN2 TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck cN2 TNM Finding v8	Cutaneous squamous cell carcinoma of the head and neck with metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-).  (from AJCC 8th Ed.)			Finding	
C133217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133217>	C133216	Head and Neck Cutaneous Squamous Cell Carcinoma cN2a TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck cN2a TNM Finding v8	Cutaneous squamous cell carcinoma of the head and neck with metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C133218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133218>	C133216	Head and Neck Cutaneous Squamous Cell Carcinoma cN2b TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck cN2b TNM Finding v8	Cutaneous squamous cell carcinoma of the head and neck with metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-).  (from AJCC 8th Ed.)			Finding	
C133219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133219>	C133216	Head and Neck Cutaneous Squamous Cell Carcinoma cN2c TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck cN2c TNM Finding v8	Cutaneous squamous cell carcinoma of the head and neck with metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-).  (from AJCC 8th Ed.)			Finding	
C13321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13321>	C13236	Gastrointestinal Fluid or Secretion|Gastrointestinal Fluids and Secretions	Fluids and secretions within the passage leading from the mouth to the anus through the pharynx, esophagus, stomach, and intestine which cause digestion.			Body Substance	
C133220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133220>	C133212	Head and Neck Cutaneous Squamous Cell Carcinoma cN3 TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck cN3 TNM Finding v8	Cutaneous squamous cell carcinoma of the head and neck with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in any lymph node(s) and clinically overt ENE(+). (from AJCC 8th Ed.)			Finding	
C133221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133221>	C133220	Head and Neck Cutaneous Squamous Cell Carcinoma cN3a TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck cN3a TNM Finding v8	Cutaneous squamous cell carcinoma of the head and neck with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C133222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133222>	C133196	Head and Neck Cutaneous Squamous Cell Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of cutaneous squamous cell carcinoma of the head and neck, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C133223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133223>	C133222	Head and Neck Cutaneous Squamous Cell Carcinoma pNX TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck pNX TNM Finding v8	Cutaneous squamous cell carcinoma of the head and neck in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)			Finding	
C133224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133224>	C471	17beta-Hydroxysteroid Dehydrogenase Type 5 Inhibitor ASP9521|(4-(2-Hydroxy-2-methylpropyl)piperidin-1-yl)(5-methoxy-1H-indol-2-yl)methanone|17bHSD5 Inhibitor ASP9521|ASP 9521|ASP-9521|ASP9521	A selective, orally bioavailable inhibitor of 17beta-hydroxysteroid dehydrogenase type 5 (17bHSD5, aldo-keto reductase 1C3; AKR1C3), with potential antineoplastic activity. Upon administration, ASP9521 selectively binds to and inhibits the activity of 17bHSD5. This prevents the conversion of the adrenal androgens dehydroepiandrosterone and androstenedione into 5-androstenediol and testosterone. By blocking testosterone production, ASP9521 may inhibit the growth of testosterone-dependent cancers such as castration-resistant prostate cancer (CRPC). 17bHSD5, expressed both in normal prostate tissue and in prostate cancer (PC), plays a crucial role in persistent production of androgens despite castration; its expression is associated with increased malignancy of PC.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C133225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133225>	C133222	Head and Neck Cutaneous Squamous Cell Carcinoma pN0 TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck pN0 TNM Finding v8	Cutaneous squamous cell carcinoma of the head and neck without metastasis in the regional lymph nodes.  (from AJCC 8th Ed.)			Finding	
C133226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133226>	C133222	Head and Neck Cutaneous Squamous Cell Carcinoma pN1 TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck pN1 TNM Finding v8	Cutaneous squamous cell carcinoma of the head and neck with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-).  (from AJCC 8th Ed.)			Finding	
C133227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133227>	C2201|C129825	mTOR Inhibitor GDC-0349|(S)-1-ethyl-3-(4-(4-(3-methylmorpholino)-7-(oxetan-3-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)phenyl)urea|GDC 0349|GDC-0349|GDC-0349|GDC0349|RG7603	An orally bioavailable, ATP-competitive, tetrahydroquinazoline (THQ)-based inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. Upon administration, GDC-0349 selectively binds to and inhibits the activity of mTOR, which may result in both the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase belonging to the phosphatidylinositol-3 (PI3K) kinase-related kinase (PIKK) family, plays an important role in the PI3K/Akt/mTOR signaling pathway that regulates cell growth and proliferation, and its expression or activity is frequently dysregulated in human cancers.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C133228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133228>	C133222	Head and Neck Cutaneous Squamous Cell Carcinoma pN2 TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck pN2 TNM Finding v8	Cutaneous squamous cell carcinoma of the head and neck with metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-).  (from AJCC 8th Ed.)			Finding	
C133229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133229>	C133228	Head and Neck Cutaneous Squamous Cell Carcinoma pN2a TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck pN2a TNM Finding v8	Cutaneous squamous cell carcinoma of the head and neck with metastasis in a single ipsilateral or contralateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C13322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13322>	C13442	Endometrial|ENDOMETRIAL|endometrial	Relating to or composed of endometrium.			Body Location or Region	CDISC SEND Microscopic Findings Result Modifier Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C133230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133230>	C547	Avexitide|9-39-Exendin 4|AVEXITIDE|Ex(9-39)NH2|Exendin (9-39)|Exendin 3, 1-de-L-histidine-2-de-L-serine-3-de-L-aspartic acid-4-deglycine-5-de-L-threonine-6-de-L-phenylalanine-7-de-L-threonine-8-de-L-serine-|Exendin(9-39)amide|LYS-ASN-GIY-GIY-PRO-SER-SER-GIY-ALA-PRO-PRO-PRO-SER-NH2	A truncated form of the glucagon-like peptide 1 receptor (GLP-1R) agonist exendin-4 peptide, with GLP-1 receptor (GLP-1R) antagonistic and GLP-1R-mediated signaling inhibiting activities. Upon administration, avexitide competitively binds to and inhibits the activity of GLP-1R, thereby inhibiting GLP-1/GLP-1R-mediated signaling. This antagonizes the glucagonostatic and the insulinotropic effects of GLP-1. By abrogating GLP-1-mediated simulation of insulin release and reduction of glucagon secretion after food intake, exendin 9-39 may be used to help study the potential effects of overproduction of GLP-1 on food intake, weight loss and glucose levels. GLP-1R, located on pancreatic beta cells, is overexpressed on certain tumor cell types. GLP-1 is a gastrointestinal (GI) and insulinotropic hormone that is released after a meal and plays a key role in the regulation of blood glucose levels.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C133231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133231>	C133228	Head and Neck Cutaneous Squamous Cell Carcinoma pN2b TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck pN2b TNM Finding v8	Cutaneous squamous cell carcinoma of the head and neck with metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-).  (from AJCC 8th Ed.)			Finding	
C133232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133232>	C133228	Head and Neck Cutaneous Squamous Cell Carcinoma pN2c TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck pN2c TNM Finding v8	Cutaneous squamous cell carcinoma of the head and neck with metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-).  (from AJCC 8th Ed.)			Finding	
C133233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133233>	C133222	Head and Neck Cutaneous Squamous Cell Carcinoma pN3 TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck pN3 TNM Finding v8	Cutaneous squamous cell carcinoma of the head and neck with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes, any with ENE(+). (from AJCC 8th Ed.)			Finding	
C133234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133234>	C133233	Head and Neck Cutaneous Squamous Cell Carcinoma pN3a TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck pN3a TNM Finding v8	Cutaneous squamous cell carcinoma of the head and neck with metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-). (from AJCC 8th Ed.)			Finding	
C133235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133235>	C133233	Head and Neck Cutaneous Squamous Cell Carcinoma pN3b TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck pN3b TNM Finding v8	Cutaneous squamous cell carcinoma of the head and neck with metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes, any with ENE(+). (from AJCC 8th Ed.)			Finding	
C133236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133236>	C133220	Head and Neck Cutaneous Squamous Cell Carcinoma cN3b TNM Finding v8|Cutaneous Squamous Cell Carcinoma of the Head and Neck cN3b TNM Finding v8	Cutaneous squamous cell carcinoma of the head and neck with metastasis in any lymph node(s) and ENE(+). (from AJCC 8th Ed.)			Finding	
C133237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133237>	C20181	Encase|Enclose	To completely and closely surround.			Functional Concept	
C133238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133238>	C62554	Niraparib Tosylate Monohydrate|2H-Indazole-7-carboxamide, 2-(4-(3S)-3-piperidinylphenyl)-, 4-Methylbenzenesulfonate, Hydrate (1:1:1)|NIRAPARIB TOSYLATE|Niraparib Tosylate Hydrate|Zejula	An orally bioavailable, hydrated, tosylate salt form of niraparib, an inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2 (PARP-1 and -2), with antineoplastic activity. Upon administration, niraparib binds to and inhibits the activity of PARP-1 and -2, thereby inhibiting PARP-1 and -2-mediated DNA repair, enhancing the accumulation of DNA strand breaks, promoting genomic instability and resulting in apoptosis. The PARP family of proteins catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C13323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13323>	C13236	Vitreous Humor|VITREOUS HUMOR|Vitreous Fluid|Vitreous Fluid|vitreous humor	The clear colorless transparent jelly that fills the posterior chamber of the eyeball.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|mCode Genomic Specimen Type Value Set|mCode Terminology
C133240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133240>	C54452	SPL Blood Form Donor Type Terminology|Structured Product Labeling Blood Form Donor Type Terminology	Terminology used to qualify the information pertaining to blood form donor types in the framework of the Structured Product Labeling documents.			Intellectual Product	FDA Structured Product Labeling Terminology
C133241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133241>	C54452	SPL Blood Form Establishment Functions Terminology|Structured Product Labeling Blood Form Establishment Functions Terminology	Terminology used to qualify the information pertaining to establishment functions in the framework of the Structured Product Labeling documents.			Intellectual Product	FDA Structured Product Labeling Terminology
C133242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133242>	C54452	SPL Blood Form Establishment Type Terminology|Structured Product Labeling Blood Form Establishment Type Terminology	Terminology used to qualify the information pertaining to blood form establishments in the framework of the Structured Product Labeling documents.			Intellectual Product	FDA Structured Product Labeling Terminology
C133243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133243>	C54452	SPL Blood Form Product Type Terminology|Structured Product Labeling Blood Form Product Type Terminology	Terminology used to qualify the information pertaining to blood form product types in the framework of the Structured Product Labeling documents.			Intellectual Product	FDA Structured Product Labeling Terminology
C133245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133245>	C54452	SPL Blood Form Type of Ownership Terminology|Structured Product Labeling Blood Form Type of Ownership Terminology	Terminology used to qualify the information pertaining to blood forms types of ownership in the framework of the Structured Product Labeling documents.			Intellectual Product	FDA Structured Product Labeling Terminology
C133247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133247>	C54452	SPL Tissue Form Donor Type Terminology|Structured Product Labeling Tissue Form Donor Type Terminology	Terminology used to qualify the information pertaining to tissue form donor types in the framework of the Structured Product Labeling documents.			Intellectual Product	FDA Structured Product Labeling Terminology
C133248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133248>	C54452	SPL Tissue Form Establishment Functions Terminology|Structured Product Labeling Blood Form Establishment Functions	Terminology used to qualify the information pertaining to tissue form establishment functions in the framework of the Structured Product Labeling documents.			Intellectual Product	FDA Structured Product Labeling Terminology
C133249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133249>	C54452	SPL Tissue Form Establishment Type Terminology|Structured Product Labeling Tissue Form Establishment Type Terminology	Terminology used to qualify the information pertaining to tissue form establishment types in the framework of the Structured Product Labeling documents.			Intellectual Product	FDA Structured Product Labeling Terminology
C13324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13324>	C13442	Hematopoietic|HEMATOPOETIC	Pertaining to or related to the formation of blood cells.			Qualitative Concept	CDISC SEND Microscopic Findings Result Modifier Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C133250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133250>	C54452	SPL Tissue Form Product Type Terminology|Structured Product Labeling Tissue Form Product Type Terminology	Terminology used to qualify the information pertaining to tissue form product types in the framework of the Structured Product Labeling documents.			Intellectual Product	FDA Structured Product Labeling Terminology
C133251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133251>	C54452	SPL Tissue Form Product Group Terminology|Structured Product Labeling Tissue Form Product Group Terminology	Terminology used to qualify the information pertaining to tissue form product groups in the framework of the Structured Product Labeling documents.			Intellectual Product	FDA Structured Product Labeling Terminology
C133252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133252>	C4819|C34447|C213333	Head and Neck Cutaneous Squamous Cell Carcinoma|Cutaneous Squamous Cell Carcinoma of the Head and Neck|Cutaneous Squamous Cell Carcinoma of the Head and Neck	A squamous cell carcinoma that arises from the skin of the head and neck.			Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology
C133253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133253>	C133252	Head and Neck Cutaneous Squamous Cell Carcinoma by AJCC v8 Stage|Cutaneous Squamous Cell Carcinoma of the Head and Neck by AJCC v8 Stage|Tumor Stage (Pathological)	A term that refers to the staging of cutaneous squamous cell carcinoma of the head and neck according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C133254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133254>	C3493|C2926	Lung Non-Small Cell Squamous Carcinoma|Non-Small Cell Squamous Lung Cancer|Non-Small Cell Squamous Lung Carcinoma|Squamous Non-Small Cell Lung Carcinoma	A squamous cell carcinoma that arises from the lung. It is characterized by the presence of large malignant cells. It includes the clear cell and papillary variants of squamous cell carcinoma.	Non-Small Cell Squamous Lung Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133255>	C133253	Stage 0 Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8|Stage 0 Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8|Stage 0 Head and Neck Squamous Cell Cancer	Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0 Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133256>	C133253	Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8|Stage I|Stage I Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8|Stage I Head and Neck Squamous Cell Cancer	Stage I includes: T1, N0, M0. T1: Tumor smaller than 2 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133257>	C133253	Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8|Stage II|Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8|Stage II Head and Neck Squamous Cell Cancer	Stage II includes: T2, N0, M0. T2: Tumor 2 cm or larger, but smaller than 4 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133258>	C133253	Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8|Stage III|Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8|Stage III Head and Neck Squamous Cell Cancer	Stage III includes: (T3, N0, M0); (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T3: Tumor 4 cm or larger in greatest dimension or minor bone erosion or perineural invasion or deep invasion. Deep invasion is defined as invasion beyond the subcutaneous fat or larger than 6 mm; perineural invasion for T3 classification is defined as tumor cells within the nerve sheath of a nerve lying deeper than the dermis or measuring 0.1 mm or larger in caliber, or presenting with clinical or radiographic involvement of named nerves without skull base invasion or transgression. T1: Tumor smaller than 2 cm in greatest dimension.  T2: Tumor 2 cm or larger, but smaller than 4 cm in greatest dimension. N0: No regional lymph node metastasis. N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-). M0: No distant metastasis. (AJCC 8th ed.)	Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133259>	C133253	Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8|Stage IV|Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8|Stage IV Head and Neck Squamous Cell Cancer	Stage IV includes: (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (Any T, N3, M0); (T4, Any N, M0); (Any T, Any N, M1). T1: Tumor smaller than 2 cm in greatest dimension. T2: Tumor 2 cm or larger, but smaller than 4 cm in greatest dimension. T3: Tumor 4 cm or larger in greatest dimension or minor bone erosion or perineural invasion or deep invasion. Deep invasion is defined as invasion beyond the subcutaneous fat or larger than 6 mm; perineural invasion for T3 classification is defined as tumor cells within the nerve sheath of a nerve lying deeper than the dermis or measuring 0.1 mm or larger in caliber, or presenting with clinical or radiographic involvement of named nerves without skull base invasion or transgression. T4: Tumor with gross cortical bone/marrow, skull base invasion and/or skull base foramen invasion. N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-).  N3: Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral lymph node larger than 3 cm in greatest dimension and ENE(+); or metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes, any with ENE(+). M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C13325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13325>	C13236	Serum|SERUM|Sera|Sera|serum	The clear portion of the blood that remains after the removal of the blood cells and the clotting proteins.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C133260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133260>	C78311	Cryoprecipitated Antihemophilic Factor|Cryoprecipitated AHF|Cryoprecipitated AHF	A preparation containing antihemophilic factor obtained from a single unit of plasma.			Pharmacologic Substance	FDA Structured Product Labeling Terminology|SPL Blood Form Product Type Terminology
C133261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133261>	C13347	Bone Marrow Aspirate|BONE MARROW, LIQUID|Human Bone Marrow Aspirate	Aspirate from bone marrow.			Tissue	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|FDA Structured Product Labeling Terminology|GDC Terminology|GDC Value Terminology|SPL Tissue Form Product Type Terminology
C133262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133262>	C32725	Derived Placental Blood Cell|Human Placental Blood Derived Cells	Cells collected from placental blood.			Cell	FDA Structured Product Labeling Terminology|SPL Tissue Form Product Type Terminology
C133263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133263>	C51963	Cord Blood Bank|Cord blood bank	A facility whose primary operation is cord blood recovery, processing, and storage for future autologous use or use of the stem cells to treat other people.			Health Care Related Organization	FDA Structured Product Labeling Terminology|SPL Tissue Form Establishment Type Terminology
C133264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133264>	C51963	Hospital Blood Bank	A hospital (or facility located within a hospital) that routinely collects or processes whole blood or blood components.			Health Care Related Organization	FDA Structured Product Labeling Terminology|SPL Blood Form Establishment Type Terminology
C133265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133265>	C51963	Non-Hospital Community Blood Bank|Community (Non-Hospital) Blood Bank	A commercial or non-profit blood collection/processing facility, not located in a hospital, that may perform product testing and routinely distributes blood and/or blood products to one or more hospitals.			Health Care Related Organization	FDA Structured Product Labeling Terminology|SPL Blood Form Establishment Type Terminology
C133266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133266>	C81304	Plasma Product|Plasma	The fluid (noncellular) portion of the circulating blood, as distinguished from the serum that is the fluid portion of the blood.			Body Substance	FDA Structured Product Labeling Terminology|SPL Blood Form Product Type Terminology
C133267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133267>	C81304	Allogeneic Blood Product Donation|Allogeneic	Blood or blood product donations intended for transfusion to other than the donor.			Body Substance	FDA Structured Product Labeling Terminology|SPL Blood Form Donor Type Terminology
C133268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133268>	C81304	Autologous Blood Product Donation|Autologous	Blood or blood product donations intended for transfusion at a later time to the donor.			Body Substance	FDA Structured Product Labeling Terminology|SPL Blood Form Donor Type Terminology
C133269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133269>	C81304	Dedicated Blood Product Donation|Dedicated	Donations arranged by the collecting facility to support a specific recipient on a frequent basis.			Body Substance	FDA Structured Product Labeling Terminology|SPL Blood Form Donor Type Terminology
C13326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13326>	C13446	Metaphase Plate	The plane of the spindle approximately equidistant from the two poles along which the chromosomes are lined up during mitosis or meiosis.			Cell Component	
C133270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133270>	C81304	Designated Blood Product Donation|Designated	Donations from a donor called by the collecting facility to provide products for a specific recipient in some future therapeutic procedure, e.g. specifically matched blood for patients with antibodies.			Body Substance	FDA Structured Product Labeling Terminology|SPL Blood Form Donor Type Terminology
C133271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133271>	C81304	Diagnostic Use Designated Blood Product|Blood Products for Diagnostic Use	Whole blood, red blood cells, or platelets intended for diagnostic use.			Body Substance	FDA Structured Product Labeling Terminology|SPL Blood Form Product Type Terminology
C133272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133272>	C81304	Directed Blood Product Donation|Directed	Donations from a donor who presents to the collecting facility at the request of another person intending to provide products to be used by that person during some future therapeutic procedure.			Body Substance	FDA Structured Product Labeling Terminology|SPL Blood Form Donor Type Terminology
C133273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133273>	C81304	Granulocytes Product|Granulocytes	Granulocytes collected from a single donor and suspended in a specific volume of original plasma intended for patient infusion.			Body Substance	FDA Structured Product Labeling Terminology|SPL Blood Form Product Type Terminology
C133274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133274>	C81304	Human Peripheral or Cord Blood Cell Product|Human Peripheral And Cord Blood Cell Product	Cells from human blood or umbilical cord blood for transplantation or infusion.			Body Substance	FDA Structured Product Labeling Terminology|SPL Tissue Form Product Group Terminology
C133275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133275>	C15657	Blood Irradiation|Irradiated|Irradiated Blood Product	Irradiation of blood products before transfusion.			Therapeutic or Preventive Procedure	FDA Structured Product Labeling Terminology|SPL Blood Form Establishment Functions Terminology
C133276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133276>	C15657	Leukodepletion|Leukocyte poor blood preparation|Leukocytes Reduced|Leukocytes Reduced Blood Product|Leukodepleted|Leukoreduction	Processing of blood products before issue to remove leukocytes.			Therapeutic or Preventive Procedure	FDA Structured Product Labeling Terminology|SPL Blood Form Establishment Functions Terminology
C133277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133277>	C81304	Other Blood Form Product|Other	Another blood form product type other than the ones that are explicitly identified in this value set.			Body Substance	FDA Structured Product Labeling Terminology|SPL Blood Form Product Type Terminology
C133278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133278>	C81304	Platelets Product|Platelets|Platelets|Platelets|Platelets	Platelets collected from a single donor and suspended in a specified volume of original plasma.	Platelets Product		Body Substance	AML Authorized Value Terminology|AML Transfusion Medicine Procedures Table|CTRP Agent Terminology|CTRP Terminology|FDA Structured Product Labeling Terminology|HL Authorized Value Terminology|HL Transfusion Medicine Procedures Table|SPL Blood Form Product Type Terminology
C133279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133279>	C81304	Pooled Blood Products|Pooled	Individual components, e.g. cryoprecipitated antihemophilic factor (AHF), whole blood-derived platelet concentrates, that are combined using an aseptic technique.			Body Substance	FDA Structured Product Labeling Terminology|SPL Blood Form Establishment Functions Terminology
C13327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13327>	C13984	Hemidesmosome	Half desmosomes that occur on the basal surface of the stratum basalis of stratified squamous epithelium.			Cell Component	
C133280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133280>	C81304	Red Blood Cells Product|RBC|RBC|Red Blood Cells|Red Blood Cells	Red blood cells remaining after separating plasma from human blood, or collected by apheresis.			Body Substance	AML Authorized Value Terminology|AML Transfusion Medicine Procedures Table|FDA Structured Product Labeling Terminology|HL Transfusion Medicine Procedures Table|HL Variable Terminology|SPL Blood Form Product Type Terminology
C133281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133281>	C81304	Source Leukocytes|WBC	White blood cells intended as source material for further manufacturing use.			Body Substance	AML Authorized Value Terminology|AML Transfusion Medicine Procedures Table|FDA Structured Product Labeling Terminology|SPL Blood Form Product Type Terminology
C133282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133282>	C15657	Blood Product Pathogen Reduction|Pathogen Reduced	Exposure to a chemical and/or radiation based processing system intended to reduce the risk of transfusion-transmitted infections in blood and blood components.			Therapeutic or Preventive Procedure	FDA Structured Product Labeling Terminology|SPL Blood Form Establishment Functions Terminology
C133283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133283>	C133287	Human Cells, Tissues, and Cellular and Tissue-Based Products Communicable Disease Testing|HCT/P Communicable Disease Testing|Testing for Relevant Communicable Disease Agents and Diseases	Testing Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) donors for infectious diseases.			Laboratory Procedure	FDA Structured Product Labeling Terminology|SPL Tissue Form Establishment Functions Terminology
C133284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133284>	C84731	Human Cells, Tissues, and Cellular and Tissue-Based Products Packing|HCT/P Packing|Package	Placing Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) in containers that may or may not be in direct contact with the product.			Activity	FDA Structured Product Labeling Terminology|SPL Tissue Form Establishment Functions Terminology
C133285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133285>	C113056	Human Cells, Tissues, and Cellular and Tissue-Based Products Processing|HCT/P Processing|Process	Activities performed on Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) other than recovery, donor screening and testing, storage, labeling, packaging or distribution.			Activity	FDA Structured Product Labeling Terminology|SPL Tissue Form Establishment Functions Terminology
C133286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133286>	C113015	Human Cells, Tissues, and Cellular and Tissue-Based Products Recovery|HCT/P Recovery|Recover	Obtaining Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) from a human donor for use in a human recipient.			Activity	FDA Structured Product Labeling Terminology|SPL Tissue Form Establishment Functions Terminology
C133287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133287>	C204971	Human Cells, Tissues, and Cellular and Tissue-Based Products Screening|HCT/P Screening|Screen	To evaluate and screen Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) donors for communicable disease risks.			Activity	FDA Structured Product Labeling Terminology|SPL Tissue Form Establishment Functions Terminology
C133288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133288>	C179748	Human Cells, Tissues, and Cellular and Tissue-Based Products Storage|HCT/P Storage|Store	Holding Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) for future processing and/or distribution.			Activity	FDA Structured Product Labeling Terminology|SPL Tissue Form Establishment Functions Terminology
C133289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133289>	C45273	Human Cells, Tissues, and Cellular and Tissue-Based Products Distribution|Distribute|HCT/P Distribution	Conveyance or shipment of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) that has met all release criteria.			Activity	FDA Structured Product Labeling Terminology|SPL Tissue Form Establishment Functions Terminology
C13328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13328>	C34070	Caveola|Caveolae	A small pocket, vesicle, cave, or recess communicating with the outside of a cell and extending inward, indenting the cytoplasm and the cell membrane. Such caveolae may be pinched off to form free vesicles within the cytoplasm. They are considered to be sites of uptake of materials into the cell, expulsion of materials from the cell, or sites of addition or removal of cell (unit) membrane to or from the cell surface.			Cell Component	
C133290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133290>	C84732	Human Cells, Tissues, and Cellular and Tissue-Based Products Labeling|HCT/P Labeling|Label	Written information on the container or records that accompany Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps).			Activity	FDA Structured Product Labeling Terminology|SPL Tissue Form Establishment Functions Terminology
C133291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133291>	C133287|C113021	Human Cells, Tissues, and Cellular and Tissue-Based Products Microorganism Testing Only|HCT/P Microorganism Testing Only|Testing for Microorganisms Only	Testing a representative sample of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) to detect microorganisms is the only function performed by the establishment.			Laboratory Procedure	FDA Structured Product Labeling Terminology|SPL Tissue Form Establishment Functions Terminology
C133292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133292>	C15657	Store and Distribute to Others	Storage of products under controlled conditions for distribution to other firms.			Activity	FDA Structured Product Labeling Terminology|SPL Blood Form Establishment Functions Terminology
C133293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133293>	C15657	Whole Blood or Product Preparation|Prepare	The preparation of whole blood or any of its components.			Therapeutic or Preventive Procedure	FDA Structured Product Labeling Terminology|SPL Blood Form Establishment Functions Terminology
C133294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133294>	C15657	Whole Blood or Product Procurement|Collect	The procurement of whole blood or blood products for transfusion or further manufacturing into injectable or non-injectable products.			Health Care Activity	FDA Structured Product Labeling Terminology|SPL Blood Form Establishment Functions Terminology
C133295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133295>	C32222	Demineralized Bone Tissue|Human Demineralized Bone Matrix	Bone that has had most of the mineralized components removed while retaining collagen and noncollagenous proteins.			Tissue	FDA Structured Product Labeling Terminology|SPL Tissue Form Product Type Terminology
C133296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133296>	C101674	Human Cells, Tissues, and Cellular and Tissue-Based Products Not Specified Elsewhere|HCT/P Not Specified Elsewhere|Other Human, Cell and Tissue Products (HCT/Ps)	Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) not specified in other groups.			Qualitative Concept	FDA Structured Product Labeling Terminology|SPL Tissue Form Product Group Terminology
C133297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133297>	C211570	Fertility Clinic that Manufactures Human Cells, Tissues, and Cellular and Tissue-Based Products|Fertility Clinic that Manufactures HCT/P|Fertility clinic	Clinics that perform assisted reproductive technologies and manufacture reproductive Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps).			Health Care Related Organization	FDA Structured Product Labeling Terminology|SPL Tissue Form Establishment Type Terminology
C133298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133298>	C226693	None of the Above|None of the above	None of the choices above are suitable.			Intellectual Product	FDA Structured Product Labeling Terminology|SPL Tissue Form Establishment Type Terminology
C133299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133299>	C38186	Licensed Biologics Manufacturer|Manufacturer of Licensed Device	A licensed biologics manufacturing facility responsible for production and distribution of medical devices intended for use in the US.			Health Care Related Organization	FDA Structured Product Labeling Terminology|SPL Blood Form Establishment Type Terminology
C13329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13329>	C13230	Rough Endoplasmic Reticulum|Ergastoplasm|Granular Endoplasmic Reticulum|Rough ER|Rough-Surfaced Endoplasmic Reticulum|rER	Membrane organelle of eukaryotes that forms sheets and tubules. Contains the receptor for the signal receptor particle and binds ribosomes engaged in translating mRNA for secreted proteins and the majority of transmembrane proteins. Also a site of membrane lipid synthesis. The membrane is very similar to the nuclear outer membrane. The lumen contains a number of proteins that possess the C terminal signal KDEL.			Cell Component	
C1332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1332>	C67439|C443	Etidronic Acid|(1-Hydroxyethylidene)bisphosphonic Acid|(1-Hydroxyethylidene)diphosphonic Acid|EHDP|EHDP|ETIDRONIC ACID|Ethane-1-hydroxy-1,1-diphosphonic Acid|Ethane-1-hydroxy-1,1-diphosphonic acid|Etidronate|etidronate	As a member of the family of drugs known as bisphosphonates, etidronate differs from endogenous pyrophosphate in its resistance to enzymatic hydrolysis.  This agent adsorbs to hydroxyapatite cells and reduces the number of osteoclasts, thereby inhibiting abnormal bone resorption.  Etidronate may also directly stimulate bone formation by osteoblasts. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C133300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133300>	C38186	Blood Products Broker, Distributor, Warehouse|Broker/Warehouse	A broker, distributor, or warehouse that stores and redistributes source material for further manufacture, such as recovered plasma, source plasma, and whole blood, red blood cells, or platelets for diagnostic product use.			Health Care Related Organization	FDA Structured Product Labeling Terminology|SPL Blood Form Establishment Type Terminology
C133301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133301>	C38186	Blood Products Collection Facility|Collection Facility	A facility that performs blood collections or apheresis.			Health Care Related Organization	FDA Structured Product Labeling Terminology|SPL Blood Form Establishment Type Terminology
C133302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133302>	C38186	Blood Products Component Preparation Facility|Component Preparation Facility	An intermediate processing facility that prepares components from blood collected by a mobile or fixed collection site but does not perform product testing.			Health Care Related Organization	FDA Structured Product Labeling Terminology|SPL Blood Form Establishment Type Terminology
C133303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133303>	C38186	Blood Products Distribution Center|Distribution Center	A facility that stores blood or blood products for transfusion under specific controlled conditions prior to shipping it to the final user.			Health Care Related Organization	FDA Structured Product Labeling Terminology|SPL Blood Form Establishment Type Terminology
C133304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133304>	C38186	Blood Products Irradiation Facility|Irradiation Facility	A facility that performs the irradiation of blood components.			Health Care Related Organization	FDA Structured Product Labeling Terminology|SPL Blood Form Establishment Type Terminology
C133305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133305>	C15785	Medicare Approved Hospital Transfusion Service|Hospital Transfusion Service - Approved Medicare	A facility in compliance with the Clinical Laboratory Improvement Amendments Act of 1988 (42 U.S.C. 236a), that performs compatibility testing and transfusion of blood and blood components, but which neither routinely collect nor process blood and blood components. The facility has met equivalent requirements as determined by the Centers for Medicare and Medicaid Services.			Health Care Related Organization	FDA Structured Product Labeling Terminology|SPL Blood Form Establishment Type Terminology
C133306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133306>	C15785	Non-Medicare Approved Hospital Transfusion Service|Hospital Transfusion Service - Not Approved Medicare	A facility in compliance with the Clinical Laboratory Improvement Amendments Act of 1988 (42 U.S.C. 236a), but not Centers for Medicare and Medicaid Services compliant, that performs compatibility testing and transfusion of blood and blood components, but which neither routinely collects nor processes blood and blood components.			Health Care Related Organization	FDA Structured Product Labeling Terminology|SPL Blood Form Establishment Type Terminology
C133307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133307>	C54131	Cooperative Association	Business organization formed by a group of individuals for their mutual benefit.			Organization	FDA Structured Product Labeling Terminology|SPL Blood Form Type of Ownership Terminology
C133308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133308>	C54131	County Municipal Hospital Authority|County/Municipal/Hospital Authority	Owned by a territorial division of the local government within a state and has corporate status and powers of self-government.			Organization	FDA Structured Product Labeling Terminology|SPL Blood Form Type of Ownership Terminology
C133309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133309>	C54131	Federal Non-Military Ownership|Federal (non-military)	Owned by the federal government and receives federal government funding.			Organization	FDA Structured Product Labeling Terminology|SPL Blood Form Type of Ownership Terminology
C13330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13330>	C25937	Outer Mitochondrial Membrane|Mitochondrial Outer Membrane|Outer Membrane of the Mitochondrion	The mitochondrial outer membrane contains the multi-subunit machinery responsible for the specific recognition and translocation of precursor proteins.			Cell Component	
C133310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133310>	C54131	For-Profit Corporation|Corporation (for Profit)	An organization which aims to earn profit through its operations and is concerned with its own interests.			Organization	FDA Structured Product Labeling Terminology|SPL Blood Form Type of Ownership Terminology
C133311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133311>	C54131	Non-Profit Corporation|Corporation (Non-Profit)	Special type of corporation that has been organized to meet specific tax-exempt purposes. To qualify for nonprofit status, the corporation must be formed to benefit: (1) the public, (2) a specific group of individuals, or (3) the membership of the nonprofit.			Organization	FDA Structured Product Labeling Terminology|SPL Blood Form Type of Ownership Terminology
C133312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133312>	C54131	Single Proprietorship	An unincorporated business with a single owner who pays personal income tax on profits earned from the business. Ownership of a business establishment by one individual.			Organization	FDA Structured Product Labeling Terminology|SPL Blood Form Type of Ownership Terminology
C133313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133313>	C54131	State Ownership|State	Owned by the state and receives state government funding.			Organization	FDA Structured Product Labeling Terminology|SPL Blood Form Type of Ownership Terminology
C133314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133314>	C101674	Reproductive Human Cells, Tissues, and Cellular and Tissue-Based Products from Anonymous Donor|Anonymous|Reproductive HCT/P from Anonymous Donor	Reproductive Human Cells, Tissues and Tissue based Products (HCT/Ps) donated by a donor to a recipient who doesn't know and isn't known by the recipient before donation.			Pharmacologic Substance	FDA Structured Product Labeling Terminology|SPL Tissue Form Donor Type Terminology
C133315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133315>	C101674	Reproductive Human Cells, Tissues, and Cellular and Tissue-Based Products from Known Donor to Directed Recipient|Directed|Reproductive HCT/P from Known Donor to Directed Recipient	Reproductive Human Cells, Tissues and Tissue based Products (HCT/Ps) donated by a donor to a specific recipient who knows and is known by the recipient before donation.			Pharmacologic Substance	FDA Structured Product Labeling Terminology|SPL Tissue Form Donor Type Terminology
C133316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133316>	C12981	Reproductive Human Cells, Tissues, and Cellular and Tissue-Based Products from Sexually Intimate Partner|Reproductive HCT/P from Sexually Intimate Partner|Sexually intimate partner	Reproductive Human Cells, Tissues and Tissue based Products (HCT/Ps) donated by a donor to a recipient who is a sexually intimate partner.			Pharmacologic Substance	FDA Structured Product Labeling Terminology|SPL Tissue Form Donor Type Terminology
C133317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133317>	C12950	Inner Membrane Amniotic Membrane Tissue|Human Amniotic Membrane	Tissue derived from the inner membrane of amniotic sac.			Tissue	FDA Structured Product Labeling Terminology|SPL Tissue Form Product Type Terminology
C133318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133318>	C12950	Umbilical Cord Tissue|Human Umbilical Cord Tissue	Tissue derived from the umbilical cord.			Tissue	FDA Structured Product Labeling Terminology|SPL Tissue Form Product Type Terminology
C133319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133319>	C21541	Apheresis Collection Facility|Apheresis collection facility	A facility whose primary operation is peripheral blood stem cells and mononuclear cell collection by apheresis.			Health Care Related Organization	FDA Structured Product Labeling Terminology|SPL Tissue Form Establishment Type Terminology
C13331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13331>	C25937	Inner Mitochondrial Membrane|Inner Membrane of the Mitochondrion|Mitochondrial Inner Membrane	The inner mitochondrial membrane encloses a fluid-filled matrix and is elaborately folded with shelf-like cristae projecting into the matrix. The components of electron transport chain are integral part of the inner membrane.			Cell Component	
C133320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133320>	C21541	Eye Bank|Eye bank	A facility whose operations include collection, processing and distribution of ocular tissues.			Health Care Related Organization	FDA Structured Product Labeling Terminology|SPL Tissue Form Establishment Type Terminology
C133321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133321>	C21541	Human Cells, Tissues, and Cellular and Tissue-Based Products Satellite Recovery Facility|HCT/P Satellite Recovery Facility|Satellite recovery establishment	A facility with Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) recovery as the primary operation and a parent establishment that has a registration number.			Health Care Related Organization	FDA Structured Product Labeling Terminology|SPL Tissue Form Establishment Type Terminology
C133322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133322>	C21541	Hospital Based Cell or Tissue Processing Facility|Hospital based cell or tissue processing facility	A cell or tissue processing facility that is located within a hospital.			Health Care Related Organization	FDA Structured Product Labeling Terminology|SPL Tissue Form Establishment Type Terminology
C133323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133323>	C21541	Non-Hospital Based Cell or Tissue Processing Facility|Non-hospital based cell or tissue processing facility	A cell or tissue processing facility that is not located within a hospital.			Health Care Related Organization	FDA Structured Product Labeling Terminology|SPL Tissue Form Establishment Type Terminology
C133324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133324>	C21541	Organ and Tissue Procurement Facility|Organ and tissue procurement organization	An organ procurement organization that also recovers tissues.			Health Care Related Organization	FDA Structured Product Labeling Terminology|SPL Tissue Form Establishment Type Terminology
C133325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133325>	C21541	Plasmapheresis Center	A facility licensed by the FDA/CBER that collects source plasma or therapeutic exchange plasma for commercial distribution.			Health Care Related Organization	FDA Structured Product Labeling Terminology|SPL Blood Form Establishment Type Terminology
C133326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133326>	C21541	Tissue Irradiation Facility|Irradiation facility only	A facility that irradiates body tissue products.			Health Care Related Organization	FDA Structured Product Labeling Terminology|SPL Tissue Form Establishment Type Terminology
C133327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133327>	C134278	Blood Product Bacterial Testing 24 Hours Prior to Transfusion|Bacterial Testing	A qualitative immunoassay for the detection of aerobic and anaerobic gram-positive and gram-negative bacteria in leukocyte reduced apheresis platelets or pre-storage pools of up to six (6) leukocyte reduced whole blood derived platelets within 24 hours prior to transfusion.			Laboratory Procedure	FDA Structured Product Labeling Terminology|SPL Blood Form Establishment Functions Terminology
C133328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133328>	C12958	Hematopoietic Progenitor Cells from Apheresis|Human HPC, Apheresis	Peripheral blood collected by apheresis as a source of hematopoietic progenitor cells.			Cell	FDA Structured Product Labeling Terminology|SPL Tissue Form Product Type Terminology
C133329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133329>	C12958	Hematopoietic Progenitor Cells from Cord Blood|Human HPC, Cord Blood	Blood collected from the umbilical cord as a source of hematopoietic progenitor cells.			Cell	FDA Structured Product Labeling Terminology|SPL Tissue Form Product Type Terminology
C13332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13332>	C225418	Bilateral|BILATERAL|Right and Left|Right and left (qualifier value)|bilateral	Affecting both sides of the body or a matched pair of organs.			Qualitative Concept	ALL Adverse Events Table|ALL Authorized Value Terminology|CDISC SDTM Laterality Terminology|CDISC SDTM Terminology|CDISC SEND Microscopic Findings Result Modifier Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF2 History and Physical Exam at Diagnosis Table|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Radiation Therapy Table|EWS Tumor Assessment Table|GCT Authorized Value Terminology|GCT Biopsy/Surgical Procedures Table|GCT Tumor Assessment Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Radiation Therapy Table|mCode Laterality Qualifier Value Set|mCode Radiotherapy Treatment Location Qualifier Value Set|mCode Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table
C133330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133330>	C37984	Community or Hospital Associated Blood Products Testing Facility|Product Testing Laboratory - Associated with Community or Hospital Blood Bank	A separately operated and owned establishment that performs routine blood and plasma donor testing for a community or hospital blood bank.			Health Care Related Organization	FDA Structured Product Labeling Terminology|SPL Blood Form Establishment Type Terminology
C133331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133331>	C204068	Independently Owned Blood Products Testing Facility|Product Testing Laboratory - Independent	A separately operated and owned facility that performs routine blood and plasma donor testing.			Health Care Related Organization	FDA Structured Product Labeling Terminology|SPL Blood Form Establishment Type Terminology
C133332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133332>	C35681	Donor Retested Negative|Donor Retested	A test result of negative infectious disease markers at subsequent testing of blood products that have been stored for a minimum of 112 days.			Laboratory or Test Result	FDA Structured Product Labeling Terminology|SPL Blood Form Establishment Functions Terminology
C133333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133333>	C15191	Automated Pheresis|Automated Apheresis	The procurement of red blood cells, platelets, leukocytes, granulocytes, or plasma by automated equipment.			Therapeutic or Preventive Procedure	FDA Structured Product Labeling Terminology|SPL Blood Form Establishment Functions Terminology
C133334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133334>	C15191	Manual Pheresis|Manual Apheresis	Procedures such as plasmapheresis, plateletpheresis, and leukapheresis, in which unneeded portions of the whole blood are returned to the donor.			Therapeutic or Preventive Procedure	FDA Structured Product Labeling Terminology|SPL Blood Form Establishment Functions Terminology
C133335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133335>	C802	Blood Bank Reagent|Blood Bank Reagents	Diagnostic substances manufactured for commercial distribution used to characterize and determine the acceptability of blood products for transfusion purposes. These include reagent red blood cells, blood grouping reagents, antibody to HBsAg, etc.			Indicator, Reagent, or Diagnostic Aid	FDA Structured Product Labeling Terminology|SPL Blood Form Product Type Terminology
C133336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133336>	C70830	Platelets Additive Solution|PAS|Platelets PAS (Platelets Additive Solution)	Isotonic crystalloid nutrient media solution designed to replace a portion of plasma for the storage of apheresis platelet products, allowing the volume of plasma transfused to be decreased.			Pharmacologic Substance	FDA Structured Product Labeling Terminology|SPL Blood Form Product Type Terminology
C133337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133337>	C12801	Cardiac Tissue				Tissue	
C133338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133338>	C133337	Heart Valve Tissue|Human Heart Valve	Tissue derived from the heart valves that allow blood flow through the heart.			Tissue	FDA Structured Product Labeling Terminology|SPL Tissue Form Product Type Terminology
C133339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133339>	C12801	Non-Valve Cardiac Conduit Tissue|Human Cardiac Tissue Non-valved	Tissue derived from a cardiac outflow tract from which the valve structure is rendered nonfunctional, or a segment of cardiac conduit.			Tissue	FDA Structured Product Labeling Terminology|SPL Tissue Form Product Type Terminology
C13333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13333>	C32530	Tight Junction|Occluding Junction|Zonula Occludens	Found near the apical surface of cells in simple epithelia. Forms a sealing "gasket" around the cell by the fusion of adjacent cell membranes which encircle the apical cell surface like a belt or fence. Prevents fluid moving through the intercellular gap and the lateral diffusion of intrinsic membrane proteins between apical and basolateral domains of the plasma membrane as well as occludes the movement of solute molecules between cells. Various proteins components of this junction have been identified, but how they are linked to form the ultrastructure of the junction is not known.			Cell Component	
C133340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133340>	C12801	Ocular Tissue|Human Ocular Tissue	Different types of tissues from the human eye.			Tissue	FDA Structured Product Labeling Terminology|SPL Tissue Form Product Group Terminology
C133341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133341>	C12801	Placenta Tissue without Amniotic Elements|Human Placenta	The placenta and tissue derived from the placenta (other than amniotic membrane).			Tissue	FDA Structured Product Labeling Terminology|SPL Tissue Form Product Type Terminology
C133342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133342>	C133266	PF24 Plasma	The fluid portion of one unit of human blood intended for transfusion which has been separated from whole blood and placed at -18 degrees C or colder within 24 hours from whole blood collection. When prepared by automated apheresis the product is stored at 1 degree to 6 degrees C within 8 hours of collection and frozen at -18 degrees C or colder within 24 hours of collection.			Body Substance	FDA Structured Product Labeling Terminology|SPL Blood Form Product Type Terminology
C133343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133343>	C133266	PF24RT24 Plasma	Plasma Frozen within 24 Hours after Phlebotomy held at Room Temperature Up To 24 Hours after Phlebotomy (PF24RT24). Plasma prepared from automated apheresis collections can be held at room temperature for up 24 hours after collection and then frozen at -18 degrees C or colder.			Body Substance	FDA Structured Product Labeling Terminology|SPL Blood Form Product Type Terminology
C133344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133344>	C133266	Recovered Plasma	Plasma that has been collected from whole blood and is intended for further manufacture.			Body Substance	FDA Structured Product Labeling Terminology|SPL Blood Form Product Type Terminology
C133345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133345>	C133266	Plasma, Cryoprecipitated Reduced|Plasma Cryoprecipitated Reduced	Plasma from which cryoprecipitated antihemophilic factor (AHF) has been removed.			Body Substance	FDA Structured Product Labeling Terminology|SPL Blood Form Product Type Terminology
C133346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133346>	C133266	Single Donor Plasma|Liquid Plasma	Single donor plasma separated from red donor cells within 26 days after phlebotomy (40 days when citrate phosphate dextrose adenine (CPDA-1) is used as the anticoagulant) and stored at 1-6 degrees C.			Body Substance	FDA Structured Product Labeling Terminology|SPL Blood Form Product Type Terminology
C133347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133347>	C133266	Source Plasma	Plasma collected by apheresis and is intended for further manufacturing to prepare plasma derivatives.			Body Substance	FDA Structured Product Labeling Terminology|SPL Blood Form Product Type Terminology
C133348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133348>	C133266	Therapeutic Exchange Plasma|TEP	Plasma obtained from a patient who undergoes plasma exchange (also called therapeutic plasmapheresis).	Therapeutic Exchange Plasma		Body Substance	CTRP Agent Terminology|CTRP Terminology|FDA Structured Product Labeling Terminology|SPL Blood Form Product Type Terminology
C133349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133349>	C133278	Extended Dating Platelets|Platelets Extended Dating	Platelets that have been tested for bacteria using an FDA-cleared rapid bacterial detection device labeled as a safety measure, following testing with a growth-based quality control test cleared by the FDA for platelet components, that can support extending the expiration date of platelets past 5 days.			Body Substance	FDA Structured Product Labeling Terminology|SPL Blood Form Product Type Terminology
C13334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13334>	C13298	Minisatellite Repeat|Minisatellite|Minisatellite Repeats|Minisatellites|VNTR|Variable Number Tandem Repeat|Variable Number of Tandem Repeats	Tandem arrays of moderately repetitive (5-50 repeats) short (10-60 bases) DNA sequences found dispersed throughout the genome and clustered near telomeres.  Their degree of repetition is two to several hundred at each locus.  Loci number in the thousands but each locus shows a distinctive repeat unit.			Nucleotide Sequence	
C133350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133350>	C133278	Washed Platelets|Platelets Washed|Platelets, Washed	Whole blood derived or apheresis collected platelets washed with normal saline or saline-buffered with acid citrate dextrose formula-A (ACD-A) or citrate using manual or automated methods. The washed platelets are stored at 20-24 degrees C for up to 4 hours.			Body Substance	FDA Structured Product Labeling Terminology|SPL Blood Form Product Type Terminology
C133351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133351>	C133280	Deglycerolized Red Blood Cells|Red Blood Cells Deglycerolized|Red Blood Cells, Deglycerolized	Red blood cells washed free of the glycerol in which they have been stored.			Body Substance	FDA Structured Product Labeling Terminology|SPL Blood Form Product Type Terminology
C133352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133352>	C133280	Frozen Red Blood Cells|Red Blood Cells Frozen|Red Blood Cells, Frozen	Red blood cells stored at an ultra-low temperature in the presence of a cryoprotective agent. These may be preserved for long periods of time.			Body Substance	FDA Structured Product Labeling Terminology|SPL Blood Form Product Type Terminology
C133353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133353>	C133280	Rejuvenated Frozen Red Blood Cells|Red Blood Cells Rejuvenated Frozen|Red Blood Cells, Rejuvenated, Frozen	Red blood cells treated with a rejuvenating solution, then frozen and stored at ultra-low temperatures in the presence of a cryoprotective agent.			Body Substance	FDA Structured Product Labeling Terminology|SPL Blood Form Product Type Terminology
C133354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133354>	C133280	Reconstituted Red Blood Cells|Red Blood Cells Reconstituted|Red Blood Cells, Reconstituted	Red blood cells to which plasma is added to prepare a whole blood product, often with a designated specific hematocrit.			Body Substance	FDA Structured Product Labeling Terminology|SPL Blood Form Product Type Terminology
C133355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133355>	C133280	Rejuvenated, Frozen, Deglycerolized Red Blood Cells|Red Blood Cells Rejuvenated Frozen Deglycerolized|Red Blood Cells, Rejuvenated, Frozen, Deglycerolized	Red blood cells treated with a rejuvenating solution, then frozen using a cryoprotective agent, and finally, washed free of the rejuvenating solution and glycerol.			Body Substance	FDA Structured Product Labeling Terminology|SPL Blood Form Product Type Terminology
C133356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133356>	C133280	Rejuvenated Red Blood Cells|Red Blood Cells Rejuvenated|Red Blood Cells, Rejuvenated	Red blood cells treated to restore cell integrity with a rejuvenating solution, such as pyruvate inosine.			Body Substance	FDA Structured Product Labeling Terminology|SPL Blood Form Product Type Terminology
C133357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133357>	C133280	Washed Red Blood Cells|Red Blood Cells Washed|Red Blood Cells, Washed	Red blood cells typically washed using normal saline with or without small amounts of dextrose using manual or automated methods. The washed red blood cells are stored at 1-6 degrees C for up to 24 hours.			Body Substance	FDA Structured Product Labeling Terminology|SPL Blood Form Product Type Terminology
C133358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133358>	C54131	U.S. Military Ownership|U.S. Military	Operated by the U.S. Military and receives federal government funding.			Conceptual Entity	FDA Structured Product Labeling Terminology|SPL Blood Form Type of Ownership Terminology
C133359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133359>	C28500	Iodinated Polyethylene Glycol-based Hydrogel Tissue Marker|PEG-based Hydrogel Tissue Marker|Radiopaque Polymer Hydrogel Imaging Agent|TraceIT|TraceIT Hydrogel|TraceIT Tissue Marker	A radiopaque hydrogel containing cross-linked, iodinated polyethylene glycol (PEG) particles in a viscous carrier, with potential use as a contrast agent to enhance marking of soft tissue during a surgical procedure and concomitant radiotherapy upon computed tomography (CT), magnetic resonance (MR) and ultrasound imaging. Upon intratumoral injection, iodinated PEG-based hydrogel tissue marker localizes to and is maintained in soft tissue. Upon MR, ultrasound and/or CT imaging, the visualization of the tumor tissue is enhanced, which can facilitate tumor removal and image-guided radiotherapeutic treatment. The hydrogel particles are stable and visible through 3 months, after which they liquefy, and are absorbed by the body and cleared in the urine.	Iodinated Polyethylene Glycol-based Hydrogel Tissue Marker		Indicator, Reagent, or Diagnostic Aid|Organic Chemical	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C13335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13335>	C13377	Origin of Replication|ARS|Autonomously Replicating Sequence|ORI|Replication Origin	A DNA sequence necessary and sufficient for initiation of DNA replication.			Nucleotide Sequence	
C133360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133360>	C12981	Human Cells, Tissues, and Cellular and Tissue-Based Products from Blood Vessel Tissue|HCT/P from Blood Vessel Tissue|Human Vascular Tissue	Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) from the human circulatory or vascular system.			Clinical Attribute	FDA Structured Product Labeling Terminology|SPL Tissue Form Product Group Terminology
C133361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133361>	C48233	Digestive System Cancer TNM Finding v8	A finding about one or more characteristics of digestive system cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C133362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133362>	C101674	Human Cells, Tissues, and Cellular and Tissue-Based Products from Cardiac Tissue|Human Cardiac Tissue	Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) from the human heart.			Pharmacologic Substance	FDA Structured Product Labeling Terminology|SPL Tissue Form Product Group Terminology
C133363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133363>	C133361	Upper Gastrointestinal Tract Cancer TNM Finding v8	A finding about one or more characteristics of upper gastrointestinal tract cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C133364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133364>	C101674	Human Cells, Tissues, and Cellular and Tissue-Based Products from Musculoskeletal Tissue|Human Musculoskeletal Tissue	Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) from the human muscular and skeletal system.			Pharmacologic Substance	FDA Structured Product Labeling Terminology|SPL Tissue Form Product Group Terminology
C133365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133365>	C133363	Esophagus and Esophagogastric Junction Cancer TNM Finding v8	A finding about one or more characteristics of esophagus and esophagogastric junction cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to carcinomas including squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, undifferentiated carcinoma, neuroendocrine cancers, and adenocarcinoma with neuroendocrine features. Sarcomas, nonepithelial cancers, and gastrointestinal stromal tumors are not staged using this staging system. (from AJCC 8th Ed.)			Finding	
C133366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133366>	C133365	Esophagus and Esophagogastric Junction Cancer Clinical TNM Finding v8|Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) Clinical TNM Finding v8	A clinical finding about one or more characteristics of esophagus and esophagogastric junction cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C133367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133367>	C133371	Esophagus and Esophagogastric Junction Cancer cM0 TNM Finding v8|Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) cM0 TNM Finding v8	Esophagus and esophagogastric junction cancer without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C133368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133368>	C133371	Esophagus and Esophagogastric Junction Cancer cM1 TNM Finding v8|Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) cM1 TNM Finding v8|cM1	Esophagus and esophagogastric junction cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology
C133369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133369>	C133365	Esophagus and Esophagogastric Junction Cancer Pathologic TNM Finding v8|Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of esophagus and esophagogastric junction cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C13336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13336>	C13314	PA700 Regulatory Module|19S Proteasome Regulatory Particle|19S Regulatory Particle|PA700 Protein|PA700 Protein Complex	Ubiquitinated proteins are degraded by a 26S ATP-dependent protease complex, composed of a 20S catalytic proteasome and two 19S PA700 regulatory modules.  The multi-subunit PA700 complex binds two sites of the 20S proteasome and is composed of at least six related ATPases and approximately fifteen non-ATPase polypeptides.  Each of the ATPases, PSMC1-6, contains an AAA (ATPases associated with diverse cellular activities) domain.  A protein complex containing p42 and p50 enhances PA700 activation of the proteasome.			Amino Acid, Peptide, or Protein|Cell Component	
C133370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133370>	C133369	Esophagus and Esophagogastric Junction Cancer Pathologic Distant Metastasis TNM Finding v8|Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) Pathologic Distant Metastasis TNM Finding v8|Pathologic Distant Metastasis Status (pM)	A pathologic finding about one or more characteristics of esophagus and esophagogastric junction cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology
C133371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133371>	C133366	Esophagus and Esophagogastric Junction Cancer Clinical Distant Metastasis TNM Finding v8|Clinical Distant Metastasis Status (cM)|Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of esophagus and esophagogastric junction cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology
C133372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133372>	C133370	Esophagus and Esophagogastric Junction Cancer pM1 TNM Finding v8|Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pM1 TNM Finding v8|pM1	Esophagus and esophagogastric junction cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology
C133373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133373>	C133369	Esophagus and Esophagogastric Junction Cancer Pathologic Primary Tumor TNM Finding v8|Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) Pathologic Primary Tumor TNM Finding v8|Pathologic Primary Tumor Status (pT)	A pathologic finding about one or more characteristics of esophagus and esophagogastric junction cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology
C133374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133374>	C133373	Esophagus and Esophagogastric Junction Cancer pTX TNM Finding v8|Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pTX TNM Finding v8|pTX	Esophagus and esophagogastric junction cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology
C133375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133375>	C133373	Esophagus and Esophagogastric Junction Cancer pT0 TNM Finding v8|Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pT0 TNM Finding v8|pT0	Esophagus and esophagogastric junction cancer with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology
C133376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133376>	C133373	Esophagus and Esophagogastric Junction Cancer pTis TNM Finding v8|Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pTis TNM Finding v8|pTis	Esophagus and esophagogastric junction cancer with a finding of high-grade dysplasia, defined as malignant cells confined to the epithelium by the basement membrane. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology
C133377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133377>	C133373	Esophagus and Esophagogastric Junction Cancer pT1 TNM Finding v8|Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pT1 TNM Finding v8|pT1	Esophagus and esophagogastric junction cancer with tumor invading the lamina propria, muscularis mucosae, or submucosa. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology
C133378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133378>	C133377	Esophagus and Esophagogastric Junction Cancer pT1a TNM Finding v8|Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pT1a TNM Finding v8|pT1a	Esophagus and esophagogastric junction cancer with tumor invading the lamina propria or muscularis mucosae. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology
C133379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133379>	C133377	Esophagus and Esophagogastric Junction Cancer pT1b TNM Finding v8|Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pT1b TNM Finding v8|pT1b	Esophagus and esophagogastric junction cancer with tumor invading the submucosa. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology
C13337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13337>	C13049	Germinal Center	Sites in secondary lymphoid tissue where follicular dendritic cells present antigens to B-cells and follicular helper T-cells.			Tissue	
C133380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133380>	C133373	Esophagus and Esophagogastric Junction Cancer pT2 TNM Finding v8|Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pT2 TNM Finding v8|pT2	Esophagus and esophagogastric junction cancer with tumor invading the muscularis propria. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology
C133381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133381>	C133373	Esophagus and Esophagogastric Junction Cancer pT3 TNM Finding v8|Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pT3 TNM Finding v8|pT3	Esophagus and esophagogastric junction cancer with tumor invading adventitia. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology
C133382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133382>	C133373	Esophagus and Esophagogastric Junction Cancer pT4 TNM Finding v8|Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pT4 TNM Finding v8|pT4	Esophagus and esophagogastric junction cancer with tumor invading adjacent structures. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology
C133383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133383>	C133382	Esophagus and Esophagogastric Junction Cancer pT4a TNM Finding v8|Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pT4a TNM Finding v8|pT4a	Esophagus and esophagogastric junction cancer with tumor invading the pleura, pericardium, azygos vein, diaphragm, or peritoneum. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology
C133384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133384>	C133382	Esophagus and Esophagogastric Junction Cancer pT4b TNM Finding v8|Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pT4b TNM Finding v8|pT4b	Esophagus and esophagogastric junction cancer with tumor invading other adjacent structures, such as the aorta, vertebral body, or airway. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology
C133385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133385>	C133369	Esophagus and Esophagogastric Junction Cancer Pathologic Regional Lymph Nodes TNM Finding v8|Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) Pathologic Regional Lymph Nodes TNM Finding v8|Pathologic Regional Lymph Node Status (pN)	A pathologic finding about one or more characteristics of esophagus and esophagogastric junction cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology
C133386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133386>	C133385	Esophagus and Esophagogastric Junction Cancer pNX TNM Finding v8|Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pNX TNM Finding v8|pNX	Esophagus and esophagogastric junction cancer in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology
C133387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133387>	C133385	Esophagus and Esophagogastric Junction Cancer pN0 TNM Finding v8|Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pN0 TNM Finding v8|pN0	Esophagus and esophagogastric junction cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology
C133388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133388>	C133385	Esophagus and Esophagogastric Junction Cancer pN1 TNM Finding v8|Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pN1 TNM Finding v8|pN1	Esophagus and esophagogastric junction cancer with metastasis in one or two regional lymph nodes. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology
C133389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133389>	C133385	Esophagus and Esophagogastric Junction Cancer pN2 TNM Finding v8|Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pN2 TNM Finding v8|pN2	Esophagus and esophagogastric junction cancer with metastasis in three to six regional lymph nodes. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology
C13338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13338>	C13298	Microsatellite Repeat|Microsatellite|Microsatellite Repeats|Microsatellites|microsatellite	A variety of simple di-, tri-, tetra-, and pentanucleotide tandem repeats that are dispersed in the euchromatic arms of most chromosomes.			Nucleotide Sequence	
C133390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133390>	C133385	Esophagus and Esophagogastric Junction Cancer pN3 TNM Finding v8|Esophagus and Esophagogastric Junction Cancer (Squamous Cell Carcinoma and Adenocarcinoma) pN3 TNM Finding v8|pN3	Esophagus and esophagogastric junction cancer with metastasis in seven or more regional lymph nodes. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology
C133391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133391>	C36279	Esophageal Squamous Cell Carcinoma Location Category	Location of esophageal squamous cell carcinoma is defined by the position of the epicenter of the tumor in the esophagus. Location plays a role in the stage grouping of esophageal squamous carcinomas. (from AJCC 8th Ed.)			Finding	
C133392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133392>	C133391	Esophageal Squamous Cell Carcinoma Location Category X	Esophageal squamous cell carcinoma with unknown location. (from AJCC 8th Ed.)			Finding	
C133393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133393>	C133391	Esophageal Squamous Cell Carcinoma Location Category Upper	Esophageal squamous cell carcinoma located in the cervical esophagus to lower border of azygos vein. (from AJCC 8th Ed.)			Finding	
C133394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133394>	C133391	Esophageal Squamous Cell Carcinoma Location Category Middle	Esophageal squamous cell carcinoma located in the lower border of azygos vein to lower border of inferior pulmonary vein. (from AJCC 8th Ed.)			Finding	
C133395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133395>	C133391	Esophageal Squamous Cell Carcinoma Location Category Lower	Esophageal squamous cell carcinoma located in the lower border of inferior pulmonary vein to stomach, including gastroesophageal junction. (from AJCC 8th Ed.)			Finding	
C133396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133396>	C68616	Planned Start Date|Proposed Start Date	The calendar date that an event or activity is intended to begin.			Temporal Concept	
C133397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133397>	C68617	Planned End Date|Proposed End Date	The calendar date that an event or activity is intended to be completed.			Temporal Concept	
C133398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133398>	C48698	Postneoadjuvant Therapy Pathologic TNM Finding|ypTNM Finding	Pathologic TNM staging performed with access to postneoadjuvant therapy information only.			Finding	
C133399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133399>	C3513	Esophageal Cancer by AJCC v8 Stage|Esophageal Carcinoma by AJCC v8 Stage	A term that refers to the staging of esophageal carcinoma according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C13339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13339>	C13426	SH2 Domain	A region of protein sequence similarity among members of the SRC family of cytoplasmic tyrosine kinases, and other proteins. The SH2 domain usually mediates binding to phosphotyrosine and neighboring residues of target proteins.			Amino Acid Sequence	
C1333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1333>	C360	Dexrazoxane|(+)-(S)-4,4'-(1-Methyl-1,2-ethanediyl)di(2,6-piperazinedione)|2, 6-Piperazinedione, 4,4'-propylenedi-, (P)- (8CI)|2,6-Piperazinedione, 4, 4'-(1-methyl-1,2-ethanediyl)bis-, (S)- (9CI)|2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-,(S)-(9CI)|2,6-Piperazinedione, 4,4'propylenedi-,(P)-(8CI)|ADR 529|ADR-529|ADR529|DEXRAZOXANE|ICRF 187|ICRF-187|ICRF-187|ICRF187|Razoxane (+)-form|Soluble ICRF (L-isomer)|dexrazoxane	A bisdioxopiperazine with iron-chelating, chemoprotective, cardioprotective, and antineoplastic activities. After hydrolysis to an active form that is similar to ethylenediaminetetraacetic acid (EDTA), dexrazoxane chelates iron, limiting the formation of free radical-generating anthracycline-iron complexes, which may minimize anthracycline-iron complex-mediated oxidative damage to cardiac and soft tissues. This agent also inhibits the catalytic activity of topoisomerase II, which may result in tumor cell growth inhibition.	Dexrazoxane		Organic Chemical|Pharmacologic Substance	AML Authorized Value Terminology|AML Concomitant Medication Table|CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|HL Authorized Value Terminology|HL Concomitant Medication Table|NCIt Antineoplastic Agent Terminology
C133400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133400>	C4025|C133399	Esophageal Adenocarcinoma by AJCC v8 Stage	A term that refers to the staging of esophageal adenocarcinoma according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C133401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133401>	C133400	Esophageal Adenocarcinoma by AJCC v8 Clinical Stage|Esophageal Adenocarcinoma by AJCC v8 cTNM Stage	A term that refers to the clinical staging of esophageal adenocarcinoma according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C133402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133402>	C133401	Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8|Stage 0 Esophageal Adenocarcinoma	Stage 0 includes: Tis, N0, M0. Tis: High-grade dysplasia, defined as malignant cells confined to the epithelium by the basement membrane. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133403>	C133401	Clinical Stage I Esophageal Adenocarcinoma AJCC v8|Stage I Esophageal Adenocarcinoma	Stage I includes: T1, N0, M0. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Clinical Stage I Esophageal Adenocarcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133404>	C133401	Clinical Stage II Esophageal Adenocarcinoma AJCC v8|Stage II Esophageal Adenocarcinoma	Stage II includes: IIA: T1, N1, M0; IIB: T2, N0, M0. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Clinical Stage II Esophageal Adenocarcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133405>	C133404	Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8|Stage IIA Esophageal Adenocarcinoma	Stage IIA includes: T1, N1, M0. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133406>	C133404	Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8|Stage IIB Esophageal Adenocarcinoma	Stage IIB includes: T2, N0, M0. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133407>	C133401	Clinical Stage III Esophageal Adenocarcinoma AJCC v8|Stage III Esophageal Adenocarcinoma	Stage III includes: (T2, N1, M0); (T3, N0-1, M0); (T4a, N0-1, M0). T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Clinical Stage III Esophageal Adenocarcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133408>	C133401	Clinical Stage IV Esophageal Adenocarcinoma AJCC v8|Stage IV Esophageal Adenocarcinoma	Stage IV includes: IVA: (T1-4a, N2, M0); (T4b, N0-2, M0); (Any T, N3, M0); IVB: (Any T, Any N, M1). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)	Clinical Stage IV Esophageal Adenocarcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133409>	C133408	Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8|Stage IVA Esophageal Adenocarcinoma	Stage IVA includes: (T1-4a, N2, M0); (T4b, N0-2, M0); (Any T, N3, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13340>	C13426	SH3 Domain|SRC Homology Region 3 Domain	A region of protein sequence similarity among members of the SRC family of cytoplasmic tyrosine kinases, and other proteins. The SH3 domain is a protein-binding domain that interacts with cytoskeletal proteins.			Amino Acid Sequence	
C133410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133410>	C133408	Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8|Stage IVB Esophageal Adenocarcinoma	Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)	Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133411>	C91221|C4025	Esophageal Adenocarcinoma by AJCC v7 Stage	A term that refers to the staging of esophageal adenocarcinoma according to the American Joint Committee on Cancer, 7th edition.			Neoplastic Process	
C133412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133412>	C133400	Esophageal Adenocarcinoma by AJCC v8 Pathologic Stage|Esophageal Adenocarcinoma Tumor Stage Pathologic|Esophageal Adenocarcinoma by AJCC v8 pTNM Stage	A term that refers to the pathologic staging of esophageal adenocarcinoma according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology
C133413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133413>	C133412	Pathologic Stage 0 Esophageal Adenocarcinoma AJCC v8|0|Stage 0 Esophageal Adenocarcinoma	Stage 0 includes: Tis, N0, M0, GN/A. Tis: High-grade dysplasia, defined as malignant cells confined to the epithelium by the basement membrane. N0: No regional lymph node metastasis. M0: No distant metastasis. GN/A: Grade non-applicable. (AJCC 8th ed.)	Pathologic Stage 0 Esophageal Adenocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133414>	C133412	Pathologic Stage I Esophageal Adenocarcinoma AJCC v8|I|Stage I Esophageal Adenocarcinoma	Stage I includes: IA: (T1a, N0, M0, G1); (T1a, N0, M0, GX); IB: (T1a, N0, M0, G2); (T1b, N0, M0, G1-2); (T1b, N0, M0, GX); IC: (T1, N0, M0, G3); (T2, N0, M0, G1-2). T1a: Tumor invades the lamina propria or muscularis mucosae. T1b: Tumor invades the submucosa. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well-differentiated. GX: Grade cannot be assessed. G2: Moderately differentiated. G3: Poorly differentiated, undifferentiated. (AJCC 8th ed.)	Pathologic Stage I Esophageal Adenocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133415>	C133414	Pathologic Stage IA Esophageal Adenocarcinoma AJCC v8|IA|Stage IA Esophageal Adenocarcinoma	Stage IA includes: (T1a, N0, M0, G1); (T1a, N0, M0, GX). T1a: Tumor invades the lamina propria or muscularis mucosae. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well-differentiated. GX: Grade cannot be assessed. (AJCC 8th ed.)	Pathologic Stage IA Esophageal Adenocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133416>	C133414	Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8|IB|Stage IB Esophageal Adenocarcinoma	Stage IB includes: (T1a, N0, M0, G2); (T1b, N0, M0, G1-2); (T1b, N0, M0, GX). T1a: Tumor invades the lamina propria or muscularis mucosae. T1b: Tumor invades the submucosa. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well-differentiated. GX: Grade cannot be assessed. G2: Moderately differentiated. (AJCC 8th ed.)	Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133417>	C133414	Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8|IC|Stage IC Esophageal Adenocarcinoma	Stage IC includes: (T1, N0, M0, G3); (T2, N0, M0, G1-2). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well-differentiated. G2: Moderately differentiated. G3: Poorly differentiated, undifferentiated. (AJCC 8th ed.)	Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133418>	C133412	Pathologic Stage II Esophageal Adenocarcinoma AJCC v8|II|Stage II Esophageal Adenocarcinoma	Stage II includes: IIA: (T2, N0, M0, G3); (T2, N0, M0, GX); IIB: (T1, N1, M0, Any G); (T3, N0, M0, Any G). T2: Tumor invades the muscularis propria. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T3: Tumor invades adventitia. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. GX: Grade cannot be assessed. G3: Poorly differentiated, undifferentiated. (AJCC 8th ed.)	Pathologic Stage II Esophageal Adenocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133419>	C133418	Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8|IIA|Stage IIA Esophageal Adenocarcinoma	Stage IIA includes: (T2, N0, M0, G3); (T2, N0, M0, GX). T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. GX: Grade cannot be assessed. G3: Poorly differentiated, undifferentiated. (AJCC 8th ed.)	Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C13341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13341>	C13425	Helix-Turn-Helix Motif|HTH DNA Binding Domain|Helix-Turn-Helix	A DNA binding domain comprised of two or more alpha helical amino acid sequences that are linked by short flexible chains of amino acids. The interactions between the helices determine the domain structure and its DNA binding specificity.			Amino Acid Sequence	
C133420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133420>	C133418	Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8|IIB|Stage IIB Esophageal Adenocarcinoma	Stage IIB includes: (T1, N1, M0, Any G); (T3, N0, M0, Any G). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T3: Tumor invades adventitia. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133421>	C133412	Pathologic Stage III Esophageal Adenocarcinoma AJCC v8|III|Stage III Esophageal Adenocarcinoma	Stage III includes: IIIA: (T1, N2, M0, Any G); (T2, N1, M0, Any G); IIIB: (T2, N2, M0, Any G); (T3, N1-2, M0, Any G); (T4a, N0-1, M0, Any G). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Pathologic Stage III Esophageal Adenocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133422>	C133421	Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8|IIIA|Stage IIIA Esophageal Adenocarcinoma	Stage IIIA includes: (T1, N2, M0, Any G); (T2, N1, M0, Any G). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133423>	C133421	Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8|IIIB|Stage IIIB Esophageal Adenocarcinoma	Stage IIIB includes: (T2, N2, M0, Any G); (T3, N1-2, M0, Any G); (T4a, N0-1, M0, Any G). T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133424>	C133412	Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8|IV|Stage IV Esophageal Adenocarcinoma	Stage IV includes: IVA: (T4a, N2, M0, Any G); (T4b, N0-2, M0, Any G); (Any T, N3, M0, Any G); IVB: (Any T, Any N, M1, Any G). T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)	Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133425>	C133424	Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8|IVA|Stage IVA Esophageal Adenocarcinoma	Stage IVA includes: (T4a, N2, M0, Any G); (T4b, N0-2, M0, Any G); (Any T, N3, M0, Any G). T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133426>	C133424	Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8|IVB|Stage IVB Esophageal Adenocarcinoma	Stage IVB includes: Any T, Any N, M1, Any G. M1: Distant metastasis. (AJCC 8th ed.)	Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8	Obsolete_Concept	Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133427>	C18004	International Neuroblastoma Risk Group Staging System|INRGSS|inrg stage|inrg_stage	A clinical staging system for neuroblastoma based on preoperative imaging and determined prior to any treatment, including surgery. It includes two stages of localized disease (L1 and L2) and two stages of metastatic disease (M and MS).			Classification	GDC Property Terminology|GDC Terminology
C133428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133428>	C133427	INRG Stage L1|International Neuroblastoma Risk Group Stage L1|L1	Locoregional neuroblastoma without image defined risk factors (IDRFs).	INRG Stage L1		Classification	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C133429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133429>	C133427	INRG Stage L2|International Neuroblastoma Risk Group Stage L2|L2	Locoregional neuroblastoma with one or more image defined risk factors (IDRFs).	INRG Stage L2		Classification	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C13342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13342>	C13806	Immunoglobulin Hypervariable Region|CDR|Complementarity Determining Region|Complementarity-Determining Region|Hypervariable Loop	Within the variable domain of an antibody molecule are three regions called hypervariable regions, areas of high sequence diversity.  These regions form the surfaces that are responsible for antigen binding interactions.  Also known as complementarity determining region or hypervariable loop.			Amino Acid Sequence	
C133430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133430>	C133427	INRG Stage M|International Neuroblastoma Risk Group Stage M|M	Neuroblastoma with distant metastatic disease (except MS).	INRG Stage M		Classification	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C133431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133431>	C133427	INRG Stage MS|International Neuroblastoma Risk Group Stage MS|Ms	INRG stage L1 or L2 neuroblastoma with metastatic disease confined to the skin and/or liver and/or bone marrow.	INRG Stage MS		Classification	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C133432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133432>	C133400	Esophageal Adenocarcinoma by AJCC v8 Postneoadjuvant Therapy Stage|Esophageal Adenocarcinoma by AJCC v8 ypTNM Stage	A term that refers to the postneoadjuvant therapy staging of esophageal adenocarcinoma according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C133433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133433>	C133432	Postneoadjuvant Therapy Stage I Esophageal Adenocarcinoma AJCC v8|Stage I Esophageal Adenocarcinoma	Stage I includes: T0-2, N0, M0. T0: No evidence of primary tumor. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Postneoadjuvant Therapy Stage I Esophageal Adenocarcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133434>	C133432	Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8|Stage II Esophageal Adenocarcinoma	Stage II includes: T3, N0, M0. T3: Tumor invades adventitia. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133435>	C133432	Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8|Stage III Esophageal Adenocarcinoma	Stage III includes: IIIA: (T0-2, N1, M0); IIIB: (T3, N1, M0); (T0-3, N2, M0); (T4a, N0, M0). T0: No evidence of primary tumor. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133436>	C133435	Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8|Stage IIIA Esophageal Adenocarcinoma	Stage IIIA includes: T0-2, N1, M0. T0: No evidence of primary tumor. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133437>	C133435	Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8|Stage IIIB Esophageal Adenocarcinoma	Stage IIIB includes: (T3, N1, M0); (T0-3, N2, M0); (T4a, N0, M0). T0: No evidence of primary tumor. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133438>	C133432	Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8|Stage IV Esophageal Adenocarcinoma	Stage IV includes: IVA: (T4a, N1-2, M0); (T4a, NX, M0); (T4b, N0-2, M0); (Any T, N3, M0); IVB: (Any T, Any N, M1). T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. NX: Regional lymph nodes cannot be assessed. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)	Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133439>	C133438	Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8|Stage IVA Esophageal Adenocarcinoma	Stage IVA includes: (T4a, N1-2, M0); (T4a, NX, M0); (T4b, N0-2, M0); (Any T, N3, M0). T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. NX: Regional lymph nodes cannot be assessed. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13343>	C13806	Immunoglobulin Hinge Region	A region of relative flexibility between the variable and constant regions of an antibody molecule.			Amino Acid, Peptide, or Protein	
C133440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133440>	C133438	Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8|Stage IVB Esophageal Adenocarcinoma	Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)	Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133441>	C21514	Too Early|Premature|TE-Too Early|Too Soon	At a point before the usual, expected, or specified time.			Temporal Concept	GDC Terminology|GDC Value Terminology
C133442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133442>	C91221|C4024	Esophageal Squamous Cell Carcinoma by AJCC v7 Stage	A term that refers to the staging of esophageal squamous cell carcinoma according to the American Joint Committee on Cancer, 7th edition.			Neoplastic Process	
C133443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133443>	C4024|C133399	Esophageal Squamous Cell Carcinoma by AJCC v8 Stage	A term that refers to the staging of esophageal squamous cell carcinoma according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C133444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133444>	C133443	Esophageal Squamous Cell Carcinoma by AJCC v8 Clinical Stage|Esophageal Squamous Cell Carcinoma by AJCC v8 cTNM Stage	A term that refers to the clinical staging of esophageal squamous cell carcinoma according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C133445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133445>	C133443	Esophageal Squamous Cell Carcinoma by AJCC v8 Pathologic Stage|Esophageal Squamous Cell Carcinoma Tumor Stage Pathologic|Esophageal Squamous Cell Carcinoma by AJCC v8 pTNM Stage	A term that refers to the pathologic staging of esophageal squamous cell carcinoma according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology
C133446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133446>	C133443	Esophageal Squamous Cell Carcinoma by AJCC v8 Postneoadjuvant Therapy Stage|Esophageal Squamous Cell Carcinoma by AJCC v8 ypTNM Stage	A term that refers to the postneoadjuvant therapy staging of esophageal squamous cell carcinoma according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C133447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133447>	C133444	Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8|Stage 0 Esophageal Squamous Cell Cancer	Stage 0 includes: Tis, N0, M0. Tis: High-grade dysplasia, defined as malignant cells confined to the epithelium by the basement membrane. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133448>	C133444	Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8|Stage I Esophageal Squamous Cell Cancer	Stage I includes: T1, N0-1, M0. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133449>	C133444	Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8|Stage II Esophageal Squamous Cell Cancer	Stage II includes: (T2, N0-1, M0); (T3, N0, M0). T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13344>	C225418	Topical|topical				Spatial Concept	
C133450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133450>	C133444	Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8|Stage III Esophageal Squamous Cell Cancer	Stage III includes: (T3, N1, M0); (T1-3, N2, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133451>	C133444	Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8|Stage IV Esophageal Squamous Cell Cancer	Stage IV includes: IVA: (T4, N0-2, M0); (Any T, N3, M0); IVB: (Any T, Any N, M1). T4: Tumor invades adjacent structures. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)	Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133452>	C133451	Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8|Stage IVA Esophageal Squamous Cell Cancer	Stage IVA includes: (T4, N0-2, M0); (Any T, N3, M0). T4: Tumor invades adjacent structures. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133453>	C133451	Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8|Stage IVB Esophageal Squamous Cell Cancer	Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)	Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133454>	C133446	Postneoadjuvant Therapy Stage I Esophageal Squamous Cell Carcinoma AJCC v8|Stage I Esophageal Squamous Cell Cancer	Stage I includes: T0-2, N0, M0. T0: No evidence of primary tumor. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Postneoadjuvant Therapy Stage I Esophageal Squamous Cell Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133455>	C133446	Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma AJCC v8|Stage II Esophageal Squamous Cell Cancer	Stage II includes: T3, N0, M0. T3: Tumor invades adventitia. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133456>	C133446	Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8|Stage III Esophageal Squamous Cell Cancer	Stage III includes: IIIA: (T0-2, N1, M0); IIIB: (T3, N1, M0); (T0-3, N2, M0); (T4a, N0, M0). T0: No evidence of primary tumor. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133457>	C133456	Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8|Stage IIIA Esophageal Squamous Cell Cancer	Stage IIIA includes: T0-2, N1, M0. T0: No evidence of primary tumor. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133458>	C133456	Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8|Stage IIIB Esophageal Squamous Cell Cancer	Stage IIIB includes: (T3, N1, M0); (T0-3, N2, M0); (T4a, N0, M0). T0: No evidence of primary tumor. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133459>	C133446	Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8|Stage IV Esophageal Squamous Cell Cancer	Stage IV includes: IVA: (T4a, N1-2, M0); (T4a, NX, M0); (T4b, N0-2, M0); (Any T, N3, M0); IVB: (Any T, Any N, M1). T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. NX: Regional lymph nodes cannot be assessed. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)	Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13345>	C25761	Stoma|stoma				Acquired Abnormality	
C133460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133460>	C133459	Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8|Stage IVA Esophageal Squamous Cell Cancer	Stage IVA includes: (T4a, N1-2, M0); (T4a, NX, M0); (T4b, N0-2, M0); (Any T, N3, M0). T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. NX: Regional lymph nodes cannot be assessed. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133461>	C133459	Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8|Stage IVB Esophageal Squamous Cell Cancer	Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)	Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133462>	C20993	Curie Scoring System|CURIESC|Curie Absolute Score|Curie Absolute Score|Curie Method|Curie Score|Curie Score|Curie mIBG-Scoring System	A semi-quantitative scoring system, developed at the Curie Institute in France, used for staging neuroblastoma patients at diagnosis and for response assessment following induction chemotherapy. Following whole-body 123I-mIBG scanning, osteomedullary involvement is scored for 9 skeletal segments plus a tenth score for soft tissue involvement.			Classification	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C133463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133463>	C97928	ALK Protein Variant|ALK Tyrosine Kinase Receptor Protein Variant|Anaplastic Lymphoma Kinase Protein Variant|CD246 Antigen Protein Variant	A variation in the amino acid sequence for the ALK tyrosine kinase receptor protein.			Cell or Molecular Dysfunction	Pediatric Oncology Target Molecular Abnormalities Terminology
C133464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133464>	C133463	ALK NP_004295.2:p.R1275X|ALK Arg1275Xxx|ALK NP_004295.2:p.Arg1275Xxx|ALK R1275 Mutation|ALK R1275X|ALK Tyrosine Kinase Receptor Arg1275Xxx|ALK Tyrosine Kinase Receptor R1275X|ALK p.Arg1275Xxx|ALK p.R1275X|Anaplastic Lymphoma Kinase Arg1275Xxx|Anaplastic Lymphoma Kinase R1275X|CD246 Antigen Arg1275Xxx|CD246 Antigen R1275X|NP_004295.2:p.Arg1275Xxx|NP_004295.2:p.R1275X	A change in the amino acid residue at position 1170 in the ALK tyrosine kinase receptor protein where arginine has been replaced by another amino acid.			Cell or Molecular Dysfunction	
C133465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133465>	C133463	ALK NP_004295.2:p.F1174X|ALK F1174 Mutation|ALK F1174X|ALK NP_004295.2:p.Phe1174Xxx|ALK Phe1174Xxx|ALK Tyrosine Kinase Receptor F1174X|ALK Tyrosine Kinase Receptor Phe1174Xxx|ALK p.F1174X|ALK p.Phe1174Xxx|Anaplastic Lymphoma Kinase F1174X|Anaplastic Lymphoma Kinase Phe1174Xxx|CD246 Antigen F1174X|CD246 Antigen Phe1174Xxx|NP_004295.2:p.F1174X|NP_004295.2:p.Phe1174Xxx	A change in the amino acid residue at position 1174 in the ALK tyrosine kinase receptor protein where phenylalanine has been replaced by another amino acid.			Cell or Molecular Dysfunction	
C133466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133466>	C133463	ALK NP_004295.2:p.F1245X|ALK F1245 Mutation|ALK F1245X|ALK NP_004295.2:p.Phe1245Xxx|ALK Phe1245Xxx|ALK Tyrosine Kinase Receptor F1245X|ALK Tyrosine Kinase Receptor Phe1245Xxx|ALK p.F1245X|ALK p.Phe1245Xxx|Anaplastic Lymphoma Kinase F1245X|Anaplastic Lymphoma Kinase Phe1245Xxx|CD246 Antigen F1245X|CD246 Antigen Phe1245Xxx|NP_004295.2:p.F1245X|NP_004295.2:p.Phe1245Xxx	A change in the amino acid residue at position 1245 in the ALK tyrosine kinase receptor protein where phenylalanine has been replaced by another amino acid.			Cell or Molecular Dysfunction	
C133467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133467>	C217122	Curie Extension Score|Curie Method|Curie mIBG-Scoring System	A score assigned to a Curie body segment to indicate the quantity of metastases.			Intellectual Product	
C133468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133468>	C217122	Curie Intensity Score	A score assigned to a Curie body segment to indicate the strength of 123I-mIBG uptake.			Intellectual Product	
C133469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133469>	C133467	Curie Extension Score 0	No metastatic sites within a segment.			Intellectual Product	
C13346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13346>	C225418	Intravenous|IV|IV|intravenous				Spatial Concept	
C133470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133470>	C133467	Curie Extension Score 1	One metastatic site within a segment.			Intellectual Product	
C133471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133471>	C133467	Curie Extension Score 2	More than one metastatic site within a segment.			Intellectual Product	
C133472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133472>	C133467	Curie Extension Score 3	Diffuse involvement within a segment (>50% of the segment).			Intellectual Product	
C133473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133473>	C133468	Curie Intensity Score 0	No uptake within a segment.			Intellectual Product	
C133474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133474>	C133468	Curie Intensity Score 1	Doubtful uptake within a segment.			Intellectual Product	
C133475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133475>	C133468	Curie Intensity Score 2	Definite uptake within a segment, but less uptake than in the liver.			Intellectual Product	
C133476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133476>	C137952	ALK NM_004304.4:c.3509T>A|ALK Receptor Tyrosine Kinase c.3509T>A|ALK c.3509T>A|Anaplastic Lymphoma Kinase (Ki-1) c.3509T>A|Anaplastic Lymphoma Receptor Tyrosine Kinase c.3509T>A|CD246 c.3509T>A|NM_004304.4:c.3509T>A	A nucleotide substitution at position 3509 of the coding sequence of the ALK gene where thymine has been mutated to adenine.			Cell or Molecular Dysfunction	
C133477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133477>	C133468	Curie Intensity Score 3	Intense uptake, greater than in the liver.			Intellectual Product	
C133478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133478>	C133463	ALK NP_004295.2:p.I1170N|ALK I1170N|ALK Ile1170Asn|ALK NP_004295.2:p.Ile1170Asn|ALK Tyrosine Kinase Receptor I1170N|ALK Tyrosine Kinase Receptor Ile1170Asn|ALK p.I1170N|ALK p.Ile1170Asn|Anaplastic Lymphoma Kinase I1170N|Anaplastic Lymphoma Kinase Ile1170Asn|CD246 Antigen I1170N|CD246 Antigen Ile1170Asn|NP_004295.2:p.I1170N|NP_004295.2:p.Ile1170Asn	A change in the amino acid residue at position 1170 in the ALK tyrosine kinase receptor protein where isoleucine has been replaced by asparagine.			Cell or Molecular Dysfunction	
C133479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133479>	C137952	ALK NM_004304.4:c.3509T>G|ALK Receptor Tyrosine Kinase c.3509T>G|ALK c.3509T>G|Anaplastic Lymphoma Kinase (Ki-1) c.3509T>G|Anaplastic Lymphoma Receptor Tyrosine Kinase c.3509T>G|CD246 c.3509T>G|NM_004304.4:c.3509T>G	A nucleotide substitution at position 3509 of the coding sequence of the ALK gene where thymine has been mutated to guanine.			Cell or Molecular Dysfunction	
C13347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13347>	C204466	Aspirate|ASPIRATE|aspirate	Fluid withdrawn from a body cavity, organ, cyst, or tumor.			Body Substance	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C133480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133480>	C133463	ALK NP_004295.2:p.I1170S|ALK I1170S|ALK Ile1170Ser|ALK NP_004295.2:p.Ile1170Ser|ALK Tyrosine Kinase Receptor I1170S|ALK Tyrosine Kinase Receptor Ile1170Ser|ALK p.I1170S|ALK p.Ile1170Ser|Anaplastic Lymphoma Kinase I1170S|Anaplastic Lymphoma Kinase Ile1170Ser|CD246 Antigen I1170S|CD246 Antigen Ile1170Ser|NP_004295.2:p.I1170S|NP_004295.2:p.Ile1170Ser	A change in the amino acid residue at position 1170 in the ALK tyrosine kinase receptor protein where isoleucine has been replaced by serine.			Cell or Molecular Dysfunction	
C133481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133481>	C137952	ALK NM_004304.4:c.3512T>A|ALK Receptor Tyrosine Kinase c.3512T>A|ALK c.3512T>A|Anaplastic Lymphoma Kinase (Ki-1) c.3512T>A|Anaplastic Lymphoma Receptor Tyrosine Kinase c.3512T>A|CD246 c.3512T>A|NM_004304.4:c.3512T>A	A nucleotide substitution at position 3512 of the coding sequence of the ALK gene where thymine has been mutated to adenine.	ALK NM_004304.4:c.3512T>A		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133482>	C137952	ALK NM_004304.4:c.3512_3513delinsAT|ALK NM_004304.4:c.3512_3513TC>AT|ALK NM_004304.4:c.3512_3513delTCinsAT|ALK Receptor Tyrosine Kinase c.3512_3513TC>AT|ALK c.3512_3513TC>AT|ALK c.3512_3513delTCinsAT|Anaplastic Lymphoma Kinase (Ki-1) c.3512_3513TC>AT|Anaplastic Lymphoma Receptor Tyrosine Kinase c.3512_3513TC>AT|CD246 c.3512_3513TC>AT|CD246 c.3512_3513delTCinsAT|NM_004304.4:c.3512_3513TC>AT|NM_004304.4:c.3512_3513delTCinsAT|NM_004304.4:c.3512_3513delinsAT	A complex nucleotide substitution where the nucleotide sequence at positions 3512 and 3513 of the coding sequence of the ALK gene where thymine-cytosine has been mutated to adenine-thymine.	ALK NM_004304.4:c.3512_3513delinsAT		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133483>	C133463	ALK NP_004295.2:p.I1171N|ALK I1171N|ALK Ile1171Asn|ALK NP_004295.2:p.Ile1171Asn|ALK Tyrosine Kinase Receptor I1171N|ALK Tyrosine Kinase Receptor Ile1171Asn|ALK p.I1171N|ALK p.Ile1171Asn|Anaplastic Lymphoma Kinase I1171N|Anaplastic Lymphoma Kinase Ile1171Asn|CD246 Antigen I1171N|CD246 Antigen Ile1171Asn|NP_004295.2:p.I1171N|NP_004295.2:p.Ile1171Asn	A change in the amino acid residue at position 1171 in the ALK tyrosine kinase receptor protein where isoleucine has been replaced by asparagine.	ALK NP_004295.2:p.I1171N		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133484>	C137952	ALK NM_004304.4:c.3833A>C|ALK Receptor Tyrosine Kinase c.3833A>C|ALK c.3833A>C|Anaplastic Lymphoma Kinase (Ki-1) c.3833A>C|Anaplastic Lymphoma Receptor Tyrosine Kinase c.3833A>C|CD246 c.3833A>C|NM_004304.4:c.1278	A nucleotide substitution at position 3833 of the coding sequence of the ALK gene where adenine has been mutated to cytosine.			Cell or Molecular Dysfunction	
C133485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133485>	C133463	ALK NP_004295.2:p.Y1278S|ALK NP_004295.2:p.Tyr1278Ser|ALK Tyr1278Ser|ALK Tyrosine Kinase Receptor Tyr1278Ser|ALK Tyrosine Kinase Receptor Y1278S|ALK Y1278S|ALK p.Tyr1278Ser|ALK p.Y1278S|Anaplastic Lymphoma Kinase Tyr1278Ser|Anaplastic Lymphoma Kinase Y1278S|CD246 Antigen Tyr1278Ser|CD246 Antigen Y1278S|NP_004295.2:p.Tyr1278Ser|NP_004295.2:p.Y1278S	A change in the amino acid residue at position 1278 in the ALK tyrosine kinase receptor protein where tyrosine has been replaced by serine.			Cell or Molecular Dysfunction	
C133486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133486>	C137952	ALK NM_004304.4:c.3575G>C|ALK Receptor Tyrosine Kinase c.3575G>C|ALK c.3575G>C|Anaplastic Lymphoma Kinase (Ki-1) c.3575G>C|Anaplastic Lymphoma Receptor Tyrosine Kinase c.3575G>C|CD246 c.3575G>C|NM_004304.4:c.3575G>C	A nucleotide substitution at position 3575 of the coding sequence of the ALK gene where guanine has been mutated to cytosine.			Cell or Molecular Dysfunction	
C133487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133487>	C133463	ALK NP_004295.2:p.R1192P|ALK Arg1192Pro|ALK NP_004295.2:p.Arg1192Pro|ALK R1192P|ALK Tyrosine Kinase Receptor Arg1192Pro|ALK Tyrosine Kinase Receptor R1192P|ALK p.Arg1192Pro|ALK p.R1192P|Anaplastic Lymphoma Kinase Arg1192Pro|Anaplastic Lymphoma Kinase R1192P|CD246 Antigen Arg1192Pro|CD246 Antigen R1192P|NP_004295.2:p.Arg1192Pro|NP_004295.2:p.R1192P	A change in the amino acid residue at position 1192 in the ALK tyrosine kinase receptor protein where arginine has been replaced by proline.			Cell or Molecular Dysfunction	
C133488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133488>	C137952	ALK NM_004304.4:c.3497T>G|ALK Receptor Tyrosine Kinase c.3497T>G|ALK c.3497T>G|Anaplastic Lymphoma Kinase (Ki-1) c.3497T>G|Anaplastic Lymphoma Receptor Tyrosine Kinase c.3497T>G|CD246 c.3497T>G|NM_004304.4:c.3497T>G	A nucleotide substitution at position 3497 of the coding sequence of the ALK gene where thymine has been mutated to guanine.			Cell or Molecular Dysfunction	
C133489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133489>	C133463	ALK NP_004295.2:p.M1166R|ALK M1166R|ALK Met1166Arg|ALK NP_004295.2:p.Met1166Arg|ALK Tyrosine Kinase Receptor M1166R|ALK Tyrosine Kinase Receptor Met1166Arg|ALK p.M1166R|ALK p.Met1166Arg|Anaplastic Lymphoma Kinase M1166R|Anaplastic Lymphoma Kinase Met1166Arg|CD246 Antigen M1166R|CD246 Antigen Met1166Arg|NP_004295.2:p.M1166R|NP_004295.2:p.Met1166Arg	A change in the amino acid residue at position 1166 in the ALK tyrosine kinase receptor protein where methionine has been replaced by arginine.			Cell or Molecular Dysfunction	
C13348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13348>	C13442	Genital|Genital structure (body structure)|genital	The group of organs and glands involved with having a child. In women, these are the uterus (womb), the fallopian tubes, the ovaries, and the vagina (birth canal). The reproductive system in men includes the testes, the prostate, and the penis.			Body Part, Organ, or Organ Component	mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C133490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133490>	C137952	ALK NM_004304.4:c.3586C>A|ALK Receptor Tyrosine Kinase c.3586C>A|ALK c.3586C>A|Anaplastic Lymphoma Kinase (Ki-1) c.3586C>A|Anaplastic Lymphoma Receptor Tyrosine Kinase c.3586C>A|CD246 c.3586C>A|NM_004304.4:c.3586C>A	A nucleotide substitution at position 3586 of the coding sequence of the ALK gene where cytosine has been mutated to adenine.	ALK NM_004304.4:c.3586C>A		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133491>	C133463	ALK NP_004295.2:p.L1196M|ALK L1196M|ALK Leu1196Met|ALK NP_004295.2:p.Leu1196Met|ALK Tyrosine Kinase Receptor L1196M|ALK Tyrosine Kinase Receptor Leu1196Met|ALK p.L1196M|ALK p.Leu1196Met|Anaplastic Lymphoma Kinase L1196M|Anaplastic Lymphoma Kinase Leu1196Met|CD246 Antigen L1196M|CD246 Antigen Leu1196Met|NP_004295.2:p.L1196M|NP_004295.2:p.Leu1196Met	A change in the amino acid residue at position 1196 in the ALK tyrosine kinase receptor protein where leucine has been replaced by methionine.	ALK NP_004295.2:p.L1196M		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133492>	C137952	ALK NM_004304.4:c.3383G>C|ALK Receptor Tyrosine Kinase c.3383G>C|ALK c.3383G>C|Anaplastic Lymphoma Kinase (Ki-1) c.3383G>C|Anaplastic Lymphoma Receptor Tyrosine Kinase c.3383G>C|CD246 c.3383G>C|NM_004304.4:c.3383G>C	A nucleotide substitution at position 3383 of the coding sequence of the ALK gene where guanine has been mutated to cytosine.			Cell or Molecular Dysfunction	
C133493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133493>	C133463	ALK NP_004295.2:p.G1128A|ALK G1128A|ALK Gly1128Ala|ALK NP_004295.2:p.Gly1128Ala|ALK Tyrosine Kinase Receptor G1128A|ALK Tyrosine Kinase Receptor Gly1128Ala|ALK p.G1128A|ALK p.Gly1128Ala|Anaplastic Lymphoma Kinase G1128A|Anaplastic Lymphoma Kinase Gly1128Ala|CD246 Antigen G1128A|CD246 Antigen Gly1128Ala|NP_004295.2:p.G1128A|NP_004295.2:p.Gly1128Ala	A change in the amino acid residue at position 1128 in the ALK tyrosine kinase receptor protein where glycine has been replaced by alanine.			Cell or Molecular Dysfunction	
C133494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133494>	C7056	Large B-Cell Lymphoma with IRF4 Rearrangement|LBCL with IRF4 Rearrangement	A large B-cell lymphoma that usually affects the Waldeyer ring and/or cervical lymph nodes and less often the gastrointestinal tract. It occurs most commonly in children and young adults and is low stage. It is characterized by a follicular, follicular and diffuse, or pure diffuse growth pattern resembling follicular lymphoma grade 3B or a diffuse large B-cell lymphoma. Most cases have IG/IRF4 rearrangements. BCL2 rearrangements are not present. Some cases that belong in this category lack an IRF4 rearrangement but have strong IRF4/MUM1 expression. This lymphoma is more aggressive than pediatric-type follicular lymphomas.	Large B-Cell Lymphoma with IRF4 Rearrangement		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133495>	C133155	IRF4 Gene Rearrangement|Interferon Regulatory Factor 4 Gene Rearrangement|LSIRF Gene Rearrangement|MUM1 Gene Rearrangement|Multiple Myeloma Oncogene 1 Gene Rearrangement	A molecular abnormality indicating rearrangement of the IRF4 gene.	IRF4 Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133496>	C76121	Patient-Device Interaction Problem|Patient Device Interaction Problem	Problem related to the interaction between the patient and a medical device.			Event	CDRH Medical Device Problem Terminology
C133497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133497>	C62814	Loosening of Implant Not Related to Bone-Ingrowth	Problem associated with the loss of direct anchorage of an implanted device over time or due to an injury.			Event	CDRH Medical Device Problem Terminology
C133498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133498>	C63041	Component Misassembled	A device is found to have one or more components incorrectly assembled when delivered to the user facility.			Event	CDRH Medical Device Problem Terminology
C133499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133499>	C6906|C153823|C142849	Recurrent Atypical Teratoid/Rhabdoid Tumor	The reemergence of an atypical teratoid/rhabdoid tumor after a period of remission.	Recurrent Atypical Teratoid/Rhabdoid Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13349>	C13442	Myeloid|myeloid	A type of white blood cell. Neutrophils, eosinophils, and basophils are granulocytes.			Qualitative Concept	
C1334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1334>	C45812	Vitamin B6|VIT B6|Vitamin B 6|Vitamin B-6|vitamin B6	A group of water-soluble vitamins essential for metabolism and normal physiological functions. B6 vitamins, including pyridoxine, pyridoxal, and pyridoxamine, are converted in vivo to pyridoxal phosphate, a cofactor necessary for the synthesis of amino acids, neurotransmitters, and sphingolipids.  More than 100 enzymes involved in protein metabolism require vitamin B6 as a cofactor. Vitamin B6 is essential to red blood cell, nervous system, and immune systems functions and helps maintain normal blood glucose levels. Vitamin B6 is found in a wide variety of foods including cereals, beans, meat, poultry, fish, and some fruits and vegetables. (NCI04)	Vitamin B6		Vitamin	CTRP Agent Terminology|CTRP Biomarker Terminology|CTRP Terminology
C133500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133500>	C62982	Low pH	pH lower than expected and/or anticipated.			Event	CDRH Medical Device Problem Terminology
C133501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133501>	C213367|C153238	Metastatic Breast Carcinoma in the Central Nervous System|Breast Carcinoma Metastatic in the CNS|Breast Carcinoma Metastatic in the Central Nervous System|Metastatic Breast Cancer in the Central Nervous System	A carcinoma that has spread to the central nervous system from its original site in the breast, through the hematogenous route.	Breast Carcinoma Metastatic in the Central Nervous System		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133503>	C213367|C153202	Metastatic Lung Carcinoma in the Central Nervous System|Lung Carcinoma Metastatic in the CNS|Lung Carcinoma Metastatic in the Central Nervous System|Metastatic Lung Cancer in the Central Nervous System	A carcinoma that has spread to the central nervous system from its original site in the lung, through the hematogenous route.	Lung Carcinoma Metastatic in the Central Nervous System		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133504>	C8925|C4015	Metastatic Melanoma in the Central Nervous System|Melanoma Metastatic in the CNS|Melanoma Metastatic in the Central Nervous System	A melanoma that has spread to the central nervous system from its original site of growth, through the hematogenous route.	Melanoma Metastatic in the Central Nervous System		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133505>	C62968	Device Explosion|Explosion	Problem with the device associated with the violent bursting due to the sudden expansion of air, gas or fluid.			Event	CDRH Medical Device Problem Terminology
C133507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133507>	C63248	Material Too Soft or Flexible|Material Too Soft/Flexible	Problem associated with the device material that results in the material's inability to maintain the desired shape or support function.			Event	CDRH Medical Device Problem Terminology
C133509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133509>	C62968	Material Split, Cut or Torn	Problem associated with materials comprising the device are split, cut or torn due to external forces (e.g. wrenching or laceration) or internal forces (e.g. exceeding the tensile stress limits belonging to the materials used in the device construction).			Event	CDRH Medical Device Problem Terminology
C13350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13350>	C13442	Lymphocytic|LYMPHOCYTIC|lymphocytic	Of or pertaining to lymphocytes.			Qualitative Concept	CDISC SEND Microscopic Findings Result Modifier Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C133510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133510>	C63041	Ejection Problem	Problems associated with the inability of or unexpected removal or separation of the device from its physical location.			Event	CDRH Medical Device Problem Terminology
C133511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133511>	C133510	Failure to Eject	Problem associated with the inability to remove or discharge device from the location of use.			Event	CDRH Medical Device Problem Terminology
C133512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133512>	C63041	Firing Problem	Problem associated with the device not discharging as intended.			Event	CDRH Medical Device Problem Terminology
C133513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133513>	C62961	Physical Resistance/Sticking	Problem associated with the lack of movement in the device due parts sticking or seizing.			Event	CDRH Medical Device Problem Terminology
C133514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133514>	C62923	Sharp Edges	The device has undesirable sharp edges which can cause harm or damage.			Event	CDRH Medical Device Problem Terminology
C133516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133516>	C62814	Device Fell	Problem associated with the device or a component unexpectedly being dropped or moving down from an intended place.			Event	CDRH Medical Device Problem Terminology
C133517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133517>	C63025	Device Complete Loss of Power|Complete Loss of Power	Problem associated with the lack of power to run a device.			Event	CDRH Medical Device Problem Terminology
C133518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133518>	C49236	Line of Therapy	The sequence of therapies administered to a patient.			Therapeutic or Preventive Procedure	
C133519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133519>	C133445	Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8|0|Stage 0 Esophageal Squamous Cell Cancer	Stage 0 includes: Tis, N0, M0, GN/A, Tumor location: Any. Tis: High-grade dysplasia, defined as malignant cells confined to the epithelium by the basement membrane. N0: No regional lymph node metastasis. M0: No distant metastasis. GN/A: Grade non-applicable. (AJCC 8th ed.)	Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C13351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13351>	C13442	Axillary|axillary	Pertaining to the armpit area, including the lymph nodes that are located there.			Spatial Concept	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C133520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133520>	C63025	Intermittent Loss of Power	Problem associated with an intermittent disruption to the power to run the device.			Event	CDRH Medical Device Problem Terminology
C133521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133521>	C133445	Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC v8|Stage I Esophageal Squamous Cell Cancer	Stage I includes: IA: (T1a, N0, M0, G1, Tumor location: Any); (T1a, N0, M0, GX, Tumor location: Any); IB: (T1a, N0, M0, G2-3, Tumor location: Any); (T1b, N0, M0, G1-3, Tumor location: Any); (T1b, N0, M0, GX, Tumor location: Any); (T2, N0, M0, G1, Tumor location: Any). T1a: Tumor invades the lamina propria or muscularis mucosae. T1b: Tumor invades the submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well-differentiated. GX: Grade cannot be assessed. G2: Moderately differentiated. G3: Poorly differentiated, undifferentiated. (AJCC 8th ed.)	Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133522>	C133518	Fourth-Line Therapy|Fourth Line Treatment|Fourth line of therapy|Fourth-Line Treatment	Treatment that is given when the first three treatments don't work, or stop working.			Therapeutic or Preventive Procedure	
C133523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133523>	C63007	Interrogation Problem	Problems associated with the device's ability to respond to signals from a system designed to interrogate its status.			Event	CDRH Medical Device Problem Terminology
C133524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133524>	C133518	Fifth-Line Therapy|Fifth Line Treatment|Fifth line of therapy|Fifth-Line Treatment	Treatment that is given when the first four treatments don't work, or stop working.			Therapeutic or Preventive Procedure	
C133525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133525>	C133521	Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC v8|IA|Stage IA Esophageal Squamous Cell Cancer	Stage IA includes: (T1a, N0, M0, G1, Tumor location: Any); (T1a, N0, M0, GX, Tumor location: Any). T1a: Tumor invades the lamina propria or muscularis mucosae. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well-differentiated. GX: Grade cannot be assessed. (AJCC 8th ed.)	Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133526>	C133518	Sixth-Line Therapy|Sixth Line Treatment|Sixth line of therapy|Sixth-Line Treatment	Treatment that is given when the first five treatments don't work, or stop working.			Therapeutic or Preventive Procedure	
C133527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133527>	C63007	Unintended Electrical Shock	The device delivers unintended electrical shock.			Event	CDRH Medical Device Problem Terminology
C133528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133528>	C133518	Seventh-Line Therapy|Seventh Line Treatment|Seventh line of therapy|Seventh-Line Treatment	Treatment that is given when the first six treatments don't work, or stop working.			Therapeutic or Preventive Procedure	
C133529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133529>	C133518	Eighth-Line Therapy|Eighth Line Treatment|Eighth line of therapy|Eighth-Line Treatment	Treatment that is given when the first seven treatments don't work, or stop working.			Therapeutic or Preventive Procedure	
C13352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13352>	C225418	Intraperitoneal|IP|intraperitoneal	Relating to the peritoneal cavity as the intended site of administration.			Spatial Concept	EDQM Health Care Terminology|EDQM-HC Intended Site of Administration Terminology
C133530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133530>	C133521	Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC v8|IB|Stage IB Esophageal Squamous Cell Cancer	Stage IB includes: (T1a, N0, M0, G2-3, Tumor location: Any); (T1b, N0, M0, G1-3, Tumor location: Any); (T1b, N0, M0, GX, Tumor location: Any); (T2, N0, M0, G1, Tumor location: Any). T1a: Tumor invades the lamina propria or muscularis mucosae. T1b: Tumor invades the submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well-differentiated. GX: Grade cannot be assessed. G2: Moderately differentiated. G3: Poorly differentiated, undifferentiated. (AJCC 8th ed.)	Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133531>	C46126	Seventh|7th	Following the sixth position in an ordering or series; coming next after the sixth and just before the eighth in position.			Conceptual Entity	GDC Terminology|GDC Value Terminology
C133532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133532>	C133445	Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8|Stage II Esophageal Squamous Cell Cancer	Stage II includes: IIA: (T2, N0, M0, G2-3, Tumor location: Any); (T2, N0, M0, GX, Tumor location: Any); (T3, N0, M0, Any G, Tumor location: Lower); (T3, N0, M0, G1, Tumor location: Upper/middle); IIB: (T3, N0, M0, G2-3, Tumor location: Upper/middle); (T3, N0, M0, GX, Tumor location: Any); (T3, N0, M0, Any G, Tumor location: Unknown); (T1, N1, M0, Any G, Tumor location: Any). T2: Tumor invades the muscularis propria. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T3: Tumor invades adventitia. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. GX: Grade cannot be assessed. G1: Well-differentiated. G2: Moderately differentiated. G3: Poorly differentiated, undifferentiated. (AJCC 8th ed.)	Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133533>	C46126	Eighth|8th	Following the seventh position in an ordering or series; coming next after the seventh and just before the ninth in position.			Conceptual Entity	GDC Terminology|GDC Value Terminology
C133534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133534>	C133532	Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8|IIA|Stage IIA Esophageal Squamous Cell Cancer	Stage IIA includes: (T2, N0, M0, G2-3, Tumor location: Any); (T2, N0, M0, GX, Tumor location: Any); (T3, N0, M0, Any G, Tumor location: Lower); (T3, N0, M0, G1, Tumor location: Upper/middle). T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. N0: No regional lymph node metastasis. M0: No distant metastasis. GX: Grade cannot be assessed. G1: Well-differentiated. G2: Moderately differentiated. G3: Poorly differentiated, undifferentiated. (AJCC 8th ed.)	Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133535>	C133532	Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8|IIB|Stage IIB Esophageal Squamous Cell Cancer	Stage IIB includes: (T3, N0, M0, G2-3, Tumor location: Upper/middle); (T3, N0, M0, GX, Tumor location: Any); (T3, N0, M0, Any G, Tumor location: Unknown); (T1, N1, M0, Any G, Tumor location: Any). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T3: Tumor invades adventitia. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. GX: Grade cannot be assessed. G2: Moderately differentiated. G3: Poorly differentiated, undifferentiated (AJCC 8th ed.)	Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133536>	C133445	Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8|Stage III Esophageal Squamous Cell Cancer	Stage III includes: IIIA: (T1, N2, M0, Any G, Tumor location: Any); (T2, N1, M0, Any G, Tumor location: Any); IIIB: (T2, N2, M0, Any G, Tumor location: Any); (T3, N1-2, M0, Any G, Tumor location: Any); (T4a, N0-1, M0, Any G, Tumor location: Any). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133537>	C133536	Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8|IIIA|Stage IIIA Esophageal Squamous Cell Cancer	Stage IIIA includes: (T1, N2, M0, Any G, Tumor location: Any); (T2, N1, M0, Any G, Tumor location: Any). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133538>	C133536	Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8|IIIB|Stage IIIB Esophageal Squamous Cell Cancer	Stage IIIB includes: (T2, N2, M0, Any G, Tumor location: Any); (T3, N1-2, M0, Any G, Tumor location: Any); (T4a, N0-1, M0, Any G, Tumor location: Any). T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133539>	C133445	Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8|Stage IV Esophageal Squamous Cell Cancer	Stage IV includes: IVA: (T4a, N2, M0, Any G, Tumor location: Any); (T4b, N0-2, M0, Any G, Tumor location: Any); (Any T, N3, M0, Any G, Tumor location: Any); IVB: (Any T, Any N, M1, Any G, Tumor location: Any). T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)	Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13353>	C225418	Subcutaneous|SUBCUTANEOUS|subcutaneous				Spatial Concept	CDISC SEND Microscopic Findings Result Modifier Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C133540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133540>	C210987|C124800	Dapolsertib|DAPOLSERTIB|Dual PIM/FLT3 Kinase Inhibitor|PIM/FLT3 Kinase Inhibitor SEL24|SEL 24|SEL24|SEL24-B489	An orally available inhibitor of PIM family serine/threonine protein kinases and mutant forms of FMS-related tyrosine kinase 3 (FLT3; STK1) with potential antineoplastic activity. Upon oral administration, dapolsertib binds to and inhibits the kinase activities of PIM-1, -2 and -3, and mutant forms of FLT3, which may result in the interruption of the G1/S phase cell cycle transition, an inhibition of cell proliferation, and an induction of apoptosis in tumor cells that overexpress PIMs or express mutant forms of FLT3. FLT3, a tyrosine kinase receptor that is overexpressed or mutated in various cancers, plays a role in signaling pathways that regulate hematopoietic progenitor cell proliferation, and in leukemic cell proliferation and survival. PIM kinases, downstream effectors of many cytokine and growth factor signaling pathways, including the FLT3 signaling pathway, play key roles in cell cycle progression and apoptosis inhibition and may be overexpressed in various malignancies.	Dapolsertib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C133541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133541>	C133539	Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8|IVA|Stage IVA Esophageal Squamous Cell Cancer	Stage IVA includes: (T4a, N2, M0, Any G, Tumor location: Any); (T4b, N0-2, M0, Any G, Tumor location: Any); (Any T, N3, M0, Any G, Tumor location: Any). T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133542>	C133539	Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8|IVB|Stage IVB Esophageal Squamous Cell Cancer	Stage IVB includes: Any T, Any N, M1, Any G, Tumor location: Any. M1: Distant metastasis. (AJCC 8th ed.)	Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133543>	C78275	Crizanlizumab|Adakveo|CRIZANLIZUMAB|Crizanlizumab-tmca|SEG 101|SEG-101|SEG101|SelG1	A humanized monoclonal immunoglobulin G1 anti-P-selectin antibody with vaso-protective and anti-vaso-occlusive properties. Upon administration, crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand-1 (PSGL-1; SELPLG) on neutrophils and monocytes. P-selectin, a glycoprotein that functions as a cell adhesion molecule (CAM), translocates to the surface of activated endothelial cells and platelets, upon stimulation, where it binds to its ligand and mediates the rolling of platelets and neutrophils on activated endothelial cells. Therefore, blockade of p-selectin may inhibit platelet aggregation, maintain blood flow and minimize sickle cell-related pain crises (SCPC).	Crizanlizumab		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C133544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133544>	C63005	Unexpected Shutdown	Problem associated with the device unexpectedly powering down.			Event	CDRH Medical Device Problem Terminology
C133545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133545>	C62941	Audible Prompt/Feedback|Audible Prompt/Feedback Problem	Problem with any deviation from the documented specifications of a device that relates to audible feedback.			Event	CDRH Medical Device Problem Terminology
C133546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133546>	C63088	No Visual Prompts/Feedback	Problem associated with the device ceasing to provide visual feedback.			Event	CDRH Medical Device Problem Terminology
C133547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133547>	C62941	Tactile Prompts/Feedback	Problem with any deviation from the documented specifications of the device that relates to tactile feedback, e.g. device vibrational prompt.			Event	CDRH Medical Device Problem Terminology
C133548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133548>	C9296	Gastroesophageal Junction Adenocarcinoma by AJCC v8 Stage	A term that refers to the staging of gastroesophageal junction adenocarcinoma according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C133549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133549>	C133548	Gastroesophageal Junction Adenocarcinoma by AJCC v8 Clinical Stage|Gastroesophageal Junction Adenocarcinoma by AJCC v8 cTNM Stage	A term that refers to the clinical staging of gastroesophageal junction adenocarcinoma according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C133550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133550>	C133549	Clinical Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage 0 includes: Tis, N0, M0. Tis: High-grade dysplasia, defined as malignant cells confined to the epithelium by the basement membrane. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C133551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133551>	C133547	Inappropriate Tactile Prompt/Feedback	Problem with tactile feedback which does not guide a device user to the correct action.			Event	CDRH Medical Device Problem Terminology
C133552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133552>	C133549	Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage I includes: T1, N0, M0. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C133553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133553>	C133549	Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage II includes: IIA: T1, N1, M0; IIB: T2, N0, M0. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C133554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133554>	C133553	Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage IIA includes: T1, N1, M0. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C133555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133555>	C133553	Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage IIB includes: T2, N0, M0. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C133556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133556>	C133549	Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage III includes: (T2, N1, M0); (T3, N0-1, M0); (T4a, N0-1, M0). T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C133557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133557>	C133549	Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage IV includes: IVA: (T1-4a, N2, M0); (T4b, N0-2, M0); (Any T, N3, M0); IVB: (Any T, Any N, M1). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C133558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133558>	C133557	Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage IVA includes: (T1-4a, N2, M0); (T4b, N0-2, M0); (Any T, N3, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C133559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133559>	C133547	No Tactile Prompts/Feedback	Problem associated with the device ceasing to provide tactile feedback.			Event	CDRH Medical Device Problem Terminology
C13355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13355>	C13377	Chromosome Arm|chromosome arm|chromosome_arm	Under the microscope chromosomes appear as thin, thread-like structures. They all have a short arm and long arm separated by a primary constriction called the centromere. The short arm is designated as p and the long arm as q.			Gene or Genome	GDC Property Terminology|GDC Terminology
C133560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133560>	C133557	Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C133561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133561>	C63002	Intermittent Energy Output	Problem associated with the energy output from the device being inconsistent over time.			Event	CDRH Medical Device Problem Terminology
C133562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133562>	C62941	Radiation Output Problem	Problem with the device's intended output of radiation.			Event	CDRH Medical Device Problem Terminology
C133563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133563>	C133548	Gastroesophageal Junction Adenocarcinoma by AJCC v8 Pathologic Stage|Gastroesophageal Junction Adenocarcinoma by AJCC v8 pTNM Stage	A term that refers to the pathologic staging of gastroesophageal junction adenocarcinoma according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C133564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133564>	C133563	Pathologic Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage 0 includes: Tis, N0, M0, GN/A. Tis: High-grade dysplasia, defined as malignant cells confined to the epithelium by the basement membrane. N0: No regional lymph node metastasis. M0: No distant metastasis. GN/A: Grade non-applicable. (AJCC 8th ed.)			Neoplastic Process	
C133565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133565>	C133563	Pathologic Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage I includes: IA: (T1a, N0, M0, G1); (T1a, N0, M0, GX); IB: (T1a, N0, M0, G2); (T1b, N0, M0, G1-2); (T1b, N0, M0, GX); IC: (T1, N0, M0, G3); (T2, N0, M0, G1-2). T1a: Tumor invades the lamina propria or muscularis mucosae. T1b: Tumor invades the submucosa. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well-differentiated. GX: Grade cannot be assessed. G2: Moderately differentiated. G3: Poorly differentiated, undifferentiated. (AJCC 8th ed.)			Neoplastic Process	
C133566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133566>	C133565	Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage IA includes: (T1a, N0, M0, G1); (T1a, N0, M0, GX). T1a: Tumor invades the lamina propria or muscularis mucosae. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well-differentiated. GX: Grade cannot be assessed. (AJCC 8th ed.)			Neoplastic Process	
C133567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133567>	C133565	Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage IB includes: (T1a, N0, M0, G2); (T1b, N0, M0, G1-2); (T1b, N0, M0, GX). T1a: Tumor invades the lamina propria or muscularis mucosae. T1b: Tumor invades the submucosa. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well-differentiated. GX: Grade cannot be assessed. G2: Moderately differentiated. (AJCC 8th ed.)			Neoplastic Process	
C133568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133568>	C133565	Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage IC includes: (T1, N0, M0, G3); (T2, N0, M0, G1-2). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. G1: Well-differentiated. G2: Moderately differentiated. G3: Poorly differentiated, undifferentiated. (AJCC 8th ed.)			Neoplastic Process	
C133569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133569>	C133562	Radiation Output Failure	Problem associated with the absence of radiation output from radiological or diagnostic devices.			Event	CDRH Medical Device Problem Terminology
C13356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13356>	C13236	Plasma|PLASMA|plasma	Plasma is the fluid (noncellular) portion of the circulating blood, as distinguished from the serum that is the fluid portion of the blood obtained by removal of the fibrin clot and blood cells after coagulation.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C133570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133570>	C133563	Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage II includes: IIA: (T2, N0, M0, G3); (T2, N0, M0, GX); IIB: (T1, N1, M0, Any G); (T3, N0, M0, Any G). T2: Tumor invades the muscularis propria. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T3: Tumor invades adventitia. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. GX: Grade cannot be assessed. G3: Poorly differentiated, undifferentiated. (AJCC 8th ed.)			Neoplastic Process	
C133571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133571>	C133562	Unexpected/Unintended Radiation Output	Device-emitted radiation when it was not supposed to. This applies to devices which are intended to emit radiation, and the radiation being emitted from the correct part of the device, but at an incorrect time.			Event	CDRH Medical Device Problem Terminology
C133572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133572>	C133570	Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage IIA includes: (T2, N0, M0, G3); (T2, N0, M0, GX). T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. GX: Grade cannot be assessed. G3: Poorly differentiated, undifferentiated. (AJCC 8th ed.)			Neoplastic Process	
C133573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133573>	C133570	Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage IIB includes: (T1, N1, M0, Any G); (T3, N0, M0, Any G). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T3: Tumor invades adventitia. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C133574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133574>	C62848	Non-Reproducible Results|Non Reproducible Results	Device results that cannot be reliably reproduced.			Event	CDRH Medical Device Problem Terminology
C133575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133575>	C133563	Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage III includes: IIIA: (T1, N2, M0, Any G); (T2, N1, M0, Any G); IIIB: (T2, N2, M0, Any G); (T3, N1-2, M0, Any G); (T4a, N0-1, M0, Any G). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C133576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133576>	C62922	Excessive Heating	Problem associated with the device which has a warming or heating function, and is producing excessive heat.			Event	CDRH Medical Device Problem Terminology
C133577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133577>	C133575	Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage IIIA includes: (T1, N2, M0, Any G); (T2, N1, M0, Any G). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C133578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133578>	C63305	Application Program Freezes or Fails to Launch	Problem associated with an application program which freezes and/or fails to launch.			Event	CDRH Medical Device Problem Terminology
C133579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133579>	C133575	Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage IIIB includes: (T2, N2, M0, Any G); (T3, N1-2, M0, Any G); (T4a, N0-1, M0, Any G). T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C133580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133580>	C133563	Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage IV includes: IVA: (T4a, N2, M0, Any G); (T4b, N0-2, M0, Any G); (Any T, N3, M0, Any G); IVB: (Any T, Any N, M1, Any G). T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C133581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133581>	C133580	Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage IVA includes: (T4a, N2, M0, Any G); (T4b, N0-2, M0, Any G); (Any T, N3, M0, Any G). T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C133582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133582>	C133580	Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage IVB includes: Any T, Any N, M1, Any G. M1: Distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C133583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133583>	C133548	Gastroesophageal Junction Adenocarcinoma by AJCC v8 Postneoadjuvant Therapy Stage|Gastroesophageal Junction Adenocarcinoma by AJCC v8 ypTNM Stage	A term that refers to the postneoadjuvant therapy staging of gastroesophageal junction adenocarcinoma according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C133584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133584>	C133583	Postneoadjuvant Therapy Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage I includes: T0-2, N0, M0. T0: No evidence of primary tumor. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C133585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133585>	C133583	Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage II includes: T3, N0, M0. T3: Tumor invades adventitia. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C133586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133586>	C133583	Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage III includes: IIIA: (T0-2, N1, M0); IIIB: (T3, N1, M0); (T0-3, N2, M0); (T4a, N0, M0). T0: No evidence of primary tumor. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C133587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133587>	C133586	Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage IIIA includes: T0-2, N1, M0. T0: No evidence of primary tumor. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C133588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133588>	C133586	Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage IIIB includes: (T3, N1, M0); (T0-3, N2, M0); (T4a, N0, M0). T0: No evidence of primary tumor. T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor invades adventitia. T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C133589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133589>	C133583	Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage IV includes: IVA: (T4a, N1-2, M0); (T4a, NX, M0); (T4b, N0-2, M0); (Any T, N3, M0); IVB: (Any T, Any N, M1). T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. NX: Regional lymph nodes cannot be assessed. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C133590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133590>	C133589	Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage IVA includes: (T4a, N1-2, M0); (T4a, NX, M0); (T4b, N0-2, M0); (Any T, N3, M0). T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. NX: Regional lymph nodes cannot be assessed. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C133591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133591>	C133589	Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8	Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C133592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133592>	C7164|C4937	Recurrent Classic Hodgkin Lymphoma|Recurrent Classical Hodgkin Lymphoma|Recurrent Classical Hodgkin Lymphoma|Relapsed Classical Hodgkin Lymphoma	The reemergence of classic Hodgkin lymphoma after a period of remission.	Recurrent Classic Hodgkin Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133593>	C63269	Program or Algorithm Execution Problem	Problem associated with execution problems relating to program or algorithm.			Event	CDRH Medical Device Problem Terminology
C133594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133594>	C63305	Unintended Application Program Shut Down	Problem associated with an unintended shut down by malfunction of the application program.			Event	CDRH Medical Device Problem Terminology
C133595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133595>	C133363	Gastric Cancer TNM Finding v8|Gastric Carcinoma TNM Finding v8	A finding about one or more characteristics of gastric cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to all carcinomas that arise in the stomach. Gastrointestinal stromal tumors, sarcomas, lymphomas and well-differentiated neuroendocrine tumors (G1 and G2) are not staged using this staging system. (from AJCC 8th Ed.)			Finding	
C133596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133596>	C133595	Gastric Cancer Clinical TNM Finding v8|Gastric Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of gastric cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C133597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133597>	C133596	Gastric Cancer Clinical Distant Metastasis TNM Finding v8|Clinical Distant Metastasis Status (cM)|Gastric Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of gastric cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C133598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133598>	C133597	Gastric Cancer cM0 TNM Finding v8|Gastric Carcinoma cM0 TNM Finding v8	Gastric cancer without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C133599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133599>	C133593	Delayed Program or Algorithm Execution	Problem associated with a delayed execution relating to program or algorithm.			Event	CDRH Medical Device Problem Terminology
C13359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13359>	C13442	Gastrointestinal|GI|Gastroenteral|gastrointestinal	Pertaining to the stomach and intestines.			Body Location or Region	EDQM Health Care Terminology|EDQM-HC Intended Site of Administration Terminology|GDC Terminology|GDC Value Terminology
C1335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1335>	C2087	Aminothiadiazole|1,3, 4-Thiadiazol-2-amine (9CI)|1,3, 4-Thiadiazol-2-amine (9CI)|1,3, 4-Thiadiazole, 2-Amino- (8CI)|1,3, 4-Thiadiazole, 2-amino- (8CI)|1,3,4-Thiadiazole, 2-Amino|1,3,4-Thiadiazole, 2-amino|2-AMINO-1,3,4-THIADIAZOLE|2-Amino-1,3,4-thiadiazole|2-Amino-1,3,4-thiadiazole|2-Amino-1-thia-3,4-diazole|2-Amino-1-thia-3,4-diazole|2-Aminothiadiazole|2-Aminothiadiazole|ATDA|Amino 134-Thiadiazole|FDA 0084|FDA 0084	A synthetic derivative of nicotinamide adenine dinucleotide (NAD). Aminothiadiazole competitively inhibits inosine 5-monophosphate dehydrogenase, thereby disrupting the regulation of cell proliferation and differentiation in a number of cells.  This agent is also a selective human adenosine A3 receptor antagonist. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C133600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133600>	C133597	Gastric Cancer cM1 TNM Finding v8|Gastric Carcinoma cM1 TNM Finding v8|cM1	Gastric cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C133601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133601>	C133595	Gastric Cancer Pathologic TNM Finding v8|Gastric Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of gastric cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C133602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133602>	C133601	Gastric Cancer Pathologic Distant Metastasis TNM Finding v8|Gastric Carcinoma Pathologic Distant Metastasis TNM Finding v8|Pathologic Distant Metastasis Status (pM)	A pathologic finding about one or more characteristics of gastric cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C133603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133603>	C133593	Intermittent Program or Algorithm Execution	Problem associated with intermittent execution relating to program or algorithm.			Event	CDRH Medical Device Problem Terminology
C133604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133604>	C133602	Gastric Cancer pM1 TNM Finding v8|Gastric Carcinoma pM1 TNM Finding v8|pM1	Gastric cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C133605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133605>	C133601	Gastric Cancer Pathologic Primary Tumor TNM Finding v8|Gastric Carcinoma Pathologic Primary Tumor TNM Finding v8|Pathologic Primary Tumor Status (pT)	A pathologic finding about one or more characteristics of gastric cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C133606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133606>	C133605	Gastric Cancer pTX TNM Finding v8|Gastric Carcinoma pTX TNM Finding v8|pTX	Gastric cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C133607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133607>	C133605	Gastric Cancer pT0 TNM Finding v8|Gastric Carcinoma pT0 TNM Finding v8|pT0	Gastric cancer with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C133608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133608>	C133605	Gastric Cancer pTis TNM Finding v8|Gastric Carcinoma pTis TNM Finding v8|pTis	Gastric cancer with a finding of carcinoma in situ: intraepithelial tumor without invasion of the lamina propria, high grade dysplasia. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C133609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133609>	C133605	Gastric Cancer pT1 TNM Finding v8|Gastric Carcinoma pT1 TNM Finding v8|pT1	Gastric cancer with tumor invading the lamina propria, muscularis mucosae, or submucosa. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C13360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13360>	C13442	Thoracic|THORACIC|thoracic				Spatial Concept	CDISC SEND Microscopic Findings Result Modifier Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C133610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133610>	C133609	Gastric Cancer pT1a TNM Finding v8|Gastric Carcinoma pT1a TNM Finding v8|pT1a	Gastric cancer with tumor invading the lamina propria or muscularis mucosae. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C133611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133611>	C133609	Gastric Cancer pT1b TNM Finding v8|Gastric Carcinoma pT1b TNM Finding v8|pT1b	Gastric cancer with tumor invading the submucosa. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C133612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133612>	C133605	Gastric Cancer pT2 TNM Finding v8|Gastric Carcinoma pT2 TNM Finding v8|pT2	Gastric cancer with tumor invading the muscularis propria. A tumor may penetrate the muscularis propria with extension into the gastrocolic or gastrohepatic ligaments, or into the greater or lesser omentum, without perforation of the visceral peritoneum covering these structures. In this case, the tumor is classified as T3. If there is perforation of the visceral peritoneum covering the gastric ligaments or the omentum, the tumor should be classified as T4. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C133613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133613>	C133605	Gastric Cancer pT3 TNM Finding v8|Gastric Carcinoma pT3 TNM Finding v8|pT3	Gastric cancer with tumor penetrating the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. The adjacent structures of the stomach include the spleen, transverse colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small intestine, and retroperitoneum. Intramural extension to the duodenum or esophagus is not considered invasion of an adjacent structure, but is classified using the depth of the greatest invasion in any of these sites. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C133614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133614>	C133605	Gastric Cancer pT4 TNM Finding v8|Gastric Carcinoma pT4 TNM Finding v8|pT4	Gastric cancer with tumor invading the serosa (visceral peritoneum) or adjacent structures. The adjacent structures of the stomach include the spleen, transverse colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small intestine, and retroperitoneum. Intramural extension to the duodenum or esophagus is not considered invasion of an adjacent structure, but is classified using the depth of the greatest invasion in any of these sites. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C133615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133615>	C133614	Gastric Cancer pT4a TNM Finding v8|Gastric Carcinoma pT4a TNM Finding v8|pT4a	Gastric cancer with tumor invading the serosa (visceral peritoneum). (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C133616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133616>	C133614	Gastric Cancer pT4b TNM Finding v8|Gastric Carcinoma pT4b TNM Finding v8|pT4b	Gastric cancer with tumor invading adjacent structures/organs. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C133617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133617>	C133601	Gastric Cancer Pathologic Regional Lymph Nodes TNM Finding v8|Gastric Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8|Pathologic Regional Lymph Node Status (pN)	A pathologic finding about one or more characteristics of gastric cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C133618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133618>	C133617	Gastric Cancer pNX TNM Finding v8|Gastric Carcinoma pNX TNM Finding v8|pNX	Gastric cancer in which the regional lymph node(s) cannot be assessed.  (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C133619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133619>	C133617	Gastric Cancer pN0 TNM Finding v8|Gastric Carcinoma pN0 TNM Finding v8|pN0	Gastric cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C13361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13361>	C13442	Nuclear|Intranuclear|NUCLEAR	Pertaining to the nucleus.			Qualitative Concept	CDISC SEND Microscopic Findings Result Modifier Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C133620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133620>	C133617	Gastric Cancer pN1 TNM Finding v8|Gastric Carcinoma pN1 TNM Finding v8|pN1	Gastric cancer with metastasis in one or two regional lymph nodes. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C133621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133621>	C133617	Gastric Cancer pN2 TNM Finding v8|Gastric Carcinoma pN2 TNM Finding v8|pN2	Gastric cancer with metastasis in three to six regional lymph nodes. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C133622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133622>	C133617	Gastric Cancer pN3 TNM Finding v8|Gastric Carcinoma pN3 TNM Finding v8|pN3	Gastric cancer with metastasis in seven or more regional lymph nodes. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C133623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133623>	C133622	Gastric Cancer pN3a TNM Finding v8|Gastric Carcinoma pN3a TNM Finding v8|pN3a	Gastric cancer with metastasis in seven to fifteen regional lymph nodes. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C133624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133624>	C133622	Gastric Cancer pN3b TNM Finding v8|Gastric Carcinoma pN3b TNM Finding v8|pN3b	Gastric cancer with metastasis in sixteen or more regional lymph nodes. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C133625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133625>	C133593	Program or Algorithm Execution Failure	Problem associated with the failure of a program or algorithm to execute. Sudden /unexpected interruption to a program's execution.			Event	CDRH Medical Device Problem Terminology
C133626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133626>	C62952	Incomplete or Inadequate Connection	Problem associated with a partial linking of the device whereby the device may appear to be connected however only a partial, intermittent or no transfer of liquid, gas, electricity, or information can be accomplished.			Event	CDRH Medical Device Problem Terminology
C133627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133627>	C63271	Intermittent Communication Failure	Inconsistent or lack of intended communication of data among internal components or with other external devices.			Event	CDRH Medical Device Problem Terminology
C133628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133628>	C62833	Suction Failure	Problem associated with the complete inability to provide suction.			Event	CDRH Medical Device Problem Terminology
C133629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133629>	C63075	Priming Problem	Problem associated with the preparation of the device to begin pumping.			Event	CDRH Medical Device Problem Terminology
C13362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13362>	C13442	Cardiopulmonary|cardiopulmonary	Pertaining to both the heart and the lungs.			Body Part, Organ, or Organ Component	
C133630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133630>	C133629	Incomplete or Inadequate Priming	Problem associated with not adequately preparing the device.			Event	CDRH Medical Device Problem Terminology
C133631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133631>	C63013	Activation Problem	Problem associated with the activation of a device.			Event	CDRH Medical Device Problem Terminology
C133632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133632>	C63013	Separation Problem	Problem associated with the detachment or separation of device.			Event	CDRH Medical Device Problem Terminology
C133633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133633>	C133632	Difficult or Delayed Separation	Problem associated with users experiencing difficulty or delay with detachment or separation of the device.			Event	CDRH Medical Device Problem Terminology
C133634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133634>	C133632	Premature Separation	Problem associated with an early and unexpected detachment or separation of the device from the system.			Event	CDRH Medical Device Problem Terminology
C133635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133635>	C62997	Fail Safe did not Operate|Fail-Safe Did Not Operate	Problem associated with the device fail-safe mechanism, which did not function or function in a non effective way, compromising safe use of the device.			Event	CDRH Medical Device Problem Terminology
C133636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133636>	C62983	Unintended Compatibility Problem|Unintended Compatibility	Problem associated with the ability of two or more devices which are intended to be incompatible but are able to work or fit together.			Event	CDRH Medical Device Problem Terminology
C133637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133637>	C63099	Failure to Adequately Clean|Failure to Clean Adequately	Problem associated with the failure of the device or operator to remove any visible soil, foreign material or organism deposits on the external surfaces, crevices, and joints of the device.			Event	CDRH Medical Device Problem Terminology
C133638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133638>	C4911	Gastric Cancer by AJCC v8 Stage|Gastric Carcinoma by AJCC v8 Stage	A term that refers to the staging of gastric cancer according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C133639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133639>	C133638	Gastric Cancer by AJCC v8 Clinical Stage|Gastric Cancer by AJCC v8 cTNM Stage|Gastric Carcinoma by AJCC v8 Clinical Stage	A term that refers to the clinical staging of gastric cancer according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C13363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13363>	C13442	Colorectal|Colon or Rectum|colorectal	Relating to the colon and rectum, or to the entire large bowel.			Spatial Concept	
C133640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133640>	C133638	Gastric Cancer by AJCC v8 Pathologic Stage|Gastric Cancer by AJCC v8 pTNM Stage|Gastric Carcinoma by AJCC v8 Pathologic Stage|Tumor Stage (Pathologic)	A term that refers to the pathologic staging of gastric cancer according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C133641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133641>	C133638	Gastric Cancer by AJCC v8 Postneoadjuvant Therapy Stage|Gastric Cancer by AJCC v8 ypTNM Stage|Gastric Carcinoma by AJCC v8 Postneoadjuvant Therapy Stage	A term that refers to the postneoadjuvant therapy staging of gastric cancer according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C133642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133642>	C62976	Illegible Information	Problem associated with information unable to be read or deciphered.			Event	CDRH Medical Device Problem Terminology
C133643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133643>	C62976	Inaccurate Information	Problem associated with imprecise, inexact information.			Event	CDRH Medical Device Problem Terminology
C133644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133644>	C62976	Unclear Information	Problem associated with ambiguous, confusing information.			Event	CDRH Medical Device Problem Terminology
C133645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133645>	C62976	Missing Information	Absence of information e.g. labeling, instruction for use.			Event	CDRH Medical Device Problem Terminology
C133646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133646>	C62958	Misassembly during Maintenance/Repair|Misassembly During Maintenance/Repair	Problem associated with incorrect assembly of the device or constituents during maintenance or repair.			Event	CDRH Medical Device Problem Terminology
C133647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133647>	C133639	Clinical Stage 0 Gastric Cancer AJCC v8|Clinical Stage 0 Gastric Carcinoma AJCC v8|Stage 0 Gastric (Stomach) Cancer	Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ: intraepithelial tumor without invasion of the lamina propria, high grade dysplasia. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Clinical Stage 0 Gastric Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133648>	C133639	Clinical Stage I Gastric Cancer AJCC v8|Clinical Stage I Gastric Carcinoma AJCC v8|Stage I Gastric (Stomach) Cancer	Stage I includes: (T1, N0, M0); (T2, N0, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Clinical Stage I Gastric Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133649>	C133639	Clinical Stage II Gastric Cancer AJCC v8|Clinical Stage II Gastric Carcinoma AJCC v8|Stage II Gastric (Stomach) Cancer	Stage II includes: IIA: (T1, N1, N2, or N3, M0); (T2, N1, N2, or N3, M0); IIB: (T3, N0, M0); (T4a, N0, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. T4a: Tumor invades the serosa (visceral peritoneum). N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Clinical Stage II Gastric Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13364>	C33904	Autocrine Systems|Autocrine	Organ systems involved in self-stimulation through cellular production of a factor and a specific receptor for it.			Body System	
C133650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133650>	C133639	Clinical Stage III Gastric Cancer AJCC v8|Clinical Stage III Gastric Carcinoma AJCC v8|Stage III Gastric (Stomach) Cancer	Stage III includes: (T3, N1, N2, or N3, M0); (T4a, N1, N2, or N3, M0). T3: Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. T4a: Tumor invades the serosa (visceral peritoneum). N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Clinical Stage III Gastric Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133651>	C133639	Clinical Stage IV Gastric Cancer AJCC v8|Clinical Stage IV Gastric Carcinoma AJCC v8|Stage IV Gastric (Stomach) Cancer	Stage IV includes: IVA: (T4b, Any N, M0); IVB: (Any T, Any N, M1). T4b: Tumor invades adjacent structures/organs. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)	Clinical Stage IV Gastric Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133652>	C133651	Clinical Stage IVA Gastric Cancer AJCC v8|Clinical Stage IVA Gastric Carcinoma AJCC v8|Stage IVA Gastric (Stomach) Cancer	Stage IVA includes: (T4b, Any N, M0): T4b: Tumor invades adjacent structures/organs. M0: No distant metastasis. (AJCC 8th ed.)	Clinical Stage IVA Gastric Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133653>	C133651	Clinical Stage IVB Gastric Cancer AJCC v8|Clinical Stage IVB Gastric Carcinoma AJCC v8|Stage IVB Gastric (Stomach) Cancer	Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)	Clinical Stage IVB Gastric Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133654>	C133640	Pathologic Stage 0 Gastric Cancer AJCC v8|0|Pathologic Stage 0 Gastric Carcinoma AJCC v8|Stage 0 Gastric (Stomach) Cancer	Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ: intraepithelial tumor without invasion of the lamina propria, high grade dysplasia. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Pathologic Stage 0 Gastric Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133655>	C133640	Pathologic Stage I Gastric Cancer AJCC v8|Pathologic Stage I Gastric Carcinoma AJCC v8|Stage I Gastric (Stomach) Cancer	Stage I includes: IA: (T1, N0, M0); IB: (T1, N1, M0); (T2, N0, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Pathologic Stage I Gastric Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133656>	C133655	Pathologic Stage IA Gastric Cancer AJCC v8|IA|Pathologic Stage IA Gastric Carcinoma AJCC v8|Stage IA Gastric (Stomach) Cancer	Stage IA includes: (T1, N0, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Pathologic Stage IA Gastric Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133657>	C133655	Pathologic Stage IB Gastric Cancer AJCC v8|IB|Pathologic Stage IB Gastric Carcinoma AJCC v8|Stage IB Gastric (Stomach) Cancer	Stage IB includes: (T1, N1, M0); (T2, N0, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Pathologic Stage IB Gastric Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133658>	C16615	DLX1 Gene|DLX1|DLX1|Distal-Less Homeobox 1 Gene	This gene may be involved in brain and facial development.	DLX1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C133659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133659>	C133640	Pathologic Stage II Gastric Cancer AJCC v8|Pathologic Stage II Gastric Carcinoma AJCC v8|Stage II Gastric (Stomach) Cancer	Stage II includes: IIA: (T1, N2, M0); (T2, N1, M0); (T3, N0, M0); IIB: (T1, N3a, M0); (T2, N2, M0); (T3, N1, M0); (T4a, N0, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. T4a: Tumor invades the serosa (visceral peritoneum). N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3a: Tumor with metastasis in seven to fifteen regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Pathologic Stage II Gastric Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13365>	C13282	Spindle Pole Body	The spindle pole body (SPB) is the microtubule organizing center (MTOC) in the yeast Saccharomyces that plays a pivotal role in such diverse processes as mitosis, budding, and mating. (from Cell. 1997;89:1077-86)			Cell Component	
C133660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133660>	C133659	Pathologic Stage IIA Gastric Cancer AJCC v8|IIA|Pathologic Stage IIA Gastric Carcinoma AJCC v8|Stage IIA Gastric (Stomach) Cancer	Stage IIA includes: (T1, N2, M0); (T2, N1, M0); (T3, N0, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Pathologic Stage IIA Gastric Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133661>	C133658	DLX1 wt Allele|Distal-Less Homeo Box 1 Gene|Distal-Less Homeobox 1 wt Allele	Human DLX1 wild-type allele is located in the vicinity of 2q31.1 and is approximately 5 kb in length. This allele, which encodes homeobox protein DLX-1, may play a role in brain and facial morphogenesis.	DLX1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133662>	C133659	Pathologic Stage IIB Gastric Cancer AJCC v8|IIB|Pathologic Stage IIB Gastric Carcinoma AJCC v8|Stage IIB Gastric (Stomach) Cancer	Stage IIB includes: (T1, N3a, M0); (T2, N2, M0); (T3, N1, M0); (T4a, N0, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. T4a: Tumor invades the serosa (visceral peritoneum). N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3a: Tumor with metastasis in seven to fifteen regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Pathologic Stage IIB Gastric Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133663>	C133640	Pathologic Stage III Gastric Cancer AJCC v8|Pathologic Stage III Gastric Carcinoma AJCC v8|Stage III Gastric (Stomach) Cancer	Stage III includes: IIIA: (T2, N3a, M0); (T3, N2, M0); (T4a, N1, M0); (T4a, N2, M0); (T4b, N0, M0); IIIB: (T1, N3b, M0); (T2, N3b, M0); (T3, N3a, M0); (T4a, N3a, M0); (T4b, N1, M0); (T4b, N2, M0); IIIC: (T3, N3b, M0); (T4a, N3b, M0); (T4b, N3a, M0); (T4b, N3b, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. T4a: Tumor invades the serosa (visceral peritoneum). T4b: Tumor invades adjacent structures/organs. N0: No regional lymph node metastasis.  N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3a: Tumor with metastasis in seven to fifteen regional lymph nodes. N3b: Tumor with metastasis in sixteen or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Pathologic Stage III Gastric Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133664>	C17207	Homeobox Protein DLX-1|DLX1	Homeobox protein DLX-1 (255 aa, ~27 kDa) is encoded by the human DLX1 gene. This protein may be involved in the development of the brain, skull and face.	Homeobox Protein DLX-1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133665>	C133663	Pathologic Stage IIIA Gastric Cancer AJCC v8|IIIA|Pathologic Stage IIIA Gastric Carcinoma AJCC v8|Stage IIIA Gastric (Stomach) Cancer	Stage IIIA includes: (T2, N3a, M0); (T3, N2, M0); (T4a, N1, M0); (T4a, N2, M0); (T4b, N0, M0). T2: Tumor invades the muscularis propria. T3: Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. T4a: Tumor invades the serosa (visceral peritoneum). T4b: Tumor invades adjacent structures/organs.  N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3a: Tumor with metastasis in seven to fifteen regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Pathologic Stage IIIA Gastric Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133666>	C133663	Pathologic Stage IIIB Gastric Cancer AJCC v8|IIIB|Pathologic Stage IIIB Gastric Carcinoma AJCC v8|Stage IIIB Gastric (Stomach) Cancer	Stage IIIB includes: (T1, N3b, M0); (T2, N3b, M0); (T3, N3a, M0); (T4a, N3a, M0); (T4b, N1, M0); (T4b, N2, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. T4a: Tumor invades the serosa (visceral peritoneum). T4b: Tumor invades adjacent structures/organs. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3a: Tumor with metastasis in seven to fifteen regional lymph nodes. N3b: Tumor with metastasis in sixteen or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Pathologic Stage IIIB Gastric Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133667>	C133663	Pathologic Stage IIIC Gastric Cancer AJCC v8|IIIC|Pathologic Stage IIIC Gastric Carcinoma AJCC v8|Stage IIIC Gastric (Stomach) Cancer	Stage IIIC includes: (T3, N3b, M0); (T4a, N3b, M0); (T4b, N3a, M0); (T4b, N3b, M0). T3: Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. T4a: Tumor invades the serosa (visceral peritoneum). T4b: Tumor invades adjacent structures/organs. N3a: Tumor with metastasis in seven to fifteen regional lymph nodes. N3b: Tumor with metastasis in sixteen or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Pathologic Stage IIIC Gastric Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133668>	C133640	Pathologic Stage IV Gastric Cancer AJCC v8|IV|Pathologic Stage IV Gastric Carcinoma AJCC v8|Stage IV Gastric (Stomach) Cancer	Stage IV includes: Any T, Any N. M1: Distant metastasis. (AJCC 8th ed.)	Pathologic Stage IV Gastric Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C133669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133669>	C97927|C148101	PTCH1 Gene Mutation|PTC Gene Mutation|PTC1 Gene Mutation|PTCH Gene Mutation|Patched 1 Gene Mutation|Patched Homolog (Drosophila) Gene Mutation|Patched Homolog 1 Gene Mutation	A change in the nucleotide sequence of the PTCH1 gene.	PTCH1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C13366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13366>	C34070	Coated Pit	Specialized depressions on the cell surface involved in receptor-mediated endocytosis; the visible proteinaceous layer on the cytosolic side of the depression provides the coated appearance.			Amino Acid, Peptide, or Protein	
C133670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133670>	C133641	Postneoadjuvant Therapy Stage I Gastric Cancer AJCC v8|Postneoadjuvant Therapy Stage I Gastric Carcinoma AJCC v8|Stage I Gastric (Stomach) Cancer	Stage I includes: (T1, N0, M0); (T2, N0, M0); (T1, N1, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Postneoadjuvant Therapy Stage I Gastric Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133671>	C133641	Postneoadjuvant Therapy Stage II Gastric Cancer AJCC v8|Postneoadjuvant Therapy Stage II Gastric Carcinoma AJCC v8|Stage II Gastric (Stomach) Cancer	Stage II includes: (T3, N0, M0); (T2, N1, M0); (T1, N2, M0); (T4a, N0, M0); (T3, N1, M0); (T2, N2, M0); (T1, N3, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. T3: Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. T4a: Tumor invades the serosa (visceral peritoneum). N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Postneoadjuvant Therapy Stage II Gastric Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133672>	C133641	Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8|Postneoadjuvant Therapy Stage III Gastric Carcinoma AJCC v8|Stage III Gastric (Stomach) Cancer	Stage III includes: (T4a, N1, M0); (T3, N2, M0); (T2, N3, M0); (T4b, N0, M0); (T4b, N1, M0); (T4a, N2, M0); (T3, N3, M0); (T4b, N2, M0); (T4b, N3, M0); (T4a, N3, M0). T2: Tumor invades the muscularis propria. T3: Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. T4a: Tumor invades the serosa (visceral peritoneum). T4b: Tumor invades adjacent structures/organs. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133673>	C133641	Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8|Postneoadjuvant Therapy Stage IV Gastric Carcinoma AJCC v8|Stage IV Gastric (Stomach) Cancer	Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)	Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133674>	C45581	BRAF Gene Amplification|B-RAF Gene Amplification|B-RAF1 Gene Amplification|v-raf Murine Sarcoma Viral Oncogene Homolog B1 Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the BRAF gene.	BRAF Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C133675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133675>	C45581	RAF1 Gene Amplification|CRAF/RAF1 Gene Amplification|NS5 Gene Amplification|RAF Gene Amplification|RAF-1 Gene Amplification|Raf-1 Proto-Oncogene, Serine/Threonine Kinase Gene Amplification|c-Raf Gene Amplification|cRAF Gene Amplification|v-RAF-1 Murine Leukemia Viral Oncogene Homolog 1 Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the RAF1 gene.	RAF1 Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133676>	C97927|C136425	RAF1 Gene Mutation|NS5 Gene Mutation|RAF Gene Mutation|RAF-1 Gene Mutation|Raf-1 Proto-Oncogene, Serine/Threonine Kinase Gene Mutation|c-Raf Gene Mutation|cRAF Gene Mutation|v-RAF-1 Murine Leukemia Viral Oncogene Homolog 1 Gene Mutation	A change in the nucleotide sequence of the RAF1 gene.	RAF1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133677>	C156029	RET Gene Amplification|Ret Proto-Oncogene Amplification|Ret Proto-Oncogene Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the RET gene.	RET Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C133678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133678>	C156029	KIT Gene Amplification|CD117 Gene Amplification|KIT Amplification|KIT Proto-Oncogene Tyrosine Protein Kinase Gene Amplification|c-KIT Gene Amplification|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the KIT gene.	KIT Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C133679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133679>	C186958|C16606	PTCH1 Gene Deletion|PTC Gene Deletion|PTC1 Gene Deletion|PTCH Gene Deletion|Patched 1 Gene Deletion|Patched Homolog (Drosophila) Gene Deletion|Patched Homolog 1 Gene Deletion	A molecular abnormality referring to the loss of at least one copy of the PTCH1 gene.	PTCH1 Gene Deletion		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C13367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13367>	C13341	Homeo Domain|Homeo Box|Homeobox|Homeodomain	The DNA-binding homeo domain was originally identified in transcription factor proteins encoded by homeobox genes (homeotic genes).  The homeo domain is structurally similar to the helix-turn-helix DNA-binding domain of CRO and Lambda repressor.			Amino Acid Sequence	
C133680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133680>	C79087|C16606	ATM Gene Deletion|A-T Mutated Gene Deletion|AT Mutated Gene Deletion|ATM Serine/Threonine Kinase Gene Deletion|Ataxia Telangiectasia Mutated Gene Deletion	A molecular abnormality referring to the loss of at least one copy of the ATM gene.	ATM Gene Deletion		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C133681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133681>	C133649	Clinical Stage IIA Gastric Cancer AJCC v8|Clinical Stage IIA Gastric Carcinoma AJCC v8|Stage IIA Gastric (Stomach) Cancer	Stage IIA includes: (T1, N1, N2, or N3, M0); (T2, N1, N2, or N3, M0). T1: Tumor invades the lamina propria, muscularis mucosae, or submucosa. T2: Tumor invades the muscularis propria. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes. N3: Tumor with metastasis in seven or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Clinical Stage IIA Gastric Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133682>	C133649	Clinical Stage IIB Gastric Cancer AJCC v8|Clinical Stage IIB Gastric Carcinoma AJCC v8|Stage IIB Gastric (Stomach) Cancer	Stage IIB includes: (T3, N0, M0); (T4a, N0, M0). T3: Tumor penetrates the subserosal connective tissue without invasion of the visceral peritoneum or adjacent structures. T4a: Tumor invades the serosa (visceral peritoneum). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Clinical Stage IIB Gastric Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133683>	C97927|C141240	EPHA2 Gene Mutation|ECK Gene Mutation|EPH Receptor A2 Gene Mutation|Ephrin Receptor A2 Gene Mutation	A change in the nucleotide sequence of the EPHA2 gene.	EPHA2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133684>	C97927	FYN Gene Mutation|FYN Oncogene Related to SRC, FGR, YES Gene Mutation|FYN Proto-Oncogene, Src Family Tyrosine Kinase Gene Mutation|SLK Gene Mutation|SRC/YES-Related Novel Gene Mutation|SRC/YES-Related Oncogene Gene Mutation|SYN Gene Mutation	A change in the nucleotide sequence of the FYN gene.	FYN Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133685>	C97927	YES1 Gene Mutation|YES Proto-Oncogene 1, Src Family Tyrosine Kinase Gene Mutation|YES1 Proto-Oncogene, Src Family Tyrosine Kinase Gene|Yamaguchi Sarcoma Oncogene|Yes Gene Mutation|c-YES Gene Mutation|c-Yes|v-Yes-1 Yamaguchi Sarcoma Viral Oncogene Homolog 1 Gene Mutation	A change in the nucleotide sequence of the YES1 gene.	YES1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133686>	C97927|C137953	MTOR Gene Mutation|FK506 Binding Protein 12-Rapamycin Associated Protein 1 Gene Mutation|FRAP Gene Mutation|FRAP1 Gene Mutation|MTOR mutation|Mammalian Target of Rapamycin Gene Mutation|Mechanistic Target of Rapamycin Gene Mutation|Rapamycin and FKBP12 Target 1 Gene Mutation	A change in the nucleotide sequence of the MTOR gene.	MTOR Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C133687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133687>	C97927	CSF1R Gene Mutation|C-FMS Gene Mutation|CD115 Gene Mutation|CSF-1R Gene Mutation|CSFR Gene Mutation|Colony Stimulating Factor 1 Receptor Gene Mutation|FMS Gene Mutation|M-CSF-R Gene Mutation|Macrophage Colony-Stimulating Factor 1 Receptor Gene Mutation|McDonough Feline Sarcoma Viral (V-Fms) Oncogene Homolog Gene Mutation	A change in the nucleotide sequence of the CSF1R gene.	CSF1R Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133688>	C97927	SRC Gene Mutation|ASV Gene Mutation|SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase Gene Mutation|SRC1 Gene Mutation|c-SRC Gene Mutation|v-SRC Avian Sarcoma (Schmidt-Ruppin A-2) Viral Oncogene Homolog Gene Mutation	A change in the nucleotide sequence of the SRC gene.	SRC Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133689>	C97927	LCK Gene Mutation|LCK Proto-Oncogene, Src Family Tyrosine Kinase Gene Mutation|LSK Gene Mutation|Lymphocyte-Specific Protein Tyrosine Kinase Gene Mutation	A change in the nucleotide sequence of the LCK gene.	LCK Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13368>	C13248	Keratin Filament	A class of intermediate filaments that form a network within epithelial cells and anchor to desmosomes, thus imparting tensile strength to the tissue			Cell Component	
C133690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133690>	C97927	LYN Gene Mutation|JTK8 Gene Mutation|LYN Proto-Oncogene, Src Family Tyrosine Kinase Gene Mutation|v-Yes-1 Yamaguchi Sarcoma Viral Oncogene Homolog Gene Mutation	A change in the nucleotide sequence of the LYN gene.	LYN Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133691>	C2167|C129825	Aumolertinib|AUMOLERTINIB|Almonertinib|EGFR Tyrosine Kinase Inhibitor HS-10296|EQ143|HS 10296|HS-10296|HS10296	An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. Upon administration, aumolertinib binds to and inhibits EGFR T790M, a secondarily acquired resistance mutation, inhibits the tyrosine kinase activity of EGFR T790M, prevents EGFR T790M-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells. EGFR, a receptor tyrosine kinase that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.	Aumolertinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C133692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133692>	C36345	MYC Protein Overexpression|Class E Basic Helix-Loop-Helix Protein 39 Protein Overexpression|MYC Overexpression|MYC Transcription Factor Protein Overexpression|Myc Proto-Oncogene Protein Overexpression|Proto-Oncogene c-Myc Protein Overexpression|bHLHe39 Protein Overexpression	A molecular abnormality indicating the presence of an abnormally high level of the Myc proto-oncogene protein.	MYC Protein Overexpression		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133693>	C79087|C3420	11q Translocation|t(11q)	A cytogenetic abnormality that refers to any translocation involving the long arm of chromosome 11.	11q Translocation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133694>	C171053|C16606	TP53 Gene Deletion|TP53 Deletion|Tumor Protein p53 Gene Deletion|p53 Deletion|p53 Gene Deletion	A molecular abnormality referring to the loss of at least one copy of the TP53 gene.	TP53 Gene Deletion		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C133695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133695>	C131783	Homologous Recombination Repair Gene Mutation|HHR Gene Mutation|HRR Gene Mutation|Homologous Recombination Pathway Gene Mutation|Recombination Repair Gene Mutation	A change in the nucleotide sequence of a gene involved in homologous recombination-type DNA repair processes.	Homologous Recombination Repair Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133696>	C97927	RB1 Gene Mutation|RB Gene Mutation|RB1 Gene Variant|RB1 Variant|RB1 gene mutation|Retinoblastoma 1 Gene Mutation|Retinoblastoma Gene Mutation	A change in the nucleotide sequence of the RB1 gene.	RB1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133697>	C133155	TFE3 Gene Rearrangement|RCCP2 Gene Rearrangement|RCCX1 Gene Rearrangement|TFEA Gene Rearrangement|Transcription Factor Binding to IGHM Enhancer 3 Gene Rearrangement|Transcription Factor E3 Gene Rearrangement|bHLHe33 Gene Rearrangement	A molecular abnormality indicating rearrangement of the TFE3 gene.	TFE3 Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133698>	C97927|C193283	SRSF2 Gene Mutation|SC35 Gene Mutation|SFRS2 Gene Mutation|Serine and Arginine Rich Splicing Factor 2 Gene Mutation|Serine/Arginine-Rich Splicing Factor 2 Gene Mutation|Splicing Factor, Arginine/Serine-Rich 2 Gene Mutation	A change in the nucleotide sequence of the SRSF2 gene.	SRSF2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133699>	C16606|C129438	SRSF2 Gene Deletion|SC35 Gene Deletion|SFRS2 Gene Deletion|Serine and Arginine Rich Splicing Factor 2 Gene Deletion|Serine/Arginine-Rich Splicing Factor 2 Gene Deletion|Splicing Factor, Arginine/Serine-Rich 2 Gene Deletion	A molecular abnormality referring to the loss of at least one copy of the SRSF2 gene.	SRSF2 Gene Deletion		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13369>	C48043	Alpha Helix	A right-handed spiral conformation; the a-helix has a pitch of 5.4 A and has 3.6 amino acid residues per turn; every main chain C=O and N-H group is hydrogen-bonded to a peptide bond 4 residues away; the peptide planes are roughly parallel with the helix axis and the dipoles within the helix are aligned, i.e. all C=O groups point in the same direction and all N-H groups point the other way; side chains point outward from helix axis and are generally oriented towards its amino-terminal end.  (from expasy.org)			Spatial Concept	
C1336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1336>	C798|C2157|C1556	Cladribine|2-CdA|2-Chloro-2-Deoxyadenosine|2-Chlorodeoxyadenosine|2CDA|CLADRIBINE|CdA|Cladribina|Leustat|Leustatin|Leustatine|RWJ-26251|cladribine	A purine nucleoside antimetabolite analogue. Cladribine triphosphate, a phosphorylated metabolite of cladribine, incorporates into DNA, resulting in single-strand breaks in DNA, depletion of nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP), and apoptosis.  Because this agent is resistant to adenosine deaminase, an enzyme that inactivates some antineoplastic agents, it is selectively toxic to lymphocytes and monocytes which exhibit little deoxynucleotide deaminase activity. (NCI04)	Cladribine		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	AML Authorized Value Terminology|AML Total Dose Table|CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C133700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133700>	C97927	U2AF1 Gene Mutation|FP793 Gene Mutation|RN Gene Mutation|RNU2AF1 Gene Mutation|U2 Small Nuclear RNA Auxiliary Factor 1 Gene Mutation|U2AF35 Gene Mutation|U2AFBP Gene Mutation	A change in the nucleotide sequence of the U2AF1 gene.	U2AF1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133701>	C97927	ZRSR2 Gene Mutation|U2AF1-RS2 Gene Mutation|U2AF1L2 Gene Mutation|U2AF1RS2 Gene Mutation|URP Gene Mutation|ZC3H22 Gene Mutation|Zinc Finger CCCH-type, RNA Binding Motif and Serine/Arginine Rich 2 Gene Mutation	A change in the nucleotide sequence of the ZRSR2 gene.	ZRSR2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133702>	C97927|C193282	SF3B1 Gene Mutation|Hsh155 Gene Mutation|MDS Gene Mutation|PRP10 Gene Mutation|PRPF10 Gene Mutation|Pre-mRNA Processing 10 Gene Mutation|SAP155 Gene Mutation|SF3B, 155-kD Subunit Gene Mutation|SF3b155 Gene Mutation|Spliceosome-Associated Protein, 155-kD Gene Mutation|Splicing Factor 3b Subunit 1 Gene Mutation|Splicing Factor 3b, Subunit 1 Gene Mutation|Splicing Factor 3b, Subunit 1, 155kDa Gene Mutation	A change in the nucleotide sequence of the SF3B1 gene.	SF3B1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133703>	C177692	CDH3 Positive|CADP Positive|Cadherin 3 Positive|Cadherin, Placental Positive|Cadherin-3 Positive|P-Cadherin Positive|PCAD Positive|Placental Cadherin Positive	Indicates that CDH3 expression has been detected in a sample.	CDH3 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133704>	C35682	FGF Family Alteration Positive|FGF Alteration|FGF Alteration Positive|Fibroblast Growth Factor Alteration|Fibroblast Growth Factor Alteration Positive|Fibroblast Growth Factor Family Alteration|Fibroblast Growth Factor Family Alteration Positive	Indicates that mutation, overexpression or rearrangement of an FGF family member has been detected in a sample.	FGF Family Alteration Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133705>	C35682	FGFR Family Alteration Positive|FGFR Alteration|FGFR Alteration Positive|Fibroblast Growth Factor Receptor Alteration|Fibroblast Growth Factor Receptor Alteration Positive|Fibroblast Growth Factor Receptor Family Alteration|Fibroblast Growth Factor Receptor Family Alteration Positive	Indicates that mutation, overexpression or rearrangement of an FGFR family member has been detected in a sample.	FGFR Family Alteration Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133706>	C131783	Mismatch Repair Gene Mutation|DNA Mismatch Repair Gene Mutation|MMR Gene Mutation|MMR Mutation|mismatch repair mutation|mismatch_repair_mutation	A change in the nucleotide sequence of a gene involved in DNA mismatch repair.	Mismatch Repair Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Property Terminology|GDC Terminology
C133707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133707>	C94299|C165233	ALK Negative|ALK Receptor Tyrosine Kinase Negative|ALK Tyrosine Kinase Receptor Negative|Anaplastic Lymphoma Kinase Negative|Anaplastic Lymphoma Kinase Receptor Negative|Anaplastic Lymphoma Receptor Tyrosine Kinase Negative|CD246 Antigen Negative|CD246 Negative	Indicates that expression of ALK has not been detected in a sample.	ALK Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133708>	C25870	Ubiquitin-Conjugating Enzyme Gene|E2 Ubiquitin-Conjugating Enzyme Gene|UBC|UBE2	Genes encoding enzymes that catalyze the second step in the ubiquitination reaction via the transfer of ubiquitin from E1 ubiquitin-activating enzymes to themselves.			Gene or Genome	
C133709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133709>	C7624|C34447|C162652	Recurrent Head and Neck Squamous Cell Carcinoma|Recurrent Head and Neck Squamous Cell Cancer|Recurrent Squamous Cell Carcinoma of the Head and Neck	The reemergence of squamous cell carcinoma in the head and neck region after a period of remission.	Recurrent Head and Neck Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13370>	C13299	Cis-Acting Sequence|Cis-Acting Locus	Cis-acting locus is a section of DNA that affects the activity of DNA sequences on that same molecule of DNA.			Gene or Genome|Nucleotide Sequence	
C133710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133710>	C25870	Ubiquitin-Transferase Gene|E3 Ubiquitin-Transferase Gene	Genes encoding enzymes that catalyze the third step in the ubiquitination reaction via the transfer of ubiquitin from E2 ubiquitin-conjugating enzymes to the final protein substrate.			Gene or Genome	
C133711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133711>	C16259	E2 Ubiquitin-Conjugating Enzyme|Ubiquitin Carrier Enzyme|Ubiquitin Carrier Protein|Ubiquitin-Conjugating Enzyme|Ubiquitin-Conjugating Enzyme E2	An aminoacyltransferase that catalyzes the second step in the ubiquitination reaction via the transfer of activated ubiquitin from an E1 ubiquitin-activating enzyme to itself via transthioesterification.			Amino Acid, Peptide, or Protein|Enzyme	
C133713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133713>	C8559|C167332	Locally Advanced Paraganglioma|Locally Advanced Malignant Paraganglioma	A paraganglioma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Paraganglioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133714>	C16796	E1 Ubiquitin-Activating Enzyme|EC 6.2.1.45|EC 6.3.2.19, Formerly|Ubiquitin-Activating Enzyme	A ligase that catalyzes the first step in the ubiquitination reaction via the ligation of the C-terminal lysine of ubiquitin to the E1 enzyme in an ATP-dependent reaction.	E1 Ubiquitin-Activating Enzyme		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133715>	C13426	YEATS Domain|YNK7, ENL, AF-9 and TFIIF Small Subunit Domain|Yaf9, ENL, AF9, Taf14, and Sas5 Homology Domain	A protein domain whose structure is comprised of an immunoglobulin-like fold that is found in various chromatin modification factors and may bind to modified lysines in other proteins.			Amino Acid Sequence	
C133716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133716>	C7724	Small Intestinal Cancer by AJCC v7 Stage|Small Intestinal Carcinoma by AJCC v7 Stage	A term that refers to the staging of small intestinal cancer according to the American Joint Committee on Cancer, 7th edition.			Neoplastic Process	
C133717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133717>	C1966	Boron-dipyrromethene-modified Olaparib Fluorescent Imaging Agent|ABY-029|AZD2281-BODIPY FL|BODIPY-modified Olaparib Fluorescent Imaging Agent|Boron, (4-((3-((4-(3-(5-((3,5-dimethyl-2H-pyrrol-2-ylidene-kappaN)methyl)-1H-pyrrol-2-yl-kappaN)-1-oxopropyl)-1-piperazinyl)carbonyl)-4-fluorophenyl)methyl)-1(2H)-phthalazinonato)difluoro-, (T-4)-|Fluorescent PARP1 Inhibitor PARPi-FL|Fluorescent PARPi Binding Imaging Agent PARPi-FL|OLAPARIB-BODIPY FL|Olaparib-BODIPY FL|PARPi-FL	A poly (ADP-ribose) polymerase type 1 (PARP1) fluorescence imaging agent based on the PARP1 inhibitor olaparib, in which the cyclopropane group of olaparib is replaced by the green fluorescent dye boron-dipyrromethene (BODIPY) fluorophore (FL), with potential fluorescent imaging activity. Upon administration of the fluorescent PARP1 inhibitor PARPi-FL, the olaparib binding moiety specifically targets and binds to PARP1, which is often overexpressed on cancer cells. Upon fluorescent imaging, the PARP1-expressing cancer cells can be visualized. PARP1, the nuclear enzyme that catalyzes post-translational ADP-ribosylation of nuclear proteins, is activated by single-strand (SS) DNA breaks and overexpressed in certain tumor cells; it plays a key role in DNA repair, tumor cell resistance and survival.	Boron-dipyrromethene-modified Olaparib Fluorescent Imaging Agent		Indicator, Reagent, or Diagnostic Aid	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C133718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133718>	C200766|C176018	Vadacabtagene Leraleucel|Anti-CD19/CD28/zeta Modified CAR CD3+ T Lymphocytes JCAR015|JCAR 015|JCAR 15|JCAR015|VADACABTAGENE LERALEUCEL	Genetically modified CD3-positive-enriched autologous T-lymphocytes transduced with a replication incompetent gamma retroviral vector expressing a chimeric T-cell antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv), fused to the extracellular, transmembrane and intracellular signaling domains of the T-cell co-stimulatory receptor CD28 and the cytoplasmic signaling domain of the zeta chain of the TCR/CD3 complex (CD3-zeta) (CAR19-28z), with potential antineoplastic activities. Upon intravenous administration, vadacabtagene leraleucel,is directed to CD19-expressing tumor cells, and, upon binding to the T-cells, induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. The CD28 co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19. The inclusion of the CD28 signaling domain may increase proliferation of T-cells and antitumor activity compared to the inclusion of the CD3-zeta chain alone.			Cell|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C133719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133719>	C2167|C129825	Alflutinib Mesylate|ASK 120067|ASK-120067|ASK120067|AST 2818 Mesylate|AST2818 Mesylate|FIRMONERTINIB MESYLATE|Furmonertinib Mesylate|Ivesa	The mesylate salt form of alflutinib, an orally available selective inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. Upon administration, alflutinib specifically binds to and inhibits the tyrosine kinase activity of EGFR T790M, a secondarily acquired resistance mutation. This prevents EGFR T790M-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells. EGFR, a receptor tyrosine kinase that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. Compared to some other EGFR inhibitors, alflutinib may have therapeutic benefits in tumors with T790M-mediated drug resistance.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C13371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13371>	C73499|C63581	5' Untranslated Region|5' UTR|5'-UTR|5'UTR	Sequences on the 5' end of messenger RNAs that are not translated into protein.  5'UTR extends from the transcription start site to just before the ATG translation initiation codon.  This region contains the ribosome binding site and other transcription and translation regulating sequences.			Nucleotide Sequence	
C133720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133720>	C1934	Arsenic Trioxide Capsule Formulation ORH 2014|Arsenic Trioxide Formulation ORH 2014|As2O3 Formulation ORH 2014|ORH 2014|Oral Arsenic Trioxide Formulation	An orally bioavailable capsule formulation of the inorganic toxic compound arsenic trioxide (As2O3), with potential antineoplastic activity. Although the mechanism of action (MoA) of As2O3 is not well understood, upon oral administration of ORH 2014, As2O3 appears to bind to DNA, prevent DNA synthesis, and cause DNA fragmentation, which leads to an induction of apoptosis in proliferating cells, including tumor cells. In addition, As2O3 causes damage to and induces degradation of the promyelocytic leukemia protein/retinoic acid receptor-alpha (PML/RARa) fusion protein, and inhibits the activity of the enzyme thioredoxin reductase.	Arsenic Trioxide Capsule Formulation ORH 2014		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C133721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133721>	C63074	Misassembled During Installation	Problem associated with the use of the device characterized by incorrect assembly of device components, parts or constituents.			Event	CDRH Medical Device Problem Terminology
C133722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133722>	C62917	Device Migration Problem|Migration	Problem with all or part of an implanted or invasive device moving from its intended location within the body.			Event	CDRH Medical Device Problem Terminology
C133723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133723>	C62781|C148281	Contrast-Enhanced Subharmonic Ultrasound Imaging	A variation of contrast-enhanced ultrasound imaging that centers the receiving bandwidth at half the transmitting frequency in order to suppress tissue signals during vascular imaging studies.	Contrast-Enhanced Subharmonic Ultrasound Imaging		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C133724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133724>	C85026|C28193	Brown-Vialetto-Van Laere Syndrome 1|BVVLS1|Bulbar Palsy, Progressive, with Sensorineural Deafness	An autosomal recessive neurologic condition caused by mutation(s) in the SLC52A3 gene, encoding solute carrier family 52, riboflavin transporter, member 3. It is characterized by sensorineural hearing loss and varying cranial nerve palsies, usually affecting the motor components of the seventh and ninth to twelfth cranial nerves. Spinal motor nerves are often affected. Mutations in SLC52A3 may result in Faxio-Lone disease, which is a similar condition, but sensorineural deafness is not present.			Disease or Syndrome	Cellosaurus Disease Terminology
C133725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133725>	C84773	Familial Hypertrophic Cardiomyopathy Type 4|CMH4	An autosomal dominant condition caused by mutation(s) in the MYBPC3 gene, encoding MYBPC3 protein. It is characterized by severe neonatal hypertrophic cardiomyopathy.			Disease or Syndrome	Cellosaurus Disease Terminology
C133726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133726>	C54131	Foundation Medicine Inc|FMI|Foundation Medicine	A biotechnology company which develops and manufactures genomic analysis diagnostics based on next-generation sequencing technology for detection of solid and circulating cancers.			Organization	
C133727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133727>	C53543|C28193	Hypoparathyroidism-Intellectual Developmental Disorder-Dysmorphism Syndrome|HRDS|Hypoparathyroidism with Short Stature, Mental Retardation, and Seizures|Hypoparathyroidism, Congenital, Associated with Dysmorphism, Growth Retardation, and Developmental Delay|Hypoparathyroidism-Retardation-Dysmorphism Syndrome|Sanjad-Sakati Syndrome	An autosomal recessive condition caused by mutation(s) in the TBCE gene, encoding tubulin-specific chaperone E. It is characterized by congenital hypoparathyroidism, mental retardation, seizures and developmental delay.			Disease or Syndrome	Cellosaurus Disease Terminology
C133728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133728>	C54131	CARIS Life Sciences|CARIS	A biotechnology company that specializes in molecular profiling of cancers and identification of targets for treatment.			Organization	
C133729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133729>	C85865|C84392|C53543	Intellectual Developmental Disorder, X-linked 1|MRX1|Mental Retardation, X-linked 1|Nonsyndromic X-Linked Cognitive Disability	An X-linked dominant condition caused by mutation(s) in the IQSEC2 gene, encoding IQ motif and SEC7 domain-containing protein 2. It is characterized by substantially impaired intellectual functioning and behavioral abnormalities.			Disease or Syndrome	Cellosaurus Disease Terminology
C13372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13372>	C13734	Response Element|Response Elements	A nucleotide sequence that plays a role in the expression of a nearby gene because it can be recognized by specific transcription factors or coregulatory proteins.			Nucleotide Sequence	
C133730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133730>	C84828	Muscular Dystrophy-Dystroglycanopathy (Limb-Girdle) Type C, 1|LGMD2K|Limb-Girdle Muscular Dystrophy Type 2K|MDDGC1	An autosomal recessive limb-girdle muscular dystrophy caused by mutations in the POMT1 gene, encoding protein O-mannosyl-transferase 1. It is characterized by mental retardation without structural brain abnormalities and limb-girdle muscular dystrophy.			Disease or Syndrome	Cellosaurus Disease Terminology
C133731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133731>	C7813|C3819	Refractory Primary Amyloidosis	A primary amyloidosis that does not respond to treatment.	Refractory Primary Amyloidosis		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133732>	C3819|C172289|C131500	Recurrent Primary Amyloidosis	The reemergence of primary amyloidosis after a period of remission.	Recurrent Primary Amyloidosis		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133733>	C9330	Appendix Carcinoma by AJCC v7 Stage|Appendiceal Carcinoma by AJCC v7 Stage	A term that refers to the staging of appendiceal carcinoma according to the American Joint Committee on Cancer, 7th edition. Carcinoid tumors are staged separately. (from AJCC 7th Ed.)			Neoplastic Process	
C133734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133734>	C13426	PDZ Domain|DHR Domain|Discs-Large Homologous Region|GLGF Domain|Gly-Leu-Gly-Phe Domain|Glycine-Leucine-Glycine-Phenylalanine Domain|PSD95, Dlg1, Zo-1 Domain	A globular protein domain of 80 to 90 amino acids comprising six beta-strands and two alpha-helices that plays a role in anchoring receptor proteins in the membrane to cytoskeletal components.			Amino Acid Sequence	
C133735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133735>	C15230	Yttrium-90 Microsphere Radioembolization|Yttrium Y 90 Microsphere Therapy|Yttrium-90 Radioembolization	Antineoplastic treatment consisting of catheter injection of yttrium Y 90 microspheres. When injected into the tumor vascular bed, yttrium Y 90 microspheres occlude tumor blood vessels and deliver a cytotoxic dose of beta radiation to the tumor site, which may result in tumor cell death and tumor regression.	Yttrium-90 Microsphere Radioembolization		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C133736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133736>	C8836|C7164	Refractory Classic Hodgkin Lymphoma|Refractory Classical Hodgkin Lymphoma|Refractory Classical Hodgkin Lymphoma	A classic Hodgkin lymphoma that is resistant to treatment.	Refractory Classical Hodgkin Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133737>	C132146|C120186	Refractory Malignant Solid Neoplasm|Refractory Malignant Solid Tumor|Refractory Malignant Solid Tumor	A malignant solid neoplasm that does not respond to treatment.	Refractory Malignant Solid Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133738>	C134989	Rabbit Plasmacytoma	Plasmacytoma that occurs in a rabbit.			Neoplastic Process	Cellosaurus Disease Terminology
C133739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133739>	C134989	Rabbit Oral Cavity Squamous Cell Carcinoma	Oral cavity squamous cell carcinoma that occurs in a rabbit.			Neoplastic Process	Cellosaurus Disease Terminology
C13373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13373>	C73499|C63582	3' Untranslated Region|3' UTR|3'-UTR|3'UTR	Sequences on the 3' end of messenger RNAs that are not translated into protein. The 3'UTR is involved in many post-transcriptional regulatory pathways, including regulating translation efficiency, mRNA stability, and polyadenylation signals.			Nucleotide Sequence	
C133740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133740>	C134989	Rabbit Fibroma	Fibroma that occurs in a rabbit.			Neoplastic Process	Cellosaurus Disease Terminology
C133741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133741>	C134989	Rabbit Cutaneous Lymphoma	Cutaneous lymphoma that occurs in a rabbit.			Neoplastic Process	Cellosaurus Disease Terminology
C133742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133742>	C84392|C53543	Intellectual Developmental Disorder, Autosomal Dominant 9|MRD9|Mental Retardation, Autosomal Dominant 9|NESCAV Syndrome	An autosomal dominant condition caused by mutation(s) in the KIF1A gene, encoding kinesin-like protein KIF1A. It is characterized by microcephaly, intellectual disability, and delayed psychomotor development. The condition is progressive, occurs in early infancy, and is of variable severity.			Disease or Syndrome	Cellosaurus Disease Terminology
C133743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133743>	C53543|C28193	Cortical Dysplasia-Focal Epilepsy Syndrome|CDFE Syndrome	An autosomal recessive condition caused by mutation(s) in the CNTNAP2 gene, encoding contactin-associated protein-like 2. It is characterized by normal development until the onset of intractable focal seizures at age 1-9. After the onset of seizures, language regression, intellectual disability, hyperactivity, and impulsive behaviors begin to occur. The majority of children eventually fulfill the criteria for autism spectrum disorder.			Disease or Syndrome	Cellosaurus Disease Terminology
C133744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133744>	C27607	Pterygium|Pterygium of Conjunctiva and Cornea	A wedge-shaped, benign, degenerative fibrovascular lesion arising from the bulbar conjunctiva and extending to the cornea. It is caused by chronic exposure to solar ultraviolet radiation, heat, and dust. It may cause severe vision loss.			Disease or Syndrome	Cellosaurus Disease Terminology
C133745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133745>	C707	Gamma-hydroxy-1,N(2)-propanodeoxyguanosine|3-(2'-Deoxy-beta-d-erythro-pentofuranosyl)-5,6,7,8-tetrahydro-8-hydroxypyrimido[1,2-a] Purin-10(3H)-one|Acr-dG3|Acrolein-dG3|g-OH-PdG|g-OHPdG|gamma-OH-PdG|gamma-OHPdG	A mutagenic and carcinogenic cyclic 1,N2-propanodeoxy (Pd) DNA adduct derived from the reaction of deoxyguanosine (dG) in DNA with the environmentally widely available or endogenously produced mutagenic and carcinogenic unsaturated aldehyde acrolein (Acr) that can potentially be used as a biomarker for exposure to Acr, the formation of certain forms of cancer and the presence of oxidative stress. The formation of gamma-hydroxy-1,N(2)-propanodeoxyguanosine (g-OH-PdG) damages DNA and stimulates the formation of tumors. Also, as Acr is formed due to oxidation of certain polyunsaturated fatty acids (PUFAs), mostly omega-3-PUFA, the lipid peroxidation-derived DNA adduct g-OH-PdG can potentially be used as a biomarker to assess the presence of oxidized PUFAs, the level of oxidative stress and the extent of oxidative DNA damage.	Gamma-hydroxy-1,N(2)-propanodeoxyguanosine		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology
C133746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133746>	C48572	Packs per Day|Pack a Day|Pack/Day	The number of cigarettes smoked in a 24 hour period, considered in 20-cigarette units.			Quantitative Concept	
C133747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133747>	C173812	Treatment Based on Genomic Alteration Question|Treatment Based on Genomic Alteration	A question to determine if any therapeutic interventions, planned or performed, are tailored to an individual's specific genetic change or defect.			Intellectual Product	
C133748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133748>	C137858	Is Patient Eligible for Systemic Therapy in Provider's Opinion Question|Eligibility for Systemic Therapy|Is Patient Eligible for Systemic Therapy in Provider's Opinion|Is the patient eligible to receive systemic therapy in provider's opinion|Patient Eligibility for Systemic Therapy	A question regarding the eligibility of a patient for systemic therapy, based on the medical provider's opinion.			Intellectual Product	
C133749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133749>	C173812	Treatment Planned Prior to Return of Genomic Testing Not Already Recorded Question|Is there any treatment planned to take place prior to return of genomic testing results that has not already been recorded|Treatment Planned Prior to Return of Genomic Testing Not Already Recorded	A question to determine if there are plans for treatment prior to the results of genetic testing that have not yet been recorded.			Intellectual Product	
C13374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13374>	C13298	Intracisternal A-Particle|IAP	Retroviral-like intracisternal A particles.  High copy number family of repeated elements in the mouse with a typical proviral organization.  Expressed very early in mouse development (2-8 cell stage) and in transformed cells.  Mutant alleles of various genes contain newly-integrated IAP genes.			Nucleotide Sequence	
C133750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133750>	C19975	Consortium for Molecular and Cellular Characterization of Screen-Detected Lesions|MCL	A consortium consisting of independent, multi-disciplinary teams that undertake comprehensive molecular and cellular characterizations of tumor tissue, cell, and microenvironment components to distinguish screen-detected early lesions from interval and symptom-detected cancers.			Professional or Occupational Group	
C133752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133752>	C33209|C13046	Hepatoduodenal Ligament	The portion of the lesser omentum between the liver and the duodenum, containing the hepatic artery, the common bile duct, the portal vein, lymphatic vessels, and the hepatic plexus of nerves.			Anatomical Structure	
C133753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133753>	C33103	Mesenteric Root	The origin of the mesentery arising from the parietal peritoneum.			Anatomical Structure	
C133754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133754>	C34028	Renal Pedicle	The recessed central fissure of the kidney, though which pass the ureter and vessels of the kidney.			Body Part, Organ, or Organ Component	
C133755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133755>	C34076	Sciatic Notch	Either of the two notches on the dorsal border of each side of the pelvis that when closed off by the sacrospinous and sacrotuberous ligaments form the corresponding sciatic foramina.			Anatomical Structure	
C133756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133756>	C34076	Neural Foramen|Intervetebral Foramen	Any of the openings between the vertebrae, through which pass the spinal nerve roots.			Anatomical Structure	
C133757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133757>	C12679	Iliac Vessel	Any of the branches of the vessels arising from the common iliac artery or vein, located in the pelvis.			Body Part, Organ, or Organ Component	
C133759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133759>	C2462	Free Radioiodine|Free Radioactive Iodine	Radioactive iodine that is not attached to another molecule.			Indicator, Reagent, or Diagnostic Aid	
C13375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13375>	C13377	Chromosome Fragile Site|FRAGILE SITE|Fragile Site	Heritable sensitive regions of chromosomes which show up in vitro as non-staining bands. They are associated with chromosome breakage and other aberrations. No abnormal phenotype has been definitely identified with autosomal fragile sites, but some rare autosomal recessive disorders may be due to homozygosity for fragile sites. A fragile site on the X chromosome is associated with Fragile X Syndrome. Fragile sites are designated by the letters "fra" followed by the designation for the specific chromosome and locus.			Anatomical Abnormality|Cell or Molecular Dysfunction|Nucleotide Sequence	CDISC SDTM Genomic Symbol Type Response Terminology|CDISC SDTM Terminology|Cellosaurus Disease Terminology|Clinical Data Interchange Standards Consortium Terminology
C133760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133760>	C62439	Five Hundred	The natural number greater than 499 and less than 501 and the quantity that it denotes.			Quantitative Concept	
C133761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133761>	C133361	Lower Gastrointestinal Tract Cancer TNM Finding v8	A finding about one or more characteristics of lower gastrointestinal tract cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C133762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133762>	C133761	Anal Cancer TNM Finding v8|Anal Canal and Perianal (Anal Margin) Carcinoma TNM Finding v8|Anal Carcinoma TNM Finding v8	A finding about one or more characteristics of anal cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to all carcinomas arising in the anal canal, including carcinomas that arise within anorectal fistulas and those arising in the perianal area (anal margin). High-grade neuroendocrine carcinomas (small cell neuroendocrine carcinoma and large cell neuroendocrine carcinoma) are staged using this system. There is no AJCC staging system for anal mucosal melanomas and anal well-differentiated neuroendocrine tumors. (from AJCC 8th Ed.)			Finding	
C133763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133763>	C133762	Anal Cancer Clinical TNM Finding v8|Anal Canal and Perianal (Anal Margin) Carcinoma Clinical TNM Finding v8|Anal Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of anal cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C133764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133764>	C133763	Anal Cancer Clinical Distant Metastasis TNM Finding v8|Anal Canal and Perianal (Anal Margin) Carcinoma Clinical Distant Metastasis TNM Finding v8|Anal Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of anal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C133765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133765>	C133764	Anal Cancer cM0 TNM Finding v8|Anal Canal and Perianal (Anal Margin) Carcinoma cM0 TNM Finding v8|Anal Carcinoma cM0 TNM Finding v8	Anal cancer without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C133766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133766>	C133764	Anal Cancer cM1 TNM Finding v8|Anal Canal and Perianal (Anal Margin) Carcinoma cM1 TNM Finding v8|Anal Carcinoma cM1 TNM Finding v8	Anal cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C133767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133767>	C133762	Anal Cancer Pathologic TNM Finding v8|Anal Canal and Perianal (Anal Margin) Carcinoma Pathologic TNM Finding v8|Anal Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of anal cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C133768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133768>	C133767	Anal Cancer Pathologic Distant Metastasis TNM Finding v8|Anal Canal and Perianal (Anal Margin) Carcinoma Pathologic Distant Metastasis TNM Finding v8|Anal Carcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of anal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C133769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133769>	C133768	Anal Cancer pM1 TNM Finding v8|Anal Canal and Perianal (Anal Margin) Carcinoma pM1 TNM Finding v8|Anal Carcinoma pM1 TNM Finding v8	Anal cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C133770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133770>	C133767	Anal Cancer Pathologic Primary Tumor TNM Finding v8|Anal Canal and Perianal (Anal Margin) Carcinoma Pathologic Primary Tumor TNM Finding v8|Anal Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of anal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C133771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133771>	C133770	Anal Cancer pTX TNM Finding v8|Anal Canal and Perianal (Anal Margin) Carcinoma pTX TNM Finding v8|Anal Carcinoma pTX TNM Finding v8	Anal cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C133772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133772>	C133770	Anal Cancer pT0 TNM Finding v8|Anal Canal and Perianal (Anal Margin) Carcinoma pT0 TNM Finding v8|Anal Carcinoma pT0 TNM Finding v8	Anal cancer with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C133773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133773>	C133770	Anal Cancer pTis TNM Finding v8|Anal Canal and Perianal (Anal Margin) Carcinoma pTis TNM Finding v8|Anal Carcinoma pTis TNM Finding v8	Anal cancer with a finding of high-grade squamous intraepithelial lesion (previously termed carcinoma in situ, Bowen disease, anal intraepithelial neoplasia II-III, high-grade anal intraepithelial neoplasia). (from AJCC 8th Ed.)			Finding	
C133774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133774>	C133770	Anal Cancer pT1 TNM Finding v8|Anal Canal and Perianal (Anal Margin) Carcinoma pT1 TNM Finding v8|Anal Carcinoma pT1 TNM Finding v8	Anal cancer with tumor 2 cm or smaller. (from AJCC 8th Ed.)			Finding	
C133775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133775>	C133770	Anal Cancer pT2 TNM Finding v8|Anal Canal and Perianal (Anal Margin) Carcinoma pT2 TNM Finding v8|Anal Carcinoma pT2 TNM Finding v8	Anal cancer with tumor larger than 2 cm but equal to or smaller than 5 cm. (from AJCC 8th Ed.)			Finding	
C133776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133776>	C133770	Anal Cancer pT3 TNM Finding v8|Anal Canal and Perianal (Anal Margin) Carcinoma pT3 TNM Finding v8|Anal Carcinoma pT3 TNM Finding v8	Anal cancer with tumor larger than 5 cm. (from AJCC 8th Ed.)			Finding	
C133777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133777>	C1966	Anti-CD20 Monoclonal Antibody-FITC|Anti-CD20-FITC|Anti-CD20-Fluorescein Isothiocyanate|CD20-FITC	An immunoconjugate composed of a monoclonal antibody directed against the human antigen CD20 that is conjugated to the fluorescein derivative and fluorochrome fluorescein isothiocyanate (FITC), with potential use for imaging and detection of CD20-expressing cells. Upon application of anti-CD20-FITC to a cell preparation, anti-CD20-FITC targets and binds to CD20-expressing cells. Then, CD20-expressing cells in the sample can be imaged using fluorescence-based imaging techniques or separated from other cells present in the preparation using fluorescence-activated cell sorting (FACS). CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B-cells during most stages of B-cell development; it is involved in the regulation of B-cell differentiation and is overexpressed on certain types of cancer cells.			Indicator, Reagent, or Diagnostic Aid	
C133778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133778>	C133770	Anal Cancer pT4 TNM Finding v8|Anal Canal and Perianal (Anal Margin) Carcinoma pT4 TNM Finding v8|Anal Carcinoma pT4 TNM Finding v8	Anal cancer with tumor of any size invading adjacent organ(s), such as the vagina, urethra, or bladder. (from AJCC 8th Ed.)			Finding	
C133779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133779>	C133767	Anal Cancer Pathologic Regional Lymph Nodes TNM Finding v8|Anal Canal and Perianal (Anal Margin) Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8|Anal Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of anal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C13377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13377>	C13446	Chromosome Structure|Chromosomal Organization|Chromosomal Structure|Chromosome Organization	The 3-D organization of histones and other proteins on chromosomal DNA in the nucleus and allow for its form and function during cellular growth and division.			Cell Component	
C133780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133780>	C133779	Anal Cancer pNX TNM Finding v8|Anal Canal and Perianal (Anal Margin) Carcinoma pNX TNM Finding v8|Anal Carcinoma pNX TNM Finding v8	Anal cancer in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)			Finding	
C133781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133781>	C133779	Anal Cancer pN0 TNM Finding v8|Anal Canal and Perianal (Anal Margin) Carcinoma pN0 TNM Finding v8|Anal Carcinoma pN0 TNM Finding v8	Anal cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)			Finding	
C133782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133782>	C133779	Anal Cancer pN1 TNM Finding v8|Anal Canal and Perianal (Anal Margin) Carcinoma pN1 TNM Finding v8|Anal Carcinoma pN1 TNM Finding v8	Anal cancer with metastasis in inguinal, mesorectal, internal iliac, or external iliac nodes. (from AJCC 8th Ed.)			Finding	
C133783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133783>	C133782	Anal Cancer pN1a TNM Finding v8|Anal Canal and Perianal (Anal Margin) Carcinoma pN1a TNM Finding v8|Anal Carcinoma pN1a TNM Finding v8	Anal cancer with metastasis in inguinal, mesorectal, or internal iliac lymph nodes. (from AJCC 8th Ed.)			Finding	
C133784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133784>	C133782	Anal Cancer pN1b TNM Finding v8|Anal Canal and Perianal (Anal Margin) Carcinoma pN1b TNM Finding v8|Anal Carcinoma pN1b TNM Finding v8	Anal cancer with metastasis in external iliac lymph nodes. (from AJCC 8th Ed.)			Finding	
C133785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133785>	C133782	Anal Cancer pN1c TNM Finding v8|Anal Canal and Perianal (Anal Margin) Carcinoma pN1c TNM Finding v8|Anal Carcinoma pN1c TNM Finding v8	Anal cancer with metastasis in external iliac with any N1a nodes. (from AJCC 8th Ed.)			Finding	
C133786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133786>	C41206	Funded Institution	The institution where the funded principal investigator is on staff.			Organization	
C133787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133787>	C7489	Anal Canal Cancer by AJCC v6 and v7 Stage|Anal Canal Carcinoma by AJCC v6 and v7 Stage|Anal Carcinoma by AJCC v6 and v7 Stage	A term that refers to the staging of anal canal cancer according to the American Joint Committee on Cancer, 6th and 7th editions. This staging system applies to carcinomas arising in the anal canal only; melanomas, carcinoid tumors, sarcomas, and perianal tumors are not included. (from AJCC 6th and 7th Eds.)			Neoplastic Process	
C133788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133788>	C21114	TNFSF14 Gene|TNFSF14|TNFSF14|Tumor Necrosis Factor Superfamily Member 14 Gene	This gene is involved in both T-cell proliferation and tumor cell apoptosis.			Gene or Genome	
C133789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133789>	C133788	TNFSF14 wt Allele|CD258|HVEML|LIGHT|LTg|Tumor Necrosis Factor (Ligand) Superfamily, Member 14 Gene|Tumor Necrosis Factor Superfamily Member 14 wt Allele|Tumor Necrosis Factor Superfamily, Member 14 Gene|UNQ391/PRO726	Tumor necrosis factor ligand superfamily member 14 (240 aa, ~26 kDa) is encoded by the human TNFSF14 gene. This protein is involved in the regulation of both T-cell proliferation and apoptosis.			Gene or Genome	
C13378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13378>	C33904	Fundus|Fundic|fundus	The bottom portion or the portion that is furthest from the opening of a hollow organ.			Anatomical Structure	
C133790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133790>	C20500	Tumor Necrosis Factor Ligand Superfamily Member 14|CD258|CD258 Antigen|HVEM-L|Herpes Virus Entry Mediator Ligand|Herpesvirus Entry Mediator Ligand|LIGHT|TNFSF14|Tumor Necrosis Factor Ligand 1D	Tumor necrosis factor ligand superfamily member 14 (240 aa, ~26 kDa) is encoded by the human TNFSF14 gene. This protein is involved in the regulation of both T-cell proliferation and apoptosis.			Amino Acid, Peptide, or Protein	
C133791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133791>	C21114	TNFSF9 Gene|TNFSF9|TNFSF9|Tumor Necrosis Factor Superfamily Member 9 Gene	This gene plays a role in T-lymphocyte activation.	TNFSF9 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C133792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133792>	C133791	TNFSF9 wt Allele|4-1BB-L|4-1BB-L, Mouse, Homolog of Gene|CD137L|Homolog of Mouse 4-1BB-L Gene|TNLG5A|Tumor Necrosis Factor (Ligand) Superfamily, Member 9 Gene|Tumor Necrosis Factor Ligand Superfamily, Member 9 Gene|Tumor Necrosis Factor Superfamily Member 9 wt Allele	Human TNFSF9 wild-type allele is located in the vicinity of 19p13.3 and is approximately 7 kb in length. This allele, which encodes tumor necrosis factor ligand superfamily member 9 protein, is involved in antigen presentation, T-lymphocyte proliferation and cytotoxic T-cell stimulation.	TNFSF9 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133793>	C20500	Tumor Necrosis Factor Ligand Superfamily Member 9|4-1BB Ligand|4-1BB-L|4-1BBL|Receptor 4-1BB Ligand|TNFSF9|Tumor Necrosis Factor Ligand 5A	Tumor necrosis factor ligand superfamily member 9 (254 aa, ~27 kDa) is encoded by the human TNFSF9 gene. This protein plays a role in the costimulation of T-cells.	Tumor Necrosis Factor Ligand Superfamily Member 9		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133794>	C9291	Anal Cancer by AJCC v8 Stage|Anal Canal and Perianal (Anal Margin) Carcinoma by AJCC v8 Stage|Anal Carcinoma by AJCC v8 Stage	A term that refers to the staging of anal cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to all carcinomas arising in the anal canal, including carcinomas that arise within anorectal fistulas and those arising in the perianal area (anal margin). High-grade neuroendocrine carcinomas (small cell neuroendocrine carcinoma and large cell neuroendocrine carcinoma) are staged using this system. There is no AJCC staging system for anal mucosal melanomas and anal well-differentiated neuroendocrine tumors. (from AJCC 8th Ed.)			Neoplastic Process	
C133795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133795>	C133794	Stage 0 Anal Cancer AJCC v8|Stage 0 Anal Canal and Perianal (Anal Margin) Carcinoma AJCC v8|Stage 0 Anal Cancer|Stage 0 Anal Carcinoma AJCC v8	Stage 0 includes: Tis, N0, M0. Tis: High-grade squamous intraepithelial lesion (previously termed carcinoma in situ, Bowen disease, anal intraepithelial neoplasia II-III, high-grade anal intraepithelial neoplasia). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0 Anal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133796>	C133794	Stage I Anal Cancer AJCC v8|Stage I Anal Canal and Perianal (Anal Margin) Carcinoma AJCC v8|Stage I Anal Cancer|Stage I Anal Carcinoma AJCC v8	Stage I includes: T1, N0, M0. T1: Tumor 2 cm or smaller. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Anal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133797>	C133794	Stage II Anal Cancer AJCC v8|Stage II Anal Canal and Perianal (Anal Margin) Carcinoma AJCC v8|Stage II Anal Cancer|Stage II Anal Carcinoma AJCC v8	Stage II includes: IIA: T2, N0, M0; IIB: T3, N0, M0. T2: Tumor larger than 2 cm but equal to or smaller than 5 cm. T3: Tumor larger than 5 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Anal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133798>	C133797	Stage IIA Anal Cancer AJCC v8|Stage IIA Anal Canal and Perianal (Anal Margin) Carcinoma AJCC v8|Stage IIA Anal Cancer|Stage IIA Anal Carcinoma AJCC v8	Stage IIA includes: T2, N0, M0. T2: Tumor larger than 2 cm but equal to or smaller than 5 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIA Anal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133799>	C133797	Stage IIB Anal Cancer AJCC v8|Stage IIB Anal Canal and Perianal (Anal Margin) Carcinoma AJCC v8|Stage IIB Anal Cancer|Stage IIB Anal Carcinoma AJCC v8	Stage IIB includes: T3, N0, M0. T3: Tumor larger than 5 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIB Anal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13379>	C13303	Protein Domain|Domain|Feature|Motif|Protein Feature|Protein Motif|Protein Region|Region|Signature|domain	A structurally or functionally defined protein region.			Amino Acid Sequence	
C1337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1337>	C47796	Cevimeline Hydrochloride|AF-102B|CEVIMELINE HYDROCHLORIDE|Evoxac|Evoxac|cevimeline hydrochloride	A cholinergic analogue with glandular secretion stimulatory activity. Cevimeline binds to and activates muscarinic receptors, thereby increasing the secretions in exocrine salivary and sweat glands. This cholinergic agonist also increases the tone of smooth muscle in the gastrointestinal and urinary tracts. Cevimeline is being studied as a treatment for dry mouth caused by radiation therapy to the head and neck.	Cevimeline Hydrochloride		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C133800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133800>	C133794	Stage III Anal Cancer AJCC v8|Stage III Anal Canal and Perianal (Anal Margin) Carcinoma AJCC v8|Stage III Anal Cancer|Stage III Anal Carcinoma AJCC v8	Stage III includes: IIIA: (T1, N1, M0); (T2, N1, M0); IIIB: (T4, N0, M0); IIIC: (T3, N1, M0); (T4, N1, M0). T1: Tumor 2 cm or smaller. T2: Tumor larger than 2 cm but equal to or smaller than 5 cm. T3: Tumor larger than 5 cm. T4: Tumor of any size invading adjacent organ(s), such as the vagina, urethra, or bladder. N0: No regional lymph node metastasis. N1: Metastasis in inguinal, mesorectal, internal iliac, or external iliac nodes. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Anal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133801>	C133800	Stage IIIA Anal Cancer AJCC v8|Stage IIIA Anal Canal and Perianal (Anal Margin) Carcinoma AJCC v8|Stage IIIA Anal Cancer|Stage IIIA Anal Carcinoma AJCC v8	Stage IIIA includes: (T1, N1, M0); (T2, N1, M0). T1: Tumor 2 cm or smaller. T2: Tumor larger than 2 cm but equal to or smaller than 5 cm. N1: Metastasis in inguinal, mesorectal, internal iliac, or external iliac nodes. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIA Anal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133802>	C133800	Stage IIIB Anal Cancer AJCC v8|Stage IIIB Anal Canal and Perianal (Anal Margin) Carcinoma AJCC v8|Stage IIIB Anal Cancer|Stage IIIB Anal Carcinoma AJCC v8	Stage IIIB includes: T4, N0, M0. T4: Tumor of any size invading adjacent organ(s), such as the vagina, urethra, or bladder. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIB Anal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133803>	C133800	Stage IIIC Anal Cancer AJCC v8|Stage IIIC Anal Canal and Perianal (Anal Margin) Carcinoma AJCC v8|Stage IIIC Anal Cancer|Stage IIIC Anal Carcinoma AJCC v8	Stage IIIC includes: (T3, N1, M0); (T4, N1, M0). T3: Tumor larger than 5 cm. T4: Tumor of any size invading adjacent organ(s), such as the vagina, urethra, or bladder. N1: Metastasis in inguinal, mesorectal, internal iliac, or external iliac nodes. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIC Anal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133804>	C133794	Stage IV Anal Cancer AJCC v8|Stage IV Anal Canal and Perianal (Anal Margin) Carcinoma AJCC v8|Stage IV Anal Cancer|Stage IV Anal Carcinoma AJCC v8	Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Anal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133805>	C131123	FDA Pharmaceutical Quality/CMC Terminology|FDA Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Terminology|PQ/CMC Terminology|PQ/CMC Terminology	A category of terminology used to qualify the information pertaining to Pharmaceutical Quality/Chemistry, Manufacturing and Controls.			Intellectual Product	FDA Terminology
C133807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133807>	C133805	PQ/CMC Test Category Terminology|Pharmaceutical Quality/CMC Test Category Terminology|Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Test Category Terminology	A category of terminology used to qualify the information pertaining to test categories in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.			Intellectual Product	FDA Pharmaceutical Quality/CMC Terminology
C133809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133809>	C25939	AKR1B1 Gene|AKR1B1|AKR1B1|Aldo-Keto Reductase Family 1 Member B Gene	This gene plays a role in the NADPH-dependent metabolism of aldehydes.			Gene or Genome	
C13380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13380>	C198953	5q|Chromosome 5 Distal Arm|Chromosome 5 Long Arm|Chromosome 5q	Distal (long) arm of chromosome 5	5q		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133810>	C133809	AKR1B1 wt Allele|ADR|ALDR1|ALR2|AR|Aldo-Keto Reductase Family 1 Member B wt Allele|Aldo-Keto Reductase Family 1, Member B1 (Aldose Reductase) Gene|Aldo-Keto Reductase Family 1, Member B1 Gene	Human AKR1B1 wild-type allele is located in the vicinity of 7q33 and is approximately 17 kb in length. This allele, which encodes aldose reductase protein, is involved in the metabolism of glucose, toxic aldehydes and steroids. This gene is associated with the development of diabetic complications.			Gene or Genome	
C133811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133811>	C16946	Aldose Reductase|AKR1B1|AR|Aldehyde Reductase|Aldehyde Reductase 1|Aldo-Keto Reductase Family 1 Member B1|EC 1.1.1.21|Lii5-2 CTCL Tumor Antigen|Low Km Aldose Reductase	Aldose reductase (316 aa, ~36 kDa) is encoded by the human AKR1B1 gene. This protein plays a role in glucose metabolism.			Amino Acid, Peptide, or Protein|Enzyme	
C133812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133812>	C177692	CD11c Positive|AlphaX Integrin Chain Positive|Antigen Cd11c (P150), Alpha Polypeptide Positive|Axb2 Positive|CD11 Antigen-Like Family Member C Positive|CD11c Antigen Positive|Cr4 Positive|ITGAX Positive|Integrin Alpha X Positive|Integrin Alpha-X Positive|Leu M5 Positive|Leukocyte Adhesion Glycoprotein P150,95, Alpha Chain Positive|Leukocyte Adhesion Receptor P150,95 Positive|Leukocyte Surface Antigen P150, 95 Positive|Myeloid Membrane Antigen, Alpha Subunit Positive|p150 95 Integrin Alpha Chain Positive	An indication that CD11c expression has been detected in a sample.	CD11c Positive		Laboratory or Test Result	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133813>	C177692	IGHV4-34 Positive|Ig Heavy Chain V-II Region ARH-77 Positive|Immunoglobulin Heavy Variable 4-34 Positive	An indication that IGHV4-34 expression has been detected in a sample.	IGHV4-34 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133814>	C177692	PRAME Positive|CT130 Positive|Cancer/Testis Antigen 130 Positive|MAPE Positive|Melanoma Antigen Preferentially Expressed in Tumors Positive|OIP-4 Positive|OIP4 Positive|Opa-Interacting Protein 4 Positive|PRAME Expression Positive|Preferentially Expressed Antigen in Melanoma Positive	An indication that PRAME expression has been detected in a sample.	PRAME Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133815>	C165233	CD25 Negative|CD25 Antigen Negative|IDDM10 Negative|IL2R Negative|IL2R, Alpha Chain Negative|IL2RA Negative|Interleukin 2 Receptor, Alpha Negative|Interleukin-2 Receptor Alpha Chain Negative|Interleukin-2 Receptor Subunit Alpha Negative|TCGFR Negative	An indication that CD25 expression was not detected in a sample.	CD25 Negative		Laboratory or Test Result	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133816>	C165233	CD103 Negative|Alpha Polypeptide Negative|CD103 Antigen Negative|HML-1 Antigen Negative|HUMINAE Negative|Human Mucosal Lymphocyte Antigen 1, Alpha Subunit Negative|ITGAE Negative|Integrin Alpha-E Negative|Integrin, Alpha E (Antigen CD103, Human Mucosal Lymphocyte Antigen 1 Negative|Integrin, Alpha-E Negative|Mucosal Lymphocyte 1 Antigen Negative	An indication that CD103 expression was not detected in a sample.	CD103 Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133817>	C171083	Polyclonality|Polyclonal	Having, or deriving from, two or more progenitors.			Conceptual Entity	
C133818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133818>	C213143	Anti-AG7 Antibody-drug Conjugate AbGn-107|ADC AbGn-107|Ab1-18Hr1|AbGn-107|AbGn107|Anti-AG7 ADC AbGn-107	An antibody-drug conjugate (ADC) composed of a monoclonal antibody that targets the tumor-associated antigen (TAA) AG7 and is linked, through a hydrophilic, self-immolative linker, to a proprietary cytotoxic payload, with potential antineoplastic activity. Upon administration of AbGn-107 the antibody moiety targets and binds to the AG7 antigen expressed on a variety of cancer cells. Upon binding and internalization, the linker is cleaved and the payload is released, binds to tubulin, inhibits tubulin polymerization and kills the AG7-expressing tumor cells.	Anti-AG7 Antibody-drug Conjugate AbGn-107		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C133819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133819>	C223203	EED Inhibitor MAK683|EED PPI Inhibitor MAK683|EED Protein-protein Interaction Inhibitor MAK683|Ectodermal Embryonic Development Inhibitor MAK683|MAK 683|MAK-683|MAK683	An inhibitor of embryonic ectoderm development protein (EED) and allosteric inhibitor of polycomb repressive complex 2 (PRC2), with potential antineoplastic activity. Upon administration, MAK683 selectively binds to the domain of EED that interacts with trimethylated lysine 27 on histone 3 (H3K27me3), which leads to a conformational change in the EED H3K27me3-binding pocket and prevents the interaction of EED with the histone methyltransferase enhancer zeste homolog 2 (EZH2). Disruption of the EED-EZH2 protein-protein interaction (PPI) results in a loss of H3K27me3-stimulated PRC2 activity and prevents H3K27 trimethylation. This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased tumor cell proliferation in EZH2-mutated and PRC2-dependent cancer cells. PRC2, a histone H3 lysine 27 methyltransferase and multi-protein complex comprised of EZH2, EED and suppressor of zeste 12 (SUZ12), plays a key role in gene regulation, especially during embryonic development. EZH2, the catalytic subunit of PRC2, is overexpressed or mutated in a variety of cancer cells. EED is essential for the histone methyltransferase activity of PRC2 because EED directly binds to H3K27me3.	EED Inhibitor MAK683		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C13381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13381>	C198952	8p|Chromosome 8 Proximal Arm|Chromosome 8 Short Arm|Chromosome 8p	Proximal (short) arm of chromosome 8	8p		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133821>	C217030|C213472|C212990|C199169|C141136	Repotrectinib|ALK/ROS1/NTRK/SRC/FAK Multikinase Inhibitor TPX-0005|Augtyro|Multi-kinase Inhibitor TPX-0005|Multikinase Inhibitor TPX-0005|REPOTRECTINIB|TPX 0005|TPX-0005|TPX0005	An orally available inhibitor of multiple kinases, including the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), the neurotrophic tyrosine receptor kinase (NTRK) types 1, 2 and 3, the proto-oncogene SRC, and focal adhesion kinase (FAK), with potential antineoplastic activity. Upon oral administration, repotrectinib binds to and inhibits wild-type, point mutants and fusion proteins of ALK, ROS1, NTRK1-3, SRC, FAK and, to a lesser extent, other kinases. Inhibition of these kinases leads to the disruption of downstream signaling pathways and the inhibition of cell growth of tumors in which these kinases are overexpressed, rearranged or mutated.	Repotrectinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C133822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133822>	C1511	Zirconium Zr 89 DFO-Pertuzumab|(89)Zr-pertuzumab|89Zr-DFO-pertuzumab|PERTUZUMAB DEFEROXAMINE ZIRCONIUM ZR-89|Zr 89-DFO-pertuzumab	A radioimmunoconjugate composed of pertuzumab, a humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the tyrosine kinase receptor human epidermal growth factor-2 (HER2; HER-2), and linked, via the chelator desferrioxamine (DFO), to the radioisotope zirconium Zr 89 (Zr89), with potential use in imaging of HER-2-expressing tumor cells upon positron emission tomography (PET). Upon administration of zirconium Zr 89-DFO-pertuzumab, the pertuzumab moiety targets and binds to HER-2. After binding and internalization into HER-2-expressing tumor cells, Zr89 facilitates the visualization and detection of HER-2-expressing tumor cells using PET. This assesses HER2-expression and may predict or evaluate the tumor's response to certain HER-2-targeting chemotherapeutics.	Zirconium Zr 89 DFO-Pertuzumab		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C133823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133823>	C142078	3D-expanded Placenta-derived Cells PLX-R18|PLX R18|PLX RAD|PLX-R18|PLX-R18 Cells|PLacental eXpanded-R18	A population of proprietary, off-the-shelf, three-dimensional (3D)-expanded, allogeneic placenta-derived stromal cells that can potentially be used to increase hematopoietic recovery from hematological disorders or after a hematopoietic stem cell transplant (HSCT). Upon intramuscular (IM) injection of placental expanded (PLX)-R18, these cells secrete a range of specific hematopoietic, regenerative proteins depending on their in vivo environment. The secreted proteins are involved in maintenance, renewal, proliferation, differentiation, and mobilization of hematopoietic progenitor cells (HPCs), and include, but are not limited to, granulocyte colony-stimulating factor (GCSF), monocyte chemoattractant protein-1 (MCP-1/CCL2), MCP-3 (CCL7), interleukin-6 (IL-6), and IL-8. This increases the number of colony-forming hematopoietic progenitors in the bone marrow, regenerates the bone marrow hematopoietic cells, and elevates and restores blood cell production.	3D-expanded Placenta-derived Cells PLX-R18		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C133824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133824>	C2140	Copper Chloride Formulation|CuCl2 Formulation	A formulation containing the compound copper chloride (CuCl2), that can potentially be used to enhance Cu levels in cancer cells in order to elevate the antitumor activity of chemotherapeutic agents that are dependent on Cu for their activity. Upon intravenous administration of CuCl2, the mineral Cu is selectively taken up by and accumulates in cancer cells. In the presence of certain chemotherapeutic agents whose mechanism of action (MoA) is dependent on Cu, this formulation may enhance their cytotoxic activity.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C133825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133825>	C133761	Small Intestine Cancer TNM Finding v8|Small Intestine Carcinoma TNM Finding v8	A finding about one or more characteristics of small intestine cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to carcinomas of the nonampullary duodenum, jejunum, and ileum. Only adenocarcinomas are assigned a stage group. Nonadenocarcinomas arising in the small intestine should have a TNM assigned but are not assigned a stage classification. (from AJCC 8th Ed.)			Finding	
C133826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133826>	C133825	Small Intestine Cancer Clinical TNM Finding v8|Small Intestine Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of small intestine cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C133827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133827>	C133826	Small Intestine Cancer Clinical Distant Metastasis TNM Finding v8|Small Intestine Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of small intestine cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C133828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133828>	C133827	Small Intestine Cancer cM0 TNM Finding v8|Small Intestine Carcinoma cM0 TNM Finding v8	Small intestine cancer without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C133829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133829>	C133827	Small Intestine Cancer cM1 TNM Finding v8|Small Intestine Carcinoma cM1 TNM Finding v8	Small intestine cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C13382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13382>	C198952	17p|Chromosome 17 Proximal Arm|Chromosome 17 Short Arm|Chromosome 17p	Proximal (short) arm of chromosome 17	17p		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133830>	C133825	Small Intestine Cancer Pathologic TNM Finding v8|Small Intestine Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of small intestine cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C133831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133831>	C133830	Small Intestine Cancer Pathologic Distant Metastasis TNM Finding v8|Small Intestine Carcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of small intestine cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C133832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133832>	C133831	Small Intestine Cancer pM1 TNM Finding v8|Small Intestine Carcinoma pM1 TNM Finding v8	Small intestine cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C133833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133833>	C133830	Small Intestine Cancer Pathologic Primary Tumor TNM Finding v8|Small Intestine Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of small intestine cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C133834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133834>	C133833	Small Intestine Cancer pTX TNM Finding v8|Small Intestine Carcinoma pTX TNM Finding v8	Small intestine cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C133835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133835>	C133833	Small Intestine Cancer pT0 TNM Finding v8|Small Intestine Carcinoma pT0 TNM Finding v8	Small intestine cancer with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C133836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133836>	C133833	Small Intestine Cancer pTis TNM Finding v8|Small Intestine Carcinoma pTis TNM Finding v8	Small intestine cancer with a finding of high grade dysplasia/carcinoma in situ. (from AJCC 8th Ed.)			Finding	
C133837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133837>	C133833	Small Intestine Cancer pT1 TNM Finding v8|Small Intestine Carcinoma pT1 TNM Finding v8	Small intestine cancer with tumor invading the lamina propria or submucosa. (from AJCC 8th Ed.)			Finding	
C133838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133838>	C133837	Small Intestine Cancer pT1a TNM Finding v8|Small Intestine Carcinoma pT1a TNM Finding v8	Small intestine cancer with tumor invading the lamina propria. (from AJCC 8th Ed.)			Finding	
C133839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133839>	C96963|C3482|C162255	Metastatic Digestive System Carcinoma|Metastatic Digestive System Cancer|Metastatic Gastrointestinal Carcinoma|Metastatic Gastrointestinal System Cancer|Metastatic Gastrointestinal System Carcinoma	A carcinoma that arises from the gastrointestinal system and has metastasized to other anatomic sites.	Metastatic Digestive System Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13383>	C198953	18q|Chromosome 18 Distal Arm|Chromosome 18 Long Arm|Chromosome 18q	Distal (long) arm of chromosome 18	18q		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133840>	C133837	Small Intestine Cancer pT1b TNM Finding v8|Small Intestine Carcinoma pT1b TNM Finding v8	Small intestine cancer with tumor invading the submucosa. (from AJCC 8th Ed.)			Finding	
C133841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133841>	C133833	Small Intestine Cancer pT2 TNM Finding v8|Small Intestine Carcinoma pT2 TNM Finding v8	Small intestine cancer with tumor invading the muscularis propria. (from AJCC 8th Ed.)			Finding	
C133842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133842>	C133833	Small Intestine Cancer pT3 TNM Finding v8|Small Intestine Carcinoma pT3 TNM Finding v8	Small intestine cancer with tumor invading through the muscularis propria into the subserosa, or extending into nonperitonealized perimuscular tissue (mesentery or retroperitoneum) without serosal penetration. For T3 tumors, the nonperitonealized perimuscular tissue is, for the jejunum and ileum, part of the mesentery and, for the duodenum in areas where serosa is lacking, part of the interface with the pancreas. (from AJCC 8th Ed.)			Finding	
C133843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133843>	C133833	Small Intestine Cancer pT4 TNM Finding v8|Small Intestine Carcinoma pT4 TNM Finding v8	Small intestine cancer with tumor perforating the visceral peritoneum or directly invading other organs or structures (e.g., other loops of small intestine, mesentery of adjacent loops of bowel, and abdominal wall by way of serosa; for duodenum only, invasion of pancreas or bile duct). (from AJCC 8th Ed.)			Finding	
C133844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133844>	C16615	POU1F1 Gene|POU Class 1 Homeobox 1 Gene|POU1F1|POU1F1	This gene is involved in the regulation of genes associated with pituitary development.			Gene or Genome	
C133845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133845>	C133844	POU1F1 wt Allele|CPHD1|GHF-1|PIT1|POU Class 1 Homeobox 1 wt Allele|POU Domain Class 1, Transcription Factor 1 Gene|POU Domain, Class 1, Transcription Factor 1 Gene|POU1F1a|Pit-1|Pituitary Transcript Factor 1 Gene	Human POU1F1 wild-type allele is located in the vicinity of 3p11.2 and is approximately 17 kb in length. This allele, which encodes pituitary-specific positive transcription factor 1 protein, plays a role in pituitary development and hormone expression. Mutations in this gene results in combined pituitary hormone deficiency.			Gene or Genome	
C133846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133846>	C133805	PQ/CMC Batch Utilization Terminology|Pharmaceutical Quality/CMC Batch Utilization Terminology|Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Batch Utilization Terminology	A category of terminology used to qualify the information pertaining to batch utilization in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.			Intellectual Product	FDA Pharmaceutical Quality/CMC Terminology
C133848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133848>	C133805	PQ/CMC Chemical Structure Data File Type Terminology|Pharmaceutical Quality/CMC Chemical Structure Data File Type Terminology|Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Chemical Structure Data File Type Terminology	A category of terminology used to qualify the information pertaining to chemical structure data file types in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.			Intellectual Product	FDA Pharmaceutical Quality/CMC Terminology
C133849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133849>	C133805	PQ/CMC Closure Type Terminology|Pharmaceutical Quality/CMC Closure Type Terminology|Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Closure Type Terminology	A category of terminology used to qualify the information pertaining to closure types in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.			Intellectual Product	FDA Pharmaceutical Quality/CMC Terminology
C13384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13384>	C198953	7q|Chromosome 7 Distal Arm|Chromosome 7 Long Arm|Chromosome 7q	Distal (long) arm of chromosome 7			Gene or Genome	
C133851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133851>	C133805	PQ/CMC Conformance to Criteria Terminology|Pharmaceutical Quality/CMC Conformance to Criteria Terminology|Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Conformance to Criteria Terminology	A category of terminology used to qualify the information pertaining to conformance to criteria in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.			Intellectual Product	FDA Pharmaceutical Quality/CMC Terminology
C133852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133852>	C133805	PQ/CMC Container Orientation Terminology|Pharmaceutical Quality/CMC Container Orientation Terminology|Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Container Orientation Terminology	A category of terminology used to qualify the information pertaining to container orientation in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.			Intellectual Product	FDA Pharmaceutical Quality/CMC Terminology
C133853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133853>	C133805	PQ/CMC Container Type Terminology|Pharmaceutical Quality/CMC Container Type Terminology|Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Container Type Terminology	A category of terminology used to qualify the information pertaining to container types in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.			Intellectual Product	FDA Pharmaceutical Quality/CMC Terminology
C133856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133856>	C133805	PQ/CMC Impurity Classification Terminology|Pharmaceutical Quality/CMC Impurity Classification Terminology|Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Impurity Classification Terminology	A category of terminology used to qualify the information pertaining to impurity classification in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.			Intellectual Product	FDA Pharmaceutical Quality/CMC Terminology
C133858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133858>	C133805	PQ/CMC Interpretation Code (numeric) Terminology|Pharmaceutical Quality/CMC Interpretation Code (numeric) Terminology|Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Interpretation Code (numeric) Terminology	A category of terminology used to qualify the information pertaining to numeric interpretation codes in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.			Intellectual Product	FDA Pharmaceutical Quality/CMC Terminology
C133859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133859>	C103175	PQ/CMC Manufacturing Site Unique Identifier Type Terminology|Pharmaceutical Quality/CMC Manufacturing Site Unique Identifier Type Terminology|Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Manufacturing Site Unique Identifier Type Terminology	A category of terminology used to qualify the information pertaining to manufacturing site unique identifier types in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.			Intellectual Product	
C13385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13385>	C13432	5q31|Chromosome 5q31	A chromosome band present on 5q			Gene or Genome	
C133860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133860>	C133805	PQ/CMC Quality Benchmark Terminology|Pharmaceutical Quality/CMC Quality Benchmark Terminology|Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Quality Benchmark Terminology	A category of terminology used to qualify the information pertaining to quality benchmarks in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.			Intellectual Product	FDA Pharmaceutical Quality/CMC Terminology
C133862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133862>	C133805	PQ/CMC Source Type Terminology|Pharmaceutical Quality/CMC Source Type Terminology|Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Source Type Terminology	A category of terminology used to qualify the information pertaining to source types in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.			Intellectual Product	FDA Pharmaceutical Quality/CMC Terminology
C133863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133863>	C133805	PQ/CMC Specification Status Terminology|Pharmaceutical Quality/CMC Specification Status Terminology|Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Specification Status Terminology	A category of terminology used to qualify the information pertaining to specification statuses in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.			Intellectual Product	FDA Pharmaceutical Quality/CMC Terminology
C133864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133864>	C133805	PQ/CMC Specification Type Terminology|Pharmaceutical Quality/CMC Specification Type Terminology|Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Specification Type Terminology	A category of terminology used to qualify the information pertaining to specification types in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.			Intellectual Product	FDA Pharmaceutical Quality/CMC Terminology
C133865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133865>	C133805	PQ/CMC Storage Conditions Terminology|Pharmaceutical Quality/CMC Storage Conditions Terminology|Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Storage Conditions Terminology	A category of terminology used to qualify the information pertaining to storage conditions in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.			Intellectual Product	FDA Pharmaceutical Quality/CMC Terminology
C133866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133866>	C133805	PQ/CMC Study Type Terminology|Pharmaceutical Quality/CMC Study Type Terminology|Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Study Type Terminology	A category of terminology used to qualify the information pertaining to study types in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.			Intellectual Product	FDA Pharmaceutical Quality/CMC Terminology
C133867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133867>	C133805	PQ/CMC Test Method Origin Terminology|Pharmaceutical Quality/CMC Test Method Origin Terminology|Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Test Method Origin Terminology	A category of terminology used to qualify the information pertaining to test method origins in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.			Intellectual Product	FDA Pharmaceutical Quality/CMC Terminology
C133868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133868>	C133805	PQ/CMC Test Usage Terminology|Pharmaceutical Quality/CMC Test Usage Terminology|Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Test Usage Terminology	A category of terminology used to qualify the information pertaining to test usage in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.			Intellectual Product	FDA Pharmaceutical Quality/CMC Terminology
C133869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133869>	C103175	PQ/CMC Testing Site Unique Identifier Type Terminology|Pharmaceutical Quality/CMC Testing Site Unique Identifier Type Terminology|Pharmaceutical Quality/Chemistry, Manufacturing, and Controls Testing Site Unique Identifier Terminology	A category of terminology used to qualify the information pertaining to testing site unique identifiers in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.			Intellectual Product	
C13386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13386>	C13432	7q31|Chromosome 7q31	A chromosome band present on 7q			Gene or Genome	
C133871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133871>	C17207	Pituitary-Specific Positive Transcription Factor 1|GHF-1|Growth Hormone Factor 1|POU Domain, Class 1, Transcription Factor 1|POU1F1|Pit-1|Pituitary-Specific Transcription Factor 1	Pituitary-specific positive transcription factor 1 (291 aa, ~33 kDa) is encoded by the human POU1F1 gene. This protein is involved in both the development and function of the pituitary gland.			Amino Acid, Peptide, or Protein	
C133872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133872>	C133830	Small Intestine Cancer Pathologic Regional Lymph Nodes TNM Finding v8|Small Intestine Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of small intestine cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C133873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133873>	C133872	Small Intestine Cancer pNX TNM Finding v8|Small Intestine Carcinoma pNX TNM Finding v8	Small intestine cancer in which the regional lymph node(s) cannot be assessed.  (from AJCC 8th Ed.)			Finding	
C133874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133874>	C133872	Small Intestine Cancer pN0 TNM Finding v8|Small Intestine Carcinoma pN0 TNM Finding v8	Small intestine cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)			Finding	
C133875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133875>	C133872	Small Intestine Cancer pN1 TNM Finding v8|Small Intestine Carcinoma pN1 TNM Finding v8	Small intestine cancer with metastasis in one or two regional lymph nodes. (from AJCC 8th Ed.)			Finding	
C133876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133876>	C133872	Small Intestine Cancer pN2 TNM Finding v8|Small Intestine Carcinoma pN2 TNM Finding v8	Small intestine cancer with metastasis in three or more regional lymph nodes. (from AJCC 8th Ed.)			Finding	
C133877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133877>	C20401|C191767	Anti-CD40 Monoclonal Antibody|Anti-CD40 MoAb	Any monoclonal antibody directed against the antigen cluster of differentiation 40 (CD40).			Chemical Viewed Functionally	
C133878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133878>	C20401|C163952	Anti-EGFR Monoclonal Antibody|Anti-EGFR MoAb	Any monoclonal antibody directed against epidermal growth factor receptor (EGFR).			Chemical Viewed Functionally	
C133879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133879>	C20401|C164035	Anti-FGFR Monoclonal Antibody|Anti-FGFR MoAb	Any monoclonal antibody directed against te antigen fibroblast growth factor receptor (FGFR).			Chemical Viewed Functionally	
C13387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13387>	C13432	17p12|Chromosome 17p12	A chromosome band present on 17p			Gene or Genome	
C133880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133880>	C25997	TANK Gene|TANK|TANK|TRAF Family Member Associated NFKB Activator Gene	This gene plays a role in the inhibition of tumor necrosis factor receptor family-dependent signaling.			Gene or Genome	
C133881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133881>	C133880	TANK wt Allele|I-TRAF|ITRAF|TRAF Family Member Associated NFKB Activator wt Allele|TRAF2	Human TANK wild-type allele is located in the vicinity of 2q24.2 and is approximately 99 kb in length. This allele, which encodes TRAF family member-associated NF-kappa-B activator protein, is involved in the regulation of tumor necrosis factor receptor-associated factor- and I-kappa-B-kinase-dependent signaling.			Gene or Genome	
C133882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133882>	C26231	TRAF Family Member-Associated NF-Kappa-B Activator|I-TRAF|TANK|TRAF Family Member-Associated NFKB Activator|TRAF-Associated NF-Kappa-B Activator|TRAF-Interacting Protein	TRAF family member-associated NF-kappa-B activator (425 aa, ~48 kDa) is encoded by the human TANK gene. This protein plays a role in the sequestration of tumor necrosis factor receptor-associated factors.			Amino Acid, Peptide, or Protein	
C133883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133883>	C134989	Rabbit Uterine Carcinoma	Uterine carcinoma that occurs in a rabbit.			Neoplastic Process	Cellosaurus Disease Terminology
C133884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133884>	C2902	Plasminogen Activator Inhibitor-1 Deficiency	An autosomal recessive condition caused by mutation(s) in the PAI1 gene, encoding plasminogen activator inhibitor 1. It is characterized by increased bleeding following trauma, injury, or surgery and in women, menorrhagia.			Disease or Syndrome	Cellosaurus Disease Terminology
C133885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133885>	C27555	Anetoderma	A dermatologic condition characterized by focal loss of elastic tissue. Clinically it presents with atrophic depressions or saccular outpouchings of the skin.			Disease or Syndrome	Cellosaurus Disease Terminology
C133886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133886>	C75467	Charcot-Marie-Tooth Disease Type 2K|Axonal Charcot-Marie-Tooth Disease Type 2K|CMT2K	A rare subtype of Charcot-Marie-Tooth Disease that is caused by inherited mutations in the GDAP1 gene.			Disease or Syndrome	Cellosaurus Disease Terminology
C133887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133887>	C53543	Acute Hepatic Porphyria|ALAD Deficiency|Delta-Aminolevulinate Dehydratase Deficiency|Porphobilinogen Synthase Deficiency	A family of rare genetic disorders characterized by episodes of severe, potentially life-threatening abdominal pain and neuropsychiatric symptoms due to abnormal heme production in the liver.			Disease or Syndrome	Cellosaurus Disease Terminology
C133889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133889>	C26003	KLK6 Gene|KLK6|KLK6|Kallikrein Related Peptidase 6 Gene	This gene is involved in protein processing.			Gene or Genome	
C13388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13388>	C13432	8p22|Chromosome 8p22	A chromosome band present on 8p			Gene or Genome	
C133890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133890>	C133889	KLK6 wt Allele|Bssp|Kallikrein 6 (Neurosin, Zyme) Gene|Kallikrein Related Peptidase 6 wt Allele|Klk7|PRSS18|PRSS9|Protease, Serine, 18 Gene|Protease, Serine, 9 Gene|SP59|hK6	Human KLK6 wild-type allele is located in the vicinity of 19q13.41 and is approximately 11 kb in length. This allele, which encodes kallikrein-6 protein, plays a role in post-translational protein processing.			Gene or Genome	
C133891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133891>	C17123	Kallikrein-6|EC 3.4.21.-|KLK6|Kallikrein 6|Neurosin|Protease M|SP59|Serine Protease 18|Serine Protease 9|Zyme	Kallikrein-6 (244 aa, ~27 kDa) is encoded by the human KLK6 gene. This protein is involved in the proteolytic processing of substrates.			Amino Acid, Peptide, or Protein|Enzyme	
C133893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133893>	C7888	Small Intestinal Adenocarcinoma by AJCC v8 Stage	A term that refers to the staging of small intestinal adenocarcinoma according to the American Joint Committee on Cancer, 8th edition. Nonadenocarcinomas arising in the small intestine should have a TNM assigned but are not assigned a stage classification. (from AJCC 8th Ed.)			Neoplastic Process	
C133894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133894>	C133893	Stage 0 Small Intestinal Adenocarcinoma AJCC v8|Stage 0 Small Intestinal Adenocarcinoma	Stage 0 includes: Tis, N0, M0. Tis: High grade dysplasia/carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0 Small Intestinal Adenocarcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133895>	C133893	Stage I Small Intestinal Adenocarcinoma AJCC v8|Stage I Small Intestinal Adenocarcinoma	Stage I includes: T1-2, N0, M0. T1: Tumor invading the lamina propria or submucosa. T2: Tumor invading the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Small Intestinal Adenocarcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133896>	C133893	Stage II Small Intestinal Adenocarcinoma AJCC v8|Stage II Small Intestinal Adenocarcinoma	Stage II includes: IIA: T3, N0, M0; IIB: T4, N0, M0. T3: Tumor invading through the muscularis propria into the subserosa, or extending into nonperitonealized perimuscular tissue (mesentery or retroperitoneum) without serosal penetration. For T3 tumors, the nonperitonealized perimuscular tissue is, for the jejunum and ileum, part of the mesentery and, for the duodenum in areas where serosa is lacking, part of the interface with the pancreas. T4: Tumor perforating the visceral peritoneum or directly invading other organs or structures (e.g., other loops of small intestine, mesentery of adjacent loops of bowel, and abdominal wall by way of serosa; for duodenum only, invasion of pancreas or bile duct). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Small Intestinal Adenocarcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133897>	C133896	Stage IIA Small Intestinal Adenocarcinoma AJCC v8|Stage IIA Small Intestinal Adenocarcinoma	Stage IIA includes: T3, N0, M0. T3: Tumor invading through the muscularis propria into the subserosa, or extending into nonperitonealized perimuscular tissue (mesentery or retroperitoneum) without serosal penetration. For T3 tumors, the nonperitonealized perimuscular tissue is, for the jejunum and ileum, part of the mesentery and, for the duodenum in areas where serosa is lacking, part of the interface with the pancreas. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIA Small Intestinal Adenocarcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133898>	C133896	Stage IIB Small Intestinal Adenocarcinoma AJCC v8|Stage IIB Small Intestinal Adenocarcinoma	Stage IIB includes: T4, N0, M0. T4: Tumor perforating the visceral peritoneum or directly invading other organs or structures (e.g., other loops of small intestine, mesentery of adjacent loops of bowel, and abdominal wall by way of serosa; for duodenum only, invasion of pancreas or bile duct). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIB Small Intestinal Adenocarcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133899>	C133893	Stage III Small Intestinal Adenocarcinoma AJCC v8|Stage III Small Intestinal Adenocarcinoma	Stage III includes: IIIA: Any T, N1, M0; IIIB: Any T, N2, M0. N1: Metastasis in one or two regional lymph nodes. N2: Metastasis in three or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Small Intestinal Adenocarcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13389>	C198953	11q|Chromosome 11 Distal Arm|Chromosome 11 Long Arm|Chromosome 11q	Distal (long) arm of chromosome 11	11q		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C1338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1338>	C2150|C1660	Didox|3,4-Dihydroxybenzohydroxamic Acid|3,4-Dihydroxybenzohydroxamic acid|DIDOX	A ribonucleotide reductase inhibitor with activity against retroviruses. Didox inhibits retrovirus replication by depleting the deoxynucleotides obligatory for synthesis of the proviral DNA intermediate of retrovirus replication.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology
C133900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133900>	C133899	Stage IIIA Small Intestinal Adenocarcinoma AJCC v8|Stage IIIA Small Intestinal Adenocarcinoma	Stage IIIA includes: Any T, N1, M0. N1: Metastasis in one or two regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIA Small Intestinal Adenocarcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133901>	C133899	Stage IIIB Small Intestinal Adenocarcinoma AJCC v8|Stage IIIB Small Intestinal Adenocarcinoma	Stage IIIB includes: Any T, N2, M0. N2: Metastasis in three or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIB Small Intestinal Adenocarcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C133902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133902>	C133893	Stage IV Small Intestinal Adenocarcinoma AJCC v8|Stage IV Small Intestinal Adenocarcinoma	Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Small Intestinal Adenocarcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13390>	C13432	11q23|Chromosome 11q23	A chromosome band present on 11q	11q23		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133910>	C171252	MDL Molfile Format|MDL Molfile|MOLFILE|MOLFILE|Molecular Design Limited Molefile|Molfile	A chemical text file format developed by Molecular Design Limited (MDL) that represent information about molecular atoms, bonds, connectivity and coordinates. The file extension is .mol.			Intellectual Product	pFDA Bioinformatics/Genomics Terminology|PQ/CMC Chemical Structure Data File Type Terminology|precisionFDA Terminology
C133914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133914>	C45788	Valve-up	A position in which the valve indicator is pointing up.			Spatial Concept	PQ/CMC Container Orientation Terminology
C133915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133915>	C45788	Valve-down	A position in which the valve indicator is pointing down.			Spatial Concept	PQ/CMC Container Orientation Terminology
C13391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13391>	C13338	BAT Locus|BAT Loci	Microsatellite repeats that have been used as markers of microsatellite instability.  BAT26, a poly(A) tract in MSH2 intron 5, is one example of a BAT locus.  Presence of alterations in the BAT26 locus, detected in stool samples, may be an easy and non-invasive detection method for colorectal cancer.			Gene or Genome	
C13392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13392>	C198952	3p|Chromosome 3 Proximal Arm|Chromosome 3 Short Arm|Chromosome 3p	Proximal (short) arm of chromosome 3	3p		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133931>	C73537	Raw Materials/Excipients/Intermediates/Reagents Specification|Raw Materials/Excipients/Intermediates/Reagents	The specification which is applied to the raw materials, excipients, intermediates or reagents.			Gene or Genome	PQ/CMC Specification Type Terminology
C133935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133935>	C96147|C96146	Temperature 5 (+/-) 3 Degrees C|5 +/- 3 degrees C|5 Degrees C (+/-) 3 Degrees C	Storage at 5 degrees C (+/-) 3 degrees C.			Qualitative Concept	PQ/CMC Storage Conditions Terminology
C133936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133936>	C96147|C96146	Temperature -20 (+/-) 5 Degrees C|-20 +/- 5 degrees C|-20 Degrees C (+/-) 5 Degrees C	Storage at -20 degrees C (+/-) 5 degrees C.			Qualitative Concept	PQ/CMC Storage Conditions Terminology
C13393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13393>	C33904	Lobe|lobe	A portion of an organ, such as the liver, lung, breast, or brain.			Body Part, Organ, or Organ Component	
C133940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133940>	C96147	Temperature 40 (+/-) 2 Degrees C and Relative Humidity Not More Than 25%|40 Degrees C (+/-) 2 Degrees C and Relative Humidity Not More Than 25%|40 degrees C +/- 2 degrees C/not more than (NMT) 25%RH	Storage at 40 degrees C (+/-) 2 degrees C and Relative Humidity not more than 25%.			Qualitative Concept	PQ/CMC Storage Conditions Terminology
C13394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13394>	C13442	Myelogenous|myelogenous	Referring to myelocytes, a type of white blood cell. Also called myeloid.			Qualitative Concept	
C13395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13395>	C186973|C186972|C119608	t(8;21)(q22;q22)|Eight-Twenty-One|t(8;21)(q21.3;q22)|t(8;21)(q22;q22.1)	A cytogenetic abnormality that involves a translocation between 8q22 and 21q22. It is associated with the development of acute myeloid leukemia with RUNX1-RUNX1T1 fusion protein expression.	t(8;21)(q22;q22)		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C133961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133961>	C134259	Deliverable Volume/Fill Volume Test|Deliverable Volume/Fill Volume	Tests designed to provide assurance that the liquids will, when transferred from the original container, deliver the volume of dosage form that is declared on the label of the article.			Laboratory Procedure	PQ/CMC Test Category Terminology
C133964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133964>	C204971	Heavy Metals/Elemental Impurities Analysis	Analytical procedures that determine the amount of elemental impurities in drug products or drug product components.			Laboratory Procedure	
C13396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13396>	C12535	Allogeneic Lymphocyte|Lymphocytes, Allogeneic	A cell that is antigenically distinct from other lymphocytes.			Cell	
C133974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133974>	C134259	Crystallinity Analysis|Crystallinity	The detection and quantification of the amount of amorphous material within a highly crystalline substance.			Laboratory Procedure	PQ/CMC Test Category Terminology
C133975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133975>	C134265	Tablet Friability Determination|Friability	The percent loss of a tablet due to mechanical action that results in fracture or breaking during the test.			Laboratory Procedure	PQ/CMC Test Category Terminology
C133979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133979>	C134259	Viscosity/Rheological Property Analysis|Viscosity/Rheological Properties	The determination of the thickness of a fluid and other properties related to the flow of a material.			Laboratory Procedure	PQ/CMC Test Category Terminology
C13397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13397>	C13404	B-DNA|B-Form DNA|Right-Handed DNA	A duplex of DNA is formed by two complementary chains that are arranged in an anti-parallel manner. B-DNA is about 20 Angstrom in diameter and a right-handed double helix with a wide major groove easily accessible to proteins and narrow minor groove. B-DNA is the most common DNA conformation in vivo and the favored conformation at high water concentrations. Base pairs are nearly perpendicular to the helix axis and sugar pucker is C2'-endo.			Nucleic Acid, Nucleoside, or Nucleotide	
C133983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133983>	C74957	Pyrogenicity/Endotoxin Assessment|Pyrogenicity/Endotoxin	Tests to measure the ability of a substance to produce an endotoxin or febrile and/or inflammatory reaction in response to administration of a substance.			Laboratory Procedure	PQ/CMC Test Category Terminology
C133985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133985>	C134259	Redispersibility Measurement|Redispersibility	A measurement of the time necessary for settled components to remix uniformly.			Laboratory Procedure	PQ/CMC Test Category Terminology
C13398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13398>	C34055	Embryonic Fluid|Embryonic Fluids|Embryonic Tissue, Fluids, Secretions	Fluids surrounding or related to an embryo.			Body Substance	GDC Terminology|GDC Value Terminology
C133990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133990>	C171258	Commercial Batch|Commercial	A product batch intended for marketing.			Entity	PQ/CMC Batch Utilization Terminology
C133991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133991>	C171258	Development Batch|Development	A batch produced during the characterization and process definition for the desired product.			Entity	PQ/CMC Batch Utilization Terminology
C133992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133992>	C171258	Clinical Batch|Clinical	A batch produced for use in clinical trials.			Entity	PQ/CMC Batch Utilization Terminology
C133993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133993>	C171258	Validation Batch|Validation	A batch intended for use in verification and demonstration of suitability of the designed process.			Entity	PQ/CMC Batch Utilization Terminology
C133994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133994>	C171258	Bioequivalence Batch|Bioequivalence	A batch produced and used for the purposes of determining bioequivalence of the product.			Entity	PQ/CMC Batch Utilization Terminology
C133995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133995>	C103240	Experimentally Determined Chemical Structure	Chemical structure derived from an investigative process using instrumentation.			Intellectual Product	
C133996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133996>	C171252	MDL Structure-data File Format|MDL SDF|MDL Structure-data File|Molecular Design Limited Structure-data File|SDF|Structure Data File	A family of chemical text file formats developed by Molecular Design Limited (MDL) that represent multiple chemical structural records and associated data fields. The file extension is .sd or .sdf.			Intellectual Product	pFDA Bioinformatics/Genomics Terminology|PQ/CMC Chemical Structure Data File Type Terminology|precisionFDA Terminology
C133997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133997>	C171252	Macromolecular CIF|macromolecular Crystallographic Information File|mmCIF|mmCIF (large molecules)	A standard text file format for representing crystallographic information of large molecules. The file extension is .mcif.			Intellectual Product	PQ/CMC Chemical Structure Data File Type Terminology
C133998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133998>	C105758	Does Not Conform|Does not conform	An observation that the item of interest does not match required specifications.			Conceptual Entity	PQ/CMC Conformance to Criteria Terminology
C133999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C133999>	C45788	Inverted	To place upside down.			Spatial Concept	PQ/CMC Container Orientation Terminology
C13399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13399>	C13717	All Sites	Anything relevant to all anatomic sites - non-specific.			Body Location or Region	
C1339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1339>	C582	BW A773U|1,3-Propanediol, 2-((3-fluoranthenylmethyl)amino)-2-methyl-, Hydrochloride|773U82 HYDROCHLORIDE|773U82 Hydrochloride|BW 773U82|BW-A 773U|BW-A-773U	The hydrochloride salt form of 73U82, a three substituted fluoranthene derivative of the 2-(arylmethylamino)-1,3-propanediol family, with potential antineoplastic activity. Upon administration, BW-A-773U intercalates with DNA, causing inhibition of DNA synthesis.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C134000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134000>	C158423	Organic Impurity|Organic Impurities	Any unwanted organic compound that is present in specifically defined substances or products and is generated during the manufacturing process or is created upon degradation during storage.			Chemical Viewed Functionally	
C134001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134001>	C158423	Inorganic Impurity|Inorganic|Inorganic Impurities	Any unwanted inorganic compound generated during the manufacturing process of a particular substance or product.			Chemical Viewed Functionally	PQ/CMC Impurity Classification Terminology
C134002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134002>	C134259	Residual Solvent Test|Residual Solvent|Residual Solvents	Tests performed to determine if organic volatile chemicals that are used or produced in manufacture of drug substance or excipients, or in the preparation of drug products are present in the pharmaceuticals.			Laboratory Procedure	PQ/CMC Test Subcategory Terminology
C134003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134003>	C70663	Data Universal Numbering System|D-U-N-S|D-U-N-S NUMBER|D-U-N-S Number|DUNS|DUNS|DUNS Numbers|Data Universal Number System	A proprietary system developed and regulated by Dun & Bradstreet that assigns a unique nine digit numeric identifier to a single business entity location.			Intellectual Product	CDISC Dictionary Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|PQ/CMC Organization-Site Identifier Type Terminology
C134004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134004>	C70663	Facility FDA Establishment Identifier|FEI|FEI|Facility FEI	A unique identifier assigned by the Food and Drug Administration (FDA) to track inspections of a regulated establishment or facility. They are also used to track generic drug user fee acts (GDUFA) facility fee payments.			Intellectual Product	PQ/CMC Organization-Site Identifier Type Terminology
C134005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134005>	C25364	Central File Number|CFN|CFN	A seven digit number assigned by the Food and Drug Administration (FDA).			Intellectual Product	PQ/CMC Organization-Site Identifier Type Terminology
C134006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134006>	C16048	United States Pharmacopeia-National Formulary|USP-NF	An official publication managed and maintained by the US Pharamacopeial Convention, that gives the composition, description, method of preparation, and dosage for drugs.			Intellectual Product	PQ/CMC Quality Benchmark Terminology
C134007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134007>	C16048	European Pharmacopeia|EP	A European reference publication from that is a legal and scientific benchmark for pharmacopoeial standards.			Intellectual Product	PQ/CMC Quality Benchmark Terminology
C134008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134008>	C16048	Japanese Pharmacopeia|JP	A reference publication considered the official pharmacopoeia of Japan that is published under the authority of the Ministry of Health, Labour and Welfare.			Intellectual Product	PQ/CMC Quality Benchmark Terminology
C134009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134009>	C16048	Company Standard	A trademarked, copyrighted standard belonging to an organization.			Intellectual Product	PQ/CMC Quality Benchmark Terminology
C13400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13400>	C13717	Other Anatomic Site|Anatomic Sites, Other|Other	An atomic site other than those already listed.			Body Location or Region	CTDC Value Terminology
C134010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134010>	C25425	Tentative Approval|Tentatively Approved	Provisional approval of a specification.			Activity	PQ/CMC Specification Status Terminology
C134011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134011>	C25425	Not Approved	A specification that has not yet been approved.			Activity	PQ/CMC Specification Status Terminology
C134012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134012>	C25375	Reported in a CBE or AR	The specification may be used without prior approval, and was submitted in a changes being effected (CBE) supplement or an annual report (AR).			Intellectual Product	PQ/CMC Specification Status Terminology
C134014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134014>	C96147|C96146	Temperature 25 (+/-) 2 Degrees C and Relative Humidity 60% (+/-) 5%|25 +/- 2 degrees C/60% +/- 5%RH|25 Degrees C (+/-) 2 Degrees C and 60% Relative Humidity (+/-) 5% Relative Humidity	Storage at 25 degrees C (+/-) 2 degrees C and 60% Relative Humidity (+/-) 5% Relative Humidity.			Qualitative Concept	PQ/CMC Storage Conditions Terminology
C134015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134015>	C96147|C96146	Temperature 30 (+/-) 2 Degrees C and Relative Humidity 65% (+/-) 5%|30 +/- 2 degrees C/65% +/- 5%RH|30 Degrees C (+/-) 2 Degrees C and 65% Relative Humidity (+/-) 5% Relative Humidity	Storage at 30 degrees C (+/-) 2 degrees C and 65% Relative Humidity (+/-) 5% Relative Humidity.			Qualitative Concept	PQ/CMC Storage Conditions Terminology
C134016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134016>	C96147|C96146	Temperature 40 (+/-) 2 Degrees C and Relative Humidity 75% (+/-) 5%|40 +/- 2 degrees C/75% +/- 5%RH|40 Degrees C (+/-) 2 Degrees C and 75% Relative Humidity (+/-) 5% Relative Humidity	Storage at 40 degrees C (+/-) 2 degrees C and 75% Relative Humidity (+/-) 5% Relative Humidity.			Qualitative Concept	PQ/CMC Storage Conditions Terminology
C134017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134017>	C96147|C96146	Temperature 30 (+/-) 2 Degrees C and Relative Humidity 75% (+/-) 5%|30 +/- 2 degrees C/75% +/- 5%RH|30 Degrees C (+/-) 2 Degrees C and 75% Relative Humidity (+/-) 5% Relative Humidity	Storage at 30 degrees C (+/-) 2 degrees C and 75% Relative Humidity (+/-) 5% Relative Humidity.			Qualitative Concept	PQ/CMC Storage Conditions Terminology
C134018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134018>	C96147	Temperature 25 (+/-) 2 Degrees C and Relative Humidity 40% (+/-) 5%|25 +/- 2 degrees C/40% +/- 5%RH|25 Degrees C (+/-) 2 Degrees C and 40% Relative Humidity (+/-) 5% Relative Humidity	Storage at 25 degrees C (+/-) 2 degrees C and 40% Relative Humidity (+/-) 5% Relative Humidity.			Qualitative Concept	PQ/CMC Storage Conditions Terminology
C134019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134019>	C96147	Temperature 30 (+/-) 2 Degrees C and Relative Humidity 35% (+/-) 5%|30 Degrees C (+/-) 2 Degrees C and 35% Relative Humidity (+/-) 5% Relative Humidity|30 degrees C +/- 2 degrees C/35%RH +/- 5%RH	Storage at 30 degrees C (+/-) 2 degrees C and 35% Relative Humidity (+/-) 5% Relative Humidity.			Qualitative Concept	PQ/CMC Storage Conditions Terminology
C13401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13401>	C34062	Breast Fluid or Secretion|Breast Fluids and Secretions|Mammary Gland Fluids and Secretions	Any of the secretions of the breast.			Body Substance	
C134020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134020>	C54362	ZBTB20 Gene|ZBTB20|ZBTB20|Zinc Finger and BTB Domain Containing 20 Gene	This gene may play a role in gene transcription.			Gene or Genome	
C134021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134021>	C73537	Drug Product Specification|Drug Product	The specification which is applied to the drug product.			Conceptual Entity	PQ/CMC Specification Type Terminology
C134022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134022>	C73537	Drug Substance Specification|Drug Substance	The specification which is applied to the drug substance.			Conceptual Entity	PQ/CMC Specification Type Terminology
C134024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134024>	C134020	ZBTB20 wt Allele|DKFZp566F123|DPZF|HOF|ODA-8S|PRIMS|ZNF288|Zinc Finger and BTB Domain Containing 20 wt Allele	Human ZBTB20 wild-type allele is located in the vicinity of 3q13.31 and is approximately 833 kb in length. This allele, which encodes zinc finger and BTB domain-containing protein 20, may be involved in transcriptional regulation. Mutation of the gene is associated with Primrose syndrome.			Gene or Genome	
C134025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134025>	C26199	Zinc Finger and BTB Domain-Containing Protein 20|BTB/POZ Zinc Finger Protein DPZF|Dendritic Cell-Derived BTB/POZ Zinc Finger|Dendritic-Derived BTB/POZ Zinc Finger Protein|ZBTB20|Zinc Finger Protein 288|Zinc Finger- and BTB Domain-Containing Protein 20	Zinc finger and BTB domain-containing protein 20 (741 aa, ~81 kDa) is encoded by the human ZBTB20 gene. This protein may play a role in the regulation of gene expression.			Amino Acid, Peptide, or Protein	
C134026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134026>	C25457	Standard Environmental Condition|Standard	A single set of environmental conditions.			Conceptual Entity	PQ/CMC Study Type Terminology
C134027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134027>	C25457	Cycled-Simple Environmental Condition|Cycled-Simple	A set of two alternating environmental conditions.			Conceptual Entity	PQ/CMC Study Type Terminology
C134028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134028>	C25457	Complex Environmental Condition|Complex	Multiple phases with different sets of environmental conditions.			Conceptual Entity	PQ/CMC Study Type Terminology
C134029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134029>	C54343	Release Determination|Release	For determination of acceptability for use of a material, drug or a drug substance.			Functional Concept	PQ/CMC Test Usage Terminology
C13402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13402>	C14134	Chromatin Structure	The more readily stainable portion of the cell nucleus, forming a network of nuclear fibrils within the achromatin of a cell. It is a deoxyribonucleic acid attached to a protein (primarily histone) structure base and is the carrier of genes in inheritance. It occurs in two states, euchromatin and heterochromatin, with different staining properties, and during cell division, it coils and folds to form the chromosomes.			Cell Component	
C134030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134030>	C54343	Stability Determination|Stability	For determination of maintained performance parameters on storage over time, of a material, drug or a drug substance.			Functional Concept	PQ/CMC Test Usage Terminology
C134031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134031>	C54343	Release and Stability Determination	For determination at release and on stability when test and acceptance criteria are the same in both cases.			Functional Concept	
C134032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134032>	C25209	Analyte Specificity	The ability to assess unequivocally the analyte in the presence of other components which may be expected to be present.			Quantitative Concept	
C134033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134033>	C25209	Analytical Procedure Linearity	The ability (within a given range) to obtain test results which are directly proportional to the concentration (amount) of analyte in a sample.			Quantitative Concept	
C134034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134034>	C20194	WAC Gene|WAC|WAC|WW Domain Containing Adaptor With Coiled-Coil Gene	This gene is involved in chromatin remodeling and DNA damage responses.			Gene or Genome	
C134035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134035>	C134034	WAC wt Allele|BM-016|DESSH|FLJ31290|KIAA1844|MGC10753|PRO1741|WW Domain Containing Adaptor With Coiled-Coil wt Allele|WW Domain-Containing Adaptor With Coiled Coil Gene|Wwp4	Human WAC wild-type allele is located in the vicinity of 10p12.1 and is approximately 91 kb in length. This allele, which encodes WW domain-containing adapter protein with coiled-coil, plays a role in both DNA damage responses and chromatin remodeling. Mutation of the gene is associated with Desanto-Shinawi syndrome.			Gene or Genome	
C134036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134036>	C18466	WW Domain-Containing Adapter Protein With Coiled-Coil|WW Domain Containing Adaptor With Coiled-Coil|WW Domain-Containing Adapter With Coiled-Coil|WW Domain-Containing Adaptor With Coiled Coil	WW domain-containing adapter protein with coiled-coil (647 aa, ~71 kDa) is encoded by the human WAC gene. This protein is involved in chromatin modification.			Amino Acid, Peptide, or Protein	
C134037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134037>	C133761	Appendiceal Cancer TNM Finding v8	A finding about one or more characteristics of appendiceal cancer, following the rules of the TNM AJCC v8 classification system. Carcinomas and well-differentiated neuroendocrine tumors (carcinoids) are separately categorized. (from AJCC 8th Ed.)			Finding	
C134039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134039>	C134037	Appendiceal Carcinoma TNM Finding v8	A finding about one or more characteristics of appendiceal carcinoma, following the rules of the TNM AJCC v8 classification system. This staging system applies to carcinomas of the appendix, including high-grade neuroendocrine carcinomas, mixed adenoneuroendocrine carcinomas, and goblet cell carcinoids. Well-differentiated neuroendocrine tumors (carcinoids) are staged according to the classification for neuroendocrine tumors of the appendix. (from AJCC 8th Ed.)			Finding	
C13403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13403>	C13282	Contractile System	Contractile system directs cell movement and is responsible for maintaining or changing cell shape. The system consists of many specialized cytoplasmic proteins, including actin, myosin, tubulin, kinesin, other cytoskeletal and contractile system proteins. (NCI)			Cell Component	
C134040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134040>	C134039	Appendiceal Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of appendiceal carcinoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C134041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134041>	C134040	Appendiceal Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of appendiceal carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C134042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134042>	C134041	Appendiceal Carcinoma cM0 TNM Finding v8	Appendiceal carcinoma without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C134043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134043>	C134041	Appendiceal Carcinoma cM1 TNM Finding v8	Appendiceal carcinoma with distant metastasis. (from AJCC 8th Ed.)			Finding	
C134044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134044>	C134043	Appendiceal Carcinoma cM1a TNM Finding v8	Appendiceal carcinoma with intraperitoneal acellular mucin, without identifiable tumor cells in the disseminated peritoneal mucinous deposits. (from AJCC 8th Ed.)			Finding	
C134045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134045>	C134043	Appendiceal Carcinoma cM1b TNM Finding v8	Appendiceal carcinoma with intraperitoneal metastasis only, including peritoneal mucinous deposits containing tumor cells. (from AJCC 8th Ed.)			Finding	
C134046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134046>	C134043	Appendiceal Carcinoma cM1c TNM Finding v8	Appendiceal carcinoma with metastasis to sites other than peritoneum. (from AJCC 8th Ed.)			Finding	
C134047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134047>	C134039	Appendiceal Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of appendiceal carcinoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C134048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134048>	C134047	Appendiceal Carcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of appendiceal carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C134049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134049>	C134048	Appendiceal Carcinoma pM1 TNM Finding v8	Appendiceal carcinoma with distant metastasis. (from AJCC 8th Ed.)			Finding	
C13404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13404>	C14134	DNA Structure	The structure of a DNA molecule, consisting of its primary nucleotide sequence as well as its secondary and tertiary arrangement in space.			Chemical Viewed Structurally	
C134050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134050>	C134049	Appendiceal Carcinoma pM1a TNM Finding v8	Appendiceal carcinoma with intraperitoneal acellular mucin, without identifiable tumor cells in the disseminated peritoneal mucinous deposits. (from AJCC 8th Ed.)			Finding	
C134052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134052>	C134049	Appendiceal Carcinoma pM1b TNM Finding v8	Appendiceal carcinoma with intraperitoneal metastasis only, including peritoneal mucinous deposits containing tumor cells. (from AJCC 8th Ed.)			Finding	
C134053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134053>	C134049	Appendiceal Carcinoma pM1c TNM Finding v8	Appendiceal carcinoma with metastasis to sites other than peritoneum. (from AJCC 8th Ed.)			Finding	
C134054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134054>	C134047	Appendiceal Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of appendiceal carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C134055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134055>	C134054	Appendiceal Carcinoma pTX TNM Finding v8	Appendiceal carcinoma in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C134056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134056>	C134054	Appendiceal Carcinoma pT0 TNM Finding v8	Appendiceal carcinoma with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C13405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13405>	C13671	Drug Binding Site	The reactive parts of a macromolecule that directly participate in its specific combination with a drug.			Chemical Viewed Functionally|Molecular Function	
C13406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13406>	C13379	MYC Box	MYC boxes I and II, found in the N termini of all members of the MYC protein family, function to direct the degradation of the c-MYC protein. Both MYC boxes I and II contain sufficient information to independently direct the degradation of otherwise stably expressed proteins to which they are fused. At least part of the MYC box-directed degradation occurs via the proteasome.			Amino Acid Sequence	
C13407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13407>	C13738	Peptide Conformation	The 3-D structure of peptides.			Spatial Concept	
C13408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13408>	C16946	Lysine-Specific Demethylase 5B|AT Rich Interactive Domain 1B Protein|CT31|Cancer/Testis Antigen 31|EC 1.14.11.-|Histone Demethylase JARID1B|JARID1B|Jumonji Protein|Jumonji/ARID Domain-Containing Protein 1B|KDM5B|PLU-1|PLU-1 Protein|PUT 1|PUT1|Putative DNA/Chromatin Binding Motif 1|RBBP2H1A|RBP2-H1|RBP2-Like Protein|Retinoblastoma-Binding Protein 2 Homolog 1|Retinoblastoma-Binding Protein 2 Homolog 1A	Lysine-specific demethylase 5B (1544 aa, ~176 kDa) is encoded by the human KDM5B gene. This protein plays a role in both histone modification and transcriptional regulation.			Amino Acid, Peptide, or Protein|Enzyme	
C134095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134095>	C134054	Appendiceal Carcinoma pTis TNM Finding v8	Appendiceal carcinoma with a finding of carcinoma in situ (intramucosal carcinoma; invasion of the lamina propria or extension into but not through the muscularis mucosae). (from AJCC 8th Ed.)			Finding	
C134096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134096>	C134054	Low-Grade Appendiceal Mucinous Neoplasm (LAMN) pTis TNM Finding v8	Low-grade appendiceal mucinous neoplasm confined by the muscularis propria. Acellular mucin or mucinous epithelium may invade into the muscularis propria. T1 and T2 are not applicable to LAMN. Acellular mucin or mucinous epithelium that extends into the subserosa or serosa should be classified as T3 or T4a, respectively. (from AJCC 8th Ed.)			Finding	
C134097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134097>	C134054	Appendiceal Carcinoma pT1 TNM Finding v8	Appendiceal carcinoma with tumor invading the submucosa (through the muscularis mucosa but not into the muscularis propria). (from AJCC 8th Ed.)			Finding	
C134098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134098>	C134054	Appendiceal Carcinoma pT2 TNM Finding v8	Appendiceal carcinoma with tumor invading the muscularis propria. (from AJCC 8th Ed.)			Finding	
C134099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134099>	C134054	Appendiceal Carcinoma pT3 TNM Finding v8	Appendiceal carcinoma with tumor invading through the muscularis propria into the subserosa or the mesoappendix. (from AJCC 8th Ed.)			Finding	
C13409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13409>	C13236	Skin Fluid or Secretion|Skin Fluid and Secretion|Skin Fluids and Secretions|Skin-Fluids, Secretions	Secretions of the skin.			Body Substance	
C1340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1340>	C1594	Valrubicin|AD 32|AD 32|AD 32|AD-32|AD32|N-Trifluoroacetyladriamycin-14-valerate|N-Trifluoroacetyladriamycin-14-valerate|VALRUBICIN|Valstar|Valtaxin|valrubicin	A semisynthetic derivative of the antineoplastic anthracycline antibiotic doxorubicin. With a mechanism of action that appears to differ from doxorubicin, valrubicin is converted intracytoplasmically into N-trifluoroacetyladriamycin, which interacts with topoisomerase II, stabilizing the complex between the enzyme and DNA; consequently, DNA replication and repair and RNA and protein synthesis are inhibited and the cell cycle is arrested in the G2 phase. In addition, this agent accumulates in the cell cytoplasm where it inhibits protein kinase C (PKC). Valrubicin is less cardiotoxic than doxorubicin when administered systemically; applied topically, this agent shows excellent tissue penetration. Structurally, the trifluoro-acetyl moiety on the amino group of the glycoside and the valerate moiety appear to result in a lipophilicity that is greater than of doxorubicin, resulting in increased intracytoplasmic concentrations.	Valrubicin		Antibiotic|Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C134100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134100>	C134054	Appendiceal Carcinoma pT4 TNM Finding v8	Appendiceal carcinoma with tumor invading the visceral peritoneum, including the acellular mucin or mucinous epithelium involving the serosa of the appendix or mesoappendix, and/or directly invading adjacent organs or structures. (from AJCC 8th Ed.)			Finding	
C134101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134101>	C134100	Appendiceal Carcinoma pT4a TNM Finding v8	Appendiceal carcinoma with tumor invading through the visceral peritoneum, including the acellular mucin or mucinous epithelium involving the serosa of the appendix or serosa of the mesoappendix. (from AJCC 8th Ed.)			Finding	
C134102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134102>	C134100	Appendiceal Carcinoma pT4b TNM Finding v8	Appendiceal carcinoma with tumor directly invading or adhering to adjacent organs or structures. (from AJCC 8th Ed.)			Finding	
C134103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134103>	C134047	Appendiceal Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of appendiceal carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C134104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134104>	C134103	Appendiceal Carcinoma pNX TNM Finding v8	Appendiceal carcinoma in which the regional lymph node(s) cannot be assessed.  (from AJCC 8th Ed.)			Finding	
C134105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134105>	C134103	Appendiceal Carcinoma pN0 TNM Finding v8	Appendiceal carcinoma with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)			Finding	
C134106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134106>	C134103	Appendiceal Carcinoma pN1 TNM Finding v8	Appendiceal carcinoma in which one to three regional lymph nodes are positive (tumor in lymph node measuring 0.2 mm or more) or any number of tumor deposits is present, and all identifiable lymph nodes are negative. (from AJCC 8th Ed.)			Finding	
C134107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134107>	C134106	Appendiceal Carcinoma pN1a TNM Finding v8	Appendiceal carcinoma in which one regional lymph node is positive. (from AJCC 8th Ed.)			Finding	
C134108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134108>	C134106	Appendiceal Carcinoma pN1b TNM Finding v8	Appendiceal carcinoma in which two to three regional lymph nodes are positive. (from AJCC 8th Ed.)			Finding	
C134109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134109>	C134106	Appendiceal Carcinoma pN1c TNM Finding v8	Appendiceal carcinoma in which no regional lymph nodes are positive, but there are tumor deposits in the subserosa or mesentery. (from AJCC 8th Ed.)			Finding	
C13410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13410>	C13379	Transmembrane Domain|TM Domain|Transmembrane Region	The portion of an integral membrane protein crossing through the plasma lemma (cell membrane) or that of an internal vesicle. This region is highly hydrophobic, approximately 20 amino acids long, and bordered by charged amino acids.			Amino Acid Sequence	
C134110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134110>	C134103	Appendiceal Carcinoma pN2 TNM Finding v8	Appendiceal carcinoma in which four or more regional lymph nodes are positive. (from AJCC 8th Ed.)			Finding	
C134113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134113>	C204844	Syringe Functionality Testing|Syringe Functionality	Testing a syringe to verify it functions properly.			Laboratory Procedure	PQ/CMC Test Category Terminology
C134114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134114>	C134259	Total Organic Carbon Measurement|Total Organic Carbon	An indirect measure of organic molecules present in pharmaceutical waters measured as carbon.			Laboratory Procedure	PQ/CMC Test Category Terminology
C134115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134115>	C204891	Uniformity of Dosage Units Analysis|Uniformity of Dosage Unit	An evaluation of the content uniformity in terms of amount of drug substance among dosage units.			Qualitative Concept	PQ/CMC Test Subcategory Terminology
C134116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134116>	C134259	Water Content Determination	Determining the quantity of water contained in a material.			Laboratory Procedure	
C134117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134117>	C9330	Appendix Carcinoma by AJCC v8 Stage|Appendiceal Carcinoma by AJCC v8 Stage	A term that refers to the staging of appendiceal carcinoma according to the American Joint Committee on Cancer, 8th edition. This staging system applies to carcinomas of the appendix, including high-grade neuroendocrine carcinomas, mixed adenoneuroendocrine carcinomas, and goblet cell carcinoids. Well-differentiated neuroendocrine tumors (carcinoids) are staged according to the classification for neuroendocrine tumors of the appendix. (from AJCC 8th Ed.)			Neoplastic Process	
C134118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134118>	C134117	Stage 0 Appendix Carcinoma AJCC v8|Stage 0 Appendiceal Carcinoma AJCC v8|Stage 0 Appendix Cancer	Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ (intramucosal carcinoma; invasion of the lamina propria or extension into but not through the muscularis mucosae). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0 Appendix Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134119>	C42598|C134117	Stage 0 Low Grade Appendix Mucinous Neoplasm (LAMN) AJCC v8|Stage 0 Low Grade Appendiceal Mucinous Neoplasm (LAMN)|Stage 0 Low-Grade Appendix Mucinous Neoplasm (LAMN) AJCC v8	Stage 0 includes: Tis(LAMN), N0, M0. Tis(LAMN): Low-grade appendiceal mucinous neoplasm confined by the muscularis propria. Acellular mucin or mucinous epithelium may invade into the muscularis propria. T1 and T2 are not applicable to LAMN. Acellular mucin or mucinous epithelium that extends into the subserosa or serosa should be classified as T3 or T4a, respectively. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0 Low-Grade Appendiceal Mucinous Neoplasm (LAMN) AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13411>	C13717	Unspecified Anatomic Sites|Unspecified Site	Research that isn't focused on a specific site.			Body Location or Region	
C134120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134120>	C134117	Stage I Appendix Carcinoma AJCC v8|Stage I Appendiceal Carcinoma AJCC v8|Stage I Appendix Cancer	Stage I includes: (T1, N0, M0); (T2, N0, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Appendix Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134121>	C134117	Stage II Appendix Carcinoma AJCC v8|Stage II Appendiceal Carcinoma AJCC v8|Stage II Appendix Cancer	Stage II includes: IIA: T3, N0, M0; IIB: T4a, N0, M0; IIC: T4b, N0, M0. T3: Tumor invades through the muscularis propria into the subserosa or the mesoappendix. T4a: Tumor invades through the visceral peritoneum, including the acellular mucin or mucinous epithelium involving the serosa of the appendix or serosa of the mesoappendix. T4b: Tumor directly invades or adheres to adjacent organs or structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Appendix Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134122>	C134121	Stage IIA Appendix Carcinoma AJCC v8|Stage IIA Appendiceal Carcinoma AJCC v8|Stage IIA Appendix Cancer	Stage IIA includes: T3, N0, M0. T3: Tumor invades through the muscularis propria into the subserosa or the mesoappendix. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIA Appendix Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134123>	C134121	Stage IIB Appendix Carcinoma AJCC v8|Stage IIB Appendiceal Carcinoma AJCC v8|Stage IIB Appendix Cancer	Stage IIB includes: T4a, N0, M0. T4a: Tumor invades through the visceral peritoneum, including the acellular mucin or mucinous epithelium involving the serosa of the appendix or serosa of the mesoappendix. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIB Appendix Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134124>	C134121	Stage IIC Appendix Carcinoma AJCC v8|Stage IIC Appendiceal Carcinoma AJCC v8|Stage IIC Appendix Cancer	Stage IIC includes: T4b, N0, M0. T4b: Tumor directly invades or adheres to adjacent organs or structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIC Appendix Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134125>	C134117	Stage III Appendix Carcinoma AJCC v8|Stage III Appendiceal Carcinoma AJCC v8|Stage III Appendix Cancer	Stage III includes: IIIA: (T1, N1, M0); (T2, N1, M0); IIIB: (T3, N1, M0); (T4, N1, M0); IIIC: (Any T, N2, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. T3: Tumor invades through the muscularis propria into the subserosa or the mesoappendix. T4: Tumor invades the visceral peritoneum, including the acellular mucin or mucinous epithelium involving the serosa of the appendix or mesoappendix, and/or directly invades adjacent organs or structures. N1: One to three regional lymph nodes are positive (tumor in lymph node measuring 0.2 mm or more) or any number of tumor deposits is present, and all identifiable lymph nodes are negative. N2: Four or more regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Appendix Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134126>	C134125	Stage IIIA Appendix Carcinoma AJCC v8|Stage IIIA Appendiceal Carcinoma AJCC v8|Stage IIIA Appendix Cancer	Stage IIIA includes: (T1, N1, M0); (T2, N1, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. N1: One to three regional lymph nodes are positive (tumor in lymph node measuring 0.2 mm or more) or any number of tumor deposits is present, and all identifiable lymph nodes are negative. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIA Appendix Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134127>	C134125	Stage IIIB Appendix Carcinoma AJCC v8|Stage IIIB Appendiceal Carcinoma AJCC v8|Stage IIIB Appendix Cancer	Stage IIIB includes: (T3, N1, M0); (T4, N1, M0). T3: Tumor invades through the muscularis propria into the subserosa or the mesoappendix. T4: Tumor invades the visceral peritoneum, including the acellular mucin or mucinous epithelium involving the serosa of the appendix or mesoappendix, and/or directly invades adjacent organs or structures. N1: One to three regional lymph nodes are positive (tumor in lymph node measuring 0.2 mm or more) or any number of tumor deposits is present, and all identifiable lymph nodes are negative. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIB Appendix Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134128>	C134125	Stage IIIC Appendix Carcinoma AJCC v8|Stage IIIC Appendiceal Carcinoma AJCC v8|Stage IIIC Appendix Cancer	Stage IIIC includes: Any T, N2, M0. N2: Four or more regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIC Appendix Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134129>	C134117	Stage IV Appendix Carcinoma AJCC v8|Stage IV Appendiceal Carcinoma AJCC v8|Stage IV Appendix Cancer	Stage IV includes: IVA: (Any T, N0, M1a); (Any T, Any N, M1b, G1); IVB: (Any T, Any N, M1b, G2, G3, or GX); IVC: (Any T, Any N, M1c, Any G). N0: No regional lymph node metastasis. M1a: Intraperitoneal acellular mucin, without identifiable tumor cells in the disseminated peritoneal mucinous deposits. M1b: Intraperitoneal metastasis only, including peritoneal mucinous deposits containing tumor cells. M1c: Metastasis to sites other than peritoneum. G1: Well differentiated. G2: Moderately differentiated. G3: Poorly differentiated. GX: Grade cannot be assessed. (AJCC 8th ed.)	Stage IV Appendix Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13412>	C13379	V3 Loop|V3 Loop of HIV-1	Third hypervariable region (V3) of the gp120 HIV envelope protein.			Amino Acid Sequence	
C134130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134130>	C134129	Stage IVA Appendix Carcinoma AJCC v8|Stage IVA Appendiceal Carcinoma AJCC v8|Stage IVA Appendix Cancer	Stage IVA includes: (Any T, N0, M1a); (Any T, Any N, M1b, G1). N0: No regional lymph node metastasis. M1a: Intraperitoneal acellular mucin, without identifiable tumor cells in the disseminated peritoneal mucinous deposits. M1b: Intraperitoneal metastasis only, including peritoneal mucinous deposits containing tumor cells. G1: Well differentiated. (AJCC 8th ed.)	Stage IVA Appendix Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134131>	C134129	Stage IVB Appendix Carcinoma AJCC v8|Stage IVB Appendiceal Carcinoma AJCC v8|Stage IVB Appendix Cancer	Stage IVB includes: Any T, Any N, M1b, G2, G3, or GX. M1b: Intraperitoneal metastasis only, including peritoneal mucinous deposits containing tumor cells. G2: Moderately differentiated. G3: Poorly differentiated. GX: Grade cannot be assessed.  (AJCC 8th ed.)	Stage IVB Appendix Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134132>	C134129	Stage IVC Appendix Carcinoma AJCC v8|Stage IVC Appendiceal Carcinoma AJCC v8|Stage IVC Appendix Cancer	Stage IVC includes: Any T, Any N, M1c, Any G. M1c: Metastasis to sites other than peritoneum. (AJCC 8th ed.)	Stage IVC Appendix Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134133>	C133761	Colorectal Cancer TNM Finding v8|Colorectal Carcinoma TNM Finding v8	A finding about one or more characteristics of colorectal cancer, following the rules of the TNM AJCC v8 classification system. Adenocarcinomas, high-grade neuroendocrine carcinomas, and squamous cell carcinomas of the colon and rectum are covered by this staging system. Appendiceal carcinomas, anal carcinomas, and well-differentiated neuroendocrine tumors (carcinoids) are not covered by this staging system. (from AJCC 8th Ed.)			Finding	
C134134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134134>	C134133	Colorectal Cancer Clinical TNM Finding v8|Colorectal Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of colorectal cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C134135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134135>	C134134	Colorectal Cancer Clinical Distant Metastasis TNM Finding v8|Colorectal Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of colorectal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C134136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134136>	C134135	Colorectal Cancer cM0 TNM Finding v8|Colorectal Carcinoma cM0 TNM Finding v8	Colorectal cancer without evidence of distant metastasis by imaging, etc.; no evidence of tumor in distant sites or organs. This category is not assigned by pathologists. (from AJCC 8th Ed.)			Finding	
C134137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134137>	C134135	Colorectal Cancer cM1 TNM Finding v8|Colorectal Carcinoma cM1 TNM Finding v8	Colorectal cancer with metastasis to one or more distant sites or organs or peritoneal metastasis is identified. (from AJCC 8th Ed.)			Finding	
C134139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134139>	C25981	MAGI3 Gene|MAGI3|MAGI3|Membrane Associated Guanylate Kinase, WW and PDZ Domain Containing 3 Gene	This gene plays a role in protein-protein interactions that regulate signaling.			Gene or Genome	
C13413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13413>	C13442	Whole Organism	Considering the organism as a whole			Spatial Concept	
C134140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134140>	C134139	MAGI3 wt Allele|KIAA1634|MAGI-3|Membrane Associated Guanylate Kinase, WW and PDZ Domain Containing 3 wt Allele|Membrane-Associated Guanylate Kinase, WW and PDZ Domains-Containing, 3 Gene|dJ730K3.2	Human MAGI3 wild-type allele is located in the vicinity of 1p13.2 and is approximately 295 kb in length. This allele, which encodes membrane-associated guanylate kinase, WW and PDZ domain-containing protein 3, is involved in the modulation of signal transduction.			Gene or Genome	
C134141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134141>	C134137	Colorectal Cancer cM1a TNM Finding v8|Colorectal Carcinoma cM1a TNM Finding v8	Colorectal cancer with metastasis to one site or organ without peritoneal metastasis. (from AJCC 8th Ed.)			Finding	
C134142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134142>	C134137	Colorectal Cancer cM1b TNM Finding v8|Colorectal Carcinoma cM1b TNM Finding v8	Colorectal cancer with metastasis to two or more sites or organs without peritoneal metastasis. (from AJCC 8th Ed.)			Finding	
C134143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134143>	C134137	Colorectal Cancer cM1c TNM Finding v8|Colorectal Carcinoma cM1c TNM Finding v8	Colorectal cancer with metastasis to the peritoneal surface alone or with other site or organ metastases. (from AJCC 8th Ed.)			Finding	
C134145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134145>	C134133	Colorectal Cancer Pathologic TNM Finding v8|Colorectal Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of colorectal cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C134147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134147>	C134145	Colorectal Cancer Pathologic Distant Metastasis TNM Finding v8|Colorectal Carcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of colorectal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C134148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134148>	C134147	Colorectal Cancer pM1 TNM Finding v8|Colorectal Carcinoma pM1 TNM Finding v8	Colorectal cancer with metastasis to one or more distant sites or organs or peritoneal metastasis is identified. (from AJCC 8th Ed.)			Finding	
C134149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134149>	C134148	Colorectal Cancer pM1a TNM Finding v8|Colorectal Carcinoma pM1a TNM Finding v8	Colorectal cancer with metastasis to one site or organ without peritoneal metastasis. (from AJCC 8th Ed.)			Finding	
C134150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134150>	C134148	Colorectal Cancer pM1b TNM Finding v8|Colorectal Carcinoma pM1b TNM Finding v8	Colorectal cancer with metastasis to two or more sites or organs without peritoneal metastasis. (from AJCC 8th Ed.)			Finding	
C134151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134151>	C134148	Colorectal Cancer pM1c TNM Finding v8|Colorectal Carcinoma pM1c TNM Finding v8	Colorectal cancer with metastasis to the peritoneal surface alone or with other site or organ metastases. (from AJCC 8th Ed.)			Finding	
C134152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134152>	C134145	Colorectal Cancer Pathologic Primary Tumor TNM Finding v8|Colorectal Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of colorectal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C134153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134153>	C3270|C173565	Refractory Neuroblastoma	A neuroblastoma that does not respond to treatment.	Refractory Neuroblastoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134154>	C3208|C172280	Refractory Lymphoma	A lymphoma that does not respond to treatment.	Refractory Lymphoma		Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134155>	C26231	Membrane-Associated Guanylate Kinase, WW and PDZ Domain-Containing Protein 3|MAGI-3|MAGI3|Membrane-Associated Guanylate Kinase Inverted 3|Membrane-Associated Guanylate Kinase with Inverted Structure 3|Membrane-Associated Guanylate Kinase-Related 3	Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 3 (1506 aa, ~166 kDa) is encoded by the human MAGI3 gene. This protein plays a role in adaptor signaling protein activity.			Amino Acid, Peptide, or Protein	
C134156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134156>	C134152	Colorectal Cancer pTX TNM Finding v8|Colorectal Carcinoma pTX TNM Finding v8	Colorectal cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C134157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134157>	C3208|C172133	Recurrent Lymphoma	The reemergence of a lymphoma after a period of remission.	Recurrent Lymphoma		Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134158>	C134152	Colorectal Cancer pT0 TNM Finding v8|Colorectal Carcinoma pT0 TNM Finding v8	Colorectal cancer with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C134159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134159>	C134152	Colorectal Cancer pTis TNM Finding v8|Colorectal Carcinoma pTis TNM Finding v8	Colorectal cancer with a finding of carcinoma in situ, intramucosal carcinoma (involvement of lamina propria with no extension through muscularis mucosae). (from AJCC 8th Ed.)			Finding	
C13415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13415>	C225418	Intravesical|intravesical				Spatial Concept	EDQM Health Care Terminology|EDQM-HC Intended Site of Administration Terminology
C134160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134160>	C134152	Colorectal Cancer pT1 TNM Finding v8|Colorectal Carcinoma pT1 TNM Finding v8	Colorectal cancer with tumor invading the submucosa (through the muscularis mucosa but not into the muscularis propria). (from AJCC 8th Ed.)			Finding	
C134161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134161>	C134152	Colorectal Cancer pT2 TNM Finding v8|Colorectal Carcinoma pT2 TNM Finding v8	Colorectal cancer with tumor invading the muscularis propria. (from AJCC 8th Ed.)			Finding	
C134162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134162>	C134152	Colorectal Cancer pT3 TNM Finding v8|Colorectal Carcinoma pT3 TNM Finding v8	Colorectal cancer with tumor invading through the muscularis propria into pericolorectal tissues. (from AJCC 8th Ed.)			Finding	
C134163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134163>	C134152	Colorectal Cancer pT4 TNM Finding v8|Colorectal Carcinoma pT4 TNM Finding v8	Colorectal cancer with tumor invading the visceral peritoneum or invading or adhering to adjacent organ or structure. (from AJCC 8th Ed.)			Finding	
C134164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134164>	C134163	Colorectal Cancer pT4a TNM Finding v8|Colorectal Carcinoma pT4a TNM Finding v8	Colorectal cancer with tumor invading through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). (from AJCC 8th Ed.)			Finding	
C134165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134165>	C134163	Colorectal Cancer pT4b TNM Finding v8|Colorectal Carcinoma pT4b TNM Finding v8	Colorectal cancer with tumor directly invading or adhering to adjacent organs or structures. (from AJCC 8th Ed.)			Finding	
C134166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134166>	C134145	Colorectal Cancer Pathologic Regional Lymph Nodes TNM Finding v8|Colorectal Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of colorectal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C134167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134167>	C134166	Colorectal Cancer pNX TNM Finding v8|Colorectal Carcinoma pNX TNM Finding v8	Colorectal cancer in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)			Finding	
C134168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134168>	C9294|C7628	Refractory Histiocytic and Dendritic Cell Neoplasm	A histiocytic and dendritic cell neoplasm that does not respond to treatment.	Refractory Histiocytic and Dendritic Cell Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134169>	C134166	Colorectal Cancer pN0 TNM Finding v8|Colorectal Carcinoma pN0 TNM Finding v8	Colorectal cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)			Finding	
C13416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13416>	C13236	Adrenal Fluid or Secretion|Adrenal Fluids and Secretions|Adrenal-Fluids, Secretions	Epinephrine and norepinephrine from the medulla and steroid hormones from the cortex.			Body Substance	
C134170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134170>	C134166	Colorectal Cancer pN1 TNM Finding v8|Colorectal Carcinoma pN1 TNM Finding v8	Colorectal cancer in which one to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. (from AJCC 8th Ed.)			Finding	
C134171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134171>	C134170	Colorectal Cancer pN1a TNM Finding v8|Colorectal Carcinoma pN1a TNM Finding v8	Colorectal cancer in which one regional lymph node is positive. (from AJCC 8th Ed.)			Finding	
C134172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134172>	C9294|C4798	Recurrent Histiocytic and Dendritic Cell Neoplasm	The reemergence of a histiocytic and dendritic cell neoplasm after a period of remission.	Recurrent Histiocytic and Dendritic Cell Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134173>	C134170	Colorectal Cancer pN1b TNM Finding v8|Colorectal Carcinoma pN1b TNM Finding v8	Colorectal cancer in which two or three regional lymph nodes are positive. (from AJCC 8th Ed.)			Finding	
C134174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134174>	C134170	Colorectal Cancer pN1c TNM Finding v8|Colorectal Carcinoma pN1c TNM Finding v8	Colorectal cancer in which no regional lymph nodes are positive, but there are tumor deposits in the subserosa, mesentery, or nonperitonealized pericolic, or perirectal/mesorectal tissues. (from AJCC 8th Ed.)			Finding	
C134175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134175>	C3107|C134172	Recurrent Langerhans Cell Histiocytosis	The reemergence of Langerhans cell histiocytosis after a period of remission.	Recurrent Langerhans Cell Histiocytosis		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134176>	C134166	Colorectal Cancer pN2 TNM Finding v8|Colorectal Carcinoma pN2 TNM Finding v8	Colorectal cancer in which four or more regional lymph nodes are positive. (from AJCC 8th Ed.)			Finding	
C134177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134177>	C3107|C134168	Refractory Langerhans Cell Histiocytosis	Langerhans cell histiocytosis that does not respond to treatment.	Refractory Langerhans Cell Histiocytosis		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134178>	C134176	Colorectal Cancer pN2a TNM Finding v8|Colorectal Carcinoma pN2a TNM Finding v8	Colorectal cancer in which four to six regional lymph nodes are positive. (from AJCC 8th Ed.)			Finding	
C134179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134179>	C134176	Colorectal Cancer pN2b TNM Finding v8|Colorectal Carcinoma pN2b TNM Finding v8	Colorectal cancer in which seven or more regional lymph nodes are positive. (from AJCC 8th Ed.)			Finding	
C134180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134180>	C2955	Colorectal Cancer by AJCC v8 Stage|Colorectal Carcinoma by AJCC v8 Stage	A term that refers to the staging of colorectal cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to adenocarcinomas, high-grade neuroendocrine carcinomas, and squamous cell carcinomas of the colon and rectum. Appendiceal carcinomas, anal carcinomas, and well-differentiated neuroendocrine tumors (carcinoids) are not covered by this staging system. (from AJCC 8th Ed.)			Neoplastic Process	
C134182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134182>	C134180	Stage 0 Colorectal Cancer AJCC v8|Stage 0 Colorectal (Colon or Rectal) Cancer|Stage 0 Colorectal Carcinoma AJCC v8	Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ, intramucosal carcinoma (involvement of lamina propria with no extension through muscularis mucosae). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0 Colorectal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134183>	C133710	ARIH1 Gene|ARIH1|ARIH1|Ariadne RBR E3 Ubiquitin Protein Ligase 1 Gene	This gene is involved in the ubiquitination of protein substrates.			Gene or Genome	
C134184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134184>	C134183	ARIH1 wt Allele|ARI|Ariadne (Drosophila) Homolog, Ubiquitin-Conjugating Enzyme E2-Binding Protein, 1 Gene|Ariadne Homolog, Ubiquitin-Conjugating Enzyme E2 Binding Protein, 1 (Drosophila) Gene|Ariadne Homolog, Ubiquitin-Conjugating Enzyme E2 Binding Protein, 1 Gene|Ariadne RBR E3 Ubiquitin Protein Ligase 1 wt Allele|Ariadne, Drosophila, Homolog Of Gene|Ariadne, Drosophila, Homolog Of, 1 Gene|HARI|HHARI|HUSSY-27|MOP6|UBCH7BP	Human ARIH1 wild-type allele is located in the vicinity of 15q24.1 and is approximately 129 kb in length. This allele, which encodes E3 ubiquitin-protein ligase ARIH1 protein, plays a role in the modulation of ubiquitination.			Gene or Genome	
C134185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134185>	C134180	Stage I Colorectal Cancer AJCC v8|Stage I Colorectal (Colon or Rectal) Cancer|Stage I Colorectal Carcinoma AJCC v8	Stage I includes: (T1, N0, M0); (T2, N0, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Colorectal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134186>	C134180	Stage II Colorectal Cancer AJCC v8|Stage II Colorectal (Colon or Rectal) Cancer|Stage II Colorectal Carcinoma AJCC v8	Stage II includes: IIA: T3, N0, M0; IIB: T4a, N0, M0; IIC: T4b, N0, M0. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). T4b: Tumor directly invades or adheres to adjacent organs or structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Colorectal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134187>	C134186	Stage IIA Colorectal Cancer AJCC v8|Stage IIA Colorectal (Colon or Rectal) Cancer|Stage IIA Colorectal Carcinoma AJCC v8	Stage IIA includes: T3, N0, M0. T3: Tumor invades through the muscularis propria into pericolorectal tissues. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIA Colorectal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134188>	C134186	Stage IIB Colorectal Cancer AJCC v8|Stage IIB Colorectal (Colon or Rectal) Cancer|Stage IIB Colorectal Carcinoma AJCC v8	Stage IIB includes: T4a, N0, M0. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIB Colorectal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134189>	C21254	E3 Ubiquitin-Protein Ligase ARIH1|ARI-1|EC 2.3.2.31|H7-AP2|MOP-6|Monocyte Protein 6|Protein Ariadne-1 Homolog|UbcH7-Binding Protein|UbcM4-Interacting Protein|Ubiquitin-Conjugating Enzyme E2-Binding Protein 1	E3 ubiquitin-protein ligase ARIH1 (557 aa, ~64 kDa) is encoded by the human ARIH1 gene. This protein is involved in protein ubiquitination.			Amino Acid, Peptide, or Protein|Enzyme	
C13418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13418>	C13236	Head and Neck Fluids and Secretions|Head and Neck, Fluids, Secretions|Head and Neck-Fluids, Secretions	Secretions and fluids from the area of the body generally construed to comprise base of skull and facial bones, sinuses, orbits, salivary glands, oral cavity, oropharynx, larynx, thyroid, facial and neck musculature and lymph nodes draining these areas.			Body Substance	
C134190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134190>	C134186	Stage IIC Colorectal Cancer AJCC v8|Stage IIC Colorectal (Colon or Rectal) Cancer|Stage IIC Colorectal Carcinoma AJCC v8	Stage IIC includes: T4b, N0, M0. T4b: Tumor directly invades or adheres to adjacent organs or structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIC Colorectal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134191>	C134180	Stage III Colorectal Cancer AJCC v8|Stage III Colorectal (Colon or Rectal) Cancer|Stage III Colorectal Carcinoma AJCC v8	Stage III includes: IIIA: (T1-T2, N1/N1c, M0); (T1, N2a, M0); IIIB: (T3-T4a, N1/N1c, M0); (T2-T3, N2a, M0); (T1-T2, N2b, M0); IIIC: (T4a, N2a, M0); (T3-T4a, N2b, M0); (T4b, N1-N2, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). T4b: Tumor directly invades or adheres to adjacent organs or structures. N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N1c: No regional lymph nodes are positive, but there are tumor deposits in the subserosa, mesentery, or nonperitonealized pericolic, or perirectal/mesorectal tissues. N2: Four or more regional lymph nodes are positive. N2a: Four to six regional lymph nodes are positive. N2b: Seven or more regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Colorectal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134192>	C134191	Stage IIIA Colorectal Cancer AJCC v8|Stage IIIA Colorectal (Colon or Rectal) Cancer|Stage IIIA Colorectal Carcinoma AJCC v8	Stage IIIA includes: (T1-T2, N1/N1c, M0); (T1, N2a, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N1c: No regional lymph nodes are positive, but there are tumor deposits in the subserosa, mesentery, or nonperitonealized pericolic, or perirectal/mesorectal tissues. N2a: Four to six regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIA Colorectal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134193>	C134191	Stage IIIB Colorectal Cancer AJCC v8|Stage IIIB Colorectal (Colon or Rectal) Cancer|Stage IIIB Colorectal Carcinoma AJCC v8	Stage IIIB includes: (T3-T4a, N1/N1c, M0); (T2-T3, N2a, M0); (T1-T2, N2b, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N1c: No regional lymph nodes are positive, but there are tumor deposits in the subserosa, mesentery, or nonperitonealized pericolic, or perirectal/mesorectal tissues. N2a: Four to six regional lymph nodes are positive. N2b: Seven or more regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIB Colorectal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134194>	C134191	Stage IIIC Colorectal Cancer AJCC v8|Stage IIIC Colorectal (Colon or Rectal) Cancer|Stage IIIC Colorectal Carcinoma AJCC v8	Stage IIIC includes: (T4a, N2a, M0); (T3-T4a, N2b, M0); (T4b, N1-N2, M0). T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). T4b: Tumor directly invades or adheres to adjacent organs or structures. N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N2: Four or more regional lymph nodes are positive. N2a: Four to six regional lymph nodes are positive. N2b: Seven or more regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIC Colorectal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134195>	C134180	Stage IV Colorectal Cancer AJCC v8|Stage IV Colorectal (Colon or Rectal) Cancer|Stage IV Colorectal Carcinoma AJCC v8	Stage IV includes: IVA: (Any T, Any N, M1a); IVB: (Any T, Any N, M1b); IVC: (Any T, Any N, M1c). M1a: Metastasis to one site or organ without peritoneal metastasis. M1b: Metastasis to two or more sites or organs without peritoneal metastasis. M1c: Metastasis to the peritoneal surface alone or with other site or organ metastases. (AJCC 8th ed.)	Stage IV Colorectal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134196>	C134195	Stage IVA Colorectal Cancer AJCC v8|Stage IVA Colorectal (Colon or Rectal) Cancer|Stage IVA Colorectal Carcinoma AJCC v8	Stage IVA includes: Any T, Any N, M1a. M1a: Metastasis to one site or organ without peritoneal metastasis. (AJCC 8th ed.)	Stage IVA Colorectal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134197>	C134195	Stage IVB Colorectal Cancer AJCC v8|Stage IVB Colorectal (Colon or Rectal) Cancer|Stage IVB Colorectal Carcinoma AJCC v8	Stage IVB includes: Any T, Any N, M1b. M1b: Metastasis to two or more sites or organs without peritoneal metastasis.  (AJCC 8th ed.)	Stage IVB Colorectal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134198>	C134195	Stage IVC Colorectal Cancer AJCC v8|Stage IVC Colorectal (Colon or Rectal) Cancer|Stage IVC Colorectal Carcinoma AJCC v8	Stage IVC includes: Any T, Any N, M1c. M1c: Metastasis to the peritoneal surface alone or with other site or organ metastases. (AJCC 8th ed.)	Stage IVC Colorectal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13419>	C13420	Multiple Cancer Sites	More than one cancer site.			Spatial Concept	
C1341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1341>	C1757	Tyrphostin A51|AG 183	A kind of Protein tyrosine kinase inhibitor involved in cell proliferation and differentiation. (NCI)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C13420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13420>	C13717	Multiple Anatomic Sites|Multiple Sites, Person	Present at many sites of the body.			Body Location or Region	
C13421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13421>	C13426|C13313	Histone Fold|Histone-Fold	A protein structural element originally identified in the core histones.  It is of the helix-loop-helix type and is involved in protein-protein interactions via a "handshake" motif with a histone fold partner.  Also involved in protein-DNA interactions.			Amino Acid Sequence	
C13422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13422>	C13425	HMG Domain|HMG Box|High Mobility Group Domain	Each HMG subfamily is a distinct set of proteins with identifiable structural characteristics and a specific type of targets to induce characteristic changes in the structure of its binding site.			Amino Acid Sequence	
C13423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13423>	C13341	POU Domain	The POU domain is a bipartite DNA binding domain recognized originally as a shared structural motif in the Pit-1, Oct-1/Oct-2, and Unc-86 transcription factors (POU).  It is comprised by a C-terminal homeo domain, and an N-terminal POU-specific domain, separated by a non-conserved linker.  The POU-specific domain, like the homeo domain, is folded in a helix-turn-helix motif.			Amino Acid Sequence	
C134240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134240>	C25209	Analytical Procedure Range	The interval between the upper and lower concentration (amounts) of analyte in the sample (including these concentrations) for which it has been demonstrated that the analytical procedure has a suitable level of precision, accuracy and linearity.			Quantitative Concept	
C134242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134242>	C25209	Analytical Procedure Accuracy	The closeness of agreement between the value which is accepted either as a conventional true value or an accepted reference value and the value found.			Quantitative Concept	
C134243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134243>	C25209	Analytical Procedure Precision	The closeness of agreement (degree of scatter) between a series of measurements obtained from multiple sampling of the same homogeneous sample under the prescribed conditions. Precision may be considered at three levels: repeatability, intermediate precision and reproducibility.			Quantitative Concept	
C134244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134244>	C25209	Analytical Procedure Detection Limit	The lowest amount of analyte in a sample which can be detected but not necessarily quantitated as an exact value.			Quantitative Concept	
C134245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134245>	C25209	Analytical Procedure Robustness	The measure of a procedure's capacity to remain unaffected by small, but deliberate variations in method parameters and provides an indication of its reliability during normal usage.			Quantitative Concept	
C134246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134246>	C25209	System Suitability	The tests are based on the concept that the equipment, electronics, analytical operations, and samples to be analyzed constitute an integral system that can be evaluated as such. System suitability test parameters to be established for a particular procedure depend on the type of procedure being validated.			Quantitative Concept	
C134248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134248>	C25209	Analytical Procedure Quantitation Limit	The lowest amount of analyte in a sample which can be quantitatively determined with suitable precision and accuracy.			Quantitative Concept	
C134249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134249>	C92019	Container Closure Integrity Testing|Container Closure Integrity	An assessment of the structural characteristics of the container closure system to ensure the required specifications for integrity are met.			Qualitative Concept	PQ/CMC Test Category Terminology
C13424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13424>	C13341	Winged Helix|Winged Helix DNA-Binding Domain|Winged Helix-Turn-Helix|wHTH	A helix-turn-helix type DNA binding domain comprised of two loops formed by twisted antiparallel beta-sheets that resemble wings (W1 and W2), three alpha helices (H1, H2 and H3) and three beta-strands (S1, S2 and S3), which are arranged as follows: H1-S1-H2-H3-S2-W1-S3-W2.			Amino Acid Sequence	
C134250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134250>	C204891	Content Uniformity Test|Uniformity	An assessment of the quality of the sameness of the contents of a substance.			Qualitative Concept	PQ/CMC Test Category Terminology
C134251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134251>	C4910|C134180	Colon Cancer by AJCC v8 Stage|Colon Carcinoma by AJCC v8 Stage	A term that refers to the staging of colon cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to adenocarcinomas, high-grade neuroendocrine carcinomas, and squamous cell carcinomas of the colon. (from AJCC 8th Ed.)			Neoplastic Process	
C134252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134252>	C204844	Pharmaceutical Disintegration Test|Disintegration	Test to determine whether tablets or capsules disintegrate within the prescribed time when placed in a liquid medium at the experimental conditions.			Qualitative Concept	PQ/CMC Test Category Terminology
C134253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134253>	C204844	Pharmaceutical Dissolution Test|Dissolution	Test to determine compliance with the requirements of the material of interest dissolving into solution.			Qualitative Concept	PQ/CMC Test Category Terminology
C134254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134254>	C204844	Impurities/Degradation Products/Related Substances Test|Impurities/Degradation Products/Related Substances	Analytical procedures that determine the presence of a component of the material that is not the chemical entity defined as the material.			Qualitative Concept	PQ/CMC Test Subcategory Terminology
C134255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134255>	C134259	Loss on Drying Measurement|LOD|Loss on Drying	The determination of the total change in weight of a material as a result of drying. It determines the moisture content of a sample			Laboratory Procedure	PQ/CMC Test Category Terminology
C134256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134256>	C49188|C204844	Microbial Limit Determination|Microbial Limits	An assessment of the total number of viable aerobic microorganisms present in a product and the semi-quantitative estimation of the relative number of specific types of microbes present based on an established specification for production quality.			Quantitative Concept	PQ/CMC Test Category Terminology
C134257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134257>	C134259	Particle Size Distribution Analysis|PSD|Particle Size Distribution	Analytical procedures that utilize mechanical sieving for deducing the particle-size distribution of a powdered solid.			Qualitative Concept	PQ/CMC Test Category Terminology
C134258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134258>	C9382|C134180	Rectal Cancer by AJCC v8 Stage|Rectal Carcinoma by AJCC v8 Stage	A term that refers to the staging of rectal cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to adenocarcinomas, high-grade neuroendocrine carcinomas, and squamous cell carcinomas of the rectum. (from AJCC 8th Ed.)			Neoplastic Process	
C134259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134259>	C15336	Physicochemical Property Characterization|Physico-chemical Characterization|Physico-chemical Property Analysis|Physicochemical Characterization|Physicochemical Property Analysis|Physicochemical Property Testing	The assessment and/or determination of the physical and chemical characteristics of a substance or material.			Laboratory Procedure	
C13425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13425>	C13671	DNA Binding Domain|DNA Binding Motif|Protein Motifs, DNA-Binding	A region of a protein that interacts with DNA. Among the various recognized structural motifs present in DNA binding domains are the helix-loop-helix and the zinc-finger.			Amino Acid Sequence	
C134260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134260>	C134259	Powder Bulk Density Measurement|Bulk Density	The ratio of the mass of an untapped powder sample and its volume including the contribution of the interparticulate void volume.			Laboratory Procedure	PQ/CMC Test Category Terminology
C134261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134261>	C134259	Clarity of Solution Measurement|Clarity of Solution	Measurement of the turbidity of the solution.			Laboratory Procedure	PQ/CMC Test Subcategory Terminology
C134262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134262>	C64546	Color of Solution Measurement|Color of Solution	The color of a solution compared to that of a standard solution.			Laboratory Procedure	PQ/CMC Test Subcategory Terminology
C134263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134263>	C134259	Conductivity Measurement|Conductivity	A measure of the ion-facilitated electron current through a material.			Laboratory Procedure	PQ/CMC Test Category Terminology
C134264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134264>	C134259	Hardness Measurement|Hardness	The determination of the breaking point and structural integrity of a material.			Laboratory Procedure	PQ/CMC Test Category Terminology
C134265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134265>	C204844	Tablet Property Analysis	Characteristics of a tablet, which include weight, length, thickness, diameter, color and shape.			Laboratory Procedure	
C134266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134266>	C134259	Tap Density Determination|Tap Density	Determination of the density, compared to the bulk density, of dry particles, expressed in mass/volume, obtained by mechanically tapping a cylinder containing the powder sample until no more change in volume occurs.			Quantitative Concept	PQ/CMC Test Category Terminology
C134267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134267>	C134259	Plume Geometry Test|Plume Geometry	A test that measures the spray pattern characteristics, including shape and size of the evolving spray cloud under defined experimental and instrumental test conditions.			Qualitative Concept	PQ/CMC Test Category Terminology
C134269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134269>	C134259	Polymorphic Form Determination|Polymorphism	Tests to determine the crystalline form of a particular solid material.			Qualitative Concept	PQ/CMC Test Category Terminology
C13426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13426>	C13671	Protein Binding Domain|Protein Binding Motif|Protein-Protein Interaction Domain	Protein Binding Domains are structural motifs responsible for the peptide/protein binding activity of proteins.			Amino Acid Sequence	
C134270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134270>	C204844	Potency Assay|Potency	The determination of the strength of a material, as measured by the ability to produce a specific response. The potency of a pharmacologic substance is measured by the amount needed to produce a certain effect.			Laboratory Procedure	PQ/CMC Test Category Terminology
C134271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134271>	C134251|C134182	Stage 0 Colon Cancer AJCC v8|Stage 0 Colon Cancer	Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ, intramucosal carcinoma (involvement of lamina propria with no extension through muscularis mucosae). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0 Colon Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134272>	C134259	Reconstitution Time Measurement|Reconstitution Time	Measurement of how long it takes to restore something dried to its original state of liquid.			Laboratory Procedure	PQ/CMC Test Category Terminology
C134273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134273>	C134251|C134185	Stage I Colon Cancer AJCC v8|Stage I Colon Cancer	Stage I includes: (T1, N0, M0); (T2, N0, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Colon Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134274>	C134251|C134186	Stage II Colon Cancer AJCC v8|Stage II Colon Cancer	Stage II includes: IIA: T3, N0, M0; IIB: T4a, N0, M0; IIC: T4b, N0, M0. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). T4b: Tumor directly invades or adheres to adjacent organs or structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Colon Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134276>	C134259	Residue on Ignition Measurement|Residue on Ignition	The amount of residual substance not volatilized after a sample is ignited.			Laboratory Procedure	PQ/CMC Test Category Terminology
C134277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134277>	C134259	Spray Pattern Assessment|Spray Pattern	Tests to determine the size of the mist formed by spraying. The measurement is made for the longest axis (x axis), and the ratio of longest to shortest axes (x/y ratio).			Laboratory Procedure	PQ/CMC Test Category Terminology
C134278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134278>	C49188	Sterility Test|Sterility|Sterility Assay|Sterility Assay	An assay done under aseptic conditions to ensure that there are no contaminating microorganisms present in the sample.			Laboratory Procedure	PQ/CMC Test Category Terminology
C134279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134279>	C45306	Sub-Visible Particle|Sub-Visible Particulate	Insoluble, unintentionally present particulate matter usually in the range of 1-100 microns.			Substance	
C13427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13427>	C13453|C13425	Zinc-Binding, DNA-Binding Motif|Zinc Finger|Zinc Finger Domain	Zinc-binding, DNA-binding motifs in proteins contain amino acids that are folded into a single DNA-binding structural unit around a zinc atom.			Amino Acid Sequence	
C134280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134280>	C134274|C134187	Stage IIA Colon Cancer AJCC v8|Stage IIA Colon Cancer	Stage IIA includes: T3, N0, M0. T3: Tumor invades through the muscularis propria into pericolorectal tissues. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIA Colon Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134281>	C134274|C134188	Stage IIB Colon Cancer AJCC v8|Stage IIB Colon Cancer	Stage IIB includes: T4a, N0, M0. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIB Colon Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134282>	C134274|C134190	Stage IIC Colon Cancer AJCC v8|Stage IIC Colon Cancer	Stage IIC includes: T4b, N0, M0. T4b: Tumor directly invades or adheres to adjacent organs or structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIC Colon Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134283>	C134251|C134191	Stage III Colon Cancer AJCC v8|Stage III Colon Cancer	Stage III includes: IIIA: (T1-T2, N1/N1c, M0); (T1, N2a, M0); IIIB: (T3-T4a, N1/N1c, M0); (T2-T3, N2a, M0); (T1-T2, N2b, M0); IIIC: (T4a, N2a, M0); (T3-T4a, N2b, M0); (T4b, N1-N2, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). T4b: Tumor directly invades or adheres to adjacent organs or structures. N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N1c: No regional lymph nodes are positive, but there are tumor deposits in the subserosa, mesentery, or nonperitonealized pericolic, or perirectal/mesorectal tissues. N2: Four or more regional lymph nodes are positive. N2a: Four to six regional lymph nodes are positive. N2b: Seven or more regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Colon Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134284>	C134283|C134192	Stage IIIA Colon Cancer AJCC v8|Stage IIIA Colon Cancer	Stage IIIA includes: (T1-T2, N1/N1c, M0); (T1, N2a, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N1c: No regional lymph nodes are positive, but there are tumor deposits in the subserosa, mesentery, or nonperitonealized pericolic, or perirectal/mesorectal tissues. N2a: Four to six regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIA Colon Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134285>	C134283|C134193	Stage IIIB Colon Cancer AJCC v8|Stage IIIB Colon Cancer	Stage IIIB includes: (T3-T4a, N1/N1c, M0); (T2-T3, N2a, M0); (T1-T2, N2b, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N1c: No regional lymph nodes are positive, but there are tumor deposits in the subserosa, mesentery, or nonperitonealized pericolic, or perirectal/mesorectal tissues. N2a: Four to six regional lymph nodes are positive. N2b: Seven or more regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIB Colon Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134286>	C134283|C134194	Stage IIIC Colon Cancer AJCC v8|Stage IIIC Colon Cancer	Stage IIIC includes: (T4a, N2a, M0); (T3-T4a, N2b, M0); (T4b, N1-N2, M0). T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). T4b: Tumor directly invades or adheres to adjacent organs or structures. N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N2: Four or more regional lymph nodes are positive. N2a: Four to six regional lymph nodes are positive. N2b: Seven or more regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIC Colon Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134287>	C134251|C134195	Stage IV Colon Cancer AJCC v8|Stage IV Colon Cancer	Stage IV includes: IVA: (Any T, Any N, M1a); IVB: (Any T, Any N, M1b); IVC: (Any T, Any N, M1c). M1a: Metastasis to one site or organ without peritoneal metastasis. M1b: Metastasis to two or more sites or organs without peritoneal metastasis. M1c: Metastasis to the peritoneal surface alone or with other site or organ metastases. (AJCC 8th ed.)	Stage IV Colon Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134288>	C134287|C134196	Stage IVA Colon Cancer AJCC v8|Stage IVA Colon Cancer	Stage IVA includes: Any T, Any N, M1a. M1a: Metastasis to one site or organ without peritoneal metastasis. (AJCC 8th ed.)	Stage IVA Colon Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134289>	C134287|C134197	Stage IVB Colon Cancer AJCC v8|Stage IVB Colon Cancer	Stage IVB includes: Any T, Any N, M1b. M1b: Metastasis to two or more sites or organs without peritoneal metastasis.  (AJCC 8th ed.)	Stage IVB Colon Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13428>	C13427	Hormone Receptor DNA-Binding Domain|C4 Zinc Finger|Zinc Twist Motif	One of three structural motifs observed in DNA binding domains of zinc proteins.  Originally identified in the glucocorticoid receptor, it's also known as the C4 zinc finger, or the zinc twist.  Each of two zinc atoms is bound to four cysteine residues; the zinc twist is represented by a helical DNA recognition site located between the two zinc atoms.			Amino Acid Sequence	
C134290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134290>	C134287|C134198	Stage IVC Colon Cancer AJCC v8|Stage IVC Colon Cancer	Stage IVC includes: Any T, Any N, M1c. M1c: Metastasis to the peritoneal surface alone or with other site or organ metastases. (AJCC 8th ed.)	Stage IVC Colon Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134291>	C134258|C134182	Stage 0 Rectal Cancer AJCC v8|Stage 0 Rectal Cancer	Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ, intramucosal carcinoma (involvement of lamina propria with no extension through muscularis mucosae). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0 Rectal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134292>	C134258|C134185	Stage I Rectal Cancer AJCC v8|Stage I Rectal Cancer	Stage I includes: (T1, N0, M0); (T2, N0, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Rectal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134293>	C134258|C134186	Stage II Rectal Cancer AJCC v8|Stage II Rectal Cancer	Stage II includes: IIA: T3, N0, M0; IIB: T4a, N0, M0; IIC: T4b, N0, M0. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). T4b: Tumor directly invades or adheres to adjacent organs or structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Rectal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134294>	C134293|C134187	Stage IIA Rectal Cancer AJCC v8|Stage IIA Rectal Cancer	Stage IIA includes: T3, N0, M0. T3: Tumor invades through the muscularis propria into pericolorectal tissues. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIA Rectal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134295>	C134293|C134188	Stage IIB Rectal Cancer AJCC v8|Stage IIB Rectal Cancer	Stage IIB includes: T4a, N0, M0. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIB Rectal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134296>	C134293|C134190	Stage IIC Rectal Cancer AJCC v8|Stage IIC Rectal Cancer	Stage IIC includes: T4b, N0, M0. T4b: Tumor directly invades or adheres to adjacent organs or structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIC Rectal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134297>	C134258|C134191	Stage III Rectal Cancer AJCC v8|Stage III Rectal Cancer	Stage III includes: IIIA: (T1-T2, N1/N1c, M0); (T1, N2a, M0); IIIB: (T3-T4a, N1/N1c, M0); (T2-T3, N2a, M0); (T1-T2, N2b, M0); IIIC: (T4a, N2a, M0); (T3-T4a, N2b, M0); (T4b, N1-N2, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). T4b: Tumor directly invades or adheres to adjacent organs or structures. N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N1c: No regional lymph nodes are positive, but there are tumor deposits in the subserosa, mesentery, or nonperitonealized pericolic, or perirectal/mesorectal tissues. N2: Four or more regional lymph nodes are positive. N2a: Four to six regional lymph nodes are positive. N2b: Seven or more regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Rectal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134298>	C134297|C134192	Stage IIIA Rectal Cancer AJCC v8|Stage IIIA Rectal Cancer	Stage IIIA includes: (T1-T2, N1/N1c, M0); (T1, N2a, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N1c: No regional lymph nodes are positive, but there are tumor deposits in the subserosa, mesentery, or nonperitonealized pericolic, or perirectal/mesorectal tissues. N2a: Four to six regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIA Rectal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134299>	C134297|C134193	Stage IIIB Rectal Cancer AJCC v8|Stage IIIB Rectal Cancer	Stage IIIB includes: (T3-T4a, N1/N1c, M0); (T2-T3, N2a, M0); (T1-T2, N2b, M0). T1: Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria). T2: Tumor invades the muscularis propria. T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N1c: No regional lymph nodes are positive, but there are tumor deposits in the subserosa, mesentery, or nonperitonealized pericolic, or perirectal/mesorectal tissues. N2a: Four to six regional lymph nodes are positive. N2b: Seven or more regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIB Rectal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13429>	C13427	Zinc Cluster|C6 Zinc Cluster	The zinc cluster is one of three structural motifs observed in the DNA-binding domains of zinc proteins.  In the "zinc cluster" two zinc atoms are liganded by six cysteine residues.  Originally identified in the GAL4 transactivator, it is also known as the C6 zinc cluster, binuclear cluster, and the Zn(II)2Cys6 motif.			Amino Acid Sequence	
C1342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1342>	C253	Ametantrone|1,4-bis[[2-[(2-Hydroxyethyl)amino]ethyl]amino]9,10-anthracenedione|9, 10-Anthracenedione, 1, 4-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-|AMETANTRONE	A topoisomerase II inhibitor of the anthrapyrazole family that causes covalent cross-links in DNA of tumor cells.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C134300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134300>	C134297|C134194	Stage IIIC Rectal Cancer AJCC v8|Stage IIIC Rectal Cancer	Stage IIIC includes: (T4a, N2a, M0); (T3-T4a, N2b, M0); (T4b, N1-N2, M0). T3: Tumor invades through the muscularis propria into pericolorectal tissues. T4a: Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and continuous invasion of tumor through areas of inflammation to the surface of the visceral peritoneum). T4b: Tumor directly invades or adheres to adjacent organs or structures. N1: One to three regional lymph nodes are positive (tumor in lymph nodes measuring 0.2 mm or more), or any number of tumor deposits are present and all identifiable lymph nodes are negative. N2: Four or more regional lymph nodes are positive. N2a: Four to six regional lymph nodes are positive. N2b: Seven or more regional lymph nodes are positive. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIC Rectal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134301>	C134258|C134195	Stage IV Rectal Cancer AJCC v8|Stage IV Rectal Cancer	Stage IV includes: IVA: (Any T, Any N, M1a); IVB: (Any T, Any N, M1b); IVC: (Any T, Any N, M1c). M1a: Metastasis to one site or organ without peritoneal metastasis. M1b: Metastasis to two or more sites or organs without peritoneal metastasis. M1c: Metastasis to the peritoneal surface alone or with other site or organ metastases. (AJCC 8th ed.)	Stage IV Rectal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134302>	C134301|C134196	Stage IVA Rectal Cancer AJCC v8|Stage IVA Rectal Cancer	Stage IVA includes: Any T, Any N, M1a. M1a: Metastasis to one site or organ without peritoneal metastasis. (AJCC 8th ed.)	Stage IVA Rectal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134303>	C134301|C134197	Stage IVB Rectal Cancer AJCC v8|Stage IVB Rectal Cancer	Stage IVB includes: Any T, Any N, M1b. M1b: Metastasis to two or more sites or organs without peritoneal metastasis.  (AJCC 8th ed.)	Stage IVB Rectal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134304>	C134301|C134198	Stage IVC Rectal Cancer AJCC v8|Stage IVC Rectal Cancer	Stage IVC includes: Any T, Any N, M1c. M1c: Metastasis to the peritoneal surface alone or with other site or organ metastases. (AJCC 8th ed.)	Stage IVC Rectal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134305>	C20401|C200483|C129822	Anti-LAG-3 Monoclonal Antibody|Anti LAG-3 MoAb|Anti-LAG3 Monoclonal Antibody	Any monoclonal antibody directed against the antigen lymphocyte-activation gene 3 (LAG-3; CD223).	Anti-LAG-3 Monoclonal Antibody		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C134308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134308>	C21295	TNRC6B Gene|TNRC6B|TNRC6B|Trinucleotide Repeat Containing 6B Gene	This gene plays a role in RNA binding and RNA-mediated gene silencing.			Gene or Genome	
C134309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134309>	C134308	TNRC6B wt Allele|KIAA1093|Trinucleotide Repeat Containing 6B wt Allele|Trinucleotide Repeat-Containing 6B Gene|Trinucleotide Repeat-Containing Gene 6B	Human TNRC6B wild-type allele is located in the vicinity of 22q13.1 and is approximately 291 kb in length. This allele, which encodes trinucleotide repeat-containing gene 6B protein is involved in translational repression.			Gene or Genome	
C13430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13430>	C13202	Mitotic Chromosome	Condensed chromosomes observed during the M phase of the cell cycle.  Individual chromosomes can be discerned and differentiated morphologically.			Cell Component	
C134310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134310>	C21298	Trinucleotide Repeat-Containing Gene 6B Protein|TNRC6B	Trinucleotide repeat-containing gene 6B protein (1833 aa, ~194 kDa) is encoded by the human TNRC6B gene. This protein plays a role in RNA-mediated repression of translation.			Amino Acid, Peptide, or Protein	
C134311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134311>	C25939	KDM3A Gene|KDM3A|KDM3A|Lysine Demethylase 3A Gene	This gene is involved in the negative regulation of histone H3 methylation.	KDM3A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C134312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134312>	C134311	KDM3A wt Allele|JHDM2A|JHMD2A|JMJD1|JMJD1A|Jumonji Domain Containing 1 Gene|Jumonji Domain Containing 1A Gene|KIAA0742|Lysine (K)-Specific Demethylase 3A Gene|Lysine Demethylase 3A wt Allele|TSGA|Testis-Specific Gene A	Human KDM3A wild-type allele is located in the vicinity of 2p11.2 and is approximately 52 kb in length. This allele, which encodes lysine-specific demethylase 3A protein, plays a role in the metabolism of histone H3.			Gene or Genome	
C134313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134313>	C16946	Lysine-Specific Demethylase 3A|EC 1.14.11.-|JmjC Domain-Containing Histone Demethylase 2A|JmjC Domain-Containing Histone Demethylation Protein 2A|Jumonji C Domain-Containing Histone Demethylase 2A|Jumonji Domain-Containing Protein 1A|K-Specific Demethylase 3A|KDM3A|Testis-Specific Protein A	Lysine-specific demethylase 3A (1321 aa, ~147 kDa) is encoded by the human KDM3A gene. This protein is involved in the demethylation of lysine-9 of histone H3 (H3K9).			Amino Acid, Peptide, or Protein|Enzyme	
C134314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134314>	C107581	FGFR2 NP_000132.3:p.V679F|CD332 Antigen V679F|CD332 Antigen Val679Phe|FGFR-2 V679F|FGFR-2 Val679Phe|FGFR2 NP_000132.3:p.Val679Phe|FGFR2 V564F|FGFR2 V679F|FGFR2 Val564Phe|FGFR2 Val679Phe|FGFR2 p.V564F|FGFR2 p.V679F|FGFR2 p.Val564Phe|FGFR2 p.Val679Phe|Fibroblast Growth Factor Receptor 2 V679F|Fibroblast Growth Factor Receptor 2 Val679Phe|KGFR V679F|KGFR Val679Phe|Keratinocyte Growth Factor Receptor V679F|Keratinocyte Growth Factor Receptor Val679Phe|NP_000132.3:p.V679F|NP_000132.3:p.Val679Phe|NP_001138385.1:p.V564F|NP_001138388.1:p.Val564Phe	A change in the amino acid residue at position 679 in the fibroblast growth factor receptor 2 protein where valine has been replaced by phenylalanine.			Cell or Molecular Dysfunction	
C134315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134315>	C217122	Mantle Cell Lymphoma International Prognostic Index Combined Biologic Index|MIPI-c|MIPI-c Score|MIPIb|MIPIb Score|Mantle Cell Lymphoma International Prognostic Index-Combined	A scoring system designed to classify a patient's risk of mantle cell lymphoma progression or relapse and overall survival following therapy. It uses the criteria of patient's age, ECOG performance status, serum LDH activity, WBC count and Ki-67 index to classify patients into low risk, medium risk or high risk groups. The MIPIb score is calculated using the formula: [0.03535 x age (years)] + 0.6978 (if ECOG > 1) + [1.367 x log10(LDH/ULN)] + [0.9393 x log10(WBC count)] + [0.02142 x Ki-67 (%)]. A score < 5.7 indicates low risk disease, 5.7 - 6.5 indicates intermediate risk, and 6.5 or greater high risk.			Intellectual Product	
C134316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134316>	C21295	RAVER2 Gene|RAVER2|RAVER2|Ribonucleoprotein, PTB Binding 2 Gene	This gene plays a role in binding single stranded RNA.			Gene or Genome	
C134317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134317>	C134316	RAVER2 wt Allele|FLJ10770|KIAA1579|Raver2, Mouse, Homolog of Gene|Ribonucleoprotein, PTB Binding 2 wt Allele|Ribonucleoprotein, PTB-Binding 2 Gene	Human RAVER2 wild-type allele is located in the vicinity of 1p31.3 and is approximately 88 kb in length. This allele, which encodes ribonucleoprotein PTB-binding 2 protein, is involved in RNA binding.			Gene or Genome	
C134318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134318>	C21298	Ribonucleoprotein PTB-Binding 2|Protein Raver-2|RAVER2	Ribonucleoprotein PTB-binding 2 (691 aa, ~74 kDa) is encoded by the human RAVER2 gene. This protein plays a role in RNA binding and may affect RNA processing.			Amino Acid, Peptide, or Protein	
C134319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134319>	C3171|C172281|C148431	Refractory Acute Myeloid Leukemia|Refractory AML|Refractory Acute Myeloid Leukemia (AML)	An acute myeloid leukemia that does not respond to treatment.	Refractory Acute Myeloid Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13431>	C13202	Interphase Chromosome	Interphase chromosomes are decondensed chromosomes that reside in the interphase nucleus in the form of chromatin. Two types of chromatin, euchromatin and heterochromatin, can be discerned microscopically.			Temporal Concept	
C13432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13432>	C13377	Chromosome Band|Chromosomal Band|Chromosomal Bands|band|cytoband	Chromosomal bands observed after staining with specific dyes.  The band pattern is the result of differential interactions between the dye and nonadjacent chromosomal regions.			Cell Component	GDC Property Terminology|GDC Terminology
C13433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13433>	C13434	Chromatin Fiber|30 nm Chromatin Fiber|30 nm Fiber|Chromatin Fibril	A level of DNA packaging in chromatin above that of the nucleosome, the fundamental subunit of chromatin structure.  The chromatin fiber has a thickness of about 30 nanometers and results from the folding of a linear array of nucleosomes (thickness about 10 nm) into a more compact fiber.			Cell Component	
C13434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13434>	C13402	Higher Order Chromatin Structure|Higher Order Chromatin Folding|Higher Order Structure	Refers to various levels of DNA packaging in the chromosomes above that of the nucleosome.  Includes the chromatin fiber and higher levels of folding such as loops.			Cell Component	
C13435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13435>	C13434	Chromatin Loop|Chromatin Loop Domains|DNA Loop	A higher order chromatin structure above the level of the chromatin fiber.  The organization of chromatin into loops permits the partitioning of chromatin into topologically independent domains, and is thought to facilitate its compartmentation into functionally independent regions.			Cell Component	
C13436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13436>	C34070	Chromosome Territory|Chromosomal Territory	The physical volume occupied by a specific chromosome in the interphase nucleus.  The territories from distinct chromosomes do not appear to overlap, preventing an intermingling of the decondensed chromatin.  Relative to a nuclear landmark (e.g. nucleolus), chromosome territories appear to differ from cell to cell.			Spatial Concept	
C13437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13437>	C13377	Matrix Attachment Region|MAR	Regions of chromosomal DNA attached to a structural component of the interphase nucleus termed the nuclear matrix, permitting the partitioning of DNA in the chromosomes into looped chromatin domains.			Nucleic Acid, Nucleoside, or Nucleotide	
C13438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13438>	C13426	Death Domain	The death domain is a protein region, approximately 80 amino acids long, that is required for transmission of the cytotoxic signal of apoptosis and is present in the TNF receptor, FAS, and several downstream signaling molecules.  Transmission of the apoptotic signal requires the functional interaction of proteins via the death domain.			Amino Acid Sequence	
C13439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13439>	C13426	TRAF Domain|TNF Receptor-Associated Factor Motif|TRAF Motif	The TRAF domain is the portion of TRAF family adaptor proteins which bind to TNF receptor cytoplasmic domain. It is the C-terminal homology region of 230 amino acids of signal-transducing proteins associated with members of the TNFR superfamily. This domain is involved in a variety of specific protein-protein interactions.			Amino Acid Sequence	
C1343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1343>	C1509	Aminosyn|Aminosyn RF	An amino acid mixture for nutritional support			Amino Acid, Peptide, or Protein|Pharmacologic Substance	NCI Drug Dictionary Terminology
C13441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13441>	C13298	Short Tandem Repeat|STR|Simple Sequence Repeat	Area of repetitive DNA within the genome consisting of multiple, end-to-end copies of a short DNA sequence usually comprised of di-, tri-, or tetranucleotide repeat units.	Short Tandem Repeat		Nucleotide Sequence	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13442>	C41009	Anatomy Qualifier|Anatomic Qualifier|Anatomy Qualifiers	An adjectival term used to specify a region of the body or other concepts associated with the body.			Spatial Concept	
C13443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13443>	C13806	Immunoglobulin Heavy Chain Diversity Region|IGH-D	The portion of the immunoglobulin heavy chain hypervariable region of immunoglobulin molecules that is found between the variable (V) and joining (J) elements.	Immunoglobulin Heavy Chain Diversity Region		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134448>	C156880	Pimitespib|3-Ethyl-4-(3-(1-methylethyl)-4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo(3,4-b)pyridin-1-yl)benzamide|HSP90alpha/beta Inhibitor TAS-116|Heat Shock Protein 90 alpha/beta Inhibitor TAS-116|PIMITESPIB|TAS 116|TAS-116|TAS116	A specific inhibitor of heat shock protein 90 (Hsp90) subtypes alpha and beta, with potential antineoplastic and chemo/radiosensitizing activities. Upon oral administration, pimitespib specifically binds to and inhibits the activity of Hsp90 alpha and beta; this results in the proteasomal degradation of oncogenic client proteins, which inhibits client protein dependent-signaling, induces apoptosis, and inhibits the proliferation of cells overexpressing HSP90alpha/beta. Hsp90, a family of molecular chaperone proteins that are upregulated in a variety of tumor cells, plays a key role in the conformational maturation, stability, and function of "client" proteins within the cell,; many of which are involved in signal transduction, cell cycle regulation and apoptosis, including kinases, cell-cycle regulators, transcription factors and hormone receptors. As TAS-116 selectively inhibits cytosolic HSP90alpha and beta only and does not inhibit HSP90 paralogs, such as endoplasmic reticulum GRP94 or mitochondrial TRAP1, this agent may have less off-target toxicity as compared to non-selective HSP90 inhibitors.	Pimitespib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C13444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13444>	C19335	Bone and Cartilage Funding|Bone and Cartilage	Research dollars spent on bone or cartilage research.			Classification	
C134452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134452>	C138155|C103223	NTRK1 Gene Alteration Positive|MTC Gene Alteration Positive|Neurotrophic Tyrosine Kinase Receptor 1 Gene Alteration Positive|Neurotrophic Tyrosine Kinase, Receptor, Type 1 Gene Alteration Positive|TRK Gene Alteration Positive|TRK1 Gene Alteration Positive|TRKA Gene Alteration Positive|Trk-A Gene Alteration Positive|p140-TrkA Gene Alteration Positive	A finding indicating that mutation, overexpression or rearrangement of the NTRK1 gene has been detected in a sample.	NTRK1 Gene Alteration Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134453>	C138155|C103223	NTRK2 Gene Alteration Positive|Neurotrophic Tyrosine Kinase Receptor 2 Gene Alteration Positive|Neurotrophic Tyrosine Kinase Receptor Type 2 Gene Alteration Positive|TRKB Gene Alteration Positive|TRKB Tyrosine Kinase Gene Alteration Positive|Tropomyosin-Related Kinase B Gene Alteration Positive	A finding indicating that mutation, overexpression or rearrangement of the NTRK2 gene has been detected in a sample.	NTRK2 Gene Alteration Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134454>	C35682|C103223	ROS1 Gene Alteration Positive|Genetic Defect in ROS1|MCF3 Gene Alteration Positive|ROS Gene Alteration Positive|ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene Alteration Positive|ROS1 Gene Defect|ROS1 Gene Defect Detected|ROS1 Gene Defect Positive|c-ros-1 Gene Alteration Positive	A finding indicating that mutation, overexpression or rearrangement of the ROS1 gene has been detected in a sample.	ROS1 Gene Alteration Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134455>	C133361	Hepatobiliary System Cancer TNM Finding v8|Hepatobiliary System Carcinoma TNM Finding v8	A finding about one or more characteristics of hepatobiliary system cancer, following the rules of the TNM AJCC v8 classification system. (from AJCC 8th Ed.)			Finding	
C134456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134456>	C138155|C103223	NTRK3 Gene Alteration Positive|Neurotrophic Tyrosine Kinase Receptor 3 Gene Alteration Positive|Neurotrophic Tyrosine Kinase Receptor Type 3 Gene Alteration Positive|Neurotrophic Tyrosine Kinase, Receptor, Type 3 Gene Alteration Positive|TRKC Gene Alteration Positive	A finding indicating that mutation, overexpression or rearrangement of the NTRK3 gene has been detected in a sample.	NTRK3 Gene Alteration Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134457>	C134455	Hepatocellular Carcinoma TNM Finding v8|Liver Cell Carcinoma TNM Finding v8	A finding about one or more characteristics of hepatocellular carcinoma, following the rules of the TNM AJCC v8 classification system. This staging system applies to hepatocellular carcinomas and fibrolamellar carcinomas (fibrolamellar variant of hepatocellular carcinoma). Intrahepatic cholangiocarcinomas, combined hepatocellular-cholangiocarcinomas, and sarcomas of the liver are not staged using this staging system. (from AJCC 8th Ed.)			Finding	
C134458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134458>	C35682|C103223	ALK Gene Alteration Positive|ALK Gene Defect|ALK Gene Defect Detected|ALK Gene Defect Positive|Anaplastic Lymphoma Kinase Gene Alteration Positive|Anaplastic Lymphoma Receptor Tyrosine Kinase Gene Alteration Positive|CD246 Gene Alteration Positive|Genetic Defect in ALK	A finding indicating that mutation, overexpression or rearrangement of the ALK gene has been detected in a sample.	ALK Gene Alteration Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134459>	C134457	Hepatocellular Carcinoma Clinical TNM Finding v8|Liver Cell Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of hepatocellular carcinoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C13445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13445>	C13377	Gene Feature|Gene Organization|Gene Structure|Gene Structure/Organization|Seq Feature|Sequence Feature	The structural elements that comprise a gene or transcription unit. Gene structures include the transcription initiation site, the protein coding sequences, intervening sequences, and the transcription termination or polyadenylation sites as well as the regulatory elements (enhancers, silencers, and the promoter) that lie outside the boundaries of the transcribed unit.			Gene or Genome	
C134460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134460>	C134459	Hepatocellular Carcinoma Clinical Distant Metastasis TNM Finding v8|Clinical Distant Metastasis Status (cM)|Liver Cell Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of hepatocellular carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C134461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134461>	C134460	Hepatocellular Carcinoma cM0 TNM Finding v8|Liver Cell Carcinoma cM0 TNM Finding v8	Hepatocellular carcinoma without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C134462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134462>	C134460	Hepatocellular Carcinoma cM1 TNM Finding v8|Liver Cell Carcinoma cM1 TNM Finding v8|cM1	Hepatocellular carcinoma with distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C134463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134463>	C177692	BCL2 Positive|Apoptosis Regulator Bcl-2 Positive|B-Cell CLL/Lymphoma 2 Positive|B-Cell Leukemia/Lymphoma 2 Positive|BCL-2 Positive|BCL2 Expression	An indication that BCL2 expression has been detected in a sample.	BCL2 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134464>	C134457	Hepatocellular Carcinoma Pathologic TNM Finding v8|Liver Cell Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of hepatocellular carcinoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C134465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134465>	C128662	EGFR Exon 19 Insertion Mutation|EGFR Exon 19 Insertion|ERBB Exon 19 Insertion Mutation|ERBB1 Exon 19 Insertion Mutation|Epidermal Growth Factor Receptor Gene Exon 19 Insertion Mutation|HER1 Exon 19 Insertion Mutation	A molecular genetic abnormality indicating the presence of an in-frame insertion mutation occurring within exon 19 of the EGFR gene.	EGFR Exon 19 Insertion Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134466>	C134464	Hepatocellular Carcinoma Pathologic Distant Metastasis TNM Finding v8|Liver Cell Carcinoma Pathologic Distant Metastasis TNM Finding v8|Pathologic Distant Metastasis Status (pM)	A pathologic finding about one or more characteristics of hepatocellular carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C134467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134467>	C134466	Hepatocellular Carcinoma pM1 TNM Finding v8|Liver Cell Carcinoma pM1 TNM Finding v8|pM1	Hepatocellular carcinoma with distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C134468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134468>	C180944|C177687	BRAF V600 Wild Type|B-RAF V600 Wild Type|B-RAF1 V600 Wild Type|BRAF V600 Mutation Negative|BRAF V600 Wildtype|BRAF V600 wt|BRAF V600V|BRAF p.V600V|Serine/Threonine-Protein Kinase B-raf V600 Wild Type	A genetic finding indicating that codon 600 of the BRAF gene encodes the wild type amino acid, valine.	BRAF V600 Wild Type		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134469>	C134464	Hepatocellular Carcinoma Pathologic Primary Tumor TNM Finding v8|Liver Cell Carcinoma Pathologic Primary Tumor TNM Finding v8|Pathologic Primary Tumor Status (pT)	A pathologic finding about one or more characteristics of hepatocellular carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C13446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13446>	C13282	Nuclear Structure	Any structures that are enclosed within nucleus are considered nuclear structure, including any macromolecular structures. (NCI)			Cell Component	
C134470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134470>	C134469	Hepatocellular Carcinoma pTX TNM Finding v8|Liver Cell Carcinoma pTX TNM Finding v8|pTX	Hepatocellular carcinoma in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C134471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134471>	C134469	Hepatocellular Carcinoma pT0 TNM Finding v8|Liver Cell Carcinoma pT0 TNM Finding v8|pT0	Hepatocellular carcinoma with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C134472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134472>	C134469	Hepatocellular Carcinoma pT1 TNM Finding v8|Liver Cell Carcinoma pT1 TNM Finding v8|pT1	Hepatocellular carcinoma with solitary tumor equal to or less than 2 cm, or larger than 2 cm without vascular invasion. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C134473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134473>	C97927	APC Gene Mutation|APC, WNT Signaling Pathway Regulator Gene Mutation|Adenomatosis Polyposis Gene Mutation|BTPS2 Gene Mutation|FAP Gene Mutation|FPC Gene Mutation|PPP1R46 Gene Mutation	A change in the nucleotide sequence of the APC gene.	APC Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134474>	C134472	Hepatocellular Carcinoma pT1a TNM Finding v8|Liver Cell Carcinoma pT1a TNM Finding v8|pT1a	Hepatocellular carcinoma with solitary tumor equal to or less than 2 cm. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C134475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134475>	C134472	Hepatocellular Carcinoma pT1b TNM Finding v8|Liver Cell Carcinoma pT1b TNM Finding v8|pT1b	Hepatocellular carcinoma with solitary tumor larger than 2 cm without vascular invasion. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C134476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134476>	C134469	Hepatocellular Carcinoma pT2 TNM Finding v8|Liver Cell Carcinoma pT2 TNM Finding v8|pT2	Hepatocellular carcinoma with solitary tumor larger than 2 cm with vascular invasion, or multiple tumors, none larger than 5 cm. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C134477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134477>	C134469	Hepatocellular Carcinoma pT3 TNM Finding v8|Liver Cell Carcinoma pT3 TNM Finding v8|pT3	Hepatocellular carcinoma with multiple tumors, at least one of which is larger than 5 cm. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C134478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134478>	C20988	NECTIN4 Gene|NECTIN4|NECTIN4|Nectin Cell Adhesion Molecule 4 Gene	This gene is involved in the modulation of cell-cell adhesion.	NECTIN4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C134479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134479>	C134469	Hepatocellular Carcinoma pT4 TNM Finding v8|Liver Cell Carcinoma pT4 TNM Finding v8|pT4	Hepatocellular carcinoma with single tumor or multiple tumors of any size involving a major branch of the portal vein or hepatic vein, or tumor(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of visceral peritoneum. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C13447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13447>	C13303	Nonexchangeable Site	A binding site where a ligand is permanently bound.			Chemical Viewed Functionally	
C134480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134480>	C134478	NECTIN4 wt Allele|EDSS1|LNIR|Nectin Cell Adhesion Molecule 4 wt Allele|PRR4|PVRL4|Poliovirus Receptor-Like 4 Gene|Poliovirus Receptor-Related 4 Gene	Human NECTIN4 wild-type allele is located in the vicinity of 1q23.3 and is approximately 19 kb in length. This allele, which encodes nectin-4 protein, plays a role in cell-cell adhesion. Mutation of the gene is associated with ectodermal dysplasia-syndactyly syndrome 1.	NECTIN4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134481>	C134464	Hepatocellular Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8|Liver Cell Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8|Pathologic Regional Lymph Node Status (pN)	A pathologic finding about one or more characteristics of hepatocellular carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C134482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134482>	C134481	Hepatocellular Carcinoma pNX TNM Finding v8|Liver Cell Carcinoma pNX TNM Finding v8|pNX	Hepatocellular carcinoma in which the regional lymph node(s) cannot be assessed.  (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C134483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134483>	C16393	Nectin-4|Ig Superfamily Receptor LNIR|NECTIN4|Nectin 4|Nectin Cell Adhesion Molecule 4|Poliovirus Receptor-Related 4|Poliovirus Receptor-Related Protein 4	Nectin-4 (510 aa, ~55 kDa) is encoded by the human NECTIN4 gene. This protein is involved in cell-cell adhesion.	Nectin-4		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134484>	C134481	Hepatocellular Carcinoma pN0 TNM Finding v8|Liver Cell Carcinoma pN0 TNM Finding v8|pN0	Hepatocellular carcinoma with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C134485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134485>	C134481	Hepatocellular Carcinoma pN1 TNM Finding v8|Liver Cell Carcinoma pN1 TNM Finding v8|pN1	Hepatocellular carcinoma with regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C134486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134486>	C94299|C177692	NECTIN4 Positive|Ig Superfamily Receptor LNIR Positive|Nectin 4 Positive|Nectin Cell Adhesion Molecule 4 Positive|Nectin-4 Positive|PVRL4 Positive|Poliovirus Receptor-Like 4 Positive|Poliovirus Receptor-Related 4 Positive	An indication that NECTIN4 expression has been detected in a sample.	NECTIN4 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134487>	C189831|C158949	ALK Gene Rearrangement Negative|ALK Rearrangement Negative|Anaplastic Lymphoma Kinase Gene Rearrangement Negative|Anaplastic Lymphoma Receptor Tyrosine Kinase Gene Rearrangement Negative|CD246 Gene Rearrangement Negative|No rearrangement detected	A genetic finding indicating that rearrangement of the ALK gene has not been detected in a sample.	ALK Gene Rearrangement Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134488>	C134487	ALK Gene Translocation Negative|ALK Translocation Negative|Anaplastic Lymphoma Kinase Gene Translocation Negative|Anaplastic Lymphoma Receptor Tyrosine Kinase Gene Translocation Negative|CD246 Gene Translocation Negative	A genetic finding indicating that translocations involving the ALK gene have not been detected in a sample.	ALK Gene Translocation Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134489>	C97928	BTK Protein Variant|ATK Protein Variant|Agammaglobulinaemia Tyrosine Kinase Protein Variant|B-Cell Progenitor Kinase Protein Variant|BPK Protein Variant|Bruton Tyrosine Kinase Protein Variant|Tyrosine-Protein Kinase BTK Protein Variant	A variation in the amino acid sequence of the tyrosine-protein kinase BTK protein.	BTK Protein Variant		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13448>	C13282	Microtubule Bundle	It is the aggregated products of microtubules during mitosis where chromosomes line up prior to the segregation process. Many antineoplastic agents cause cytotoxicity by inducing microtubular bundle formation irreversibly. (NCI)			Cell Component	
C134490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134490>	C134489	BTK NP_000052.1:p.C481X|ATK C481X|ATK Cys481Xxx|Agammaglobulinaemia Tyrosine Kinase C481X|Agammaglobulinaemia Tyrosine Kinase Cys481Xxx|B-Cell Progenitor Kinase C481X|B-Cell Progenitor Kinase Cys481Xxx|BPK C481X|BPK Cys481Xxx|BTK C481X|BTK C481X Mutation|BTK Cys481Xxx|BTK NP_000052.1:p.Cys481Xxx|BTK p.C481X|BTK p.Cys481Xxx|Bruton Tyrosine Kinase C481X|Bruton Tyrosine Kinase Cys481Xxx|Cysteine-481 BTK Mutation|NP_000052.1:p.C481X|NP_000052.1:p.Cys481Xxx|Tyrosine-Protein Kinase BTK C481X|Tyrosine-Protein Kinase BTK Cys481Xxx	A change in the cysteine at position 481 of the tyrosine-protein kinase BTK protein to another amino acid.	BTK NP_000052.1:p.C481X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134491>	C177692	MLANA Positive|Antigen LB39-AA Positive|Antigen SK29-AA Positive|MART 1 Positive|MART-1 Antigen Positive|MART-1 Positive|MART1 Positive|Melan A Positive|Melan-A Positive|Melanoma Antigen Recognized by T Cells 1 Positive|Melanoma Antigen Recognized by T-Cells 1 Positive	An indication that MLANA expression has been detected in a sample.	MLANA Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134492>	C177692	GPC3 Positive|Glypican 3 Positive|Glypican Proteoglycan 3 Positive|Glypican-3 Positive|MXR7 Positive|OCI-5 Positive	An indication that GPC3 expression has been detected in a sample.	GPC3 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134494>	C177687	Activating EGFR Gene Mutation Negative|Activating EGFR Mutation Negative|Activating ERBB Mutation Negative|Activating ERBB1 Mutation Negative|Activating HER1 Mutation Negative|Activating c-erbB1 Mutation Negative|EGFR Activating Mutation Negative|Epidermal Growth Factor Receptor Activating Mutation Negative	A genetic finding indicating that mutations in the EGFR gene which encode constitutively active forms of the epidermal growth factor receptor protein are not present in a sample.	Activating EGFR Gene Mutation Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134495>	C94299|C177692	KDR Positive|CD309 Antigen Positive|CD309 Positive|FLK-1 Positive|Fetal Liver Kinase 1 Positive|Kinase Insert Domain Receptor Positive|Protein-Tyrosine Kinase Receptor Flk-1 Positive|VEGFR-2 Positive|VEGFR2 Positive|Vascular Endothelial Growth Factor Receptor 2 Positive	An indication that KDR expression has been detected in a sample.	KDR Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134496>	C94299|C177692	IL13RA2 Positive|CD213a2 Antigen Positive|CT19 Positive|Cancer/Testis Antigen 19 Positive|IL-13 Receptor Subunit Alpha-2 Positive|IL-13R Subunit Alpha-2 Positive|IL-13R-Alpha-2 Positive|IL-13RA2 Positive|IL13BP Positive|IL13Ralpha2 Positive|Interleukin 13 Binding Protein Positive|Interleukin 13 Receptor Alpha 2 Chain Positive|Interleukin 13 Receptor Subunit Alpha 2 Positive|Interleukin 13 Receptor, Alpha 2 Positive|Interleukin-13 Receptor Subunit Alpha-2 Positive|Interleukin-13-Binding Protein Positive	An indication that IL13RA2 expression has been detected in a sample.	IL13RA2 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134497>	C94299|C177692	FGFR2 Positive|BEK Positive|CD332 Antigen Positive|CD332 Positive|ECT1 Positive|FGFR-2 Positive|Fibroblast Growth Factor Receptor 2 Positive|K-SAM Positive|KGFR Positive|Keratinocyte Growth Factor Receptor Positive	An indication that FGFR2 expression has been detected in a sample.	FGFR2 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134498>	C14208	Powassan Virus|POW	A positive-sense single-stranded RNA virus in the genus Flavivirus. It is the causative agent of Powassan Disease, an infection of the central nervous system associated with encephalitis and/or meningitis. The virus is maintained in a cycle between ticks and small-to-medium-sized rodents.			Virus	
C134499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134499>	C178120|C136425	Activating RAF Mutation|Activating RAF Family Gene Mutation|Activating Rapidly Accelerated Fibrosarcoma Family Gene Mutation|Activating Rapidly Accelerated Fibrosarcoma Family Kinase Gene Mutation|RAF Family Activating Gene Mutation	A mutation in a RAF family gene that encodes a constitutively active serine/threonine-protein kinase and results in aberrant activation of its downstream pathways.	Activating RAF Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13449>	C13738	RNA Conformation	Related to the secondary level of structural organization of RNA.  RNA can be found in various conformations, including double- as well as single-stranded, and in loops.			Spatial Concept	
C1344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1344>	C1934	Pivaloyloxymethylbutyrate|AN-9|AN-9|Pivanex	An acyloxyalkyl ester prodrug of butyric acid. Pivaloyloxymethylbutyrate inhibits histone deacetylase, resulting in cell differentiation, cell growth inhibition, and apoptosis. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C134500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134500>	C94299|C177692	PTPRC Positive|B220 Positive|CD45 Antigen Positive|CD45 Positive|CD45 Positive|CD45R Positive|GP180 Positive|L-CA Positive|LCA Positive|LY5 Positive|Leukocyte Common Antigen Positive|Protein Tyrosine Phosphatase, Receptor Type C Positive|Protein Tyrosine Phosphatase, Receptor Type, C Positive|Receptor-Type Tyrosine-Protein Phosphatase C Positive|T200 Positive	An indication that PTPRC expression has been detected in a sample.	PTPRC Positive		Laboratory or Test Result	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134501>	C94299|C177692	EGFR Positive|ERBB Positive|ERBB1 Positive|Epidermal Growth Factor Receptor Positive|HER1 Positive|c-erbB1 Positive	An indication that EGFR expression has been detected in a sample.	EGFR Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134502>	C64430	NOXA BH3 Priming|PMAIP1 BH3 Priming	An assay that indirectly quantitates the expression of the antiapoptotic protein, induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1; EAT), in a biological sample. Mitochondria or whole cells are isolated from a patient sample and stained with JC-1. In healthy cells with high mitochondrial membrane potential, JC-1 forms aggregates that emit red fluorescence, while in apoptotic cells with low mitochondrial membrane potential, JC-1 remains a monomer, which emits green fluorescence. The isolate is then exposed to a peptide comprised of the BH3 domain of phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1; NOXA), which specifically binds to and inhibits the antiapoptotic activity of MCL1. Then the mitochondrial outer membrane permeability (MOMP) is assessed by determining the ratio of red and green JC-1 fluorescence.	NOXA BH3 Priming		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134504>	C141248|C132005	Deleterious RAD51B Gene Mutation|Deleterious R51H2 Gene Mutation|Deleterious RAD51 Paralog B Gene Mutation|Deleterious RAD51L1 Gene Mutation|Deleterious REC2 Gene Mutation	A change in the nucleotide sequence of the RAD51B gene that is associated with increased risk of disease.	Deleterious RAD51B Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134505>	C93102|C131796	Deleterious CDK12 Gene Mutation|Deleterious CDC2 Related Protein Kinase 7 Gene Mutation|Deleterious CRK7 Gene Mutation|Deleterious CRKR Gene Mutation|Deleterious CRKRS Gene Mutation|Deleterious Cdc2-Related Kinase, Arginine/Serine-Rich Gene Mutation|Deleterious Cyclin Dependent Kinase 12 Gene Mutation|Deleterious Cyclin-Dependent Kinase 12 Gene Mutation	A change in the nucleotide sequence of the CDK12 gene that is associated with increased risk of disease.	Deleterious CDK12 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134506>	C20396	PPP2R2A Gene|PPP2R2A|PPP2R2A|Protein Phosphatase 2 Regulatory Subunit Balpha Gene	This gene is involved in the regulation of protein phosphatase 2 activity.	PPP2R2A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C134507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134507>	C134506	PPP2R2A wt Allele|B55-Alpha Gene|B55A|B55ALPHA|PR52A|PR55-Alpha Gene|PR55A|PR55alpha|Protein Phosphatase 2 (Formerly 2A), Regulatory Subunit B (PR 52), Alpha Isoform Gene|Protein Phosphatase 2 Regulatory Subunit Balpha wt Allele|Protein Phosphatase 2, Regulatory Subunit B, Alpha Gene	Human PPP2R2A wild-type allele is located in the vicinity of 8p21.2 and is approximately 81 kb in length. This allele, which encodes serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform protein, plays a role in the regulation of protein phosphatase 2 activity.	PPP2R2A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134508>	C34083	Serine/Threonine-Protein Phosphatase 2A 55 kDa Regulatory Subunit B Alpha Isoform|PP2A Subunit B Isoform Alpha|PP2A Subunit B Isoform B55-Alpha|PP2A Subunit B Isoform PR55-Alpha|PP2A Subunit B Isoform R2-Alpha|PPP2R2A	Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform (447 aa, ~52 kDa) is encoded by the human PPP2R2A gene. This protein is involved in the modulation of protein phosphatase 2 activity.	Serine/Threonine-Protein Phosphatase 2A 55 kDa Regulatory Subunit B Alpha Isoform		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134509>	C93102|C156750	Deleterious PPP2R2A Gene Mutation|Deleterious B55-Alpha Gene Mutation|Deleterious B55A Gene Mutation|Deleterious B55ALPHA Gene Mutation|Deleterious PR52A Gene Mutation|Deleterious PR55-Alpha Gene Mutation|Deleterious PR55A Gene Mutation|Deleterious PR55alpha Gene Mutation|Deleterious Protein Phosphatase 2 Regulatory Subunit Balpha Gene Mutation	A change in the nucleotide sequence of the PPP2R2A gene that is associated with increased risk of disease.	Deleterious PPP2R2A Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13450>	C13313	bHLH Domain	The bHLH domain is a bipartite DNA-binding domain containing a basic region upstream of an amphipathic helix-loop-helix region. The basic region interacts with DNA and the HLH motif mediates protein dimerization.			Amino Acid Sequence	
C134510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134510>	C93102|C156024	Deleterious FANCL Gene Mutation|Deleterious FAAP43 Gene Mutation|Deleterious Fanconi Anemia Complementation Group L Gene Mutation|Deleterious Fanconi Anemia, Complementation Group L Gene Mutation|Deleterious PHD Finger Protein 9 Gene Mutation|Deleterious PHF9 Gene Mutation|Deleterious POG Gene Mutation	A change in the nucleotide sequence of the FANCL gene that is associated with increased risk of disease.	Deleterious FANCL Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134511>	C93102|C40458	Deleterious CHEK2 Gene Mutation|Deleterious CDS1 Gene Mutation|Deleterious CHK2 Checkpoint Homolog (S. pombe) Gene Mutation|Deleterious CHK2 Gene Mutation|Deleterious Checkpoint Kinase 2 Gene Mutation|Deleterious LFS2 Gene Mutation|Deleterious RAD53 Gene Mutation|Deleterious hCds1 Gene Mutation	A change in the nucleotide sequence of the CHEK2 gene that is associated with increased risk of disease.	Deleterious CHEK2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C134512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134512>	C93102|C131788	Deleterious CHEK1 Gene Mutation|Deleterious CHK1 Checkpoint Homolog (S. pombe) Gene Mutation|Deleterious CHK1 Gene Mutation|Deleterious Checkpoint Kinase 1 Gene Mutation	A change in the nucleotide sequence of the CHEK1 gene that is associated with increased risk of disease.	Deleterious CHEK1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134513>	C93102|C40459	Deleterious ATM Gene Mutation|Deleterious A-T Mutated Gene Mutation|Deleterious AT Mutated Gene Mutation|Deleterious ATM Serine/Threonine Kinase Gene Mutation|Deleterious Ataxia Telangiectasia Mutated Gene Mutation	A change in the nucleotide sequence of the ATM gene that is associated with increased risk of disease.	Deleterious ATM Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C134514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134514>	C35417	Intrahepatic Cholangiocarcinoma by AJCC v7 Stage	A term that refers to the staging of intrahepatic cholangiocarcinoma according to the American Joint Committee on Cancer, 7th edition.			Neoplastic Process	
C134515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134515>	C3099	Hepatocellular Carcinoma by AJCC v8 Stage|Liver Cell Carcinoma by AJCC v8 Stage|Tumor Stage (Pathologic)	A term that refers to the staging of hepatocellular carcinoma according to the American Joint Committee on Cancer, 8th edition. This staging system applies to hepatocellular carcinomas and fibrolamellar carcinomas (fibrolamellar variant of hepatocellular carcinoma). Intrahepatic cholangiocarcinomas, combined hepatocellular-cholangiocarcinomas, and sarcomas of the liver are not staged using this staging system. (from AJCC 8th Ed.)			Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C134516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134516>	C7116|C134515	Stage I Hepatocellular Carcinoma AJCC v8|Stage I Hepatocellular Cancer|Stage I Liver Cell Carcinoma AJCC v8	Stage I includes: IA (T1a, N0, M0); IB (T1b, N0, M0). T1a: Solitary tumor equal to or less than 2 cm.  T1b: Solitary tumor larger than 2 cm without vascular invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Hepatocellular Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134517>	C134516	Stage IA Hepatocellular Carcinoma AJCC v8|IA|Stage IA Hepatocellular Cancer|Stage IA Liver Cell Carcinoma AJCC v8	Stage IA includes: T1a, N0, M0. T1a: Solitary tumor equal to or less than 2 cm.  N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IA Hepatocellular Carcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134518>	C134516	Stage IB Hepatocellular Carcinoma AJCC v8|IB|Stage IB Hepatocellular Cancer|Stage IB Liver Cell Carcinoma AJCC v8	Stage IB includes: T1b, N0, M0. T1b: Solitary tumor larger than 2 cm without vascular invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IB Hepatocellular Carcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134519>	C7117|C134515	Stage II Hepatocellular Carcinoma AJCC v8|II|Stage II Hepatocellular Cancer|Stage II Liver Cell Carcinoma AJCC v8	Stage II includes: T2, N0, M0. T2: Solitary tumor larger than 2 cm with vascular invasion, or multiple tumors, none larger than 5 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Hepatocellular Carcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C13451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13451>	C13202	Pre-Condensed Chromosomes|Genetics, Pre-Condensed Chromosomes	It refers to the chromosome status during the prophase of mitotic division. (NCI)			Cell Component	
C134520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134520>	C7118|C134515	Stage III Hepatocellular Carcinoma AJCC v8|Stage III Hepatocellular Cancer|Stage III Liver Cell Carcinoma AJCC v8	Stage III includes: IIIA: (T3, N0, M0); IIIB: (T4, N0, M0). T3: Multiple tumors, at least one of which is larger than 5 cm. T4: Single tumor or multiple tumors of any size involving a major branch of the portal vein or hepatic vein, or tumor(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of visceral peritoneum. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Hepatocellular Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134521>	C134520	Stage IIIA Hepatocellular Carcinoma AJCC v8|IIIA|Stage IIIA Hepatocellular Cancer|Stage IIIA Liver Cell Carcinoma AJCC v8	Stage IIIA includes: T3, N0, M0. T3: Multiple tumors, at least one of which is larger than 5 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIA Hepatocellular Carcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134522>	C134520	Stage IIIB Hepatocellular Carcinoma AJCC v8|IIIB|Stage IIIB Hepatocellular Cancer|Stage IIIB Liver Cell Carcinoma AJCC v8	Stage IIIB includes: T4, N0, M0. T4: Single tumor or multiple tumors of any size involving a major branch of the portal vein or hepatic vein, or tumor(s) with direct invasion of adjacent organs other than the gallbladder or with perforation of visceral peritoneum. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIB Hepatocellular Carcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134523>	C7121|C134515	Stage IV Hepatocellular Carcinoma AJCC v8|Stage IV Hepatocellular Cancer|Stage IV Liver Cell Carcinoma AJCC v8	Stage IV includes: IVA: (Any T, N1, M0); IVB: (Any T, Any N, M1). N1: Regional lymph node metastasis. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Hepatocellular Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134524>	C7122|C134523	Stage IVA Hepatocellular Carcinoma AJCC v8|IVA|Stage IVA Hepatocellular Cancer|Stage IVA Liver Cell Carcinoma AJCC v8	Stage IVA includes: Any T, N1, M0. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IVA Hepatocellular Carcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134525>	C7123|C134523	Stage IVB Hepatocellular Carcinoma AJCC v8|IVB|Stage IVB Hepatocellular Cancer|Stage IVB Liver Cell Carcinoma AJCC v8	Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)	Stage IVB Hepatocellular Carcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134526>	C134533	Canine Neoplasm	A neoplasm that occurs in dogs.			Neoplastic Process	Cellosaurus Disease Terminology
C134527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134527>	C134533	Bovine Neoplasm	A neoplasm that occurs in cattle.			Neoplastic Process	
C134528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134528>	C134533	Feline Experimental Organism Diagnosis	A condition that is relevant to either disease states or models of disease in cats.			Classification	
C13452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13452>	C33904	Other Body Fluids and Secretions|Other Body Fluids, Secretions	Liquid substances produced by living organisms to fulfill specific functions or excreted as waste. Secretions do not include hormones or enzymes.			Body Substance	
C134530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134530>	C134533	Leporine Experimental Organism Diagnosis	A condition that is relevant to either disease states or models of disease in rabbits.			Classification	
C134533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134533>	C134576	Non-Human or Experimental Organism Neoplasm by Organism|Experimental Organism Neoplasm by Organism	A neoplasm grouping that is based on the classification of the affected non-human organism; this includes neoplasms occurring in organisms used in research settings.			Neoplastic Process	
C134534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134534>	C134533	Galline Experimental Organism Diagnosis	A condition that is relevant to either disease states or models of disease in chickens.			Classification	
C134535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134535>	C134533	Equine Experimental Organism Diagnosis	A condition that is relevant to either disease states or models of disease in horses.			Classification	
C13453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13453>	C13671	Metal Binding Site	The specific parts of a protein molecule that directly participate in its interactions with a metal ion.			Amino Acid Sequence	
C13454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13454>	C13189	Linear Sequence Epitope	An epitope composed of adjacent amino acids			Spatial Concept	
C134556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134556>	C135005	Chicken Bursal Lymphoma	A malignant lymphoma that arises in the bursa of Fabricius in a chicken.			Neoplastic Process	Cellosaurus Disease Terminology
C134557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134557>	C135005	Chicken Fibrosarcoma	Fibrosarcoma that occurs in a chicken.			Neoplastic Process	Cellosaurus Disease Terminology
C134558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134558>	C135005	Chicken Hepatoma	Hepatoma that occurs in a chicken.			Neoplastic Process	Cellosaurus Disease Terminology
C134559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134559>	C134528	Feline Bronchioloalveolar Lung Carcinoma	Bronchioloalveolar lung carcinoma that occurs in a cat.			Neoplastic Process	Cellosaurus Disease Terminology
C13455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13455>	C13200	Sister Chromatid	Sister chromatids are the two newly synthesized daughter chromatids derived from the same chromosome parent.  During chromosomal pairing in meiosis, recombination occurs exclusively between non-sister chromatids.			Cell Component	
C134560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134560>	C134528	Feline Fibrosarcoma	Fibrosarcoma that occurs in a cat.			Neoplastic Process	Cellosaurus Disease Terminology
C134561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134561>	C136555	Gerbil Fibroma	Fibroma that occurs in a gerbil.			Neoplastic Process	Cellosaurus Disease Terminology
C134562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134562>	C136559	Goldfish Erythrophoroma	A red-pigmented tumor that occurs in a goldfish.			Neoplastic Process	Cellosaurus Disease Terminology
C134563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134563>	C134533	Guinea Pig Colon Adenocarcinoma	Adenocarcinoma that occurs in a guinea pig.			Neoplastic Process	Cellosaurus Disease Terminology
C134564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134564>	C134533	Guinea Pig Leukemia	Leukemia that occurs in a guinea pig.			Neoplastic Process	Cellosaurus Disease Terminology
C134565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134565>	C134988	Hamster Buccal Pouch Carcinoma	Buccal pouch carcinoma that occurs in a hamster.			Neoplastic Process	Cellosaurus Disease Terminology
C134566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134566>	C134988	Hamster Cholangiocarcinoma	Cholangiocarcinoma that occurs in a hamster.			Neoplastic Process	Cellosaurus Disease Terminology
C134567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134567>	C134988	Hamster Ductus Deferens Leiomyosarcoma	Ductus deferens leiomyosarcoma that occurs in a hamster.			Neoplastic Process	Cellosaurus Disease Terminology
C134568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134568>	C134988	Hamster Uterine Leiomyosarcoma	Uterine leiomyosarcoma that occurs in a hamster.			Neoplastic Process	Cellosaurus Disease Terminology
C134569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134569>	C134535	Horse Melanoma	Melanoma that occurs in a horse.			Neoplastic Process	Cellosaurus Disease Terminology
C13456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13456>	C12551	Bone Marrow Stem Cell|Bone Marrow Blood-Forming Cell|Bone Marrow Blood-Forming Cells|Bone Marrow Stem Cells	A hematopoietic stem cell found in the bone marrow.	Bone Marrow Blood-Forming Cell		Cell	
C134570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134570>	C23988	Mouse Basal Cell Carcinoma	Basal Cell carcinoma that occurs in a mouse.			Neoplastic Process	Cellosaurus Disease Terminology
C134571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134571>	C136559	Medaka Hepatoma|Oryzias latipes Hepatoma	Hepatoma that occurs in Oryzias latipes.			Neoplastic Process	Cellosaurus Disease Terminology
C134572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134572>	C135006	Medaka Melanoma|Oryzias latipes Melanoma	Melanoma that occurs in Oryzias latipes.			Neoplastic Process	Cellosaurus Disease Terminology
C134573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134573>	C136559	Rainbow Trout Hepatoma|Oncorhynchus mykiss Hepatoma	Hepatoma that occurs in Oncorhynchus mykiss.			Neoplastic Process	Cellosaurus Disease Terminology
C134574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134574>	C134533	Xenopus Neoplasm	A neoplasm that occurs in Xenopus.			Neoplastic Process	Cellosaurus Disease Terminology
C134575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134575>	C135006	Xiphophorus Melanoma	Melanoma that occurs in Xiphophorus.			Neoplastic Process	Cellosaurus Disease Terminology
C134576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134576>	C22187	Non-Human or Experimental Organism Neoplasm|Experimental Organism Neoplasm	A neoplastic condition occurring in a non-human organism; this includes neoplasms occurring in organisms used in research settings.			Neoplastic Process	
C134577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134577>	C134455	Intrahepatic Bile Duct Cancer TNM Finding v8|Intrahepatic Bile Duct Carcinoma TNM Finding v8	A finding about one or more characteristics of intrahepatic bile duct cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to intrahepatic cholangiocarcinomas, combined hepatocellular-cholangiocarcinomas (mixed hepatocholangiocarcinomas), and primary neuroendocrine tumors of the liver. Primary sarcomas of the liver, pure hepatocellular carcinomas, hilar cholangiocarcinomas, and gallbladder carcinomas are not staged using this staging system. (from AJCC 8th Ed.)			Finding	
C134578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134578>	C134577	Intrahepatic Bile Duct Cancer Clinical TNM Finding v8|Intrahepatic Bile Duct Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of intrahepatic bile duct cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C134579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134579>	C134578	Intrahepatic Bile Duct Cancer Clinical Distant Metastasis TNM Finding v8|Intrahepatic Bile Duct Cancer Clinical Distant Metastasis (cM)|Intrahepatic Bile Duct Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of intrahepatic bile duct cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C13457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13457>	C71457	Cytoplasmic Domain|Cytoplasmic Tail|Cytosolic Domain	The part of a transmembrane protein which projects into the cytoplasm.			Spatial Concept	
C134580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134580>	C134579	Intrahepatic Bile Duct Cancer cM0 TNM Finding v8|Intrahepatic Bile Duct Carcinoma cM0 TNM Finding v8	Intrahepatic bile duct cancer without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C134581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134581>	C134579	Intrahepatic Bile Duct Cancer cM1 TNM Finding v8|Intrahepatic Bile Duct Carcinoma cM1 TNM Finding v8|cM1	Intrahepatic bile duct cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134582>	C134577	Intrahepatic Bile Duct Cancer Pathologic TNM Finding v8|Intrahepatic Bile Duct Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of intrahepatic bile duct cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C134584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134584>	C134582	Intrahepatic Bile Duct Cancer Pathologic Distant Metastasis TNM Finding v8|Intrahepatic Bile Duct Cancer Pathologic Distant Metastasis (pM)|Intrahepatic Bile Duct Carcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of intrahepatic bile duct cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134585>	C134584	Intrahepatic Bile Duct Cancer pM1 TNM Finding v8|Intrahepatic Bile Duct Carcinoma pM1 TNM Finding v8|pM1	Intrahepatic bile duct cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134586>	C134582	Intrahepatic Bile Duct Cancer Pathologic Primary Tumor TNM Finding v8|Intrahepatic Bile Duct Cancer Pathologic Primary Tumor Status (pT)|Intrahepatic Bile Duct Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of intrahepatic bile duct cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134587>	C25997	AKAP6 Gene|A-Kinase Anchoring Protein 6 Gene|AKAP6|AKAP6	This gene is involved in the regulation of protein kinase A-dependent signaling.			Gene or Genome	
C134588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134588>	C134586	Intrahepatic Bile Duct Cancer pTX TNM Finding v8|Intrahepatic Bile Duct Carcinoma pTX TNM Finding v8|pTX	Intrahepatic bile duct cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134589>	C134587	AKAP6 wt Allele|A Kinase (PRKA) Anchor Protein 6 Gene|A-Kinase Anchor Protein, 100 kD Gene|A-Kinase Anchoring Protein 6 wt Allele|ADAP100|ADAP6|AKAP100|KIAA0311|PRKA6|mAKAP	Human AKAP6 wild-type allele is located in the vicinity of 14q12 and is approximately 508 kb in length. This allele, which encodes A-kinase anchor protein 6, plays a role in the propagation of cyclic adenosine monophosphate (cAMP)-mediated signaling.			Gene or Genome	
C13458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13458>	C71457	Extracellular Domain|External Domain	Any part of a transmembrane protein that projects into the environment surrounding a cell.			Spatial Concept	
C134590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134590>	C134586	Intrahepatic Bile Duct Cancer pT0 TNM Finding v8|Intrahepatic Bile Duct Carcinoma pT0 TNM Finding v8|pT0	Intrahepatic bile duct cancer with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134591>	C134586	Intrahepatic Bile Duct Cancer pTis TNM Finding v8|Intrahepatic Bile Duct Carcinoma pTis TNM Finding v8|pTis	Intrahepatic bile duct cancer with a finding of carcinoma in situ (intraductal tumor). (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134592>	C26231	A-Kinase Anchor Protein 6|A-Kinase Anchor Protein 100 kDa|AKAP 100|AKAP-6|AKAP6|PRKA6|Protein Kinase A Anchoring Protein 6|Protein Kinase A-Anchoring Protein 6|mAKAP	A-kinase anchor protein 6 (2319 aa, ~257 kDa) is encoded by the human AKAP6 gene. This protein is involved in the positive regulation of protein kinase A-mediated signaling.			Amino Acid, Peptide, or Protein	
C134593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134593>	C134586	Intrahepatic Bile Duct Cancer pT1 TNM Finding v8|Intrahepatic Bile Duct Carcinoma pT1 TNM Finding v8|pT1	Intrahepatic bile duct cancer with solitary tumor equal to or less than 5 cm, or larger than 5 cm without vascular invasion. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134594>	C134593	Intrahepatic Bile Duct Cancer pT1a TNM Finding v8|Intrahepatic Bile Duct Carcinoma pT1a TNM Finding v8|pT1a	Intrahepatic bile duct cancer with solitary tumor equal to or less than 5 cm without vascular invasion. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134595>	C134593	Intrahepatic Bile Duct Cancer pT1b TNM Finding v8|Intrahepatic Bile Duct Carcinoma pT1b TNM Finding v8|pT1b	Intrahepatic bile duct cancer with solitary tumor larger than 5 cm without vascular invasion. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134596>	C134586	Intrahepatic Bile Duct Cancer pT2 TNM Finding v8|Intrahepatic Bile Duct Carcinoma pT2 TNM Finding v8|pT2	Intrahepatic bile duct cancer with solitary tumor with intrahepatic vascular invasion, or multiple tumors, with or without vascular invasion. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134597>	C134586	Intrahepatic Bile Duct Cancer pT3 TNM Finding v8|Intrahepatic Bile Duct Carcinoma pT3 TNM Finding v8|pT3	Intrahepatic bile duct cancer with tumor perforating the visceral peritoneum. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134598>	C134586	Intrahepatic Bile Duct Cancer pT4 TNM Finding v8|Intrahepatic Bile Duct Carcinoma pT4 TNM Finding v8|pT4	Intrahepatic bile duct cancer with tumor involving local extrahepatic structures by direct invasion. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134599>	C134582	Intrahepatic Bile Duct Cancer Pathologic Regional Lymph Nodes TNM Finding v8|Intrahepatic Bile Duct Cancer Pathologic Regional Lymph Node Status (pN)|Intrahepatic Bile Duct Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of intrahepatic bile duct cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C13459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13459>	C14073	Protease Domain|Proteolytic Domain	The portion of a proteolytic protein which causes hydrolysis and cleavage of other protein polypeptides.			Amino Acid Sequence	
C1345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1345>	C67439|C443	Pamidronate Disodium|Aminomux|Aredia|GCP-23339A|PAMIDRONATE DISODIUM	The disodium salt of the synthetic bisphosphonate pamidronate. Although its mechanism of action is not completely understood, pamidronate appears to adsorb to calcium phosphate crystals in bone, blocking their dissolution by inhibiting osteoclast-mediated bone resorption. This agent does not inhibit bone mineralization and formation.	Pamidronate Disodium		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C134600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134600>	C134599	Intrahepatic Bile Duct Cancer pNX TNM Finding v8|Intrahepatic Bile Duct Carcinoma pNX TNM Finding v8|pNX	Intrahepatic bile duct cancer in which the regional lymph node(s) cannot be assessed.  (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134601>	C134599	Intrahepatic Bile Duct Cancer pN0 TNM Finding v8|Intrahepatic Bile Duct Carcinoma pN0 TNM Finding v8|pN0	Intrahepatic bile duct cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134603>	C134599	Intrahepatic Bile Duct Cancer pN1 TNM Finding v8|Intrahepatic Bile Duct Carcinoma pN1 TNM Finding v8|pN1	Intrahepatic bile duct cancer with regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134604>	C7927	Intrahepatic Bile Duct Cancer by AJCC v8 Stage|Intrahepatic Bile Duct Cancer Tumor Stage (Pathologic)|Intrahepatic Bile Duct Carcinoma by AJCC v8 Stage	A term that refers to the staging of intrahepatic bile duct cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to intrahepatic cholangiocarcinomas, combined hepatocellular-cholangiocarcinomas (mixed hepatocholangiocarcinomas), and primary neuroendocrine tumors of the liver. Primary sarcomas of the liver, pure hepatocellular carcinomas, hilar cholangiocarcinomas, and gallbladder carcinomas are not staged using this staging system. (from AJCC 8th Ed.)			Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134605>	C25802	LMF1 Gene|LMF1|LMF1|Lipase Maturation Factor 1 Gene	This gene plays a role in protein maturation.			Gene or Genome	
C134607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134607>	C134605	LMF1 wt Allele|C16orf26|Chromosome 16 Open Reading Frame 26 Gene|FLJ12681|FLJ22302|HMFN1876|JFP11|Lipase Maturation Factor 1 wt Allele|TMEM112|TMEM112A	Human LMF1 wild-type allele is located in the vicinity of 16p13.3 and is approximately 128 kb in length. This allele, which encodes lipase maturation factor 1 protein, is involved in the activation of lipoprotein lipase. Mutation of the gene is associated with combined lipase deficiency.			Gene or Genome	
C134608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134608>	C17764	Lipase Maturation Factor 1|LMF1|Transmembrane Protein 112	Lipase maturation factor 1 (567 aa, ~65 kDa) is encoded by the human LMF1 gene. This protein plays a role in the maturation of lipoprotein lipase.			Amino Acid, Peptide, or Protein	
C134609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134609>	C134604	Stage 0 Intrahepatic Bile Duct Cancer AJCC v8|Stage 0 Intrahepatic Bile Duct Cancer|Stage 0 Intrahepatic Bile Duct Carcinoma AJCC v8	Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ (intraductal tumor). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0 Intrahepatic Bile Duct Cancer AJCC v8		Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C13460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13460>	C13296	Proximal Enhancer Element|Proximal Enhancer Elements	Enhancer sequences found nearby to the gene it regulates.			Nucleotide Sequence	
C134610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134610>	C7116|C134604	Stage I Intrahepatic Bile Duct Cancer AJCC v8|Stage I Intrahepatic Bile Duct Cancer|Stage I Intrahepatic Bile Duct Carcinoma AJCC v8	Stage I includes: IA (T1a, N0, M0); IB (T1b, N0, M0). T1a: Solitary tumor equal to or less than 5 cm without vascular invasion.  T1b: Solitary tumor larger than 5 cm without vascular invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Intrahepatic Bile Duct Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134611>	C134610	Stage IA Intrahepatic Bile Duct Cancer AJCC v8|Stage IA Intrahepatic Bile Duct Cancer|Stage IA Intrahepatic Bile Duct Carcinoma AJCC v8	Stage IA includes: T1a, N0, M0. T1a: Solitary tumor equal to or less than 5 cm without vascular invasion.  N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IA Intrahepatic Bile Duct Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134612>	C134610	Stage IB Intrahepatic Bile Duct Cancer AJCC v8|Stage IB Intrahepatic Bile Duct Cancer|Stage IB Intrahepatic Bile Duct Carcinoma AJCC v8	Stage IB includes: T1b, N0, M0. T1b: Solitary tumor larger than 5 cm without vascular invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IB Intrahepatic Bile Duct Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134613>	C26006	HEATR3 Gene|HEAT Repeat Containing 3 Gene|HEATR3|HEATR3	This gene is involved in nuclear import and assembly of ribonucleoproteins.			Gene or Genome	
C134614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134614>	C7117|C134604	Stage II Intrahepatic Bile Duct Cancer AJCC v8|Stage II Intrahepatic Bile Duct Cancer|Stage II Intrahepatic Bile Duct Carcinoma AJCC v8	Stage II includes: T2, N0, M0. T2: Solitary tumor with intrahepatic vascular invasion, or multiple tumors, with or without vascular invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Intrahepatic Bile Duct Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134615>	C7118|C134604	Stage III Intrahepatic Bile Duct Cancer AJCC v8|Stage III Intrahepatic Bile Duct Cancer|Stage III Intrahepatic Bile Duct Carcinoma AJCC v8	Stage III includes: IIIA: (T3, N0, M0); IIIB: (T4, N0, M0); (Any T, N1, M0). T3: Tumor perforating the visceral peritoneum. T4: Tumor involving local extrahepatic structures by direct invasion. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Intrahepatic Bile Duct Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134616>	C134615	Stage IIIA Intrahepatic Bile Duct Cancer AJCC v8|Stage IIIA Intrahepatic Bile Duct Cancer|Stage IIIA Intrahepatic Bile Duct Carcinoma AJCC v8	Stage IIIA includes: T3, N0, M0. T3: Tumor perforating the visceral peritoneum. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIA Intrahepatic Bile Duct Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134617>	C134613	HEATR3 wt Allele|FLJ20718|HEAT Repeat Containing 3 wt Allele|SYO1	Human HEATR3 wild-type allele is located in the vicinity of 16q12.1 and is approximately 40 kb in length. This allele, which encodes HEAT repeat-containing protein 3, plays a role in transporting ribosomal proteins and RNAs into the nucleus.			Gene or Genome	
C134618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134618>	C134615	Stage IIIB Intrahepatic Bile Duct Cancer AJCC v8|Stage IIIB Intrahepatic Bile Duct Cancer|Stage IIIB Intrahepatic Bile Duct Carcinoma AJCC v8	Stage IIIB includes: (T4, N0, M0); (Any T, N1, M0). T4: Tumor involving local extrahepatic structures by direct invasion. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIB Intrahepatic Bile Duct Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134619>	C7121|C134604	Stage IV Intrahepatic Bile Duct Cancer AJCC v8|Stage IV Intrahepatic Bile Duct Cancer|Stage IV Intrahepatic Bile Duct Carcinoma AJCC v8	Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Intrahepatic Bile Duct Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13461>	C13296	Distal Enhancer Elements	Enhancer sequences found at a distance from the gene it regulates.			Nucleotide Sequence	
C134620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134620>	C208191	Mirasol-treated Allogeneic Platelets|Allogeneic MIR PLTs|Allogeneic Mirasol PRT-treated Platelets|Allogeneic Mirasol Platelets	A preparation of allogeneic platelets that have been treated with Mirasol, a proprietary pathogen reduction technology (PRT) system, and can potentially be used to improve symptoms associated with thrombocytopenia. Upon apheresis, platelets are treated with the patented PRT system, which includes treatment of the platelets with riboflavin (vitamin B2) and broad-spectrum ultraviolet (UV) light. The treatment causes irreversible changes to the RNA and DNA of a broad range of pathogens, including viruses, bacteria, parasites and white blood cells (WBCs), which prevents them from replicating and causing disease. After ex vivo treatment and upon transfusion, the Mirasol-treated allogeneic platelets may reduce thrombocytopenia and prevent bleeding. By preventing the replication of contaminating pathogens, Mirasol treatment improves transfusion safety. Inactivation of WBCs may reduce transfusion reactions and immunological complications in patients.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C134621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134621>	C16386	HEAT Repeat-Containing Protein 3|HEATR3|Symportin|Symportin 1|Synchronized Import Protein 1	HEAT repeat-containing protein 3 (680 aa, ~75 kDa) is encoded by the human HEATR3 gene. This protein is involved in nuclear import of RNAs and RNA-binding proteins.			Amino Acid, Peptide, or Protein	
C134622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134622>	C63467	Cisplatin/Methotrexate Regimen|Cisplatin and Methotrexate|Cisplatin-Methotrexate|Cisplatin-Methotrexate Regimen|Cisplatin/Methotrexate|PM	A regimen consisting of cisplatin and methotrexate that can be used for the treatment of bladder cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C134623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134623>	C63502|C203473|C159893|C159454	GNP Regimen|Abraxane-Gemictabine Regimen|Abraxane/Gemcitabine Regimen|GEMCNPAC Regimen|GNP|Gemcitabine and nab-Paclitaxel|Gemcitabine-Albumin-bound Paclitaxel Regimen|Gemcitabine-Nab-paclitaxel Regimen|Gemcitabine/Nab-paclitaxel|Nab-paclitaxel/Gemcitabine	A regimen consisting of gemcitabine and nab-paclitaxel, an albumin-bound formulation of paclitaxel, that can be used for the treatment of ampullary, small bowel and pancreatic adenocarcinomas and biliary tract cancers. A modified version may be used for the treatment of pancreatic adenocarcinoma.	GNP Regimen		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C134624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134624>	C199143	Human Cancer Models Initiative|HCMI|Human Cancer Models Initiative (HCMI)	A collaboration between the National Cancer Institute, Cancer Research UK, the Wellcome Trust Sanger Institute, and the foundation Hubrecht Organoid Technology to generate new models of cancer that more accurately represent human tumors than existing cell line models.			Professional or Occupational Group	
C134625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134625>	C28533	SLC16A8 Gene|SLC16A8|SLC16A8|Solute Carrier Family 16 Member 8 Gene	This gene plays a role in lactate transport in the retina.			Gene or Genome	
C134626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134626>	C134625	SLC16A8 wt Allele|MCT3|REMP|Solute Carrier 16 (Monocarboxylic Acid Transporters), Member 8 Gene|Solute Carrier Family 16 (Monocarboxylate Transporter), Member 8 Gene|Solute Carrier Family 16 Member 8 wt Allele|Solute Carrier Family 16, Member 8 (Monocarboxylic Acid Transporter 3) Gene|Solute Carrier Family 16, Member 8 Gene	Human SLC16A8 wild-type allele is located in the vicinity of 22q13.1 and is approximately 6 kb in length. This allele, which encodes monocarboxylate transporter 3 protein, is involved in the transport of lactate and other monocarboxylates.			Gene or Genome	
C134627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134627>	C16386	Monocarboxylate Transporter 3|MCT 3|SLC16A8|Solute Carrier Family 16 Member 8	Monocarboxylate transporter 3 (504 aa, ~52 kDa) is encoded by the human SLC16A8 gene. This protein plays a role in transmembrane transport of monocarboxylates.			Amino Acid, Peptide, or Protein	
C134628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134628>	C20194	CCDC26 Gene|CCDC26|CCDC26|CCDC26 Long Non-Coding RNA Gene	This gene may be involved in the modulation of cellular responses to retinoic acid.			Gene or Genome	
C134629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134629>	C134628	CCDC26 wt Allele|CCDC26 Long Non-Coding RNA wt Allele|MGC27434|RAM	Human CCDC26 wild-type allele is located in the vicinity of 8q24.21 and is approximately 329 kb in length. This allele, which encodes CCDC26 long non-coding RNA and/or putative coiled-coil domain-containing protein 26, may play a role in the cellular response to retinoic acid.			Gene or Genome	
C13462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13462>	C13296	Upstream Enhancer	An enhancer which is located 5' of the gene it regulates.			Nucleotide Sequence	
C134630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134630>	C18466	Putative Coiled-Coil Domain-Containing Protein 26|CCDC26|Coiled-Coil Domain-Containing Protein 26|Retinoic Acid Modulator	Putative coiled-coil domain-containing protein 26 (109 aa, ~13 kDa) is encoded by the human CCDC26 gene. This protein may play a role in the cellular response to retinoic acid.			Amino Acid, Peptide, or Protein	
C134631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134631>	C88924	CCDC26 Long Non-Coding RNA|CCDC26|CCDC26 LincRNA|CCDC26 LncRNA|CCDC26 Long Noncoding RNA|RAM LincRNA|RAM LncRNA|Retinoic Acid Modulator Long Non-Coding RNA	CCDC26 long non-coding RNA (~1.7 kb) is encoded by the human CCDC26 gene. This long non-coding RNA may be involved in retinoic acid-mediated cellular processes.			Nucleic Acid, Nucleoside, or Nucleotide	
C134632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134632>	C26057	RTEL1 Gene|RTEL1|RTEL1|RTEL1|Regulator of Telomere Elongation Helicase 1 Gene	This gene plays a role in telomere maintenance and the regulation of meiotic crossover recombination.	RTEL1 Gene		Gene or Genome	CCPS Genetics Terminology|Childhood Cancer Predisposition Study Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C134633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134633>	C134632	RTEL1 wt Allele|C20orf41|Chromosome 20 Open Reading Frame 41 Gene|DKCA4|DKCB5|DKFZP434C013|KIAA1088|NHL|PFBMFT3|RTEL|Regulator of Telomere Elongation Helicase 1 wt Allele|bK3184A7.3	Human RTEL1 wild-type allele is located in the vicinity of 20q13.33 and is approximately 38 kb in length. This allele, which encodes regulator of telomere elongation helicase 1 protein, is involved in telomere and chromosome maintenance. Mutation of the gene is associated with telomere-related pulmonary fibrosis and/or bone marrow failure 3 and dyskeratosis congenita types autosomal dominant 4 and autosomal recessive 5.	RTEL1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134634>	C16517	Regulator of Telomere Elongation Helicase 1|EC 3.6.4.12|Novel Helicase-Like|Novel Helicase-Like Protein|RTEL1|Regulator of Telomere Length|Telomere Length Regulator	Regulator of telomere elongation helicase 1 (1219 aa, ~134 kDa) is encoded by the human RTEL1 gene. This protein plays a role in the maintenance of chromosomes and telomeres.	Regulator of Telomere Elongation Helicase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134635>	C134455	Gallbladder Cancer TNM Finding v8|Gallbladder Carcinoma TNM Finding v8	A finding about one or more characteristics of gallbladder cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to gallbladder carcinomas. Well-differentiated neuroendocrine tumors and sarcomas are not staged using this staging system. (from AJCC 8th Ed.)			Finding	
C134636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134636>	C134635	Gallbladder Cancer Clinical TNM Finding v8|Gallbladder Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of gallbladder cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C134637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134637>	C134636	Gallbladder Cancer Clinical Distant Metastasis TNM Finding v8|Gallbladder Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of gallbladder cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C134638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134638>	C134637	Gallbladder Cancer cM0 TNM Finding v8|Gallbladder Carcinoma cM0 TNM Finding v8	Gallbladder cancer without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C134639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134639>	C134637	Gallbladder Cancer cM1 TNM Finding v8|Gallbladder Carcinoma cM1 TNM Finding v8	Gallbladder cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C13463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13463>	C13296	Downstream Enhancer	An enhancer which is located 3' of the gene it regulates.			Nucleotide Sequence	
C134640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134640>	C134635	Gallbladder Cancer Pathologic TNM Finding v8|Gallbladder Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of gallbladder cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C134641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134641>	C134640	Gallbladder Cancer Pathologic Distant Metastasis TNM Finding v8|Gallbladder Carcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of gallbladder cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C134642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134642>	C134641	Gallbladder Cancer pM1 TNM Finding v8|Gallbladder Carcinoma pM1 TNM Finding v8	Gallbladder cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C134643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134643>	C134640	Gallbladder Cancer Pathologic Primary Tumor TNM Finding v8|Gallbladder Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of gallbladder cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C134644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134644>	C134643	Gallbladder Cancer pTX TNM Finding v8|Gallbladder Carcinoma pTX TNM Finding v8	Gallbladder cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C134645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134645>	C134643	Gallbladder Cancer pT0 TNM Finding v8|Gallbladder Carcinoma pT0 TNM Finding v8	Gallbladder cancer with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C134646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134646>	C134643	Gallbladder Cancer pTis TNM Finding v8|Gallbladder Carcinoma pTis TNM Finding v8	Gallbladder cancer with a finding of carcinoma in situ. (from AJCC 8th Ed.)			Finding	
C134647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134647>	C134643	Gallbladder Cancer pT1 TNM Finding v8|Gallbladder Carcinoma pT1 TNM Finding v8	Gallbladder cancer with tumor invading the lamina propria or muscular layer. (from AJCC 8th Ed.)			Finding	
C134648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134648>	C134647	Gallbladder Cancer pT1a TNM Finding v8|Gallbladder Carcinoma pT1a TNM Finding v8	Gallbladder cancer with tumor invading the lamina propria. (from AJCC 8th Ed.)			Finding	
C134649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134649>	C134647	Gallbladder Cancer pT1b TNM Finding v8|Gallbladder Carcinoma pT1b TNM Finding v8	Gallbladder cancer with tumor invading the muscular layer. (from AJCC 8th Ed.)			Finding	
C13464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13464>	C13442	Vaginal and Other Genital	An anatomical qualifier that describes any part of the vagina or female genitalia.			Body Location or Region	
C134650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134650>	C134643	Gallbladder Cancer pT2 TNM Finding v8|Gallbladder Carcinoma pT2 TNM Finding v8	Gallbladder cancer with tumor invading the perimuscular connective tissue on the peritoneal side, without involvement of the serosa (visceral peritoneum); or tumor invading the perimuscular connective tissue on the hepatic side, with no extension into the liver. (from AJCC 8th Ed.)			Finding	
C134651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134651>	C134650	Gallbladder Cancer pT2a TNM Finding v8|Gallbladder Carcinoma pT2a TNM Finding v8	Gallbladder cancer with tumor invading the perimuscular connective tissue on the peritoneal side, without involvement of the serosa (visceral peritoneum). (from AJCC 8th Ed.)			Finding	
C134652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134652>	C134650	Gallbladder Cancer pT2b TNM Finding v8|Gallbladder Carcinoma pT2b TNM Finding v8	Gallbladder cancer with tumor invading the perimuscular connective tissue on the hepatic side, with no extension into the liver. (from AJCC 8th Ed.)			Finding	
C134653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134653>	C134643	Gallbladder Cancer pT3 TNM Finding v8|Gallbladder Carcinoma pT3 TNM Finding v8	Gallbladder cancer with tumor perforating the serosa (visceral peritoneum) and/or directly invading the liver and/or one other adjacent organ or structure, such as the stomach, duodenum, colon, pancreas, omentum, or extrahepatic bile ducts. (from AJCC 8th Ed.)			Finding	
C134654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134654>	C134643	Gallbladder Cancer pT4 TNM Finding v8|Gallbladder Carcinoma pT4 TNM Finding v8	Gallbladder cancer with tumor invading the main portal vein or hepatic artery or invading two or more extrahepatic organs or structures. (from AJCC 8th Ed.)			Finding	
C134655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134655>	C134640	Gallbladder Cancer Pathologic Regional Lymph Nodes TNM Finding v8|Gallbladder Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of gallbladder cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C134656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134656>	C134655	Gallbladder Cancer pNX TNM Finding v8|Gallbladder Carcinoma pNX TNM Finding v8	Gallbladder cancer in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)			Finding	
C134657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134657>	C134655	Gallbladder Cancer pN0 TNM Finding v8|Gallbladder Carcinoma pN0 TNM Finding v8	Gallbladder cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)			Finding	
C134658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134658>	C134655	Gallbladder Cancer pN1 TNM Finding v8|Gallbladder Carcinoma pN1 TNM Finding v8	Gallbladder cancer with metastases to one to three regional lymph nodes. (from AJCC 8th Ed.)			Finding	
C134659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134659>	C134655	Gallbladder Cancer pN2 TNM Finding v8|Gallbladder Carcinoma pN2 TNM Finding v8	Gallbladder cancer with metastases to four or more regional lymph nodes. (from AJCC 8th Ed.)			Finding	
C13465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13465>	C13722	Bronchial Secretion				Body Substance	
C134660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134660>	C3844	Gallbladder Cancer by AJCC v8 Stage|Gallbladder Carcinoma by AJCC v8 Stage	A term that refers to the staging of gallbladder cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to gallbladder carcinomas. Well-differentiated neuroendocrine tumors and sarcomas are not staged using this staging system. (from AJCC 8th Ed.)			Neoplastic Process	
C134661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134661>	C25942	POLR3K Gene|POLR3K|POLR3K|RNA Polymerase III Subunit K Gene	This gene is involved in the transcription of DNA into small RNAs.			Gene or Genome	
C134662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134662>	C134661	POLR3K wt Allele|C11|C11-RNP3|My010|Polymerase (RNA) III (DNA Directed) Polypeptide K, 12.3 kDa Gene|Polymerase (RNA) III Subunit K Gene|Polymerase III, RNA, Subunit K Gene|RNA Polymerase III Subunit K wt Allele|RNA Polymerase III, 12.3-kD Subunit Gene|RPC10|RPC11|RPC11, S. cerevisiae, Homolog of Gene|RPC12.5	Human POLR3K wild-type allele is located in the vicinity of 16p13.3 and is approximately 7 kb in length. This allele, which encodes DNA-directed RNA polymerase III subunit RPC10 protein, plays a role in the synthesis of small RNAs and in immunity.			Gene or Genome	
C134663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134663>	C134660	Stage 0 Gallbladder Cancer AJCC v8|Stage 0 Gallbladder Cancer|Stage 0 Gallbladder Carcinoma AJCC v8	Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0 Gallbladder Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134665>	C134660	Stage I Gallbladder Cancer AJCC v8|Stage I Gallbladder Cancer|Stage I Gallbladder Carcinoma AJCC v8	Stage I includes: T1, N0, M0. T1: Tumor invading the lamina propria or muscular layer. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Gallbladder Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134667>	C134660	Stage II Gallbladder Cancer AJCC v8|Stage II Gallbladder Cancer|Stage II Gallbladder Carcinoma AJCC v8	Stage II includes: IIA: T2a, N0, M0; IIB: T2b, N0, M0. T2a: Tumor invading the perimuscular connective tissue on the peritoneal side, without involvement of the serosa (visceral peritoneum). T2b: Tumor invading the perimuscular connective tissue on the hepatic side, with no extension into the liver. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Gallbladder Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134668>	C17104	DNA-Directed RNA Polymerase III Subunit RPC10|DNA-Directed RNA Polymerase III Subunit K|DNA-Directed RNA Polymerases III 12.5 kDa Polypeptide|HsC11p|POLR3K|RNA Polymerase III 12.5 kDa Subunit|RNA Polymerase III Subunit C10|RNA Polymerase III Subunit C11|RNA Polymerase III Subunit CII|RPC11|RPC12.5|hRPC11	DNA-directed RNA polymerase III subunit RPC10 (108 aa, ~12 kDa) is encoded by the human POLR3K gene. This protein is involved in innate immunity and small RNA synthesis.			Amino Acid, Peptide, or Protein|Enzyme	
C13466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13466>	C13432	20q13	A chromosome band present on 20q	20q13		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134670>	C134667	Stage IIA Gallbladder Cancer AJCC v8|Stage IIA Gallbladder Cancer|Stage IIA Gallbladder Carcinoma AJCC v8	Stage IIA includes: T2a, N0, M0. T2a: Tumor invading the perimuscular connective tissue on the peritoneal side, without involvement of the serosa (visceral peritoneum). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIA Gallbladder Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134671>	C134667	Stage IIB Gallbladder Cancer AJCC v8|Stage IIB Gallbladder Cancer|Stage IIB Gallbladder Carcinoma AJCC v8	Stage IIB includes: T2b, N0, M0. T2b: Tumor invading the perimuscular connective tissue on the hepatic side, with no extension into the liver. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIB Gallbladder Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134672>	C134660	Stage III Gallbladder Cancer AJCC v8|Stage III Gallbladder Cancer|Stage III Gallbladder Carcinoma AJCC v8	Stage III includes: IIIA: (T3, N0, M0); IIIB: (T1-3, N1, M0). T1: Tumor invading the lamina propria or muscular layer. T2: Tumor invading the perimuscular connective tissue on the peritoneal side, without involvement of the serosa (visceral peritoneum); or tumor invading the perimuscular connective tissue on the hepatic side, with no extension into the liver. T3: Tumor perforating the serosa (visceral peritoneum) and/or directly invading the liver and/or one other adjacent organ or structure, such as the stomach, duodenum, colon, pancreas, omentum, or extrahepatic bile ducts. N0: No regional lymph node metastasis. N1: Metastases to one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Gallbladder Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134673>	C134672	Stage IIIA Gallbladder Cancer AJCC v8|Stage IIIA Gallbladder Cancer|Stage IIIA Gallbladder Carcinoma AJCC v8	Stage IIIA includes: T3, N0, M0. T3: Tumor perforating the serosa (visceral peritoneum) and/or directly invading the liver and/or one other adjacent organ or structure, such as the stomach, duodenum, colon, pancreas, omentum, or extrahepatic bile ducts. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIA Gallbladder Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134674>	C134672	Stage IIIB Gallbladder Cancer AJCC v8|Stage IIIB Gallbladder Cancer|Stage IIIB Gallbladder Carcinoma AJCC v8	Stage IIIB includes: T1-3, N1, M0. T1: Tumor invading the lamina propria or muscular layer. T2: Tumor invading the perimuscular connective tissue on the peritoneal side, without involvement of the serosa (visceral peritoneum); or tumor invading the perimuscular connective tissue on the hepatic side, with no extension into the liver. T3: Tumor perforating the serosa (visceral peritoneum) and/or directly invading the liver and/or one other adjacent organ or structure, such as the stomach, duodenum, colon, pancreas, omentum, or extrahepatic bile ducts. N1: Metastases to one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIB Gallbladder Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134675>	C134660	Stage IV Gallbladder Cancer AJCC v8|Stage IV Gallbladder Cancer|Stage IV Gallbladder Carcinoma AJCC v8	Stage IV includes: IVA: T4, N0-1, M0; IVB: (Any T, N2, M0); (Any T, Any N, M1). T4: Tumor invading the main portal vein or hepatic artery or invading two or more extrahepatic organs or structures. N0: No regional lymph node metastasis. N1: Metastases to one to three regional lymph nodes. N2: Metastases to four or more regional lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Gallbladder Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134676>	C134675	Stage IVA Gallbladder Cancer AJCC v8|Stage IVA Gallbladder Cancer|Stage IVA Gallbladder Carcinoma AJCC v8	Stage IVA includes: T4, N0-1, M0. T4: Tumor invading the main portal vein or hepatic artery or invading two or more extrahepatic organs or structures. N0: No regional lymph node metastasis. N1: Metastases to one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Stage IVA Gallbladder Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134678>	C134675	Stage IVB Gallbladder Cancer AJCC v8|Stage IVB Gallbladder Cancer|Stage IVB Gallbladder Carcinoma AJCC v8	Stage IVB includes: (Any T, N2, M0); (Any T, Any N, M1). N2: Metastases to four or more regional lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)	Stage IVB Gallbladder Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134679>	C21295	SNRNP25 Gene|SNRNP25|SNRNP25|Small Nuclear Ribonucleoprotein U11/U12 Subunit 25 Gene	This gene plays a role in pre-mRNA processing.			Gene or Genome	
C13467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13467>	C13432	9q34.1	A chromosome band present on 9q			Gene or Genome	
C134680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134680>	C134679	SNRNP25 wt Allele|C16orf33|Chromosome 16 Open Reading Frame 33 Gene|Small Nuclear Ribonucleoprotein 25kDa (U11/U12) Gene|Small Nuclear Ribonucleoprotein U11/U12 Subunit 25 wt Allele|U11/U12 25kDa Subunit Gene	Human SNRNP25 wild-type allele is located in the vicinity of 16p13.3 and is approximately 5 kb in length. This allele, which encodes U11/U12 small nuclear ribonucleoprotein 25 kDa protein, is involved in mRNA processing.			Gene or Genome	
C134681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134681>	C21298	U11/U12 Small Nuclear Ribonucleoprotein 25 kDa Protein|Minus-99 Protein|SNRNP25|U11/U12 SnRNP 25 kDa Protein|U11/U12 SnRNP 25K|U11/U12-25K	U11/U12 small nuclear ribonucleoprotein 25 kDa protein (132 aa, ~15 kDa) is encoded by the human SNRNP25 gene. This protein plays a role in the removal of U2- and U12-type introns from pre-mRNAs.			Amino Acid, Peptide, or Protein	
C134682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134682>	C25997	PICK1 Gene|PICK1|PICK1|Protein Interacting with PRKCA 1 Gene	This gene is involved in the regulation of receptor signaling, localization and internalization.			Gene or Genome	
C134683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134683>	C134682	PICK1 wt Allele|MGC15204|PICK|PRKCABP|Protein Interacting with PRKCA 1 wt Allele|Protein Kinase C, Alpha Binding Protein Gene|dJ1039K5	Human PICK1 wild-type allele is located in the vicinity of 22q13.1 and is approximately 19 kb in length. This allele, which encodes PRKCA-binding protein, plays a role in the trafficking and internalization of signaling receptors.			Gene or Genome	
C134684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134684>	C26231	PRKCA-Binding Protein|PICK1|Protein Interacting with C Kinase 1|Protein Interacting with PRKCA|Protein Kinase C-Alpha-Binding Protein	PRKCA-binding protein (415 aa, ~47 kDa) is encoded by the human PICK1 gene. This protein is involved in the modulation of receptor signaling, localization and internalization.			Amino Acid, Peptide, or Protein	
C134685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134685>	C26110	PRMT1 Gene|PRMT1|PRMT1|Protein Arginine Methyltransferase 1 Gene	This gene plays a role in the regulation of transcription via the methylation of histones and chromatin.	PRMT1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C134686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134686>	C134685	PRMT1 wt Allele|ANM1|HCP1|HMT1 (HnRNP Methyltransferase, S. cerevisiae)-Like 2 Gene|HMT1 HnRNP Methyltransferase-Like 2 (S. cerevisiae) Gene|HMT1-Like 2|HRMT1L2|IR1B4|Protein Arginine Methyltransferase 1 wt Allele	Human PRMT1 wild-type allele is located in the vicinity of 19q13.33 and is approximately 13 kb in length. This allele, which encodes protein arginine N-methyltransferase 1 protein, is involved in the methylation of histone H4 and chromatin.	PRMT1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134687>	C16849	Protein Arginine N-Methyltransferase 1|EC 2.1.1.319|Heterogeneous Nuclear Ribonucleoprotein Methyltransferase 1-Like 2|Histone-Arginine N-Methyltransferase PRMT1|Interferon Receptor 1-Bound Protein 4|PRMT1	Protein arginine N-methyltransferase 1 (361 aa, ~42 kDa) is encoded by the human PRMT1 gene. This protein plays a role in the methylation of the guanidino nitrogens of arginyl residues in substrate proteins.	Protein Arginine N-Methyltransferase 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134688>	C20923	OR51B4 Gene|OR51B4|OR51B4|Olfactory Receptor Family 51 Subfamily B Member 4 Gene	This gene is involved in the perception of a smell.			Gene or Genome	
C134689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134689>	C134688	OR51B4 wt Allele|HOR5'Beta1|HOR5Beta1|Olfactory Receptor Family 51 Subfamily B Member 4 wt Allele|Olfactory Receptor, Family 51, Subfamily B, Member 4 Gene	Human OR51B4 wild-type allele is located in the vicinity of 11p15.4 and is approximately 1 kb in length. This allele, which encodes olfactory receptor 51B4 protein, plays a role in olfaction.			Gene or Genome	
C13468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13468>	C13432	1q24-q25	A chromosome band present on 1q			Gene or Genome	
C134690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134690>	C18239	Olfactory Receptor 51B4|OR51B4|Odorant Receptor HOR5'beta1|Odorant Receptor HOR5beta1	Olfactory receptor 51B4 (310 aa, ~35 kDa) is encoded by the human OR51B4 gene. This protein is involved in G protein-coupled receptor-mediated signaling following exposure to odorant molecules.			Amino Acid, Peptide, or Protein|Receptor	
C134691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134691>	C20745	MYO1E Gene|MYO1E|MYO1E|Myosin IE Gene	This gene plays a role in lipid localization and vesicular transport.			Gene or Genome	
C134692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134692>	C134691	MYO1E wt Allele|FSGS6|HuncM-IC|MGC104638|MYO1C|Myosin IC Gene|Myosin IE wt Allele	Human MYO1E wild-type allele is located in the vicinity of 15q22.2 and is approximately 240 kb in length. This allele, which encodes unconventional myosin-Ie protein, is involved in the transport of lipids and cytoplasmic vesicles. Mutation of the gene is associated with focal segmental glomerulosclerosis type 6.			Gene or Genome	
C134693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134693>	C16492	Unconventional Myosin-Ie|MYO1E|Myosin-Ic|Unconventional Myosin 1E	Unconventional myosin-Ie (1108 aa, ~127 kDa) is encoded by the human MYO1E gene. This protein plays a role in the intracellular movement of lipids and vesicles.			Amino Acid, Peptide, or Protein	
C134694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134694>	C25784	RAN Gene|RAN|RAN|RAN, Member RAS Oncogene Family Gene	This gene is involved in nucleocytoplasmic transport.			Gene or Genome	
C134695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134695>	C134694	RAN wt Allele|ARA24|Gsp1|OK/SW-cl.81|RAN, Member RAS Oncogene Family wt Allele|TC4	Human RAN wild-type allele is located in the vicinity of 12q24.33 and is approximately 6 kb in length. This allele, which encodes GTP-binding nuclear protein Ran, plays a role in nuclear import and export of proteins and RNAs.			Gene or Genome	
C134696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134696>	C18277	GTP-Binding Nuclear Protein Ran|Androgen Receptor-Associated Protein 24|GTPase Ran|Guanosine Triphosphatase Ran|RAN|Ras-Like Protein TC4|Ras-Related Nuclear Protein	GTP-binding nuclear protein Ran (216 aa, ~24 kDa) is encoded by the human RAN gene. This protein is involved in nucleocytoplasmic transport of proteins and RNAs.			Amino Acid, Peptide, or Protein|Enzyme	
C134697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134697>	C214993	Praluzatamab Ravtansine|ADC CX-2009|Anti-CD166-DM4 CX-2009|CX-2009|PDC CX-2009|PRALUZATAMAB RAVTANSINE	A probody drug conjugate (PDC) composed of a recombinant antibody targeting the tumor-associated antigen (TAA) CD166, which is masked by a cleavable masking peptide, and conjugated to the cytotoxic agent maytansinoid DM4, with potential antineoplastic activity. Upon administration of praluzatamab ravtansine and migration to the tumor microenvironment (TME), the cleavable masking peptide, which prevent anti-CD166 antibody binding to the CD166 expressed on both normal cells and tumor cells, is proteolytically cleaved by tumor-associated proteases that are specifically present in the TME. This enables the anti-CD166 antibody moiety of CX-2009 to selectively bind to, be internalized by, and deliver DM4 into CD166-expressing tumor cells. Following internalization, DM4 is released, binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of CD166-expressing tumor cells. The masking peptide prevents binding of the anti-CD166 antibody to CD166 in normal tissues, thereby minimizing toxicities.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C134698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134698>	C25872	MELK Gene|MELK|MELK|Maternal Embryonic Leucine Zipper Kinase Gene	This gene plays a role in cell cycle regulation, stem cell renewal, apoptosis, splicing regulation and the proliferation of neural progenitors.			Gene or Genome	
C134699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134699>	C134698	MELK wt Allele|HPK38|Maternal Embryonic Leucine Zipper Kinase wt Allele	Human MELK wild-type allele is located in the vicinity of 9p13.2 and is approximately 105 kb in length. This allele, which encodes maternal embryonic leucine zipper kinase, is involved in protein phosphorylation. Mutation of the gene may be associated with neoplastic diseases.			Gene or Genome	
C13469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13469>	C13432	14q32.3	A chromosome band present on 14q			Gene or Genome	
C1346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1346>	C1590	Asaley|Asalex|Asalex|Ethyl ester of N-acetyl-DL-sarcolysyl-L-leucine|L-Leucine, N-[N-acetyl-4-[bis(2-chloroethyl)amino]-DL-phenylalanyl]-, ethyl ester (9CI)|L-Leucine, N-[N-acetyl-4-[bis-(2-chloroethyl)amino]-DL-phenylalanyl]-, ethylester|L-leucine, N-[N-acetyl-4-[bis(2-chloroethyl)amino]-DL-phenylalanyl]-, ethyl ester (9CI)|L-leucine, N-[N-acetyl-4-[bis-(2-chloroethyl)amino]-DL-phenylalanyl]-, ethylester|Leucine, N-[N-acetyl-3-[p-[bis(2-chloroethyl)amino]phenyl]-DL-alanyl]-, ethyl ester, L- (8CI)|ethyl ester of N-acetyl-DL-sarcolysyl-L-leucine|leucine, N-[N-acetyl-3-[p-[bis(2-chloroethyl)amino]phenyl]-DL-alanyl]-, ethyl ester, L- (8CI)	An L-leucine derivative of melphalan with antineoplastic activity. Asaley alkylates and crosslinks DNA, resulting in disruption of DNA synthesis. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C134700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134700>	C18152	Maternal Embryonic Leucine Zipper Kinase|Protein Kinase Eg3|Protein Kinase PK38|Tyrosine-Protein Kinase MELK|hMELK|hPK38|pEg3 Kinase	Maternal embryonic leucine zipper kinase (651 aa, ~75 kDa) is encoded by the human MELK gene. This protein plays a role in the mediation of protein phosphorylation that regulates cell cycle, cell death and cell proliferation.			Amino Acid, Peptide, or Protein|Enzyme	
C134701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134701>	C177692	CD2 Positive|CD2 Molecule Positive|LFA-2 Positive|T11 Positive	An indication that CD2 expression has been detected in a sample.	CD2 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134702>	C63358	Capecitabine/Methotrexate/Vinorelbine Regimen|Capecitabine-Methotrexate-Vinorelbine Regimen|Capecitabine/Methotrexate/Vinorelbine Tartrate Regimen|Xeloda-Methotrexate-Navelbine Regimen|Xeloda/Methotrexate/Navelbine Regimen	A regimen composed of capecitabine, methotrexate and vinorelbine that can potentially be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|NCI Drug Dictionary Terminology|Pharmacotherapy Regimens
C134703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134703>	C80699	MIR506 Gene|MIR506|MIR506|MicroRNA 506 Gene	This gene may be involved in RNA silencing.			Gene or Genome	
C134704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134704>	C134703	MIR506 wt Allele|MIRN506|Micro RNA 506 Gene|MicroRNA 506 wt Allele|hsa-mir-506|miRNA506|mir-506	Human MIR506 wild-type allele is located in the vicinity of Xq27.3 and is 124 bp in length. This allele, which encodes MIR506 pre-miRNA, may play a role in the regulation of gene expression.			Gene or Genome	
C134705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134705>	C25968	MIR506 Pre-miRNA	MIR506 pre-miRNA (124 bases) is encoded by the human MIR506 gene. This oligoribonucleotide may be involved in the post-transcriptional regulation of gene expression.			Nucleic Acid, Nucleoside, or Nucleotide	
C134706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134706>	C54362	USF3 Gene|USF3|USF3|Upstream Transcription Factor Family Member 3 Gene	This gene may play a role in gene transcription or glycan metabolism.			Gene or Genome	
C134707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134707>	C134706	USF3 wt Allele|KIAA2018|Upstream Transcription Factor Family Member 3 wt Allele|Upstream Transcription Factor Family, Member 3 Gene	Human USF3 wild-type allele is located in the vicinity of 3q13.2 and is approximately 48 kb in length. This allele, which encodes basic helix-loop-helix domain-containing protein USF3, may be involved in transcription regulation.			Gene or Genome	
C134708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134708>	C26199	Basic Helix-Loop-Helix Domain-Containing Protein USF3|USF3|Upstream Transcription Factor 3	Basic helix-loop-helix domain-containing protein USF3 (2245 aa, ~242 kDa) is encoded by the human USF3 gene. This protein may play a role in the regulation of gene transcription.			Amino Acid, Peptide, or Protein	
C134709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134709>	C20194	MLKL Gene|MLKL|MLKL|Mixed Lineage Kinase Domain Like Pseudokinase Gene	This gene is involved in cell death activation.	MLKL Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C13470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13470>	C13432	Xp11.2-p11.4	A chromosome band present on Xp			Gene or Genome	
C134710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134710>	C134709	MLKL wt Allele|FLJ34389|Mixed Lineage Kinase Domain Like Pseudokinase wt Allele|hMLKL	Human MLKL wild-type allele is located in the vicinity of 16q23.1 and is approximately 29 kb in length. This allele, which encodes mixed lineage kinase domain-like protein, plays a role in the promotion of cellular necrosis.	MLKL wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134711>	C18466	Mixed Lineage Kinase Domain-Like Protein|MLKL|Mixed Lineage Kinase Domain Like|Mixed Lineage Kinase Domain-Like|hMLKL	Mixed lineage kinase domain-like protein (471 aa, ~54 kDa) is encoded by the human MLKL gene. This protein is involved in tumor necrosis factor-dependent necroptosis.	Mixed Lineage Kinase Domain-Like Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134712>	C134455	Perihilar Bile Duct Cancer TNM Finding v8|Hilar Cholangiocarcinoma TNM Finding v8|Perihilar Cholangiocarcinoma TNM Finding v8	A finding about one or more characteristics of perihilar bile duct cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to perihilar cholangiocarcinomas. Well-differentiated neuroendocrine tumors and sarcomas are not staged using this staging system. (from AJCC 8th Ed.)			Finding	
C134714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134714>	C134712	Perihilar Bile Duct Cancer Clinical TNM Finding v8|Hilar Cholangiocarcinoma Clinical TNM Finding v8|Perihilar Cholangiocarcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of perihilar bile duct cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C134715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134715>	C134714	Perihilar Bile Duct Cancer Clinical Distant Metastasis TNM Finding v8|Hilar Cholangiocarcinoma Clinical Distant Metastasis TNM Finding v8|Perihilar Bile Duct Cancer Clinical Distant Metastasis (cM)|Perihilar Cholangiocarcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of perihilar bile duct cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134716>	C134715	Perihilar Bile Duct Cancer cM0 TNM Finding v8|Hilar Cholangiocarcinoma cM0 TNM Finding v8|Perihilar Cholangiocarcinoma cM0 TNM Finding v8	Perihilar bile duct cancer without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C134717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134717>	C134715	Perihilar Bile Duct Cancer cM1 TNM Finding v8|Hilar Cholangiocarcinoma cM1 TNM Finding v8|Perihilar Cholangiocarcinoma cM1 TNM Finding v8|cM1	Perihilar bile duct cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134718>	C134712	Perihilar Bile Duct Cancer Pathologic TNM Finding v8|Hilar Cholangiocarcinoma Pathologic TNM Finding v8|Perihilar Cholangiocarcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of perihilar bile duct cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C134719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134719>	C134718	Perihilar Bile Duct Cancer Pathologic Distant Metastasis TNM Finding v8|Hilar Cholangiocarcinoma Pathologic Distant Metastasis TNM Finding v8|Perihilar Bile Duct Cancer Pathologic Distant Metastasis (pM)|Perihilar Cholangiocarcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of perihilar bile duct cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C13471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13471>	C13432	3p21.3	A chromosome band present on 3p			Gene or Genome	
C134720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134720>	C134719	Perihilar Bile Duct Cancer pM1 TNM Finding v8|Hilar Cholangiocarcinoma pM1 TNM Finding v8|Perihilar Cholangiocarcinoma pM1 TNM Finding v8|pM1	Perihilar bile duct cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134721>	C134718	Perihilar Bile Duct Cancer Pathologic Primary Tumor TNM Finding v8|Hilar Cholangiocarcinoma Pathologic Primary Tumor TNM Finding v8|Perihilar Bile Duct Cancer Pathologic Primary Tumor Status (pT)|Perihilar Cholangiocarcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of perihilar bile duct cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134722>	C134721	Perihilar Bile Duct Cancer pTX TNM Finding v8|Hilar Cholangiocarcinoma pTX TNM Finding v8|Perihilar Cholangiocarcinoma pTX TNM Finding v8|pTX	Perihilar bile duct cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134723>	C134721	Perihilar Bile Duct Cancer pT0 TNM Finding v8|Hilar Cholangiocarcinoma pT0 TNM Finding v8|Perihilar Cholangiocarcinoma pT0 TNM Finding v8|pT0	Perihilar bile duct cancer with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134724>	C134721	Perihilar Bile Duct Cancer pTis TNM Finding v8|Hilar Cholangiocarcinoma pTis TNM Finding v8|Perihilar Cholangiocarcinoma pTis TNM Finding v8|pTis	Perihilar bile duct cancer with a finding of carcinoma in situ/high grade dysplasia. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134725>	C134721	Perihilar Bile Duct Cancer pT1 TNM Finding v8|Hilar Cholangiocarcinoma pT1 TNM Finding v8|Perihilar Cholangiocarcinoma pT1 TNM Finding v8|pT1	Perihilar bile duct cancer with tumor confined to the bile duct, with extension up to the muscle layer or fibrous tissue. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134726>	C134721	Perihilar Bile Duct Cancer pT2 TNM Finding v8|Hilar Cholangiocarcinoma pT2 TNM Finding v8|Perihilar Cholangiocarcinoma pT2 TNM Finding v8|pT2	Perihilar bile duct cancer with tumor invading beyond the wall of the bile duct to surrounding adipose tissue, or tumor invading adjacent hepatic parenchyma. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134727>	C134726	Perihilar Bile Duct Cancer pT2a TNM Finding v8|Hilar Cholangiocarcinoma pT2a TNM Finding v8|Perihilar Cholangiocarcinoma pT2a TNM Finding v8|pT2a	Perihilar bile duct cancer with tumor invading beyond the wall of the bile duct to surrounding adipose tissue. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134728>	C134726	Perihilar Bile Duct Cancer pT2b TNM Finding v8|Hilar Cholangiocarcinoma pT2b TNM Finding v8|Perihilar Cholangiocarcinoma pT2b TNM Finding v8|pT2b	Perihilar bile duct cancer with tumor invading adjacent hepatic parenchyma. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134729>	C134721	Perihilar Bile Duct Cancer pT3 TNM Finding v8|Hilar Cholangiocarcinoma pT3 TNM Finding v8|Perihilar Cholangiocarcinoma pT3 TNM Finding v8|pT3	Perihilar bile duct cancer with tumor invading unilateral branches of the portal vein or hepatic artery. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C13472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13472>	C13432	2pter-p12	A chromosome band present on 2p			Gene or Genome	
C134730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134730>	C134721	Perihilar Bile Duct Cancer pT4 TNM Finding v8|Hilar Cholangiocarcinoma pT4 TNM Finding v8|Perihilar Cholangiocarcinoma pT4 TNM Finding v8|pT4	Perihilar bile duct cancer with tumor invading the main portal vein or its branches bilaterally, or the common hepatic artery; or unilateral second-order biliary radicals with contralateral portal vein or hepatic artery involvement. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134731>	C134718	Perihilar Bile Duct Cancer Pathologic Regional Lymph Nodes TNM Finding v8|Hilar Cholangiocarcinoma Pathologic Regional Lymph Nodes TNM Finding v8|Perihilar Bile Duct Cancer Pathologic Regional Lymph Node Status (pN) TNM Finding v8|Perihilar Cholangiocarcinoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of perihilar bile duct cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134732>	C134731	Perihilar Bile Duct Cancer pNX TNM Finding v8|Hilar Cholangiocarcinoma pNX TNM Finding v8|Perihilar Cholangiocarcinoma pNX TNM Finding v8|pNX	Perihilar bile duct cancer in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134733>	C134731	Perihilar Bile Duct Cancer pN0 TNM Finding v8|Hilar Cholangiocarcinoma pN0 TNM Finding v8|Perihilar Cholangiocarcinoma pN0 TNM Finding v8|pN0	Perihilar bile duct cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134734>	C134731	Perihilar Bile Duct Cancer pN1 TNM Finding v8|Hilar Cholangiocarcinoma pN1 TNM Finding v8|Perihilar Cholangiocarcinoma pN1 TNM Finding v8|pN1	Perihilar bile duct cancer with one to three positive lymph nodes typically involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134735>	C134731	Perihilar Bile Duct Cancer pN2 TNM Finding v8|Hilar Cholangiocarcinoma pN2 TNM Finding v8|Perihilar Cholangiocarcinoma pN2 TNM Finding v8|pN2	Perihilar bile duct cancer with four or more positive lymph nodes involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134736>	C174459	Bismuth-Corlette Hilar Cholangiocarcinoma Classification|Bismuth-Corlette Perihilar Cholangiocarcinoma Classification	A classification system of hilar cholangiocarcinoma that describes the location and extent of biliary infiltration by tumor. (AJCC 8th ed.)			Classification	
C134737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134737>	C134736	Type I Bismuth-Corlette Hilar Cholangiocarcinoma|Type I Bismuth-Corlette Perihilar Cholangiocarcinoma	Tumor is limited to the common hepatic duct, below the level of the confluence of the right and left hepatic ducts. (AJCC 8th ed.)			Classification	
C134738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134738>	C134736	Type II Bismuth-Corlette Hilar Cholangiocarcinoma|Type II Bismuth-Corlette Perihilar Cholangiocarcinoma	Tumor involves the confluence of the right and left hepatic ducts. (AJCC 8th ed.)			Classification	
C134739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134739>	C134736	Type IIIa Bismuth-Corlette Hilar Cholangiocarcinoma|Type IIIa Bismuth-Corlette Perihilar Cholangiocarcinoma	Tumor with type II involvement plus extension to the right 2nd-order ducts. (AJCC 8th ed.)			Classification	
C13473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13473>	C13432	1p21-p13	A chromosome band present on 1p			Gene or Genome	
C134740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134740>	C134736	Type IIIb Bismuth-Corlette Hilar Cholangiocarcinoma|Type IIIb Bismuth-Corlette Perihilar Cholangiocarcinoma	Tumor with type II involvement plus extension to the left 2nd-order ducts. (AJCC 8th ed.)			Classification	
C134741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134741>	C134736	Type IV Bismuth-Corlette Hilar Cholangiocarcinoma|Type IV Bismuth-Corlette Perihilar Cholangiocarcinoma	Tumor extends into both right and left 2nd-order ducts. (AJCC 8th ed.)			Classification	
C134742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134742>	C36077	Hilar Cholangiocarcinoma by AJCC v7 Stage|Perihilar Cholangiocarcinoma by AJCC v7 Stage	A term that refers to the staging of hilar cholangiocarcinoma according to the American Joint Committee on Cancer, 7th edition.			Neoplastic Process	
C134743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134743>	C36077	Hilar Cholangiocarcinoma by AJCC v8 Stage|Hilar Cholangiocarcinoma Tumor Stage (Pathologic)|Perihilar Cholangiocarcinoma by AJCC v8 Stage	A term that refers to the staging of hilar cholangiocarcinoma according to the American Joint Committee on Cancer, 8th edition. Hilar well-differentiated neuroendocrine tumors and sarcomas are not staged using this staging system. (from AJCC 8th Ed.)			Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134744>	C134743	Stage 0 Hilar Cholangiocarcinoma AJCC v8|0|Stage 0 Hilar Cholangiocarcinoma|Stage 0 Perihilar Cholangiocarcinoma AJCC v8	Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ/high grade dysplasia. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0 Hilar Cholangiocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134745>	C134743	Stage I Hilar Cholangiocarcinoma AJCC v8|I|Stage I Hilar Cholangiocarcinoma|Stage I Perihilar Cholangiocarcinoma AJCC v8	Stage I includes: T1, N0, M0. T1: Tumor confined to the bile duct, with extension up to the muscle layer or fibrous tissue. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Hilar Cholangiocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134746>	C134743	Stage II Hilar Cholangiocarcinoma AJCC v8|II|Stage II Hilar Cholangiocarcinoma|Stage II Perihilar Cholangiocarcinoma AJCC v8	Stage II includes: T2a-b, N0, M0. T2a: Tumor invading beyond the wall of the bile duct to surrounding adipose tissue. T2b: Tumor invading adjacent hepatic parenchyma. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Hilar Cholangiocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134747>	C134743	Stage III Hilar Cholangiocarcinoma AJCC v8|III|Stage III Hilar Cholangiocarcinoma|Stage III Perihilar Cholangiocarcinoma AJCC v8	Stage III includes: IIIA: (T3, N0, M0); IIIB: (T4, N0, M0); IIIC: (Any T, N1, M0). T3: Tumor invading unilateral branches of the portal vein or hepatic artery. T4: Tumor invading the main portal vein or its branches bilaterally, or the common hepatic artery; or unilateral second-order biliary radicals with contralateral portal vein or hepatic artery involvement. N0: No regional lymph node metastasis. N1: One to three positive lymph nodes typically involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Hilar Cholangiocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134748>	C134747	Stage IIIA Hilar Cholangiocarcinoma AJCC v8|IIIA|Stage IIIA Hilar Cholangiocarcinoma|Stage IIIA Perihilar Cholangiocarcinoma AJCC v8	Stage IIIA includes: T3, N0, M0. T3: Tumor invading unilateral branches of the portal vein or hepatic artery. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIA Hilar Cholangiocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134749>	C134747	Stage IIIB Hilar Cholangiocarcinoma AJCC v8|IIIB|Stage IIIB Hilar Cholangiocarcinoma|Stage IIIB Perihilar Cholangiocarcinoma AJCC v8	Stage IIIB includes: T4, N0, M0. T4: Tumor invading the main portal vein or its branches bilaterally, or the common hepatic artery; or unilateral second-order biliary radicals with contralateral portal vein or hepatic artery involvement. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIB Hilar Cholangiocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C13474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13474>	C13432	19q13.1	A chromosome band present on 19q			Gene or Genome	
C134750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134750>	C134747	Stage IIIC Hilar Cholangiocarcinoma AJCC v8|IIIC|Stage IIIC Hilar Cholangiocarcinoma|Stage IIIC Perihilar Cholangiocarcinoma AJCC v8	Stage IIIC includes: Any T, N1, M0. N1: One to three positive lymph nodes typically involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIC Hilar Cholangiocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134751>	C134743	Stage IV Hilar Cholangiocarcinoma AJCC v8|IV|Stage IV Hilar Cholangiocarcinoma|Stage IV Perihilar Cholangiocarcinoma AJCC v8	Stage IV includes: IVA: (Any T, N2, M0); IVB: (Any T, Any N, M1). N2: Four or more positive lymph nodes involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Hilar Cholangiocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134752>	C134751	Stage IVA Hilar Cholangiocarcinoma AJCC v8|IVA|Stage IVA Hilar Cholangiocarcinoma|Stage IVA Perihilar Cholangiocarcinoma AJCC v8	Stage IVA includes: Any T, N2, M0. N2: Four or more positive lymph nodes involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Stage IVA Hilar Cholangiocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134753>	C134751	Stage IVB Hilar Cholangiocarcinoma AJCC v8|IVB|Stage IVB Hilar Cholangiocarcinoma|Stage IVB Perihilar Cholangiocarcinoma AJCC v8	Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)	Stage IVB Hilar Cholangiocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134755>	C35417|C134604	Intrahepatic Cholangiocarcinoma by AJCC v8 Stage	A term that refers to the staging of intrahepatic cholangiocarcinoma according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C134756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134756>	C134755|C134609	Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8|0|Stage 0 Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)	Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ (intraductal tumor). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134757>	C134755|C134610	Stage I Intrahepatic Cholangiocarcinoma AJCC v8|I|Stage I Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)	Stage I includes: IA (T1a, N0, M0); IB (T1b, N0, M0). T1a: Solitary tumor equal or less than 5 cm without vascular invasion.  T1b: Solitary tumor larger than 5 cm without vascular invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Intrahepatic Cholangiocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134758>	C134757|C134611	Stage IA Intrahepatic Cholangiocarcinoma AJCC v8|IA|Stage IA Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)	Stage IA includes: T1a, N0, M0. T1a: Solitary tumor equal or less than 5 cm without vascular invasion.  N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IA Intrahepatic Cholangiocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134759>	C134757|C134612	Stage IB Intrahepatic Cholangiocarcinoma AJCC v8|IB|Stage IB Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)	Stage IB includes: T1b, N0, M0. T1b: Solitary tumor larger than 5 cm without vascular invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IB Intrahepatic Cholangiocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C13475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13475>	C13432	18q21.3	A chromosome band present on 18q			Gene or Genome	
C134760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134760>	C134755|C134614	Stage II Intrahepatic Cholangiocarcinoma AJCC v8|II|Stage II Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)	Stage II includes: T2, N0, M0. T2: Solitary tumor with intrahepatic vascular invasion, or multiple tumors, with or without vascular invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Intrahepatic Cholangiocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134761>	C134755|C134615	Stage III Intrahepatic Cholangiocarcinoma AJCC v8|III|Stage III Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)	Stage III includes: IIIA: (T3, N0, M0); IIIB: (T4, N0, M0); (Any T, N1, M0). T3: Tumor perforating the visceral peritoneum. T4: Tumor involving local extrahepatic structures by direct invasion. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Intrahepatic Cholangiocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134762>	C134761|C134616	Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8|IIIA|Stage IIIA Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)	Stage IIIA includes: T3, N0, M0. T3: Tumor perforating the visceral peritoneum. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134763>	C134761|C134618	Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8|IIIB|Stage IIIB Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)	Stage IIIB includes: (T4, N0, M0); (Any T, N1, M0). T4: Tumor involving local extrahepatic structures by direct invasion. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134764>	C134755|C134619	Stage IV Intrahepatic Cholangiocarcinoma AJCC v8|IV|Stage IV Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)	Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Intrahepatic Cholangiocarcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134765>	C2124	Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside|Alpha-methyl-4-[F-18]-fluoro-4-deoxy-d-glucopyranoside|Alpha-methyl-4-deoxy-4-(18F)fluoro-D-glucopyranoside|METHYL 4-DEOXY-4-FLUORO-.ALPHA.-D-GLUCOPYRANOSIDE. F-18|Me-4(18F)DG|Me-4FDG|Me4FDG|a-methyl-4[18F]-4-deoxy-D-glucopyranoside	A radioconjugate and sodium-dependent glucose transporter (SGLT)-specific tracer that is composed of a glucose analog labeled with the positron-emitting radioactive isotope fluorine F18, and can be used for tumor cell imaging upon positron emission tomography (PET). Upon administration, alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside (Me4FDG) is specifically taken up by SGLT-expressing tumor cells. The fluorine F 18 moiety can be visualized upon PET imaging and this agent can be used both as a tracer for sugar uptake by and for imaging and staging of certain tumor cell types. Glucose is a major metabolic substrate required for cancer cell survival and growth and is taken up by cancer cells at a much higher rate compared to normal cells. SGLTs, especially SGLT type 2 (SGLT2), are overexpressed on certain tumor cell types and play key roles in glucose transport in these cells. Me4FDG is not transported by glucose uniporter proteins (GLUTs). In contrast, Me4FDG is not transported by glucose transporters (GLUTs).			Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C134766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134766>	C134533	Baboon Lymphoma	Lymphoma that occurs in a baboon.			Neoplastic Process	Cellosaurus Disease Terminology
C134767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134767>	C134527	Bovine Lymphosarcoma	Lymphosarcoma that occurs in a cow.			Neoplastic Process	Cellosaurus Disease Terminology
C134768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134768>	C134527	Bovine Rectal Myxoma	A myxoma that occurs in the rectum of a cow.			Neoplastic Process	Cellosaurus Disease Terminology
C134769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134769>	C134533	Duck Neoplasm	A neoplasm that occurs in a duck.			Neoplastic Process	Cellosaurus Disease Terminology
C13476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13476>	C13432	19q13.1-q13.2	A chromosome band present on 19q			Gene or Genome	
C134770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134770>	C134528	Feline Erythroleukemia	Erythroleukemia that occurs in a cat.			Neoplastic Process	Cellosaurus Disease Terminology
C134771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134771>	C134533	Frog Pronephric Kidney Tumor	A kidney neoplasm of the pronephric cell type that occurs in a frog.			Neoplastic Process	Cellosaurus Disease Terminology
C134772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134772>	C136555	Gerbil Fibrosarcoma	Fibrosarcoma that occurs in a gerbil.			Neoplastic Process	Cellosaurus Disease Terminology
C134773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134773>	C136555	Gerbil Melanoma	Melanoma that occurs in a gerbil.			Neoplastic Process	Cellosaurus Disease Terminology
C134774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134774>	C134533	Gibbon Lymphosarcoma	Lymphosarcoma that occurs in a gibbon.			Neoplastic Process	Cellosaurus Disease Terminology
C134775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134775>	C134988	Hamster Kidney Tumor	A kidney neoplasm that occurs in a hamster.			Neoplastic Process	Cellosaurus Disease Terminology
C134776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134776>	C134988	Hamster Lymphoma	Lymphoma that occurs in a hamster.			Neoplastic Process	Cellosaurus Disease Terminology
C134777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134777>	C134988	Hamster Lymphosarcoma	Lymphosarcoma that occurs in a hamster.			Neoplastic Process	Cellosaurus Disease Terminology
C134778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134778>	C134535	Horse Lymphoma	Lymphoma that occurs in a horse.			Neoplastic Process	Cellosaurus Disease Terminology
C134779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134779>	C23988	Mouse Rectum Carcinoma	Carcinoma that occurs in the rectum of a mouse.			Neoplastic Process	Cellosaurus Disease Terminology
C13477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13477>	C13432	22q11	A chromosome band present on 22q			Gene or Genome	
C134780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134780>	C23988	Mouse Reticulum Cell Sarcoma	Reticulum cell sarcoma that occurs in a mouse.			Neoplastic Process	Cellosaurus Disease Terminology
C134781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134781>	C134533	Ovine Sinus Tumor	A neoplasm that occurs in the sinus of a sheep.			Neoplastic Process	Cellosaurus Disease Terminology
C134783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134783>	C134533	Rhesus Monkey Lymphoma	Lymphoma that occurs in a rhesus monkey.			Neoplastic Process	Cellosaurus Disease Terminology
C134784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134784>	C134533	Rhesus Monkey Mammary Tumor	A mammary neoplasm that occurs in a rhesus monkey.			Neoplastic Process	Cellosaurus Disease Terminology
C134785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134785>	C134533	Zebra Finch Neoplasm	A neoplasm that occurs in a zebra finch.			Neoplastic Process	Cellosaurus Disease Terminology
C134786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134786>	C134533	Porcine Lymphoma	Lymphoma that occurs in a pig.			Neoplastic Process	Cellosaurus Disease Terminology
C134787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134787>	C215000|C20401	Anti-TIGIT Monoclonal Antibody|Anti-TIGIT MoAb|Anti-immunoglobulin (Ig) and Immunoreceptor Tyrosine-based iInhibitory Motif Monoclonal Antibody	Any monoclonal antibody against TIGIT.	Anti-TIGIT Monoclonal Antibody		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C134788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134788>	C134455	Distal Bile Duct Cancer TNM Finding v8|Distal Bile Duct Carcinoma TNM Finding v8|Distal Bile Duct Tumor AJCC v8 TNM Finding	A finding about one or more characteristics of distal bile duct cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to bile duct adenocarcinomas, biliary intraepithelial neoplasia, high-grade neuroendocrine carcinomas, and papillary carcinomas. Tumors arising in the ampulla of Vater, sarcomas, and well-differentiated neuroendocrine tumors (carcinoids) are not staged using this staging system. (from AJCC 8th Ed.)			Finding	
C134789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134789>	C134788	Distal Bile Duct Cancer Clinical TNM Finding v8|Distal Bile Duct Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of distal bile duct cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C13478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13478>	C13432	1p32	A chromosome band present on 1p			Gene or Genome	
C134790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134790>	C134789	Distal Bile Duct Cancer Clinical Distant Metastasis TNM Finding v8|Distal Bile Duct Cancer Clinical Distant Metastasis Status (cM)|Distal Bile Duct Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of distal bile duct cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134791>	C134790	Distal Bile Duct Cancer cM0 TNM Finding v8|Distal Bile Duct Carcinoma cM0 TNM Finding v8|Distal Bile Duct Tumor cM0 TNM AJCC v8	Distal bile duct cancer without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C134793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134793>	C134790	Distal Bile Duct Cancer cM1 TNM Finding v8|Distal Bile Duct Carcinoma cM1 TNM Finding v8|Distal Bile Duct Tumor cM1 TNM AJCC v8|cM1	Distal bile duct cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134794>	C134788	Distal Bile Duct Cancer Pathologic TNM Finding v8|Distal Bile Duct Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of distal bile duct cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C134795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134795>	C134794	Distal Bile Duct Cancer Pathologic Distant Metastasis TNM Finding v8|Distal Bile Duct Cancer Pathologic Distant Metastasis Status (pM)|Distal Bile Duct Carcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of distal bile duct cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134796>	C134795	Distal Bile Duct Cancer pM1 TNM Finding v8|Distal Bile Duct Carcinoma pM1 TNM Finding v8|Distal Bile Duct Tumor pM1 TNM AJCC v8|pM1	Distal bile duct cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134797>	C134794	Distal Bile Duct Cancer Pathologic Primary Tumor TNM Finding v8|Distal Bile Duct Cancer Pathologic Primary Tumor Status (pT)|Distal Bile Duct Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of distal bile duct cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134798>	C134797	Distal Bile Duct Cancer pTX TNM Finding v8|Distal Bile Duct Carcinoma pTX TNM Finding v8|Distal Bile Duct Tumor pTX TNM AJCC v8|pTX	Distal bile duct cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134799>	C134797	Distal Bile Duct Cancer pTis TNM Finding v8|Distal Bile Duct Carcinoma pTis TNM Finding v8|Distal Bile Duct Tumor pTis TNM AJCC v8|pTis	Distal bile duct cancer with a finding of carcinoma in situ/high-grade dysplasia. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C13479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13479>	C13432	10p13	A chromosome band present on 10p			Gene or Genome	
C1347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1347>	C797|C2139|C2080	Azimexon|2-Aziridinecarboxamide, 1-[1-(2-cyano-1-aziridinyl)-1-methylethyl]|2-Cyanaziridinyl-2-carbamoyl-aziridinyl-1-propane|AZ|AZIMEXON|Azimexone|BM 12.531|BM12531	Azimexon (2-cyanaziridinyl-2-carbamoyl-aziridinyl-1-propane) is a derivative of 2-cyanaziridine. Immunostimulant which shows therapeutic effects in tumor models and experimental infections in vitro, enhancing T lymphocyte transformation and phagocytosis. The mode of action of azimexon is unknown. It has been suggested that azimexon may alkylate DNA. In cancer patients it increases leukocytosis, blood active T rosettes, T4/T8 ratio, and is used as an adjuvant to chemotherapy in the treatment of melanoma and myeloma.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C134800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134800>	C134797	Distal Bile Duct Cancer pT1 TNM Finding v8|Distal Bile Duct Carcinoma pT1 TNM Finding v8|Distal Bile Duct Tumor pT1 TNM AJCC v8|pT1	Distal bile duct cancer with tumor invading the bile duct wall with a depth less than 5 mm. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134801>	C134797	Distal Bile Duct Cancer pT2 TNM Finding v8|Distal Bile Duct Carcinoma pT2 TNM Finding v8|Distal Bile Duct Tumor pT2 TNM AJCC v8|pT2	Distal bile duct cancer with tumor invading the bile duct wall with a depth of 5-12 mm. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134802>	C134797	Distal Bile Duct Cancer pT3 TNM Finding v8|Distal Bile Duct Carcinoma pT3 TNM Finding v8|Distal Bile Duct Tumor pT3 TNM AJCC v8|pT3	Distal bile duct cancer with tumor invading the bile duct wall with a depth greater than 12 mm. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134803>	C134797	Distal Bile Duct Cancer pT4 TNM Finding v8|Distal Bile Duct Carcinoma pT4 TNM Finding v8|Distal Bile Duct Tumor pT4 TNM AJCC v8|pT4	Distal bile duct cancer with tumor involving the celiac axis, superior mesenteric artery, and/or common hepatic artery. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134804>	C134794	Distal Bile Duct Cancer Pathologic Regional Lymph Nodes TNM Finding v8|Distal Bile Duct Cancer Pathologic Regional Lymph Node Status (pN)|Distal Bile Duct Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of distal bile duct cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134805>	C134804	Distal Bile Duct Cancer pNX TNM Finding v8|Distal Bile Duct Carcinoma pNX TNM Finding v8|Distal Bile Duct Tumor pNX TNM AJCC v8|pNX	Distal bile duct cancer in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134806>	C134804	Distal Bile Duct Cancer pN0 TNM Finding v8|Distal Bile Duct Carcinoma pN0 TNM Finding v8|Distal Bile Duct Tumor pN0 TNM AJCC v8|pN0	Distal bile duct cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134808>	C134804	Distal Bile Duct Cancer pN1 TNM Finding v8|Distal Bile Duct Carcinoma pN1 TNM Finding v8|Distal Bile Duct Tumor pN1 TNM AJCC v8|pN1	Distal bile duct cancer with metastasis in one to three regional lymph nodes. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134809>	C134804	Distal Bile Duct Cancer pN2 TNM Finding v8|Distal Bile Duct Carcinoma pN2 TNM Finding v8|Distal Bile Duct Tumor pN2 TNM AJCC v8|pN2	Distal bile duct cancer with metastasis in four or more regional lymph nodes. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C13480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13480>	C13432	7q34	A chromosome band present on 7q	7q34		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134810>	C7109	Distal Bile Duct Cancer by AJCC v7 Stage|Distal Bile Duct Carcinoma by AJCC v7 Stage	A term that refers to the staging of distal bile duct cancer according to the American Joint Committee on Cancer, 7th edition.			Neoplastic Process	
C134811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134811>	C7109	Distal Bile Duct Cancer by AJCC v8 Stage|Distal Bile Duct Cancer Tumor Stage (Pathologic)|Distal Bile Duct Carcinoma by AJCC v8 Stage|Distal Bile Duct Tumor AJCC v8 Stage	A term that refers to the staging of distal bile duct cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to bile duct adenocarcinomas, biliary intraepithelial neoplasia, high-grade neuroendocrine carcinomas, and papillary carcinomas that arise from the distal bile duct. Tumors arising in the ampulla of Vater, sarcomas, and well-differentiated neuroendocrine tumors (carcinoids) are not staged using this staging system. (from AJCC 8th Ed.)			Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C134812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134812>	C134811	Stage 0 Distal Bile Duct Cancer AJCC v8|0|Stage 0 Distal Bile Duct Carcinoma AJCC v8|Stage 0 Distal Bile Duct Tumor AJCC v8|Stage 0 Extrahepatic (Distal) Bile Duct Cancer|stage 0 extrahepatic bile duct carcinoma in situ	Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ/high-grade dysplasia. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0 Distal Bile Duct Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134813>	C134811	Stage I Distal Bile Duct Cancer AJCC v8|I|Stage I Distal Bile Duct Carcinoma AJCC v8|Stage I Distal Bile Duct Tumor AJCC v8|Stage I Extrahepatic (Distal) Bile Duct Cancer|stage I extrahepatic bile duct cancer	Stage I includes: T1, N0, M0. T1: Tumor invading the bile duct wall with a depth less than 5 mm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Distal Bile Duct Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134814>	C134811	Stage II Distal Bile Duct Cancer AJCC v8|II|Stage II Distal Bile Duct Carcinoma AJCC v8|Stage II Extrahepatic (Distal) Bile Duct Cancer|stage II extrahepatic bile duct cancer	Stage II includes: IIA: (T1, N1, M0); (T2, N0, M0); IIB: (T2, N1, M0); (T3, N0, M0); (T3, N1, M0). T1: Tumor invading the bile duct wall with a depth less than 5 mm. T2: Tumor invading the bile duct wall with a depth of 5-12 mm. T3: Tumor invading the bile duct wall with a depth greater than 12 mm. N0: No regional lymph node metastasis. N1: Metastasis in one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Distal Bile Duct Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134815>	C134814	Stage IIA Distal Bile Duct Cancer AJCC v8|IIA|Stage IIA Distal Bile Duct Carcinoma AJCC v8|Stage IIA Distal Bile Duct Tumor AJCC v8|Stage IIA Extrahepatic (Distal) Bile Duct Cancer	Stage IIA includes: (T1, N1, M0); (T2, N0, M0). T1: Tumor invading the bile duct wall with a depth less than 5 mm. T2: Tumor invading the bile duct wall with a depth of 5-12 mm. N0: No regional lymph node metastasis. N1: Metastasis in one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIA Distal Bile Duct Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134816>	C134814	Stage IIB Distal Bile Duct Cancer AJCC v8|IIB|Stage IIB Distal Bile Duct Carcinoma AJCC v8|Stage IIB Distal Bile Duct Tumor AJCC v8|Stage IIB Extrahepatic (Distal) Bile Duct Cancer	Stage IIB includes: (T2, N1, M0); (T3, N0, M0); (T3, N1, M0). T2: Tumor invading the bile duct wall with a depth of 5-12 mm. T3: Tumor invading the bile duct wall with a depth greater than 12 mm. N0: No regional lymph node metastasis. N1: Metastasis in one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIB Distal Bile Duct Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134817>	C134811	Stage III Distal Bile Duct Cancer AJCC v8|III|Stage III Distal Bile Duct Carcinoma AJCC v8|Stage III Extrahepatic (Distal) Bile Duct Cancer|stage III extrahepatic bile duct cancer	Stage III includes: IIIA: (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); IIIB: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T1: Tumor invading the bile duct wall with a depth less than 5 mm. T2: Tumor invading the bile duct wall with a depth of 5-12 mm. T3: Tumor invading the bile duct wall with a depth greater than 12 mm. T4: Tumor involving the celiac axis, superior mesenteric artery, and/or common hepatic artery. N0: No regional lymph node metastasis. N1: Metastasis in one to three regional lymph nodes. N2: Metastasis in four or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Distal Bile Duct Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134818>	C134817	Stage IIIA Distal Bile Duct Cancer AJCC v8|IIIA|Stage IIIA Distal Bile Duct Carcinoma AJCC v8|Stage IIIA Distal Bile Duct Tumor AJCC v8|Stage IIIA Extrahepatic (Distal) Bile Duct Cancer	Stage IIIA includes: (T1, N2, M0); (T2, N2, M0); (T3, N2, M0). T1: Tumor invading the bile duct wall with a depth less than 5 mm. T2: Tumor invading the bile duct wall with a depth of 5-12 mm. T3: Tumor invading the bile duct wall with a depth greater than 12 mm. N2: Metastasis in four or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIA Distal Bile Duct Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134819>	C134817	Stage IIIB Distal Bile Duct Cancer AJCC v8|IIIB|Stage IIIB Distal Bile Duct Carcinoma AJCC v8|Stage IIIB Distal Bile Duct Tumor AJCC v8|Stage IIIB Extrahepatic (Distal) Bile Duct Cancer	Stage IIIB includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Tumor involving the celiac axis, superior mesenteric artery, and/or common hepatic artery. N0: No regional lymph node metastasis. N1: Metastasis in one to three regional lymph nodes. N2: Metastasis in four or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIB Distal Bile Duct Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C13481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13481>	C13432	17q21	A chromosome band present on 17q			Gene or Genome	
C134820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134820>	C134811	Stage IV Distal Bile Duct Cancer AJCC v8|IV|Stage IV Distal Bile Duct Carcinoma AJCC v8|Stage IV Distal Bile Duct Tumor AJCC v8|Stage IV Extrahepatic (Distal) Bile Duct Cancer|Stage IV Extrahepatic Bile Duct Cancer|stage IV extrahepatic bile duct cancer	Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Distal Bile Duct Cancer AJCC v8|Stage IV Extrahepatic Bile Duct Cancer		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134821>	C913	Tasonermin|1-157-Tumor Necrosis Factor Alfa-1a (Human)|TASONERMIN|Tumor Necrosis Factor, Human Recombinant				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C134822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134822>	C54131	Atara Biotherapeutics	A privately-held drug development company that is developing cancer treatments based on allogeneic cytotoxic T lymphocyte immunotherapy.			Organization	
C134823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134823>	C54131	Bellicum Pharmaceuticals	A biopharmaceutical company focused on developing cellular immunotherapies for hematological cancers, solid tumors, and orphan inherited blood diseases.			Organization	
C134824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134824>	C54131	Mesoblast Limited|Mesoblast	An Australian biotechnology company that is developing a proprietary technology platform based on allogeneic mesenchymal lineage adult stem cells (MLCs) to target inflammatory ailments, cardiovascular disease, and back pain.			Organization	
C134825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134825>	C20993	Geriatric Screening Tool|G-8|G8|Geriatric Screening tool (G-8)	A screening tool for geriatric oncology patients consisting of 7 questions from the Mini Nutritional Assessment and one question relative to the age of patient.			Intellectual Product	
C134827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134827>	C20993	Cancer and Aging Research Group Chemo Toxicity Calculator|CARG Score|Cancer and Aging Research Group (CARG) Score|Cancer and Aging Research Group Chemo Toxicity Calculator (CARG)|Cancer and Aging Research Group Score	A clinical assessment tool designed to evaluate the risk for chemotherapy toxicity in geriatric cancer patients. The tool captures sociodemographics, tumor and treatment variables, laboratory test results, and geriatric assessment domains.			Intellectual Product	
C134828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134828>	C1287	Balugrastim|BALUGRASTIM|CG-10639|CG10639|Human serum albumin (585 residues) fusion protein with des-(1-alanine,37-valine,38-serine,39-gutamic acid)-human granulocyte colony-stimulating factor (pluripoietin)|Serum albumin (human), fusion protein with granulocyte colony-stimulating factor (human)				Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C134829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134829>	C1287	Empegfilgrastim|1-(N-(4-(omega-Methoxypoly(oxyethylene))butyl)-L-methionine))human granulocyte colony-stimulating factor (pluripoietin)|BCD 017|BCD-017|BCD017|EMPEGFILGRASTIM	A long-acting form and covalent conjugate of recombinant human granulocyte colony-stimulating factor (G-CSF) filgrastim with 30 kDa polyethylene glycol (PEG), with potential hematopoietic activity. Upon administration, empegfilgrastim acts similarly to endogenous G-CSF and binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. Therefore, this agent may prevent the incidence and shorten the duration of chemotherapy-induced neutropenia. Conjugation of the cytokine with a PEG molecule significantly increases this agent's therapeutic half-life compared to filgrastim.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C13482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13482>	C13432	13q12.3	A chromosome band present on 13q			Gene or Genome	
C134831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134831>	C6078|C160978	Eyelid Sebaceous Gland Carcinoma|Eyelid SGC|Sebaceous Gland Carcinoma of the Eyelid	A sebaceous gland carcinoma affecting the eyelid. It arises from the meibomian glands, glands of Zeis, or glands associated with the caruncle. It usually affects elderly women and is characterized by high rate of local recurrence, regional, and distant metastases.			Neoplastic Process	
C134832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134832>	C60758	Supervisor|Administrator|Administrator/Supervisor	An individual who is responsible for managing or operating a business, organization, team or department.			Professional or Occupational Group	
C134833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134833>	C60758	Non-Healthcare Professional|NON-HEALTH CARE PROFESSIONAL	An individual qualified in a profession outside the healthcare field.			Professional or Occupational Group	CDISC SDTM Evaluator Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C134834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134834>	C142811|C121974	Recurrent B Acute Lymphoblastic Leukemia, BCR-ABL1-Like|Recurrent B Acute Lymphoblastic Leukemia with BCR-ABL1-Like Features|Recurrent B Acute Lymphoblastic Leukemia with BCR::ABL1-Like Features|Recurrent B Acute Lymphoblastic Leukemia, BCR::ABL1-Like|Recurrent B-Acute Lymphoblastic Leukemia, BCR-ABL1-Like|Recurrent B-Acute Lymphoblastic Leukemia, BCR::ABL1-Like|Recurrent Ph-Like Acute Lymphoblastic Leukemia|Recurrent Ph-Like Acute Lymphoblastic Leukemia	The reemergence of  B acute lymphoblastic leukemia, BCR-ABL1-like after a period of remission.	Recurrent Ph-Like Acute Lymphoblastic Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134835>	C142812|C121974	Refractory B Acute Lymphoblastic Leukemia, BCR-ABL1-Like|Refractory B Acute Lymphoblastic Leukemia with BCR-ABL1-Like Features|Refractory B Acute Lymphoblastic Leukemia, BCR::ABL1-Like|Refractory B-Acute Lymphoblastic Leukemia with BCR::ABL1-Like Features|Refractory B-Acute Lymphoblastic Leukemia, BCR::ABL1-Like|Refractory Ph-Like Acute Lymphoblastic Leukemia|Refractory Ph-Like Acute Lymphoblastic Leukemia	A B acute lymphoblastic leukemia, BCR-ABL1-like that does not respond to treatment.	Refractory Ph-Like Acute Lymphoblastic Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134836>	C134455	Ampulla of Vater Cancer TNM Finding v8|Ampulla of Vater Carcinoma TNM Finding v8	A finding about one or more characteristics of ampulla of Vater cancer, following the rules of the TNM AJCC v8 classification system. This staging system and classification does not apply to well-differentiated neuroendocrine (carcinoid) tumors but does apply to high-grade neuroendocrine carcinomas, such as small cell carcinoma and large cell neuroendocrine carcinoma. (from AJCC 8th Ed.)			Finding	
C134837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134837>	C134836	Ampulla of Vater Cancer Clinical TNM Finding v8|Ampulla of Vater Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of ampulla of Vater cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C134838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134838>	C28676	Alloantigen-specific Allogeneic Type 1 Regulatory T Cells T-allo10|Alloantigen-specific TR1 Cells Allo10|Alloantigen-specific Type 1 Tregs T-allo10|Donor-derived Host Alloantigen-specific IL-10 Anergized T Cells|T-allo10|T-allo10 Cells	A preparation of allogeneic CD4+ cells that were ex vivo stimulated with alloantigens, which involves exposing the cells to host antigen-presenting cells (APCs), in the presence of the immunomodulatory cytokine interleukin-10 (IL-10), with potential to prevent graft-versus-host disease (GvHD). The stimulation of the CD4+ cells by exposure to alloantigens plus IL-10 induces the differentiation of alloantigen-specific type 1 T regulatory (TR1) cells, which are hyporesponsive to the alloantigens. Upon infusion of T-allo10 and prior to donor hematopoietic stem cell transplantation (HSCT), the alloantigen-specific type 1 regulatory T-cells are tolerant to the alloantigens and suppress alloreactive immune responses by donor CD4+ and CD8+ T-cells. This may ultimately prevent GvHD. IL-10 plays a key role in controlling inflammation, down-regulating immune responses, and inducing immunological tolerance. IL-10 induces both a long lasting antigen specific T-cell anergy and the differentiation of TR1 cells.	Alloantigen-specific Allogeneic Type 1 Regulatory T Cells T-allo10		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C134839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134839>	C134837	Ampulla of Vater Cancer Clinical Distant Metastasis TNM Finding v8|Ampulla of Vater Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of ampulla of Vater cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C13483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13483>	C13432	11q23.3	A chromosome band present on 11q			Gene or Genome	
C134840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134840>	C134839	Ampulla of Vater Cancer cM0 TNM Finding v8|Ampulla of Vater Carcinoma cM0 TNM Finding v8	Ampulla of Vater cancer without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C134841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134841>	C134839	Ampulla of Vater Cancer cM1 TNM Finding v8|Ampulla of Vater Carcinoma cM1 TNM Finding v8	Ampulla of Vater cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C134842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134842>	C134836	Ampulla of Vater Cancer Pathologic TNM Finding v8|Ampulla of Vater Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of ampulla of Vater cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C134843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134843>	C134842	Ampulla of Vater Cancer Pathologic Distant Metastasis TNM Finding v8|Ampulla of Vater Carcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of ampulla of Vater cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C134844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134844>	C134843	Ampulla of Vater Cancer pM1 TNM Finding v8|Ampulla of Vater Carcinoma pM1 TNM Finding v8	Ampulla of Vater cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C134845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134845>	C134842	Ampulla of Vater Cancer Pathologic Primary Tumor TNM Finding v8|Ampulla of Vater Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of ampulla of Vater cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C134846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134846>	C134845	Ampulla of Vater Cancer pTX TNM Finding v8|Ampulla of Vater Carcinoma pTX TNM Finding v8	Ampulla of Vater cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C134847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134847>	C134845	Ampulla of Vater Cancer pT0 TNM Finding v8|Ampulla of Vater Carcinoma pT0 TNM Finding v8	Ampulla of Vater cancer with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C134848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134848>	C134845	Ampulla of Vater Cancer pTis TNM Finding v8|Ampulla of Vater Carcinoma pTis TNM Finding v8	Ampulla of Vater cancer with a finding of carcinoma in situ. (from AJCC 8th Ed.)			Finding	
C134849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134849>	C134845	Ampulla of Vater Cancer pT1 TNM Finding v8|Ampulla of Vater Carcinoma pT1 TNM Finding v8	Ampulla of Vater cancer with tumor limited to ampulla of Vater or sphincter of Oddi or tumor invading beyond the sphincter of Oddi (perisphincteric invasion) and/or into the duodenal submucosa. (from AJCC 8th Ed.)			Finding	
C13484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13484>	C13432	11q13	A chromosome band present on 11q	11q13		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134850>	C134849	Ampulla of Vater Cancer pT1a TNM Finding v8|Ampulla of Vater Carcinoma pT1a TNM Finding v8	Ampulla of Vater cancer with tumor limited to ampulla of Vater or sphincter of Oddi. (from AJCC 8th Ed.)			Finding	
C134851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134851>	C134849	Ampulla of Vater Cancer pT1b TNM Finding v8|Ampulla of Vater Carcinoma pT1b TNM Finding v8	Ampulla of Vater cancer with tumor invading beyond the sphincter of Oddi (perisphincteric invasion) and/or into the duodenal submucosa. (from AJCC 8th Ed.)			Finding	
C134852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134852>	C134845	Ampulla of Vater Cancer pT2 TNM Finding v8|Ampulla of Vater Carcinoma pT2 TNM Finding v8	Ampulla of Vater cancer with tumor invading into the muscularis propria of the duodenum. (from AJCC 8th Ed.)			Finding	
C134853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134853>	C134845	Ampulla of Vater Cancer pT3 TNM Finding v8|Ampulla of Vater Carcinoma pT3 TNM Finding v8	Ampulla of Vater cancer with tumor directly invading the pancreas (up to 0.5 cm) or tumor extending more than 0.5 cm into the pancreas, or extending into peripancreatic or periduodenal tissue or duodenal serosa without involvement of the celiac axis or superior mesenteric artery. (from AJCC 8th Ed.)			Finding	
C134854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134854>	C134853	Ampulla of Vater Cancer pT3a TNM Finding v8|Ampulla of Vater Carcinoma pT3a TNM Finding v8	Ampulla of Vater cancer with tumor directly invading the pancreas (up to 0.5 cm). (from AJCC 8th Ed.)			Finding	
C134855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134855>	C134853	Ampulla of Vater Cancer pT3b TNM Finding v8|Ampulla of Vater Carcinoma pT3b TNM Finding v8	Ampulla of Vater cancer with tumor extending more than 0.5 cm into the pancreas, or extending into peripancreatic tissue or duodenal serosa without involvement of the celiac axis or superior mesenteric artery. (from AJCC 8th Ed.)			Finding	
C134856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134856>	C134845	Ampulla of Vater Cancer pT4 TNM Finding v8|Ampulla of Vater Carcinoma pT4 TNM Finding v8	Ampulla of Vater cancer with tumor involving the celiac axis, superior mesenteric artery, and/or common hepatic artery, irrespective of size. (from AJCC 8th Ed.)			Finding	
C134857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134857>	C134842	Ampulla of Vater Cancer Pathologic Regional Lymph Nodes TNM Finding v8|Ampulla of Vater Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of ampulla of Vater cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C134858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134858>	C134857	Ampulla of Vater Cancer pNX TNM Finding v8|Ampulla of Vater Carcinoma pNX TNM Finding v8	Ampulla of Vater cancer in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)			Finding	
C134859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134859>	C134857	Ampulla of Vater Cancer pN0 TNM Finding v8|Ampulla of Vater Carcinoma pN0 TNM Finding v8	Ampulla of Vater cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)			Finding	
C13485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13485>	C13432	16q22.1	A chromosome band present on 16q			Gene or Genome	
C134860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134860>	C134857	Ampulla of Vater Cancer pN1 TNM Finding v8|Ampulla of Vater Carcinoma pN1 TNM Finding v8	Ampulla of Vater cancer with metastasis to one to three regional lymph nodes. (from AJCC 8th Ed.)			Finding	
C134861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134861>	C134857	Ampulla of Vater Cancer pN2 TNM Finding v8|Ampulla of Vater Carcinoma pN2 TNM Finding v8	Ampulla of Vater cancer with metastasis to four or more regional lymph nodes. (from AJCC 8th Ed.)			Finding	
C134862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134862>	C177692	GLI1 Positive|GLI Family Zinc Finger 1 Positive|GLI Positive|Glioma Associated Oncogene Homolog 1 Positive|Glioma-Associated Oncogene 1 Positive|Glioma-Associated Oncogene Family Zinc Finger 1 Positive|Zinc Finger Protein GLI1 Positive	An indication that GLI1 expression has been detected in a sample.	GLI1 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134863>	C3908|C133716	Ampulla of Vater Cancer by AJCC v7 Stage|Ampulla of Vater Carcinoma by AJCC v7 Stage	A term that refers to the staging of ampulla of Vater cancer according to the American Joint Committee on Cancer, 7th edition.			Neoplastic Process	
C134864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134864>	C3908	Ampulla of Vater Cancer by AJCC v8 Stage|Ampulla of Vater Carcinoma by AJCC v8 Stage	A term that refers to the staging of ampulla of Vater cancer according to the American Joint Committee on Cancer, 8th edition. This staging system does not apply to well-differentiated neuroendocrine (carcinoid) tumors but does apply to high-grade neuroendocrine carcinomas, such as small cell carcinoma and large cell neuroendocrine carcinoma. (from AJCC 8th Ed.)			Neoplastic Process	
C134865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134865>	C134864	Stage 0 Ampulla of Vater Cancer AJCC v8|Stage 0 Ampulla of Vater Cancer|Stage 0 Ampulla of Vater Carcinoma AJCC v8	Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0 Ampulla of Vater Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134866>	C134864	Stage I Ampulla of Vater Cancer AJCC v8|Stage I Ampulla of Vater Cancer|Stage I Ampulla of Vater Carcinoma AJCC v8	Stage I includes: IA: (T1a, N0, M0); IB: (T1b, N0, M0); (T2, N0, M0). T1a: Tumor limited to ampulla of Vater or sphincter of Oddi. T1b: Tumor invading beyond the sphincter of Oddi (perisphincteric invasion) and/or into the duodenal submucosa. T2: Tumor invading into the muscularis propria of the duodenum. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Ampulla of Vater Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134867>	C134866	Stage IA Ampulla of Vater Cancer AJCC v8|Stage IA Ampulla of Vater Cancer|Stage IA Ampulla of Vater Carcinoma AJCC v8	Stage IA includes: T1a, N0, M0. T1a: Tumor limited to ampulla of Vater or sphincter of Oddi. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IA Ampulla of Vater Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134868>	C134866	Stage IB Ampulla of Vater Cancer AJCC v8|Stage IB Ampulla of Vater Cancer|Stage IB Ampulla of Vater Carcinoma AJCC v8	Stage IB includes: (T1b, N0, M0); (T2, N0, M0). T1b: Tumor invading beyond the sphincter of Oddi (perisphincteric invasion) and/or into the duodenal submucosa. T2: Tumor invading into the muscularis propria of the duodenum. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IB Ampulla of Vater Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134869>	C134864	Stage II Ampulla of Vater Cancer AJCC v8|Stage II Ampulla of Vater Cancer|Stage II Ampulla of Vater Carcinoma AJCC v8	Stage II includes: IIA: T3a, N0, M0; IIB: T3b, N0, M0. T3a: Tumor directly invading the pancreas (up to 0.5 cm). T3b: Tumor extending more than 0.5 cm into the pancreas, or extending into peripancreatic tissue or duodenal serosa without involvement of the celiac axis or superior mesenteric artery. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Ampulla of Vater Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13486>	C13432	12q14	A chromosome band present on 12q			Gene or Genome	
C134870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134870>	C134869	Stage IIA Ampulla of Vater Cancer AJCC v8|Stage IIA Ampulla of Vater Cancer|Stage IIA Ampulla of Vater Carcinoma AJCC v8	Stage IIA includes: T3a, N0, M0. T3a: Tumor directly invading the pancreas (up to 0.5 cm). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIA Ampulla of Vater Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134871>	C134869	Stage IIB Ampulla of Vater Cancer AJCC v8|Stage IIB Ampulla of Vater Cancer|Stage IIB Ampulla of Vater Carcinoma AJCC v8	Stage IIB includes: T3b, N0, M0. T3b: Tumor extending more than 0.5 cm into the pancreas, or extending into peripancreatic tissue or duodenal serosa without involvement of the celiac axis or superior mesenteric artery. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIB Ampulla of Vater Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134872>	C134864	Stage III Ampulla of Vater Cancer AJCC v8|Stage III Ampulla of Vater Cancer|Stage III Ampulla of Vater Carcinoma AJCC v8	Stage III includes: IIIA: (T1a, N1, M0); (T1b, N1, M0); (T2, N1, M0); (T3a, N1, M0); (T3b, N1, M0); IIIB: (T4, Any N, M0); (Any T, N2, M0). T1a: Tumor limited to ampulla of Vater or sphincter of Oddi. T1b: Tumor invading beyond the sphincter of Oddi (perisphincteric invasion) and/or into the duodenal submucosa. T2: Tumor invading into the muscularis propria of the duodenum. T3a: Tumor directly invading the pancreas (up to 0.5 cm). T3b: Tumor extending more than 0.5 cm into the pancreas, or extending into peripancreatic tissue or duodenal serosa without involvement of the celiac axis or superior mesenteric artery. T4: Tumor involving the celiac axis, superior mesenteric artery, and/or common hepatic artery, irrespective of size. N1: Metastasis to one to three regional lymph nodes. N2: Metastasis to four or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Ampulla of Vater Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134873>	C134872	Stage IIIA Ampulla of Vater Cancer AJCC v8|Stage IIIA Ampulla of Vater Cancer|Stage IIIA Ampulla of Vater Carcinoma AJCC v8	Stage IIIA includes: (T1a, N1, M0); (T1b, N1, M0); (T2, N1, M0); (T3a, N1, M0); (T3b, N1, M0). T1a: Tumor limited to ampulla of Vater or sphincter of Oddi. T1b: Tumor invading beyond the sphincter of Oddi (perisphincteric invasion) and/or into the duodenal submucosa. T2: Tumor invading into the muscularis propria of the duodenum. T3a: Tumor directly invading the pancreas (up to 0.5 cm). T3b: Tumor extending more than 0.5 cm into the pancreas, or extending into peripancreatic tissue or duodenal serosa without involvement of the celiac axis or superior mesenteric artery. N1: Metastasis to one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIA Ampulla of Vater Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134874>	C134872	Stage IIIB Ampulla of Vater Cancer AJCC v8|Stage IIIB Ampulla of Vater Cancer|Stage IIIB Ampulla of Vater Carcinoma AJCC v8	Stage IIIB includes: (T4, Any N, M0); (Any T, N2, M0). T4: Tumor involving the celiac axis, superior mesenteric artery, and/or common hepatic artery, irrespective of size. N2: Metastasis to four or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIB Ampulla of Vater Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134875>	C134864	Stage IV Ampulla of Vater Cancer AJCC v8|Stage IV Ampulla of Vater Cancer|Stage IV Ampulla of Vater Carcinoma AJCC v8	Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Ampulla of Vater Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134876>	C42934	Chewable Gel Dosage Form|Chewable Gel|Chewable Gel|GEL, CHEWABLE|Gummie|Gummie|Gummy	A formed or molded oral gel dosage form that maintains its shape, is elastic, and yields to mastication.			Biomedical or Dental Material	CDISC SDTM Dosage Form Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Structured Product Labeling Terminology|SPL Pharmaceutical Dosage Form Terminology
C134877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134877>	C134455	Pancreatic Cancer TNM Finding v8|Exocrine Pancreatic Cancer TNM Finding v8|Pancreatic Carcinoma TNM Finding v8	A finding about one or more characteristics of pancreatic cancer, following the rules of the TNM AJCC v8 classification system. This classification applies to pancreatic ductal adenocarcinoma, acinar cell carcinoma, intraductal papillary mucinous neoplasm with associated invasive carcinoma, intraductal tubulopapillary neoplasm with associated invasive carcinoma, colloid carcinoma, mucinous cystic neoplasm with associated invasive carcinoma, solid pseudopapillary neoplasm, large cell neuroendocrine carcinoma, small cell neuroendocrine carcinoma, and pancreatoblastoma. Well-differentiated neuroendocrine tumors are not staged using this staging system. (from AJCC 8th Ed.)			Finding	
C134878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134878>	C134877	Pancreatic Cancer Clinical TNM Finding v8|Pancreatic Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of pancreatic cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C134879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134879>	C134878	Pancreatic Cancer Clinical Distant Metastasis TNM Finding v8|Clinical Staging: Distant Metastasis (cM)|Pancreatic Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of pancreatic cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Pancreatic Baseline Form|CPTAC Terminology
C13487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13487>	C13432	6p21.2	A chromosome band present on 6p			Gene or Genome	
C134880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134880>	C134879	Pancreatic Cancer cM0 TNM Finding v8|Pancreatic Carcinoma cM0 TNM Finding v8|cM0	Pancreatic cancer without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Pancreatic Baseline Form|CPTAC Terminology
C134881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134881>	C134879	Pancreatic Cancer cM1 TNM Finding v8|Pancreatic Carcinoma cM1 TNM Finding v8|cM1	Pancreatic cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Pancreatic Baseline Form|CPTAC Terminology
C134882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134882>	C134877	Pancreatic Cancer Pathologic TNM Finding v8|Pancreatic Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of pancreatic cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C134883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134883>	C134882	Pancreatic Cancer Pathologic Distant Metastasis TNM Finding v8|Pancreatic Carcinoma Pathologic Distant Metastasis TNM Finding v8|Pathologic Staging: Distant Metastasis (pM)	A pathologic finding about one or more characteristics of pancreatic cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Pancreatic Baseline Form|CPTAC Terminology
C134884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134884>	C134883	Pancreatic Cancer pM1 TNM Finding v8|Pancreatic Carcinoma pM1 TNM Finding v8|pM1	Pancreatic cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Pancreatic Baseline Form|CPTAC Terminology
C134885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134885>	C134882	Pancreatic Cancer Pathologic Primary Tumor TNM Finding v8|Pancreatic Carcinoma Pathologic Primary Tumor TNM Finding v8|Pathologic Staging: Primary Tumor (pT)	A pathologic finding about one or more characteristics of pancreatic cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Pancreatic Baseline Form|CPTAC Terminology
C134886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134886>	C134885	Pancreatic Cancer pTX TNM Finding v8|Pancreatic Carcinoma pTX TNM Finding v8|pTX	Pancreatic cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Pancreatic Baseline Form|CPTAC Terminology
C134887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134887>	C134885	Pancreatic Cancer pT0 TNM Finding v8|Pancreatic Carcinoma pT0 TNM Finding v8|pT0	Pancreatic cancer with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Pancreatic Baseline Form|CPTAC Terminology
C134888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134888>	C134885	Pancreatic Cancer pTis TNM Finding v8|Pancreatic Carcinoma pTis TNM Finding v8|pTis	Pancreatic cancer with a finding of carcinoma in situ. This includes high-grade pancreatic intraepithelial neoplasia (PanIn-3), intraductal papillary mucinous neoplasm with high-grade dysplasia, intraductal tubulopapillary neoplasm with high-grade dysplasia, and mucinous cystic neoplasm with high-grade dysplasia. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Pancreatic Baseline Form|CPTAC Terminology
C134889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134889>	C134885	Pancreatic Cancer pT1 TNM Finding v8|Pancreatic Carcinoma pT1 TNM Finding v8|pT1	Pancreatic cancer with tumor measuring 2 cm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Pancreatic Baseline Form|CPTAC Terminology
C13488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13488>	C13432	11p15.5	A chromosome band present on 11p			Gene or Genome	
C134890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134890>	C134889	Pancreatic Cancer pT1a TNM Finding v8|Pancreatic Carcinoma pT1a TNM Finding v8	Pancreatic cancer with tumor measuring 0.5 cm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C134891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134891>	C134889	Pancreatic Cancer pT1b TNM Finding v8|Pancreatic Carcinoma pT1b TNM Finding v8	Pancreatic cancer with tumor measuring more than 0.5 cm and less than 1 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C134892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134892>	C134889	Pancreatic Cancer pT1c TNM Finding v8|Pancreatic Carcinoma pT1c TNM Finding v8	Pancreatic cancer with tumor measuring 1-2 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C134893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134893>	C134885	Pancreatic Cancer pT2 TNM Finding v8|Pancreatic Carcinoma pT2 TNM Finding v8|pT2	Pancreatic cancer with tumor measuring more than 2 cm and 4 cm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Pancreatic Baseline Form|CPTAC Terminology
C134894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134894>	C134885	Pancreatic Cancer pT3 TNM Finding v8|Pancreatic Carcinoma pT3 TNM Finding v8|pT3	Pancreatic cancer with tumor measuring more than 4 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Pancreatic Baseline Form|CPTAC Terminology
C134895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134895>	C134885	Pancreatic Cancer pT4 TNM Finding v8|Pancreatic Carcinoma pT4 TNM Finding v8|pT4	Pancreatic cancer with tumor involving the celiac axis, superior mesenteric artery, and/or common hepatic artery, regardless of size. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Pancreatic Baseline Form|CPTAC Terminology
C134896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134896>	C134882	Pancreatic Cancer Pathologic Regional Lymph Nodes TNM Finding v8|Pancreatic Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8|Pathologic Staging: Regional Lymph Nodes (pN)	A pathologic finding about one or more characteristics of pancreatic cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Pancreatic Baseline Form|CPTAC Terminology
C134897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134897>	C134896	Pancreatic Cancer pNX TNM Finding v8|Pancreatic Carcinoma pNX TNM Finding v8|pNX	Pancreatic cancer in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Pancreatic Baseline Form|CPTAC Terminology
C134898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134898>	C134896	Pancreatic Cancer pN0 TNM Finding v8|Pancreatic Carcinoma pN0 TNM Finding v8|pN0	Pancreatic cancer with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Pancreatic Baseline Form|CPTAC Terminology
C134899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134899>	C134896	Pancreatic Cancer pN1 TNM Finding v8|Pancreatic Carcinoma pN1 TNM Finding v8|pN1	Pancreatic cancer with metastasis in one to three regional lymph nodes. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Pancreatic Baseline Form|CPTAC Terminology
C13489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13489>	C13432	9p21	A chromosome band present on 9p	9p21		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C1348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1348>	C697|C574	Atrimustine|ATRIMUSTINE|Bestrabucil|Estradiol 3-benzoate 17-glycolate, 4-(p-(bis(2-chloroethyl)amino)phenyl)butyrate|KM2210	The benzoate of a estradiol-chlorambucil conjugate. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C134900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134900>	C134896	Pancreatic Cancer pN2 TNM Finding v8|Pancreatic Carcinoma pN2 TNM Finding v8	Pancreatic cancer with metastasis in four or more regional lymph nodes. (from AJCC 8th Ed.)			Finding	
C134901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134901>	C3420|C132020	BCL6 Gene Translocation|B-Cell CLL/Lymphoma 6 Gene Translocation|BCL5 Gene Translocation|BCL6 Translocation|Bcl-6 Gene Translocation|LAZ3 Gene Translocation|ZBTB27 Gene Translocation|ZNF51 Gene Translocation|Zinc Finger Protein 51 Gene Translocation	A cytogenetic abnormality that refers to any translocation involving the BCL6 gene.	BCL6 Gene Translocation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C134902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134902>	C207229	Pancreatic Cancer by AJCC v6 and v7 Stage|Pancreatic Carcinoma by AJCC v6 and v7 Stage	A term that refers to the staging of exocrine and endocrine pancreatic cancer including well-differentiated neuroendocrine tumors according to the American Joint Committee on Cancer, 6th and 7th editions.			Neoplastic Process	
C134903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134903>	C173981|C173219	Have Aches in Joints and/or Muscles Question|Have Aches in Joints and/or Muscles|I ache or hurt in my joints and/or muscles|Joints and muscle aches	A question about whether an individual has aches in joints and/or muscles.			Intellectual Product	
C134904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134904>	C91126	Have a Lot of Pain Question|Have a Lot of Pain|I hurt a lot	A question about whether an individual has a lot of pain.			Intellectual Product	
C134905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134905>	C173812|C173130	Become Nauseated During Medical Treatments Question|Become Nauseated During Medical Treatments|I become sick to my stomach when I have medical treatments	A question about whether an individual becomes nauseated during medical treatments.			Intellectual Product	
C134906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134906>	C173063	Food Does Not Taste Good Question|Food Does Not Taste Good|Food does not taste very good to me	A question about whether food does not taste very good to an individual.			Intellectual Product	
C134907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134907>	C173812|C173597|C173130	Become Nauseated While Thinking About Medical Treatments Question|Become Nauseated While Thinking About Medical Treatments|I become sick to my stomach when I think about medical treatments	A question about whether an individual becomes nauseated while thinking about medical treatments.			Intellectual Product	
C134908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134908>	C173130	Feel Too Nauseated to Eat Question|Feel Too Nauseated to Eat|I feel too sick to my stomach to eat	A question about whether an individual feels too nauseous to eat.			Intellectual Product	
C134909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134909>	C207229	Pancreatic Cancer by AJCC v8 Stage|Pancreatic Carcinoma by AJCC v8 Stage|Tumor Stage (Pathological)	A term that refers to the staging of pancreatic cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to pancreatic ductal adenocarcinoma, acinar cell carcinoma, intraductal papillary mucinous neoplasm with associated invasive carcinoma, intraductal tubulopapillary neoplasm with associated invasive carcinoma, colloid carcinoma, mucinous cystic neoplasm with associated invasive carcinoma, solid pseudopapillary neoplasm, large cell neuroendocrine carcinoma, small cell neuroendocrine carcinoma, and pancreatoblastoma. Well-differentiated neuroendocrine tumors are not staged using this staging system. (from AJCC 8th Ed.)			Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Pancreatic Baseline Form|CPTAC Terminology
C13490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13490>	C13432	14q24.3-q31	A chromosome band present on 14q			Gene or Genome	
C134911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134911>	C173130	Some Foods and Smells Cause Nausea Question|Some Foods and Smells Cause Nausea|Some foods and smells make me sick to my stomach	A question about whether some foods and smells make an individual nauseous.			Intellectual Product	
C134912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134912>	C173346	Needle Sticks Cause Pain Question|Needle Sticks Cause Pain|Needle sticks hurt	A question about whether needle sticks cause pain for an individual.			Intellectual Product	
C134913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134913>	C173386	Get Anxious About Having Blood Drawn Question|Get Anxious About Having Blood Drawn|I get scared when I have to have blood tests	A question about whether an individual gets anxious about having blood drawn.			Intellectual Product	
C134914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134914>	C134909	Stage 0 Pancreatic Cancer AJCC v8|Stage 0 Pancreatic Cancer|Stage 0 Pancreatic Carcinoma AJCC v8	Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. This includes high-grade pancreatic intraepithelial neoplasia (PanIn-3), intraductal papillary mucinous neoplasm with high-grade dysplasia, intraductal tubulopapillary neoplasm with high-grade dysplasia, and mucinous cystic neoplasm with high-grade dysplasia.  N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0 Pancreatic Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134915>	C134909	Stage I Pancreatic Cancer AJCC v8|Stage I Pancreatic Cancer|Stage I Pancreatic Carcinoma AJCC v8	Stage I includes: IA: (T1, N0, M0); IB: (T2, N0, M0). T1: Tumor measuring 2 cm or less in greatest dimension. T2: Tumor measuring more than 2 cm and 4 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Pancreatic Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134916>	C173386	Get Anxious About Having Needle Sticks Question|Get Anxious About Having Needle Sticks|I get scared about having needle sticks	A question about whether an individual gets anxious about having needle sticks.			Intellectual Product	
C134917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134917>	C134915	Stage IA Pancreatic Cancer AJCC v8|Stage IA|Stage IA Pancreatic Cancer|Stage IA Pancreatic Carcinoma AJCC v8	Stage IA includes: T1, N0, M0. T1: Tumor measuring 2 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IA Pancreatic Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Pancreatic Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134918>	C173386|C173145	Get Anxious When Waiting to See Doctor Question|Get Anxious When Waiting to See Doctor|I get scared when I am waiting to see the doctor	A question about whether an individual gets anxious when waiting to see the doctor.			Intellectual Product	
C134919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134919>	C173386|C173145	Get Anxious About Going to Doctor Question|Get Anxious About Going to Doctor|I get scared when I have to go to the doctor	A question about whether an individual gets anxious about going to the doctor.			Intellectual Product	
C13491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13491>	C13432	10p11.2	A chromosome band present on 10p			Gene or Genome	
C134920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134920>	C134915	Stage IB Pancreatic Cancer AJCC v8|Stage IB|Stage IB Pancreatic Cancer|Stage IB Pancreatic Carcinoma AJCC v8	Stage IB includes: T2, N0, M0. T2: Tumor measuring more than 2 cm and 4 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IB Pancreatic Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Pancreatic Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134921>	C134909	Stage II Pancreatic Cancer AJCC v8|Stage II Pancreatic Cancer|Stage II Pancreatic Carcinoma AJCC v8	Stage II includes: IIA: (T3, N0, M0); IIB: (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T1: Tumor measuring 2 cm or less in greatest dimension. T2: Tumor measuring more than 2 cm and 4 cm or less in greatest dimension. T3: Tumor measuring more than 4 cm in greatest dimension. N0: No regional lymph node metastasis. N1: Metastasis in one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Pancreatic Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C134922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134922>	C173386	Get Anxious About Going to Hospital Question|Get Anxious About Going to Hospital|I get scared when I have to go to the hospital	A question about whether an individual gets anxious about going to the hospital.			Intellectual Product	
C134923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134923>	C173934|C173933|C173812	Worry About Side Effects from Medical Treatments Question|I worry about side effects from medical treatments|Worry About Side Effects from Medical Treatments	A question about whether an individual worries about side effects from medical treatments.			Intellectual Product	
C134924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134924>	C173934|C173812	Worry About Whether or not Medical Treatments are Working Question|I worry about whether or not my medical treatments are working|Worry About Whether or not Medical Treatments are Working	A question about whether an individual worries about whether medical treatments are working.			Intellectual Product	
C134925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134925>	C134921	Stage IIA Pancreatic Cancer AJCC v8|Stage IIA|Stage IIA Pancreatic Cancer|Stage IIA Pancreatic Carcinoma AJCC v8	Stage IIA includes: T3, N0, M0. T3: Tumor measuring more than 4 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIA Pancreatic Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Pancreatic Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134926>	C173934	Worry That Cancer Will Reoccur or Relapse Question|I worry that my cancer will come back or relapse|Worry That Cancer Will Reoccur or Relapse	A question about whether an individual worries that their cancer will reoccur or relapse.			Intellectual Product	
C134927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134927>	C134921	Stage IIB Pancreatic Cancer AJCC v8|Stage IIB|Stage IIB Pancreatic Cancer|Stage IIB Pancreatic Carcinoma AJCC v8	Stage IIB includes: (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T1: Tumor measuring 2 cm or less in greatest dimension. T2: Tumor measuring more than 2 cm and 4 cm or less in greatest dimension. T3: Tumor measuring more than 4 cm in greatest dimension. N1: Metastasis in one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIB Pancreatic Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Pancreatic Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134928>	C134909	Stage III Pancreatic Cancer AJCC v8|Stage III|Stage III Pancreatic Cancer|Stage III Pancreatic Carcinoma AJCC v8	Stage III includes: (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4, Any N, M0). T1: Tumor measuring 2 cm or less in greatest dimension. T2: Tumor measuring more than 2 cm and 4 cm or less in greatest dimension. T3: Tumor measuring more than 4 cm in greatest dimension. T4: Tumor involving the celiac axis, superior mesenteric artery, and/or common hepatic artery, regardless of size. N2: Metastasis in four or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Pancreatic Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Pancreatic Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134929>	C173398	Difficulty Figuring Out What To Do When Something is Bothersome Question|Difficulty Figuring Out What To Do When Something is Bothersome|It is hard for me to figure out what to do when something bothers me	A question about whether an individual has difficulty figuring out what to do when something bothers them.			Intellectual Product	
C13492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13492>	C13432	17p13.3	A chromosome band present on 17p			Gene or Genome	
C134930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134930>	C134909	Stage IV Pancreatic Cancer AJCC v8|Stage IV|Stage IV Pancreatic Cancer|Stage IV Pancreatic Carcinoma AJCC v8	Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Pancreatic Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Pancreatic Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C134931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134931>	C173398	Difficulty Working with Numbers or Math Question|Difficulty Working with Numbers or Math|I have trouble solving math problems|Trouble solving math problems	A question about whether an individual has difficulty working with numbers or math.			Intellectual Product	
C134932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134932>	C173398	Trouble Writing School Papers or Reports Question|I have trouble writing school papers or reports|Trouble Writing School Papers or Reports	A question about whether an individual has trouble writing school papers or reports.			Intellectual Product	
C134933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134933>	C173398	Difficulty Paying Attention To Things Question|Difficulty Paying Attention To Things|I have trouble paying attention|It is hard for me to pay attention to things	A question about whether an individual has difficulty paying attention to things.			Intellectual Product	Multidimensional Fatigue Symptom Inventory-Short Form|Pediatric Quality of Life Inventory Cancer Module
C134934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134934>	C176426|C173398	Difficulty Remembering What is Read Question|Difficulty Remembering What is Read|It is hard for me to remember what I read	A question about whether an individual has difficulty remembering what they read.			Intellectual Product	
C134935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134935>	C176022|C173160	Feel Not Good Looking Question|Feel Not Good Looking|I feel I am not good looking	A question about whether an individual feels that he/she is not good looking.			Intellectual Product	
C134936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134936>	C91102	Dislike Other People Seeing Scars Question|Dislike Other People Seeing Scars|Dislike Others Seeing Scars|I don't like other people to see my scars	A question about whether an individual does not like other people to see his/her scars.			Intellectual Product	
C134937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134937>	C173601	Embarrassed About Others Seeing Body Question|Embarrassed About Other People Seeing Body|Embarrassed About Others Seeing Body|I am embarrassed when others see my body	A question about whether an individual is embarrassed about others seeking his/her body.			Intellectual Product	
C134938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134938>	C173398|C135578	Difficulty Telling Doctors and Nurses About Feelings Question|Difficulty Telling Doctors and Nurses About Feelings|It is hard for me to tell the doctors and nurses how I feel	A question about whether an individual has difficulty telling the doctors and nurses how he/she feels.			Intellectual Product	
C134939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134939>	C173398|C135578	Difficulty Asking Questions to Doctors or Nurses Question|It is hard for me to ask the doctors and nurses	A question about whether an individual has difficulty asking the doctors or nurses questions.			Intellectual Product	
C13493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13493>	C13432	5q33-q35	A chromosome band present on 5q			Gene or Genome	
C134940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134940>	C173398	Difficulty Explaining Illness to Others Question|Difficulty Explaining Illness to Others|It is hard for me to explain my illness to other people	A question about whether an individual has difficulty explaining his/her illness to others.			Intellectual Product	
C134941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134941>	C85865|C104003	X-Linked Thrombocytopenia with Beta-Thalassemia|XLTT	An X-linked recessive condition caused by mutation(s) in the GATA1 gene encoding erythroid transcription factor. It is characterized by thrombocytopenia, hemolytic anemia, and impairment of hemoglobin chain synthesis.			Disease or Syndrome	
C134942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134942>	C60311	Rat Neoplasms	A neoplasm arising in a rat.			Neoplastic Process	Cellosaurus Disease Terminology
C134943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134943>	C134533	Budgerigar Fibrosarcoma	Fibrosarcoma that occurs in a budgerigar.			Neoplastic Process	Cellosaurus Disease Terminology
C134944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134944>	C134526	Canine Pancreatic Carcinoma	Pancreatic carcinoma that occurs in a dog.			Neoplastic Process	Cellosaurus Disease Terminology
C134945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134945>	C135005	Chicken Monocytic Leukemia	Monocytic leukemia that occurs in a chicken.			Neoplastic Process	Cellosaurus Disease Terminology
C134946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134946>	C134988	Hamster Insulinoma	Insulinoma that occurs in a hamster.			Neoplastic Process	Cellosaurus Disease Terminology
C134947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134947>	C22980	Mouse Leydig Cell Tumor	A Leydig cell tumor that occurs in a mouse.			Neoplastic Process	Cellosaurus Disease Terminology
C134949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134949>	C136559	Pike Sarcoma	Sarcoma that occurs in a pike.			Neoplastic Process	Cellosaurus Disease Terminology
C13494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13494>	C13432	10q11-q12	A chromosome band present on 10q			Gene or Genome	
C134950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134950>	C134533	Quail Fibrosarcoma	Fibrosarcoma that occurs in a quail.			Neoplastic Process	Cellosaurus Disease Terminology
C134951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134951>	C134533	Suncus Murinus Mammary Tumor	A mammary tumor that occurs in Suncus murinus.			Neoplastic Process	Cellosaurus Disease Terminology
C134952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134952>	C75467	Charcot-Marie-Tooth Disease Type 2A|Axonal Charcot-Marie-Tooth Disease Type 2A2|CMT2A	Charcot-Marie-Tooth caused by mutation(s) in the MFN2 gene, encoding mitofusin-2. It results in peripheral axonal neuropathy.			Disease or Syndrome	
C134953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134953>	C75467	Charcot-Marie-Tooth Disease Type 2E|CMT2E	A form of Charcot-Marie-Tooth disease which is inherited in an autosomal dominant manner. It is caused by mutation(s) in the NEFL gene, encoding neurofilament light polypeptide. It results in peripheral axonal neuropathy.			Disease or Syndrome	Cellosaurus Disease Terminology
C134954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134954>	C75467	Charcot-Marie-Tooth Disease Type 4J|CMT4J	A form of Charcot-Marie-Tooth disease which is inherited in an autosomal recessive manner. It is caused by mutation(s) in the FIG4 gene, encoding polyphosphoinositide phosphatase. It results in peripheral demyelinating motor and sensory neuropathy.			Disease or Syndrome	Cellosaurus Disease Terminology
C134955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134955>	C134533	Bat Skin Tumor	A skin tumor that occurs in a bat.			Neoplastic Process	Cellosaurus Disease Terminology
C134956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134956>	C134526	Canine Acanthomatous Epulis	A tumor arising from odontogenic epithelium and occurs in a dog.			Neoplastic Process	Cellosaurus Disease Terminology
C134957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134957>	C134988	Hamster Chondrosarcoma	A chondrosarcoma that occurs in a hamster.			Neoplastic Process	Cellosaurus Disease Terminology
C134958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134958>	C24163	Hemangioendothelioma of the Mouse Thyroid Gland	A neoplasm that arises from vascular endothelium and occurs in the thyroid gland of a mouse.			Neoplastic Process	Cellosaurus Disease Terminology
C134959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134959>	C134533	Marmoset Lymphoma	Lymphoma that occurs in a marmoset.			Neoplastic Process	Cellosaurus Disease Terminology
C13495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13495>	C13432	20q11.2	A chromosome band present on 20q			Gene or Genome	
C134960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134960>	C24036	Mouse Adrenal Gland Pheochromocytoma	A pheochromocytoma that occurs in the adrenal gland of a mouse.			Neoplastic Process	Cellosaurus Disease Terminology
C134961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134961>	C23125	Mouse Submandibular Gland Neoplasm	A tumor arising in the submandibular gland of a mouse.			Neoplastic Process	Cellosaurus Disease Terminology
C134962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134962>	C136559	Poeciliopsis Lucida Hepatocellular Carcinoma	Hepatocellular carcinoma that occurs in Poeciliopsis lucida.			Neoplastic Process	Cellosaurus Disease Terminology
C134963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134963>	C134533	Seal Lymphoma	A lymphoma that occurs in a seal.			Neoplastic Process	Cellosaurus Disease Terminology
C134964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134964>	C134533	Tamarin Colon Adenocarcinoma	Adenocarcinoma arising in the colon of a tamarin.			Neoplastic Process	Cellosaurus Disease Terminology
C134965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134965>	C125238	Memorial Symptom Assessment Scale (MSAS) 10-18|MSAS 10-18|Memorial Symptom Assessment Scale (Pediatrics 10-18)|Memorial Symptom Assessment Scale 10-18	A patient-rated questionnaire designed to evaluate the prevalence, characteristics, and distress to children with cancer aged 10-18. This 30-question instrument was adapted from a previously-validated adult version.			Intellectual Product	
C134966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134966>	C85429	MSAS Frequency Score Likert Scale|Memorial Symptom Assessment Scale (Pediatrics 10-18) Frequency Score 4 Point Scale	A scale for the subjective scoring of event frequency that ranges from 1: Almost Never to 4: Almost Always designed for use with the Memorial Symptom Assessment Scale (MSAS) 10-18.			Intellectual Product	
C134967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134967>	C2152|C155322	BRAFV600/PI3K Inhibitor ASN003|ASN 003|ASN-003|ASN003	A selective inhibitor of mutated forms of B-RAF kinase at amino acid position 600 (BRAFV600), including BRAFV600E, the alpha, delta and, to a lesser extent, beta isoforms of phosphatidylinositide 3-kinase (PI3K), including mutated forms of PI3KCA, which encodes the p110-alpha catalytic subunit of the class I PI3K, and the phosphatase and tensin homologs (PTEN) with loss-of-function mutation, with potential antineoplastic activity. Upon administration of ASN003, this agent selectively targets, binds to and inhibits the activity of BRAFV600 mutants as well as mutated isoforms of PI3K. This inhibits signaling through B-RAF- and PI3K/mechanistic target of rapamycin (mTOR)-mediated pathways and inhibits cellular proliferation in tumor cells with BRAFV600 mutations, those expressing PI3K and/or those driven by PTEN. Dysregulation of the B-RAF- and PI3K-mediated pathways is frequently seen in a variety of tumors and results in increased tumor cell growth and survival. Dual targeting of both pathways may increase efficacy and anti-tumor potential compared to the targeting of just one pathway by a selective B-RAF inhibitor or selective PI3K pathway inhibitor alone.	BRAFV600/PI3K Inhibitor ASN003		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C134968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134968>	C27993	Drug Shortage	A deficit in the availability of a pharmaceutical agent because the supply is insufficient to meet the actual or predicted therapeutic demand.			Qualitative Concept	
C134969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134969>	C28108	AIDS-Related Kaposi Sarcoma Stage	A term that refers to the staging of AIDS-related Kaposi sarcoma according to the AIDS Clinical Trials Group system. The latter incorporates the extent of tumor (T), the status of the immune system (I), as measured by the number of CD4 cells present in the blood, and the extent of involvement within the body or systemic illness (S). Under each major heading, there are 2 subgroups: either a 0 (good risk) or a 1 (poor risk) group. (American Cancer Society)			Classification	
C13496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13496>	C13432	7p12	A chromosome band present on 7p			Gene or Genome	
C134970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134970>	C134969	AIDS-Related Kaposi Sarcoma T (Tumor) Status	A term that refers to the tumor status of AIDS-related Kaposi sarcoma according to the AIDS Clinical Trials Group system. (American Cancer Society)			Classification	
C134971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134971>	C134970	AIDS-Related Kaposi Sarcoma T0 (Good Risk): Localized Tumor	AIDS-related Kaposi sarcoma is only in the skin and/or the lymph nodes, and/or there is only a small amount of disease on the palate. The Kaposi sarcoma lesions in the mouth are flat rather than raised. (American Cancer Society)			Classification	
C134972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134972>	C134970	AIDS-Related Kaposi Sarcoma T1 (Poor Risk): Widespread Tumor	AIDS-related Kaposi sarcoma with widespread lesions.			Classification	
C134973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134973>	C134972	AIDS-Related Kaposi Sarcoma T1 (Poor Risk): Edema or Ulceration|AIDS-Related Kaposi Sarcoma T1: Edema or Ulceration|Stage 1 - Edema or Ulceration	AIDS-related Kaposi sarcoma with edema or ulceration due to the tumor.			Classification	
C134974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134974>	C134972	AIDS-Related Kaposi Sarcoma T1 (Poor Risk): Extensive Oral Involvement|AIDS-Related Kaposi Sarcoma T1: Extensive Oral Involvement|Stage 1 - Extensive Oral	AIDS-related Kaposi sarcoma with lesions that are nodular and/or lesions in roof of the mouth.			Classification	
C134975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134975>	C134972	AIDS-Related Kaposi Sarcoma T1 (Poor Risk): Gastrointestinal Tract Involvement|AIDS-Related Kaposi Sarcoma T1: Gastrointestinal Tract Involvement|Stage 1 - Gastrointestinal	AIDS-related Kaposi sarcoma involving the esophagus, stomach, or intestines.			Classification	
C134976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134976>	C134972	AIDS-Related Kaposi Sarcoma T1 (Poor Risk): Pulmonary Involvement|AIDS-Related Kaposi Sarcoma T1: Pulmonary Involvement|Stage 1 - Pulmonary	AIDS-related Kaposi sarcoma involving the lungs.			Classification	
C134977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134977>	C134972	AIDS-Related Kaposi Sarcoma T1 (Poor Risk): Other Non-Nodal Viscera Involvement	AIDS-related Kaposi sarcoma involving organs other than the lungs or gastrointestinal tract. It includes liver, bladder, reproductive tract, heart, and endocrine organs.			Classification	
C134978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134978>	C134969	AIDS-Related Kaposi Sarcoma I (Immune System) Status	A term that refers to the immune system status of AIDS-related Kaposi sarcoma according to the AIDS Clinical Trials Group system. The immune status is assessed using the CD4 count test. (American Cancer Society)			Classification	
C134979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134979>	C134978	AIDS-Related Kaposi Sarcoma I0 (Good Risk)	AIDS-related Kaposi sarcoma in which the CD4 cell count is 150 or more cells per cubic mm.			Classification	
C13497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13497>	C13432	8q22-q23	A chromosome band present on 8q			Gene or Genome	
C134980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134980>	C134978	AIDS-Related Kaposi Sarcoma I1 (Poor Risk)	AIDS-related Kaposi sarcoma in which the CD4 cell count is lower than 150 cells per cubic mm.			Classification	
C134981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134981>	C134969	AIDS-Related Kaposi Sarcoma S (Systemic Illness) Status	A term that refers to the systemic illness status of AIDS-related Kaposi sarcoma according to the AIDS Clinical Trials Group system. (American Cancer Society)			Classification	
C134982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134982>	C134981	AIDS-Related Kaposi Sarcoma S0 (Good Risk)	AIDS-related Kaposi sarcoma in which no systemic illness is present; there is no history of opportunistic infections or thrush and no B symptoms lasting more than 2 weeks. The Karnofsky performance status score is 70 or higher. (American Cancer Society)			Classification	
C134983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134983>	C134981	AIDS-Related Kaposi Sarcoma S1 (Poor Risk)	AIDS-related Kaposi sarcoma in which systemic illness is present; one or more of the following is true: history of opportunistic infections or thrush; one or more B symptoms is present; Karnofsky performance status score is under 70; other HIV-related illness is present, such as neurological disease or lymphoma. (American Cancer Society)			Classification	
C134984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134984>	C134969	AIDS-Related Kaposi Sarcoma Overall Risk Group	The overall risk group for AIDS-related Kaposi sarcoma based on the tumor, immune system, and systemic illness status. Since highly active antiretroviral therapy became available to treat HIV, the immune system status has become less important and is often not counted in determining the risk group. (American Cancer Society)			Classification	
C134985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134985>	C134984	AIDS-Related Kaposi Sarcoma Good Risk	The following combinations of tumor and systemic illness status define good risk AIDS-related Kaposi sarcoma: T0 S0, T1 S0, or T0 S1. T0: Localized tumor. T1: Widespread tumor. S0: No systemic illness is present. S1: Systemic illness is present. (American Cancer Society)			Classification	
C134986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134986>	C134984	AIDS-Related Kaposi Sarcoma Poor Risk	The following combination of tumor and systemic illness status define poor risk AIDS-related Kaposi sarcoma: T1 S1. T1: Widespread tumor. S1: Systemic illness is present. (American Cancer Society)			Classification	
C134987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134987>	C159438	Selpercatinib|6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitrile|LOXO 292|LOXO-292|LOXO292|RET Kinase Inhibitor LOXO-292|Retevmo|Retsevmo|SELPERCATINIB|WHO 10967	An orally bioavailable selective inhibitor of wild-type, mutant and fusion products involving the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET), with potential antineoplastic activity. Upon oral administration, selpercatinib selectively binds to and targets wild-type RET as well as various RET mutants and RET-containing fusion products. This results in an inhibition of cell growth of tumors cells that exhibit increased RET activity. In addition, selpercatinib targets, binds to and inhibits vascular endothelial growth factor receptor 1 (VEGFR1) and 3 (VEGFR3), and fibroblast growth factor receptor 1 (FGFR1), 2 (FGFR2), and 3 (FGFR3). RET overexpression, activating mutations, and fusions result in the upregulation and/or overactivation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role in the development and progression of these cancers.	Selpercatinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C134988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134988>	C134533	Hamster Neoplasm	A neoplasm occurring in a hamster.			Neoplastic Process	Cellosaurus Disease Terminology
C134989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134989>	C134530	Rabbit Neoplasm	A neoplasm occurring in a rabbit.			Neoplastic Process	Cellosaurus Disease Terminology
C13498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13498>	C13432	Xp11.2	A chromosome band present on Xp			Gene or Genome	
C134990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134990>	C134988	Hamster Adrenal Carcinoma	Carcinoma arising from the adrenal gland and occurring in a hamster.			Neoplastic Process	Cellosaurus Disease Terminology
C134991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134991>	C134988	Hamster Lung Carcinoma	Carcinoma arising from the lung and occurring in a hamster.			Neoplastic Process	Cellosaurus Disease Terminology
C134992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134992>	C134988	Hamster Fibrosarcoma	Fibrosarcoma that occurs in a hamster.			Neoplastic Process	Cellosaurus Disease Terminology
C134993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134993>	C134988	Hamster Pituitary Carcinoma	Carcinoma arising in the pituitary gland and occurring in a hamster.			Neoplastic Process	Cellosaurus Disease Terminology
C134994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134994>	C134988	Hamster Small Intestinal Neoplasm	A neoplasm that occurs in the small intestine of a hamster.			Neoplastic Process	Cellosaurus Disease Terminology
C134995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134995>	C134535	Horse Sarcoid	A fibroblastic tumor that occurs in the skin of a horse.			Neoplastic Process	Cellosaurus Disease Terminology
C134996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134996>	C23994	Mouse Histiocytic and Dendritic Cell Neoplasm	A tumor arising from histiocytes and dendritic cells and occurring in a mouse.			Neoplastic Process	Cellosaurus Disease Terminology
C134997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134997>	C22058	Mouse Thymic Lymphoma	A lymphoma that arises in the thymus of a mouse.			Neoplastic Process	Cellosaurus Disease Terminology
C134998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134998>	C134989	Rabbit Papilloma|Shope Papilloma	A rabbit papilloma that is associated with infection by the Shope papilloma virus.			Neoplastic Process	Cellosaurus Disease Terminology
C134999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C134999>	C134533	Rattlesnake Fibroma	A fibroma that occurs in a rattlesnake.			Neoplastic Process	Cellosaurus Disease Terminology
C13499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13499>	C13432	12q23	A chromosome band present on 12q			Gene or Genome	
C1349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1349>	C578	Recombinant Inhibin B|Inhibin B	A recombinant therapeutic agent which is chemically identical to or similar to an endogenous glycoprotein which inhibits pituitary production of follicle-stimulating hormone (FSH).  Produced and secreted by the testis or ovarian follicle, endogenous inhibin B contributes to the control of gametogenesis, embryonic and fetal development, and hematopoiesis. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C135000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135000>	C134533	Seal Lymphosarcoma	Lymphosarcoma that occurs in a seal.			Neoplastic Process	Cellosaurus Disease Terminology
C135001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135001>	C134533	Turtle Neoplasm	A neoplasm that occurs in a turtle.			Neoplastic Process	Cellosaurus Disease Terminology
C135002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135002>	C136559	Walleye Dermal Sarcoma	Sarcoma arising from the connective tissue of the dermis and occurring in a walleye.			Neoplastic Process	Cellosaurus Disease Terminology
C135003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135003>	C134533	Budgerigar Testicular Carcinoma	Carcinoma that arises in the testicle of a budgerigar.			Neoplastic Process	Cellosaurus Disease Terminology
C135004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135004>	C135005	Chicken Lymphoma	Lymphoma that occurs in a chicken.			Neoplastic Process	Cellosaurus Disease Terminology
C135005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135005>	C134534	Chicken Neoplasm	A neoplasm that occurs in a chicken.			Neoplastic Process	Cellosaurus Disease Terminology
C135006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135006>	C136559	Fish Melanoma	Melanoma that occurs in a fish.			Neoplastic Process	Cellosaurus Disease Terminology
C135008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135008>	C134528	Feline Reticulum Cell Sarcoma	Reticulum cell sarcoma that occurs in a cat.			Neoplastic Process	Cellosaurus Disease Terminology
C135009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135009>	C25364	Sponsor Study Reference Identifier|SPREFID|SPREFID|Sponsor's Study Reference ID|Sponsor's Study Reference ID|Sponsor's Study Reference ID	The reference identifier that is assigned by the sponsor and by which the study is known to the sponsor.			Intellectual Product	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C13500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13500>	C13432	12p12	A chromosome band present on 12p			Gene or Genome	
C135010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135010>	C103175	CDISC SDTM Pharmacogenomics/Genetics Methods and Supporting Information Test Code Terminology|SDTM-PGTSTCD	Terminology associated with the pharmacogenomics/genetics methods and supporting information test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	
C135011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135011>	C103175	CDISC SDTM Pharmacogenomics/Genetics Methods and Supporting Information Test Name Terminology|SDTM-PGTST	Terminology associated with the pharmacogenomics/genetics methods and supporting information test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	
C135012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135012>	C66830	CDISC SDTM AJCC Tumor Grade Response Terminology|AJCC Tumor Grade Response|AJCCGRD|SDTM-AJCCGRD	Terminology associated with the AJCC tumor grade response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135013>	C103175	CDISC SDTM Pharmacogenomics/Genetics Findings Result Category Terminology|GENRCAT|Pharmacogenomics/Genetics Findings Result Category|SDTM-GENRCAT	Terminology associated with the pharmacogenomics/genetics findings result category codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	
C135014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135014>	C192109|C128494	Dispense Limited Quantity	The dispenser must dispense only a limited quantity of the drug.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C135015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135015>	C192109|C128494	Prescribe Limited Quantity	The prescriber must prescribe only a limited quantity of the drug.			Activity	FDA Structured Product Labeling Terminology|SPL REMS Requirement Terminology
C135016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135016>	C97927	PHOX2B Gene Mutation|NBLST2 Gene Mutation|NBPhox Gene Mutation|Neuroblastoma Paired-Type Homeobox Gene Mutation|PMX2B Gene Mutation|Paired Mesoderm Homeobox 2b Gene Mutation|Paired-Like Homeobox 2b Gene Mutation	A change in the nucleotide sequence of the PHOX2B gene.	PHOX2B Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C135017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135017>	C2926	Lung Non-Squamous Non-Small Cell Carcinoma|Non-Squamous Non-Small Cell Lung Cancer|Non-Squamous Non-Small Cell Lung Carcinoma|Non-squamous	A non-small cell lung carcinoma without evidence of squamous differentiation.	Non-Squamous Non-Small Cell Lung Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135018>	C1752|C1663	Neoantigen-HSP70 Peptide Cancer Vaccine AGEN2017|AGEN 2017|AGEN-2017|AGEN2017|ASV|ASV AGEN2017|AutoSynVax|AutoSynVax AGEN2017|AutoSynVax Vaccine|Autologous Cancer Vaccine AGEN2017|Neoantigen Vaccine AGEN2017	A proprietary, personalized autologous synthetic cancer vaccine composed of patient-specific synthetic cancer neo-epitopes complexed with heat shock protein 70 (HSP 70; HSP70), with potential immunostimulating and antineoplastic activities. Upon administration of the neoantigen-HSP70 peptide cancer vaccine AGEN2017, the HSPs present the neoantigens to antigen presenting cells (APCs) and help elicit a potent neoantigen-specific T-cell-based anti-tumor immune response, thereby killing the neoantigen-expressing cancer cells. HSP70 is able to the transport the neo-epitopes, activate APCs and enhance the T-cell-mediated immune response.	Neoantigen-HSP70 Peptide Cancer Vaccine AGEN2017		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C135019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135019>	C133361	Digestive System Neuroendocrine Tumor TNM Finding v8	A finding about one or more characteristics of a digestive system neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system.			Finding	
C13501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13501>	C13432	7q32-q36	A chromosome band present on 7q			Gene or Genome	
C135020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135020>	C135019	Gastric Neuroendocrine Tumor TNM Finding v8	A finding about one or more characteristics of a gastric neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system. This classification system applies to gastric "carcinoid" tumors (NET G1 and G2, and rare well-differentiated G3). Gastric high-grade neuroendocrine carcinoma and gastric mixed adenoneuroendocrine carcinoma are not included in this classification system. (from AJCC 8th Ed.)			Finding	
C135021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135021>	C135020	Gastric Neuroendocrine Tumor Clinical TNM Finding v8	A clinical finding about one or more characteristics of a gastric neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system.			Finding	
C135022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135022>	C135021	Gastric Neuroendocrine Tumor Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of a gastric neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C135023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135023>	C135022	Gastric Neuroendocrine Tumor cM0 TNM Finding v8	Gastric neuroendocrine tumor without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C135024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135024>	C135022	Gastric Neuroendocrine Tumor cM1 TNM Finding v8	Gastric neuroendocrine tumor with distant metastasis. (from AJCC 8th Ed.)			Finding	
C135025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135025>	C135024	Gastric Neuroendocrine Tumor cM1a TNM Finding v8	Gastric neuroendocrine tumor with metastasis confined to liver. (from AJCC 8th Ed.)			Finding	
C135026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135026>	C135024	Gastric Neuroendocrine Tumor cM1b TNM Finding v8	Gastric neuroendocrine tumor with metastasis in at least one extrahepatic site (e.g., lung, ovary, nonregional lymph node, peritoneum, bone). (from AJCC 8th Ed.)			Finding	
C135027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135027>	C135024	Gastric Neuroendocrine Tumor cM1c TNM Finding v8	Gastric neuroendocrine tumor with both hepatic and extrahepatic metastases. (from AJCC 8th Ed.)			Finding	
C135028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135028>	C135020	Gastric Neuroendocrine Tumor Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of a gastric neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system.			Finding	
C135029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135029>	C135028	Gastric Neuroendocrine Tumor Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of a gastric neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C13502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13502>	C13432	3p11.2	A chromosome band present on 3p			Gene or Genome	
C135030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135030>	C135029	Gastric Neuroendocrine Tumor pM1 TNM Finding v8	Gastric neuroendocrine tumor with distant metastasis. (from AJCC 8th Ed.)			Finding	
C135031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135031>	C135030	Gastric Neuroendocrine Tumor pM1a TNM Finding v8	Gastric neuroendocrine tumor with metastasis confined to liver. (from AJCC 8th Ed.)			Finding	
C135032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135032>	C135030	Gastric Neuroendocrine Tumor pM1b TNM Finding v8	Gastric neuroendocrine tumor with metastasis in at least one extrahepatic site (e.g., lung, ovary, nonregional lymph node, peritoneum, bone). (from AJCC 8th Ed.)			Finding	
C135033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135033>	C135030	Gastric Neuroendocrine Tumor pM1c TNM Finding v8	Gastric neuroendocrine tumor with both hepatic and extrahepatic metastases. (from AJCC 8th Ed.)			Finding	
C135034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135034>	C135028	Gastric Neuroendocrine Tumor Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of a gastric neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C135035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135035>	C135034	Gastric Neuroendocrine Tumor pTX TNM Finding v8	Gastric neuroendocrine tumor in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C135036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135036>	C135034	Gastric Neuroendocrine Tumor pT0 TNM Finding v8	Gastric neuroendocrine tumor with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C135037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135037>	C135034	Gastric Neuroendocrine Tumor pT1 TNM Finding v8	Gastric neuroendocrine tumor invading the lamina propria or submucosa and is less than or equal to 1 cm in size. (from AJCC 8th Ed.)			Finding	
C135038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135038>	C135034	Gastric Neuroendocrine Tumor pT2 TNM Finding v8	Gastric neuroendocrine tumor invading the muscularis propria or is greater than 1 cm in size. (from AJCC 8th Ed.)			Finding	
C135039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135039>	C135034	Gastric Neuroendocrine Tumor pT3 TNM Finding v8	Gastric neuroendocrine tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. (from AJCC 8th Ed.)			Finding	
C13503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13503>	C13432	19p13.1	A chromosome band present on 19p			Gene or Genome	
C135040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135040>	C135034	Gastric Neuroendocrine Tumor pT4 TNM Finding v8	Gastric neuroendocrine tumor invading visceral peritoneum (serosa) or other organs or adjacent structures. (from AJCC 8th Ed.)			Finding	
C135041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135041>	C135028	Gastric Neuroendocrine Tumor Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of a gastric neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C135042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135042>	C135041	Gastric Neuroendocrine Tumor pNX TNM Finding v8	Gastric neuroendocrine tumor in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)			Finding	
C135043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135043>	C135041	Gastric Neuroendocrine Tumor pN0 TNM Finding v8	Gastric neuroendocrine tumor with no metastasis to regional lymph nodes. (from AJCC 8th Ed.)			Finding	
C135044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135044>	C135041	Gastric Neuroendocrine Tumor pN1 TNM Finding v8	Gastric neuroendocrine tumor with regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C135045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135045>	C95871	Gastric Neuroendocrine Tumor by AJCC v8 Stage	A term that refers to the staging of a gastric neuroendocrine tumor according to the American Joint Committee on Cancer, 8th edition. This staging system applies to gastric "carcinoid" tumors (NET G1 and G2, and rare well-differentiated G3). Gastric high-grade neuroendocrine carcinoma and gastric mixed adenoneuroendocrine carcinoma are not included in this staging system. (from AJCC 8th Ed.)			Neoplastic Process	
C135046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135046>	C135045	Stage I Gastric Neuroendocrine Tumor AJCC v8|Stage I Gastric Neuroendocrine Tumor	Stage I includes: T1, N0, M0. T1: Tumor invading the lamina propria or submucosa and is less than or equal to 1 cm in size. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Gastric Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135047>	C135045	Stage II Gastric Neuroendocrine Tumor AJCC v8|Stage II Gastric Neuroendocrine Tumor	Stage II includes: (T2, N0, M0); (T3, N0, M0). T2: Tumor invading the muscularis propria or is greater than 1 cm in size. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Gastric Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135048>	C135045	Stage III Gastric Neuroendocrine Tumor AJCC v8|Stage III Gastric Neuroendocrine Tumor	Stage III includes: (T1, N1, M0); (T2, N1, M0); (T3, N1, M0); (T4, N0, M0); (T4, N1, M0). T1: Tumor invading the lamina propria or submucosa and is less than or equal to 1 cm in size. T2: Tumor invading the muscularis propria or is greater than 1 cm in size. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. T4: Tumor invading visceral peritoneum (serosa) or other organs or adjacent structures. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Gastric Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135049>	C135045	Stage IV Gastric Neuroendocrine Tumor AJCC v8|Stage IV Gastric Neuroendocrine Tumor	Stage IV includes: (T1, N0, N1, M1); (T2, N0, N1, M1); (T3, N0, N1, M1); (T4, N0, N1, M1). T1: Tumor invading the lamina propria or submucosa and is less than or equal to 1 cm in size. T2: Tumor invading the muscularis propria or is greater than 1 cm in size. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. T4: Tumor invading visceral peritoneum (serosa) or other organs or adjacent structures. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Gastric Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13504>	C13432	17q21.1	A chromosome band present on 17q			Gene or Genome	
C135050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135050>	C135019	Duodenal and Ampulla of Vater Neuroendocrine Tumor TNM Finding v8|Duodenum and Ampulla of Vater Neuroendocrine Tumor TNM Finding v8	A finding about one or more characteristics of a duodenum and ampulla of Vater neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system. This classification system applies to well-differentiated neuroendocrine tumors of the duodenum and ampulla of Vater. Carcinomas of the duodenum, including high-grade (grade 3), poorly differentiated neuroendocrine carcinomas and carcinomas of the ampulla of Vater, including high-grade (grade 3), poorly differentiated neuroendocrine carcinomas are not included in this classification system. (from AJCC 8th Ed.)			Finding	
C135051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135051>	C135050	Duodenal and Ampulla of Vater Neuroendocrine Tumor Clinical TNM Finding v8|Duodenum and Ampulla of Vater Neuroendocrine Tumor Clinical TNM Finding v8	A clinical finding about one or more characteristics of a duodenum and ampulla of Vater neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system.			Finding	
C135052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135052>	C135051	Duodenal and Ampulla of Vater Neuroendocrine Tumor Clinical Distant Metastasis TNM Finding v8|Duodenum and Ampulla of Vater Neuroendocrine Tumor Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of a duodenum and ampulla of Vater neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C135053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135053>	C135052	Duodenal and Ampulla of Vater Neuroendocrine Tumor cM0 TNM Finding v8|Duodenum and Ampulla of Vater Neuroendocrine Tumor cM0 TNM Finding v8	Duodenum and ampulla of Vater neuroendocrine tumor without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C135054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135054>	C135052	Duodenal and Ampulla of Vater Neuroendocrine Tumor cM1 TNM Finding v8|Duodenum and Ampulla of Vater Neuroendocrine Tumor cM1 TNM Finding v8	Duodenum and ampulla of Vater neuroendocrine tumor with distant metastasis. (from AJCC 8th Ed.)			Finding	
C135055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135055>	C135054	Duodenal and Ampulla of Vater Neuroendocrine Tumor cM1a TNM Finding v8|Duodenum and Ampulla of Vater Neuroendocrine Tumor cM1a TNM Finding v8	Duodenum and ampulla of Vater neuroendocrine tumor with metastasis confined to liver. (from AJCC 8th Ed.)			Finding	
C135056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135056>	C135054	Duodenal and Ampulla of Vater Neuroendocrine Tumor cM1b TNM Finding v8|Duodenum and Ampulla of Vater Neuroendocrine Tumor cM1b TNM Finding v8	Duodenum and ampulla of Vater neuroendocrine tumor with metastasis in at least one extrahepatic site (e.g., lung, ovary, nonregional lymph node, peritoneum, bone). (from AJCC 8th Ed.)			Finding	
C135057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135057>	C135054	Duodenal and Ampulla of Vater Neuroendocrine Tumor cM1c TNM Finding v8|Duodenum and Ampulla of Vater Neuroendocrine Tumor cM1c TNM Finding v8	Duodenum and ampulla of Vater neuroendocrine tumor with both hepatic and extrahepatic metastases. (from AJCC 8th Ed.)			Finding	
C135058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135058>	C208191	Autologous Peripheral Blood Mononuclear Cells|Autologous PBMC|Autologous PBMCs|Autologous Peripheral Blood Mononuclear Cell|Therapeutic PBMCs	A preparation of autologous peripheral blood mononuclear cells (PBMCs).	Autologous Peripheral Blood Mononuclear Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology
C135059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135059>	C135050	Duodenal and Ampulla of Vater Neuroendocrine Tumor Pathologic TNM Finding v8|Duodenum and Ampulla of Vater Neuroendocrine Tumor Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of a duodenum and ampulla of Vater neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system.			Finding	
C13505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13505>	C13432	12q13	A chromosome band present on 12q			Gene or Genome	
C135060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135060>	C135059	Duodenal and Ampulla of Vater Neuroendocrine Tumor Pathologic Distant Metastasis TNM Finding v8|Duodenum and Ampulla of Vater Neuroendocrine Tumor Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of a duodenum and ampulla of Vater neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C135061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135061>	C135060	Duodenal and Ampulla of Vater Neuroendocrine Tumor pM1 TNM Finding v8|Duodenum and Ampulla of Vater Neuroendocrine Tumor pM1 TNM Finding v8	Duodenum and ampulla of Vater neuroendocrine tumor with distant metastasis. (from AJCC 8th Ed.)			Finding	
C135062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135062>	C135061	Duodenal and Ampulla of Vater Neuroendocrine Tumor pM1a TNM Finding v8|Duodenum and Ampulla of Vater Neuroendocrine Tumor pM1a TNM Finding v8	Duodenum and ampulla of Vater neuroendocrine tumor with metastasis confined to liver. (from AJCC 8th Ed.)			Finding	
C135063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135063>	C135061	Duodenal and Ampulla of Vater Neuroendocrine Tumor pM1b TNM Finding v8|Duodenum and Ampulla of Vater Neuroendocrine Tumor pM1b TNM Finding v8	Duodenum and ampulla of Vater neuroendocrine tumor with metastasis in at least one extrahepatic site (e.g., lung, ovary, nonregional lymph node, peritoneum, bone). (from AJCC 8th Ed.)			Finding	
C135064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135064>	C135061	Duodenal and Ampulla of Vater Neuroendocrine Tumor pM1c TNM Finding v8|Duodenum and Ampulla of Vater Neuroendocrine Tumor pM1c TNM Finding v8	Duodenum and ampulla of Vater neuroendocrine tumor with both hepatic and extrahepatic metastases. (from AJCC 8th Ed.)			Finding	
C135065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135065>	C135059	Duodenal and Ampulla of Vater Neuroendocrine Tumor Pathologic Primary Tumor TNM Finding v8|Duodenum and Ampulla of Vater Neuroendocrine Tumor Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of a duodenum and ampulla of Vater neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C135066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135066>	C135065	Duodenal and Ampulla of Vater Neuroendocrine Tumor pTX TNM Finding v8|Duodenum and Ampulla of Vater Neuroendocrine Tumor pTX TNM Finding v8	Duodenum and ampulla of Vater neuroendocrine tumor in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C135067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135067>	C135065	Duodenal and Ampulla of Vater Neuroendocrine Tumor pT1 TNM Finding v8|Duodenum and Ampulla of Vater Neuroendocrine Tumor pT1 TNM Finding v8	Duodenum neuroendocrine tumor invading the mucosa or submucosa only and is equal or less than 1 cm; Ampulla of Vater neuroendocrine tumor measuring 1 cm or less and is confined within the sphincter of Oddi. (from AJCC 8th Ed.)			Finding	
C135068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135068>	C135065	Duodenal and Ampulla of Vater Neuroendocrine Tumor pT2 TNM Finding v8|Duodenum and Ampulla of Vater Neuroendocrine Tumor pT2 TNM Finding v8	Duodenum neuroendocrine tumor invading the muscularis propria or measuring more than 1 cm; Ampulla of Vater neuroendocrine tumor invading through the sphincter of Oddi into duodenal submucosa or muscularis propria, or measuring more than 1 cm. (from AJCC 8th Ed.)			Finding	
C135069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135069>	C135065	Duodenal and Ampulla of Vater Neuroendocrine Tumor pT3 TNM Finding v8|Duodenum and Ampulla of Vater Neuroendocrine Tumor pT3 TNM Finding v8	Duodenum and ampulla of Vater neuroendocrine tumor invading the pancreas or peripancreatic adipose tissue. (from AJCC 8th Ed.)			Finding	
C13506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13506>	C13432	2q33.3-q34	A chromosome band present on 2q			Gene or Genome	
C135070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135070>	C135065	Duodenal and Ampulla of Vater Neuroendocrine Tumor pT4 TNM Finding v8|Duodenum and Ampulla of Vater Neuroendocrine Tumor pT4 TNM Finding v8	Duodenum and ampulla of Vater neuroendocrine tumor invading the visceral peritoneum (serosa) or other organs. (from AJCC 8th Ed.)			Finding	
C135071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135071>	C135059	Duodenal and Ampulla of Vater Neuroendocrine Tumor Pathologic Regional Lymph Nodes TNM Finding v8|Duodenum and Ampulla of Vater Neuroendocrine Tumor Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of a duodenum and ampulla of Vater neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C135072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135072>	C135071	Duodenal and Ampulla of Vater Neuroendocrine Tumor pNX TNM Finding v8|Duodenum and Ampulla of Vater Neuroendocrine Tumor pNX TNM Finding v8	Duodenum and ampulla of Vater neuroendocrine tumor in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)			Finding	
C135073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135073>	C135071	Duodenal and Ampulla of Vater Neuroendocrine Tumor pN0 TNM Finding v8|Duodenum and Ampulla of Vater Neuroendocrine Tumor pN0 TNM Finding v8	Duodenum and ampulla of Vater neuroendocrine tumor without regional lymph node involvement. (from AJCC 8th Ed.)			Finding	
C135074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135074>	C135071	Duodenal and Ampulla of Vater Neuroendocrine Tumor pN1 TNM Finding v8|Duodenum and Ampulla of Vater Neuroendocrine Tumor pN1 TNM Finding v8	Duodenum and ampulla of Vater neuroendocrine tumor with regional lymph node involvement. (from AJCC 8th Ed.)			Finding	
C135075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135075>	C135080	Duodenal Neuroendocrine Tumor by AJCC v8 Stage	A term that refers to the staging of a duodenal neuroendocrine tumor according to the American Joint Committee on Cancer, 8th edition. This staging system applies to well-differentiated neuroendocrine tumors of the duodenum. Carcinomas of the duodenum, including high-grade (grade 3), poorly differentiated neuroendocrine carcinomas are not included in this staging system. (from AJCC 8th Ed.)			Neoplastic Process	
C135076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135076>	C135075	Stage I Duodenal Neuroendocrine Tumor AJCC v8|Stage I Duodenal Neuroendocrine Tumor	Stage I includes: T1, N0, M0. T1: Tumor invading the mucosa or submucosa only and is equal or less than 1 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Duodenal Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135077>	C135075	Stage II Duodenal Neuroendocrine Tumor AJCC v8|Stage II Duodenal Neuroendocrine Tumor	Stage II includes: (T2, N0, M0); (T3, N0, M0). T2: Tumor invading the muscularis propria or measuring more than 1 cm. T3: Tumor invading the pancreas or peripancreatic adipose tissue. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Duodenal Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135078>	C135075	Stage III Duodenal Neuroendocrine Tumor AJCC v8|Stage III Duodenal Neuroendocrine Tumor	Stage III includes: (T4, N0, M0); (Any T, N1, M0). T4: Tumor invading the visceral peritoneum (serosa) or other organs. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Duodenal Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135079>	C135075	Stage IV Duodenal Neuroendocrine Tumor AJCC v8|Stage IV Duodenal Neuroendocrine Tumor	Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Duodenal Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13507>	C13432	21q22.3	A chromosome band present on 21q			Gene or Genome	
C135080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135080>	C2995|C207852	Duodenal Neuroendocrine Tumor|Duodenal Well Differentiated Neuroendocrine Neoplasm|Duodenal Well-Differentiated Neuroendocrine Neoplasm	A well-differentiated, low-, intermediate-, or high-grade neoplasm with neuroendocrine differentiation that arises from the duodenum.			Neoplastic Process	Cellosaurus Disease Terminology
C135081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135081>	C95981	Ampulla of Vater Neuroendocrine Tumor by AJCC v8 Stage	A term that refers to the staging of an ampulla of Vater neuroendocrine tumor according to the American Joint Committee on Cancer, 8th edition. This staging system applies to well-differentiated neuroendocrine tumors of the ampulla of Vater. Carcinomas of the ampulla of Vater, including high-grade (grade 3), poorly differentiated neuroendocrine carcinomas are not included in this staging system. (from AJCC 8th Ed.)			Neoplastic Process	
C135082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135082>	C135081	Stage I Ampulla of Vater Neuroendocrine Tumor AJCC v8|Stage I Ampulla of Vater Neuroendocrine Tumor	Stage I includes: T1, N0, M0. T1: Tumor measuring 1 cm or less and is confined within the sphincter of Oddi. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Ampulla of Vater Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135083>	C135081	Stage II Ampulla of Vater Neuroendocrine Tumor AJCC v8|Stage II Ampulla of Vater Neuroendocrine Tumor	Stage II includes: (T2, N0, M0); (T3, N0, M0). T2: Tumor invading through the sphincter of Oddi into duodenal submucosa or muscularis propria, or measuring more than 1 cm. T3: Tumor invading the pancreas or peripancreatic adipose tissue. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Ampulla of Vater Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135084>	C135081	Stage III Ampulla of Vater Neuroendocrine Tumor AJCC v8|Stage III Ampulla of Vater Neuroendocrine Tumor	Stage III includes: (T4, N0, M0); (Any T, N1, M0). T4: Tumor invading the visceral peritoneum (serosa) or other organs. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Ampulla of Vater Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135085>	C135081	Stage IV Ampulla of Vater Neuroendocrine Tumor AJCC v8|Stage IV Ampulla of Vater Neuroendocrine Tumor	Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Ampulla of Vater Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135087>	C53543	Schimke Immunoosseous Dysplasia|Schimke Immuno-Osseous Dysplasia	An autosomal recessive condition caused by mutation(s) in the SMARCAL1 gene, encoding SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A-like protein 1. It is characterized by short stature, intrauterine growth restriction, microdontia, depressed nasal bridge, skeletal dysplasia, immune complex nephritis and immune deficiency.			Disease or Syndrome	Cellosaurus Disease Terminology
C135088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135088>	C53543	Spondyloperipheral Dysplasia	An autosomal dominant condition caused by mutation(s) in the COL2A1 gene, encoding collagen alpha-1(II) chain. It is characterized by short stature, pugilistic facies, midface hypoplasia, spondyloepiphyseal dysplasia, kyphosis, short ulna, and absent styloid process. Mutation(s) in the same gene are responsible for Kniest dysplasia.			Disease or Syndrome	Cellosaurus Disease Terminology
C135089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135089>	C91105	Pediatric Quality of Life Inventory Cancer Module|Pediatric Quality of Life Inventory Cancer-Specific Module|PedsQL Cancer Module|PedsQL-Cancer	A complement to the Pediatric Quality of Life generic core scales designed to provide greater measurement sensitivity for patients with cancer. This module has 25 items comprising 8 dimensions for use with children aged 2 to 18 years.			Intellectual Product	
C13508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13508>	C13432	1q21-q23	A chromosome band present on 1q			Gene or Genome	
C135090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135090>	C8401|C208152	Jejunal Neuroendocrine Tumor|Jejunal Well Differentiated Neuroendocrine Neoplasm|Jejunal Well-Differentiated Neuroendocrine Neoplasm	A well-differentiated, low-, intermediate-, or high-grade neoplasm with neuroendocrine differentiation that arises from the jejunum.			Neoplastic Process	
C135091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135091>	C177174	TLR 2/6/9 Agonist PUL-042|Inhalation Solution PUL-042|PUL 042|PUL-042|Pam2/M362|Pam2/M362 Combination|Pam2CSK4 Acetate/ODN M362|Pam2CSK4 Acetate/ODN M362 Combination|Solution PUL-042|TLR Agonist PUL-042|Toll-like Receptor Agonist PUL-042	A solution consisting of a combination of two toll-like receptor (TLR) ligands: Pam2CSK4 acetate (Pam2), a synthetic diacylated lipopeptide (LP) that is an agonist of TLR2 and TLR6 (TLR2/6) and the TLR9 agonist oligodeoxynucleotide (ODN) M362, which contains unmethylated CpG-based dinucleotides, with potential immunostimulating activity. Upon administration via inhalation of the PUL-042 solution, the components in PUL-042 bind to and activate TLRs on lung epithelial cells. This induces the epithelial cells to produce peptides and reactive oxygen species (ROS) against pathogens, including bacteria, fungi and viruses, that are present in the lungs. M362, through binding of the CpG motifs to TLR9 and subsequent TLR9-mediated signaling, initiates the innate immune system and activates macrophages, natural killer (NK) cells, B-cells, and plasmacytoid dendritic cells (pDCs), stimulates interferon-alpha (IFN-a) production and induces a T-helper 1 cells (Th1)-mediated immune response. Pam2CSK4, through TLR2/6, activates the production of T-helper 2 cells (Th2), leading to the production of Th2-specific cytokines. Altogether, this protects against and kills the pathogens present in the lungs and prevents pulmonary infection. TLRs play fundamental roles in both pathogen recognition and the activation of innate immunity.	TLR 2/6/9 Agonist PUL-042		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C135092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135092>	C3130|C208152	Ileal Neuroendocrine Tumor|Ileal Well Differentiated Neuroendocrine Neoplasm|Ileal Well-Differentiated Neuroendocrine Neoplasm	A well-differentiated, low-, intermediate-, or high-grade neoplasm with neuroendocrine differentiation that arises from the ileum.			Neoplastic Process	
C135093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135093>	C135019	Jejunum and Ileum Neuroendocrine Tumor TNM Finding v8	A finding about one or more characteristics of a jejunum and ileum neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system. This classification system applies to small bowel "carcinoid" tumors (NET G1 and G2, and rare well-differentiated G3) arising in the jejunum and ileum. This classification system does not apply to high-grade neuroendocrine carcinomas, mixed adenoneuroendocrine carcinomas, and neuroendocrine tumors of the duodenum. (from AJCC 8th Ed.)			Finding	
C135094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135094>	C135093	Jejunum and Ileum Neuroendocrine Tumor Clinical TNM Finding v8	A clinical finding about one or more characteristics of a jejunum and ileum neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system.			Finding	
C135095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135095>	C135094	Jejunum and Ileum Neuroendocrine Tumor Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of a jejunum and ileum neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C135096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135096>	C135095	Jejunum and Ileum Neuroendocrine Tumor cM0 TNM Finding v8	Jejunum and ileum neuroendocrine tumor without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C135097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135097>	C135095	Jejunum and Ileum Neuroendocrine Tumor cM1 TNM Finding v8	Jejunum and ileum neuroendocrine tumor with distant metastasis. (from AJCC 8th Ed.)			Finding	
C135098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135098>	C135097	Jejunum and Ileum Neuroendocrine Tumor cM1a TNM Finding v8	Jejunum and ileum neuroendocrine tumor with metastasis confined to liver. (from AJCC 8th Ed.)			Finding	
C135099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135099>	C135097	Jejunum and Ileum Neuroendocrine Tumor cM1b TNM Finding v8	Jejunum and ileum neuroendocrine tumor with metastasis in at least one extrahepatic site (e.g., lung, ovary, nonregional lymph node, peritoneum, bone). (from AJCC 8th Ed.)			Finding	
C13509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13509>	C13432	12p13	A chromosome band present on 12p			Gene or Genome	
C1350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1350>	C1556	Beta-Thioguanine Deoxyriboside|.beta.-2'-Deoxy-6-thioguanosine|.beta.-2'-Deoxythioguanosine|.beta.-2'-Deoxythiol guanosine|.beta.-Thioguanine deoxyriboside|1,9-dihydro-6H-purine-6-thione, 2-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)|2'-Deoxythioguanosine|2'-Desoxy-6-thioguanosine|2'-deoxythioguanosine|2'-desoxy-6-thioguanosine|6-Mercaptoguaninedeoxyriboside|6-Mercaptoguaninedeoxyriboside|6H-Purine-6-thione, 2-amino-9-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-1,9-dihydro-|9H-Purine-6-thiol, 2-amino-9-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-, monohydrate|9H-purine-6-thiol, 2-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl) monohydrate|ATEGANOSINE|Ateganosine|B-TGDR|BTG|Beta Thioguanine Deoxyriboside|Thioguanine 9.beta.D-2'-deoxyriboside|beta-2'-deoxy-6-thioguanosine|beta-2'-deoxythioguanosine|beta-2'-deoxythiol guanosine|thioguanine 9-beta-D-2'-deoxyriboside	A thiopurine nucleoside derivative with antineoplastic activity. After conversion to the triphosphate, beta-thioguanine deoxyriboside is incorporated into DNA, resulting in inhibition of DNA replication.  This agent is cytotoxic against leukemia cell lines and has demonstrated some activity against leukemia cells in vivo.  Beta-thioguanine deoxyriboside demonstrates antineoplastic activity against 6-thioguanine-resistant tumor cells. (NCI04)			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C135100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135100>	C135097	Jejunum and Ileum Neuroendocrine Tumor cM1c TNM Finding v8	Jejunum and ileum neuroendocrine tumor with both hepatic and extrahepatic metastases. (from AJCC 8th Ed.)			Finding	
C135101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135101>	C135093	Jejunum and Ileum Neuroendocrine Tumor Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of a jejunum and ileum neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system.			Finding	
C135102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135102>	C135101	Jejunum and Ileum Neuroendocrine Tumor Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of a jejunum and ileum neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C135103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135103>	C135102	Jejunum and Ileum Neuroendocrine Tumor pM1 TNM Finding v8	Jejunum and ileum neuroendocrine tumor with distant metastasis. (from AJCC 8th Ed.)			Finding	
C135104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135104>	C135103	Jejunum and Ileum Neuroendocrine Tumor pM1a TNM Finding v8	Jejunum and ileum neuroendocrine tumor with metastasis confined to liver. (from AJCC 8th Ed.)			Finding	
C135105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135105>	C135103	Jejunum and Ileum Neuroendocrine Tumor pM1b TNM Finding v8	Jejunum and ileum neuroendocrine tumor with metastasis in at least one extrahepatic site (e.g., lung, ovary, nonregional lymph node, peritoneum, bone). (from AJCC 8th Ed.)			Finding	
C135106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135106>	C135103	Jejunum and Ileum Neuroendocrine Tumor pM1c TNM Finding v8	Jejunum and ileum neuroendocrine tumor with both hepatic and extrahepatic metastases. (from AJCC 8th Ed.)			Finding	
C135107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135107>	C135101	Jejunum and Ileum Neuroendocrine Tumor Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of a jejunum and ileum neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C135108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135108>	C135107	Jejunum and Ileum Neuroendocrine Tumor pTX TNM Finding v8	Jejunum and ileum neuroendocrine tumor in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C135109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135109>	C135107	Jejunum and Ileum Neuroendocrine Tumor pT0 TNM Finding v8	Jejunum and ileum neuroendocrine tumor with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C13510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13510>	C13432	3q24-q28	A chromosome band present on 3q			Gene or Genome	
C135110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135110>	C135107	Jejunum and Ileum Neuroendocrine Tumor pT1 TNM Finding v8	Jejunum and ileum neuroendocrine tumor invading lamina propria or submucosa and measuring 1 cm or less in size. (from AJCC 8th Ed.)			Finding	
C135111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135111>	C135107	Jejunum and Ileum Neuroendocrine Tumor pT2 TNM Finding v8	Jejunum and ileum neuroendocrine tumor invading muscularis propria or measuring more than 1 cm in size.  (from AJCC 8th Ed.)			Finding	
C135112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135112>	C135107	Jejunum and Ileum Neuroendocrine Tumor pT3 TNM Finding v8	Jejunum and ileum neuroendocrine tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. (from AJCC 8th Ed.)			Finding	
C135113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135113>	C135107	Jejunum and Ileum Neuroendocrine Tumor pT4 TNM Finding v8	Jejunum and ileum neuroendocrine tumor invading visceral peritoneum (serosa) or other organs or adjacent structures. (from AJCC 8th Ed.)			Finding	
C135114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135114>	C135101	Jejunum and Ileum Neuroendocrine Tumor Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of a jejunum and ileum neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C135115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135115>	C135114	Jejunum and Ileum Neuroendocrine Tumor pNX TNM Finding v8	Jejunum and ileum neuroendocrine tumor in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)			Finding	
C135116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135116>	C135114	Jejunum and Ileum Neuroendocrine Tumor pN0 TNM Finding v8	Jejunum and ileum neuroendocrine tumor without regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C135117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135117>	C135114	Jejunum and Ileum Neuroendocrine Tumor pN1 TNM Finding v8	Jejunum and ileum neuroendocrine tumor with regional lymph node metastasis in less than 12 nodes. (from AJCC 8th Ed.)			Finding	
C135118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135118>	C135114	Jejunum and Ileum Neuroendocrine Tumor pN2 TNM Finding v8	Jejunum and ileum neuroendocrine tumor with large mesenteric masses (larger than 2 cm) and/or extensive nodal deposits (12 or greater), especially those that encase the superior mesenteric vessels. (from AJCC 8th Ed.)			Finding	
C135119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135119>	C135090	Jejunal Neuroendocrine Tumor by AJCC v8 Stage	A term that refers to the staging of a jejunal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system. This classification system applies to small bowel "carcinoid" tumors (NET G1 and G2, and rare well-differentiated G3) arising in the jejunum. This classification system does not apply to high-grade neuroendocrine carcinomas, mixed adenoneuroendocrine carcinomas, and neuroendocrine tumors of the duodenum. (from AJCC 8th Ed.)			Neoplastic Process	
C13511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13511>	C13432	22q12	A chromosome band present on 22q			Gene or Genome	
C135120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135120>	C135119	Stage I Jejunal Neuroendocrine Tumor AJCC v8|Stage I Jejunal Neuroendocrine Tumor	Stage I includes: T1, N0, M0. T1: Tumor invading lamina propria or submucosa and measuring 1 cm or less in size. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Jejunal Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135121>	C135119	Stage II Jejunal Neuroendocrine Tumor AJCC v8|Stage II Jejunal Neuroendocrine Tumor	Stage II includes: (T2, N0, M0); (T3, N0, M0). T2: Tumor invading muscularis propria or measuring more than 1 cm in size. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Jejunal Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135122>	C135119	Stage III Jejunal Neuroendocrine Tumor AJCC v8|Stage III Jejunal Neuroendocrine Tumor	Stage III includes: (T1, N1, N2, M0); (T2, N1, N2, M0); (T3, N1, N2, M0); (T4, N0, M0); (T4, N1, N2, M0). T1: Tumor invading lamina propria or submucosa and measuring 1 cm or less in size. T2: Tumor invading muscularis propria or measuring more than 1 cm in size. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. T4: Tumor invading visceral peritoneum (serosa) or other organs or adjacent structures. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis in less than 12 nodes. N2: Large mesenteric masses (larger than 2 cm) and/or extensive nodal deposits (12 or greater), especially those that encase the superior mesenteric vessels. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Jejunal Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135123>	C135119	Stage IV Jejunal Neuroendocrine Tumor AJCC v8|Stage IV Jejunal Neuroendocrine Tumor	Stage IV includes: (T1, N0, N1, N2, M1); (T2, N0, N1, N2, M1); (T3, N0, N1, N2, M1); (T4, N0, N1, N2, M1). T1: Tumor invading lamina propria or submucosa and measuring 1 cm or less in size. T2: Tumor invading muscularis propria or measuring more than 1 cm in size. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. T4: Tumor invading visceral peritoneum (serosa) or other organs or adjacent structures. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis in less than 12 nodes. N2: Large mesenteric masses (larger than 2 cm) and/or extensive nodal deposits (12 or greater), especially those that encase the superior mesenteric vessels. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Jejunal Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135124>	C135092	Ileal Neuroendocrine Tumor by AJCC v8 Stage	A term that refers to the staging of an ileal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system. This classification system applies to small bowel "carcinoid" tumors (NET G1 and G2, and rare well-differentiated G3) arising in the ileum. This classification system does not apply to high-grade neuroendocrine carcinomas, mixed adenoneuroendocrine carcinomas, and neuroendocrine tumors of the duodenum. (from AJCC 8th Ed.)			Neoplastic Process	
C135125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135125>	C135124	Stage I Ileal Neuroendocrine Tumor AJCC v8|Stage I Ileal Neuroendocrine Tumor	Stage I includes: T1, N0, M0. T1: Tumor invading lamina propria or submucosa and measuring 1 cm or less in size. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Ileal Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135126>	C135124	Stage II Ileal Neuroendocrine Tumor AJCC v8|Stage II Ileal Neuroendocrine Tumor	Stage II includes: (T2, N0, M0); (T3, N0, M0). T2: Tumor invading muscularis propria or measuring more than 1 cm in size. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Ileal Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135127>	C135124	Stage III Ileal Neuroendocrine Tumor AJCC v8|Stage III Ileal Neuroendocrine Tumor	Stage III includes: (T1, N1, N2, M0); (T2, N1, N2, M0); (T3, N1, N2, M0); (T4, N0, M0); (T4, N1, N2, M0). T1: Tumor invading lamina propria or submucosa and measuring 1 cm or less in size. T2: Tumor invading muscularis propria or measuring more than 1 cm in size. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. T4: Tumor invading visceral peritoneum (serosa) or other organs or adjacent structures. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis in less than 12 nodes. N2: Large mesenteric masses (larger than 2 cm) and/or extensive nodal deposits (12 or greater), especially those that encase the superior mesenteric vessels. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Ileal Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135128>	C135124	Stage IV Ileal Neuroendocrine Tumor AJCC v8|Stage IV Ileal Neuroendocrine Tumor	Stage IV includes: (T1, N0, N1, N2, M1); (T2, N0, N1, N2, M1); (T3, N0, N1, N2, M1); (T4, N0, N1, N2, M1). T1: Tumor invading lamina propria or submucosa and measuring 1 cm or less in size. T2: Tumor invading muscularis propria or measuring more than 1 cm in size. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. T4: Tumor invading visceral peritoneum (serosa) or other organs or adjacent structures. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis in less than 12 nodes. N2: Large mesenteric masses (larger than 2 cm) and/or extensive nodal deposits (12 or greater), especially those that encase the superior mesenteric vessels. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Ileal Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135129>	C95404	Digestive System Neuroendocrine Tumor by AJCC v7 Stage|Digestive System Neuroendocrine Neoplasm by AJCC v7 Stage	A term that refers to the staging of a digestive system neuroendocrine tumor, following the rules of the TNM AJCC v7 classification system.			Neoplastic Process	
C13512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13512>	C13432	4q34-q35	A chromosome band present on 4q			Gene or Genome	
C135130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135130>	C135019	Appendix Neuroendocrine Tumor TNM Finding v8	A finding about one or more characteristics of an appendiceal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system. This classification system applies to appendiceal NETs (carcinoid tumors) (NET G1 and G2, and rare well-differentiated G3). It does not apply to high-grade neuroendocrine carcinomas (NEC), goblet cell carcinoids, mixed adenocarcinomas, and adenocarcinomas of the appendix. (from AJCC 8th Ed.)			Finding	
C135131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135131>	C135130	Appendix Neuroendocrine Tumor Clinical TNM Finding v8	A clinical finding about one or more characteristics of an appendiceal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system.			Finding	
C135132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135132>	C135131	Appendix Neuroendocrine Tumor Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of an appendiceal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C135133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135133>	C135132	Appendix Neuroendocrine Tumor cM0 TNM Finding v8	Appendix neuroendocrine tumor without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C135134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135134>	C135132	Appendix Neuroendocrine Tumor cM1 TNM Finding v8	Appendix neuroendocrine tumor with distant metastasis. (from AJCC 8th Ed.)			Finding	
C135135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135135>	C135134	Appendix Neuroendocrine Tumor cM1a TNM Finding v8	Appendix neuroendocrine tumor with metastasis confined to liver. (from AJCC 8th Ed.)			Finding	
C135136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135136>	C135134	Appendix Neuroendocrine Tumor cM1b TNM Finding v8	Appendix neuroendocrine tumor with metastasis in at least one extrahepatic site (e.g., lung, ovary, nonregional lymph node, peritoneum, bone). (from AJCC 8th Ed.)			Finding	
C135137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135137>	C135134	Appendix Neuroendocrine Tumor cM1c TNM Finding v8	Appendix neuroendocrine tumor with both hepatic and extrahepatic metastases. (from AJCC 8th Ed.)			Finding	
C135138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135138>	C135130	Appendix Neuroendocrine Tumor Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of an appendiceal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system.			Finding	
C135139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135139>	C135138	Appendix Neuroendocrine Tumor Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of an appendiceal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C13513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13513>	C13432	15q26.1	A chromosome band present on 15q			Gene or Genome	
C135140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135140>	C135139	Appendix Neuroendocrine Tumor pM1 TNM Finding v8	Appendix neuroendocrine tumor with distant metastasis. (from AJCC 8th Ed.)			Finding	
C135141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135141>	C135140	Appendix Neuroendocrine Tumor pM1a TNM Finding v8	Appendix neuroendocrine tumor with metastasis confined to liver. (from AJCC 8th Ed.)			Finding	
C135142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135142>	C135140	Appendix Neuroendocrine Tumor pM1b TNM Finding v8	Appendix neuroendocrine tumor with metastasis in at least one extrahepatic site (e.g., lung, ovary, nonregional lymph node, peritoneum, bone). (from AJCC 8th Ed.)			Finding	
C135143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135143>	C135140	Appendix Neuroendocrine Tumor pM1c TNM Finding v8	Appendix neuroendocrine tumor with both hepatic and extrahepatic metastases. (from AJCC 8th Ed.)			Finding	
C135144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135144>	C135138	Appendix Neuroendocrine Tumor Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of an appendiceal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C135145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135145>	C135144	Appendix Neuroendocrine Tumor pTX TNM Finding v8	Appendix neuroendocrine tumor in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C135146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135146>	C135144	Appendix Neuroendocrine Tumor pT0 TNM Finding v8	Appendix neuroendocrine tumor with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C135147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135147>	C135144	Appendix Neuroendocrine Tumor pT1 TNM Finding v8	Appendix neuroendocrine tumor measuring 2 cm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C135148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135148>	C135144	Appendix Neuroendocrine Tumor pT2 TNM Finding v8	Appendix neuroendocrine tumor measuring more than 2 cm but less than or equal to 4 cm.  (from AJCC 8th Ed.)			Finding	
C135149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135149>	C135144	Appendix Neuroendocrine Tumor pT3 TNM Finding v8	Appendix neuroendocrine tumor measuring more than 4 cm or with subserosal invasion or involvement of the mesoappendix. (from AJCC 8th Ed.)			Finding	
C13514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13514>	C13432	11q13.3	A chromosome band present on 11q			Gene or Genome	
C135150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135150>	C135144	Appendix Neuroendocrine Tumor pT4 TNM Finding v8	Appendix neuroendocrine tumor perforating the peritoneum or directly invading other adjacent organs or structures (excluding direct mural extension to adjacent subserosa of adjacent bowel), e.g., abdominal wall and skeletal muscle. (from AJCC 8th Ed.)			Finding	
C135151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135151>	C135138	Appendix Neuroendocrine Tumor Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of an appendiceal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C135152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135152>	C135151	Appendix Neuroendocrine Tumor pNX TNM Finding v8	Appendix neuroendocrine tumor in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)			Finding	
C135153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135153>	C135151	Appendix Neuroendocrine Tumor pN0 TNM Finding v8	Appendix neuroendocrine tumor without regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C135154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135154>	C135151	Appendix Neuroendocrine Tumor pN1 TNM Finding v8	Appendix neuroendocrine tumor with regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C135155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135155>	C96422|C135129	Appendix Neuroendocrine Tumor by AJCC v7 Stage	A term that refers to the staging of an appendiceal neuroendocrine tumor, following the rules of the TNM AJCC v7 classification system.			Neoplastic Process	
C135156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135156>	C96422	Appendix Neuroendocrine Tumor by AJCC v8 Stage	A term that refers to the staging of an appendiceal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system. This staging system applies to appendiceal NETs (carcinoid tumors) (NET G1 and G2, and rare well-differentiated G3). High-grade neuroendocrine carcinomas (NEC), goblet cell carcinoids, mixed adenocarcinomas, and adenocarcinomas of the appendix are not staged using this staging system. (from AJCC 8th Ed.)			Neoplastic Process	
C135157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135157>	C135156	Stage I Appendix Neuroendocrine Tumor AJCC v8|Stage I Appendix Neuroendocrine Tumor	Stage I includes: T1, N0, M0. T1: Tumor measuring 2 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Appendix Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135158>	C135156	Stage II Appendix Neuroendocrine Tumor AJCC v8|Stage II Appendix Neuroendocrine Tumor	Stage II includes: (T2, N0, M0); (T3, N0, M0). T2: Tumor measuring more than 2 cm but less than or equal to 4 cm. T3: Tumor measuring more than 4 cm or with subserosal invasion or involvement of the mesoappendix. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Appendix Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135159>	C135156	Stage III Appendix Neuroendocrine Tumor AJCC v8|Stage III Appendix Neuroendocrine Tumor	Stage III includes: (T1, N1, M0); (T2, N1, M0); (T3, N1, M0); (T4, N0, M0); (T4, N1, M0). T1: Tumor measuring 2 cm or less in greatest dimension. T2: Tumor measuring more than 2 cm but less than or equal to 4 cm. T3: Tumor measuring more than 4 cm or with subserosal invasion or involvement of the mesoappendix. T4: Tumor perforating the peritoneum or directly invading other adjacent organs or structures (excluding direct mural extension to adjacent subserosa of adjacent bowel), e.g., abdominal wall and skeletal muscle. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Appendix Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13515>	C13432	1p36.2-p36.1	A chromosome band present on 1p			Gene or Genome	
C135160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135160>	C135156	Stage IV Appendix Neuroendocrine Tumor AJCC v8|Stage IV Appendix Neuroendocrine Tumor	Stage IV includes: (T1, N0, N1, M1); (T2, N0, N1, M1); (T3, N0, N1, M1); (T4, N0, N1, M1). T1: Tumor measuring 2 cm or less in greatest dimension. T2: Tumor measuring more than 2 cm but less than or equal to 4 cm. T3: Tumor measuring more than 4 cm or with subserosal invasion or involvement of the mesoappendix. T4: Tumor perforating the peritoneum or directly invading other adjacent organs or structures (excluding direct mural extension to adjacent subserosa of adjacent bowel), e.g., abdominal wall and skeletal muscle. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Appendix Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135161>	C135019	Colorectal Neuroendocrine Tumor TNM Finding v8	A finding about one or more characteristics of a colorectal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system. This classification system applies to colorectal "carcinoid" tumors (neuroendocrine tumor G1 and G2, and rare-well differentiated G3). It does not apply to high-grade neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas of the colon and rectum. (from AJCC 8th Ed.)			Finding	
C135162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135162>	C135161	Colorectal Neuroendocrine Tumor Clinical TNM Finding v8	A clinical finding about one or more characteristics of a colorectal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system.			Finding	
C135163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135163>	C135162	Colorectal Neuroendocrine Tumor Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of a colorectal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C135164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135164>	C135163	Colorectal Neuroendocrine Tumor cM0 TNM Finding v8	Colorectal neuroendocrine tumor without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C135165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135165>	C135163	Colorectal Neuroendocrine Tumor cM1 TNM Finding v8	Colorectal neuroendocrine tumor with distant metastasis. (from AJCC 8th Ed.)			Finding	
C135166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135166>	C135165	Colorectal Neuroendocrine Tumor cM1a TNM Finding v8	Colorectal neuroendocrine tumor with metastasis confined to liver. (from AJCC 8th Ed.)			Finding	
C135167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135167>	C135165	Colorectal Neuroendocrine Tumor cM1b TNM Finding v8	Colorectal neuroendocrine tumor with metastasis in at least one extrahepatic site (e.g., lung, ovary, nonregional lymph node, peritoneum, bone). (from AJCC 8th Ed.)			Finding	
C135168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135168>	C135165	Colorectal Neuroendocrine Tumor cM1c TNM Finding v8	Colorectal neuroendocrine tumor with both hepatic and extrahepatic metastases. (from AJCC 8th Ed.)			Finding	
C135169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135169>	C135161	Colorectal Neuroendocrine Tumor Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of a colorectal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system.			Finding	
C13516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13516>	C13432	14q13	A chromosome band present on 14q			Gene or Genome	
C135170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135170>	C135169	Colorectal Neuroendocrine Tumor Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of a colorectal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C135171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135171>	C135170	Colorectal Neuroendocrine Tumor pM1 TNM Finding v8	Colorectal neuroendocrine tumor with distant metastasis. (from AJCC 8th Ed.)			Finding	
C135172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135172>	C13019	Eye Fundus|FUNDUS OF THE EYE|Fundus of the Eye|Retinal Fundus	The interior surface of the eye opposite the lens including the retina, optic disc, macula, fovea, and posterior pole.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135173>	C135171	Colorectal Neuroendocrine Tumor pM1a TNM Finding v8	Colorectal neuroendocrine tumor with metastasis confined to liver. (from AJCC 8th Ed.)			Finding	
C135174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135174>	C135171	Colorectal Neuroendocrine Tumor pM1b TNM Finding v8	Colorectal neuroendocrine tumor with metastasis in at least one extrahepatic site (e.g., lung, ovary, nonregional lymph node, peritoneum, bone). (from AJCC 8th Ed.)			Finding	
C135175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135175>	C135171	Colorectal Neuroendocrine Tumor pM1c TNM Finding v8	Colorectal neuroendocrine tumor with both hepatic and extrahepatic metastases. (from AJCC 8th Ed.)			Finding	
C135176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135176>	C26713	Nuclear Cataract|NS|Nuclear Sclerotic Cataract	A type of cataract that forms deep in the central zone (nucleus) of the lens. Nuclear cataracts are usually associated with aging.			Disease or Syndrome	
C135177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135177>	C26713	Cortical Cataract|CS|Cortical Spoking Cataract	A type of cataract that occurs in the lens cortex. It is characterized by white, wedge-like opacities that start in the periphery of the lens and work their way to the center in a spoke-like fashion.			Disease or Syndrome	
C135178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135178>	C135169	Colorectal Neuroendocrine Tumor Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of a colorectal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C135179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135179>	C135178	Colorectal Neuroendocrine Tumor pNX TNM Finding v8	Colorectal neuroendocrine tumor in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)			Finding	
C13517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13517>	C13432	11q24.1-q24.3	A chromosome band present on 11q			Gene or Genome	
C135180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135180>	C26713	Posterior Subcapsular Cataract|PSC	A type of cataract that forms in the most posterior cortical layer of the lens, directly under the lens capsule. This type of cataract tends to occur in younger patients than cortical or nuclear sclerotic cataracts.			Disease or Syndrome	
C135181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135181>	C135178	Colorectal Neuroendocrine Tumor pN0 TNM Finding v8	Colorectal neuroendocrine tumor without regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C135182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135182>	C135178	Colorectal Neuroendocrine Tumor pN1 TNM Finding v8	Colorectal neuroendocrine tumor with regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C135183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135183>	C135169	Colorectal Neuroendocrine Tumor Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of a colorectal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C135184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135184>	C135183	Colorectal Neuroendocrine Tumor pTX TNM Finding v8	Colorectal neuroendocrine tumor in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C135185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135185>	C135183	Colorectal Neuroendocrine Tumor pT0 TNM Finding v8	Colorectal neuroendocrine tumor with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C135186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135186>	C135183	Colorectal Neuroendocrine Tumor pT1 TNM Finding v8	Colorectal neuroendocrine tumor invading the lamina propria or submucosa and measuring 2 cm or less. (from AJCC 8th Ed.)			Finding	
C135187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135187>	C135186	Colorectal Neuroendocrine Tumor pT1a TNM Finding v8	Colorectal neuroendocrine tumor measuring less than 1 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C135188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135188>	C135186	Colorectal Neuroendocrine Tumor pT1b TNM Finding v8	Colorectal neuroendocrine tumor measuring 1-2 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C135189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135189>	C29629|C266	Diphenoxylate Hydrochloride/Atropine Sulfate|Diphenoxylate Hydrochloride and Atropine Sulfate|Lomotil	A formulation containing the hydrochloride salt form of diphenoxylate, a synthetic opioid of the phenylpiperidine class, and the sulfate salt form of the anticholinergic agent atropine, with antidiarrheal activity. Upon oral administration, diphenoxylate acts on opioid receptors in the gastrointestinal (GI) tract, thereby decreasing GI motility, prolonging transit time, and preventing diarrhea. Through its anticholinergic effects, atropine prevents deliberate over-usage of diphenoxylate by triggering very unpleasant side effects (SEs), such as severe weakness and nausea.	Diphenoxylate Hydrochloride/Atropine Sulfate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C13518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13518>	C13432	13q12	A chromosome band present on 13q			Gene or Genome	
C135190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135190>	C135183	Colorectal Neuroendocrine Tumor pT2 TNM Finding v8	Colorectal neuroendocrine tumor invading the muscularis propria or measuring more than 2 cm with invasion of the lamina propria or submucosa.  (from AJCC 8th Ed.)			Finding	
C135191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135191>	C135183	Colorectal Neuroendocrine Tumor pT3 TNM Finding v8	Colorectal neuroendocrine tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. (from AJCC 8th Ed.)			Finding	
C135192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135192>	C135183	Colorectal Neuroendocrine Tumor pT4 TNM Finding v8	Colorectal neuroendocrine tumor invading the visceral peritoneum (serosa) or other organs or adjacent structures. (from AJCC 8th Ed.)			Finding	
C135193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135193>	C135176	Nuclear Cataract Grade 1	A stage of nuclear sclerotic cataract marked by mild yellowing and sclerosis of the lens nucleus. (Modified LOCS II)			Disease or Syndrome	
C135194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135194>	C135176	Nuclear Cataract Grade 2	A stage of nuclear sclerotic cataract marked by moderate yellowing and sclerosis of the lens nucleus. (Modified LOCS II)			Disease or Syndrome	
C135195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135195>	C135176	Nuclear Cataract Grade 3	A stage of nuclear sclerotic cataract marked by pronounced yellowing and sclerosis of the lens nucleus. (Modified LOCS II)			Disease or Syndrome	
C135196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135196>	C135176	Nuclear Cataract Grade 4	A stage of nuclear sclerotic cataract marked by severe yellowing and sclerosis of the lens nucleus. (Modified LOCS II)			Disease or Syndrome	
C135197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135197>	C135177	Cortical Cataract Grade 1	A stage of cortical cataract characterized by 10% of the intrapupillary space obscured by opacity. (Modified LOCS II)			Disease or Syndrome	
C135198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135198>	C135177	Cortical Cataract Grade 2	A stage of cortical cataract characterized by 10-50% of the intrapupillary space obscured by opacity. (Modified LOCS II)			Disease or Syndrome	
C135199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135199>	C135177	Cortical Cataract Grade 3	A stage of cortical cataract characterized by 50-90% of the intrapupillary space obscured by opacity. (Modified LOCS II)			Disease or Syndrome	
C13519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13519>	C13432	14q24.3	A chromosome band present on 14q			Gene or Genome	
C1351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1351>	C29701|C2080	Bismuth Subcitrate|BISMUTH SUBCITRATE|Bismuth Tripotassium Dicitrate|Bismuth subcitrate|Colloidal Bismuth Subcitrate|De-Noltab|Tripotassium Dicitratobismuthate|Tripotassium dicitratobismuthate	A mineral compound that is used to treat duodenal and gastric ulcers associated with Helicobacter pylori.			Inorganic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C135200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135200>	C135177	Cortical Cataract Grade 4	A stage of cortical cataract characterized by greater than 90% of the intrapupillary space obscured by opacity. (Modified LOCS II)			Disease or Syndrome	
C135201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135201>	C135180	Posterior Subcapsular Cataract Grade 1	A stage of posterior subcapsular cataract characterized by 3% of the posterior capsule obscured by opacity. (Modified LOCS II)			Disease or Syndrome	
C135202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135202>	C135180	Posterior Subcapsular Cataract Grade 2	A stage of posterior subcapsular cataract characterized by 30% of the posterior capsule obscured by opacity. (Modified LOCS II)			Disease or Syndrome	
C135203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135203>	C135180	Posterior Subcapsular Cataract Grade 3	A stage of posterior subcapsular cataract characterized by 50% of the posterior capsule obscured by opacity. (Modified LOCS II)			Disease or Syndrome	
C135204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135204>	C135180	Posterior Subcapsular Cataract Grade 4	A stage of posterior subcapsular cataract characterized by greater than 50% of the posterior capsule obscured by opacity. (Modified LOCS II)			Disease or Syndrome	
C135205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135205>	C96159	Colorectal Neuroendocrine Tumor by AJCC v8 Stage	A term that refers to the staging of a colorectal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system. This staging system applies to colorectal "carcinoid" tumors (neuroendocrine tumor G1 and G2, and rare-well differentiated G3). High-grade neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas of the colon and rectum are not staged using this staging system. (from AJCC 8th Ed.)			Neoplastic Process	
C135206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135206>	C135205	Stage I Colorectal Neuroendocrine Tumor AJCC v8|Stage I Colorectal Neuroendocrine Tumor	Stage I includes: T1, N0, M0. T1: Tumor invading the lamina propria or submucosa and measuring 2 cm or less. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Colorectal Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135207>	C135205	Stage IIA Colorectal Neuroendocrine Tumor AJCC v8|Stage IIA Colorectal Neuroendocrine Tumor	Stage IIA includes: T2, N0, M0. T2: Tumor invading the muscularis propria or measuring more than 2 cm with invasion of the lamina propria or submucosa. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIA Colorectal Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135208>	C135205	Stage IIB Colorectal Neuroendocrine Tumor AJCC v8|Stage IIB Colorectal Neuroendocrine Tumor	Stage IIB includes: T3, N0, M0. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIB Colorectal Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135209>	C135205	Stage IIIA Colorectal Neuroendocrine Tumor AJCC v8|Stage IIIA Colorectal Neuroendocrine Tumor	Stage IIIA includes: T4, N0, M0. T4: Tumor invading the visceral peritoneum (serosa) or other organs or adjacent structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIA Colorectal Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13520>	C13432	2p23-p22	A chromosome band present on 2p			Gene or Genome	
C135210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135210>	C135205	Stage IIIB Colorectal Neuroendocrine Tumor AJCC v8|Stage IIIB Colorectal Neuroendocrine Tumor	Stage IIIB includes: (T1, N1, M0); (T2, N1, M0); (T3, N1, M0); (T4, N1, M0). T1: Tumor invading the lamina propria or submucosa and measuring 2 cm or less. T2: Tumor invading the muscularis propria or measuring more than 2 cm with invasion of the lamina propria or submucosa. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. T4: Tumor invading the visceral peritoneum (serosa) or other organs or adjacent structures. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIB Colorectal Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135211>	C135205	Stage IV Colorectal Neuroendocrine Tumor AJCC v8|Stage IV Colorectal Neuroendocrine Tumor	Stage IV includes: (T1, Any N, M1); (T2, Any N, M1); (T3, Any N, M1); (T4, Any N, M1). T1: Tumor invading the lamina propria or submucosa and measuring 2 cm or less. T2: Tumor invading the muscularis propria or measuring more than 2 cm with invasion of the lamina propria or submucosa. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. T4: Tumor invading the visceral peritoneum (serosa) or other organs or adjacent structures. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Colorectal Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135212>	C96159|C5697	Colon Neuroendocrine Tumor|Colon Well Differentiated Neuroendocrine Neoplasm|Colon Well-Differentiated Neuroendocrine Neoplasm	A well-differentiated, low-, intermediate-, or high-grade neoplasm with neuroendocrine differentiation that arises from the colon.			Neoplastic Process	
C135213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135213>	C96159|C5698	Rectal Neuroendocrine Tumor|Rectal Well Differentiated Neuroendocrine Neoplasm|Rectal Well-Differentiated Neuroendocrine Neoplasm	A well-differentiated, low-, intermediate-, or high-grade neoplasm with neuroendocrine differentiation that arises from the rectum.			Neoplastic Process	Cellosaurus Disease Terminology
C135214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135214>	C135212|C135205	Colon Neuroendocrine Tumor by AJCC v8 Stage	A term that refers to the staging of a colon neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system. This staging system applies to colon "carcinoid" tumors (neuroendocrine tumor G1 and G2, and rare-well differentiated G3). High-grade neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas of the colon are not staged using this staging system. (from AJCC 8th Ed.)			Neoplastic Process	
C13521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13521>	C13432	6q21	A chromosome band present on 6q	6q21		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13522>	C13432	12q13.2-q13.3	A chromosome band present on 12q			Gene or Genome	
C13523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13523>	C13432	2q14	A chromosome band present on 2q			Gene or Genome	
C13524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13524>	C13432	7p13	A chromosome band present on 7p			Gene or Genome	
C13525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13525>	C13432	4q21	A chromosome band present on 4q			Gene or Genome	
C13526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13526>	C198952	1p|Chromosome 1 Proximal Arm|Chromosome 1 Short Arm|Chromosome 1p	Proximal (short) arm of chromosome 1	1p		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13527>	C13432	1p36.3	A chromosome band present on 1p			Gene or Genome	
C13528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13528>	C198953	1q|Chromosome 1 Distal Arm|Chromosome 1 Long Arm|Chromosome 1q	Distal (long) arm of chromosome 1	1q		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13529>	C198952	11p|Chromosome 11 Proximal Arm|Chromosome 11 Short Arm	Proximal (short) arm of chromosome 11			Gene or Genome	
C1352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1352>	C2259	Recombinant Brain-Derived Growth Factors|BDNF|Brain-Derived Neurotrophic Factor	Recombinant therapeutic agents chemically identical to or similar to endogenous nerve growth factors (neurotrophins) that play vital roles in the development of the nervous system.  Brain-derived growth factors may also regulate hematopoiesis and immune cell function.  Examples of brain-derived growth factors include nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). (NCI04)			Chemical Viewed Functionally	
C13530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13530>	C198952	10p|Chromosome 10 Proximal Arm|Chromosome 10 Short Arm	Proximal (short) arm of chromosome 10			Gene or Genome	
C13531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13531>	C198953	10q|Chromosome 10 Distal Arm|Chromosome 10 Long Arm	Distal (long) arm of chromosome 10	10q		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13532>	C198952	12p|Chromosome 12 Proximal Arm|Chromosome 12 Short Arm	Proximal (short) arm of chromosome 12			Gene or Genome	
C13533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13533>	C198953	12q|Chromosome 12 Distal Arm|Chromosome 12 Long Arm	Distal (long) arm of chromosome 12			Gene or Genome	
C13534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13534>	C198953	13q|Chromosome 13 Distal Arm|Chromosome 13 Long Arm	Distal (long) arm of chromosome 13	13q		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13535>	C198952	13p|Chromosome 13 Proximal Arm|Chromosome 13 Short Arm	Proximal (short) arm of chromosome 13			Gene or Genome	
C135368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135368>	C135214|C135206	Stage I Colon Neuroendocrine Tumor AJCC v8|Stage I Colon Neuroendocrine Tumor	Stage I includes: T1, N0, M0. T1: Tumor invading the lamina propria or submucosa and measuring 2 cm or less. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Colon Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135369>	C135214|C135207	Stage IIA Colon Neuroendocrine Tumor AJCC v8|Stage IIA Colon Neuroendocrine Tumor	Stage IIA includes: T2, N0, M0. T2: Tumor invading the muscularis propria or measuring more than 2 cm with invasion of the lamina propria or submucosa. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIA Colon Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13536>	C13432	20q11-q12	A chromosome band present on 20q			Gene or Genome	
C135370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135370>	C135214|C135208	Stage IIB Colon Neuroendocrine Tumor AJCC v8|Stage IIB Colon Neuroendocrine Tumor	Stage IIB includes: T3, N0, M0. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIB Colon Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135371>	C42703	Tumor Tissue Origin|TUMTORI|Tissue obtained from	A characterization of the tumor tissue site based on whether disease has spread (e.g., primary or metastatic site).			Conceptual Entity	CDISC SDTM Biospecimen Characteristics Test Code Terminology|CDISC SDTM Biospecimen Characteristics Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF7 Pathology Review Table
C135372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135372>	C35552	End Diastolic Volume|EDV|End Diastolic Blood Volume|Heart Chamber Volume at End Ventricular Diastole	The volume of blood remaining in a heart chamber at end ventricular diastole.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135373>	C35552	End Systolic Volume|ESV|End Systolic Blood Volume|Heart Chamber Volume at End Ventricular Systole	The volume of blood remaining in a heart chamber at end ventricular systole.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135374>	C99524	Calculated Left Ventricular Ejection Fraction|LVEF_C|Left Ventricular Ejection Fraction, Cal|Left Ventricular Ejection Fraction, Cal|Left Ventricular Ejection Fraction, Calculated|Left ventriculography EF	The percent or fraction of the left ventricular end diastolic volume ejected in systole, which is calculated as the left ventricular stroke volume divided by the left ventricular end diastolic volume.			Quantitative Concept	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 7: Diagnostic Procedures Terminology|CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135375>	C99524	Estimated Left Ventricular Ejection Fraction|LVEF_E|Left Ventricular Ejection Fraction, Est|Left Ventricular Ejection Fraction, Est|Left Ventricular Ejection Fraction, Estimated	A visual estimation of the volume of blood ejected from the left ventricle during ventricular systole.			Quantitative Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135376>	C217189	Estimated Mean Blood Pressure|MEANBP_E|Mean Blood Pressure, Estimated|Mean Blood Pressure, Estimated	The estimated average blood pressure.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135377>	C139032	Major Axis Cross-sectional Diameter|MJDIA|Major Axis Cross-sec. Diameter|Major Axis Cross-sec. Diameter	The cross sectional diameter of a tissue, organ, or structure measured along its major axis.			Spatial Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135378>	C139032	Minor Axis Cross-sectional Diameter|MNDIA|Minor Axis Cross-sec. Diameter|Minor Axis Cross-sec. Diameter	The cross sectional diameter of a tissue, organ, or structure measured along its minor axis.			Spatial Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135379>	C181043	Pulmonary Arterial Hypertension Indicator|PAHTNIND|Pulmonary Arterial Hypertension Ind|Pulmonary Arterial Hypertension Ind	An indication as to whether there is hypertension in the pulmonary artery.			Conceptual Entity	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13537>	C198952	14p|Chromosome 14 Proximal Arm|Chromosome 14 Short Arm|Chromosome 14p	Proximal (short) arm of chromosome 14			Gene or Genome	
C135380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135380>	C35552	Calculated Right Ventricular Ejection Fraction|RVEF_C|Right Ventricular Ejection Fraction, Cal|Right Ventricular Ejection Fraction, Cal|Right Ventricular Ejection Fraction, Calculated	The percent or fraction of the right ventricular end diastolic volume ejected in systole, which is calculated as the right ventricular stroke volume divided by the right ventricular end diastolic volume.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135381>	C35552	Estimated Right Ventricular Ejection Fraction|RVEF_E|Right Ventricular Ejection Fraction, Est|Right Ventricular Ejection Fraction, Est|Right Ventricular Ejection Fraction, Estimated	A visual estimation of the volume of blood ejected from the right ventricle during ventricular systole.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135382>	C53530	Long Term Care Hospital|LONG TERM CARE HOSPITAL	A hospital equipped and staffed to provide prolonged care to patients.			Health Care Related Organization	CDISC SDTM Discharge Disposition Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135383>	C213228	Age at Death|AGEDTH|Age At Date of Death	The age at which death occurred.			Organism Attribute	CDISC SDTM Death Diagnosis Test Code Terminology|CDISC SDTM Death Diagnosis Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C135384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135384>	C25180	Autopsy Indicator|AUTOPIND|Was Autopsy Performed	An indication as to whether an autopsy was performed.			Conceptual Entity	CDISC SDTM Death Diagnosis Test Code Terminology|CDISC SDTM Death Diagnosis Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF1 Registration Table
C135385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135385>	C25180	Death Certification Indicator|DTHCOIND|Death Certificate Obtained Indicator|Death Certificate Obtained Indicator	An indication as to whether a death certificate was obtained.			Conceptual Entity	CDISC SDTM Death Diagnosis Test Code Terminology|CDISC SDTM Death Diagnosis Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135386>	C25180	Hospital Medical Record Indicator|HMROIND|Hospital Medical Record Obtained Ind|Hospital Medical Record Obtained Ind|Hospital Medical Record Obtained Indicator	An indication as to whether medical records were obtained from the hospital.			Conceptual Entity	CDISC SDTM Death Diagnosis Test Code Terminology|CDISC SDTM Death Diagnosis Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135387>	C87881	Lead Site aVF-Ventral|LEAD aVF-VENTRAL	An augmented unipolar electrocardiogram limb lead in which the positive electrode is situated at the hindquarters proximal to the sacrum and the negative electrode is a combination of the electrode behind the right ear near the right mastoid process and the electrode near the apex of the heart (located in the ICS of left 5-6 rib close to the sternum). (CDISC)			Spatial Concept	CDISC SDTM Electrocardiogram Lead Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135388>	C87881	Lead Site aVL-Axial|LEAD aVL-AXIAL	An augmented unipolar electrocardiogram limb lead in which the positive electrode is near the apex of the heart (located in the ICS of left 5-6 rib close to the sternum) and the negative electrode is a combination of the electrode behind the right ear near the right mastoid process and the electrode on hindquarters proximal to the sacrum. (CDISC)			Spatial Concept	CDISC SDTM Electrocardiogram Lead Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135389>	C87881	Lead Site aVR-Dorsal|LEAD aVR-DORSAL	An augmented unipolar electrocardiogram limb lead in which the positive electrode is behind the right ear near the right mastoid process and the negative electrode is a combination of the electrode at the hindquarters proximal to the sacrum and the electrode near the apex of the heart (located in the ICS of left 5-6 rib close to the sternum). (CDISC)			Spatial Concept	CDISC SDTM Electrocardiogram Lead Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C13538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13538>	C198953	14q|Chromosome 14 Distal Arm|Chromosome 14 Long Arm|Chromosome 14q	Distal (long) arm of chromosome 14	14q		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C135390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135390>	C87881	Lead Site Axial|LEAD AXIAL	A bipolar electrocardiogram limb lead which records the voltage between the positive electrode near the apex of the heart (located in the ICS of left 5-6 rib close to the sternum) and the negative electrode behind the right ear near the right mastoid process. (CDISC)			Spatial Concept	CDISC SDTM Electrocardiogram Lead Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135391>	C87881	Lead Site Dorsal|LEAD DORSAL	A bipolar electrocardiogram limb lead which records the voltage between the negative electrode behind the right ear near the right mastoid process and the positive electrode on the hindquarters proximal to the sacrum. (CDISC)			Spatial Concept	CDISC SDTM Electrocardiogram Lead Terminology|CDISC SDTM Terminology|CDISC SEND ECG Lead Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135392>	C87881	Lead Site Ventral|LEAD VENTRAL	A bipolar electrocardiogram limb lead which records the voltage with the positive electrode on the hindquarters proximal to the sacrum and the negative electrode near the apex of the heart (located in the ICS of left 5-6 rib close to the sternum). (CDISC)			Spatial Concept	CDISC SDTM Electrocardiogram Lead Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135393>	C41328	Junctional Escape Rhythm by ECG Finding|JUNCTIONAL ESCAPE RHYTHM	An electrocardiographic finding of a junctional rhythm that arises as a physiologic response to extreme slowing or arrest of sinus node activity. In this setting, a faster junctional rhythm may be a normal response to a very slow or absent sinus rate. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135394>	C41328	Nonconducted P Wave Physiology Not Defined by ECG Finding|NONCONDUCTED P WAVE PHYSIOLOGY NOT DEFINED	An electrocardiographic finding of a P wave that either does not conduct to the ventricle or that does not result in ventricular activation.			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135395>	C41328	Supraventricular Escape Beat by ECG Finding|SUPRAVENTRICULAR ESCAPE BEAT|Supraventricular Escape Complex|Supraventricular Escape Complexes	An electrocardiographic finding of a compensatory supraventricular complex that occurs following a prolonged RR interval. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135396>	C41079	CDISC Findings About Class|FINDINGS ABOUT|Findings About	This SDTM class is a specialization of the findings general observation class. It is intended, as its name implies, to be used when collected data represent findings about an event or intervention that cannot be represented within an event or intervention record, or as a supplemental qualifier to such a record.			Conceptual Entity	CDISC Define-XML General Observation Class Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135397>	C125939	ABO A1 Subtype Determination|ABO A1 Subtype|ABO A1 Subtype|ABOA1	The characterization of the ABO blood group A1 subtype in an individual.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135398>	C74675	Acetaminophen Measurement|ACETAMIN|Acetaminophen|Acetaminophen|Paracetamol	The determination of the amount of acetaminophen in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135399>	C51948	Basophilic Metamyelocyte Count|BASOMM|Basophilic Metamyelocytes|Basophilic Metamyelocytes	The determination of the amount of basophilic metamyelocytes present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C13539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13539>	C198953	15q|Chromosome 15 Distal Arm|Chromosome 15 Long Arm	Distal (long) arm of chromosome 15	15q		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C1353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1353>	C94726	Granisetron Hydrochloride|Endo-N-(9-methyl-9-azabicyclo [3.3.1] non-3-yl)-1-methyl-1H-indazole-3-carboxamide Hydrochloride|GRANISETRON HYDROCHLORIDE|Kytril|Kytril|Kytril|granisetron hydrochloride	The hydrochloride salt of an indazole derivative with antiemetic properties. As a selective serotonin receptor antagonist, granisetron competitively blocks the action of serotonin at 5-hydroxytryptamine3 (5-HT3) receptors, resulting in the suppression of chemotherapy- and radiotherapy-induced nausea and vomiting.	Granisetron Hydrochloride		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C135400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135400>	C51948	Basophilic Myelocyte Count|BASOMYL|Basophilic Myelocytes|Basophilic Myelocytes	The determination of the amount of basophilic myelocytes present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135401>	C51948	Segmented Basophil Count|BASOSG|Basophils, Segmented|Basophils, Segmented	The determination of the amount of segmented basophils present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135402>	C74689	Synthetic Cannabinoid Measurement|CANNABS|Cannabinoids, Synthetic|Cannabinoids, Synthetic	The determination of the amount of synthetic cannabinoids present in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135403>	C80160	Complement Ba Measurement|Ba Fragment of Complement Factor B|Ba Fragment of Complement Factor B|Ba Fragment of Factor B|Ba Fragment of Factor B|CBA|Complement Ba|Complement Ba	The determination of the amount of Ba fragment of complement factor B in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135404>	C210012|C210010	Chikungunya Virus Antibody Measurement	The determination of the amount of the Chikungunya virus antibodies in a biological sample.			Laboratory Procedure	
C135405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135405>	C48938	Columnar Epithelial Cells to Non-Squamous Epithelial Cells Ratio Measurement|CLEPNSQE|Columnar Epi Cells/Non-Squam Epi Cells|Columnar Epi Cells/Non-Squam Epi Cells	The determination of the ratio of columnar epithelial cells compared to non-squamous epithelial cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135406>	C81971|C163537	Clostridium tetani Toxoid IgG Antibody Measurement	The determination of the amount of the Clostridium tetani toxoid IgG antibody in a biological sample.			Laboratory Procedure	
C135407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135407>	C174304	Dicalcium Phosphate Crystals Measurement|CYDCPHOS|Dicalcium Phosphate Crystals|Dicalcium Phosphate Crystals	The determination of the amount of dicalcium phosphate crystals in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135408>	C135409	DNA Fragmentation Index|DFI	The determination of the amount of the deoxyribonucleic acid fragmentation within the nucleated cells in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135409>	C49237|C17632	Deoxyribonucleic Acid Measurement|DNA|DNA Measurement|Deoxyribonucleic Acid|Deoxyribonucleic Acid	The determination of the amount of deoxyribonucleic acid (DNA) in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C13540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13540>	C198952	15p|Chromosome 15 Proximal Arm|Chromosome 15 Short Arm	Proximal (short) arm of chromosome 15			Gene or Genome	
C135410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135410>	C81972	Ebola Virus IgM Antibody Measurement	The determination of the amount of the Ebola virus IgM antibodies in a biological sample.			Laboratory Procedure	
C135411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135411>	C67208	Eosinophils to Non-Squamous Epithelial Cells Ratio Measurement|EOSNSQE|Eosinophils/Non-Squam Epi Cells|Eosinophils/Non-Squam Epi Cells	The determination of the ratio of eosinophils compared to non-squamous epithelial cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135412>	C64550	Segmented Eosinophil Count|EOSSG|Eosinophils, Segmented|Eosinophils, Segmented	The determination of the amount of segmented eosinophils present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135413>	C48938	Non-Squamous Epithelial Cell Count|EPINSQCE|Non-Squamous Epithelial Cells|Non-Squamous Epithelial Cells	The determination of the amount of non-squamous epithelial cells present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135414>	C48938	Epithelial Cells to Non-Squamous Epithelial Cells Ratio Measurement|EPINSQE|Epi Cells/Non-Squam Epi Cells|Epi Cells/Non-Squam Epi Cells	The determination of the ratio of epithelial cells compared to non-squamous epithelial cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135415>	C67208	Erythroid Maturation Index|ERCEMIDX	The determination of the ratio of the sum of erythroid maturation phase cells (pool) to the sum of erythroid proliferative phase cells (pool) present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135416>	C48938	Erythroid Maturation Pool Count|ERCEMPOL|Erythroid Maturation Pool|Erythroid Maturation Pool	The determination of the amount of erythroid maturation phase cells (polychromatic rubricytes, normochromic rubricytes, and metarubricytes) present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135417>	C67208	Erythroid Proliferation Index|ERCEPIDX	The determination of the ratio of the sum of erythroid proliferative phase cells (pool) to the sum of erythroid maturation phase cells (pool) present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135418>	C48938	Erythroid Proliferation Pool Count|ERCEPPOL|Erythroid Proliferation Pool|Erythroid Proliferation Pool	The determination of the amount of erythroid proliferative phase cells (rubriblasts, prorubricytes, and basophilic rubricytes) present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135419>	C64430	C-Terminal Fibroblast Growth Factor 23 Measurement|FGF23C|Fibroblast Growth Factor 23, C-Terminal|Fibroblast Growth Factor 23, C-Terminal	The determination of the amount of the C-terminal fibroblast growth factor 23 in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C13541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13541>	C198952	16p|Chromosome 16 Proximal Arm|Chromosome 16 Short Arm	Proximal (short) arm of chromosome 16			Gene or Genome	
C135420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135420>	C96650	Intact Fibroblast Growth Factor 23 Measurement|FGF23I|Fibroblast Growth Factor 23, Intact|Fibroblast Growth Factor 23, Intact	The determination of the amount of the intact fibroblast growth factor 23 in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135421>	C49188	Flagellates Measurement|FLAGEL|Flagellates|Flagellates	Examination of a biological specimen to detect the presence of any flagellates or protozoans that possess flagella.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135422>	C64430	Growth Differentiation Factor 11 Measurement|BMP-11|BMP11 Measurement|Bone Morphogenetic Protein 11|Bone Morphogenetic Protein 11 Measurement|GDF11|GDF11 Measurement|Growth Differentiation Factor 11|Growth Differentiation Factor 11|Growth/Differentiation Factor 11 Measurement	The determination of the amount of growth differentiation factor 11 in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135423>	C64430	Growth Differentiation Factor 8 Measurement|GDF8|GDF8 Measurement|Growth Differentiation Factor 8|Growth Differentiation Factor 8|Growth/Differentiation Factor 8 Measurement|MSTN Measurement|Myostatin|Myostatin Measurement	The determination of the amount of growth differentiation factor 8 in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135424>	C210012	Hepatitis C Virus Core Antigen Measurement|HCCAG|HCV Core Antigen Measurement|Hepatitis C Virus Core Antigen|Hepatitis C Virus Core Antigen	The determination of the amount of hepatitis C virus core antigen in a biological sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135425>	C64848	Hemoglobin Tetramer Measurement|HGBTET|Hemoglobin Tetramer|Hemoglobin Tetramer	The determination of the amount of hemoglobin tetramer in a biological sample.	Hemoglobin Tetramer Measurement		Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C135426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135426>	C64430	Hepatocyte Growth Factor Measurement|HGF|HGF Measurement|Hepatocyte Growth Factor|Hepatocyte Growth Factor	The determination of the amount of hepatocyte growth factor in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135427>	C67208	Hairy Cells to Total Cells Ratio Measurement|HRYCECE|Hairy Cells/Total Cells|Hairy Cells/Total Cells	The determination of the ratio of hairy cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135428>	C67208	Hairy Cells to Leukocytes Ratio Measurement|HRYCELE|Hairy Cells/Leukocytes|Hairy Cells/Leukocytes	The determination of the ratio of hairy cells (B-cell lymphocytes with hairy projections from the cytoplasm) compared to all leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C13542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13542>	C198953	16q|Chromosome 16 Distal Arm|Chromosome 16 Long Arm	Distal (long) arm of chromosome 16	16q		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C135430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135430>	C67208	Lymphocytes to Non-Squamous Epithelial Cells Ratio Measurement|LYMNSQE|Lymphocytes/Non-Squam Epi Cells|Lymphocytes/Non-Squam Epi Cells	The determination of the ratio of lymphocytes compared to non-squamous epithelial cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135431>	C67208	Macrophages to Non-Squamous Epithelial Cells Ratio Measurement|MCPHNSQE|Macrophages/Non-Squam Epi Cells|Macrophages/Non-Squam Epi Cells	The determination of the ratio of macrophages compared to non-squamous epithelial cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135432>	C49286	Megakaryocyte and Megakaryoblast Morphology Assessment|MKCMKBMP|Megakaryocyte and Megakaryoblast Morph|Megakaryocyte and Megakaryoblast Morph|Megakaryocyte and Megakaryoblast Morphology	An examination or assessment of the form and structure of megakaryocytes and megakaryoblasts present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135433>	C67208	Monocytes to Non-Squamous Epithelial Cells Ratio Measurement|MONONSQE|Monocytes/Non-Squam Epi Cells|Monocytes/Non-Squam Epi Cells	The determination of the ratio of monocytes compared to non-squamous epithelial cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135434>	C67208	Myeloid Maturation Index|MYCEMIDX	The determination of the ratio of the sum of myeloid maturation phase cells (pool) to the sum of myeloid proliferative phase cells (pool) present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135435>	C48938	Myeloid Maturation Pool Count|MYCEMPOL|Myeloid Maturation Pool|Myeloid Maturation Pool	The determination of the amount of myeloid maturation phase cells (metamyelocytes, band neutrophils, and segmented neutrophils) present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135436>	C67208	Myeloid Proliferation Index|MYCEPIDX	The determination of the ratio of the sum of myeloid proliferative phase cells (pool) to the sum of myeloid maturation phase cells (pool) present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135437>	C48938	Myeloid Proliferation Pool Count|MYCEPPOL|Myeloid Proliferation Pool|Myeloid Proliferation Pool	The determination of the amount of myeloid proliferative phase cells (myeloblasts, promyelocytes, and myelocytes) present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135438>	C67208	Neutrophils to Non-Squamous Epithelial Cells Ratio Measurement|NEUTNSQE|Neutrophils/Non-Squam Epi Cells|Neutrophils/Non-Squam Epi Cells	The determination of the ratio of neutrophils compared to non-squamous epithelial cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135439>	C64430	Nerve Growth Factor Measurement|NGF|NGF Measurement|Nerve Growth Factor|Nerve Growth Factor	The determination of the amount of nerve growth factor in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C13543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13543>	C198953	17q|Chromosome 17 Distal Arm|Chromosome 17 Long Arm	Distal (long) arm of chromosome 17	17q		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C135440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135440>	C51951	Estimated Platelets Measurement|PLATEST|Platelets, Estimated|Platelets, Estimated	The estimated amount of platelets in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135441>	C51946	Dysmorphic Erythrocyte Count|Dysmorphic Erythrocytes|Dysmorphic Erythrocytes|RBCDYSM	The determination of the amount of dysmorphic erythrocytes present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135442>	C74895	Retinyl Palmitate Measurement|RETPALM|Retinol Palmitate|Retinyl Palmitate|Retinyl Palmitate|Vitamin A Palmitate|Vitamin A Palmitate Measurement	The determination of the amount of endogenous retinyl palmitate in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135443>	C74749	Skeletal Troponin I Measurement|STROPONI|Skeletal Troponin I|Skeletal Troponin I|sTnl|sTnl Measurement	The determination of the amount of total skeletal troponin I in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135444>	C64430	Thrombomodulin Measurement|BDCA3|THBD|THBD Measurement|Thrombomodulin|Thrombomodulin	The determination of the amount of thrombomodulin in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135445>	C120665	Thymidine Kinase 1 Measurement|TK1|TK1 Measurement|Thymidine Kinase 1|Thymidine Kinase 1|Thymidine Kinase, Cytosolic	The determination of the amount of thymidine kinase 1 in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135446>	C120665	Thymidine Kinase 2 Measurement|TK2|TK2 Measurement|Thymidine Kinase 2|Thymidine Kinase 2|Thymidine Kinase, Mitochondrial	The determination of the amount of thymidine kinase 2 in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135447>	C135443	Troponin I Type 1 Measurement|Slow-Twitch Skeletal Muscle Troponin I|Slow-Twitch Skeletal Muscle Troponin I Measurement|TNNI1 Measurement|TROPONI1|Troponin I Type 1|Troponin I Type 1|ssTnI|ssTnI Measurement	The determination of the amount of troponin I type 1 (slow twitch skeletal muscle) in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135448>	C74749	Troponin I Type 3 Measurement|Cardiac Troponin I|Cardiac Troponin I Measurement|TNNC1|TNNI3 Measurement|TROPONI3|Troponin I Type 3|Troponin I Type 3|cTnI|cTnI Measurement	The determination of the amount of troponin I type 3 (cardiac muscle) in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135449>	C135450	Trypsin 1 and Trypsinogen 1 Measurement|TRP1TRG1|Trypsin 1 and Trypsinogen 1|Trypsin 1 and Trypsinogen 1	The determination of the amount of the trypsin 1 and trypsinogen 1 in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C13544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13544>	C198952	18p|Chromosome 18 Proximal Arm|Chromosome 18 Short Arm	Proximal (short) arm of chromosome 18			Gene or Genome	
C135450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135450>	C64430	Trypsin and Trypsinogen Measurement|TRPTRG|Trypsin and Trypsinogen|Trypsin and Trypsinogen	The determination of the amount of the total trypsin and total trypsinogen in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135451>	C67208	Leukocytes to Total Cells Ratio Measurement|Leukocytes/Total Cells|Leukocytes/Total Cells|Leukocytes/Total Cells|WBC/Total Cells|WBCCE|WBCCE	The determination of the ratio of leukocytes compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Cell Phenotyping Test Code Terminology|CDISC SDTM Cell Phenotyping Test Name Terminology|CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135452>	C17156	Accelerator Mass Spectrometry|ACCELERATOR MASS SPECTROMETRY|AMS|AMS	A type of mass spectrometry in which ions in the sample are accelerated to very high kinetic energies, thus allowing for the separation of rare isotopes from more abundant isotopes.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135453>	C19236	Freezing Point Depression|FREEZING POINT DEPRESSION	The addition of a solute to a solvent that results in a decrease in the temperature at which the solute-solvent mixture freezes.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135454>	C30014	Gas Chromatography and Flame Ionization Detection|GC/FID|GC/FID|Gas Chromatography/Flame Ionization Detector	A method that combines a flame ionization detector with a gas chromatograph to identify and quantify organic species within a gas stream.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135455>	C179019|C116640	Multiplexed Bead Based Immunoassay|FMIA|Fluorescent Microsphere Immunoassay|MULTIPLEXED BEAD BASED IMMUNOASSAY|Multiplex Bead Array Assay	A type of solid-phase immunoassay that uses distinctly colored microbeads coated with one or more reagents, which may be antigens, antibodies, oligonucleotides, enzyme substrates, or receptors, for the simultaneous detection and measurement of one or many analytes within a single sample.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|SeroNet Authorized Values|SeroNet Study Descriptors
C135456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135456>	C16809	Phase-Contrast Magnetic Resonance Imaging|PCMR|PHASE-CONTRAST MRI|Phase-Contrast MRI	A form of MRI in which a phase shift between flowing tissue and static tissue is generated in order to determine the quantity and velocity of blood flow.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135457>	C19645|C153598	Population Sequencing|POPULATION SEQUENCING	A process by which the individual genomes of most or all of an entire population of a species undergoes a large-scale comparison of the DNA sequences within that population, using probabilistic matching tools. Such comparison allows for the study of microevolution within a population.			Molecular Biology Research Technique	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135458>	C17455	Raji Cell Enzyme Immunoassay|RAJI CELL EIA|Raji Cell EIA	A type of complement receptor-dependent immune complex assay that uses Raji cells washed with anti-IgA, anti-IgG, anti-IgM, and anti-Ig (A+G+M) conjugated with an enzyme to detect the presence of circulating immune complexes in biologic fluids.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135459>	C17057	Raji Cell Radioimmunoassay|RAJI CELL RIA|Raji Cell RIA	A type of complement receptor-dependent immune complex assay that uses radiolabeled anti-IgA, anti-IgG, or anti-IgM Raji cells to detect the presence of soluble immune complexes in biologic fluids.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C13545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13545>	C198952	19p|Chromosome 19 Proximal Arm|Chromosome 19 Short Arm	Proximal (short) arm of chromosome 19			Gene or Genome	
C135460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135460>	C86202	Bordetella holmesii|BORDETELLA HOLMESII|CDC Nonoxidizer Group 2				Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135461>	C18000	AJCC Tumor Grade|AJCC TUMOR GRADE	An assessment of the cellular differentiation of a tumor as per the American Joint Committee on Cancer (AJCC) tumor grading scale.			Classification	CDISC SDTM Microscopic Findings Test Detail Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135462>	C28076	Banff Renal Quantitative Criteria Score|BANFF QUANTITATIVE CRITERIA SCORE RENAL	A score originally developed by Solez et al. (1993), and assigned based on the histologic evaluation of kidney allograft biopsies and the Banff Working Classification from the Banff Foundation for Allograft Pathology.			Classification	CDISC SDTM Microscopic Findings Test Detail Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135463>	C18190	Arteriolar Hyaline Thickening Assessment|ARTLRHYT|Arteriolar Hyaline Thickening|Arteriolar Hyaline Thickening	An evaluation of the presence or degree of arteriolar hyaline thickening present in a sample.			Diagnostic Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135464>	C18190	Banff Renal Diagnostic Category Assessment|BANFRDX|Banff Diagnostic Category Renal|Banff Diagnostic Category Renal	The histologic evaluation and diagnosis of the type of renal allograft rejection based on kidney biopsies and the Banff Working Classification from the Banff Foundation for Allograft Pathology.			Diagnostic Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135465>	C18190	Glomerulitis Assessment|GLOMLTIS|Glomerulitis|Glomerulitis	An evaluation of the presence or degree of glomerulitis present in a sample.			Diagnostic Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135466>	C18190	Glomerulopathy Assessment|GLOMPATH|Glomerulopathy|Glomerulopathy	An evaluation of the presence or degree of glomerulopathy present in a sample.			Diagnostic Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135467>	C18190	Intimal Arteritis Assessment|INTMART|Intimal Arteritis|Intimal Arteritis	An evaluation of the presence or degree of intimal arteritis present in a sample.			Diagnostic Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135468>	C127765	Interstitial Fibrosis Assessment|INTSFBRO|Interstitial Fibrosis|Interstitial Fibrosis	An evaluation of the presence or degree of interstitial fibrosis present in a sample.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135469>	C18190	Mononuclear Cell Interstitial Inflammation Assessment|MCINTINF|Mononuc Cell Interstitial Inflammation|Mononuc Cell Interstitial Inflammation	An evaluation of the presence or degree of mononuclear cell interstitial inflammation present in a sample.			Diagnostic Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13546>	C198953	19q|Chromosome 19 Distal Arm|Chromosome 19 Long Arm	Distal (long) arm of chromosome 19	19q		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C135470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135470>	C18190	Mitotic Figure Assessment|MITOFIG|Mitotic Figure|Mitotic Figure|Mitotic Figures	An evaluation of the presence or degree of mitotic figures present in a sample.			Diagnostic Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135471>	C18190	Mesangial Matrix Assessment|MSNGMTRX|Mesangial Matrix|Mesangial Matrix	An evaluation of the presence or degree of mesangial matrix present in a sample.			Diagnostic Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135472>	C64430	Platelet Endothelial Cell Adhesion Molecule 1 Measurement|CD31 Antigen|CD31 Measurement|PECAM|PECAM Measurement|PECAM-1|PECAM1|PECAM1|PECAM1|PECAM1 Measurement|Platelet And Endothelial Cell Adhesion Molecule 1|Platelet Endo Cell Adhesion Molecule 1|Platelet Endo Cell Adhesion Molecule 1|Platelet Endothelial Adhesion Molecule|Platelet Endothelial Adhesion Molecule 1|Platelet Endothelial Cell Adhesion Molecule Measurement|Soluble CD31	The determination of the amount of platelet endothelial cell adhesion molecule 1 in a biological sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135473>	C18190	Peritubular Capillaritis Assessment|PTBCPLTS|Peritubular Capillaritis|Peritubular Capillaritis	An evaluation of the presence or degree of peritubular capillaritis present in a sample.			Diagnostic Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135474>	C18190	Tubular Atrophy Assessment|TUBATRO|Tubular Atrophy|Tubular Atrophy	An evaluation of the presence or degree of tubular atrophy present in a sample.			Diagnostic Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135475>	C18190	Tubulitis Assessment|TUBULTIS|Tubulitis|Tubulitis	An evaluation of the presence or degree of tubulitis present in a sample.			Diagnostic Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135476>	C18190	Vascular Fibrous Intimal Thickening Assessment|VFBINTMT|Vascular Fibrous Intimal Thickening|Vascular Fibrous Intimal Thickening	An evaluation of the presence or degree of vascular fibrous intimal thickening present in a sample.			Diagnostic Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135477>	C181043	Bone Marrow Disease Involvement Indicator|BMIVLIND|Bone Marrow Involvement Indicator|Bone Marrow Involvement Indicator	An indication as to whether disease is present in the bone marrow.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Tumor Response Assessment Test Code Terminology|CDISC SDTM Tumor Response Assessment Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C135478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135478>	C20641	Clinical Performance Status|CPRFSTAT	An assessment of the clinical performance, as measured by a rating or scale, as a condition of disease response to therapy.			Qualitative Concept	CDISC SDTM Terminology|CDISC SDTM Tumor Response Assessment Test Code Terminology|CDISC SDTM Tumor Response Assessment Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C135479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135479>	C50995	Disease Response in Liver|LIVRRESP|Liver Response|Liver Response	An assessment of the disease response to therapy within the involved liver.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Assessment Test Code Terminology|CDISC SDTM Tumor Response Assessment Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C13547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13547>	C198952	2p|Chromosome 2 Proximal Arm|Chromosome 2 Short Arm	Proximal (short) arm of chromosome 2	2p		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C135480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135480>	C50995	Non-Target Enhancing Lesion Response|NTERESP|Non-Target Enhancing Response|Non-Target Enhancing Response	An assessment of the response to the therapy of the non-target enhancing lesion.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Assessment Test Code Terminology|CDISC SDTM Tumor Response Assessment Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C135481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135481>	C50995	Non-Target Non-Enhancing Lesion Response|NTNERESP|Non-Target Non-Enhancing Response|Non-Target Non-Enhancing Response	An assessment of the response to the therapy of the non-target non-enhancing lesion.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Assessment Test Code Terminology|CDISC SDTM Tumor Response Assessment Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C135482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135482>	C50995	Disease Response in Spleen|SPLNRESP|Spleen Response|Spleen Response	An assessment of the disease response to therapy within the involved spleen.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Assessment Test Code Terminology|CDISC SDTM Tumor Response Assessment Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C135483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135483>	C83430	Steroid Use Status|STRUSTAT	An assessment of steroid usage as a condition of disease response to therapy.			Qualitative Concept	CDISC SDTM Terminology|CDISC SDTM Tumor Response Assessment Test Code Terminology|CDISC SDTM Tumor Response Assessment Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C135484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135484>	C63479	Gene Expression Level Analysis	The determination of the level of gene transcription in a biological specimen. (CDISC)			Laboratory Procedure	GDC Terminology|GDC Value Terminology
C135485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135485>	C18881	Genetic Sub-Region Sequencing|Genetic Sub-Region Sequence	The determination of the sequence of nucleotide residues along a genetic sub-region of interest.			Laboratory Procedure	
C135486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135486>	C18309	Predicted Single Nucleotide Polymorphism Frequency	The determination of the anticipated or extrapolated frequency of a single nucleotide polymorphism within a single interbreeding population.			Laboratory Procedure	
C135487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135487>	C19770	Genetic Sequence Length	The determination of the number of base pairs that compose a nucleotide sequence.			Laboratory Procedure	
C135488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135488>	C164874	Genetic Sequence Start Location	The determination of the location on a nucleotide sequence that is considered to be the beginning of a genetic region of interest.			Spatial Concept	
C135489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135489>	C43242	Concentration at Half Tmax|CHTMAX	The concentration that occurs at the midpoint time between dosing time and Tmax. (CDISC)			Conceptual Entity	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C13548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13548>	C198953	2q|Chromosome 2 Distal Arm|Chromosome 2 Long Arm	Distal (long) arm of chromosome 2	2q		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C135490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135490>	C43242	Fraction Unbound|FU	The ratio of free drug concentration to the total concentration.			Conceptual Entity	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135491>	C43242	Half Tmax|HTMAX	The midpoint time between dosing time and Tmax. (CDISC)			Conceptual Entity	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135492>	C43242	Lambda Z Span|LAMZSPN|Lambda z Span|Lambda z Span	The interval of time covered by the data points used in the terminal disposition phase regression analysis, divided by half life; this yields the terminal disposition phase duration expressed as the number of half lives. (CDISC)			Conceptual Entity	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135493>	C38081	Elastance|ELSTNCE	A measure of the resistance of a system to expand, i.e. the pressure change that is required to elicit a unit volume change in the lungs; elastance is the reciprocal of compliance.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135494>	C38081	Maximal Expiratory Pressure|MEP|MEP	The greatest amount of pressure that can be generated by exhaling against a mouthpiece, which is a measure of the strength of respiratory muscles.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135495>	C38081	Percent Predicted Maximal Expiratory Pressure|MEPPP|Percent Predicted MEP|Percent Predicted MEP|Percent Predicted MEP	The greatest amount of pressure that can be generated by exhaling against a mouthpiece, which is a measure of the strength of respiratory muscles expressed as a proportion of the predicted normal value.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135496>	C38081	Maximal Inspiratory Pressure|MIP|MIP|NIF|Negative Inspiratory Force	The greatest amount of pressure that can be generated during inhalation against a fully occluded airway, which is used to measure the strength of respiratory muscles.	Maximal Inspiratory Pressure		Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C135497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135497>	C38081	Percent Predicted Maximal Inspiratory Pressure|MIPPP|Percent Predicted MIP|Percent Predicted MIP|Percent Predicted MIP	The greatest amount of pressure that can be generated during inhalation against a fully occluded airway, which is used to measure the strength of respiratory muscles expressed as a proportion of the predicted normal value.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135498>	C38081	Peak Cough Flow|CPF|Cough Peak Flow|PCF|PCF	The maximum rate of air flow expelled through the mouth, endotracheal, or tracheostomy tube during a cough.	Peak Cough Flow		Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C135499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135499>	C38081	Pulmonary Blood Flow Assessment	An evaluation of the perfusion of a specific lung segment.			Diagnostic Procedure	
C13549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13549>	C198953	20q|Chromosome 20 Distal Arm|Chromosome 20 Long Arm	Distal (long) arm of chromosome 20	20q		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C1354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1354>	C582	Crisnatol Mesylate|BW A770U Mesylate|CRISNATOL MESYLATE|Crisnatol|crisnatol mesylate				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C135500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135500>	C25337	Number of Biological Brothers|BIOBRON|Number of Brothers, Biological|Number of Brothers, Biological	The number of brothers that are biologically related to the subject.			Quantitative Concept	CDISC SDTM Subject Characteristic Test Code Terminology|CDISC SDTM Subject Characteristic Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135501>	C25337	Number of Biological Sisters|BIOSISN|Number of Sisters, Biological|Number of Sisters, Biological	The number of sisters that are biologically related to the subject.			Quantitative Concept	CDISC SDTM Subject Characteristic Test Code Terminology|CDISC SDTM Subject Characteristic Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135502>	C25180	Living with Subject Indicator|LVSBJIND	An indication as to whether the associated person is living with the subject.			Conceptual Entity	CDISC SDTM Subject Characteristic Test Code Terminology|CDISC SDTM Subject Characteristic Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135503>	C70714	Gelatinous Specimen|GELLED|Gelled Specimen	A specimen that has a gelatinous consistency.			Qualitative Concept	CDISC SDTM Specimen Condition Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135504>	C70714	Solidified Specimen|SOLIDIFIED	A specimen that has no tendency to flow under moderate stress, and/or that resists forces (such as compression) that tend to deform it, and/or that retains a definite size and shape.			Qualitative Concept	CDISC SDTM Specimen Condition Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135505>	C70714	Specimen with Unexpected Odor|UNEXPECTED ODOR	A specimen that has an odor that is either not anticipated or normal.			Qualitative Concept	CDISC SDTM Specimen Condition Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135506>	C103347	Absolute Change from Nadir in Organ Enlargement|ACNDOREN|Absolute Change Nadir in Organ Enlarge|Absolute Change Nadir in Organ Enlarge|Absolute Change Nadir in Organ Enlargement	The current organ enlargement minus the lowest organ enlargement previously recorded.			Diagnostic Procedure	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C135507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135507>	C125006	Quantitative Organ Enlargement Assessment|ORENLQN|Organ Enlargement, Quantitative|Organ Enlargement, Quantitative	A quantitative assessment of an increase in organ size or dimension.			Activity	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C135508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135508>	C171082	Organ State|ORSTATE|Organ Status	A condition or state of an organ at a particular time.			Qualitative Concept	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C135509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135509>	C25334	Organ Craniocaudal Length Measurement|ORVERLN|Organ Vertical Length|Organ Vertical Length|Organ Vertical Length	The linear extent along the craniocaudal axis from one end of an organ to the other end.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C13550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13550>	C198952	20p|Chromosome 20 Proximal Arm|Chromosome 20 Short Arm	Proximal (short) arm of chromosome 20			Gene or Genome	
C135510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135510>	C96621	Percent Change from Baseline in Organ Enlargement|PCBSOREN|Percent Change Baseline in Organ Enlarge|Percent Change Baseline in Organ Enlarge|Percent Change Baseline in Organ Enlargement	The current organ enlargement minus the baseline organ enlargement, divided by the baseline organ enlargement, multiplied by 100.			Diagnostic Procedure	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C135511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135511>	C96622	Percent Change from Nadir in Organ Enlargement|PCNDOREN|Percent Change Nadir in Organ Enlarge|Percent Change Nadir in Organ Enlarge|Percent Change Nadir in Organ Enlargement	The current organ enlargement minus the lowest organ enlargement previously recorded, divided by the lowest organ enlargement previously recorded, multiplied by 100.			Diagnostic Procedure	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C135512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135512>	C96622	Percent Change from Nadir in Product of Perpendicular Diameters|PCNPPD|Percent Change Nadir in PPD|Percent Change Nadir in PPD|Percent Change from Nadir in PPD	The current area minus the lowest area previously recorded, divided by the lowest area previously recorded, multiplied by 100.			Diagnostic Procedure	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C135513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135513>	C40352	Product of Perpendicular Diameters|PPD|PPD	The diameter multiplied by its perpendicular diameter.			Diagnostic Procedure	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C135514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135514>	C117960	Delayed Graft Function Diagnostic Criteria Name|DGFCRIT|Delayed Graft Function Diagnostic Criteria|Delayed Graft Function Dx Criteria|Delayed Graft Function Dx Criteria	The name of a standard criterion from which a judgment concerning an occurrence of a delayed graft function (DGF) can be established.			Idea or Concept	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C135515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135515>	C48207	Per Ten Thousand|/10*4|/10*4|/10*4|/10^4|/10^4|/10^4|/10^4|per 10 thousand	A unit, equal to ten thousand entities, is used as a denominator to build a derived unit expressed as a ratio.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C135516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135516>	C48207	Per Hundred Thousand|/10*5|/10*5|/10^5|/10^5|/10^5	A unit, equal to one hundred thousand entities, is used as a denominator to build a derived unit expressed as a ratio.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135517>	C67332	Per Centimeter of Water|/cmH2O|/cmH2O|/cmH2O|/cm[H2O]|/cm[H2O]|/cm[H2O]|per centimeter of water	A unit of pressure equal to one centimeter of water used as a denominator to build a derived unit expressed as a ratio.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C135518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135518>	C67332	Centimeter of Water Times Second per Milliliter|cmH2O*s/mL|cmH2O*s/mL|cm[H2O].s/mL|cm[H2O].s/mL|cm[H2O].s/ml|cm[H2O].s/ml	A unit of measure for pressure change that is expressed by multiplying cmH2O by seconds, and then dividing that product by the volume of air flow in milliliters			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135519>	C67332	Centimeter of Water Times Second Squared per Milliliter|cmH2O*s2/mL|cmH2O*s2/mL|cm[H2O].s2/mL|cm[H2O].s2/mL|cm[H2O].s2/ml|cm[H2O].s2/ml	A unit of measure for pressure change that is expressed by multiplying cmH2O by seconds, multiplying that product by seconds, then dividing that subsequent product by the volume of air flow in milliliters			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C13551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13551>	C198952	21p|Chromosome 21 Proximal Arm|Chromosome 21 Short Arm	Proximal (short) arm of chromosome 21	21p		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C135520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135520>	C67332	Centimeter of Water per Milliliter|cmH2O/mL|cmH2O/mL|cm[H2O]/mL|cm[H2O]/mL|cm[H2O]/ml|cm[H2O]/ml	A unit of measure for pressure change that is expressed in cmH2O per milliliter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135521>	C67332	Milliliter Times Centimeter of Water|mL*cmH2O|mL*cmH2O|mL.cm[H2O]|mL.cm[H2O]|ml.cm[H2O]|ml.cm[H2O]	A unit of measure for volume change calculation expressed by multiplying the volume of air flow in mL by the air pressure in cmH2O.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135522>	C135508	Graft Status|GRFTSTAT	The condition of the donated organ or tissue.			Qualitative Concept	CDISC SDTM Terminology|CDISC SDTM Urinary System Test Code Terminology|CDISC SDTM Urinary System Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C135523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135523>	C19697	Femur/Femorotibial Joint|BONE, FEMUR/JOINT, FEMOROTIBIAL	A tissue sample that contains the femur and femorotibial joint.			Tissue	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C135524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135524>	C135214|C135209	Stage IIIA Colon Neuroendocrine Tumor AJCC v8|Stage IIIA Colon Neuroendocrine Tumor	Stage IIIA includes: T4, N0, M0. T4: Tumor invading the visceral peritoneum (serosa) or other organs or adjacent structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIA Colon Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135525>	C135214|C135210	Stage IIIB Colon Neuroendocrine Tumor AJCC v8|Stage IIIB Colon Neuroendocrine Tumor	Stage IIIB includes: (T1, N1, M0); (T2, N1, M0); (T3, N1, M0); (T4, N1, M0). T1: Tumor invading the lamina propria or submucosa and measuring 2 cm or less. T2: Tumor invading the muscularis propria or measuring more than 2 cm with invasion of the lamina propria or submucosa. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. T4: Tumor invading the visceral peritoneum (serosa) or other organs or adjacent structures. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIB Colon Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135526>	C135214|C135211	Stage IV Colon Neuroendocrine Tumor AJCC v8|Stage IV Colon Neuroendocrine Tumor	Stage IV includes: (T1, Any N, M1); (T2, Any N, M1); (T3, Any N, M1); (T4, Any N, M1). T1: Tumor invading the lamina propria or submucosa and measuring 2 cm or less. T2: Tumor invading the muscularis propria or measuring more than 2 cm with invasion of the lamina propria or submucosa. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. T4: Tumor invading the visceral peritoneum (serosa) or other organs or adjacent structures. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Colon Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135527>	C135213|C135205	Rectal Neuroendocrine Tumor by AJCC v8 Stage	A term that refers to the staging of a rectal neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system. This staging system applies to rectal "carcinoid" tumors (neuroendocrine tumor G1 and G2, and rare-well differentiated G3). High-grade neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas of the rectum are not staged using this staging system. (from AJCC 8th Ed.)			Neoplastic Process	
C135528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135528>	C135527|C135206	Stage I Rectal Neuroendocrine Tumor AJCC v8|Stage I Rectal Neuroendocrine Tumor	Stage I includes: T1, N0, M0. T1: Tumor invading the lamina propria or submucosa and measuring 2 cm or less. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Rectal Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135529>	C135527|C135207	Stage IIA Rectal Neuroendocrine Tumor AJCC v8|Stage IIA Rectal Neuroendocrine Tumor	Stage IIA includes: T2, N0, M0. T2: Tumor invading the muscularis propria or measuring more than 2 cm with invasion of the lamina propria or submucosa. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIA Rectal Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13552>	C198953	21q|Chromosome 21 Distal Arm|Chromosome 21 Long Arm	Distal (long) arm of chromosome 21			Gene or Genome	
C135530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135530>	C135527|C135208	Stage IIB Rectal Neuroendocrine Tumor AJCC v8|Stage IIB Rectal Neuroendocrine Tumor	Stage IIB includes: T3, N0, M0. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIB Rectal Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135531>	C135527|C135209	Stage IIIA Rectal Neuroendocrine Tumor AJCC v8|Stage IIIA Rectal Neuroendocrine Tumor	Stage IIIA includes: T4, N0, M0. T4: Tumor invading the visceral peritoneum (serosa) or other organs or adjacent structures. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIA Rectal Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135532>	C135527|C135210	Stage IIIB Rectal Neuroendocrine Tumor AJCC v8|Stage IIIB Rectal Neuroendocrine Tumor	Stage IIIB includes: (T1, N1, M0); (T2, N1, M0); (T3, N1, M0); (T4, N1, M0). T1: Tumor invading the lamina propria or submucosa and measuring 2 cm or less. T2: Tumor invading the muscularis propria or measuring more than 2 cm with invasion of the lamina propria or submucosa. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. T4: Tumor invading the visceral peritoneum (serosa) or other organs or adjacent structures. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIB Rectal Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135533>	C135527|C135211	Stage IV Rectal Neuroendocrine Tumor AJCC v8|Stage IV Rectal Neuroendocrine Tumor	Stage IV includes: (T1, Any N, M1); (T2, Any N, M1); (T3, Any N, M1); (T4, Any N, M1). T1: Tumor invading the lamina propria or submucosa and measuring 2 cm or less. T2: Tumor invading the muscularis propria or measuring more than 2 cm with invasion of the lamina propria or submucosa. T3: Tumor invading through the muscularis propria into subserosal tissue without penetration of overlying serosa. T4: Tumor invading the visceral peritoneum (serosa) or other organs or adjacent structures. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Rectal Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135534>	C28681|C138180|C129826	Autologous MAGE-A3/A6-specific TCR Gene-engineered Lymphocytes KITE-718|Autologous Anti-MAGE-A3/A6 TCR-transduced T Cells KITE-718|KITE 718|KITE-718|MAGE-A3/A6 T Cell Receptor Engineered T-Cells|MAGE-A3/A6 T-Cell Receptor Engineered T-Cells KITE-718|MAGE-A3/A6 TCR Engineered T-lymphocytes|MAGEA3/A6-targeted TCR-transduced T-Cells KITE-718|TCR-transduced Autologous T-Cells KITE-718	Human autologous T-lymphocytes genetically modified to express a T-cell receptor (TCR) that specifically targets human melanoma-associated antigen A3 (MAGE-A3) and MAGE-A6 (MAGEA3/A6; MAGE-A3/A6), with potential antineoplastic activity. Peripheral blood mononuclear cells (PBMCs) are isolated from a patient, transduced with a gene expressing a TCR specific for the MAGE-A3/A6 antigens, expanded ex vivo, and reintroduced into the patient. Then, the autologous MAGE-A3/A6-specific TCR gene engineered lymphocytes KITE-718 target and bind to tumor cells expressing the MAGE-A3 and/or MAGE-A6 antigens. This halts the growth of and kills MAGE-A3/A6-expressing cancer cells. The tumor-associated antigens MAGE-A3 and MAGE-A6 are overexpressed on a variety of tumor cell types.	Autologous MAGE-A3/A6-specific TCR Gene-engineered Lymphocytes KITE-718		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C135536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135536>	C135019	Pancreatic Neuroendocrine Tumor TNM Finding v8	A finding about one or more characteristics of a pancreatic neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system. This classification system applies to well-differentiated neuroendocrine tumors arising in the pancreas. It does not apply to carcinomas of the pancreas, including high-grade (grade 3), poorly differentiated neuroendocrine carcinomas. (from AJCC 8th Ed.)			Finding	
C135537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135537>	C135536	Pancreatic Neuroendocrine Tumor Clinical TNM Finding v8	A clinical finding about one or more characteristics of a pancreatic neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system.			Finding	
C135538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135538>	C135537	Pancreatic Neuroendocrine Tumor Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of a pancreatic neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C135539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135539>	C135538	Pancreatic Neuroendocrine Tumor cM0 TNM Finding v8	Pancreatic neuroendocrine tumor without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C13553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13553>	C198953	22q|Chromosome 22 Distal Arm|Chromosome 22 Long Arm	Distal (long) arm of chromosome 22	22q		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C135540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135540>	C135538	Pancreatic Neuroendocrine Tumor cM1 TNM Finding v8	Pancreatic neuroendocrine tumor with distant metastasis. (from AJCC 8th Ed.)			Finding	
C135541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135541>	C135540	Pancreatic Neuroendocrine Tumor cM1a TNM Finding v8	Pancreatic neuroendocrine tumor with metastasis confined to liver. (from AJCC 8th Ed.)			Finding	
C135542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135542>	C135540	Pancreatic Neuroendocrine Tumor cM1b TNM Finding v8	Pancreatic neuroendocrine tumor with metastasis in at least one extrahepatic site (e.g., lung, ovary, nonregional lymph node, peritoneum, bone). (from AJCC 8th Ed.)			Finding	
C135543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135543>	C135540	Pancreatic Neuroendocrine Tumor cM1c TNM Finding v8	Pancreatic neuroendocrine tumor with both hepatic and extrahepatic metastases. (from AJCC 8th Ed.)			Finding	
C135544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135544>	C135536	Pancreatic Neuroendocrine Tumor Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of a pancreatic neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system.			Finding	
C135545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135545>	C135544	Pancreatic Neuroendocrine Tumor Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of a pancreatic neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C135546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135546>	C135545	Pancreatic Neuroendocrine Tumor pM1 TNM Finding v8	Pancreatic neuroendocrine tumor with distant metastasis. (from AJCC 8th Ed.)			Finding	
C135547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135547>	C135546	Pancreatic Neuroendocrine Tumor pM1a TNM Finding v8	Pancreatic neuroendocrine tumor with metastasis confined to liver. (from AJCC 8th Ed.)			Finding	
C135548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135548>	C135546	Pancreatic Neuroendocrine Tumor pM1b TNM Finding v8	Pancreatic neuroendocrine tumor with metastasis in at least one extrahepatic site (e.g., lung, ovary, nonregional lymph node, peritoneum, bone). (from AJCC 8th Ed.)			Finding	
C135549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135549>	C135546	Pancreatic Neuroendocrine Tumor pM1c TNM Finding v8	Pancreatic neuroendocrine tumor with both hepatic and extrahepatic metastases. (from AJCC 8th Ed.)			Finding	
C13554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13554>	C198952	22p|Chromosome 22 Proximal Arm|Chromosome 22 Short Arm	Proximal (short) arm of chromosome 22			Gene or Genome	
C135550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135550>	C135544	Pancreatic Neuroendocrine Tumor Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of a pancreatic neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C135551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135551>	C135550	Pancreatic Neuroendocrine Tumor pTX TNM Finding v8	Pancreatic neuroendocrine tumor in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C135552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135552>	C135550	Pancreatic Neuroendocrine Tumor pT1 TNM Finding v8	Pancreatic neuroendocrine tumor limited to the pancreas and measuring less than 2 cm. Limited to the pancreas means there is no invasion of adjacent organs (stomach, spleen, colon, adrenal gland) or the wall of large vessels (celiac axis or the superior mesenteric artery). Extension of tumor into peripancreatic adipose tissue is not a basis for staging. (from AJCC 8th Ed.)			Finding	
C135553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135553>	C135550	Pancreatic Neuroendocrine Tumor pT2 TNM Finding v8	Pancreatic neuroendocrine tumor limited to the pancreas and measuring 2-4 cm. (from AJCC 8th Ed.)			Finding	
C135554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135554>	C135550	Pancreatic Neuroendocrine Tumor pT3 TNM Finding v8	Pancreatic neuroendocrine tumor limited to the pancreas and measuring more than 4 cm; or tumor invading the duodenum or bile duct. (from AJCC 8th Ed.)			Finding	
C135555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135555>	C135550	Pancreatic Neuroendocrine Tumor pT4 TNM Finding v8	Pancreatic neuroendocrine tumor invading adjacent organs (stomach, spleen, colon, adrenal gland) or the wall of large vessels (celiac axis or the superior mesenteric artery). (from AJCC 8th Ed.)			Finding	
C135556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135556>	C135544	Pancreatic Neuroendocrine Tumor Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of a pancreatic neuroendocrine tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C135557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135557>	C135556	Pancreatic Neuroendocrine Tumor pNX TNM Finding v8	Pancreatic neuroendocrine tumor in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)			Finding	
C135558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135558>	C135556	Pancreatic Neuroendocrine Tumor pN0 TNM Finding v8	Pancreatic neuroendocrine tumor without regional lymph node involvement. (from AJCC 8th Ed.)			Finding	
C135559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135559>	C135556	Pancreatic Neuroendocrine Tumor pN1 TNM Finding v8	Pancreatic neuroendocrine tumor with regional lymph node involvement. (from AJCC 8th Ed.)			Finding	
C13555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13555>	C198953	3q|Chromosome 3 Distal Arm|Chromosome 3 Long Arm	Distal (long) arm of chromosome 3	3q		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C135560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135560>	C27720	Pancreatic Neuroendocrine Tumor by AJCC v8 Stage	A term that refers to the staging of a pancreatic neuroendocrine tumor, following the American Joint Committee on Cancer (AJCC) v8 staging guidelines. This staging system applies to well-differentiated neuroendocrine tumors arising in the pancreas. Carcinomas of the pancreas, including high-grade (grade 3), poorly differentiated neuroendocrine carcinomas are not staged using this staging system. (from AJCC 8th Ed.)			Neoplastic Process	
C135561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135561>	C135560	Stage I Pancreatic Neuroendocrine Tumor AJCC v8|Stage I Pancreatic Neuroendocrine Tumor	Stage I includes: T1, N0, M0. T1: Tumor limited to the pancreas and measuring less than 2 cm. N0: No regional lymph node involvement. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Pancreatic Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135562>	C135560	Stage II Pancreatic Neuroendocrine Tumor AJCC v8|Stage II Pancreatic Neuroendocrine Tumor	Stage II includes: (T2, N0, M0); (T3, N0, M0). T2: Tumor limited to the pancreas and measuring 2-4 cm. T3: Tumor limited to the pancreas and measuring more than 4 cm; or tumor invading the duodenum or bile duct. N0: No regional lymph node involvement. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Pancreatic Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135563>	C135560	Stage III Pancreatic Neuroendocrine Tumor AJCC v8|Stage III Pancreatic Neuroendocrine Tumor	Stage III includes: (T4, N0, M0); (Any T, N1, M0). T4: Tumor invading adjacent organs (stomach, spleen, colon, adrenal gland) or the wall of large vessels (celiac axis or the superior mesenteric artery). N0: No regional lymph node involvement. N1: Regional lymph node involvement. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Pancreatic Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135564>	C135560	Stage IV Pancreatic Neuroendocrine Tumor AJCC v8|Stage IV Pancreatic Neuroendocrine Tumor	Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Pancreatic Neuroendocrine Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C135565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135565>	C82995	Brunner's Gland Hyperplasia	A rare hyperplastic lesion of Brunner's gland in the duodenum. Although it is usually asymptomatic and discovered incidentally during upper gastrointestinal endoscopy, it may cause hemorrhage.			Disease or Syndrome	
C135566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135566>	C124351	History and Physical Exam|H&P|History and Physical|History and Physical Examination	A record of the medical history and physical examination findings for a patient collected at the time of admission.	History and Physical Exam		Clinical Attribute	CTRP Intervention Terminology|CTRP Terminology
C135567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135567>	C74760|C64858	24 Hour Urine for Total Protein|24 Hour Urine Protein|24 Hour Urine Protein Test|24 h Urine for Total Protein|24-Hour Urine Protein|24-Hour Urine Protein Test|24h PTU	The measurement of the total protein present in a urine sample that was collected over a period of 24 hours.	24 Hour Urine for Total Protein		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C135568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135568>	C16536	Urine Protein Electrophoresis|UPEP	An electrophoresis-based laboratory test performed to determine the concentrations of globulin proteins in the urine.	Urine Protein Electrophoresis		Molecular Biology Research Technique	CTRP Biomarker Terminology|CTRP Intervention Terminology|CTRP Terminology
C135569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135569>	C54536	Urine Immunofixation Electrophoresis|UIFE	An immunofixation-based laboratory test performed to detect and type monoclonal immunoglobulins present in a urine sample.			Molecular Biology Research Technique	
C13556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13556>	C198953	4q|Chromosome 4 Distal Arm|Chromosome 4 Long Arm	Distal (long) arm of chromosome 4			Gene or Genome	
C135570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135570>	C111233	Serum Quantitative Immunoglobulins|Serum Total Immunoglobulins	The determination of the total amount of IgG, IgM, and IgA present in a serum sample.	Serum Quantitative Immunoglobulins		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Terminology
C135571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135571>	C54536	Serum Immunofixation Electrophoresis|SIFE	An immunofixation-based laboratory test performed to detect and type monoclonal immunoglobulins present in a serum sample.			Molecular Biology Research Technique	
C135572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135572>	C74942	Serum Viscosity|Serum Viscosity Measurement	A measurement of the resistance of a serum sample to flow because of shear stress.			Laboratory Procedure	
C135573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135573>	C49131	Bone Marrow Staining	The examination of a bone marrow sample using a histological staining method.			Laboratory Procedure	
C135574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135574>	C177692	MAGEA6 Positive|MAGE-A6 Positive|MAGE3B Positive|Melanoma-Associated Antigen 6 Positive	An indication that melanoma-associated antigen 6 expression has been detected in a sample.	MAGEA6 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C135575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135575>	C177692	MAGEA3 Positive|HIP8 Positive|HYPD Positive|MAGE-3 Positive|MAGE-A3 Positive|MAGE3 Positive|Melanoma-Associated Antigen 3 Positive	An indication that melanoma-associated antigen 3 expression has been detected in a sample.	MAGEA3 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C135576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135576>	C91105	Patient Oriented Prostate Utility Scale|PORPUS|Patient Oriented Prostate Utility Scale (PORPUS)	A 10-item self-report questionnaire that measures quality of life for men with prostate cancer.			Intellectual Product	
C135577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135577>	C173346	Pain and Disturbing Body Sensations Question|Pain and Disturbing Body Sensations|Pain and Disturbing Body Sensations (e.g. hot flashes, painful swelling of breasts, nausea)	A question about an individual's level of pain and disturbing body sensations.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135578>	C173145	Communication with Doctor Question|Ability to Communicate with Doctor|Communication With Doctor (primary caregiver for prostate cancer, may be specialist or family doctor)|Communication with Doctor	A question about an individual's ability to communicate with their doctor.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135579>	C173803	Urinary Frequency and Urgency Question|Urinary Frequency (need to pass urine frequently during the day or night) and Urgency (difficulty delaying urination after the urge is felt to urinate, ability to "hold it")|Urinary Frequency and Urgency	A question about an individual's frequency and urgency of passing urine.			Intellectual Product	Patient Oriented Prostate Utility Scale
C13557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13557>	C198952	4p|Chromosome 4 Proximal Arm|Chromosome 4 Short Arm	Proximal (short) arm of chromosome 4	4p		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C135580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135580>	C173938|C173358	Bowel Problems Frequency Question|Bowel Problems Frequency|Bowel problems: diarrhea, rectal discomfort (pain, burning or irritation) or constipation|Frequency of Bowel Problems	A question about the frequency of an individual's bowel problems.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135581>	C176246	No Pain and No Disturbing Body Sensations|No pain and no disturbing body sensations	A response indicating that an individual has or had no pain and no disturbing body sensations.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135582>	C226614|C176246	Mild Pain or Disturbing Body Sensations Not Limiting Activities|Mild pain or disturbing body sensations that do not limit any activities (for example: work, social, sexual, sleep)	A response indicating that an individual had mild pain or disturbing body sensations, but  that they do or did not limit activities.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135583>	C226614|C176246	Moderate Pain or Disturbing Body Sensations that Limit Few Activities|Moderate pain or disturbing body sensations that limit a few activities	A response indicating that an individual has or had moderate pain or disturbing body sensations that limited a few activities.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135584>	C226614|C176246	Moderate to Severe Pain or Disturbing Body Sensations that Limit Some Activities|Moderate to severe pain or disturbing body sensations that limit some activities	A response indicating that an individual has or had moderate to severe pain or disturbing body sensations that limited some activities.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135585>	C226614|C176246	Severe Pain or Disturbing Body Sensations that Limit Many Activities|Severe pain or disturbing body sensations that limit many activities	A response indicating that an individual has or had severe pain or disturbing body sensations that limited many activities.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135586>	C226663	Very Full of Energy, Lots of Pep|Very full of energy, lots of pep	A response indicating that an individual is or was very full of energy, with lots of pep.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135587>	C226663|C226614	Fairly Energetic, No Limitation of Activities|Fairly energetic, no limitation of activities (for example: work, social, sexual)	A response indicating that an individual is or was fairly energetic, with no limitation of activities.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135588>	C226663|C226614	Moderate Reduction in Energy or Pep that Limits a Few Activities|Moderate reduction in energy or pep that limits a few activities	A response indicating that an individual has or had a moderate reduction in energy or pep that limited a few activities.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135589>	C226663|C226614	Generally Low Energy or Pep that Limits Some Activities|Generally low energy or pep that limits some activities	A response indicating that an individual has or had generally low energy or pep that limited some activities.			Intellectual Product	Patient Oriented Prostate Utility Scale
C13558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13558>	C198952	5p|Chromosome 5 Proximal Arm|Chromosome 5 Short Arm	Proximal (short) arm of chromosome 5			Gene or Genome	
C135590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135590>	C226663|C226614	No Energy or Pep at All; Feel Drained, Many Activities are Limited|No energy or pep at all. I feel drained, and many activities are limited	A response indicating that an individual has or had no energy or pep at all; felt drained, with many activities limited.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135591>	C226725|C226668	Most Times Feel Supported by Spouse, Family, and Friends|Feel Supported by Spouse, Family, and Friends Most Times|Feel Supported by Spouse, Family, and Friends Most of the Time|Most of the time feel supported by my spouse, family and friends	A response indicating that an individual feels or felt supported by spouse, family, and friends at most times.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135592>	C226725|C226668	Fair Amount of Time Feel Supported by Spouse, Family, and Friends|A fair amount of the time feel supported by my spouse, family and friends|Feel Supported by Spouse, Family, and Friends Fair Amount of the Time	A response indicating that an individual feels or felt supported by spouse, family, and friends a fair amount of the time.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135593>	C226725|C226668	Occasionally Feel Supported by Spouse, Family and Friends|Feel Supported by Spouse, Family, and Friends Occasionally|Occasionally feel supported by my spouse, family and friends	A response indicating that an individual feels or felt supported by spouse, family, and friends only occasionally.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135594>	C226725|C226668	Rarely Feel Supported by Spouse, Family and Friends|Feel Supported by Spouse, Family, and Friends Only Rarely|Rarely feel supported by my spouse, family, and friends	A response indicating that an individual feels or felt supported by spouse, family, and friends only rarely.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135595>	C226920|C176242	Always Able to Express Concerns to Doctor and Get Needed Information or Advice|Always able to express my concerns to my Doctor and get all the information or advice I need	A response indicating that an individual is or was always able to express concerns to their doctor and get the needed information or advice.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135596>	C226920|C176242	Most of the Time, Able to Express Concerns to Doctor and Get Needed Information or Advice|Most of the time, able to express my concerns to my Doctor and get all the information or advice I need	A response indicating that an individual is or was able to express concerns to their doctor and get the needed information or advice most of the time.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135597>	C226920|C176242	Some of the Time, Able to Express Concerns to Doctor and Get Needed Information or Advice|Some of the time, able to express my concerns to my Doctor and get all the information or advice I need	A response indicating that an individual is or was able to express concerns to their doctor and get the needed information or advice some of the time.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135598>	C226920|C176242	Rarely Able to Express my Concerns to Doctor and Get Needed Information or Advice|Rarely able to express my concerns to my Doctor and get all the information or advice I need	A response indicating that an individual is or was rarely able to express concerns to their doctor and get the needed information or advice.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135599>	C226746|C226674	Generally Happy and Free from Worry, Sadness, or Frustration|Generally happy and free from worry, sadness, or frustration	A response indicating that an individual is generally happy and free from worry, sadness, or frustration.			Intellectual Product	Patient Oriented Prostate Utility Scale
C13559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13559>	C198952	6p|Chromosome 6 Proximal Arm|Chromosome 6 Short Arm	Proximal (short) arm of chromosome 6			Gene or Genome	
C1355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1355>	C137864	Calcium Citrate|2-Hydroxy-1,2,3-propanetricarboxylic Acid, Calcium Salt (2:3)|Acicontral|CALCIUM CITRATE|Citracal|Tricalcium Citrate	The citrate salt of calcium. An element necessary for normal nerve, muscle, and cardiac function, calcium as the citrate salt helps to maintain calcium balance and prevent bone loss when taken orally. This agent may also be chemopreventive for colon and other cancers. (NCI04)	Calcium Citrate		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C135600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135600>	C226746	Little Worry, Sadness, or Frustration|A little worry, sadness, or frustration	A response indicating that an individual has a little worry, sadness, or frustration.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135601>	C226746	Moderate Worry, Sadness, or Frustration|Moderate worry, sadness, or frustration	A response indicating that an individual has moderate worry, sadness, or frustration.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135602>	C226746	Quite a bit of Worry, Sadness, or Frustration|Quite a bit of worry, sadness, or frustration	A response indicating that an individual has quite a bit of worry, sadness, and frustration.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135603>	C226746	Extreme Worry, Sadness, or Frustration|Extreme worry, sadness, or frustration	A response indicating that an individual has extreme worry, sadness, or frustration.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135604>	C226650	No Urinary Frequency or Urgency|No urinary frequency or urgency	A response indicating that an individual feels or felt no urinary frequency or urgency.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135605>	C226650	Little Urinary Frequency or Urgency; Does not Interfere with Sleep or Other Activities|A little urinary frequency or urgency, does not interfere with sleep or other activities (for example: work, social); no need to plan ahead	A response indicating that an individual feels or felt a little urinary frequency or urgency, but it does not interfere with sleep or other activities.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135606>	C226650|C177167	Some Urinary Frequency or Urgency that Interferes with Sleep or Other Activities; May Need to Plan Ahead|Some urinary frequency or urgency that interferes with sleep or other activities; may need to plan ahead	A response indicating that an individual feels or felt some urinary frequency or urgency that interferes with sleep or other activities and that may make it necessary to plan ahead.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135607>	C226650	Quite a Bit of Urinary Frequency or Urgency; Need to be Near Bathroom Most of the Time|Quite a bit of urinary frequency or urgency; need to be near a bathroom most of the time	A response indicating that an individual feels or felt quite a bit of urinary frequency or urgency, making it necessary to be near a bathroom most of the time.			Intellectual Product	
C135608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135608>	C226650	Extreme Urinary Frequency or Urgency; Need to be Near a Bathroom Always|Extreme urinary frequency or urgency; need to be near a bathroom always	A response indicating that an individual feels or felt extreme urinary frequency or urgency, making it necessary to be near a bathroom always.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135609>	C226568|C176245	Never, Under Any Circumstances Leak Urine or Lose Bladder Control|Never, under any circumstances leak urine or lose bladder control	A response indicating that an individual never, under any circumstances leaks urine or loses bladder control.			Intellectual Product	Patient Oriented Prostate Utility Scale
C13560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13560>	C198953	6q|Chromosome 6 Distal Arm|Chromosome 6 Long Arm	Distal (long) arm of chromosome 6			Gene or Genome	
C135610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135610>	C226568|C177167	On Rare Occasions, Leak Urine or Lose Bladder Control, Does not Interfere with Any Activities|Leak Urine or Lose Bladder Control On Rare Occasions, Does not Interfere with Any Activities|On rare occasions, leak urine or lose bladder control, does not interfere with any activities (for example: work, social, sexual, sleep)	A response indicating that an individual, on rare occasions, leaks urine or loses bladder control but that it does not interfere with any activities.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135611>	C226568|C177167	Occasionally Leak Urine or Lose Bladder Control, Interferes with Few Activities|Leak Urine or Lose Bladder Control Occasionally, Interferes with Few Activities|Occasionally leak urine or lose bladder control, interferes with a few activities	A response indicating that an individual occasionally leaks urine or loses bladder control and it interferes with a few activities.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135612>	C61199|C129821	Neural Stem Cells-expressing CRAd-S-pk7|CRAd-S-pk7 loaded NSCs|NSC-CRAd-S-pk7|NSC-CRAd-S-pk7 Virotherapeutic|NSCs loaded with CRAd-S-pk7|SC-CRAd-Survivin-pk7	Neural stem cells (NSCs) that are transfected with the gliomatropic oncolytic adenovirus (OV) CRAd-S-pk7, a conditionally replicative oncolytic adenoviral (CRAd) vector that contains the tumor-specific survivin promoter (S) and a fiber protein polylysine modification (pk7), with potential antineoplastic activity. Upon intracerebral administration of NSC loaded with CRAd-S-pk7, the NSCs preferentially migrate towards tumor cells, and the polylysine moiety of the modified fiber protein expressed by the viral vector specifically targets and binds to tumor-specific heparan sulfate proteoglycans. Subsequently, the virus can infect the tumor cells and viral replication is initiated because E1 gene expression is controlled by the tumor-specific promoter for survivin. This results in the specific lysis of the glioma cells. The pk7 fiber modification and the survivin promoter enable tumor-specific infectivity, and transcriptional targeting and preferential replication in glioma cells, while sparing the surrounding normal brain parenchyma. The pK7 is comprised of a heparan sulfate binding domain incorporated into the fiber protein of the adenovirus.	Neural Stem Cells-expressing CRAd-S-pk7		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C135613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135613>	C2363	Amikacin Inhalation Solution|BAY41 6551|BAY41-6551	A solution for inhalation containing the aminoglycoside antibiotic amikacin, with anti-bacterial activity. Upon aerosolized administration using the Pulmonary Drug Delivery System (PDDS), amikacin irreversibly binds to the 30S ribosomal subunit of susceptible organisms, thereby interfering with the activity of the translation initiation complex, which leads to both the misreading of mRNA and the production of non-functional or toxic peptides, and prevents normal protein synthesis. This kills susceptible bacteria.	Amikacin Inhalation Solution		Antibiotic|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C135614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135614>	C226568|C177167	Moderate Amount of the Time, Leak Urine or Lose Bladder Control, Interferes with Some Activities|A moderate amount of the time, leak urine or lose bladder control, interferes with some activities|Leak Urine or Lose Bladder Control Moderate Amount of the Time, Interferes with Some Activities	A response indicating that an individual leaks urine or loses bladder control a moderate amount of the time and it interferes with some activities.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135615>	C17423	Polymyxin-B Immobilized Fiber PMX-20R|PMX Cartridge|PMX-20R|Toraymyxin	A cartridge containing a polystyrene-based composite woven fiber that is covalently attached to the anti-microbial cyclic cationic polypeptide antibiotic polymyxin-B (PMX) and can potentially be used for hemoperfusion purposes. Upon extracorporeal treatment, a patient's blood flows through the fibers in the polymyxin-B immobilized fiber PMX-20R cartridge and the circulating endotoxins from the blood are selectively adsorbed by PMX, which has positively charged amino groups that bind to the negatively charged site in the lipid A portion of the lipopolysaccharide (LPS) layer of the bacterial cell membrane. This removes endotoxins from the blood and, upon administration of the blood back into the patient, helps treat or reduce the incidence of endotoxemia and sepsis.	Polymyxin-B Immobilized Fiber PMX-20R		Medical Device	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C135616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135616>	C94297	Androgen Receptor Splice Variant 7 Positive|AR-v7 Positive|AR-v7 Positive|AR3 Positive|Androgen Receptor Splice Variant 3 Positive	An indication that androgen receptor splice variant 3 expression has been detected in a sample.	AR-v7 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C135617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135617>	C226568|C177167	Most of the Time, Leak Urine or Have Poor Bladder Control, Interferes with Many Activities|Leak Urine or Have Poor Bladder Control Most of the Time, Interferes with Many Activities|Most of the time, leak urine or have poor bladder control, interferes with many activities	A response indicating that an individual leaks urine or has poor bladder control most of the time and it interferes with many activities.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135618>	C226650	Require Clamp, Catheter, or Collecting Bag Because of Leaking Urine or Poor Bladder Control	A response indicating that an individual requires a clamp, catheter, or collecting bag because of leaking urine or poor bladder control.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135619>	C932	Liposomal Vinorelbine Tartrate|TLC-178|TLC178	A formulation of the tartrate salt form of vinorelbine, a semisynthetic vinca alkaloid, encapsulated within liposomes, with potential antineoplastic activity. Upon intravenous administration, vinorelbine binds to tubulin within tumor cells and prevents the formation of the mitotic spindle, resulting in cell cycle arrest, induction of apoptosis and an inhibition of tumor cell growth. Compared to the administration of vinorelbine alone, the liposomal formulation improves drug penetration into tumors and decreases drug clearance, thereby increasing vinorelbine's efficacy while lowering the toxicity profile.	Liposomal Vinorelbine Tartrate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology
C13561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13561>	C198952	7p|Chromosome 7 Proximal Arm|Chromosome 7 Short Arm	Proximal (short) arm of chromosome 7			Gene or Genome	
C135620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135620>	C175563	Full Erections Sufficient for Intercourse|Full erections sufficient for intercourse	A response indicating that an individual achieves/maintains full erections sufficient for intercourse.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135621>	C175563	Erections Sufficient for Intercourse, but Some Reduction in Firmness|Erections sufficient for intercourse, but some reduction in firmness	A response indicating that an individual achieves/maintains erections sufficient for intercourse, but has some reduction in firmness.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135622>	C175563	Erections Sufficient for Masturbation or Foreplay Only|Erections sufficient for masturbation or foreplay only	A response indicating that an individual achieves/maintains erections sufficient for masturbation or foreplay only.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135623>	C175563	Erections, But Not Firm Enough for Any Sexual Activity|Erections, but not firm enough for any sexual activity	A response indicating that an individual achieves/maintains erections, but not firm enough for any sexual activity.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135624>	C175563	No Erections at All|No erections at all	A response indicating that an individual achieves no erections at all.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135625>	C176252	Normal Amount of Sexual Drive and Interest|Normal amount of sexual drive and interest for you	A response indicating that an individual has or had their normal amount of sexual drive and interest.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135627>	C192728	Belzutifan|BELZUTIFAN|HIF-2alpha Inhibitor PT2977|MK 6482|MK-6482|MK6482|PT 2977|PT-2977|PT2977|Welireg	An orally active, small molecule inhibitor of hypoxia inducible factor (HIF)-2alpha (HIF-2a), with potential antineoplastic activity. Upon oral administration, belzutifan binds to and blocks the function of HIF-2alpha, thereby preventing HIF-2alpha heterodimerization and its subsequent binding to DNA. This results in decreased transcription and expression of HIF-2alpha downstream target genes, many of which regulate hypoxic signaling. This inhibits cell growth and survival of HIF-2alpha-expressing tumor cells. HIF-2alpha, the alpha subunit for the heterodimeric transcription factor HIF-2, is overexpressed in many cancers and promotes tumorigenesis.	Belzutifan		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C135628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135628>	C176252	Little Decrease of Sexual Drive or Interest|A little decrease of sexual drive or interest for you	A response indicating that an individual has or had a little decrease of sexual drive or interest.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135629>	C1946	HDAC6 Inhibitor KA2507|HDAC6i KA2507|KA-2507|KA2507	An orally bioavailable inhibitor of histone deacetylase (HDAC) type 6 (HDAC6; HDAC-6), with potential antineoplastic activity. Upon administration, KA2507 targets, binds to and inhibits the activity of HDAC6. This results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. Specifically, inhibition of HDAC6 prevents STAT3 activity, which leads to a reduction in programmed death-1 (PD-1) expression. Eventually, this results in a selective transcription of tumor suppressor genes, tumor suppressor protein-mediated inhibition of tumor cell division and an induction of apoptosis in tumor cells that overexpress HDAC6. HDAC6, which is upregulated in many tumor cell types, deacetylates chromatin histone proteins.	HDAC6 Inhibitor KA2507		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C13562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13562>	C198953	8q|Chromosome 8 Distal Arm|Chromosome 8 Long Arm	Distal (long) arm of chromosome 8	8q		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C135630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135630>	C176252	No Sexual Drive or Interest|No sexual drive or interest	A response indicating that an individual has or had no sexual drive or interest.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135631>	C93221|C275|C2459	Grape Seed Extract Supplement|GSE|GSE Supplement	An orally bioavailable dietary supplement composed of an extract from grape seeds containing high amounts of polyphenols, particularly lower proanthocyanidin oligomers (OPCs) and catechins, with antioxidant and chemopreventive activities. Upon administration, the active components in the grape seed extract (GSE) scavenge free radicals, protect against oxidation of low-density lipoprotein (LDL), and inhibit cell damage due to reactive oxygen species (ROS). This inhibits oxidative stress and protects against DNA damage. GSE also inhibits enzymes involved in inflammation, cell replication and DNA synthesis, and induces the expression of anti-oxidant enzymes. This may inhibit growth and induce apoptosis of cancer cells.	Grape Seed Extract Supplement		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C135632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135632>	C201282|C200367	Vixtimotamab|AMV 564|AMV-564|AMV564|Anti-CD33 Antigen/CD3 Receptor Bispecific Monoclonal Antibody AMV564|CD33 x CD3 Tandem Diabody AMV-56|CD33/CD3 TandAbs AMV564|CNTO-3953|T652|VIXTIMOTAMAB	An anti-CD33/anti-CD3 bispecific tetravalent antibody, with potential immunostimulatory and antineoplastic activities. Anti-CD33/CD3 tetravalent bispecific monoclonal antibody AMV564 possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD33, a tumor-associated antigen (TAA) overexpressed on the surface of a variety of tumor cell types. Upon infusion of vixtimotamab, this bispecific antibody binds to CD3-expressing T-cells and CD33-expressing tumor cells, thereby crosslinking CD33-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in a potent CTL-mediated cell lysis of CD33-expressing cells. CD33, a glycoprotein expressed by a variety of cancers, including the majority of acute myeloid leukemias (AMLs), and normal non-pluripotent hematopoietic stem cells, plays a key role in tumor initiation, proliferation and progression.	Vixtimotamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C135633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135633>	C128036	Anti-CTLA4 Monoclonal Antibody BMS-986218|BMS 986218|BMS-986218|Monoclonal Antibody BMS-986218	A Fc-modified monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA4 monoclonal antibody BMS-986218 targets and binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system. Removal of the fucose sugar units from the antibody's Fc region, enhances its activity and decreases the toxicity of BMS-986218.	Anti-CTLA4 Monoclonal Antibody BMS-986218		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C135634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135634>	C28681|C201547	Autologous Tumor Infiltrating Lymphocytes LN-145|Autologous TILs LN-145|Autologous Tumor-infiltrating Lymphocytes LN-145|LN-145|LN145	A proprietary preparation of autologous tumor infiltrating lymphocytes (TILs), with potential immunomodulating activity. The autologous TILs are isolated from an autologous tumor sample and expanded ex vivo in the presence of interleukin-2 (IL-2). Upon infusion of the autologous TILs LN-145 back into the patient, the cells specifically recognize, target and kill the patient's tumor cells.	Autologous Tumor Infiltrating Lymphocytes LN-145		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C135635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135635>	C176252	Moderate Decrease of Sexual Drive or Interest|Moderate decrease of sexual drive or interest for you	A response indicating that an individual has or had a moderate decrease of sexual drive or interest.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135636>	C176252	Substantial Decrease of Sexual Drive or Interest|Substantial decrease of sexual drive or interest for you	A response indicating that an individual has or had a substantial decrease of sexual drive or interest.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135637>	C226641	No Diarrhea, Rectal Discomfort, or Constipation|No diarrhea, rectal discomfort, or constipation	A response indicating that an individual has or had no diarrhea, rectal discomfort, or constipation.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135638>	C226641	Have Occasional Diarrhea, Rectal Discomfort, or Constipation|Occasionally have diarrhea, rectal discomfort, or constipation	A response indicating that an individual occasionally has or had diarrhea, rectal discomfort, or constipation.			Intellectual Product	Patient Oriented Prostate Utility Scale
C135639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135639>	C226641	Have Frequent Diarrhea, Rectal Discomfort, or Constipation|Frequently have diarrhea, rectal discomfort, or constipation	A response indicating that an individual frequently has or had diarrhea, rectal discomfort, or constipation.			Intellectual Product	Patient Oriented Prostate Utility Scale
C13563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13563>	C198952	9p|Chromosome 9 Proximal Arm|Chromosome 9 Short Arm	Proximal (short) arm of chromosome 9	9p		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C135640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135640>	C226641	Have Nearly Constant Diarrhea, Rectal Discomfort, or Constipation|Nearly always have diarrhea, rectal discomfort, or constipation	A response indicating that an individual nearly always has or had diarrhea, rectal discomfort, or constipation.			Intellectual Product	Patient Oriented Prostate Utility Scale
C13564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13564>	C198953	9q|Chromosome 9 Distal Arm|Chromosome 9 Long Arm	Distal (long) arm of chromosome 9	9q		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13565>	C198952	Xp|Chromosome X Proximal Arm|Chromosome X Short Arm	Proximal (short) arm of chromosome X			Gene or Genome	
C13566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13566>	C198953	Xq|Chromosome X Distal Arm|Chromosome X Long Arm	Distal (long) arm of chromosome X			Gene or Genome	
C135677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135677>	C103175	CDISC Clinical Classification PASI Test Name Terminology|CC-PASI TEST	Test names of clinical classification questions associated with the Psoriasis Area and Severity Index (PASI) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	
C135678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135678>	C103175	CDISC Clinical Classification PASI Test Code Terminology|CC-PASI TESTCD	Test codes of clinical classification questions associated with the Psoriasis Area and Severity Index (PASI) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	
C135679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135679>	C100110	CDISC Questionnaire BEBQ Concurrent Version Test Name Terminology|BEBQ01TN|Baby Eating Behaviour Questionnaire Concurrent Version Questionnaire Test Name|QS-BEBQ Concurrent Version TEST	Test names of questionnaire questions associated with the Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13567>	C13432	6p25-p23	A chromosome band present on 6p			Gene or Genome	
C135680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135680>	C100110	CDISC Questionnaire BEBQ Concurrent Version Test Code Terminology|BEBQ01TC|Baby Eating Behaviour Questionnaire Concurrent Version Questionnaire Test Code|QS-BEBQ Concurrent Version TESTCD	Test codes of questionnaire questions associated with the Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135681>	C100110	CDISC Questionnaire BEBQ Retrospective Version Test Name Terminology|BEBQ02TN|Baby Eating Behaviour Questionnaire Retrospective Version Questionnaire Test Name|QS-BEBQ Retrospective Version TEST	Test names of questionnaire questions associated with the Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135682>	C100110	CDISC Questionnaire BEBQ Retrospective Version Test Code Terminology|BEBQ02TC|Baby Eating Behaviour Questionnaire Retrospective Version Questionnaire Test Code|QS-BEBQ Retrospective Version TESTCD	Test codes of questionnaire questions associated with the Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135683>	C103175	CDISC Questionnaire CGI Original Version Test Name Terminology|QS-CGI Original Version TEST	Test names of questionnaire questions associated with the Clinical Global Impression Original Version (CGI Original Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	
C135684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135684>	C103175	CDISC Questionnaire CGI Original Version Test Code Terminology|QS-CGI Original Version TESTCD	Test codes of questionnaire questions associated with the Clinical Global Impression Original Version (CGI Original Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	
C135685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135685>	C100110	CDISC Questionnaire CGI Generic Modification Version Test Name Terminology|CGI02TN|Clinical Global Impression Generic Modification Version Questionnaire Test Name|QS-CGI Generic Modification Version TEST	Test names of questionnaire questions associated with the Clinical Global Impression Generic Modification Version (CGI Generic Modification Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135686>	C100110	CDISC Questionnaire CGI Generic Modification Version Test Code Terminology|CGI02TC|Clinical Global Impression Generic Modification Version Questionnaire Test Code|QS-CGI Generic Modification Version TESTCD	Test codes of questionnaire questions associated with the Clinical Global Impression Generic Modification Version (CGI Generic Modification Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135687>	C100110	CDISC Questionnaire PGI Generic Modification Version Test Name Terminology|PGI01TN|Patient Global Impression Generic Modification Version Questionnaire Test Name|QS-PGI Generic Modification Version TEST	Test names of questionnaire questions associated with the Patient Global Impression Generic Modification Version (PGI Generic Modification Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135688>	C100110	CDISC Questionnaire PGI Generic Modification Version Test Code Terminology|PGI01TC|Patient Global Impression Generic Modification Version Questionnaire Test Code|QS-PGI Generic Modification Version TESTCD	Test codes of questionnaire questions associated with the Patient Global Impression Generic Modification Version (PGI Generic Modification Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135689>	C100110	CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|LEC01TN|Life Events Checklist for DSM-5 Standard Version Questionnaire Test Name|QS-LEC-5 Standard Version TEST	Test names of questionnaire questions associated with the Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13568>	C13432	1p32-p31	A chromosome band present on 1p			Gene or Genome	
C135690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135690>	C100110	CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|LEC01TC|Life Events Checklist for DSM-5 Standard Version Questionnaire Test Code|QS-LEC-5 Standard Version TESTCD	Test codes of questionnaire questions associated with the Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135691>	C100110	CDISC Questionnaire PCL-5 Test Name Terminology|PCL01TN|QS-PCL-5 TEST|The PTSD Checklist for DSM-5 Questionnaire Test Name	Test names of questionnaire questions associated with the PTSD Checklist for DSM-5 (PCL-5) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135692>	C100110	CDISC Questionnaire PCL-5 Test Code Terminology|PCL01TC|QS-PCL-5 TESTCD|The PTSD Checklist for DSM-5 Questionnaire Test Code	Test codes of questionnaire questions associated with the PTSD Checklist for DSM-5 (PCL-5) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135693>	C100110	CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|PODCI1TN|Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version Questionnaire Test Name|QS-PODCI Pediatric Parent-Reported Version TEST	Test names of questionnaire questions associated with the Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135694>	C100110	CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|PODCI1TC|Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version Questionnaire Test Code|QS-PODCI Pediatric Parent-Reported Version TESTCD	Test codes of questionnaire questions associated with the Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135695>	C100110	CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|PODCI2TN|Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version Questionnaire Test Name|QS-PODCI Adolescent Parent-Reported Version TEST	Test names of questionnaire questions associated with the Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135696>	C100110	CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|PODCI2TC|Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version Questionnaire Test Code|QS-PODCI Adolescent Parent-Reported Version TESTCD	Test codes of questionnaire questions associated with the Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135697>	C100110	CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|PODCI3TN|Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version Questionnaire Test Name|QS-PODCI Adolescent Self-Reported Version TEST	Test names of questionnaire questions associated with the Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135698>	C100110	CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|PODCI3TC|Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version Questionnaire Test Code|QS-PODCI Adolescent Self-Reported Version TESTCD	Test codes of questionnaire questions associated with the Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135699>	C100110	CDISC Questionnaire RAND Social Support Survey Test Name Terminology|QS-RAND Social Support Survey TEST|RAND Social Support Survey Instrument Questionnaire Test Name|RSSS01TN	Test names of questionnaire questions associated with the RAND Social Support Survey Instrument (RAND Social Support Survey) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13569>	C13432	19p13.2	A chromosome band present on 19p			Gene or Genome	
C1356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1356>	C2139	Carbetimer|CARBETIMER|N-137|NED-137|carbethimer|carboxyaminidate	Carbetimer (carboxyimamidate) is a low molecular weight derivatized copolymer of ethylene and maleic anhydride.  It has demonstrated antitumor activity against several animal models.  It has calcium chelation activity but seems to inhibit growth of sensitive cells by disrupting nucleoside uptake and metabolism.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C135700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135700>	C100110	CDISC Questionnaire RAND Social Support Survey Test Code Terminology|QS-RAND Social Support Survey TESTCD|RAND Social Support Survey Instrument Questionnaire Test Code|RSSS01TC	Test codes of questionnaire questions associated with the RAND Social Support Survey Instrument (RAND Social Support Survey) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135701>	C211913	PASI Clinical Classification Question	A question associated with the PASI clinical classification.			Intellectual Product	
C135702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135702>	C211913	BEBQ Concurrent Version Questionnaire Question	A question associated with the BEBQ Concurrent Version questionnaire.			Intellectual Product	
C135703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135703>	C211913	BEBQ Retrospective Version Questionnaire Question	A question associated with the BEBQ Retrospective Version questionnaire.			Intellectual Product	
C135704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135704>	C211913	CGI Original Version Questionnaire Question	A question associated with the CGI Original Version questionnaire.			Intellectual Product	
C135705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135705>	C211913	CGI Generic Modification Version Questionnaire Question	A question associated with the CGI Generic Modification Version questionnaire.			Intellectual Product	
C135706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135706>	C211913	PGI Generic Modification Version Questionnaire Question	A question associated with the PGI Generic Modification Version questionnaire.			Intellectual Product	
C135707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135707>	C211913	LEC-5 Standard Version Questionnaire Question	A question associated with the LEC-5 Standard Version questionnaire.			Intellectual Product	
C135708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135708>	C211913	PCL-5 Questionnaire Question	A question associated with the PCL-5 questionnaire.			Intellectual Product	
C135709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135709>	C211913	PODCI Pediatric Parent-Reported Version Questionnaire Question	A question associated with the PODCI Pediatric Parent-Reported Version questionnaire.			Intellectual Product	
C13570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13570>	C13432	11p11.2	A chromosome band present on 11p			Gene or Genome	
C135710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135710>	C211913	PODCI Adolescent Parent-Reported Version Questionnaire Question	A question associated with the PODCI Adolescent Parent-Reported Version questionnaire.			Intellectual Product	
C135711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135711>	C211913	PODCI Adolescent Self-Reported Version Questionnaire Question	A question associated with the PODCI Adolescent Self-Reported Version questionnaire.			Intellectual Product	
C135712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135712>	C211913	RAND Social Support Survey Questionnaire Question	A question associated with the RAND Social Support Survey questionnaire.			Intellectual Product	
C135715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135715>	C41361	KRAS Exon 2 Mutation|KRAS-2 Exon 2 Mutation|KRAS2 Exon 2 Mutation|c-K-ras Exon 2 Mutation|v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Exon 2 Mutation	A molecular genetic abnormality indicating the presence of a mutation in exon 2 of the KRAS gene.	KRAS Exon 2 Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C135716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135716>	C41361	KRAS Exon 3 Mutation|KRAS Exon 3 Gene Mutation|KRAS-2 Exon 3 Mutation|KRAS2 Exon 3 Mutation|c-K-ras Exon 3 Mutation|v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Exon 3 Mutation	A molecular genetic abnormality indicating the presence of a mutation in exon 3 of the KRAS gene.	KRAS Exon 3 Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C135717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135717>	C41361	KRAS Exon 4 Mutation|KRAS Exon 4 Gene Mutation|KRAS-2 Exon 4 Mutation|KRAS2 Exon 4 Mutation|c-K-ras Exon 4 Mutation|v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Exon 4 Mutation	A molecular genetic abnormality indicating the presence of a mutation in exon 4 of the KRAS gene.	KRAS Exon 4 Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C135718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135718>	C41381	NRAS Exon 2 Mutation|N-RAS Exon 2 Mutation|NRAS Exon 2 Gene Mutation|Neuroblastoma RAS Viral Oncogene Homolog Exon 2 Mutation	A molecular genetic abnormality indicating the presence of a mutation in exon 2 of the NRAS gene.	NRAS Exon 2 Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C135719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135719>	C41381	NRAS Exon 3 Mutation|N-RAS Exon 3 Mutation|NRAS Exon 3 Gene Mutation|Neuroblastoma RAS Viral Oncogene Homolog Exon 3 Mutation	A molecular genetic abnormality indicating the presence of a mutation in exon 3 of the NRAS gene.	NRAS Exon 3 Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13571>	C13432	4q11-q12	A chromosome band present on 4q			Gene or Genome	
C135720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135720>	C41381	NRAS Exon 4 Mutation|N-RAS Exon 4 Mutation|NRAS Exon 4 Gene Mutation|Neuroblastoma RAS Viral Oncogene Homolog Exon 4 Mutation	A molecular genetic abnormality indicating the presence of a mutation in exon 4 of the NRAS gene.	NRAS Exon 4 Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C135721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135721>	C21895	Mouse Erythroleukemia	Erythroleukemia that occurs in a mouse.			Neoplastic Process	
C135722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135722>	C60400	Rat Erythroleukemia	Erythroleukemia that occurs in a rat.			Neoplastic Process	Cellosaurus Disease Terminology
C135723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135723>	C134988	Hamster Mammary Carcinoma	Carcinoma of the mammary gland that occurs in a hamster.			Neoplastic Process	Cellosaurus Disease Terminology
C135724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135724>	C134528	Feline Large Granular Lymphocyte Lymphoma	A T-cell leukemia in which there is a persistent increase in the number of large granular lymphocytes in the peripheral blood and occurring in a cat.			Neoplastic Process	Cellosaurus Disease Terminology
C135725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135725>	C9460	Cockayne Syndrome Type A	Cockayne syndrome caused by mutation(s) in the ERCC8 gene, encoding DNA excision repair protein ERCC-8.			Disease or Syndrome	Cellosaurus Disease Terminology
C135726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135726>	C9460	Cockayne Syndrome Type B	Cockayne syndrome caused by mutation(s) in the ERCC6 gene, encoding DNA excision repair protein ERCC-6.			Disease or Syndrome	Cellosaurus Disease Terminology
C135727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135727>	C15189	Liquid Biopsy|Plasma Biopsy	Sampling and analysis of non-solid biological material (primarily blood), usually to determine if cancer cells or circulating-free cancer DNA is present.			Diagnostic Procedure	GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C135728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135728>	C158375	Mammoplasty Patient|Breast Mammoplasty Patient|Breast Reconstruction Patient	A person who is undergoing mammoplasty.	Mammoplasty Patient		Patient or Disabled Group	CTRP Intervention Terminology|CTRP Terminology
C135729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135729>	C98357	EGFR NM_005228.3:c.1474A>C|EGFR S492R Gene Mutation|EGFR c.1474A>C|ERBB c.1474A>C|ERBB1 c.1474A>C|Epidermal Growth Factor Receptor Gene c.1474A>C|HER1 c.1474A>C|NM_005228.3:c.1474A>C	A nucleotide substitution at position 1474 of the coding sequence of the EGFR gene where adenine has been mutated to cytosine.	EGFR NM_005228.3:c.1474A>C		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13572>	C13432	12p12.1	A chromosome band present on 12p			Gene or Genome	
C135730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135730>	C98357	EGFR NM_005228.3:c.1476C>A|EGFR S492R Gene Mutation|EGFR c.1476C>A|ERBB c.1476C>A|ERBB1 c.1476C>A|Epidermal Growth Factor Receptor Gene c.1476C>A|HER1 c.1476C>A|NM_005228.3:c.1476C>A	A nucleotide substitution at position 1476 of the coding sequence of the EGFR gene where cytosine has been mutated to adenine.	EGFR NM_005228.3:c.1476C>A		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C135731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135731>	C98356	EGFR NP_005219.2:p.S492R|EGFR NP_005219.2:p.Ser492Arg|EGFR S492R|EGFR S492R Mutation|EGFR Ser492Arg|EGFR p.S492R|EGFR p.Ser492Arg|Epidermal Growth Factor Receptor S492R|Epidermal Growth Factor Receptor Ser492Arg|NP_005219.2:p.Ser492Arg|Proto-Oncogene c-ErbB-1 S492R|Proto-Oncogene c-ErbB-1 Ser492Arg|Receptor Tyrosine-Protein Kinase erbB-1 S492R|Receptor Tyrosine-Protein Kinase erbB-1 Ser492Arg	A change in the amino acid residue at position 492 in the epidermal growth factor receptor protein where serine has been replaced by arginine.	EGFR NP_005219.2:p.S492R		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C135732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135732>	C15209	Colectomy with Diversion	Surgical diversion of the gastrointestinal tract performed in conjunction with a colectomy.			Therapeutic or Preventive Procedure	
C135733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135733>	C51652	Bypass of Impending Intestinal Obstruction	Surgical bypass of an impending intestinal obstruction.			Therapeutic or Preventive Procedure	
C135734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135734>	C118969	Psoriasis Area and Severity Index Clinical Classification|PASI	A standardized survey developed by Fredriksson and Pettersson in 1978 to calculate the intensity and extent of psoriatic plaques before, during, and after retinoid treatment in chronic plaquetype psoriasis. The instrument utilizes a 5-point rating scale to measure intensity and assigns a numerical score for the percentage of anatomical involvement.			Intellectual Product	
C135735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135735>	C91105	Baby Eating Behaviour Questionnaire Concurrent Version|BEBQ CONCURRENT|BEBQ Concurrent Version|BEBQ01	A standardized 18-item concurrent parent-report questionnaire developed by Llewellyn et al in 2010 as a psychometric measure of infant appetite during the 0-3-month period of exclusive milk-feeding. The instrument, which is derived from the Children's Eating Behaviour Questionnaire, was designed to characterize appetite traits that might confer susceptibility to gain weight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135736>	C91105	Baby Eating Behaviour Questionnaire Retrospective Version|BEBQ RETROSPECTIVE|BEBQ Retrospective Version|BEBQ02	A standardized 18-item retrospective parent-report questionnaire developed by Llewellyn et al in 2010 as a psychometric measure of infant appetite during the 0-3-month period of exclusive milk-feeding. The instrument, which is derived from the Children's Eating Behaviour Questionnaire, was designed to characterize appetite traits that might confer susceptibility to gain weight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135738>	C91105	Clinical Global Impression Generic Modification Version Questionnaire|CGI|CGI Generic Modification Version|CGI02	A modified version of a standardized questionnaire published in 1976 by Guy et al. that was initially created to provide a clinician-determined summary measure of a patient's global functioning prior to and after initiating a study medication. It has been modified for use in any disease/condition concept use case.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135739>	C91105	Patient Global Impression Generic Modification Version Questionnaire|PGI|PGI Generic Modification Version|PGI01	A modified, generic version of a standardized questionnaire, developed as a patient reported outcomes counterpart for the Clinical Global Impressions scale published by Guy et al. in 1976, that assesses a patient's perception of their condition.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13573>	C13432	1p35-p34.3	A chromosome band present on 1p			Gene or Genome	
C135740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135740>	C91105	Life Events Checklist for DSM-5 Standard Version Questionnaire|LEC-5 STANDARD VERSION|LEC-5 Standard Version|LEC01	A standardized 17-item self-report measure, published in 2013, that is used to investigate exposure to potentially traumatic events that meet diagnostic criterion A for post-traumatic stress disorder (PTSD) according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). The instrument is used to assess exposure to 16 event categories known to potentially result in PTSD or distress, as well as an additional item addressing any other extraordinarily stressful events not captured by the 16 categories, in adults 18 years of age and older.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135741>	C91105	The PTSD Checklist for DSM-5 Questionnaire|PCL-5|PCL-5|PCL01	A standardized 20-item self-report measure, published in 2013, that is used to assess the 20 Diagnostic and Statistical Manual of Mental Disorders (DSM-5) symptoms of post-traumatic stress disorder (PTSD), using a 5-point Likert-type intensity scale, ranging from zero (not at all) to four (extremely).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135742>	C91105	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version Questionnaire|PODCI - PEDIATRIC PARENT REPORTED|PODCI Pediatric Parent-Reported Version|PODCI1	A standardized 86-item parent-report questionnaire, developed by the American Academy of Orthopaedic Surgeons and the Pediatric Orthopaedic Society of North America (POSNA) in 1998 to assess the overall health, pain, and ability to participate in normal daily activities in patients 10 years of age or younger. The instrument includes five scales: upper extremity and physical function, transfer and mobility tasks, sports/physical functioning, pain/comfort, treatment expectations, happiness, and satisfaction with symptoms, as well as a Global Functioning scale that consists of the mean of the values for the first four scales.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135743>	C91105	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version Questionnaire|PODCI - ADOLESCENT PARENT REPORTED|PODCI Adolescent Parent-Reported Version|PODCI2	A standardized 86-item parent-report questionnaire, developed by the American Academy of Orthopaedic Surgeons and the Pediatric Orthopaedic Society of North America (POSNA) in 1998 to assess the overall health, pain, and ability to participate in normal daily activities in patients 11 to 18 years of age. The instrument includes five scales: upper extremity and physical function, transfer and mobility tasks, sports/physical functioning, pain/comfort, treatment expectations, happiness, and satisfaction with symptoms, as well as a Global Functioning scale that consists of the mean of the values for the first four scales.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135744>	C91105	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version Questionnaire|PODCI - ADOLESCENT SELF REPORTED|PODCI Adolescent Self-Reported Version|PODCI3	A standardized 83-item self-report questionnaire, developed by the American Academy of Orthopaedic Surgeons and the Pediatric Orthopaedic Society of North America (POSNA) in 1998 to assess the overall health, pain, and ability to participate in normal daily activities in patients 11 to 18 years of age. The instrument includes five scales: upper extremity and physical function, transfer and mobility tasks, sports/physical functioning, pain/comfort, treatment expectations, happiness, and satisfaction with symptoms, as well as a Global Functioning scale that consists of the mean of the values for the first four scales.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135745>	C91105	RAND Social Support Survey Instrument Questionnaire|RAND SOCIAL SUPPORT SURVEY INSTRUMENT|RAND Social Support Survey|RSSS01	A standardized 19-item survey developed by Cathy Donalds Helbourne and Anita L. Stewart in 1991 for the assessment of recent thinking about the various dimensions of social support in patients with chronic conditions in the Medical Outcomes Study (MOS). The instrument measures five dimensions of social support: emotional support, informational support, tangible support, positive social interaction, and affectionate support.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135746>	C135701	PASI - Head (H): Erythema (E)	Psoriasis Area and Severity Index (PASI) Head (H): Erythema (E).			Intellectual Product	
C135747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135747>	C135701	PASI - Head (H): Infiltration (I)	Psoriasis Area and Severity Index (PASI) Head (H): Infiltration (I).			Intellectual Product	
C135748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135748>	C135701	PASI - Head (H): Desquamation (D)	Psoriasis Area and Severity Index (PASI) Head (H): Desquamation (D).			Intellectual Product	
C135749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135749>	C135701	PASI - Head (H): Sum = E+I+D	Psoriasis Area and Severity Index (PASI) Head (H): Sum = E + I + D.			Intellectual Product	
C13574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13574>	C13432	8q13	A chromosome band present on 8q			Gene or Genome	
C135750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135750>	C135701	PASI - Head (H): Area Score	Psoriasis Area and Severity Index (PASI) Head (H): Area score.			Intellectual Product	
C135751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135751>	C135701	PASI - Head (H): Sum X Area	Psoriasis Area and Severity Index (PASI) Head (H): Sum x area.			Intellectual Product	
C135752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135752>	C135701	PASI - Head (H): Sum X Area X 0.1	Psoriasis Area and Severity Index (PASI) Head (H): Sum x area x 0.1.			Intellectual Product	
C135753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135753>	C135701	PASI - Trunk (T): Erythema (E)	Psoriasis Area and Severity Index (PASI) Trunk (T): Erythema (E).			Intellectual Product	
C135754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135754>	C135701	PASI - Trunk (T): Infiltration (I)	Psoriasis Area and Severity Index (PASI) Trunk (T): Infiltration (I).			Intellectual Product	
C135755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135755>	C135701	PASI - Trunk (T): Desquamation (D)	Psoriasis Area and Severity Index (PASI) Trunk (T): Desquamation (D).			Intellectual Product	
C135756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135756>	C135701	PASI - Trunk (T): Sum = E+I+D	Psoriasis Area and Severity Index (PASI) Trunk (T): Sum = E + I + D.			Intellectual Product	
C135757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135757>	C135701	PASI - Trunk (T): Area Score	Psoriasis Area and Severity Index (PASI) Trunk (T): Area score.			Intellectual Product	
C135758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135758>	C135701	PASI - Trunk (T): Sum X Area	Psoriasis Area and Severity Index (PASI) Trunk (T): Sum x area.			Intellectual Product	
C135759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135759>	C135701	PASI - Trunk (T): Sum X Area X 0.3	Psoriasis Area and Severity Index (PASI) Trunk (T): Sum x area x 0.3.			Intellectual Product	
C135760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135760>	C135701	PASI - Upper Extremities (U): Erythema (E)	Psoriasis Area and Severity Index (PASI) Upper Extremities (U): Erythema (E).			Intellectual Product	
C135761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135761>	C135701	PASI - Upper Extremities (U): Infiltration (I)	Psoriasis Area and Severity Index (PASI) Upper Extremities (U): Infiltration (I).			Intellectual Product	
C135762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135762>	C135701	PASI - Upper Extremities (U): Desquamation (D)	Psoriasis Area and Severity Index (PASI) Upper Extremities (U): Desquamation (D).			Intellectual Product	
C135763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135763>	C135701	PASI - Upper Extremities (U): Sum = E+I+D	Psoriasis Area and Severity Index (PASI) Upper Extremities (U): Sum = E + I + D.			Intellectual Product	
C135764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135764>	C135701	PASI - Upper Extremities (U): Area Score	Psoriasis Area and Severity Index (PASI) Upper Extremities (U): Area score.			Intellectual Product	
C135765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135765>	C135701	PASI - Upper Extremities (U): Sum X Area	Psoriasis Area and Severity Index (PASI) Upper Extremities (U): Sum x area.			Intellectual Product	
C135766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135766>	C135701	PASI - Upper Extremities (U): Sum X Area X 0.2	Psoriasis Area and Severity Index (PASI) Upper Extremities (U): Sum x area x 0.2.			Intellectual Product	
C135767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135767>	C135701	PASI - Lower Extremities (L): Erythema (E)	Psoriasis Area and Severity Index (PASI) Lower Extremities (L): Erythema (E).			Intellectual Product	
C135768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135768>	C135701	PASI - Lower Extremities (L): Infiltration (I)	Psoriasis Area and Severity Index (PASI) Lower Extremities (L): Infiltration (I).			Intellectual Product	
C135769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135769>	C135701	PASI - Lower Extremities (L): Desquamation (D)	Psoriasis Area and Severity Index (PASI) Lower Extremities (L): Desquamation (D).			Intellectual Product	
C13576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13576>	C13432	18q21.1	A chromosome band present on 18q			Gene or Genome	
C135770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135770>	C135701	PASI - Lower Extremities (L): Sum = E+I+D	Psoriasis Area and Severity Index (PASI) Lower Extremities (L): Sum = E + I + D.			Intellectual Product	
C135771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135771>	C135701	PASI - Lower Extremities (L): Area Score	Psoriasis Area and Severity Index (PASI) Lower Extremities (L): Area score.			Intellectual Product	
C135772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135772>	C135701	PASI - Lower Extremities (L): Sum X Area	Psoriasis Area and Severity Index (PASI) Lower Extremities (L): Sum x area.			Intellectual Product	
C135773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135773>	C135701	PASI - Lower Extremities (L): Sum X Area X 0.4	Psoriasis Area and Severity Index (PASI) Lower Extremities (L): Sum x area x 0.4.			Intellectual Product	
C135774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135774>	C135701	PASI - Total Sum	Psoriasis Area and Severity Index (PASI) Total sum.			Intellectual Product	
C135775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135775>	C135702	BEBQ Concurrent Version - Baby Seems Contented Feeding|BEBQ01-Baby Seems Contented Feeding|BEBQ01-Baby Seems Contented Feeding|BEBQ0101	Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) My baby seems contented while feeding.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Code Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135776>	C135702	BEBQ Concurrent Version - Baby Frequently Wants More Milk|BEBQ01-Baby Frequently Wants More Milk|BEBQ01-Baby Frequently Wants More Milk|BEBQ0102	Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) My baby frequently wants more milk than I provide.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Code Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135777>	C135702	BEBQ Concurrent Version - Baby Loves Milk|BEBQ01-Baby Loves Milk|BEBQ01-Baby Loves Milk|BEBQ0103	Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) My baby loves milk.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Code Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135778>	C135702	BEBQ Concurrent Version - Baby Has a Big Appetite|BEBQ01-Baby Has a Big Appetite|BEBQ01-Baby Has a Big Appetite|BEBQ0104	Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) My baby has a big appetite.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Code Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135779>	C135702	BEBQ Concurrent Version - Baby Finishes Feeding Quickly|BEBQ01-Baby Finishes Feeding Quickly|BEBQ01-Baby Finishes Feeding Quickly|BEBQ0105	Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) My baby finishes feeding quickly.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Code Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13577>	C13432	16q22-q23	A chromosome band present on 16q			Gene or Genome	
C135780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135780>	C135702	BEBQ Concurrent Version - Baby Becomes Distressed Feeding|BEBQ01-Baby Becomes Distressed Feeding|BEBQ01-Baby Becomes Distressed Feeding|BEBQ0106	Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) My baby becomes distressed while feeding.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Code Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135781>	C135702	BEBQ Concurrent Version - Baby Gets Full Up Easily|BEBQ01-Baby Gets Full Up Easily|BEBQ01-Baby Gets Full Up Easily|BEBQ0107	Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) My baby gets full up easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Code Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135782>	C135702	BEBQ Concurrent Version - Baby Would Take Too Much Milk|BEBQ01-Baby Would Take Too Much Milk|BEBQ01-Baby Would Take Too Much Milk|BEBQ0108	Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) If allowed to, my baby would take too much milk.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Code Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135783>	C135702	BEBQ Concurrent Version - Baby Takes More Than 30 Minutes|BEBQ01-Baby Takes More Than 30 Minutes|BEBQ01-Baby Takes More Than 30 Minutes|BEBQ0109	Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) My baby takes more than 30 minutes to finish feeding.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Code Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135784>	C135702	BEBQ Concurrent Version - Gets Full Before Taking All Milk|BEBQ01-Gets Full Before Taking All Milk|BEBQ01-Gets Full Before Taking All Milk|BEBQ0110	Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) My baby gets full before taking all the milk I think he/she should have.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Code Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135785>	C135702	BEBQ Concurrent Version - Baby Feeds Slowly|BEBQ01-Baby Feeds Slowly|BEBQ01-Baby Feeds Slowly|BEBQ0111	Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) My baby feeds slowly.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Code Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135786>	C135702	BEBQ Concurrent Version - Just Eaten Is Happy to Feed Again|BEBQ01-Just Eaten Is Happy to Feed Again|BEBQ01-Just Eaten Is Happy to Feed Again|BEBQ0112	Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) Even when my baby has just eaten well he/she is happy to feed again if offered.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Code Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135787>	C135702	BEBQ Concurrent Version - Difficult Manage Complete Feed|BEBQ01-Difficult Manage Complete Feed|BEBQ01-Difficult Manage Complete Feed|BEBQ0113	Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) My baby finds it difficult to manage a complete feed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Code Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135788>	C135702	BEBQ Concurrent Version - Baby Is Always Demanding a Feed|BEBQ01-Baby Is Always Demanding a Feed|BEBQ01-Baby Is Always Demanding a Feed|BEBQ0114	Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) My baby is always demanding a feed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Code Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135789>	C135702	BEBQ Concurrent Version - Baby Sucks More and More Slowly|BEBQ01-Baby Sucks More and More Slowly|BEBQ01-Baby Sucks More and More Slowly|BEBQ0115	Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) My baby sucks more and more slowly during the course of a feed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Code Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13578>	C13432	17q25	A chromosome band present on 17q			Gene or Genome	
C135790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135790>	C135702	BEBQ Concurrent Version - Baby Would Always Be Feeding|BEBQ01-Baby Would Always Be Feeding|BEBQ01-Baby Would Always Be Feeding|BEBQ0116	Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) If given the chance, my baby would always be feeding.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Code Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135791>	C135702	BEBQ Concurrent Version - Baby Enjoys Feeding Time|BEBQ01-Baby Enjoys Feeding Time|BEBQ01-Baby Enjoys Feeding Time|BEBQ0117	Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) My baby enjoys feeding time.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Code Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135792>	C135702	BEBQ Concurrent Version - Take a Feed Within 30 Minutes|BEBQ01-Take a Feed Within 30 Minutes|BEBQ01-Take a Feed Within 30 Minutes|BEBQ0118	Baby Eating Behaviour Questionnaire Concurrent Version (BEBQ Concurrent Version) My baby can easily take a feed within 30 minutes of the last one.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Code Terminology|CDISC Questionnaire BEBQ Concurrent Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135793>	C135703	BEBQ Retrospective Version - Baby Seemed Contented Feeding|BEBQ02-Baby Seemed Contented Feeding|BEBQ02-Baby Seemed Contented Feeding|BEBQ0201	Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) My baby seemed contented while feeding.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Code Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135794>	C135703	BEBQ Retrospective Version - Baby Frequently Wanted More Milk|BEBQ02-Baby Frequently Wanted More Milk|BEBQ02-Baby Frequently Wanted More Milk|BEBQ0202	Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) My baby frequently wanted more milk than I provided.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Code Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135795>	C135703	BEBQ Retrospective Version - Baby Loved Milk|BEBQ02-Baby Loved Milk|BEBQ02-Baby Loved Milk|BEBQ0203	Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) My baby loved milk.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Code Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135796>	C135703	BEBQ Retrospective Version - Baby Had a Big Appetite|BEBQ02-Baby Had a Big Appetite|BEBQ02-Baby Had a Big Appetite|BEBQ0204	Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) My baby had a big appetite.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Code Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135797>	C135703	BEBQ Retrospective Version - Baby Finished Feeding Quickly|BEBQ02-Baby Finished Feeding Quickly|BEBQ02-Baby Finished Feeding Quickly|BEBQ0205	Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) My baby finished feeding quickly.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Code Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135798>	C135703	BEBQ Retrospective Version - Baby Became Distressed Feeding|BEBQ02-Baby Became Distressed Feeding|BEBQ02-Baby Became Distressed Feeding|BEBQ0206	Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) My baby became distressed while feeding.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Code Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135799>	C135703	BEBQ Retrospective Version - Baby Got Full Up Easily|BEBQ02-Baby Got Full Up Easily|BEBQ02-Baby Got Full Up Easily|BEBQ0207	Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) My baby got full up easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Code Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13579>	C13432	6q24-q27	A chromosome band present on 6q			Gene or Genome	
C1357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1357>	C67421	Mivobulin Isethionate|CI 980|CI-980|CI-980|CI980|MIVOBULIN ISETHIONATE|mivobulin isethionate	The isethionate salt of mivobulin, a synthetic colchicine analogue with potential antineoplastic activity. Mivobulin isethionate binds to tubulin, thereby inhibiting microtubule polymerization and mitosis.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C135800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135800>	C135703	BEBQ Retrospective Version - Baby Would Take Too Much Milk|BEBQ02-Baby Would Take Too Much Milk|BEBQ02-Baby Would Take Too Much Milk|BEBQ0208	Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) If allowed to, my baby would take too much milk.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Code Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135801>	C135703	BEBQ Retrospective Version - Baby Took More Than 30 Minutes|BEBQ02-Baby Took More Than 30 Minutes|BEBQ02-Baby Took More Than 30 Minutes|BEBQ0209	Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) My baby took more than 30 minutes to finish feeding.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Code Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135802>	C135703	BEBQ Retrospective Version - Got Full Before Taking All Milk|BEBQ02-Got Full Before Taking All Milk|BEBQ02-Got Full Before Taking All Milk|BEBQ0210	Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) My baby got full before taking all the milk I think he/she should have.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Code Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135803>	C135703	BEBQ Retrospective Version - Baby Fed Slowly|BEBQ02-Baby Fed Slowly|BEBQ02-Baby Fed Slowly|BEBQ0211	Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) My baby fed slowly.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Code Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135804>	C135703	BEBQ Retrospective Version - Just Eaten Happy to Feed Again|BEBQ02-Just Eaten Happy to Feed Again|BEBQ02-Just Eaten Happy to Feed Again|BEBQ0212	Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) Even when my baby had just eaten well he/she was happy to feed again if offered.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Code Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135805>	C135703	BEBQ Retrospective Version - Difficult Manage Complete Feed|BEBQ02-Difficult Manage Complete Feed|BEBQ02-Difficult Manage Complete Feed|BEBQ0213	Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) My baby found it difficult to manage a complete feed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Code Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135806>	C135703	BEBQ Retrospective Version - Baby Was Always Demanding a Feed|BEBQ02-Baby Was Always Demanding a Feed|BEBQ02-Baby Was Always Demanding a Feed|BEBQ0214	Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) My baby was always demanding a feed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Code Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135807>	C135703	BEBQ Retrospective Version - Baby Sucked More and More Slowly|BEBQ02-Baby Sucked More and More Slowly|BEBQ02-Baby Sucked More and More Slowly|BEBQ0215	Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) My baby sucked more and more slowly during the course of a feed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Code Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135808>	C135703	BEBQ Retrospective Version - Baby Would Always Be Feeding|BEBQ02-Baby Would Always Be Feeding|BEBQ02-Baby Would Always Be Feeding|BEBQ0216	Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) If given the chance, my baby would always be feeding.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Code Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135809>	C135703	BEBQ Retrospective Version - Baby Enjoyed Feeding Time|BEBQ02-Baby Enjoyed Feeding Time|BEBQ02-Baby Enjoyed Feeding Time|BEBQ0217	Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) My baby enjoyed feeding time.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Code Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13580>	C13432	14q23	A chromosome band present on 14q			Gene or Genome	
C135810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135810>	C135703	BEBQ Retrospective Version - Take a Feed Within 30 Minutes|BEBQ02-Take a Feed Within 30 Minutes|BEBQ02-Take a Feed Within 30 Minutes|BEBQ0218	Baby Eating Behaviour Questionnaire Retrospective Version (BEBQ Retrospective Version) My baby could easily take a feed within 30 minutes of the last one.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Code Terminology|CDISC Questionnaire BEBQ Retrospective Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135811>	C135704	CGI Original Version - Severity of Illness	Clinical Global Impression Original Version (CGI Original Version) Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?			Intellectual Product	
C135812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135812>	C135704	CGI Original Version - Global Improvement	Clinical Global Impression Original Version (CGI Original Version) Rate total improvement whether or not, in your judgement, it is due entirely to drug treatment. Compared to his condition at admission to the project, how much has he changed?			Intellectual Product	
C135813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135813>	C135704	CGI Original Version - Efficacy Index	Clinical Global Impression Original Version (CGI Original Version) Rate this item on the basis of drug effect only. Select the terms which best describe the degrees of therapeutic effect and side effects.			Intellectual Product	
C135814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135814>	C135705	CGI Generic Modification Version - Severity|CGI02-Severity|CGI02-Severity|CGI0201	Clinical Global Impression Generic Modification Version (CGI Generic Modification Version) Considering your total clinical experience with this particular population, how severe is the subject's condition at this time?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CGI Generic Modification Version Test Code Terminology|CDISC Questionnaire CGI Generic Modification Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135815>	C135705	CGI Generic Modification Version - Change|CGI02-Change|CGI02-Change|CGI0202	Clinical Global Impression Generic Modification Version (CGI Generic Modification Version) Rate total change whether or not, in your judgement, it is due entirely to drug treatment. Compared to the subject's condition <at previously assessed protocol specified time point>, how much has the subject changed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CGI Generic Modification Version Test Code Terminology|CDISC Questionnaire CGI Generic Modification Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135816>	C135705	CGI Generic Modification Version - Improvement|CGI02-Improvement|CGI02-Improvement|CGI0203	Clinical Global Impression Generic Modification Version (CGI Generic Modification Version) Rate total improvement whether or not, in your judgement, it is due entirely to drug treatment. Compared to the subject's condition <at previously assessed protocol specified time point>, how much has the subject improved?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire CGI Generic Modification Version Test Code Terminology|CDISC Questionnaire CGI Generic Modification Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135817>	C135706	PGI Generic Modification Version - Severity|PGI01-Severity|PGI01-Severity|PGI0101	Patient Global Impression Generic Modification Version (PGI Generic Modification Version) Considering all the ways your condition impacts you, how severe is your condition at this time?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PGI Generic Modification Version Test Code Terminology|CDISC Questionnaire PGI Generic Modification Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135818>	C135706	PGI Generic Modification Version - Change|PGI01-Change|PGI01-Change|PGI0102	Patient Global Impression Generic Modification Version (PGI Generic Modification Version) Compared to <previously assessed protocol specified time point> how much has your condition changed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PGI Generic Modification Version Test Code Terminology|CDISC Questionnaire PGI Generic Modification Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135819>	C135706	PGI Generic Modification Version - Improvement|PGI01-Improvement|PGI01-Improvement|PGI0103	Patient Global Impression Generic Modification Version (PGI Generic Modification Version) Compared to <previously assessed protocol specified time point> how much has your condition improved?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PGI Generic Modification Version Test Code Terminology|CDISC Questionnaire PGI Generic Modification Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13581>	C13432	5q21-q22	A chromosome band present on 5q			Gene or Genome	
C135820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135820>	C135707	LEC-5 Standard Version - Natural Disaster: Happened|LEC01-Natural Disaster: Happened|LEC01-Natural Disaster: Happened|LEC0101A	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Natural disaster (for example, flood, hurricane, tornado, earthquake): Happened to me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135821>	C135707	LEC-5 Standard Version - Natural Disaster: Witnessed|LEC01-Natural Disaster: Witnessed|LEC01-Natural Disaster: Witnessed|LEC0101B	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Natural disaster (for example, flood, hurricane, tornado, earthquake): Witnessed it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135822>	C135707	LEC-5 Standard Version - Natural Disaster: Learned|LEC01-Natural Disaster: Learned|LEC01-Natural Disaster: Learned|LEC0101C	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Natural disaster (for example, flood, hurricane, tornado, earthquake): Learned about it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135823>	C135707	LEC-5 Standard Version - Natural Disaster: Job|LEC01-Natural Disaster: Job|LEC01-Natural Disaster: Job|LEC0101D	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Natural disaster (for example, flood, hurricane, tornado, earthquake): Part of my job.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135824>	C135707	LEC-5 Standard Version - Natural Disaster: Not Sure|LEC01-Natural Disaster: Not Sure|LEC01-Natural Disaster: Not Sure|LEC0101E	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Natural disaster (for example, flood, hurricane, tornado, earthquake): Not sure.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135825>	C135707	LEC-5 Standard Version - Natural Disaster: Not Apply|LEC01-Natural Disaster: Not Apply|LEC01-Natural Disaster: Not Apply|LEC0101F	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Natural disaster (for example, flood, hurricane, tornado, earthquake): Doesn't apply.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135826>	C135707	LEC-5 Standard Version - Fire or Explosion: Happened|LEC01-Fire or Explosion: Happened|LEC01-Fire or Explosion: Happened|LEC0102A	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Fire or explosion: Happened to me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135827>	C135707	LEC-5 Standard Version - Fire or Explosion: Witnessed|LEC01-Fire or Explosion: Witnessed|LEC01-Fire or Explosion: Witnessed|LEC0102B	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Fire or explosion: Witnessed it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135828>	C135707	LEC-5 Standard Version - Fire or Explosion: Learned|LEC01-Fire or Explosion: Learned|LEC01-Fire or Explosion: Learned|LEC0102C	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Fire or explosion: Learned about it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135829>	C135707	LEC-5 Standard Version - Fire or Explosion: Job|LEC01-Fire or Explosion: Job|LEC01-Fire or Explosion: Job|LEC0102D	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Fire or explosion: Part of my job.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13582>	C13432	Xq26.3-q27.1	A chromosome band present on Xq			Gene or Genome	
C135830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135830>	C135707	LEC-5 Standard Version - Fire or Explosion: Not Sure|LEC01-Fire or Explosion: Not Sure|LEC01-Fire or Explosion: Not Sure|LEC0102E	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Fire or explosion: Not sure.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135831>	C135707	LEC-5 Standard Version - Fire or Explosion: Not Apply|LEC01-Fire or Explosion: Not Apply|LEC01-Fire or Explosion: Not Apply|LEC0102F	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Fire or explosion: Doesn't apply.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135832>	C135707	LEC-5 Standard Version - Transportation Accident: Happened|LEC01-Transportation Accident: Happened|LEC01-Transportation Accident: Happened|LEC0103A	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Transportation accident (for example, car accident, boat accident, train wreck, plane crash): Happened to me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135833>	C135707	LEC-5 Standard Version - Transportation Accident: Witnessed|LEC01-Transportation Accident: Witnessed|LEC01-Transportation Accident: Witnessed|LEC0103B	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Transportation accident (for example, car accident, boat accident, train wreck, plane crash): Witnessed it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135834>	C135707	LEC-5 Standard Version - Transportation Accident: Learned|LEC01-Transportation Accident: Learned|LEC01-Transportation Accident: Learned|LEC0103C	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Transportation accident (for example, car accident, boat accident, train wreck, plane crash): Learned about it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135835>	C135707	LEC-5 Standard Version - Transportation Accident: Job|LEC01-Transportation Accident: Job|LEC01-Transportation Accident: Job|LEC0103D	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Transportation accident (for example, car accident, boat accident, train wreck, plane crash): Part of my job.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135836>	C135707	LEC-5 Standard Version - Transportation Accident: Not Sure|LEC01-Transportation Accident: Not Sure|LEC01-Transportation Accident: Not Sure|LEC0103E	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Transportation accident (for example, car accident, boat accident, train wreck, plane crash): Not sure.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135837>	C135707	LEC-5 Standard Version - Transportation Accident: Not Apply|LEC01-Transportation Accident: Not Apply|LEC01-Transportation Accident: Not Apply|LEC0103F	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Transportation accident (for example, car accident, boat accident, train wreck, plane crash): Doesn't apply.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135838>	C135707	LEC-5 Standard Version - Serious Accident: Happened|LEC01-Serious Accident: Happened|LEC01-Serious Accident: Happened|LEC0104A	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Serious accident at work, home, or during recreational activity: Happened to me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135839>	C135707	LEC-5 Standard Version - Serious Accident: Witnessed|LEC01-Serious Accident: Witnessed|LEC01-Serious Accident: Witnessed|LEC0104B	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Serious accident at work, home, or during recreational activity: Witnessed it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13583>	C13432	12q13-q14	A chromosome band present on 12q	12q13-q14		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C135840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135840>	C135707	LEC-5 Standard Version - Serious Accident: Learned|LEC01-Serious Accident: Learned|LEC01-Serious Accident: Learned|LEC0104C	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Serious accident at work, home, or during recreational activity: Learned about it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135841>	C135707	LEC-5 Standard Version - Serious Accident: Job|LEC01-Serious Accident: Job|LEC01-Serious Accident: Job|LEC0104D	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Serious accident at work, home, or during recreational activity: Part of my job.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135842>	C135707	LEC-5 Standard Version - Serious Accident: Not Sure|LEC01-Serious Accident: Not Sure|LEC01-Serious Accident: Not Sure|LEC0104E	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Serious accident at work, home, or during recreational activity: Not sure.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135843>	C135707	LEC-5 Standard Version - Serious Accident: Not Apply|LEC01-Serious Accident: Not Apply|LEC01-Serious Accident: Not Apply|LEC0104F	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Serious accident at work, home, or during recreational activity: Doesn't apply.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135844>	C135707	LEC-5 Standard Version - Toxic Substance: Happened|LEC01-Toxic Substance: Happened|LEC01-Toxic Substance: Happened|LEC0105A	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Exposure to toxic substance (for example, dangerous chemicals, radiation): Happened to me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135845>	C135707	LEC-5 Standard Version - Toxic Substance: Witnessed|LEC01-Toxic Substance: Witnessed|LEC01-Toxic Substance: Witnessed|LEC0105B	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Exposure to toxic substance (for example, dangerous chemicals, radiation): Witnessed it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135846>	C135707	LEC-5 Standard Version - Toxic Substance: Learned|LEC01-Toxic Substance: Learned|LEC01-Toxic Substance: Learned|LEC0105C	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Exposure to toxic substance (for example, dangerous chemicals, radiation): Learned about it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135847>	C135707	LEC-5 Standard Version - Toxic Substance: Job|LEC01-Toxic Substance: Job|LEC01-Toxic Substance: Job|LEC0105D	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Exposure to toxic substance (for example, dangerous chemicals, radiation): Part of my job.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135848>	C135707	LEC-5 Standard Version - Toxic Substance: Not Sure|LEC01-Toxic Substance: Not Sure|LEC01-Toxic Substance: Not Sure|LEC0105E	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Exposure to toxic substance (for example, dangerous chemicals, radiation): Not sure.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135849>	C135707	LEC-5 Standard Version - Toxic Substance: Not Apply|LEC01-Toxic Substance: Not Apply|LEC01-Toxic Substance: Not Apply|LEC0105F	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Exposure to toxic substance (for example, dangerous chemicals, radiation): Doesn't apply.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13584>	C13432	19p13.1-p13.2	A chromosome band present on 19p			Gene or Genome	
C135850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135850>	C135707	LEC-5 Standard Version - Physical Assault: Happened|LEC01-Physical Assault: Happened|LEC01-Physical Assault: Happened|LEC0106A	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Physical assault (for example, being attacked, hit, slapped, kicked, beaten up): Happened to me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135851>	C135707	LEC-5 Standard Version - Physical Assault: Witnessed|LEC01-Physical Assault: Witnessed|LEC01-Physical Assault: Witnessed|LEC0106B	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Physical assault (for example, being attacked, hit, slapped, kicked, beaten up): Witnessed it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135852>	C135707	LEC-5 Standard Version - Physical Assault: Learned|LEC01-Physical Assault: Learned|LEC01-Physical Assault: Learned|LEC0106C	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Physical assault (for example, being attacked, hit, slapped, kicked, beaten up): Learned about it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135853>	C135707	LEC-5 Standard Version - Physical Assault: Job|LEC01-Physical Assault: Job|LEC01-Physical Assault: Job|LEC0106D	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Physical assault (for example, being attacked, hit, slapped, kicked, beaten up): Part of my job.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135854>	C135707	LEC-5 Standard Version - Physical Assault: Not Sure|LEC01-Physical Assault: Not Sure|LEC01-Physical Assault: Not Sure|LEC0106E	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Physical assault (for example, being attacked, hit, slapped, kicked, beaten up): Not sure.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135855>	C135707	LEC-5 Standard Version - Physical Assault: Not Apply|LEC01-Physical Assault: Not Apply|LEC01-Physical Assault: Not Apply|LEC0106F	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Physical assault (for example, being attacked, hit, slapped, kicked, beaten up): Doesn't apply.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135856>	C135707	LEC-5 Standard Version - Assault With a Weapon: Happened|LEC01-Assault With a Weapon: Happened|LEC01-Assault With a Weapon: Happened|LEC0107A	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Assault with a weapon (for example, being shot, stabbed, threatened with a knife, gun, bomb): Happened to me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135857>	C135707	LEC-5 Standard Version - Assault With a Weapon: Witnessed|LEC01-Assault With a Weapon: Witnessed|LEC01-Assault With a Weapon: Witnessed|LEC0107B	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Assault with a weapon (for example, being shot, stabbed, threatened with a knife, gun, bomb): Witnessed it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135858>	C135707	LEC-5 Standard Version - Assault With a Weapon: Learned|LEC01-Assault With a Weapon: Learned|LEC01-Assault With a Weapon: Learned|LEC0107C	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Assault with a weapon (for example, being shot, stabbed, threatened with a knife, gun, bomb): Learned about it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135859>	C135707	LEC-5 Standard Version - Assault With a Weapon: Job|LEC01-Assault With a Weapon: Job|LEC01-Assault With a Weapon: Job|LEC0107D	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Assault with a weapon (for example, being shot, stabbed, threatened with a knife, gun, bomb): Part of my job.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13585>	C13432	8q11	A chromosome band present on 8q			Gene or Genome	
C135860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135860>	C135707	LEC-5 Standard Version - Assault With a Weapon: Not Sure|LEC01-Assault With a Weapon: Not Sure|LEC01-Assault With a Weapon: Not Sure|LEC0107E	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Assault with a weapon (for example, being shot, stabbed, threatened with a knife, gun, bomb): Not sure.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135861>	C135707	LEC-5 Standard Version - Assault With a Weapon: Not Apply|LEC01-Assault With a Weapon: Not Apply|LEC01-Assault With a Weapon: Not Apply|LEC0107F	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Assault with a weapon (for example, being shot, stabbed, threatened with a knife, gun, bomb): Doesn't apply.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135862>	C135707	LEC-5 Standard Version - Sexual Assault: Happened|LEC01-Sexual Assault: Happened|LEC01-Sexual Assault: Happened|LEC0108A	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sexual assault (rape, attempted rape, made to perform any type of sexual act through force or threat of harm): Happened to me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135863>	C135707	LEC-5 Standard Version - Sexual Assault: Witnessed|LEC01-Sexual Assault: Witnessed|LEC01-Sexual Assault: Witnessed|LEC0108B	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sexual assault (rape, attempted rape, made to perform any type of sexual act through force or threat of harm): Witnessed it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135864>	C135707	LEC-5 Standard Version - Sexual Assault: Learned|LEC01-Sexual Assault: Learned|LEC01-Sexual Assault: Learned|LEC0108C	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sexual assault (rape, attempted rape, made to perform any type of sexual act through force or threat of harm): Learned about it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135865>	C135707	LEC-5 Standard Version - Sexual Assault: Job|LEC01-Sexual Assault: Job|LEC01-Sexual Assault: Job|LEC0108D	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sexual assault (rape, attempted rape, made to perform any type of sexual act through force or threat of harm): Part of my job.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135866>	C135707	LEC-5 Standard Version - Sexual Assault: Not Sure|LEC01-Sexual Assault: Not Sure|LEC01-Sexual Assault: Not Sure|LEC0108E	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sexual assault (rape, attempted rape, made to perform any type of sexual act through force or threat of harm): Not sure.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135867>	C135707	LEC-5 Standard Version - Sexual Assault: Not Apply|LEC01-Sexual Assault: Not Apply|LEC01-Sexual Assault: Not Apply|LEC0108F	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sexual assault (rape, attempted rape, made to perform any type of sexual act through force or threat of harm): Doesn't apply.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135868>	C135707	LEC-5 Standard Version - Unwanted Sex Experience: Happened|LEC01-Unwanted Sex Experience: Happened|LEC01-Unwanted Sex Experience: Happened|LEC0109A	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Other unwanted or uncomfortable sexual experience: Happened to me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135869>	C135707	LEC-5 Standard Version - Unwanted Sex Experience: Witnessed|LEC01-Unwanted Sex Experience: Witnessed|LEC01-Unwanted Sex Experience: Witnessed|LEC0109B	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Other unwanted or uncomfortable sexual experience: Witnessed it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13586>	C13432	1p34	A chromosome band present on 1p			Gene or Genome	
C135870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135870>	C135707	LEC-5 Standard Version - Unwanted Sex Experience: Learned|LEC01-Unwanted Sex Experience: Learned|LEC01-Unwanted Sex Experience: Learned|LEC0109C	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Other unwanted or uncomfortable sexual experience: Learned about it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135871>	C135707	LEC-5 Standard Version - Unwanted Sex Experience: Job|LEC01-Unwanted Sex Experience: Job|LEC01-Unwanted Sex Experience: Job|LEC0109D	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Other unwanted or uncomfortable sexual experience: Part of my job.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135872>	C135707	LEC-5 Standard Version - Unwanted Sex Experience: Not Sure|LEC01-Unwanted Sex Experience: Not Sure|LEC01-Unwanted Sex Experience: Not Sure|LEC0109E	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Other unwanted or uncomfortable sexual experience: Not sure.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135873>	C135707	LEC-5 Standard Version - Unwanted Sex Experience: Not Apply|LEC01-Unwanted Sex Experience: Not Apply|LEC01-Unwanted Sex Experience: Not Apply|LEC0109F	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Other unwanted or uncomfortable sexual experience: Doesn't apply.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135874>	C135707	LEC-5 Standard Version - Combat or Exposure to War-Zone: Happened|LEC01-Combat/Exp to War-Zone: Happened|LEC01-Combat/Exp to War-Zone: Happened|LEC0110A	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Combat or exposure to a war-zone (in the military or as a civilian): Happened to me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135875>	C135707	LEC-5 Standard Version - Combat or Exposure to War-Zone: Witnessed|LEC01-Combat/Exp to War-Zone: Witnessed|LEC01-Combat/Exp to War-Zone: Witnessed|LEC0110B	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Combat or exposure to a war-zone (in the military or as a civilian): Witnessed it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135876>	C135707	LEC-5 Standard Version - Combat or Exposure to War-Zone: Learned|LEC01-Combat/Exp to War-Zone: Learned|LEC01-Combat/Exp to War-Zone: Learned|LEC0110C	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Combat or exposure to a war-zone (in the military or as a civilian): Learned about it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135877>	C135707	LEC-5 Standard Version - Combat or Exposure to War-Zone: Job|LEC01-Combat/Exp to War-Zone: Job|LEC01-Combat/Exp to War-Zone: Job|LEC0110D	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Combat or exposure to a war-zone (in the military or as a civilian): Part of my job.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135878>	C135707	LEC-5 Standard Version - Combat or Exposure to War-Zone: Not Sure|LEC01-Combat/Exp to War-Zone: Not Sure|LEC01-Combat/Exp to War-Zone: Not Sure|LEC0110E	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Combat or exposure to a war-zone (in the military or as a civilian): Not sure.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135879>	C135707	LEC-5 Standard Version - Combat or Exposure to War-Zone: Not Apply|LEC01-Combat/Exp to War-Zone: Not Apply|LEC01-Combat/Exp to War-Zone: Not Apply|LEC0110F	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Combat or exposure to a war-zone (in the military or as a civilian): Doesn't apply.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13587>	C13432	2p16	A chromosome band present on 2p			Gene or Genome	
C135880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135880>	C135707	LEC-5 Standard Version - Captivity: Happened|LEC01-Captivity: Happened|LEC01-Captivity: Happened|LEC0111A	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Captivity (for example, being kidnapped, abducted, held hostage, prisoner of war): Happened to me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135881>	C135707	LEC-5 Standard Version - Captivity: Witnessed|LEC01-Captivity: Witnessed|LEC01-Captivity: Witnessed|LEC0111B	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Captivity (for example, being kidnapped, abducted, held hostage, prisoner of war): Witnessed it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135882>	C135707	LEC-5 Standard Version - Captivity: Learned|LEC01-Captivity: Learned|LEC01-Captivity: Learned|LEC0111C	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Captivity (for example, being kidnapped, abducted, held hostage, prisoner of war): Learned about it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135883>	C135707	LEC-5 Standard Version - Captivity: Job|LEC01-Captivity: Job|LEC01-Captivity: Job|LEC0111D	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Captivity (for example, being kidnapped, abducted, held hostage, prisoner of war): Part of my job.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135884>	C135707	LEC-5 Standard Version - Captivity: Not Sure|LEC01-Captivity: Not Sure|LEC01-Captivity: Not Sure|LEC0111E	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Captivity (for example, being kidnapped, abducted, held hostage, prisoner of war): Not sure.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135885>	C135707	LEC-5 Standard Version - Captivity: Not Apply|LEC01-Captivity: Not Apply|LEC01-Captivity: Not Apply|LEC0111F	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Captivity (for example, being kidnapped, abducted, held hostage, prisoner of war): Doesn't apply.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135886>	C135707	LEC-5 Standard Version - Life-threatening Illness: Happened|LEC01-Life-threatening Illness: Happened|LEC01-Life-threatening Illness: Happened|LEC0112A	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Life-threatening illness or injury: Happened to me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135887>	C135707	LEC-5 Standard Version - Life-threatening Illness: Witnessed|LEC01-Life-threatening Illness: Witness|LEC01-Life-threatening Illness: Witness|LEC0112B	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Life-threatening illness or injury: Witnessed it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135888>	C135707	LEC-5 Standard Version - Life-threatening Illness: Learned|LEC01-Life-threatening Illness: Learned|LEC01-Life-threatening Illness: Learned|LEC0112C	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Life-threatening illness or injury: Learned about it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135889>	C135707	LEC-5 Standard Version - Life-threatening Illness: Job|LEC01-Life-threatening Illness: Job|LEC01-Life-threatening Illness: Job|LEC0112D	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Life-threatening illness or injury: Part of my job.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13588>	C13432	6q22-q23	A chromosome band present on 6q			Gene or Genome	
C135890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135890>	C135707	LEC-5 Standard Version - Life-threatening Illness: Not Sure|LEC01-Life-threatening Illness: Not Sure|LEC01-Life-threatening Illness: Not Sure|LEC0112E	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Life-threatening illness or injury: Not sure.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135891>	C135707	LEC-5 Standard Version - Life-threatening Illness: Not Apply|LEC01-Life-threatening Illness: No Apply|LEC01-Life-threatening Illness: No Apply|LEC0112F	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Life-threatening illness or injury: Doesn't apply.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135892>	C135707	LEC-5 Standard Version - Severe Human Suffering: Happened|LEC01-Severe Human Suffering: Happened|LEC01-Severe Human Suffering: Happened|LEC0113A	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Severe human suffering: Happened to me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135893>	C135707	LEC-5 Standard Version - Severe Human Suffering: Witnessed|LEC01-Severe Human Suffering: Witnessed|LEC01-Severe Human Suffering: Witnessed|LEC0113B	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Severe human suffering: Witnessed it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135894>	C135707	LEC-5 Standard Version - Severe Human Suffering: Learned|LEC01-Severe Human Suffering: Learned|LEC01-Severe Human Suffering: Learned|LEC0113C	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Severe human suffering: Learned about it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135895>	C135707	LEC-5 Standard Version - Severe Human Suffering: Job|LEC01-Severe Human Suffering: Job|LEC01-Severe Human Suffering: Job|LEC0113D	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Severe human suffering: Part of my job.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135896>	C135707	LEC-5 Standard Version - Severe Human Suffering: Not Sure|LEC01-Severe Human Suffering: Not Sure|LEC01-Severe Human Suffering: Not Sure|LEC0113E	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Severe human suffering: Not sure.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135897>	C135707	LEC-5 Standard Version - Severe Human Suffering: Not Apply|LEC01-Severe Human Suffering: Not Apply|LEC01-Severe Human Suffering: Not Apply|LEC0113F	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Severe human suffering: Doesn't apply.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135898>	C135707	LEC-5 Standard Version - Sudden Violent Death: Happened|LEC01-Sudden Violent Death: Happened|LEC01-Sudden Violent Death: Happened|LEC0114A	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sudden violent death (for example, homicide, suicide): Happened to me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135899>	C135707	LEC-5 Standard Version - Sudden Violent Death: Witnessed|LEC01-Sudden Violent Death: Witnessed|LEC01-Sudden Violent Death: Witnessed|LEC0114B	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sudden violent death (for example, homicide, suicide): Witnessed it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13589>	C13432	8q22	A chromosome band present on 8q	8q22		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C1358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1358>	C1592	Recombinant CTAP III|CTAP III	Connective Tissue-Activating Peptide III is a platelet-derived growth factor that stimulates in fibroblasts mitogenesis, extracellular matrix synthesis, glucose metabolism, and plasminogen activator synthesis through interaction with a GPCR.  It is present in platelet granules, released by inducers of platelet aggregation, and is chemoattractant for fibroblasts, presumably for repair.  Pro-platelet basic protein is the precursor of platelet basic protein (PBP) and CTAP III.  Upon platelet activation they are released and processed in plasma to beta-thromboglobulin and neutrophil-activating peptide-2.  The thrombocidins TC1 and TC2 are variants of NAP2 and CTAP III, respectively.  TC1 and TC2 differ from NAP2 and CTAP III by their bactericidal and fungicidal properties, which apparently do not involve pore formation.  (from OMIM 121010 and NCI)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C135900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135900>	C135707	LEC-5 Standard Version - Sudden Violent Death: Learned|LEC01-Sudden Violent Death: Learned|LEC01-Sudden Violent Death: Learned|LEC0114C	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sudden violent death (for example, homicide, suicide): Learned about it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135901>	C135707	LEC-5 Standard Version - Sudden Violent Death: Job|LEC01-Sudden Violent Death: Job|LEC01-Sudden Violent Death: Job|LEC0114D	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sudden violent death (for example, homicide, suicide): Part of my job.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135902>	C135707	LEC-5 Standard Version - Sudden Violent Death: Not Sure|LEC01-Sudden Violent Death: Not Sure|LEC01-Sudden Violent Death: Not Sure|LEC0114E	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sudden violent death (for example, homicide, suicide): Not sure.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135903>	C135707	LEC-5 Standard Version - Sudden Violent Death: Not Apply|LEC01-Sudden Violent Death: Not Apply|LEC01-Sudden Violent Death: Not Apply|LEC0114F	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sudden violent death (for example, homicide, suicide): Doesn't apply.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135904>	C135707	LEC-5 Standard Version - Sudden Accidental Death: Happened|LEC01-Sudden Accidental Death: Happened|LEC01-Sudden Accidental Death: Happened|LEC0115A	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sudden accidental death: Happened to me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135905>	C135707	LEC-5 Standard Version - Sudden Accidental Death: Witnessed|LEC01-Sudden Accidental Death: Witnessed|LEC01-Sudden Accidental Death: Witnessed|LEC0115B	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sudden accidental death: Witnessed it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135906>	C135707	LEC-5 Standard Version - Sudden Accidental Death: Learned|LEC01-Sudden Accidental Death: Learned|LEC01-Sudden Accidental Death: Learned|LEC0115C	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sudden accidental death: Learned about it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135907>	C135707	LEC-5 Standard Version - Sudden Accidental Death: Job|LEC01-Sudden Accidental Death: Job|LEC01-Sudden Accidental Death: Job|LEC0115D	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sudden accidental death: Part of my job.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135908>	C135707	LEC-5 Standard Version - Sudden Accidental Death: Not Sure|LEC01-Sudden Accidental Death: Not Sure|LEC01-Sudden Accidental Death: Not Sure|LEC0115E	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sudden accidental death: Not sure.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135909>	C135707	LEC-5 Standard Version - Sudden Accidental Death: Not Apply|LEC01-Sudden Accidental Death: Not Apply|LEC01-Sudden Accidental Death: Not Apply|LEC0115F	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Sudden accidental death: Doesn't apply.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13590>	C13432	20q13.1	A chromosome band present on 20q			Gene or Genome	
C135910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135910>	C135707	LEC-5 Standard Version - Serious Injury Caused: Happened|LEC01-Serious Injury Caused: Happened|LEC01-Serious Injury Caused: Happened|LEC0116A	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Serious injury, harm, or death you caused to someone else: Happened to me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135911>	C135707	LEC-5 Standard Version - Serious Injury Caused: Witnessed|LEC01-Serious Injury Caused: Witnessed|LEC01-Serious Injury Caused: Witnessed|LEC0116B	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Serious injury, harm, or death you caused to someone else: Witnessed it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135912>	C135707	LEC-5 Standard Version - Serious Injury Caused: Learned|LEC01-Serious Injury Caused: Learned|LEC01-Serious Injury Caused: Learned|LEC0116C	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Serious injury, harm, or death you caused to someone else: Learned about it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135913>	C135707	LEC-5 Standard Version - Serious Injury Caused: Job|LEC01-Serious Injury Caused: Job|LEC01-Serious Injury Caused: Job|LEC0116D	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Serious injury, harm, or death you caused to someone else: Part of my job.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135914>	C135707	LEC-5 Standard Version - Serious Injury Caused: Not Sure|LEC01-Serious Injury Caused: Not Sure|LEC01-Serious Injury Caused: Not Sure|LEC0116E	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Serious injury, harm, or death you caused to someone else: Not sure.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135915>	C135707	LEC-5 Standard Version - Serious Injury Caused: Not Apply|LEC01-Serious Injury Caused: Not Apply|LEC01-Serious Injury Caused: Not Apply|LEC0116F	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Serious injury, harm, or death you caused to someone else: Doesn't apply.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135916>	C135707	LEC-5 Standard Version - Other Stressful Event: Happened|LEC01-Other Stressful Event: Happened|LEC01-Other Stressful Event: Happened|LEC0117A	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Any other very stressful event or experience: Happened to me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135917>	C135707	LEC-5 Standard Version - Other Stressful Event: Witnessed|LEC01-Other Stressful Event: Witnessed|LEC01-Other Stressful Event: Witnessed|LEC0117B	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Any other very stressful event or experience: Witnessed it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135918>	C135707	LEC-5 Standard Version - Other Stressful Event: Learned|LEC01-Other Stressful Event: Learned|LEC01-Other Stressful Event: Learned|LEC0117C	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Any other very stressful event or experience: Learned about it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135919>	C135707	LEC-5 Standard Version - Other Stressful Event: Job|LEC01-Other Stressful Event: Job|LEC01-Other Stressful Event: Job|LEC0117D	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Any other very stressful event or experience: Part of my job.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13591>	C13432	8q24	A chromosome band present on 8q	8q24		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C135920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135920>	C135707	LEC-5 Standard Version - Other Stressful Event: Not Sure|LEC01-Other Stressful Event: Not Sure|LEC01-Other Stressful Event: Not Sure|LEC0117E	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Any other very stressful event or experience: Not sure.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135921>	C135707	LEC-5 Standard Version - Other Stressful Event: Not Apply|LEC01-Other Stressful Event: Not Apply|LEC01-Other Stressful Event: Not Apply|LEC0117F	Life Events Checklist for DSM-5 Standard Version (LEC-5 Standard Version) Any other very stressful event or experience: Doesn't apply.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire LEC-5 Standard Version Test Code Terminology|CDISC Questionnaire LEC-5 Standard Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135922>	C135708	PCL-5 - Repeated Disturbing Memories|PCL01-Repeated Disturbing Memories|PCL01-Repeated Disturbing Memories|PCL0101	The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Repeated, disturbing, and unwanted memories of the stressful experience?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PCL-5 Test Code Terminology|CDISC Questionnaire PCL-5 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135923>	C135708	PCL-5 - Repeated Disturbing Dreams|PCL01-Repeated Disturbing Dreams|PCL01-Repeated Disturbing Dreams|PCL0102	The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Repeated, disturbing dreams of the stressful experience?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PCL-5 Test Code Terminology|CDISC Questionnaire PCL-5 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135924>	C135708	PCL-5 - Suddenly Feeling Happening Again|PCL01-Suddenly Feeling Happening Again|PCL01-Suddenly Feeling Happening Again|PCL0103	The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Suddenly feeling or acting as if the stressful experience were actually happening again (as if you were actually back there reliving it)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PCL-5 Test Code Terminology|CDISC Questionnaire PCL-5 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135925>	C135708	PCL-5 - Feel Upset When Reminded|PCL01-Feel Upset When Reminded|PCL01-Feel Upset When Reminded|PCL0104	The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Feeling very upset when something reminded you of the stressful experience?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PCL-5 Test Code Terminology|CDISC Questionnaire PCL-5 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135926>	C135708	PCL-5 - Strong Physical Reactions|PCL01-Strong Physical Reactions|PCL01-Strong Physical Reactions|PCL0105	The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Having strong physical reactions when something reminded you of the stressful experience (for example, heart pounding, trouble breathing, sweating)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PCL-5 Test Code Terminology|CDISC Questionnaire PCL-5 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135927>	C135708	PCL-5 - Avoid Memories, Thoughts or Feelings|PCL01-Avoid Memories/Thoughts/Feelings|PCL01-Avoid Memories/Thoughts/Feelings|PCL0106	The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Avoiding memories, thoughts, or feelings related to the stressful experience?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PCL-5 Test Code Terminology|CDISC Questionnaire PCL-5 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135928>	C135708	PCL-5 - Avoid External Reminders|PCL01-Avoid External Reminders|PCL01-Avoid External Reminders|PCL0107	The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Avoiding external reminders of the stressful experience (for example, people, places, conversations, activities, objects, or situations)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PCL-5 Test Code Terminology|CDISC Questionnaire PCL-5 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135929>	C135708	PCL-5 - Trouble Remembering Important Parts|PCL01-Trouble Remembering Important Part|PCL01-Trouble Remembering Important Part|PCL0108	The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Trouble remembering important parts of the stressful experience?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PCL-5 Test Code Terminology|CDISC Questionnaire PCL-5 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13592>	C13432	1p34.3	A chromosome band present on 1p			Gene or Genome	
C135930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135930>	C135708	PCL-5 - Strong Negative Beliefs|PCL01-Strong Negative Beliefs|PCL01-Strong Negative Beliefs|PCL0109	The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Having strong negative beliefs about yourself, other people, or the world (for example, having thoughts such as: I am bad, there is something seriously wrong with me, no one can be trusted, the world is completely dangerous)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PCL-5 Test Code Terminology|CDISC Questionnaire PCL-5 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135931>	C135708	PCL-5 - Blaming Yourself or Someone Else|PCL01-Blaming Yourself/Someone Else|PCL01-Blaming Yourself/Someone Else|PCL0110	The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Blaming yourself or someone else for the stressful experience or what happened after it?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PCL-5 Test Code Terminology|CDISC Questionnaire PCL-5 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135932>	C135708	PCL-5 - Strong Negative Feelings|PCL01-Strong Negative Feelings|PCL01-Strong Negative Feelings|PCL0111	The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Having strong negative feelings such as fear, horror, anger, guilt, or shame?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PCL-5 Test Code Terminology|CDISC Questionnaire PCL-5 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135933>	C135708	PCL-5 - Loss of Interest in Activities|PCL01-Loss of Interest in Activities|PCL01-Loss of Interest in Activities|PCL0112	The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Loss of interest in activities that you used to enjoy?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PCL-5 Test Code Terminology|CDISC Questionnaire PCL-5 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135934>	C135708	PCL-5 - Feeling Distant From People|PCL01-Feeling Distant From People|PCL01-Feeling Distant From People|PCL0113	The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Feeling distant or cut off from other people?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PCL-5 Test Code Terminology|CDISC Questionnaire PCL-5 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135935>	C135708	PCL-5 - Trouble Experiencing Positive Feelings|PCL01-Trouble Experiencing Pos Feelings|PCL01-Trouble Experiencing Pos Feelings|PCL0114	The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Trouble experiencing positive feelings (for example, being unable to feel happiness or have loving feelings for people close to you)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PCL-5 Test Code Terminology|CDISC Questionnaire PCL-5 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135936>	C135708	PCL-5 - Irritable Behavior or Angry Outbursts|PCL01-Irritable Behavior/Angry Outbursts|PCL01-Irritable Behavior/Angry Outbursts|PCL0115	The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Irritable behavior, angry outbursts, or acting aggressively?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PCL-5 Test Code Terminology|CDISC Questionnaire PCL-5 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135937>	C135708	PCL-5 - Taking Too Many Risks or Cause Harm|PCL01-Taking Too Many Risks/Cause Harm|PCL01-Taking Too Many Risks/Cause Harm|PCL0116	The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Taking too many risks or doing things that could cause you harm?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PCL-5 Test Code Terminology|CDISC Questionnaire PCL-5 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135938>	C135708	PCL-5 - Being Super Alert or Watchful|PCL01-Being Superalert/Watchful/on Guard|PCL01-Being Superalert/Watchful/on Guard|PCL0117	The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Being "superalert" or watchful or on guard?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PCL-5 Test Code Terminology|CDISC Questionnaire PCL-5 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135939>	C135708	PCL-5 - Feeling Jumpy or Easily Startled|PCL01-Feeling Jumpy or Easily Startled|PCL01-Feeling Jumpy or Easily Startled|PCL0118	The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Feeling jumpy or easily startled?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PCL-5 Test Code Terminology|CDISC Questionnaire PCL-5 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13593>	C13432	2p24.1	A chromosome band present on 2p			Gene or Genome	
C135940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135940>	C135708	PCL-5 - Having Difficulty Concentrating|PCL01-Having Difficulty Concentrating|PCL01-Having Difficulty Concentrating|PCL0119	The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Having difficulty concentrating?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PCL-5 Test Code Terminology|CDISC Questionnaire PCL-5 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135941>	C135708	PCL-5 - Trouble Falling or Staying Asleep|PCL01-Trouble Falling or Staying Asleep|PCL01-Trouble Falling or Staying Asleep|PCL0120	The PTSD Checklist for DSM-5 (PCL-5) In the past month, how much were you bothered by: Trouble falling or staying asleep?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PCL-5 Test Code Terminology|CDISC Questionnaire PCL-5 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135942>	C135709	PODCI Pediatric Parent-Reported Version - Lift Heavy Books|PODCI1-Lift Heavy Books|PODCI1-Lift Heavy Books|PODCI101	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, was it easy or hard for your child to: Lift heavy books?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135943>	C135709	PODCI Pediatric Parent-Reported Version - Pour a Half Gallon of Milk|PODCI1-Pour a Half Gallon of Milk|PODCI1-Pour a Half Gallon of Milk|PODCI102	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, was it easy or hard for your child to: Pour a half gallon of milk?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135944>	C135709	PODCI Pediatric Parent-Reported Version - Open a Jar Been Opened Before|PODCI1-Open a Jar Been Opened Before|PODCI1-Open a Jar Been Opened Before|PODCI103	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, was it easy or hard for your child to: Open a jar that has been opened before?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135945>	C135709	PODCI Pediatric Parent-Reported Version - Use a Fork and Spoon|PODCI1-Use a Fork and Spoon|PODCI1-Use a Fork and Spoon|PODCI104	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, was it easy or hard for your child to: Use a fork and spoon?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135946>	C135709	PODCI Pediatric Parent-Reported Version - Comb His or Her Hair|PODCI1-Comb His/Her Hair|PODCI1-Comb His/Her Hair|PODCI105	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, was it easy or hard for your child to: Comb his/her hair?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135947>	C135709	PODCI Pediatric Parent-Reported Version - Button Buttons|PODCI1-Button Buttons|PODCI1-Button Buttons|PODCI106	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, was it easy or hard for your child to: Button buttons?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135948>	C135709	PODCI Pediatric Parent-Reported Version - Put on His or Her Coat|PODCI1-Put on His/Her Coat|PODCI1-Put on His/Her Coat|PODCI107	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, was it easy or hard for your child to: Put on his/her coat?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135949>	C135709	PODCI Pediatric Parent-Reported Version - Write With a Pencil|PODCI1-Write With a Pencil|PODCI1-Write With a Pencil|PODCI108	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, was it easy or hard for your child to: Write with a pencil?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13594>	C13432	1p36.3-p36.2	A chromosome band present on 1p			Gene or Genome	
C135950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135950>	C135709	PODCI Pediatric Parent-Reported Version - Miss School Because of Health|PODCI1-Miss School Because of Health|PODCI1-Miss School Because of Health|PODCI109	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) On average, over the last 12 months, how often did your child miss school (preschool, day care, camp, etc.) because of his/her health?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135951>	C135709	PODCI Pediatric Parent-Reported Version - How He or She Looks|PODCI1-How He/She Looks|PODCI1-How He/She Looks|PODCI110	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, how happy has your child been with: How he/she looks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135952>	C135709	PODCI Pediatric Parent-Reported Version - His or Her Body|PODCI1-His/Her Body|PODCI1-His/Her Body|PODCI111	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, how happy has your child been with: His/her body?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135953>	C135709	PODCI Pediatric Parent-Reported Version - What Clothes or Shoes He or She Wear|PODCI1-What Clothes/Shoes He/She Wear|PODCI1-What Clothes/Shoes He/She Wear|PODCI112	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, how happy has your child been with: What clothes or shoes he/she can wear?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135954>	C135709	PODCI Pediatric Parent-Reported Version - Ability Do Same Things Friends Do|PODCI1-Ability Do Same Things Friends Do|PODCI1-Ability Do Same Things Friends Do|PODCI113	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, how happy has your child been with: His/her ability to do the same things his/her friends do?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135955>	C135709	PODCI Pediatric Parent-Reported Version - His or Her Health in General|PODCI1-His/Her Health in General|PODCI1-His/Her Health in General|PODCI114	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, how happy has your child been with: His/her health in general?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135956>	C135709	PODCI Pediatric Parent-Reported Version - Feel Sick and Tired|PODCI1-Feel Sick and Tired|PODCI1-Feel Sick and Tired|PODCI115	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, how much of the time: Did your child feel sick and tired?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135957>	C135709	PODCI Pediatric Parent-Reported Version - Full of Pep and Energy|PODCI1-Full of Pep and Energy|PODCI1-Full of Pep and Energy|PODCI116	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, how much of the time: Were your child full of pep and energy?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135958>	C135709	PODCI Pediatric Parent-Reported Version - Pain or Discomfort Interfere With Activities|PODCI1-Pain/Discom Inter With Activities|PODCI1-Pain/Discom Inter With Activities|PODCI117	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, how much of the time: Did pain or discomfort interfere with your child's activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135959>	C135709	PODCI Pediatric Parent-Reported Version - Run Short Distances|PODCI1-Run Short Distances|PODCI1-Run Short Distances|PODCI118	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, has it been easy or hard for your child to: Run short distances?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13595>	C13432	22q12.2	A chromosome band present on 22q			Gene or Genome	
C135960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135960>	C135709	PODCI Pediatric Parent-Reported Version - Bicycle or Tricycle|PODCI1-Bicycle or Tricycle|PODCI1-Bicycle or Tricycle|PODCI119	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, has it been easy or hard for your child to: Bicycle or tricycle?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135961>	C135709	PODCI Pediatric Parent-Reported Version - Climb Three Flights of Stairs|PODCI1-Climb Three Flights of Stairs|PODCI1-Climb Three Flights of Stairs|PODCI120	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, has it been easy or hard for your child to: Climb three flights of stairs?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135962>	C135709	PODCI Pediatric Parent-Reported Version - Climb One Flight of Stairs|PODCI1-Climb One Flight of Stairs|PODCI1-Climb One Flight of Stairs|PODCI121	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, has it been easy or hard for your child to: Climb one flight of stairs?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135963>	C135709	PODCI Pediatric Parent-Reported Version - Walk More Than a Mile|PODCI1-Walk More Than a Mile|PODCI1-Walk More Than a Mile|PODCI122	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, has it been easy or hard for your child to: Walk more than a mile?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135964>	C135709	PODCI Pediatric Parent-Reported Version - Walk Three Blocks|PODCI1-Walk Three Blocks|PODCI1-Walk Three Blocks|PODCI123	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, has it been easy or hard for your child to: Walk three blocks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135965>	C135709	PODCI Pediatric Parent-Reported Version - Walk One Block|PODCI1-Walk One Block|PODCI1-Walk One Block|PODCI124	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, has it been easy or hard for your child to: Walk one block?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135966>	C135709	PODCI Pediatric Parent-Reported Version - Get On and Off a Bus|PODCI1-Get On and Off a Bus|PODCI1-Get On and Off a Bus|PODCI125	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, has it been easy or hard for your child to: Get on and off a bus?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135967>	C135709	PODCI Pediatric Parent-Reported Version - Need Help Walking and Climbing|PODCI1-Need Help Walking and Climbing|PODCI1-Need Help Walking and Climbing|PODCI126	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) How often does your child need help from another person for walking and climbing?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135968>	C135709	PODCI Pediatric Parent-Reported Version - Use Assistive Devices for Walking|PODCI1-Use Assistive Devices for Walking|PODCI1-Use Assistive Devices for Walking|PODCI127	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) How often does your child use assistive devices (such as braces, crutches, or wheelchair) for walking and climbing?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135969>	C135709	PODCI Pediatric Parent-Reported Version - Stand Washing Hands at a Sink|PODCI1-Stand Washing Hands at a Sink|PODCI1-Stand Washing Hands at a Sink|PODCI128	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, has it been easy or hard for your child to: Stand while washing his/her hands and face at a sink?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13596>	C13432	10q24	A chromosome band present on 10q			Gene or Genome	
C135970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135970>	C135709	PODCI Pediatric Parent-Reported Version - Sit in Chair Without Holding On|PODCI1-Sit in Chair Without Holding On|PODCI1-Sit in Chair Without Holding On|PODCI129	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, has it been easy or hard for your child to: Sit in a regular chair without holding on?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135971>	C135709	PODCI Pediatric Parent-Reported Version - Get On and Off a Toilet or Chair|PODCI1-Get On and Off a Toilet or Chair|PODCI1-Get On and Off a Toilet or Chair|PODCI130	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, has it been easy or hard for your child to: Get on and off a toilet or chair?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135972>	C135709	PODCI Pediatric Parent-Reported Version - Get In and Out of Bed|PODCI1-Get In and Out of Bed|PODCI1-Get In and Out of Bed|PODCI131	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, has it been easy or hard for your child to: Get in and out of bed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135973>	C135709	PODCI Pediatric Parent-Reported Version - Turn Door Knobs|PODCI1-Turn Door Knobs|PODCI1-Turn Door Knobs|PODCI132	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, has it been easy or hard for your child to: Turn door knobs?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135974>	C135709	PODCI Pediatric Parent-Reported Version - Bend Over and Pick Up Something|PODCI1-Bend Over and Pick Up Something|PODCI1-Bend Over and Pick Up Something|PODCI133	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, has it been easy or hard for your child to: Bend over from a standing position and pick up something off the floor?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135975>	C135709	PODCI Pediatric Parent-Reported Version - Need Help Sitting and Standing|PODCI1-Need Help Sitting and Standing|PODCI1-Need Help Sitting and Standing|PODCI134	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) How often does your child need help from another person for sitting and standing?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135976>	C135709	PODCI Pediatric Parent-Reported Version - Use Assistive Devices for Sitting|PODCI1-Use Assistive Devices for Sitting|PODCI1-Use Assistive Devices for Sitting|PODCI135	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) How often does your child use assistive devices (such as braces, crutches, or wheelchair) for sitting and standing?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135977>	C135709	PODCI Pediatric Parent-Reported Version - Participate in Outdoor Activities|PODCI1-Participate in Outdoor Activities|PODCI1-Participate in Outdoor Activities|PODCI136	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) Can your child participate in recreational outdoor activities with other children the same age (For example: bicycling, tricycling, skating, hiking, jogging)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135978>	C135709	PODCI Pediatric Parent-Reported Version - Outdoor Limited by: Pain|PODCI1-Outdoor Limited by: Pain|PODCI1-Outdoor Limited by: Pain|PODCI137	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "no" to Question 36 above, was your child's activity limited by: Pain?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135979>	C135709	PODCI Pediatric Parent-Reported Version - Outdoor Limited by: Health|PODCI1-Outdoor Limited by: Health|PODCI1-Outdoor Limited by: Health|PODCI138	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "no" to Question 36 above, was your child's activity limited by: General health?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13597>	C13432	3p23-p21	A chromosome band present on 3p			Gene or Genome	
C135980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135980>	C135709	PODCI Pediatric Parent-Reported Version - Outdoor Limited by: Instructions|PODCI1-Outdoor Limited by: Instructions|PODCI1-Outdoor Limited by: Instructions|PODCI139	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "no" to Question 36 above, was your child's activity limited by: Doctor or parent instructions?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135981>	C135709	PODCI Pediatric Parent-Reported Version - Outdoor Limited by: Fear|PODCI1-Outdoor Limited by: Fear|PODCI1-Outdoor Limited by: Fear|PODCI140	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "no" to Question 36 above, was your child's activity limited by: Fear the other kids won't like him/her?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135982>	C135709	PODCI Pediatric Parent-Reported Version - Outdoor Limited by: Dislike|PODCI1-Outdoor Limited by: Dislike|PODCI1-Outdoor Limited by: Dislike|PODCI141	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "no" to Question 36 above, was your child's activity limited by: Dislike of recreational outdoor activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135983>	C135709	PODCI Pediatric Parent-Reported Version - Outdoor Limited by: Too Young|PODCI1-Outdoor Limited by: Too Young|PODCI1-Outdoor Limited by: Too Young|PODCI142	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "no" to Question 36 above, was your child's activity limited by: Too young?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135984>	C135709	PODCI Pediatric Parent-Reported Version - Outdoor Limited by: Season|PODCI1-Outdoor Limited by: Season|PODCI1-Outdoor Limited by: Season|PODCI143	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "no" to Question 36 above, was your child's activity limited by: Activity not in season?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135985>	C135709	PODCI Pediatric Parent-Reported Version - Participate in Pickup Games|PODCI1-Participate in Pickup Games|PODCI1-Participate in Pickup Games|PODCI144	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) Can your child participate in pickup games or sports with other children the same age (For example: tag, dodge ball, basketball, soccer, catch, jump rope, touch football, hop scotch)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135986>	C135709	PODCI Pediatric Parent-Reported Version - Games Limited by: Pain|PODCI1-Games Limited by: Pain|PODCI1-Games Limited by: Pain|PODCI145	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "no" to Question 44 above, was your child's activity limited by: Pain?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135987>	C135709	PODCI Pediatric Parent-Reported Version - Games Limited by: Health|PODCI1-Games Limited by: Health|PODCI1-Games Limited by: Health|PODCI146	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "no" to Question 44 above, was your child's activity limited by: General health?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135988>	C135709	PODCI Pediatric Parent-Reported Version - Games Limited by: Instructions|PODCI1-Games Limited by: Instructions|PODCI1-Games Limited by: Instructions|PODCI147	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "no" to Question 44 above, was your child's activity limited by: Doctor or parent instructions?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135989>	C135709	PODCI Pediatric Parent-Reported Version - Games Limited by: Fear|PODCI1-Games Limited by: Fear|PODCI1-Games Limited by: Fear|PODCI148	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "no" to Question 44 above, was your child's activity limited by: Fear the other kids won't like him/her?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13598>	C13432	8q24.1	A chromosome band present on 8q			Gene or Genome	
C135990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135990>	C135709	PODCI Pediatric Parent-Reported Version - Games Limited by: Dislike|PODCI1-Games Limited by: Dislike|PODCI1-Games Limited by: Dislike|PODCI149	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "no" to Question 44 above, was your child's activity limited by: Dislike of pickup games or sports?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135991>	C135709	PODCI Pediatric Parent-Reported Version - Games Limited by: Too Young|PODCI1-Games Limited by: Too Young|PODCI1-Games Limited by: Too Young|PODCI150	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "no" to Question 44 above, was your child's activity limited by: Too young?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135992>	C135709	PODCI Pediatric Parent-Reported Version - Games Limited by: Season|PODCI1-Games Limited by: Season|PODCI1-Games Limited by: Season|PODCI151	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "no" to Question 44 above, was your child's activity limited by: Activity not in season?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135993>	C135709	PODCI Pediatric Parent-Reported Version - Participate in Competitive Sports|PODCI1-Participate in Competitive Sports|PODCI1-Participate in Competitive Sports|PODCI152	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) Can your child participate in competitive level sports with other children the same age (For example: hockey, basketball, soccer, football, baseball, swimming, running [track or cross country], gymnastics, or dance)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135994>	C135709	PODCI Pediatric Parent-Reported Version - Competitive Sports Limited by: Pain|PODCI1-Comp Sports Limited by: Pain|PODCI1-Comp Sports Limited by: Pain|PODCI153	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "no" to Question 52 above, was your child's activity limited by: Pain?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135995>	C135709	PODCI Pediatric Parent-Reported Version - Competitive Sports Limited by: Health|PODCI1-Comp Sports Limited by: Health|PODCI1-Comp Sports Limited by: Health|PODCI154	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "no" to Question 52 above, was your child's activity limited by: General health?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135996>	C135709	PODCI Pediatric Parent-Reported Version - Competitive Sports Limited by: Instruction|PODCI1-Comp Sports Limited by: Instruct|PODCI1-Comp Sports Limited by: Instruct|PODCI155	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "no" to Question 52 above, was your child's activity limited by: Doctor or parent instructions?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135997>	C135709	PODCI Pediatric Parent-Reported Version - Competitive Sports Limited by: Fear|PODCI1-Comp Sports Limited by: Fear|PODCI1-Comp Sports Limited by: Fear|PODCI156	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "no" to Question 52 above, was your child's activity limited by: Fear the other kids won't like him/her?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135998>	C135709	PODCI Pediatric Parent-Reported Version - Competitive Sports Limited by: Dislike|PODCI1-Comp Sports Limited by: Dislike|PODCI1-Comp Sports Limited by: Dislike|PODCI157	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "no" to Question 52 above, was your child's activity limited by: Dislike of pickup games or sports?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C135999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C135999>	C135709	PODCI Pediatric Parent-Reported Version - Competitive Sports Limited by: Too Young|PODCI1-Comp Sports Limited by: Too Young|PODCI1-Comp Sports Limited by: Too Young|PODCI158	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "no" to Question 52 above, was your child's activity limited by: Too young?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13599>	C13432	1p13	A chromosome band present on 1p			Gene or Genome	
C1359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1359>	C2133|C1557	Cyclopentenyl Cytosine|2(1H)-Pyrimidinone, 4-amino-1-[4, 5-dihydroxy- 3-(hydroxymethyl)-2-cyclopenten-1-yl]-|CPE-C|CYCLOPENTENYL CYTOSINE|Cyclopentenylcytosine|Cyclopentenylcytosine|Cyclopentenylcytosine Triphosphate	A pro-drug carbocyclic analogue of cytidine with antineoplastic and antiviral activities. Cyclopentenyl cytosine (CPEC) is converted to the active metabolite cyclopentenyl cytosine 5'-triphosphate (CPEC-TP); CPEC-TP competitively inhibits cytidine triphosphate (CTP) synthase, thereby depleting intracellular cytidine pools and inhibiting DNA and RNA synthesis. This agent may also induce differentiation of some tumor cell types. The antiviral activity of this agent is broad-spectrum.			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C136000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136000>	C135709	PODCI Pediatric Parent-Reported Version - Competitive Sports Limited by: Season|PODCI1-Comp Sports Limited by: Season|PODCI1-Comp Sports Limited by: Season|PODCI159	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "no" to Question 52 above, was your child's activity limited by: Activity not in season?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136001>	C135709	PODCI Pediatric Parent-Reported Version - Get Together With Friends|PODCI1-Get Together With Friends|PODCI1-Get Together With Friends|PODCI160	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) How often in the last week did your child get together and do things with friends?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136002>	C135709	PODCI Pediatric Parent-Reported Version - Friends Limited by: Pain|PODCI1-Friends Limited by: Pain|PODCI1-Friends Limited by: Pain|PODCI161	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "sometimes" or "never or rarely" to Question 60 above, was your child's activity limited by: Pain?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136003>	C135709	PODCI Pediatric Parent-Reported Version - Friends Limited by: Health|PODCI1-Friends Limited by: Health|PODCI1-Friends Limited by: Health|PODCI162	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "sometimes" or "never or rarely" to Question 60 above, was your child's activity limited by: General health?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136004>	C135709	PODCI Pediatric Parent-Reported Version - Friends Limited by: Instructions|PODCI1-Friends Limited by: Instructions|PODCI1-Friends Limited by: Instructions|PODCI163	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "sometimes" or "never or rarely" to Question 60 above, was your child's activity limited by: Doctor or parent instructions?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136005>	C135709	PODCI Pediatric Parent-Reported Version - Friends Limited by: Fear|PODCI1-Friends Limited by: Fear|PODCI1-Friends Limited by: Fear|PODCI164	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "sometimes" or "never or rarely" to Question 60 above, was your child's activity limited by: Fear the other kids won't like him/her?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136006>	C135709	PODCI Pediatric Parent-Reported Version - Friends Limited by: Not Around|PODCI1-Friends Limited by: Not Around|PODCI1-Friends Limited by: Not Around|PODCI165	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "sometimes" or "never or rarely" to Question 60 above, was your child's activity limited by: Friends not around?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136007>	C135709	PODCI Pediatric Parent-Reported Version - Participate in Gym or Recess|PODCI1-Participate in Gym/Recess|PODCI1-Participate in Gym/Recess|PODCI166	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) How often in the last week did your child participate in gym/recess?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136008>	C135709	PODCI Pediatric Parent-Reported Version - Gym Limited by: Pain|PODCI1-Gym Limited by: Pain|PODCI1-Gym Limited by: Pain|PODCI167	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "sometimes" or "never or rarely" to Question 66 above, was your child's activity limited by: Pain?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136009>	C135709	PODCI Pediatric Parent-Reported Version - Gym Limited by: Health|PODCI1-Gym Limited by: Health|PODCI1-Gym Limited by: Health|PODCI168	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "sometimes" or "never or rarely" to Question 66 above, was your child's activity limited by: General health?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13600>	C13432	1q23-q31	A chromosome band present on 1q			Gene or Genome	
C136010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136010>	C135709	PODCI Pediatric Parent-Reported Version - Gym Limited by: Instructions|PODCI1-Gym Limited by: Instructions|PODCI1-Gym Limited by: Instructions|PODCI169	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "sometimes" or "never or rarely" to Question 66 above, was your child's activity limited by: Doctor or parent instructions?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136011>	C135709	PODCI Pediatric Parent-Reported Version - Gym Limited by: Fear|PODCI1-Gym Limited by: Fear|PODCI1-Gym Limited by: Fear|PODCI170	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "sometimes" or "never or rarely" to Question 66 above, was your child's activity limited by: Fear the other kids won't like him/her?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136012>	C135709	PODCI Pediatric Parent-Reported Version - Gym Limited by: Dislike|PODCI1-Gym Limited by: Dislike|PODCI1-Gym Limited by: Dislike|PODCI171	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "sometimes" or "never or rarely" to Question 66 above, was your child's activity limited by: Dislike of gym/recess?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136013>	C135709	PODCI Pediatric Parent-Reported Version - Gym Limited by: Not in Session|PODCI1-Gym Limited by: Not in Session|PODCI1-Gym Limited by: Not in Session|PODCI172	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "sometimes" or "never or rarely" to Question 66 above, was your child's activity limited by: School not in session?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136014>	C135709	PODCI Pediatric Parent-Reported Version - Gym Limited by: Not Attend School|PODCI1-Gym Limited by: Not Attend School|PODCI1-Gym Limited by: Not Attend School|PODCI173	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If you answered "sometimes" or "never or rarely" to Question 66 above, was your child's activity limited by: Does not attend school?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136015>	C135709	PODCI Pediatric Parent-Reported Version - Easy to Make Friends|PODCI1-Easy to Make Friends|PODCI1-Easy to Make Friends|PODCI174	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) Is it easy or hard for your child to make friends with children his/her own age?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136016>	C135709	PODCI Pediatric Parent-Reported Version - Pain During the Last Week|PODCI1-Pain During the Last Week|PODCI1-Pain During the Last Week|PODCI175	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) How much pain has your child had during the last week?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136017>	C135709	PODCI Pediatric Parent-Reported Version - Pain Interfere With Activities|PODCI1-Pain Interfere With Activities|PODCI1-Pain Interfere With Activities|PODCI176	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) During the last week, how much did pain interfere with your child's normal activities (including at home, outside of the home, and at school)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136018>	C135709	PODCI Pediatric Parent-Reported Version - Have Pain Relief|PODCI1-Have Pain Relief|PODCI1-Have Pain Relief|PODCI177	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) As a result of my child's treatment, I expect my child: To have pain relief.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136019>	C135709	PODCI Pediatric Parent-Reported Version - Look Better|PODCI1-Look Better|PODCI1-Look Better|PODCI178	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) As a result of my child's treatment, I expect my child: To look better.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13601>	C13432	15q25-q26	A chromosome band present on 15q			Gene or Genome	
C136020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136020>	C135709	PODCI Pediatric Parent-Reported Version - Feel Better|PODCI1-Feel Better|PODCI1-Feel Better|PODCI179	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) As a result of my child's treatment, I expect my child: To feel better about himself/herself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136021>	C135709	PODCI Pediatric Parent-Reported Version - Sleep More Comfortably|PODCI1-Sleep More Comfortably|PODCI1-Sleep More Comfortably|PODCI180	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) As a result of my child's treatment, I expect my child: To sleep more comfortably.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136022>	C135709	PODCI Pediatric Parent-Reported Version - Able to Do Activities at Home|PODCI1-Able to Do Activities at Home|PODCI1-Able to Do Activities at Home|PODCI181	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) As a result of my child's treatment, I expect my child: To be able to do activities at home.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136023>	C135709	PODCI Pediatric Parent-Reported Version - Able to Do More at School|PODCI1-Able to Do More at School|PODCI1-Able to Do More at School|PODCI182	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) As a result of my child's treatment, I expect my child: To be able to do more at school.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136024>	C135709	PODCI Pediatric Parent-Reported Version - Able to Do More Play|PODCI1-Able to Do More Play|PODCI1-Able to Do More Play|PODCI183	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) As a result of my child's treatment, I expect my child: To be able to do more play or recreational activities (biking, walking, doing things with friends).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136025>	C135709	PODCI Pediatric Parent-Reported Version - Able to Do More Sports|PODCI1-Able to Do More Sports|PODCI1-Able to Do More Sports|PODCI184	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) As a result of my child's treatment, I expect my child: To be able to do more sports.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136026>	C135709	PODCI Pediatric Parent-Reported Version - Free From Pain as Adult|PODCI1-Free From Pain as Adult|PODCI1-Free From Pain as Adult|PODCI185	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) As a result of my child's treatment, I expect my child: To be free from pain or disability as an adult.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136027>	C135709	PODCI Pediatric Parent-Reported Version - Spend Rest of Life With Condition|PODCI1-Spend Rest of Life With Condition|PODCI1-Spend Rest of Life With Condition|PODCI186	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) If your child had to spend the rest of his/her life with his/her bone and muscle condition as it is right now, how would you feel about it?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136028>	C135709	PODCI Pediatric Parent-Reported Version - Upper Extremity and Physical Function Scale|PODCI1-Up Extremity/Phys Function Scale|PODCI1-Up Extremity/Phys Function Scale|PODCI187	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) Upper extremity and physical function core scale.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136029>	C135709	PODCI Pediatric Parent-Reported Version - Transfer and Basic Mobility Scale|PODCI1-Transfer/Basic Mobility Scale|PODCI1-Transfer/Basic Mobility Scale|PODCI188	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) Transfer and basic mobility core scale.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13602>	C13432	22q12.3-q13.1	A chromosome band present on 22q			Gene or Genome	
C136030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136030>	C135709	PODCI Pediatric Parent-Reported Version - Sports and Physical Function Scale|PODCI1-Sports/Phys Function Scale|PODCI1-Sports/Phys Function Scale|PODCI189	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) Sports and physical functioning core scale.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136031>	C135709	PODCI Pediatric Parent-Reported Version - Pain or Comfort Scale|PODCI1-Pain/Comfort Scale|PODCI1-Pain/Comfort Scale|PODCI190	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) Pain/comfort core scale.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136032>	C135709	PODCI Pediatric Parent-Reported Version - Happiness Scale|PODCI1-Happiness Scale|PODCI1-Happiness Scale|PODCI191	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) Happiness core scale.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136033>	C135709	PODCI Pediatric Parent-Reported Version - Global Functioning Scale|PODCI1-Global Functioning Scale|PODCI1-Global Functioning Scale|PODCI192	Pediatric Outcomes Data Collection Instrument, Pediatric Parent-Reported Version (PODCI Pediatric Parent-Reported Version) Global functioning scale.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Pediatric Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136034>	C135710	PODCI Adolescent Parent-Reported Version - Lift Heavy Books|PODCI2-Lift Heavy Books|PODCI2-Lift Heavy Books|PODCI201	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, was it easy or hard for your child to: Lift heavy books?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136035>	C135710	PODCI Adolescent Parent-Reported Version - Pour a Half Gallon of Milk|PODCI2-Pour a Half Gallon of Milk|PODCI2-Pour a Half Gallon of Milk|PODCI202	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, was it easy or hard for your child to: Pour a half gallon of milk?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136036>	C135710	PODCI Adolescent Parent-Reported Version - Open a Jar Been Opened Before|PODCI2-Open a Jar Been Opened Before|PODCI2-Open a Jar Been Opened Before|PODCI203	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, was it easy or hard for your child to: Open a jar that has been opened before?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136037>	C135710	PODCI Adolescent Parent-Reported Version - Use a Fork and Spoon|PODCI2-Use a Fork and Spoon|PODCI2-Use a Fork and Spoon|PODCI204	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, was it easy or hard for your child to: Use a fork and spoon?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136038>	C135710	PODCI Adolescent Parent-Reported Version - Comb His or Her Hair|PODCI2-Comb His/Her Hair|PODCI2-Comb His/Her Hair|PODCI205	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, was it easy or hard for your child to: Comb his/her hair?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136039>	C135710	PODCI Adolescent Parent-Reported Version - Button Buttons|PODCI2-Button Buttons|PODCI2-Button Buttons|PODCI206	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, was it easy or hard for your child to: Button buttons?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13603>	C13432	6p21	A chromosome band present on 6p	6p21		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136040>	C135710	PODCI Adolescent Parent-Reported Version - Put on His or Her Coat|PODCI2-Put on His/Her Coat|PODCI2-Put on His/Her Coat|PODCI207	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, was it easy or hard for your child to: Put on his/her coat?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136041>	C135710	PODCI Adolescent Parent-Reported Version - Write With a Pencil|PODCI2-Write With a Pencil|PODCI2-Write With a Pencil|PODCI208	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, was it easy or hard for your child to: Write with a pencil?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136042>	C135710	PODCI Adolescent Parent-Reported Version - Miss School Because of Health|PODCI2-Miss School Because of Health|PODCI2-Miss School Because of Health|PODCI209	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) On average, over the last 12 months, how often did your child miss school (camp, etc.) because of his/her health?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136043>	C135710	PODCI Adolescent Parent-Reported Version - How He or She Looks|PODCI2-How He/She Looks|PODCI2-How He/She Looks|PODCI210	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, how happy has your child been with: How he/she looks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136044>	C135710	PODCI Adolescent Parent-Reported Version - His or Her Body|PODCI2-His/Her Body|PODCI2-His/Her Body|PODCI211	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, how happy has your child been with: His/her body?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136045>	C135710	PODCI Adolescent Parent-Reported Version - What Clothes or Shoes He or She Wear|PODCI2-What Clothes/Shoes He/She Wear|PODCI2-What Clothes/Shoes He/She Wear|PODCI212	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, how happy has your child been with: What clothes or shoes he/she can wear?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136046>	C135710	PODCI Adolescent Parent-Reported Version - Ability Do Same Things Friends Do|PODCI2-Ability Do Same Things Friends Do|PODCI2-Ability Do Same Things Friends Do|PODCI213	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, how happy has your child been with: His/her ability to do the same things his/her friends do?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136047>	C135710	PODCI Adolescent Parent-Reported Version - His or Her Health in General|PODCI2-His/Her Health in General|PODCI2-His/Her Health in General|PODCI214	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, how happy has your child been with: His/her health in general?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136048>	C135710	PODCI Adolescent Parent-Reported Version - Feel Sick and Tired|PODCI2-Feel Sick and Tired|PODCI2-Feel Sick and Tired|PODCI215	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, how much of the time: Did your child feel sick and tired?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136049>	C135710	PODCI Adolescent Parent-Reported Version - Full of Pep and Energy|PODCI2-Full of Pep and Energy|PODCI2-Full of Pep and Energy|PODCI216	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, how much of the time: Were your child full of pep and energy?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13604>	C13432	9q31	A chromosome band present on 9q			Gene or Genome	
C136050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136050>	C135710	PODCI Adolescent Parent-Reported Version - Pain or Discomfort Interfere With Activities|PODCI2-Pain/Discom Inter With Activities|PODCI2-Pain/Discom Inter With Activities|PODCI217	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, how much of the time: Did pain or discomfort interfere with your child's activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136051>	C135710	PODCI Adolescent Parent-Reported Version - Run Short Distances|PODCI2-Run Short Distances|PODCI2-Run Short Distances|PODCI218	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, has it been easy or hard for your child to: Run short distances?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136052>	C135710	PODCI Adolescent Parent-Reported Version - Bicycle or Tricycle|PODCI2-Bicycle or Tricycle|PODCI2-Bicycle or Tricycle|PODCI219	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, has it been easy or hard for your child to: Bicycle or tricycle?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136053>	C135710	PODCI Adolescent Parent-Reported Version - Climb Three Flights of Stairs|PODCI2-Climb Three Flights of Stairs|PODCI2-Climb Three Flights of Stairs|PODCI220	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, has it been easy or hard for your child to: Climb three flights of stairs?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136054>	C135710	PODCI Adolescent Parent-Reported Version - Climb One Flight of Stairs|PODCI2-Climb One Flight of Stairs|PODCI2-Climb One Flight of Stairs|PODCI221	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, has it been easy or hard for your child to: Climb one flight of stairs?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136055>	C135710	PODCI Adolescent Parent-Reported Version - Walk More Than a Mile|PODCI2-Walk More Than a Mile|PODCI2-Walk More Than a Mile|PODCI222	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, has it been easy or hard for your child to: Walk more than a mile?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136056>	C135710	PODCI Adolescent Parent-Reported Version - Walk Three Blocks|PODCI2-Walk Three Blocks|PODCI2-Walk Three Blocks|PODCI223	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, has it been easy or hard for your child to: Walk three blocks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136057>	C135710	PODCI Adolescent Parent-Reported Version - Walk One Block|PODCI2-Walk One Block|PODCI2-Walk One Block|PODCI224	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, has it been easy or hard for your child to: Walk one block?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136058>	C135710	PODCI Adolescent Parent-Reported Version - Get On and Off a Bus|PODCI2-Get On and Off a Bus|PODCI2-Get On and Off a Bus|PODCI225	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, has it been easy or hard for your child to: Get on and off a bus?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136059>	C135710	PODCI Adolescent Parent-Reported Version - Need Help Walking and Climbing|PODCI2-Need Help Walking and Climbing|PODCI2-Need Help Walking and Climbing|PODCI226	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) How often does your child need help from another person for walking and climbing?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13605>	C13432	3p25	A chromosome band present on 3p			Gene or Genome	
C136060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136060>	C135710	PODCI Adolescent Parent-Reported Version - Use Assistive Devices for Walking|PODCI2-Use Assistive Devices for Walking|PODCI2-Use Assistive Devices for Walking|PODCI227	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) How often does your child use assistive devices (such as braces, crutches, or wheelchair) for walking and climbing?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136061>	C135710	PODCI Adolescent Parent-Reported Version - Stand Washing Hands at a Sink|PODCI2-Stand Washing Hands at a Sink|PODCI2-Stand Washing Hands at a Sink|PODCI228	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, has it been easy or hard for your child to: Stand while washing his/her hands and face at a sink?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136062>	C135710	PODCI Adolescent Parent-Reported Version - Sit in Chair Without Holding On|PODCI2-Sit in Chair Without Holding On|PODCI2-Sit in Chair Without Holding On|PODCI229	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, has it been easy or hard for your child to: Sit in a regular chair without holding on?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136063>	C135710	PODCI Adolescent Parent-Reported Version - Get On and Off a Toilet or Chair|PODCI2-Get On and Off a Toilet or Chair|PODCI2-Get On and Off a Toilet or Chair|PODCI230	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, has it been easy or hard for your child to: Get on and off a toilet or chair?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136064>	C135710	PODCI Adolescent Parent-Reported Version - Get In and Out of Bed|PODCI2-Get In and Out of Bed|PODCI2-Get In and Out of Bed|PODCI231	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, has it been easy or hard for your child to: Get in and out of bed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136065>	C135710	PODCI Adolescent Parent-Reported Version - Turn Door Knobs|PODCI2-Turn Door Knobs|PODCI2-Turn Door Knobs|PODCI232	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, has it been easy or hard for your child to: Turn door knobs?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136066>	C135710	PODCI Adolescent Parent-Reported Version - Bend Over and Pick Up Something|PODCI2-Bend Over and Pick Up Something|PODCI2-Bend Over and Pick Up Something|PODCI233	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, has it been easy or hard for your child to: Bend over from a standing position and pick up something off the floor?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136067>	C135710	PODCI Adolescent Parent-Reported Version - Need Help Sitting and Standing|PODCI2-Need Help Sitting and Standing|PODCI2-Need Help Sitting and Standing|PODCI234	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) How often does your child need help from another person for sitting and standing?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136068>	C135710	PODCI Adolescent Parent-Reported Version - Use Assistive Devices for Sitting|PODCI2-Use Assistive Devices for Sitting|PODCI2-Use Assistive Devices for Sitting|PODCI235	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) How often does your child use assistive devices (such as braces, crutches, or wheelchair) for sitting and standing?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136069>	C135710	PODCI Adolescent Parent-Reported Version - Participate in Outdoor Activities|PODCI2-Participate in Outdoor Activities|PODCI2-Participate in Outdoor Activities|PODCI236	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) Can your child participate in recreational outdoor activities with other children the same age (For example: bicycling, skating, hiking, jogging)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13606>	C13432	7p22-p15	A chromosome band present on 7p			Gene or Genome	
C136070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136070>	C135710	PODCI Adolescent Parent-Reported Version - Outdoor Limited by: Pain|PODCI2-Outdoor Limited by: Pain|PODCI2-Outdoor Limited by: Pain|PODCI237	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "no" to Question 36 above, was your child's activity limited by: Pain?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136071>	C135710	PODCI Adolescent Parent-Reported Version - Outdoor Limited by: Health|PODCI2-Outdoor Limited by: Health|PODCI2-Outdoor Limited by: Health|PODCI238	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "no" to Question 36 above, was your child's activity limited by: General health?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136072>	C135710	PODCI Adolescent Parent-Reported Version - Outdoor Limited by: Instructions|PODCI2-Outdoor Limited by: Instructions|PODCI2-Outdoor Limited by: Instructions|PODCI239	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "no" to Question 36 above, was your child's activity limited by: Doctor or parent instructions?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136073>	C135710	PODCI Adolescent Parent-Reported Version - Outdoor Limited by: Fear|PODCI2-Outdoor Limited by: Fear|PODCI2-Outdoor Limited by: Fear|PODCI240	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "no" to Question 36 above, was your child's activity limited by: Fear the other kids won't like him/her?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136074>	C135710	PODCI Adolescent Parent-Reported Version - Outdoor Limited by: Dislike|PODCI2-Outdoor Limited by: Dislike|PODCI2-Outdoor Limited by: Dislike|PODCI241	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "no" to Question 36 above, was your child's activity limited by: Dislike of recreational outdoor activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136075>	C135710	PODCI Adolescent Parent-Reported Version - Outdoor Limited by: Too Young|PODCI2-Outdoor Limited by: Too Young|PODCI2-Outdoor Limited by: Too Young|PODCI242	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "no" to Question 36 above, was your child's activity limited by: Too young?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136076>	C135710	PODCI Adolescent Parent-Reported Version - Outdoor Limited by: Season|PODCI2-Outdoor Limited by: Season|PODCI2-Outdoor Limited by: Season|PODCI243	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "no" to Question 36 above, was your child's activity limited by: Activity not in season?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136077>	C135710	PODCI Adolescent Parent-Reported Version - Participate in Pickup Games|PODCI2-Participate in Pickup Games|PODCI2-Participate in Pickup Games|PODCI244	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) Can your child participate in pickup games or sports with other children the same age (For example: tag, dodge ball, basketball, softball, soccer, catch, jump rope, touch football, hop scotch)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136078>	C135710	PODCI Adolescent Parent-Reported Version - Games Limited by: Pain|PODCI2-Games Limited by: Pain|PODCI2-Games Limited by: Pain|PODCI245	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "no" to Question 44 above, was your child's activity limited by: Pain?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136079>	C135710	PODCI Adolescent Parent-Reported Version - Games Limited by: Health|PODCI2-Games Limited by: Health|PODCI2-Games Limited by: Health|PODCI246	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "no" to Question 44 above, was your child's activity limited by: General health?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13607>	C13432	2cen-q13	A chromosome band present on 22q			Gene or Genome	
C136080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136080>	C135710	PODCI Adolescent Parent-Reported Version - Games Limited by: Instructions|PODCI2-Games Limited by: Instructions|PODCI2-Games Limited by: Instructions|PODCI247	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "no" to Question 44 above, was your child's activity limited by: Doctor or parent instructions?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136081>	C135710	PODCI Adolescent Parent-Reported Version - Games Limited by: Fear|PODCI2-Games Limited by: Fear|PODCI2-Games Limited by: Fear|PODCI248	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "no" to Question 44 above, was your child's activity limited by: Fear the other kids won't like him/her?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136082>	C135710	PODCI Adolescent Parent-Reported Version - Games Limited by: Dislike|PODCI2-Games Limited by: Dislike|PODCI2-Games Limited by: Dislike|PODCI249	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "no" to Question 44 above, was your child's activity limited by: Dislike of pickup games or sports?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136083>	C135710	PODCI Adolescent Parent-Reported Version - Games Limited by: Too Young|PODCI2-Games Limited by: Too Young|PODCI2-Games Limited by: Too Young|PODCI250	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "no" to Question 44 above, was your child's activity limited by: Too young?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136084>	C135710	PODCI Adolescent Parent-Reported Version - Games Limited by: Season|PODCI2-Games Limited by: Season|PODCI2-Games Limited by: Season|PODCI251	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "no" to Question 44 above, was your child's activity limited by: Activity not in season?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136085>	C135710	PODCI Adolescent Parent-Reported Version - Participate in Competitive Sports|PODCI2-Participate in Competitive Sports|PODCI2-Participate in Competitive Sports|PODCI252	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) Can your child participate in competitive level sports with other children the same age (For example: hockey, basketball, soccer, football, baseball, swimming, running [track or cross country], gymnastics, or dance)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136086>	C135710	PODCI Adolescent Parent-Reported Version - Competitive Sports Limited by: Pain|PODCI2-Comp Sports Limited by: Pain|PODCI2-Comp Sports Limited by: Pain|PODCI253	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "no" to Question 52 above, was your child's activity limited by: Pain?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136087>	C135710	PODCI Adolescent Parent-Reported Version - Competitive Sports Limited by: Health|PODCI2-Comp Sports Limited by: Health|PODCI2-Comp Sports Limited by: Health|PODCI254	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "no" to Question 52 above, was your child's activity limited by: General health?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136088>	C135710	PODCI Adolescent Parent-Reported Version - Competitive Sports Limited by: Instructions|PODCI2-Comp Sports Limited by: Instruct|PODCI2-Comp Sports Limited by: Instruct|PODCI255	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "no" to Question 52 above, was your child's activity limited by: Doctor or parent instructions?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136089>	C135710	PODCI Adolescent Parent-Reported Version - Competitive Sports Limited by: Fear|PODCI2-Comp Sports Limited by: Fear|PODCI2-Comp Sports Limited by: Fear|PODCI256	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "no" to Question 52 above, was your child's activity limited by: Fear the other kids won't like him/her?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13608>	C13432	13q14.2	A chromosome band present on 13q			Gene or Genome	
C136090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136090>	C135710	PODCI Adolescent Parent-Reported Version - Competitive Sports Limited by: Dislike|PODCI2-Comp Sports Limited by: Dislike|PODCI2-Comp Sports Limited by: Dislike|PODCI257	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "no" to Question 52 above, was your child's activity limited by: Dislike of pickup games or sports?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136091>	C135710	PODCI Adolescent Parent-Reported Version - Competitive Sports Limited by: Too Young|PODCI2-Comp Sports Limited by: Too Young|PODCI2-Comp Sports Limited by: Too Young|PODCI258	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "no" to Question 52 above, was your child's activity limited by: Too young?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136092>	C135710	PODCI Adolescent Parent-Reported Version - Competitive Sports Limited by: Season|PODCI2-Comp Sports Limited by: Season|PODCI2-Comp Sports Limited by: Season|PODCI259	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "no" to Question 52 above, was your child's activity limited by: Activity not in season?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136093>	C135710	PODCI Adolescent Parent-Reported Version - Get Together With Friends|PODCI2-Get Together With Friends|PODCI2-Get Together With Friends|PODCI260	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) How often in the last week did your child get together and do things with friends?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136094>	C135710	PODCI Adolescent Parent-Reported Version - Friends Limited by: Pain|PODCI2-Friends Limited by: Pain|PODCI2-Friends Limited by: Pain|PODCI261	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "sometimes" or "never or rarely" to Question 60 above, was your child's activity limited by: Pain?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136095>	C135710	PODCI Adolescent Parent-Reported Version - Friends Limited by: Health|PODCI2-Friends Limited by: Health|PODCI2-Friends Limited by: Health|PODCI262	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "sometimes" or "never or rarely" to Question 60 above, was your child's activity limited by: General health?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136096>	C135710	PODCI Adolescent Parent-Reported Version - Friends Limited by: Instructions|PODCI2-Friends Limited by: Instructions|PODCI2-Friends Limited by: Instructions|PODCI263	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "sometimes" or "never or rarely" to Question 60 above, was your child's activity limited by: Doctor or parent instructions?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136097>	C135710	PODCI Adolescent Parent-Reported Version - Friends Limited by: Fear|PODCI2-Friends Limited by: Fear|PODCI2-Friends Limited by: Fear|PODCI264	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "sometimes" or "never or rarely" to Question 60 above, was your child's activity limited by: Fear the other kids won't like him/her?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136098>	C135710	PODCI Adolescent Parent-Reported Version - Friends Limited by: Not Around|PODCI2-Friends Limited by: Not Around|PODCI2-Friends Limited by: Not Around|PODCI265	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "sometimes" or "never or rarely" to Question 60 above, was your child's activity limited by: Friends not around?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136099>	C135710	PODCI Adolescent Parent-Reported Version - Participate in Gym or Recess|PODCI2-Participate in Gym/Recess|PODCI2-Participate in Gym/Recess|PODCI266	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) How often in the last week did your child participate in gym/recess?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13609>	C13432	2p13-p12	A chromosome band present on 2p			Gene or Genome	
C1360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1360>	C272	Cytembena|(E)-3-p-Anisoyl-3-bromoacrylic Acid Sodium Salt|2-Butenoic Acid, 3-Bromo-4-(4-methoxyphenyl)-4-oxo-, Sodium Salt, (Z)- (9CI)|2-Butenoic acid, 3-bromo-4-(4-methoxyphenyl)-4-oxo-, sodium salt, (Z)- (9CI)|Acrylic acid, 3-p-anisoyl-3-bromo-, sodium salt|CTB|Cytembena Spofa|SODIUM BROMEBRATE|Sodium Bromebrate|Sodium cis-Beta-4-methoxybenzoyl-beta-bromacrylate|WR-149912	A cytostatic agent that interferes with DNA synthesis.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C136100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136100>	C135710	PODCI Adolescent Parent-Reported Version - Gym Limited by: Pain|PODCI2-Gym Limited by: Pain|PODCI2-Gym Limited by: Pain|PODCI267	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "sometimes" or "never or rarely" to Question 66 above, was your child's activity limited by: Pain?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136101>	C135710	PODCI Adolescent Parent-Reported Version - Gym Limited by: Health|PODCI2-Gym Limited by: Health|PODCI2-Gym Limited by: Health|PODCI268	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "sometimes" or "never or rarely" to Question 66 above, was your child's activity limited by: General health?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136102>	C135710	PODCI Adolescent Parent-Reported Version - Gym Limited by: Instructions|PODCI2-Gym Limited by: Instructions|PODCI2-Gym Limited by: Instructions|PODCI269	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "sometimes" or "never or rarely" to Question 66 above, was your child's activity limited by: Doctor or parent instructions?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136103>	C135710	PODCI Adolescent Parent-Reported Version - Gym Limited by: Fear|PODCI2-Gym Limited by: Fear|PODCI2-Gym Limited by: Fear|PODCI270	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "sometimes" or "never or rarely" to Question 66 above, was your child's activity limited by: Fear the other kids won't like him/her?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136104>	C135710	PODCI Adolescent Parent-Reported Version - Gym Limited by: Dislike|PODCI2-Gym Limited by: Dislike|PODCI2-Gym Limited by: Dislike|PODCI271	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "sometimes" or "never or rarely" to Question 66 above, was your child's activity limited by: Dislike of gym/recess?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136105>	C135710	PODCI Adolescent Parent-Reported Version - Gym Limited by: Not in Session|PODCI2-Gym Limited by: Not in Session|PODCI2-Gym Limited by: Not in Session|PODCI272	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "sometimes" or "never or rarely" to Question 66 above, was your child's activity limited by: School not in session?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136106>	C135710	PODCI Adolescent Parent-Reported Version - Gym Limited by: Not Attend School|PODCI2-Gym Limited by: Not Attend School|PODCI2-Gym Limited by: Not Attend School|PODCI273	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If you answered "sometimes" or "never or rarely" to Question 66 above, was your child's activity limited by: Does not attend school?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136107>	C135710	PODCI Adolescent Parent-Reported Version - Easy to Make Friends|PODCI2-Easy to Make Friends|PODCI2-Easy to Make Friends|PODCI274	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) Is it easy or hard for your child to make friends with children his/her own age?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136108>	C135710	PODCI Adolescent Parent-Reported Version - Pain During the Last Week|PODCI2-Pain During the Last Week|PODCI2-Pain During the Last Week|PODCI275	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) How much pain has your child had during the last week?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136109>	C135710	PODCI Adolescent Parent-Reported Version - Pain Interfere With Activities|PODCI2-Pain Interfere With Activities|PODCI2-Pain Interfere With Activities|PODCI276	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) During the last week, how much did pain interfere with your child's normal activities (including at home, outside of the home, and at school)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13610>	C13432	10q11.2	A chromosome band present on 10q			Gene or Genome	
C136110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136110>	C135710	PODCI Adolescent Parent-Reported Version - Have Pain Relief|PODCI2-Have Pain Relief|PODCI2-Have Pain Relief|PODCI277	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) As a result of my child's treatment, I expect my child: To have pain relief.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136111>	C135710	PODCI Adolescent Parent-Reported Version - Look Better|PODCI2-Look Better|PODCI2-Look Better|PODCI278	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) As a result of my child's treatment, I expect my child: To look better.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136112>	C135710	PODCI Adolescent Parent-Reported Version - Feel Better|PODCI2-Feel Better|PODCI2-Feel Better|PODCI279	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) As a result of my child's treatment, I expect my child: To feel better about himself/herself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136113>	C135710	PODCI Adolescent Parent-Reported Version - Sleep More Comfortably|PODCI2-Sleep More Comfortably|PODCI2-Sleep More Comfortably|PODCI280	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) As a result of my child's treatment, I expect my child: To sleep more comfortably.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136114>	C135710	PODCI Adolescent Parent-Reported Version - Able to Do Activities at Home|PODCI2-Able to Do Activities at Home|PODCI2-Able to Do Activities at Home|PODCI281	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) As a result of my child's treatment, I expect my child: To be able to do activities at home.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136115>	C135710	PODCI Adolescent Parent-Reported Version - Able to Do More at School|PODCI2-Able to Do More at School|PODCI2-Able to Do More at School|PODCI282	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) As a result of my child's treatment, I expect my child: To be able to do more at school.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136116>	C135710	PODCI Adolescent Parent-Reported Version - Able to Do More Play|PODCI2-Able to Do More Play|PODCI2-Able to Do More Play|PODCI283	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) As a result of my child's treatment, I expect my child: To be able to do more play or recreational activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136117>	C135710	PODCI Adolescent Parent-Reported Version - Able to Do More Sports|PODCI2-Able to Do More Sports|PODCI2-Able to Do More Sports|PODCI284	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) As a result of my child's treatment, I expect my child: To be able to do more sports.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136118>	C135710	PODCI Adolescent Parent-Reported Version - Free From Pain as Adult|PODCI2-Free From Pain as Adult|PODCI2-Free From Pain as Adult|PODCI285	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) As a result of my child's treatment, I expect my child: To be free from pain or disability as an adult.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136119>	C135710	PODCI Adolescent Parent-Reported Version - Spend Rest of Life With Condition|PODCI2-Spend Rest of Life With Condition|PODCI2-Spend Rest of Life With Condition|PODCI286	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) If your child had to spend the rest of his/her life with his/her bone and muscle condition as it is right now, how would you feel about it?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13611>	C13432	6q21-q22	A chromosome band present on 6q			Gene or Genome	
C136120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136120>	C135710	PODCI Adolescent Parent-Reported Version - Upper Extremity and Physical Function Scale|PODCI2-Up Extremity/Phys Function Scale|PODCI2-Up Extremity/Phys Function Scale|PODCI287	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) Upper extremity and physical function core scale.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136121>	C135710	PODCI Adolescent Parent-Reported Version - Transfer and Basic Mobility Scale|PODCI2-Transfer/Basic Mobility Scale|PODCI2-Transfer/Basic Mobility Scale|PODCI288	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) Transfer and basic mobility core scale.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136122>	C135710	PODCI Adolescent Parent-Reported Version - Sports and Physical Function Scale|PODCI2-Sports/Phys Function Scale|PODCI2-Sports/Phys Function Scale|PODCI289	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) Sports and physical functioning core scale.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136123>	C135710	PODCI Adolescent Parent-Reported Version - Pain or Comfort Scale|PODCI2-Pain/Comfort Scale|PODCI2-Pain/Comfort Scale|PODCI290	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) Pain/comfort core scale.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136124>	C135710	PODCI Adolescent Parent-Reported Version - Happiness Scale|PODCI2-Happiness Scale|PODCI2-Happiness Scale|PODCI291	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) Happiness core scale.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136125>	C135710	PODCI Adolescent Parent-Reported Version - Global Functioning Scale|PODCI2-Global Functioning Scale|PODCI2-Global Functioning Scale|PODCI292	Pediatric Outcomes Data Collection Instrument, Adolescent Parent-Reported Version (PODCI Adolescent Parent-Reported Version) Global functioning scale.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Parent-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136126>	C135711	PODCI Adolescent Self-Reported Version - Lift Heavy Books|PODCI3-Lift Heavy Books|PODCI3-Lift Heavy Books|PODCI301	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, was it easy or hard for you to: Lift heavy books?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136127>	C135711	PODCI Adolescent Self-Reported Version - Pour a Half Gallon of Milk|PODCI3-Pour a Half Gallon of Milk|PODCI3-Pour a Half Gallon of Milk|PODCI302	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, was it easy or hard for you to: Pour a half gallon of milk?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136128>	C135711	PODCI Adolescent Self-Reported Version - Open a Jar Been Opened Before|PODCI3-Open a Jar Been Opened Before|PODCI3-Open a Jar Been Opened Before|PODCI303	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, was it easy or hard for you to: Open a jar that has been opened before?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136129>	C135711	PODCI Adolescent Self-Reported Version - Use a Fork and Spoon|PODCI3-Use a Fork and Spoon|PODCI3-Use a Fork and Spoon|PODCI304	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, was it easy or hard for you to: Use a fork and spoon?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13612>	C13432	1q22-q24	A chromosome band present on 1q			Gene or Genome	
C136130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136130>	C135711	PODCI Adolescent Self-Reported Version - Comb Your Hair|PODCI3-Comb Your Hair|PODCI3-Comb Your Hair|PODCI305	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, was it easy or hard for you to: Comb your hair?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136131>	C135711	PODCI Adolescent Self-Reported Version - Button Buttons|PODCI3-Button Buttons|PODCI3-Button Buttons|PODCI306	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, was it easy or hard for you to: Button buttons?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136132>	C135711	PODCI Adolescent Self-Reported Version - Put on Your Coat|PODCI3-Put on Your Coat|PODCI3-Put on Your Coat|PODCI307	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, was it easy or hard for you to: Put on your coat?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136133>	C135711	PODCI Adolescent Self-Reported Version - Write With a Pencil|PODCI3-Write With a Pencil|PODCI3-Write With a Pencil|PODCI308	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, was it easy or hard for you to: Write with a pencil?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136134>	C135711	PODCI Adolescent Self-Reported Version - Miss School Because of Health|PODCI3-Miss School Because of Health|PODCI3-Miss School Because of Health|PODCI309	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) On average, over the last 12 months, how often did you miss school (camp, etc.) because of your health?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136135>	C135711	PODCI Adolescent Self-Reported Version - How You Look|PODCI3-How You Look|PODCI3-How You Look|PODCI310	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, how happy have you been with: How you look?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136136>	C135711	PODCI Adolescent Self-Reported Version - Your Body|PODCI3-Your Body|PODCI3-Your Body|PODCI311	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, how happy have you been with: Your body?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136137>	C135711	PODCI Adolescent Self-Reported Version - What Clothes or Shoes You Can Wear|PODCI3-What Clothes/Shoes You Can Wear|PODCI3-What Clothes/Shoes You Can Wear|PODCI312	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, how happy have you been with: What clothes or shoes you can wear?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136138>	C135711	PODCI Adolescent Self-Reported Version - Ability Do Same Things Friends Do|PODCI3-Ability Do Same Things Friends Do|PODCI3-Ability Do Same Things Friends Do|PODCI313	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, how happy have you been with: Your ability to do the same things your friends do?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136139>	C135711	PODCI Adolescent Self-Reported Version - Your Health in General|PODCI3-Your Health in General|PODCI3-Your Health in General|PODCI314	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, how happy have you been with: Your health in general?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13613>	C13432	22q11.2	A chromosome band present on 22q			Gene or Genome	
C136140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136140>	C135711	PODCI Adolescent Self-Reported Version - Feel Sick and Tired|PODCI3-Feel Sick and Tired|PODCI3-Feel Sick and Tired|PODCI315	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, how much of the time: Did you feel sick and tired?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136141>	C135711	PODCI Adolescent Self-Reported Version - Full of Pep and Energy|PODCI3-Full of Pep and Energy|PODCI3-Full of Pep and Energy|PODCI316	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, how much of the time: Were you full of pep and energy?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136142>	C135711	PODCI Adolescent Self-Reported Version - Pain or Discomfort Interfere With Activities|PODCI3-Pain/Discom Inter With Activities|PODCI3-Pain/Discom Inter With Activities|PODCI317	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, how much of the time: Did pain or discomfort interfere with your activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136143>	C135711	PODCI Adolescent Self-Reported Version - Run Short Distances|PODCI3-Run Short Distances|PODCI3-Run Short Distances|PODCI318	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, has it been easy or hard for you to: Run short distances?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136144>	C135711	PODCI Adolescent Self-Reported Version - Bicycle or Tricycle|PODCI3-Bicycle or Tricycle|PODCI3-Bicycle or Tricycle|PODCI319	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, has it been easy or hard for you to: Bicycle or tricycle?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136145>	C135711	PODCI Adolescent Self-Reported Version - Climb Three Flights of Stairs|PODCI3-Climb Three Flights of Stairs|PODCI3-Climb Three Flights of Stairs|PODCI320	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, has it been easy or hard for you to: Climb three flights of stairs?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136146>	C135711	PODCI Adolescent Self-Reported Version - Climb One Flight of Stairs|PODCI3-Climb One Flight of Stairs|PODCI3-Climb One Flight of Stairs|PODCI321	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, has it been easy or hard for you to: Climb one flight of stairs?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136147>	C135711	PODCI Adolescent Self-Reported Version - Walk More Than a Mile|PODCI3-Walk More Than a Mile|PODCI3-Walk More Than a Mile|PODCI322	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, has it been easy or hard for you to: Walk more than a mile?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136148>	C135711	PODCI Adolescent Self-Reported Version - Walk Three Blocks|PODCI3-Walk Three Blocks|PODCI3-Walk Three Blocks|PODCI323	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, has it been easy or hard for you to: Walk three blocks?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136149>	C135711	PODCI Adolescent Self-Reported Version - Walk One Block|PODCI3-Walk One Block|PODCI3-Walk One Block|PODCI324	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, has it been easy or hard for you to: Walk one block?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13614>	C13432	11p12-p11.22	A chromosome band present on 11p			Gene or Genome	
C136150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136150>	C135711	PODCI Adolescent Self-Reported Version - Get On and Off a Bus|PODCI3-Get On and Off a Bus|PODCI3-Get On and Off a Bus|PODCI325	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, has it been easy or hard for you to: Get on and off a bus?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136151>	C135711	PODCI Adolescent Self-Reported Version - Need Help Walking and Climbing|PODCI3-Need Help Walking and Climbing|PODCI3-Need Help Walking and Climbing|PODCI326	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) How often do you need help from another person for walking and climbing?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136152>	C135711	PODCI Adolescent Self-Reported Version - Use Assistive Devices for Walking|PODCI3-Use Assistive Devices for Walking|PODCI3-Use Assistive Devices for Walking|PODCI327	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) How often do you use assistive devices (such as braces, crutches, or wheelchair) for walking and climbing?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136153>	C135711	PODCI Adolescent Self-Reported Version - Stand Washing Hands at a Sink|PODCI3-Stand Washing Hands at a Sink|PODCI3-Stand Washing Hands at a Sink|PODCI328	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, has it been easy or hard for you to: Stand while washing your hands and face at a sink?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136154>	C135711	PODCI Adolescent Self-Reported Version - Sit in Chair Without Holding On|PODCI3-Sit in Chair Without Holding On|PODCI3-Sit in Chair Without Holding On|PODCI329	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, has it been easy or hard for you to: Sit in a regular chair without holding on?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136155>	C135711	PODCI Adolescent Self-Reported Version - Get On and Off a Toilet or Chair|PODCI3-Get On and Off a Toilet or Chair|PODCI3-Get On and Off a Toilet or Chair|PODCI330	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, has it been easy or hard for you to: Get on and off a toilet or chair?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136156>	C135711	PODCI Adolescent Self-Reported Version - Get In and Out of Bed|PODCI3-Get In and Out of Bed|PODCI3-Get In and Out of Bed|PODCI331	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, has it been easy or hard for you to: Get in and out of bed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136157>	C135711	PODCI Adolescent Self-Reported Version - Turn Door Knobs|PODCI3-Turn Door Knobs|PODCI3-Turn Door Knobs|PODCI332	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, has it been easy or hard for you to: Turn door knobs?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136158>	C135711	PODCI Adolescent Self-Reported Version - Bend Over and Pick Up Something|PODCI3-Bend Over and Pick Up Something|PODCI3-Bend Over and Pick Up Something|PODCI333	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, has it been easy or hard for you to: Bend over from a standing position and pick up something off the floor?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136159>	C135711	PODCI Adolescent Self-Reported Version - Need Help Sitting and Standing|PODCI3-Need Help Sitting and Standing|PODCI3-Need Help Sitting and Standing|PODCI334	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) How often do you need help from another person for sitting and standing?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136160>	C135711	PODCI Adolescent Self-Reported Version - Use Assistive Devices for Sitting|PODCI3-Use Assistive Devices for Sitting|PODCI3-Use Assistive Devices for Sitting|PODCI335	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) How often do you use assistive devices (such as braces, crutches, or wheelchair) for sitting and standing?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136161>	C135711	PODCI Adolescent Self-Reported Version - Participate in Outdoor Activities|PODCI3-Participate in Outdoor Activities|PODCI3-Participate in Outdoor Activities|PODCI336	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) Can you participate in recreational outdoor activities with other kids the same age (For example: bicycling, skating, hiking, jogging)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136162>	C135711	PODCI Adolescent Self-Reported Version - Outdoor Limited by: Pain|PODCI3-Outdoor Limited by: Pain|PODCI3-Outdoor Limited by: Pain|PODCI337	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered "no" to Question 36 above, was your activity limited by: Pain?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136163>	C135711	PODCI Adolescent Self-Reported Version - Outdoor Limited by: Health|PODCI3-Outdoor Limited by: Health|PODCI3-Outdoor Limited by: Health|PODCI338	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered "no" to Question 36 above, was your activity limited by: General health?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136164>	C135711	PODCI Adolescent Self-Reported Version - Outdoor Limited by: Instructions|PODCI3-Outdoor Limited by: Instructions|PODCI3-Outdoor Limited by: Instructions|PODCI339	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered "no" to Question 36 above, was your activity limited by: Doctor or parent instructions?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136165>	C135711	PODCI Adolescent Self-Reported Version - Outdoor Limited by: Fear|PODCI3-Outdoor Limited by: Fear|PODCI3-Outdoor Limited by: Fear|PODCI340	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered "no" to Question 36 above, was your activity limited by: Fear the other kids won't like you?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136166>	C135711	PODCI Adolescent Self-Reported Version - Outdoor Limited by: Dislike|PODCI3-Outdoor Limited by: Dislike|PODCI3-Outdoor Limited by: Dislike|PODCI341	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered "no" to Question 36 above, was your activity limited by: Dislike of recreational outdoor activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136167>	C135711	PODCI Adolescent Self-Reported Version - Outdoor Limited by: Season|PODCI3-Outdoor Limited by: Season|PODCI3-Outdoor Limited by: Season|PODCI342	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered "no" to Question 36 above, was your activity limited by: Activity not in season?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136168>	C135711	PODCI Adolescent Self-Reported Version - Participate in Pickup Games|PODCI3-Participate in Pickup Games|PODCI3-Participate in Pickup Games|PODCI343	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) Can you participate in pickup games or sports with other kids the same age (For example: tag, dodge ball, basketball, softball, soccer, catch, jump rope, touch football, hop scotch)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136169>	C135711	PODCI Adolescent Self-Reported Version - Games Limited by: Pain|PODCI3-Games Limited by: Pain|PODCI3-Games Limited by: Pain|PODCI344	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered "no" to Question 43 above, was your activity limited by: Pain?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13616>	C13432	11p15	A chromosome band present on 11p	11p15		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136170>	C135711	PODCI Adolescent Self-Reported Version - Games Limited by: Health|PODCI3-Games Limited by: Health|PODCI3-Games Limited by: Health|PODCI345	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered "no" to Question 43 above, was your activity limited by: General health?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136171>	C135711	PODCI Adolescent Self-Reported Version - Games Limited by: Instructions|PODCI3-Games Limited by: Instructions|PODCI3-Games Limited by: Instructions|PODCI346	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered "no" to Question 43 above, was your activity limited by: Doctor or parent instructions?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136172>	C135711	PODCI Adolescent Self-Reported Version - Games Limited by: Fear|PODCI3-Games Limited by: Fear|PODCI3-Games Limited by: Fear|PODCI347	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered "no" to Question 43 above, was your activity limited by: Fear the other kids won't like you?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136173>	C135711	PODCI Adolescent Self-Reported Version - Games Limited by: Dislike|PODCI3-Games Limited by: Dislike|PODCI3-Games Limited by: Dislike|PODCI348	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered "no" to Question 43 above, was your activity limited by: Dislike of pickup games or sports?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136174>	C135711	PODCI Adolescent Self-Reported Version - Games Limited by: Season|PODCI3-Games Limited by: Season|PODCI3-Games Limited by: Season|PODCI349	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered "no" to Question 43 above, was your activity limited by: Activity not in season?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136175>	C135711	PODCI Adolescent Self-Reported Version - Participate in Competitive Sports|PODCI3-Participate in Competitive Sports|PODCI3-Participate in Competitive Sports|PODCI350	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) Can you participate in competitive level sports with other kids the same age (For example: hockey, basketball, soccer, football, baseball, swimming, running [track or cross country], gymnastics, or dance)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136176>	C135711	PODCI Adolescent Self-Reported Version - Competitive Sports Limited by: Pain|PODCI3-Comp Sports Limited by: Pain|PODCI3-Comp Sports Limited by: Pain|PODCI351	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered "no" to Question 50 above, was your activity limited by: Pain?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136177>	C135711	PODCI Adolescent Self-Reported Version - Competitive Sports Limited by: Health|PODCI3-Comp Sports Limited by: Health|PODCI3-Comp Sports Limited by: Health|PODCI352	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered "no" to Question 50 above, was your activity limited by: General health?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136178>	C135711	PODCI Adolescent Self-Reported Version - Competitive Sports Limited by: Instructions|PODCI3-Comp Sports Limited by: Instruct|PODCI3-Comp Sports Limited by: Instruct|PODCI353	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered "no" to Question 50 above, was your activity limited by: Doctor or parent instructions?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136179>	C135711	PODCI Adolescent Self-Reported Version - Competitive Sports Limited by: Fear|PODCI3-Comp Sports Limited by: Fear|PODCI3-Comp Sports Limited by: Fear|PODCI354	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered "no" to Question 50 above, was your activity limited by: Fear the other kids won't like you?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13617>	C13432	6p21.1-p21.3	A chromosome band present on 6p			Gene or Genome	
C136180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136180>	C135711	PODCI Adolescent Self-Reported Version - Competitive Sports Limited by: Dislike|PODCI3-Comp Sports Limited by: Dislike|PODCI3-Comp Sports Limited by: Dislike|PODCI355	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered "no" to Question 50 above, was your activity limited by: Dislike of pickup games or sports?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136181>	C135711	PODCI Adolescent Self-Reported Version - Competitive Sports Limited by: Season|PODCI3-Comp Sports Limited by: Season|PODCI3-Comp Sports Limited by: Season|PODCI356	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered "no" to Question 50 above, was your activity limited by: Activity not in season?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136182>	C135711	PODCI Adolescent Self-Reported Version - Get Together With Friends|PODCI3-Get Together With Friends|PODCI3-Get Together With Friends|PODCI357	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) How often in the last week did you get together and do things with friends?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136183>	C135711	PODCI Adolescent Self-Reported Version - Friends Limited by: Pain|PODCI3-Friends Limited by: Pain|PODCI3-Friends Limited by: Pain|PODCI358	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered "sometimes" or "never or rarely" to Question 57 above, was your activity limited by: Pain?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136184>	C135711	PODCI Adolescent Self-Reported Version - Friends Limited by: Health|PODCI3-Friends Limited by: Health|PODCI3-Friends Limited by: Health|PODCI359	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered "sometimes" or "never or rarely" to Question 57 above, was your activity limited by: General health?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136185>	C135711	PODCI Adolescent Self-Reported Version - Friends Limited by: Instructions|PODCI3-Friends Limited by: Instructions|PODCI3-Friends Limited by: Instructions|PODCI360	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered "sometimes" or "never or rarely" to Question 57 above, was your activity limited by: Doctor or parent instructions?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136186>	C135711	PODCI Adolescent Self-Reported Version - Friends Limited by: Fear|PODCI3-Friends Limited by: Fear|PODCI3-Friends Limited by: Fear|PODCI361	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered "sometimes" or "never or rarely" to Question 57 above, was your activity limited by: Fear the other kids won't like you?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136187>	C135711	PODCI Adolescent Self-Reported Version - Friends Limited by: Not Around|PODCI3-Friends Limited by: Not Around|PODCI3-Friends Limited by: Not Around|PODCI362	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered "sometimes" or "never or rarely" to Question 57 above, was your activity limited by: Friends not around?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136188>	C135711	PODCI Adolescent Self-Reported Version - Participate in Gym or Recess|PODCI3-Participate in Gym/Recess|PODCI3-Participate in Gym/Recess|PODCI363	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) How often in the last week did you participate in gym/recess?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136189>	C135711	PODCI Adolescent Self-Reported Version - Gym Limited by: Pain|PODCI3-Gym Limited by: Pain|PODCI3-Gym Limited by: Pain|PODCI364	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered "sometimes" or "never or rarely" to Question 63 above, was your activity limited by: Pain?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13618>	C13432	19q13	A chromosome band present on 19q			Gene or Genome	
C136190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136190>	C135711	PODCI Adolescent Self-Reported Version - Gym Limited by: Health|PODCI3-Gym Limited by: Health|PODCI3-Gym Limited by: Health|PODCI365	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered "sometimes" or "never or rarely" to Question 63 above, was your activity limited by: General health?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136191>	C135711	PODCI Adolescent Self-Reported Version - Gym Limited by: Instructions|PODCI3-Gym Limited by: Instructions|PODCI3-Gym Limited by: Instructions|PODCI366	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered "sometimes" or "never or rarely" to Question 63 above, was your activity limited by: Doctor or parent instructions?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136192>	C135711	PODCI Adolescent Self-Reported Version - Gym Limited by: Fear|PODCI3-Gym Limited by: Fear|PODCI3-Gym Limited by: Fear|PODCI367	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered "sometimes" or "never or rarely" to Question 63 above, was your activity limited by: Fear the other kids won't like you?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136193>	C135711	PODCI Adolescent Self-Reported Version - Gym Limited by: Dislike|PODCI3-Gym Limited by: Dislike|PODCI3-Gym Limited by: Dislike|PODCI368	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered "sometimes" or "never or rarely" to Question 63 above, was your activity limited by: Dislike of gym/recess?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136194>	C135711	PODCI Adolescent Self-Reported Version - Gym Limited by: Not in Session|PODCI3-Gym Limited by: Not in Session|PODCI3-Gym Limited by: Not in Session|PODCI369	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered "sometimes" or "never or rarely" to Question 63 above, was your activity limited by: School not in session?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136195>	C135711	PODCI Adolescent Self-Reported Version - Gym Limited by: Not Attend School|PODCI3-Gym Limited by: Not Attend School|PODCI3-Gym Limited by: Not Attend School|PODCI370	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you answered "sometimes" or "never or rarely" to Question 63 above, was your activity limited by: I don't attend school?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136196>	C135711	PODCI Adolescent Self-Reported Version - Easy to Make Friends|PODCI3-Easy to Make Friends|PODCI3-Easy to Make Friends|PODCI371	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) Is it easy or hard for you to make friends with kids your own age?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136197>	C135711	PODCI Adolescent Self-Reported Version - Pain During the Last Week|PODCI3-Pain During the Last Week|PODCI3-Pain During the Last Week|PODCI372	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) How much pain have you had during the last week?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136198>	C135711	PODCI Adolescent Self-Reported Version - Pain Interfere With Activities|PODCI3-Pain Interfere With Activities|PODCI3-Pain Interfere With Activities|PODCI373	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) During the last week, how much did pain interfere with your normal activities (including at home, outside of the home, and at school)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136199>	C135711	PODCI Adolescent Self-Reported Version - Have Pain Relief|PODCI3-Have Pain Relief|PODCI3-Have Pain Relief|PODCI374	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) As a result of my treatment, I expect: To have pain relief.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13619>	C13432	17q11.2	A chromosome band present on 17q			Gene or Genome	
C1361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1361>	C1946	Depudecin|(2R,3S,4S,5E,7S,8S,9R)-2,9- Dihydroxy-3,4;7,8-diepoxy-undeca-5,10-diene|(2S-(2R*(E(2R*(S*),3R*)),3R*(S*)))-alpha-Ethenyl-3-(2-(3-(1-hydroxyethyl)oxiranyl)ethenyl)oxiranemethanol|Oxiranemethanol, Alpha-ethenyl-3-(2-(3-(1-hydroxyethyl) oxiranyl)ethenyl)-, (2S- (2R*(E(2R*(S*),3R*)),3R*(S*)))-	Depudecin is a fungal metabolite that reverts the rounded phenotype of NIH 3T3 fibroblasts transformed with v-ras and v-src oncogenes to the flattened phenotype of the non-transformed parental cells. The mechanism of de-transformation induced by this agent had not been determined. However, depudecin has been demonstrated to inhibit histone deacetylase (HDAC) activity effectively both in vivo and in vitro.			Organic Chemical|Pharmacologic Substance	
C136200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136200>	C135711	PODCI Adolescent Self-Reported Version - Look Better|PODCI3-Look Better|PODCI3-Look Better|PODCI375	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) As a result of my treatment, I expect: To look better.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136201>	C135711	PODCI Adolescent Self-Reported Version - Feel Better|PODCI3-Feel Better|PODCI3-Feel Better|PODCI376	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) As a result of my treatment, I expect: To feel better about myself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136202>	C135711	PODCI Adolescent Self-Reported Version - Sleep More Comfortably|PODCI3-Sleep More Comfortably|PODCI3-Sleep More Comfortably|PODCI377	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) As a result of my treatment, I expect: To sleep more comfortably.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136203>	C135711	PODCI Adolescent Self-Reported Version - Able to Do Activities at Home|PODCI3-Able to Do Activities at Home|PODCI3-Able to Do Activities at Home|PODCI378	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) As a result of my treatment, I expect: To be able to do activities at home.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136204>	C135711	PODCI Adolescent Self-Reported Version - Able to Do More at School|PODCI3-Able to Do More at School|PODCI3-Able to Do More at School|PODCI379	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) As a result of my treatment, I expect: To be able to do more at school.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136205>	C135711	PODCI Adolescent Self-Reported Version - Able to Do More Play|PODCI3-Able to Do More Play|PODCI3-Able to Do More Play|PODCI380	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) As a result of my treatment, I expect: To be able to do more play or recreational activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136206>	C135711	PODCI Adolescent Self-Reported Version - Able to Do More Sports|PODCI3-Able to Do More Sports|PODCI3-Able to Do More Sports|PODCI381	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) As a result of my treatment, I expect: To be able to do more sports.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136207>	C135711	PODCI Adolescent Self-Reported Version - Free From Pain as Adult|PODCI3-Free From Pain as Adult|PODCI3-Free From Pain as Adult|PODCI382	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) As a result of my treatment, I expect: To be free from pain or disability as an adult.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136208>	C135711	PODCI Adolescent Self-Reported Version - Spend Rest of Life With Condition|PODCI3-Spend Rest of Life With Condition|PODCI3-Spend Rest of Life With Condition|PODCI383	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) If you had to spend the rest of your life with your bone and muscle condition as it is right now, how would you feel about it?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136209>	C135711	PODCI Adolescent Self-Reported Version - Upper Extremity and Physical Function Scale|PODCI3-Up Extremity/Phys Function Scale|PODCI3-Up Extremity/Phys Function Scale|PODCI384	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) Upper extremity and physical function core scale.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13620>	C13432	3p22	A chromosome band present on 3p			Gene or Genome	
C136210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136210>	C135711	PODCI Adolescent Self-Reported Version - Transfer and Basic Mobility Scale|PODCI3-Transfer/Basic Mobility Scale|PODCI3-Transfer/Basic Mobility Scale|PODCI385	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) Transfer and basic mobility core scale.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136211>	C135711	PODCI Adolescent Self-Reported Version - Sports and Physical Function Scale|PODCI3-Sports/Phys Function Scale|PODCI3-Sports/Phys Function Scale|PODCI386	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) Sports and physical functioning core scale.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136212>	C135711	PODCI Adolescent Self-Reported Version - Pain or Comfort Scale|PODCI3-Pain/Comfort Scale|PODCI3-Pain/Comfort Scale|PODCI387	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) Pain/comfort core scale.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136213>	C135711	PODCI Adolescent Self-Reported Version - Happiness Scale|PODCI3-Happiness Scale|PODCI3-Happiness Scale|PODCI388	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) Happiness core scale.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136214>	C135711	PODCI Adolescent Self-Reported Version - Global Functioning Scale|PODCI3-Global Functioning Scale|PODCI3-Global Functioning Scale|PODCI389	Pediatric Outcomes Data Collection Instrument, Adolescent Self-Reported Version (PODCI Adolescent Self-Reported Version) Global functioning scale.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Code Terminology|CDISC Questionnaire PODCI Adolescent Self-Reported Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136215>	C135712	RAND Social Support Survey - Count on to Listen to You|RSSS01-Count on to Listen to You|RSSS01-Count on to Listen to You|RSSS0101	RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone you can count on to listen to you when you need to talk.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND Social Support Survey Test Code Terminology|CDISC Questionnaire RAND Social Support Survey Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136216>	C135712	RAND Social Support Survey - Give You Info to Help Understand|RSSS01-Give You Info to Help Understand|RSSS01-Give You Info to Help Understand|RSSS0102	RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone to give you information to help you understand a situation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND Social Support Survey Test Code Terminology|CDISC Questionnaire RAND Social Support Survey Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136217>	C135712	RAND Social Support Survey - Give You Advice About a Crisis|RSSS01-Give You Advice About a Crisis|RSSS01-Give You Advice About a Crisis|RSSS0103	RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone to give you good advice about a crisis.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND Social Support Survey Test Code Terminology|CDISC Questionnaire RAND Social Support Survey Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136218>	C135712	RAND Social Support Survey - Confide in or Talk to About Yourself|RSSS01-Confide in/Talk to About Yourself|RSSS01-Confide in/Talk to About Yourself|RSSS0104	RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone to confide in or talk to about yourself or your problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND Social Support Survey Test Code Terminology|CDISC Questionnaire RAND Social Support Survey Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136219>	C135712	RAND Social Support Survey - Advice You Really Want|RSSS01-Advice You Really Want|RSSS01-Advice You Really Want|RSSS0105	RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone whose advice you really want.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND Social Support Survey Test Code Terminology|CDISC Questionnaire RAND Social Support Survey Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13621>	C13432	3q27	A chromosome band present on 3q	3q27		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136220>	C135712	RAND Social Support Survey - Share Your Private Worries and Fears|RSSS01-Share Your Private Worries/Fears|RSSS01-Share Your Private Worries/Fears|RSSS0106	RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone to share your most private worries and fears with.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND Social Support Survey Test Code Terminology|CDISC Questionnaire RAND Social Support Survey Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136221>	C135712	RAND Social Support Survey - Suggestions to Deal With Personal Problem|RSSS01-Turn to Suggestions Personal Prob|RSSS01-Turn to Suggestions Personal Prob|RSSS0107	RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone to turn to for suggestions about how to deal with a personal problem.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND Social Support Survey Test Code Terminology|CDISC Questionnaire RAND Social Support Survey Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136222>	C135712	RAND Social Support Survey - Understands Your Problems|RSSS01-Understands Your Problems|RSSS01-Understands Your Problems|RSSS0108	RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone who understands your problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND Social Support Survey Test Code Terminology|CDISC Questionnaire RAND Social Support Survey Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136223>	C135712	RAND Social Support Survey - Help If You Were Confined to Bed|RSSS01-Help If You Were Confined to Bed|RSSS01-Help If You Were Confined to Bed|RSSS0109	RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone to help you if you were confined to bed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND Social Support Survey Test Code Terminology|CDISC Questionnaire RAND Social Support Survey Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136224>	C135712	RAND Social Support Survey - Take You to the Doctor If Needed|RSSS01-Take You to the Doctor If Needed|RSSS01-Take You to the Doctor If Needed|RSSS0110	RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone to take you to the doctor if you needed it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND Social Support Survey Test Code Terminology|CDISC Questionnaire RAND Social Support Survey Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136225>	C135712	RAND Social Support Survey - Prepare Your Meals If Unable|RSSS01-Prepare Your Meals If Unable|RSSS01-Prepare Your Meals If Unable|RSSS0111	RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone to prepare your meals if you were unable to do it yourself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND Social Support Survey Test Code Terminology|CDISC Questionnaire RAND Social Support Survey Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136226>	C135712	RAND Social Support Survey - Help With Daily Chores If Sick|RSSS01-Help With Daily Chores If Sick|RSSS01-Help With Daily Chores If Sick|RSSS0112	RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone to help with daily chores if you were sick.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND Social Support Survey Test Code Terminology|CDISC Questionnaire RAND Social Support Survey Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136227>	C135712	RAND Social Support Survey - Shows You Love and Affection|RSSS01-Shows You Love and Affection|RSSS01-Shows You Love and Affection|RSSS0113	RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone who shows you love and affection.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND Social Support Survey Test Code Terminology|CDISC Questionnaire RAND Social Support Survey Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136228>	C135712	RAND Social Support Survey - Love and Make You Feel Wanted|RSSS01-Love and Make You Feel Wanted|RSSS01-Love and Make You Feel Wanted|RSSS0114	RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone to love and make you feel wanted.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND Social Support Survey Test Code Terminology|CDISC Questionnaire RAND Social Support Survey Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136229>	C135712	RAND Social Support Survey - Hugs You|RSSS01-Hugs You|RSSS01-Hugs You|RSSS0115	RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone who hugs you.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND Social Support Survey Test Code Terminology|CDISC Questionnaire RAND Social Support Survey Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13622>	C13432	17q11.2-q12	A chromosome band present on 17q			Gene or Genome	
C136230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136230>	C135712	RAND Social Support Survey - Have a Good Time With|RSSS01-Have a Good Time With|RSSS01-Have a Good Time With|RSSS0116	RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone to have a good time with.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND Social Support Survey Test Code Terminology|CDISC Questionnaire RAND Social Support Survey Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136231>	C135712	RAND Social Support Survey - Get Together With for Relaxation|RSSS01-Get Together With for Relaxation|RSSS01-Get Together With for Relaxation|RSSS0117	RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone to get together with for relaxation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND Social Support Survey Test Code Terminology|CDISC Questionnaire RAND Social Support Survey Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136232>	C135712	RAND Social Support Survey - Do Something Enjoyable With|RSSS01-Do Something Enjoyable With|RSSS01-Do Something Enjoyable With|RSSS0118	RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone to do something enjoyable with.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND Social Support Survey Test Code Terminology|CDISC Questionnaire RAND Social Support Survey Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136233>	C135712	RAND Social Support Survey - Help You Get Your Mind Off Things|RSSS01-Help You Get Your Mind Off Things|RSSS01-Help You Get Your Mind Off Things|RSSS0119	RAND Social Support Survey Instrument (RAND Social Support Survey) How often is each of the following kinds of support available to you if you need it: Someone to do things with to help you get your mind off things.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire RAND Social Support Survey Test Code Terminology|CDISC Questionnaire RAND Social Support Survey Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136234>	C100118	MMSE - Level of Consciousness|MMS1-Level of Consciousness|MMS1-Level of Consciousness|MMS113	Mini-Mental State Examination (MMSE) Assessment of level of consciousness.			Intellectual Product	CDISC Functional Test MMSE Test Code Terminology|CDISC Functional Test MMSE Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136235>	C177780|C177683	MET Gene Fusion Positive|HGFR Fusion Gene Positive|Hepatocyte Growth Factor Receptor Fusion Gene Positive|MET Fusion Gene Positive|MET Fusion Gene Positive|MET Proto-Oncogene, Receptor Tyrosine Kinase Fusion Gene Positive|c-MET Gene Fusion Positive	An indication that a MET fusion gene has been detected in a sample.	MET Fusion Gene Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136236>	C16490	Cervical/Vaginal Cytology	Cytologic evaluation of cells collected from the uterine cervix and/or vagina.			Laboratory Procedure	
C136237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136237>	C94463	Upper Vaginectomy	The surgical removal of the upper part of the vagina.			Therapeutic or Preventive Procedure	
C136238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136238>	C15256	Modified Radical Hysterectomy	The surgical removal of the uterus and surrounding structures, including bilateral pelvic lymph nodes, the parametrium, and the upper one-third to one-half of the vagina. The amount of parametria and uterosacral ligament removed with the uterus is less than that removed during a radical hysterectomy.			Therapeutic or Preventive Procedure	
C13623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13623>	C13432	3p24.1-p22	A chromosome band present on 3p			Gene or Genome	
C136240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136240>	C157366|C156098	Rectal Carcinoma Metastatic in the Liver	A carcinoma that originates from the rectum and has spread to the liver.			Neoplastic Process	
C136241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136241>	C65070|C210232|C159457	Bevacizumab/Cisplatin/Paclitaxel Regimen|Cisplatin, Paclitaxel, Bevacizumab|Cisplatin, Paclitaxel, Bevacizumab-adcd|Cisplatin, Paclitaxel, Bevacizumab-awwb|Cisplatin, Paclitaxel, Bevacizumab-aybi|Cisplatin, Paclitaxel, Bevacizumab-bvzr|Cisplatin, Paclitaxel, Bevacizumab-equi|Cisplatin, Paclitaxel, Bevacizumab-maly|Cisplatin, Paclitaxel, Bevacizumab-onbe|Cisplatin, Paclitaxel, Bevacizumab-tnjn|Cisplatin-Paclitaxel-Bevacizumab|Cisplatin-Paclitaxel-Bevacizumab Regimen|Cisplatin/Paclitaxel/Bevacizumab|Cisplatin/Paclitaxel/Bevacizumab Regimen|Platinol-Taxol-Avastin Regimen|Platinol/Taxol/Avastin Regimen	A regimen consisting of bevacizumab, cisplatin and paclitaxel that is used for the treatment of vaginal, vulvar and cervical cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136242>	C65070|C210232	Bevacizumab/Paclitaxel/Topotecan Regimen|Hycamtin-Taxol-Avastin Regimen|Hycamtin/Taxol/Avastin Regimen|PACLTOPO+BEVA Regimen|Paclitaxel, Topotecan, Bevacizumab|Paclitaxel, Topotecan, Bevacizumab-adcd|Paclitaxel, Topotecan, Bevacizumab-awwb|Paclitaxel, Topotecan, Bevacizumab-aybi|Paclitaxel, Topotecan, Bevacizumab-bvzr|Paclitaxel, Topotecan, Bevacizumab-equi|Paclitaxel, Topotecan, Bevacizumab-maly|Paclitaxel, Topotecan, Bevacizumab-onbe|Paclitaxel, Topotecan, Bevacizumab-tnjn|TPB Regimen|Topotecan-Paclitaxel-Bevacizumab|Topotecan-Paclitaxel-Bevacizumab Regimen|Topotecan/Paclitaxel/Bevacizumab|Topotecan/Paclitaxel/Bevacizumab Regimen	A regimen consisting of topotecan, paclitaxel and bevacizumab that is used for the treatment of cervical and vaginal cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136243>	C63586|C203473|C191676|C159893	Bevacizumab/Capecitabine Regimen|Avastin-Xeloda|Bevacizumab-Capecitabine|Bevacizumab/Capecitabine|Capecitabine and Bevacizumab|Capecitabine and Bevacizumab-adcd|Capecitabine and Bevacizumab-awwb|Capecitabine and Bevacizumab-aybi|Capecitabine and Bevacizumab-bvzr|Capecitabine and Bevacizumab-equi|Capecitabine and Bevacizumab-maly|Capecitabine and Bevacizumab-onbe|Capecitabine and Bevacizumab-tnjn|Capecitabine-Bevacizumab|Capecitabine-Bevacizumab Regimen|Capecitabine/Bevacizumab|Capecitabine/Bevacizumab Regimen|Xeloda-Avastin Regimen|Xeloda/Avastin Regimen	A regimen consisting of bevacizumab and capecitabine that may be used for the treatment of colorectal cancer, small bowel , ampullary and appendiceal adenocarcinoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136244>	C63586	Capecitabine/Cetuximab Regimen|Capecitabine-Cetuximab|Capecitabine-Cetuximab Regimen|Capecitabine/Cetuximab|Xeloda/Erbitux Regimen	A regimen consisting of capecitabine and cetuximab that is used for the treatment of colon cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136245>	C63586	Capecitabine/Panitumumab Regimen|Capecitabine-Panitumumab|Capecitabine-Panitumumab Regimen|Capecitabine/Panitumumab|Xeloda-Vectibix Regimen|Xeloda/Vectibix Regimen	A regimen consisting of capecitabine and panitumumab that is used for the treatment of colon cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136246>	C63586	FOLFOX-Cetuximab Regimen|FOLFOX Plus Cetuximab|FOLFOX Plus Erbitux|FOLFOX-Cetuximab|FOLFOX/Cetuximab|FOLFOX/Cetuximab Regimen|FOLFOX/Erbitux Regimen|Folinic Acid/Fluorouracil/Oxaliplatin/Cetuximab Regimen|Leucovorin/Fluorouracil/Oxaliplatin/Cetuximab	A regimen consisting of leucovorin, fluorouracil and oxaliplatin (FOLFOX), plus cetuximab that is used for the treatment of colon cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136247>	C63586	FOLFOX-Panitumumab Regimen|FOLFOX Plus Panitumumab|FOLFOX Plus Vectibix|FOLFOX-Panitumumab|FOLFOX/Panitumumab|FOLFOX/Panitumumab Regimen|FOLFOX/Vectibix|FOLFOX/Vectibix Regimen|Folinic Acid/Fluorouracil/Oxaliplatin/Panitumumab Regimen|Leucovorin/Fluorouracil/Oxaliplatin/Panitumumab	A regimen consisting of leucovorin, fluorouracil and oxaliplatin (FOLFOX), plus panitumumab that is used for the treatment of colon cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136248>	C63586|C63522	FOLFOX-Bevacizumab Regimen|FOLFOX Plus Avastin|FOLFOX Plus Bevacizumab|FOLFOX-Avastin Regimen|FOLFOX/Avastin Regimen|FOLFOX/Bevacizumab Regimen|FOLFOX4 and Bevacizumab|FOLFOX4 and Bevacizumab-adcd|FOLFOX4 and Bevacizumab-awwb|FOLFOX4 and Bevacizumab-aybi|FOLFOX4 and Bevacizumab-bvzr|FOLFOX4 and Bevacizumab-equi|FOLFOX4 and Bevacizumab-maly|FOLFOX4 and Bevacizumab-onbe|FOLFOX4 and Bevacizumab-tnjn|Folfox + Bevacizumab|Folfox + Bevacizumab Regimen|Folinic Acid/Fluorouracil/Oxaliplatin/Bevacizumab Regimen|Leucovorin/Fluorouracil/Oxaliplatin/Bevacizumab	A regimen consisting of leucovorin, fluorouracil and oxaliplatin (FOLFOX), plus bevacizumab that is used for the treatment of colon cancer and mucinous neoplasms of the ovary.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136249>	C63586	FOLFIRI-Panitumumab Regimen|FOLFIRI Plus Panitumumab|FOLFIRI Plus Vectibix|FOLFIRI and Panitumumab|FOLFIRI-Vectibix Regimen|FOLFIRI/Panitumumab Regimen|FOLFIRI/Vectibix Regimen|Folinic Acid/Fluorouracil/Irinotecan/Panitumumab Regimen	A regimen consisting of leucovorin, fluorouracil and irinotecan (FOLFIRI), plus panitumumab that is used for the treatment of colorectal cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C13624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13624>	C13432	21q22.1	A chromosome band present on 21q			Gene or Genome	
C136250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136250>	C63586|C191676	FOLFIRI-Ziv-aflibercept Regimen|FOLFIRI|FOLFIRI Plus Zaltrap|FOLFIRI Plus Ziv-aflibercept|FOLFIRI and Ziv-aflibercept|FOLFIRI-Zaltrap Regimen|FOLFIRI/Zaltrap|FOLFIRI/Zaltrap Regimen|FOLFIRI/Ziv-aflibercept|FOLFIRI/Ziv-aflibercept Regimen|Folinic Acid-Fluorouracil-Irinotecan-Ziv-aflibercept|Folinic Acid/Fluorouracil/Irinotecan/Ziv-aflibercept	A regimen consisting of leucovorin, fluorouracil and irinotecan (FOLFIRI), plus ziv-aflibercept that is used for the treatment of appendiceal adenocarcinoma and colorectal cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C136251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136251>	C63719|C63586|C63361|C191676	FOLFIRI-Ramucirumab Regimen|FOLFIRI Plus Cyramza|FOLFIRI Plus Ramucirumab|FOLFIRI and Ramucirumab|FOLFIRI-Cyramza|FOLFIRI-Cyramza Regimen|FOLFIRI-Ramucirumab|FOLFIRI/Cyramza|FOLFIRI/Cyramza Regimen|FOLFIRI/Ramucirumab|FOLFIRI/Ramucirumab Regimen|Folinic Acid/Fluorouracil/Irinotecan/Ramucirumab	A regimen consisting of leucovorin, fluorouracil and irinotecan (FOLFIRI), plus ramucirumab that is used for the treatment of appendiceal adenocarcinoma, colon, esophageal and esophagogastric junction, gastric and rectal cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136252>	C63586	FOLFOXIRI Regimen|FOLFOXIRI|FOLFOXIRI|Folinic Acid/Fluorouracil/Oxaliplatin/Irinotecan|Leucovorin-Fluorouracil-Oxaliplatin-Irinotecan|Leucovorin/Fluorouracil/Oxaliplatin/Irinotecan	A regimen consisting of fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFOXIRI) that is used for the treatment of colon cancer.			Therapeutic or Preventive Procedure	SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C136253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136253>	C63586	FOLFOXIRI-Bevacizumab Regimen|FOLFOXIRI Plus Avastin|FOLFOXIRI Plus Bevacizumab|FOLFOXIRI-Avastin Regimen|FOLFOXIRI/Avastin Regimen|FOLFOXIRI/Bevacizumab Regimen|Folinic Acid/Fluorouracil/Oxaliplatin/Irinotecan Plus Bevacizumab|Leucovorin-Fluorouracil-Oxaliplatin-Irinotecan Plus Avastin|Leucovorin/Fluorouracil/Oxaliplatin/Irinotecan/Bevacizumab	A regimen consisting of fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFOXIRI), plus bevacizumab that is used for the treatment of colon cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136254>	C63586|C63502|C203473|C191676	Bolus Fluorouracil/Leucovorin Regimen|Bolus 5-FU/LV|Bolus 5-FU/LV Regimen|Bolus 5-FU/Leucovorin|Bolus 5-Fluorouracil-Leucovorin|Bolus Fluorouracil-Leucovorin Regimen|Bolus Fluorouracil/Folinic Acid|LV5FU2	A regimen consisting of bolus fluorouracil and leucovorin that is used for the treatment of colon cancer, and ampullary, appendiceal, small bowel, and pancreatic adenocarcinoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C136255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136255>	C63586|C159893	Bevacizumab/Fluorouracil Bolus/Leucovorin Regimen|Bolus 5-FU/LV Plus Bevacizumab|Bolus 5-FU/LV Plus Bevacizumab Regimen|Bolus Fluorouracil/Leucovorin Plus Avastin Regimen|Bolus Fluorouracil/Leucovorin Plus Bevacizumab|Bolus Fluorouracil/Leucovorin/Avastin Regimen|Bolus Fluorouracil/Leucovorin/Bevacizumab|Bolus Fluorouracil/Leucovorin/Bevacizumab Regimen	A regimen consisting of bolus fluorouracil, leucovorin and bevacizumab that is used for the treatment of colorectal cancer and small bowel adenocarcinoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136256>	C63586|C63361|C210232|C203473|C191676|C159893|C159435	Fluorouracil Infusional/Leucovorin Regimen|Infusional 5-FU/LV|Infusional 5-FU/LV Regimen|Infusional 5-FU/Leucovorin|Infusional Fluorouracil-Leucovorin Regimen|Infusional Fluorouracil/Folinic Acid|Infusional Fluorouracil/Leucovorin|Infusional Fluorouracil/Leucovorin Regimen	A regimen consisting of infusional fluorouracil and leucovorin that is used for the treatment of colon, vaginal, and gastric cancers, ampullary adenocarcinoma, and thymomas and thymic carcinomas.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136257>	C63586|C203473|C191676|C159893	Infusional Fluorouracil/Leucovorin/Bevacizumab Regimen|Infusional 5-FU/LV Plus Bevacizumab|Infusional Fluorouracil-Leucovorin-Bevacizumab Regimen|Infusional Fluorouracil/Leucovorin Plus Avastin|Infusional Fluorouracil/Leucovorin/Avastin|Infusional Fluorouracil/leucovorin Plus Bevacizumab	A regimen consisting of infusional fluorouracil, leucovorin and bevacizumab that is used for the treatment of colorectal cancer, and ampullary, appendiceal and small bowel adenocarcinoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136258>	C63586|C191676|C159893	Bevacizumab/Irinotecan Regimen|Irinotecan and Bevacizumab|Irinotecan and Bevacizumab-adcd|Irinotecan and Bevacizumab-awwb|Irinotecan and Bevacizumab-aybi|Irinotecan and Bevacizumab-bvzr|Irinotecan and Bevacizumab-equi|Irinotecan and Bevacizumab-maly|Irinotecan and Bevacizumab-onbe|Irinotecan and Bevacizumab-tnjn|Irinotecan-Avastin Regimen|Irinotecan-Bevacizumab|Irinotecan-Bevacizumab Regimen|Irinotecan/Avastin Regimen|Irinotecan/Bevacizumab|Irinotecan/Bevacizumab Regimen	A regimen consisting of irinotecan and bevacizumab that can be used for the treatment of colorectal cancer, appendiceal adenocarcinoma, and small bowel adenocarcinoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136259>	C63586|C191676	Irinotecan/Ziv-aflibercept Regimen|Irinotecan-Zaltrap Regimen|Irinotecan-Ziv-aflibercept|Irinotecan-Ziv-aflibercept Regimen|Irinotecan/Zaltrap Regimen|Irinotecan/Ziv-aflibercept	A regimen consisting of irinotecan and ziv-aflibercept that is used for the treatment of appendiceal adenocarcinoma and colorectal cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C13625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13625>	C13432	7q33-q35	A chromosome band present on 7q			Gene or Genome	
C136260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136260>	C63719|C63586|C63361|C191676	Irinotecan/Ramucirumab Regimen|Irinotecan-Cyramza Regimen|Irinotecan-Ramucirumab|Irinotecan-Ramucirumab Regimen|Irinotecan/Cyramza Regimen|Irinotecan/Ramucirumab	A regimen consisting of irinotecan and ramucirumab that is used for the treatment of appendiceal adenocarcinoma, colon, esophageal and esophagogastric junction, gastric and rectal cancers.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136261>	C63496	Bendamustine/Bortezomib/Dexamethasone Regimen|BBD|BBD|BVD|Bendamustine-Bortezomib-Dexamethasone|Bendamustine-Bortezomib-Dexamethasone Regimen|Bendamustine/Bortezomib/Dexamethasone|Treanda/Velcade/Dexamethasone	A regimen consisting of bendamustine, bortezomib and dexamethasone that is used for the treatment of plasma cell myeloma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136262>	C63496	BLD Regimen|BLD|BLD|BRD|Bendamustine-Lenalidomide-Dexamethasone Regimen|Bendamustine/Dexamethasone/Lenalidomide|Bendamustine/Lenalidomide/Dexamethasone|Bendamustine/Lenalidomide/Dexamethasone Regimen|Treanda/Revlimid/Dexamethasone	A regimen consisting of bendamustine, lenalidomide and dexamethasone that is used for the treatment of plasma cell (multiple) myeloma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136263>	C63496	Bortezomib/Liposomal Doxorubicin Regimen|Bortezomib-Liposomal Doxorubicin|Bortezomib-Liposomal Doxorubicin Regimen|Bortezomib/Liposomal Doxorubicin	A regimen consisting of bortezomib and liposomal doxorubicin that is used for the treatment of plasma cell myeloma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136264>	C63496	KRd Regimen|CRd|Carfilzomib-Lenalidomide-Dexamethasone|Carfilzomib-Lenalidomide-Dexamethasone Regimen|Carfilzomib//Dexamethasone /Lenalidomide|Carfilzomib/Lenalidomide/Dexamethasone|Carfilzomib/Lenalidomide/Dexamethasone Regimen|KRd|KRd|Kyprolis/Revlimid/Dexamethasone	A regimen consisting of carfilzomib, lenalidomide and dexamethasone that is used for the treatment of plasma cell (multiple) myeloma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136265>	C63496|C159461	Carfilzomib/Dexamethasone Regimen|Carfilzomib and Dexamethasone (Kd)|Carfilzomib-Dexamethasone|Carfilzomib-Dexamethasone Regimen|Carfilzomib/Dexamethasone|KD|KD Regimen|Kyprolis/Dexamethasone	A regimen consisting of carfilzomib and dexamethasone that is used for the treatment of plasma cell myeloma and systemic light chain amyloidosis.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136266>	C63496|C159461	CRd Regimen|CLD|CRd|CRd|Cyclophosphamide-Lenalidomide-Dexamethasone|Cyclophosphamide-Lenalidomide-Dexamethasone Regimen|Cyclophosphamide/Dexamethasone/Lenalidomide|Cyclophosphamide/Lenalidomide/Dexamethasone|Cyclophosphamide/Lenalidomide/Dexamethasone Regimen|RdC	A regimen consisting of cyclophosphamide, lenalidomide and dexamethasone that can be used for the treatment of plasma cell myeloma and systemic light chain amyloidosis.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136267>	C63496	Dara-Vd Regimen|DVD|Dara-Vd|Dara-Vd|Daratumumab-Bortezomib-Dexamethasone|Daratumumab-Bortezomib-Dexamethasone Regimen|Daratumumab/Bortezomib/Dexamethasone|Daratumumab/Bortezomib/Dexamethasone Regimen|Darzalex/Velcade/Dexamethasone	A regimen consisting of daratumumab, bortezomib and dexamethasone that is used for the treatment of plasma cell myeloma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136268>	C63496|C159461	Dara-Rd Regimen|Dara-Rd|Dara-Rd|Daratumumab-Lenalidomide-Dexamethasone|Daratumumab-Lenalidomide-Dexamethasone Regimen|Daratumumab/Lenalidomide/Dexamethasone|Daratumumab/Lenalidomide/Dexamethasone Regimen|Darzalex/Revlimid/Dexamethasone	A regimen consisting of daratumumab, lenalidomide and dexamethasone that is used for the treatment of plasma cell myeloma and systemic light chain amyloidosis.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136269>	C63496	VTD-PACE Regimen|Bortezomib-Thalidomide-Dexamethasone-Cisplatin-Doxorubicin-Cyclophosphamide-Etoposide Regimen|DT-PACE Plus Bortezomib|DT-PACE Plus Velcade|DT-PACE-Bortezomib Regimen|DT-PACE/Bortezomib Regimen|VDT-PACE|VDT-PACE Regimen|VTD-PACE|VTD-PACE|Velcade/Thalomid/Decadron/Platinol/Adriamycin/Cytoxan/Vepesid Regimen	A regimen consisting of dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide and etoposide (DT-PACE), plus bortezomib (VTD-PACE) that is used for the treatment of plasma cell myeloma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C13626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13626>	C13432	3q21-q25	A chromosome band present on 3q			Gene or Genome	
C136270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136270>	C63496	Elo-Rd Regimen|Dexamethasone/Elotuzumab/Lenalidomide/|Elo-Rd|Elo-Rd|Elotuzumab-Lenalidomide-Dexamethasone|Elotuzumab-Lenalidomide-Dexamethasone Regimen|Elotuzumab/Lenalidomide/Dexamethasone|Elotuzumab/Lenalidomide/Dexamethasone Regimen|Empliciti/Revlimid/Dexamethasone|Lenalidomide/Dexamethasone/Elotuzumab	A regimen consisting of elotuzumab, lenalidomide and dexamethasone that is used for the treatment of plasma cell myeloma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136271>	C63496	Elo-Vd Regimen|Bortezomib/Dexamethasone/Elotuzumab|Elo-Vd|Elo-Vd|Elotuzumab-Bortezomib-Dexamethasone|Elotuzumab-Bortezomib-Dexamethasone Regimen|Elotuzumab/Bortezomib/Dexamethasone|Elotuzumab/Bortezomib/Dexamethasone Regimen|Empliciti/Velcade/Dexamethasone	A regimen consisting of elotuzumab, bortezomib and dexamethasone that is used for the treatment of plasma cell myeloma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136272>	C63496|C159461	IRd Regimen|IRD Regimen|IRd|Ixazomib-Lenalidomide-Dexamethasone|Ixazomib-Lenalidomide-Dexamethasone Regimen|Ixazomib/Lenalidomide/Dexamethasone|Ixazomib/Lenalidomide/Dexamethasone Regimen|Ixazomib/Revlimid/Dexamethasone|Ninlaro/Revlimid/Dexamethasone|Ninlaro/Revlimid/Dexamethasone	A regimen consisting of ixazomib, lenalidomide and dexamethasone that may be used for the treatment of plasma cell (multiple) myeloma and systemic light chain (AL) amyloidosis.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136273>	C63496|C159461	Dexamethasone/Ixazomib Regimen|Ixazomib and Dexamethasone|Ixazomib-Dexamethasone|Ixazomib-Dexamethasone Regimen|Ixazomib/Dexamethasone|Ixazomib/Dexamethasone Regimen|Ninlaro/Dexamethasone	A regimen consisting of ixazomib and dexamethasone that may be used for the treatment of plasma cell myeloma and systemic light chain (AL) amyloidosis.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136274>	C63496	Low-dose Dexamethasone/Lenalidomide Regimen|Lenalidomide Plus Low-dose Dexamethasone Regimen|Lenalidomide-Low-dose Dexamethasone|Lenalidomide/Low-dose Dexamethasone|Lenalidomide/Low-dose Dexamethasone Regimen|Rd Regimen|Revlimid/Low-dose Dexamethasone|Revlimid/Low-dose Dexamethasone Regimen	A regimen consisting of lenalidomide and low-dose dexamethasone that is used for the treatment of plasma cell myeloma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136275>	C63496	Bortezomib/Dexamethasone/Panobinostat Regimen|Bortezomib and Dexamethasone (Vd) and Panobinostat|Farydak/Velcade/Dexamethasone|Panobinostat-Bortezomib-Dexamethasone|Panobinostat-Bortezomib-Dexamethasone Regimen|Panobinostat/Bortezomib/Dexamethasone|Panobinostat/Bortezomib/Dexamethasone Regimen	A regimen consisting of panobinostat, bortezomib and dexamethasone that is used for the treatment of plasma cell myeloma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136276>	C63496	Carfilzomib/Panobinostat Regimen|Carfilzomib and Panobinostat|Farydak/Kyprolis|Panobinostat-Carfilzomib|Panobinostat-Carfilzomib Regimen|Panobinostat/Carfilzomib|Panobinostat/Carfilzomib Regimen	A regimen consisting of panobinostat and carfilzomib that is used for the treatment of plasma cell myeloma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136277>	C63496	Dexamethasone/Pomalidomide Regimen|PomDex|Pomalidomide and Dexamethasone (Pd)|Pomalidomide-Dexamethasone|Pomalidomide-Dexamethasone Regimen|Pomalidomide/Dexamethasone|Pomalidomide/Dexamethasone Regimen	A regimen consisting of pomalidomide and dexamethasone that is used for the treatment of plasma cell myeloma and systemic light chain amyloidosis.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136278>	C63496	PVD Regimen|B-Pd|Bortezomib/Pomalidomide/Dexamethasone|PVD|PVD|Pomalidomide-Bortezomib-Dexamethasone|Pomalidomide-Bortezomib-Dexamethasone Regimen|Pomalidomide/Bortezomib/Dexamethasone|Pomalidomide/Bortezomib/Dexamethasone Regimen|Pomalidomide/Velcade/Dexamethasone|Pomalidomide/Velcade/Dexamethasone Regimen	A regimen consisting of pomalidomide, bortezomib and dexamethasone that is used for the treatment of plasma cell myeloma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136279>	C63496	KPD Regimen|CPD|Carfilzomib/Dexamethasone/Pomalidomide|Carfilzomib/Pomalidomide/Dexamethasone|KPD|KPD|Kyprolis/Pomalidomide/Dexamethasone|Pomalidomide-Carfilzomib-Dexamethasone|Pomalidomide-Carfilzomib-Dexamethasone Regimen|Pomalidomide/Carfilzomib/Dexamethasone|Pomalidomide/Carfilzomib/Dexamethasone Regimen|Pomalidomide/Kyprolis/Dexamethasone	A regimen consisting of pomalidomide, carfilzomib and dexamethasone that is used for the treatment of plasma cell myeloma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C13627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13627>	C13432	6p21.3	A chromosome band present on 6p			Gene or Genome	
C136280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136280>	C63496	PCD Regimen|Cyclophosphamide/Pomalidomide/Dexamethasone|PCD|PCD|PomCyDex|Pomalidomide-Cyclophosphamide-Dexamethasone|Pomalidomide-Cyclophosphamide-Dexamethasone Regimen|Pomalidomide/Cyclophosphamide/Dexamethasone|Pomalidomide/Cyclophosphamide/Dexamethasone Regimen	A regimen consisting of pomalidomide, cyclophosphamide and dexamethasone that is used for the treatment of plasma cell myeloma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136281>	C63360	Bevacizumab/Carboplatin/Pemetrexed Regimen|Avastin/Carboplatin/Alimta|Bevacizumab-Carboplatin-Pemetrexed|Bevacizumab-Carboplatin-Pemetrexed Regimen|Bevacizumab/Carboplatin/Pemetrexed|Carboplatin, Pemetrexed, Bevacizumab|Carboplatin, Pemetrexed, Bevacizumab-adcd|Carboplatin, Pemetrexed, Bevacizumab-awwb|Carboplatin, Pemetrexed, Bevacizumab-aybi|Carboplatin, Pemetrexed, Bevacizumab-bvzr|Carboplatin, Pemetrexed, Bevacizumab-equi|Carboplatin, Pemetrexed, Bevacizumab-maly|Carboplatin, Pemetrexed, Bevacizumab-onbe|Carboplatin, Pemetrexed, Bevacizumab-tnjn	A regimen consisting of bevacizumab, carboplatin and pemetrexed that is used for the treatment of non-small cell lung cancer (NSCLC).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136282>	C63360	Bevacizumab/Cisplatin/Pemetrexed Regimen|Avastin/Cisplatin/Pemetrexed|Bevacizumab-Cisplatin-Pemetrexed|Bevacizumab-Cisplatin-Pemetrexed Regimen|Bevacizumab/Cisplatin/Pemetrexed|Cisplatin, Pemetrexed, Bevacizumab|Cisplatin, Pemetrexed, Bevacizumab-adcd|Cisplatin, Pemetrexed, Bevacizumab-awwb|Cisplatin, Pemetrexed, Bevacizumab-aybi|Cisplatin, Pemetrexed, Bevacizumab-bvzr|Cisplatin, Pemetrexed, Bevacizumab-equi|Cisplatin, Pemetrexed, Bevacizumab-maly|Cisplatin, Pemetrexed, Bevacizumab-onbe	A regimen consisting of bevacizumab, cisplatin and pemetrexed that is used for the treatment of non-small cell lung cancer (NSCLC).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136283>	C63524|C63522|C63360|C63358|C159901|C159900	Carboplatin/Nab-paclitaxel Regimen|Albumin-bound Paclitaxel/Carboplatin|Carboplatin and nab-Paclitaxel|Carboplatin-Albumin-bound Paclitaxel|Carboplatin-Albumin-bound Paclitaxel Regimen|Carboplatin/Abraxane Regimen|Carboplatin/Albumin-bound Paclitaxel|Nab-P/C Regimen|Nab-PC Regimen|Nab-paclitaxel/Carboplatin|Nab-paclitaxel/Carboplatin Regimen	A regimen consisting of carboplatin and nab-paclitaxel, an albumin-bound formulation of paclitaxel, that is used for the treatment of non-small cell lung cancer (NSCLC), breast, ovarian, fallopian tube and primary peritoneal cancers, and cutaneous melanoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136284>	C63787|C63360|C159458	Carboplatin/Pemetrexed Regimen|Carboplatin and Pemetrexed|Carboplatin-Alimta Regimen|Carboplatin-Pemetrexed|Carboplatin-Pemetrexed Regimen|Carboplatin/Pemetrexed	A regimen consisting of carboplatin and pemetrexed that is used for the treatment of non-small cell lung cancer (NSCLC), thyroid cancer, and malignant peritoneal and pleural mesothelioma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136285>	C63360	Docetaxel/Ramucirumab Regimen|Cyramza/Docetaxel Regimen|Docetaxel and Ramucirumab|Ramucirumab-Docetaxel|Ramucirumab-Docetaxel Regimen|Ramucirumab/Docetaxel|Ramucirumab/Docetaxel Regimen	A regimen consisting of ramucirumab and docetaxel that is used for the treatment of non-small cell lung cancer (NSCLC).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C136286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136286>	C97928	MET Protein Variant|C-MET Protein Variant|HGF Receptor Protein Variant|HGFR Protein Variant|Hepatocyte Growth Factor Receptor Protein Variant|Proto-Oncogene c-Met Protein Variant|Scatter Factor Receptor Protein Variant|Tyrosine-Protein Kinase Met Protein Variant	A variation in the amino acid sequence for the hepatocyte growth factor receptor protein.	MET Protein Variant		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C136287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136287>	C136286	MET NP_000236.2:p.Y1003X|C-MET Tyr1003Xxx|C-MET Y1003X|HGF Receptor Tyr1003Xxx|HGF Receptor Y1003X|HGFR Tyr1003Xxx|HGFR Y1003X|Hepatocyte Growth Factor Receptor Tyr1003Xxx|Hepatocyte Growth Factor Receptor Y1003X|MET NP_000236.2:p.Tyr1003Xxx|NP_000236.2:p.Tyr1003Xxx|NP_000236.2:p.Y1003X|Proto-Oncogene c-Met Tyr1003Xxx|Proto-Oncogene c-Met Y1003X|Scatter Factor Receptor Tyr1003Xxx|Scatter Factor Receptor Y1003X|Tyrosine-Protein Kinase Met Tyr1003Xxx|Tyrosine-Protein Kinase Met Y1003X	A change in the amino acid residue at position 1003 in the hepatocyte growth factor receptor protein where tyrosine has been replaced by another amino acid.	MET NP_000236.2:p.Y1003X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136288>	C94466	Radical Trachelectomy	Surgical removal of the uterine cervix and pelvic lymph nodes.			Therapeutic or Preventive Procedure	
C136289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136289>	C51662	Para-Aortic Lymph Node Biopsy|Para-Aortic Lymph Node Sampling	A surgical procedure in which a single or multiple para-aortic lymph nodes are removed for microscopic examination.			Diagnostic Procedure	
C13628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13628>	C13432	17p13.1	A chromosome band present on 17p	17p13.1		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136290>	C91061|C15305	Segmental Resection of the Lung|Segmentectomy of the Lung	Surgical removal of a section of a lobe of the lung.			Therapeutic or Preventive Procedure	
C136291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136291>	C217126|C165599	Abdominal Wall Fat Pad Biopsy	Biopsy of the subcutaneous fat of the abdominal wall.			Diagnostic Procedure	
C136292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136292>	C48233	Thoracic Cancer TNM Finding v8	A finding about one or more characteristics of thoracic cancer, following the rules of the TNM AJCC v8 classification system. It refers to thymic tumors, lung carcinoma, and malignant pleural mesothelioma.			Finding	
C136293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136293>	C136292	Thymus Tumor TNM Finding v8|Thymic Tumor TNM Finding v8	A finding about one or more characteristics of a thymus tumor, following the rules of the TNM AJCC v8 classification system. This classification system applies to thymomas, thymic carcinomas, thymic neuroendocrine tumors, and combined thymic carcinomas. (from AJCC 8th Ed.)			Finding	
C136294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136294>	C136293	Thymus Tumor Clinical TNM Finding v8|Thymic Tumor Clinical TNM Finding v8	A clinical finding about one or more characteristics of a thymus tumor, following the rules of the TNM AJCC v8 classification system.			Finding	
C136295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136295>	C136294	Thymus Tumor Clinical Distant Metastasis TNM Finding v8|Thymic Tumor Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of a thymus tumor, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C136296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136296>	C136295	Thymus Tumor cM0 TNM Finding v8|Thymic Tumor cM0 TNM Finding v8	Thymus tumor without evidence of pleural, pericardial, or distant metastasis. (from AJCC 8th Ed.)			Finding	
C136297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136297>	C136295	Thymus Tumor cM1 TNM Finding v8|Thymic Tumor cM1 TNM Finding v8	Thymus tumor with pleural, pericardial, or distant metastasis. (from AJCC 8th Ed.)			Finding	
C136298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136298>	C136297	Thymus Tumor cM1a TNM Finding v8|Thymic Tumor cM1a TNM Finding v8	Thymus tumor with separate pleural or pericardial nodule(s). (from AJCC 8th Ed.)			Finding	
C136299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136299>	C136297	Thymus Tumor cM1b TNM Finding v8|Thymic Tumor cM1b TNM Finding v8	Thymus tumor with pulmonary intraparenchymal nodule or distant organ metastasis. (from AJCC 8th Ed.)			Finding	
C13629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13629>	C13432	1q42.1	A chromosome band present on 1q			Gene or Genome	
C1362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1362>	C521	Dexamethasone Sodium Phosphate|Cebedex|Corson|Corson|DEXAMETHASONE SODIUM PHOSPHATE|Dalalone|Decaject|Dekasol LA|Dexacen|Dexamethasone Sodium Phosphates|Dexasone|Dezone|ReadySharp Dexamethasone|Soludecadron|Solurex|Topidex	A sodium phosphate salt form of Dexamethasone, a synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)	Dexamethasone Sodium Phosphate		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C136300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136300>	C136293	Thymus Tumor Pathologic TNM Finding v8|Thymic Tumor Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of a thymus tumor, following the rules of the TNM AJCC v8 classification system.			Finding	
C136301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136301>	C136300	Thymus Tumor Pathologic Distant Metastasis TNM Finding v8|Thymic Tumor Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of a thymus tumor, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C136302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136302>	C136301	Thymus Tumor pM1 TNM Finding v8|Thymic Tumor pM1 TNM Finding v8	Thymus tumor with pleural, pericardial, or distant metastasis. (from AJCC 8th Ed.)			Finding	
C136303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136303>	C136302	Thymus Tumor pM1a TNM Finding v8|Thymic Tumor pM1a TNM Finding v8	Thymus tumor with separate pleural or pericardial nodule(s). (from AJCC 8th Ed.)			Finding	
C136304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136304>	C136302	Thymus Tumor pM1b TNM Finding v8|Thymic Tumor pM1b TNM Finding v8	Thymus tumor with pulmonary intraparenchymal nodule or distant organ metastasis. (from AJCC 8th Ed.)			Finding	
C136305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136305>	C136300	Thymus Tumor Pathologic Primary Tumor TNM Finding v8|Thymic Tumor Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of a thymus tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C136306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136306>	C136305	Thymus Tumor pTX TNM Finding v8|Thymic Tumor pTX TNM Finding v8	Thymus tumor in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C136307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136307>	C136305	Thymus Tumor pT0 TNM Finding v8|Thymic Tumor pT0 TNM Finding v8	Thymus tumor without evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C136308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136308>	C136305	Thymus Tumor pT1 TNM Finding v8|Thymic Tumor pT1 TNM Finding v8	Thymus tumor which is encapsulated or extends into the mediastinal fat; may involve the mediastinal pleura. (from AJCC 8th Ed.)			Finding	
C136309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136309>	C136308	Thymus Tumor pT1a TNM Finding v8|Thymic Tumor pT1a TNM Finding v8	Thymus tumor with no mediastinal pleura involvement. (from AJCC 8th Ed.)			Finding	
C13630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13630>	C13432	1p36	A chromosome band present on 1p	1p36		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136310>	C136308	Thymus Tumor pT1b TNM Finding v8|Thymic Tumor pT1b TNM Finding v8	Thymus tumor with direct invasion of mediastinal pleura. (from AJCC 8th Ed.)			Finding	
C136311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136311>	C136305	Thymus Tumor pT2 TNM Finding v8|Thymic Tumor pT2 TNM Finding v8	Thymus tumor with direct invasion of the pericardium (either partial or full thickness). (from AJCC 8th Ed.)			Finding	
C136312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136312>	C136305	Thymus Tumor pT3 TNM Finding v8|Thymic Tumor pT3 TNM Finding v8	Thymus tumor with direct invasion into any of the following: lung, brachiocephalic vein, superior vena cava, phrenic nerve, chest wall, or extrapericardial pulmonary artery or veins. (from AJCC 8th Ed.)			Finding	
C136313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136313>	C136305	Thymus Tumor pT4 TNM Finding v8|Thymic Tumor pT4 TNM Finding v8	Thymus tumor with invasion into any of the following: aorta (ascending, arch, or descending), arch vessels, intrapericardial pulmonary artery, myocardium, trachea, esophagus. (from AJCC 8th Ed.)			Finding	
C136314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136314>	C136300	Thymus Tumor Pathologic Regional Lymph Nodes TNM Finding v8|Thymic Tumor Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of a thymus tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C136315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136315>	C136314	Thymus Tumor pNX TNM Finding v8|Thymic Tumor pNX TNM Finding v8	Thymus tumor in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)			Finding	
C136316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136316>	C136314	Thymus Tumor pN0 TNM Finding v8|Thymic Tumor pN0 TNM Finding v8	Thymus tumor without regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C136317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136317>	C136314	Thymus Tumor pN1 TNM Finding v8|Thymic Tumor pN1 TNM Finding v8	Thymus tumor with metastasis in anterior (perithymic) lymph nodes. (from AJCC 8th Ed.)			Finding	
C136318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136318>	C136314	Thymus Tumor pN2 TNM Finding v8|Thymic Tumor pN2 TNM Finding v8	Thymus tumor with metastasis in deep intrathoracic or cervical lymph nodes. (from AJCC 8th Ed.)			Finding	
C136319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136319>	C125238	Memorial Symptom Assessment Scale (MSAS) 7-12|MSAS 7-12|Memorial Symptom Assessment Scale (Pediatrics 7-12)|Memorial Symptom Assessment Scale 7-12	A patient-rated questionnaire designed to evaluate the prevalence, characteristics, and distress to young children with cancer aged 7-12. This 8-question instrument was adapted from a previously-validated adult version.			Intellectual Product	
C13631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13631>	C13432	3p21-p14	A chromosome band present on 3p			Gene or Genome	
C136320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136320>	C6450	Thymus Epithelial Neoplasm by AJCC v8 Stage|Thymic Epithelial Neoplasm by AJCC v8 Stage	A term that refers to the staging of a thymus epithelial neoplasm, following the rules of the TNM AJCC v8 classification system. This staging system applies to thymomas, thymus carcinomas, thymus neuroendocrine tumors, and combined thymus carcinomas. (AJCC 8th Ed.)			Neoplastic Process	
C136321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136321>	C25616	Yesterday or Today|Yesterday or today	The time period consisting of the current day and the preceding day.			Temporal Concept	Memorial Symptom Assessment Scale (MSAS) 7-12
C136322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136322>	C136320	Stage I Thymus Epithelial Neoplasm AJCC v8|Stage I Thymic Epithelial Neoplasm AJCC v8|Stage I Thymus Epithelial Neoplasm	Stage I includes: T1a, b, N0, M0. T1a: Tumor with no mediastinal pleura involvement. T1b: Tumor with direct invasion of mediastinal pleura. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Thymus Epithelial Neoplasm AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136323>	C136320	Stage II Thymus Epithelial Neoplasm AJCC v8|Stage II Thymic Epithelial Neoplasm AJCC v8|Stage II Thymus Epithelial Neoplasm	Stage II includes: T2, N0, M0. T2: Tumor with direct invasion of the pericardium (either partial or full thickness). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Thymus Epithelial Neoplasm AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136324>	C25616	Last 2 Days|Last 2 days|Last Two Days|Past 2 Days|Past Two Days	The 48 hour period occurring just before the present time.			Temporal Concept	Memorial Symptom Assessment Scale (MSAS) 7-12
C136325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136325>	C136320	Stage III Thymus Epithelial Neoplasm AJCC v8|Stage III Thymic Epithelial Neoplasm AJCC v8|Stage III Thymus Epithelial Neoplasm	Stage III includes: IIIA: (T3, N0, M0); IIIB: (T4, N0, M0). T3: Tumor with direct invasion into any of the following: lung, brachiocephalic vein, superior vena cava, phrenic nerve, chest wall, or extrapericardial pulmonary artery or veins. T4: Tumor with invasion into any of the following: aorta (ascending, arch, or descending), arch vessels, intrapericardial pulmonary artery, myocardium, trachea, esophagus. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Thymus Epithelial Neoplasm AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136326>	C25616	Last 2 Nights|Last 2 nights|Last Two Nights|Past 2 Nights|Past Two Nights	The period of time consisting of the previous night and the night before the previous night.			Temporal Concept	Memorial Symptom Assessment Scale (MSAS) 7-12
C136327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136327>	C136325	Stage IIIA Thymus Epithelial Neoplasm AJCC v8|Stage IIIA Thymic Epithelial Neoplasm AJCC v8	Stage IIIA includes: T3, N0, M0. T3: Tumor with direct invasion into any of the following: lung, brachiocephalic vein, superior vena cava, phrenic nerve, chest wall, or extrapericardial pulmonary artery or veins. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C136328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136328>	C136325	Stage IIIB Thymus Epithelial Neoplasm AJCC v8|Stage IIIB Thymic Epithelial Neoplasm AJCC v8	Stage IIIB includes: T4, N0, M0. T4: Tumor with invasion into any of the following: aorta (ascending, arch, or descending), arch vessels, intrapericardial pulmonary artery, myocardium, trachea, esophagus. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C136329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136329>	C136320	Stage IV Thymus Epithelial Neoplasm AJCC v8|Stage IV Thymic Epithelial Neoplasm AJCC v8|Stage IV Thymus Epithelial Neoplasm	Stage IV includes: IVA: (Any T, N1, M0); (Any T, N0,1, M1a); IVB: (Any T, N2, M0, M1a); (Any T, Any N, M1b). N0: No regional lymph node metastasis. N1: Metastasis in anterior (perithymic) lymph nodes. N2: Metastasis in deep intrathoracic or cervical lymph nodes. M0: No distant metastasis. M1a: Separate pleural or pericardial nodule(s). M1b: Pulmonary intraparenchymal nodule or distant organ metastasis. (AJCC 8th ed.)	Stage IV Thymus Epithelial Neoplasm AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13632>	C13432	11p13	A chromosome band present on 11p			Gene or Genome	
C136330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136330>	C136329	Stage IVA Thymus Epithelial Neoplasm AJCC v8|Stage IVA Thymic Epithelial Neoplasm AJCC v8|Stage IVA Thymus Epithelial Neoplasm	Stage IVA includes: (Any T, N1, M0); (Any T, N0,1, M1a). N0: No regional lymph node metastasis. N1: Metastasis in anterior (perithymic) lymph nodes. M0: No distant metastasis. M1a: Separate pleural or pericardial nodule(s). (AJCC 8th ed.)	Stage IVA Thymus Epithelial Neoplasm AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136331>	C136329	Stage IVB Thymus Epithelial Neoplasm AJCC v8|Stage IVB Thymic Epithelial Neoplasm AJCC v8|Stage IVB Thymus Epithelial Neoplasm	Stage IVB includes: (Any T, N2, M0, M1a); (Any T, Any N, M1b). N2: Metastasis in deep intrathoracic or cervical lymph nodes. M0: No distant metastasis. M1a: Separate pleural or pericardial nodule(s). M1b: Pulmonary intraparenchymal nodule or distant organ metastasis. (AJCC 8th ed.)	Stage IVB Thymus Epithelial Neoplasm AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136332>	C176242	A Very Short Time|A very short time|Very Short	A response indicating that something happens or happened for a very short time.			Intellectual Product	Memorial Symptom Assessment Scale (MSAS) 7-12
C136333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136333>	C175311	A Medium Amount of Time|A Medium Amount|A Medium Amount of the Time|A medium amount|Medium	A response indicating that something happens or happened for a medium amount of time.			Intellectual Product	Memorial Symptom Assessment Scale (MSAS) 7-12
C136334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136334>	C226692	A Medium Amount|A medium amount|Medium	A response indicating that something is or was of a moderate amount, intensity, or duration.			Intellectual Product	Memorial Symptom Assessment Scale (MSAS) 7-12
C136335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136335>	C173935	More Tired Than Usual Question|Did you feel more tired yesterday or today than you usually do|More Tired Than Usual	A question about whether an individual feels or felt more tired than usual.			Intellectual Product	Memorial Symptom Assessment Scale (MSAS) 7-12
C136336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136336>	C15209	Colectomy with En Bloc Removal of Regional Lymph Nodes	Surgical removal of the colon and regional lymph nodes.			Therapeutic or Preventive Procedure	
C136337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136337>	C173935	How Long Feeling Tired Lasted Question|How Long Feeling Tired Lasted|How long did feeling tired last	A question about how long an individual's tired feeling lasted.			Intellectual Product	Memorial Symptom Assessment Scale (MSAS) 7-12
C136338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136338>	C173935	How Tired Question|How Tired|How tired did you feel	A question about how tired an individual felt.			Intellectual Product	Memorial Symptom Assessment Scale (MSAS) 7-12
C136339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136339>	C173935|C173561	How Much Bothered by Being Tired Question|How Much Bothered by Being Tired|How much did being tired bother you or trouble you	A question about how much being tired bothered or troubled an individual.			Intellectual Product	Memorial Symptom Assessment Scale (MSAS) 7-12
C13633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13633>	C13432	18p11.31-p11.21	A chromosome band present on 18p			Gene or Genome	
C136340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136340>	C173160	How Long Felt Sad Question|How Long Feel Sad|How Long Felt Sad|How long did you feel sad	A question about how long an individual felt sad.			Intellectual Product	Memorial Symptom Assessment Scale (MSAS) 7-12
C136341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136341>	C173160	How Sad Question|How Sad|How Sad You Felt|How sad did you feel	A question about how sad an individual felt.			Intellectual Product	Memorial Symptom Assessment Scale (MSAS) 7-12
C136342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136342>	C16450	Colonoscopy with Marking of Cancerous Polyp	A procedure in which the location of a cancerous polyp is marked with a dye during colonoscopy, for the purpose of identifying the site for later, possible resection.			Health Care Activity	
C136343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136343>	C173561|C173160	How Much Feeling Sad Bothered or Troubled You Question|How Much Feeling Sad Bothered or Troubled You|How much did feeling sad bother or trouble you	A question about how much an individual was bothered or troubled by feeling sad.			Intellectual Product	Memorial Symptom Assessment Scale (MSAS) 7-12
C136344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136344>	C15332	Complete Parametrectomy	Surgical removal of the parametrial tissues.			Therapeutic or Preventive Procedure	
C136345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136345>	C3411|C136320	Thymoma by AJCC v8 Stage	A term that refers to the staging of thymoma, following the rules of the TNM AJCC v8 classification system.			Neoplastic Process	
C136346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136346>	C19770	Determination of Tumor DNA Mismatch Repair Status|Determination of Tumor MMR Status	An assessment of the DNA mismatch repair (MMR) status of a cancerous neoplasm.			Laboratory Procedure	
C136347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136347>	C172828	Were Itchy Question|Were Itchy|Were You Itchy|Were you itchy yesterday or today	A question about whether an individual feels or felt itchy.			Intellectual Product	Memorial Symptom Assessment Scale (MSAS) 7-12
C136348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136348>	C136345|C136322	Stage I Thymoma AJCC v8|Stage I Thymoma	Stage I includes: T1a, b, N0, M0. T1a: Tumor with no mediastinal pleura involvement. T1b: Tumor with direct invasion of mediastinal pleura. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Thymoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136349>	C136345|C136323	Stage II Thymoma AJCC v8|Stage II Thymoma	Stage II includes: T2, N0, M0. T2: Tumor with direct invasion of the pericardium (either partial or full thickness). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Thymoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13634>	C13372	Retinoic Acid Response Element|RARE	A cis-acting transcription regulatory element.  It is bound by the retinoic acid receptors.			Gene or Genome	
C136350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136350>	C136345|C136325	Stage III Thymoma AJCC v8|Stage III Thymoma	Stage III includes: IIIA: (T3, N0, M0); IIIB: (T4, N0, M0). T3: Tumor with direct invasion into any of the following: lung, brachiocephalic vein, superior vena cava, phrenic nerve, chest wall, or extrapericardial pulmonary artery or veins. T4: Tumor with invasion into any of the following: aorta (ascending, arch, or descending), arch vessels, intrapericardial pulmonary artery, myocardium, trachea, esophagus. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Thymoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136351>	C136350|C136327	Stage IIIA Thymoma AJCC v8|Stage IIIA Thymoma	Stage IIIA includes: T3, N0, M0. T3: Tumor with direct invasion into any of the following: lung, brachiocephalic vein, superior vena cava, phrenic nerve, chest wall, or extrapericardial pulmonary artery or veins. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIA Thymoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136352>	C136350|C136328	Stage IIIB Thymoma AJCC v8|Stage IIIB Thymoma	Stage IIIB includes: T4, N0, M0. T4: Tumor with invasion into any of the following: aorta (ascending, arch, or descending), arch vessels, intrapericardial pulmonary artery, myocardium, trachea, esophagus. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIB Thymoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136353>	C136345|C136329	Stage IV Thymoma AJCC v8|Stage IV Thymoma	Stage IV includes: IVA: (Any T, N1, M0); (Any T, N0,1, M1a); IVB: (Any T, N2, M0, M1a); (Any T, Any N, M1b). N0: No regional lymph node metastasis. N1: Metastasis in anterior (perithymic) lymph nodes. N2: Metastasis in deep intrathoracic or cervical lymph nodes. M0: No distant metastasis. M1a: Separate pleural or pericardial nodule(s). M1b: Pulmonary intraparenchymal nodule or distant organ metastasis. (AJCC 8th ed.)	Stage IV Thymoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136354>	C136353|C136330	Stage IVA Thymoma AJCC v8|Stage IVA Thymoma	Stage IVA includes: (Any T, N1, M0); (Any T, N0,1, M1a). N0: No regional lymph node metastasis. N1: Metastasis in anterior (perithymic) lymph nodes. M0: No distant metastasis. M1a: Separate pleural or pericardial nodule(s). (AJCC 8th ed.)	Stage IVA Thymoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136355>	C172828	How Much Time Itchy Question|How Much Time Itchy|How much of the time were you itchy	A question about how much of the time an individual was itchy.			Intellectual Product	Memorial Symptom Assessment Scale (MSAS) 7-12
C136356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136356>	C136353|C136331	Stage IVB Thymoma AJCC v8|Stage IVB Thymoma	Stage IVB includes: (Any T, N2, M0, M1a); (Any T, Any N, M1b). N2: Metastasis in deep intrathoracic or cervical lymph nodes. M0: No distant metastasis. M1a: Separate pleural or pericardial nodule(s). M1b: Pulmonary intraparenchymal nodule or distant organ metastasis. (AJCC 8th ed.)	Stage IVB Thymoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136357>	C172828	How Itchy Question|How Itchy|How itchy were you	A question about how itchy an individual was.			Intellectual Product	Memorial Symptom Assessment Scale (MSAS) 7-12
C136358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136358>	C173561|C172828	How Much Bothered by Being Itchy Question|How Much Bothered by Being Itchy|How Much Bothered or Troubled by Being Itchy|How much did being itchy bother you or trouble you	A question about how much being itchy bothered or troubled an individual.			Intellectual Product	Memorial Symptom Assessment Scale (MSAS) 7-12
C136359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136359>	C173346	How Much Time Have Pain Question|How Much Time Felt Pain|How Much Time Have Pain|How much of the time did you have pain	A question about how much of the time an individual felt pain.			Intellectual Product	Memorial Symptom Assessment Scale (MSAS) 7-12
C13635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13635>	C13313	bHLH-Zip Domain	Tripartite DNA binding domain containing a basic region, a helix-loop-helix, and a leucine zipper.			Amino Acid Sequence	
C136360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136360>	C173346	How Much Pain Felt Question|How Much Pain Felt|How much pain did you feel	A question about how much pain an individual felt.			Intellectual Product	
C136361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136361>	C173561|C173346	How Much Bothered by Pain Question|How Much Bothered by Pain|How Much Bothered or Troubled by Pain|How much did the pain bother you or trouble you	A question about how much pain bothered or troubled an individual.			Intellectual Product	Memorial Symptom Assessment Scale (MSAS) 7-12
C136362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136362>	C173934	How Much Time Feel Worried Question|How Much Time Feel Worried|How much of the time did you feel worried	A question about how much of the time an individual felt worried.			Intellectual Product	Memorial Symptom Assessment Scale (MSAS) 7-12
C136363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136363>	C173934	How Worried Question|How Worried|How Worried You Felt|How Worried You Felt|How worried did you feel	A question about how worried an individual feels or felt.			Intellectual Product	Memorial Symptom Assessment Scale (MSAS) 7-12
C136364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136364>	C173934|C173561	How Much Bothered by Feeling Worried Question|How Much Bothered by Feeling Worried|How Much Bothered by Worry|How Much Bothered or Troubled by Worry|How much did feeling worried bother you or trouble you	A question about how much feeling worried bothered or troubled an individual.			Intellectual Product	Memorial Symptom Assessment Scale (MSAS) 7-12
C136365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136365>	C188083|C173160	Feel Like Eating as Normal Question|Did you feel like eating yesterday or today as you normally do|Feel Like Eating as Normal	A question about whether an individual feels or felt like eating as normal.			Intellectual Product	Memorial Symptom Assessment Scale (MSAS) 7-12
C136366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136366>	C173160	How Long Not Feeling Like Eating Lasted Question|How Long Not Feeling Like Eating Lasted|How long did this last	A question about how long not feeling like eating lasted.			Intellectual Product	Memorial Symptom Assessment Scale (MSAS) 7-12
C136367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136367>	C173561|C173398|C173160	How Much Bothered by Not Feeling Like Eating Question|How Much Bothered by Not Feeling Like Eating|How Much Bothered or Troubled by Not Feeling Like Eating|How Much Not Feeling Like Eating Bothered or Troubled You|How much did this bother you or trouble you	A question about how bothered or troubled an individual was by not feeling like eating.			Intellectual Product	Memorial Symptom Assessment Scale (MSAS) 7-12
C136368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136368>	C173604|C173219	Feel Like Going to Vomit Question|Did you feel like you were going to vomit (or going to throw up) yesterday or today|Feel Like Going to Vomit|Feel Like Going to Vomit or Throw Up	A question about whether an individual feels or felt like they were going to vomit or throw up.			Intellectual Product	Memorial Symptom Assessment Scale (MSAS) 7-12
C136369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136369>	C173604|C173219	How Much of the Time Feel Like Could Vomit Question|How Much Time Feeling Like You Could Vomit or Throw Up|How Much of the Time Feel Like Could Vomit|How much of the time did you feel like you could vomit (or could throw up)	A question about how much of the time did an individual felt like they could vomit or throw up.			Intellectual Product	
C13636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13636>	C13367	HD-ZIP Domain	Bipartite DNA binding domain containing a homeo domain and a leucine zipper.			Amino Acid Sequence	
C136370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136370>	C173604|C173561|C173398|C173219	How Much Bothered by Feeling Like Could Vomit Question|How Much Bothered or Troubled by Feeling Like Could Vomit|How much did this feeling bother you or trouble you	A question about how much feeling like vomiting or throwing up bothered or troubled an individual.			Intellectual Product	Memorial Symptom Assessment Scale (MSAS) 7-12
C136371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136371>	C104294	Have Trouble Going To Sleep Question|Did you have trouble going to sleep the last 2 nights|Have Trouble Falling Asleep|Have Trouble Going To Sleep|I had trouble falling asleep	A question about whether an individual has or had trouble going to sleep.			Intellectual Product	Impact of Events Scale-Revised|Memorial Symptom Assessment Scale (MSAS) 7-12
C136372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136372>	C173925|C173561|C173398|C173045	How Much Bothered by Not Being Able to Sleep Question|How Much Bothered by Not Being Able to Sleep|How Much Bothered or Troubled by Not Being Able to Sleep|How much did not being able to sleep bother you or trouble you	A question about how much not being able to sleep bothered or troubled an individual.			Intellectual Product	Memorial Symptom Assessment Scale (MSAS) 7-12
C136373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136373>	C173561	How Much Bothered by Something Else Question|How Much Bothered by Something Else|How Much Bothered or Troubled by Something Else|How much did this bother you or trouble you	A question about how much anything else bothered or troubled an individual.			Intellectual Product	Memorial Symptom Assessment Scale (MSAS) 7-12
C136374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136374>	C222813	Pleural Diffuse Malignant Mesothelioma by AJCC v7 Stage	A term that refers to the staging of pleural diffuse malignant mesothelioma, following the rules of the TNM AJCC v7 classification system.			Neoplastic Process	
C136375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136375>	C18072	KNG1 Gene Product	A protein encoded by the KNG1 gene.			Amino Acid, Peptide, or Protein	
C136376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136376>	C1746	CALCA Gene Product	A protein encoded by the CALCA gene.			Amino Acid, Peptide, or Protein	
C136377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136377>	C136376	Calcitonin Precursor|Alpha-Type CGRP|CALCA|CGRP-I|Calcitonin|Calcitonin Gene-Related Peptide|Calcitonin Gene-Related Peptide 1|Calcitonin Gene-Related Peptide I|Prepro-CALCA|Preprocalcitonin	Calcitonin precursor (141 aa, ~15 kDa) is encoded by the human CALCA gene. This protein plays a role in calcium flux and bone resorption.	Calcitonin Precursor		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136378>	C173160	Anything Else Made You Feel Bad or Sick Question|Anything Else Made You Feel Bad or Sick|If you had anything else which made you feel bad or sick yesterday or today, write it here|Something Else Made You Feel Bad or Sick	A question about whether an individual has had anything else make them feel bad or sick.			Intellectual Product	Memorial Symptom Assessment Scale (MSAS) 7-12
C136379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136379>	C136292	Pleural Diffuse Malignant Mesothelioma TNM Finding v8	A finding about one or more characteristics of pleural malignant mesothelioma, following the rules of the TNM AJCC v8 classification system. This classification system applies to pleural diffuse malignant mesothelioma only. Localized pleural malignant mesotheliomas and other primary tumors of the pleura are not included in this classification. (from AJCC 8th Ed.)			Finding	
C13637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13637>	C13721|C13341	HT-Zip Domain	Bipartite DNA binding domain containing a helix-turn and a leucine zipper.			Amino Acid Sequence	
C136380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136380>	C136379	Pleural Diffuse Malignant Mesothelioma Clinical TNM Finding v8	A clinical finding about one or more characteristics of pleural diffuse malignant mesothelioma, following the rules of the TNM AJCC v8 classification system.			Finding	
C136381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136381>	C136380	Pleural Diffuse Malignant Mesothelioma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of pleural diffuse malignant mesothelioma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C136382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136382>	C136381	Pleural Diffuse Malignant Mesothelioma cM0 TNM Finding v8	Pleural diffuse malignant mesothelioma without distant metastasis. (from AJCC 8th Ed.)			Finding	
C136383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136383>	C136381	Pleural Diffuse Malignant Mesothelioma cM1 TNM Finding v8	Pleural diffuse malignant mesothelioma with distant metastasis. (from AJCC 8th Ed.)			Finding	
C136384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136384>	C136379	Pleural Diffuse Malignant Mesothelioma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of pleural diffuse malignant mesothelioma, following the rules of the TNM AJCC v8 classification system.			Finding	
C136385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136385>	C136384	Pleural Diffuse Malignant Mesothelioma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of pleural diffuse malignant mesothelioma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C136386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136386>	C136385	Pleural Diffuse Malignant Mesothelioma pM1 TNM Finding v8	Pleural diffuse malignant mesothelioma with distant metastasis. (from AJCC 8th Ed.)			Finding	
C136387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136387>	C136384	Pleural Diffuse Malignant Mesothelioma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of pleural diffuse malignant mesothelioma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C136388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136388>	C136387	Pleural Diffuse Malignant Mesothelioma pTX TNM Finding v8	Pleural diffuse malignant mesothelioma in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C136389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136389>	C136387	Pleural Diffuse Malignant Mesothelioma pT0 TNM Finding v8	Pleural diffuse malignant mesothelioma without evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C13638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13638>	C13432	15q21-q22	A chromosome band present on 15q			Gene or Genome	
C136390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136390>	C136387	Pleural Diffuse Malignant Mesothelioma pT1 TNM Finding v8	Pleural diffuse malignant mesothelioma with tumor limited to the ipsilateral parietal with or without involvement of visceral pleura, mediastinal pleura, and diaphragmatic pleura. (from AJCC 8th Ed.)			Finding	
C136391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136391>	C136387	Pleural Diffuse Malignant Mesothelioma pT2 TNM Finding v8	Pleural diffuse malignant mesothelioma with tumor involving each of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of diaphragmatic muscle and/or extension of tumor from visceral pleura into the underlying pulmonary parenchyma. (from AJCC 8th Ed.)			Finding	
C136392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136392>	C136387	Pleural Diffuse Malignant Mesothelioma pT3 TNM Finding v8	Pleural diffuse malignant mesothelioma in which the tumor is locally advanced but potentially resectable. The tumor involves all the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of the endothoracic fascia, extension into the mediastinal fat, solitary, completely resectable focus of tumor extending into the soft tissues of the chest wall, and/or nontransmural involvement of the pericardium. (from AJCC 8th Ed.)			Finding	
C136393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136393>	C136387	Pleural Diffuse Malignant Mesothelioma pT4 TNM Finding v8	Pleural diffuse malignant mesothelioma in which the tumor is locally advanced and technically unresectable. The tumor involves all the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: diffuse extension or multifocal masses of tumor in the chest wall, with or without associated rib destruction, direct transdiaphragmatic extension of tumor to the peritoneum, direct extension of tumor to the contralateral pleura, direct extension of tumor to mediastinal organs, direct extension of tumor into the spine, and/or tumor extending through to the internal surface of the pericardium with or without a pericardial effusion; or tumor involving the myocardium. (from AJCC 8th Ed.)			Finding	
C136394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136394>	C136384	Pleural Diffuse Malignant Mesothelioma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of pleural diffuse malignant mesothelioma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C136395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136395>	C136394	Pleural Diffuse Malignant Mesothelioma pNX TNM Finding v8	Pleural diffuse malignant mesothelioma in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)			Finding	
C136396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136396>	C136394	Pleural Diffuse Malignant Mesothelioma pN0 TNM Finding v8	Pleural diffuse malignant mesothelioma without regional lymph node metastases. (from AJCC 8th Ed.)			Finding	
C136397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136397>	C136394	Pleural Diffuse Malignant Mesothelioma pN1 TNM Finding v8	Pleural diffuse malignant mesothelioma with metastases in the ipsilateral bronchopulmonary, hilar, or mediastinal (including the internal mammary, peridiaphragmatic, pericardial fat pad, or intercostal) lymph nodes. (from AJCC 8th Ed.)			Finding	
C136398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136398>	C136394	Pleural Diffuse Malignant Mesothelioma pN2 TNM Finding v8	Pleural diffuse malignant mesothelioma with metastases in the contralateral mediastinal, ipsilateral, or contralateral supraclavicular lymph nodes. (from AJCC 8th Ed.)			Finding	
C136399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136399>	C222813	Pleural Diffuse Malignant Mesothelioma by AJCC v8 Stage	A term that refers to the staging of pleural malignant mesothelioma, following the rules of the TNM AJCC v8 classification system. This staging system applies to pleural diffuse malignant mesothelioma only. Localized pleural malignant mesotheliomas and other primary tumors of the pleura are not staged using this staging system. (from AJCC 8th Ed.)			Neoplastic Process	
C13639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13639>	C13445	Poly-A Addition Site	The site within the 3' untranslated region of a gene where polyadenylation of the transcribed RNA takes place.  Usually consists of the sequence AATAAA.			Nucleotide Sequence	
C1363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1363>	C292	Diaziquone|1,4-Cyclohexadiene-1,4-dicarbamic acid, 2, 5-bis(1-aziridinyl)-3,6-dioxo-, diethyl ester|1,4-cyclohexadiene-1,4-dicarbamic acid, 2, 5-bis(1-aziridinyl)-3,6-dioxo-, diethyl ester|1,4-cyclohexadiene-1,4-dicarbamic acid,2,5-bis(1-aziridinyl)-3,6-dioxo,-diethyl ester|2,5-bis(1-aciridinyl)-3,6-bis(ethoxycarbonylamino)-1,4-benzoquinone|2,5-bis(1-aziridinyl)-3,6-bis(ethoxycarbonylamino)-1,4-benzoquinone|2,5-bis(1-aziridinyl)-3,6-dioxo-1,4-cyclohexadiene-1,4-dicarbamic acid diethyl ester|2,5-diaziridinyl-3,6-bis(ethoxycarbonyl-amino)-1,4-benzoquinone|AZQ|AZQ|Aziridinyl Benzoquinone|Aziridinylbenzoquinone|Aziridinylbenzoquinone carbamic acid|CI-904|Carbamic acid, [2,5-bis(1-aziridinyl)-3,6-dioxo-1, 4-cyclohexadiene-1,4-diyl]bis-, diethyl ester (9CI)|DIAZIQUONE|[2,5-bis(1-aziridinyl)-3,6-dioxo-1,4-cyclohexadiene-1,4-diyl]biscarbamic acid diethyl ester|carbamic acid, [2,5-bis(1-aziridinyl)-3,6-dioxo-1, 4-cyclohexadiene-1,4-diyl]bis-, diethyl ester (9CI)|diaziquone	A water-soluble, synthetic aziridinylbenzoquinone with potential antineoplastic activity. Bioactivation of aziridinylbenzoquinone RH1 occurs through the two-electron reduction of the quinone to the hydroquinone by the two-electron quinone reductase DT-diaphorase (DTD). The resultant hydroquinone selectively alkylates and cross-links DNA at the 5'-GNC-3' sequence, inihibiting DNA replication, inducing apoptosis, and inhibiting tumor cell proliferation. DTD is over-expressed in many tumors relative to normal tissue, including lung, colon, breast and liver tumors.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C136400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136400>	C136399	Stage I Pleural Diffuse Malignant Mesothelioma AJCC v8|Stage I Pleural Malignant Mesothelioma	Stage I includes: IA: (T1, N0, M0); IB: (T2 or T3, N0, M0). T1: Tumor limited to the ipsilateral parietal with or without involvement of visceral pleura, mediastinal pleura, and diaphragmatic pleura. T2: Tumor involving each of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of diaphragmatic muscle and/or extension of tumor from visceral pleura into the underlying pulmonary parenchyma. T3: Tumor is locally advanced but potentially resectable. The tumor involves all the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of the endothoracic fascia, extension into the mediastinal fat, solitary, completely resectable focus of tumor extending into the soft tissues of the chest wall, and/or nontransmural involvement of the pericardium. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Pleural Malignant Mesothelioma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136401>	C136400	Stage IB Pleural Diffuse Malignant Mesothelioma AJCC v8|Stage IB Pleural Malignant Mesothelioma	Stage IB includes: T2 or T3, N0, M0. T2: Tumor involving each of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of diaphragmatic muscle and/or extension of tumor from visceral pleura into the underlying pulmonary parenchyma. T3: Tumor is locally advanced but potentially resectable. The tumor involves all the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of the endothoracic fascia, extension into the mediastinal fat, solitary, completely resectable focus of tumor extending into the soft tissues of the chest wall, and/or nontransmural involvement of the pericardium. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)	Stage IB Pleural Malignant Mesothelioma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136402>	C136399	Stage II Pleural Diffuse Malignant Mesothelioma AJCC v8|Stage II Pleural Malignant Mesothelioma	Stage II includes: (T1, N1, M0); (T2, N1, M0). T1: Tumor limited to the ipsilateral parietal with or without involvement of visceral pleura, mediastinal pleura, and diaphragmatic pleura. T2: Tumor involving each of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of diaphragmatic muscle and/or extension of tumor from visceral pleura into the underlying pulmonary parenchyma. N1: Metastases in the ipsilateral bronchopulmonary, hilar, or mediastinal (including the internal mammary, peridiaphragmatic, pericardial fat pad, or intercostal) lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Pleural Malignant Mesothelioma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136403>	C136399	Stage III Pleural Diffuse Malignant Mesothelioma AJCC v8|Stage III Pleural Malignant Mesothelioma	Stage III includes: IIIA: (T3, N1, M0); IIIB: (T1-3, N2, M0); (T4, Any N, M0). T1: Tumor limited to the ipsilateral parietal with or without involvement of visceral pleura, mediastinal pleura, and diaphragmatic pleura. T2: Tumor involving each of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of diaphragmatic muscle and/or extension of tumor from visceral pleura into the underlying pulmonary parenchyma. T3: Tumor is locally advanced but potentially resectable. The tumor involves all the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of the endothoracic fascia, extension into the mediastinal fat, solitary, completely resectable focus of tumor extending into the soft tissues of the chest wall, and/or nontransmural involvement of the pericardium. T4: Tumor is locally advanced and technically unresectable. The tumor involves all the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: diffuse extension or multifocal masses of tumor in the chest wall, with or without associated rib destruction, direct transdiaphragmatic extension of tumor to the peritoneum, direct extension of tumor to the contralateral pleura, direct extension of tumor to mediastinal organs, direct extension of tumor into the spine, and/or tumor extending through to the internal surface of the pericardium with or without a pericardial effusion; or tumor involving the myocardium. N1: Metastases in the ipsilateral bronchopulmonary, hilar, or mediastinal (including the internal mammary, peridiaphragmatic, pericardial fat pad, or intercostal) lymph nodes. N2: Metastases in the contralateral mediastinal, ipsilateral, or contralateral supraclavicular lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Pleural Malignant Mesothelioma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136404>	C136403	Stage IIIA Pleural Diffuse Malignant Mesothelioma AJCC v8|Stage IIIA Pleural Malignant Mesothelioma	Stage IIIA includes: T3, N1, M0. T3: Tumor is locally advanced but potentially resectable. The tumor involves all the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of the endothoracic fascia, extension into the mediastinal fat, solitary, completely resectable focus of tumor extending into the soft tissues of the chest wall, and/or nontransmural involvement of the pericardium. N1: Metastases in the ipsilateral bronchopulmonary, hilar, or mediastinal (including the internal mammary, peridiaphragmatic, pericardial fat pad, or intercostal) lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIA Pleural Malignant Mesothelioma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136405>	C136403	Stage IIIB Pleural Diffuse Malignant Mesothelioma AJCC v8|Stage IIIB Pleural Malignant Mesothelioma	Stage IIIB includes: (T1-3, N2, M0); (T4, Any N, M0). T1: Tumor limited to the ipsilateral parietal with or without involvement of visceral pleura, mediastinal pleura, and diaphragmatic pleura. T2: Tumor involving each of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of diaphragmatic muscle and/or extension of tumor from visceral pleura into the underlying pulmonary parenchyma. T3: Tumor is locally advanced but potentially resectable. The tumor involves all the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: involvement of the endothoracic fascia, extension into the mediastinal fat, solitary, completely resectable focus of tumor extending into the soft tissues of the chest wall, and/or nontransmural involvement of the pericardium. T4: Tumor is locally advanced and technically unresectable. The tumor involves all the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following features: diffuse extension or multifocal masses of tumor in the chest wall, with or without associated rib destruction, direct transdiaphragmatic extension of tumor to the peritoneum, direct extension of tumor to the contralateral pleura, direct extension of tumor to mediastinal organs, direct extension of tumor into the spine, and/or tumor extending through to the internal surface of the pericardium with or without a pericardial effusion; or tumor involving the myocardium. N2: Metastases in the contralateral mediastinal, ipsilateral, or contralateral supraclavicular lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIB Pleural Malignant Mesothelioma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136406>	C136399	Stage IV Pleural Diffuse Malignant Mesothelioma AJCC v8|Stage IV Pleural Malignant Mesothelioma	Stage IV includes: Any T, Any N, M1. M1: Distant metastasis present. (AJCC 8th ed.)	Stage IV Pleural Malignant Mesothelioma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136407>	C2270	GNRH1 Gene Product	A protein encoded by the GNRH1 gene.			Amino Acid, Peptide, or Protein	
C136408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136408>	C136407	Gonadoliberin-1|GNRH1|GnRH I|GnRH-Associated Peptide I|GnRH-I|Gonadoliberin 1|Gonadoliberin I|Gonadorelin|Gonadotropin Releasing Hormone 1|Gonadotropin-Releasing Hormone 1|Gonadotropin-Releasing Hormone I|LH-RH I|Leutinizing-Releasing Hormone|Luliberin I|Luteinizing Hormone-Releasing Hormone I|PIF|Prolactin Release-Inhibiting Factor	Gonadoliberin-1 (10 aa, ~1 kDa) is encoded by the human GNRH1 gene. This protein is involved in stimulating the secretion of both luteinizing and follicle-stimulating hormones (LH and FSH, respectively).			Amino Acid, Peptide, or Protein|Hormone	
C136409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136409>	C136400	Stage IA Pleural Diffuse Malignant Mesothelioma AJCC v8|Stage IA Pleural Malignant Mesothelioma	Stage IA includes: T1, N0, M0. T1: Tumor limited to the ipsilateral parietal with or without involvement of visceral pleura, mediastinal pleura, and diaphragmatic pleura. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)	Stage IA Pleural Malignant Mesothelioma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13640>	C13432	5q21	A chromosome band present on 5q			Gene or Genome	
C136410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136410>	C8881|C6447|C3537	Malignant Retroperitoneal Germ Cell Tumor	A rare malignant germ cell tumor that arises from the retroperitoneum.	Malignant Retroperitoneal Germ Cell Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136411>	C167155	Blasts 5 Percent or More of Bone Marrow Nucleated Cells|Blasts Greater than or Equal to 5 Percent of Bone Marrow Nucleated Cells	A microscopic finding indicating the presence of blasts constituting at least 5% of the nucleated cells in a bone marrow aspirate.	Blasts 5 Percent or More of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C136412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136412>	C2183	TRH Gene Product	A protein encoded by the TRH gene.			Amino Acid, Peptide, or Protein	
C136413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136413>	C136412	Thyrotropin-Releasing Hormone|TRF|TRH|TSH-Releasing Factor|Thyroliberin|Thyrotropin Releasing Hormone|Thyrotropin-Releasing Factor	Thyrotropin-releasing hormone (3 aa, ~0.4  kDa) is encoded by the human TRH gene. This protein plays a role in the positive regulation of thyrotropin (thyroid-stimulating hormone; TSH) production and release.			Amino Acid, Peptide, or Protein|Hormone	
C136414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136414>	C63442	EPOCH-O Regimen|DA EPOCH-O|Dose-Adjusted Etoposide-Prednisone- Vincristine-Cyclophosphamide-Ofatumumab|Dose-adjusted EPOCH-Ofatumumab|Dose-adjusted Etoposide/Vincristine/Doxorubicin/Cyclophosphamide/Prednisone Plus Ofatumumab Regimen|EPOCH Plus Arzerra|EPOCH Plus Ofatumumab|EPOCH-O|Etoposide-Prednisone-Oncovin-Cyclophosphamide-Hydroxydaunorubicin-Ofatumumab Regimen|O-EPOCH|O-EPOCH Regimen	A regimen consisting of etoposide, prednisone, vincristine (Oncovin), cyclophosphamide, doxorubicin (hydroxydaunorubicin) and ofatumumab, which may be used for the treatment of various aggressive non-Hodgkin lymphomas.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|NCI Drug Dictionary Terminology|Pharmacotherapy Regimens
C136415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136415>	C138961	PSA Level Less than Two|<2|Less than Two|PSA Level Less than 2	An indication that a blood concentration of prostate specific antigen below 2 ng/mL was detected in a sample.	PSA Level Less than Two		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136416>	C213692|C129825	Vecabrutinib|BIIB-062|BIIB062|BSK-4841|FP-182|SNS 062|SNS-062|SNS062|VECABRUTINIB	An orally available second-generation, reversible inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), with potential antineoplastic activity. Upon administration, vecabrutinib non-covalently binds to and inhibits the activity of both wild-type and the C481S mutated form of BTK, a resistance mutation in the BTK active site in which cysteine is substituted for serine at residue 481. This prevents the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B-cells that overexpress BTK. Compared to other BTK inhibitors, SNS-062 does not require interaction with the BTK C481 site and inhibits the proliferation of cells harboring the BTK C481S mutation. Other irreversible BTK inhibitors covalently bind to the C481 site to inhibit BTK's activity; the C481S mutation prevents that binding. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.	Vecabrutinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C136417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136417>	C141240	PDGFR Family Gene Mutation|Mutant PDGFR|Mutant PDGFR Family Gene|PDGFR Family Mutation|PDGFR Gene Mutation|PDGFR Mutation|Platelet Derived Growth Factor Receptor Family Gene Mutation	A change in the nucleotide sequence in a PDGFR family gene.	PDGFR Family Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C136418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136418>	C129825	NEDD8 Activating Enzyme E1 Inhibitor TAS4464|NAE Inhibitor TAS4464|TAS-4464|TAS4464	An inhibitor of NEDD8 (neural precursor cell expressed, developmentally down-regulated 8) activating enzyme E1 (NAE), with potential antineoplastic activity. Upon administration, TAS4464 selectively binds to and inhibits NAE, which prevents NAE/NEDD8-mediated signaling and prevents the NEDD8 conjugation of cullin-RING ligase complexes (CRLs). This inactivates the CRLs leading to an accumulation of CRL substrate proteins, such as CDT1, p27, p21 and phosphorylated IkappaB, and inactivates nuclear factor-kappaB (NF-kB) as well as downregulates anti-apoptotic proteins. This causes cell cycle dysregulation, induces apoptosis, and inhibits tumor cell proliferation and survival. NAE catalyzes the first step in the NEDD8 conjugation (neddylation) pathway which controls cancer cell growth and survival through activation of CRLs.	NEDD8 Activating Enzyme E1 Inhibitor TAS4464		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C136419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136419>	C141240	VEGFR Family Gene Mutation|Mutant VEGFR|Mutant VEGFR Family Gene|VEGFR Family Mutation|VEGFR Mutation|Vascular Endothelial Growth Factor Receptor Family Gene Mutation	A change in the nucleotide sequence in a VEGFR family gene.	VEGFR Family Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13641>	C13432	10q24.3-10qter	A chromosome band present on 10q			Gene or Genome	
C136420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136420>	C36327	JAK Family Gene Mutation|JAK Family Mutation|JAK Mutation|Janus Kinase Family Gene Mutation|Mutant JAK|Mutant JAK Family Gene	A change in the nucleotide sequence in a JAK family gene.	JAK Family Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136421>	C36327	STAT Family Gene Mutation|Mutant STAT|Mutant STAT Family Gene|STAT Family Mutation|STAT Mutation|Signal Transducer and Activator of Transcription Family Gene Mutation	A change in the nucleotide sequence in a STAT family gene.	STAT Family Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136422>	C36327	MEK Family Gene Mutation|MAP2K Family Gene Mutation|MAPKK Family Gene Mutation|MEK Family Mutation|MEK Mutation|Mitogen-Activated Protein Kinase Kinase Family Gene Mutation|Mutant MEK|Mutant MEK Family Gene	A change in the nucleotide sequence in a MEK family gene.	MEK Family Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136423>	C36327	ERK Family Gene Mutation|ERK Family Mutation|ERK Gene Mutation|ERK Mutation|Extracellular Signal-Regulated Kinase Family Gene Mutation|MAP Kinase Family Gene Mutation|MAPK Family Gene Mutation|MAPK Gene Mutation|Mitogen-Activated Protein Kinase Family Gene Mutation|Mutant ERK|Mutant ERK Family Gene	A change in the nucleotide sequence in a ERK family gene.	ERK Family Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136425>	C36327	RAF Family Gene Mutation|Mutant RAF|Mutant RAF Family Gene|RAF Family Mutation|RAF Mutation|Rapidly Accelerated Fibrosarcoma Family Gene Mutation|Rapidly Accelerated Fibrosarcoma Family Kinase Gene Mutation	A change in the nucleotide sequence in a RAF family gene.	RAF Family Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136426>	C129823	Anti-GD3 Antibody-drug Conjugate PF-06688992|Anti-GD3 ADC PF-06688992|GD3 ADC PF-06688992|PF 06688992|PF-06688992|PF-06688992	An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the ganglioside GD3, a surface antigen expressed on many malignant melanoma cells, and linked to an as of yet not fully elucidated chemotherapeutic agent, with potential antineoplastic activity. Upon administration of the ADC PF-06688992, the antibody moiety targets and binds to GD3 expressed on melanoma cells. Upon internalization, the chemotherapeutic agent specifically kills the GD3-positive cells. GD3 represents a major surface marker on most human melanoma cells and is not expressed on most other types of normal, healthy cells.	Anti-GD3 Antibody-drug Conjugate PF-06688992		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C136427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136427>	C34447|C224628|C165174	Unresectable Head and Neck Squamous Cell Carcinoma	A squamous cell carcinoma that arises from the head and neck region and is not amenable to surgical resection.			Neoplastic Process	
C136428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136428>	C932|C1450	Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6|Cisplatin/Vinblastine Formulation with Cell Penetration Enhancer INT230-6|INT 230-6|INT230-6	A formulation composed of three agents in a fixed ratio: two chemotherapeutic agents, the platinum compound cisplatin and the vinca alkaloid vinblastine, and a proprietary amphiphilic excipient that acts as a penetration enhancer, with potential antineoplastic activity. Upon intra-tumoral (IT) injection of INT230-6, the dispersion/cell penetration enhancer excipient of INT230-6 facilitates dispersion of the two drugs throughout the tumor tissue and enables increased cellular uptake of these agents into tumor cells. Once inside the cell, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, which results in apoptosis and cell growth inhibition. Vinblastine kills the tumor cells through binding to tubulin and thereby inhibits microtubule formation, resulting in disruption of the mitotic spindle assembly and cell cycle arrest of tumor. In addition, the tumor cell killing leads to recruitment of dendritic cells (DCs) and induces a tumor-specific T-cell-mediated immune response that attacks both the injected tumor and distant tumor lesions. Local administration of both cisplatin and vinblastine, without the diffusion/penetration enhancer, results in to poor diffusion and a lack of cellular uptake of the agents; INT230-6 increases the intracellular concentration of cisplatin and vinblastine, thereby improving efficacy.	Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C136429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136429>	C94726	Extended-release Granisetron Polymer Formulation|ER Granisetron Injectable Formulation|Granisetron Extended-release Injection|Granisetron Extended-release Polymer-based Injectable Formulation|Sustol	An extended-release (ER), polymer-based injectable formulation containing the indazole derivative granisetron, a selective serotonin (5-hydroxytryptamine; 5-HT) receptor type 3 (5-HT3) antagonist, with anti-emetic activity. Upon subcutaneous administration, granisetron is released from the polymer in a sustained manner, which is based upon the controlled hydrolysis of the polymers, and selectively binds to and inhibits the activity of the 5-HT3 receptors located peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone (CTZ) of the area postrema. By preventing stimulation of 5-HT3 receptors, granisetron is able to suppress chemotherapy-induced nausea and vomiting (CINV). Compared to the injection of granisetron alone, injection of the polymer-based formulation allows for therapeutic levels of granisetron over an extended period of time.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C13642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13642>	C13432	15q23-15q24	A chromosome band present on 15q			Gene or Genome	
C136430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136430>	C136292	Lung Cancer TNM Finding v8	A finding about one or more characteristics of lung cancer, following the rules of the TNM AJCC v8 classification system. This classification system derives from analyses of the new retrospective and prospective databases of the International Association for the Study of Lung Cancer (IASLC). These databases contain information on patients diagnosed with lung cancer from 1999 to 2010 originating from 35 different databases in 16 countries around the world. This classification system applies to carcinomas of the lung, including non-small cell and small cell carcinomas, and bronchopulmonary carcinoid tumors. It does not apply to sarcomas or other rare tumors of the lung. (from AJCC 8th Ed.)			Finding	
C136431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136431>	C136430	Lung Cancer Clinical TNM Finding v8	A clinical finding about one or more characteristics of lung cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C136432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136432>	C136431	Lung Cancer Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of lung cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C136433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136433>	C136432	Lung Cancer cM0 TNM Finding v8|cM0	Lung cancer without distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C136434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136434>	C136432	Lung Cancer cM1 TNM Finding v8|cM1	Lung cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C136435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136435>	C136434	Lung Cancer cM1a TNM Finding v8|cM1a	Lung cancer with separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodules or malignant pleural or pericardial effusion. Most pleural (pericardial) effusions with lung cancer are a result of the tumor. In a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumor, and the fluid is nonbloody and not an exudate. If these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging descriptor. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C136436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136436>	C136434	Lung Cancer cM1b TNM Finding v8|cM1b	Lung cancer with single extrathoracic metastasis in a single organ (including involvement of a single nonregional node). (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C136437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136437>	C136434	Lung Cancer cM1c TNM Finding v8	Lung cancer with multiple extrathoracic metastases in a single organ or in multiple organs. (from AJCC 8th Ed.)			Finding	
C136438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136438>	C136430	Lung Cancer Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of lung cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C136439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136439>	C136438	Lung Cancer Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of lung cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C13643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13643>	C13432	16q22.2	A chromosome band present on 16q			Gene or Genome	
C136440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136440>	C136439	Lung Cancer pM1 TNM Finding v8	Lung cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C136441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136441>	C136440	Lung Cancer pM1a TNM Finding v8	Lung cancer with separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodules or malignant pleural or pericardial effusion. Most pleural (pericardial) effusions with lung cancer are a result of the tumor. In a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumor, and the fluid is nonbloody and not an exudate. If these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging descriptor. (from AJCC 8th Ed.)			Finding	
C136442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136442>	C136440	Lung Cancer pM1b TNM Finding v8	Lung cancer with single extrathoracic metastasis in a single organ (including involvement of a single nonregional node). (from AJCC 8th Ed.)			Finding	
C136443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136443>	C136440	Lung Cancer pM1c TNM Finding v8	Lung cancer with multiple extrathoracic metastases in a single organ or in multiple organs. (from AJCC 8th Ed.)			Finding	
C136444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136444>	C136438	Lung Cancer Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of lung cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C136445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136445>	C136444	Lung Cancer pTX TNM Finding v8	Lung cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C136446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136446>	C136444	Lung Cancer pT0 TNM Finding v8	Lung cancer without evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C136447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136447>	C136444	Lung Cancer pTis TNM Finding v8	Lung cancer with a finding of carcinoma in situ. Squamous cell carcinoma in situ (SCIS). Adenocarcinoma in situ (AIS): adenocarcinoma with pure lepidic pattern, 3 cm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C136448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136448>	C136444	Lung Cancer pT1 TNM Finding v8	Lung cancer with tumor 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus). (from AJCC 8th Ed.)			Finding	
C136449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136449>	C136448	Lung Cancer pT1mi TNM Finding v8	Lung cancer with minimally invasive adenocarcinoma: adenocarcinoma (3 cm or less in greatest dimension) with a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. (from AJCC 8th Ed.)			Finding	
C13644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13644>	C13432	2p23	A chromosome band present on 2p			Gene or Genome	
C136450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136450>	C136448	Lung Cancer pT1a TNM Finding v8	Lung cancer with tumor 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. (from AJCC 8th Ed.)			Finding	
C136451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136451>	C136448	Lung Cancer pT1b TNM Finding v8	Lung cancer with tumor measuring more than 1 cm but 2 cm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C136452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136452>	C136448	Lung Cancer pT1c TNM Finding v8	Lung cancer with tumor measuring more than 2 cm but 3 cm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C136453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136453>	C136444	Lung Cancer pT2 TNM Finding v8	Lung cancer with tumor measuring more than 3 cm but 5 cm or less in greatest dimension or having any of the following features: involves the main bronchus regardless of distance to the carina, but without involvement of the carina, invades visceral pleura (extends through the elastic layer-PL1 or extends to the surface of the visceral pleura-PL2), or is associated with atelectasis or obstructive pneumonitis that extends to the hilar region, involving part or all of the lung. T2 tumors with these features are classified as T2a if they measure 4 cm or less or if the size cannot be determined and T2b if they measure more than 4 cm but 5 cm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C136454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136454>	C136453	Lung Cancer pT2a TNM Finding v8	Lung cancer with tumor measuring more than 3 cm but 4 cm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C136455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136455>	C136453	Lung Cancer pT2b TNM Finding v8	Lung cancer with tumor measuring more than 4 cm but 5 cm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C136456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136456>	C136444	Lung Cancer pT3 TNM Finding v8	Lung cancer with tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. (from AJCC 8th Ed.)			Finding	
C136457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136457>	C136444	Lung Cancer pT4 TNM Finding v8	Lung cancer with tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. (from AJCC 8th Ed.)			Finding	
C136458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136458>	C136438	Lung Cancer Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of lung cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C136459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136459>	C136458	Lung Cancer pNX TNM Finding v8	Lung cancer in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)			Finding	
C13645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13645>	C13432	9q34	A chromosome band present on 9q			Gene or Genome	
C136460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136460>	C136458	Lung Cancer pN0 TNM Finding v8	Lung cancer without regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C136461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136461>	C136458	Lung Cancer pN1 TNM Finding v8	Lung cancer with metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. (from AJCC 8th Ed.)			Finding	
C136462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136462>	C136458	Lung Cancer pN2 TNM Finding v8	Lung cancer with metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s). (from AJCC 8th Ed.)			Finding	
C136463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136463>	C136458	Lung Cancer pN3 TNM Finding v8	Lung cancer with metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s). (from AJCC 8th Ed.)			Finding	
C136464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136464>	C53543	Acrodysostosis 1|ACRDYS1	An autosomal dominant skeletal dysplasia caused by mutation(s) in the PRKAR1A gene, encoding cAMP-dependent protein kinase type I-alpha regulatory subunit. It is characterized by short stature, brachydactyly, and characteristic facial features.  Resistance to multiple hormones is a common finding.			Disease or Syndrome	
C136465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136465>	C129822|C128037	Balstilimab|AGEN 2034|AGEN-2034|AGEN2034|BALSTILIMAB	A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1; PDCD1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, balstilimab binds to PD-1, and thereby blocks its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-cells. PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.	Balstilimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C136466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136466>	C1663	Personalized Genomic Vaccine 001|Multi-Peptide Therapeutic Vaccine 001|PGV 001|PGV-001|PGV001|Personalized Peptide Vaccine 001|Personalized Peptides Plus Poly-ICLC Vaccine 001	A synthetic peptide-based, personalized cancer vaccine consisting of multiple patient-specific tumor peptides, which are immunogenic and unique to the patient's tumor, combined with the immunostimulant polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC), with potential immunomodulating and antineoplastic activities. Upon vaccination with the personalized genomic vaccine 001 (PGV001), the peptides stimulate the host immune system to mount a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. The adjuvant Poly-ICLC is added to boost the immune response to the peptides and together will expand immune cells to target cancer. The adjuvant poly-ICLC is a ligand for toll-like receptor-3 (TLR3) and induces the release of cytokines which may help to boost the immune response against the selected neoantigens.			Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology
C136467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136467>	C4878	Lung Cancer by AJCC v8 Stage|Tumor Stage (Pathological)	A term that refers to the staging of lung cancer, following the rules of the TNM AJCC v8 classification system. This staging system derives from analyses of the new retrospective and prospective databases of the International Association for the Study of Lung Cancer (IASLC). These databases contain information on patients diagnosed with lung cancer from 1999 to 2010 originating from 35 different databases in 16 countries around the world. This staging system applies to carcinomas of the lung, including non-small cell and small cell carcinomas, and bronchopulmonary carcinoid tumors. It does not apply to sarcomas or other rare tumors of the lung. (AJCC 8th Ed.)			Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C136468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136468>	C5641|C136467	Occult Lung Cancer AJCC v8|Occult Lung Cancer|Occult Lung Carcinoma AJCC v8	Occult lung cancer includes: TX, N0, M0. TX: Primary tumor cannot be assessed. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Occult Lung Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136469>	C136467	Stage 0 Lung Cancer AJCC v8|Stage 0 Lung Cancer|Stage 0 Lung Carcinoma AJCC v8	Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. Squamous cell carcinoma in situ (SCIS). Adenocarcinoma in situ (AIS): adenocarcinoma with pure lepidic pattern, 3 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0 Lung Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13646>	C13432	16p13.3	A chromosome band present on 16p			Gene or Genome	
C136470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136470>	C136467	Stage I Lung Cancer AJCC v8|Stage I|Stage I Lung Cancer	Stage I includes: IA1: (T1mi, N0, M0); (T1a, N0, M0); IA2: (T1b, N0, M0); IA3: (T1c, N0, M0); IB: (T2a, N0, M0). T1mi: Minimally invasive adenocarcinoma: adenocarcinoma (3 cm or less in greatest dimension) with a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Lung Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C136471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136471>	C136470	Stage IA1 Lung Cancer AJCC v8|Stage IA1 Lung Cancer	Stage IA1 includes: (T1mi, N0, M0); (T1a, N0, M0). T1mi: Minimally invasive adenocarcinoma: adenocarcinoma (3 cm or less in greatest dimension) with a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)	Stage IA1 Lung Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136472>	C136470	Stage IA2 Lung Cancer AJCC v8|Stage IA2 Lung Cancer	Stage IA2 includes: T1b, N0, M0. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)	Stage IA2 Lung Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136473>	C136470	Stage IA3 Lung Cancer AJCC v8|Stage IA3 Lung Cancer	Stage IA3 includes: T1c, N0, M0. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)	Stage IA3 Lung Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136474>	C136470	Stage IB Lung Cancer AJCC v8|Stage IB|Stage IB Lung Cancer	Stage IB includes: T2a, N0, M0. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)	Stage IB Lung Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C136475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136475>	C136467	Stage II Lung Cancer AJCC v8|Stage II|Stage II Lung Cancer	Stage II includes: IIA: (T2b, N0, M0); IIB: (T1a, N1, M0); (T1b, N1, M0); (T1c, N1, M0); (T2a, N1, M0); (T2b, N1, M0); (T3, N0, M0). T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension.  T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension.  T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. N0: No regional lymph node metastases. N1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Lung Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C136476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136476>	C136475	Stage IIA Lung Cancer AJCC v8|Stage IIA|Stage IIA Lung Cancer	Stage IIA includes: T2b, N0, M0. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension.  N0: No regional lymph node metastases. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIA Lung Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C136477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136477>	C136475	Stage IIB Lung Cancer AJCC v8|Stage IIB|Stage IIB Lung Cancer	Stage IIB includes: (T1a, N1, M0); (T1b, N1, M0); (T1c, N1, M0); (T2a, N1, M0); (T2b, N1, M0); (T3, N0, M0). T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. N0: No regional lymph node metastases. N1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIB Lung Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C136478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136478>	C136467	Stage III Lung Cancer AJCC v8|Stage III|Stage III Lung Cancer	Stage III includes: IIIA: (T1a, N2, M0); (T1b, N2, M0); (T1c, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T4, N0, M0); (T4, N1, M0); IIIB: (T1a, N3, M0); (T1b, N3, M0); (T1c, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N2, M0); (T4, N2, M0); IIIC: (T3, N3, M0); (T4, N3, M0). T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. T4: Tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. N0: No regional lymph node metastases. N1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. N2: Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s). N3: Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)	Stage III Lung Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C136479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136479>	C136478	Stage IIIA Lung Cancer AJCC v8|Stage IIIA|Stage IIIA Lung Cancer	Stage IIIA includes: (T1a, N2, M0); (T1b, N2, M0); (T1c, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T4, N0, M0); (T4, N1, M0). T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. T4: Tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. N0: No regional lymph node metastases. N1: Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension. N2: Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIA Lung Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C13647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13647>	C13432	2p22-p21	A chromosome band present on 2p			Gene or Genome	
C136480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136480>	C136478	Stage IIIB Lung Cancer AJCC v8|Stage IIIB|Stage IIIB Lung Cancer	Stage IIIB includes: (T1a, N3, M0); (T1b, N3, M0); (T1c, N3, M0); (T2a, N3, M0); (T2b, N3, M0); (T3, N2, M0); (T4, N2, M0). T1a: Tumor measuring 1 cm or less in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon. T1b: Tumor measuring more than 1 cm but 2 cm or less in greatest dimension. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. T2a: Tumor measuring more than 3 cm but 4 cm or less in greatest dimension. T2b: Tumor measuring more than 4 cm but 5 cm or less in greatest dimension. T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. T4: Tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. N2: Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s). N3: Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIB Lung Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C136481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136481>	C136478	Stage IIIC Lung Cancer AJCC v8|Stage IIIC Lung Cancer	Stage IIIC includes: (T3, N3, M0); (T4, N3, M0). T3: Tumor measuring more than 5 cm but 7 cm or less in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary. T4: Tumor measuring more than 7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary. N3: Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIC Lung Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136482>	C136467	Stage IV Lung Cancer AJCC v8|Stage IV|Stage IV Lung Cancer	Stage IV includes: IVA: (Any T, Any N, M1a); (Any T, Any N, M1b); IVB: (Any T, Any N, M1c). M1a: Tumor with separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodules or malignant pleural or pericardial effusion. Most pleural (pericardial) effusions with lung cancer are a result of the tumor. In a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumor, and the fluid is nonbloody and not an exudate. If these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging descriptor. M1b: Tumor with single extrathoracic metastasis in a single organ (including involvement of a single nonregional node). M1c: Tumor with multiple extrathoracic metastases in a single organ or in multiple organs. (AJCC 8th ed.)	Stage IV Lung Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C136483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136483>	C136482	Stage IVA Lung Cancer AJCC v8|Stage IVA Lung Cancer	Stage IVA includes: (Any T, Any N, M1a); (Any T, Any N, M1b). M1a: Tumor with separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodules or malignant pleural or pericardial effusion. Most pleural (pericardial) effusions with lung cancer are a result of the tumor. In a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumor, and the fluid is nonbloody and not an exudate. If these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging descriptor. M1b: Tumor with single extrathoracic metastasis in a single organ (including involvement of a single nonregional node). (AJCC 8th ed.)	Stage IVA Lung Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136484>	C136482	Stage IVB Lung Cancer AJCC v8|Stage IVB Lung Cancer	Stage IVB includes: Any T, Any N, M1c. M1c: Tumor with multiple extrathoracic metastases in a single organ or in multiple organs. (AJCC 8th ed.)	Stage IVB Lung Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136485>	C27975	Stage IA3	A stage term referring to invasive lung cancer. It includes: T1c, N0, M0. T1c: Tumor measuring more than 2 cm but 3 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (adapted from AJCC)			Clinical Attribute	GDC Terminology|GDC Value Terminology
C136486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136486>	C4123|C3512|C226343	Lung Adenocarcinoma In Situ|Bronchioloalveolar Carcinoma|Lung AIS	A localized non-invasive adenocarcinoma of the lung measuring 3 cm or less. It is characterized by a pure lepidic growth pattern and the lack of stromal, vascular, or pleural invasion.	Lung Adenocarcinoma In Situ		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136487>	C25499	Last Two Scheduled Appointments|Last two scheduled appointments	The two scheduled appointments preceding the present day.			Event	Patient Oriented Prostate Utility Scale
C136488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136488>	C3167|C172280|C148431	Refractory Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia (ALL)	An acute lymphoblastic leukemia that does not respond to treatment.	Refractory Acute Lymphoblastic Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136489>	C53972|C134168	Refractory Erdheim-Chester Disease	Erdheim-Chester disease that does not respond to treatment.	Refractory Erdheim-Chester Disease		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13648>	C13432	2q32	A chromosome band present on 2q			Gene or Genome	
C136490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136490>	C3512|C136491	Lung Adenocarcinoma by AJCC v7 Stage	A term that refers to the staging of lung adenocarcinoma, following the rules of the TNM AJCC v7 classification system.			Neoplastic Process	
C136491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136491>	C91232|C2926	Lung Non-Small Cell Cancer by AJCC v7 Stage|Lung Non-Small Cell Carcinoma by AJCC v7 Stage	A term that refers to the staging of non-small cell lung carcinoma, following the rules of the TNM AJCC v7 classification system.			Neoplastic Process	
C136492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136492>	C9133|C136491	Lung Adenosquamous Carcinoma by AJCC v7 Stage	A term that refers to the staging of adenosquamous lung carcinoma, following the rules of the TNM AJCC v7 classification system.			Neoplastic Process	
C136493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136493>	C4450|C136491	Lung Large Cell Carcinoma by AJCC v7 Stage	A term that refers to the staging of large cell lung carcinoma, following the rules of the TNM AJCC v7 classification system.			Neoplastic Process	
C136494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136494>	C91232|C3493	Lung Squamous Cell Carcinoma by AJCC v7 Stage	A term that refers to the staging of squamous cell lung carcinoma, following the rules of the TNM AJCC v7 classification system.			Neoplastic Process	
C136496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136496>	C91232|C4917	Lung Small Cell Carcinoma by AJCC v7 Stage|Small Cell Lung Carcinoma by AJCC v7 Stage	A term that refers to the staging of small cell lung carcinoma, following the rules of the TNM AJCC v7 classification system.			Neoplastic Process	
C136497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136497>	C91105	Quality of Life Questionnaire - Head & Neck 35|QLQ-H&N35|Quality of Life Questionnaire-Head & Neck 35 (QLQ-H&N35)	A questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) consisting of 35 questions designed to assess quality of life in head and neck cancer patients.			Intellectual Product	
C136498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136498>	C173346|C173150	Extent Have Pain in Mouth Question|Extent Have Pain in Mouth|Extent of Pain in Mouth|Have you had pain in your mouth	A question about the extent to which an individual has or had pain in their mouth.			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C136499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136499>	C173346|C173150	Extent Have Pain in Jaw Question|Extent Have Pain in Jaw|Extent of Pain in Jaw|Have you had pain in your jaw	A question about the extent to which an individual has or had pain in their jaw.			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C13649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13649>	C13432	7p22	A chromosome band present on 7p			Gene or Genome	
C1364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1364>	C784|C574|C1976	Didemnin B|15H-Pyrrolol[2,1-f][1,15,4,7,10,20]dioxatetraazacyclotri-cosine, Cyclic Peptide Deriv. (9CI)|DIDEMNIN B|Didemnin|L-Tyrosine, N-[1-[N-[4-[[3-Hydroxy-4-[[N-[N-[1-(2-hydroxy-1-oxopropyl)- L-prolyl]-N-methyl-L-leucyl]-L-threonyl]amino]-5-methyl-1-oxoheptyl]oxy]-2,5-dimethyl-1,3-dioxohexyl]-L-leucyl]- L-prolyl]-N,O-dimethyl-, phi-lactone (9CI)|L-Tyrosine, N-[1-[N-[4-[[3-Hydroxy-4-[[N-[N-[1-(2-hydroxy-1-oxopropyl)- L-prolyl]-N-methyl-L-leucyl]-L-threonyl]amino]-5-methyl-1-oxoheptyl]oxy]-2,5-dimethyl-1,3-dioxohexyl]-L-leucyl]- L-prolyl]-N,O-dimethyl-, phi-lactone (9CI)	A cyclic depsipeptide extracted from the Caribbean tunicate Trididemnum cyanophorum.  Didemnin B activates caspase, thereby inducing apoptosis, and prevents eukaryotic elongation factor 2 (eEF-2)-dependent translocation, thereby inhibiting protein synthesis.  This agent also has immunosuppressive and antiviral properties. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C136500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136500>	C173150	Extent Have Soreness in Mouth Question|Extent Have Soreness in Mouth|Extent of Soreness in Mouth|Have you had soreness in your mouth	A question about the extent to which an individual has or had soreness in their mouth.			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C136501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136501>	C173346|C173150	Extent Have Painful Throat Question|Extent Have Painful Throat|Extent of Painful Throat|Have you had a painful throat	A question about the extent to which an individual has or had a painful throat.			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C136502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136502>	C173150|C113180	Extent Have Problems Swallowing Liquids Question|Extent Have Problems Swallowing Liquids|Extent of Problems Swallowing Liquids|Have you had problems swallowing liquids	A question about the extent to which an individual has or had problems swallowing liquids.			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C136503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136503>	C173150|C113192	Extent Have Problems Swallowing Pureed Food Question|Extent Have Problems Swallowing Pureed Food|Extent of Problems Swallowing Pureed Food|Have you had problems swallowing pureed food	A question about the extent to which an individual has or had problems swallowing pureed food.			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C136504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136504>	C173150|C113192	Extent Have Problems Swallowing Solid Food Question|Extent Have Problems Swallowing Solid Food|Extent of Problems Swallowing Solid Food|Have you had problems swallowing solid food	A question about the extent to which an individual has or had problems swallowing solid food.			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C136505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136505>	C173454|C173150	Extent Have Choking when Swallowing Question|Extent Have Choking when Swallowing|Extent of Choking when Swallowing|Have you choked when swallowing	A question about the extent to which an individual has or had choking when swallowing.			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C136506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136506>	C173150	Extent Have Problems with Teeth Question|Extent Have Problems with Teeth|Extent of Problems with Teeth|Have you had problems with your teeth	A question about the extent to which an individual has or had problems with their teeth.			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C136507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136507>	C173150	Extent Have Problems Opening Mouth Wide Question|Extent Have Problems Opening Mouth Wide|Extent of Problems Opening Mouth Wide|Have you had problems opening your mouth wide	A question about the extent to which an individual has or had problems opening their mouth wide.			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C136508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136508>	C173150	Extent Have Dry Mouth Question|Extent Have Dry Mouth|Extent of Dry Mouth|Have you had a dry mouth	A question about the extent to which an individual has or had a dry mouth.			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C136509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136509>	C173150	Extent Have Sticky Saliva Question|Extent Have Sticky Saliva|Extent of Sticky Saliva|Have you had sticky saliva	A question about the extent to which an individual has or had sticky saliva.			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C13650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13650>	C13432	10q23.31	A chromosome band present on 10q			Gene or Genome	
C136510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136510>	C173150	Extent Have Problems with Sense of Smell Question|Extent Have Problems with Sense of Smell|Extent of Problems with Sense of Smell|Have you had problems with your sense of smell	A question about the extent to which an individual has or had problems with their sense of smell.			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C136511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136511>	C173063	Extent Have Problems with Sense of Taste Question|Extent Have Problems with Sense of Taste|Extent of Problems with Sense of Taste|Have you had problems with your sense of taste	A question about the extent to which an individual has or had problems with their sense of taste.			Intellectual Product	
C136512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136512>	C173134	Extent Have Cough Question|Cough Extent|Extent Have Cough|Extent of Cough|Have you coughed	A question about the extent to which an individual has or had coughing.			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C136513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136513>	C173937|C173150	Extent Have Hoarse Voice Question|Extent Have Hoarse Voice|Extent of Hoarse Voice|Have you been hoarse	A question about the extent to which an individual has or had a hoarse voice.			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C136515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136515>	C129839	HDM2-binding Peptide PNC-27|PNC 27|PNC-27|PNC-27 Anti-Cancer Peptide	A human double minute 2 (HDM2)-binding peptide comprised of a carboxy terminal p53 leader sequence (amino acids 12-26) linked to a membrane residency peptide (MRP), which facilitates penetration of the tumor cell plasma membrane, with potential antineoplastic activity. HDM2-binding peptide PNC-27 binds to HDM2, which is expressed in the plasma membrane of certain cancer cells, and induces transmembrane pore formation, resulting in tumor cell necrosis that is independent of p53 activity. HDM2, a zinc finger protein and negative regulator of the p53 pathway, is often overexpressed by cancer cells and has been implicated in cancer cell proliferation and survival.			Pharmacologic Substance	
C136516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136516>	C281	Pritelivir|AIC-316|AIC316|BAY 57-1293|Benzeneacetamide, N-(5-(Aminosulfonyl)-4-methyl-2-thiazolyl)-N-methyl-4-(2-pyridinyl)-|Benzeneacetamide, N-(5-(aminosulfonyl)-4-methyl-2-thiazolyl)-N-methyl-4-(2-pyridinyl)-|N-(5-(Aminiosulfonyl)-4-methyl-1,3-thiazol-2-yl)-N-methyl-2-(4-(2-pyridinyl)phenyl)acetamide|N-methyl-N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-(4-pyridin-2-ylphenyl)acetamide|PRITELIVIR	A thiazolylamide and helicase-primase enzyme inhibitor that is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). Pritelivir inhibits the helicase-primase complex and prevents helicase or primase catalytic cycling of viral DNA, which interferes with DNA replication and growth. This agent does not require activation by HSV thymidine kinase and has a longer plasma half-life than nucleoside analogues.	Pritelivir		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C136517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136517>	C9477|C212992|C203285|C148038	Recurrent Anaplastic Astrocytoma	The reemergence of anaplastic astrocytoma after a period of remission.	Recurrent Anaplastic Astrocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136518>	C94764|C203267|C153837	Recurrent Diffuse Intrinsic Pontine Glioma|Recurrent Diffuse Intrinsic Pontine Glioma (DIPG)	The reemergence of diffuse intrinsic pontine glioma after a period of remission.	Recurrent Diffuse Intrinsic Pontine Glioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136519>	C94764|C203369|C153845	Refractory Diffuse Intrinsic Pontine Glioma|Refractory Diffuse Intrinsic Pontine Glioma (DIPG)	Diffuse intrinsic pontine glioma that is resistant to treatment.	Refractory Diffuse Intrinsic Pontine Glioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13651>	C13432	19p13	A chromosome band present on 19p			Gene or Genome	
C136520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136520>	C173150	Extent Have Felt Ill Question|Extent Have Felt Ill|Have you felt ill	A question about the extent to which an individual feels or felt ill.			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C136521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136521>	C173150|C172982	Extent Appearance Bothers You Question|Extent Appearance Bothers You|Has your appearance bothered you	A question about the extent to which an individual's appearance bothers or bothered them.			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C136522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136522>	C188083|C173150	Extent Have Trouble Eating Question|Extent Have Trouble Eating|Extent of Trouble Eating|Have you had problems eating|Have you had trouble eating	A question about the extent to which an individual has or had trouble eating.			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C136523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136523>	C173151|C136522	Extent Have Trouble Eating in Front of Family Question|Extent Have Trouble Eating in Front of Family|Extent of Trouble Eating in Front of Family|Have you had problems eating in front of your family|Have you had trouble eating in front of your family	A question about the extent to which an individual has or had trouble eating in front of their family.			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C136524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136524>	C136522	Extent Have Trouble Eating in Front of Other People Question|Extent Have Trouble Eating in Front of Other People|Extent of Trouble Eating in Front of Other People|Have you had problems eating in front of other people|Have you had trouble eating in front of other people	A question about the extent to which an individual has or had trouble eating in front of other people.			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C136525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136525>	C173398|C173150	Extent Have Trouble Enjoying Meals Question|Extent Have Trouble Enjoying Meals|Extent of Trouble Enjoying Meals|Have you had problems enjoying your meals|Have you had trouble enjoying your meals	A question about the extent to which an individual has or had trouble enjoying meals.			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C136526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136526>	C173398|C173150	Extent Have Trouble Talking to Other People Question|Extent Have Trouble Talking to Other People|Extent of Trouble Talking to Other People|Have you had problems talking to other people|Have you had trouble talking to other people	A question about the extent to which an individual has or had trouble talking to other people.			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C136527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136527>	C173398|C173150	Extent Have Trouble Talking on the Telephone Question|Extent Have Trouble Talking on the Telephone|Extent of Trouble Talking on the Telephone|Have you had problems talking on the telephone|Have you had trouble talking on the telephone	A question about the extent to which an individual has or had trouble talking on the telephone.			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C136528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136528>	C173398|C173151|C173150	Extent Have Trouble Having Social Contact with Family Question|Extent Have Trouble Having Social Contact with Family|Extent of Trouble Having Social Contact with Family|Have you had trouble having social contact with your family	A question about the extent to which an individual has or had trouble having social contact with their family.			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C136529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136529>	C173398|C173150	Extent Have Trouble Having Social Contact with Friends Question|Extent Have Trouble Having Social Contact with Friends|Extent of Trouble Having Social Contact with Friends|Have you had trouble having social contact with friends	A question about the extent to which an individual has or had trouble having social contact with friends.			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C13652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13652>	C13432	1p13.3	A chromosome band present on 1p			Gene or Genome	
C136530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136530>	C173398|C173150	Extent Have Trouble Going out in Public Question|Extent Have Trouble Going out in Public|Extent of Trouble Going out in Public|Have you had problems going out in public|Have you had trouble going out in public	A question about the extent to which an individual has or had trouble going out in public.			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C136531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136531>	C173398|C173151|C173150	Extent Have Trouble Having Physical Contact with Family or Friends Question|Extent Have Trouble Having Physical Contact with Family or Friends|Extent of Trouble Having Physical Contact with Family or Friends|Have you had trouble having physical contact with family or friends	A question about the extent to which an individual has or had having physical contact with family or friends.			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C136532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136532>	C173704|C173160|C173150	Extent Feel Less Interest in Sex Question|Extent Feel Less Interest in Sex|Have you felt less interest in sex	A question about the extent to which an individual feels or felt less interest in sex.			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C136533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136533>	C173704|C173160|C173150	Extent Feel Less Sexual Enjoyment Question|Extent Feel Less Sexual Enjoyment|Extent Feel Less Sexual Enjoyment|Have you felt less sexual enjoyment	A question about the extent to which an individual feels or felt less sexual enjoyment.			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C136534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136534>	C138961	PSA Level Greater than or Equal to Ten|PSA Level 10 or Greater|PSA Level Greater than or Equal to 10|PSA Level Ten or Greater	A blood concentration of prostate specific antigen greater than or equal to 10 ng/mL.	PSA Level Greater than or Equal to Ten		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136535>	C173984	Have Used Pain-killers Question|Have Used Pain Medication|Have Used Pain-killers|Have you used pain-killers|Taken Pain Medication|Used Pain Medication	A question about whether an individual uses or used pain-killers.			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C136536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136536>	C173984	Have Taken Nutritional Supplements Question|Have Taken Nutritional Supplements Other Than Vitamins|Have you taken any nutritional supplements (excluding vitamins)	A question about whether an individual has or had taken any nutritional supplements (excluding vitamins).			Intellectual Product	Quality of Life Questionnaire - Head & Neck 35
C136537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136537>	C91102	Have Used Feeding Tube Question|Have Used Feeding Tube|Have you used a feeding tube|Used Feeding Tube	A question about whether an individual uses or used a feeding tube.			Intellectual Product	
C136538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136538>	C67477	Ravtansine|DM 4|DM-4|DM4|MAYTANSINOID DM4|N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)-maytansine|N2'-[4-[(3-carboxypropyl)dithio]-4-methyl-1-oxo-2-sulfopentyl]-N2'-deacetylmaytansine	A tubulin-binding maytansinoid. Ravtansine binds to tubulin at the maytansine-binding site, which disrupts microtubule assembly/disassembly dynamics and inhibits mitosis.	Ravtansine		Organic Chemical|Pharmacologic Substance	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C136539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136539>	C91105|C21154	Swallowing Impairment Scale|SIS-6|Swallowing Impairment Scale (SIS-6)	A questionnaire designed to measure symptoms of swallowing dysfunction.			Intellectual Product	
C13653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13653>	C13432	6q14.3-16.1	A chromosome band present on 6q			Gene or Genome	
C136540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136540>	C173454	Requires Great Effort to Swallow Question|It requires great effort to swallow|Requires Great Effort to Swallow	A question about how often an individual feels or felt that it requires great effort to swallow.			Intellectual Product	Swallowing Impairment Scale
C136541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136541>	C173454|C173219	Feel a Throat Obstacle During Swallowing Question|Feel a Throat Obstacle During Swallowing|I feel a throat obstacle during swallowing	A question about how often an individual feels or felt a throat obstacle during swallowing.			Intellectual Product	Swallowing Impairment Scale
C136542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136542>	C173219	Feel Pharyngeal Annoyance During Bolus Transit Question|Feel Pharyngeal Annoyance During Bolus Transit|I feel pharyngeal annoyance during bolus transit	A question about how often an individual feels or felt pharyngeal annoyance during bolus transit.			Intellectual Product	Swallowing Impairment Scale
C136543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136543>	C173134	Cough During Bolus Transit Question|Cough During Bolus Transit|I cough during bolus transit	A question about how often an individual coughs or coughed during bolus transit.			Intellectual Product	Swallowing Impairment Scale
C136544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136544>	C173219	Feel Sensation of Foreign Body in Pharynx Question|Feel Sensation of Foreign Body in Pharynx|I feel a sensation of a foreign body in my pharynx	A question about how often an individual feels or felt a sensation of a foreign body in their pharynx.			Intellectual Product	Swallowing Impairment Scale
C136545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136545>	C113180	Have Some Difficulties Swallowing Fluids Question|Have Some Difficulties Swallowing Fluids|I have some difficulties swallowing fluids	A question about how often an individual has or had some difficulties swallowing fluids.			Intellectual Product	Swallowing Impairment Scale
C136546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136546>	C20995|C121547	Neck Pain Scale|Neck Pain Visual Analog Scale	A visual analogue scale designed to measure neck pain.			Intellectual Product	
C136547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136547>	C221032	Neck Pain Score 0|0 = No Pain|No Pain	A subjective score of 0 on a visual analogue scale that ranges from 0: No Pain to 10: Excruciating.			Intellectual Product	Neck Pain Scale
C136548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136548>	C221032	Neck Pain Score 1|1	A subjective score of 1 on a visual analogue scale that ranges from 0: No Pain to 10: Excruciating.			Intellectual Product	Neck Pain Scale
C136549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136549>	C221032	Neck Pain Score 2|2= Mild|Mild Pain	A subjective score of 2 on a visual analogue scale that ranges from 0: No Pain to 10: Excruciating.			Intellectual Product	Neck Pain Scale
C13654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13654>	C13432	12q12-12q14	A chromosome band present on 12q			Gene or Genome	
C136550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136550>	C221032	Neck Pain Score 3|3	A subjective score of 3 on a visual analogue scale that ranges from 0: No Pain to 10: Excruciating.			Intellectual Product	Neck Pain Scale
C136551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136551>	C221032	Neck Pain Score 4|4 = Moderate|Moderate Pain	A subjective score of 4 on a visual analogue scale that ranges from 0: No Pain to 10: Excruciating.			Intellectual Product	Neck Pain Scale
C136552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136552>	C221032	Neck Pain Score 5|5	A subjective score of 5 on a visual analogue scale that ranges from 0: No Pain to 10: Excruciating.			Intellectual Product	Neck Pain Scale
C136553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136553>	C221032	Neck Pain Score 6|6 = Severe|Severe Pain	A subjective score of 6 on a visual analogue scale that ranges from 0: No Pain to 10: Excruciating.			Intellectual Product	Neck Pain Scale
C136554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136554>	C221032	Neck Pain Score 7|7	A subjective score of 7 on a visual analogue scale that ranges from 0: No Pain to 10: Excruciating.			Intellectual Product	Neck Pain Scale
C136555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136555>	C134533	Gerbil Experimental Organism Diagnosis	A condition that is relevant to either disease states or models of disease in gerbils (Subfamily Gerbillinae.)			Classification	
C136556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136556>	C221032	Neck Pain Score 8|8= Very Severe|Very Severe Pain	A subjective score of 8 on a visual analogue scale that ranges from 0: No Pain to 10: Excruciating.			Intellectual Product	Neck Pain Scale
C136557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136557>	C221032	Neck Pain Score 9|9	A subjective score of 9 on a visual analogue scale that ranges from 0: No Pain to 10: Excruciating.			Intellectual Product	Neck Pain Scale
C136558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136558>	C221032	Neck Pain Score 10|10 = Excruciating|Excruciating Pain	A subjective score of 10 on a visual analogue scale that ranges from 0: No Pain to 10: Excruciating.			Intellectual Product	Neck Pain Scale
C136559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136559>	C134533	Fish Experimental Organism Diagnosis	A condition that is relevant to either disease states or models of disease in fish.			Classification	
C13655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13655>	C13432	19q13.2	A chromosome band present on 19q			Gene or Genome	
C136560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136560>	C36285|C36280	Apparent Sporadic Paraganglioma or Pheochromocytoma|Apparent Sporadic	A paraganglioma-pheochromocytoma that is not associated with a clear genetic mutation.			Finding	
C136561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136561>	C48233	Bone Cancer TNM Finding v8	A finding about one or more characteristics of bone cancer, following the rules of the TNM AJCC v8 classification system. This classification system applies to osteosarcoma, chondrosarcoma, Ewing sarcoma, spindle cell sarcoma, hemangioendothelioma, angiosarcoma, fibrosarcoma/myofibroid sarcoma, chordoma, adamantinoma, and other cancers arising in the bone. It does not apply to primary malignant lymphoma of the bone and multiple myeloma. (from AJCC 8th Ed.)			Finding	
C136562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136562>	C136561	Bone Cancer Clinical TNM Finding v8	A clinical finding about one or more characteristics of bone cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C136563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136563>	C136562	Bone Cancer Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of bone cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C136564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136564>	C136563	Bone Cancer cM0 TNM Finding v8	Bone cancer without distant metastasis. (from AJCC 8th Ed.)			Finding	
C136565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136565>	C136563	Bone Cancer cM1 TNM Finding v8	Bone cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C136566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136566>	C136565	Bone Cancer cM1a TNM Finding v8	Bone cancer with metastasis in the lung. (from AJCC 8th Ed.)			Finding	
C136567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136567>	C177696	IDH Family Wildtype|IDH Family Gene Mutation Negative|IDH Gene Family Wildtype|IDH Gene Mutation Negative|IDH Mutation Negative|IDH Wild Type|IDH Wildtype|IDH wt Allele|IDP Gene Mutation Negative|Isocitrate Dehydrogenase (NADP+) Gene Family Wildtype|Isocitrate Dehydrogenase Gene Family Wild Type|Negative|No	A genetic finding indicating that no nucleotide sequence change has been detected in any IDH family gene.	IDH Family Wildtype		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136568>	C136565	Bone Cancer cM1b TNM Finding v8	Bone cancer with metastasis in the bone or other distant sites. (from AJCC 8th Ed.)			Finding	
C136569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136569>	C136561	Bone Cancer Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of bone cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C13656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13656>	C13432	14q12	A chromosome band present on 14q			Gene or Genome	
C136570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136570>	C136569	Bone Cancer Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of bone cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C136571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136571>	C136570	Bone Cancer pM1 TNM Finding v8	Bone cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C136572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136572>	C136571	Bone Cancer pM1a TNM Finding v8	Bone cancer with metastasis in the lung. (from AJCC 8th Ed.)			Finding	
C136573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136573>	C136571	Bone Cancer pM1b TNM Finding v8	Bone cancer with metastasis in the bone or other distant sites. (from AJCC 8th Ed.)			Finding	
C136574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136574>	C138961	PSA Level Greater than or Equal to One|PSA Level 1 or Greater|PSA Level 1.0 or Greater|PSA Level Greater than or Equal to 1|PSA Level One or Greater	A blood concentration of prostate specific antigen greater than or equal to 1 ng/mL.	PSA Level Greater than or Equal to One		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136575>	C136569	Bone Cancer Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of bone cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C136576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136576>	C136575	Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of appendicular skeleton, trunk, skull, and facial bones cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C136577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136577>	C136576	Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer pTX TNM Finding v8	Appendicular skeleton, trunk, skull, and facial bones cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C136578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136578>	C136576	Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer pT0 TNM Finding v8	Appendicular skeleton, trunk, skull, and facial bones cancer without evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C136579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136579>	C136576	Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer pT1 TNM Finding v8	Appendicular skeleton, trunk, skull, and facial bones cancer with tumor measuring 8 cm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C13657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13657>	C25334	Nucleosomal Repeat Length	Nucleosomal repeat length is approximately 200 base pairs of DNA within which 146 base pairs are highly protected. (NCI)			Quantitative Concept	
C136580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136580>	C136576	Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer pT2 TNM Finding v8	Appendicular skeleton, trunk, skull, and facial bones cancer with tumor measuring more than 8 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C136581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136581>	C136576	Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer pT3 TNM Finding v8	Appendicular skeleton, trunk, skull, and facial bones cancer with discontinuous tumors in the primary bone site. (from AJCC 8th Ed.)			Finding	
C136582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136582>	C136575	Spine Cancer Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of spine cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C136583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136583>	C136582	Spine Cancer pTX TNM Finding v8	Spine cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C136584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136584>	C136582	Spine Cancer pT0 TNM Finding v8	Spine cancer without evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C136585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136585>	C136582	Spine Cancer pT1 TNM Finding v8	Spine cancer with tumor confined to one vertebral segment or two adjacent vertebral segments. (from AJCC 8th Ed.)			Finding	
C136586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136586>	C136582	Spine Cancer pT2 TNM Finding v8	Spine cancer with tumor confined to three adjacent vertebral segments. (from AJCC 8th Ed.)			Finding	
C136587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136587>	C136582	Spine Cancer pT3 TNM Finding v8	Spine cancer with tumor confined to four or more adjacent vertebral segments, or any nonadjacent vertebral segments. (from AJCC 8th Ed.)			Finding	
C136588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136588>	C136582	Spine Cancer pT4 TNM Finding v8	Spine cancer with tumor extending into the spinal canal or great vessels. (from AJCC 8th Ed.)			Finding	
C136589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136589>	C136588	Spine Cancer pT4a TNM Finding v8	Spine cancer with tumor extending into the spinal canal. (from AJCC 8th Ed.)			Finding	
C13658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13658>	C13432	3p14.2	A chromosome band present on 3p			Gene or Genome	
C136590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136590>	C136588	Spine Cancer pT4b TNM Finding v8	Spine cancer with evidence of gross vascular invasion or tumor thrombus in the great vessels. (from AJCC 8th Ed.)			Finding	
C136591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136591>	C136575	Pelvis Cancer Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of pelvis cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C136592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136592>	C136591	Pelvis Cancer pTX TNM Finding v8	Pelvis cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C136593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136593>	C136591	Pelvis Cancer pT0 TNM Finding v8	Pelvis cancer without evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C136594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136594>	C136591	Pelvis Cancer pT1 TNM Finding v8	Pelvis cancer with tumor confined to one pelvic segment with no extraosseous extension. (from AJCC 8th Ed.)			Finding	
C136595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136595>	C136594	Pelvis Cancer pT1a TNM Finding v8	Pelvis cancer with tumor confined to one pelvic segment with no extraosseous extension and measuring 8 cm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C136596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136596>	C136594	Pelvis Cancer pT1b TNM Finding v8	Pelvis cancer with tumor confined to one pelvic segment with no extraosseous extension and measuring more than 8 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C136597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136597>	C136591	Pelvis Cancer pT2 TNM Finding v8	Pelvis cancer with tumor confined to one pelvic segment with extraosseous extension or two segments without extraosseous extension. (from AJCC 8th Ed.)			Finding	
C136598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136598>	C136597	Pelvis Cancer pT2a TNM Finding v8	Pelvis cancer with tumor confined to one pelvic segment with extraosseous extension or two segments without extraosseous extension and measuring 8 cm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C136599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136599>	C136597	Pelvis Cancer pT2b TNM Finding v8	Pelvis cancer with tumor confined to one pelvic segment with extraosseous extension or two segments without extraosseous extension and measuring more than 8 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C13659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13659>	C13432	16p13.1	A chromosome band present on 16p			Gene or Genome	
C1365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1365>	C2082	Dimesna|2,2'-Dithio-bis-ethanesulfonate, Disodium Salt|2,2'-Dithiobisethanesulfonic Acid, Disodium Salt|2,2'-Dithiobisethanesulfonic Acid, Disodium Salt|BNP7787|DIMESNA|LP 300|LP-300|LP300|Mesna Disulfide|Tavocept|dimesna	The disodium salt form of dithio-ethane sulfonate, a dimer of mesna and a disulfide bond disrupting agent (DDA), with uroprotective, nephroprotective, chemoprotective, chemosensitizing and chemo-enhancing activities. Upon administration, dimesna is able to modify cysteine on various proteins, such as the kinases EGFR, MET and ROS1, thereby disrupting extracellular disulfide bonds and modulating the activity of these proteins. This inhibits their signaling pathways and downregulates proliferative signaling in cancer cells in which these kinases are overexpressed. This may also enhance the activity of other kinase inhibitors targeting the same proteins. In the kidneys, dimesna undergoes reduction to the free thiol compound, mesna, which reacts chemically with the urotoxic ifosfamide metabolites acrolein and 4-hydroxy-ifosfamide, resulting in their detoxification. This agent also inhibits cyclophosphamide-induced hemorrhagic cystitis. In addition, dimesna reduces toxicities associated with taxanes and platinum-based chemotherapeutic agents.	Dimesna		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C136600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136600>	C136591	Pelvis Cancer pT3 TNM Finding v8	Pelvis cancer with tumor spanning two pelvic segments with extraosseous extension. (from AJCC 8th Ed.)			Finding	
C136601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136601>	C136600	Pelvis Cancer pT3a TNM Finding v8	Pelvis cancer with tumor spanning two pelvic segments with extraosseous extension and measuring 8 cm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C136602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136602>	C136600	Pelvis Cancer pT3b TNM Finding v8	Pelvis cancer with tumor spanning two pelvic segments with extraosseous extension and measuring more than 8 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C136603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136603>	C136591	Pelvis Cancer pT4 TNM Finding v8	Pelvis cancer with tumor spanning three pelvic segments or crossing the sacroiliac joint. (from AJCC 8th Ed.)			Finding	
C136604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136604>	C136603	Pelvis Cancer pT4a TNM Finding v8	Pelvis cancer with tumor involving the sacroiliac joint and extending medial to the sacral neuroforamen. (from AJCC 8th Ed.)			Finding	
C136605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136605>	C136603	Pelvis Cancer pT4b TNM Finding v8	Pelvis cancer with tumor encasement of external iliac vessels or presence of gross tumor thrombus in major pelvic vessels. (from AJCC 8th Ed.)			Finding	
C136606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136606>	C136569	Bone Cancer Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of bone cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C136607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136607>	C136606	Bone Cancer pNX TNM Finding v8	Bone cancer in which the regional lymph nodes cannot be assessed.  (from AJCC 8th Ed.)			Finding	
C136608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136608>	C136606	Bone Cancer pN0 TNM Finding v8	Bone cancer without regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C136609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136609>	C136606	Bone Cancer pN1 TNM Finding v8	Bone cancer with regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C13660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13660>	C13299	Translocation Breakpoint	The point on a chromosome where the normal DNA sequence is juxtaposed with DNA from another chromosome.  Usually expressed as a band number designation (eg. t(9;22) (q34;q11) Philadelphia Chromosome)	Translocation Breakpoint		Spatial Concept	CTRP Biomarker Terminology|CTRP Terminology
C136610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136610>	C4016	Bone Cancer by AJCC v7 Stage	A term that refers to the staging of bone cancer, following the rules of the TNM AJCC v7 classification system.			Neoplastic Process	
C136611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136611>	C138961	PSA Level Less than Fifty|PSA Level Less than 50	A blood concentration of prostate specific antigen less than or equal to 50 ng/mL.	PSA Level Less than Fifty		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136612>	C4016	Bone Cancer by AJCC v8 Stage|Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer by AJCC v8 Stage	A term that refers to the staging of appendicular skeleton, trunk, skull, and facial bones cancer, following the rules of the TNM AJCC v8 classification system. This staging system applies to osteosarcoma, chondrosarcoma, Ewing sarcoma, spindle cell sarcoma, hemangioendothelioma, angiosarcoma, fibrosarcoma/myofibroid sarcoma, chordoma, adamantinoma, and other cancers arising in the bone. It does not apply to primary malignant lymphoma of the bone and multiple myeloma. There are no AJCC prognostic stage groupings for spine and pelvis. (from AJCC 8th Ed.)			Neoplastic Process	
C136613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136613>	C136612	Stage I Bone Cancer AJCC v8|Stage I Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer AJCC v8|Stage I Bone Cancer	Stage I includes: IA: (T1, N0, M0, G1 or GX); IB: (T2, N0, M0, G1 or GX); (T3, N0, M0, G1 or GX). T1: Tumor measuring 8 cm or less in greatest dimension. T2: Tumor measuring more than 8 cm in greatest dimension. T3: Discontinuous tumors in the primary bone site. N0: No regional lymph node metastasis. M0: No distant metastasis. GX: Grade cannot be assessed. G1: Well differentiated, low grade. (AJCC 8th ed.)	Stage I Bone Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136614>	C136613	Stage IA Bone Cancer AJCC v8|Stage IA Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer AJCC v8|Stage IA Bone Cancer	Stage IA includes: T1, N0, M0, G1 or GX. T1: Tumor measuring 8 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. GX: Grade cannot be assessed. G1: Well differentiated, low grade. (AJCC 8th ed.)	Stage IA Bone Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136615>	C136613	Stage IB Bone Cancer AJCC v8|Stage IB Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer AJCC v8|Stage IB Bone Cancer	Stage IB includes: (T2, N0, M0, G1 or GX); (T3, N0, M0, G1 or GX). T2: Tumor measuring more than 8 cm in greatest dimension. T3: Discontinuous tumors in the primary bone site. N0: No regional lymph node metastasis. M0: No distant metastasis. GX: Grade cannot be assessed. G1: Well differentiated, low grade. (AJCC 8th ed.)	Stage IB Bone Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136616>	C136612	Stage II Bone Cancer AJCC v8|Stage II Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer AJCC v8|Stage II Bone Cancer	Stage II includes: IIA: (T1, N0, M0, G2 or G3); IIB: (T2, N0, M0, G2 or G3). T1: Tumor measuring 8 cm or less in greatest dimension. T2: Tumor measuring more than 8 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. G2: Moderately differentiated, high grade. G3: Poorly differentiated, high grade. (AJCC 8th ed.)	Stage II Bone Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136617>	C136616	Stage IIA Bone Cancer AJCC v8|Stage IIA Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer AJCC v8|Stage IIA Bone Cancer	Stage IIA includes: T1, N0, M0, G2 or G3. T1: Tumor measuring 8 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. G2: Moderately differentiated, high grade. G3: Poorly differentiated, high grade. (AJCC 8th ed.)	Stage IIA Bone Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136618>	C136616	Stage IIB Bone Cancer AJCC v8|Stage IIB Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer AJCC v8|Stage IIB Bone Cancer	Stage IIB includes: T2, N0, M0, G2 or G3. T2: Tumor measuring more than 8 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. G2: Moderately differentiated, high grade. G3: Poorly differentiated, high grade. (AJCC 8th ed.)	Stage IIB Bone Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136619>	C136612	Stage III Bone Cancer AJCC v8|Stage III Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer AJCC v8|Stage III Bone Cancer	Stage III includes: T3, N0, M0, G2 or G3. T3: Discontinuous tumors in the primary bone site. N0: No regional lymph node metastasis. M0: No distant metastasis. G2: Moderately differentiated, high grade. G3: Poorly differentiated, high grade. (AJCC 8th ed.)	Stage III Bone Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13661>	C13372	Cyclic AMP Response Element|CRE|cAMP Response Element	A promoter sequence which interacts with CRE binding proteins to modulate gene expression in response to the level of cAMP in the cell.			Gene or Genome	
C136620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136620>	C136612	Stage IV Bone Cancer AJCC v8|Stage IV Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer AJCC v8|Stage IV Bone Cancer	Stage IV includes: IVA: (Any T, N0, M1a, Any G); IVB: (Any T, N1, Any M, Any G); (Any T, Any N, M1b, Any G). N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M1a: Metastasis in the lung. M1b: Metastasis in the bone or other distant sites. (AJCC 8th ed.)	Stage IV Bone Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136621>	C136620	Stage IVA Bone Cancer AJCC v8|Stage IVA Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer AJCC v8|Stage IVA Bone Cancer	Stage IVA includes: Any T, N0, M1a, Any G. N0: No regional lymph node metastasis. M1a: Metastasis in the lung. (AJCC 8th ed.)	Stage IVA Bone Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136622>	C136620	Stage IVB Bone Cancer AJCC v8|Stage IVB Appendicular Skeleton, Trunk, Skull, and Facial Bones Cancer AJCC v8|Stage IVB Bone Cancer	Stage IVB includes: (Any T, N1, Any M, Any G); (Any T, Any N, M1b, Any G). N1: Regional lymph node metastasis. M1b: Metastasis in the bone or other distant sites. (AJCC 8th ed.)	Stage IVB Bone Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136623>	C97927	SMARCB1 Gene Mutation|BAF47 Gene Mutation|Ini1 Gene Mutation|SNF5 Gene Mutation|SNF5L1 Gene Mutation|SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily B, Member 1 Gene Mutation|Snr1 Gene Mutation|hSNFS Gene Mutation	A change in the nucleotide sequence of the SMARCB1 gene.	SMARCB1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C136624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136624>	C123583	Small Cell Lung Carcinoma Transformation|Lung Adenocarcinoma Transformation|SCLC Transformation	A term that usually refers to the histological transformation of EGFR mutation-positive lung non-small cell carcinoma to small cell carcinoma in response to treatment with tyrosine kinase inhibitors, resulting in resistance to first-line tyrosine kinase inhibitors. It may also refer to rare cases of lung adenocarcinoma carrying KRAS G12C mutation that are transformed into small cell carcinoma before treatment.	Small Cell Lung Carcinoma Transformation		Finding	CTRP Biomarker Terminology|CTRP Terminology
C136625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136625>	C219858|C133155	NFKB2 Gene Rearrangement|H2TF1 Gene Rearrangement|LYT-10 Gene Rearrangement|LYT10 Gene Rearrangement|NF-kB2 Gene Rearrangement|Nuclear Factor Kappa B Subunit 2 Gene Rearrangement|p100 Gene Rearrangement|p49/p100 Gene Rearrangement|p52 Gene Rearrangement	A molecular abnormality indicating rearrangement of the NFKB2 gene.	NFKB2 Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136626>	C21176	Pyruvate Kinase PKM Isoform M2 Dimer|M2-PK|Tumor M2-PK	A homodimer of the pyruvate kinase PKM isoform M2. This enzyme complex promotes cellular metabolism and is overexpressed in tumors.	Pyruvate Kinase PKM Isoform M2 Dimer		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136627>	C36214	Blasts 21-30 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that 21-30 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts 21-30 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C136628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136628>	C138961	PSA Level Greater than Five|PSA Level Greater than 5	A blood concentration of prostate specific antigen greater than 5 ng/mL.	PSA Level Greater than Five		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136629>	C97927	ESR1 Gene Mutation|ER Gene Mutation|ERA Gene Mutation|ESR Gene Mutation|ESRA Gene Mutation|Estrogen Receptor 1 Gene Mutation|Estrogen Receptor Gene Mutation|NR3A1 Gene Mutation	A change in the nucleotide sequence of the ESR1 gene.	ESR1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13662>	C13372	Androgen Response Element|ARE	Androgen response element is the target binding element for activated androgen receptor homodimer.  The consensus sequence for this high-affinity androgen receptor-binding is the palindromic sequence GGT/AACAnnnTGTTCT, though could deviate considerably in natural promoter sequences.  The most well-characterized in this regard is the promoter of the PSA (prostate-specific antigen) gene.			Gene or Genome	
C136630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136630>	C81326|C162517	Elevated Alpha-Fetoprotein|Elevated AFP|Elevated Alpha Fetoprotein	A finding indicating elevated concentrations of alpha-fetoprotein in a sample.	Elevated Alpha-Fetoprotein		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136631>	C81326	Elevated Human Chorionic Gonadotropin|Elevated HCG|Elevated Human Chorionicgonadotropin	A finding indicating elevated concentrations of human chorionic gonadotropin in a sample.	Elevated Human Chorionic Gonadotropin		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136632>	C9312|C136610	Bone Sarcoma by AJCC v7 Stage	A term that refers to the staging of bone sarcoma, following the rules of the TNM AJCC v7 classification system.			Neoplastic Process	
C136633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136633>	C4834|C136632	Osteosarcoma by AJCC v7 Stage|Primary Bone Osteosarcoma by AJCC v7 Stage	A term that refers to the staging of osteosarcoma, following the rules of the TNM AJCC v7 classification system.			Neoplastic Process	
C136634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136634>	C18133|C128919	Non-synonymous FLT3 Gene Mutation|FLT3 Missense Mutation|Non-synonymous CD135 Gene Mutation|Non-synonymous FLK2 Gene Mutation|Non-synonymous FLT3 Gene Mutant|Non-synonymous FMS-Related Tyrosine Kinase 3 Gene Mutation	A point mutation in the FLT3 gene that encodes an amino acid substitution in the receptor-type tyrosine-protein kinase FLT3 protein.	Non-synonymous FLT3 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136635>	C39712|C18133	Non-synonymous KIT Gene Mutation|C-KIT Missense Mutation|KIT Missense Mutation|Non-synonymous CD117 Gene Mutation|Non-synonymous KIT Proto-Oncogene Tyrosine Protein Kinase Gene Mutation|Non-synonymous V-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Gene Mutation|Non-synonymous c-KIT Gene Mutation	A point mutation in the KIT gene that encodes an amino acid substitution in the mast/stem cell growth factor receptor Kit protein.	Non-synonymous KIT Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136636>	C18133|C132229	Non-synonymous RAS Family Gene Mutation|RAS Family Gene Missense Mutation	A point mutation in a gene that is a member of the RAS gene family that encodes an amino acid substitution in a RAS family protein.	Non-synonymous RAS Family Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136637>	C18133|C136425	Non-synonymous RAF Family Gene Mutation|Non-Synonymous Rapidly Accelerated Fibrosarcoma Family Gene Mutation|Non-Synonymous Rapidly Accelerated Fibrosarcoma Kinase Family Gene Mutation|RAF Family Gene Missense Mutation	A point mutation in a gene that is a member of the RAF gene family that encodes an amino acid substitution in a RAF family protein.	Non-synonymous RAF Family Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136638>	C18133|C136423	Non-synonymous MAPK Family Gene Mutation|ERK Family Gene Missense Mutation|MAPK Family Gene Missense Mutation|Non-synonymous ERK Family Gene Mutation|Non-synonymous Extracellular Signal-Regulated Kinase Family Gene Mutation|Non-synonymous Mitogen-Activated Protein Kinase Family Gene Mutation	A point mutation in a gene that is a member of the MAPK gene family that encodes an amino acid substitution in a MAPK family protein.	Non-synonymous MAPK Family Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136639>	C18133|C136422	Non-synonymous MAP2K Family Gene Mutation|MAP2K Family Gene Missense Mutation|MEK Family Gene Missense Mutation|Non-synonymous MAPKK Family Gene Mutation|Non-synonymous MEK Family Gene Mutation|Non-synonymous Mitogen-Activated Protein Kinase Kinase Family Gene Mutation	A point mutation in a gene that is a member of the MAP2K gene family that encodes an amino acid substitution in a MAP2K family protein.	Non-synonymous MAP2K Family Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13663>	C13425	SANT Domain|MYB-Like DNA-Binding Domain|SWI3/ADA2/N-CoR/TFIIIB Domain	The SANT domain is found in several transcriptional regulatory proteins identified through consistent homology to the c-MYB repeat DNA binding domain, suggesting that SANT domains also bind DNA. Folded into three alpha helices as doublets or singlets in many proteins, the SANT domain family specifically recognizes the sequence YAAC(G/T)G. The SANT domain is a repeated motif in N-CoR, the nuclear receptor co-repressor. Single copies of SANT occur in yeast nuclear chromatin remodeling proteins SWI3 (SWI/SNF transcription subunit), ADA2 (ADA adaptor/HAT complex), and a TFIIIB transcription subunit. SANT domains may mediate functional interactions with histone N-terminal tails. (NCI)			Amino Acid Sequence	
C136640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136640>	C18133|C136421	Non-synonymous STAT Family Gene Mutation|Non-synonymous Signal Transducer and Activator of Transcription Family Gene Mutation|STAT Family Gene Missense Mutation	A point mutation in a gene that is a member of the STAT gene family that encodes an amino acid substitution in a STAT family protein.	Non-synonymous STAT Family Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136641>	C18133|C136420	Non-synonymous JAK Family Gene Mutation|JAK Family Gene Missense Mutation|Non-synonymous Janus Kinase Family Gene Mutation	A point mutation in a gene that is a member of the JAK gene family that encodes an amino acid substitution in a JAK family protein.	Non-synonymous JAK Family Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136642>	C18133|C136419	Non-synonymous VEGFR Family Gene Mutation|Non-synonymous Vascular Endothelial Growth Factor Receptor Family Gene Mutation|VEGFR Family Gene Missense Mutation	A point mutation in a gene that is a member of the VEGFR gene family that encodes an amino acid substitution in a VEGFR family protein.	Non-synonymous VEGFR Family Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136643>	C18133|C136417	Non-synonymous PDGFR Family Gene Mutation|Non-synonymous Platelet Derived Growth Factor Receptor Family Gene Mutation|PDGFR Family Gene Missense Mutation	A point mutation in a gene that is a member of the PDGFR gene family that encodes an amino acid substitution in a PDGFR family protein.	Non-synonymous PDGFR Family Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136644>	C36327	NOTCH Family Gene Mutation|NOTCH Gene Mutation|Notch Receptor Gene Family Mutation	A change in the nucleotide sequence of a gene that is a member of the NOTCH gene family.	NOTCH Family Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136645>	C97927	CBL Gene Mutation|C-CBL Gene Mutation|Cas-Br-M Murine Ecotropic Retroviral Transforming Sequence Gene Mutation|Casitas B-Lineage Lymphoma Proto-Oncogene Mutation|Cbl Proto-Oncogene Gene Mutation|RNF55 Gene Mutation	A change in the nucleotide sequence of the CBL gene.	CBL Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136646>	C138961	PSA Level Greater than Twenty|PSA Level Greater than 20	A blood concentration of prostate specific antigen greater than 20 ng/mL.	PSA Level Greater than Twenty		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136647>	C97927|C136420	JAK3 Gene Mutation|JAK-3 Gene Mutation|JAK3|JAKL Gene Mutation|Janus Kinase 3 (A Protein Tyrosine Kinase, Leukocyte) Gene Mutation|Janus Kinase 3 Gene Mutation|Janus Kinase, Leukocyte Gene Mutation|L-JAK Gene Mutation|LJAK Gene Mutation	A change in the nucleotide sequence of the JAK3 gene.	JAK3 Gene Mutation		Cell or Molecular Dysfunction	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C136648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136648>	C142112	Blasts 10 Percent or More of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that at least 10 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts 10 Percent or More of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C136649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136649>	C7804|C4028|C162652	Recurrent Cervical Squamous Cell Carcinoma|Recurrent Cervical Squamous Cell Cancer|Relapsed Cervical Squamous Cell Carcinoma	The reemergence of cervical squamous cell carcinoma after a period of remission.	Recurrent Cervical Squamous Cell Carcinoma, Not Otherwise Specified		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13664>	C13432	10q11	A chromosome band present on 10q			Gene or Genome	
C136650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136650>	C7804|C4519	Recurrent Cervical Adenosquamous Carcinoma|Recurrent Cervical Adenosquamous Cancer|Relapsed Cervical Adenosquamous Carcinoma	The reemergence of cervical adenosquamous carcinoma after a period of remission.	Recurrent Cervical Adenosquamous Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136651>	C4029|C206197|C159565	Recurrent Cervical Adenocarcinoma|Relapsed Cervical Adenocarcinoma	The reemergence of cervical adenocarcinoma after a period of remission.	Recurrent Cervical Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136653>	C85865|C104003	X-linked Thrombocytopenia, with or without Dyserythropoietic Anemia|XLTDA	An X-linked condition caused by mutation(s) in the GATA1 gene, encoding erythroid transcription factor. It is characterized by thrombocytopenia, as well as abnormal platelet function and morphology. Dyserythropoietic anemia of variable severity may also be present.			Disease or Syndrome	
C136654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136654>	C48233	Soft Tissue Sarcoma TNM Finding v8	A finding about one or more characteristics of soft tissue sarcoma, following the rules of the TNM AJCC v8 classification system. This classification system applies to soft tissue sarcomas that arise in the following areas: head and neck, trunk and extremities, gastrointestinal tract, genitourinary tract, viscera and retroperitoneum, gynecologic sites, breast, lung, pleura, mediastinum, and other unusual histologies and sites. It does not apply to desmoid tumor/deep fibromatosis (no AJCC staging system available) and Kaposi sarcoma (no AJCC staging system available; AIDS Clinical Trials Group system TIS (tumor, immune system, systemic illness) staging may be used). (from AJCC 8th Ed.)			Finding	
C136655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136655>	C136654	Soft Tissue Sarcoma of the Head and Neck TNM Finding v8|Soft Tissue Sarcoma Head and Neck TNM Finding v8	A finding about one or more characteristics of soft tissue sarcoma of the head and neck, following the rules of the TNM AJCC v8 classification system. This classification system applies to soft tissue sarcomas of the head and neck except angiosarcoma, rhabdomyosarcoma of the embryonal and alveolar subtype, Kaposi sarcoma, and dermatofibrosarcoma protuberans, which do not share the same behavior and natural history. This is a new classification system that needs data collection before defining a stage grouping for head and neck sarcomas. Sarcomas of the orbit are staged according to the orbital sarcoma classification system. (from AJCC 8th Ed.)			Finding	
C136656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136656>	C136655	Soft Tissue Sarcoma of the Head and Neck Clinical TNM Finding v8	A clinical finding about one or more characteristics of soft tissue sarcoma of the head and neck, following the rules of the TNM AJCC v8 classification system.			Finding	
C136657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136657>	C136656	Soft Tissue Sarcoma of the Head and Neck Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of soft tissue sarcoma of the head and neck, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C136658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136658>	C136657	Soft Tissue Sarcoma of the Head and Neck cM0 TNM Finding v8	Soft tissue sarcoma of the head and neck without distant metastasis. (from AJCC 8th Ed.)			Finding	
C136659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136659>	C136657	Soft Tissue Sarcoma of the Head and Neck cM1 TNM Finding v8	Soft tissue sarcoma of the head and neck with distant metastasis. (from AJCC 8th Ed.)			Finding	
C13665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13665>	C13432	17q23-q24	A chromosome band present on 17q			Gene or Genome	
C136660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136660>	C136655	Soft Tissue Sarcoma of the Head and Neck Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of soft tissue sarcoma of the head and neck, following the rules of the TNM AJCC v8 classification system.			Finding	
C136661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136661>	C136660	Soft Tissue Sarcoma of the Head and Neck Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of soft tissue sarcoma of the head and neck, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C136662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136662>	C136661	Soft Tissue Sarcoma of the Head and Neck pM1 TNM Finding v8	Soft tissue sarcoma of the head and neck with distant metastasis. (from AJCC 8th Ed.)			Finding	
C136663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136663>	C136660	Soft Tissue Sarcoma of the Head and Neck Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of soft tissue sarcoma of the head and neck, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C136664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136664>	C136663	Soft Tissue Sarcoma of the Head and Neck pTX TNM Finding v8	Soft tissue sarcoma of the head and neck in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C136665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136665>	C136663	Soft Tissue Sarcoma of the Head and Neck pT1 TNM Finding v8	Soft tissue sarcoma of the head and neck with tumor measuring 2 cm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C136666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136666>	C136663	Soft Tissue Sarcoma of the Head and Neck pT2 TNM Finding v8	Soft tissue sarcoma of the head and neck with tumor measuring more than 2 cm but 4 cm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C136667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136667>	C136663	Soft Tissue Sarcoma of the Head and Neck pT3 TNM Finding v8	Soft tissue sarcoma of the head and neck with tumor measuring more than 4 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C136668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136668>	C136663	Soft Tissue Sarcoma of the Head and Neck pT4 TNM Finding v8	Soft tissue sarcoma of the head and neck with tumor invading adjoining structures. (from AJCC 8th Ed.)			Finding	
C136669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136669>	C136668	Soft Tissue Sarcoma of the Head and Neck pT4a TNM Finding v8	Soft tissue sarcoma of the head and neck with tumor invading the orbit, skull base/dura, central compartment viscera, facial skeleton, or pterygoid muscles. (from AJCC 8th Ed.)			Finding	
C13666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13666>	C13432	3q25.1-q26.1	A chromosome band present on 3q			Gene or Genome	
C136670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136670>	C136668	Soft Tissue Sarcoma of the Head and Neck pT4b TNM Finding v8	Soft tissue sarcoma of the head and neck with tumor invading the brain parenchyma, prevertebral muscle, central nervous system via perineural spread, or carotid artery encasement. (from AJCC 8th Ed.)			Finding	
C136671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136671>	C136660	Soft Tissue Sarcoma of the Head and Neck Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of soft tissue sarcoma of the head and neck, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C136672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136672>	C136671	Soft Tissue Sarcoma of the Head and Neck pN0 TNM Finding v8	Soft tissue sarcoma of the head and neck without regional lymph node metastases or unknown lymph node status. (from AJCC 8th Ed.)			Finding	
C136673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136673>	C136671	Soft Tissue Sarcoma of the Head and Neck pN1 TNM Finding v8	Soft tissue sarcoma of the head and neck with regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C136674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136674>	C136654	Soft Tissue Sarcoma of the Trunk and Extremities TNM Finding v8|Soft Tissue Sarcoma Trunk and Extremities TNM Finding v8	A finding about one or more characteristics of soft tissue sarcoma of the trunk and extremities, following the rules of the TNM AJCC v8 classification system. (from AJCC 8th Ed.)			Finding	
C136675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136675>	C136674	Soft Tissue Sarcoma of the Trunk and Extremities Clinical TNM Finding v8	A clinical finding about one or more characteristics of soft tissue sarcoma of the trunk and extremities, following the rules of the TNM AJCC v8 classification system.			Finding	
C136676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136676>	C136675	Soft Tissue Sarcoma of the Trunk and Extremities Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of soft tissue sarcoma of the trunk and extremities, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C136677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136677>	C136676	Soft Tissue Sarcoma of the Trunk and Extremities cM0 TNM Finding v8	Soft tissue sarcoma of the trunk and extremities without distant metastasis. (from AJCC 8th Ed.)			Finding	
C136678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136678>	C136676	Soft Tissue Sarcoma of the Trunk and Extremities cM1 TNM Finding v8	Soft tissue sarcoma of the trunk and extremities with distant metastasis. (from AJCC 8th Ed.)			Finding	
C136679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136679>	C136674	Soft Tissue Sarcoma of the Trunk and Extremities Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of soft tissue sarcoma of the trunk and extremities, following the rules of the TNM AJCC v8 classification system.			Finding	
C13667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13667>	C13432	4q31.1-q31.2	A chromosome band present on 4q			Gene or Genome	
C136680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136680>	C136679	Soft Tissue Sarcoma of the Trunk and Extremities Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of soft tissue sarcoma of the trunk and extremities, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C136681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136681>	C136680	Soft Tissue Sarcoma of the Trunk and Extremities pM1 TNM Finding v8	Soft tissue sarcoma of the trunk and extremities with distant metastasis. (from AJCC 8th Ed.)			Finding	
C136682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136682>	C136679	Soft Tissue Sarcoma of the Trunk and Extremities Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of soft tissue sarcoma of the trunk and extremities, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C136683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136683>	C136682	Soft Tissue Sarcoma of the Trunk and Extremities pTX TNM Finding v8	Soft tissue sarcoma of the trunk and extremities in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C136684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136684>	C136682	Soft Tissue Sarcoma of the Trunk and Extremities pT0 TNM Finding v8	Soft tissue sarcoma of the trunk and extremities with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C136685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136685>	C136682	Soft Tissue Sarcoma of the Trunk and Extremities pT1 TNM Finding v8	Soft tissue sarcoma of the trunk and extremities with tumor measuring 5 cm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C136686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136686>	C136682	Soft Tissue Sarcoma of the Trunk and Extremities pT2 TNM Finding v8	Soft tissue sarcoma of the trunk and extremities with tumor measuring more than 5 cm and less than or equal to 10 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C136687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136687>	C136682	Soft Tissue Sarcoma of the Trunk and Extremities pT3 TNM Finding v8	Soft tissue sarcoma of the trunk and extremities with tumor measuring more than 10 cm and less than or equal to 15 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C136688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136688>	C136682	Soft Tissue Sarcoma of the Trunk and Extremities pT4 TNM Finding v8	Soft tissue sarcoma of the trunk and extremities with tumor measuring more than 15 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C136689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136689>	C136679	Soft Tissue Sarcoma of the Trunk and Extremities Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of soft tissue sarcoma of the trunk and extremities, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C13668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13668>	C13432	7q35-q36	A chromosome band present on 7q			Gene or Genome	
C136690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136690>	C136689	Soft Tissue Sarcoma of the Trunk and Extremities pN0 TNM Finding v8	Soft tissue sarcoma of the trunk and extremities without regional lymph node metastasis or unknown lymph node status. (from AJCC 8th Ed.)			Finding	
C136691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136691>	C136689	Soft Tissue Sarcoma of the Trunk and Extremities pN1 TNM Finding v8	Soft tissue sarcoma of the trunk and extremities with regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C136693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136693>	C9306	Soft Tissue Sarcoma by AJCC v8 Stage	A term that refers to the staging of soft tissue sarcoma, following the rules of the TNM AJCC v8 classification system.	Soft Tissue Sarcoma by AJCC v8 Stage		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136694>	C165190|C136693	Soft Tissue Sarcoma of the Trunk and Extremities by AJCC v8 Stage|Soft Tissue Sarcoma Trunk and Extremities by AJCC v8 Stage	A term that refers to the staging of soft tissue sarcoma of the trunk and extremities, following the rules of the TNM AJCC v8 classification system.			Neoplastic Process	
C136695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136695>	C21183	NUP98 Gene Product	A protein encoded by the NUP98 gene.			Amino Acid, Peptide, or Protein	
C136696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136696>	C136694	Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8|Stage I Soft Tissue Sarcoma of the Trunk and Extremities	Stage I includes: IA: (T1, N0, M0, G1, GX); IB: (T2, T3, T4, N0, M0, G1, GX). T1: Tumor measuring 5 cm or less in greatest dimension. T2: Tumor measuring more than 5 cm and less than or equal to 10 cm in greatest dimension. T3: Tumor measuring more than 10 cm and less than or equal to 15 cm in greatest dimension. T4: Tumor measuring more than 15 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. GX: Grade cannot be assessed. G1: Total differentiation, mitotic count and necrosis score of 2 or 3. (AJCC 8th ed.)	Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136697>	C136695	Nuclear Pore Complex Protein Nup98-Nup96|NUP196|NUP98-NUP96 Precursor|NUP98-NUP96 Precursor Protein|Nup98-96|Nup98-Nup96	Nuclear pore complex protein Nup98-Nup96 (1817 aa, ~198 kDa) is encoded by the human NUP98 gene. This protein may play a role in nuclear pore complex assembly and bidirectional transport across the nuclear pore complex.	Nuclear Pore Complex Protein Nup98-Nup96		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C136698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136698>	C136696	Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8|Stage IA Soft Tissue Sarcoma of the Trunk and Extremities	Stage IA includes: T1, N0, M0, G1, GX. T1: Tumor measuring 5 cm or less in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. GX: Grade cannot be assessed. G1: Total differentiation, mitotic count and necrosis score of 2 or 3. (AJCC 8th ed.)	Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13669>	C13432	9p22.3	A chromosome band present on 9p			Gene or Genome	
C1366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1366>	C67502	Doxorubicin-HPMA Conjugate|Doxorubicin-HPMA|Doxorubicin-HPMA Copolymer Conjugate|HPMA-Doxorubicin|P(GFLG)-ADR|PK1	A copolymer conjugate of the antineoplastic anthracycline doxorubicin and the water-soluble polymer N-(2-hydroxypropyl) methacrylamide (HPMA). Doxorubicin, an intercalator and a topoisomerase II inhibitor, prevents DNA replication and ultimately inhibits protein synthesis. This agent also generates oxygen free radicals, resulting in cytotoxic lipid peroxidation of cell membrane lipid. HPMA conjugation enhances the permeability and retention of this agent within the tumor vasculature. Poorly cleared by the lymphatic system, this formulation undergoes increased cleavage by tumor cell lysosomal proteinases, resulting in increased, sustained intracellular concentrations of free doxorubicin. Compared to other doxorubicin-containing formulations, this formulation may exhibit an improved toxicity profile due to the lower concentrations of free doxorubicin to which non-malignant tissues are exposed.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C136700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136700>	C136696	Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8|Stage IB Soft Tissue Sarcoma of the Trunk and Extremities	Stage IB includes: T2, T3, T4, N0, M0, G1, GX. T2: Tumor measuring more than 5 cm and less than or equal to 10 cm in greatest dimension. T3: Tumor measuring more than 10 cm and less than or equal to 15 cm in greatest dimension. T4: Tumor measuring more than 15 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. GX: Grade cannot be assessed. G1: Total differentiation, mitotic count and necrosis score of 2 or 3. (AJCC 8th ed.)	Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136701>	C136694	Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8|Stage II Soft Tissue Sarcoma of the Trunk and Extremities	Stage II includes: T1, N0, M0, G2, G3. T1: Tumor measuring 5 cm or less in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. G2: Total differentiation, mitotic count and necrosis score of 4 or 5. G3: Total differentiation, mitotic count and necrosis score of 6, 7, or 8. (AJCC 8th ed.)	Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136702>	C136694	Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8|Stage III Soft Tissue Sarcoma of the Trunk and Extremities	Stage III includes: IIIA: (T2, N0, M0, G2, G3); IIIB: (T3, T4, N0, M0, G2, G3). T2: Tumor measuring more than 5 cm and less than or equal to 10 cm in greatest dimension. T3: Tumor measuring more than 10 cm and less than or equal to 15 cm in greatest dimension. T4: Tumor measuring more than 15 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. G2: Total differentiation, mitotic count and necrosis score of 4 or 5. G3: Total differentiation, mitotic count and necrosis score of 6, 7, or 8. (AJCC 8th ed.)	Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136703>	C136702	Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8|Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities	Stage IIIA includes: T2, N0, M0, G2, G3. T2: Tumor measuring more than 5 cm and less than or equal to 10 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. G2: Total differentiation, mitotic count and necrosis score of 4 or 5. G3: Total differentiation, mitotic count and necrosis score of 6, 7, or 8. (AJCC 8th ed.)	Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136705>	C136702	Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8|Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities	Stage IIIB includes: T3, T4, N0, M0, G2, G3. T3: Tumor measuring more than 10 cm and less than or equal to 15 cm in greatest dimension. T4: Tumor measuring more than 15 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. G2: Total differentiation, mitotic count and necrosis score of 4 or 5. G3: Total differentiation, mitotic count and necrosis score of 6, 7, or 8. (AJCC 8th ed.)	Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136706>	C136694	Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8|Stage IV Soft Tissue Sarcoma of the Trunk and Extremities	Stage IV includes: (Any T, N1, M0, Any G); (Any T, Any N, M1, Any G). N1: Regional lymph node metastasis. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136707>	C9306	Soft Tissue Sarcoma by AJCC v7 Stage	A term that refers to the staging of soft tissue sarcoma, following the rules of the TNM AJCC v7 classification system.			Neoplastic Process	
C136708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136708>	C6339	Uterine Corpus Sarcoma by AJCC v7 Stage	A term that refers to the staging of uterine corpus sarcoma, following the rules of the TNM AJCC v7 classification system.			Neoplastic Process	
C136709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136709>	C9480|C3512|C26712	Invasive Lung Mucinous Adenocarcinoma|Invasive mucinous adenocarcinoma|Mucinous Bronchioloalveolar Carcinoma|Mucinous Invasive Lung Adenocarcinoma	An invasive adenocarcinoma that arises from the lung. It is characterized by the presence of tall columnar cells and mucin production. This category refers to cases formerly classified as mucinous bronchioloalveolar carcinoma, excluding cases that meet the criteria for adenocarcinoma in situ or mucinous minimally invasive adenocarcinoma.	Invasive Lung Mucinous Adenocarcinoma		Neoplastic Process	Cellosaurus Disease Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Morphology PT Terminology|Mapped ICDO3.1 Morphology Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C13670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13670>	C13432	Xq26.1	A chromosome band present on Xq			Gene or Genome	
C136710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136710>	C4126|C3512	Lung Enteric Adenocarcinoma|Enteric adenocarcinoma|Pulmonary Intestinal-Type Adenocarcinoma	A well-differentiated adenocarcinoma located in the lung periphery. It resembles colorectal adenocarcinoma with acinar and/or cribriform architecture and papillotubular structures.			Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C136711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136711>	C49164	Immune-Modified Response Evaluation Criteria in Solid Tumors|Immune-Modified Response Evaluation Criteria in Solid Tumors (iRECIST)|iRECIST|iRECIST	A modification of the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, for use as a standard approach to solid tumor measurements and definitions for objective change in tumor size in cancer clinical trials in which an immunotherapy is used.			Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C136712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136712>	C36292	Mismatch Repair Deficiency|Deficient DNA Mismatch Repair|MMR Deficiency|MMR Deficient|MMRd|Mismatch Repair Deficient|dMMR	A finding indicating that a cellular sample has high microsatellite instability and/or a functional loss of a protein involved in the DNA mismatch repair process.	Mismatch Repair Deficiency		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136713>	C3493	Lung Keratinizing Squamous Cell Carcinoma|Keratinizing Squamous Cell Lung Carcinoma|Keratinizing squamous cell carcinoma	A squamous cell lung carcinoma characterized by the presence of keratinization, pearl formation, and/or intercellular bridges.			Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C136714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136714>	C3493|C211551	Lung Non-Keratinizing Squamous Cell Carcinoma|Lung Nonkeratinizing Squamous Cell Carcinoma|Non-Keratinizing Squamous Cell Lung Carcinoma|Non-keratinizing squamous cell carcinoma	A squamous cell lung carcinoma characterized by the absence of keratinization, pearl formation, and intercellular bridges.			Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C136715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136715>	C35867	Intercellular Bridges Present	A microscopic finding indicating the presence of intercellular bridges connecting adjacent cells in a tissue sample.			Finding	
C136716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136716>	C136486	Lung Non-Mucinous Adenocarcinoma In Situ	Lung adenocarcinoma in situ characterized by the presence of type II pneumocyte and/or Clara cell differentiation. Almost all cases of lung adenocarcinoma in situ are non-mucinous.			Neoplastic Process	GDC Terminology|GDC Value Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C136717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136717>	C136486	Lung Mucinous Adenocarcinoma In Situ	A very rare lung adenocarcinoma in situ variant characterized by the presence of tall columnar cells with basal nuclei and abundant cytoplasmic mucin.			Neoplastic Process	GDC Terminology|GDC Value Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C136718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136718>	C21140	KISS1 Gene Product	A protein encoded by the KISS1 gene.			Amino Acid, Peptide, or Protein	
C136719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136719>	C3493|C27093|C226343	Lung Squamous Cell Carcinoma In Situ|LUSC-CIS|Lung SCIS|Squamous Cell Lung Carcinoma In Situ	An intraepithelial squamous cell carcinoma that arises from the bronchial epithelium without evidence of invasion.	Lung Squamous Cell Carcinoma In Situ		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13671>	C13379	Ligand Binding Domain|Binding Site|Binding Site Domain	A Binding Site Domain is a region of protein that physically interacts stereospecifically, and usually at high affinity, with a specific ligand, substrate, or a specific domain of some complex target biomolecule, such as a protein, lipid, carbohydrate, or nucleic acid. Typically, but not necessarily, the interaction results in protein conformational alteration and functional modification.			Amino Acid Sequence	
C136720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136720>	C686	NPY Gene Product	A protein encoded by the NPY gene.			Amino Acid, Peptide, or Protein	
C136721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136721>	C136720	Pro-Neuropeptide Y|Prepro-Neuropeptide Y	Pro-neuropeptide Y (97 aa, ~11 kDa) is encoded by the human NPY gene. This protein plays a role in the regulation of feeding behavior.			Amino Acid, Peptide, or Protein	
C136722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136722>	C1746	AGT Gene Product	A protein encoded by the human AGT gene.			Amino Acid, Peptide, or Protein	
C136723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136723>	C136722	Angiotensinogen|AGT|Pre-Angiotensinogen|Serpin A8	Angiotensinogen (485 aa, ~53 kDa) is encoded by the human AGT gene. This protein plays a role in the regulation of blood pressure, body fluid and electrolyte homeostasis.			Amino Acid, Peptide, or Protein	
C136724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136724>	C136654	Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs TNM Finding v8|Soft Tissue Sarcoma Abdomen And Thoracic Visceral Organs TNM Finding v8	A finding about one or more characteristics of soft tissue sarcoma of the abdomen and thoracic visceral organs, following the rules of the TNM AJCC v8 classification system. This classification system does not apply to desmoplastic small round cell tumor, epithelioid hemangioendothelioma, inflammatory myofibroblastic tumor, perivascular epithelioid cell tumor (PEComa), solitary fibrous tumor, gastrointestinal stromal tumor (GIST), uterine leiomyosarcoma, and retroperitoneal leiomyosarcoma.  This is a new classification system and there is no recommended prognostic stage grouping at this time. (from AJCC 8th Ed.)			Finding	
C136725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136725>	C136724	Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs Clinical TNM Finding v8	A clinical finding about one or more characteristics of soft tissue sarcoma of the abdomen and thoracic visceral organs, following the rules of the TNM AJCC v8 classification system.			Finding	
C136726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136726>	C136725	Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of soft tissue sarcoma of the abdomen and thoracic visceral organs, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C136727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136727>	C136726	Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs cM0 TNM Finding v8	Soft tissue sarcoma of the abdomen and thoracic visceral organs without distant metastases. (from AJCC 8th Ed.)			Finding	
C136728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136728>	C136726	Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs cM1 TNM Finding v8	Soft tissue sarcoma of the abdomen and thoracic visceral organs with distant metastases. (from AJCC 8th Ed.)			Finding	
C136729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136729>	C136724	Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of soft tissue sarcoma of the abdomen and thoracic visceral organs, following the rules of the TNM AJCC v8 classification system.			Finding	
C13672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13672>	C13453|C13426	LIM Domain|CRR Domain|Cysteine Rich Region	The LIM domain is a zinc binding, cysteine rich motif consisting of two tandemly repeated zinc fingers. Unlike GATA type zinc fingers, LIM domains do not bind DNA but instead mediate protein-protein interactions. Functionally, LIM domain containing proteins have been implicated in cell lineage specification, cytoskeletal organization, and organ development.			Amino Acid Sequence	
C136730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136730>	C136729	Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of soft tissue sarcoma of the abdomen and thoracic visceral organs, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C136731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136731>	C136730	Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pM1 TNM Finding v8	Soft tissue sarcoma of the abdomen and thoracic visceral organs with distant metastases. (from AJCC 8th Ed.)			Finding	
C136732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136732>	C136729	Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of soft tissue sarcoma of the abdomen and thoracic visceral organs, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C136733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136733>	C136732	Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pTX TNM Finding v8	Soft tissue sarcoma of the abdomen and thoracic visceral organs in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C136734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136734>	C136732	Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pT1 TNM Finding v8	Soft tissue sarcoma of the abdomen and thoracic visceral organs, organ confined. (from AJCC 8th Ed.)			Finding	
C136735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136735>	C136732	Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pT2 TNM Finding v8	Soft tissue sarcoma of the abdomen and thoracic visceral organs with tumor extending into tissue beyond organ. (from AJCC 8th Ed.)			Finding	
C136736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136736>	C136735	Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pT2a TNM Finding v8	Soft tissue sarcoma of the abdomen and thoracic visceral organs with tumor invading serosa or visceral peritoneum. (from AJCC 8th Ed.)			Finding	
C136737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136737>	C136735	Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pT2b TNM Finding v8	Soft tissue sarcoma of the abdomen and thoracic visceral organs with tumor extending beyond serosa (mesentery). (from AJCC 8th Ed.)			Finding	
C136738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136738>	C136732	Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pT3 TNM Finding v8	Soft tissue sarcoma of the abdomen and thoracic visceral organs with tumor invading another organ. (from AJCC 8th Ed.)			Finding	
C136739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136739>	C136732	Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pT4 TNM Finding v8	Soft tissue sarcoma of the abdomen and thoracic visceral organs with multifocal involvement. (from AJCC 8th Ed.)			Finding	
C13673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13673>	C13432	19p13.3	A chromosome band present on 19p			Gene or Genome	
C136740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136740>	C136739	Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pT4a TNM Finding v8	Soft tissue sarcoma of the abdomen and thoracic visceral organs with multifocal involvement (two sites). (from AJCC 8th Ed.)			Finding	
C136741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136741>	C136739	Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pT4b TNM Finding v8	Soft tissue sarcoma of the abdomen and thoracic visceral organs with multifocal involvement (three to five sites). (from AJCC 8th Ed.)			Finding	
C136742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136742>	C136739	Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pT4c TNM Finding v8	Soft tissue sarcoma of the abdomen and thoracic visceral organs with multifocal involvement (more than five sites). (from AJCC 8th Ed.)			Finding	
C136743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136743>	C136729	Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of soft tissue sarcoma of the abdomen and thoracic visceral organs, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C136744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136744>	C136743	Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pN0 TNM Finding v8	Soft tissue sarcoma of the abdomen and thoracic visceral organs without lymph node involvement or unknown lymph node status. (from AJCC 8th Ed.)			Finding	
C136745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136745>	C136743	Soft Tissue Sarcoma of the Abdomen and Thoracic Visceral Organs pN1 TNM Finding v8	Soft tissue sarcoma of the abdomen and thoracic visceral organs with lymph node involvement. (from AJCC 8th Ed.)			Finding	
C136746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136746>	C177687|C165233	IDH1 R132H Negative|Cytosolic NADP-Isocitrate Dehydrogenase Protein Arg132His Negative|Cytosolic NADP-Isocitrate Dehydrogenase Protein R132H Negative|IDH1 Arg132His Negative|IDH1 NP_005887.2:p.Arg132His Negative|IDH1 NP_005887.2:p.R132H Negative|IDH1 R132H Substitution Negative|IDH1 p.Arg132His Negative|IDH1 p.R132H Negative|Isocitrate Dehydrogenase [NADP] Cytoplasmic Arg132His Negative|Isocitrate Dehydrogenase [NADP] Cytoplasmic R132H Negative|NP_005887.2:p.Arg132His Negative|NP_005887.2:p.R132H Negative	A finding indicating that a mutation of the IDH1 gene encoding the amino acid substitution Arg132His (R132H) in the isocitrate dehydrogenase [NADP] cytoplasmic protein has not been detected in a sample.	IDH1 R132H Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136747>	C136748	Proglucagon|Preproglucagon|Pro-Glucagon	Proglucagon  (180 aa, ~21 kDa) is encoded by the human GCG gene. This protein is involved in appetite, digestion, and glucose metabolism and homeostasis.			Amino Acid, Peptide, or Protein	
C136748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136748>	C1746	GCG Gene Product	A protein encoded by the GCG gene.			Amino Acid, Peptide, or Protein	
C136749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136749>	C136654	Gastrointestinal Stromal Tumor TNM Finding v8|GIST TNM Finding v8	A finding about one or more characteristics of gastrointestinal stromal tumor (GIST), following the rules of the TNM AJCC v8 classification system. This classification system does not apply to pediatric GIST, familial GIST (germline mutant KIT or PDGFRA), or syndromic GIST (no AJCC staging system available). (from AJCC 8th Ed.)			Finding	
C13674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13674>	C13432	12q14.3-q15	A chromosome band present on 12q			Gene or Genome	
C136750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136750>	C136749	Gastrointestinal Stromal Tumor Clinical TNM Finding v8|GIST Clinical TNM Finding v8	A clinical finding about one or more characteristics of gastrointestinal stromal tumor, following the rules of the TNM AJCC v8 classification system.			Finding	
C136751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136751>	C136750	Gastrointestinal Stromal Tumor Clinical Distant Metastasis TNM Finding v8|GIST Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of gastrointestinal stromal tumor, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C136752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136752>	C136751	Gastrointestinal Stromal Tumor cM0 TNM Finding v8|GIST cM0 TNM Finding v8	Gastrointestinal stromal tumor without distant metastasis. (from AJCC 8th Ed.)			Finding	
C136753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136753>	C136751	Gastrointestinal Stromal Tumor cM1 TNM Finding v8|GIST cM1 TNM Finding v8	Gastrointestinal stromal tumor with distant metastasis. (from AJCC 8th Ed.)			Finding	
C136754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136754>	C136749	Gastrointestinal Stromal Tumor Pathologic TNM Finding v8|GIST Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of gastrointestinal stromal tumor, following the rules of the TNM AJCC v8 classification system.			Finding	
C136755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136755>	C136754	Gastrointestinal Stromal Tumor Pathologic Distant Metastasis TNM Finding v8|GIST Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of gastrointestinal stromal tumor, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C136756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136756>	C136755	Gastrointestinal Stromal Tumor pM1 TNM Finding v8|GIST pM1 TNM Finding v8	Gastrointestinal stromal tumor with distant metastasis. (from AJCC 8th Ed.)			Finding	
C136757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136757>	C136754	Gastrointestinal Stromal Tumor Pathologic Primary Tumor TNM Finding v8|GIST Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of gastrointestinal stromal tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C136758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136758>	C136757	Gastrointestinal Stromal Tumor pTX TNM Finding v8|GIST pTX TNM Finding v8	Gastrointestinal stromal tumor in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C136759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136759>	C136757	Gastrointestinal Stromal Tumor pT0 TNM Finding v8|GIST pT0 TNM Finding v8	Gastrointestinal stromal tumor with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C13675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13675>	C13432	9q22.3	A chromosome band present on 9q			Gene or Genome	
C136760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136760>	C136757	Gastrointestinal Stromal Tumor pT1 TNM Finding v8|GIST pT1 TNM Finding v8	Gastrointestinal stromal tumor measuring 2 cm or less. (from AJCC 8th Ed.)			Finding	
C136761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136761>	C136757	Gastrointestinal Stromal Tumor pT2 TNM Finding v8|GIST pT2 TNM Finding v8	Gastrointestinal stromal tumor measuring more than 2 cm but not more than 5 cm. (from AJCC 8th Ed.)			Finding	
C136762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136762>	C136757	Gastrointestinal Stromal Tumor pT3 TNM Finding v8|GIST pT3 TNM Finding v8	Gastrointestinal stromal tumor measuring more than 5 cm but not more than 10 cm. (from AJCC 8th Ed.)			Finding	
C136763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136763>	C136757	Gastrointestinal Stromal Tumor pT4 TNM Finding v8|GIST pT4 TNM Finding v8	Gastrointestinal stromal tumor measuring more than 10 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C136764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136764>	C136754	Gastrointestinal Stromal Tumor Pathologic Regional Lymph Nodes TNM Finding v8|GIST Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of gastrointestinal stromal tumor, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C136765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136765>	C136764	Gastrointestinal Stromal Tumor pN0 TNM Finding v8|GIST pN0 TNM Finding v8	Gastrointestinal stromal tumor without regional lymph node metastasis or unknown lymph node status. (from AJCC 8th Ed.)			Finding	
C136766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136766>	C136764	Gastrointestinal Stromal Tumor pN1 TNM Finding v8|GIST pN1 TNM Finding v8	Gastrointestinal stromal tumor with regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C136767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136767>	C53999|C136693	Gastrointestinal Stromal Tumor by AJCC v8 Stage|GIST by AJCC v8 Stage	A term that refers to the staging of gastrointestinal stromal tumor (GIST), following the rules of the TNM AJCC v8 classification system. This staging system does not apply to pediatric GIST, familial GIST (germline mutant KIT or PDGFRA), or syndromic GIST (no AJCC staging system available). (from AJCC 8th Ed.)			Neoplastic Process	
C136768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136768>	C136767	Gastric and Omental Gastrointestinal Stromal Tumor by AJCC v8 Stage|Gastric and Omental GIST by AJCC v8 Stage	A term that refers to the staging of gastric and omental gastrointestinal stromal tumor (GIST), following the rules of the TNM AJCC v8 classification system. (from AJCC 8th Ed.)			Neoplastic Process	
C136769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136769>	C136767	Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor by AJCC v8 Stage|Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal GIST by AJCC v8 Stage	A term that refers to the staging of small intestinal, esophageal, colorectal, mesenteric, and peritoneal gastrointestinal stromal tumor (GIST), following the rules of the TNM AJCC v8 classification system. (from AJCC 8th Ed.)			Neoplastic Process	
C13676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13676>	C13432	8q24.12-q24.13	A chromosome band present on 8q			Gene or Genome	
C136770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136770>	C136768	Stage I Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8|Stage I Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST)|Stage I Gastric and Omental GIST AJCC v8	Stage I includes: IA: (T1 or T2, N0, M0, Low Mitotic Rate); IB: (T3, N0, M0, Low Mitotic Rate). T1: Tumor measuring 2 cm or less. T2: Tumor measuring more than 2 cm but not more than 5 cm. T3: Tumor measuring more than 5 cm but not more than 10 cm. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. Low Mitotic Rate: Five or fewer mitoses per 5 square millimeters, or per 50 HPF. (AJCC 8th ed.)	Stage I Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136771>	C136770	Stage IA Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8|Stage IA Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST)|Stage IA Gastric and Omental GIST AJCC v8	Stage IA includes: T1 or T2, N0, M0, Low Mitotic Rate. T1: Tumor measuring 2 cm or less. T2: Tumor measuring more than 2 cm but not more than 5 cm. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. Low Mitotic Rate: Five or fewer mitoses per 5 square millimeters, or per 50 HPF. (AJCC 8th ed.)	Stage IA Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136772>	C136770	Stage IB Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8|Stage IB Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST)|Stage IB Gastric and Omental GIST AJCC v8	Stage IB includes: T3, N0, M0, Low Mitotic Rate. T3: Tumor measuring more than 5 cm but not more than 10 cm. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. Low Mitotic Rate: Five or fewer mitoses per 5 square millimeters, or per 50 HPF. (AJCC 8th ed.)	Stage IB Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136773>	C136768	Stage II Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8|Stage II Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST)|Stage II Gastric and Omental GIST AJCC v8	Stage II includes: (T1, N0, M0, High Mitotic Rate); (T2, N0, M0, High Mitotic Rate); (T4, N0, M0, Low Mitotic Rate). T1: Tumor measuring 2 cm or less. T2: Tumor measuring more than 2 cm but not more than 5 cm. T4: Tumor measuring more than 10 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. High Mitotic Rate: Over 5 mitoses per 5 square millimeters, or per 50 HPF. Low Mitotic Rate: Five or fewer mitoses per 5 square millimeters, or per 50 HPF. (AJCC 8th ed.)	Stage II Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136774>	C136768	Stage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8|Stage III Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST)|Stage III Gastric and Omental GIST AJCC v8	Stage III includes: IIIA: (T3, N0, M0, High Mitotic Rate); IIIB: (T4, N0, M0, High Mitotic Rate). T3: Tumor measuring more than 5 cm but not more than 10 cm. T4: Tumor measuring more than 10 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. High Mitotic Rate: Over 5 mitoses per 5 square millimeters, or per 50 HPF. (AJCC 8th ed.)	Stage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136775>	C136774	Stage IIIA Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8|Stage IIIA Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST)|Stage IIIA Gastric and Omental GIST AJCC v8	Stage IIIA includes: T3, N0, M0, High Mitotic Rate. T3: Tumor measuring more than 5 cm but not more than 10 cm. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. High Mitotic Rate: Over 5 mitoses per 5 square millimeters, or per 50 HPF. (AJCC 8th ed.)	Stage IIIA Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136776>	C2124	PSMA-targeting Agent-Technetium Tc99m EC0652|99mTc-EC0652|DUPA-99mTc|DUPA-99mTc EC0652|EC 0652|EC-0652|EC0652|Radiodiagnostic EC0652	A radioconjugate composed of 2-[3-(1, 3-dicarboxy propyl)-ureido] pentanedioic acid (DUPA), a prostate-specific membrane antigen (PSMA)-targeting ligand, linked to the radioisotope technetium Tc 99m (Tc99m), that can potentially be used as a radioimaging agent for PSMA-overexpressing tumor cells. Upon administration, the PSMA-targeting moiety of EC0652 targets and binds to PSMA-expressing tumors. Upon uptake and single-photon emission computed tomography (SPECT) imaging, PSMA-expressing tumors can be visualized and identified. In turn, PSMA-overexpression can be used to evaluate both the efficacy of and response to certain PSMA-targeting cytotoxic agents. PSMA, a tumor-associated antigen (TAA), is overexpressed by most prostate cancers.	PSMA-targeting Agent-Technetium Tc99m EC0652		Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C136777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136777>	C136774	Stage IIIB Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8|Stage IIIB Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST)|Stage IIIB Gastric and Omental GIST AJCC v8	Stage IIIB includes: T4, N0, M0, High Mitotic Rate. T4: Tumor measuring more than 10 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. High Mitotic Rate: Over 5 mitoses per 5 square millimeters, or per 50 HPF. (AJCC 8th ed.)	Stage IIIB Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136778>	C136768	Stage IV Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8|Stage IV Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST)|Stage IV Gastric and Omental GIST AJCC v8	Stage IV includes: (Any T, N1, M0, Any Mitotic Rate); (Any T, Any N, M1, Any Mitotic Rate). N1: Regional lymph node metastasis. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136779>	C129823	Anti-RNF43 Antibody-drug Conjugate SC-006|ADC SC-006|Anti-RNF43 ADC SC-006|SC 006|SC-006|SC-006|SC006	An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) ring finger protein 43 (RNF43), linked to a DNA crosslinking pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of anti-RNF43 ADC SC-006 targets and binds to RNF43 expressed on tumor cells. Upon binding and internalization, the cytotoxic PBD moiety is released and forms highly cytotoxic DNA interstrand cross-links, thereby blocking cell division and killing RNF43-expressing cancer cells. RNF43, a single-span transmembrane E3 ubiquitin ligase, is overexpressed by certain tumor cell types and a negative regulator of the Wnt signaling pathway.	Anti-RNF43 Antibody-drug Conjugate SC-006		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C13677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13677>	C13432	6p24	A chromosome band present on 6p			Gene or Genome	
C136780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136780>	C136769	Stage I Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8|Stage I Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal GIST AJCC v8|Stage I Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor (GIST)	Stage I includes: T1 or T2, N0, M0, Low Mitotic Rate. T1: Tumor measuring 2 cm or less. T2: Tumor measuring more than 2 cm but not more than 5 cm. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. Low Mitotic Rate: Five or fewer mitoses per 5 square millimeters, or per 50 HPF. (AJCC 8th ed.)	Stage I Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136781>	C136769	Stage II Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8|Stage II Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal GIST AJCC v8|Stage II Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor (GIST)	Stage II includes: T3, N0, M0, Low Mitotic Rate. T3: Tumor measuring more than 5 cm but not more than 10 cm. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. Low Mitotic Rate: Five or fewer mitoses per 5 square millimeters, or per 50 HPF. (AJCC 8th ed.)	Stage II Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136782>	C138180|C129826	CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR|CD8+ and CD4+ Donor Memory T-cells-expressing pRRLSIN iC9-HA1 TCR2-RQR-CD8|HA-1 TCR CD8+ and CD4+ Tm Cells|HA-1 TCR T Cells	A preparation of CD4+ and CD8+ central memory (CM) T-lymphocytes isolated from the peripheral blood of a transplant donor and transduced with a lentiviral vector (LV) (pRRLSIN) expressing a minor H antigen (HA-1(H); HA1(H)) T-cell receptor (TCR) containing the suicide gene inducible caspase 9 (iCasp9 or iC9)-HA1 TCR2-RQR-CD8 transgene (pRRLSIN iC9-HA1 TCR2-RQR-CD8; HA-1 TCR LV), with potential immunostimulating and antineoplastic activities. Upon intravenous administration and after allogeneic hematopoietic stem cell transplantation (HSCT), the CD8+ and CD4+ donor memory T cells-expressing HA1-specific TCR are directed to and induce selective toxicity in HA1-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If administration of the T-cells lead to unacceptable side effects, a dimerizing agent rimiducid (AP1903), which binds to the FKBP12-F36V drug-binding domain and activates caspase 9, can be administered; caspase-9 activation results in the apoptosis of the administered TCR-modified T-cells. HA1(H) is a tumor-associated antigen (TAA) that is selectively and highly expressed on leukemic stem cells and blasts, but not in normal non-hematopoietic cells. RQR includes a CD20 epitope, and a CD34 epitope that facilitates both purification and cell tracking of the transduced T-cells with an anti-CD34 monoclonal antibody.	CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C136783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136783>	C136769	Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8|Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal GIST AJCC v8|Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor (GIST)	Stage III includes: IIIA: (T1, N0, M0, High Mitotic Rate); (T4, N0, M0, Low Mitotic Rate); IIIB: (T2, N0, M0, High Mitotic Rate); (T3, N0, M0, High Mitotic Rate); (T4, N0, M0, High Mitotic Rate). T1: Tumor measuring 2 cm or less. T2: Tumor measuring more than 2 cm but not more than 5 cm. T3: Tumor measuring more than 5 cm but not more than 10 cm. T4: Tumor measuring more than 10 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. High Mitotic Rate: Over 5 mitoses per 5 square millimeters, or per 50 HPF. Low Mitotic Rate: Five or fewer mitoses per 5 square millimeters, or per 50 HPF. (AJCC 8th ed.)	Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136784>	C136783	Stage IIIA Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8|Stage IIIA Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal GIST AJCC v8|Stage IIIA Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor (GIST)	Stage IIIA includes: (T1, N0, M0, High Mitotic Rate); (T4, N0, M0, Low Mitotic Rate). T1: Tumor measuring 2 cm or less. T4: Tumor measuring more than 10 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. High Mitotic Rate: Over 5 mitoses per 5 square millimeters, or per 50 HPF. Low Mitotic Rate: Five or fewer mitoses per 5 square millimeters, or per 50 HPF. (AJCC 8th ed.)	Stage IIIA Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136785>	C136783	Stage IIIB Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8|Stage IIIB Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal GIST AJCC v8|Stage IIIB Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor (GIST)	Stage IIIB includes: (T2, N0, M0, High Mitotic Rate); (T3, N0, M0, High Mitotic Rate); (T4, N0, M0, High Mitotic Rate). T2: Tumor measuring more than 2 cm but not more than 5 cm. T3: Tumor measuring more than 5 cm but not more than 10 cm. T4: Tumor measuring more than 10 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. High Mitotic Rate: Over 5 mitoses per 5 square millimeters, or per 50 HPF. (AJCC 8th ed.)	Stage IIIB Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136786>	C136769	Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8|Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal GIST AJCC v8|Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor (GIST)	Stage IV includes: (Any T, N1, M0, Any Mitotic Rate); (Any T, Any N, M1, Any Mitotic Rate). N1: Regional lymph node metastasis. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136787>	C2270	GNRH2 Gene Product	A protein encoded by the GNRH2 gene.			Amino Acid, Peptide, or Protein	
C136788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136788>	C136787	Gonadoliberin-2|GNRH2|GnRH II|GnRH-II|Gonadoliberin II|Gonadotropin Releasing Hormone 2|Gonadotropin-Releasing Hormone 2|Gonadotropin-Releasing Hormone II|LH-RH II|LH-RHII|Luliberin II|Luteinizing Hormone-Releasing Hormone II	Gonadoliberin-2 (10 aa, ~1 kDa) is encoded by the human GNRH2 gene. This protein is involved in the stimulation of luteinizing hormone and follicle-stimulating hormone secretion.			Amino Acid, Peptide, or Protein|Hormone	
C136789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136789>	C1746	VIP Gene Product	A protein encoded by the VIP gene.			Amino Acid, Peptide, or Protein	
C13678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13678>	C13432	7p12.3-p12.1	A chromosome band present on 7p			Gene or Genome	
C136790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136790>	C136789	VIP Peptides|Prepro-VIP|VIP	VIP peptides (170 aa, ~19 kDa) is encoded by the human VIP gene. This protein plays a role in the regulation of vasodilation.	VIP Peptides		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136791>	C16436	CHGA Gene Product	A protein encoded by the CHGA gene.			Amino Acid, Peptide, or Protein	
C136792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136792>	C136654	Soft Tissue Sarcoma of the Retroperitoneum TNM Finding v8|Retroperitoneal Soft Tissue Sarcoma TNM Finding v8|Soft Tissue Sarcoma Retroperitoneum TNM Finding v8	A finding about one or more characteristics of soft tissue sarcoma of the retroperitoneum, following the rules of the TNM AJCC v8 classification system. This classification system applies to common sarcomas in the retroperitoneum. (from AJCC 8th Ed.)			Finding	
C136793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136793>	C136792	Soft Tissue Sarcoma of the Retroperitoneum Clinical TNM Finding v8|Retroperitoneal Soft Tissue Sarcoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of soft tissue sarcoma of the retroperitoneum, following the rules of the TNM AJCC v8 classification system.			Finding	
C136794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136794>	C136793	Soft Tissue Sarcoma of the Retroperitoneum Clinical Distant Metastasis TNM Finding v8|Retroperitoneal Soft Tissue Sarcoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of soft tissue sarcoma of the retroperitoneum, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C136795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136795>	C136794	Soft Tissue Sarcoma of the Retroperitoneum cM0 TNM Finding v8|Retroperitoneal Soft Tissue Sarcoma cM0 TNM Finding v8	Soft tissue sarcoma of the retroperitoneum without distant metastasis. (from AJCC 8th Ed.)			Finding	
C136796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136796>	C136794	Soft Tissue Sarcoma of the Retroperitoneum cM1 TNM Finding v8|Retroperitoneal Soft Tissue Sarcoma cM1 TNM Finding v8	Soft tissue sarcoma of the retroperitoneum with distant metastasis. (from AJCC 8th Ed.)			Finding	
C136797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136797>	C136792	Soft Tissue Sarcoma of the Retroperitoneum Pathologic TNM Finding v8|Retroperitoneal Soft Tissue Sarcoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of soft tissue sarcoma of the retroperitoneum, following the rules of the TNM AJCC v8 classification system.			Finding	
C136798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136798>	C136797	Soft Tissue Sarcoma of the Retroperitoneum Pathologic Distant Metastasis TNM Finding v8|Retroperitoneal Soft Tissue Sarcoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of soft tissue sarcoma of the retroperitoneum, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C136799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136799>	C136798	Soft Tissue Sarcoma of the Retroperitoneum pM1 TNM Finding v8|Retroperitoneal Soft Tissue Sarcoma pM1 TNM Finding v8	Soft tissue sarcoma of the retroperitoneum with distant metastasis. (from AJCC 8th Ed.)			Finding	
C13679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13679>	C13432	4q25-q27	A chromosome band present on 4q			Gene or Genome	
C1367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1367>	C582|C1968	Elliptinium Acetate|6H-Pyrido[4, 3-b]carbazolium, 9-hydroxy-2,5,11-trimethyl-acetate (salt)|9-Hydroxy-2,5,11-trimethyl-6H-pyrido[4,3-b]carbazolium Acetate (Salt)|9-Hydroxy-2-methylellipticinium Acetate|9-Hydroxy-2-methylellipticinium acetate|Celiptium|Celiptium|ELLIPTINIUM ACETATE|N-2-Methyl-9-hydroxyellipticinium Acetate	Acetate salt of elliptinium, a derivative of the alkaloid ellipticine isolated from species of the plant family Apocynaceae, including Bleekeria vitensis, a plant with anti-cancer properties.  As a topoisomerase II inhibitor and intercalating agent, elliptinium stabilizes the cleavable complex of topoisomerase II and induces DNA breakages, thereby inhibiting DNA replication and RNA and protein synthesis.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C136800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136800>	C136797	Soft Tissue Sarcoma of the Retroperitoneum Pathologic Primary Tumor TNM Finding v8|Retroperitoneal Soft Tissue Sarcoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of soft tissue sarcoma of the retroperitoneum, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C136801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136801>	C136800	Soft Tissue Sarcoma of the Retroperitoneum pTX TNM Finding v8|Retroperitoneal Soft Tissue Sarcoma pTX TNM Finding v8	Soft tissue sarcoma of the retroperitoneum in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C136802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136802>	C136800	Soft Tissue Sarcoma of the Retroperitoneum pT0 TNM Finding v8|Retroperitoneal Soft Tissue Sarcoma pT0 TNM Finding v8	Soft tissue sarcoma of the retroperitoneum with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C136803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136803>	C136800	Soft Tissue Sarcoma of the Retroperitoneum pT1 TNM Finding v8|Retroperitoneal Soft Tissue Sarcoma pT1 TNM Finding v8	Soft tissue sarcoma of the retroperitoneum measuring 5 cm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C136804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136804>	C136800	Soft Tissue Sarcoma of the Retroperitoneum pT2 TNM Finding v8|Retroperitoneal Soft Tissue Sarcoma pT2 TNM Finding v8	Soft tissue sarcoma of the retroperitoneum measuring more than 5 cm and less than or equal to 10 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C136805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136805>	C136800	Soft Tissue Sarcoma of the Retroperitoneum pT3 TNM Finding v8|Retroperitoneal Soft Tissue Sarcoma pT3 TNM Finding v8	Soft tissue sarcoma of the retroperitoneum measuring more than 10 cm and less than or equal to 15 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C136806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136806>	C136800	Soft Tissue Sarcoma of the Retroperitoneum pT4 TNM Finding v8|Retroperitoneal Soft Tissue Sarcoma pT4 TNM Finding v8	Soft tissue sarcoma of the retroperitoneum measuring more than 15 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C136807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136807>	C224213	Anti-CLDN6/9 Antibody-drug Conjugate SC-004|Anti-CLDN6/9 ADC SC-004|SC 004|SC-004|SC-004|SC004	An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody directed against claudin-6 (CLDN6; CLDN-6) and claudin-9 (CLDN9; CLDN-9) linked to a cytotoxic pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of anti-CLDN6/9 ADC SC-004 targets and binds to CLDN6/9 expressed on tumor cells, and the PBD moiety is released. Then the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of CLDN6/9-overexpressing tumor cells. CLDN6, a transmembrane tight-junction protein and embryonic antigen, is overexpressed on a variety of tumor cells but is not expressed on normal, healthy adult cells. CLDN6 and CLDN9 differ at only 3 out of 76 residues in their extracellular loops, and CLDN9 is highly expressed in some normal tissues in addition to some tumors.	Anti-CLDN6/9 Antibody-drug Conjugate SC-004		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C136808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136808>	C136797	Soft Tissue Sarcoma of the Retroperitoneum Pathologic Regional Lymph Nodes TNM Finding v8|Retroperitoneal Soft Tissue Sarcoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of soft tissue sarcoma of the retroperitoneum, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C136809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136809>	C136808	Soft Tissue Sarcoma of the Retroperitoneum pN0 TNM Finding v8|Retroperitoneal Soft Tissue Sarcoma pN0 TNM Finding v8	Soft tissue sarcoma of the retroperitoneum without regional lymph node metastasis or unknown lymph node status. (from AJCC 8th Ed.)			Finding	
C13680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13680>	C13432	15q15-q21.1	A chromosome band present on 15q			Gene or Genome	
C136810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136810>	C136808	Soft Tissue Sarcoma of the Retroperitoneum pN1 TNM Finding v8|Retroperitoneal Soft Tissue Sarcoma pN1 TNM Finding v8	Soft tissue sarcoma of the retroperitoneum with regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C136811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136811>	C4832|C136693	Retroperitoneal Sarcoma by AJCC v8 Stage|Soft Tissue Sarcoma Retroperitoneum by AJCC v8 Stage	A term that refers to the staging of retroperitoneal soft tissue sarcoma, following the rules of the TNM AJCC v8 classification system. This staging system applies to common sarcomas in the retroperitoneum. (from AJCC 8th Ed.)			Neoplastic Process	
C136812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136812>	C136811	Stage I Retroperitoneal Sarcoma AJCC v8|Stage I Retroperitoneal Sarcoma	Stage I includes: IA: (T1, N0, M0, G1, GX); IB: (T2, T3, T4, N0, M0, G1, GX). T1: Tumor measuring 5 cm or less in greatest dimension. T2: Tumor measuring more than 5 cm and less than or equal to 10 cm in greatest dimension. T3: Tumor measuring more than 10 cm and less than or equal to 15 cm in greatest dimension. T4: Tumor measuring more than 15 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. GX: Grade cannot be assessed. G1: Total differentiation, mitotic count and necrosis score of 2 or 3. (AJCC 8th ed.)	Stage I Retroperitoneal Sarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136813>	C136812	Stage IA Retroperitoneal Sarcoma AJCC v8|Stage IA Retroperitoneal Sarcoma|Stage IA Soft Tissue Retroperitoneal Sarcoma AJCC v8	Stage IA includes: T1, N0, M0, G1, GX. T1: Tumor measuring 5 cm or less in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. GX: Grade cannot be assessed. G1: Total differentiation, mitotic count and necrosis score of 2 or 3. (AJCC 8th ed.)	Stage IA Retroperitoneal Sarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136814>	C136812	Stage IB Retroperitoneal Sarcoma AJCC v8|Stage IB Retroperitoneal Sarcoma|Stage IB Soft Tissue Retroperitoneal Sarcoma AJCC v8	Stage IB includes: T2, T3, T4, N0, M0, G1, GX. T2: Tumor measuring more than 5 cm and less than or equal to 10 cm in greatest dimension. T3: Tumor measuring more than 10 cm and less than or equal to 15 cm in greatest dimension. T4: Tumor measuring more than 15 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. GX: Grade cannot be assessed. G1: Total differentiation, mitotic count and necrosis score of 2 or 3. (AJCC 8th ed.)	Stage IB Retroperitoneal Sarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136815>	C136811	Stage II Retroperitoneal Sarcoma AJCC v8|Stage II Retroperitoneal Sarcoma|Stage II Soft Tissue Retroperitoneal Sarcoma AJCC v8	Stage II includes: T1, N0, M0, G2, G3. T1: Tumor measuring 5 cm or less in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. G2: Total differentiation, mitotic count and necrosis score of 4 or 5. G3: Total differentiation, mitotic count and necrosis score of 6, 7, or 8. (AJCC 8th ed.)	Stage II Retroperitoneal Sarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136816>	C136811	Stage III Retroperitoneal Sarcoma AJCC v8|Stage III Retroperitoneal Sarcoma	Stage III includes: IIIA: (T2, N0, M0, G2, G3); IIIB: (T3, T4, N0, M0, G2, G3); (Any T, N1, M0, Any G). T2: Tumor measuring more than 5 cm and less than or equal to 10 cm in greatest dimension. T3: Tumor measuring more than 10 cm and less than or equal to 15 cm in greatest dimension. T4: Tumor measuring more than 15 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. N1: Regional lymph node metastasis. M0: No distant metastasis. G2: Total differentiation, mitotic count and necrosis score of 4 or 5. G3: Total differentiation, mitotic count and necrosis score of 6, 7, or 8. (AJCC 8th ed.)	Stage III Retroperitoneal Sarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136817>	C136816	Stage IIIA Retroperitoneal Sarcoma AJCC v8|Stage IIIA Retroperitoneal Sarcoma|Stage IIIA Soft Tissue Retroperitoneal Sarcoma AJCC v8	Stage IIIA includes: T2, N0, M0, G2, G3. T2: Tumor measuring more than 5 cm and less than or equal to 10 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. M0: No distant metastasis. G2: Total differentiation, mitotic count and necrosis score of 4 or 5. G3: Total differentiation, mitotic count and necrosis score of 6, 7, or 8. (AJCC 8th ed.)	Stage IIIA Retroperitoneal Sarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136818>	C136816	Stage IIIB Retroperitoneal Sarcoma AJCC v8|Stage IIIB Retroperitoneal Sarcoma|Stage IIIB Soft Tissue Retroperitoneal Sarcoma AJCC v8	Stage IIIB includes: (T3, T4, N0, M0, G2, G3); (Any T, N1, M0, Any G). T3: Tumor measuring more than 10 cm and less than or equal to 15 cm in greatest dimension. T4: Tumor measuring more than 15 cm in greatest dimension. N0: No regional lymph node metastasis or unknown lymph node status. N1: Regional lymph node metastasis. M0: No distant metastasis. G2: Total differentiation, mitotic count and necrosis score of 4 or 5. G3: Total differentiation, mitotic count and necrosis score of 6, 7, or 8. (AJCC 8th ed.)	Stage IIIB Retroperitoneal Sarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136819>	C136811	Stage IV Retroperitoneal Sarcoma AJCC v8|Stage IV Retroperitoneal Sarcoma|Stage IV Soft Tissue Retroperitoneal Sarcoma AJCC v8	Stage IV includes: Any T, Any N, M1, Any G. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Retroperitoneal Sarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13681>	C13432	8p11.2-p11.1	A chromosome band present on 8p			Gene or Genome	
C136820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136820>	C25499	Pain Crisis	An event in which the patient reports pain that is severe, uncontrolled, and causing distress for the patient, family members, or both.			Event	
C136821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136821>	C141215|C129822	Rituximab and Hyaluronidase Human|Rituxan Hycela|Rituximab Plus Hyaluronidase|Rituximab and hyaluronidase human|Rituximab/Hyaluronidase|Rituximab/Hyaluronidase Human	A combination preparation of rituximab, a genetically engineered chimeric murine/human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against the CD20 antigen, and the recombinant form of the human enzyme hyaluronidase, with antineoplastic activity. Upon subcutaneous administration of rituximab and hyaluronidase human, the hyaluronidase reversibly depolymerizes the polysaccharide hyaluronan in the subcutaneous tissue. This increases the permeability of the subcutaneous tissue and enhances the absorption of rituximab into the systemic circulation. In turn, rituximab targets and binds to CD20 expressed on tumor cells, and induces tumor cell lysis primarily through the induction of complement dependent cytotoxicity (CDC) and antibody-dependent cell mediated cytotoxicity (ADCC).  When administered subcutaneously, hyaluronidase, an endoglycosidase, increases the dispersion and absorption of co-administered drugs.  CD20 is expressed on the surface of pre-B and mature B-lymphocytes, and is overexpressed in a variety of B-cell malignancies.	Rituximab and Hyaluronidase Human		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C136822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136822>	C200418	Tamnorzatinib|Axl/Mer Inhibitor ONO-7475|Axl/Mer RTK Inhibitor ONO-7475|ONO 7475|ONO-7475|TAMNORZATINIB	An orally available and selective inhibitor of the receptor tyrosine kinases (RTKs) Axl (UFO) and Mer, with potential antineoplastic activity. Upon administration, tamnorzatinib targets and binds to both Axl and Mer, and prevents their activity. This blocks Axl- and Mer-mediated signal transduction pathways, and inhibits proliferation and migration of Axl- and Mer-overexpressing tumor cells. Axl and Mer, both members of the TAM (Tyro3, Axl and Mer) family of RTKs, are overexpressed by many tumor cell types. They play key roles in tumor cell proliferation, survival, invasion, angiogenesis and metastasis, and their expression is associated with drug resistance and poor prognosis.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C136823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136823>	C181114	Teclistamab|JNJ 64007957|JNJ-64007957|JNJ64007957|TECLISTAMAB|Teclistamab-cqyv|Tecvayli	A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, with potential antineoplastic activity. Upon administration, teclistamab binds to both CD3 on T-cells and BCMA expressed on malignant plasma cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against BCMA-expressing plasma cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.	Teclistamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C136824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136824>	C263	Therapeutic Human Antithrombin-III|ANTITHROMBIN III HUMAN|AT-III|AT-III (Human)|Antithrombin|Antithrombin III|Antithrombin III|Antithrombin-III|Human AT-III|Thrombate III	A form of the human glycoprotein antithrombin-III (AT-III), which is produced recombinantly or isolated from human plasma, with anticoagulant activity. Upon administration, antithrombin-III binds to and blocks thrombin activity, and prevents thrombus formation.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C136825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136825>	C9498|C204790	Cutaneous Spitz Melanocytoma|AST|STUMP|Skin Atypical Spitz Nevus|Skin Atypical Spitz Tumor|Skin Atypical Spitz Tumor of Uncertain Malignant Potential|Skin Melanocytic Tumor of Unknown Malignant Potential|Skin Pagetoid Spitz Nevus|Skin Spitz Melanocytoma|Skin Spitz Tumor with One or More Atypical Features|Skin Spitzoid Tumor of Uncertain Malignant Potential	A junctional or compound cutaneous melanocytic neoplasm not fulfilling the histopathologic criteria of melanoma but with one of the following features: asymmetry, predominance of single melanocytes over nests in lesions 4 mm or larger, ulceration, large dermal sheets of melanocytes, lack of maturation in dermis, deep dermal mitotic figures, extensive involvement of subcutis, and nuclear pleomorphism. (Mod Pathol 2006;19: S21)			Neoplastic Process	
C136826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136826>	C62634	Regimen Used to Treat Retinoblastoma	Any regimen that can be used for the treatment of retinoblastoma.			Therapeutic or Preventive Procedure	
C136827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136827>	C20181	Determine|Determination|Determined	The establishment of a state or result.			Activity	
C136828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136828>	C2189	Calcium Release-activated Channels Inhibitor RP4010|CRAC Inhibitor RP4010|RP 4010|RP-4010|RP4010	A calcium (Ca2+) release-activated channel (CRAC) inhibitor, with potential antineoplastic activity. Upon administration, RP4010 binds to and inhibits CRACs, thereby preventing the transport of extracellular Ca2+ into the cell and inhibiting the subsequent activation of Ca2+-mediated signaling and transcription of target genes. CRACs, specialized plasma membrane Ca2+ ion channels composed of the plasma membrane based Orai channels and the endoplasmic reticulum (ER) stromal interaction molecules (STIMs), play key roles in calcium homeostasis and are over-activated in a number of cancer cell types. Aberrant activation of CRACs leads to increased cancer cell proliferation.	Calcium Release-activated Channels Inhibitor RP4010		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C136829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136829>	C16672	Small Heat Shock Protein|HSPB|Heat Shock Protein Family B|Heat Shock Protein Family B (Small)|Small Heat Shock Protein Family|sHSP Family|sHsp	A family of chaperone proteins with subunit molecular masses of 12-43 kDa. The members are characterized by the presence of a highly conserved stretch of 80-100 amino acids in their C-terminal domains called the alpha-crystallin domain (ACD). Class I small heat shock proteins (sHsps) are widely expressed and play a role in cell survival. Class II sHsps are expressed in tissue-specific patterns and may be involved in the differentiation, development and specific functionality for the tissues they are expressed in.			Amino Acid, Peptide, or Protein	
C13682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13682>	C13432	10q26	A chromosome band present on 10q			Gene or Genome	
C136830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136830>	C16447	COL4A3 Gene Product	A protein encoded by the COL4A3 gene.			Amino Acid, Peptide, or Protein	
C136831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136831>	C48233	Skin Cancer TNM Finding v8	A finding about one or more characteristics of skin cancer, following the rules of the TNM AJCC v8 classification system. It applies to Merkel cell carcinoma and melanoma of the skin. (from AJCC 8th Ed.)			Finding	
C136832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136832>	C136831	Merkel Cell Carcinoma TNM Finding v8|Neuroendocrine Carcinoma of the Skin TNM Finding v8	A finding about one or more characteristics of Merkel cell carcinoma (primary cutaneous neuroendocrine carcinoma), following the rules of the TNM AJCC v8 classification system. (from AJCC 8th Ed.)			Finding	
C136833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136833>	C136832	Merkel Cell Carcinoma Clinical TNM Finding v8|Neuroendocrine Carcinoma of the Skin Clinical TNM Finding v8	A clinical finding about one or more characteristics of Merkel cell carcinoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C136834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136834>	C136833	Merkel Cell Carcinoma Clinical Distant Metastasis TNM Finding v8|Neuroendocrine Carcinoma of the Skin Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of Merkel cell carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C136835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136835>	C136834	Merkel Cell Carcinoma cM0 TNM Finding v8|Neuroendocrine Carcinoma of the Skin cM0 TNM Finding v8	Merkel cell carcinoma without distant metastasis detected on clinical and/or radiologic examination. (from AJCC 8th Ed.)			Finding	
C136836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136836>	C136834	Merkel Cell Carcinoma cM1 TNM Finding v8|Neuroendocrine Carcinoma of the Skin cM1 TNM Finding v8	Merkel cell carcinoma with distant metastasis detected on clinical and/or radiologic examination. (from AJCC 8th Ed.)			Finding	
C136837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136837>	C136836	Merkel Cell Carcinoma cM1a TNM Finding v8|Neuroendocrine Carcinoma of the Skin cM1a TNM Finding v8	Merkel cell carcinoma with metastasis to distant skin, distant subcutaneous tissue, or distant lymph node(s). (from AJCC 8th Ed.)			Finding	
C136838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136838>	C136836	Merkel Cell Carcinoma cM1b TNM Finding v8|Neuroendocrine Carcinoma of the Skin cM1b TNM Finding v8	Merkel cell carcinoma with metastasis to lung. (from AJCC 8th Ed.)			Finding	
C136839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136839>	C136836	Merkel Cell Carcinoma cM1c TNM Finding v8|Neuroendocrine Carcinoma of the Skin cM1c TNM Finding v8	Merkel cell carcinoma with metastasis to all other visceral sites. (from AJCC 8th Ed.)			Finding	
C13683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13683>	C13432	19p13.1-p12	A chromosome band present on 19p			Gene or Genome	
C136840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136840>	C136833	Merkel Cell Carcinoma Clinical Primary Tumor TNM Finding v8|Neuroendocrine Carcinoma of the Skin Clinical Primary Tumor TNM Finding v8	A clinical finding about one or more characteristics of Merkel cell carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C136841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136841>	C136840	Merkel Cell Carcinoma cTX TNM Finding v8|Neuroendocrine Carcinoma of the Skin cTX TNM Finding v8	Merkel cell carcinoma in which the primary tumor cannot be assessed (e.g., curetted). (from AJCC 8th Ed.)			Finding	
C136842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136842>	C136840	Merkel Cell Carcinoma cT0 TNM Finding v8|Neuroendocrine Carcinoma of the Skin cT0 TNM Finding v8	Merkel cell carcinoma with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C136843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136843>	C136840	Merkel Cell Carcinoma Tis TNM Finding v8|Neuroendocrine Carcinoma of the Skin Tis TNM Finding v8	Merkel cell carcinoma with a finding of in situ primary tumor. (from AJCC 8th Ed.)			Finding	
C136844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136844>	C136840	Merkel Cell Carcinoma cT1 TNM Finding v8|Neuroendocrine Carcinoma of the Skin cT1 TNM Finding v8	Merkel cell carcinoma with maximum clinical tumor diameter equal to or less than 2 cm. (from AJCC 8th Ed.)			Finding	
C136845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136845>	C136840	Merkel Cell Carcinoma cT2 TNM Finding v8|Neuroendocrine Carcinoma of the Skin cT2 TNM Finding v8	Merkel cell carcinoma with maximum clinical tumor diameter more than 2 cm but equal to or less than 5 cm. (from AJCC 8th Ed.)			Finding	
C136846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136846>	C136840	Merkel Cell Carcinoma cT3 TNM Finding v8|Neuroendocrine Carcinoma of the Skin cT3 TNM Finding v8	Merkel cell carcinoma with maximum clinical tumor diameter more than 5 cm. (from AJCC 8th Ed.)			Finding	
C136847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136847>	C136840	Merkel Cell Carcinoma cT4 TNM Finding v8|Neuroendocrine Carcinoma of the Skin cT4 TNM Finding v8	Merkel cell carcinoma with primary tumor invading fascia, muscle, cartilage, or bone. (from AJCC 8th Ed.)			Finding	
C136848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136848>	C136833	Merkel Cell Carcinoma Clinical Regional Lymph Nodes TNM Finding v8|Neuroendocrine Carcinoma of the Skin Clinical Regional Lymph Nodes TNM Finding v8	A clinical finding about one or more characteristics of Merkel cell carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C136849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136849>	C136848	Merkel Cell Carcinoma cNX TNM Finding v8|Neuroendocrine Carcinoma of the Skin cNX TNM Finding v8	Merkel cell carcinoma in which the regional lymph nodes cannot be clinically assessed (e.g., previously removed for another reason, or because of body habitus). (from AJCC 8th Ed.)			Finding	
C13684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13684>	C13432	16q22	A chromosome band present on 16q			Gene or Genome	
C136850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136850>	C136848	Merkel Cell Carcinoma cN0 TNM Finding v8|Neuroendocrine Carcinoma of the Skin cN0 TNM Finding v8	Merkel cell carcinoma without regional lymph node metastasis detected on clinical and/or radiologic examination. (from AJCC 8th Ed.)			Finding	
C136851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136851>	C136848	Merkel Cell Carcinoma cN1 TNM Finding v8|Neuroendocrine Carcinoma of the Skin cN1 TNM Finding v8	Merkel cell carcinoma with metastasis in regional lymph node(s). (from AJCC 8th Ed.)			Finding	
C136852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136852>	C136848	Merkel Cell Carcinoma cN2 TNM Finding v8|Neuroendocrine Carcinoma of the Skin cN2 TNM Finding v8	Merkel cell carcinoma with in-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) without lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C136853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136853>	C136848	Merkel Cell Carcinoma cN3 TNM Finding v8|Neuroendocrine Carcinoma of the Skin cN3 TNM Finding v8	Merkel cell carcinoma with in-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) with lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C136854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136854>	C136832	Merkel Cell Carcinoma Pathologic TNM Finding v8|Neuroendocrine Carcinoma of the Skin Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of Merkel cell carcinoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C136855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136855>	C136854	Merkel Cell Carcinoma Pathologic Distant Metastasis TNM Finding v8|Neuroendocrine Carcinoma of the Skin Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of Merkel cell carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C136856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136856>	C136855	Merkel Cell Carcinoma pM1 TNM Finding v8|Neuroendocrine Carcinoma of the Skin pM1 TNM Finding v8	Merkel cell carcinoma with distant metastasis microscopically confirmed. (from AJCC 8th Ed.)			Finding	
C136857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136857>	C136856	Merkel Cell Carcinoma pM1a TNM Finding v8|Neuroendocrine Carcinoma of the Skin pM1a TNM Finding v8	Merkel cell carcinoma with metastasis to distant skin, distant subcutaneous tissue, or distant lymph node(s), microscopically confirmed. (from AJCC 8th Ed.)			Finding	
C136858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136858>	C136856	Merkel Cell Carcinoma pM1b TNM Finding v8|Neuroendocrine Carcinoma of the Skin pM1b TNM Finding v8	Merkel cell carcinoma with metastasis to lung, microscopically confirmed. (from AJCC 8th Ed.)			Finding	
C136859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136859>	C136856	Merkel Cell Carcinoma pM1c TNM Finding v8|Neuroendocrine Carcinoma of the Skin pM1c TNM Finding v8	Merkel cell carcinoma with metastasis to all other distant sites, microscopically confirmed. (from AJCC 8th Ed.)			Finding	
C13685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13685>	C13432	4q12-q13	A chromosome band present on 4q			Gene or Genome	
C136860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136860>	C136854	Merkel Cell Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8|Neuroendocrine Carcinoma of the Skin Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of Merkel cell carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C136861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136861>	C136860	Merkel Cell Carcinoma pNX TNM Finding v8|Neuroendocrine Carcinoma of the Skin pNX TNM Finding v8	Merkel cell carcinoma in which the regional lymph nodes cannot be assessed (e.g., previously removed for another reason or not removed for pathologic evaluation). (from AJCC 8th Ed.)			Finding	
C136862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136862>	C136860	Merkel Cell Carcinoma pN0 TNM Finding v8|Neuroendocrine Carcinoma of the Skin pN0 TNM Finding v8	Merkel cell carcinoma without regional lymph node metastasis detected on pathologic examination. (from AJCC 8th Ed.)			Finding	
C136863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136863>	C136860	Merkel Cell Carcinoma pN1 TNM Finding v8|Neuroendocrine Carcinoma of the Skin pN1 TNM Finding v8	Merkel cell carcinoma with metastasis in regional lymph node(s). (from AJCC 8th Ed.)			Finding	
C136864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136864>	C136863	Merkel Cell Carcinoma pN1a(sn) TNM Finding v8|Neuroendocrine Carcinoma of the Skin pN1a(sn) TNM Finding v8	Merkel cell carcinoma with clinically occult regional lymph node metastasis identified only by sentinel lymph node biopsy. (from AJCC 8th Ed.)			Finding	
C136865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136865>	C136863	Merkel Cell Carcinoma pN1a TNM Finding v8|Neuroendocrine Carcinoma of the Skin pN1a TNM Finding v8	Merkel cell carcinoma with clinically occult regional lymph node metastasis following lymph node dissection. (from AJCC 8th Ed.)			Finding	
C136866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136866>	C136863	Merkel Cell Carcinoma pN1b TNM Finding v8|Neuroendocrine Carcinoma of the Skin pN1b TNM Finding v8	Merkel cell carcinoma with clinically and/or radiologically detected regional lymph node metastasis, microscopically confirmed. (from AJCC 8th Ed.)			Finding	
C136867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136867>	C136860	Merkel Cell Carcinoma pN2 TNM Finding v8|Neuroendocrine Carcinoma of the Skin pN2 TNM Finding v8	Merkel cell carcinoma with in-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) without lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C136868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136868>	C136860	Merkel Cell Carcinoma pN3 TNM Finding v8|Neuroendocrine Carcinoma of the Skin pN3 TNM Finding v8	Merkel cell carcinoma with in-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) with lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C136869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136869>	C173385	Cutaneous Merkel Cell Carcinoma by AJCC v7 Stage|Cutaneous Neuroendocrine Carcinoma of the Skin by AJCC v7 Stage	A term that refers to the staging of Merkel cell carcinoma (primary cutaneous neuroendocrine carcinoma), following the rules of the TNM AJCC v7 classification system.			Neoplastic Process	
C13686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13686>	C13432	3q26.3-q27	A chromosome band present on 3q			Gene or Genome	
C136870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136870>	C173385	Cutaneous Merkel Cell Carcinoma by AJCC v8 Stage|Neuroendocrine Carcinoma of the Skin by AJCC v8 Stage	A term that refers to the staging of Merkel cell carcinoma (primary cutaneous neuroendocrine carcinoma), following the rules of the TNM AJCC v8 classification system.			Neoplastic Process	
C136871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136871>	C136870	Cutaneous Merkel Cell Carcinoma by AJCC v8 Clinical Stage|Neuroendocrine Carcinoma of the Skin by AJCC v8 Clinical Stage	A term that refers to the clinical staging of Merkel cell carcinoma (primary cutaneous neuroendocrine carcinoma), following the rules of the TNM AJCC v8 classification system.			Neoplastic Process	
C136872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136872>	C136871	Clinical Stage 0 Cutaneous Merkel Cell Carcinoma AJCC v8|Clinical Stage 0 Neuroendocrine Carcinoma of the Skin AJCC v8	Stage 0 includes: Tis, N0, M0. Tis: In situ primary tumor. N0: No regional lymph node metastasis detected on clinical and/or radiologic examination. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)			Neoplastic Process	
C136873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136873>	C136871	Clinical Stage I Cutaneous Merkel Cell Carcinoma AJCC v8|Clinical Stage I Neuroendocrine Carcinoma of the Skin AJCC v8	Stage I includes: T1, N0, M0. T1: Maximum clinical tumor diameter equal to or less than 2 cm. N0: No regional lymph node metastasis detected on clinical and/or radiologic examination. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)			Neoplastic Process	
C136874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136874>	C136871	Clinical Stage II Cutaneous Merkel Cell Carcinoma AJCC v8|Clinical Stage II Neuroendocrine Carcinoma of the Skin AJCC v8	Stage II includes: IIA: (T2-3, N0, M0); IIB: (T4, N0, M0). T2: Maximum clinical tumor diameter more than 2 cm but equal to or less than 5 cm. T3: Maximum clinical tumor diameter more than 5 cm. T4: Primary tumor invades fascia, muscle, cartilage, or bone. N0: No regional lymph node metastasis detected on clinical and/or radiologic examination. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)			Neoplastic Process	
C136875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136875>	C136874	Clinical Stage IIA Cutaneous Merkel Cell Carcinoma AJCC v8|Clinical Stage IIA Neuroendocrine Carcinoma of the Skin AJCC v8	Stage IIA includes: T2-3, N0, M0. T2: Maximum clinical tumor diameter more than 2 cm but equal to or less than 5 cm. T3: Maximum clinical tumor diameter more than 5 cm. N0: No regional lymph node metastasis detected on clinical and/or radiologic examination. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)			Neoplastic Process	
C136876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136876>	C136874	Clinical Stage IIB Cutaneous Merkel Cell Carcinoma AJCC v8|Clinical Stage IIB Neuroendocrine Carcinoma of the Skin AJCC v8	Stage IIB includes: T4, N0, M0. T4: Primary tumor invades fascia, muscle, cartilage, or bone. N0: No regional lymph node metastasis detected on clinical and/or radiologic examination. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)			Neoplastic Process	
C136877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136877>	C136871	Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8|Clinical Stage III Neuroendocrine Carcinoma of the Skin AJCC v8	Stage III includes: T0-4, N1-3, M0. T0: No evidence of primary tumor. T1: Maximum clinical tumor diameter equal to or less than 2 cm. T2: Maximum clinical tumor diameter more than 2 cm but equal to or less than 5 cm. T3: Maximum clinical tumor diameter more than 5 cm. T4: Primary tumor invades fascia, muscle, cartilage, or bone. N1: Metastasis in regional lymph node(s). N2: In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) without lymph node metastasis. N3: In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) with lymph node metastasis. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)			Neoplastic Process	
C136878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136878>	C136871	Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8|Clinical Stage IV Neuroendocrine Carcinoma of the Skin AJCC v8	Stage IV includes: T0-4, Any N, M1. T0: No evidence of primary tumor. T1: Maximum clinical tumor diameter equal to or less than 2 cm. T2: Maximum clinical tumor diameter more than 2 cm but equal to or less than 5 cm. T3: Maximum clinical tumor diameter more than 5 cm. T4: Primary tumor invades fascia, muscle, cartilage, or bone. M1: Distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)			Neoplastic Process	
C136879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136879>	C221112	London Deauville Criteria Point Scale X|London Deauville Criteria PET Point X|PET Score X|PET Score X|X	New areas of uptake unlikely to be related to lymphoma.			Intellectual Product	CDISC SDTM London Deauville Criteria Point Scale 2014 Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13687>	C13432	12q12-q13	A chromosome band present on 12q			Gene or Genome	
C136880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136880>	C136870	Cutaneous Merkel Cell Carcinoma by AJCC v8 Pathologic Stage|Neuroendocrine Carcinoma of the Skin by AJCC v8 Pathologic Stage	A term that refers to the pathologic staging of Merkel cell carcinoma (primary cutaneous neuroendocrine carcinoma), following the rules of the TNM AJCC v8 classification system.			Neoplastic Process	
C136881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136881>	C136880	Pathologic Stage 0 Cutaneous Merkel Cell Carcinoma AJCC v8|Pathologic Stage 0 Neuroendocrine Carcinoma of the Skin AJCC v8	Stage 0 includes: Tis, N0, M0. Tis: In situ primary tumor. N0: No regional lymph node metastasis detected on pathologic examination. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)			Neoplastic Process	
C136882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136882>	C136880	Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8|Pathologic Stage I Neuroendocrine Carcinoma of the Skin AJCC v8	Stage I includes: T1, N0, M0. T1: Maximum clinical tumor diameter equal to or less than 2 cm. N0: No regional lymph node metastasis detected on pathologic examination. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)			Neoplastic Process	
C136883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136883>	C136880	Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8|Pathologic Stage II Neuroendocrine Carcinoma of the Skin AJCC v8	Stage II includes: IIA: (T2-3, N0, M0); IIB: (T4, N0, M0). T2: Maximum clinical tumor diameter more than 2 cm but equal to or less than 5 cm. T3: Maximum clinical tumor diameter more than 5 cm. T4: Primary tumor invades fascia, muscle, cartilage, or bone. N0: No regional lymph node metastasis detected on pathologic examination. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)			Neoplastic Process	
C136884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136884>	C136883	Pathologic Stage IIA Cutaneous Merkel Cell Carcinoma AJCC v8|Pathologic Stage IIA Neuroendocrine Carcinoma of the Skin AJCC v8	Stage IIA includes: T2-3, N0, M0. T2: Maximum clinical tumor diameter more than 2 cm but equal to or less than 5 cm. T3: Maximum clinical tumor diameter more than 5 cm. N0: No regional lymph node metastasis detected on pathologic examination. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)			Neoplastic Process	
C136885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136885>	C136883	Pathologic Stage IIB Cutaneous Merkel Cell Carcinoma AJCC v8|Pathologic Stage IIB Neuroendocrine Carcinoma of the Skin AJCC v8	Stage IIB includes: T4, N0, M0. T4: Primary tumor invades fascia, muscle, cartilage, or bone. N0: No regional lymph node metastasis detected on pathologic examination. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)			Neoplastic Process	
C136886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136886>	C136880	Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8|Pathologic Stage III Neuroendocrine Carcinoma of the Skin AJCC v8	Stage III includes: IIIA: (T1-4, N1a(sn) or N1a, M0); (T0, N1b, M0); IIIB: (T1-4, N1b-3, M0). T0: No evidence of primary tumor. T1: Maximum clinical tumor diameter equal to or less than 2 cm. T2: Maximum clinical tumor diameter more than 2 cm but equal to or less than 5 cm. T3: Maximum clinical tumor diameter more than 5 cm. T4: Primary tumor invades fascia, muscle, cartilage, or bone. N1a(sn): Clinically occult regional lymph node metastasis identified only by sentinel lymph node biopsy. N1a: Clinically occult regional lymph node metastasis following lymph node dissection. N1b: Clinically and/or radiologically detected regional lymph node metastasis, microscopically confirmed. N2: In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) without lymph node metastasis. N3: In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) with lymph node metastasis. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)			Neoplastic Process	
C136887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136887>	C136886	Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8|Pathologic Stage IIIA Neuroendocrine Carcinoma of the Skin AJCC v8	Stage IIIA includes: (T1-4, N1a(sn) or N1a, M0); (T0, N1b, M0). T0: No evidence of primary tumor. T1: Maximum clinical tumor diameter equal to or less than 2 cm. T2: Maximum clinical tumor diameter more than 2 cm but equal to or less than 5 cm. T3: Maximum clinical tumor diameter more than 5 cm. T4: Primary tumor invades fascia, muscle, cartilage, or bone. N1a(sn): Clinically occult regional lymph node metastasis identified only by sentinel lymph node biopsy. N1a: Clinically occult regional lymph node metastasis following lymph node dissection. N1b: Clinically and/or radiologically detected regional lymph node metastasis, microscopically confirmed. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)			Neoplastic Process	
C136888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136888>	C136886	Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8|Pathologic Stage IIIB Neuroendocrine Carcinoma of the Skin AJCC v8	Stage IIIB includes: T1-4, N1b-3, M0. T1: Maximum clinical tumor diameter equal to or less than 2 cm. T2: Maximum clinical tumor diameter more than 2 cm but equal to or less than 5 cm. T3: Maximum clinical tumor diameter more than 5 cm. T4: Primary tumor invades fascia, muscle, cartilage, or bone. N1b: Clinically and/or radiologically detected regional lymph node metastasis, microscopically confirmed. N2: In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) without lymph node metastasis. N3: In-transit metastasis (discontinuous from primary tumor; located between primary tumor and draining regional nodal basin, or distal to the primary tumor) with lymph node metastasis. M0: No distant metastasis detected on clinical and/or radiologic examination. (AJCC 8th ed.)			Neoplastic Process	
C136889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136889>	C136880	Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8|Pathologic Stage IV Neuroendocrine Carcinoma of the Skin AJCC v8	Stage IV includes: T0-4, Any N, M1. T0: No evidence of primary tumor. T1: Maximum clinical tumor diameter equal to or less than 2 cm. T2: Maximum clinical tumor diameter more than 2 cm but equal to or less than 5 cm. T3: Maximum clinical tumor diameter more than 5 cm. T4: Primary tumor invades fascia, muscle, cartilage, or bone. M1: Distant metastasis microscopically confirmed. (AJCC 8th ed.)			Neoplastic Process	
C13688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13688>	C13432	22q11.21	A chromosome band present on 22q			Gene or Genome	
C136891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136891>	C2167|C213472|C159156	Neratinib Maleate|2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-, (2Z)-2-butenedioate (1:1)|HKI-272 Maleate|NERATINIB MALEATE ANHYDROUS|Nerlynx	The maleate salt form of neratinib, an orally available, quinazoline-based, irreversible inhibitor of both the receptor tyrosine kinases (RTKs) human epidermal growth factor receptor 2 (HER2; ERBB2) and human epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, neratinib targets and covalently binds to the cysteine residue in the ATP-binding pockets of both HER2 and EGFR. This inhibits their activity and results in the inhibition of downstream signal transduction events, induces cell cycle arrest, apoptosis and ultimately decreases cellular proliferation in HER2- and EGFR-expressing tumor cells. EGFR and HER2, RTKs that are mutated or overactivated in many tumor cell types, play key roles in tumor cell proliferation and tumor vascularization.	Neratinib Maleate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C136892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136892>	C136831	Cutaneous Melanoma TNM Finding v8|Melanoma of the Skin TNM Finding v8	A finding about one or more characteristics of cutaneous melanoma, following the rules of the TNM AJCC v8 classification system. This classification system does not apply to melanoma of the conjunctiva, melanoma of the uvea, mucosal melanoma arising in the head and neck, and mucosal melanoma of the urethra, vagina, rectum, and anus. (from AJCC 8th Ed.)			Finding	
C136893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136893>	C136892	Cutaneous Melanoma Clinical TNM Finding v8|Melanoma of the Skin Clinical TNM Finding v8	A clinical finding about one or more characteristics of cutaneous melanoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C136894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136894>	C136893	Cutaneous Melanoma Clinical Distant Metastasis TNM Finding v8|Clinical Staging: Distant Metastasis (cM)|Melanoma of the Skin Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of cutaneous melanoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136895>	C136894	Cutaneous Melanoma cM0 TNM Finding v8|Melanoma of the Skin cM0 TNM Finding v8|cM0	Cutaneous melanoma without evidence of distant metastasis. LDH level is not applicable. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136896>	C136894	Cutaneous Melanoma cM1 TNM Finding v8|Melanoma of the Skin cM1 TNM Finding v8|cM1	Cutaneous melanoma with evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136897>	C136896	Cutaneous Melanoma cM1a TNM Finding v8|Melanoma of the Skin cM1a TNM Finding v8|cM1a	Cutaneous melanoma with distant metastasis to skin, soft tissue including muscle, and/or nonregional lymph node. LDH level not recorded or unspecified. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136898>	C136897	Cutaneous Melanoma cM1a(0) TNM Finding v8|Melanoma of the Skin cM1a(0) TNM Finding v8	Cutaneous melanoma with distant metastasis to skin, soft tissue including muscle, and/or nonregional lymph node. LDH level not elevated. (from AJCC 8th Ed.)			Finding	
C136899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136899>	C136897	Cutaneous Melanoma cM1a(1) TNM Finding v8|Melanoma of the Skin cM1a(1) TNM Finding v8	Cutaneous melanoma with distant metastasis to skin, soft tissue including muscle, and/or nonregional lymph node. LDH level elevated. (from AJCC 8th Ed.)			Finding	
C13689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13689>	C13432	8q13-qter	A chromosome band present on 8q			Gene or Genome	
C1368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1368>	C1592	Recombinant ENA-78|ENA-78|LIX|Lipopolysaccharide-Induced CXC Chemokine	Epithelial neutrophil activating peptide-78.  A 78 amino acid member of the CXC family of chemokines, produced and secreted upon stimulation by interleukin 1 beta or tumor necrosis factor alpha.  Stimulates chemotactic migration of neutrophils, monocytes, lymphocytes, and fibroblasts.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C136900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136900>	C136896	Cutaneous Melanoma cM1b TNM Finding v8|Melanoma of the Skin cM1b TNM Finding v8|cM1b	Cutaneous melanoma with distant metastasis to lung with or without M1a sites of disease. LDH level not recorded or unspecified. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136901>	C136900	Cutaneous Melanoma cM1b(0) TNM Finding v8|Melanoma of the Skin cM1b(0) TNM Finding v8	Cutaneous melanoma with distant metastasis to lung with or without M1a sites of disease. LDH level not elevated. (from AJCC 8th Ed.)			Finding	
C136902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136902>	C136900	Cutaneous Melanoma cM1b(1) TNM Finding v8|Melanoma of the Skin cM1b(1) TNM Finding v8	Cutaneous melanoma with distant metastasis to lung with or without M1a sites of disease. LDH level elevated. (from AJCC 8th Ed.)			Finding	
C136903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136903>	C136896	Cutaneous Melanoma cM1c TNM Finding v8|Melanoma of the Skin cM1c TNM Finding v8|cM1c	Cutaneous melanoma with distant metastasis to non-CNS visceral sites with or without M1a or M1b sites of disease.  LDH level not recorded or unspecified. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136904>	C136903	Cutaneous Melanoma cM1c(0) TNM Finding v8|Melanoma of the Skin cM1c(0) TNM Finding v8	Cutaneous melanoma with distant metastasis to non-CNS visceral sites with or without M1a or M1b sites of disease.  LDH level not elevated. (from AJCC 8th Ed.)			Finding	
C136905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136905>	C136903	Cutaneous Melanoma cM1c(1) TNM Finding v8|Melanoma of the Skin cM1c(1) TNM Finding v8	Cutaneous melanoma with distant metastasis to non-CNS visceral sites with or without M1a or M1b sites of disease.  LDH level elevated. (from AJCC 8th Ed.)			Finding	
C136906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136906>	C136896	Cutaneous Melanoma cM1d TNM Finding v8|Melanoma of the Skin cM1d TNM Finding v8	Cutaneous melanoma with distant metastasis to CNS with or without M1a, M1b, or M1c sites of disease.  LDH level not recorded or unspecified. (from AJCC 8th Ed.)			Finding	
C136907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136907>	C136906	Cutaneous Melanoma cM1d(0) TNM Finding v8|Melanoma of the Skin cM1d(0) TNM Finding v8	Cutaneous melanoma with distant metastasis to CNS with or without M1a, M1b, or M1c sites of disease.  LDH level normal. (from AJCC 8th Ed.)			Finding	
C136908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136908>	C136906	Cutaneous Melanoma cM1d(1) TNM Finding v8|Melanoma of the Skin cM1d(1) TNM Finding v8	Cutaneous melanoma with distant metastasis to CNS with or without M1a, M1b, or M1c sites of disease.  LDH level elevated. (from AJCC 8th Ed.)			Finding	
C136909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136909>	C136893	Cutaneous Melanoma Clinical Regional Lymph Nodes TNM Finding v8|Melanoma of the Skin Clinical Regional Lymph Nodes TNM Finding v8	A clinical finding about one or more characteristics of cutaneous melanoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes. The TNM clinical and pathologic regional lymph nodes classifications of cutaneous melanoma are not the same. TNM clinical regional lymph nodes findings are based on clinical/radiographic examination of the regional lymph nodes (clinically detected regional lymph node metastasis). (from AJCC 8th Ed.)			Finding	
C13690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13690>	C13432	6q22	A chromosome band present on 6q			Gene or Genome	
C136910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136910>	C136909	Cutaneous Melanoma cNX TNM Finding v8|Melanoma of the Skin cNX TNM Finding v8	Cutaneous melanoma in which the regional lymph nodes are not assessed (e.g., sentinel lymph node biopsy is not performed, regional lymph nodes were previously removed for another reason). Exception: pathological N category is not required for T1 melanomas, use cN. Presence of in-transit, satellite, and/or microsatellite metastases: No.  (from AJCC 8th Ed.)			Finding	
C136911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136911>	C136909	Cutaneous Melanoma cN0 TNM Finding v8|Melanoma of the Skin cN0 TNM Finding v8	Cutaneous melanoma without regional lymph node metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: No.  (from AJCC 8th Ed.)			Finding	
C136912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136912>	C136909	Cutaneous Melanoma cN1 TNM Finding v8|Melanoma of the Skin cN1 TNM Finding v8	Cutaneous melanoma with one tumor-involved node or in-transit satellite, and/or microsatellite metastases with no tumor-involved nodes. (from AJCC 8th Ed.)			Finding	
C136913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136913>	C136912	Cutaneous Melanoma cN1b TNM Finding v8|Melanoma of the Skin cN1b TNM Finding v8	Cutaneous melanoma with one clinically detected nodal metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: No.  (from AJCC 8th Ed.)			Finding	
C136914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136914>	C136912	Cutaneous Melanoma cN1c TNM Finding v8|Melanoma of the Skin cN1c TNM Finding v8	Cutaneous melanoma with no regional lymph node disease. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. (from AJCC 8th Ed.)			Finding	
C136915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136915>	C136909	Cutaneous Melanoma cN2 TNM Finding v8|Melanoma of the Skin cN2 TNM Finding v8	Cutaneous melanoma with two or three tumor-involved nodes or in-transit satellite, and/or microsatellite metastases with one tumor-involved node. (from AJCC 8th Ed.)			Finding	
C136916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136916>	C136915	Cutaneous Melanoma cN2b TNM Finding v8|Melanoma of the Skin cN2b TNM Finding v8	Cutaneous melanoma with two or three nodal metastases at least one of which was clinically detected. Presence of in-transit, satellite, and/or microsatellite metastases: No.  (from AJCC 8th Ed.)			Finding	
C136917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136917>	C136915	Cutaneous Melanoma cN2c TNM Finding v8|Melanoma of the Skin cN2c TNM Finding v8	Cutaneous melanoma with one clinically detected metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. (from AJCC 8th Ed.)			Finding	
C136918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136918>	C136909	Cutaneous Melanoma cN3 TNM Finding v8|Melanoma of the Skin cN3 TNM Finding v8	Cutaneous melanoma with four or more tumor-involved nodes or in-transit satellite, and/or microsatellite metastases with two or more tumor-involved nodes, or any number of matted nodes without or with in-transit, satellite, and/or microsatellite metastases. (from AJCC 8th Ed.)			Finding	
C136919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136919>	C136918	Cutaneous Melanoma cN3b TNM Finding v8|Melanoma of the Skin cN3b TNM Finding v8	Cutaneous melanoma with four or more nodal metastases, at least one of which was clinically detected, or presence of any number of matted nodes. Presence of in-transit, satellite, and/or microsatellite metastases: No.  (from AJCC 8th Ed.)			Finding	
C13691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13691>	C13432	13q12-q13	A chromosome band present on 13q			Gene or Genome	
C136920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136920>	C136918	Cutaneous Melanoma cN3c TNM Finding v8|Melanoma of the Skin cN3c TNM Finding v8	Cutaneous melanoma with two or more clinically detected nodal metastases and/or presence of any number of matted nodes. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. (from AJCC 8th Ed.)			Finding	
C136921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136921>	C136892	Cutaneous Melanoma Pathologic TNM Finding v8|Melanoma of the Skin Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of cutaneous melanoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C136922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136922>	C136921	Cutaneous Melanoma Pathologic Distant Metastasis TNM Finding v8|Melanoma of the Skin Pathologic Distant Metastasis TNM Finding v8|Pathologic Staging: Distant Metastasis (pM)	A pathologic finding about one or more characteristics of cutaneous melanoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136923>	C136922	Cutaneous Melanoma pM1 TNM Finding v8|Melanoma of the Skin pM1 TNM Finding v8|pM1	Cutaneous melanoma with evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136924>	C136923	Cutaneous Melanoma pM1a TNM Finding v8|Melanoma of the Skin pM1a TNM Finding v8|pM1a	Cutaneous melanoma with distant metastasis to skin, soft tissue including muscle, and/or nonregional lymph node. LDH level not recorded or unspecified. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136925>	C136924	Cutaneous Melanoma pM1a(0) TNM Finding v8|Melanoma of the Skin pM1a(0) TNM Finding v8	Cutaneous melanoma with distant metastasis to skin, soft tissue including muscle, and/or nonregional lymph node. LDH level not elevated. (from AJCC 8th Ed.)			Finding	
C136926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136926>	C136924	Cutaneous Melanoma pM1a(1) TNM Finding v8|Melanoma of the Skin pM1a(1) TNM Finding v8	Cutaneous melanoma with distant metastasis to skin, soft tissue including muscle, and/or nonregional lymph node. LDH level elevated. (from AJCC 8th Ed.)			Finding	
C136927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136927>	C136923	Cutaneous Melanoma pM1b TNM Finding v8|Melanoma of the Skin pM1b TNM Finding v8|pM1b	Cutaneous melanoma with distant metastasis to lung with or without M1a sites of disease. LDH level not recorded or unspecified. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136928>	C136927	Cutaneous Melanoma pM1b(0) TNM Finding v8|Melanoma of the Skin pM1b(0) TNM Finding v8	Cutaneous melanoma with distant metastasis to lung with or without M1a sites of disease. LDH level not elevated. (from AJCC 8th Ed.)			Finding	
C136929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136929>	C136927	Cutaneous Melanoma pM1b(1) TNM Finding v8|Melanoma of the Skin pM1b(1) TNM Finding v8	Cutaneous melanoma with distant metastasis to lung with or without M1a sites of disease. LDH level elevated. (from AJCC 8th Ed.)			Finding	
C13692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13692>	C13432	8q24.11-q24.13	A chromosome band present on 8q			Gene or Genome	
C136930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136930>	C136923	Cutaneous Melanoma pM1c TNM Finding v8|Melanoma of the Skin pM1c TNM Finding v8|pM1c	Cutaneous melanoma with distant metastasis to non-CNS visceral sites with or without M1a or M1b sites of disease.  LDH level not recorded or unspecified. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136931>	C136930	Cutaneous Melanoma pM1c(0) TNM Finding v8|Melanoma of the Skin pM1c(0) TNM Finding v8	Cutaneous melanoma with distant metastasis to non-CNS visceral sites with or without M1a or M1b sites of disease.  LDH level not elevated. (from AJCC 8th Ed.)			Finding	
C136932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136932>	C136930	Cutaneous Melanoma pM1c(1) TNM Finding v8|Melanoma of the Skin pM1c(1) TNM Finding v8	Cutaneous melanoma with distant metastasis to non-CNS visceral sites with or without M1a or M1b sites of disease.  LDH level elevated. (from AJCC 8th Ed.)			Finding	
C136934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136934>	C136923	Cutaneous Melanoma pM1d TNM Finding v8|Melanoma of the Skin pM1d TNM Finding v8	Cutaneous melanoma with distant metastasis to CNS with or without M1a, M1b, or M1c sites of disease.  LDH level not recorded or unspecified. (from AJCC 8th Ed.)			Finding	
C136935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136935>	C136934	Cutaneous Melanoma pM1d(0) TNM Finding v8|Melanoma of the Skin pM1d(0) TNM Finding v8	Cutaneous melanoma with distant metastasis to CNS with or without M1a, M1b, or M1c sites of disease.  LDH level normal. (from AJCC 8th Ed.)			Finding	
C136936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136936>	C136934	Cutaneous Melanoma pM1d(1) TNM Finding v8|Melanoma of the Skin pM1d(1) TNM Finding v8	Cutaneous melanoma with distant metastasis to CNS with or without M1a, M1b, or M1c sites of disease.  LDH level elevated. (from AJCC 8th Ed.)			Finding	
C136937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136937>	C136921	Cutaneous Melanoma Pathologic Primary Tumor TNM Finding v8|Melanoma of the Skin Pathologic Primary Tumor TNM Finding v8|Pathologic Staging: Primary Tumor (pT)	A pathologic finding about one or more characteristics of cutaneous melanoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136938>	C136937	Cutaneous Melanoma pTX TNM Finding v8|Melanoma of the Skin pTX TNM Finding v8|pTX	Cutaneous melanoma in which the primary tumor thickness cannot be assessed (e.g., diagnosis by curettage). Thickness: Not applicable. Ulceration status: Not applicable. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136939>	C136937	Cutaneous Melanoma pT0 TNM Finding v8|Melanoma of the Skin pT0 TNM Finding v8|pT0	Cutaneous melanoma with no evidence of primary tumor (e.g., unknown primary or completely regressed melanoma). Thickness: Not applicable. Ulceration status: Not applicable. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C13693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13693>	C13432	11p12-p11	A chromosome band present on 11p			Gene or Genome	
C136940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136940>	C136937	Cutaneous Melanoma pTis TNM Finding v8|Melanoma of the Skin pTis TNM Finding v8|pTis	Cutaneous melanoma with a finding of melanoma in situ. Thickness: Not applicable. Ulceration status: Not applicable. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136941>	C136937	Cutaneous Melanoma pT1 TNM Finding v8|Melanoma of the Skin pT1 TNM Finding v8|pT1	Cutaneous melanoma measuring 1.0 mm or less in thickness. Ulceration status: Unknown or unspecified. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136942>	C136941	Cutaneous Melanoma pT1a TNM Finding v8|Melanoma of the Skin pT1a TNM Finding v8|pT1a	Cutaneous melanoma measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136943>	C136941	Cutaneous Melanoma pT1b TNM Finding v8|Melanoma of the Skin pT1b TNM Finding v8|pT1b	Cutaneous melanoma measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136944>	C136937	Cutaneous Melanoma pT2 TNM Finding v8|Melanoma of the Skin pT2 TNM Finding v8|pT2	Cutaneous melanoma measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Unknown or unspecified. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136945>	C136944	Cutaneous Melanoma pT2a TNM Finding v8|Melanoma of the Skin pT2a TNM Finding v8|pT2a	Cutaneous melanoma measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136946>	C136944	Cutaneous Melanoma pT2b TNM Finding v8|Melanoma of the Skin pT2b TNM Finding v8|pT2b	Cutaneous melanoma measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: With ulceration. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136947>	C136937	Cutaneous Melanoma pT3 TNM Finding v8|Melanoma of the Skin pT3 TNM Finding v8|pT3	Cutaneous melanoma measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: Unknown or unspecified. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136948>	C136947	Cutaneous Melanoma pT3a TNM Finding v8|Melanoma of the Skin pT3a TNM Finding v8|pT3a	Cutaneous melanoma measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: Without ulceration. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136949>	C136947	Cutaneous Melanoma pT3b TNM Finding v8|Melanoma of the Skin pT3b TNM Finding v8|pT3b	Cutaneous melanoma measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: With ulceration. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C13694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13694>	C13432	1p36.13-p36.11	A chromosome band present on 1p			Gene or Genome	
C136950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136950>	C136937	Cutaneous Melanoma pT4 TNM Finding v8|Melanoma of the Skin pT4 TNM Finding v8|pT4	Cutaneous melanoma measuring more than 4.0 mm in thickness. Ulceration status: Unknown or unspecified. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136951>	C136950	Cutaneous Melanoma pT4a TNM Finding v8|Melanoma of the Skin pT4a TNM Finding v8|pT4a	Cutaneous melanoma measuring more than 4.0 mm in thickness. Ulceration status: Without ulceration. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136952>	C136950	Cutaneous Melanoma pT4b TNM Finding v8|Melanoma of the Skin pT4b TNM Finding v8|pT4b	Cutaneous melanoma measuring more than 4.0 mm in thickness. Ulceration status: With ulceration. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136953>	C136921	Cutaneous Melanoma Pathologic Regional Lymph Nodes TNM Finding v8|Melanoma of the Skin Pathologic Regional Lymph Nodes TNM Finding v8|Pathologic Staging: Regional Lymph Nodes (pN)	A pathologic finding about one or more characteristics of cutaneous melanoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes. The TNM pathologic and clinical regional lymph nodes classifications of cutaneous melanoma are not the same. TNM pathologic findings are based on the microscopic examination of the regional lymph nodes, usually detected by lymphatic mapping and sentinel lymph node biopsy (clinically occult regional lymph node metastasis). (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136954>	C136953	Cutaneous Melanoma pNX TNM Finding v8|Melanoma of the Skin pNX TNM Finding v8|pNX	Cutaneous melanoma in which the regional lymph nodes are not assessed (e.g., sentinel lymph node biopsy is not performed, regional lymph nodes were previously removed for another reason). Exception: pathological N category is not required for T1 melanomas, use cN. Presence of in-transit, satellite, and/or microsatellite metastases: No.  (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136955>	C136953	Cutaneous Melanoma pN0 TNM Finding v8|Melanoma of the Skin pN0 TNM Finding v8|pN0	Cutaneous melanoma without regional lymph node metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: No.  (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136956>	C136953	Cutaneous Melanoma pN1 TNM Finding v8|Melanoma of the Skin pN1 TNM Finding v8|pN1	Cutaneous melanoma with one tumor-involved node or in-transit satellite, and/or microsatellite metastases with no tumor-involved nodes. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136957>	C136956	Cutaneous Melanoma pN1a TNM Finding v8|Melanoma of the Skin pN1a TNM Finding v8|pN1a	Cutaneous melanoma with one clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No.  (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136958>	C136956	Cutaneous Melanoma pN1c TNM Finding v8|Melanoma of the Skin pN1c TNM Finding v8	Cutaneous melanoma with no regional lymph node disease. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. (from AJCC 8th Ed.)			Finding	
C136959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136959>	C136953	Cutaneous Melanoma pN2 TNM Finding v8|Melanoma of the Skin pN2 TNM Finding v8|pN2	Cutaneous melanoma with two or three tumor-involved nodes or in-transit satellite, and/or microsatellite metastases with one tumor-involved node. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C13695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13695>	C13432	17q21.3	A chromosome band present on 17q			Gene or Genome	
C136960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136960>	C136959	Cutaneous Melanoma pN2a TNM Finding v8|Melanoma of the Skin pN2a TNM Finding v8|pN2a	Cutaneous melanoma with two or three clinically occult nodal metastases (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No.  (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136961>	C136959	Cutaneous Melanoma pN2c TNM Finding v8|Melanoma of the Skin pN2c TNM Finding v8|pN2c	Cutaneous melanoma with one clinically occult nodal metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136962>	C217122	Follicular Lymphoma International Prognostic Index|FILIPI|FILIPI Score|Follicular Lymphoma International Prognostic Index (FLIPI Score)	A prognostic index designed to be used for patients with follicular lymphoma to stratify them by risk. The index uses 5 parameters: age (greater than or equal to 60 years vs less than 60 years), Ann Arbor stage (III-IV vs I-II), hemoglobin level (less than 120 g/L vs greater than or equal to 120 g/L), number of nodal areas involved (greater than 4 vs less than or equal to 4), serum LDH level (above normal vs normal or below) and divides patients into 3 risk groups: low (0-1 risk factors), intermediate (2 risk factors), high (greater than or equal to 3 risk factors).			Intellectual Product	
C136963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136963>	C136953	Cutaneous Melanoma pN3 TNM Finding v8|Melanoma of the Skin pN3 TNM Finding v8|pN3	Cutaneous melanoma with four or more tumor-involved nodes or in-transit satellite, and/or microsatellite metastases with two or more tumor-involved nodes, or any number of matted nodes without or with in-transit, satellite, and/or microsatellite metastases. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C136964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136964>	C136963	Cutaneous Melanoma pN3a TNM Finding v8|Melanoma of the Skin pN3a TNM Finding v8	Cutaneous melanoma with four or more clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No.  (from AJCC 8th Ed.)			Finding	
C136965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136965>	C136962	FLIPI Score 0-1, Low Risk|FLIPI Score 0-1|Follicular Lymphoma International Prognostic Index Score 0-1	A score indicating that a patient has 0 or 1 risk factors associated with follicular lymphoma and is considered in the low risk group.			Intellectual Product	
C136966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136966>	C136963	Cutaneous Melanoma pN3c TNM Finding v8|Melanoma of the Skin pN3c TNM Finding v8	Cutaneous melanoma with two or more clinically occult nodal metastases. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. (from AJCC 8th Ed.)			Finding	
C136967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136967>	C136962	FLIPI Score 2, Intermediate Risk|FLIPI Score 2|Follicular Lymphoma International Prognostic Index Score 2	A score indicating that a patient has 2 risk factors associated with follicular lymphoma and is considered in the intermediate risk group.			Intellectual Product	
C136968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136968>	C136962	FLIPI Score Greater than or Equal to 3, High Risk|FLIPI Score Greater than or Equal to 3|Follicular Lymphoma International Prognostic Index Score Greater than or Equal to 3	A score indicating that a patient has 3 or more risk factors associated with follicular lymphoma and is considered in the high risk group.			Intellectual Product	
C136969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136969>	C88924	Deleted In Lymphocytic Leukemia 1 Non-Protein Coding RNA|DLEU1|Deleted In Lymphocytic Leukemia 1 Long Non-Protein Coding RNA|LINCRNA21|Long Intergenic Non-Protein Coding RNA 21|Long Non-Coding RNA 21|NCRNA00021|Non-Coding RNA 21|Non-Protein Coding RNA 21	Deleted in lymphocytic leukemia 1 non-protein coding RNA (~3 kb) is encoded by the human DLEU1 gene. This non-coding RNA may be involved in tumor suppression.			Nucleic Acid, Nucleoside, or Nucleotide	
C13696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13696>	C13432	13q14.1-q14.2	A chromosome band present on 13q			Gene or Genome	
C136970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136970>	C93102|C128820	Deleterious EPCAM Gene Mutation|Deleterious Epithelial Cell Adhesion Molecule Gene Mutation|Deleterious TACSTD1 Gene Mutation	A change in the nucleotide sequence of the EPCAM gene that is associated with increased risk of disease.	Deleterious EPCAM Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136971>	C6913|C133592	Recurrent Lymphocyte-Rich Classic Hodgkin Lymphoma|Recurrent Lymphocyte-Rich Classical Hodgkin Lymphoma|Recurrent Lymphocyte-Rich Classical Hodgkin Lymphoma	The reemergence of lymphocyte-rich classic Hodgkin lymphoma after a period of remission.	Recurrent Lymphocyte-Rich Classical Hodgkin Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C136972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136972>	C210981	Intermediate Atypical Prostate Carcinoma|IAC|Intermediate Atypical Carcinoma|Intermediate Atypical Metastatic Castration-Resistant Prostate Cancer|Intermediate Atypical Metastatic Castration-Resistant Prostate Carcinoma|Intermediate Atypical mCRPC	An aggressive, castration-resistant, histologically distinct, metastatic carcinoma arising from the prostate gland. It is characterized by the presence of a pure population of cytologically bland malignant epithelial cells with moderate to abundant cytoplasm and rare mitotic figures. The prognosis is poor.			Neoplastic Process	
C136973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136973>	C88924	Long Intergenic Non-Protein Coding RNA 1565|LINC01565	Long intergenic non-protein coding RNA 1565 (~3 kb) is encoded by the human LINC01565 gene. This non-coding RNA may be involved the suppression of cell growth.			Nucleic Acid, Nucleoside, or Nucleotide	
C136975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136975>	C20694	LMNA Gene Product	A protein encoded by the LMNA gene.			Amino Acid, Peptide, or Protein	
C136976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136976>	C136975	Lamin-A/C|70 kDa Lamin|Lamin A|Lamin C|Lamin-A|Lamin-C|Renal Carcinoma Antigen NY-REN-32	Lamin-A/C (646 aa, ~72 kDa)  is encoded by the human LMNA gene. This protein plays a role in the formation of the nuclear lamina.	Lamin-A/C		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C136977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136977>	C136559	Rainbow Trout Mesothelioma	A neoplasm arising from the mesothelium that occurs in Oncorhynchus mykiss.			Neoplastic Process	Cellosaurus Disease Terminology
C136978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136978>	C134533	Devil Facial Tumor Disease|DFTD	A transmissible neoplastic disease that occurs in the Tasmanian devil. It is spread by biting and is characterized by tumors on the face and mouth.			Neoplastic Process	
C136979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136979>	C37254	Tricuspid Valve Regurgitation Velocity|TRJV|TRV|Tricuspid Regurgitant Jet Velocity|Tricuspid Regurgitation Jet Velocity|Tricuspid Regurgitation Velocity	A measurement of the backward flow of blood through the tricuspid valve during right ventricle contraction. It correlates with pulmonary artery systolic pressure at rest and with exercise. A tricuspid regurgitation velocity greater than or equal to 2.5 m/sec on echocardiography is a surrogate marker for pulmonary hypertension in adults with sickle cell disease.			Sign or Symptom	
C13697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13697>	C13432	18p11.3	A chromosome band present on 18p			Gene or Genome	
C136981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136981>	C67437	Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310|Anti-EphA2 Antibody-targeted Nanoliposome MM-310|Anti-EphA2 Docetaxel-based Nanoliposome MM-310|EphA2-targeted Docetaxel Nanoliposome MM-310|MM 310|MM-310|MM310	A formulation containing nanoparticles composed of liposomes that are conjugated to scFv antibody fragments directed against the ephrin receptor A2 (EphA2; Ephrin A2) and a proprietary prodrug of docetaxel, a poorly water-soluble, second-generation taxane analog, with potential antineoplastic activity. Upon intravenous administration of the anti-EphA2 antibody-directed liposomal docetaxel prodrug MM-310, the anti-EphA2 moiety selectively targets and binds to cells expressing EphI3:I12A2. Following accumulation of MM-310, docetaxel is slowly released from MM-310 and accumulates at the tumor site due to the unique characteristics of the tumor vasculature. In turn, docetaxel is taken up by tumor cells, where it binds to and stabilizes the beta-subunit of tubulin, thereby stabilizing microtubules and inhibiting microtubule disassembly. This results in cell cycle arrest and the induction of cell death. The cell-surface receptor EphA2, a member of the ephrin family of receptor tyrosine kinases (RTKs) that are involved in mammalian development, is overexpressed by a variety of cancer cell types and plays an important role in tumor growth; its expression is associated with poor prognosis. Compared to free docetaxel, MM-310 increases docetaxel's half-life, and provides enhanced and specific accumulation in EphA2-expressing tumors, thereby increasing docetaxel's efficacy while lowering its systemic toxicity.	Anti-EphA2 Antibody-directed Liposomal Docetaxel Prodrug MM-310		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C136982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136982>	C28681|C138180|C129826	TCR-specific, alpha Fetoprotein-enhanced Autologous T Lymphocytes|AFP-C332 CTLs|AFP-C332 T Cells|AFPC332|Anti-AFP TCR-expressing Autologous CTLs|Autologous Genetically Modified AFPC332 T Cells|Autologous Genetically Modified AFPC332 T-cells	A preparation of human autologous T-lymphocytes transduced with a viral vector encoding for a T-cell receptor (TCR) specific for human alpha-fetoprotein (AFP), with potential antineoplastic activity. Following administration, the TCR-specific, alpha fetoprotein-enhanced autologous T-lymphocytes recognize and bind to AFP antigen-positive cells, which results in lysis and killing of AFP-positive cancer cells. AFP is overexpressed in a variety of cancers.	TCR-specific, alpha Fetoprotein-enhanced Autologous T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C136983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136983>	C207912|C201282|C129822	Obrindatamab|B7-H3 x CD3 DART Protein|B7-H3 x CD3 Dual-affinity Re-targeting Protein MGD009|DART Protein MGD009|Dual-affinity B7-H3/CD3-targeted Protein MGD009|MGD 009|MGD-009|MGD009|OBRINDATAMAB|Orlotamab	An Fc-bearing humanized bispecific dual-affinity re-targeting (DART) protein composed of Fv regions derived from monoclonal antibodies against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration of obrindatamab, the anti-B7-H3 component targets and binds to the cell surface antigen B7-H3; at the same time, the anti-CD3 component binds to human CD3. This cross-links the T-cells to B7-H3-expressing tumor cells, activates and redirects endogenous T-cells to kill B7-H3-expressing tumor cells, and inhibits proliferation of B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells but is minimally expressed by normal human tissues. B7-H3 is a negative regulator of T-cell activation and its overexpression plays a key role in immuno-evasion, tumor cell invasion and metastasis, and its expression is correlated with poor prognosis.	Obrindatamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C136984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136984>	C1931	Chinese Herbal Medicine YQ1|YQ1	A Chinese herbal medicine, with potential immunostimulating and antineoplastic activities. Although the mechanism of action is currently unknown, upon administration, YQ1 may cause an induction of apoptosis and an inhibition of tumor cell proliferation. YQ1 might target cancer stem cells (CSCs).			Pharmacologic Substance	NCI Drug Dictionary Terminology
C136985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136985>	C129822	Murlentamab|3C23K|Anti-AMHR2 Monoclonal Antibody GM102|Anti-AMHR2 Monoclonal Antibody GM10II|GM 102|GM102|GM102 Antibody|GM10II|MURLENTAMAB	An engineered, humanized, low fucose monoclonal antibody against mullerian hormone receptor II (Müllerian Inhibiting Substance Receptor II; AMHR2; AMHRII), with potential antineoplastic activity. Upon administration, murlentamab targets, binds to and inhibits AMHR2 and its downstream signaling pathways. GM102 primarily induces antibody dependent cellular cytotoxicity (ADCC) directed against AMHR2-expressing tumor cells through binding to CD16 (Fc-gammaRIIIa) that is present on immune effector cells. Decreased antibody fucosylation increases its affinity for binding to CD16 and ultimately enhances ADCC. AMHR2 is expressed in a subset of gynecological cancers.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C136986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136986>	C137999|C129826	LMP1-specific Chimeric Antigen Receptor-expressing T Lymphocytes|Anti-LMP1 CAR T Cells|LMP1-CAR-CTLs|LMP1-CAR-T Cells	A preparation of cytotoxic T-lymphocytes (CTL) transfected with a chimeric antigen receptor (CAR) specifically recognizing the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1; LMP-1), with potential antineoplastic activity. Upon administration of the LMP1-specific CAR-expressing T lymphocytes to patients with LMP1-positive tumors, the CTLs specifically target and lyse tumor cells expressing LMP1, thereby inhibiting tumor cell proliferation. The tumor-associated antigen (TAA) LMP1 is expressed in various malignancies, including nasopharyngeal cancer and EBV-positive Hodgkin lymphoma.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology
C136987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136987>	C215224|C206430	Patritumab Deruxtecan|Anti-HER3 Antibody-drug Conjugate U3 1402|PATRITUMAB DERUXTECAN|U3 1402|U3-1402|U3-1402a	An antibody-drug conjugate (ADC) composed of patritumab, a monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3),linked to the topoisomerase I inhibitor DX 8951, a semisynthetic, water-soluble derivative of camptothecin, with potential antineoplastic activity. Upon administration of patritumab deruxtecan, the patritumab moiety targets and binds to HER3. After internalization, DX 8951 inhibits topoisomerase I activity by stabilizing the complex between topoisomerase I and DNA and inhibiting religation of DNA breaks, thereby inhibiting DNA replication and triggering apoptotic cell death. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors.	Patritumab Deruxtecan		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C136988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C136988>	C74536	N-acetylcysteine/Simethicone Solution	An oral solution composed of N-acetylcysteine, a synthetic N-acetyl derivative of the endogenous amino acid L-cysteine, and simethicone, a mixture of polydimethylsiloxanes and hydrated silica gel, with mucolytic and antifoaming activities. Upon oral administration of the mucolytic solution, N-acetylcysteine breaks down disulfide bonds in mucoproteins, resulting in liquification of mucus in the upper respiratory tract. Simethicone reduces the surface tension of gas bubbles causing them to coalesce into larger bubbles that can be passed more easily. This increases the passage of mucus and gas bubbles from the upper digestive tract. This may also increase visibility of the gastric mucosa during upper endoscopy.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C13698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13698>	C13432	20q12-q13	A chromosome band present on 20q			Gene or Genome	
C13699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13699>	C13432	10q21	A chromosome band present on 10q			Gene or Genome	
C1369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1369>	C496	Recombinant Fibroblast Growth Factor 6|FGF-6|FGF6|HBGF-6|HST-2	A recombinant therapeutic agent which is chemically identical to or similar to endogenous fibroblast growth factor 6 (FGF-6).  Because of the mitogenic effects of FGF-6 on fibroblasts and endothelial cells and the stimulatory effects of FGF-6 on muscle stem cell migration, therapeutic FGF-6 has a potential role in wound healing and muscle regeneration. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C13700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13700>	C13432	7q21.1	A chromosome band present on 7q			Gene or Genome	
C13701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13701>	C13432	19q13.3-q13.4	A chromosome band present on 19q			Gene or Genome	
C13702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13702>	C13432	8p23.1-p21.3	A chromosome band present on 8p			Gene or Genome	
C13703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13703>	C13432	5q33.2-q33.3	A chromosome band present on 5q			Gene or Genome	
C13704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13704>	C13432	1q21-q22	A chromosome band present on 1q			Gene or Genome	
C13705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13705>	C13432	3p24.3	A chromosome band present on 3p			Gene or Genome	
C13706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13706>	C13432	12p12.3	A chromosome band present on 12p			Gene or Genome	
C13707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13707>	C13432	3q26	A chromosome band present on 3q			Gene or Genome	
C13708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13708>	C13432	3p21	A chromosome band present on 3p			Gene or Genome	
C13709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13709>	C13432	4q25	A chromosome band present on 4q			Gene or Genome	
C1370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1370>	C496	Recombinant Fibroblast Growth Factor 5|FGF5|HBGF-5	A recombinant form of the heparin-binding fibroblast growth factor 5 (FGF-5).  FGF-5 may function as a growth factor during embryogenesis and may have a role in wound repair throughout adulthood because of its mitogenic effects on fibroblasts and endothelial cells.  Overexpressed in certain tumor cell types, this agent may promote tumor growth and angiogenesis. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C13710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13710>	C13432	3p26-p25	A chromosome band present on 3p			Gene or Genome	
C13711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13711>	C13432	15q22-q24	A chromosome band present on 15q			Gene or Genome	
C13712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13712>	C13432	2q31-q33	A chromosome band present on 2q			Gene or Genome	
C13713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13713>	C13236	Male Genital System Fluid or Secretion|Genital System, Male, Fluids, Secretions|Male Genital System Fluids and Secretions|Sperm, Fluids, Secretions	Sperm and the fluid it is suspended in.			Body Substance	
C13714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13714>	C13432	5q35.1	A chromosome band present on 5q			Gene or Genome	
C13716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13716>	C13734	Internal Ribosome Entry Site|IRES|Ribosome Entry Site	Internal ribosome entry site (IRES) is a translational cis-acting element that directs ribosomes to the start codon by a cap-independent mechanism.  IRESs are usually about 450 nucleotides in length and were first identified in picornavirus RNAs.  IRESs can fold into a stable secondary hairpin structure to be incompatible with efficient translation by ribosomal scanning. (NCI)			Gene or Genome	
C13717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13717>	C33904	Anatomic Site|Anatomic Location|Anatomic Sites|Anatomical Location|Anatomical_Location|LOC|Location|Location|Site|Topographic (Anatomic) Site|Topographic Site	Named locations of or within the body.			Body Location or Region	Canine Glioma Project Property Terminology|CDISC Root Variable Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Medical History Form|CPTAC Melanoma Follow-Up Form|CPTAC Surgery-Anesthesia Form|CPTAC Terminology|ICDC Terminology|Oral Mucositis Rating Scale
C13718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13718>	C13372	Hypoxia-Responsive Elements	DNA sequences in a gene's promoter region that mediate expression during hypoxia.  Since unlike normal tissues, solid tumors frequently have regions of hypoxia, suicide genes controlled by hypoxia-responsive elements may provide a means for cancer-specific gene therapy.			Gene or Genome	
C13719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13719>	C13424	ETS Domain	Usually C-terminal, the conserved ETS (Erythroblast Transformation Specific) Domain of 85-90 amino acids, rich in positively-charged and aromatic residues, binds to purine-rich DNA with a GGAA/T core. Identified in many transcription factors, many ETS-proteins modulate gene expression through protein-protein interactions with other transcriptional factors and co-factors. Most ETS-proteins are nuclear targets of RAS-MAPK signaling; some affect cell proliferation or apoptosis-related genes. Several are expressed in specific cell lineages to regulate development and differentiation. Deregulated ETS-gene expression or chimeric ETS-proteins are associated with leukemias, some tumors, invasion and metastasis. (NCI)			Amino Acid Sequence	
C1371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1371>	C275|C177298	Fosquidone|FOSQUIDONE|GR 63178A|GR 63178A	A water-soluble pentacyclic pyrolloquinone analogue of mitoquidone with potential antineoplastic activity. Currently, the mechanism of action of fosquidone is unknown. In vitro studies indicate that this agent does not bind to DNA or inhibit topoisomerases.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C13720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13720>	C13671	RNA Recognition Motif|Putative RNA-Binding Region|RBD|RNA Binding Domain|RNP Domain|RNP Motif|RNP-1 Signature|RRM	RNA Binding Domains (RBD) mediate the interaction of RNAs with RNA-binding proteins. RBDs of about 90 amino acids consist of a four-stranded beta sheet adjacent to two alpha helixes. Within RBDs, conserved RNP-1 and RNP-2 motifs on the central beta sheets lie side by side; their side chains contact RNA.			Amino Acid Sequence	
C13721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13721>	C13425	bZIP Domain|Basic Leucine Zipper	Bipartite DNA binding domain containing a basic region directly interacting with DNA, and a leucine zipper mediating dimerization through contacts with a protein partner.			Amino Acid Sequence	
C13722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13722>	C13236	Respiratory System Fluid or Secretion|Respiratory System Fluid and Secretion|Respiratory System Fluids and Secretions|Respiratory System-Fluids, Secretions	Fluids and secretions relating to the respiratory system.			Body Substance	
C13723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13723>	C21176	DNA Repair Complex|Repair Complex	Initial or intermediate protein-DNA complexes present during the process of DNA repair.			Amino Acid, Peptide, or Protein|Enzyme	
C13724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13724>	C13299	Central DNA Flap Sequence	In Lentivirus, a central strand displacement event consecutive to central initiation and termination of plus strand synthesis creates a plus strand overlap: the central DNA flap.  This feature promotes efficient nuclear import and viral replication in non-dividing cells. (from Cell 2000;101:173-85)			Nucleotide Sequence	
C13725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13725>	C13404	G-Quartets|G-Quadruplex|G-Quadruplexes|G-Quadruplexes DNA|G-Quartet Structures|G-Tetrads|G4-DNA	G-quadruplexes are multi-stranded structures held together by square planes of four guanines ('G-quartets') interacting by forming Hoogsteen hydrogen bonds. G-quartet structures has been developed as novel anti-HIV agents. Several critical structure-activity relationships between HIV-1 integrase and G-quartet oligonucleotides have been demonstrated.			Nucleic Acid, Nucleoside, or Nucleotide	
C13726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13726>	C13432	1p32-q12	A chromosome band present on 1p			Gene or Genome	
C13727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13727>	C226401|C186972|C171626|C155992|C128657	t(12;21)(p13.2;q22.1)|t(12;21)(p13;q22)|t(12;21)(p13;q22)	A translocation between chromosomes 12 and 21 involved in TEL-AML1 oncogene formation. The translocation produces a chimeric gene encoding a protein consisting of the N-terminal HLH domain of the TEL ETS-like transcription factor fused with a nearly complete AML1 protein. t(12;21) is the most frequent translocation causing ALL, accounting for 20% of ALL cases.			Cell or Molecular Dysfunction	ALL Authorized Value Terminology|ALL Molecular Analysis Table
C13728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13728>	C13432	15q23-q25	A chromosome band present on 15q			Gene or Genome	
C13729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13729>	C13432	21q22.2	A chromosome band present on 21q			Gene or Genome	
C1372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1372>	C2159|C1968	Fostriecin|2H-pyran-2-one,5,6-dihydro-6-(3,6,13-trihydroxy-3-methyl-4-(phosphonooxy)-1,7,9,11,-tridecatetraenyl)-,trans|FOSTRIECIN|FST|Phosphotrienin|Phosphotrienin	An anti-tumor antibiotic isolated from the bacterium Streptomyces pulveraceus. Fostriecin inhibits topoisomerase II catalytic activity, resulting in impaired DNA and RNA synthesis in various malignant cell types.  This agent also inhibits serine/threonine protein phosphatase type 2A in some tumor cell types, thereby interfering with cellular proliferation and differentiation. (NCI04)			Antibiotic|Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C13730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13730>	C13432	4q13-q21	A chromosome band present on 4q			Gene or Genome	
C13731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13731>	C225418	Intraventricular|Intra-ventricular	Located within a ventricle of the brain or heart.			Spatial Concept	CRF7 Pathology Review Table
C13732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13732>	C13426	Bromodomain	A motif common in chromatin remodeling factors. It consists of approximately 110 amino acids in a left-handed up-and-down four helix bundle with a left handed twist. A hydrophobic pocket in the bromodomain creates an acetyl-lysine binding domain. Bromodomain-containing proteins may recruit remodeling complexes to acetylated chromatin regions.			Amino Acid Sequence	
C13733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13733>	C13432	5p15.33	A chromosome band present on 5p			Gene or Genome	
C13734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13734>	C13445	Regulatory Element|Regulatory Region	Any DNA sequence involved in the regulation of genetic processes such as transcription and replication.			Nucleotide Sequence	
C13735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13735>	C33089|C14070	Plasma Membrane|Cell Membrane|Plasmalemma|plasma membrane	The semipermeable membrane that encloses the cytoplasm of a cell.	Plasma Membrane		Cell Component	CTRP Biomarker Terminology|CTRP Terminology
C13736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13736>	C13984	Zonula Adherens|AJ|Adherens Junction|Intermediate Junction	The best understood cell-cell junction required for adhesion between cells in the epithelium. It seals adjacent epithelial cells together, preventing the passage of most dissolved molecules from one side of the epithelial sheet to the other. Adherens junctions are located most apically in insect cells and just basal to the tight junction in vertebrate cells. It is formed by the fusion of adjacent cell membranes which encircle the apical cell surface like a belt or fence based on homophilic association between molecules of the transmembrane protein E-cadherin, which is linked on its cytoplasmic side to the actin cytoskeleton via b-catenin (Drosophila Armadillo) and a-catenin. The adherens junctions and associated cytoskeleton form a continuous band (zonula adherens) around the apical circumference of each cell, thus uniting the cells of the epithelium into a coherent sheet.			Cell Component	
C13737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13737>	C13314	20S Proteasome|20S Catalytic Proteasome|20S Core Proteasome|20S Proteosome	The 20S proteasome, as proteolytic core of the proteasome system, is essential in ATP dependent ubiquitin protein complex degradation and in antigen processing in antigen presenting cell. It has 13-15 subunits each of which has three or four different peptidase activities. 26S proteasomes may be formed in an ATP dependent fashion from a 20S proteasome and additional components, CF1 (660 kD), CF2 (250 kD) and CF3 (600 kD). The 20S proteasome interacts with additional subunits, PA700 and PA28, to form an ATP-dependent multicatalytic proteinase complex (MPC) involved in the ATP ubiquitin degradation pathway.	20S Proteasome		Amino Acid, Peptide, or Protein|Cell Component	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13738>	C176811	Conformation|Conformal	The three-dimensional arrangement of something in space. Often refers to the arrangement of the side groups on a molecule which can freely rotate into different positions without breaking any bonds.			Spatial Concept	
C13739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13739>	C28147	Blastocyst|Blastosphere|Blastula	An embryo made up of two groups of cells. One group will develop into the fetus and the other will become the placenta.			Embryonic Structure	
C1373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1373>	C784	Girodazole|3-Amino-1-[4-(2 amino-1H-imidazolyl)]-propanol, 2HCl|Giroline|RP 49532A	A compound isolated from the marine sponge Pseudaxinyssa cantharella exhibiting anti-tumor activity.  Studies indicate girodazole acts during the elongation/termination steps of protein synthesis, resulting in protein synthesis inhibition. (NCI)			Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C13740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13740>	C34237	Inner Cell Mass|Embryoblast	A small group of cells found in the blastocyst cavity surrounded by a wall of trophoblast cells that eventually will form the embryo.			Embryonic Structure	
C13741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13741>	C13422	AT Hook Motif|AT Hook Domain|ATH	Highly conserved peptide motifs of the HMG-I(Y) proteins that preferentially bind to the AT-rich minor groove of DNA. The AT hook motif tethers and unwinds the minor groove of the DNA with very little specificity for the DNA sequence. The AT hook motif has a narrow DNA recognition surface that is devoid of hydrophobic amino acids and that does not significantly distort the B-form DNA structure.			Amino Acid Sequence	
C13742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13742>	C13404	Minor Groove	The smaller of the two types of spiral grooves found on a right-handed DNA double helix; located between the sugar phosphate backbones of two DNA strands.			Spatial Concept	
C13743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13743>	C13404	Major Groove	One of the two types of grooves found in a right-handed double helix, running between the sugar phosphate backbones of each strand.			Spatial Concept	
C13744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13744>	C13422	HMG-Box|HMG-1 Domain	The HMG-Box Domain binds to and bends the minor groove of the DNA. This domain can recognize and bind to altered DNA conformations, such as stem-loops, four-way junctions, and specifically kinked or underwound DNA. (Mol Cell Biol 1999 Aug;19(8):5237-46)			Amino Acid Sequence	
C13745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13745>	C13422	Nucleosome Binding Domain|NBD	The Nucleosomal Binding Domain anchors HMG-14 and HMG-17, two canonical HMG proteins, to nucleosomes. HMG-14 and HMG-17 are the only nuclear proteins known to specifically recognize the genetic structure of the 146-bp nucleosome, i.e., the building block of the chromatin fiber. Although the target of HMG-14/-17 is the nucleosome, the main function of these proteins is to change the architecture of the higher-order chromatin structure. These changes are mediated through the C-terminal region of the proteins. The nucleosomal binding domain anchors these HMG proteins to the nucleosome cores to facilitate HMG-14/-17-dependent changes in chromatin structure.			Amino Acid Sequence	
C13746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13746>	C13453|C13426	Ring Finger Domain|Ring Finger|Ring Finger Motif|Ring-Type Zinc Finger Domain	The RING finger is a specialized type of Zn-finger consisting of 40 to 60 residues, which has the consensus sequence CX2CX(9-39)CX(1-3)HX(2-3)C/HX2CX(4-48)CX2C, that binds two atoms of zinc, and is involved in mediating protein-protein interactions. The RING domain mediates the interaction with the appropriate E2 enzyme. Unlike HECT E3 enzymes that form a thiol-ester with ubiquitin, RING fingers likely mediate ubiquitination by facilitating the direct transfer of ubiquitin from E2 enzyme to lysine residues on the target substrate.			Amino Acid, Peptide, or Protein	
C13747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13747>	C13432	14q11	A chromosome band present on 14q			Gene or Genome	
C13748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13748>	C13432	3p21.3-p21.2	A chromosome band present on 3p			Gene or Genome	
C13749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13749>	C13432	Xq28	A chromosome band present on Xq			Gene or Genome	
C1374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1374>	C1910	Goserelin|6-[O-(1,1-Dimethylethyl)-D-serine]-10-deglycinamide Luteinizing Hormone-Releasing Factor (Pig) 2-(aminocarbonyl)hydrazide|GOSERELIN|ICI-118630|goserelin	A synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. Goserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Prolonged administration of goserelin inhibits the secretion of pituitary gonadotropin, thereby decreasing levels of testosterone (in males) and estradiol (in females).  Administration of this agent in a depot formulation may result in the regression of sex hormone-sensitive tumors and a reduction in sex organ size and function. (NCI04)	Goserelin		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCIt Antineoplastic Agent Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C13750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13750>	C13432	5q11-q12	A chromosome band present on 5q			Gene or Genome	
C13751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13751>	C13432	13q22-q34	A chromosome band present on 13q			Gene or Genome	
C13752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13752>	C13432	5q13-q14	A chromosome band present on 5q			Gene or Genome	
C13753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13753>	C13432	7q36.1	A chromosome band present on 7q			Gene or Genome	
C13754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13754>	C13432	11q22-q23	A chromosome band present on 11q			Gene or Genome	
C13755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13755>	C13432	Xq25	A chromosome band present on Xq			Gene or Genome	
C13756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13756>	C13432	20q13.3	A chromosome band present on 20q			Gene or Genome	
C13757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13757>	C13432	22q11-q13	A chromosome band present on 22q			Gene or Genome	
C13758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13758>	C13432	3p26.2	A chromosome band present on 3p			Gene or Genome	
C13759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13759>	C13432	1q42-q43	A chromosome band present on 1q			Gene or Genome	
C1375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1375>	C597|C45564	Guanidinium Cation|Guanidinium	The cationic form and conjugate acid of the strongly basic compound guanidine.			Organic Chemical|Pharmacologic Substance	
C13760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13760>	C13432	5q12.2-q13.3	A chromosome band present on 5q			Gene or Genome	
C13761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13761>	C13432	3q22.1	A chromosome band present on 3q			Gene or Genome	
C13762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13762>	C13432	19p13.3-p13.2|19p13.3-2	A chromosome band present on 19p			Gene or Genome	
C13763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13763>	C13432	2q35	A chromosome band present on 2q			Gene or Genome	
C137645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137645>	C3510	Cutaneous Melanoma by AJCC v8 Stage|Melanoma of the Skin by AJCC v8 Stage	A term that refers to the staging of cutaneous melanoma, following the rules of the TNM AJCC v8 classification system. This staging system does not apply to melanoma of the conjunctiva, melanoma of the uvea, mucosal melanoma arising in the head and neck, and mucosal melanoma of the urethra, vagina, rectum, and anus. (from AJCC 8th Ed.)			Neoplastic Process	
C137646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137646>	C137645	Cutaneous Melanoma by AJCC v8 Clinical Stage|Melanoma of the Skin by AJCC v8 Clinical Stage	A term that refers to the clinical staging of cutaneous melanoma, following the rules of the TNM AJCC v8 classification system.			Neoplastic Process	
C137647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137647>	C137646	Clinical Stage 0 Cutaneous Melanoma AJCC v8|Clinical Stage 0 Melanoma of the Skin AJCC v8|Stage 0 Cutaneous (Skin) Melanoma	Stage 0 includes: Tis, N0, M0. Tis: Melanoma in situ. Thickness: Not applicable. Ulceration status: Not applicable. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)	Clinical Stage 0 Cutaneous Melanoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C137648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137648>	C137646	Clinical Stage I Cutaneous Melanoma AJCC v8|Clinical Stage I Melanoma of the Skin AJCC v8|Stage I Cutaneous (Skin) Melanoma	Stage I includes: IA: (T1a, N0, M0); IB: (T1b, N0, M0); (T2a, N0, M0). T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)	Clinical Stage I Cutaneous Melanoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C137649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137649>	C137648	Clinical Stage IA Cutaneous Melanoma AJCC v8|Clinical Stage IA Melanoma of the Skin AJCC v8|Stage IA Cutaneous (Skin) Melanoma	Stage IA includes: T1a, N0, M0. T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)	Clinical Stage IA Cutaneous Melanoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13764>	C13432	3q21	A chromosome band present on 3q			Gene or Genome	
C137650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137650>	C137648	Clinical Stage IB Cutaneous Melanoma AJCC v8|Clinical Stage IB Melanoma of the Skin AJCC v8|Stage IB Cutaneous (Skin) Melanoma	Stage IB includes: (T1b, N0, M0); (T2a, N0, M0). T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)	Clinical Stage IB Cutaneous Melanoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C137651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137651>	C137646	Clinical Stage II Cutaneous Melanoma AJCC v8|Clinical Stage II Melanoma of the Skin AJCC v8|Stage II Cutaneous (Skin) Melanoma	Stage II includes: IIA: (T2b, N0, M0); (T3a, N0, M0); IIB: (T3b, N0, M0); (T4a, N0, M0); IIC: (T4b, N0, M0). T2b: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: With ulceration. T3a: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: Without ulceration. T3b: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: With ulceration. T4a: Tumor measuring more than 4.0 mm in thickness. Ulceration status: Without ulceration. T4b: Tumor measuring more than 4.0 mm in thickness. Ulceration status: With ulceration.  N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)	Clinical Stage II Cutaneous Melanoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C137652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137652>	C137651	Clinical Stage IIA Cutaneous Melanoma AJCC v8|Clinical Stage IIA Melanoma of the Skin AJCC v8|Stage IIA Cutaneous (Skin) Melanoma	Stage IIA includes: (T2b, N0, M0); (T3a, N0, M0). T2b: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: With ulceration. T3a: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)	Clinical Stage IIA Cutaneous Melanoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C137653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137653>	C137651	Clinical Stage IIB Cutaneous Melanoma AJCC v8|Clinical Stage IIB Melanoma of the Skin AJCC v8|Stage IIB Cutaneous (Skin) Melanoma	Stage IIB includes: (T3b, N0, M0); (T4a, N0, M0). T3b: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: With ulceration. T4a: Tumor measuring more than 4.0 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)	Clinical Stage IIB Cutaneous Melanoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C137654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137654>	C137651	Clinical Stage IIC Cutaneous Melanoma AJCC v8|Clinical Stage IIC Melanoma of the Skin AJCC v8|Stage IIC Cutaneous (Skin) Melanoma	Stage IIC includes: T4b, N0, M0. T4b: Tumor measuring more than 4.0 mm in thickness. Ulceration status: With ulceration.  N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)	Clinical Stage IIC Cutaneous Melanoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C137655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137655>	C137646	Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage III Melanoma of the Skin AJCC v8|Stage III Cutaneous (Skin) Melanoma	Stage III includes: Any T, Tis, N1 or More, M0. Tis: Melanoma in situ. Thickness: Not applicable. Ulceration status: Not applicable. N1: One tumor-involved node or in-transit, satellite, and/or microsatellite metastases with no tumor-involved nodes. N2: Two or three tumor-involved nodes or in-transit, satellite, and/or microsatellite metastases with one tumor-involved node. N3: Four or more tumor-involved nodes or in-transit, satellite, and/or microsatellite metastases with two or more tumor-involved nodes, or any number of matted nodes without or with in-transit, satellite, and/or microsatellite metastases. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)	Clinical Stage III Cutaneous Melanoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C137656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137656>	C137646	Clinical Stage IV Cutaneous Melanoma AJCC v8|Clinical Stage IV Melanoma of the Skin AJCC v8|Stage IV Cutaneous (Skin) Melanoma	Stage IV includes: Any T, Any N, M1. M1: Evidence of distant metastasis. (AJCC 8th ed.)	Clinical Stage IV Cutaneous Melanoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C137657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137657>	C137645	Cutaneous Melanoma by AJCC v8 Pathologic Stage|Melanoma of the Skin by AJCC v8 Pathologic Stage|Tumor Stage (Pathological)	A term that refers to the pathologic staging of cutaneous melanoma, following the rules of the TNM AJCC v8 classification system.			Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C137658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137658>	C217122	Follicular Lymphoma International Prognostic Index 2|FLIPI-2	A prognostic index designed to be used for patients with follicular lymphoma to stratify them by risk. The index uses 5 parameters: age (less than 60 years or greater than or equal to 60 years), serum beta 2 microglobulin (normal or elevated), hemoglobin level (less than 12 g/dL or greater than or equal to 12 g/dL), bone marrow involvement (present or absent), longest diameter of largest involved node (less than 6cm or greater than or equal to 6cm) and divides patients into 3 risk groups: low (0 risk factors), intermediate (1-2 risk factors), high (3-5 risk factors).			Intellectual Product	
C137659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137659>	C137658	FLIPI-2 Score 0, Low Risk|FLIPI-2 Score 0|Follicular Lymphoma International Prognostic Index 2 Score 0	A score indicating that a patient has 0 risk factors associated with follicular lymphoma and is considered in the low risk group.			Intellectual Product	
C13765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13765>	C13432	8q11.2	A chromosome band present on 8q			Gene or Genome	
C137660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137660>	C137658	FLIPI-2 Score 1-2, Intermediate Risk|FLIPI-2 Score 1-2|Follicular Lymphoma International Prognostic Index 2 Score 1-2	A score indicating that a patient has 1-2 risk factors associated with follicular lymphoma and is considered in the intermediate risk group.			Intellectual Product	
C137661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137661>	C137658	FLIPI-2 Score 3-5, High Risk|FLIPI-2 Score 3-5|Follicular Lymphoma International Prognostic Index 2 Score 3-5	A score indicating that a patient has 3-5 risk factors associated with follicular lymphoma and is considered in the high risk group.			Intellectual Product	
C137662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137662>	C137657	Pathologic Stage 0 Cutaneous Melanoma AJCC v8|Melanoma in situ, unspecified|Pathologic Stage 0 Melanoma of the Skin AJCC v8|Stage 0|Stage 0 Cutaneous (Skin) Melanoma	Stage 0 includes: Tis, N0, M0. Tis: Melanoma in situ. Thickness: Not applicable. Ulceration status: Not applicable. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)	Pathologic Stage 0 Cutaneous Melanoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology|mCode Cancer Disorder Value Set|mCode Elixhauser Malignant Solid Tumors in Situ Value Set|mCode Melanoma In-Situ Disorder Value Set|mCode Primary Cancer Disorder Value Set|mCode Terminology
C137663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137663>	C137657	Pathologic Stage I Cutaneous Melanoma AJCC v8|Pathologic Stage I Melanoma of the Skin AJCC v8|Stage I Cutaneous (Skin) Melanoma	Stage I includes: IA: (T1a, N0, M0); (T1b, N0, M0); IB: (T2a, N0, M0). T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)	Pathologic Stage I Cutaneous Melanoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C137664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137664>	C137663	Pathologic Stage IA Cutaneous Melanoma AJCC v8|Pathologic Stage IA Melanoma of the Skin AJCC v8|Stage IA|Stage IA Cutaneous (Skin) Melanoma	Stage IA includes: (T1a, N0, M0); (T1b, N0, M0). T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)	Pathologic Stage IA Cutaneous Melanoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C137665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137665>	C137663	Pathologic Stage IB Cutaneous Melanoma AJCC v8|Pathologic Stage IB Melanoma of the Skin AJCC v8|Stage IB|Stage IB Cutaneous (Skin) Melanoma	Stage IB includes: T2a, N0, M0. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)	Pathologic Stage IB Cutaneous Melanoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C137666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137666>	C137657	Pathologic Stage II Cutaneous Melanoma AJCC v8|Pathologic Stage II Melanoma of the Skin AJCC v8|Stage II Cutaneous (Skin) Melanoma	Stage II includes: IIA: (T2b, N0, M0); (T3a, N0, M0); IIB: (T3b, N0, M0); (T4a, N0, M0); IIC: (T4b, N0, M0). T2b: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: With ulceration. T3a: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: Without ulceration. T3b: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: With ulceration. T4a: Tumor measuring more than 4.0 mm in thickness. Ulceration status: Without ulceration. T4b: Tumor measuring more than 4.0 mm in thickness. Ulceration status: With ulceration.  N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)	Pathologic Stage II Cutaneous Melanoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C137667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137667>	C137666	Pathologic Stage IIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIA Melanoma of the Skin AJCC v8|Stage IIA|Stage IIA Cutaneous (Skin) Melanoma	Stage IIA includes: (T2b, N0, M0); (T3a, N0, M0). T2b: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: With ulceration. T3a: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)	Pathologic Stage IIA Cutaneous Melanoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C137668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137668>	C137666	Pathologic Stage IIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIB Melanoma of the Skin AJCC v8|Stage IIB|Stage IIB Cutaneous (Skin) Melanoma	Stage IIB includes: (T3b, N0, M0); (T4a, N0, M0). T3b: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: With ulceration. T4a: Tumor measuring more than 4.0 mm in thickness. Ulceration status: Without ulceration. N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)	Pathologic Stage IIB Cutaneous Melanoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C137669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137669>	C137666	Pathologic Stage IIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIC Melanoma of the Skin AJCC v8|Stage IIC|Stage IIC Cutaneous (Skin) Melanoma	Stage IIC includes: T4b, N0, M0. T4b: Tumor measuring more than 4.0 mm in thickness. Ulceration status: With ulceration.  N0: No regional lymph node metastasis detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)	Pathologic Stage IIC Cutaneous Melanoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C13766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13766>	C13432	22q13.1	A chromosome band present on 22q			Gene or Genome	
C137670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137670>	C137657	Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage III Melanoma of the Skin AJCC v8|Stage III Cutaneous (Skin) Melanoma	Stage III includes: IIIA: (T1a/b-T2a, N1a or N2a, M0); IIIB: (T0, N1b, N1c, M0); (T1a/b-T2a, N1b/c or N2b, M0); (T2b/T3a, N1a-N2b, M0); IIIC: (T0, N2b, N2c, N3b or N3c); (T1a-T3a, N2c or N3a/b/c, M0); (T3b/T4a, Any N greater than or equal to N1, M0); (T4b, N1a-N2c, M0); IIID: (T4b, N3a/b/c, M0). T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. T0: No evidence of primary tumor (e.g., unknown primary or completely regressed melanoma). Thickness: Not applicable. Ulceration status: Not applicable. T2b: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: With ulceration. T3a: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: Without ulceration. T3b: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: With ulceration. T4a: Tumor measuring more than 4.0 mm in thickness. Ulceration status: Without ulceration. T4b: Tumor measuring more than 4.0 mm in thickness. Ulceration status: With ulceration.  N1a: One clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No.  N2a: Two or three clinically occult nodal metastases (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. N1b: One clinically detected nodal metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: No. N1c: No regional lymph node disease. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. N2b: Two or three nodal metastases at least one of which was clinically detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. N2c: One clinically occult nodal metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. N3b: Four or more nodal metastases, at least one of which was clinically detected, or presence of any number of matted nodes. Presence of in-transit, satellite, and/or microsatellite metastases: No. N3c: Two or more clinically occult nodal metastases. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. N3a: Four or more clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)	Pathologic Stage III Cutaneous Melanoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C137671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137671>	C137670	Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIA Melanoma of the Skin AJCC v8|Stage IIIA|Stage IIIA Cutaneous (Skin) Melanoma	Stage IIIA includes: T1a/b-T2a, N1a or N2a, M0. T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. N1a: One clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No.  N2a: Two or three clinically occult nodal metastases (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No.  M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)	Pathologic Stage IIIA Cutaneous Melanoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C137672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137672>	C137670	Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Melanoma of the Skin AJCC v8|Stage IIIB|Stage IIIB Cutaneous (Skin) Melanoma	Stage IIIB includes: (T0, N1b, N1c, M0); (T1a/b-T2a, N1b/c or N2b, M0); (T2b/T3a, N1a-N2b, M0). T0: No evidence of primary tumor (e.g., unknown primary or completely regressed melanoma). Thickness: Not applicable. Ulceration status: Not applicable. T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration.  T2b: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: With ulceration. T3a: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: Without ulceration. N1b: One clinically detected nodal metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: No. N1c: No regional lymph node disease. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. N2b: Two or three nodal metastases at least one of which was clinically detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. N1a: One clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. N2a: Two or three clinically occult nodal metastases (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)	Pathologic Stage IIIB Cutaneous Melanoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C137673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137673>	C137670	Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Melanoma of the Skin AJCC v8|Stage IIIC|Stage IIIC Cutaneous (Skin) Melanoma	Stage IIIC includes: (T0, N2b, N2c, N3b or N3c); (T1a-T3a, N2c or N3a/b/c, M0); (T3b/T4a, Any N greater than or equal to N1, M0); (T4b, N1a-N2c, M0). T0: No evidence of primary tumor (e.g., unknown primary or completely regressed melanoma). Thickness: Not applicable. Ulceration status: Not applicable. T1a: Tumor measuring less than 0.8 mm in thickness. Ulceration status: Without ulceration. T1b: Tumor measuring less than 0.8 mm in thickness with ulceration, or 0.8-1.0 mm with or without ulceration. T2a: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: Without ulceration. T2b: Tumor measuring more than 1.0 and equal to or less than 2.0 mm in thickness. Ulceration status: With ulceration. T3a: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: Without ulceration. T3b: Tumor measuring more than 2.0 and equal to or less than 4.0 mm in thickness. Ulceration status: With ulceration. T4a: Tumor measuring more than 4.0 mm in thickness. Ulceration status: Without ulceration. T4b: Tumor measuring more than 4.0 mm in thickness. Ulceration status: With ulceration.  N2b: Two or three nodal metastases at least one of which was clinically detected. Presence of in-transit, satellite, and/or microsatellite metastases: No. N2c: One clinically occult nodal metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. N3b: Four or more nodal metastases, at least one of which was clinically detected, or presence of any number of matted nodes. Presence of in-transit, satellite, and/or microsatellite metastases: No. N3c: Two or more clinically occult nodal metastases. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. N3a: Four or more clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. N1a: One clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. N1b: One clinically detected nodal metastasis. Presence of in-transit, satellite, and/or microsatellite metastases: No. N1c: No regional lymph node disease. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. N2a: Two or three clinically occult nodal metastases (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)	Pathologic Stage IIIC Cutaneous Melanoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C137674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137674>	C4872	Occult Breast Carcinoma	Breast carcinoma presenting with isolated axillary lymphadenopathy, without clinical or mammographic evidence of breast tumor.			Neoplastic Process	
C137675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137675>	C137670	Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IIID Melanoma of the Skin AJCC v8|Stage IIID Cutaneous (Skin) Melanoma	Stage IIID includes: T4b, N3a/b/c, M0. T4b: Tumor measuring more than 4.0 mm in thickness. Ulceration status: With ulceration.  N3a: Four or more clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. N3b: Four or more nodal metastases, at least one of which was clinically detected, or presence of any number of matted nodes. Presence of in-transit, satellite, and/or microsatellite metastases: No. N3c: Two or more clinically occult nodal metastases. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. M0: No evidence of distant metastasis. LDH level is not applicable. (AJCC 8th ed.)	Pathologic Stage IIID Cutaneous Melanoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C137676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137676>	C27970	Stage IIID	Locally advanced cancer that has spread to nearby organs but not to distant anatomic sites. The definition of stage IIID depends on the particular type of cancer that it refers to; for example, for cutaneous melanoma, stage IIID is defined as follows: T4b, N3a/b/c, M0. T4b: Tumor measuring more than 4.0 mm in thickness. Ulceration status: With ulceration. N3a: Four or more clinically occult nodal metastasis (i.e., detected by sentinel lymph node biopsy). Presence of in-transit, satellite, and/or microsatellite metastases: No. N3b: Four or more nodal metastases, at least one of which was clinically detected, or presence of any number of matted nodes. Presence of in-transit, satellite, and/or microsatellite metastases: No. N3c: Two or more clinically occult nodal metastases. Presence of in-transit, satellite, and/or microsatellite metastases: Yes. M0: No evidence of distant metastasis. LDH level is not applicable. (partially adapted from AJCC 8th ed.)			Clinical Attribute	GDC Terminology|GDC Value Terminology
C137677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137677>	C137657	Pathologic Stage IV Cutaneous Melanoma AJCC v8|Pathologic Stage IV Melanoma of the Skin AJCC v8|Stage IV|Stage IV Cutaneous (Skin) Melanoma	Stage IV includes: Any T, Tis, Any N, M1. Tis: Melanoma in situ. Thickness: Not applicable. Ulceration status: Not applicable. M1: Evidence of distant metastasis. (AJCC 8th ed.)	Pathologic Stage IV Cutaneous Melanoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C137678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137678>	C33027	Intramammary Lymph Node|Intramammary Node|Lymph Node(s) Mammary	Any of the lymph nodes located within the breast parenchyma.			Anatomical Structure	GDC Terminology|GDC Value Terminology
C13767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13767>	C13432	2q21	A chromosome band present on 2q			Gene or Genome	
C137680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137680>	C63496	DPACE Regimen|Cisplatin/Cyclophosphamide/Dexamethasone/Doxorubicin/Etoposide|Cisplatin/Cyclophosphamide/Dexamethasone/Doxorubicin/Etoposide Regimen|D-PACE|D-PACE|DPACE|Decadron/Platinol/Adriamycin/Cytoxan/Etoposide Regimen|Dexamethasone-Cisplatin-Doxorubicin-Cyclophosphamide-Etoposide Regimen|Dexamethasone/Cisplatin/Doxorubicin/Cyclophosphamide/Etoposide|Dexamethasone/Cisplatin/Doxorubicin/Cyclophosphamide/Etoposide Regimen	A regimen consisting of dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide that may be used as a salvage regimen for aggressive and/or refractory plasma cell myeloma.	DPACE Regimen		Therapeutic or Preventive Procedure	CTRP Agent Terminology|CTRP Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C137681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137681>	C63496	DCEP Regimen|DCEP|DCEP|DCEP|Dexamethasone-Cyclophosphamide-Etoposide-Cisplatin|Dexamethasone-Cytoxan-Vepesid-Platinol|Dexamethasone/Cyclophosphamide/Etoposide/Cisplatin|Dexamethasone/Cyclophosphamide/Etoposide/Cisplatin Regimen	A regimen consisting of dexamethasone, cyclophosphamide, etoposide, and cisplatin that may be used as a salvage regimen for relapsed and/or refractory plasma cell myeloma and/or as a mobilization regimen, followed by granulocyte colony-stimulating factor (G-CSF), for peripheral blood stem cell (PBSC) collection in plasma cell myeloma.	DCEP Regimen		Therapeutic or Preventive Procedure	CTRP Agent Terminology|CTRP Terminology|HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|NCI Drug Dictionary Terminology|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C137682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137682>	C129822|C128037	Budigalimab|ABBV 181|ABBV-181|ABBV181|BUDIGALIMAB	A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1; PDCD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody ABBV-181 targets and binds to PD-1, thereby blocking its binding to the PD-1 ligand, programmed cell death-1 ligand 1 (PD-L1), and preventing the activation of PD-1/PD-L1 downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs). PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.	Budigalimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C137683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137683>	C26170	Protease Inhibitor Formulation LB1148|LB-1148|LB1148	A proprietary formulation comprised of the serine protease inhibitor tranexamic acid (TXA), polyethylene glycol (PEG), electrolytes, and sugar, with potential GI protective activity. After reconstitution in water and upon oral or enteral administration before abdominal surgery, TXA in the protease inhibitor formulation LB1148 targets and inhibits several serine proteases in the gastrointestinal (GI) tract, thereby preventing and protecting the intestinal mucosa against degradation, which preserves gastrointestinal (GI) integrity, function and motility. By inhibiting digestive proteases, the intestinal mucosal barrier is preserved during acute physiologic shock, which may prevent multi-organ failure, postoperative ileus and surgical intra-abdominal adhesions. PEG enhances transport of TXA through the GI tract. The other components provide energy and balance dietary electrolytes, thereby promoting healing of the GI barrier.	Protease Inhibitor Formulation LB1148		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C137684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137684>	C25616	Weekend	The time period comprising Saturday and Sunday, and sometimes considered to include Friday night.			Temporal Concept	
C137685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137685>	C137698	Blasts Under 5 Percent of Bone Marrow Nucleated Cells|Blasts Less Than 5 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that less than 5 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts Under 5 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C137686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137686>	C138961	PSA Level Greater than Ten|PSA Level Greater than 10	A blood concentration of prostate specific antigen greater than 10 ng/mL.	PSA Level Greater than Ten		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C137687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137687>	C138961	PSA Level Ten to Twenty|PSA Level 10 to 20|PSA Level Between 10 and 20|PSA Level Between Ten and Twenty|PSA Level Greater than 10 but Less than 20|PSA Level Greater than Ten but Less than Twenty	A blood concentration of prostate specific antigen between 10 and 20 ng/mL.	PSA Level Ten to Twenty		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C137688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137688>	C138961	PSA Level Less than Twenty|PSA Level Less than 20	A blood concentration of prostate specific antigen less than 20 ng/mL.	PSA Level Less than Twenty		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C137689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137689>	C138961	PSA Level Less than Ten|PSA Level Less than 10	A blood concentration of prostate specific antigen less than 10 ng/mL.	PSA Level Less than Ten		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13768>	C13432	6p12	A chromosome band present on 6p			Gene or Genome	
C137690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137690>	C74095|C165233	CD20 Negative|CD20 Antigen Negative|Leu-16 Negative|MS4A1 Negative	An indication that CD20 expression has not been detected in a sample.	CD20 Negative		Laboratory or Test Result	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C137691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137691>	C97927	DICER1 Gene Mutation|DCR-1 Gene Mutation|DCR1 Gene Mutation|DICER Gene Mutation|DICER1 mutation|Dicer 1, Double-Stranded RNA-Specific Endoribonuclease Gene Mutation|Dicer 1, Ribonuclease III Gene Mutation|Dicer 1, Ribonuclease Type III Gene Mutation|HERNA Gene Mutation|MNG1 Gene Mutation|RMSE2 Gene Mutation	A change in the nucleotide sequence of the DICER1 gene.	DICER1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C137692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137692>	C138961	PSA Level Greater than 2.5|PSA Levels Greater than 2.5	A blood concentration of prostate specific antigen greater than 2.5 ng/mL.	PSA Level Greater than 2.5		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C137693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137693>	C35681	Human Immunodeficiency Virus Negative|HIV Negative|Negative	Indicates that human immunodeficiency virus has not been detected in a sample.	Human Immunodeficiency Virus Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C137694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137694>	C146669|C136648	Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells|Myeloblasts Greater than or Equal to 10 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that at least 10 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells of myeloid origin.	Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C137695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137695>	C137701	Blasts 20 Percent or Less of Bone Marrow Nucleated Cells|Blasts Less than or Equal to 20 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that 20 percent or less of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts 20 Percent or Less of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C137696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137696>	C138961	PSA Level Two to Forty|PSA Level 2 to 40	A blood concentration of prostate specific antigen between 2 and 40 ng/mL.	PSA Level Two to Forty		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C137697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137697>	C138961	PSA Level Greater than or Equal to Two|PSA Level 2 or Greater|PSA Level 2.0 or Greater|PSA Level Greater than or Equal to 2|PSA Level Greater than or Equal to 2.0|PSA Level Two or Greater	A blood concentration of prostate specific antigen greater than or equal to 2 ng/mL.	PSA Level Greater than or Equal to Two		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C137698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137698>	C41398	Blasts 5 Percent or Less of Bone Marrow Nucleated Cells|Blasts Less than or Equal to 5 Percent of Bone Marrow Nucleated Cells|M1 (less than 5% blasts)	A semi-quantitative microscopic finding indicating that 5 percent or less of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts 5 Percent or Less of Bone Marrow Nucleated Cells		Laboratory or Test Result	ALL Authorized Value Terminology|ALL Lab Table|CTRP Biomarker Terminology|CTRP Terminology
C137699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137699>	C138961	PSA Level Less than Fifteen|PSA Level Less than 15	A blood concentration of prostate specific antigen less than 15 ng/mL.	PSA Level Less than Fifteen		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13769>	C13432	7q21.3-q22.1	A chromosome band present on 7q			Gene or Genome	
C1376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1376>	C67422	Halichondrin B|HALICHONDRIN B	A complex macrolide polyether from marine sponge genera, such as Halichondria, Axinella, Phakellia, and Lissodendoryx that binds to tubulin, thereby inhibiting mitosis. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology
C137700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137700>	C138961	PSA Level Less than or Equal to Eighty|PSA Level 80 or Less|PSA Level Eighty or Less|PSA Level Less than or Equal to 80	A blood concentration of prostate specific antigen less than or equal to 80 ng/mL.	PSA Level Less than or Equal to Eighty		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C137701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137701>	C156690	Blasts Under 25 Percent of Bone Marrow Nucleated Cells|Blasts Less than 25 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that less than 25 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts Under 25 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C137702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137702>	C138961	PSA Level Greater than or Equal to Twenty|PSA Level 20 or Greater|PSA Level Greater than or Equal to 20|PSA Level Twenty or Greater	A blood concentration of prostate specific antigen greater than or equal to 20 ng/mL.	PSA Level Greater than or Equal to Twenty		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C137703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137703>	C142113	Blasts 5-10 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that between 5 and 10 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts 5-10 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C137704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137704>	C36220	Blasts 10-19 Percent of Peripheral Blood White Cells|Blasts Between 5 and 19 Percent of Peripheral Blood White Cells	A semi-quantitative microscopic finding indicating that between 10 and 19 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.	Blasts 10-19 Percent of Peripheral Blood White Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C137705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137705>	C138961	PSA Level Greater than or Equal to Four|PSA Level 4 or Greater|PSA Level Four or Greater|PSA Level Greater than or Equal to 4	A blood concentration of prostate specific antigen greater than or equal to 4 ng/mL.	PSA Level Greater than or Equal to Four		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C137706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137706>	C137695	Blasts 11-20 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that between 11 and 20 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts 11-20 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C137707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137707>	C138961	PSA Level 0.5 to Fifty|PSA Greater than 0.5 but less than 50|PSA Level 0.5 to 50|PSA Level 0.5 to 50|PSA Level Between 0.5 and 50|PSA Level Between 0.5 and Fifty|PSA Level Greater than 0.5 but less than 50	A blood concentration of prostate specific antigen between 0.5 and 50 ng/mL.	PSA Level 0.5 to 50		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C137708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137708>	C138961	PSA Level Greater than or Equal to Twenty-Five|PSA Level 25 or Greater|PSA Level Greater than or Equal to 25|PSA Level Greater than or Equal to Twenty Five|PSA Level Twenty Five or Greater|PSA Level Twenty-Five or Greater	A blood concentration of prostate specific antigen greater than or equal to 25 ng/mL.	PSA Level Greater than or Equal to Twenty-Five		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C137709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137709>	C35867	Tumor Margin Configuration|Margin|Tumor Border Configuration	Describes the morphologic appearance where a tumor meets the adjacent tissue.			Finding	CRF6 DIPG Imaging Assessment Morphology Table|CRF6 DMG Imaging Assessment Morphology Table
C13770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13770>	C13432	2q33	A chromosome band present on 2q			Gene or Genome	
C137710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137710>	C137709	Infiltrative Tumor Margin|Infiltrative|Infiltrative|Infiltrative Tumor Border|Infiltrative Tumor Border Configuration|Infiltrative Tumor Margin Present	Describes a tumor border that is invading the adjacent tissue.			Finding	CRF6 DIPG Imaging Assessment Morphology Table|CRF6 DMG Imaging Assessment Morphology Table
C13771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13771>	C13432	7q21.3	A chromosome band present on 7q			Gene or Genome	
C13772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13772>	C13432	2q22-q23	A chromosome band present on 2q			Gene or Genome	
C13773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13773>	C13432	7q22.1	A chromosome band present on 7q			Gene or Genome	
C13774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13774>	C13432	8p12-p11.2	A chromosome band present on 8p			Gene or Genome	
C13775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13775>	C13432	5q23-q31	A chromosome band present on 5q			Gene or Genome	
C13776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13776>	C13432	1q41	A chromosome band present on 1q			Gene or Genome	
C13777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13777>	C13432	6p21.1	A chromosome band present on 6p			Gene or Genome	
C13778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13778>	C13432	7p12-p11.2	A chromosome band present on 7p			Gene or Genome	
C137799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137799>	C19690	Generalized Competing Event Model for Cancer Risk|GCE|Generalized Competing Event Model	A stratification method that can be used to identify groups of patients at highest risk for a poor outcome and therefore most likely to benefit from treatment intensification.			Research Activity	
C13779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13779>	C13432	Xq13.1	A chromosome band present on Xq			Gene or Genome	
C137800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137800>	C62554	Rucaparib|6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-|8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one|AG 14447|AG-14447|AG14447|RUCAPARIB	An orally bioavailable tricyclic indole and inhibitor of poly(ADP-ribose) polymerases (PARPs) 1 (PARP1), 2 (PARP2) and 3 (PARP3), with potential chemo/radiosensitizing and antineoplastic activities. Upon administration, rucaparib selectively binds to PARP1, 2 and 3 and inhibits PARP-mediated DNA repair. This enhances the accumulation of DNA strand breaks, promotes genomic instability and induces cell cycle arrest and apoptosis. This may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy. PARPs are enzymes activated by single-strand DNA breaks that catalyze the post-translational ADP-ribosylation of nuclear proteins, which induces signaling and the recruitment of other proteins to repair damaged DNA. The PARP-mediated repair pathway plays a key role in DNA repair and is dysregulated in a variety of cancer cell types.	Rucaparib		Pharmacologic Substance	CTRP Intervention Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCIt Antineoplastic Agent Terminology
C137801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137801>	C22187	Non-Human or Experimental Organism Finding|Experimental Organism Finding	An observation based on clinical, laboratory or molecular evidence, as it relates to conditions occurring in a non-human organism; this includes observations of evidence for organisms used in research settings.			Finding	
C137802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137802>	C22187	Non-Human or Experimental Organism Non-Neoplastic Disorder|Experimental Organism Non-Neoplastic Disorder	A non-neoplastic disorder affecting a non-human organism; this includes disorders occurring in organisms used in research settings.			Disease or Syndrome	
C137805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137805>	C17204	Computed Tomography with Contrast|CONTRAST ENHANCED CT SCAN|CT Scan With Contrast|CT Scan with Contrast|CT with Contrast|Contrast Enhanced Computed Tomography|Contrast-enhanced Computed Tomography	Computed tomography that uses a contrast agent to visualize anatomic structures.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C137806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137806>	C17204	Computed Tomography without Contrast|CT SCAN WITHOUT CONTRAST|CT Scan without Contrast|CT without Contrast	Computed tomography that does not use a contrast agent to visualize anatomic structures.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C137807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137807>	C134315	Low Risk Mantle Cell Lymphoma International Prognostic Index Combined Biologic Index	Low risk MIPI score (0-3) and Ki-67 less than 30%. Low risk MIPI-c equals a MIPI-c score of 0.			Intellectual Product	
C137808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137808>	C134315	Low-Intermediate Risk Mantle Cell Lymphoma International Prognostic Index Combined Biologic Index	Low risk MIPI score (0-3) and Ki-67 greater than or equal to 30% or Intermediate risk MIPI score (4-5) and Ki-67 less than 30%. MIPI-c low-intermediate risk equals a MIPI-c score of 1.			Intellectual Product	
C137809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137809>	C134315	High-Intermediate Risk Mantle Cell Lymphoma International Prognostic Index Combined Biologic Index	Intermediate risk MIPI score (4-5) and Ki-67 greater than or equal to 30% or High risk MIPI score (6-11) and Ki-67 less than 30%. A MIPI-c high-intermediate risk equals a MIPI-c score of 2.			Intellectual Product	
C13780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13780>	C13432	6q27	A chromosome band present on 6q			Gene or Genome	
C137810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137810>	C134315	High Risk Mantle Cell Lymphoma International Prognostic Index Combined Biologic Index	High risk MIPI score (6-11) and Ki-67 greater than or equal to 30%. A MIPI-c high risk equals a MIPI-c score of 3.			Intellectual Product	
C137811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137811>	C17146	Electronic Patient-reported Outcome System|Electronic Patient-reported Outcome|ePRO|ePRO|ePro	Any of various systems designed to collect treatment outcome data directly from patients by electronic means.	Electronic Patient-reported Outcome System		Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C137812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137812>	C15313	Radiation Boost|BOOST|Boost Radiation|Boost Radiation Therapy|Boost Radiotherapy|Radiation Therapy Boost|Radiotherapy Boost	One or more extra radiation treatments targeted at the tumor bed, given after the regular sessions of radiation are complete.	Radiation Boost		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|GCT Radiation Therapy Table|GCT Variable Terminology|GDC Terminology|GDC Value Terminology
C137813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137813>	C128940	Biopsy Specimen Radiography|Biospecimen Radiography|Specimen Radiography	Radiographic examination of a specimen obtained by biopsy or surgical procedure.	Biopsy Specimen Radiography		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C137814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137814>	C15680	Core Biopsy with Placement of Image-Detectable Marker|Marker Biopsy	A core biopsy and simultaneous implantation of an image-detectable marker for the purpose of future localization of the biopsy site.	Core Biopsy with Placement of Image-Detectable Marker		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C137815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137815>	C25167	Distance of Closest Surgical Margin|Closest Distance Between Tumor and Resection Margin|Distance of Tumor from Closest Margin|Distance of Tumor from Closest Surgical Margin|Least Distance to Closest Margin|TUMOR_FROM_MARGIN|TUMOR_FROM_MARGIN|margin distance|margin_distance	The distance of the closest surgical margin from tumor after surgical resection of the tumor. The closest distance between a tumor and its resection margin has prognostic significance.			Finding	EWS Biopsy/Surgical Procedures Table|EWS Variable Terminology|GDC Property Terminology|GDC Terminology|OS Biopsy/Surgical Procedures Table|OS Variable Terminology
C137816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137816>	C93202	F-18 Sodium Fluoride Positron Emission Tomography and Computed Tomography Scan|F-18 Sodium Fluoride PET/CT	An imaging procedure that combines F-18 sodium fluoride PET with a CT scan to overlay activity data onto detailed anatomic images.			Diagnostic Procedure	
C137817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137817>	C103400	FDG-Positron Emission Tomography and Computed Tomography Scan|FDG PET/CT	An imaging procedure that combines FDG PET with a CT scan to overlay activity data onto detailed anatomic images.			Diagnostic Procedure	
C137818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137818>	C146993	Androgen Receptor Antagonist TAS3681|AR Antagonist TAS3681|Androgen Receptor Inhibitor TAS3681|TAS 3681|TAS3681	An orally bioavailable inhibitor of the androgen receptor (AR), with potential antineoplastic activity. Upon oral administration, AR inhibitor TAS3681 specifically binds to AR. This prevents AR activation, downregulates AR and prevents AR-mediated signaling. This inhibits cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in proliferation, survival and chemoresistance of tumor cells.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C137819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137819>	C200765|C176018	Allogeneic CD19-specific Universal CAR19-expressing T-lymphocytes|ALLO-501|S68587|TCR/CD52-deficient RQR8+ CD19-CAR+ T-cells|UCART 19|UCART19 Cells|Universal Chimeric Antigen Receptor T-cell 19|Universal TALEN Gene-edited CART19 Cells	A preparation of allogeneic, frozen, 'off-the-shelf', universal transcription activator-like effector nuclease (TALEN)-engineered, gene-edited T-lymphocytes expressing a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19, and containing a RQR8 transgene, with potential immunostimulating and antineoplastic activities. Using TALEN technology, the T-cell receptor (TCR) alpha chain and CD52 genes are deleted from the CAR19 T-cells. Upon infusion, allogeneic universal CD19-specific CAR-modified T cells (UCART19) specifically target and bind to CD19-expressing tumor cells, thereby selectively lysing CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Deletion of the CD52 gene makes the modified donor T-cells resistant to the anti-CD52 monoclonal antibody alemtuzumab, which is used during lymphodepletion. The knockout of the TCR alpha gene eliminates TCR expression and is intended to abrogate the potential induction of graft-versus-host disease (GvHD) by the donor T-cells. The gene-edited allogeneic, frozen UCART19 have reduced production times and provide off-the-shelf CAR-T cells when compared to autologous CAR-T cells, which use the patient's own cells and are produced on an individual basis. The protein expressed by the RQR8 transgene contains epitopes from CD34 and CD20, which allows tracking of the UCART19 cells with a clinically-approved anti-CD34 antibody. Additionally if the UCART19 cells cause unacceptable side effects, the CD20 portion of the protein permits selective depletion of the UCART19 cells when the anti-CD20 monoclonal antibody rituximab is administered.	Allogeneic CD19-specific Universal CAR19-expressing T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C13781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13781>	C13432	3q21-q28	A chromosome band present on 3q			Gene or Genome	
C137820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137820>	C141146	Anti-TIM3 Monoclonal Antibody LY3321367|LY 3321367|LY-3321367|LY3321367	A monoclonal antibody against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, the anti-TIM-3 monoclonal antibody LY3321367 binds to TIM-3 expressed on certain T-cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.	Anti-TIM3 Monoclonal Antibody LY3321367		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C137821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137821>	C129823	Anti-ASCT2 Antibody-drug Conjugate MEDI7247|Anti-ASCT2 ADC MEDI7247|Anti-ASCT2/PBD ADC MEDI7247|MEDI 7247|MEDI-7247|MEDI7247	An antibody-drug conjugate (ADC) consisting of a human monoclonal antibody against neutral amino acid transporter B(0) (ASCT2; SLC1A5) that is site-specifically conjugated, via a protease-cleavable linker, to the cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of anti-ASCT2 ADC MEDI7247, the antibody moiety targets and binds to ASCT2 expressed on cancer cells. Upon antibody/antigen binding, internalization and linker cleavage, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of ASCT2-overexpressing tumor cells. ASCT2, a neutral amino acid transporter that mediates the uptake of glutamine, is overexpressed in a variety of cancer cell types.	Anti-ASCT2 Antibody-drug Conjugate MEDI7247		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C137822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137822>	C1511	Zirconium Zr 89 Crefmirlimab Berdoxam|89Zr-Crefmirlimab Berdoxam|89Zr-Desferrioxamine-IAB22M2C|89Zr-Df-Crefmirlimab|89Zr-Df-IAB22M2C|ZIRCONIUM ZR-89 CREFMIRLIMAB BERDOXAM|Zirconium Zr 89-Df-Crefmirlimab|Zirconium Zr 89-Df-IAB22M2C|Zirconium Zr-89 Crefmirlimab Berdoxam	A radioimmunoconjugate comprised of a minibody (Mb), an inert antibody fragment against the human CD8-antigen on CD8-positive T-cells, conjugated to the chelator desferrioxamine (Df) and labeled with the radioisotope zirconium Zr 89, with potential positron emission tomography (PET) imaging activity. Upon administration, zirconium Zr 89 crefmirlimab berdoxam  specifically targets and binds to the CD8 antigen expressed on T-cells. This enables PET detection of the radioisotope moiety, and may allow the imaging, tracking and quantification of CD8-expressing T-cells. This may detect CD8-positive T-cell distribution and activity, and may help determine the patient's response to cancer immunotherapeutic agents. CD8-positive T-cells play a key role in the eradication of cancer cells. Although the Mb has the same antigen specificity and binding affinity as the full-length antibody, the Mb does not activate or induce the proliferation of CD8-positive T-cells.	Zirconium Zr 89 Crefmirlimab Berdoxam		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C137823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137823>	C62761	Personalized Live-attenuated Double-deleted Listeria monocytogenes|Patient-specific LADD|Personalized LADD|pLADD	A proprietary, personalized live, attenuated, double-deleted (pLADD) strain of the Gram-positive bacterium Listeria monocytogenes encoding multiple, patient-specific neoantigens, with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, the tumor-associated antigens (TAAs) expressed in pLADD are taken up by antigen-presenting cells (APCs), including dendritic cells (DCs), and are processed and presented to the immune system by both major histocompatibility complex (MHC) class I and II molecules. This activates the immune system and leads to both an innate immune response and the recruitment and activation of tumor-specific cytotoxic T-lymphocytes (CTLs) against the TAAs specifically expressed by the patient's tumor cells, which eventually results in tumor cell lysis.			Bacterium|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C137824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137824>	C20401|C157400	Leronlimab|LERONLIMAB|PA14|PRO 140|PRO-140|PRO140|WHO 10751	A humanized immunoglobulin (Ig) G4 monoclonal antibody against CC chemokine receptor 5 (CCR5; CD195), with potential activity as a human immunodeficiency virus (HIV) entry blocker and potential protective activity against graft-versus-host disease (GvHD). Upon administration, leronlimab targets and binds to CCR5 expressed on T-cells. This blocks HIV cell entry, which prevents HIV infection and/or reduces HIV viral load. In addition, blocking CCR5 by PRO 140 decreases CCR5-mediated signaling and the CCR5-induced migration of donor cells into tissues after an allogeneic hematopoietic cell transplantation (HCT). Blocking CCR5 may therefore prevent or reduce GvHD. CCR5, a co-receptor needed for HIV cell entry, plays a key role in immunomodulation. Expressed on monocytes, activated T-cells and dendritic cells (DCs), CCR5 can regulate chemotaxis. Lymphocyte trafficking via chemokine receptors, such as CCR5, and recruitment to target organs, plays a critical role in alloreactive responses.	Leronlimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C137825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137825>	C168619	Enasidenib Mesylate|2-Methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol Methanesulfonate|2-Propanol, 2-Methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-, Methanesulfonate (1:1)|AG-221 Mesylate|CC 90007|CC-90007|CC90007|ENASIDENIB MESYLATE|Enasidenib Methanesulfonate|Idhifa	The mesylate salt form of enasidenib, an orally available inhibitor of specific mutant forms of the mitochondrial enzyme isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits various mutant forms of IDH2, including the IDH2 variants R140Q, R172S, and R172K, which inhibits the formation of 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH2-expressing tumor cells. IDH2, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by blocking differentiation and the production of the oncometabolite 2HG.	Enasidenib Mesylate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology
C137826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137826>	C471	Isocitrate Dehydrogenase Inhibitor|IDH Inhibitor	Any agent that inhibits isocitrate dehydrogenase (IDH).			Chemical Viewed Functionally	
C137827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137827>	C136712	Mismatch Repair Protein Deficiency|MMR Protein Deficiency|MMR Protein Deficient|Mismatch Repair Protein Deficient|Non-Proficient Mismatch Repair|Non-pMMR|dMMR	A finding indicating that a cellular sample has a functional loss of a protein involved in the DNA mismatch repair process.	Mismatch Repair Protein Deficiency		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C137828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137828>	C49237	Comprehensive Metabolic Panel|CMP|Chem 12|Chemistry Panel|Chemistry Screen|SMA 12	A broad screening tool that measures glucose, electrolytes and metabolites in blood serum to evaluate organ function and check for conditions such as diabetes, liver disease, and kidney disease.			Laboratory Procedure	
C137829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137829>	C61547	Fertility Preservation Counseling|Counseling for Fertility Preservation	Professional guidance designed to provide information and address the emotional issues which arise in fertility preservation patients.			Health Care Activity	
C13782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13782>	C13432	14q11.2	A chromosome band present on 14q			Gene or Genome	
C137830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137830>	C61547	Breast Cancer Risk Reduction Counseling|Breast Cancer Risk Reduction and Counseling|Counseling Regarding Breast Cancer Risk Reduction	Professional guidance designed to present the risks and benefits of various prevention strategies for reducing breast cancer risk, include lifestyle modifications, chemoprevention, surgical approaches, and pharmacotherapy.	Breast Cancer Risk Reduction Counseling		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C137831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137831>	C71323	Discussion Regarding the Termination of Pregnancy Due to Cancer Diagnosis	Discussions between a physician and a pregnant cancer patient regarding the effects of anticancer drugs on the developing fetus or the possibility of long-term complications after the exposure to drugs and radiation, as well as complications to treatment, with the goal toward deciding if the pregnany should be terminated.			Organism Function	
C137832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137832>	C35869	Sentinel Lymph Node Not Identified|Unidentified Sentinel Lymph Node	An indication that sentinel lymph node mapping was attempted but that it did not identify a sentinel lymph node.			Finding	
C137833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137833>	C217443|C15361	Ultrasound-Guided Fine-Needle Aspiration|Ultrasound-Guided Fine Needle Aspiration	The use of ultrasound imaging to guide needle aspiration.	Ultrasound-Guided Fine-Needle Aspiration		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C137834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137834>	C93022|C15680	Ultrasound-Guided Core Biopsy	The use of ultrasound imaging to guide core biopsy.			Diagnostic Procedure	
C137835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137835>	C181716|C124480	Specimen Blood Volume|Blood Volume	The liquid volume of blood in a container or specimen.			Quantitative Concept	
C137837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137837>	C124480	Blood Volume|Body Blood Volume|Circulating Blood Volume	The total volume of blood in the circulatory system of an individual.			Quantitative Concept	
C137838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137838>	C222542	PX-478 Free Base|PX-478 FREE BASE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C137839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137839>	C4018	Breast Pleomorphic Lobular Carcinoma In Situ|Non-Invasive Pleomorphic Lobular Carcinoma of the Breast|PLCIS|Pleomorphic Lobular Breast Carcinoma In Situ|Pleomorphic Lobular Carcinoma in Situ of the Breast|pLCIS	Breast lobular carcinoma in situ characterized by the presence of neoplastic large cells with marked nuclear pleomorphism.			Neoplastic Process	GDC Terminology|GDC Value Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C13783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13783>	C13432	3q13.31	A chromosome band present on 3q			Gene or Genome	
C137840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137840>	C20993	Quality of Life in Neurological Disorders|Neuro-QoL	A set of self-reported and proxy-reported measures of physical, mental, and social health for adults and children living with a neurological condition.			Intellectual Product	
C137841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137841>	C62289	Neuro-QoL Adult Self-Reported Mental Health Domain	A domain of the Quality of Life in Neurological Disorders that assesses the status of an adult individual's mental health.			Functional Concept	Quality of Life in Neurological Disorders
C137842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137842>	C62289	Neuro QoL Cognitive Function Subdomain|Cognitive Function Subdomain	The collection of Neuro-QoL item scales that assess perceived difficulties in cognitive abilities related to both executive function and general concerns.			Functional Concept	Quality of Life in Neurological Disorders
C137843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137843>	C176426	Have to Read Something Several Times to Understand Question|Have to Read Something Several Times to Understand|Have to Read Things Several Times to Understand Them|I had to read something several times to understand it|I have to read things several times to understand them	A question about whether an individual has or had to read something several times to understand it.			Intellectual Product	Quality of Life in Neurological Disorders
C137844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137844>	C176426|C173509|C173398	Current Difficulty Reading and Following Complex Instructions Question|Current Difficulty Reading and Following Complex Instructions|How much DIFFICULTY do you currently have reading and following complex instructions (e.g., directions for a new medication)	A question about how much difficulty an individual currently has reading and following complex instructions.			Intellectual Product	Quality of Life in Neurological Disorders
C137845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137845>	C173509|C173398	Current Difficulty Planning and Keeping Appointments Not Part of Weekly Routine Question|Current Difficulty Planning and Keeping Appointments Not Part of Weekly Routine|How much DIFFICULTY do you currently have planning for and keeping appointments that are not part of your weekly routine, (e.g., a therapy or doctor appointment, or a social gathering with friends and family)	A question about how much difficulty an individual currently has planning for and keeping appointments that are not part of their weekly routine.			Intellectual Product	Quality of Life in Neurological Disorders
C137846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137846>	C173787|C173509|C173398	Current Difficulty Managing Time to do Most Daily Activities Question|Current Difficulty Managing Time to do Most Daily Activities|How much DIFFICULTY do you currently have managing your time to do most of your daily activities	A question about how much difficulty an individual currently has managing their time to do most of their daily activities.			Intellectual Product	Quality of Life in Neurological Disorders
C137847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137847>	C173509|C173398	Current Difficulty Learning New Tasks or Instructions Question|Current Difficulty Learning New Tasks or Instructions|How much DIFFICULTY do you currently have learning new tasks or instructions	A question about how much difficulty an individual currently has learning new tasks or instructions.			Intellectual Product	Quality of Life in Neurological Disorders
C137848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137848>	C15755	Central Lumpectomy with Resection of the Nipple-Areolar Complex|Central Lumpectomy Including Excision of the Nipple-Areolar Complex|Central Lumpectomy Including NAC	Breast-sparing surgery that removes diseased tissue from the central part of the breast, including the nipple and areola.			Therapeutic or Preventive Procedure	
C137849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137849>	C51698	Biopsy of Nipple and Areola|Biopsy of NAC|Biopsy of the Nipple-Areolar Complex	Removal of tissue from the nipple and areola for microscopic examination.			Diagnostic Procedure	
C13784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13784>	C13432	8q24.12	A chromosome band present on 8q			Gene or Genome	
C137850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137850>	C137849	Full-Thickness Skin Biopsy of Nipple and Areola|Full-Thickness Skin Biopsy of NAC|Full-Thickness Skin Biopsy of Nipple-Areolar Complex	Removal of full-thickness skin tissue from the nipple and areola for microscopic examination.			Diagnostic Procedure	
C137851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137851>	C51698|C15680	Core Biopsy of Breast|Breast Core Biopsy	The removal of breast tissue using a needle with a relatively large diameter, for microscopic examination.			Diagnostic Procedure	
C137852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137852>	C83119	Palpation Finding|Finding by Palpation	The results of a palpation examination.			Finding	
C137853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137853>	C35867	Largest Dimension of Residual Neoplasm|Greasest Size of Residual Neoplasm|Greatest Dimension of Residual Neoplasm	The largest single dimension of the residual tumor after surgical resection.			Finding	
C137854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137854>	C198359	Gynecological Examination|Gynecological Exam	Physical examination pertaining to the female reproductive system.			Diagnostic Procedure	
C137855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137855>	C25305	Psychological Assessment|Assessment of Psychological Status|Evaluation of Patient's Psychological Status|Mental Health Assessment	The act of determining, usually through interviews and observation, the status of an individual's psychological well being.	Psychological Assessment		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C137856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137856>	C137855	Assessment of Distress|Assessment of Psychological Distress|Evaluation of Patient's Distress	The act of determining, usually through interviews and observation, the status of an individual's distress.			Diagnostic Procedure	
C137857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137857>	C9291|C151906	Refractory Anal Carcinoma|Refractory Anal Cancer	Anal carcinoma that does not respond to treatment.	Refractory Anal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C137858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137858>	C91102	Eligibility for a Procedure Question|Eligibility for a Procedure|Patient Eligibility for a Procedure	A question pertaining to patient's eligibility to undergo a certain procedure.			Intellectual Product	
C137859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137859>	C168732	Eligibility for Breast-Conserving Surgery Question|Eligibility for Breast-Conserving Surgery|Patient Eligibility for Breast-Conserving Surgery	A question pertaining to patient's eligibility to undergo a breast conserving surgery.			Intellectual Product	
C13785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13785>	C13432	1p22	A chromosome band present on 1p			Gene or Genome	
C137860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137860>	C133748	Eligibility for Pre-operative Systemic Therapy Question|Eligibility for Pre-operative Systemic Therapy|Patient's Eligibility for Pre-operative Systemic Therapy	A question pertaining to patient's eligibility to undergo a pre-operative systemic therapy.			Intellectual Product	
C137861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137861>	C137859	Eligibility Criteria for Breast Conserving Surgery Except for Tumor Size Question|Eligibility Criteria for Breast Conserving Surgery Except for Tumor Size|Fulfills Eligibility Criteria for Breast Conserving Surgery Except for Tumor Size|Patient Fulfills Eligibility Criteria for Breast Conserving Surgery Except for Tumor Size|Patient Meets Eligibility Criteria for Breast Conserving Surgery Except for Tumor Size	An assessment of patient's eligibility for breast conserving surgery showing that all criteria for a breast-conserving surgery are met, except tumor size.			Intellectual Product	
C137862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137862>	C3770|C155937|C142808|C138184	Refractory Pancreatic Neuroendocrine Carcinoma|Refractory Pancreatic Neuroendocrine Cancer	Pancreatic neuroendocrine carcinoma that does not respond to treatment.	Refractory Pancreatic Neuroendocrine Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C137863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137863>	C28676|C201545	Allogeneic CD3- CD19- CD57+ NKG2C+ NK Cells FATE-NK100|Adaptive Memory NKs Cells FATE-NK100|Adaptive Memory Natural Killer Cells FATE-NK100|Adaptive NKs Cells FATE-NK100|FATE NK100|FATE-NK100	A preparation of pharmacologically-enriched, allogeneic natural killer (NK) cells derived from a related but not completely matched human leukocyte antigen (HLA)-haploidentical donor that is seropositive for cytomegalovirus (CMV+), with potential cytolytic and antineoplastic activities. Upon leukapheresis, the donor peripheral blood mononuclear cells (PBMCs) are treated to remove T-lymphocytes (CD3+) and B-lymphocytes (CD19+). The remaining leukocytes are cultured for 7 days with the cytokine interleukin-15 (IL-15) and a small molecule inhibitor of glycogen synthase kinase 3-beta (GSK3beta) to generate the adaptive, CD3- CD19- CD57+ NKG2C+ NK cells FATE-NK100 ex vivo. Upon infusion of the allogeneic CD3- CD19- CD57+ NKG2C+ NK cells FATE-NK100, these cells selectively recognize and bind to tumor cells, and secrete perforins, granzymes, and cytokines, which results in cancer cell lysis. Exposure to CMV induces the expression of the memory-like activating receptor NKG2C and the maturation marker CD57 in the isolated NK cells, making them more potent than those not pre-exposed to CMV. CD57 both enhances the effector function of NK cells and stimulates CD16-dependent signaling. Treatment with IL-15 enhances NK cell proliferation and survival. The GSK3beta inhibitor induces preferential expansion of CD57+ NK cells that exhibit enhanced interferon (IFN)-gamma production.	Allogeneic CD3- CD19- CD57+ NKG2C+ NK Cells FATE-NK100		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C137864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137864>	C1505	Calcium Supplement|Dietary Calcium Supplement	A dietary supplement containing the mineral calcium.			Pharmacologic Substance	
C137866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137866>	C200766|C176018	Autologous CD19 CAR+ EGFRt + CD4+ and CD8+ T Cells|Autologous Anti-CD19CAR-CD28-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes	A preparation of a defined ratio of CD4+ and CD8+ autologous T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-CD19 single chain variable fragment (scFv), derived from the CD19-specific murine immunoglobulin (Ig) G1 monoclonal antibody FMC63, fused to the signaling domain of CD28, the zeta chain of the TCR/CD3 complex (CD3-zeta), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, the autologous CD19 CAR+ EGFRt + CD4+ and CD8+ T-cells are directed to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a cetuximab-induced antibody dependent cellular cytotoxicity (ADCC) response.	Autologous CD19 CAR+ EGFRt + CD4+ and CD8+ T Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C137867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137867>	C49236	Repeat Previous Treatment	Following primary therapy, administration of a second course of therapy.			Therapeutic or Preventive Procedure	
C137868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137868>	C137817	FDG-Positron Emission Tomography/Computed Tomography of an Area of Interest|Area of Interest 18F FDG PET/CT|Area of Interest FDG-PET/CT|Area of Interest FDG-Positron Emission Tomography/Computed Tomography|FDG PET/CT Area of Interest|PET/CT, Area of Interest, FDG|Positron Emission Tomography/Computed Tomography, Area of Interest, FDG	Positron emission tomography combined with computed tomography of an anatomical area of interest with the use of the contrast agent fludeoxyglucose F 18 (18F-FDG) to enhance the image.			Diagnostic Procedure	
C137869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137869>	C137817	FDG-Positron Emission Tomography/Computed Tomography from the Skull Base to Mid-thigh|FDG PET/CT Skull Base to Mid-thigh|PET/CT, Skull Base to Mid-thigh, FDG|Positron Emission Tomography/Computed Tomography, Skull Base to Mid-thigh, FDG|Skull Base to Mid-thigh 18F FDG PET/CT|Skull Base to Mid-thigh FDG-PET/CT|Skull Base to Mid-thigh FDG-Positron Emission Tomography/Computed Tomography|Skull Base to Mid-thigh PET/CT Scan with FDG	Positron emission tomography combined with computed tomography of the region encompassing the skull base to the mid-thigh with the use of the contrast agent fludeoxyglucose F 18 (18F-FDG) to enhance the image.			Diagnostic Procedure	
C13786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13786>	C13432	16q24.3	A chromosome band present on 16q			Gene or Genome	
C137870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137870>	C114184	Magnetic Resonance Imaging of the Pelvis without Contrast|MRI of the Pelvis without Contrast|Pelvic MRI without Contrast|Pelvic Magnetic Resonance Imaging without Contrast	Magnetic resonance imaging of the pelvis without the use of a contrast agent.	Magnetic Resonance Imaging of the Pelvis without Contrast		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C137871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137871>	C178628|C114184	Magnetic Resonance Imaging of the Whole Body without Contrast|WB-MRI without Contrast|Whole Body MRI without Contrast|Whole Body Magnetic Resonance Imaging without Contrast|Whole-body MRI without Contrast	Magnetic resonance imaging of the entire body of a patient without the use of a contrast agent.			Diagnostic Procedure	
C137872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137872>	C114184	Magnetic Resonance Imaging of the Abdomen without Contrast|Abdominal MRI without Contrast|MRI of the Abdomen without Contrast	Magnetic resonance imaging of the abdomen without the use of a contrast agent.	Magnetic Resonance Imaging of the Abdomen without Contrast		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C137873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137873>	C114184	Magnetic Resonance Imaging of the Abdomen and Pelvis without Contrast|Abdominal/Pelvic MRI without Contrast|MRI of the Abdomen and Pelvis without Contrast	Magnetic resonance imaging of the abdomen and pelvis, without the use of a contrast agent.			Diagnostic Procedure	
C137874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137874>	C114184	Magnetic Resonance Imaging of the Brain without Contrast|Brain MRI without Contrast|Brain Magnetic Resonance Imaging without Contrast|Head MRI without Contrast	Magnetic resonance imaging of the brain without the use of a contrast agent.			Diagnostic Procedure	
C137875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137875>	C114184	Magnetic Resonance Imaging of the Breast without Contrast|Breast MRI without Contrast|Breast Magnetic Resonance Imaging without Contrast	Magnetic resonance imaging of the breast without the use of a contrast agent.	Magnetic Resonance Imaging of the Breast without Contrast		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C137876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137876>	C128940	Bone Radiography|Bone Radiograph	Radiographic imaging of bone.			Diagnostic Procedure	
C137877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137877>	C132008	Staging of Lung Cancer to Rule Out Progression|Lung Staging to Rule Out Progression	Staging of lung cancer using invasive and/or imaging modalities to assess progression of disease.			Diagnostic Procedure	
C137878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137878>	C137805	Computed Tomography of the Abdomen with Contrast|Abdominal CT with Contrast|CT of the Abdomen with Contrast	Computed tomography of the abdomen with the use of a contrast agent to enhance the image.			Diagnostic Procedure	
C137879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137879>	C137805	Multiphasic Computed Tomography of the Abdomen|Abdominal CT, Multiphasic|Multiphasic CT of the Abdomen	Multiphasic computed tomography of the abdomen.			Diagnostic Procedure	
C13787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13787>	C13432	8q12-q13	A chromosome band present on 8q			Gene or Genome	
C137880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137880>	C137805	Computed Tomography of the Abdomen and Pelvis with Contrast|Abdominal/Pelvic CT with Contrast|CT of the Abdomen and Pelvis with Contrast	Computed tomography of the abdomen and pelvis with the use of a contrast agent to enhance the image.			Diagnostic Procedure	
C137881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137881>	C137805	Multiphasic Computed Tomography of the Abdomen and Pelvis|Abdominal/pelvic CT, Multiphasic|Multiphasic CT of the Abdomen and Pelvis	Multiphasic computed tomography of the abdomen and pelvis.			Diagnostic Procedure	
C137882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137882>	C137805	Computed Tomography of the Brain with Contrast|Brain CT with Contrast|Head CT with Contrast	Computed tomography of the brain with the use of a contrast agent to enhance the image.	Computed Tomography of the Brain with Contrast		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C137883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137883>	C191501|C137805	Computed Tomography of the Chest with Contrast|Chest CT with Contrast	Computed tomography of the chest with the use of a contrast agent to enhance the image.			Diagnostic Procedure	
C137884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137884>	C137805	Computed Tomography of the Chest and Abdomen with Contrast|Chest/Abdominal CT with Contrast	Computed tomography of the chest and abdomen with the use of a contrast agent to enhance the image.			Diagnostic Procedure	
C137885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137885>	C137805	Computed Tomography of the Chest, Abdomen and Pelvis with Contrast|Chest/Abdominal/Pelvic CT with Contrast	Computed tomography of the chest, abdomen and pelvis with the use of a contrast agent to enhance the image.			Diagnostic Procedure	
C137886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137886>	C137805	Computed Tomography of Skeletal Metastases with Contrast|CT of Skeletal Metastatic Sites with Contrast	Computed tomography of sites with skeletal metastases with the use of a contrast agent to enhance the image.			Diagnostic Procedure	
C137887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137887>	C137805	Computed Tomography of a Primary Disease Site with Contrast|CT with Contrast of Primary Site|Computed Tomography of Primary Site with Contrast	Computed tomography of the primary site of a disease with the use of a contrast agent to enhance the image.			Diagnostic Procedure	
C137888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137888>	C137805	Computed Tomography of an Anatomical Site of Interest with Contrast|CT with Contrast of Area of Interest|Computed Tomography of an Area of Interest with Contrast	Computed tomography of an anatomical site of interest with the use of a contrast agent to enhance the image.			Diagnostic Procedure	
C137889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137889>	C137805	Computed Tomography of the Inguinal Region with Contrast|CT with Contrast of Inguinal Region|Inguinal Region CT with Contrast	Computed tomography of the inguinal region with the use of a contrast agent to enhance the image.			Diagnostic Procedure	
C13788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13788>	C13432	Xq11-q13	A chromosome band present on Xq			Gene or Genome	
C137890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137890>	C137805	Computed Tomography of a Lymph Node Basin with Contrast|CT with Contrast of the Nodal Basin|Lymphatic Basin CT with Contrast	Computed tomography of one or more lymphatic basins with the use of a contrast agent to enhance the image.			Diagnostic Procedure	
C137891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137891>	C137805	Computed Tomography of the Head and Neck with Contrast|Head/Neck CT with Contrast	Computed tomography of the head and neck with the use of a contrast agent to enhance the image.			Diagnostic Procedure	
C137892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137892>	C137805	Computed Tomography of the Neck with Contrast|CT Scan of the Neck with Contrast|Neck CT with Contrast|Neck Computed Tomography with Contrast	Computed tomography of the neck with the use of a contrast agent to enhance the image.			Diagnostic Procedure	
C137893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137893>	C137805	Computed Tomography of the Neck, Chest, Abdomen and Pelvis with Contrast|CT Scan of the Neck/Chest/Abdomen/Pelvis with Contrast|Neck/Chest/Abdominal/Pelvic CT with Contrast|Neck/Chest/Abdominal/Pelvic Computed Tomography with Contrast	Computed tomography of the neck, chest, abdomen and pelvis with the use of a contrast agent to enhance the image.			Diagnostic Procedure	
C137894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137894>	C137805	Computed Tomography of the Pelvis with Contrast|CT Scan of the Pelvis with Contrast|Pelvic CT with Contrast|Pelvic Computed Tomography with Contrast	Computed tomography of the pelvis with the use of a contrast agent to enhance the image.			Diagnostic Procedure	
C137895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137895>	C137806	Computed Tomography of the Abdomen without Contrast|Abdominal CT without Contrast|CT of the Abdomen without Contrast	Computed tomography of the abdomen without the use of a contrast agent.			Diagnostic Procedure	
C137896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137896>	C137806	Computed Tomography of the Abdomen and Pelvis without Contrast|Abdominal/Pelvic CT without Contrast|CT of the Abdomen and Pelvis without Contrast	Computed tomography of the abdomen and pelvis without the use of a contrast agent.			Diagnostic Procedure	
C137897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137897>	C137806	Computed Tomography of the Brain without Contrast|Brain CT without Contrast|Brain CT without contrast|Head CT without Contrast	Computed tomography of the brain without the use of a contrast agent.			Diagnostic Procedure	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|Appendix 7: Diagnostic Procedures Terminology
C137898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137898>	C191501|C137806	Computed Tomography of the Chest without Contrast|Chest CT without Contrast	Computed tomography of the chest without the use of a contrast agent.			Diagnostic Procedure	
C137899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137899>	C137806	Computed Tomography of the Chest and Abdomen without Contrast|Chest/Abdominal CT without Contrast	Computed tomography of the chest and abdomen without the use of a contrast agent.			Diagnostic Procedure	
C13789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13789>	C13432	10p15.1	A chromosome band present on 10p			Gene or Genome	
C1378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1378>	C97453	Antimoniotungstate|21-Tungsto-9-antimonate|5-Tungsto-2-antimonate|Ammonium 5-Tungsto-2-antimonate|HPA-23|HPA-23|Heteropolyanion-23|Hexaoctacontaoxononaantimonateheneicosatungstate(19-) Heptadecaammonium Disodium	A non-nucleoside reverse transcriptase inhibitor. Antimoniotungstate is a mineral condensed ion with a cryptic structure.			Inorganic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C137900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137900>	C137806	Computed Tomography of the Chest, Abdomen and Pelvis without Contrast|Chest/Abdominal/Pelvic CT without Contrast	Computed tomography of the chest, abdomen and pelvis without the use of a contrast agent.	Computed Tomography of the Chest, Abdomen and Pelvis without Contrast		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C137901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137901>	C137806	Computed Tomography of an Anatomical Site of Interest without Contrast|CT without Contrast of Area of Interest|Computed Tomography of an Area of Interest without Contrast	Computed tomography of an anatomical site of interest without the use of a contrast agent.			Diagnostic Procedure	
C137902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137902>	C16809	Magnetic Resonance Imaging of a Primary Site with and without Contrast|MRI with and without Contrast of Primary Site|Magnetic Resonance Imaging with and without Contrast of Primary Site	Magnetic resonance imaging of the primary site without a contrast agent to enhance the image.			Diagnostic Procedure	
C137903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137903>	C137806	Computed Tomography of the Neck, Chest, Abdomen and Pelvis without Contrast|CT Scan of the Neck/Chest/Abdomen/Pelvis without Contrast|Neck/Chest/Abdominal/Pelvic CT without Contrast|Neck/Chest/Abdominal/Pelvic Computed Tomography without Contrast	Computed tomography of the neck, chest, abdomen and pelvis without the use of a contrast agent.			Diagnostic Procedure	
C137904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137904>	C137806	Computed Tomography of the Pelvis without Contrast|CT Scan of the Pelvis without Contrast|Pelvic CT without Contrast|Pelvic Computed Tomography without Contrast	Computed tomography of the pelvis without the use of a contrast agent.			Diagnostic Procedure	
C137905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137905>	C137816	Sodium Fluoride Positron Emission Tomography/Computed Tomography from the Skull Base to Mid-thigh|18F-NaF Skull Base to Mid-thigh PET/CT Scan|PET/CT, Skull Base to Mid-thigh, Sodium Fluoride|Positron Emission Tomography/Computed Tomography, Skull Base to Mid-thigh, Sodium Fluoride|Skull Base to Mid-thigh 18F-NaF Positron Emission Tomography/Computed Tomography|Skull Base to Mid-thigh PET/CT Scan with Sodium Fluoride|Skull Base to Mid-thigh Sodium Fluoride Positron Emission Tomography/Computed Tomography	Positron emission tomography combined with computed tomography of the region encompassing the skull base to the mid-thigh with the use of the contrast agent sodium fluoride F 18 (18F-NaF) to enhance the image.			Diagnostic Procedure	
C137906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137906>	C137816	Sodium Fluoride Positron Emission Tomography/Computed Tomography of the Whole Body|18F-NaF Whole-body PET/CT Scan|NaF PET/CT WB|PET/CT, Whole Body, Sodium Fluoride|Sodium Fluoride WB PET-CT|WB PET/CT Scan with Sodium Fluoride|Whole Body 18F-NaF Positron Emission Tomography/Computed Tomography|Whole Body Sodium Fluoride Positron Emission Tomography/Computed Tomography	Positron emission tomography combined with computed tomography of the whole body with the use of the contrast agent sodium fluoride F 18 (18F-NaF) to enhance the image.			Diagnostic Procedure	
C137907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137907>	C137817	FDG-Positron Emission Tomography/Computed Tomography of the Whole Body|EXPLORER Scanner|PET/CT, Whole Body, FDG|Positron Emission Tomography/Computed Tomography, Whole Body, FDG|Total-Body Positron Emission Tomography/Computed Tomography|WB PET/CT Scan with FDG|Whole Body FDG-PET/CT|Whole Body FDG-Positron Emission Tomography/Computed Tomography|Whole Body [18]F- Fludeoxyglucose Positron Emission Tomography/Computed Tomography|Whole-body 18F FDG PET/CT|Whole-body FDG-PET/CT|[18]F-FDG PET/CT	Positron emission tomography combined with computed tomography of the whole body, with the use of the contrast agent fludeoxyglucose F 18 (18F-FDG) to enhance the image.	FDG-Positron Emission Tomography/Computed Tomography of the Whole Body		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C137909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137909>	C15652	Computed Tomography Assisted Biopsy|CT Assisted Biopsy|CT Guided Biopsy|Computed Tomography Biopsy|Computed Tomography-Guided Needle Biopsy	Biopsy of tissue using computed tomography as an aid in directing a biopsy needle into the area of interest.	Computed Tomography Assisted Biopsy		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C13790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13790>	C13432	20q13.33	A chromosome band present on 20q			Gene or Genome	
C137910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137910>	C15675	Interruption of Chemotherapy	Discontinuation of chemotherapy, most often due to toxicity or unacceptable side effects.			Therapeutic or Preventive Procedure	
C137911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137911>	C16809	Magnetic Resonance Imaging of the Abdomen and Pelvis with and without Contrast|Abdominal/Pelvic MRI with and without Contrast|MRI of the Abdomen and Pelvis with and without Contrast	Magnetic resonance imaging of the abdomen and pelvis, with and without the use of a contrast agent to enhance the image.			Diagnostic Procedure	
C137912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137912>	C16809	Magnetic Resonance Imaging of Bone|Bone MRI	Magnetic resonance imaging of bone.			Diagnostic Procedure	
C137913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137913>	C16809	Magnetic Resonance Imaging of the Brain with and without Contrast|Brain MRI|Brain MRI with and without Contrast|Brain Magnetic Resonance Imaging with and without Contrast|Head MRI with and without Contrast	Magnetic resonance imaging of the brain with and without the use of a contrast agent to enhance the image.	Magnetic Resonance Imaging of the Brain with and without Contrast		Diagnostic Procedure	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|Appendix 7: Diagnostic Procedures Terminology|CTRP Intervention Terminology|CTRP Terminology
C137914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137914>	C16809	Magnetic Resonance Imaging of the Breast with and without Contrast|Breast MRI with and without Contrast|Breast Magnetic Resonance Imaging with and without Contrast	Magnetic resonance imaging of the breast with and without the use of a contrast agent to enhance the image.			Diagnostic Procedure	
C137915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137915>	C16809	Magnetic Resonance Imaging of the Heart|Cardiac MRI|Cardiac MRI|Cardiac MRI|Cardiac MRI|Heart MRI	Magnetic resonance imaging of the heart.	Magnetic Resonance Imaging of the Heart		Diagnostic Procedure	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|ACC/AHA COVID-19 Appendix Variables|ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|Appendix 7: Diagnostic Procedures Terminology|CTRP Intervention Terminology|CTRP Terminology
C137916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137916>	C16809	Magnetic Resonance Imaging of the Chest with and without Contrast|Chest MRI with and without Contrast|Chest Magnetic Resonance Imaging with and without Contrast	Magnetic resonance imaging of the chest with and without the use of a contrast agent to enhance the image.			Diagnostic Procedure	
C137917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137917>	C16809	Endorectal Magnetic Resonance Imaging|Endorectal MRI	Magnetic resonance imaging done from inside the rectum that usually utilizes a surface coil within a latex balloon to generate the magnetic field.			Diagnostic Procedure	
C137918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137918>	C16809	Magnetic Resonance Imaging of the Head and Neck with and without Contrast|Head and Neck Magnetic Resonance Imaging with and without Contrast|Head/Neck MRI with and without Contrast	Magnetic resonance imaging of the head and neck with and without the use of a contrast agent to enhance the image.			Diagnostic Procedure	
C137919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137919>	C16809	Magnetic Resonance Imaging of an Area of Interest with and without Contrast|MRI with and without Contrast of Area of Interest|Magnetic Resonance Imaging with and without Contrast of Area of Interest	Magnetic resonance imaging of an anatomical area of interest with and without a contrast agent to enhance the image.			Diagnostic Procedure	
C13791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13791>	C13432	10q24-q25.2	A chromosome band present on 10q			Gene or Genome	
C137920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137920>	C16809	Magnetic Resonance Imaging of the Neck with and without Contrast|MRI of the Neck with and without Contrast|Neck Computed Tomography with and without Contrast|Neck MRI with and without Contrast	Magnetic resonance imaging of the neck with and without a contrast agent to enhance the image.			Diagnostic Procedure	
C137921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137921>	C178628	Magnetic Resonance Imaging of the Whole Body with and without Contrast|WB-MRI with and without Contrast|Whole Body MRI with and without Contrast|Whole Body Magnetic Resonance Imaging with and without Contrast|Whole-body MRI with and without Contrast	Magnetic resonance imaging of the whole body with and without the use of a contrast agent to enhance the image.			Diagnostic Procedure	
C137922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137922>	C191501	Low Dose Computed Tomography of the Chest|LDCT|Low Dose Chest Computed Tomography|Low-dose Chest CT|Low-dose Chest Computed Tomography	Computed tomography (CT) of the chest that uses less radiation than a standard chest CT.	Low Dose Computed Tomography of the Chest		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C137923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137923>	C17204	Low Dose Computed Tomography of the Whole Body|Low-dose Whole-body CT|Whole Body Low Dose CT|Whole Body Low Dose Computed Tomography|Whole-body Low-dose CT	Computed tomography (CT) of the whole body that uses less radiation than a standard CT.			Diagnostic Procedure	
C137924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137924>	C17230	Axillary Lymph Node Ultrasound	Ultrasound of one or more lymph nodes in the axillary area.			Health Care Activity	
C137925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137925>	C17230	Ultrasound of the Neck|Neck Ultrasound	An ultrasound of the neck.			Health Care Activity	
C137926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137926>	C17230	Regional Lymph Node Ultrasound	An ultrasound of one or more lymph nodes in an anatomical area of interest.			Health Care Activity	
C137927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137927>	C38101	X-ray of an Area of Interest|Area of Interest X-ray|X-ray Imaging of Area of Interest	An X-ray of an anatomical area of interest.			Diagnostic Procedure	
C137928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137928>	C38101	X-ray of Primary Site|Primary Site X-ray|X-ray Imaging of Primary Site	An X-ray of the primary site.			Diagnostic Procedure	
C137929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137929>	C16809	Magnetic Resonance Imaging of the Abdomen with and without Contrast|Abdominal MRI with and without Contrast|MRI of the Abdomen with and without Contrast	Magnetic resonance imaging of the abdomen with and without the use of a contrast agent to enhance the image.	Magnetic Resonance Imaging of the Abdomen with and without Contrast		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C13792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13792>	C13432	Xq22.1	A chromosome band present on Xq			Gene or Genome	
C137930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137930>	C46087|C179164	Multiphasic Magnetic Resonance Imaging of the Abdomen|Abdominal MRI, Multiphasic|Multiphasic MRI of the Abdomen	Multiphasic magnetic resonance imaging of the abdomen.			Diagnostic Procedure	
C137931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137931>	C46087|C179164	Multiphasic Magnetic Resonance imaging of the Abdomen and Pelvis|Abdominal/Pelvic MRI, Multiphasic|Multiphasic MRI of the Abdomen and Pelvis	Multiphasic magnetic resonance imaging of the abdomen and pelvis.			Diagnostic Procedure	
C137932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137932>	C46087	Magnetic Resonance Imaging of Skeletal Metastatic Sites with Contrast|MRI of Skeletal Metastatic Sites with Contrast	Magnetic resonance imaging of skeletal metastatic sites with the use of a contrast agent to enhance the image.			Diagnostic Procedure	
C137933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137933>	C16809	Magnetic Resonance Imaging of the Pelvis with and without Contrast|MRI of the Pelvis with and without Contrast|Pelvic MRI with and without Contrast|Pelvic Magnetic Resonance Imaging with and without Contrast	Magnetic resonance imaging of the pelvis with and without the use of a contrast agent to enhance the image.			Diagnostic Procedure	
C137934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137934>	C51662	Mediastinal Lymph Node Biopsy	Removal or sampling of lymph nodes in the mediastinum.			Diagnostic Procedure	
C137935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137935>	C51662	Supraclavicular Lymph Node Biopsy	Removal or sampling of lymph nodes in the supraclavicular area.			Diagnostic Procedure	
C137936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137936>	C71316	Superior Vena Cava Stent Placement|SVC Stenting	Placement of a stent in the superior vena cava.			Therapeutic or Preventive Procedure	
C137937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137937>	C79416	Bilateral Diagnostic Mammogram	Mammography of both breasts for the purpose of diagnosis of disease.			Diagnostic Procedure	
C137938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137938>	C25688	Status of Correlation between Radiographic Image and Pathologic Finding|Correlation between Radiological and Pathological Findings	A qualifier used to describe the agreement between radiographic and pathologic findings.			Finding	
C137939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137939>	C137938	Radiographic Image Correlates with Tumor Pathology Finding|Rradiographic Findings Correlate with Histologic Findings	An indication that the results from radiographic and pathological testing correlate.			Finding	
C13793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13793>	C13432	5q11.2-q13.1	A chromosome band present on 5q			Gene or Genome	
C137940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137940>	C137938	Radiographic Image Not Correlated with Tumor Pathology Finding|Radiographic Findings Do not Correlate with Histologic Findings	An indication that the results from radiographic and pathological testing do not correlate.			Finding	
C137941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137941>	C192108	Risk Assessment for Hereditary Breast Cancer|Assessment of Risk of Hereditary Breast Cancer|Genetic/Familial Assessment of Risk of Breast Cancer|Hereditary Breast Cancer Risk Assessment	Assessment of an individual's specific predispositions for hereditary breast cancer, such as presence of a gene mutation.			Health Care Activity	
C137942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137942>	C15367	Risk Assessment for Thromboembolism|Assessment of Risk of Thromboembolism|Thromboembolism Risk Assessment	Analysis of risk factors that affect the development of thromboembolism, such as age or comorbidities.			Health Care Activity	
C137943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137943>	C53285	Patient Decision|Patient's Decision	A position, opinion or judgment reached after consideration by a patient.			Activity	
C137944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137944>	C137943	Patient Intends to Continue Pregnancy|Intends to Continue Pregnancy|Intent to Continue Pregnancy	An indication that a patient intends to continue pregnancy.			Activity	
C137945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137945>	C137943	Patient Requests Pregnancy Termination|Intent to Terminate Pregnancy|Patient Intends to Terminate Pregnancy|Patients Decides to Discontinue Pregnancy|Requests Pregnancy Termination	An indication that a patient requests to terminate pregnancy.			Activity	
C137946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137946>	C176710	Breast Lump Palpated|Breast Lump Palpable|O/E-Breast Lump Palpated|On Examination-Breast Lump Palpable|On Examination-Breast Lump Palpated	Palpation exam confirms presence of a breast lump.			Finding	
C137947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137947>	C176710	Breast Lump Not Palpated|Breast Lump Not Palpable|No Palpable Breast Lump|O/E-No Breast Lump Palpated|On Examination-Breast Lump Not Palpable|On Examination-No Breast Lump Palpable	No lump was palpated during breast examination.			Finding	
C137948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137948>	C51975	Meditation-Based Stress Reduction Program|MBSR|MBSR(BC)|Meditation-Based Stress Reduction|Meditation-Based Stress Reduction (Breast Cancer)|Meditation-Based Stress Reduction for Breast Cancer	A clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress.	Meditation-Based Stress Reduction Program		Mental Process	CTRP Intervention Terminology|CTRP Terminology
C137949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137949>	C199143	Foundation for the Accreditation of Cellular Therapy|FACT	A non-profit corporation co-founded by the International Society for Cellular Therapy and the American Society of Blood and Marrow Transplantation for the purposes of voluntary inspection and accreditation in the field of cellular therapy. Founded in 1996, FACT establishes standards for high quality medical and laboratory practice in cellular therapies. FACT Standards are evidence-based requirements set by world-renowned experts vested in the improvement and progress of cellular therapy.			Professional or Occupational Group	
C13794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13794>	C13432	11p15.3	A chromosome band present on 11p			Gene or Genome	
C137950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137950>	C147920|C129818	Vosilasarm|EP 0062|EP-0062|EP0062|RAD 140|RAD-140|RAD140|SARM RAD140|Selective Androgen Receptor Modulator RAD140|Testolone|VOSILASARM	An orally bioavailable, non-steroidal selective androgen receptor modulator (SARM), with potential tissue-selective androgenic/anti-androgenic activities. Upon oral administration, vosilasarm acts as an agonist in select tissues, such as skeletal muscle and bone, where it binds to and activates androgen receptors (ARs). In the prostate and breasts, vosilasarm acts as an antagonist and blocks AR activation and AR-mediated cellular proliferation. Therefore, this agent may improve bone formation and muscle mass and strength, and may inhibit both the growth of the prostate in males and AR-dependent breast cancer cell proliferation. Compared to anabolic agents, SARMs have reduced androgenic properties.	Vosilasarm		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C137951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137951>	C1512|C1420	Belzupacap Sarotalocan|AU-011|BELZUPACAP SAROTALOCAN|HPV-NP AU-011|Human Papillomavirus Virus-like Particles Conjugated with IR700 Dye AU-011|Light-activated AU-011|VNC AU-011|Viral Nanoparticle Conjugates AU-011	A formulation composed of nanoparticles derived from the human papillomavirus (HPV-NPs) and conjugated to the infrared (IR)-activated fluorescent dye IR700 (IR-700), with potential antineoplastic activity. Upon intravitreal injection of belzupacap sarotalocan, the HPV-NPs target and bind to heparan-sulfated proteoglycans (HSPG) expressed by ocular melanoma cells. Upon irradiation with near-IR (NIR) light, the photosensitizer IR700 becomes activated, generates reactive oxygen species (ROS) and selectively damages the melanoma cell membrane, which induces necrosis of the melanoma cells while sparing the surrounding, healthy non-HSPG-expressing tissue, and potentially preserving vision. HSPGs are overexpressed on a variety of cancer cell types.	Belzupacap Sarotalocan		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C137952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137952>	C81945|C18133	Non-synonymous ALK Gene Mutation|ALK Missense Mutation|Non-synonymous ALK Receptor Tyrosine Kinase Gene Mutation|Non-synonymous Anaplastic Lymphoma Kinase Receptor Gene Mutation|Non-synonymous Anaplastic Lymphoma Receptor Tyrosine Kinase Gene Mutation|Non-synonymous CD246 Gene Mutation	A point mutation in the ALK gene that encodes an amino acid substitution in the ALK tyrosine kinase receptor protein.			Cell or Molecular Dysfunction	
C137953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137953>	C36327	PI3K/MTOR Pathway Mutation|PI3K/AKT/MTOR Pathway Gene Alteration|PI3K/AKT/MTOR Pathway Mutation|PI3K/MTOR Pathway Gene Alteration|PI3K/MTOR Pathway Gene Mutation|Phosphatidylinositol 3 Kinase/Anaplastic Lymphoma Kinase Receptor/Mammalian Target of Rapamycin Pathway Mutation|Phosphatidylinositol 3 Kinase/Mammalian Target of Rapamycin Pathway Mutation	A change in the sequence of one or more genes that are involved in the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) signaling pathway.	PI3K/MTOR Pathway Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C137954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137954>	C25870	BCAT1 Gene|BCAT1|BCAT1|BCT1|Branched Chain Amino Acid Transaminase 1 Gene	This gene is involved in amino acid catabolism.			Gene or Genome	
C137955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137955>	C137954	BCAT1 wt Allele|BCT1|Branched Chain Amino Acid Transaminase 1 wt Allele|Branched Chain Aminotransferase 1, Cytosolic Gene|ECA39|MECA39|PNAS121|PP18	Human BCAT1 wild-type allele is located in the vicinity of 12p12.1 and is approximately 139 kb in length. This allele, which encodes branched-chain-amino-acid aminotransferase, cytosolic protein, plays a role in the catabolism of branched-chain amino acids. Mutation of the gene is associated with hypervalinemia and hyperleucine-isoleucinemia.			Gene or Genome	
C137956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137956>	C21489	Branched-Chain-Amino-Acid Aminotransferase, Cytosolic|BCAT(c)|BCAT1|Branched Chain Amino-Acid Transaminase 1, Cytosolic|Branched-Chain Aminotransferase 1|Branched-Chain Aminotransferase 1, Cytosolic|EC 2.6.1.42|Placental Protein 18|Protein ECA39	Branched-chain-amino-acid aminotransferase, cytosolic (386 aa, ~43 kDa) is encoded by the human BCAT1 gene. This protein is involved in transamination of leucine, isoleucine, and valine.			Amino Acid, Peptide, or Protein|Enzyme	
C137957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137957>	C34786	Long QT Syndrome 2|LQT2	An autosomal dominant condition caused by mutation(s) in the KCNH2 gene, encoding potassium voltage-gated channel subfamily H member 2. It is characterized by a prolonged QT interval that may result in torsade de pointes, ventricular fibrillation and/or sudden cardiac death.			Disease or Syndrome	Cellosaurus Disease Terminology
C137958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137958>	C20745	TMSB4X Gene|TMSB4X|TMSB4X|Thymosin Beta 4, X-Linked Gene	This gene plays a role in the sequestration of actin monomers.			Gene or Genome	
C137959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137959>	C34786	Long QT Syndrome 3|LQT3	An autosomal dominant condition caused by mutation(s) in the SCN5A gene, encoding sodium channel protein type 5 subunit alpha. It is characterized by a prolonged QT interval that may result in torsade de pointes, ventricular fibrillation and/or sudden cardiac death.			Disease or Syndrome	Cellosaurus Disease Terminology
C13795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13795>	C13432	6p21.31	A chromosome band present on 6p			Gene or Genome	
C137960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137960>	C137958	TMSB4X wt Allele|FX|PTMB4|TB4X|THYB4|TMSB4|Thymosin Beta 4, X-Linked wt Allele|Thymosin, Beta 4, X Chromosome Gene|Thymosin, Beta-4 Gene|Thymosin, Beta-4, X Chromosome Gene	Human TMSB4X wild-type allele is located in the vicinity of Xp22.2 and is approximately 2 kb in length. This allele, which encodes thymosin beta-4 protein, is involved in the inhibition of actin polymerization.			Gene or Genome	
C137961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137961>	C20745	TMSB4Y Gene|TMSB4Y|TMSB4Y|Thymosin Beta 4, Y-Linked Gene	This gene is involved in the downregulation of actin polymerization.			Gene or Genome	
C137962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137962>	C137961	TMSB4Y wt Allele|TB4Y|Thymosin Beta 4, Y-Linked wt Allele|Thymosin, Beta 4, Y Chromosome Gene|Thymosin, Beta-4 Gene|Thymosin, Beta-4, Y Chromosome Gene	Human TMSB4Y wild-type allele is located in the vicinity of Yq11.221 and is approximately 2 kb in length. This allele, which encodes thymosin beta-4, Y-chromosomal protein, plays a role in G actin sequestration.			Gene or Genome	
C137963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137963>	C16492	Thymosin Beta-4|Fx|Prothymosin Beta-4|T Beta-4|TMSB4X	Thymosin beta-4 (44 aa, ~5 kDa) is encoded by the human TMSB4X gene. This protein plays a role in the downregulation of actin polymerization.			Amino Acid, Peptide, or Protein	
C137964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137964>	C16492	Thymosin Beta-4, Y-Chromosomal|TMSB4Y|Thymosin Beta-4, Y Isoform	Thymosin beta-4, Y-chromosomal (44 aa, ~5 kDa) is encoded by the human TMSB4Y gene. This protein is involved in the inhibition of actin polymerization.			Amino Acid, Peptide, or Protein	
C137965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137965>	C26057	PIF1 Gene|PIF1|PIF1|PIF1 5'-to-3' DNA Helicase Gene	This gene plays a role in the DNA maintenance.			Gene or Genome	
C137966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137966>	C137965	PIF1 wt Allele|C15orf20|Chromosome 15 Open Reading Frame 20 Gene|FLJ22692|PIF|PIF1 5'-to-3' DNA Helicase Homolog (S. cerevisiae) Gene|PIF1 5'-to-3' DNA Helicase Homolog Gene|PIF1 5'-to-3' DNA Helicase wt Allele|PIF1, S. cerevisiae, Homolog of Gene|Petite Integration Frequency 1 Gene	Human PIF1 wild-type allele is located in the vicinity of 15q22.31 and is approximately 12 kb in length. This allele, which encodes ATP-dependent DNA helicase PIF1 protein, is involved in the maintenance of nuclear, mitochondrial and telomeric DNA.			Gene or Genome	
C137967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137967>	C16517	ATP-Dependent DNA Helicase PIF1|DNA Repair and Recombination Helicase PIF1|EC 3.6.4.12|PIF1|PIF1/RRM3 DNA Helicase-Like Protein	ATP-dependent DNA helicase PIF1 (641 aa, ~70 kDa) is encoded by the human PIF1 gene. This protein plays a role in the unwinding of G-quadruplex DNA and RNA-DNA hybrids.			Amino Acid, Peptide, or Protein|Enzyme	
C137968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137968>	C20420	BPTF Gene|BPTF|BPTF|Bromodomain PHD Finger Transcription Factor Gene	This gene is involved in histone-dependent regulation of transcription.			Gene or Genome	
C137969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137969>	C137968	BPTF wt Allele|Bromodomain PHD Finger Transcription Factor wt Allele|FAC1|FALZ|NURF301|NURF301, Drosophila, Homolog of Gene	Human BPTF wild-type allele is located in the vicinity of 17q24.2 and is approximately 159 kb in length. This allele, which encodes nucleosome-remodeling factor subunit BPTF protein, plays a role in the regulation of gene transcription.			Gene or Genome	
C13796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13796>	C13432	1p35.2	A chromosome band present on 1p			Gene or Genome	
C137970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137970>	C17207	Nucleosome-Remodeling Factor Subunit BPTF|Bromodomain and PHD Domain Transcription Factor|Bromodomain and PHD Finger-Containing Transcription Factor|Fetal Alz-50 Clone 1 Protein|Fetal Alz-50 Reactive Clone 1|Fetal Alzheimer Antigen|Nucleosome Remodeling Factor, Large Subunit	Nucleosome-remodeling factor subunit BPTF (3046 aa, ~338 kDa) is encoded by the human BPTF gene. This protein is involved in chromatin remodeling and transcriptional regulation.			Amino Acid, Peptide, or Protein	
C137971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137971>	C18437	RRAGD Gene|RRAGD|RRAGD|Ras Related GTP Binding D Gene	This gene plays a role in both GTP-binding and mTOR complex 1 (mTORC1) signaling.			Gene or Genome	
C137972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137972>	C137971	RRAGD wt Allele|DKFZP761H171|RAGD|Ras Related GTP Binding D wt Allele|bA11D8.2.1	Human RRAGD wild-type allele is located in the vicinity of 6q15 and is approximately 48 kb in length. This allele, which encodes Ras-related GTP-binding protein D, is involved in both mTOR complex 1 (mTORC1) signaling and GTP-binding.			Gene or Genome	
C137973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137973>	C18277	Ras-Related GTP-Binding Protein D|RAS-Related GTP Binding D|RRAGD|Rag D|Rag D Protein|RagD	Ras-related GTP-binding protein D (400 aa, ~46 kDa) is encoded by the human RRAGD gene. This protein plays a role in both GTP-binding and lysosomal localization of mTOR complex 1 (mTORC1).			Amino Acid, Peptide, or Protein|Enzyme	
C137974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137974>	C33904	Adnexa|Appendage	An appendage or accessory structure of an adjacent or related organ.			Body Part, Organ, or Organ Component	GDC Terminology|GDC Value Terminology
C137975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137975>	C26000	LAMA3 Gene|LAMA3|LAMA3|Laminin Subunit Alpha 3 Gene	This gene is involved in cell-matrix adhesion and cell migration.			Gene or Genome	
C137976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137976>	C137975	LAMA3 wt Allele|BM600|E170|Epiligrin, 170-kD Subunit Gene|LAM3, Alpha-3 Subunit Gene|LAMNA|LOCS|Laminin 5, Alpha-3 Subunit Gene|Laminin Subunit Alpha 3 wt Allele|Laminin, Alpha 3 (Nicein (150kD), Kalinin (165kD), BM600 (150kD), Epilegrin) Gene|Laminin, Alpha 3 Gene	Human LAMA3 wild-type allele is located in the vicinity of 18q11.2 and is approximately 266 kb in length. This allele, which encodes laminin subunit alpha-3 protein, plays a role in cell-matrix attachment.			Gene or Genome	
C137977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137977>	C17351	Laminin Subunit Alpha-3|BM600 150kD Subunit|E170|Epiligrin 170 kDa Subunit|Epiligrin Alpha 3 Subunit|Epiligrin Subunit Alpha|Kalinin 165kD Subunit|Kalinin Subunit Alpha|LAMA3|Laminin A3|Laminin-5 Subunit Alpha|Laminin-6 Subunit Alpha|Laminin-7 Subunit Alpha|Nicein 150kD Subunit|Nicein Subunit Alpha	Laminin subunit alpha-3 (3333 aa, ~367 kDa) is encoded by the human LAMA3 gene. This protein is involved in both cell-matrix adhesion and the organization of the extracellular matrix.			Amino Acid, Peptide, or Protein	
C137978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137978>	C25939	SESN1 Gene|SESN1|SESN1|Sestrin 1 Gene	This gene plays a role in leucine binding and the regulation of stress response signaling.			Gene or Genome	
C137979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137979>	C137978	SESN1 wt Allele|PA26|SEST1|Sestrin 1 wt Allele|p53 Activated Gene 26	Human SESN1 wild-type allele is located in the vicinity of 6q21 and is approximately 108 kb in length. This allele, which encodes sestrin-1 protein, is involved in stress response signaling.			Gene or Genome	
C13797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13797>	C13432	1p13.1	A chromosome band present on 1p			Gene or Genome	
C137980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137980>	C16946	Sestrin-1|EC 1.11.1.-|SESN1|Sestrin 1|p53 Regulated PA26 Nuclear Protein|p53-Regulated Protein PA26	Sestrin-1 (492 aa, ~57 kDa) is encoded by the human SESN1 gene. This protein plays a role in leucine sensing.			Amino Acid, Peptide, or Protein|Enzyme	
C137981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137981>	C20347	TAX1BP1 Gene|TAX1BP1|TAX1BP1|Tax1 Binding Protein 1 Gene	This gene is involved in the inhibition of apoptosis.			Gene or Genome	
C137982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137982>	C137981	TAX1BP1 wt Allele|CALCOCO3|PRO0105|T6BP|TXBP151|Tax1 (Human T-Cell Leukemia Virus Type I) Binding Protein 1 Gene|Tax1 Binding Protein 1 wt Allele	Human TAX1BP1 wild-type allele is located in the vicinity of 7p15.2 and is approximately 105 kb in length. This allele, which encodes Tax1-binding protein 1, plays a role in apoptosis inhibition.			Gene or Genome	
C137983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137983>	C19928	Tax1-Binding Protein 1|Human T-Cell Leukemia Virus Type 1-Binding Protein|TAX1BP1|TRAF6-Binding Protein|Tax1 Binding Protein 1	Tax1-binding protein 1 (789 aa, ~91 kDa) is encoded by the human TAX1BP1 gene. This protein is involved in the inhibition of tumor necrosis factor-induced apoptosis.			Amino Acid, Peptide, or Protein	
C137984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137984>	C25994	APELA Gene|APELA|APELA|Apelin Receptor Early Endogenous Ligand Gene	This gene plays a role in endoderm differentiation, heart development and angiogenesis.			Gene or Genome	
C137985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137985>	C137984	APELA wt Allele|Apelin Receptor Early Endogenous Ligand wt Allele|ELA|ELABELA|Ende|LOC100506013|Toddler Gene|tdl	Human APELA wild-type allele is located in the vicinity of 4q32.3 and is approximately 22 kb in length. This allele, which encodes apelin receptor early endogenous ligand protein, is involved in apelin receptor binding and in the development of the heart and cardiovascular system.			Gene or Genome	
C137986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137986>	C1746	Apelin Receptor Early Endogenous Ligand|APELA|ELA|Protein Elabela|Protein Toddler	Apelin receptor early endogenous ligand (54 aa, ~7 kDa) is encoded by the human APELA gene. This protein plays a role in heart and cardiovascular system development.			Amino Acid, Peptide, or Protein|Hormone	
C137987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137987>	C2124	Carbon C 11 Glutamine|11C-Gln|11C-glutamine|GLUTAMINE 5-C-11|[11C]-glutamine	Upon intravenous administration of 11C-glutamine, glutamine is preferentially taken up by cancer cells. Upon PET, the biodistribution and uptake by cancer cells can be assessed. Tumor cells use the amino acid glutamine for nutritional purposes including energy production and growth; as tumor cells proliferate more rapidly than normal healthy cells, glutamine uptake is higher in certain cancer cells.	Carbon C 11 Glutamine		Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C137988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137988>	C124800	FLT3 Inhibitor FF-10101 Succinate|FF-10101 Succinate|FF-10101-01|FF10101 Succinate	The succinate salt form of FF-10101, a FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2) inhibitor, with potential antineoplastic activity. Upon administration of FLT3 inhibitor FF-10101 succinate (FF-10101-01), FF-10101 irreversibly binds to and inhibits the activity of FLT3. This inhibits the proliferation of FLT3-expressing cancer cells. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B lineage neoplasms and in acute myeloid leukemias.	FLT3 Inhibitor FF-10101 Succinate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C137989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137989>	C137990	Mcl-1 Inhibitor AZD5991|AZD-5991|AZD-5991|AZD5991|MCL1 Inhibitor AZD5991	An inhibitor of induced myeloid leukemia cell differentiation protein (myeloid cell leukemia-1; Mcl-1; Bcl2-L-3), with potential pro-apoptotic and antineoplastic activities. Upon administration, AZD5991 binds to Mcl-1, thereby preventing the binding of Mcl-1 to and inactivation of certain pro-apoptotic proteins, and promoting apoptosis of cells overexpressing Mcl-1. Mcl-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C13798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13798>	C13432	6q22.1-q22.3	A chromosome band present on 6q			Gene or Genome	
C137990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137990>	C192025	Mcl-1 Inhibitor|Mcl1 Inhibitor	Any agent that inhibits Mcl-1.			Chemical Viewed Functionally	
C137991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137991>	C129823	Rolinsatamab Talirine|ABBV 176|ABBV-176|ABBV176|ADC ABBV-176|ROLINSATAMAB TALIRINE	An antibody-drug conjugate (ADC) composed of rolinsatamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against the prolactin receptor (PRLR), linked, via a maleimidocaproyl-valine-alanine dipeptide protease-cleavable linker, to talirine, a cytotoxic DNA minor groove crosslinking agent and pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon intravenous administration of rolinsatamab talirine, the rolinsatamab moiety targets and binds to PRLR expressed on tumor cells. Upon binding, internalization and linker cleavage, talirine is released and the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks and inhibits DNA replication, and results in G2/M cell cycle arrest and cell death, and inhibits the proliferation of PRLR-expressing tumor cells. PRLR, a tumor-associated antigen (TAA), is overexpressed by a variety of tumor cell types.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C137992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137992>	C28107	Gleason Grade Group 1|1|Grade Group 1|Group 1	Gleason grade defined by Gleason score less than or equal to 6. (ISUP, 2014)			Classification	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C137993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137993>	C28107	Gleason Grade Group 2|2|Grade Group 2|Group 2	Gleason grade defined by Gleason score 3+4=7. (ISUP, 2014)			Classification	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C137994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137994>	C28107	Gleason Grade Group 3|3|Grade Group 3|Group 3	Gleason grade defined by Gleason score 4+3=7. (ISUP, 2014)			Classification	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C137995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137995>	C28107	Gleason Grade Group 4|4|Grade Group 4|Group 4	Gleason grade defined by Gleason score 4+4=8, Gleason score 3+5=8, or Gleason score 5+3=8. (ISUP, 2014)	Gleason Grade Group 4		Classification	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C137996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137996>	C28107	Gleason Grade Group 5|5|Grade Group 5|Group 5	Gleason grade defined by Gleason score 9-10. (ISUP, 2014)			Classification	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C137997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137997>	C16830	Integra Dermal Regeneration Template|Integra Dermal Substitute|Integra Template	A proprietary bilayer membrane system for skin replacement. It is composed of a dermal replacement layer made of a porous matrix of cross-linked bovine tendon collagen and glycosaminoglycan manufactured with a controlled porosity and defined degradation rate, and an epidermal substitute layer made of polysiloxane silicone to control moisture loss from the wound.	Integra Dermal Regeneration Template		Entity	CTRP Intervention Terminology|CTRP Terminology
C137998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137998>	C18059	Smokeless Tobacco Use|Tobacco, Smokeless	Use of smokeless tobacco in any form, e.g., chewing or sniffing.	Smokeless Tobacco Use		Individual Behavior	CTRP Terminology|GDC Terminology|GDC Value Terminology
C137999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C137999>	C213868	Chimeric Antigen Receptor T-cells|CAR T Cell|CAR T Cell Preparation|CAR T Cells|CAR T Cells Preparation|CAR T-cells|CAR-T Cell|CAR-T Cells|CAR-modified T-cells|Chimeric Antigen Receptor T-Cell Therapy|Chimeric-antigen Receptor T-lymphocytes	Autologous or allogeneic T-lymphocytes that are engineered to contain a chimeric antigen receptor (CAR) that specifically targets a particular antigen.	Chimeric Antigen Receptor T-cells		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C13799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13799>	C13432	11q22.3	A chromosome band present on 11q	11q22.3		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C1379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1379>	C2116|C203977	Fulvestrant|7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol|FULVESTRANT|Faslodex|Faslodex|Faslodex(ICI 182,780)|ICI 182,780|ICI 182780|ICI-182780|ICI182780|ZD 9238|ZD-9238|ZD9238|fulvestrant	A synthetic estrogen receptor antagonist.  Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines. (NCI04)	Fulvestrant		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C138000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138000>	C173803|C118873	How Often Have Sensation of Not Emptying Bladder Completely after Finish Urinating Question|How Often Have Sensation of Not Emptying Bladder Completely after Urinating|How often have you had a sensation of not emptying your bladder completely after you finished urinating	A question about how often an individual has or had a sensation of not emptying their bladder completely after they finished urinating.			Intellectual Product	American Urological Association Symptom Score
C138001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138001>	C173803|C118873	How Often Have to Urinate Again Less Than 2 Hours after Finish Urinating Question|How Often Have to Urinate Again Less Than 2 Hours after Finish Urinating|How Often Have to Urinate Again Less Than 2 Hours after Urinating|How often have you had to urinate again less than 2 hours after you finished urinating	A question about how often an individual has or had to urinate again less than 2 hours after they finished urinating.			Intellectual Product	American Urological Association Symptom Score
C138002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138002>	C173803|C118873	How Often Have Stopped and Started Again Several Times When Urinating Question|How Often Have Stopped and Started Again Several Times When Urinating|How often have you found you stopped and started again several times when you urinated	A question about how often an individual has or had to stop and start again several times when they urinate.			Intellectual Product	American Urological Association Symptom Score
C138003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138003>	C173803|C173398|C118873	How Often Have Difficulty Postponing Urination Question|How Often Have Difficulty Postponing Urination|How often have you found it difficult to postpone urination	A question about how often an individual has or had found it difficult to postpone urination.			Intellectual Product	American Urological Association Symptom Score
C138004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138004>	C173803|C118873	How Often Have Weak Urinary Stream Question|How Often Have Weak Urinary Stream|How often have you had a weak urinary stream	A question about how often an individual has or had a weak urinary stream.			Intellectual Product	American Urological Association Symptom Score
C138005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138005>	C173803|C118873	How Often Have to Push or Strain to Begin Urination Question|How Often Have to Push or Strain to Begin Urinating|How Often Have to Push or Strain to Begin Urination|How often have you had to push or strain to begin urination	A question about how often an individual has or had to push or strain to begin urination.			Intellectual Product	American Urological Association Symptom Score
C138006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138006>	C173925|C173803	How Many Times Typically Get Up to Urinate During Nighttime Sleep Question|How Many Times Typically Get Up to Urinate During Nighttime|How Many Times Typically Get Up to Urinate During Nighttime Sleep|How many times did you most typically get up to urinate from the time you went to bed at night until the time you got up in the morning	A question about the most typical number of times an individual has or had to get up to urinate from the time they went to bed at night until the time they got up in the morning.			Intellectual Product	American Urological Association Symptom Score
C138007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138007>	C173803|C173509|C173160	Feeling about Current Urinary Condition for Rest of Life Question|Feeling about Current Urinary Condition for Rest of Life|If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that	A question about how an individual feels or felt about spending the rest of their life with their urinary condition just the way it is now.			Intellectual Product	American Urological Association Symptom Score
C138008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138008>	C25515	Less than One Time in Five|Less than 1 time in 5	A response indicating that something happens or happened less than one in five times.			Quantitative Concept	American Urological Association Symptom Score
C138009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138009>	C175311	About Half the Time|About half the time	A response indicating that something happens or happened about half of the time.			Quantitative Concept	American Urological Association Symptom Score
C13800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13800>	C13432	12q15	A chromosome band present on 12q			Gene or Genome	
C138010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138010>	C176250	Mostly Satisfied				Intellectual Product	American Urological Association Symptom Score
C138011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138011>	C176250	Mostly Dissatisfied	A response indicating that an individual is or has been mostly dissatisfied.			Intellectual Product	American Urological Association Symptom Score
C138012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138012>	C226674	Unhappy	A response indicating that an individual is or has been unhappy.			Intellectual Product	American Urological Association Symptom Score
C138013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138013>	C37869|C165799	Recurrent Gray-Zone Lymphoma|Recurrent B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma|Recurrent B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma|Recurrent B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma|Recurrent Gray Zone Lymphoma	The reemergence of gray-zone lymphoma after a period of remission.	Recurrent B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C138014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138014>	C7228|C37869	Refractory Gray-Zone Lymphoma|Refractory B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma|Refractory B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma|Refractory B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma|Refractory Gray Zone Lymphoma	A gray-zone lymphoma that is resistant to treatment.	Refractory B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C138015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138015>	C8852	Recurrent Extranodal Diffuse Large B-cell Lymphoma|Recurrent Extranodal Diffuse Large B-Cell Lymphoma	The reemergence of extranodal diffuse large B-cell lymphoma after a period of remission.	Recurrent Extranodal Diffuse Large B-Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C138016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138016>	C36334|C142126	SMARCA4 Gene Inactivation|Inactivating BAF190 Gene Mutation|Inactivating BAF190A Gene Mutation|Inactivating BRG-1 Gene Mutation|Inactivating BRG1 Gene Mutation|Inactivating BRM/SWI2-Related Gene 1 Mutation|Inactivating SMARCA4 Gene Mutation|Inactivating SNF2 Gene Mutation|Inactivating SNF2-Beta Gene Mutation|Inactivating SNF2L4 Mutation|Inactivating SNF2LB Gene Mutation|Inactivating SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily A, Member 4 Gene Mutation|Inactivating SWI2 Gene Mutation|Inactivating hSNF2b Gene Mutation|SMARCA4 Inactivating Gene Mutation|SMARCA4 Loss of Function|SMARCA4 Loss of Function Mutation	A mutation in the SMARCA4 gene that either inhibits expression of the SMARCA4 protein or results in the translation of an inactive SMARCA4 protein.	SMARCA4 Gene Inactivation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C138018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138018>	C8853	Refractory Extranodal Diffuse Large B-cell Lymphoma|Refractory Extranodal Diffuse Large B-Cell Lymphoma	An extranodal diffuse large B-cell lymphoma that is resistant to treatment.	Refractory Extranodal Diffuse Large B-Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C138019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138019>	C212063|C182030|C134157	Recurrent Central Nervous System Lymphoma	The reemergence of central nervous system lymphoma after a period of remission.	Recurrent Central Nervous System Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13801>	C13432	1p22.1	A chromosome band present on 1p			Gene or Genome	
C138020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138020>	C212063|C134154	Refractory Central Nervous System Lymphoma	A central nervous system lymphoma that is resistant to treatment.	Refractory Central Nervous System Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C138021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138021>	C6810|C150533|C134157|C131500	Recurrent Testicular Lymphoma	The reemergence of testicular lymphoma after a period of remission.	Recurrent Testicular Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C138022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138022>	C6810|C150534|C134154	Refractory Testicular Lymphoma	A testicular lymphoma that is resistant to treatment.	Refractory Testicular Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C138023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138023>	C4671|C170726|C134157|C131500	Recurrent Breast Lymphoma	The reemergence of breast lymphoma after a period of remission.	Recurrent Breast Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C138024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138024>	C4671|C134154	Refractory Breast Lymphoma	A breast lymphoma that is resistant to treatment.	Refractory Breast Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C138025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138025>	C8852|C4342	Recurrent Intravascular Large B-Cell Lymphoma|Recurrent Intravascular B-Cell Lymphoma	The reemergence of intravascular large B-cell lymphoma after a period of remission.	Recurrent Intravascular Large B-Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C138026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138026>	C8853|C4342	Refractory Intravascular Large B-Cell Lymphoma|Refractory Intravascular B-Cell Lymphoma	An intravascular large B-cell lymphoma that is resistant to treatment.	Refractory Intravascular Large B-Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C138027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138027>	C45194|C203667|C178553	Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type|Recurrent Primary Cutaneous (Skin) Diffuse Large B-Cell Lymphoma, Leg Type	The reemergence of primary cutaneous diffuse large B-cell lymphoma, leg type after a period of remission.	Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C138028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138028>	C45194|C203669|C178555	Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type|Refractory Primary Cutaneous (Skin) Diffuse Large B-Cell Lymphoma, Leg Type	A primary cutaneous diffuse large B-cell lymphoma, leg type that is resistant to treatment.	Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C138029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138029>	C63358	AC Followed by Docetaxel/Trastuzumab Regimen|AC Followed by Docetaxel + Trastuzumab|AC-Docetaxel + Trastuzumab|AC-T Plus Trastuzumab|AC-TH|AC-TH (Docetaxel)|AC-TH (Docetaxel) (trastuzumab-anns)|AC-TH (Docetaxel) (trastuzumab-dkst)|AC-TH (Docetaxel) (trastuzumab-dttb)|AC-TH (Docetaxel) (trastuzumab-herw)|AC-TH (Docetaxel) (trastuzumab-pkrb)|AC-TH (Docetaxel) (trastuzumab-qyyp)|AC-TH (Docetaxel) (trastuzumab-strf)|AC-TH (Docetaxel) (trastuzumab-zerc)|AC-Taxotere/Herceptin|Doxorubicin/Cyclophosphamide Followed by Docetaxel + Trastuzumab|Doxorubicin/Cyclophosphamide Followed by Docetaxel/Trastuzumab	A regimen consisting of cyclophosphamide and doxorubicin followed by docetaxel and trastuzumab, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C13802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13802>	C13302	Beta Sheet|Beta Pleated Sheet	In a b-sheet two or more polypeptide chains run alongside each other and are linked in a regular manner by hydrogen bonds between the main chain C=O and N-H groups. The R-groups (side chains) of neighbouring residues in a b-strand point in opposite directions; beta sheets can be parallel, anti-parallel or mixed. (from expasy.org)			Spatial Concept	
C138030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138030>	C63358	AC Followed by Docetaxel Regimen|AC Followed by Docetaxel|AC-D|AC-D|AC-Docetaxel|AC-T|AC-Taxotere|Doxorubicin/Cyclophosphamide Followed by Docetaxel	A regimen consisting of cyclophosphamide and doxorubicin followed by docetaxel, used as a neoadjuvant or adjuvant treatment for breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C138031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138031>	C63358	AC Followed by Pertuzumab/Trastuzumab/Docetaxel Regimen|AC Followed by Docetaxel + Pertuzumab + Trastuzumab|AC Followed by Docetaxel + Trastuzumab + Pertuzumab|AC Followed by Pertuzumab + Trastuzumab + Docetaxel|AC Followed by Pertuzumab-Trastuzumab-Docetaxel Regimen|AC-Pertuzumab + Trastuzumab + Docetaxel|AC-THP (Docetaxel)|AC-THP (Docetaxel) (trastuzumab-anns)|AC-THP (Docetaxel) (trastuzumab-dkst)|AC-THP (Docetaxel) (trastuzumab-dttb)|AC-THP (Docetaxel) (trastuzumab-herw)|AC-THP (Docetaxel) (trastuzumab-pkrb)|AC-THP (Docetaxel) (trastuzumab-qyyp)|AC-THP (Docetaxel) (trastuzumab-strf)|AC-THP (Docetaxel) (trastuzumab-zerc)|Doxorubicin/Cyclophosphamide Followed by Pertuzumab + Trastuzumab + Docetaxel|Doxorubicin/Cyclophosphamide Followed by Pertuzumab/Trastuzumab/Docetaxel	A regimen consisting of cyclophosphamide and doxorubicin followed by pertuzumab, trastuzumab, and docetaxel, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C138032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138032>	C63358	AC Followed by Pertuzumab/Trastuzumab/Paclitaxel Regimen|AC Followed by Paclitaxel + Pertuzumab + Trastuzumab|AC Followed by Paclitaxel + Trastuzumab + Pertuzumab|AC Followed by Pertuzumab + Trastuzumab + Paclitaxel|AC Followed by Pertuzumab-Trastuzumab-Paclitaxel Regimen|AC-Pertuzumab + Trastuzumab + Paclitaxel|AC-THP (Paclitaxel) (trastuzumab-anns)|AC-THP (Paclitaxel) (trastuzumab-dkst)|AC-THP (Paclitaxel) (trastuzumab-dttb)|AC-THP (Paclitaxel) (trastuzumab-herw)|AC-THP (Paclitaxel) (trastuzumab-pkrb)|AC-THP (Paclitaxel) (trastuzumab-qyyp)|AC-THP (Paclitaxel) (trastuzumab-strf)|AC-THP (Paclitaxel) (trastuzumab-zerc)|Doxorubicin/Cyclophosphamide Followed by Pertuzumab + Trastuzumab + Paclitaxel|Doxorubicin/Cyclophosphamide Followed by Pertuzumab/Trastuzumab/Paclitaxel|ddAC-THP (Paclitaxel)	A regimen consisting of cyclophosphamide and doxorubicin followed by pertuzumab, trastuzumab, and paclitaxel, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C138033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138033>	C63719|C63358	Capecitabine/Trastuzumab Regimen|Capecitabine + Trastuzumab|Capecitabine Plus Trastuzumab|Capecitabine and Trastuzumab (XH)|Capecitabine and Trastuzumab-anns (XH)|Capecitabine and Trastuzumab-dkst (XH)|Capecitabine and Trastuzumab-dttb (XH)|Capecitabine and Trastuzumab-herw (XH)|Capecitabine and Trastuzumab-pkrb (XH)|Capecitabine and Trastuzumab-qyyp (XH)|Capecitabine and Trastuzumab-strf (XH)|Capecitabine and Trastuzumab-zerc (XH)|Capecitabine-Trastuzumab|Capecitabine-Trastuzumab Regimen|Capecitabine/Trastuzumab	A regimen consisting of capecitabine and trastuzumab that can be used for the treatment of breast, esophageal and esophagogastric junction and gastric cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C138034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138034>	C63358	Cyclophosphamide/Docetaxel/Trastuzumab Regimen|Docetaxel + Cyclophosphamide + Trastuzumab|Docetaxel-Cyclophosphamide-Trastuzumab|Docetaxel-Cyclophosphamide-Trastuzumab Regimen|Docetaxel/Cyclophosphamide + Trastuzumab|Docetaxel/Cyclophosphamide Plus Trastuzumab|Docetaxel/Cyclophosphamide/Trastuzumab Regimen|TC-H (Docetaxel)|TC-H (Docetaxel) (trastuzumab-anns)|TC-H (Docetaxel) (trastuzumab-dkst)|TC-H (Docetaxel) (trastuzumab-dttb)|TC-H (Docetaxel) (trastuzumab-herw)|TC-H (Docetaxel) (trastuzumab-pkrb)|TC-H (Docetaxel) (trastuzumab-qyyp)|TC-H (Docetaxel) (trastuzumab-strf)|TC-H (Docetaxel) (trastuzumab-zerc)|TCH (Docetaxel) (trastuzumab-anns)|TCH (Docetaxel) (trastuzumab-dkst)|TCH (Docetaxel) (trastuzumab-dttb)|TCH (Docetaxel) (trastuzumab-herw)|TCH (Docetaxel) (trastuzumab-pkrb)|TCH (Docetaxel) (trastuzumab-qyyp)|TCH (Docetaxel) (trastuzumab-zerc)|TCH (Docetaxel, Cyclophosphamide)|TCyH (Docetaxel) (trastuzumab-qyyp)|TCyH (Docetaxel) (trastuzumab-strf)	A regimen consisting of docetaxel, cyclophosphamide and trastuzumab that can be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C138035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138035>	C63358	Dose-dense AC Regimen|DD AC|DDAC|Dose-dense AC|Dose-dense Adriamycin/Cytoxan|Dose-dense Cyclophosphamide and Doxorubicin (ddAC)|Dose-dense Doxorubicin-Cyclophosphamide Regimen|Dose-dense Doxorubicin/Cyclophosphamide|ddAC	A regimen consisting of doxorubicin and cyclophosphamide, used as a neoadjuvant or adjuvant treatment for breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C138036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138036>	C63358	Dose-dense AC Followed by Paclitaxel/Trastuzumab Regimen|Dose-dense AC Followed by Paclitaxel-Trastuzumab Regimen|Dose-dense AC Followed by Paclitaxel/Trastuzumab|Dose-dense Adriamycin/Cytoxan Followed by Paclitaxel/Trastuzumab|Dose-dense Doxorubicin/Cyclophosphamide Followed by Paclitaxel/Trastuzumab|ddAC-TH (Paclitaxel)|ddAC-TH (Paclitaxel) (trastuzumab-anns)|ddAC-TH (Paclitaxel) (trastuzumab-dkst)|ddAC-TH (Paclitaxel) (trastuzumab-dttb)|ddAC-TH (Paclitaxel) (trastuzumab-herw)|ddAC-TH (Paclitaxel) (trastuzumab-pkrb)|ddAC-TH (Paclitaxel) (trastuzumab-qyyp)|ddAC-TH (Paclitaxel) (trastuzumab-strf)|ddAC-TH (Paclitaxel) (trastuzumab-zerc)	A regimen consisting of doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C138037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138037>	C63358	Dose-dense AC Followed by Paclitaxel Regimen|Dose-dense AC Followed by Paclitaxel|Dose-dense AC Regimen Followed by Paclitaxel|Dose-dense AC-T|Dose-dense AC-T|Dose-dense AC-Taxol|Dose-dense Adriamycin/Cytoxan Followed by Paclitaxel|Dose-dense Doxorubicin/Cyclophosphamide Followed by Paclitaxel	A regimen consisting of doxorubicin and cyclophosphamide followed by paclitaxel, used as a neoadjuvant or adjuvant treatment for breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C138038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138038>	C63358	FEC Followed by Pertuzumab/Trastuzumab/Docetaxel Regimen|FEC Followed by Docetaxel/Trastuzumab/Pertuzumab|FEC Followed by Pertuzumab + Trastuzumab + Docetaxel|FEC-THP (Docetaxel)|FEC-THP (Docetaxel) (trastuzumab-anns)|FEC-THP (Docetaxel) (trastuzumab-dkst)|FEC-THP (Docetaxel) (trastuzumab-dttb)|FEC-THP (Docetaxel) (trastuzumab-herw)|FEC-THP (Docetaxel) (trastuzumab-pkrb)|FEC-THP (Docetaxel) (trastuzumab-qyyp)|FEC-THP (Docetaxel) (trastuzumab-strf)|FEC-THP (Docetaxel) (trastuzumab-zerc)|Fluorouracil/Epirubicin/Cyclophosphamide Followed by Pertuzumab + Trastuzumab + Docetaxel|Fluorouracil/Epirubicin/Cyclophosphamide Followed by Pertuzumab/Trastuzumab/Docetaxel	A regimen consisting of fluorouracil, epirubicin and intravenous cyclophosphamide, followed by pertuzumab, trastuzumab and docetaxel, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C138039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138039>	C63358	FEC Followed by Pertuzumab/Trastuzumab/Paclitaxel Regimen|FEC Followed by Paclitaxel/Trastuzumab/Pertuzumab|FEC Followed by Pertuzumab + Trastuzumab + Paclitaxel|FEC-THP (Paclitaxel)|FEC-THP (Paclitaxel) (trastuzumab-anns)|FEC-THP (Paclitaxel) (trastuzumab-dkst)|FEC-THP (Paclitaxel) (trastuzumab-dttb)|FEC-THP (Paclitaxel) (trastuzumab-herw)|FEC-THP (Paclitaxel) (trastuzumab-pkrb)|FEC-THP (Paclitaxel) (trastuzumab-qyyp)|FEC-THP (Paclitaxel) (trastuzumab-strf)|FEC-THP (Paclitaxel) (trastuzumab-zerc)|Fluorouracil/Epirubicin/Cyclophosphamide Followed by Pertuzumab + Trastuzumab + Paclitaxel|Fluorouracil/Epirubicin/Cyclophosphamide Followed by Pertuzumab/Trastuzumab/Paclitaxel	A regimen consisting of fluorouracil, epirubicin and intravenous cyclophosphamide, followed by pertuzumab, trastuzumab and paclitaxel, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C13803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13803>	C13377	Long Interspersed Element|LINE|LINES|Long Interspersed Nucleotide Elements	A highly repetitive retrotransposon-like sequence that is 6000-8000 base pairs in length. It may contain an RNA polymerase II promoter domain, repetitive target sequences, and open reading frames encoding proteins with endonuclease and reverse transcriptase activity.	Long Interspersed Element		Nucleotide Sequence	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138040>	C63586|C63358|C191676|C159440	Lapatinib/Trastuzumab Regimen|Lapatinib + Trastuzumab|Lapatinib + Trastuzumab Regimen|Lapatinib Plus Trastuzumab|Lapatinib and Trastuzumab|Lapatinib and Trastuzumab-anns|Lapatinib and Trastuzumab-dkst|Lapatinib and Trastuzumab-dttb|Lapatinib and Trastuzumab-herw|Lapatinib and Trastuzumab-pkrb|Lapatinib and Trastuzumab-qyyp|Lapatinib and Trastuzumab-strf|Lapatinib and Trastuzumab-zerc|Lapatinib-Trastuzumab Regimen|Lapatinib/Trastuzumab	A regimen consisting of lapatinib and trastuzumab that can be used for the treatment of bone, breast, and colorectal cancers, appendiceal adenocarcinoma, and anaplastic carcinoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C138041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138041>	C63586|C63358	Capecitabine/Lapatinib Regimen|Capecitabine and Lapatinib|Lapatinib + Capecitabine Regimen|Lapatinib Plus Capecitabine Regimen|Lapatinib-Capecitabine Regimen|Lapatinib/Capecitabine|Lapatinib/Capecitabine Regimen	A regimen consisting of capecitabine and  lapatinib that can be used in the treatment of breast and colon cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C138042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138042>	C63586|C63358|C191713|C191676|C159893|C159454	Pertuzumab/Trastuzumab Regimen|Herceptin-Perjeta|Pertuzumab + Trastuzumab|Pertuzumab Plus Trastuzumab|Pertuzumab and Trastuzumab|Pertuzumab and Trastuzumab-anns|Pertuzumab and Trastuzumab-dkst|Pertuzumab and Trastuzumab-dttb|Pertuzumab and Trastuzumab-herw|Pertuzumab and Trastuzumab-pkrb|Pertuzumab and Trastuzumab-qyyp|Pertuzumab and Trastuzumab-strf|Pertuzumab and Trastuzumab-zerc|Pertuzumab-Trastuzumab Regimen|Pertuzumab/Trastuzumab	A regimen consisting of pertuzumab and trastuzumab that may be used as a treatment for appendiceal adenocarcinoma, small bowel  adenocarcinoma, salivary gland tumors, breast, hepatobiliary and colorectal cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C138043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138043>	C63358	Docetaxel/Pertuzumab/Trastuzumab Regimen|Pertuzumab + Trastuzumab + Docetaxel|Pertuzumab-Trastuzumab-Docetaxel|Pertuzumab-Trastuzumab-Docetaxel Regimen|Pertuzumab/Trastuzumab/Docetaxel|Pertuzumab/Trastuzumab/Docetaxel Regimen|THP|THP (Docetaxel)|THP (Docetaxel) (trastuzumab-anns)|THP (Docetaxel) (trastuzumab-dkst)|THP (Docetaxel) (trastuzumab-dttb)|THP (Docetaxel) (trastuzumab-herw)|THP (Docetaxel) (trastuzumab-pkrb)|THP (Docetaxel) (trastuzumab-qyyp)|THP (Docetaxel) (trastuzumab-strf)|THP (Docetaxel) (trastuzumab-zerc)|THP (Taxotere) Regimen|Taxotere/Herceptin/Pertuzumab	A regimen consisting of pertuzumab, trastuzumab and docetaxel that can be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C138044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138044>	C63358	Pertuzumab/Trastuzumab/Docetaxel Followed by FEC Regimen|Pertuzumab + Trastuzumab + Docetaxel Followed by FEC|Pertuzumab + Trastuzumab + Docetaxel Followed by Fluorouracil/Epirubicin/Cyclophosphamide|Pertuzumab-Trastuzumab-Docetaxel Followed by Fluorouracil-Epirubicin-Cyclophosphamide|Pertuzumab/Trastuzumab/Docetaxel Followed by Fluorouracil/Epirubicin/Cyclophosphamide	A regimen consisting of pertuzumab, trastuzumab and docetaxel, followed by fluorouracil, epirubicin and intravenous cyclophosphamide, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C138045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138045>	C63358	Paclitaxel/Pertuzumab/Trastuzumab Regimen|Pertuzumab + Trastuzumab + Paclitaxel|Pertuzumab-Trastuzumab-Paclitaxel|Pertuzumab-Trastuzumab-Paclitaxel Regimen|Pertuzumab/Trastuzumab/Paclitaxel Regimen|THP (Paclitaxel)|THP (Paclitaxel) (trastuzumab-anns)|THP (Paclitaxel) (trastuzumab-dkst)|THP (Paclitaxel) (trastuzumab-dttb)|THP (Paclitaxel) (trastuzumab-herw)|THP (Paclitaxel) (trastuzumab-pkrb)|THP (Paclitaxel) (trastuzumab-qyyp)|THP (Paclitaxel) (trastuzumab-strf)|THP (Paclitaxel) (trastuzumab-zerc)|THP (Taxol) Regimen|Taxol/Herceptin/Pertuzumab	A regimen consisting of pertuzumab, trastuzumab and paclitaxel, used as a treatment for recurrent and metastatic HER-2/neu-positive breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C138046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138046>	C63358	Pertuzumab/Trastuzumab/Paclitaxel Followed by FEC Regimen|Pertuzumab + Trastuzumab + Paclitaxel Followed by FEC|Pertuzumab + Trastuzumab + Paclitaxel Followed by Fluorouracil/Epirubicin/Cyclophosphamide|Pertuzumab-Trastuzumab-Paclitaxel Followed by Fluorouracil-Epirubicin-Cyclophosphamide|Pertuzumab/Trastuzumab/Paclitaxel Followed by Fluorouracil/Epirubicin/Cyclophosphamide	A regimen consisting of pertuzumab, trastuzumab and paclitaxel, followed by fluorouracil, epirubicin and intravenous cyclophosphamide, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C138047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138047>	C63358	TCHP Regimen|Docetaxel/Carboplatin/Pertuzumab/Trastuzumab|Docetaxel/Carboplatin/Trastuzumab/Pertuzumab Regimen|TCH + P|TCH + Pertuzumab|TCH Plus Pertuzumab Regimen|TCHP|TCHP|TCHP (Docetaxel)|TCHP (Docetaxel) (trastuzumab-anns)|TCHP (Docetaxel) (trastuzumab-dkst)|TCHP (Docetaxel) (trastuzumab-dttb)|TCHP (Docetaxel) (trastuzumab-herw)|TCHP (Docetaxel) (trastuzumab-pkrb)|TCHP (Docetaxel) (trastuzumab-qyyp)|TCHP (Docetaxel) (trastuzumab-strf)|TCHP (Docetaxel) (trastuzumab-zerc)|TCHP (Docetaxel, SC Trastuzumab)|Taxotere-Carboplatin-Herceptin-Perjeta|Taxotere-Carboplatin-Herceptin-Pertuzumab	A regimen consisting of docetaxel, carboplatin, trastuzumab and pertuzumab, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C138048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138048>	C63719|C63358|C191713	Docetaxel/Trastuzumab Regimen|Docetaxel and Trastuzumab (TH)|Docetaxel and Trastuzumab-anns (TH)|Docetaxel and Trastuzumab-dkst (TH)|Docetaxel and Trastuzumab-dttb (TH)|Docetaxel and Trastuzumab-herw (TH)|Docetaxel and Trastuzumab-pkrb (TH)|Docetaxel and Trastuzumab-qyyp (TH)|Docetaxel and Trastuzumab-zerc (TH)|Docetaxel-Trastuzumab|Docetaxel-Trastuzumab Regimen|Docetaxel/Trastuzumab|T-H (Docetaxel)|T-H (Docetaxel) (trastuzumab-anns)|T-H (Docetaxel) (trastuzumab-dkst)|T-H (Docetaxel) (trastuzumab-dttb)|T-H (Docetaxel) (trastuzumab-herw)|T-H (Docetaxel) (trastuzumab-pkrb)|T-H (Docetaxel) (trastuzumab-qyyp)|T-H (Docetaxel) (trastuzumab-strf)|T-H (Docetaxel) (trastuzumab-zerc)|Taxotere/Herceptin	A regimen consisting of docetaxel and trastuzumab that may be used in the treatment of breast, esophageal and esophagogastric junction, and gastric cancers and salivary gland tumors. Docetaxel every 21 days plus trastuzumab regimen may be used for the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C13804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13804>	C13298	Short Interspersed Element|SINE|SINES|Short Interspersed Nuclear Element	SINEs.  Short, 100-300 bases long, highly repeated sequences which contain RNA polymerase III promoters. The primate Alu and the rodent B1 SINEs are derived from 7SL RNA, the RNA component of the signal recognition particle. Most other SINEs are derived from tRNAs including the MIRs (mammalian-wide interspersed repeats).			Nucleotide Sequence	
C138050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138050>	C63522|C63358|C159901|C159900	Bevacizumab/Paclitaxel Regimen|Bevacizumab-Paclitaxel|Bevacizumab-Paclitaxel Regimen|Bevacizumab/Paclitaxel|Paclitaxel and Bevacizumab|Paclitaxel and Bevacizumab-adcd|Paclitaxel and Bevacizumab-awwb|Paclitaxel and Bevacizumab-aybi|Paclitaxel and Bevacizumab-bvzr|Paclitaxel and Bevacizumab-equi|Paclitaxel and Bevacizumab-maly|Paclitaxel and Bevacizumab-onbe|Paclitaxel and Bevacizumab-tnjn	A regimen consisting of paclitaxel and bevacizumab that may be used as a treatment for breast, ovarian, fallopian tube and primary peritoneal cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C138051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138051>	C63719|C63358	Paclitaxel/Trastuzumab Regimen|PH Regimen|Paclitaxel and Trastuzumab (TH)|Paclitaxel and Trastuzumab-anns (TH)|Paclitaxel and Trastuzumab-dkst (TH)|Paclitaxel and Trastuzumab-dttb (TH)|Paclitaxel and Trastuzumab-herw (TH)|Paclitaxel and Trastuzumab-pkrb (TH)|Paclitaxel and Trastuzumab-qyyp (TH)|Paclitaxel and Trastuzumab-strf (TH)|Paclitaxel and Trastuzumab-zerc (TH)|Paclitaxel-Trastuzumab|Paclitaxel-Trastuzumab Regimen|Paclitaxel/Herceptin|Paclitaxel/Trastuzumab|T-H (Paclitaxel)|T-H (Paclitaxel) (trastuzumab-anns)|T-H (Paclitaxel) (trastuzumab-dkst)|T-H (Paclitaxel) (trastuzumab-dttb)|T-H (Paclitaxel) (trastuzumab-herw)|T-H (Paclitaxel) (trastuzumab-pkrb)|T-H (Paclitaxel) (trastuzumab-qyyp)|T-H (Paclitaxel) (trastuzumab-strf)|T-H (Paclitaxel) (trastuzumab-zerc)|TH Regimen|Taxol/Herceptin	A regimen consisting of paclitaxel and trastuzumab that may be used in the treatment of breast, esophageal and esophagogastric junction, and gastric cancers. Paclitaxel weekly plus trastuzumab regimen and dose-dense paclitaxel plus trastuzumab regimen may be used for the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C138052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138052>	C63719|C63519|C63358	Carboplatin/Paclitaxel/Trastuzumab Regimen|Carboplatin and Paclitaxel (CP) and Trastuzumab|Carboplatin and Paclitaxel (CP) and Trastuzumab-anns|Carboplatin and Paclitaxel (CP) and Trastuzumab-dkst|Carboplatin and Paclitaxel (CP) and Trastuzumab-dttb|Carboplatin and Paclitaxel (CP) and Trastuzumab-herw|Carboplatin and Paclitaxel (CP) and Trastuzumab-pkrb|Carboplatin and Paclitaxel (CP) and Trastuzumab-qyyp|Carboplatin and Paclitaxel (CP) and Trastuzumab-strf|Carboplatin and Paclitaxel (CP) and Trastuzumab-zerc|Carboplatin-Paclitaxel-Trastuzumab|Carboplatin-Paclitaxel-Trastuzumab Regimen|Carboplatin/Paclitaxel Plus Trastuzumab Regimen|Carboplatin/Paclitaxel/Trastuzumab|Paclitaxel/Carboplatin Plus Trastuzumab|Paclitaxel/Carboplatin/Trastuzumab|TCH|TPC	A regimen consisting of paclitaxel, carboplatin and trastuzumab that may be used as a treatment for breast, esophageal and esophagogastric junction, and gastric cancers and endometrial carcinoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C138053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138053>	C63358	VH Regimen|Trastuzumab-Vinorelbine Regimen|Trastuzumab/Vinorelbine Regimen|VH|Vinorelbine + Trastuzumab|Vinorelbine and Trastuzumab (VH)|Vinorelbine and Trastuzumab-anns (VH)|Vinorelbine and Trastuzumab-dkst (VH)|Vinorelbine and Trastuzumab-dttb (VH)|Vinorelbine and Trastuzumab-herw (VH)|Vinorelbine and Trastuzumab-pkrb (VH)|Vinorelbine and Trastuzumab-qyyp (VH)|Vinorelbine and Trastuzumab-strf (VH)|Vinorelbine and Trastuzumab-zerc (VH)|Vinorelbine-Trastuzumab|Vinorelbine/Herceptin|Vinorelbine/Trastuzumab	A regimen consisting of vinorelbine and trastuzumab, used as a treatment for recurrent and metastatic HER-2/neu-positive breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C138054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138054>	C63358	TC Regimen|Cyclophosphamide and Docetaxel (TC)|Cyclophosphamide/Docetaxel|Docetaxel + Cyclophosphamide|Docetaxel-Cyclophosphamide|Docetaxel/Cyclophosphamide|Docetaxel/Cyclophosphamide Regimen|TC|Taxotere/Cytoxan	A regimen consisting of docetaxel and cyclophosphamide that can be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C138056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138056>	C146656	Blasts 10 Percent or More of Peripheral Blood White Cells|Blasts Greater than or Equal to 10 Percent of Peripheral Blood White Cells	A semi-quantitative microscopic finding indicating that 10 percent or more of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.	Blasts 10 Percent or More of Peripheral Blood White Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C138057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138057>	C141297	Blasts Under 30 Percent of Bone Marrow Nucleated Cells|Blasts Less Than 30 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that less than 30 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts Under 30 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C138058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138058>	C36341	ErbB Family Pathway Deregulation|EGFR Family Pathway Deregulation|ErbB Pathway Deregulation	Aberrant activation of an ERBB family member-dependent signaling pathway.	ErbB Family Pathway Deregulation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138059>	C137943	Patient Decision Regarding Continuation of Pregnancy after Cancer Diagnosis|Patient's Decision Regarding Continuation of Pregnancy after Cancer Diagnosis	The patient's decision regarding continuation of pregnancy following a cancer diagnosis.			Activity	
C13805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13805>	C13442	Erythroid	1) Reddish in color. 2) relating to erythrocytes or their precursors.			Body System	
C138060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138060>	C97927|C141240	ERBB4 Gene Mutation|ERBB-4 Gene Mutation|Erb-B2 Receptor Tyrosine Kinase 4 Gene Mutation|HER-4 Gene Mutation|HER4 Gene Mutation|V-Erb-A Erythroblastic Leukemia Viral Oncogene Homolog 4 Gene Mutation|V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 4 Gene Mutation	A change in the nucleotide sequence of the ERBB4 gene.	ERBB4 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138061>	C41227	Distal Resection Margin|Distal|Distal Margin	The surgical margin resulting from resection of a tumor with respect to the distal border of the specimen, as it was oriented prior to excision.			Clinical Attribute	
C138062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138062>	C41227	Deep Resection Margin|Deep|Deep Margin	The surgical margin resulting from resection of a tumor with respect to the deep border of the specimen, as it was oriented prior to excision.			Clinical Attribute	
C138063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138063>	C41227	Proximal Resection Margin|Proximal|Proximal Margin	The surgical margin resulting from resection of a tumor with respect to the proximal border of the specimen, as it was oriented prior to excision.			Clinical Attribute	
C138064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138064>	C97927|C141240	ERBB3 Gene Mutation|Erb-B2 Receptor Tyrosine Kinase 3 Gene Mutation|ErbB-3 Gene Mutation|HER-3 Gene Mutation|HER3 Gene Mutation|V-Erb-A Erythroblastic Leukemia Viral Oncogene Homolog 3 Gene Mutation|V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 3 Gene Mutation|c-erbB-3 Gene Mutation|c-erbB3 Gene Mutation	A change in the nucleotide sequence of the ERBB3 gene.	ERBB3 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138065>	C150453	Blasts 50 Percent or More of Bone Marrow Nucleated Cells|Blasts Greater Than 50 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that greater than or equal to 50 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts 50 Percent or More of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C138066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138066>	C213692|C129825	Nemtabrutinib|ARQ 531|ARQ-531|ARQ531|BTK Inhibitor ARQ 531|Bruton's Tyrosine Kinase Inhibitor ARQ 531|MK-1026|NEMTABRUTINIB	An orally available reversible inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), with potential antineoplastic activity. Upon administration, nemtabrutinib non-covalently binds to and inhibits the activity of both the wild-type and the C481S mutated form of BTK, a resistance mutation in the BTK active site in which cysteine is substituted for serine at residue 481. This prevents the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B-cells that overexpress BTK. Compared to other BTK inhibitors, nemtabrutinib does not require interaction with the BTK C481 site and inhibits the proliferation of cells harboring the BTK C481S mutation. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.	Nemtabrutinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C138067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138067>	C138961	PSA Level Less than or Equal to Twenty|PSA Level 20 or Less|PSA Level Less than or Equal to 20|PSA Level Twenty or Less	A blood concentration of prostate specific antigen less than or equal to 20 ng/mL.	PSA Level Less than or Equal to Twenty		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138068>	C153241|C118377	FGFR2 Gene Translocation|BEK Gene Translocation|CD332 Gene Translocation|ECT1 Gene Translocation|FGFR-2 Gene Translocation|Fibroblast Growth Factor Receptor 2 Gene Translocation|K-SAM Gene Translocation|KGFR Gene Translocation	A cytogenetic abnormality that refers to any translocation involving the FGFR2 gene.	FGFR2 Gene Translocation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138069>	C177686	cfDNA Mutation|Cell-Free DNA Mutation|Circulating Free DNA Mutation|Circulating Free Deoxyribonucleic Acid Mutation|Mutated Cell-Free DNA|Mutated cfDNA	A genetic finding indicating the presence of mutations in the cell-free DNA that is present in a peripheral blood sample.	cfDNA Mutation		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C13806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13806>	C13379	Immunoglobulin Domain|Immunoglobulin-Like Domain	The major histocompatibility complex (MHC) molecules are made of 2 chains, alpha and beta. In class I, the alpha chain is composed of 3 extracellular domains, a transmembrane region and a cytoplasmic tail while the beta chain is of a single extracellular domain. In class II, both the alpha and the beta chains are composed of 2 extracellular domains, a transmembrane region and a cytoplasmic tail. The immunoglobulin (Ig) constant chain domains and a single extracellular domain in each type of MHC chains are homologous and approximately one hundred amino acids long, and include a conserved intra-domain disulfide bond. Members of the immunoglobulin superfamily are found in hundreds of proteins of different functions, e.g., antibodies, the giant muscle kinase titin and receptor tyrosine kinases. Immunoglobulin-like domains may be involved in protein-protein and protein-ligand interactions. (InterPro IPR007110)			Amino Acid Sequence	
C138070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138070>	C81326|C157420	Elevated CA19-9|Elevated CA 19-9|Elevated CA19-9 Antigen|Elevated Cancer Antigen 19-9|Elevated Carbohydrate Antigen 19-9	A laboratory test result indicating the presence of an increased level of the tumor-associated antigen (TAA) CA19-9 in a biological sample.	Elevated CA19-9		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C138071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138071>	C138961	PSA Level Less than 0.1	An indication that a blood concentration of prostate specific antigen below 0.1 ng/mL was detected in a sample.	PSA Level Less than 0.1		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138072>	C177694|C103223	ASS1 Gene Deficiency|ASS1 Low Expression|Argininosuccinate Synthase 1 Gene Deficiency|Argininosuccinate Synthase 1 Low	A genetic finding indicating that low expression of the ASS1 gene has been detected in a sample.	ASS1 Gene Deficiency		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138073>	C81326	Elevated CEA|Elevated Carcinoembryonic Antigen	A laboratory test result indicating the presence of an increased level of the tumor-associated antigen (TAA) CEA in a biological sample.	Elevated CEA		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138074>	C177692	GPNMB Positive|Glycoprotein Nmb Positive|Glycoprotein Nonmetastatic Melanoma Protein B Positive|NMB Positive|Transmembrane Glycoprotein Nmb Positive|gpNMB Positive	An indication that GPNMB expression has been detected in a sample.	GPNMB Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138075>	C390	Sulfur Hexafluoride Lipid Microspheres|Lumason|SF6 Lipid Microspheres|Sulfur Hexafluoride Lipid-type A Microspheres	A contrast agent composed of lipid microspheres containing an inorganic fluorinated inert gas comprised of six fluoride atoms bound to one sulfur atom (SF6), with potential contrast enhancing activity for diagnostic imaging during ultrasound procedures. Upon administration of the sulfur hexafluoride lipid microspheres, the microspheres are distributed throughout the bloodstream and into organs. The acoustic impedance of the lipid microspheres is much lower than that of the surrounding tissue and/or fluids. Therefore during ultrasound imaging, this agent reflects the ultrasound waves at the microsphere-tissue interface, which enhances the contrast between the areas where the microspheres are present and the surrounding tissues or fluids.	Sulfur Hexafluoride Lipid Microspheres		Indicator, Reagent, or Diagnostic Aid	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C138076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138076>	C201666	ATM Inhibitor M 3541|Ataxia Telangiectasia Mutated Kinase Inhibitor M 3541|M 3541|M3541	An orally bioavailable inhibitor of ataxia telangiectasia mutated kinase (ATM), with potential chemo-/radio-sensitizing and antineoplastic activities. Upon oral administration, M 3541 targets and binds to ATM, thereby inhibiting the kinase activity of ATM and ATM-mediated signaling. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, induces tumor cell apoptosis, and leads to cell death of ATM-overexpressing tumor cells. In addition, M 3541 sensitizes tumor cells to chemo- and radiotherapy. ATM, a serine/threonine protein kinase, is upregulated in a variety of cancer cell types; it is activated in response to DNA damage and plays a key role in DNA-strand repair.	ATM Inhibitor M 3541		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C138077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138077>	C25337	Number of Pulmonary Nodules|Pulmonary Nodule Count|Pulmonary Nodule Number	The number of observable tumor nodules in the lungs.			Quantitative Concept	
C138078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138078>	C25681	Size of Persistent and Solid Component of a Sub-Solid Pulmonary Nodule|Size of Persistent and Solid Component of a Subsolid Pulmonary Nodule	The size of the solid component of a solitary part-solid nodules, as observed through CT imaging.			Quantitative Concept	
C138079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138079>	C171087	Candidate	Someone or something considered as suitable or likely for something.			Qualitative Concept	
C13807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13807>	C225418	Intraepithelial|intraepithelial				Spatial Concept	
C138080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138080>	C176245|C175563	Never Have Erection When Want One|I NEVER had an erection when I wanted one	A subjective response indicating that an individual never has or had an erection when they wanted one.			Intellectual Product	The Expanded Prostate Cancer Index Composite Short Form Questionnaire
C138081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138081>	C175563	Have Erection Less Than Half the Time|I had an erection LESS THAN HALF the time I wanted one	A subjective response indicating that an individual has or had an erection less than half the time when they wanted one.			Intellectual Product	The Expanded Prostate Cancer Index Composite Short Form Questionnaire
C138082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138082>	C159207|C133710	RFWD3 Gene|RFWD3|RFWD3|Ring Finger and WD Repeat Domain 3 Gene	This gene is involved in protein ubiquitination and the DNA damage checkpoint in the cell cycle.			Gene or Genome	
C138083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138083>	C175563	Have Erection About Half the Time|I had an erection ABOUT HALF the time I wanted one	A subjective response indicating that an individual has or had an erection about half the time when they wanted one.			Intellectual Product	The Expanded Prostate Cancer Index Composite Short Form Questionnaire
C138084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138084>	C176252	Have Erection More Than Half the Time|I had an erection MORE THAN HALF the time I wanted one				Intellectual Product	The Expanded Prostate Cancer Index Composite Short Form Questionnaire
C138085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138085>	C175563	Have Erection Whenever Want One|I had an erection WHENEVER I wanted one	A subjective response indicating that an individual has or had an erection whenever they wanted one.			Intellectual Product	The Expanded Prostate Cancer Index Composite Short Form Questionnaire
C138086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138086>	C226706	No Pads per Day|0 pad per day|Zero Pads per Day	A subjective response indicating that an individual did not use any absorbent pads per day.			Intellectual Product	The Expanded Prostate Cancer Index Composite Short Form Questionnaire
C138087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138087>	C226706	One Pad per Day|1 pad per day	A subjective response indicating that an individual uses or used one absorbent pad per day.			Intellectual Product	The Expanded Prostate Cancer Index Composite Short Form Questionnaire
C138088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138088>	C226706	Two Pads per Day|2 pads per day	A subjective response indicating that an individual uses or used two absorbent pads per day.			Intellectual Product	The Expanded Prostate Cancer Index Composite Short Form Questionnaire
C138089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138089>	C226706	Three or More Pads per Day|3 or more pads per day	A subjective response indicating that an individual uses or used three or more absorbent pads per day.			Intellectual Product	The Expanded Prostate Cancer Index Composite Short Form Questionnaire
C13808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13808>	C225418	Intrahepatic|INTRAHEPATIC|intrahepatic	Within the liver.			Spatial Concept	CDISC SEND Microscopic Findings Result Modifier Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C138090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138090>	C226650	No Urinary Control|No urinary control whatsoever	A subjective response indicating that an individual has or had no urinary control.			Intellectual Product	The Expanded Prostate Cancer Index Composite Short Form Questionnaire
C138091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138091>	C138082	RFWD3 wt Allele|FANCW|FLJ10520|RNF201|Ring Finger and WD Repeat Domain 3 wt Allele	Human RFWD3 wild-type allele is located in the vicinity of 16q23.1 and is approximately 45 kb in length. This allele, which encodes E3 ubiquitin-protein ligase RFWD3 protein, plays a role in the modulation of the DNA damage checkpoint of the cell cycle. Biallelic mutations in the gene are associated with Fanconi anemia.			Gene or Genome	
C138092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138092>	C226650	Frequent Dribbling|Frequent Urinary Dribbling|Frequent dribbling	A subjective response indicating that an individual frequently dribbles urine.			Intellectual Product	The Expanded Prostate Cancer Index Composite Short Form Questionnaire
C138093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138093>	C21254|C21170	E3 Ubiquitin-Protein Ligase RFWD3|EC 2.3.2.27|RFWD3|RING Finger Protein 201|RING Finger and WD Repeat Domain-Containing Protein 3|RING Finger and WD Repeat Domains-Containing Protein 3|RING-Type E3 Ubiquitin Transferase RFWD3	E3 ubiquitin-protein ligase RFWD3 (774 aa, ~85 kDa) is encoded by the human RFWD3 gene. This protein is involved in the ubiquitination of proteins that regulate the DNA damage checkpoint during the cell cycle.			Amino Acid, Peptide, or Protein|Enzyme	
C138094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138094>	C226650	Occasional Dribbling|Occasional Urinary Dribbling|Occasional dribbling	A subjective response indicating that an individual occasionally dribbles urine.			Intellectual Product	The Expanded Prostate Cancer Index Composite Short Form Questionnaire
C138095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138095>	C226650	Total Urinary Control|Total control	A subjective response indicating that an individual has or had total urinary control.			Intellectual Product	The Expanded Prostate Cancer Index Composite Short Form Questionnaire
C138096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138096>	C28533	RBP4 Gene|RBP4|RBP4|Retinol Binding Protein 4 Gene	This gene plays a role in retinol transport.	RBP4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C138097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138097>	C138096	RBP4 wt Allele|MCOPCB10|PRO2222|RDCCAS|Retinol Binding Protein 4 wt Allele|Retinol Binding Protein 4, Plasma Gene|Retinol-Binding Protein 4, Interstitial Gene|Retinol-Binding Protein 4, Plasma Gene	Human RBP4 wild-type allele is located in the vicinity of 10q23.33 and is approximately 10 kb in length. This allele, which encodes retinol-binding protein 4, is involved in the transport of retinol. Mutation of the gene is associated with both isolated microphthalmia with coloboma and retinal dystrophy, iris coloboma and comedogenic acne syndrome.	RBP4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138098>	C16386	Retinol-Binding Protein 4|PRBP|Plasma Retinol-Binding Protein|RBP4|Retinol Binding Protein 4	Retinol-binding protein 4 (201 aa, ~23 kDa) is encoded by the human RBP4 gene. This protein plays a role in retinol transport.	Retinol-Binding Protein 4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138099>	C63358	FAC Regimen|5-Fluorouracil/Adriamycin/IV Cyclophosphamide|Cyclophosphamide/Doxorubicin/Fluorouracil|FAC|FAC|Fluorouracil-Doxorubicin-IV Cyclophosphamide|Fluorouracil/Doxorubicin/IV Cyclophosphamide|Fluorouracil/Doxorubicin/Intravenous Cyclophosphamide	A regimen consisting of fluorouracil, doxorubicin and intravenous cyclophosphamide, used as a treatment for recurrent and metastatic breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C13809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13809>	C34070	Nuclear Lamina	The nuclear lamina is a proteinaceous filamentous meshwork of lamin proteins interacting with integral proteins of the inner nuclear membrane, including emerin, and is thought to play a role in nuclear stability, chromatin structure, and gene expression. Lamins are highly conserved in evolution and members of the intermediate filament protein family. Mammalian lamins are classified into two major types, A and B, with two subspecies of each: lamins A and C for the A type and B1 and B2 for the B type. Lamins A and C arise from one gene by alternative splicing. Pre-lamin A contains a carboxyl CAAX box that can be modified by farnesylation. During mitosis, the lamina meshwork is reversibly disassembled in parallel with phosphorylation of the lamins.			Cell Component	
C1380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1380>	C593|C213431	Edodekin alfa|Cytotoxic Lymphocyte Maturation Factor|EDODEKIN ALFA|IL-12|IL-12|Interleukin 12|Interleukin-12|NM-IL-12|Natural Killer Cell Stimulatory Factor|Recombinant human interleukin-12 (IL-12) cytokine|Ro 24-7472|interleukin-12	A recombinant form of the endogenous heterodimeric cytokine interleukin-12 with potential antineoplastic activity.  Edodekin alfa binds to and activates its cell-surface receptor, stimulating the production of interferon-gamma (IFN) which, in turn, induces IFN-gamma-inducible protein-10 (IP-10) and so inhibits tumor angiogenesis. (NCI04)	Edodekin alfa		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C138100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138100>	C63358	CEF Regimen|CEF|CEF|Fluorouracil-Epirubicin-Oral Cytoxan Regimen|Fluorouracil/Epirubicin/Oral Cyclophosphamide|Oral CTX/EPI/5-FU|Oral Cyclophosphamide/Epirubicin/Fluorouracil	A regimen consisting of oral cyclophosphamide, epirubicin and fluorouracil, used as a treatment for recurrent and metastatic breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|NCI Drug Dictionary Terminology|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C138101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138101>	C25972	PTPN2 Gene|PTPN2|PTPN2|Protein Tyrosine Phosphatase, Non-Receptor Type 2 Gene	This gene is involved in the dephosphorylation of receptor tyrosine kinases.	PTPN2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|Pediatric Oncology Biomarkers/Targets Associated with Other Relevant Evidence
C138102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138102>	C138101	PTPN2 wt Allele|PTN2|PTPT|Protein Tyrosine Phosphatase, Non-Receptor Type 2 wt Allele|Protein-Tyrosine Phosphatase, T-Cell Gene|TC-PTP|TCELLPTP|TCPTP	Human PTPN2 wild-type allele is located in the vicinity of 18p11.21 and is approximately 144 kb in length. This allele, which encodes tyrosine-protein phosphatase non-receptor type 2 protein, plays a role in the modulation of receptor phosphorylation.	PTPN2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138103>	C106408	Tyrosine-Protein Phosphatase Non-Receptor Type 2|EC 3.1.3.48|PTPN2|T-Cell Protein Tyrosine Phosphatase|T-Cell Protein-Tyrosine Phosphatase|TCPTP	Tyrosine-protein phosphatase non-receptor type 2 (415 aa, ~48 kDa) is encoded by the human PTPN2 gene. This protein is involved in the removal of phosphate groups from receptor tyrosine kinase proteins.	Tyrosine-Protein Phosphatase Non-Receptor Type 2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Biomarkers/Targets Associated with Other Relevant Evidence
C138104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138104>	C25873	NEK2 Gene|NEK2|NEK2|NIMA Related Kinase 2 Gene	This gene plays a role in protein phosphorylation and the cell cycle.	NEK2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C138105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138105>	C138104	NEK2 wt Allele|HsPK21|NEK2A|NIMA (Never In Mitosis Gene A)-Related Kinase 2 Gene|NIMA Related Kinase 2 wt Allele|NLK1|Never In Mitosis Gene A-Related Kinase 2 Gene|PPP1R111|RP67|s Protein Phosphatase 1, Regulatory Subunit 111 Gene	Human NEK2 wild-type allele is located in the vicinity of 1q32.3 and is approximately 17 kb in length. This allele, which encodes serine/threonine-protein kinase Nek2 protein, is involved in both the cell cycle and protein phosphorylation. Mutation of the gene may be associated with retinitis pigmentosa.	NEK2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138106>	C17325	Serine/Threonine-Protein Kinase Nek2|EC 2.7.11.1|HsPK 21|NIMA-Related Kinase 2|Never In Mitosis A-Related Kinase 2|NimA-Like Protein Kinase 1|NimA-Related Protein Kinase 2	Serine/threonine-protein kinase Nek2 (445 aa, ~52 kDa) is encoded by the human NEK2 gene. This protein plays a role in chromosome dynamics during cell division.	Serine/Threonine-Protein Kinase Nek2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138108>	C28533	APOC1 Gene|APOC1|APOC1|Apolipoprotein C1 Gene	This gene is involved in lipid transport and metabolism.			Gene or Genome	
C138109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138109>	C138108	APOC1 wt Allele|Apo-CI|Apo-CIB|ApoC-I|ApoC-IB|Apolipoprotein C1 wt Allele	Human APOC1 wild-type allele is located in the vicinity of 19q13.32 and is approximately 5 kb in length. This allele, which encodes apolipoprotein C-I protein, plays a role in the metabolism and transport of lipids.			Gene or Genome	
C13810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13810>	C13442	Lymphoid|lymphoid				Qualitative Concept	
C138110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138110>	C16386	Apolipoprotein C-I|APOC1|Apo-CI|ApoC-I|Apolipoprotein C1|Apolipoprotein CI	Apolipoprotein C-I (83 aa, ~9 kDa) is encoded by the human APOC1 gene. This protein is involved in the regulation of lipid transport and metabolism.			Amino Acid, Peptide, or Protein	
C138111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138111>	C25993	TRPV4 Gene|TRPV4|TRPV4|Transient Receptor Potential Cation Channel Subfamily V Member 4 Gene	This gene plays a role in the regulation of osmotic pressure.			Gene or Genome	
C138112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138112>	C138111	TRPV4 wt Allele|BCYM3|CMT2C|HMSN2C|OTRPC4|SMAL|SPSMA|SSQTL1|TRP12|Transient Receptor Potential Cation Channel Subfamily V Member 4 wt Allele|Transient Receptor Potential Cation Channel, Subfamily V, Member 4 Gene|Transient Receptor Potential, Drosophila, Homolog of, 12 Gene|VRL2|VROAC	Human TRPV4 wild-type allele is located in the vicinity of 12q24.11 and is approximately 50 kb in length. This allele, which encodes transient receptor potential cation channel subfamily V member 4 protein, is involved in calcium transport and osmotic pressure regulation. Mutation of the gene is associated with various osmotic, skeletal and neuromuscular disorders.			Gene or Genome	
C138113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138113>	C20993	Sexual Health Inventory for Men|SHIM|Sexual Health Inventory for Men (SHIM)	A 5-item questionnaire for screening and diagnosis of erectile dysfunction (ED) and severity of ED in clinical practice and research.			Intellectual Product	
C138114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138114>	C173086	Confidence Can Get and Keep Erection Question|Can Get and Keep Erection Confidence Rating|Confidence Can Get and Keep Erection|How do you rate your confidence that you could get and keep an erection	A question to rate the confidence of an individual with regard to getting and keeping an erection.			Intellectual Product	Sexual Health Inventory for Men
C138115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138115>	C28505	Transient Receptor Potential Cation Channel Subfamily V Member 4|OSM9-Like Transient Receptor Potential Channel 4|Osm-9-Like TRP Channel 4|Osmosensitive Transient Receptor Potential Channel 4|TRPV4|Transient Receptor Potential Channel 12|Transient Receptor Potential Protein 12|Vanilloid Receptor-Like Channel 2|Vanilloid Receptor-Like Protein 2	Transient receptor potential cation channel subfamily V member 4 (871 aa, ~98 kDa) is encoded by the human TRPV4 gene. This protein plays a role in the modulation of calcium transport.			Amino Acid, Peptide, or Protein	
C138116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138116>	C173704|C118873	How Often Erection with Sexual Stimulation Hard Enough for Penetration Question|How Often Erection with Sexual Stimulation Hard Enough for Penetration|When you had erections with sexual stimulation, how often were your erections hard enough for penetration (entering your partner)	A question about how often an individual's erection was hard enough for penetration when the erection was due to sexual stimulation.			Intellectual Product	Sexual Health Inventory for Men
C138117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138117>	C173704|C173045|C118873	How Often Able to Maintain Erection After Penetration During Sexual Intercourse Question|During sexual intercourse, how often were you able to maintain your erection after you had penetrated (entered) your partner|How Often Able to Maintain Erection After Penetration During Sexual Intercourse	A question about how often an individual is or was able to maintain an erection after they penetrated their partner.			Intellectual Product	Sexual Health Inventory for Men
C138118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138118>	C173704|C173562	How Difficult to Maintain Erection to Complete Sexual Intercourse Question|During sexual intercourse, how difficult was it to maintain your erection to completion of intercourse|How Difficult to Maintain Erection to Complete Sexual Intercourse	A question about how difficult it is or was for an individual to maintain their erection to completion of intercourse.			Intellectual Product	Sexual Health Inventory for Men
C138119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138119>	C173792|C173704|C118873	How Often Sexual Intercourse Satisfactory Question|How Often Sexual Intercourse Satisfactory|When you attempted sexual intercourse, how often was it satisfactory for you	A question about how often sexual intercourse is or was satisfactory when attempted by an individual.			Intellectual Product	Sexual Health Inventory for Men
C13811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13811>	C13446	Nucleosome Core Particle|Core Particle|Nucleosome Core|Protein Spool|Spool	Nucleosome core particle consists of the 146 base pair highly protected DNA segment and its bound histone octamer (two of each histones H2A, H2B, H3 and H4). Nucleosome core particle, linker DNA and histone H1 comprise one structural unit of chromatin, nucleosome. (NCI)			Cell Component	
C138120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138120>	C20993	Erectile Dysfunction Severity Breakpoint	Scoring groups for the Sexual Health Inventory for Men: 1-7, Severe erectile dysfunction; 8-11, Moderate erectile dysfunction; 12-16, Mild to Moderate erectile dysfunction; 17-21,  Mild erectile dysfunction.			Intellectual Product	Sexual Health Inventory for Men
C138121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138121>	C23020	SOX11 Transcription Factor Staining Method|SOX11 Staining|SOX11 Staining Method|SRY-Related HMG-Box Gene 11 Staining Method	Any of various immunohistochemical procedures for visualizing and/or quantitating SOX11 transcription factor expression in a sample. Dysregulation of SOX11 is associated with several types of cancer and has diagnostic and prognostic value.			Laboratory Procedure	
C138122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138122>	C133155	DUSP22 Gene Rearrangement|DUSP22 Rearrangement|Dual Specificity Protein Phosphatase 22 Gene Rearrangement|LMW-DSP2 Gene Rearrangement|LMWDSP2 Gene Rearrangement|Low Molecular Weight Dual Specificity Phosphatase 2 Gene Rearrangement	A molecular abnormality indicating rearrangement of the DUSP22 gene.			Cell or Molecular Dysfunction	
C138123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138123>	C20745	MYBPC3 Gene|MYBPC3|MYBPC3|Myosin Binding Protein C, Cardiac Gene	This gene is involved in cardiac muscle cell contraction.			Gene or Genome	
C138124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138124>	C138123	MYBPC3 wt Allele|CMD1MM|CMH4|FHC|LVNC10|MYBP-C|Myosin Binding Protein C, Cardiac wt Allele	Human MYBPC3 wild-type allele is located in the vicinity of 11p11.2 and is approximately 21 kb in length. This allele, which encodes myosin-binding protein C, cardiac-type, plays a role in cardiac muscle cell contraction. Mutation of the gene is associated with hereditary hypertrophic cardiomyopathy.			Gene or Genome	
C138125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138125>	C16492	Myosin-Binding Protein C, Cardiac-Type|C-Protein, Cardiac Muscle Isoform|Cardiac MyBP-C|Cardiac Myosin-Binding Protein C|MYBPC3|Myosin-Binding Protein C, Cardiac|cMyC	Myosin-binding protein C, cardiac-type (1274 aa, ~141 kDa) is encoded by the human MYBPC3 gene. This protein is involved in cardiac muscle cell contraction.			Amino Acid, Peptide, or Protein	
C138126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138126>	C25997	WASF3 Gene|WASF3|WASF3|WASP Family Member 3 Gene	This gene plays a role in signaling and cytoskeletal remodeling.			Gene or Genome	
C138127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138127>	C138126	WASF3 wt Allele|Brush-1|KIAA0900|SCAR, Dictyostelium, Homolog of, 3 Gene|SCAR3|WAS Protein Family Member 3 Gene|WAS Protein Family, Member 3 Gene|WASP Family Member 3 wt Allele|WASP Family Verprolin-Homologous Protein 3 Gene|WASP Family, Member 3 Gene|WASP Family, Verprolin Homology Domain-Containing Protein 3 Gene|WAVE3	Human WASF3 wild-type allele is located in the vicinity of 13q12.13 and is approximately 131 kb in length. This allele, which encodes actin-binding protein WASF3 protein, is involved in cell morphology.			Gene or Genome	
C138128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138128>	C26231	Actin-Binding Protein WASF3|Protein WAVE-3|Verprolin Homology Domain-Containing Protein 3|WASF3|WASP Family Protein Member 3|WASP Family Verprolin-Homologous Protein 3|Wiskott-Aldrich Syndrome Protein Family Member 3	Actin-binding protein WASF3 (502 aa, ~55 kDa) is encoded by the human WASF3 gene. This protein plays a role in the mediation of signaling that regulates cell morphology and cytoskeletal remodeling.			Amino Acid, Peptide, or Protein	
C138129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138129>	C16830	Radiation Source	A device designed to emit radiation, either for external use or implantable.			Medical Device	
C13812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13812>	C13377	Scaffold-Associated Region	Regions of chromosomal DNA attached to structural components of metaphase (condensed) chromosomes, permitting the partitioning of DNA in the chromosomes into looped domains.  Appear to be related to similar regions denoted matrix-attachment regions that partition the chromosomal DNA in interphase chromosomes.			Gene or Genome	
C138130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138130>	C138129	CivaSheet Directional Pd103 Brachytherapy Source|CivaSheet|Low Dose Rate Planar Directional Brachytherapy Source|Permanently Implantable LDR CivaSheet	A proprietary brachytherapy source designed to deliver a radiation dose in a single direction. The device incorporates Palladium-103 as a radiation source and utilizes gold shielding to deliver the radiation dose in a unidirectional, planar manner. CivaSheet is flexible, bioabsorbable and features a polymer-encapsulated radiation source.	CivaSheet Directional Pd103 Brachytherapy Source		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C138131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138131>	C178628|C111116	Magnetic Resonance Whole Body Diffusion-Weighted Imaging|Magnetic Resonance Whole-Body Diffusion-Weighted Imaging|WB DW MRI|WB-DWI|Whole Body Magnetic Resonance Imaging Using Diffusion-Weighted Images|Whole-Body Diffusion-Weighted MRI	A non-ionizing radiation imaging modality for quantitative assessment of disease burden and therapy response. WB-DWI uses the apparent diffusion coefficient (ADC) measurement to detect and quantify disease. ADC is influenced by tissue microarchitecture and may be altered in a disease state.	Magnetic Resonance Whole-Body Diffusion-Weighted Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C138132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138132>	C20993	PROMIS Psychosocial Illness Impact-Positive|PII|PIIP|PROMIS Bank v1.0 - Psychosocial Illness Impact-Pos|PROMIS PIIP|Positive Illness Impact|Psychosocial Illness Impact-Positive	PROMIS question items and instruments designed to assess positive psychosocial (emotional and social) outcomes of illness.			Intellectual Product	
C138133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138133>	C173160	Comfortable with Who I Am Question|Comfortable with Who I Am|I am comfortable with who I am	A question about an individual being comfortable with who they are.			Intellectual Product	PROMIS Psychosocial Illness Impact-Positive
C138134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138134>	C91102	Realize Who True Friends Are Question|I realize who my real friends are|I realize who my true friends are|Realize Who Real Friends Are|Realize Who True Friends Are	A question about an individual realizing who their true friends are.			Intellectual Product	PROMIS Psychosocial Illness Impact-Positive
C138135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138135>	C91102	Can Adjust to Things I Cannot Change Question|Can Adjust to Things I Cannot Change|I can adjust to things I cannot change	A question about an individual's adjustment to things they cannot change.			Intellectual Product	PROMIS Psychosocial Illness Impact-Positive
C138136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138136>	C91102	Life is Meaningful Question|Life is Meaningful|My life is meaningful	A question about an individual's life being meaningful.			Intellectual Product	PROMIS Psychosocial Illness Impact-Positive
C138137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138137>	C91781	How True Before Illness Question|How True Before Illness|How true was this before your illness	A question about how true something was before an individual's illness.			Intellectual Product	PROMIS Psychosocial Illness Impact-Positive
C138138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138138>	C91781	How True Since Illness Question|How True Since Illness|How true is this now, since your illness	A question about how true something is since an individual's illness.			Intellectual Product	PROMIS Psychosocial Illness Impact-Positive
C13813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13813>	C13432	3q21-q24	A chromosome band present on 3q			Gene or Genome	
C138140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138140>	C21295	NCKAP1 Gene|NCK Associated Protein 1 Gene|NCKAP1|NCKAP1	This gene is involved in both lamellipodia formation and endocytosis.			Gene or Genome	
C138141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138141>	C138140	NCKAP1 wt Allele|HEM2|KIAA0587|NAP1|NAP125|NCK Associated Protein 1 wt Allele|Nck-Associated Protein, 125-kD Gene|p125Nap1	Human NCKAP1 wild-type allele is located in the vicinity of 2q32.1 and is approximately 130 kb in length. This allele, which encodes Nck-associated protein 1, plays a role in endocytosis and lamellipodia formation.			Gene or Genome	
C138142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138142>	C17728	Nck-Associated Protein 1|Membrane-Associated Protein HEM-2|NAP 1|NCKAP1|p125Nap1	Nck-associated protein 1 (1128 aa, ~129 kDa) is encoded by the human NCKAP1 gene. This protein is involved in both cell morphology and endocytosis.			Amino Acid, Peptide, or Protein	
C138143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138143>	C122407	Solid Pulmonary Nodule	A pulmonary nodule with well-defined margins and homogenous soft-tissue attenuation on CT scan examination.			Finding	
C138144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138144>	C122407	Subsolid Pulmonary Nodule|SSN|Sub-Solid Lesion|Sub-Solid Pulmonary Nodule	A term that refers to a pure ground-glass pulmonary nodule or a part-solid pulmonary nodule on CT scan examination.			Finding	
C138145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138145>	C21295	CYFIP1 Gene|CYFIP1|CYFIP1|Cytoplasmic FMR1 Interacting Protein 1 Gene	This gene plays a role in both translational repression and actin filament reorganization.			Gene or Genome	
C138146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138146>	C138145	CYFIP1 wt Allele|Cytoplasmic FMR1 Interacting Protein 1 wt Allele|KIAA0068|P140SRA-1|SHYC|SRA-1|SRA1	Human CYFIP1 wild-type allele is located in the vicinity of 15q11.2 and is approximately 114 kb in length. This allele, which encodes cytoplasmic FMR1-interacting protein 1, is involved in the repression of protein translation and the regulation of cytoskeleton remodeling.			Gene or Genome	
C138147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138147>	C17728	Cytoplasmic FMR1-Interacting Protein 1|CYFIP1|Cytoplasmic FMRP Interacting Protein 1|Specifically Rac1-Associated Protein 1|Sra-1|p140sra-1	Cytoplasmic FMR1-interacting protein 1 (1253 aa, ~145 kDa) is encoded by the human CYFIP1 gene. This protein plays a role in the regulation of both cytoskeletal dynamics and translation.			Amino Acid, Peptide, or Protein	
C138148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138148>	C138144	Pure Ground-Glass Pulmonary Nodule|GGN|Non-Solid Ground-Glass Pulmonary Nodule	A term that refers to a pulmonary nodule in which there are no completely obscured parenchymal areas by the ground-glass opacity on CT scan examination.			Finding	
C138149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138149>	C1663	Neoantigen DNA-Based Pancreatic Cancer Vaccine|Neoantigen DNA Pancreatic Cancer Vaccine|Personalized Neoantigen DNA Pancreatic Cancer Vaccine	A personalized, polyepitope DNA vaccine composed of a DNA plasmid encoding multiple, highly immunogenic tumor associated antigens (TAAs) that are specifically expressed by a patient's pancreatic cancer cells, including personalized epitopes of the TAA mesothelin, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration and electroporation of the neoantigen DNA-based pancreatic cancer vaccine, the expressed TAAs induce a specific cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing the neoantigens.	Neoantigen DNA-Based Pancreatic Cancer Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C13814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13814>	C13432	1p22-p21	A chromosome band present on 1p			Gene or Genome	
C138151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138151>	C28533	APOL1 Gene|APOL1|APOL1|Apolipoprotein L1 Gene	This gene is involved in the transport of cholesterol and other lipids.			Gene or Genome	
C138152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138152>	C138151	APOL1 wt Allele|APO-L|APOL|APOL-I|Apolipoprotein L1 wt Allele|FSGS4	Human APOL1 wild-type allele is located in the vicinity of 22q12.3 and is approximately 15 kb in length. This allele, which encodes apolipoprotein L1 protein, plays a role in the metabolism of cholesterol and other lipids. Variation of the gene is associated increased susceptibility to both focal segmental glomerulosclerosis 4 and non-diabetic end-stage renal disease.			Gene or Genome	
C138153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138153>	C16386	Apolipoprotein L1|APOL1|Apo-L|ApoL|ApoL-I|Apolipoprotein L|Apolipoprotein L 1|Apolipoprotein L-I	Apolipoprotein L1 (398 aa, ~44 kDa) is encoded by the human APOL1 gene. This protein is involved in lipid transport and metabolism.			Amino Acid, Peptide, or Protein	
C138154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138154>	C20923	APLNR Gene|APLNR|APLNR|Apelin Receptor Gene	This gene plays a role in peptide hormone-dependent G protein-coupled receptor signaling.			Gene or Genome	
C138155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138155>	C35682	TRK Receptor Family Alteration Positive|NTRK Alteration|NTRK Alteration Positive|TRK Alteration|TRK Alteration Positive|TRK Receptor Alteration|TRK Receptor Family Alteration	Indicates that mutation, overexpression, or rearrangement of an TRK receptor family member has been detected in a sample.	TRK Receptor Family Alteration Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138156>	C158948|C138155	TRK Receptor Family Fusion Positive|NTRK Family Fusion Positive|NTRK Fusion|NTRK Fusion Positive|TRK Fusion|TRK Receptor Family Fusion|TRK Receptor Fusion	Indicates that the expression of a fusion involving a TRK receptor family member has been detected in a sample.	TRK Receptor Family Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138157>	C138154	APLNR wt Allele|AGTRL1|APJ|APJ (Apelin) Receptor Gene|APJ Putative Receptor Protein Related to Angiotensin Receptor Gene|APJR|Apelin Receptor wt Allele|FLJ90771|HG11	Human APLNR wild-type allele is located in the vicinity of 11q12.1 and is approximately 4 kb in length. This allele, which encodes apelin receptor protein, is involved in the mediation of peptide hormone signaling.			Gene or Genome	
C138158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138158>	C165233|C158949	TRK Receptor Family Fusion Negative|NTRK Family Fusion Negative|NTRK Fusion Negative|Non-fusion NTRK|Non-fusion TRK|TRK Non-fusion|TRK Receptor Family Non-fusion|TRK Receptor Non-fusion	Indicates that the expression of a fusion involving a TRK receptor family member has not been detected in a sample.	TRK Receptor Family Fusion Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138159>	C18239	Apelin Receptor|APJ Receptor|APLNR|Angiotensin II Receptor-Like 1|Angiotensin Receptor-Like 1|G Protein-Coupled Receptor APJ|G-Protein Coupled Receptor APJ|G-Protein Coupled Receptor HG11|HG11 Orphan Receptor	Apelin receptor (380 aa, ~43 kDa) is encoded by the human APLNR gene. This protein plays a role in G protein-coupled receptor signaling.			Receptor	
C13815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13815>	C13432	8p21-p12	A chromosome band present on 8p			Gene or Genome	
C138160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138160>	C155765	Selitrectinib|(13E,14E,22R,6R)-35-fluoro-6-methyl-7-aza-1(5,3)-pyrazolo[1,5-a]pyrimidina-3(3,2)-pyridina-2(1,2)-pyrrolidinacyclooctaphan-8-one|BAY 2731954|LOXO 195|LOXO-195|LOXO195|SELITRECTINIB	An orally bioavailable, selective tropomyosin-related-kinase (tyrosine receptor kinase; TRK) inhibitor, with potential antineoplastic activity. Upon oral administration, selitrectinib specifically targets and binds to TRK, including the fusion proteins containing sequences from neurotrophic tyrosine receptor kinase (NTRK) types 1 (NTRK1), 2 (NTRK2), and 3 (NTRK3).  This prevents neurotrophin-TRK interaction and TRK activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress TRK and/or express NTRK fusion proteins. LOXO-195 targets specific point mutations that occur after treatment with and result in acquired resistance to another TRK inhibitor; therefore, LOXO-195 is able to overcome acquired resistance to other TRK inhibitors. TRK, a family of receptor tyrosine kinases (RTKs) activated by neurotrophins, is encoded by NTRK family genes. The expression of either mutated forms of or fusion proteins involving NTRK family members results in uncontrolled TRK signaling and plays an important role in tumor cell growth and survival.	Selitrectinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C138161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138161>	C42607	Therapy-Related Toxicity - Acceptable to Patient|Adverse Event is Acceptable to Patient|Therapy-Related Toxicity is Acceptable to Patient	Indicates that a toxicity adverse effect has been experienced by a patient, but it is not severe enough for the patient to discontinue the treatment.			Finding	
C138162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138162>	C199267	Therapy-Related Toxicity - Unacceptable to Patient|Adverse Event is Unacceptable to Patient|Therapy-Related Toxicity is Unacceptable to Patient	Indicates that a toxicity adverse effect has been experienced by a patient, and it is severe enough for the patient to discontinue the treatment.			Finding	
C138163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138163>	C42607	Endocrine Therapy Toxicity|Endocrine Toxicity|Hormonal Therapy Toxicity|Hormonal Treatment Toxicity|Hormone Therapy Toxicity	Indicates that a toxicity adverse effect has been experienced during endocrine drug treatment.			Finding	HL Adverse Events Table|HL Authorized Value Terminology|HL Protocol Treatment Modifications Table
C138164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138164>	C213665|C129825	BTK Inhibitor CT-1530|CT 1530|CT-1530|CT1530	An inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), with potential antineoplastic activity. Upon administration, CT-1530 binds to and inhibits the activity of BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C138165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138165>	C192742|C192741	Lerociclib|7',8'-Dihydro-2'-((5-(4-(1-methylethyl)-1-piperazinyl)-2-pyridinyl)amino)spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one|CDK4/6 Inhibitor G1T38|G1T38|G1T38 Free Base|GB 491|GB-491|GB491|LEROCICLIB	An orally bioavailable inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon administration, lerociclib selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation.	Lerociclib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C138166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138166>	C2959	Visceral Crisis	Severe organ dysfunction as assessed by signs, symptoms and laboratory studies, resulting from rapid progression of neoplastic disease. It is indicative of substantial visceral compromise and may serve as an indication for more aggressive therapeutic intervention.			Finding	
C138167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138167>	C4863	Prostate Carcinoma by Gene Expression Profile|Prostate Cancer by Gene Expression Profile	A header term that includes the following prostate carcinoma subtypes determined by gene expression profiling: luminal A prostate carcinoma, luminal B prostate carcinoma, and basal-like prostate carcinoma.			Neoplastic Process	
C138168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138168>	C138167	Luminal A Prostate Carcinoma|Luminal A Prostate Cancer	Prostate carcinoma associated with increased androgen receptor expression and signaling (androgen activity pathway), increased luminal markers, and a lower proliferation score than the luminal B and basal-like prostate carcinomas.			Neoplastic Process	
C138169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138169>	C138167	Luminal B Prostate Carcinoma|Luminal B Prostate Cancer	Prostate carcinoma associated with increased androgen receptor expression and signaling (androgen activity pathway), increased luminal markers, and a higher proliferation score than the luminal A prostate carcinoma. Patients with luminal B prostate carcinoma have the poorest prognosis but respond better to postoperative androgen deprivation therapy compared to patients with non-luminal B prostate carcinoma.			Neoplastic Process	
C13816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13816>	C13432	13q14	A chromosome band present on 13q	13q14		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138170>	C138167	Basal-Like Prostate Carcinoma|Basal-Like Prostate Cancer	Prostate carcinoma in which the CD49f signature is increased, the luminal markers and androgen receptor expression and signaling (androgen activity pathway) are not increased, and the proliferation score is higher than the luminal A prostate carcinoma.			Neoplastic Process	
C138171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138171>	C81315	Hyperphenylalaninemia, BH4-deficient A|6-pyruvoyl Tetrahydropterin Synthase Deficiency|HPABH4A	An autosomal recessive condition caused by mutation(s) in the PTS gene, encoding 6-pyruvoyl tetrahydrobiopterin synthase. It is characterized by BH4-defecient hyperphenylalanemia, depletion of dopamine and serotonin, and progressive cognitive and motor deficits.			Disease or Syndrome	Cellosaurus Disease Terminology
C138173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138173>	C81315	Hyperphenylalaninemia, BH4-deficient C|Dihydropteridine Reductase Deficiency|HPABH4C	An autosomal recessive condition caused by mutation(s) in the QDPR gene, encoding dihydropteridine reductase. It is characterized by BH4-defecient hyperphenylalanemia, depletion of dopamine and serotonin, and progressive cognitive and motor deficits.			Disease or Syndrome	Cellosaurus Disease Terminology
C138174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138174>	C28193	Vici Syndrome|VICIS	An autosomal recessive condition caused by mutation(s) in the EPG5 gene, encoding ectopic P granules protein 5 homolog. It is characterized by variable immunodeficiency, cleft lip/palate, cataracts, hypopigmentation, and absent corpus callosum.			Disease or Syndrome	Cellosaurus Disease Terminology
C138175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138175>	C3420|C150478	t(2;5)	A cytogenetic abnormality that involves a translocation between chromosomes 2 and 5.			Cell or Molecular Dysfunction	
C138176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138176>	C3420	t(11;18)	A cytogenetic abnormality that involves a translocation between chromosomes 11 and 18.			Cell or Molecular Dysfunction	
C138177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138177>	C17562	Epstein-Barr Encoding Region in situ Hybridization|EBER in situ Hybridization|Epstein-Barr Virus Encoding Region in situ Hybridization	Any of various in situ hybridization methods for the detection of latent Epstein-Barr virus (EBV) in tissue sections or other samples. The two small noncoding RNAs, Epstein-Barr encoding region (EBER)-1 and EBER-2, are ubiquitously expressed in all known EBV latency states.			Molecular Biology Research Technique	
C138178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138178>	C81182	Ruler|Rule	A device used for measuring, or for drawing straight lines, consisting of an elongated piece of rigid or semi-rigid material marked with units of measurement.			Manufactured Object	
C138179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138179>	C28193	Acute Chest Syndrome|ACS	A vaso-occlusive crisis of the pulmonary vasculature occurring in patients with sickle cell disease. It is characterized by the presence of a new radiodensity on a chest radiograph accompanied by fever, cough, sputum production, dyspnea, or hypoxia.			Disease or Syndrome	
C13817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13817>	C13432	11p15.1-p14	A chromosome band present on 11p			Gene or Genome	
C138180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138180>	C213868	T-cell Receptor-engineered T-cells|T-cell Receptor-engineered T Cells|T-cell Receptor-engineered T-lymphocytes|TCR T Cells|TCR T-cells|TCR-engineered T-cells|TCR-modified T Cells	T-lymphocytes that have been engineered to express a modified antigen-specific T-cell receptor (TCR). In cancer therapy, the TCR-engineered T-cell recognizes a tumor-specific protein fragment complexed with major histocompatibility complex (MHC) molecules on the surface of the tumor cells and kills the tumor cell.	T-cell Receptor-engineered T-cells		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C138181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138181>	C7182	In Situ Follicular Neoplasia|FLIS|Follicular Lymphoma In Situ|ISFN|In Situ Follicular B-Cell Neoplasm|In Situ Follicular Lymphoma	A follicular neoplasia confined to the germinal centers of the lymph nodes, without evidence of disseminated disease. It is characterized by the replacement of a germinal center by neoplastic centrocytes with uniformly intense positivity for BCL2. The surrounding mantle cuff and lymphoid architecture are intact. It has a low rate of progression to follicular lymphoma, but is often associated with prior or synchronous overt lymphoma.			Neoplastic Process	Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C138182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138182>	C200211	Neoplastic Plasma Cells 30 Percent or Less of Bone Marrow Nucleated Cells|Neoplastic Plasma Cells Less than or Equal to 30 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that 30 percent or less of the nucleated cells in a bone marrow sample are neoplastic plasma cells.	Neoplastic Plasma Cells 30 Percent or Less of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C138183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138183>	C157130	Recurrent Abdominal Neuroendocrine Neoplasm|Recurrent Abdominal Neuroendocrine Tumor|Recurrent Abdominal Neuroendocrine Tumor|Relapsed Abdominal Neuroendocrine Tumor	The reemergence of an abdominal neuroendocrine neoplasm after a period of remission.	Recurrent Abdominal Neuroendocrine Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C138184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138184>	C157131	Refractory Abdominal Neuroendocrine Neoplasm|Refractory Abdominal Neuroendocrine Tumor	An abdominal neuroendocrine neoplasm that does not respond to treatment.	Refractory Abdominal Neuroendocrine Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C138185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138185>	C213744	Duodenal-Type Follicular Lymphoma	A localized low-grade follicular lymphoma within the gastrointestinal tract, which is distinct from other gastrointestinal tract follicular lymphomas.  It has features that overlap with in situ follicular neoplasia as well as some features resembling an extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue. The prognosis is excellent.	Duodenal-Type Follicular Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C138186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138186>	C7264	Predominantly Diffuse Follicular Lymphoma with 1p36 Deletion	A predominantly diffuse, low-grade follicular lymphoma. It often presents as a large localized inguinal mass, lacks BCL2 rearrangement, and is associated with 1p36 deletion.			Neoplastic Process	
C138187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138187>	C15431	Haploidentical Hematopoietic Cell Transplantation|HLA-Haploidentical Hematopoietic Cell Transplantation|Haploidentical Stem Cell Transplantation|Stem Cell Transplantation, Haploidentical	A clinical treatment in which hematopoietic stem cells are transferred from a HLA half-matched donor to a recipient.	Haploidentical Hematopoietic Cell Transplantation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C138188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138188>	C143048	Clinical Trials Search-Application Programming Interface Disease Category Terminology|CTS-API Disease Category Terminology	Terminology subsets used for the purpose of supporting the CTS-API.			Intellectual Product	National Cancer Institute Terminology
C138189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138189>	C138188	CTS-API Disease Broad Category Terminology	Terminology subset used for the purpose of supporting the CTS-API disease broad category terminology.			Intellectual Product	
C13818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13818>	C13432	14q24.1	A chromosome band present on 14q			Gene or Genome	
C138190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138190>	C138188	CTS-API Disease Main Type Terminology	Terminology subset used for the purpose of supporting the CTS-API disease main type terminology.			Intellectual Product	
C138191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138191>	C7182	In Situ Mantle Cell Neoplasia|ISMCN|In Situ Mantle Cell Lymphoma|In Situ Mantle Cell Neoplasm	A neoplastic lymphoid process characterized by the presence of cyclin D1 positive lymphoid cells, typically in the inner mantle zones of lymphoid tissue follicles, in cases that do not suggest the diagnosis of a mantle cell lymphoma. It is often found incidentally and has a low rate of progression.			Neoplastic Process	Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C138192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138192>	C8594	Leukemic Nonnodal Mantle Cell Lymphoma	Mantle cell lymphoma involving the peripheral blood, bone marrow, and often spleen. It usually has an indolent clinical course.			Neoplastic Process	
C138193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138193>	C177696	PDGFRA Gene Mutation Negative|CD140A Gene Mutation Negative|No mutation detected|PDGFR-2 Gene Mutation Negative|PDGFR2 Gene Mutation Negative|PDGFRA Mutation Negative|PDGFRA Wild Type|PDGFRA Wildtype|PDGFRA wt|PDGFRalpha Gene Mutation Negative|Platelet-Derived Growth Factor Receptor Alpha Gene Mutation Negative|RHEPDGFRA Gene Mutation Negative|Wild-type PDGFRA	A genetic finding indicating that PDGFRA gene mutations have not been detected in a sample.	PDGFRA Gene Mutation Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138194>	C177696	KIT Gene Mutation Negative|CD117 Gene Mutation Negative|KIT Mutation Negative|KIT Proto-Oncogene Tyrosine Protein Kinase Gene Mutation Negative|KIT Wild Type|KIT Wildtype|KIT wt|No mutation detected|Wild-type KIT|c-KIT Gene Mutation Negative|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Gene Mutation Negative	A genetic finding indicating that KIT gene mutations have not been detected in a sample.	KIT Gene Mutation Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138195>	C138211	High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements|HGBL with MYC and BCL2 and/or BCL6 Rearrangements|High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements	High-grade B-cell lymphoma characterized by the abnormal rearrangement of MYC gene, BCL2 gene, and/or BCL6 gene. Patients with this type of lymphoma usually respond poorly to standard treatments and have a poor prognosis.	High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C138196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138196>	C226693	Barely Any|Barely any|Hardly Any	A response indicating a very small amount.			Intellectual Product	
C138197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138197>	C175341	Assistance with Registering|Registering with the application|Registering with the application the first time	A response indicating that an individual required assistance with registering.			Intellectual Product	
C138198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138198>	C175341	Assistance Reading Questions|Reading Questions	A response indicating that an individual required assistance reading questions.			Intellectual Product	
C138199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138199>	C175341	Assistance Entering Answers|Entering Answers	A response indicating that an individual required assistance entering answers.			Intellectual Product	
C13819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13819>	C33533	Somatosensory Receptor	Nerve endings encased in connective tissue capsules with myelinated or unmyelinated axons.			Body Part, Organ, or Organ Component	
C1381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1381>	C2843	Irinotecan Hydrochloride|CPT 11|CPT 11|CPT-11|CPT11|Campto|Camptosar|Camptosar|Camptosar|Camptothecin 11|Camptothecin-11|IRINOTECAN HYDROCHLORIDE|Irinomedac|Irinotecan Hydrochloride Trihydrate|Irinotecan Monohydrochloride Trihydrate|U 101440E|U-101440E|U101440E|irinotecan hydrochloride	The hydrochloride salt of a semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.  Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme.  One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death.  Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.	Irinotecan Hydrochloride		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C138200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138200>	C175341	Assistance Submitting Questionnaire|Submitting Questionnaires	A response indicating that an individual required assistance submitting a questionnaire.			Intellectual Product	
C138201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138201>	C175341	Assistance with Password|Password Assistance				Intellectual Product	
C138202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138202>	C226739	Used Personal Smartphone|My personal smartphone	A response indicating that an individual used their personal smartphone.			Intellectual Product	
C138203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138203>	C226739	Used Personal Tablet|My personal tablet	A response indicating that an individual used their personal tablet.			Intellectual Product	
C138204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138204>	C226739	Used Clinic's Tablet|A health care clinic tablet	A response indicating that an individual used a tablet belonging to a healthcare clinic.			Intellectual Product	
C138205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138205>	C226739	Used Family or Friend's Smartphone|My family or friend's smartphone	A response indicating that an individual used the smartphone belonging to a friend or family member.			Intellectual Product	
C138206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138206>	C217121	Boston Bowel Preparation Scale|BBPS	A tool for reporting the quality of bowel preparation that was developed to limit inter-observer variability, while preserving the ability to distinguish various degrees of bowel cleanliness. The the three broad regions of the colon: the right colon, the transverse colon, and the left colon are rated 0-3 and these segment scores are summed for a total BBPS score ranging from 0 to 9.			Intellectual Product	
C138207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138207>	C221051	Boston Bowel Preparation Segment Score 0|Segment Score 0	Unprepared colon segment with mucosa not seen due to solid stool that cannot be cleared.			Intellectual Product	Boston Bowel Preparation Scale
C138208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138208>	C221051	Boston Bowel Preparation Segment Score 1|Segment Score 1	Portion of mucosa of the colon segment seen, but other areas of the colon segment not well seen due to staining, residual stool and/or opaque liquid.			Intellectual Product	Boston Bowel Preparation Scale
C138209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138209>	C221051	Boston Bowel Preparation Segment Score 2|Segment Score 2	Minor amount of residual staining, small fragments of stool and/or opaque liquid, but mucosa of colon segment seen well.			Intellectual Product	Boston Bowel Preparation Scale
C13820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13820>	C13432	2q33.1	A chromosome band present on 2q			Gene or Genome	
C138210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138210>	C221051	Boston Bowel Preparation Segment Score 3|Segment Score 3	Entire mucosa of colon segment seen well with no residual staining, small fragments of stool or opaque liquid.			Intellectual Product	Boston Bowel Preparation Scale
C138211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138211>	C8851	High Grade B-Cell Lymphoma|HGBL|High-Grade B-Cell Lymphoma	A term that refers to high-grade B-cell lymphoma, not otherwise specified or high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.			Neoplastic Process	
C138212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138212>	C118970	CDISC Clinical Classification HAS-BLED Test Name Terminology|CC-HAS-BLED TEST|HAS-BLED Bleeding Risk Score Clinical Classification Test Name|HSB01TN	Test names of clinical classification questions associated with the HAS-BLED Bleeding Risk Score (HAS-BLED) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138213>	C118970	CDISC Clinical Classification HAS-BLED Test Code Terminology|CC-HAS-BLED TESTCD|HAS-BLED Bleeding Risk Score Clinical Classification Test Code|HSB01TC	Test codes of clinical classification questions associated with the HAS-BLED Bleeding Risk Score (HAS-BLED) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138214>	C118970	CDISC Clinical Classification LPSS Test Name Terminology|CC-LPSS TEST|LPPSS1TN|Lansky Play-Performance Status Scale Clinical Classification Test Name	Test names of clinical classification questions associated with the Lansky Play-Performance Status Scale (LPSS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138215>	C118970	CDISC Clinical Classification LPSS Test Code Terminology|CC-LPSS TESTCD|LPPSS1TC|Lansky Play-Performance Status Scale Clinical Classification Test Code	Test codes of clinical classification questions associated with the Lansky Play-Performance Status Scale (LPSS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138216>	C115302	CDISC Functional Test PUL 1.2 Test Name Terminology|FT-PUL 1.2 TEST|PUL01TN|Performance of the Upper Limb Module for DMD Version 1.2 Functional Test Test Name	Test names of functional test questions associated with the Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138217>	C115302	CDISC Functional Test PUL 1.2 Test Code Terminology|FT-PUL 1.2 TESTCD|PUL01TC|Performance of the Upper Limb Module for DMD Version 1.2 Functional Test Test Code	Test codes of functional test questions associated with the Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138218>	C115302	CDISC Functional Test PUL 2.0 Test Name Terminology|FT-PUL 2.0 TEST|PUL02TN|Performance of the Upper Limb Module for DMD Version 2.0 Functional Test Test Name	Test names of functional test questions associated with the Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138219>	C115302	CDISC Functional Test PUL 2.0 Test Code Terminology|FT-PUL 2.0 TESTCD|PUL02TC|Performance of the Upper Limb Module for DMD Version 2.0 Functional Test Test Code	Test codes of functional test questions associated with the Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13821>	C13819	Mechanoreceptor|Mechanoreceptors	A type of somatosensory receptor that detects the mechanical displacement of nerve endings and mediates touch, pressure, vibration, proprioception, and kinesthesia.			Body Part, Organ, or Organ Component	
C138220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138220>	C100110	CDISC Questionnaire FBRSI Test Name Terminology|FAC029TN|Functional Assessment of Cancer Therapy-Brain Symptom Index Questionnaire Test Name|QS-FBRSI TEST	Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138221>	C100110	CDISC Questionnaire FBRSI Test Code Terminology|FAC029TC|Functional Assessment of Cancer Therapy-Brain Symptom Index Questionnaire Test Code|QS-FBRSI TESTCD	Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138222>	C100110	CDISC Questionnaire FKSI-15 Test Name Terminology|FAC039TN|Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 Questionnaire Test Name|QS-FKSI-15 TEST	Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138223>	C100110	CDISC Questionnaire FKSI-15 Test Code Terminology|FAC039TC|Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 Questionnaire Test Code|QS-FKSI-15 TESTCD	Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138224>	C100110	CDISC Questionnaire FLSI Test Name Terminology|FAC043TN|Functional Assessment of Cancer Therapy-Lung Symptom Index Questionnaire Test Name|QS-FLSI TEST	Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Lung Symptom Index (FLSI) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138225>	C100110	CDISC Questionnaire FLSI Test Code Terminology|FAC043TC|Functional Assessment of Cancer Therapy-Lung Symptom Index Questionnaire Test Code|QS-FLSI TESTCD	Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Lung Symptom Index (FLSI) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138226>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Name Terminology|PQL14TN|Pediatric Quality of Life Neuromuscular Module Acute Version 3 Child Questionnaire Test Name|QS-PedsQL Neuromuscular Module Acute Version 3.0 Child Report TEST	Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138227>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Code Terminology|PQL14TC|Pediatric Quality of Life Neuromuscular Module Acute Version 3 Child Questionnaire Test Code|QS-PedsQL Neuromuscular Module Acute Version 3.0 Child Report TESTCD	Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138228>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Name Terminology|PQL18TN|Pediatric Quality of Life Neuromuscular Module Acute Version 3 Toddler Parent Report Questionnaire Test Name|QS-PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler TEST	Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138229>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Code Terminology|PQL18TC|Pediatric Quality of Life Neuromuscular Module Acute Version 3 Toddler Parent Report Questionnaire Test Code|QS-PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler TESTCD	Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13822>	C13819	Thermoreceptor|Thermoreceptors	A type of somatosensory receptor located mostly in the skin that detects changes in temperature; there are two classes of thermoreceptors: cold receptors and warm receptors.			Body Part, Organ, or Organ Component	
C138230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138230>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Name Terminology|PQL15TN|Pediatric Quality of Life Neuromuscular Module Acute Version 3 Child Parent Report Questionnaire Test Name|QS-PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child TEST	Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138231>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Code Terminology|PQL15TC|Pediatric Quality of Life Neuromuscular Module Acute Version 3 Child Parent Report Questionnaire Test Code|QS-PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child TESTCD	Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138232>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Name Terminology|PQL13TN|Pediatric Quality of Life Neuromuscular Module Acute Version 3 Teen Parent Report Questionnaire Test Name|QS-PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen TEST	Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138233>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Code Terminology|PQL13TC|Pediatric Quality of Life Neuromuscular Module Acute Version 3 Teen Parent Report Questionnaire Test Code|QS-PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen TESTCD	Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138234>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Name Terminology|PQL11TN|Pediatric Quality of Life Neuromuscular Module Acute Version 3 Young Adult Parent Report Questionnaire Test Name|QS-PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults TEST	Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138235>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Code Terminology|PQL11TC|Pediatric Quality of Life Neuromuscular Module Acute Version 3 Young Adult Parent Report Questionnaire Test Code|QS-PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults TESTCD	Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138236>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Name Terminology|PQL17TN|Pediatric Quality of Life Neuromuscular Module Acute Version 3 Young Child Parent Report Questionnaire Test Name|QS-PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child TEST	Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138237>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Code Terminology|PQL17TC|Pediatric Quality of Life Neuromuscular Module Acute Version 3 Young Child Parent Report Questionnaire Test Code|QS-PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child TESTCD	Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138238>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Name Terminology|PQL12TN|Pediatric Quality of Life Neuromuscular Module Acute Version 3 Teen Questionnaire Test Name|QS-PedsQL Neuromuscular Module Acute Version 3.0 Teen Report TEST	Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138239>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Code Terminology|PQL12TC|Pediatric Quality of Life Neuromuscular Module Acute Version 3 Teen Questionnaire Test Code|QS-PedsQL Neuromuscular Module Acute Version 3.0 Teen Report TESTCD	Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13823>	C13819	Proprioceptor|Proprioceptive Sensory Neuron	A primary sensory neuron that acts as a receptor of the somatic afferent component of the nervous system. It is stimulated by the contraction of muscles, movements of joints, and changes in body position.			Body Part, Organ, or Organ Component	
C138240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138240>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Name Terminology|PQL10TN|Pediatric Quality of Life Neuromuscular Module Acute Version 3 Young Adult Questionnaire Test Name|QS-PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report TEST	Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138241>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Code Terminology|PQL10TC|Pediatric Quality of Life Neuromuscular Module Acute Version 3 Young Adult Questionnaire Test Code|QS-PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report TESTCD	Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138242>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Name Terminology|PQL16TN|Pediatric Quality of Life Neuromuscular Module Acute Version 3 Young Child Questionnaire Test Name|QS-PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report TEST	Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138243>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Code Terminology|PQL16TC|Pediatric Quality of Life Neuromuscular Module Acute Version 3 Young Child Questionnaire Test Code|QS-PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report TESTCD	Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138244>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Name Terminology|PQL05TN|Pediatric Quality of Life Neuromuscular Module Version 3 Child Questionnaire Test Name|QS-PedsQL Neuromuscular Module Version 3.0 Child Report TEST	Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138245>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Code Terminology|PQL05TC|Pediatric Quality of Life Neuromuscular Module Version 3 Child Questionnaire Test Code|QS-PedsQL Neuromuscular Module Version 3.0 Child Report TESTCD	Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138246>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Name Terminology|PQL09TN|Pediatric Quality of Life Neuromuscular Module Version 3 Toddler Parent Report Questionnaire Test Name|QS-PedsQL Neuromuscular Module Version 3.0 Parent of Toddler TEST	Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138247>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Code Terminology|PQL09TC|Pediatric Quality of Life Neuromuscular Module Version 3 Toddler Parent Report Questionnaire Test Code|QS-PedsQL Neuromuscular Module Version 3.0 Parent of Toddler TESTCD	Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138248>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Name Terminology|PQL06TN|Pediatric Quality of Life Neuromuscular Module Version 3 Child Parent Report Questionnaire Test Name|QS-PedsQL Neuromuscular Module Version 3.0 Parent Report for Child TEST	Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138249>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Code Terminology|PQL06TC|Pediatric Quality of Life Neuromuscular Module Version 3 Child Parent Report Questionnaire Test Code|QS-PedsQL Neuromuscular Module Version 3.0 Parent Report for Child TESTCD	Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13824>	C25769	Muscle Spindle|Muscle Spindles	The Muscle Spindle is composed of intrafusal fibers that are located within and run parallel to the extrafusal fibers of skeletal muscle. When the extrafusal fibers are stretched, the intrafusal fibers of the spindle stretch as well. When stretching occurs, the sensory neuron from the muscle spindle signals the motor neurons located within the ventral horn of the spinal cord. This signal causes the motor neurons to fire, resulting in contraction of the muscle. This reflex arc provides negative feedback. The muscular contraction induced by the stretching works against or negates further muscle stretch. This mechanism helps to maintain proper muscle tension or tone. Although the muscle spindle helps to maintain proper muscle tension, unlike the Golgi tendon organ, it is not an indicator of muscle tension, but rather of muscle length.			Body Part, Organ, or Organ Component	
C138250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138250>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Name Terminology|PQL04TN|Pediatric Quality of Life Neuromuscular Module Version 3 Teen Parent Report Questionnaire Test Name|QS-PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen TEST	Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138251>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Code Terminology|PQL04TC|Pediatric Quality of Life Neuromuscular Module Version 3 Teen Parent Report Questionnaire Test Code|QS-PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen TESTCD	Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138252>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Name Terminology|PQL02TN|Pediatric Quality of Life Neuromuscular Module Version 3 Young Adult Parent Report Questionnaire Test Name|QS-PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report TEST	Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138253>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Code Terminology|PQL02TC|Pediatric Quality of Life Neuromuscular Module Version 3 Young Adult Parent Report Questionnaire Test Code|QS-PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report TESTCD	Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138254>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Name Terminology|PQL08TN|Pediatric Quality of Life Neuromuscular Module Version 3 Young Child Parent Report Questionnaire Test Name|QS-PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child TEST	Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138255>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Code Terminology|PQL08TC|Pediatric Quality of Life Neuromuscular Module Version 3 Young Child Parent Report Questionnaire Test Code|QS-PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child TESTCD	Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138256>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Name Terminology|PQL03TN|Pediatric Quality of Life Neuromuscular Module Version 3 Teen Questionnaire Test Name|QS-PedsQL Neuromuscular Module Version 3.0 Teen Report TEST	Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138257>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Code Terminology|PQL03TC|Pediatric Quality of Life Neuromuscular Module Version 3 Teen Questionnaire Test Code|QS-PedsQL Neuromuscular Module Version 3.0 Teen Report TESTCD	Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138258>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Name Terminology|PQL01TN|Pediatric Quality of Life Neuromuscular Module Version 3 Young Adult Questionnaire Test Name|QS-PedsQL Neuromuscular Module Version 3.0 Young Adult Report TEST	Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138259>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Code Terminology|PQL01TC|Pediatric Quality of Life Neuromuscular Module Version 3 Young Adult Questionnaire Test Code|QS-PedsQL Neuromuscular Module Version 3.0 Young Adult Report TESTCD	Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13825>	C13432	16p12	A chromosome band present on 16p			Gene or Genome	
C138260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138260>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Name Terminology|PQL07TN|Pediatric Quality of Life Neuromuscular Module Version 3 Young Child Questionnaire Test Name|QS-PedsQL Neuromuscular Module Version 3.0 Young Child Report TEST	Test names of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138261>	C100110	CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Code Terminology|PQL07TC|Pediatric Quality of Life Neuromuscular Module Version 3 Young Child Questionnaire Test Code|QS-PedsQL Neuromuscular Module Version 3.0 Young Child Report TESTCD	Test codes of questionnaire questions associated with the Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138262>	C211913	HAS-BLED Clinical Classification Question	A question associated with the HAS-BLED clinical classification.			Intellectual Product	
C138263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138263>	C211913	LPSS Clinical Classification Question	A question associated with the LPSS clinical classification.			Intellectual Product	
C138264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138264>	C211913	PUL 1.2 Functional Test Question	A question associated with the PUL 1.2 functional test.			Intellectual Product	
C138265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138265>	C211913	PUL 2.0 Functional Test Question	A question associated with the PUL 2.0 functional test.			Intellectual Product	
C138266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138266>	C211913	FBRSI Questionnaire Question	A question associated with the FBRSI questionnaire.			Intellectual Product	
C138267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138267>	C211913	FKSI-15 Questionnaire Question	A question associated with the FKSI-15 questionnaire.			Intellectual Product	
C138268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138268>	C211913	FLSI Questionnaire Question	A question associated with the FLSI questionnaire.			Intellectual Product	
C138269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138269>	C211913	PedsQL Neuromuscular Module Acute Version 3.0 Child Report Questionnaire Question	A question associated with the PedsQL Neuromuscular Module Acute Version 3.0 Child Report questionnaire.			Intellectual Product	
C13826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13826>	C33968	Golgi Tendon Organ|Golgi's Tendon Organ|Golgi's Tendon Spindle|Neurotendinous Organ|Neurotendinous Spindle	The Golgi Tendon Organ is located within the tendons found on each end of a muscle. It responds to increased muscle tension or contraction as exerted on the tendon, by inhibiting further muscle contraction, which protects against muscle damage. The proprioceptive sensory neuron of a Golgi tendon organ, projects to the motor neurons located within the ventral horn of the spinal cord, where the inhibition occurs. Unlike the muscle spindle, Golgi tendon organs do not indicate muscle length, but rather muscle tension.			Body Part, Organ, or Organ Component	
C138270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138270>	C211913	PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Questionnaire Question	A question associated with the PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler questionnaire.			Intellectual Product	
C138271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138271>	C211913	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Questionnaire Question	A question associated with the PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child questionnaire.			Intellectual Product	
C138272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138272>	C211913	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Questionnaire Question	A question associated with the PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen questionnaire.			Intellectual Product	
C138273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138273>	C211913	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Questionnaire Question	A question associated with the PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults questionnaire.			Intellectual Product	
C138274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138274>	C211913	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Questionnaire Question	A question associated with the PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child questionnaire.			Intellectual Product	
C138275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138275>	C211913	PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Questionnaire Question	A question associated with the PedsQL Neuromuscular Module Acute Version 3.0 Teen Report questionnaire.			Intellectual Product	
C138276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138276>	C211913	PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Questionnaire Question	A question associated with the PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report questionnaire.			Intellectual Product	
C138277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138277>	C211913	PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Questionnaire Question	A question associated with the PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report questionnaire.			Intellectual Product	
C138278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138278>	C211913	PedsQL Neuromuscular Module Version 3.0 Child Report Questionnaire Question	A question associated with the PedsQL Neuromuscular Module Version 3.0 Child Report questionnaire.			Intellectual Product	
C138279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138279>	C211913	PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Questionnaire Question	A question associated with the PedsQL Neuromuscular Module Version 3.0 Parent of Toddler questionnaire.			Intellectual Product	
C13827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13827>	C13432	2p23.3	A chromosome band present on 2p			Gene or Genome	
C138280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138280>	C211913	PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Questionnaire Question	A question associated with the PedsQL Neuromuscular Module Version 3.0 Parent Report for Child questionnaire.			Intellectual Product	
C138281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138281>	C211913	PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Questionnaire Question	A question associated with the PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen questionnaire.			Intellectual Product	
C138282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138282>	C211913	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Questionnaire Question	A question associated with the PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report questionnaire.			Intellectual Product	
C138283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138283>	C211913	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Questionnaire Question	A question associated with the PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child questionnaire.			Intellectual Product	
C138284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138284>	C211913	PedsQL Neuromuscular Module Version 3.0 Teen Report Questionnaire Question	A question associated with the PedsQL Neuromuscular Module Version 3.0 Teen Report questionnaire.			Intellectual Product	
C138285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138285>	C211913	PedsQL Neuromuscular Module Version 3.0 Young Adult Report Questionnaire Question	A question associated with the PedsQL Neuromuscular Module Version 3.0 Young Adult Report questionnaire.			Intellectual Product	
C138286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138286>	C211913	PedsQL Neuromuscular Module Version 3.0 Young Child Report Questionnaire Question	A question associated with the PedsQL Neuromuscular Module Version 3.0 Young Child Report questionnaire.			Intellectual Product	
C138287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138287>	C217121	Cordonnier Infectious Complications Grading Scale|Cordonnier Infection Grading Scale|Cordonnier Infection Grading Scale|Cordonnier Infection Scale	A three-level prognostic grading system that describes the severity of infectious complications occurring in allogeneic stem cell transplant (SCT) recipients.			Intellectual Product	
C138288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138288>	C217120	Cordonnier Bacterial Complication Grade	Any bacterially-focused infection complications occurring in allogeneic stem cell transplant recipients.			Intellectual Product	
C138289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138289>	C217120	Cordonnier Fungal Complication Grade	Any fungally-focused infection complications occurring in allogeneic stem cell transplant recipients.			Intellectual Product	
C13828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13828>	C13432	9q34.3	A chromosome band present on 9q			Gene or Genome	
C138290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138290>	C217120	Cordonnier Viral Complication Grade	Any virally-focused infection complications occurring in allogeneic stem cell transplant recipients.			Intellectual Product	
C138291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138291>	C217120	Cordonnier Parasitic Complication Grade	Any parasite-focused infection complications occurring in allogeneic stem cell transplant recipients.			Intellectual Product	
C138292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138292>	C217120	Cordonnier Nonmicrobially-Defined Infection Grade	Any nonmicrobally-defined infection complications occurring in allogeneic stem cell transplant recipients.			Intellectual Product	
C138293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138293>	C138288	Cordonnier Grade 1 Bacterial Complication, Outpatient Treatment Bacterial Focus|Cordonnier Grade 1 Bacterial Complication|Grade 1 Bacterial Focus Treated in Outpatients Excluding Any Form of Bronchopneumonia	Any bacterially-focused infection treated as an outpatient (e.g., urinary tract infection, angina), excluding any form of bronchopneumonia.			Intellectual Product	
C138294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138294>	C138288	Cordonnier Grade 2 Bacterial Complication, Bacteremia without Severe Sepsis|Grade 2 Bacteremia without Severe Sepsis	Any bacteremia without severe sepsis.			Intellectual Product	
C138295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138295>	C138288	Cordonnier Grade 2 Bacterial Complication Requiring Inpatient Management|Grade 2 Bacterial Focus Requiring Inpatient Management	Any bacterially-focused infection requiring treated as an inpatient.			Intellectual Product	
C138296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138296>	C138288	Cordonnier Grade 3 Bacterial Complication, Bacteremia with Severe Sepsis|Grade 3 Bacterial Infection Bacteremia with Severe Sepsis	Any bacteremia with severe sepsis.			Intellectual Product	
C138297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138297>	C138288	Cordonnier Grade 3 Bacterial Complication, Complex Bacteremia|Grade 3 Complex Bacteremia	Any complex bacteremia with deep organ involvement.			Intellectual Product	
C138298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138298>	C138289	Cordonnier Grade 1 Fungal Complication, Superficial Candida Infection|Cordonnier Grade 1 Fungal Complication|Grade 1 Superficial Candida Infection	Any superficial Candida infection.			Intellectual Product	
C138299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138299>	C138289	Cordonnier Grade 2 Fungal Complication, Deep Candida Infection without Candidemia|Grade 2 Deep Candida Infection without Candidemia	Any deep Candida infection without candidemia.			Intellectual Product	
C13829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13829>	C13432	5q13	A chromosome band present on 5q			Gene or Genome	
C1382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1382>	C1404	K 252a|9,1-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9-alpha,10-beta,12-alpha)-|Antibiotic K 252A|Antibiotic SF 2370|K-252a|K252A|K252A|Protein Kinase Inhibitor K252a|SF 2370	An indolocarbazole-based alkaloid and staurosporine analog isolated from Nocardiopsis and Actinomadura species, with kinase inhibiting activity. K252a inhibits a wide variety of enzymes, including, but not limited to, protein kinase A (PKA), C (PKC) and G (PKG), calcium (Ca2+)/calmodulin-dependent kinase type II (CaMKII), phosphorylase kinase (PhK), tropomyosin receptor kinase (Trk; neurotrophic tyrosine receptor kinase; NTRK), myosin light-chain kinase (MLCK; MYLK), mixed-lineage protein kinase 3 (MLK3), receptor-type tyrosine-protein kinase FLT3 (CD135; fms-like tyrosine kinase 3; fetal liver kinase-2; FLK2) and actin-regulating kinase PRK1 (PAK1). Inhibition of these kinases prevents the activation of signaling pathways in which these kinases play a key role.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C138300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138300>	C138289	Cordonnier Grade 2 Fungal Complication, Candidemia without Severe Sepsis|Grade 2 Candidemia without Severe Sepsis and without Focus	Any candidemia without severe sepsis and without focus.			Intellectual Product	
C138301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138301>	C138289	Cordonnier Grade 2 Fungal Complication, Aspergillus Sinusitis without Bone Involvement|Grade 2 Aspergillus Sinusitis without Bone Involvement	Any Aspergillus sinusitis without bone involvement.			Intellectual Product	
C138302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138302>	C138289	Cordonnier Grade 3 Fungal Complication, Candidemia with Either Sepsis or Deep Focus|Grade 3 Candidemia with Either Sepsis or Deep Focus	Any candidemia with either sepsis or deep focus.			Intellectual Product	
C138303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138303>	C138289	Cordonnier Grade 3 Fungal Complication, Proven or Probable Aspergillus Pneumonia|Grade 3 Proven or Probable Aspergillus Pneumonia	Any proven or probable Aspergillus pneumonia.			Intellectual Product	
C138304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138304>	C138290	Cordonnier Grade 1 Viral Complication, Mucous Herpes Simplex Virus Infection|Cordonnier Grade 1 Viral Complication|Grade 1 Mucous HSV Infection	Any mucous herpes simplex virus infection.			Intellectual Product	
C138305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138305>	C138290	Cordonnier Grade 2 Viral Complication, Varicella Zoster Virus Infection|Grade 2 VZV Infection	Any Varicella zoster virus infection.			Intellectual Product	
C138306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138306>	C138290	Cordonnier Grade 3 Viral Complication, Severe Varicella Zoster Virus Infection|Grade 3 Severe VZV Infection	Any severe Varicella zoster virus infection.			Intellectual Product	
C138307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138307>	C138290	Cordonnier Grade 3 Viral Complication, Viral Encephalitis|Grade 3 Any Viral Encephalitis	Any viral encephalitis.			Intellectual Product	
C138308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138308>	C138290	Cordonnier Grade 1 Viral Complication, Asymptomatic Cytomegalovirus Infection|Grade 1 Asymptomatic CMV Infection	Any asymptomatic cytomegalovirus infection.			Intellectual Product	
C138309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138309>	C138290	Cordonnier Grade 2 Viral Complication, Symptomatic Cytomegalovirus Infection|Grade 2 Symptomatic CMV Infection	Any symptomatic cytomegalovirus infection.			Intellectual Product	
C13830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13830>	C13432	8p11.23	A chromosome band present on 8p			Gene or Genome	
C138310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138310>	C138290	Cordonnier Grade 3 Viral Complication, Cytomegalovirus Pneumonia or Gut Disease|Grade 3 CMV Pneumonia or Gut Disease	Any cytomegalovirus pneumonia or gut disease.			Intellectual Product	
C138311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138311>	C138291	Cordonnier Grade 2 Parasitic Complication, Toxoplasmosis Infection without Organ Involvement|Cordonnier Grade 2 Parasitic Complication|Grade 2 Toxoplasmosis Infection without Organ Involvement	Any Toxoplasmosis infection without organ involvement.			Intellectual Product	
C138312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138312>	C138291	Cordonnier Grade 3 Parasitic Complication, Pneumocystis jiroveci Pneumonia|Grade 3 Pneumocystis jiroveci Pneumonia	Any Pneumocystis jiroveci pneumonia.			Intellectual Product	
C138313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138313>	C138291	Cordonnier Grade 3 Parasitic Complication, Central Nervous System or Other Organ Toxoplasmosis|Grade 3 CNS or Other Organ Toxoplasmosis	Any Toxoplasmosis infection with central nervous system involvement or other organ involvement.			Intellectual Product	
C138314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138314>	C138292	Cordonnier Grade 1 Fever of Unknown Origin in Neutropenic Patient|Grade 1 Fever of Unknown Origin in Neutropenic Patients Receiving Broad Spectrum Antibiotics	Any fever of unknown origin in a neutropenic patient receiving broad spectrum antibiotics.			Intellectual Product	
C138315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138315>	C138292	Cordonnier Grade 1 Clinically Documented Infection not Requiring Inpatient Management|Grade 1 Clinically Documented Infection not Requiring Inpatient Management	Any clinically documented infection not requiring inpatient management.			Intellectual Product	
C138316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138316>	C138292	Cordonnier Grade 2 Pneumonia or Bronchopneumonia with PaO2 Greater than 65 mmHg|Grade 2 Pneumonia or Bronchopneumonia with PaO2 Greater than 65 mmHg	Any pneumonia or bronchopneumonia with PaO2 greater than 65 mmHg.			Intellectual Product	
C138317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138317>	C138292	Cordonnier Grade 2 Infectious Symptom Requiring Inpatient Management|Grade 2 Infectious Symptoms Requiring Inpatient Management	Any infectious symptom requiring inpatient management.			Intellectual Product	
C138318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138318>	C138292	Cordonnier Grade 3 Acute Pneumonia with PaO2 Less than or Equal to 65 mmHg|Grade 3 Acute Pneumonia with PaO2 Less than or Equal to 65 mmHg	Any acute pneumonia with PaO2 less than or equal to 65 mmHg.			Intellectual Product	
C138319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138319>	C138292	Cordonnier Sepsis Syndrome Requiring Transfer to Intensive Care Unit|Grade 3 Sepsis Syndrome Requiring Transfer to Intensive Care Unit	Any sepsis syndrome requiring transfer to an intensive care unit.			Intellectual Product	
C13831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13831>	C13432	5p13.3	A chromosome band present on 5p			Gene or Genome	
C138320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138320>	C8851|C27699|C27697|C150399	HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|HHV8-Positive DLBCL, NOS|HHV8-Positive Diffuse Large B-Cell Lymphoma, NOS|Human Herpesvirus 8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|KSHV/HHV8-Positive Diffuse Large B-Cell Lymphoma	A large B-cell lymphoma characterized by the presence of a diffuse proliferation of large, atypical HHV8-positive neoplastic lymphocytes. It usually arises in association with HHV8-positive multicentric Castleman disease.			Neoplastic Process	Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C138321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138321>	C138961	PSA Level 0.1 to Fifty|PSA Level 0.1 to 50|PSA Level 0.1 to 50|PSA Level Between 0.1 and 50|PSA Level Between 0.1 and Fifty	A blood concentration of prostate specific antigen between 0.1 and 50 ng/mL.	PSA Level 0.1 to 50		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138322>	C41031	Neoplastic Plasma Cells More than 20 Percent of Bone Marrow Nucleated Cells|Neoplastic Plasma Cells Greater than 20 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that more than 20 percent of the nucleated cells in a bone marrow sample are neoplastic plasma cells.	Neoplastic Plasma Cells More than 20 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C138323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138323>	C116563	Liver Ultrasonographic Elastography|Fibroscan|TE|Transient Elastography|VCTE|Vibration-Controlled Transient Elastrography	A noninvasive test that is used to stage fibrosis in the liver. A 50-MHz wave is passed into the liver from a small transducer on the end of an ultrasound probe which measures the velocity of the shear wave (in meters per second) as this wave passes through the liver. The shear wave velocity can then be converted into liver stiffness. This technique is an alternative to liver biopsy.	Liver Ultrasonographic Elastography		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C138324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138324>	C175341	Assistance Getting Started with the Application|Help getting started with the application	A response indicating that an individual required assistance getting started with an application.			Intellectual Product	
C138325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138325>	C175341	Assistance Reading Answers|Help reading answers	A response indicating that an individual required assistance reading answers.			Intellectual Product	
C138326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138326>	C175341	Assistance Reading Questions and Answers|Help reading questions and answers	A response indicating that an individual required assistance reading questions and answers.			Intellectual Product	
C138327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138327>	C227071|C226739	Used Paper Form|Paper form	A response indicating that an individual used a paper form.			Intellectual Product	
C138328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138328>	C36279	Liver Stiffness	The modulus of elasticity of the liver, representing the resistance of the liver to deformation. Liver stiffness has been shown to be a surrogate marker of advanced fibrosis and cirrhosis. Liver stiffness, measured by transient elastography, is an independent predictor of liver failure, hepatocellular carcinoma, and mortality in cirrhotic patients coinfected with the human immunodeficiency virus or acquired immune deficiency syndrome, and hepatitis C virus.			Finding	
C13832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13832>	C13432	9p22.2	A chromosome band present on 9p			Gene or Genome	
C138330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138330>	C217122|C21154	Fibrosis-4 Score|FIB-4|FIB-4 Index|FIB-4 Score|FIB4|FIB4IDX|Fibrosis-4 Index|Fibrosis-4 Index	A noninvasive test to assess hepatic fibrosis that utilizes common laboratory findings according to the formula: age (years) x aspartate aminotransferase (AST) [U/L]/(platelets [10^9/L] x alanine aminotransferase (ALT) [U/L])^1/2).			Intellectual Product	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C138331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138331>	C15248	Continuous Venovenous Hemodialysis|CVVHD	A method for hemodialysis that removes blood from a large vein (femoral, subclavian, or internal jugular), pumps it through a dialysis circuit, and returns it into the venous circulation. This method avoids fluid shifts and other complications of conventional dialysis for patients with acute renal failure.			Therapeutic or Preventive Procedure	
C138332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138332>	C118969	HAS-BLED Bleeding Risk Score Clinical Classification|HAS-BLED|HAS-BLED|HSB01	A scoring system developed by Ron Pisters et al. in 2010 to assess the risk of bleeding in patients with atrial fibrillation. The calculated score is determined based on the presence of the following risk factors: hypertension, abnormal kidney or liver function, previous history of stroke, a history of or predisposition to bleeding, labile INR, age over 65 years, and concomitant drug and alcohol use; and ranges from 1 to 9 points.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138333>	C118969	The Lansky Play-Performance Status Scale Clinical Classification|LPPS SCALE|LPPSS1|LPSS	A parent-rated questionnaire created by Lansky et al. in 1985 to assess play activity over the past week in children ages 1 to 16 with cancer as an indicator of level of performance. Level of performance is scored from 0 to 100 based on active play, quiet play, degree of physical limitation, and degree of independence; with the interpretation ranging from fully active, normal performance (100), to moderately restricted (50 to 60), to completely disabled (10 or less).			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138334>	C222260	Performance of the Upper Limb Module for DMD 1.2 Functional Test|PUL 1.2|PUL V1.2|PUL01	A 22-item assessment scale developed by an international clinical outcomes group in 2011 to measure motor performance of the upper limb in patients with Duchenne muscular dystrophy (DMD). Functional tasks are subdivided into three dimensions that reflect disease progression from proximal to distal weakness, and from ambulatory to non-ambulatory.			Intellectual Product	CDISC Functional Test Category Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138335>	C222260	Performance of the Upper Limb Module for DMD 2.0 Functional Test|PUL 2.0|PUL V2.0|PUL02	A revised version of the Performance of the Upper Limb Module for DMD 1.2 Functional Test, which was developed by an international clinical outcomes group in 2011 to measure motor performance of the upper limb in patients with Duchenne muscular dystrophy (DMD). Functional tasks are subdivided into three dimensions that reflect disease progression from proximal to distal weakness, and from ambulatory to non-ambulatory.			Intellectual Product	CDISC Functional Test Category Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138336>	C91105	Functional Assessment of Cancer Therapy-Brain Symptom Index Questionnaire|FAC029|FBRSI|FBRSI	A 24-item complement to the Functional Assessment of Cancer Therapy-Brain (FACT-Br) questionnaire, developed by Cella et al. in 2010, that is used to assess brain tumor symptoms.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138338>	C91105	Functional Assessment of Cancer Therapy-Lung Symptom Index Questionnaire|FAC043|FLSI|FLSI	A brief subscale complement of the Functional Assessment of Cancer Therapy General Questionnaire, developed by Cella et al. in 2007, that is utilized to assess the major symptoms related to lung cancer, including dyspnea, pain, fatigue, cough, and weight loss.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138339>	C91105	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report Questionnaire|PEDSQL NEUROMUSCULAR MODULE ACUTE V3 CHILD|PQL14|PedsQL Neuromuscular Module Acute Version 3.0 Child Report	A 25-item disease specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of patient reported health related quality of life over the past seven days in children ages 8 to 12 years with neuromuscular disorders.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13833>	C13432	17q12	A chromosome band present on 17q			Gene or Genome	
C138340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138340>	C91105	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler Questionnaire|PEDSQL NEUROMUSCULAR MODULE ACUTE V3 TODDLER PARENT REPORT|PQL18|PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler	A 25-item disease specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of parent reported health related quality of life over the past seven days in children ages 2 to 4 years with neuromuscular disorders.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138341>	C91105	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child Questionnaire|PEDSQL NEUROMUSCULAR MODULE ACUTE V3 CHILD PARENT REPORT|PQL15|PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child	A 25-item disease-specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of parent reported health related quality of life over the past seven days in children ages 8 to 12 years with neuromuscular disorders.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138342>	C91105	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen Questionnaire|PEDSQL NEUROMUSCULAR MODULE ACUTE V3 TEEN PARENT REPORT|PQL13|PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen	A 25-item disease-specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of parent reported health related quality of life over the past seven days in children ages 13 to 18 years with neuromuscular disorders.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138343>	C91105	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Questionnaire|PEDSQL NEUROMUSCULAR MODULE ACUTE V3 YOUNG ADULT PARENT REPORT|PQL11|PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults	A 25-item disease-specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of parent reported health related quality of life over the past seven days in individuals ages 18 to 25 years with neuromuscular disorders.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138344>	C91105	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Questionnaire|PEDSQL NEUROMUSCULAR MODULE ACUTE V3 YOUNG CHILD PARENT REPORT|PQL17|PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child	A 25-item disease specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of parent reported health related quality of life over the past seven days in children ages 5 to 7 years with neuromuscular disorders.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138345>	C91105	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report Questionnaire|PEDSQL NEUROMUSCULAR MODULE ACUTE V3 TEEN|PQL12|PedsQL Neuromuscular Module Acute Version 3.0 Teen Report	A 25-item disease-specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of patient reported health related quality of life over the past seven days in children ages 13 to 18 years with neuromuscular disorders.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138346>	C91105	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report Questionnaire|PEDSQL NEUROMUSCULAR MODULE ACUTE V3 YOUNG ADULT|PQL10|PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report	A 25-item disease specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of patient reported health related quality of life over the past seven days in individuals ages 18 to 25 years with neuromuscular disorders.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138347>	C91105	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report Questionnaire|PEDSQL NEUROMUSCULAR MODULE ACUTE V3 YOUNG CHILD|PQL16|PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report	A 17-item disease specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure one dimension of patient reported health related quality of life over the past seven days in children ages 5 to 7 years with neuromuscular disorders.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138348>	C91105	Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report Questionnaire|PEDSQL NEUROMUSCULAR MODULE V3 CHILD|PQL05|PedsQL Neuromuscular Module Version 3.0 Child Report	A 25-item disease specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of patient reported health related quality of life over the past month in children ages 8 to 12 years with neuromuscular disorders.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138349>	C91105	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler Questionnaire|PEDSQL NEUROMUSCULAR MODULE V3 TODDLER PARENT REPORT|PQL09|PedsQL Neuromuscular Module Version 3.0 Parent of Toddler	A 25-item disease specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of parent reported health related quality of life over the past month in children ages 2 to 4 years with neuromuscular disorders.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13834>	C13432	17q12-q21.1	A chromosome band present on 17q			Gene or Genome	
C138350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138350>	C91105	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child Questionnaire|PEDSQL NEUROMUSCULAR MODULE V3 CHILD PARENT REPORT|PQL06|PedsQL Neuromuscular Module Version 3.0 Parent Report for Child	A 25-item disease specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of parent reported health related quality of life over the past month in children ages 8 to 12 years with neuromuscular disorders.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138351>	C91105	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen Questionnaire|PEDSQL NEUROMUSCULAR MODULE V3 TEEN PARENT REPORT|PQL04|PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen	A 25-item disease specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of parent reported health related quality of life over the past month in children ages 13 to 18 years with neuromuscular disorders.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138352>	C91105	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Questionnaire|PEDSQL NEUROMUSCULAR MODULE V3 YOUNG ADULT PARENT REPORT|PQL02|PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report	A 25-item disease specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of parent reported health related quality of life over the past month in individuals ages 18 to 25 years with neuromuscular disorders.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138353>	C91105	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child Questionnaire|PEDSQL NEUROMUSCULAR MODULE V3 YOUNG CHILD PARENT REPORT|PQL08|PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child	A 25-item disease specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of parent reported health related quality of life over the past month in children ages 5 to 7 years with neuromuscular disorders.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138354>	C91105	Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report Questionnaire|PEDSQL NEUROMUSCULAR MODULE V3 TEEN|PQL03|PedsQL Neuromuscular Module Version 3.0 Teen Report	A 25-item disease specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of patient reported health related quality of life over the past month in children ages 13 to 18 years with neuromuscular disorders.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138355>	C91105	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report Questionnaire|PEDSQL NEUROMUSCULAR MODULE V3 YOUNG ADULT|PQL01|PedsQL Neuromuscular Module Version 3.0 Young Adult Report	A 25-item disease specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure three dimensions of patient reported health related quality of life over the past month in patients ages 18 to 25 years with neuromuscular disorders.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138356>	C91105	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report Questionnaire|PEDSQL NEUROMUSCULAR MODULE V3 YOUNG CHILD|PQL07|PedsQL Neuromuscular Module Version 3.0 Young Child Report	A 17-item disease specific complement to the Pediatric Quality of Life Inventory instrument published by Sarah Davis et al. in 2010 that utilizes a 5-point Likert scale to measure one dimension of patient reported health related quality of life over the past month in children ages 5 to 7 years with neuromuscular disorders.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138357>	C138262	HAS-BLED - Hypertension|HSB01-Hypertension|HSB01-Hypertension|HSB0101	HAS-BLED Bleeding Risk Score (HAS-BLED) Hypertension.			Intellectual Product	CDISC Clinical Classification HAS-BLED Test Code Terminology|CDISC Clinical Classification HAS-BLED Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138358>	C138262	HAS-BLED - Abnormal Renal and Liver Function|HSB01-Abnormal Renal and Liver Function|HSB01-Abnormal Renal and Liver Function|HSB0102	HAS-BLED Bleeding Risk Score (HAS-BLED) Abnormal renal and liver function.			Intellectual Product	CDISC Clinical Classification HAS-BLED Test Code Terminology|CDISC Clinical Classification HAS-BLED Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138359>	C138262	HAS-BLED - Stroke|HSB01-Stroke|HSB01-Stroke|HSB0103	HAS-BLED Bleeding Risk Score (HAS-BLED) Stroke.			Intellectual Product	CDISC Clinical Classification HAS-BLED Test Code Terminology|CDISC Clinical Classification HAS-BLED Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13835>	C13432	6q22.33-q24.1	A chromosome band present on 6q			Gene or Genome	
C138360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138360>	C138262	HAS-BLED - Bleeding|HSB01-Bleeding|HSB01-Bleeding|HSB0104	HAS-BLED Bleeding Risk Score (HAS-BLED) Bleeding.			Intellectual Product	CDISC Clinical Classification HAS-BLED Test Code Terminology|CDISC Clinical Classification HAS-BLED Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138361>	C138262	HAS-BLED - Labile INRs|HSB01-Labile INRs|HSB01-Labile INRs|HSB0105	HAS-BLED Bleeding Risk Score (HAS-BLED) Labile INRs.			Intellectual Product	CDISC Clinical Classification HAS-BLED Test Code Terminology|CDISC Clinical Classification HAS-BLED Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138362>	C138262	HAS-BLED - Elderly|HSB01-Elderly|HSB01-Elderly|HSB0106	HAS-BLED Bleeding Risk Score (HAS-BLED) Elderly.			Intellectual Product	CDISC Clinical Classification HAS-BLED Test Code Terminology|CDISC Clinical Classification HAS-BLED Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138363>	C138262	HAS-BLED - Drugs or Alcohol|HSB01-Drugs or Alcohol|HSB01-Drugs or Alcohol|HSB0107	HAS-BLED Bleeding Risk Score (HAS-BLED) Drugs or alcohol.			Intellectual Product	CDISC Clinical Classification HAS-BLED Test Code Terminology|CDISC Clinical Classification HAS-BLED Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138364>	C138263	LPSS - Lansky Play-Performance Status|LPPSS1-Lansky Play-Performance Status|LPPSS1-Lansky Play-Performance Status|LPPSS101	The Lansky Play-Performance Status Scale (LPSS) Lansky play-performance status.			Intellectual Product	CDISC Clinical Classification LPSS Test Code Terminology|CDISC Clinical Classification LPSS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138365>	C138264	PUL 1.2 - Preferred Arm|PUL01-Preferred Arm|PUL01-Preferred Arm|PUL0101	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Preferred arm.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138366>	C138264	PUL 1.2 - Elbow Contractures|PUL01-Elbow Contractures|PUL01-Elbow Contractures|PUL0102	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Elbow contractures of the preferred arm.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138367>	C138264	PUL 1.2 - Entry Item|PUL01-Entry Item|PUL01-Entry Item|PUL01A	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Entry item.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138368>	C138264	PUL 1.2 - Shoulder Abduction to Height|PUL01-Shoulder Abduction to Shldr Hgt|PUL01-Shoulder Abduction to Shldr Hgt|PUL01B	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Shoulder abduction to shoulder height.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138369>	C138264	PUL 1.2 - Shoulder Abduction Above Height|PUL01-Shoulder Abduction Above Shldr Hgt|PUL01-Shoulder Abduction Above Shldr Hgt|PUL01C	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Shoulder abduction above shoulder height.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13836>	C13432	11q14	A chromosome band present on 11q			Gene or Genome	
C138370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138370>	C138264	PUL 1.2 - Shoulder Flexion to Height|PUL01-Shoulder Flexion to Shldr Height|PUL01-Shoulder Flexion to Shldr Height|PUL01D	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Shoulder flexion to shoulder height.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138371>	C138264	PUL 1.2 - Shoulder Flexion Above Height|PUL01-Shoulder Flexion Above Shldr Hgt|PUL01-Shoulder Flexion Above Shldr Hgt|PUL01E	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Shoulder flexion above shoulder height.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138372>	C138264	PUL 1.2 - Hand(s) to Mouth|PUL01-Hand(s) to Mouth|PUL01-Hand(s) to Mouth|PUL01F	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Hand(s) to mouth.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138373>	C138264	PUL 1.2 - Hand(s) to Table From Lap|PUL01-Hand(s) to Table From Lap|PUL01-Hand(s) to Table From Lap|PUL01G	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Hand(s) to table from lap.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138374>	C138264	PUL 1.2 - Move Weight on Table|PUL01-Move Weight on Table|PUL01-Move Weight on Table|PUL01H	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Move weight on table.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138375>	C138264	PUL 1.2 - Lifting Light Cans|PUL01-Lifting Light Cans|PUL01-Lifting Light Cans|PUL01I	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Lifting light cans.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138376>	C138264	PUL 1.2 - Lifting Light Cans Time|PUL01-Lifting Light Cans Time|PUL01-Lifting Light Cans Time|PUL01I1	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Lifting light cans, time.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138377>	C138264	PUL 1.2 - Lifting Heavy Cans|PUL01-Lifting Heavy Cans|PUL01-Lifting Heavy Cans|PUL01J	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Lifting heavy cans.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138378>	C138264	PUL 1.2 - Lifting Heavy Cans Time|PUL01-Lifting Heavy Cans Time|PUL01-Lifting Heavy Cans Time|PUL01J1	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Lifting heavy cans, time.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138379>	C138264	PUL 1.2 - Stacking Light Cans|PUL01-Stacking Light Cans|PUL01-Stacking Light Cans|PUL01K	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Stacking light cans.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13837>	C13432	19p13.12	A chromosome band present on 19p			Gene or Genome	
C138380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138380>	C138264	PUL 1.2 - Stacking Light Cans Time|PUL01-Stacking Light Cans Time|PUL01-Stacking Light Cans Time|PUL01K1	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Stacking light cans, time.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138381>	C138264	PUL 1.2 - Stacking Heavy Cans|PUL01-Stacking Heavy Cans|PUL01-Stacking Heavy Cans|PUL01L	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Stacking heavy cans.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138382>	C138264	PUL 1.2 - Stacking Heavy Cans Time|PUL01-Stacking Heavy Cans Time|PUL01-Stacking Heavy Cans Time|PUL01L1	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Stacking heavy cans, time.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138383>	C138264	PUL 1.2 - Remove Lid From Container|PUL01-Remove Lid From Container|PUL01-Remove Lid From Container|PUL01M	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Remove lid from container.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138384>	C138264	PUL 1.2 - Tearing Paper|PUL01-Tearing Paper|PUL01-Tearing Paper|PUL01N	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Tearing paper.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138385>	C138264	PUL 1.2 - Tracing Path|PUL01-Tracing Path|PUL01-Tracing Path|PUL01O	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Tracing path.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138386>	C138264	PUL 1.2 - Push on The Light|PUL01-Push on The Light|PUL01-Push on The Light|PUL01P	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Push on the light.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138387>	C138264	PUL 1.2 - Supination|PUL01-Supination|PUL01-Supination|PUL01Q	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Supination.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138388>	C138264	PUL 1.2 - Picking Up Coins|PUL01-Picking Up Coins|PUL01-Picking Up Coins|PUL01R	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Picking up coins.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138389>	C138264	PUL 1.2 - Placing Finger on Number Diagram|PUL01-Placing Finger on Number Diagram|PUL01-Placing Finger on Number Diagram|PUL01S	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Placing finger on number diagram.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13838>	C13432	5q33.2	A chromosome band present on 5q			Gene or Genome	
C138390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138390>	C138264	PUL 1.2 - Finger Pinch Grip|PUL01-Finger Pinch Grip|PUL01-Finger Pinch Grip|PUL01T	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Finger pinch grip.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138391>	C138264	PUL 1.2 - 3 Point Grip|PUL01-3 Point Grip|PUL01-3 Point Grip|PUL01U	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) 3 point grip.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138392>	C138264	PUL 1.2 - Thumb (Key) Grip|PUL01-Thumb (Key) Grip|PUL01-Thumb (Key) Grip|PUL01V	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Thumb (key) grip.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138393>	C138264	PUL 1.2 - High Level Shoulder Dimension|PUL01-High Level Shoulder Dimension|PUL01-High Level Shoulder Dimension|PUL0103	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) High level shoulder dimension score.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138394>	C138264	PUL 1.2 - Mid Level Elbow Dimension|PUL01-Mid Level Elbow Dimension|PUL01-Mid Level Elbow Dimension|PUL0104	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Mid level elbow dimension score.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138395>	C138264	PUL 1.2 - Distal Wrist or Hand Dimension|PUL01-Distal Wrist/Hand Dimension|PUL01-Distal Wrist/Hand Dimension|PUL0105	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Distal wrist and hand dimension score.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138396>	C138264	PUL 1.2 - Total Score|PUL01-Total Score|PUL01-Total Score|PUL0106	Performance of the Upper Limb Module for DMD 1.2 (PUL 1.2) Total Score.			Intellectual Product	CDISC Functional Test PUL 1.2 Test Code Terminology|CDISC Functional Test PUL 1.2 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138397>	C138265	PUL 2.0 - Entry Item|PUL02-Entry Item|PUL02-Entry Item|PUL02A	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Entry item.			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138398>	C138265	PUL 2.0 - Shoulder Abduction Arms Above Head|PUL02-Shoulder Abduction Arms Above Head|PUL02-Shoulder Abduction Arms Above Head|PUL0201	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Shoulder abduction both arms above head.			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138399>	C138265	PUL 2.0 - Raise Both Arms to Shoulder Height|PUL02-Raise Both Arms to Shoulder Height|PUL02-Raise Both Arms to Shoulder Height|PUL0202	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Raise both arms to shoulder height (elbows at shoulder height).			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13839>	C13432	11q24	A chromosome band present on 11q			Gene or Genome	
C1383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1383>	C1450	Liposomal NDDP|AROPLATIN|Aroplatin|L-NDDP|Liposomal Neodecanoic Acid Platinum Complex|Liposomal-Cisplatin Analogue|Liposomal-Entrapped Cis-Bis-Neodecanoate-trans-R,R-1,2-Diaminocyclohexane Platinum (II)	A synthetic liposomal formulation of bis-neodecanoate diaminocyclohexane platinum (NDDP), a third-generation platinum complex analogue of cisplatin, with potential antineoplastic activity. After displacement of the 2 long-chain aliphatic leaving groups (neodecanoic acid), platinum diaminocyclohexane (DACH) complexes become highly reactive and alkylate macromolecules, forming both inter- and intra-stranded DNA cross-linkings and inhibiting DNA synthesis, which results in tumor cell cytotoxicity. Because DNA mismatch-repair (MMR) complexes do not recognize DACH-platinum adducts, DNA repair mechanisms are inhibited, overcoming limitations observed with other platinum-based agents. In addition, the liposomal encapsulation improves the bioavailability of NDDP and reduces its toxicity profile.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C138400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138400>	C138265	PUL 2.0 - Flexion Shoulder Height No Weights|PUL02-Flexion Shoulder Height No Weights|PUL02-Flexion Shoulder Height No Weights|PUL0203	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Shoulder flexion to shoulder height (no weights).			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138401>	C138265	PUL 2.0 - Flexion to Shoulder Height 500g|PUL02-Flexion to Shoulder Height 500g|PUL02-Flexion to Shoulder Height 500g|PUL0204	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Shoulder flexion to shoulder height with 500g weight.			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138402>	C138265	PUL 2.0 - Flexion Above Shoulder Height 500g|PUL02-Flexion Above Shoulder Height 500g|PUL02-Flexion Above Shoulder Height 500g|PUL0205	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Shoulder flexion above shoulder height with 500g weight.			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138403>	C138265	PUL 2.0 - Flexion Above Shoulder Height 1kg|PUL02-Flexion Above Shoulder Height 1kg|PUL02-Flexion Above Shoulder Height 1kg|PUL0206	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Shoulder flexion above shoulder with 1 kg weight.			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138404>	C138265	PUL 2.0 - Hand(s) to Mouth|PUL02-Hand(s) to Mouth|PUL02-Hand(s) to Mouth|PUL0207	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Hand(s) to mouth.			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138405>	C138265	PUL 2.0 - Hands to Table From Lap|PUL02-Hands to Table From Lap|PUL02-Hands to Table From Lap|PUL0208	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Hands to table from lap.			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138406>	C138265	PUL 2.0 - Move Weight On Table 100g|PUL02-Move Weight on Table 100g|PUL02-Move Weight on Table 100g|PUL0209	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Move weight on table 100g.			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138407>	C138265	PUL 2.0 - Move Weight On Table 500g|PUL02-Move Weight on Table 500g|PUL02-Move Weight on Table 500g|PUL0210	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Move weight on table 500g.			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138408>	C138265	PUL 2.0 - Move Weight On Table 1kg|PUL02-Move Weight on Table 1kg|PUL02-Move Weight on Table 1kg|PUL0211	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Move weight on table 1kg.			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138409>	C138265	PUL 2.0 - Lift Heavy Can Diagonally|PUL02-Lift Heavy Can Diagonally|PUL02-Lift Heavy Can Diagonally|PUL0212	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Lift heavy can diagonally.			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13840>	C13432	8p22-p11	A chromosome band present on 8p			Gene or Genome	
C138410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138410>	C138265	PUL 2.0 - Stack of Three Cans|PUL02-Stack of Three Cans|PUL02-Stack of Three Cans|PUL0213	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Stack of three cans.			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138411>	C138265	PUL 2.0 - Stack of Five Cans|PUL02-Stack of Five Cans|PUL02-Stack of Five Cans|PUL0214	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Stack of five cans.			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138412>	C138265	PUL 2.0 - Remove Lid From Container|PUL02-Remove Lid From Container|PUL02-Remove Lid From Container|PUL0215	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Remove lid from container.			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138413>	C138265	PUL 2.0 - Tearing Paper|PUL02-Tearing Paper|PUL02-Tearing Paper|PUL0216	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Tearing paper.			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138414>	C138265	PUL 2.0 - Tracing Path|PUL02-Tracing Path|PUL02-Tracing Path|PUL0217	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Tracing path.			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138415>	C138265	PUL 2.0 - Push on Light|PUL02-Push on Light|PUL02-Push on Light|PUL0218	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Push on light.			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138416>	C138265	PUL 2.0 - Supination|PUL02-Supination|PUL02-Supination|PUL0219	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Supination.			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138417>	C138265	PUL 2.0 - Picking Up Coins|PUL02-Picking Up Coins|PUL02-Picking Up Coins|PUL0220	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Picking up coins.			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138418>	C138265	PUL 2.0 - Placing Finger on Number Diagram|PUL02-Placing Finger on Number Diagram|PUL02-Placing Finger on Number Diagram|PUL0221	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Placing finger on number diagram.			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138419>	C138265	PUL 2.0 - Pick Up 10g Weight Finger Pinch|PUL02-Pick Up 10g Weight Finger Pinch|PUL02-Pick Up 10g Weight Finger Pinch|PUL0222	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Pick up 10g weight finger pinch.			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13841>	C13432	8q13.1	A chromosome band present on 8q			Gene or Genome	
C138420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138420>	C138265	PUL 2.0 - Preferred Arm|PUL02-Preferred Arm|PUL02-Preferred Arm|PUL0223	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Preferred arm.			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138421>	C138265	PUL 2.0 - Right Elbow Extension ROM|PUL02-Right Elbow Extension ROM|PUL02-Right Elbow Extension ROM|PUL0224	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Right elbow extension ROM.			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138422>	C138265	PUL 2.0 - Left Elbow Extension ROM|PUL02-Left Elbow Extension ROM|PUL02-Left Elbow Extension ROM|PUL0225	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Left elbow extension ROM.			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138423>	C138265	PUL 2.0 - Right Available Supination ROM|PUL02-Right Available Supination ROM|PUL02-Right Available Supination ROM|PUL0226	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Right available supination ROM.			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138424>	C138265	PUL 2.0 - Left Available Supination ROM|PUL02-Left Available Supination ROM|PUL02-Left Available Supination ROM|PUL0227	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Left available supination ROM.			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138425>	C138265	PUL 2.0 - High Level Shoulder Dimension|PUL02-High Level Shoulder Dimension|PUL02-High Level Shoulder Dimension|PUL0228	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) High level shoulder dimension score.			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138426>	C138265	PUL 2.0 - Mid Level Elbow Dimension|PUL02-Mid Level Elbow Dimension|PUL02-Mid Level Elbow Dimension|PUL0229	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Mid level elbow dimension score.			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138427>	C138265	PUL 2.0 - Distal Wrist or Hand Dimension|PUL02-Distal Wrist/Hand Dimension|PUL02-Distal Wrist/Hand Dimension|PUL0230	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Distal wrist and hand dimension score.			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138428>	C138265	PUL 2.0 - Total Score|PUL02-Total Score|PUL02-Total Score|PUL0231	Performance of the Upper Limb Module for DMD 2.0 (PUL 2.0) Total score.			Intellectual Product	CDISC Functional Test PUL 2.0 Test Code Terminology|CDISC Functional Test PUL 2.0 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138429>	C138266	FBRSI - I Get Headaches|FAC029-I Get Headaches|FAC029-I Get Headaches|FAC02901	Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) I get headaches.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FBRSI Test Code Terminology|CDISC Questionnaire FBRSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13842>	C13432	4q12	A chromosome band present on 4q			Gene or Genome	
C138430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138430>	C138266	FBRSI - I Have Had Seizures|FAC029-I Have Had Seizures|FAC029-I Have Had Seizures|FAC02902	Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) I have had seizures (convulsions).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FBRSI Test Code Terminology|CDISC Questionnaire FBRSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138431>	C138266	FBRSI - Have Weakness in My Arms or Legs|FAC029-Have Weakness in My Arms or Legs|FAC029-Have Weakness in My Arms or Legs|FAC02903	Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) I have weakness in my arms or legs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FBRSI Test Code Terminology|CDISC Questionnaire FBRSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138432>	C138266	FBRSI - I Need Help in Caring for Myself|FAC029-I Need Help in Caring for Myself|FAC029-I Need Help in Caring for Myself|FAC02904	Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) I need help in caring for myself (bathing, dressing, eating, etc.).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FBRSI Test Code Terminology|CDISC Questionnaire FBRSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138433>	C138266	FBRSI - I Have a Lack of Energy|FAC029-I Have a Lack of Energy|FAC029-I Have a Lack of Energy|FAC02905	Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) I have a lack of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FBRSI Test Code Terminology|CDISC Questionnaire FBRSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138434>	C138266	FBRSI - Difficulty Expressing My Thoughts|FAC029-Difficulty Expressing My Thoughts|FAC029-Difficulty Expressing My Thoughts|FAC02906	Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) I have difficulty expressing my thoughts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FBRSI Test Code Terminology|CDISC Questionnaire FBRSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138435>	C138266	FBRSI - I Have Trouble With Coordination|FAC029-I Have Trouble With Coordination|FAC029-I Have Trouble With Coordination|FAC02907	Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) I have trouble with coordination.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FBRSI Test Code Terminology|CDISC Questionnaire FBRSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138436>	C138266	FBRSI - Frustrated I Cannot Do Things|FAC029-Frustrated I Cannot Do Things|FAC029-Frustrated I Cannot Do Things|FAC02908	Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) I get frustrated that I cannot do things I used to.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FBRSI Test Code Terminology|CDISC Questionnaire FBRSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138437>	C138266	FBRSI - I Have Nausea|FAC029-I Have Nausea|FAC029-I Have Nausea|FAC02909	Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) I have nausea.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FBRSI Test Code Terminology|CDISC Questionnaire FBRSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138438>	C138266	FBRSI - Able to Find the Right Words|FAC029-Able to Find the Right Words|FAC029-Able to Find the Right Words|FAC02910	Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) I am able to find the right word(s) to say what I mean.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FBRSI Test Code Terminology|CDISC Questionnaire FBRSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138439>	C138266	FBRSI - Losing Hope Against Illness|FAC029-Losing Hope Against Illness|FAC029-Losing Hope Against Illness|FAC02911	Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) I am losing hope in the fight against my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FBRSI Test Code Terminology|CDISC Questionnaire FBRSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13843>	C13432	20q12	A chromosome band present on 20q			Gene or Genome	
C138440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138440>	C138266	FBRSI - Trouble Meeting Needs of Family|FAC029-Trouble Meeting Needs of Family|FAC029-Trouble Meeting Needs of Family|FAC02912	Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) Because of my physical condition, I have trouble meeting the needs of my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FBRSI Test Code Terminology|CDISC Questionnaire FBRSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138441>	C138266	FBRSI - Worry My Condition Will Get Worse|FAC029-Worry My Condition Will Get Worse|FAC029-Worry My Condition Will Get Worse|FAC02913	Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) I worry that my condition will get worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FBRSI Test Code Terminology|CDISC Questionnaire FBRSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138442>	C138266	FBRSI - I Am Afraid of Having a Seizure|FAC029-I Am Afraid of Having a Seizure|FAC029-I Am Afraid of Having a Seizure|FAC02914	Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) I am afraid of having a seizure (convulsion).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FBRSI Test Code Terminology|CDISC Questionnaire FBRSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138443>	C138266	FBRSI - I Am Able to Enjoy Life|FAC029-I Am Able to Enjoy Life|FAC029-I Am Able to Enjoy Life|FAC02915	Functional Assessment of Cancer Therapy-Brain Symptom Index (FBRSI) I am able to enjoy life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FBRSI Test Code Terminology|CDISC Questionnaire FBRSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138444>	C138267	FKSI-15 - I Have a Lack of Energy|FAC039-I Have a Lack of Energy|FAC039-I Have a Lack of Energy|FAC03901	Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) I have a lack of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FKSI-15 Test Code Terminology|CDISC Questionnaire FKSI-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138445>	C138267	FKSI-15 - Bothered by Treatment Side Effect|FAC039-Bothered by Treatment Side Effect|FAC039-Bothered by Treatment Side Effect|FAC03902	Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) I am bothered by side effects of treatment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FKSI-15 Test Code Terminology|CDISC Questionnaire FKSI-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138446>	C138267	FKSI-15 - I Have Pain|FAC039-I Have Pain|FAC039-I Have Pain|FAC03903	Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) I have pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FKSI-15 Test Code Terminology|CDISC Questionnaire FKSI-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138447>	C138267	FKSI-15 - I Am Losing Weight|FAC039-I Am Losing Weight|FAC039-I Am Losing Weight|FAC03904	Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) I am losing weight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FKSI-15 Test Code Terminology|CDISC Questionnaire FKSI-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138448>	C138267	FKSI-15 - I Have Bone Pain|FAC039-I Have Bone Pain|FAC039-I Have Bone Pain|FAC03905	Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) I have bone pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FKSI-15 Test Code Terminology|CDISC Questionnaire FKSI-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138449>	C138267	FKSI-15 - I Feel Fatigued|FAC039-I Feel Fatigued|FAC039-I Feel Fatigued|FAC03906	Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) I feel fatigued.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FKSI-15 Test Code Terminology|CDISC Questionnaire FKSI-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13844>	C13432	20q12-q13.12	A chromosome band present on 20q			Gene or Genome	
C138450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138450>	C138267	FKSI-15 - I Am Able to Enjoy Life|FAC039-I Am Able to Enjoy Life|FAC039-I Am Able to Enjoy Life|FAC03907	Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) I am able to enjoy life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FKSI-15 Test Code Terminology|CDISC Questionnaire FKSI-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138451>	C138267	FKSI-15 - I Have Been Short of Breath|FAC039-I Have Been Short of Breath|FAC039-I Have Been Short of Breath|FAC03908	Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) I have been short of breath.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FKSI-15 Test Code Terminology|CDISC Questionnaire FKSI-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138452>	C138267	FKSI-15 - Worry My Condition Will Get Worse|FAC039-Worry My Condition Will Get Worse|FAC039-Worry My Condition Will Get Worse|FAC03909	Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) I worry that my condition will get worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FKSI-15 Test Code Terminology|CDISC Questionnaire FKSI-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138453>	C138267	FKSI-15 - I Have a Good Appetite|FAC039-I Have a Good Appetite|FAC039-I Have a Good Appetite|FAC03910	Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) I have a good appetite.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FKSI-15 Test Code Terminology|CDISC Questionnaire FKSI-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138454>	C138267	FKSI-15 - I Have Been Coughing|FAC039-I Have Been Coughing|FAC039-I Have Been Coughing|FAC03911	Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) I have been coughing.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FKSI-15 Test Code Terminology|CDISC Questionnaire FKSI-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138455>	C138267	FKSI-15 - I Am Bothered by Fevers|FAC039-I Am Bothered by Fevers|FAC039-I Am Bothered by Fevers|FAC03912	Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) I am bothered by fevers (episodes of high body temperature).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FKSI-15 Test Code Terminology|CDISC Questionnaire FKSI-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138456>	C138267	FKSI-15 - I Am Able to Work|FAC039-I Am Able to Work|FAC039-I Am Able to Work|FAC03913	Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) I am able to work (include work at home).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FKSI-15 Test Code Terminology|CDISC Questionnaire FKSI-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138457>	C138267	FKSI-15 - I Have Had Blood in My Urine|FAC039-I Have Had Blood in My Urine|FAC039-I Have Had Blood in My Urine|FAC03914	Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) I have had blood in my urine.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FKSI-15 Test Code Terminology|CDISC Questionnaire FKSI-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138458>	C138267	FKSI-15 - I Am Sleeping Well|FAC039-I Am Sleeping Well|FAC039-I Am Sleeping Well|FAC03915	Functional Assessment of Cancer Therapy-Kidney Symptom Index-15 (FKSI-15) I am sleeping well.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FKSI-15 Test Code Terminology|CDISC Questionnaire FKSI-15 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138459>	C138268	FLSI - I Have Been Short of Breath|FAC043-I Have Been Short of Breath|FAC043-I Have Been Short of Breath|FAC04301	Functional Assessment of Cancer Therapy-Lung Symptom Index (FLSI) I have been short of breath.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FLSI Test Code Terminology|CDISC Questionnaire FLSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13845>	C13432	20q11.1	A chromosome band present on 20q			Gene or Genome	
C138460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138460>	C138268	FLSI - I Have a Lack of Energy|FAC043-I Have a Lack of Energy|FAC043-I Have a Lack of Energy|FAC04302	Functional Assessment of Cancer Therapy-Lung Symptom Index (FLSI) I have a lack of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FLSI Test Code Terminology|CDISC Questionnaire FLSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138461>	C138268	FLSI - I Have Pain|FAC043-I Have Pain|FAC043-I Have Pain|FAC04303	Functional Assessment of Cancer Therapy-Lung Symptom Index (FLSI) I have pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FLSI Test Code Terminology|CDISC Questionnaire FLSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138462>	C138268	FLSI - I Am Losing Weight|FAC043-I Am Losing Weight|FAC043-I Am Losing Weight|FAC04304	Functional Assessment of Cancer Therapy-Lung Symptom Index (FLSI) I am losing weight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FLSI Test Code Terminology|CDISC Questionnaire FLSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138463>	C138268	FLSI - I Have Been Coughing|FAC043-I Have Been Coughing|FAC043-I Have Been Coughing|FAC04305	Functional Assessment of Cancer Therapy-Lung Symptom Index (FLSI) I have been coughing.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FLSI Test Code Terminology|CDISC Questionnaire FLSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138464>	C138268	FLSI - Certain Parts of Body Have Pain|FAC043-Certain Parts of Body Have Pain|FAC043-Certain Parts of Body Have Pain|FAC04306	Functional Assessment of Cancer Therapy-Lung Symptom Index (FLSI) I have certain parts of my body where I experience pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FLSI Test Code Terminology|CDISC Questionnaire FLSI Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138465>	C138269	PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard to Breathe|PQL14-Hard to Breathe|PQL14-Hard to Breathe|PQL1401	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: It is hard to breathe.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138466>	C138269	PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Get Sick Easily|PQL14-Get Sick Easily|PQL14-Get Sick Easily|PQL1402	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: I get sick easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138467>	C138269	PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Get Sores and/or Rashes|PQL14-Get Sores and/or Rashes|PQL14-Get Sores and/or Rashes|PQL1403	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: I get sores and/or rashes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138468>	C138269	PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Legs Hurt|PQL14-Legs Hurt|PQL14-Legs Hurt|PQL1404	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: My legs hurt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138469>	C138269	PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Feel Tired|PQL14-Feel Tired|PQL14-Feel Tired|PQL1405	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: I feel tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13846>	C13432	21q11.2	A chromosome band present on 21q			Gene or Genome	
C138470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138470>	C138269	PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Back Feels Stiff|PQL14-Back Feels Stiff|PQL14-Back Feels Stiff|PQL1406	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: My back feels stiff.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138471>	C138269	PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Wake Up Tired|PQL14-Wake Up Tired|PQL14-Wake Up Tired|PQL1407	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: I wake up tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138472>	C138269	PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hands Are Weak|PQL14-Hands Are Weak|PQL14-Hands Are Weak|PQL1408	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: My hands are weak.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138473>	C138269	PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard to Use Bathroom|PQL14-Hard to Use Bathroom|PQL14-Hard to Use Bathroom|PQL1409	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: It is hard to use the bathroom.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138474>	C138269	PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard to Gain or Lose Weight|PQL14-Hard to Gain/Lose Weight|PQL14-Hard to Gain/Lose Weight|PQL1410	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: It is hard to gain or lose weight when I want to.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138475>	C138269	PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard to Use Hands|PQL14-Hard to Use Hands|PQL14-Hard to Use Hands|PQL1411	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: It is hard to use my hands.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138476>	C138269	PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard to Swallow Food|PQL14-Hard to Swallow Food|PQL14-Hard to Swallow Food|PQL1412	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: It is hard to swallow food.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138477>	C138269	PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Long Time to Bathe or Shower|PQL14-Long Time to Bathe/Shower|PQL14-Long Time to Bathe/Shower|PQL1413	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: It takes me a long time to bathe or shower.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138478>	C138269	PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Get Hurt Accidentally|PQL14-Get Hurt Accidentally|PQL14-Get Hurt Accidentally|PQL1414	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: I get hurt accidentally.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138479>	C138269	PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Take Long Time to Eat|PQL14-Take Long Time to Eat|PQL14-Take Long Time to Eat|PQL1415	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: I take a long time to eat.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13847>	C13432	1p36.1	A chromosome band present on 1p			Gene or Genome	
C138480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138480>	C138269	PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard to Turn During Night|PQL14-Hard to Turn During Night|PQL14-Hard to Turn During Night|PQL1416	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: It is hard to turn myself during the night.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138481>	C138269	PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard to Go Places With Equipment|PQL14-Hard to Go Places With Equipment|PQL14-Hard to Go Places With Equipment|PQL1417	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: It is hard for me to go places with my equipment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138482>	C138269	PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard Tell Doctors and Nurses How Feel|PQL14-Hard Tell Doctors/Nurses How Feel|PQL14-Hard Tell Doctors/Nurses How Feel|PQL1418	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: It is hard for me to tell the doctors and nurses how I feel.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138483>	C138269	PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard Ask Doctors and Nurses Questions|PQL14-Hard Ask Doctors/Nurses Questions|PQL14-Hard Ask Doctors/Nurses Questions|PQL1419	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: It is hard for me to ask the doctors and nurses questions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138484>	C138269	PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard Explain Illness to People|PQL14-Hard Explain Illness to People|PQL14-Hard Explain Illness to People|PQL1420	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: It is hard for me to explain my illness to other people.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138485>	C138269	PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard for Family to Plan Activities|PQL14-Hard for Family to Plan Activities|PQL14-Hard for Family to Plan Activities|PQL1421	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: It is hard for my family to plan activities like vacations.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138486>	C138269	PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Hard for Family to Rest|PQL14-Hard for Family to Rest|PQL14-Hard for Family to Rest|PQL1422	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: It is hard for my family to get enough rest.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138487>	C138269	PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Money Problem in Our Family|PQL14-Money Problem in Our Family|PQL14-Money Problem in Our Family|PQL1423	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: I think money is a problem in our family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138488>	C138269	PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Family Has Lot of Problems|PQL14-Family Has Lot of Problems|PQL14-Family Has Lot of Problems|PQL1424	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: I think my family has a lot of problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138489>	C138269	PedsQL Neuromuscular Module Acute Version 3.0 Child Report - Do Not Have Equipment Need|PQL14-Do Not Have Equipment Need|PQL14-Do Not Have Equipment Need|PQL1425	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Child Report) In the past 7 days, how much of a problem has this been for you: I do not have the equipment I need.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13848>	C13432	12q13.1	A chromosome band present on 12q			Gene or Genome	
C138490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138490>	C138270	PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard to Breathe|PQL18-Hard to Breathe|PQL18-Hard to Breathe|PQL1801	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to breathe.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138491>	C138270	PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Get Sick Easily|PQL18-Get Sick Easily|PQL18-Get Sick Easily|PQL1802	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: My child gets sick easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138492>	C138270	PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Get Sores and/or Rashes|PQL18-Get Sores and/or Rashes|PQL18-Get Sores and/or Rashes|PQL1803	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: My child gets sores and/or rashes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138493>	C138270	PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Legs Hurt|PQL18-Legs Hurt|PQL18-Legs Hurt|PQL1804	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: My child's legs hurt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138494>	C138270	PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Feel Tired|PQL18-Feel Tired|PQL18-Feel Tired|PQL1805	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: My child feels tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138495>	C138270	PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Back Feels Stiff|PQL18-Back Feels Stiff|PQL18-Back Feels Stiff|PQL1806	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: My child's back feels stiff.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138496>	C138270	PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Wake Up Tired|PQL18-Wake Up Tired|PQL18-Wake Up Tired|PQL1807	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: My child wakes up tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138497>	C138270	PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hands Are Weak|PQL18-Hands Are Weak|PQL18-Hands Are Weak|PQL1808	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: My child's hands are weak.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138498>	C138270	PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard to Use Bathroom|PQL18-Hard to Use Bathroom|PQL18-Hard to Use Bathroom|PQL1809	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to use the bathroom.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138499>	C138270	PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard to Gain or Lose Weight|PQL18-Hard to Gain/Lose Weight|PQL18-Hard to Gain/Lose Weight|PQL1810	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to gain or lose weight when he or she wants to.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13849>	C13432	7p14-p13	A chromosome band present on 7p			Gene or Genome	
C1384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1384>	C1283	Emfilermin|EMFILERMIN|LIF|Recombinant Leukemia Inhibitory Factor	A recombinantly produced form of the leukemia inhibitory factor protein. Endogenous leukemia inhibitory factor regulates neurogenesis and hematopoiesis.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C138500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138500>	C138270	PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard to Use Hands|PQL18-Hard to Use Hands|PQL18-Hard to Use Hands|PQL1811	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to use his or her hands.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138501>	C138270	PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard to Swallow Food|PQL18-Hard to Swallow Food|PQL18-Hard to Swallow Food|PQL1812	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to swallow food.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138502>	C138270	PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Long Time to Bathe or Shower|PQL18-Long Time to Bathe/Shower|PQL18-Long Time to Bathe/Shower|PQL1813	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: It takes my child a long time to bathe or shower.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138503>	C138270	PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Get Hurt Accidentally|PQL18-Get Hurt Accidentally|PQL18-Get Hurt Accidentally|PQL1814	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: My child gets hurt accidentally.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138504>	C138270	PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Take Long Time to Eat|PQL18-Take Long Time to Eat|PQL18-Take Long Time to Eat|PQL1815	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: My child takes a long time to eat.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138505>	C138270	PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard to Turn During Night|PQL18-Hard to Turn During Night|PQL18-Hard to Turn During Night|PQL1816	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to turn him or herself during the night.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138506>	C138270	PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard to Go Places With Equipment|PQL18-Hard to Go Places With Equipment|PQL18-Hard to Go Places With Equipment|PQL1817	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to go places with his or her equipment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138507>	C138270	PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard Tell Doctors and Nurses How Feel|PQL18-Hard Tell Doctors/Nurses How Feel|PQL18-Hard Tell Doctors/Nurses How Feel|PQL1818	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to tell the doctors and nurses how he or she feels.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138508>	C138270	PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard Ask Doctors and Nurses Questions|PQL18-Hard Ask Doctors/Nurses Questions|PQL18-Hard Ask Doctors/Nurses Questions|PQL1819	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to ask the doctors and nurses questions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138509>	C138270	PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard Explain Illness to People|PQL18-Hard Explain Illness to People|PQL18-Hard Explain Illness to People|PQL1820	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to explain his or her illness to other people.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13850>	C13432	2q34-q35	A chromosome band present on 2q			Gene or Genome	
C138510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138510>	C138270	PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard for Family to Plan Activities|PQL18-Hard for Family to Plan Activities|PQL18-Hard for Family to Plan Activities|PQL1821	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: It is hard for our family to plan activities like vacations.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138511>	C138270	PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Hard for Family to Rest|PQL18-Hard for Family to Rest|PQL18-Hard for Family to Rest|PQL1822	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: It is hard for our family to get enough rest.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138512>	C138270	PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Money Problem in Our Family|PQL18-Money Problem in Our Family|PQL18-Money Problem in Our Family|PQL1823	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: I think money is a problem in our family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138513>	C138270	PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Family Has Lot of Problems|PQL18-Family Has Lot of Problems|PQL18-Family Has Lot of Problems|PQL1824	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: I think our family has a lot of problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138514>	C138270	PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler - Do Not Have Equipment Need|PQL18-Do Not Have Equipment Need|PQL18-Do Not Have Equipment Need|PQL1825	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler) In the past 7 days, how much of a problem has this been for your child: My child does not have the equipment he or she needs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138515>	C138271	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard to Breathe|PQL15-Hard to Breathe|PQL15-Hard to Breathe|PQL1501	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to breathe.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138516>	C138271	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Get Sick Easily|PQL15-Get Sick Easily|PQL15-Get Sick Easily|PQL1502	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: My child gets sick easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138517>	C138271	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Get Sores and/or Rashes|PQL15-Get Sores and/or Rashes|PQL15-Get Sores and/or Rashes|PQL1503	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: My child gets sores and/or rashes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138518>	C138271	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Legs Hurt|PQL15-Legs Hurt|PQL15-Legs Hurt|PQL1504	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: My child's legs hurt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138519>	C138271	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Feel Tired|PQL15-Feel Tired|PQL15-Feel Tired|PQL1505	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: My child feels tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13851>	C13432	6p25	A chromosome band present on 6p			Gene or Genome	
C138520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138520>	C138271	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Back Feels Stiff|PQL15-Back Feels Stiff|PQL15-Back Feels Stiff|PQL1506	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: My child's back feels stiff.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138521>	C138271	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Wake Up Tired|PQL15-Wake Up Tired|PQL15-Wake Up Tired|PQL1507	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: My child wakes up tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138522>	C138271	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hands Are Weak|PQL15-Hands Are Weak|PQL15-Hands Are Weak|PQL1508	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: My child's hands are weak.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138523>	C138271	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard to Use Bathroom|PQL15-Hard to Use Bathroom|PQL15-Hard to Use Bathroom|PQL1509	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to use the bathroom.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138524>	C138271	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard to Gain or Lose Weight|PQL15-Hard to Gain/Lose Weight|PQL15-Hard to Gain/Lose Weight|PQL1510	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to gain or lose weight when he or she wants to.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138525>	C138271	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard to Use Hands|PQL15-Hard to Use Hands|PQL15-Hard to Use Hands|PQL1511	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to use his or her hands.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138526>	C138271	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard to Swallow Food|PQL15-Hard to Swallow Food|PQL15-Hard to Swallow Food|PQL1512	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to swallow food.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138527>	C138271	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Long Time to Bathe or Shower|PQL15-Long Time to Bathe/Shower|PQL15-Long Time to Bathe/Shower|PQL1513	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: It takes my child a long time to bathe or shower.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138528>	C138271	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Get Hurt Accidentally|PQL15-Get Hurt Accidentally|PQL15-Get Hurt Accidentally|PQL1514	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: My child gets hurt accidentally.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138529>	C138271	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Take Long Time to Eat|PQL15-Take Long Time to Eat|PQL15-Take Long Time to Eat|PQL1515	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: My child takes a long time to eat.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13852>	C13432	16q24.2-q24.3	A chromosome band present on 16q			Gene or Genome	
C138530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138530>	C138271	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard to Turn During Night|PQL15-Hard to Turn During Night|PQL15-Hard to Turn During Night|PQL1516	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to turn him or herself during the night.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138531>	C138271	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard to Go Places With Equipment|PQL15-Hard to Go Places With Equipment|PQL15-Hard to Go Places With Equipment|PQL1517	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to go places with his or her equipment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138532>	C138271	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard Tell Doctors and Nurses How Feel|PQL15-Hard Tell Doctors/Nurses How Feel|PQL15-Hard Tell Doctors/Nurses How Feel|PQL1518	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to tell the doctors and nurses how he or she feels.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138533>	C138271	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard Ask Doctors and Nurses Questions|PQL15-Hard Ask Doctors/Nurses Questions|PQL15-Hard Ask Doctors/Nurses Questions|PQL1519	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to ask the doctors and nurses questions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138534>	C138271	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard Explain Illness to People|PQL15-Hard Explain Illness to People|PQL15-Hard Explain Illness to People|PQL1520	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to explain his or her illness to other people.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138535>	C138271	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard for Family to Plan Activities|PQL15-Hard for Family to Plan Activities|PQL15-Hard for Family to Plan Activities|PQL1521	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: It is hard for our family to plan activities like vacations.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138536>	C138271	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Hard for Family to Rest|PQL15-Hard for Family to Rest|PQL15-Hard for Family to Rest|PQL1522	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: It is hard for our family to get enough rest.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138537>	C138271	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Money Problem in Our Family|PQL15-Money Problem in Our Family|PQL15-Money Problem in Our Family|PQL1523	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: I think money is a problem in our family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138538>	C138271	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Family Has Lot of Problems|PQL15-Family Has Lot of Problems|PQL15-Family Has Lot of Problems|PQL1524	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: I think our family has a lot of problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138539>	C138271	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child - Do Not Have Equipment Need|PQL15-Do Not Have Equipment Need|PQL15-Do Not Have Equipment Need|PQL1525	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child) In the past 7 days, how much of a problem has this been for your child: My child does not have the equipment he or she needs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13853>	C13432	1p33-p31	A chromosome band present on 1p			Gene or Genome	
C138540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138540>	C138272	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard to Breathe|PQL13-Hard to Breathe|PQL13-Hard to Breathe|PQL1301	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: It is hard for my child to breathe.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138541>	C138272	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Get Sick Easily|PQL13-Get Sick Easily|PQL13-Get Sick Easily|PQL1302	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: My child gets sick easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138542>	C138272	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Get Sores and/or Rashes|PQL13-Get Sores and/or Rashes|PQL13-Get Sores and/or Rashes|PQL1303	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: My child gets sores and/or rashes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138543>	C138272	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Legs Hurt|PQL13-Legs Hurt|PQL13-Legs Hurt|PQL1304	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: My child's legs hurt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138544>	C138272	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Feel Tired|PQL13-Feel Tired|PQL13-Feel Tired|PQL1305	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: My child feels tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138545>	C138272	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Back Feels Stiff|PQL13-Back Feels Stiff|PQL13-Back Feels Stiff|PQL1306	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: My child's back feels stiff.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138546>	C138272	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Wake Up Tired|PQL13-Wake Up Tired|PQL13-Wake Up Tired|PQL1307	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: My child wakes up tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138547>	C138272	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hands Are Weak|PQL13-Hands Are Weak|PQL13-Hands Are Weak|PQL1308	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: My child's hands are weak.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138548>	C138272	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard to Use Bathroom|PQL13-Hard to Use Bathroom|PQL13-Hard to Use Bathroom|PQL1309	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: It is hard for my child to use the bathroom.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138549>	C138272	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard to Gain or Lose Weight|PQL13-Hard to Gain/Lose Weight|PQL13-Hard to Gain/Lose Weight|PQL1310	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: It is hard for my child to gain or lose weight when he or she wants to.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13854>	C13432	5q35.1-qter	A chromosome band present on 5q			Gene or Genome	
C138550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138550>	C138272	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard to Use Hands|PQL13-Hard to Use Hands|PQL13-Hard to Use Hands|PQL1311	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: It is hard for my child to use his or her hands.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138551>	C138272	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard to Swallow Food|PQL13-Hard to Swallow Food|PQL13-Hard to Swallow Food|PQL1312	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: It is hard for my child to swallow food.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138552>	C138272	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Long Time to Bathe or Shower|PQL13-Long Time to Bathe/Shower|PQL13-Long Time to Bathe/Shower|PQL1313	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: It takes my child a long time to bathe or shower.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138553>	C138272	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Get Hurt Accidentally|PQL13-Get Hurt Accidentally|PQL13-Get Hurt Accidentally|PQL1314	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: My child gets hurt accidentally.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138554>	C138272	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Take Long Time to Eat|PQL13-Take Long Time to Eat|PQL13-Take Long Time to Eat|PQL1315	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: My child takes a long time to eat.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138555>	C138272	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard to Turn During Night|PQL13-Hard to Turn During Night|PQL13-Hard to Turn During Night|PQL1316	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: It is hard for my child to turn him or herself during the night.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138556>	C138272	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard to Go Places With Equipment|PQL13-Hard to Go Places With Equipment|PQL13-Hard to Go Places With Equipment|PQL1317	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: It is hard for my child to go places with his or her equipment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138557>	C138272	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard Tell Doctors and Nurses How Feel|PQL13-Hard Tell Doctors/Nurses How Feel|PQL13-Hard Tell Doctors/Nurses How Feel|PQL1318	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: It is hard for my child to tell the doctors and nurses how he or she feels.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138558>	C138272	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard Ask Doctors and Nurses Questions|PQL13-Hard Ask Doctors/Nurses Questions|PQL13-Hard Ask Doctors/Nurses Questions|PQL1319	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: It is hard for my child to ask the doctors and nurses questions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138559>	C138272	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard Explain Illness to People|PQL13-Hard Explain Illness to People|PQL13-Hard Explain Illness to People|PQL1320	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: It is hard for my child to explain his or her illness to other people.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13855>	C13432	11p15.2-p14.3	A chromosome band present on 11p			Gene or Genome	
C138560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138560>	C138272	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard for Family to Plan Activities|PQL13-Hard for Family to Plan Activities|PQL13-Hard for Family to Plan Activities|PQL1321	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: It is hard for our family to plan activities like vacations.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138561>	C138272	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Hard for Family to Rest|PQL13-Hard for Family to Rest|PQL13-Hard for Family to Rest|PQL1322	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: It is hard for our family to get enough rest.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138562>	C138272	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Money Problem in Our Family|PQL13-Money Problem in Our Family|PQL13-Money Problem in Our Family|PQL1323	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: I think money is a problem in our family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138563>	C138272	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Family Has Lot of Problems|PQL13-Family Has Lot of Problems|PQL13-Family Has Lot of Problems|PQL1324	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: I think our family has a lot of problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138564>	C138272	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen - Do Not Have Equipment Need|PQL13-Do Not Have Equipment Need|PQL13-Do Not Have Equipment Need|PQL1325	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen) In the past 7 days, how much of a problem has this been for your teen: My child does not have the equipment he or she needs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138565>	C138273	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard to Breathe|PQL11-Hard to Breathe|PQL11-Hard to Breathe|PQL1101	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to breathe.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138566>	C138273	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Get Sick Easily|PQL11-Get Sick Easily|PQL11-Get Sick Easily|PQL1102	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: My child gets sick easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138567>	C138273	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Get Sores and/or Rashes|PQL11-Get Sores and/or Rashes|PQL11-Get Sores and/or Rashes|PQL1103	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: My child gets sores and/or rashes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138568>	C138273	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Legs Hurt|PQL11-Legs Hurt|PQL11-Legs Hurt|PQL1104	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: My child's legs hurt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138569>	C138273	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Feel Tired|PQL11-Feel Tired|PQL11-Feel Tired|PQL1105	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: My child feels tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13856>	C13432	1p31	A chromosome band present on 1p			Gene or Genome	
C138570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138570>	C138273	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Back Feels Stiff|PQL11-Back Feels Stiff|PQL11-Back Feels Stiff|PQL1106	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: My child's back feels stiff.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138571>	C138273	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Wake Up Tired|PQL11-Wake Up Tired|PQL11-Wake Up Tired|PQL1107	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: My child wakes up tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138572>	C138273	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hands Are Weak|PQL11-Hands Are Weak|PQL11-Hands Are Weak|PQL1108	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: My child's hands are weak.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138573>	C138273	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard to Use Bathroom|PQL11-Hard to Use Bathroom|PQL11-Hard to Use Bathroom|PQL1109	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to use the bathroom.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138574>	C138273	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard to Gain or Lose Weight|PQL11-Hard to Gain/Lose Weight|PQL11-Hard to Gain/Lose Weight|PQL1110	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to gain or lose weight when he or she wants to.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138575>	C138273	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard to Use Hands|PQL11-Hard to Use Hands|PQL11-Hard to Use Hands|PQL1111	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to use his or her hands.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138576>	C138273	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard to Swallow Food|PQL11-Hard to Swallow Food|PQL11-Hard to Swallow Food|PQL1112	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to swallow food.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138577>	C138273	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Long Time to Bathe or Shower|PQL11-Long Time to Bathe/Shower|PQL11-Long Time to Bathe/Shower|PQL1113	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: It takes my child a long time to bathe or shower.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138578>	C138273	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Get Hurt Accidentally|PQL11-Get Hurt Accidentally|PQL11-Get Hurt Accidentally|PQL1114	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: My child gets hurt accidentally.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138579>	C138273	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Take Long Time to Eat|PQL11-Take Long Time to Eat|PQL11-Take Long Time to Eat|PQL1115	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: My child takes a long time to eat.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13857>	C13432	17q24	A chromosome band present on 17q			Gene or Genome	
C138580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138580>	C138273	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard to Turn During Night|PQL11-Hard to Turn During Night|PQL11-Hard to Turn During Night|PQL1116	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to turn him or herself during the night.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138581>	C138273	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard to Go Places With Equipment|PQL11-Hard to Go Places With Equipment|PQL11-Hard to Go Places With Equipment|PQL1117	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to go places with his or her equipment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138582>	C138273	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard Tell Doctors and Nurses How Feel|PQL11-Hard Tell Doctors/Nurses How Feel|PQL11-Hard Tell Doctors/Nurses How Feel|PQL1118	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to tell the doctors and nurses how he or she feels.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138583>	C138273	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard Ask Doctors and Nurses Questions|PQL11-Hard Ask Doctors/Nurses Questions|PQL11-Hard Ask Doctors/Nurses Questions|PQL1119	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to ask the doctors and nurses questions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138584>	C138273	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard Explain Illness to People|PQL11-Hard Explain Illness to People|PQL11-Hard Explain Illness to People|PQL1120	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to explain his or her illness to other people.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138585>	C138273	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard for Family to Plan Activities|PQL11-Hard for Family to Plan Activities|PQL11-Hard for Family to Plan Activities|PQL1121	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: It is hard for our family to plan activities like vacations.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138586>	C138273	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Hard for Family to Rest|PQL11-Hard for Family to Rest|PQL11-Hard for Family to Rest|PQL1122	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: It is hard for our family to get enough rest.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138587>	C138273	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Money Problem in Our Family|PQL11-Money Problem in Our Family|PQL11-Money Problem in Our Family|PQL1123	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: I think money is a problem in our family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138588>	C138273	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Family Has Lot of Problems|PQL11-Family Has Lot of Problems|PQL11-Family Has Lot of Problems|PQL1124	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: I think our family has a lot of problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138589>	C138273	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults - Do Not Have Equipment Need|PQL11-Do Not Have Equipment Need|PQL11-Do Not Have Equipment Need|PQL1125	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults) In the past 7 days, how much of a problem has this been for your child: My child does not have the equipment he or she needs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Adults Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13858>	C13432	16q23.1	A chromosome band present on 16q			Gene or Genome	
C138590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138590>	C138274	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard to Breathe|PQL17-Hard to Breathe|PQL17-Hard to Breathe|PQL1701	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to breathe.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138591>	C138274	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Get Sick Easily|PQL17-Get Sick Easily|PQL17-Get Sick Easily|PQL1702	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: My child gets sick easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138592>	C138274	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Get Sores and/or Rashes|PQL17-Get Sores and/or Rashes|PQL17-Get Sores and/or Rashes|PQL1703	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: My child gets sores and/or rashes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138593>	C138274	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Legs Hurt|PQL17-Legs Hurt|PQL17-Legs Hurt|PQL1704	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: My child's legs hurt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138594>	C138274	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Feel Tired|PQL17-Feel Tired|PQL17-Feel Tired|PQL1705	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: My child feels tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138595>	C138274	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Back Feels Stiff|PQL17-Back Feels Stiff|PQL17-Back Feels Stiff|PQL1706	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: My child's back feels stiff.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138596>	C138274	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Wake Up Tired|PQL17-Wake Up Tired|PQL17-Wake Up Tired|PQL1707	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: My child wakes up tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138597>	C138274	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hands Are Weak|PQL17-Hands Are Weak|PQL17-Hands Are Weak|PQL1708	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: My child's hands are weak.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138598>	C138274	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard to Use Bathroom|PQL17-Hard to Use Bathroom|PQL17-Hard to Use Bathroom|PQL1709	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to use the bathroom.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138599>	C138274	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard to Gain or Lose Weight|PQL17-Hard to Gain/Lose Weight|PQL17-Hard to Gain/Lose Weight|PQL1710	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to gain or lose weight when he or she wants to.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13859>	C13432	20q13.2	A chromosome band present on 20q			Gene or Genome	
C1385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1385>	C267	Levonantradol|LEVONANTRADOL|Levonantradol HCl	A synthetic cannabinoid analogue of delta (9)-tetrahydrocannabinol (delta(9)-THC) with antiemetic and anti-analgesic properties. Although its precise mechanism of action is unknown, levonantradol appears to bind and activate the cannabinoid receptors CB1 and/or CB2. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C138600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138600>	C138274	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard to Use Hands|PQL17-Hard to Use Hands|PQL17-Hard to Use Hands|PQL1711	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to use his or her hands.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138601>	C138274	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard to Swallow Food|PQL17-Hard to Swallow Food|PQL17-Hard to Swallow Food|PQL1712	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to swallow food.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138602>	C138274	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Long Time to Bathe or Shower|PQL17-Long Time to Bathe/Shower|PQL17-Long Time to Bathe/Shower|PQL1713	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: It takes my child a long time to bathe or shower.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138603>	C138274	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Get Hurt Accidentally|PQL17-Get Hurt Accidentally|PQL17-Get Hurt Accidentally|PQL1714	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: My child gets hurt accidentally.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138604>	C138274	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Take Long Time to Eat|PQL17-Take Long Time to Eat|PQL17-Take Long Time to Eat|PQL1715	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: My child takes a long time to eat.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138605>	C138274	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard to Turn During Night|PQL17-Hard to Turn During Night|PQL17-Hard to Turn During Night|PQL1716	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to turn him or herself during the night.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138606>	C138274	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard to Go Places With Equipment|PQL17-Hard to Go Places With Equipment|PQL17-Hard to Go Places With Equipment|PQL1717	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to go places with his or her equipment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138607>	C138274	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard Tell Doctors and Nurses How Feel|PQL17-Hard Tell Doctors/Nurses How Feel|PQL17-Hard Tell Doctors/Nurses How Feel|PQL1718	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to tell the doctors and nurses how he or she feels.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138608>	C138274	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard Ask Doctors and Nurses Questions|PQL17-Hard Ask Doctors/Nurses Questions|PQL17-Hard Ask Doctors/Nurses Questions|PQL1719	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to ask the doctors and nurses questions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138609>	C138274	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard Explain Illness to People|PQL17-Hard Explain Illness to People|PQL17-Hard Explain Illness to People|PQL1720	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: It is hard for my child to explain his or her illness to other people.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13860>	C13432	1p21-p13.3	A chromosome band present on 1p			Gene or Genome	
C138610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138610>	C138274	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard for Family to Plan Activities|PQL17-Hard for Family to Plan Activities|PQL17-Hard for Family to Plan Activities|PQL1721	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: It is hard for our family to plan activities like vacations.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138611>	C138274	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Hard for Family to Rest|PQL17-Hard for Family to Rest|PQL17-Hard for Family to Rest|PQL1722	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: It is hard for our family to get enough rest.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138612>	C138274	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Money Problem in Our Family|PQL17-Money Problem in Our Family|PQL17-Money Problem in Our Family|PQL1723	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: I think money is a problem in our family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138613>	C138274	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Family Has Lot of Problems|PQL17-Family Has Lot of Problems|PQL17-Family Has Lot of Problems|PQL1724	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: I think our family has a lot of problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138614>	C138274	PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child - Do Not Have Equipment Need|PQL17-Do Not Have Equipment Need|PQL17-Do Not Have Equipment Need|PQL1725	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child) In the past 7 days, how much of a problem has this been for your child: My child does not have the equipment he or she needs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138615>	C138275	PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard to Breathe|PQL12-Hard to Breathe|PQL12-Hard to Breathe|PQL1201	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: It is hard to breathe.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138616>	C138275	PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Get Sick Easily|PQL12-Get Sick Easily|PQL12-Get Sick Easily|PQL1202	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: I get sick easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138617>	C138275	PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Get Sores and/or Rashes|PQL12-Get Sores and/or Rashes|PQL12-Get Sores and/or Rashes|PQL1203	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: I get sores and/or rashes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138618>	C138275	PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Legs Hurt|PQL12-Legs Hurt|PQL12-Legs Hurt|PQL1204	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: My legs hurt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138619>	C138275	PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Feel Tired|PQL12-Feel Tired|PQL12-Feel Tired|PQL1205	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: I feel tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13861>	C13432	7q11.1	A chromosome band present on 7q			Gene or Genome	
C138620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138620>	C138275	PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Back Feels Stiff|PQL12-Back Feels Stiff|PQL12-Back Feels Stiff|PQL1206	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: My back feels stiff.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138621>	C138275	PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Wake Up Tired|PQL12-Wake Up Tired|PQL12-Wake Up Tired|PQL1207	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: I wake up tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138622>	C138275	PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hands Are Weak|PQL12-Hands Are Weak|PQL12-Hands Are Weak|PQL1208	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: My hands are weak.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138623>	C138275	PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard to Use Bathroom|PQL12-Hard to Use Bathroom|PQL12-Hard to Use Bathroom|PQL1209	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: It is hard to use the bathroom.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138624>	C138275	PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard to Gain or Lose Weight|PQL12-Hard to Gain/Lose Weight|PQL12-Hard to Gain/Lose Weight|PQL1210	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: It is hard to gain or lose weight when I want to.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138625>	C138275	PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard to Use Hands|PQL12-Hard to Use Hands|PQL12-Hard to Use Hands|PQL1211	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: It is hard to use my hands.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138626>	C138275	PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard to Swallow Food|PQL12-Hard to Swallow Food|PQL12-Hard to Swallow Food|PQL1212	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: It is hard to swallow food.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138627>	C138275	PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Long Time to Bathe or Shower|PQL12-Long Time to Bathe/Shower|PQL12-Long Time to Bathe/Shower|PQL1213	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: It takes me a long time to bathe or shower.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138628>	C138275	PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Get Hurt Accidentally|PQL12-Get Hurt Accidentally|PQL12-Get Hurt Accidentally|PQL1214	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: I get hurt accidentally.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138629>	C138275	PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Take Long Time to Eat|PQL12-Take Long Time to Eat|PQL12-Take Long Time to Eat|PQL1215	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: I take a long time to eat.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13862>	C13432	17q23	A chromosome band present on 17q			Gene or Genome	
C138630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138630>	C138275	PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard to Turn During Night|PQL12-Hard to Turn During Night|PQL12-Hard to Turn During Night|PQL1216	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: It is hard to turn myself during the night.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138631>	C138275	PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard to Go Places With Equipment|PQL12-Hard to Go Places With Equipment|PQL12-Hard to Go Places With Equipment|PQL1217	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: It is hard for me to go places with my equipment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138632>	C138275	PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard Tell Doctors and Nurses How Feel|PQL12-Hard Tell Doctors/Nurses How Feel|PQL12-Hard Tell Doctors/Nurses How Feel|PQL1218	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: It is hard for me to tell the doctors and nurses how I feel.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138633>	C138275	PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard Ask Doctors and Nurses Questions|PQL12-Hard Ask Doctors/Nurses Questions|PQL12-Hard Ask Doctors/Nurses Questions|PQL1219	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: It is hard for me to ask the doctors and nurses questions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138634>	C138275	PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard Explain Illness to People|PQL12-Hard Explain Illness to People|PQL12-Hard Explain Illness to People|PQL1220	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: It is hard for me to explain my illness to other people.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138635>	C138275	PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard for Family to Plan Activities|PQL12-Hard for Family to Plan Activities|PQL12-Hard for Family to Plan Activities|PQL1221	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: It is hard for my family to plan activities like vacations.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138636>	C138275	PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Hard for Family to Rest|PQL12-Hard for Family to Rest|PQL12-Hard for Family to Rest|PQL1222	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: It is hard for my family to get enough rest.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138637>	C138275	PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Money Problem in Our Family|PQL12-Money Problem in Our Family|PQL12-Money Problem in Our Family|PQL1223	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: I think money is a problem in our family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138638>	C138275	PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Family Has Lot of Problems|PQL12-Family Has Lot of Problems|PQL12-Family Has Lot of Problems|PQL1224	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: I think my family has a lot of problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138639>	C138275	PedsQL Neuromuscular Module Acute Version 3.0 Teen Report - Do Not Have Equipment Need|PQL12-Do Not Have Equipment Need|PQL12-Do Not Have Equipment Need|PQL1225	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Teen Report (PedsQL Neuromuscular Module Acute Version 3.0 Teen Report) In the past 7 days, how much of a problem has this been for you: I do not have the equipment I need.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13863>	C13432	20q13.13	A chromosome band present on 20q			Gene or Genome	
C138640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138640>	C138276	PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard to Breathe|PQL10-Hard to Breathe|PQL10-Hard to Breathe|PQL1001	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: It is hard to breathe.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138641>	C138276	PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Get Sick Easily|PQL10-Get Sick Easily|PQL10-Get Sick Easily|PQL1002	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: I get sick easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138642>	C138276	PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Get Sores and/or Rashes|PQL10-Get Sores and/or Rashes|PQL10-Get Sores and/or Rashes|PQL1003	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: I get sores and/or rashes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138643>	C138276	PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Legs Hurt|PQL10-Legs Hurt|PQL10-Legs Hurt|PQL1004	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: My legs hurt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138644>	C138276	PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Feel Tired|PQL10-Feel Tired|PQL10-Feel Tired|PQL1005	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: I feel tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138645>	C138276	PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Back Feels Stiff|PQL10-Back Feels Stiff|PQL10-Back Feels Stiff|PQL1006	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: My back feels stiff.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138646>	C138276	PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Wake Up Tired|PQL10-Wake Up Tired|PQL10-Wake Up Tired|PQL1007	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: I wake up tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138647>	C138276	PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hands Are Weak|PQL10-Hands Are Weak|PQL10-Hands Are Weak|PQL1008	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: My hands are weak.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138648>	C138276	PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard to Use Bathroom|PQL10-Hard to Use Bathroom|PQL10-Hard to Use Bathroom|PQL1009	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: It is hard to use the bathroom.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138649>	C138276	PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard to Gain or Lose Weight|PQL10-Hard to Gain/Lose Weight|PQL10-Hard to Gain/Lose Weight|PQL1010	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: It is hard to gain or lose weight when I want to.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13864>	C13432	2p16.3	A chromosome band present on 2p			Gene or Genome	
C138650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138650>	C138276	PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard to Use Hands|PQL10-Hard to Use Hands|PQL10-Hard to Use Hands|PQL1011	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: It is hard to use my hands.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138651>	C138276	PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard to Swallow Food|PQL10-Hard to Swallow Food|PQL10-Hard to Swallow Food|PQL1012	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: It is hard to swallow food.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138652>	C138276	PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Long Time to Bathe or Shower|PQL10-Long Time to Bathe/Shower|PQL10-Long Time to Bathe/Shower|PQL1013	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: It takes me a long time to bathe or shower.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138653>	C138276	PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Get Hurt Accidentally|PQL10-Get Hurt Accidentally|PQL10-Get Hurt Accidentally|PQL1014	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: I get hurt accidentally.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138654>	C138276	PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Take Long Time to Eat|PQL10-Take Long Time to Eat|PQL10-Take Long Time to Eat|PQL1015	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: I take a long time to eat.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138655>	C138276	PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard to Turn During Night|PQL10-Hard to Turn During Night|PQL10-Hard to Turn During Night|PQL1016	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: It is hard to turn myself during the night.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138656>	C138276	PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard to Go Places With Equipment|PQL10-Hard to Go Places With Equipment|PQL10-Hard to Go Places With Equipment|PQL1017	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: It is hard for me to go places with my equipment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138657>	C138276	PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard Tell Doctors and Nurses How Feel|PQL10-Hard Tell Doctors/Nurses How Feel|PQL10-Hard Tell Doctors/Nurses How Feel|PQL1018	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: It is hard for me to tell the doctors and nurses how I feel.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138658>	C138276	PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard Ask Doctors and Nurses Questions|PQL10-Hard Ask Doctors/Nurses Questions|PQL10-Hard Ask Doctors/Nurses Questions|PQL1019	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: It is hard for me to ask the doctors and nurses questions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138659>	C138276	PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard Explain Illness to People|PQL10-Hard Explain Illness to People|PQL10-Hard Explain Illness to People|PQL1020	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: It is hard for me to explain my illness to other people.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13865>	C13432	10q22-q23	A chromosome band present on 10q			Gene or Genome	
C138660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138660>	C138276	PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard for Family to Plan Activities|PQL10-Hard for Family to Plan Activities|PQL10-Hard for Family to Plan Activities|PQL1021	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: It is hard for my family to plan activities like vacations.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138661>	C138276	PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Hard for Family to Rest|PQL10-Hard for Family to Rest|PQL10-Hard for Family to Rest|PQL1022	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: It is hard for my family to get enough rest.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138662>	C138276	PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Money Problem in Our Family|PQL10-Money Problem in Our Family|PQL10-Money Problem in Our Family|PQL1023	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: I think money is a problem in our family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138663>	C138276	PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Family Has Lot of Problems|PQL10-Family Has Lot of Problems|PQL10-Family Has Lot of Problems|PQL1024	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: I think my family has a lot of problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138664>	C138276	PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report - Do Not Have Equipment Need|PQL10-Do Not Have Equipment Need|PQL10-Do Not Have Equipment Need|PQL1025	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report) In the past 7 days, how much of a problem has this been for you: I do not have the equipment I need.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138665>	C138277	PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Hard to Breathe|PQL16-Hard to Breathe|PQL16-Hard to Breathe|PQL1601	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: It is hard to breathe.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138666>	C138277	PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Get Sick Easily|PQL16-Get Sick Easily|PQL16-Get Sick Easily|PQL1602	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: I get sick easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138667>	C138277	PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Get Sores and/or Rashes|PQL16-Get Sores and/or Rashes|PQL16-Get Sores and/or Rashes|PQL1603	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: I get sores and/or rashes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138668>	C138277	PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Legs Hurt|PQL16-Legs Hurt|PQL16-Legs Hurt|PQL1604	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: My legs hurt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138669>	C138277	PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Feel Tired|PQL16-Feel Tired|PQL16-Feel Tired|PQL1605	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: I feel tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13866>	C13432	14q31.1	A chromosome band present on 14q			Gene or Genome	
C138670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138670>	C138277	PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Back Feels Stiff|PQL16-Back Feels Stiff|PQL16-Back Feels Stiff|PQL1606	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: My back feels stiff.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138671>	C138277	PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Wake Up Tired|PQL16-Wake Up Tired|PQL16-Wake Up Tired|PQL1607	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: I wake up tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138672>	C138277	PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Hands Are Weak|PQL16-Hands Are Weak|PQL16-Hands Are Weak|PQL1608	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: My hands are weak.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138673>	C138277	PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Hard to Use Bathroom|PQL16-Hard to Use Bathroom|PQL16-Hard to Use Bathroom|PQL1609	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: It is hard to use the bathroom.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138674>	C138277	PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Hard to Gain or Lose Weight|PQL16-Hard to Gain/Lose Weight|PQL16-Hard to Gain/Lose Weight|PQL1610	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: It is hard to gain or lose weight when I want to.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138675>	C138277	PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Hard to Use Hands|PQL16-Hard to Use Hands|PQL16-Hard to Use Hands|PQL1611	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: It is hard to use my hands.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138676>	C138277	PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Hard to Swallow Food|PQL16-Hard to Swallow Food|PQL16-Hard to Swallow Food|PQL1612	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: It is hard to swallow food.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138677>	C138277	PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Long Time to Bathe or Shower|PQL16-Long Time to Bathe/Shower|PQL16-Long Time to Bathe/Shower|PQL1613	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: It takes me a long time to bathe or shower.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138678>	C138277	PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Get Hurt Accidentally|PQL16-Get Hurt Accidentally|PQL16-Get Hurt Accidentally|PQL1614	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: I get hurt accidentally.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138679>	C138277	PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Take Long Time to Eat|PQL16-Take Long Time to Eat|PQL16-Take Long Time to Eat|PQL1615	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: I take a long time to eat.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13867>	C13432	15q21.2	A chromosome band present on 15q			Gene or Genome	
C138680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138680>	C138277	PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Hard to Turn During Night|PQL16-Hard to Turn During Night|PQL16-Hard to Turn During Night|PQL1616	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: It is hard to turn myself during the night.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138681>	C138277	PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report - Hard to Go Places With Equipment|PQL16-Hard to Go Places With Equipment|PQL16-Hard to Go Places With Equipment|PQL1617	Pediatric Quality of Life Neuromuscular Module Acute Version 3.0 Young Child Report (PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report) Think about how you have been doing for the past 7 days. Please listen carefully to each sentence and tell me how much of a problem this is for you: It is hard for me to go places with my equipment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Acute Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138682>	C138278	PedsQL Neuromuscular Module Version 3.0 Child Report - Hard to Breathe|PQL05-Hard to Breathe|PQL05-Hard to Breathe|PQL0501	Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: It is hard to breathe.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138683>	C138278	PedsQL Neuromuscular Module Version 3.0 Child Report - Get Sick Easily|PQL05-Get Sick Easily|PQL05-Get Sick Easily|PQL0502	Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: I get sick easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138684>	C138278	PedsQL Neuromuscular Module Version 3.0 Child Report - Get Sores and/or Rashes|PQL05-Get Sores and/or Rashes|PQL05-Get Sores and/or Rashes|PQL0503	Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: I get sores and/or rashes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138685>	C138278	PedsQL Neuromuscular Module Version 3.0 Child Report - Legs Hurt|PQL05-Legs Hurt|PQL05-Legs Hurt|PQL0504	Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: My legs hurt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138686>	C138278	PedsQL Neuromuscular Module Version 3.0 Child Report - Feel Tired|PQL05-Feel Tired|PQL05-Feel Tired|PQL0505	Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: I feel tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138687>	C138278	PedsQL Neuromuscular Module Version 3.0 Child Report - Back Feels Stiff|PQL05-Back Feels Stiff|PQL05-Back Feels Stiff|PQL0506	Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: My back feels stiff.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138688>	C138278	PedsQL Neuromuscular Module Version 3.0 Child Report - Wake Up Tired|PQL05-Wake Up Tired|PQL05-Wake Up Tired|PQL0507	Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: I wake up tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138689>	C138278	PedsQL Neuromuscular Module Version 3.0 Child Report - Hands Are Weak|PQL05-Hands Are Weak|PQL05-Hands Are Weak|PQL0508	Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: My hands are weak.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13868>	C13432	13q21	A chromosome band present on 13q			Gene or Genome	
C138690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138690>	C138278	PedsQL Neuromuscular Module Version 3.0 Child Report - Hard to Use Bathroom|PQL05-Hard to Use Bathroom|PQL05-Hard to Use Bathroom|PQL0509	Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: It is hard to use the bathroom.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138691>	C138278	PedsQL Neuromuscular Module Version 3.0 Child Report - Hard to Gain or Lose Weight|PQL05-Hard to Gain/Lose Weight|PQL05-Hard to Gain/Lose Weight|PQL0510	Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: It is hard to gain or lose weight when I want to.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138692>	C138278	PedsQL Neuromuscular Module Version 3.0 Child Report - Hard to Use Hands|PQL05-Hard to Use Hands|PQL05-Hard to Use Hands|PQL0511	Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: It is hard to use my hands.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138693>	C138278	PedsQL Neuromuscular Module Version 3.0 Child Report - Hard to Swallow Food|PQL05-Hard to Swallow Food|PQL05-Hard to Swallow Food|PQL0512	Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: It is hard to swallow food.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138694>	C138278	PedsQL Neuromuscular Module Version 3.0 Child Report - Long Time to Bathe or Shower|PQL05-Long Time to Bathe/Shower|PQL05-Long Time to Bathe/Shower|PQL0513	Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: It takes me a long time to bathe or shower.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138695>	C138278	PedsQL Neuromuscular Module Version 3.0 Child Report - Get Hurt Accidentally|PQL05-Get Hurt Accidentally|PQL05-Get Hurt Accidentally|PQL0514	Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: I get hurt accidentally.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138696>	C138278	PedsQL Neuromuscular Module Version 3.0 Child Report - Take Long Time to Eat|PQL05-Take Long Time to Eat|PQL05-Take Long Time to Eat|PQL0515	Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: I take a long time to eat.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138697>	C138278	PedsQL Neuromuscular Module Version 3.0 Child Report - Hard to Turn During Night|PQL05-Hard to Turn During Night|PQL05-Hard to Turn During Night|PQL0516	Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: It is hard to turn myself during the night.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138698>	C138278	PedsQL Neuromuscular Module Version 3.0 Child Report - Hard to Go Places With Equipment|PQL05-Hard to Go Places With Equipment|PQL05-Hard to Go Places With Equipment|PQL0517	Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: It is hard for me to go places with my equipment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138699>	C138278	PedsQL Neuromuscular Module Version 3.0 Child Report - Hard Tell Doctors and Nurses How Feel|PQL05-Hard Tell Doctors/Nurses How Feel|PQL05-Hard Tell Doctors/Nurses How Feel|PQL0518	Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: It is hard for me to tell the doctors and nurses how I feel.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13869>	C13432	10q11-p12	A chromosome band present on 10q			Gene or Genome	
C1386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1386>	C461	Isosulfan Blue|ISOSULFAN BLUE|Lymphazurin|N-[4-[(4-(diethylamino)phenyl)(2,5-disulfophenyl)methylene]-2,5-cyclohexadien-1-ylidene]-N-ethyl-ethanaminium hydroxide|isosulfan blue	A synthetic visual lymphatic imaging agent.  Injected into the periphery of the tumor site, isosulfan blue localizes to the lymphatic system and aids in the surgical identification of tumor sentinel nodes which stain blue. (NCI04)	Isosulfan Blue		Indicator, Reagent, or Diagnostic Aid|Organic Chemical	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C138700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138700>	C138278	PedsQL Neuromuscular Module Version 3.0 Child Report - Hard Ask Doctors and Nurses Questions|PQL05-Hard Ask Doctors/Nurses Questions|PQL05-Hard Ask Doctors/Nurses Questions|PQL0519	Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: It is hard for me to ask the doctors and nurses questions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138701>	C138278	PedsQL Neuromuscular Module Version 3.0 Child Report - Hard Explain Illness to People|PQL05-Hard Explain Illness to People|PQL05-Hard Explain Illness to People|PQL0520	Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: It is hard for me to explain my illness to other people.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138702>	C138278	PedsQL Neuromuscular Module Version 3.0 Child Report - Hard for Family to Plan Activities|PQL05-Hard for Family to Plan Activities|PQL05-Hard for Family to Plan Activities|PQL0521	Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: It is hard for my family to plan activities like vacations.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138703>	C138278	PedsQL Neuromuscular Module Version 3.0 Child Report - Hard for Family to Rest|PQL05-Hard for Family to Rest|PQL05-Hard for Family to Rest|PQL0522	Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: It is hard for my family to get enough rest.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138704>	C138278	PedsQL Neuromuscular Module Version 3.0 Child Report - Money Problem in Our Family|PQL05-Money Problem in Our Family|PQL05-Money Problem in Our Family|PQL0523	Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: I think money is a problem in our family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138705>	C138278	PedsQL Neuromuscular Module Version 3.0 Child Report - Family Has Lot of Problems|PQL05-Family Has Lot of Problems|PQL05-Family Has Lot of Problems|PQL0524	Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: I think my family has a lot of problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138706>	C138278	PedsQL Neuromuscular Module Version 3.0 Child Report - Do Not Have Equipment Need|PQL05-Do Not Have Equipment Need|PQL05-Do Not Have Equipment Need|PQL0525	Pediatric Quality of Life Neuromuscular Module Version 3.0 Child Report (PedsQL Neuromuscular Module Version 3.0 Child Report) In the past one month, how much of a problem has this been for you: I do not have the equipment I need.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138707>	C138279	PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard to Breathe|PQL09-Hard to Breathe|PQL09-Hard to Breathe|PQL0901	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: It is hard for my child to breathe.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138708>	C138279	PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Get Sick Easily|PQL09-Get Sick Easily|PQL09-Get Sick Easily|PQL0902	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: My child gets sick easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138709>	C138279	PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Get Sores and/or Rashes|PQL09-Get Sores and/or Rashes|PQL09-Get Sores and/or Rashes|PQL0903	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: My child gets sores and/or rashes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13870>	C13432	11q13.1-q13.2	A chromosome band present on 11q			Gene or Genome	
C138710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138710>	C138279	PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Legs Hurt|PQL09-Legs Hurt|PQL09-Legs Hurt|PQL0904	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: My child's legs hurt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138711>	C138279	PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Feel Tired|PQL09-Feel Tired|PQL09-Feel Tired|PQL0905	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: My child feels tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138712>	C138279	PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Back Feels Stiff|PQL09-Back Feels Stiff|PQL09-Back Feels Stiff|PQL0906	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: My child's back feels stiff.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138713>	C138279	PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Wake Up Tired|PQL09-Wake Up Tired|PQL09-Wake Up Tired|PQL0907	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: My child wakes up tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138714>	C138279	PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hands Are Weak|PQL09-Hands Are Weak|PQL09-Hands Are Weak|PQL0908	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: My child's hands are weak.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138715>	C138279	PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard to Use Bathroom|PQL09-Hard to Use Bathroom|PQL09-Hard to Use Bathroom|PQL0909	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: It is hard for my child to use the bathroom.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138716>	C138279	PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard to Gain or Lose Weight|PQL09-Hard to Gain/Lose Weight|PQL09-Hard to Gain/Lose Weight|PQL0910	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: It is hard for my child to gain or lose weight when he or she wants to.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138717>	C138279	PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard to Use Hands|PQL09-Hard to Use Hands|PQL09-Hard to Use Hands|PQL0911	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: It is hard for my child to use his or her hands.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138718>	C138279	PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard to Swallow Food|PQL09-Hard to Swallow Food|PQL09-Hard to Swallow Food|PQL0912	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: It is hard for my child to swallow food.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138719>	C138279	PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Long Time to Bathe or Shower|PQL09-Long Time to Bathe/Shower|PQL09-Long Time to Bathe/Shower|PQL0913	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: It takes my child a long time to bathe or shower.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13871>	C13432	8p22-p21.3	A chromosome band present on 8p			Gene or Genome	
C138720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138720>	C138279	PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Get Hurt Accidentally|PQL09-Get Hurt Accidentally|PQL09-Get Hurt Accidentally|PQL0914	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: My child gets hurt accidentally.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138721>	C138279	PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Take Long Time to Eat|PQL09-Take Long Time to Eat|PQL09-Take Long Time to Eat|PQL0915	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: My child takes a long time to eat.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138722>	C138279	PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard to Turn During Night|PQL09-Hard to Turn During Night|PQL09-Hard to Turn During Night|PQL0916	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: It is hard for my child to turn him or herself during the night.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138723>	C138279	PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard to Go Places With Equipment|PQL09-Hard to Go Places With Equipment|PQL09-Hard to Go Places With Equipment|PQL0917	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: It is hard for my child to go places with his or her equipment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138724>	C138279	PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard Tell Doctors and Nurses How Feel|PQL09-Hard Tell Doctors/Nurses How Feel|PQL09-Hard Tell Doctors/Nurses How Feel|PQL0918	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: It is hard for my child to tell the doctors and nurses how he or she feels.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138725>	C138279	PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard Ask Doctors and Nurses Questions|PQL09-Hard Ask Doctors/Nurses Questions|PQL09-Hard Ask Doctors/Nurses Questions|PQL0919	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: It is hard for my child to ask the doctors and nurses questions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138726>	C138279	PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard Explain Illness to People|PQL09-Hard Explain Illness to People|PQL09-Hard Explain Illness to People|PQL0920	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: It is hard for my child to explain his or her illness to other people.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138727>	C138279	PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard for Family to Plan Activities|PQL09-Hard for Family to Plan Activities|PQL09-Hard for Family to Plan Activities|PQL0921	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: It is hard for our family to plan activities like vacations.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138728>	C138279	PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Hard for Family to Rest|PQL09-Hard for Family to Rest|PQL09-Hard for Family to Rest|PQL0922	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: It is hard for our family to get enough rest.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138729>	C138279	PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Money Problem in Our Family|PQL09-Money Problem in Our Family|PQL09-Money Problem in Our Family|PQL0923	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: I think money is a problem in our family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13872>	C13432	13q13.3	A chromosome band present on 13q			Gene or Genome	
C138730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138730>	C138279	PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Family Has Lot of Problems|PQL09-Family Has Lot of Problems|PQL09-Family Has Lot of Problems|PQL0924	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: I think our family has a lot of problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138731>	C138279	PedsQL Neuromuscular Module Version 3.0 Parent of Toddler - Do Not Have Equipment Need|PQL09-Do Not Have Equipment Need|PQL09-Do Not Have Equipment Need|PQL0925	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent of Toddler (PedsQL Neuromuscular Module Version 3.0 Parent of Toddler) In the past one month, how much of a problem has this been for your child: My child does not have the equipment he or she needs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent of Toddler Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138732>	C138280	PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard to Breathe|PQL06-Hard to Breathe|PQL06-Hard to Breathe|PQL0601	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to breathe.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138733>	C138280	PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Get Sick Easily|PQL06-Get Sick Easily|PQL06-Get Sick Easily|PQL0602	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: My child gets sick easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138734>	C138280	PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Get Sores and/or Rashes|PQL06-Get Sores and/or Rashes|PQL06-Get Sores and/or Rashes|PQL0603	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: My child gets sores and/or rashes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138735>	C138280	PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Legs Hurt|PQL06-Legs Hurt|PQL06-Legs Hurt|PQL0604	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: My child's legs hurt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138736>	C138280	PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Feel Tired|PQL06-Feel Tired|PQL06-Feel Tired|PQL0605	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: My child feels tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138737>	C138280	PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Back Feels Stiff|PQL06-Back Feels Stiff|PQL06-Back Feels Stiff|PQL0606	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: My child's back feels stiff.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138738>	C138280	PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Wake Up Tired|PQL06-Wake Up Tired|PQL06-Wake Up Tired|PQL0607	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: My child wakes up tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138739>	C138280	PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hands Are Weak|PQL06-Hands Are Weak|PQL06-Hands Are Weak|PQL0608	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: My child's hands are weak.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13873>	C13432	5q13.1	A chromosome band present on 5q			Gene or Genome	
C138740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138740>	C138280	PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard to Use Bathroom|PQL06-Hard to Use Bathroom|PQL06-Hard to Use Bathroom|PQL0609	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to use the bathroom.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138741>	C138280	PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard to Gain or Lose Weight|PQL06-Hard to Gain/Lose Weight|PQL06-Hard to Gain/Lose Weight|PQL0610	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to gain or lose weight when he or she wants to.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138742>	C138280	PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard to Use Hands|PQL06-Hard to Use Hands|PQL06-Hard to Use Hands|PQL0611	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to use his or her hands.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138743>	C138280	PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard to Swallow Food|PQL06-Hard to Swallow Food|PQL06-Hard to Swallow Food|PQL0612	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to swallow food.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138744>	C138280	PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Long Time to Bathe or Shower|PQL06-Long Time to Bathe/Shower|PQL06-Long Time to Bathe/Shower|PQL0613	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: It takes my child a long time to bathe or shower.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138745>	C138280	PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Get Hurt Accidentally|PQL06-Get Hurt Accidentally|PQL06-Get Hurt Accidentally|PQL0614	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: My child gets hurt accidentally.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138746>	C138280	PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Take Long Time to Eat|PQL06-Take Long Time to Eat|PQL06-Take Long Time to Eat|PQL0615	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: My child takes a long time to eat.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138747>	C138280	PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard to Turn During Night|PQL06-Hard to Turn During Night|PQL06-Hard to Turn During Night|PQL0616	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to turn him or herself during the night.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138748>	C138280	PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard to Go Places With Equipment|PQL06-Hard to Go Places With Equipment|PQL06-Hard to Go Places With Equipment|PQL0617	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to go places with his or her equipment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138749>	C138280	PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard Tell Doctors and Nurses How Feel|PQL06-Hard Tell Doctors/Nurses How Feel|PQL06-Hard Tell Doctors/Nurses How Feel|PQL0618	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to tell the doctors and nurses how he or she feels.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13874>	C13432	5q12-q13	A chromosome band present on 5q			Gene or Genome	
C138750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138750>	C138280	PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard Ask Doctors and Nurses Questions|PQL06-Hard Ask Doctors/Nurses Questions|PQL06-Hard Ask Doctors/Nurses Questions|PQL0619	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to ask the doctors and nurses questions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138751>	C138280	PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard Explain Illness to People|PQL06-Hard Explain Illness to People|PQL06-Hard Explain Illness to People|PQL0620	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to explain his or her illness to other people.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138752>	C138280	PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard for Family to Plan Activities|PQL06-Hard for Family to Plan Activities|PQL06-Hard for Family to Plan Activities|PQL0621	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: It is hard for our family to plan activities like vacations.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138753>	C138280	PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Hard for Family to Rest|PQL06-Hard for Family to Rest|PQL06-Hard for Family to Rest|PQL0622	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: It is hard for our family to get enough rest.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138754>	C138280	PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Money Problem in Our Family|PQL06-Money Problem in Our Family|PQL06-Money Problem in Our Family|PQL0623	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: I think money is a problem in our family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138755>	C138280	PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Family Has Lot of Problems|PQL06-Family Has Lot of Problems|PQL06-Family Has Lot of Problems|PQL0624	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: I think our family has a lot of problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138756>	C138280	PedsQL Neuromuscular Module Version 3.0 Parent Report for Child - Do Not Have Equipment Need|PQL06-Do Not Have Equipment Need|PQL06-Do Not Have Equipment Need|PQL0625	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Child) In the past one month, how much of a problem has this been for your child: My child does not have the equipment he or she needs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138757>	C138281	PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard to Breathe|PQL04-Hard to Breathe|PQL04-Hard to Breathe|PQL0401	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: It is hard for my child to breathe.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138758>	C138281	PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Get Sick Easily|PQL04-Get Sick Easily|PQL04-Get Sick Easily|PQL0402	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: My child gets sick easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138759>	C138281	PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Get Sores and/or Rashes|PQL04-Get Sores and/or Rashes|PQL04-Get Sores and/or Rashes|PQL0403	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: My child gets sores and/or rashes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13875>	C13432	Xp11.21-p11.22	A chromosome band present on Xp			Gene or Genome	
C138760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138760>	C138281	PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Legs Hurt|PQL04-Legs Hurt|PQL04-Legs Hurt|PQL0404	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: My child's legs hurt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138761>	C138281	PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Feel Tired|PQL04-Feel Tired|PQL04-Feel Tired|PQL0405	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: My child feels tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138762>	C138281	PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Back Feels Stiff|PQL04-Back Feels Stiff|PQL04-Back Feels Stiff|PQL0406	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: My child's back feels stiff.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138763>	C138281	PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Wake Up Tired|PQL04-Wake Up Tired|PQL04-Wake Up Tired|PQL0407	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: My child wakes up tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138764>	C138281	PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hands Are Weak|PQL04-Hands Are Weak|PQL04-Hands Are Weak|PQL0408	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: My child's hands are weak.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138765>	C138281	PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard to Use Bathroom|PQL04-Hard to Use Bathroom|PQL04-Hard to Use Bathroom|PQL0409	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: It is hard for my child to use the bathroom.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138766>	C138281	PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard to Gain or Lose Weight|PQL04-Hard to Gain/Lose Weight|PQL04-Hard to Gain/Lose Weight|PQL0410	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: It is hard for my child to gain or lose weight when he or she wants to.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138767>	C138281	PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard to Use Hands|PQL04-Hard to Use Hands|PQL04-Hard to Use Hands|PQL0411	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: It is hard for my child to use his or her hands.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138768>	C138281	PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard to Swallow Food|PQL04-Hard to Swallow Food|PQL04-Hard to Swallow Food|PQL0412	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: It is hard for my child to swallow food.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138769>	C138281	PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Long Time to Bathe or Shower|PQL04-Long Time to Bathe/Shower|PQL04-Long Time to Bathe/Shower|PQL0413	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: It takes my child a long time to bathe or shower.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13876>	C13432	11q13.1	A chromosome band present on 11q			Gene or Genome	
C138770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138770>	C138281	PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Get Hurt Accidentally|PQL04-Get Hurt Accidentally|PQL04-Get Hurt Accidentally|PQL0414	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: My child gets hurt accidentally.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138771>	C138281	PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Take Long Time to Eat|PQL04-Take Long Time to Eat|PQL04-Take Long Time to Eat|PQL0415	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: My child takes a long time to eat.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138772>	C138281	PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard to Turn During Night|PQL04-Hard to Turn During Night|PQL04-Hard to Turn During Night|PQL0416	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: It is hard for my child to turn him or herself during the night.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138773>	C138281	PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard to Go Places With Equipment|PQL04-Hard to Go Places With Equipment|PQL04-Hard to Go Places With Equipment|PQL0417	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: It is hard for my child to go places with his or her equipment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138774>	C138281	PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard Tell Doctors and Nurses How Feel|PQL04-Hard Tell Doctors/Nurses How Feel|PQL04-Hard Tell Doctors/Nurses How Feel|PQL0418	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: It is hard for my child to tell the doctors and nurses how he or she feels.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138775>	C138281	PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard Ask Doctors and Nurses Questions|PQL04-Hard Ask Doctors/Nurses Questions|PQL04-Hard Ask Doctors/Nurses Questions|PQL0419	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: It is hard for my child to ask the doctors and nurses questions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138776>	C138281	PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard Explain Illness to People|PQL04-Hard Explain Illness to People|PQL04-Hard Explain Illness to People|PQL0420	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: It is hard for my child to explain his or her illness to other people.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138777>	C138281	PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard for Family to Plan Activities|PQL04-Hard for Family to Plan Activities|PQL04-Hard for Family to Plan Activities|PQL0421	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: It is hard for our family to plan activities like vacations.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138778>	C138281	PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Hard for Family to Rest|PQL04-Hard for Family to Rest|PQL04-Hard for Family to Rest|PQL0422	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: It is hard for our family to get enough rest.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138779>	C138281	PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Money Problem in Our Family|PQL04-Money Problem in Our Family|PQL04-Money Problem in Our Family|PQL0423	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: I think money is a problem in our family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13877>	C13432	17p13.2	A chromosome band present on 17p			Gene or Genome	
C138780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138780>	C138281	PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Family Has Lot of Problems|PQL04-Family Has Lot of Problems|PQL04-Family Has Lot of Problems|PQL0424	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: I think our family has a lot of problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138781>	C138281	PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen - Do Not Have Equipment Need|PQL04-Do Not Have Equipment Need|PQL04-Do Not Have Equipment Need|PQL0425	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Teen (PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen) In the past one month, how much of a problem has this been for your teen: My child does not have the equipment he or she needs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Teen Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138782>	C138282	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard to Breathe|PQL02-Hard to Breathe|PQL02-Hard to Breathe|PQL0201	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: It is hard for my child to breathe.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138783>	C138282	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Get Sick Easily|PQL02-Get Sick Easily|PQL02-Get Sick Easily|PQL0202	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: My child gets sick easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138784>	C138282	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Get Sores and/or Rashes|PQL02-Get Sores and/or Rashes|PQL02-Get Sores and/or Rashes|PQL0203	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: My child gets sores and/or rashes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138785>	C138282	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Legs Hurt|PQL02-Legs Hurt|PQL02-Legs Hurt|PQL0204	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: My child's legs hurt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138786>	C138282	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Feel Tired|PQL02-Feel Tired|PQL02-Feel Tired|PQL0205	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: My child feels tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138787>	C138282	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Back Feels Stiff|PQL02-Back Feels Stiff|PQL02-Back Feels Stiff|PQL0206	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: My child's back feels stiff.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138788>	C138282	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Wake Up Tired|PQL02-Wake Up Tired|PQL02-Wake Up Tired|PQL0207	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: My child wakes up tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138789>	C138282	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hands Are Weak|PQL02-Hands Are Weak|PQL02-Hands Are Weak|PQL0208	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: My child's hands are weak.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13878>	C13432	22q13.2-q13.31	A chromosome band present on 22q			Gene or Genome	
C138790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138790>	C138282	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard to Use Bathroom|PQL02-Hard to Use Bathroom|PQL02-Hard to Use Bathroom|PQL0209	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: It is hard for my child to use the bathroom.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138791>	C138282	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard to Gain or Lose Weight|PQL02-Hard to Gain/Lose Weight|PQL02-Hard to Gain/Lose Weight|PQL0210	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: It is hard for my child to gain or lose weight when he or she wants to.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138792>	C138282	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard to Use Hands|PQL02-Hard to Use Hands|PQL02-Hard to Use Hands|PQL0211	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: It is hard for my child to use his or her hands.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138793>	C138282	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard to Swallow Food|PQL02-Hard to Swallow Food|PQL02-Hard to Swallow Food|PQL0212	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: It is hard for my child to swallow food.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138794>	C138282	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Long Time to Bathe or Shower|PQL02-Long Time to Bathe/Shower|PQL02-Long Time to Bathe/Shower|PQL0213	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: It takes my child a long time to bathe or shower.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138795>	C138282	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Get Hurt Accidentally|PQL02-Get Hurt Accidentally|PQL02-Get Hurt Accidentally|PQL0214	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: My child gets hurt accidentally.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138796>	C138282	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Take Long Time to Eat|PQL02-Take Long Time to Eat|PQL02-Take Long Time to Eat|PQL0215	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: My child takes a long time to eat.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138797>	C138282	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard to Turn During Night|PQL02-Hard to Turn During Night|PQL02-Hard to Turn During Night|PQL0216	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: It is hard for my child to turn him or herself during the night.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138798>	C138282	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard to Go Places With Equipment|PQL02-Hard to Go Places With Equipment|PQL02-Hard to Go Places With Equipment|PQL0217	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: It is hard for my child to go places with his or her equipment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138799>	C138282	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard Tell Doctors and Nurses How Feel|PQL02-Hard Tell Doctors/Nurses How Feel|PQL02-Hard Tell Doctors/Nurses How Feel|PQL0218	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: It is hard for my child to tell the doctors and nurses how he or she feels.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13879>	C13432	1p31-p22	A chromosome band present on 1p			Gene or Genome	
C1387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1387>	C912	MAGE-1 Antigen	A cancer specific antigen expressed by the melanoma antigen gene.			Amino Acid, Peptide, or Protein|Immunologic Factor	
C138800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138800>	C138282	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard Ask Doctors and Nurses Questions|PQL02-Hard Ask Doctors/Nurses Questions|PQL02-Hard Ask Doctors/Nurses Questions|PQL0219	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: It is hard for my child to ask the doctors and nurses questions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138801>	C138282	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard Explain Illness to People|PQL02-Hard Explain Illness to People|PQL02-Hard Explain Illness to People|PQL0220	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: It is hard for my child to explain his or her illness to other people.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138802>	C138282	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard for Family to Plan Activities|PQL02-Hard for Family to Plan Activities|PQL02-Hard for Family to Plan Activities|PQL0221	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: It is hard for our family to plan activities like vacations.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138803>	C138282	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Hard for Family to Rest|PQL02-Hard for Family to Rest|PQL02-Hard for Family to Rest|PQL0222	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: It is hard for our family to get enough rest.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138804>	C138282	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Money Problem in Our Family|PQL02-Money Problem in Our Family|PQL02-Money Problem in Our Family|PQL0223	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: I think money is a problem in our family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138805>	C138282	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Family Has Lot of Problems|PQL02-Family Has Lot of Problems|PQL02-Family Has Lot of Problems|PQL0224	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: I think our family has a lot of problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138806>	C138282	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report - Do Not Have Equipment Need|PQL02-Do Not Have Equipment Need|PQL02-Do Not Have Equipment Need|PQL0225	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Adults Report (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report) In the past one month, how much of a problem has this been for your child: My child does not have the equipment he or she needs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Adults Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138807>	C138283	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard to Breathe|PQL08-Hard to Breathe|PQL08-Hard to Breathe|PQL0801	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to breathe.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138808>	C138283	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Get Sick Easily|PQL08-Get Sick Easily|PQL08-Get Sick Easily|PQL0802	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: My child gets sick easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138809>	C138283	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Get Sores and/or Rashes|PQL08-Get Sores and/or Rashes|PQL08-Get Sores and/or Rashes|PQL0803	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: My child gets sores and/or rashes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13880>	C13432	2p21	A chromosome band present on 2p			Gene or Genome	
C138810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138810>	C138283	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Legs Hurt|PQL08-Legs Hurt|PQL08-Legs Hurt|PQL0804	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: My child's legs hurt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138811>	C138283	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Feel Tired|PQL08-Feel Tired|PQL08-Feel Tired|PQL0805	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: My child feels tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138812>	C138283	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Back Feels Stiff|PQL08-Back Feels Stiff|PQL08-Back Feels Stiff|PQL0806	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: My child's back feels stiff.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138813>	C138283	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Wake Up Tired|PQL08-Wake Up Tired|PQL08-Wake Up Tired|PQL0807	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: My child wakes up tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138814>	C138283	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hands Are Weak|PQL08-Hands Are Weak|PQL08-Hands Are Weak|PQL0808	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: My child's hands are weak.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138815>	C138283	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard to Use Bathroom|PQL08-Hard to Use Bathroom|PQL08-Hard to Use Bathroom|PQL0809	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to use the bathroom.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138816>	C138283	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard to Gain or Lose Weight|PQL08-Hard to Gain/Lose Weight|PQL08-Hard to Gain/Lose Weight|PQL0810	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to gain or lose weight when he or she wants to.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138817>	C138283	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard to Use Hands|PQL08-Hard to Use Hands|PQL08-Hard to Use Hands|PQL0811	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to use his or her hands.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138818>	C138283	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard to Swallow Food|PQL08-Hard to Swallow Food|PQL08-Hard to Swallow Food|PQL0812	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to swallow food.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138819>	C138283	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Long Time to Bathe or Shower|PQL08-Long Time to Bathe/Shower|PQL08-Long Time to Bathe/Shower|PQL0813	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: It takes my child a long time to bathe or shower.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13881>	C13432	1q32	A chromosome band present on 1q	1q32		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138820>	C138283	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Get Hurt Accidentally|PQL08-Get Hurt Accidentally|PQL08-Get Hurt Accidentally|PQL0814	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: My child gets hurt accidentally.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138821>	C138283	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Take Long Time to Eat|PQL08-Take Long Time to Eat|PQL08-Take Long Time to Eat|PQL0815	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: My child takes a long time to eat.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138822>	C138283	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard to Turn During Night|PQL08-Hard to Turn During Night|PQL08-Hard to Turn During Night|PQL0816	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to turn him or herself during the night.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138823>	C138283	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard to Go Places With Equipment|PQL08-Hard to Go Places With Equipment|PQL08-Hard to Go Places With Equipment|PQL0817	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to go places with his or her equipment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138824>	C138283	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard Tell Doctors and Nurses How Feel|PQL08-Hard Tell Doctors/Nurses How Feel|PQL08-Hard Tell Doctors/Nurses How Feel|PQL0818	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to tell the doctors and nurses how he or she feels.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138825>	C138283	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard Ask Doctors and Nurses Questions|PQL08-Hard Ask Doctors/Nurses Questions|PQL08-Hard Ask Doctors/Nurses Questions|PQL0819	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to ask the doctors and nurses questions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138826>	C138283	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard Explain Illness to People|PQL08-Hard Explain Illness to People|PQL08-Hard Explain Illness to People|PQL0820	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: It is hard for my child to explain his or her illness to other people.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138827>	C138283	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard for Family to Plan Activities|PQL08-Hard for Family to Plan Activities|PQL08-Hard for Family to Plan Activities|PQL0821	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: It is hard for our family to plan activities like vacations.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138828>	C138283	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Hard for Family to Rest|PQL08-Hard for Family to Rest|PQL08-Hard for Family to Rest|PQL0822	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: It is hard for our family to get enough rest.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138829>	C138283	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Money Problem in Our Family|PQL08-Money Problem in Our Family|PQL08-Money Problem in Our Family|PQL0823	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: I think money is a problem in our family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13882>	C13432	17q11-q21.3	A chromosome band present on 17q			Gene or Genome	
C138830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138830>	C138283	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Family Has Lot of Problems|PQL08-Family Has Lot of Problems|PQL08-Family Has Lot of Problems|PQL0824	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: I think our family has a lot of problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138831>	C138283	PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child - Do Not Have Equipment Need|PQL08-Do Not Have Equipment Need|PQL08-Do Not Have Equipment Need|PQL0825	Pediatric Quality of Life Neuromuscular Module Version 3.0 Parent Report for Young Child (PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child) In the past one month, how much of a problem has this been for your child: My child does not have the equipment he or she needs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Parent Report for Young Child Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138832>	C138284	PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard to Breathe|PQL03-Hard to Breathe|PQL03-Hard to Breathe|PQL0301	Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: It is hard to breathe.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138833>	C138284	PedsQL Neuromuscular Module Version 3.0 Teen Report - Get Sick Easily|PQL03-Get Sick Easily|PQL03-Get Sick Easily|PQL0302	Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: I get sick easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138834>	C138284	PedsQL Neuromuscular Module Version 3.0 Teen Report - Get Sores and/or Rashes|PQL03-Get Sores and/or Rashes|PQL03-Get Sores and/or Rashes|PQL0303	Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: I get sores and/or rashes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138835>	C138284	PedsQL Neuromuscular Module Version 3.0 Teen Report - Legs Hurt|PQL03-Legs Hurt|PQL03-Legs Hurt|PQL0304	Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: My legs hurt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138836>	C138284	PedsQL Neuromuscular Module Version 3.0 Teen Report - Feel Tired|PQL03-Feel Tired|PQL03-Feel Tired|PQL0305	Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: I feel tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138837>	C138284	PedsQL Neuromuscular Module Version 3.0 Teen Report - Back Feels Stiff|PQL03-Back Feels Stiff|PQL03-Back Feels Stiff|PQL0306	Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: My back feels stiff.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138838>	C138284	PedsQL Neuromuscular Module Version 3.0 Teen Report - Wake Up Tired|PQL03-Wake Up Tired|PQL03-Wake Up Tired|PQL0307	Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: I wake up tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138839>	C138284	PedsQL Neuromuscular Module Version 3.0 Teen Report - Hands Are Weak|PQL03-Hands Are Weak|PQL03-Hands Are Weak|PQL0308	Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: My hands are weak.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13883>	C13432	15q22.2	A chromosome band present on 15q			Gene or Genome	
C138840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138840>	C138284	PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard to Use Bathroom|PQL03-Hard to Use Bathroom|PQL03-Hard to Use Bathroom|PQL0309	Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: It is hard to use the bathroom.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138841>	C138284	PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard to Gain or Lose Weight|PQL03-Hard to Gain/Lose Weight|PQL03-Hard to Gain/Lose Weight|PQL0310	Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: It is hard to gain or lose weight when I want to.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138842>	C138284	PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard to Use Hands|PQL03-Hard to Use Hands|PQL03-Hard to Use Hands|PQL0311	Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: It is hard to use my hands.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138843>	C138284	PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard to Swallow Food|PQL03-Hard to Swallow Food|PQL03-Hard to Swallow Food|PQL0312	Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: It is hard to swallow food.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138844>	C138284	PedsQL Neuromuscular Module Version 3.0 Teen Report - Long Time to Bathe or Shower|PQL03-Long Time to Bathe/Shower|PQL03-Long Time to Bathe/Shower|PQL0313	Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: It takes me a long time to bathe or shower.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138845>	C138284	PedsQL Neuromuscular Module Version 3.0 Teen Report - Get Hurt Accidentally|PQL03-Get Hurt Accidentally|PQL03-Get Hurt Accidentally|PQL0314	Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: I get hurt accidentally.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138846>	C138284	PedsQL Neuromuscular Module Version 3.0 Teen Report - Take Long Time to Eat|PQL03-Take Long Time to Eat|PQL03-Take Long Time to Eat|PQL0315	Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: I take a long time to eat.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138847>	C138284	PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard to Turn During Night|PQL03-Hard to Turn During Night|PQL03-Hard to Turn During Night|PQL0316	Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: It is hard to turn myself during the night.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138848>	C138284	PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard to Go Places With Equipment|PQL03-Hard to Go Places With Equipment|PQL03-Hard to Go Places With Equipment|PQL0317	Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: It is hard for me to go places with my equipment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138849>	C138284	PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard Tell Doctors and Nurses How Feel|PQL03-Hard Tell Doctors/Nurses How Feel|PQL03-Hard Tell Doctors/Nurses How Feel|PQL0318	Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: It is hard for me to tell the doctors and nurses how I feel.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13884>	C13432	20pter-q12	A chromosome band present on 20p			Gene or Genome	
C138850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138850>	C138284	PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard Ask Doctors and Nurses Questions|PQL03-Hard Ask Doctors/Nurses Questions|PQL03-Hard Ask Doctors/Nurses Questions|PQL0319	Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: It is hard for me to ask the doctors and nurses questions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138851>	C138284	PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard Explain Illness to People|PQL03-Hard Explain Illness to People|PQL03-Hard Explain Illness to People|PQL0320	Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: It is hard for me to explain my illness to other people.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138852>	C138284	PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard for Family to Plan Activities|PQL03-Hard for Family to Plan Activities|PQL03-Hard for Family to Plan Activities|PQL0321	Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: It is hard for my family to plan activities like vacations.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138853>	C138284	PedsQL Neuromuscular Module Version 3.0 Teen Report - Hard for Family to Rest|PQL03-Hard for Family to Rest|PQL03-Hard for Family to Rest|PQL0322	Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: It is hard for my family to get enough rest.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138854>	C138284	PedsQL Neuromuscular Module Version 3.0 Teen Report - Money Problem in Our Family|PQL03-Money Problem in Our Family|PQL03-Money Problem in Our Family|PQL0323	Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: I think money is a problem in our family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138855>	C138284	PedsQL Neuromuscular Module Version 3.0 Teen Report - Family Has Lot of Problems|PQL03-Family Has Lot of Problems|PQL03-Family Has Lot of Problems|PQL0324	Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: I think my family has a lot of problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138856>	C138284	PedsQL Neuromuscular Module Version 3.0 Teen Report - Do Not Have Equipment Need|PQL03-Do Not Have Equipment Need|PQL03-Do Not Have Equipment Need|PQL0325	Pediatric Quality of Life Neuromuscular Module Version 3.0 Teen Report (PedsQL Neuromuscular Module Version 3.0 Teen Report) In the past one month, how much of a problem has this been for you: I do not have the equipment I need.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Teen Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138857>	C138285	PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard to Breathe|PQL01-Hard to Breathe|PQL01-Hard to Breathe|PQL0101	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: It is hard to breathe.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138858>	C138285	PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Get Sick Easily|PQL01-Get Sick Easily|PQL01-Get Sick Easily|PQL0102	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: I get sick easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138859>	C138285	PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Get Sores and/or Rashes|PQL01-Get Sores and/or Rashes|PQL01-Get Sores and/or Rashes|PQL0103	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: I get sores and/or rashes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13885>	C13432	1q42.1-q43	A chromosome band present on 1q			Gene or Genome	
C138860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138860>	C138285	PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Legs Hurt|PQL01-Legs Hurt|PQL01-Legs Hurt|PQL0104	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: My legs hurt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138861>	C138285	PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Feel Tired|PQL01-Feel Tired|PQL01-Feel Tired|PQL0105	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: I feel tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138862>	C138285	PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Back Feels Stiff|PQL01-Back Feels Stiff|PQL01-Back Feels Stiff|PQL0106	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: My back feels stiff.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138863>	C138285	PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Wake Up Tired|PQL01-Wake Up Tired|PQL01-Wake Up Tired|PQL0107	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: I wake up tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138864>	C138285	PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hands Are Weak|PQL01-Hands Are Weak|PQL01-Hands Are Weak|PQL0108	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: My hands are weak.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138865>	C138285	PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard to Use Bathroom|PQL01-Hard to Use Bathroom|PQL01-Hard to Use Bathroom|PQL0109	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: It is hard to use the bathroom.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138866>	C138285	PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard to Gain or Lose Weight|PQL01-Hard to Gain/Lose Weight|PQL01-Hard to Gain/Lose Weight|PQL0110	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: It is hard to gain or lose weight when I want to.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138867>	C138285	PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard to Use Hands|PQL01-Hard to Use Hands|PQL01-Hard to Use Hands|PQL0111	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: It is hard to use my hands.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138868>	C138285	PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard to Swallow Food|PQL01-Hard to Swallow Food|PQL01-Hard to Swallow Food|PQL0112	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: It is hard to swallow food.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138869>	C138285	PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Long Time to Bathe or Shower|PQL01-Long Time to Bathe/Shower|PQL01-Long Time to Bathe/Shower|PQL0113	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: It takes me a long time to bathe or shower.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13886>	C13432	22q11.23	A chromosome band present on 22q			Gene or Genome	
C138870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138870>	C138285	PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Get Hurt Accidentally|PQL01-Get Hurt Accidentally|PQL01-Get Hurt Accidentally|PQL0114	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: I get hurt accidentally.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138871>	C138285	PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Take Long Time to Eat|PQL01-Take Long Time to Eat|PQL01-Take Long Time to Eat|PQL0115	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: I take a long time to eat.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138872>	C138285	PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard to Turn During Night|PQL01-Hard to Turn During Night|PQL01-Hard to Turn During Night|PQL0116	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: It is hard to turn myself during the night.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138873>	C138285	PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard to Go Places With Equipment|PQL01-Hard to Go Places With Equipment|PQL01-Hard to Go Places With Equipment|PQL0117	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: It is hard for me to go places with my equipment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138874>	C138285	PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard Tell Doctors and Nurses How Feel|PQL01-Hard Tell Doctors/Nurses How Feel|PQL01-Hard Tell Doctors/Nurses How Feel|PQL0118	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: It is hard for me to tell the doctors and nurses how I feel.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138875>	C138285	PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard Ask Doctors and Nurses Questions|PQL01-Hard Ask Doctors/Nurses Questions|PQL01-Hard Ask Doctors/Nurses Questions|PQL0119	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: It is hard for me to ask the doctors and nurses questions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138876>	C138285	PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard Explain Illness to People|PQL01-Hard Explain Illness to People|PQL01-Hard Explain Illness to People|PQL0120	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: It is hard for me to explain my illness to other people.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138877>	C138285	PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard for Family to Plan Activities|PQL01-Hard for Family to Plan Activities|PQL01-Hard for Family to Plan Activities|PQL0121	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: It is hard for my family to plan activities like vacations.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138878>	C138285	PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Hard for Family to Rest|PQL01-Hard for Family to Rest|PQL01-Hard for Family to Rest|PQL0122	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: It is hard for my family to get enough rest.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138879>	C138285	PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Money Problem in Our Family|PQL01-Money Problem in Our Family|PQL01-Money Problem in Our Family|PQL0123	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: I think money is a problem in our family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13887>	C13432	1p35	A chromosome band present on 1p			Gene or Genome	
C138880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138880>	C138285	PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Family Has Lot of Problems|PQL01-Family Has Lot of Problems|PQL01-Family Has Lot of Problems|PQL0124	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: I think my family has a lot of problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138881>	C138285	PedsQL Neuromuscular Module Version 3.0 Young Adult Report - Do Not Have Equipment Need|PQL01-Do Not Have Equipment Need|PQL01-Do Not Have Equipment Need|PQL0125	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Adult Report (PedsQL Neuromuscular Module Version 3.0 Young Adult Report) In the past one month, how much of a problem has this been for you: I do not have the equipment I need.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Adult Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138882>	C138286	PedsQL Neuromuscular Module Version 3.0 Young Child Report - Hard to Breathe|PQL07-Hard to Breathe|PQL07-Hard to Breathe|PQL0701	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: It is hard to breathe.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138883>	C138286	PedsQL Neuromuscular Module Version 3.0 Young Child Report - Get Sick Easily|PQL07-Get Sick Easily|PQL07-Get Sick Easily|PQL0702	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: I get sick easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138884>	C138286	PedsQL Neuromuscular Module Version 3.0 Young Child Report - Get Sores and/or Rashes|PQL07-Get Sores and/or Rashes|PQL07-Get Sores and/or Rashes|PQL0703	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: I get sores and/or rashes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138885>	C138286	PedsQL Neuromuscular Module Version 3.0 Young Child Report - Legs Hurt|PQL07-Legs Hurt|PQL07-Legs Hurt|PQL0704	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: My legs hurt.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138886>	C138286	PedsQL Neuromuscular Module Version 3.0 Young Child Report - Feel Tired|PQL07-Feel Tired|PQL07-Feel Tired|PQL0705	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: I feel tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138887>	C138286	PedsQL Neuromuscular Module Version 3.0 Young Child Report - Back Feels Stiff|PQL07-Back Feels Stiff|PQL07-Back Feels Stiff|PQL0706	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: My back feels stiff.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138888>	C138286	PedsQL Neuromuscular Module Version 3.0 Young Child Report - Wake Up Tired|PQL07-Wake Up Tired|PQL07-Wake Up Tired|PQL0707	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: I wake up tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138889>	C138286	PedsQL Neuromuscular Module Version 3.0 Young Child Report - Hands Are Weak|PQL07-Hands Are Weak|PQL07-Hands Are Weak|PQL0708	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: My hands are weak.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13888>	C13432	4q22	A chromosome band present on 4q			Gene or Genome	
C138890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138890>	C138286	PedsQL Neuromuscular Module Version 3.0 Young Child Report - Hard to Use Bathroom|PQL07-Hard to Use Bathroom|PQL07-Hard to Use Bathroom|PQL0709	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: It is hard to use the bathroom.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138891>	C138286	PedsQL Neuromuscular Module Version 3.0 Young Child Report - Hard to Gain or Lose Weight|PQL07-Hard to Gain/Lose Weight|PQL07-Hard to Gain/Lose Weight|PQL0710	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: It is hard to gain or lose weight when I want to.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138892>	C138286	PedsQL Neuromuscular Module Version 3.0 Young Child Report - Hard to Use Hands|PQL07-Hard to Use Hands|PQL07-Hard to Use Hands|PQL0711	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: It is hard to use my hands.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138893>	C138286	PedsQL Neuromuscular Module Version 3.0 Young Child Report - Hard to Swallow Food|PQL07-Hard to Swallow Food|PQL07-Hard to Swallow Food|PQL0712	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: It is hard to swallow food.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138894>	C138286	PedsQL Neuromuscular Module Version 3.0 Young Child Report - Long Time to Bathe or Shower|PQL07-Long Time to Bathe/Shower|PQL07-Long Time to Bathe/Shower|PQL0713	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: It takes me a long time to bathe or shower.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138895>	C138286	PedsQL Neuromuscular Module Version 3.0 Young Child Report - Get Hurt Accidentally|PQL07-Get Hurt Accidentally|PQL07-Get Hurt Accidentally|PQL0714	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: I get hurt accidentally.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138896>	C138286	PedsQL Neuromuscular Module Version 3.0 Young Child Report - Take Long Time to Eat|PQL07-Take Long Time to Eat|PQL07-Take Long Time to Eat|PQL0715	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: I take a long time to eat.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138897>	C138286	PedsQL Neuromuscular Module Version 3.0 Young Child Report - Hard to Turn During Night|PQL07-Hard to Turn During Night|PQL07-Hard to Turn During Night|PQL0716	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: It is hard to turn myself during the night.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138898>	C138286	PedsQL Neuromuscular Module Version 3.0 Young Child Report - Hard to Go Places With Equipment|PQL07-Hard to Go Places With Equipment|PQL07-Hard to Go Places With Equipment|PQL0717	Pediatric Quality of Life Neuromuscular Module Version 3.0 Young Child Report (PedsQL Neuromuscular Module Version 3.0 Young Child Report) Think about how you have been doing for the last few weeks. Please listen carefully to each sentence and tell me how much of a problem this is for you: It is hard for me to go places with my equipment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Code Terminology|CDISC Questionnaire PedsQL Neuromuscular Module Version 3.0 Young Child Report Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138899>	C8851	Double-Expressor Lymphoma|DEL|Double Expressor Lymphoma|Double-Expressing Lymphoma|double expressor lymphoma|double_expressor_lymphoma	A diffuse large B-cell lymphoma characterized by double expression of MYC and BCL2 proteins without MYC and BCL2 gene aberrations. These lymphomas may have a worse prognosis than other diffuse large B-cell lymphomas, not otherwise specified, but they are not as aggressive as the high-grade B-cell lymphomas, with rearrangements of MYC and BCL2 and/or BCL6 genes.			Neoplastic Process	GDC Property Terminology|GDC Terminology
C13889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13889>	C13432	16q12	A chromosome band present on 16q			Gene or Genome	
C1388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1388>	C29636	Hydrochlorothiazide-Triamterene	A combination drug containing hydrochlorothiazide and triamterene used as a diuretic.			Pharmacologic Substance	
C138900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138900>	C40998	Neoplastic Cells with Double Expression of MYC and BCL2 Proteins Present	An immunohistochemical finding indicating the presence of double expression of MYC and BCL2 proteins in the neoplastic cells of a tumor sample.	Neoplastic Cells with Double Expression of MYC and BCL2 Proteins Present		Finding	CTRP Disease Terminology|CTRP Terminology
C138901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138901>	C83119	Body Mass Index Finding|BMI|Body Mass Index	The result of a body mass index measurement.			Finding	
C138902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138902>	C98356	EGFR NP_005219.2:p.D770_N771insGV|EGFR Asp770_Asn771insGlyVal|EGFR D770_N771insGV|EGFR NP_005219.2:p.Asp770_Asn771insGlyVal|EGFR p.Asp770_Asn771insGlyVal|EGFR p.D770_N771insGV|Epidermal Growth Factor Receptor Asp770_Asn771insGlyVal|Epidermal Growth Factor Receptor D770_N771insGV|NP_005219.2:p.Asp770_Asn771insGlyVal|NP_005219.2:p.D770_N771insGV|Proto-Oncogene c-ErbB-1 Asp770_Asn771insGlyVal|Proto-Oncogene c-ErbB-1 D770_N771insGV|Receptor Tyrosine-Protein Kinase erbB-1 Asp770_Asn771insGlyVal|Receptor Tyrosine-Protein Kinase erbB-1 D770_N771insGV	An insertion of the amino acid sequence glycine-valine between the aspartic acid at position 770 and the asparagine at position 771 of the epidermal growth factor receptor protein.			Cell or Molecular Dysfunction	
C138903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138903>	C98356	EGFR NP_005219.2:p.M766_A767insASV|EGFR M766_A767insASV|EGFR Met766_Ala767insAlaSerVal|EGFR NP_005219.2:p.Met766_Ala767insAlaSerVal|EGFR p.M766_A767insASV|EGFR p.Met766_Ala767insAlaSerVal|Epidermal Growth Factor Receptor M766_A767insASV|Epidermal Growth Factor Receptor Met766_Ala767insAlaSerVal|NP_005219.2:p.M766_A767insASV|NP_005219.2:p.Met766_Ala767insAlaSerVal|Proto-Oncogene c-ErbB-1 M766_A767insASV|Proto-Oncogene c-ErbB-1 Met766_Ala767insAlaSerVal|Receptor Tyrosine-Protein Kinase erbB-1 Met766_Ala767insAlaSerVal	An insertion of the amino acid sequence alanine-serine-valine between the methionine at position 766 and the alanine at position 767 of the epidermal growth factor receptor protein.			Cell or Molecular Dysfunction	
C138904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138904>	C98356	EGFR NP_005219.2:p.P772_H773insNP|EGFR NP_005219.2:p.Pro772_His773insAsnPro|EGFR P772_H773insNP|EGFR Pro772_His773insAsnPro|EGFR p.P772_H773insNP|EGFR p.Pro772_His773insAsnPro|Epidermal Growth Factor Receptor P772_H773insNP|Epidermal Growth Factor Receptor Pro772_His773insAsnPro|NP_005219.2:p.P772_H773insNP|NP_005219.2:p.Pro772_His773insAsnPro|Proto-Oncogene c-ErbB-1 P772_H773insNP|Proto-Oncogene c-ErbB-1 Pro772_His773insAsnPro|Receptor Tyrosine-Protein Kinase erbB-1 P772_H773insNP|Receptor Tyrosine-Protein Kinase erbB-1 Pro772_His773insAsnPro	An insertion of the amino acid sequence asparagine-proline between the proline at position 772 and the histidine at position 773 of the epidermal growth factor receptor protein.			Cell or Molecular Dysfunction	
C138905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138905>	C98356	EGFR NP_005219.2:p.P772_V774insPHV|EGFR NP_005219.2:p.Pro772_Val774insProHisVal|EGFR P772_V774insPHV|EGFR Pro772_Val774insProHisVal|EGFR p.P772_V774insPHV|EGFR p.Pro772_Val774insProHisVal|Epidermal Growth Factor Receptor P772_V774insPHV|Epidermal Growth Factor Receptor Pro772_Val774insProHisVal|NP_005219.2:p.P772_V774insPHV|NP_005219.2:p.Pro772_Val774insProHisVal|Proto-Oncogene c-ErbB-1 P772_V774insPHV|Proto-Oncogene c-ErbB-1 Pro772_Val774insProHisVal|Receptor Tyrosine-Protein Kinase erbB-1 P772_V774insPHV|Receptor Tyrosine-Protein Kinase erbB-1 Pro772_Val774insProHisVal	An insertion of the amino acid sequence proline-histidine-valine between the proline at position 772 and the valine at position 774 of the epidermal growth factor receptor protein.			Cell or Molecular Dysfunction	
C138906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138906>	C20993	G-8 Screening Tool|G-8|G8|G8 Questionnaire	A tool for the assessment of geriatric cancer patients. It combines 7 questions from the mini nutritional assessment (MNA) with one question regarding subject age. Items selected from MNA concern nutritional status, weight loss, body mass index, motor skills, psychological status, number of medications, and self-perception of health.			Intellectual Product	
C138907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138907>	C173981	Decline of Food Intake over Past 3 Months Question|Decline of Food Intake over Past 3 Months|Has food intake declined over the past 3 months due to loss of appetite, digestive problems, chewing or swallowing difficulties	A question about whether an individual had a decline in food intake over the past 3 months due to loss of appetite, digestive problems, chewing, or swallowing difficulties.			Intellectual Product	G-8 Screening Tool
C138908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138908>	C91102	Weight Loss over Past 3 Months Question|Weight Loss over Last 3 Months|Weight Loss over Past 3 Months|Weight loss during the last 3 months	A question about whether an individual had a weight loss over the past 3 months.			Intellectual Product	G-8 Screening Tool
C138909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138909>	C173981	Had Neuropsychological Problems Question|Had Neuropsychological Problems|Neuropsychological problems	A question about whether an individual has or had a neuropsychological problems.			Intellectual Product	G-8 Screening Tool
C13890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13890>	C13432	17q22-q23	A chromosome band present on 17q			Gene or Genome	
C138910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138910>	C173984	Take More than 3 Medications per Day Question|Take More than 3 Medications per Day|Takes more than 3 medications per day	A question about whether an individual takes or took more than three medications per day.			Intellectual Product	G-8 Screening Tool
C138911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138911>	C98356	EGFR NP_005219.2:p.P772_H773insNPH|EGFR NP_005219.2:p.Pro772_His773insAsnProHis|EGFR P772_H773insNPH|EGFR Pro772_His773insAsnProHis|EGFR p.P772_H773insNPH|EGFR p.Pro772_His773insAsnProHis|Epidermal Growth Factor Receptor P772_H773insNPH|Epidermal Growth Factor Receptor Pro772_His773insAsnProHis|NP_005219.2:p.P772_H773insNPH|NP_005219.2:p.Pro772_His773insAsnProHis|Proto-Oncogene c-ErbB-1 P772_H773insNPH|Proto-Oncogene c-ErbB-1 Pro772_His773insAsnProHis|Receptor Tyrosine-Protein Kinase erbB-1 P772_H773insNPH|Receptor Tyrosine-Protein Kinase erbB-1 Pro772_His773insAsnProHis	An insertion of the amino acid sequence asparagine-proline-histidine between the proline at position 772 and the histidine at position 773 of the epidermal growth factor receptor protein.			Cell or Molecular Dysfunction	
C138912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138912>	C91102	Comparison of Health Status Question|Comparison of Health Status|How does the patient consider his/her health status	A question about how an individual considers their health status in comparison to others of the same age.			Intellectual Product	G-8 Screening Tool
C138913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138913>	C125605	EGFR NM_005228.3:c.2310_2311insGGCACA|EGFR c.2305_2310dupGGCACA|EGFR c.2310_2311insGGCACA|ERBB c.2310_2311insGGCACA|ERBB1 c.2310_2311insGGCACA|Epidermal Growth Factor Receptor Gene c.2310_2311insGGCACA|HER1 c.2310_2311insGGCACA|NM_005228.3:c2310_2311insGGCACA	An insertion of six nucleotides, guanine-guanine-cytosine-adenine-cytosine-adenine, between position 2310 and 2311 of the coding sequence of the EGFR gene.			Cell or Molecular Dysfunction	
C138914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138914>	C226659	Severe Decrease in Food Intake|Severe decrease in food intake	A response indicating than an individual has or had a severe decrease in their food intake.			Intellectual Product	G-8 Screening Tool
C138915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138915>	C226659	Moderate Decrease in Food Intake|Moderate decrease in food intake	A response indicating than an individual has or had a moderate decrease in their food intake.			Intellectual Product	G-8 Screening Tool
C138916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138916>	C98356	EGFR NP_005219.2:p.D770_N771insGT|EGFR Asp770_Asn771insGlyThr|EGFR D770_N771insGT|EGFR NP_005219.2:p.Asp770_Asn771insGlyThr|EGFR p.Asp770_Asn771insGlyThr|EGFR p.D770_N771insGT|Epidermal Growth Factor Receptor Asp770_Asn771insGlyThr|Epidermal Growth Factor Receptor D770_N771insGT|NP_005219.2:p.Asp770_Asn771insGlyThr|NP_005219.2:p.D770_N771insGT|Proto-Oncogene c-ErbB-1 Asp770_Asn771insGlyThr|Proto-Oncogene c-ErbB-1 D770_N771insGT|Receptor Tyrosine-Protein Kinase erbB-1 Asp770_Asn771insGlyThr|Receptor Tyrosine-Protein Kinase erbB-1 D770_N771insGT	An insertion of the amino acid sequence glycine-threonine between the aspartic acid at position 770 and the asparagine at position 771 of the epidermal growth factor receptor protein.			Cell or Molecular Dysfunction	
C138917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138917>	C226659	No Decrease in Food Intake|No decrease in food intake	A response indicating than an individual has or had no decrease in their food intake.			Intellectual Product	G-8 Screening Tool
C138918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138918>	C178366	Weight Loss Greater Than Three Kilograms|Weight Loss Exceeding Three Kilograms|Weight loss > 3 kg	A response indicating than an individual has or had weight loss exceeding 3 kilograms.			Intellectual Product	G-8 Screening Tool
C138919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138919>	C178366	Weight Loss between 1 and 3 Kilograms|Weight loss between 1 and 3 kg	A response indicating than an individual has or had weight loss between 1 and 3 kilograms.			Intellectual Product	G-8 Screening Tool
C13891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13891>	C13432	1q21	A chromosome band present on 1q	1q21		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138920>	C125605	EGFR NM_005228.3:c.2320_2321insCCCACG|EGFR NM_005228.4:c.2315_2320dupCCCACG|EGFR c.2315_2320dupCCCACG|EGFR c.2315_2320insCCCACG|EGFR c.2320_2321insCCCACG|ERBB c.2315_2320insCCCACG|ERBB c.2320_2321insCCCACG|ERBB1 c.2315_2320insCCCACG|ERBB1 c.2320_2321insCCCACG|Epidermal Growth Factor Receptor Gene c.2315_2320insCCCACG|Epidermal Growth Factor Receptor Gene c.2320_2321insCCCACG|HER1 c.2315_2320insCCCACG|HER1 c.2320_2321insCCCACG|NM_005228.3:c.2315_2320dupCCCACG|NM_005228.3:c.2315_2320insCCCACG|NM_005228.3:c.2320_2321insCCCACG|NM_005228.4(EGFR):c.2315_2320dupCCCACG	An insertion of six nucleotides, cytosine-cytosine-cytosine-adenine-cytosine-guanine, between position 2320 and 2321 of the coding sequence of the EGFR gene.			Cell or Molecular Dysfunction	
C138921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138921>	C178366	No Weight Loss|No weight loss	A response indicating than an individual has or had no weight loss.			Intellectual Product	G-8 Screening Tool
C138922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138922>	C226573	Bed or Chair Bound|Bed or chair bound	A response indicating than an individual is or was bed or chair bound.			Intellectual Product	G-8 Screening Tool
C138923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138923>	C226573	Able to Get Out of Bed or Chair but Does Not Go Out|Able to get out of bed/chair but does not go out	A response indicating than an individual is or was able to get out of bed or chair, but did or does not go out.			Intellectual Product	G-8 Screening Tool
C138924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138924>	C98356	EGFR NP_005219.2:p.H773_V774insAH|EGFR H773_V774insAH|EGFR His773_Val774insAlaHis|EGFR NP_005219.2:p.His773_Val774insAlaHis|EGFR p.H773_V774insAH|EGFR p.His773_Val774insAlaHis|Epidermal Growth Factor Receptor H773_V774insAH|Epidermal Growth Factor Receptor His773_Val774insAlaHis|NP_005219.2:p.H773_V774insAH|NP_005219.2:p.His773_Val774insAlaHis|Proto-Oncogene c-ErbB-1 H773_V774insAH|Proto-Oncogene c-ErbB-1 His773_Val774insAlaHis|Receptor Tyrosine-Protein Kinase erbB-1 H773_V774insAH|Receptor Tyrosine-Protein Kinase erbB-1 His773_Val774insAlaHis	An insertion of the amino acid sequence alanine-histidine between the histidine at position 773 and the valine at position 774 of the epidermal growth factor receptor protein.			Cell or Molecular Dysfunction	
C138925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138925>	C226620	Goes Out|Goes out	A response indicating than an individual is or was able to go out.			Intellectual Product	G-8 Screening Tool
C138926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138926>	C226654	Severe Dementia or Depression|Severe dementia or depression	A response indicating than an individual has or had severe dementia or depression.			Intellectual Product	G-8 Screening Tool
C138927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138927>	C226654	Mild Dementia or Depression|Mild dementia or depression	A response indicating than an individual has or had mild dementia or depression.			Intellectual Product	G-8 Screening Tool
C138928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138928>	C226712	No Psychological Problems|No psychological problems	A response indicating than an individual has or had no psychological problems.			Intellectual Product	G-8 Screening Tool
C138929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138929>	C226673	Not as Good as Others|Not as good	A response indicating than an individual is not or was not as good as others.			Intellectual Product	G-8 Screening Tool
C13892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13892>	C13432	10q23.2-q23.3	A chromosome band present on 10q			Gene or Genome	
C138930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138930>	C226673	As Good as Others|As good	A response indicating than an individual is or was as good as others.			Intellectual Product	G-8 Screening Tool
C138931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138931>	C175309	Better than Others|Better	A response indicating than an individual is or was better than others.			Intellectual Product	G-8 Screening Tool
C138932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138932>	C138901	Body Mass Index Less Than 19|BMI < 19	Indicates a body mass index measurement less than 19.			Finding	G-8 Screening Tool
C138933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138933>	C138901	Body Mass Index 19 to Less Than 21|BMI 19 to < 21	Indicates a body mass index measurement greater than or equal to 19 but below 21.			Finding	G-8 Screening Tool
C138934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138934>	C138901	Body Mass Index 21 to Less Than 23|BMI 21 to < 23	Indicates a body mass index measurement greater than or equal to 21 but below 23.			Finding	G-8 Screening Tool
C138935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138935>	C138901	Body Mass Index Greater Than or Equal to 23|BMI > 23	Indicates a body mass index measurement greater than or equal to 23.			Finding	G-8 Screening Tool
C138936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138936>	C37908	Age Greater than 85 Years|Age > 85|Age Over 85 Years	An indication that an individual's age is or was greater than 85 years.			Organism Attribute	G-8 Screening Tool
C138937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138937>	C37908	Age Between 80 and 85 Years|Age 80-85	An indication that an individual's age is or was between 80 and 85 years.			Organism Attribute	G-8 Screening Tool
C138938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138938>	C37908	Age Less than 80 Years|Age < 80	An indication that an individual's age is or less than 80 years.			Organism Attribute	G-8 Screening Tool
C138939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138939>	C138961	PSA Level Less than or Equal to Fifteen|PSA Level 15 or Less|PSA Level Fifteen or Less|PSA Level Less than or Equal to 15	A blood concentration of prostate specific antigen less than or equal to 15 ng/mL.	PSA Level Less than or Equal to Fifteen		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13893>	C13432	8p11	A chromosome band present on 8p			Gene or Genome	
C138940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138940>	C138961	PSA Level Greater than or Equal to 0.1|PSA Level 0.1 or Greater	A blood concentration of prostate specific antigen greater than or equal to 0.1 ng/mL.	PSA Level Greater than or Equal to 0.1		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138941>	C94299|C177692	PDGFR Positive|PDGF Receptor Positive|PDGFR Family Positive|Platelet Derived Growth Factor Receptor Positive|Platelet-Derived Growth Factor Receptor Positive	Indicates that the expression of a member of the PDGFR family has been detected in a sample.	PDGFR Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138942>	C94299|C177692	KIT Positive|CD117 Positive|CD117 Positive|KIT Proto-Oncogene Tyrosine Protein Kinase Positive|Mast/Stem Cell Growth Factor Receptor Kit Positive|Positive|c-KIT Positive|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Positive	Indicates that KIT expression has been detected in a sample.	KIT Positive		Laboratory or Test Result	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138943>	C177692	ABL Positive|ABL Family Positive|ABL Proto-Oncogene, Non-Receptor Tyrosine Kinase Positive|Abelson Murine Leukemia Viral Oncogene Homolog Positive|Abelson Tyrosine-Protein Kinase Positive|Tyrosine-Protein Kinase ABL Positive|v-Abl Abelson Murine Leukemia Viral Oncogene Homolog Positive	Indicates that the expression of a member of the ABL family has been detected in a sample.	ABL Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138944>	C138941	PDGFRB Positive|CD140b Positive|JTK12 Positive|PDGFR-1 Positive|PDGFR1 Positive|PDGFRbeta Positive|Platelet Derived Growth Factor Receptor Beta Positive|Platelet-Derived Growth Factor Receptor Beta Positive	Indicates that PDGFRB expression has been detected in a sample.	PDGFRB Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138945>	C138961	PSA Level Less than or Equal to Ten|PSA Level 10 or Less|PSA Level Less than or Equal 10|PSA Level Ten or Less	A blood concentration of prostate specific antigen less than or equal to 10 ng/mL.	PSA Level Less than or Equal to Ten		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138946>	C138961	PSA Level Greater than 0.2	A blood concentration of prostate specific antigen greater than 0.2 ng/mL.	PSA Level Greater than 0.2		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138947>	C177692	CTAG2 Positive|Cancer/Testis Antigen 2 Positive|ESO2 Positive|L Antigen Family Member 1 Positive|LAGE 1 Positive|LAGE Positive|LAGE-1 Positive|LAGE1 Positive|NY-ESO-2 Positive	Indicates that CTAG2 expression has been detected in a sample.	CTAG2 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138948>	C138961	PSA Level Greater than Two|PSA Level Greater than 2	A blood concentration of prostate specific antigen greater than 2 ng/mL.	PSA Level Greater than Two		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138949>	C138961	PSA Level Greater than One|PSA Level Greater than 1	A blood concentration of prostate specific antigen greater than 1 ng/mL.	PSA Level Greater than One		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13894>	C13432	11p15.2-p15.1	A chromosome band present on 11p			Gene or Genome	
C138950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138950>	C177692	IGF1 Positive|IGF I Positive|IGF-1 Positive|IGF-I Positive|Insulin-Like Growth Factor 1 Positive|Insulin-Like Growth Factor I Positive|Somatomedin C Positive	Indicates that IGF1 expression has been detected in a sample.	IGF1 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138951>	C177692	Heregulin Positive|Neuregulin Positive	Indicates that heregulin expression has been detected in a sample.	Heregulin Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138952>	C138961	PSA Level Greater than or Equal to 0.2|PSA Level 0.2 or Greater	A blood concentration of prostate specific antigen greater than or equal to 0.2 ng/mL.	PSA Level Greater than or Equal to 0.2		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138953>	C165744|C158502	Androgen Receptor Negative|AR Negative|AR Negative|Negative	Indicates that expression of AR has not been detected in a sample.	AR Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138954>	C177692	NOS2 Positive|Inducible NO Synthase Positive|NOS2A Positive|Nitric Oxide Synthase 2 Positive|Nitric Oxide Synthase 2, Inducible Positive|Nitric Oxide Synthase, Inducible Positive|iNOS Positive	Indicates that NOS2 expression has been detected in a sample.	NOS2 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138955>	C177692	GUCY2C Positive|GC-C Positive|Guanylate Cyclase 2C Positive|Guanylyl Cyclase C Positive|Heat Stable Enterotoxin Receptor Positive|Heat-Stable Enterotoxin Receptor Positive|Intestinal Guanylate Cyclase Positive|STAR Positive|hSTAR Positive	Indicates that GUCY2C expression has been detected in a sample.	GUCY2C Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C138957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138957>	C70945	HPV Self-Collection|At-home HPV Self Collection|HPV Self Collection|Human Papillomavirus Self-Collection	Any of various methods or devices to allow an individual to collect their own sample for detection of human papillomavirus DNA.	HPV Self-Collection		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C138958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138958>	C117720	Uterus Absent	An indication that an individual's uterus is not present.			Finding	
C138959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138959>	C117720	Uterus Present	An indication that an individual's uterus is present.			Finding	
C13895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13895>	C13432	7p21.3	A chromosome band present on 7p			Gene or Genome	
C138960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138960>	C69218	Pregnancy Status at Time of Illness or Condition	The pregnancy status of an individual at the time of an illness or condition.			Intellectual Product	
C138961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138961>	C36292	PSA Level Finding|Biochemical marker (PSA)	A finding that indicates the amount of prostate specific antigen in a sample.			Laboratory or Test Result	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C138962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138962>	C226329	High Risk Myelodysplastic Syndrome	Myelodysplastic syndrome with more than 4.5 to 6 points, according to the revised International Prognostic Scoring System (IPSS-R).	High Risk Myelodysplastic Syndrome		Finding	CTRP Disease Terminology|CTRP Terminology
C138963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138963>	C138962	Recurrent High Risk Myelodysplastic Syndrome	The reemergence of high risk myelodysplastic syndrome after a period of remission.			Finding	
C138964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138964>	C138962	Refractory High Risk Myelodysplastic Syndrome	High risk myelodysplastic syndrome that does not respond to treatment.			Finding	
C138965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138965>	C101685	Major Axis Internal Diameter				Spatial Concept	
C138966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138966>	C101685	Minor Axis Internal Diameter				Spatial Concept	
C138967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138967>	C87802	Isometric Muscle Strength				Conceptual Entity	
C138968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138968>	C120882	Basophilic Focus|BASOPHILIC FOCUS	A group of cells that exhibit some type of cytologic alteration resulting in basophilia, and that are confined to a specific area of the sample.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C138969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138969>	C13056	Dorsal Hand Interosseus Muscle				Body Part, Organ, or Organ Component	
C13896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13896>	C13432	12p13.32	A chromosome band present on 12p			Gene or Genome	
C138970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138970>	C64848	Reticulocyte Corpuscular Hemoglobin Concentration Mean|CHCMR|CHCMr|Ret. Corpuscular HGB Concentration Mean|Ret. Corpuscular HGB Concentration Mean	An indirect measurement of the average concentration of hemoglobin per reticulocyte in a biological specimen, calculated as the ratio of hemoglobin to hematocrit.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C138971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138971>	C12958	Derived Synovial Fluid Cell|Human Synovial Fluid Derived Cells	Cells derived from the fluid found in the cavities of synovial joints.			Cell	FDA Structured Product Labeling Terminology|SPL Tissue Form Product Type Terminology
C138972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138972>	C12529	Derived Peripheral Blood Mononuclear Cell|Peripheral Blood Mononuclear cells	Mononuclear cells collected from peripheral blood.			Cell	FDA Structured Product Labeling Terminology|SPL Tissue Form Product Type Terminology
C138973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138973>	C33793	Derived Dental Pulp|Human Tooth Pulp	Dental pulp from a tooth.			Cell	FDA Structured Product Labeling Terminology|SPL Tissue Form Product Type Terminology
C138974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138974>	C217122	Glandular (Acinar)/Tubular Differentiation Score	A score assigned to a biopsy sample indicating the relative amount of cells with glandular differentiation.			Intellectual Product	
C138975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138975>	C138974	Glandular (Acinar)/Tubular Differentiation Score 1	Greater than 75% of tumor area shows glandular/tubular structures.			Intellectual Product	
C138976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138976>	C138974	Glandular (Acinar)/Tubular Differentiation Score 2	10% to 75% of tumor area shows glandular/tubular structures.			Intellectual Product	
C138977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138977>	C138974	Glandular (Acinar)/Tubular Differentiation Score 3	Less than 10% of tumor area shows glandular/tubular structures.			Intellectual Product	
C138978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138978>	C217122	Nuclear Pleomorphism Score	A score assigned to a biopsy sample based on the appearance of nuclei in a tumor.			Intellectual Product	
C138979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138979>	C138978	Nuclear Pleomorphism Score 1	Nuclei small with little increase in size in comparison with normal breast epithelial cells, regular outlines, uniform nuclear chromatin, little variation in size.			Intellectual Product	
C13897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13897>	C13432	16p13.12	A chromosome band present on 16p			Gene or Genome	
C138980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138980>	C138978	Nuclear Pleomorphism Score 2	Cells larger than normal with open vesicular nuclei, visible nucleoli, and moderate variability in both size and shape.			Intellectual Product	
C138981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138981>	C138978	Nuclear Pleomorphism Score 3	Vesicular nuclei, often with prominent nucleoli, exhibiting marked variation in size and shape, occasionally with very large and highly unusual forms.			Intellectual Product	
C138982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138982>	C217122	Mitotic Rate Score|MITOSCR|Mitotic Count Score|Mitotic Score|Mitotic Score	A score assigned to a biopsy sample to indicate the number of mitotic cells present in a tumor.			Intellectual Product	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138983>	C138982	Mitotic Rate Score 1	A finding of less than or equal to 3 mitoses per mm2 (less than or equal to 7 per 10 hpf).			Intellectual Product	
C138984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138984>	C138982	Mitotic Rate Score 2	A finding of 4-7 mitoses per mm2 (8-14 per 10 hpf).			Intellectual Product	
C138985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138985>	C138982	Mitotic Rate Score 3	A finding of greater than or equal to 8 mitoses per mm2 (greater than 15 per 10 hpf).			Intellectual Product	
C138986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138986>	C18000	Nottingham Grade|Elston-Ellis Modification of Scarff-Bloom-Richardson Grading System|Elston-Ellis modification of Scarff-Bloom-Richardson Grading System|NOTTINGHAM HISTOLOGIC GRADE|Nottingham Histologic Grade	A histologic grading system developed by Elston and Ellis as a modification of the Scarff-Bloom-Richardson grading system, based on tubule formation, nuclear pleomorphism, and mitotic counts of invasive adenocarcinomas. (CW Ellston, O Ellis. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991 Nov;19(5):403-10.)			Classification	CDISC SDTM Microscopic Findings Test Detail Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138987>	C138986	Nottingham Grade 1|G1|GRADE 1|NOTTINGHAM GRADE I|Nottingham Overall Grade 1|Overall Grade 1|Total Nottingham Score, Grade 1	Total Nottingham scores of 3, 4, or 5.			Classification	CDISC SDTM Nottingham Grading Scale Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138988>	C138986	Nottingham Grade 2|G2|GRADE 2|NOTTINGHAM GRADE II|Nottingham Overall Grade 2|Overall Grade 2|Total Nottingham Score, Grade 2	Total Nottingham scores of 6 or 7.			Classification	CDISC SDTM Nottingham Grading Scale Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C138989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138989>	C138986	Nottingham Grade 3|G3|GRADE 3|NOTTINGHAM GRADE III|Nottingham Overall Grade 3|Overall Grade 3|Total Nottingham Score, Grade 3	Total Nottingham scores of 8 or 9.			Classification	CDISC SDTM Nottingham Grading Scale Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13898>	C13432	20q12-q13.2	A chromosome band present on 20q			Gene or Genome	
C138990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138990>	C204844	Product Description/Appearance Assessment|Description/Appearance	Tests using visual inspection to assess the physical state and color of the drug substance or product.			Qualitative Concept	PQ/CMC Test Subcategory Terminology
C138991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138991>	C213472|C129825	Flumbatinib|4-(4-Methyl-piperazin-1-ylmethyl)-N-[6-methyl-5-(4-pyridin-3-yl-pyrimidin-2-ylamino)-pyridin-3-yl]-3-trifluoromethyl-benzamide|FLUMBATINIB|Flumatinib|Flumatinib|HH GV 678|HH-GV-678|HH-GV678|HHGV678	An orally bioavailable tyrosine kinase inhibitor, with potential antineoplastic activity. Upon administration, flumbatinib inhibits the wild-type forms of Bcr-Abl, platelet-derived growth factor receptor (PDGFR) and mast/stem cell growth factor receptor (SCFR; c-Kit) and forms of these proteins with certain point mutations. This results in the inhibition of both Bcr-Abl-, PDGFR- and c-Kit-mediated signal transduction pathways, and the proliferation of tumor cells in which these kinases are overexpressed. Bcr-Abl fusion protein is an abnormal, constitutively active enzyme expressed in Philadelphia chromosome positive chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML). PDGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to cell migration and the development of the microvasculature. c-kit, a receptor tyrosine kinase mutated and constitutively activated in certain tumors, plays a key role in tumor cell survival, proliferation, and differentiation.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C138992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138992>	C134259	Homogeneity Assessment	An assessment of the quality or state of being similar or comparable in kind or nature or of being uniform throughout in composition or structure.			Qualitative Concept	
C138993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138993>	C134259	Material Identification Test|Identification	Tests that establishes the characteristic and uniqueness of the substance of interest and should be able to discriminate between compounds of closely related structures which are likely to be present.			Qualitative Concept	PQ/CMC Test Category Terminology
C138994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138994>	C2152|C129825	Copanlisib Hydrochloride|5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2)|Aliqopa|BAY 80-6946 Dihydrochloride|BAY-80-6946 Dihydrochloride|COPANLISIB HYDROCHLORIDE|Copanlisib Dihydrochloride	The dihydrochloride salt form of copanlisib, a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.	Copanlisib Hydrochloride		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology
C138995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138995>	C143099|C129825	Capmatinib Hydrochloride|CAPMATINIB HYDROCHLORIDE|NVP-INC280-AAA|Tabrecta	The hydrochloride salt form of capmatinib, an orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Capmatinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.	Capmatinib Hydrochloride		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C138996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138996>	C2167|C129825	Icotinib|(1,4,7,10)Tetraoxacyclododecino(2,3-g)quinazolin-4-amine, N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-|BPI-2009|ICOTINIB	An orally available quinazoline-based inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Icotinib selectively inhibits the wild-type and several mutated forms of EGFR tyrosine kinase. This may lead to an inhibition of EGFR-mediated signal transduction and may inhibit cancer cell proliferation. EGFR, a receptor tyrosine kinase, has been upregulated in a variety of cancer cell types.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology
C138997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138997>	C213472|C1742|C129825	Catequentinib|AL 3818|AL-3818|AL3818|Anlotinib|Anlotinib|CATEQUENTINIB|Cyclopropanamine, 1-(((4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-	A receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities. Upon administration, catequentinib targets multiple RTKs, including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt tumor cell growth.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology
C138998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C138998>	C217122	G-8 Screening Tool Total Score|G-8 Total Score|G8 Total Score	The cumulative score for the G-8 geriatric assessment, summing the individual scores from the 7 nutritional questions and the age question. The score ranges from 17 (not at all impaired) to 0 (heavily impaired). A score lower or equal to 14 requires comprehensive geriatric assessment.			Intellectual Product	G-8 Screening Tool
C13899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13899>	C13432	1q32.2	A chromosome band present on 1q			Gene or Genome	
C1389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1389>	C1594	Menogaril|7(R)-O-Methylnogarol|7-(R)-O-methylnogarol|7-OMEN|7-OMEN|7-con-O-Methylnogarol|7-con-O-methylnogarol|7-con-O-methylnorgarol|MEN|MENOGARIL|MENOGARIL|Menogarol|OMEN,7-|TUT-7|U-52047|U-52047|[2R-(2alpha,3beta,4alpha,5beta,6alpha,11alpha,13alpha)]-4-(dimethylamino)-3,4,5,6,11,12,13,14-octahydro-3,5,8,10,13-pentahydroxy-11-methoxy-6,13-dimethyl-2,6-epoxy-2H-naphthaceno[1,2-b]oxocin-9,16-dione	A semisynthetic derivative of the anthracycline antineoplastic antibiotic nogalamycin.  Menogaril intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent is less cardiotoxic than doxorubicin. (NCI04)			Antibiotic|Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C139000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139000>	C1663	Glioma Lysate Vaccine GBM6-AD|GBM6-AD|GBM6-AD Lysate Protein Vaccine|Glioma Cell Lysate Vaccine GBM6-AD	An allogeneic cell lysate-based vaccine derived from the glioma stem cell line GBM6-AD, which was isolated from the brain tumor of a patient diagnosed with glioblastoma multiforme (GBM), with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration, the glioma lysate vaccine GBM6-AD exposes the immune system to an undefined amount of glioma-associated antigens (GAAs), and stimulates the immune system to mount a specific anti-tumoral, cytotoxic T-lymphocyte (CTL)-mediated response against the GAA-expressing cells, resulting in glioma cell lysis.	Glioma Lysate Vaccine GBM6-AD		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C139001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139001>	C9306|C150537|C148301	Refractory Soft Tissue Sarcoma	A soft tissue sarcoma that does not respond to treatment.	Refractory Soft Tissue Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139002>	C9306|C150536|C148302	Recurrent Soft Tissue Sarcoma	The reemergence of soft tissue sarcoma after a period of remission.	Recurrent Soft Tissue Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139003>	C1594	Micellar Nanoparticle-encapsulated Epirubicin|Epirubicin-incorporating Micelle|K-912|NC-6300|NC-6300|Nanoparticle Epirubicin	A nanoparticle-based prodrug formulation consisting of polymeric micelles encapsulating the anthracycline epirubicin, with potential antineoplastic activity. Epirubicin is covalently bound to polyethylene glycol (PEG) polyaspartate block copolymers through an acid-labile hydrazone bond and, upon suspension in an aqueous solution, a micellar structure with an outer hydrophilic PEG shell surrounding the hydrophobic epirubicin is formed. Upon administration of the micellar nanoparticle-encapsulated epirubicin, the nanoparticles are stable in the bloodstream and specifically accumulate in the tumor tissue. Due to the acidic conditions in the tumor and the pH-responsive nature of the micelles, epirubicin is released in the tumor milieu; it then intercalates into DNA and inhibits topoisomerase II, which inhibits DNA replication and interferes with synthesis of both RNA and protein. Compared to the administration of epirubicin alone, this formulation increases the water-solubility of epirubicin and increases its therapeutic effect while decreasing its cardiotoxicity.	Micellar Nanoparticle-encapsulated Epirubicin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C139004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139004>	C155727	Pan-FGFR Inhibitor LY2874455|LY-2874455|LY2874455|Pan FGFR Inhibitor LY2874455|Pan Fibroblast Growth Factor Receptor Inhibitor LY2874455	An orally bioavailable pan-inhibitor of fibroblast growth factor receptor (FGFR) family proteins, with potential antineoplastic activity. Upon oral administration, FGFR inhibitor LY2874455 binds to and inhibits FGFR subtypes 1 (FGFR1), 2 (FGFR2), 3 (FGFR3) and 4 (FGFR4), which results in the inhibition of FGFR-mediated signal transduction pathways. This inhibits both tumor angiogenesis and proliferation of FGFR-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, plays a key role in cellular proliferation, cell survival and angiogenesis.	Pan-FGFR Inhibitor LY2874455		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C139005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139005>	C3468	Follicular Helper T-Cell Lymphoma|Nodal Follicular Helper T-Cell Lymphoma|Nodal Peripheral T-Cell Lymphoma of T Follicular Helper Cell Origin|Nodal Peripheral T-Cell Lymphoma of T Follicular Helper Cell Origin|Nodal Peripheral T-Cell Lymphoma of TFH Cell Origin|TFH Lymphoma	A group of node-based peripheral T-cell lymphomas with phenotypic features of T follicular helper (TFH) cells. This category includes the following: follicular helper T-cell lymphoma, angioimmunoblastic-type; follicular helper T-cell lymphoma, follicular-type; and follicular helper T-cell lymphoma, not otherwise specified.			Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology
C139006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139006>	C28108	Durie/Salmon Stage|DS Stage	A plasma cell myeloma stage defined according to the Durie/Salmon staging system.			Classification	
C139007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139007>	C28108	International Staging System Stage|ISS Stage|iss stage|iss_stage	A plasma cell myeloma stage defined according to the international staging system.			Classification	GDC Property Terminology|GDC Terminology
C139008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139008>	C3242	Multiple Myeloma Myeloma by DS Stage|Plasma Cell Myeloma Myeloma by DS Stage	A header term that refers to the staging of multiple myeloma according to the Durie/Salmon staging system.			Neoplastic Process	
C139009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139009>	C3242	Multiple Myeloma by ISS Stage|Plasma Cell Myeloma by ISS Stage	A header term that refers to the staging of multiple myeloma according to the International Staging System.			Neoplastic Process	
C13900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13900>	C13432	19p13.2-p12	A chromosome band present on 19p			Gene or Genome	
C139010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139010>	C40998	Neoplastic Cells with TFH Cell Phenotype Present|Neoplastic Cells with T Follicular Helper Cell Phenotype Present|Neoplastic Cells with TFH Phenotype	An immunohistochemical finding indicating the presence of neoplastic lymphocytes manifesting a T follicular helper (TFH) phenotype.	Neoplastic Cells with TFH Cell Phenotype Present		Finding	CTRP Biomarker Terminology|CTRP Terminology
C139011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139011>	C139005	Follicular Helper T-Cell Lymphoma, Not Otherwise Specified|Follicular Helper T-Cell Lymphoma, NOS	Follicular helper T-cell lymphoma that does not meet the criteria for any other specifically defined entity of follicular helper T-cell lymphoma.			Neoplastic Process	
C139012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139012>	C5182|C3720	Breast Implant-Associated Anaplastic Large Cell Lymphoma|BIA-ALCL|Breast Implant Associated Anaplastic Large Cell Lymphoma (BIA ALCL)|Breast implant-associated anaplastic large cell lymphoma	A rare anaplastic large cell lymphoma that develops in individuals with breast implants. It usually presents as an accumulation of seroma fluid between the implant and the surrounding fibrous capsule. The median interval from the time of the implant to the development of lymphoma is approximately 10 years.			Neoplastic Process	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|GDC Terminology|GDC Value Terminology
C139013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139013>	C3824	Breast Implant-Related Lesion	A lesion that develops in the breast tissue following breast implant placement.			Finding	
C139014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139014>	C3721	Type D Lymphomatoid Papulosis|Type D LyP	A variant of lymphomatoid papulosis which mimics primary cutaneous aggressive epidermotropic CD8-positive cytotoxic T-cell lymphoma.			Neoplastic Process	
C139015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139015>	C3721	Type E Lymphomatoid Papulosis|Angioinvasive Lymphomatoid Papulosis Type E|Type E LyP	A variant of lymphomatoid papulosis characterized by the presence of atypical lymphocytes which exhibited distinct angioinvasion.			Neoplastic Process	
C139016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139016>	C36541	Rearrangement of 6p25.3|Rearrangement of 6p25	A cytogenetic abnormality indicating rearrangement of the DUSP22-IRF4 locus at 6p25.3.			Cell or Molecular Dysfunction	
C139017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139017>	C3721	Lymphomatoid Papulosis with DUSP22-IRF4 Gene Rearrangement|LyP with Chromosome 6p25 Rearrangement|LyP with Chromosome 6p25.3 Rearrangement|LyP with DUSP22-IRF4 Gene Rearrangement|Lymphomatoid Papulosis with Chromosome 6p25.3 Rearrangement|Lymphomatoid Papulosis with DUSP22 Locus Rearrangement	A variant of lymphomatoid papulosis associated with chromosomal rearrangements involving the DUSP22-IRF4 locus at 6p25.3.			Neoplastic Process	
C139018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139018>	C66830	CDISC SDTM Duchenne Muscular Dystrophy Findings About Test Code Terminology|DMFATSCD|Duchenne Muscular Dystrophy Findings About Test Code|SDTM-DMFATSCD	Terminology associated with the duchenne muscular dystrophy findings about test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139019>	C66830	CDISC SDTM Duchenne Muscular Dystrophy Findings About Test Name Terminology|DMFATS|Duchenne Muscular Dystrophy Findings About Test Name|SDTM-DMFATS	Terminology associated with the duchenne muscular dystrophy findings about test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13901>	C13432	17q11.2-q21.1	A chromosome band present on 17q			Gene or Genome	
C139020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139020>	C103175	CDISC Protocol Entities Clinical Trial Attribute Terminology|Clinical Trial Attribute Terminology|Clinical Trial Attribute Terminology|PROT-Att Clinical Trial	Terminology associated with the protocol entity clinical trial attribute codelist of the Clinical Data Interchange Standards Consortium (CDISC).			Intellectual Product	
C139021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139021>	C27909	Indolent Clonal T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract|ITLPD-GI|Indolent T-Cell Lymphoma of the Gastrointestinal Tract|Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract|Indolent T-cell lymphoproliferative disorder of gastrointestinal tract	A clonal T-cell lymphoproliferative disorder that can involve the mucosa in all sites of the gastrointestinal tract, but is most common in the small intestine and colon. The lymphoid cells infiltrate the lamina propria but usually do not show invasion of the epithelium. The clinical course is indolent, but most patients do not respond to conventional chemotherapy. A subset of cases progress to a higher-grade T-cell lymphoma with spread beyond the gastrointestinal tract. (WHO 2017)			Neoplastic Process	GDC Terminology|GDC Value Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C139022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139022>	C42076	Superficial Monoclonal T-Cell Infiltrate Present in Gastrointestinal Tract	A finding indicating the presence of a superficial monoclonal T-lymphocytic infiltrate in the gastrointestinal tract.			Finding	
C139023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139023>	C7764|C45250	Primary Cutaneous Acral CD8-Positive T-Cell Lymphoproliferative Disorder|Primary Cutaneous Acral CD8-Positive T-Cell LPD|Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma	A primary cutaneous T-cell lymphoproliferative disorder that presents as an acral (peripheral) lesion. It is composed of CD8-positive neoplastic T-lymphocytes. It is usually localized to a single site and has an indolent clinical course. Local or more extensive recurrences have been described in a minority of patients.			Neoplastic Process	
C139024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139024>	C3824	Acral Lesion	A lesion that arises in a peripheral site (e.g., limbs, fingers, or ears).			Finding	
C139025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139025>	C20401	Abrilumab|ABRILUMAB|AMG-181|AMG181|Immunoglobulin G, Anti-(Human Integrin Alpha4beta7) (Human Monoclonal Heavy Chain), Disulfide with Human Monoclonal Light Chain, Dimer|MEDI-7183				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C139027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139027>	C134259	Odor Detection|Odor	Determining any smells associated with a material.			Qualitative Concept	PQ/CMC Test Subcategory Terminology
C139028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139028>	C7234	Florid Follicular Hyperplasia Post-Transplant Lymphoproliferative Disorder|Florid Follicular Hyperplasia PTLD	An early lesion of post-transplant lymphoproliferative disorder with the morphologic appearance of florid follicular hyperplasia.			Disease or Syndrome	
C139029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139029>	C35867	Florid Follicular Hyperplasia	A morphologic finding indicating the presence of prominent follicular hyperplasia in a lymph node sample.			Finding	
C13902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13902>	C13432	17q23.1	A chromosome band present on 17q			Gene or Genome	
C139030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139030>	C123583	THRLBCL-Like Transformation of NLPBL|NLPBL, THRLBCL-Like|NLPHL, THRLBCL-Like|Nodular Lymphocyte Predominant B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma-Like|Nodular Lymphocyte Predominant Hodgkin Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma-Like|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma-Like Transformation of Nodular Lymphocyte Predominant B-Cell Lymphoma|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma-Like Transformation of Nodular Lymphocyte Predominant Hodgkin Lymphoma	Nodular lymphocyte predominant B-cell lymphoma (NLPBL) that has transformed, resembling T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL).			Finding	
C139031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139031>	C25298	Estimated Systolic Blood Pressure|SYSPRS_E|Systolic Pressure, Estimated|Systolic Pressure, Estimated	A quantitative estimate of the pressure in a given cardiovascular structure during ventricular systole.			Quantitative Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139032>	C25285	Cross-sectional Diameter|CSDIA	A measurement of a structure taken along the plane that is perpendicular to the long axis.			Spatial Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139033>	C181043	Aortic Coarctation Indicator|ACRCTIND	An indication as to whether there is coarctation of the aorta.			Conceptual Entity	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139034>	C35552	Aortic Preductal Coarctation Severity|APRECSEV	The assessment of the severity of preductal aortic coarctation.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139035>	C35552	Aortic Juxta-ductal Coarctation Severity|ADUCSEV|Aortic Ductal Coarctation Severity|Aortic Ductal Coarctation Severity	The assessment of the severity of juxta-ductal aortic coarctation.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139036>	C35552	Aortic Postductal Coarctation Severity|APOSCSEV	The assessment of the severity of postductal aortic coarctation.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139037>	C35552	Aortic Coarctation Severity|ACRCTSEV	The qualitative measurement of the severity of the aortic coarctation.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139038>	C181043	Aneurysm Indicator|ANEURIND	An indication as to whether there is the presence of an aneurysm.			Conceptual Entity	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139039>	C119241	Dissection Indicator|DISECIND	An indication as to whether a blood vessel has dissected.			Conceptual Entity	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13903>	C13432	8q24.1-q24.3	A chromosome band present on 8q			Gene or Genome	
C139040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139040>	C35552	Stanford Aortic Dissection Classification|STANFADC|Stanford AoD Classification|Stanford AoD Classification	The type of aortic dissection present as defined by the Stanford Classification System (Daily PO, Trueblood HW, Stinson EB, Wuerflein RD, Shumway NE. Management of acute aortic dissections. Ann Thorac Surg 1970;10(3):237-247).			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139041>	C35552	DeBakey Aortic Dissection Classification|DEBAKADC|DeBakey AoD Classification|DeBakey AoD Classification	The type of aortic dissection present as defined by the DeBakey Classification System (DeBakey ME, Henly WS, Cooley DA, Morris GC Jr, Crawford ES, Beall AC Jr. Surgical management of dissecting aneurysms of the aorta. J Thorac Cardiovasc Surg 1965;49:130-149).			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139042>	C35552	Annular Plane Systolic Excursion|APSE	The longitudinal displacement of a cardiac valve annulus toward the apex of the heart.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139043>	C35552	Myocardial Performance Index|MPI	A calculated result that uses the following formula to quantify both systolic and diastolic ventricular function: MPI = IVCT + IVRT) / V ET, in which IVCT is isovolumetric contraction time, IVRT is isovolumetric relaxation time, and V ET is ventricular ejection time.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139044>	C35552	Peak Pressure Rise Rate|PPRR	The greatest rate of increase in peak pressure during muscle contraction.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139045>	C35552	Annular S' Velocity|ANNSVEL	The peak velocity of the annular motion during ventricular systole.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139046>	C181043	Pericardial Effusion Indicator|PEFFIND	An indication as to whether there is effusion between the parietal and visceral pericardia.			Conceptual Entity	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139047>	C35552	Pericardial Effusion Size|PEFFSIZE	The size of a pericardial effusion as assessed at the point of greatest separation between the parietal and visceral pericardia.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139048>	C35552	Maximal Pericardial Effusion Width|MAXPEFFW	The measurement of the maximum separation between the parietal and visceral pericardia.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139049>	C53265	Observed Cardiac Device Type	A description of the type of cardiac device that is found in a subject.			Qualitative Concept	
C13904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13904>	C13432	14q24	A chromosome band present on 14q			Gene or Genome	
C139050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139050>	C98747	Native Cardiac Valve Intervention Type|NCVALTYP	A description of what, if any, kind of intervention has been performed on a native cardiac valve.			Functional Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139051>	C53265	Prosthetic Cardiac Valve Type|PCVALTYP	A description of the type of artificial cardiac valve in use.			Qualitative Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139052>	C127547	Minor Axis Cross-sectional Diameter at Mid Ventricular Systole|MNDIAMVS|Minor Axis Cross-sec. Diameter, MVS|Minor Axis Cross-sec. Diameter, MVS|Minor Axis Cross-sectional Diameter, Mid Ventricular Systole	The cross-sectional diameter of a cardiovascular structure measured along its minor axis at mid ventricular systole.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139053>	C127547	Major Axis Cross-sectional Diameter at Mid Ventricular Systole|MJDIAMVS|Major Axis Cross-sec. Diameter, MVS|Major Axis Cross-sec. Diameter, MVS|Major Axis Cross-sectional Diameter, Mid Ventricular Systole	The cross sectional diameter of a cardiovascular structure measured along its major axis at mid ventricular systole.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139054>	C25337	Number of Cardiac Valve Cusps|NUMCUSPS|Number of Cusps|Number of Cusps|Number of Cusps	A quantitative determination of the number of cusps composing a given cardiac valve.			Quantitative Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139055>	C181043	Cardiac Valvular Regurgitation Indicator|CVRGIND	An indication as to whether a specific cardiac valve is regurgitant.			Conceptual Entity	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139056>	C35552	Cardiac Valvular Regurgitation Likely Etiology|CVRGLE|Cardiac Valvular Regur Likely Etiology|Cardiac Valvular Regur Likely Etiology	An estimation as to the cause of the pathology responsible for the cardiac valve regurgitation.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139057>	C181043	Eccentric Regurgitant Jet Indicator|ERGJIND	An indication as to whether an eccentric regurgitant jet direction is present.			Conceptual Entity	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139058>	C138965	Major Axis Internal Diameter at End Ventricular Systole|MJIDEVS|Major Axis Internal Diameter at EVS|Major Axis Internal Diameter, EVS|Major Axis Internal Diameter, EVS|Major Axis Internal Diameter, End Ventricular Systole	The internal diameter of a cardiovascular structure measured along its major axis at end ventricular systole.			Spatial Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139059>	C138965	Major Axis Internal Diameter at End Ventricular Diastole|MJIDEVD|Major Axis Internal Diameter at EVD|Major Axis Internal Diameter, EVD|Major Axis Internal Diameter, EVD|Major Axis Internal Diameter, End Ventricular Diastole	The internal diameter of a cardiovascular structure measured along its major axis at end ventricular diastole.			Spatial Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13905>	C13432	14q11.2-q12	A chromosome band present on 14q			Gene or Genome	
C139060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139060>	C138966	Minor Axis Internal Diameter at End Ventricular Systole|MNIDEVS|Minor Axis Internal Diameter at EVS|Minor Axis Internal Diameter, EVS|Minor Axis Internal Diameter, EVS|Minor Axis Internal Diameter, End Ventricular Systole	The internal diameter of a cardiovascular structure measured along its minor axis at end ventricular systole.			Spatial Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139061>	C138966	Minor Axis Internal Diameter at End Ventricular Diastole|MNIDEVD|Minor Axis Internal Diameter at EVD|Minor Axis Internal Diameter, EVD|Minor Axis Internal Diameter, EVD|Minor Axis Internal Diameter, End Ventricular Diastole	The internal diameter of a cardiovascular structure measured along its minor axis at end ventricular diastole.			Spatial Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139062>	C181043	Heart Chamber Enlargement Indicator|HCENLIND	An indication as to whether there is an enlarged heart chamber.			Conceptual Entity	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139063>	C181043	Heart Chamber Hypertrophy Indicator|CMHYIND|Cardiac Muscle Hypertrophy Indicator|Cardiac Muscle Hypertrophy Indicator	An indication as to whether there is a hypertrophied heart chamber.			Conceptual Entity	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139064>	C48938	Lymphoid Cell Count|LYMPHOID|Lymphoid Cells|Lymphoid Cells	The determination of the amount of lymphoid cells present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139065>	C80184	Glucose-6-Phosphate Dehydrogenase Activity|G6PD Activity|G6PDA|Glucose-6-Phosphate Dehydrogenase Act|Glucose-6-Phosphate Dehydrogenase Act	The determination of the amount of glucose-6-phosphate dehydrogenase activity present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139066>	C64848	Corpuscular Hemoglobin Content|CH|CH|CHCNT|Cellular Hemoglobin Content|Erythrocyte Corpuscular Hemoglobin Content	A measurement of the mean red blood cell hemoglobin content within an individual red blood cell, calculated as the product of cell volume and cell hemoglobin concentration.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139067>	C64848	Corpuscular Hemoglobin Concentration Mean|CHCM|CHCM|Corpuscular HGB Concentration Mean|Corpuscular HGB Concentration Mean|Erythrocyte Corpuscular Hemoglobin Concentration Mean	A measurement of the average concentration of hemoglobin per erythrocyte in a biological specimen, derived from flow cytometric light scatter analysis of intact cells.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139068>	C64848	Corpuscular Hemoglobin Concentration Distribution Width|CHDW|CHDW|Corpuscular HGB Conc Distribution Width|Corpuscular HGB Conc Distribution Width|Erythrocyte Corpuscular Hemoglobin Concentration Distribution Width	A measurement of the standard deviation of hemoglobin concentrations in individual red blood cells, calculated as the standard deviation of hemoglobin content divided by the mean hemoglobin content.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139069>	C64848	Reticulocyte Corpuscular Hemoglobin Distribution Width|CHDWR|CHDWR|Ret Corpuscular HGB Conc Distr Width|Ret Corpuscular HGB Conc Distr Width	A measurement of the standard deviation of hemoglobin concentrations in reticulocytes, calculated as the standard deviation of hemoglobin content divided by the mean hemoglobin content.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C13906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13906>	C13426	BIR Domain|BIR Motif|Baculovirus Inhibitor of Apoptosis Protein Repeat|IAP Repeat|Inhibitor of Apoptosis Domain	Containing perfectly conserved histidine and cysteines residues. the BIR domain is about 70 residues long arranged in tandem repeats separated by a linker of variable length. Found in IAP (Inhibitor of Apoptosis Protein) Family proteins, it seems to confer cell death-preventing activity. Except NAIP, family members typically contain two or three BIR repeats and a C-terminal RING finger. A second group of BIR-domain-containing proteins (BIRPs) include mammalian Bruce and Survivin proteins, as well as BIR-containing proteins in yeasts and C. elegans. Survivin-like BIRPs regulate cytokinesis and mitotic spindle formation. (NCI)			Amino Acid Sequence	
C139070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139070>	C64848	Reticulocyte Hemoglobin Distribution Width|HDWR|HDWR|Ret Hemoglobin Distribution Width|Ret Hemoglobin Distribution Width|Reticulocyte Hemoglobin Concentration Distribution Width	A measurement of the distribution of the hemoglobin concentration in reticulocytes.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139071>	C64800	Red Cell Volume Distribution Width Standard Deviation|Erythrocyte Distribution Width Standard Deviation|RDW Standard Deviation|RDW Standard Deviation|RDW Standard Deviation|RDW-SD|RDWSD	A measurement of the volume dispersion within a red blood cell population, calculated as the width of the distribution curve at the 20% frequency level.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139072>	C114218	Reticulocyte Volume Distribution Width Coefficient of Variation|RDWRCV|RDWr-CV|RDWr-CV|Red Cell Volume Distribution Width Coefficient of Variation in Reticulocytes|Ret RDW Coefficient of Variation|Ret RDW Coefficient of Variation	A measurement of the volume dispersion within a reticulocyte population, calculated as the standard deviation of the mean reticulocyte volume divided by the mean reticulocyte volume, multiplied by 100 for conversion to a percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139073>	C114218	Reticulocyte Volume Distribution Width Standard Deviation|RDWRSD|RDWr Standard Deviation|RDWr-SD|Red Cell Volume Distribution Width Standard Deviation in Reticulocytes|Ret RDW Standard Deviation|Ret RDW Standard Deviation	A measurement of the volume dispersion within a reticulocyte population, calculated as the width of the distribution curve at the 20% frequency level.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139074>	C114218	Reticulocyte Volume Distribution Width|RDWR|RDWr|RDWr|Ret Volume Distribution Width|Ret Volume Distribution Width	A measurement of the volume dispersion within a reticulocyte population in a biological specimen, derived from flow cytometric pulse-height analysis and expressed as either coefficient of variation or standard deviation.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139075>	C64606	Functional Fibrinogen Measurement|FIBRINOF|Fibrinogen, Functional|Fibrinogen, Functional	The determination of the amount of functional fibrinogen present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139076>	C74692	Nordazepam Measurement|Desmethyldiazepam|Desmethyldiazepam|N-Desmethyldiazepam|N-Desmethyldiazepam|NRDZPM|Nordazepam|Nordazepam|Nordiazepam|Nordiazepam Measurement	The determination of the amount of nordazepam present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139077>	C74692	Clorazepate Measurement|CLRZPT|Clorazepate|Clorazepate	The determination of the amount of clorazepate present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139078>	C74692	Halazepam Measurement|HLZPM|Halazepam|Halazepam	The determination of the amount of halazepam present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139079>	C74692	Medazepam Measurement|MDZPM|Medazepam|Medazepam	The determination of the amount of medazepam present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C13907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13907>	C13426	UBC Domain|Ubiquitin-Conjugating Domain	The 16-kD UBC domain contains a conserved UBC motif and a conserved cysteine that accepts activated ubiquitin from E1 enzyme to form a thiol ester. Basic residues at the UBC domain N-terminus may be involved in E1 binding. UBC/E2 enzymes catalyze ubiquitination of target proteins with or without E3 'N-end' recognizing proteins. E2s can be classified on the basis of UBC structure. Poor at transferring ubiquitin to proteins on their own, Class I proteins comprise simply the UBC domain and probably require an E3 to ubiquitinate short-lived abnormal proteins prior to degradation. Class II enzymes contain different acidic C-terminal extensions of the UBC domain that appear to involve cellular localization or to mediate interaction with protein substrates for ubiquitination that results in protein modification but not degradation. Class III E2s have N-terminal extensions, but their function is unknown. (NCI)			Amino Acid Sequence	
C139080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139080>	C74692	Prazepam Measurement|PRZPM|Prazepam|Prazepam	The determination of the amount of prazepam present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139081>	C74692	Flunitrazepam Measurement|FLNTRZPM|Flunitrazepam|Flunitrazepam	The determination of the amount of flunitrazepam present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139082>	C74692	Clonazepam Measurement|CLNZPM|Clonazepam|Clonazepam	The determination of the amount of clonazepam present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139083>	C74692	Midazolam Measurement|MDZLM|Midazolam|Midazolam	The determination of the amount of midazolam present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139084>	C82624	Carbon Monoxide Measurement|CMONOX|CMONOX|Carbon Monoxide|Carbon Monoxide|Carbon Monoxide	The determination of the amount of carbon monoxide present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SDTM Tobacco Product Testing Test Code Terminology|CDISC SDTM Tobacco Product Testing Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139085>	C163539	HIV-1/2 Antibody and HIV-1 p24 Antigen Measurement|HIV-1/2 Antibody + HIV-1 p24 Antigen|HIV-1/2 Antibody + HIV-1 p24 Antigen|HIV12P24	The determination of the amount of either the HIV-1 or HIV-2 virus and the determination of HIV-1 p24 antigen present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139086>	C198277	HCV Antibody Signal to HCV Antibody Cutoff Ratio Measurement	The determination of the ratio of the Hepatitis C virus antibody signal in a biological specimen to Hepatitis C virus positive internal control. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	
C139087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139087>	C49237	Calcium to Phosphorus Ratio Measurement|CAPHOS|Calcium/Phosphate|Calcium/Phosphorus|Calcium/Phosphorus	The determination of the ratio of calcium to phosphorus in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139088>	C74886	N-Terminal ProA-type Natriuretic Peptide Measurement|ANPPRONT|N-Terminal ProA-type Natriuretic Peptide|N-Terminal ProA-type Natriuretic Peptide|N-terminal pro-Atrial Natriuretic Peptide|NT proANP II|Pro-NPPA Measurement	The determination of the amount of N-terminal proA-type natriuretic peptide present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139089>	C81971	Toxoplasma gondii IgG Antibody Measurement	The determination of the amount of Toxoplasma gondii IgG antibody present in a sample.			Laboratory Procedure	
C13908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13908>	C13432	22q13.3	A chromosome band present on 22q			Gene or Genome	
C139090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139090>	C81972	Toxoplasma gondii IgM Antibody Measurement	The determination of the amount of Toxoplasma gondii IgM antibody present in a sample.			Laboratory Procedure	
C139091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139091>	C64432	Alkaline Phosphatase Isoenzyme Measurement|ALPISOE|Alkaline Phosphatase Isoenzyme|Alkaline Phosphatase Isoenzyme	The determination of the amount of alkaline phosphatase isoenzyme present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139092>	C25337	Number of Malignant Biopsy Cores|CORBIOMN	A measurement of the total number of core biopsies that contain malignant tissue.			Quantitative Concept	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139093>	C125009	Mismatch Repair Proteins Interpretation|MMRPINTP	The determination of the meaning of multiple mismatch repair protein assessments.			Research Activity	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139094>	C185932	MutL Homolog 1 Measurement|MLH1|MLH1 Measurement|MutL Homolog 1|MutL Homolog 1	The determination of the amount of MutL homolog 1 present in a sample.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139095>	C185932	MutS Homolog 2 Measurement|MSH2|MSH2 Measurement|MutS Homolog 2|MutS Homolog 2	The determination of the amount of MutS homolog 2 present in a sample.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139096>	C185932	MutS Homolog 6 Measurement|MSH6|MSH6 Measurement|MutS Homolog 6|MutS Homolog 6	The determination of the amount of MutS homolog 6 present in a sample.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139097>	C185932	PMS1 Homolog 2 Measurement|PMS1 Homolog 2|PMS1 Homolog 2|PMS2|PMS2 Measurement	The determination of the amount of PMS1 homolog 2 present in a sample.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139098>	C64430	CDX2 Antigen Measurement|CDK-2 Antigen Measurement|CDX2 Antigen|CDX2 Antigen|CDX2AG	The determination of the amount of CDX2 antigen present in a sample.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139099>	C64430	Bradykinin Receptor B1 Measurement|BDKRB1|BDKRB1 Measurement|BK-1 Receptor|Bradykinin Receptor B1|Bradykinin Receptor B1	The determination of the amount of bradykinin receptor B1 present in a sample.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13909>	C13432	2q12.3	A chromosome band present on 2q			Gene or Genome	
C1390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1390>	C1968	Merbarone|MERBARONE	A nonsedating derivative of thiobarbituric acid and a novel catalytic topoisomerase II inhibitor with antineoplastic activity. Merbarone interferes with DNA replication via binding directly to topoisomerase II at a domain that maybe shared by other topoisomerase II cleavage-enhancing agents, ex., etoposide. Its mechanism of action appears to be a novel one, since merbarone does not intercalate DNA nor stabilize DNA-topoisomerase II cleavable complexes.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C139100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139100>	C76273	Citrobacter werkmanii|CITROBACTER WERKMANII|Citrobacter Genomospecies 7	A species of facultatively anaerobic, gram negative, rod shaped bacteria assigned to the phylum Proteobacteria; this species is motile by peritrichous flagella, it is negative for ornithine decarboxylase activity, and it is positive for growth on malonate.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139101>	C86457	Extended-spectrum Beta-lactamase Positive Klebsiella pneumoniae|KLEBSIELLA PNEUMONIAE, ESBL|Klebsiella pneumoniae, Extended-Spectrum Beta-Lactamases	A subgroup of Klebsiella pneumoniae bacteria that produce beta-lactamase and are therefore resistant to extended-spectrum beta-lactam (penicillin) antibiotics.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139102>	C86455	Extended-spectrum Beta-lactamase Positive Klebsiella oxytoca|KLEBSIELLA OXYTOCA, ESBL|Klebsiella oxytoca, Extended-Spectrum Beta-Lactamases	A subgroup of Klebsiella oxytoca bacteria that produce beta-lactamase and are therefore resistant to extended-spectrum beta-lactam (penicillin) antibiotics.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139103>	C86696	Non-Mucoid Pseudomonas aeruginosa|PSEUDOMONAS AERUGINOSA, NON-MUCOID	The wildtype form of Pseudomonas aeruginosa that does not produce an extracellular mucoid alginate.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139104>	C86696	Mucoid Pseudomonas aeruginosa|PSEUDOMONAS AERUGINOSA, MUCOID	A substrain of Pseudomonas aeruginosa that produces an exopolysaccharide alginate. Overexpression of alginate in mucoid strains causes formation of micro-colonies that are less susceptible to host defense mechanisms.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139105>	C86696	Small-Colony Variant Pseudomonas aeruginosa|PSEUDOMONAS AERUGINOSA, SMALL-COLONY VARIANT|Pseudomonas aeruginosa SCV	A phenotypic variant of Pseudomonas aeruginosa that forms smaller-than-average colonies when cultured; these variants show an increased ability to form a biofilm, and are frequently resistant to multiple antibiotics.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139106>	C77167	Arthrographis|ARTHROGRAPHIS	A genus of fungi in the phylum Ascomycota with hyaline, septate hyphae. Species in this genus are widely found in compost, decaying plant material, and soil. Some species cause rare infections in humans.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139107>	C172546	Non-Mucoid Pseudomonas aeruginosa Measurement|P. aeruginosa, Non-Mucoid|P. aeruginosa, Non-mucoid|PAERGNMC|Pseudomonas aeruginosa, Non-Mucoid	The determination of the amount of non-mucoid Pseudomonas aeruginosa present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139108>	C172546	Mucoid Pseudomonas aeruginosa Measurement|P. aeruginosa, Mucoid|P. aeruginosa, Mucoid|PAERGMUC|Pseudomonas aeruginosa, Mucoid	The determination of the amount of mucoid Pseudomonas aeruginosa present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139109>	C172546	Small-Colony Variant Pseudomonas aeruginosa Measurement|P. aeruginosa, Small-colony Variant|P. aeruginosa, Small-colony Variant|PAERGSCV|Pseudomonas aeruginosa, SCV|Pseudomonas aeruginosa, Small-colony Variant	The determination of the amount of small-colony variant Pseudomonas aeruginosa present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13910>	C13432	12q24.21	A chromosome band present on 12q			Gene or Genome	
C139110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139110>	C147460	Methicillin-resistant Staphylococcus aureus Measurement|MRSA|S. aureus, Methicillin-Resistant|S. aureus, Methicillin-resistant|Staphylococcus aureus, Methicillin-Resistant	The determination of the amount of methicillin-resistant Staphylococcus aureus present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139111>	C147460	Methicillin-susceptible Staphylococcus aureus Measurement|MSSA|S. aureus, Methicillin-Susceptible|S. aureus, Methicillin-susceptible|Staphylococcus aureus, Methicillin-Susceptible	The determination of the amount of methicillin-susceptible Staphylococcus aureus present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139112>	C49188	Stenotrophomonas maltophilia Measurement|STENMALT|Stenotrophomonas maltophilia|Stenotrophomonas maltophilia	The determination of the amount of Stenotrophomonas maltophilia present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139113>	C49188	Burkholderia Measurement|BURKHOLD|Burkholderia|Burkholderia	The determination of the amount of Burkholderia genus microorganisms present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139114>	C205055	Microbial EC50 Fold Change from Baseline|MEC50FCB	A fold change based on the concentration of a specific drug expected to produce 50 percent inhibition of population growth or replication of a microbial organism.			Laboratory or Test Result	CDISC SDTM Microbiology Susceptibility Test Code Terminology|CDISC SDTM Microbiology Susceptibility Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139115>	C205055	Microbial EC50 Fold Change from Reference|MEC50FCR|Microbial EC50 Fold Change from Ref|Microbial EC50 Fold Change from Ref	A fold change based on the concentration of a specific drug expected to produce 50 percent inhibition of the population growth or replication of a microbial organism; it is a ratio calculated by the EC50 Subject Result divided by the EC50 Reference Control Result.			Laboratory or Test Result	CDISC SDTM Microbiology Susceptibility Test Code Terminology|CDISC SDTM Microbiology Susceptibility Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139116>	C205055	Microbial EC50 Reference Control Result|MEC50R	A reference control sample response based on the concentration of a specific drug expected to produce 50 percent inhibition of the population growth or replication of a microbial organism.			Laboratory or Test Result	CDISC SDTM Microbiology Susceptibility Test Code Terminology|CDISC SDTM Microbiology Susceptibility Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139117>	C205055	Microbial EC50 Subject Result|MEC50S	A measurement of titer of a microbial organism that has been exposed to the concentration of a specific drug expected to produce 50 percent inhibition of the population growth or replication of a microbial organism.			Laboratory or Test Result	CDISC SDTM Microbiology Susceptibility Test Code Terminology|CDISC SDTM Microbiology Susceptibility Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139118>	C205055	Microbial IC50 Fold Change from Baseline|MIC50FCB	A fold change based on the concentration of a specific drug expected to produce 50 percent inhibition on the enzymatic activity of a microbial organism; it is a ratio calculated by the current IC50 Subject Result divided by the IC50 Subject Result from the baseline visit.			Laboratory or Test Result	CDISC SDTM Microbiology Susceptibility Test Code Terminology|CDISC SDTM Microbiology Susceptibility Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139119>	C205055	Microbial IC50 Fold Change from Reference|MIC50FCR|Microbial IC50 Fold Change from Ref|Microbial IC50 Fold Change from Ref	A fold change based on the concentration of a specific drug expected to produce 50 percent inhibition on the enzymatic activity of a microbial organism; it is a ratio calculated by the IC50 Subject Result divided by the IC50 Reference Control Result.			Laboratory or Test Result	CDISC SDTM Microbiology Susceptibility Test Code Terminology|CDISC SDTM Microbiology Susceptibility Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13911>	C13426	Bcl-2 Homology Domain	Proteins that are related to bcl-2 are characterized by the presence of one or more highly conserved stretches of homology with bcl-2, designated BH1, BH2, BH3, BH4. These domains control the ability of these proteins to homo- and heterodimerize with other proteins. Competitive dimerization between family members is thought to regulate their function as regulators of apoptosis.			Amino Acid Sequence	
C139120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139120>	C205055	Microbial IC50 Reference Control Result|MIC50R	A reference control sample response based on the concentration of a specific drug expected to produce 50 percent inhibition on the enzymatic activity of a microbial organism.			Laboratory or Test Result	CDISC SDTM Microbiology Susceptibility Test Code Terminology|CDISC SDTM Microbiology Susceptibility Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139121>	C205055	Microbial IC50 Subject Result|MIC50S	A measurement of the biological or biochemical reaction of a microbial organism that has been exposed to the concentration of a specific drug expected to produce 50 percent inhibition on the enzymatic activity of a microbial organism.			Laboratory or Test Result	CDISC SDTM Microbiology Susceptibility Test Code Terminology|CDISC SDTM Microbiology Susceptibility Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139122>	C205055	Microbial IC95 Fold Change from Baseline|IC95 Fold Change from Baseline|MIC95FCB	A fold change based on the concentration of a specific drug expected to produce 95 percent inhibition on the enzymatic activity of a microbial organism; it is a ratio calculated by the current IC95 Subject Result divided by the IC95 Subject Result from the baseline visit.			Laboratory or Test Result	CDISC SDTM Microbiology Susceptibility Test Code Terminology|CDISC SDTM Microbiology Susceptibility Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139123>	C205055	Microbial IC95 Fold Change from Ref|IC95 Fold Change from Reference|MIC95FCR	A fold change based on the concentration of a specific drug expected to produce 95 percent inhibition on the enzymatic activity of a microbial organism; it is a ratio calculated by the IC95 Subject Result divided by the IC95 Reference Control Result.			Laboratory or Test Result	CDISC SDTM Microbiology Susceptibility Test Code Terminology|CDISC SDTM Microbiology Susceptibility Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139124>	C205055	Microbial IC95 Reference Control Result|IC95 Reference Control Result|MIC95R	A reference control sample response based on the concentration of a specific drug expected to produce 95 percent inhibition on the enzymatic activity of a microbial organism.			Laboratory or Test Result	CDISC SDTM Microbiology Susceptibility Test Code Terminology|CDISC SDTM Microbiology Susceptibility Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139125>	C205055	Microbial IC95 Subject Result|IC95 Subject Result|MIC95S	A measurement of the biological or biochemical reaction of a microbial organism that has been exposed to the concentration of a specific drug expected to produce 95 percent inhibition on the enzymatic activity of a microbial organism.			Laboratory or Test Result	CDISC SDTM Microbiology Susceptibility Test Code Terminology|CDISC SDTM Microbiology Susceptibility Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139126>	C94189	New Non-Target Lesion Identification|NEW NON-TARGET|New Non-Index	The identification of a non-target tumor, lesion, or site of disease that will be assessed qualitatively over time, and which was not detected at baseline.			Diagnostic Procedure	CDISC SDTM Terminology|CDISC SDTM Tumor and Lesion Identification Test Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C139127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139127>	C94189	New Target Lesion Identification|NEW TARGET|New Index	The identification of a target tumor, lesion, or site of disease that will be assessed quantitatively over time, and which was not detected at baseline.			Diagnostic Procedure	CDISC SDTM Terminology|CDISC SDTM Tumor and Lesion Identification Test Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C139128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139128>	C62667	Overall Tracer Uptake Compared to Baseline|OTRCUPCB|Overall Tracer Uptake Compared to BL|Overall Tracer Uptake Compared to BL	A visually assessed combination of extent and intensity of tracer uptake, as compared to baseline.			Diagnostic Procedure	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C139129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139129>	C102356	Accumulation Ratio AUC to Last Nonzero Concentration|ARAUCLST|Accum Ratio AUC to Last Nonzero Conc|Accum Ratio AUC to Last Nonzero Conc	The area under the curve (AUC) from the time of dosing to the last measurable concentration divided by the area under the curve from the time of dosing to the last measurable concentration during the initial dosing interval.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C13912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13912>	C13911	BH1 Domain|BCL-2 Homology 1 Domain	Found in proteins that regulate apoptosis, conserved a-helix BCL-2 Homology (BH1-4) Domains are critical to protein apoptotic function and the protein ability to interact/dimerize with other family members or regulatory proteins. BH1 contains predominantly hydrophobic residues. BCL-2 family proteins dimerize among pro- and anti-apoptotic class family members. BCL-2 homodimerization appears to involve head-to-tail interaction of N-terminal BH4 resides with more distal BH1, BH2, and BH3 regions. BCL-2/BAX heterodimerization appears to involve tail-to-tail interaction of the BCL-2 BH1, BH2, and BH3 regions and the BAX BH3 domain region. BCL-2 may suppress cell death partly by binding to BAX via the BH3 domain preventing BAX homodimer formation. (NCI)			Amino Acid Sequence	
C139130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139130>	C48470	Minimum Alveolar Concentration 50 Percent|MAC50|Minimum Alveolar Concentration 50%|{MAC50}|{MAC50}	A unit of potency for inhalational gases, defined as the concentration of gas in the lung required to immobilize 50% of individuals in response to a stimulus, such as pain.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139131>	C48572	Hour Times Percent|h*%|h*%|h.%|h.%	A unit of measure for the area under an effect curve (AUEC), defined as hours times percent.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139132>	C69090	Second Times Kilopascal|Kilopascal Second|kPa*s|kPa.s|kPa.s|s*kPa|s*kPa|s.kPa|s.kPa	A unit of resistance equal to one second times one kilopascal.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139133>	C48572	Liter per Second per Kilopascal|L/s/kPa|L/s/kPa|L/s/kPa|l/s/kPa|l/s/kPa	A unit of conductance equal to the number of liters per unit of time equal to one second per unit of pressure equal to one kilopascal.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139134>	C67275	Linear Foot Pound|Linear Foot-pound|Linear Pounds Feet|Linear ft*LB|Linear ft*LB|Linear ft*lbf|[lbf_av]|pound foot|{Linear ft*LB}|{Linear ft*LB}	A unit of energy that equals the work required to move one pound a distance of one foot in the direction of the applied force.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|PQ/CMC Units of Measure Terminology
C139135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139135>	C69157	Kilocalorie per Day|kcal/d|kcal/d|kcal/d|kcal/d|kcal/day|kilocalorie per day	A unit of energy equal to one kilocalorie per day.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit for Vital Sign Result Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C139136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139136>	C3671	Tissue Rarefaction|RAREFACTION	A morphologic finding indicating reduced tissue density.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139137>	C138968	Basophilic Hypertrophic Focus|BASOPHILIC HYPERTROPHIC FOCUS	A central point or locus characterized by hypertrophy and basophilia.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139138>	C41460	Decreased Cellularity Present|CELLULARITY, DECREASED	A decrease in the number of cells as compared to a standard or norm.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139139>	C110937	Decreased Bone Tissue|BONE, DECREASED	A decrease in the amount of bone tissue as compared to a standard or norm.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C13913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13913>	C13911	BH2 Domain|BCL-2 Homology 2 Domain	Found in proteins that regulate apoptosis, conserved a-helix BCL-2 Homology (BH1-4) Domains are critical to protein apoptotic function and the protein ability to interact/dimerize with other family members or regulatory proteins. BCL-2 family proteins dimerize among pro- and anti-apoptotic class family members. BCL-2 homodimerization appears to involve head-to-tail interaction of N-terminal BH4 resides with more distal BH1, BH2, and BH3 regions. BCL-2/BAX heterodimerization appears to involve tail-to-tail interaction of the BCL-2 BH1, BH2, and BH3 regions and the BAX BH3 domain region. BCL-2 may suppress cell death partly by binding to BAX via the BH3 domain preventing BAX homodimer formation. (NCI)			Amino Acid Sequence	
C139140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139140>	C110937	Increased Bone Tissue|BONE, INCREASED	An increase in the amount of bone tissue as compared to a standard or norm.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139141>	C60925	Dental Dysplasia|DENTAL DYSPLASIA	Chronic degenerative changes of the teeth, mainly the incisors, due to trauma or inflammation. It involves abnormal development of odontogenic tissue and is characterized by abnormal deposits of dentin, cementum, and osteoid.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139142>	C137801	Denticle|DENTICLE	Tooth-like structure formed from displaced odontogenic tissue, which may include dental papilla.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139143>	C60925	Dentin Matrix Alteration|DENTIN MATRIX ALTERATION	A term that refers to alterations in the dentin matrix. Causes include dentinogenesis imperfecta and hypophosphatemic rickets.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139144>	C137801	Dentin Niche Formation|DENTIN NICHES	A finding indicating the formation of a dentin niche due to cellular alterations.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139145>	C60925	Decreased Dentin|DENTIN, DECREASED	A decrease in the amount of dentin as compared to a standard or norm.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139146>	C137801	Experimental Organism Fibro-osseous Lesion|FIBRO-OSSEOUS LESION	Accumulation of a mixed cell population of non-neoplastic mesenchymal cells along endosteal surfaces which may be associated with focal osteoclastic bone resorption and marrow fibroplasia. (INHAND)			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139147>	C137802	Fibrous Osteodystrophy|FIBROUS OSTEODYSTROPHY	The replacement of cortical bone by fibrous connective tissue that may be caused by parathyroid hormone-mediated bone resorption with secondary fibroplasia.			Disease or Syndrome	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139148>	C110937	Growth Plate Closed|GROWTH PLATE CLOSED|Physis Closed	A finding indicating that the epiphyseal plate is fully calcified.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139149>	C110937	Increased Osteoblastic Surface|OSTEOBLASTIC SURFACE, INCREASED	An increase in the amount of osteoblastic surface as compared to a standard or norm.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C13914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13914>	C13911	BH3 Domain|BH-3|BH3|Bcl-2 Homology Domain 3|Bcl-2 Homology Domain-3	The alpha-helical BH3 domain (9 amino acids) represents a minimal death domain and is essential for the activity of pro-apoptotic members of the bcl-2 family. Some of these proteins only contain a BH3 domain.	BH3 Domain		Amino Acid Sequence	CTRP Biomarker Terminology|CTRP Terminology
C139150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139150>	C110937	Increased Osteoid|OSTEOID, INCREASED	An increase in the amount of unmineralized bone matrix as compared to a standard or norm.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139151>	C3029	Osteophyte|Bone Spur|OSTEOPHYTE	A bony projection that forms on the joints of the body.			Disease or Syndrome	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139152>	C137801	Dental Pulp Concretion|PULP CONCRETION	A mass formed in the dental pulp due to local accumulation of a substance.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139153>	C110937	Decreased Physis Thickness|PHYSIS THICKNESS, DECREASED	A decrease in the dimension between the two surfaces, in comparison to a standard or norm.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139154>	C110937	Increased Physis Thickness|PHYSIS THICKNESS, INCREASED	An increase in the dimension between the two surfaces, in comparison to a standard or norm.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139155>	C35867	Infiltrate and Fibrosis|INFILTRATE/FIBROSIS	A morphologic finding indicating the presence of a cellular infiltrate associated with fibrosis in a tissue sample.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139156>	C35867	Pathologic Intimal Thickening|INTIMAL THICKENING|PIT	A term that refers to a vascular lesion characterized by an extracellular lipid pool with intimal smooth muscle cell loss typically adjacent to the medial wall in addition to varying degrees of macrophage infiltration near the lumen. (Arteriosclerosis, Thrombosis, and Vascular Biology. 2007; 27:986-989)			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139157>	C35552	Intramural Plaque|INTRAMURAL PLAQUE	The formation of an atherosclerotic plaque within the vascular wall.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139158>	C35867	Necrosis and Infiltrate|NECROSIS/INFILTRATE	A morphologic finding indicating the presence of necrosis associated with a cellular infiltrate in a tissue sample.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139159>	C35867	Necrosis and Inflammation|NECROSIS/INFLAMMATION	A morphologic finding indicating the presence of necrosis associated with an inflammatory infiltrate in a tissue sample.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C13915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13915>	C13911	BH4 Domain	BH4 is present only in the amino-terminal regions of pro-survival family bcl-2 members and is essential for the anti-apoptotic function, although deletion of BH4 does not necessarily impair the ability of BH4-containing proteins to bind to a variety of other bcl-2-related proteins.			Amino Acid Sequence	
C139160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139160>	C35867	Intimal Hyperplasia|Intimal Proliferation|PROLIFERATION, INTIMA	Thickening of the tunica intima of a blood vessel due to injury.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139161>	C137801	Valve-Derived Stromal Cell Proliferation|PROLIFERATION, STROMA, VALVE	A finding indicating proliferation of the stromal valvular cells			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139162>	C22188	Ethmoidal Nasal Turbinate|Ethmoturbinate|NASAL TURBINATE, ETHMOIDAL CONCHA	The nasal turbinates extending from the ethmoidal crest into the nasal cavity.			Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139163>	C22188	Dorsal Nasal Turbinate|NASAL TURBINATE, DORSAL CONCHA	The nasal turbinate originating from the ethmoidal crest on the inner wall of the nasal bone and extending to the maxilla.			Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139164>	C22188	Medial Nasal Turbinate|MEDIAL NASAL TURBINATE|Media Nasal Concha|NASAL TURBINATE, MIDDLE CONCHA|Nasal Middle Turbinate	The largest of the ethmoidal nasal turbinates, extending from the ethmoidal crest into the middle of the nasal cavity.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139165>	C22188	Ventral Nasal Turbinate|Maxilloturbinate|NASAL TURBINATE, VENTRAL CONCHA	The nasal turbinate originating from the conchal crest on the medial wall of the maxilla and extending into the nasal cavity.			Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139166>	C25180	Trial Registration Indicator	An indication as to whether the clinical trial has been registered with a trial registry system.			Conceptual Entity	
C139167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139167>	C25683	Source of Monetary or Material Support for Study	The organization(s) providing monetary and/or materials for the conduct of a study or trial.			Qualitative Concept	
C139168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139168>	C42614	Primary Study Sponsor Name	The name of the entity that is considered the primary sponsor for the trial or study.			Conceptual Entity	
C139169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139169>	C42614	Secondary Study Sponsor Name	The name of the entity that is considered the secondary sponsor for the trial or study.			Conceptual Entity	
C13916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13916>	C13432	11q22	A chromosome band present on 11q	11q22		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C139170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139170>	C16632	Country of Recruitment	The country in which subjects are located when enrolling in a trial or study.			Geographic Area	
C139171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139171>	C25164	Date of First Enrollment into Study|Enrollment Start Date|Study Enrollment|date of first enrollment	The calendar date on which the first subject was enrolled into a study or trial.			Temporal Concept	CDISC Glossary Terminology|GDC Terminology|GDC Value Terminology|SeroNet Study Descriptors|SeroNet Variables
C139172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139172>	C53190	Target Sample Size|Planned Sample Size	The total number of planned participants in a study or trial.			Quantitative Concept	
C139173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139173>	C25212	Secondary Endpoint|secondary endpoint	An auxiliary endpoint associated with the study or trial.			Temporal Concept	CDISC DDF Endpoint Level Value Set Terminology|CDISC DDF Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C139174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139174>	C49652	Device Feasibility Study|DEVICE FEASIBILITY	An intervention of a device product is being evaluated to determine the feasibility of the product or to test a prototype device and not health outcomes. Such studies are conducted to confirm the design and operating specifications of a device before beginning a full clinical trial. (ClinicalTrials.gov)	Device Feasibility Study		Research Activity	CDISC SDTM Terminology|CDISC SDTM Trial Indication Type Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C139175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139175>	C69260	Age at Full-Time Use|AGEFTUSE|AGEFTUSE	The age at which the full-time use of an entity occurred.			Organism Attribute	CDISC SDTM Duchenne Muscular Dystrophy Findings About Test Code Terminology|CDISC SDTM Duchenne Muscular Dystrophy Findings About Test Name Terminology|CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139176>	C80304	Extrapolation Imputation Technique|EXTRAP|Extrapolation	A method of imputation involving populating an analysis value that is outside the range of observed values and is estimated by a function of those observed values. (CDISC)			Quantitative Concept	CDISC ADaM Derivation Type Terminology|CDISC ADaM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139177>	C64493	Every Seven Days|Every 7 Days|Q7D	Every seven days.			Quantitative Concept	CDISC SDTM Frequency Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139178>	C64493	Every Night|QN	Occurring or done each night.			Quantitative Concept	CDISC SDTM Frequency Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139179>	C64493	Ten Days Per Month|10 DAYS PER MONTH|10 Days Monthly|10 Days Monthly	Ten days per month.			Quantitative Concept	CDISC SDTM Frequency Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C13917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13917>	C13432	2p11	A chromosome band present on 2p			Gene or Genome	
C139180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139180>	C64493	Seven Times Per Day|7 TIMES PER DAY|7 Times Daily|7 Times Daily	Seven times per day.			Quantitative Concept	CDISC SDTM Frequency Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139181>	C64493	Eight Times Per Day|8 TIMES PER DAY|8 Times Daily|8 Times Daily	Eight times per day.			Quantitative Concept	CDISC SDTM Frequency Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139182>	C64493	Nine Times Per Day|9 TIMES PER DAY|9 Times Daily|9 Times Daily	Nine times per day.			Quantitative Concept	CDISC SDTM Frequency Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139183>	C64493	Every Forty-Five Minutes|Every 45 Minutes|Every 45 Minutes|Q45MIN	Every forty-five minutes.			Quantitative Concept	CDISC SDTM Frequency Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139184>	C25167	Rectal Tumor to Anal Verge Distance|RTAVDIST	A measurement of the distance between the rectal tumor and the anal margin.			Quantitative Concept	CDISC SDTM Gastrointestinal Test Code Terminology|CDISC SDTM Gastrointestinal Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139185>	C13031	Anterior Cingulate Cortex|ANTERIOR CINGULATE CORTEX	The front region of the cingulate cortex that is located in the medial frontal lobe, adjacent to the corpus callosum. The anterior cingulate functions in decision making and in the regulation of emotions and physiological processes like blood pressure and heart rate.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139186>	C12680	Abdominal Region|ABDOMINAL REGION	Any portion of the body that lies within the boundary, either internally or externally, of the abdomen: superior margin, the thorax; inferior margin the pelvis; lateral margins, the ribs.			Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139187>	C34076	Anterior Superior Iliac Spine|ANTERIOR SUPERIOR ILIAC SPINE	A bony projection from the anterior region of the iliac crest that functions as the site of attachment for the sartorius and tensor fascia latae muscles and the inguinal ligament.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139188>	C33894	Capitate-Hamate Joint|CAPITATE-HAMATE JOINT	The articulation of the capitate and hamate bones in the wrist.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139189>	C33894	Capitate-Lunate Joint|CAPITATE-LUNATE JOINT	The articulation of the capitate and lunate bones in the wrist.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C13918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13918>	C13432	4q28-q31	A chromosome band present on 4q			Gene or Genome	
C139190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139190>	C52784	Hand Digit 2 Distal Phalanx|DISTAL PHALANX 2 OF THE HAND	The bone that forms the tip of the second finger, as counted from the thenar side of the hand.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139191>	C52784	Hand Digit 3 Distal Phalanx|DISTAL PHALANX 3 OF THE HAND	The bone that forms the tip of the third finger, as counted from the thenar side of the hand.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139192>	C52784	Hand Digit 4 Distal Phalanx|DISTAL PHALANX 4 OF THE HAND	The bone that forms the tip of the fourth finger, as counted from the thenar side of the hand.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139193>	C52784	Hand Digit 5 Distal Phalanx|DISTAL PHALANX 5 OF THE HAND	The bone that forms the tip of the fifth finger, as counted from the thenar side of the hand.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139194>	C32889	Distal Radioulnar Joint|DISTAL RADIOULNAR JOINT	The articulation of the head of the ulna bone and the ulnar notch of the radius; the distal radioulnar joint is a pivot joint that functions in pronation and supination of the forearm.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139195>	C33027	Epigastric Lymph Node|EPIGASTRIC LYMPH NODE	A parietal lymph node located along the inferior epigastric vessels.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139196>	C33027	Esophageal Lymph Node|ESOPHAGEAL LYMPH NODE	Any lymph node located near the esophagus, including cervical, and upper, middle, and lower thoracic lymph nodes.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139197>	C52701	First Dorsal Interosseous Muscle of the Foot|FIRST DORSAL INTEROSSEOUS MUSCLE OF THE FOOT	A dorsal interosseous muscle of the foot that originates on the lateral side of the first metatarsal and the medial side of the second metatarsal, and inserts into the medial side of the base of the proximal phalanx of the second toe.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139198>	C138969	First Dorsal Interosseous Muscle of the Hand|FIRST DORSAL INTEROSSEOUS MUSCLE OF THE HAND	A dorsal interosseous muscle of the hand that originates on the proximal half of the lateral border of the index metacarpal and the full length of the medial border of the thumb metacarpal, and inserts into the lateral side of the index finger.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139199>	C77637	Gingival Mucosa|GINGIVAL MUCOSA	The portion of the oral mucosa that surrounds the cervical aspect of teeth and the alveolar process of the jaw.			Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C13919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13919>	C13432	8q21.13	A chromosome band present on 8q			Gene or Genome	
C1391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1391>	C1591	Recombinant Macrophage Inflammatory Protein-1 Alpha|CCL3|LD78|LD78 alpha (e)|MIP-1 Alpha|MIP-1a	A recombinant therapeutic agent which is chemically identical to or similar to endogenous macrophage inflammatory protein-1, a member of the CC chemokine family produced by activated macrophages.  Macrophage inflammatory protein-1 alpha activates granulocytes and induces pro-inflammatory cytokine synthesis.  The addition of macrophage inflammatory protein-1 alpha to a vaccine consisting of a DNA immunogen or a pro-inflammatory peptide may enhance vaccine-induced host immune anti-tumor responses. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C139200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139200>	C33894	Triangular-Hamate Joint|TRIANGULAR-HAMATE JOINT|Triquetral-Hamate Joint|Triquetrum-Hamate Joint|Triquetrum-Hamate Joint	The articulation between the hamate and the triquetral bones in the wrist.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139201>	C13023	Cardiac Wall|CARDIAC WALL	All of the tissue that comprises the solid, outer structure of the heart, including the epicardium, the myocardium, and the endocardium.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139202>	C69300	Lateral Humeral Epicondyle|LATERAL HUMERAL EPICONDYLE	A bone prominence at the distal end of the humerus to which the radial collateral ligament of the elbow joint, the anconeus and supinator muscles, and the common extensor tendon are attached.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139203>	C33894	Lunotriquetral Joint|TRIANGULAR-LUNATE JOINT|Triquetral-Lunate Joint|Triquetrum-Lunate Joint	The articulation between the lunate and the triquetral bones in the wrist.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139204>	C83002	Medial Femoral Condyle|MEDIAL FEMORAL CONDYLE	A rounded bony projection on the inner side of the distal end of the femur to which the medial collateral and the posterior cruciate ligaments are attached.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139205>	C12680	Periumbilical Region|PERIUMBILICAL REGION	The region of the body that surrounds the umbilicus.			Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139206>	C34076	Posterior Superior Iliac Spine|POSTERIOR SUPERIOR ILIAC SPINE	A bony projection from the posterior region of the iliac crest that lies over the sacroiliac joint and functions as the site of attachment for the thoracolumbar fascia and the posterior sacroiliac and sacrotuberous ligaments.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139207>	C12374	Iliotibial Band|ILIOTIBIAL BAND	A dense band of avascular, regular connective tissue, it is formed as the union of the superficial and deep layers of the tensor fascia latae, creating a thick band that extends inferiorly, taking its origins from the iliac crest, the tensor fascia latae, and the gluteus maximus, travelling inferiolaterally along the thigh, and inserting on Gerdy's tubercle on the lateral aspect of the tibia. Functionally, the iliotibial band helps to flex, abduct, and medially rotate the femur at the hip joint, and it also helps to stabilize the knee laterally.			Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139208>	C128567	Distal Femur R1|DISTAL FEMUR R1	The portion of the distal femur, identified during a DXA scan, that contains primarily metaphyseal or trabecular bone.			Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C139209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139209>	C28747	Reader 3|READER 3	A reader performing the assessment that is given the designation of three.			Population Group	CDISC SDTM Medical Evaluator Identifier Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13920>	C13432	2q21-q22	A chromosome band present on 2q			Gene or Genome	
C139210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139210>	C87802	Grip Strength|GRIPSTR|GRIPSTR	An assessment of hand muscle strength that measures that force with which one holds or grasps.	Grip Strength		Conceptual Entity	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Nervous System Findings Test Code Terminology|CDISC SEND Nervous System Findings Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C139211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139211>	C87802	Pinch Strength|PINCHSTR	An assessment of hand muscle strength that measures that force with which one squeezes or compresses an object using one's thumb and one or multiple fingers.			Conceptual Entity	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139212>	C63507	Range of Motion, Abduction|ROMABDT	An assessment of joint flexibility that measures the movement of a body part pulling away from the midline of the body, in number of degrees.			Clinical Attribute	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139213>	C63507	Range of Motion, Extension|ROMEXT	An assessment of joint flexibility that measures the straightening (unbending) movement between body parts, in number of degrees.			Clinical Attribute	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139214>	C63507	Range of Motion, Dorsiflexion|ROMDORFL	An assessment of joint flexibility that measures the movement of a body part bending towards its dorsal surface, in number of degrees.			Clinical Attribute	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139215>	C138967	Isometric Muscle Strength, Extension|ISOMSEXT	An assessment of muscle strength that measures the force produced by static muscle contraction during the straightening (unbending) movement between body parts.			Conceptual Entity	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139216>	C138967	Isometric Muscle Strength, Flexion|ISOMSFL	An assessment of muscle strength that measures the force produced by static muscle contraction during the bending movement between body parts.			Conceptual Entity	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139217>	C68741	Bone Mineral Density Z-Score|BMDZ	A statistical score representing the number of standard deviations above or below what is expected for an individual's bone density based on his age, sex, weight, and race. Z-scores are most useful in evaluating low bone density in children, premenopausal women, and men younger than age fifty.			Quantitative Concept	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139218>	C19332	Total Body Fat to Total Body Mass Ratio Measurement|BODYFATP|Body Fat Percentage|Total Body Fat/Total Body Mass|Total Body Fat/Total Body Mass	The amount of an individual's total body mass that is fat, expressed as a percent.			Organism Attribute	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139219>	C19332	Lean Body Mass to Total Body Mass Ratio Measurement|LBMTBMR|Lean Body Mass/Total Body Mass|Lean Body Mass/Total Body Mass	The proportion of an individual's lean body mass to his total body weight; lean body mass is calculated by subtracting body fat from total body weight.			Organism Attribute	CDISC SDTM Terminology|CDISC SDTM Vital Sign Test Code Terminology|CDISC SDTM Vital Sign Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C139220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139220>	C25338	Brooke Modified Medical Research Council Manual Muscle Test Score, Extension|BMMTEXT|Brooke mMRC MMT Score, Extension|Brooke mMRC MMT Score, Extension|Brooke mMRC MMT Score, Extension	The numerical value that represents the result of a clinical assessment of muscle strength and function during extension that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).			Quantitative Concept	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139221>	C25338	Brooke Modified Medical Research Council Manual Muscle Test Score, Plantar Flexion|BMMTPF|Brooke mMRC MMT Score, Plantar Flex|Brooke mMRC MMT Score, Plantar Flex|Brooke mMRC MMT Score, Plantar Flexion	The numerical value that represents the result of a clinical assessment of muscle strength and function during plantar flexion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).			Quantitative Concept	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139222>	C25338	Brooke Modified Medical Research Council Manual Muscle Test Score, Flexion|BMMTFLX|Brooke mMRC MMT Score, Flexion|Brooke mMRC MMT Score, Flexion|Brooke mMRC MMT Score, Flexion	The numerical value that represents the result of a clinical assessment of muscle strength and function during flexion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).			Quantitative Concept	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139223>	C25338	Brooke Modified Medical Research Council Manual Muscle Test Score, Abduction|BMMTABDT|Brooke mMRC MMT Score, Abduction|Brooke mMRC MMT Score, Abduction|Brooke mMRC MMT Score, Abduction	The numerical value that represents the result of a clinical assessment of muscle strength and function during abduction that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).			Quantitative Concept	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139224>	C25338	Brooke Modified Medical Research Council Manual Muscle Test Score, Lateral Rotation|BMMTLR|Brooke mMRC MMT Score, Lat. Rotat.|Brooke mMRC MMT Score, Lat. Rotat.|Brooke mMRC MMT Score, Lateral Rotation	The numerical value that represents the result of a clinical assessment of muscle strength and function during lateral rotation that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).			Quantitative Concept	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139225>	C25338	Brooke Modified Medical Research Council Manual Muscle Test Score, Dorsiflexion|BMMTDORS|Brooke mMRC MMT Score, Dorsiflexion|Brooke mMRC MMT Score, Dorsiflexion|Brooke mMRC MMT Score, Dorsiflexion	The numerical value that represents the result of a clinical assessment of muscle strength and function during dorsiflexion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).			Quantitative Concept	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139226>	C25338	Brooke Modified Medical Research Council Manual Muscle Test Score, Inversion|BMMTINV|Brooke mMRC MMT Score, Inversion|Brooke mMRC MMT Score, Inversion|Brooke mMRC MMT Score, Inversion	The numerical value that represents the result of a clinical assessment of muscle strength and function during inversion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).			Quantitative Concept	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139227>	C25338	Brooke Modified Medical Research Council Manual Muscle Test Score, Eversion|BMMTEVE|Brooke mMRC MMT Score, Eversion|Brooke mMRC MMT Score, Eversion|Brooke mMRC MMT Score, Eversion	The numerical value that represents the result of a clinical assessment of muscle strength and function during eversion that is based on the Brooke Modified Medical Research Council Manual Muscle Test. (Brooke MH, Griggs RC, Mendell JR, Fenichel GM, et al. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981 May-Jun;4(3):186-97. doi:10.1002/mus.880040304).			Quantitative Concept	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139228>	C25338	Medical Research Council Manual Muscle Test Score, Extension|MMTEXT|MRC MMT Score, Extension|MRC MMT Score, Extension|MRC MMT Score, Extension	The numerical value that represents the result of a clinical assessment of muscle strength and function during extension that is based on the Medical Research Council Manual Muscle Test. (Medical Research Council. Aids to examination of the peripheral nervous system. Memorandum no. 45, superseding War Memorandum No. 7. London: Her Majesty's Stationary Office; 1976. doi:10.1016/0022-510X(77)90205-2).			Quantitative Concept	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139229>	C25338	Medical Research Council Manual Muscle Test Score, Plantar Flexion|MMTPF|MRC MMT Score, Plantar Flex|MRC MMT Score, Plantar Flex|MRC MMT Score, Plantar Flexion	The numerical value that represents the result of a clinical assessment of muscle strength and function during plantar flexion that is based on the Medical Research Council Manual Muscle Test. (Medical Research Council. Aids to examination of the peripheral nervous system. Memorandum no. 45, superseding War Memorandum No. 7. London: Her Majesty's Stationary Office; 1976. doi:10.1016/0022-510X(77)90205-2).			Quantitative Concept	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13922>	C14062|C13426	WAP Domain|WAP Motif|Whey Acidic Protein Domain	The WAP (Whey Acidic Protein) Domain contains eight characteristically-spaced cysteine residues involved in disulphide bond formation and occurs in so-called 'four-disulphide core' proteins. The spatial pattern of these conserved domain cysteines suggests that the otherwise variable domain sequences may adopt a similar fold. The overall degree of domain sequence similarity is low; a few Pro and Gly residues are reasonably well conserved, as are polar/acidic residues between Cys3 and Cys4. WAP sequences are found in Whey Acidic Protein; Elafin (a human skin elastase-specific inhibitor); rat WDNM1 Protein (involved in metastatic potential); Kallmann Syndrome Protein; and guinea pig Caltrin-Like Protein II (inhibits calcium transport into spermatozoa). (NCI)			Amino Acid Sequence	
C139230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139230>	C25338	Medical Research Council Manual Muscle Test Score, Flexion|MMTFLX|MRC MMT Score, Flexion|MRC MMT Score, Flexion|MRC MMT Score, Flexion	The numerical value that represents the result of a clinical assessment of muscle strength and function during flexion that is based on the Medical Research Council Manual Muscle. (Medical Research Council. Aids to examination of the peripheral nervous system. Memorandum no. 45, superseding War Memorandum No. 7. London: Her Majesty's Stationary Office; 1976. doi:10.1016/0022-510X(77)90205-2).			Quantitative Concept	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139231>	C25338	Medical Research Council Manual Muscle Test Score, Abduction|MMTABDT|MRC MMT Score, Abduction|MRC MMT Score, Abduction|MRC MMT Score, Abduction	The numerical value that represents the result of a clinical assessment of muscle strength and function during abduction that is based on the Medical Research Council Manual Muscle Test. (Medical Research Council. Aids to examination of the peripheral nervous system. Memorandum no. 45, superseding War Memorandum No. 7. London: Her Majesty's Stationary Office; 1976. doi:10.1016/0022-510X(77)90205-2).			Quantitative Concept	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139232>	C25338	Medical Research Council Manual Muscle Test Score, Lateral Rotation|MMTLR|MRC MMT Score, Lat. Rotat.|MRC MMT Score, Lat. Rotat.|MRC MMT Score, Lateral Rotation	The numerical value that represents the result of a clinical assessment of muscle strength and function during lateral rotation that is based on the Medical Research Council Manual Muscle Test. (Medical Research Council. Aids to examination of the peripheral nervous system. Memorandum no. 45, superseding War Memorandum No. 7. London: Her Majesty's Stationary Office; 1976. doi:10.1016/0022-510X(77)90205-2).			Quantitative Concept	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139233>	C25338	Medical Research Council Manual Muscle Test Score, Dorsiflexion|MMTDORS|MRC MMT Score, Dorsiflexion|MRC MMT Score, Dorsiflexion|MRC MMT Score, Dorsiflexion	The numerical value that represents the result of a clinical assessment of muscle strength and function during dorsiflexion that is based on the Medical Research Council Manual Muscle Test. (Medical Research Council. Aids to examination of the peripheral nervous system. Memorandum no. 45, superseding War Memorandum No. 7. London: Her Majesty's Stationary Office; 1976. doi:10.1016/0022-510X(77)90205-2).			Quantitative Concept	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139234>	C25338	Medical Research Council Manual Muscle Test Score, Inversion|MMTINV|MRC MMT Score, Inversion|MRC MMT Score, Inversion|MRC MMT Score, Inversion	The numerical value that represents the result of a clinical assessment of muscle strength and function during inversion that is based on the Medical Research Council Manual Muscle Test. (Medical Research Council. Aids to examination of the peripheral nervous system. Memorandum no. 45, superseding War Memorandum No. 7. London: Her Majesty's Stationary Office; 1976. doi:10.1016/0022-510X(77)90205-2).			Quantitative Concept	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139235>	C25338	Medical Research Council Manual Muscle Test Score, Eversion|MMTEVE|MRC MMT Score, Eversion|MRC MMT Score, Eversion|MRC MMT Score, Eversion	The numerical value that represents the result of a clinical assessment of muscle strength and function during eversion that is based on the Medical Research Council Manual Muscle Test. (Medical Research Council. Aids to examination of the peripheral nervous system. Memorandum no. 45, superseding War Memorandum No. 7. London: Her Majesty's Stationary Office; 1976. doi:10.1016/0022-510X(77)90205-2).			Quantitative Concept	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139236>	C74590	Failure To Meet Continuation Criteria|FAILURE TO MEET CONTINUATION CRITERIA	An indication that the subject has not been able to meet protocol-defined continuation criteria and will not continue to participate in the clinical trial.			Intellectual Product	CDISC SDTM Reason for Non-Completion Terminology|CDISC SDTM Terminology|CDISC SDTM Tobacco Study Completion/Reason for Non-Completion Terminology|Clinical Data Interchange Standards Consortium Terminology
C139237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139237>	C74590	Randomized By Mistake|RANDOMIZED BY MISTAKE|Randomized in Error	An indication that the subject was randomized but should not have been.			Intellectual Product	CDISC SDTM Reason for Non-Completion Terminology|CDISC SDTM Terminology|CDISC SDTM Tobacco Study Completion/Reason for Non-Completion Terminology|Clinical Data Interchange Standards Consortium Terminology
C139238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139238>	C74590	Randomized By Mistake With Study Treatment|RANDOMIZED BY MISTAKE WITH STUDY TREATMENT	An indication that the subject was randomized but should not have been, and was subsequently given study treatment.			Intellectual Product	CDISC SDTM Reason for Non-Completion Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139239>	C74590	Randomized By Mistake Without Study Treatment|RANDOMIZED BY MISTAKE WITHOUT STUDY TREATMENT	An indication that the subject was randomized but should not have been, and was subsequently not given study treatment.			Intellectual Product	CDISC SDTM Reason for Non-Completion Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13923>	C13432	3p22-p21.3	A chromosome band present on 3p			Gene or Genome	
C139240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139240>	C74590	Non-Compliance With Non-Study Device|NON-COMPLIANCE WITH NON-STUDY DEVICE	An indication that a subject has not agreed with, or followed the instructions related to, the non-study device.			Intellectual Product	CDISC SDTM Reason for Non-Completion Terminology|CDISC SDTM Terminology|CDISC SDTM Tobacco Study Completion/Reason for Non-Completion Terminology|Clinical Data Interchange Standards Consortium Terminology
C139241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139241>	C74590	Non-Compliance With Study Device|NON-COMPLIANCE WITH STUDY DEVICE	An indication that a subject has not agreed with, or followed the instructions related to, the study device.			Intellectual Product	CDISC SDTM Reason for Non-Completion Terminology|CDISC SDTM Terminology|CDISC SDTM Tobacco Study Completion/Reason for Non-Completion Terminology|Clinical Data Interchange Standards Consortium Terminology
C139242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139242>	C25337	Number of Eye Chart Lines Read|NUMLINRD|Number of Lines Read|Number of Lines Read	The number of lines read by the subject during an eye chart assessment.			Quantitative Concept	CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139243>	C38081	Forced Expiratory Volume in 0.05 Second to FVC Ratio Measurement|EV_05FVC|Forced Expiratory Volume in 0.05 S/FVC|Forced Expiratory Volume in 0.05 S/FVC|Forced Expiratory Volume in 0.05 Seconds over FVC	The ratio of the volume of gas that is forcibly exhaled during the first 0.05 seconds following maximal inhalation to that of the forced vital capacity.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139244>	C38081	Forced Expiratory Volume in 0.1 Second to FVC Ratio Measurement|EV_1FVC|Forced Expiratory Volume in 0.1 S/FVC|Forced Expiratory Volume in 0.1 S/FVC|Forced Expiratory Volume in 0.1 Seconds over FVC	The ratio of the volume of gas that is forcibly exhaled during the first 0.1 seconds following maximal inhalation to that of the forced vital capacity.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139245>	C38081	Forced Expiratory Volume in 0.2 Second to FVC Ratio Measurement|EV_2FVC|Forced Expiratory Volume in 0.2 S/FVC|Forced Expiratory Volume in 0.2 S/FVC|Forced Expiratory Volume in 0.2 Seconds over FVC	The ratio of the volume of gas that is forcibly exhaled during the first 0.2 seconds following maximal inhalation to that of the forced vital capacity.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139246>	C38081	Forced Expiratory Volume in 0.05 Second|FEV 0.05s|FEV_05	The volume of air that can be forcibly exhaled during the first 0.05 second following maximal inhalation.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139247>	C38081	Forced Expiratory Volume in 0.1 Second|FEV 0.1s|FEV_1	The volume of air that can be forcibly exhaled during the first 0.1 second following maximal inhalation.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139248>	C38081	Forced Expiratory Volume in 0.2 Second|FEV 0.2s|FEV_2	The volume of air that can be forcibly exhaled during the first 0.2 second following maximal inhalation.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139249>	C38081	Forced Expiratory Volume at Peak Expiratory Flow|FEV at PEF|FEV at PEF|FEV at PEF|FEV_PEF	The volume of gas that is forcibly exhaled at the peak of expiratory flow.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13924>	C13432	3q13.1-q13.2	A chromosome band present on 3q			Gene or Genome	
C139250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139250>	C38081	Forced Expiratory Flow in 0.05 Second|FEF 0.05s|FEF_05	The forced expiratory flow rate during the first 0.05 seconds of a forced exhalation.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139251>	C38081	Forced Expiratory Flow in 0.1 Second|FEF 0.1s|FEF_1	The forced expiratory flow rate during the first 0.1 seconds of a forced exhalation.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139252>	C38081	Forced Expiratory Flow in 0.2 Second|FEF 0.2s|FEF_2	The forced expiratory flow rate during the first 0.2 seconds of a forced exhalation.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139253>	C38081	Forced Expiratory Flow at 50 Percent Forced Vital Capacity|FEF50|FEF50|Forced Expiratory Flow 50%|Forced Expiratory Flow 50%	The mean forced expiratory flow rate at 50% of the forced vital capacity.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139254>	C38081	Pulmonary Inertance|INERTANC|Inertance|Inertance	The measure of the force of the column of air in the conducting airways.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139255>	C38081	Quasi-Static Compliance|QUASCOMP	The static elastic recoil pressure of the lungs at a given lung volume.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139256>	C38081	Salazar-Knowles Equation Parameter A|SALKA	A representation of the exponential function described by the Salazar-Knowles equation, and an estimation of a subject's inspiratory capacity.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139257>	C38081	Salazar-Knowles Equation Parameter B|SALKB	The difference between the volume at total lung capacity and the hypothesized volume at a transpulmonary pressure of zero.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139258>	C38081	Salazar-Knowles Equation, K Parameter|SALKK|Salazar-Knowles Equation, K|Salazar-Knowles Equation, K	The reflection of the curvature of the upper portion of the deflationary limb of the pressure-volume curve.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139259>	C38081	Peak Expiratory Flow Time|PEF Time|PEFTIME	The time from the start of the test until the subject reaches his maximum expiratory gas flow rate.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13925>	C13432	11pter-p13	A chromosome band present on 11p			Gene or Genome	
C139260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139260>	C38081	Tissue Elastance|TSUELAS	A reflection of energy conservation within a given tissue.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139261>	C38081	Tissue Hysteresivity Measurement|TSUHYS|Tissue Hysteresivity|Tissue Hysteresivity	The energy dissipated relative to the elastic energy stored in the tissue in a P-V cycle. Fredberg, J.J., Stamenovic, D. (1 December 1989). On the Imperfect Elasticity of Lung Tissue. Journal of Applied Physiology, Vol. 67. Retrieved from https://owl.english.purdue.edu/owl/resource/560/10/			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139262>	C38081	Forced Expiratory Volume in 0.5 Second|FEV 0.5s|FEV_5	The volume of air that can be forcibly exhaled during the first half second following maximal inhalation.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139263>	C38081	Forced Inspiratory Vital Capacity|FIVC|FIVC	The difference in lung volume between maximal expiration to residual volume followed immediately by full inspiration to total lung capacity during forceful inhalation.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139264>	C25180	Pregnancy Indicator|PREGIND|Pregnant Indicator|Pregnant Indicator	An indication as to whether the individual is pregnant.			Conceptual Entity	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139265>	C178141|C122190	Number of Full Term Live Births|BRTHFTN|Number Full Term Live Births|Number Full Term Live Births	A measurement of the total number of live birth events at which the gestational age of the neonate is 39 weeks and 0 days through 40 weeks and 6 days.			Organism Attribute	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139266>	C178141|C122193	Number of Premature Live Births|BRTHPRN	A measurement of the total number of live birth events at which the gestational age of the neonate is less than 37 weeks and 0 days.			Organism Attribute	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139267>	C25337	Number of Stillbirths|BRTHSTN	A measurement of the total number of birth events at which the fetus is of at least 20 weeks gestation, or of a birth weight of at least 350 grams if the gestational age is unknown, which is born without signs of life at the time of delivery, and with an Apgar score of zero at both one and five minutes.			Quantitative Concept	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139268>	C17102	Minimal Risk|MINIMAL RISK	The potential future harm that may arise from some present action or attribute or condition is minimal.			Conceptual Entity	CDISC SDTM Protocol Risk Assessment Response Codelist|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139269>	C159525	Donor Status at Time of Organ Donation|DSTATTOD	The donor's state or condition of being either living or brain dead at the time of organ harvesting.			Qualitative Concept	CDISC SDTM Subject Characteristic Test Code Terminology|CDISC SDTM Subject Characteristic Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13926>	C13432	11q23.1	A chromosome band present on 11q			Gene or Genome	
C139270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139270>	C25457	Deceased Donor Donation Condition|DDDTYPE|Deceased Donor Donation Type|Deceased Donor Donation Type	The conditions under which an organ is harvested from a dead donor, including the condition of the donor and the environment.			Conceptual Entity	CDISC SDTM Subject Characteristic Test Code Terminology|CDISC SDTM Subject Characteristic Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139271>	C25180	CDC HIV High Risk Donor Indicator|HIVHRIND	An indication as to whether an organ donor may fall into one or more behavioral categories associated with increased risk of human immunodeficiency virus (HIV) infection, as defined by the 1994 Centers for Disease Control (CDC) Public Health Service Criteria for High Risk Behavior (Guidelines for preventing transmission of human immunodeficiency virus through transplantation of human tissue and organs. Centers for Disease Control and Prevention. MMWR Recomm Rep 1994; 43: 1-17).			Conceptual Entity	CDISC SDTM Subject Characteristic Test Code Terminology|CDISC SDTM Subject Characteristic Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139272>	C171103	Blinded Status at SDTM Dataset Generation	The blinding status of the trial at the point in time when the SDTM datasets are generated.			Qualitative Concept	
C139273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139273>	C25164	Clinical Study Report Archive Date|CSRARDTC	The date when the clinical study report was archived.			Temporal Concept	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C139274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139274>	C25180	Extension Trial Indicator|EXTTIND	An indication as to whether the clinical trial is an extension trial.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C139275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139275>	C25180	Post Authorization Safety Study Indicator|PASSIND|Post Authorization Safety Study Ind|Post Authorization Safety Study Ind	An indication as to whether the clinical study is a post authorization safety study.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C139276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139276>	C93625|C71465	Planned Treatment Duration|PTRTDUR	The period of time during which the treatment is intended to be given.			Temporal Concept	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C139277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139277>	C15367	Protocol Risk Assessment|PROTRSK	The potential future harm that may arise from some protocol-related activity.			Health Care Activity	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C139278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139278>	C74944	Sample Viability Percent Measurement|Sample Viability Percent|Sample Viability Percent|VBLSPCT	A measurement of the percent of a cell or tissue sample that is viable.			Laboratory Procedure	CDISC SDTM Biospecimen Characteristics Test Code Terminology|CDISC SDTM Biospecimen Characteristics Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139279>	C25180	Sample Viability Indicator|VBLSIND	An indication as to whether the sample contains viable cells or tissues.			Conceptual Entity	CDISC SDTM Biospecimen Characteristics Test Code Terminology|CDISC SDTM Biospecimen Characteristics Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C13927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13927>	C13432	17q23-q25	A chromosome band present on 17q			Gene or Genome	
C139280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139280>	C210043|C19235	A260 to A280 Ratio|A260/A280 Ratio|A260/A280 Ratio|A260:A280|A260A280|a260 a280 ratio|a260_a280_ratio	An assessment of nucleic acid purity that is measured by determining the ratio of light absorbance of the nucleic acid sample at 260nm and 280nm respectively.			Molecular Biology Research Technique	CDISC SDTM Biospecimen Characteristics Test Code Terminology|CDISC SDTM Biospecimen Characteristics Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Property Terminology|GDC Terminology
C139281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139281>	C210043|C19235	A260 to A230 Ratio|A260/A230 Ratio|A260/A230 Ratio|A260:A230|A260A230	An assessment of nucleic acid purity that is measured by determining the ratio of light absorbance of the nucleic acid sample at 260nm and 230nm respectively.			Molecular Biology Research Technique	CDISC SDTM Biospecimen Characteristics Test Code Terminology|CDISC SDTM Biospecimen Characteristics Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139282>	C25284	Fluorescent Tag Type|FLUORLBL|Fluorescent Label|Fluorescent Label	The type of fluorescent label or dye that is used in a fluorescence-based assay.			Functional Concept	CDISC SDTM Biospecimen Characteristics Test Code Terminology|CDISC SDTM Biospecimen Characteristics Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C139283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139283>	C25337	Number of Nucleotide Markers Exhibiting Instability	The total number of nucleotide repeat markers tested that exhibit instability in a biological specimen.			Quantitative Concept	
C139284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139284>	C63331	Percent of Nucleotide Markers Exhibiting Instability|msi score|msi_score	The relative measurement (percentage) of nucleotide repeat markers exhibiting instability to all nucleotide repeat markers tested in a biological specimen.			Laboratory Procedure	GDC Property Terminology|GDC Terminology
C139285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139285>	C63331	Microsatellite Instability Overall Status|MICROSATELLITE INSTABILITY OVERALL STATUS|MSI Overall Status|MSIOSTAT|Microsatellite Instability Overall Stat|Microsatellite Instability Status|msi status|msi_status	The state or condition of a subject's microsatellite sequences with respect to the inability of their mismatch repair (MMR) proteins to fix a DNA replication error.			Laboratory Procedure	CDISC SDTM Genomic Findings Test Detail Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Property Terminology|GDC Terminology
C139286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139286>	C63331	Microsatellite Stability Assessment|MSI Assessment	An assessment of the variability in length of an individual's microsatellite sequences; microsatellite length instability may be due to mismatch repair protein mutation.			Laboratory Procedure	
C139287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139287>	C226739	Used Family or Friend's Tablet|My family or friend's tablet	A response indicating that an individual used a tablet belonging to a friend or family member.			Intellectual Product	
C139288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139288>	C3468|C27693|C190402	Primary Nodal EBV-Positive T-Cell/NK-Cell Lymphoma|EBV-Positive Nodal T-and NK-Cell Lymphoma|Node-Based EBV-Positive Peripheral T-Cell Lymphoma|Node-Based Epstein-Barr Virus -Positive Peripheral T-Cell Lymphoma|Primary EBV-Positive Nodal T-Cell or NK-Cell Lymphoma|Primary Nodal EBV-Positive T-Cell or NK-Cell Lymphoma|Primary Nodal Epstein-Barr Virus-Positive T-Cell/NK-Cell Lymphoma	An EBV-positive T-cell/NK-cell lymphoma that arises from the lymph nodes. It is characterized by a monomorphic pattern of infiltration and abscence of the angiodestruction and necrosis seen in extranodal NK/T-cell lymphomas. These lymphomas are more common in elderly patient, or in the setting of immune deficiency. (WHO 2017)		Provisional_Concept	Neoplastic Process	
C139289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139289>	C42585	Glandular (Acinar)/Tubular Differentiation	A morphologic finding indicating the presence of acinar and tubular differentiation  in a tissue sample of an epithelial neoplasm.			Finding	
C139290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139290>	C79086|C133155	TP63 Gene Rearrangement|AIS Gene Rearrangement|B(p51A) Gene Rearrangement|B(p51B) Gene Rearrangement|EEC3 Gene Rearrangement|KET Gene Rearrangement|LMS Gene Rearrangement|NBP Gene Rearrangement|OFC8 Gene Rearrangement|P63 Gene Rearrangement|P73H Gene Rearrangement|P73L Gene Rearrangement|RHS Gene Rearrangement|SHFM4 Gene Rearrangement|TP53CP Gene Rearrangement|TP53L Gene Rearrangement|TP73L Gene Rearrangement|Tumor Protein p53-Competing Protein Gene Rearrangement|Tumor Protein p53-Like Gene Rearrangement|Tumor Protein p63 Gene Rearrangement|Tumor Protein p73-Like Gene Rearrangement|p40 Gene Rearrangement|p51 Gene Rearrangement|p53CP Gene Rearrangement|p63 Gene Rearrangement|p73H Gene Rearrangement|p73L Gene Rearrangement	A molecular abnormality indicating rearrangement of the TP63 gene.			Cell or Molecular Dysfunction	
C139291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139291>	C162653|C148153|C129861	Advanced Head and Neck Squamous Cell Carcinoma|Advanced Head and Neck Squamous Cell Cancer	A head and neck squamous cell carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Head and Neck Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139292>	C19851	TAF12 Gene Product	A protein encoded by the TAF12 gene.			Amino Acid, Peptide, or Protein	
C139294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139294>	C15239	Patient Navigation|Patient Navigation Program|Patient Navigator Program	A healthcare service that is designed to guide a patient through the healthcare system and reduce barriers to timely screening, follow-up, diagnosis, treatment, and supportive care.	Patient Navigation Program		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C139295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139295>	C217122	IPSS Risk Score|International Prognostic Scoring System for Myelodysplastic Syndrome Risk Score	The total score for myelodysplastic syndrome progression that considers the percentage of blasts in bone marrow (scored on a scale from zero to 2), chromosome abnormalities (scored from zero to 1), and the patient's blood counts (scored as zero or 0.5).			Intellectual Product	International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes
C139296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139296>	C217119	IPSS Risk Category|International Prognostic Scoring System for Myelodysplastic Syndrome Risk Category	The risk category for myelodysplastic syndrome progression that is derived from IPSS risk score.			Intellectual Product	International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes
C139297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139297>	C139295	IPSS Risk Score 0|International Prognostic Scoring System for Myelodysplastic Syndrome Risk Score 0	An International Prognostic Scoring System for Myelodysplastic Syndrome risk score of 0, corresponding to low risk.			Intellectual Product	
C139298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139298>	C139295	IPSS Risk Score 0.5 to 1.0|International Prognostic Scoring System for Myelodysplastic Syndrome Risk Score 0.5 to 1.0	An International Prognostic Scoring System for Myelodysplastic Syndrome risk score of 0.5 to 1.0, corresponding to intermediate-1 risk.			Intellectual Product	
C139299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139299>	C139295	IPSS Risk Score 1.5 to 2.0|International Prognostic Scoring System for Myelodysplastic Syndrome Risk Score 1.5 to 2.0	An International Prognostic Scoring System for Myelodysplastic Syndrome risk score of 1.5-2.0, corresponding to intermediate-2 risk.			Intellectual Product	
C13929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13929>	C13426	Cadherin Domain	Evolutionary related to desmosomal desmogleins, cadherins contain a signal sequence, a propeptide of around 130 residues, an extracellular domain of around 600 residues, a single transmembrane domain, and a well-conserved C-terminal cytoplasmic domain of about 150 residues. The extracellular domain typically consists of four Cadherin Domain repeats of about 110 residues; an adjacent fifth domain contains four conserved cysteines. The domain includes conserved Asp and Arg residues that may be involved in calcium binding. Tissue-specific cadherin glycoproteins are responsible for homophilic calcium-dependent cell-cell adhesion likely involved in cell type sorting during morphogenesis, histogenesis, and regeneration. They may also regulate tight and gap junctions. (NCI)			Amino Acid Sequence	
C1392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1392>	C663	Mitomycin B|Azirino(2',3':3,4)pyrrolo(1,2-a)indole-4,7-dione, 1,1a,2,8,8a,8b-hexahydro-8a-hydroxy-8-(hydroxymethyl)-6-methoxy-1,5-dimethyl-, 8-carbamate|MITOMYCIN B	A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus.  Bioreduced mitomycin B generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis. (NCI04)			Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C139300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139300>	C139295	IPSS Risk Score Greater than or Equal to 2.5|International Prognostic Scoring System for Myelodysplastic Syndrome Risk Score Greater than or Equal to 2.5	An International Prognostic Scoring System for Myelodysplastic Syndrome risk score greater than or equal to 2.5, corresponding to high risk.			Intellectual Product	
C139301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139301>	C139296	IPSS Risk Category Low|IPSS Low Risk|International Prognostic Scoring System for Myelodysplastic Syndrome Low Risk Category|Low|Low Risk Myelodysplastic Syndrome|Low Risk Myelodysplastic Syndrome	An International Prognostic Scoring System for Myelodysplastic Syndrome risk category that predicts a low likelihood for progression.	Low Risk Myelodysplastic Syndrome		Intellectual Product	CTRP Disease Terminology|CTRP Terminology
C139302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139302>	C139296	IPSS Risk Category Intermediate-1|IPSS Intermediate-1 Risk|Intermediate-1|International Prognostic Scoring System for Myelodysplastic Syndrome Intermediate-1 Risk Category	An International Prognostic Scoring System for Myelodysplastic Syndrome risk category that predicts a low-intermediate likelihood for progression.	IPSS Risk Category Intermediate-1		Intellectual Product	CTRP Disease Terminology|CTRP Terminology
C139303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139303>	C139296	IPSS Risk Category Intermediate-2|IPSS Intermediate-2 Risk|Intermediate-2|International Prognostic Scoring System for Myelodysplastic Syndrome Intermediate-2 Risk Category	An International Prognostic Scoring System for Myelodysplastic Syndrome risk category that predicts a high-interdemiate likelihood for progression.	IPSS Risk Category Intermediate-2		Intellectual Product	CTRP Disease Terminology|CTRP Terminology
C139304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139304>	C139296	IPSS Risk Category High|High|IPSS High Risk|International Prognostic Scoring System for Myelodysplastic Syndrome High Risk Category	An International Prognostic Scoring System for Myelodysplastic Syndrome risk category that predicts a high likelihood for progression.			Intellectual Product	
C139305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139305>	C15958	RAS Protein Family Activation Assay|RAS/RAF Activation Assay	An in vitro assay that can indirectly detect the activation of small GTPases in the RAS family through the staining of phosphorylated forms of MEK (MAP2K) family proteins (pMEK). A farnesylated RAS family protein is anchored to an in vitro model of the plasma membrane and, under different conditions, is co-incubated with both a RAF family protein, which binds to and is activated by active RAS proteins, and a MEK family protein, which is phosphorylated by active RAF proteins. pMEK is detected using a donor bead coated with anti-MEK antibodies that is capable of oxidizing an acceptor molecule attached to an anti-pMEK antibody. When the donor and acceptor are in close proximity, the acceptor molecule is oxidized and can be visualized using electron microscopy.			Research Activity	
C139306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139306>	C16462	Exascale Computer System|Exascale Computing	Refers to computer systems capable of a quintillion (10^18) calculations each second. This computing power is expected to facilitate the analysis of data sets that would require too much time with currently available systems. Such analysis would allow more realistic simulations of the complex processes and relationships behind many natural processes. This will have practical applications in everything from precision medicine to regional climate, water use to materials science, nuclear physics to national security.			Manufactured Object	
C139307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139307>	C213308	Genomic Data Commons|GDC	A project of the The National Cancer Institute, the Genomic Data Commons is an expandable knowledge network supporting the import and standardization of genomic and clinical data from cancer research programs in support of precision medicine in oncology.			Research Activity	
C139308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139308>	C19975	Genomics of Drug Sensitivity in Cancer|GDSC	Part of a Wellcome Trust funded collaboration between The Cancer Genome Project at the Wellcome Trust Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA) designed to to improve cancer treatments by discovering therapeutic biomarkers that can be used to identify patients most likely to respond to an anticancer drug.			Research Activity	
C139309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139309>	C20313	NCI-60 Cell Line|NCI-60|NCI-60 Cell Panel	A panel of 60 different human cancer cell lines grown in culture that were selected to be used in a drug-screening program to identify and characterize novel compounds for growth inhibition or killing of tumor cell lines.			Cell	
C13930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13930>	C13432	16p11.2	A chromosome band present on 16p			Gene or Genome	
C13931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13931>	C13432	9q33	A chromosome band present on 9q			Gene or Genome	
C13932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13932>	C13432	12q22	A chromosome band present on 12q			Gene or Genome	
C13933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13933>	C13432	9q32	A chromosome band present on 9q			Gene or Genome	
C13934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13934>	C13432	Xq26	A chromosome band present on Xq			Gene or Genome	
C13935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13935>	C13432	1q23	A chromosome band present on 1q			Gene or Genome	
C13936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13936>	C13432	1q25	A chromosome band present on 1q			Gene or Genome	
C13937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13937>	C13379	EGF-Like Domain	A sequence of about thirty to forty amino-acid residues long found in the sequence of epidermal growth factor (EGF) has been shown to be present, in a conserved form, in a large number of other, mostly animal proteins. The list of proteins currently known to contain one or more copies of an EGF-like pattern is large and varied. The functional significance of EGF domains in what appear to be unrelated proteins is not yet clear. However, a common feature is that these repeats are found in the extracellular domain of membrane-bound proteins or in proteins known to be secreted (exception: prostaglandin G/H synthase). The EGF domain includes six cysteine residues which have been shown (in EGF) to be involved in disulfide bonds. The main structure is a two-stranded beta-sheet followed by a loop to a C-terminal short two-stranded sheet. Subdomains between the conserved cysteines vary in length. (InterPro IPR006209)			Amino Acid Sequence	
C13938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13938>	C13426	Disintegrin Domain	It is an integrin binding domain originally identified in ADAM family proteins. (NCI)			Amino Acid Sequence	
C139390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139390>	C48233	Breast Cancer TNM Finding v8|Breast Carcinoma TNM Finding v8	A finding about one or more characteristics of breast cancer, following the rules of the TNM AJCC v8 classification system. This classification system applies to invasive (infiltrating) carcinoma of the breast and ductal carcinoma in situ of the breast. It does not apply to breast sarcoma, phyllodes tumor, and breast lymphoma. (from AJCC 8th Ed.)			Finding	
C139391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139391>	C139390	Breast Cancer Clinical TNM Finding v8|Breast Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of breast cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C139392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139392>	C139391	Breast Cancer Clinical Distant Metastasis TNM Finding v8|Breast Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of breast cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C139393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139393>	C139392	Breast Cancer cM0 TNM Finding v8|Breast Carcinoma cM0 TNM Finding v8	Breast cancer without clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the cM0 category. (from AJCC 8th Ed.)			Finding	
C139394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139394>	C139393	Breast Cancer cM0(i+) TNM Finding v8|Breast Carcinoma cM0(i+) TNM Finding v8	Breast cancer in which there is no clinical or radiographic evidence of distant metastases in the presence of tumor cells or deposits no larger than 0.2 mm detected microscopically or by molecular techniques in circulating blood, bone marrow, or other nonregional nodal tissue in a patient without symptoms or signs of metastases. (from AJCC 8th Ed.)			Finding	
C139395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139395>	C139392	Breast Cancer cM1 TNM Finding v8|Breast Carcinoma cM1 TNM Finding v8	Breast cancer with distant metastases detected by clinical and radiographic means and/or histologically proven metastases larger than 0.2 mm. (from AJCC 8th Ed.)			Finding	
C139396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139396>	C139391	Breast Cancer Clinical Regional Lymph Nodes TNM Finding v8|Breast Carcinoma Clinical Regional Lymph Nodes TNM Finding v8	A clinical finding about one or more characteristics of breast cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C139397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139397>	C139396	Breast Cancer cNX TNM Finding v8|Breast Carcinoma cNX TNM Finding v8	Breast cancer in which regional lymph nodes cannot be assessed (e.g., previously removed). The cNX category is used sparingly in cases where regional lymph nodes have previously been surgically removed or where there is no documentation of physical examination of the axilla. (from AJCC 8th Ed.)			Finding	
C139398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139398>	C139396	Breast Cancer cN0 TNM Finding v8|Breast Carcinoma cN0 TNM Finding v8	Breast cancer with no regional lymph node metastases (by imaging or clinical examination). (from AJCC 8th Ed.)			Finding	
C139399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139399>	C139396	Breast Cancer cN1 TNM Finding v8|Breast Carcinoma cN1 TNM Finding v8	Breast cancer with metastasis to movable ipsilateral level I, II axillary lymph node(s). (from AJCC 8th Ed.)			Finding	
C13939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13939>	C13432	17q11-q12	A chromosome band present on 17q			Gene or Genome	
C1393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1393>	C1591	Recombinant Monocyte Chemoattractant Protein-1|CCL2|HC11|Human Macrophage Chemoattractant Protein-1|MCAF|MCP-1|Monocyte Chemoattractant Protein 1|Monocyte Chemotactic Protein-1|Monocyte Chemotactic and Activating Factor	A recombinant therapeutic agent which is chemically identical to or similar to endogenous human monocyte chemoattractant protein-1, a member of the CC chemokine family which is chemotactic for monocytes. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C139400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139400>	C139399	Breast Cancer cN1mi TNM Finding v8|Breast Carcinoma cN1mi TNM Finding v8	Breast cancer with micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). cN1mi is rarely used but may be appropriate in cases where sentinel node biopsy is performed before tumor resection, most likely to occur in cases treated with neoadjuvant therapy. (from AJCC 8th Ed.)			Finding	
C139401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139401>	C139396	Breast Cancer cN2 TNM Finding v8|Breast Carcinoma cN2 TNM Finding v8	Breast cancer with metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases. (from AJCC 8th Ed.)			Finding	
C139402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139402>	C139401	Breast Cancer cN2a TNM Finding v8|Breast Carcinoma cN2a TNM Finding v8	Breast cancer with metastases in ipsilateral level I, II axillary lymph nodes fixed to one another (matted) or to other structures. (from AJCC 8th Ed.)			Finding	
C139403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139403>	C139401	Breast Cancer cN2b TNM Finding v8|Breast Carcinoma cN2b TNM Finding v8	Breast cancer with metastases only in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases. (from AJCC 8th Ed.)			Finding	
C139404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139404>	C139396	Breast Cancer cN3 TNM Finding v8|Breast Carcinoma cN3 TNM Finding v8	Breast cancer with metastases in ipsilateral infraclavicular (level III axillary) lymph node(s) with or without level I, II axillary lymph node involvement; or in ipsilateral internal mammary lymph node(s) with level I, II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement. (from AJCC 8th Ed.)			Finding	
C139405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139405>	C139404	Breast Cancer cN3a TNM Finding v8|Breast Carcinoma cN3a TNM Finding v8	Breast cancer with metastases in ipsilateral infraclavicular lymph node(s). (from AJCC 8th Ed.)			Finding	
C139406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139406>	C139404	Breast Cancer cN3b TNM Finding v8|Breast Carcinoma cN3b TNM Finding v8	Breast cancer with metastases in ipsilateral internal mammary lymph node(s) and axillary lymph node(s). (from AJCC 8th Ed.)			Finding	
C139407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139407>	C139404	Breast Cancer cN3c TNM Finding v8|Breast Carcinoma cN3c TNM Finding v8	Breast cancer with metastases in ipsilateral supraclavicular lymph node(s). (from AJCC 8th Ed.)			Finding	
C139408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139408>	C139390	Breast Cancer Pathologic TNM Finding v8|Breast Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of breast cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C139409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139409>	C139408	Breast Cancer Pathologic Distant Metastasis TNM Finding v8|Breast Carcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of breast cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C13940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13940>	C13432	9p11.2	A chromosome band present on 9p			Gene or Genome	
C139410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139410>	C139409	Breast Cancer pM1 TNM Finding v8|Breast Carcinoma pM1 TNM Finding v8	Breast cancer with distant metastases detected by clinical and radiographic means and/or histologically proven metastases larger than 0.2 mm. (from AJCC 8th Ed.)			Finding	
C139411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139411>	C139408	Breast Cancer Pathologic Primary Tumor TNM Finding v8|Breast Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of breast cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor. Lobular carcinoma in situ (LCIS) is a benign entity and is removed from TNM staging in the AJCC Cancer Staging Manual, 8th Edition. (from AJCC 8th Ed.)			Finding	
C139412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139412>	C139411	Breast Cancer pTX TNM Finding v8|Breast Carcinoma pTX TNM Finding v8	Breast cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C139413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139413>	C139411	Breast Cancer pT0 TNM Finding v8|Breast Carcinoma pT0 TNM Finding v8	Breast cancer with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C139414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139414>	C139411	Breast Cancer pTis (DCIS) TNM Finding v8|Breast Carcinoma pTis (DCIS) TNM Finding v8|Tis (DCIS)	Breast cancer with a finding of ductal carcinoma in situ. Lobular carcinoma in situ (LCIS) is a benign entity and is removed from TNM staging in the AJCC Cancer Staging Manual, 8th Edition. (from AJCC 8th Ed.)			Finding	GDC Terminology|GDC Value Terminology
C139415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139415>	C139411	Breast Cancer pTis (Paget) TNM Finding v8|Breast Carcinoma pTis (Paget) TNM Finding v8|Tis (Paget's)	Paget disease of the nipple not associated with invasive carcinoma and/or carcinoma in situ (DCIS) in the underlying breast parenchyma. Carcinomas in the breast parenchyma associated with Paget disease are categorized based on the size and characteristics of the parenchymal disease, although the presence of Paget disease should still be noted. (from AJCC 8th Ed.)			Finding	GDC Terminology|GDC Value Terminology
C139416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139416>	C139411	Breast Cancer pT1 TNM Finding v8|Breast Carcinoma pT1 TNM Finding v8	Breast cancer with tumor size 20 mm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C139417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139417>	C139416	Breast Cancer pT1mi TNM Finding v8|Breast Carcinoma pT1mi TNM Finding v8	Breast cancer with tumor size 1 mm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C139418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139418>	C139416	Breast Cancer pT1a TNM Finding v8|Breast Carcinoma pT1a TNM Finding v8	Breast cancer with tumor size more than 1 mm, but not more than 5 mm in greatest dimension (round any measurement 1.0-1.9 mm to 2 mm). (from AJCC 8th Ed.)			Finding	
C139419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139419>	C139416	Breast Cancer pT1b TNM Finding v8|Breast Carcinoma pT1b TNM Finding v8	Breast cancer with tumor size more than 5 mm, but not more than 10 mm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C13941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13941>	C13432	14q32	A chromosome band present on 14q	14q32		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C139420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139420>	C139416	Breast Cancer pT1c TNM Finding v8|Breast Carcinoma pT1c TNM Finding v8	Breast cancer with tumor size more than 10 mm, but not more than 20 mm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C139421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139421>	C139411	Breast Cancer pT2 TNM Finding v8|Breast Carcinoma pT2 TNM Finding v8	Breast cancer with tumor size more than 20 mm, but not more than 50 mm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C139422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139422>	C139411	Breast Cancer pT3 TNM Finding v8|Breast Carcinoma pT3 TNM Finding v8	Breast cancer with tumor size more than 50 mm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C139423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139423>	C139411	Breast Cancer pT4 TNM Finding v8|Breast Carcinoma pT4 TNM Finding v8	Breast cancer with tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. (from AJCC 8th Ed.)			Finding	
C139424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139424>	C139423	Breast Cancer pT4a TNM Finding v8|Breast Carcinoma pT4a TNM Finding v8	Breast cancer with extension to the chest wall; invasion or adherence to pectoralis muscle in the absence of invasion of chest wall structures does not qualify as T4. (from AJCC 8th Ed.)			Finding	
C139425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139425>	C139423	Breast Cancer pT4b TNM Finding v8|Breast Carcinoma pT4b TNM Finding v8	Breast cancer with ulceration and/or ipsilateral macroscopic satellite nodules and/or edema (including peau d'orange) of the skin that does not meet the criteria for inflammatory carcinoma. (from AJCC 8th Ed.)			Finding	
C139426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139426>	C139423	Breast Cancer pT4c TNM Finding v8|Breast Carcinoma pT4c TNM Finding v8	Breast cancer in which both T4a and T4b are present. (from AJCC 8th Ed.)			Finding	
C139427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139427>	C139423	Breast Cancer pT4d TNM Finding v8|Breast Carcinoma pT4d TNM Finding v8	Breast cancer meeting the criteria of inflammatory carcinoma. (from AJCC 8th Ed.)			Finding	
C139428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139428>	C139408	Breast Cancer Pathologic Regional Lymph Nodes TNM Finding v8|Breast Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of breast cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C139429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139429>	C139428	Breast Cancer pNX TNM Finding v8|Breast Carcinoma pNX TNM Finding v8	Breast cancer in which regional lymph nodes cannot be assessed (e.g., not removed for pathological study or previously removed).  (from AJCC 8th Ed.)			Finding	
C13942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13942>	C13432	17p13-p12	A chromosome band present on 17p			Gene or Genome	
C139430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139430>	C139428	Breast Cancer pN0 TNM Finding v8|Breast Carcinoma pN0 TNM Finding v8	Breast cancer in which no regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. (from AJCC 8th Ed.)			Finding	
C139431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139431>	C139430	Breast Cancer pN0(i+) TNM Finding v8|Breast Carcinoma pN0(i+) TNM Finding v8	Breast cancer with ITCs only (malignant cell clusters no larger than 0.2 mm) in regional lymph node(s). (from AJCC 8th Ed.)			Finding	
C139432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139432>	C139430	Breast Cancer pN0(mol+) TNM Finding v8|Breast Carcinoma pN0(mol+) TNM Finding v8	Breast cancer with positive molecular findings by reverse transcriptase polymerase chain reaction (RT-PCR); no ITCs detected. (from AJCC 8th Ed.)			Finding	
C139433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139433>	C139428	Breast Cancer pN1 TNM Finding v8|Breast Carcinoma pN1 TNM Finding v8	Breast cancer with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. (from AJCC 8th Ed.)			Finding	
C139434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139434>	C139433	Breast Cancer pN1mi TNM Finding v8|Breast Carcinoma pN1mi TNM Finding v8	Breast cancer with micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). (from AJCC 8th Ed.)			Finding	
C139435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139435>	C139433	Breast Cancer pN1a TNM Finding v8|Breast Carcinoma pN1a TNM Finding v8	Breast cancer with metastases in 1-3 axillary lymph nodes, at least one metastasis larger than 2.0 mm. (from AJCC 8th Ed.)			Finding	
C139436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139436>	C139433	Breast Cancer pN1b TNM Finding v8|Breast Carcinoma pN1b TNM Finding v8	Breast cancer with metastases in ipsilateral internal mammary sentinel nodes, excluding ITCs. (from AJCC 8th Ed.)			Finding	
C139437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139437>	C139433	Breast Cancer pN1c TNM Finding v8|Breast Carcinoma pN1c TNM Finding v8	Breast cancer with pN1a and pN1b combined. (from AJCC 8th Ed.)			Finding	
C139438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139438>	C139428	Breast Cancer pN2 TNM Finding v8|Breast Carcinoma pN2 TNM Finding v8	Breast cancer with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. (from AJCC 8th Ed.)			Finding	
C139439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139439>	C139438	Breast Cancer pN2a TNM Finding v8|Breast Carcinoma pN2a TNM Finding v8	Breast cancer with metastasis in 4-9 axillary lymph nodes (at least one tumor deposit larger than 2.0 mm). (from AJCC 8th Ed.)			Finding	
C13943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13943>	C13432	7q31.1	A chromosome band present on 7q			Gene or Genome	
C139440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139440>	C139438	Breast Cancer pN2b TNM Finding v8|Breast Carcinoma pN2b TNM Finding v8	Breast cancer with metastases in clinically detected internal mammary lymph nodes with or without microscopic confirmation; with pathologically negative axillary nodes. (from AJCC 8th Ed.)			Finding	
C139441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139441>	C139428	Breast Cancer pN3 TNM Finding v8|Breast Carcinoma pN3 TNM Finding v8	Breast cancer with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. (from AJCC 8th Ed.)			Finding	
C139442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139442>	C139441	Breast Cancer pN3a TNM Finding v8|Breast Carcinoma pN3a TNM Finding v8	Breast cancer with metastases in 10 or more axillary lymph nodes (at least one tumor deposit larger than 2.0 mm); or metastases to the infraclavicular (level III axillary) lymph nodes. (from AJCC 8th Ed.)			Finding	
C139443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139443>	C139441	Breast Cancer pN3b TNM Finding v8|Breast Carcinoma pN3b TNM Finding v8	Breast cancer with pN1a or pN2a in the presence of cN2b (positive internal mammary nodes by imaging); or pN2a in the presence of pN1b. (from AJCC 8th Ed.)			Finding	
C139444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139444>	C139441	Breast Cancer pN3c TNM Finding v8|Breast Carcinoma pN3c TNM Finding v8	Breast cancer with metastases in ipsilateral supraclavicular lymph nodes. (from AJCC 8th Ed.)			Finding	
C139445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139445>	C28108	Breast Cancer Anatomic Stage|Breast Carcinoma Anatomic Stage	Breast cancer staging used in global regions where biomarker tests are not routinely available.			Classification	
C139446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139446>	C28108	Breast Cancer Prognostic Stage|Breast Carcinoma Prognostic Stage	Breast cancer staging used in countries in which biomarker tests are routinely performed.			Classification	
C139447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139447>	C54028	Testing of Device from Same Lot/Batch Returned from User	The investigation employed relevant empirical testing of the device of the same lot or batch than that of the suspected device in the reported adverse event in order to support the identification of possible causes for the adverse event. The device was returned from the user. Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the latest relevant standards.			Functional Concept	CDRH Cause Investigation - Type of Investigation Terminology
C139448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139448>	C54028	Testing of Device from Other Lot/Batch Retained by Manufacturer	The investigation employed relevant empirical testing of the device of another lot or batch than that of the suspected device in the reported adverse event in order to support the identification of possible causes for the adverse event. This includes devices without a lot/batch designation. Testing was performed using the device retained by the manufacturer (i.e. was not shipped). Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the latest relevant standards.			Functional Concept	CDRH Cause Investigation - Type of Investigation Terminology
C139449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139449>	C54028	Testing of Device from Other Lot/Batch Returned from User|Testing of Device from Other Lot/Batch Returned From User	The investigation employed relevant empirical testing of the device of another lot or batch than that of the suspected device in the reported adverse event in order to support the identification of possible causes for the adverse event. This includes devices without a lot/batch designation. The device was returned from the user. Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the technical file. Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the latest relevant standards.			Functional Concept	CDRH Cause Investigation - Type of Investigation Terminology
C13944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13944>	C13432	8q21	A chromosome band present on 8q			Gene or Genome	
C139450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139450>	C54028	Testing of Model Variant	The investigation employed relevant empirical testing of a model variant of the device involved in the reported adverse event in order to support the identification of possible causes for the adverse event through plausibility reasoning. A model variant is not identical to the actual device, but shares relevant characteristics with the device involved. Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the latest relevant standards.			Functional Concept	CDRH Cause Investigation - Type of Investigation Terminology
C139451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139451>	C54028	Testing of Raw/Starting Materials	The investigation employed relevant empirical testing of the materials used in construction of the device involved in the reported adverse event in order to support the identification of possible causes for the adverse event. Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the latest relevant standards.			Functional Concept	CDRH Cause Investigation - Type of Investigation Terminology
C139452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139452>	C54028	Testing of Patient Sample or Reference Material Using Manufacturer's Device	The investigation employed relevant empirical testing of a patient sample or reference material using the device (usually an IVD) involved in the reported adverse event in order to support the identification of possible causes for the adverse event. Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the latest relevant standards.			Functional Concept	
C139453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139453>	C54028	Testing of Patient Sample or Reference Material Using Reference Method	The investigation employed relevant empirical testing of a patient sample or reference material using an appropriate reference method to the device (usually an IVD) involved in the reported adverse event in order to support the identification of possible causes for the adverse event. Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the latest relevant standards.			Functional Concept	CDRH Cause Investigation - Type of Investigation Terminology
C139454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139454>	C54028	Testing of Patient Sample or Reference Material Using Competitor's Device	The investigation employed relevant empirical testing of a patient sample or reference material using a competitor's device that is comparable to the device (usually an IVD) involved in the reported adverse event in order to support the identification of possible causes for the adverse event. Relevant testing would typically be based on test methods used for evaluating safety and performance as described in the latest relevant standards.			Functional Concept	CDRH Cause Investigation - Type of Investigation Terminology
C139455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139455>	C54028	Historical Data Analysis	The investigation involved the analysis of historical adverse events data of the actual device involved in the adverse event and/or of products from the same and/or different batches/lots.			Functional Concept	CDRH Cause Investigation - Type of Investigation Terminology
C139456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139456>	C54028	Trend Analysis	The investigation involved trend analysis of adverse event of the actual device involved in the adverse event and/or of products from the same and/or different batches/lots. It should be noted that trend analysis typically is not considered sufficient as a stand-alone method, but should be used in conjunction with other investigation methods for providing for instance complementary information.			Functional Concept	CDRH Cause Investigation - Type of Investigation Terminology
C139457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139457>	C54028	Communication/Interviews	The investigation involved communication/interviews (either interpersonal or through technical means, e.g. phone, e-mail) with persons close to the adverse event, e.g. healthcare professionals (doctors, nurses etc.), the affected patient(s) or other users including, where appropriate, relatives or others engaged in caring for the affected patient.			Functional Concept	CDRH Cause Investigation - Type of Investigation Terminology
C139458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139458>	C54028	Analysis of Information Provided by User/Third Party	The investigation involved the analysis of relevant information provided by the user (e.g. healthcare professional, patient, clinical engineer) or a third party (e.g. testing facility) in view of supporting the identification of possible causes for the adverse event.			Functional Concept	CDRH Cause Investigation - Type of Investigation Terminology
C139459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139459>	C54028	Device Not Manufactured by Reporting Manufacturer	Further information was obtained which established that the manufacturer of the device involved was not the one to which it was initially attributed. This includes mistaken identity or falsified device.			Functional Concept	CDRH Cause Investigation - Type of Investigation Terminology
C13945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13945>	C13426	FHA Domain|Forkhead-Associated Domain	The FHA (Forkhead-Associated) domain is a phosphopeptide recognition domain found in many regulatory proteins. It displays specificity for phosphothreonine-containing epitopes but will also recognize phosphotyrosine with relatively high affinity. It spans approximately 80-100 amino acid residues folded into an 11-stranded sandwich, which sometimes contain small helical insertions between the loops connecting the strands. To date, genes encoding FHA-containing proteins have been identified in eubacterial and eukaryotic but not aracheal genomes. The domain is present in a diverse range of proteins, such as kinases, phosphatases, kinesins, transcription factors, RNA-binding proteins and metabolic enzymes which partake in many different cellular processes. DNA repair, signal transduction, vesicular transport and protein degradation are just a few examples.			Amino Acid Sequence	
C139460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139460>	C54028	Device Not Returned	The actual device involved in the adverse event was not returned for testing despite requests by manufacturer.			Functional Concept	CDRH Cause Investigation - Type of Investigation Terminology
C139461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139461>	C54028	Device Discarded	The actual device involved in the adverse event had been already discarded and thus irretrievably lost for testing.			Functional Concept	CDRH Cause Investigation - Type of Investigation Terminology
C139462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139462>	C54028	Incomplete Device Returned	The device was returned incompletely, lacking parts, components or accessories that would be required for appropriate testing and analysis of root causes.			Functional Concept	CDRH Cause Investigation - Type of Investigation Terminology
C139463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139463>	C54028	Device Not Accessible for Testing	The actual device involved in the adverse event is not readily accessible for testing (e.g. remains implanted in patient).			Functional Concept	CDRH Cause Investigation - Type of Investigation Terminology
C139464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139464>	C54028	Type of Investigation Not Yet Determined	Details to determine the type of investigation are not yet available, but are being sought. Do not use this code if the investigation is complete.			Functional Concept	CDRH Cause Investigation - Type of Investigation Terminology
C139465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139465>	C48655	Insufficient Information Available	The information available relating to the reported event is not sufficient to identify either the manufacturer, the device, or other essential information.			Functional Concept	CDRH Cause Investigation - Type of Investigation Terminology
C139466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139466>	C54029	Appropriate Investigation Findings Term/Code Not Available	Problem is not adequately described by any other term.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139467>	C54029	Patient Sample Problem	Problems that occurred due to endogenous or exogenous interferent in the sample, or unexpected variation in the target analyte/marker.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139468>	C54029	Transport/Storage Problem Identified	Problems was caused by transport or storage conditions.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139469>	C54030	Appropriate Investigation Conclusion Term/Code Not Available	The concluded cause is not adequately described by any other term.			Functional Concept	CDRH Cause Investigation - Investigation Conclusion Terminology
C139470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139470>	C54030	Cause Traced to Non-Device Related Factors |Cause Traced to Non-Device Related Factors	The adverse event that occurred is not attributable to a device.			Functional Concept	CDRH Cause Investigation - Investigation Conclusion Terminology
C139471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139471>	C54030	Cause Not Established	The investigation findings do not lead to a clear conclusion about the cause of the reported adverse event.			Functional Concept	CDRH Cause Investigation - Investigation Conclusion Terminology
C139472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139472>	C54030	Cause Traced to Component Failure	Expected or random component failure without any design or manufacturing issue.			Functional Concept	CDRH Cause Investigation - Investigation Conclusion Terminology
C139473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139473>	C54030	Cause Traced to Environment	Problems caused by exposure to environmental conditions outside the expected range.			Functional Concept	CDRH Cause Investigation - Investigation Conclusion Terminology
C139474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139474>	C54030	Cause Traced to Transport/Storage	Problems traced to the inappropriate transport or storage of the device.			Functional Concept	CDRH Cause Investigation - Investigation Conclusion Terminology
C139475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139475>	C54030	Falsified Device	Devices that deliberately and/or fraudulently misrepresent their identity, composition or source.			Functional Concept	CDRH Cause Investigation - Investigation Conclusion Terminology
C139476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139476>	C54030	Design Change Validation Inadequate	Problems traced to inadequate or lack of validation of design changes of the device leading to malfunction or unintended properties of the device including possible hazards for persons using the device.			Functional Concept	CDRH Cause Investigation - Investigation Conclusion Terminology
C139477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139477>	C54030	Design Inadequate for Purpose	Problems traced to design/design features of the device that do not support or interfere with the intended purpose of the device.			Functional Concept	CDRH Cause Investigation - Investigation Conclusion Terminology
C139478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139478>	C54030	Human Factors Engineering - Device Difficult to Assemble	Problems traced to inadequate design of the component parts and/or assembly steps resulting in the device not being able to be assembled correctly.			Functional Concept	CDRH Cause Investigation - Investigation Conclusion Terminology
C139479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139479>	C54030	Human Factors Engineering - Device Difficult to Operate	Problems traced to inappropriate and/or inadequate assessment and engineering design of the device to accommodate how or where the device will be used.			Functional Concept	CDRH Cause Investigation - Investigation Conclusion Terminology
C13947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13947>	C13432	1p36.11	A chromosome band present on 1p			Gene or Genome	
C139480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139480>	C54030	Human Factors Engineering - Device Difficult to Reprocess	Problems traced to inadequate design of the reprocessing steps and/or the device resulting in the device remaining unclean.			Functional Concept	CDRH Cause Investigation - Investigation Conclusion Terminology
C139481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139481>	C54030	Cause Traced to Missing or Inadequate Safety Measures	Problems traced to inadequate design or complete lack of safety measures leading to device malfunction or unintended properties of the device including possible hazards for persons using the device.			Functional Concept	CDRH Cause Investigation - Investigation Conclusion Terminology
C139482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139482>	C54030	Sabotage or Intentional Misuse	Problems occurred because of willful damage or reckless misuse. This term indicates that there was an apparent intent to cause damage or injury.			Functional Concept	CDRH Cause Investigation - Investigation Conclusion Terminology
C139483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139483>	C54029	Cytotoxicity Problem Identified	The device was found to have an undesirable level of toxicity to living cells.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139484>	C54029	Unintended Presence of Allergens	Unintended or unexpected presence of allergens in the device.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139485>	C54029	Device Incorrectly Assembled During Reprocessing	Incorrect assembly of the device following reprocessing.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139486>	C54029	Device Incorrectly Cleaned During Reprocessing	The cleaning procedure is not followed correctly or used inappropriate cleaning materials.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139487>	C54029	Device Incorrectly Disinfected/Sterilized During Reprocessing|Device Incorrectly Disinfected/Sterilised During Reprocessing	The disinfection/sterilization process was incorrect and/or the wrong products for disinfection/sterilization were used.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139488>	C54029	Network Communication Problem	Communications problems between devices within a network system.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139489>	C54029	Electrical/Electronic Component Problem Identified	The performance of an electrical or electronic component was found to be inadequate.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C13948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13948>	C13432	12p11.1	A chromosome band present on 12p			Gene or Genome	
C139490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139490>	C54029	Unintended Emission	Problems due to unintended emission of electromagnetic energy by the device.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139491>	C54029	Ambient Light Problem Identified	Device performance was affected by ambient light. This term applies to the direct effects of ambient light on the device, and to the user's ability to operate the device (e.g. to read device output).			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139492>	C63276	Contamination of Environment by Device	Operation of the device results in contamination of the nearby environment e.g. dust, dirt, smoke, heat or biological material.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139493>	C54029	Environmental Pressure Problem Identified	Device performance was affected by the pressure, or changes in pressure, of the environment in which it was used.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139494>	C54029	Device Not Compatible With Another Device	A device that malfunctions due to being used in combination with, or in the presence of, another device.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139495>	C54029	Unintended Compatibility Identified	The device was confirmed to be compatible with another device with which the device is intended to be incompatible.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139496>	C54029	Inadequate or Incorrect Instructions for Maintenance	Inadequate or incorrect information in the instructions for maintenance.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139497>	C54029	Maintenance of Manufacturing Machinery	Problems caused by failure to maintain manufacturing equipment used to produce the device.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139498>	C54029	Inadequate Physicochemical Properties	Problems that occur due to the physicochemical properties.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139499>	C54029	Incorrect Dimension	Problems caused by incorrect physical dimensions of the device or one of its parts.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C13949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13949>	C13432	4q32.2	A chromosome band present on 4q			Gene or Genome	
C1394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1394>	C2139	Mifamurtide|CGP 19835A Lipid|Junovan|L-Alaninamide, N-(N-acetylmuramoyl)-L-alanyl-D-alpha-glutaminyl-N-((7R)-4-hydroxy-4-oxido-10-oxo-7-((1-oxohexadecyl)oxy)-3,5,9-trioxa-4-phosphapentacos-1-yl)-, Monosodium Salt, Hydrate|L-MTP-PE|L-MTP-PE|MEPACT|MIFAMURTIDE|MTP-PE Liposome|Mepact|Muramyl Tripeptide Phosphatidylethanolamine Liposome|MuramylNAc-Ala-isoGln-Lys-tripeptide-PE|mifamurtide|muramyl tripeptide phosphatidylethanolamine	A liposomal formulation containing a muramyl dipeptide (MDP) analogue with potential immunomodulatory and antineoplastic activities. Muramyl tripeptide phosphatidylethanolamine (MTP-PE), a derivative of the mycobacterial cell wall component MDP, activates both monocytes and macrophages. Activated macrophages secrete cytokines and induce the recruitment and activation of other immune cells, which may result in indirect tumoricidal effects. Liposomal encapsulation of MTP-PE prolongs its half-life and enhances tissue targeting.	Mifamurtide		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|OS Authorized Value Terminology|OS Total Dose Table
C139500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139500>	C54029	Leakage/Seal	Problems caused by inadequate/broken seal within the device.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139501>	C54029	Incorrect Interpretation of Results/Data	Problems resulting from the incorrect interpretation by the user of the results or data provided by the device.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139502>	C54029	Light Source Problem Identified	Problems with the optical properties of a device such as diopter, glare, and irradiance or glistening.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139503>	C54029	Packaging Contains Incorrect or Incomplete Device	Problems that occurred because the packaging contained an incorrect or incomplete device (missing components).			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139504>	C54029	Packaging Contains Unintended Material	Problems that occurred because unintended material was packaged with the device.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139505>	C54029	Packaging Materials Problem	Problems that occurred because of the composition or type of packaging materials was inappropriate for the device.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139506>	C54029	Alarm System Problem Identified	A system intended to warn of a potentially unsafe condition did not operate correctly.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139507>	C54029	Fail-safe Problem Identified	A system intended to prevent unsafe operation of the device did not operate correctly.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139508>	C54029	Missing or Inadequate Safety Measures Identified	Safety measures are inadequately applied or missing.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139509>	C54029	Premature Indicator Activation Identified	A system intended to indicate the device status was triggered prematurely.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C13950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13950>	C34070	Nucleoplasm	The nuclear contents other than the nucleolus.			Cell Component	
C139510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139510>	C54029	Problem of Device to Self-Test	Malfunction of the device's self-test system.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139511>	C54029	Problem to Auto Stop	An auto stop function of a device did not operate correctly.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139512>	C54029	Reset Problem Identified	The device does not reset properly.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139513>	C54029	Shielding Problem	Inadequate shielding of/by the device.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139514>	C54029	Data Storage or Loss of Data	Storage of data was unsuccessful in total or in part.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139515>	C54029	Erroneous Data Transfer	The device software fails to transfer the expected data within a system or to another device.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139516>	C54029	Software Maintenance Problem Identified	The device software was not maintained/updated properly.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139517>	C54029	Excessive Cooling Identified	The device cooled the patient or another device more than intended or expected during operation.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139518>	C54029	Excessive Heating Identified	The device delivered more heat than intended or expected during operation. This applies to devices which are intended to deliver heat.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139519>	C54029	Inadequate Cooling Identified	The device did not sufficiently cool the patient or another device during operation.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C13951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13951>	C34070	Nuclear Pore Complex|NPC	Signal-mediated nuclear import and export proceed through the nuclear pore complex (NPC). NPC is comprised of approximately 50 unique proteins collectively known as nucleoporins. NPC functions in the nuclear transport of protein and RNA. (NCI)			Cell Component	
C139520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139520>	C54029	Overheating Problem Identified	The device was found to become hotter than expected during operation. This applies to devices which are not intended to deliver heat.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139521>	C54029	Device Problem Related to Variant/Mutant|Problem Related to Variant/Mutant	Device performance affected by variant/mutant which is not covered in the labelling.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139522>	C54029	Known Interferent	Known interferent in the sample identified.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139523>	C54029	New or Unknown Interferent	New or unknown endogenous or exogenous interferent (sample) identified.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139524>	C54029	Pre-analytical Handling Problem	Incorrect pre-analytical handling of patient's sample by the user.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139525>	C54030	Adverse Event Related to Commutability	The adverse event occurred because the material being used to calibrate or assess IVD performance did not have similar properties to those of human samples, leading to inappropriate bias and erroneous results. Examples of materials include: reference materials, calibrators, proficiency testing samples.			Functional Concept	CDRH Cause Investigation - Investigation Conclusion Terminology
C139526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139526>	C54030	Adverse Event Related to Procedure	The adverse event occurred during the procedure and the device had no influence on event.			Functional Concept	CDRH Cause Investigation - Investigation Conclusion Terminology
C139527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139527>	C49484	Not Assessed|Assessment Not Done|Evaluation Not Done|Not Evaluated|Not examined	Indicates that an assessment was not performed.			Qualitative Concept	
C139528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139528>	C175341	Very Little Assistance|Very Little	A response indicating that an individual needed very little assistance.			Intellectual Product	
C139529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139529>	C226739	Used Family or Friend's Smartphone or Tablet|My family or friend's smartphone or tablet	A response indicating that an individual used a smartphone or tablet belonging to a friend or family member.			Intellectual Product	
C13952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13952>	C13432	5q35	A chromosome band present on 5q			Gene or Genome	
C139530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139530>	C175341	Assistance Installing the App|Installing the app	A response indicating that an individual required assistance with installing the app.			Intellectual Product	
C139531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139531>	C175341	Assistance with Log-in|Log-In Assistance	A response indicating that an individual required assistance with logging in.			Intellectual Product	
C139532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139532>	C4872	Breast Cancer by AJCC v8 Stage|Breast Carcinoma by AJCC v8 Stage	A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. It applies to invasive (infiltrating) carcinoma of the breast and ductal carcinoma in situ of the breast. It does not apply to breast sarcoma, phyllodes tumor, and breast lymphoma. (from AJCC 8th Ed.)			Neoplastic Process	
C139533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139533>	C139532	Breast Cancer by AJCC v8 Anatomic Stage|Breast Carcinoma by AJCC v8 Anatomic Stage	A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should only be used in global regions where biomarker tests are not routinely available. (from AJCC 8th Ed.)			Neoplastic Process	
C139534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139534>	C139533	Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage 0 Breast Carcinoma AJCC v8|Stage 0 Breast Cancer	Stage 0 includes: Tis, N0, M0. Tis: Ductal carcinoma in situ. Lobular carcinoma in situ is a benign entity and is removed from TNM staging in the AJCC Cancer Staging Manual, 8th Edition. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)	Anatomic Stage 0 Breast Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139535>	C139533	Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage I Breast Carcinoma AJCC v8|Stage I Breast Cancer	Stage I includes: IA: (T1, N0, M0); IB: (T0, N1mi, M0); (T1, N1mi, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1mi: Tumor with micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)	Anatomic Stage I Breast Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139536>	C139535	Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IA Breast Carcinoma AJCC v8|Stage IA Breast Cancer	Stage IA includes: T1, N0, M0. T1: Tumor measuring 20 mm or less in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)	Anatomic Stage IA Breast Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139537>	C139535	Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage IB Breast Carcinoma AJCC v8|Stage IB Breast Cancer	Stage IB includes: (T0, N1mi, M0); (T1, N1mi, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. N1mi: Tumor with micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)	Anatomic Stage IB Breast Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139538>	C139533	Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage II Breast Carcinoma AJCC v8|Stage II Breast Cancer	Stage II includes: IIA: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0); IIB: (T2, N1, M0); (T3, N0, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)	Anatomic Stage II Breast Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139539>	C139538	Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIA Breast Carcinoma AJCC v8|Stage IIA Breast Cancer	Stage IIA includes: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)	Anatomic Stage IIA Breast Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13953>	C13432	20pter-p12	A chromosome band present on 20p			Gene or Genome	
C139540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139540>	C139538	Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage IIB Breast Carcinoma AJCC v8|Stage IIB Breast Cancer	Stage IIB includes: (T2, N1, M0); (T3, N0, M0). T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)	Anatomic Stage IIB Breast Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139541>	C139533	Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage III Breast Carcinoma AJCC v8|Stage III Breast Cancer	Stage III includes: IIIA: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0); IIIB: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0); IIIC: (Any T, N3, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)	Anatomic Stage III Breast Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139542>	C139541	Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Carcinoma AJCC v8|Stage IIIA Breast Cancer	Stage IIIA includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)	Anatomic Stage IIIA Breast Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139543>	C139541	Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Carcinoma AJCC v8|Stage IIIB Breast Cancer	Stage IIIB includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)	Anatomic Stage IIIB Breast Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139544>	C139541	Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Carcinoma AJCC v8|Stage IIIC Breast Cancer	Stage IIIC includes: Any T, N3, M0. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)	Anatomic Stage IIIC Breast Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139545>	C139533	Anatomic Stage IV Breast Cancer AJCC v8|Anatomic Stage IV Breast Carcinoma AJCC v8|Stage IV Breast Cancer	Stage IV includes: Any T, Any N, M1. M1: Distant metastases detected by clinical and radiographic means and/or histologically proven metastases larger than 0.2 mm. (AJCC 8th ed.)	Anatomic Stage IV Breast Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139546>	C4611|C139547	Anal Fibroadenoma|Anal Ectopic Fibroadenoma	A benign epithelial-stromal neoplasm that arises from the anus and resembles the breast fibroadenoma.			Neoplastic Process	
C139547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139547>	C7617|C3743	Fibroadenoma of Anogenital Mammary-Type Glands|Fibroadenoma of Anogenital Mammary-Like Glands|Perineal Ectopic Fibroadenoma	A benign epithelial-stromal neoplasm that arises from the perineum and resembles the breast fibroadenoma.			Neoplastic Process	
C139548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139548>	C6930|C3611	Vulvar Composite Hidradenoma Papilliferum and Fibroadenoma|Vulvar Composite Papillary Hidradenoma and Fibroadenoma	A benign composite neoplasm that arises from the vulva and is characterized by mixed histopathologic features of hidradenoma papilliferum and fibroadenoma.			Neoplastic Process	
C139549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139549>	C201282	Cevostamab|Anti-FCRH5 x Anti-CD3 Bi-specific T-cell Engager BFCR4350A|Anti-FCRH5/CD3 BiTE Antibody BFCR4350A|Anti-FCRH5/CD3 TDB BFCR4350A|BFCR4350A|CEVOSTAMAB|FCRH5/CD3 T Cell Dependent Bispecific Antibody BFCR4350A|FCRH5/CD3 TDB Antibody BFCR4350A|RO7187797|Recombinant Anti-FCRH5 x Anti-CD3 Bi-specific T-cell Engager BFCR4350A	A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) Fc receptor-like protein 5 (FCRH5; CD307; FCRL5; IRTA2; BXMAS1) and one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of cevostamab, the bispecific antibody binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and FCRH5 found on FCRH5-expressing tumor cells. This activates and crosslinks CTLs with FCRH5-expressing tumor cells, which results in the CTL-mediated cell death of FCRH5-expressing tumor cells. FCRH5, an immune receptor translocation-associated protein/Fc receptor homolog (IRTA/FCRH) family member and a B-cell lineage marker, is overexpressed on myeloma cells.	Cevostamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C13954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13954>	C13432	2q35-q36	A chromosome band present on 2q			Gene or Genome	
C139550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139550>	C226773|C226765	CCR2/CCR5 Antagonist BMS-813160|(S)-1-[(1S,2R,4R)-4-isopropyl(methyl)amino)-2-propylcyclohexyl]-3-(6(trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-2-one|BMS-813160|BMS-813160	An antagonist of both human C-C chemokine receptor types 2 (CCR2; CD192) and 5 (CCR5; CD195), with potential immunomodulating and antineoplastic activities. Upon administration, CCR2/CCR5 antagonist BMS-813160 specifically binds and prevents the activation of both CCR2 and CCR5. This inhibits the activation of CCR2/CCR5-mediated signal transduction pathways and may inhibit inflammatory processes, angiogenesis, tumor cell migration, tumor cell proliferation and invasion. The G-protein coupled chemokine receptors CCR2 and CCR5 are expressed on the surface of monocytes and macrophages, and stimulate their migration and infiltration; they play key roles in inflammation and autoimmune disease. CCR2 and CCR5 are overexpressed in certain cancer cell types, and are also involved in angiogenesis, and in tumor cell migration, proliferation and metastasis.	CCR2/CCR5 Antagonist BMS-813160		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C139551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139551>	C717	Oncolytic HSV-1 rQNestin34.5v.2|Genetically Engineered HSV-1 Virus rQNestin34.5v.2|Oncolytic rQNestin34.5v.2|Oncolytic rQNestin34.5v.2 HSV Virus|rQNestin34.5v.2	A neuroattenuated, replication-competent, recombinant and genetically-engineered herpes simplex virus type 1 (HSV-1), with potential oncolytic and immunostimulating activities. In rQNestin34.5v.2, the UL39 gene encoding for the viral ribonucleotide reductase large subunit infected cell protein 6 (ICP6) and both endogenous copies of the gamma34.5 gene that encodes for the RL1 neurovirulence protein infected cell protein 34.5 (ICP34.5), which is needed for robust viral growth in an infected cell, are deleted, and one copy of the gamma34.5 gene is reinserted under control of a nestin promoter, which is selectively activated in gliomas. Upon intratumoral administration, oncolytic HSV-1 rQNestin34.5v.2 preferentially infects and replicates within the rapidly dividing, glioma cells, thereby directly lysing tumor cells. The released virus particles, in turn, infect and replicate in neighboring tumor cells, thereby further killing tumor cells. rQNestin34.5v.2 also elicits a tumor-specific systemic immune and cytotoxic T-lymphocyte (CTL) response, thereby killing nearby non-infected tumor cells. By inactivating UL39, viral ribonucleotide reductase activity is disrupted, resulting in the inhibition of nucleotide metabolism and viral DNA synthesis in non-dividing, healthy cells but not in dividing cells. Glioma-selective expression of ICP34.5 imparts tumor selectivity by preventing replication in healthy cells.	Oncolytic HSV-1 rQNestin34.5v.2		Pharmacologic Substance|Virus	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C139552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139552>	C213863	Mevociclib|CDK7 Inhibitor SY-1365|MEVOCICLIB|SY-1365|SY1365	A selective inhibitor of cyclin-dependent kinase 7 (CDK7), with potential antineoplastic activity. Upon administration, SY-1365 binds to and inhibits CDK7, thereby inhibiting CDK7-mediated signal transduction pathways. This inhibits cell growth of CDK7-overexpressing tumor cells. CDK7, a serine/threonine kinase, plays a key role in cell proliferation; CDK7 is overexpressed in a variety of tumor cell types.	Mevociclib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C139553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139553>	C133877	Giloralimab|ABBV-927|Agonistic Anti-CD40 Monoclonal Antibody ABBV-927|Anti-CD40 Agonist Monoclonal Antibody ABBV-927|Anti-CD40 Monoclonal Antibody ABBV-927|GILORALIMAB|PR-1614645	An agonistic monoclonal antibody directed against the B-cell surface antigen CD40, with potential antineoplastic activity. Upon administration, giloralimab binds to CD40 on a variety of immune cell types. This induces CD40-dependent signaling pathways, triggers the proliferation and activation of antigen-presenting cells (APCs), and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells and plays a key role in the activation of the immune system.	Giloralimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C139554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139554>	C139532	Breast Cancer by AJCC v8 Prognostic Stage|Breast Cancer by AJCC v8 Prognostic Stage Group|Breast Carcinoma by AJCC v8 Prognostic Stage	A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should be used in countries where HER2, ER, and PR biomarker tests are routinely performed for patient care (U.S., Canada, etc.). (from AJCC 8th Ed.)			Neoplastic Process	
C139555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139555>	C139554	Prognostic Stage 0 Breast Cancer AJCC v8|Prognostic Stage 0 Breast Carcinoma AJCC v8|Stage 0 Breast Cancer	Stage 0 includes: Tis, N0, M0, G1-3, HER2 Status: Any, ER Status: Any, PR Status: Any. Tis: Ductal carcinoma in situ. Lobular carcinoma in situ is a benign entity and is removed from TNM staging in the AJCC Cancer Staging Manual, 8th Edition. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)	Prognostic Stage 0 Breast Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139556>	C139554	Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage I Breast Carcinoma AJCC v8|Stage I Breast Cancer	Stage I includes: IA: (T1, N0, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T1, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (T0-1, N1mi, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T0-1, N1mi, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (MultiGene Panel-Oncotype Dx Recurrence Score Less Than 11, T1-2, N0, M0, G1-3, HER2 Status: Negative, ER Status: Positive, PR Status: Any); IB: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1-3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N1, M0, G1-3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N1, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1-2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)	Prognostic Stage I Breast Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139557>	C139556	Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IA Breast Carcinoma AJCC v8|Stage IA Breast Cancer	Stage IA includes: (T1, N0, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T1, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (T0-1, N1mi, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T0-1, N1mi, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (MultiGene Panel-Oncotype Dx Recurrence Score Less Than 11, T1-2, N0, M0, G1-3, HER2 Status: Negative, ER Status: Positive, PR Status: Any). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)	Prognostic Stage IA Breast Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139558>	C139556	Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage IB Breast Carcinoma AJCC v8|Stage IB Breast Cancer	Stage IB includes: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1-3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N1, M0, G1-3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N1, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1-2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)	Prognostic Stage IB Breast Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139559>	C185612	Batoprotafib|BATOPROTAFIB|PTPN11 Inhibitor TNO155|SHP2 Inhibitor TNO155|TNO155	An inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic activity. Upon oral administration,batoprotafib binds to and inhibits SHP2. This prevents SHP2-mediated signaling, inhibits MAPK signaling and prevents growth of SHP2-expressing tumor cells. SHP2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the RAS-RAF-ERK signaling pathway. SHP2 also regulates programmed cell death 1 (PD-1)-mediated signal transduction and is involved in immune checkpoint modulation.	Batoprotafib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C13955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13955>	C13984	Desmosome|Desmosomes|Macula Adherens|Spot Desmosome	Desmosomes are intercellular anchoring junctions that anchor intermediate filaments at membrane-associated plaques in adjoining cells.  Desmosomes assemble in response to cell-cell contact and raised levels of extracellular calcium. Sensitivity to calcium levels is lost as desmosomes mature.			Cell Component	
C139561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139561>	C224821	Orilanolimab|Anti-FcRn Monoclonal Antibody SYNT001|Immunoglobulin G4, Anti-(Human FcRn Receptor) (Humanized Monoclonal SYNT001 gamma4-Chain), Disulfide with Humanized Monoclonal SYNT001 kappa-Chain, Dimer|ORILANOLIMAB|SYNT 001|SYNT-001|SYNT001	A monoclonal antibody that targets the neonatal crystallizable fragment receptor (FcRn), with potential immunomodulating activity. Upon administration, orilanolimab targets and binds to FcRn at the immunoglobulin G (IgG) binding site, thereby preventing the interaction between FcRn and the serum protein IgG. By preventing FcRn/IgG binding, orilanolimab blocks the FcRn-mediated rescue of IgG, enables IgG degradation and prevents IgG-mediated inflammation. IgG plays a key role in many autoimmune diseases and is an important factor in inflammatory processes.	Orilanolimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C139562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139562>	C12664	Upper Abdomen	The superior portion of the abdomen.			Body Location or Region	
C139564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139564>	C38631	Superior Thoracic Aperture|Thoracic Inlet	The superior opening of the thorax whose margin comprises the upper border of the first thoracic vertebra, the first ribs, and the manubrium.			Body Part, Organ, or Organ Component	
C139565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139565>	C35427	Malignant Neoplasm of Lung - Multiple Primary Sites|MPLC|Multiple Primary Lung Cancers	Lung cancer comprising malignant neoplasms from two or more sites, as determined by clinicopathological assessment.			Neoplastic Process	
C139566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139566>	C48935	Mediastinal Lymph Node Dissection	A surgical procedure in which all or most all of the lymph nodes are removed from the mediastinum.	Mediastinal Lymph Node Dissection		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C139567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139567>	C158758	En Bloc Resection	A surgical procedure in which organs or tissues are removed as a whole.			Health Care Activity	
C139568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139568>	C15655	Tunneled Pleural Catheter Drainage	A surgical procedure in which a hollow, flexible tube is placed in the thoracic cavity and exits the body through a tunneled path under the skin.			Therapeutic or Preventive Procedure	
C139569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139569>	C139554	Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage II Breast Carcinoma AJCC v8|Stage II Breast Cancer	Stage II includes: IIA: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); IIB: (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)	Prognostic Stage II Breast Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13956>	C14114	EF-Hand Domain|EF Hand|EF-Hand|EF-Hand Calcium-Binding Motif|EF-Hand Motif	Forming a single Ca2+-binding site in many calcium-binding proteins, the basic EF-Hand Domain consists of a conserved 12-residue loop region between two perpendicular 10-12 residue alpha helices (helix-loop-helix). Ca2+ interacts with loop residues in a pentagonal bipyramidal configuration; each loop residue is important for Ca2+ coordination. Loop residues 1, 3, 5, 7, 9, and 12 (invariant Glu or Asp) are directly necessary for Ca2+ binding. Amino-acid variations at positions 1, 3, 5, 7, and 9 alter ion affinity. Single or multiple domains cause structural/functional variations. EF-hand Proteins are grouped into either regulatory/signaling or structural/buffering/transport categories. Ca2+ binding to regulatory proteins induces conformational/functional change; Ca2+ binding to structural proteins seems to provide a Ca2+ buffer. (NCI)			Amino Acid Sequence	
C139570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139570>	C93159	Endobronchial Stent Placement|Endobronchial Stenting	Placement of a stent in a bronchus.			Health Care Activity	
C139571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139571>	C139569	Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIA Breast Carcinoma AJCC v8|Stage IIA Breast Cancer	Stage IIA includes: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)	Prognostic Stage IIA Breast Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139572>	C139569	Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage IIB Breast Carcinoma AJCC v8|Stage IIB Breast Cancer	Stage IIB includes: (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)	Prognostic Stage IIB Breast Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139573>	C122408	Synchronous Nodules with Dominant Lesion(s)	A finding of multiple pulmonary nodules in which radiologic imaging demonstrates the presence of a dominant lesion.			Finding	
C139574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139574>	C122408	Synchronous Nodules without Dominant Lesion(s)	A finding of multiple pulmonary nodules in which radiologic imaging shows no evidence of a dominant lesion.			Finding	
C139575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139575>	C54029	Device Incorrectly Reprocessed	Problems associated with the failure to properly and adequately reprocess the device.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139576>	C54029	Sterilization Problem Identified	Problems that occurred during terminal sterilization by the manufacturer.			Functional Concept	CDRH Cause Investigation - Investigation Findings Terminology
C139578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139578>	C4809	R0|No Residual Tumor|R0 - Complete Resection, Negative Margins|R0 - Complete Resection, Negative Margins|R0 - Complete Resection, Negative Margins|R0: No residual tumor|R0: No residual tumor and negative microscopic margins in resected specimen.	No detectable presence of residual tumor after treatment			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|GCT Authorized Value Terminology|GCT Biopsy/Surgical Procedures Table|GDC Terminology|GDC Value Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table
C139579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139579>	C4809	R1|Microscopic Residual Tumor|R1 - Complete Resection, Positive Margins|R1 - Complete Resection, Positive Margins|R1 - Complete Resection, Positive Margins - Microscopically Positive|R1: Microscopic residual tumor|R1: Microscopic residual tumor. No gross residual disease but positive microscopic margins.	Presence of microscopic residual tumor after treatment.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|GCT Authorized Value Terminology|GCT Biopsy/Surgical Procedures Table|GDC Terminology|GDC Value Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table
C13957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13957>	C13432	1q43-q44	A chromosome band present on 1q			Gene or Genome	
C139580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139580>	C4809	R2|Gross Residual Tumor|Macroscopic Residual Tumor|R2 - Gross Residual Disease|R2 - Gross Residual Disease|R2 - Gross Residual Disease|R2: Macroscopic residual tumor|R2: Macroscopic residual tumor. Grossly visible residual disease.	Presence of macroscopic residual tumor after treatment.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|GCT Authorized Value Terminology|GCT Biopsy/Surgical Procedures Table|GDC Terminology|GDC Value Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table
C139581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139581>	C4809	RX|RX: Presence of residual tumor cannot be assessed|RX: The presence of residual tumor or margin status cannot be assessed.|Residual Tumor Cannot Be Assessed|Residual Tumor Unknown	Presence of residual tumor after treatment cannot be assessed.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form|GDC Terminology|GDC Value Terminology
C139582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139582>	C139554	Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage III Breast Carcinoma AJCC v8|Stage III Breast Cancer	Stage III includes: IIIA: (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); IIIB: (T2, N1, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); IIIC: (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any ); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)	Prognostic Stage III Breast Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139583>	C139582	Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Carcinoma AJCC v8|Stage IIIA Breast Cancer	Stage IIIA includes: (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); ( T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)	Prognostic Stage IIIA Breast Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139584>	C139582	Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Carcinoma AJCC v8|Stage IIIB Breast Cancer	Stage IIIB includes: (T2, N1, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)	Prognostic Stage IIIB Breast Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139585>	C139582	Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Carcinoma AJCC v8|Stage IIIC Breast Cancer	Stage IIIC includes: (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any ); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)	Prognostic Stage IIIC Breast Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139587>	C139554	Prognostic Stage IV Breast Cancer AJCC v8|Prognostic Stage IV Breast Carcinoma AJCC v8|Stage IV Breast Cancer	Stage IV includes: Any T, Any N, M1, G1-3, HER2 Status: Any, ER Status: Any, PR Status: Any. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M1: Distant metastases detected by clinical and radiographic means and/or histologically proven metastases larger than 0.2 mm. (AJCC 8th ed.)	Prognostic Stage IV Breast Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139588>	C153562	MGMT Gene Promoter Hypermethylation|Hypermethylated MGMT Gene Promoter|Methylguanine-DNA Methyltransferase Gene Promoter Hypermethylation|O-6-Methylguanine-DNA Methyltransferase Gene Promoter Hypermethylation	A genetic finding indicating an excess of DNA methylation in the promoter region of the MGMT gene.	MGMT Gene Promoter Hypermethylation		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C139589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139589>	C48233	Female Reproductive System Cancer TNM Finding v8	A finding about one or more characteristics of female reproductive system cancer, following the rules of the TNM AJCC v8 classification system. The TNM categories have been defined to correspond to the FIGO stages. Some amendments have been made in collaboration with FIGO, and the classifications now published have the approval of FIGO, AJCC, and all other national TNM committees of the Union for International Cancer Control (UICC). (from AJCC 8th Ed.)			Finding	
C13958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13958>	C13432	3q26.3	A chromosome band present on 3q			Gene or Genome	
C139590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139590>	C139589	Vulvar Cancer TNM Finding v8|Vulvar Carcinoma TNM Finding v8	A finding about one or more characteristics of vulvar cancer, following the rules of the TNM AJCC v8 classification system. This classification system applies to all carcinomas of the vulva. Melanoma of the vulva is staged according to the classification for melanoma of the skin.   (from AJCC 8th Ed.)			Finding	
C139591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139591>	C139590	Vulvar Cancer Clinical TNM Finding v8|Vulvar Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of vulvar cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C139592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139592>	C139591	Vulvar Cancer Clinical Distant Metastasis TNM Finding v8|Vulvar Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of vulvar cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C139593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139593>	C139592	Vulvar Cancer cM0 TNM Finding v8|Vulvar Carcinoma cM0 TNM Finding v8	Vulvar cancer without evidence of distant metastasis (no pathological M0; use clinical M to complete stage group). (from AJCC 8th Ed.)			Finding	
C139594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139594>	C139592	Vulvar Cancer cM1 TNM Finding v8|Vulvar Carcinoma cM1 TNM Finding v8	Vulvar cancer with distant metastasis (including pelvic lymph node metastasis). (from AJCC 8th Ed.)			Finding	
C139595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139595>	C139590	Vulvar Cancer Pathologic TNM Finding v8|Vulvar Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of vulvar cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C139596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139596>	C139595	Vulvar Cancer Pathologic Distant Metastasis TNM Finding v8|Vulvar Carcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of vulvar cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C139597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139597>	C139596	Vulvar Cancer pM1 TNM Finding v8|Vulvar Carcinoma pM1 TNM Finding v8	Vulvar cancer with distant metastatis. (from AJCC 8th Ed.)			Finding	
C139598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139598>	C139595	Vulvar Cancer Pathologic Primary Tumor TNM Finding v8|Vulvar Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of vulvar cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor. The definitions of the T categories correspond to the stages accepted by FIGO. (from AJCC 8th Ed.)			Finding	
C139599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139599>	C139598	Vulvar Cancer pTX TNM Finding v8|Vulvar Carcinoma pTX TNM Finding v8	Vulvar cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C13959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13959>	C13432	4q13.3-q21.1	A chromosome band present on 4q			Gene or Genome	
C1395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1395>	C932|C67422	Vinorelbine Tartrate|Biovelbin|Eunades|KW 2307|KW-2307|KW2307|NVB|Navelbine|Navelbine|Navelbine Ditartrate|Navelbine ditartrate|VINORELBINE TARTRATE|Vinorelbine Ditartrate|vinorelbine tartrate	The ditartrate salt of a semisynthetic vinca alkaloid derived from the leaves of the periwinkle plant (Vinca rosea) with antineoplastic properties.  Vinorelbine binds to tubulin, thereby inhibiting tubulin polymerization into microtubules and spindle formation and resulting in apoptosis of susceptible cancer cells. Inhibition of mitotic microtubules correlates with antitumor activity, whereas inhibition of axonal microtubules seems to correlate with vinorelbine's neurotoxicity. Compared to related vinca alkaloids, vinorelbine is more selective against mitotic than axonal microtubules in vitro, which may account for its decreased neurotoxicity.  This agent is also a radiation-sensitizing agent. (NCI04)	Vinorelbine Tartrate		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C139600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139600>	C139598	Vulvar Cancer pT0 TNM Finding v8|Vulvar Carcinoma pT0 TNM Finding v8	Vulvar cancer with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C139601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139601>	C139598	Vulvar Cancer pT1 TNM Finding v8|Vulvar Cancer FIGO Stage I|Vulvar Carcinoma FIGO Stage I|Vulvar Carcinoma pT1 TNM Finding v8	Vulvar cancer with tumor confined to the vulva and/or perineum. Multifocal lesions should be designated as such. The largest lesion or the lesion with the greatest depth of invasion will be the target lesion identified to address the highest pT stage. Depth of invasion is defined as the measurement of the tumor from the epithelial-stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion. (from AJCC 8th Ed.)			Finding	
C139602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139602>	C139601	Vulvar Cancer pT1a TNM Finding v8|Vulvar Cancer FIGO Stage IA|Vulvar Carcinoma FIGO Stage IA|Vulvar Carcinoma pT1a TNM Finding v8	Vulvar cancer with lesion measuring 2 cm or less, confined to the vulva and/or perineum, and with stromal invasion of 1.0 mm or less. (from AJCC 8th Ed.)			Finding	
C139603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139603>	C139601	Vulvar Cancer pT1b TNM Finding v8|Vulvar Cancer FIGO Stage IB|Vulvar Carcinoma FIGO Stage IB|Vulvar Carcinoma pT1b TNM Finding v8	Vulvar cancer with lesion measuring more than 2 cm, or any size with stromal invasion of more than 1.0 mm, confined to the vulva and/or perineum. (from AJCC 8th Ed.)			Finding	
C139604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139604>	C139598	Vulvar Cancer pT2 TNM Finding v8|Vulvar Cancer FIGO Stage II|Vulvar Carcinoma FIGO Stage II|Vulvar Carcinoma pT2 TNM Finding v8	Vulvar cancer with tumor of any size with extension to adjacent perineal structures (lower/distal third of the urethra, lower/distal third of the vagina, anal involvement). (from AJCC 8th Ed.)			Finding	
C139605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139605>	C139598	Vulvar Cancer pT3 TNM Finding v8|Vulvar Cancer FIGO Stage IVA|Vulvar Carcinoma FIGO Stage IVA|Vulvar Carcinoma pT3 TNM Finding v8	Vulvar cancer with tumor of any size with extension to any of the following: upper/proximal two-thirds of the urethra, upper/proximal two-thirds of the vagina, bladder mucosa, or rectal mucosa; or fixed to pelvic bone. (from AJCC 8th Ed.)			Finding	
C139606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139606>	C139595	Vulvar Cancer Pathologic Regional Lymph Nodes TNM Finding v8|Vulvar Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of vulvar cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C139607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139607>	C139606	Vulvar Cancer pNX TNM Finding v8|Vulvar Carcinoma pNX TNM Finding v8	Vulvar cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C139608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139608>	C139606	Vulvar Cancer pN0 TNM Finding v8|Vulvar Carcinoma pN0 TNM Finding v8	Vulvar cancer with no regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C139609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139609>	C139608	Vulvar Cancer pN0(i+) TNM Finding v8|Vulvar Carcinoma pN0(i+) TNM Finding v8	Vulvar cancer with isolated tumor cells in regional lymph node(s) no greater than 0.2 mm. (from AJCC 8th Ed.)			Finding	
C13960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13960>	C13426	SAM Domain|SAM Motif|Sterile Alpha Domain|Sterile Alpha Motif	The approximately 70 amino acid SAM (Sterile Alpha Motif) domain has been identified in over 400 different proteins with diverse cellular function, from yeast to man. SAM domains have been implicated in mediating protein-protein interaction via the formation of homo and hetero-typic oligomers. The residues at the interface of the EphA4 and EphB2 SAM domain homodimers have been mapped, but the factors that determine specificity remain to be determined. (Pawson Lab, SLRI, Mount Sinai Hospital, 2003)			Amino Acid Sequence	
C139610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139610>	C139606	Vulvar Cancer pN1 TNM Finding v8|Vulvar Cancer FIGO Stage III|Vulvar Carcinoma FIGO Stage III|Vulvar Carcinoma pN1 TNM Finding v8	Vulvar cancer with regional lymph node metastasis with one or two lymph node metastases each less than 5 mm, or one lymph node metastasis equal to 5 mm. (from AJCC 8th Ed.)			Finding	
C139611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139611>	C139610	Vulvar Cancer pN1a TNM Finding v8|Vulvar Cancer FIGO Stage IIIA|Vulvar Carcinoma FIGO Stage IIIA|Vulvar Carcinoma pN1a TNM Finding v8	Vulvar cancer with regional lymph node metastasis with one or two lymph node metastases each less than 5 mm. It includes micrometastasis, N1mi. (from AJCC 8th Ed.)			Finding	
C139612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139612>	C139610	Vulvar Cancer pN1b TNM Finding v8|Vulvar Cancer FIGO Stage IIIA|Vulvar Carcinoma FIGO Stage IIIA|Vulvar Carcinoma pN1b TNM Finding v8	Vulvar cancer with one lymph node metastasis equal to 5 mm. (from AJCC 8th Ed.)			Finding	
C139613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139613>	C139606	Vulvar Cancer pN2 TNM Finding v8|Vulvar Carcinoma pN2 TNM Finding v8	Vulvar cancer with regional lymph node metastasis with three or more lymph node metastases each less than 5 mm, or two or more lymph node metastases equal to 5 mm, or lymph node(s) with extranodal extension. (from AJCC 8th Ed.)			Finding	
C139614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139614>	C139613	Vulvar Cancer pN2a TNM Finding v8|Vulvar Cancer FIGO Stage IIIB|Vulvar Carcinoma FIGO Stage IIIB|Vulvar Carcinoma pN2a TNM Finding v8	Vulvar cancer with three or more lymph node metastases each less than 5 mm. It includes micrometastasis, N2mi. (from AJCC 8th Ed.)			Finding	
C139615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139615>	C139613	Vulvar Cancer pN2b TNM Finding v8|Vulvar Cancer FIGO Stage IIIB|Vulvar Carcinoma FIGO Stage IIIB|Vulvar Carcinoma pN2b TNM Finding v8	Vulvar cancer with two or more lymph node metastases equal to 5 mm. (from AJCC 8th Ed.)			Finding	
C139616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139616>	C139613	Vulvar Cancer pN2c TNM Finding v8|Vulvar Cancer FIGO Stage IIIC|Vulvar Carcinoma FIGO Stage IIIC|Vulvar Carcinoma pN2c TNM Finding v8	Vulvar cancer with lymph node(s) metastasis with extranodal extension. (from AJCC 8th Ed.)			Finding	
C139617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139617>	C139606	Vulvar Cancer pN3 TNM Finding v8|Vulvar Cancer FIGO Stage IVA|Vulvar Carcinoma FIGO Stage IVA|Vulvar Carcinoma pN3 TNM Finding v8	Vulvar cancer with fixed or ulcerated regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C139618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139618>	C4866	Vulvar Cancer by AJCC v8 Stage|Vulvar Carcinoma by AJCC v8 Stage	A term that refers to the staging of vulvar cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to all carcinomas of the vulva. Melanoma of the vulva is staged according to the classification for melanoma of the skin. (AJCC 8th Ed.)			Neoplastic Process	
C139619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139619>	C139618	Stage I Vulvar Cancer AJCC v8|Stage I Vulvar Cancer|Stage I Vulvar Carcinoma AJCC v8	Stage I includes: T1, N0, M0. T1: Tumor confined to the vulva and/or perineum. Multifocal lesions should be designated as such. The largest lesion or the lesion with the greatest depth of invasion will be the target lesion identified to address the highest pT stage. Depth of invasion is defined as the measurement of the tumor from the epithelial-stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage I Vulvar Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13961>	C13432	15q22.1-q22.33	A chromosome band present on 15q			Gene or Genome	
C139620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139620>	C139619	Stage IA Vulvar Cancer AJCC v8|Stage IA Vulvar Cancer|Stage IA Vulvar Carcinoma AJCC v8	Stage IA includes: T1a, N0, M0. T1a: Lesion measuring 2 cm or less, confined to the vulva and/or perineum, and with stromal invasion of 1.0 mm or less. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IA Vulvar Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139621>	C139619	Stage IB Vulvar Cancer AJCC v8|Stage IB Vulvar Cancer|Stage IB Vulvar Carcinoma AJCC v8	Stage IB includes: T1b, N0, M0. T1b: Lesion measuring more than 2 cm, or any size with stromal invasion of more than 1.0 mm, confined to the vulva and/or perineum. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 8th Ed.)	Stage IB Vulvar Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139622>	C139618	Stage II Vulvar Cancer AJCC v8|Stage II Vulvar Cancer|Stage II Vulvar Carcinoma AJCC v8	Stage II includes: T2, N0, M0. T2: Tumor of any size with extension to adjacent perineal structures (lower/distal third of the urethra, lower/distal third of the vagina, anal involvement). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage II Vulvar Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139623>	C139618	Stage III Vulvar Cancer AJCC v8|Stage III Vulvar Cancer|Stage III Vulvar Carcinoma AJCC v8	Stage III includes: T1-T2, N1-N2c, M0. T1: Tumor confined to the vulva and/or perineum. Multifocal lesions should be designated as such. The largest lesion or the lesion with the greatest depth of invasion will be the target lesion identified to address the highest pT stage. Depth of invasion is defined as the measurement of the tumor from the epithelial-stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion. T2: Tumor of any size with extension to adjacent perineal structures (lower/distal third of the urethra, lower/distal third of the vagina, anal involvement). N1: Regional lymph node metastasis with one or two lymph node metastases each less than 5 mm, or one lymph node metastasis equal to 5 mm. N2a: Three or more lymph node metastases each less than 5 mm. It includes micrometastasis, N2mi. N2b: Two or more lymph node metastases equal to 5 mm. N2c: Lymph node(s) metastasis with extranodal extension. M0: No distant metastasis. (AJCC 8th Ed.)	Stage III Vulvar Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139624>	C139623	Stage IIIA Vulvar Cancer AJCC v8|Stage IIIA Vulvar Cancer|Stage IIIA Vulvar Carcinoma AJCC v8	Stage IIIA includes: T1-T2, N1, M0. T1: Tumor confined to the vulva and/or perineum. Multifocal lesions should be designated as such. The largest lesion or the lesion with the greatest depth of invasion will be the target lesion identified to address the highest pT stage. Depth of invasion is defined as the measurement of the tumor from the epithelial-stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion. T2: Tumor of any size with extension to adjacent perineal structures (lower/distal third of the urethra, lower/distal third of the vagina, anal involvement). N1: Regional lymph node metastasis with one or two lymph node metastases each less than 5 mm, or one lymph node metastasis equal to 5 mm. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIIA Vulvar Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139625>	C139623	Stage IIIB Vulvar Cancer AJCC v8|Stage IIIB Vulvar Cancer|Stage IIIB Vulvar Carcinoma AJCC v8	Stage IIIB includes: T1-T2, N2a, N2b, M0. T1: Tumor confined to the vulva and/or perineum. Multifocal lesions should be designated as such. The largest lesion or the lesion with the greatest depth of invasion will be the target lesion identified to address the highest pT stage. Depth of invasion is defined as the measurement of the tumor from the epithelial-stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion. T2: Tumor of any size with extension to adjacent perineal structures (lower/distal third of the urethra, lower/distal third of the vagina, anal involvement). N2a: Three or more lymph node metastases each less than 5 mm. It includes micrometastasis, N2mi. N2b: Two or more lymph node metastases equal to 5 mm. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIIB Vulvar Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139626>	C139623	Stage IIIC Vulvar Cancer AJCC v8|Stage IIIC Vulvar Cancer|Stage IIIC Vulvar Carcinoma AJCC v8	Stage IIIC includes: T1-T2, N2c, M0. T1: Tumor confined to the vulva and/or perineum. Multifocal lesions should be designated as such. The largest lesion or the lesion with the greatest depth of invasion will be the target lesion identified to address the highest pT stage. Depth of invasion is defined as the measurement of the tumor from the epithelial-stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion. T2: Tumor of any size with extension to adjacent perineal structures (lower/distal third of the urethra, lower/distal third of the vagina, anal involvement). N2c: Lymph node(s) metastasis with extranodal extension. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIIC Vulvar Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139627>	C139618	Stage IV Vulvar Cancer AJCC v8|Stage IV Vulvar Cancer|Stage IV Vulvar Carcinoma AJCC v8	Stage IV includes: T1-T3, N3, M0-M1. T1: Tumor confined to the vulva and/or perineum. Multifocal lesions should be designated as such. The largest lesion or the lesion with the greatest depth of invasion will be the target lesion identified to address the highest pT stage. Depth of invasion is defined as the measurement of the tumor from the epithelial-stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion. T2: Tumor of any size with extension to adjacent perineal structures (lower/distal third of the urethra, lower/distal third of the vagina, anal involvement). T3: Tumor of any size with extension to any of the following: upper/proximal two-thirds of the urethra, upper/proximal two-thirds of the vagina, bladder mucosa, or rectal mucosa; or fixed to pelvic bone. N3: Fixed or ulcerated regional lymph node metastasis. M0: No distant metastasis. M1: Distant metastasis (including pelvic lymph node metastasis). (from AJCC 8th Ed.)	Stage IV Vulvar Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139628>	C139627	Stage IVA Vulvar Cancer AJCC v8|Stage IVA Vulvar Cancer|Stage IVA Vulvar Carcinoma AJCC v8	Stage IVA includes: (T1-T2, N3, M0); (T3, Any N, M0). T1: Tumor confined to the vulva and/or perineum. Multifocal lesions should be designated as such. The largest lesion or the lesion with the greatest depth of invasion will be the target lesion identified to address the highest pT stage. Depth of invasion is defined as the measurement of the tumor from the epithelial-stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion. T2: Tumor of any size with extension to adjacent perineal structures (lower/distal third of the urethra, lower/distal third of the vagina, anal involvement). T3: Tumor of any size with extension to any of the following: upper/proximal two-thirds of the urethra, upper/proximal two-thirds of the vagina, bladder mucosa, or rectal mucosa; or fixed to pelvic bone. N3: Fixed or ulcerated regional lymph node metastasis. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage IVA Vulvar Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13962>	C13432	6p24.3	A chromosome band present on 6p			Gene or Genome	
C139630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139630>	C139627	Stage IVB Vulvar Cancer AJCC v8|Stage IVB Vulvar Cancer|Stage IVB Vulvar Carcinoma AJCC v8	Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis (including pelvic lymph node metastasis). (from AJCC 8th Ed.)	Stage IVB Vulvar Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139632>	C139589	Vaginal Cancer TNM Finding v8|Vaginal Carcinoma TNM Finding v8	A finding about one or more characteristics of vaginal cancer, following the rules of the TNM AJCC v8 classification system. This classification system applies to all carcinomas of the vagina. There is no AJCC staging system for mucosal melanoma of the vagina. (from AJCC 8th Ed.)			Finding	
C139633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139633>	C139632	Vaginal Cancer Clinical TNM Finding v8|Vaginal Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of vaginal cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C139634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139634>	C139633	Vaginal Cancer Clinical Distant Metastasis TNM Finding v8|Vaginal Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of vaginal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C139635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139635>	C139634	Vaginal Cancer cM0 TNM Finding v8|Vaginal Carcinoma cM0 TNM Finding v8	Vaginal cancer without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C139636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139636>	C139634	Vaginal Cancer cM1 TNM Finding v8|Vaginal Carcinoma cM1 TNM Finding v8	Vaginal cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C139637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139637>	C139632	Vaginal Cancer Pathologic TNM Finding v8|Vaginal Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of vaginal cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C139638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139638>	C139637	Vaginal Cancer Pathologic Distant Metastasis TNM Finding v8|Vaginal Carcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of vaginal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C139639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139639>	C139638	Vaginal Cancer pM1 TNM Finding v8|Vaginal Carcinoma pM1 TNM Finding v8	Vaginal cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C13963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13963>	C13432	16p12-p11.2	A chromosome band present on 16p			Gene or Genome	
C139640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139640>	C139637	Vaginal Cancer Pathologic Primary Tumor TNM Finding v8|Vaginal Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of vaginal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor. The definitions of the T categories correspond to the stages accepted by FIGO. (from AJCC 8th Ed.)			Finding	
C139641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139641>	C139640	Vaginal Cancer pTX TNM Finding v8|Vaginal Carcinoma pTX TNM Finding v8	Vaginal cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C139642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139642>	C139640	Vaginal Cancer pT0 TNM Finding v8|Vaginal Carcinoma pT0 TNM Finding v8	Vaginal cancer with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C139643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139643>	C139640	Vaginal Cancer pT1 TNM Finding v8|Vaginal Cancer FIGO Stage I|Vaginal Carcinoma FIGO Stage I|Vaginal Carcinoma pT1 TNM Finding v8	Vaginal cancer with tumor confined to the vagina. (from AJCC 8th Ed.)			Finding	
C139644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139644>	C139643	Vaginal Cancer pT1a TNM Finding v8|Vaginal Cancer FIGO Stage I|Vaginal Carcinoma FIGO Stage I|Vaginal Carcinoma pT1a TNM Finding v8	Vaginal cancer with tumor confined to the vagina, measuring 2.0 cm or less. (from AJCC 8th Ed.)			Finding	
C139645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139645>	C139643	Vaginal Cancer pT1b TNM Finding v8|Vaginal Cancer FIGO Stage I|Vaginal Carcinoma FIGO Stage I|Vaginal Carcinoma pT1b TNM Finding v8	Vaginal cancer with tumor confined to the vagina, measuring more than 2.0 cm. (from AJCC 8th Ed.)			Finding	
C139646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139646>	C139640	Vaginal Cancer pT2 TNM Finding v8|Vaginal Cancer FIGO Stage II|Vaginal Carcinoma FIGO Stage II|Vaginal Carcinoma pT2 TNM Finding v8	Vaginal cancer with tumor invading paravaginal tissues but not to pelvic sidewall. (from AJCC 8th Ed.)			Finding	
C139647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139647>	C139646	Vaginal Cancer pT2a TNM Finding v8|Vaginal Cancer FIGO Stage II|Vaginal Carcinoma FIGO Stage II|Vaginal Carcinoma pT2a TNM Finding v8	Vaginal cancer with tumor invading paravaginal tissues but not to pelvic wall, measuring 2.0 cm or less. (from AJCC 8th Ed.)			Finding	
C139648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139648>	C139646	Vaginal Cancer pT2b TNM Finding v8|Vaginal Cancer FIGO Stage II|Vaginal Carcinoma FIGO Stage II|Vaginal Carcinoma pT2b TNM Finding v8	Vaginal cancer with tumor invading paravaginal tissues but not to pelvic wall, measuring more than 2.0 cm. (from AJCC 8th Ed.)			Finding	
C139649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139649>	C139640	Vaginal Cancer pT3 TNM Finding v8|Vaginal Cancer FIGO Stage III|Vaginal Carcinoma FIGO Stage III|Vaginal Carcinoma pT3 TNM Finding v8	Vaginal cancer with tumor extending to the pelvic sidewall and/or involving the lower third of the vagina and/or causing hydronephrosis or nonfunctioning kidney. Pelvic sidewall is defined as the muscle, fascia, neurovascular structures, or skeletal portions of the bony pelvis. (from AJCC 8th Ed.)			Finding	
C13964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13964>	C13432	10q21.1	A chromosome band present on 10q			Gene or Genome	
C139650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139650>	C139640	Vaginal Cancer pT4 TNM Finding v8|Vaginal Cancer FIGO Stage IVA|Vaginal Carcinoma FIGO Stage IVA|Vaginal Carcinoma pT4 TNM Finding v8	Vaginal cancer with tumor invading the mucosa of the bladder or rectum and/or extending beyond the true pelvis (bullous edema is not sufficient evidence to classify a tumor as T4). (from AJCC 8th Ed.)			Finding	
C139651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139651>	C2846	Alpha-glucosidase Inhibitor|AGI|AGIs|Alpha-Glucosidase Inhibitor	Any agent that inhibits the enzyme alpha-glucosidase located in the intestines. This prevents the breakdown of complex carbohydrates to glucose and other monosaccharides, which results in decreased intestinal absorption of monosaccharides.			Chemical Viewed Functionally	GDC Terminology|GDC Value Terminology
C139652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139652>	C139637	Vaginal Cancer Pathologic Regional Lymph Nodes TNM Finding v8|Vaginal Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of vaginal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C139653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139653>	C139652	Vaginal Cancer pNX TNM Finding v8|Vaginal Carcinoma pNX TNM Finding v8	Vaginal cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C139654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139654>	C139652	Vaginal Cancer pN0 TNM Finding v8|Vaginal Carcinoma pN0 TNM Finding v8	Vaginal cancer with no regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C139655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139655>	C139654	Vaginal Cancer pN0(i+) TNM Finding v8|Vaginal Carcinoma pN0(i+) TNM Finding v8	Vaginal cancer with isolated tumor cells in regional lymph node(s) no greater than 0.2 mm. (from AJCC 8th Ed.)			Finding	
C139656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139656>	C139652	Vaginal Cancer pN1 TNM Finding v8|Vaginal Cancer FIGO Stage III|Vaginal Carcinoma FIGO Stage III|Vaginal Carcinoma pN1 TNM Finding v8	Vaginal cancer with pelvic or inguinal lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C139657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139657>	C3917	Vaginal Cancer by AJCC v8 Stage|Vaginal Carcinoma by AJCC v8 Stage	A term that refers to the staging of vaginal cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to all carcinomas of the vagina. There is no AJCC staging system for mucosal melanoma of the vagina. (from AJCC 8th Ed.)			Neoplastic Process	
C139658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139658>	C139657	Stage I Vaginal Cancer AJCC v8|Stage I Vaginal Cancer|Stage I Vaginal Carcinoma AJCC v8	Stage I includes: IA: T1a, N0, M0; IB: T1b, N0, M0. T1a: Tumor confined to the vagina, measuring 2.0 cm or less. T1b: Tumor confined to the vagina, measuring more than 2.0 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage I Vaginal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139659>	C139658	Stage IA Vaginal Cancer AJCC v8|Stage IA Vaginal Cancer|Stage IA Vaginal Carcinoma AJCC v8	Stage IA includes: T1a, N0, M0. T1a: Tumor confined to the vagina, measuring 2.0 cm or less. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IA Vaginal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13965>	C13379	Trefoil Motif|P Domain|P-Type Domain|TFF Domain|Trefoil|Trefoil Domain	Domain found in various secretory polypeptides that has highly conserved cysteine residues that are disulfide bonded in such a way as to generate a trefoil structure (bonded 1-5, 2-4, 3-6). There are also highly conserved A, G and W residues. (The Dictionary of Cell and Molecular Biology - Online)			Amino Acid Sequence	
C139660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139660>	C139658	Stage IB Vaginal Cancer AJCC v8|Stage IB Vaginal Cancer|Stage IB Vaginal Carcinoma AJCC v8	Stage IB includes: T1b, N0, M0. T1b: Tumor confined to the vagina, measuring more than 2.0 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IB Vaginal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139661>	C139657	Stage II Vaginal Cancer AJCC v8|Stage II Vaginal Cancer|Stage II Vaginal Carcinoma AJCC v8	Stage II includes: IIA: T2a, N0, M0; IIB: T2b, N0, M0. T2a: Tumor invading paravaginal tissues but not to pelvic wall, measuring 2.0 cm or less. T2b: Tumor invading paravaginal tissues but not to pelvic wall, measuring more than 2.0 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage II Vaginal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139662>	C139661	Stage IIA Vaginal Cancer AJCC v8|Stage IIA Vaginal Cancer|Stage IIA Vaginal Carcinoma AJCC v8	Stage IIA includes: T2a, N0, M0. T2a: Tumor invading paravaginal tissues but not to pelvic wall, measuring 2.0 cm or less. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIA Vaginal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139663>	C28510	CIC/DUX4 Fusion Gene|CIC-DUX4|CIC-DUX4 Fusion Gene|CIC::DUX4 Fusion Gene|Capicua Homolog (Drosophila)/Double Homeobox 4 Fusion Gene|Capicua Transcriptional Repressor/Double Homeobox 4 Fusion Gene|t(4;19)/CIC-DUX4 Fusion Gene	A fusion gene that results from a chromosomal translocation t(4;19)(q35;q13) which fuses exon 20 of the CIC gene to exon 1 of the DUX4 gene. This fusion is associated with soft tissue sarcoma.	CIC/DUX4 Fusion Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|EWS Authorized Value Terminology|EWS Molecular Analysis Table
C139664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139664>	C139661	Stage IIB Vaginal Cancer AJCC v8|Stage IIB Vaginal Cancer|Stage IIB Vaginal Carcinoma AJCC v8	Stage IIB includes: T2b, N0, M0. T2b: Tumor invading paravaginal tissues but not to pelvic wall, measuring more than 2.0 cm. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIB Vaginal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139665>	C139657	Stage III Vaginal Cancer AJCC v8|Stage III Vaginal Cancer|Stage III Vaginal Carcinoma AJCC v8	Stage III includes: (T1-T3, N1, M0); (T3, N0, M0). T1: Tumor confined to the vagina. T2: Tumor invading paravaginal tissues but not to pelvic sidewall. T3: Tumor extending to the pelvic sidewall and/or involving the lower third of the vagina and/or causing hydronephrosis or nonfunctioning kidney. N0: No regional lymph node metastasis. N1: Pelvic or inguinal lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage III Vaginal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139666>	C28510	BCOR/CCNB3 Fusion Gene|BCL6 Corepresso-Cyclin B3 Fusion Gene|BCL6 Corepressor/Cyclin B3 Fusion Gene|BCOR-CCNB3 Fusion Gene|BCOR::CCNB3 Fusion Gene|CCNB3-BCOR	A fusion gene that results from a paracentric chromosomal inversion inv(X)(p11.4;p11.22) which fuses the stop codon of the BCOR gene to exon 5 of the CCNB3 gene. This fusion is associated with bone sarcomas.	BCOR/CCNB3 Fusion Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|EWS Authorized Value Terminology|EWS Molecular Analysis Table
C139667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139667>	C139657	Stage IV Vaginal Cancer AJCC v8|Stage IV Vaginal Cancer|Stage IV Vaginal Carcinoma AJCC v8	Stage IV includes: IVA: T4, Any N, M0; IVB: Any T, Any N, M1. T4: Tumor invading the mucosa of the bladder or rectum and/or extending beyond the true pelvis (bullous edema is not sufficient evidence to classify a tumor as T4). M0: No distant metastasis. M1: Distant metastasis. (from AJCC 8th Ed.)	Stage IV Vaginal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139668>	C201195	EWSR1/PBX1 Fusion Gene|EWS-PBX1 Fusion Gene|EWS/PBX1 Fusion Gene|EWSR1-PBX1|EWSR1-PBX1 Fusion Gene|EWSR1::PBX1 Fusion Gene	A fusion gene that results from a chromosomal translocation t(1;22)(q23;q12) which fuses exon 8 of the EWSR1 gene to exon 5 of the PBX1 gene. This fusion may be associated with myoepithelioma.			Gene or Genome	EWS Authorized Value Terminology|EWS Molecular Analysis Table
C139669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139669>	C139667	Stage IVA Vaginal Cancer AJCC v8|Stage IVA Vaginal Cancer|Stage IVA Vaginal Carcinoma AJCC v8	Stage IVA includes: T4, Any N, M0. T4: Tumor invading the mucosa of the bladder or rectum and/or extending beyond the true pelvis (bullous edema is not sufficient evidence to classify a tumor as T4). M0: No distant metastasis. (from AJCC 8th Ed.)	Stage IVA Vaginal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13966>	C13432	18p11.32	A chromosome band present on 18p			Gene or Genome	
C139670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139670>	C139667	Stage IVB Vaginal Cancer AJCC v8|Stage IVB Vaginal Cancer|Stage IVB Vaginal Carcinoma AJCC v8	Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis. (from AJCC 8th Ed.)	Stage IVB Vaginal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139671>	C25840	CCNB3 Gene|CCNB3|CCNB3|Cyclin B3 Gene	This gene plays a role in the regulation of mitosis and meiosis.	CCNB3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C139673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139673>	C139671	CCNB3 wt Allele|CYCB3|Cyclin B3 wt Allele	Human CCNB3 wild-type allele is located in the vicinity of Xp11.22 and is approximately 149 kb in length. This allele, which encodes G2/mitotic-specific cyclin-B3 protein, is involved in the progression of the cell cycle. A paracentric chromosomal inversion inv(X)(p11.4;p11.22) fuses this gene and the BCOR gene; this fusion is associated with bone sarcomas.	CCNB3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C139674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139674>	C19151	Oligometastasis|oligometastasis	A disease state that refers to a limited number of clinically detectable metastases, an intermediate state between purely localized disease and widespread metastases.	Oligometastasis		Pathologic Function	CTRP Disease Terminology|CTRP Terminology
C139675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139675>	C17349	G2/Mitotic-Specific Cyclin-B3|CCNB3|Cyclin B3|Cyclin-B3|G2/Mitotic-Specific Cyclin B3	G2/mitotic-specific cyclin-B3 (1395 aa, ~158 kDa) is encoded by the human CCNB3 gene. This protein plays a role in cell cycle regulation.	G2/Mitotic-Specific Cyclin-B3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C139676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139676>	C17561	CIC/DUX4 Fusion Protein|CIC-DUX4 Fusion Protein|CIC::DUX4 Fusion Protein|Protein Capicua Homolog/Double Homeobox 4 Fusion Protein|Protein Capicua Homolog::Double Homeobox 4 Fusion Protein	A fusion protein encoded by the CIC/DUX4 fusion gene. This protein is comprised of the majority of the protein capicua homolog, including the DNA-binding high-mobility group (HMG)-box and 15 of 16 putative MAPK phosphorylation sites, fused to the C-terminus of double homeobox protein 4, which results in the loss of both of its DNA-binding homeodomains.	CIC/DUX4 Fusion Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C139677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139677>	C17561	BCOR/CCNB3 Fusion Protein|BCL6 Co-Repressor/Cyclin B3 Fusion Protein|BCL6 Co-Repressor/Cyclin-B3 Fusion Protein|BCL6 Co-Repressor/G2/Mitotic-Specific Cyclin-B3 Fusion Protein|BCL6 Co-Repressor::G2/Mitotic-Specific Cyclin-B3 Fusion Protein|BCOR-CCNB3 Fusion Protein|BCOR::CCNB3 Fusion Protein	A fusion protein encoded by the BCOR/CCNB3 fusion gene. This protein is comprised of the BCL6 co-repressor protein, which includes its three ankyrin domains, fused to the C-terminal portion of the G2/mitotic-specific cyclin-B3, which includes its two cyclin domains.	BCOR/CCNB3 Fusion Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C139678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139678>	C17561	EWSR1/PBX1 Fusion Protein|EWS-PBX1 Fusion Protein|EWS/PBX1 Fusion Protein|EWSR1-PBX1 Fusion Protein|EWSR1::PBX1 Fusion Protein|RNA-Binding Protein EWS/Pre-B-Cell Leukemia Pre-Transcription Factor 1 Fusion Protein	A fusion protein encoded by the EWSR1/PBX1 fusion gene. This protein is comprised of the transactivation domain of the RNA-binding protein EWS fused to the C-terminal DNA binding homeodomain of the pre-B-cell leukemia transcription factor 1 protein.			Amino Acid, Peptide, or Protein	
C139679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139679>	C226739	Used Someone Else's Smartphone or Tablet|Someone else's smartphone or tablet	A response indicating that an individual used a smartphone or tablet other than their own, a friend or family member's, or the clinic's.			Intellectual Product	
C13967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13967>	C13379	Coiled-Coil Domain|4-3 Hydrophobic Repeat|Coiled Coil|Coiled Coil Domain|Coiled-Coil|Left-Handed Twist	A domain that stabilizes alpha helices in proteins through a very efficient burial of hydrophobic side chains so that polar water molecules do not access them. As a result, the helices are quite stable. In fact, many structural proteins (keratins, tropomyosin, laminin) that have to bear considerable stress have a coiled-coil domain. Two basic essential features are common: (1) the overall secondary structure is alpha helical, (2) the hydrophobic residues are arranged on one side of the helices. The typical positioning of the hydrophobic residues in the coiled-coil domain can be often recognized from primary structure of the protein. The helices can be parallel or antiparallel. The former is common when the helices belong to different polypeptides and the latter prevails in coiled coils made up from a single polypeptide chain. The number of helices in the coil varies usually between 2 and 4.			Amino Acid Sequence	
C139680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139680>	C15292	Stepped Palliative Care	A form of palliative care where all patients receive care for their condition, but with a minimum of required contact with specialty trained clinician and more intensive treatment reserved for those who do not benefit sufficiently from the less intensive treatments. A key element of this model is that patients must be monitored systematically and "stepped up" to more intensive treatment if the minimal level of care does not achieve sufficient health gains.	Stepped Palliative Care		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C139681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139681>	C7056|C216069	Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma	Histologic transformation of a follicular lymphoma to an aggressive diffuse large B-cell lymphoma.	Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139682>	C139589	Cervical Cancer TNM Finding v8|Cervical Carcinoma TNM Finding v8	A finding about one or more characteristics of cervical cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C139683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139683>	C139682	Cervical Cancer Clinical TNM Finding v8|Cervical Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of cervical cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C139684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139684>	C139683	Cervical Cancer Clinical Distant Metastasis TNM Finding v8|Cervical Carcinoma Clinical Distant Metastasis TNM Finding v8|Clinical Distant Metastasis Status (cM)	A clinical finding about one or more characteristics of cervical cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C139685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139685>	C139684	Cervical Cancer cM0 TNM Finding v8|Cervical Carcinoma cM0 TNM Finding v8	Cervical cancer in which there is no evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C139686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139686>	C139684	Cervical Cancer cM1 TNM Finding v8|Cervical Cancer FIGO Stage IVB|Cervical Carcinoma FIGO Stage IVB|Cervical Carcinoma cM1 TNM Finding v8|cM1	Cervical cancer with distant metastasis (including peritoneal spread or involvement of the supraclavicular, mediastinal, or distant lymph nodes; lung; liver; or bone). (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C139687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139687>	C139683	Cervical Cancer Clinical Primary Tumor TNM Finding v8|Cervical Carcinoma Clinical Primary Tumor TNM Finding v8	A clinical finding about one or more characteristics of cervical cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C139688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139688>	C139687	Cervical Cancer cTX TNM Finding v8|Cervical Carcinoma cTX TNM Finding v8	Cervical cancer in which primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C139689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139689>	C139687	Cervical Cancer cT0 TNM Finding v8|Cervical Carcinoma cT0 TNM Finding v8	Cervical cancer with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C13968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13968>	C13432	8p23.1	A chromosome band present on 8p			Gene or Genome	
C139690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139690>	C139687	Cervical Cancer cT1 TNM Finding v8|Cervical Cancer FIGO Stage I|Cervical Carcinoma FIGO Stage I|Cervical Carcinoma cT1 TNM Finding v8	Cervical carcinoma confined to uterus (extension to corpus should be disregarded). (from AJCC 8th Ed.)			Finding	
C139691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139691>	C139690	Cervical Cancer cT1b TNM Finding v8|Cervical Cancer FIGO Stage IB|Cervical Carcinoma FIGO Stage IB|Cervical Carcinoma cT1b TNM Finding v8	Cervical cancer with clinically visible lesion confined to the cervix. (from AJCC 8th Ed.)			Finding	
C139692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139692>	C139691	Cervical Cancer cT1b1 TNM Finding v8|Cervical Cancer FIGO Stage IB1|Cervical Carcinoma FIGO Stage IB1|Cervical Carcinoma cT1b1 TNM Finding v8	Cervical cancer with clinically visible lesion 4.0 cm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C139693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139693>	C139691	Cervical Cancer cT1b2 TNM Finding v8|Cervical Cancer FIGO Stage IB2|Cervical Carcinoma FIGO Stage IB2|Cervical Carcinoma cT1b2 TNM Finding v8	Cervical cancer with clinically visible lesion more than 4.0 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C139694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139694>	C139687	Cervical Cancer cT2 TNM Finding v8|Cervical Cancer FIGO Stage II|Cervical Carcinoma FIGO Stage II|Cervical Carcinoma cT2 TNM Finding v8	Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina. (from AJCC 8th Ed.)			Finding	
C139695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139695>	C139694	Cervical Cancer cT2a TNM Finding v8|Cervical Cancer FIGO Stage IIA|Cervical Carcinoma FIGO Stage IIA|Cervical Carcinoma cT2a TNM Finding v8	Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina without parametrial invasion. (from AJCC 8th Ed.)			Finding	
C139696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139696>	C139695	Cervical Cancer cT2a1 TNM Finding v8|Cervical Cancer FIGO Stage IIA1|Cervical Carcinoma FIGO Stage IIA1|Cervical Carcinoma cT2a1 TNM Finding v8	Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina without parametrial invasion. Clinically visible lesion 4.0 cm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C139697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139697>	C139695	Cervical Cancer cT2a2 TNM Finding v8|Cervical Cancer FIGO Stage IIA2|Cervical Carcinoma FIGO Stage IIA2|Cervical Carcinoma cT2a2 TNM Finding v8	Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina without parametrial invasion. Clinically visible lesion more than 4.0 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C139698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139698>	C139694	Cervical Cancer cT2b TNM Finding v8|Cervical Cancer FIGO Stage IIB|Cervical Carcinoma FIGO Stage IIB|Cervical Carcinoma cT2b TNM Finding v8	Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina with parametrial invasion. (from AJCC 8th Ed.)			Finding	
C139699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139699>	C139687	Cervical Cancer cT3 TNM Finding v8|Cervical Cancer FIGO Stage III|Cervical Carcinoma FIGO Stage III|Cervical Carcinoma cT3 TNM Finding v8	Cervical cancer extending to pelvic sidewall and/or involving the lower third of vagina, and/or causing hydronephrosis or nonfunctioning kidney. The pelvic sidewall is defined as the muscle, fascia, neurovascular structures, and skeletal portions of the bony pelvis. (from AJCC 8th Ed.)			Finding	
C13969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13969>	C13432	9p23	A chromosome band present on 9p			Gene or Genome	
C139700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139700>	C139699	Cervical Cancer cT3a TNM Finding v8|Cervical Cancer FIGO Stage IIIA|Cervical Carcinoma FIGO Stage IIIA|Cervical Carcinoma cT3a TNM Finding v8	Cervical cancer involving the lower third of vagina but not extending to pelvic wall. (from AJCC 8th Ed.)			Finding	
C139701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139701>	C139699	Cervical Cancer cT3b TNM Finding v8|Cervical Cancer FIGO Stage IIIB|Cervical Carcinoma FIGO Stage IIIB|Cervical Carcinoma cT3b TNM Finding v8	Cervical cancer extending to pelvic wall and/or causing hydronephrosis or nonfunctioning kidney. (from AJCC 8th Ed.)			Finding	
C139702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139702>	C139687	Cervical Cancer cT4 TNM Finding v8|Cervical Cancer FIGO Stage IVA|Cervical Carcinoma FIGO Stage IVA|Cervical Carcinoma cT4 TNM Finding v8	Cervical cancer invading the mucosa of the bladder or rectum, and/or extending beyond the true pelvis (bullous edema is not sufficient to classify a tumor as T4). (from AJCC 8th Ed.)			Finding	
C139703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139703>	C139682	Cervical Cancer Pathologic TNM Finding v8|Cervical Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of cervical cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C139704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139704>	C139703	Cervical Cancer Pathologic Distant Metastasis TNM Finding v8|Cervical Carcinoma Pathologic Distant Metastasis TNM Finding v8|Pathologic Distant Metastasis Status (pM)	A pathologic finding about one or more characteristics of cervical cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C139705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139705>	C139704	Cervical Cancer pM1 TNM Finding v8|Cervical Cancer FIGO Stage IVB|Cervical Carcinoma FIGO Stage IVB|Cervical Carcinoma pM1 TNM Finding v8|pM1	Cervical cancer with distant metastasis (including peritoneal spread or involvement of the supraclavicular, mediastinal, or distant lymph nodes; lung; liver; or bone). (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C139706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139706>	C139703	Cervical Cancer Pathologic Primary Tumor TNM Finding v8|Cervical Carcinoma Pathologic Primary Tumor TNM Finding v8|Pathologic Primary Tumor Status (pT)	A pathologic finding about one or more characteristics of cervical cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C139707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139707>	C139706	Cervical Cancer pTX TNM Finding v8|Cervical Carcinoma pTX TNM Finding v8|pTX	Cervical cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C139708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139708>	C139706	Cervical Cancer pT0 TNM Finding v8|Cervical Carcinoma pT0 TNM Finding v8|pT0	Cervical cancer with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C139709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139709>	C139706	Cervical Cancer pT1 TNM Finding v8|Cervical Cancer FIGO Stage I|Cervical Carcinoma FIGO Stage I|Cervical Carcinoma pT1 TNM Finding v8|pT1	Cervical carcinoma confined to uterus (extension to corpus should be disregarded). (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C13970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13970>	C13314	26S ATP-Dependent Proteasome|26S ATP-Dependent Protease|26S Proteasome|26S Proteasome Complex|26S Proteosome	Proteasomes are large multicatalytic proteolytic complexes found in all eukaryotic cells, and simpler forms have been found in archaebacteria and certain eubacteria.  In eukaryotes, the 20S proteasome also exists as the central core of the 26S (2000 kDa) proteasome complex, which catalyzes the degradation of ubiquitin-conjugated proteins and contains an additional 19S complex, composed of regulatory proteins and six ATPases.	26S ATP-Dependent Proteasome		Amino Acid, Peptide, or Protein|Cell Component	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C139710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139710>	C139709	Cervical Cancer pT1a TNM Finding v8|Cervical Cancer FIGO Stage IA|Cervical Carcinoma FIGO Stage IA|Cervical Carcinoma pT1a TNM Finding v8|pT1a	Invasive cervical carcinoma diagnosed only by microscopy. Stromal invasion with a maximum depth of 5.0 mm measured from the base of the epithelium and a horizontal spread of 7.0 mm or less. Vascular space involvement, venous or lymphatic, does not affect classification. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C139711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139711>	C139710	Cervical Cancer pT1a1 TNM Finding v8|Cervical Cancer FIGO Stage IA1|Cervical Carcinoma FIGO Stage IA1|Cervical Carcinoma pT1a1 TNM Finding v8|pT1a1	Invasive cervical carcinoma with measured stromal invasion of 3.0 mm or less in depth and 7.0 mm or less in horizontal spread. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C139712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139712>	C139710	Cervical Cancer pT1a2 TNM Finding v8|Cervical Cancer FIGO Stage IA2|Cervical Carcinoma FIGO Stage IA2|Cervical Carcinoma pT1a2 TNM Finding v8|pT1a2	Invasive cervical carcinoma with measured stromal invasion of more than 3.0 mm and not more than 5.0 mm, with a horizontal spread of 7.0 mm or less. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C139713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139713>	C139709	Cervical Cancer pT1b TNM Finding v8|Cervical Cancer FIGO Stage IB|Cervical Carcinoma FIGO Stage IB|Cervical Carcinoma pT1b TNM Finding v8|pT1b	Cervical cancer with clinically visible lesion confined to the cervix or microscopic lesion greater than T1a/IA2. It includes all macroscopically visible lesions, even those with superficial invasion. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C139714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139714>	C139713	Cervical Cancer pT1b1 TNM Finding v8|Cervical Cancer FIGO Stage IB1|Cervical Carcinoma FIGO Stage IB1|Cervical Carcinoma pT1b1 TNM Finding v8|pT1b1	Cervical cancer with clinically visible lesion 4.0 cm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C139715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139715>	C139713	Cervical Cancer pT1b2 TNM Finding v8|Cervical Cancer FIGO Stage IB2|Cervical Carcinoma FIGO Stage IB2|Cervical Carcinoma pT1b2 TNM Finding v8|pT1b2	Cervical cancer with clinically visible lesion more than 4.0 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C139716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139716>	C139706	Cervical Cancer pT2 TNM Finding v8|Cervical Cancer FIGO Stage II|Cervical Carcinoma FIGO Stage II|Cervical Carcinoma pT2 TNM Finding v8|pT2	Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C139717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139717>	C139716	Cervical Cancer pT2a TNM Finding v8|Cervical Cancer FIGO Stage IIA|Cervical Carcinoma FIGO Stage IIA|Cervical Carcinoma pT2a TNM Finding v8|pT2a	Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina without parametrial invasion. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C139718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139718>	C139717	Cervical Cancer pT2a1 TNM Finding v8|Cervical Cancer FIGO Stage IIA1|Cervical Carcinoma FIGO Stage IIA1|Cervical Carcinoma pT2a1 TNM Finding v8|pT2a1	Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina without parametrial invasion. Clinically visible lesion 4.0 cm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C139719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139719>	C139717	Cervical Cancer pT2a2 TNM Finding v8|Cervical Cancer FIGO Stage IIA2|Cervical Carcinoma FIGO Stage IIA2|Cervical Carcinoma pT2a2 TNM Finding v8|pT2a2	Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina without parametrial invasion. Clinically visible lesion more than 4.0 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C13971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13971>	C13432	8q21-q24	A chromosome band present on 8q			Gene or Genome	
C139720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139720>	C139716	Cervical Cancer pT2b TNM Finding v8|Cervical Cancer FIGO Stage IIB|Cervical Carcinoma FIGO Stage IIB|Cervical Carcinoma pT2b TNM Finding v8|pT2b	Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina with parametrial invasion. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C139721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139721>	C139706	Cervical Cancer pT3 TNM Finding v8|Cervical Cancer FIGO Stage III|Cervical Carcinoma FIGO Stage III|Cervical Carcinoma pT3 TNM Finding v8|pT3	Cervical cancer extending to pelvic sidewall and/or involving the lower third of vagina, and/or causing hydronephrosis or nonfunctioning kidney. The pelvic sidewall is defined as the muscle, fascia, neurovascular structures, and skeletal portions of the bony pelvis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C139722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139722>	C139721	Cervical Cancer pT3a TNM Finding v8|Cervical Cancer FIGO Stage IIIA|Cervical Carcinoma FIGO Stage IIIA|Cervical Carcinoma pT3a TNM Finding v8|pT3a	Cervical cancer involving the lower third of vagina but not extending to pelvic wall. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C139723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139723>	C139721	Cervical Cancer pT3b TNM Finding v8|Cervical Cancer FIGO Stage IIIB|Cervical Carcinoma FIGO Stage IIIB|Cervical Carcinoma pT3b TNM Finding v8|pT3b	Cervical cancer extending to pelvic wall and/or causing hydronephrosis or nonfunctioning kidney. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C139724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139724>	C139706	Cervical Cancer pT4 TNM Finding v8|Cervical Cancer FIGO Stage IVA|Cervical Carcinoma FIGO Stage IVA|Cervical Carcinoma pT4 TNM Finding v8|pT4	Cervical cancer invading the mucosa of the bladder or rectum, and/or extending beyond the true pelvis (bullous edema is not sufficient to classify a tumor as T4). (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C139725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139725>	C139703	Cervical Cancer Pathologic Regional Lymph Nodes TNM Finding v8|Cervical Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8|Pathologic Regional Lymph Node Status (pN)	A pathologic finding about one or more characteristics of cervical cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C139726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139726>	C139725	Cervical Cancer pNX TNM Finding v8|Cervical Carcinoma pNX TNM Finding v8|pNX	Cervical cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C139727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139727>	C139725	Cervical Cancer pN0 TNM Finding v8|Cervical Carcinoma pN0 TNM Finding v8|pN0	Cervical cancer with no regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C139728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139728>	C139727	Cervical Cancer pN0(i+) TNM Finding v8|Cervical Carcinoma pN0(i+) TNM Finding v8|pN0(i+)	Cervical cancer with isolated tumor cells in regional lymph node(s) no greater than 0.2 mm. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C139729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139729>	C139725	Cervical Cancer pN1 TNM Finding v8|Cervical Carcinoma pN1 TNM Finding v8|pN1	Cervical cancer with regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C13972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13972>	C13432	2p14-p13	A chromosome band present on 2p			Gene or Genome	
C139730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139730>	C28681|C213868	Autologous ACTR-CD16-CD28-expressing T-lymphocytes ACTR707|ACTR707|ACTR707 Cells|ACTR707 T-cells	A preparation of autologous T-lymphocytes that have been genetically modified, using proprietary Antibody-Coupled T-cell Receptor (ACTR) technology, to express a chimeric protein containing, at least, the extracellular Fc receptor domain of CD16, normally found on certain immune cells, such as natural killer (NK) cells, coupled to the co-stimulatory signaling domain of CD28, with potential immunostimulating and antineoplastic activities. Upon reintroduction into the patient with co-administration of a cancer-specific antibody, the co-administered antibody targets and binds to the tumor-associated antigen (TAA) expressed on the tumor cell. In turn, the autologous ACTR-CD16-CD28-expressing T-lymphocytes ACTR707 bind to the antibody, become activated and induce the destruction of the tumor cells by a) releasing cytotoxins that directly kill cancer cells; b) releasing cytokines that trigger an immune response and recruit other immune-mediated killer cells to kill the tumor cells; c) targeting and killing adjacent tumor cells that are not bound to the antibody; d) inducing T-cell proliferation and thereby further enhancing the T-cell mediated tumor cell attack. Compared to other T-cell products, ACTR-based products do not target a specific TAA and can potentially be used in a variety of tumors because targeting is based on the specificity of the co-administered antibody.	Autologous ACTR-CD16-CD28-expressing T-lymphocytes ACTR707		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C139731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139731>	C201195	EWSR1/ZNF444 Fusion Gene|EWS-ZNF444 Fusion Gene|EWS/ZNF444 Fusion Gene|EWSR1-ZNF444|EWSR1-ZNF444 Fusion Gene|EWSR1::ZNF444 Fusion Gene	A fusion gene that results from a chromosomal translocation t(19;22)(q13;q12) which fuses exon 8 of the EWSR1 gene to exon 5 of the ZNF444 gene. This fusion may be associated with myoepithelioma.			Gene or Genome	EWS Authorized Value Terminology|EWS Molecular Analysis Table
C139732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139732>	C17561	EWSR1/ZNF444 Fusion Protein|EWS-ZNF444 Fusion Protein|EWS/ZNF444 Fusion Protein|EWSR1-ZNF444 Fusion Protein|EWSR1::ZNF444 Fusion Protein|RNA-Binding Protein EWS/Zinc Finger Protein 444 Fusion Protein	A fusion protein encoded by the EWSR1/ZNF444 fusion gene. This protein is comprised of the transactivation domain of the RNA-binding protein EWS fused to the last six C-terminal amino acids of zinc finger protein 444.			Amino Acid, Peptide, or Protein	
C139733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139733>	C9039	Cervical Cancer by AJCC v8 Stage|Cervical Carcinoma by AJCC v8 Stage	A term that refers to the staging of cervical cancer according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C139734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139734>	C139733	Stage I Cervical Cancer AJCC v8|I|Stage I Cervical Cancer|Stage I Cervical Carcinoma AJCC v8	Stage I includes: T1, Any N, M0. T1: Tumor confined to uterus (extension to corpus should be disregarded). M0: No distant metastasis. (AJCC 8th Ed.)	Stage I Cervical Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C139735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139735>	C139734	Stage IA Cervical Cancer AJCC v8|IA|Stage IA Cervical Cancer|Stage IA Cervical Carcinoma AJCC v8	Stage IA includes: T1a, Any N, M0. T1a: Tumor diagnosed only by microscopy. Stromal invasion with a maximum depth of 5.0 mm measured from the base of the epithelium and a horizontal spread of 7.0 mm or less. Vascular space involvement, venous or lymphatic, does not affect classification. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IA Cervical Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C139736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139736>	C139735	Stage IA1 Cervical Cancer AJCC v8|IA1|Stage IA1 Cervical Cancer|Stage IA1 Cervical Carcinoma AJCC v8	Stage IA1 includes: T1a1, Any N, M0. T1a1: Invasive cervical carcinoma with measured stromal invasion of 3.0 mm or less in depth and 7.0 mm or less in horizontal spread. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IA1 Cervical Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C139737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139737>	C139735	Stage IA2 Cervical Cancer AJCC v8|IA2|Stage IA2 Cervical Cancer|Stage IA2 Cervical Carcinoma AJCC v8	Stage IA2 includes: T1a2, Any N, M0. T1a2: Invasive cervical carcinoma with measured stromal invasion of more than 3.0 mm and not more than 5.0 mm, with a horizontal spread of 7.0 mm or less. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IA2 Cervical Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C139738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139738>	C139734	Stage IB Cervical Cancer AJCC v8|IB|Stage IB Cervical Cancer|Stage IB Cervical Carcinoma AJCC v8	Stage IB includes: T1b, Any N, M0. T1b: Tumor with clinically visible lesion confined to the cervix or microscopic lesion greater than T1a/IA2. It includes all macroscopically visible lesions, even those with superficial invasion. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IB Cervical Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C139739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139739>	C139738	Stage IB1 Cervical Cancer AJCC v8|IB1|Stage IB1 Cervical Cancer|Stage IB1 Cervical Carcinoma AJCC v8	Stage IB1 includes: T1b1, Any N, M0. T1b1: Tumor with clinically visible lesion 4.0 cm or less in greatest dimension. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IB1 Cervical Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C13973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13973>	C13432	1q32-q41	A chromosome band present on 1q			Gene or Genome	
C139740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139740>	C139738	Stage IB2 Cervical Cancer AJCC v8|IB2|Stage IB2 Cervical Cancer|Stage IB2 Cervical Carcinoma AJCC v8	Stage IB2 includes: T1b2, Any N, M0. T1b2: Tumor with clinically visible lesion more than 4.0 cm in greatest dimension. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IB2 Cervical Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C139742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139742>	C137858	Status of Tumor Eligibility for Definitive Local Therapy Question|Status of Tumor|Status of Tumor Eligibility for Definitive Local Therapy	The status of a tumor based on its characteristics, such as morphology, location, size, presence or absence of carcinoma in situ, vascular invasion, metastasis, and other empirical features with or without biological and molecular basis, that is eligible for definitive local therapy (e.g. surgery, radiation or ablation that is chosen as the primary treatment modality).			Intellectual Product	
C139743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139743>	C139733	Stage II Cervical Cancer AJCC v8|II|Stage II Cervical Cancer|Stage II Cervical Carcinoma AJCC v8	Stage II includes: T2, Any N, M0. T2: Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina. M0: No distant metastasis. (AJCC 8th Ed.)	Stage II Cervical Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C139744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139744>	C139743	Stage IIA Cervical Cancer AJCC v8|IIA|Stage IIA Cervical Cancer|Stage IIA Cervical Carcinoma AJCC v8	Stage IIA includes: T2a, Any N, M0. T2a: Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina without parametrial invasion. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIA Cervical Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C139745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139745>	C139744	Stage IIA1 Cervical Cancer AJCC v8|IIA1|Stage IIA1 Cervical Cancer|Stage IIA1 Cervical Carcinoma AJCC v8	Stage IIA1 includes: T2a1, Any N, M0. T2a1: Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina without parametrial invasion. Clinically visible lesion 4.0 cm or less in greatest dimension. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIA1 Cervical Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C139746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139746>	C139744	Stage IIA2 Cervical Cancer AJCC v8|IIA2|Stage IIA2 Cervical Cancer|Stage IIA2 Cervical Carcinoma AJCC v8	Stage IIA2 includes: T2a2, Any N, M0. T2a2: Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina without parametrial invasion. Clinically visible lesion more than 4.0 cm in greatest dimension. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIA2 Cervical Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C139747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139747>	C25681	Biopsy Specimen Size	The physical dimensions of a biopsy specimen.			Quantitative Concept	
C139748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139748>	C139743	Stage IIB Cervical Cancer AJCC v8|IIB|Stage IIB Cervical Cancer|Stage IIB Cervical Carcinoma AJCC v8	Stage IIB includes: T2b, Any N, M0. T2b: Cervical carcinoma invading beyond the uterus but not to the pelvic wall or to lower third of vagina with parametrial invasion. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIB Cervical Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C139749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139749>	C139733	Stage III Cervical Cancer AJCC v8|III|Stage III Cervical Cancer|Stage III Cervical Carcinoma AJCC v8	Stage III includes: T3, Any N, M0. T3: Tumor extending to pelvic sidewall and/or involving the lower third of vagina, and/or causing hydronephrosis or nonfunctioning kidney. M0: No distant metastasis. (AJCC 8th Ed.)	Stage III Cervical Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C13974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13974>	C13453	TRIM Motif|RBCC/TRIM Motif|TRIM Domain|Tripartite Domain|Tripartite Motif	The TRIM motif includes three cysteine-rich zinc-binding domains, a RING finger, a B-box, and a coiled-coil region. The order of the sub-domains is conserved, with the RING finger, B-box and coiled -coil domains arranged from the N to C-terminus. However, the number of B-boxes can vary. (NCI)			Amino Acid Sequence	
C139750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139750>	C139749	Stage IIIA Cervical Cancer AJCC v8|IIIA|Stage IIIA Cervical Cancer|Stage IIIA Cervical Carcinoma AJCC v8	Stage IIIA includes: T3a, Any N, M0. T3a: Tumor involving the lower third of vagina but not extending to pelvic wall. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIIA Cervical Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C139751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139751>	C226792|C137934	Mediastinal Lymph Node Sampling	A surgical procedure in which a single or multiple mediastinal lymph nodes are removed for microscopic examination.			Diagnostic Procedure	
C139752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139752>	C139749	Stage IIIB Cervical Cancer AJCC v8|IIIB|Stage IIIB Cervical Cancer|Stage IIIB Cervical Carcinoma AJCC v8	Stage IIIB includes: T3b, Any N, M0. T3b: extending to pelvic wall and/or causing hydronephrosis or nonfunctioning kidney. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIIB Cervical Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C139753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139753>	C139733	Stage IV Cervical Cancer AJCC v8|IV|Stage IV Cervical Cancer|Stage IV Cervical Carcinoma AJCC v8	Stage IV includes: IVA: T4, Any N, M0; IVB: Any T, Any N, M1. T4: Tumor invading the mucosa of the bladder or rectum, and/or extending beyond the true pelvis (bullous edema is not sufficient to classify a tumor as T4). M0: No distant metastasis. M1: Distant metastasis (including peritoneal spread or involvement of the supraclavicular, mediastinal, or distant lymph nodes; lung; liver; or bone). (from AJCC 8th Ed.)	Stage IV Cervical Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C139754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139754>	C139753	Stage IVA Cervical Cancer AJCC v8|IVA|Stage IVA Cervical Cancer|Stage IVA Cervical Carcinoma AJCC v8	Stage IVA includes: T4, Any N, M0. T4: Tumor invading the mucosa of the bladder or rectum, and/or extending beyond the true pelvis (bullous edema is not sufficient to classify a tumor as T4). M0: No distant metastasis. (from AJCC 8th Ed.)	Stage IVA Cervical Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C139755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139755>	C139753	Stage IVB Cervical Cancer AJCC v8|IVB|Stage IVB Cervical Cancer|Stage IVB Cervical Carcinoma AJCC v8	Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis (including peritoneal spread or involvement of the supraclavicular, mediastinal, or distant lymph nodes; lung; liver; or bone). (from AJCC 8th Ed.)	Stage IVB Cervical Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C139756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139756>	C514	Isavuconazonium Sulfate|1-((2R,3R)-3-(4-(4-Cyanophenyl)-1,3-thiazol-2-yl)-2-(2,5-difluorophenyl)-2-hydroxybutyl)-4-((1RS)-1-((methyl(3-((((methylamino)acetyl)oxy)methyl)pyridin-2-yl)carbamoyl)oxy)ethyl)-1H-1,2,4-triazol-4-ium Monosulfate|BAL8557-002|Cresemba|Cresemba|Glycine, N-methyl-, (2-(((1-(1-((2R,3R)-3-(4-(4-cyanophenyl)-2-thiazolyl)-2-(2,5-difluorophenyl)-2-hydroxybutyl)-4H-1,2,4-triazolium-4-yl)ethoxy)carbonyl)methylamino)-3-pyridinyl)methyl Ester, Sulfate (1:1)|ISAVUCONAZONIUM SULFATE	The sulfate ester form of isavuconazonium, a prodrug of the triazole antifungal agent isavuconazole, with broad-spectrum antifungal activity. Upon administration, isavuconazonium sulfate is hydrolyzed by plasma esterases to yield the active moiety isavuconazole. Isavuconazole binds to and inhibits the fungal cytochrome P450 family enzyme lanosterol 14-alpha-demethylase (CYP51), which catalyzes the demethylation of lanosterol to yield ergosterol, an important component of the fungal cell membrane. Inhibition of CYP51 leads to a decrease in fungal ergosterol production and disrupts synthesis of the fungal cell membrane, which decreases membrane integrity, increases cell membrane permeability and promotes the loss of essential intracellular elements. This results in fungal cell lysis and death.	Isavuconazonium Sulfate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C139757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139757>	C173902|C139589	Uterine Corpus Carcinoma and Carcinosarcoma TNM Finding v8	A finding about one or more characteristics of uterine corpus carcinoma or carcinosarcoma, following the rules of the TNM AJCC v8 classification system. This classification system does not apply to uterine corpus sarcomas: leiomyosarcomas, endometrial stromal sarcomas, and adenosarcomas. These sarcomas are staged according to the classification for uterine corpus sarcomas. (from AJCC 8th Ed.)			Finding	
C139758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139758>	C139757	Uterine Corpus Carcinoma and Carcinosarcoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of uterine corpus carcinoma or carcinosarcoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C139759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139759>	C139758	Uterine Corpus Carcinoma and Carcinosarcoma Clinical Distant Metastasis TNM Finding v8|Clinical Staging: Distant Metastasis (cM)	A clinical finding about one or more characteristics of uterine corpus carcinoma or carcinosarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C13975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13975>	C13426	RSXpSXP Motif|RSXpSXP Domain	The 14-3-3 family of proteins mediates signal transduction by binding to phosphoserine-containing proteins. RSXpSXP Motif is one of two different binding motifs that are present in nearly all known 14-3-3 binding proteins. The14-3-3 dimer binds tightly to single molecules containing tandem repeats of phosphoserine motifs, implicating bidentate association as a signaling mechanism with molecules such as Raf, BAD, and Cbl. (from OMIM)			Amino Acid Sequence	
C139760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139760>	C139759	Uterine Corpus Carcinoma and Carcinosarcoma cM0 TNM Finding v8|cM0	Uterine corpus carcinoma or carcinosarcoma without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C139761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139761>	C139759	Uterine Corpus Carcinoma and Carcinosarcoma cM1 TNM Finding v8|Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage IVB|cM1	Uterine corpus carcinoma or carcinosarcoma with distant metastasis (includes metastasis to inguinal lymph nodes, intraperitoneal disease, lung, liver, or bone. It excludes metastasis to pelvic or para-aortic lymph nodes, vagina, uterine serosa, or adnexa). (from AJCC 8th Ed.)	Uterine Corpus Carcinoma and Carcinosarcoma cM1 TNM Finding v8		Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CTRP Disease Terminology|CTRP Terminology
C139762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139762>	C139757	Uterine Corpus Carcinoma and Carcinosarcoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of uterine corpus carcinoma or carcinosarcoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C139763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139763>	C139762	Uterine Corpus Carcinoma and Carcinosarcoma Pathologic Distant Metastasis TNM Finding v8|Pathologic Staging: Distant Metastasis (pM)	A pathologic finding about one or more characteristics of uterine corpus carcinoma or carcinosarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C139764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139764>	C139763	Uterine Corpus Carcinoma and Carcinosarcoma pM1 TNM Finding v8|Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage IVB|pM1	Uterine corpus carcinoma or carcinosarcoma with distant metastasis (includes metastasis to inguinal lymph nodes, intraperitoneal disease, lung, liver, or bone. It excludes metastasis to pelvic or para-aortic lymph nodes, vagina, uterine serosa, or adnexa). (from AJCC 8th Ed.)	Uterine Corpus Carcinoma and Carcinosarcoma pM1 TNM Finding v8		Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CTRP Disease Terminology|CTRP Terminology
C139765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139765>	C139762	Uterine Corpus Carcinoma and Carcinosarcoma Pathologic Primary Tumor TNM Finding v8|Pathologic Staging: Primary Tumor (pT)	A pathologic finding about one or more characteristics of uterine corpus carcinoma or carcinosarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor. The definitions of the T categories correspond to the stages accepted by FIGO. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C139766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139766>	C139765	Uterine Corpus Carcinoma and Carcinosarcoma pTX TNM Finding v8|pTX	Uterine corpus carcinoma or carcinosarcoma in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C139767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139767>	C139765	Uterine Corpus Carcinoma and Carcinosarcoma pT0 TNM Finding v8|pT0	Uterine corpus carcinoma or carcinosarcoma with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C139768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139768>	C139765	Uterine Corpus Carcinoma and Carcinosarcoma pT1 TNM Finding v8|Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage I|pT1 (FIGO I)	Uterine corpus carcinoma or carcinosarcoma with tumor confined to the corpus uteri, including endocervical glandular involvement. (from AJCC 8th Ed.)	Uterine Corpus Carcinoma and Carcinosarcoma pT1 TNM Finding v8		Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CTRP Disease Terminology|CTRP Terminology
C139769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139769>	C139768	Uterine Corpus Carcinoma and Carcinosarcoma pT1a TNM Finding v8|Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage IA|pT1a (FIGO IA)	Uterine corpus carcinoma or carcinosarcoma with tumor limited to the endometrium or invading less than half the myometrium. (from AJCC 8th Ed.)	Uterine Corpus Carcinoma and Carcinosarcoma pT1a TNM Finding v8		Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CTRP Disease Terminology|CTRP Terminology
C13976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13976>	C13426	RXY/FXpSXP Motif|RXY/FXpSXP Domain	The 14-3-3 family of proteins mediates signal transduction by binding to phosphoserine-containing proteins. RXY/FXpSXP Motif is one of two different binding motifs that are present in nearly all known 14-3-3 binding proteins. The14-3-3 dimer binds tightly to single molecules containing tandem repeats of phosphoserine motifs, implicating bidentate association as a signaling mechanism with molecules such as Raf, BAD, and Cbl. (from OMIM)			Amino Acid Sequence	
C139770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139770>	C139768	Uterine Corpus Carcinoma and Carcinosarcoma pT1b TNM Finding v8|Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage IB|pT1b (FIGO IB)	Uterine corpus carcinoma or carcinosarcoma with tumor invading one half or more of the myometrium. (from AJCC 8th Ed.)	Uterine Corpus Carcinoma and Carcinosarcoma pT1b TNM Finding v8		Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CTRP Disease Terminology|CTRP Terminology
C139771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139771>	C139765	Uterine Corpus Carcinoma and Carcinosarcoma pT2 TNM Finding v8|Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage II|pT2 (FIGO II)	Uterine corpus carcinoma or carcinosarcoma with tumor invading the stromal connective tissue of the cervix but not extending beyond the uterus. Does not include endocervical glandular involvement. (from AJCC 8th Ed.)	Uterine Corpus Carcinoma and Carcinosarcoma pT2 TNM Finding v8		Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CTRP Disease Terminology|CTRP Terminology
C139772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139772>	C139765	Uterine Corpus Carcinoma and Carcinosarcoma pT3 TNM Finding v8|Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage III	Uterine corpus carcinoma or carcinosarcoma with tumor involving serosa, adnexa, vagina, or parametrium. (from AJCC 8th Ed.)	Uterine Corpus Carcinoma and Carcinosarcoma pT3 TNM Finding v8		Finding	CTRP Disease Terminology|CTRP Terminology
C139773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139773>	C139772	Uterine Corpus Carcinoma and Carcinosarcoma pT3a TNM Finding v8|Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage IIIA|pT3a (FIGO IIIA)	Uterine corpus carcinoma or carcinosarcoma with tumor involving the serosa and/or adnexa (direct extension or metastasis). (from AJCC 8th Ed.)	Uterine Corpus Carcinoma and Carcinosarcoma pT3a TNM Finding v8		Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CTRP Disease Terminology|CTRP Terminology
C139774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139774>	C139772	Uterine Corpus Carcinoma and Carcinosarcoma pT3b TNM Finding v8|Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage IIIB|pT3b (FIGO IIIB)	Uterine corpus carcinoma or carcinosarcoma with vaginal involvement (direct extension or metastasis) or parametrial involvement. (from AJCC 8th Ed.)	Uterine Corpus Carcinoma and Carcinosarcoma pT3b TNM Finding v8		Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CTRP Disease Terminology|CTRP Terminology
C139775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139775>	C139765	Uterine Corpus Carcinoma and Carcinosarcoma pT4 TNM Finding v8|Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage IVA|pT4 (FIGO IVA)	Uterine corpus carcinoma or carcinosarcoma with tumor invading the bladder mucosa and/or bowel mucosa (bullous edema is not sufficient to classify a tumor as T4). (from AJCC 8th Ed.)	Uterine Corpus Carcinoma and Carcinosarcoma pT4 TNM Finding v8		Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CTRP Disease Terminology|CTRP Terminology
C139776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139776>	C139762	Uterine Corpus Carcinoma and Carcinosarcoma Pathologic Regional Lymph Nodes TNM Finding v8|Pathologic Staging: Regional Lymph Nodes (pN)	A pathologic finding about one or more characteristics of uterine corpus carcinoma or carcinosarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C139777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139777>	C139776	Uterine Corpus Carcinoma and Carcinosarcoma pNX TNM Finding v8|pNX	Uterine corpus carcinoma or carcinosarcoma in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C139778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139778>	C139776	Uterine Corpus Carcinoma and Carcinosarcoma pN0 TNM Finding v8|pN0	Uterine corpus carcinoma or carcinosarcoma with no regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C139779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139779>	C139778	Uterine Corpus Carcinoma and Carcinosarcoma pN0(i+) TNM Finding v8	Uterine corpus carcinoma or carcinosarcoma with isolated tumor cells in regional lymph node(s) no greater than 0.2 mm. (from AJCC 8th Ed.)			Finding	
C13977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13977>	C13379	Phosphoserine Motif|Phosphoserine Domain	A protein motif containing a phosphorylated serine residue. These motifs can influence both protein-protein interactions and cellular signaling.			Amino Acid Sequence	
C139780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139780>	C139776	Uterine Corpus Carcinoma and Carcinosarcoma pN1 TNM Finding v8|FIGO Stage IIIC1 Uterine Cancer|Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage IIIC1|pN1 (FIGO IIIC1)	Uterine corpus carcinoma or carcinosarcoma with regional lymph node metastasis to pelvic lymph nodes. (from AJCC 8th Ed.)	FIGO Stage IIIC1 Uterine Cancer		Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CTRP Disease Terminology|CTRP Terminology
C139781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139781>	C139780	Uterine Corpus Carcinoma and Carcinosarcoma pN1mi TNM Finding v8|Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage IIIC1	Uterine corpus carcinoma or carcinosarcoma with regional lymph node metastasis (greater than 0.2 mm but nor greater than 2.0 mm in diameter) to pelvic lymph nodes. (from AJCC 8th Ed.)	Uterine Corpus Carcinoma and Carcinosarcoma pN1mi TNM Finding v8		Finding	CTRP Disease Terminology|CTRP Terminology
C139782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139782>	C139780	Uterine Corpus Carcinoma and Carcinosarcoma pN1a TNM Finding v8|Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage IIIC1	Uterine corpus carcinoma or carcinosarcoma with regional lymph node metastasis (greater than 2.0 mm in diameter) to pelvic lymph nodes. (from AJCC 8th Ed.)	Uterine Corpus Carcinoma and Carcinosarcoma pN1a TNM Finding v8		Finding	CTRP Disease Terminology|CTRP Terminology
C139783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139783>	C139776	Uterine Corpus Carcinoma and Carcinosarcoma pN2 TNM Finding v8|FIGO Stage IIIC2 Uterine Cancer|Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage IIIC2|pN2 (FIGO IIIC2)	Uterine corpus carcinoma or carcinosarcoma with regional lymph node metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes. (from AJCC 8th Ed.)	FIGO Stage IIIC2 Uterine Cancer		Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CTRP Disease Terminology|CTRP Terminology
C139784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139784>	C139783	Uterine Corpus Carcinoma and Carcinosarcoma pN2mi TNM Finding v8|Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage IIIC2	Uterine corpus carcinoma or carcinosarcoma with regional lymph node metastasis (greater than 0.2 mm but not greater than 2.0 mm in diameter) to para-aortic lymph nodes, with or without positive pelvic lymph nodes. (from AJCC 8th Ed.)	Uterine Corpus Carcinoma and Carcinosarcoma pN2mi TNM Finding v8		Finding	CTRP Disease Terminology|CTRP Terminology
C139785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139785>	C139783	Uterine Corpus Carcinoma and Carcinosarcoma pN2a TNM Finding v8|Uterine Corpus Carcinoma and Carcinosarcoma FIGO Stage IIIC2	Uterine corpus carcinoma or carcinosarcoma with regional lymph node metastasis (greater than 2.0 mm in diameter) to para-aortic lymph nodes, with or without positive pelvic lymph nodes. (from AJCC 8th Ed.)	Uterine Corpus Carcinoma and Carcinosarcoma pN2a TNM Finding v8		Finding	CTRP Disease Terminology|CTRP Terminology
C139786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139786>	C35883	Blasts 50 Percent or Less of Bone Marrow Nucleated Cells|Blasts Less than or Equal to 50 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that 50 percent or less of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts 50 Percent or Less of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C139787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139787>	C35682|C175007	Human Anti-Mouse Antibodies Positive|HAMA Positive|Human Anti-Mouse Antibodies Present	Indicates that human anti-mouse antibodies have been detected in a sample.	Human Anti-Mouse Antibodies Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C139788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139788>	C94299|C177692	IL2RB Positive|CD122 Antigen Positive|CD122 Positive|High Affinity IL-2 Receptor Subunit Beta Positive|IL-2 Receptor Subunit Beta Positive|IL-2R Subunit Beta Positive|IL-2RB Positive|IL15RB Positive|IL2 Receptor Beta Positive|Interleukin 15 Receptor Beta Positive|Interleukin 2 Receptor Beta Positive|Interleukin-2 Receptor Beta Chain Positive	Indicates that IL2RB expression has been detected in a sample.	IL2RB Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C139789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139789>	C177692	CD8 Positive|CD8 Antigen Positive|CD8 Co-Receptor Positive|T-Cell Surface Glycoprotein CD8 Positive	Indicates that expression of the CD8 complex has been detected in a sample.	CD8 Positive		Laboratory or Test Result	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13978>	C13432	14q21-q22	A chromosome band present on 14q			Gene or Genome	
C139790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139790>	C177692	CD57 Positive|CD57 Antigen Positive|HNK-1 Positive|HNK1 Positive|Human Natural Killer-1 Antigen Positive|L2/HNK-1 Positive|Leu7 Positive	Indicates that expression of the tumor antigen CD57 has been detected in a sample.	CD57 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C139791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139791>	C138961	PSA Level Greater than 0.1	A blood concentration of prostate specific antigen that is greater than 0.1 ng/mL.	PSA Level Greater than 0.1		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C139792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139792>	C138961	PSA Level Greater than or Equal to Five|PSA Level 5 or Greater|PSA Level Five or Greater|PSA Level Greater than or Equal to 5	A blood concentration of prostate specific antigen greater than or equal to 5 ng/mL.	PSA Level Greater than or Equal to Five		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C139793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139793>	C177692	STEAP1 Positive|Metalloreductase STEAP1 Positive|PRSS24 Positive|STEAP Positive|Six Transmembrane Epithelial Antigen of the Prostate 1 Positive	Indicates that STEAP1 expression has been detected in a sample.	STEAP1 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C139794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139794>	C82612|C178120	Activating PTPN11 Gene Mutation|Activating PTPN11 Mutation|Activating PTPN11 Mutation|BPTP3 Activating Mutation|PTP-1D Activating Mutation|PTP2C Activating Mutation|PTPN11 Activating Gene Mutation|PTPN11 Activating Mutation|Protein Tyrosine Phosphatase, Non-Receptor Type 11 Activating Mutation|SH-PTP2 Activating Mutation|SHP-2 Activating Mutation|SHP2 Activating Mutation	A change in the nucleotide sequence of the PTPN11 gene that results in constitutive activation of both tyrosine-protein phosphatase non-receptor type 11 and its downstream signaling pathways.	Activating PTPN11 Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C139795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139795>	C40430|C134499	Activating BRAF Mutation|Activating BRAF Gene Mutation|Activating BRAF1 Mutation|B-RAF Activating Mutation|B-RAF1 Activating Mutation|B-Raf Proto-Oncogene, Serine/Threonine Kinase Activating Mutation|BRAF Activating Mutation|v-raf Murine Sarcoma Viral Oncogene Homolog B Activating Mutation|v-raf Murine Sarcoma Viral Oncogene Homolog B1 Activating Mutation	A change in the nucleotide sequence of the BRAF gene that results in constitutive activation of both serine/threonine-protein kinase B-raf and its downstream signaling pathways.	Activating BRAF Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C139796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139796>	C41381|C128901	Activating NRAS Mutation|N-RAS Activating Mutation|NRAS Activating Mutation|NRAS Proto-Oncogene, GTPase Activating Mutation|NRAS1 Activating Mutation|Neuroblastoma RAS Viral Oncogene Homolog Activating Mutation	A change in the nucleotide sequence of the NRAS gene that results in constitutive activation of both oncogene N-Ras protein and its downstream signaling pathways.	Activating NRAS Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C139798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139798>	C45934|C128901	Activating HRAS Mutation|C-H-RAS Activating Mutation|C-HA-RAS1 Activating Mutation|H-ras Activating Mutation|HRAS Activating Mutation|HRAS1 Activating Mutation|HRas Proto-Oncogene, GTPase Activating Mutation|Ha-ras Activating Mutation|Harvey Rat Sarcoma Viral Oncogene Homolog Activating Mutation|RASH1 Activating Mutation	A change in the nucleotide sequence of the HRAS gene that results in constitutive activation of both oncogene H-Ras protein and its downstream signaling pathways.	Activating HRAS Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C139799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139799>	C21176	T-Cell Surface Glycoprotein CD8|CD8|CD8 Antigen|CD8 Co-Receptor|CD8 Complex	A dimeric protein complex that functions as a co-receptor for the T-cell receptor and is involved with both signal transduction in and antigen interactions with T-lymphocytes. CD8 is commonly composed of a heterodimer of the T-cell surface glycoprotein CD8 alpha and beta chains, but functional homodimers of the alpha chain also exist.	T-Cell Surface Glycoprotein CD8		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C13979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13979>	C13432	1q22-q25	A chromosome band present on 1q			Gene or Genome	
C1397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1397>	C19170	Protein E6, Human Papillomavirus Type 16|HPV 16 E6 Peptide|HPV-16 E6|HPV-16 E6 Peptide|HPV-16 Protein E6|HPV16 E6|Human Papillomavirus 16 E6 Peptide|Human Papillomavirus Type 16 E6 Protein|Protein E6	Protein E6 (158 aa, ~19 kDa) is encoded by the human papillomavirus type 16 E6 gene. This protein is involved in both transcriptional activation and degradation of cellular tumor antigen p53.	Protein E6, Human Papillomavirus Type 16		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C139800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139800>	C155712	Trastuzumab/Tesirine Antibody-drug Conjugate ADCT-502|ADC ADCT-502|ADCT 502|ADCT-502|ADCT502|Anti-HER2/PBD ADC ADCT 502	An antibody-drug conjugate (ADC) consisting of an engineered version of the humanized monoclonal anti-human epidermal growth factor receptor 2 (HER2) immunoglobulin G1 (IgG1) trastuzumab that is site-specifically conjugated, via a cleavable linker, to the cytotoxic, DNA cross-linking pyrrolobenzodiazepine (PBD) dimer-based drug tesirine, which targets DNA minor grooves, with potential antineoplastic activity. Upon administration, the trastuzumab moiety of trastuzumab/tesirine ADC ADCT-502 targets the cell surface antigen HER2, which is expressed on various cancer cells. Upon antibody/antigen binding, internalization of the ADC and cleavage of the linker, the cytotoxic PBD moiety is released. The imine groups of tesirine bind to the N2 positions of guanines on opposite strands of DNA. This induces interstrand cross-links in the minor groove of DNA, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death and inhibits the proliferation of HER2-overexpressing tumor cells. The tumor-associated antigen (TAA) HER2 is expressed by various solid tumors and is associated with a poor prognosis.	Trastuzumab/Tesirine Antibody-drug Conjugate ADCT-502		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C139801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139801>	C61574	Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v8 Stage|Tumor Stage (Pathological)	A term that refers to the staging of uterine corpus cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to carcinomas and carcinosarcomas. It does not apply to uterine corpus sarcomas: leiomyosarcomas, endometrial stromal sarcomas, and adenosarcomas. These sarcomas are staged according to the classification for uterine corpus sarcomas. (from AJCC 8th Ed.)			Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C139802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139802>	C139801	Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8|Stage I|Stage I Uterine (including Endometrial) Cancer	Stage I includes: T1, N0, M0. T1: Uterine corpus carcinoma or carcinosarcoma with tumor confined to the corpus uteri, including endocervical glandular involvement. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage I Uterine Corpus Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CTRP Disease Terminology|CTRP Terminology
C139803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139803>	C139802	Stage IA Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8|Stage IA Uterine (including Endometrial) Cancer	Stage IA includes: T1a, N0, M0. T1a: Uterine corpus carcinoma or carcinosarcoma with tumor limited to the endometrium or invading less than half the myometrium. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IA Uterine Corpus Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139804>	C139802	Stage IB Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8|Stage IB Uterine (including Endometrial) Cancer	Stage IB includes: T1b, N0, M0. T1b: Uterine corpus carcinoma or carcinosarcoma with tumor invading one half or more of the myometrium. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IB Uterine Corpus Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139805>	C139801	Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8|Stage II|Stage II Uterine (including Endometrial) Cancer	Stage II includes: T2, N0, M0. T2: Uterine corpus carcinoma or carcinosarcoma with tumor invading the stromal connective tissue of the cervix but not extending beyond the uterus. Does not include endocervical glandular involvement. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage II Uterine Corpus Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CTRP Disease Terminology|CTRP Terminology
C139806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139806>	C139801	Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8|Stage III|Stage III Uterine (including Endometrial) Cancer	Stage III includes: T3, N0, M0. T3: Uterine corpus carcinoma or carcinosarcoma with tumor involving serosa, adnexa, vagina, or parametrium. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage III Uterine Corpus Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CTRP Disease Terminology|CTRP Terminology
C139807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139807>	C139806	Stage IIIA Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8|Stage IIIA Uterine (including Endometrial) Cancer	Stage IIIA includes: T3a, N0, M0. T3a: Uterine corpus carcinoma or carcinosarcoma with tumor involving the serosa and/or adnexa (direct extension or metastasis). N0: No regional lymph node metastasis. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage IIIA Uterine Corpus Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139808>	C139806	Stage IIIB Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8|Stage IIIB Uterine (including Endometrial) Cancer	Stage IIIB includes: T3b, N0, M0. T3b: Uterine corpus carcinoma or carcinosarcoma with vaginal involvement (direct extension or metastasis) or parametrial involvement. N0: No regional lymph node metastasis. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage IIIB Uterine Corpus Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139809>	C139806	Stage IIIC Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8|Stage IIIC Uterine (including Endometrial) Cancer	Stage IIIC includes: IIIC1: T1-T3, N1/N1mi/N1a, M0; IIIC2: T1-T3, N2/N2mi/N2a, M0. T1: Uterine corpus carcinoma or carcinosarcoma with tumor confined to the corpus uteri, including endocervical glandular involvement. T2: Uterine corpus carcinoma or carcinosarcoma with tumor invading the stromal connective tissue of the cervix but not extending beyond the uterus. Does not include endocervical glandular involvement. T3: Uterine corpus carcinoma or carcinosarcoma with tumor involving serosa, adnexa, vagina, or parametrium. N1: Regional lymph node metastasis to pelvic lymph nodes. N1mi: Regional lymph node metastasis (greater than 0.2 mm but nor greater than 2.0 mm in diameter) to pelvic lymph nodes. N1a: Regional lymph node metastasis (greater than 2.0 mm in diameter) to pelvic lymph nodes. N2: Regional lymph node metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes. N2mi: Regional lymph node metastasis (greater than 0.2 mm but not greater than 2.0 mm in diameter) to para-aortic lymph nodes, with or without positive pelvic lymph nodes. N2a: Regional lymph node metastasis (greater than 2.0 mm in diameter) to para-aortic lymph nodes, with or without positive pelvic lymph nodes. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage IIIC Uterine Corpus Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13980>	C13432	1q23-q25	A chromosome band present on 1q			Gene or Genome	
C139810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139810>	C139809	Stage IIIC1 Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8|Stage IIIC1 Uterine (including Endometrial) Cancer	Stage IIIC1 includes: T1-T3, N1/N1mi/N1a, M0. T1: Uterine corpus carcinoma or carcinosarcoma with tumor confined to the corpus uteri, including endocervical glandular involvement. T2: Uterine corpus carcinoma or carcinosarcoma with tumor invading the stromal connective tissue of the cervix but not extending beyond the uterus. Does not include endocervical glandular involvement. T3: Uterine corpus carcinoma or carcinosarcoma with tumor involving serosa, adnexa, vagina, or parametrium. N1: Regional lymph node metastasis to pelvic lymph nodes. N1mi: Regional lymph node metastasis (greater than 0.2 mm but nor greater than 2.0 mm in diameter) to pelvic lymph nodes. N1a: Regional lymph node metastasis (greater than 2.0 mm in diameter) to pelvic lymph nodes. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage IIIC1 Uterine Corpus Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139811>	C139809	Stage IIIC2 Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8|Stage IIIC2 Uterine (including Endometrial) Cancer	Stage IIIC2 includes: T1-T3, N2/N2mi/N2a, M0. T1: Uterine corpus carcinoma or carcinosarcoma with tumor confined to the corpus uteri, including endocervical glandular involvement. T2: Uterine corpus carcinoma or carcinosarcoma with tumor invading the stromal connective tissue of the cervix but not extending beyond the uterus. Does not include endocervical glandular involvement. T3: Uterine corpus carcinoma or carcinosarcoma with tumor involving serosa, adnexa, vagina, or parametrium. N2: Regional lymph node metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes. N2mi: Regional lymph node metastasis (greater than 0.2 mm but not greater than 2.0 mm in diameter) to para-aortic lymph nodes, with or without positive pelvic lymph nodes. N2a: Regional lymph node metastasis (greater than 2.0 mm in diameter) to para-aortic lymph nodes, with or without positive pelvic lymph nodes. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage IIIC2 Uterine Corpus Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139812>	C139801	Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8|Stage IV|Stage IV Uterine (including Endometrial) Cancer	Stage IV includes: IVA: T4, Any N, M0; IVB: Any T, Any N, M1. T4: Uterine corpus carcinoma or carcinosarcoma with tumor invading the bladder mucosa and/or bowel mucosa (bullous edema is not sufficient to classify a tumor as T4). M0: No distant metastasis. M1: Distant metastasis (includes metastasis to inguinal lymph nodes, intraperitoneal disease, lung, liver, or bone. It excludes metastasis to pelvic or para-aortic lymph nodes, vagina, uterine serosa, or adnexa). (from AJCC 8th Ed.)	Stage IV Uterine Corpus Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CTRP Disease Terminology|CTRP Terminology
C139813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139813>	C139812	Stage IVA Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8|Stage IVA Uterine (including Endometrial) Cancer	Stage IVA includes: T4, Any N, M0. T4: Uterine corpus carcinoma or carcinosarcoma with tumor invading the bladder mucosa and/or bowel mucosa (bullous edema is not sufficient to classify a tumor as T4). M0: No distant metastasis. (from AJCC 8th Ed.)	Stage IVA Uterine Corpus Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139814>	C139812	Stage IVB Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8|Stage IVB Uterine (including Endometrial) Cancer	Stage IVB includes: Any T, Any N, M1. M1: Distant metastasis (includes metastasis to inguinal lymph nodes, intraperitoneal disease, lung, liver, or bone. It excludes metastasis to pelvic or para-aortic lymph nodes, vagina, uterine serosa, or adnexa). (from AJCC 8th Ed.)	Stage IVB Uterine Corpus Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139815>	C139589	Uterine Corpus Sarcoma TNM Finding v8	A finding about one or more characteristics of uterine corpus sarcoma, following the rules of the TNM AJCC v8 classification system. This classification system applies to sarcomas arising in the uterine corpus (leiomyosarcomas, endometrial stromal sarcomas, and adenosarcomas). Carcinosarcomas are staged according to the classification for uterine corpus carcinomas and carcinosarcomas. (from AJCC 8th Ed.)			Finding	
C139816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139816>	C139815	Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma TNM Finding v8	A finding about one or more characteristics of uterine corpus leiomyosarcoma or endometrial stromal sarcoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C139817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139817>	C139816	Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of uterine corpus leiomyosarcoma or endometrial stromal sarcoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C139818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139818>	C139817	Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of uterine corpus leiomyosarcoma or endometrial stromal sarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C139819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139819>	C139818	Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma cM0 TNM Finding v8	Uterine corpus leiomyosarcoma or endometrial stromal sarcoma without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C13981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13981>	C13432	17q11	A chromosome band present on 17q			Gene or Genome	
C139820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139820>	C139818	Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma cM1 TNM Finding v8|Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma FIGO Stage IVB	Uterine corpus leiomyosarcoma or endometrial stromal sarcoma with distant metastasis (excluding adnexa, pelvic, and abdominal tissues). (from AJCC 8th Ed.)			Finding	
C139821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139821>	C139816	Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of uterine corpus leiomyosarcoma or endometrial stromal sarcoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C139822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139822>	C139821	Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of uterine corpus leiomyosarcoma or endometrial stromal sarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C139823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139823>	C139822	Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pM1 TNM Finding v8|Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma FIGO Stage IVB	Uterine corpus leiomyosarcoma or endometrial stromal sarcoma with distant metastasis (excluding adnexa, pelvic, and abdominal tissues). (from AJCC 8th Ed.)			Finding	
C139824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139824>	C139821	Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of uterine corpus leiomyosarcoma or endometrial stromal sarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor. The definitions of the T categories correspond to the stages accepted by FIGO. (from AJCC 8th Ed.)			Finding	
C139825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139825>	C139824	Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pTX TNM Finding v8	Uterine corpus leiomyosarcoma or endometrial stromal sarcoma in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C139826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139826>	C139824	Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pT0 TNM Finding v8	Uterine corpus leiomyosarcoma or endometrial stromal sarcoma with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C139827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139827>	C139824	Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pT1 TNM Finding v8|Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma FIGO Stage I	Uterine corpus leiomyosarcoma or endometrial stromal sarcoma with tumor limited to the uterus. (from AJCC 8th Ed.)			Finding	
C139828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139828>	C139827	Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pT1a TNM Finding v8|Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma FIGO Stage IA	Uterine corpus leiomyosarcoma or endometrial stromal sarcoma with tumor limited to the uterus, measuring 5 cm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C139829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139829>	C139827	Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pT1b TNM Finding v8|Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma FIGO Stage IB	Uterine corpus leiomyosarcoma or endometrial stromal sarcoma with tumor limited to the uterus, measuring more than 5 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C13982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13982>	C13432	12q11-q14	A chromosome band present on 12q			Gene or Genome	
C139830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139830>	C139824	Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pT2 TNM Finding v8|Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma FIGO Stage II	Uterine corpus leiomyosarcoma or endometrial stromal sarcoma with tumor extending beyond the uterus, within the pelvis. (from AJCC 8th Ed.)			Finding	
C139831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139831>	C139830	Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pT2a TNM Finding v8|Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma FIGO Stage IIA	Uterine corpus leiomyosarcoma or endometrial stromal sarcoma with tumor extending beyond the uterus, within the pelvis and involving adnexa. (from AJCC 8th Ed.)			Finding	
C139832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139832>	C139830	Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pT2b TNM Finding v8|Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma FIGO Stage IIB	Uterine corpus leiomyosarcoma or endometrial stromal sarcoma with tumor involving other pelvic tissues. (from AJCC 8th Ed.)			Finding	
C139833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139833>	C139824	Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pT3 TNM Finding v8|Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma FIGO Stage III	Uterine corpus leiomyosarcoma or endometrial stromal sarcoma with tumor infiltrating abdominal tissues. (from AJCC 8th Ed.)			Finding	
C139834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139834>	C139833	Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pT3a TNM Finding v8|Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma FIGO Stage IIIA	Uterine corpus leiomyosarcoma or endometrial stromal sarcoma with tumor infiltrating abdominal tissues at one site. (from AJCC 8th Ed.)			Finding	
C139835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139835>	C139833	Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pT3b TNM Finding v8|Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma FIGO Stage IIIB	Uterine corpus leiomyosarcoma or endometrial stromal sarcoma with tumor infiltrating abdominal tissues at more than one site. (from AJCC 8th Ed.)			Finding	
C139836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139836>	C139824	Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pT4 TNM Finding v8|Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma FIGO Stage IVA	Uterine corpus leiomyosarcoma or endometrial stromal sarcoma with tumor invading bladder or rectum. (from AJCC 8th Ed.)			Finding	
C139837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139837>	C139821	Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of uterine corpus leiomyosarcoma or endometrial stromal sarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C139838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139838>	C139837	Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pNX TNM Finding v8	Uterine corpus leiomyosarcoma or endometrial stromal sarcoma in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C139839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139839>	C139837	Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pN0 TNM Finding v8	Uterine corpus leiomyosarcoma or endometrial stromal sarcoma with no regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C13983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13983>	C34070	Cell Junction	Cell junction is the specialized focal contact between cell-cell or cell-matrix in all tissues.  Cell junctions have various functions either communication, anchoring or organization.  There are specific protein associated with subtype of cell junctions and most of the junctions are too small to be resolved by light microscope.			Body Space or Junction	
C139840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139840>	C139839	Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pN0(i+) TNM Finding v8	Uterine corpus leiomyosarcoma or endometrial stromal sarcoma with isolated tumor cells in regional lymph node(s) no greater than 0.2 mm. (from AJCC 8th Ed.)			Finding	
C139841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139841>	C139837	Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma pN1 TNM Finding v8|Uterine Corpus Leiomyosarcoma and Endometrial Stromal Sarcoma FIGO Stage IIIC	Uterine corpus leiomyosarcoma or endometrial stromal sarcoma with regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C139842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139842>	C139815	Uterine Corpus Adenosarcoma TNM Finding v8	A finding about one or more characteristics of uterine corpus adenosarcoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C139843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139843>	C139842	Uterine Corpus Adenosarcoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of uterine corpus adenosarcoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C139844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139844>	C139843	Uterine Corpus Adenosarcoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of uterine corpus  adenosarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C139845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139845>	C139844	Uterine Corpus Adenosarcoma cM0 TNM Finding v8	Uterine corpus adenosarcoma without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C139846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139846>	C139844	Uterine Corpus Adenosarcoma cM1 TNM Finding v8|Uterine Corpus Adenosarcoma FIGO Stage IVB	Uterine corpus adenosarcoma with distant metastasis (excluding adnexa, pelvic, and abdominal tissues). (from AJCC 8th Ed.)			Finding	
C139847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139847>	C139842	Uterine Corpus Adenosarcoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of uterine corpus adenosarcoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C139848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139848>	C139847	Uterine Corpus Adenosarcoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of uterine corpus adenosarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C139849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139849>	C139848	Uterine Corpus Adenosarcoma pM1 TNM Finding v8|Uterine Corpus Adenosarcoma FIGO Stage IVB	Uterine corpus adenosarcoma with distant metastasis (excluding adnexa, pelvic, and abdominal tissues). (from AJCC 8th Ed.)			Finding	
C13984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13984>	C32530	Anchoring Junction|Adhering Junction|Adhesive Junction	Anchoring junctions typically are observed as "spot welds" between cells in many types of epithelia. Detail structures can be seen only with EM.			Cell Component	
C139850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139850>	C139847	Uterine Corpus Adenosarcoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of uterine corpus adenosarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor. The definitions of the T categories correspond to the stages accepted by FIGO. (from AJCC 8th Ed.)			Finding	
C139851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139851>	C139850	Uterine Corpus Adenosarcoma pTX TNM Finding v8	Uterine corpus adenosarcoma in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C139852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139852>	C139850	Uterine Corpus Adenosarcoma pT0 TNM Finding v8	Uterine corpus adenosarcoma with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C139853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139853>	C139850	Uterine Corpus Adenosarcoma pT1 TNM Finding v8|Uterine Corpus Adenosarcoma FIGO Stage I	Uterine corpus adenosarcoma with tumor limited to the uterus. (from AJCC 8th Ed.)			Finding	
C139854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139854>	C139853	Uterine Corpus Adenosarcoma pT1a TNM Finding v8|Uterine Corpus Adenosarcoma FIGO Stage IA	Uterine corpus adenosarcoma with tumor limited to the endometrium/endocervix. (from AJCC 8th Ed.)			Finding	
C139855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139855>	C139853	Uterine Corpus Adenosarcoma pT1b TNM Finding v8|Uterine Corpus Adenosarcoma FIGO Stage IB	Uterine corpus adenosarcoma with tumor invading to less than half of the myometrium. (from AJCC 8th Ed.)			Finding	
C139856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139856>	C139853	Uterine Corpus Adenosarcoma pT1c TNM Finding v8|Uterine Corpus Adenosarcoma FIGO Stage IC	Uterine corpus adenosarcoma with tumor invading more than half of the myometrium. (from AJCC 8th Ed.)			Finding	
C139857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139857>	C139850	Uterine Corpus Adenosarcoma pT2 TNM Finding v8|Uterine Corpus Adenosarcoma FIGO Stage II	Uterine corpus adenosarcoma with tumor extending beyond the uterus, within the pelvis. (from AJCC 8th Ed.)			Finding	
C139858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139858>	C139857	Uterine Corpus Adenosarcoma pT2a TNM Finding v8|Uterine Corpus Adenosarcoma FIGO Stage IIA	Uterine corpus adenosarcoma with tumor extending beyond the uterus, within the pelvis and involving adnexa. (from AJCC 8th Ed.)			Finding	
C139859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139859>	C139857	Uterine Corpus Adenosarcoma pT2b TNM Finding v8|Uterine Corpus Adenosarcoma FIGO Stage IIB	Uterine corpus adenosarcoma with tumor involving other pelvic tissues. (from AJCC 8th Ed.)			Finding	
C13985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13985>	C13984	Fascia Adherens	Fascia adherens, similar to a zonula adherens, is a half Z line found in the cardiac muscle as one of the three intercalated disks.  They anchor actin filaments from terminal sarcomeres and transmit contractile force between myocytes. (NCI)			Cell Component	
C139860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139860>	C139850	Uterine Corpus Adenosarcoma pT3 TNM Finding v8|Uterine Corpus Adenosarcoma FIGO Stage III	Uterine corpus adenosarcoma with tumor infiltrating abdominal tissues. (from AJCC 8th Ed.)			Finding	
C139861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139861>	C139860	Uterine Corpus Adenosarcoma pT3a TNM Finding v8|Uterine Corpus Adenosarcoma FIGO Stage IIIA	Uterine corpus adenosarcoma with tumor infiltrating abdominal tissues at one site. (from AJCC 8th Ed.)			Finding	
C139862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139862>	C139860	Uterine Corpus Adenosarcoma pT3b TNM Finding v8|Uterine Corpus Adenosarcoma FIGO Stage IIIB	Uterine corpus adenosarcoma with tumor infiltrating abdominal tissues at more than one site. (from AJCC 8th Ed.)			Finding	
C139863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139863>	C139850	Uterine Corpus Adenosarcoma pT4 TNM Finding v8|Uterine Corpus Adenosarcoma FIGO Stage IVA	Uterine corpus adenosarcoma with tumor invading bladder or rectum. (from AJCC 8th Ed.)			Finding	
C139864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139864>	C139847	Uterine Corpus Adenosarcoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of uterine corpus adenosarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C139865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139865>	C139864	Uterine Corpus Adenosarcoma pNX TNM Finding v8	Uterine corpus adenosarcoma in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C139866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139866>	C139864	Uterine Corpus Adenosarcoma pN0 TNM Finding v8	Uterine corpus adenosarcoma with no regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C139867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139867>	C139866	Uterine Corpus Adenosarcoma pN0(i+) TNM Finding v8	Uterine corpus adenosarcoma with isolated tumor cells in regional lymph node(s) no greater than 0.2 mm. (from AJCC 8th Ed.)			Finding	
C139868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139868>	C139864	Uterine Corpus Adenosarcoma pN1 TNM Finding v8|Uterine Corpus Adenosarcoma FIGO Stage IIIC	Uterine corpus adenosarcoma with regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C139869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139869>	C6339	Uterine Corpus Sarcoma by AJCC v8 Stage	A term that refers to the staging of uterine corpus sarcoma according to the American Joint Committee on Cancer, 8th edition. This staging system applies to leiomyosarcomas, endometrial stromal sarcomas, and adenosarcomas of the uterine corpus. It does not apply to carcinosarcomas which are staged according to the carcinomas and carcinosarcomas of the uterine corpus. (from AJCC 8th Ed.)			Neoplastic Process	
C13986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13986>	C13432	10q24-q26	A chromosome band present on 10q			Gene or Genome	
C139870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139870>	C6340|C139869	Uterine Corpus Leiomyosarcoma by AJCC v8 Stage	A term that refers to the staging of uterine corpus leiomyosarcoma according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C139871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139871>	C139870	Stage I Uterine Corpus Leiomyosarcoma AJCC v8|Stage I Uterine Corpus Leiomyosarcoma	Stage I includes: T1, N0, M0. T1: Uterine corpus leiomyosarcoma with tumor limited to the uterus. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage I Uterine Corpus Leiomyosarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139872>	C139871	Stage IA Uterine Corpus Leiomyosarcoma AJCC v8|Stage IA Uterine Corpus Leiomyosarcoma	Stage IA includes: T1a, N0, M0. T1a: Uterine corpus leiomyosarcoma with tumor limited to the uterus, measuring 5 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IA Uterine Corpus Leiomyosarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139873>	C139871	Stage IB Uterine Corpus Leiomyosarcoma AJCC v8|Stage IB Uterine Corpus Leiomyosarcoma	Stage IB includes: T1b, N0, M0. T1b: Uterine corpus leiomyosarcoma with tumor limited to the uterus, measuring more than 5 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IB Uterine Corpus Leiomyosarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139874>	C139870	Stage II Uterine Corpus Leiomyosarcoma AJCC v8|Stage II Uterine Corpus Leiomyosarcoma	Stage II includes: T2, N0, M0. T2: Uterine corpus leiomyosarcoma with tumor extending beyond the uterus, within the pelvis. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage II Uterine Corpus Leiomyosarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139875>	C139870	Stage III Uterine Corpus Leiomyosarcoma AJCC v8|Stage III Uterine Corpus Leiomyosarcoma	Stage III includes: IIIA: T3a, N0, M0; IIIB: T3b, N0, M0; IIIC: T1-3, N1, M0. T1: Uterine corpus leiomyosarcoma with tumor limited to the uterus. T2: Uterine corpus leiomyosarcoma with tumor extending beyond the uterus, within the pelvis. T3: Uterine corpus leiomyosarcoma with tumor infiltrating abdominal tissues. T3a: Uterine corpus leiomyosarcoma with tumor infiltrating abdominal tissues at one site. T3b: Uterine corpus leiomyosarcoma with tumor infiltrating abdominal tissues at more than one site. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage III Uterine Corpus Leiomyosarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139876>	C139875	Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIA Uterine Corpus Leiomyosarcoma	Stage IIIA includes: T3a, N0, M0. T3a: Uterine corpus leiomyosarcoma with tumor infiltrating abdominal tissues at one site. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139877>	C139875	Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIB Uterine Corpus Leiomyosarcoma	Stage IIIB includes: T3b, N0, M0. T3b: Uterine corpus leiomyosarcoma with tumor infiltrating abdominal tissues at more than one site. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139878>	C139875	Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIC Uterine Corpus Leiomyosarcoma	Stage IIIC includes: T1-3, N1, M0. T1: Uterine corpus leiomyosarcoma with tumor limited to the uterus. T2: Uterine corpus leiomyosarcoma with tumor extending beyond the uterus, within the pelvis. T3: Uterine corpus leiomyosarcoma with tumor infiltrating abdominal tissues. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139879>	C139870	Stage IV Uterine Corpus Leiomyosarcoma AJCC v8|Stage IV Uterine Corpus Leiomyosarcoma	Stage IV includes: IVA: T4, Any N, M0; IVB: Any T, Any N, M1. T4: Uterine corpus leiomyosarcoma with tumor invading bladder or rectum. M0: No distant metastasis. M1: Distant metastasis (excluding adnexa, pelvic, and abdominal tissues). (from AJCC 8th Ed.)	Stage IV Uterine Corpus Leiomyosarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13987>	C13432	2p13-q13	A chromosome band present on 2p			Gene or Genome	
C139880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139880>	C139879	Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8|Stage IVA Uterine Corpus Leiomyosarcoma	Stage IVA includes: T4, Any N, M0. T4: Uterine corpus leiomyosarcoma with tumor invading bladder or rectum. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139881>	C139879	Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8|Stage IVB Uterine Corpus Leiomyosarcoma	Stage IVB includes: Any T, Any N, M1. M1: M1: Distant metastasis (excluding adnexa, pelvic, and abdominal tissues). (from AJCC 8th Ed.)	Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139882>	C40219|C139869	Uterine Corpus Endometrial Stromal Sarcoma by AJCC v8 Stage	A term that refers to the staging of uterine corpus endometrial stroma sarcoma according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C139883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139883>	C139882	Stage I Uterine Corpus Endometrial Stromal Sarcoma AJCC v8|Stage I Uterine Corpus Endometrial Stromal Sarcoma	Stage I includes: T1, N0, M0. T1: Uterine corpus endometrial stroma sarcoma with tumor limited to the uterus. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage I Uterine Corpus Endometrial Stromal Sarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139884>	C139883	Stage IA Uterine Corpus Endometrial Stromal Sarcoma AJCC v8|Stage IA Uterine Corpus Endometrial Stromal Sarcoma	Stage IA includes: T1a, N0, M0. T1a: Uterine corpus endometrial stroma sarcoma with tumor limited to the uterus, measuring 5 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IA Uterine Corpus Endometrial Stromal Sarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139885>	C139883	Stage IB Uterine Corpus Endometrial Stromal Sarcoma AJCC v8|Stage IB Uterine Corpus Endometrial Stromal Sarcoma	Stage IB includes: T1b, N0, M0. T1b: Uterine corpus endometrial stroma sarcoma with tumor limited to the uterus, measuring more than 5 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IB Uterine Corpus Endometrial Stromal Sarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139886>	C139882	Stage II Uterine Corpus Endometrial Stromal Sarcoma AJCC v8|Stage II Uterine Corpus Endometrial Stromal Sarcoma	Stage II includes: T2, N0, M0. T2: Uterine corpus endometrial stroma sarcoma with tumor extending beyond the uterus, within the pelvis. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage II Uterine Corpus Endometrial Stromal Sarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139887>	C139882	Stage III Uterine Corpus Endometrial Stromal Sarcoma AJCC v8|Stage III Uterine Corpus Endometrial Stromal Sarcoma	Stage III includes: IIIA: T3a, N0, M0; IIIB: T3b, N0, M0; IIIC: T1-3, N1, M0. T1: Uterine corpus endometrial stroma sarcoma with tumor limited to the uterus. T2: Uterine corpus endometrial stroma sarcoma with tumor extending beyond the uterus, within the pelvis. T3: Uterine corpus endometrial stroma sarcoma with tumor infiltrating abdominal tissues. T3a: Uterine corpus endometrial stroma sarcoma with tumor infiltrating abdominal tissues at one site. T3b: Uterine corpus endometrial stroma sarcoma with tumor infiltrating abdominal tissues at more than one site. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage III Uterine Corpus Endometrial Stromal Sarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139888>	C139887	Stage IIIA Uterine Corpus Endometrial Stromal Sarcoma AJCC v8|Stage IIIA Uterine Corpus Endometrial Stromal Sarcoma	Stage IIIA includes: T3a, N0, M0. T3a: Uterine corpus endometrial stroma sarcoma with tumor infiltrating abdominal tissues at one site. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIIA Uterine Corpus Endometrial Stromal Sarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139889>	C139887	Stage IIIB Uterine Corpus Endometrial Stromal Sarcoma AJCC v8|Stage IIIB Uterine Corpus Endometrial Stromal Sarcoma	Stage IIIB includes: T3b, N0, M0. T3b: Uterine corpus endometrial stroma sarcoma with tumor infiltrating abdominal tissues at more than one site. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIIB Uterine Corpus Endometrial Stromal Sarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13988>	C13432	5q31.1	A chromosome band present on 5q	5q31.1		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C139890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139890>	C139887	Stage IIIC Uterine Corpus Endometrial Stromal Sarcoma AJCC v8|Stage IIIC Uterine Corpus Endometrial Stromal Sarcoma	Stage IIIC includes: T1-3, N1, M0. T1: Uterine corpus endometrial stroma sarcoma with tumor limited to the uterus. T2: Uterine corpus endometrial stroma sarcoma with tumor extending beyond the uterus, within the pelvis. T3: Uterine corpus endometrial stroma sarcoma with tumor infiltrating abdominal tissues. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIIC Uterine Corpus Endometrial Stromal Sarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139891>	C139882	Stage IV Uterine Corpus Endometrial Stromal Sarcoma AJCC v8|Stage IV Uterine Corpus Endometrial Stromal Sarcoma	Stage IV includes: IVA: T4, Any N, M0; IVB: Any T, Any N, M1. T4: Uterine corpus endometrial stroma sarcoma with tumor invading bladder or rectum. M0: No distant metastasis. M1: Distant metastasis (excluding adnexa, pelvic, and abdominal tissues). (from AJCC 8th Ed.)	Stage IV Uterine Corpus Endometrial Stromal Sarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139892>	C139891	Stage IVA Uterine Corpus Endometrial Stromal Sarcoma AJCC v8|Stage IVA Uterine Corpus Endometrial Stromal Sarcoma	Stage IVA includes: T4, Any N, M0. T4: Uterine corpus endometrial stroma sarcoma with tumor invading bladder or rectum. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage IVA Uterine Corpus Endometrial Stromal Sarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139893>	C139891	Stage IVB Uterine Corpus Endometrial Stromal Sarcoma AJCC v8|Stage IVB Uterine Corpus Endometrial Stromal Sarcoma	Stage IVB includes: Any T, Any N, M1. M1: M1: Distant metastasis (excluding adnexa, pelvic, and abdominal tissues). (from AJCC 8th Ed.)	Stage IVB Uterine Corpus Endometrial Stromal Sarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139894>	C6336|C139869	Uterine Corpus Adenosarcoma by AJCC v8 Stage	A term that refers to the staging of uterine corpus adenosarcoma according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C139895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139895>	C139894	Stage I Uterine Corpus Adenosarcoma AJCC v8|Stage I Uterine Corpus Adenosarcoma	Stage I includes: T1, N0, M0. T1: Uterine corpus adenosarcoma with tumor limited to the uterus. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage I Uterine Corpus Adenosarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139896>	C139895	Stage IA Uterine Corpus Adenosarcoma AJCC v8|Stage IA Uterine Corpus Adenosarcoma	Stage IA includes: T1a, N0, M0. T1a: Uterine corpus adenosarcoma with tumor limited to the endometrium/endocervix. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IA Uterine Corpus Adenosarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139897>	C139895	Stage IB Uterine Corpus Adenosarcoma AJCC v8|Stage IB Uterine Corpus Adenosarcoma	Stage IB includes: T1b, N0, M0. T1b: Uterine corpus adenosarcoma with tumor invading to less than half of the myometrium. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IB Uterine Corpus Adenosarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139898>	C139895	Stage IC Uterine Corpus Adenosarcoma AJCC v8|Stage IC Uterine Corpus Adenosarcoma	Stage IC includes: T1c, N0, M0. T1c: Uterine corpus adenosarcoma with tumor invading more than half of the myometrium. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IC Uterine Corpus Adenosarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139899>	C139894	Stage II Uterine Corpus Adenosarcoma AJCC v8|Stage II Uterine Corpus Adenosarcoma	Stage II includes: T2, N0, M0. T2: Uterine corpus adenosarcoma with tumor extending beyond the uterus, within the pelvis. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage II Uterine Corpus Adenosarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13989>	C13432	13q14.3	A chromosome band present on 13q			Gene or Genome	
C1398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1398>	C471|C272	Sparfosic Acid|L-Aspartic acid, N-(phosphonoacetyl)-|N-Phosphonacetyl-L-aspartate|N-phosphonacetyl-L-aspartate|PALA|PALA|PALA|Phosphonacetyl-L-aspartic Acid|SPARFOSIC ACID|Sparfosate	A stable transition state analogue for an aspartate transcarbamylase-catalyzed reaction with antineoplastic activity. Sparfosic acid is a stable transition analogue of the activated complex for the reaction catalyzed by aspartate transcarbamylase, the first step in the pyrimidine biosynthetic pathway. This agent inhibits de novo pyrimidine biosynthesis and increases the extent to which fluorouracil metabolites are incorporated into RNA.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C139900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139900>	C139894	Stage III Uterine Corpus Adenosarcoma AJCC v8|Stage III Uterine Corpus Adenosarcoma	Stage III includes: IIIA: T3a, N0, M0; IIIB: T3b, N0, M0; IIIC: T1-3, N1, M0. T1: Uterine corpus adenosarcoma with tumor limited to the uterus. T2: Uterine corpus adenosarcoma with tumor extending beyond the uterus, within the pelvis. T3: Uterine corpus adenosarcoma with tumor infiltrating abdominal tissues. T3a: Uterine corpus adenosarcoma with tumor infiltrating abdominal tissues at one site. T3b: Uterine corpus adenosarcoma with tumor infiltrating abdominal tissues at more than one site. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage III Uterine Corpus Adenosarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139901>	C139900	Stage IIIA Uterine Corpus Adenosarcoma AJCC v8|Stage IIIA Uterine Corpus Adenosarcoma	Stage IIIA includes: T3a, N0, M0. T3a: Uterine corpus adenosarcoma with tumor infiltrating abdominal tissues at one site. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIIA Uterine Corpus Adenosarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139902>	C139900	Stage IIIB Uterine Corpus Adenosarcoma AJCC v8|Stage IIIB Uterine Corpus Adenosarcoma	Stage IIIB includes: T3b, N0, M0. T3b: Uterine corpus adenosarcoma with tumor infiltrating abdominal tissues at more than one site. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIIB Uterine Corpus Adenosarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139903>	C139900	Stage IIIC Uterine Corpus Adenosarcoma AJCC v8|Stage IIIC Uterine Corpus Adenosarcoma	Stage IIIC includes: T1-3, N1, M0. T1: Uterine corpus adenosarcoma with tumor limited to the uterus. T2: Uterine corpus adenosarcoma with tumor extending beyond the uterus, within the pelvis. T3: Uterine corpus adenosarcoma with tumor infiltrating abdominal tissues. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIIC Uterine Corpus Adenosarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139904>	C139894	Stage IV Uterine Corpus Adenosarcoma AJCC v8|Stage IV Uterine Corpus Adenosarcoma	Stage IV includes: IVA: T4, Any N, M0; IVB: Any T, Any N, M1. T4: Uterine corpus adenosarcoma with tumor invading bladder or rectum. M0: No distant metastasis. M1: Distant metastasis (excluding adnexa, pelvic, and abdominal tissues). (from AJCC 8th Ed.)	Stage IV Uterine Corpus Adenosarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139905>	C139904	Stage IVA Uterine Corpus Adenosarcoma AJCC v8|Stage IVA Uterine Corpus Adenosarcoma	Stage IVA includes: T4, Any N, M0. T4: Uterine corpus adenosarcoma with tumor invading bladder or rectum. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage IVA Uterine Corpus Adenosarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139906>	C139904	Stage IVB Uterine Corpus Adenosarcoma AJCC v8|Stage IVB Uterine Corpus Adenosarcoma	Stage IVB includes: Any T, Any N, M1. M1: M1: Distant metastasis (excluding adnexa, pelvic, and abdominal tissues). (from AJCC 8th Ed.)	Stage IVB Uterine Corpus Adenosarcoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139907>	C25994	NPPA Gene|NPPA|NPPA|Natriuretic Peptide A Gene	This gene is involved in both cardiac homeostasis and pregnancy.			Gene or Genome	
C139908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139908>	C139907	NPPA wt Allele|ANF|ANP|ATFB6|ATRST2|CDD|CDD-ANF|CDP|Natriuretic Peptide A wt Allele|PND	Human NPPA wild-type allele is located in the vicinity of 1p36.22 and is approximately 3 kb in length. This allele, which encodes natriuretic peptides A, plays a role in the regulation of natriuresis, diuresis, and vasodilation. Mutation of the gene is associated with atrial fibrillation familial type 6 and atrial standstill type 2.			Gene or Genome	
C139909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139909>	C1746	NPPA Gene Product	A protein encoded by the NPPA gene.			Amino Acid, Peptide, or Protein|Hormone	
C13990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13990>	C13432	10q22.1-q23	A chromosome band present on 10q			Gene or Genome	
C139910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139910>	C139909	Natriuretic Peptides A|Atrial Natriuretic Polypeptides|CDD|CDP|Cardiodilatin|Cardiodilatin-Related Peptide|NPPA|Natriuretic Peptide Precursor A|Prepronatriodilatin	Natriuretic peptides A (153 aa, ~17 kDa) is encoded by the human NPPA gene. This protein is involved in uterine artery remodeling, trophoblast invasion, natriuresis, diuresis, and vasodilation.			Amino Acid, Peptide, or Protein|Hormone	
C139911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139911>	C139909	Atrial Natriuretic Factor|ANF|ANP|Atrial Natriuretic Peptide|Atrionatriuretic Factor|Atriopeptin|Cardionatrin|NPPA	Atrial natriuretic factor (28 aa, ~3 kDa) is encoded by the human NPPA gene. This protein is involved in both cardiac homeostasis and pregnancy.			Amino Acid, Peptide, or Protein|Hormone	
C139912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139912>	C25994	NMB Gene|NMB|NMB|Neuromedin B Gene	This gene is involved in smooth muscle contraction.			Gene or Genome	
C139913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139913>	C139912	NMB wt Allele|MGC17211|MGC2277|MGC3936|Neuromedin B wt Allele	Human NMB wild-type allele is located in the vicinity of 15q25.2 and is approximately 3 kb in length. This allele, which encodes neuromedin-B precursor protein, plays a role in the regulation of smooth muscle contraction.			Gene or Genome	
C139914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139914>	C1746	NMB Gene Product	A protein encoded by the NMB gene.			Hormone	
C139915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139915>	C139914	Neuromedin-B Precursor|NMB|Neuromedin-B|Pro Neuromedin-B|Pro-Neuromedin-B|Proneuromedin B|Proneuromedin-B	Neuromedin-B precursor (121 aa, ~13 kDa) is encoded by the human NMB gene. This protein is involved in smooth muscle contraction.			Amino Acid, Peptide, or Protein|Hormone	
C139916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139916>	C139914	Neuromedin-B|NMB|Neuromedin B|Neuromedin-Beta	Neuromedin-B (10 aa, ~1 kDa) is encoded by the human NMB gene. This protein plays a role in the stimulation of smooth muscle contraction.			Amino Acid, Peptide, or Protein|Hormone	
C139917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139917>	C20709	ESRRB Gene|ESRRB|ESRRB|Estrogen Related Receptor Beta Gene	This gene plays a role in transcriptional regulation of genes that regulate the maintainance of self-renewal and pluripotency of embryonic and trophoblast stem cells.			Gene or Genome	
C139918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139918>	C139917	ESRRB wt Allele|DFNB35|Deafness, Autosomal Recessive 35 Gene|ERR2|ERRb|ERRbeta|ESRL2|Estrogen Related Receptor Beta wt Allele|Estrogen-Related Receptor, Beta Gene|NR3B2	Human ESRRB wild-type allele is located in the vicinity of 14q24.3 and is approximately 191 kb in length. This allele, which encodes steroid hormone receptor ERR2 protein, is involved in rod cell survival and inner ear development. Mutation of the gene is associated with autosomal recessive deafness type 35.			Gene or Genome	
C139919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139919>	C18108	Steroid Hormone Receptor ERR2|ERR Beta-2|ERR-Beta|ESRRB|Estrogen Receptor-Like 2|Estrogen-Related Nuclear Receptor Beta|Estrogen-Related Receptor 2|Estrogen-Related Receptor Beta|NR3B2|Nuclear Receptor ERRB2|Nuclear Receptor Subfamily 3 Group B Member 2	Steroid hormone receptor ERR2 (508 aa, ~56 kDa) is encoded by the human ESRRB gene. This protein plays a role in inner ear development, stem cell maintenance and rod cell survival.			Amino Acid, Peptide, or Protein|Receptor	
C13991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13991>	C13432	5q32-q34	A chromosome band present on 5q			Gene or Genome	
C139920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139920>	C28533	SLC39A4 Gene|SLC39A4|SLC39A4|Solute Carrier Family 39 Member 4 Gene	This gene is involved in zinc homeostasis.			Gene or Genome	
C139921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139921>	C139920	SLC39A4 wt Allele|AEZ|AWMS2|Acrodermatitis Enteropathica, Zinc-Deficiency Type Gene|Solute Carrier Family 39 (Zinc Transporter), Member 4 Gene|Solute Carrier Family 39 Member 4 wt Allele|ZIP4	Human SLC39A4 wild-type allele is located in the vicinity of 8q24.3 and is approximately 8 kb in length. This allele, which encodes zinc transporter ZIP4 protein, plays a role in cellular zinc homeostasis. Mutations in the gene are associated with acrodermatitis enteropathica.			Gene or Genome	
C139922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139922>	C16386	Zinc Transporter ZIP4|SLC39A4|Solute Carrier Family 39 Member 4|ZIP-4|Zrt- And Irt-Like Protein 4	Zinc transporter ZIP4 (647 aa, ~68 kDa) is encoded by the human SLC39A4 gene. This protein is involved in zinc ion transport.			Amino Acid, Peptide, or Protein	
C139923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139923>	C171324	Breath Carbon Monoxide Monitor|Smokerlyzer	A device designed to measure carbon monoxide in a smoker's breath as a means toward smoking cessation.	Breath Carbon Monoxide Monitor		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C139924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139924>	C54259	CAGE1 Gene|CAGE1|CAGE1|Cancer Antigen 1 Gene	This gene may play a role in testes development and carcinogenesis.			Gene or Genome	
C139925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139925>	C139924	CAGE1 wt Allele|CT3|CT95|CTAG3|Cancer Antigen 1 wt Allele|Cancer/Testis Antigen Gene 1|bA69L16.7	Human CAGE1 wild-type allele is located in the vicinity of 6p24.3 and is approximately 63 kb in length. This allele, which encodes cancer-associated gene 1 protein, may be involved in testes development and carcinogenesis. Aberrant expression is associated with several cancers.			Gene or Genome	
C139926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139926>	C54672	Cancer-Associated Gene 1 Protein|CAGE-1|CAGE1|CT3|Cancer/Testis Antigen 3|Cancer/Testis Antigen 95	Cancer-associated gene 1 protein (777 aa, ~90 kDa) is encoded by the human CAGE1 gene. This protein may play a role in testes development and carcinogenesis.			Amino Acid, Peptide, or Protein	
C139927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139927>	C139589	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma TNM Finding v8	A finding about one or more characteristics of ovarian, fallopian tube, or primary peritoneal carcinoma, following the rules of the TNM AJCC v8 classification system. Nonepithelial primary ovarian cancers may be staged using this classification but should be reported separately. (from AJCC 8th Ed.)			Finding	
C139928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139928>	C139927	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of ovarian, fallopian tube, or primary peritoneal carcinoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C139929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139929>	C139928	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of ovarian, fallopian tube, or primary peritoneal carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C13992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13992>	C13432	2q33-q36	A chromosome band present on 2q			Gene or Genome	
C139930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139930>	C139929	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma cM0 TNM Finding v8	Ovarian, fallopian tube, or primary peritoneal carcinoma without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C139931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139931>	C139929	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma cM1 TNM Finding v8|Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IV	Ovarian, fallopian tube, or primary peritoneal carcinoma with distant metastasis, including pleural effusion with positive cytology; liver or splenic parenchymal metastasis; metastasis to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside the abdominal cavity); and transmural involvement of intestine. (from AJCC 8th Ed.)			Finding	
C139932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139932>	C139931	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma cM1a TNM Finding v8|Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IVA	Ovarian, fallopian tube, or primary peritoneal carcinoma with pleural effusion with positive cytology. (from AJCC 8th Ed.)			Finding	
C139933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139933>	C139931	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma cM1b TNM Finding v8|Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IVB	Ovarian, fallopian tube, or primary peritoneal carcinoma with liver or splenic parenchymal metastases; metastases to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside the abdominal cavity); transmural involvement of intestine. (from AJCC 8th Ed.)			Finding	
C139934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139934>	C139927	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of ovarian, fallopian tube, or primary peritoneal carcinoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C139935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139935>	C139934	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of ovarian, fallopian tube, or primary peritoneal carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C139936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139936>	C139935	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pM1 TNM Finding v8|Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IV	Ovarian, fallopian tube, or primary peritoneal carcinoma with distant metastasis, including pleural effusion with positive cytology; liver or splenic parenchymal metastasis; metastasis to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside the abdominal cavity); and transmural involvement of intestine. (from AJCC 8th Ed.)			Finding	
C139937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139937>	C139936	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pM1a TNM Finding v8|Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IVA	Ovarian, fallopian tube, or primary peritoneal carcinoma with pleural effusion with positive cytology. (from AJCC 8th Ed.)			Finding	
C139938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139938>	C139936	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pM1b TNM Finding v8|Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IVB	Ovarian, fallopian tube, or primary peritoneal carcinoma with liver or splenic parenchymal metastases; metastases to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside the abdominal cavity); transmural involvement of intestine. (from AJCC 8th Ed.)			Finding	
C139939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139939>	C139934	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of ovarian, fallopian tube, or primary peritoneal carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor. The definitions of the T categories correspond to the stages accepted by FIGO. (from AJCC 8th Ed.)			Finding	
C13993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13993>	C13432	1p35-p31.3	A chromosome band present on 1p			Gene or Genome	
C139940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139940>	C139939	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pTX TNM Finding v8	Ovarian, fallopian tube, or primary peritoneal carcinoma in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C139941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139941>	C139939	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT0 TNM Finding v8	Ovarian, fallopian tube, or primary peritoneal carcinoma with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C139942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139942>	C139939	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT1 TNM Finding v8|Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage I	Ovarian, fallopian tube, or primary peritoneal carcinoma with tumor limited to ovaries (one or both) or fallopian tube(s). (from AJCC 8th Ed.)			Finding	
C139943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139943>	C139942	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT1a TNM Finding v8|Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IA	Ovarian, fallopian tube, or primary peritoneal carcinoma with tumor limited to one ovary (capsule intact) or fallopian tube surface; no malignant cells in ascites or peritoneal washings. (from AJCC 8th Ed.)			Finding	
C139944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139944>	C139942	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT1b TNM Finding v8|Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IB	Ovarian, fallopian tube, or primary peritoneal carcinoma with tumor limited to one or both ovaries (capsules intact) or fallopian tubes; no tumor on ovarian or fallopian tube surface; no malignant cells in ascites or peritoneal washings. (from AJCC 8th Ed.)			Finding	
C139945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139945>	C139942	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT1c TNM Finding v8|Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IC	Ovarian, fallopian tube, or primary peritoneal carcinoma with tumor limited to one or both ovaries or fallopian tubes, with any of the following: surgical spill, capsule ruptured before surgery or tumor on ovarian or fallopian tube surface, or malignant cells in ascites or peritoneal washings. (from AJCC 8th Ed.)			Finding	
C139946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139946>	C139945	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT1c1 TNM Finding v8|Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IC1	Ovarian, fallopian tube, or primary peritoneal carcinoma with tumor limited to one or both ovaries or fallopian tubes, with surgical spill. (from AJCC 8th Ed.)			Finding	
C139947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139947>	C139945	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT1c2 TNM Finding v8|Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IC2	Ovarian, fallopian tube, or primary peritoneal carcinoma with tumor limited to one or both ovaries or fallopian tubes, with capsule ruptured before surgery or tumor on ovarian or fallopian tube surface. (from AJCC 8th Ed.)			Finding	
C139948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139948>	C139945	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT1c3 TNM Finding v8|Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IC3	Ovarian, fallopian tube, or primary peritoneal carcinoma with tumor limited to one or both ovaries or fallopian tubes with malignant cells in ascites or peritoneal washings. (from AJCC 8th Ed.)			Finding	
C139949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139949>	C139939	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT2 TNM Finding v8|Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage II	Ovarian, fallopian tube, or primary peritoneal carcinoma with tumor involving one or both ovaries or fallopian tubes with pelvic extension below pelvic brim or primary peritoneal cancer. (from AJCC 8th Ed.)			Finding	
C13994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13994>	C13432	12q22-q23	A chromosome band present on 12q			Gene or Genome	
C139950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139950>	C139949	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT2a TNM Finding v8|Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IIA	Ovarian, fallopian tube, or primary peritoneal carcinoma with extension and/or implants on the uterus and/or fallopian tube(s) and/or ovaries. (from AJCC 8th Ed.)			Finding	
C139951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139951>	C139949	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT2b TNM Finding v8|Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IIB	Ovarian, fallopian tube, or primary peritoneal carcinoma with extension to and/or implants on other pelvic tissues. (from AJCC 8th Ed.)			Finding	
C139952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139952>	C139939	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT3 TNM Finding v8|Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage III	Ovarian, fallopian tube, or primary peritoneal carcinoma with tumor involving one or both ovaries or fallopian tubes, or primary peritoneal cancer, with microscopically confirmed peritoneal metastasis outside the pelvis and/or metastasis to the retroperitoneal (pelvic and/or para-aortic) lymph nodes. (from AJCC 8th Ed.)			Finding	
C139953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139953>	C139952	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT3a TNM Finding v8|Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IIIA2	Ovarian, fallopian tube, or primary peritoneal carcinoma with microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. (from AJCC 8th Ed.)			Finding	
C139954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139954>	C139952	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT3b TNM Finding v8|Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IIIB	Ovarian, fallopian tube, or primary peritoneal carcinoma with macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension with or without metastasis to the retroperitoneal lymph nodes. (from AJCC 8th Ed.)			Finding	
C139955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139955>	C139952	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pT3c TNM Finding v8|Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IIIC	Ovarian, fallopian tube, or primary peritoneal carcinoma with macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension with or without metastasis to the retroperitoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ). (from AJCC 8th Ed.)			Finding	
C139956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139956>	C139934	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of ovarian, fallopian tube, or primary peritoneal carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C139957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139957>	C139956	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pNX TNM Finding v8	Ovarian, fallopian tube, or primary peritoneal carcinoma in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C139958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139958>	C139956	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pN0 TNM Finding v8	Ovarian, fallopian tube, or primary peritoneal carcinoma with no regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C139959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139959>	C139958	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pN0(i+) TNM Finding v8	Ovarian, fallopian tube, or primary peritoneal carcinoma with isolated tumor cells in regional lymph node(s) no greater than 0.2 mm. (from AJCC 8th Ed.)			Finding	
C13995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13995>	C13432	9q22.32	A chromosome band present on 9q			Gene or Genome	
C139960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139960>	C139956	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pN1 TNM Finding v8|Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IIIA1	Ovarian, fallopian tube, or primary peritoneal carcinoma with positive retroperitoneal lymph nodes only (histologically confirmed). (from AJCC 8th Ed.)			Finding	
C139961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139961>	C139960	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pN1a TNM Finding v8|Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IIIA1i	Ovarian, fallopian tube, or primary peritoneal carcinoma with metastasis up to 10 mm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C139962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139962>	C139960	Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma pN1b TNM Finding v8|Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma FIGO Stage IIIA1ii	Ovarian, fallopian tube, or primary peritoneal carcinoma with metastasis more than 10 mm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C139963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139963>	C4908	Ovarian Cancer by AJCC v8 Stage|Ovarian Carcinoma by AJCC v8 Stage	A term that refers to the staging of ovarian cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to ovarian carcinomas. Nonepithelial primary ovarian cancers may be staged using this classification but should be reported separately. (from AJCC 8th Ed.)			Neoplastic Process	
C139964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139964>	C139963	Stage I Ovarian Cancer AJCC v8|Stage I Ovarian Cancer|Stage I Ovarian Carcinoma AJCC v8	Stage I includes: T1, N0, M0. T1: Ovarian cancer with tumor limited to ovaries (one or both). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage I Ovarian Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139965>	C139964	Stage IA Ovarian Cancer AJCC v8|Stage IA Ovarian Cancer|Stage IA Ovarian Carcinoma AJCC v8	Stage IA includes: T1a, N0, M0. T1a: Ovarian cancer with tumor limited to one ovary (capsule intact); no malignant cells in ascites or peritoneal washings. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IA Ovarian Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139966>	C139964	Stage IB Ovarian Cancer AJCC v8|Stage IB Ovarian Cancer|Stage IB Ovarian Carcinoma AJCC v8	Stage IB includes: T1b, N0, M0. T1b: Ovarian cancer with tumor limited to one or both ovaries (capsules intact); no tumor on ovarian surface; no malignant cells in ascites or peritoneal washings. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IB Ovarian Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139967>	C139964	Stage IC Ovarian Cancer AJCC v8|Stage IC Ovarian Cancer|Stage IC Ovarian Carcinoma AJCC v8	Stage IC includes: T1c, N0, M0. T1c: Ovarian cancer with tumor limited to one or both ovaries, with any of the following: surgical spill, capsule ruptured before surgery or tumor on ovarian surface, or malignant cells in ascites or peritoneal washings. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IC Ovarian Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139968>	C139963	Stage II Ovarian Cancer AJCC v8|Stage II Ovarian Cancer|Stage II Ovarian Carcinoma AJCC v8	Stage II includes: T2, N0, M0. T2: Ovarian cancer with tumor involving one or both ovaries with pelvic extension below pelvic brim. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage II Ovarian Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139969>	C139968	Stage IIA Ovarian Cancer AJCC v8|Stage IIA Ovarian Cancer|Stage IIA Ovarian Carcinoma AJCC v8	Stage IIA includes: T2a, N0, M0. T2a: Ovarian cancer with tumor extension and/or implants on the uterus and/or fallopian tube(s) and/or ovaries. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIA Ovarian Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13996>	C13432	7q22	A chromosome band present on 7q			Gene or Genome	
C139970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139970>	C139968	Stage IIB Ovarian Cancer AJCC v8|Stage IIB Ovarian Cancer|Stage IIB Ovarian Carcinoma AJCC v8	Stage IIB includes: T2b, N0, M0. T2b: Ovarian cancer with tumor extension to and/or implants on other pelvic tissues. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIB Ovarian Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139971>	C139963	Stage III Ovarian Cancer AJCC v8|Stage III Ovarian Cancer|Stage III Ovarian Carcinoma AJCC v8	Stage III includes: IIIA1: T1/2, N1, M0; IIIA2: T3a, N0/N1, M0; IIIB: T3b, N0/N1, M0; IIIC: T3c, N0/N1, M0. T1: Ovarian cancer with tumor limited to ovaries (one or both). T2: Ovarian cancer with tumor involving one or both ovaries with pelvic extension below pelvic brim. T3a: Ovarian cancer with microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. T3b: Ovarian cancer with macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension with or without metastasis to the retroperitoneal lymph nodes. T3c: Ovarian cancer with macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension with or without metastasis to the retroperitoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ). N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)	Stage III Ovarian Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139972>	C139971	Stage IIIA Ovarian Cancer AJCC v8|Stage IIIA Ovarian Cancer|Stage IIIA Ovarian Carcinoma AJCC v8	Stage IIIA includes: IIIA1: T1/2, N1, M0; IIIA2: T3a, N0/N1, M0. T1: Ovarian cancer with tumor limited to ovaries (one or both). T2: Ovarian cancer with tumor involving one or both ovaries with pelvic extension below pelvic brim. T3a: Ovarian cancer with microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIIA Ovarian Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139973>	C139972	Stage IIIA1 Ovarian Cancer AJCC v8|Stage IIIA1 Ovarian Cancer|Stage IIIA1 Ovarian Carcinoma AJCC v8	Stage IIIA1 includes: T1/2, N1, M0. T1: Ovarian cancer with tumor limited to ovaries (one or both). T2: Ovarian cancer with tumor involving one or both ovaries with pelvic extension below pelvic brim. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIIA1 Ovarian Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139974>	C139972	Stage IIIA2 Ovarian Cancer AJCC v8|Stage IIIA2 Ovarian Cancer|Stage IIIA2 Ovarian Carcinoma AJCC v8	Stage IIIA2 includes: T3a, N0/N1, M0. T3a: Ovarian cancer with microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIIA2 Ovarian Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139975>	C139971	Stage IIIB Ovarian Cancer AJCC v8|Stage IIIB Ovarian Cancer|Stage IIIB Ovarian Carcinoma AJCC v8	Stage IIIB includes: T3b, N0/N1, M0. T3b: Ovarian cancer with macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension with or without metastasis to the retroperitoneal lymph nodes. N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIIB Ovarian Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139976>	C139971	Stage IIIC Ovarian Cancer AJCC v8|Stage IIIC Ovarian Cancer|Stage IIIC Ovarian Carcinoma AJCC v8	Stage IIIC includes: T3c, N0/N1, M0. T3c: Ovarian cancer with macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension with or without metastasis to the retroperitoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ). N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIIC Ovarian Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139977>	C139963	Stage IV Ovarian Cancer AJCC v8|Stage IV Ovarian Cancer|Stage IV Ovarian Carcinoma AJCC v8	Stage IV includes: Any T, Any N, M1: M1: Distant metastasis, including pleural effusion with positive cytology; liver or splenic parenchymal metastasis; metastasis to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside the abdominal cavity); and transmural involvement of intestine. (from AJCC 8th Ed.)	Stage IV Ovarian Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139978>	C139977	Stage IVA Ovarian Cancer AJCC v8|Stage IVA Ovarian Cancer|Stage IVA Ovarian Carcinoma AJCC v8	Stage IVA includes: Any T, Any N, M1a. M1a: Ovarian cancer with pleural effusion with positive cytology. (from AJCC 8th Ed.)	Stage IVA Ovarian Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139979>	C139977	Stage IVB Ovarian Cancer AJCC v8|Stage IVB Ovarian Cancer|Stage IVB Ovarian Carcinoma AJCC v8	Stage IVB includes: Any T, Any N, M1b. M1b: Ovarian cancer with liver or splenic parenchymal metastases; metastases to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside the abdominal cavity); transmural involvement of intestine. (from AJCC 8th Ed.)	Stage IVB Ovarian Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13997>	C13432	7q21-q22	A chromosome band present on 7q			Gene or Genome	
C139980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139980>	C27977	Stage IIIA1	A stage term that applies to ovarian and fallopian tube carcinoma and indicates that the tumor is limited to ovaries (one or both) or fallopian tube(s) or the tumor involves one or both ovaries or fallopian tubes with pelvic extension below pelvic brim. There are positive retroperitoneal lymph nodes only (histologically confirmed) and no distant metastasis. (adapted from AJCC 8th Ed.)			Clinical Attribute	GDC Terminology|GDC Value Terminology
C139981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139981>	C27977	Stage IIIA2	A stage term that applies to ovarian and fallopian tube carcinoma and indicates the presence of microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. There is no distant metastasis. (adapted from AJCC 8th Ed.)			Clinical Attribute	GDC Terminology|GDC Value Terminology
C139982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139982>	C15839	Pre-operative Evaluation|Preoperative Evaluation	An examination of an individual to determine their health status prior to a surgical procedure and their suitability for the procedure.			Research Activity	
C139983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139983>	C3867	Fallopian Tube Cancer by AJCC v8 Stage|Fallopian Tube Carcinoma by AJCC v8 Stage	A term that refers to the staging of fallopian tube cancer according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C139984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139984>	C139983	Stage I Fallopian Tube Cancer AJCC v8|Stage I Fallopian Tube Cancer|Stage I Fallopian Tube Carcinoma AJCC v8	Stage I includes: T1, N0, M0. T1: Fallopian tube cancer with tumor limited to fallopian tube(s). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage I Fallopian Tube Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139985>	C139984	Stage IA Fallopian Tube Cancer AJCC v8|Stage IA Fallopian Tube Cancer|Stage IA Fallopian Tube Carcinoma AJCC v8	Stage IA includes: T1a, N0, M0. T1a: Fallopian tube cancer with tumor limited to fallopian tube surface; no malignant cells in ascites or peritoneal washings N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IA Fallopian Tube Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139986>	C139984	Stage IB Fallopian Tube Cancer AJCC v8|Stage IB Fallopian Tube Cancer|Stage IB Fallopian Tube Carcinoma AJCC v8	Stage IB includes: T1b, N0, M0. T1b: Fallopian tube cancer with tumor limited to fallopian tubes; no tumor on fallopian tube surface; no malignant cells in ascites or peritoneal washings. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IB Fallopian Tube Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139987>	C139984	Stage IC Fallopian Tube Cancer AJCC v8|Stage IC Fallopian Tube Cancer|Stage IC Fallopian Tube Carcinoma AJCC v8	Stage IC includes: T1c, N0, M0. T1c: Fallopian tube cancer with tumor limited to fallopian tubes, with any of the following: surgical spill, capsule ruptured before surgery or tumor on fallopian tube surface, or malignant cells in ascites or peritoneal washings. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IC Fallopian Tube Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139988>	C139983	Stage II Fallopian Tube Cancer AJCC v8|Stage II Fallopian Tube Cancer|Stage II Fallopian Tube Carcinoma AJCC v8	Stage II includes: T2, N0, M0. T2: Fallopian tube cancer with tumor involving fallopian tubes with pelvic extension below pelvic brim. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage II Fallopian Tube Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139989>	C139988	Stage IIA Fallopian Tube Cancer AJCC v8|Stage IIA Fallopian Tube Cancer|Stage IIA Fallopian Tube Carcinoma AJCC v8	Stage IIA includes: T2a, N0, M0. T2a: Fallopian tube cancer with extension and/or implants on the uterus and/or fallopian tube(s) and/or ovaries. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIA Fallopian Tube Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13998>	C13432	6q24-q25	A chromosome band present on 6q			Gene or Genome	
C139990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139990>	C139988	Stage IIB Fallopian Tube Cancer AJCC v8|Stage IIB Fallopian Tube Cancer|Stage IIB Fallopian Tube Carcinoma AJCC v8	Stage IIB includes: T2b, N0, M0. T2b: Fallopian tube cancer with tumor extension to and/or implants on other pelvic tissues. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIB Fallopian Tube Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139991>	C139983	Stage III Fallopian Tube Cancer AJCC v8|Stage III Fallopian Tube Cancer|Stage III Fallopian Tube Carcinoma AJCC v8	Stage III includes: IIIA1: T1/2, N1, M0; IIIA2: T3a, N0/N1, M0; IIIB: T3b, N0/N1, M0; IIIC: T3c, N0/N1, M0. T1: Fallopian tube cancer with tumor limited to fallopian tube(s). T2: Fallopian tube cancer with tumor involving fallopian tubes with pelvic extension below pelvic brim. T3a: Fallopian tube cancer with microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. T3b: Fallopian tube cancer with macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension with or without metastasis to the retroperitoneal lymph nodes. T3c: Fallopian tube cancer with macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension with or without metastasis to the retroperitoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ). N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)	Stage III Fallopian Tube Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139992>	C139991	Stage IIIA Fallopian Tube Cancer AJCC v8|Stage IIIA Fallopian Tube Cancer|Stage IIIA Fallopian Tube Carcinoma AJCC v8	Stage IIIA includes: IIIA1: T1/2, N1, M0; IIIA2: T3a, N0/N1, M0. T1: Fallopian tube cancer with tumor limited to fallopian tube(s). T2: Fallopian tube cancer with tumor involving fallopian tubes with pelvic extension below pelvic brim. T3a: Fallopian tube cancer with microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIIA Fallopian Tube Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139993>	C139992	Stage IIIA1 Fallopian Tube Cancer AJCC v8|Stage IIIA1 Fallopian Tube Cancer|Stage IIIA1 Fallopian Tube Carcinoma AJCC v8	Stage IIIA1 includes: T1/2, N1, M0. T1: T1: Fallopian tube cancer with tumor limited to fallopian tube(s). T2: Fallopian tube cancer with tumor involving fallopian tubes with pelvic extension below pelvic brim. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIIA1 Fallopian Tube Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139994>	C139992	Stage IIIA2 Fallopian Tube Cancer AJCC v8|Stage IIIA2 Fallopian Tube Cancer|Stage IIIA2 Fallopian Tube Carcinoma AJCC v8	Stage IIIA2 includes: T3a, N0/N1, M0. T3a: T3a: Fallopian tube cancer with microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIIA2 Fallopian Tube Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139995>	C139991	Stage IIIB Fallopian Tube Cancer AJCC v8|Stage IIIB Fallopian Tube Cancer|Stage IIIB Fallopian Tube Carcinoma AJCC v8	Stage IIIB includes: T3b, N0/N1, M0. T3b: Fallopian tube cancer with macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension with or without metastasis to the retroperitoneal lymph nodes. N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIIB Fallopian Tube Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139996>	C139991	Stage IIIC Fallopian Tube Cancer AJCC v8|Stage IIIC Fallopian Tube Cancer|Stage IIIC Fallopian Tube Carcinoma AJCC v8	Stage IIIC includes: T3c, N0/N1, M0. T3c: Fallopian tube cancer with macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension with or without metastasis to the retroperitoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ). N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIIC Fallopian Tube Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139997>	C139983	Stage IV Fallopian Tube Cancer AJCC v8|Stage IV Fallopian Tube Cancer|Stage IV Fallopian Tube Carcinoma AJCC v8	Stage IV includes: Any T, Any N, M1: M1: Distant metastasis, including pleural effusion with positive cytology; liver or splenic parenchymal metastasis; metastasis to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside the abdominal cavity); and transmural involvement of intestine. (from AJCC 8th Ed.)	Stage IV Fallopian Tube Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139998>	C139997	Stage IVA Fallopian Tube Cancer AJCC v8|Stage IVA Fallopian Tube Cancer|Stage IVA Fallopian Tube Carcinoma AJCC v8	Stage IVA includes: Any T, Any N, M1a. M1a: Fallopian tube cancer with pleural effusion with positive cytology. (from AJCC 8th Ed.)	Stage IVA Fallopian Tube Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C139999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C139999>	C139997	Stage IVB Fallopian Tube Cancer AJCC v8|Stage IVB Fallopian Tube Cancer|Stage IVB Fallopian Tube Carcinoma AJCC v8	Stage IVB includes: Any T, Any N, M1b. M1b: Fallopian tube cancer with liver or splenic parenchymal metastases; metastases to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside the abdominal cavity); transmural involvement of intestine. (from AJCC 8th Ed.)	Stage IVB Fallopian Tube Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C13999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C13999>	C13432	15q24-q25	A chromosome band present on 15q			Gene or Genome	
C1399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1399>	C2311	Peplomycin|(S)-n1-[3-[(1-phenylethyl)amino]propyl]bleomycinamide|PEP|PEPLEOMYCIN|PEPLOMYCIN|Pepleomycin|n1-[3[[(S)-alpha-methylbenzyl]amino]propyl]bleomycinamide	A semisynthetic analog of Bleomycin, a mixture of several basic glycopeptide antineoplastic antibiotics isolated from Streptomyces verticillus.  Peplomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals that cause single- and double-stranded breaks in DNA.  This agent appears to show greater antitumor activity than bleomycin; its use is limited due to pulmonary toxicity. (NCI04)			Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C140000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140000>	C20420	PAX9 Gene|PAX9|PAX9|Paired Box 9 Gene	This gene is involved in the development of thymus, parathyroid glands, teeth and other skeletal elements.			Gene or Genome	
C140001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140001>	C140000	PAX9 wt Allele|Paired Box 9 wt Allele|Paired Box Gene 9|Paired Domain Gene 9	Human PAX9 wild-type allele is located in the vicinity of 14q13.3 and is approximately 22 kb in length. This allele, which encodes paired box protein Pax-9, plays a role in fetal development. Mutation of the gene is associated with selective tooth agenesis type 3 and cleft palate.			Gene or Genome	
C140002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140002>	C17207	Paired Box Protein Pax-9|PAX9	Paired box protein Pax-9 (341 aa, ~36 kDa) is encoded by the human PAX9 gene. This protein is involved in transcriptional regulation during fetal development.			Amino Acid, Peptide, or Protein	
C140003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140003>	C40022	Primary Peritoneal Cancer by AJCC v7 Stage|Primary Peritoneal Carcinoma by AJCC v7 Stage	A term that refers to the staging of primary peritoneal cancer according to the American Joint Committee on Cancer, 7th edition.			Neoplastic Process	
C140004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140004>	C40022	Primary Peritoneal Cancer by AJCC v8 Stage|Primary Peritoneal Carcinoma by AJCC v8 Stage	A term that refers to the staging of primary peritoneal cancer according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C140005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140005>	C140004	Stage II Primary Peritoneal Cancer AJCC v8|Stage II Primary Peritoneal Cancer|Stage II Primary Peritoneal Carcinoma AJCC v8	Stage II includes: T2, N0, M0. T2: Primary peritoneal cancer. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage II Primary Peritoneal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140006>	C140005	Stage IIA Primary Peritoneal Cancer AJCC v8|Stage IIA Primary Peritoneal Cancer|Stage IIA Primary Peritoneal Carcinoma AJCC v8	Stage IIA includes: T2a, N0, M0. T2a: Primary peritoneal cancer with extension and/or implants on the uterus and/or fallopian tube(s) and/or ovaries. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIA Primary Peritoneal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140007>	C140005	Stage IIB Primary Peritoneal Cancer AJCC v8|Stage IIB Primary Peritoneal Cancer|Stage IIB Primary Peritoneal Carcinoma AJCC v8	Stage IIB includes: T2b, N0, M0. T2b: Primary peritoneal cancer with tumor extension to and/or implants on other pelvic tissues. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIB Primary Peritoneal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140008>	C140004	Stage III Primary Peritoneal Cancer AJCC v8|Stage III Primary Peritoneal Cancer|Stage III Primary Peritoneal Carcinoma AJCC v8	Stage III includes: IIIA: T3a, N0/N1, M0; IIIB: T3b, N0/N1, M0; IIIC: T3c, N0/N1, M0. T3a: Primary peritoneal cancer with microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. T3b: Primary peritoneal cancer with macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension with or without metastasis to the retroperitoneal lymph nodes. T3c: Primary peritoneal cancer with macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension with or without metastasis to the retroperitoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ). N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)	Stage III Primary Peritoneal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140009>	C140008	Stage IIIA Primary Peritoneal Cancer AJCC v8|Stage IIIA Primary Peritoneal Cancer|Stage IIIA Primary Peritoneal Carcinoma AJCC v8	Stage IIIA includes: T3a, N0/N1, M0. T3a: Primary peritoneal cancer with microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes. N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIIA Primary Peritoneal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C14000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14000>	C13432	15q21.1-q21.2	A chromosome band present on 15q			Gene or Genome	
C140010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140010>	C140008	Stage IIIB Primary Peritoneal Cancer AJCC v8|Stage IIIB Primary Peritoneal Cancer|Stage IIIB Primary Peritoneal Carcinoma AJCC v8	Stage IIIB includes: T3b, N0/N1, M0. T3b: Primary peritoneal cancer with macroscopic peritoneal metastasis beyond pelvis 2 cm or less in greatest dimension with or without metastasis to the retroperitoneal lymph nodes. N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIIB Primary Peritoneal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140011>	C140008	Stage IIIC Primary Peritoneal Cancer AJCC v8|Stage IIIC Primary Peritoneal Cancer|Stage IIIC Primary Peritoneal Carcinoma AJCC v8	Stage IIIC includes: T3c, N0/N1, M0. T3c: Primary peritoneal cancer with macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension with or without metastasis to the retroperitoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ). N0: No regional lymph node metastasis. N1: Positive retroperitoneal lymph nodes only (histologically confirmed). M0: No distant metastasis. (AJCC 8th Ed.)	Stage IIIC Primary Peritoneal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140012>	C140004	Stage IV Primary Peritoneal Cancer AJCC v8|Stage IV Primary Peritoneal Cancer|Stage IV Primary Peritoneal Carcinoma AJCC v8	Stage IV includes: Any T, Any N, M1: M1: Distant metastasis, including pleural effusion with positive cytology; liver or splenic parenchymal metastasis; metastasis to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside the abdominal cavity); and transmural involvement of intestine. (from AJCC 8th Ed.)	Stage IV Primary Peritoneal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140013>	C140012	Stage IVA Primary Peritoneal Cancer AJCC v8|Stage IVA Primary Peritoneal Cancer|Stage IVA Primary Peritoneal Carcinoma AJCC v8	Stage IVA includes: Any T, Any N, M1a. M1a: Primary peritoneal cancer with pleural effusion with positive cytology. (from AJCC 8th Ed.)	Stage IVA Primary Peritoneal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140014>	C140012	Stage IVB Primary Peritoneal Cancer AJCC v8|Stage IVB Primary Peritoneal Cancer|Stage IVB Primary Peritoneal Carcinoma AJCC v8	Stage IVB includes: Any T, Any N, M1b. M1b: Primary peritoneal cancer with liver or splenic parenchymal metastases; metastases to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside the abdominal cavity); transmural involvement of intestine. (from AJCC 8th Ed.)	Stage IVB Primary Peritoneal Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140015>	C139589	Gestational Trophoblastic Neoplasm TNM Finding v8	A finding about one or more characteristics of a gestational trophoblastic neoplasm, following the rules of the TNM AJCC v8 classification system. This classification applies to the following placental neoplasms: invasive hydatidiform mole, choriocarcinoma, placental site trophoblastic tumor, and epithelioid trophoblastic tumor. Complete and partial hydatidiform tumors are not included in this classification. (from AJCC 8th Ed.)			Finding	
C140016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140016>	C140015	Gestational Trophoblastic Neoplasm Clinical TNM Finding v8	A clinical finding about one or more characteristics of a gestational trophoblastic neoplasm, following the rules of the TNM AJCC v8 classification system.			Finding	
C140017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140017>	C140016	Gestational Trophoblastic Neoplasm Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of a gestational trophoblastic neoplasm, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C140018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140018>	C140017	Gestational Trophoblastic Neoplasm cM0 TNM Finding v8	Gestational trophoblastic neoplasm without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C140019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140019>	C140017	Gestational Trophoblastic Neoplasm cM1 TNM Finding v8	Gestational trophoblastic neoplasm with distant metastasis. (from AJCC 8th Ed.)			Finding	
C14001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14001>	C13432	1p35.1-p36.23	A chromosome band present on 1p			Gene or Genome	
C140020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140020>	C140019	Gestational Trophoblastic Neoplasm cM1a TNM Finding v8|Gestational Trophoblastic Neoplasm FIGO Stage III	Gestational trophoblastic neoplasm with lung metastasis. (from AJCC 8th Ed.)			Finding	
C140021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140021>	C140019	Gestational Trophoblastic Neoplasm cM1b TNM Finding v8|Gestational Trophoblastic Neoplasm FIGO Stage IV	Gestational trophoblastic neoplasm with all other distant metastases. (from AJCC 8th Ed.)			Finding	
C140022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140022>	C140015	Gestational Trophoblastic Neoplasm Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of a gestational trophoblastic neoplasm, following the rules of the TNM AJCC v8 classification system.			Finding	
C140023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140023>	C140022	Gestational Trophoblastic Neoplasm Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of a gestational trophoblastic neoplasm, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C140024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140024>	C140023	Gestational Trophoblastic Neoplasm pM1 TNM Finding v8	Gestational trophoblastic neoplasm with distant metastasis. (from AJCC 8th Ed.)			Finding	
C140025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140025>	C140024	Gestational Trophoblastic Neoplasm pM1a TNM Finding v8|Gestational Trophoblastic Neoplasm FIGO Stage III	Gestational trophoblastic neoplasm with lung metastasis. (from AJCC 8th Ed.)			Finding	
C140026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140026>	C140024	Gestational Trophoblastic Neoplasm pM1b TNM Finding v8|Gestational Trophoblastic Neoplasm FIGO Stage IV	Gestational trophoblastic neoplasm with all other distant metastases. (from AJCC 8th Ed.)			Finding	
C140027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140027>	C140022	Gestational Trophoblastic Neoplasm Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of a gestational trophoblastic neoplasm, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C140028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140028>	C140027	Gestational Trophoblastic Neoplasm pTX TNM Finding v8	Gestational trophoblastic neoplasm in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C140029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140029>	C140027	Gestational Trophoblastic Neoplasm pT0 TNM Finding v8	Gestational trophoblastic neoplasm with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C14002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14002>	C13432	8q22.3-q23	A chromosome band present on 8q			Gene or Genome	
C140030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140030>	C140027	Gestational Trophoblastic Neoplasm pT1 TNM Finding v8|Gestational Trophoblastic Neoplasm FIGO Stage I	Gestational trophoblastic neoplasm in which the tumor is confined to uterus. (from AJCC 8th Ed.)			Finding	
C140031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140031>	C140027	Gestational Trophoblastic Neoplasm pT2 TNM Finding v8|Gestational Trophoblastic Neoplasm FIGO Stage II	Gestational trophoblastic neoplasm in which the tumor extends to other genital structures (ovary, tube, vagina, broad ligaments) by metastasis or direct extension. (from AJCC 8th Ed.)			Finding	
C140032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140032>	C4699	Gestational Trophoblastic Tumor by AJCC v7 Stage	A term that refers to the staging of gestational trophoblastic tumor according to the American Joint Committee on Cancer, 7th edition.			Neoplastic Process	
C140033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140033>	C180633	Gestational Trophoblastic Neoplasm by AJCC v8 Stage	A term that refers to the staging of a gestational trophoblastic neoplasm according to the American Joint Committee on Cancer, 8th edition. This classification applies to the following neoplasms: invasive hydatidiform mole, gestational choriocarcinoma, placental site trophoblastic tumor, and epithelioid trophoblastic tumor. Complete and partial hydatidiform moles are not included in this classification. The current FIGO classification includes an anatomic stage designated by Roman numeral I, II, III, or IV, followed by the risk factor score expressed in Arabic numerals (e.g., Stage II: 4, Stage IV: 9).  (from AJCC 8th Ed.)			Neoplastic Process	
C140034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140034>	C140033	Stage I Gestational Trophoblastic Neoplasm AJCC v8	Stage I includes: T1, M0. T1: Gestational trophoblastic neoplasm in which the tumor is confined to uterus. M0: No distant metastasis. (AJCC 8th Ed.)			Neoplastic Process	
C140035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140035>	C140033	Stage II Gestational Trophoblastic Neoplasm AJCC v8	Stage II includes: T2, M0. T2: Gestational trophoblastic neoplasm in which the tumor extends to other genital structures (ovary, tube, vagina, broad ligaments) by metastasis or direct extension. M0: No distant metastasis. (AJCC 8th Ed.)			Neoplastic Process	
C140036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140036>	C140033	Stage III Gestational Trophoblastic Neoplasm AJCC v8	Stage III includes: Any T, M1a. M1a: Gestational trophoblastic neoplasm with lung metastasis. (AJCC 8th Ed.)			Neoplastic Process	
C140037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140037>	C140033	Stage IV Gestational Trophoblastic Neoplasm AJCC v8	Stage IV includes: Any T, M1b. M1b: Gestational trophoblastic neoplasm with all other distant metastases. (AJCC 8th Ed.)			Neoplastic Process	
C140038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140038>	C20194	NPIPB8 Gene|NPIPB8|NPIPB8|Nuclear Pore Complex Interacting Protein Family Member B8 Gene	This gene may be involved in the function of nuclear pores.			Gene or Genome	
C140039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140039>	C140038	NPIPB8 wt Allele|Nuclear Pore Complex Interacting Protein Family Member B8 wt Allele|Nuclear Pore Complex Interacting Protein Family, Member B8 Gene	Human NPIPB8 wild-type allele is located in the vicinity of 16p11.2 and is approximately 34 kb in length. This allele, which encodes nuclear pore complex-interacting protein family member B8 protein, may play a role in nuclear transport.			Gene or Genome	
C14003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14003>	C13432	4q26-q32	A chromosome band present on 4q			Gene or Genome	
C140040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140040>	C18466	Nuclear Pore Complex-Interacting Protein Family Member B8|NPIPB8	Nuclear pore complex-interacting protein family member B8 (432 aa, ~50 kDa) is encoded by the human NPIPB8 gene. This protein may be involved in nuclear pore-dependent transport.			Amino Acid, Peptide, or Protein	
C140041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140041>	C134787|C129820	Vibostolimab|MK 7684|MK-7684|MK7684|T-cell Immunoglobulin and Immunoreceptor Tyrosine-based Inhibitory Motif Inhibitor MK-7684|TIGIT Inhibitor MK-7684|TIGIT-targeting Agent MK-7684|VIBOSTOLIMAB	An antagonistic agent targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT; T-cell immunoreceptor with Ig and ITIM domains; T-cell immunoglobulin and ITIM domain), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, vibostolimab targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs) and natural killer (NK) cells, thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5), which are expressed on T-cells, NK cells and certain cancer cells. This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as NK cells and CD8+ T-cells, and activates CD226-mediated signaling. This activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family and an immune inhibitory receptor, is overexpressed on tumor antigen-specific CD8+ T-cells and CD8+ TILs and plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.	Vibostolimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C140042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140042>	C15192	Plasma Transfusion|Plasma Infusion	The infusion of plasma into the bloodstream.			Therapeutic or Preventive Procedure	
C140043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140043>	C48233	Male Reproductive System Cancer TNM Finding v8	A finding about one or more characteristics of male reproductive system cancer, following the rules of the TNM AJCC v8 classification system. This classification system applies to penile cancer, prostate cancer, and testicular cancer.			Finding	
C140044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140044>	C140043	Penile Cancer TNM Finding v8|Penile Squamous Cell Carcinoma TNM Finding v8	A finding about one or more characteristics of penile cancer, following the rules of the TNM AJCC v8 classification system. This classification system applies to penile squamous cell carcinoma and associated histologic subtypes. It does not apply to urethral carcinomas, sarcomas, and melanomas. (from AJCC 8th Ed.)			Finding	
C140045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140045>	C140044	Penile Cancer Clinical TNM Finding v8|Penile Squamous Cell Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of penile cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C140046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140046>	C140045	Penile Cancer Clinical Distant Metastasis TNM Finding v8|Penile Squamous Cell Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of penile cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C140047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140047>	C140046	Penile Cancer cM0 TNM Finding v8|Penile Squamous Cell Carcinoma cM0 TNM Finding v8	Penile cancer without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C140048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140048>	C140046	Penile Cancer cM1 TNM Finding v8|Penile Squamous Cell Carcinoma cM1 TNM Finding v8	Penile cancer with distant metastasis present. (from AJCC 8th Ed.)			Finding	
C140049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140049>	C140045	Penile Cancer Clinical Regional Lymph Nodes TNM Finding v8|Penile Squamous Cell Carcinoma Clinical Regional Lymph Nodes TNM Finding v8	A clinical finding about one or more characteristics of penile cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C14004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14004>	C13432	3p21.1	A chromosome band present on 3p			Gene or Genome	
C140050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140050>	C140049	Penile Cancer cNX TNM Finding v8|Penile Squamous Cell Carcinoma cNX TNM Finding v8	Penile cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C140051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140051>	C140049	Penile Cancer cN0 TNM Finding v8|Penile Squamous Cell Carcinoma cN0 TNM Finding v8	Penile cancer with no palpable or visibly enlarged inguinal lymph nodes. (from AJCC 8th Ed.)			Finding	
C140052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140052>	C140049	Penile Cancer cN1 TNM Finding v8|Penile Squamous Cell Carcinoma cN1 TNM Finding v8	Penile cancer with palpable mobile unilateral inguinal lymph node. (from AJCC 8th Ed.)			Finding	
C140053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140053>	C140049	Penile Cancer cN2 TNM Finding v8|Penile Squamous Cell Carcinoma cN2 TNM Finding v8	Penile cancer with palpable mobile two or more unilateral inguinal nodes or bilateral inguinal lymph nodes. (from AJCC 8th Ed.)			Finding	
C140054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140054>	C140049	Penile Cancer cN3 TNM Finding v8|Penile Squamous Cell Carcinoma cN3 TNM Finding v8	Penile cancer with palpable fixed inguinal nodal mass or pelvic lymphadenopathy unilateral or bilateral. (from AJCC 8th Ed.)			Finding	
C140055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140055>	C140044	Penile Cancer Pathologic TNM Finding v8|Penile Squamous Cell Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of penile cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C140056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140056>	C140055	Penile Cancer Pathologic Distant Metastasis TNM Finding v8|Penile Squamous Cell Carcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of penile cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C140057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140057>	C140056	Penile Cancer pM1 TNM Finding v8|Penile Squamous Cell Carcinoma pM1 TNM Finding v8	Penile cancer with distant metastasis present. (from AJCC 8th Ed.)			Finding	
C140058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140058>	C140055	Penile Cancer Pathologic Primary Tumor TNM Finding v8|Penile Squamous Cell Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of penile cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C140059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140059>	C140058	Penile Cancer pTX TNM Finding v8|Penile Squamous Cell Carcinoma pTX TNM Finding v8	Penile cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C14005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14005>	C13432	2p12	A chromosome band present on 2p			Gene or Genome	
C140060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140060>	C140058	Penile Cancer pT0 TNM Finding v8|Penile Squamous Cell Carcinoma pT0 TNM Finding v8	Penile cancer with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C140061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140061>	C140058	Penile Cancer pTis TNM Finding v8|Penile Squamous Cell Carcinoma pTis TNM Finding v8	Penile cancer with a finding of carcinoma in situ (penile intraepithelial neoplasia [PeIN]). (from AJCC 8th Ed.)			Finding	
C140062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140062>	C140058	Penile Cancer pTa TNM Finding v8|Penile Squamous Cell Carcinoma pTa TNM Finding v8	Penile cancer with a finding of noninvasive localized squamous cell carcinoma. (from AJCC 8th Ed.)			Finding	
C140063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140063>	C140058	Penile Cancer pT1 TNM Finding v8|Penile Squamous Cell Carcinoma pT1 TNM Finding v8	Glans: Penile cancer with tumor invading lamina propria. Foreskin: Penile cancer with tumor invading dermis, lamina propria, or dartos fascia. Shaft: Penile cancer with tumor invading connective tissue between epidermis and corpora regardless of location. All sites with or without lymphovascular invasion or perineural invasion and is or is not high grade. (from AJCC 8th Ed.)			Finding	
C140064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140064>	C140063	Penile Cancer pT1a TNM Finding v8|Penile Squamous Cell Carcinoma pT1a TNM Finding v8	Penile cancer with tumor without lymphovascular invasion or perineural invasion and is not high grade (i.e., grade 3 or sarcomatoid). (from AJCC 8th Ed.)			Finding	
C140065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140065>	C140063	Penile Cancer pT1b TNM Finding v8|Penile Squamous Cell Carcinoma pT1b TNM Finding v8	Penile cancer with tumor exhibiting lymphovascular invasion and/or perineural invasion or is high grade (i.e., grade 3 or sarcomatoid). (from AJCC 8th Ed.)			Finding	
C140066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140066>	C140058	Penile Cancer pT2 TNM Finding v8|Penile Squamous Cell Carcinoma pT2 TNM Finding v8	Penile cancer with tumor invading into corpus spongiosum (either glans or ventral shaft) with or without urethral invasion. (from AJCC 8th Ed.)			Finding	
C140067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140067>	C140058	Penile Cancer pT3 TNM Finding v8|Penile Squamous Cell Carcinoma pT3 TNM Finding v8	Penile cancer with tumor invading into corpora cavernosum (including tunica albuginea) with or without urethral invasion. (from AJCC 8th Ed.)			Finding	
C140068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140068>	C140058	Penile Cancer pT4 TNM Finding v8|Penile Squamous Cell Carcinoma pT4 TNM Finding v8	Penile cancer with tumor invading into adjacent structures (i.e., scrotum, prostate, pubic bone). (from AJCC 8th Ed.)			Finding	
C140069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140069>	C140055	Penile Cancer Pathologic Regional Lymph Nodes TNM Finding v8|Penile Squamous Cell Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of penile cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C14006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14006>	C13432	4p13	A chromosome band present on 4p			Gene or Genome	
C140070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140070>	C140069	Penile Cancer pNX TNM Finding v8|Penile Squamous Cell Carcinoma pNX TNM Finding v8	Penile cancer in which lymph node metastasis cannot be established. (from AJCC 8th Ed.)			Finding	
C140071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140071>	C140069	Penile Cancer pN0 TNM Finding v8|Penile Squamous Cell Carcinoma pN0 TNM Finding v8	Penile cancer with no lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C140072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140072>	C140069	Penile Cancer pN1 TNM Finding v8|Penile Squamous Cell Carcinoma pN1 TNM Finding v8	Penile cancer with two or less unilateral inguinal metastases, no extranodal extension. (from AJCC 8th Ed.)			Finding	
C140073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140073>	C140069	Penile Cancer pN2 TNM Finding v8|Penile Squamous Cell Carcinoma pN2 TNM Finding v8	Penile cancer with three or more unilateral inguinal metastases or bilateral metastases. (from AJCC 8th Ed.)			Finding	
C140074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140074>	C140069	Penile Cancer pN3 TNM Finding v8|Penile Squamous Cell Carcinoma pN3 TNM Finding v8	Penile cancer with extranodal extension of lymph node metastases or pelvic lymph node metastases. (from AJCC 8th Ed.)			Finding	
C140075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140075>	C9061	Penile Cancer by AJCC v8 Stage|Penile Squamous Cell Carcinoma by AJCC v8 Stage|Squamous Cell Carcinoma of the Penis by AJCC v8 Stage	A term that refers to the staging of penile cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to penile squamous cell carcinoma and associated histologic subtypes. It does not apply to urethral carcinomas, sarcomas, and melanomas. (from AJCC 8th Ed.)			Neoplastic Process	
C140076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140076>	C140075	Stage 0 Penile Cancer AJCC v8|Stage 0 Penile Cancer|Stage 0 Penile Squamous Cell Carcinoma AJCC v8|Stage 0 Squamous Cell Carcinoma of the Penis AJCC v8	Stage 0 includes: 0is: Tis, N0, M0; 0a: Ta, N0, M0. Tis: Penile cancer with a finding of carcinoma in situ (penile intraepithelial neoplasia [PeIN]). Ta: Penile cancer with a finding of noninvasive localized squamous cell carcinoma. N0: No lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0 Penile Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140077>	C140076	Stage 0is Penile Cancer AJCC v8|Stage 0is Penile Cancer|Stage 0is Penile Squamous Cell Carcinoma AJCC v8|Stage 0is Squamous Cell Carcinoma of the Penis AJCC v8	Stage 0is includes: Tis, N0, M0. Tis: Penile cancer with a finding of carcinoma in situ (penile intraepithelial neoplasia [PeIN]). N0: No lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0is Penile Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140078>	C140076	Stage 0a Penile Cancer AJCC v8|Stage 0a Penile Cancer|Stage 0a Penile Squamous Cell Carcinoma AJCC v8|Stage 0a Squamous Cell Carcinoma of the Penis AJCC v8	Stage 0a includes: Ta, N0, M0. Ta: Penile cancer with a finding of noninvasive localized squamous cell carcinoma. N0: No lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0a Penile Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140079>	C140075	Stage I Penile Cancer AJCC v8|Stage I Penile Cancer|Stage I Penile Squamous Cell Carcinoma AJCC v8|Stage I Squamous Cell Carcinoma of the Penis AJCC v8	Stage I includes: T1a, N0, M0. T1a: Penile cancer with tumor without lymphovascular invasion or perineural invasion and is not high grade (i.e., grade 3 or sarcomatoid). N0: No lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Penile Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C14007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14007>	C13432	2p13.1	A chromosome band present on 2p			Gene or Genome	
C140080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140080>	C140075	Stage II Penile Cancer AJCC v8|Stage II Penile Cancer|Stage II Penile Squamous Cell Carcinoma AJCC v8|Stage II Squamous Cell Carcinoma of the Penis AJCC v8	Stage II includes: IIA: (T1b, N0, M0); (T2, N0, M0); IIB: (T3, N0, M0). T1b: Penile cancer with tumor exhibiting lymphovascular invasion and/or perineural invasion or is high grade (i.e., grade 3 or sarcomatoid). T2: Penile cancer with tumor invading into corpus spongiosum (either glans or ventral shaft) with or without urethral invasion. T3: Penile cancer with tumor invading into corpora cavernosum (including tunica albuginea) with or without urethral invasion. N0: No lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Penile Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140081>	C140080	Stage IIA Penile Cancer AJCC v8|Stage IIA Penile Cancer|Stage IIA Penile Squamous Cell Carcinoma AJCC v8|Stage IIA Squamous Cell Carcinoma of the Penis AJCC v8	Stage IIA includes: (T1b, N0, M0); (T2, N0, M0). T1b: Penile cancer with tumor exhibiting lymphovascular invasion and/or perineural invasion or is high grade (i.e., grade 3 or sarcomatoid). T2: Penile cancer with tumor invading into corpus spongiosum (either glans or ventral shaft) with or without urethral invasion. N0: No lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIA Penile Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140083>	C140080	Stage IIB Penile Cancer AJCC v8|Stage IIB Penile Cancer|Stage IIB Penile Squamous Cell Carcinoma AJCC v8|Stage IIB Squamous Cell Carcinoma of the Penis AJCC v8	Stage IIB includes: T3, N0, M0. T3: Penile cancer with tumor invading into corpora cavernosum (including tunica albuginea) with or without urethral invasion. N0: No lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIB Penile Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140084>	C140075	Stage III Penile Cancer AJCC v8|Stage III Penile Cancer|Stage III Penile Squamous Cell Carcinoma AJCC v8|Stage III Squamous Cell Carcinoma of the Penis AJCC v8	Stage III includes: IIIA: T1-3, N1, M0; IIIB: T1-3, N2, M0. T1: Glans: Penile cancer with tumor invading lamina propria. Foreskin: Penile cancer with tumor invading dermis, lamina propria, or dartos fascia. Shaft: Penile cancer with tumor invading connective tissue between epidermis and corpora regardless of location. All sites with or without lymphovascular invasion or perineural invasion and is or is not high grade. T2: Penile cancer with tumor invading into corpus spongiosum (either glans or ventral shaft) with or without urethral invasion. T3: Penile cancer with tumor invading into corpora cavernosum (including tunica albuginea) with or without urethral invasion. N1: Penile cancer with two or less unilateral inguinal metastases, no extranodal extension. N2: Penile cancer with three or more unilateral inguinal metastases or bilateral metastases. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Penile Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140085>	C140084	Stage IIIA Penile Cancer AJCC v8|Stage IIIA Penile Cancer|Stage IIIA Penile Squamous Cell Carcinoma AJCC v8|Stage IIIA Squamous Cell Carcinoma of the Penis AJCC v8	Stage IIIA includes: T1-3, N1, M0. T1: Glans: Penile cancer with tumor invading lamina propria. Foreskin: Penile cancer with tumor invading dermis, lamina propria, or dartos fascia. Shaft: Penile cancer with tumor invading connective tissue between epidermis and corpora regardless of location. All sites with or without lymphovascular invasion or perineural invasion and is or is not high grade. T2: Penile cancer with tumor invading into corpus spongiosum (either glans or ventral shaft) with or without urethral invasion. T3: Penile cancer with tumor invading into corpora cavernosum (including tunica albuginea) with or without urethral invasion. N1: Penile cancer with two or less unilateral inguinal metastases, no extranodal extension. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIA Penile Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140086>	C140084	Stage IIIB Penile Cancer AJCC v8|Stage IIIB Penile Cancer|Stage IIIB Penile Squamous Cell Carcinoma AJCC v8|Stage IIIB Squamous Cell Carcinoma of the Penis AJCC v8	Stage IIIB includes: T1-3, N2, M0. T1: Glans: Penile cancer with tumor invading lamina propria. Foreskin: Penile cancer with tumor invading dermis, lamina propria, or dartos fascia. Shaft: Penile cancer with tumor invading connective tissue between epidermis and corpora regardless of location. All sites with or without lymphovascular invasion or perineural invasion and is or is not high grade. T2: Penile cancer with tumor invading into corpus spongiosum (either glans or ventral shaft) with or without urethral invasion. T3: Penile cancer with tumor invading into corpora cavernosum (including tunica albuginea) with or without urethral invasion. N2: Penile cancer with three or more unilateral inguinal metastases or bilateral metastases. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIB Penile Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140087>	C140075	Stage IV Penile Cancer AJCC v8|Stage IV Penile Cancer|Stage IV Penile Squamous Cell Carcinoma AJCC v8|Stage IV Squamous Cell Carcinoma of the Penis AJCC v8	Stage IV includes: (T4, Any N, M0); (Any T, N3, M0); (Any T, Any N, M1). T4: Penile cancer with tumor invading into adjacent structures (i.e., scrotum, prostate, pubic bone). N3: Penile cancer with extranodal extension of lymph node metastases or pelvic lymph node metastases. M1: Distant metastasis present. (AJCC 8th ed.)	Stage IV Penile Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140088>	C20194	CDKN2B-AS1 Gene|CDKN2B Antisense RNA 1 Gene|CDKN2B-AS1|CDKN2B-AS1	This gene plays a role in the epigenetic silencing of genes in the CDKN2B-CDKN2A gene cluster.			Gene or Genome	
C140089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140089>	C140088	CDKN2B-AS1 wt Allele|ANRIL|CDKN2B Antisense RNA (Non-Protein Coding) Gene|CDKN2B Antisense RNA 1 (Non-Protein Coding) Gene|CDKN2B Antisense RNA 1 wt Allele|CDKN2B Antisense RNA Gene|CDKN2B-AS|CDKN2BAS|NCRNA00089|Non-Protein Coding RNA 89 Gene|PCAT12|Prostate Cancer Associated Transcript 12 Gene|RP11-145E5.4|p15AS	Human CDKN2B-AS1 wild-type allele is located in the vicinity of 9p21.3 and is approximately 126 kb in length. This allele, which encodes CDKN2B antisense RNA 1, is involved in epigenetic silencing of nearby genes. Loss of expression of the gene may be associated with increased susceptibility for cardiovascular disease, melanoma and several other cancers, intracranial aneurysm, type-2 diabetes, periodontitis, Alzheimer's disease, endometriosis, frailty in the elderly, and glaucoma.			Gene or Genome	
C14008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14008>	C13432	20p12	A chromosome band present on 20p			Gene or Genome	
C140090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140090>	C88924	CDKN2B Antisense RNA 1|Antisense Noncoding RNA in the INK4 Locus|Antisense RNA in the INK4 Locus|CDKN2B Antisense RNA|CDKN2B-AS1|Non-Protein Coding RNA 89|Prostate Cancer Associated Transcript 12|p15 Antisense RNA	CDKN2B antisense RNA 1 (~4 kb) is encoded by the human CDKN2B-AS1 gene. This non-coding RNA plays a role in the modulation of the expression of genes in the CDKN2B-CDKN2A gene cluster.			Nucleic Acid, Nucleoside, or Nucleotide	
C140091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140091>	C8701|C151957	Refractory Transformed Non-Hodgkin Lymphoma|Refractory Transformed Lymphoma	A transformed non-Hodgkin lymphoma that is resistant to treatment.			Neoplastic Process	
C140092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140092>	C63442	AspaMetDex Regimen|Aspa-Met-Dex|AspaMetDex|AspaMetDex|AspaMetDex (Erwinaze)|Asparaginase-Methotrexate-Dexamethasone|L-asparaginase/Methotrexate/Dexamethasone	A regimen consisting of L-asparaginase, methotrexate and dexamethasone that can be used for the treatment of non-Hodgkin lymphoma (NHL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C140093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140093>	C63356	AVD Regimen|AVD|AVD|Adriamycin-Vinblastine-Dacarbazine|Dacarbazine/Doxorubicin/Vinblastine|Doxorubicin/Vinblastine/Dacarbazine	A regimen consisting of doxorubicin, vinblastine and dacarbazine that can be used for the treatment of Hodgkin lymphoma (HL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C140094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140094>	C63442|C63356	BR Regimen|B-R Regimen|BR|Bendamustine Plus Rituximab|Bendamustine and Rituximab (BR)|Bendamustine and Rituximab-abbs (BR)|Bendamustine and Rituximab-arrx (BR)|Bendamustine and Rituximab-blit (BR)|Bendamustine and Rituximab-pvvr (BR)|Bendamustine and Rituximab-rite (BR)|Bendamustine and Rituximab-rixa (BR)|Bendamustine and Rituximab-rixi (BR)|Bendamustine-Rituximab|Bendamustine/Rituximab|Bendamustine/Rituximab Regimen|R-B	A regimen consisting of bendamustine and rituximab that can be used for the treatment of non-Hodgkin lymphoma (NHL), including chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, Waldenstrom macroglobulinemia and lymphoplasmacytic lymphoma, gastric and nongastric mucosa-associated lymphoid tissue (MALT) lymphoma, and nodal and splenic marginal zone lymphoma, and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C140095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140095>	C63442	R-DHAP Regimen|R-DHAP|R-DHAP|R-DHAP|R-DHAP (rituximab-abbs)|R-DHAP (rituximab-arrx)|R-DHAP (rituximab-blit)|R-DHAP (rituximab-pvvr)|R-DHAP (rituximab-rite)|R-DHAP (rituximab-rixa)|R-DHAP (rituximab-rixi)|RDHAP|Rituximab Plus Cisplatin/Cytarabine/Dexamethasone|Rituximab-DHAP|Rituximab-Dexamethasone-High Dose ARA-C-Platinol|Rituximab-Dexamethasone-High Dose Cytarabine-Cisplatin|Rituximab/Dexamethasone/High-dose Ara-C/Platinol	A regimen consisting rituximab, dexamethasone, high dose cytarabine and cisplatin that can be used for the treatment of diffuse large B-cell lymphoma, nodular lymphocyte-predominant Hodgkin lymphoma, and mantle cell lymphoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C140096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140096>	C63442	IVAC Regimen|High-dose Cytarabine/Etoposide/Ifosfamide|IVAC|Ifosfamide/Etoposide/High Dose Cytarabine|Ifosfamide/VP-16/ARA-C	A regimen consisting of ifosfamide, etoposide and high-dose cytarabine that can be used for the treatment of T-cell lymphoma, HIV-related B-cell lymphomas and diffuse large B-cell lymphoma (DLBCL).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C140097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140097>	C63443|C63442	Dose-adjusted EPOCH-R Regimen|DA-EPOCH-R|DA-R-EPOCH|DA-R-EPOCH|DA-R-EPOCH (rituximab-abbs)|DA-R-EPOCH (rituximab-arrx)|DA-R-EPOCH (rituximab-blit)|DA-R-EPOCH (rituximab-pvvr)|DA-R-EPOCH (rituximab-rite)|DA-R-EPOCH (rituximab-rixa)|DA-R-EPOCH (rituximab-rixi)|Dose-adjusted Etoposide/Prednisone/Vincristine/Cyclophosphamide/Doxorubicin/Rituximab|Dose-adjusted R-EPOCH Regimen|Dose-adjusted Rituximab-Etoposide-Prednisone-Oncovin-Cyclophosphamide-Hydroxydaunorubicin Regimen|R-DA-EPOCH|R-DA-EPOCH Regimen	A regimen consisting of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (EPOCH-R) in a dose-adjusted (DA) version that can be used for the treatment of AIDS-related B-cell lymphomas, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C140098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140098>	C63442	DeVIC Regimen|DeVIC|Dexamethasone-Etoposide-Ifosfamide-Carboplatin|Dexamethasone/Etoposide/Ifosfamide/Carboplatin	A regimen consisting of dexamethasone, etoposide, ifosfamide and carboplatin that can be used for the treatment of non-Hodgkin lymphoma (NHL).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C140099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140099>	C63442|C63356	R-ESHAP Regimen|Cytarabine-Cisplatin-Etoposide-Methylprednisolone-Rituximab|Cytarabine/Cisplatin/Etoposide/Methylprednisolone/Rituxan|Cytarabine/Cisplatin/Etoposide/Methylprednisolone/Rituximab|ESHAP Plus Rituximab|ESHAP-R|Etoposide-Solumedrol-High Dose Ara-C-Platinol-Rituximab Regimen|Etoposide/Methylprednisolone/Cytarabine/Cisplatin Plus Rituximab|Etoposide/Methylprednisolone/High-dose Cytarabine/Cisplatin|Etoposide/Solumedrol/High Dose Ara-C/Platinol/Rituximab Regimen|R-ESHAP|R-ESHAP|R-ESHAP (rituximab-abbs)|R-ESHAP (rituximab-arrx)|R-ESHAP (rituximab-blit)|R-ESHAP (rituximab-pvvr)|R-ESHAP (rituximab-rite)|R-ESHAP (rituximab-rixa)|R-ESHAP (rituximab-rixi)|Rituximab-Etoposide-Methylprednisolone-High-dose Cytarabine-Cisplatin|Rituximab-Etoposide-Solu-Medrol-High-dose Ara-C-Platinol|Rituximab/Etoposide/Solumedrol/High-dose Cytarabine/Cisplatin	A regimen consisting of rituximab, etoposide, methylprednisolone, high-dose cytarabine and cisplatin that can be used in the treatment of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C14009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14009>	C13432	4p14-q21	A chromosome band present on 4p			Gene or Genome	
C1400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1400>	C2311	Peplomycin Sulfate|N1-(3-(((S)-(alpha-methylbenzyl))amino)propyl)bleomycinamide Sulfate (1:1) (Salt)|NK-631|PEPLOMYCIN SULFATE|Pepleo	The sulfate salt of the bleomycin analogue peplomycin.  Peplomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals that cause single- and double-stranded breaks in DNA.  This agent appears to show greater antitumor activity than bleomycin; its use is limited due to pulmonary toxicity. (NCI04)			Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C140100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140100>	C63442|C63356	GDP Regimen|Cisplatin-Dexamethasone-Gemcitabine|Cisplatin/Dexamethasone/Gemcitabine|Cisplatin/Dexamethasone/Gemcitabine Regimen|Cisplatin/Gemcitabine/Decadron|Cisplatin/Gemcitabine/Decadron|GDP|GDP|Gemcitabine-Dexamethasone-Platinol|Gemcitabine/Dexamethasone/Cisplatin	A regimen consisting of gemcitabine, dexamethasone and cisplatin that can be used in the treatment of Hodgkin lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), T-cell lymphoma, and mycosis fungoides/Sezary syndrome.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C140101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140101>	C63442|C63356	R-GDP Regimen|Cisplatin/Dexamethasone/Gemcitabine/Rituximab|GDP Plus RITU Regimen|GDP-R Regimen|GDP/Rituximab|Gemcitabine-Dexamethasone-Platinol-Rituximab|R-GDP|R-GDP|R-GDP (rituximab-abbs)|R-GDP (rituximab-arrx)|R-GDP (rituximab-blit)|R-GDP (rituximab-pvvr)|R-GDP (rituximab-rite)|R-GDP (rituximab-rixa)|R-GDP (rituximab-rixi)|Rituximab/Gemcitabine/Dexamethasone/Cisplatin	A regimen consisting of rituximab, gemcitabine, dexamethasone and cisplatin that can be used in the treatment of Hodgkin lymphoma (HL), Burkitt lymphhoma, and diffuse large B-cell lymphoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C140102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140102>	C63588|C63442	Cytarabine/High-dose Methotrexate Regimen|HD MTX Plus HD AraC|HD-MTX/ARA-C|HD-MTX/ARA-C Regimen|HD-Methotrexate/Cytarabine|High-dose MTX/ARA-C Regimen|High-dose Methotrexate Plus High-dose Cytarabine	A regimen consisting of high-dose (HD) methotrexate (MTX) plus HD cytarabine (AraC) that can be used in the treatment of central nervous system (CNS) lymphoma, acute lymphoblastic leukemia (ALL)., and refractory or relapsed (RR) non-Hodgkin lymphoma (NHL).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C140103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140103>	C63588|C63442	Cytarabine/High-dose Methotrexate/Rituximab Regimen|Cytarabine, Methotrexate, Rituximab|Cytarabine, Methotrexate, Rituximab-abbs|Cytarabine, Methotrexate, Rituximab-arrx|Cytarabine, Methotrexate, Rituximab-blit|Cytarabine, Methotrexate, Rituximab-pvvr|Cytarabine, Methotrexate, Rituximab-rite|Cytarabine, Methotrexate, Rituximab-rixa|Cytarabine, Methotrexate, Rituximab-rixi|R-HD-MTX/ARA-C|R-HD-MTX/ARA-C Regimen|Rituximab Plus HD MTX Plus HD AraC|Rituximab-HD-MTX/ARA-C|Rituximab-High-dose Methotrexate-High-dose Cytarabine|Rituximab/HD-Methotrexate/Cytarabine|Rituximab/High-dose MTX/ARA-C Regimen	A regimen consisting of cytarabine, high-dose methotrexate and rituximab that can be used in the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, and mantle cell lymphoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C140104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140104>	C63443|C63442	R-Hyper-CVAD Regimen|Hyper-CVAD Plus Rituximab|HyperCVAD-Rituximab|HyperCVAD/Rituximab|R-HCVAD|R-Hyper-CVAD|R-HyperCVAD|Rituximab Plus HyperCVAD|Rituximab and Hyperfractionated Cyclophosphamide-Vincristine-Adriamycin-Dexamethasone Regimen|Rituximab-HyperCVAD	A regimen consisting of cyclophosphamide, vincristine, doxorubicin and dexamethasone, administered on a hyperfractionated schedule, plus rituximab that may be used to treat HIV-related B-cell lymphoma, Burkitt lymphoma, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, and acute lymphoblastic leukemia (ALL).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C140105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140105>	C63442|C63356	IVE Regimen|IVE|IVE|Ifosfamide-Epirubicin-Etoposide|Ifosfamide/Epirubicin/Etoposide	A regimen consisting of ifosfamide, epirubicin and etoposide that can be used in the treatment of non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), and as a stem cell mobilization regimen.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C140106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140106>	C140180	MATRix Regimen|HD-MTX/HD-ARAC/Thiotepa/Rituximab|MATRix|MATRix|MATRix (rituximab-abbs)|MATRix (rituximab-arrx)|MATRix (rituximab-blit)|MATRix (rituximab-pvvr)|MATRix (rituximab-rite)|MATRix (rituximab-rixa)|MATRix (rituximab-rixi)|Methotrexate-Cytarabine-Thiotepa-Rituximab|Methotrexate/Cytarabine/Thiotepa/Rituximab	A regimen consisting of high-dose methotrexate, high-dose cytarabine, thiotepa and rituximab that can be used in the treatment of central nervous system (CNS) lymphoma and as a conditioning regimen for autologous stem cell transplantation (ASCT).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C140107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140107>	C140180	MRT Regimen|MRT|MT-R|MT-R|MT-R (rituximab-abbs)|MT-R (rituximab-arrx)|MT-R (rituximab-blit)|MT-R (rituximab-pvvr)|MT-R (rituximab-rite)|MT-R (rituximab-rixa)|MT-R (rituximab-rixi)|MT-R Regimen|Methotrexate-Rituximab-Temozolomide|Methotrexate/Rituximab/Temozolomide|Methotrexate/Temozolomide/Rituximab	A regimen consisting of methotrexate, rituximab and temozolomide that can be used in the treatment of central nervous system (CNS) lymphoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C140108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140108>	C140180	MPV Regimen|MPV|MPV|Methotrexate-Procarbazine-Vincristine|Methotrexate/Procarbazine/Vincristine	A regimen consisting of methotrexate, procarbazine and vincristine that can be used in the treatment of central nervous system (CNS) lymphoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C140109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140109>	C140180	R-MPV Regimen|R-MPV|R-MPV|R-MPV|R-MPV (rituximab-abbs)|R-MPV (rituximab-arrx)|R-MPV (rituximab-blit)|R-MPV (rituximab-pvvr)|R-MPV (rituximab-rite)|R-MPV (rituximab-rixa)|R-MPV (rituximab-rixi)|Rituximab-Methotrexate-Procarbazine-Vincristine|Rituximab/Methotrexate/Procarbazine/Vincristine	A regimen consisting of rituximab, methotrexate, procarbazine and vincristine that can be used in the treatment of central nervous system (CNS) lymphoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C14010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14010>	C13432	6p11.1	A chromosome band present on 6p			Gene or Genome	
C140110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140110>	C63442	Nordic Regimen|Maxi-R-CHOP/R-HiDAC|Nordic|R-MaxiCHOP Plus R-HDAraC|Rituximab Plus Cyclophosphamide/Hydroxydaunorubicin/Oncovin/Prednisone and R-HD-Ara-C|Rituximab Plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone Alternating with Rituximab Plus High-Dose Cytarabine|Rituximab Plus Maxi-CHOP Alternating with Rituximab Plus HD Ara-C|Rituximab Plus Maxi-CHOP Alternating with Rituximab Plus High-Dose Cytarabine|Rituximab with Alternating Cycles of Maxi-CHOP and High-dose Cytarabine|Rituximab/Maxi-CHOP Alternating with Rituximab/High-Dose Cytarabine|maxi-R-CHOP/R-HiDAC|maxi-R-CHOP/R-HiDAC (rituximab-abbs)|maxi-R-CHOP/R-HiDAC (rituximab-arrx)|maxi-R-CHOP/R-HiDAC (rituximab-blit)|maxi-R-CHOP/R-HiDAC (rituximab-pvvr)|maxi-R-CHOP/R-HiDAC (rituximab-rite)|maxi-R-CHOP/R-HiDAC (rituximab-rixa)|maxi-R-CHOP/R-HiDAC (rituximab-rixi)	A regimen consisting of cycles of rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone (Maxi-CHOP), alternating with rituximab with high-dose (HD) cytarabine that can be used in the treatment of mantle cell lymphoma (MCL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C140111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140111>	C63442	R-BAC Regimen|Bendamustine/Cytarabine/Rituximab|R-BAC|R-BAC|R-BAC (rituximab-abbs)|R-BAC (rituximab-arrx)|R-BAC (rituximab-blit)|R-BAC (rituximab-pvvr)|R-BAC (rituximab-rite)|R-BAC (rituximab-rixa)|R-BAC (rituximab-rixi)|RBAC Regimen|Rituximab-Bendamustine-Cytarabine|Rituximab/Bendamustine/Ara-C	A regimen consisting of rituximab, bendamustine and cytarabine that can be used in the treatment of mantle cell lymphoma (MCL). RBAC500 regimen, consisting of bendamustine, low-dose cytarabine and rituximab, may be used for the treatment of MCL.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C140112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140112>	C63442|C191727|C140180	R-Squared Regimen|Lenalidomide and Rituximab (R2)|Lenalidomide and Rituximab-abbs (R2)|Lenalidomide and Rituximab-arrx (R2)|Lenalidomide and Rituximab-blit (R2)|Lenalidomide and Rituximab-pvvr (R2)|Lenalidomide and Rituximab-rite (R2)|Lenalidomide and Rituximab-rixa (R2)|Lenalidomide and Rituximab-rixi (R2)|Lenalidomide-Rituximab|Lenalidomide/Rituximab|Lenalidomide/Rituximab Regimen|R-squared|R2 Regimen|Revlimid/Rituxan|Rituximab/Lenalidomide	A regimen consisting of lenalidomide and rituximab that can be used in the treatment of primary central nervous system (CNS) lymphoma, Castleman disease, and non-Hodgkin lymphoma, including chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, gastric and nongastric mucosa-associated lymphoid tissue (MALT) lymphoma, and nodal and splenic marginal zone lymphoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C140113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140113>	C63442	SMILE Regimen|Dexamethasone-Methotrexate-Ifosfamide-L-asparaginase-Etoposide|Dexamethasone/Methotrexate/Ifosfamide/L-asparaginase/Etoposide|SMILE|SMILE|SMILE	A regimen consisting of dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide that can be used in the treatment of natural killer (NK)/T-cell lymphoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C140114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140114>	C63442	VIPD Regimen|Etoposide-Ifosfamide-Cisplatin-Dexamethasone|Etoposide/Ifosfamide/Cisplatin/Dexamethasone|VIPD|VIPD	A regimen consisting of etoposide, ifosfamide, cisplatin and dexamethasone that can be used in the treatment of natural killer (NK)/T-cell lymphoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C140115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140115>	C63588|C63443|C63442	R-HyperCVAD Alternating with High-dose MTX AraC/Rituximab Regimen|R-HCVAD Plus Methotrexate/Cytarabine|R-Hyper-CVAD/R-MA|R-Hyper-CVAD/R-MA (rituximab-abbs)|R-Hyper-CVAD/R-MA (rituximab-arrx)|R-Hyper-CVAD/R-MA (rituximab-blit)|R-Hyper-CVAD/R-MA (rituximab-pvvr)|R-Hyper-CVAD/R-MA (rituximab-rite)|R-Hyper-CVAD/R-MA (rituximab-rixa)|R-Hyper-CVAD/R-MA (rituximab-rixi)|R-HyperCVAD Alternating with High-dose MTX AraC Regimen|R-HyperCVAD/HD MTX AraC Regimen|R-HyperCVAD/MTX/AraC|R-hyperCVAD Alternating with R-Methotrexate-Cytarabine|Rituximab Plus Hyper-CVAD Alternating with R-Methotrexate/Cytarabine|Rituximab Plus HyperCVAD Alternating with R-Methotrexate/Cytarabine|Rituximab Plus HyperCVAD Alternating with Rituximab Plus High-dose Cytarabine and Methotrexate|Rituximab Plus HyperCVAD Alternating with Rituximab-Methotrexate/Cytarabine|Rituximab-Hyperfractionated Cyclophosphamide-Vincristine-Adriamycin-Dexamethasone Alternating with Rituximab/Cytarabine/Methotrexate	A regimen consisting of rituximab, cyclophosphamide, vincristine, doxorubicin and dexamethasone, administered on a hyperfractionated schedule, and alternating with rituximab, and high-dose methotrexate and cytarabine that can be used for the treatment of mantle cell lymphoma (MCL), AIDS-related B-cell lymphomas, Burkitt lymphoma, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), acute lymphoblastic leukemia (ALL), and T-cell lymphoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C140116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140116>	C26003	LPA Gene|LPA|LPA|Lipoprotein(a) Gene	This gene is involved in lipid metabolism, proteolysis and the inhibition of tissue-type plasminogen activator.			Gene or Genome	
C140117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140117>	C140116	LPA wt Allele|AK38|APOA|Apolipoprotein(a) Gene|LP|Lipoprotein(a) wt Allele|Lipoprotein, Lp(a) Gene	Human LPA wild-type allele is located within 6q25.3-q26 and is approximately 134 kb in length. This allele, which encodes apolipoprotein(a) protein, plays a role in proteolysis, lipid metabolism and the regulation of thrombolysis. Aberrant expression of the gene is associated with atherosclerosis.			Gene or Genome	
C140118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140118>	C17123	Apolipoprotein(a)|Antiangiogenic AK38 Protein|Apo(a)|EC 3.4.21.-|LPA|Lp(a)	Apolipoprotein(a) (4548 aa, ~501 kDa) is encoded by the human LPA gene. This protein is involved in the regulation of thrombosis and lipid metabolism.			Amino Acid, Peptide, or Protein|Enzyme	
C140119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140119>	C140043	Prostate Cancer TNM Finding v8|Prostate Carcinoma TNM Finding v8|Staging-T Category	A finding about one or more characteristics of prostate cancer, following the rules of the TNM AJCC v8 classification system. This classification system applies to adenocarcinomas and squamous cell carcinomas of the prostate gland. It does not apply to sarcomas, urothelial cell carcinomas, and urothelial carcinoma of bladder involving prostate. (from AJCC 8th Ed.)			Finding	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C14011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14011>	C13432	6p24-p23	A chromosome band present on 6p			Gene or Genome	
C140120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140120>	C140119	Prostate Cancer Clinical TNM Finding v8|Prostate Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of prostate cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C140121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140121>	C140120	Prostate Cancer Clinical Distant Metastasis TNM Finding v8|Clinical Distant Metastasis Status (cM)|Prostate Carcinoma Clinical Distant Metastasis TNM Finding v8|Staging-M	A clinical finding about one or more characteristics of prostate cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C140122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140122>	C140121	Prostate Cancer cM0 TNM Finding v8|M0|Prostate Carcinoma cM0 TNM Finding v8	Prostate cancer without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C140123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140123>	C140121	Prostate Cancer cM1 TNM Finding v8|Prostate Carcinoma cM1 TNM Finding v8|cM1	Prostate cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology
C140124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140124>	C140123	Prostate Cancer cM1a TNM Finding v8|M1a|Prostate Carcinoma cM1a TNM Finding v8|cM1a	Prostate cancer with metastasis to nonregional lymph node(s). (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C140125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140125>	C140123	Prostate Cancer cM1b TNM Finding v8|M1b|Prostate Carcinoma cM1b TNM Finding v8|cM1b	Prostate cancer with metastasis to bone(s). (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C140126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140126>	C140123	Prostate Cancer cM1c TNM Finding v8|M1c|Prostate Carcinoma cM1c TNM Finding v8|cM1c	Prostate cancer with metastasis to other site(s) with or without bone disease. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C140127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140127>	C140120	Prostate Cancer Clinical Primary Tumor TNM Finding v8|Prostate Carcinoma Clinical Primary Tumor TNM Finding v8|Staging-T	A clinical finding about one or more characteristics of prostate cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C140128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140128>	C140127	Prostate Cancer cTX TNM Finding v8|Prostate Carcinoma cTX TNM Finding v8|Tx	Prostate cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C140129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140129>	C140127	Prostate Cancer cT0 TNM Finding v8|Prostate Carcinoma cT0 TNM Finding v8	Prostate cancer with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C14012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14012>	C13432	1p35-p32	A chromosome band present on 1p			Gene or Genome	
C140130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140130>	C140127	Prostate Cancer cT1 TNM Finding v8|Prostate Carcinoma cT1 TNM Finding v8	Prostate cancer with clinically inapparent tumor that is not palpable. (from AJCC 8th Ed.)			Finding	
C140131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140131>	C140130	Prostate Cancer cT1a TNM Finding v8|Prostate Carcinoma cT1a TNM Finding v8|T1a	Prostate cancer in which the tumor is an incidental histologic finding in 5% or less of tissue resected. (from AJCC 8th Ed.)			Finding	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C140132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140132>	C140130	Prostate Cancer cT1b TNM Finding v8|Prostate Carcinoma cT1b TNM Finding v8|T1b	Prostate cancer in which the tumor is an incidental histologic finding in more than 5% of tissue resected. (from AJCC 8th Ed.)			Finding	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C140133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140133>	C140130	Prostate Cancer cT1c TNM Finding v8|Prostate Carcinoma cT1c TNM Finding v8|T1c	Prostate cancer in which the tumor is identified by needle biopsy found in one or both sides, but not palpable. (from AJCC 8th Ed.)			Finding	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C140134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140134>	C140127	Prostate Cancer cT2 TNM Finding v8|Prostate Carcinoma cT2 TNM Finding v8	Prostate cancer in which the tumor is palpable and confined within the prostate. (from AJCC 8th Ed.)			Finding	
C140135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140135>	C140134	Prostate Cancer cT2a TNM Finding v8|Prostate Carcinoma cT2a TNM Finding v8|T2a	Prostate cancer in which the tumor involves one-half of one side or less. (from AJCC 8th Ed.)			Finding	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C140136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140136>	C20194	C5orf67 Gene|C5orf67|C5orf67|Chromosome 5 Open Reading Frame 67 Gene	This gene may play a role in longevity.			Gene or Genome	
C140137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140137>	C140134	Prostate Cancer cT2b TNM Finding v8|Prostate Carcinoma cT2b TNM Finding v8|T2b	Prostate cancer in which the tumor involves more than one-half of one side but not both sides. (from AJCC 8th Ed.)			Finding	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C140138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140138>	C140134	Prostate Cancer cT2c TNM Finding v8|Prostate Carcinoma cT2c TNM Finding v8|T2c	Prostate cancer in which the tumor involves both sides. (from AJCC 8th Ed.)			Finding	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C140139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140139>	C140127	Prostate Cancer cT3 TNM Finding v8|Prostate Carcinoma cT3 TNM Finding v8	Prostate cancer with extraprostatic tumor that is not fixed or does not invade adjacent structures. (from AJCC 8th Ed.)			Finding	
C14013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14013>	C13432	12pter-p12	A chromosome band present on 12p			Gene or Genome	
C140140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140140>	C140136	C5orf67 wt Allele|Chromosome 5 Open Reading Frame 67 wt Allele	Human C5orf67 wild-type allele is located in the vicinity of 5q11.2 and is approximately 95 kb in length. This allele, which encodes uncharacterized protein C5orf67, may be involved in lifespan.			Gene or Genome	
C140141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140141>	C140139	Prostate Cancer cT3a TNM Finding v8|Prostate Carcinoma cT3a TNM Finding v8|T3a	Prostate cancer with extraprostatic extension (unilateral or bilateral). (from AJCC 8th Ed.)			Finding	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C140142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140142>	C140139	Prostate Cancer cT3b TNM Finding v8|Prostate Carcinoma cT3b TNM Finding v8|T3b	Prostate cancer in which the tumor invades seminal vesicle(s). (from AJCC 8th Ed.)			Finding	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C140143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140143>	C140127	Prostate Cancer cT4 TNM Finding v8|Prostate Carcinoma cT4 TNM Finding v8|T4	Prostate cancer in which the tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall. (from AJCC 8th Ed.)			Finding	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C140144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140144>	C18466	Uncharacterized Protein C5orf67|C5orf67	Uncharacterized protein C5orf67 (127 aa, ~14 kDa) is encoded by the human C5orf67 gene. This protein may play a role in lifespan.			Amino Acid, Peptide, or Protein	
C140145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140145>	C140119	Prostate Cancer Pathologic TNM Finding v8|Pathologic|Prostate Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of prostate cancer, following the rules of the TNM AJCC v8 classification system.			Finding	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C140146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140146>	C140145	Prostate Cancer Pathologic Distant Metastasis TNM Finding v8|Pathologic Distant Metastasis Status (pM)|Prostate Carcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of prostate cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology
C140147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140147>	C140146	Prostate Cancer pM1 TNM Finding v8|Prostate Carcinoma pM1 TNM Finding v8|pM1	Prostate cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology
C140148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140148>	C140147	Prostate Cancer pM1a TNM Finding v8|Prostate Carcinoma pM1a TNM Finding v8|pM1a	Prostate cancer with metastasis to nonregional lymph node(s). (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology
C140149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140149>	C140147	Prostate Cancer pM1b TNM Finding v8|Prostate Carcinoma pM1b TNM Finding v8|pM1b	Prostate cancer with metastasis to bone(s). (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology
C14014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14014>	C13432	3q13.3-q21	A chromosome band present on 3q			Gene or Genome	
C140150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140150>	C140147	Prostate Cancer pM1c TNM Finding v8|Prostate Carcinoma pM1c TNM Finding v8|pM1c	Prostate cancer with metastasis to other site(s) with or without bone disease. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology
C140151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140151>	C140145	Prostate Cancer Pathologic Primary Tumor TNM Finding v8|Pathologic Primary Tumor Status (pT)|Prostate Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of prostate cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor. There is no pathologic T1 classification.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology
C140152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140152>	C140151	Prostate Cancer pT2 TNM Finding v8|Prostate Carcinoma pT2 TNM Finding v8|pT2	Prostate cancer which is organ confined. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology
C140153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140153>	C140151	Prostate Cancer pT3 TNM Finding v8|Prostate Carcinoma pT3 TNM Finding v8|pT3	Prostate cancer with extraprostatic extension. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology
C140154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140154>	C140153	Prostate Cancer pT3a TNM Finding v8|Prostate Carcinoma pT3a TNM Finding v8|pT3a	Prostate cancer with extraprostatic extension (unilateral or bilateral) or microscopic invasion of bladder neck. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology
C140155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140155>	C140153	Prostate Cancer pT3b TNM Finding v8|Prostate Carcinoma pT3b TNM Finding v8|pT3b	Prostate cancer with tumor invading seminal vesicle(s). (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology
C140156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140156>	C140151	Prostate Cancer pT4 TNM Finding v8|Prostate Carcinoma pT4 TNM Finding v8|pT4	Prostate cancer in which the tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology
C140157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140157>	C140145	Prostate Cancer Pathologic Regional Lymph Nodes TNM Finding v8|Pathologic Regional Lymph Node Status (pN)|Prostate Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8|Staging-N	A pathologic finding about one or more characteristics of prostate cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C140158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140158>	C140157	Prostate Cancer pNX TNM Finding v8|NX|Prostate Carcinoma pNX TNM Finding v8|pNX	Prostate cancer in which the regional nodes were not assessed. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C140159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140159>	C140157	Prostate Cancer pN0 TNM Finding v8|N0|Prostate Carcinoma pN0 TNM Finding v8|pN0	Prostate cancer with no positive regional nodes. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C14015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14015>	C13432	10q22.3	A chromosome band present on 10q			Gene or Genome	
C140160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140160>	C140157	Prostate Cancer pN1 TNM Finding v8|N1|Prostate Carcinoma pN1 TNM Finding v8|pN1	Prostate cancer with metastases in regional node(s). (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C140161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140161>	C28108	Whitmore-Jewett Stage	A prostate cancer stage defined according to the Whitmore-Jewett staging system criteria.			Classification	
C140163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140163>	C4863	Prostate Cancer by AJCC v8 Stage|Prostate Carcinoma by AJCC v8 Stage|Tumor Stage (Pathologic)	A term that refers to the staging of prostate cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to adenocarcinomas and squamous cell carcinomas of the prostate gland. It does not apply to sarcomas, urothelial cell carcinomas, and urothelial carcinoma of bladder involving prostate. (from AJCC 8th Ed.)			Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology
C140164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140164>	C140163	Stage I Prostate Cancer AJCC v8|I|Stage I Prostate Cancer|Stage I Prostate Carcinoma AJCC v8	Stage I includes: (cT1a-c, cT2a, N0, M0, PSA less than 10, Grade Group 1); (pT2, N0, M0, PSA less than 10, Grade Group 1). cT1a: Prostate cancer in which the tumor is an incidental histologic finding in 5% or less of tissue resected. cT1b: Prostate cancer in which the tumor is an incidental histologic finding in more than 5% of tissue resected. cT1c: Prostate cancer in which the tumor is identified by needle biopsy found in one or both sides, but not palpable. cT2a: Prostate cancer in which the tumor involves one-half of one side or less. pT2: Prostate cancer which is organ confined. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 1: Gleason Score 6 or less, Gleason Pattern 3 or less+3. (AJCC 8th ed.)	Stage I Prostate Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C140165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140165>	C140163	Stage II Prostate Cancer AJCC v8|Stage II Prostate Cancer|Stage II Prostate Carcinoma AJCC v8	Stage II includes: IIA: (cT1a-c, cT2a, N0, M0, PSA equal or more than 10 and less than 20, Grade Group 1); (cT2b-c, N0, M0, PSA less than 20, Grade Group 1); IIB: T1-2, N0, M0, PSA less than 20, Grade Group 2; IIC: (T1-2, N0, M0, PSA less than 20, Grade Group 3); (T1-2, N0, M0, PSA less than 20, Grade Group 4). cT1a: Prostate cancer in which the tumor is an incidental histologic finding in 5% or less of tissue resected. cT1b: Prostate cancer in which the tumor is an incidental histologic finding in more than 5% of tissue resected. cT1c: Prostate cancer in which the tumor is identified by needle biopsy found in one or both sides, but not palpable. cT2a: Prostate cancer in which the tumor involves one-half of one side or less. cT2b: Prostate cancer in which the tumor involves more than one-half of one side but not both sides. cT2c: Prostate cancer in which the tumor involves both sides. T1: Prostate cancer with clinically inapparent tumor that is not palpable. T2: Prostate cancer in which the tumor is palpable and confined within the prostate. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 1: Gleason Score 6 or less, Gleason Pattern 3 or less+3. Grade Group 2: Gleason Score 7, Gleason Pattern 3+4. Grade Group 3: Gleason Score 7, Gleason Pattern 4+3. Grade Group 4: Gleason Score 8, Gleason Pattern 4+4. (AJCC 8th ed.)	Stage II Prostate Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140166>	C140165	Stage IIA Prostate Cancer AJCC v8|IIA|Stage IIA Prostate Cancer|Stage IIA Prostate Carcinoma AJCC v8	Stage IIA includes: (cT1a-c, cT2a, N0, M0, PSA equal or more than 10 and less than 20, Grade Group 1); (cT2b-c, N0, M0, PSA less than 20, Grade Group 1). cT1a: Prostate cancer in which the tumor is an incidental histologic finding in 5% or less of tissue resected. cT1b: Prostate cancer in which the tumor is an incidental histologic finding in more than 5% of tissue resected. cT1c: Prostate cancer in which the tumor is identified by needle biopsy found in one or both sides, but not palpable. cT2a: Prostate cancer in which the tumor involves one-half of one side or less. cT2b: Prostate cancer in which the tumor involves more than one-half of one side but not both sides. cT2c: Prostate cancer in which the tumor involves both sides. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 1: Gleason Score 6 or less, Gleason Pattern 3 or less+3. (AJCC 8th ed.)	Stage IIA Prostate Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C140167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140167>	C140165	Stage IIB Prostate Cancer AJCC v8|IIB|Stage IIB Prostate Cancer|Stage IIB Prostate Carcinoma AJCC v8	Stage IIB includes: T1-2, N0, M0, PSA less than 20, Grade Group 2. T1: Prostate cancer with clinically inapparent tumor that is not palpable. T2: Prostate cancer in which the tumor is palpable and confined within the prostate. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 2: Gleason Score 7, Gleason Pattern 3+4. (AJCC 8th ed.)	Stage IIB Prostate Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C140168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140168>	C140165	Stage IIC Prostate Cancer AJCC v8|IIC|Stage IIC Prostate Cancer|Stage IIC Prostate Carcinoma AJCC v8	Stage IIC includes: (T1-2, N0, M0, PSA less than 20, Grade Group 3); (T1-2, N0, M0, PSA less than 20, Grade Group 4). T1: Prostate cancer with clinically inapparent tumor that is not palpable. T2: Prostate cancer in which the tumor is palpable and confined within the prostate. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 3: Gleason Score 7, Gleason Pattern 4+3. Grade Group 4: Gleason Score 8, Gleason Pattern 4+4. (AJCC 8th ed.)	Stage IIC Prostate Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C140169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140169>	C140163	Stage III Prostate Cancer AJCC v8|Stage III Prostate Cancer|Stage III Prostate Carcinoma AJCC v8	Stage III includes: IIIA: T1-2, N0, M0, PSA 20 or more, Grade Group 1-4; IIIB: T3-4, N0, M0, PSA: Any, Grade Group 1-4; IIIC: Any T, N0, M0, PSA: Any, Grade Group 5. T1: Prostate cancer with clinically inapparent tumor that is not palpable. T2: Prostate cancer in which the tumor is palpable and confined within the prostate. T3: Prostate cancer with extraprostatic tumor that is not fixed or does not invade adjacent structures. T4: Prostate cancer in which the tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 1: Gleason Score 6 or less, Gleason Pattern 3 or less+3. Grade Group 2: Gleason Score 7, Gleason Pattern 3+4. Grade Group 3: Gleason Score 7, Gleason Pattern 4+3. Grade Group 4: Gleason Score 8, Gleason Pattern 4+4. Grade Group 5: Gleason Score 9 or 10, Gleason Pattern 4+5, or 5+4, or 5+5. (AJCC 8th ed.)	Stage III Prostate Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C14016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14016>	C13432	2q33-q34	A chromosome band present on 2q			Gene or Genome	
C140170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140170>	C140169	Stage IIIA Prostate Cancer AJCC v8|IIIA|Stage IIIA Prostate Cancer|Stage IIIA Prostate Carcinoma AJCC v8	Stage IIIA includes: T1-2, N0, M0, PSA 20 or more, Grade Group 1-4; T1: Prostate cancer with clinically inapparent tumor that is not palpable. T2: Prostate cancer in which the tumor is palpable and confined within the prostate. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 1: Gleason Score 6 or less, Gleason Pattern 3 or less+3. Grade Group 2: Gleason Score 7, Gleason Pattern 3+4. Grade Group 3: Gleason Score 7, Gleason Pattern 4+3. Grade Group 4: Gleason Score 8, Gleason Pattern 4+4. (AJCC 8th ed.)	Stage IIIA Prostate Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C140171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140171>	C140169	Stage IIIB Prostate Cancer AJCC v8|IIIB|Stage IIIB Prostate Cancer|Stage IIIB Prostate Carcinoma AJCC v8	Stage IIIB includes: T3-4, N0, M0, PSA: Any, Grade Group 1-4; T3: Prostate cancer with extraprostatic tumor that is not fixed or does not invade adjacent structures. T4: Prostate cancer in which the tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 1: Gleason Score 6 or less, Gleason Pattern 3 or less+3. Grade Group 2: Gleason Score 7, Gleason Pattern 3+4. Grade Group 3: Gleason Score 7, Gleason Pattern 4+3. Grade Group 4: Gleason Score 8, Gleason Pattern 4+4. (AJCC 8th ed.)	Stage IIIB Prostate Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C140172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140172>	C140169	Stage IIIC Prostate Cancer AJCC v8|IIIC|Stage IIIC Prostate Cancer|Stage IIIC Prostate Carcinoma AJCC v8	Stage IIIC includes: Any T, N0, M0, PSA: Any, Grade Group 5. N0: Prostate cancer with no positive regional nodes. M0: Prostate cancer without evidence of distant metastasis. Grade Group 5: Gleason Score 9 or 10, Gleason Pattern 4+5, or 5+4, or 5+5. (AJCC 8th ed.)	Stage IIIC Prostate Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C140173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140173>	C140163	Stage IV Prostate Cancer AJCC v8|Stage IV Prostate Cancer|Stage IV Prostate Carcinoma AJCC v8	Stage IV includes: IVA: Any T, N1, M0, PSA: Any, Grade Group: Any; IVB: Any T, N0, M1, PSA: Any, Grade Group: Any. N0: Prostate cancer with no positive regional nodes. N1: Prostate cancer with metastases in regional node(s). M0: Prostate cancer without evidence of distant metastasis. M1: Prostate cancer with distant metastasis. (AJCC 8th ed.)	Stage IV Prostate Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140174>	C140173	Stage IVA Prostate Cancer AJCC v8|IVA|Stage IVA Prostate Cancer|Stage IVA Prostate Carcinoma AJCC v8	Stage IVA includes: Any T, N1, M0, PSA: Any, Grade Group: Any. N1: Prostate cancer with metastases in regional node(s). M0: Prostate cancer without evidence of distant metastasis. (AJCC 8th ed.)	Stage IVA Prostate Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C140175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140175>	C140173	Stage IVB Prostate Cancer AJCC v8|IVB|Stage IVB Prostate Cancer|Stage IVB Prostate Carcinoma AJCC v8	Stage IVB includes: Any T, N0, M1, PSA: Any, Grade Group: Any. N0: Prostate cancer with no positive regional nodes. M1: Prostate cancer with distant metastasis. (AJCC 8th ed.)	Stage IVB Prostate Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C140176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140176>	C20194	MSANTD1 Gene|MSANTD1|MSANTD1|Myb/SANT DNA Binding Domain Containing 1 Gene	This gene may be involved in both DNA binding and chromatin remodeling.			Gene or Genome	
C140177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140177>	C14349	Subviral Satellite|Satellite	A subviral agent composed of nucleic acid that depends on the co-infection of a host cell with a helper virus for its replication.			Virus	
C140178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140178>	C140176	MSANTD1 wt Allele|C4orf44|Chromosome 4 Open Reading Frame 44 Gene|LOC345222|Myb/SANT DNA Binding Domain Containing 1 wt Allele|Myb/SANT-Like DNA-Binding Domain Containing 1 Gene	Human MSANTD1 wild-type allele is located in the vicinity of 4p16.3 and is approximately 3 kb in length. This allele, which encodes Myb/SANT-like DNA-binding domain-containing protein 1, may play a role in chromatin remodeling.			Gene or Genome	
C140179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140179>	C18466	Myb/SANT-Like DNA-Binding Domain-Containing Protein 1|MSANTD1	Myb/SANT-like DNA-binding domain-containing protein 1 (278 aa, ~32 kDa) is encoded by the human MSANTD1 gene. This protein may be involved in binding to both histones and DNA.			Amino Acid, Peptide, or Protein	
C14017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14017>	C13432	Xp22.2	A chromosome band present on Xp			Gene or Genome	
C140180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140180>	C214804	Regimen Used to Treat Central Nervous System Neoplasm|Chemotherapy Regimen Used to Treat CNS Neoplasm	Any regimen that can be used for the treatment of any type of central nervous system (CNS) neoplasms.			Therapeutic or Preventive Procedure	
C140181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140181>	C20923	CELSR2 Gene|CELSR2|CELSR2|Cadherin EGF LAG Seven-Pass G-Type Receptor 2 Gene	This gene plays a role in cell-cell signaling during the development of the nervous system.			Gene or Genome	
C140182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140182>	C140181	CELSR2 wt Allele|ADGRC2|CDHF10|Cadherin EGF LAG Seven-Pass G-Type Receptor 2 wt Allele|Cadherin, EGF LAG Seven-Pass G-Type Receptor 2 (Flamingo Homolog, Drosophila) Gene|Cadherin, EGF LAG Seven-Pass G-Type Receptor 2 Gene|Cadherin, EGF LAG Seven-Pass G-Type Receptor 2, Flamingo (Drosophila) Homolog Gene|EGF-Like-Domain, Multiple 2 Gene|EGFL2|Epidermal Growth Factor-Like 2 Gene|Flamingo (Drosophila) Homolog 3 Gene|Flamingo (Drosophila) Homolog Gene|Flamingo1|KIAA0279|MEGF3|Multiple Epidermal Growth Factor-Like Domains 3 Gene	Human CELSR2 wild-type allele is located in the vicinity of 1p13.3 and is approximately 26 kb in length. This allele, which encodes cadherin EGF LAG seven-pass G-type receptor 2 protein, is involved in cell-cell signaling.			Gene or Genome	
C140183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140183>	C18239|C16373	Cadherin EGF LAG Seven-Pass G-Type Receptor 2|Adhesion G Protein-Coupled Receptor C2|CELSR2|Cadherin Family Member 10|EGF-Like Protein 2|Epidermal Growth Factor-Like Protein 2|Flamingo Homolog 3|Multiple EGF-Like Domains Protein 3|Multiple Epidermal Growth Factor-Like Domains Protein 3	Cadherin EGF LAG seven-pass G-type receptor 2 (2923 aa, ~317 kDa) is encoded by the human CELSR2 gene. This protein plays a role in Wnt signaling and neural development.			Amino Acid, Peptide, or Protein|Receptor	
C140184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140184>	C131871	HLA-A1101 Positive Cells Present|HLA-A*1101 Positive|HLA-A*1101 Positive Cells Present|HLA-A*11:01 Positive|HLA-A*11:01 Positive Cells Present|HLA-A1101 Positive	A laboratory test result indicating the presence of HLA-A1101 positive cells in a tissue sample.	HLA-A1101 Positive Cells Present		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C140185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140185>	C26940	Post-Mastectomy Pain Syndrome	Chronic pain following mastectomy or lumpectomy that usually affects the anterior thorax, axilla, and/or medial upper arm.	Post-Mastectomy Pain Syndrome		Sign or Symptom	CTRP Disease Terminology|CTRP Terminology
C140186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140186>	C140043	Testicular Cancer TNM Finding v8	A finding about one or more characteristics of testicular cancer, following the rules of the TNM AJCC v8 classification system. This classification system applies to postpubertal germ cell tumors of the testis and malignant sex cord-stromal tumors of the testis. It does not apply to spermatocytic tumors (no AJCC staging system), nonmalignant sex cord-/gonadal -stromal tumors (no AJCC staging system), prepubertal germ cell tumors (no AJCC staging system), hematolymphoid tumors (hematologic malignancies staging system), and paratesticular neoplasms (no AJCC staging system).  (from AJCC 8th Ed.)			Finding	
C140187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140187>	C140186	Testicular Cancer Clinical TNM Finding v8	A clinical finding about one or more characteristics of testicular cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C140188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140188>	C140187	Testicular Cancer Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of testicular cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C140189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140189>	C140188	Testicular Cancer cM0 TNM Finding v8	Testicular cancer without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C14018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14018>	C13432	8p21	A chromosome band present on 8p			Gene or Genome	
C140190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140190>	C140188	Testicular Cancer cM1 TNM Finding v8	Testicular cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C140191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140191>	C140190	Testicular Cancer cM1a TNM Finding v8	Testicular cancer with non-retroperitoneal nodal or pulmonary metastases. (from AJCC 8th Ed.)			Finding	
C140192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140192>	C140190	Testicular Cancer cM1b TNM Finding v8	Testicular cancer with non-pulmonary visceral metastases. (from AJCC 8th Ed.)			Finding	
C140193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140193>	C140187	Testicular Cancer Clinical Primary Tumor TNM Finding v8	A clinical finding about one or more characteristics of testicular cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C140194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140194>	C140193	Testicular Cancer cTX TNM Finding v8	Testicular cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C140195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140195>	C140193	Testicular Cancer cT0 TNM Finding v8	Testicular cancer with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C140196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140196>	C140193	Testicular Cancer cTis TNM Finding v8	Testicular cancer with a finding of germ cell neoplasia in situ. (from AJCC 8th Ed.)			Finding	
C140197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140197>	C140193	Testicular Cancer cT4 TNM Finding v8	Testicular cancer in which the tumor invades scrotum with or without vascular/lymphatic invasion. (from AJCC 8th Ed.)			Finding	
C140198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140198>	C140187	Testicular Cancer Clinical Regional Lymph Nodes TNM Finding v8	A clinical finding about one or more characteristics of testicular cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C140199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140199>	C140198	Testicular Cancer cNX TNM Finding v8	Testicular cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C14019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14019>	C13432	21q21.2	A chromosome band present on 21q			Gene or Genome	
C1401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1401>	C1590	Piperazinedione|2, 5-Piperazinedione, 3,6-bis-(5-chloro-2-piperidyl)-, dihydrochloride|2, 5-piperazinedione, 3,6-bis-(5-chloro-2-piperidyl)-, dihydrochloride|2,5-Piperazinedione, 3, 6-bis(5-chloro-2-piperidinyl)-, dihydrochloride, [3S-[3.alpha.(2S*,5R*),6.alpha.(2S*,5R*)]]- (9CI)|2,5-piperazinedione, 3, 6-bis(5-chloro-2-piperidinyl)-, dihydrochloride, [3S-[3alpha(2S*,5R*),6alpha(2S*,5R*)]]- (9CI)|593A|593A|Compound 593A|Compound 593A|Merck Compound 593A|PZD|PZD dihydrochloride, 3,6-bis(5-chloro-2-piperidinyl)-, dihydrochloride|PZD dihydrochloride, 3,6-bis(5-chloro-2-piperidinyl)-, dihydrochloride	A crystalline antibiotic fermentation product isolated from the bacterium Streptomyces griseoluteus with antineoplastic activity. Piperazinedione alkylates DNA at the N-7 position of guanine, inhibiting DNA replication and inducing cell cycle arrest.			Antibiotic|Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C140200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140200>	C140198	Testicular Cancer cN0 TNM Finding v8	Testicular cancer with no regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C140201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140201>	C140198	Testicular Cancer cN1 TNM Finding v8	Testicular cancer with metastases in a lymph node mass 2 cm or smaller in greatest dimension or multiple lymph nodes, none larger than 2 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C140202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140202>	C140198	Testicular Cancer cN2 TNM Finding v8	Testicular cancer with metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension or multiple lymph nodes, any one mass larger than 2 cm but not larger than 5 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C140203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140203>	C140198	Testicular Cancer cN3 TNM Finding v8	Testicular cancer with metastasis with a lymph node mass larger than 5 cm in greatest dimensi. (from AJCC 8th Ed.)			Finding	
C140204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140204>	C140186	Testicular Cancer Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of testicular cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C140205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140205>	C140204	Testicular Cancer Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of testicular cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C140206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140206>	C140205	Testicular Cancer pM1 TNM Finding v8	Testicular cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C140207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140207>	C140206	Testicular Cancer pM1a TNM Finding v8	Testicular cancer with non-retroperitoneal nodal or pulmonary metastases. (from AJCC 8th Ed.)			Finding	
C140208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140208>	C140206	Testicular Cancer pM1b TNM Finding v8	Testicular cancer with non-pulmonary visceral metastases. (from AJCC 8th Ed.)			Finding	
C140209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140209>	C140204	Testicular Cancer Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of testicular cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C14020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14020>	C13432	3p14.3-p14.2	A chromosome band present on 3p			Gene or Genome	
C140210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140210>	C140209	Testicular Cancer pTX TNM Finding v8	Testicular cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C140211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140211>	C140209	Testicular Cancer pT0 TNM Finding v8	Testicular cancer with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C140212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140212>	C140209	Testicular Cancer pTis TNM Finding v8	Testicular cancer with a finding of germ cell neoplasia in situ. (from AJCC 8th Ed.)			Finding	
C140213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140213>	C140209	Testicular Cancer pT1 TNM Finding v8	Testicular cancer which is limited to testis (including rete testis invasion) without lymphovascular invasion. (from AJCC 8th Ed.)			Finding	
C140214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140214>	C140213	Testicular Cancer pT1a TNM Finding v8	Testicular cancer which is limited to testis (including rete testis invasion) without lymphovascular invasion and is smaller than 3 cm in size. This pT1 subclassification applies only to pure seminomas. (from AJCC 8th Ed.)			Finding	
C140215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140215>	C140213	Testicular Cancer pT1b TNM Finding v8	Testicular cancer which is limited to testis (including rete testis invasion) without lymphovascular invasion and is 3 cm or larger in size. This pT1 subclassification applies only to pure seminomas. (from AJCC 8th Ed.)			Finding	
C140216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140216>	C140209	Testicular Cancer pT2 TNM Finding v8	Testicular cancer which is limited to testis (including rete testis invasion) with lymphovascular invasion or invades hilar soft tissue or epididymis or penetrates visceral mesothelial layer covering the external surface of tunica albuginea with or without lymphovascular invasion. (from AJCC 8th Ed.)			Finding	
C140217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140217>	C140209	Testicular Cancer pT3 TNM Finding v8	Testicular cancer in which the tumor invades spermatic cord with or without lymphovascular invasion. (from AJCC 8th Ed.)			Finding	
C140218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140218>	C140209	Testicular Cancer pT4 TNM Finding v8	Testicular cancer in which the tumor invades scrotum with or without lymphovascular invasion. (from AJCC 8th Ed.)			Finding	
C140219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140219>	C140204	Testicular Cancer Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of testicular cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C14021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14021>	C13432	4q13.1	A chromosome band present on 4q			Gene or Genome	
C140220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140220>	C140219	Testicular Cancer pNX TNM Finding v8	Testicular cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C140221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140221>	C140219	Testicular Cancer pN0 TNM Finding v8	Testicular cancer with no regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C140222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140222>	C140219	Testicular Cancer pN1 TNM Finding v8	Testicular cancer with metastasis with a lymph node mass 2 cm or smaller in greatest dimension and less than or equal to five nodes positive, none larger than 2 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C140223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140223>	C140219	Testicular Cancer pN2 TNM Finding v8	Testicular cancer with metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension; or more than five nodes positive, none larger than 5 cm; or evidence of extranodal extension of tumor. (from AJCC 8th Ed.)			Finding	
C140224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140224>	C140219	Testicular Cancer pN3 TNM Finding v8	Testicular cancer with metastasis with a lymph node mass larger than 5 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C140225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140225>	C7251	Testicular Cancer by AJCC v8 Stage	A term that refers to the staging of testicular cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to postpubertal germ cell tumors of the testis and malignant sex cord-stromal tumors of the testis. It does not apply to spermatocytic tumors (no AJCC staging system), nonmalignant sex cord-/gonadal -stromal tumors (no AJCC staging system), prepubertal germ cell tumors (no AJCC staging system), hematolymphoid tumors (hematologic malignancies staging system), and paratesticular neoplasms (no AJCC staging system).  (from AJCC 8th Ed.)			Neoplastic Process	
C140226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140226>	C140225	Stage 0 Testicular Cancer AJCC v8|Stage 0 Testicular Cancer	Stage 0 includes: pTis, N0, M0, S0. pTis: Testicular cancer with a finding of germ cell neoplasia in situ. N0: Testicular cancer with no regional lymph node metastasis. M0: Testicular cancer without evidence of distant metastasis. S0: Marker study levels within normal limits. (AJCC 8th ed.)	Stage 0 Testicular Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140227>	C140225	Stage I Testicular Cancer AJCC v8|Stage I Testicular Cancer	Stage I includes: pT1-T4, N0, M0, SX. pT1: Testicular cancer which is limited to testis (including rete testis invasion) without lymphovascular invasion. pT2: Testicular cancer which is limited to testis (including rete testis invasion) with lymphovascular invasion or invades hilar soft tissue or epididymis or penetrates visceral mesothelial layer covering the external surface of tunica albuginea with or without lymphovascular invasion. pT3: Testicular cancer in which the tumor invades spermatic cord with or without lymphovascular invasion. pT4: Testicular cancer in which the tumor invades scrotum with or without lymphovascular invasion. N0: Testicular cancer with no regional lymph node metastasis. M0: Testicular cancer without evidence of distant metastasis. SX: Marker studies not available or not performed. (AJCC 8th ed.)	Stage I Testicular Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140228>	C140227	Stage IA Testicular Cancer AJCC v8|Stage IA Testicular Cancer	Stage IA includes: pT1, N0, M0, S0. pT1: Testicular cancer which is limited to testis (including rete testis invasion) without lymphovascular invasion. N0: Testicular cancer with no regional lymph node metastasis. M0: Testicular cancer without evidence of distant metastasis. S0: Marker study levels within normal limits. (AJCC 8th ed.)	Stage IA Testicular Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140229>	C140227	Stage IB Testicular Cancer AJCC v8|Stage IB Testicular Cancer	Stage IB includes: (pT2, N0, M0, S0); (pT3, N0, M0, S0); (pT4, N0, M0, S0). pT2: Testicular cancer which is limited to testis (including rete testis invasion) with lymphovascular invasion or invades hilar soft tissue or epididymis or penetrates visceral mesothelial layer covering the external surface of tunica albuginea with or without lymphovascular invasion. pT3: Testicular cancer in which the tumor invades spermatic cord with or without lymphovascular invasion. pT4: Testicular cancer in which the tumor invades scrotum with or without lymphovascular invasion. N0: Testicular cancer with no regional lymph node metastasis. M0: Testicular cancer without evidence of distant metastasis. S0: Marker study levels within normal limits. (AJCC 8th ed.)	Stage IB Testicular Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C14022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14022>	C13432	22q12.1	A chromosome band present on 22q			Gene or Genome	
C140232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140232>	C140227	Stage IS Testicular Cancer AJCC v8|Stage IS Testicular Cancer	Stage IS includes: Any pT/TX, N0, M0, S1-3. TX: Testicular cancer in which the primary tumor cannot be assessed. N0: Testicular cancer with no regional lymph node metastasis. M0: Testicular cancer without evidence of distant metastasis. S1: LDH less than 1.5 x N and hCG (mlU/mL) less than 5,000 and AFP (ng/mL) less than 1,000. S2: LDH 1.5-10 x N or hCG (mlU/mL) 5,000-50,000 or AFP (ng/mL) 1,000-10,000. S3: LDH more than 10 x N or hCG (mlU/mL) more than 50,000 or AFP (ng/mL) more than 10,000. N indicates the upper limit of normal for the LDH assay. (AJCC 8th ed.)	Stage IS Testicular Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140233>	C140225	Stage II Testicular Cancer AJCC v8|Stage II Testicular Cancer	Stage II includes: Any pT/TX, N1-3, M0, SX. TX: Testicular cancer in which the primary tumor cannot be assessed. N1: Testicular cancer with metastasis with a lymph node mass 2 cm or smaller in greatest dimension and less than or equal to five nodes positive, none larger than 2 cm in greatest dimension. N2: Testicular cancer with metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension; or more than five nodes positive, none larger than 5 cm; or evidence of extranodal extension of tumor. N3: Testicular cancer with metastasis with a lymph node mass larger than 5 cm in greatest dimension. M0: Testicular cancer without evidence of distant metastasis. SX: Marker studies not available or not performed. (AJCC 8th ed.)	Stage II Testicular Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140234>	C140233	Stage IIA Testicular Cancer AJCC v8|Stage IIA Testicular Cancer	Stage IIA includes: (Any pT/TX, N1, M0, S0); (Any pT/TX, N1, M0, S1). TX: Testicular cancer in which the primary tumor cannot be assessed. N1: Testicular cancer with metastasis with a lymph node mass 2 cm or smaller in greatest dimension and less than or equal to five nodes positive, none larger than 2 cm in greatest dimension. M0: Testicular cancer without evidence of distant metastasis. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N and hCG (mlU/mL) less than 5,000 and AFP (ng/mL) less than 1,000. N indicates the upper limit of normal for the LDH assay. (AJCC 8th ed.)	Stage IIA Testicular Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140235>	C140233	Stage IIB Testicular Cancer AJCC v8|Stage IIB Testicular Cancer	Stage IIB includes: (Any pT/TX, N2, M0, S0); (Any pT/TX, N2, M0, S1). TX: Testicular cancer in which the primary tumor cannot be assessed. N2: Testicular cancer with metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension; or more than five nodes positive, none larger than 5 cm; or evidence of extranodal extension of tumor. M0: Testicular cancer without evidence of distant metastasis. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N and hCG (mlU/mL) less than 5,000 and AFP (ng/mL) less than 1,000. N indicates the upper limit of normal for the LDH assay. (AJCC 8th ed.)	Stage IIB Testicular Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140236>	C140233	Stage IIC Testicular Cancer AJCC v8|Stage IIC Testicular Cancer	Stage IIC includes: (Any pT/TX, N3, M0, S0); (Any pT/TX, N3, M0, S1). TX: Testicular cancer in which the primary tumor cannot be assessed. N3: Testicular cancer with metastasis with a lymph node mass larger than 5 cm in greatest dimension. M0: Testicular cancer without evidence of distant metastasis. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N and hCG (mlU/mL) less than 5,000 and AFP (ng/mL) less than 1,000. N indicates the upper limit of normal for the LDH assay. (AJCC 8th ed.)	Stage IIC Testicular Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140237>	C140225	Stage III Testicular Cancer AJCC v8|Stage III Testicular Cancer	Stage III includes: Any pT/TX, Any N, M1, SX. TX: Testicular cancer in which the primary tumor cannot be assessed. M1: Testicular cancer with distant metastasis. SX: Marker studies not available or not performed. (AJCC 8th ed.)	Stage III Testicular Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140238>	C140237	Stage IIIA Testicular Cancer AJCC v8|Stage IIIA Testicular Cancer	Stage IIIA includes: (Any pT/TX, Any N, M1a, S0); (Any pT/TX, Any N, M1a, S1). TX: Testicular cancer in which the primary tumor cannot be assessed. M1a: Testicular cancer with non-retroperitoneal nodal or pulmonary metastases. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N and hCG (mlU/mL) less than 5,000 and AFP (ng/mL) less than 1,000. N indicates the upper limit of normal for the LDH assay. (AJCC 8th ed.)	Stage IIIA Testicular Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140239>	C140237	Stage IIIB Testicular Cancer AJCC v8|Stage IIIB Testicular Cancer	Stage IIIB includes: (Any pT/TX, N1-3, M0, S2); (Any pT/TX, Any N, M1a, S2). TX: Testicular cancer in which the primary tumor cannot be assessed. N1: Testicular cancer with metastasis with a lymph node mass 2 cm or smaller in greatest dimension and less than or equal to five nodes positive, none larger than 2 cm in greatest dimension. N2: Testicular cancer with metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension; or more than five nodes positive, none larger than 5 cm; or evidence of extranodal extension of tumor. N3: Testicular cancer with metastasis with a lymph node mass larger than 5 cm in greatest dimension. M0: Testicular cancer without evidence of distant metastasis. M1a: Testicular cancer with non-retroperitoneal nodal or pulmonary metastases. S2: LDH 1.5-10 x N or hCG (mlU/mL) 5,000-50,000 or AFP (ng/mL) 1,000-10,000. N indicates the upper limit of normal for the LDH assay. (AJCC 8th ed.)	Stage IIIB Testicular Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C14023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14023>	C13432	Xq22-q23	A chromosome band present on Xq			Gene or Genome	
C140240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140240>	C140237	Stage IIIC Testicular Cancer AJCC v8|Stage IIIC Testicular Cancer	Stage IIIC includes: (Any pT/TX, N1-3, M0, S3); (Any pT/TX, Any N, M1a, S3); (Any pT/TX, Any N, M1b, Any S). TX: Testicular cancer in which the primary tumor cannot be assessed. N1: Testicular cancer with metastasis with a lymph node mass 2 cm or smaller in greatest dimension and less than or equal to five nodes positive, none larger than 2 cm in greatest dimension. N2: Testicular cancer with metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension; or more than five nodes positive, none larger than 5 cm; or evidence of extranodal extension of tumor. N3: Testicular cancer with metastasis with a lymph node mass larger than 5 cm in greatest dimension. M0: Testicular cancer without evidence of distant metastasis. M1a: Testicular cancer with non-retroperitoneal nodal or pulmonary metastases. M1b: Testicular cancer with non-pulmonary visceral metastases. S3: LDH more than 10 x N or hCG (mlU/mL) more than 50,000 or AFP (ng/mL) more than 10,000. N indicates the upper limit of normal for the LDH assay. (AJCC 8th ed.)	Stage IIIC Testicular Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140241>	C7251	Testicular Cancer by AJCC v6 and v7 Stage	A term that refers to the staging of testicular cancer according to the American Joint Committee on Cancer, 6th and 7th editions.			Neoplastic Process	
C140242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140242>	C25993	BSND Gene|BSND|BSND|Barttin CLCNK Type Accessory Beta Subunit Gene	This gene is involved in chloride transport.			Gene or Genome	
C140243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140243>	C140242	BSND wt Allele|BART|Bartter Syndrome, Infantile, With Sensorineural Deafness (Barttin) 2 Gene|Barttin CLCNK Type Accessory Beta Subunit wt Allele|DFNB73|Deafness, Autosomal Recessive 73 Gene	Human BSND wild-type allele is located in the vicinity of 1p32.3 and is approximately 12 kb in length. This allele, which encodes Barttin protein, plays a role in the modulation of chloride transport. Mutation of the gene is associated with Bartter syndrome with sensorineural deafness.			Gene or Genome	
C140244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140244>	C28505	Barttin|BSND|Barttin CLCNK-Type Chloride Channel Accessory Beta Subunit	Barttin (320 aa, ~35 kDa) is encoded by the human BSND gene. This protein is involved in chloride transport.			Amino Acid, Peptide, or Protein	
C140245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140245>	C20923	GPR15 Gene|G Protein-Coupled Receptor 15 Gene|GPR15|GPR15	This gene plays a role in T-cell homing.			Gene or Genome	
C140246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140246>	C140245	GPR15 wt Allele|BOB|G Protein-Coupled Receptor 15 wt Allele	Human GPR15 wild-type allele is located in the vicinity of 3q11.2 and is approximately 1 kb in length. This allele, which encodes G-protein coupled receptor 15 protein, is involved in the migration of regulatory T-cells (Tregs).			Gene or Genome	
C140247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140247>	C18239	G-Protein Coupled Receptor 15|BoB|Brother of Bonzo|G Protein-Coupled Receptor 15|GPR15	G-protein coupled receptor 15 (360 aa, ~41 kDa) is encoded by the human GPR15 gene. This protein plays a role in the modulation of T-cell migration.			Amino Acid, Peptide, or Protein|Receptor	
C140248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140248>	C135718	NRAS NM_002524.4:c.35G>T|N-ras c.35G>T|NM_002524.4:c.35G>T|NRAS G12V (c.35G>T) mutation|NRAS c.35G>T|NRAS1 c.35G>T|Neuroblastoma RAS Viral (v-ras) Oncogene Homolog c.35G>T	A nucleotide substitution at position 35 of the coding sequence of the NRAS gene where guanine has been mutated to thymine.	NRAS NM_002524.4:c.35G>T		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C140249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140249>	C107483	NRAS NP_002515.1:p.G12V|GTPase NRas G12V|GTPase NRas Gly12Val|NP_002515.1:p.G12V|NP_002515.1:p.Gly12Val|NRAS G12V|NRAS G12V Mutation|NRAS Gly12Val|NRAS NP_002515.1:p.Gly12Val|NRAS p.G12V|NRAS p.Gly12Val|Transforming Protein N-Ras G12V|Transforming Protein N-Ras Gly12Val	A change in the amino acid residue at position 12 in the GTPase NRas protein where glycine has been replaced by valine.	NRAS NP_002515.1:p.G12V		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C14024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14024>	C13432	1q22	A chromosome band present on 1q			Gene or Genome	
C140250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140250>	C45934	HRAS NM_005343.3:c.35G>T|C-H-RAS c.35G>T|C-HA-RAS1 c.35G>T|H-ras c.35G>T|HRAS c.35G>T|HRAS1 c.35G>T|HRas Proto-Oncogene, GTPase c.35G>T|Ha-ras c.35G>T|Harvey Rat Sarcoma Viral Oncogene Homolog c.35G>T|NM_005343.3:c.35G>T|RASH1 c.35G>T|v-Ha-ras Harvey Rat Sarcoma Viral Oncogene Homolog c.35G>T	A nucleotide substitution at position 35 of the coding sequence of the HRAS gene where guanine has been mutated to thymine.	HRAS NM_005343.3:c.35G>T		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C140251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140251>	C177784	HRAS Protein Variant|GTPase HRas Protein Variant|H-Ras Protein Variant|H-Ras-1 Protein Variant|Ha-Ras Protein Variant|Ha-Ras1 Protein Variant|Harvey Rat Sarcoma Viral Oncoprotein Protein Variant|c-H-ras Protein Variant	A variation in the amino acid sequence for the GTPase HRas protein.	HRAS Protein Variant		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C140252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140252>	C45934	HRAS NM_005343.3:c.35_36delinsTA|C-H-RAS c.35_36delGCinsTA|C-HA-RAS1 c.35_36delGCinsTA|H-ras c.35_36delGCinsTA|HRAS NM_005343.3:c.35_36GC>TA|HRAS NM_005343.3:c.35_36delGCinsTA|HRAS NM_005343.3:c.35_36delGCinsTA|HRAS c.35_36GC>TA|HRAS c.35_36delGCinsTA|HRAS1 c.35_36delGCinsTA|HRas Proto-Oncogene, GTPase c.35_36delGCinsTA|Ha-ras c.35_36delGCinsTA|Harvey Rat Sarcoma Viral Oncogene Homolog c.35_36delGCinsTA|NM_005343.3:c.35_36GC>TA|NM_005343.3:c.35_36delGCinsTA|NM_005343.3:c.35_36delinsTA|RASH1 c.35_36delGCinsTA|v-Ha-ras Harvey Rat Sarcoma Viral Oncogene Homolog c.35_36delGCinsTA	A complex substitution where the nucleotide sequence at positions 35 and 36 of the coding sequence of the HRAS gene has changed from guanine-cytosine to thymine-adenine.	HRAS NM_005343.3:c.35_36delGCinsTA		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C140253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140253>	C156884	HRAS NP_005334.1:p.G12V|GTPase HRas G12V|GTPase HRas Gly12Val|H-Ras G12V|H-Ras Gly12Val|H-Ras-1 G12V|H-Ras-1 Gly12Val|HRAS G12V|HRAS G12V Mutation|HRAS Gly12Val|HRAS NP_005334.1:p.Gly12Val|HRAS p.G12V|HRAS p.Gly12Val|Ha-Ras G12V|Ha-Ras Gly12Val|Ha-Ras1 G12V|Ha-Ras1 Gly12Val|Harvey Rat Sarcoma Viral Oncoprotein G12V|Harvey Rat Sarcoma Viral Oncoprotein Gly12Val|NP_005334.1:p.G12V|NP_005334.1:p.Gly12Val|c-H-ras G12V|c-H-ras Gly12Val	A change in the amino acid residue at position 12 in the GTPase HRas protein where glycine has been replaced by valine.	HRAS NP_005334.1:p.G12V		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C140254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140254>	C20420	RREB1 Gene|RREB1|RREB1|Ras Responsive Element Binding Protein 1 Gene	This gene is involved in binding to RAS-responsive elements (RREs) in the promoters of target genes.			Gene or Genome	
C140255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140255>	C140254	RREB1 wt Allele|FINB|HNT|Hindsight Homolog (Drosophila) Gene|Hindsight Homolog Gene|LZ321|RREB-1|Ras Responsive Element Binding Protein 1 wt Allele|Zep-1	Human RREB1 wild-type allele is located in the vicinity of 6p24.3 and is approximately 144 kb in length. This allele, which encodes Ras-responsive element-binding protein 1, plays a role in Ras signaling-dependent transcriptional regulation.			Gene or Genome	
C140256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140256>	C17207	Ras-Responsive Element-Binding Protein 1|Finger Protein In Nuclear Bodies|RREB-1|RREB1|Raf-Responsive Zinc Finger Protein LZ321|Ras-Responsive Element Binding Protein 1|Zep-1|Zinc Finger Motif Enhancer-Binding Protein 1	Ras-responsive element-binding protein 1 (1687 aa, ~181 kDa) is encoded by the human RREB1 gene. This protein is involved in Ras signaling-dependent gene transcription.			Amino Acid, Peptide, or Protein	
C140257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140257>	C51763|C51698	Percutaneous Breast Biopsy|Percutaneous Biopsy of Breast	The extraction of a sample of breast tissue taken via the insertion of a needle through the skin and into the breast.	Percutaneous Breast Biopsy		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C140258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140258>	C18004	Enneking Staging System|Enneking Staging System for Malignant Musculoskeletal Tumors|Enneking Staging for Malignant Musculoskeletal Tumors|MSTS Staging System|MSTS System|enneking msts stage|enneking_msts_stage	A staging system for malignant mesenchymal tumors that takes into account the surgical grade, local extent, and presence or absence of metastasis.			Classification	GDC Property Terminology|GDC Terminology
C140259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140259>	C140258	Enneking Surgical Grade|MSTS Grade|enneking msts grade|enneking_msts_grade	A description of malignant mesenchymal tumors based on cell morphological features.			Classification	GDC Property Terminology|GDC Terminology
C14025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14025>	C13432	13p12	A chromosome band present on 13p			Gene or Genome	
C140260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140260>	C140259	Enneking Low Surgical Grade|G1|Low Grade|Low Grade (G1)|MSTS Low Surgical Grade	A low-grade lesion, corresponding to Broder's Grades 1 or 2, with a low risk for distant spread (< 25%). These tumors are characterized by low mitotic rates, low nuclear to cytoplasmic ratio, and limited pleomorphism.			Classification	GDC Terminology|GDC Value Terminology
C140261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140261>	C140259	Enneking High Surgical Grade|G2|High Grade|High Grade (G2)|MSTS High Surgical Grade	A high-grade lesion, corresponding to Broder's Grades 3 and 4, having a higher incidence of metastasis and characterized histologically by mitotic figures, prominent nucleoli, and pleomorphism.			Classification	GDC Terminology|GDC Value Terminology
C140262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140262>	C140258	Enneking Tumor Type|MSTS Tumor Type|enneking msts tumor site|enneking_msts_tumor_site	A description of malignant mesenchymal tumors based on tumor extent.			Classification	GDC Property Terminology|GDC Terminology
C140263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140263>	C140262	Intracompartmental Tumor|Intracompartmental|Intracompartmental (T1)|MSTS Intracompartmental|T1	Bone tumors are confined within the cortex of the bone.			Classification	GDC Terminology|GDC Value Terminology
C140264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140264>	C35625	Genetic Macular Dystrophy	Macular dystrophy that is related to a change in a gene.			Disease or Syndrome	Cellosaurus Disease Terminology
C140265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140265>	C140262	Extracompartmental Tumor|Extracompartmental|Extracompartmental (T2)|MSTS Extracompartmental|T2	Bone tumors extend beyond the bone cortex.			Classification	GDC Terminology|GDC Value Terminology
C140266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140266>	C140258	Enneking Metastasis|MSTS Metastasis|enneking msts metastasis|enneking_msts_metastasis	A description of malignant mesenchymal tumors based on presence or absence of metastasis.			Classification	GDC Property Terminology|GDC Terminology
C140267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140267>	C4802	Hereditary Spastic Paraplegia|Hereditary spastic paraplegia	Spastic paraplegia that is transmitted from parent to child.			Disease or Syndrome	Cellosaurus Disease Terminology|mCode Elixhauser Neurological Movement Disorder Value Set|mCode Terminology
C140268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140268>	C26702	Hereditary Cerebellar Ataxia|Hereditary ataxia, unspecified	Cerebellar ataxia that is transmitted from parent to child.			Disease or Syndrome	Cellosaurus Disease Terminology|mCode Elixhauser Neurological Movement Disorder Value Set|mCode Terminology
C14026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14026>	C13432	8q24.3	A chromosome band present on 8q			Gene or Genome	
C140270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140270>	C18004	International Society of Pediatric Oncology Staging System|SIOP Staging System	A staging system for Wilms' Tumor that is based on the extent of tumor spread at surgery, after the patient has received neo-adjuvant chemotherapy.			Classification	
C140271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140271>	C180522	Children's Oncology Group/National Wilms' Tumor Study Group Staging System|COG/NWTSG Staging System|Childrens Oncology Group/National Wilms Tumor Study Group Staging System	A staging system for Wilms' Tumor that is based on the postoperative, pre-chemotherapy pathological features and findings relating to the extent of tumor spread.			Classification	
C140272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140272>	C18004	SIOP/COG/NWTSG Staging System	A staging system for Wilms' Tumor that combines the International Society of Pediatric Oncology Staging System and the Children's Oncology Group/National Wilms' Tumor Study Group Staging System.			Classification	
C140273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140273>	C48233	Urinary Tract Cancer TNM Finding v8|Urinary Tract Carcinoma TNM Finding v8	A finding about one or more characteristics of urinary tract cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C140274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140274>	C140273	Kidney Cancer TNM Finding v8|Kidney Carcinoma TNM Finding v8	A finding about one or more characteristics of kidney cancer, following the rules of the TNM AJCC v8 classification system. This classification system applies to carcinomas arising in the kidney. It does not apply to urothelial carcinomas (are staged according to the classification for renal pelvis and ureter), lymphomas (are staged according to the classification for Hodgkin and non-Hodgkin lymphoma), sarcomas (are staged according to the classification for soft tissue sarcoma of the abdomen and thoracic visceral organs), and Wilms tumor (no AJCC staging system).  (from AJCC 8th Ed.)			Finding	
C140275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140275>	C140274	Kidney Cancer Clinical TNM Finding v8|Kidney Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of kidney cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C140276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140276>	C140275	Kidney Cancer Clinical Distant Metastasis TNM Finding v8|Clinical Staging: Distant Metastasis (cM)|Kidney Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of kidney cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C140277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140277>	C140276	Kidney Cancer cM0 TNM Finding v8|Kidney Carcinoma cM0 TNM Finding v8|cM0	Kidney cancer without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C140278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140278>	C140276	Kidney Cancer cM1 TNM Finding v8|Kidney Carcinoma cM1 TNM Finding v8|cM1	Kidney cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C140279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140279>	C140274	Kidney Cancer Pathologic TNM Finding v8|Kidney Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of kidney cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C14027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14027>	C13432	4p16	A chromosome band present on 4p	4p16		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C140280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140280>	C140279	Kidney Cancer Pathologic Distant Metastasis TNM Finding v8|Kidney Carcinoma Pathologic Distant Metastasis TNM Finding v8|Pathologic Staging: Distant Metastasis (pM)	A pathologic finding about one or more characteristics of kidney cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C140281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140281>	C140280	Kidney Cancer pM1 TNM Finding v8|Kidney Carcinoma pM1 TNM Finding v8|pM1	Kidney cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C140282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140282>	C140279	Kidney Cancer Pathologic Primary Tumor TNM Finding v8|Kidney Carcinoma Pathologic Primary Tumor TNM Finding v8|Pathologic Staging: Primary Tumor (pT)	A pathologic finding about one or more characteristics of kidney cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C140283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140283>	C140282	Kidney Cancer pTX TNM Finding v8|Kidney Carcinoma pTX TNM Finding v8|pTX	Kidney cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C140284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140284>	C140282	Kidney Cancer pT0 TNM Finding v8|Kidney Carcinoma pT0 TNM Finding v8|pT0	Kidney cancer with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C140285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140285>	C140282	Kidney Cancer pT1 TNM Finding v8|Kidney Carcinoma pT1 TNM Finding v8|pT1	Kidney cancer in which the tumor measures 7 cm or less in greatest dimension and is limited to the kidney. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C140286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140286>	C140285	Kidney Cancer pT1a TNM Finding v8|Kidney Carcinoma pT1a TNM Finding v8|pT1a	Kidney cancer in which the tumor measures 4 cm or less in greatest dimension and is limited to the kidney. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C140287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140287>	C140285	Kidney Cancer pT1b TNM Finding v8|Kidney Carcinoma pT1b TNM Finding v8|pT1b	Kidney cancer in which the tumor measures more than 4 cm but 7 cm or less in greatest dimension and is limited to the kidney. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C140288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140288>	C140282	Kidney Cancer pT2 TNM Finding v8|Kidney Carcinoma pT2 TNM Finding v8|pT2	Kidney cancer in which the tumor measures more than 7 cm in greatest dimension and is limited to the kidney. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C140289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140289>	C140288	Kidney Cancer pT2a TNM Finding v8|Kidney Carcinoma pT2a TNM Finding v8|pT2a	Kidney cancer in which the tumor measures more than 7 cm but 10 cm or less in greatest dimension and is limited to the kidney. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C14028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14028>	C13432	19q12	A chromosome band present on 19q			Gene or Genome	
C140290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140290>	C140288	Kidney Cancer pT2b TNM Finding v8|Kidney Carcinoma pT2b TNM Finding v8|pT2b	Kidney cancer in which the tumor measures more than 10 cm in greatest dimension and is limited to the kidney. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C140291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140291>	C140282	Kidney Cancer pT3 TNM Finding v8|Kidney Carcinoma pT3 TNM Finding v8|pT3	Kidney cancer in which the tumor extends into major veins or perinephric tissues, but not into the ipsilateral adrenal gland and not beyond Gerota's fascia. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C140292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140292>	C140291	Kidney Cancer pT3a TNM Finding v8|Kidney Carcinoma pT3a TNM Finding v8|pT3a	Kidney cancer in which the tumor extends into the renal vein or its segmental branches, or invades the pelvicalyceal system, or invades perirenal and/or renal sinus fat but not beyond Gerota's fascia. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C140293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140293>	C140291	Kidney Cancer pT3b TNM Finding v8|Kidney Carcinoma pT3b TNM Finding v8|pT3b	Kidney cancer in which the tumor extends into the vena cava below the diaphragm. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C140294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140294>	C140291	Kidney Cancer pT3c TNM Finding v8|Kidney Carcinoma pT3c TNM Finding v8|pT3c	Kidney cancer in which the tumor extends into the vena cava above the diaphragm or invades the wall of the vena cava. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C140295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140295>	C140282	Kidney Cancer pT4 TNM Finding v8|Kidney Carcinoma pT4 TNM Finding v8|pT4	Kidney cancer in which the tumor invades beyond Gerota's fascia (including contiguous extension into the ipsilateral adrenal gland). (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C140296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140296>	C140279	Kidney Cancer Pathologic Regional Lymph Nodes TNM Finding v8|Kidney Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8|Pathologic Staging: Regional Lymph Nodes (pN)	A pathologic finding about one or more characteristics of kidney cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C140297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140297>	C140296	Kidney Cancer pNX TNM Finding v8|Kidney Carcinoma pNX TNM Finding v8|pNX	Kidney cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C140298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140298>	C140296	Kidney Cancer pN0 TNM Finding v8|Kidney Carcinoma pN0 TNM Finding v8|pN0	Kidney cancer with no regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C140299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140299>	C140296	Kidney Cancer pN1 TNM Finding v8|Kidney Carcinoma pN1 TNM Finding v8|pN1	Kidney cancer with metastasis in regional lymph node(s). (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C14029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14029>	C13432	15q15.2	A chromosome band present on 15q			Gene or Genome	
C1402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1402>	C521	Prednisolone Sodium Phosphate|Ak-Pred|Inflamase|Key-Pred SP|Millipred|Orapred|Orapred ODT|PREDNISOLONE SODIUM PHOSPHATE|Pediapred|Polypred|Predmix|Prednabene|Prednesol|Prednisol|Prednisolone Sodium Phosphate ODT|Predsol|Veripred 20	The sodium phosphate salt form of prednisolone, a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. As a glucocorticoid receptor agonist, prednisolone sodium phosphate binds to specific intracellular glucocorticoid receptors, and causes the ligand- receptor complex to be translocated to the nucleus where it initiates the transcription of glucocorticoid-responsive genes such as various cytokines and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both potent mediators of inflammation. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology
C140300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140300>	C20420	ILF2 Gene|ILF2|ILF2|Interleukin Enhancer Binding Factor 2 Gene	This gene plays a role in mRNA localization, DNA repair and the regulation of IL2 gene expression.			Gene or Genome	
C140301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140301>	C140272	SIOP/COG/NWTSG Stage I|Stage I	Wilms' tumor is limited to the kidney and completely excised; the tumor was not ruptured before or during removal; the vessels of the renal sinus are not involved beyond 2 mm; there is no residual tumor present beyond the margins of excision.			Classification	GDC Terminology|GDC Value Terminology
C140302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140302>	C140272	SIOP/COG/NWTSG y-Stage I|SIOP/COG/NWTSG Stage I-y	The assessment of stage I Wilms' tumor was performed after neoadjuvant therapy was given.			Classification	
C140303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140303>	C140272	SIOP/COG/NWTSG Stage II|Stage II	Wilms' tumor extends beyond the kidney but is completely excised; no residual tumor is apparent at or beyond the margins of the excision; tumor thrombus in vessels outside the kidney is Stage II if the thrombus is removed en bloc with the tumor.			Classification	GDC Terminology|GDC Value Terminology
C140304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140304>	C140272	SIOP/COG/NWTSG y-Stage II|SIOP/COG/NWTSG Stage II-y	The assessment of stage III Wilms' tumor was performed after neoadjuvant therapy was given.			Classification	
C140305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140305>	C140272	SIOP/COG/NWTSG Stage III|Stage III	Residual Wilms' tumor confined to the abdomen; Lymph nodes in the renal hilum, the periaortic chains, or beyond are found to contain tumor; diffuse peritoneal contamination by the tumor; implants are found on the peritoneal surfaces; tumor extends beyond the surgical margins either microscopically or grossly; tumor is not completely resectable because of local infiltration into vital structures.			Classification	GDC Terminology|GDC Value Terminology
C140306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140306>	C140272	SIOP/COG/NWTSG y-Stage III|SIOP/COG/NWTSG Stage III-y	The assessment of stage III Wilms' tumor was performed after neoadjuvant therapy was given.			Classification	
C140307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140307>	C140272	SIOP/COG/NWTSG Stage IV|Stage IV	Presence of hematogenous metastases or metastases to distant lymph nodes.			Classification	GDC Terminology|GDC Value Terminology
C140308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140308>	C140300	ILF2 wt Allele|Interleukin Enhancer Binding Factor 2 wt Allele|Interleukin Enhancer Binding Factor 2, 45kD Gene|Interleukin Enhancer Binding Factor 2, 45kDa Gene|NF45|Nuclear Factor of Activated T-Cells, 45-kDa Gene|PRO3063	Human ILF2 wild-type allele is located in the vicinity of 1q21.3 and is approximately 9 kb in length. This allele, which encodes interleukin enhancer-binding factor 2 protein, is involved in DNA repair, mRNA localization, the modulation of IL2 gene expression.			Gene or Genome	
C140309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140309>	C17207	Interleukin Enhancer-Binding Factor 2|ILF2|Nuclear Factor of Activated T-Cells 45 kDa	Interleukin enhancer-binding factor 2 (390 aa, ~43 kDa) is encoded by the human ILF2 gene. This protein plays a role in the regulation of IL2 gene transcription, nonhomologous end joining DNA repair and mRNA export.			Amino Acid, Peptide, or Protein	
C14030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14030>	C13432	20q13.2-q13.3	A chromosome band present on 20q			Gene or Genome	
C140310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140310>	C200766|C176023	Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing Memory T-lymphocytes bb21217|Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing Memory T-Cells bb21217|BB 21217|bb-21217|bb21217	A preparation of autologous memory T-lymphocytes transduced, ex vivo, with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-B-cell maturation antigen (BCMA) single chain variable fragment (scFv) fused to the signaling domain of 4-1BB (CD137) and a CD3-zeta T-cell activation domain, with potential immunostimulating and antineoplastic activities. Upon intravenous administration back into the patient, the autologous anti-BCMA-CAR-4-1BB-CD3zeta-expressing memory T-lymphocytes bb21217 are directed to, and induce selective toxicity in, BCMA-expressing tumor cells. BCMA, a tumor specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma survival. BCMA is overexpressed on malignant plasma cells.	Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing Memory T-lymphocytes bb21217		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C140311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140311>	C54362	NELFE Gene|NELFE|NELFE|Negative Elongation Factor Complex Member E Gene	This gene is involved in RNA binding and transcriptional elongation.			Gene or Genome	
C140312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140312>	C140311	NELFE wt Allele|D6S45|Major Histocompatibility Complex Gene RD|NELF-E|Negative Elongation Factor Complex Member E wt Allele|RD|RDBP|RDP	Human NELFE wild-type allele is located in the vicinity of 6p21.33 and is approximately 7 kb in length. This allele, which encodes negative elongation factor E protein, plays a role in transcript elongation and RNA binding.			Gene or Genome	
C140313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140313>	C49164	Immune-related Response Evaluation Criteria In Solid Tumors|irRECIST	A set of criteria for capturing the unidimensional measurements which are used to assess the effect of immunotherapeutic agents on solid tumors based on elements of Immune-related RECIST (irRECIST).			Intellectual Product	
C140314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140314>	C26199	Negative Elongation Factor E|NELF-E|NELFE|Negative Elongation Factor Polypeptide E|RD RNA Binding Protein|RD RNA-Binding Protein|RNA-Binding Protein RD	Negative elongation factor E (380 aa, ~43 kDa) is encoded by the human NELFE gene. This protein is involved in RNA binding and the regulation of transcript elongation.			Amino Acid, Peptide, or Protein	
C140315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140315>	C140313	irRECIST Partial Response|irPR|irPR	A decrease of 30% or more in TMTB relative to baseline, non-target lesions are irNN, and no unequivocal progression of new non-measurable lesions.			Intellectual Product	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C140316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140316>	C140313	irRECIST Complete Response|irCR|irCR	A complete disappearance of all measurable and non-measurable lesions. Lymph nodes must decrease to < 10 mm in short axis. Confirmation of response is not mandatory.			Intellectual Product	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C140317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140317>	C140313	irRECIST Stable Disease|irSD|irSD	A failure to meet criteria for irCR or irPR in the absence of irPD.			Intellectual Product	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C140318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140318>	C140313	irRECIST No Baseline Disease|irNN	No target disease was identified at baseline and at follow-up the patient fails to meet criteria for irCR or irPD.			Intellectual Product	
C140319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140319>	C140313	irRECIST Progressive Disease|irPD|irPD	A minimum 20% increase and minimum 5 mm absolute increase in total measured tumor burden compared to nadir, or irPD for non-target or new non-measurable lesions. Confirmation of progression is recommended minimum 4 weeks after the first irPD assessment.			Intellectual Product	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C14031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14031>	C13432	4q34.1-q34.3	A chromosome band present on 4q			Gene or Genome	
C140320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140320>	C140313	irRECIST Non-Evaluable|irNE	Used in exceptional cases where insufficient data exists.			Intellectual Product	
C140321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140321>	C140313	irRECIST No Disease|irND	Used in adjuvant setting when no disease is detected.			Intellectual Product	
C140322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140322>	C9385	Renal Cell Cancer by AJCC v8 Stage|Renal Cell Carcinoma by AJCC v8 Stage|Tumor Stage (Pathological)	A term that refers to the staging of kidney cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to carcinomas arising in the kidney. It does not apply to urothelial carcinomas (are staged according to the classification for renal pelvis and ureter), lymphomas (are staged according to the classification for Hodgkin and non-Hodgkin lymphoma), sarcomas (are staged according to the classification for soft tissue sarcoma of the abdomen and thoracic visceral organs), and Wilms tumor (no AJCC staging system). (from AJCC 8th Ed.)			Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C140323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140323>	C140322	Stage I Renal Cell Cancer AJCC v8|Stage I|Stage I Renal Cell Cancer|Stage I Renal Cell Carcinoma AJCC v8	Stage I includes: T1, N0, M0. T1: Tumor measuring 7 cm or less in greatest dimension, limited to the kidney. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Renal Cell Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C140324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140324>	C140322	Stage II Renal Cell Cancer AJCC v8|Stage II|Stage II Renal Cell Cancer|Stage II Renal Cell Carcinoma AJCC v8	Stage II includes: T2, N0, M0. T2: Tumor measuring more than 7 cm in greatest dimension, limited to the kidney. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Renal Cell Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C140325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140325>	C140322	Stage III Renal Cell Cancer AJCC v8|Stage III|Stage III Renal Cell Cancer|Stage III Renal Cell Carcinoma AJCC v8	Stage III includes: (T1, N1, M0); (T2, N1, M0); (T3, N0, M0); (T3, N1, M0). T1: Tumor measuring 7 cm or less in greatest dimension, limited to the kidney. T2: Tumor measuring more than 7 cm in greatest dimension, limited to the kidney. T3: Tumor extending into major veins or perinephric tissues, but not into the ipsilateral adrenal gland and not beyond Gerota's fascia. N0: No regional lymph node metastasis. N1: Metastasis in regional lymph node(s). M0: No distant metastasis. (AJCC 8th ed.)	Stage III Renal Cell Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C140326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140326>	C140322	Stage IV Renal Cell Cancer AJCC v8|Stage IV|Stage IV Renal Cell Cancer|Stage IV Renal Cell Carcinoma AJCC v8	Stage IV includes: (T4, Any N, M0); (Any T, Any N, M1). T4: Tumor invading beyond Gerota's fascia (including contiguous extension into the ipsilateral adrenal gland). M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Renal Cell Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C140327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140327>	C16546	Volumetric Laser Endomicroscopy|NvisionVLE|NvisionVLE Imaging System	An endoscopic imaging technology that uses optical coherence tomography with near infrared light and balloon-centered imaging probes to produce scans of 6 cm segments of the esophagus, with surface and subsurface image depth greater than 3 mm with 7 micron axial resolution. These high-speed scans allow real-time diagnosis of surface and subsurface abnormalities and can guide endoscopic treatment.	Volumetric Laser Endomicroscopy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C140328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140328>	C154621|C140329	Advanced Non-Functioning Neuroendocrine Tumor|Advanced Non-Functioning Well Differentiated Neuroendocrine Neoplasm|Advanced Nonfunctional Neuroendocrine Tumor|Advanced Nonfunctional Well Differentiated Neuroendocrine Neoplasm|Advanced Nonfunctioning Well Differentiated Neuroendocrine Neoplasm	A non-functioning neuroendocrine tumor that has spread extensively to other anatomic sites or is no longer responding to treatment.			Neoplastic Process	
C140329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140329>	C94760|C147065	Metastatic Non-Functioning Neuroendocrine Tumor|Metastatic Non-Functioning Well Differentiated Neuroendocrine Neoplasm|Metastatic Nonfunctional Neuroendocrine Tumor|Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm|Metastatic Nonfunctional Well Differentiated Neuroendocrine Tumor|Metastatic Nonfunctioning Well Differentiated Neuroendocrine Neoplasm	A non-functioning, well-differentiated neuroendocrine neoplasm that has spread from the original site of growth to another anatomic site.	Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C14032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14032>	C13432	6q26-q27	A chromosome band present on 6q			Gene or Genome	
C140330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140330>	C36214	Blasts 25 Percent or More of Bone Marrow Nucleated Cells|Blasts 25% or More of Bone Marrow Nucleated Cells|Blasts Greater than or Equal to 25 Percent of Bone Marrow Nucleated Cells|M3 (greater than 25% blasts)	A semi-quantitative microscopic finding indicating that 25 percent or more of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts 25 Percent or More of Bone Marrow Nucleated Cells		Laboratory or Test Result	ALL Authorized Value Terminology|ALL Lab Table|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C140331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140331>	C140273	Renal Pelvis and Ureter Cancer TNM Finding v8|Renal Pelvis and Ureter Urothelial Carcinoma TNM Finding v8	A finding about one or more characteristics of renal pelvis and ureter cancer, following the rules of the TNM AJCC v8 classification system. This classification system applies to renal pelvis and ureter urothelial (transitional cell) carcinoma, including histologic variants micropapillary and nested subtypes. It does not apply to renal cell carcinomas (are staged according to the classification for kidney), renal medullary carcinomas (are staged according to the classification for kidney), collecting duct carcinomas (are staged according to the classification for kidney),  lymphomas (are staged according to the classification for Hodgkin and non-Hodgkin lymphoma), and mesenchymal tumors (are staged according to the classification for soft tissue sarcoma of the abdomen and thoracic visceral organs). (from AJCC 8th Ed.)			Finding	
C140332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140332>	C140331	Renal Pelvis and Ureter Cancer Clinical TNM Finding v8|Renal Pelvis and Ureter Urothelial Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of renal pelvis and ureter cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C140333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140333>	C140332	Renal Pelvis and Ureter Cancer Clinical Distant Metastasis TNM Finding v8|Renal Pelvis and Ureter Urothelial Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of renal pelvis and ureter cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C140334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140334>	C140333	Renal Pelvis and Ureter Cancer cM0 TNM Finding v8|Renal Pelvis and Ureter Urothelial Carcinoma cM0 TNM Finding v8	Renal pelvis and ureter cancer without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C140335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140335>	C140333	Renal Pelvis and Ureter Cancer cM1 TNM Finding v8|Renal Pelvis and Ureter Urothelial Carcinoma cM1 TNM Finding v8	Renal pelvis and ureter cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C140336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140336>	C140331	Renal Pelvis and Ureter Cancer Pathologic TNM Finding v8|Renal Pelvis and Ureter Urothelial Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of renal pelvis and ureter cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C140337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140337>	C140336	Renal Pelvis and Ureter Cancer Pathologic Distant Metastasis TNM Finding v8|Renal Pelvis and Ureter Urothelial Carcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of renal pelvis and ureter cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C140338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140338>	C140337	Renal Pelvis and Ureter Cancer pM1 TNM Finding v8|Renal Pelvis and Ureter Urothelial Carcinoma pM1 TNM Finding v8	Renal pelvis and ureter cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C140339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140339>	C140336	Renal Pelvis and Ureter Cancer Pathologic Primary Tumor TNM Finding v8|Renal Pelvis and Ureter Urothelial Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of renal pelvis and ureter cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C14033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14033>	C13432	4p16.3	A chromosome band present on 4p	4p16.3		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C140340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140340>	C140339	Renal Pelvis and Ureter Cancer pTX TNM Finding v8|Renal Pelvis and Ureter Urothelial Carcinoma pTX TNM Finding v8	Renal pelvis and ureter cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C140341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140341>	C140339	Renal Pelvis and Ureter Cancer pT0 TNM Finding v8|Renal Pelvis and Ureter Urothelial Carcinoma pT0 TNM Finding v8	Renal pelvis and ureter cancer with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C140342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140342>	C140339	Renal Pelvis and Ureter Cancer pTa TNM Finding v8|Renal Pelvis and Ureter Urothelial Carcinoma pTa TNM Finding v8	Renal pelvis and ureter cancer with a finding of papillary noninvasive carcinoma. (from AJCC 8th Ed.)			Finding	
C140343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140343>	C140339	Renal Pelvis and Ureter Cancer pTis TNM Finding v8|Renal Pelvis and Ureter Urothelial Carcinoma pTis TNM Finding v8	Renal pelvis and ureter cancer with a finding of carcinoma in situ. (from AJCC 8th Ed.)			Finding	
C140344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140344>	C140339	Renal Pelvis and Ureter Cancer pT1 TNM Finding v8|Renal Pelvis and Ureter Urothelial Carcinoma pT1 TNM Finding v8	Renal pelvis and ureter cancer in which the tumor invades subepithelial connective tissue. (from AJCC 8th Ed.)			Finding	
C140345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140345>	C140339	Renal Pelvis and Ureter Cancer pT2 TNM Finding v8|Renal Pelvis and Ureter Urothelial Carcinoma pT2 TNM Finding v8	Renal pelvis and ureter cancer in which the tumor invades the muscularis. (from AJCC 8th Ed.)			Finding	
C140346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140346>	C140339	Renal Pelvis and Ureter Cancer pT3 TNM Finding v8|Renal Pelvis and Ureter Urothelial Carcinoma pT3 TNM Finding v8	For renal pelvis only: Tumor invades beyond muscularis into peripelvic fat or into the renal parenchyma. For ureter only: Tumor invades beyond muscularis into periureteric fat. (from AJCC 8th Ed.)			Finding	
C140347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140347>	C140339	Renal Pelvis and Ureter Cancer pT4 TNM Finding v8|Renal Pelvis and Ureter Urothelial Carcinoma pT4 TNM Finding v8	Renal pelvis and ureter cancer in which the tumor invades adjacent organs, or through the kidney into the perinephric fat. (from AJCC 8th Ed.)			Finding	
C140348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140348>	C140336	Renal Pelvis and Ureter Cancer Pathologic Regional Lymph Nodes TNM Finding v8|Renal Pelvis and Ureter Urothelial Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of renal pelvis and ureter cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C140349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140349>	C140348	Renal Pelvis and Ureter Cancer pNX TNM Finding v8|Renal Pelvis and Ureter Urothelial Carcinoma pNX TNM Finding v8	Renal pelvis and ureter cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C14034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14034>	C13432	20q12-q13.1	A chromosome band present on 20q			Gene or Genome	
C140350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140350>	C140348	Renal Pelvis and Ureter Cancer pN0 TNM Finding v8|Renal Pelvis and Ureter Urothelial Carcinoma pN0 TNM Finding v8	Renal pelvis and ureter cancer with no regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C140351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140351>	C140348	Renal Pelvis and Ureter Cancer pN1 TNM Finding v8|Renal Pelvis and Ureter Urothelial Carcinoma pN1 TNM Finding v8	Renal pelvis and ureter cancer with metastasis in a single lymph node, 2 cm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C140352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140352>	C140348	Renal Pelvis and Ureter Cancer pN2 TNM Finding v8|Renal Pelvis and Ureter Urothelial Carcinoma pN2 TNM Finding v8	Renal pelvis and ureter cancer with metastasis in a single lymph node, more than 2 cm in greatest dimension; or multiple lymph nodes. (from AJCC 8th Ed.)			Finding	
C140353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140353>	C1511	Copper 64 Cu-DOTA-daratumumab|64Cu-DOTA-daratumumab|Copper Cu 64 Daratumumab	A radioimmunoconjugate containing daratumumab, a human immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against the cell surface glycoprotein CD38, conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), and labeled with the radioisotope copper Cu 64, with potential diagnostic properties upon positron emission tomography (PET) imaging. The monoclonal antibody moiety of copper Cu 64-DOTA-daratumumab specifically targets and binds to cell surface antigen CD38. Upon binding, the radioisotope moiety may be detected using PET, thereby allowing the imaging and quantification of CD38-expressing tumor cells. CD38, a cell surface glycoprotein, is expressed on various hematopoietic cells and is overexpressed on multiple myeloma (MM) cells.	Copper 64 Cu-DOTA-daratumumab		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C140355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140355>	C7716	Renal Pelvis and Ureter Cancer by AJCC v8 Stage|Renal Pelvis and Ureter Urothelial Carcinoma by AJCC v8 Stage	A term that refers to the staging of renal pelvis and ureter cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to renal pelvis and ureter urothelial (transitional cell) carcinoma, including histologic variants micropapillary and nested subtypes. It does not apply to renal cell carcinomas (are staged according to the classification for kidney), renal medullary carcinomas (are staged according to the classification for kidney), collecting duct carcinomas (are staged according to the classification for kidney),  lymphomas (are staged according to the classification for Hodgkin and non-Hodgkin lymphoma), and mesenchymal tumors (are staged according to the classification for soft tissue sarcoma of the abdomen and thoracic visceral organs). (from AJCC 8th Ed.)			Neoplastic Process	
C140356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140356>	C7355|C140355	Renal Pelvis Cancer by AJCC v8 Stage|Renal Pelvis Urothelial Carcinoma by AJCC v8 Stage	A term that refers to the staging of renal pelvis cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to renal pelvis urothelial (transitional cell) carcinoma, including histologic variants micropapillary and nested subtypes. It does not apply to renal cell carcinomas (are staged according to the classification for kidney), renal medullary carcinomas (are staged according to the classification for kidney), collecting duct carcinomas (are staged according to the classification for kidney),  lymphomas (are staged according to the classification for Hodgkin and non-Hodgkin lymphoma), and mesenchymal tumors (are staged according to the classification for soft tissue sarcoma of the abdomen and thoracic visceral organs). (from AJCC 8th Ed.)			Neoplastic Process	
C140357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140357>	C4830|C140355	Ureter Cancer by AJCC v8 Stage|Ureter Urothelial Carcinoma by AJCC v8 Stage	A term that refers to the staging of ureter cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to ureter urothelial (transitional cell) carcinoma, including histologic variants micropapillary and nested subtypes. (from AJCC 8th Ed.)			Neoplastic Process	
C140358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140358>	C140355	Stage 0a Renal Pelvis and Ureter Cancer AJCC v8|Stage 0a Renal Pelvis and Ureter Cancer|Stage 0a Renal Pelvis and Ureter Urothelial Carcinoma AJCC v8	Stage 0a includes: Ta, N0, M0. Ta: Papillary noninvasive carcinoma. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0a Renal Pelvis and Ureter Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140359>	C140358|C140356	Stage 0a Renal Pelvis Cancer AJCC v8|Stage 0a Renal Pelvis Cancer|Stage 0a Renal Pelvis Urothelial Carcinoma AJCC v8	Stage 0a includes: Ta, N0, M0. Ta: Papillary noninvasive carcinoma. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0a Renal Pelvis Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C14035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14035>	C13432	Xp11.22	A chromosome band present on Xp			Gene or Genome	
C140360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140360>	C140358|C140357	Stage 0a Ureter Cancer AJCC v8|Stage 0a Ureter Cancer|Stage 0a Ureter Urothelial Carcinoma AJCC v8	Stage 0a includes: Ta, N0, M0. Ta: Papillary noninvasive carcinoma. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0a Ureter Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140361>	C140355	Stage 0is Renal Pelvis and Ureter Cancer AJCC v8|Stage 0is Renal Pelvis and Ureter Cancer|Stage 0is Renal Pelvis and Ureter Urothelial Carcinoma AJCC v8	Stage 0is includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0is Renal Pelvis and Ureter Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140362>	C140361|C140356	Stage 0is Renal Pelvis Cancer AJCC v8|Stage 0is Renal Pelvis Cancer|Stage 0is Renal Pelvis Urothelial Carcinoma AJCC v8	Stage 0is includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0is Renal Pelvis Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140363>	C140361|C140357	Stage 0is Ureter Cancer AJCC v8|Stage 0is Ureter Cancer|Stage 0is Ureter Urothelial Carcinoma AJCC v8	Stage 0is includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0is Ureter Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140364>	C140355	Stage I Renal Pelvis and Ureter Cancer AJCC v8|Stage I Renal Pelvis and Ureter Cancer|Stage I Renal Pelvis and Ureter Urothelial Carcinoma AJCC v8	Stage I includes: T1, N0, M0. T1: Tumor invades subepithelial connective tissue. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Renal Pelvis and Ureter Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140365>	C140364|C140356	Stage I Renal Pelvis Cancer AJCC v8|Stage I Renal Pelvis Cancer|Stage I Renal Pelvis Urothelial Carcinoma AJCC v8	Stage I includes: T1, N0, M0. T1: Tumor invades subepithelial connective tissue. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Renal Pelvis Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140366>	C140364|C140357	Stage I Ureter Cancer AJCC v8|Stage I Ureter Cancer|Stage I Ureter Urothelial Carcinoma AJCC v8	Stage I includes: T1, N0, M0. T1: Tumor invades subepithelial connective tissue. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Ureter Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140367>	C140355	Stage II Renal Pelvis and Ureter Cancer AJCC v8|Stage II Renal Pelvis and Ureter Cancer|Stage II Renal Pelvis and Ureter Urothelial Carcinoma AJCC v8	Stage II includes: T2, N0, M0. T2: Tumor invades the muscularis. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Renal Pelvis and Ureter Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140368>	C140367|C140356	Stage II Renal Pelvis Cancer AJCC v8|Stage II Renal Pelvis Cancer|Stage II Renal Pelvis Urothelial Carcinoma AJCC v8	Stage II includes: T2, N0, M0. T2: Tumor invades the muscularis. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Renal Pelvis Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140369>	C140367|C140357	Stage II Ureter Cancer AJCC v8|Stage II Ureter Cancer|Stage II Ureter Urothelial Carcinoma AJCC v8	Stage II includes: T2, N0, M0. T2: Tumor invades the muscularis. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Ureter Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C14036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14036>	C13432	11q13.5	A chromosome band present on 11q			Gene or Genome	
C140370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140370>	C140355	Stage III Renal Pelvis and Ureter Cancer AJCC v8|Stage III Renal Pelvis and Ureter Cancer|Stage III Renal Pelvis and Ureter Urothelial Carcinoma AJCC v8	Stage III includes: T3, N0, M0. T3: For renal pelvis only: Tumor invades beyond muscularis into peripelvic fat or into the renal parenchyma. For ureter only: Tumor invades beyond muscularis into periureteric fat. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Renal Pelvis and Ureter Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140371>	C140370|C140356	Stage III Renal Pelvis Cancer AJCC v8|Stage III Renal Pelvis Cancer|Stage III Renal Pelvis Urothelial Carcinoma AJCC v8	Stage III includes: T3, N0, M0. T3: Tumor invades beyond muscularis into peripelvic fat or into the renal parenchyma. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Renal Pelvis Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140372>	C140370|C140357	Stage III Ureter Cancer AJCC v8|Stage III Ureter Cancer|Stage III Ureter Urothelial Carcinoma AJCC v8	Stage III includes: T3, N0, M0. T3: Tumor invades beyond muscularis into periureteric fat. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Ureter Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140373>	C140355	Stage IV Renal Pelvis and Ureter Cancer AJCC v8|Stage IV Renal Pelvis and Ureter Cancer|Stage IV Renal Pelvis and Ureter Urothelial Carcinoma AJCC v8	Stage IV includes: (T4, N0, M0); (Any T, N1, M0); (Any T, N2, M0); (Any T, Any N, M1). T4: Tumor invades adjacent organs, or through the kidney into the perinephric fat. N0: No regional lymph node metastasis. N1: Metastasis in a single lymph node, 2 cm or less in greatest dimension. N2: Metastasis in a single lymph node, more than 2 cm in greatest dimension; or multiple lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Renal Pelvis and Ureter Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140374>	C140373|C140356	Stage IV Renal Pelvis Cancer AJCC v8|Stage IV Renal Pelvis Cancer|Stage IV Renal Pelvis Urothelial Carcinoma AJCC v8	Stage IV includes: (T4, N0, M0); (Any T, N1, M0); (Any T, N2, M0); (Any T, Any N, M1). T4: Tumor invades adjacent organs, or through the kidney into the perinephric fat. N0: No regional lymph node metastasis. N1: Metastasis in a single lymph node, 2 cm or less in greatest dimension. N2: Metastasis in a single lymph node, more than 2 cm in greatest dimension; or multiple lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Renal Pelvis Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140375>	C140373|C140357	Stage IV Ureter Cancer AJCC v8|Stage IV Ureter Cancer|Stage IV Ureter Urothelial Carcinoma AJCC v8	Stage IV includes: (T4, N0, M0); (Any T, N1, M0); (Any T, N2, M0); (Any T, Any N, M1). T4: Tumor invades adjacent organs, or through the kidney into the perinephric fat. N0: No regional lymph node metastasis. N1: Metastasis in a single lymph node, 2 cm or less in greatest dimension. N2: Metastasis in a single lymph node, more than 2 cm in greatest dimension; or multiple lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Ureter Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140376>	C7716	Renal Pelvis and Ureter Cancer by AJCC v7 Stage|Renal Pelvis and Ureter Urothelial Carcinoma by AJCC v7 Stage	A term that refers to the staging of renal pelvis and ureter cancer according to the American Joint Committee on Cancer, 7th edition.			Neoplastic Process	
C140377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140377>	C7355|C140376	Renal Pelvis Cancer by AJCC v7 Stage|Renal Pelvis Urothelial Carcinoma by AJCC v7 Stage	A term that refers to the staging of renal pelvis cancer according to the American Joint Committee on Cancer, 7th edition.			Neoplastic Process	
C140378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140378>	C4830|C140376	Ureter Cancer by AJCC v7 Stage|Ureter Urothelial Carcinoma by AJCC v7 Stage	A term that refers to the staging of ureter cancer according to the American Joint Committee on Cancer, 7th edition.			Neoplastic Process	
C140379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140379>	C155765	Pan-TRK Inhibitor ONO-7579|ONO 7579|ONO-7579|ONO-7579|ONO7579|TRK Inhibitor ONO-7579	An orally bioavailable, selective pan-tropomyosin-related-kinase (tyrosine receptor kinase; TRK) inhibitor, with potential antineoplastic activity. Upon oral administration, ONO-7579 specifically targets and binds to TRK and fusion proteins containing sequences from neurotrophic tyrosine receptor kinase (NTRK) types 1 (NTRK1; TrkA), 2 (NTRK2; TrkB), and 3 (NTRK3; TrkC).  This inhibits neurotrophin-TRK interaction and TRK activation, thereby preventing the activation of downstream signaling pathways and resulting in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress TRK and/or express NTRK fusion proteins. TRK, a family of receptor tyrosine kinases (RTKs) activated by neurotrophins, is encoded by NTRK family genes.The expression of either mutated forms of, or fusion proteins involving, NTRK family members results in uncontrolled TRK signaling, which plays an important role in tumor cell growth, survival, invasion and treatment resistance.	Pan-TRK Inhibitor ONO-7579		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C14037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14037>	C13432	1q42	A chromosome band present on 1q			Gene or Genome	
C140380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140380>	C140273	Bladder Cancer TNM Finding v8|Bladder Carcinoma TNM Finding v8|Tumor Stage (Pathologic)	A finding about one or more characteristics of bladder cancer, following the rules of the TNM AJCC v8 classification system. This classification system applies to carcinomas arising in the bladder. The typical carcinoma of the bladder is urothelial carcinoma. These carcinomas may include other histologic elements, including adenocarcinoma, squamous cell carcinoma, and small cell neuroendocrine carcinoma, but should be classified as urothelial unless the cancer is composed entirely of the alternative histology. All histologic cell types that are derived primarily from the urinary bladder epithelium should follow this classification system. It does not apply to prostatic urothelial carcinomas (are staged according to the classification for urethra), lymphomas (are staged according to the classification for Hodgkin and non-Hodgkin lymphoma), and sarcomas (are staged according to the classification for soft tissue sarcoma of the abdomen and thoracic visceral organs).  (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C140381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140381>	C140380	Bladder Cancer Clinical TNM Finding v8|Bladder Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of bladder cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C140382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140382>	C140381	Bladder Cancer Clinical Distant Metastasis TNM Finding v8|Bladder Carcinoma Clinical Distant Metastasis TNM Finding v8|Clinical Distant Metastasis Status (cM)	A clinical finding about one or more characteristics of bladder cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C140383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140383>	C140382	Bladder Cancer cM0 TNM Finding v8|Bladder Carcinoma cM0 TNM Finding v8	Bladder cancer without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C140384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140384>	C140382	Bladder Cancer cM1 TNM Finding v8|Bladder Carcinoma cM1 TNM Finding v8|cM1	Bladder cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C140385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140385>	C140384	Bladder Cancer cM1a TNM Finding v8|Bladder Carcinoma cM1a TNM Finding v8|cM1a (non-regional lymph nodes)	Bladder cancer with distant metastasis limited to lymph nodes beyond the common iliacs. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C140386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140386>	C140384	Bladder Cancer cM1b TNM Finding v8|Bladder Carcinoma cM1b TNM Finding v8|cM1b (other)	Bladder cancer with non-lymph node distant metastases. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C140387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140387>	C140380	Bladder Cancer Pathologic TNM Finding v8|Bladder Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of bladder cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C140388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140388>	C140387	Bladder Cancer Pathologic Distant Metastasis TNM Finding v8|Bladder Carcinoma Pathologic Distant Metastasis TNM Finding v8|Pathologic Distant Metastasis Status (pM)	A pathologic finding about one or more characteristics of bladder cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C140389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140389>	C140388	Bladder Cancer pM1 TNM Finding v8|Bladder Carcinoma pM1 TNM Finding v8|pM1	Bladder cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C14038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14038>	C13432	19p13.11	A chromosome band present on 19p			Gene or Genome	
C140390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140390>	C140389	Bladder Cancer pM1a TNM Finding v8|Bladder Carcinoma pM1a TNM Finding v8|pM1a (non-regional lymph nodes)	Bladder cancer with distant metastasis limited to lymph nodes beyond the common iliacs. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C140391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140391>	C140389	Bladder Cancer pM1b TNM Finding v8|Bladder Carcinoma pM1b TNM Finding v8|pM1b (other)	Bladder cancer with non-lymph node distant metastases. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C140392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140392>	C140387	Bladder Cancer Pathologic Primary Tumor TNM Finding v8|Bladder Carcinoma Pathologic Primary Tumor TNM Finding v8|Pathologic Primary Tumor Status (pT)	A pathologic finding about one or more characteristics of bladder cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C140393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140393>	C140392	Bladder Cancer pTX TNM Finding v8|Bladder Carcinoma pTX TNM Finding v8	Bladder cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C140394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140394>	C140392	Bladder Cancer pT0 TNM Finding v8|Bladder Carcinoma pT0 TNM Finding v8|pT0	Bladder cancer with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C140395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140395>	C140392	Bladder Cancer pTa TNM Finding v8|Bladder Carcinoma pTa TNM Finding v8|pTa	Bladder cancer with a finding of non-invasive papillary carcinoma. (from AJCC 8th Ed.)	Bladder Cancer pT1 TNM Finding v8		Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Terminology
C140396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140396>	C140392	Bladder Cancer pTis TNM Finding v8|Bladder Carcinoma pTis TNM Finding v8|pTis	Bladder cancer with a finding of urothelial carcinoma in situ: "flat tumor". (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C140397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140397>	C140392	Bladder Cancer pT1 TNM Finding v8|Bladder Carcinoma pT1 TNM Finding v8|pT1	Bladder cancer with tumor invading lamina propria (subepithelial connective tissue). (from AJCC 8th Ed.)	Bladder Cancer pT1 TNM Finding v8		Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Terminology
C140398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140398>	C140392	Bladder Cancer pT2 TNM Finding v8|Bladder Carcinoma pT2 TNM Finding v8|pT2	Bladder cancer with tumor invading muscularis propria. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C140399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140399>	C140398	Bladder Cancer pT2a TNM Finding v8|Bladder Carcinoma pT2a TNM Finding v8|pT2a	Bladder cancer with tumor invading superficial muscularis propria (inner half). (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C14039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14039>	C13432	3p21.3-p21.1	A chromosome band present on 3p			Gene or Genome	
C1403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1403>	C521	Prednisolone Sodium Succinate|PREDNISOLONE SODIUM SUCCINATE|Precortalon Aquosum|Prednisolone sodium succinate	The sodium succinate salt form of prednisolone, a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisolone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C140400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140400>	C140398	Bladder Cancer pT2b TNM Finding v8|Bladder Carcinoma pT2b TNM Finding v8|pT2b	Bladder cancer with tumor invading deep muscularis propria (outer half). (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C140401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140401>	C140392	Bladder Cancer pT3 TNM Finding v8|Bladder Carcinoma pT3 TNM Finding v8|pT3	Bladder cancer with tumor invading perivesical soft tissue. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C140402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140402>	C140401	Bladder Cancer pT3a TNM Finding v8|Bladder Carcinoma pT3a TNM Finding v8|pT3a	Bladder cancer with tumor invading perivesical soft tissue, microscopically. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C140403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140403>	C140401	Bladder Cancer pT3b TNM Finding v8|Bladder Carcinoma pT3b TNM Finding v8|pT3b	Bladder cancer with tumor invading perivesical soft tissue, macroscopically (extravesical mass). (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C140404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140404>	C140392	Bladder Cancer pT4 TNM Finding v8|Bladder Carcinoma pT4 TNM Finding v8|pT4	Bladder cancer with extravesical tumor directly invading any of the following: prostatic stroma, seminal vesicles, uterus, vagina, pelvic wall, abdominal wall. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C140405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140405>	C140404	Bladder Cancer pT4a TNM Finding v8|Bladder Carcinoma pT4a TNM Finding v8|pT4a	Bladder cancer with extravesical tumor invading directly into prostatic stroma, uterus, vagina. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C140406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140406>	C140404	Bladder Cancer pT4b TNM Finding v8|Bladder Carcinoma pT4b TNM Finding v8|pT4b	Bladder cancer with extravesical tumor invading pelvic wall, abdominal wall. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C140407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140407>	C140387	Bladder Cancer Pathologic Regional Lymph Nodes TNM Finding v8|Bladder Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8|Pathologic Regional Lymph Node Status (pN)	A pathologic finding about one or more characteristics of bladder cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C140408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140408>	C140407	Bladder Cancer pNX TNM Finding v8|Bladder Carcinoma pNX TNM Finding v8|pNX	Bladder cancer in which the lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C140409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140409>	C140407	Bladder Cancer pN0 TNM Finding v8|Bladder Carcinoma pN0 TNM Finding v8|pN0	Bladder cancer with no lymph node metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C14040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14040>	C13432	2p22.3-p21	A chromosome band present on 2p			Gene or Genome	
C140410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140410>	C140407	Bladder Cancer pN1 TNM Finding v8|Bladder Carcinoma pN1 TNM Finding v8|pN1	Bladder cancer with single regional lymph node metastasis in the true pelvis (perivesical, obturator, internal and external iliac, or sacral lymph node). (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C140411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140411>	C140407	Bladder Cancer pN2 TNM Finding v8|Bladder Carcinoma pN2 TNM Finding v8|pN2	Bladder cancer with multiple regional lymph node metastasis in the true pelvis (perivesical, obturator, internal and external iliac, or sacral lymph node metastasis). (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C140412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140412>	C140407	Bladder Cancer pN3 TNM Finding v8|Bladder Carcinoma pN3 TNM Finding v8|pN3	Bladder cancer with lymph node metastasis to the common iliac lymph nodes. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C140413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140413>	C16977	Hypermutation Phenotype|Hypermutator Phenotype	A genetic marker marked by the presence of mutations in genes that maintain genomic integrity, which leads to greatly increased rates of mutation for the rest of the genome and may induce malignant transformation.	Hypermutation Phenotype		Organism Attribute	CTRP Biomarker Terminology|CTRP Terminology
C140414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140414>	C117282	IDH2 NP_002159.2:p.R172W|IDH2 Arg172Trp|IDH2 NP_002159.2:p.Arg172Trp|IDH2 R172W|IDH2 R172W Mutation|IDH2 p.Arg172Trp|Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial Arg172Trp|Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial R172W|Isocitrate Dehydrogenase [NADP], Mitochondrial Arg172Trp|Isocitrate Dehydrogenase [NADP], Mitochondrial R172W|NP_002159.2:p.Arg172Trp|NP_002159.2:p.R172W	A change in the amino acid residue at position 172 in the isocitrate dehydrogenase [NADP], mitochondrial protein where arginine has been replaced by tryptophan.	IDH2 NP_002159.2:p.R172W		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C140415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140415>	C219645	IDH2 NM_002168.3:c.514A>T|IDH c.514A>T|IDH2 c.514A>T|Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial c.514A>T|Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial c.514A>T|NM_002168.3:c.514A>T	A nucleotide substitution at position 514 of the coding sequence of the IDH2 gene where adenine has been mutated to thymine.			Cell or Molecular Dysfunction	
C140416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140416>	C4912	Bladder Cancer by AJCC v8 Stage|Bladder Carcinoma by AJCC v8 Stage	A term that refers to the staging of bladder cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to carcinomas arising in the bladder. The typical carcinoma of the bladder is urothelial carcinoma. These carcinomas may include other histologic elements, including adenocarcinoma, squamous cell carcinoma, and small cell neuroendocrine carcinoma, but should be classified as urothelial unless the cancer is composed entirely of the alternative histology. All histologic cell types that are derived primarily from the urinary bladder epithelium should follow this staging system. It does not apply to prostatic urothelial carcinomas (are staged according to the classification for urethra), lymphomas (are staged according to the classification for Hodgkin and non-Hodgkin lymphoma), and sarcomas (are staged according to the classification for soft tissue sarcoma of the abdomen and thoracic visceral organs).  (from AJCC 8th Ed.)			Neoplastic Process	
C140417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140417>	C140416	Stage 0a Bladder Cancer AJCC v8|0a|Stage 0a Bladder Cancer|Stage 0a Bladder Carcinoma AJCC v8	Stage 0a includes: Ta, N0, M0. Ta: Non-invasive papillary carcinoma. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0a Bladder Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C140418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140418>	C140416	Stage 0is Bladder Cancer AJCC v8|0is|Stage 0is Bladder Cancer|Stage 0is Bladder Carcinoma AJCC v8	Stage 0is includes: Tis, N0, M0. Tis: Urothelial carcinoma in situ: "flat tumor". N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0is Bladder Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C140419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140419>	C140416	Stage I Bladder Cancer AJCC v8|I|Stage I Bladder Cancer|Stage I Bladder Carcinoma AJCC v8	Stage I includes: T1, N0, M0. T1: Tumor invades lamina propria (subepithelial connective tissue). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Bladder Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C14041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14041>	C13432	19q13.3	A chromosome band present on 19q			Gene or Genome	
C140420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140420>	C140416	Stage II Bladder Cancer AJCC v8|II|Stage II Bladder Cancer|Stage II Bladder Carcinoma AJCC v8	Stage II includes: (T2a, N0, M0); (T2b, N0, M0). T2a: Tumor invades superficial muscularis propria (inner half). T2b: Tumor invades deep muscularis propria (outer half). N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Bladder Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C140421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140421>	C140416	Stage III Bladder Cancer AJCC v8|Stage III Bladder Cancer|Stage III Bladder Carcinoma AJCC v8	Stage III includes: IIIA: (T3a, T3b, T4a, N0, M0); (T1-T4a, N1, M0); IIIB: (T1-T4a, N2, N3, M0). T1: Tumor invades lamina propria (subepithelial connective tissue). T2: Tumor invades muscularis propria. T3: Tumor invades perivesical soft tissue. T3a: Tumor invades perivesical soft tissue, microscopically. T3b: Tumor invades perivesical soft tissue, macroscopically (extravesical mass). T4a: Extravesical tumor invades directly into prostatic stroma, uterus, vagina. N0: No regional lymph node metastasis. N1: Single regional lymph node metastasis in the true pelvis (perivesical, obturator, internal and external iliac, or sacral lymph node). N2: Multiple regional lymph node metastasis in the true pelvis (perivesical, obturator, internal and external iliac, or sacral lymph node metastasis). N3: Lymph node metastasis to the common iliac lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Bladder Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140422>	C140421	Stage IIIA Bladder Cancer AJCC v8|IIIA|Stage IIIA Bladder Cancer|Stage IIIA Bladder Carcinoma AJCC v8	Stage IIIA includes: (T3a, T3b, T4a, N0, M0); (T1-T4a, N1, M0). T1: Tumor invades lamina propria (subepithelial connective tissue). T2: Tumor invades muscularis propria. T3: Tumor invades perivesical soft tissue. T3a: Tumor invades perivesical soft tissue, microscopically. T3b: Tumor invades perivesical soft tissue, macroscopically (extravesical mass). T4a: Extravesical tumor invades directly into prostatic stroma, uterus, vagina. N0: No regional lymph node metastasis. N1: Single regional lymph node metastasis in the true pelvis (perivesical, obturator, internal and external iliac, or sacral lymph node). M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIA Bladder Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C140423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140423>	C140421	Stage IIIB Bladder Cancer AJCC v8|IIIB|Stage IIIB Bladder Cancer|Stage IIIB Bladder Carcinoma AJCC v8	Stage IIIB includes: T1-T4a, N2, N3, M0. T1: Tumor invades lamina propria (subepithelial connective tissue). T2: Tumor invades muscularis propria. T3: Tumor invades perivesical soft tissue. T4a: Extravesical tumor invades directly into prostatic stroma, uterus, vagina. N2: Multiple regional lymph node metastasis in the true pelvis (perivesical, obturator, internal and external iliac, or sacral lymph node metastasis). N3: Lymph node metastasis to the common iliac lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)	Stage IIIB Bladder Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C140424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140424>	C140416	Stage IV Bladder Cancer AJCC v8|Stage IV Bladder Cancer|Stage IV Bladder Carcinoma AJCC v8	Stage IV includes: IVA: (T4b, N0, M0); (Any T, Any N, M1a); IVB: (Any T, Any N, M1b). T4b: Extravesical tumor invades pelvic wall, abdominal wall. N0: No regional lymph node metastasis. M0: No distant metastasis. M1a: Distant metastasis limited to lymph nodes beyond the common iliacs. M1b: Non-lymph node distant metastases. (AJCC 8th ed.)	Stage IV Bladder Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140425>	C140424	Stage IVA Bladder Cancer AJCC v8|IVA|Stage IVA Bladder Cancer|Stage IVA Bladder Carcinoma AJCC v8	Stage IVA includes: (T4b, N0, M0); (Any T, Any N, M1a). T4b: Extravesical tumor invades pelvic wall, abdominal wall. N0: No regional lymph node metastasis. M0: No distant metastasis. M1a: Distant metastasis limited to lymph nodes beyond the common iliacs. (AJCC 8th ed.)	Stage IVA Bladder Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C140426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140426>	C140424	Stage IVB Bladder Cancer AJCC v8|IVB|Stage IVB Bladder Cancer|Stage IVB Bladder Carcinoma AJCC v8	Stage IVB includes: Any T, Any N, M1b. M1b: Non-lymph node distant metastases. (AJCC 8th ed.)	Stage IVB Bladder Cancer AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C140427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140427>	C164008|C129820	Modakafusp Alfa|Anti-CD38-targeted IgG4-attenuated IFNa TAK-573|Anti-CD38-targeted IgG4-attenuated IFNa TAK-573|Anti-CD38-targeted IgG4-attenuated Interferon Alpha TAK-573|CD38-targeted IgG4 Fused with Attenuated IFNa|MODAKAFUSP ALFA|TAK-573|TEV-48573	A proprietary preparation composed of an immunoglobulin G4 (IgG4) directed against the cell surface glycoprotein CD-38 (CD38) that is fused to an attenuated form of human interferon alpha (IFN alpha; IFNa), with potential immunomodulating and antineoplastic activities. Upon administration, modakafusp alfa specifically targets and binds to CD38 on CD38-positive tumor cells. In turn, the IFNa moiety binds to cell-surface IFN receptors, and activates IFN-mediated signal transduction pathways, which results in the transcription and translation of genes whose products may cause antiproliferative effects in CD38-positive tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.	Anti-CD38-targeted IgG4-attenuated IFNa TAK-573		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C140428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140428>	C140273	Urethral Cancer TNM Finding v8|Urethral Carcinoma TNM Finding v8	A finding about one or more characteristics of urethral cancer, following the rules of the TNM AJCC v8 classification system. This classification system applies to urothelial (transitional cell), squamous, and glandular carcinomas of the urethra and to urothelial (transitional cell) carcinomas of the prostate and prostatic urethra. It does not apply to squamous cell carcinomas of the penile foreskin (are staged according to the classification for penis), primary urothelial carcinomas of the bladder with transmural involvement of the prostate (are staged according to the classification for urinary bladder), prostatic adenocarcinomas (are staged according to the classification for prostate), mucosal melanomas of the urethra (no AJCC staging system), lymphomas (are staged according to the classification for Hodgkin and non-Hodgkin lymphoma), and sarcomas (are staged according to the classification for soft tissue sarcoma of the abdomen and thoracic visceral organs).  (from AJCC 8th Ed.)			Finding	
C140429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140429>	C140428	Urethral Cancer Clinical TNM Finding v8|Urethral Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of urethral cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C14042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14042>	C13426	BRCT Domain|Breast Cancer Carboxy-Terminal Domain	BRCT domain was first identified in C-terminal domain of breast cancer associated protein and was found in many proteins that regulate the cellular response to DNA repair, where these domains act as multi-purpose protein-protein interaction modules. Crystallography study reveals that two ~95 amino acid BRCT repeats within the domain adopt similar structures that pack together in a head-to-tail arrangement. (NCI)			Amino Acid Sequence	
C140430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140430>	C140429	Urethral Cancer Clinical Distant Metastasis TNM Finding v8|Urethral Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of urethral cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C140431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140431>	C140430	Urethral Cancer cM0 TNM Finding v8|Urethral Carcinoma cM0 TNM Finding v8	Urethral cancer without evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C140432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140432>	C140430	Urethral Cancer cM1 TNM Finding v8|Urethral Carcinoma cM1 TNM Finding v8	Urethral cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C140433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140433>	C140428	Urethral Cancer Pathologic TNM Finding v8|Urethral Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of urethral cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C140434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140434>	C140433	Urethral Cancer Pathologic Distant Metastasis TNM Finding v8|Urethral Carcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of urethral cancer, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C140435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140435>	C140434	Urethral Cancer pM1 TNM Finding v8|Urethral Carcinoma pM1 TNM Finding v8	Urethral cancer with distant metastasis. (from AJCC 8th Ed.)			Finding	
C140436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140436>	C140433	Urethral Cancer Pathologic Primary Tumor TNM Finding v8|Urethral Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of urethral cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C140437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140437>	C140436	Male Penile Urethra and Female Urethra Cancer Pathologic Primary Tumor TNM Finding v8|Male Penile Urethra and Female Urethra Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of cancer in the male penile urethra and female urethra, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C140438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140438>	C140437	Male Penile Urethra and Female Urethra Cancer pTX TNM Finding v8|Male Penile Urethra and Female Urethra Carcinoma pTX TNM Finding v8	Urethral cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C140439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140439>	C140437	Male Penile Urethra and Female Urethra Cancer pT0 TNM Finding v8|Male Penile Urethra and Female Urethra Carcinoma pT0 TNM Finding v8	Urethral cancer with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C14043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14043>	C13671	Walker-A Motif|Walker-A Domain	The ATP binding cassette (ABC) is the largest protein family known and many of its members are membrane proteins (ABC transporters) active in the transport of a wide variety of substances across membranes. ABC proteins are identified by the presence of one or two cytosolically oriented ATP-binding cassettes or nucleotide-binding domains (NBD) of about 200 amino acid residues. Each NBD contains three typical motifs: the Walker A motif, GX4GK(ST), the Walker B motif and the ABC signature or C motif. Walker A and B motifs are found in other nucleotide-binding proteins, including P-, F- and V-ATPases, G proteins, adenylate kinase, myosin, phosphofructokinase and ATP/ADP exchangers. Although the overall similarity between ABC proteins can be very low, their NBDs share an average of 30-40 % similarity.			Amino Acid Sequence	
C140440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140440>	C140437	Male Penile Urethra and Female Urethra Cancer pTa TNM Finding v8|Male Penile Urethra and Female Urethra Carcinoma pTa TNM Finding v8	Urethral cancer with a finding of non-invasive papillary carcinoma. (from AJCC 8th Ed.)			Finding	
C140441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140441>	C140437	Male Penile Urethra and Female Urethra Cancer pTis TNM Finding v8|Male Penile Urethra and Female Urethra Carcinoma pTis TNM Finding v8	Urethral cancer with a finding of carcinoma in situ. (from AJCC 8th Ed.)			Finding	
C140442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140442>	C140437	Male Penile Urethra and Female Urethra Cancer pT1 TNM Finding v8|Male Penile Urethra and Female Urethra Carcinoma pT1 TNM Finding v8	Urethral cancer with tumor invading subepithelial connective tissue. (from AJCC 8th Ed.)			Finding	
C140443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140443>	C140437	Male Penile Urethra and Female Urethra Cancer pT2 TNM Finding v8|Male Penile Urethra and Female Urethra Carcinoma pT2 TNM Finding v8	Urethral cancer with tumor invading any of the following: corpus spongiosum, periurethral muscle. (from AJCC 8th Ed.)			Finding	
C140444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140444>	C140437	Male Penile Urethra and Female Urethra Cancer pT3 TNM Finding v8|Male Penile Urethra and Female Urethra Carcinoma pT3 TNM Finding v8	Urethral cancer with tumor invading any of the following: corpus cavernosum, anterior vagina. (from AJCC 8th Ed.)			Finding	
C140445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140445>	C140437	Male Penile Urethra and Female Urethra Cancer pT4 TNM Finding v8|Male Penile Urethra and Female Urethra Carcinoma pT4 TNM Finding v8	Urethral cancer with tumor invading other adjacent organs (e.g., invasion of the bladder wall). (from AJCC 8th Ed.)			Finding	
C140446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140446>	C140436	Prostatic Urethra Cancer Pathologic Primary Tumor TNM Finding v8|Prostatic Urethra Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of cancer in the prostatic urethra, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C140447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140447>	C140446	Prostatic Urethra Cancer pTis TNM Finding v8|Prostatic Urethra Carcinoma pTis TNM Finding v8	Urethral cancer with a finding of carcinoma in situ involving the prostatic urethra or periurethral or prostatic ducts without stromal invasion. (from AJCC 8th Ed.)			Finding	
C140448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140448>	C140446	Prostatic Urethra Cancer pT1 TNM Finding v8|Prostatic Urethra Carcinoma pT1 TNM Finding v8	Urethral cancer with tumor invading urethral subepithelial connective tissue immediately underlying the urothelium. (from AJCC 8th Ed.)			Finding	
C140449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140449>	C140446	Prostatic Urethra Cancer pT2 TNM Finding v8|Prostatic Urethra Carcinoma pT2 TNM Finding v8	Urethral cancer with tumor invading the prostatic stroma surrounding ducts either by direct extension from the urothelial surface or by invasion from prostatic ducts. (from AJCC 8th Ed.)			Finding	
C14044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14044>	C13426	PWWP Domain	Around 70 amino acids and weakly conserved, the PWWP Domain is named after a conserved Pro-Trp-Trp-Pro motif often found as multiple copies in proteins that contain chromatin-association domains or in cell growth and differentiation transcription factors, such as WHSC1 (C-terminus) and ASH1/Trithorax Group proteins. Although its function is unknown, the amino acid composition suggests that it may be involved in protein-protein interactions. The domain N-terminal half resembles a barrel-like five-stranded structure; the C-terminal half contains a five-helix bundle. The halves form a module that exhibits positive electrostatic potential. Alone, the domain binds DNA in vitro, probably through its basic surface. (NCI)			Amino Acid Sequence	
C140450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140450>	C140446	Prostatic Urethra Cancer pT3 TNM Finding v8|Prostatic Urethra Carcinoma pT3 TNM Finding v8	Urethral cancer with tumor invading the periprostatic fat. (from AJCC 8th Ed.)			Finding	
C140451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140451>	C140446	Prostatic Urethra Cancer pT4 TNM Finding v8|Prostatic Urethra Carcinoma pT4 TNM Finding v8	Urethral cancer with tumor invading other adjacent organs (e.g., extraprostatic invasion of the bladder wall, rectal wall). (from AJCC 8th Ed.)			Finding	
C140452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140452>	C140433	Urethral Cancer Pathologic Regional Lymph Nodes TNM Finding v8|Urethral Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of urethral cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C140453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140453>	C140452	Urethral Cancer pNX TNM Finding v8|Urethral Carcinoma pNX TNM Finding v8	Urethral cancer in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C140454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140454>	C140452	Urethral Cancer pN0 TNM Finding v8|Urethral Carcinoma pN0 TNM Finding v8	Urethral cancer with no regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C140455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140455>	C140452	Urethral Cancer pN1 TNM Finding v8|Urethral Carcinoma pN1 TNM Finding v8	Urethral cancer with single regional lymph node metastasis in the inguinal region or true pelvis [perivesical, obturator, internal (hypogastric) and external iliac], or presacral lymph node. (from AJCC 8th Ed.)			Finding	
C140456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140456>	C140452	Urethral Cancer pN2 TNM Finding v8|Urethral Carcinoma pN2 TNM Finding v8	Urethral cancer with multiple regional lymph node metastasis in the inguinal region or true pelvis [perivesical, obturator, internal (hypogastric) and external iliac], or presacral lymph node. (from AJCC 8th Ed.)			Finding	
C140457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140457>	C9106	Urethral Cancer by AJCC v8 Stage|Urethral Carcinoma by AJCC v8 Stage	A term that refers to the staging of urethral cancer according to the American Joint Committee on Cancer, 8th edition. This staging system applies to urothelial (transitional cell), squamous, and glandular carcinomas of the urethra and to urothelial (transitional cell) carcinomas of the prostate and prostatic urethra. It does not apply to squamous cell carcinomas of the penile foreskin (are staged according to the classification for penis), primary urothelial carcinomas of the bladder with transmural involvement of the prostate (are staged according to the classification for urinary bladder), prostatic adenocarcinomas (are staged according to the classification for prostate), mucosal melanomas of the urethra (no AJCC staging system), lymphomas (are staged according to the classification for Hodgkin and non-Hodgkin lymphoma), and sarcomas (are staged according to the classification for soft tissue sarcoma of the abdomen and thoracic visceral organs).  (from AJCC 8th Ed.)			Neoplastic Process	
C140458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140458>	C140457	Stage 0a Urethral Cancer AJCC v8|Stage 0a Urethral Cancer|Stage 0a Urethral Carcinoma AJCC v8	Stage 0a includes: Ta, N0, M0. Ta: For male penile urethra and female urethra: Non-invasive papillary carcinoma. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0a Urethral Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140459>	C140457	Stage 0is Urethral Cancer AJCC v8|Stage 0is Urethral Cancer|Stage 0is Urethral Carcinoma AJCC v8	Stage 0is includes: Tis, N0, M0. Tis: For male penile urethra and female urethra: Carcinoma in situ. For prostatic urethra: Carcinoma in situ involving the prostatic urethra or periurethral or prostatic ducts without stromal invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage 0is Urethral Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C14045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14045>	C13432	3q13	A chromosome band present on 3q			Gene or Genome	
C140460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140460>	C140457	Stage I Urethral Cancer AJCC v8|Stage I Urethral Cancer|Stage I Urethral Carcinoma AJCC v8	Stage I includes: T1, N0, M0. T1: For male penile urethra and female urethra: Tumor invades subepithelial connective tissue. For prostatic urethra: Tumor invades urethral subepithelial connective tissue immediately underlying the urothelium. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage I Urethral Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140461>	C140457	Stage II Urethral Cancer AJCC v8|Stage II Urethral Cancer|Stage II Urethral Carcinoma AJCC v8	Stage II includes: T2, N0, M0. T2: For male penile urethra and female urethra: Tumor invades any of the following: corpus spongiosum, periurethral muscle. For prostatic urethra: Tumor invades the prostatic stroma surrounding ducts either by direct extension from the urothelial surface or by invasion from prostatic ducts. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)	Stage II Urethral Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140462>	C140457	Stage III Urethral Cancer AJCC v8|Stage III Urethral Cancer|Stage III Urethral Carcinoma AJCC v8	Stage III includes: (T1, N1, M0); (T2, N1, M0); (T3, N0, M0); (T3, N1, M0). T1: For male penile urethra and female urethra: Tumor invades subepithelial connective tissue. For prostatic urethra: Tumor invades urethral subepithelial connective tissue immediately underlying the urothelium. T2: For male penile urethra and female urethra: Tumor invades any of the following: corpus spongiosum, periurethral muscle. For prostatic urethra: Tumor invades the prostatic stroma surrounding ducts either by direct extension from the urothelial surface or by invasion from prostatic ducts. T3: For male penile urethra and female urethra: Tumor invades any of the following: corpus cavernosum, anterior vagina. For prostatic urethra: Tumor invades the periprostatic fat. N0: No regional lymph node metastasis. N1: Single regional lymph node metastasis in the inguinal region or true pelvis [perivesical, obturator, internal (hypogastric) and external iliac], or presacral lymph node. M0: No distant metastasis. (AJCC 8th ed.)	Stage III Urethral Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140463>	C140457	Stage IV Urethral Cancer AJCC v8|Stage IV Urethral Cancer|Stage IV Urethral Carcinoma AJCC v8	Stage IV includes: (T4, N0, M0); (T4, N1, M0); (Any T, N2, M0); (Any T, Any N, M1). T4: For male penile urethra and female urethra: Tumor invades other adjacent organs (e.g., invasion of the bladder wall). For prostatic urethra: Tumor invades other adjacent organs (e.g., extraprostatic invasion of the bladder wall, rectal wall). N0: No regional lymph node metastasis. N1: Single regional lymph node metastasis in the inguinal region or true pelvis [perivesical, obturator, internal (hypogastric) and external iliac], or presacral lymph node. N2: Multiple regional lymph node metastasis in the inguinal region or true pelvis [perivesical, obturator, internal (hypogastric) and external iliac], or presacral lymph node. M0: No distant metastasis. M1: Distant metastasis. (AJCC 8th ed.)	Stage IV Urethral Cancer AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140464>	C9106	Urethral Cancer by AJCC v7 Stage|Urethral Carcinoma by AJCC v7 Stage	A term that refers to the staging of urethral cancer according to the American Joint Committee on Cancer, 7th edition.			Neoplastic Process	
C140465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140465>	C177692	DLL3 Positive|Delta Like Canonical Notch Ligand 3 Positive|Delta-Like 3 Positive|Delta3 Positive|Drosophila Delta Homolog 3 Positive	An indication that DLL3 expression has been detected in a sample.	DLL3 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C140466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140466>	C124351	Evaluation of Response to Treatment|Evaluating Response to Treatment|Evaluation of Treatment Response	An assessment of the effectiveness of therapeutic intervention.			Activity	
C140467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140467>	C34076	Foramen Ovale of the Skull	An opening in the sphenoid bone at the base of the skull where several nerves, arteries, and veins exit the skull.			Anatomical Structure	
C140468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140468>	C34076	Neck of the Humerus, Surgical	The constriction on the proximal end of the humerus just below the tuberosities of the humerus.			Anatomical Structure	
C140469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140469>	C48233	Ophthalmic Sites Cancer TNM Finding v8	A finding about one or more characteristics of ophthalmic sites cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C14046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14046>	C13432	5p15.1-p14	A chromosome band present on 5p			Gene or Genome	
C140470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140470>	C140469	Eyelid Carcinoma TNM Finding v8	A finding about one or more characteristics of eyelid carcinoma, following the rules of the TNM AJCC v8 classification system. This classification system applies to all primary carcinomas of the eyelid, including basal cell carcinoma (BCC), squamous cell carcinoma (SCC), sebaceous carcinoma, and other rare carcinomas, such as all varieties of sweat gland carcinoma (e.g., eccrine carcinoma). It does not apply to carcinomas of the head and neck with direct extension to eyelid (are staged according to the cutaneous squamous cell carcinomas of the head and neck), Merkel cell carcinomas of the eyelid (are staged according to the classification for Merkel cell carcinomas), and melanomas of the eyelid (are staged according to the classification for melanomas of the skin).  (from AJCC 8th Ed.)			Finding	
C140471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140471>	C140470	Eyelid Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of eyelid carcinoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C140472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140472>	C140471	Eyelid Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of eyelid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C140473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140473>	C140472	Eyelid Carcinoma cM0 TNM Finding v8	Eyelid carcinoma with no evidence of distant metastasis. (from AJCC 8th Ed.)			Finding	
C140474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140474>	C140472	Eyelid Carcinoma cM1 TNM Finding v8	Eyelid carcinoma with distant metastasis. (from AJCC 8th Ed.)			Finding	
C140475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140475>	C140471	Eyelid Carcinoma Clinical Regional Lymph Nodes TNM Finding v8	A clinical finding about one or more characteristics of eyelid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C140476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140476>	C140475	Eyelid Carcinoma cNX TNM Finding v8	Eyelid carcinoma in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C140477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140477>	C140475	Eyelid Carcinoma cN0 TNM Finding v8	Eyelid carcinoma with no evidence of lymph node involvement. (from AJCC 8th Ed.)			Finding	
C140478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140478>	C140475	Eyelid Carcinoma cN1 TNM Finding v8	Eyelid carcinoma with metastasis in a single ipsilateral regional lymph node, measuring 3 cm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C140479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140479>	C140478	Eyelid Carcinoma cN1a TNM Finding v8	Eyelid carcinoma with metastasis in a single ipsilateral regional lymph node, measuring 3 cm or less in greatest dimension based on clinical evaluation or imaging findings. (from AJCC 8th Ed.)			Finding	
C14047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14047>	C13379	Immunoreceptor Tyrosine-Based Motif	Short sequences of amino acids that contain tyrosine and are found in immunoglobulin receptor proteins. Phosphorylation of the tyrosine can influence signal transduction.			Amino Acid Sequence	
C140480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140480>	C140475	Eyelid Carcinoma cN2 TNM Finding v8	Eyelid carcinoma with metastasis in a single ipsilateral regional lymph node, measuring more than 3 cm in greatest dimension, or in bilateral or contralateral lymph nodes. (from AJCC 8th Ed.)			Finding	
C140481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140481>	C140480	Eyelid Carcinoma cN2a TNM Finding v8	Eyelid carcinoma with metastasis in a single ipsilateral regional lymph node, measuring more than 3 cm in greatest dimension, or in bilateral or contralateral lymph nodes documented based on clinical evaluation or imaging findings. (from AJCC 8th Ed.)			Finding	
C140482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140482>	C140470	Eyelid Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of eyelid carcinoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C140483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140483>	C140482	Eyelid Carcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of eyelid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C140484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140484>	C140483	Eyelid Carcinoma pM1 TNM Finding v8	Eyelid carcinoma with distant metastasis. (from AJCC 8th Ed.)			Finding	
C140485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140485>	C140482	Eyelid Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of eyelid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C140486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140486>	C140485	Eyelid Carcinoma pTX TNM Finding v8	Eyelid carcinoma in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C140487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140487>	C140485	Eyelid Carcinoma pT0 TNM Finding v8	Eyelid carcinoma with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C140488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140488>	C140485	Eyelid Carcinoma pTis TNM Finding v8	Eyelid carcinoma with a finding of carcinoma in situ. (from AJCC 8th Ed.)			Finding	
C140489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140489>	C140485	Eyelid Carcinoma pT1 TNM Finding v8	Eyelid carcinoma with tumor measuring 10 mm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C14048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14048>	C14047	ITAM|ARAM|Ag Recognition Activation Motif|Antigen Recognition Activation Motif|Immunoreceptor Tyr-Based Activation Motif|Immunoreceptor Tyrosine-Based Activation Motif|TAM|Tyrosine-Based Activation Motif	ITAM (Immunoreceptor Tyrosine-based Activation Motif) or ARAM (Ag Recognition Activation Motif) (Y-X-X-L-(X)6-8-Y-X-X-L), a protein domain involved in STP, binds to SH2 domain, e.g. in CD247/x chain, FceRI g chain, or DAP12. Phosphorylated immunoreceptor signaling motifs (ITAMs) exhibit unique abilities to bind and activate Lyn and Syk tyrosine kinases. Motif may be dually phosphorylated on tyrosine that links antigen receptors to downstream signaling machinery.	ITAM		Amino Acid Sequence	CTRP Biomarker Terminology|CTRP Terminology
C140490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140490>	C140489	Eyelid Carcinoma pT1a TNM Finding v8	Eyelid carcinoma with tumor measuring 10 mm or less in greatest dimension without invasion of the tarsal plate or eyelid margin. (from AJCC 8th Ed.)			Finding	
C140491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140491>	C140489	Eyelid Carcinoma pT1b TNM Finding v8	Eyelid carcinoma with tumor measuring 10 mm or less in greatest dimension with invasion of the tarsal plate or eyelid margin. (from AJCC 8th Ed.)			Finding	
C140492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140492>	C140489	Eyelid Carcinoma pT1c TNM Finding v8	Eyelid carcinoma with tumor measuring 10 mm or less in greatest dimension involving the full thickness of the eyelid. (from AJCC 8th Ed.)			Finding	
C140493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140493>	C140485	Eyelid Carcinoma pT2 TNM Finding v8	Eyelid carcinoma with tumor measuring more than 10 mm but 20 mm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C140494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140494>	C140493	Eyelid Carcinoma pT2a TNM Finding v8	Eyelid carcinoma with tumor measuring more than 10 mm but 20 mm or less in greatest dimension without invasion of the tarsal plate or eyelid margin. (from AJCC 8th Ed.)			Finding	
C140495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140495>	C140493	Eyelid Carcinoma pT2b TNM Finding v8	Eyelid carcinoma with tumor measuring more than 10 mm but 20 mm or less in greatest dimension with invasion of the tarsal plate or eyelid margin. (from AJCC 8th Ed.)			Finding	
C140496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140496>	C140493	Eyelid Carcinoma pT2c TNM Finding v8	Eyelid carcinoma with tumor measuring more than 10 mm but 20 mm or less in greatest dimension involving the full thickness of the eyelid. (from AJCC 8th Ed.)			Finding	
C140497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140497>	C140485	Eyelid Carcinoma pT3 TNM Finding v8	Eyelid carcinoma with tumor measuring more than 20 mm but 30 mm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C140498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140498>	C140497	Eyelid Carcinoma pT3a TNM Finding v8	Eyelid carcinoma with tumor measuring more than 20 mm but 30 mm or less in greatest dimension without invasion of the tarsal plate or eyelid margin. (from AJCC 8th Ed.)			Finding	
C140499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140499>	C140497	Eyelid Carcinoma pT3b TNM Finding v8	Eyelid carcinoma with tumor measuring more than 20 mm but 30 mm or less in greatest dimension with invasion of the tarsal plate or eyelid margin. (from AJCC 8th Ed.)			Finding	
C14049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14049>	C14047	ITIM|Immunoreceptor Tyrosine-Based Inhibitor Motif|Immunoreceptor Tyrosine-Based Inhibitory Motif	ITIM (immunoreceptor Tyr-based inhibition motif) (I/V-X-Y-X-X-L), a protein domain involved in STP, binds to SH2 domain in SHP1 and SHP2, e.g., in KIR family.			Amino Acid Sequence	
C1404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1404>	C471	Protein Kinase Inhibitor	Any substance that inhibits protein kinase, an enzyme that catalyzes the addition of a phosphate group to a protein and is active in many diverse signaling pathways.	Protein Kinase Inhibitor		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C140500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140500>	C140497	Eyelid Carcinoma pT3c TNM Finding v8	Eyelid carcinoma with tumor measuring more than 20 mm but 30 mm or less in greatest dimension involving the full thickness of the eyelid. (from AJCC 8th Ed.)			Finding	
C140501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140501>	C140485	Eyelid Carcinoma pT4 TNM Finding v8	Any eyelid carcinoma invading adjacent ocular, orbital, or facial structures. (from AJCC 8th Ed.)			Finding	
C140502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140502>	C140501	Eyelid Carcinoma pT4a TNM Finding v8	Eyelid carcinoma with tumor invading ocular or intraorbital structures. (from AJCC 8th Ed.)			Finding	
C140503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140503>	C140501	Eyelid Carcinoma pT4b TNM Finding v8	Eyelid carcinoma with tumor invading (or eroding through) the bony walls of the orbit or extending to the paranasal sinuses or invading the lacrimal sac/nasolacrimal duct or brain. (from AJCC 8th Ed.)			Finding	
C140504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140504>	C140482	Eyelid Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of eyelid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C140505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140505>	C140504	Eyelid Carcinoma pNX TNM Finding v8	Eyelid carcinoma in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C140506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140506>	C140504	Eyelid Carcinoma pN0 TNM Finding v8	Eyelid carcinoma with no evidence of lymph node involvement. (from AJCC 8th Ed.)			Finding	
C140507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140507>	C140504	Eyelid Carcinoma pN1 TNM Finding v8	Eyelid carcinoma with metastasis in a single ipsilateral regional lymph node, measuring 3 cm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C140508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140508>	C140507	Eyelid Carcinoma pN1b TNM Finding v8	Eyelid carcinoma with metastasis in a single ipsilateral regional lymph node, measuring 3 cm or less in greatest dimension based on lymph node biopsy. (from AJCC 8th Ed.)			Finding	
C140509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140509>	C140504	Eyelid Carcinoma pN2 TNM Finding v8	Eyelid carcinoma with metastasis in a single ipsilateral regional lymph node, measuring more than 3 cm in greatest dimension, or in bilateral or contralateral lymph nodes. (from AJCC 8th Ed.)			Finding	
C14050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14050>	C13303	Post-Translational Modification Site|Post-Translational Protein Modification Site|Posttranslational Modification Site|Posttranslational Protein Modification Site|STRUCTURAL ATTACHMENT POINT	A post-translational modification site refers to amino acid residues within a peptide that act as acceptors for any modifications that do not happen concurrent with translation.			Amino Acid Sequence	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C140510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140510>	C140509	Eyelid Carcinoma pN2b TNM Finding v8	Eyelid carcinoma with metastasis in a single ipsilateral regional lymph node, measuring more than 3 cm in greatest dimension, or in bilateral or contralateral lymph nodes documented based on microscopic findings on lymph node biopsy. (from AJCC 8th Ed.)			Finding	
C140511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140511>	C6078	Eyelid Carcinoma by AJCC v7 Stage	A term that refers to the staging of eyelid carcinoma according to the American Joint Committee on Cancer, 7th edition.			Neoplastic Process	
C140512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140512>	C49237	Bromide Measurement	A quantitative measurement for assessing the amount of bromide present in a sample.			Laboratory Procedure	
C140513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140513>	C6078	Eyelid Carcinoma by AJCC v8 Stage	A term that refers to the staging of eyelid carcinoma according to the American Joint Committee on Cancer, 8th edition. This staging system applies to all primary carcinomas of the eyelid, including basal cell carcinoma (BCC), squamous cell carcinoma (SCC), sebaceous carcinoma, and other rare carcinomas, such as all varieties of sweat gland carcinoma (e.g., eccrine carcinoma). It does not apply to carcinomas of the head and neck with direct extension to eyelid (are staged according to the cutaneous squamous cell carcinomas of the head and neck), Merkel cell carcinomas of the eyelid (are staged according to the classification for Merkel cell carcinomas), and melanomas of the eyelid (are staged according to the classification for melanomas of the skin).  (from AJCC 8th Ed.)			Neoplastic Process	
C140515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140515>	C140513	Stage 0 Eyelid Carcinoma AJCC v8	Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No evidence of lymph node involvement. M0: No distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C140516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140516>	C140513	Stage I Eyelid Carcinoma AJCC v8	Stage I includes: IA: T1, N0, M0; IB: T2a, N0, M0. T1: Tumor measuring 10 mm or less in greatest dimension. T2a: Tumor measuring more than 10 mm but 20 mm or less in greatest dimension without invasion of the tarsal plate or eyelid margin. N0: No evidence of lymph node involvement. M0: No distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C140517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140517>	C140516	Stage IA Eyelid Carcinoma AJCC v8	Stage IA includes: T1, N0, M0. T1: Tumor measuring 10 mm or less in greatest dimension. N0: No evidence of lymph node involvement. M0: No distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C140518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140518>	C140516	Stage IB Eyelid Carcinoma AJCC v8	Stage IB includes: T2a, N0, M0. T2a: Tumor measuring more than 10 mm but 20 mm or less in greatest dimension without invasion of the tarsal plate or eyelid margin. N0: No evidence of lymph node involvement. M0: No distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C140519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140519>	C140513	Stage II Eyelid Carcinoma AJCC v8	Stage II includes: IIA: T2b-c, T3, N0, M0; IIB: T4, N0, M0. T2b: Tumor measuring more than 10 mm but 20 mm or less in greatest dimension with invasion of the tarsal plate or eyelid margin. T2c: Tumor measuring more than 10 mm but 20 mm or less in greatest dimension involving the full thickness of the eyelid. T3: Tumor measuring more than 20 mm but 30 mm or less in greatest dimension. T4: Any eyelid carcinoma invading adjacent ocular, orbital, or facial structures. N0: No evidence of lymph node involvement. M0: No distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C14051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14051>	C14050	N-Glycosylation Site	A glycosylation site is an amino acid residue within a peptide that accepts oligosaccharide via amide linkage, specifically through amide nitrogen of asparagine via N-acetylglucosamine, as one of the post-translational modifications.			Amino Acid Sequence	
C140520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140520>	C140519	Stage IIA Eyelid Carcinoma AJCC v8	Stage IIA includes: T2b-c, T3, N0, M0: T2b: Tumor measuring more than 10 mm but 20 mm or less in greatest dimension with invasion of the tarsal plate or eyelid margin. T2c: Tumor measuring more than 10 mm but 20 mm or less in greatest dimension involving the full thickness of the eyelid. T3: Tumor measuring more than 20 mm but 30 mm or less in greatest dimension. N0: No evidence of lymph node involvement. M0: No distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C140521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140521>	C140519	Stage IIB Eyelid Carcinoma AJCC v8	Stage IIB includes: T4, N0, M0. T4: Any eyelid carcinoma invading adjacent ocular, orbital, or facial structures. N0: No evidence of lymph node involvement. M0: No distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C140522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140522>	C140513	Stage III Eyelid Carcinoma AJCC v8	Stage III includes: IIIA: Any T, N1, M0; IIIB: Any T, N2, M0. N1: Metastasis in a single ipsilateral regional lymph node, measuring 3 cm or less in greatest dimension. N2: Metastasis in a single ipsilateral regional lymph node, measuring more than 3 cm in greatest dimension, or in bilateral or contralateral lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C140523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140523>	C140522	Stage IIIA Eyelid Carcinoma AJCC v8	Stage IIIA includes: Any T, N1, M0. N1: Metastasis in a single ipsilateral regional lymph node, measuring 3 cm or less in greatest dimension. M0: No distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C140524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140524>	C140522	Stage IIIB Eyelid Carcinoma AJCC v8	Stage IIIB includes: Any T, N2, M0. N2: Metastasis in a single ipsilateral regional lymph node, measuring more than 3 cm in greatest dimension, or in bilateral or contralateral lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C140525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140525>	C140513	Stage IV Eyelid Carcinoma AJCC v8	Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)			Neoplastic Process	
C140526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140526>	C53076	Posterior Tibialis Muscle|TIBIALIS POSTERIOR MUSCLE	A muscle of the lower leg that is located in the deep posterior compartment, originating on the inner posterior borders of the tibia and fibula, with further attachments to the interosseous membrane; the tendon of the posterior tibialis muscle, the posterior tibial tendon, terminates by dividing into plantar, main and recurring components, all of which have terminal insertions: plantar portion inserts into the bases of the second, third and fourth metatarsals; the intermediate and lateral cuneiforms, and the cuboid; the main portion inserts into the tuberosity of the navicular and the plantar surface of the medial cuneiform; the recurrent portion inserts into the sustentaculum tali of he calcaneus. The muscle functions to stabilize the ankle, as well as invert and plantar flex the foot at the ankle.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C140527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140527>	C140469	Conjunctival Carcinoma TNM Finding v8	A finding about one or more characteristics of conjunctival carcinoma, following the rules of the TNM AJCC v8 classification system. This classification system applies only to carcinoma of the conjunctiva. Other tumors of the conjunctiva, including secondary conjunctival tumors (e.g., intraocular tumors extending through the conjunctiva, such as uveal melanoma or uveal non-Hodgkin lymphoma, and orbital tumors extending into the conjunctiva, such as rhabdomyosarcoma), are not classified using this schema. Conjunctival lymphomas are staged according to the classification for ocular adnexal lymphoma and conjunctival melanomas are staged according to the classification for conjunctival melanoma. There is no proposal for anatomic stage and prognostic groups for conjunctival carcinoma. (from AJCC 8th Ed.)			Finding	
C140528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140528>	C140527	Conjunctival Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of conjunctival carcinoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C140529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140529>	C140528	Conjunctival Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of conjunctival carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C14052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14052>	C14050	Myristic Acylation Site|Myristoylation Site	It refers to amino acid residue within a peptide that accepts covalent linkage of fatty acid, myristoyl group (C13H27-) as one of the co-translational modifications. N-myristoylation, catalyzed by N-myristoyltransferase, is the amide modification of proteins by the addition of a myristoyl group to an N-terminal glycine residue. (NCI)			Amino Acid Sequence	
C140530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140530>	C140529	Conjunctival Carcinoma cM0 TNM Finding v8	Conjunctival carcinoma with no distant metastasis. (from AJCC 8th Ed.)			Finding	
C140531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140531>	C140529	Conjunctival Carcinoma cM1 TNM Finding v8	Conjunctival carcinoma with distant metastasis. (from AJCC 8th Ed.)			Finding	
C140532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140532>	C140527	Conjunctival Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of conjunctival carcinoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C140533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140533>	C140532	Conjunctival Carcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of conjunctival carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C140534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140534>	C140533	Conjunctival Carcinoma pM1 TNM Finding v8	Conjunctival carcinoma with distant metastasis. (from AJCC 8th Ed.)			Finding	
C140535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140535>	C140532	Conjunctival Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of conjunctival carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C140536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140536>	C140535	Conjunctival Carcinoma pTX TNM Finding v8	Conjunctival carcinoma in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C140537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140537>	C140535	Conjunctival Carcinoma pT0 TNM Finding v8	Conjunctival carcinoma with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C140538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140538>	C140535	Conjunctival Carcinoma pTis TNM Finding v8	Conjunctival carcinoma with a finding of carcinoma in situ. (from AJCC 8th Ed.)			Finding	
C140539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140539>	C140535	Conjunctival Carcinoma pT1 TNM Finding v8	Conjunctival carcinoma with tumor measuring 5 mm or less in greatest dimension and invading through the conjunctival basement membrane without invasion of adjacent structures. (from AJCC 8th Ed.)			Finding	
C14053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14053>	C14050	Palmitic Acylation Site|Palmitoylation Site	It refers to amino acid residue within a peptide that accepts fatty acid, palmitoyl group (C15H31-)as one of the reversible post-translational modifications. Protein palmitoylation is a thioester bond between palmitoyl-CoA and cysteine thiol. (NCI)			Amino Acid Sequence	
C140540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140540>	C140535	Conjunctival Carcinoma pT2 TNM Finding v8	Conjunctival carcinoma with tumor measuring more than 5 mm in greatest dimension and invading through the conjunctival basement membrane without invasion of adjacent structures. (from AJCC 8th Ed.)			Finding	
C140541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140541>	C140535	Conjunctival Carcinoma pT3 TNM Finding v8	Conjunctival carcinoma with tumor invading adjacent structures (excluding the orbit). (from AJCC 8th Ed.)			Finding	
C140542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140542>	C140535	Conjunctival Carcinoma pT4 TNM Finding v8	Conjunctival carcinoma with tumor invading the orbit with or without further extension. (from AJCC 8th Ed.)			Finding	
C140543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140543>	C140542	Conjunctival Carcinoma pT4a TNM Finding v8	Conjunctival carcinoma with tumor invading orbital soft tissues without bone invasion. (from AJCC 8th Ed.)			Finding	
C140544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140544>	C140542	Conjunctival Carcinoma pT4b TNM Finding v8	Conjunctival carcinoma with tumor invading bone. (from AJCC 8th Ed.)			Finding	
C140545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140545>	C140542	Conjunctival Carcinoma pT4c TNM Finding v8	Conjunctival carcinoma with tumor invading adjacent paranasal sinuses. (from AJCC 8th Ed.)			Finding	
C140546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140546>	C140542	Conjunctival Carcinoma pT4d TNM Finding v8	Conjunctival carcinoma with tumor invading brain. (from AJCC 8th Ed.)			Finding	
C140547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140547>	C140532	Conjunctival Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of conjunctival carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C140548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140548>	C140547	Conjunctival Carcinoma pNX TNM Finding v8	Conjunctival carcinoma in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C140549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140549>	C140547	Conjunctival Carcinoma pN0 TNM Finding v8	Conjunctival carcinoma with no regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C14054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14054>	C14050	Phosphorylation Site	Generally refers to amino acids residues that were covalently modified by phosphate group (PO4-). (NCI)			Amino Acid Sequence	
C140550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140550>	C140547	Conjunctival Carcinoma pN1 TNM Finding v8	Conjunctival carcinoma with regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C140552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140552>	C201544	Anti-PSMA/PBD ADC MEDI3726|ADC MEDI3726|ADCT 401|ADCT-401|ADCT401|MEDI 3726|MEDI-3726|MEDI-3726|MEDI3726	An antibody-drug conjugate (ADC) consisting of an engineered version of anti-human prostate-specific membrane antigen (PSMA) monoclonal antibody J591 conjugated, via a valine-alanine dipeptide linker, to tesirine, a cytotoxic, DNA minor groove crosslinking agent and pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of anti-PSMA/PBD ADC MEDI3726, the antibody moiety targets the cell surface antigen PSMA, which is found on prostate cancer cells. Upon antibody/antigen binding, internalization and lysosome-mediated cleavage of the dipeptide linker, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of PSMA-overexpressing tumor cells. PSMA is overexpressed by prostate cancers; its expression is associated with poor prognosis and metastasis.	Anti-PSMA/PBD ADC MEDI3726		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C140553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140553>	C62554	Simmiparib|SMOCL-9112	An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) 1 (PARP1) and 2 (PARP2), with potential antineoplastic activity. Upon oral administration, simmiparib selectively binds to PARP and prevents PARP-mediated DNA repair of breaks in single-stranded DNA via the base excision repair pathway. This induces the accumulation of DNA strand breaks, promotes genomic instability, induces G2/M arrest and leads to apoptosis. PARP is activated by single-strand DNA breaks and catalyzes post-translational ADP-ribosylation of nuclear proteins, which signal and recruit other proteins to repair damaged DNA.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C140554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140554>	C1907	Botanical Extract DCB-BO1301|DCB BO 1301|DCB BO1301|DCB-BO1301|Zhaohe Cao-based Botanical Drug DCB-BO1301	A proprietary botanical, galactolipid-enriched extract derived from the edible plant Crassocephalum crepidioides (Zhaohe Cao), with potential anti-inflammatory and antineoplastic activities. Upon oral administration, DCB-BO1301 may inhibit the growth of certain types of tumor cells, although the exact mechanism of action has yet to be fully elucidated.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C140555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140555>	C2124	Carbon C 14-AC0010|14C-AC0010|14C-labeled AC0010|[14C] AC0010	A radioconjugate composed of AC0010, an orally available, third generation, selective inhibitor of mutant forms of the epidermal growth factor receptor (EGFR), including the second-site resistance mutation T790M, that is labeled with the radioisotope carbon C 14, with potential use in evaluating the pharmacokinetic profile of AC0010. Upon administration, the AC0010 moiety specifically and irreversibly binds to and inhibits the activity of mutant forms of EGFR. Labeling of AC0010 with the radioactive tracer carbon C 14 allows for the evaluation of AC0010's pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME).			Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	NCI Drug Dictionary Terminology
C140556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140556>	C140469	Conjunctival Melanoma TNM Finding v8	A finding about one or more characteristics of conjunctival melanoma, following the rules of the TNM AJCC v8 classification system. This classification system applies to melanomas arising from the bulbar and palpebral conjunctiva and from the caruncle. Primary eyelid melanomas are staged according to the classification for melanoma of the skin and secondary involvement of the conjunctiva by extraocular uveal melanoma is staged according to the classification for uveal melanoma. There is no proposal for anatomic stage and prognostic groups for conjunctival melanoma. (from AJCC 8th Ed.)			Finding	
C140557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140557>	C140556	Conjunctival Melanoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of conjunctival melanoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C140558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140558>	C140557	Conjunctival Melanoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of conjunctival melanoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C140559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140559>	C140558	Conjunctival Melanoma cM0 TNM Finding v8	Conjunctival melanoma with no distant metastasis. (from AJCC 8th Ed.)			Finding	
C14055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14055>	C14108|C14056	YDYVHL Motif|YDYVHL Domain	YDYVHL (tyrosine-aspartic acid-tyrosine-valine-histidine-leucine) is a preferred substrate sequence by focal adhesion kinase.  The phosphorylated YDYVHL containing protein recruits src family kinases, which can then phosphorylate other tyrosine residues within the peptide. (NCI)			Amino Acid Sequence	
C140560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140560>	C140558	Conjunctival Melanoma cM1 TNM Finding v8	Conjunctival melanoma with distant metastasis. (from AJCC 8th Ed.)			Finding	
C140561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140561>	C140557	Conjunctival Melanoma Clinical Primary Tumor TNM Finding v8	A clinical finding about one or more characteristics of conjunctival melanoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C140562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140562>	C140561	Conjunctival Melanoma cTX TNM Finding v8	Conjunctival melanoma in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C140563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140563>	C140561	Conjunctival Melanoma cT0 TNM Finding v8	Conjunctival melanoma with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C140564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140564>	C140561	Conjunctival Melanoma cT1 TNM Finding v8	Conjunctival melanoma with tumor of the bulbar conjunctiva. (from AJCC 8th Ed.)			Finding	
C140565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140565>	C140564	Conjunctival Melanoma cT1a TNM Finding v8	Conjunctival melanoma with tumor of the bulbar conjunctiva, involving less than 1 quadrant. (from AJCC 8th Ed.)			Finding	
C140566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140566>	C140564	Conjunctival Melanoma cT1b TNM Finding v8	Conjunctival melanoma with tumor of the bulbar conjunctiva, involving 1 or more to less than 2 quadrants. (from AJCC 8th Ed.)			Finding	
C140567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140567>	C140564	Conjunctival Melanoma cT1c TNM Finding v8	Conjunctival melanoma with tumor of the bulbar conjunctiva, involving 2 or more to less than 3 quadrants. (from AJCC 8th Ed.)			Finding	
C140568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140568>	C140564	Conjunctival Melanoma cT1d TNM Finding v8	Conjunctival melanoma with tumor of the bulbar conjunctiva, involving 3 or more quadrants. (from AJCC 8th Ed.)			Finding	
C140569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140569>	C140561	Conjunctival Melanoma cT2 TNM Finding v8	Conjunctival melanoma with tumor of the nonbulbar (forniceal, palpebral, tarsal) conjunctiva, and tumor involving the caruncle. (from AJCC 8th Ed.)			Finding	
C14056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14056>	C14054	Tyrosine Phosphorylation Site	It refers to amino acid tyrosine residue that was covalently modified by phosphate group (PO4-). (NCI)			Amino Acid Sequence	
C140570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140570>	C140569	Conjunctival Melanoma cT2a TNM Finding v8	Conjunctival melanoma with noncaruncular tumor, and 1 or less quadrant of the nonbulbar conjunctiva involved. (from AJCC 8th Ed.)			Finding	
C140571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140571>	C140569	Conjunctival Melanoma cT2b TNM Finding v8	Conjunctival melanoma with noncaruncular tumor, and more than 1 quadrant of the nonbulbar conjunctiva involved. (from AJCC 8th Ed.)			Finding	
C140572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140572>	C140569	Conjunctival Melanoma cT2c TNM Finding v8	Conjunctival melanoma with caruncular tumor, and 1 or less quadrant of the nonbulbar conjunctiva involved. (from AJCC 8th Ed.)			Finding	
C140573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140573>	C140569	Conjunctival Melanoma cT2d TNM Finding v8	Conjunctival melanoma with caruncular tumor, and more than 1 quadrant of the nonbulbar conjunctiva involved. (from AJCC 8th Ed.)			Finding	
C140574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140574>	C140561	Conjunctival Melanoma cT3 TNM Finding v8	Conjunctival melanoma with tumor of any size with local invasion. (from AJCC 8th Ed.)			Finding	
C140575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140575>	C140574	Conjunctival Melanoma cT3a TNM Finding v8	Conjunctival melanoma with tumor of any size invading the globe. (from AJCC 8th Ed.)			Finding	
C140576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140576>	C140574	Conjunctival Melanoma cT3b TNM Finding v8	Conjunctival melanoma with tumor of any size invading the eyelid. (from AJCC 8th Ed.)			Finding	
C140577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140577>	C140574	Conjunctival Melanoma cT3c TNM Finding v8	Conjunctival melanoma with tumor of any size invading the orbit. (from AJCC 8th Ed.)			Finding	
C140578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140578>	C140574	Conjunctival Melanoma cT3d TNM Finding v8	Conjunctival melanoma with tumor of any size invading the nasolacrimal duct and/or lacrimal sac and/or paranasal sinuses. (from AJCC 8th Ed.)			Finding	
C140579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140579>	C140561	Conjunctival Melanoma cT4 TNM Finding v8	Conjunctival melanoma with tumor of any size invading the central nervous system. (from AJCC 8th Ed.)			Finding	
C14057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14057>	C14054	Serine Phosphorylation Site	It refers to amino acid serine residue that was covalently modified by phosphate group (PO4-). (NCI)			Amino Acid Sequence	
C140580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140580>	C140556	Conjunctival Melanoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of conjunctival melanoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C140581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140581>	C140580	Conjunctival Melanoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of conjunctival melanoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C140582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140582>	C140581	Conjunctival Melanoma pM1 TNM Finding v8	Conjunctival melanoma with distant metastasis. (from AJCC 8th Ed.)			Finding	
C140583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140583>	C140580	Conjunctival Melanoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of conjunctival melanoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C140584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140584>	C140583	Conjunctival Melanoma pTX TNM Finding v8	Conjunctival melanoma in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C140585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140585>	C140583	Conjunctival Melanoma pT0 TNM Finding v8	Conjunctival melanoma with no evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C140586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140586>	C140583	Conjunctival Melanoma pTis TNM Finding v8	Conjunctival melanoma confined to the conjunctival epithelium. (from AJCC 8th Ed.)			Finding	
C140587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140587>	C140583	Conjunctival Melanoma pT1 TNM Finding v8	Conjunctival melanoma with tumor of the bulbar conjunctiva. (from AJCC 8th Ed.)			Finding	
C140588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140588>	C140587	Conjunctival Melanoma pT1a TNM Finding v8	Conjunctival melanoma with tumor of the bulbar conjunctiva invading the substantia propria, not more than 2.0 mm in thickness. (from AJCC 8th Ed.)			Finding	
C140589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140589>	C140587	Conjunctival Melanoma pT1b TNM Finding v8	Conjunctival melanoma with tumor of the bulbar conjunctiva invading the substantia propria, more than 2.0 mm in thickness. (from AJCC 8th Ed.)			Finding	
C14058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14058>	C14054	Threonine Phosphorylation Site	It refers to amino acid threonine residue that was covalently modified by phosphate group (PO4-). (NCI)			Amino Acid Sequence	
C140590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140590>	C140583	Conjunctival Melanoma pT2 TNM Finding v8	Conjunctival melanoma with tumor of the nonbulbar (forniceal, palpebral, tarsal) conjunctiva, and tumor involving the caruncle. (from AJCC 8th Ed.)			Finding	
C140591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140591>	C140590	Conjunctival Melanoma pT2a TNM Finding v8	Conjunctival melanoma with tumor of the nonbulbar conjunctiva with invasion of the substantia propria, not more than 2.0 mm in thickness. (from AJCC 8th Ed.)			Finding	
C140592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140592>	C140590	Conjunctival Melanoma pT2b TNM Finding v8	Conjunctival melanoma with tumor of the nonbulbar conjunctiva with invasion of the substantia propria, more than 2.0 mm in thickness. (from AJCC 8th Ed.)			Finding	
C140593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140593>	C140583	Conjunctival Melanoma pT3 TNM Finding v8	Conjunctival melanoma with tumor of any size with local invasion. (from AJCC 8th Ed.)			Finding	
C140594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140594>	C140593	Conjunctival Melanoma pT3a TNM Finding v8	Conjunctival melanoma with tumor of any size invading the globe. (from AJCC 8th Ed.)			Finding	
C140595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140595>	C140593	Conjunctival Melanoma pT3b TNM Finding v8	Conjunctival melanoma with tumor of any size invading the eyelid. (from AJCC 8th Ed.)			Finding	
C140596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140596>	C140593	Conjunctival Melanoma pT3c TNM Finding v8	Conjunctival melanoma with tumor of any size invading the orbit. (from AJCC 8th Ed.)			Finding	
C140597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140597>	C140593	Conjunctival Melanoma pT3d TNM Finding v8	Conjunctival melanoma with tumor of any size invading the nasolacrimal duct and/or lacrimal sac and/or paranasal sinuses. (from AJCC 8th Ed.)			Finding	
C140598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140598>	C140583	Conjunctival Melanoma pT4 TNM Finding v8	Conjunctival melanoma with tumor of any size invading the central nervous system. (from AJCC 8th Ed.)			Finding	
C140599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140599>	C140580	Conjunctival Melanoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of conjunctival melanoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C14059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14059>	C14108|C14056	YXXP Motif|YXXP Domain	YXXP (tyrosine-X-X-Proline), a substrate sequence preferred by Abl tyrosine kinases, is part of the SH2 domain that mediates certain interactions of SH2 containing proteins.  Although both phosphorylated- and unphosphorylated-YXXP can interacts with SH2 containing proteins, the SH2 domain obtain sufficient binding specificity from the recognition of adjacent residues to allow discrimination between different phosphorylated sites. (NCI)			Amino Acid Sequence	
C1405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1405>	C1744	Valspodar|6-[(2S,4R,6E)-4-Methyl-2-(methylamino)-3-oxo-6-octenoic Acid]cyclosporin D|6-[(2S,4R,6E)-4-Methyl-2-(methylamino)-3-oxo-6-octenoic Acid]cyclosporin D|Amdray|Cyclo((2S,4R,6E)-4-methyl-2-(methylamino)-3-oxo-6-octenoyl)-L-valyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-me|PSC 833|PSC-833|PSC833|SZD PSC 833|VALSPODAR|VP16	An analogue of cyclosporin-A. Valspodar inhibits p-glycoprotein, the multidrug resistance efflux pump, thereby restoring the retention and activity of some drugs in some drug-resistant tumor cells. This agent also induces caspase-mediated apoptosis. (NCI04)	Valspodar		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C140600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140600>	C140599	Conjunctival Melanoma pNX TNM Finding v8	Conjunctival melanoma in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C140601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140601>	C140599	Conjunctival Melanoma pN0 TNM Finding v8	Conjunctival melanoma with no regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C140602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140602>	C140599	Conjunctival Melanoma pN1 TNM Finding v8	Conjunctival melanoma with regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C140603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140603>	C140469	Uveal Melanoma TNM Finding v8	A finding about one or more characteristics of uveal melanoma, following the rules of the TNM AJCC v8 classification system. This classification system applies to malignant melanoma of the iris, ciliary body, and choroid. Cutaneous melanoma metastatic to the iris, ciliary body, and choroid is staged according to the classification for melanoma of the skin and secondary intraocular extension of conjunctival melanoma is staged according to the classification for conjunctival melanoma. (from AJCC 8th Ed.)			Finding	
C140604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140604>	C140603	Uveal Melanoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of uveal melanoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C140605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140605>	C140604	Uveal Melanoma Clinical Distant Metastasis TNM Finding v8|Clinical Distant Metastasis Status (cM)	A clinical finding about one or more characteristics of uveal melanoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.	Uveal Melanoma Clinical Distant Metastasis TNM Finding v8		Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form|CTRP Disease Terminology|CTRP Terminology
C140606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140606>	C140605	Uveal Melanoma cM0 TNM Finding v8	Uveal melanoma with no distant metastasis by clinical classification. (from AJCC 8th Ed.)			Finding	
C140607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140607>	C140605	Uveal Melanoma cM1 TNM Finding v8|cM1	Uveal melanoma with distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C140608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140608>	C140607	Uveal Melanoma cM1a TNM Finding v8	Uveal melanoma with largest diameter of the largest metastasis 3.0 cm or less. (from AJCC 8th Ed.)			Finding	
C140609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140609>	C140607	Uveal Melanoma cM1b TNM Finding v8	Uveal melanoma with largest diameter of the largest metastasis 3.1-8.0 cm. (from AJCC 8th Ed.)			Finding	
C14060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14060>	C14054	PKC Phosphorylation Site	It refers to amino acid residues that can be the target for protein kinase C phosphorylation. (NCI)			Amino Acid Sequence	
C140610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140610>	C140607	Uveal Melanoma cM1c TNM Finding v8	Uveal melanoma with largest diameter of the largest metastasis 8.1 cm or more. (from AJCC 8th Ed.)			Finding	
C140611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140611>	C140603	Uveal Melanoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of uveal melanoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C140612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140612>	C140611	Uveal Melanoma Pathologic Distant Metastasis TNM Finding v8|Pathologic Distant Metastasis Status (pM)	A pathologic finding about one or more characteristics of uveal melanoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.	Uveal Melanoma Pathologic Distant Metastasis TNM Finding v8		Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form|CTRP Disease Terminology|CTRP Terminology
C140613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140613>	C140612	Uveal Melanoma pM1 TNM Finding v8	Uveal melanoma with distant metastasis. (from AJCC 8th Ed.)			Finding	
C140614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140614>	C140613	Uveal Melanoma pM1a TNM Finding v8|pTM1a	Uveal melanoma with largest diameter of the largest metastasis 3.0 cm or less. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C140615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140615>	C140613	Uveal Melanoma pM1b TNM Finding v8|pTM1b	Uveal melanoma with largest diameter of the largest metastasis 3.1-8.0 cm. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C140616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140616>	C140613	Uveal Melanoma pM1c TNM Finding v8|pTM1c	Uveal melanoma with largest diameter of the largest metastasis 8.1 cm or more. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C140617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140617>	C140611	Iris Melanoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of iris melanoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C140618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140618>	C140617	Iris Melanoma pT1 TNM Finding v8	Iris melanoma with tumor limited to the iris. (from AJCC 8th Ed.)			Finding	
C140619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140619>	C140618	Iris Melanoma pT1a TNM Finding v8	Iris melanoma with tumor limited to the iris, not more than 3 clock hours in size. (from AJCC 8th Ed.)			Finding	
C14061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14061>	C13369	Amphipathic Alpha Helix	The amphipathic helix motif is characterized by a repeating pattern of polar (P) and non-polar (N) side-chains that can be summarized as PxNPPNx. These clusters varied in length from 6 to 15 residues. The conserved non-polar positions are marked by a distinct absence of Asp, Asn and Ser, while other polar side chains are sometimes allowed.			Spatial Concept	
C140620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140620>	C140618	Iris Melanoma pT1b TNM Finding v8	Iris melanoma with tumor limited to the iris, more than 3 clock hours in size. (from AJCC 8th Ed.)			Finding	
C140621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140621>	C140618	Iris Melanoma pT1c TNM Finding v8	Iris melanoma with tumor limited to the iris with secondary glaucoma. (from AJCC 8th Ed.)			Finding	
C140622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140622>	C140617	Iris Melanoma pT2 TNM Finding v8	Iris melanoma with tumor confluent with or extending into the ciliary body, choroid, or both. (from AJCC 8th Ed.)			Finding	
C140623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140623>	C140622	Iris Melanoma pT2a TNM Finding v8	Iris melanoma with tumor confluent with or extending into the ciliary body, without secondary glaucoma. (from AJCC 8th Ed.)			Finding	
C140624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140624>	C140622	Iris Melanoma pT2b TNM Finding v8	Iris melanoma with tumor confluent with or extending into the ciliary body and choroid, without secondary glaucoma. (from AJCC 8th Ed.)			Finding	
C140625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140625>	C140622	Iris Melanoma pT2c TNM Finding v8	Iris melanoma with tumor confluent with or extending into the ciliary body, choroid, or both, with secondary glaucoma. (from AJCC 8th Ed.)			Finding	
C140626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140626>	C140617	Iris Melanoma pT3 TNM Finding v8	Iris melanoma with tumor confluent with or extending into the ciliary body, choroid, or both, with scleral extension. (from AJCC 8th Ed.)			Finding	
C140627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140627>	C140617	Iris Melanoma pT4 TNM Finding v8	Iris melanoma with extrascleral extension. (from AJCC 8th Ed.)			Finding	
C140628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140628>	C140627	Iris Melanoma pT4a TNM Finding v8	Iris melanoma with extrascleral extension 5 mm or less in largest diameter. (from AJCC 8th Ed.)			Finding	
C140629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140629>	C140627	Iris Melanoma pT4b TNM Finding v8	Iris melanoma with extrascleral extension more than 5 mm in largest diameter. (from AJCC 8th Ed.)			Finding	
C14062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14062>	C13303	Disulfide Linkage|Disulfide Bond	A disulfide linkage is a covalent bond between 2 sulfide atoms from the thiol group of 2 cysteine residues (S-S). They occur both interstrand and intrastrand.			Amino Acid Sequence	
C140630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140630>	C140611	Choroidal and Ciliary Body Melanoma Pathologic Primary Tumor TNM Finding v8|Pathologic Primary Tumor Status (pT)	A pathologic finding about one or more characteristics of choroidal and ciliary body melanoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C140631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140631>	C140630	Choroidal and Ciliary Body Melanoma pT1 TNM Finding v8|pT1	Choroidal and ciliary body melanoma, tumor size category 1. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C140632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140632>	C140631	Choroidal and Ciliary Body Melanoma pT1a TNM Finding v8|pT1a	Choroidal and ciliary body melanoma, tumor size category 1 without ciliary body involvement and extraocular extension. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C140633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140633>	C140631	Choroidal and Ciliary Body Melanoma pT1b TNM Finding v8|pT1b	Choroidal and ciliary body melanoma, tumor size category 1 with ciliary body involvement. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C140634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140634>	C140631	Choroidal and Ciliary Body Melanoma pT1c TNM Finding v8|pT1c	Choroidal and ciliary body melanoma, tumor size category 1 without ciliary body involvement but with extraocular extension 5 mm or less in largest diameter. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C140635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140635>	C140631	Choroidal and Ciliary Body Melanoma pT1d TNM Finding v8|pT1d	Choroidal and ciliary body melanoma, tumor size category 1 with ciliary body involvement and extraocular extension 5 mm or less in largest diameter. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C140636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140636>	C140630	Choroidal and Ciliary Body Melanoma pT2 TNM Finding v8|pT2	Choroidal and ciliary body melanoma, tumor size category 2. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C140637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140637>	C140636	Choroidal and Ciliary Body Melanoma pT2a TNM Finding v8|pT2a	Choroidal and ciliary body melanoma, tumor size category 2 without ciliary body involvement and extraocular extension. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C140638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140638>	C140636	Choroidal and Ciliary Body Melanoma pT2b TNM Finding v8|pT2b	Choroidal and ciliary body melanoma, tumor size category 2 with ciliary body involvement. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C140639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140639>	C140636	Choroidal and Ciliary Body Melanoma pT2c TNM Finding v8|pT2c	Choroidal and ciliary body melanoma, tumor size category 2 without ciliary body involvement but with extraocular extension 5 mm or less in largest diameter. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C14063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14063>	C13379	Globular Region	A protein region consisting of a hydrophilic surface and a hydrophobic core.			Amino Acid Sequence	
C140640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140640>	C140636	Choroidal and Ciliary Body Melanoma pT2d TNM Finding v8|pT2d	Choroidal and ciliary body melanoma, tumor size category 2 with ciliary body involvement and extraocular extension 5 mm or less in largest diameter. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C140641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140641>	C140630	Choroidal and Ciliary Body Melanoma pT3 TNM Finding v8|pT3	Choroidal and ciliary body melanoma, tumor size category 3. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C140642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140642>	C140641	Choroidal and Ciliary Body Melanoma pT3a TNM Finding v8|pT3a	Choroidal and ciliary body melanoma, tumor size category 3 without ciliary body involvement and extraocular extension. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C140643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140643>	C140641	Choroidal and Ciliary Body Melanoma pT3b TNM Finding v8|pT3b	Choroidal and ciliary body melanoma, tumor size category 3 with ciliary body involvement. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C140644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140644>	C140641	Choroidal and Ciliary Body Melanoma pT3c TNM Finding v8|pT3c	Choroidal and ciliary body melanoma, tumor size category 3 without ciliary body involvement but with extraocular extension 5 mm or less in largest diameter. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C140645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140645>	C140641	Choroidal and Ciliary Body Melanoma pT3d TNM Finding v8|pT3d	Choroidal and ciliary body melanoma, tumor size category 3 with ciliary body involvement and extraocular extension 5 mm or less in largest diameter. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C140646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140646>	C140630	Choroidal and Ciliary Body Melanoma pT4 TNM Finding v8|pT4	Choroidal and ciliary body melanoma, tumor size category 4. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C140647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140647>	C140646	Choroidal and Ciliary Body Melanoma pT4a TNM Finding v8|pT4a	Choroidal and ciliary body melanoma, tumor size category 4 without ciliary body involvement and extraocular extension. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C140648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140648>	C140646	Choroidal and Ciliary Body Melanoma pT4b TNM Finding v8|pT4b	Choroidal and ciliary body melanoma, tumor size category 4 with ciliary body involvement. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C140649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140649>	C140646	Choroidal and Ciliary Body Melanoma pT4c TNM Finding v8|pT4c	Choroidal and ciliary body melanoma, tumor size category 4 without ciliary body involvement but with extraocular extension 5 mm or less in largest diameter. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C14064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14064>	C13303	Tertiary Protein Structure	Tertiary structure describes the folding of the polypeptide chain to assemble the different secondary structure elements in a particular arrangement.			Amino Acid Sequence	
C140650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140650>	C140646	Choroidal and Ciliary Body Melanoma pT4d TNM Finding v8|pT4d	Choroidal and ciliary body melanoma, tumor size category 4 with ciliary body involvement and extraocular extension 5 mm or less in largest diameter. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C140651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140651>	C140646	Choroidal and Ciliary Body Melanoma pT4e TNM Finding v8|pT4e	Choroidal and ciliary body melanoma, any tumor size category with extraocular extension more than 5 mm in largest diameter. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C140652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140652>	C140611	Uveal Melanoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of uveal melanoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C140653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140653>	C140652	Uveal Melanoma pN1 TNM Finding v8|pN1	Uveal melanoma with regional lymph node metastasis or discrete tumor deposits in the orbit. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C140654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140654>	C140653	Uveal Melanoma pN1a TNM Finding v8|pN1a	Uveal melanoma with metastasis in one or more regional lymph node(s). (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C140655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140655>	C140653	Uveal Melanoma pN1b TNM Finding v8|pN1b	Uveal melanoma in which no regional lymph nodes are positive, but there are discrete tumor deposits in the orbit that are not contiguous to the eye. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C140657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140657>	C63442	BAC Regimen|BAC|Bendamustine-Cytarabine|Bendamustine/Ara-C|Bendamustine/Cytarabine	A regimen consisting of bendamustine and cytarabine that can be used in the treatment of mantle-cell lymphoma (MCL).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C140658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140658>	C63442	R-ACVBP Regimen|ACVBP-R|Doxorubicin/Cyclophosphamide/Vindesine/Bleomycin/Prednisone/Rituximab|R-ACVBP|R-ACVBP|R-ACVBP (rituximab-abbs)|R-ACVBP (rituximab-arrx)|R-ACVBP (rituximab-blit)|R-ACVBP (rituximab-pvvr)|R-ACVBP (rituximab-rite)|R-ACVBP (rituximab-rixa)|R-ACVBP (rituximab-rixi)|Rituximab-Doxorubicin-Cyclophosphamide-Vindesine-Bleomycin-Prednisone|Rituximab/Doxorubicin/Cyclophosphamide/Vindesine/Bleomycin/Prednisone	A regimen consisting of doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone and rituximab that can be used in the treatment of non-Hodgkin lymphoma (NHL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C140659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140659>	C7712	Choroidal and Ciliary Body Melanoma by AJCC v8 Stage|Posterior Uveal Melanoma by AJCC v8 Stage	A term that refers to the staging of choroidal and ciliary body melanoma, following the rules of the TNM AJCC v8 classification system.			Neoplastic Process	
C140660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140660>	C140659	Stage I Choroidal and Ciliary Body Melanoma AJCC v8|Stage I Choroidal and Ciliary Body Melanoma|Stage I Posterior Uveal Melanoma AJCC v8	Stage I includes: T1a, N0, M0. T1a: Tumor size category 1 without ciliary body involvement and extraocular extension.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 8th ed.)	Stage I Choroidal and Ciliary Body Melanoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140661>	C140659	Stage II Choroidal and Ciliary Body Melanoma AJCC v8|Stage II Choroidal and Ciliary Body Melanoma|Stage II Posterior Uveal Melanoma AJCC v8	Stage II includes: IIA (T1b-d, N0, M0); (T2a, N0, M0); IIB (T2b, N0, M0); (T3a, N0, M0).  T1b: Tumor size category 1 with ciliary body involvement.  T1c: Tumor size category 1 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in largest diameter.  T1d: Tumor size category 1 with ciliary body involvement and extraocular extension less than or equal to 5 mm in largest diameter. T2a: Tumor size category 2 without ciliary body involvement and extraocular extension. T2b: Tumor size category 2 with ciliary body involvement. T3a: Tumor size category 3 without ciliary body involvement and extraocular extension. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 8th ed.)	Stage II Choroidal and Ciliary Body Melanoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140662>	C140661	Stage IIA Choroidal and Ciliary Body Melanoma AJCC v8|Stage IIA Choroidal and Ciliary Body Melanoma|Stage IIA Posterior Uveal Melanoma AJCC v8	Stage IIA includes: (T1b-d, N0, M0); (T2a, N0, M0).  T1b: Tumor size category 1 with ciliary body involvement.  T1c: Tumor size category 1 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in largest diameter.  T1d: Tumor size category 1 with ciliary body involvement and extraocular extension less than or equal to 5 mm in largest diameter. T2a: Tumor size category 2 without ciliary body involvement and extraocular extension. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 8th ed.)	Stage IIA Choroidal and Ciliary Body Melanoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140663>	C140661	Stage IIB Choroidal and Ciliary Body Melanoma AJCC v8|Stage IIB Choroidal and Ciliary Body Melanoma|Stage IIB Posterior Uveal Melanoma AJCC v8	Stage IIB includes: (T2b, N0, M0); (T3a, N0, M0).  T2b: Tumor size category 2 with ciliary body involvement. T3a: Tumor size category 3 without ciliary body involvement and extraocular extension. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 8th ed.)	Stage IIB Choroidal and Ciliary Body Melanoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140664>	C140659	Stage III Choroidal and Ciliary Body Melanoma AJCC v8|Stage III Choroidal and Ciliary Body Melanoma|Stage III Posterior Uveal Melanoma AJCC v8	Stage III includes: IIIA (T2c-d, N0, M0); (T3b-c, N0, M0); (T4a, N0, M0); IIIB (T3d, N0, M0); (T4b-c, N0, M0); IIIC: (T4d-e, N0, M0). T2c: Tumor size category 2 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in largest diameter. T2d: Tumor size category 2 with ciliary body involvement and extraocular extension less than or equal to 5 mm in largest diameter. T3b: Tumor size category 3 with ciliary body involvement. T3c: Tumor size category 3 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in largest diameter. T4a: Tumor size category 4 without ciliary body involvement and extraocular extension. T3d: Tumor size category 3 with ciliary body involvement and extraocular extension less than or equal to 5 mm in largest diameter.  T4b: Tumor size category 4 with ciliary body involvement. T4c: Tumor size category 4 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in largest diameter. T4d: Tumor size category 4 with ciliary body involvement and extraocular extension less than or equal to 5 mm in largest diameter. T4e: Any tumor size category with extraocular extension more than 5 mm in largest diameter. N0: No regional lymph node metastasis. M0: No distant metastasis.  (AJCC 8th ed.)	Stage III Choroidal and Ciliary Body Melanoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140665>	C140664	Stage IIIA Choroidal and Ciliary Body Melanoma AJCC v8|Stage IIIA Choroidal and Ciliary Body Melanoma|Stage IIIA Posterior Uveal Melanoma AJCC v8	Stage IIIA includes: (T2c-d, N0, M0); (T3b-c, N0, M0); (T4a, N0, M0). T2c: Tumor size category 2 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in largest diameter. T2d: Tumor size category 2 with ciliary body involvement and extraocular extension less than or equal to 5 mm in largest diameter. T3b: Tumor size category 3 with ciliary body involvement. T3c: Tumor size category 3 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in largest diameter. T4a: Tumor size category 4 without ciliary body involvement and extraocular extension. N0: No regional lymph node metastasis. M0: No distant metastasis.  (AJCC 8th ed.)	Stage IIIA Choroidal and Ciliary Body Melanoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140666>	C140664	Stage IIIB Choroidal and Ciliary Body Melanoma AJCC v8|Stage IIIB Choroidal and Ciliary Body Melanoma|Stage IIIB Posterior Uveal Melanoma AJCC v8	Stage IIIB includes: (T3d, N0, M0); (T4b-c, N0, M0). T3d: Tumor size category 3 with ciliary body involvement and extraocular extension less than or equal to 5 mm in largest diameter.  T4b: Tumor size category 4 with ciliary body involvement. T4c: Tumor size category 4 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in largest diameter. N0: No regional lymph node metastasis. M0: No distant metastasis.  (AJCC 8th ed.)	Stage IIIB Choroidal and Ciliary Body Melanoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140667>	C140664	Stage IIIC Choroidal and Ciliary Body Melanoma AJCC v8|Stage IIIC Choroidal and Ciliary Body Melanoma|Stage IIIC Posterior Uveal Melanoma AJCC v8	Stage IIIC includes: T4d-e, N0, M0. T4d: Tumor size category 4 with ciliary body involvement and extraocular extension less than or equal to 5 mm in largest diameter. T4e: Any tumor size category with extraocular extension more than 5 mm in largest diameter. N0: No regional lymph node metastasis. M0: No distant metastasis.  (AJCC 8th ed.)	Stage IIIC Choroidal and Ciliary Body Melanoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140668>	C140659	Stage IV Choroidal and Ciliary Body Melanoma AJCC v8|Stage IV Choroidal and Ciliary Body Melanoma|Stage IV Posterior Uveal Melanoma AJCC v8	Stage IV includes: (Any T, N1, M0); (Any T, Any N, M1a-c). N1: Regional lymph node metastasis or discrete tumor deposits in the orbit. M0: No distant metastasis. M1a: Distant metastasis, with the largest diameter of the largest metastasis measuring 3 cm or less. M1b: Distant metastasis, with the largest diameter of the largest metastasis measuring 3.1-8.0 cm. M1c: Distant metastasis, with the largest diameter of the largest metastasis measuring 8.1 cm or more.  (AJCC 8th ed.)	Stage IV Choroidal and Ciliary Body Melanoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140669>	C123598	Minor Response in Neuroblastoma|Minimal Response in Neuroblastoma	Partial response or complete response in at least one component (i.e., soft tissue, bone, and bone marrow disease) but at least one other component with stable disease; no component with progressive disease. (J Clin Oncol 35: 2580-2587, 2017)			Finding	
C14066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14066>	C13432	7q21.2-q22.1	A chromosome band present on 7q			Gene or Genome	
C140670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140670>	C28384	Total Measured Tumor Burden|TMTB	The sum of the longest diameters of non-nodal target and new measurable lesions, and the short axes of nodal target and new measurable lesions.			Quantitative Concept	
C140671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140671>	C3270|C206692	Progressive Neuroblastoma|Progressive Disease in Neuroblastoma	A neuroblastoma that is worsening in terms of extent or severity.			Neoplastic Process	
C140672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140672>	C7712	Uveal Melanoma by AJCC v7 Stage|Tumor Stage (Pathologic)	A term that refers to the staging of uveal melanoma, following the rules of the TNM AJCC v7 classification system.			Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C140673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140673>	C63442	R-CHOPE Regimen|R-CHOEP|R-CHOEP Regimen|R-CHOPE|Rituximab-Cyclophosphamide-Doxorubicin-Etoposide-Prednisone-Vincristine|Rituximab/Cyclophosphamide/Doxorubicin/Etoposide/Prednisone/Vincristine	A regimen consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone and etoposide that can be used in the treatment of non-Hodgkin lymphomas (NHL). R-CHOPE differs from R-EPOCH in the drug doses and schedule of the administration of the various drugs.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C140674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140674>	C63787|C63360	Carboplatin/Pembrolizumab/Pemetrexed Regimen|Carboplatin, Pemetrexed, Pembrolizumab|Carboplatin-Keytruda-Alimta|Carboplatin-Pembrolizumab-Pemetrexed|Carboplatin-Pembrolizumab-Pemetrexed Regimen|Carboplatin/Pembrolizumab/Pemetrexed	A regimen consisting of carboplatin, pembrolizumab and pemetrexed that can be used in the treatment of non-small cell lung cancer (NSCLC), and peritoneal and pleural mesothelioma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C140675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140675>	C140469	Retinoblastoma TNM Finding v8	A finding about one or more characteristics of retinoblastoma, following the rules of the TNM AJCC v8 classification system. This classification does not apply to central nervous system component of "trilateral retinoblastoma" (is staged according to the classification for brain and spinal cord), retinoma (or retinocytoma) (no AJCC staging system), and medulloepithelioma (no AJCC staging system). (from AJCC 8th Ed.)			Finding	
C140676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140676>	C140675	Retinoblastoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of retinoblastoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C140677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140677>	C140676	Retinoblastoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of retinoblastoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C140678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140678>	C140677	Retinoblastoma cM0 TNM Finding v8	Retinoblastoma with no signs or symptoms of intracranial or distant metastasis. (from AJCC 8th Ed.)			Finding	
C140679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140679>	C140677	Retinoblastoma cM1 TNM Finding v8	Retinoblastoma with distant metastasis without microscopic confirmation. (from AJCC 8th Ed.)			Finding	
C14067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14067>	C13432	14q31	A chromosome band present on 14q			Gene or Genome	
C140680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140680>	C140679	Retinoblastoma cM1a TNM Finding v8	Retinoblastoma with tumor(s) involving any distant site (e.g., bone marrow, liver) on clinical or radiologic tests. (from AJCC 8th Ed.)			Finding	
C140681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140681>	C140679	Retinoblastoma cM1b TNM Finding v8	Retinoblastoma with tumor involving the CNS on radiologic imaging (not including trilateral retinoblastoma). (from AJCC 8th Ed.)			Finding	
C140682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140682>	C140676	Retinoblastoma Clinical Primary Tumor TNM Finding v8	A clinical finding about one or more characteristics of retinoblastoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor. Each eye is scored for cT criteria, and the cT category for the patient is based on the most advanced eye. (from AJCC 8th Ed.)			Finding	
C140683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140683>	C140682	Retinoblastoma cTX TNM Finding v8	Unknown evidence of intraocular tumor. (from AJCC 8th Ed.)			Finding	
C140684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140684>	C140682	Retinoblastoma cT0 TNM Finding v8	No evidence of intraocular tumor. (from AJCC 8th Ed.)			Finding	
C140685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140685>	C140682	Retinoblastoma cT1 TNM Finding v8	Intraretinal tumor(s) with subretinal fluid 5 mm or less from the base of any tumor. (from AJCC 8th Ed.)			Finding	
C140686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140686>	C140685	Retinoblastoma cT1a TNM Finding v8	Tumors 3 mm or less and further than 1.5 mm from disc and fovea. (from AJCC 8th Ed.)			Finding	
C140687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140687>	C140685	Retinoblastoma cT1b TNM Finding v8	Tumors more than 3 mm or closer than 1.5 mm from disc and fovea. (from AJCC 8th Ed.)			Finding	
C140688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140688>	C140682	Retinoblastoma cT2 TNM Finding v8	Intraocular tumor(s) with retinal detachment, vitreous seeding, or subretinal seeding. (from AJCC 8th Ed.)			Finding	
C140689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140689>	C140688	Retinoblastoma cT2a TNM Finding v8	Subretinal fluid more than 5 mm from the base of any tumor. (from AJCC 8th Ed.)			Finding	
C14068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14068>	C13379	Acidic Region	Any portion of a protein molecule with a net negative charge.			Amino Acid Sequence	
C140690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140690>	C140688	Retinoblastoma cT2b TNM Finding v8	Vitreous seeding and/or subretinal seeding. (from AJCC 8th Ed.)			Finding	
C140691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140691>	C140682	Retinoblastoma cT3 TNM Finding v8	Advanced intraocular tumor(s). (from AJCC 8th Ed.)			Finding	
C140692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140692>	C140691	Retinoblastoma cT3a TNM Finding v8	Phthisis or pre-phthisis bulbi. (from AJCC 8th Ed.)			Finding	
C140693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140693>	C140691	Retinoblastoma cT3b TNM Finding v8	Tumor invasion of choroid, pars plana, ciliary body, lens, zonules, iris, or anterior chamber. (from AJCC 8th Ed.)			Finding	
C140694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140694>	C140691	Retinoblastoma cT3c TNM Finding v8	Raised intraocular pressure with neovascularization and/or buphthalmos. (from AJCC 8th Ed.)			Finding	
C140695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140695>	C140691	Retinoblastoma cT3d TNM Finding v8	Hyphema and/or massive vitreous hemorrhage. (from AJCC 8th Ed.)			Finding	
C140696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140696>	C140691	Retinoblastoma cT3e TNM Finding v8	Aseptic orbital cellulitis. (from AJCC 8th Ed.)			Finding	
C140697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140697>	C140682	Retinoblastoma cT4 TNM Finding v8	Extraocular tumor(s) involving orbit, including optic nerve. (from AJCC 8th Ed.)			Finding	
C140698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140698>	C140697	Retinoblastoma cT4a TNM Finding v8	Radiologic evidence of retrobulbar optic nerve involvement or thickening of optic nerve or involvement of orbital tissues. (from AJCC 8th Ed.)			Finding	
C140699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140699>	C140697	Retinoblastoma cT4b TNM Finding v8	Extraocular tumor clinically evident with proptosis and/or an orbital mass. (from AJCC 8th Ed.)			Finding	
C14069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14069>	C13379	Cysteine-Rich Domain	The Cysteine-Rich Domain is usually found in two copies per protein. It contains up to four conserved cysteines. The family includes a subunit from heterodisulfide reductase and a subunit from glycolate oxidase and glycerol-3-phosphate dehydrogenase. (Pfam PF02754)			Amino Acid Sequence	
C1406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1406>	C1821	Idoxifene|1-[2-[4-[(1E)-1-(4-Iodophenyl)-2-phenyl-1-butenyl]phenoxy]ethyl]pyrrolidine|IDOXIFENE|Pyrrolidino-4-iodotamoxifen|SB-223030|idoxifene				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C140700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140700>	C140676	Retinoblastoma Clinical Regional Lymph Nodes TNM Finding v8	A clinical finding about one or more characteristics of retinoblastoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C140701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140701>	C140700	Retinoblastoma cNX TNM Finding v8	Retinoblastoma in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C140702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140702>	C140700	Retinoblastoma cN0 TNM Finding v8	Retinoblastoma with no regional lymph node involvement. (from AJCC 8th Ed.)			Finding	
C140703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140703>	C140700	Retinoblastoma cN1 TNM Finding v8	Retinoblastoma with evidence of preauricular, submandibular, and cervical lymph node involvement. (from AJCC 8th Ed.)			Finding	
C140704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140704>	C140675	Retinoblastoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of retinoblastoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C140705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140705>	C140704	Retinoblastoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of retinoblastoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C140706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140706>	C140705	Retinoblastoma pM1 TNM Finding v8	Retinoblastoma with distant metastasis with microscopic confirmation. (from AJCC 8th Ed.)			Finding	
C140707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140707>	C140706	Retinoblastoma pM1a TNM Finding v8	Retinoblastoma with pathological evidence of tumor at any distant site (e.g., bone marrow, liver, or other). (from AJCC 8th Ed.)			Finding	
C140708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140708>	C140706	Retinoblastoma pM1b TNM Finding v8	Retinoblastoma with pathological evidence of tumor in the cerebrospinal fluid or CNS parenchyma. (from AJCC 8th Ed.)			Finding	
C140709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140709>	C140704	Retinoblastoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of retinoblastoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C14070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14070>	C14135	Cellular Membrane|Cell Membrane	Any of the lipid bilayer membranes within a cell.			Cell Component	
C140710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140710>	C140709	Retinoblastoma pNX TNM Finding v8	Retinoblastoma in which regional lymph node involvement cannot be assessed.  (from AJCC 8th Ed.)			Finding	
C140711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140711>	C140709	Retinoblastoma pN0 TNM Finding v8	Retinoblastoma with no lymph node involvement. (from AJCC 8th Ed.)			Finding	
C140712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140712>	C140709	Retinoblastoma pN1 TNM Finding v8	Retinoblastoma with regional lymph node involvement. (from AJCC 8th Ed.)			Finding	
C140713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140713>	C140704	Retinoblastoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of retinoblastoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C140714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140714>	C140713	Retinoblastoma pTX TNM Finding v8	Unknown evidence of intraocular tumor. (from AJCC 8th Ed.)			Finding	
C140715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140715>	C140713	Retinoblastoma pT0 TNM Finding v8	No evidence of intraocular tumor. (from AJCC 8th Ed.)			Finding	
C140716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140716>	C140713	Retinoblastoma pT1 TNM Finding v8	Intraocular tumor(s) without any local invasion, focal choroidal invasion, or pre-or intralaminar involvement of the optic nerve head. (from AJCC 8th Ed.)			Finding	
C140717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140717>	C140713	Retinoblastoma pT2 TNM Finding v8	Intraocular tumor(s) with local invasion. (from AJCC 8th Ed.)			Finding	
C140718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140718>	C140717	Retinoblastoma pT2a TNM Finding v8	Concomitant focal choroidal invasion and pre-or intralaminar involvement of the optic nerve head. (from AJCC 8th Ed.)			Finding	
C140719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140719>	C140717	Retinoblastoma pT2b TNM Finding v8	Tumor invasion of stroma of iris and/or trabecular meshwork and/or Schlemm's canal. (from AJCC 8th Ed.)			Finding	
C14071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14071>	C13671	NAD-Binding Domain|NAD-Binding Fold	The Gly-rich NAD-Binding Domain (often N-terminal) is often found in metabolic enzymes involved in glycolysis, glyconeogenesis, and the citric acid cycle, such as GAPDH (glyceraldehyde-3-phosphate oxidation and phosphorylation), lactate dehydrogenases (lactate to pyruvate conversion), and malate dehydrogenases (malate to oxaloacetate interconversion). (NCI)			Amino Acid Sequence	
C140720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140720>	C140713	Retinoblastoma pT3 TNM Finding v8	Intraocular tumor(s) with significant local invasion. (from AJCC 8th Ed.)			Finding	
C140721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140721>	C140720	Retinoblastoma pT3a TNM Finding v8	Massive choroidal invasion (more than 3 mm in largest diameter, or multiple foci of focal choroidal involvement totaling more than 3 mm, or any full-thickness choroidal involvement). (from AJCC 8th Ed.)			Finding	
C140722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140722>	C140720	Retinoblastoma pT3b TNM Finding v8	Retrolaminar invasion of the optic nerve head, not involving the transected end of the optic nerve. (from AJCC 8th Ed.)			Finding	
C140723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140723>	C140720	Retinoblastoma pT3c TNM Finding v8	Any partial-thickness involvement of the sclera within the inner two thirds. (from AJCC 8th Ed.)			Finding	
C140724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140724>	C140720	Retinoblastoma pT3d TNM Finding v8	Full-thickness invasion into the outer third of the sclera and/or invasion into or around emissary channels. (from AJCC 8th Ed.)			Finding	
C140725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140725>	C140713	Retinoblastoma pT4 TNM Finding v8	Evidence of extraocular tumor: tumor at the transected end of the optic nerve, tumor in the meningeal spaces around the optic nerve, full-thickness invasion of the sclera with invasion of the episclera, adjacent adipose tissue, extraocular muscle, bone, conjunctiva, or eyelids. (from AJCC 8th Ed.)			Finding	
C140726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140726>	C140675	Retinoblastoma Heritable Trait (H) Finding v8	A finding about a heritable trait of retinoblastoma, following the rules of the AJCC v8 classification system.			Finding	
C140727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140727>	C140726	Retinoblastoma HX Finding v8	Unknown or insufficient evidence of a constitutional RB1 gene mutation. (from AJCC 8th Ed.)			Finding	
C140728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140728>	C140726	Retinoblastoma H0 Finding v8	Normal RB1 alleles in blood tested with demonstrated high-sensitivity assays. (from AJCC 8th Ed.)			Finding	
C140729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140729>	C140726	Retinoblastoma H1 Finding v8	Bilateral retinoblastoma, retinoblastoma with an intracranial primitive neuroectodermal tumor (i.e., trilateral retinoblastoma), patient with family history of retinoblastoma, or molecular definition of a constitutional RB1 gene mutation. (from AJCC 8th Ed.)			Finding	
C14072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14072>	C14071	GXGXXXG Motif	The GXGXXXG Motif is often found it the NAD-binding domain (often N-terminal) in metabolic enzymes involved in glycolysis, glyconeogenesis, and the citric acid cycle, such as GAPDH (glyceraldehyde-3-phosphate oxidation and phosphorylation), lactate dehydrogenases (lactate to pyruvate conversion), and malate dehydrogenases (malate to oxaloacetate interconversion). (NCI)			Amino Acid Sequence	
C140730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140730>	C63442	FCM Regimen|FCM|FCM|Fludarabine-Cyclophosphamide-Mitoxantrone|Fludarabine-Cyclophosphamide-Mitoxantrone Regimen|Fludarabine/Cyclophosphamide/Mitoxantrone|Fludarabine/Cyclophosphamide/Mitoxantrone Regimen	A regimen consisting of fludarabine, cyclophosphamide and mitoxantrone that can be used in the treatment of non-Hodgkin lymphoma (NHL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C140731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140731>	C63442	R-GemOx Regimen|GEMOX-R|GemOx-Rituximab|GemOx/Rituximab|R-GemOx|R-GemOx|R-GemOx|R-GemOx (rituximab-abbs)|R-GemOx (rituximab-arrx)|R-GemOx (rituximab-blit)|R-GemOx (rituximab-pvvr)|R-GemOx (rituximab-rite)|R-GemOx (rituximab-rixa)|R-GemOx (rituximab-rixi)|Rituximab-Gemcitabine-Oxaliplatin|Rituximab/Gemcitabine/Oxaliplatin	A regimen consisting of rituximab, gemcitabine and oxaliplatin used in the treatment of diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C140732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140732>	C63442|C63356	GVD Regimen|GVD|GVD|GVD|Gemcitabine-Vinorelbine-Pegylated Liposomal Doxorubicin|Gemcitabine/Vinorelbine/Doxil|Gemcitabine/Vinorelbine/Liposomal Doxorubicin Regimen|Gemcitabine/Vinorelbine/Pegylated Liposomal Doxorubicin	A regimen consisting of gemcitabine, vinorelbine and pegylated liposomal doxorubicin used for the treatment of Hodgkin lymphoma (HL), T-cell lymphomas, and mycosis fungoides and Sezary syndrome.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C140733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140733>	C63356	R-GVD Regimen|Gemcitabine-Vinorelbine-Pegylated Liposomal Doxorubicin-Rituximab|Gemcitabine/Vinorelbine/Doxil/Rituximab|Gemcitabine/Vinorelbine/Pegylated Liposomal Doxorubicin/Rituximab|R-GVD|Rituximab/Gemcitabine/Vinorelbine/Pegylated Liposomal Doxorubicin	A regimen consisting of rituximab, gemcitabine, vinorelbine and pegylated liposomal doxorubicin that can be used in the treatment of Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C140734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140734>	C63442	R-CHOP Alternating with R-DHAP Regimen|Cyclophosphamide/Doxorubicin/Prednisone/Rituximab/Vincristine Alternating with Rituximab Plus Cisplatin/Cytarabine/Dexamethasone|Cyclophosphamide/Doxorubicin/Prednisone/Rituximab/Vincristine-Rituximab/Cisplatin/Cytarabine/Dexamethasone|R-CHOP Alternating with R-DHAP|R-CHOP/R-DHAP|R-CHOP/R-DHAP|R-CHOP/R-DHAP (rituximab-abbs)|R-CHOP/R-DHAP (rituximab-arrx)|R-CHOP/R-DHAP (rituximab-blit)|R-CHOP/R-DHAP (rituximab-pvvr)|R-CHOP/R-DHAP (rituximab-rite)|R-CHOP/R-DHAP (rituximab-rixa)|R-CHOP/R-DHAP (rituximab-rixi)|R-CHOP/R-DHAP Regimen	A regimen that alternates rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with rituximab, dexamethasone, high-dose cytarabine and cisplatin (R-DHAP), and can be used in the treatment of mantle cell lymphoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C140735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140735>	C176022|C173792	Satisfaction with How You Look in Mirror Clothed Question|How you look in the mirror clothed|Satisfaction with How You Look in Mirror Clothed	A question about how satisfied or dissatisfied an individual is or was about how they look in the mirror clothed.			Intellectual Product	BREAST-Q
C140736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140736>	C173792	Satisfaction with How Comfortably Bras Fit Question|How comfortably your bras fit|Satisfaction with How Comfortably Bras Fit	A question about how satisfied or dissatisfied an individual is or was about how comfortably their bras fit.			Intellectual Product	BREAST-Q
C140737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140737>	C173792|C173045	Satisfaction with Being able to Wear Clothing That is Fitted Question|Being able to wear clothing that is more fitted|Satisfaction with Being able to Wear Clothing That is Fitted	A question about how satisfied or dissatisfied an individual is or was about being able to wear clothing that is fitted.			Intellectual Product	BREAST-Q
C140738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140738>	C176022|C173792	Satisfaction with How You Look in Mirror Unclothed Question|How you look in the mirror unclothed|Satisfaction with How You Look in Mirror Unclothed	A question about how satisfied or dissatisfied an individual is or was about how they look in the mirror unclothed.			Intellectual Product	BREAST-Q
C140739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140739>	C173086|C118873	How Often Felt Confident in Social Setting Question|Confident in a social setting|How Often Felt Confident in Social Setting	A question about how often an individual feels or felt confident in a social setting			Intellectual Product	BREAST-Q
C14073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14073>	C13671	Substrate Interaction Domain|Substrate Domain	A Substrate Domain is a protein region that physically interacts stereospecifically, and usually at high affinity, with a specific target substrate. In enzymes, the substrate domain is often, though not necessarily, coincident with the catalytic domain. Typically, substrate interaction results in some protein conformational alteration and functional modification. (NCI)			Amino Acid Sequence	
C140740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140740>	C173160|C118873	How Often Felt Emotionally Able to do Things You Want to do Question|Emotionally able to do the things that you want to do|How Often Felt Emotionally Able to do Things You Want to do	A question about how often an individual feels or felt emotionally able to do things they want to do.			Intellectual Product	BREAST-Q
C140741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140741>	C173160|C118873	How Often Felt Emotionally Healthy Question|Emotionally healthy|How Often Felt Emotionally Healthy	A question about how often an individual feels or felt emotionally healthy.			Intellectual Product	BREAST-Q
C140742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140742>	C173160|C118873	How Often Felt of Equal Worth to Other Women Question|How Often Felt of Equal Worth to Other Women|Of equal worth to other women	A question about how often an individual feels or felt of equal worth to other women.			Intellectual Product	BREAST-Q
C140743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140743>	C173086|C118873	How Often Felt Self-confident Question|How Often Felt Self-confident|Self-confident	A question about how often an individual feels or felt self-confident.			Intellectual Product	BREAST-Q
C140744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140744>	C173160|C118873	How Often Felt Feminine in Your Clothes Question|Feminine in your clothes|How Often Felt Feminine in Your Clothes	A question about how often an individual feels or felt feminine in their clothes.			Intellectual Product	BREAST-Q
C140745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140745>	C173160|C118873	How Often Felt Accepting of Your Body Question|Accepting of your body|How Often Felt Accepting of Your Body	A question about how often an individual feels or felt accepting of their body.			Intellectual Product	BREAST-Q
C140746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140746>	C173160|C118873	How Often Felt Normal Question|How Often Felt Normal|Normal	A question about how often an individual feels or felt normal.			Intellectual Product	BREAST-Q
C140748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140748>	C173160|C118873	How Often Felt Like Other Women Question|How Often Felt Like Other Women|Like other women	A question about how often an individual feels or felt like other women.			Intellectual Product	BREAST-Q
C140749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140749>	C173160|C118873	How Often Felt Attractive Question|Attractive|How Often Felt Attractive	A question about how often an individual feels or felt attractive.			Intellectual Product	BREAST-Q
C14074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14074>	C14073	ATPase Domain	A protein domain that binds ATP and catalyzes its convertion to ADP and inorganic phosphate.			Amino Acid Sequence	
C140750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140750>	C7541	Retinoblastoma by AJCC v8 Stage	A term that refers to the staging of retinoblastoma according to the American Joint Committee on Cancer, 8th edition. This staging system does not apply to central nervous system component of "trilateral retinoblastoma" (is staged according to the classification for brain and spinal cord), retinoma (or retinocytoma) (no AJCC staging system), and medulloepithelioma (no AJCC staging system). (from AJCC 8th Ed.)			Neoplastic Process	
C140751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140751>	C140750	Retinoblastoma by AJCC v8 Clinical Stage	A term that refers to the clinical staging of retinoblastoma according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C140752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140752>	C140751	Clinical Stage I Retinoblastoma AJCC v8	Stage I includes: cT1, cT2, cT3, cN0, cM0, Any H. cT1: Intraretinal tumor(s) with subretinal fluid 5 mm or less from the base of any tumor. cT2: Intraocular tumor(s) with retinal detachment, vitreous seeding, or subretinal seeding. cT3: Advanced intraocular tumor(s). cN0: No regional lymph node involvement. cM0: No signs or symptoms of intracranial or distant metastasis. HX: Unknown or insufficient evidence of a constitutional RB1 gene mutation. H0: Normal RB1 alleles in blood tested with demonstrated high-sensitivity assays. H1: Bilateral retinoblastoma, retinoblastoma with an intracranial primitive neuroectodermal tumor (i.e., trilateral retinoblastoma), patient with family history of retinoblastoma, or molecular definition of a constitutional RB1 gene mutation. (AJCC 8th ed.)			Neoplastic Process	
C140753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140753>	C140751	Clinical Stage II Retinoblastoma AJCC v8	Stage II includes: cT4a, cN0, cM0, Any H. cT4a: Radiologic evidence of retrobulbar optic nerve involvement or thickening of optic nerve or involvement of orbital tissues. cN0: No regional lymph node involvement. cM0: No signs or symptoms of intracranial or distant metastasis. HX: Unknown or insufficient evidence of a constitutional RB1 gene mutation. H0: Normal RB1 alleles in blood tested with demonstrated high-sensitivity assays. H1: Bilateral retinoblastoma, retinoblastoma with an intracranial primitive neuroectodermal tumor (i.e., trilateral retinoblastoma), patient with family history of retinoblastoma, or molecular definition of a constitutional RB1 gene mutation. (AJCC 8th ed.)			Neoplastic Process	
C140754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140754>	C140751	Clinical Stage III Retinoblastoma AJCC v8	Stage III includes: (cT4b, cN0, cM0, Any H); (Any cT, cN1, cM0, Any H). cT4b: Extraocular tumor clinically evident with proptosis and/or an orbital mass. cN0: No regional lymph node involvement. cN1: Evidence of preauricular, submandibular, and cervical lymph node involvement. cM0: No signs or symptoms of intracranial or distant metastasis. HX: Unknown or insufficient evidence of a constitutional RB1 gene mutation. H0: Normal RB1 alleles in blood tested with demonstrated high-sensitivity assays. H1: Bilateral retinoblastoma, retinoblastoma with an intracranial primitive neuroectodermal tumor (i.e., trilateral retinoblastoma), patient with family history of retinoblastoma, or molecular definition of a constitutional RB1 gene mutation. (AJCC 8th ed.)			Neoplastic Process	
C140755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140755>	C140751	Clinical Stage IV Retinoblastoma AJCC v8	Stage IV includes: Any cT, Any N, cM1 or pM1, Any H. cM1: Distant metastasis without microscopic confirmation. pM1: Distant metastasis with microscopic confirmation. HX: Unknown or insufficient evidence of a constitutional RB1 gene mutation. H0: Normal RB1 alleles in blood tested with demonstrated high-sensitivity assays. H1: Bilateral retinoblastoma, retinoblastoma with an intracranial primitive neuroectodermal tumor (i.e., trilateral retinoblastoma), patient with family history of retinoblastoma, or molecular definition of a constitutional RB1 gene mutation. (AJCC 8th ed.)			Neoplastic Process	
C140756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140756>	C140750	Retinoblastoma by AJCC v8 Pathologic Stage	A term that refers to the pathologic staging of retinoblastoma according to the American Joint Committee on Cancer, 8th edition.			Neoplastic Process	
C140757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140757>	C140756	Pathologic Stage I Retinoblastoma AJCC v8	Stage I includes: pT1, pT2, pT3, pN0, cM0, Any H. pT1: Intraocular tumor(s) without any local invasion, focal choroidal invasion, or pre-or intralaminar involvement of the optic nerve head. pT2: Intraocular tumor(s) with local invasion. pT3: Intraocular tumor(s) with significant local invasion. pN0: No lymph node involvement. cM0: No signs or symptoms of intracranial or distant metastasis. HX: Unknown or insufficient evidence of a constitutional RB1 gene mutation. H0: Normal RB1 alleles in blood tested with demonstrated high-sensitivity assays. H1: Bilateral retinoblastoma, retinoblastoma with an intracranial primitive neuroectodermal tumor (i.e., trilateral retinoblastoma), patient with family history of retinoblastoma, or molecular definition of a constitutional RB1 gene mutation. (AJCC 8th ed.)			Neoplastic Process	
C140758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140758>	C140756	Pathologic Stage II Retinoblastoma AJCC v8	Stage II includes: pT4, pN0, cM0, Any H. pT4: Evidence of extraocular tumor: tumor at the transected end of the optic nerve, tumor in the meningeal spaces around the optic nerve, full-thickness invasion of the sclera with invasion of the episclera, adjacent adipose tissue, extraocular muscle, bone, conjunctiva, or eyelids. pN0: No lymph node involvement. cM0: No signs or symptoms of intracranial or distant metastasis. HX: Unknown or insufficient evidence of a constitutional RB1 gene mutation. H0: Normal RB1 alleles in blood tested with demonstrated high-sensitivity assays. H1: Bilateral retinoblastoma, retinoblastoma with an intracranial primitive neuroectodermal tumor (i.e., trilateral retinoblastoma), patient with family history of retinoblastoma, or molecular definition of a constitutional RB1 gene mutation. (AJCC 8th ed.)			Neoplastic Process	
C140759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140759>	C140756	Pathologic Stage III Retinoblastoma AJCC v8	Stage III includes: Any pT, pN1, cM0, Any H. pN1: Regional lymph node involvement. cM0: No signs or symptoms of intracranial or distant metastasis. HX: Unknown or insufficient evidence of a constitutional RB1 gene mutation. H0: Normal RB1 alleles in blood tested with demonstrated high-sensitivity assays. H1: Bilateral retinoblastoma, retinoblastoma with an intracranial primitive neuroectodermal tumor (i.e., trilateral retinoblastoma), patient with family history of retinoblastoma, or molecular definition of a constitutional RB1 gene mutation. (AJCC 8th ed.)			Neoplastic Process	
C14075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14075>	C14073	Tyrosine Kinase Domain	A protein domain that binds a protein and catalyzes the covalent addition of a phosphate group specifically to a tyrosine residue.			Amino Acid Sequence	
C140760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140760>	C140756	Pathologic Stage IV Retinoblastoma AJCC v8	Stage IV includes: Any pT, Any N, cM1 or pM1, Any H. cM1: Distant metastasis without microscopic confirmation. pM1: Distant metastasis with microscopic confirmation. HX: Unknown or insufficient evidence of a constitutional RB1 gene mutation. H0: Normal RB1 alleles in blood tested with demonstrated high-sensitivity assays. H1: Bilateral retinoblastoma, retinoblastoma with an intracranial primitive neuroectodermal tumor (i.e., trilateral retinoblastoma), patient with family history of retinoblastoma, or molecular definition of a constitutional RB1 gene mutation. (AJCC 8th ed.)			Neoplastic Process	
C140761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140761>	C175990|C173346|C118873	How Often Experienced Pain in Muscles of Your Chest Question|How Often Experienced Pain in Muscles of Your Chest|Pain in the muscles of your chest	A question about how often an individual has experienced pain in the muscles of their chest.			Intellectual Product	BREAST-Q
C140762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140762>	C175990|C173398|C118873	How Often Experienced Difficulty Lifting or Moving Your Arms Question|Difficulty lifting or moving your arms|How Often Experienced Difficulty Lifting or Moving Your Arms	A question about how often an individual has experienced difficulty lifting or moving their arms.			Intellectual Product	BREAST-Q
C140763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140763>	C173925|C173791|C173518|C173398|C118873	How Often Experienced Difficulty Sleeping Because of Discomfort in Breast Area Question|Difficulty sleeping because of discomfort in your breast area|How Often Experienced Difficulty Sleeping Because of Discomfort in Breast Area	A question about how often an individual has experienced difficulty sleeping because of discomfort in their breast area.			Intellectual Product	BREAST-Q
C140764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140764>	C175990|C173791|C118873	How Often Experienced Tightness in Your Breast Area Question|How Often Experienced Tightness in Your Breast Area|Tightness in your breast area	A question about how often an individual has experienced tightness in their breast area.			Intellectual Product	BREAST-Q
C140765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140765>	C173791|C173219|C118873	How Often Experienced Nagging Feeling in Your Breast Area Question|How Often Experienced Nagging Feeling in Your Breast Area|Nagging feeling in your breast area	A question about how often an individual has experienced a nagging feeling in their breast area.			Intellectual Product	BREAST-Q
C140767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140767>	C175990|C173791|C118873	How Often Experienced Pulling in Your Breast Area Question|How Often Experienced Pulling in Your Breast Area|Pulling in your breast area	A question about how often an individual has experienced pulling in their breast area.			Intellectual Product	BREAST-Q
C140768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140768>	C175990|C173791|C118873	How Often Experienced Tenderness in Your Breast Area Question|How Often Experienced Tenderness in Your Breast Area|Tenderness in your breast area	A question about how often an individual has experienced tenderness in their breast area.			Intellectual Product	BREAST-Q
C140769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140769>	C175990|C173791|C173346|C118873	How Often Experienced Sharp Pains in Your Breast Area Question|How Often Experienced Sharp Pains in Your Breast Area|Sharp pains in your breast area	A question about how often an individual has experienced sharp pains in their breast area.			Intellectual Product	BREAST-Q
C14076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14076>	C13379	DH Domain|DBL-Homology Domain|Dbl Homology Domain|RhoGEF Domain	The Dbl homology (DH) or RhoGEF domain consists of a 150 amino acid region that induces Rho family GTPases to displace GDP. This effectively activates the Rho GTPase by allowing binding to GTP, which is in excess over GDP in the cell. The DH domain is invariably proceeded by a pleckstrin homology (PH) domain. While not absolutely required for catalysis of nucleotide exchange, the PH domain appears to greatly increase catalytic efficiency in many cases. Rho proteins control actin dynamics, gene expression, membrane trafficking, growth factor signaling, and cellular transformation. Proteins encoding DH domains (RhoGEFs) also play a role in these events as they function as the primary activators of Rho GTPases. In fact, many RhoGEFs were identified based on their transforming activity, which was abrogated upon disruption of their DH domain. (Pawson Lab, SLRI, Mount Sinai Hospital, 2003)			Amino Acid Sequence	
C140770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140770>	C175990|C173791|C173219|C118873	How Often Experienced Aching Feeling in Your Breast Area Question|Aching feeling in your breast area|How Often Experienced Aching Feeling in Your Breast Area	A question about how often an individual has experienced an aching feeling in their breast area.			Intellectual Product	BREAST-Q
C140771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140771>	C173791|C173219|C118873	How Often Experienced Throbbing Feeling in Your Breast Area Question|How Often Experienced Throbbing Feeling in Your Breast Area|Throbbing feeling in your breast area	A question about how often an individual has experienced a throbbing feeling in their breast area.			Intellectual Product	BREAST-Q
C140772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140772>	C173791|C173593|C118873	How Often Experienced Swelling of Arm on Side You Had Breast Surgery Question|How Often Experienced Swelling of Arm on Side You Had Breast Surgery|Swelling of the arm (lymphedema) on the side(s) that you had your breast surgery	A question about how often an individual has experienced swelling of the arm on the side they had breast surgery.			Intellectual Product	BREAST-Q
C140773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140773>	C140469	Lacrimal Gland Carcinoma TNM Finding v8	A finding about one or more characteristics of carcinomas of the lacrimal gland, following the rules of the TNM AJCC v8 classification system. There is no AJCC staging system for carcinomas of the nasolacrimal sac. Lymphomas are staged according to the classification for ocular adnexal lymphomas. No stage groupings are currently recommended for lacrimal gland carcinomas. (from AJCC 8th Ed.)			Finding	
C140774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140774>	C140773	Lacrimal Gland Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of lacrimal gland carcinoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C140775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140775>	C140774	Lacrimal Gland Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of lacrimal gland carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C140776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140776>	C140775	Lacrimal Gland Carcinoma cM0 TNM Finding v8	Lacrimal gland carcinoma with no distant metastasis. (from AJCC 8th Ed.)			Finding	
C140777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140777>	C140775	Lacrimal Gland Carcinoma cM1 TNM Finding v8	Lacrimal gland carcinoma with distant metastasis. (from AJCC 8th Ed.)			Finding	
C140778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140778>	C140773	Lacrimal Gland Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of lacrimal gland carcinoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C140779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140779>	C140778	Lacrimal Gland Carcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of lacrimal gland carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C14077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14077>	C13379	PH Domain|Pleckstrin Homology Domain|Pleckstrin-Homology Domain	Pleckstrin-homology (PH) domains are protein modules of approximately 120 amino acids found in a wide variety of signaling proteins in organisms ranging from yeast to humans. Some PH domains bind with high affinity (low mM or nM Kd) to specific phosphoinositides such as phosphatidyl-inositol (PI) -4,5-bisphosphate, PI-3,4-P2 or PI-3,4,5-P3. Binding to phosphoinositides may allow PH proteins to respond to lipid messengers for example by relocation to membranes. The C-termini of some PH domains have also been reported to bind the beta/lambda subunits of heterotrimeric G proteins.			Amino Acid Sequence	
C140780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140780>	C140779	Lacrimal Gland Carcinoma pM1 TNM Finding v8	Lacrimal gland carcinoma with distant metastasis. (from AJCC 8th Ed.)			Finding	
C140781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140781>	C140778	Lacrimal Gland Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of lacrimal gland carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C140782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140782>	C140781	Lacrimal Gland Carcinoma pTX TNM Finding v8	Primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C140783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140783>	C140781	Lacrimal Gland Carcinoma pT0 TNM Finding v8	No evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C140784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140784>	C140781	Lacrimal Gland Carcinoma pT1 TNM Finding v8	Lacrimal gland carcinoma with tumor measuring 2 cm or less in greatest dimension with or without extraglandular extension into the orbital soft tissue. (from AJCC 8th Ed.)			Finding	
C140785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140785>	C140784	Lacrimal Gland Carcinoma pT1a TNM Finding v8	Lacrimal gland carcinoma with tumor measuring 2 cm or less in greatest dimension with or without extraglandular extension into the orbital soft tissue with no periosteal or bone involvement. (from AJCC 8th Ed.)			Finding	
C140786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140786>	C140784	Lacrimal Gland Carcinoma pT1b TNM Finding v8	Lacrimal gland carcinoma with tumor measuring 2 cm or less in greatest dimension with or without extraglandular extension into the orbital soft tissue with periosteal involvement only. (from AJCC 8th Ed.)			Finding	
C140787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140787>	C140784	Lacrimal Gland Carcinoma pT1c TNM Finding v8	Lacrimal gland carcinoma with tumor measuring 2 cm or less in greatest dimension with or without extraglandular extension into the orbital soft tissue with periosteal and bone involvement. (from AJCC 8th Ed.)			Finding	
C140788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140788>	C140781	Lacrimal Gland Carcinoma pT2 TNM Finding v8	Lacrimal gland carcinoma with tumor measuring more than 2 cm but 4 cm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C140789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140789>	C140788	Lacrimal Gland Carcinoma pT2a TNM Finding v8	Lacrimal gland carcinoma with tumor measuring more than 2 cm but 4 cm or less in greatest dimension with no periosteal or bone involvement. (from AJCC 8th Ed.)			Finding	
C14078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14078>	C13426	RHO Effector Domain|HR1 Domain|Hr1 Repeat|REM Repeat	The REM repeat, which is also called rho effector or HR1 domain, was first described as a three times repeated homology region of the N-terminal non-catalytic part of protein kinase PRK1(PKN). The first two of these repeats were later shown to bind the small G protein rho known to activate PKN in its GTP-bound form. Similar rho-binding domains also occur in a number of other protein kinases and in the rho-binding proteins rhophilin and rhotekin. Recently, the structure of the N-terminal REM repeat complexed with RhoA has been determined by X-ray crystallography. It forms an antiparallel coiled-coil fold termed an ACC finger.			Amino Acid Sequence	
C140790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140790>	C140788	Lacrimal Gland Carcinoma pT2b TNM Finding v8	Lacrimal gland carcinoma with tumor measuring more than 2 cm but 4 cm or less in greatest dimension with periosteal involvement only. (from AJCC 8th Ed.)			Finding	
C140791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140791>	C140788	Lacrimal Gland Carcinoma pT2c TNM Finding v8	Lacrimal gland carcinoma with tumor measuring more than 2 cm but 4 cm or less in greatest dimension with periosteal and bone involvement. (from AJCC 8th Ed.)			Finding	
C140792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140792>	C140781	Lacrimal Gland Carcinoma pT3 TNM Finding v8	Lacrimal gland carcinoma with tumor measuring more than 4 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C140793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140793>	C140792	Lacrimal Gland Carcinoma pT3a TNM Finding v8	Lacrimal gland carcinoma with tumor measuring more than 4 cm in greatest dimension with no periosteal or bone involvement. (from AJCC 8th Ed.)			Finding	
C140794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140794>	C140792	Lacrimal Gland Carcinoma pT3b TNM Finding v8	Lacrimal gland carcinoma with tumor measuring more than 4 cm in greatest dimension with periosteal involvement only. (from AJCC 8th Ed.)			Finding	
C140795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140795>	C140792	Lacrimal Gland Carcinoma pT3c TNM Finding v8	Lacrimal gland carcinoma with tumor measuring more than 4 cm in greatest dimension with periosteal and bone involvement. (from AJCC 8th Ed.)			Finding	
C140796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140796>	C140781	Lacrimal Gland Carcinoma pT4 TNM Finding v8	Lacrimal gland carcinoma with involvement of adjacent structures, including sinuses, temporal fossa, pterygoid fossa, superior orbital fissure, cavernous sinus, or brain. (from AJCC 8th Ed.)			Finding	
C140797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140797>	C173704|C173086|C118873	How Often Feel Confident Sexually Question|Confident sexually|How Often Feel Confident Sexually	A question about how often an individual feels confident sexually.			Intellectual Product	BREAST-Q
C140798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140798>	C140796	Lacrimal Gland Carcinoma pT4a TNM Finding v8	Lacrimal gland carcinoma with involvement of adjacent structures, including sinuses, temporal fossa, pterygoid fossa, superior orbital fissure, cavernous sinus, or brain and measuring 2 cm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C140799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140799>	C140796	Lacrimal Gland Carcinoma pT4b TNM Finding v8	Lacrimal gland carcinoma with involvement of adjacent structures, including sinuses, temporal fossa, pterygoid fossa, superior orbital fissure, cavernous sinus, or brain and measuring more than 2 cm but 4 cm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C14079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14079>	C13425	Transcriptional Activation Domain	A DNA-binding domain binds to a specific DNA sequence and a transcriptional activation domain interacts with the basal transcriptional machinery. An association of a transcriptional activation domain with a DNA-binding domain promotes the assembly of RNA polymerase II complexes at the TATA box and increase transcription. (NCI)			Amino Acid Sequence	
C1407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1407>	C1757	RG 13022|RG-13022|Tyrphostin RG-13022	A tyrosine kinase inhibitor that selectively inhibits epidermal growth factor receptor, epidermal factor-stimulated HER14 cell proliferation, and tumor growth in vivo. (NCI)			Organic Chemical|Pharmacologic Substance	
C140800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140800>	C173704|C173160|C118873	How Often Feel Sexually Attractive in Your Clothes Question|How Often Feel Sexually Attractive in Your Clothes|Sexually attractive in your clothes	A question about how often an individual feels sexually attractive in their clothes.			Intellectual Product	BREAST-Q
C140801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140801>	C140796	Lacrimal Gland Carcinoma pT4c TNM Finding v8	Lacrimal gland carcinoma with involvement of adjacent structures, including sinuses, temporal fossa, pterygoid fossa, superior orbital fissure, cavernous sinus, or brain and measuring more than 4 cm in greatest dimension. (from AJCC 8th Ed.)			Finding	
C140802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140802>	C140778	Lacrimal Gland Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of lacrimal gland carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C140803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140803>	C140802	Lacrimal Gland Carcinoma pNX TNM Finding v8	Lacrimal gland carcinoma in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C140804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140804>	C140802	Lacrimal Gland Carcinoma pN0 TNM Finding v8	Lacrimal gland carcinoma with no regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C140805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140805>	C140802	Lacrimal Gland Carcinoma pN1 TNM Finding v8	Lacrimal gland carcinoma with regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C140806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140806>	C173704|C173160|C118873	How Often Feel Comfortable or at Ease During Sexual Activity Question|Comfortable/at ease during sexual activity|How Often Feel Comfortable or at Ease During Sexual Activity	A question about how often an individual feels comfortable or at ease during sexual activity.			Intellectual Product	BREAST-Q
C140807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140807>	C173792|C173704|C118873	How Often Feel Satisfied with Your Sex-Life Question|How Often Feel Satisfied with Your Sex-Life|Satisfied with your sex-life	A question about how often an individual feels satisfied with their sex-life.			Intellectual Product	BREAST-Q
C140808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140808>	C173791|C173704|C173086|C118873	How Often Feel Confident Sexually About How Your Breast Area Looks When Unclothed Question|Confident sexually about how your breast area looks when unclothed|How Often Feel Confident Sexually About How Your Breast Area Looks When Unclothed	A question about how often an individual feels confident sexually about how their breast area looks when unclothed.			Intellectual Product	BREAST-Q
C140809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140809>	C173704|C173160|C118873	How Often Feel Sexually Attractive When Unclothed Question|How Often Feel Sexually Attractive When Unclothed|Sexually attractive when unclothed	A question about how often an individual feels sexually attractive when unclothed.			Intellectual Product	BREAST-Q
C14080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14080>	C13453	DAG/PE-Binding Domain|C1 Domain|DAG Binding Domain|Diacylglycerol Binding Domain|Phorbol Ester Binding Domain|Protein Kinase C Conserved Region 1 Domain	The cysteine-rich N-terminal DAG/PE (Diacylglycerol/Phorbol Ester)-Binding (C1) Domain of PKC isoforms interacts with phorbol ester or with the phospholipid-derived second messenger diacylglycerol. C1 contains one or two copies of a Cys-rich domain about 50 amino-acid residues long; the domain binds two zinc ions, probably involving the conserved cysteines and histidines. Bound to DAG, C1 domains are involved in recruitment of proteins to the membrane via basic residues that interact with lipid head groups. Part of the domain contains two beta sheets that form a cavity and a short C-terminal alpha helix; another contains two zinc-binding sites that maintain the domain fold. Binding of diacylglycerol, or phorbol ester, to the domain results in modification of protein function. (NCI)			Amino Acid Sequence	
C140810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140810>	C173050	Breast Cancer Surgeon was Professional Question|Breast Cancer Surgeon was Professional|Was professional	A question about whether an individual's breast cancer surgeon was professional.			Intellectual Product	BREAST-Q
C140811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140811>	C173050	Breast Cancer Surgeon Gave You Confidence Question|Breast Cancer Surgeon Gave You Confidence|Gave you confidence	A question about whether an individual's breast cancer surgeon gave them confidence.			Intellectual Product	BREAST-Q
C140812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140812>	C174127|C173050	Breast Cancer Surgeon Involved You in Decision Making Question|Breast Cancer Surgeon Involved You in Decision Making|Involved you in the decision-making process	A question about whether an individual's breast cancer surgeon involved them in the decision-making process.			Intellectual Product	BREAST-Q
C140813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140813>	C173050	Breast Cancer Surgeon was Reassuring Question|Breast Cancer Surgeon was Reassuring|Was reassuring	A question about whether an individual's breast cancer surgeon was reassuring.			Intellectual Product	BREAST-Q
C140814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140814>	C173050	Breast Cancer Surgeon Answered all Questions Question|Answered all your questions|Breast Cancer Surgeon Answered all Questions	A question about whether an individual's breast cancer surgeon answered all their questions.			Intellectual Product	BREAST-Q
C140815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140815>	C173160|C173050	Breast Cancer Surgeon Made You Comfortable Question|Breast Cancer Surgeon Made You Comfortable|Made you feel comfortable	A question about whether an individual's breast cancer surgeon made them feel comfortable.			Intellectual Product	BREAST-Q
C140816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140816>	C173050	Breast Cancer Surgeon was Thorough Question|Breast Cancer Surgeon was Thorough|Was thorough	A question about whether an individual's breast cancer surgeon was thorough.			Intellectual Product	BREAST-Q
C140817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140817>	C173050	Breast Cancer Surgeon Was Easy to Talk to Question|Breast Cancer Surgeon Was Easy to Talk to|Was easy to talk to	A question about whether an individual's breast cancer surgeon was easy to talk to.			Intellectual Product	BREAST-Q
C140818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140818>	C173050	Breast Cancer Surgeon Understood what You Wanted Question|Breast Cancer Surgeon Understood what You Wanted|Understood what you wanted	A question about whether an individual's breast cancer surgeon understood what they wanted.			Intellectual Product	BREAST-Q
C140819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140819>	C173050	Breast Cancer Surgeon was Sensitive Question|Breast Cancer Surgeon was Sensitive|Was sensitive	A question about whether an individual's breast cancer surgeon was sensitive.			Intellectual Product	BREAST-Q
C14081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14081>	C13671	Estrogen Binding Domain	The Estrogen Binding Domain is an all-helical ligand-binding domain within its nuclear hormone receptor. Steroid hormones, such as estrogen, and their receptors regulate eukaryotic gene expression, affecting target cell proliferation and differentiation. Hormone-receptor complexes recognize discrete DNA sequences upstream of transcription start sites. (NCI)			Amino Acid Sequence	
C140820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140820>	C173050	Breast Cancer Surgeon Made Time for Your Concerns Question|Breast Cancer Surgeon Made Time for Your Concerns|Made time for your concerns	A question about whether an individual's breast cancer surgeon made time for their concerns.			Intellectual Product	BREAST-Q
C140821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140821>	C173050	Breast Cancer Surgeon was Available when You had Concerns Question|Breast Cancer Surgeon was Available when You had Concerns|Was available when you had concerns	A question about whether an individual's breast cancer surgeon was available when they had concerns.			Intellectual Product	BREAST-Q
C140822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140822>	C173145	Medical Team was Professional Question|Medical Team was Professional|Were Professional	A question about whether an individual's medical team was professional.			Intellectual Product	BREAST-Q
C140823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140823>	C173145	Medical Team Treated You with Respect Question|Medical Team Treated You with Respect|Treated you with respect	A question about whether an individual's medical team treated them with respect.			Intellectual Product	BREAST-Q
C140824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140824>	C173145	Medical Team was Knowledgeable Question|Medical Team was Knowledgeable|Were knowledgeable	A question about whether an individual's medical team was knowledgeable.			Intellectual Product	BREAST-Q
C140825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140825>	C173145	Medical Team was Friendly and Kind Question|Medical Team was Friendly and Kind|Were friendly and kind	A question about whether an individual's medical team was friendly and kind.			Intellectual Product	BREAST-Q
C140826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140826>	C173160	Medical Team Made You Feel Comfortable Question|Made you feel comfortable|Medical Team Made You Feel Comfortable	A question about whether an individual's medical team made them feel comfortable.			Intellectual Product	BREAST-Q
C140827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140827>	C173145	Medical Team was Thorough Question|Medical Team was Thorough|Were Thorough	A question about whether an individual's medical team was thorough.			Intellectual Product	BREAST-Q
C140828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140828>	C173145	Medical Team Made Time for Your Concerns Question|Made time for your concerns|Medical Team Made Time for Your Concerns	A question about whether an individual's medical team made time for their concerns.			Intellectual Product	BREAST-Q
C140829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140829>	C91102	Office Staff was Professional Question|Office Staff was Professional|Were Professional	A question about whether an individual's office staff was professional.			Intellectual Product	BREAST-Q
C14082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14082>	C13671	GTP Binding Domain	Associated with binding and hydrolysis of GTP, the highly conserved GTP-Binding Domain is typically found in signaling RAS-related proteins of the small GTPase superfamily. (NCI)			Amino Acid Sequence	
C140830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140830>	C91102	Office Staff Treated You with Respect Question|Office Staff Treated You with Respect|Treated you with respect	A question about whether an individual's office staff treated them with respect.			Intellectual Product	BREAST-Q
C140831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140831>	C91102	Office Staff was Knowledgeable Question|Office Staff was Knowledgeable|Were knowledgeable	A question about whether an individual's office staff was knowledgeable.			Intellectual Product	BREAST-Q
C140832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140832>	C140469	Orbital Sarcoma TNM Finding v8	A finding about one or more characteristics of orbital sarcoma, following the rules of the TNM AJCC v8 classification system. This classification does not apply to osseous and cartilaginous tumors arising in bone (are staged according to the classification for bone), secondary tumors that arise in adjacent periorbital sites with orbital invasion (are staged according to the classification for primary site of tumor), lacrimal gland carcinomas (are staged according to the classification for lacrimal gland carcinoma), and lacrimal gland sarcomas (are staged according to the classification for soft tissue sarcoma of the head and neck). There is no proposal for anatomic stage and prognostic groups for orbital sarcomas at this time. (from AJCC 8th Ed.)			Finding	
C140833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140833>	C140832	Orbital Sarcoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of orbital sarcoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C140834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140834>	C140833	Orbital Sarcoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of orbital sarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C140835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140835>	C140834	Orbital Sarcoma cM0 TNM Finding v8	Orbital sarcoma with no distant metastasis. (from AJCC 8th Ed.)			Finding	
C140836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140836>	C140834	Orbital Sarcoma cM1 TNM Finding v8	Orbital sarcoma with distant metastasis. (from AJCC 8th Ed.)			Finding	
C140837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140837>	C140832	Orbital Sarcoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of orbital sarcoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C140838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140838>	C140837	Orbital Sarcoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of orbital sarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C140839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140839>	C140838	Orbital Sarcoma pM1 TNM Finding v8	Orbital sarcoma with distant metastasis. (from AJCC 8th Ed.)			Finding	
C14083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14083>	C13187	Basolateral Sorting Signal|BASS	The polymeric immunoglobulin receptor is a model system to study protein traffic in epithelial cells. This receptor travels first to the basolateral surface where it can bind polymeric IgA or IgM. The receptor is then endocytosed and delivered to endosomes. The receptor is sorted into transcytotic vesicles which are exocytosed at the apical surface. The 103 amino acid cytoplasmic domain of the receptor contains several sorting signals. The 17 residues closest to the membrane are an autonomous signal for basolateral sorting. For endocytosis there are two signals, both of which contain tyrosines. Finally, transcytosis is signaled by serine phosphorylation. (From PubMed PMID1813030 and NCI)			Amino Acid Sequence	
C140840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140840>	C140837	Orbital Sarcoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of orbital sarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C140841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140841>	C140840	Orbital Sarcoma pTX TNM Finding v8	Primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C140842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140842>	C140840	Orbital Sarcoma pT0 TNM Finding v8	No evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C140843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140843>	C140840	Orbital Sarcoma pT1 TNM Finding v8	Orbital sarcoma with tumor measuring 2 cm or less in greatest dimension. (from AJCC 8th Ed.)			Finding	
C140844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140844>	C140840	Orbital Sarcoma pT2 TNM Finding v8	Orbital sarcoma with tumor measuring more than 2 cm in greatest diameter without invasion of bony walls or globe. (from AJCC 8th Ed.)			Finding	
C140845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140845>	C140840	Orbital Sarcoma pT3 TNM Finding v8	Orbital sarcoma with tumor of any size with invasion of bony walls. (from AJCC 8th Ed.)			Finding	
C140846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140846>	C140840	Orbital Sarcoma pT4 TNM Finding v8	Orbital sarcoma with tumor of any size with invasion of globe or periorbital structures, including eyelid, conjunctiva, temporal fossa, nasal cavity, paranasal sinuses, and/or central nervous system. (from AJCC 8th Ed.)			Finding	
C140847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140847>	C140837	Orbital Sarcoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of orbital sarcoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C140848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140848>	C140847	Orbital Sarcoma pNX TNM Finding v8	Orbital sarcoma in which the regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C140849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140849>	C140847	Orbital Sarcoma pN0 TNM Finding v8	Orbital sarcoma with no regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C14084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14084>	C13379	KDEL Motif|KDEL Domain	A motif found at the C termini of several luminal proteins of the ER that serves to mediate the retention of resident proteins of the ER lumen through retrieval from post-ER compartments ER via a transport mechanism involving vesicular and tubular elements.			Amino Acid Sequence	
C140850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140850>	C140847	Orbital Sarcoma pN1 TNM Finding v8	Orbital sarcoma with regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C140851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140851>	C140469	Ocular Adnexal Lymphoma TNM Finding v8	A finding about one or more characteristics of ocular adnexal lymphoma, following the rules of the TNM AJCC v8 classification system. The lymphomas staged according to this system are primary lymphomas arising in the ocular adnexa-namely, the conjunctiva, eyelids, lacrimal gland, lacrimal drainage apparatus, and other orbital tissues surrounding the eye. Secondary ocular adnexal lymphomas and intraocular lymphomas are staged according to the classification for Hodgkin and non-Hodgkin lymphoma. There is no prognostic stage grouping for ocular adnexal lymphomas. (from AJCC 8th Ed.)			Finding	
C140852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140852>	C140851	Ocular Adnexal Lymphoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of ocular adnexal lymphoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C140853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140853>	C140852	Ocular Adnexal Lymphoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of ocular adnexal lymphoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C140854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140854>	C140853	Ocular Adnexal Lymphoma cM0 TNM Finding v8	Ocular adnexal lymphoma with no evidence of involvement of other extranodal sites. (from AJCC 8th Ed.)			Finding	
C140855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140855>	C140853	Ocular Adnexal Lymphoma cM1a TNM Finding v8	Ocular adnexal lymphoma with noncontiguous involvement of tissues or organs external to the ocular adnexa (e.g., parotid glands, submandibular gland, lung, liver, spleen, kidney, breast). (from AJCC 8th Ed.)			Finding	
C140856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140856>	C140853	Ocular Adnexal Lymphoma cM1b TNM Finding v8	Ocular adnexal lymphoma with lymphomatous involvement of the bone marrow. (from AJCC 8th Ed.)			Finding	
C140857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140857>	C140853	Ocular Adnexal Lymphoma cM1c TNM Finding v8	Ocular adnexal lymphoma with both M1a and M1b involvement. (from AJCC 8th Ed.)			Finding	
C140858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140858>	C140851	Ocular Adnexal Lymphoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of ocular adnexal lymphoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C140859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140859>	C140858	Ocular Adnexal Lymphoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of ocular adnexal lymphoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C14085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14085>	C13379	DIX Domain	A domain involved in homo- and hetero-oligomerization.			Amino Acid Sequence	
C140860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140860>	C140859	Ocular Adnexal Lymphoma pM1a TNM Finding v8	Ocular adnexal lymphoma with noncontiguous involvement of tissues or organs external to the ocular adnexa (e.g., parotid glands, submandibular gland, lung, liver, spleen, kidney, breast). (from AJCC 8th Ed.)			Finding	
C140861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140861>	C140859	Ocular Adnexal Lymphoma pM1b TNM Finding v8	Ocular adnexal lymphoma with lymphomatous involvement of the bone marrow. (from AJCC 8th Ed.)			Finding	
C140862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140862>	C140859	Ocular Adnexal Lymphoma pM1c TNM Finding v8	Ocular adnexal lymphoma with both M1a and M1b involvement. (from AJCC 8th Ed.)			Finding	
C140863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140863>	C140858	Ocular Adnexal Lymphoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of ocular adnexal lymphoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C140864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140864>	C140863	Ocular Adnexal Lymphoma pTX TNM Finding v8	Lymphoma extent not specified. (from AJCC 8th Ed.)			Finding	
C140865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140865>	C140863	Ocular Adnexal Lymphoma pT0 TNM Finding v8	No evidence of lymphoma. (from AJCC 8th Ed.)			Finding	
C140866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140866>	C140863	Ocular Adnexal Lymphoma pT1 TNM Finding v8	Ocular adnexal lymphoma involving the conjunctiva alone without eyelid or orbital involvement. (from AJCC 8th Ed.)			Finding	
C140867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140867>	C140863	Ocular Adnexal Lymphoma pT2 TNM Finding v8	Ocular adnexal lymphoma with orbital involvement with or without conjunctival involvement. (from AJCC 8th Ed.)			Finding	
C140868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140868>	C140863	Ocular Adnexal Lymphoma pT3 TNM Finding v8	Ocular adnexal lymphoma with preseptal eyelid involvement with or without orbital involvement and with or without conjunctival involvement. (from AJCC 8th Ed.)			Finding	
C140869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140869>	C140863	Ocular Adnexal Lymphoma pT4 TNM Finding v8	Orbital adnexal lymphoma and extraorbital lymphoma extending beyond the orbit to adjacent structures, such as bone, maxillofacial sinuses, and brain. (from AJCC 8th Ed.)			Finding	
C14086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14086>	C13187	Mitochondrial Import Sequence|MTS|Mitochondrial Targeting Signal	An amino acid sequence that directs the post-translational transport of a protein to the mitochondria. The sequence contains an alternating pattern of hydrophobic and positively charged amino acids.			Amino Acid Sequence	
C140870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140870>	C140858	Ocular Adnexal Lymphoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of ocular adnexal lymphoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C140871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140871>	C140870	Ocular Adnexal Lymphoma pNX TNM Finding v8	Involvement of lymph nodes not assessed. (from AJCC 8th Ed.)			Finding	
C140872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140872>	C140870	Ocular Adnexal Lymphoma pN0 TNM Finding v8	Ocular adnexal lymphoma with no evidence of lymph node involvement. (from AJCC 8th Ed.)			Finding	
C140873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140873>	C140870	Ocular Adnexal Lymphoma pN1 TNM Finding v8	Ocular adnexal lymphoma with involvement of lymph node region or regions draining the ocular adnexal structures and superior to the mediastinum (preauricular, parotid, submandibular, and cervical nodes). (from AJCC 8th Ed.)			Finding	
C140874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140874>	C140873	Ocular Adnexal Lymphoma pN1a TNM Finding v8	Ocular adnexal lymphoma with involvement of a single lymph node region superior to the mediastinum. (from AJCC 8th Ed.)			Finding	
C140875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140875>	C140873	Ocular Adnexal Lymphoma pN1b TNM Finding v8	Ocular adnexal lymphoma with involvement of two or more lymph node regions, superior to the mediastinum. (from AJCC 8th Ed.)			Finding	
C140876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140876>	C140870	Ocular Adnexal Lymphoma pN2 TNM Finding v8	Ocular adnexal lymphoma with involvement of lymph node regions of the mediastinum. (from AJCC 8th Ed.)			Finding	
C140877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140877>	C140870	Ocular Adnexal Lymphoma pN3 TNM Finding v8	Ocular adnexal lymphoma with diffuse or disseminated involvement of peripheral and central lymph node regions. (from AJCC 8th Ed.)			Finding	
C140878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140878>	C91102	Office Staff was Friendly and Kind Question|Office Staff was Friendly and Kind|Were friendly and kind	A question about whether an individual's office staff was friendly and kind.			Intellectual Product	BREAST-Q
C140879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140879>	C173160	Office Staff Made You Feel Comfortable Question|Made you feel comfortable|Office Staff Made You Feel Comfortable	A question about whether an individual's office staff made them feel comfortable.			Intellectual Product	BREAST-Q
C14087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14087>	C13187	Membrane Localization Motif|Membrane Localization Domain	An amino acid sequence that directs a protein to become localized in or at the cell membrane. This targeting is determined either by the presence of hydrophobic amino acid residues or by post-translational modification that adds a hydrophobic molecule to the protein at this site.			Amino Acid Sequence	
C140880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140880>	C91102	Office Staff was Thorough Question|Office Staff was Thorough|Were Thorough	A question about whether an individual's office staff was thorough.			Intellectual Product	BREAST-Q
C140881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140881>	C91102	Office Staff Made Time for Your Concerns Question|Made time for your concerns	A question about whether an individual's office staff made time for their concerns.			Intellectual Product	BREAST-Q
C140882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140882>	C20993	Graded Prognostic Assessment|GPA	A prognostic index for patients with brain metastases. The GPA incorporates age, Karnofsky performance status, number of extracranial metastases, and number of brain metastases.			Intellectual Product	
C140883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140883>	C140882	Disease-specific Graded Prognostic Assessment|DS-GPA|Diagnosis-specific Graded Prognostic Assessment	A 4-tiered score that stratifies patients with common primary tumours metastasizing to the brain (malignant melanoma, lung, breast, kidney and gastrointestinal cancers) into subgroups with different prognoses. It takes into account that brain metastases from different primary tumor sites respond differently to radiation therapy.			Intellectual Product	
C140884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140884>	C217122	Graded Prognostic Assessment Score|DS-GPA Score|Disease-specific Graded Prognostic Assessment Score|GPS Score	A 4-tiered score that stratifies patients with common primary tumors metastasizing to the brain (malignant melanoma, lung, breast, kidney and gastrointestinal cancers) into subgroups with different prognoses. The score is based on age, Karnofsky performance status, number of extracranial metastases, number of brain metastases, and site of primary tumor.			Intellectual Product	
C140885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140885>	C49165	Robot-Assisted Surgery|Navigation and Robotics|Navigation and Robotics|Robot Assisted|Robotic Surgery	A surgical technique that uses a specially designed robotic system to aid with the surgical procedure.	Robot-Assisted Surgery		Therapeutic or Preventive Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Codelists Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Treatments Codelist|CPTAC Uveal Melanoma Baseline Form|CTRP Intervention Terminology|CTRP Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table
C140886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140886>	C15357	Ivor Lewis Esophagectomy|ILE	A type of esophagectomy where an esophageal tumor is removed through an abdominal incision and a right thoracotomy. The esophagogastric anastomosis is located in the upper chest.			Therapeutic or Preventive Procedure	
C140887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140887>	C15357	McKeown Esophagectomy|ME|McKeown Procedure|Tri-incisional Esophagectomy	A type of esophagectomy that involves a right thoracotomy, laparotomy, and left neck incision for creation of a cervical anastomosis. It is appropriate in patients with tumors located above the gastro-esophageal junction up to the level of the clavicles and is the preferred approach for locally advanced esophageal carcinomas.			Therapeutic or Preventive Procedure	
C140888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140888>	C15357	Transhiatal Esophagectomy	A type of esophagectomy where the esophageal tumor is removed through an abdominal incision and a left neck incision, without a thoracotomy. The esophagogastric anastomosis is located in the neck.			Therapeutic or Preventive Procedure	
C140889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140889>	C20993	Mandard Grading System	A tumor regression grading (TRG) system commonly used for upper gastrointestinal carcinomas.			Intellectual Product	
C14088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14088>	C14050|C13187	Monobasic Proteolytic Cleavage Site	A site on a protein that is a target for enzymatic cleavage, where the residue on the amino terminal side of the cleavage site is a basic amino acid that is not adjacent to other basic amino acids.			Amino Acid Sequence	
C140890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140890>	C222042	Tumor Regression Grade 1|TRG 1	Complete regression; fibrosis without detectable tumor.			Intellectual Product	
C140891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140891>	C222042	Tumor Regression Grade 2|TRG 2	Presence of fibrosis with scattered tumor cells.			Intellectual Product	
C140892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140892>	C222042	Tumor Regression Grade 3|TRG 3	Presence of fibrosis and tumor cells with a preponderance of fibrosis.			Intellectual Product	
C140893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140893>	C222042	Tumor Regression Grade 4|TRG 4	Presence of fibrosis and tumor cells with preponderance of tumor cells.			Intellectual Product	
C140894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140894>	C222042	Tumor Regression Grade 5|TRG 5	Presence of tumor without changes of regression.			Intellectual Product	
C140895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140895>	C48233	Endocrine System Cancer TNM Finding v8	A finding about one or more characteristics of endocrine system cancer, following the rules of the TNM AJCC v8 classification system.			Finding	
C140896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140896>	C140895	Thyroid Carcinoma TNM Finding v8	A finding about one or more characteristics of thyroid carcinoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C140897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140897>	C140896	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma TNM Finding v8	A finding about one or more characteristics of papillary, follicular, Hurthle cell, poorly differentiated, and anaplastic (undifferentiated) thyroid carcinoma, following the rules of the TNM AJCC v8 classification system. Medullary thyroid cancers are staged according to the classification for thyroid-medullary. Thyroid lymphomas are staged according to the classification for Hodgkin and non-Hodgkin lymphoma. There are no AJCC staging systems for thyroid cancer arising from thyroglossal duct cyst and thyroid cancer in malignant struma ovarii. (from AJCC 8th Ed.)			Finding	
C140898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140898>	C140897	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma Clinical TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of papillary, follicular, Hurthle cell, poorly differentiated, and anaplastic thyroid carcinoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C140899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140899>	C140898	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma Clinical Distant Metastasis TNM Finding v8|Clinical Distant Metastasis Status (cM)|Differentiated and Anaplastic Thyroid Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of papillary, follicular, Hurthle cell, poorly differentiated, and anaplastic thyroid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C14089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14089>	C13187	Nuclear Localization Signal|NLS	An amino acid sequence that directs the post-translational transport of a protein to the nucleus. The sequence contains positively charged amino acids such as arginine and lysine.			Amino Acid Sequence	
C1408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1408>	C280	Rifabutin|LM-427|Mycobutin|Mycobutin|RIFABUTIN|rifabutin	A semisynthetic ansamycin antibiotic with potent antimycobacterial properties.  Rifabutin inhibits bacterial DNA-dependent RNA polymerase, thereby suppressing the initiation of RNA formation and leading to inhibition of RNA synthesis and transcription. (NCI04)			Antibiotic|Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C140900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140900>	C140899	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma cM0 TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma cM0 TNM Finding v8	No distant metastasis. (from AJCC 8th Ed.)			Finding	
C140901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140901>	C140899	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma cM1 TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma cM1 TNM Finding v8|cM1	Distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C140902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140902>	C140898	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma Clinical Regional Lymph Nodes TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma Clinical Regional Lymph Nodes TNM Finding v8	A clinical finding about one or more characteristics of papillary, follicular, Hurthle cell, poorly differentiated, and anaplastic thyroid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C140903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140903>	C140902	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma cNX TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma cNX TNM Finding v8	Regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C140904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140904>	C140902	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma cN0 TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma cN0 TNM Finding v8	No evidence of locoregional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C140905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140905>	C140904	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma cN0b TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma cN0b TNM Finding v8	No radiologic or clinical evidence of locoregional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C140906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140906>	C140902	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma cN1 TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma cN1 TNM Finding v8	Metastasis to regional nodes. (from AJCC 8th Ed.)			Finding	
C140907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140907>	C140906	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma cN1a TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma cN1a TNM Finding v8	Metastasis to level VI or VII (pretracheal, paratracheal, or prelaryngeal /Delphian, or upper mediastinal) lymph nodes. This can be unilateral or bilateral disease. (from AJCC 8th Ed.)			Finding	
C140908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140908>	C140906	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma cN1b TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma cN1b TNM Finding v8	Metastasis to unilateral, bilateral, or contralateral lateral neck lymph nodes (levels I, II, III, IV, or V) or retropharyngeal lymph nodes. (from AJCC 8th Ed.)			Finding	
C140909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140909>	C140897	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma Pathologic TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of papillary, follicular, Hurthle cell, poorly differentiated, and anaplastic thyroid carcinoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C14090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14090>	C13187	Signal Peptide|Leader Sequence|Signal Sequence	The N-terminal sequence of a secreted protein that interacts with a signal recognition particle and is required for transport through the cell membrane.			Amino Acid Sequence	
C140910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140910>	C140909	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma Pathologic Distant Metastasis TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma Pathologic Distant Metastasis TNM Finding v8|Pathologic Distant Metastasis Status (pM)	A pathologic finding about one or more characteristics of papillary, follicular, Hurthle cell, poorly differentiated, and anaplastic thyroid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C140911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140911>	C140910	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pM1 TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma pM1 TNM Finding v8|pM1	Distant metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C140912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140912>	C140909	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma Pathologic Primary Tumor TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma Pathologic Primary Tumor TNM Finding v8|Pathologic Primary Tumor Status (pT)	A pathologic finding about one or more characteristics of papillary, follicular, Hurthle cell, poorly differentiated, and anaplastic thyroid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C140913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140913>	C140912	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pTX TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma pTX TNM Finding v8|pTX	Primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C140914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140914>	C140912	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT0 TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma pT0 TNM Finding v8|pT0	No evidence of primary tumor. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C140915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140915>	C140912	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT1 TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma pT1 TNM Finding v8|pT1	Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C140916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140916>	C140915	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT1a TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma pT1a TNM Finding v8|pT1a	Tumor measuring 1 cm or less in greatest dimension limited to the thyroid. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C140917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140917>	C140915	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT1b TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma pT1b TNM Finding v8|pT1b	Tumor measuring more than 1 cm but 2 cm or less in greatest dimension limited to the thyroid. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C140918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140918>	C140912	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT2 TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma pT2 TNM Finding v8|pT2	Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C140919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140919>	C140912	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT3 TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma pT3 TNM Finding v8|pT3	Tumor measuring more than 4 cm in greatest dimension limited to the thyroid, or gross extrathyroidal extension invading only strap muscles. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C140920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140920>	C140919	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT3a TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma pT3a TNM Finding v8|pT3a	Tumor measuring more than 4 cm in greatest dimension limited to the thyroid. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C140921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140921>	C140919	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT3b TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma pT3b TNM Finding v8|pT3b	Gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles) from a tumor of any size. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C140922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140922>	C140912	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT4 TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma pT4 TNM Finding v8|pT4	Tumor of any size with gross extrathyroidal extension. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C140923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140923>	C140922	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT4a TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma pT4a TNM Finding v8|pT4a	Gross extrathyroidal extension invading subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve from a tumor of any size. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C140924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140924>	C140922	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pT4b TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma pT4b TNM Finding v8|pT4b	Gross extrathyroidal extension invading prevertebral fascia or encasing the carotid artery or mediastinal vessels from a tumor of any size. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C140925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140925>	C140909	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8|Pathologic Regional Lymph Node Status (pN)	A pathologic finding about one or more characteristics of papillary, follicular, Hurthle cell, poorly differentiated, and anaplastic thyroid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C140926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140926>	C140925	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pNX TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma pNX TNM Finding v8|pNX	Regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C140927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140927>	C140925	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pN0 TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma pN0 TNM Finding v8|pN0	No evidence of locoregional lymph node metastasis. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C140928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140928>	C140927	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pN0a TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma pN0a TNM Finding v8|pN0a	One or more cytologically or histologically confirmed benign lymph nodes. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C140929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140929>	C140925	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pN1 TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma pN1 TNM Finding v8|pN1	Metastasis to regional nodes. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C14092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14092>	C13720	KH Domain|K Homology Domain	First identified in human hnRNPK protein, the conserved KH Domain of around 45-70 amino acids is present in a variety of nucleic acid-binding proteins. The domain may bind RNA in vivo. KH motifs are found in one or multiple copies, interspersed with RGG repeats, that may function cooperatively or, in single motif proteins, independently. KH domains can be separated into two groups: type-1 (beta-alpha-alpha-beta-beta-alpha) and type-2 (alpha-beta-beta-alpha-alpha-beta). The VIGXXGXXI sequence is preserved in the RNA binding motif between helix 1 and 2 (type-1) and helix 2 and 3 (type-2). The beta sheets are supported by alpha helixes. (NCI)			Amino Acid Sequence	
C140930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140930>	C173792|C173791	Satisfaction with Shape of Your Reconstructed Breasts When Wearing Bra Question|Satisfaction with Shape of Your Reconstructed Breasts When Wearing Bra|The shape of your reconstructed breast(s) when you are wearing a bra	A question about how satisfied or dissatisfied an individual is or was with the shape of their reconstructed breasts when they are wearing a bra.			Intellectual Product	BREAST-Q
C140931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140931>	C173792	Satisfaction with How Normal You Feel in Your Clothes Question|How normal you feel in your clothes|Satisfaction with How Normal You Feel in Your Clothes	A question about how satisfied or dissatisfied an individual is or was with how normal you feel in your clothes.			Intellectual Product	BREAST-Q
C140932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140932>	C140929	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pN1a TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma pN1a TNM Finding v8|pN1a	Metastasis to level VI or VII (pretracheal, paratracheal, or prelaryngeal/Delphian, or upper mediastinal) lymph nodes. This can be unilateral or bilateral disease. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C140933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140933>	C91102	Satisfaction with Size of Your Reconstructed Breasts Question|Satisfaction with Size of Your Reconstructed Breasts|The size of your reconstructed breast(s)	A question about an individual's satisfaction with the size of their reconstructed breasts.			Intellectual Product	BREAST-Q
C140934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140934>	C173792|C173791	Satisfaction with How Your Breasts Line up in Relation to Each Other Question|How your breasts are lined up in relation to each other|Satisfaction with How Your Breasts Line up in Relation to Each Other	A question about how satisfied or dissatisfied an individual is or was with how their breasts are lined up in relation to each other.			Intellectual Product	BREAST-Q
C140935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140935>	C140929	Papillary, Follicular, Hurthle Cell, Poorly Differentiated, and Anaplastic Thyroid Carcinoma pN1b TNM Finding v8|Differentiated and Anaplastic Thyroid Carcinoma pN1b TNM Finding v8|pN1b	Metastasis to unilateral, bilateral, or contralateral lateral neck lymph nodes (levels I, II, III, IV, or V) or retropharyngeal lymph nodes. (from AJCC 8th Ed.)			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C140936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140936>	C173792|C173791	Satisfaction with Softness of Reconstructed Breasts Question|Satisfaction with Softness of Reconstructed Breasts|The softness of your reconstructed breast(s)	A question about how satisfied or dissatisfied an individual is or was with the softness of their reconstructed breasts.			Intellectual Product	BREAST-Q
C140937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140937>	C173792|C173791	Satisfaction with How Equal in Size Your Breasts are to Each Other Question|How equal in size your breasts are to each other|Satisfaction with How Equal in Size Your Breasts are to Each Other	A question about how satisfied or dissatisfied an individual is or was with how equal in size their breasts are to each other.			Intellectual Product	BREAST-Q
C140938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140938>	C176022|C173792|C173791	Satisfaction with How Natural Your Reconstructed Breasts Look Question|How natural your reconstructed breast(s) looks	A question about how satisfied or dissatisfied an individual is or was with how natural their reconstructed breasts look.			Intellectual Product	BREAST-Q
C140939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140939>	C173792|C173791	Satisfaction with How Naturally Your Reconstructed Breasts Sits and Hangs Question|How naturally your reconstructed breast(s) sits/hangs|Satisfaction with How Naturally Your Reconstructed Breasts Sits and Hangs	A question about how satisfied or dissatisfied an individual is or was with how naturally their reconstructed breasts sits and hangs.			Intellectual Product	BREAST-Q
C14093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14093>	C13426	SET Domain	SET domains appear to be protein-protein interaction domains. SET domains mediate interactions with a family of proteins that display similarity with dual-specificity phosphatases (dsPTPases). The SET domain genes are widely represented in the eukaryotic genomes. Proteins bearing the widely distributed SET domain (ca. 130 amino acid) contribute to epigenetic mechanisms of gene regulation by methylation of lysine residues in histones and other proteins. The SET domain appears generally as one part of a larger multidomain protein. It appears that the varied domains that occur together with the SET domain are involved in recognizing protein substrates and ''reading'' histone tails in order to dictate which (if any) of their multiple lysine residues should get methylated. (From Pfam PF00856)			Amino Acid Sequence	
C140940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140940>	C173792|C173791	Satisfaction with How Your Reconstructed Breasts Feel to Touch Question|How your reconstructed breast(s) feels to touch|Satisfaction with How Your Reconstructed Breasts Feel to Touch	A question about how satisfied or dissatisfied an individual is or was with how their reconstructed breasts feels to touch.			Intellectual Product	BREAST-Q
C140941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140941>	C173792|C173791	Satisfaction with How Much Your Reconstructed Breasts Feel Like a Natural Part of Your Body Question|How much your reconstructed breast(s) feels like a natural part of your body|Satisfaction with How Much Your Reconstructed Breasts Feel Like a Natural Part of Your Body	A question about how satisfied or dissatisfied an individual is or was with how much their reconstructed breasts feels like a natural part of your body.			Intellectual Product	BREAST-Q
C140942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140942>	C173792|C173791	Satisfaction with How Closely Matched Your Breasts are to Each Other Question|How closely matched (similar) your breasts are to each other|Satisfaction with How Closely Matched Your Breasts are to Each Other	A question about how satisfied or dissatisfied an individual is or was with how closely matched or similar their breasts are to each other.			Intellectual Product	BREAST-Q
C140943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140943>	C173792	Satisfaction with Amount of Rippling of Your Implants That You Can See Question|Satisfaction with Amount of Rippling of Your Implants That You Can See|The amount of rippling (wrinkling) of your implant(s) that you can see	A question about how satisfied or dissatisfied an individual is or was with the amount of rippling or wrinkling of their implants that they can see.			Intellectual Product	BREAST-Q
C140944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140944>	C173792	Satisfaction with Amount of Rippling of Your Implants That you Can Feel Question|Satisfaction with Amount of Rippling of Your Implants That you Can Feel|The amount of rippling (wrinkling) of your implant(s) that you can feel	A question about how satisfied or dissatisfied an individual is or was with the amount of rippling or wrinkling of their implants that they can feel.			Intellectual Product	BREAST-Q
C140945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140945>	C175990|C173398|C118873	How Often Experienced Difficulty Sitting up Because Abdominal Muscle Weakness Question|Difficulty sitting up because of abdominal muscle weakness (e.g. getting out of bed)|How Often Experienced Difficulty Sitting up Because Abdominal Muscle Weakness	A question about how often an individual has or had experienced difficulty sitting up because of abdominal muscle weakness (e.g.getting out of bed).			Intellectual Product	BREAST-Q
C140946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140946>	C175990|C173398|C118873	How Often Experienced Difficulty Doing Everyday Activities Because of Abdominal Muscle Weakness Question|Difficulty doing everyday activities because of abdominal muscle weakness (e.g. making your bed)|How Often Experienced Difficulty Doing Everyday Activities Because of Abdominal Muscle Weakness	A question about how often an individual has or had experienced difficulty doing everyday activities because of abdominal muscle weakness (e.g.making their bed).			Intellectual Product	BREAST-Q
C140947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140947>	C175990|C173518|C118873	How Often Experienced Abdominal Discomfort Question|Abdominal discomfort|How Often Experienced Abdominal Discomfort	A question about how often an individual experienced abdominal discomfort.			Intellectual Product	BREAST-Q
C140948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140948>	C175990|C118873	How Often Experienced Abdominal Bloating Question|Abdominal bloating|How Often Experienced Abdominal Bloating	A question about how often an individual experienced abdominal bloating.			Intellectual Product	BREAST-Q
C140949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140949>	C175990|C118873	How Often Experienced Abdominal Bulging Question|Abdominal bulging|How Often Experienced Abdominal Bulging	A question about how often an individual experienced abdominal bulging.			Intellectual Product	BREAST-Q
C14094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14094>	C13425	ARID Domain|AT-Rich Interaction Domain|AT-Rich Interactive Domain|BRIGHT Domain	The approximately 100-amino acid ARID (AT-Rich Interaction Domain) DNA-binding domain occurs in some transcriptional regulators (and perhaps modifiers of chromatin structure) involved in embryonic development, cell lineage, and cell cycle control. The domain shows more diversity in structure and function than the highly conserved sequence suggests: at least six alpha helices separated by beta-strands, loops, or turns. Although Bright, dead ringer, and MRF-2 preferentially bind to AT-rich sites, DNA binding of ARID-proteins is not necessarily sequence specific; ARID protein p270 of the SWI-SNF complex exhibits non-specific DNA binding activity. ARID family proteins may be involved in a wide range of DNA interactions. Inappropriate expression of ARID proteins is increasingly implicated in tumorigenesis.			Amino Acid Sequence	
C140950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140950>	C175990|C118873	How Often Experienced Tightness in Abdomen Question|How Often Experienced Tightness in Abdomen|Tightness in your abdomen	A question about how often an individual experienced tightness in their abdomen.			Intellectual Product	BREAST-Q
C140951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140951>	C175990|C118873	How Often Experienced Pulling in Abdomen Question|How Often Experienced Pulling in Abdomen|Pulling in your abdomen	A question about how often an individual experienced pulling in their abdomen.			Intellectual Product	BREAST-Q
C140952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140952>	C176022|C173792	Satisfaction with How Your Abdomen Looks When Unclothed Question|How your abdomen (tummy area) looks when unclothed|Satisfaction with How Your Abdomen Looks When Unclothed	A question about how satisfied or dissatisfied an individual is or was with how their abdomen (tummy area) looks when unclothed.			Intellectual Product	BREAST-Q
C140953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140953>	C173792	Satisfaction with Position of Navel Question|Satisfaction with Position of Navel|The position of your navel (belly button)	A question about how satisfied or dissatisfied an individual is or was with the position of their navel (belly button).			Intellectual Product	BREAST-Q
C140954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140954>	C176022|C173792	Satisfaction with Appearance of Abdominal Scars Question|How your abdominal scars look|Satisfaction with Appearance of Abdominal Scars	A question about how satisfied or dissatisfied an individual is or was with how their abdominal scars look.			Intellectual Product	BREAST-Q
C140958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140958>	C8054|C140959	Thyroid Gland Follicular Carcinoma by AJCC v7 Stage	A term that refers to the staging of follicular thyroid gland carcinoma, following the rules of the TNM AJCC v7 classification system.			Neoplastic Process	
C140959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140959>	C7153	Differentiated Thyroid Gland Carcinoma by AJCC v7 Stage	A term that refers to the staging of differentiated thyroid gland carcinoma, following the rules of the TNM AJCC v7 classification system.			Neoplastic Process	
C14095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14095>	C13426	BTB/POZ Domain|BTB (POZ)|BTB (POZ) Domain|BTB Domain|POZ Domain	The BTB/POZ domain is an approximately 120 amino acid long, hydrophobic region found in two distinct classes of transcriptional regulators that contain either a C-terminal basic leucine zipper motif (POK proteins) or a Zn-finger region (Bach proteins).  This domain has been shown to form homo-dimers in a number of BTB/POZ domain containing proteins. (NCI)			Amino Acid Sequence	
C140960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140960>	C4035|C140959	Thyroid Gland Papillary Carcinoma by AJCC v7 Stage	A term that refers to the staging of papillary thyroid gland carcinoma, following the rules of the TNM AJCC v7 classification system.			Neoplastic Process	
C140961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140961>	C90530	Differentiated Thyroid Gland Carcinoma Under 45 Years AJCC v7 Stage	A differentiated thyroid gland carcinoma stage for patients under 45 years of age defined according to the AJCC 7th edition criteria.			Classification	
C140962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140962>	C132248	Differentiated Thyroid Gland Carcinoma Under 55 Years AJCC v8 Stage	A differentiated thyroid gland carcinoma stage for patients under 55 years of age defined according to the AJCC 8th edition criteria.			Classification	
C140963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140963>	C90530	Differentiated Thyroid Gland Carcinoma 45 Years and Older AJCC v7 Stage	A differentiated thyroid gland carcinoma stage for patients 45 years and older defined according to the AJCC 7th edition criteria.			Classification	
C140964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140964>	C132248	Differentiated Thyroid Gland Carcinoma 55 Years and Older AJCC v8 Stage	A differentiated thyroid gland carcinoma stage for patients 55 years and older defined according to the AJCC 8th edition criteria.			Classification	
C140965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140965>	C7153	Differentiated Thyroid Gland Carcinoma by AJCC v8 Stage	A term that refers to the staging of differentiated thyroid gland carcinoma, following the rules of the TNM AJCC v8 classification system.			Neoplastic Process	
C140966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140966>	C140965	Stage I Differentiated Thyroid Gland Carcinoma AJCC v8|Stage I Differentiated Thyroid Gland Cancer	Stage I includes: Under 55 years: Any T, Any N, M0. 55 years and older: (T1, N0/NX, M0); (T2, N0/NX, M0).  T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. N0: No evidence of locoregional lymph node metastasis. NX: Regional lymph nodes cannot be assessed. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage I Differentiated Thyroid Gland Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140967>	C140966	Stage I Differentiated Thyroid Gland Carcinoma Under 55 Years AJCC v8|Stage I Differentiated Thyroid Gland Cancer Under 55 Years	Stage I includes: Any T, Any N, M0. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage I Differentiated Thyroid Gland Carcinoma Under 55 Years AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140968>	C140966	Stage I Differentiated Thyroid Gland Carcinoma 55 Years and Older AJCC v8|Stage I Differentiated Thyroid Gland Cancer 55 Years and Older	Stage I includes: (T1, N0/NX, M0); (T2, N0/NX, M0).  T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. N0: No evidence of locoregional lymph node metastasis. NX: Regional lymph nodes cannot be assessed. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage I Differentiated Thyroid Gland Carcinoma 55 Years and Older AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140969>	C140965	Stage II Differentiated Thyroid Gland Carcinoma AJCC v8|Stage II Differentiated Thyroid Gland Cancer	Stage II includes: Under 55 years: Any T, Any N, M1; 55 years and older: (T1, N1, M0); (T2, N1, M0); (T3a/T3b, Any N, M0). T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. T3a: Tumor measuring more than 4 cm in greatest dimension limited to the thyroid. T3b: Gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles) from a tumor of any size. N1: Metastasis to regional nodes. M0: No distant metastasis. M1: Distant metastasis. (from AJCC 8th Ed.)	Stage II Differentiated Thyroid Gland Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140970>	C140969	Stage II Differentiated Thyroid Gland Carcinoma Under 55 Years AJCC v8|Stage II Differentiated Thyroid Gland Cancer Under 55 Years	Stage II includes: Any T, Any N, M1. M1: Distant metastasis. (from AJCC 8th Ed.)	Stage II Differentiated Thyroid Gland Carcinoma Under 55 Years AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140971>	C140969	Stage II Differentiated Thyroid Gland Carcinoma 55 Years and Older AJCC v8|Stage II Differentiated Thyroid Gland Cancer 55 Years and Older	Stage II includes: (T1, N1, M0); (T2, N1, M0); (T3a/T3b, Any N, M0). T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. T3a: Tumor measuring more than 4 cm in greatest dimension limited to the thyroid. T3b: Gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles) from a tumor of any size. N1: Metastasis to regional nodes. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage II Differentiated Thyroid Gland Carcinoma 55 Years and Older AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140972>	C140965	Stage III Differentiated Thyroid Gland Carcinoma AJCC v8|Stage III Differentiated Thyroid Gland Cancer	Stage III includes: 55 years and older: T4a, Any N, M0. T4a: Gross extrathyroidal extension invading subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve from a tumor of any size. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage III Differentiated Thyroid Gland Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140973>	C140965	Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IV Differentiated Thyroid Gland Cancer	Stage IV includes: IVA: 55 years and older: T4b, Any N, M0; IVB: 55 years and older: Any T, Any N, M1. T4b: Gross extrathyroidal extension invading prevertebral fascia or encasing the carotid artery or mediastinal vessels from a tumor of any size. M0: No distant metastasis. M1: Distant metastasis. (from AJCC 8th Ed.)	Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140974>	C140973	Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IVA Differentiated Thyroid Gland Cancer	Stage IVA includes: 55 years and older: T4b, Any N, M0. T4b: Gross extrathyroidal extension invading prevertebral fascia or encasing the carotid artery or mediastinal vessels from a tumor of any size. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140975>	C140973	Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8|Stage IVB Differentiated Thyroid Gland Cancer	Stage IVB includes: 55 years and older: Any T, Any N, M1. M1: Distant metastasis. (from AJCC 8th Ed.)	Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140976>	C4035|C140965	Thyroid Gland Papillary Carcinoma by AJCC v8 Stage|Tumor Stage (Pathologic)	A term that refers to the staging of papillary thyroid gland carcinoma, following the rules of the TNM AJCC v8 classification system.			Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C140977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140977>	C140976|C140966	Stage I Thyroid Gland Papillary Carcinoma AJCC v8|I|Stage I Thyroid Gland Papillary Cancer	Stage I includes: Under 55 years: Any T, Any N, M0. 55 years and older: (T1, N0/NX, M0); (T2, N0/NX, M0).  T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. N0: No evidence of locoregional lymph node metastasis. NX: Regional lymph nodes cannot be assessed. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage I Thyroid Gland Papillary Carcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CTRP Disease Terminology|CTRP Terminology
C140978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140978>	C140977|C140967	Stage I Thyroid Gland Papillary Carcinoma Under 55 Years AJCC v8|I Under 55 Years|Stage I Thyroid Gland Papillary Cancer Under 55 Years	Stage I includes: Any T, Any N, M0. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage I Thyroid Gland Papillary Carcinoma Under 55 Years AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CTRP Disease Terminology|CTRP Terminology
C140979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140979>	C140977|C140968	Stage I Thyroid Gland Papillary Carcinoma 55 Years and Older AJCC v8|II 55 Years and Older|Stage I Thyroid Gland Papillary Cancer 55 Years and Older	Stage I includes: (T1, N0/NX, M0); (T2, N0/NX, M0).  T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. N0: No evidence of locoregional lymph node metastasis. NX: Regional lymph nodes cannot be assessed. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage I Thyroid Gland Papillary Carcinoma 55 Years and Older AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CTRP Disease Terminology|CTRP Terminology
C14097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14097>	C13427	C3H1 Zinc Finger|Zinc Finger C-X8-C-X5-C-X3-H Type	Zinc finger domains are thought to be involved in DNA-binding. Different types exist depending on the cysteine residue positions. C-X8-C-X5-C-X3-H type zinc finger proteins often function in cell cycle or growth regulation, e.g. human TIS11B (butyrate response factor 1) and mouse TTP nuclear protein. The splicing factor U2AF 35-kD subunit, which mediates protein-protein and protein-RNA interactions required for 3-prime splice site selection, also contains this domain. Different CCCH zinc finger proteins interact with the 3-prime UTR of various mRNA. This type of zinc finger is often present in two copies. (NCI)			Amino Acid Sequence	
C140980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140980>	C140976|C140969	Stage II Thyroid Gland Papillary Carcinoma AJCC v8|II|Stage II Thyroid Gland Papillary Cancer	Stage II includes: Under 55 years: Any T, Any N, M1; 55 years and older: (T1, N1, M0); (T2, N1, M0); (T3a/T3b, Any N, M0). T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. T3a: Tumor measuring more than 4 cm in greatest dimension limited to the thyroid. T3b: Gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles) from a tumor of any size. N1: Metastasis to regional nodes. M0: No distant metastasis. M1: Distant metastasis. (from AJCC 8th Ed.)	Stage II Thyroid Gland Papillary Carcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CTRP Disease Terminology|CTRP Terminology
C140981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140981>	C140980|C140970	Stage II Thyroid Gland Papillary Carcinoma Under 55 Years AJCC v8|II Under Years|Stage II Thyroid Gland Papillary Cancer Under 55 Years	Stage II includes: Any T, Any N, M1. M1: Distant metastasis. (from AJCC 8th Ed.)	Stage II Thyroid Gland Papillary Carcinoma Under 55 Years AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CTRP Disease Terminology|CTRP Terminology
C140982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140982>	C140980|C140971	Stage II Thyroid Gland Papillary Carcinoma 55 Years and Older AJCC v8|II 55 Years and Older|Stage II Thyroid Gland Papillary Cancer 55 Years and Older	Stage II includes: (T1, N1, M0); (T2, N1, M0); (T3a/T3b, Any N, M0). T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. T3a: Tumor measuring more than 4 cm in greatest dimension limited to the thyroid. T3b: Gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles) from a tumor of any size. N1: Metastasis to regional nodes. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage II Thyroid Gland Papillary Carcinoma 55 Years and Older AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CTRP Disease Terminology|CTRP Terminology
C140983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140983>	C140976|C140972	Stage III Thyroid Gland Papillary Carcinoma AJCC v8|III|Stage III Thyroid Gland Papillary Cancer	Stage III includes: 55 years and older: T4a, Any N, M0. T4a: Gross extrathyroidal extension invading subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve from a tumor of any size. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage III Thyroid Gland Papillary Carcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CTRP Disease Terminology|CTRP Terminology
C140984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140984>	C140976|C140973	Stage IV Thyroid Gland Papillary Carcinoma AJCC v8|IV|Stage IV Thyroid Gland Papillary Cancer	Stage IV includes: IVA: 55 years and older: T4b, Any N, M0; IVB: 55 years and older: Any T, Any N, M1. T4b: Gross extrathyroidal extension invading prevertebral fascia or encasing the carotid artery or mediastinal vessels from a tumor of any size. M0: No distant metastasis. M1: Distant metastasis. (from AJCC 8th Ed.)	Stage IV Thyroid Gland Papillary Carcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CTRP Disease Terminology|CTRP Terminology
C140985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140985>	C140984|C140974	Stage IVA Thyroid Gland Papillary Carcinoma AJCC v8|IVA|Stage IVA Thyroid Gland Papillary Cancer	Stage IVA includes: 55 years and older: T4b, Any N, M0. T4b: Gross extrathyroidal extension invading prevertebral fascia or encasing the carotid artery or mediastinal vessels from a tumor of any size. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage IVA Thyroid Gland Papillary Carcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CTRP Disease Terminology|CTRP Terminology
C140986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140986>	C140984|C140975	Stage IVB Thyroid Gland Papillary Carcinoma AJCC v8|IVB|Stage IVB Thyroid Gland Papillary Cancer	Stage IVB includes: 55 years and older: Any T, Any N, M1. M1: Distant metastasis. (from AJCC 8th Ed.)	Stage IVB Thyroid Gland Papillary Carcinoma AJCC v8		Neoplastic Process	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CTRP Disease Terminology|CTRP Terminology
C140987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140987>	C8054|C140965	Thyroid Gland Follicular Carcinoma by AJCC v8 Stage	A term that refers to the staging of follicular thyroid gland carcinoma, following the rules of the TNM AJCC v8 classification system.			Neoplastic Process	
C140988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140988>	C140987|C140966	Stage I Thyroid Gland Follicular Carcinoma AJCC v8|Stage I Thyroid Gland Follicular Cancer	Stage I includes: Under 55 years: Any T, Any N, M0. 55 years and older: (T1, N0/NX, M0); (T2, N0/NX, M0).  T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. N0: No evidence of locoregional lymph node metastasis. NX: Regional lymph nodes cannot be assessed. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage I Thyroid Gland Follicular Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140989>	C140988|C140967	Stage I Thyroid Gland Follicular Carcinoma Under 55 Years AJCC v8|Stage I Thyroid Gland Follicular Cancer Under 55 Years	Stage I includes: Any T, Any N, M0. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage I Thyroid Gland Follicular Carcinoma Under 55 Years AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C14098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14098>	C13453	PHD Finger|C4HC3 Zinc Finger|PHD Finger Domain|PHD Finger Motif|PHD-Finger|Plant Homeodomain (PHD) Type Zinc Finger	A C4HC3 zinc-finger-like motif, the PHD finger is found in nuclear proteins thought involved in chromatin-mediated transcriptional regulation. Single or multiple fingers are found. A specific function is not yet known, but it could be involved in protein-protein interactions important for assembly/activity of multi-component transcriptional regulatory complexes. In CBP it is an integral part of the acetyltransferase enzymatic core domain and contributes to CBP transcriptional activity. PHD fingers fold into an interleaved Zn-finger chelating two Zn ions in an atypical cross-braced conformation also shared by the FYVE and RING fingers; the zinc sites are located at opposite ends of a beta-sheet. Surrounding loops vary significantly in length and sequence between these three domains. (NCI)			Amino Acid Sequence	
C140990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140990>	C140988|C140968	Stage I Thyroid Gland Follicular Carcinoma 55 Years and Older AJCC v8|Stage I Thyroid Gland Follicular Cancer 55 Years and Older	Stage I includes: (T1, N0/NX, M0); (T2, N0/NX, M0).  T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. N0: No evidence of locoregional lymph node metastasis. NX: Regional lymph nodes cannot be assessed. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage I Thyroid Gland Follicular Carcinoma 55 Years and Older AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140991>	C140987|C140969	Stage II Thyroid Gland Follicular Carcinoma AJCC v8|Stage II Thyroid Gland Follicular Cancer	Stage II includes: Under 55 years: Any T, Any N, M1; 55 years and older: (T1, N1, M0); (T2, N1, M0); (T3a/T3b, Any N, M0). T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. T3a: Tumor measuring more than 4 cm in greatest dimension limited to the thyroid. T3b: Gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles) from a tumor of any size. N1: Metastasis to regional nodes. M0: No distant metastasis. M1: Distant metastasis. (from AJCC 8th Ed.)	Stage II Thyroid Gland Follicular Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140992>	C140991|C140970	Stage II Thyroid Gland Follicular Carcinoma Under 55 Years AJCC v8|Stage II Thyroid Gland Follicular Cancer Under 55 Years	Stage II includes: Any T, Any N, M1. M1: Distant metastasis. (from AJCC 8th Ed.)	Stage II Thyroid Gland Follicular Carcinoma Under 55 Years AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140993>	C140991|C140971	Stage II Thyroid Gland Follicular Carcinoma 55 Years and Older AJCC v8|Stage II Thyroid Gland Follicular Cancer 55 Years and Older	Stage II includes: (T1, N1, M0); (T2, N1, M0); (T3a/T3b, Any N, M0). T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. T3a: Tumor measuring more than 4 cm in greatest dimension limited to the thyroid. T3b: Gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles) from a tumor of any size. N1: Metastasis to regional nodes. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage II Thyroid Gland Follicular Carcinoma 55 Years and Older AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140994>	C1966	NIR Fluorochrome VM110|NIRF Imaging Agent VM110|Prosense VM110|VM110	A synthetic near infrared fluorescent (NIRF) imaging agent that can potentially be used to detect the presence of certain cancers. Upon intravenous administration, VM110 is specifically cleaved by certain proteases, including cathepsins B, L, and S, and plasmin, which are highly expressed in various types of cancer. Proteolysis liberates a highly fluorescent cleavage product, which can be detected in vivo by NIRF imaging techniques. Thus, tumor cells can be visualized and the presence of micrometastases may be assessed.	NIR Fluorochrome VM110		Indicator, Reagent, or Diagnostic Aid	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C140995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140995>	C140987|C140972	Stage III Thyroid Gland Follicular Carcinoma AJCC v8|Stage III Thyroid Gland Follicular Cancer	Stage III includes: 55 years and older: T4a, Any N, M0. T4a: Gross extrathyroidal extension invading subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve from a tumor of any size. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage III Thyroid Gland Follicular Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140996>	C140987|C140973	Stage IV Thyroid Gland Follicular Carcinoma AJCC v8|Stage IV Thyroid Gland Follicular Cancer	Stage IV includes: IVA: 55 years and older: T4b, Any N, M0; IVB: 55 years and older: Any T, Any N, M1. T4b: Gross extrathyroidal extension invading prevertebral fascia or encasing the carotid artery or mediastinal vessels from a tumor of any size. M0: No distant metastasis. M1: Distant metastasis. (from AJCC 8th Ed.)	Stage IV Thyroid Gland Follicular Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140997>	C140996|C140974	Stage IVA Thyroid Gland Follicular Carcinoma AJCC v8|Stage IVA Thyroid Gland Follicular Cancer	Stage IVA includes: 55 years and older: T4b, Any N, M0. T4b: Gross extrathyroidal extension invading prevertebral fascia or encasing the carotid artery or mediastinal vessels from a tumor of any size. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage IVA Thyroid Gland Follicular Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140998>	C140996|C140975	Stage IVB Thyroid Gland Follicular Carcinoma AJCC v8|Stage IVB Thyroid Gland Follicular Cancer	Stage IVB includes: 55 years and older: Any T, Any N, M1. M1: Distant metastasis. (from AJCC 8th Ed.)	Stage IVB Thyroid Gland Follicular Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C140999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C140999>	C3878	Thyroid Gland Anaplastic Carcinoma by AJCC v7 Stage|Thyroid Gland Undifferentiated (Anaplastic) Carcinoma by AJCC v7 Stage	A term that refers to the staging of thyroid gland anaplastic carcinoma, following the rules of the TNM AJCC v7 classification system.			Neoplastic Process	
C1409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1409>	C1558	Carbenicillin Indanyl Sodium|CARBENICILLIN INDANYL SODIUM|Geocillin|Geocillin	The sodium salt of indanyl carbenicillin, a broad-spectrum, semi-synthetic carboxypenicillin antibiotic with bactericidal activity. Carbenicillin acylates C-terminal domain of penicillin-sensitive transpeptidase, resulting in opening the lactam ring of the antibiotic. This inactivation prevents the formation of the cross-linkage of peptidoglycan strands, thereby inhibiting the third and last stage of bacterial cell wall synthesis. As a result, cell wall integrity is compromised and cell lysis may follow. This agent is used mainly for gram-negative infections, and has limited gram-positive coverage.			Antibiotic|Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C141000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141000>	C3878	Thyroid Gland Anaplastic Carcinoma by AJCC v8 Stage|Thyroid Gland Undifferentiated (Anaplastic) Carcinoma by AJCC v8 Stage	A term that refers to the staging of thyroid gland anaplastic carcinoma, following the rules of the TNM AJCC v8 classification system.			Neoplastic Process	
C141001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141001>	C141000	Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVA Thyroid Gland Undifferentiated (Anaplastic) Carcinoma AJCC v8|Undifferentiated (Anaplastic) Stage IVA Thyroid Gland Cancer	Stage IVA includes: T1-T3a, N0/NX, M0. T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. T3a: Tumor measuring more than 4 cm in greatest dimension limited to the thyroid. N0: No evidence of locoregional lymph node metastasis. NX: Regional lymph nodes cannot be assessed. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage IVA Thyroid Gland Undifferentiated (Anaplastic) Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C141003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141003>	C141000	Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVB Thyroid Gland Undifferentiated (Anaplastic) Carcinoma AJCC v8|Undifferentiated (Anaplastic) Stage IVB Thyroid Gland Cancer	Stage IVB includes: (T1-T3a, N1, M0); (T3b, Any N, M0); (T4, Any N, M0). T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but 4 cm or less in greatest dimension limited to the thyroid. T3a: Tumor measuring more than 4 cm in greatest dimension limited to the thyroid. T3b: Gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles) from a tumor of any size. T4: Tumor of any size with gross extrathyroidal extension. N1: Metastasis to regional nodes. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage IVB Thyroid Gland Undifferentiated (Anaplastic) Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C141004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141004>	C141000	Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8|Stage IVC Thyroid Gland Undifferentiated (Anaplastic) Carcinoma AJCC v8|Undifferentiated (Anaplastic) Stage IVC Thyroid Gland Cancer	Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (from AJCC 8th Ed.)	Stage IVC Thyroid Gland Undifferentiated (Anaplastic) Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C141005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141005>	C25164	Contact Date|Date of Contact	The date on which a direct or indirect interaction between individuals or organizations occurred.			Temporal Concept	
C141006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141006>	C140896	Medullary Thyroid Carcinoma TNM Finding v8	A finding about one or more characteristics of medullary thyroid carcinoma, following the rules of the TNM AJCC v8 classification system. Differentiated and anaplastic thyroid carcinomas are staged according to the classification for thyroid-differentiated and anaplastic carcinoma. (from AJCC 8th Ed.)			Finding	
C141007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141007>	C141006	Medullary Thyroid Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of medullary thyroid carcinoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C141008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141008>	C141007	Medullary Thyroid Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of medullary thyroid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C141009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141009>	C141008	Medullary Thyroid Carcinoma cM0 TNM Finding v8	No distant metastasis. (from AJCC 8th Ed.)			Finding	
C14100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14100>	C13426	Ankyrin Repeat|ANK Domain|ANK Repeat|Ankyrin Repeat Domain	Ankyrin Repeats are tandem modules of about 33 amino acids. The conserved domain structure has been described as side-by-side anti-parallel alpha helices connected by intervening beta hairpin motifs or as beta, alpha, alpha, beta secondary structures or as an L-shaped beta-hairpin and two alpha-helices. The repeats associate to form a higher order structure. Despite sequence variation, the domain core maintains a stable surface of contact residues to mediate protein-protein interactions. Target protein binding involves contacts by the beta hairpin tips and the helical bundle surface facing the Ankyrin groove. ANK repeats have been identified in over 1700 functionally diverse proteins, primarily from eukaryotes; no common theme among the protein targets has been identified. The Ankyrin cytoskeletal protein is composed almost entirely of these repeats.			Amino Acid Sequence	
C141010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141010>	C141008	Medullary Thyroid Carcinoma cM1 TNM Finding v8	Distant metastasis. (from AJCC 8th Ed.)			Finding	
C141011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141011>	C141007	Medullary Thyroid Carcinoma Clinical Regional Lymph Nodes TNM Finding v8	A clinical finding about one or more characteristics of medullary thyroid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C141012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141012>	C141011	Medullary Thyroid Carcinoma cNX TNM Finding v8	Regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C141013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141013>	C141011	Medullary Thyroid Carcinoma cN0 TNM Finding v8	No evidence of locoregional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C141014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141014>	C141013	Medullary Thyroid Carcinoma cN0b TNM Finding v8	No radiologic or clinical evidence of locoregional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C141015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141015>	C141011	Medullary Thyroid Carcinoma cN1 TNM Finding v8	Metastasis to regional nodes. (from AJCC 8th Ed.)			Finding	
C141016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141016>	C141015	Medullary Thyroid Carcinoma cN1a TNM Finding v8	Metastasis to level VI or VII (pretracheal, paratracheal, or prelaryngeal/Delphian, or upper mediastinal) lymph nodes. This can be unilateral or bilateral disease. (from AJCC 8th Ed.)			Finding	
C141017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141017>	C141015	Medullary Thyroid Carcinoma cN1b TNM Finding v8	Metastasis to unilateral, bilateral, or contralateral lateral neck lymph node levels I, II, III, IV, or V or retropharyngeal lymph nodes. (from AJCC 8th Ed.)			Finding	
C141018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141018>	C141006	Medullary Thyroid Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of medullary thyroid carcinoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C141019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141019>	C141018	Medullary Thyroid Carcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of medullary thyroid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C14101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14101>	C13426	Armadillo Repeat|ARM Domain|ARM Repeat|Armadillo/Beta-Catenin-Like Repeat|Beta-Catenin Binding Repeat|Beta-Catenin-Binding Domain|Beta-Catenin-Like Repeat	Identified in over 240 functionally diverse proteins from yeast to man, ARM Repeats are approximately 40-amino acids long and composed of two longer anti-parallel helices (H2 and H3) that follow a perpendicular short helix (H1). Tandem repeats form a right-handed superhelix (3 helixes per unit); tight repeat packing creates a cylindrical hydrophobic core throughout the structure. Lined by highly conserved residues, the positively charged groove of the superhelix appears to mediate interaction with acidic surfaces of target proteins. Despite amino acid variability, ARM repeat structures are highly conserved. Though involved in protein-protein interactions, no common features among target proteins have been identified. ARM repeats have a common phylogenetic origin with the HEAT repeat; both contain seven highly conserved hydrophobic residues.			Amino Acid Sequence	
C141020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141020>	C141019	Medullary Thyroid Carcinoma pM1 TNM Finding v8	Distant metastasis. (from AJCC 8th Ed.)			Finding	
C141021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141021>	C141018	Medullary Thyroid Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of medullary thyroid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C141022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141022>	C141021	Medullary Thyroid Carcinoma pTX TNM Finding v8	Primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C141023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141023>	C141021	Medullary Thyroid Carcinoma pT0 TNM Finding v8	No evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C141024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141024>	C141021	Medullary Thyroid Carcinoma pT1 TNM Finding v8	Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. (from AJCC 8th Ed.)			Finding	
C141025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141025>	C141024	Medullary Thyroid Carcinoma pT1a TNM Finding v8	Tumor measuring 1 cm or less in greatest dimension limited to the thyroid. (from AJCC 8th Ed.)			Finding	
C141026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141026>	C141024	Medullary Thyroid Carcinoma pT1b TNM Finding v8	Tumor measuring more than 1 cm but 2 cm or less in greatest dimension limited to the thyroid. (from AJCC 8th Ed.)			Finding	
C141027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141027>	C141021	Medullary Thyroid Carcinoma pT2 TNM Finding v8	Tumor measuring more than 2 cm but less than 4 cm in greatest dimension limited to the thyroid. (from AJCC 8th Ed.)			Finding	
C141028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141028>	C141021	Medullary Thyroid Carcinoma pT3 TNM Finding v8	Tumor measuring 4 cm or more in greatest dimension or with extrathyroidal extension. (from AJCC 8th Ed.)			Finding	
C141029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141029>	C141028	Medullary Thyroid Carcinoma pT3a TNM Finding v8	Tumor measuring 4 cm or more in greatest dimension limited to the thyroid. (from AJCC 8th Ed.)			Finding	
C141030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141030>	C141028	Medullary Thyroid Carcinoma pT3b TNM Finding v8	Tumor of any size with gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid or omohyoid muscles). (from AJCC 8th Ed.)			Finding	
C141031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141031>	C141021	Medullary Thyroid Carcinoma pT4 TNM Finding v8	Advanced disease. (from AJCC 8th Ed.)			Finding	
C141032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141032>	C141031	Medullary Thyroid Carcinoma pT4a TNM Finding v8	Moderately advanced disease; tumor of any size with gross extrathyroidal extension into the nearby tissues of the neck, including subcutaneous soft tissue, larynx, trachea, esophagus, or recurrent laryngeal nerve. (from AJCC 8th Ed.)			Finding	
C141033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141033>	C141031	Medullary Thyroid Carcinoma pT4b TNM Finding v8	Very advanced disease; tumor of any size with extension towards the spine or into nearby large blood vessels, invading the prevertebral fascia, or encasing the carotid artery or mediastinal vessels. (from AJCC 8th Ed.)			Finding	
C141034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141034>	C141018	Medullary Thyroid Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of medullary thyroid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C141035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141035>	C141034	Medullary Thyroid Carcinoma pNX TNM Finding v8	Regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C141036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141036>	C141034	Medullary Thyroid Carcinoma pN0 TNM Finding v8	No evidence of locoregional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C141037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141037>	C141036	Medullary Thyroid Carcinoma pN0a TNM Finding v8	One or more cytologically or histologically confirmed benign lymph nodes. (from AJCC 8th Ed.)			Finding	
C141038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141038>	C141034	Medullary Thyroid Carcinoma pN1 TNM Finding v8	Metastasis to regional nodes. (from AJCC 8th Ed.)			Finding	
C141039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141039>	C141038	Medullary Thyroid Carcinoma pN1a TNM Finding v8	Metastasis to level VI or VII (pretracheal, paratracheal, or prelaryngeal/Delphian, or upper mediastinal) lymph nodes. This can be unilateral or bilateral disease. (from AJCC 8th Ed.)			Finding	
C14103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14103>	C13426	F-Box Domain|F Box|F Box Domain|F-Box	The F-box consists of three helices. The H1 helix packs orthogonally with the H2-H3 antiparallel pair. The F-box domain is a 42-48 amino acid conserved domain found at the N-terminus of F-box proteins. F-box proteins act as adaptor components of the modular E3 ubiquitin ligase SCF complex that functions in phosphorylation mediated ubiquitination. The F-box domain mediates interaction with Skp1, which links F-box proteins to a core ubiquitin-ligase complex composed of Rbx1, cdc53/Cul1 and the E2 conjugating enzyme cdc34. The C-terminal region of F-box proteins are also composed of various modular domain that interact with target substrates, often in a phosphorylation dependant manner.			Amino Acid Sequence	
C141040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141040>	C141038	Medullary Thyroid Carcinoma pN1b TNM Finding v8	Metastasis to unilateral, bilateral, or contralateral lateral neck lymph nodes levels I, II, III, IV, or V or retropharyngeal lymph nodes. (from AJCC 8th Ed.)			Finding	
C141041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141041>	C3879	Thyroid Gland Medullary Carcinoma by AJCC v7 Stage	A term that refers to the staging of thyroid gland medullary carcinoma, following the rules of the TNM AJCC v7 classification system.			Neoplastic Process	
C141042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141042>	C3879	Thyroid Gland Medullary Carcinoma by AJCC v8 Stage	A term that refers to the staging of thyroid gland medullary carcinoma, following the rules of the TNM AJCC v8 classification system. Differentiated and anaplastic thyroid gland carcinomas are staged according to the classification for thyroid-differentiated and anaplastic carcinoma. (from AJCC 8th Ed.)			Neoplastic Process	
C141043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141043>	C141042	Stage I Thyroid Gland Medullary Carcinoma AJCC v8|Stage I Thyroid Gland Medullary Cancer	Stage I includes: T1, N0, M0. T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. N0: No evidence of locoregional lymph node metastasis. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage I Thyroid Gland Medullary Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C141044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141044>	C141042	Stage II Thyroid Gland Medullary Carcinoma AJCC v8|Stage II Thyroid Gland Medullary Cancer	Stage II includes: (T2, N0, M0); (T3, N0, M0). T2: Tumor measuring more than 2 cm but less than 4 cm in greatest dimension limited to the thyroid. T3: Tumor measuring 4 cm or more in greatest dimension or with extrathyroidal extension. N0: No evidence of locoregional lymph node metastasis. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage II Thyroid Gland Medullary Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C141045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141045>	C141042	Stage III Thyroid Gland Medullary Carcinoma AJCC v8|Stage III Thyroid Gland Medullary Cancer	Stage III includes: T1-3, N1a, M0. T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but less than 4 cm in greatest dimension limited to the thyroid. T3: Tumor measuring 4 cm or more in greatest dimension or with extrathyroidal extension. N1a: Metastasis to level VI or VII (pretracheal, paratracheal, or prelaryngeal/Delphian, or upper mediastinal) lymph nodes. This can be unilateral or bilateral disease. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage III Thyroid Gland Medullary Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C141046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141046>	C141042	Stage IV Thyroid Gland Medullary Carcinoma AJCC v8|Stage IV Thyroid Gland Medullary Cancer	Stage IV includes: IVA: (T4a, Any N, M0); (T1-3, N1b, M0); IVB: (T4b, Any N, M0); IVC: (Any T, Any N, M1). T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but less than 4 cm in greatest dimension limited to the thyroid. T3: Tumor measuring 4 cm or more in greatest dimension or with extrathyroidal extension. T4a: Moderately advanced disease; tumor of any size with gross extrathyroidal extension into the nearby tissues of the neck, including subcutaneous soft tissue, larynx, trachea, esophagus, or recurrent laryngeal nerve. T4b: Very advanced disease; tumor of any size with extension towards the spine or into nearby large blood vessels, invading the prevertebral fascia, or encasing the carotid artery or mediastinal vessels. N1b: Metastasis to unilateral, bilateral, or contralateral lateral neck lymph nodes levels I, II, III, IV, or V or retropharyngeal lymph nodes. M0: No distant metastasis. M1: Distant metastasis. (from AJCC 8th Ed.)	Stage IV Thyroid Gland Medullary Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C141047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141047>	C141046	Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVA Thyroid Gland Medullary Cancer	Stage IVA includes: (T4a, Any N, M0); (T1-3, N1b, M0). T1: Tumor measuring 2 cm or less in greatest dimension limited to the thyroid. T2: Tumor measuring more than 2 cm but less than 4 cm in greatest dimension limited to the thyroid. T3: Tumor measuring 4 cm or more in greatest dimension or with extrathyroidal extension. T4a: Moderately advanced disease; tumor of any size with gross extrathyroidal extension into the nearby tissues of the neck, including subcutaneous soft tissue, larynx, trachea, esophagus, or recurrent laryngeal nerve. N1b: Metastasis to unilateral, bilateral, or contralateral lateral neck lymph nodes levels I, II, III, IV, or V or retropharyngeal lymph nodes. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C141048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141048>	C141046	Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVB Thyroid Gland Medullary Cancer	Stage IVB includes: T4b, Any N, M0. T4b: Very advanced disease; tumor of any size with extension towards the spine or into nearby large blood vessels, invading the prevertebral fascia, or encasing the carotid artery or mediastinal vessels. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C141049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141049>	C141046	Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8|Stage IVC Thyroid Gland Medullary Cancer	Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (from AJCC 8th Ed.)	Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C14104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14104>	C13426	GSK-Binding Domain	The GSK-Binding Domain of AXIN2 mediates interaction with GSK3-Beta. Involved in regulation of the WNT signaling pathway, AXIN2 organizes an APC/Beta-Catenin/GSK3-Beta/ AXIN2 complex that leads to Beta-Catenin degradation. (NCI)			Amino Acid Sequence	
C141050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141050>	C200766|C176018	Autologous Anti-CD19 Chimeric Antigen Receptor T-cells C-CAR011|Autologous Anti-CD19 CAR-T Cells C-CAR011|Autologous Anti-CD19 CART Cells C-CAR011|Autologous CD19-specific CAR-T Cells C-CAR011|C-CAR011	A proprietary preparation of autologous T-lymphocytes that have been genetically modified and transduced with a lentiviral vector expressing a second-generation chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed, costimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR T-cells C-CAR011 target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology
C141052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141052>	C140895	Parathyroid Carcinoma TNM Finding v8	A finding about one or more characteristics of parathyroid carcinoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C141053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141053>	C141052	Parathyroid Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of parathyroid carcinoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C141054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141054>	C141053	Parathyroid Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of parathyroid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C141055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141055>	C141054	Parathyroid Carcinoma cM0 TNM Finding v8	No distant metastasis. (from AJCC 8th Ed.)			Finding	
C141056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141056>	C141054	Parathyroid Carcinoma cM1 TNM Finding v8	Distant metastasis. (from AJCC 8th Ed.)			Finding	
C141057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141057>	C141052	Parathyroid Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of parathyroid carcinoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C141058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141058>	C141057	Parathyroid Carcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of parathyroid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C141059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141059>	C141058	Parathyroid Carcinoma pM1 TNM Finding v8	Distant metastasis. (from AJCC 8th Ed.)			Finding	
C14105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14105>	C13426	PKC Binding Site				Amino Acid Sequence	
C141060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141060>	C141057	Parathyroid Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of parathyroid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C141061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141061>	C141060	Parathyroid Carcinoma pTX TNM Finding v8	Primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C141062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141062>	C141060	Parathyroid Carcinoma pT0 TNM Finding v8	No evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C141063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141063>	C141060	Parathyroid Carcinoma pTis TNM Finding v8	Atypical parathyroid neoplasm (neoplasm of uncertain malignant potential). (from AJCC 8th Ed.)			Finding	
C141064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141064>	C141060	Parathyroid Carcinoma pT1 TNM Finding v8	Tumor localized to the parathyroid gland with extension limited to soft tissue. (from AJCC 8th Ed.)			Finding	
C141065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141065>	C141060	Parathyroid Carcinoma pT2 TNM Finding v8	Tumor with direct invasion into the thyroid gland. (from AJCC 8th Ed.)			Finding	
C141066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141066>	C141060	Parathyroid Carcinoma pT3 TNM Finding v8	Tumor with direct invasion into recurrent laryngeal nerve, esophagus, trachea, skeletal muscle, adjacent lymph nodes, or thymus. (from AJCC 8th Ed.)			Finding	
C141067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141067>	C141060	Parathyroid Carcinoma pT4 TNM Finding v8	Tumor with direct invasion into major blood vessel or spine. (from AJCC 8th Ed.)			Finding	
C141068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141068>	C141057	Parathyroid Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of parathyroid carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C141069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141069>	C141068	Parathyroid Carcinoma pNX TNM Finding v8	Regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C14106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14106>	C13426	Proline-Rich Domain|Pro-Rich|Proline Rich Domain|Proline Rich Region|Proline-Rich Region	Proline-Rich Domains may be involved in heterotypic protein-protein interactions in signal transduction or other pathways. Found in signaling and structural proteins, WW domains are composed of approximately 40 amino acids folded as a stable, triple stranded beta-sheet that recognize proline-rich sequences. Some WW domains show a remarkable similarity to SH3 domains, which also appear to recognize some proline-rich sequences. Ena/VASP (Drosophila Enabled/Vasodilator-Stimulated Phosphoprotein) Family members regulate actin filament assembly, often through association with binding partners that display a proline-rich FPPPP motif. Ena/VASP proteins interact with these partners via the highly conserved Ena/VASP homology 1 (EVH1) domain. (NCI)			Amino Acid Sequence	
C141070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141070>	C141068	Parathyroid Carcinoma pN0 TNM Finding v8	No regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C141071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141071>	C141068	Parathyroid Carcinoma pN1 TNM Finding v8	Regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C141072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141072>	C141071	Parathyroid Carcinoma pN1a TNM Finding v8	Metastasis to level VI (pretracheal, paratracheal, and prelaryngeal/Delphian lymph nodes), or superior mediastinal lymph nodes (level VII). (from AJCC 8th Ed.)			Finding	
C141073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141073>	C141071	Parathyroid Carcinoma pN1b TNM Finding v8	Metastasis to unilateral, bilateral, or contralateral cervical (levels I, II, III, IV, or V) or retropharyngeal nodes. (from AJCC 8th Ed.)			Finding	
C141076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141076>	C8511|C4878	Refractory Lung Carcinoma	Lung carcinoma that does not respond to treatment.			Neoplastic Process	
C141077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141077>	C9050|C9049	Recurrent Extensive Stage Lung Small Cell Carcinoma|Recurrent Extensive Stage Small Cell Lung Carcinoma	The reemergence of extensive stage lung small cell carcinoma after a period of remission.			Neoplastic Process	
C141078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141078>	C9049|C150581	Refractory Extensive Stage Lung Small Cell Carcinoma|Refractory Extensive Stage Small Cell Lung Carcinoma	Extensive stage small cell lung carcinoma that does not respond to treatment.			Neoplastic Process	
C141079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141079>	C140895	Adrenal Cortical Carcinoma TNM Finding v8	A finding about one or more characteristics of adrenal cortical carcinoma, following the rules of the TNM AJCC v8 classification system. Adrenal medullary pheochromocytoma is staged according to the classification for adrenal neuroendocrine tumors. There is no AJCC staging system for neuroblastic tumors of the adrenal gland. (from AJCC 8th Ed.)			Finding	
C14107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14107>	C13426	RGS Domain|RGS-Signaling Domain|Regulators of G Protein Signaling Domain	Typically 120 amino acids long, the RGS (Regulator of G protein Signaling) Domain is found in over 20 human proteins, bind activated G-alpha subunits, and are responsible for GAP function. Through other domains (e.g., DEP, PDZ, or PH) RGS proteins link to other signaling molecules. RGS domains contain conserved contiguous, or dispersed, GH subdomains (GH1, 2, and 3). All RGS domains share a tertiary structure of nine alpha helixes that form a right-handed anti-parallel bundle of helixes 4-7 and a terminal bundle of helixes 1-3 and 8-9. The 3-4, 5-6, and 7-8 helix loops form an interaction surface between RGS4 and Ga(i). RGS domains allosterically stabilize the G-alpha GTP binding pocket, accelerating GTPase activity. Thus, RGS Family members rapidly inactivate G protein signal transmission from seven transmembrane receptors in GPCR signaling pathways. (NCI)			Amino Acid Sequence	
C141080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141080>	C141079	Adrenal Cortical Carcinoma Clinical TNM Finding v8	A clinical finding about one or more characteristics of adrenal cortical carcinoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C141081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141081>	C141080	Adrenal Cortical Carcinoma Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of adrenal cortical carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C141082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141082>	C141081	Adrenal Cortical Carcinoma cM0 TNM Finding v8	No distant metastasis. (from AJCC 8th Ed.)			Finding	
C141083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141083>	C141081	Adrenal Cortical Carcinoma cM1 TNM Finding v8	Distant metastasis. (from AJCC 8th Ed.)			Finding	
C141084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141084>	C141079	Adrenal Cortical Carcinoma Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of adrenal cortical carcinoma, following the rules of the TNM AJCC v8 classification system.			Finding	
C141085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141085>	C141084	Adrenal Cortical Carcinoma Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of adrenal cortical carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C141086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141086>	C141085	Adrenal Cortical Carcinoma pM1 TNM Finding v8	Distant metastasis. (from AJCC 8th Ed.)			Finding	
C141087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141087>	C141084	Adrenal Cortical Carcinoma Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of adrenal cortical carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C141088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141088>	C141087	Adrenal Cortical Carcinoma pTX TNM Finding v8	Primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C141089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141089>	C141087	Adrenal Cortical Carcinoma pT0 TNM Finding v8	No evidence of primary tumor. (from AJCC 8th Ed.)			Finding	
C14108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14108>	C13426	SH2-Binding Motif|SH2-Binding Domain	Typically found in signaling proteins, the SH2-Binding Motif mediates regulated high-affinity physical interaction (binding) with the target SH2 (SRC Homology 2) domain. SH2 domains of ~100 amino acids bind to specific phosphotyrosine (pY)-containing motifs with dissociation constants of ~50-500 nM. A conserved pocket of SH2 domains recognizes the pY, and a more variable pocket binds residues C-terminal to pY that confer specificity. SH2 domains balance high affinity for pY and recognition of adjacent residues to allow specific discrimination. The SH2 domain, an anti-parallel b-sheet between a-helices, provides a positively charged b-sheet pocket for binding of pY moieties, and an extended b-sheet surface for binding residues C-terminal to pY. B-sheet surface differences have significant effects on ligand-specificity. (NCI)			Amino Acid Sequence	
C141090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141090>	C141087	Adrenal Cortical Carcinoma pT1 TNM Finding v8	Tumor measuring 5 cm or less in greatest dimension, with no extra-adrenal invasion. (from AJCC 8th Ed.)			Finding	
C141091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141091>	C141087	Adrenal Cortical Carcinoma pT2 TNM Finding v8	Tumor measuring more than 5 cm in greatest dimension, with no extra-adrenal invasion. (from AJCC 8th Ed.)			Finding	
C141092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141092>	C141087	Adrenal Cortical Carcinoma pT3 TNM Finding v8	Tumor of any size with local invasion but not invading adjacent organs. (from AJCC 8th Ed.)			Finding	
C141093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141093>	C141087	Adrenal Cortical Carcinoma pT4 TNM Finding v8	Tumor of any size that invades adjacent organs (kidney, diaphragm, pancreas, spleen, or liver) or large blood vessels (renal vein or vena cava). (from AJCC 8th Ed.)			Finding	
C141094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141094>	C141084	Adrenal Cortical Carcinoma Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of adrenal cortical carcinoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C141095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141095>	C141094	Adrenal Cortical Carcinoma pNX TNM Finding v8	Regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C141096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141096>	C141094	Adrenal Cortical Carcinoma pN0 TNM Finding v8	No regional lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C141097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141097>	C141094	Adrenal Cortical Carcinoma pN1 TNM Finding v8	Metastasis in regional lymph node(s). (from AJCC 8th Ed.)			Finding	
C141098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141098>	C9325	Adrenal Cortical Carcinoma by AJCC v7 Stage|Adrenal Cortex Carcinoma by AJCC v7 Stage	A term that refers to the staging of adrenal cortical carcinoma, following the rules of the TNM AJCC v7 classification system.			Neoplastic Process	
C141099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141099>	C28108	ENSAT Stage|European Network for the Study of Adrenal Tumors Stage	An adrenal cancer stage defined according to the European Network for the Study of Adrenal Tumors (ENSAT) criteria.			Classification	
C14109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14109>	C13426	SH3-Binding Motif|SH3-Binding Domain	Typically found in proteins involved in signaling pathways, the SH3-Binding Motif is a peptide sequence that mediates regulated high-affinity physical interaction (binding) with the SH3 (SRC Homology 3) domain in target protein partners. The SH3-binding motif often share proline-rich stretches containing a common PXXP motif. (NCI)			Amino Acid Sequence	
C1410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1410>	C387	Recombinant Human Stem Cell Factor|Mast Cell Growth Factor|Steel Factor|c-Kit Ligand	A therapeutic glycoprotein cytokine chemically identical to or similar to endogenous human stem cell factor with hematopoietic activity. Recombinant human stem cell factor (rhSCF) binds to the receptor tyrosine kinase c-kit, which may stimulate the growth of peripheral blood progenitor cells (PBPCs). This agent works synergistically with other hematopoietic growth factors. rhSCF may promote bone marrow recovery after myeloablative therapies and procedures.			Chemical Viewed Functionally	NCI Drug Dictionary Terminology
C141100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141100>	C9325	Adrenal Cortical Carcinoma by AJCC v8 Stage|Adrenal Cortex Carcinoma by AJCC v8 Stage	A term that refers to the staging of adrenal cortical carcinoma, following the rules of the TNM AJCC v8 classification system. Adrenal medullary pheochromocytoma is staged according to the classification for adrenal neuroendocrine tumors. There is no AJCC staging system for neuroblastic tumors of the adrenal gland. (from AJCC 8th Ed.)			Neoplastic Process	
C141101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141101>	C141100	Stage I Adrenal Cortical Carcinoma AJCC v8|Stage I Adrenal Cortex Cancer|Stage I Adrenal Cortex Carcinoma AJCC v8	Stage I includes: T1, N0, M0. T1: Tumor measuring 5 cm or less in greatest dimension, with no extra-adrenal invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage I Adrenal Cortex Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C141102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141102>	C141100	Stage II Adrenal Cortical Carcinoma AJCC v8|Stage II Adrenal Cortex Cancer|Stage II Adrenal Cortex Carcinoma AJCC v8	Stage II includes: T2, N0, M0. T2: Tumor measuring more than 5 cm in greatest dimension, with no extra-adrenal invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (from AJCC 8th Ed.)	Stage II Adrenal Cortex Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C141103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141103>	C141100	Stage III Adrenal Cortical Carcinoma AJCC v8|Stage III Adrenal Cortex Cancer|Stage III Adrenal Cortex Carcinoma AJCC v8	Stage III includes: (T1, N1, M0); (T2, N1, M0); (T3, Any N, M0); (T4, Any N, M0). T1: Tumor measuring 5 cm or less in greatest dimension, with no extra-adrenal invasion. T2: Tumor measuring more than 5 cm in greatest dimension, with no extra-adrenal invasion. T3: Tumor of any size with local invasion but not invading adjacent organs. T4: Tumor of any size that invades adjacent organs (kidney, diaphragm, pancreas, spleen, or liver) or large blood vessels (renal vein or vena cava). N1: Metastasis in regional lymph node(s). M0: No distant metastasis. (from AJCC 8th Ed.)	Stage III Adrenal Cortex Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C141104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141104>	C141100	Stage IV Adrenal Cortical Carcinoma AJCC v8|Stage IV Adrenal Cortex Cancer|Stage IV Adrenal Cortex Carcinoma AJCC v8	Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (from AJCC 8th Ed.)	Stage IV Adrenal Cortex Carcinoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C141105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141105>	C140895	Pheochromocytoma and Paraganglioma TNM Finding v8|Adrenal-Neuroendocrine Tumor TNM Finding v8	A finding about one or more characteristics of pheochromocytoma and paraganglioma, following the rules of the TNM AJCC v8 classification system. This classification system applies to the adrenal medulla pheochromocytomas and sympathetic paragangliomas. Parasympathetic paragangliomas are not staged because they are largely benign. This staging system does not apply to neuroendocrine tumors of the pancreas (are staged according to the classification for neuroendocrine tumors of the pancreas) and carotid body tumors (not staged). (from AJCC 8th Ed.)			Finding	
C141106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141106>	C141105	Pheochromocytoma and Paraganglioma Clinical TNM Finding v8|Adrenal-Neuroendocrine Tumor Clinical TNM Finding v8	A clinical finding about one or more characteristics of pheochromocytoma and paraganglioma, following the rules of the TNM AJCC v8 classification system.			Finding	
C141107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141107>	C141106	Pheochromocytoma and Paraganglioma Clinical Distant Metastasis TNM Finding v8|Adrenal-Neuroendocrine Tumor Clinical Distant Metastasis TNM Finding v8	A clinical finding about one or more characteristics of pheochromocytoma and paraganglioma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C141108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141108>	C141107	Pheochromocytoma and Paraganglioma cM0 TNM Finding v8|Adrenal-Neuroendocrine Tumor cM0 TNM Finding v8	No distant metastasis. (from AJCC 8th Ed.)			Finding	
C141109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141109>	C141107	Pheochromocytoma and Paraganglioma cM1 TNM Finding v8|Adrenal-Neuroendocrine Tumor cM1 TNM Finding v8	Distant metastasis. (from AJCC 8th Ed.)			Finding	
C14110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14110>	C14109	PXXP Motif|PXXP Domain	The SH3 domain, often seen in signaling pathway proteins, frequently binds to a conserved PXXP Motif usually found in proline-rich regions of target proteins. The SH3 domain contains a site located between the RT and n-SRC loops that binds the PXXP motif, which then adopts a poly-proline type II (PPII) conformation. PXXP motifs are often clustered and have residues that contribute to binding specificity. Class I motifs have an amino to carboxy terminal binding orientation and include sites specific for the SRC oncoprotein. More promiscuous in their binding, Class II motifs have a carboxy to amino terminal binding orientation, PXXP can be in either of two positions, and they have basic residues at the C-terminus. (NCI)			Amino Acid Sequence	
C141110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141110>	C141109	Pheochromocytoma and Paraganglioma cM1a TNM Finding v8|Adrenal-Neuroendocrine Tumor cM1a TNM Finding v8	Distant metastasis to only bone. (from AJCC 8th Ed.)			Finding	
C141111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141111>	C141109	Pheochromocytoma and Paraganglioma cM1b TNM Finding v8|Adrenal-Neuroendocrine Tumor cM1b TNM Finding v8	Distant metastasis to only distant lymph nodes/liver or lung. (from AJCC 8th Ed.)			Finding	
C141112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141112>	C141109	Pheochromocytoma and Paraganglioma cM1c TNM Finding v8|Adrenal-Neuroendocrine Tumor cM1c TNM Finding v8	Distant metastasis to bone plus multiple other sites. (from AJCC 8th Ed.)			Finding	
C141113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141113>	C141105	Pheochromocytoma and Paraganglioma Pathologic TNM Finding v8|Adrenal-Neuroendocrine Tumor Pathologic TNM Finding v8	A pathologic finding about one or more characteristics of pheochromocytoma and paraganglioma, following the rules of the TNM AJCC v8 classification system.			Finding	
C141114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141114>	C141113	Pheochromocytoma and Paraganglioma Pathologic Distant Metastasis TNM Finding v8|Adrenal-Neuroendocrine Tumor Pathologic Distant Metastasis TNM Finding v8	A pathologic finding about one or more characteristics of pheochromocytoma and paraganglioma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.			Finding	
C141115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141115>	C141114	Pheochromocytoma and Paraganglioma pM1 TNM Finding v8|Adrenal-Neuroendocrine Tumor pM1 TNM Finding v8	Distant metastasis. (from AJCC 8th Ed.)			Finding	
C141116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141116>	C141115	Pheochromocytoma and Paraganglioma pM1a TNM Finding v8|Adrenal-Neuroendocrine Tumor pM1a TNM Finding v8	Distant metastasis to only bone. (from AJCC 8th Ed.)			Finding	
C141117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141117>	C141115	Pheochromocytoma and Paraganglioma pM1b TNM Finding v8|Adrenal-Neuroendocrine Tumor pM1b TNM Finding v8	Distant metastasis to only distant lymph nodes/liver or lung. (from AJCC 8th Ed.)			Finding	
C141118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141118>	C141115	Pheochromocytoma and Paraganglioma pM1c TNM Finding v8|Adrenal-Neuroendocrine Tumor pM1c TNM Finding v8	Distant metastasis to bone plus multiple other sites. (from AJCC 8th Ed.)			Finding	
C141119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141119>	C141113	Pheochromocytoma and Paraganglioma Pathologic Primary Tumor TNM Finding v8|Adrenal-Neuroendocrine Tumor Pathologic Primary Tumor TNM Finding v8	A pathologic finding about one or more characteristics of pheochromocytoma and paraganglioma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.			Finding	
C14111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14111>	C13426	WD Repeat|G-Beta Repeat|Trp-Asp Repeat|Tryptophan-Aspartate Repeat|WD Domain|WD40 Domain	WD40 Repeats are found in signal transduction, mRNA processing, cytoskeletal assembly, and cell cycle proteins; none are catalytic. G-beta is the prototypic WD40 protein. WD-40 proteins contain 5-8 repeats of about 40 residues, with a central Trp-Asp (WD) motif. The repeats may span the entire protein or make up either terminal or the central section. WD40 domains serve as a platform to which proteins stably or reversibly bind; some may recognize phosphoSer and -Thr peptides. The repeat forms a closed ring propeller with seven blades each composed of a four-stranded anti-parallel b-sheet. Each repeat forms the first three strands of one blade and the last strand in the next blade. The last C-terminal repeat completes the blade of the first repeat. Residues on the propeller top surface likely coordinate interactions with other proteins or ligands.			Amino Acid Sequence	
C141120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141120>	C141119	Pheochromocytoma and Paraganglioma pTX TNM Finding v8|Adrenal-Neuroendocrine Tumor pTX TNM Finding v8	Primary tumor cannot be assessed. (from AJCC 8th Ed.)			Finding	
C141121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141121>	C141119	Pheochromocytoma pT1 TNM Finding v8|Adrenal-Neuroendocrine Tumor pT1 TNM Finding v8	Pheochromocytoma measuring less than 5 cm in greatest dimension, with no extra-adrenal invasion. (from AJCC 8th Ed.)			Finding	
C141122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141122>	C141119	Pheochromocytoma and Paraganglioma pT2 TNM Finding v8|Adrenal-Neuroendocrine Tumor pT2 TNM Finding v8	Pheochromocytoma measuring 5 cm or more in greatest dimension or paraganglioma-sympathetic of any size, with no extra-adrenal invasion. (from AJCC 8th Ed.)			Finding	
C141123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141123>	C141119	Pheochromocytoma and Paraganglioma pT3 TNM Finding v8|Adrenal-Neuroendocrine Tumor pT3 TNM Finding v8	Tumor of any size with invasion into surrounding tissues (e.g., liver, pancreas, spleen, kidneys). (from AJCC 8th Ed.)			Finding	
C141124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141124>	C141113	Pheochromocytoma and Paraganglioma Pathologic Regional Lymph Nodes TNM Finding v8|Adrenal-Neuroendocrine Tumor Pathologic Regional Lymph Nodes TNM Finding v8	A pathologic finding about one or more characteristics of pheochromocytoma and paraganglioma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C141125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141125>	C141124	Pheochromocytoma and Paraganglioma pNX TNM Finding v8|Adrenal-Neuroendocrine Tumor pNX TNM Finding v8	Regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C141126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141126>	C141124	Pheochromocytoma and Paraganglioma pN0 TNM Finding v8|Adrenal-Neuroendocrine Tumor pN0 TNM Finding v8	No lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C141127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141127>	C141124	Pheochromocytoma and Paraganglioma pN1 TNM Finding v8|Adrenal-Neuroendocrine Tumor pN1 TNM Finding v8	Regional Lymph node metastasis. (from AJCC 8th Ed.)			Finding	
C141128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141128>	C4216	Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma by AJCC v8 Stage	A term that refers to the staging of adrenal gland pheochromocytoma and sympathetic paraganglioma, following the rules of the TNM AJCC v8 classification system. Parasympathetic paragangliomas are not staged because they are largely benign. This staging system does not apply to neuroendocrine tumors of the pancreas (are staged according to the classification for neuroendocrine tumors of the pancreas) and carotid body tumors (not staged). (from AJCC 8th Ed.)			Neoplastic Process	
C141129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141129>	C141128	Stage I Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8	Stage I includes: T1, N0, M0. T1: Pheochromocytoma measuring less than 5 cm in greatest dimension, with no extra-adrenal invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (from AJCC 8th Ed.)			Neoplastic Process	
C14112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14112>	C13432	9q32-q34	A chromosome band present on 9q			Gene or Genome	
C141130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141130>	C141128	Stage II Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8	Stage II includes: T2, N0, M0. T2: Pheochromocytoma measuring 5 cm or more in greatest dimension or paraganglioma-sympathetic of any size, with no extra-adrenal invasion. N0: No regional lymph node metastasis. M0: No distant metastasis. (from AJCC 8th Ed.)			Neoplastic Process	
C141131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141131>	C141128	Stage III Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8	Stage III includes: (T1, N1, M0); (T2, N1, M0); (T3, Any N, M0). T1: Pheochromocytoma measuring less than 5 cm in greatest dimension, with no extra-adrenal invasion. T2: Pheochromocytoma measuring 5 cm or more in greatest dimension or paraganglioma-sympathetic of any size, with no extra-adrenal invasion. T3: Tumor of any size with invasion into surrounding tissues (e.g., liver, pancreas, spleen, kidneys). N1: Regional lymph node metastasis. M0: No distant metastasis. (from AJCC 8th Ed.)			Neoplastic Process	
C141132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141132>	C141128	Stage IV Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8	Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (from AJCC 8th Ed.)			Neoplastic Process	
C141133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141133>	C18004	PRETEXT Staging System|PRETEXT Staging|Pretreatment Extent of Disease	A staging system designed by the International Childhood Liver Tumor Strategy Group (SIOPEL) for staging and risk stratification of liver tumors. A PRETEXT stage number is based on the number of contiguous liver sections not involved by tumor, corresponding to a rough estimate of the difficulty of the expected surgical procedure. It is used to describe tumor extent before any therapy, thus allowing more effective comparison between studies conducted by different groups.			Classification	
C141134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141134>	C20993	BREAST-Q	A patient-reported outcome measure designed to provide information about the impact and effectiveness of breast surgery. It consists of 5 modules: augmentation, reduction (or mastopexy), breast conserving therapy, mastectomy, and post-mastectomy reconstruction. Each module is divided into multiple scales that can be used independently.			Intellectual Product	
C141135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141135>	C141137|C129820	Linrodostat|(R)-N-(4-chlorophenyl)-2-((1S,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propenamide|BMS 986205|BMS-986205|BMS986205|IDO-1 Inhibitor BMS-986205|Indoleamine-pyrrole 2,3-Dioxygenase Inhibitor BMS-986205|LINRODOSTAT|ONO-7701	An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon administration, linrodostat specifically targets and binds to IDO1, a cytosolic enzyme responsible for the oxidation of the amino acid tryptophan into the immunosuppressive metabolite kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, BMS-986205 restores and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes, and causes a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL) response against the IDO1-expressing tumor cells, thereby inhibiting the growth of IDO1-expressing tumor cells. IDO1, overexpressed by multiple tumor cell types, plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system.	Linrodostat		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C141136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141136>	C1967	ALK Inhibitor|Anaplastic Lymphoma Kinase Inhibitor	Any agent that inhibits the activity of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK).			Chemical Viewed Functionally	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology
C141137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141137>	C471|C141144	IDO1 Inhibitor|IDO Inhibitor	Any agent that inhibits the activity of the enzyme indoleamine 2,3-dioxygenase 1 (IDO1; IDO).	IDO1 Inhibitor		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C141138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141138>	C28108	Ann Arbor Stage	A lymphoma anatomic stage defined according to the Ann Arbor classification criteria.			Classification	
C141139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141139>	C27268	Lymphoma by Ann Arbor Stage	An anatomic stage for Hodgkin and non-Hodgkin lymphomas  based on the Ann Arbor classification criteria.			Neoplastic Process	
C14113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14113>	C13432	14q24-q31	A chromosome band present on 14q			Gene or Genome	
C141140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141140>	C3211|C141139	Non-Hodgkin Lymphoma by Ann Arbor Stage	An anatomic stage for non-Hodgkin lymphomas based on the Ann Arbor classification criteria.			Neoplastic Process	
C141141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141141>	C9357|C141139	Hodgkin Lymphoma by Ann Arbor Stage	An anatomic stage for Hodgkin lymphomas based on the Ann Arbor classification criteria.			Neoplastic Process	
C141142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141142>	C9265	Mycosis Fungoides and Sezary Syndrome by AJCC v7 Stage	A term that refers to the staging of mycosis fungoides and Sezary syndrome, following the rules of the TNM AJCC v7 classification system.			Neoplastic Process	
C141143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141143>	C3246|C141142	Mycosis Fungoides by AJCC v7 Stage	A term that refers to the staging of mycosis fungoides, following the rules of the TNM AJCC v7 classification system.			Neoplastic Process	
C141144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141144>	C308	Immune Checkpoint Modulator	Any agent that modulates the immune checkpoint pathway, either by blocking any inhibitory immune checkpoint protein or by activating any stimulatory immune checkpoint protein.	Immune Checkpoint Modulator		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C141145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141145>	C20401|C141144	Anti-ICOS Monoclonal Antibody	Any monoclonal antibody that is directed against inducible T-cell co-stimulator (ICOS; CD278).			Chemical Viewed Functionally	
C141146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141146>	C20401|C143250|C129822	Anti-TIM-3 Monoclonal Antibody|TIM-3 Inhibitor	Any monoclonal antibody that targets the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2).	Anti-TIM-3 Monoclonal Antibody		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C141147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141147>	C28108	Lugano Stage	An adult non-Hodgkin lymphoma and adult and childhood Hodgkin lymphoma stage defined according to the Lugano classification criteria.			Classification	
C141148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141148>	C7587|C141205	Lugano Classification Adult Lymphoma by AJCC v8 Stage	A staging system for adult Hodgkin and adult non-Hodgkin lymphomas based on the Lugano classification criteria. This staging system does not apply to ocular adnexal lymphomas (are staged according to the classification for ocular adnexal lymphoma), pediatric lymphomas (are staged according to the classification for pediatric lymphoma), primary cutaneous lymphomas (are staged according to the classification for primary cutaneous lymphoma), and multiple myelomas (are staged according to the classification for plasma cell myeloma). (from AJCC 8th Ed.)			Neoplastic Process	
C141149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141149>	C141148	Lugano Classification Limited Stage Adult Lymphoma AJCC v8	Limited stage adult lymphoma based on the Lugano classification criteria. It includes stages I, IE, II, and IIE. (from AJCC 8th Ed.)			Neoplastic Process	
C14114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14114>	C13453	Calcium-Binding Domain|Calcium-Binding Motif	Many calcium-binding proteins belong to the same evolutionary family and share a type of calcium-binding domain known as the EF-hand. This type of domain consists of a twelve residue loop flanked on both side by a twelve residue alpha-helical domain. In an EF-hand loop the calcium ion is coordinated in a pentagonal bipyramidal configuration. The six residues involved in the binding are in positions 1, 3, 5, 7, 9 and 12; these residues are denoted by X, Y, Z, -Y, -X and -Z. The invariant Glu or Asp at position 12 provides two oxygens for liganding Ca (bidentate ligand). (From InterPro IPR002048)			Amino Acid Sequence	
C141150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141150>	C141149	Lugano Classification Stage I Adult Lymphoma AJCC v8	Stage I: Involvement of a single lymphatic site (i.e., nodal region, Waldeyer's ring, thymus, or spleen). (from AJCC 8th Ed.)			Neoplastic Process	
C141151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141151>	C141149	Lugano Classification Stage IE Adult Lymphoma AJCC v8	Stage IE: Single extralymphatic site in the absence of nodal involvement (rare in Hodgkin lymphoma). (from AJCC 8th Ed.)			Neoplastic Process	
C141152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141152>	C141149	Lugano Classification Stage II Adult Lymphoma AJCC v8	Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm. (from AJCC 8th Ed.)			Neoplastic Process	
C141153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141153>	C141149	Lugano Classification Stage IIE Adult Lymphoma AJCC v8	Stage IIE: Contiguous extralymphatic extension from a nodal site with or without involvement of other lymph node regions on the same side of the diaphragm. (from AJCC 8th Ed.)			Neoplastic Process	
C141154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141154>	C38655|C141152	Lugano Classification Stage II Bulky Adult Lymphoma AJCC v8	Stage II Bulky: Stage II with disease bulk. (from AJCC 8th Ed.)			Neoplastic Process	
C141155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141155>	C141148	Lugano Classification Advanced Stage Adult Lymphoma AJCC v8	Advanced stage adult lymphoma based on the Lugano classification criteria. It includes stages III and IV. (from AJCC 8th Ed.)			Neoplastic Process	
C141156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141156>	C141155	Lugano Classification Stage III Adult Lymphoma AJCC v8	Stage III: Involvement of lymph node regions on both sides of the diaphragm; nodes above the diaphragm with spleen involvement. (from AJCC 8th Ed.)			Neoplastic Process	
C141157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141157>	C141155	Lugano Classification Stage IV Adult Lymphoma AJCC v8	Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or noncontiguous extralymphatic organ involvement in conjunction with nodal stage II disease; or any extralymphatic organ involvement in nodal stage III disease. Stage IV includes any involvement of the CSF, bone marrow, liver, or lungs (other than by direct extension in stage IIE disease). (from AJCC 8th Ed.)			Neoplastic Process	
C141158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141158>	C7704|C141148	Lugano Classification Adult Non-Hodgkin Lymphoma by AJCC v8 Stage	A staging system for adult non-Hodgkin lymphomas based on the Lugano classification criteria. This staging system does not apply to ocular adnexal lymphomas (are staged according to the classification for ocular adnexal lymphoma), pediatric non-Hodgkin lymphomas (are staged according to the St. Jude Children's Research Hospital staging system), primary cutaneous lymphomas (are staged according to the classification for primary cutaneous lymphoma), and multiple myelomas (are staged according to the classification for plasma cell myeloma). (from AJCC 8th Ed.)			Neoplastic Process	
C141159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141159>	C141158|C141149	Lugano Classification Limited Stage Adult Non-Hodgkin Lymphoma AJCC v8	Limited stage adult non-Hodgkin lymphoma based on the Lugano classification criteria. It includes stages I, IE, II, and IIE. (from AJCC 8th Ed.)	Lugano Classification Limited Stage Adult Non-Hodgkin Lymphoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C14115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14115>	C13432	3q22.2	A chromosome band present on 3q			Gene or Genome	
C141160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141160>	C141159|C141150	Lugano Classification Stage I Adult Non-Hodgkin Lymphoma AJCC v8	Stage I: Involvement of a single lymphatic site (i.e., nodal region, Waldeyer's ring, thymus, or spleen). (from AJCC 8th Ed.)			Neoplastic Process	
C141161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141161>	C141159|C141151	Lugano Classification Stage IE Adult Non-Hodgkin Lymphoma AJCC v8	Stage IE: Single extralymphatic site in the absence of nodal involvement. (from AJCC 8th Ed.)			Neoplastic Process	
C141162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141162>	C141159|C141152	Lugano Classification Stage II Adult Non-Hodgkin Lymphoma AJCC v8	Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm. (from AJCC 8th Ed.)			Neoplastic Process	
C141163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141163>	C141159|C141153	Lugano Classification Stage IIE Adult Non-Hodgkin Lymphoma AJCC v8	Stage IIE: Contiguous extralymphatic extension from a nodal site with or without involvement of other lymph node regions on the same side of the diaphragm. (from AJCC 8th Ed.)			Neoplastic Process	
C141164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141164>	C141162|C141154	Lugano Classification Stage II Bulky Adult Non-Hodgkin Lymphoma AJCC v8	Stage II Bulky: Stage II with disease bulk. (from AJCC 8th Ed.)			Neoplastic Process	
C141165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141165>	C141158|C141155	Lugano Classification Advanced Stage Adult Non-Hodgkin Lymphoma AJCC v8	Advanced stage adult non-Hodgkin lymphoma based on the Lugano classification criteria. It includes stages III and IV. (from AJCC 8th Ed.)			Neoplastic Process	
C141166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141166>	C141165|C141156	Lugano Classification Stage III Adult Non-Hodgkin Lymphoma AJCC v8	Stage III: Involvement of lymph node regions on both sides of the diaphragm; nodes above the diaphragm with spleen involvement. (from AJCC 8th Ed.)			Neoplastic Process	
C141167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141167>	C141165|C141157	Lugano Classification Stage IV Adult Non-Hodgkin Lymphoma AJCC v8	Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or noncontiguous extralymphatic organ involvement in conjunction with nodal stage II disease; or any extralymphatic organ involvement in nodal stage III disease. Stage IV includes any involvement of the CSF, bone marrow, liver, or lungs (other than by direct extension in stage IIE disease). (from AJCC 8th Ed.)			Neoplastic Process	
C141168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141168>	C9357|C141205	Lugano Classification Hodgkin Lymphoma by AJCC v8 Stage	A staging system for Hodgkin lymphomas based on the Lugano classification criteria. Staging for childhood Hodgkin lymphoma is the same as for the adult counterpart. (from AJCC 8th Ed.)			Neoplastic Process	
C141169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141169>	C141168	Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8	Limited stage Hodgkin lymphoma based on the Lugano classification criteria. It includes stages I, IE, II, and IIE. (from AJCC 8th Ed.)	Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C14116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14116>	C13432	12p13.2	A chromosome band present on 12p			Gene or Genome	
C141170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141170>	C141169	Lugano Classification Stage I Hodgkin Lymphoma AJCC v8	Stage I: Involvement of a single lymphatic site (i.e., nodal region, Waldeyer's ring, thymus, or spleen). (from AJCC 8th Ed.)			Neoplastic Process	
C141171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141171>	C141169	Lugano Classification Stage IE Hodgkin Lymphoma AJCC v8	Stage IE: Single extralymphatic site in the absence of nodal involvement (rare in Hodgkin lymphoma). (from AJCC 8th Ed.)			Neoplastic Process	
C141172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141172>	C141169	Lugano Classification Stage II Hodgkin Lymphoma AJCC v8	Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm. (from AJCC 8th Ed.)			Neoplastic Process	
C141173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141173>	C141169	Lugano Classification Stage IIE Hodgkin Lymphoma AJCC v8	Stage IIE: Contiguous extralymphatic extension from a nodal site with or without involvement of other lymph node regions on the same side of the diaphragm. (from AJCC 8th Ed.)			Neoplastic Process	
C141174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141174>	C38655|C141172	Lugano Classification Stage II Bulky Hodgkin Lymphoma AJCC v8	Stage II Bulky: Stage II with disease bulk. (from AJCC 8th Ed.)			Neoplastic Process	
C141175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141175>	C141168	Lugano Classification Advanced Stage Hodgkin Lymphoma AJCC v8	Advanced stage Hodgkin lymphoma based on the Lugano classification criteria. It includes stages III and IV. (from AJCC 8th Ed.)			Neoplastic Process	
C141176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141176>	C141175	Lugano Classification Stage III Hodgkin Lymphoma AJCC v8	Stage III: Involvement of lymph node regions on both sides of the diaphragm; nodes above the diaphragm with spleen involvement. (from AJCC 8th Ed.)			Neoplastic Process	
C141177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141177>	C141175	Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8	Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or noncontiguous extralymphatic organ involvement in conjunction with nodal stage II disease; or any extralymphatic organ involvement in nodal stage III disease. Stage IV includes any involvement of the CSF, bone marrow, liver, or lungs (other than by direct extension in stage IIE disease). (from AJCC 8th Ed.)			Neoplastic Process	
C141178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141178>	C7714|C141202|C141168	Lugano Classification Childhood Hodgkin Lymphoma by AJCC v8 Stage	A staging system for childhood Hodgkin lymphomas based on the Lugano classification criteria. Staging for childhood Hodgkin lymphoma is the same as for the adult counterpart. (from AJCC 8th Ed.)			Neoplastic Process	
C141179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141179>	C141178|C141169	Lugano Classification Limited Stage Childhood Hodgkin Lymphoma AJCC v8	Limited stage childhood Hodgkin lymphoma based on the Lugano classification criteria. It includes stages I, IE, II, and IIE. (from AJCC 8th Ed.)			Neoplastic Process	
C14117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14117>	C47935	EXO I Motif|EXO I Domain	A conserved amino acid sequence (Asp-X-Glu) in DNA polymerases that is required for 3' > 5' exonuclease activity.			Amino Acid Sequence	
C141180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141180>	C141179|C141170	Lugano Classification Stage I Childhood Hodgkin Lymphoma AJCC v8	Stage I: Involvement of a single lymphatic site (i.e., nodal region, Waldeyer's ring, thymus, or spleen). (from AJCC 8th Ed.)			Neoplastic Process	
C141181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141181>	C141179|C141171	Lugano Classification Stage IE Childhood Hodgkin Lymphoma AJCC v8	Stage IE: Single extralymphatic site in the absence of nodal involvement (rare in Hodgkin lymphoma). (from AJCC 8th Ed.)			Neoplastic Process	
C141182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141182>	C141179|C141172	Lugano Classification Stage II Childhood Hodgkin Lymphoma AJCC v8	Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm. (from AJCC 8th Ed.)			Neoplastic Process	
C141183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141183>	C141179|C141173	Lugano Classification Stage IIE Childhood Hodgkin Lymphoma AJCC v8	Stage IIE: Contiguous extralymphatic extension from a nodal site with or without involvement of other lymph node regions on the same side of the diaphragm. (from AJCC 8th Ed.)			Neoplastic Process	
C141184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141184>	C141182|C141174	Lugano Classification Stage II Bulky Childhood Hodgkin Lymphoma AJCC v8	Stage II Bulky: Stage II with disease bulk. (from AJCC 8th Ed.)			Neoplastic Process	
C141185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141185>	C141178|C141175	Lugano Classification Advanced Stage Childhood Hodgkin Lymphoma AJCC v8	Advanced stage childhood Hodgkin lymphoma based on the Lugano classification criteria. It includes stages III and IV. (from AJCC 8th Ed.)			Neoplastic Process	
C141186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141186>	C141185|C141176	Lugano Classification Stage III Childhood Hodgkin Lymphoma AJCC v8	Stage III: Involvement of lymph node regions on both sides of the diaphragm; nodes above the diaphragm with spleen involvement. (from AJCC 8th Ed.)			Neoplastic Process	
C141187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141187>	C141185|C141177	Lugano Classification Stage IV Childhood Hodgkin Lymphoma AJCC v8	Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or noncontiguous extralymphatic organ involvement in conjunction with nodal stage II disease; or any extralymphatic organ involvement in nodal stage III disease. Stage IV includes any involvement of the bone marrow, liver, or lungs (other than by direct extension in stage IIE disease). (from AJCC 8th Ed.)			Neoplastic Process	
C141189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141189>	C7702|C141168|C141148	Lugano Classification Adult Hodgkin Lymphoma by AJCC v8 Stage	A staging system for adult Hodgkin lymphomas based on the Lugano classification criteria. Staging for adult Hodgkin lymphoma is the same as for the childhood counterpart. (from AJCC 8th Ed.)			Neoplastic Process	
C14118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14118>	C47935	EXO II Motif|EXO II Domain	A conserved amino acid sequence (Asn-(X)3-Phe-Asp) in DNA polymerases that is required for 3' > 5' exonuclease activity.			Amino Acid Sequence	
C141190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141190>	C141189|C141169|C141149	Lugano Classification Limited Stage Adult Hodgkin Lymphoma AJCC v8	Limited stage adult Hodgkin lymphoma based on the Lugano classification criteria. It includes stages I, IE, II, and IIE. (from AJCC 8th Ed.)	Lugano Classification Limited Stage Adult Hodgkin Lymphoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C141191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141191>	C141190|C141170|C141150	Lugano Classification Stage I Adult Hodgkin Lymphoma AJCC v8	Stage I: Involvement of a single lymphatic site (i.e., nodal region, Waldeyer's ring, thymus, or spleen). (from AJCC 8th Ed.)			Neoplastic Process	
C141192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141192>	C141190|C141171|C141151	Lugano Classification Stage IE Adult Hodgkin Lymphoma AJCC v8	Stage IE: Single extralymphatic site in the absence of nodal involvement (rare in Hodgkin lymphoma). (from AJCC 8th Ed.)			Neoplastic Process	
C141193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141193>	C141190|C141172|C141152	Lugano Classification Stage II Adult Hodgkin Lymphoma AJCC v8	Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm. (from AJCC 8th Ed.)			Neoplastic Process	
C141194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141194>	C141190|C141173|C141153	Lugano Classification Stage IIE Adult Hodgkin Lymphoma AJCC v8	Stage IIE: Contiguous extralymphatic extension from a nodal site with or without involvement of other lymph node regions on the same side of the diaphragm. (from AJCC 8th Ed.)			Neoplastic Process	
C141195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141195>	C141193|C141174|C141154	Lugano Classification Stage II Bulky Adult Hodgkin Lymphoma AJCC v8	Stage II Bulky: Stage II with disease bulk. (from AJCC 8th Ed.)			Neoplastic Process	
C141196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141196>	C141189|C141175|C141155	Lugano Classification Advanced Stage Adult Hodgkin Lymphoma AJCC v8	Advanced stage adult Hodgkin lymphoma based on the Lugano classification criteria. It includes stages III and IV. (from AJCC 8th Ed.)			Neoplastic Process	
C141197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141197>	C141196|C141176|C141156	Lugano Classification Stage III Adult Hodgkin Lymphoma AJCC v8	Stage III: Involvement of lymph node regions on both sides of the diaphragm; nodes above the diaphragm with spleen involvement. (from AJCC 8th Ed.)			Neoplastic Process	
C141198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141198>	C141196|C141177|C141157	Lugano Classification Stage IV Adult Hodgkin Lymphoma AJCC v8	Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs, with or without associated lymph node involvement; or noncontiguous extralymphatic organ involvement in conjunction with nodal stage II disease; or any extralymphatic organ involvement in nodal stage III disease. Stage IV includes any involvement of the CSF, bone marrow, liver, or lungs (other than by direct extension in stage IIE disease). (from AJCC 8th Ed.)			Neoplastic Process	
C141199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141199>	C28108	Stage IE	A stage term referring to Hodgkin or non-Hodgkin lymphoma involving a single extralymphatic site in the absence of nodal involvement. (from AJCC 8th Ed.)			Classification	
C14119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14119>	C47935	EXO III Motif|EXO III Domain	A conserved amino acid sequence (Tyr-(X)3-Asp) in DNA polymerases that is required for 3' > 5' exonuclease activity.			Amino Acid Sequence	
C1411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1411>	C67437|C1490	Paclitaxel|5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester with (2R,3S)-N-Benzoyl-3-phenylisoserine|Anzatax|Asotax|Bristaxol|PACLITAXEL|Praxel|Taxol|Taxol|Taxol|Taxol Konzentrat|[2aR-[2a Alpha,4beta,4a beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a alpha,12b alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester|paclitaxel	A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)	Paclitaxel		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GCT Authorized Value Terminology|GCT Total Dose Table|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C141200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141200>	C28108	Stage IIE	A stage term referring to Hodgkin or non-Hodgkin lymphoma with contiguous extralymphatic extension from a nodal site with or without involvement of other lymph node regions on the same side of the diaphragm. (from AJCC 8th Ed.)			Classification	
C141201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141201>	C19589	Cytopathic Effect|CPE|Cytopathogenic Effect|Viral Cytopathic Change	Structural changes in host cells that are caused by viral invasion.			Pathologic Function	
C141202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141202>	C5165|C141205	Childhood Lymphoma by AJCC v8 Stage	Staging systems for Hodgkin and non-Hodgkin lymphomas of childhood. Different systems are used for Hodgkin lymphoma and non-Hodgkin lymphoma of childhood. Staging of childhood Hodgkin lymphoma is the same as for the adult counterpart and is based on the Lugano classification criteria. The Ann Arbor staging system has been found to be inappropriate for staging of the non-Hodgkin lymphomas of childhood. The St. Jude staging system has been widely accepted and remains the recommended staging system for non-Hodgkin lymphomas of childhood. (from AJCC 8th Ed.)			Neoplastic Process	
C141203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141203>	C138961	PSA Level Greater than or Equal to 0.05|PSA Level 0.05 or Greater	A blood concentration of prostate specific antigen greater than or equal to 0.05 ng/mL.	PSA Level Greater than or Equal to 0.05		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141204>	C138961	PSA Level Less than 0.7	A blood concentration of prostate specific antigen less than 0.7 ng/mL.	PSA Level Less than 0.7		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141205>	C27268	Lymphoma by AJCC v8 Stage	A term that refers to the staging of Hodgkin lymphoma and non-Hodgkin lymphoma according to the AJCC v8 classification guidelines.			Neoplastic Process	
C141206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141206>	C3163	Chronic Lymphocytic Leukemia- Modified Rai Staging System	A term that refers to the staging of chronic lymphocytic leukemia according to modified Rai staging system. This system is mainly used in North America.			Neoplastic Process	
C141207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141207>	C28108	Rai Stage	A stage term that refers to the modified Rai staging system which is used for the staging of chronic lymphocytic leukemia.			Classification	
C141208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141208>	C3163	Chronic Lymphocytic Leukemia- Binet Staging System	A term that refers to the staging of chronic lymphocytic leukemia according to Binet staging system. This system is in wide use outside the United States.			Neoplastic Process	
C141209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141209>	C141208	Stage A Chronic Lymphocytic Leukemia	Findings: Lymphocytosis only; Survival (months): more than 120. (from AJCC 8th Ed.)			Neoplastic Process	
C14120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14120>	C13432	10q24.1	A chromosome band present on 10q			Gene or Genome	
C141210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141210>	C141208	Stage B Chronic Lymphocytic Leukemia	Findings: Lymphocytosis and adenopathy; Survival (months): 95. (from AJCC 8th Ed.)			Neoplastic Process	
C141211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141211>	C141208	Stage C Chronic Lymphocytic Leukemia	Findings: Lymphocytosis, adenopathy, and enlarged spleen and/or liver; Survival (months): 72. (from AJCC 8th Ed.)			Neoplastic Process	
C141212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141212>	C28108	Binet Stage	A stage term that refers to the Binet staging system which is used for the staging of chronic lymphocytic leukemia.			Classification	
C141213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141213>	C17254	65 kDa Phosphoprotein|65 kDa Matrix Phosphoprotein|CMV UL83|Human Cytomegalovirus UL83|Phosphoprotein UL83|Tegument Protein UL83|pp65	65 kDa phosphoprotein (561 aa, ~63 kDa) is encoded by the cytomegalovirus UL83 gene. This protein plays a role in both the inhibition of the host antiviral immune response and the transactivation of viral major immediate-early genes.	65 kDa Phosphoprotein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141214>	C176022|C173792	Satisfaction with How Natural Your Reconstructed Nipples Look Question|How natural your reconstructed nipple(s) look|Satisfaction with How Natural Your Reconstructed Nipples Look	A question about how satisfied or dissatisfied an individual is or was with how natural their reconstructed nipples look.			Intellectual Product	
C141215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141215>	C20401|C164034	Anti-CD20 Monoclonal Antibody	Any monoclonal antibody that targets CD20.			Chemical Viewed Functionally	
C141216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141216>	C28108	St. Jude Stage	A stage defined according to St. Jude Children's Research Hospital staging system for childhood non-Hodgkin lymphoma.			Classification	
C141217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141217>	C7706|C141202	St. Jude Childhood Non-Hodgkin Lymphoma by AJCC v8 Stage	A staging system for childhood non-Hodgkin Lymphomas based on the St. Jude Children's Research Hospital staging system. The Ann Arbor staging system has been found to be inappropriate for staging of the non-Hodgkin lymphomas of childhood. The St. Jude staging system has been widely accepted for more than three decades and remains the recommended staging system for childhood non-Hodgkin lymphomas. (from AJCC 8th Ed.)			Neoplastic Process	
C141218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141218>	C141217	St. Jude Stage I Childhood Non-Hodgkin Lymphoma AJCC v8	Stage I: A single tumor (extranodal) or single anatomic area (nodal), with the exclusion of the mediastinum or abdomen. (from AJCC 8th Ed.)	St. Jude Stage I Childhood Non-Hodgkin Lymphoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C141219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141219>	C141217	St. Jude Stage II Childhood Non-Hodgkin Lymphoma AJCC v8	Stage II: A single tumor (extranodal) with regional node involvement. Two or more nodal areas on the same side of the diaphragm. Two single (extranodal) tumors with or without regional node involvement on the same side of the diaphragm. A primary gastrointestinal tract tumor, usually in the ileocecal area, with or without involvement of associated mesenteric nodes only. (from AJCC 8th Ed.)	St. Jude Stage II Childhood Non-Hodgkin Lymphoma AJCC v8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C14121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14121>	C13432	8p22-p21	A chromosome band present on 8p			Gene or Genome	
C141220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141220>	C141217	St. Jude Stage III Childhood Non-Hodgkin Lymphoma AJCC v8	Stage III: Two single tumors (extranodal) on opposite sides of the diaphragm. Two or more nodal areas above and below the diaphragm. All the primary intrathoracic tumors (mediastinal, pleural, and thymic). All extensive primary intra-abdominal disease. All paraspinal or epidural tumors, regardless of other tumor site(s). (from AJCC 8th Ed.)			Neoplastic Process	
C141221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141221>	C141217	St. Jude Stage IV Childhood Non-Hodgkin Lymphoma AJCC v8	Stage IV: Any tumor, with initial CNS and/or bone marrow involvement. (from AJCC 8th Ed.)			Neoplastic Process	
C141222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141222>	C9283|C141141	Lymphocyte-Depleted Classic Hodgkin Lymphoma by Ann Arbor Stage|Lymphocyte-Depleted Classical Hodgkin Lymphoma by Ann Arbor Stage	An anatomic stage for lymphocyte-depleted classic Hodgkin lymphoma based on the Ann Arbor classification criteria.			Neoplastic Process	
C141223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141223>	C3518|C141141	Nodular Sclerosis Classic Hodgkin Lymphoma by Ann Arbor Stage|Nodular Sclerosis Classical Hodgkin Lymphoma by Ann Arbor Stage	An anatomic stage for nodular sclerosis classic Hodgkin lymphoma based on the Ann Arbor classification criteria.			Neoplastic Process	
C141224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141224>	C3517|C141141	Mixed Cellularity Classic Hodgkin Lymphoma by Ann Arbor Stage|Mixed Cellularity Classical Hodgkin Lymphoma by Ann Arbor Stage	An anatomic stage for mixed cellularity classic Hodgkin lymphoma based on the Ann Arbor classification criteria.			Neoplastic Process	
C141225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141225>	C7258	Nodular Lymphocyte Predominant B-Cell Lymphoma by Ann Arbor Stage|Nodular Lymphocyte Predominant Hodgkin Lymphoma by Ann Arbor Stage	An anatomic stage for nodular lymphocyte predominant B-cell lymphoma based on the Ann Arbor classification criteria.			Neoplastic Process	
C141226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141226>	C7702|C141141	Adult Hodgkin Lymphoma by Ann Arbor Stage	An anatomic stage for adult Hodgkin lymphoma based on the Ann Arbor classification criteria.			Neoplastic Process	
C141227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141227>	C7714|C141141	Childhood Hodgkin Lymphoma by Ann Arbor Stage	An anatomic stage for childhood Hodgkin lymphoma based on the Ann Arbor classification criteria.			Neoplastic Process	
C141228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141228>	C226660	No Dysphagia|Able to eat normal diet (no dysphagia)	A response indicating that an individual is able to eat a normal diet.			Intellectual Product	
C141229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141229>	C226660	Dysphagia to Normal Solids|Able to eat some solid food (dysphagia to normal solids)	A response indicating that an individual is able to eat only some solid food.			Intellectual Product	
C14122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14122>	C13432	10p15-p14	A chromosome band present on 10p			Gene or Genome	
C141230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141230>	C226660	Dysphagia to Soft Solids|Able to eat semisolids only (dysphagia to soft solids)	A response indicating that an individual is able to eat only some semisolids.			Intellectual Product	
C141231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141231>	C226660	Dysphagia to Solids and Liquids|Able to swallow liquids only (dysphagia to solids and liquids)	A response indicating that an individual is able to only swallow liquids.			Intellectual Product	
C141232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141232>	C226714|C178367|C175322	Inability to Swallow Saliva|Inability to Swallow|Unable to swallow (inability to swallow saliva)	A response indicating that an individual is unable to swallow.			Intellectual Product	
C141233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141233>	C93102|C179406	Deleterious BRCA Gene Mutation|Deleterious BRCA Family Mutation|Deleterious BRCA Gene Family Mutation|Deleterious BRCA Mutation	A change in the nucleotide sequence of a gene in the BRCA family that is associated with increased risk of disease.	Deleterious BRCA Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C141234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141234>	C26683	Beta-2-Microglobulin Greater than 3 g/mL|B2M Greater than 3 g/mL|B2M Greater than Three g/mL|Beta-2 Microglobulin Greater than 3 g/mL|Beta-2 Microglobulin Greater than Three g/mL|Beta-2-Microglobulin Greater than Three g/mL	A laboratory test result indicating that beta-2-microglobulin is present in a sample at concentrations exceeding 3 g/mL.	Beta-2-Microglobulin Greater than 3 g/mL		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141235>	C7704|C141140	Adult Non-Hodgkin Lymphoma by Ann Arbor Stage	An anatomic stage for adult non-Hodgkin lymphoma based on the Ann Arbor classification criteria.			Neoplastic Process	
C141236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141236>	C7706|C141140	Childhood Non-Hodgkin Lymphoma by Ann Arbor Stage	An anatomic stage for childhood non-Hodgkin lymphoma based on the Ann Arbor classification criteria.			Neoplastic Process	
C141237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141237>	C2950	Chromosome 13 Abnormality	An irregularity in the structure of chromosome 13.	Chromosome 13 Abnormality		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141238>	C40419	Bile Duct Leakage	The leakage of bile into the abdominal cavity as a result of injury to the bile duct.			Finding	
C141239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141239>	C34497	Coma Greater than 24 Hours|Coma Longer than 24 Hours	An indication that coma has lasted more than 24 hours.			Finding	
C14123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14123>	C13432	5q33.2-qter	A chromosome band present on 5q			Gene or Genome	
C141240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141240>	C36327	Receptor Tyrosine Kinase Gene Mutation|RTK Family Gene Mutation|RTK Family Mutation|RTK Gene Mutation|Receptor Tyrosine Kinase Family Gene Mutation|Tyrosine Kinase Receptor Family Mutation|Tyrosine Kinase Receptor Gene Mutation|Tyrosine Kinase Receptor Mutation	A change in the nucleotide sequence of a receptor tyrosine kinase family gene.	Receptor Tyrosine Kinase Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141241>	C28554	Death During, or within 90 Days of, Index Hospital Admission|Death Less than 90 Days or During Index Hospital Admission	An indication that death occurred on or within 90 days of a patient's initial admission to a hospital.			Finding	
C141242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141242>	C36279	Postoperative Delayed Gastric Emptying|Delayed Gastric Emptying After Surgery	Delayed stomach emptying as a result of surgery.			Finding	
C141243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141243>	C3457|C141140	B-Cell Non-Hodgkin Lymphoma by Ann Arbor Stage	An anatomic stage for B-cell non-Hodgkin lymphoma based on the Ann Arbor classification criteria.			Neoplastic Process	
C141244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141244>	C2959	Graft, Prosthesis, or Flap Failure|Failure of Graft, Prosthesis, or Flap	A failure of function of a graft, flap, or prosthesis.			Finding	
C141245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141245>	C50634	Liver Insufficiency|Hepatic Insufficiency	The inability of the liver to perform its normal synthetic and metabolic functions.			Finding	
C141246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141246>	C45233	Ventilation Greater than 48 Hours	An indication that respiratory ventilation was in use for more than 48 hours.			Finding	
C141247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141247>	C3466|C141140	T-Cell Non-Hodgkin Lymphoma by Ann Arbor Stage	An anatomic stage for T-cell non-Hodgkin lymphoma based on the Ann Arbor classification criteria.			Neoplastic Process	
C141248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141248>	C93102|C133695	Deleterious Homologous Recombination Pathway Gene Mutation|Deleterious HHR Gene Mutation|Deleterious Homologous Recombination Pathway Mutation|Deleterious Recombination Repair Gene Mutation	A change in the nucleotide sequence of a gene involved in homologous recombination-type DNA repair processes that is associated with increased risk of disease.	Deleterious Homologous Recombination Pathway Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141249>	C35682	Human Herpesvirus 1 Positive|HHV-1 Positive|HHV1 Positive|HSV-1 Positive|HSV1 Positive|Herpes Simplex Virus 1 Positive|Herpes Simplex Virus Type 1 Positive|Human Alphaherpesvirus 1 Positive|Human Herpes Virus 1 Positive|Human Herpes Virus-1 Positive|Human Herpesvirus-1 Positive	An indication that human herpesvirus 1 has been detected in a sample.	Human Herpesvirus 1 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C14124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14124>	C13432	17q21-q23	A chromosome band present on 17q			Gene or Genome	
C141250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141250>	C8868|C141243	B Lymphoblastic Lymphoma by Ann Arbor Stage|B-Lymphoblastic Lymphoma by Ann Arbor Stage	An anatomic stage for B lymphoblastic lymphoma based on the Ann Arbor classification criteria.			Neoplastic Process	
C141251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141251>	C36327	CCAAT Enhancer Binding Protein Gene Mutation|C/EBP Gene Mutation|C/EBP Mutation|CCAAT Enhancer Binding Protein Mutation	A change in the nucleotide sequence of a CCAAT enhancer binding protein family gene.	CCAAT Enhancer Binding Protein Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141252>	C97927	RNF43 Gene Mutation|RNF124 Gene Mutation|Ring Finger Protein 43 Gene Mutation|URCC Gene Mutation	A change in the nucleotide sequence of the RNF43 gene.	RNF43 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141253>	C2912|C141243	Burkitt Lymphoma by Ann Arbor Stage	An anatomic stage for Burkitt lymphoma based on the Ann Arbor classification criteria.			Neoplastic Process	
C141254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141254>	C8851|C141243	Diffuse Large B-Cell Lymphoma by Ann Arbor Stage	An anatomic stage for diffuse large B-cell lymphoma based on the Ann Arbor classification criteria.			Neoplastic Process	
C141255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141255>	C3209|C141243	Follicular Lymphoma by Ann Arbor Stage	An anatomic stage for follicular lymphoma based on the Ann Arbor classification criteria.			Neoplastic Process	
C141256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141256>	C3212|C141243	Lymphoplasmacytic Lymphoma by Ann Arbor Stage	An anatomic stage for lymphoplasmacytic lymphoma based on the Ann Arbor classification criteria.			Neoplastic Process	
C141257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141257>	C4337|C141243	Mantle Cell Lymphoma by Ann Arbor Stage	An anatomic stage for mantle cell lymphoma based on the Ann Arbor classification criteria.			Neoplastic Process	
C141258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141258>	C4341|C141243	Marginal Zone Lymphoma by Ann Arbor Stage	An anatomic stage for marginal zone lymphoma based on the Ann Arbor classification criteria.			Neoplastic Process	
C141259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141259>	C7540|C141243	Small Lymphocytic Lymphoma by Ann Arbor Stage	An anatomic stage for small lymphocytic lymphoma based on the Ann Arbor classification criteria.			Neoplastic Process	
C14125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14125>	C13432	4q31.23	A chromosome band present on 4q			Gene or Genome	
C141260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141260>	C3898|C141258	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue by Ann Arbor Stage	An anatomic stage for extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue based on the Ann Arbor classification criteria.			Neoplastic Process	
C141261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141261>	C8863|C141258	Nodal Marginal Zone Lymphoma by Ann Arbor Stage	An anatomic stage for nodal marginal zone lymphoma based on the Ann Arbor classification criteria.			Neoplastic Process	
C141262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141262>	C9280|C141254	Primary Mediastinal Large B-Cell Lymphoma by Ann Arbor Stage|Primary Mediastinal (Thymic) Large B-Cell Lymphoma by Ann Arbor Stage	An anatomic stage for primary mediastinal large B-cell lymphoma based on the Ann Arbor classification criteria.			Neoplastic Process	
C141263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141263>	C4074|C141254	Centroblastic Lymphoma by Ann Arbor Stage	An anatomic stage for centroblastic lymphoma based on the Ann Arbor classification criteria.			Neoplastic Process	
C141264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141264>	C18520	Phosphorylated Proto-Oncogene Tyrosine-Protein Kinase Src|Phospho-Proto-Oncogene Tyrosine-Protein Kinase Src|Phospho-Src|Phosphorylated SRC	A post-translationally modified form of proto-oncogene tyrosine-protein kinase Src where one or more serine, threonine and/or the tyrosine residues are phosphorylated. Phosphorylation of the tyrosine at residue position 530 inhibits Src kinase activity, while phosphorylation of the tyrosine at residue position 419 results in Src activation.	Phosphorylated Proto-Oncogene Tyrosine-Protein Kinase Src		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141265>	C67208	Regulatory T-Cell to Effector T-Cell Ratio Measurement|Ratio of Regulatory T Cells to T Effector Cells|Regulatory T Cell to Effector T Cell Ratio Measurement	The determination of the ratio of regulatory T-cells (Tregs) compared to effector T-cells present in a sample.	Regulatory T-Cell to Effector T-Cell Ratio Measurement		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Terminology
C141266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141266>	C17728	KDR Gene Product	A protein encoded by the KDR gene.	KDR Gene Product		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141267>	C141266	Soluble Vascular Endothelial Growth Factor Receptor 2|Soluble CD309|Soluble Flk-1|Soluble Fms-Like Tyrosine Kinase-1|Soluble KDR|Soluble VEGFR2|sFLK-1|sKDR|sVEGFR-2|sVEGFR2	Soluble vascular endothelial growth factor receptor 2 is encoded by the human KDR gene. This protein may play a role as a decoy receptor for vascular endothelial growth factors (VEGF)-1, 2 and 3.	Soluble Vascular Endothelial Growth Factor Receptor 2		Amino Acid, Peptide, or Protein|Enzyme|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141268>	C50479	Cardiac Arrest Requiring Cardiopulmonary Resuscitation|Cardiac arrest requiring CPR	Cardiac arrest that is treated by CPR and/or defibrillation, regardless of outcome.			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|Appendix 9: Therapeutic and Supportive Procedures for COVID-19 Terminology|Mechanical Support Terminology
C141269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141269>	C37981	Unplanned Intubation	An intubation procedure that was unexpected.			Health Care Activity	
C14126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14126>	C13432	5q32	A chromosome band present on 5q			Gene or Genome	
C141270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141270>	C64431	Albumin to Bilirubin Ratio Measurement	The determination of the ratio of albumin compared to bilirubin in a biological sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	
C141271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141271>	C67208	Neutrophil to Lymphocyte Ratio Measurement|NEUTLY|NLR|Neutrophils/Lymphocytes|Neutrophils/Lymphocytes|Neutrophils/Lymphocytes	The determination of the ratio of neutrophils compared to lymphocytes present in a biological sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C141272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141272>	C3468|C141247	Mature T- and NK-Cell Lymphoma by Ann Arbor Stage	An anatomic stage for mature T- and NK-cell non-Hodgkin lymphomas based on the Ann Arbor classification criteria.			Neoplastic Process	
C141273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141273>	C213665	Poseltinib|2-Propenamide, N-(3-((2-((4-(4-methyl-1-piperazinyl)phenyl)amino)furo(3,2-d)pyrimidin-4-yl)oxy)phenyl)-|HM71224|LY3337641|POSELTINIB	An inhibitor of Bruton's tyrosine kinase (BTK) with potential anti-inflammatory activity. Upon administration, poseltinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents  the activation of BTK-mediated  inflammatory pathways.	Poseltinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C141274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141274>	C35682	Phosphorylated Signal Transducer and Activator of Transcription 3 Positive|Phospho-STAT3 Positive|Phospho-Signal Transducer and Activator of Transcription 3 Positive|PhosphoSTAT3|PhosphoSTAT3 Positive|pSTAT3 Positive	An indication that phosphorylated forms of the signal transducer and activator of transcription 3 protein have been detected in a sample.	Phosphorylated Signal Transducer and Activator of Transcription 3 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141275>	C36344|C156029	AXL Gene Amplification|ARK Gene Amplification|AXL Receptor Tyrosine Kinase Gene Amplification|JTK11 Gene Amplification|Tyro7 Gene Amplification|UFO Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the AXL gene.	AXL Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141276>	C97927|C141240	AXL Gene Mutation|ARK Gene Mutation|AXL Receptor Tyrosine Kinase Gene Mutation|JTK11 Gene Mutation|Tyro7 Gene Mutation|UFO Gene Mutation	A change in the nucleotide sequence of the AXL gene.	AXL Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141277>	C79089	Serum CA125 Measurement|Serum CA-125|Serum CA125|Serum Cancer Antigen 125 Measurement	The determination of the amount of cancer antigen 125 present in a blood serum sample.	Serum CA125 Measurement		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Intervention Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141278>	C35682	Adenovirus Positive|AdV Positive	An indication that adenovirus has been detected in a sample.	Adenovirus Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C141279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141279>	C118487	65 kDa Phosphoprotein Antibody|Anti-66 kDa Phosphoprotein Antibody|Anti-CMV 66 kDa Phosphoprotein Antibody|Anti-CMV pp65 Antibody|Anti-Phosphoprotein UL83 Antibody|Anti-pp65 Antibody|CMV 66 kDa Phosphoprotein Antibody|CMV pp65 Antibody|Phosphoprotein UL83 Antibody|pp65 Antibody	Any immunoglobulin that recognizes the CMV protein 65 kDa phosphoprotein.	65 kDa Phosphoprotein Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C14127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14127>	C13432	4q11-q13	A chromosome band present on 4q			Gene or Genome	
C141280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141280>	C35682|C175007	66 kDa Phosphoprotein Antibody Positive|Anti-66 kDa Phosphoprotein Antibody Positive|Anti-CMV 66 kDa Phosphoprotein Antibody Positive|Anti-CMV pp65 Antibody Positive|Anti-Phosphoprotein UL83 Antibody Positive|Anti-pp65 Antibody Positive|CMV 66 kDa Phosphoprotein Antibody Positive|CMV pp65 Antibody Positive|Phosphoprotein UL83 Antibody Positive|pp65 Antibody Positive	An indication that antibodies that recognize the CMV 65 kDa phosphoprotein have been detected in a sample.	66 kDa Phosphoprotein Antibody Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141281>	C165233	SHH Negative|HHG1 Negative|Sonic Hedgehog Homolog Negative|Sonic Hedgehog Negative	An indication that SHH expression has not been detected in a sample.	SHH Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141282>	C165233	Wnt Negative|Wingless-Type MMTV Integration Site Family Negative|Wnt Family Negative	An indication that the expression of Wnt family members has not been detected in a sample.	Wnt Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141283>	C3184|C141272|C141235	Adult T-Cell Leukemia/Lymphoma by Ann Arbor Stage	An anatomic stage for adult T-cell leukemia/lymphoma based on the Ann Arbor classification criteria.			Neoplastic Process	
C141284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141284>	C3720|C141272	Noncutaneous Anaplastic Large Cell Lymphoma by Ann Arbor Stage	An anatomic stage for noncutaneous anaplastic large cell lymphoma based on the Ann Arbor classification criteria.			Neoplastic Process	
C141285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141285>	C53462	Commute|Commuting|Commuting	To travel regularly between locations, especially between home and a work location.			Activity	
C141286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141286>	C53462	Transportation|Mode of Transportation|Transportation Service	Methods of traveling from one place to another.	Transportation		Activity	CTRP Intervention Terminology|CTRP Terminology
C141287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141287>	C141286	Public Transportation|Mass Transit|Public Transit|Public Transport	Forms of transportation that run on fixed routes and are available to the public, usually for a set fare.			Activity	
C141288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141288>	C141286	Shuttle Service|Shuttle|Shuttle Transport	A transportation service that makes frequent trips between two places.			Activity	
C141289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141289>	C213072	Taxi Service|Cab|Cab Service|Taxi	A transportation service that uses hired cars and drivers.			Activity	
C14128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14128>	C34055	Yolk Sac|SAC, YOLK	Membranous sac on the ventral aspect of the developing embryo that acts as a primitive circulatory system as well as providing nourishment.			Embryonic Structure	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C141290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141290>	C141286	Driven|Got a Ride	Transportation in a vehicle as a passenger.			Activity	
C141291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141291>	C16632	Parking|Parking Service|Parking Space	A designated location where a vehicle may be left.			Geographic Area	
C141292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141292>	C5636|C141284|C141236	Noncutaneous Childhood Anaplastic Large Cell Lymphoma by Ann Arbor Stage	An anatomic stage for noncutaneous childhood anaplastic large cell lymphoma based on the Ann Arbor classification criteria.			Neoplastic Process	
C141294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141294>	C7528|C141272	Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type by Ann Arbor Stage|Angioimmunoblastic T-Cell Lymphoma by Ann Arbor Stage	An anatomic stage for follicular helper T-cell lymphoma, angioimmunoblastic-type  based on the Ann Arbor classification criteria.			Neoplastic Process	
C141295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141295>	C4737|C141272	Enteropathy-Associated T-Cell Lymphoma by Ann Arbor Stage	An anatomic stage for enteropathy-associated T-cell lymphoma based on the Ann Arbor classification criteria.			Neoplastic Process	
C141296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141296>	C4684|C141272	Nasal Type NK/T-Cell Lymphoma by Ann Arbor Stage	An anatomic stage for nasal type NK/T-cell lymphoma based on the Ann Arbor classification criteria.			Neoplastic Process	
C141297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141297>	C177442	Blasts 30 Percent or Less of Bone Marrow Nucleated Cells|Blasts Less than or Equal to 30 Percent of Bone Marrow Nucleated Cells|Blasts Under 31 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that 30 percent or less of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts 30 Percent or Less of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C141298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141298>	C2521	FPV Vaccine CV301|Boost Vaccine FPV-CV301|FPV-CV-301|FPV-CV301|Fowlpox-based FPV-CV301	A cancer vaccine consisting of a recombinant fowlpox viral (FPV) vector encoding both the two human tumor-associated antigens (TAAs) carcinoembryonic antigen (CEA) and mucin-1 (MUC-1), and TRICOM, which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration following the administration of a proprietary modified vaccinia Ankara developed by Bavarian Nordic-based prime vaccine MVA-BN-CV301, the FPV vaccine CV301, which is used as a booster vaccine, activates a cytotoxic T-lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells. In addition, the CV301-dependent anti-tumor CTL response upregulates the expression of programmed cell death ligand 1 (PD-L1); therefore, when FPV-CV301 is combined with a programmed cell death 1 (PD-1) immune checkpoint inhibitor, the antitumor effect may be increased. The TAAs CEA and MUC-1 are overexpressed in a variety of cancers.	FPV Vaccine CV301		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C141299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141299>	C155993	Blasts 5 Percent or More of Peripheral Blood White Cells|Blasts Greater than or Equal to 5 Percent of Peripheral Blood White Cells	A semi-quantitative microscopic finding indicating that 5 percent or more of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.	Blasts 5 Percent or More of Peripheral Blood White Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C14129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14129>	C13432	5q23	A chromosome band present on 5q			Gene or Genome	
C1412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1412>	C61101	Teicoplanin|MDL-507|TEICOPLANIN|Tagocid|Targocid|Targosid|Teichomycin|Teichomycin A2|Teicoplanin A2|teicoplanin	A glycopeptide antibiotic complex isolated from the bacterium Actinoplanes teichomyceticus. Teicoplanin inhibits peptidoglycan polymerization, resulting in inhibition of bacterial cell wall synthesis and cell death. (NCI04)			Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C141300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141300>	C177692	CCND2 Positive|Cyclin D2 Positive|Cyclin-D2 Positive	An indication that CCND2 expression has been detected in a sample.	CCND2 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141301>	C177692	CCND3 Positive|Cyclin D3 Positive|Cyclin-D3 Positive	An indication that CCND3 expression has been detected in a sample.	CCND3 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141302>	C177692	ABCB11 Positive|ABC16 Positive|ATP Binding Cassette Subfamily B Member 11 Positive|ATP-Binding Cassette Subfamily B Member 11 Positive|BRIC2 Positive|BSEP Positive|Bile Salt Export Pump Positive|P Glycoprotein 4 Positive|PGY4 Positive|SPGP Positive	An indication that ABCB11 expression has been detected in a sample.	ABCB11 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141303>	C48233	Primary Cutaneous Lymphoma TNM Finding v8	A finding about one or more characteristics of primary cutaneous lymphoma [mycosis fungoides and Sezary syndrome (MF/SS) and primary cutaneous B-cell/T-cell (non-MF/SS) lymphomas], following the rules of the TNM v8 classification system. Both MF/SS and primary cutaneous B-cell/T-cell (non-MF/SS) lymphomas have TNM classification systems. MF/SS has a formal prognostic stage groups system proposed by the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organisation for Research and Treatment of Cancer (EORTC). There is no prognostic stage groups system for primary cutaneous B-cell/T-cell (non-MF/SS) lymphomas at this time. This classification system does not apply to eyelid skin lymphomas (are staged according to the classification for ocular adnexal lymphoma).  (from AJCC 8th Ed.)			Finding	
C141304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141304>	C141303	Mycosis Fungoides and Sezary Syndrome TNM Finding v8	A finding about one or more characteristics of mycosis fungoides and Sezary syndrome, following the rules of the TNM AJCC v8 classification system. This classification is based on the ISCL/EORTC revision to the classification of mycosis fungoides and Sezary syndrome. (from AJCC 8th Ed.)			Finding	
C141305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141305>	C177692	ABCB4 Positive|ABC21 Positive|ATP Binding Cassette Subfamily B Member 4 Positive|ATP-Binding Cassette Subfamily B Member 4 Positive|MDR3 Positive|Multidrug Resistance Protein 3 Positive|P Glycoprotein 3 Positive|PGY3 Positive	An indication that ABCB4 expression has been detected in a sample.	ABCB4 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141306>	C141304	Mycosis Fungoides and Sezary Syndrome Distant Metastasis TNM Finding v8	A finding about one or more characteristics of mycosis fungoides and Sezary syndrome, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases (visceral). (from AJCC 8th Ed.)			Finding	
C141307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141307>	C141306	Mycosis Fungoides and Sezary Syndrome M0 TNM Finding v8	No visceral organ involvement. (from AJCC 8th Ed.)			Finding	
C141308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141308>	C141306	Mycosis Fungoides and Sezary Syndrome M1 TNM Finding v8	Visceral involvement (must have pathology confirmation and organ involved should be specified). Note: for viscera, spleen and liver may be diagnosed by imaging criteria. (from AJCC 8th Ed.)			Finding	
C141309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141309>	C141304	Mycosis Fungoides and Sezary Syndrome Lymph Nodes TNM Finding v8	A finding about one or more characteristics of mycosis fungoides and Sezary syndrome, following the rules of the TNM AJCC v8 classification system as they pertain to staging of peripheral lymph nodes.			Finding	
C14130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14130>	C13432	3q13.12	A chromosome band present on 3q			Gene or Genome	
C141310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141310>	C141309	Mycosis Fungoides and Sezary Syndrome NX TNM Finding v8	Clinically abnormal peripheral lymph nodes; no histologic confirmation. (from AJCC 8th Ed.)			Finding	
C141311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141311>	C141309	Mycosis Fungoides and Sezary Syndrome N0 TNM Finding v8	No clinically abnormal peripheral lymph nodes; biopsy not required. Note: for node, abnormal peripheral lymph node(s) indicates any palpable peripheral node that on physical examination is firm, irregular, clustered, fixed or 1.5 cm or larger in diameter. Node groups examined on physical examination include cervical, supraclavicular, epitrochlear, axillary, and inguinal. Central nodes, which generally are not amenable to pathological assessment, currently are not considered in the nodal classification unless used to establish N3 histopathologically. (from AJCC 8th Ed.)			Finding	
C141312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141312>	C141309	Mycosis Fungoides and Sezary Syndrome N1 TNM Finding v8	Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. Note: EORTC N1 classification includes: Dutch grade 1: dermatopathic lymphadenopathy. NCI LN0: no atypical lymphocytes. NCI LN1: occasional and isolated atypical lymphocytes (not arranged in clusters). NCI LN2: many atypical lymphocytes or lymphocytes in 3-6 cell clusters. (from AJCC 8th Ed.)			Finding	
C141313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141313>	C35682|C175007	HTLV-1 Antibody Positive|Anti-HTLV-1 Antibody Positive|Anti-HTLV-I Antibody Positive|Anti-Human T-Cell Lymphotropic Virus 1 Antibody Positive|Anti-Human T-Lymphotropic Virus 1 Antibody Positive|HTLV-I Antibody Positive|Human T-Cell Lymphotropic Virus 1 Antibody Positive|Human T-Lymphotropic Virus 1 Antibody Positive	An indication that antibodies that recognize the human T-cell lymphotropic virus 1 have been detected in a sample.	HTLV-1 Antibody Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C141314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141314>	C141312	Mycosis Fungoides and Sezary Syndrome N1a TNM Finding v8	Clone negative. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene. (from AJCC 8th Ed.)			Finding	
C141315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141315>	C141312	Mycosis Fungoides and Sezary Syndrome N1b TNM Finding v8	Clone positive. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene. (from AJCC 8th Ed.)			Finding	
C141316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141316>	C141309	Mycosis Fungoides and Sezary Syndrome N2 TNM Finding v8	Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. Note: EORTC N2 classification includes Dutch grade 2: dermatopathic lymphadenopathy; early involvement by mycosis fungoides (presence of cerebriform nuclei less than 7.5 micrometers). NCI LN3: aggregates of atypical lymphocytes; nodal architecture preserved. (from AJCC 8th Ed.)			Finding	
C141317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141317>	C94299|C177692	RET Positive|Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret Positive|Proto-Oncogene c-Ret Positive|Ret Proto-Oncogene Positive|Tyrosine-Protein Kinase Receptor RET Positive	An indication that RET expression has been detected in a sample.	RET Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141318>	C141316	Mycosis Fungoides and Sezary Syndrome N2a TNM Finding v8	Clone negative. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene.  (from AJCC 8th Ed.)			Finding	
C141319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141319>	C141316	Mycosis Fungoides and Sezary Syndrome N2b TNM Finding v8	Clone positive. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene. (from AJCC 8th Ed.)			Finding	
C14131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14131>	C13379	UBA Domain|Ubiquitin-Associated Domain	UBA domains are a commonly occurring sequence motif of approximately 45 amino acid residues that are found in diverse proteins involved in the ubiquitin/proteasome pathway, DNA excision-repair, and cell signaling via protein kinases. The human homologue of yeast Rad23A is one example of a nucleotide excision-repair protein that contains both an internal and a C-terminal UBA domain.			Amino Acid Sequence	
C141320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141320>	C141309	Mycosis Fungoides and Sezary Syndrome N3 TNM Finding v8	Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3-4 or NCI LN4; clone positive or negative. Note: EORTC N3 classification includes: Dutch grade 3: partial effacement of lymph node architecture; many atypical cerebriform mononuclear cells. Dutch grade 4: complete effacement of lymph node. NCI LN4: partial/complete effacement of nodal architecture by atypical lymphocytes or frankly neoplastic cells. (from AJCC 8th Ed.)			Finding	
C141321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141321>	C35681	Epstein-Barr Virus Negative|EBV Negative|Epstein Barr Virus Negative|HHV-4 Negative|HHV4 Negative|Human Herpesvirus 4 Negative|Human Herpesvirus-4 Negative|Negative	An indication that Epstein-Barr virus has not been detected in a sample.	Epstein-Barr Virus Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C141322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141322>	C141304	Mycosis Fungoides and Sezary Syndrome Peripheral Blood Involvement TNM Finding v8	A finding about one or more characteristics of mycosis fungoides and Sezary syndrome, following the rules of the TNM AJCC v8 classification system as they pertain to peripheral blood involvement.			Finding	
C141323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141323>	C141322	Mycosis Fungoides and Sezary Syndrome B0 TNM Finding v8	Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). Note: for blood, Sezary cells are defined as lymphocytes with hyperconvoluted cerebriform nuclei. If Sezary cells cannot be used to determine tumor burden for B2, then one of the following modified ISCL criteria along with a positive clonal rearrangement of the TCR may be used instead: (1) expanded CD4+ or CD3+ cells with CD4/CD8 ratio of 10 or more, (2) expanded CD4+ cells with abnormal immunophenotype including loss of CD7 or CD26. (from AJCC 8th Ed.)			Finding	
C141324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141324>	C141323	Mycosis Fungoides and Sezary Syndrome B0a TNM Finding v8	Clone negative. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene. (from AJCC 8th Ed.)			Finding	
C141325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141325>	C141323	Mycosis Fungoides and Sezary Syndrome B0b TNM Finding v8	Clone positive. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene. (from AJCC 8th Ed.)			Finding	
C141326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141326>	C141322	Mycosis Fungoides and Sezary Syndrome B1 TNM Finding v8	Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary) cells but does not meet the criteria of B2. (from AJCC 7th Ed.)			Finding	
C141327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141327>	C141326	Mycosis Fungoides and Sezary Syndrome B1a TNM Finding v8	Clone negative. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene. (from AJCC 8th Ed.)			Finding	
C141328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141328>	C141326	Mycosis Fungoides and Sezary Syndrome B1b TNM Finding v8	Clone positive. Note: A T-cell clone is defined by polymerase chain reaction (PCR) or Southern blot analysis of the TCR gene. (from AJCC 8th Ed.)			Finding	
C141329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141329>	C141322	Mycosis Fungoides and Sezary Syndrome B2 TNM Finding v8	High blood tumor burden: 1,000 per microliter or more Sezary cells with positive clone. Note 1: for blood, Sezary cells are defined as lymphocytes with hyperconvoluted cerebriform nuclei. If Sezary cells cannot be used to determine tumor burden for B2, then one of the following modified ISCL criteria along with a positive clonal rearrangement of the TCR may be used instead: (1) expanded CD4+ or CD3+ cells with CD4/CD8 ratio of 10 or more, (2) expanded CD4+ cells with abnormal immunophenotype including loss of CD7 or CD26. Note 2: A T-cell clone is defined by PCR or Southern blot analysis of the T-cell receptor gene. (from AJCC 8th Ed.)			Finding	
C14132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14132>	C13432	6p22.3	A chromosome band present on 6p			Gene or Genome	
C141330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141330>	C141304	Mycosis Fungoides and Sezary Syndrome Primary Tumor TNM Finding v8	A finding about one or more characteristics of mycosis fungoides and Sezary syndrome, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor (skin).			Finding	
C141331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141331>	C141330	Mycosis Fungoides and Sezary Syndrome T1 TNM Finding v8	Limited patches, papules, and/or plaques covering less than 10% of the skin surface. Note: for skin, patch indicates any size skin lesion without significant elevation or induration. Presence/absence of hypo- or hyperpigmentation, scale, crusting, and/or poikiloderma should be noted. Plaque indicates any size skin lesion that is elevated or indurated. Presence or absence of scale, crusting, and/or poikiloderma should be noted. Histologic features such as folliculotropism, large-cell transformation (more than 25% large cells), and CD30 positivity or negativity, as well as clinical features such as ulceration are important to document. (from AJCC 8th Ed.)			Finding	
C141332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141332>	C141331	Mycosis Fungoides and Sezary Syndrome T1a TNM Finding v8	T1a (patch only). (from AJCC 8th Ed.)			Finding	
C141333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141333>	C141331	Mycosis Fungoides and Sezary Syndrome T1b TNM Finding v8	T1b (plaque +/- patch). (from AJCC 8th Ed.)			Finding	
C141334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141334>	C141330	Mycosis Fungoides and Sezary Syndrome T2 TNM Finding v8	Patches, papules, or plaques covering 10% or more of the skin surface.  (from AJCC 8th Ed.)			Finding	
C141335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141335>	C141334	Mycosis Fungoides and Sezary Syndrome T2a TNM Finding v8	T2a (patch only). (from AJCC 8th Ed.)			Finding	
C141336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141336>	C141334	Mycosis Fungoides and Sezary Syndrome T2b TNM Finding v8	T2b (plaque +/- patch). (from AJCC 8th Ed.)			Finding	
C141337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141337>	C141330	Mycosis Fungoides and Sezary Syndrome T3 TNM Finding v8	One or more tumors (equal or greater than 1 cm in diameter). Note: for skin, tumor indicates at least 1 cm diameter solid or nodular lesion with evidence of depth and/or vertical growth. Note the total number of lesions, total volume of lesions, largest size lesion, and region of body involved. Also note whether there is histologic evidence of large-cell transformation. Phenotyping for CD30 is encouraged. (from AJCC 8th Ed.)			Finding	
C141338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141338>	C141330	Mycosis Fungoides and Sezary Syndrome T4 TNM Finding v8	Confluence of erythema covering 80% or more of body surface area. (from AJCC 8th Ed.)			Finding	
C141339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141339>	C45581	PIK3CB Gene Amplification|P110BETA Gene Amplification|PI3KBETA Gene Amplification|PIK3C1 Gene Amplification|Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta Gene Amplification|p110-Beta Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the PIK3CB gene.	PIK3CB Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C14133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14133>	C13432	11p15.4	A chromosome band present on 11p			Gene or Genome	
C141340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141340>	C97927|C157554	PIK3CB Gene Mutation|P110BETA Gene Mutation|PI3KBETA Gene Mutation|PIK3C1 Gene Mutation|Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta Gene Mutation|p110-Beta Gene Mutation	A change in the nucleotide sequence of the PIK3CB gene.	PIK3CB Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141341>	C94626	Sequential Chemoradiation	Treatment in which radiation therapy is administered after the completion of chemotherapy.			Therapeutic or Preventive Procedure	
C141342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141342>	C94626	Concurrent Chemoradiation|chemo concurrent to radiation|chemo_concurrent_to_radiation	Treatment in which radiation therapy is administered at the same time as chemotherapy.	Concurrent Chemoradiation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|GDC Property Terminology|GDC Terminology|GDC Value Terminology
C141343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141343>	C16535	Strontium-90 Beta Radiation	Beta radiation produced by the decay of strontium-90.			Natural Phenomenon or Process	Cellosaurus Resistance and Transformant Physical Factor Terminology
C141344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141344>	C27979	Stage IVA1|IVA2	A mycosis fungoides/Sezary syndrome stage defined as follows: T1-4, N0-2, M0, B2. T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. T2: Patches, papules, or plaques covering 10% or more of the skin surface. T3: One or more tumors (equal or greater than 1 cm in diameter). T4: Confluence of erythema covering 80% or more of body surface area. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. M0: No visceral organ involvement. B2: High blood tumor burden: 1,000 per microliter or more Sezary cells with positive clone. (AJCC 8th ed.)			Clinical Attribute	
C141345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141345>	C27979	Stage IVA2|IVA2	A mycosis fungoides/Sezary syndrome stage defined as follows: T1-4, N3, M0, B0-2. T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. T2: Patches, papules, or plaques covering 10% or more of the skin surface. T3: One or more tumors (equal or greater than 1 cm in diameter). T4: Confluence of erythema covering 80% or more of body surface area. N3: Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3-4 or NCI LN4; clone positive or negative. M0: No visceral organ involvement.  B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. B2: High blood tumor burden: 1,000 per microliter or more Sezary cells with positive clone. (AJCC 8th ed.)			Clinical Attribute	
C141346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141346>	C9265|C141205	Mycosis Fungoides and Sezary Syndrome by AJCC v8 Stage	A term that refers to the staging of mycosis fungoides and Sezary syndrome, following the rules of the TNM AJCC v8 classification system. This prognostic stage groups system is based on the ISCL/EORTC revision to the staging of mycosis fungoides and Sezary syndrome. There is no prognostic stage groups system for primary cutaneous B-cell/T-cell (non-mycosis fungoides/Sezary syndrome) lymphomas at this time. This staging system does not apply to eyelid skin lymphomas (are staged according to the classification for ocular adnexal lymphoma).  (from AJCC 8th Ed.)			Neoplastic Process	
C141347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141347>	C141346	Stage I Mycosis Fungoides and Sezary Syndrome AJCC v8	Stage I includes: IA (T1, N0, M0, B0,1); IB (T2, N0, M0, B0,1). T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. T2: Patches, papules, or plaques covering 10% or more of the skin surface. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. M0: No visceral organ involvement. B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. (AJCC 8th ed.)			Neoplastic Process	
C141348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141348>	C141347	Stage IA Mycosis Fungoides and Sezary Syndrome AJCC v8	Stage IA includes: T1, N0, M0, B0,1. T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. M0: No visceral organ involvement. B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. (AJCC 8th ed.)			Neoplastic Process	
C141349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141349>	C141347	Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8	Stage IB includes: T2, N0, M0, B0,1. T2: Patches, papules, or plaques covering 10% or more of the skin surface. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. M0: No visceral organ involvement. B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. (AJCC 8th ed.)			Neoplastic Process	
C14134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14134>	C21599	Macromolecular Structure|Molecular Structure	Any very large complex molecule including, proteins, nucleic acids and carbohydrates, especially refering to the particular arrangement of its component atoms and groups.			Chemical Viewed Structurally	
C141350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141350>	C141346	Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8	Stage II includes: IIA (T1,2, N1,2, M0, B0,1); IIB (T3, N0-2, M0, B0,1). T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. T2: Patches, papules, or plaques covering 10% or more of the skin surface. T3: One or more tumors (equal or greater than 1 cm in diameter). N0: No clinically abnormal peripheral lymph nodes; biopsy not required. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. M0: No visceral organ involvement. B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. (AJCC 8th ed.)			Neoplastic Process	
C141351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141351>	C141350	Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8	Stage IIA includes:  T1-2, N1,2, M0, B0,1. T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. T2: Patches, papules, or plaques covering 10% or more of the skin surface. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. M0: No visceral organ involvement. B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. (AJCC 8th ed.)			Neoplastic Process	
C141352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141352>	C141350	Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8	Stage IIB includes: T3, N0-2, M0, B0,1. T3: One or more tumors (equal or greater than 1 cm in diameter). N0: No clinically abnormal peripheral lymph nodes; biopsy not required. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. M0: No visceral organ involvement. B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. (AJCC 8th ed.)			Neoplastic Process	
C141353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141353>	C141346	Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8	Stage III includes: (T4, N0-2, M0, B0,1); IIIA (T4, N0-2, M0, B0); IIIB (T4, N0-2, M0, B1). T4: Confluence of erythema covering 80% or more of body surface area. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. M0: No visceral organ involvement. B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. (AJCC 8th ed.)			Neoplastic Process	
C141354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141354>	C141353	Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8	Stage IIIA includes: T4, N0-2, M0, B0. T4: Confluence of erythema covering 80% or more of body surface area. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. M0: No visceral organ involvement. B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). (AJCC 8th ed.)			Neoplastic Process	
C141355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141355>	C141353	Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8	Stage IIIB includes: T4, N0-2, M0, B1. T4: Confluence of erythema covering 80% or more of body surface area. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. M0: No visceral organ involvement. B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. (AJCC 8th ed.)			Neoplastic Process	
C141356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141356>	C141346	Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8	Stage IV includes: IVA1 (T1-4, N0-2, M0, B2); IVA2 (T1-4, N3, M0, B0-2); IVB (T1-4, N0-3, M1, B0-2). T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. T2: Patches, papules, or plaques covering 10% or more of the skin surface. T3: One or more tumors (equal or greater than 1 cm in diameter). T4: Confluence of erythema covering 80% or more of body surface area. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. N3: Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3-4 or NCI LN4; clone positive or negative. M0: No visceral organ involvement.  M1: Visceral involvement (must have pathology confirmation and organ involved should be specified). B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. B2: High blood tumor burden: 1,000 per microliter or more Sezary cells with positive clone. (AJCC 8th ed.)			Neoplastic Process	
C141357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141357>	C141356	Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8	Stage IVA1 includes: T1-4, N0-2, M0, B2. T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. T2: Patches, papules, or plaques covering 10% or more of the skin surface. T3: One or more tumors (equal or greater than 1 cm in diameter). T4: Confluence of erythema covering 80% or more of body surface area. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. M0: No visceral organ involvement. B2: High blood tumor burden: 1,000 per microliter or more Sezary cells with positive clone. (AJCC 8th ed.)			Neoplastic Process	
C141358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141358>	C141356	Stage IVA2 Mycosis Fungoides and Sezary Syndrome AJCC v8	Stage IVA2 includes: T1-4, N3, M0, B0-2. T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. T2: Patches, papules, or plaques covering 10% or more of the skin surface. T3: One or more tumors (equal or greater than 1 cm in diameter). T4: Confluence of erythema covering 80% or more of body surface area. N3: Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3-4 or NCI LN4; clone positive or negative. M0: No visceral organ involvement. B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. B2: High blood tumor burden: 1,000 per microliter or more Sezary cells with positive clone. (AJCC 8th ed.)			Neoplastic Process	
C141359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141359>	C141356	Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v8	Stage IVB includes: T1-4, N0-3, M1, B0-2. T1: Limited patches, papules, and/or plaques covering less than 10% of the skin surface. T2: Patches, papules, or plaques covering 10% or more of the skin surface. T3: One or more tumors (equal or greater than 1 cm in diameter). T4: Confluence of erythema covering 80% or more of body surface area. N0: No clinically abnormal peripheral lymph nodes; biopsy not required. N1: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or National Cancer Institute (NCI) LN0-2. N2: Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3. N3: Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3-4 or NCI LN4; clone positive or negative. M1: Visceral involvement (must have pathology confirmation and organ involved should be specified). B0: Absence of significant blood involvement: 5% or less of peripheral blood lymphocytes are atypical (Sezary cells). B1: Low blood tumor burden: more than 5% of peripheral blood lymphocytes are atypical (Sezary cells) but does not meet the criteria of B2. B2: High blood tumor burden: 1,000 per microliter or more Sezary cells with positive clone. (AJCC 8th ed.)			Neoplastic Process	
C14135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14135>	C34070	Cell Structure	The components of the cell and how they are arranged.			Cell Component	
C141360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141360>	C177692	SLC39A6 Positive|LIV-1 Positive|LIV1 Positive|Solute Carrier Family 39 Member 6 Positive|ZIP-6 Positive|Zinc Transporter ZIP6 Positive	An indication that SLC39A6 expression has been detected in a sample.	SLC39A6 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141361>	C177692	MAGEC1 Positive|CT7 Positive|CT7.1 Positive|Cancer/Testis Antigen 7.1 Positive|MAGE Family Member C1 Positive|MAGE-C1 Positive|Melanoma Antigen Family C1 Positive|Melanoma-Associated Antigen C1 Positive	An indication that MAGEC1 expression has been detected in a sample.	MAGEC1 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141362>	C97927|C96865	AKT2 Gene Mutation|AKT Serine/Threonine Kinase 2 Gene Mutation|HIHGHH Gene Mutation|PKBB Gene Mutation|PKBBETA Gene Mutation|PRKBB Gene Mutation|RAC-BETA Gene Mutation|RAC-PK-Beta Gene Mutation|v-akt Murine Thymoma Viral Oncogene Homolog 2 Gene Mutation	A change in the nucleotide sequence of the AKT2 gene.	AKT2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141363>	C165233	MME Negative|CALLA Negative|CD10 Negative|CD10 Negative|Common ALL Antigen Negative|Common Acute Lymphoblastic Leukemia Antigen Negative|Membrane Metalloendopeptidase Negative|NEP Negative|Neprilysin Negative|SFE Negative|Skin Fibroblast Elastase Negative	An indication that MME expression has not been detected in a sample.	MME Negative		Laboratory or Test Result	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141364>	C36345	CCND2 Protein Overexpression|Cyclin D2 Protein Overexpression|Cyclin-D2 Protein Overexpression|G1/S-Specific Cyclin D2 Protein Overexpression|G1/S-Specific Cyclin-D2 Protein Overexpression	A molecular abnormality indicating the presence of an abnormally high level of the G1/S-specific cyclin-D2 protein.	CCND2 Protein Overexpression		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141365>	C134533	Porcine Leukemia	Leukemia that occurs in a pig.			Neoplastic Process	Cellosaurus Disease Terminology
C141366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141366>	C34375	Hemoglobin Lepore Syndrome	A beta thalassemia resulting from an unequal crossover/recombination event involving portions of the delta and beta globin genes, resulting in underproduction of the abnormal delta-beta globin.			Disease or Syndrome	Cellosaurus Disease Terminology
C141367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141367>	C3452	Xeroderma Pigmentosum Variant Type|XPV	A type of xeroderma pigmentosum resulting from mutation(s) in the POLH gene, encoding DNA polymerase eta. This form of the disease is characterized by normal DNA excision repair, but defective post-replication repair of DNA at UV-damaged sites.			Disease or Syndrome	Cellosaurus Disease Terminology
C141368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141368>	C36345	CCND3 Protein Overexpression|Cyclin D3 Protein Overexpression|Cyclin-D3 Protein Overexpression|G1/S-Specific Cyclin D3 Protein Overexpression|G1/S-Specific Cyclin-D3 Protein Overexpression	A molecular abnormality indicating the presence of an abnormally high level of the G1/S-specific cyclin-D3 protein.	CCND3 Protein Overexpression		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141369>	C138961	PSA Level Greater than 0.03	A blood concentration of prostate specific antigen greater than 0.03 ng/mL.	PSA Level Greater than 0.03		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C14136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14136>	C38625	Extracellular Structure	Any structures that are not enclosed intracellularly are considered extracellular structure, including structures on the cell surface. (NCI)			Anatomical Structure	
C141370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141370>	C178120|C138064	Activating ERBB3 Mutation|Activating Erb-B2 Receptor Tyrosine Kinase 3 Gene Mutation|Activating ErbB-3 Gene Mutation|Activating HER-3 Gene Mutation|Activating HER3 Gene Mutation|Activating V-Erb-A Erythroblastic Leukemia Viral Oncogene Homolog 3 Gene Mutation|Activating V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 3 Gene Mutation|Activating c-erbB-3 Gene Mutation|Activating c-erbB3 Gene Mutation	A change in the nucleotide sequence of the ERBB3 gene that results in constitutive activation of receptor tyrosine-protein kinase erbB-3 and its downstream signaling pathways.	Activating ERBB3 Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141372>	C141303	Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma TNM Finding v8|Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome TNM Finding v8	A finding about one or more characteristics of primary cutaneous B-cell/T-cell [non-mycosis fungoides/Sezary syndrome (non-MF/SS)] lymphoma, following the rules of the TNM AJCC v8 classification system. There is no stage group system for non-MF/SS primary cutaneous lymphomas- including cutaneous T-cell, B-cell, and NK-cell lymphomas. (from AJCC 8th Ed.)			Finding	
C141373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141373>	C141372	Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma Distant Metastasis TNM Finding v8|Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome Distant Metastasis TNM Finding v8	A finding about one or more characteristics of primary cutaneous B-cell/T-cell (non-MF/SS) lymphoma, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases. (from AJCC 8th Ed.)			Finding	
C141374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141374>	C141373	Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma M0 TNM Finding v8|Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome M0 TNM Finding v8	No evidence of extracutaneous non-lymph node disease. (from AJCC 8th Ed.)			Finding	
C141375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141375>	C141373	Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma M1 TNM Finding v8|Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome M1 TNM Finding v8	Extracutaneous non-lymph node disease present. (from AJCC 8th Ed.)			Finding	
C141376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141376>	C141372	Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma Lymph Nodes TNM Finding v8|Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome Lymph Nodes TNM Finding v8	A finding about one or more characteristics of primary cutaneous B-cell/T-cell (non-MF/SS) lymphoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.			Finding	
C141377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141377>	C141376	Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma NX TNM Finding v8|Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome NX TNM Finding v8	Regional lymph nodes cannot be assessed. (from AJCC 8th Ed.)			Finding	
C141378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141378>	C141376	Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma N0 TNM Finding v8|Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome N0 TNM Finding v8	No clinical or pathological lymph node involvement. (from AJCC 8th Ed.)			Finding	
C141379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141379>	C141376	Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma N1 TNM Finding v8|Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome N1 TNM Finding v8	Involvement of one peripheral node region that drains an area of current or prior skin involvement. (from AJCC 8th Ed.)			Finding	
C141380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141380>	C141376	Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma N2 TNM Finding v8|Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome N2 TNM Finding v8	Involvement of two or more peripheral node regions or involvement of any lymph node region that does not drain an area of current or prior skin involvement. (from AJCC 8th Ed.)			Finding	
C141381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141381>	C141376	Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma N3 TNM Finding v8|Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome N3 TNM Finding v8	Involvement of central lymph nodes. (from AJCC 8th Ed.)			Finding	
C141382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141382>	C141372	Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma Primary Tumor TNM Finding v8|Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome Primary Tumor TNM Finding v8	A finding about one or more characteristics of primary cutaneous B-cell/T-cell (non-MF/SS) lymphoma, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor (skin).			Finding	
C141383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141383>	C141382	Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma T1 TNM Finding v8|Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome T1 TNM Finding v8	Solitary skin involvement. (from AJCC 8th Ed.)			Finding	
C141384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141384>	C141383	Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma T1a TNM Finding v8|Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome T1a TNM Finding v8	Solitary lesion measuring less than 5 cm. (from AJCC 8th Ed.)			Finding	
C141385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141385>	C141383	Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma T1b TNM Finding v8|Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome T1b TNM Finding v8	Solitary lesion measuring 5 cm or more. (from AJCC 8th Ed.)			Finding	
C141386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141386>	C141382	Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma T2 TNM Finding v8|Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome T2 TNM Finding v8	Regional skin involvement: multiple lesions limited to one body region or two contiguous body regions.  (from AJCC 8th Ed.)			Finding	
C141387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141387>	C141386	Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma T2a TNM Finding v8|Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome T2a TNM Finding v8	All disease encompassing in a less than 15-cm circular area. (from AJCC 8th Ed.)			Finding	
C141388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141388>	C141386	Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma T2b TNM Finding v8|Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome T2b TNM Finding v8	All disease encompassing in a 15-cm or more and less than 30-cm circular area. (from AJCC 8th Ed.)			Finding	
C14138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14138>	C28102	Aggressive|Aggression|aggressive	Describes a tumor or condition that develops, grows, or spreads rapidly.			Qualitative Concept	
C141390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141390>	C141386	Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma T2c TNM Finding v8|Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome T2c TNM Finding v8	All disease encompassing in a 30-cm or more circular area. (from AJCC 8th Ed.)			Finding	
C141391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141391>	C141382	Primary Cutaneous B-Cell/T-Cell (Non-MF/SS) Lymphoma T3 TNM Finding v8|Primary Cutaneous Lymphoma Other Than Mycosis Fungoides and Sézary Syndrome T3 TNM Finding v8	Generalized skin involvement. (from AJCC 8th Ed.)			Finding	
C141392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141392>	C28108	RISS Stage|Revised International Staging System Stage	A plasma cell myeloma stage defined according to the Revised International Staging System (RISS) criteria.			Classification	
C141393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141393>	C3242	Multiple Myeloma by RISS Stage|Plasma Cell Myeloma by RISS Stage|Plasma Cell Myeloma by Revised International Staging System Stage	A staging system for multiple myeloma based on the Revised International Staging System (RISS) criteria. This staging system does not apply to smoldering multiple myeloma (no AJCC staging system), monoclonal gammopathy of undetermined significance (no AJCC staging system), and Waldenstrom macroglobulinemia (no AJCC staging system). (from AJCC 8th Ed.)			Neoplastic Process	
C141394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141394>	C141393	RISS Stage I Multiple Myeloma|RISS Stage I Plasma Cell Myeloma|Revised International Staging System Stage I Plasma Cell Myeloma	Serum beta-2-microglobulin less than 3.5 mg/L and serum albumin 3.5 g/dL or more and no high-risk cytogenetics and normal LDH. High risk cytogenetics consist of one or more of the following: del17p, t(4;14), or t(14;16). (from AJCC 8th Ed.)			Neoplastic Process	
C141395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141395>	C141393	RISS Stage II Multiple Myeloma|RISS Stage II Plasma Cell Myeloma|Revised International Staging System Stage II Plasma Cell Myeloma	Not stage I or III. (from AJCC 8th Ed.)			Neoplastic Process	
C141396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141396>	C141393	RISS Stage III Multiple Myeloma|RISS Stage III Plasma Cell Myeloma|Revised International Staging System Stage IIII Plasma Cell Myeloma	Serum beta-2-microglobulin 5.5 mg/L or more and high-risk cytogenetics and/or high LDH. High risk cytogenetics consist of one or more of the following: del17p, t(4;14), or t(14;16). (from AJCC 8th Ed.)			Neoplastic Process	
C141397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141397>	C35682	Epstein-Barr Virus DNA Positive|EBV DNA Positive|HHV-4 DNA Positive|HHV4 DNA Positive|Human Herpesvirus 4 DNA Positive|Human Herpesvirus-4 DNA Positive	An indication that Epstein-Barr virus DNA has been detected in a sample.	Epstein-Barr Virus DNA Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C141398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141398>	C36315	Loss of Chromosome 4p|4p Deletion|del(4p)	A cytogenetic abnormality that refers to loss of all or part of the short arm of chromosome 4 (4p).	Loss of Chromosome 4p		Cell or Molecular Dysfunction	Cellosaurus Disease Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141399>	C35682|C103223	Wnt Family Gene Alteration Positive|Wingless-Type MMTV Integration Site Family Gene Alteration|Wingless-Type MMTV Integration Site Family Gene Alteration Positive|Wnt Gene Alteration|Wnt Gene Alteration Positive|Wnt Signaling Gene Alteration|Wnt Signaling Gene Alteration Positive	An indication that mutation, overexpression, or rearrangement of an Wnt gene family member has been detected in a sample.	Wnt Family Gene Alteration Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C14139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14139>	C171083	Immunocompromised|Immunocompromised Host|Immunocompromised Host|Immunocompromised Patient|Immunocompromised Patient|Immunosuppressed|Immunosuppressed|Immunosuppressed Host|Immunosuppressed Host|Immunosuppressed Patient|Immunosuppressed Patient|immunocompromised	A loss of any arm of immune functions, resulting in potential or actual increase in infections. This state may be reached secondary to specific genetic lesions, syndromes with unidentified or polygenic causes, acquired deficits from other disease states, or as result of therapy for other diseases or conditions.			Clinical Attribute	NICHD Terminology|Pediatric Infectious Disease Terminology|Pediatric Rheumatology Terminology|SeroNet Authorized Values|SeroNet Study Descriptors
C1413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1413>	C2843	Topotecan|(s)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione|9-[(dimethylamino)methyl]-10-hydroxy-(20S)-camptothecin|Hycamptamine|TOPOTECAN|Topotecan Lactone|topotecan	A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Topotecan inhibits topoisomerase I activity by stabilizing the topoisomerase I-DNA covalent complexes during S phase of cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery.	Topotecan		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCIt Antineoplastic Agent Terminology
C141400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141400>	C35682	BK Virus Positive|BKV Papovavirus Positive|BKV Positive|Polyomavirus BK Positive	An indication that BK virus has been detected in a sample.	BK Virus Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C141401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141401>	C35682	Human Herpesvirus 6 Positive|HHV-6 Positive|HHV6 Positive|Human Herpes Virus 6 Positive|Human Herpes Virus-6 Positive|Human Herpesvirus-6 Positive	An indication that human herpesvirus 6 has been detected in a sample.	Human Herpesvirus 6 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C141402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141402>	C35682	JC Virus Positive|JC Polyomavirus Virus Positive|JCV Positive|Polyomavirus JC Positive	An indication that JC virus has been detected in a sample.	JC Virus Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C141403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141403>	C171054|C133155	DDIT3 Gene Rearrangement|C/EBPzeta Gene Rearrangement|CEBPZ Gene Rearrangement|CHOP-10 Gene Rearrangement|CHOP10 Gene Rearrangement|DDIT3 Rearrangement|DNA Damage Inducible Transcript 3 Gene Rearrangement|DNA-Damage-Inducible Transcript 3 Gene Rearrangement|GADD153 Gene Rearrangement	A molecular abnormality indicating rearrangement of the DDIT3 gene.	DDIT3 Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141404>	C177692	SLC45A2 Positive|AIM-1 Positive|AIM1 Positive|MATP Positive|Melanoma Antigen AIM1 Positive|OCA4 Positive|SHEP5 Positive|Solute Carrier Family 45 Member 2 Positive	An indication that SLC45A2 expression has been detected in a sample.	SLC45A2 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141405>	C35682	Hepatitis B Virus Positive|HBV Positive|Hep B Positive	An indication that hepatitis virus B has been detected in a sample.	Hepatitis B Virus Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141406>	C138961	PSA Level Less than Twenty Five|PSA Level Less than 25|PSA Level Less than Twenty-Five	A blood concentration of prostate specific antigen less than 25 ng/mL.	PSA Level Less than Twenty Five		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141407>	C177692	SCGB2A2 Positive|MGB1 Positive|Mammaglobin 1 Positive|Mammaglobin A Positive|Mammaglobin-1 Positive|Mammaglobin-A Positive|Secretoglobin 2A2 Positive|Secretoglobin Family 2A Member 2 Positive|UGB2 Positive	An indication that SCGB2A2 expression has been detected in a sample.	SCGB2A2 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141408>	C165233|C103223	UGT1A1*28 Allele Negative|UGT1A1*28 Absent|UGT1A1*28 Negative	An indication that UGT1A1*28 expression has not been detected in a sample.	UGT1A1*28 Allele Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C14140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14140>	C28102	Acute|ACUTE|acute	Having a severe and rapid onset of symptoms with short duration.	Acute		Qualitative Concept	CDISC SEND Chronicity Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C141410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141410>	C217122	Simplified Preoperative Assessment for Appendix Tumor Score|SPAAT|SPAAT Score	A set of imaging criteria, based on preoperative CT scans, used to predict the likelihood for complete cytoreduction in patients with low-grade mucinous adenocarcinoma (LGMA) of the appendix. A score is determined by the presence of scalloping at 4 anatomic sites and the absence or presence of mesenteric foreshortening of the small bowel. A score under 3 is a significant predictor for complete cytoreduction.			Intellectual Product	
C141411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141411>	C141410	SPAAT Score 0|SPAAT 0	A subjective score of 0 on a prognostic scale that ranges from 0 to 7.			Intellectual Product	
C141412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141412>	C141410	SPAAT Score 1|SPAAT 1	A subjective score of 1 on a prognostic scale that ranges from 0 to 7.			Intellectual Product	
C141413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141413>	C141410	SPAAT Score 2|SPAAT 2	A subjective score of 2 on a prognostic scale that ranges from 0 to 7.			Intellectual Product	
C141414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141414>	C141410	SPAAT Score 3|SPAAT 3	A subjective score of 3 on a prognostic scale that ranges from 0 to 7.			Intellectual Product	
C141415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141415>	C141410	SPAAT Score 4|SPAAT 4	A subjective score of 4 on a prognostic scale that ranges from 0 to 7.			Intellectual Product	
C141416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141416>	C141410	SPAAT Score 5|SPAAT 5	A subjective score of 5 on a prognostic scale that ranges from 0 to 7.			Intellectual Product	
C141417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141417>	C141410	SPAAT Score 6|SPAAT 6	A subjective score of 6 on a prognostic scale that ranges from 0 to 7.			Intellectual Product	
C141418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141418>	C141410	SPAAT Score 7|SPAAT 7	A subjective score of 7 on a prognostic scale that ranges from 0 to 7.			Intellectual Product	
C141419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141419>	C26170	Eflepedocokin Alfa|EFLEPEDOCOKIN ALFA|F-652|IL-22 Dimer F-652|IL-22 IgG2-Fc|Promenakin|Recombinant Human IL-22 IgG2-Fc|Recombinant Human Interleukin-22 IgG2-Fc	A recombinant fusion protein consisting of human cytokine interleukin 22 (IL-22) fused to a human immunoglobulin G2 (IgG2)-Fc, with potential cell protective activity. Upon intravenous administration of eflepedocokin alfa, IL-22 binds to its cognate receptor IL-22R, which is highly expressed in parenchymal tissues and epithelial cells at mucosal surfaces. This leads to the activation of IL-22/IL-22R-mediated signal transduction pathways, and results in the activation of signal transducer and activator of transcription 3 (STAT3). STAT3 activation may have a protective and regenerative effect and may protect against the development of various inflammatory and immunological diseases. Specifically, recombinant human IL-22 IgG2-Fc may protect intestinal stem cells from dying due to acute graft-versus-host disease (aGvHD). IL-22, produced by various immune cells and upregulated during inflammation, plays a key role in controlling immune responses and bacterial infection, and in the enhancement of intestinal barrier function, gut immunity, and tissue repair.	Eflepedocokin Alfa		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C14141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14141>	C28102	Chronic|CHRONIC|chronic	Usually used to describe a condition that is persistent and long standing.	Chronic		Qualitative Concept	CDISC SEND Chronicity Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C141420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141420>	C213143|C155712	Anti-HER2-vc0101 ADC PF-06804103|Anti-HER2-vcAur0101 ADC PF-06804103|Anti-NG-HER2 ADC PF-06804103|Anti-NG-Her2-vc0101 ADC PF-06804103|Antibody-drug Conjugate PF-06804103|PF 06804103|PF-06804103|PF06804103	A proprietary antibody-drug conjugate (ADC) composed of a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) site-specifically linked, via a protease cleavable linker, to an analog of dolastatin 10, Auristatin-0101, with potential antineoplastic activity. Upon administration, anti-HER2-vc0101 ADC PF-06804103 targets HER2 expressed on tumor cells. Upon binding, internalization and cleavage, Auristatin-0101 binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and apoptosis of HER2-expressing tumor cells. HER2, a tumor-associated antigen (TAA), is overexpressed on a variety of cancer cells.	Anti-HER2-vc0101 ADC PF-06804103		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C141421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141421>	C134787	Anti-TIGIT Monoclonal Antibody ASP8374|ASP 8374|ASP-8374|ASP-8374|ASP8374|PTZ-201	A fully human, immunoglobulin G4 (IgG4) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory and immunostimulating activities. Upon administration, anti-TIGIT monoclonal antibody ASP8374 targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.	Anti-TIGIT Monoclonal Antibody ASP8374		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C141422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141422>	C28310	Neoantigen-loaded Autologous Dendritic Cell Vaccine|Autologous Tumor Peptide-loaded Mature DC Vaccine	A personalized, peptide-based therapeutic dendritic cell (DC) vaccine consisting of autologous DCs loaded with immunogenic peptides derived from autologous cancer cells, with potential immunomodulating and antineoplastic activities. Upon leukapheresis, mature DCs are loaded with immunogenic neoantigens. Vaccination with the neoantigen-loaded autologous DC vaccine stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis.	Neoantigen-loaded Autologous Dendritic Cell Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C141423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141423>	C85865|C34568	Ehlers-Danlos Syndrome, Type V	An X-linked condition characterized by joint hyperextensibility, mild skin hyperelastisity, and abnormal scarring. The molecular basis for this condition has not been fully elucidated.			Disease or Syndrome	Cellosaurus Disease Terminology
C141424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141424>	C84392|C53543	Intellectual Developmental Disorder, Autosomal Dominant 1|MRD1|Mental Retardation, Autosomal Dominant 1	An autosomal dominant condition caused by mutation(s) in the MBD5 gene, encoding methyl-CpG-binding domain protein 5. It is characterized by severe developmental and cognitive delay, short stature, craniofacial dysmorphism, and seizures.			Disease or Syndrome	Cellosaurus Disease Terminology
C141425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141425>	C213665|C129825	Spebrutinib Besylate|2-Propenamide, N-(3-((5-fluoro-2-((4-(2-methoxyethoxy)phenyl)amino)-4-pyrimidinyl)amino)phenyl)-, Benzenesulfonate (1:1)|CC-292 Besylate|N-(3-((5-fluoro-2-((4-(2-methoxyethoxy)phenyl)amino)pyrimidin-4-yl)amino)phenyl)prop-2-enamide Benzenesulfonate|SPEBRUTINIB BESYLATE	The besylate salt form of spebrutinib, an orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity. Upon administration, spebrutinib targets and covalently binds to BTK, thereby preventing its activity. By irreversibly inhibiting BTK, administration of this agent may lead to an inhibition of B cell receptor (BCR) signaling and may inhibit cell proliferation of B-cell malignancies. BTK, a cytoplasmic tyrosine kinase and member of the Tec family of kinases, plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C141426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141426>	C213665|C129825	Tirabrutinib Hydrochloride|GS-4059 Hydrochloride|ONO-4059 Hydrochloride|TIRABRUTINIB HYDROCHLORIDE|Velexbru	The hydrochloride salt form of tirabrutinib, an orally available formulation containing an inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity. Upon administration, tirabrutinib covalently binds to BTK within B cells, thereby preventing B cell receptor signaling and impeding B cell development. As a result, this agent may inhibit the proliferation of B cell malignancies. BTK, a cytoplasmic tyrosine kinase and member of the Tec family of kinases, plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C141427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141427>	C213665	Evobrutinib|1-(4-((6-Amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino)-methyl)-piperidin-1-yl)-propenone|EVOBRUTINIB	An inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, evobrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C141428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141428>	C213665|C129825	Zanubrutinib|(S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide|BGB 3111|BGB-3111|BGB3111|BTK-InhB|Brukinsa|ZANUBRUTINIB	An inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, zanubrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival.	Zanubrutinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C141429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141429>	C213865|C200258|C192741	Riviciclib Hydrochloride|RIVICICLIB HYDROCHLORIDE	The hydrochloride salt form of riviciclib, a flavone and cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. Riviciclib selectively binds to and inhibits Cdk4/cyclin D1, Cdk1/cyclin B and Cdk9/cyclin T1, serine/threonine kinases that play key roles in the regulation of the cell cycle and cellular proliferation. Inhibition of these kinases leads to cell cycle arrest during the G1/S transition, thereby leading to an induction of apoptosis, and inhibition of tumor cell proliferation.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C141430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141430>	C192742|C192741	Voruciclib|2-(2-Chloro-4-(trifluoromethyl)phenyl)-5,7-dihydroxy-8-((2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl)-4H-1-benzopyran-4-one|P1446A-05|VORUCICLIB	A cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Upon administration, voruciclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6). This inhibits retinoblastoma (Rb) protein phosphorylation early in the G1 phase, which prevents CDK-mediated G1-S phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.	Voruciclib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C141431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141431>	C129824	Briciclib|2-Methoxy-5-(((2-(2,4,6-trimethoxyphenyl)ethenyl)sulfonyl)methyl)phenyl Dihydrogen Phosphate|BRICICLIB|ON-014185	A benzyl styryl sulfone analog, and a phosphate ester prodrug of ON 013100, with potential antineoplastic activity. Upon hydrolysis, briciclib is converted to ON 013100, which blocks cyclin D mRNA translation and decreases protein expression of cyclin D. This may induce cell cycle arrest and apoptosis in cancer cells overexpressing cyclin D and eventually decrease tumor cell proliferation. Cyclin D, a member of the cyclin family of cell cycle regulators, plays a key role in cell cycle division and is often overexpressed in a variety of hematologic and solid tumors and is correlated with poor prognosis. suppresses cyclin D1 accumulation in cancer cells.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C141432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141432>	C162996	Milademetan|2,6-Anhydro-5-((((3'R,4'S,5'R)-6'"-chloro-4'-(2-chloro-3-fluoro-4-pyridinyl)-1'",2'"-dihydro-4,4-dimethyl-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-3,4,5-trideoxy-L-erythro-hexonamide|DS-3032|MILADEMETAN|RAIN-32	An orally available MDM2 (murine double minute 2) antagonist with potential antineoplastic activity. Upon oral administration, milademetan binds to, and prevents the binding of MDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the proteasome-mediated enzymatic degradation of p53 is inhibited and the transcriptional activity of p53 is restored. This results in the restoration of p53 signaling and leads to the p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein and a negative regulator of the p53 pathway, is overexpressed in cancer cells; it has been implicated in cancer cell proliferation and survival.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C141433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141433>	C63358	Dose-dense AC Followed by Dose-Dense Paclitaxel Regimen|ACT Dose Dense|ACT Dose-dense|DD AC Followed by DD Paclitaxel Regimen|DD ACT Regimen|Dose-dense AC Followed by Dose-dense Paclitaxel|Dose-dense AC Regimen Followed by Dose-dense Paclitaxel|Dose-dense ACT Regimen|Dose-dense Adriamycin/Cytoxan Followed by Dose-dense Taxol|Dose-dense Doxorubicin/Cyclophosphamide Followed by Dose-dense Paclitaxel|ddAC-ddT	A regimen consisting of dose-dense cyclophosphamide and doxorubicin followed by dose-dense paclitaxel that can be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C141434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141434>	C68748	HER2/Neu Positive by FISH	A laboratory test result indicating the presence of HER2/Neu in a tissue sample using fluorescence in situ hybridization.			Laboratory or Test Result	
C141435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141435>	C68749	HER2/Neu Negative by FISH|ERBB2 Negative by FISH|HER2 Negative by FISH	A laboratory test result indicating the absence of HER2/Neu in a tissue sample using fluorescence in situ hybridization.	HER2/Neu Negative by FISH		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141436>	C210736	Roxadustat|(((4-Hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl)amino)acetic Acid|ASP 1517|FG 4592|FG-4592|ROXADUSTAT	An orally bioavailable, hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), with potential anti-anemic activity. Upon administration, roxadustat binds to and inhibits HIF-PHI, an enzyme responsible for the degradation of transcription factors in the HIF family under normal oxygen conditions. This prevents HIF breakdown and promotes HIF activity. Increased HIF activity leads to an increase in endogenous erythropoietin production, thereby enhancing erythropoiesis. It also reduces the expression of the peptide hormone hepcidin, improves iron availability, and boosts hemoglobin (Hb) levels. HIF regulates the expression of genes in response to reduced oxygen levels, including genes required for erythropoiesis and iron metabolism.	Roxadustat		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C141437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141437>	C92896	Early Third Trimester	The period of gestation generally corresponding to the first half of the third trimester.			Temporal Concept	
C141438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141438>	C92896	Late Third Trimester	The period of gestation generally corresponding to the last half of the third trimester.			Temporal Concept	
C141439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141439>	C16830	NovoTTF-200A Device|NovoTTF-200A|NovoTTF-200A System	A second generation tumor treatment field (TTF; TTField) device.	NovoTTF-200A Device		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C14143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14143>	C28099	Malignant|MALIGNANT|malignant	Refers to abnormal cell activity manifested by decreased control over growth and function, causing tumor growth or spread into surrounding tissue and adverse effects to the host.	Malignant		Qualitative Concept	CDISC SEND Microscopic Histopathology Result Category Terminology|CDISC SEND Terminology|CDISC SEND Tumor Findings Histopathology Result Category Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|ICDC Terminology|ICDC Value Terminology
C141440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141440>	C29750|C129824	Uproleselan Sodium|UPROLESELAN SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C141441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141441>	C177244	Autosomal Dominant Lateral Temporal Lobe Epilepsy|ETL1|Epilepsy, Familial Temporal Lobe 1	An autosomal dominant condition caused by mutation(s) in the LGI1 gene, encoding leucine-rich glioma-inactivated protein 1. It is characterized by partial seizures originating in the temporal lobe and often accompanied by auditory sensory manifestations.			Disease or Syndrome	Cellosaurus Disease Terminology
C141442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141442>	C53543	GTP Cyclohydrolase I Deficiency|GTPCH Deficiency	An autosomal recessive condition caused by mutation(s) in the GCH1 gene, encoding GTP cyclohydrolase 1. It is characterized by hyperphenylalaninemia and GTP cyclohydrolase 1-deficient dopa-responsive dystonia.			Disease or Syndrome	Cellosaurus Disease Terminology
C141443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141443>	C143099	PF-04217903 Monophosphate|1H-Pyrazole-1-ethanol, 4-(1-(6-Quinolinylmethyl)-1H-1,2,3-triazolo(4,5-b)pyrazin-6-yl)-, Phosphate (1:1)|PF-04217903 MONOPHOSPHATE	The monophosphate form of PF-04217903, an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity. MET tyrosine kinase inhibitor PF-04217903 selectively binds to and inhibits c-Met, disrupting the c-Met signaling pathway, which may result in the inhibition of tumor cell growth, migration and invasion of tumor cells, and the induction of death in tumor cells expressing c-Met. The receptor tyrosine kinase c-Met, also known as hepatocyte growth factor (HGF) receptor, is overexpressed or mutated in many tumor cell types, playing an important role in tumor cell proliferation, survival, invasion, and metastasis and angiogenesis.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C141444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141444>	C177692	HLA-A*0201 HA-1 Positive Cells Present|HLA-A*02:01 HA-1 Positive Cells Present|HLA-A0201 HA-1 Positive Cells Present	An indication that cells that are expressing the peptide/major histocompatibility protein complex (pMHC) comprised of a minor histocompatibility peptide antigen (HA-1) bound to HLA-A*0201 are present in a sample.	HLA-A*0201 HA-1 Positive Cells Present		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141445>	C4673|C148423	Recurrent Acute Biphenotypic Leukemia|Acute Biphenotypic Leukemia in Relapse	The reemergence of acute biphenotypic leukemia after a period of remission.	Recurrent Acute Biphenotypic Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C141446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141446>	C9298|C172626	Recurrent Acute Undifferentiated Leukemia|Acute Undifferentiated Leukemia in Relapse	The reemergence of acute undifferentiated leukemia after a period of remission.	Recurrent Acute Undifferentiated Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C141447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141447>	C141458	Progesterone Receptor Positive by Immunohistochemistry Less than 1 Percent	An immunohistochemical staining finding indicating that less than 1 percent of the cells in a tissue sample are expressing progesterone receptor.	Progesterone Receptor Positive by Immunohistochemistry Less than 1 Percent		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141448>	C141458	Progesterone Receptor Positive by Immunohistochemistry 1-10 Percent	An immunohistochemical staining finding indicating that 1-10 percent of the cells in a tissue sample are expressing progesterone receptor.	Progesterone Receptor Positive by Immunohistochemistry 1-10 Percent		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141449>	C141458	Progesterone Receptor Positive by Immunohistochemistry 11-20 Percent	An immunohistochemical staining finding indicating that 11-20 percent of the cells in a tissue sample are expressing progesterone receptor.			Laboratory or Test Result	
C14144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14144>	C28099	Anaplastic|ANAPLASTIC|Undifferentiated|anaplastic		Anaplastic		Qualitative Concept	CDISC SEND Microscopic Findings Result Modifier Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Terminology
C141450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141450>	C141458	Progesterone Receptor Positive by Immunohistochemistry 21-30 Percent	An immunohistochemical staining finding indicating that 21-30 percent of the cells in a tissue sample are expressing progesterone receptor.			Laboratory or Test Result	
C141451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141451>	C141458	Progesterone Receptor Positive by Immunohistochemistry 31-40 Percent	An immunohistochemical staining finding indicating that 31-40 percent of the cells in a tissue sample are expressing progesterone receptor.			Laboratory or Test Result	
C141452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141452>	C141458	Progesterone Receptor Positive by Immunohistochemistry 41-50 Percent	An immunohistochemical staining finding indicating that 41-50 percent of the cells in a tissue sample are expressing progesterone receptor.			Laboratory or Test Result	
C141453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141453>	C141458	Progesterone Receptor Positive by Immunohistochemistry 51-60 Percent	An immunohistochemical staining finding indicating that 51-60 percent of the cells in a tissue sample are expressing progesterone receptor.			Laboratory or Test Result	
C141454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141454>	C141458	Progesterone Receptor Positive by Immunohistochemistry 61-70 Percent	An immunohistochemical staining finding indicating that 61-70 percent of the cells in a tissue sample are expressing progesterone receptor.			Laboratory or Test Result	
C141455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141455>	C141458	Progesterone Receptor Positive by Immunohistochemistry 71-80 Percent	An immunohistochemical staining finding indicating that 71-80 percent of the cells in a tissue sample are expressing progesterone receptor.			Laboratory or Test Result	
C141456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141456>	C141458	Progesterone Receptor Positive by Immunohistochemistry 81-90 Percent	An immunohistochemical staining finding indicating that 81-90 percent of the cells in a tissue sample are expressing progesterone receptor.			Laboratory or Test Result	
C141457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141457>	C141458	Progesterone Receptor Positive by Immunohistochemistry 91-100 Percent	An immunohistochemical staining finding indicating that 91-100 percent of the cells in a tissue sample are expressing progesterone receptor.			Laboratory or Test Result	
C141458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141458>	C40998|C15496	Progesterone Receptor Positive by Immunohistochemistry	An immunohistochemical staining finding indicating that cells in a tissue sample are expressing progesterone receptor.			Laboratory or Test Result	
C141459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141459>	C222318|C210686|C129820	Cergutuzumab Amunaleukin|CEA-IL-2variant|CEA-IL2v|CERGUTUZUMAB AMUNALEUKIN|RG-7813|RG7813|RO-6895882|RO6895882	A recombinant fusion protein comprised of cergutuzumab, a genetically engineered human immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against carcinoembryonic antigen (CEA, CEACAM5, CD66e), linked to amunaleukin, an engineered, mutated variant form of interleukin-2 (IL-2v), with potential immunostimulating and antineoplastic activities. Upon administration of cergutuzumab amunaleukin, the cergutuzumab moiety recognizes and binds to CEA, thereby specifically targeting IL-2v to CEA-expressing tumor tissue. Subsequently, the IL-2v moiety stimulates a local immune response, which activates both natural killer (NK) cells and cytotoxic T-cells, and eventually leads to tumor cell killing. CEA is a cell surface protein that is expressed on a wide variety of cancer cells. The mutations found in IL-2v inhibit its binding to IL-2 receptor-alpha (CD25, IL2Ra), which prevents the activation of regulatory T-cells (Tregs); however, IL-2v is able to bind to and induce signaling through IL-2Rbetagamma, which allows the preferential expansion of NK cells and CD8-positive T-cells. The Fc domain of cergutuzumab is modified to prevent Fc-gamma binding and downstream effector functions.	Cergutuzumab Amunaleukin		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C14145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14145>	C28102	Indolent|indolent	Slow growing; causing little or no pain or annoyance.			Qualitative Concept	
C141460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141460>	C28681	IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells|IL13 [EQ]BBzeta/truncated CD19[t]+ Naive and Memory T Cells|IL13 [EQ]BBzeta/truncated CD19[t]+ TN/MEM Cells|IL13Ra2-specific-hinge-optimized-4-1BB-CAR/truncated CD19-expressing Autologous TN/MEM Lymphocytes	A preparation of ex vivo expanded, genetically modified autologous naïve and memory T-cells (TN/MEM) transduced with a replication incompetent, self-inactivating (SIN) lentiviral vector expressing a hinge-optimized, chimeric antigen receptor (CAR) specific for interleukin-13 receptor alpha 2 (IL13Ra2), and containing the cluster of differentiation 137 (CD137; 4-1BB) co-stimulatory signaling domain fused to the signaling domain of the T-cell antigen receptor complex zeta chain (CD3-zeta), and a truncated form of human cluster of differentiation 19 (CD19t), with potential immunostimulating and antineoplastic activities. Upon intratumoral or intracavitary administration, IL13Ra2-specific hinge-optimized 4-1BB-co-stimulatory CAR/truncated CD19-expressing autologous TN/MEM cells are directed to, and induce selective toxicity and cytolysis in, IL13Ra2-expressing tumor cells. IL13Ra2, overexpressed by a variety of tumor cell types, is associated with increased proliferation, migration and invasiveness of tumor cells. The co-stimulatory signaling domain enhances both proliferation of T-cells and antitumor activity. Hinge optimization prevents the recognition and clearance of the CAR by endogenous Fc receptors (FcRs). CD19t is used as a surface marker to both track and quantify the modified T-cells in vivo.	IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C141461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141461>	C28108	Occult Stage|OC|Occult	A stage term that refers to a cancer in which the primary site is unknown (not detectable by clinical or radiologic examination). The definition of occult stage depends on the particular type of cancer that it refers to; for example, for breast cancer, occult stage is defined as cancer presenting with axillary lymph node metastasis without a primary in the breast being found; for non-small cell lung carcinoma, occult stage is defined as cancer detectable by sputum cytology only and the primary tumor is undetectable radiographically or during bronchoscopy.			Classification	
C141462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141462>	C199143	National Program of Cancer Registries|NPCR	Established by Congress through the Cancer Registries Amendment Act in 1992, and administered by CDC, the National Program of Cancer Registries (NPCR) collects data on cancer occurrence (including the type, extent, and location of the cancer), the type of initial treatment, and outcomes. It supports central cancer registries in 46 states, the District of Columbia, Puerto Rico, the U.S. Pacific Island Jurisdictions, and the U.S. Virgin Islands.			Professional or Occupational Group	
C141463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141463>	C25717	Presumed Alive|Presumed Living	The assumption that a person is still living.			Clinical Attribute	
C141464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141464>	C45971	Recode|Recoding	To apply a new, corrected, or updated code value.			Occupational Activity	
C141465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141465>	C157196|C15492	Estrogen Receptor Positive by Immunohistochemistry	An immunohistochemical staining finding indicating that cells in a tissue sample are expressing estrogen receptor.			Laboratory or Test Result	
C141466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141466>	C141465	Estrogen Receptor Positive by Immunohistochemistry Less than 1 Percent|Estrogen Receptor Positive by Immunohistochemistry Less than 1%	An immunohistochemical staining finding indicating that less than 1 percent of the cells in a tissue sample are expressing estrogen receptor.	Estrogen Receptor Positive by Immunohistochemistry Less than 1 Percent		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141467>	C141465	Estrogen Receptor Positive by Immunohistochemistry 1-10 Percent	An immunohistochemical staining finding indicating that 1-10 percent of the cells in a tissue sample are expressing estrogen receptor.	Estrogen Receptor Positive by Immunohistochemistry 1-10 Percent		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C141468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141468>	C141465	Estrogen Receptor Positive by Immunohistochemistry 11-20 Percent	An immunohistochemical staining finding indicating that 11-20 percent of the cells in a tissue sample are expressing estrogen receptor.			Laboratory or Test Result	
C141469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141469>	C141465	Estrogen Receptor Positive by Immunohistochemistry 21-30 Percent	An immunohistochemical staining finding indicating that 21-30 percent of the cells in a tissue sample are expressing estrogen receptor.			Laboratory or Test Result	
C14146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14146>	C28102	Localized|Localised|localized				Spatial Concept	
C141470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141470>	C141465	Estrogen Receptor Positive by Immunohistochemistry 31-40 Percent	An immunohistochemical staining finding indicating that 31-40 percent of the cells in a tissue sample are expressing estrogen receptor.			Laboratory or Test Result	
C141471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141471>	C141465	Estrogen Receptor Positive by Immunohistochemistry 41-50 Percent	An immunohistochemical staining finding indicating that 41-50 percent of the cells in a tissue sample are expressing estrogen receptor.			Laboratory or Test Result	
C141472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141472>	C141465	Estrogen Receptor Positive by Immunohistochemistry 51-60 Percent	An immunohistochemical staining finding indicating that 51-60 percent of the cells in a tissue sample are expressing estrogen receptor.			Laboratory or Test Result	
C141473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141473>	C141465	Estrogen Receptor Positive by Immunohistochemistry 61-70 Percent	An immunohistochemical staining finding indicating that 61-70 percent of the cells in a tissue sample are expressing estrogen receptor.			Laboratory or Test Result	
C141474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141474>	C141465	Estrogen Receptor Positive by Immunohistochemistry 71-80 Percent	An immunohistochemical staining finding indicating that 71-80 percent of the cells in a tissue sample are expressing estrogen receptor.			Laboratory or Test Result	
C141475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141475>	C141465	Estrogen Receptor Positive by Immunohistochemistry 81-90 Percent	An immunohistochemical staining finding indicating that 81-90 percent of the cells in a tissue sample are expressing estrogen receptor.			Laboratory or Test Result	
C141476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141476>	C141465	Estrogen Receptor Positive by Immunohistochemistry 91-100 Percent	An immunohistochemical staining finding indicating that 91-100 percent of the cells in a tissue sample are expressing estrogen receptor.			Laboratory or Test Result	
C141477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141477>	C49484	Not Performed|NP|Not performed	An indicator that specifies that an activity did not occur.			Conceptual Entity	CRF6 DIPG Imaging Assessment MRS Table|CRF6 DIPG Imaging Assessment Perfusion Table|CRF6 DIPG Imaging Assessment Signal Characteristics Table|CRF6 DMG Imaging Assessment MRS Table|CRF6 DMG Imaging Assessment Perfusion Table|CRF6 DMG Imaging Assessment Signal Characteristics Table|GDC Terminology|GDC Value Terminology
C141478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141478>	C20189	Not Allowed To Collect|not allowed to collect	An indicator that specifies that a collection event was not permitted.			Conceptual Entity	GDC Terminology|GDC Value Terminology
C141479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141479>	C63360	Bevacizumab/Pemetrexed Regimen|Bevacizumab-Pemetrexed|Bevacizumab-Pemetrexed Regimen|Bevacizumab/Pemetrexed|Pemetrexed and Bevacizumab|Pemetrexed and Bevacizumab-adcd|Pemetrexed and Bevacizumab-awwb|Pemetrexed and Bevacizumab-aybi|Pemetrexed and Bevacizumab-bvzr|Pemetrexed and Bevacizumab-equi|Pemetrexed and Bevacizumab-maly|Pemetrexed and Bevacizumab-onbe|Pemetrexed and Bevacizumab-tnjn	A regimen consisting of bevacizumab and pemetrexed that can be used in the treatment of non-small cell lung cancer (NSCLC).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C14147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14147>	C28099	Nonmelanomatous|nonmelanomatous		Nonmelanomatous		Qualitative Concept	CTRP Terminology
C141480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141480>	C68749|C185751	HER2/Neu Negative by Immunohistochemistry	A laboratory test result indicating the absence of HER2/Neu in a tissue sample using immunohistochemical staining.			Laboratory or Test Result	
C141481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141481>	C68748|C185751	HER2/Neu Positive by Immunohistochemistry	An immunohistochemical staining finding indicating that cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.			Laboratory or Test Result	
C14148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14148>	C28100	Nonmetastatic|nonmetastatic				Qualitative Concept	
C141493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141493>	C141481	HER2/Neu Positive by Immunohistochemistry Less than 1 Percent	An immunohistochemical staining finding indicating that less than 1 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.			Laboratory or Test Result	
C141494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141494>	C141481	HER2/Neu Positive by Immunohistochemistry 1-10 Percent	An immunohistochemical staining finding indicating that 1-10 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.			Laboratory or Test Result	
C141495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141495>	C141481	HER2/Neu Positive by Immunohistochemistry 11-20 Percent	An immunohistochemical staining finding indicating that 11-20 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.			Laboratory or Test Result	
C141496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141496>	C141481	HER2/Neu Positive by Immunohistochemistry 21-30 Percent	An immunohistochemical staining finding indicating that 21-30 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.			Laboratory or Test Result	
C141497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141497>	C141481	HER2/Neu Positive by Immunohistochemistry 31-40 Percent	An immunohistochemical staining finding indicating that 31-40 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.			Laboratory or Test Result	
C141498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141498>	C141481	HER2/Neu Positive by Immunohistochemistry 41-50 Percent	An immunohistochemical staining finding indicating that 41-50 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.			Laboratory or Test Result	
C141499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141499>	C141481	HER2/Neu Positive by Immunohistochemistry 51-60 Percent	An immunohistochemical staining finding indicating that 51-60 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.			Laboratory or Test Result	
C14149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14149>	C27992	Osteolytic|osteolytic				Pathologic Function	
C1414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1414>	C1821	Trioxifene Mesylate|3,4-Dihydro-2-(p-methoxyphenyl)-1-naphthyl p-(2-(1-pyrrolidinyl)ethoxy)phenyl Ketone Methanesulfonate|Compound 133314|LY-133314|TRIOXIFENE MESYLATE|Trioxifene Mesilate	A mesylate salt form of trioxifene, a nonsteroidal selective estrogen receptor modulator (SERM).  Trioxifene competitively inhibits the binding of estradiol to estrogen receptor alpha (ER alpha), resulting in ER alpha-mediated gene expression.  Clinical development of Trioxifene has not proceeded because of lack of superior results over tamoxifen and side effect profile. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C141500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141500>	C141481	HER2/Neu Positive by Immunohistochemistry 61-70 Percent	An immunohistochemical staining finding indicating that 61-70 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.			Laboratory or Test Result	
C141501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141501>	C141481	HER2/Neu Positive by Immunohistochemistry 71-80 Percent	An immunohistochemical staining finding indicating that 71-80 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.			Laboratory or Test Result	
C141502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141502>	C141481	HER2/Neu Positive by Immunohistochemistry 81-90 Percent	An immunohistochemical staining finding indicating that 81-90 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.			Laboratory or Test Result	
C141503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141503>	C141481	HER2/Neu Positive by Immunohistochemistry 91-100 Percent	An immunohistochemical staining finding indicating that 91-100 percent of the cells in a tissue sample are expressing receptor tyrosine-protein kinase erbB-2.			Laboratory or Test Result	
C141504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141504>	C156880	SNX 5422|Glycine, Trans-4-((2-(aminocarbonyl)-5-(4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo-3-(trifluoromethyl)-1H-indazol-1-yl)phenyl)amino)cyclohexyl Ester|PF 04929113|PF-04929113|SNX-5422|SNX-5422				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C141505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141505>	C63719|C63361	Cisplatin/Fluorouracil/Trastuzumab Regimen|CFT|Cisplatin and Fluorouracil (CF) and Trastuzumab|Cisplatin and Fluorouracil (CF) and Trastuzumab-anns|Cisplatin and Fluorouracil (CF) and Trastuzumab-dkst|Cisplatin and Fluorouracil (CF) and Trastuzumab-dttb|Cisplatin and Fluorouracil (CF) and Trastuzumab-herw|Cisplatin and Fluorouracil (CF) and Trastuzumab-pkrb|Cisplatin and Fluorouracil (CF) and Trastuzumab-qyyp|Cisplatin and Fluorouracil (CF) and Trastuzumab-strf|Cisplatin and Fluorouracil (CF) and Trastuzumab-zerc|Cisplatin-Fluorouracil-Trastuzumab|Cisplatin-Fluorouracil-Trastuzumab Regimen|Cisplatin/5-FU/Trastuzumab|Cisplatin/Fluorouracil/Leucovorin Plus Trastuzumab|Cisplatin/Fluorouracil/Trastuzumab	A regimen consisting of cisplatin, fluorouracil and trastuzumab that can be used in the treatment of esophageal and esophagogastric junction, and gastric cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C141506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141506>	C63719|C63361|C159454	Capecitabine/Cisplatin Regimen|CX|Capecitabine and Cisplatin (CX)|Capecitabine-Cisplatin|Capecitabine-Cisplatin Regimen|Capecitabine/Cisplatin|Cisplatin/Capecitabine Regimen|XP|Xeloda-Platinol|Xeloda/Platinol	A regimen consisting of capecitabine and cisplatin that can be used in the treatment of gastric, hepatobiliary, esophageal and esophagogastric junction cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C141507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141507>	C63719|C63361	ECX Regimen|Capecitabine-Cisplatin-Epirubicin|Capecitabine-Cisplatin-Epirubicin Regimen|Capecitabine/Cisplatin/Epirubicin|Capecitabine/Cisplatin/Epirubicin Regimen|Cisplatin-Epirubicin-Xeloda|Cisplatin/Epirubicin/Xeloda|ECX|ECX|ECX	A regimen consisting of capecitabine, cisplatin and epirubicin that can be used in the treatment of a variety of cancers, such as gastric, ovarian, pancreatic, and esophageal cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C141508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141508>	C63719|C63361	EOX Regimen|Capecitabine-Epirubicin-Oxaliplatin|Capecitabine-Epirubicin-Oxaliplatin Regimen|Capecitabine/Epirubicin/Oxaliplatin|Capecitabine/Epirubicin/Oxaliplatin Regimen|EOX|EOX|EOX|Epirubicin-Oxaliplatin-Xeloda|Epirubicin/Oxaliplatin/Xeloda	A regimen consisting of capecitabine, epirubicin and oxaliplatin that can be used in the treatment of esophageal and gastric cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C141509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141509>	C217121	Malignant Bowel Obstruction Color Code Scale|MBO|MBO Color Scale|MBO Scale|Malignant Bowel Obstruction Color Code System Scale	A scale using colors to describe the severity and level of care required by an individual to manage their malignant bowel obstruction.			Intellectual Product	
C14150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14150>	C28101	Tumor-Derived|tumor-derived				Functional Concept	
C141510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141510>	C226696|C226641	Malignant Bowel Obstruction Resolved, Self Managing|Resolved, self managing	A response indicating that an individual's malignant bowel obstruction is resolved and they are managing their care without assistance.			Intellectual Product	Malignant Bowel Obstruction Color Code Scale
C141511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141511>	C226696|C226641	No Malignant Bowel Obstruction, Issues with Constipation|No MBO, but issues with constipation	A response indicating that an individual is not experiencing malignant bowel obstruction symptoms but has issues with constipation.			Intellectual Product	Malignant Bowel Obstruction Color Code Scale
C141512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141512>	C226696	Malignant Bowel Obstruction, Ambulatory Care Management|MBO, ambulatory management	A response indicating that an individual is experiencing malignant bowel obstruction symptoms and is receiving ambulatory care.			Intellectual Product	Malignant Bowel Obstruction Color Code Scale
C141513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141513>	C226696	Malignant Bowel Obstruction, Inpatient Care Management|MBO, inpatient management	A response indicating that an individual is experiencing malignant bowel obstruction symptoms and is receiving care while in hospital.			Intellectual Product	Malignant Bowel Obstruction Color Code Scale
C141514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141514>	C226696	Malignant Bowel Obstruction, Best Supportive Care Palliative Team Management|Best supportive care, primarily managed by Palliative Care Team	A response indicating that an individual is experiencing malignant bowel obstruction symptoms and is receiving best supportive care primarily managed by a palliative care team.			Intellectual Product	Malignant Bowel Obstruction Color Code Scale
C141515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141515>	C128462	Birabresib Dihydrate|6H-Thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-6-acetamide, 4-(4-Chlorophenyl)-N-(4-hydroxyphenyl)-2,3,9-trimethyl-, Hydrate (1:2), (6S)-|BIRABRESIB DIHYDRATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C141516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141516>	C308	Iberdomide Hydrochloride|2,6-Piperidinedione, 3-(1,3-dihydro-4-((4-(4-morpholinylmethyl)phenyl)methoxy)-1-oxo-2H-isoindol-2-yl)-, Hydrochloride (1:1), (3S)-|CC-220 Hydrochloride|IBERDOMIDE HYDROCHLORIDE	The hydrochloride salt form of iberdomide, a modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and pro-apoptotic activities. Upon administration, iberdomide specifically binds to the cereblon (CRBN) part of the ligase complex, thereby affecting the ubiquitin E3 ligase activity, and targeting certain substrate proteins for ubiquitination. This induces the proteasome-mediated degradation of certain transcription factors, including Ikaros (IKZF1) and Aiolos (IKZF3) which are transcriptional repressors in T-cells. This leads to a reduction of their protein levels, and the modulation of the immune system, including activation of T-lymphocytes. In addition, this leads to a downregulation of other proteins, including interferon regulatory factor 4 (IRF4), which plays a key role in the proliferation of certain cancer cell types. CRBN, the substrate recognition component of the E3 ubiquitin ligase complex, plays a key role in the ubiquitination of certain proteins.	Iberdomide Hydrochloride		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C141517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141517>	C36912	Atypical Glandular Cell-Favor Neoplasia	An abnormal endocervical or endometrial cell found in a cervical smear with cytologic features suggestive of a neoplastic process.			Cell	
C141518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141518>	C36912	Atypical Endocervical Cell	An abnormal endocervical cell found in a cervical smear. It may be related to an inflammatory or neoplastic process.			Cell	
C141519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141519>	C36913	Atypical Squamous Cell-Favor High-Grade Squamous Intraepithelial Lesion|ASC-Favor HSIL|Atypical Squamous Cell-Favor HSIL	An abnormal squamous cell found in a cervical smear with cytologic features suggestive of high-grade squamous intraepithelial lesion.			Cell	
C14151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14151>	C28103	Unresectable|No Resection|Non-Resectable|unresectable	Not capable of being removed by surgery.			Clinical Attribute	NICHD Terminology|Pediatric Hematology-Oncology Terminology
C141520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141520>	C20993	Distress Assessment and Response Tool|DART|Distress Assessment and Response Tool (DART)	A short, self-assessment to measure an individual's physical symptoms, emotional burden and practical concerns that could interfere with their ability to engage in cancer treatment.			Intellectual Product	
C141521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141521>	C91126	Feel Pain Question|Feel Pain|Pain	A question about whether an individual feels or felt pain.			Intellectual Product	Distress Assessment and Response Tool
C141522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141522>	C175254	Pain Score 0|DART Pain Score 0	A subjective score of 0 on a pain scale that ranges from 0: No Pain to 10: Worst Possible Pain.			Intellectual Product	Distress Assessment and Response Tool
C141523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141523>	C175254	Pain Score 1|DART Pain Score 1	A subjective score of 1 on a pain scale that ranges from 0: No Pain to 10: Worst Possible Pain.			Intellectual Product	Distress Assessment and Response Tool
C141524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141524>	C175254	Pain Score 2|DART Pain Score 2	A subjective score of 2 on a pain scale that ranges from 0: No Pain to 10: Worst Possible Pain.			Intellectual Product	Distress Assessment and Response Tool
C141525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141525>	C175254	Pain Score 3|DART Pain Score 3	A subjective score of 3 on a pain scale that ranges from 0: No Pain to 10: Worst Possible Pain.			Intellectual Product	Distress Assessment and Response Tool
C141526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141526>	C175254	Pain Score 4|DART Pain Score 4	A subjective score of 4 on a pain scale that ranges from 0: No Pain to 10: Worst Possible Pain.			Intellectual Product	Distress Assessment and Response Tool
C141527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141527>	C175254	Pain Score 5|DART Pain Score 5	A subjective score of 5 on a pain scale that ranges from 0: No Pain to 10: Worst Possible Pain.			Intellectual Product	Distress Assessment and Response Tool
C141528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141528>	C175254	Pain Score 6|DART Pain Score 6	A subjective score of 6 on a pain scale that ranges from 0: No Pain to 10: Worst Possible Pain.			Intellectual Product	Distress Assessment and Response Tool
C141529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141529>	C175254	Pain Score 7|DART Pain Score 7	A subjective score of 7 on a pain scale that ranges from 0: No Pain to 10: Worst Possible Pain.			Intellectual Product	Distress Assessment and Response Tool
C14152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14152>	C28102	Hematogenous|hematogenous	Originating in the blood, or disseminated by the circulation or through the bloodstream.			Qualitative Concept	
C141530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141530>	C175254	Pain Score 8|DART Pain Score 8	A subjective score of 8 on a pain scale that ranges from 0: No Pain to 10: Worst Possible Pain.			Intellectual Product	Distress Assessment and Response Tool
C141531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141531>	C175254	Pain Score 9|DART Pain Score 9	A subjective score of 9 on a pain scale that ranges from 0: No Pain to 10: Worst Possible Pain.			Intellectual Product	Distress Assessment and Response Tool
C141532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141532>	C175254	Pain Score 10|DART Pain Score 10	A subjective score of 10 on a pain scale that ranges from 0: No Pain to 10: Worst Possible Pain.			Intellectual Product	Distress Assessment and Response Tool
C141533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141533>	C121547	Tiredness Visual Analogue Scale|Tiredness|Visual Analogue Tiredness Scale	A scale of tiredness from 0 to 10 on which the patient marks the current level of tiredness experienced.			Intellectual Product	Distress Assessment and Response Tool
C141534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141534>	C221023	Tiredness Score 0	A subjective score of 0 on a tiredness scale that ranges from 0: No Tiredness to 10: Worst Possible Tiredness.			Intellectual Product	
C141535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141535>	C221023	Tiredness Score 1	A subjective score of 1 on a tiredness scale that ranges from 0: No Tiredness to 10: Worst Possible Tiredness.			Intellectual Product	
C141536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141536>	C221023	Tiredness Score 2	A subjective score of 2 on a tiredness scale that ranges from 0: No Tiredness to 10: Worst Possible Tiredness.			Intellectual Product	
C141537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141537>	C221023	Tiredness Score 3	A subjective score of 3 on a tiredness scale that ranges from 0: No Tiredness to 10: Worst Possible Tiredness.			Intellectual Product	
C141538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141538>	C221023	Tiredness Score 4	A subjective score of 4 on a tiredness scale that ranges from 0: No Tiredness to 10: Worst Possible Tiredness.			Intellectual Product	
C141539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141539>	C221023	Tiredness Score 5	A subjective score of 5 on a tiredness scale that ranges from 0: No Tiredness to 10: Worst Possible Tiredness.			Intellectual Product	
C141540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141540>	C221023	Tiredness Score 6	A subjective score of 6 on a tiredness scale that ranges from 0: No Tiredness to 10: Worst Possible Tiredness.			Intellectual Product	
C141541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141541>	C221023	Tiredness Score 7	A subjective score of 7 on a tiredness scale that ranges from 0: No Tiredness to 10: Worst Possible Tiredness.			Intellectual Product	
C141542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141542>	C221023	Tiredness Score 8	A subjective score of 8 on a tiredness scale that ranges from 0: No Tiredness to 10: Worst Possible Tiredness.			Intellectual Product	
C141543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141543>	C221023	Tiredness Score 9	A subjective score of 9 on a tiredness scale that ranges from 0: No Tiredness to 10: Worst Possible Tiredness.			Intellectual Product	
C141544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141544>	C221023	Tiredness Score 10	A subjective score of 10 on a tiredness scale that ranges from 0: No Tiredness to 10: Worst Possible Tiredness.			Intellectual Product	
C141545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141545>	C121547	Drowsiness Visual Analogue Scale|Drowsiness|Visual Analogue Drowsiness Scale	A scale of drowsiness from 0 to 10 on which the patient marks the current level of drowsiness experienced.			Intellectual Product	Distress Assessment and Response Tool
C141546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141546>	C221024	Drowsiness Score 0	A subjective score of 0 on a drowsiness scale that ranges from 0: No Drowsiness to 10: Worst Possible Drowsiness.			Intellectual Product	
C141547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141547>	C221024	Drowsiness Score 1	A subjective score of 1 on a drowsiness scale that ranges from 0: No Drowsiness to 10: Worst Possible Drowsiness.			Intellectual Product	
C141548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141548>	C221024	Drowsiness Score 2	A subjective score of 2 on a drowsiness scale that ranges from 0: No Drowsiness to 10: Worst Possible Drowsiness.			Intellectual Product	
C141549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141549>	C221024	Drowsiness Score 3	A subjective score of 3 on a drowsiness scale that ranges from 0: No Drowsiness to 10: Worst Possible Drowsiness.			Intellectual Product	
C141550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141550>	C221024	Drowsiness Score 4	A subjective score of 4 on a drowsiness scale that ranges from 0: No Drowsiness to 10: Worst Possible Drowsiness.			Intellectual Product	
C141551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141551>	C9175	Malignant Bowel Obstruction|MBO	Obstruction of the bowel by an advanced malignant tumor. It is a complication especially in patients with an advanced abdominal malignant tumor.			Finding	
C141552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141552>	C221024	Drowsiness Score 5	A subjective score of 5 on a drowsiness scale that ranges from 0: No Drowsiness to 10: Worst Possible Drowsiness.			Intellectual Product	
C141553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141553>	C221024	Drowsiness Score 6	A subjective score of 6 on a drowsiness scale that ranges from 0: No Drowsiness to 10: Worst Possible Drowsiness.			Intellectual Product	
C141554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141554>	C221024	Drowsiness Score 7	A subjective score of 7 on a drowsiness scale that ranges from 0: No Drowsiness to 10: Worst Possible Drowsiness.			Intellectual Product	
C141555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141555>	C221024	Drowsiness Score 8	A subjective score of 8 on a drowsiness scale that ranges from 0: No Drowsiness to 10: Worst Possible Drowsiness.			Intellectual Product	
C141556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141556>	C221024	Drowsiness Score 9	A subjective score of 9 on a drowsiness scale that ranges from 0: No Drowsiness to 10: Worst Possible Drowsiness.			Intellectual Product	
C141557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141557>	C221024	Drowsiness Score 10	A subjective score of 10 on a drowsiness scale that ranges from 0: No Drowsiness to 10: Worst Possible Drowsiness.			Intellectual Product	
C141558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141558>	C173130	Feel Nausea Question|Feel Nausea|Nausea	A question about whether an individual feels or felt nausea.			Intellectual Product	Distress Assessment and Response Tool
C141559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141559>	C121547	Nausea Visual Analogue Scale|Nausea|Visual Analogue Nausea Scale	A nausea scale from 0 to 10 on which the patient marks the current level of nausea experienced.			Intellectual Product	Distress Assessment and Response Tool
C14155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14155>	C13442	Alveolar|ALVEOLAR	Of or relating to the alveoli.	Alveolar		Qualitative Concept	CDISC SEND Microscopic Findings Result Modifier Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C141560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141560>	C221025	DART Nausea Score 0|Nausea Score 0	A subjective score of 0 on a nausea scale that ranges from 0: No Nausea to 10: Worst Possible Nausea.			Intellectual Product	Distress Assessment and Response Tool
C141561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141561>	C221025	DART Nausea Score 1|Nausea Score 1	A subjective score of 1 on a nausea scale that ranges from 0: No Nausea to 10: Worst Possible Nausea.			Intellectual Product	Distress Assessment and Response Tool
C141562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141562>	C221025	DART Nausea Score 2|Nausea Score 2	A subjective score of 2 on a nausea scale that ranges from 0: No Nausea to 10: Worst Possible Nausea.			Intellectual Product	Distress Assessment and Response Tool
C141563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141563>	C221025	DART Nausea Score 3|Nausea Score 3	A subjective score of 3 on a nausea scale that ranges from 0: No Nausea to 10: Worst Possible Nausea.			Intellectual Product	Distress Assessment and Response Tool
C141564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141564>	C221025	DART Nausea Score 4|Nausea Score 4	A subjective score of 4 on a nausea scale that ranges from 0: No Nausea to 10: Worst Possible Nausea.			Intellectual Product	Distress Assessment and Response Tool
C141565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141565>	C221025	DART Nausea Score 5|Nausea Score 5	A subjective score of 5 on a nausea scale that ranges from 0: No Nausea to 10: Worst Possible Nausea.			Intellectual Product	Distress Assessment and Response Tool
C141566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141566>	C221025	DART Nausea Score 6|Nausea Score 6	A subjective score of 6 on a nausea scale that ranges from 0: No Nausea to 10: Worst Possible Nausea.			Intellectual Product	Distress Assessment and Response Tool
C141567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141567>	C221025	DART Nausea Score 7|Nausea Score 7	A subjective score of 7 on a nausea scale that ranges from 0: No Nausea to 10: Worst Possible Nausea.			Intellectual Product	Distress Assessment and Response Tool
C141568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141568>	C221025	DART Nausea Score 8|Nausea Score 8	A subjective score of 8 on a nausea scale that ranges from 0: No Nausea to 10: Worst Possible Nausea.			Intellectual Product	Distress Assessment and Response Tool
C141569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141569>	C221025	DART Nausea Score 9|Nausea Score 9	A subjective score of 9 on a nausea scale that ranges from 0: No Nausea to 10: Worst Possible Nausea.			Intellectual Product	Distress Assessment and Response Tool
C14156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14156>	C27993	Apoptotic|APOPTOTIC	Pertaining to apoptosis.	Apoptotic		Qualitative Concept	CDISC SDTM Cell State Response Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C141570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141570>	C221025	DART Nausea Score 10|Nausea Score 10	A subjective score of 10 on a nausea scale that ranges from 0: No Nausea to 10: Worst Possible Nausea.			Intellectual Product	Distress Assessment and Response Tool
C141571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141571>	C121547	Lack of Appetite Visual Analogue Scale|Lack of Appetite|Visual Analogue Lack of Appetite Scale	A lack of appetite scale from 0 to 10 on which the patient marks the current level of lack of appetite experienced.			Intellectual Product	Distress Assessment and Response Tool
C141572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141572>	C221026	Lack of Appetite Score 0	A subjective score of 0 on an appetite scale that ranges from 0: No Lack of Appetite to 10: Worst Possible Lack of Appetite.			Intellectual Product	Distress Assessment and Response Tool
C141573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141573>	C221026	Lack of Appetite Score 1	A subjective score of 1 on an appetite scale that ranges from 0: No Lack of Appetite to 10: Worst Possible Lack of Appetite.			Intellectual Product	Distress Assessment and Response Tool
C141574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141574>	C221026	Lack of Appetite Score 2	A subjective score of 2 on an appetite scale that ranges from 0: No Lack of Appetite to 10: Worst Possible Lack of Appetite.			Intellectual Product	Distress Assessment and Response Tool
C141575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141575>	C221026	Lack of Appetite Score 3	A subjective score of 3 on an appetite scale that ranges from 0: No Lack of Appetite to 10: Worst Possible Lack of Appetite.			Intellectual Product	Distress Assessment and Response Tool
C141576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141576>	C221026	Lack of Appetite Score 4	A subjective score of 4 on an appetite scale that ranges from 0: No Lack of Appetite to 10: Worst Possible Lack of Appetite.			Intellectual Product	Distress Assessment and Response Tool
C141577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141577>	C221026	Lack of Appetite Score 5	A subjective score of 5 on an appetite scale that ranges from 0: No Lack of Appetite to 10: Worst Possible Lack of Appetite.			Intellectual Product	Distress Assessment and Response Tool
C141578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141578>	C221026	Lack of Appetite Score 6	A subjective score of 6 on an appetite scale that ranges from 0: No Lack of Appetite to 10: Worst Possible Lack of Appetite.			Intellectual Product	Distress Assessment and Response Tool
C141579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141579>	C221026	Lack of Appetite Score 7	A subjective score of 7 on an appetite scale that ranges from 0: No Lack of Appetite to 10: Worst Possible Lack of Appetite.			Intellectual Product	Distress Assessment and Response Tool
C14157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14157>	C28099	Borderline	Straddling the dividing line between two categories.	Borderline		Qualitative Concept	CTRP Terminology
C141580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141580>	C221026	Lack of Appetite Score 8	A subjective score of 8 on an appetite scale that ranges from 0: No Lack of Appetite to 10: Worst Possible Lack of Appetite.			Intellectual Product	Distress Assessment and Response Tool
C141581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141581>	C221026	Lack of Appetite Score 9	A subjective score of 9 on an appetite scale that ranges from 0: No Lack of Appetite to 10: Worst Possible Lack of Appetite.			Intellectual Product	Distress Assessment and Response Tool
C141582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141582>	C221026	Lack of Appetite Score 10	A subjective score of 10 on an appetite scale that ranges from 0: No Lack of Appetite to 10: Worst Possible Lack of Appetite.			Intellectual Product	Distress Assessment and Response Tool
C141583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141583>	C121547	Shortness of Breath Visual Analogue Scale|Shortness of Breath|Visual Analogue Shortness of Breath Scale	A shortness of breath scale from 0 to 10 on which the patient marks the current level of shortness of breath experienced.			Intellectual Product	Distress Assessment and Response Tool
C141584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141584>	C221027	Shortness of Breath Score 0	A subjective score of 0 on a shortness of breath scale that ranges from 0: No Shortness of Breath to 10: Worst Possible Shortness of Breath.			Intellectual Product	Distress Assessment and Response Tool
C141585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141585>	C221027	Shortness of Breath Score 1	A subjective score of 1 on a shortness of breath scale that ranges from 0: No Shortness of Breath to 10: Worst Possible Shortness of Breath.			Intellectual Product	Distress Assessment and Response Tool
C141586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141586>	C221027	Shortness of Breath Score 2	A subjective score of 2 on a shortness of breath scale that ranges from 0: No Shortness of Breath to 10: Worst Possible Shortness of Breath.			Intellectual Product	Distress Assessment and Response Tool
C141587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141587>	C221027	Shortness of Breath Score 3	A subjective score of 3 on a shortness of breath scale that ranges from 0: No Shortness of Breath to 10: Worst Possible Shortness of Breath.			Intellectual Product	Distress Assessment and Response Tool
C141588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141588>	C221027	Shortness of Breath Score 4	A subjective score of 4 on a shortness of breath scale that ranges from 0: No Shortness of Breath to 10: Worst Possible Shortness of Breath.			Intellectual Product	Distress Assessment and Response Tool
C141589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141589>	C221027	Shortness of Breath Score 5	A subjective score of 5 on a shortness of breath scale that ranges from 0: No Shortness of Breath to 10: Worst Possible Shortness of Breath.			Intellectual Product	Distress Assessment and Response Tool
C14158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14158>	C18000	High Grade|High|high grade	Used to describe tumor samples that exhibit poorly differentiated or undifferentiated cells. They are generally expected to be fast growing and aggressive.	High Grade		Classification	GDC Terminology|GDC Value Terminology|ICDC Terminology|ICDC Value Terminology
C141590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141590>	C221027	Shortness of Breath Score 6	A subjective score of 6 on a shortness of breath scale that ranges from 0: No Shortness of Breath to 10: Worst Possible Shortness of Breath.			Intellectual Product	Distress Assessment and Response Tool
C141591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141591>	C221027	Shortness of Breath Score 7	A subjective score of 7 on a shortness of breath scale that ranges from 0: No Shortness of Breath to 10: Worst Possible Shortness of Breath.			Intellectual Product	Distress Assessment and Response Tool
C141592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141592>	C221027	Shortness of Breath Score 8	A subjective score of 8 on a shortness of breath scale that ranges from 0: No Shortness of Breath to 10: Worst Possible Shortness of Breath.			Intellectual Product	Distress Assessment and Response Tool
C141593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141593>	C221027	Shortness of Breath Score 9	A subjective score of 9 on a shortness of breath scale that ranges from 0: No Shortness of Breath to 10: Worst Possible Shortness of Breath.			Intellectual Product	Distress Assessment and Response Tool
C141594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141594>	C221027	Shortness of Breath Score 10	A subjective score of 10 on a shortness of breath scale that ranges from 0: No Shortness of Breath to 10: Worst Possible Shortness of Breath.			Intellectual Product	Distress Assessment and Response Tool
C141595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141595>	C121547	Depression Visual Analogue Scale|Depression|Visual Analogue Depression Scale	A depression scale from 0 to 10 on which the patient marks the current level of depression experienced.			Intellectual Product	Distress Assessment and Response Tool
C141596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141596>	C221028	Depression Score 0	A subjective score of 0 on a depression scale that ranges from 0: No Depression to 10: Worst Possible Depression.			Intellectual Product	Distress Assessment and Response Tool
C141597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141597>	C221028	Depression Score 1	A subjective score of 1 on a depression scale that ranges from 0: No Depression to 10: Worst Possible Depression.			Intellectual Product	Distress Assessment and Response Tool
C141598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141598>	C221028	Depression Score 2	A subjective score of 2 on a depression scale that ranges from 0: No Depression to 10: Worst Possible Depression.			Intellectual Product	Distress Assessment and Response Tool
C141599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141599>	C221028	Depression Score 3	A subjective score of 3 on a depression scale that ranges from 0: No Depression to 10: Worst Possible Depression.			Intellectual Product	Distress Assessment and Response Tool
C14159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14159>	C28099	Invasive	Marked by a tendency to spread, especially into healthy surrounding tissue.	Invasive		Qualitative Concept	CTRP Terminology
C1415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1415>	C744|C259	Vesnarinone|1-(3,4-Dimethoxybenzoyl)-4-(1,2,3,4-tetrahydro-2-oxo-6-quinolinyl)piperazine|3,4-Dihydro-6-(4-(3,4-dimethoxybenzoyl)-1-pip- erazinyl)- 2(1H)-quinolinone|Arkin|Arkin-Z|DRG-0210|Pieranometazine|Piperazine, 1-(3,4-dimethoxybenzoyl)-4-(1,2,3,4-tetrahydr- o -2-oxo-6-quinolinyl)|VESNARINONE	A cardiotonic quinolinone derivative, that suppresses cell proliferation and induces apoptosis by inducing the expression of p21, an inhibitor of cyclin dependent kinase activity in p53-mediated cell cycle arrest. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C141600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141600>	C221028	Depression Score 4	A subjective score of 4 on a depression scale that ranges from 0: No Depression to 10: Worst Possible Depression.			Intellectual Product	Distress Assessment and Response Tool
C141601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141601>	C221028	Depression Score 5	A subjective score of 5 on a depression scale that ranges from 0: No Depression to 10: Worst Possible Depression.			Intellectual Product	Distress Assessment and Response Tool
C141602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141602>	C221028	Depression Score 6	A subjective score of 6 on a depression scale that ranges from 0: No Depression to 10: Worst Possible Depression.			Intellectual Product	Distress Assessment and Response Tool
C141603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141603>	C221028	Depression Score 7	A subjective score of 7 on a depression scale that ranges from 0: No Depression to 10: Worst Possible Depression.			Intellectual Product	Distress Assessment and Response Tool
C141604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141604>	C221028	Depression Score 8	A subjective score of 8 on a depression scale that ranges from 0: No Depression to 10: Worst Possible Depression.			Intellectual Product	Distress Assessment and Response Tool
C141605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141605>	C221028	Depression Score 9	A subjective score of 9 on a depression scale that ranges from 0: No Depression to 10: Worst Possible Depression.			Intellectual Product	Distress Assessment and Response Tool
C141606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141606>	C221028	Depression Score 10	A subjective score of 10 on a depression scale that ranges from 0: No Depression to 10: Worst Possible Depression.			Intellectual Product	Distress Assessment and Response Tool
C141607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141607>	C121547	Anxiety Visual Analogue Scale|Anxiety|Visual Analogue Anxiety Scale	An anxiety scale from 0 to 10 on which the patient marks the current level of anxiety experienced.			Intellectual Product	Distress Assessment and Response Tool
C141608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141608>	C221029	Anxiety Score 0	A subjective score of 0 on an anxiety scale that ranges from 0: No Anxiety to 10: Worst Possible Anxiety.			Intellectual Product	Distress Assessment and Response Tool
C141609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141609>	C221029	Anxiety Score 1	A subjective score of 1 on an anxiety scale that ranges from 0: No Anxiety to 10: Worst Possible Anxiety.			Intellectual Product	Distress Assessment and Response Tool
C14160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14160>	C28099	In Situ|in situ	In the natural or normal place, confined to the site of origin without invasion of neighboring tissues.	In Situ		Spatial Concept	CTRP Terminology
C141610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141610>	C221029	Anxiety Score 2	A subjective score of 2 on an anxiety scale that ranges from 0: No Anxiety to 10: Worst Possible Anxiety.			Intellectual Product	Distress Assessment and Response Tool
C141611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141611>	C221029	Anxiety Score 3	A subjective score of 3 on an anxiety scale that ranges from 0: No Anxiety to 10: Worst Possible Anxiety.			Intellectual Product	Distress Assessment and Response Tool
C141612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141612>	C221029	Anxiety Score 4	A subjective score of 4 on an anxiety scale that ranges from 0: No Anxiety to 10: Worst Possible Anxiety.			Intellectual Product	Distress Assessment and Response Tool
C141613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141613>	C221029	Anxiety Score 5	A subjective score of 5 on an anxiety scale that ranges from 0: No Anxiety to 10: Worst Possible Anxiety.			Intellectual Product	Distress Assessment and Response Tool
C141614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141614>	C221029	Anxiety Score 6	A subjective score of 6 on an anxiety scale that ranges from 0: No Anxiety to 10: Worst Possible Anxiety.			Intellectual Product	Distress Assessment and Response Tool
C141615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141615>	C221029	Anxiety Score 7	A subjective score of 7 on an anxiety scale that ranges from 0: No Anxiety to 10: Worst Possible Anxiety.			Intellectual Product	Distress Assessment and Response Tool
C141616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141616>	C221029	Anxiety Score 8	A subjective score of 8 on an anxiety scale that ranges from 0: No Anxiety to 10: Worst Possible Anxiety.			Intellectual Product	Distress Assessment and Response Tool
C141617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141617>	C221029	Anxiety Score 9	A subjective score of 9 on an anxiety scale that ranges from 0: No Anxiety to 10: Worst Possible Anxiety.			Intellectual Product	Distress Assessment and Response Tool
C141618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141618>	C221029	Anxiety Score 10	A subjective score of 10 on an anxiety scale that ranges from 0: No Anxiety to 10: Worst Possible Anxiety.			Intellectual Product	Distress Assessment and Response Tool
C141619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141619>	C121547	Well Being Visual Analogue Scale|Visual Analogue Well Being Scale|Wellbeing	An overall well being scale from 0 to 10 on which the patient marks the current level of well being experienced.			Intellectual Product	Distress Assessment and Response Tool
C141620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141620>	C221030	Well-Being Score 0	A subjective score of 0 on a well-being scale that ranges from 0: No Well-Being to 10: Worst Possible Well-Being.			Intellectual Product	Distress Assessment and Response Tool
C141621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141621>	C221030	Well-Being Score 1	A subjective score of 1 on a well-being scale that ranges from 0: No Well-Being to 10: Worst Possible Well-Being.			Intellectual Product	Distress Assessment and Response Tool
C141622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141622>	C221030	Well-Being Score 2	A subjective score of 2 on a well-being scale that ranges from 0: No Well-Being to 10: Worst Possible Well-Being.			Intellectual Product	Distress Assessment and Response Tool
C141623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141623>	C221030	Well-Being Score 3	A subjective score of 3 on a well-being scale that ranges from 0: No Well-Being to 10: Worst Possible Well-Being.			Intellectual Product	Distress Assessment and Response Tool
C141624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141624>	C221030	Well-Being Score 4	A subjective score of 4 on a well-being scale that ranges from 0: No Well-Being to 10: Worst Possible Well-Being.			Intellectual Product	Distress Assessment and Response Tool
C141625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141625>	C221030	Well-Being Score 5	A subjective score of 5 on a well-being scale that ranges from 0: No Well-Being to 10: Worst Possible Well-Being.			Intellectual Product	Distress Assessment and Response Tool
C141626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141626>	C221030	Well-Being Score 6	A subjective score of 6 on a well-being scale that ranges from 0: No Well-Being to 10: Worst Possible Well-Being.			Intellectual Product	Distress Assessment and Response Tool
C141627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141627>	C221030	Well-Being Score 7	A subjective score of 7 on a well-being scale that ranges from 0: No Well-Being to 10: Worst Possible Well-Being.			Intellectual Product	Distress Assessment and Response Tool
C141628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141628>	C221030	Well-Being Score 8	A subjective score of 8 on a well-being scale that ranges from 0: No Well-Being to 10: Worst Possible Well-Being.			Intellectual Product	Distress Assessment and Response Tool
C141629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141629>	C221030	Well-Being Score 9	A subjective score of 9 on a well-being scale that ranges from 0: No Well-Being to 10: Worst Possible Well-Being.			Intellectual Product	Distress Assessment and Response Tool
C141630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141630>	C221030	Well-Being Score 10	A subjective score of 10 on a well-being scale that ranges from 0: No Well-Being to 10: Worst Possible Well-Being.			Intellectual Product	Distress Assessment and Response Tool
C141632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141632>	C2124	Gallium Ga 68 Boclatixafortide|68GA-CPCR4-2|68Ga Pentixafor|CPCR4-2 GA-68|GALLIUM (68GA) BOCLATIXAFORTIDE|Ga-68 Pentixafor|Ga68 Pentixafor|Gallium (68GA) Boclatixafortide|Gallium Ga 68 Pentixafor|Pentixafor Gallium GA-68|[68Ga] Pentixafor	A radioconjugate composed of a synthetic, cyclic pentapeptide analog of stromal-cell derived factor-1 (SDF-1 or CXCL12), which is a ligand for chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), that is radiolabeled, via the macrocyclic chelating agent dodecanetetraacetic acid (DOTA), with the radioisotope gallium Ga 68 (Ga68; 68Ga), with potential use for imaging CXCR4-expressing cells upon positron emission tomography (PET)/computed tomography (CT). Upon administration of 68Ga pentixafor, the pentixafor moiety targets and binds to CXCR4-expressing cancer cells. Upon PET/CT, CXCR4-expressing cancer cells can be visualized and the expression status of the receptor can be assessed. CXCR4, a marker of poorly differentiated cells, is overexpressed on various cancer cells, and plays a key role in tumor growth, progression, invasiveness and metastasis.	Gallium Ga 68 Boclatixafortide		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C141633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141633>	C173981	Have Other Problem Question|Have Other Problem|Other Problem	A question about whether an individual has or had another problem not previously mentioned or specified.			Intellectual Product	Distress Assessment and Response Tool
C141634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141634>	C121547	Other Problem Visual Analogue Scale|Other Problem|Visual Analogue Other Problem Scale	A scale for reporting another problem, which ranges from 0 to 10, on which the patient marks the current level of the other problem experienced.			Intellectual Product	Distress Assessment and Response Tool
C141635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141635>	C221031	Other Problem Score 0	A subjective score of 0 on a scale that ranges from 0: No Other Problem to 10: Worst Possible Other Problem.			Intellectual Product	Distress Assessment and Response Tool
C141636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141636>	C221031	Other Problem Score 1	A subjective score of 1 on a scale that ranges from 0: No Other Problem to 10: Worst Possible Other Problem.			Intellectual Product	Distress Assessment and Response Tool
C141637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141637>	C221031	Other Problem Score 2	A subjective score of 2 on a scale that ranges from 0: No Other Problem to 10: Worst Possible Other Problem.			Intellectual Product	Distress Assessment and Response Tool
C141638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141638>	C221031	Other Problem Score 3	A subjective score of 3 on a scale that ranges from 0: No Other Problem to 10: Worst Possible Other Problem.			Intellectual Product	Distress Assessment and Response Tool
C141639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141639>	C221031	Other Problem Score 4	A subjective score of 4 on a scale that ranges from 0: No Other Problem to 10: Worst Possible Other Problem.			Intellectual Product	Distress Assessment and Response Tool
C14163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14163>	C28099	Mucinous|MUCINOUS|mucinous	Containing or resembling mucin.	Mucinous		Qualitative Concept	CDISC SEND Microscopic Findings Result Modifier Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Terminology
C141640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141640>	C221031	Other Problem Score 5	A subjective score of 5 on a scale that ranges from 0: No Other Problem to 10: Worst Possible Other Problem.			Intellectual Product	Distress Assessment and Response Tool
C141641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141641>	C221031	Other Problem Score 6	A subjective score of 6 on a scale that ranges from 0: No Other Problem to 10: Worst Possible Other Problem.			Intellectual Product	Distress Assessment and Response Tool
C141642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141642>	C221031	Other Problem Score 7	A subjective score of 7 on a scale that ranges from 0: No Other Problem to 10: Worst Possible Other Problem.			Intellectual Product	Distress Assessment and Response Tool
C141643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141643>	C221031	Other Problem Score 8	A subjective score of 8 on a scale that ranges from 0: No Other Problem to 10: Worst Possible Other Problem.			Intellectual Product	Distress Assessment and Response Tool
C141644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141644>	C221031	Other Problem Score 9	A subjective score of 9 on a scale that ranges from 0: No Other Problem to 10: Worst Possible Other Problem.			Intellectual Product	Distress Assessment and Response Tool
C141645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141645>	C221031	Other Problem Score 10	A subjective score of 10 on a scale that ranges from 0: No Other Problem to 10: Worst Possible Other Problem.			Intellectual Product	Distress Assessment and Response Tool
C141646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141646>	C217121	Daily Activity Rating Scale|I would generally rate my activity as (shade one)	A scale from 0 to 4 for an individual to rate their perception of their daily activities.			Intellectual Product	Distress Assessment and Response Tool
C141647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141647>	C222043	Normal Activity with No Limitations|Normal with no limitations|Score 0	A response indicating that an individual's activity is normal with no limitations.			Intellectual Product	Distress Assessment and Response Tool
C141648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141648>	C222043	Not Normal but Fairly Active|Not my normal self, but able to be up and about with fairly normal activities|Score 1	A response indicating that an individual is not their normal self, but able to be up and about with fairly normal activity.			Intellectual Product	Distress Assessment and Response Tool
C141649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141649>	C222043	Not Feeling Well; in Bed or Chair Less than Half Day|Not feeling up to most things, but in bed or chair less than half the day|Score 2	A response indicating that an individual is not feeling up to most things, but in bed or chair less than half the day.			Intellectual Product	Distress Assessment and Response Tool
C14164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14164>	C13442	Myoepithelial	Derived from epithelial cells and destined to become a part of the muscular system; having the characteristics of both muscle and epithelium.	Myoepithelial		Qualitative Concept	
C141650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141650>	C222043	Little Activity; in Bed or Chair Most of Day|Able to do little activity and spend most of the day in bed or chair|Score 3	A response indicating that an individual is able to do little activity and spends most of the day in bed or chair.			Intellectual Product	Distress Assessment and Response Tool
C141651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141651>	C222043	Bedridden; Rarely Out of Bed|Pretty much bedridden, rarely out of bed|Score 4	A response indicating that an individual is pretty much bedridden, rarely out of bed.			Intellectual Product	Distress Assessment and Response Tool
C141652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141652>	C118970	CDISC Clinical Classification VALG Test Name Terminology|CC-VALG TEST|VALG01TN|Veterans Administration Lung Study Group Clinical Classification Test Name	Test names of clinical classification questions associated with the Veterans Administration Lung Study Group (VALG) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141653>	C118970	CDISC Clinical Classification VALG Test Code Terminology|CC-VALG TESTCD|VALG01TC|Veterans Administration Lung Study Group Clinical Classification Test Code	Test codes of clinical classification questions associated with the Veterans Administration Lung Study Group (VALG) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141654>	C118970	CDISC Clinical Classification AJCC v7 Test Name Terminology|AJCC TNM Staging System 7th Edition Clinical Classification Test Name|AJCC1TN|CC-AJCC v7 TEST	Test names of clinical classification questions associated with the AJCC Cancer Staging Manual 7th Edition (AJCC v7) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141655>	C118970	CDISC Clinical Classification AJCC v7 Test Code Terminology|AJCC TNM Staging System 7th Edition Clinical Classification Test Code|AJCC1TC|CC-AJCC v7 TESTCD	Test codes of clinical classification questions associated with the AJCC Cancer Staging Manual 7th Edition (AJCC v7) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141656>	C115302	CDISC Functional Test 10-Meter Walk/Run Test Name Terminology|10-Meter Walk/Run Functional Test Test Name|FT-10 Meter Walk/Run TEST|TENMW1TN	Test names of functional test questions associated with the Ten Meter Walk/Run Test (10 Meter Walk/Run) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141657>	C115302	CDISC Functional Test 10-Meter Walk/Run Test Code Terminology|10-Meter Walk/Run Functional Test Test Code|FT-10 Meter Walk/Run TESTCD|TENMW1TC	Test codes of functional test questions associated with the Ten Meter Walk/Run Test (10 Meter Walk/Run) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141658>	C115302	CDISC Functional Test Rising From Floor Test Name Terminology|FT-Rising From Floor TEST|RISEF1TN|Rising From Floor Functional Test Test Name	Test names of functional test questions associated with the Rising From Floor Test (Rising From Floor) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141659>	C115302	CDISC Functional Test Rising From Floor Test Code Terminology|FT-Rising From Floor TESTCD|RISEF1TC|Rising From Floor Functional Test Test Code	Test codes of functional test questions associated with the Rising From Floor Test (Rising From Floor) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14165>	C27993	Normal|NORMAL	Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.	Normal		Conceptual Entity	CDISC SDTM Normal Abnormal Response Terminology|CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Result Terminology|CDISC SEND Terminology|CDISC SEND Within Normal Limits Results Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C141660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141660>	C115302	CDISC Functional Test 4-Stair Descend Test Name Terminology|4-Stair Descend Functional Test Test Name|D4STR1TN|FT-4 Stair Descend TEST	Test names of questionnaire questions associated with the Four Stair Descend Test (4 Stair Descend) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141661>	C115302	CDISC Functional Test 4-Stair Descend Test Code Terminology|4-Stair Descend Functional Test Test Code|D4STR1TC|FT-4 Stair Descend TESTCD	Test codes of questionnaire questions associated with the Four Stair Descend Test (4 Stair Descend) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141662>	C115302	CDISC Functional Test 4-Stair Ascend Test Name Terminology|4-Stair Ascend Functional Test Test Name|A4STR1TN|FT-4 Stair Ascend TEST	Test names of questionnaire questions associated with the Four Stair Ascend Test (4 Stair Ascend) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141663>	C115302	CDISC Functional Test 4-Stair Ascend Test Code Terminology|4-Stair Ascend Functional Test Test Code|A4STR1TC|FT-4 Stair Ascend TESTCD	Test codes of questionnaire questions associated with the Four Stair Ascend Test (4 Stair Ascend) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141664>	C100110	CDISC Questionnaire IPAQ Short Last 7 Days Self-administered Format Version Test Name Terminology|IPAQ04TN|International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format Questionnaire Test Name|QS-IPAQ Short Last 7 Days Self-administered Format Version TEST	Test names of questionnaire questions associated with the International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141665>	C100110	CDISC Questionnaire IPAQ Short Last 7 Days Self-administered Format Version Test Code Terminology|IPAQ04TC|International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format Questionnaire Test Code|QS-IPAQ Short Last 7 Days Self-administered Format Version TESTCD	Test codes of questionnaire questions associated with the International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141666>	C100110	CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Name Terminology|IPAQ03TN|International Physical Activity Questionnaire (October 2002) Long Last 7 Days Self-Administered Format Questionnaire Test Name|QS-IPAQ Long Last 7 Days Self-Administered Format Version TEST	Test names of questionnaire questions associated with the International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141667>	C100110	CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Code Terminology|IPAQ03TC|International Physical Activity Questionnaire (October 2002) Long Last 7 Days Self-Administered Format Questionnaire Test Code|QS-IPAQ Long Last 7 Days Self-Administered Format Version TESTCD	Test codes of questionnaire questions associated with the International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141668>	C100110	CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|IPAQ02TN|International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format Questionnaire Test Name|QS-IPAQ Long Last 7 Days Telephone Format Version TEST	Test names of questionnaire questions associated with the International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141669>	C100110	CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|IPAQ02TC|International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format Questionnaire Test Code|QS-IPAQ Long Last 7 Days Telephone Format Version TESTCD	Test codes of questionnaire questions associated with the International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14166>	C28099	Papillary|PAPILLARY	Of or relating to or resembling papilla.	Papillary		Qualitative Concept	CDISC SEND Microscopic Findings Result Modifier Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Terminology
C141670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141670>	C100110	CDISC Questionnaire IPAQ Short Last 7 Days Telephone Format Version Test Name Terminology|IPAQ01TN|International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format Questionnaire Test Name|QS-IPAQ Short Last 7 Days Telephone Format Version TEST	Test names of questionnaire questions associated with the International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141671>	C100110	CDISC Questionnaire IPAQ Short Last 7 Days Telephone Format Version Test Code Terminology|IPAQ01TC|International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format Questionnaire Test Code|QS-IPAQ Short Last 7 Days Telephone Format Version TESTCD	Test codes of questionnaire questions associated with the International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141672>	C100110	CDISC Questionnaire DRRI-2 Test Name Terminology|DRRI1TN|Deployment Risk and Resilience Inventory-2 Questionnaire Test Name|QS-DRRI-2 TEST	Test names of questionnaire questions associated with the Deployment Risk and Resilience Inventory-2 (DRRI-2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141673>	C100110	CDISC Questionnaire DRRI-2 Test Code Terminology|DRRI1TC|Deployment Risk and Resilience Inventory-2 Questionnaire Test Code|QS-DRRI-2 TESTCD	Test codes of questionnaire questions associated with the Deployment Risk and Resilience Inventory-2 (DRRI-2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141674>	C211913	VALG Clinical Classification Question	A question associated with the VALG clinical classification.			Intellectual Product	
C141675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141675>	C211913	AJCC v7 Clinical Classification Question	A question associated with the AJCC v7 clinical classification.			Intellectual Product	
C141676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141676>	C211913	10 Meter Walk/Run Functional Test Question	A question associated with the 10 Meter Walk/Run functional test.			Intellectual Product	
C141677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141677>	C211913	Rising From Floor Functional Test Question	A question associated with the Rising From Floor functional test.			Intellectual Product	
C141678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141678>	C211913	4 Stair Descend Functional Test Question	A question associated with the 4 Stair Descend functional test.			Intellectual Product	
C141679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141679>	C211913	4 Stair Ascend Functional Test Question	A question associated with the 4 Stair Ascend functional test.			Intellectual Product	
C141680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141680>	C211913	IPAQ Short Last 7 Days Self-administered Format Version Questionnaire Question	A question associated with the IPAQ Short Last 7 Days Self-administered Format Version questionnaire.			Intellectual Product	
C141681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141681>	C211913	IPAQ Long Last 7 Days Self-Administered Format Version Questionnaire Question	A question associated with the IPAQ Long Last 7 Days Self-Administered Format Version questionnaire.			Intellectual Product	
C141682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141682>	C211913	IPAQ Long Last 7 Days Telephone Format Version Questionnaire Question	A question associated with the IPAQ Long Last 7 Days Telephone Format Version questionnaire.			Intellectual Product	
C141683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141683>	C211913	IPAQ Short Last 7 Days Telephone Format Version Questionnaire Question	A question associated with the IPAQ Short Last 7 Days Telephone Format Version questionnaire.			Intellectual Product	
C141684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141684>	C211913	DRRI-2 Questionnaire Question	A question associated with the DRRI-2 questionnaire.			Intellectual Product	
C141685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141685>	C118969	Veterans Administration Lung Study Group Clinical Classification|VALG|VALG|VALG01	A standardized two-stage classification system that was developed by the Veterans Administration Lung Study Group (VALG) in 1957 for the clinical staging of lung cancer as limited or extensive based on the anatomical scope of the disease.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141686>	C222260	10-Meter Walk/Run Test Functional Test|10 Meter Walk/Run|10-METER WALK/RUN|TENMW1|Ten Meter Walk/Run	A timed function test, one of a series of exercise testing modalities that were initially introduced in the 1960s, that assesses functional mobility by measuring walking or running speed in meters per second over ten meters.			Intellectual Product	CDISC Functional Test Category Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141687>	C222260	Rising From Floor Test Functional Test|RISEF1; Stand From Supine|RISING FROM FLOOR|Rising From Floor	A timed function test created by Araujo et al. (2012) that measures the time taken and techniques utilized to sit and rise from the floor with the minimum amount of support as a predictor of overall health and life expectancy.			Intellectual Product	CDISC Functional Test Category Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141688>	C222260	Four Stair Descend Test Functional Test|4 Stair Descend|4-STAIR DESCEND|D4STR1	A timed function test, one of a series of exercise testing modalities that were initially introduced in the 1960s, that measures functional mobility by assessing the time taken and techniques used to descend four standard-size stairs.			Intellectual Product	CDISC Functional Test Category Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141689>	C222260	Four Stair Ascend Test Functional Test|4 Stair Ascend|4-STAIR ASCEND|A4STR1	A timed function test, one of a series of exercise testing modalities that were initially introduced in the 1960s, that measures functional mobility by assessing the time taken and techniques used to climb four standard-size stairs.			Intellectual Product	CDISC Functional Test Category Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14168>	C28099	Serous|SEROUS|serous	Of or producing or containing serum.	Serous		Qualitative Concept	CDISC SEND Microscopic Findings Result Modifier Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Terminology
C141690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141690>	C91105	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format|IPAQ Short Last 7 Days Self-administered Format Version|IPAQ-SF SELF-ADMINISTERED VERSION|IPAQ04	A standardized self-administered 9-item questionnaire, developed by Booth et al. in 2000, that assesses physical activity lasting at least 10 minutes during the past seven days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141691>	C91105	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format|IPAQ Long Last 7 Days Self-Administered Format Version|IPAQ-LF SELF-ADMINISTERED VERSION|IPAQ03	A standardized self-administered 31-item questionnaire, developed by Booth et al. in 2000, that assesses physical activity lasting at least 10 minutes during the past seven days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141692>	C91105	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format|IPAQ Long Last 7 Days Telephone Format Version|IPAQ-LF PHONE VERSION|IPAQ02	A standardized 31-item questionnaire, developed by Booth et al. in 2000, that is administered over the telephone and assesses physical activity lasting at least 10 minutes during the past seven days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141693>	C91105	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format|IPAQ Short Last 7 Days Telephone Format Version|IPAQ-SF PHONE VERSION|IPAQ01	A standardized 9-item questionnaire, developed by Booth et al. in 2000, that is administered over the telephone and assesses physical activity lasting at least 10 minutes during the past seven days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141694>	C91105	Deployment Risk and Resilience Inventory-2 Questionnaire|DRRI-2|DRRI-2|DRRI1	A revision of the Deployment Risk and Resilience Inventory instrument, originally developed by King et al. in 2003, that utilizes 17 distinct scales to assess predeployment, deployment, and postdeployment psychosocial risk and resilience factors in returning war veterans.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141695>	C141674	VALG - Cancer Stage|VALG01-Cancer Stage|VALG01-Cancer Stage|VALG0101	Veterans Administration Lung Study Group (VALG) Cancer stage.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification VALG Test Code Terminology|CDISC Clinical Classification VALG Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141696>	C141675	AJCC v7 - Primary Tumor (T)|AJCC1-Primary Tumor (T)|AJCC1-Primary Tumor (T)|AJCC101	AJCC Cancer Staging Manual 7th Edition (AJCC v7) Primary tumor (T).			Intellectual Product	CDISC Clinical Classification AJCC v7 Test Code Terminology|CDISC Clinical Classification AJCC v7 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141697>	C141675	AJCC v7 - Regional Lymph Nodes (N)|AJCC1-Regional Lymph Nodes (N)|AJCC1-Regional Lymph Nodes (N)|AJCC102	AJCC Cancer Staging Manual 7th Edition (AJCC v7) Regional lymph nodes (N).			Intellectual Product	CDISC Clinical Classification AJCC v7 Test Code Terminology|CDISC Clinical Classification AJCC v7 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141698>	C141675	AJCC v7 - Distant Metastasis (M)|AJCC1-Distant Metastasis (M)|AJCC1-Distant Metastasis (M)|AJCC103	AJCC Cancer Staging Manual 7th Edition (AJCC v7) Distant metastasis (M).			Intellectual Product	CDISC Clinical Classification AJCC v7 Test Code Terminology|CDISC Clinical Classification AJCC v7 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141699>	C141675	AJCC v7 - Anatomic Stage|AJCC1-Anatomic Stage|AJCC1-Anatomic Stage|AJCC104	AJCC Cancer Staging Manual 7th Edition (AJCC v7) Anatomic stage.			Intellectual Product	CDISC Clinical Classification AJCC v7 Test Code Terminology|CDISC Clinical Classification AJCC v7 Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14169>	C28099	Tubular|TUBULAR	Shaped like a tube; of or pertaining to a tubule.	Tubular		Qualitative Concept	CDISC SEND Microscopic Findings Result Modifier Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Terminology
C1416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1416>	C222	Improsulfan Hydrochloride|1-Propanol, 3,3'-, Dimethanesulfonate (Ester), Hydrochloride|1-Propanol, 3,3'-, dimethanesulfonate (ester), hydrochloride|1-Propanol, 3,3'-Iminobis-, Dimethanesulfonate (Ester), Hydrochloride (9CI)|1-Propanol, 3,3'-iminobis-, dimethanesulfonate (ester), hydrochloride (9CI)|1-Propanol, 3,3'-iminodi-, Dimethanesulfonate (Ester), Hydrochloride (8CI)|1-Propanol, 3,3'-iminodi-, dimethanesulfonate (ester), hydrochloride (8CI)|1-Propanol-3,3'-iminodidimethanesulfonatehydrochloride|1-Propanol-3,3'-iminodidimethanesulfonatehydrochloride|3, 3'-Dimesyloxydipropylamine HCl|3, 3'-Dimesyloxydipropylamine Hydrochloride|3, 3'-Dimesyloxydipropylamine hydrochloride|3, 3'-Iminodi-1-propanol Di(methanesulfonate) HCl|3, 3'-Iminodi-1-propanol Di(methanesulfonate) Hydrochloride|3, 3'-Iminodi-1-propanol Dimethanesulfonate Ester HCl|3, 3'-Iminodi-1-propanol Dimethanesulfonate Ester Hydrochloride|3, 3'-Iminodi-1-propanol di(methanesulfonate) hydrochloride|3, 3'-Iminodi-1-propanol dimethanesulfonate ester hydrochloride|3,3'-Imidodi-1-propanol, Dimethanesulfonate (Ester) HCl|3,3'-Imidodi-1-propanol, Dimethanesulfonate (Ester), Hydrochloride|3,3'-Imidodi-1-propanol, dimethanesulfonate (ester), hydrochloride|Bis(3-mesyloxypropyl)amine HCl|Bis(3-mesyloxypropyl)amine Hydrochloride|Bis(3-mesyloxypropyl)amine hydrochloride|Compound 864|Compound 864|IMPROSULFAN HYDROCHLORIDE|IPD Hydrochloride|IPD hydrochloride|NCI-C01547|NCI-C01547|Yoshi 864|Yoshi 864|Yoshi-864	An alkylsulfonate. Yoshi-864 alkylates and crosslinks DNA, thereby inhibiting DNA replication. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C141700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141700>	C141676	10-Meter Walk/Run - Time to Walk/Run 10 Meters|TENMW1-Time to Walk/Run 10 Meters|TENMW1-Time to Walk/Run 10 Meters|TENMW102	Ten Meter Walk/Run Test (10 Meter Walk/Run) Time to walk or run 10 meters.			Intellectual Product	CDISC Functional Test 10-Meter Walk/Run Test Code Terminology|CDISC Functional Test 10-Meter Walk/Run Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141701>	C141676	10-Meter Walk/Run - Test Grade|TENMW1-Test Grade|TENMW1-Test Grade|TENMW104	Ten Meter Walk/Run Test (10 Meter Walk/Run) Test grade.			Intellectual Product	CDISC Functional Test 10-Meter Walk/Run Test Code Terminology|CDISC Functional Test 10-Meter Walk/Run Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141702>	C141677	Rising From Floor - Time to Rise From Floor|RISEF1-Time to Rise From Floor|RISEF1-Time to Rise From Floor|RISEF102	Rising From Floor Test (Rising From Floor) Time to rise from supine position.			Intellectual Product	CDISC Functional Test Rising From Floor Test Code Terminology|CDISC Functional Test Rising From Floor Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141703>	C141677	Rising From Floor - Test Grade|RISEF1-Test Grade|RISEF1-Test Grade|RISEF104	Rising From Floor Test (Rising From Floor) Test grade.			Intellectual Product	CDISC Functional Test Rising From Floor Test Code Terminology|CDISC Functional Test Rising From Floor Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141704>	C141678	4-Stair Descend - Time to Do 4-Stair Descend|D4STR1-Time to Do 4-Stair Descend|D4STR1-Time to Do 4-Stair Descend|D4STR102	Four Stair Descend Test (4 Stair Descend) Time taken to descend 4 stairs.			Intellectual Product	CDISC Functional Test 4-Stair Descend Test Code Terminology|CDISC Functional Test 4-Stair Descend Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141705>	C141678	4-Stair Descend - Test Grade|D4STR1-Test Grade|D4STR1-Test Grade|D4STR104	Four Stair Descend Test (4 Stair Descend) Test grade.			Intellectual Product	CDISC Functional Test 4-Stair Descend Test Code Terminology|CDISC Functional Test 4-Stair Descend Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141706>	C141679	4-Stair Ascend - Time to Do 4-Stair Ascend|A4STR1-Time to Do 4-Stair Ascend|A4STR1-Time to Do 4-Stair Ascend|A4STR102	Four Stair Ascend Test (4 Stair Ascend) Time taken to ascend 4 stairs.			Intellectual Product	CDISC Functional Test 4-Stair Ascend Test Code Terminology|CDISC Functional Test 4-Stair Ascend Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141707>	C141679	4-Stair Ascend - Test Grade|A4STR1-Test Grade|A4STR1-Test Grade|A4STR104	Four Stair Ascend Test (4 Stair Ascend) Test grade.			Intellectual Product	CDISC Functional Test 4-Stair Ascend Test Code Terminology|CDISC Functional Test 4-Stair Ascend Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141708>	C141680	IPAQ Short Last 7 Days Self-administered Format Version - Days Vigorous Physical Activities|IPA04-Days Vigorous Physical Activities|IPA04-Days Vigorous Physical Activities|IPA0401	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) During the last 7 days, on how many days did you do vigorous physical activities like heavy lifting, digging, aerobics, or fast bicycling?: days per week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Self-administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Self-administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141709>	C141680	IPAQ Short Last 7 Days Self-administered Format Version - No Vigorous Physical Activities	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) During the last 7 days, on how many days did you do vigorous physical activities like heavy lifting, digging, aerobics, or fast bicycling?: No vigorous physical activities.			Intellectual Product	
C14170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14170>	C28099	Villous|VILLOUS	Abounding in, or covered with, fine hairs.	Villous		Qualitative Concept	CDISC SEND Microscopic Findings Result Modifier Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Terminology
C141710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141710>	C141680	IPAQ Short Last 7 Days Self-administered Format Version - Vigorous Physical Hr and Min per Day|IPA04-Vigorous Physical Hr & Min per Day|IPA04-Vigorous Physical Hr & Min per Day|IPA0402	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) How much time did you usually spend doing vigorous physical activities on one of those days?: hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Self-administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Self-administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141711>	C141680	IPAQ Short Last 7 Days Self-administered Format Version - Vigorous Physical Minutes per Day	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) How much time did you usually spend doing vigorous physical activities on one of those days?: minutes per day.			Intellectual Product	
C141712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141712>	C141680	IPAQ Short Last 7 Days Self-administered Format Version - Time Vigorous Don't Know/Not Sure	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) How much time did you usually spend doing vigorous physical activities on one of those days?: Don't know/Not sure.			Intellectual Product	
C141713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141713>	C141680	IPAQ Short Last 7 Days Self-administered Format Version - Days Moderate Physical Activities|IPA04-Days Moderate Physical Activities|IPA04-Days Moderate Physical Activities|IPA0403	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) During the last 7 days, on how many days did you do moderate physical activities like carrying light loads, bicycling at a regular pace, or doubles tennis?: days per week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Self-administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Self-administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141714>	C141680	IPAQ Short Last 7 Days Self-administered Format Version - No Moderate Physical Activities	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) During the last 7 days, on how many days did you do moderate physical activities like carrying light loads, bicycling at a regular pace, or doubles tennis?: No moderate physical activities.			Intellectual Product	
C141715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141715>	C141680	IPAQ Short Last 7 Days Self-administered Format Version - Moderate Physical Hr and Min per Day|IPA04-Moderate Physical Hr & Min per Day|IPA04-Moderate Physical Hr & Min per Day|IPA0404	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) How much time did you usually spend doing moderate physical activities on one of those days?: hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Self-administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Self-administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141716>	C141680	IPAQ Short Last 7 Days Self-administered Format Version - Moderate Physical Minutes per Day	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) How much time did you usually spend doing moderate physical activities on one of those days?: minutes per day.			Intellectual Product	
C141717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141717>	C141680	IPAQ Short Last 7 Days Self-administered Format Version - Time Moderate Don't Know/Not Sure	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) How much time did you usually spend doing moderate physical activities on one of those days?: Don't know/Not sure.			Intellectual Product	
C141718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141718>	C141680	IPAQ Short Last 7 Days Self-administered Format Version - Days Walk at Least 10 Minutes|IPA04-Days Walk at Least 10 Minutes|IPA04-Days Walk at Least 10 Minutes|IPA0405	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) During the last 7 days, on how many days did you walk for at least 10 minutes at a time?: days per week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Self-administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Self-administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141719>	C141680	IPAQ Short Last 7 Days Self-administered Format Version - No Walking	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) During the last 7 days, on how many days did you walk for at least 10 minutes at a time?: No walking.			Intellectual Product	
C141720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141720>	C141680	IPAQ Short Last 7 Days Self-administered Format Version - Walking Hr and Min per Day|IPA04-Walking Hr & Min per Day|IPA04-Walking Hr & Min per Day|IPA0406	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) How much time did you usually spend walking on one of those days?: hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Self-administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Self-administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141721>	C141680	IPAQ Short Last 7 Days Self-administered Format Version - Walking Minutes per Day	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) How much time did you usually spend walking on one of those days?: minutes per day.			Intellectual Product	
C141722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141722>	C141680	IPAQ Short Last 7 Days Self-administered Format Version - Time Walking Don't Know/Not Sure	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) How much time did you usually spend walking on one of those days?: Don't know/Not sure.			Intellectual Product	
C141723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141723>	C141680	IPAQ Short Last 7 Days Self-administered Format Version - Sitting Weekday Hr and Min per Day|IPA04-Sitting Weekday Hr & Min per Day|IPA04-Sitting Weekday Hr & Min per Day|IPA0407	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) During the last 7 days, how much time did you spend sitting on a weekday?: hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Self-administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Self-administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141724>	C141680	IPAQ Short Last 7 Days Self-administered Format Version - Sitting Weekday Minutes per Day	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) During the last 7 days, how much time did you spend sitting on a weekday?: minutes per day.			Intellectual Product	
C141725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141725>	C141680	IPAQ Short Last 7 Days Self-administered Format Version - Time Sitting Don't Know/Not Sure	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Self-Administered Format (IPAQ Short Last 7 Days Self-administered Format Version) During the last 7 days, how much time did you spend sitting on a weekday?: Don't know/Not sure.			Intellectual Product	
C141726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141726>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Currently Have Job or Unpaid Work|IPA03-Currently Have Job or Unpaid Work|IPA03-Currently Have Job or Unpaid Work|IPA0301	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) Do you currently have a job or do any unpaid work outside your home?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141727>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Days Vigorous as Part of Work|IPA03-Days Vigorous as Part of Work|IPA03-Days Vigorous as Part of Work|IPA0302	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you do vigorous physical activities like heavy lifting, digging, heavy construction, or climbing up stairs as part of your work?: days per week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141728>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - No Vigorous Job-related Activity	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you do vigorous physical activities like heavy lifting, digging, heavy construction, or climbing up stairs as part of your work?: No vigorous job-related physical activity.			Intellectual Product	
C141729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141729>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Vigorous Work Hr and Min per Day|IPA03-Vigorous Work Hr & Min per Day|IPA03-Vigorous Work Hr & Min per Day|IPA0303	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days doing vigorous physical activities as part of your work?: hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14172>	C28099	Benign|BENIGN|benign	For neoplasms, a non-infiltrating and non-metastasizing neoplastic process that is characterized by the absence of morphologic features associated with malignancy (e.g., severe atypia, nuclear pleomorphism, tumor cell necrosis, and abnormal mitoses). For other conditions, a process that is mild in nature and not dangerous to health.	Benign		Qualitative Concept	CDISC SDTM Terminology|CDISC SDTM Tumor and Lesion Identification Test Result Terminology|CDISC SEND Microscopic Histopathology Result Category Terminology|CDISC SEND Terminology|CDISC SEND Tumor Findings Histopathology Result Category Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Terminology|ICDC Terminology|ICDC Value Terminology
C141730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141730>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Vigorous Work Minutes per Day	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days doing vigorous physical activities as part of your work?: minutes per day.			Intellectual Product	
C141731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141731>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Days Moderate as Part of Work|IPA03-Days Moderate as Part of Work|IPA03-Days Moderate as Part of Work|IPA0304	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you do moderate physical activities like carrying light loads as part of your work?: days per week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141732>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - No Moderate Job-related Activity	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you do moderate physical activities like carrying light loads as part of your work?: No moderate job-related physical activity.			Intellectual Product	
C141733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141733>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Moderate Work Hr and Min per Day|IPA03-Moderate Work Hr & Min per Day|IPA03-Moderate Work Hr & Min per Day|IPA0305	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days doing moderate physical activities as part of your work?: hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141734>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Moderate Work Minutes per Day	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days doing moderate physical activities as part of your work?: minutes per day.			Intellectual Product	
C141735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141735>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Days Walk as Part of Your Work|IPA03-Days Walk as Part of Your Work|IPA03-Days Walk as Part of Your Work|IPA0306	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you walk for at least 10 minutes at a time as part of your work?: days per week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141736>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - No Job-related Walking	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you walk for at least 10 minutes at a time as part of your work?: No job-related walking.			Intellectual Product	
C141737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141737>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Walking Work Hr and Min per Day|IPA03-Walking Work Hr & Min per Day|IPA03-Walking Work Hr & Min per Day|IPA0307	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days walking as part of your work?: hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141738>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Walking Work Minutes per Day	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days walking as part of your work?: minutes per day.			Intellectual Product	
C141739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141739>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Days Travel in a Motor Vehicle|IPA03-Days Travel in a Motor Vehicle|IPA03-Days Travel in a Motor Vehicle|IPA0308	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you travel in a motor vehicle like a train, bus, car or tram?: days per week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14173>	C28102	Recurrent	Occurring again.	Recurrent		Qualitative Concept	
C141740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141740>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - No Traveling in a Motor Vehicle	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you travel in a motor vehicle like a train, bus, car or tram?: No traveling in a motor vehicle.			Intellectual Product	
C141741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141741>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Traveling Hr and Min per Day|IPA03-Traveling Hr & Min per Day|IPA03-Traveling Hr & Min per Day|IPA0309	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days traveling in a train, bus, car, tram, or other kind of motor vehicle?: hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141742>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Traveling Minutes per Day	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days traveling in a train, bus, car, tram, or other kind of motor vehicle?: minutes per day.			Intellectual Product	
C141743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141743>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Days Bicycle Place to Place|IPA03-Days Bicycle Place to Place|IPA03-Days Bicycle Place to Place|IPA0310	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you bicycle for at least 10 minutes at a time to go from place to place?: days per week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141744>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - No Bicycling From Place to Place	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you bicycle for at least 10 minutes at a time to go from place to place?: No bicycling from place to place.			Intellectual Product	
C141745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141745>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Bicycle Hr and Min per Day|IPA03-Bicycle Hr & Min per Day|IPA03-Bicycle Hr & Min per Day|IPA0311	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days to bicycle from place to place?: hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141746>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Bicycle Minutes per Day	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days to bicycle from place to place?: minutes per day.			Intellectual Product	
C141747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141747>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Days Walk Place to Place|IPA03-Days Walk Place to Place|IPA03-Days Walk Place to Place|IPA0312	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you walk for at least 10 minutes at a time to go from place to place?: days per week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141748>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - No Walking From Place to Place	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you walk for at least 10 minutes at a time to go from place to place?: No walking from place to place.			Intellectual Product	
C141749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141749>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Walking Place Hr and Min per Day|IPA03-Walking Place Hr & Min per Day|IPA03-Walking Place Hr & Min per Day|IPA0313	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days walking from place to place?: hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14174>	C27992	Metastatic|METASTATIC|metastatic	A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site.	Metastatic		Finding	CDISC SEND Microscopic Histopathology Result Category Terminology|CDISC SEND Terminology|CDISC SEND Tumor Findings Histopathology Result Category Terminology|Clinical Data Interchange Standards Consortium Terminology
C141750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141750>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Walking Place Minutes per Day	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days walking from place to place?: minutes per day.			Intellectual Product	
C141751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141751>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Days Vigorous in the Garden/Yard|IPA03-Days Vigorous in the Garden/Yard|IPA03-Days Vigorous in the Garden/Yard|IPA0314	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you do vigorous physical activities like heavy lifting, chopping wood, shoveling snow, or digging in the garden or yard?: days per week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141752>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - No Vigorous Activity Garden/Yard	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you do vigorous physical activities like heavy lifting, chopping wood, shoveling snow, or digging in the garden or yard?: No vigorous activity in garden or yard.			Intellectual Product	
C141753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141753>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Vigorous Garden Hr and Min per Day|IPA03-Vigorous Garden Hr & Min per Day|IPA03-Vigorous Garden Hr & Min per Day|IPA0315	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days doing vigorous physical activities in the garden or yard?: hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141754>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Vigorous Garden Minutes per Day	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days doing vigorous physical activities in the garden or yard?: minutes per day.			Intellectual Product	
C141755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141755>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Days Moderate in the Garden/Yard|IPA03-Days Moderate in the Garden/Yard|IPA03-Days Moderate in the Garden/Yard|IPA0316	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you do moderate activities like carrying light loads, sweeping, washing windows, and raking in the garden or yard?: days per week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141756>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - No Moderate Activity Garden/Yard	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you do moderate activities like carrying light loads, sweeping, washing windows, and raking in the garden or yard?: No moderate activity in garden or yard.			Intellectual Product	
C141757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141757>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Moderate Garden Hr and Min per Day|IPA03-Moderate Garden Hr & Min per Day|IPA03-Moderate Garden Hr & Min per Day|IPA0317	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days doing moderate physical activities in the garden or yard?: hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141758>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Moderate Garden Minutes per Day	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days doing moderate physical activities in the garden or yard?: minutes per day.			Intellectual Product	
C141759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141759>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Days Moderate Inside Home|IPA03-Days Moderate Inside Home|IPA03-Days Moderate Inside Home|IPA0318	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you do moderate activities like carrying light loads, washing windows, scrubbing floors and sweeping inside your home?: days per week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14175>	C28099	Diffuse|DIFFUSE|Widespread|diffuse	Widely spread; not localized or confined.	Diffuse		Qualitative Concept	CDISC SEND Distribution Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C141760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141760>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - No Moderate Activity Inside Home	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you do moderate activities like carrying light loads, washing windows, scrubbing floors and sweeping inside your home?: No moderate activity inside home.			Intellectual Product	
C141761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141761>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Moderate Home Hr and Min per Day|IPA03-Moderate Home Hr & Min per Day|IPA03-Moderate Home Hr & Min per Day|IPA0319	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days doing moderate physical activities inside your home?: hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141762>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Moderate Home Minutes per Day	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days doing moderate physical activities inside your home?: minutes per day.			Intellectual Product	
C141763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141763>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Days Walk in Leisure Time|IPA03-Days Walk in Leisure Time|IPA03-Days Walk in Leisure Time|IPA0320	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you walk for at least 10 minutes at a time in your leisure time?: days per week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141764>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - No Walking in Leisure Time	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you walk for at least 10 minutes at a time in your leisure time?: No walking in leisure time.			Intellectual Product	
C141765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141765>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Walking Leisure Hr and Min per Day|IPA03-Walking Leisure Hr & Min per Day|IPA03-Walking Leisure Hr & Min per Day|IPA0321	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days walking in your leisure time?: hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141766>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Walking Leisure Minutes per Day	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days walking in your leisure time?: minutes per day.			Intellectual Product	
C141767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141767>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Days Vigorous in Leisure Time|IPA03-Days Vigorous in Leisure Time|IPA03-Days Vigorous in Leisure Time|IPA0322	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you do vigorous physical activities like aerobics, running, fast bicycling, or fast swimming in your leisure time?: days per week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141768>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - No Vigorous Activity Leisure Time	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you do vigorous physical activities like aerobics, running, fast bicycling, or fast swimming in your leisure time?: No vigorous activity in leisure time.			Intellectual Product	
C141769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141769>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Vigorous Leisure Hr and Min per Day|IPA03-Vigorous Leisure Hr & Min per Day|IPA03-Vigorous Leisure Hr & Min per Day|IPA0323	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days doing vigorous physical activities in your leisure time?: hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141770>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Vigorous Leisure Minutes per Day	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days doing vigorous physical activities in your leisure time?: minutes per day.			Intellectual Product	
C141771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141771>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Days Moderate in Leisure Time|IPA03-Days Moderate in Leisure Time|IPA03-Days Moderate in Leisure Time|IPA0324	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you do moderate physical activities like bicycling at a regular pace, swimming at a regular pace, and doubles tennis in your leisure time?: days per week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141772>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - No Moderate Activity Leisure Time	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, on how many days did you do moderate physical activities like bicycling at a regular pace, swimming at a regular pace, and doubles tennis in your leisure time?: No moderate activity in leisure time.			Intellectual Product	
C141773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141773>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Moderate Leisure Hr and Min per Day|IPA03-Moderate Leisure Hr & Min per Day|IPA03-Moderate Leisure Hr & Min per Day|IPA0325	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days doing moderate physical activities in your leisure time?: hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141774>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Moderate Leisure Minutes per Day	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) How much time did you usually spend on one of those days doing moderate physical activities in your leisure time?: minutes per day.			Intellectual Product	
C141775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141775>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Sitting Weekday Hr and Min per Day|IPA03-Sitting Weekday Hr & Min per Day|IPA03-Sitting Weekday Hr & Min per Day|IPA0326	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, how much time did you usually spend sitting on a weekday?: hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141776>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Sitting Weekday Minutes per Day	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, how much time did you usually spend sitting on a weekday?: minutes per day.			Intellectual Product	
C141777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141777>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Sitting Weekend Hr and Min per Day|IPA03-Sitting Weekend Hr & Min per Day|IPA03-Sitting Weekend Hr & Min per Day|IPA0327	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, how much time did you usually spend sitting on a weekend day?: hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Self-Administered Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141778>	C141681	IPAQ Long Last 7 Days Self-Administered Format Version - Sitting Weekend Minutes per Day	International Physical Activity Questionnaire (August 2002) Long Last 7 Days Self-Administered Format (IPAQ Long Last 7 Days Self-Administered Format Version) During the last 7 days, how much time did you usually spend sitting on a weekend day?: minutes per day.			Intellectual Product	
C141779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141779>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Currently Have Job or Unpaid Work|IPA02-Currently Have Job or Unpaid Work|IPA02-Currently Have Job or Unpaid Work|IPA0201	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) Do you currently have a job or do any unpaid work outside your home?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141780>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Days Vigorous as Part of Work|IPA02-Days Vigorous as Part of Work|IPA02-Days Vigorous as Part of Work|IPA0202	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) During the last 7 days, on how many days did you do vigorous physical activities as part of your work?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141781>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Vigorous Work Hr and Min per Day|IPA02-Vigorous Work Hr & Min per Day|IPA02-Vigorous Work Hr & Min per Day|IPA0203A	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days doing vigorous physical activities as part of your work?: Hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141782>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Vigorous Work Minutes per Day	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days doing vigorous physical activities as part of your work?: Minutes per day.			Intellectual Product	
C141783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141783>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Vigorous Work Hr and Min per Week|IPA02-Vigorous Work Hr & Min per Week|IPA02-Vigorous Work Hr & Min per Week|IPA0203B	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing vigorous physical activities as part of your work?: Hours and minutes per week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141784>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Vigorous Work Minutes per Week	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing vigorous physical activities as part of your work?: Minutes per week.			Intellectual Product	
C141785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141785>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Days Moderate as Part of Work|IPA02-Days Moderate as Part of Work|IPA02-Days Moderate as Part of Work|IPA0204	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) During the last 7 days, on how many days did you do moderate physical activities as part of your work?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141786>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Moderate Work Hr and Min per Day|IPA02-Moderate Work Hr & Min per Day|IPA02-Moderate Work Hr & Min per Day|IPA0205A	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days doing moderate physical activities as part of your work?: Hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141787>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Moderate Work Minutes per Day	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days doing moderate physical activities as part of your work?: Minutes per day.			Intellectual Product	
C141788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141788>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Moderate Work Hr and Min per Week|IPA02-Moderate Work Hr & Min per Week|IPA02-Moderate Work Hr & Min per Week|IPA0205B	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing moderate physical activities as part of your work?: Hours and minutes per week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141789>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Moderate Work Minutes per Week	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing moderate physical activities as part of your work?: Minutes per week.			Intellectual Product	
C141790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141790>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Days Walk as Part of Your Work|IPA02-Days Walk as Part of Your Work|IPA02-Days Walk as Part of Your Work|IPA0206	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) During the last 7 days, on how many days did you walk as part of your work?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141791>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Walking Work Hr and Min per Day|IPA02-Walking Work Hr & Min per Day|IPA02-Walking Work Hr & Min per Day|IPA0207A	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days walking as part of your work?: Hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141792>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Walking Work Minutes per Day	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days walking as part of your work?: Minutes per day.			Intellectual Product	
C141793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141793>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Walking Work Hr and Min per Week|IPA02-Walking Work Hr & Min per Week|IPA02-Walking Work Hr & Min per Week|IPA0207B	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent walking over the last 7 days as part of your work?: Hours and minutes per week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141794>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Walking Work Minutes per Week	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent walking over the last 7 days as part of your work?: Minutes per week.			Intellectual Product	
C141795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141795>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Days Travel in a Motor Vehicle|IPA02-Days Travel in a Motor Vehicle|IPA02-Days Travel in a Motor Vehicle|IPA0208	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) During the last 7 days, on how many days did you travel in a motor vehicle like a train, bus, car or tram?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141796>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Traveling Hr and Min per Day|IPA02-Traveling Hr & Min per Day|IPA02-Traveling Hr & Min per Day|IPA0209A	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days traveling in a car, bus, train or other kind of motor vehicle?: Hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141797>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Traveling Minutes per Day	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days traveling in a car, bus, train or other kind of motor vehicle?: Minutes per day.			Intellectual Product	
C141798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141798>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Traveling Hr and Min per Week|IPA02-Traveling Hr & Min per Week|IPA02-Traveling Hr & Min per Week|IPA0209B	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days traveling in a motor vehicle?: Hours and minutes per week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141799>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Traveling Minutes per Week	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days traveling in a motor vehicle?: Minutes per week.			Intellectual Product	
C14179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14179>	C14348	Adenoviridae|ADENOVIRIDAE|ADV|Adenovirus|Adenovirus|adenovirus	A group of DNA containing viruses which infect mammals and are capable of causing respiratory disease, including one form of the common cold.	Adenoviridae		Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C1417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1417>	C1910	Goserelin Acetate|D-Ser(bu(t))(6)azgly(10)-LHRH Acetate|GOSERELIN ACETATE|ZDX|Zoladex|Zoladex	The acetate salt of a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH).  Continuous, prolonged administration of goserelin in males results in inhibition of pituitary gonadotropin secretion, leading to a significant decline in testosterone production; in females, prolonged administration results in a decrease in estradiol production. (NCI04)	Goserelin Acetate		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C141800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141800>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Days Bicycle Place to Place|IPA02-Days Bicycle Place to Place|IPA02-Days Bicycle Place to Place|IPA0210	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) During the last 7 days, on how many days did you bicycle to go from place to place?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141801>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Bicycle Hr and Min per Day|IPA02-Bicycle Hr & Min per Day|IPA02-Bicycle Hr & Min per Day|IPA0211A	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days to bicycle from place to place?: Hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141802>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Bicycle Minutes per Day	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days to bicycle from place to place?: Minutes per day.			Intellectual Product	
C141803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141803>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Bicycling Hr and Min per Week|IPA02-Bicycling Hr & Min per Week|IPA02-Bicycling Hr & Min per Week|IPA0211B	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent bicycling over the last 7 days to travel from place to place?: Hours and minutes per week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141804>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Bicycling Minutes per Week	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent bicycling over the last 7 days to travel from place to place?: Minutes per week.			Intellectual Product	
C141805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141805>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Days Walk Place to Place|IPA02-Days Walk Place to Place|IPA02-Days Walk Place to Place|IPA0212	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) During the last 7 days, on how many days did you walk to go from place to place?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141806>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Walking Place Hr and Min per Day|IPA02-Walking Place Hr & Min per Day|IPA02-Walking Place Hr & Min per Day|IPA0213A	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days walking from place to place?: Hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141807>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Walking Place Minutes per Day	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days walking from place to place?: Minutes per day.			Intellectual Product	
C141808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141808>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Walking Place Hr and Min per Week|IPA02-Walking Place Hr & Min per Week|IPA02-Walking Place Hr & Min per Week|IPA0213B	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days walking from place to place?: Hours and minutes per week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141809>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Walking Place Minutes per Week	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days walking from place to place?: Minutes per week.			Intellectual Product	
C14180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14180>	C14282	Amphibia|Amphibian|Amphibians	A taxonomic class of vertebrates that include frogs, toads, newts, salamanders, and gymnophiona. Amphibians are cold blooded land animals that lay eggs in the water. The juveniles of this class metamorphose from water-breathing organisms to air-breathing organisms upon adult maturation.			Amphibian	
C141810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141810>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Days Vigorous in the Garden/Yard|IPA02-Days Vigorous in the Garden/Yard|IPA02-Days Vigorous in the Garden/Yard|IPA0214	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) During the last 7 days, on how many days did you do vigorous physical activities in the garden or yard?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141811>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Vigorous Garden Hr and Min per Day|IPA02-Vigorous Garden Hr & Min per Day|IPA02-Vigorous Garden Hr & Min per Day|IPA0215A	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days doing vigorous physical activities in the garden or yard?: Hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141812>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Vigorous Garden Minutes per Day	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days doing vigorous physical activities in the garden or yard?: Minutes per day.			Intellectual Product	
C141813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141813>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Vigorous Garden Hr and Min per Week|IPA02-Vigorous Garden Hr & Min per Week|IPA02-Vigorous Garden Hr & Min per Week|IPA0215B	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing vigorous physical activities in the garden or yard?: Hours and minutes per week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141814>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Vigorous Garden Minutes per Week	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing vigorous physical activities in the garden or yard?: Minutes per week.			Intellectual Product	
C141815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141815>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Days Moderate in the Garden/Yard|IPA02-Days Moderate in the Garden/Yard|IPA02-Days Moderate in the Garden/Yard|IPA0216	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) During the last 7 days, on how many days did you do moderate activities in the garden or yard?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141816>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Moderate Garden Hr and Min per Day|IPA02-Moderate Garden Hr & Min per Day|IPA02-Moderate Garden Hr & Min per Day|IPA0217A	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days doing moderate physical activities in the garden or yard?: Hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141817>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Moderate Garden Minutes per Day	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days doing moderate physical activities in the garden or yard?: Minutes per day.			Intellectual Product	
C141818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141818>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Moderate Garden Hr and Min per Week|IPA02-Moderate Garden Hr & Min per Week|IPA02-Moderate Garden Hr & Min per Week|IPA0217B	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing moderate physical activities in the garden or yard?: Hours and minutes per week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141819>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Moderate Garden Minutes per Week	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing moderate physical activities in the garden or yard?: Minutes per week.			Intellectual Product	
C14181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14181>	C14349	Animal Virus|Viruses, Animal	An animal pathogen that is a virus.			Virus	
C141820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141820>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Days Moderate Inside Your Home|IPA02-Days Moderate Inside Your Home|IPA02-Days Moderate Inside Your Home|IPA0218	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) During the last 7 days, on how many days did you do moderate activities inside your home?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141821>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Moderate Home Hr and Min per Day|IPA02-Moderate Home Hr & Min per Day|IPA02-Moderate Home Hr & Min per Day|IPA0219A	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days doing moderate physical activities inside your home?: Hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141822>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Moderate Home Minutes per Day	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days doing moderate physical activities inside your home?: Minutes per day.			Intellectual Product	
C141823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141823>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Moderate Home Hr and Min per Week|IPA02-Moderate Home Hr & Min per Week|IPA02-Moderate Home Hr & Min per Week|IPA0219B	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing moderate physical activities inside your home?: Hours and minutes per week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141824>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Moderate Home Minutes per Week	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing moderate physical activities inside your home?: Minutes per week.			Intellectual Product	
C141825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141825>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Days Walk in Your Leisure Time|IPA02-Days Walk in Your Leisure Time|IPA02-Days Walk in Your Leisure Time|IPA0220	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) Not counting any walking you have already mentioned, during the last 7 days, on how many days did you walk for at least 10 minutes at a time in your leisure time?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141826>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Walking Leisure Hr and Min per Day|IPA02-Walking Leisure Hr & Min per Day|IPA02-Walking Leisure Hr & Min per Day|IPA0221A	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days walking in your leisure time?: Hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141827>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Walking Leisure Minutes Per Day	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days walking in your leisure time?: Minutes per day.			Intellectual Product	
C141828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141828>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Walking Leisure Hr and Min per Week|IPA02-Walking Leisure Hr & Min per Week|IPA02-Walking Leisure Hr & Min per Week|IPA0221B	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days walking in your leisure time?: Hours and minutes per week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141829>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Walking Leisure Minutes per Week	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days walking in your leisure time?: Minutes per week.			Intellectual Product	
C14182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14182>	C25796	Animal|ANIMAL|Animalia|Animals|Metazoa|Metazoa Kingdom	A living organism that has membranous cell walls, requires oxygen and organic foods, and is capable of voluntary movement, as distinguished from a plant or mineral.			Animal	BRIDG Class Terminology|BRIDG Terminology|Dose Denominator Qualifier ICSR Terminology|FDA Individual Case Safety Report Terminology|PQ/CMC Source Type Terminology
C141830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141830>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Days Vigorous in Your Leisure Time|IPA02-Days Vigorous in Your Leisure Time|IPA02-Days Vigorous in Your Leisure Time|IPA0222	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) During the last 7 days, on how many days did you do vigorous physical activities in your leisure time?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141831>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Vigorous Leisure Hr and Min per Day|IPA02-Vigorous Leisure Hr & Min per Day|IPA02-Vigorous Leisure Hr & Min per Day|IPA0223A	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days doing vigorous physical activities in your leisure time?: Hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141832>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Vigorous Leisure Minutes per Day	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days doing vigorous physical activities in your leisure time?: Minutes per day.			Intellectual Product	
C141833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141833>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Vigorous Leisure Hr and Min per Week|IPA02-Vigorous Leisure Hr & Min per Week|IPA02-Vigorous Leisure Hr & Min per Week|IPA0223B	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing vigorous physical activities in your leisure time?: Hours and minutes per week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141834>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Vigorous Leisure Minutes per Week	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing vigorous physical activities in your leisure time?: Minutes per week.			Intellectual Product	
C141835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141835>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Days Moderate in Your Leisure Time|IPA02-Days Moderate in Your Leisure Time|IPA02-Days Moderate in Your Leisure Time|IPA0224	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) During the last 7 days, on how many days did you do moderate physical activities in your leisure time?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141836>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Moderate Leisure Hr and Min per Day|IPA02-Moderate Leisure Hr & Min per Day|IPA02-Moderate Leisure Hr & Min per Day|IPA0225A	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days doing moderate physical activities in your leisure time?: Hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141837>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Moderate Leisure Minutes per Day	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time did you usually spend on one of those days doing moderate physical activities in your leisure time?: Minutes per day.			Intellectual Product	
C141838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141838>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Moderate Leisure Hr and Min per Week|IPA02-Moderate Leisure Hr & Min per Week|IPA02-Moderate Leisure Hr & Min per Week|IPA0225B	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing moderate physical activities in your leisure time?: Hours and minutes per week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141839>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Moderate Leisure Minutes per Week	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing moderate physical activities in your leisure time? Minutes per week.			Intellectual Product	
C14183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14183>	C14354	Laboratory Animal	A grouping of those animals that are commonly used as subjects in laboratory research.			Animal	
C141840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141840>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Sitting Weekday Hr and Min per Day|IPA02-Sitting Weekday Hr & Min per Day|IPA02-Sitting Weekday Hr & Min per Day|IPA0226A	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) During the last 7 days, how much time did you usually spend sitting on a weekday?: Hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141841>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Sitting Weekday Minutes per Day	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) During the last 7 days, how much time did you usually spend sitting on a weekday?: Minutes per day.			Intellectual Product	
C141842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141842>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Sitting Hr and Min on Wednesday|IPA02-Sitting Hr & Min on Wednesday|IPA02-Sitting Hr & Min on Wednesday|IPA0226B	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time in total did you spend sitting on Wednesday?: Hours and minutes on Wednesday.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141843>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Sitting Minutes per Wednesday	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time in total did you spend sitting on Wednesday?: Minutes per Wednesday.			Intellectual Product	
C141844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141844>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Sitting Weekend Hr and Min per Day|IPA02-Sitting Weekend Hr & Min per Day|IPA02-Sitting Weekend Hr & Min per Day|IPA0227A	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) During the last 7 days, how much time did you usually spend sitting on a weekend day?: Hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141845>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Sitting Weekend Minutes per Day	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) During the last 7 days, how much time did you usually spend sitting on a weekend day?: Minutes per day.			Intellectual Product	
C141846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141846>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Sitting Hr and Min on Saturday|IPA02-Sitting Hr & Min on Saturday|IPA02-Sitting Hr & Min on Saturday|IPA0227B	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time in total did you spend sitting on Saturday?: Hours and minutes on Saturday.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Long Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141847>	C141682	IPAQ Long Last 7 Days Telephone Format Version - Sitting Minutes per Saturday	International Physical Activity Questionnaire (November 2002) Long Last 7 Days Telephone Format (IPAQ Long Last 7 Days Telephone Format Version) How much time in total did you spend sitting on Saturday?: Minutes per Saturday.			Intellectual Product	
C141848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141848>	C141683	IPAQ Short Last 7 Days Telephone Format Version - Days Vigorous Physical Activities|IPA01-Days Vigorous Physical Activities|IPA01-Days Vigorous Physical Activities|IPA0101	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) During the last 7 days, on how many days did you do vigorous physical activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141849>	C141683	IPAQ Short Last 7 Days Telephone Format Version - Vigorous Physical Hr and Min per Day|IPA01-Vigorous Physical Hr & Min per Day|IPA01-Vigorous Physical Hr & Min per Day|IPA0102A	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) How much time did you usually spend doing vigorous physical activities on one of those days?: Hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14184>	C14183	Transgenic Animal|Animals, Transgenic|Transgenic|Transgenics	Experimental organism whose genome has been altered by the transfer of a gene or genes from another species or breed.			Animal	
C141850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141850>	C141683	IPAQ Short Last 7 Days Telephone Format Version - Vigorous Physical Minutes per Day	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) How much time did you usually spend doing vigorous physical activities on one of those days?: Minutes per day.			Intellectual Product	
C141851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141851>	C141683	IPAQ Short Last 7 Days Telephone Format Version - Total Vigorous Hr and Min per Week|IPA01-Total Vigorous Hr & Min per Week|IPA01-Total Vigorous Hr & Min per Week|IPA0102B	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) How much time in total would you spend over the last 7 days doing vigorous physical activities?: Hours and minutes per week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141852>	C141683	IPAQ Short Last 7 Days Telephone Format Version - Total Vigorous Minutes per Week	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) How much time in total would you spend over the last 7 days doing vigorous physical activities?: Minutes per week.			Intellectual Product	
C141853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141853>	C141683	IPAQ Short Last 7 Days Telephone Format Version - Days Moderate Physical Activities|IPA01-Days Moderate Physical Activities|IPA01-Days Moderate Physical Activities|IPA0103	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) During the last 7 days, on how many days did you do moderate physical activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141854>	C141683	IPAQ Short Last 7 Days Telephone Format Version - Moderate Physical Hr and Min per Day|IPA01-Moderate Physical Hr & Min per Day|IPA01-Moderate Physical Hr & Min per Day|IPA0104A	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) How much time did you usually spend doing moderate physical activities on one of those days?: Hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141855>	C141683	IPAQ Short Last 7 Days Telephone Format Version - Moderate Physical Minutes per Day	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) How much time did you usually spend doing moderate physical activities on one of those days?: Minutes per day.			Intellectual Product	
C141856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141856>	C141683	IPAQ Short Last 7 Days Telephone Format Version - Total Moderate Hr and Min per Week|IPA01-Total Moderate Hr & Min per Week|IPA01-Total Moderate Hr & Min per Week|IPA0104B	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing moderate physical activities?: Hours and minutes per week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141857>	C141683	IPAQ Short Last 7 Days Telephone Format Version - Total Moderate Minutes per Week	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) What is the total amount of time you spent over the last 7 days doing moderate physical activities?: Minutes per week.			Intellectual Product	
C141858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141858>	C141683	IPAQ Short Last 7 Days Telephone Format Version - Days Walk at Least 10 Minutes|IPA01-Days Walk at Least 10 Minutes|IPA01-Days Walk at Least 10 Minutes|IPA0105	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) During the last 7 days, on how many days did you walk for at least 10 minutes at a time?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141859>	C141683	IPAQ Short Last 7 Days Telephone Format Version - Walking Hr and Min per Day|IPA01-Walking Hr & Min per Day|IPA01-Walking Hr & Min per Day|IPA0106A	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) How much time did you usually spend walking on one of those days?: Hours and minutes per day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14185>	C79108	Armadillo|Dasypodidae|Mammals, Armadillos	Any of several small, burrowing, chiefly nocturnal mammals with body covered with strong horny plates.			Mammal	
C141860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141860>	C141683	IPAQ Short Last 7 Days Telephone Format Version - Walking Minutes per Day	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) How much time did you usually spend walking on one of those days?: Minutes per day.			Intellectual Product	
C141861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141861>	C141683	IPAQ Short Last 7 Days Telephone Format Version - Total Walking Hr and Min per Week|IPA01-Total Walking Hr & Min per Week|IPA01-Total Walking Hr & Min per Week|IPA0106B	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) What is the total amount of time you spent walking over the last 7 days?: Hours and minutes per week.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141862>	C141683	IPAQ Short Last 7 Days Telephone Format Version - Total Walking Minutes per Week	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) What is the total amount of time you spent walking over the last 7 days?: Minutes per week.			Intellectual Product	
C141863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141863>	C141683	IPAQ Short Last 7 Days Telephone Format Version - Sitting Hr and Min per Weekday|IPA01-Sitting Hr & Min per Weekday|IPA01-Sitting Hr & Min per Weekday|IPA0107A	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) During the last 7 days, how much time did you usually spend sitting on a weekday?: Hours and minutes per weekday.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141864>	C141683	IPAQ Short Last 7 Days Telephone Format Version - Sitting Minutes per Weekday	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) During the last 7 days, how much time did you usually spend sitting on a weekday?: Minutes per weekday.			Intellectual Product	
C141865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141865>	C141683	IPAQ Short Last 7 Days Telephone Format Version - Total Sitting Hr and Min Wednesday|IPA01-Total Sitting Hr & Min Wednesday|IPA01-Total Sitting Hr & Min Wednesday|IPA0107B	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) What is the total amount of time you spent sitting last Wednesday?: Hours and minutes on Wednesday.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Telephone Format Version Test Code Terminology|CDISC Questionnaire IPAQ Short Last 7 Days Telephone Format Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141866>	C141683	IPAQ Short Last 7 Days Telephone Format Version - Total Sitting Minutes on Wednesday	International Physical Activity Questionnaire (August 2002) Short Last 7 Days Telephone Format (IPAQ Short Last 7 Days Telephone Format Version) What is the total amount of time you spent sitting last Wednesday?: Minutes on Wednesday.			Intellectual Product	
C141867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141867>	C141684	DRRI-2 - A: Someone Close to Me Died|DRRI1-A: Someone Close to Me Died|DRRI1-A: Someone Close to Me Died|DRRI1A01	Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: someone close to me died.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141868>	C141684	DRRI-2 - A: Went Through Divorce/Was Left|DRRI1-A: Went Through Divorce/Was Left|DRRI1-A: Went Through Divorce/Was Left|DRRI1A02	Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: I went through a divorce or was left by a significant other.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141869>	C141684	DRRI-2 - A: Robbed/Had My Home Broken Into|DRRI1-A: Robbed/Had My Home Broken Into|DRRI1-A: Robbed/Had My Home Broken Into|DRRI1A03	Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: I was robbed or had my home broken into.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14186>	C14268	Alpharetrovirus|Avian Retrovirus|Retroviruses, Type C, Avian|Type C Avian Retrovirus	An rna-type retrovirus with a c-type morphology. The viruses have a widespread distribution and include both exogenous (vertical and horizontal transmission) and endogenous viruses of chickens and some other birds. Avian Leukosis virus is the type species. Distantly related endogenous sequences are found in birds and mammals. Virus infections are associated with malignancies and some other diseases such as wasting, and osteopetrosis. Many oncogene-containing members of the genus have been isolated.			Virus	
C141870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141870>	C141684	DRRI-2 - A: Saw/Heard Physical Fight Parent|DRRI1-A: Saw/Heard Physical Fight Parent|DRRI1-A: Saw/Heard Physical Fight Parent|DRRI1A04	Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: I saw or heard physical fighting between my parents or caregivers.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141871>	C141684	DRRI-2 - A: Physically Punished by Parent|DRRI1-A: Physically Punished by Parent|DRRI1-A: Physically Punished by Parent|DRRI1A05	Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: I was physically punished by a parent or primary caregiver.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141872>	C141684	DRRI-2 - A: Unwanted Sex Activity Childhood|DRRI1-A: Unwanted Sex Activity Childhood|DRRI1-A: Unwanted Sex Activity Childhood|DRRI1A06	Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: I experienced unwanted sexual activity as a result of force, threat of harm, or manipulation during childhood (before age 18).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141873>	C141684	DRRI-2 - A: Unwanted Sex Activity Adulthood|DRRI1-A: Unwanted Sex Activity Adulthood|DRRI1-A: Unwanted Sex Activity Adulthood|DRRI1A07	Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: I experienced unwanted sexual activity as a result of force, threat of harm, or manipulation during adulthood (age 18 or later).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141874>	C141684	DRRI-2 - A: Experienced Natural Disaster|DRRI1-A: Experienced Natural Disaster|DRRI1-A: Experienced Natural Disaster|DRRI1A08	Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: I experienced a natural disaster (for example, a hurricane), a fire, or an accident in which I or someone close to me was hurt or had serious property damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141875>	C141684	DRRI-2 - A: Someone Close Serious Illness|DRRI1-A: Someone Close Serious Illness|DRRI1-A: Someone Close Serious Illness|DRRI1A09	Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: someone close to me experienced a serious illness, injury, or mental health problem (for example, cancer, alcohol/drug problem).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141876>	C141684	DRRI-2 - A: Witnessed Someone Assaulted|DRRI1-A: Witnessed Someone Assaulted|DRRI1-A: Witnessed Someone Assaulted|DRRI1A10	Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: I witnessed someone being seriously assaulted or killed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141877>	C141684	DRRI-2 - A: Lost My Job/Trouble Finding Job|DRRI1-A: Lost My Job/Trouble Finding Job|DRRI1-A: Lost My Job/Trouble Finding Job|DRRI1A11	Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: I lost my job or had serious trouble finding a job.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141878>	C141684	DRRI-2 - A: Emotionally Mistreated|DRRI1-A: Emotionally Mistreated|DRRI1-A: Emotionally Mistreated|DRRI1A12	Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: I was emotionally mistreated (for example, ignored or repeatedly told I was no good).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141879>	C141684	DRRI-2 - A: Serious Financial Problems|DRRI1-A: Serious Financial Problems|DRRI1-A: Serious Financial Problems|DRRI1A13	Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: I experienced serious financial problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14187>	C14250	Bacteria|BACTERIA|Bacteria, Eubacteria|Bacterium|Bacterium|Bacterium|Eubacteria|Eubacteria|bacteria	Unicellular, prokaryotic organisms that reproduce by cell division and usually have cell walls; can be shaped like spheres, rods or spirals and can be found in virtually any environment.			Bacterium	ALL Adverse Events Table|ALL Authorized Value Terminology|AML Adverse Events Table|AML Authorized Value Terminology|CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|CDISC SEND Biological Challenge Agent Category Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL Adverse Events Table|HL Authorized Value Terminology|NICHD Terminology|Pediatric Infectious Disease Terminology
C141880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141880>	C141684	DRRI-2 - A: Serious Physical Health Problem|DRRI1-A: Serious Physical Health Problem|DRRI1-A: Serious Physical Health Problem|DRRI1A14	Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: I experienced serious physical or mental health problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141881>	C141684	DRRI-2 - A: Dangerous Military Duties|DRRI1-A: Dangerous Military Duties|DRRI1-A: Dangerous Military Duties|DRRI1A15	Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: I participated in dangerous military duties.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141882>	C141684	DRRI-2 - A: Injured by Person - Childhood|DRRI1-A: Injured by Person - Childhood|DRRI1-A: Injured by Person - Childhood|DRRI1A16	Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: I was seriously physically injured by another person (for example, hit or beaten up) during childhood (before age 18).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141883>	C141684	DRRI-2 - A: Injured by Person - Adulthood|DRRI1-A: Injured by Person - Adulthood|DRRI1-A: Injured by Person - Adulthood|DRRI1A17	Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: I was seriously physically injured by another person (for example, hit or beaten up) during adulthood (age 18 or later).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141884>	C141684	DRRI-2 - A: Stressful Legal Problems|DRRI1-A: Stressful Legal Problems|DRRI1-A: Stressful Legal Problems|DRRI1A18	Deployment Risk and Resilience Inventory-2 (DRRI-2) Before deployment: I experienced stressful legal problems (for example, being sued, suing someone else, or being in a custody battle).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141885>	C141684	DRRI-2 - B: Got Along Well With My Family|DRRI1-B: Got Along Well With My Family|DRRI1-B: Got Along Well With My Family|DRRI1B01	Deployment Risk and Resilience Inventory-2 (DRRI-2) During childhood: I got along well with my family members.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141886>	C141684	DRRI-2 - B: Felt Like I Fit in With Family|DRRI1-B: Felt Like I Fit in With Family|DRRI1-B: Felt Like I Fit in With Family|DRRI1B02	Deployment Risk and Resilience Inventory-2 (DRRI-2) During childhood: I felt like I fit in with my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141887>	C141684	DRRI-2 - B: Family Knew What I Thought/Felt|DRRI1-B: Family Knew What I Thought/Felt|DRRI1-B: Family Knew What I Thought/Felt|DRRI1B03	Deployment Risk and Resilience Inventory-2 (DRRI-2) During childhood: family members knew what I thought and how I felt about things.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141888>	C141684	DRRI-2 - B: Contribution Family Appreciated|DRRI1-B: Contribution Family Appreciated|DRRI1-B: Contribution Family Appreciated|DRRI1B04	Deployment Risk and Resilience Inventory-2 (DRRI-2) During childhood: I felt like my contributions to my family were appreciated.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141889>	C141684	DRRI-2 - B: Shared Interests With Family|DRRI1-B: Shared Interests With Family|DRRI1-B: Shared Interests With Family|DRRI1B05	Deployment Risk and Resilience Inventory-2 (DRRI-2) During childhood: I shared many common interests and activities with family members.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14188>	C14349	Bacteriophage|Phage|Viruses, Bacterial	A non-taxonomic grouping of viruses that infect and lyse certain bacteria and archaea.			Virus	
C141890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141890>	C141684	DRRI-2 - B: Opinions Were Valued by Family|DRRI1-B: Opinions Were Valued by Family|DRRI1-B: Opinions Were Valued by Family|DRRI1B06	Deployment Risk and Resilience Inventory-2 (DRRI-2) During childhood: my opinions were valued by other family members.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141891>	C141684	DRRI-2 - B: I Was Affectionate With Family|DRRI1-B: I Was Affectionate With Family|DRRI1-B: I Was Affectionate With Family|DRRI1B07	Deployment Risk and Resilience Inventory-2 (DRRI-2) During childhood: I was affectionate with family members.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141892>	C141684	DRRI-2 - B: Played Important Role in Family|DRRI1-B: Played Important Role in Family|DRRI1-B: Played Important Role in Family|DRRI1B08	Deployment Risk and Resilience Inventory-2 (DRRI-2) During childhood: I played an important role in my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141893>	C141684	DRRI-2 - B: Spent My Free Time With Family|DRRI1-B: Spent My Free Time With Family|DRRI1-B: Spent My Free Time With Family|DRRI1B09	Deployment Risk and Resilience Inventory-2 (DRRI-2) During childhood: I spent as much of my free time with family members as possible.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141894>	C141684	DRRI-2 - B: Family Told Me When Problem|DRRI1-B: Family Told Me When Problem|DRRI1-B: Family Told Me When Problem|DRRI1B10	Deployment Risk and Resilience Inventory-2 (DRRI-2) During childhood: family members told me when they were having a problem.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141895>	C141684	DRRI-2 - B: I Could Be Myself Around Family|DRRI1-B: I Could Be Myself Around Family|DRRI1-B: I Could Be Myself Around Family|DRRI1B11	Deployment Risk and Resilience Inventory-2 (DRRI-2) During childhood: I could be myself around family members.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141896>	C141684	DRRI-2 - B: Input Sought Family Decisions|DRRI1-B: Input Sought Family Decisions|DRRI1-B: Input Sought Family Decisions|DRRI1B12	Deployment Risk and Resilience Inventory-2 (DRRI-2) During childhood: my input was sought on important family decisions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141897>	C141684	DRRI-2 - C: Climate Was Uncomfortable|DRRI1-C: Climate Was Uncomfortable|DRRI1-C: Climate Was Uncomfortable|DRRI1C01	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: the climate was uncomfortable.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141898>	C141684	DRRI-2 - C: Deal With Annoying Animals|DRRI1-C: Deal With Annoying Animals|DRRI1-C: Deal With Annoying Animals|DRRI1C02	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I had to deal with annoying animals, insects, or plants.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141899>	C141684	DRRI-2 - C: Food Was of Very Poor Quality|DRRI1-C: Food Was of Very Poor Quality|DRRI1-C: Food Was of Very Poor Quality|DRRI1C03	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: the food I had to eat was of very poor quality (for example, bad or old MREs).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14189>	C14282	Aves|Avian|Bird|Birds	A taxonomic class of egg-laying, endothermic vertebrates. The forelimbs of these bipedal animals have been modified to form wings. Modern birds have beaks with no teeth and their bodies are covered in feathers.			Bird	
C1418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1418>	C67439|C443|C2136	Clodronate Disodium|Bonefos|Bonefos|CL2MDP|CLODRONATE DISODIUM|Clasteon|Clodronate|Clodronic Acid Disodium Salt|Dichloromethylene Diphosphonate|Difosfonal|Loron|Mebonat|Ossiten|clodronate	The disodium salt of a nitrogen-free bisphosphonate analog of naturally occurring pyrophosphate. Clodronate binds to calcium and inhibits osteoclastic bone resorption and hydroxyapatite crystal formation and dissolution, resulting in a reduction of bone turnover. This agent may control malignancy-associated hypercalcemia, inhibit osteolytic bone metastasis and decrease pain.	Clodronate Disodium		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology
C141900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141900>	C141684	DRRI-2 - C: Conditions Extremely Unsanitary|DRRI1-C: Conditions Extremely Unsanitary|DRRI1-C: Conditions Extremely Unsanitary|DRRI1C04	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: the conditions I lived in were extremely unsanitary.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141901>	C141684	DRRI-2 - C: Didn't Have Bathrooms|DRRI1-C: Didn't Have Bathrooms|DRRI1-C: Didn't Have Bathrooms|DRRI1C05	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I didn't have access to bathrooms or showers when I needed them.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141902>	C141684	DRRI-2 - C: Wasn't Able to Get Privacy|DRRI1-C: Wasn't Able to Get Privacy|DRRI1-C: Wasn't Able to Get Privacy|DRRI1C06	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I wasn't able to get as much privacy as I needed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141903>	C141684	DRRI-2 - C: I Was Exposed to Awful Smells|DRRI1-C: I Was Exposed to Awful Smells|DRRI1-C: I Was Exposed to Awful Smells|DRRI1C07	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was exposed to awful smells.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141904>	C141684	DRRI-2 - C: I Was Subjected to Loud Noises|DRRI1-C: I Was Subjected to Loud Noises|DRRI1-C: I Was Subjected to Loud Noises|DRRI1C08	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was subjected to loud noises.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141905>	C141684	DRRI-2 - C: Restricted Because Local Custom|DRRI1-C: Restricted Because Local Custom|DRRI1-C: Restricted Because Local Custom|DRRI1C09	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: my daily activities were restricted because of local religious or ethnic customs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141906>	C141684	DRRI-2 - C: Wasn't Able to Rest|DRRI1-C: Wasn't Able to Rest|DRRI1-C: Wasn't Able to Rest|DRRI1C10	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I wasn't able to get rest when I needed it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141907>	C141684	DRRI-2 - C: Wasn't Able to Contact Home|DRRI1-C: Wasn't Able to Contact Home|DRRI1-C: Wasn't Able to Contact Home|DRRI1C11	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I wasn't able to contact home when I needed to.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141908>	C141684	DRRI-2 - C: Hassle With Heavy/Annoying Gear|DRRI1-C: Hassle With Heavy/Annoying Gear|DRRI1-C: Hassle With Heavy/Annoying Gear|DRRI1C12	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I had to hassle with putting on and taking off heavy or annoying gear.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141909>	C141684	DRRI-2 - C: Not Allowed to Get Job Done|DRRI1-C: Not Allowed to Get Job Done|DRRI1-C: Not Allowed to Get Job Done|DRRI1C13	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was not allowed to do the things I needed to do to get my job done.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14190>	C14251	Bovine Papillomavirus|BPV	A group of double-stranded DNA viruses that cause warts on the skin and alimentary track of cattle and other mammals.			Virus	
C141910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141910>	C141684	DRRI-2 - C: Not Have Adequate Shelter|DRRI1-C: Not Have Adequate Shelter|DRRI1-C: Not Have Adequate Shelter|DRRI1C14	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I did not have adequate shelter from uncomfortable living conditions (for example, heat, cold, wet, etc.).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141911>	C141684	DRRI-2 - D: Went on Combat Patrols/Missions|DRRI1-D: Went on Combat Patrols/Missions|DRRI1-D: Went on Combat Patrols/Missions|DRRI1D01	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I went on combat patrols or missions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141912>	C141684	DRRI-2 - D: Assault on Entrenched Positions|DRRI1-D: Assault on Entrenched Positions|DRRI1-D: Assault on Entrenched Positions|DRRI1D02	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I took part in an assault on entrenched or fortified positions that involved naval and/or land forces.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141913>	C141684	DRRI-2 - D: Witnessed Someone Unit Wounded|DRRI1-D: Witnessed Someone Unit Wounded|DRRI1-D: Witnessed Someone Unit Wounded|DRRI1D03	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I personally witnessed someone from my unit or an ally unit being seriously wounded or killed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141914>	C141684	DRRI-2 - D: Encountered Land Mines|DRRI1-D: Encountered Land Mines|DRRI1-D: Encountered Land Mines|DRRI1D04	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I encountered land or water mines, booby traps, or roadside bombs (for example, IEDs).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141915>	C141684	DRRI-2 - D: Exposed Hostile Incoming Fire|DRRI1-D: Exposed Hostile Incoming Fire|DRRI1-D: Exposed Hostile Incoming Fire|DRRI1D05	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was exposed to hostile incoming fire.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141916>	C141684	DRRI-2 - D: Exposed to Friendly Fire|DRRI1-D: Exposed to Friendly Fire|DRRI1-D: Exposed to Friendly Fire|DRRI1D06	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was exposed to "friendly" fire.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141917>	C141684	DRRI-2 - D: Vehicle/Part of Convoy Attacked|DRRI1-D: Vehicle/Part of Convoy Attacked|DRRI1-D: Vehicle/Part of Convoy Attacked|DRRI1D07	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was in a vehicle (for example, a "humvee", helicopter, or boat) or part of a convoy that was attacked.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141918>	C141684	DRRI-2 - D: Part of Unit Fired on Enemy|DRRI1-D: Part of Unit Fired on Enemy|DRRI1-D: Part of Unit Fired on Enemy|DRRI1D08	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was part of a land or naval artillery unit that fired on enemy combatants.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141919>	C141684	DRRI-2 - D: Witnessed Enemy Wounded/Killed|DRRI1-D: Witnessed Enemy Wounded/Killed|DRRI1-D: Witnessed Enemy Wounded/Killed|DRRI1D09	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I personally witnessed enemy combatants being seriously wounded or killed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14191>	C14321	Cat|CAT|FELIS CATUS|Feline Species|Felis catus|Felis domesticus|Felis silvestris catus|Mammals, Cats	The domesticated feline mammal, Felis catus, which is kept as a house pet.			Mammal	CDISC SEND Genus and Species Response Terminology|CDISC SEND Laboratory Animal Species Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C141920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141920>	C141684	DRRI-2 - D: Witnessed Civilians Wounded|DRRI1-D: Witnessed Civilians Wounded|DRRI1-D: Witnessed Civilians Wounded|DRRI1D10	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I personally witnessed civilians (for example, women and children) being seriously wounded or killed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141921>	C141684	DRRI-2 - D: Injured Combat-Related Incident|DRRI1-D: Injured Combat-Related Incident|DRRI1-D: Injured Combat-Related Incident|DRRI1D11	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was injured in a combat-related incident.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141922>	C141684	DRRI-2 - D: Fired My Weapon Enemy Combatant|DRRI1-D: Fired My Weapon Enemy Combatant|DRRI1-D: Fired My Weapon Enemy Combatant|DRRI1D12	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I fired my weapon at enemy combatants.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141923>	C141684	DRRI-2 - D: Think I Wounded/Killed Someone|DRRI1-D: Think I Wounded/Killed Someone|DRRI1-D: Think I Wounded/Killed Someone|DRRI1D13	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I think I wounded or killed someone during combat operations.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141924>	C141684	DRRI-2 - D: Locating Explosive Devices|DRRI1-D: Locating Explosive Devices|DRRI1-D: Locating Explosive Devices|DRRI1D14	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was involved in locating or disarming explosive devices.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141925>	C141684	DRRI-2 - D: Searching Homes/Buildings|DRRI1-D: Searching Homes/Buildings|DRRI1-D: Searching Homes/Buildings|DRRI1D15	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was involved in searching or clearing homes, buildings, or other locations.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141926>	C141684	DRRI-2 - D: Participate Hand-to-hand Combat|DRRI1-D: Participate Hand-to-hand Combat|DRRI1-D: Participate Hand-to-hand Combat|DRRI1D16	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I participated in hand-to-hand combat.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141927>	C141684	DRRI-2 - D: Search/Disarm Potential Enemy|DRRI1-D: Search/Disarm Potential Enemy|DRRI1-D: Search/Disarm Potential Enemy|DRRI1D17	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was involved in searching and/or disarming potential enemy combatants.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141928>	C141684	DRRI-2 - E: Saw People Begging for Food|DRRI1-E: Saw People Begging for Food|DRRI1-E: Saw People Begging for Food|DRRI1E01	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I saw people begging for food.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141929>	C141684	DRRI-2 - E: Saw Refugees Who Had Lost Homes|DRRI1-E: Saw Refugees Who Had Lost Homes|DRRI1-E: Saw Refugees Who Had Lost Homes|DRRI1E02	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I saw refugees who had lost their homes or belongings.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14192>	C14323	Cow|BOVINE|Bos bovis|Bos primigenius taurus|Bos taurus|Bovine|Bovine Species|Cattle|Cattle	Domesticated ungulates that are raised for beef, dairy products, and leather, and used for labor.			Mammal	CDISC SEND Laboratory Animal Species Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C141930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141930>	C141684	DRRI-2 - E: Observed Homes Been Destroyed|DRRI1-E: Observed Homes Been Destroyed|DRRI1-E: Observed Homes Been Destroyed|DRRI1E03	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I observed homes or communities that had been destroyed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141931>	C141684	DRRI-2 - E: Took Care Injured/Dying People|DRRI1-E: Took Care Injured/Dying People|DRRI1-E: Took Care Injured/Dying People|DRRI1E04	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I took care of injured or dying people.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141932>	C141684	DRRI-2 - E: Saw Civilians After Wounded|DRRI1-E: Saw Civilians After Wounded|DRRI1-E: Saw Civilians After Wounded|DRRI1E05	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I saw civilians after they had been severely wounded or disfigured.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141933>	C141684	DRRI-2 - E: Saw Combatants Had Been Wounded|DRRI1-E: Saw Combatants Had Been Wounded|DRRI1-E: Saw Combatants Had Been Wounded|DRRI1E06	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I saw enemy combatants after they had been severely wounded or disfigured.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141934>	C141684	DRRI-2 - E: Saw Americans Had Been Wounded|DRRI1-E: Saw Americans Had Been Wounded|DRRI1-E: Saw Americans Had Been Wounded|DRRI1E07	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I saw Americans or allies after they had been severely wounded or disfigured.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141935>	C141684	DRRI-2 - E: Saw Bodies of Dead Enemy|DRRI1-E: Saw Bodies of Dead Enemy|DRRI1-E: Saw Bodies of Dead Enemy|DRRI1E08	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I saw the bodies of dead enemy combatants.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141936>	C141684	DRRI-2 - E: Saw Bodies of Dead Americans|DRRI1-E: Saw Bodies of Dead Americans|DRRI1-E: Saw Bodies of Dead Americans|DRRI1E09	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I saw the bodies of dead Americans or allies.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141937>	C141684	DRRI-2 - E: Saw Bodies of Dead Civilians|DRRI1-E: Saw Bodies of Dead Civilians|DRRI1-E: Saw Bodies of Dead Civilians|DRRI1E10	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I saw the bodies of dead civilians.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141938>	C141684	DRRI-2 - E: Interacted With Detainees|DRRI1-E: Interacted With Detainees|DRRI1-E: Interacted With Detainees|DRRI1E11	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I interacted with detainees or prisoners of war.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141939>	C141684	DRRI-2 - E: Sight/Sound/Smell Dead Animals|DRRI1-E: Sight/Sound/Smell Dead Animals|DRRI1-E: Sight/Sound/Smell Dead Animals|DRRI1E12	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was exposed to the sight, sound, or smell of dead or dying animals.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14193>	C14189	Chicken|CHICKEN|CHICKEN|Domestic Chicken|GALLUS GALLUS|Gallus domesticus|Gallus gallus domesticus|Gallus gallus domesticus	The common domestic fowl, Gallus gallus.			Bird	CDISC SEND Genus and Species Response Terminology|CDISC SEND Laboratory Animal Species Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C141940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141940>	C141684	DRRI-2 - E: Involved Handling Human Remains|DRRI1-E: Involved Handling Human Remains|DRRI1-E: Involved Handling Human Remains|DRRI1E13	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was involved in handling human remains.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141941>	C141684	DRRI-2 - F: Took Preventative Pills|DRRI1-F: Took Preventative Pills|DRRI1-F: Took Preventative Pills|DRRI1F01	Deployment Risk and Resilience Inventory-2 (DRRI-2) Either in preparation for or during my deployment: I took preventative pills (for example, to protect against nerve gas).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141942>	C141684	DRRI-2 - F: Received Vaccinations|DRRI1-F: Received Vaccinations|DRRI1-F: Received Vaccinations|DRRI1F02	Deployment Risk and Resilience Inventory-2 (DRRI-2) Either in preparation for or during my deployment: I received preventative vaccinations by injection (for example, to prevent anthrax or botulism).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141943>	C141684	DRRI-2 - F: Exposed to Nerve Gas Agents|DRRI1-F: Exposed to Nerve Gas Agents|DRRI1-F: Exposed to Nerve Gas Agents|DRRI1F03	Deployment Risk and Resilience Inventory-2 (DRRI-2) Either in preparation for or during my deployment: I was exposed to nerve gas agents (for example, sarin).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141944>	C141684	DRRI-2 - F: Exposed to Mustard Gas|DRRI1-F: Exposed to Mustard Gas|DRRI1-F: Exposed to Mustard Gas|DRRI1F04	Deployment Risk and Resilience Inventory-2 (DRRI-2) Either in preparation for or during my deployment: I was exposed to mustard gas or other blistering agents.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141945>	C141684	DRRI-2 - F: Exposed Government-issued DEET|DRRI1-F: Exposed Government-issued DEET|DRRI1-F: Exposed Government-issued DEET|DRRI1F05	Deployment Risk and Resilience Inventory-2 (DRRI-2) Either in preparation for or during my deployment: I was exposed to government-issued DEET-containing insect repellents.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141946>	C141684	DRRI-2 - F: Exposed to Other Pesticides|DRRI1-F: Exposed to Other Pesticides|DRRI1-F: Exposed to Other Pesticides|DRRI1F06	Deployment Risk and Resilience Inventory-2 (DRRI-2) Either in preparation for or during my deployment: I was exposed to other pesticides (for example, in flea collars, uniforms, or the environment).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141947>	C141684	DRRI-2 - F: Exposed to Smoke/Air Pollution|DRRI1-F: Exposed to Smoke/Air Pollution|DRRI1-F: Exposed to Smoke/Air Pollution|DRRI1F07	Deployment Risk and Resilience Inventory-2 (DRRI-2) Either in preparation for or during my deployment: I was exposed to smoke or other air pollution.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141948>	C141684	DRRI-2 - F: Exposed to Diesel/Fuel on Skin|DRRI1-F: Exposed to Diesel/Fuel on Skin|DRRI1-F: Exposed to Diesel/Fuel on Skin|DRRI1F08	Deployment Risk and Resilience Inventory-2 (DRRI-2) Either in preparation for or during my deployment: I was exposed to diesel or other petrochemical fuel on my skin.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141949>	C141684	DRRI-2 - F: Exposed to Fumes From Heaters|DRRI1-F: Exposed to Fumes From Heaters|DRRI1-F: Exposed to Fumes From Heaters|DRRI1F09	Deployment Risk and Resilience Inventory-2 (DRRI-2) Either in preparation for or during my deployment: I was exposed to fumes or exhaust from heaters or generators, including heaters in tents.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14194>	C14376	Chimera|Chimeric|chimeric	An organism with tissues derived from two or more genotypes; composed of parts that are of different origin.			Organism	
C141950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141950>	C141684	DRRI-2 - F: Exposed to Depleted Uranium|DRRI1-F: Exposed to Depleted Uranium|DRRI1-F: Exposed to Depleted Uranium|DRRI1F10	Deployment Risk and Resilience Inventory-2 (DRRI-2) Either in preparation for or during my deployment: I was exposed to depleted uranium in munitions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141951>	C141684	DRRI-2 - F: Exposed to Burning Trash/Feces|DRRI1-F: Exposed to Burning Trash/Feces|DRRI1-F: Exposed to Burning Trash/Feces|DRRI1F11	Deployment Risk and Resilience Inventory-2 (DRRI-2) Either in preparation for or during my deployment: I was exposed to burning trash or burning feces.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141952>	C141684	DRRI-2 - F: Exposed to Chlorine Gas|DRRI1-F: Exposed to Chlorine Gas|DRRI1-F: Exposed to Chlorine Gas|DRRI1F12	Deployment Risk and Resilience Inventory-2 (DRRI-2) Either in preparation for or during my deployment: I was exposed to chlorine gas.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141953>	C141684	DRRI-2 - F: Exposed to Nuclear Weapons|DRRI1-F: Exposed to Nuclear Weapons|DRRI1-F: Exposed to Nuclear Weapons|DRRI1F13	Deployment Risk and Resilience Inventory-2 (DRRI-2) Either in preparation for or during my deployment: I was exposed to nuclear, biological, or chemical weapons.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141954>	C141684	DRRI-2 - G: Concerned Infectious Disease|DRRI1-G: Concerned Infectious Disease|DRRI1-G: Concerned Infectious Disease|DRRI1G01	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was concerned about getting an infectious disease.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141955>	C141684	DRRI-2 - G: Health Might Suffer NBC Agents|DRRI1-G: Health Might Suffer NBC Agents|DRRI1-G: Health Might Suffer NBC Agents|DRRI1G02	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was concerned that my health might suffer due to exposure to nuclear, biological, or chemical (NBC) agents.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141956>	C141684	DRRI-2 - G: Felt in Danger of Being Wounded|DRRI1-G: Felt in Danger of Being Wounded|DRRI1-G: Felt in Danger of Being Wounded|DRRI1G03	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I felt I was in great danger of being wounded (for example, losing a limb).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141957>	C141684	DRRI-2 - G: Concerned Medicine Make Me Sick|DRRI1-G: Concerned Medicine Make Me Sick|DRRI1-G: Concerned Medicine Make Me Sick|DRRI1G04	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was concerned that the medicine I was given to protect me from illness would make me sick.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141958>	C141684	DRRI-2 - G: Concerned Encounter Explosive|DRRI1-G: Concerned Encounter Explosive|DRRI1-G: Concerned Encounter Explosive|DRRI1G05	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was concerned that I would encounter an explosive device (for example, a roadside bomb, mine, or booby trap).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141959>	C141684	DRRI-2 - G: Feared Sick From Pesticides|DRRI1-G: Feared Sick From Pesticides|DRRI1-G: Feared Sick From Pesticides|DRRI1G06	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I feared that I would become sick from pesticides (for example, bug spray) or other routinely used chemicals.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14195>	C77184	Cryptococcus neoformans|B. neoformans|Blastomyces neoformans|C. neoformans|CRYPTOCOCCUS NEOFORMANS|Crypto|D. neoformans|Debaryomyces neoformans|Filobasidiella neoformans|L. neoformans|Lipomyces neoformans|S. neoformans|Saccharomyces neoformans|T. neoformans|Torula neoformans|Torulopsis neoformans	A species of the fungus cryptococcus, the causative agent of cryptococcosis.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141960>	C141684	DRRI-2 - G: Concern Rocket/Mortar Would Hit|DRRI1-G: Concern Rocket/Mortar Would Hit|DRRI1-G: Concern Rocket/Mortar Would Hit|DRRI1G07	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was concerned that a rocket or mortar would hit our living quarters.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141961>	C141684	DRRI-2 - G: Concerned Depleted Uranium|DRRI1-G: Concerned Depleted Uranium|DRRI1-G: Concerned Depleted Uranium|DRRI1G08	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was concerned that I might be exposed to depleted uranium in munitions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141962>	C141684	DRRI-2 - G: Thought I Would Never Survive|DRRI1-G: Thought I Would Never Survive|DRRI1-G: Thought I Would Never Survive|DRRI1G09	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I thought I would never survive.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141963>	C141684	DRRI-2 - G: Concerned Taken Hostage|DRRI1-G: Concerned Taken Hostage|DRRI1-G: Concerned Taken Hostage|DRRI1G10	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was concerned that I might be taken hostage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141964>	C141684	DRRI-2 - G: Concerned Locals Against Us|DRRI1-G: Concerned Locals Against Us|DRRI1-G: Concerned Locals Against Us|DRRI1G11	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was concerned that the locals who were supposed to be helping us were actually working against us.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141965>	C141684	DRRI-2 - G: Concerned Trapped in Crossfire|DRRI1-G: Concerned Trapped in Crossfire|DRRI1-G: Concerned Trapped in Crossfire|DRRI1G12	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was concerned about being trapped in the crossfire of rival factions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141966>	C141684	DRRI-2 - H: Had All Supplies Needed|DRRI1-H: Had All Supplies Needed|DRRI1-H: Had All Supplies Needed|DRRI1H01	Deployment Risk and Resilience Inventory-2 (DRRI-2) In preparation for deployment: I had all the supplies and equipment needed to get my job done.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141967>	C141684	DRRI-2 - H: Confident Ability Use Equipment|DRRI1-H: Confident Ability Use Equipment|DRRI1-H: Confident Ability Use Equipment|DRRI1H02	Deployment Risk and Resilience Inventory-2 (DRRI-2) In preparation for deployment: the training I received made me feel confident in my ability to use my equipment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141968>	C141684	DRRI-2 - H: Prepared to Deal With Climate|DRRI1-H: Prepared to Deal With Climate|DRRI1-H: Prepared to Deal With Climate|DRRI1H03	Deployment Risk and Resilience Inventory-2 (DRRI-2) In preparation for deployment: the training I received prepared me to deal with the region's climate.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141969>	C141684	DRRI-2 - H: Accurately Informed About Role|DRRI1-H: Accurately Informed About Role|DRRI1-H: Accurately Informed About Role|DRRI1H04	Deployment Risk and Resilience Inventory-2 (DRRI-2) In preparation for deployment: I was accurately informed about the role my unit was expected to play in the deployment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14196>	C14217	Cytomegalovirus|CMV|CMV|CMV, CYTOMEGALOVIRUS|CYTOMEGALOVIRUS|Cytomegalovirus (CMV) Infection|HUMAN HERPESVIRUS 5|HUMAN HERPESVIRUS 5|cytomegalovirus	A genus of the family herpesviridae, subfamily betaherpesvirinae, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions.	Cytomegalovirus		Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C141970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141970>	C141684	DRRI-2 - H: Had Enough Gear in Case Attack|DRRI1-H: Had Enough Gear in Case Attack|DRRI1-H: Had Enough Gear in Case Attack|DRRI1H05	Deployment Risk and Resilience Inventory-2 (DRRI-2) In preparation for deployment: I had enough gear to protect myself in case of an attack.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141971>	C141684	DRRI-2 - H: Training for Deployment|DRRI1-H: Training for Deployment|DRRI1-H: Training for Deployment|DRRI1H06	Deployment Risk and Resilience Inventory-2 (DRRI-2) In preparation for deployment: I received appropriate training for the nature of the deployment I experienced.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141972>	C141684	DRRI-2 - H: Military Duties What I Expected|DRRI1-H: Military Duties What I Expected|DRRI1-H: Military Duties What I Expected|DRRI1H07	Deployment Risk and Resilience Inventory-2 (DRRI-2) In preparation for deployment: my military duties and assignments were what I expected.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141973>	C141684	DRRI-2 - H: Prepared to Operate as Team|DRRI1-H: Prepared to Operate as Team|DRRI1-H: Prepared to Operate as Team|DRRI1H08	Deployment Risk and Resilience Inventory-2 (DRRI-2) In preparation for deployment: my unit was well-prepared to operate as a team during deployment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141974>	C141684	DRRI-2 - H: Confident to Perform Tasks|DRRI1-H: Confident to Perform Tasks|DRRI1-H: Confident to Perform Tasks|DRRI1H09	Deployment Risk and Resilience Inventory-2 (DRRI-2) In preparation for deployment: the training I received made me feel confident in my ability to perform tasks assigned to me during deployment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141975>	C141684	DRRI-2 - H: Taught Me Everything I Needed|DRRI1-H: Taught Me Everything I Needed|DRRI1-H: Taught Me Everything I Needed|DRRI1H10	Deployment Risk and Resilience Inventory-2 (DRRI-2) In preparation for deployment: the training I received taught me everything I needed to know for deployment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141976>	C141684	DRRI-2 - I: Family Sincerely Interested|DRRI1-I: Family Sincerely Interested|DRRI1-I: Family Sincerely Interested|DRRI1I01	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: family members and/or friends at home were sincerely interested in hearing what was going on with me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141977>	C141684	DRRI-2 - I: Had Family I Could Talk To|DRRI1-I: Had Family I Could Talk To|DRRI1-I: Had Family I Could Talk To|DRRI1I02	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I had family members or friends at home I could talk to when I had a problem.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141978>	C141684	DRRI-2 - I: Could Count on Family Advice|DRRI1-I: Could Count on Family Advice|DRRI1-I: Could Count on Family Advice|DRRI1I03	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I could count on my family members or friends at home for good advice.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141979>	C141684	DRRI-2 - I: Relatives Look Out for Family|DRRI1-I: Relatives Look Out for Family|DRRI1-I: Relatives Look Out for Family|DRRI1I04	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: relatives or friends at home could be counted on to look out for the well-being of my family or other dependents (including pets).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14197>	C14227	Diptera|Flies	A large order of insects having a single pair of wings and sucking or piercing mouths; includes true flies and mosquitoes and gnats and crane flies.			Eukaryote	
C141980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141980>	C141684	DRRI-2 - I: Relatives Take Care of Finances|DRRI1-I: Relatives Take Care of Finances|DRRI1-I: Relatives Take Care of Finances|DRRI1I05	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: relatives or friends at home could be counted on to take care of my finances, property, or belongings if needed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141981>	C141684	DRRI-2 - I: Happy Communication From Home|DRRI1-I: Happy Communication From Home|DRRI1-I: Happy Communication From Home|DRRI1I06	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was happy with the amount of communication I received from people at home.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141982>	C141684	DRRI-2 - I: Happy With Support From Home|DRRI1-I: Happy With Support From Home|DRRI1-I: Happy With Support From Home|DRRI1I07	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I was happy with the amount of support I received from people at home.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141983>	C141684	DRRI-2 - I: People at Home Show They Cared|DRRI1-I: People at Home Show They Cared|DRRI1-I: People at Home Show They Cared|DRRI1I08	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: people at home did things to show they cared about me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141984>	C141684	DRRI-2 - J: My Unit Was Like Family to Me|DRRI1-J: My Unit Was Like Family to Me|DRRI1-J: My Unit Was Like Family to Me|DRRI1J01	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: my unit was like family to me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141985>	C141684	DRRI-2 - J: People in Unit Were Trustworthy|DRRI1-J: People in Unit Were Trustworthy|DRRI1-J: People in Unit Were Trustworthy|DRRI1J02	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: people in my unit were trustworthy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141986>	C141684	DRRI-2 - J: Fellow Unit Appreciated Efforts|DRRI1-J: Fellow Unit Appreciated Efforts|DRRI1-J: Fellow Unit Appreciated Efforts|DRRI1J03	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: my fellow unit members appreciated my efforts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141987>	C141684	DRRI-2 - J: Felt Valued Fellow Unit Members|DRRI1-J: Felt Valued Fellow Unit Members|DRRI1-J: Felt Valued Fellow Unit Members|DRRI1J04	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I felt valued by my fellow unit members.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141988>	C141684	DRRI-2 - J: Unit Interested My Well-being|DRRI1-J: Unit Interested My Well-being|DRRI1-J: Unit Interested My Well-being|DRRI1J05	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: members of my unit were interested in my well-being.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141989>	C141684	DRRI-2 - J: Unit Interested What I Thought|DRRI1-J: Unit Interested What I Thought|DRRI1-J: Unit Interested What I Thought|DRRI1J06	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: my fellow unit members were interested in what I thought and how I felt about things.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14198>	C14316	Disease Vector|Disease Vectors|Vector|Vector (Infectious Agent)	An invertebrate animal (e.g., tick, mite, mosquito, bloodsucking fly) capable of transmitting an infectious agent among vertebrates.			Eukaryote	NICHD Terminology|Pediatric Infectious Disease Terminology
C141990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141990>	C141684	DRRI-2 - J: Leader Interested What Thought|DRRI1-J: Leader Interested What Thought|DRRI1-J: Leader Interested What Thought|DRRI1J07	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: my unit leader(s) were interested in what I thought and how I felt about things.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141991>	C141684	DRRI-2 - J: Felt Like My Efforts Counted|DRRI1-J: Felt Like My Efforts Counted|DRRI1-J: Felt Like My Efforts Counted|DRRI1J08	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I felt like my efforts really counted to the leaders in my unit.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141992>	C141684	DRRI-2 - J: Service Appreciated by Leaders|DRRI1-J: Service Appreciated by Leaders|DRRI1-J: Service Appreciated by Leaders|DRRI1J09	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: my service was appreciated by the leaders in my unit.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141993>	C141684	DRRI-2 - J: Could Go to Leaders If Problem|DRRI1-J: Could Go to Leaders If Problem|DRRI1-J: Could Go to Leaders If Problem|DRRI1J10	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I could go to unit leaders for help if I had a problem or concern.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141994>	C141684	DRRI-2 - J: Leaders Interested in Welfare|DRRI1-J: Leaders Interested in Welfare|DRRI1-J: Leaders Interested in Welfare|DRRI1J11	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: the leaders of my unit were interested in my personal welfare.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141995>	C141684	DRRI-2 - J: Felt Valued by Leaders of Unit|DRRI1-J: Felt Valued by Leaders of Unit|DRRI1-J: Felt Valued by Leaders of Unit|DRRI1J12	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I felt valued by the leaders of my unit.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141996>	C141684	DRRI-2 - K: Treated in Overly Critical Way|DRRI1-K: Treated in Overly Critical Way|DRRI1-K: Treated in Overly Critical Way|DRRI1K01	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, the people I worked with: treated me in an overly critical way.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141997>	C141684	DRRI-2 - K: Uncooperative Working With Me|DRRI1-K: Uncooperative Working With Me|DRRI1-K: Uncooperative Working With Me|DRRI1K02	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, the people I worked with: behaved in way that was uncooperative when working with me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141998>	C141684	DRRI-2 - K: Had to Work Harder Prove Myself|DRRI1-K: Had to Work Harder Prove Myself|DRRI1-K: Had to Work Harder Prove Myself|DRRI1K03	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, the people I worked with: treated me as if I had to work harder than others to prove myself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C141999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C141999>	C141684	DRRI-2 - K: Questioned My Abilities Perform|DRRI1-K: Questioned My Abilities Perform|DRRI1-K: Questioned My Abilities Perform|DRRI1K04	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, the people I worked with: questioned my abilities or commitment to perform my job effectively.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14199>	C14249	DNA Tumor Virus	A virus which uses DNA to code its genome and causes tumors in animals.			Virus	
C1419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1419>	C2124	Technetium Tc-99m Sestamibi|Cardiolite|Miraluma|TECHNETIUM TC-99M SESTAMIBI|Tc 99m Sestamibi|Tc-99m MIBI|Tc99m Sestamibi|Technetium (99mTc) Sestamibi	Sestamibi is a large synthetic molecule of the isonitrile family, which can be labeled with Tc99m.  It passes through cells membranes passively, collecting in cells with large numbers of mitochondria.  It is often used for imaging of the thyroid and parathyroid.			Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C142000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142000>	C141684	DRRI-2 - K: My Mistakes Worse Than Others|DRRI1-K: My Mistakes Worse Than Others|DRRI1-K: My Mistakes Worse Than Others|DRRI1K05	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, the people I worked with: acted as though my mistakes were worse than others'.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142001>	C141684	DRRI-2 - K: Make My Job More Difficult|DRRI1-K: Make My Job More Difficult|DRRI1-K: Make My Job More Difficult|DRRI1K06	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, the people I worked with: tried to make my job more difficult to do.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142002>	C141684	DRRI-2 - K: Put Me Down|DRRI1-K: Put Me Down|DRRI1-K: Put Me Down|DRRI1K07	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, the people I worked with: "put me down" or treated me in a condescending way.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142003>	C141684	DRRI-2 - K: Threatened My Physical Safety|DRRI1-K: Threatened My Physical Safety|DRRI1-K: Threatened My Physical Safety|DRRI1K08	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, the people I worked with: threatened my physical safety.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142004>	C141684	DRRI-2 - K: Made Crude Sexual Remarks at Me|DRRI1-K: Made Crude Sexual Remarks at Me|DRRI1-K: Made Crude Sexual Remarks at Me|DRRI1K09	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, the people I worked with: made crude and offensive sexual remarks directed at me, either publicly or privately.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142005>	C141684	DRRI-2 - K: Spread Rumors Sexual Activities|DRRI1-K: Spread Rumors Sexual Activities|DRRI1-K: Spread Rumors Sexual Activities|DRRI1K10	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, the people I worked with: spread negative rumors about my sexual activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142006>	C141684	DRRI-2 - K: Tried to Talk into Sexual Acts|DRRI1-K: Tried to Talk into Sexual Acts|DRRI1-K: Tried to Talk into Sexual Acts|DRRI1K11	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, the people I worked with: tried to talk me into participating in sexual acts when I didn't want to.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142007>	C141684	DRRI-2 - K: Authority Pressure Unwanted Sex|DRRI1-K: Authority Pressure Unwanted Sex|DRRI1-K: Authority Pressure Unwanted Sex|DRRI1K12	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, the people I worked with: used a position of authority to pressure me into unwanted sexual activity.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142008>	C141684	DRRI-2 - K: Offered Reward Take Part in Sex|DRRI1-K: Offered Reward Take Part in Sex|DRRI1-K: Offered Reward Take Part in Sex|DRRI1K13	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, the people I worked with: offered me a specific reward or special treatment to take part in sexual behavior.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142009>	C141684	DRRI-2 - K: Threatened Me If Not Sex|DRRI1-K: Threatened Me If Not Sex|DRRI1-K: Threatened Me If Not Sex|DRRI1K14	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, the people I worked with: threatened me with some sort of retaliation if I was not sexually cooperative (for example, the threat of negative review or physical violence).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14200>	C14283	DNA Virus|Virus, DNA|Virus-DNA|Viruses, DNA	A virus that has DNA as its genetic material and does not use an RNA intermediate during replication.			Virus	
C142010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142010>	C141684	DRRI-2 - K: Touched Sexual Way Against Will|DRRI1-K: Touched Sexual Way Against Will|DRRI1-K: Touched Sexual Way Against Will|DRRI1K15	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, the people I worked with: touched me in a sexual way against my will.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142011>	C141684	DRRI-2 - K: Physically Forced to Have Sex|DRRI1-K: Physically Forced to Have Sex|DRRI1-K: Physically Forced to Have Sex|DRRI1K16	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, the people I worked with: physically forced me to have sex.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142012>	C141684	DRRI-2 - L: Effect Deployment Relationship|DRRI1-L: Effect Deployment Relationship|DRRI1-L: Effect Deployment Relationship|DRRI1L01	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, I was concerned about: the effect of the deployment on my relationship with my spouse or significant other.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142013>	C141684	DRRI-2 - L: Missing Out on Children Growth|DRRI1-L: Missing Out on Children Growth|DRRI1-L: Missing Out on Children Growth|DRRI1L02	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, I was concerned about: missing out on my children's growth and development.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142014>	C141684	DRRI-2 - L: Missing Family Events at Home|DRRI1-L: Missing Family Events at Home|DRRI1-L: Missing Family Events at Home|DRRI1L03	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, I was concerned about: missing important family events at home such as birthdays, weddings, funerals, graduations, etc.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142015>	C141684	DRRI-2 - L: Safety and Well-being of Spouse|DRRI1-L: Safety and Well-being of Spouse|DRRI1-L: Safety and Well-being of Spouse|DRRI1L04	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, I was concerned about: the safety and well-being of my spouse or significant other.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142016>	C141684	DRRI-2 - L: Safety and Well-being of Child|DRRI1-L: Safety and Well-being of Child|DRRI1-L: Safety and Well-being of Child|DRRI1L05	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, I was concerned about: the safety and well-being of my child(ren).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142017>	C141684	DRRI-2 - L: Unable to Help Family If Crisis|DRRI1-L: Unable to Help Family If Crisis|DRRI1-L: Unable to Help Family If Crisis|DRRI1L06	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, I was concerned about: being unable to help my family if there was some kind of crisis or emergency.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142018>	C141684	DRRI-2 - L: Inability Manage Family Affairs|DRRI1-L: Inability Manage Family Affairs|DRRI1-L: Inability Manage Family Affairs|DRRI1L07	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, I was concerned about: my inability to directly manage or control family affairs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142019>	C141684	DRRI-2 - L: Damaging Career Because Deploy|DRRI1-L: Damaging Career Because Deploy|DRRI1-L: Damaging Career Because Deploy|DRRI1L08	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, I was concerned about: damaging my career because of the deployment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14201>	C14331	Dog|CANIS FAMILIARIS|Canine|Canine Species|Canis canis|Canis domesticus|Canis familiaris|Canis lupus familiaris|DOG|Mammals, Dogs	The domestic dog, Canis familiaris.			Mammal	CDISC SEND Genus and Species Response Terminology|CDISC SEND Laboratory Animal Species Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142020>	C141684	DRRI-2 - L: Care Child/Dependents Receiving|DRRI1-L: Care Child/Dependents Receiving|DRRI1-L: Care Child/Dependents Receiving|DRRI1L09	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, I was concerned about: the care that my child(ren) or other dependents were receiving.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142021>	C141684	DRRI-2 - L: Being Cheated on by My Spouse|DRRI1-L: Being Cheated on by My Spouse|DRRI1-L: Being Cheated on by My Spouse|DRRI1L10	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, I was concerned about: being cheated on by my spouse or significant other.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142022>	C141684	DRRI-2 - L: Family Ability Cope With Stress|DRRI1-L: Family Ability Cope With Stress|DRRI1-L: Family Ability Cope With Stress|DRRI1L11	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, I was concerned about: my family's ability to cope with the stress of the deployment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142023>	C141684	DRRI-2 - L: Spouse Ability Manage Household|DRRI1-L: Spouse Ability Manage Household|DRRI1-L: Spouse Ability Manage Household|DRRI1L12	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, I was concerned about: my spouse or significant other's ability to manage the household (for example, chores, bills, home repairs, etc.).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142024>	C141684	DRRI-2 - L: Losing My Civilian Job|DRRI1-L: Losing My Civilian Job|DRRI1-L: Losing My Civilian Job|DRRI1L13	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, I was concerned about: losing my civilian job because of the deployment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142025>	C141684	DRRI-2 - L: Effect Relationship My Children|DRRI1-L: Effect Relationship My Children|DRRI1-L: Effect Relationship My Children|DRRI1L14	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, I was concerned about: the effect of the deployment on my relationship with my child(ren).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142026>	C141684	DRRI-2 - L: My Family Financial Situation|DRRI1-L: My Family Financial Situation|DRRI1-L: My Family Financial Situation|DRRI1L15	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment, I was concerned about: my family's financial situation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142027>	C141684	DRRI-2 - M: Problems Get in Touch Family|DRRI1-M: Problems Get in Touch Family|DRRI1-M: Problems Get in Touch Family|DRRI1M01	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I had problems getting in touch with a family member or other loved one.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142028>	C141684	DRRI-2 - M: Someone Close Serious Illness|DRRI1-M: Someone Close Serious Illness|DRRI1-M: Someone Close Serious Illness|DRRI1M02	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: someone close to me experienced a serious illness, injury, or mental health problem (for example, cancer, alcohol/drug problem).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142029>	C141684	DRRI-2 - M: Family Member Passed Away|DRRI1-M: Family Member Passed Away|DRRI1-M: Family Member Passed Away|DRRI1M03	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: a family member or other loved one passed away.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14202>	C14197	Drosophila	A genus of small, American flies, Diptera. The best known species is D. Melanogaster, often called the fruit fly, but more correctly termed the vinegar fly. First investigated by T.H.Morgan and his group, it has been extensively used in genetic studies. More recently it has been used for studies of embryonic development.			Eukaryote	
C142030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142030>	C141684	DRRI-2 - M: My Family Had Money Problems|DRRI1-M: My Family Had Money Problems|DRRI1-M: My Family Had Money Problems|DRRI1M04	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: my family had money problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142031>	C141684	DRRI-2 - M: Spouse Cheated on Me|DRRI1-M: Spouse Cheated on Me|DRRI1-M: Spouse Cheated on Me|DRRI1M05	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: a spouse or significant other cheated on me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142032>	C141684	DRRI-2 - M: Spouse Suspected I Cheated|DRRI1-M: Spouse Suspected I Cheated|DRRI1-M: Spouse Suspected I Cheated|DRRI1M06	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: a spouse or significant other suspected that I had cheated on him/her.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142033>	C141684	DRRI-2 - M: Relationship With Spouse Ended|DRRI1-M: Relationship With Spouse Ended|DRRI1-M: Relationship With Spouse Ended|DRRI1M07	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: my relationship with a spouse or significant other ended.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142034>	C141684	DRRI-2 - M: Had Major Conflict With Family|DRRI1-M: Had Major Conflict With Family|DRRI1-M: Had Major Conflict With Family|DRRI1M08	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I had a major conflict with a family member or other loved one.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142035>	C141684	DRRI-2 - M: Family Had Difficulty Adjusting|DRRI1-M: Family Had Difficulty Adjusting|DRRI1-M: Family Had Difficulty Adjusting|DRRI1M09	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: a family member or other loved one had serious difficulty adjusting to my absence.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142036>	C141684	DRRI-2 - M: My Home Was Robbed|DRRI1-M: My Home Was Robbed|DRRI1-M: My Home Was Robbed|DRRI1M10	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: my home was robbed and/or my belongings were stolen.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142037>	C141684	DRRI-2 - M: Family Member Wasted Money|DRRI1-M: Family Member Wasted Money|DRRI1-M: Family Member Wasted Money|DRRI1M11	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: a family member or other person I trusted wasted or mismanaged my money.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142038>	C141684	DRRI-2 - M: Loved One Things I Disapproved|DRRI1-M: Loved One Things I Disapproved|DRRI1-M: Loved One Things I Disapproved|DRRI1M12	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: I learned that a loved one was doing things I disapproved of.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142039>	C141684	DRRI-2 - M: Fam Dangerous Military Duties|DRRI1-M: Fam Dangerous Military Duties|DRRI1-M: Fam Dangerous Military Duties|DRRI1M13	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: a family member or other loved one participated in dangerous military duties.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14203>	C14256	Enterovirus|ENTEROVIRUS	A (+) strand single strand RNA virus of the picornavirus family.  Poliovirus is an enterovirus.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142040>	C141684	DRRI-2 - M: Family Got Into Trouble|DRRI1-M: Family Got Into Trouble|DRRI1-M: Family Got Into Trouble|DRRI1M14	Deployment Risk and Resilience Inventory-2 (DRRI-2) During deployment: a family member got into trouble at home, at school, or in the community.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142041>	C141684	DRRI-2 - N: Robbed/Had My Home Broken Into|DRRI1-N: Robbed/Had My Home Broken Into|DRRI1-N: Robbed/Had My Home Broken Into|DRRI1N01	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I was robbed or had my home broken into.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142042>	C141684	DRRI-2 - N: Unwanted Sexual Activity|DRRI1-N: Unwanted Sexual Activity|DRRI1-N: Unwanted Sexual Activity|DRRI1N02	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I experienced unwanted sexual activity as a result of force, threat or harm, or manipulation.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142043>	C141684	DRRI-2 - N: Went Through Divorce/Was Left|DRRI1-N: Went Through Divorce/Was Left|DRRI1-N: Went Through Divorce/Was Left|DRRI1N03	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I went through a divorce or have been left by a partner or significant other.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142044>	C141684	DRRI-2 - N: Problems Getting Healthcare|DRRI1-N: Problems Getting Healthcare|DRRI1-N: Problems Getting Healthcare|DRRI1N04	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I had problems getting access to adequate healthcare.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142045>	C141684	DRRI-2 - N: Experienced Natural Disaster|DRRI1-N: Experienced Natural Disaster|DRRI1-N: Experienced Natural Disaster|DRRI1N05	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I experienced a natural disaster (for example, a hurricane), a fire, or an accident in which I or someone close to me was hurt or had serious property damage.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142046>	C141684	DRRI-2 - N: Someone Close Serious Illness|DRRI1-N: Someone Close Serious Illness|DRRI1-N: Someone Close Serious Illness|DRRI1N06	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: someone close to me has experienced a serious illness, injury, or mental health problem (for example, cancer, alcohol/drug problem).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142047>	C141684	DRRI-2 - N: Witnessed Someone Assaulted|DRRI1-N: Witnessed Someone Assaulted|DRRI1-N: Witnessed Someone Assaulted|DRRI1N07	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I have witnessed someone being seriously assaulted or killed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142048>	C141684	DRRI-2 - N: Lost My Job/Trouble Finding Job|DRRI1-N: Lost My Job/Trouble Finding Job|DRRI1-N: Lost My Job/Trouble Finding Job|DRRI1N08	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I lost my job or had serious trouble finding a job.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142049>	C141684	DRRI-2 - N: Emotionally Mistreated|DRRI1-N: Emotionally Mistreated|DRRI1-N: Emotionally Mistreated|DRRI1N09	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I have been emotionally mistreated (for example, ignored or repeatedly told I was no good).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14204>	C14217	Epstein-Barr Virus|EBV|EBV|EBV|EPSTEIN-BARR VIRUS|Epstein Barr Virus|Epstein-Barr virus|HHV-4|HHV-4|HUMAN HERPESVIRUS 4|Human Gammaherpesvirus 4|Human Gammaherpesvirus 4|Human Herpesvirus 4|Human Herpesvirus 4|Lymphocryptovirus|Virus-Epstein-Barr	A species of Herpetoviridae that is responsible for infectious mononucleosis (glandular fever). Discovered in 1964, this virus has been associated with Burkitt's lymphoma in South African children and with nasopharyngeal carcinoma in Asian populations.	Epstein-Barr Virus		Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142050>	C141684	DRRI-2 - N: Serious Financial Problems|DRRI1-N: Serious Financial Problems|DRRI1-N: Serious Financial Problems|DRRI1N10	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I have experienced serious financial problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142051>	C141684	DRRI-2 - N: Serious Physical Health Problem|DRRI1-N: Serious Physical Health Problem|DRRI1-N: Serious Physical Health Problem|DRRI1N11	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I have experienced serious physical or mental health problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142052>	C141684	DRRI-2 - N: Stressful Legal Problems|DRRI1-N: Stressful Legal Problems|DRRI1-N: Stressful Legal Problems|DRRI1N12	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I have experienced stressful legal problems (for example, being sued, suing someone else, or being in a custody battle).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142053>	C141684	DRRI-2 - N: Injured by Another Person|DRRI1-N: Injured by Another Person|DRRI1-N: Injured by Another Person|DRRI1N13	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I have been seriously physically injured by another person (for example, hit or beaten up).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142054>	C141684	DRRI-2 - N: Someone Close to Me Has Died|DRRI1-N: Someone Close to Me Has Died|DRRI1-N: Someone Close to Me Has Died|DRRI1N14	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: someone close to me has died.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142055>	C141684	DRRI-2 - O: People Made Me Feel at Home|DRRI1-O: People Made Me Feel at Home|DRRI1-O: People Made Me Feel at Home|DRRI1O01	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: the American people made me feel at home.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142056>	C141684	DRRI-2 - O: People Made Me Feel Proud|DRRI1-O: People Made Me Feel Proud|DRRI1-O: People Made Me Feel Proud|DRRI1O02	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: people made me feel proud to have served my country in the Armed Forces.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142057>	C141684	DRRI-2 - O: Family Make Me Better When Down|DRRI1-O: Family Make Me Better When Down|DRRI1-O: Family Make Me Better When Down|DRRI1O03	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: my family members and/or friends make me feel better when I am down.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142058>	C141684	DRRI-2 - O: Go to Family When Need Advice|DRRI1-O: Go to Family When Need Advice|DRRI1-O: Go to Family When Need Advice|DRRI1O04	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I can go to family members or friends when I need good advice.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142059>	C141684	DRRI-2 - O: Family/Friends Understand|DRRI1-O: Family/Friends Understand|DRRI1-O: Family/Friends Understand|DRRI1O05	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: my family and friends understand what I have been through in the Armed Forces.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14205>	C117713	Equine Infectious Anemia Virus|EIAV	A species of lentivirus, subgenus equine lentiviruses, causing acute and chronic infection in horses. It is transmitted mechanically by biting flies, mosquitoes, and midges, and iatrogenically through unsterilized equipment. Chronic infection often consists of acute episodes with remissions.			Virus	
C142060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142060>	C141684	DRRI-2 - O: I Can Talk About My Deployment|DRRI1-O: I Can Talk About My Deployment|DRRI1-O: I Can Talk About My Deployment|DRRI1O06	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: there are family and/or friends with whom I can talk about my deployment experiences.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142061>	C141684	DRRI-2 - O: Family Would Lend Money|DRRI1-O: Family Would Lend Money|DRRI1-O: Family Would Lend Money|DRRI1O07	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: my family members or friends would lend me money if I needed it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142062>	C141684	DRRI-2 - O: Family Would Help Move|DRRI1-O: Family Would Help Move|DRRI1-O: Family Would Help Move|DRRI1O08	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: my family members or friends would help me move my belongings if I needed help.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142063>	C141684	DRRI-2 - O: Someone Would Help With Tasks|DRRI1-O: Someone Would Help With Tasks|DRRI1-O: Someone Would Help With Tasks|DRRI1O09	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: if I were unable to attend to daily chores, there is someone who would help me with these tasks.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142064>	C141684	DRRI-2 - O: When Ill Family Will Help Out|DRRI1-O: When Ill Family Will Help Out|DRRI1-O: When Ill Family Will Help Out|DRRI1O10	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: when I am ill, family members or friends will help out until I am well.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142065>	C141684	DRRI-2 - P: Input Sought Family Decisions|DRRI1-P: Input Sought Family Decisions|DRRI1-P: Input Sought Family Decisions|DRRI1P01	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: my input is sought on important family decisions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142066>	C141684	DRRI-2 - P: Feel Like I Fit in With Family|DRRI1-P: Feel Like I Fit in With Family|DRRI1-P: Feel Like I Fit in With Family|DRRI1P02	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I feel like I fit in with my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142067>	C141684	DRRI-2 - P: Family Know What I Think/Feel|DRRI1-P: Family Know What I Think/Feel|DRRI1-P: Family Know What I Think/Feel|DRRI1P03	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: family members know what I think and how I feel about things.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142068>	C141684	DRRI-2 - P: Contribution Family Appreciated|DRRI1-P: Contribution Family Appreciated|DRRI1-P: Contribution Family Appreciated|DRRI1P04	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I feel like my contributions to my family are appreciated.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142069>	C141684	DRRI-2 - P: Share Interests With Family|DRRI1-P: Share Interests With Family|DRRI1-P: Share Interests With Family|DRRI1P05	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I share many common interests and activities with family members.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14206>	C77208	Escherichia coli|E. coli|E. coli|ESCHERICHIA COLI|ESCHERICHIA COLI	A common, gram negative gut bacterium that has been studied intensively by geneticists because of its small genome size, normal lack of pathogenicity, and ease of growth in the laboratory.	Escherichia coli		Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|CDISC SEND Laboratory Animal Species Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142070>	C141684	DRRI-2 - P: Opinions Valued by Family|DRRI1-P: Opinions Valued by Family|DRRI1-P: Opinions Valued by Family|DRRI1P06	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: my opinions are valued by other family members.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142071>	C141684	DRRI-2 - P: I am Affectionate With Family|DRRI1-P: I am Affectionate With Family|DRRI1-P: I am Affectionate With Family|DRRI1P07	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I am affectionate with family members.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142072>	C141684	DRRI-2 - P: Play Important Role in Family|DRRI1-P: Play Important Role in Family|DRRI1-P: Play Important Role in Family|DRRI1P08	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I play an important role in my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142073>	C141684	DRRI-2 - P: Spend My Free Time With Family|DRRI1-P: Spend My Free Time With Family|DRRI1-P: Spend My Free Time With Family|DRRI1P09	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I spend as much of my free time with family members as possible.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142074>	C141684	DRRI-2 - P: Family Tell Me When Problem|DRRI1-P: Family Tell Me When Problem|DRRI1-P: Family Tell Me When Problem|DRRI1P10	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: family members tell me when they are having a problem.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142075>	C141684	DRRI-2 - P: Can Be Myself Around Family|DRRI1-P: Can Be Myself Around Family|DRRI1-P: Can Be Myself Around Family|DRRI1P11	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I can be myself around family members.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142076>	C141684	DRRI-2 - P: I Get Along Well With My Family|DRRI1-P: I Get Along Well With My Family|DRRI1-P: I Get Along Well With My Family|DRRI1P12	Deployment Risk and Resilience Inventory-2 (DRRI-2) Since returning: I get along well with my family members.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire DRRI-2 Test Code Terminology|CDISC Questionnaire DRRI-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142077>	C134305	Favezelimab|Anti-LAG-3 Monoclonal Antibody MK-4280|Anti-LAG3 Monoclonal Antibody MK-4280|FAVEZELIMAB|MK 4280|MK-4280|MK4280	A humanized, immunoglobulin G4 (IgG4) monoclonal antibody (MAb) directed against the inhibitory receptor lymphocyte activation gene-3 protein (LAG3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, favezelimab binds to LAG3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells, and negatively regulates both proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.	Favezelimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C142078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142078>	C308|C208191	Adoptive Cell Therapy Agent|ACT Agent|Adoptive Cell Transfer Agent|Adoptive Cell-based Agent|Adoptive Cellular Therapy Agent|Adoptive Immunotherapy|Cellular Immunotherapy Agent|Cellular Therapy Product	A preparation of allogeneic or autologous cells that is meant to be administered to a patient and may have an immunotherapeutic effect.	Adoptive Cell Therapy Agent		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C142079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142079>	C84828	Limb-Girdle Muscular Dystrophy Type 2A|Autosomal Recessive Muscular Dystrophy Limb-Girdle 1|LGMD2A|LGMDR1	An autosomal recessive condition caused by mutation(s) in the CAPN3 gene, encoding calpain-3. It is characterized by muscular dystrophy, primarily affecting the proximal muscles, resulting in difficulty walking.			Disease or Syndrome	Cellosaurus Disease Terminology
C14207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14207>	C14282	Fish|FISH|Fish (NOS)	A grouping of jawed and jawless vertebrate animals usually having fins and a covering of scales or plates, breathing by means of gills, and living almost entirely in the water.			Fish	CDISC SEND Laboratory Animal Species Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142080>	C84828	Limb-Girdle Muscular Dystrophy Type 2B|Autosomal Recessive Muscular Dystrophy Limb-Girdle 2|LGMD2B|LGMDR2	An autosomal recessive condition caused by mutation(s) in the DYSF gene, encoding dysferlin. It is characterized by progressive muscular dystrophy, primarily affecting the proximal muscles, resulting in difficulty walking.			Disease or Syndrome	Cellosaurus Disease Terminology
C142081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142081>	C84828	Limb-Girdle Muscular Dystrophy Type 2D|Autosomal Recessive Muscular Dystrophy Limb-Girdle 3|LGMD2D|LGMDR3	An autosomal recessive condition caused by mutation(s) in the SGCA gene, encoding alpha-sarcoglycan. It is characterized by progressive muscular dystrophy, primarily affecting the proximal muscles, resulting in difficulty walking.			Disease or Syndrome	Cellosaurus Disease Terminology
C142082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142082>	C84828	Limb-Girdle Muscular Dystrophy Type 2Z|Autosomal Recessive Muscular Dystrophy Limb-Girdle 21|LGMD2Z|LGMDR21	An autosomal recessive condition caused by mutation(s) in the POGLUT1 gene, encoding protein O-glucosyltransferase 1. It is characterized by progressive muscular dystrophy, primarily affecting the proximal muscles, resulting in difficulty walking.			Disease or Syndrome	Cellosaurus Disease Terminology
C142083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142083>	C53543	Coenzyme Q10 Deficiency	A genetically heterogeneous condition, typically inherited in an autosomal recessive fashion, characterized by coenzyme Q10 deficiency.			Disease or Syndrome	Cellosaurus Disease Terminology
C142084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142084>	C53543|C2902	Bleeding Disorder, Platelet-Type 17|BDPLT17	An autosomal dominant condition caused by mutation(s) in the GFI1B gene, encoding zinc finger protein Gfi-1b. It is characterized by a tendency for increased bleeding due to abnormal platelet function.			Disease or Syndrome	Cellosaurus Disease Terminology
C142085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142085>	C53543	Aromatic L-Amino-Acid Decarboxylase Deficiency|AADC Deficiency	An autosomal recessive condition caused by mutation(s) in the DDC gene, encoding aromatic-L-amino-acid decarboxylase. It is characterized by combined serotonin and catecholamine deficiency, resulting in severe neurologic dysfunction usually beginning in infancy or childhood.			Disease or Syndrome	Cellosaurus Disease Terminology
C142086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142086>	C2196	Fascin Inhibitor NP-G2-044|2-Methyl-N-(1-((4-(trifluoromethyl)phenyl)methyl)-1H-indazol-3-yl)-3-furancarboxamide|NP G2 044|NP-G2-044|NP-G2-044	An orally available inhibitor of the protein fascin, with potential antineoplastic activity. Upon oral administration, NP-G2-044 targets and binds to fascin, thereby preventing the interaction of fascin with actin filaments, thereby preventing actin bundling and filopodia formation. By preventing actin cytoskeletal reorganization, the dynamic changes in cell shape that are necessary for tumor cell migration and invasion to occur are impaired, and tumor cell migration and metastasis are inhibited. Fascin, the main actin cross-linker protein in filopodia, is upregulated in many types of metastatic tumor cells while its expression is low or absent in normal adult epithelial cells; its expression is correlated with aggressive phenotypes, poor prognosis, and shorter survival. Filopodia, finger-like plasma membrane protrusions that are formed upon remodeling of the actin cytoskeleton, are found at a high frequency in metastatic tumor cells and their presence is correlated with tumor cell invasiveness.	Fascin Inhibitor NP-G2-044		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C142087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142087>	C39877	FGFR3 NM_000142.4:c.1948A>G|CD333 c.1948A>G|FGFR3 c.1948A>G|Fibroblast Growth Factor Receptor 3 c.1948A>G|JTK4 c.1948A>G|NM_000142.4:c.1948A>G	A nucleotide substitution at position 1948 of the coding sequence of the FGFR3 gene where adenine has been mutated to guanine.	FGFR3 NM_000142.4:c.1948A>G		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142088>	C128903	FGFR3 NP_000133.1:p.K650E|CD333 Antigen K650E|CD333 Antigen Lys650Glu|FGFR-3 K650E|FGFR-3 Lys650Glu|FGFR-3 p.K650E|FGFR-3 p.Lys650Glu|FGFR3 K650E|FGFR3 K652E Mutation|FGFR3 Lys650Glu|FGFR3 NP_000133.1:p.Lys650Glu|FGFR3 NP_001156685.1:p.K652E|FGFR3 NP_001156685.1:p.Lys652Glu|FGFR3 p.K650E|FGFR3 p.Lys650Glu|Fibroblast Growth Factor Receptor 3 K650E|Fibroblast Growth Factor Receptor 3 Lys650Glu|NP_000133.1:p.K650E|NP_000133.1:p.Lys650Glu|NP_001156685.1:p.K652E|NP_001156685.1:p.Lys652Glu|Tyrosine Kinase JTK4 K650E|Tyrosine Kinase JTK4 Lys650Glu	A change in the amino acid residue at position 250 in the fibroblast growth factor receptor 3 protein where lysine has been replaced by glutamic acid.	FGFR3 NP_000133.1:p.K650E		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142089>	C136634	FLT3 NM_004119.2:c.2525A>G|CD135 c.2525A>G|FLK2 c.2525A>G|FLT3 c.2525A>G|FMS-Related Tyrosine Kinase 3 c.2525A>G|NM_004119.2:c.2525A>G	A nucleotide substitution at position 2525 of the coding sequence of the FLT3 gene where adenine has been mutated to guanine.	FLT3 NM_004119.2:c.2525A>G		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C14208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14208>	C113201	Flavivirus|Arboviruses Group B|FLAVIVIRUS	A genus of enveloped viruses with a genome consisting of a single molecule of linear positive-sense single-stranded RNA.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142090>	C167187	FLT3 NP_004110.2:p.Y842C|CD135 Antigen Tyr842Cys|CD135 Antigen Y842C|FLT3 NP_004110.2:p.Tyr842Cys|FLT3 Tyr842Cys|FLT3 Y842C|FLT3 Y842C Mutation|FLT3 p.Tyr842Cys|FLT3 p.Y842C|Fetal Liver Kinase-2 Tyr842Cys|Fetal Liver Kinase-2 Y842C|Flt-3 Receptor Tyr842Cys|Flt-3 Receptor Y842C|Fms-Related Tyrosine Kinase 3 Tyr842Cys|Fms-Related Tyrosine Kinase 3 Y842C|NP_004110.2:p.Tyr842Cys|NP_004110.2:p.Y842C|Receptor-Type Tyrosine-Protein Kinase FLT3 Tyr842Cys|Receptor-Type Tyrosine-Protein Kinase FLT3 Y842C|Stem Cell Tyrosine Kinase 1 Tyr842Cys|Stem Cell Tyrosine Kinase 1 Y842C	A change in the amino acid residue at position 842 in the receptor-type tyrosine-protein kinase FLT3 protein where tyrosine has been replaced by cysteine.	FLT3 NP_004110.2:p.Y842C		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142091>	C81326	Elevated Catecholamine Metabolites	A finding indicating elevated concentrations of catecholamine metabolites in a biological sample.	Elevated Catecholamine Metabolites		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C142092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142092>	C35682	Rous Sarcoma Virus Positive|RSV Positive	An indication that rous sarcoma virus has been detected in a sample.	Rous Sarcoma Virus Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C142093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142093>	C177692	Merkel Cell Polyomavirus T Antigen Positive|MCPyV TAg Positive|Merkel Cell Polyomavirus TAg Positive	An indication that the expression of the Merkel cell polyomavirus T antigen has been detected in a sample.	Merkel Cell Polyomavirus T Antigen Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C142094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142094>	C138961	PSA Level Greater than or Equal to 0.01|PSA Level 0.01 or Greater	A blood concentration of prostate specific antigen greater than or equal to 0.01 ng/mL.	PSA Level Greater than or Equal to 0.01		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142095>	C165233	CD3 Negative|CD3 Antigen Negative|CD3 Complex Negative|T-Cell Surface Glycoprotein CD3 Negative|T3 Complex Negative	An indication that expression of CD3 has not been detected in a sample.	CD3 Negative		Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142096>	C177692	HLA-DP4 Positive Cells Present|HLA-DP*04 Positive|HLA-DP*04 Positive Cells Present|HLA-DP4 Antigen Positive|HLA-DP4 Positive	An indication that the expression of major histocompatibility complex, class II DP protein in which haplotype of the alpha subunit is HLA-DPA1*0103 and haplotype of the beta subunit is either HLA-DPB1*0401 or HLA-DPB1*0402 allele of the HLA-DPB1 gene is present in a cell or tissue sample.	HLA-DP4 Positive Cells Present		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142097>	C177692	HLA-A*26 Positive Cells Present|HLA-A*26 Positive|HLA-A26 Positive|HLA-A26 Positive Cells Present	A laboratory test result indicating the presence of HLA-A*26 positive cells in a tissue sample.	HLA-A*26 Positive Cells Present		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142098>	C138961	PSA Level Less than One Hundred Fifty|PSA Level Less than 150|PSA Level Less than One Hundred and Fifty	A blood concentration of prostate specific antigen less than 150 ng/mL.	PSA Level Less than One Hundred Fifty		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142099>	C92976	Trisomy 21 Mosaicism|Mosaicism for Trisomy 21	The presence of cells with and without three copies of chromosome 21 in either somatic or germinal tissue.	Trisomy 21 Mosaicism		Cell or Molecular Dysfunction	AML Authorized Value Terminology|AML Medical History Table|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C14209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14209>	C25796	Fungus|FUNGI|FUNGUS|Fungi|Fungi|fungus	A kingdom of eukaryotic, heterotrophic organisms that live as saprobes or parasites, including mushrooms, yeasts, smuts, molds, etc. They reproduce either sexually or asexually, and have life cycles that range from simple to complex. Filamentous fungi refer to those that grow as multicellular colonies (mushrooms and molds).			Fungus	ALL Adverse Events Table|ALL Authorized Value Terminology|AML Adverse Events Table|AML Authorized Value Terminology|CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|CDISC SEND Biological Challenge Agent Category Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL Adverse Events Table|HL Authorized Value Terminology|NICHD Terminology|Pediatric Infectious Disease Terminology
C1420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1420>	C1909	Photosensitizing Agent|Photosensitizer|Photosensitizers|photosensitizer|photosensitizing agent	Any pharmaceutical that is administered as an inactive precursor that can be converted to its pharmacologically active form through exposure to ultraviolet radiation or sunlight.			Chemical Viewed Functionally	
C142100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142100>	C138961	PSA Level 0.1 to 0.7|PSA Level Between 0.1 and 0.7	A blood concentration of prostate specific antigen between 0.1 ng/mL and 0.7 ng/mL.	PSA Level 0.1 to 0.7		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142101>	C178120|C133686	Activating MTOR Gene Mutation|Activating FK506 Binding Protein 12-Rapamycin Associated Protein 1 Gene Mutation|Activating FRAP Gene Mutation|Activating FRAP1 Gene Mutation|Activating Mammalian Target of Rapamycin Gene Mutation|Activating Mechanistic Target of Rapamycin Gene Mutation|Activating Rapamycin and FKBP12 Target 1 Gene Mutation|MTOR Activating Mutation	A change in the nucleotide sequence of the MTOR gene that results in constitutive activation of serine/threonine-protein kinase mTOR and its downstream signaling pathways.	Activating MTOR Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142102>	C131557	CTAG1B Positive|CT6.1B Positive|Cancer/Testis Antigen 1B Positive|ESO1B Positive|LAGE-2B Positive|LAGE2B Positive|NY-ESO-1B Positive	An indication that CTAG1B expression has been detected in a sample.	CTAG1B Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142103>	C174149|C136411	Lymphoblasts 5 Percent or More of Bone Marrow Nucleated Cells|Lymphoblasts Greater than or Equal to 5 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that 5 percent or more of the nucleated cells in a bone marrow sample are immature mononuclear cells of lymphoid origin.	Lymphoblasts 5 Percent or More of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C142104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142104>	C210974|C187275	Elevated Serum CA-125 Tumor Antigen|Elevated Serum CA-125|Elevated Serum CA-125 Tumor Antigen Levels|Elevated Serum CA125|Elevated Serum Cancer Antigen 125|Elevated Serum Carbohydrate Antigen 125	A finding indicating elevated concentrations of the tumor antigen CA-125 in a blood serum sample.	Elevated Serum CA-125 Tumor Antigen		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142105>	C94299|C177692|C150617	FGFR2b Positive|FGFR-2 IIIb Positive|FGFR2 IIIb Positive|FGFR2(IIIb) Positive|FGFR2-IIIb Positive|FGFR2IIIb Expression Positive|FGFR2IIIb Positive|FGFR2b Expression Positive|Fibroblast Growth Factor Receptor 2 Isoform IIIb Positive	An indication that FGFR2b expression has been detected in a sample.	FGFR2b Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142106>	C138961	PSA Level Ten to Fifteen|PSA Level 10 to 15|PSA Level Between 10 and 15|PSA Level Between Ten and Fifteen	A blood concentration of prostate specific antigen between 10 ng/mL and 15 ng/mL.	PSA Level Ten to Fifteen		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142107>	C216183	Neoplastic Plasma Cells 10 Percent of Bone Marrow Nucleated Cells	A microscopic finding indicating that 10 percent of the nucleated cells in a bone marrow sample are neoplastic plasma cells.	Neoplastic Plasma Cells 10 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C142108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142108>	C94299|C177692	CTLA4 Positive|CD152 Antigen Positive|CD152 Positive|CTLA-4 Positive|Cytotoxic T Lymphocyte-Associated 4 Positive|Cytotoxic T-Lymphocyte Protein 4 Positive|Cytotoxic T-Lymphocyte-Associated Antigen 4 Positive|Cytotoxic T-Lymphocyte-Associated Protein 4 Positive	An indication that CTLA4 expression has been detected in a sample.	CTLA4 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142109>	C138961	PSA Level Less than 0.2	A blood concentration of prostate specific antigen less than 0.2 ng/mL.	PSA Level Less than 0.2		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C14210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14210>	C14323	Goat|Caprine Species|GOAT|Mammals, Goats	Any of various hollow-horned, bearded ruminant mammals of the genus Capra, originally of mountainous areas of the Old World, especially any of the domesticated forms of C. hircus, raised for wool, milk, and meat. (from American Heritage Dictionary on line)			Mammal	CDISC SEND Laboratory Animal Species Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142110>	C69410	HLA-A*24:02 Positive Cells Present|HLA-A*2402 Positive|HLA-A*2402 Positive Cells Present|HLA-A*24:02 Positive|HLA-A2402 Positive|HLA-A2402 Positive Cells Present	A laboratory test result indicating the presence of HLA-A*24:02 positive cells in a tissue sample.	HLA-A*24:02 Positive Cells Present		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142111>	C176685	Neoplastic Plasma Cells More than 5 Percent of Peripheral Blood White Cells|Neoplastic Plasma Cells Greater than 5 Percent of Peripheral Blood White Cells	A microscopic finding indicating that more than 5 percent of the nucleated cells in a peripheral leukocyte sample are neoplastic plasma cells.	Neoplastic Plasma Cells More than 5 Percent of Peripheral Blood White Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C142112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142112>	C136411	Blasts More than 5 Percent of Bone Marrow Nucleated Cells|Blasts Greater than 5 Percent of Bone Marrow Nucleated Cells|Blasts Over 5 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that more than 5 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts More than 5 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C142113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142113>	C143153	Blasts 10 Percent or Less of Bone Marrow Nucleated Cells|Blasts Less than or Equal to 10 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that at most 10 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts 10 Percent or Less of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C142114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142114>	C177683|C142135|C134458	ALK Gene Fusion Positive|ALK Fusion Gene Positive|ALK Fusion Gene Positive|ALK Fusion Gene Present|ALK Fusion Oncogene Positive|Anaplastic Lymphoma Kinase Fusion Gene Positive|Anaplastic Lymphoma Kinase Fusion Oncogene Positive|Anaplastic Lymphoma Receptor Tyrosine Kinase Fusion Gene Alteration Positive|CD246 Fusion Gene Positive	An indication that an ALK fusion gene has been detected in a sample.	ALK Fusion Gene Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142115>	C98304|C178120	Activating AKT1 Gene Mutation|AKT1 Activating Mutation|Activating AKT Gene Mutation|Activating v-akt Murine Thymoma Viral Oncogene Homolog 1 Gene Mutation	A change in the nucleotide sequence of the AKT1 gene that results in constitutive activation of RAC-alpha serine/threonine-protein kinase and its downstream signaling pathways.	Activating AKT1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142116>	C96271|C126340	Activating PIK3CA Gene Mutation|Activating PI3K-Alpha Gene Mutation|Activating PI3KCA Gene Mutation|Activating Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Gene Mutation|Activating p110-alpha Gene Mutation|PIK3CA Activating Mutation|PIK3CA Activation Mutation|PIK3CA Gain of Function Gene Mutation|PIK3CA Gain of Function Mutation	A change in the nucleotide sequence of the PIK3CA gene that results in constitutive activation of phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform and its downstream signaling pathways.	Activating PIK3CA Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142117>	C132894|C126340	Activating PIK3R1 Gene Mutation|Activating GRB1 Gene Mutation|Activating Phosphoinositide-3-Kinase Regulatory Subunit 1 Gene Mutation|Activating p85-ALPHA Gene Mutation|PIK3R1 Activating Mutation	A change in the nucleotide sequence of the PIK3R1 gene that results in constitutive activation of phosphatidylinositol 3-kinase regulatory subunit alpha and its downstream signaling pathways.	Activating PIK3R1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142118>	C170406|C126340	Activating PIK3R2 Gene Mutation|Activating P85B Gene Mutation|Activating Phosphoinositide-3-Kinase Regulatory Subunit 2 Gene Mutation|Activating p85-BETA Gene Mutation|PIK3R2 Activating Mutation	A change in the nucleotide sequence of the PIK3R2 gene that results in constitutive activation of phosphatidylinositol 3-kinase regulatory subunit beta and its downstream signaling pathways.	Activating PIK3R2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142119>	C177692	FGF19 Positive|FGF-19 Positive|Fibroblast Growth Factor 19 Positive|Fibroblast Growth Factor-19 Positive	An indication that FGF19 expression has been detected in a sample.	FGF19 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C14211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14211>	C79103	Guinea Pig|CAVIA PORCELLUS|Cavia porcellus|GUINEA PIG|Mammals, Guinea Pigs	The domesticated guinea pig, Cavia porcellus.			Mammal	CDISC SEND Genus and Species Response Terminology|CDISC SEND Laboratory Animal Species Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142120>	C200213|C162040	ATM Biallelic Inactivation|A-T Mutated Gene Deletion|AT Mutated Biallelic Gene Inactivation|ATM Biallelic Gene Inactivation|ATM Serine/Threonine Kinase Biallelic Gene Inactivation|Ataxia Telangiectasia Mutated Biallelic Gene Inactivation	The presence of mutations in both alleles of the ATM gene that either lead to loss of expression of the ATM protein or result in the translation of an inactive ATM protein.	ATM Biallelic Inactivation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142121>	C36688|C150641	BRCA1 Biallelic Inactivation|BRCA1 Biallelic Gene Inactivation|BROVCA1 Biallelic Gene Inactivation|Breast Cancer 1 Biallelic Gene Inactivation|Breast Cancer 1, Early Onset Biallelic Gene Inactivation|Breast Cancer Type 1 Susceptibility Biallelic Gene Inactivation	The presence of mutations in both alleles of the BRCA1 gene that either lead to loss of expression of the BRCA1 protein or result in the translation of an inactive BRCA1 protein.	BRCA1 Biallelic Inactivation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142122>	C36689|C129829	BRCA2 Biallelic Inactivation|BRCA2 Biallelic Gene Inactivation|BRCC2 Biallelic Gene Inactivation|BROVCA2 Biallelic Gene Inactivation|Breast Cancer 2 Biallelic Gene Inactivation|Breast Cancer 2, Early Onset Biallelic Gene Inactivation|Breast Cancer Type 2 Susceptibility Biallelic Gene Inactivation|FANCD1 Biallelic Gene Inactivation|XRCC11 Biallelic Gene Inactivation	The presence of mutations in both alleles of the BRCA2 gene that either lead to loss of expression of the BRCA2 protein or result in the translation of an inactive BRCA2 protein.	BRCA2 Biallelic Inactivation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142123>	C94299|C177692	ROR1 Positive|NTRKR1 Positive|Receptor Tyrosine Kinase-Like Orphan Receptor 1 Positive	An indication that ROR1 expression has been detected in a sample.	ROR1 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142124>	C35877|C35682	Activated B-Cell Positive|ABC Positive|Activated B Cell Positive|Activated B Cells Present|Activated B Lymphocyte Positive|Activated B Lymphocytes Present|Activated B-Cells Present|Activated B-Lymphocyte Positive|Activated B-Lymphocytes Present	An indication that actively proliferating and differentiating B-lymphocytes have been detected in a sample.	Activated B-Cell Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C142125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142125>	C97311|C178120	Activating EZH2 Gene Mutation|ENX-1 Gain of Function Mutation|EZH2 Activating Mutation|EZH2 Gain of Function|EZH2 Gain of Function|EZH2 Gain of Function Gene Mutation|EZH2 Gain of Function Mutation|Enhancer of Zeste 2 Polycomb Repressive Complex 2 Subunit Gene Gain of Function Mutation|KMT6A Gain of Function Mutation	A mutation in the EZH2 gene that leads to increased histone-lysine N-methyltransferase EZH2 activity.	EZH2 Gain of Function		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142126>	C97927	SMARCA4 Gene Mutation|BAF190 Gene Mutation|BAF190A Gene Mutation|BRG-1 Gene Mutation|BRG1 Gene Mutation|BRM/SWI2-Related Gene 1 Mutation|SMARCA4 mutation|SNF2 Gene Mutation|SNF2-Beta Gene Mutation|SNF2L4 Mutation|SNF2LB Gene Mutation|SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily A, Member 4 Gene Mutation|SWI2 Gene Mutation|hSNF2b Gene Mutation	A change in the nucleotide sequence of the SMARCA4 gene.	SMARCA4 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C142127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142127>	C171068	HTLV-1 Positive|HTLV-I Positive|Human T Cell Lymphotropic Virus 1 Positive|Human T-Cell Lymphotropic Virus 1 Positive|Human T-Lymphotropic Virus 1 Positive	An indication that HTLV-1 was detected in a sample.	HTLV-1 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C142128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142128>	C138961	PSA Level Less than Thirty|PSA Level Less than 30	A blood concentration of prostate specific antigen less than 30 ng/mL.	PSA Level Less than Thirty		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142129>	C138961	PSA Level Less than or Equal to Thirty|PSA Level 30 or Less|PSA Level Less than or Equal to 30|PSA Level Thirty or Less	A blood concentration of prostate specific antigen less than or equal to 30 ng/mL.	PSA Level Less than or Equal to Thirty		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C14212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14212>	C79741	Hamster|HAMSTER|Mammals, Hamsters|Mesocricetus	Any member of four genera of the rodent family Cricetidae; short-tailed Old World burrowing rodents with large cheek pouches.			Mammal	CDISC SEND Laboratory Animal Species Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142130>	C35682|C103223	MAPK Gene Alteration Positive|ERK Alteration Positive|ERK Family Alteration Positive|ERK Family Gene Alteration Positive|Extracellular Signal-Regulated Kinase Family Gene Alteration Positive|MAPK Family Gene Alteration Positive|Mitogen-Activated Protein Kinase Family Gene Alteration Positive	A finding indicating that mutation, overexpression or rearrangement of a MAPK family gene has been detected in a sample.	MAPK Gene Alteration Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142131>	C205056	Increasing Levels of Measurable Residual Disease|Increasing Levels of Minimal Residual Disease|Increasing Levels of Minimal Residual Disease|Increasing MRD	A finding indicating an increased presence of residual disease over time.	Increasing Levels of Minimal Residual Disease		Finding	CTRP Biomarker Terminology|CTRP Terminology
C142132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142132>	C39877|C153103	Activating FGFR3 Gene Mutation|Activating CD333 Gene Mutation|Activating FGFR-3 Gene Mutation|Activating FGFR3 Mutation|Activating Fibroblast Growth Factor Receptor 3 Gene Mutation|Activating JTK4 Gene Mutation|FGFR3 Activating Mutation|FGFR3 Gain of Function Gene Mutation|FGFR3 Gain of Function Mutation|Gain of Function FGFR3 Mutation	A change in the nucleotide sequence of the FGFR3 gene that results in constitutive activation of fibroblast growth factor 3 and its downstream signaling pathways.	Activating FGFR3 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142133>	C177692	CTNNB1 Positive|Beta Catenin Positive|Beta-Catenin Positive|CTNNB Positive|Catenin Beta-1 Positive	An indication that CTNNB1 expression has been detected in a sample.	CTNNB1 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142134>	C177692	KRAS Positive|GTPase Kras Positive|KRAS Proto-Oncogene, GTPase Positive|KRAS-2 Positive|RASK Positive|c-K-ras Positive|p21 K-Ras Positive|v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Positive	An indication that KRAS expression has been detected in a sample.	KRAS Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142135>	C158948	ALK Fusion Positive|ALK Tyrosine Kinase Receptor Fusion Positive|Anaplastic Lymphoma Kinase Fusion Positive|CD246 Antigen Fusion Positive	An indication that ALK fusion expression has been detected in a sample.	ALK Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142136>	C158948	t(11;14) Positive	A cytogenetic finding indicating that the translocation t(11;14) has been detected in a sample.	t(11;14) Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142137>	C1962|C129820	Lipid Nanoparticle Encapsulated OX40L mRNA-2416|Lipid Nanoparticle Encapsulated mRNA Encoding Human OX40L|mRNA 2416|mRNA-2416	A proprietary formulation consisting of a lipid nanoparticle encapsulating a synthetic messenger RNA (mRNA) encoding the human co-stimulatory protein tumor necrosis factor ligand superfamily member 4 (TNFSF4; OX40 Ligand; OX40L), with potential immunomodulatory and antitumor activities. Although the mechanism of action has not been completely characterized, following intratumoral injection of lipid nanoparticle encapsulated OX40L mRNA-2416, the lipid nanoparticle moiety presumably binds to the plasma membrane of nearby cells and releases the OX40L mRNA into the cell. The OX40L mRNA is then translated by the cellular protein translation machinery to produce OX40L protein, which is then expressed on the plasma membrane of the cells that internalized the OX40L mRNA. OX40L binds to and activates signaling pathways downstream of its cognate receptor tumor necrosis factor receptor superfamily member 4 (TNFRSF4; OX40), which is expressed on activated T-cells. OX40L/OX40 binding promotes increased cytokine production, which can induce proliferation of memory and effector T-lymphocytes. Altogether, this may enhance an immune response that promotes the killing of nearby tumor cells. OX40L, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) ligand family, provides a co-stimulatory signal for the proliferation and survival of activated T cells.	Lipid Nanoparticle Encapsulated OX40L mRNA-2416		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C142138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142138>	C20194	FTH1P5 Gene|FTH1P5|FTH1P5|Ferritin Heavy Chain 1 Pseudogene 5 Gene|Ferritin, Heavy Polypeptide 1 Pseudogene 5 Gene|Ferritin, Heavy Polypeptide Pseudogene 1 Gene|Ferritin, Heavy Polypeptide-Like 5 Gene	Human FTH1P5 gene is located in the vicinity of 6p12.3 and is approximately 1 kb in length. The product is a processed pseudogene, which produces an RNA transcript but does not encode a protein product.			Gene or Genome	
C142139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142139>	C39619|C1663	Synthetic hTERT DNA Vaccine INO-1401|INO-1401|SynCon TERT	A DNA vaccine consisting of a plasmid encoding a synthetic, full-length sequence of the tumor-associated antigen (TAA) telomerase reverse transcriptase (TERT), which was derived from the consensus sequence from humans and primates and contains two immunogenic mutations (SynCon TERT), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration of INO-1401 in combination with electroporation, TERT protein is expressed and activates the immune system to mount a cytotoxic T-cell (CTL) response against telomerase-expressing tumor cells, which may result in tumor cell death. TERT is the catalytic subunit of telomerase and synthesizes telomeric DNA at the chromosome ends. Telomerase prolongs the functional lifespan of cells via the restoration and maintenance of telomere length. Abnormally activated in tumorigenesis, TERT is expressed by many types of human cancer cells, but its expression is low or non-existent in normal cells.	Synthetic hTERT DNA Vaccine INO-1401		Immunologic Factor|Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C14213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14213>	C112028	Hantavirus|HANTAVIRUS	A genus of single-stranded, segmented, negative-sense RNA viruses in the family bunyaviridae. These viruses are transmitted by aerosolized rodent excreta or rodent bites.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142140>	C38617	Pharyngeal Recess|Fossa of Rosenmuller	A recess located behind the ostium of the eustachian tube. It is the most common site of origin for nasopharyngeal carcinoma.			Body Part, Organ, or Organ Component	
C142142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142142>	C20181	Life	The biochemical phenomenon that distinguishes organisms from inorganic matter. It is characterized by growth, metabolism, and reproduction.			Conceptual Entity	
C142143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142143>	C21295	SSB Gene|SSB|SSB|Sjogren Syndrome Antigen B Gene	This gene is involved in binding to both transfer and messenger RNA.			Gene or Genome	
C142144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142144>	C142143	SSB wt Allele|LARP3|La|La Ribonucleoprotein Domain Family, Member 3 Gene|La/SSB|SS-B|Sjogren Syndrome Antigen B (Autoantigen La) Gene|Sjogren Syndrome Antigen B wt Allele	Human SSB wild-type allele is located in the vicinity of 2q31.1 and is approximately 20 kb in length. This allele, which encodes Lupus La protein, plays a role in metabolism of both tRNA and mRNA.			Gene or Genome	
C142145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142145>	C21298	Lupus La Protein|Autoantigen La|La Autoantigen|La Ribonucleoprotein|Lupus La Antigen|SS-B|SS-B/La Protein|SSB|Sjoegren Syndrome Type B Antigen	Lupus La protein (408 aa, ~47 kDa) is encoded by the human SSB gene. This protein is involved in the modulation of tRNA and mRNA metabolism.			Amino Acid, Peptide, or Protein	
C142146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142146>	C132494	Neck Lymph Node Boundary Levels I-IV|Neck Lymph Node Levels I-IV	A grouping of lymph nodes comprising neck lymph node boundary levels I-IV.			Finding	
C142147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142147>	C132494	Neck Lymph Node Boundary Levels II-IV|Neck Lymph Node Levels II-IV	A grouping of lymph nodes comprising neck lymph node boundary levels II-IV.			Finding	
C142148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142148>	C124327	Serial Transverse Cross-Sectioning|Bread Loafing|Bread-Loafing Technique	A histological method used to determine surgical margin for skin tumors. The process involves cutting a specimen into 3 or more sections and examining a thin slice from each cut face.			Laboratory Procedure	
C142149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142149>	C8652|C80307	Refractory Waldenstrom Macroglobulinemia	A Waldenstrom macroglobulinemia that does not respond to treatment.	Refractory Waldenstrom Macroglobulinemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C14214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14214>	C54085|C14348	Hepadnavirus	A family of hepatotropic DNA viruses which contains double-stranded DNA genomes and causes hepatitis in humans and animals. Contains two genera: avihepadnavirus and orthohepadnavirus.			Virus	
C142150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142150>	C20988	MAG Gene|MAG|MAG|Myelin Associated Glycoprotein Gene	This gene plays a role in myelin sheath maintenance.			Gene or Genome	
C142151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142151>	C142150	MAG wt Allele|GMA|Myelin Associated Glycoprotein wt Allele|S-MAG|SIGLEC-4A|SIGLEC4A|SPG75	Human MAG wild-type allele is located in the vicinity of 19q13.12 and is approximately 22 kb in length. This allele, which encodes myelin-associated glycoprotein, is involved in axon myelination. Mutation of the gene is associated with autosomal recessive spastic paraplegia 75.			Gene or Genome	
C142152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142152>	C16393	Myelin-Associated Glycoprotein|MAG|Sialic Acid Binding Ig-Like Lectin 4A|Sialic Acid-Binding Immunoglobulin-Like Lectin 4A|Siglec-4a	Myelin-associated glycoprotein (626 aa, ~69 kDa) is encoded by the human MAG gene. This protein plays a role in the maintenance of axon myelination.			Amino Acid, Peptide, or Protein	
C142153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142153>	C21295	APOH Gene|APOH|APOH|Apolipoprotein H Gene	This gene is involved in binding to glycosaminoglycans and phospholipids.			Gene or Genome	
C142154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142154>	C142153	APOH wt Allele|Apolipoprotein H (Beta-2-Glycoprotein I) Gene|Apolipoprotein H wt Allele|B2G1|B2GP1|BG|Glycoprotein 1, Beta-2 Gene|Glycoprotein I, Beta-2 Gene	Human APOH wild-type allele is located in the vicinity of 17q24.2 and is approximately 44 kb in length. This allele, which encodes beta-2-glycoprotein 1, may play a role in lipoprotein metabolism, coagulation, and the production of antiphospholipid autoantibodies.			Gene or Genome	
C142155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142155>	C17728	Beta-2-Glycoprotein 1|APC Inhibitor|APOH|Activated Protein C-Binding Protein|Anticardiolipin Cofactor|Apo-H|Apo-H|Apolipoprotein H|Apolipoprotein H|B2GPI|B2GPI|BETA-2 GLYCOPROTEIN 1|Beta(2)GPI|Beta-2 Glycoprotein 1|Beta-2-Glycoprotein I|Beta-2-Glycoprotein I	Beta-2-glycoprotein 1 (345 aa, ~38 kDa) is encoded by the human APOH gene. This protein is involved in binding to phospholipids, glycosaminoglycans and other negatively charged substances.	Beta-2-Glycoprotein 1		Amino Acid, Peptide, or Protein	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142156>	C27993	Concordance|Concordant	An agreement of findings.			Conceptual Entity	
C142157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142157>	C25404	Delineate|Delineated|Delineation	To describe something precisely or to indicate the exact position of a boundary or border.			Activity	
C142158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142158>	C41009	Aversion|Averse	A strong dislike or disinclination.			Conceptual Entity	
C142159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142159>	C20673	MRTFB Gene|MKL2|MRTFB|MRTFB|Myocardin Related Transcription Factor B Gene	This gene plays a role in the coactivation of transcription.			Gene or Genome	
C14215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14215>	C14216|C14214	Hepatitis B Virus|HBV|HBV|HEPATITIS B VIRUS|HEPATITIS B VIRUS|Virus-Hepatitis B|hepatitis B virus	Hepatitis B Virus (HBV) is the prototype of the Hepadnavirus Family.  Included in the family are the Woodchuck Hepatitis Virus (WHV) and the Duck Hepatitis B Virus (DHBV) which provide animal models of infection.  The HBV genome is a partially double stranded circular DNA.  A viral reverse transcriptase is bound to the 5' extremity of the long strand.	Hepatitis B Virus		Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142160>	C142159	MRTFB wt Allele|FLJ31823|KIAA1243|MKL and Myocardin Family Member 2 Gene|MKL/Myocardin Like 2 Gene|MKL1/Myocardin Like 2 Gene|MKL2|MRTF-B|Myocardin Related Transcription Factor B wt Allele|Myocardin-Related Transcription Factor B, Mouse, Homolog of Gene|NPD001	Human MRTFB wild-type allele is located in the vicinity of 16p13.12 and is approximately 195 kb in length. This allele, which encodes myocardin-related transcription factor B protein, is involved in skeletal myogenesis. A translocation t(11;16)(q13;p13) that fuses this gene to the C11orf95 gene is associated with chondroid lipoma.			Gene or Genome	
C142161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142161>	C26199	Myocardin-Related Transcription Factor B|CTA-276F8.1|MKL/Myocardin-Like Protein 2|MKL2|MRTF-B|MRTFB|Megakaryoblastic Leukemia 2|Myocardin Related Transcription Factor B	Myocardin-related transcription factor B (1088 aa, ~118 kDa) is encoded by the human MRTFB gene. This protein plays a role in both transcriptional activation and skeletal muscle differentiation.			Amino Acid, Peptide, or Protein	
C142162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142162>	C28510	ZFTA/MKL2 Fusion Gene|C11orf95-MKL2 Fusion Gene|C11orf95-MRTFB Fusion Gene|C11orf95/MKL2 Fusion Gene|C11orf95/MRTFB Fusion Gene|MKL2/C11ORF95 Fusion Gene|ZFTA-MRTFB Fusion Gene|ZFTA/MRTFB Fusion Gene|ZFTA::MKL2 Fusion Gene|ZFTA::MRTFB Fusion Gene	A fusion gene that results from a translocation t(11;16)(q13;p13), which fuses exons 1 through 5 of the ZFTA gene to exons 9 through 13 of the MKL2 gene. This rearrangement is associated with chondroid lipoma.			Gene or Genome	
C142163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142163>	C17561	ZFTA/MKL2 Fusion Protein|C11orf95-MKL2 Fusion Protein|C11orf95-MRTFB Fusion Protein|C11orf95/MKL2 Fusion Protein|C11orf95/MRTFB Fusion Protein|Uncharacterized Protein C11orf95-MKL/Myocardin-Like Protein 2 Fusion Protein|Uncharacterized Protein C11orf95/MKL/Myocardin-Like Protein 2 Fusion Protein|ZFTA-MRTFB Fusion Protein|ZFTA/MRTFB Fusion Protein|ZFTA::MKL2 Fusion Protein|ZFTA::MRTFB Fusion Protein|Zinc Finger Translocation-Associated Protein-MKL/Myocardin-Like Protein 2 Fusion Protein|Zinc Finger Translocation-Associated Protein/MKL/Myocardin-Like Protein 2 Fusion Protein	A fusion protein (1247 aa, ~137 kDa) encoded by the ZFTA/MKL2 fusion gene. This protein is comprised of the glutamic acid-rich and proline-rich regions of zinc finger translocation-associated protein fused to the SAP domain, coiled-coil region, and C-terminal proline-rich region of MKL/myocardin-like protein 2.			Amino Acid, Peptide, or Protein	
C142164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142164>	C17453	Teaching Rounds|Rounds	A teaching conference or meeting at which clinical problems are discussed.			Event	
C142165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142165>	C25716	Hospital Rounds|Rounds	The act of seeing patients in the hospital, or another in-patient setting, to evaluate treatment, assess current course, and document the patient's progress.			Individual Behavior	
C142166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142166>	C70656	Transition Point	The point at which something changes from one form to another.			Spatial Concept	
C142167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142167>	C471	Levoketoconazole|(-)-(2S,4R)-Ketoconazole|2S,4R Ketoconazole|2S,4R-Ketoconazole|COR-003|COR003|Ethanone, 1-(4-(4-(((2S,4R)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)-|Ketoconazole, (2S,4R)-|LEVOKETOCONAZOLE|NormoCort|Recorlev	An orally available levorotary enantiomer of ketoconazole with potential steroidogenesis inhibitory activity. Following oral administration, levoketoconazole inhibits three cytochrome P450 family enzymes involved in glucocorticoid biosynthesis, 11beta-hydroxylase (CYP11B1), 17alpha-hydroxylase/17,20-lyase (CYP17A1) and steroid 21-hydroxylase (CYP21A2), which reduces the circulating levels of glucocorticoids. Therefore, this agent may normalize the high concentration of cortisol in the blood seen in patients with Cushing syndrome. Compared to racemic ketoconazole, the levo form is a more potent inhibitor of glucocorticoid synthesis. Additionally, this enantiomer is less likely to inhibit cholesterol 7alpha-hydroxylase (CYP7A1); therefore, its use may reduce the risk of hepatoxicity. Cushing syndrome is caused by high levels of cortisol in the blood either due to excessive production and secretion of corticosteroids, which is often the result of adrenocorticotropic hormone (ACTH)-secreting pituitary or adrenocortical neoplasms, or the use of synthetic corticosteroids.	Levoketoconazole		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C142168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142168>	C129822|C128037	Retifanlimab|INCMGA 0012|INCMGA-0012|INCMGA00012|INCMGA0012|MGA 012|MGA-012|MGA012|RETIFANLIMAB|Retifanlimab-dlwr|Zynyz	A proprietary humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, retifanlimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.	Retifanlimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C142169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142169>	C25492	Abscopal Effect|Abscopal Effect After Radiotherapy|Abscopal Response	The ability of localized radiation to trigger systemic antitumor effects.			Phenomenon or Process	
C14216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14216>	C14349	Hepatitis Virus	A non-taxonomic classification of unrelated viruses that cause liver inflammation and dysfunction.			Virus	
C142170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142170>	C45501	On Treatment|Under Treatment	A patient is receiving treatment.			Clinical Attribute	HL Authorized Value Terminology|HL Patient Reported Outcomes Metadata Table|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C142171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142171>	C98986	Methylmalonic Aciduria, cblA Type	An autosomal recessive form of methylmalonic aciduria, caused by mutation(s) in the MMAA gene, encoding MMAA protein.			Disease or Syndrome	Cellosaurus Disease Terminology
C142172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142172>	C98986	Methylmalonic Aciduria, cblB Type	An autosomal recessive form of methylmalonic aciduria, caused by mutation(s) in the MMAB gene, encoding cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial.			Disease or Syndrome	Cellosaurus Disease Terminology
C142173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142173>	C84765	Homocystinuria-Megaloblastic Anemia, cblE Complementation Type|HMAE|Methylcobalamin Deficiency, cblE Type	An autosomal recessive condition caused by mutation(s) in the MTRR gene, encoding methionine synthase reductase. It is characterized by homocystinuria and megaloblastic anemia.			Disease or Syndrome	Cellosaurus Disease Terminology
C142174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142174>	C219868	Methylmalonic Aciduria and Homocystinuria, cblC Type	An autosomal recessive form of combined methylmalonic aciduria and homocystinuria, caused by mutation(s) in the MMACHC gene, encoding methylmalonic aciduria and homocystinuria type C protein.			Disease or Syndrome	Cellosaurus Disease Terminology
C142175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142175>	C25284	Study Type|STUDY_TYPE|STYPE|Study Type Classification|clinical study type|clinical_study_type	The nature of the investigation or the investigational use for which the study is being done.			Research Activity	CDISC DDF Study Design Attribute Terminology|CDISC DDF Terminology|CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology|HL Subject Characteristics Table|HL Variable Terminology|ICDC Property Terminology|ICDC Terminology|SeroNet Study Descriptors|SeroNet Variables
C142176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142176>	C1511	Lutetium Lu 177 Anti-CA19-9 Monoclonal Antibody 5B1|177Lu Human Monoclonal Antibody 5B1|177Lu-CHX-A''-DTPA-HuMab-5B1|Lu 177 Anti-CA19-9 Monoclonal Antibody 5B1|MVT-1075|MVT-1075	A radioimmunoconjugate comprised of a human monoclonal antibody (huMAb-5B1) against the carbohydrate antigen sialyl Lewis A (carbohydrate antigen 19-9; CA19-9) that is conjugated to the chelator 2-(p-isothiocyanatobenzyl)-cyclohexyl-diethylenetriaminepentaacetic acid (CHX-A''-DTPA) and labeled with the beta-emitting radioisotope lutetium Lu 177 (Lu 177), with radioisotopic activity and potential use as an antineoplastic radiotherapeutic and an imaging agent in both planar imaging and single-photon emission computed tomography (SPECT). The antibody moiety of Lu 177 anti-CA19-9 monoclonal antibody 5B1 targets and binds to CA19-9-expressing tumor cells. This may promote killing of CA19-9-expressing tumor cells through the local induction of both complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). Additionally, upon binding and internalization, the Lu 177 moiety can deliver a cytotoxic dose of beta radiation to the CA19-9-expressing tumor cells. Furthermore, the radioisotope moiety may be imaged using planar imaging and SPECT, thus allowing evaluation of the pharmacokinetic profile of the agent, and the imaging and quantification of CA19-9-expressing tumor cells, respectively. CA19-9, a Lewis-type carbohydrate antigen overexpressed on a number of different tumor cell types, plays a key role in tumor cell survival and metastasis.	Lutetium Lu 177 Anti-CA19-9 Monoclonal Antibody 5B1		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C142177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142177>	C163968	Pemrametostat|EPZ015938|GSK-3326595|GSK3326595|PEMRAMETOSTAT|PRMT5 Inhibitor GSK3326595|Protein Arginine Methyltransferase 5 Inhibitor GSK3326595	An orally available, selective small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), with potential antiproliferative and antineoplastic activities. Although the mechanism of action has not been completely determined, pemrametostat binds to the substrate recognition site of PRMT5 following oral administration and inhibits its methyltransferase activity, which decreases the levels of both monomethylated and dimethylated arginine residues in histones H2A, H3 and H4 and modulates the expression of genes involved in several cellular processes, including cell proliferation. Therefore, this agent may increase the expression of antiproliferative genes and/or decrease the expression of genes that promote cell proliferation and may lead to decreased growth of rapidly proliferating cells, including cancer cells. PRTM5, an arginine methyltransferase that can catalyze the formation of both omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA) on histones and a variety of other protein substrates, is overexpressed in several neoplasms.	Pemrametostat		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C142178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142178>	C42076	Diffuse Proliferation of Pulmonary Neuroendocrine Cells Present	A morphologic finding indicating the presence of a diffuse proliferation of neuroendocrine cells in the lung parenchyma.			Finding	
C142179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142179>	C66830	CDISC SDTM Arm Null Reason Response Terminology|ARMNULRS|Arm Null Reason|SDTM-ARMNULRS	Terminology associated with the arm null reason response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14217>	C14348	Herpesvirus|Herpes Virus|Herpesviridae|Virus-Herpes|herpesvirus	A heterogeneous family of morphologically similar viruses, all of which contain double-stranded DNA and which infect man and a wide variety of other vertebrates. Infections produce type A inclusion bodies; in many instances, infection may remain latent for many years, even in the presence of specific circulating antibodies. Virions are enveloped, ether-sensitive, and vary up to 200 nm in diameter; the nucleocapsids are 100 nm in diameter and of icosahedral symmetry, with 162 capsomeres. The family includes herpes simplex virus, cytomegalovirus, EB virus (all of which infect humans) and many others.	Herpesvirus		Virus	CTRP Biomarker Terminology|CTRP Terminology
C142180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142180>	C16830	Endorectal Coil|ERC	A thin wire covered with a latex balloon that is inserted into the rectum to enhance the local magnetic field during MRI of the prostate and surrounding tissues.	Endorectal Coil		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C142181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142181>	C51701|C15680	8-Core Prostate Biopsy	A prostate biopsy collection protocol that consists of sextant cores plus 2 lateral peripheral zone cores.			Diagnostic Procedure	
C142182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142182>	C51701|C15680	12-Core Prostate Biopsy	A prostate biopsy collection protocol that consists of sextant cores plus 6 lateral peripheral zone cores.			Diagnostic Procedure	
C142183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142183>	C51701|C15680	Sextant Core Biopsy|Sextant Biopsy Protocol|Sextant Biopsy Technique	A prostate biopsy collection protocol in which 6 biopsies are obtained in the parasagittal plane halfway between the lateral border and midline of the prostate on both right and left sides from the base, mid-gland, and apex.			Diagnostic Procedure	
C142184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142184>	C17634	4Kscore|4K|4Kscore Blood Test	A proprietary blood test for prostate cancer screening that measures four kallikrein markers (total, free, and intact prostate-specific antigen, and human kallikrein-related peptidase 2 [hK2]).			Laboratory Procedure	
C142185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142185>	C74590	Protocol Violation|PROTOCOL VIOLATION|protocol violation	A significant departure from processes or procedures that were required by the protocol. Violations often result in data that are not deemed evaluable for a per-protocol analysis, and may require that the subject(s) who violate the protocol be discontinued from the study. Compare to protocol deviation. (CDISC Glossary)			Research Activity	CDISC Glossary Terminology|CDISC SDTM Reason for Non-Completion Terminology|CDISC SDTM Terminology|CDISC SDTM Tobacco Study Completion/Reason for Non-Completion Terminology|Clinical Data Interchange Standards Consortium Terminology
C142186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142186>	C19771	Oncotype DX Genomic Prostate Score|Oncotype DX GPS	A proprietary multi-gene assay that analyzes expression of 17 genes across four genetic pathways to predict prostate cancer aggressiveness.	Oncotype DX Genomic Prostate Score		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C142187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142187>	C66830	CDISC SDTM Vaccines Findings About Test Code Terminology|SDTM-VNFATSCD|VNFATSCD|Vaccines Findings About Test Code	Terminology associated with the vaccines findings about test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142189>	C66830	CDISC SDTM Vaccines Findings About Test Name Terminology|SDTM-VNFATS|VNFATS|Vaccines Findings About Test Name	Terminology associated with the vaccines findings about test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14218>	C112410	Human Herpesvirus 6|HHV-6|HHV-6|HHV6|HUMAN HERPESVIRUS 6|HUMAN HERPESVIRUS 6|Herpes Simplex Virus 6|Herpes Virus 6|Human Betaherpesvirus 6|Human Herpesvirus-6|Human betaherpesvirus 6|Virus-HHV6	A human herpesvirus that has been found in certain lymphoproliferative disorders, replicates in a number of different types of leukocytes, and is associated with the childhood disease roseola (exanthema subitum).	Human Herpesvirus 6		Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142191>	C103175	CDISC Protocol Entities Clinical Study Attribute Terminology|Clinical Study Attribute Terminology|Clinical Study Attribute Terminology|PROT-Att Clinical Study	Terminology associated with the protocol entity clinical study attribute codelist of the Clinical Data Interchange Standards Consortium (CDISC).			Intellectual Product	
C142192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142192>	C70705	Study Variable|Variable|study variable	A variable identified as relevant to a particular clinical study.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142193>	C28533|C158414	ABCD1 Gene|ABCD1|ABCD1|ATP Binding Cassette Subfamily D Member 1 Gene	This gene plays a role in the import of fatty acids and acyl-coenzyme A (acylCoA)-conjugated fatty acids into the peroxisome.	ABCD1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C142194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142194>	C142193	ABCD1 wt Allele|ABC42|ALD|ALDP|AMN|ATP Binding Cassette Subfamily D Member 1 wt Allele|ATP-Binding Cassette, Sub-Family D (ALD), Member 1 Gene|ATP-Binding Cassette, Subfamily D, Member 1 Gene	Human ABCD1 wild-type allele is located in the vicinity of Xq28 and is approximately 20 kb in length. This allele, which encodes ATP-binding cassette sub-family D member protein, is involved in fatty acid import into the peroxisome. Mutation of the gene is associated with adrenoleukodystrophy and adult adrenomyeloneuropathy.	ABCD1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142195>	C17750|C158419	ATP-Binding Cassette Sub-Family D Member 1|ABCD1|ALDP|Adrenoleukodystrophy Protein|EC 7.6.2.4	ATP-binding cassette sub-family D member (745 aa, ~83 kDa) is encoded by the human ABCD1 gene. This protein plays a role in the peroxisomal import of fatty acids and fatty acyl-coenzyme A (acylCoA) esters.	ATP-Binding Cassette Sub-Family D Member 1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142196>	C28533	Globin Gene|Globin Gene Family	A family of genes whose members encode globin family proteins, which are globular heme-containing proteins and include androglobin, cryoglobin, hemoglobin subunits, myoglobin and neuroglobin.			Gene or Genome	
C142197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142197>	C26006	KPNB1 Gene|KPNB1|KPNB1|Karyopherin Subunit Beta 1 Gene	This gene is involved in nuclear import.			Gene or Genome	
C142198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142198>	C142197	KPNB1 wt Allele|IMB1|IPO1|IPOB|Impnb|Karyopherin (Importin) Beta 1 Gene|Karyopherin Subunit Beta 1 wt Allele|MGC2155|MGC2156|MGC2157|NTF97	Human KPNB1 wild-type allele is located in the vicinity of 17q21.32 and is approximately 36 kb in length. This allele, which encodes importin subunit beta-1 protein, plays a role in nuclear import. Aberrant expression of the gene may be associated with several neoplastic diseases.			Gene or Genome	
C142199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142199>	C16386	Importin Subunit Beta-1|Importin 1|Importin 90|Importin Beta-1|Importin Beta-1 Subunit|Importin-90|KPNB1|Karyopherin Beta-1|Karyopherin Subunit Beta-1|Nuclear Factor p97|PTAC97	Importin subunit beta-1 (876 aa, ~97 kDa) is encoded by the human KPNB1 gene. This protein is involved in nuclear import.			Amino Acid, Peptide, or Protein	
C14219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14219>	C117716	Human Immunodeficiency Virus|HIV|HIV|HIV|HUMAN IMMUNODEFICIENCY VIRUS|Virus-HIV|human immunodeficiency virus	The virus isolated and recognized as the etiologic agent of AIDS. HIV-1 is classified as a lentivirus, a subtype of retroviruses.	Human Immunodeficiency Virus		Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C1421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1421>	C512	Oxygen Radical|Oxygen Radicals|ROS|Reactive Oxygen Species	Organic or inorganic chemicals that contain an oxygen atom with an unpaired electron. This unstable electron configuration causes these chemicals to be highly reactive with other molecules.	Oxygen Radical		Chemical Viewed Functionally|Element, Ion, or Isotope	CTRP Biomarker Terminology|CTRP Terminology
C142200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142200>	C20988	NECTIN2 Gene|NECTIN2|NECTIN2|Nectin Cell Adhesion Molecule 2 Gene	This gene plays a role in T-cell signaling, viral entry and adherens junction organization.	NECTIN2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C142201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142201>	C142200	NECTIN2 wt Allele|CD112|HVEB|Nectin 2 Gene|Nectin Cell Adhesion Molecule 2 wt Allele|PRR2|PVRL2|PVRR2|Poliovirus Receptor-Like 2 Gene|Poliovirus Receptor-Related 2 (Herpesvirus Entry Mediator B) Gene|Poliovirus Receptor-Related 2 Gene	Human NECTIN2 wild-type allele is located in the vicinity of 19q13.32 and is approximately 43 kb in length. This allele, which encodes nectin-2 protein, is involved in viral entry, adherens junction organization and the modulation of receptor-mediated signaling in T-cells. Variation in the gene in subjects with multiple sclerosis may be associated with the severity of the disorder.	NECTIN2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142202>	C16393	Nectin-2|CD112|CD112 Antigen|Herpes Virus Entry Mediator B|Herpesvirus Entry Mediator B|Herpesvirus Entry Protein B|HveB|NECTIN2|Nectin 2|Nectin Cell Adhesion Molecule 2|PVRL-2|PVRL2|Poliovirus Receptor-Like 2|Poliovirus Receptor-Related 2|Poliovirus Receptor-Related Protein 2	Nectin-2 (538 aa, ~58 kDa) is encoded by the human NECTIN2 gene. This protein plays a role in adherens junction organization, the regulation of T-cell signaling, and host cell entry of herpes simplex virus and pseudorabies virus.	Nectin-2		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142205>	C28681|C213868	Autologous CD4 and CD8 Positive Truncated CD19-expressing Antigen Presenting T-cells|Autologous CD19t T-APC|Autologous CD19t T-Antigen Presenting Cells|Autologous T-cell Antigen Presenting Cells Expressing CD19t|Autologous T-cell Antigen Presenting Cells Expressing Truncated CD19	A preparation of ex vivo expanded, autologous CD4 and CD8 positive antigen presenting T-cells (T-APCs), genetically modified with a transgene encoding a truncated form of human cluster of differentiation 19 (CD19t), with potential immunostimulating activity. Upon infusion, autologous CD19t-expressing T-APCs may stimulate the proliferation and activation of preadministered therapeutic CD19-targeted chimeric antigen receptor T-cells (CAR-T). This may both improve the persistence of the therapeutic CAR-T-cells and prevent relapse in patients with CD19 positive leukemia or lymphoma. CD19 is a B-cell specific cell surface antigen that is expressed in all B-cell lineage malignancies.	Autologous CD4 and CD8 Positive Truncated CD19-expressing Antigen Presenting T-cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C142206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142206>	C25870	ZNF451 Gene|ZNF451|ZNF451|Zinc Finger Protein 451 Gene	This gene is involved in protein sumoylation.			Gene or Genome	
C142207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142207>	C142206	ZNF451 wt Allele|COASTER|KIAA0576|KIAA1702|Zinc Finger Protein 451 wt Allele|dJ417I1.1	Human ZNF451 wild-type allele is located in the vicinity of 6p12.1 and is approximately 83 kb in length. This allele, which encodes E3 SUMO-protein ligase ZNF451 protein, plays a role in post-translational sumoylation.			Gene or Genome	
C142208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142208>	C16259	E3 SUMO-Protein Ligase ZNF451|Coactivator For Steroid Receptors|E3 SUMO-Protein Transferase ZNF451|EC 2.3.2.-|ZATT|ZNF451|Zinc Finger Protein 451	E3 SUMO-protein ligase ZNF451 (1061 aa, ~121 kDa) is encoded by the human ZNF451 gene. This protein is involved in the sumoylation of protein substrates.			Amino Acid, Peptide, or Protein|Enzyme	
C142209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142209>	C20921	DENND3 Gene|DENN Domain Containing 3 Gene|DENND3|DENND3	This gene is involved in the modulation of Ras-related protein Rab-12 activity.			Gene or Genome	
C14220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14220>	C14219	Human Immunodeficiency Virus 1|HIV-1|HIV-1|HUMAN IMMUNODEFICIENCY VIRUS 1|Human Immunodeficiency Virus, Type 1|LAV-1	Any viral organism that can be assigned to the species Human Immunodeficiency virus 1.	Human Immunodeficiency Virus 1		Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C142210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142210>	C142209	DENND3 wt Allele|DENN Domain Containing 3 wt Allele|DENN/MADD Domain Containing 3 Gene|KIAA0870	Human DENND3 wild-type allele is located in the vicinity of 8q24.3 and is approximately 79 kb in length. This allele, which encodes DENN domain-containing protein 3, plays a role in guanine nucleotide exchange.			Gene or Genome	
C142211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142211>	C17494	DENN Domain-Containing Protein 3|DENN/MADD Domain-Containing Protein 3|DENND3	DENN domain-containing protein 3 (1198 aa, ~136 kDa) is encoded by the human DENND3 gene. This protein is involved in the activation of Ras-related protein Rab-12 through guanine nucleotide exchange.			Amino Acid, Peptide, or Protein|Enzyme	
C142212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142212>	C20420	ZNF608 Gene|ZNF608|ZNF608|Zinc Finger Protein 608 Gene	This gene plays a role in transcriptional repression and DNA binding.			Gene or Genome	
C142213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142213>	C142212	ZNF608 wt Allele|DKFZp434M098|KIAA1281|NY-REN-36	Human ZNF608 wild-type allele is located in the vicinity of 5q23.2 and is approximately 112 kb in length. This allele, which encodes zinc finger protein 608, is involved in transcriptional repression.			Gene or Genome	
C142214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142214>	C17207	Zinc Finger Protein 608|Renal Carcinoma Antigen NY-REN-36|ZNF608	Zinc finger protein 608 (1512 aa, ~162 kDa) is encoded by the human ZNF608 gene. This protein plays a role in the repression of gene transcription.			Amino Acid, Peptide, or Protein	
C142215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142215>	C18437	RRAGC Gene|RRAGC|RRAGC|Ras Related GTP Binding C Gene	This gene is involved in the localization of the mammalian target of rapamycin complex 1 (mTORC1).			Gene or Genome	
C142216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142216>	C142215	RRAGC wt Allele|FLJ13311|GTR2|RAGC|Ras Related GTP Binding C wt Allele|Ras-Related GTP Binding C Gene|TIB929	Human RRAGC wild-type allele is located in the vicinity of 1p34.3 and is approximately 22 kb in length. This allele, which encodes Ras-related GTP-binding protein C, plays a role in regulating the localization of the mammalian target of rapamycin complex 1 (mTORC1).			Gene or Genome	
C142217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142217>	C18277	Ras-Related GTP-Binding Protein C|GTPase-Interacting Protein 2|RRAGC|Rag C|Rag C Protein|RagC|TIB929	Ras-related GTP-binding protein C (399 aa, ~44 kDa) is encoded by the human RRAGC gene. This protein is involved in the localization of the mammalian target of rapamycin complex 1 (mTORC1).			Amino Acid, Peptide, or Protein|Enzyme	
C142218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142218>	C20194	KLHL14 Gene|KLHL14|KLHL14|Kelch Like Family Member 14 Gene	This gene may play a role in the regulation of protein folding.			Gene or Genome	
C142219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142219>	C142218	KLHL14 wt Allele|KIAA1384|Kelch Like Family Member 14 wt Allele|Kelch-Like 14 (Drosophila) Gene|Kelch-Like 14 Gene	Human KLHL14 wild-type allele is located in the vicinity of 18q12.1 and is approximately 100 kb in length. This allele, which encodes kelch-like protein 14, may be involved in protein folding.			Gene or Genome	
C14221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14221>	C14219	Human Immunodeficiency Virus 2|HIV-2|HIV-2|HUMAN IMMUNODEFICIENCY VIRUS 2|Human Immunodeficiency Virus, Type 2|LAV-2	Any viral organism that can be assigned to the species Human Immunodeficiency virus 2.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142220>	C18466	Kelch-Like Protein 14|KLHL14|Printor|Protein Interactor of Torsin A|Protein Interactor of Torsin-1A|Protein Interactor of TorsinA	Kelch-like protein 14 (628 aa, ~71 kDa) is encoded by the human KLHL14 gene. This protein may play a role in protein folding.			Amino Acid, Peptide, or Protein	
C142221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142221>	C26110	SETD1B Gene|SET Domain Containing 1B Gene|SETD1B|SETD1B	This gene is involved in post-translational methylation of the lysine at position 4 in histone H3.			Gene or Genome	
C142222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142222>	C142221	SETD1B wt Allele|KIAA1076|KMT2G|SET Domain Containing 1B wt Allele|Set1B	Human SETD1B wild-type allele is located in the vicinity of 12q24.31 and is approximately 29 kb in length. This allele, which encodes histone-lysine N-methyltransferase SETD1B protein, plays a role in methylation of histone H3.			Gene or Genome	
C142223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142223>	C16849	Histone-Lysine N-Methyltransferase SETD1B|EC 2.1.1.43|Lysine N-Methyltransferase 2G|Lysine-Specific Methyltransferase 2G|SET1B|SETD1B|hSET1B	Histone-lysine N-methyltransferase SETD1B (1966 aa, ~213 kDa) is encoded by the human SETD1B gene. This protein is involved in catalyzing the methylation of lysine-4 in histone H3.			Amino Acid, Peptide, or Protein|Enzyme	
C142224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142224>	C20420	ZNF292 Gene|ZNF292|ZNF292|Zinc Finger Protein 292 Gene	This gene plays a role in growth hormone signaling-dependent regulation of transcription.			Gene or Genome	
C142226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142226>	C135706	PGI Generic Modification Version - Overall Health	Patient Global Impression Generic Modification Version (PGI Generic Modification Version) How was your overall health?			Intellectual Product	
C142227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142227>	C142224	ZNF292 wt Allele|KIAA0530|Nbla00365|ZFP292|ZN-16|ZN16|Zn-15|bA393I2.3	Human ZNF292 wild-type allele is located in the vicinity of 6q14.3 and is approximately 111 kb in length. This allele, which encodes zinc finger protein 292, is involved in transcriptional regulation. Mutations in the gene may be associated with gastric cancer, colorectal cancer and chronic lymphocytic leukemia.			Gene or Genome	
C142228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142228>	C17207	Zinc Finger Protein 292|16 Zinc-Finger Domain Protein|ZNF292	Zinc finger protein 292 (2723 aa, ~305 kDa) is encoded by the human ZNF292 gene. This protein plays a role in the regulation of gene expression.			Amino Acid, Peptide, or Protein	
C142229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142229>	C26057	INO80 Gene|INO80|INO80|INO80 Complex Subunit Gene	This gene is involved in double-stranded DNA-dependent ATPase activity, UV-damage excision repair, DNA replication and chromosome segregation.			Gene or Genome	
C14222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14222>	C14313	Horse|Equine|Equine Species|Equus caballus|HORSE	The domestic horse, Equus caballus.			Mammal	CDISC SEND Laboratory Animal Species Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142230>	C142229	INO80 wt Allele|Homolog of Yeast INO80 Gene|INO80 Complex Homolog 1 (S. cerevisiae) Gene|INO80 Complex Homolog 1 Gene|INO80 Complex Subunit wt Allele|INO80 Complex, Catalytic Subunit Gene|INO80 Complex, Subunit A Gene|INO80 Homolog (S. cerevisiae) Gene|INO80, S. cerevisae, Homolog of Gene|INO80A|INOC1|KIAA1259|hINO80	Human INO80 wild-type allele is located in the vicinity of 15q15.1 and is approximately 137 kb in length. This allele, which encodes DNA helicase INO80 protein, plays a role in DNA helicase activity.			Gene or Genome	
C142231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142231>	C16517	DNA Helicase INO80|EC 3.6.4.12|INO80|INO80 Complex Homolog 1|INO80 Complex Subunit A|INO80 Homolog|Putative DNA Helicase INO80 Complex Homolog 1|hINO80	DNA helicase INO80 (1556 aa, ~177 kDa) is encoded by the human INO80 gene. This protein is involved in the ATP-depending unwinding of DNA helices.			Amino Acid, Peptide, or Protein|Enzyme	
C142232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142232>	C81971	Streptococcus pneumoniae IgG Antibody Measurement	The determination of the amount of Streptococcus pneumoniae IgG antibody present in a sample.	Streptococcus pneumoniae IgG Antibody Measurement		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Terminology
C142233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142233>	C99208	Minimum Angle of Resolution|MNARS	The smallest angle of separation that allows an image-forming device to distinguish two objects as distinct entities.			Finding	CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142234>	C25636	Digital Sampling Rate|DIGSMPRT	The number of digital samples taken or recorded per unit of time.			Conceptual Entity	CDISC SDTM Device Properties Test Code Terminology|CDISC SDTM Device Properties Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142235>	C53265	Type of Electrical Current Sensor|ECSNRTYP|Electrical Current Sensor Type|Electrical Current Sensor Type	A description of the sensor used to detect electrical current.			Qualitative Concept	CDISC SDTM Device Properties Test Code Terminology|CDISC SDTM Device Properties Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142236>	C25180	Continuous Audio Recording Made Indicator|CAUDRIND|Continuous Audio Recording Indicator|Continuous Audio Recording Indicator	An indication as to whether a continuous audio recording is made during the assessment.			Conceptual Entity	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142237>	C25180	Pulse Oximeter Use Indicator|PULOXIND|Pulse Oximeter Indicator|Pulse Oximeter Indicator	An indication as to whether a pulse oximeter is used in the assessment.			Conceptual Entity	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142238>	C173188	Subject Assigned to Arm But Not Treated|ASSIGNED, NOT TREATED	The subject, who met eligibility criteria, was assigned to an arm but was not treated.			Qualitative Concept	CDISC SDTM Arm Null Reason Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142239>	C70732	Subject Not Assigned to Arm|NOT ASSIGNED	The subject, who met eligibility criteria, was not assigned to an arm and was not treated.			Qualitative Concept	CDISC SDTM Arm Null Reason Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14223>	C14347	HTLV-1|Adult T-cell Leukemia Lymphoma ATLL|Adult T-cell Lymphoma Virus Type 1|HTLV-I|HUMAN T-LYMPHOTROPIC VIRUS 1|Human T-Lymphotropic Virus 1|Human T-Lymphotropic Virus, Type I|Virus-HTLV-I|human T-cell leukemia virus type 1|human T-cell lymphotropic virus type 1	A human deltaretrovirus related to HTLV-2. Human T-lymphotropic virus-1 (HTLV-1) is associated with adult T-cell leukemia (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).	HTLV-1		Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C142240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142240>	C70732	Subject Received Unplanned Treatment|UNPLANNED TREATMENT	The subject, who met eligibility criteria, was assigned to an arm but received treatment not associated with any of the planned arms.			Qualitative Concept	CDISC SDTM Arm Null Reason Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142241>	C54126	Fractional Area Change|FAC	The percent reduction in the area of a given structure with the following formula: (EDA-ESA)/EDA times 100, where EDA is end diastolic area and ESA is end systolic area.			Quantitative Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142242>	C112025|C100084	Estimated Mass of Left Ventricle|LVMAS_E|Left Ventricular Mass, Estimated|Left Ventricular Mass, Estimated	The weight of the left ventricle in grams as estimated by a formula that uses estimated measurements from echocardiographic exams, as well as constants like the specific gravity of the myocardium. Left ventricular mass is estimated using the following equation, LV Mass (g) = 0.8 {1.04[([LVEDD + IVSd + PWd]^3 - LVEDD^3)]} + 0.6, where LVEDD is LV end-diastolic dimension, IVSd is interventricular septal thickness at end-diastole, and PWd is posterior wall thickness at end-diastole.			Diagnostic Procedure	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142243>	C112025|C100084	Left Ventricular Mass Index|LVMASIDX	The left ventricular mass divided by the subject's body surface area.			Diagnostic Procedure	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142244>	C181043	Cardiac Valvular Stenosis Indicator|VLSTNIND	An indication as to whether the cardiac valve in question has stenosis.			Conceptual Entity	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142245>	C35552	Cardiac Valve Stenosis Likely Etiology|VLSTNSLE	A description of the likely cause of the pathology responsible for the cardiac valve stenosis.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142246>	C41328	Supraventricular Premature Complex With Unknown Origin by ECG Finding|SUPRAVENTRICULAR PREMATURE COMPLEX, ORIGIN UNKNOWN|Supraventricular Premature Complexes, Origin Unknown	An electrocardiographic finding of an ectopic impulse originating from the atria or atrioventricular junction for which the site of origin cannot be determined from the surface electrocardiographic recording; there may be one or more occurrences during an electrocardiographic recording.			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142247>	C25158	Immediate Release Capsule Dosage Form|CAPSULE, IMMEDIATE RELEASE	A capsule dosage form that is designed to release its active and/or inert ingredient(s) upon administration with no enhanced, delayed or extended release effect.			Biomedical or Dental Material	CDISC SDTM Dosage Form Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142248>	C42998	Immediate Release Tablet Dosage Form|TABLET, IMMEDIATE RELEASE	A tablet dosage form that is designed to release its active and/or inert ingredient(s) upon administration with no enhanced, delayed or extended release effect.			Biomedical or Dental Material	CDISC SDTM Dosage Form Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142249>	C142232	Streptococcus pneumoniae Serotype 1 IgG Antibody Measurement	The determination of the amount of Streptococcus pneumoniae serotype 1 IgG antibody present in a sample.			Laboratory Procedure	
C14224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14224>	C14347	HTLV-2|HTLV-II|HTLV-II|HUMAN T-LYMPHOTROPIC VIRUS 2|Human T-Lymphotropic Virus 2|Human T-Lymphotropic Virus, Type II|Virus-HTLV-II	A human deltaretrovirus related to HTLV-1. Although human T-lymphotropic virus-2 (HTVL-2) has been isolated in association with specific diseases it has not been shown to have a causal relationship with any disease.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142250>	C142232	Streptococcus pneumoniae Serotype 2 IgG Antibody Measurement	The determination of the amount of Streptococcus pneumoniae serotype 2 IgG antibody present in a sample.			Laboratory Procedure	
C142251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142251>	C142232	Streptococcus pneumoniae Serotype 3 IgG Antibody Measurement	The determination of the amount of Streptococcus pneumoniae serotype 3 IgG antibody present in a sample.			Laboratory Procedure	
C142252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142252>	C142232	Streptococcus pneumoniae Serotype 4 IgG Antibody Measurement	The determination of the amount of Streptococcus pneumoniae serotype 4 IgG antibody present in a sample.			Laboratory Procedure	
C142253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142253>	C142232	Streptococcus pneumoniae Serotype 5 IgG Antibody Measurement	The determination of the amount of Streptococcus pneumoniae serotype 5 IgG antibody present in a sample.			Laboratory Procedure	
C142254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142254>	C142232	Streptococcus pneumoniae Serotype 6B IgG Antibody Measurement	The determination of the amount of Streptococcus pneumoniae serotype 6B IgG antibody present in a sample.			Laboratory Procedure	
C142255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142255>	C142232	Streptococcus pneumoniae Serotype 7F IgG Antibody Measurement	The determination of the amount of Streptococcus pneumoniae serotype 7F IgG antibody present in a sample.			Laboratory Procedure	
C142256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142256>	C142232	Streptococcus pneumoniae Serotype 8 IgG Antibody Measurement	The determination of the amount of Streptococcus pneumoniae serotype 8 IgG antibody present in a sample.			Laboratory Procedure	
C142257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142257>	C142232	Streptococcus pneumoniae Serotype 9N IgG Antibody Measurement	The determination of the amount of Streptococcus pneumoniae serotype 9N IgG antibody present in a sample.			Laboratory Procedure	
C142258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142258>	C142232	Streptococcus pneumoniae Serotype 9V IgG Antibody Measurement	The determination of the amount of Streptococcus pneumoniae serotype 9V IgG antibody present in a sample.			Laboratory Procedure	
C142259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142259>	C142232	Streptococcus pneumoniae Serotype 10A IgG Antibody Measurement	The determination of the amount of Streptococcus pneumoniae serotype 10A IgG antibody present in a sample.			Laboratory Procedure	
C14225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14225>	C79740	Human|HUMAN|Homo sapiens|Homo sapiens|Human, General	The bipedal primate mammal, Homo sapiens; belonging to man or mankind; pertaining to man or to the race of man; use of man as experimental subject or unit of analysis in research.			Human	CDISC SEND Laboratory Animal Species Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|PQ/CMC Source Type Terminology
C142260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142260>	C142232	Streptococcus pneumoniae Serotype 11A IgG Antibody Measurement	The determination of the amount of Streptococcus pneumoniae serotype 11A IgG antibody present in a sample.			Laboratory Procedure	
C142261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142261>	C142232	Streptococcus pneumoniae Serotype 12F IgG Antibody Measurement	The determination of the amount of Streptococcus pneumoniae serotype 12F IgG antibody present in a sample.			Laboratory Procedure	
C142262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142262>	C142232	Streptococcus pneumoniae Serotype 14 IgG Antibody Measurement	The determination of the amount of Streptococcus pneumoniae serotype 14 IgG antibody present in a sample.			Laboratory Procedure	
C142263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142263>	C142232	Streptococcus pneumoniae Serotype 15B IgG Antibody Measurement	The determination of the amount of Streptococcus pneumoniae serotype 15B IgG antibody present in a sample.			Laboratory Procedure	
C142264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142264>	C142232	Streptococcus pneumoniae Serotype 17F IgG Antibody Measurement	The determination of the amount of Streptococcus pneumoniae serotype 17F IgG antibody present in a sample.			Laboratory Procedure	
C142265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142265>	C142232	Streptococcus pneumoniae Serotype 18C IgG Antibody Measurement	The determination of the amount of Streptococcus pneumoniae serotype 18C IgG antibody present in a sample.			Laboratory Procedure	
C142266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142266>	C142232	Streptococcus pneumoniae Serotype 19F IgG Antibody Measurement	The determination of the amount of Streptococcus pneumoniae serotype 19F IgG antibody present in a sample.			Laboratory Procedure	
C142267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142267>	C142232	Streptococcus pneumoniae Serotype 19A IgG Antibody Measurement	The determination of the amount of Streptococcus pneumoniae serotype 19A IgG antibody present in a sample.			Laboratory Procedure	
C142268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142268>	C142232	Streptococcus pneumoniae Serotype 20 IgG Antibody Measurement	The determination of the amount of Streptococcus pneumoniae serotype 20 IgG antibody present in a sample.			Laboratory Procedure	
C142269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142269>	C142232	Streptococcus pneumoniae Serotype 22F IgG Antibody Measurement	The determination of the amount of Streptococcus pneumoniae serotype 22F IgG antibody present in a sample.			Laboratory Procedure	
C14226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14226>	C14251	Human Papillomavirus|HPV|HPV|HPV|HUMAN PAPILLOMAVIRUS|HUMAN PAPILLOMAVIRUS|Human Papilloma Virus|Human Papilloma Virus|Human Papilloma Virus|human papillomavirus	A strain of papillomavirus that can infect the skin and mucous membranes of humans.	Human Papillomavirus		Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NICHD Terminology|Pediatric Immunization Terminology
C142270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142270>	C142232	Streptococcus pneumoniae Serotype 23F IgG Antibody Measurement	The determination of the amount of Streptococcus pneumoniae serotype 23F IgG antibody present in a sample.			Laboratory Procedure	
C142271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142271>	C142232	Streptococcus pneumoniae Serotype 33F IgG Antibody Measurement	The determination of the amount of Streptococcus pneumoniae serotype 33F IgG antibody present in a sample.			Laboratory Procedure	
C142272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142272>	C64430	Alpha Synuclein Protein Measurement|ASYNP|Alpha Synuclein Protein|Alpha Synuclein Protein|SCNA Protein Measurement	The determination of the amount of alpha synuclein protein present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142273>	C64430	Cocaine Amphetamine-Regulated Transcript Protein Measurement|CART|CARTP|CARTPT Protein Measurement|Cocaine Amphetamine-Reg Transcript Prot|Cocaine Amphetamine-Reg Transcript Prot|Cocaine and Amphetamine-Regulated Transcript Protein	The determination of the amount of cocaine amphetamine-regulated transcript protein present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142274>	C74690	Cocaine, Benzoylecgonine, and/or Ecgonine Measurement|COCBNZEC|Cocaine Benzoylecgonine Ecgonine|Cocaine Benzoylecgonine Ecgonine	The determination of the amount of cocaine, benzoylecgonine, and/or ecgonine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142275>	C105585	Estimated Average Glucose Measurement|EAG|EAGLUC|Estimated Average Glucose|Glucose, Estimated|Glucose, Estimated Average|Glucose, Estimated Average	A computed estimate of the blood glucose based on the value of the glycated hemoglobin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142276>	C74760	Globulin to Creatinine Ratio Measurement|GLBCREAT|Globulin/Creatinine|Globulin/Creatinine	The determination of the ratio of globulin compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142277>	C119274	Beta-1 Globulin to Total Beta Protein Ratio Measurement|Beta-1 Globulin/Beta Protein|Beta-1 Globulin/Beta Protein|GLOBB1BP	The determination of the ratio of beta-1 globulin compared to beta protein present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142278>	C163539	HIV-1 and HIV-2 Antibodies and HIV p24 Antigen Measurement	The determination of the amount of HIV-1 antibody, HIV-2 antibody, and HIV p24 antigen present in a sample.			Laboratory Procedure	
C142279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142279>	C64430	Huntingtin Protein Measurement|HTT Protein Measurement|HTTP|Huntingtin Protein|Huntingtin Protein|Total Huntingtin Protein	The determination of the amount of huntingtin protein present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C14227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14227>	C77917	Insect|Insecta|Invertebrates, Insects	A taxonomic class of arthropods that includes praying mantises, dragonflies, grasshoppers, true bugs, flies, bees, wasps, ants, butterflies, moths, and beetles.			Eukaryote	PQ/CMC Source Type Terminology
C142280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142280>	C142279	Mutant Huntingtin Protein Measurement|HTTPM|Huntingtin Protein, Mutant|Huntingtin Protein, Mutant|Mutant HTT Protein Measurement	The determination of the amount of mutant huntingtin protein present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142281>	C225442	Interleukin 1 Receptor-Like 1 Measurement|IL1RL1|Interleukin 1 Receptor-Like 1|Interleukin 1 Receptor-Like 1|Protein ST2|sST2	The determination of the amount of interleukin 1 receptor-like 1 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142282>	C64430	Interleukin 2 Receptor Subunit Alpha Measurement|IL-2Ra|IL2RA|Interleukin 2 Receptor Subunit Alpha|Interleukin 2 Receptor Subunit Alpha|Soluble CD25|sCD25	The determination of the amount of interleukin 2 receptor subunit alpha present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142283>	C64430	Interleukin 2 Receptor Subunit Beta Measurement|IL-2Rb|IL2RB|Interleukin 2 Receptor Subunit Beta|Interleukin 2 Receptor Subunit Beta	The determination of the amount of interleukin 2 receptor subunit beta present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142284>	C134259	Liquefaction Time Measurement|LIQUFT|Liquefaction Time|Liquefaction Time	The determination of the amount of the time it takes for a gelatinous or semi-solid substance to change to a liquid.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142285>	C64430	Neurofilament Light Chain Protein Measurement|NEFL|NEFL Protein Measurement|NF-L|NFLP|Neurofilament Light Chain Protein|Neurofilament Light Chain Protein|Neurofilament Light Polypeptide|Protein Phosphatase 1, Regulatory Subunit 110	The determination of the amount of neurofilament light chain protein present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142286>	C74663	Normal Sperm to Total Sperm Ratio Measurement|NSPMTSPM|Normal Sperm/Total Sperm|Normal Sperm/Total Sperm|Sperm Morphology	The determination of the ratio of normal sperm compared to total sperm present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142287>	C28133	Ovalocyte Count|OVALCY|Ovalocytes|Ovalocytes	The determination of the amount of ovalocytes present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142288>	C48938	Round Cell Count|ROUNDCE|Round Cells|Round Cells	The determination of the amount of round shaped cells, mainly comprised of white blood cells and immature spermatogenic cells, present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142289>	C64430	Renal Papillary Antigen 1 Measurement|RPA1|Renal Papillary Antigen 1|Renal Papillary Antigen 1	The determination of the amount of renal papillary antigen 1 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C14228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14228>	C14376	Invertebrate|Invertebrata|Invertebrates|Invertebrates, General	An animal lacking a vertebral column. This group consists of 98% of all animal species.			Eukaryote	
C142290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142290>	C74957	Sperm Agglutination Measurement|SPMAGGLU|Sperm Agglutination|Sperm Agglutination	The determination of the amount of the motile spermatozoa agglutination present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142291>	C74957	Sperm Aggregation Measurement|SPMAGGR|Sperm Aggregation|Sperm Aggregation	The determination of the amount of immotile spermatozoa aggregation present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142293>	C74689	11-Nor-Delta9-THC-9-Carboxylic Acid Measurement|11-Nor-Delta9-THC-9-Carboxylic Acid|11-Nor-Delta9-THC-9-Carboxylic Acid|THC-COOH|THCCOOH	The determination of the amount of 11-nor-delta-9-THC-9-carboxylic acid present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142294>	C64430	YKL-40 Protein Measurement|CHI3L1 Protein Measurement|Chitinase-3-Like Protein 1|YKL-40 Protein|YKL-40 Protein|YKL40P	The determination of the amount of YKL-40 protein present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142295>	C34076	Calcaneal Tuberosity|CALCANEAL TUBEROSITY	A roughened surface on the superior portion of the posterior half of the calcaneus, where the calcaneal (Achilles) tendon inserts.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142296>	C33904	L4-L5 Intervertebral Space|L4-L5 INTERVERTEBRAL SPACE	The space between the L4 and L5 vertebrae.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142297>	C12863	Hand Digit 2 Middle Phalanx|MIDDLE PHALANX 2 OF THE HAND	A long bone in the second finger, as counted from the thenar side of the hand; it is located between, and articulates with, the proximal and distal phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142298>	C12863	Hand Digit 3 Middle Phalanx|MIDDLE PHALANX 3 OF THE HAND	A long bone in the third finger, as counted from the thenar side of the hand; it is located between, and articulates with, the proximal and distal phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142299>	C12863	Hand Digit 4 Middle Phalanx|MIDDLE PHALANX 4 OF THE HAND	A long bone in the fourth finger, as counted from the thenar side of the hand; it is located between, and articulates with, the proximal and distal phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C14229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14229>	C14260	JC Virus|Human polyomavirus (type JC)|JC Polyomavirus|JC VIRUS|JCV|John Cunningham Virus|Polyomavirus hominis 2|polyomavirus JC	One of two polyomaviruses found in humans. JC virus can infect the respiratory system, kidneys, or brain, sometimes causing the fatal progressive multifocal leukoencephalopathy in the latter case. It is very widespread with approximately 80 percent of the adult population in the United States having antibodies to and JC. (from WordIQ.com)	JC Virus		Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C1422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1422>	C798|C390	Perflubron|Imagent GI|PERFLUBRON|PFOB|Perfluorooctylbromide	A synthetic radiopaque liquid form of perfluorooctyl bromide.  Used as a contrast agent for magnetic resonance imaging (MRI), perflubron is also used as a liquid ventilation agent to improve pulmonary gas exchange and lung compliance and may be used in surgery to reduce or eliminate the need for donor blood.  Ventilation with perfluorocarbon fluid improves lung function in conditions involving surfactant deficiency and dysfunction, including respiratory distress syndrome and adult respiratory distress syndrome. (NCI04)			Indicator, Reagent, or Diagnostic Aid|Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C142300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142300>	C12863	Hand Digit 5 Middle Phalanx|MIDDLE PHALANX 5 OF THE HAND	A long bone in the fifth finger, as counted from the thenar side of the hand; it is located between, and articulates with, the proximal and distal phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142301>	C33027	Nuchal Lymph Node|NUCHAL LYMPH NODE	Any lymph node located in the posterior of the neck, including the postauricular, superficial occipital, middle posterior cervical chain, and lower posterior cervical chain.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142302>	C33027	Parapharyngeal Lymph Node|PARAPHARYNGEAL LYMPH NODE	Any lymph node located in the potential space of the neck, which is bounded superiorly by the base of the skull, inferiorly by the greater cornu of the hyoid bone, anteriorly by the investing fascia of the deep cervical fascia covering the medial pterygoid muscle, posteriorly by the prevertebral layer of the deep cervical fascia, medially by the middle (pretracheal) layer of the deep cervical fascia, and laterally by the investing fascia of the deep cervical fascia covering the deep lobe of the parotid.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142303>	C13019	Posterior Pole of the Eye|POSTERIOR POLE OF THE EYE	The scleral curvature of the eye comprising the retina, inclusive of the macula and optic disc.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142304>	C52786	Hand Digit 2 Proximal Phalanx|PROXIMAL PHALANX 2 OF THE HAND	A long bone in the second finger, as counted from the thenar side of the hand; it is located between, and articulates with, the second metacarpal and the middle phalanx.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142305>	C52786	Hand Digit 3 Proximal Phalanx|PROXIMAL PHALANX 3 OF THE HAND	A long bone in the third finger, as counted from the thenar side of the hand; it is located between, and articulates with, the third metacarpal and the middle phalanx.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142306>	C52786	Hand Digit 4 Proximal Phalanx|PROXIMAL PHALANX 4 OF THE HAND	A long bone in the fourth finger, as counted from the thenar side of the hand; it is located between, and articulates with, the fourth metacarpal and the middle phalanx.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142307>	C52786	Hand Digit 5 Proximal Phalanx|PROXIMAL PHALANX 5 OF THE HAND	A long bone in the fifth finger, as counted from the thenar side of the hand; it is located between, and articulates with, the fifth metacarpal and the middle phalanx.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142308>	C13031	Brainstem Portion of the Pyramidal Tracts|PYRAMIDAL TRACTS, BRAINSTEM	The segments of the corticospinal and corticobulbar tracts that either traverse or terminate in the brainstem.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142309>	C13031	Internal Capsule of the Pyramidal Tracts|PYRAMIDAL TRACTS, INTERNAL CAPSULE	The segments of the corticospinal and corticobulbar tracts that traverse the internal capsule.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C14230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14230>	C14306	Lymphocytic Choriomeningitis Virus|LCMV	A species of single-stranded, negative-sense RNA viruses in the genus arenavirus and family arenaviridae. It is spread by rodents and causes meningitis and encephalitis.			Virus	
C142310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142310>	C33894	Radius-Lunate Joint|RADIUS-LUNATE JOINT	The articulation of the radius and the lunate bone in the wrist.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142311>	C12680	Rectovaginal Space|RECTOVAGINAL SPACE	The anatomical space located between the vagina and rectum, extending from the superior border of the perineal body to the underside of the rectouterine Douglas pouch, which has its formal borders noted thusly: anteriorly by the rectovaginal septum; posteriorly by the anterior rectal wall; and laterally by the descending rectal septa that separate the rectovaginal space from the pararectal space on each side. - Abby is this different to C33447?			Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142312>	C34007	Renal Fossa|RENAL FOSSA	The usual retroperitoneal location of the kidney in the dorsolumbar region of the body.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142313>	C33027	Retroauricular Lymph Node|Mastoid Lymph Node|Posterior Auricular Lymph Node|RETROAURICULAR LYMPH NODE	The lymph nodes located immediately posterior to the ear; also known as the mastoid lymph nodes or the posterior auricular lymph nodes.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142314>	C33894	Scaphoid-Lunate Joint|SCAPHOID-LUNATE JOINT	The articulation of the scaphoid and lunate bones in the wrist.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142315>	C33894	Scaphoid-Radius Joint|SCAPHOID-RADIUS JOINT	The articulation of the radius and the scaphoid bone in the wrist.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142316>	C33894	Scaphoid-Trapezoid Joint|SCAPHOID-TRAPEZOID JOINT	The articulation of the scaphoid and trapezoid bones in the wrist.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142317>	C33561	Skin Between the Eyebrows|SKIN BETWEEN EYEBROWS	The integumentary covering located medial to the orbital ridges and superior to the nose.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142318>	C12295	Skin Of The Back|SKIN OF THE BACK	The integumentary covering of the back.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142319>	C33561	Skin Of The Chin|SKIN OF THE CHIN	The integumentary covering of the chin.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C14231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14231>	C161029	Macaque|Macaca|Macacus|Macaques	Any of several species of short-tailed monkeys of the genus Macaca.			Mammal	
C142320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142320>	C33027	Splenic Lymph Node|Lymph Node(s) Splenic|SPLENIC LYMPH NODE|Splenic lymph nodes|splenic lymph node	Any lymph node located along the splenic artery that receives afferent drainage from the pancreas, spleen, and stomach, and which generally has their efferents join the celiac group of preaortic lymph nodes.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|UBERON Terminology
C142322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142322>	C33027	Submental Lymph Node|SUBMENTAL LYMPH NODE|Suprahyoid Lymph Node|Suprahyoid Lymph Nodes	The lymph nodes located between the anterior bellies of the digastric muscles.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142323>	C34007	Supraclavicular Fossa|SUPRACLAVICULAR FOSSA	A depression found at the base of the neck that is bounded thusly: superiorly by the posterior belly of the omohyoid muscle; inferiorly by the clavicle; and medially by the sternocleidomastoid muscle.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142325>	C12372	Thoracic Artery|THORACIC ARTERY	An artery that branches from the axillary artery or one of its branches, and which supplies the muscles and organs of the thorax.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142326>	C33894	Trapezium-Trapezoid Joint|TRAPEZIUM-TRAPEZOID JOINT	The articulation of the trapezium and trapezoid bones in the wrist.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142327>	C33894	Trapezoid-Capitate Joint|TRAPEZOID-CAPITATE JOINT	The articulation of the trapezoid and capitate bones in the wrist.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142328>	C13035	Upper Urinary System|UPPER URINARY SYSTEM|Upper Urinary Tract|Upper Urinary Tract	The division of the urinary tract comprising the kidney and the ureters.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142329>	C12372	Uterine Artery|UTERINE ARTERY	An artery that arises most often as a branch of the anterior division of the internal iliac artery; it continues medially in the pelvis within the base of the broad ligament, to the exterior surface of the uterus where it branches into the descending, transverse, and ascending divisions, which further branch into the following: the helicine branches that supply the uterus; the vaginal branch, which anastomoses with the vaginal artery to supply vagina; the ovarian branch, which anastomoses with ovarian artery to supply the ovaries; and the tubal branch that supplies the fallopian tubes.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C14232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14232>	C14231	Cynomolgus Monkey|CYNOMOLGUS|CYNOMOLGUS|Crab Eating Macaque|Cynomolgus|Cynomolgus Macaque|MACACA FASCICULARIS|Macaca cynomolgus|Macaca cynomolgus|Macaca fascicularis|Macaca irus	A macaque, Macaca fascicularis (M. cynomolgus), found mostly in southeastern Asia, Borneo, and the Philippines.			Mammal	CDISC SEND Genus and Species Response Terminology|CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142330>	C166041|C132301	Hepatitis C Virus RNA Measurement|HCRNA|Hepatitis C RNA|Hepatitis C RNA Measurement|Hepatitis C Virus RNA|Hepatitis C Virus RNA|Hepatitis C Virus RNA|Hepatitis C Virus RNA	The determination of the amount of hepatitis C virus RNA present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C142331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142331>	C49188|C132301	Hepatitis E Virus RNA Measurement|HERNA|Hepatitis E Virus RNA|Hepatitis E Virus RNA	The determination of the amount of hepatitis E virus RNA present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142332>	C17723	Clinical Pathologist|CLINICAL PATHOLOGIST|Pathology Clinical Pathology	A physician specializing in medical diagnosis based on both the macroscopic and the microscopic changes to tissues and organs caused by a disease.			Biomedical Occupation or Discipline	CDISC SDTM Evaluator Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142333>	C17723	Forensic Pathologist|FORENSIC PATHOLOGIST	A physician specializing in the diagnosis of both the cause of death and the manner of death of another human being.			Biomedical Occupation or Discipline	CDISC SDTM Evaluator Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142334>	C62662	Clauss Method|CLAUSS METHOD	An in vitro method to determine the rate of fibrin clot formation, in which diluted plasma (with thrombin-dependency removed) is mixed with high concentrations of thrombin. This reaction is run in tandem with a control sample and compared.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142335>	C103512	Contrast Enhanced PET-CT Scan|CONTRAST ENHANCED PET/CT SCAN	A form of PET/CT imaging in which radiopharmaceuticals is either ingested or injected intravenously in an attempt to enhance the collected images for diagnostic purposes.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142336>	C17455	Fluorescent Enzyme Immunoassay|ELFA|Enzyme-linked Fluorescence Assay|Enzyme-linked Fluorescent Immunoassay|FEIA|FLUORESCENT ENZYME IMMUNOASSAY	An assay technique that uses enzymes, which when bound to the substrate transform into a fluorescent product, to detect the presence of a substance, usually an antigen.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142337>	C23044	Immunofluorescent Staining Method|IMMUNOFLUORESCENT STAIN|Immunofluorescence	A microscopy staining method that utilizes immunofluorescent markers for use with histological applications of preserved cells.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C142338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142338>	C16856	Immunomagnetic Fluorescence Microscopy|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY	An imaging technique in which fluorescently labeled cells are immunomagnetically selected and imaged by a semi-automated fluorescence microscope.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142339>	C19236	Kinetic Chromogenic Assay|KINETIC CHROMOGENIC ASSAY	A bioassay in which a biological specimen is incubated with a kinetic substrate, followed by optical analysis of color change.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C14233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14233>	C14231	Rhesus Monkey|MACACA MULATTA|Macaca mulatta|RHESUS|Rhesus|Rhesus Macaque|Rhesus Macaque	A pale brown macaque (Macaca mulatta) native to India, China, and other parts of Asia; often used in medical research. A medium-sized diurnal primate, the Macaca mulatta has a diet of plant material and insects that it can store in pouches in its mouth. The rhesus monkey has an inquisitive, destructive nature with a tendency to bite and pinch; captive breeds are used almost exclusively for medical research. The rhesus monkey has a long history in biomedical research owing to its relative ease in upkeep, most famously utilized in the study of the rhesus factor in human blood groups, the effects of space travel on humans, as well as being the first cloned and transgenic primate.			Mammal	CDISC SEND Genus and Species Response Terminology|CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142340>	C38060	Landolt Ring|LANDOLT RING	A standard test of visual acuity, a symbol, in the shape of the letter C, is presented to the patient who must identify on which side of the symbol the gap is present. Both the size of the gap and the size of the symbol are reduced until the subject makes a predetermined rate of errors, thus ending the test.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142341>	C202400	Micro-Latex Particle-Mediated Immunoassay|Latex Agglutination|Latex Fixation|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY	An assay technique used to test a individual's antigen-antibody immune response, which involves coating microbeads of latex with pathogen-specific antigens or antibodies, mixing them with the subject's fluid of interest, and then observing for any agglutination.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142342>	C103512	PET-CT Scan Without Contrast|PET/CT SCAN WITHOUT CONTRAST	A form of PET/CT imaging in which radiopharmaceuticals is not used.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142343>	C19236	Potentiometry|ISE Method|Ion Selective Electrode Method|POTENTIOMETRY	An electroanalytical technique in which the electrical potential of a solution is measured to determine the composition of the sample, by comparing the constant potential of the reference electrode with the actual potential of the indicator electrode.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142344>	C17562	Silver-Enhanced in Situ Hybridization|SISH|SISH	A type of in situ hybridization that uses a hybridization probe linked to an enzyme that elicits neutralization and deposition of silver onto the probe target site.			Molecular Biology Research Technique	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142345>	C38060	Teller Acuity Cards|TELLER ACUITY CARDS	A diagrammatic method to test visual acuity that uses a set of cards with parallel lines, used for those individuals who are unable to provide a verbal response to questions, including infants, toddlers, and other non verbal individuals.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142346>	C28076	International Society of Urological Pathology Gleason Grade Group|Epstein ISUP Grade Group|ISUP|ISUP GLEASON GRADE GROUP|gleason grade group|gleason_grade_group	A grading system for prostatic adenocarcinoma based on modified Gleason cellular differentiation patterns and Gleason primary and secondary scores (Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA; Grading Committee. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016 Feb;40(2):244-52.)			Classification	CDISC SDTM Microscopic Findings Test Detail Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Property Terminology|GDC Terminology
C142347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142347>	C45781	Intraepidermal Nerve Fiber Density|IENFDEN	An evaluation of intraepidermal nerve fiber density present in a specimen.			Conceptual Entity	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142348>	C64430	PAX3-FKHR Fusion Protein Measurement|PAX3-FKHR Fusion Protein|PAX3-FKHR Fusion Protein|PAX3FKHR	The determination of the amount of PAX3-FKHR fusion protein present in a sample.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142349>	C74590	Protocol-Specified Withdrawal Criterion Met|PROTOCOL-SPECIFIED WITHDRAWAL CRITERION MET	An indication that the patient has met one or multiple protocol-specified withdrawal criteria and has been withdrawn from the study.			Intellectual Product	CDISC SDTM Reason for Non-Completion Terminology|CDISC SDTM Terminology|CDISC SDTM Tobacco Study Completion/Reason for Non-Completion Terminology|Clinical Data Interchange Standards Consortium Terminology
C14234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14234>	C14282	Mammalia|Mammal|Mammalian|Mammals, General	A class of warm-blooded vertebrate animals having the skin more or less covered with hair; young are born alive except for the small subclass of monotremes and nourished with milk.			Mammal	
C142351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142351>	C142233	Log10 Minimum Angle of Resolution|MNARSLOG|Minimum Angle of Resolution, Log10|Minimum Angle of Resolution, Log10	The base-10 logarithm of the minimum angle of resolution achieved by an individual during testing.			Finding	CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142352>	C99208	Near-Point Accommodation|NRPNTACC	The minimum distance from the retina that an object remains in clear focus.			Finding	CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142353>	C99208	Number of Characters Read|NUMCHRRD	The number of letters read by the subject during an eye chart assessment.			Finding	CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142354>	C99208	Number of Characters Unread|NUMCHRUR	The number of letters not able to be read by the subject during an eye chart assessment.			Finding	CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142355>	C99208	Number of Lines Unread|NUMLINUR	The number of lines not able to be read by the subject during an eye chart assessment.			Finding	CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142356>	C35571	iRECIST Confirmed Progressive Disease|iCPD	Radiographic progression which has been confirmed by additional imaging showing worsening of initial progression.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C142357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142357>	C4870	iRECIST Complete Response|iCR	The disappearance of all signs of cancer following an initial apparent radiographic progression.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C142358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142358>	C18058	iRECIST Partial Response|iPR	A finding indicating that there is a decrease based on a predetermined threshold in the size and the extent of tissue involvement by cancer following an initial apparent radiographic progression.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C142359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142359>	C18213	iRECIST Stable Disease|iSD	Cancer that is neither decreasing nor increasing in extent or severity based on predetermined boundaries following an initial apparent radiographic progression.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C14235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14235>	C14291	Mouse Mammary Tumor Virus|MMTV	Type B retrovirus.  Etiologic agent of mouse mammary tumors.  Transmitted horizontally through the lactating mammary gland and vertically through the germline.  Mechanism of tumorigenesis involves the activation of cellular int genes by promoter/enhancer insertion.			Virus	
C142360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142360>	C35571	iRECIST Unconfirmed Progressive Disease|iUPD	Apparent radiographic progression which requires confirmation, per criteria, with additional imaging.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C142361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142361>	C4870	Non iRECIST Complete Response-Non iRECIST Unconfirmed Progressive Disease|NON-iCR/NON-iUPD	Persistence of one or more non-target lesion(s) without unequivocal progression following an initial apparent radiographic progression.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C142362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142362>	C181043	New Lesion Indicator|NEWLIND	An indication as to whether a lesion is newly identified, in comparison to a previous timepoint.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Tumor Response Assessment Test Code Terminology|CDISC SDTM Tumor Response Assessment Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C142363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142363>	C181043	New Lesion Worsening Indicator|NEWLWIND	An indication as to whether a previously identified new lesion(s) is showing signs of worsening.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Tumor Response Assessment Test Code Terminology|CDISC SDTM Tumor Response Assessment Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C142364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142364>	C181043	Non-Target Lesion Worsening Indicator|NTLWIND	An indication as to whether a non-target lesion is showing signs of worsening.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Tumor Response Assessment Test Code Terminology|CDISC SDTM Tumor Response Assessment Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C142365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142365>	C38114	Intrasurgical Site Route of Administration|INTRASURGICAL SITE	Administration within the site of surgery.			Functional Concept	CDISC SDTM Route of Administration Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142366>	C204466	Discharge Body Fluid|DISCHARGE|Discharge|Discharge Fluid	Normal or abnormal secretions expelled from a body location.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142367>	C73432	Further Enlargement|FURTHER ENLARGEMENT	An increase in size, volume, quantity or scope in comparison to a previous enlarged state.			Activity	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C142368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142368>	C134576	Experimental Organism Benign Mesoblastic Nephroma|MESOBLASTIC NEPHROMA, BENIGN	A congenital benign neoplasm of the kidney characterized by the presence of interlacing bundles of homogenous spindle cells with small basophilic nuclei and scant eosinophilic cytoplasm.			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C142369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142369>	C38617	Temple|TEMPLE	The flat area on either side of the head that is located posterior to the eye and forehead, anterior to the ear, and superior to the cheek bone.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C14236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14236>	C14291	Mason-Pfizer Monkey Virus|MPMV	Mason-Pfizer Monkey Virus; causes AIDS-like disease (NCI)			Virus	
C142370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142370>	C49346	Striatum Nuclei|STRIATUM	A group of subcortical nuclei of the basal ganglia comprising the caudate and putamen dorsally, and the nucleus accumbens as well as the olfactory tubercle ventrally.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142371>	C277	Amprolium|2-Picolinium, 1-((4-Amino-2-propyl-5-pyrimidinyl)methyl)-, Chloride|AMPROLIUM CHLORIDE|Pyridinium, 1-((4-Amino-2-propyl-5-pyrimidinyl)methyl)-2-methyl-, Chloride				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142372>	C29711|C2846	Camiglibose Anhydrous|CAMIGLIBOSE ANHYDROUS				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142373>	C357	Cefetecol Anhydrous|CEFETECOL ANHYDROUS				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142374>	C201170	Adenosine A2A Receptor Antagonist NIR178|A2AR Antagonist NIR178|NIR 178	An orally bioavailable immune checkpoint inhibitor and antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, A2AR antagonist NIR178 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This prevents tumor-released adenosine from interacting with the A2A receptors, thereby blocking the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits their proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression.	Adenosine A2A Receptor Antagonist NIR178		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C142375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142375>	C20917	BRINP3 Gene|BMP/Retinoic Acid Inducible Neural Specific 3 Gene|BRINP3|BRINP3	This gene plays a role in cell cycle arrest and neuronal differentiation.			Gene or Genome	
C142376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142376>	C142375	BRINP3 wt Allele|BMP/Retinoic Acid Inducible Neural Specific 3 wt Allele|DBCCR1L|DBCCR1L1|FAM5C|Family With Sequence Similarity 5, Member C Gene	Human BRINP3 wild-type allele is located in the vicinity of 1q31.1 and is approximately 381 kb in length. This allele, which encodes BMP/retinoic acid-inducible neural-specific protein 3, is involved in neuronal differentiation and cell cycle arrest. Aberrant expression of the gene may be associated with pituitary tumors, tongue squamous cell carcinomas, ulcerative colitis, and peri-implantitis. Hypermethylation of the gene may be a marker for gastric cancer.			Gene or Genome	
C142377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142377>	C17761	BMP/Retinoic Acid-Inducible Neural-Specific Protein 3|BMP/Retinoic Acid Inducible Neural Specific 3|BRINP3|Bone Morphogenetic Protein/Retinoic Acid Inducible Neural-Specific 3|Bone Morphogenetic Protein/Retinoic Acid-Inducible Neural-Specific Protein 3|DBCCR1-Like Protein 1|Protein FAM5C	BMP/retinoic acid-inducible neural-specific protein 3 (766 aa, ~88 kDa) is encoded by the human BRINP3 gene. This protein plays a role in promoting cell cycle arrest to induce neuronal differentiation.			Amino Acid, Peptide, or Protein	
C142378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142378>	C93407	Clinical Outcome Assessment|COA|clinical outcome assessment (COA)	A measure of a patient's symptoms, overall mental state, or the effects of a disease or condition on how the patient functions as reported by the patient, a clinician, or an observer.			Functional Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142379>	C43381	Data Entry|data entry	The process by which original, source data is inputed by a human into a digital, structured format for later use and analysis.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C14237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14237>	C14309	Measles morbillivirus|MEASLES MORBILLIVIRUS|MEASLES VIRUS|Measles Virus|Measles Virus|Measles Virus|Rougeole Virus|Rubeola Virus|SSPEV|Subacute Sclerosing Panencephalitis Virus|measles virus	A morbillivirus that causes the childhood disease measles and is responsible for subacute sclerosing panencephalitis.	Measles Virus		Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142380>	C47903	Hypertext Markup Language|HTML|HyperText Markup Language (HTML)	A standard markup language used to display content on a web page, as specified by the World Wide Web Consortium (W3C).			Language	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142381>	C20181	Interoperability|interoperability	The capability of two or more systems or components to use and transfer information reciprocally.			Classification	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142382>	C70821	Adequate and Well-controlled Study|adequate and well-controlled studies	A controlled clinical study with the characteristics specified in Title 21, Section 314.126 of the FDA Code of Federal Regulations, including: a clear statement of the objectives of the investigation and a summary of the proposed methods of analysis in the protocol; a design that permits a valid comparison with a control to provide a quantitative assessment of the effect; a method of subject selection that provides adequate assurance that the subject has the disease or condition that the treatment is directed at; a method of assigning patients to treatment and control groups that minimizes bias and assures comparability of the groups; adequate measures taken to minimize bias, by the subjects, observers and the data analysts; methods of assessment of subjects' response that are well-defined and reliable; and an analysis of the results of the study that is adequate to assess the effect of the drug or device.			Research Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142383>	C42636	Administrable Dosage Form|administrable dosage form				Biomedical or Dental Material	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142384>	C25466	Admission Criteria|admission criteria	The set of qualifications for selecting the target population for a clinical trial. This includes screening for any single qualification that excludes a subject from the trial.			Idea or Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142385>	C41332	Adverse Drug Reaction|ADR|Adverse Drug Experience|adverse drug experience|adverse drug reaction (ADR)	Any detrimental or unintended response associated with the use of a medication in humans.			Finding	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142387>	C43369	Alpha Error|alpha error	In statistics, alpha is the probability of a Type 1 error, when one incorrectly rejects the null hypothesis, creating a false positive.			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142388>	C199143	American National Standards Institute|ANSI|American National Standards Institute (ANSI)	An institution founded in 1918 that facilitates the development of American National Standards by accrediting the procedures of standards developing organizations. ANSI itself does not develop standards.			Professional or Occupational Group	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142389>	C47824	Analysis Dataset|analysis dataset	An organized collection of data or information to be used for the analysis of results for a clinical study.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C14238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14238>	C14246	Mouse|MOUSE|Mammals, Mice|Mice|Murine|Mus	Any of numerous species of small rodents belonging to the genus Mus and various related genera of the family Muridae.			Mammal	CDISC SEND Laboratory Animal Species Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142390>	C199140	Analysis Set of Subjects|analysis set	A set of subjects whose data are to be included in the main analyses and defined in the statistical section of the clinical trial protocol. (IHC)			Population Group	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142391>	C142192	Analysis Variable|analysis variables	A changeable factor used in the assessment of the statistical hypothesis outlined in the protocol and/or statistical analysis plan.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142392>	C45970	Anonymization|anonymization|anonymize	The process of removing the association between identifying data and the data subject in order to protect privacy.			Activity	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C142393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142393>	C42608	Applet|App|applet	A small application designed to perform a specific function within another application.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142394>	C68821	Applicable Regulatory Requirement|applicable regulatory requirement(s)	A law or regulation that addresses the conduct of a clinical trial of investigational products. (ICH)			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142395>	C25375	Audit Report|audit report	A written evaluation by the auditor of the results of the analysis. (ICH)			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142396>	C25375	Audit Trail|audit trail	Documentation that allows reconstruction of the course of events. (ICH)			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142397>	C80450	Back Translation|back translation (natural language)	The process of translating a document back to it originally published language.			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142398>	C70821	Balanced Study|balanced study	A study in which there is an equal distribution of individuals across groups or arms.			Research Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142399>	C71292	Bandwidth|Data Throughput|bandwidth	An indicator of the speed of data flow on a transmission path.			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C14239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14239>	C15156	Nude Mouse|Athymic Mouse|Athymic Nude Mouse|NU|NU|Nude|athymic, nude mouse|nu/nu	A hairless mutant mouse with thymic hypoplasia, lacking T-cells.  They are unable to reject transplants.	Nude Mouse		Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C1423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1423>	C697	Perfosfamide|2-[bis(2-chloroethyl)amino]-4-hydroperoxytetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide|4'-Hydroperoxycyclophosphamide|4-HC|4-Hydroperoxycyclophosphamide|4-Hydroperoxycyclophosphamide|4-Hydroperoxycyclophosphamide|4-Pergamid|Hydroperoxycyclophosphamide|PERFOSFAMIDE|Pergamid|cis-2-[bis(2-chloroethyl)amino]tetrahydro-3H-1,3,2-oxazaphosphorin-4-yl hydroperoxide P-oxide|cis-4-hydroperoxycyclophosphamide	The active metabolite of the nitrogen mustard cyclophosphamide with potent antineoplastic and immunosuppressive properties. Perfosfamide alkylates DNA, thereby inhibiting DNA replication and RNA and protein synthesis. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C142400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142400>	C25217	Baseline Assessment|baseline assessment|baseline assessment	Examination of an individual prior to an event or intervention.			Activity	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C142401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142401>	C42605	Baseline Characteristics|baseline characteristics	Subject data gathered prior to an event or intervention, which may include medical history, demographic, and clinical data.			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142402>	C43369	Baseline Imbalance|baseline imbalance	A systematic error in creating intervention groups, such that they differ with respect to prognosis. That is, the groups differ in measured or unmeasured baseline characteristics because of the way participants were selected or assigned. (ICH E9)			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142403>	C19233	Bayesian Approach|Bayesian approaches	Approaches to data analysis that provide a posterior probability distribution for some parameter (e.g., treatment effect), derived from the observed data and a prior probability distribution for the parameter. The posterior distribution is then used as the basis for statistical inference. (ICH E9)			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142404>	C19044	Bayesian Statistics|Bayesian statistics	Statistical method that assigns a probability distribution to some parameter (e.g., treatment effect), based on experience or best guesses before experimentation and data collection and that apply Bayes' theorem to revise the probabilities and distributions after obtaining experimental data.			Quantitative Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142405>	C43369	Beta Error|beta error	In statistics, beta is the probability of a Type 2 error, when one incorrectly accepts the null hypothesis, creating a false negative.			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142406>	C25474	Biometric Signature|biometric signature	A verified characteristic mark of an individual's identity based on measurement of the individual's unique physical feature(s) or repeatable action(s).			Idea or Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142407>	C42729	Blind Review|blind review	Checking and assessing data prior to breaking the blind, for the purpose of finalizing the planned analysis. (ICH)			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142408>	C459	Blinded Medication|Masked Medications|blinded (masked) medications	Medicinal products, with or without the drug under study, which have the same appearance to ensure that neither the subject nor investigator can determine which medication is being administered.			Pharmacologic Substance	CDISC Glossary Terminology
C142409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142409>	C2861	Carry-Over Effect|carry-over effect	Therapeutic responses that continue beyond cessation of treatment, and sometimes, beyond a pharmaceutical product's established biological action.			Finding	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C14240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14240>	C14184	Transgenic Mouse|Transgenic Mice	A mouse whose genome has been altered by the inclusion of foreign genetic material. The technique involves microinjection of foreign DNA fragments into the nucleus of a fertilized egg. The inserted gene becomes integrated into every cell and tissue of the mouse.			Mammal	
C142410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142410>	C25474	Case Report Form Data|CRF Data|CRF data	Information collected from a subject and presented on a case report form.			Idea or Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142411>	C25375	Case Report Tabulation|case report tabulations (CRT)	Lists of information that are organized in some fashion.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142412>	C25474	Categorical Data|categorical data	Types of data which may be divided into groups.			Idea or Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142413>	C25217	Causality Assessment|causality assessment	A medical determination about the likely connection between an adverse event and a treatment or product being studied.			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142414>	C42754	CDISC Classifier Role|role (CDISC classifier)	Classifier for variables that describe observations in the SDTM. Role is a metadata attribute that determines the type of information conveyed by an observation-describing variable and standardizes rules for using the describing variable. (CDISC)			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142415>	C114457	CDISC Library|CDISC SHARE|CDISC Shared Health And Research Electronic Library	A global, accessible electronic library that enables precise and standardized data element definitions to be used within applications and across studies to improve biomedical research and its link with healthcare. (CDISC)			Manufactured Object	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142416>	C81893	CDISC Standard|CDISC standards	A standard set of data models, controlled vocabularies, and exchange standards developed by the Clinical Data Interchange Standards Consortium (CDISC), and intended to address the life-cycle of clinical trial development and electronic submission of clinical data; including protocol representation, data collection, tabulation, and analysis.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142417>	C67336	Certified Copy|certified copy	Reproduction of a primary document, in any format, that has on it an endorsement or certificate that it is a true 'copy' of the primary document.			Physical Object	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142418>	C17089	Certified IRB Professional|certified IRB professional (CIP)	An individual certified to administer and oversee the activities of an institutional review board. The individual must satisfy education and employment requirements and pass an examination conducted by the applied research ethics national association, which is the membership division of Public Responsibility in Medicine and Research.			Professional or Occupational Group	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142419>	C15426	Clean Database|clean database	A database in which all errors have been detected and resolved.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C14241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14241>	C14244	Moloney Leukemia Virus|M-MuLV|M-MuLV|MLV|MURINE LEUKEMIA VIRUS SUBTYPE MOLONEY|MoMuLV|MoMuLV|Moloney Murine Leukemia Virus|Moloney Murine Leukemia Virus M-MuLV|Moloney Virus|Rat Moloney Murine Leukemia Virus MoMuLV	A positive sense, single-stranded RNA (ssRNA) retrovirus species belonging to the Gammaretrovirus genus. It is a causative agent for lymphoid leukemia in mice and other mammals.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142420>	C42883	Clean File|clean file	A single file in which all errors have been detected and resolved.			Manufactured Object	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142421>	C16464	Client Computer|client	A personal computer or workstation that relies on a server computer for many resources.			Manufactured Object	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142422>	C25387	Clinical Benefit|clinical benefit|clinical benefit	An effect of a therapeutic intervention that prolongs life, improves function, and/or improves the way a subject feels.			Idea or Concept	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C142423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142423>	C94778	Clinical Clarification|clinical clarification	The resolution to a question about the clinical trial, by sponsor staff.			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142424>	C25619	Clinical Development Plan|CDP|ClinicalDevelopmentPlan|clinical development plan	A descriptive record of the clinical investigations to be executed with a particular treatment, substance or device. This is usually done to obtain marketing approval.			Activity	BRIDG Class Terminology|BRIDG Terminology|CDISC DDF Reference Identifier Type Value Set Terminology|CDISC DDF Terminology|CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142425>	C19498	Clinical Document|clinical document	Any electronic or written record of clinical observations.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142426>	C25619	Clinical Document Architecture|clinical document architecture	A Health Level 7 specification containing the structure and semantics that clinical documents should follow in order to facilitate data exchange.			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142427>	C62143	Clinical Encounter|Patient Encounter|clinical encounter	Any physical or virtual contact between a patient (or trial subject) and healthcare provider at which an assessment or activity takes place.	Clinical Encounter		Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C142428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142428>	C25687	Clinical Equipoise|equipoise	A state of uncertainty regarding the therapeutic advantages of one treatment over another.			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142429>	C20181	Clinical Generalizability|Generalizability|generalizability|generalizability	The extent to which the findings of a clinical trial can be reliably extrapolated from the subjects who participated in the trial to a broader patient population and a broader range of clinical settings. (ICH)			Classification	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology|FDA-NIH Modernizing Research and Evidence Glossary Terminology
C14242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14242>	C14244	Moloney Sarcoma Virus|MMSV|MoMSV|MoMuSV|Moloney Murine Sarcoma Virus	A positive sense, single-stranded RNA (ssRNA), replication-defective retrovirus species belonging to the Gammaretrovirus genus. It is a causative agent for sarcomas in mice and other mammals.			Virus	
C142430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142430>	C41198	Clinical Investigation|clinical investigation	Any experiment that involves a test article and one or more human subjects, and must either meet the requirements for prior submission to the FDA or the results of which are to be submitted to or inspected by the FDA later as part of an application for a research or marketing permit.			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142431>	C25474	Clinical Item|item	A discrete piece of clinical information represented in a way that humans or machines can understand and interpret.			Idea or Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142432>	C37984	Clinical Laboratory|laboratory (clinical)	A laboratory that analyzes patient or subject samples collected as part of healthcare treatment or clinical research.			Organization	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142433>	C142192	Clinical Outcomes Assessment Concept of Interest|COA COI|concept of interest	The characteristic or variable that is measured in a clinical outcome assessment.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142434>	C25365	Clinical Outcomes Assessment Context of Use|context of use	A description of the purpose and criteria for use of a clinical outcome assessment.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142435>	C15429	Clinical Research and Development|clinical research|clinical research and development	The development and testing of a drug, device, or therapy in human subjects to determine safety and efficacy.			Health Care Activity	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C142436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142436>	C70705	Clinical Study Anchor|Anchor|anchor	A planned activity within a clinical study that marks a transition between epochs or elements within the clinical study.			Intellectual Product	CDISC Glossary Terminology|CDRH Medical Device Component Terminology|Clinical Data Interchange Standards Consortium Terminology
C142437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142437>	C41002	Clinical Study Data Element|clinical study data element	A data element associated with a clinical study.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142438>	C48835	Clinical Study Functional Role|functional roles (in a study)	The responsibility assumed by a person administering any activities within a clinical study.			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142439>	C25375	Clinical Study Report|clinical study report	A written description of a study of any therapeutic, prophylactic, or diagnostic agent conducted in human subjects, in which the clinical and statistical description, presentations, and analysis are fully integrated into a single report. (ICH E6)			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C14243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14243>	C14262	Monkey|MONKEY|Monkeys	Any haplorhine primate not belonging to the family Tarsiidae, Hylobatidae, Pongidae, or Hominidae; this does not correspond to any taxon. This group is divided into Old World monkeys (Cercopithecidae) and New World monkeys (Callitrichidae and Cebidae).  Many types are used as an experimental model for human disease and drug testing.			Mammal	CDISC SEND Laboratory Animal Species Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142440>	C41192	Clinical Trial Authorization|clinical trial authorization	Authorization from an regulatory agency to undertake a clinical trial.			Governmental or Regulatory Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142441>	C25474	Clinical Trial Data|clinical trial data	Information collected during the course of a scientifically-controlled study of the safety and efficacy of a therapeutic agent, such as a drug or vaccine, using consenting human subjects.			Idea or Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142442>	C15320	Clinical Trial Design Configuration|design configuration	The relative arrangement of the portions of a clinical trial's design.			Research Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142443>	C25619	Clinical Trial Development Plan|development plan	An ordered program of clinical trials, each with specific objectives, with the intent of developing an investigational product from preliminary preclinical testing through to marketing authorization.			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142444>	C70732	Study Subject Discontinuation|Clinical Trial Participant Discontinuation|Study Discontinuation|discontinuation|discontinue (participant)	The act of concluding participation by an enrolled subject prior to completion of all protocol-required elements in a trial. NOTE: Four categories of discontinuation are distinguished: a) dropout: Active discontinuation by a subject (also a noun referring to such a discontinued subject); b) investigator initiated discontinuation (e.g., for cause); c) loss to follow-up: cessation of participation without notice or action by the subject; d) sponsor initiated discontinuation. Note that subject discontinuation does not necessarily imply exclusion of subject data from analysis. "Termination of subject" has a history of synonymous use, but is now considered nonstandard. [After ICH E3, section 10.1 and FDA Guidance for Industry: Submission of Abbreviated Reports & Synopses in Support of Marketing Applications, IV A]			Qualitative Concept	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology|HL Authorized Value Terminology|HL Off Protocol Therapy/Study Table
C142445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142445>	C70668	Clinical Trial Dropout|dropout	A subject who stops participating in a clinical trial before the last visit or observation that is required by the study protocol.			Human	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142446>	C73530	Clinical Trial Exemption|clinical trial exemption (CTX)	A process that allows sponsors to apply for approval for each clinical study while granting an exemption from the requirement to hold a clinical trial certificate (CTC).			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142447>	C48191	Clinical Trial Information|clinical trial information	Any and all information related to a clinical study, including study or trial data, data integrity information, and administration.			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142448>	C53604	Clinical Trial Inspection|inspection	The act by a regulatory authority(ies) of conducting an official review of documents, facilities, records, and any other resources that are deemed by the authority(ies) to be related to the clinical trial and that may be located at the site of the trial, at the sponsor's and/or contract research organization's (CRO's) facilities, or at other establishments deemed appropriate by the regulatory authority(ies). (ICH)			Governmental or Regulatory Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142449>	C93406	Clinical Trial Material|clinical trial materials	A term of art referring to the entire set of goods and equipment that are given to a researcher by the trial sponsor, in order to carry out the clinical trial.			Research Device	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C14244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14244>	C14305	Mouse Leukemia Virus|MURINE LEUKEMIA VIRUS|MuLV|Murine Leukemia Virus|Murine Leukemia Virus MLV|Murine Leukemia Virus MuLV	Type C retroviruses that cause leukemia in mice.  Includes the Abelson, AKR, Friend, Moloney, Gross, and other leukemia viruses.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142450>	C93415	Clinical Trial Objective|Study Objective|objective|objective	The main purpose of an investigation that can be measured objectively to determine whether the treatment or intervention being studied is beneficial.			Idea or Concept	CDISC DDF Entities Terminology|CDISC DDF Terminology|CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C142451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142451>	C25320	Clinical Trial Protocol|clinical protocol|protocol|protocol|study protocol	A document that describes the objective(s), design, methodology, statistical considerations, and organization of a trial. The protocol usually also gives the background and rationale for the trial, but these could be provided in other protocol referenced documents. Throughout the ICH GCP Guideline the term protocol refers to protocol and protocol amendments. NOTE: Present usage can refer to any of three distinct entities: 1) the plan (i.e., content) of a protocol, 2) the protocol document, and 3) a series of tests or treatments (as in oncology). [ICH E6 Glossary]			Intellectual Product	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C142452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142452>	C15426	Clinical Trial Registry|clinical trial registry	A publicly available database of clinical trial summary information, which may include purpose of the study, recruiting status, condition and medical product under study, study design, trial phase, participation criteria, contact information, primary outcome measure, and results.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142453>	C142378	Clinician-reported Outcome|ClinRO|clinician-reported outcome (ClinRO)	An assessment from a qualified medical professional based on examination of a subject's health status.			Functional Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142454>	C16048	Codelist|codelist	A list of standard terms and meanings that represent the allowable values for a data item.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142455>	C63474	Cognitive Debriefing|cognitive debriefing	The process of testing an instrument or patient questionnaire with target populations to see if it is understood as intended by the creators of the tool.			Therapeutic or Preventive Procedure	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142456>	C48191	Commercially Confidential Information|commercially confidential information (CCI)	Private information from clinical documents that, if allowed to become public, would impair the genuine financial interest of the company who holds the application.			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142457>	C70821	Comparative Study|comparative study	A type of trial in which the drug of interest is compared against another drug or placebo.			Research Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142458>	C25759	Comparator|comparator|comparator (product)	An investigational or marketed product (i.e., active control), or placebo, used as a reference in a clinical trial. (ICH)			Intellectual Product	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C142459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142459>	C43530	Computer System or Software Supplier|supplier (system)	An individual or entity whose business is to supply computer systems or software to the consumer.			Professional or Occupational Group	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C14245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14245>	C14326	Mumps Virus|MUMPS RUBULAVIRUS|MUMPS VIRUS|Mumps orthorubulavirus|Rubulavirus Mumps	A type of paramyxovirus. It spreads from person to person through coughs, sneezes and saliva, as well as through contact with contaminated items and surfaces. Once the mumps virus enters the body, it passes into the bloodstream and can spread to many different glands and to the brain.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142460>	C208218	Confirmatory Trial|confirmatory trial	A type of phase 3 clinical trial in which the previously characterized actions of a therapeutic intervention, in an earlier phase trial, are verified.			Research Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142461>	C25217	Conformity Assessment|conformity assessment	The means by which regulated products are determined to meet the standards of the European Medicine Agency's Essential Requirements.			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142462>	C17089	Consumer Safety Officer|consumer safety officer (CSO)	An official of the Food and Drug Administration who coordinates the review process of sponsor applications.			Professional or Occupational Group	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142463>	C25461	Contingent Subject Trial Contact|contingent subject trial contact	Planned response to an anticipated but conditional event in a clinical trial. (CDISC)			Human	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142464>	C61299	Control of Electronic Records|Electronic Records Control|control of electronic records	The process by which electronic records are created and maintained in a database for regulated clinical investigations such that the data can be considered adequate and accurate.			Functional Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142465>	C78508	Coordinating Committee|coordinating committee	A committee that a sponsor may organize to coordinate the conduct of a multicenter trial. (ICH)			Population Group	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142466>	C37948	Cumulative Enrollment|enrollment (cumulative)	The number of active and former participants.			Health Care Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142467>	C37948	Current Enrollment|enrollment (current)	The number of active participants.			Health Care Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142468>	C19332	Daily Living|Daily Living Function|functioning|functions	Ability of a patient or subject to successfully perform tasks required for daily living.			Organism Attribute	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142469>	C43384	Data Acquisition|data acquisition	Information input into a systematic, automated format from another device or automated source.			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C14246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14246>	C14270	Muridae	Taxonomic family which includes mice, rats, and gerbils.			Mammal	
C142470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142470>	C25404	Data Capture|data capture	The process by which data is collected de novo from the source.	Data Capture		Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C142471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142471>	C94778	Data Clarification|data clarification	The explanation or answer supplied in response to a data query.			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142472>	C19498	Data Collection Instrument|data collection instruments	An electronic or hard copy mechanism used to collect and assemble clinical information.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142473>	C43369	Data Discrepancy|discrepancy				Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142474>	C25364	Data Element Identifier|data element identifier	Information associated with a data element that includes the origin of the data element, the date and time of entry, and the identification number of the study subject to whom the data element applies. (FDA)			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142475>	C103180	Data Encryption Standard|data encryption standard (DES)	A Federal Information Processing Standards (FIPs) approved cryptographic algorithm for enciphering and deciphering binary coded information. The standard specifies both enciphering and deciphering operations, which are based on a 64-bit binary key.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142476>	C62446	Data Integrity|data integrity	The overall accuracy and consistency of information and processes for data control and use.			Qualitative Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142477>	C45513	Data Integrity Verification|data integrity verification	Authentication of information for logical dependability by a manually administered process.			Qualitative Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142478>	C71292	Data Interchange|data interchange	Transferring information between two or more individuals or electronic tools while protecting the validity and accuracy of the information.			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142479>	C51070	Data Item|Data Element Item|data item	A named component of a data element, usually the smallest component. (ANSI)			Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C14247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14247>	C14186	Avian Myeloblastosis Virus	A retro-transcribing virus, of the genus Alpharetrovirus and the family Retroviridae, that causes anemia and malignant disease in wild and domestic fowl.			Virus	
C142480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142480>	C41116	Data Item Query|query	A question concerning an error or inconsistency within a data item collected as part of a clinical study; usually a request from a sponsor or representative to the investigator.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142481>	C61372	Data Item Query Management|query management	The process of conducting, controlling, or supervising data queries. This may include data review, discrepancy generation, and resolution of errors or inconsistencies.			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142482>	C75906	Data Item Query Resolution|query resolution	The satisfactory closure of a data item query.			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142483>	C43432	Data Listing|data listing	A group of information elements that are arranged by topic.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142484>	C17735	Data Management Convention|data management conventions	Procedures and policies for data management (e.g., documented procedure(s) for resolving self-evident changes). (ICH)			Governmental or Regulatory Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142485>	C47925	Data Mapping|mapping	The process of connecting an item or symbol to a code or concept.			Machine Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142486>	C62608	Data Message|message (HL7)	The atomic unit of data transferred between systems. It comprises a group of segments in a defined sequence, each message has a message type that defines its purpose. (HL7)			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142487>	C16866	Common Data Model|CDM|Common Data Model (CDM)|Data Model|data model	Representation of standards recognized to represent information, including official expression and structure of elements as well as the relationship between elements, to retain the expected meaning.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA-NIH Modernizing Research and Evidence Glossary Terminology
C142488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142488>	C61256	Data Monitoring|data monitoring	Review of clinical information to determine veracity, thoroughness, and dependability.			Activity	CDISC Glossary Terminology
C142489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142489>	C199143	Data Monitoring Committee|DMC|DMOC|DSMB|DSMB|DSMC|Data Monitoring Committee/Data and Safety Monitoring Board (DMC/DSMB)|Data Monitoring and Oversight Committee|Data Safety Monitoring Board|Data and Safety Monitoring Board|Data and Safety Monitoring Board|Data and Safety Monitoring Board|Data and Safety Monitoring Committee DSMB|IDMC|Independent Data Monitoring Committee|data monitoring committee (DMC)	A group of experts that periodically assess information from an ongoing clinical study, including participant's safety and trial effectiveness.			Professional or Occupational Group	CDISC DDF Study Role Code Value Set Terminology|CDISC DDF Terminology|CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C14248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14248>	C14182	Nematoda|NEMATODA|Nematode|Roundworm|Roundworms	The taxonomic class whose members are unsegmented worms with an elongated rounded body pointed at both ends.			Animal	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142490>	C52095	Data Originator|data originator	The creating entity for each information element that identifies the source of the information capture in the electronic case report form for a clinical investigation. The source could be a person, computer system, device or instrument. (FDA)			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142491>	C25283	Data Quality|data quality	The condition of information that describes its credibility, authenticity, and appropriateness for its function. Important aspects include source recognition, accuracy, innovativeness, and information on changes to the data.			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142492>	C25669	Data Security|data security	The degree to which data are protected from the risk of accidental or malicious alteration or destruction and from unauthorized access or disclosure. (FDA)			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142493>	C25466	Data Selection Criteria|data selection criteria	The guidelines for choosing and moving specific information elements from the time and place of patient care to the patient report and forward from there to a database and eventually broader population analyses.			Idea or Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142494>	C60824	Data Storage|data storage	To maintain data by placing the data, or a copy of the data, onto an electronically accessible device for preservation (either in plain-text or encrypted format). (HL7)			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142495>	C48910	Data Subject|data subject	The person to whom data refers.			Functional Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142496>	C142487	Data Submission Model|submission model	Standards for information provided to authorizing officials for marketing purposes.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142497>	C25404	Data Transcription|transcription	The process by which oral source data is transformed into written language.			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142499>	C71292	Data Transmission|transmit	The transfer of information from one source to another.			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C14249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14249>	C14349	Tumor Virus|Oncogenic Virus|Tumor Viruses	A virus capable of transforming a cell to a malignant phenotype. (BioTech Life Science Dictionary)			Virus	
C1424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1424>	C54630|C45711	Sulforaphane|(+/-)-Sulforaphane|1-Isothiocyanato-4-(methylsulfinyl)butane|1-isothiocyanato-4-methylsulfinyl-butane|SULFORAPHANE|Sulfaforaphane|Sulforafan|Sulphoraphane	A naturally-occurring phytochemical belonging to the class of isothiocyanates.  As the aglycone metabolite of glucosinolate glucoraphanin (sulforaphane glucosinolate), sulforaphane acts as an antioxidant and potent stimulator of endogenous detoxifying enzymes.  This agent displays anticarcinogenic properties due to its ability to induce phase II detoxification enzymes, such as glutathione S-transferase and quinone reductase, thereby providing protection against certain carcinogens and toxic, reactive oxygen species.  Broccoli sprouts contain large amounts of sulforaphane, which is also found in other cruciferous vegetables including cabbage and kale. (NCI04)	Sulforaphane		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C142500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142500>	C15381	Data Validation|data validation	Process used to determine if data are inaccurate, incomplete, or unreasonable. The process may include format checks, completeness checks, check key tests, reasonableness checks, limit checks, and checking for compliance with applicable standards, rules, and conventions. (ISO)			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142501>	C45513	Data Verification|Verification of Data|verification of data	The checking of information for correctness or compliance with applicable standards, rules, and conventions. (FDA)			Qualitative Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142502>	C70865	Database Frozen|frozen	A database staus, which usually occurs prior to a database lock, in which the database does not permit any additional changes unless the database is unfrozen.			Qualitative Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142503>	C61286	Database Lock|database lock	A database status, that occurs after the final database freeze event, in which the database disallows any additional changes. Database unlocking may occur but requires certain permissions.			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142504>	C78269	Decision Rule|decision rule	Succinct statement of how a determination will be reached based upon the expected foreseen clinical benefits in terms of outcomes of the primary endpoint. (FDA)			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142505>	C19498	Declaration of Helsinki	A guiding statement, created by the World Medical Association (WMA) in Helsinki, Finland in 1964, that details a set of ethical principles for physicians and other participants in medical research. It has undergone a number of revisions over the years.			Geographic Area	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142506>	C81893	Define.xml|Define-XML	A CDISC standard describing the Extensible Markup Language (XML) data definition file, or metadata describing the format and content of submitted data sets, which is required for submitting clinical trial data to regulatory authorities.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142507>	C25474	De-identified Information|de-identified information	A dataset that has removed or obscured personally identifiable information such that any remaining information cannot be traced to an individual subject.			Idea or Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142508>	C25474	Demographic Data|demographic|demographic data	Aspects of individuals or groups of individuals in a study, including basic descriptive information like age and sex.			Idea or Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|ICDC Node Terminology|ICDC Terminology
C142509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142509>	C142192	Dependent Variable|dependent variable	In an experimental modification of independent factors, the factors that are anticipated to alter as a result.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C14250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14250>		Organism|BiologicEntity|Organismal|Organisms|Taxon|organism	A living entity.			Organism	BRIDG Class Terminology|BRIDG Terminology|NICHD Terminology
C142510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142510>	C142192	Derived Variable|derived variable				Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142511>	C25396	Direct Access|direct access				Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142512>	C142379	Direct Data Entry|direct entry				Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142513>	C25364	Direct Identifier|direct identifier				Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142514>	C70865	Document Legally Authenticated|legal authentication	A completion status in which a document has been signed manually or electronically by the individual who is legally responsible for that document. (HL7)			Qualitative Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142515>	C19498	Document Type Definition|DTD|document type definition (DTD)				Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142516>	C15697	Dosage Regimen|dosage regimen	The specific way a therapeutic drug is to be taken, including formulation, route of administration, dose, dosing interval, and treatment duration.			Functional Concept	CDISC Glossary Terminology
C142517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142517>	C53294	Dose Strength|Dosage Strength(s)|dose strength	The amount of active drug substance in each dosage unit.			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|ICH M11 Protocol Section 6 Data Element Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C142518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142518>	C49658	Double-Dummy|double-dummy	A technique for retaining the blind in a clinical trial with two treatment groups and two non-identical treatments by administering the active form of the first treatment and a placebo in place of the second treatment to one group, and a placebo in place of the first treatment and the active form of the second treatment to the other group.			Research Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142519>	C43431	Drug Development Process|drug development process	The process by which an investigational product is brought to the market through a series of preclinical and clinical testing, regulatory review, and approval.			Research Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C14251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14251>	C14253	Papillomavirus|Papilloma Virus|Virus-Papilloma	A genus of viruses (family Papovaviridae) containing DNA, having virions about 55 nm in diameter, and including the papilloma and warts viruses of man and other animals, some of which are associated with inductions of carcinoma.			Virus	
C142520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142520>	C142380	Dynamic Hypertext Markup Language|Dynamic HTML|dynamic HTML				Language	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142521>	C86058	Edit Check|edit check	A process, usually automated, that is used to check the validity of the input in a data field.			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142522>	C20189	Effectiveness|effectiveness|effectiveness	The extent to which a diagnostic or therapeutic product achieves its intended effect in the typical clinical setting.			Conceptual Entity	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C142523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142523>	C40988	Electronic Case Report Form|eCRF|eCRF (electronic case report form)				Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142524>	C40988	Electronic Case Report Tabulation|eCRT|eCRT (electronic case report tabulation)	The collection of digital data and documentation for a clinical study that is submitted for regulatory review.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142525>	C25198	Electronic Certified Copy|eCertified Copy|eCertified copy	A copy of original information represented in digital format that has been verified by a dated signature as being an exact copy.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142526>	C208217	Electronic Clinical Trial|eClinical Trial|eClinical investigation|eClinical study|eClinical trial	A clinical trial in which computerized systems are used to plan, collect, access, exchange, and archive data.			Research Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142527>	C142470	Electronic Data Capture|EDC|EDC (electronic data capture)	The use of a computerized system to collect clinical trial data.			Health Care Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142528>	C64382	Electronic Data Capture Activation|activation (EDC)	The act or process of enabling an electronic data capture system to acquire data.			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142529>	C25198	Electronic Health Record|EHR|EHR (electronic health record)|From Electronic Health Record	A digital version of a patient's medical history.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA-NIH Modernizing Research and Evidence Glossary Terminology|SeroNet Authorized Values|SeroNet Study Descriptors
C14252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14252>	C161029	Baboon|BABOON|Baboons|Papio	A large terrestrial monkey found in Africa and Arabia, it is the largest non-hominid member of the primate order. This primate has a long dog-like muzzles, close-set eyes, heavy powerful jaws, thick fur, a short tail and often brightly colored ischial callosities.			Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142530>	C42608	Electronic Personal Health Record|ePHR|electronic personal health record (ePHR)	A computer application that is used by patients to access, manage, and share their digitally represented health information in a private, secure, and confidential environment.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142531>	C25198	Electronic Record|electronic record	A collection of digital data that is managed and processed by a computer system.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142533>	C25678	Electronic Signature|eSignature|eSignature|electronic signature	An electronic version of an individual's name or personal mark used to sign electronic documents, signifying that the writing which precedes accords with one's wishes and intentions.			Conceptual Entity	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C142534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142534>	C25474	Electronic Source Data|eSource Data|eSource data	Digital information in original records, and certified copies of digital information in original records.			Idea or Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142535>	C19498	Electronic Source Document|eSource Document|eSource document	An original record containing digital data.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142536>	C25198	Electronic Source Record|eSource|eSource Record	A collection of original digital data, and certified copies of collections of original digital data.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142537>	C154486	Electronic Source Report Form|eSRF|eSRF (electronic source report form)	A digital form that is used to capture and manage original data.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142538>	C81906	Electronic System Deployment|deployment	The process by which an electronic clinical trial system is deployed for field use, including providing or disseminating capture devices, tokens, or passwords for users of an activated system.			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142539>	C208218	Equivalence Trial|equivalence|equivalence trial	A clinical trial with the objective of demonstrating clinical insignificance between the responses to two or more treatments.			Research Activity	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C14253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14253>	C14348	Papovavirus|Virus-Papova	A non-taxonomic group of animal viruses associated with or causing papillomas or polyomas.			Virus	
C142540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142540>	C19498	Essential Trial Document|essential documents	A document that demonstrates the compliance of the investigator, sponsor, and monitor of a clinical trial with all applicable regulatory requirements and the standards of Good Clinical Practice.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142541>	C78508	Ethics Committee|ethics committee	An independent group that comprises medical, scientific, and non-scientific members, and is tasked with the continuing review and approval of a clinical trial's protocol, methods, and informed consent process to ensure the protection of the rights, safety, and wellbeing of participants.			Population Group	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142542>	C81893	European Harmonized Standard|harmonized standard	A document of guidelines for activities or their results that is established as a European Norm, approved and recognized by all Member States and published in the Official Journal of the European Communities (OJEC).			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142543>	C199143	European Medicines Agency|EMA|European Medicines Agency (EMA)	A public health agency based in London that is responsible for the scientific evaluation, supervision, and safety monitoring of medicines in the European Union.			Organization	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142544>	C79889	European Union Competent Authority|Competent Authority (CA)|EU CA	The managing organization, approved by a European Member State government, responsible for ensuring compliance with national regulations.			Classification	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142545>	C19711	European Union Notified Body|EU-NB|NB|Notified Body (NB)	An organization designated by an EU country to assess the conformity of certain products before being placed on the market. These bodies carry out tasks related to conformity assessment procedures.			Population Group	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142546>	C71470	Evaluable for Safety and Efficacy|evaluable (for efficacy and safety)	Patients who meet a clinical trial's inclusion criteria for safety analysis and efficacy evaluation.			Qualitative Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142547>	C208217	Exploratory Investigational New Drug Study|Exploratory IND Study|Exploratory Investigational New Drug Trial|exploratory IND study	A type of clinical trial that involves low dosage and short duration of drug exposure for a limited number of study participants with the intent of gathering preliminary data on the mechanism of action, pharmacodynamics, pharmacokinetics, or bioavailability of promising therapeutic candidate agents in human subjects.			Research Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142548>	C41002	Extensible Markup Language Data Element|XML Data Element|eXtensible markup language (XML) data element	A component of an extensible markup language (XML) document that is used to encapsulate pieces of data and may be delimited by start and end tags or an empty element tag.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142549>	C29862	Extraction Transformation Load|ETL|extraction transformation load (ETL)	A data integration process that involves collecting data from source systems, preparing and transforming the data according to business requirements, and loading them into a data warehouse.			Functional Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C14254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14254>	C125641|C117721	Human Parainfluenza Virus 1|HA2|HPIV-1|HPIV-1|HUMAN PARAINFLUENZA VIRUS 1|Hemadsorption Type 2 Virus|Human Parainfluenza Virus Type 1|Human Respirovirus 1	A single-stranded, negative-sense RNA virus of the paramyxovirus group that causes croup in children.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142550>	C19498	FDA Action Letter|action letter	A letter from the Food and Drug Administration to a study sponsor announcing an agency decision about approval or non-approval. Action letters include Untitled and Warning Letters.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142551>	C70805	FDA Approvable Letter|approvable letter	A letter from the Food and Drug Administration to a study sponsor that lists issues to be resolved before an approval can be issued.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142552>	C43608	FDA Clinical Outcome Assessment Qualification|COA Qualification|clinical outcome assessment (COA) qualification	FDA confirmation that a clinical outcome assessment is a reliable measure for a specific interpretation and application within the stated context of use.			Functional Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142553>	C115464	FDA Memorandum of Understanding|MOU|memorandum of understanding (MOU)	A formal document outlining an agreement between the US Food and Drug Administration and another entity.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142554>	C70805	FDA Not Approvable Letter|not approvable letter	A letter from the Food and Drug Administration to a study sponsor indicating deficiencies in an application that preclude approval of a drug, device, or treatment.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142555>	C19498	FDA Regulation Preamble|preamble	A section preceding the text of a final FDA regulation published in the Federal Register. (FDA)			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142556>	C70805	FDA Warning Letter|Warning Letter	A written communication from FDA notifying an individual or firm that the agency considers one or more products, practices, processes, or other activities to be in violation of the Federal FD&C Act, or other acts, and that failure of the responsible party to take appropriate and prompt action to correct and prevent any future repeat of the violation may result in administrative and/or regulatory enforcement action without further notice. (FDA)			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142557>	C16840	Feels|feels				Mental Process	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142558>	C37939	First Subject In Date Time|FPI - date, time|first patient in - date, time|first subject in - date, time (FSI - date, time)	The date and time when the first individual is enrolled into a clinical study.			Temporal Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142559>	C68806	First Subject In Identity|FPI - identity|first patient in - identity|first subject in - identity (FSI - identity)	The name of the first individual who is enrolled into a clinical study.			Qualitative Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C14255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14255>	C14346	Paramyxoviridae	A family of negative-strand single-strand RNA viruses which includes Mumps and Measles viruses.			Virus	
C142560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142560>	C37939	First Subject Screened Date Time|first patient screened - date, time|first subject screened - date, time	The date and time when the first individual is screened for a clinical study.			Temporal Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142561>	C68806	First Subject Screened Identity|first patient screened - identity|first subject screened - identity	The name of the first individual who is screened for a clinical study.			Qualitative Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142562>	C37939	First Subject Treated Date Time|first patient treated - date, time|first subject treated - date, time	The date and time when the first individual is administered the test article or placebo in a clinical trial.			Temporal Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142563>	C68806	First Subject Treated Identity|first patient treated - identity|first subject treated - identity	The name of the first individual who is administered the test article or placebo in a clinical trial.			Qualitative Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142564>	C15600	First-in-Human Study|first-in-humans study|first-in-man study	A type of phase 1 clinical trial in which the test product is administered to human beings for the first time.			Research Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142565>	C19044	Frequentist Method|Frequentist Inference|Frequentist Statistics|frequentist methods	Statistical methods, such as significance tests and confidence intervals, which can be interpreted in terms of the frequency of certain outcomes occurring in hypothetical repeated realizations of the same experimental situation. (ICH)			Quantitative Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142566>	C142192	Global Assessment Variable|global assessment variable	A single variable, usually a scale of ordered categorical ratings, which integrates objective variables and the investigator's overall impression about the state or change in state of a subject. (ICH)			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142567>	C20189	Granularity|granularity	A data unit, as part of the whole collection of data, that has a high level of detail in distinct parts.			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142568>	C15787	Group Sequential Design|SEQUENTIAL|Sequential|group sequential design	A type of clinical investigation format that evaluates data at predefined stages or after a specific number of patients have participated with specific stopping criteria based on statistical significance.			Research Activity	CDISC Glossary Terminology|CDISC SDTM Intervention Model Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|ICH M11 Intervention Model Value Set Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C142569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142569>	C25678	Handwritten Signature|handwritten signature	The scripted name or legal mark of an individual written by that individual and executed or adopted with the present intention to authenticate a writing in a permanent form. (FDA)			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C14256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14256>	C14351	Picornavirus|Picornaviridae	A family of non-enveloped, positive-stranded RNA viruses with an icosahedral capsid.			Virus	
C142570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142570>	C17047	Health-related Quality of Life|health-related quality of life (HRQoL)	A patient's perception of the effect of illness and treatment on their physical and mental health.			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142571>	C19498	HL7 Document|document (HL7)				Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142572>	C62503	Huriet Law	A French regulation covering the initiation and conduct of all interventional clinical studies, which seeks to protect the participants within interventional trials as well as those individuals and entities that sponsor the trial.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142573>	C25704	Hypertext|hypertext	Words or phrases in an electronic document or web page, usually displayed as colored, underlined text, that if clicked on, permit individuals to immediately move to another section of the webpage or electronic document.			Manufactured Object	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142574>	C25759	Hypothesis To Test|hypothesis to test				Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142575>	C19498	ICH Common Technical Document|Common Technical Document	A record format agreed upon by the International Council for Harmonisation to organize applications to regulatory authorities for registration of pharmaceuticals for human use. (ICH)			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142576>	C20181	ICH Type Of Comparison|type of comparison	Within the context of ICH, this data element describes how treatment arms will be compared within the clinical trial, to include trials that show superiority, non-equivalence, or non-inferiority, or dose-response relationships.			Classification	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142577>	C126368	Impartial Witness|impartial witness	A person who is independent of the trial, who cannot be unfairly influenced by people involved with the trial, who attends the informed consent process if the subject or the subject's legally acceptable representative cannot read, and who reads the informed consent form and any other written information supplied to the subject. (ICH)			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142578>	C78508	Independent Data Monitoring Committee|IDMC|independent data monitoring committee (IDMC)	A committee established by the sponsor to assess at intervals the progress of a clinical trial, safety data, and critical efficacy variables and recommend to the sponsor whether to continue, modify, or terminate the trial. (ICH)			Population Group	CDISC DDF Study Role Code Value Set Terminology|CDISC DDF Terminology|CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|ICH M11 Independent Committee Name Value Set Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C142579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142579>	C78508	Independent Ethics Committee|IEC|independent ethics committee (IEC)	A separate body such as an institutional, regional, national or supranational committee, made up of medical/scientific professionals and non-scientific members, whose responsibility it is to ensure the protection of the rights, safety, and well-being of human subjects involved in a clinical trial. It tries to provide public assurance of that protection by reviewing and approving the trial protocol, the suitability of the investigator(s), facilities, methods, and materials to be used in documenting informed consent of the trial subjects. (ICH)			Population Group	CDISC Glossary Terminology
C14257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14257>	C14349	Plant Virus|Viruses, Plant	Viruses that replicate in and may produce diseases of higher plants.			Virus	
C142580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142580>	C19498	Independent Ethics Committee Opinion|opinion (in relation to independent ethics committee)	The judgment and/or the advice provided by an independent ethics committee. (ICH)			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142581>	C25364	Indirect Identifier|indirect identifier|quasi identifer	Data which, when combined with other information, may enable the identification of a particular individual.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142582>	C25391	Interim Analysis|Interim Analyses|interim analysis(es)	A statistical comparison of intervention groups at any timepoint prior to the official end of the clinical trial.			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|ICH M11 Protocol Section 10 Data Element Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C142583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142583>	C25211	Interim Analysis Schedule|interim analysis schedule	Specification of the intervening time period or stage of information when interim analyses are planned to take place.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142584>	C25164	International Marketing Authorization Birth Date|International Birth Date|international birth date (IBD)	The date that marketing authorization is first granted to a company in any country for a new product. (ICH)			Temporal Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142585>	C97054	International Nonproprietary Name|INN|INN|international nonproprietary name (INN)	A unique, internationally consistent and globally recognized name which identifies pharmaceutical substances or active pharmaceutical ingredients and is public property.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|ICH M11 Protocol Section 1 Data Element Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology|PQ/CMC Substance Name Type Terminology
C142586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142586>	C37900	Internet Service Provider|ISP|internet service provider (ISP)	A business providing its customers with connection to the Internet and other related services.	Internet Service Provider		Functional Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C142587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142587>	C41161	Investigational Product	A pharmaceutical form of an active ingredient or placebo being tested or used as a reference in a clinical trial, including a product with a marketing authorization when used or assembled (formulated or packaged) in a way different from the approved form, or when used for an unapproved indication, or when used to gain further information about an approved use. NOTE: CDISC includes test articles in its definition of investigational products. (ICH)			Conceptual Entity	
C142588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142588>	C19498	Investigational Subject Case History|case history	The detailed documentation about an individual in a clinical trial that is compiled and managed by the investigator. This includes information on informed consent, medical records and other observations.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142589>	C41161	Investigational Treatment	Any agent or product being assessed in a clinical trial.			Conceptual Entity	
C14258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14258>	C25796	Plant|Plants|Plants, General|Viridiplantae	Any living organism that typically synthesizes its food from inorganic substances, possesses cellulose cell walls, responds slowly and often permanently to a stimulus, lacks specialized sense organs and nervous system, and has no powers of locomotion. (EPA Terminology Reference System)			Plant	PQ/CMC Source Type Terminology
C142590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142590>	C29862	Investigator Recruitment Process|recruitment (investigators)	A set of actions used by sponsors to identify and select clinical assessors to serve in a clinical study.			Functional Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142591>	C17089	Investigator/Institution|investigator/institution	An expression meaning the study leader and/or organization, as required by the applicable regulatory requirements. (ICH)			Professional or Occupational Group	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142592>	C42777	Item Definition|item definition	The formal specification of the properties of an element or field of data in study or trial. (CDISC)			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142593>	C42777	Item Group Definition|item group definition	The formal specification of the properties of a group of related items.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142594>	C114459	Janus Clinical Trials Repository Model|Janus CTR|Janus conceptual model	The design for a standards-based infrastructure to support the receipt, validation, storage, and analysis of clinical trial data at the US Food and Drug Administration.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142595>	C189151	Janus Study Data Repository|Janus study data repository	An electronic repository within the US Food and Drug Administration containing subject-level clinical and nonclinical study data submitted to the FDA as part of a regulatory submission.			Manufactured Object	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142596>	C37939	Last Subject In Date Time|LPI - date, time|last patient in - date, time|last subject in - date, time (LSI - date, time)	The date and/or date and time when the final participant in a clinical trial is enrolled.			Temporal Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142597>	C68806	Last Subject In Identity|LPI - identity|last patient in - identity|last subject in - identity (LSI - identity)	The identity of the final subject to enroll in a clinical trial.			Qualitative Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142598>	C37939	Last Subject Last Visit Date Time|last subject last visit - date, time (LSLV - date, time)|last subject out/complete (LSC/LPC or LSO/LPO) - date, time)	The date and or date and time when the final participant has reached a planned or achieved milestone representing the completion of the trial.			Temporal Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142599>	C68806	Last Subject Last Visit Identity|LPC-dentity|LPO - identity|LSC - identity|LSO - identity|last subject complete - identity|last subject last visit - identity (LSLV - identity)|last subject out - identity	The identity of the final subject to reach the final scheduled visit, which is a planned or achieved milestone representing the completion of the trial.			Qualitative Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C14259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14259>	C14203	Poliovirus|ENC|Enterovirus C|Human enterovirus C|POLIOVIRUS|POLIOVIRUS|Polio Virus	An enterovirus comprised of an single-stranded positive sense RNA genome and a protein capsid. This virus is the human pathogen that causes poliomyelitis.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NICHD Terminology|Pediatric Immunization Terminology
C1425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1425>	C226471	Eucerin	A moisturizing skincare formulation used for various skin conditions including dry skin conditions associated with eczema, psoriasis, chapped or chafed skin. (NCI)	Eucerin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C142600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142600>	C17089	Legally Acceptable Representative|LAR|LEGALLY AUTHORIZED REPRESENTATIVE|legally acceptable representative	An individual or juridical or other body authorized under applicable law to consent, on behalf of a prospective subject, to the subject's participation in the clinical trial. (ICH)			Professional or Occupational Group	CDISC Glossary Terminology|CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142601>	C208219	Low-interventional Clinical Trial|low-interventional clinical trial	A clinical trial that is non-interventional by design but includes diagnostic or monitoring procedures that carry minimal risk or impact on patients.			Research Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142602>	C79751	Marketing Authorization Procedure|marketing authorization procedure	A formal procedure by which a regulatory agency grants an applicant authorization for the marketing or free distribution of a product after evaluation for safety, efficacy and quality.			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142603>	C208218	Marketing Support Trials|marketing support trials	A type of clinical trial in which the therapeutic benefits of a marketed product are either clarified or preferentially compared to another marketed product.			Research Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142604>	C15787	Matched-Pair Design|matched-pair design	A type of parallel trial in which investigators identify pairs of subjects who are identical with respect to relevant factors, then randomize them so that one receives Treatment A and the other Treatment B. (CDISC Glossary)			Research Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142605>	C1708	Medicinal Product|medicinal product	Any substance or combination of substances that may be administered to human beings (or animals) for treating or preventing disease, or with the intent to make a medical diagnosis or to restore, correct or modify physiological functions. (IDMP)			Chemical Viewed Functionally	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142606>	C96095	Medicinal Product Identifier|medicinal product identifier	A worldwide unique identifier allocated to a medicinal product that is supplementary to any existing identifier approved by a regulatory authority in the country of authorization.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142607>	C42614	Medicinal Product Name|medicinal product name	The name assigned to a medicinal product as approved by a regulatory authority of the country of authorization.			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142608>	C199143	Medicines And Healthcare Products Regulatory Agency|MHRA|Medicines and Healthcare products Regulatory agency (MHRA)	A government agency of the United Kingdom responsible for ensuring that medicines and medical devices work, and are acceptably safe. (MHRA)			Professional or Occupational Group	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142609>	C208219	Mega-Trial|large sample trial|mega-trials	A type of clinical trial in which 10,000 or more subjects are enrolled.			Research Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C14260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14260>	C14253	Polyomavirus|POLYOMAVIRUS|Polyoma	A genus of double-stranded DNA viruses. The viral particles are not enveloped and are icosahedral in structure.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142610>	C25474	Missing Data|missing data	Required or expected data that is not present, which may be due to non-completion or corruption.			Idea or Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA-NIH Modernizing Research and Evidence Glossary Terminology
C142611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142611>	C70824	Multi-Institutional Clinical Study	A clinical study that is being conducted at multiple locations.			Research Activity	
C142612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142612>	C16779	Natural Language|natural language	Spoken or written language as used in ordinary communications between individuals and groups.			Language	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142613>	C48191	New Safety Information|new safety information	Pharmaceutical data received from factual, observational sources such as adverse event reports, clinical or post-approval studies or other scientific studies about a severe or unexpected severe hazard related to the pharmaceutical after approval or following the most recent assessment of the drug.			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142614>	C208219	N-of-1 Trial|N of 1 Trial|N-of-1 Study|n-of-1 study	A clinical trial that uses a single individual as the entire study population. This subject receives different treatments and control treatments with the goal of determining the best intervention for an individual patient using objective data-driven criteria.			Research Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA-NIH Modernizing Research and Evidence Glossary Terminology
C142615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142615>	C70821	Non-Interventional Study|Non-Interventional Observational Study|Noninterventional (Observational) Study|non-interventional study	A study where the medicinal product(s) is (are) prescribed in the usual manner in accordance with the terms of the marketing authorization. The assignment of the patient to a particular therapeutic strategy is not decided in advance by a trial protocol but falls within current practice and the prescription of the medicine is clearly separated from the decision to include the patient in the study. No additional diagnostic or monitoring procedures shall be applied to the patients and epidemiological methods shall be used for the analysis of collected data. (EU Clinical Trial Directive EC/20/2001 definitions)			Research Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA-NIH Modernizing Research and Evidence Glossary Terminology
C142616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142616>	C53228	Null Hypothesis|null hypothesis	A statistical method to test if observations are significant or due to chance. It proposes that no statistical significance exists in a set of given observations and attempts to show that no variation exists between variables or that a single variable is no different than its mean. It is presumed to be true until statistical evidence nullifies it for an alternative hypothesis.			Quantitative Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142617>	C19498	Nuremberg Code	A set of ten ethical principles for human experimentation established as a result of the Nuremberg trials at the end of the Second World War.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142618>	C25209	Objective Measurement	Any measurement that is not subject to observer assessment, such as those registered by an instrument.			Quantitative Concept	
C142619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142619>	C116518	Observer Assessment|observer assessment	Any assessment made by an observer, as opposed to a device.	Observer Assessment		Health Care Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C14261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14261>	C14348	Poxvirus|Poxviridae	A family of enveloped, double-stranded DNA viruses that infect mammals, birds, and insects. It is divided into two subfamilies: chordopoxvirinae, poxviruses of vertebrates, and entomopoxvirinae, poxviruses of insects.			Virus	
C142620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142620>	C142378	Observer-reported Outcome|ObsRO|observer-reported outcome (ObsRO)	A clinical outcome assessment that is reported by someone other than the patient or a healthcare professional.			Functional Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142621>	C171160	Open To Enrollment|Study Open to Enrollment|open to enrollment	An indication that a study is able to add subjects.			Functional Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142622>	C16866	Operational Model|Operational Definition|operational model	A design model that lays out how a study will be carried out in order to fulfill its objectives.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA-NIH Modernizing Research and Evidence Glossary Terminology
C142623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142623>	C25474	Original Data|original data	The values reported in the initial documents used to record study data.			Idea or Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142624>	C71473	Pairing|matching|pairing	A subject selection method whereby subjects with similar characteristics are assigned as a pair, with the intention that each will receive different treatment within the course of the clinical trial.			Research Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142625>	C40988	Paper Case Report Form|CRF (paper)	A case report form that is printed on paper.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142626>	C48573	Password Aging|Password Expiration|password aging	A system for computer access control that requires a user to create a new password at set intervals.			Event	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142627>	C42883	Patient File|patient file	A file containing demographic, medical, and treatment information pertaining to an individual patient.			Manufactured Object	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142628>	C20181	Patient Reported Outcome Stem|PRO Stem|stem	The prompt, question or instruction in a patient-reported outcome item. (CDISC Glossary)			Classification	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142629>	C20181	Patient-reported Outcome Item|PRO Item|PRO Question|item (PRO)	A question, statement, or task and its pre-specified response values within a patient-reported outcome instrument.			Classification	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C14262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14262>	C14234	Primate|Mammals, Primates|Primates	The taxonomic order of mammals that includes man, monkeys, and lemurs.			Mammal	
C142630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142630>	C20181	Patient-Reported Outcome Item Generation|PRO Item Generation|item generation	The process for identifying the individual questions, statements, or tasks within a patient reported outcome (PRO) instrument.			Classification	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142631>	C19498	Patient-Reported Survey Instrument|instrument	A document or collection or documents that contain a patient-reported survey (e.g., questionnaire) in addition to the information and instructions that document how to use the survey.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142632>	C142378	Performance Outcome|PerfO|performance outcome (PerfO)	A clinical outcome assessment in which a task is performed by a subject under the administration of a healthcare professional.			Functional Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142633>	C25492	Period Effect|period effect	A change which occurs at a particular time, affecting all age groups and cohorts uniformly.			Phenomenon or Process	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142634>	C25474	Permanent Data|permanent data	Data that is not, under normal circumstances, subject to change.			Idea or Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142635>	C47824	Per-Protocol Analysis Set|per-protocol analysis set	The set of data generated by the subset of subjects who complied with the protocol sufficiently to ensure that these data would be likely to exhibit the effects of treatment according to the underlying scientific model. (ICH)			Idea or Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142636>	C16527	Pharmacoeconomics|pharmacoeconomics	A scientific discipline, and subdivision of Health Economics, that compares one pharmaceutical product or treatment to another with respect to various cost comparison measures.			Occupation or Discipline	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142637>	C15719	Pharmacovigilance|pharmacovigilance|pharmacovigilance	Surveillance of drug performance, including detection, monitoring, and prevention of adverse effects by substances with pharmacological activity.			Health Care Activity	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C142638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142638>	C25499	Planned Trial Subject Contact|subject trial contact	Any intended, protocol-defined activity involving data collection from a study subject.			Event	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142639>	C71473	Postmarketing Commitment|postmarketing commitment (PMC)	A candidate's agreement to carry out investigations or trials that are not required by any legal provision.			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C14263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14263>	C14376	Prokaryote|Prokaryotes|Prokaryotic Cells	Organisms without a cell nucleus or any other membrane-bound organelles. Most prokaryotes are bacteria but the group includes both the Bacteria and the Archaea. Eukaryota, Bacteria, and Archaea are now considered the top nodes of a three-domain taxonomy system.			Organism	
C142640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142640>	C15719	Postmarketing Surveillance|post-market surveillance|postmarketing surveillance	Programs to identify adverse events that did not appear during the drug approval process.			Health Care Activity	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C142641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142641>	C208218	Pragmatic Trial|Pragmatic Clinical Trial|pragmatic trial	A study designed to test the effectiveness of an intervention in a broad routine clinical practice.			Research Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA-NIH Modernizing Research and Evidence Glossary Terminology
C142642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142642>	C63536	Preclinical Study|Preclinical Trial|preclinical studies|preclinical study	An investigation that tests a drug, procedure or medical treatment in animals to determine any toxic effects before trials can be carried out in humans.			Research Activity	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology|SeroNet Authorized Values|SeroNet Study Descriptors
C142643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142643>	C68617	Primary Completion Date|primary completion date	The date on which the last clinical study subject was given the final intervention or examination in order to obtain information to support the primary outcome.			Temporal Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142644>	C142192	Primary Outcome Variable|primary outcome variable	The study outcome factor of greatest priority that contributes to the main objective of the trial.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142645>	C28282	Prognostic Covariate|covariate (prognostic)	A variable that directly or indirectly impacts the outcome of a clinical trial.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142646>	C70821	Prospective Study|prospective study|prospective study	A type of study in which participants are enrolled into the study before they develop the disease or outcome in question.			Research Activity	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C142647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142647>	C90492	Protected Personal Data|PII|PPD|PPD|PPI|Personal Data|Personally Identifiable Information|Personally Protected Information|protected personal data (PPD)	Any representation of information that permits the identity of an individual to whom the information applies to be reasonably inferred by either direct or indirect means.			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142648>	C25425	Protocol Approval by Sponsor|protocol approval (Sponsor)	An indication that the sponsor, including all reviewers, have approved the protocol.			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142649>	C93406	Protocol Background Material|background material	Any documentation that pertains to the further understanding of a study protocol.			Research Device	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C14264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14264>	C14358	Rabbit|Mammals, Rabbits|RABBIT|RABBIT	Various members of the family Leporidae, especially those of the genus Sylvilagus.			Mammal	CDISC SEND Laboratory Animal Species Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142650>	C93452	Protocol Referenced Documents|protocol referenced documents	A citation to a publication that is significantly related to a study protocol.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142651>	C103167	Proxy Data Origin|proxy (as an origin of outcome measures)	An indication that the source of clinical trial data comes from a person other than the subject.			Idea or Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142652>	C198997	Proxy Respondent|proxy respondent	A person in a clinical trial other than the subject who provides responses about the subject on their behalf, but not as an observer.			Human	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142653>	C142378	Proxy-reported Outcome|proxy-reported outcome	A clinical outcome assessment that is reported by someone other than the patient as if he or she is the patient.			Functional Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142654>	C45417	Pseudonymization|pseudonymization|pseudonymize	A form of encryption where identifiable parts of personal data are replaced with unique artificial identifiers in order to de-identify the data within a specific context.			Qualitative Concept	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C142655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142655>	C73622	Psychometric Instrument Reliability|psychometric reliability|reliability, psychometric	The extent to which the administration of a psychometric instrument and the data collected from that administration is accurate, repeatable, and sensitive.			Quantitative Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142656>	C16237	Psychometric Validation|psychometric validation|validity, psychometric	The means of authenticating the robustness of clinical trial questionnaires and end result research to establish that they quantify what they were created to quantify.			Occupational Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142657>	C142192	Qualitative Variable|qualitative variable	Variables that cannot be represent by a number, used to describe data that fits into categories.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142658>	C142192	Quantitative Variable|quantitative variable	A variable that can be expressed with numeric values.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142659>	C1708	Radiopharmaceutical Medicinal Product|radiopharmaceutical medicinal product	A radioactive compound that is administered to patients for diagnostic or therapeutic purposes.			Chemical Viewed Functionally	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C14265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14265>	C14180	Frog|FROG|Frogs	An amphibian in the order Anura, which includes the toads. The commonest frog genera are Rana (grass frogs) and Hyla (tree frogs).			Amphibian	CDISC SEND Laboratory Animal Species Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142660>	C52580	Random Allocation|random allocation	The process of resource distribution that is done by chance.			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142661>	C48693	Random Number Table|random number table	A chart containing numbers, with or without duplication and arranged with no discernable pattern. This table may be used as a statistical tool for selection assignment.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142662>	C70837	Random Sample Population|random sample	The target group that is chosen via a sampling methodology created to provide an equal probability of being chosen.			Population Group	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142663>	C25474	Raw Data|raw data	The original information, collected from the primary source.			Idea or Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142664>	C71737	Recruitment Period|recruitment period	The interval of time during which subjects are to be enrolled in a clinical study.			Research Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142665>	C25702	Recruitment Target|recruitment target	The total number of study subjects to be collected for entry into the study to fulfill the protocol conditions.			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142666>	C199143	Regulated Clinical Research and Information Management|RCRIM|RCRIM	A technical committee within Health Level 7 (HL7) that deals with regulated clinical research and information.			Professional or Occupational Group	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142667>	C78269	Repeat Activity Until Rule|repeat rule	A rule that sets the conditions under which a repeating activity will stop.			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142668>	C28362	Research Hypothesis|Study Hypothesis|hypothesis|research hypothesis	The proposed assertion about which the study will determine to prove or disprove.			Conceptual Entity	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C142669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142669>	C17102	Residual Risk|residual risk	Risk that remains after risk control measures have been taken.			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C14266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14266>	C160998	Rattus norvegicus|Common Rat|Norway Rat|RATTUS NORVEGICUS	The common rat, Rattus norvegicus, often used as an experimental organism.			Mammal	CDISC SEND Genus and Species Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142670>	C25374	Response Option|response option	Choices for replies to questions or instructions on patient-reported outcomes.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142671>	C71473	Results Posting|Results Submission|results posting (results submission)	The process of submitting and updating summary information about the conclusions of a clinical study to a structured, publicly accessible, Web-based results database, such as the ClinicalTrials.gov results database. (clinicaltrials.gov)			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142672>	C25164	Results Posting Date|Results Submission Date|results posting date (results submission date)	The date and time that the summary information about the conclusions of the clinical study are submitted to a structured, publicly accessible, Web-based results database, such as the ClinicalTrials.gov results database. (clinicaltrials.gov)			Temporal Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142673>	C71473	Retrospective Data Capture|retrospective data capture	Data that is collected after the fact, originating from subject recall or memory.			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142674>	C15789	Risk Based Monitoring|Risk-Based Monitoring|risk-based monitoring	An approach to clinical trial monitoring that involves identifying, assessing, monitoring and mitigating the risks that could affect the quality or safety of a study.			Governmental or Regulatory Activity	CDISC Glossary Terminology
C142675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142675>	C81893	SAFE-Biopharma Standard|BioPharma Digital Identity and Signature Standard|SAFE|SAFE	A standard established by the biopharmaceutical industry to digitally identify subscribers, mitigating legal, regulatory, and other business risks associated with electronic transactions.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142676>	C70705	Safety and Tolerability|safety and tolerability	The aspects of medical product evaluation associated with risk to the subject/patient and the degree to which overt adverse effects can be tolerated.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142677>	C49157	Sample Size Adjustment|sample size adjustment	A change to a previously determined sample population size for a study, following a review of blinded information during an intermediate point in the study.			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142678>	C25211	Schedule Of Assessments|schedule of assessments|schedule of assessments	A sequential representation of planned protocol events and activities that pertain to patient assessment within the study.			Intellectual Product	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C142679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142679>	C48355	Secondary Sponsor|secondary sponsor	Additional individuals, organizations or other legal persons, if any, that have agreed with the primary sponsor to take on sponsorship responsibilities. (WHO)			Human	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C14267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14267>	C14308	Human Respiratory Syncytial Virus|HUMAN RESPIRATORY SYNCYTIAL VIRUS|Human RSV|RSV|RSV|RSV|Respiratory Syncytial Virus|hRSV|hRSV|respiratory syncytial virus	A negative-sense, enveloped RNA virus. The virion is variable in shape and size with an average diameter of between 120 and 300 nm.	Human Respiratory Syncytial Virus		Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C142680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142680>	C142192	Secondary Outcome Variable|secondary outcome variable	A factor or condition subject to change in a clinical trial that is used to evaluate additional effects of the intervention not included in the primary outcome measure.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142681>	C25446	Self-Evident Change|self-evident change	An information error that can be quickly and accurately fixed based on existing data on the form.			Qualitative Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142682>	C142381	Semantic Interoperability|semantic interoperability	The ability of computer systems to share data with unambiguous meaning.			Classification	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142683>	C25474	Sensitive Data|Sensitive Personal Data|sensitive data	Any information that, in the event of re-identification, would harm a patient in terms of employability, reputation, insurability, or self-esteem or results in loss of income. (HIPAA)			Idea or Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142684>	C70705	Sequence Arm	An outlined set of steps that correspond to a therapeutic intervention for a clinical trial.			Intellectual Product	
C142685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142685>	C142385	Serious Adverse Drug Reaction|Serious ADR|Serious Adverse Drug Reaction (SADR)|serious adverse drug reaction	A noxious and unintended response to a medicinal product occurring at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in a persistent or significant disability/incapacity, or results in a congenital anomaly/birth defect.			Finding	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C142686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142686>	C52680	Serious Adverse Experience|SAE|serious adverse experience (SAE)	A situation referring to a severe reaction, risk or indication against use of a treatment or device.			Finding	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142687>	C17102	Serious Risk|serious risk				Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142688>	C43382	Signal of a Serious Risk|signal of a serious risk	Information related to a serious adverse drug experience associated with use of a drug and derived from-(a) a clinical trial; (b) adverse event reports; (c) a post-approval study; (d) peer-reviewed biomedical literature; (e) data derived from the post-market REMs. [505-1(b) of FD&C Act (21 USC. 355-1(b)]			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142689>	C48261	Site Screening|screening (of sites)	The process by which a location is monitored and assessed to ensure that the venue and staff are appropriate for clinical study work.			Diagnostic Procedure	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C14268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14268>	C54085|C14351	Retroviridae|Retrovirus|Retroviruses|Virus-Retrovirus|retrovirus	A family of viruses that possess RNA-dependent DNA polymerases (reverse transcriptases) and contain two identical molecules of positive sense, single-stranded RNA of high molecular weight.  This RNA serves as a template for the synthesis of a complementary DNA, which may be integrated into the host DNA. Virions are enveloped.			Virus	
C142690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142690>	C16237	Software Validation|software validation	A process of confirmation by examination and provision of objective evidence that software specifications conform to user needs and intended uses and that the particular requirements implemented through software can be consistently fulfilled.			Research Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142692>	C19498	Source Document|source documents	The original information in a variety of media, which may substantiate information contained in an electronic record of the study.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142693>	C45513	Source Document Verification|source document verification (SDV)	Confirming the accuracy, authenticity, and thoroughness of a primary record by comparing it to original evidence and reports.			Qualitative Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142694>	C45306	Specified Substance|specified substance	Substance defined by groups of elements that describes multi-substance materials or specifies further information on substances relevant to the description of Medicinal Products. (IDMP)			Substance	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142695>	C17089	Sponsor-Investigator|sponsor-investigator	An individual person who both initiates and conducts, alone or with others, a clinical trial and under whose immediate direction the investigational product is administered to, dispensed to, or used by a subject. (FDA)			Professional or Occupational Group	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142696>	C94396	Standard Treatment|standard treatment	A therapy approved by a health regulatory authority and in wide use, which is considered to be the standard of care for the management of a specific disease or condition.			Health Care Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142697>	C20181	Stochastic|stochastic	The determination by chance or probability.			Classification	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142698>	C70705	Stopping Rules|Trial Stopping Rules|stopping rules	A set of circumstances in which the study should be stopped early, keeping in mind the statistical reliability of the circumstances.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|ICH M11 Protocol Section 4 Data Element Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C142699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142699>	C25474	Structured Data|structured data	Structured health record information is divided into discrete fields, and may be enumerated, numeric, or codified. examples of structured health information include: patient address (non-codified, but discrete field); diastolic blood pressure (numeric); coded result observation; coded diagnosis; patient risk assessment questionnaire with multiple-choice answers. Context may determine whether or not data are unstructured, e.g., a progress note might be standardized and structured in some eHR-s (e.g., subjective/objective/ assessment/Plan) but unstructured in others. (HL7)			Idea or Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C14269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14269>	C14283	RNA Virus|Virus-RNA|Viruses, RNA	A virus whose genome consists of RNA.			Virus	
C1426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1426>	C1504	Recombinant Heregulin|Heregulin	A growth factor of the EGF family that induces growth and differentiation of epithelial, glial and muscle cells in culture.  It binds the receptor erbB3 which will heterodimerize with HER-2/erbB2.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C142700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142700>	C103180	Structured Product Labeling|SPL|structured product label (SPL)	A Health Level 7 (HL7) ANSI-approved document markup standard that specifies the structure and semantics for the exchange of product information. (HL7)			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142701>	C15320	Study Branch|arm|branch	A planned point in time within the study design in which there is a subdivision of subjects to particular procedures or treatment groups.			Body Part, Organ, or Organ Component	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|ICDC Property Terminology|ICDC Terminology
C142702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142702>	C68617	Study Completion Date|Study End Date|study completion date	The date on which the concluding information for a clinical investigation is completed. Usually, this is when the last subject has a final visit or any other protocol-defined completion date.			Temporal Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142703>	C25759	Study Control|control	A comparator treatment in a clinical trial against which the treatment under study is evaluated. (ICH)	Study Control		Intellectual Product	CDISC Glossary Terminology|CTRP Intervention Terminology|CTRP Terminology
C142704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142704>	C25365	Study Description|Clinical Study Description|clinical study description|clinical_study_description|study description	Specific, essential aspects of an investigation that are detailed, including structure,  blinding, dosage, and participant demographics.			Intellectual Product	CDISC DDF Clinical Study Attribute Terminology|CDISC DDF Terminology|CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|ICDC Property Terminology|ICDC Terminology
C142705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142705>	C80263	Study Design Rationale|Overall Rationale for Trial Design|study design rationale	Justification for the type investigation method employed by the study.			Classification	CDISC DDF Study Design Attribute Terminology|CDISC DDF Terminology|CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|ICH M11 Protocol Section 4 Data Element Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C142707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142707>	C71473	Study Monitoring|Trial Monitoring|study monitoring	The act of overseeing the progress of a clinical trial and of ensuring that it is conducted, recorded, and reported in accordance with the protocol, standard operating procedures (SOPs), good clinical practice (GCP), and the applicable regulatory requirement(s). (ICH)			Activity	CDISC Glossary Terminology
C142708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142708>	C25375	Study Monitoring Report|monitoring report	A written report from the monitor to the sponsor after each site visit and/or other trial-related communication according to the sponsor's SOPs. (ICH)			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142709>	C25716	Study Monitoring Visit|monitoring visit	A visit to a study site to review the progress of a clinical study and to ensure protocol adherence, accuracy of data, safety of subjects, and compliance with regulatory requirements and good clinical practice guidelines. (ICH)			Individual Behavior	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C14270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14270>	C14234	Rodentia|Mammals, Rodents|Rodent|Rodents	The taxonomic order of mammals that includes mice, rats, guinea pigs, squirrels, beavers, and many others.			Mammal	
C142710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142710>	C41189	Study Participant|Participant|study participant|study participant	Any individiual that has a role in a study, including study personnel and study subjects.			Functional Concept	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology|ICH M11 Terminology|ICH M11 Trial Blinding Role Value Set Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C142711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142711>	C25164	Study Publication Date|Publication Date|study publication date	The date of publication of an abstract or article pertaining to a particular clinical study.			Temporal Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF8 Pathology Review Targeted Genomics Table
C142712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142712>	C71473	Study Reconstruction|reconstruction (of a study)	The process for eClinical trials where the FDA expects archival trial records that support review of the data as well as the processes used for obtaining and managing the data so that the trustworthiness of results can be evaluated. (FDA)			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142713>	C68617	Study Report Completion Date|study report completion date	The date on which the investigation documentation is finalized and no other changes will be made.			Temporal Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142714>	C25431	Study Start|study start	The official beginning of a clinical study, as specified in the clinical study report.			Temporal Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142715>	C168928	Study Subject Enrolled|Enrolled|Enrolled|Subject Registered|enrolled	The study subject is/was enrolled.			Qualitative Concept	ALL Authorized Value Terminology|ALL Subject Characteristics Table|AML Authorized Value Terminology|AML Subject Characteristics Table|CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142717>	C25499	Subject Data Event|subject data event	Information produced, compiled, or examined during a visit with a clinical trial subject.			Event	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142718>	C17102	Subject Risk|risk|risks of a research study				Conceptual Entity	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C142719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142719>	C71473	Subject Termination	Premature discontinuation of an individual's participation in a clinical trial.			Activity	
C14271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14271>	C77167	Saccharomyces cerevisiae|Bakers Yeast|Brewers Yeast|S. capensis|S. cerevisiae|S. italicus|S. oviformis|S. uvarum var. melibiosus|SACCHAROMYCES CEREVISIAE|SACCHAROMYCES CEREVISIAE|Saccharomyces capensis|Saccharomyces italicus|Saccharomyces oviformis|Saccharomyces uvarum var. melibiosus	A species of unicellular fungus used as a research subject and in baking and beer brewing.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142720>	C25178	Subject Well-Being|well-being (of the trial subjects)	The physical and mental integrity of the individuals participating in a clinical study. (ICH)			Idea or Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142721>	C48261	Substance Screening|screen/screening (of substances)	Random or targeted evaluation of material using biochemical tests or assays constructed to identify a particular biological aspect or action.			Diagnostic Procedure	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142722>	C208218	Superiority Trial|superiority trial|superiority trial	A trial with the primary objective of showing that the response to the investigational product is superior to a comparative agent (active or placebo control). (ICH)			Research Activity	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C142723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142723>	C142192	Supporting Variable	A factor or condition subject to change that is not a primary or secondary variable but may provide additional information to enhance the assessment of clinical effect.			Intellectual Product	
C142724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142724>	C16342	Surrogate Marker|surrogate marker	In a clinical trial, an assessment of an intervention's effects that takes the place of a patient-based conclusion.			Functional Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142725>	C142192	Surrogate Variable|surrogate variable	A factor or condition subject to change that provides an indirect measurement of effect in situations where direct measurement of clinical effect is not feasible or practical. (ICH)			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142726>	C50651	System Migration|migration	The act of moving a computer system and its data from one operational environment to another.			Natural Phenomenon or Process	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142727>	C47824	Tabulation Dataset|tabulation dataset	Standardized clinical trial information arranged in a table.			Idea or Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142728>	C199140	Target Study Population|Study Design Population|Target Population|target population	The population within the general population for which the study results can be generalized. For interventional trials, a group of patients to which the indication of an investigational or authorized medicinal product applies. (ISO)			Population Group	CDISC DDF Entities Terminology|CDISC DDF Terminology|CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142729>	C37900	Technology Provider|technology provider|technology vendor	An individual or organization that sells software applications or computer hardware.	Technology Provider		Functional Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C14272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14272>	C86010	Serratia marcescens|S. marcescens|SERRATIA MARCESCENS|SERRATIA MARCESCENS	A species of motile, Gram-negative enterobacteria in the phylum Proteobacteria, differentiated from other Gram-negative bacteria by its ability to perform casein hydrolysis.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142730>	C16048	Terminology|terminology	A standardized, finite set of concepts, designations, and relationships for a specialized subject area.			Classification	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142731>	C25387	Treatment Benefit|treatment benefit	The direct or indirect impact of treatment as measured by outcome assessments of a patient's feelings, level of functioning, or survival.			Idea or Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142732>	C54216	Treatment Contrast Interaction|interaction (qualitative and quantitative)|treatment contrast interaction	The situation in which a treatment contrast (e.g., difference between investigational product and control) is dependent on another factor (e.g., center). A quantitative interaction refers to the case where the magnitude of the contrast differs at the different levels of the factor, whereas for a qualitative interaction, the direction of the contrast differs for at least one level of the factor. (ICH)			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142733>	C154678	Treatment-Emergent Adverse Event|Adverse Effects of Medical Treatment|treatment-emergent adverse event	A situation that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state. (ICH)			Finding	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C142734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142734>	C71473	Trial Compliance|compliance (in relation to trials)	Adherence to clinical trial-related requirements, good clinical practice (GCP) requirements, and the applicable regulatory requirements. (ICH)			Health Care Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142735>	C105752	Trial Design Element|Study Design Element|trial design element				Conceptual Entity	CDISC DDF Entities Terminology|CDISC DDF Terminology|CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142736>	C16866	Trial Design Model	A standard structure for representing the planned sequence of events and the treatment plan of a clinical trial. (CDISC)			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142737>	C51877	Trial Statistician|study statistician|trial statistician	A statistician who has a combination of education, training and experience to be responsible for the statistical aspects of the trial. (ICH)			Professional or Occupational Group	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C142738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142738>	C71473	Trial Subject Replacement|replacement	The process of enrolling a trial subject to compensate for another participant that has left the clinical trial.			Activity	CDISC Glossary Terminology
C142739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142739>	C70757	Trial Termination|Trial Terminated|termination (of a clinical trial)|termination (of a research study)	The discontinuation of a clinical trial prior to the planned end date.			Functional Concept	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C14273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14273>	C14323	Sheep|Ovine|SHEEP	Any one of several species of ruminants of the genus Ovis, native of the higher mountains of both hemispheres, but most numerous in Asia; the domestic sheep, Ovis aries.			Mammal	CDISC SEND Laboratory Animal Species Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142740>	C45259	Trustworthy Electronic Record|trustworthy (electronic records)	A characteristic of an electronic record, specifically data quality and integrity, that indicates fitness for safety and efficacy recommendations.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142741>	C43369	Type 3 Error|Type III Error|type 3 (or type III) error	In statistics, the probability of a Type 3 error, when one correctly rejects the null hypothesis, but the reason for rejecting it is incorrect. In the context of study interventions, this means that one incorrectly determines that the less useful treatment is more useful.			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142742>	C49068	Unblinding|TREATMENT UNBLINDED|Unblinded|Unmasking|unblinding	The process by which identifying information for a patient or group of outcomes from a clinical trial is revealed to the subject and/or investigators conducting the clinical study.			Functional Concept	CDISC Glossary Terminology|CDISC SDTM Other Disposition Event Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142743>	C25196	Unequal Randomization	A type of sorting to allocate subjects/patients in a clinical trial into groups at different rates.			Health Care Activity	
C142744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142744>	C41334	Unexpected Adverse Drug Reaction|unexpected adverse drug reaction	An adverse drug reaction, whose nature, severity, specificity, or outcome is not consistent with the term or description used in the applicable product information (e.g., IB for an unapproved investigational product or PI/summary of product characteristics for an approved product, and/or scientific literature). (ICH)			Finding	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142745>	C17102	Unexpected Serious Risk|unexpected serious risk	A serious adverse drug experience that is not listed in the labeling of a drug, or that may be symptomatically or pathophysiologically related to an adverse drug experience identified in the labeling, but differs because of greater severity, specificity, or prevalence. [505-1(b) of FD&C Act (21 USC. 355-1(b)			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142746>	C15336	User Site Testing|UST|user site testing (UST)	Any examination of software/hardware functionality that takes place outside of the developer's controlled environment.			Occupational Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142747>	C41189	Vulnerable Subjects|vulnerable subjects	Volunteers for clinical studies who may be unreasonably persuaded to participate by perceived benefits, or fear of punishment by superiors.			Functional Concept	CDISC Glossary Terminology
C142748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142748>	C17146	Web Browser|web browser	A software tool that enables Internet navigation to Web sites and other online resources using Hypertext Transfer Protocol (HTTP).			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142749>	C19498	Web Page|web page	A hypertext document on the World Wide Web that may incorporate text, graphics, sound, and/or other features.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C14274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14274>	C117716	Simian Immunodeficiency Virus|SIV	An HIV-like virus that infects monkeys, chimpanzees, and other non-human primates. (AIDS Info HIV Glossary)			Virus	
C142750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142750>	C48297	Web Server|web server	A remote computer or program that delivers Hypertext Markup Language (HTML) pages to a user's computer.			Manufactured Object	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142751>	C19498	XML Document Root|document root				Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142752>	C45513	Source Data Verification|source data verification	Confirming the accuracy, authenticity, and thoroughness of information by comparing it to original information and records.			Qualitative Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142753>	C43382	System Alert|Warning|alert	A high-priority signal that is sent to a specific person by way of a system, according to an established set of rules.			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C142754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142754>	C25784	RAB12 Gene|RAB12|RAB12|RAB12, Member RAS Oncogene Family Gene	This gene is involved in intracellular membrane and protein trafficking.			Gene or Genome	
C142755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142755>	C142754	RAB12 wt Allele|RAB12, Member RAS Oncogene Family wt Allele|Rab-12	Human RAB12 wild-type allele is located in the vicinity of 18p11.22 and is approximately 30 kb in length. This allele, which encodes Ras-related protein Rab-12, plays a role in vesicle transport.			Gene or Genome	
C142756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142756>	C18549	Ras-Related Protein Rab-12|RAB12|Ras-Associated Protein Rab12	Ras-related protein Rab-12 (244 aa, ~27 kDa) is encoded by the human RAB12 gene. This protein is involved in the regulation of trafficking of intracellular vesicles.			Amino Acid, Peptide, or Protein|Enzyme	
C142757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142757>	C25804|C25802	TOR1A Gene|TOR1A|TOR1A|Torsin Family 1 Member A Gene	This gene plays a role in post-translational processing of proteins.			Gene or Genome	
C142758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142758>	C142757	TOR1A wt Allele|DQ2|DYT1|Dystonia 1, Torsion (Autosomal Dominant; Torsin A) Gene|TA|TORA|Torsin A Gene|Torsin Family 1 Member A wt Allele|Torsin Family 1, Member A (Torsin A) Gene	Human TOR1A wild-type allele is located in the vicinity of 9q34.11 and is approximately 11 kb in length. This allele, which encodes torsin-1A protein, is involved in chaperone activity. Mutation of the gene is associated with autosomal dominant torsion dystonia 1.			Gene or Genome	
C142759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142759>	C17764|C16701	Torsin-1A|Dystonia 1 Protein|EC 3.6.4.-|TOR1A|Torsin 1A|Torsin A|Torsin ATPase 1|Torsin ATPase-1A|Torsin Family 1 Member A	Torsin-1A (332 aa, ~38 kDa) is encoded by the human TOR1A gene. This protein plays a role in protein folding, maturation and localization.			Amino Acid, Peptide, or Protein|Enzyme	
C14275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14275>	C14354	Specific Pathogen Free Organism|SPF Organism|Specific-Pathogen-Free Organism	An organism that is born and reared in an environment that is lacking a select individual disease-causing organism or a whole class of pathogens.			Organism	
C142760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142760>	C28533	SLC38A9 Gene|SLC38A9|SLC38A9|Solute Carrier Family 38 Member 9 Gene	This gene is involved in signaling and lysosomal amino acid transport.			Gene or Genome	
C142761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142761>	C142760	SLC38A9 wt Allele|FLJ90709|Solute Carrier Family 38 Member 9 wt Allele|Solute Carrier Family 38, Member 9 Gene|URLC11	Human SLC38A9 wild-type allele is located in the vicinity of 5q11.2 and is approximately 147 kb in length. This allele, which encodes sodium-coupled neutral amino acid transporter 9 protein, plays a role in both amino acid sensing and the regulation of mammalian target of rapamycin complex 1 (mTORC1) activity.			Gene or Genome	
C142762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142762>	C16386	Sodium-Coupled Neutral Amino Acid Transporter 9|SLC38A9|Solute Carrier Family 38 Member 9|Up-Regulated In Lung Cancer 11|Upregulated In Lung Cancer 11	Sodium-coupled neutral amino acid transporter 9 (561 aa, ~64 kDa) is encoded by the human SLC38A9 gene. This protein is involved in amino acid sensing, amino acid transport and activation of the mammalian target of rapamycin complex 1 (mTORC1).			Amino Acid, Peptide, or Protein	
C142763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142763>	C80699	MIR509-1 Gene|MIR509-1|MIR509-1|MicroRNA 509-1 Gene	This gene is involved in silencing gene transcription.			Gene or Genome	
C142764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142764>	C80699	MIR509-2 Gene|MIR509-2|MIR509-2|MicroRNA 509-2 Gene	This gene is involved in the silencing of transcription.			Gene or Genome	
C142765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142765>	C142763	MIR509-1 wt Allele|MIRN509|MIRN509-1|Micro RNA 509 Gene|Micro RNA 509-1 Gene|MicroRNA 509 Gene|MicroRNA 509-1 wt Allele|hsa-mir-509|hsa-mir-509-1|miRNA509-1|mir-509-1	Human MIR509-1 wild-type allele is located in the vicinity of Xq27.3 and is approximately 94 bases in length. This allele, which encodes MIR509-1 pre-miRNA, plays a role in the modulation of target gene expression.			Gene or Genome	
C142766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142766>	C142764	MIR509-2 wt Allele|MIRN509-2|Micro RNA 509-2 Gene|MicroRNA 509-2 wt Allele|hsa-mir-509-2|mir-509-2	Human MIR509-2 wild-type allele is located in the vicinity Xq27.3 and is approximately 91 bases in length. This allele, which encodes MIR509-2 pre-miRNA, plays a role in gene silencing.			Gene or Genome	
C142767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142767>	C25968	MIR509-1 Pre-miRNA	MIR509-1 pre-miRNA is an oligonucleotide (94 bases) that is encoded by the human MIR509-1 gene and is involved in the regulation of gene expression.			Nucleic Acid, Nucleoside, or Nucleotide	
C142768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142768>	C25968	MIR509-2 Pre-miRNA	MIR509-2 pre-miRNA is an oligonucleotide (91 bases) that is encoded by the human MIR509-2 gene and may play a role in the regulation of gene expression.			Nucleic Acid, Nucleoside, or Nucleotide	
C142769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142769>	C25966	MicroRNA 509-5p|hsa-mir-509-5p|miR-509-5p|miRNA 509-5p	A 21 ribonucleotide sequence that is a final product of the processing of either MIR509-1 pre-miRNA or MIR509-2 pre-miRNA. This oligonucleotide may be involved in the negative regulation of gene expression.			Nucleic Acid, Nucleoside, or Nucleotide	
C14276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14276>	C14244	Spleen Focus-Forming Virus|Friend Spleen Focus-Forming Virus	Defective virus found in certain strains of Friend virus, detected by its ability to form foci in spleens of mice and believed to be responsible in those strains for the production of a leukemia associated with polycythaemia rather than anemia. (DictionaryBarn.com)			Virus	
C142770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142770>	C80699	MIR1243 Gene|MIR1243|MIR1243|MicroRNA 1243 Gene	This gene is involved in epigenetics.			Gene or Genome	
C142771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142771>	C142770	MIR1243 wt Allele|MIRN1243|MicroRNA 1243 wt Allele|hsa-mir-1243|mir-1243	Human MIR1243 wild-type allele is located in the vicinity of 4q25 and is approximately 93 kb in length. This allele, which encodes MIR1243 pre-miRNA, is involved in the regulation of target mRNA translation.			Gene or Genome	
C142772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142772>	C25968	MIR1243 Pre-miRNA	MIR1243 pre-miRNA is an oligonucleotide (93 bases) that is encoded by the human MIR1243 gene and may play a role in the regulation of gene expression.			Nucleic Acid, Nucleoside, or Nucleotide	
C142773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142773>	C25966	MicroRNA 1243|hsa-miR-1243|mir-1243	A 22 ribonucleotide sequence that is a final product of the processing of MIR1243 pre-miRNA. This oligonucleotide may be involved in the regulation of gene expression.			Nucleic Acid, Nucleoside, or Nucleotide	
C142774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142774>	C94422|C15745	Hyperfractionated Accelerated Radiation Delivered with Integrated Neck Surgery|HARDWINS	The integration of planned neck surgery subsequent to the delivery of hyperfractionated accelerated radiation.	Hyperfractionated Accelerated Radiation Delivered with Integrated Neck Surgery		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C142775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142775>	C199143	The Danish Head and Neck Cancer Group|DAHANCA	A permanent working group under the Danish Society for Head and Neck Oncology with the primary aim to develop national guidelines for the treatment of head and neck cancer in Denmark.			Professional or Occupational Group	
C142776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142776>	C20500	Tumor Necrosis Factor Ligand Superfamily Member 18|AITR Ligand|AITRL|Activation-Inducible TNF-Related Ligand|GITR Ligand|Glucocorticoid-Induced TNF-Related Ligand|Glucocorticoid-Induced TNFR-Related Protein Ligand|TNFSF18|Tumor Necrosis Factor Ligand 2A|Tumor Necrosis Factor Superfamily Member 18|hGITRL	Tumor necrosis factor ligand superfamily member 18 (199 aa, ~23 kDa) is encoded by the human TNFSF18 gene. This protein plays a role in the positive regulation of both activation and proliferation of T-cells.			Amino Acid, Peptide, or Protein	
C142778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142778>	C158344	Immobilization|Immobilization Technique	The application of a restraint to restrict normal movement of an individual's body, limb, or joint.			Activity	
C142779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142779>	C219700	Active Breathing Control|ABC|Active Breath Control	Technique associated with control of breathing used to restrict movement of the body during medical procedures.	Active Breathing Control		Activity	CTRP Intervention Terminology|CTRP Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C14277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14277>	C14347	Simian T-Lymphotropic Virus Type I|STLV|Simian T-Lymphotropic Virus I	A single-stranded reverse-transcribing RNA retrovirus of the genus deltaretrovirus that infects a wide range of non-human primates.			Virus	
C142781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142781>	C45716|C3576	Thoracic NUT Carcinoma|Thoracic NMC	A highly aggressive, poorly differentiated carcinoma that arises from the thoracic structures. It is characterized by mutations and rearrangement of the NUT gene. It usually presents at an advanced stage with pleuritic chest pain and pleural effusion, non-productive cough, shortness of breath, and weigh loss.			Neoplastic Process	
C142783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142783>	C45612|C38150	Lung PEComa|Lung PEComatous Tumor	A lung tumor that arises from perivascular epithelioid cells (PECs).			Neoplastic Process	
C142784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142784>	C4454|C142783|C121791	Benign Lung PEComa	A benign lung tumor that arises from perivascular epithelioid cells (PECs).			Neoplastic Process	
C142785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142785>	C7377|C142783|C121792	Lung Malignant PEComa|Malignant Lung PEComa	A malignant lung tumor that arises from perivascular epithelioid cells (PECs).			Neoplastic Process	
C142786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142786>	C78272	Orexin Receptor Antagonist|Orexin Antagonist	Any agent that inhibits the activity of the orexin receptor.			Chemical Viewed Functionally	
C142787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142787>	C19568	Viral Transduction|Transduction|Transduction	The transfer of genetic material from one microorganism to another by a viral agent.			Molecular Function	CBDD Process Terminology|CBDD Terminology
C142788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142788>	C49109	Ivospemin Hydrochloride|Diethyl Dihydroxyhomospermine|HO2-DEHSPM|IVOSPEMIN HYDROCHLORIDE|Polyamine Analogue SBP-101|SBP 101 Tetrahydrochloride|SBP-101 Tetrahydrochloride	The hydrochloride salt form of ivospemin, an analogue of naturally occurring polyamine (PA), with potential antineoplastic activity. Upon subcutaneous administration,  ivospemin displaces endogenous PAs from PA-binding sites on the cell surface, which prevents internalization of PA. This inhibits PA-dependent cell cycle processes and results in cell cycle arrest, the induction of apoptosis, and inhibition of tumor cell proliferation. PA uptake is upregulated in various tumor types and increased levels of PA leads to enhanced tumor cell growth.	Ivospemin Hydrochloride		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C142789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142789>	C78272	Neurokinin-3 Receptor Antagonist|NK3 Antagonist|NK3 Receptor Antagonist	Any agent that inhibits the activity of the neurokinin type 3 receptor.			Chemical Viewed Functionally	
C14278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14278>	C85984	Streptomyces|STREPTOMYCES	A genus of Gram-positive bacteria in the phylum Actinobacteria that contains over 500 separate species. Streptomyces spp. produce over 60% of all clinically relevant antibiotics, including antibacterial and antifungal agents.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142790>	C118969	Lugano Lymphoma Response Classification	A lymphoma response criteria system developed at the 11th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, June 2011.			Intellectual Product	
C142791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142791>	C142790	Lugano Lymphoma Response Classification Complete Remission by CT|CR|Complete Remission	Target nodes/nodal masses must regress to less than or equal to 1.5 cm in the longest transverse diameter. Complete disappearance of radiologic evidence of disease. No extralymphatic sites of disease. Organ enlargement regress to normal. Bone marrow normal by morphology; if indeterminate, IHC negative.			Intellectual Product	
C142792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142792>	C142790	Lugano Lymphoma Response Classification Partial Remission by CT|PR|Partial Remission	For multiple lesions, greater than or equal to 50 percent decrease in the sum of the product of the perpendicular diameters of up to six target measurable nodes and extranodal sites. If only a single lesion is present, greater than or equal to 50 percent decrease in the cross product of the longest transverse diameter and perpendicular diameter.. Spleen must have regressed by >50% in length beyond normal" to the definition.			Intellectual Product	
C142793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142793>	C142790	Lugano Lymphoma Response Classification No Response/Stable Disease by CT|NR/SD|No Response/Stable Response	Less than 50 percent decrease from baseline in  the sum of the product of the perpendicular diameters of up to 6 dominant, measurable nodes and extranodal sites; no criteria for progressive disease are met.			Intellectual Product	
C142794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142794>	C142790	Lugano Lymphoma Response Classification Progressive Disease by CT|PD|Progressive Disease	Progressive disease is assigned with at least one of the following: an individual node must be abnormal with the longest transverse diameter greater than 1.5 cm or an increase by greater than or equal to 50 percent from the product of the perpendicular diameter nadir; an increase in the longest transverse diameter or shortest transverse diameter from nadir 0.5 cm for lesions less than or equal to 2 cm or 1.0 cm for lesions greater than 2 cm. New or recurrent splenomegaly; a new node >1.5 cm in any axis; new or recurrent bone marrow involvement.			Intellectual Product	
C142795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142795>	C142790	Lugano Lymphoma Response Classification Complete Remission by PET|CR|Complete Remission	A score of 1, 2, or 3 on a 5-point PET scale in nodal or extranodal sites with or without a residual mass. No evidence of FDG-avid disease in the marrow.			Intellectual Product	
C142796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142796>	C142790	Lugano Lymphoma Response Classification Partial Remission by PET|PR|Partial Remission	A score of 4 or 5 on a 5-point PET scale with reduced uptake compared with baseline and residual mass(es) of any size. Residual uptake higher than uptake in normal marrow but reduced compared to baseline.			Intellectual Product	
C142797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142797>	C142790	Lugano Lymphoma Response Classification No Response/Stable Disease by PET|NR/SD|No Response/Stable Disease	A score of 4 or 5 on a 5-point PET scale with no significant change in FDG uptake from baseline, at interim or end of treatment. No change in the bone marrow from baseline.			Intellectual Product	
C142798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142798>	C142790	Lugano Lymphoma Response Classification Progressive Disease by PET|PD|Progressive Disease	A score of 4 or 5 on a 5-point PET scale with an increase in intensity of uptake from baseline and/or new FDG-avid foci consistent with lymphoma at interim or end of treatment assessment.			Intellectual Product	
C142799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142799>	C116977	CTRP Biomarker Terminology|Clinical Trials Reporting Program Biomarker Terminology	A set of terms that is comprised of the biomarkers referenced in NCI-sponsored clinical trials.			Intellectual Product	
C14279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14279>	C14260	SV40|Simian Vacuolating Virus 40|Simian Virus 40|Virus-SV40|simian virus 40	A small (40 to 45 nm) DNA virus of the genus Polyomavirus, family Papovaviridae; the cause of seemingly inapparent infections in monkeys, especially rhesus, and a common contaminant of monkey cell cultures; the virus may cause inapparent infection in humans and may be excreted in stools of children for several weeks; it can produce fibrosarcoma in suckling hamsters, and transformation may occur in human diploid cells; it may also form "hybrid" virus in cells also infected with certain adenoviruses.	SV40		Virus	CTRP Biomarker Terminology|CTRP Terminology
C1427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1427>	C2018	Rogletimide|Pyridoglutethimide|Pyridoglutethimide|ROGLETIMIDE	An orally active aminoglutethimide derivative with potential antineoplastic activity. Rogletimide reversibly inhibits the activity of aromatase, a cytochrome P450 family enzyme found in many tissues and the key enzyme in the oxidative aromatization process of androgens to estrogens. In estrogen-dependent cancers, the inhibition of aromatase by this agent leads to a reduction in the synthesis of estrogen, thereby inhibiting estrogen-mediated signal transduction and consequently reducing tumor cell growth. In addition, rogletimide also inhibits enzymes that catalyzing conversion of cholesterol to corticosteroids.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C142800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142800>	C142799	CTRP Molecular Genetic Biomarker Terminology|Clinical Trials Reporting Program Molecular Genetic Biomarker Terminology	A set of terms that is comprised of any biomarkers related to genes (i.e. genes, alleles, proteins, molecular abnormalities, or any related findings or assays) referenced in NCI-sponsored clinical trials.			Intellectual Product	
C142801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142801>	C142800	CTRP Reference Gene Terminology|Clinical Trials Reporting Program Reference Gene Terminology	A set of terms that is comprised of all the genes referenced in NCI-sponsored clinical trials.			Intellectual Product	
C142802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142802>	C122814	Developmental and Epileptic Encephalopathy 19|DEE19|EIEE19|Early Infantile Epileptic Encephalopathy 19	An autosomal dominant form of early infantile epileptic encephalopathy, caused by mutation(s) in the GABRA1 gene, encoding gamma-aminobutyric acid receptor subunit alpha-1.			Disease or Syndrome	Cellosaurus Disease Terminology
C142803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142803>	C85865|C122814	Developmental and Epileptic Encephalopathy 36|DEE36|EIEE36|Early Infantile Epileptic Encephalopathy 36	An X-linked dominant form of early infantile epileptic encephalopathy, caused by mutation(s) in the ALG13 gene, encoding putative bifunctional UDP-N-acetylglucosamine transferase and deubiquitinase ALG13.			Disease or Syndrome	Cellosaurus Disease Terminology
C142804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142804>	C7636	Epilepsy, Progressive Myoclonic 7|EPM7	An autosomal dominant form of early progressive myoclonic epilepsy, caused by mutation(s) in the KCNC1 gene, encoding potassium voltage-gated channel subfamily C member 1.			Disease or Syndrome	Cellosaurus Disease Terminology
C142805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142805>	C34513	Gelatinous Drop-Like Corneal Dystrophy|CDGDL	An autosomal recessive corneal dystrophy caused by mutation(s) in the TACSTD2 gene, encoding tumor-associated calcium signal transducer 2. It is characterized by severe corneal amyloidosis that may result in blindness.			Disease or Syndrome	Cellosaurus Disease Terminology
C142806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142806>	C53543	Transcobalamin II Deficiency|Transcobalamin II deficiency	An autosomal recessive condition caused by mutation(s) in the TCN2 gene, encoding transcobalamin-2. it is characterized by failure to thrive, megaloblastic anemia, and pancytopenia.			Disease or Syndrome	Cellosaurus Disease Terminology|mCode Elixhauser Deficiency Anemia Value Set|mCode Terminology
C142807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142807>	C200766|C176023	Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143|Autologous Anti-BCMA-CAR CD4+/CD8+ Cells|Autologous Anti-BCMA-CAR-expressing CD8+ and CD4+ T-lymphocytes|BCMA CAR-CD4+/CD8+ T-cells|BCMA-specific CAR-expressing CD4+/CD8+ T-lymphocytes|FCARH143	A preparation of ex vivo expanded autologous CD8+ and CD4+ T-cells that have been genetically modified to express a chimeric antigen receptor (CAR) specific for human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.	Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C142808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142808>	C207229|C185305	Refractory Pancreatic Carcinoma	Pancreatic carcinoma that does not respond to treatment.			Neoplastic Process	
C142809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142809>	C177692|C157420	CA19-9 Antigen Positive|CA 19-9 Positive|CA19-9 Positive|Cancer Antigen 19-9 Positive|Carbohydrate Antigen 19-9 Positive|SLeA Positive|Sialyl Le(a) Antigen Positive|Sialyl LeA Positive|Sialyl LewisA Positive|Sialyl-Lewis A Positive|Sialylated Lewis (a) Antigen Positive|Sialylated Lewis a Antigen Positive	An indication that expression of the carbohydrate antigen CA19-9 has been detected in a sample.	CA19-9 Antigen Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C14280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14280>	C160991	Sus scrofa domestica|Domestic Pig	The domestic pig Sus scrofa domestica.			Mammal	
C142810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142810>	C3167|C193424|C148429	Recurrent Acute Lymphoblastic Leukemia|Acute lymphoblastic leukemia, in relapse	The reemergence of acute lymphoblastic leukemia after a period of remission.			Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|mCode Cancer Disorder Value Set|mCode Elixhauser Leukemia Value Set|mCode Primary Cancer Disorder Value Set|mCode Primary Malignant Neoplasm Disorder Value Set|mCode Terminology
C142811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142811>	C8644|C204124|C142810	Recurrent B Acute Lymphoblastic Leukemia|Recurrent B-Cell Acute Lymphoblastic Leukemia	The reemergence of B acute lymphoblastic leukemia after a period of remission.	Recurrent B Acute Lymphoblastic Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C142812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142812>	C8644|C204126|C136488	Refractory B Acute Lymphoblastic Leukemia|Refractory B-Cell Acute Lymphoblastic Leukemia	A B acute lymphoblastic leukemia that does not respond to treatment.	Refractory B Acute Lymphoblastic Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C142813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142813>	C2189	CD44 Targeted Agent SPL-108|SPL 108|SPL-108	A proprietary agent that targets the cancer stem cell (CSC) antigen CD44, with potential antineoplastic activity. Although the mechanism of action has not been elucidated, following subcutaneous administration, CD44 targeted agent SPL-108 binds to CD44 and prevents the activation of various CD44-mediated signal transduction pathways, which may lead to reduced proliferation of CD44-expressing tumor stem cells. CD44, a transmembrane glycoprotein and hyaluronic acid receptor, is expressed in healthy tissue and overexpressed in numerous cancer cell types; it plays a key role in the proliferation, migration and survival of tumor cells.	CD44 Targeted Agent SPL-108		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C142814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142814>	C2594	Autologous Dendritic Cells Pulsed with MART-1 (26-35) Peptide|Autologous MART-1 (26-35) Peptide Pulsed DC Vaccine|Autologous MART-1 (26-35) Peptide Pulsed Dendritic Cell Vaccine	A cell-based vaccine consisting of autologous HLA-A2*0201-restricted dendritic cells (DC), which were derived from patient-harvested adherent peripheral blood monocytes cultured in vitro with granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4), that were pulsed with a peptide fragment comprised of amino acid residues 26 through 35 of melanoma antigen recognized by T-cells 1 (MART-1 (26-35)), with potential immunostimulatory and antineoplastic activities. Upon intradermal vaccination, autologous DC pulsed with MART-1 (26-35) peptide may stimulate the host immune system to mount a cytotoxic T-lymphocyte immune response against tumor cells expressing MART-1. MART-1, a protein involved in melanosome biogenesis, is overexpressed by melanoma cells. The MART-1 (26-35) peptide is highly immunogenic for the HLA-A2*0201 haplotype.	Autologous Dendritic Cells Pulsed with MART-1 (26-35) Peptide		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C142815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142815>	C15896	Imaging Core Lab|Core Lab	A shared facility for imaging services.			Organization	
C142816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142816>	C17369	Conventional Imaging|Conventional CT|Conventional MRI|Conventional US	Imaging using computed tomography, magnetic resonance imaging, or ultrasound.			Diagnostic Procedure	
C142817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142817>	C3824	Perfusion Computed Tomography Target Lesion	A target lesion that has been identified by computed tomography perfusion imaging.			Finding	
C142818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142818>	C69408	HLA-A*0207 Positive Cells Present|HLA-A*0207 Positive|HLA-A*02:07 Positive|HLA-A*02:07 Positive Cells Present|HLA-A0207 Positive	An indication that cells expressing HLA-A*0207 have been detected in a sample.	HLA-A*0207 Positive Cells Present		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142819>	C16830	Breast Cancer Locator|BCL	A 3D-printed form that matches a patient's breast shape while in the supine MRI and surgical position. The form includes an outline of the breast cancer on the breast surface, at the point where the cancer is closest to the skin, and includes cylinders for precise placement of marker dye and a marker wire.	Breast Cancer Locator		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C14281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14281>	C96524	Vaccinia Virus|VACCINIA VIRUS|VACCINIA VIRUS|VV|Vaccinia	DNA viruses used in several biotechnology applications, including expression vector systems.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142821>	C134787	Etigilimab|Anti-TIGIT OMP-313M32|ETIGILIMAB|Immunoglobulin G1, Anti-(Human Receptor TIGIT(T-cell Immunoreceptor with Ig and iTIM Domains)) (Humanized Mouse Monoclonal OMP-313M32 Gamma1-chain), Disulfide with Humanized Mouse Monoclonal OMP-313M32 Kappa-chain, Dimer|OMP 313M32|OMP-313M32|WHO 10742	A monoclonal antibody targeting the human co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, etigilimab binds to TIGIT expressed on various immune cells, including T-cells, and prevents the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8-positive T-cells, and leads to CD226 dimerization and CD226-mediated signaling. This activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion and the inhibition of antiviral immune responses.	Etigilimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C142822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142822>	C20401|C129822	Zigakibart|Anti-A PRoliferation-Inducing Ligand Monoclonal Antibody BION-1301|Anti-APRIL Monoclonal Antibody BION-1301|Anti-TNFSF13 Monoclonal Antibody BION-1301|BION-1301|ZIGAKIBART	A humanized monoclonal antibody targeting a proliferation-inducing ligand (APRIL; tumor necrosis factor ligand superfamily member 13; TNFSF13), with potential antineoplastic and immune checkpoint inhibitory activities. Upon administration, zigakibart binds to APRIL and inhibits its binding to both of its receptors, B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and transmembrane activator and CAML Interactor (TACI; tumor necrosis factor receptor superfamily member 13B; TNFRSF13B). This inhibits the activation of both BCMA and TACI, and their downstream signaling pathways, which prevents tumor growth, tumor cell adhesion to bone marrow cells and immune suppression. Additionally, zigakibart may reduce APRIL-induced drug resistance which occurs in some tumors. APRIL, an extracellular protein and member of the tumor necrosis factor ligand superfamily (TNFSF), is expressed by bone marrow plasma cells and myeloid cells, and overexpressed in multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and colorectal carcinoma. APRIL induces immune suppression and tumor progression through the activation of BCMA- and TACI-dependent signaling pathways.	Zigakibart		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C142823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142823>	C45612|C190095|C188963	Congenital Peribronchial Myofibroblastic Tumor|Congenital Bronchopulmonary Leiomyosarcoma|Congenital Fibrosarcoma|Congenital Mesenchymal Malformation of Lung|Congenital Pulmonary Myofibroblastic Tumor|Congenital peribronchial myofibroblastic tumor|Neonatal Pulmonary Hamartoma	A rare lung neoplasm that occurs in the intrauterine and perinatal period. It is characterized by the proliferation of spindle cells in an interstitial, peribronchial pattern. Surgical resection of the involved lung parenchyma is the treatment of choice.			Neoplastic Process	GDC Terminology|GDC Value Terminology
C142824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142824>	C42076	Peribronchial Proliferation of Neoplastic Cells Present	A morphologic finding indicating the proliferation of neoplastic cells around bronchi in the lung parenchyma.			Finding	
C142825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142825>	C53677|C4860	Pulmonary Artery Intimal Sarcoma|Intimal Sarcoma of the Pulmonary Artery|PAIS|PAS|PIS|Pulmonary Artery Sarcoma|Pulmonary Intimal Sarcoma|Pulmonary artery intimal sarcoma	A sarcoma arising from the arterial intima of pulmonary arteries.			Neoplastic Process	Cellosaurus Disease Terminology|GDC Terminology|GDC Value Terminology
C142826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142826>	C20401|C129822	Anti-Caprin-1 Monoclonal Antibody TRK-950|TRK 950|TRK-950|TRK-950|TRK950	A humanized monoclonal antibody directed against cell cycle associated protein 1 (cytoplasmic activation- and proliferation-associated protein 1; Caprin-1; CAPRIN1; RNA granule protein 105; RNG105), with potential antineoplastic activity. Upon administration, anti-Caprin-1 monoclonal antibody TRK-950 targets and binds to Caprin-1 expressed on tumor cells. This may induce antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), thereby killing Caprin-1-expressing tumor cells. Caprin-1 is overexpressed on certain tumor cell types and plays a key role in tumor cell proliferation and metastasis.	Anti-Caprin-1 Monoclonal Antibody TRK-950		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C142827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142827>	C4860	Primary Pulmonary Myxoid Sarcoma with EWSR1-CREB1 Fusion|Low-Grade Malignant Myxoid Endobronchial Tumor|PPMS|Primary Pulmonary Myxoid Sarcoma|Primary Pulmonary Myxoid Sarcoma with EWSR1::CREB1 Fusion|Pulmonary Myxoid Sarcoma with EWSR1-CREB1 Translocation|Pulmonary myxoid sarcoma with EWSR1-CREB1 translocation	A sarcoma that arises from the lung. It is related to a bronchus and is often predominantly endobronchial. It is characterized by the proliferation of round and spindle cells within a myxoid stroma. It is associated with the presence of an EWSR1::CREB1 fusion gene.			Neoplastic Process	GDC Terminology|GDC Value Terminology
C142828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142828>	C45612|C40392	Lung Myoepithelial Tumor	A very rare, benign or malignant lung tumor with myoepithelial differentiation.			Neoplastic Process	
C142829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142829>	C7442|C4454|C142828	Lung Myoepithelioma|Benign Lung Myoepithelioma	A very rare benign lung tumor with myoepithelial differentiation.			Neoplastic Process	
C14282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14282>	C14182	Vertebrata|Vertebrate|Vertebrate Animals|Vertebrates	A subphylum of animals consisting of those having a bony or cartilaginous vertebral column.			Vertebrate	
C142830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142830>	C7596|C4878|C223194|C142828	Lung Myoepithelial Carcinoma	A very rare malignant lung tumor with myoepithelial differentiation.			Neoplastic Process	
C142831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142831>	C217486|C2143|C129825	Methionine Aminopeptidase 2 Inhibitor M8891|M8891|MetAP2 Inhibitor M8891	A proprietary orally available inhibitor of methionine aminopeptidase 2 (MetAP2), which cleaves the amino-terminal methionine residue from nascent proteins, with potential antiangiogenic and antineoplastic activities. Upon administration, MetAP2 inhibitor M8891 inhibits MetAP2 aminopeptidase activity and impairs protein synthesis, which may lead to a decrease in endothelial cell proliferation. Decreased proliferation of endothelial cells results in reductions of both angiogenesis and the growth and spread of solid tumors that are dependent on new blood vessel formation. MetAP2, a metallopeptidase, is involved in promoting protein synthesis and endothelial cell proliferation.	Methionine Aminopeptidase 2 Inhibitor M8891		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C142832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142832>	C27993	Presumed|Presume	Likely to be true; accepted as true.			Qualitative Concept	
C142833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142833>	C213906|C150701	Pulmonary Langerhans Cell Histiocytosis|PLCH|Pulmonary Eosinophilic Granuloma|Pulmonary Histiocytosis X	Langerhans cell histiocytosis affecting the lungs. It is characterized by an interstitial proliferation of Langerhans cells in the lung parenchyma. Most patients are current or former smokers. Steroids are the mainstay therapy for this condition.			Neoplastic Process	
C142834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142834>	C201173|C200766|C176018	Autologous CD19/CD22 Chimeric Antigen Receptor T-cells CT120|Autologous Anti-CD19/CD22 CAR-T Cells|Autologous CD19/CD22 CAR T Cells|Autologous CD19/CD22 CAR T-cells|Autologous CD19/CD22 Chimeric Antigen Receptor T Cells|CD19/CD22 Bispecific CAR-T|CD19/CD22 CAR-T|CT 120|CT-120|CT120	A preparation of autologous human T-lymphocytes engineered to express a chimeric T-cell receptor (chimeric antigen receptor or CAR) consisting of one or more binding domains targeting the tumor-associated antigens (TAAs) CD19 and CD22 and fused to one or more co-stimulatory TCR-signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous CD19/CD22 CAR T-cells CT120 bind to CD19 and CD22 on the surface of, and induce selective toxicity against, tumor cells expressing CD19 and CD22. CD19 and CD22, both transmembrane phosphoglycoproteins expressed on the surface of cells in the B lineage, are overexpressed on malignant B-cells.	Autologous CD19/CD22 Chimeric Antigen Receptor T-cells CT120		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C142835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142835>	C153242	FOLR2 Positive|BETA-HFR Positive|FR-Beta Positive|FRbeta Positive|Folate Receptor 2 Positive|Folate Receptor Beta Positive|Folate Receptor, Fetal/Placental Positive|Placental Folate-Binding Protein Positive	An indication that folate receptor beta has been detected in a sample.	FOLR2 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142836>	C165233	BRAF Negative|B-RAF Negative|B-RAF1 Negative|KRAB Negative|RAFB1 Negative|Serine/Threonine-Protein Kinase B-Raf Negative|v-raf Murine Sarcoma Viral Oncogene Homolog B Negative	An indication that BRAF expression has not been detected in a sample.	BRAF Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142837>	C165233	NRAS Negative|GTPase Nras Negative|N-Ras Negative|Neuroblastoma RAS Viral Oncogene Homolog Negative|p21 N-Ras Negative	An indication that NRAS expression has not been detected in a sample.	NRAS Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142838>	C82341|C176696	Spinocerebellar Ataxia Type 6|SCA6	An autosomal recessive spinocerebellar ataxia caused by an expanded CAG repeat in the CACNA1A gene, encoding voltage-dependent P/Q-type calcium channel subunit alpha-1A. It is an almost pure cerebellar syndrome, with onset typically between the ages of 20 to 60.			Disease or Syndrome	Cellosaurus Disease Terminology
C142839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142839>	C165233|C158949	ROS1 Fusion Negative|MCF3 Fusion Negative|Proto-Oncogene Tyrosine-Protein Kinase ROS Fusion Negative|Proto-Oncogene c-Ros Fusion Negative|Proto-Oncogene c-Ros-1 Fusion Negative|ROS Fusion Negative|ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Fusion Negative|Receptor Tyrosine Kinase c-Ros Oncogene 1 Fusion Negative|c-Ros-1 Fusion Negative	An indication that the expression of a fusion involving ROS1 has not been detected in a sample.	ROS1 Fusion Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C14283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14283>	C14250	Virus|VIRUS|Viruses|Viruses|Viruses, General|virus	An infectious agent which consists of two parts, genetic material and a protein coat. These organisms lack independent metabolism, and they must infect the cells of other types of organisms to reproduce. Most viruses are capable of passing through fine filters that retain bacteria, and are not visible through a light microscope.			Virus	ALL Adverse Events Table|ALL Authorized Value Terminology|AML Adverse Events Table|AML Authorized Value Terminology|CDISC SEND Biological Challenge Agent Category Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL Adverse Events Table|HL Authorized Value Terminology|NICHD Terminology|Pediatric Infectious Disease Terminology
C142841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142841>	C177692	SPA17 Positive|CT22 Positive|Cancer/Testis Antigen 22 Positive|SP17 Positive|Sp17-1 Positive|Sperm Autoantigenic Protein 17 Positive|Sperm Protein 17 Positive|Sperm Surface Protein Sp17 Positive	An indication that SPA17 expression has been detected in a sample.	SPA17 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142842>	C177692	AKAP4 Positive|A-Kinase Anchor Protein 4 Positive|AKAP 82 Positive|AKAP-4 Positive|AKAP82 Positive|CT99 Positive|Cancer/Testis Antigen 99 Positive|HI Positive|Major Sperm Fibrous Sheath Protein Positive|PRKA4 Positive|Protein Kinase A-Anchoring Protein 4 Positive|Testis-Specific Gene HI Positive	An indication that AKAP4 expression has been detected in a sample.	AKAP4 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142843>	C177692	ROPN1 Positive|CT91 Positive|Cancer/Testis Antigen 91 Positive|ROPN1A Positive|Rhophilin Associated Tail Protein Positive|Ropporin Positive|Ropporin-1A Positive	An indication that ROPN1 expression has been detected in a sample.	ROPN1 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142844>	C177692	PTTG1 Positive|PTTG Positive|Pituitary Tumor-Transforming 1 Positive|Securin Positive|TUTR1 Positive|Tumor-Transforming Protein 1 Positive	An indication that PTTG1 expression has been detected in a sample.	PTTG1 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142845>	C177692	SPANXB1 Positive|CT11.2 Positive|Cancer/Testis Antigen 11.2 Positive|SPAN-Xb Positive|SPANX Family Member B1 Positive|SPANX-B Positive|Sperm Protein Associated With the Nucleus on the X Chromosome B/F Positive|Sperm Protein Associated With the Nucleus on the X Chromosome B1 Positive	An indication that  SPANXB1 expression has been detected in a sample.	SPANXB1 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142846>	C97927|C166407	CCND1 Gene Mutation|BCL-1 Gene Mutation|BCL1 Gene Mutation|CCND1 mutation|Cyclin D1 Gene Mutation|PRAD1 Gene Mutation	A change in the nucleotide sequence of the CCND1 gene.	CCND1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C142847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142847>	C1509|C129825	Troriluzole|BHV 4157|BHV-4157|Glycinamide, Glycylglycyl-N2-methyl-N-(6-(trifluoromethoxy)-2-benzothiazolyl)-|TRORILUZOLE|Trigriluzole	A formulation comprised of a prodrug form of the benzothiazole derivative riluzole, with potential anti-depressant, anxiolytic and antineoplastic activities. Following oral administration, troriluzole is converted into the active form riluzole. While the mechanism of action of riluzole is unknown, its pharmacological activities, some of which may be related to its effect, include the following: 1) an inhibitory effect on glutamate release, 2) inactivation of voltage-dependent sodium channels, and 3) interference with intracellular events that follow transmitter binding at excitatory amino acid receptors. These activities may result in myorelaxation and sedation due to the blockade of glutamatergic neurotransmission. Additionally, these activities may result in the inhibition of enzymes that are necessary for cell growth, which may decrease tumor cell growth and metastasis.	Troriluzole		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C142848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142848>	C4822|C153823|C132506	Recurrent Malignant Glioma|Recurrent High Grade Glioma|Recurrent High-Grade Glioma	The reemergence of malignant glioma after a period of remission.	Recurrent Malignant Glioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C142849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142849>	C4813|C3808	Recurrent Rhabdoid Tumor	The reemergence of rhabdoid tumor after a period of remission.	Recurrent Rhabdoid Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C14284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14284>	C14225	Woman|Human, Female	An adult, female human.			Population Group	
C142850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142850>	C9341|C173565|C153286	Refractory Peripheral Primitive Neuroectodermal Tumor	Peripheral primitive neuroectodermal tumor that does not respond to treatment.	Refractory Peripheral Primitive Neuroectodermal Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C142851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142851>	C3359|C139001	Refractory Rhabdomyosarcoma	Rhabdomyosarcoma that does not respond to treatment.	Refractory Rhabdomyosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C142852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142852>	C61252	Cerebral Adrenoleukodystrophy|CALD	A subtype of adrenoleukodystrophy (ALD) occurring in approximately 40 percent of boys with ALD, primarily affecting the cerebrum, resulting in rapidly declining neurocognitive function and in most patients, premature death.			Disease or Syndrome	
C142853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142853>	C4817|C153286|C148301	Refractory Ewing Sarcoma	Ewing sarcoma that does not respond to treatment.	Refractory Ewing Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C142854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142854>	C3728|C120186	Refractory Hepatoblastoma	A hepatoblastoma that does not respond to treatment.	Refractory Hepatoblastoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C142855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142855>	C4822|C153842|C147107	Refractory Malignant Glioma	Malignant glioma that does not respond to treatment.	Refractory Malignant Glioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C142856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142856>	C3222|C153845	Refractory Medulloblastoma	Medulloblastoma that does not respond to treatment.	Refractory Medulloblastoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C142857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142857>	C9145|C148301	Refractory Osteosarcoma	Osteosarcoma that does not respond to treatment.	Refractory Osteosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C142858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142858>	C3808|C120186	Refractory Rhabdoid Tumor	Rhabdoid tumor that does not respond to treatment.	Refractory Rhabdoid Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C142859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142859>	C63358	Letrozole/Palbociclib Regimen|Femara/Ibrance|Letrozole + Palbociclib|Letrozole and Palbociclib|Letrozole-Palbociclib|Letrozole-Palbociclib Regimen|Letrozole/Palbociclib|Palbociclib + Letrozole	A regimen consisting of letrozole and palbociclib that can be used in the treatment of breast cancer.	Letrozole/Palbociclib Regimen		Therapeutic or Preventive Procedure	CTRP Agent Terminology|CTRP Terminology|HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|NCI Drug Dictionary Terminology|Pharmacotherapy Regimens
C14285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14285>	C14265	Xenopus	Any of various aquatic, tongueless, clawed frogs of the genus Xenopus, native to southern Africa, especially X. laevis, widely used in the study of vertebrate development.			Amphibian	
C142860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142860>	C63358	Lapatinib/Letrozole Regimen|Lapatinib + Letrozole|Lapatinib Plus Letrozole|Lapatinib and Letrozole|Lapatinib-Letrozole|Lapatinib-Letrozole Regimen|Tykerb/Femara	A regimen consisting of lapatinib and letrozole that is used as a treatment for breast cancer.	Lapatinib/Letrozole Regimen		Therapeutic or Preventive Procedure	CTRP Agent Terminology|CTRP Terminology|HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|NCI Drug Dictionary Terminology|Pharmacotherapy Regimens
C142861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142861>	C6959|C203285|C148038	Recurrent Anaplastic Oligoastrocytoma	The reemergence of anaplastic oligoastrocytoma after a period of remission.			Neoplastic Process	
C142862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142862>	C4326|C203285|C148038	Recurrent Anaplastic Oligodendroglioma	The reemergence of anaplastic oligodendroglioma after a period of remission.			Neoplastic Process	
C142863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142863>	C63358	Everolimus/Exemestane Regimen|Afinitor/Aromasin|Everolimus + Exemestane|Everolimus and Exemestane|Everolimus-Exemestane|Everolimus-Exemestane Regimen|Everolimus/Exemestane	A regimen consisting of everolimus and exemestane that is used as a treatment for breast cancer.	Everolimus/Exemestane Regimen		Therapeutic or Preventive Procedure	CTRP Agent Terminology|CTRP Terminology|HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|NCI Drug Dictionary Terminology|Pharmacotherapy Regimens
C142864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142864>	C200766|C176023	Autologous Anti-BCMA-CAR Expressing Stem Memory T-cells P-BCMA-101|Autologous Anti-BCMA Centyrin-based Chimeric Antigen Receptor-expressing Tscm|Autologous P-BCMA-101 CAR-T Cells|Autologous P-BCMA-101 CAR-T-cells|Autologous P-BCMA-101 CARTyrin-T cells|P-BCMA-101	A preparation consisting of autologous T-cells that are enriched to be primarily stem memory T-cells (Tscm) and are transfected by electroporation with a proprietary transposon-based DNA plasmid vector (PiggyBac) containing an undisclosed selection gene and encoding both an unidentified human-derived safety switch and a chimeric antigen receptor (CAR) based on a proprietary non-immunoglobulin scaffold molecule Centyrin (CARTyrin), which specifically recognizes human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-BCMA-CAR-expressing Tscm P-BCMA-101 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. Use of CARTyrin may elicit less immunotoxicity than agents based on antibody-derived single chain variable fragments (scFv), and this agent may exhibit increased persistence and decreased exhaustion for the administered T-cells. If significant side effects occur, the safety switch mechanism can induce the rapid attenuation or elimination of P-BCMA-101. BCMA, a tumor-specific antigen and a member of the tumor necrosis factor receptor superfamily (TNFRSF) that binds to both a proliferation-inducing ligand (APRIL; TNFSF13) and B-cell activating factor (BAFF; TNFSF13B), plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and is overexpressed on malignant plasma cells.	Autologous Anti-BCMA-CAR Expressing Stem Memory T-cells P-BCMA-101		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C142865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142865>	C128037	Anti-PD-1 Monoclonal Antibody Sym021|Anti-PD1 Monoclonal Antibody Sym021|SYM-021|Sym021	A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1 , PCD-1; PDCD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody Sym021 binds to and inhibits PD-1 activation and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF), is expressed on T-cells and functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death ligand 1 (PD-L1) or 2 (PD-L2). Activated PD-1 plays an important role in tumor evasion from host immunity.	Anti-PD-1 Monoclonal Antibody Sym021		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C142866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142866>	C308|C214995|C129825	Numidargistat|Arginase Inhibitor INCB001158|CB-1158|CB1158|INCB001158|NUMIDARGISTAT	An orally available inhibitor of arginase, a manganese-dependent enzyme that hydrolyzes the amino acid arginine to form ornithine and urea, with potential immunomodulating and antineoplastic activities. Upon administration, numidargistat inhibits the breakdown of arginine by arginase, which is produced by myeloid cells, and restores arginine levels. This allows arginine to stimulate the synthesis of nitric oxide and the secretion of pro-inflammatory cytokines and chemokines, which induces the proliferation and activation of T-cells. Therefore, this agent may prevent the immunosuppressive effects of tumor-infiltrating myeloid cells and promote lymphocyte-mediated immune responses against tumor cells. Arginase is produced by neutrophils, macrophages and myeloid-derived suppressor cells (MDSC) and plays a role in inflammation-associated immunosuppression.	Numidargistat		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C142867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142867>	C173324|C156096	Metastatic Microsatellite Stable Colorectal Carcinoma|Metastatic Microsatellite Stable Colorectal Cancer	A microsatellite stable carcinoma that arises from the colon or rectum and has metastasized to other anatomic sites.			Neoplastic Process	
C142868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142868>	C162475|C142867	Advanced Microsatellite Stable Colorectal Carcinoma|Advanced Microsatellite Stable Colorectal Cancer	A microsatellite stable carcinoma that arises from the colon or rectum and has spread extensively to other anatomic sites or is no longer responding to treatment.			Neoplastic Process	
C142869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142869>	C27814|C162751	Metastatic Bile Duct Carcinoma|Metastatic Bile Duct Cancer|Metastatic Biliary Tract Cancer|Metastatic Biliary Tract Carcinoma	A carcinoma that arises from the intrahepatic or extrahepatic bile ducts and has metastasized to other anatomic sites.			Neoplastic Process	
C14286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14286>	C14209	Yeast|YEAST	Various single-celled members of the fungal families, ascomycetes, basidiomycetes and imperfect fungi that tend to be unicellular for the greater part of their life cycle.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|NICHD Terminology|Pediatric Infectious Disease Terminology
C142870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142870>	C171331|C142869	Advanced Bile Duct Carcinoma|Advanced Bile Duct Cancer|Advanced Biliary Tract Cancer|Advanced Biliary Tract Carcinoma	A carcinoma that arises from the intrahepatic or extrahepatic bile ducts and has spread extensively to other anatomic sites or is no longer responding to treatment.			Neoplastic Process	
C142871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142871>	C78808	Real Imager 8|RI8|RI8 Imaging Device	A proprietary imaging system designed to determine breast health through the acquisition and analysis of 3D imaging biomarkers. It provides a radiation-free complement for mammography particularly suited for women with dense breast tissue.			Manufactured Object	
C142872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142872>	C18520	Histone H3 Trimethyl Lys36|H3K36me3|H3K36me3|Histone H3 Trimethyl Lys37|Histone H3 Trimethyl Lysine 36|Histone H3 Trimethyl Lysine 37|Trimethylated Histone H3 at Lysine 36	A post-translationally modified form of histone H3 where the lysine residue at position 36 is trimethylated. This modification may be involved in defining exon boundaries; it also may be a marker for genes targeted for transcriptional repression.	Histone H3 Trimethyl Lys36		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C142874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142874>	C94626	Long Course Chemoradiotherapy|LCCRT	Chemoradiotherapy generally consisting of 45 Gy given in 25 fractions over 5 weeks with concomitant chemotherapy as a radiosensitizer.	Long Course Chemoradiotherapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C142875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142875>	C94626	Short Course Chemoradiotherapy|SCCRT	Chemoradiotherapy generally consisting of 25 Gy in 5 fractions given in 1 week with concomitant chemotherapy as a radiosensitizer.	Short Course Chemoradiotherapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C142876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142876>	C7162|C150545|C134157|C131500	Recurrent Primary Cutaneous Lymphoma|Recurrent Primary Cutaneous (Skin) Lymphoma	The reemergence of primary cutaneous lymphoma after a period of remission.	Recurrent Primary Cutaneous Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C142877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142877>	C7162|C150546|C134154	Refractory Primary Cutaneous Lymphoma|Refractory Primary Cutaneous (Skin) Lymphoma	A primary cutaneous lymphoma that does not respond to treatment.	Refractory Primary Cutaneous Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C142878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142878>	C156029	ROS1 Gene Amplification|MCF3 Gene Amplification|ROS Gene Amplification|ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene Amplification|c-ros-1 Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the ROS1 gene.	ROS1 Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142879>	C132847	KRAS Gene Mutation Negative|KRAS Wild-Type|KRAS Wildtype|KRAS wt|KRAS-2 Gene Mutation Negative|KRAS2 Gene Mutation Negative|Negative|No mutation detected|c-K-ras Gene Mutation Negative|v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Gene Mutation Negative	A genetic finding indicating that KRAS gene mutations have not been detected in a sample.	KRAS Gene Mutation Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C14287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14287>	C14207	Zebrafish|Brachydanio rerio|Brachydanio rerio|Cyprinus rerio|DANIO RERIO|Danio frankei|Danio rerio|Zebra danio	Brachydanio rerio, species of small freshwater aquarium fish with a transparent embryo making it possible to follow progeny of single cells until quite late stages of development. This, together with the availability of mutant lines make it an important preparation for the study of vertebrate cell lineage and developmental biology.			Fish	CDISC SEND Genus and Species Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142880>	C3749|C142851	Refractory Alveolar Rhabdomyosarcoma	Alveolar rhabdomyosarcoma that does not respond to treatment.	Refractory Alveolar Rhabdomyosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C142881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142881>	C8824|C3749	Recurrent Alveolar Rhabdomyosarcoma	The reemergence of alveolar rhabdomyosarcoma after a period of remission.	Recurrent Alveolar Rhabdomyosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C142882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142882>	C7402|C204124|C193424|C150043	Recurrent Hairy Cell Leukemia|Hairy cell leukemia, in relapse|Relapsed Hairy Cell Leukemia	The reemergence of hairy cell leukemia after a period of remission.	Recurrent Hairy Cell Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|mCode Cancer Disorder Value Set|mCode Elixhauser Leukemia Value Set|mCode Primary Cancer Disorder Value Set|mCode Primary Malignant Neoplasm Disorder Value Set|mCode Terminology
C142884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142884>	C25447	Friability	A finding indicating the tendency of a tissue sample or solid substance to break into small pieces under pressure or contact.			Finding	
C142885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142885>	C26764	Post-Abortion Endometritis|Postabortal Endometritis	Endometritis that develops following an abortion.			Disease or Syndrome	
C142886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142886>	C117720	Hydrosalpinx	Fluid accumulation and dilatation of the fallopian tube due to tubal blockage.			Finding	
C142887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142887>	C200766|C176018	Autologous Anti-CD19 Chimeric Antigen Receptor T-cells SJCAR19|Autologous Anti-CD19 CAR-T Cells SJCAR19|Autologous Anti-CD19 CART Cells SJCAR19|Autologous CD19-specific CAR-T Cells SJCAR19|SJCAR19	A proprietary preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed, costimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR T-cells SJCAR19 target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.	Autologous Anti-CD19 Chimeric Antigen Receptor T-cells SJCAR19		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C142888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142888>	C28681|C138180|C129826	Anti-K-RAS G12V mTCR-transduced Autologous Peripheral Blood Lymphocytes|Anti-K-RAS G12V mTCR-transduced Autologous PBLs|Anti-KRAS G12V mTCR-transduced Autologous Peripheral Blood Lymphocytes	Autologous peripheral blood lymphocytes (PBLs) transduced with an HLA class I histocompatibility antigen A*11:01 (HLA-A1101)-restricted murine T-cell receptor (mTCR) that recognizes the glycine to valine point mutation at position 12 (G12V) variant of K-RAS, with potential antineoplastic activity. HLA-A1101 positive PBLs are harvested from a K-RAS G12V-expressing cancer patient and transfected with a retroviral vector that encodes anti-K-RAS G12V mTCR. The transduced PBLs are then expanded in culture. When reintroduced to the patient, these anti-K-RAS G12V mTCR-expressing PBLs target and bind to K-RAS G12V-overexpressing tumor cells, which results in both cytokine secretion and tumor cell lysis. K-RAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutation of K-RAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.	Anti-K-RAS G12V mTCR-transduced Autologous Peripheral Blood Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C142889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142889>	C201282|C155711	Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody GBR 1302|Anti-HER2 x Anti-CD3 Bispecific Monoclonal Antibody GBR 1302|GBR 1302|GBR-1302	An anti-human epidermal growth factor receptor 2 (HER2)/anti-CD3 bispecific monoclonal antibody with potential immunostimulatory and antineoplastic activities. Anti-HER2/Anti-CD3 bispecific monoclonal antibody GBR 1302 possesses two antigen recognition sites, one for HER2, a tyrosine kinase receptor overexpressed by many cancer cell types, and one for the CD3 complex, a group of T-cell surface glycoproteins that interact with the T-cell receptor (TCR). Upon administration of GBR 1302, this bispecific monoclonal antibody simultaneously binds to both CD3-expressing T-cells and HER2-expressing cancer cells, thereby crosslinking HER2-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated lysis of HER2-expressing tumor cells. HER2 plays a key role in tumor cell proliferation and tumor vascularization.	Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody GBR 1302		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C14288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14288>	C117714	Feline Immunodeficiency Virus|FIV	A lentivirus causing acquired immunodeficiency in cats. The FIV virus is transmitted in the saliva or blood, commonly through the bite wound from an infected cat. Strictly a feline disease, FIV cannot be transmitted to humans.			Virus	
C142890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142890>	C192997|C163760	Cinrebafusp Alfa|Anti-HER2 Monoclonal Antibody/Anti-CD137 Anticalin Bispecific Fusion Protein PRS-343|CINREBAFUSP ALFA|PRS-343	A bivalent, bispecific fusion protein comprised of an anti-human epidermal growth factor receptor (HER2) monoclonal antibody linked to a CD137-targeting anticalin with potential immunostimulatory and antineoplastic activities. Upon administration of cinrebafusp alfa, CD137 clustering is promoted by bridging CD137-positive T-cells with HER2-positive tumor cells, leading to the recruitment of tumor antigen-specific cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated lysis of HER2-expressing tumor cells. HER2 plays a key role in tumor cell proliferation and tumor vascularization. CD137 is a costimulatory immunoreceptor and a member of the tumor necrosis factor receptor superfamily (TNFRSF). Anticalins are synthetic antigen-binding proteins derived from lipocalins. Structurally dissimilar to antibodies, anticalins are able to bind to smaller antigens and exhibit improved tissue penetration.	Cinrebafusp Alfa		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C142891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142891>	C28193	Brugada Syndrome|Right Bundle Branch Block, ST Segment Elevation, and Sudden Death Syndrome	A genetically heterogeneous condition characterized by complete or incomplete right bundle branch block accompanied by ST elevation in leads V1-V3. There is a high incidence of ventricular arrhythmia that may result in sudden death.			Disease or Syndrome	Cellosaurus Disease Terminology
C142892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142892>	C84773	Familial Hypertrophic Cardiomyopathy Type 2|CMH2	An autosomal dominant subtype of familial hypertrophic cardiomyopathy caused by mutation(s) in the TNNT2 gene, encoding troponin T, cardiac muscle.			Disease or Syndrome	Cellosaurus Disease Terminology
C142893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142893>	C140267	Spastic Paraplegia 3A|Strumpell Disease	An autosomal dominant subtype of hereditary spastic paraplegia caused by mutation(s) in the ATL1 gene, encoding atlastin-1.			Disease or Syndrome	Cellosaurus Disease Terminology
C142894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142894>	C34786	Long QT Syndrome 8|LQT8|Timothy Syndrome	An autosomal dominant condition caused by mutation(s) in the CACNA1C gene, encoding voltage-dependent L-type calcium channel subunit alpha-1C. It is characterized by a prolonged QT interval that may result in torsade de pointes, ventricular fibrillation and/or sudden cardiac death.			Disease or Syndrome	Cellosaurus Disease Terminology
C142895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142895>	C188776	Abafilcon A|ABAFILCON A				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142896>	C48149	Abediterol Napadisylate|ABEDITEROL NAPADISYLATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142897>	C1946|C129825	Abexinostat Hydrochloride|ABEXINOSTAT HYDROCHLORIDE	The hydrochloride salt form of abexinostat, an orally bioavailable hydroxamate-based pan-inhibitor of histone deacetylase (HDAC), with potential antineoplastic and radiosensitizing activities. Upon administration, abexinostat inhibits HDAC, resulting in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling; the selective transcription of tumor suppressor genes; and the tumor suppressor protein-mediated inhibition of tumor cell division and induction of tumor cell apoptosis. In addition, abexinostat decreases the expression of the DNA-repair protein RAD51, thereby reducing the RAD51 protein, preventing repair of DNA double-strand breaks and increasing sensitivity of tumor cells to DNA damaging agents. HDAC, upregulated in many tumor types, is an enzyme that is responsible for the deacetylation of chromatin histone proteins.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142898>	C126712	Acorafloxacin Hydrochloride|ACORAFLOXACIN HYDROCHLORIDE				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142899>	C2578	Adomiparin|ADOMIPARIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C14289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14289>	C14296	Helicobacter pylori|Campylobacter pylori|Campylobacter pylori|H. pylori|H. pylori|H. pylori|H. pylori|HELICOBACTER PYLORI	Bacteria that cause stomach inflammation (gastritis) and ulcers in the stomach. This bacteria is the most common cause of ulcers worldwide. It is often referred to as H. pylori. H. pylori infection is usually acquired from contaminated food and water and through person to person spread. The infection is common in crowded living conditions with poor sanitation. In countries with poor sanitation, 90% of the adult population can be infected. In the U.S., 30% of the adult population is infected. One out of six patients with H. pylori infection develops ulcers of the duodenum or the stomach. This bacteria is also believed to be associated with stomach cancer and a rare type of lymph gland tumor called gastric MALT lymphoma. Infected persons usually carry the infection indefinitely, unless treated with medications to eradicate the bacteria. (MedicineNet.com)	Helicobacter pylori		Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C1428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1428>	C97452	Stavudine|1-(2,3-Dideoxy-beta-glycero-pent-2-enofuranosyl)thymine|2',3'-Didehydro-3'-deoxythymidine|3'-Deoxy-2'-thymidinene|3'-Deoxy-2'-thymidinene|BMY-27857|Didehydrodeoxythymidine|Dideoxydidehydrothymidine|STAVUDINE|Zerit|d4T|stavudine	A nucleoside reverse transcriptase inhibitor analog of thymidine. Stavudine has been recommended to undergo phase-out management due to its long-term, irreversible side-effects.			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C142900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142900>	C1291	Afovirsen Sodium|AFOVIRSEN SODIUM				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142901>	C1937	Aftobetin Hydrochloride|AFTOBETIN HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142902>	C155764	Afuresertib Hydrochloride|AFURESERTIB HYDROCHLORIDE	The hydrochloride salt form of afuresertib, an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B), with potential antineoplastic activity. Upon oral administration, afuresertib binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142903>	C29705	Aganepag Ethanediol|AGANEPAG ETHANEDIOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142904>	C29705	Aganepag Isopropyl|AGANEPAG ISOPROPYL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142906>	C47793	Aladorian Sodium|ALADORIAN SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142907>	C258	Alamecin|ALAMECIN				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142908>	C2124	Albumin, Aggregated Iodinated I-131 Serum|ALBUMIN, AGGREGATED IODINATED I-131 SERUM				Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142909>	C67502	Aldoxorubicin Hydrochloride|ALDOXORUBICIN HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C14290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14290>	C14268	Lentivirus|LENTIVIRUS|Lentivirinae|Virus-Lenti	A genus of the family Retroviridae consisting of non-oncogenic retroviruses that produce multi-organ diseases characterized by long incubation periods and persistent infection. Lentiviruses are unique in that they contain open reading frames (ORFs) between the pol and env genes and in the 3' env region. Five serogroups are recognized, reflecting the mammalian hosts with which they are associated. HIV-1 is the type species.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142910>	C258	Alexomycin|ALEXOMYCIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142911>	C1291	Alicaforsen Sodium|ALICAFORSEN SODIUM				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142912>	C209713	Alisertib Sodium|ALISERTIB SODIUM|MLN8237 Sodium|MLN8237-004	The sodium salt form of alisertib, a second-generation, orally bioavailable,  selective inhibitor of the serine/threonine protein kinase Aurora A kinase, with potential antineoplastic activity. Upon oral administration, alisertib targets, binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation in susceptible cancer cells. Aurora A kinase localizes to the spindle poles and to spindle microtubules during mitosis, and is thought to regulate spindle assembly. Aberrant expression of Aurora kinases occurs in a wide variety of cancers and plays a key role in cancer cell proliferation.	Alisertib Sodium		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C142913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142913>	C47794	Alniditan Dihydrochloride|ALNIDITAN DIHYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142914>	C188776	Alphafilcon A|ALPHAFILCON A				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142916>	C45678	Aluminum Chlorohydrate|ALUMINUM CHLOROHYDRATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142917>	C45678	Aluminum Chlorohydrex Propylene Glycol|ALUMINUM CHLOROHYDREX PROPYLENE GLYCOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142918>	C45678	Aluminum Sesquichlorohydrate|ALUMINUM SESQUICHLOROHYDRATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142919>	C257	Amfenac Sodium|AMFENAC SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C14291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14291>	C14268	Betaretrovirus|Retroviruses, Type B, Mammalian|Type B Mammalian Retrovirus|Type B Virus|Type D Retrovirus	A genus of single-stranded, reverse-transcribing RNA retroviruses with type B or type C morphology. It is the genus to which the mouse mammary tumor virus (MMTV) belongs.			Virus	
C142920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142920>	C45678	Amicloral|AMICLORAL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142921>	C93038	Amifampridine Phosphate|AMIFAMPRIDINE PHOSPHATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142922>	C574	Amiselimod Hydrochloride|AMISELIMOD HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142923>	C265	Amitifadine Hydrochloride|AMITIFADINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142924>	C126567	Angiotensin II Acetate|ANGIOTENSIN II ACETATE|Giapreza	The acetate salt form of therapeutic angiotensin II, a synthetic form of the endogenous angiotensin II, a peptide hormone of the renin-angiotensin-aldosterone system (RAAS) that causes vasoconstriction and an increase in blood pressure, that may be used for the treatment of septic or other distributive shock. Upon administration, therapeutic angiotensin II binds to angiotensin II type 1 receptor on vascular smooth muscle cells which leads to Ca2+/calmodulin-dependent phosphorylation of myosin. This causes smooth muscle contraction and results in vasoconstriction and an increase in blood pressure. Therapeutic angiotensin II also increases blood pressure by stimulating the release of the steroid hormone aldosterone, which regulates the renal absorption of water and sodium.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C142925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142925>	C94431	Anivamersen Sodium|ANIVAMERSEN SODIUM				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142926>	C1930	Anoxomer|ANOXOMER				Food	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142927>	C45678	Antimony Trisulfide|ANTIMONY TRISULFIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142928>	C1291	Apatorsen Sodium|APATORSEN SODIUM				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142929>	C1509	Aptiganel Hydrochloride|APTIGANEL HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142930>	C29710	Aripiprazole Cavoxil|ARIPIPRAZOLE CAVOXIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142931>	C29710	Aripiprazole Lauroxil|ARIPIPRAZOLE LAUROXIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142932>	C47793	Artilide Fumarate|ARTILIDE FUMARATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142933>	C241	Asalhydromorphone|ASALHYDROMORPHONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142934>	C241	Asalhydromorphone Hydrochloride|ASALHYDROMORPHONE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142935>	C201688	Asvasiran Sodium|ASVASIRAN SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142936>	C1291	Atesidorsen Sodium|ATESIDORSEN SODIUM				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142937>	C210771	Atopaxar Hydrobromide|ATOPAXAR HYDROBROMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142938>	C210771	Atopaxar Hydrochloride|ATOPAXAR HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142939>	C29704	Atropine Oxide Hydrochloride|ATROPINE OXIDE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C14293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14293>	C14268	Spumavirus|Foamy Retrovirus|Foamy Virus	Genus of retroviruses which establish persistent, but non pathogenic infections in mammals and primates, including humans, chimpanzees, cattle, and cats. It is unique among retroviruses in having infectious particles that carry DNA rather than RNA. Similar to hepadnaviruses, spumaviruses bud from the endoplasmic reticulum instead of the plasma membrane. Infected cells accumulate vacuoles, giving them a foamy appearance and are often involved in syncytium formation.			Virus	
C142940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142940>	C78283	Avacincaptad Pegol Sodium|AVACINCAPTAD PEGOL SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142941>	C210737	Avatrombopag Maleate|1-(3-Chloro-5-((4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2- yl)carbamoyl)pyridin-2-yl)piperidine-4-carboxylic acid mono-(2Z)-but-2-enedioate|4-Piperidinecarboxylic Acid, 1-(3-Chloro-5-(((4-(4-chloro-2-thienyl)-5-(4-cyclohexyl-1- piperazinyl)-2-thiazolyl)amino)carbonyl)-2-pyridinyl)-, (2Z)-2-butenedioate (1:1)|AVATROMBOPAG MALEATE|E5501 Maleate	The maleate salt form of avatrombopag, an orally available platelet thrombopoietin receptor (TPOR; MPL) agonist, with potential megakaryopoiesis stimulating activity. Upon administration, avatrombopag binds to and stimulates TPOR, which may lead to the proliferation and differentiation of megakaryocytes from bone marrow progenitor cells. This increases the production of platelets and may prevent chemotherapy-induced thrombocytopenia (CIT). TPOR is a cytokine receptor and member of the hematopoietin receptor superfamily.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C142942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142942>	C183118	Avibactam Sodium|AVIBACTAM SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142943>	C681	Axelopran Sulfate|AXELOPRAN SULFATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142944>	C308	Azarole|AZAROLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142945>	C208191	Azficel-T|AZFICEL-T				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142946>	C87053	Batefenterol Succinate|BATEFENTEROL SUCCINATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142947>	C47795	Bavisant Dihydrochloride|BAVISANT DIHYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142948>	C783|C281	Beclabuvir Hydrochloride|BECLABUVIR HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142949>	C280	Bedaquiline Fumarate|BDQ Fumarate|BEDAQUILINE FUMARATE|R403323|Sirturo|Sirturo	The fumarate salt form of bedaquiline, an orally bioavailable diarylquinoline antimycobacterial agent, that can be used in the treatment of pulmonary multi-drug resistant tuberculosis (MDR-TB). Upon oral administration, bedaquiline specifically binds to subunit c of Mycobacterium tuberculosis (M. tuberculosis) adenosine 5'-triphosphate (ATP) synthase, thereby preventing ATP synthase activity. This inhibits ATP synthesis in M. tuberculosis, thereby blocking its energy metabolism and killing M. tuberculosis.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C14294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14294>	C15156	SCID Mouse|SCID|severe combined immune deficiency	Severe combined immunodeficient (SCID) mice like their human counterparts with immunodeficiency diseases are helpless not only to fight infection but also to reject transplanted tissue. These animals lack both T and B-cells and are used extensively in researches of immune disease or tissue transplantation.	SCID Mouse		Mammal	
C142950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142950>	C226471	Bentoquatam|BENTOQUATAM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142951>	C67413	Benzhydrocodone Hydrochloride|BENZHYDROCODONE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142952>	C29576	Bevantolol Hydrochloride|BEVANTOLOL HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142953>	C94431|C78283	Bevasiranib Sodium|BEVASIRANIB SODIUM				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142954>	C29707	Biclodil Hydrochloride|BICLODIL HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142955>	C157401	Bictegravir Sodium|BICTEGRAVIR SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142956>	C29710	Bifeprunox Mesylate|BIFEPRUNOX MESYLATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142957>	C265	Bipenamol Hydrochloride|BIPENAMOL HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142958>	C20401	Birtamimab|Anti-amyloid Monoclonal Antibody NEOD001|BIRTAMIMAB|NEOD 001|NEOD-001|NEOD001	A monoclonal antibody against amyloid with potential use in the treatment of amyloid light chain (AL) and AA amyloidosis. Upon intravenous administration, birtamimab specifically binds to amyloid fibrils. This prevents the formation of amyloid deposits in certain organs and facilitates their clearance. It also reduces the level of amyloid deposits in organs and prevents organ dysfunction.	Birtamimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C142959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142959>	C78276	Bisacodyl Tannex|BISACODYL TANNEX				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C14295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14295>	C14304|C14216	Hepatitis E Virus|HEPATITIS E VIRUS|HEV|HEV|hepatitis E virus	A member of the genus Hepevirus, it is a single-stranded, positive-sense RNA virus with icosahedral shape that causes Hepatitis E.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142960>	C78311	Bisobrin Lactate|BISOBRIN LACTATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142961>	C29797	Bisoxatin Acetate|BISOXATIN ACETATE				Hazardous or Poisonous Substance|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142962>	C254	Bispyrithione Magsulfex|BISPYRITHIONE MAGSULFEX				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142963>	C173066	Bivalirudin Trifluoroacetate|Angiomax|Angiox|BIVALIRUDIN TRIFLUOROACETATE	The trifluoroacetate salt form of bivalirudin, a 20 amino acid long synthetic peptide, with thrombin-specific anticoagulant activity. Upon intravenous administration, bivalirudin reversibly binds thrombin, free as well as clot bound, at the catalytic site and the anion-binding exosite, thereby preventing the formation and activation of fibrin, factor XIIIa, and other coagulation factors. Bivalirudin is primarily used during coronary angioplasty procedures, in combination with aspirin, in patients with unstable angina.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142964>	C45678	Bornyl Acetate|BORNYL ACETATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142965>	C73579	Bradanicline Hydrochloride|BRADANICLINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142966>	C258	Brilacidin Tetrahydrochloride|BRILACIDIN TETRAHYDROCHLORIDE				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142967>	C241	Brivoligide Sodium|BRIVOLIGIDE SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142968>	C74536	Bromhexine Hydrochloride|BROMHEXINE HYDROCHLORIDE|Benzenemethanamine, 2-Amino-3,5-dibromo-N-cyclohexyl-N-methyl-, Monohydrochloride|Viscolyt	The hydrochloride salt form of bromhexine, a secretolytic, with mucolytic activity. Upon administration, bromhexine increases lysosomal activity and enhances hydrolysis of acid mucopolysaccharide polymers in the respiratory tract. This increases the production of serous mucus in the respiratory tract, which makes the phlegm thinner and decreases mucus viscosity. This contributes to its secretomotoric effect, and allows the cilia to more easily transport the phlegm out of the lungs. This clears mucus from the respiratory tract and may aid in the treatment of respiratory disorders associated with abnormal viscid mucus, excessive mucus secretion and impaired mucus transport.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C142969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142969>	C29710	Bromperidol Decanoate|BROMPERIDOL DECANOATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C14296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14296>	C85940	Helicobacter|HELICOBACTER	A genus of gram-negative helical, curved, or straight microaerophilic bacteria with rounded ends and multiple sheathed flagella (unipolar or bipolar and lateral) with terminal bulbs. Form nonpigmented, translucent colonies, 1-2 mm in diameter. Catalase and oxidase positive. Found in gastric mucosa of primates, including human beings and ferrets. Some species are associated with gastric and peptic ulcers and gastric cancer. The type species is Helicobacter pylori.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C142970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142970>	C47793	Bucainide Maleate|BUCAINIDE MALEATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142971>	C29576	Bucindolol Hydrochloride|BUCINDOLOL HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142972>	C29576	Bunolol Hydrochloride|BUNOLOL HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142973>	C1404	Buparlisib Hydrochloride|BUPARLISIB HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142974>	C241	Butacetin|BUTACETIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142975>	C245	Butamben Picrate|BUTAMBEN PICRATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142976>	C66917	Butamirate Citrate|BUTAMIRATE CITRATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142977>	C2363	Butirosin Sulfate|BUTIROSIN SULFATE				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142978>	C134305	Encelimab|Anti-LAG-3 Monoclonal Antibody TSR-033|Anti-LAG3 Monoclonal Antibody TSR-033|Anti-Lymphocyte Activation Gene 3 Protein Monoclonal Antibody TSR-033|ENCELIMAB|TSR 033|TSR-033|TSR033	A humanized, immunoglobulin G4 (IgG4) monoclonal antibody directed against the inhibitory receptor lymphocyte activation gene 3 protein (LAG3; LAG-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration,encelimab binds to LAG3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells, and negatively regulates both proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.	Encelimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C142979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142979>	C581	Insulin Degludec|(1A-21A),(1B-29B)-Insulin (human), 29B-(N6-(N-(15-carboxy-1-oxopentadecyl)-L-gamma-glutamyl)-L-lysine)-|INSULIN DEGLUDEC|NN1250|Tresiba	A recombinant, long-acting analog of human insulin, with blood glucose-lowering activity. Upon subcutaneous injection, insulin degludec forms a multi-hexameric depot from which insulin monomers are slowly released into the systemic circulation. Insulin regulates glucose metabolism by binding to insulin receptors on muscle and fat cells, which stimulates the cellular uptake of glucose and lowers blood glucose levels. Insulin inhibits the liver's conversion of stored glycogen into glucose, which also contributes to lower blood glucose levels. In addition, insulin inhibits lipolysis in adipose tissue, inhibits proteolysis, and enhances protein synthesis. Insulin degludec doesn't contain the amino acid threonine that is found at position B30 in human insulin; additionally, the lysine at position B29 is conjugated to hexadecanedioic acid, which allows the formation of the multi-hexamers upon subcutaneous injection. The phenol and zinc present in the pharmaceutical formulation promote a di-hexameric state of insulin degludec.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C14297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14297>	C79740	Chimpanzee|CHIMPANZEE|Chimp|Common Chimpanzee|Pan Species|Pan troglodytes	Pan troglodytes, an anthropoid ape that inhabits the tropical rain forests of Africa and is used for experimental purposes because of its susceptibility to some human diseases and in behavioral studies because of its high level of intelligence.			Mammal	CDISC SEND Laboratory Animal Species Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C142980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142980>	C203976	Selective Estrogen Receptor Covalent Antagonist H3B-6545|H3B 6545|H3B-6545|H3B-6545|H3B6545|SERCA H3B-6545	An orally available, selective and covalent antagonist of estrogen receptor alpha (ERalpha; ERa; ESR1; nuclear receptor subfamily 3, group A, member 1; NR3A1), with potential antineoplastic activity. Upon oral administration, selective estrogen receptor covalent antagonist (SERCA) H3B-6545 selectively and covalently binds to a cysteine that is unique to ERalpha and is not present in other nuclear hormone receptors, thereby inhibiting the activity of ERalpha. This inhibits the growth and survival of ERalpha-expressing cancer cells. ERalpha, a nuclear hormone receptor, is often overexpressed and/or mutated in a variety of cancer cell types. It plays a key role in tumor cell proliferation and survival.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C142981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142981>	C67502	Zoptarelin Doxorubicin Acetate|ZOPTARELIN DOXORUBICIN ACETATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142982>	C6913|C133736	Refractory Lymphocyte-Rich Classic Hodgkin Lymphoma|Refractory Lymphocyte-Rich Classical Hodgkin Lymphoma|Refractory Lymphocyte-Rich Classical Hodgkin Lymphoma	A lymphocyte-rich classic Hodgkin lymphoma that does not respond to treatment.	Refractory Lymphocyte-Rich Classical Hodgkin Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C142983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142983>	C4815|C151907|C150539	Refractory Thyroid Gland Carcinoma|Refractory Thyroid Cancer|Refractory Thyroid Gland Cancer	A thyroid gland carcinoma that is resistant to treatment.	Refractory Thyroid Gland Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C142984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142984>	C191	Polychemotherapy	Chemotherapy involving the simultaneous administration of two or more cytotoxic drugs.			Therapeutic or Preventive Procedure	
C142985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142985>	C15342	Autologous Transplantation|Autologous Transplant	Transplantation in which the patient is their own donor.			Therapeutic or Preventive Procedure	
C142987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142987>	C25337	Number of Metastases	An indication of the number of metastatic tumors detected.			Quantitative Concept	
C142988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142988>	C27993	Limited|Limit	Restricted or in amount, size, or extent.			Qualitative Concept	
C142990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142990>	C21295	SPA17 Gene|SPA17|SPA17|Sperm Autoantigenic Protein 17 Gene	This gene plays a role in binding to carbohydrates in the zona pellucida.	SPA17 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C142991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142991>	C142990	SPA17 wt Allele|CT22|SP17|SP17-1|Sperm Autoantigenic Protein 17 wt Allele	Human SPA17 wild-type allele is located in the vicinity of 11q24.2 and is approximately 24 kb in length. This allele, which encodes sperm surface protein Sp17, is involved in the binding of spermatozoa to oocytes. Aberrant expression may be associated with neoplastic disease.	SPA17 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142992>	C17728	Sperm Surface Protein Sp17|CT22|Cancer/Testis Antigen 22|SPA17|Sp17|Sp17-1|Sperm Autoantigenic Protein 17|Sperm Protein 17	Sperm surface protein Sp17 (151 aa, ~17 kDa) is encoded by the human SPA17 gene. This protein plays a role in the binding of spermatozoa to the carbohydrates in the zona pellucida.	Sperm Surface Protein Sp17		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142993>	C47794	Vabicaserin Hydrochloride|VABICASERIN HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142994>	C25997	AKAP4 Gene|A-Kinase Anchoring Protein 4 Gene|AKAP4|AKAP4	This gene is involved in both sperm motility and protein kinase A binding.	AKAP4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C142995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142995>	C142994	AKAP4 wt Allele|A Kinase (PRKA) Anchor Protein 4 Gene|A-Kinase Anchor Protein, 82-kD Gene|A-Kinase Anchoring Protein 4 wt Allele|AKAP 82|AKAP-4|AKAP82|CT99|FSC1|FSC1, Mouse, Homolog of Gene|HI|Testis-Specific Gene HI|hAKAP82|p82	Human AKAP4 wild-type allele is located in the vicinity of Xp11.22 and is approximately 10 kb in length. This allele, which encodes A-kinase anchor protein 4, plays a role in both protein kinase A localization and sperm motility. Aberrant expression may be associated with neoplastic disease.	AKAP4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142996>	C26231	A-Kinase Anchor Protein 4|A-Kinase Anchor Protein 82 kDa|A-Kinase Anchoring Protein 4|AKAP 82|AKAP-4|AKAP4|HI|Major Sperm Fibrous Sheath Protein|PRKA4|Protein Kinase A Anchoring Protein 4|Protein Kinase A-Anchoring Protein 4|hAKAP82	A-kinase anchor protein 4 (854 aa, ~94 kDa) is encoded by the human AKAP4 gene. This protein is involved in the localization of protein kinase A in sperm.	A-Kinase Anchor Protein 4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C142997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142997>	C29696	Tubocurarine Chloride Anhydrous|TUBOCURARINE CHLORIDE ANHYDROUS				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142998>	C155764	Triciribine|1,4,5,6,8-Pentaazaacenaphthylen-3-amine, 1,5-Dihydro-5-methyl-1-beta-D-ribofuranosyl-|Pentaazacentopthylene|TRICIRIBINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C142999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C142999>	C25974	Tasidotin Hydrochloride|TASIDOTIN HYDROCHLORIDE|Tasidotin HCl				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C14299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14299>	C14350	Parvovirus|Parvoviridae	A family of very small DNA viruses containing a single linear molecule of single-stranded DNA and consisting of two subfamilies: parvovirinae and densovirinae. They infect both vertebrates and invertebrates.			Virus	
C1429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1429>	C62799	Vapreotide|BMY-41606|Docrised|RC-160|VAPREOTIDE|vapreotide	A synthetic cyclic octapeptide analogue of somatostatin with direct and indirect antitumor effects. Vapreotide binds to somatostatin receptors (SSTR), specifically SSTR-2 and to SSTR-5 with a lesser affinity, in the similar behaviors as other octapeptide somatostatin analogues. Like octreotide, this agent has direct and indirect antitumor effects via inhibiting the release of growth hormone and other peptides that regulate release of insulin, gastrointestinal hormones. Furthermore, vapreotide may also be useful for inducing hemostasis in cases of acute hemorrhage of the upper gastrointestinal tract.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C143000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143000>	C263	Semuloparin Sodium|SEMULOPARIN SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C143001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143001>	C47795	Sibopirdine Anhydrous|5H-Cyclopenta(2,1-b-3,4-b')dipyridine, 5,5-Bis(4-pyridinylmethyl)-|SIBOPIRDINE ANHYDROUS				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C143002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143002>	C20401	Lifastuzumab|LIFASTUZUMAB|MNIB2126A|NaPi3b				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C143003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143003>	C2139	Spirogermanium Hydrochloride|2-(3-(Dimethylamino)propyl)-8,8-diethyl-2-aza-8-germaspiro(4.5)decane Dihydrochloride|2-Aza-8-germaspiro(4.5)decane-2-propanamine, 8,8-Diethyl-N,N-dimethyl-, Dihydrochloride|2-Aza-8-germaspiro[4.5]decane-2-propanamine, 8, 8-diethyl-N,N-dimethyl-, dihydrochloride|8,8-Diethyl-N,N-dimethyl-2-aza-8-germaspiro(4.5)decane-2-propanamine Dihydrochloride|SPIROGERMANIUM HYDROCHLORIDE|Spirogermanium HCl|Spirogermanium hydrochloride				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C143004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143004>	C2143	Squalamine|3-((3-(4-(Aminobutyl)amino)propyl)amio)cholestane-7,24-diol 24-(Hydrogen Sulfate), (3beta,5alpha,7alpha,24R)-|Cholestane-7,24-diol, 3-((3-(4-(Aminobutyl)amino)propyl)amio)-, 24-(Hydrogen sulfate), (3beta,5alpha,7alpha,24R)-|SQUALAMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C143005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143005>	C29697	Sodium Picosulfate Anhydrous|4,4'-(2-Pyridylmethylene)diphenol Bis(hydrogen Sulfate) Disodium Salt|SODIUM PICOSULFATE ANHYDROUS				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C143006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143006>	C177175	CpG Oligodeoxynucleotide TLR9 Agonist DV281|CPG ODN TLR9 Agonist DV281|DV 281|DV-281|DV-281|DV281|TLR9 Agonist DV281	A proprietary synthetic, aerosolized C-class CpG oligodeoxynucleotide-based (ODN) agonist of toll-like receptor 9 (TLR9), with potential immunostimulating activity. Upon inhalation, CpG ODN TLR9 agonist DV281 specifically targets, binds to and activates TLR9 expressed by plasmacytoid dendritic cells (pDCs) and B-cells. This initiates immune signaling pathways and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against antigens expressed by lung cancer cells. TLR9, a member of the TLR family, plays a fundamental role in pathogen recognition and activation of the innate immune system.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C143007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143007>	C28172	Breath Actuated Nebulizer|BAN|Breath-Actuated Nebulizer	A nebulizer that creates an aerosol in response to the patient's inspiratory flow.			Medical Device	
C143008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143008>	C20194	ROPN1 Gene|ROPN1|ROPN1|Rhophilin Associated Tail Protein 1 Gene	This gene plays a role in spermatozoa capacitation.	ROPN1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C143009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143009>	C143008	ROPN1 wt Allele|CT91|ODF6|RHPNAP1|ROPN1A|Rhophilin Associated Tail Protein 1 wt Allele|Ropporin Gene|Ropporin, Rhophilin Associated Protein Gene	Human ROPN1 wild-type allele is located in the vicinity of 3q21.1 and is approximately 23 kb in length. This allele, which encodes ropporin-1A protein, is involved in sperm capacitation. Aberrant expression may be associated with neoplastic disease.	ROPN1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C14300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14300>	C14186	Rous Sarcoma Virus|RSV	A species of single-stranded, reverse-transcribing RNA retrovirus of the genus alpharetrovirus and the family retroviridae. It is the first oncovirus described in the literature and was found to cause sarcoma in chickens.			Virus	
C143010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143010>	C18466	Ropporin-1A|CT91|Cancer/Testis Antigen 91|Outer Dense Fiber of Sperm Tails 6|ROPN1|Rhophilin Associated Tail Protein 1|Rhophilin-Associated Protein 1A|Ropporin|Testis Secretory Sperm-Binding Protein Li 239w	Ropporin-1A (212 aa, ~24 kDa) is encoded by the human ROPN1 gene. This protein plays a role in sperm motility and capacitation.	Ropporin-1A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C143012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143012>	C7903|C4819|C162652	Recurrent Skin Squamous Cell Carcinoma|Recurrent Cutaneous Squamous Cell Carcinoma	The reemergence of squamous cell carcinoma of the skin after a period of remission.			Neoplastic Process	
C143013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143013>	C4819|C4104|C170811	Metastatic Skin Squamous Cell Carcinoma|Metastatic Cutaneous Squamous Cell Carcinoma	Squamous cell carcinoma of the skin which has spread to other anatomic sites.			Neoplastic Process	
C143014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143014>	C3273	Neurofibromatosis Type 1 with Inoperable, Progressive, Symptomatic Plexiform Neurofibromas|NF Type 1 with Inoperable, Progressive, Symptomatic Plexiform Neurofibromas	Progressive, symptomatic neurofibromatosis type 1 associated with plexiform neurofibromas that cannot be removed surgically without risk of substantial morbidity.			Disease or Syndrome	
C143015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143015>	C35461	Inoperable Disease	Disease state in which the surgical removal of a tumor is not feasible or useful.	Inoperable Disease		Finding	CTRP Disease Terminology|CTRP Terminology
C143016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143016>	C25997	WDR26 Gene|WD Repeat Domain 26 Gene|WDR26|WDR26	This gene is involved in the regulation of heterotrimeric G protein localization and activity.			Gene or Genome	
C143017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143017>	C143016	WDR26 wt Allele|CDW2|FLJ21016|GID Complex Subunit 7 Homolog (S. cerevisiae) Gene|GID Complex, Subunit 7 Gene|GID7|Glucose-Induced Degradation-Deficient Protein 7, S. cerevisiae, Homolog of Gene|MIP2|PRO0852|SKDEAS|WD Repeat Domain 26 wt Allele	Human WDR26 wild-type allele is located within 1q42.11-q42.12 and is approximately 52 kb in length. This allele, which encodes WD repeat-containing protein 26, plays a role in the regulation of G protein activity. Mutation of the gene is associated with Skraban-Deardorff syndrome.			Gene or Genome	
C143018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143018>	C26231	WD Repeat-Containing Protein 26|CUL4- and DDB1-Associated WDR Protein 2|GID Complex Subunit 7 Homolog|Myocardial Ischemic Preconditioning Up-Regulated Protein 2|Myocardial Ischemic Preconditioning Upregulated Protein 2|WDR26	WD repeat-containing protein 26 (661 aa, ~72 kDa) is encoded by the human WDR26 gene. This protein is involved in the localization of G beta-gamma complexes.			Amino Acid, Peptide, or Protein	
C143019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143019>	C21275	METAP2 Gene|METAP2|METAP2|Methionyl Aminopeptidase 2 Gene	This gene plays a role in the removal of the amino-terminal methionine from nascent proteins.	METAP2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C14301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14301>	C14348|C14188	Bacteriophage P1|Enterobacteria Phage P1	A double-stranded DNA virus that infects E. coli and other enteric bacteria. Additionally, this phage is used in molecular biotechnology as a cloning vector for eukaryotic DNA.			Virus	
C143020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143020>	C143019	METAP2 wt Allele|MAP2|MNPEP|Methionyl Aminopeptidase 2 wt Allele|p67|p67eIF2	Human METAP2 wild-type allele is located in the vicinity of 12q22 and is approximately 42 kb in length. This allele, which encodes methionine aminopeptidase 2 protein, is involved in nascent protein processing and the regulation of angiogenesis.	METAP2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C143021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143021>	C16843	Methionine Aminopeptidase 2|EC 3.4.11.18|EIF-2-Associated p67 Homolog|Eukaryotic Initiation Factor 2-Associated Protein, 67-kD|Initiation Factor 2 Associated 67 kDa Glycoprotein|Initiation Factor 2-Associated 67 kDa Glycoprotein|MAP 2|METAP2|MetAP 2|Methionyl Aminopeptidase 2|Peptidase M|Testicular Tissue Protein Li 17|p67|p67eIF2	Methionine aminopeptidase 2 (478 aa, ~53 kDa) is encoded by the human METAP2 gene. This protein plays a role in both the steric hindrance of phosphorylation of the alpha subunit of eukaryotic initiation factor 2 (EIF2S1) and the removal of the amino-terminal methionine from nascent proteins.	Methionine Aminopeptidase 2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C143022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143022>	C20921	RHPN1 Gene|RHPN1|RHPN1|Rhophilin Rho GTPase Binding Protein 1 Gene	This gene is involved in GTP binding.			Gene or Genome	
C143023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143023>	C143022	RHPN1 wt Allele|KIAA1929|ODF5|RHOPHILIN|RHPN|Rhophilin Rho GTPase Binding Protein 1 wt Allele	Human RHPN1 wild-type allele is located in the vicinity of 8q24.3 and is approximately 15 kb in length. This allele, which encodes rhophilin-1 protein, plays a role in GTP binding, cytoskeletal modeling and signal transduction.			Gene or Genome	
C143024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143024>	C18515	Rhophilin-1|GTP-Rho-Binding Protein 1|Outer Dense Fiber of Sperm Tails 5|PKN-Related Rho-Binding Protein|RHPN1|Rho GTPase-Binding Protein 1|Rhophilin 1|Rhophilin Rho GTPase Binding Protein 1	Rhophilin-1 (695 aa, ~76 kDa) is encoded by the human RHPN1 gene. This protein is involved in cytoskeletal modeling and signal transduction.			Amino Acid, Peptide, or Protein	
C143025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143025>	C270	Pinacidil Anhydrous|2-Cyano-3-(4-pyridinyl)-1-(1,2,2-trimethylpropyl)guanidine|Guanidine, N-cyano-N'-4-pyridinyl-N''-(1,2,2-trimethylpropyl)-|PINACIDIL ANHYDROUS				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C143026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143026>	C21114	TNFSF18 Gene|TNFSF18|TNFSF18|Tumor Necrosis Factor Superfamily Member 18 Gene	This gene plays a role in the modulation of T-cell activation and proliferation.			Gene or Genome	
C143027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143027>	C143026	TNFSF18 wt Allele|AITRL|GITRL|TL6|TNF Superfamily Member 18 wt Allele|TNLG2A|Tumor Necrosis Factor (Ligand) Superfamily, Member 18 Gene|Tumor Necrosis Factor Superfamily, Member 18 Gene|UNQ149/PRO175|hGITRL	Human TNFSF18 wild-type allele is located in the vicinity of 1q25.1 and is approximately 11 kb in length. This allele, which encodes tumor necrosis factor ligand superfamily member 18 protein, is involved in the positive regulation of T-cell survival.			Gene or Genome	
C143028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143028>	C49337	Formalin-Fixed Paraffin-Embedded|FFPE|FFPE|FFPE	Refers to a process where a sample is preserved with formalin and then embedded into a paraffin block for sectioning.			Laboratory Procedure	GDC Terminology|GDC Value Terminology|ICDC Terminology|ICDC Value Terminology
C143029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143029>	C171257	Waterpipe|Bong|Water Pipe	A device for smoking herbal substances that filters and cools the smoke by passing it through water.			Manufactured Object	
C14302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14302>	C14348|C14188	Bacteriophage T4|Coliphage T4|Enterobacteria Phage T4	A double-stranded DNA virus that infects bacteria such as E. coli.			Virus	
C143030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143030>	C15656	Intraoperative Nerve Monitoring|IONM|Intraoperative Neuromonitoring|Intraoperative Neurophysiological Monitoring	The use of electrophysiological methods to evaluate the functional integrity of neural structures during surgery.			Health Care Activity	
C143031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143031>	C21295	A1CF Gene|A1CF|A1CF|A1CF|APOBEC1 Complementation Factor Gene	This gene is involved in the deamination of APOB mRNA.			Gene or Genome	GDC Terminology|GDC Value Terminology
C143032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143032>	C143031	A1CF wt Allele|ACF|ACF64|ACF65|APOBEC1 Complementation Factor wt Allele|APOBEC1CF|ASP|Apobec-1 Complementation Factor (ACF) (ASP) Gene	Human A1CF wild-type allele is located in the vicinity of 10q11.23 and is approximately 86 kb in length. This allele, which encodes APOBEC1 complementation factor, plays a role in RNA binding and mRNA metabolism.			Gene or Genome	
C143033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143033>	C21298	APOBEC1 Complementation Factor|A1CF|APOBEC-1 Stimulating Protein|APOBEC1-Stimulating Protein|Apo-B RNA Editing Protein	APOBEC1 complementation factor (594 aa, ~65 kDa) is encoded by the human A1CF gene. This protein is involved in binding to and metabolism of APOB mRNA. Missense mutations in the gene may be associated with melanoma and other neoplastic diseases.			Amino Acid, Peptide, or Protein	
C143034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143034>	C204256|C1572	Adenoviral Brachyury Vaccine ETBX-051|Ad5-brachyury vaccine|ETBX 051|ETBX-051|ETBX-051	A therapeutic cancer vaccine composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human transcription factor brachyury encoded, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the adenoviral brachyury vaccine ETBX-051 expresses the brachyury protein. The expressed brachyury may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing brachyury, thereby resulting in both immune-mediated inhibition of tumor cell proliferation and tumor cell death. Deletion of the E1, E2b and E3 genes from Ad5 prevents anti-adenovirus immune responses. Brachyury, a tumor-associated antigen (TAA) and member of the T-box family of transcription factors, is overexpressed in a variety of tumor types. It plays an important role in cancer progression and metastasis.	Adenoviral Brachyury Vaccine ETBX-051		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C143035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143035>	C204256|C1572	Adenoviral MUC1 Vaccine ETBX-061|Ad5-MUC1 vaccine|ETBX 061|ETBX-061|ETBX-061	A therapeutic cancer vaccine composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human glycoprotein mucin 1 (MUC1) encoded, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the adenoviral MUC1 vaccine ETBX-061 expresses the MUC1 protein. The expressed MUC1 may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing MUC1, thereby resulting in both immune-mediated inhibition of tumor cell proliferation and tumor cell death. Deletion of the E1, E2b and E3 genes from Ad5 prevents anti-adenovirus immune responses. MUC1, a tumor-associated antigen (TAA) and type I transmembrane protein, is overexpressed in a variety of tumor types. It plays an important role in cancer progression and metastasis.	Adenoviral MUC1 Vaccine ETBX-061		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C143036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143036>	C21295	DCAF12L2 Gene|DCAF12L2|DCAF12L2|DCAF12L2|DDB1 and CUL4 Associated Factor 12 Like 2 Gene	This gene may play a role in protein complex formation.			Gene or Genome	GDC Terminology|GDC Value Terminology
C143037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143037>	C143036	DCAF12L2 wt Allele|DDB1 and CUL4 Associated Factor 12 Like 2 wt Allele|WD Repeat Domain 40C Gene|WDR40C	Human DCAF12L2  wild-type allele is located in the vicinity of Xq25 and is approximately 3 kb in length. This allele, which encodes DDB1- and CUL4-associated factor 12-like protein 2, is involved in protein-protein interactions. Mutations in the gene may be associated with colorectal cancer.			Gene or Genome	
C143038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143038>	C17728	DDB1- and CUL4-Associated Factor 12-Like Protein 2|DCAF12L2|WD Repeat-Containing Protein 40C|WDR40C	DDB1- and CUL4-associated factor 12-like protein 2 (463 aa, ~51 kDa) is encoded by the human DCAF12L2 gene. This protein plays a role in the modulation of protein-protein interactions.			Amino Acid, Peptide, or Protein	
C143039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143039>	C20923	CYSLTR2 Gene|CYSLTR2|CYSLTR2|CYSLTR2|Cysteinyl Leukotriene Receptor 2 Gene	This gene is involved in cysteinyl leukotriene binding and signal transduction.	CYSLTR2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C14303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14303>	C14248	Caenorhabditis elegans|C. elegans	A roundworm of the phylum Nematoda often utilized as a biological model system for research.			Eukaryote	
C143040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143040>	C143039	CYSLTR2 wt Allele|CYSLT2|CYSLT2R|Cysteinyl Leukotriene Receptor 2 wt Allele|GPCR21|HG57|HPN321|KPG_011|PSEC0146|hGPCR21	Human CYSLTR2 wild-type allele is located in the vicinity of 13q14.2 and is approximately 58 kb in length. This allele, which encodes cysteinyl leukotriene receptor 2, plays a role in leukotriene-dependent signaling. Mutations in the gene may be associated with uveal melanoma.	CYSLTR2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C143041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143041>	C18239	Cysteinyl Leukotriene Receptor 2|CYSLTR2|CysLT(2)|Cysteinyl Leukotriene CysLT2 Receptor|G-Protein Coupled Receptor GPCR21|G-Protein Coupled Receptor HG57|HPN321|hGPCR21	Cysteinyl leukotriene receptor 2 (346 aa, ~40 kDa) is encoded by the human CYSLTR2 gene. This protein is involved in the mediation of cysteinyl leukotriene-dependent signal transdution.	Cysteinyl Leukotriene Receptor 2		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C143042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143042>	C20194	CSMD3 Gene|CSMD3|CSMD3|CSMD3|CUB and Sushi Multiple Domains 3 Gene	This gene plays a role in neuronal development.			Gene or Genome	GDC Terminology|GDC Value Terminology
C143043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143043>	C143042	CSMD3 wt Allele|CUB and Sushi Multiple Domains 3 wt Allele|KIAA1894	Human CSMD3 wild-type allele is located in the vicinity of 8q23.3 and is approximately 1215 kb in length. This allele, which encodes CUB and sushi domain-containing protein 3, is involved in dendrite development.			Gene or Genome	
C143044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143044>	C18466	CUB and Sushi Domain-Containing Protein 3|CSMD3	CUB and sushi domain-containing protein 3 (3707 aa, ~406 kDa) is encoded by the human CSMD3 gene. This protein plays a role in the development of neuronal projections.			Amino Acid, Peptide, or Protein	
C143045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143045>	C270	Quinuclium Bromide Anhydrous|1-Azoniabicyclo(2.2.2)octane, 1-methyl-3-oxo-4-phenyl-, Bromide|1-Methyl-3-oxo-4-phenyl-1-azoniabicyclo(2.2.2)octane, Bromide|QUINUCLIUM BROMIDE ANHYDROUS				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C143046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143046>	C2149|C129825	Ralimetinib|3H-Imidazo(4,5-b)pyridin-2-amine, 5-(2-(1,1-Dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-(2,2-dimethylpropyl)-|LY2228820 Free Base|RALIMETINIB	A tri-substituted imidazole derivative and orally available, p38 mitogen-activated protein kinase (MAPK) inhibitor, with potential anti-inflammatory and antineoplastic activities. Upon administration, ralimetinib inhibits the activity of p38, particularly the alpha and beta isoforms, thereby inhibiting MAPKAPK2 phosphorylation and preventing p38 MAPK-mediated signaling. This may inhibit the production of a variety of cytokines involved in inflammation, cellular proliferation and angiogenesis such as tumor necrosis factor alpha (TNFa), interleukin (IL)-1, -6 and -8, vascular endothelial growth factor, and macrophage inflammatory protein-1 alpha. Ultimately this induces apoptosis and reduces tumor cell proliferation. In addition, inhibition of the p38 MAPK pathway by ralimetinib increases the antineoplastic activity of certain chemotherapeutic agents. p38 MAPK, a serine/threonine protein kinase that is often upregulated in cancer cells, plays a crucial role in tumor cell proliferation, angiogenesis and metastasis.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C143047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143047>	C155727	Derazantinib Hydrochloride|AQ14741087|ARQ 087.2HCl|ARQ-087 Dihydrochloride|Benzo(H)quinazolin-2-amine, 6-(2-Fluorophenyl)-5,6-dihydro-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-, Hydrochloride (1:2), (6R)-|DERAZANTINIB HYDROCHLORIDE|Derazantinib Dihydrochloride				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C143048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143048>	C54443	National Cancer Institute Terminology	Terminology sets that are designed to fulfill the need to have consistent coding, analysis, and data sharing across a broad range of National Cancer Institute (NCI) resources.			Intellectual Product	
C143049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143049>	C21295	CRNKL1 Gene|CRNKL1|CRNKL1|CRNKL1|Crooked Neck Pre-mRNA Splicing Factor 1 Gene	This gene is involved in RNA binding and pre-mRNA splicing.			Gene or Genome	GDC Terminology|GDC Value Terminology
C14304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14304>	C14351	Caliciviridae|CALICIVIRIDAE	A family of single-stranded, non-segmented, positive-sense RNA viruses with a hexagonal/spherical capsid and no envelope. These viruses can be spread by the fecal-oral or respiratory route and infection typically leads to acute gastroenteritis.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C143050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143050>	C143049	CRNKL1 wt Allele|CGI-201|CLF|CRN|Clf1|Crn, Crooked Neck-Like 1 (Drosophila) Gene|Crooked Neck (Drosophila Crn Homolog)-Like 1 Gene|Crooked Neck Pre-mRNA Splicing Factor 1 wt Allele|Crooked Neck Pre-mRNA Splicing Factor-Like 1 (Drosophila) Gene|Crooked Neck, Drosophila, Homolog of Gene|Crooked Neck-Like 1 Gene|HCRN|MSTP021|SYF3	Human CRNKL1 wild-type allele is located in the vicinity of 20p11.23 and is approximately 22 kb in length. This allele, which encodes crooked neck-like protein 1, plays a role in pre-mRNA splicing. Mutations in the gene may be associated with basal cell cancer.			Gene or Genome	
C143051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143051>	C21298	Crooked Neck-Like Protein 1|CRNKL1|Crooked Neck Homolog|Crooked Neck Pre-mRNA Splicing Factor 1|SYF3 Pre-mRNA-Splicing Factor|hCrn	Crooked neck-like protein 1 (848 aa, ~100 kDa) is encoded by the human CRNKL1 gene. This protein is involved in splicing of pre-mRNA.			Amino Acid, Peptide, or Protein	
C143052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143052>	C26001	COL3A1 Gene|COL3A1|COL3A1|COL3A1|Collagen Type III Alpha 1 Chain Gene	This gene plays a role in collagen formation in connective tissues.	COL3A1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C143053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143053>	C143052	COL3A1 wt Allele|Collagen Type III Alpha 1 Chain wt Allele|Collagen, Blood Vessel Gene|Collagen, Fetal Gene|Collagen, Type III, Alpha 1 Gene|Collagen, Type III, Alpha-1 Gene|EDS4A|Ehlers-Danlos Syndrome Type IV, Autosomal Dominant Gene	Human COL3A1 wild-type allele is located in the vicinity of 2q32.2 and is approximately 38 kb in length. This allele, which encodes collagen alpha-1(III) chain protein, is involved in collagen formation. Mutations in this gene are associated with Ehlers-Danlos syndrome type IV, aortic and arterial aneurysms and lipoblastoma.	COL3A1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C143054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143054>	C16447	COL3A1 Gene Product	A protein encoded by the COL3A1 gene.			Amino Acid, Peptide, or Protein	
C143055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143055>	C143054	Collagen Alpha-1(III) Chain|Alpha-1 Type 3 Collagen|Alpha-1 Type III Collagen|Alpha1 (III) Collagen|COL3A1|Collagen Type 3 Alpha 1 Chain|Collagen Type III Alpha 1 Chain	Collagen alpha-1(III) chain (1466 aa, ~139 kDa) is encoded by the human COL3A1 gene. This protein plays a role in connective tissue organization.	Collagen Alpha-1(III) Chain		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C143056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143056>	C21295	CNBD1 Gene|CNBD1|CNBD1|CNBD1|Cyclic Nucleotide Binding Domain Containing 1 Gene	This gene is involved in cyclic nucleotide binding.			Gene or Genome	GDC Terminology|GDC Value Terminology
C143057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143057>	C143056	CNBD1 wt Allele|Cyclic Nucleotide Binding Domain Containing 1 wt Allele|FLJ35802	Human CNBD1 wild-type allele is located in the vicinity of 8q21.3 and is approximately 749 kb in length. This allele, which encodes cyclic nucleotide-binding domain-containing protein 1, plays a role in cyclic nucleotide binding. Mutations in the gene may be associated with gastric cancer and colorectal cancer.			Gene or Genome	
C143058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143058>	C17728	Cyclic Nucleotide-Binding Domain-Containing Protein 1|CNBD1	Cyclic nucleotide-binding domain-containing protein 1 (436 aa, ~50 kDa) is encoded by the human CNBD1 gene. This protein is involved in cyclic nucleotide binding.			Amino Acid, Peptide, or Protein	
C143059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143059>	C2685	Prime Cancer Vaccine MVA-BN-CV301|MVA-BN Vaccine CV301|MVA-BN-CV301|Modified Vaccinia Ankara-Bavarian Nordic Vaccine CV301|Prime Vaccine CV301	A cancer priming vaccine consisting of a proprietary version of the recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN), encoding both the two human tumor-associated antigens (TAAs) carcinoembryonic antigen (CEA) and mucin-1 (MUC-1), and TRICOM, which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration of MVA-BN-CV301, followed by multiple boosting doses of the fowlpox virus (FPV) vaccine CV301, a cytotoxic T-lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells is activated. In addition, the CV301-dependent anti-tumor CTL response upregulates the expression of programmed cell death ligand 1 (PD-L1); therefore, when CV301 is combined with a programmed cell death 1 (PD-1) immune checkpoint inhibitor, the antitumor effect may be increased. CEA and MUC-1 are overexpressed in a variety of cancers.	Prime Cancer Vaccine MVA-BN-CV301		Immunologic Factor|Pharmacologic Substance|Virus	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C14305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14305>	C14268	Gammaretrovirus|Retroviruses, Type C, Mammalian|Type C Mammalian Retrovirus	A genus of the family Retroviridae. Some species contain oncogenes that may cause leukemias or sarcomas. Some Gammaretrovirus genomes share sequences with endogenous viral elements (ERV) found in mammalian genomes..			Virus	
C143060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143060>	C28681	Autologous Gamma-retroviral MSGV1 139 scFv EGFRvIII CAR Gene-modified T Cells|Gamma-retroviral MSGV1 139 scFv EGFRvIII CAR Gene-modified Autologous T-lymphocytes|MSGV1-EGFRvIII-specific CAR-transduced Autologous T Lymphocytes|MSGv1-EGFRvIII-CAR Autologous T Cells	A preparation of autologous T-lymphocytes transduced with the gamma retroviral vector MSGV1 expressing a chimeric T-cell antigen receptor (CAR) consisting of a single-chain variable fragment (scFv) from a specific antibody clone (mAb139) that targets a mutant form of epidermal growth factor receptor (EGFR) known as variant III (EGFRvIII; EGFR-vIII), with potential antineoplastic activity. Upon intratumoral administration, the gamma-retroviral MSGV1 139 scFv EGFRvIII CAR gene-modified T-cells specifically target and bind to tumor cells expressing EGFRvIII, leading to selective cytotoxicity in EGFRvIII-expressing tumor cells. EGFRvIII, a tumor-associated antigen (TAA) encoded by an in-frame deletion of exons 2-7 in the EGFR gene, is specifically overexpressed by a subset of tumor cells and is not expressed in normal, healthy cells. It plays a key role in tumor cell proliferation, tumor angiogenesis and radio- and chemoresistance.	Autologous Gamma-retroviral MSGV1 139 scFv EGFRvIII CAR Gene-modified T Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C143061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143061>	C25870	CHST11 Gene|CHST11|CHST11|CHST11|Carbohydrate Sulfotransferase 11 Gene	This gene plays a role in the metabolism of chondroitin sulfate.			Gene or Genome	GDC Terminology|GDC Value Terminology
C143062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143062>	C143061	CHST11 wt Allele|C4ST|C4ST-1|C4ST1|Carbohydrate (Chondroitin 4) Sulfotransferase 11 Gene|Carbohydrate Sulfotransferase 11 wt Allele|HSA269537	Human CHST11 wild-type allele is located in the vicinity of 12q23.3 and is approximately 307 kb in length. This allele, which encodes carbohydrate sulfotransferase 11 protein, is involved in chondroitin sulfate metabolism. A chromosomal translocation involving this gene and the IgH locus, t(12;14)(q23;q32), may be associated with B-cell chronic lymphocytic leukemia.			Gene or Genome	
C143063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143063>	C17210	Carbohydrate Sulfotransferase 11|C4S-1|C4ST-1|C4ST1|CHST11|Chondroitin 4-O-Sulfotransferase 1|Chondroitin 4-Sulfotransferase 1|EC 2.8.2.5	Carbohydrate sulfotransferase 11 (352 aa, ~42 kDa) is encoded by the human CHST11 gene. This protein plays a role in the sulfation of chondroitin.			Amino Acid, Peptide, or Protein|Enzyme	
C143064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143064>	C21240	LARP4B Gene|LARP4B|LARP4B|LARP4B|La Ribonucleoprotein Domain Family Member 4B Gene	This gene is involved in RNA metabolism and translation.			Gene or Genome	GDC Terminology|GDC Value Terminology
C143065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143065>	C143064	LARP4B wt Allele|KIAA0217|LARP5|La Ribonucleoprotein Domain Family Member 4B wt Allele|La Ribonucleoprotein Domain Family, Member 4B Gene|La Ribonucleoprotein Domain Family, Member 5 Gene	Human LARP4B wild-type allele is located in the vicinity of 10p15.3 and is approximately 181 kb in length. This allele, which encodes La-related protein 4B, plays a role in translation. Mutations in the gene may be associated with acute myeloid leukemia, glioma and colorectal cancer.			Gene or Genome	
C143066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143066>	C38576	La-Related Protein 4B|LARP4B|La Ribonucleoprotein Domain Family Member 4B|La Ribonucleoprotein Domain Family Member 5|La-Related Protein 5	La-related protein 4B (738 aa, ~81 kDa) is encoded by the human LARP4B gene. This protein is involved in the positive regulation of translation.			Amino Acid, Peptide, or Protein	
C143067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143067>	C155727	FGFR4 Antagonist INCB062079|FGFR4 Inhibitor INCB062079|Fibroblast Growth Factor Receptor 4 Antagonist INCB062079|Fibroblast Growth Factor Receptor 4 Antagonist INCB062079|INCB 062079|INCB-062079|INCB062079|INCB62079	An orally bioavailable, selective inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon oral administration, FGFR4 antagonist INCB062079 specifically and irreversibly binds to the cysteine residue at position 552 (Cys 552) that is within the active site of FGFR4. This blocks FGFR4 autophosphorylation and activation of receptor tyrosine kinase activity that would normally occur after binding to its ligand fibroblast growth factor 19 (FGF19), which both inhibits FGFR4-mediated signaling and leads to an inhibition of tumor cell proliferation in FGF19- and FGFR4-overexpressing cells. FGFR4, a receptor tyrosine kinase, is involved in angiogenesis and in the proliferation, differentiation, and survival of tumor cells. FGFR4 expression is associated with poor prognosis. FGF19 is overexpressed by certain tumor cell types.	Fibroblast Growth Factor Receptor 4 Antagonist INCB062079		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C143068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143068>	C141137|C129820	IDO-1 Inhibitor LY3381916|IDO1 Inhibitor LY3381916|LY-3381916|LY-3381916|LY3381916	An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1; IDO-1), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1 inhibitor LY3381916 specifically targets and binds to IDO1, a cytosolic enzyme responsible for the oxidation of the amino acid tryptophan into the immunosuppressive metabolite kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, LY3381916 restores and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes, and causes a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL) response against the IDO1-expressing tumor cells, thereby inhibiting the growth of IDO1-expressing tumor cells. IDO1, overexpressed by multiple tumor cell types, plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system.	IDO-1 Inhibitor LY3381916		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C143069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143069>	C25942|C19676	POLG Gene|DNA Polymerase Gamma, Catalytic Subunit Gene|POLG|POLG|POLG	This gene plays a role in the replication of mitochondrial DNA.			Gene or Genome	GDC Terminology|GDC Value Terminology
C14306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14306>	C14346	Arenavirus|ARENAVIRUS	A genus of negative-sense, single-stranded, RNA viruses of the family Arenaviridae that are spherical in shape and enveloped in a lipid membrane. The mechanism of replication is unknown, however new virions containing host ribosomes bud off of the surface of host cells. These zoonotic viruses are found mostly in rodent reservoirs, although the Tacaribe virus was isolated from a bat.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C143070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143070>	C143069	POLG wt Allele|DNA Polymerase Gamma, Catalytic Subunit wt Allele|MDP1|MIRAS|MTDPS4A|MTDPS4B|PEO|POLG1|POLGA|Polymerase (DNA Directed), Gamma Gene|Polymerase (DNA) Gamma, Catalytic Subunit Gene|Polymerase, DNA, Gamma Gene|Polymerase, DNA, Gamma-1 Gene|SANDO|SCAE	Human POLG wild-type allele is located in the vicinity of 15q26.1 and is approximately 30 kb in length. This allele, which encodes DNA polymerase subunit gamma-1 protein, is involved in mitochondrial DNA replication. Mutations in the gene are associated with colorectal cancer, progressive external ophthalmoplegia with mitochondrial DNA deletions 1 (PEOA1), sensory ataxic neuropathy dysarthria and ophthalmoparesis (SANDO), Alpers-Huttenlocher syndrome (AHS), and mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE).			Gene or Genome	
C143071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143071>	C21170|C16512	DNA Polymerase Subunit Gamma-1|EC 2.7.7.7|Mitochondrial DNA Polymerase Catalytic Subunit|POLG|PolG-Alpha	DNA polymerase subunit gamma-1 (1239 aa, ~140 kDa) is encoded by the human POLG gene. This protein plays a role in mitochondrial DNA replication.			Amino Acid, Peptide, or Protein|Enzyme	
C143072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143072>	C21295	PABPC1 Gene|PABPC1|PABPC1|PABPC1|Poly(A) Binding Protein Cytoplasmic 1 Gene	This gene is involved in binding to poly(A)RNA.			Gene or Genome	GDC Terminology|GDC Value Terminology
C143073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143073>	C143072	PABPC1 wt Allele|PAB1|PABP|PABP1|PABPC2|PABPL1|Poly(A) Binding Protein Cytoplasmic 1 wt Allele|Poly(A) Binding Protein, Cytoplasmic 2 Gene|Poly(A)-Binding Protein, Cytoplasmic 2 Gene|Polyadenylate-Binding Protein, Cytoplasmic, 1 Gene	Human PABPC1 wild-type allele is located in the vicinity of 8q22.3 and is approximately 37 kb in length. This allele, which encodes polyadenylate-binding protein 1, plays a role in mRNA binding. Mutations in the gene may be associated with head and neck squamous cell carcinoma and biliary tract carcinoma.			Gene or Genome	
C143074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143074>	C21298	Polyadenylate-Binding Protein 1|PABP-1|PABPC1|Poly(A)-Binding Protein 1	Polyadenylate-binding protein 1 (636 aa, ~71 kDa) is encoded by the human PABPC1 gene. This protein is involved in binding to the poly(A) tail of mRNA.			Amino Acid, Peptide, or Protein	
C143075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143075>	C25997	NBEA Gene|NBEA|NBEA|NBEA|Neurobeachin Gene	This gene plays a role in membrane-targeting of protein kinase A.			Gene or Genome	GDC Terminology|GDC Value Terminology
C143076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143076>	C143075	NBEA wt Allele|BCL8B|FLJ10197|KIAA1544|LYST2|Neurobeachin wt Allele	Human NBEA wild-type allele is located in the vicinity of 13q13.3 and is approximately 731 kb in length. This allele, which encodes neurobeachin protein, is involved the localization of protein kinase A. Mutations in or aberrant expression of the gene may be associated with autism, multiple myeloma and colorectal carcinoma.			Gene or Genome	
C143077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143077>	C26231	Neurobeachin|Lysosomal-Trafficking Regulator 2|NBEA|Protein BCL8B	Neurobeachin (2946 aa, ~328 kDa) is encoded by the human NBEA gene. This protein plays a role in protein kinase A localization.			Amino Acid, Peptide, or Protein	
C143078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143078>	C20849	S100A7 Gene|S100 Calcium Binding Protein A7 Gene|S100A7|S100A7|S100A7	This gene is involved in both calcium binding and antimicrobial activity.			Gene or Genome	GDC Terminology|GDC Value Terminology
C143079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143079>	C143078	S100A7 wt Allele|PSOR1|S100 Calcium Binding Protein A7 (Psoriasin 1) Gene|S100 Calcium Binding Protein A7 wt Allele|S100 Calcium-Binding Protein A7 (Psoriasin 1) Gene|S100A7c	Human S100A7 wild-type allele is located in the vicinity of 1q21.3 and is approximately 3 kb in length. This allele, which encodes protein S100-A7, plays a role in calcium binding, epidermal development and antimicrobial activity. Aberrant overexpression is associated with hyperproliferative skin diseases and mutations in the gene may be associated with melanoma and T-cell lymphoma.			Gene or Genome	
C14307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14307>	C14255	Paramyxovirinae	The subfamily of Paramyxoviridae which includes Mumps and Measles viruses.			Virus	
C143080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143080>	C29924	Protein S100-A7|Psoriasin|Psoriasin 1|S100 Calcium-Binding Protein A7|S100A7	Protein S100-A7 (101 aa, ~11 kDa) is encoded by the human S100A7 gene. This protein is involved in antimicrobial activity, calcium binding and epidermal development.			Amino Acid, Peptide, or Protein	
C143081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143081>	C48698	Posttherapy Clinical TNM Finding|ycTNM Finding	Clinical TNM staging performed following systemic therapy or radiation.			Finding	
C143082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143082>	C20194	RGPD3 Gene|RANBP2-Like and GRIP Domain Containing 3 Gene|RGPD3|RGPD3|RGPD3	This gene may play a role in the localization of the GTPase Ran.			Gene or Genome	GDC Terminology|GDC Value Terminology
C143083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143083>	C143082	RGPD3 wt Allele|RANBP2-Like and GRIP Domain Containing 3 wt Allele|RGP3	Human RGPD3 wild-type allele is located in the vicinity of 2q12.2 and is approximately 77 kb in length. This allele, which encodes RanBP2-like and GRIP domain-containing protein 3, may involved in GTP-binding nuclear protein Ran localization. Mutations in the gene may be associated with endometrioid adenocarcinoma.			Gene or Genome	
C143084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143084>	C18466	RanBP2-Like and GRIP Domain-Containing Protein 3|RGPD3	RanBP2-like and GRIP domain-containing protein 3 (1758 aa, ~197 kDa) is encoded by the human RGPD3 gene. This protein may play a role in the localization of GTP-binding nuclear protein Ran.			Amino Acid, Peptide, or Protein	
C143085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143085>	C7228|C4341|C183514	Refractory Marginal Zone Lymphoma	A marginal zone lymphoma that does not respond to treatment.	Refractory Marginal Zone Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C143086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143086>	C47793	Prajmalium Bitartrate|17R,21-alpha-Dihydroxy-4-propylajmalanium Hydrogen Tartrate|Ajmalanium, 17,21-Dihydroxy-4-propyl-, (17R,21alpha)-, Salt with (2R,3R)-2,3-dihydroxybutanedioic Acid (1:1)|PRAJMALIUM BITARTRATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C143087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143087>	C39713	Maxacalcitol|(+)-(5Z,7E,20S)-20-(3-Hydroxy-3-methylbutoxy)-9,10-secopregna-5,7,10(19)-triene-1alpha,3beta-diol|1,3-Cyclohexanediol, 4-Methylene-5-((2E)-((1S,3aS,7aS)-octahydro-1-((1S)-1-(3-hydroxy-3-methylbutoxy)ethyl)-7a-methyl-4H-inden-4-ylidene)ethylidene)-, (1R,3S,5Z)-|22-Oxa-1,25-dihydroxyvitamin D3|22-Oxa-calcitriol|MAXACALCITOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C143088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143088>	C2021	Nolatrexed|2-Amino-6-methyl-5-(4-pyridylthio)-4(3H)-quinazolinone|NOLATREXED	A water-soluble lipophilic quinazoline folate analog, with antineoplastic activity. Upon administration, nolatrexed occupies the folate binding site of thymidylate synthase, resulting in inhibition of thymidylate synthase activity and thymine nucleotide synthesis with subsequent inhibition of DNA replication, DNA damage, S-phase cell cycle arrest, and caspase-dependent apoptosis. Nolatrexed also exhibits radiosensitizing activity.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology
C143089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143089>	C521	Naflocort Anhydrous|2'H-Naphtho(2',3':16,17)pregna-1,4-diene-3,20-dione, 9-Fluoro-1',4'-dihydro-11,21-dihydroxy-, (11beta,16beta)-|NAFLOCORT ANHYDROUS				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C14308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14308>	C14255	Pneumovirinae	A subfamily of Paramyxoviridae which includes human respiratory syncytial virus.			Virus	
C143090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143090>	C20194	PRPF40B Gene|PRPF40B|PRPF40B|PRPF40B|Pre-mRNA Processing Factor 40 Homolog B Gene	This gene may be involved in mRNA splicing.			Gene or Genome	GDC Terminology|GDC Value Terminology
C143091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143091>	C143090	PRPF40B wt Allele|HYPC|PRP40 Homolog, Pre-mRNA Processing Factor B Gene|PRP40 Pre-mRNA Processing Factor 40 Homolog B (S. cerevisiae) Gene|PRP40 Pre-mRNA Processing Factor 40 Homolog B (Yeast) Gene|PRP40, S. cerevisiae, Homolog of, B Gene|Pre-mRNA Processing Factor 40 Homolog B wt Allele|Precursor mRNA-Processing Factor 40, S. cerevisiae, Homolog of, B  Gene	Human PRPF40B wild-type allele is located in the vicinity of 12q13.12 and is approximately 76 kb in length. This allele, which encodes pre-mRNA-processing factor 40 homolog B protein, may play a role in mRNA splicing. Mutations in the gene may be associated with myelodysplastic syndrome, melanoma and colon carcinoma.			Gene or Genome	
C143092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143092>	C18466	Pre-mRNA-Processing Factor 40 Homolog B|Huntingtin Interacting Protein C|Huntingtin Yeast Partner C|Huntingtin-Interacting Protein C|PRPF40B	Pre-mRNA-processing factor 40 homolog B (871 aa, ~99 kDa) is encoded by the human PRPF40B gene. This protein may be involved in splicing of pre-mRNA.			Amino Acid, Peptide, or Protein	
C143093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143093>	C20988	CDH10 Gene|CDH10|CDH10|CDH10|Cadherin 10 Gene	This gene plays a role in the modulation of neuronal cell shape and cell-cell adhesion.			Gene or Genome	GDC Terminology|GDC Value Terminology
C143094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143094>	C143093	CDH10 wt Allele|Cadherin 10 Type 2 Gene|Cadherin 10 wt Allele|Cadherin 10, Type 2 (T2-Cadherin) Gene	Human CDH10 wild-type allele is located within 5p14.2-p14.1 and is approximately 158 kb in length. This allele, which encodes cadherin-10 protein, is involved in cell-cell adhesion. Mutations in the gene may be associated with melanoma, pancreatic ductal adenocarcinoma, lung squamous cell carcinoma and colorectal cancer.			Gene or Genome	
C143095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143095>	C16373	Cadherin-10|CDH10|Cadherin 10|T2-Cadherin	Cadherin-10 (788 aa, ~88 kDa) is encoded by the human CDH10 gene. This protein plays a role in cell-cell adhesion.			Amino Acid, Peptide, or Protein	
C143096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143096>	C20988	CDH17 Gene|CDH17|CDH17|CDH17|Cadherin 17 Gene	This gene is involved in cell-cell adhesion and intestinal proton-dependent peptide transport.	CDH17 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C143097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143097>	C143096	CDH17 wt Allele|CDH16|Cadherin 16, Formerly Gene|Cadherin 17 wt Allele|Cadherin, Liver-Intestine Gene|Cadherin-16 Gene|HPT-1|HPT1|LI Cadherin (Liver-Intestine) Gene	Human CDH17 wild-type allele is located in the vicinity of 8q22.1 and is approximately 90 kb in length. This allele, which encodes cadherin-17 protein, plays a role in cell-cell adhesion and peptide transport. Mutations in the gene may be associated with melanoma.	CDH17 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C143098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143098>	C16373	Cadherin-17|CDH17|Cadherin 17|HPT-1 Cadherin|Human Intestinal Peptide-Associated Transporter HPT-1|Human Peptide Transporter 1|Intestinal Peptide-Associated Transporter HPT-1|LI Cadherin|LI-Cadherin|Liver-Intestine Cadherin	Cadherin-17 (832 aa, ~92 kDa) is encoded by the human CDH17 gene. This protein is involved in cell-cell adhesion and intestinal proton-dependent peptide absorption.	Cadherin-17		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C143099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143099>	C1967|C164000	c-Met Inhibitor|HGFR Inhibitor|Hepatocyte Growth Factor Receptor Inhibitor|MET Inhibitor	Any small molecule that inhibits the enzymatic activity of the receptor tyrosine kinase c-Met (hepatocyte growth factor receptor; HGFR).	c-Met Inhibitor		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C14309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14309>	C14307	Morbillivirus|MORBILLIVIRUS	A genus of Paramyxovirinae which includes Measles Virus			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C1430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1430>	C67437|C1490	Cephalomannine|CEPHALOMANNINE	A diterpene taxane obtained from the bark and leaves of the yew tree (Taxus brevifolia) and can convert to taxol. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C143100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143100>	C54362	ZNF429 Gene|ZNF429|ZNF429|ZNF429|Zinc Finger Protein 429 Gene	This gene may play a role in the regulation of gene transcription.			Gene or Genome	GDC Terminology|GDC Value Terminology
C143101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143101>	C143100	ZNF429 wt Allele|Zinc Finger Protein 429 wt Allele	Human ZNF429 wild-type allele is located in the vicinity of 19p12 and is approximately 60 kb in length. This allele, which encodes zinc finger protein 429, may be involved in transcriptional regulation.			Gene or Genome	
C143102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143102>	C26199	Zinc Finger Protein 429|ZNF429	Zinc finger protein 429 (674 aa, ~78 kDa) is encoded by the human ZNF429 gene. This protein may play a role in the regulation of transcription.			Amino Acid, Peptide, or Protein	
C143103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143103>	C54362	ZNF479 Gene|ZNF479|ZNF479|ZNF479|Zinc Finger Protein 479 Gene	This gene may play a role in the regulation of gene transcription.			Gene or Genome	GDC Terminology|GDC Value Terminology
C143104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143104>	C143103	ZNF479 wt Allele|HKr19|KR19|Zinc Finger Protein 479 wt Allele	Human ZNF479 wild-type allele is located in the vicinity of 7p11.2 and is approximately 22 kb in length. This allele, which encodes zinc finger protein 479, may play a role in the regulation of gene transcription.			Gene or Genome	
C143105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143105>	C26199	Zinc Finger Protein 479|HKr19|KRAB Zinc Finger Protein KR19|ZNF479|Zinc Finger Protein Kr19	Zinc finger protein 479 (524 aa, ~61 kDa) is encoded by the human ZNF479 gene. This protein may be involved in transcriptional repression.			Amino Acid, Peptide, or Protein	
C143106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143106>	C25873	WNK2 Gene|WNK Lysine Deficient Protein Kinase 2 Gene|WNK2|WNK2|WNK2	This gene plays a role in electrolyte homeostasis, cell signaling, cell survival, and cellular proliferation.			Gene or Genome	GDC Terminology|GDC Value Terminology
C143107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143107>	C143106	WNK2 wt Allele|KIAA1760|NY-CO-43|P/OKcl.13|PRKWNK2|Protein Kinase, Lysine-Deficient 2 Gene|SDCCAG43|WNK Lysine Deficient Protein Kinase 2 wt Allele	Human WNK2 wild-type allele is located in the vicinity of 9q22.31 and is approximately 136 kb in length. This allele, which encodes serine/threonine-protein kinase WNK2 protein, is involved in serine/threonine phosphorylation of substrates that regulate electrolyte homeostasis and signal transduction.			Gene or Genome	
C143108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143108>	C17325	Serine/Threonine-Protein Kinase WNK2|Antigen NY-CO-43|EC 2.7.11.1|Protein Kinase Lysine-Deficient 2|Protein Kinase with No Lysine 2|Serologically Defined Colon Cancer Antigen 43	Serine/threonine-protein kinase WNK2 (2297 aa, ~243 kDa) is encoded by the human WNK2 gene. This protein plays a role in the regulation of cell signaling and ion transport.			Amino Acid, Peptide, or Protein|Enzyme	
C143109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143109>	C20194	FAM47C Gene|FAM47C|FAM47C|FAM47C|Family with Sequence Similarity 47 Member C Gene	This gene has no known function.			Gene or Genome	GDC Terminology|GDC Value Terminology
C14310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14310>	C14307	Paramyxovirus|RESPIROVIRUS|paramyxovirus	A single-stranded, negative-sense RNA virus of the Paramyxoviridae family.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C143110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143110>	C143109	FAM47C wt Allele|Family with Sequence Similarity 47 Member C wt Allele|Family with Sequence Similarity 47, Member C Gene	Human FAM47C wild-type allele is located in the vicinity of Xp21.1 and is approximately 3 kb in length. This allele, which encodes putative protein FAM47C, has no known function.			Gene or Genome	
C143111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143111>	C18466	Putative Protein FAM47C|Family with Sequence Similarity 47 Member C	Putative protein FAM47C (1035 aa, ~115 kDa) is encoded by the human FAM47C gene. This protein has no known function.			Amino Acid, Peptide, or Protein	
C143112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143112>	C20194	FAM135B Gene|FAM135B|FAM135B|FAM135B|Family with Sequence Similarity 135 Member B Gene	This gene may play a role in the metabolism of lipids.			Gene or Genome	GDC Terminology|GDC Value Terminology
C143113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143113>	C143112	FAM135B wt Allele|C8ORFK32|Family with Sequence Similarity 135 Member B wt Allele|Family with Sequence Similarity 135, Member B Gene	Human FAM135B wild-type allele is located in the vicinity of 8q24.23 and is approximately 367 kb in length. This allele, which encodes protein FAM135B, may be involved in cholesterol metabolism.			Gene or Genome	
C143114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143114>	C18466	Protein FAM135B|Family with Sequence Similarity 135 Member B	Protein FAM135B (1406 aa, ~156 kDa) is encoded by the human FAM135B gene. This protein may play a role in lipid metabolism.			Amino Acid, Peptide, or Protein	
C143115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143115>	C20745	CTNNA2 Gene|CTNNA2|CTNNA2|CTNNA2|Catenin Alpha 2 Gene	This gene is involved in cell-cell adhesion and cellular differentiation in the nervous system.			Gene or Genome	GDC Terminology|GDC Value Terminology
C143116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143116>	C143115	CTNNA2 wt Allele|CAP-R|CAPR|CT114|CTNR|Cadherin-Associated Protein, Related Gene|Catenin (Cadherin-Associated Protein), Alpha 2 Gene|Catenin Alpha 2 wt Allele|Catenin, Alpha-2 Gene	Human CTNNA2 wild-type allele is located in the vicinity of 2p12 and is approximately 1464 kb in length. This allele, which encodes catenin alpha-2 protein, plays a role in neuronal differentiation.			Gene or Genome	
C143117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143117>	C16492	Catenin Alpha-2|Alpha N-Catenin|Alpha-Catenin-Related Protein|Alpha-N-Catenin|CTNNA2|Cancer/Testis Antigen 114|Catenin Alpha 2	Catenin alpha-2 (953 aa, ~105 kDa) is encoded by the human CTNNA2 gene. This protein is involved in neuronal differentiation and neural development.			Amino Acid, Peptide, or Protein	
C143118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143118>	C26048	RGS7 Gene|RGS7|RGS7|RGS7|Regulator of G Protein Signaling 7 Gene	This gene plays a role in the inhibition of both G protein-coupled receptor signaling and signal transduction.			Gene or Genome	GDC Terminology|GDC Value Terminology
C143119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143119>	C143118	RGS7 wt Allele|Regulator of G Protein Signaling 7 wt Allele	Human RGS7 wild-type allele is located in the vicinity of 1q43 and is approximately 582 kb in length. This allele, which encodes regulator of G-protein signaling 7 protein, is involved in the stimulation of G alpha activation.			Gene or Genome	
C14311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14311>	C112419	Human Herpesvirus 1|HERPES SIMPLEX VIRUS 1|HHV-1|HHV-1|HHV1|HSV-1|HSV-1|HSV1|HUMAN HERPESVIRUS 1|Herpes Simplex Virus 1|Herpes Simplex Virus Type 1|Human Alphaherpesvirus 1|Human alphaherpesvirus 1	HSV is a nuclear replicating, icosahedral, enveloped DNA virus. The HSV envelope contains at least 8 glycoproteins. The matrix or tegument which contacts both the envelope and the capsid contains at least 15-20 proteins. There are two types of HSV - Type 1 and Type 2.  The Type 1 virus causes cold sores.  Most people get Type 1 infections during infancy or childhood. The Type 2 virus causes genital sores. Most people get Type 2 infections following sexual contact with an infected person.	Human Herpesvirus 1		Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C143120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143120>	C18166	Regulator of G-Protein Signaling 7|RGS7|Regulator of G Protein Signaling 7|Regulator of G-Protein Signalling 7	Regulator of G-protein signaling 7 (495 aa, ~58 kDa) is encoded by the human RGS7 gene. This protein plays a role in the promotion of G alpha protein GTPase activity.			Amino Acid, Peptide, or Protein	
C143121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143121>	C26110	PRDM2 Gene|PR/SET Domain 2 Gene|PRDM2|PRDM2|PRDM2	This gene is involved in both methylation of histone H3 and transcriptional regulation.			Gene or Genome	GDC Terminology|GDC Value Terminology
C143122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143122>	C143121	PRDM2 wt Allele|HUMHOXY1|KMT8|KMT8A|MTB-ZF|PR Domain 2 Gene|PR Domain Containing 2, with ZNF Domain Gene|PR/SET Domain 2 wt Allele|RIZ|RIZ2	Human PRDM2 wild-type allele is located in the vicinity of 1p36.21 and is approximately 125 kb in length. This allele, which encodes PR domain zinc finger protein 2, plays a role in protein methyltransferase activity.			Gene or Genome	
C143123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143123>	C16849	PR Domain Zinc Finger Protein 2|EC 2.1.1.43|GATA-3 Binding Protein G3B|GATA-3-Binding Protein G3B|Lysine N-Methyltransferase 8|MTB-ZF|MTE-Binding Protein|PR Domain-Containing Protein 2|PRDM2|Retinoblastoma Protein-Binding Zinc Finger Protein|Retinoblastoma Protein-Binding Zinc Finger Protein RIZ|Retinoblastoma Protein-Interacting Zinc Finger Protein|Zinc Finger Protein RIZ|Zinc-Finger DNA-Binding Protein	PR domain zinc finger protein 2 (1718 aa, ~189 kDa) is encoded by the human PRDM2 gene. This protein is involved in both transcriptional regulation and the methylation of histone H3.			Amino Acid, Peptide, or Protein|Enzyme	
C143124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143124>	C20420	FOXR1 Gene|FOXR1|FOXR1|FOXR1|Forkhead Box R1 Gene	This gene plays a role in DNA binding and transcriptional regulation.			Gene or Genome	GDC Terminology|GDC Value Terminology
C143125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143125>	C143124	FOXR1 wt Allele|DLNB13|FOXN5|Forkhead Box R1 wt Allele	Human FOXR1 wild-type allele is located in the vicinity of 11q23.3 and is approximately 10 kb in length. This allele, which encodes forkhead box protein R1, is involved in the modulation of gene transcription.			Gene or Genome	
C143126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143126>	C17207	Forkhead Box Protein R1|FOXR1|Forkhead Box Protein N5	Forkhead box protein R1 (292 aa, ~33 kDa) is encoded by the human FOXR1 gene. This protein plays a role in the regulation of gene expression.			Amino Acid, Peptide, or Protein	
C143127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143127>	C25941	FKBP9 Gene|FK506 Binding Protein 9 Gene|FKBP9|FKBP9|FKBP9	This gene is involved in chaperone-mediated protein folding.			Gene or Genome	GDC Terminology|GDC Value Terminology
C143128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143128>	C143127	FKBP9 wt Allele|FK506 Binding Protein 9 wt Allele|FK506 Binding Protein 9, 63 kDa Gene|FK506-Binding Protein 9 (63 kD) Gene|FK506-Binding Protein, 60-kD Gene|FK506-Binding Protein, 63-kD Gene|FKBP60|FKBP63|PPIase	Human FKBP9 wild-type allele is located in the vicinity of 7p14.3 and is approximately 50 kb in length. This allele, which encodes peptidyl-prolyl cis-trans isomerase FKBP9 protein, plays a role in protein folding.			Gene or Genome	
C143129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143129>	C16759	Peptidyl-Prolyl Cis-Trans Isomerase FKBP9|63 kDa FK506-Binding Protein|63 kDa FKBP|EC 5.2.1.8|FK506 Binding Protein 9|FK506-Binding Protein 9|FKBP-63|FKBP-9|FKBP9|PPIase FKBP9|Rotamase	Peptidyl-prolyl cis-trans isomerase FKBP9 (570 aa, ~63 kDa) is encoded by the human FKBP9 gene. This protein is involved in chaperone-mediated protein folding.			Amino Acid, Peptide, or Protein|Enzyme	
C14312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14312>	C14216|C113202	Hepatitis C Virus|HCV|HCV|HEPATITIS C VIRUS|Hepatitis C|Virus-Hepatitis C	A small, enveloped, positive sense single strand RNA virus in the family Flaviviridae. The genome consists of a single RNA molecule with a single open reading frame.	Hepatitis C Virus		Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C143130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143130>	C26000	FBLN2 Gene|FBLN2|FBLN2|FBLN2|Fibulin 2 Gene	This gene plays a role in protein-protein interactions in the extracellular matrix.			Gene or Genome	GDC Terminology|GDC Value Terminology
C143131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143131>	C143130	FBLN2 wt Allele|Fibulin 2 wt Allele	Human FBLN2 wild-type allele is located in the vicinity of 3p25.1 and is approximately 89 kb in length. This allele, which encodes fibulin-2 protein, is involved in the structure of the extracellular matrix.			Gene or Genome	
C143132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143132>	C17351	Fibulin-2|FBLN2|FIBL-2	Fibulin-2 (1184 aa, ~127 kDa) is encoded by the human FBLN2 gene. This protein plays a role in matrix protein interactions.			Amino Acid, Peptide, or Protein	
C143133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143133>	C20988	FAT3 Gene|FAT Atypical Cadherin 3 Gene|FAT3|FAT3|FAT3	This gene is involved in cell adhesion and neurite development.			Gene or Genome	GDC Terminology|GDC Value Terminology
C143134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143134>	C143133	FAT3 wt Allele|CDHF15|CDHR10|FAT Atypical Cadherin 3 wt Allele|FAT Tumor Suppressor Homolog 3 (Drosophila) Gene|FAT Tumor Suppressor, Drosophila, Homolog of, 3 Gene|KIAA1989|hFat3	Human FAT3 wild-type allele is located in the vicinity of 11q14.3 and is approximately 582 kb in length. This allele, which encodes protocadherin Fat 3 protein, plays a role in neurite development.			Gene or Genome	
C143135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143135>	C16393	Protocadherin Fat 3|Cadherin Family Member 15|Cadherin-Related Family Member 10|FAT Tumor Suppressor Homolog 3|hFat3	Protocadherin Fat 3 (4589 aa, ~506 kDa) is encoded by the human FAT3 gene. This protein is involved in cell-cell adhesion.			Amino Acid, Peptide, or Protein	
C143137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143137>	C18437	ARFRP1 Gene|ADP Ribosylation Factor Related Protein 1 Gene|ARFRP1|ARFRP1	This gene plays a role in protein sorting and GTPase activity.			Gene or Genome	
C143138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143138>	C143137	ARFRP1 wt Allele|ADP Ribosylation Factor Related Protein 1 wt Allele|ARL18|ARP|Arp1	Human ARFRP1 wild-type allele is located in the vicinity of 20q13.33 and is approximately 9 kb in length. This allele, which encodes ADP-ribosylation factor-related protein 1, is involved in GTPase activity and trans-Golgi protein localization.			Gene or Genome	
C143139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143139>	C18277	ADP-Ribosylation Factor-Related Protein 1|ARF-Related Protein 1|ARFRP1|ARP|Helicase-Like Protein NHL|SCG10 Like-Protein	ADP-ribosylation factor-related protein 1 (201 aa, ~23 kDa) is encoded by the human ARFRP1 gene. This protein plays a role in protein localization.			Amino Acid, Peptide, or Protein|Enzyme	
C14313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14313>	C79107	Equidae	Taxonomic family which includes horses, zebras, and asses.			Mammal	
C143140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143140>	C28681|C129826	Tabelecleucel|ATA 129|ATA-129|ATA129|Allogeneic EBV-specific CTLs ATA129|Allogeneic EBV-specific Cytotoxic T-lymphocytes|CTLs ATA129|EBV-CTLs|Ebvallo|TABELECLEUCEL|Tab-cel|Teb-cel	Allogeneic cytotoxic T-lymphocytes (CTLs) selective for the tumor-associated antigens (TAAs) expressed by the Epstein-Barr virus (EBV), with potential immunostimulating and antineoplastic activities. Upon administration, and after hematopoietic cell transplants (HCT) or solid organ transplants (SOT), or during certain other immunocompromised states, tabelecleucel targets and binds to EBV-associated antigens expressed on EBV-infected cells. This results in lysis of EBV-infected cells and prevents growth of EBV-associated cancer cells. EBV is associated with a variety of cancers and post-transplant lymphoproliferative disorders (EBV+ PTLD).	Tabelecleucel		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C143141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143141>	C28394	Topical VBP-926 Solution|VBP 926|VBP-926|VBP-926 Solution	A topical solution with potential anti-inflammatory activity. Upon topical application to the affected area, VBP-926 may help reduce paronychia. Iatrogenic paronychia is associated with chemotherapy treatment.	Topical VBP-926 Solution		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C143142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143142>	C18437	ARF1 Gene|ADP Ribosylation Factor 1 Gene|ARF1|ARF1	This gene is involved in protein trafficking through the endoplasmic reticulum and Golgi apparatus.			Gene or Genome	
C143143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143143>	C143142	ARF1 wt Allele|ADP Ribosylation Factor 1 wt Allele	Human ARF1 wild-type allele is located in the vicinity of 1q42.13 and is approximately 17 kb in length. This allele, which encodes ADP-ribosylation factor 1 protein, plays a role in intracellular protein trafficking.			Gene or Genome	
C143144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143144>	C18277	ADP-Ribosylation Factor 1|ARF1	ADP-ribosylation factor 1 (181 aa, ~21 kDa) is encoded by the human ARF1 gene. This protein is involved in both activation of the cholera toxin catalytic subunit and protein localization.			Amino Acid, Peptide, or Protein|Enzyme	
C143145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143145>	C18277	ADP-Ribosylation Factor 6|ARF6	ADP-ribosylation factor 6 (175 aa, ~20 kDa) is encoded by the human ARF6 gene. This protein plays a role in protein localization and the remodeling of both lipid membranes and the cytoskeleton.			Amino Acid, Peptide, or Protein|Enzyme	
C143146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143146>	C18437	ARF6 Gene|ADP Ribosylation Factor 6 Gene|ARF6|ARF6	This gene plays a role in vesicle trafficking, membrane lipid remodeling and cytoskeleton reorganization.			Gene or Genome	
C143147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143147>	C143146	ARF6 wt Allele|ADP Ribosylation Factor 6 wt Allele	Human ARF6 wild-type allele is located in the vicinity of 14q21.3 and is approximately 4 kb in length. This allele, which encodes ADP-ribosylation factor 6, is involved in both membrane and protein trafficking.			Gene or Genome	
C143148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143148>	C93200|C116510	Transrectal Ultrasonography Guided Biopsy|TRUS Biopsy|TRUS-Guided Biopsy	A procedure that uses transrectal ultrasound to image the prostate and guide the placement of a biopsy needles to obtain a tissue sample.	Transrectal Ultrasonography Guided Biopsy		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C143149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143149>	C25207	PSA Doubling Time|PSA-DT|PSADT|Prostate Specific Antigen Doubling Time	The number of months observed or calculated for PSA to increase two-fold.	PSA Doubling Time		Temporal Concept	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C14314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14314>	C14183	SENCAR Mouse	A mouse strain that was selectively bred to be highly susceptible to agents and procedures that induce carcinogenesis, primarily skin carcinogenesis; these mice have a low incidence of spontaneous tumor formation.			Mammal	
C143150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143150>	C111116	Restriction Spectrum Imaging|RSI|RSI-MRI|Restriction Spectrum MRI|Restriction Spectrum Magnetic Resonance Imaging	A diffusion-weighted MRI technique that utilizes data obtained from multiple b-values and diffusion directions to measure diffusion orientation and length scale; it has been used to identify distinct microscopic tissues based on water diffusion behavior.	Restriction Spectrum Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C143151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143151>	C28108	Masaoka-Koga Stage|masaoka stage|masaoka_stage	A thymoma stage defined according to the Masaoka-Koga staging criteria.			Classification	GDC Property Terminology|GDC Terminology
C143152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143152>	C36220	Blasts Under 15 Percent of Peripheral Blood White Cells|Blasts Less than 15 Percent of Peripheral Blood White Cells	A semi-quantitative microscopic finding indicating that less than 15 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.	Blasts Under 15 Percent of Peripheral Blood White Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C143153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143153>	C160963	Blasts Under 15 Percent of Bone Marrow Nucleated Cells|Blasts Less than 15 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that less than 15 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts Under 15 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C143154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143154>	C146673	Blasts Under 30 Percent of Peripheral Blood White Cells|Blasts Less than 30 Percent of Peripheral Blood White Cells	A semi-quantitative microscopic finding indicating that less than 30 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.	Blasts Under 30 Percent of Peripheral Blood White Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C143156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143156>	C201174|C200766|C176018	Anti-CD19-CD20-CAR-CD3zeta-4-1BB-expressing Autologous T-lymphocytes|Anti-CD19/CD20 CAR Autologous T-lymphocytes|Autologous CAR-20/19-T Cells	Autologous T-lymphocytes that have been transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) of anti-CD19 in tandem with an anti-CD20 scFv, and coupled to the cytoplasmic portion of the zeta chain of the human T-cell receptor (CD3zeta), and the co-stimulatory molecule 4-1BB (CD137), with potential immunostimulating and antineoplastic activities. Upon transfusion, anti-CD19-CD20-CAR-CD3zeta-4-1BB-expressing autologous T-lymphocytes recognize and direct T-cells to CD19- or CD20-expressing tumor B-cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19- or CD20-expressing tumor cells, and causes tumor cell lysis. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C143157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143157>	C28676|C201545	Allogeneic Nicotinamide-expanded Natural Killer Cells|Allogeneic NAM NK Cells|Allogeneic NAM NKs|Donor Nicotinamide expanded-Natural Killer Cells	Allogeneic, nicotinamide (NAM)-expanded natural killer (NK) cells, with potential cytolytic and antineoplastic activities. Upon administration, the allogeneic NAM-expanded NK cells may lyse cancer cells. These cells also secrete pro-inflammatory cytokines, which further stimulate an anti-tumor immune response. Ex-vivo treatment with the vitamin B3 derivative NAM increases the in-vivo homing, retention and proliferation potential of the NK cells.	Allogeneic Nicotinamide-expanded Natural Killer Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C143158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143158>	C25974	Microtubule Inhibitor SCB01A|6-Methoxy-3-(3',4',5'-trimethoxybenzoyl) Indole|BPR 0L075|DBPR104|SB 01|SCB 01A|SCB-01A|SCB01A	An aroylindole derivative and tubulin polymerization inhibitor, with potential tubulin-inhibiting, vascular-disrupting and antineoplastic activities. Upon administration, tubulin polymerization inhibitor SCB01A binds at the colchicine binding site of tubulin and prevents its polymerization in tumor blood vessel endothelial cells and in tumor cells. This blocks the formation of the mitotic spindle and leads to both cell cycle arrest at the G2/M phase and tumor cell apoptosis. Also, this agent's effect on the tumor blood vessel endothelial cells leads to a disruption of the tumor vasculature and tumor blood flow, which deprives tumor cells of nutrients and induces tumor cell apoptosis.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C143159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143159>	C129986	Hou Gu Mi Xi|TCM Hou Gu Mi Xi|Traditional Chinese Medicine Hou Gu Mi Xi	An orally bioavailable dietary supplement and a formulation derived from the traditional Chinese medicine (TCM) Shen Ling Bai Zhu San, that can potentially be used to ameliorate spleen deficiency and improve symptoms of digestive disorders. Shen Ling Bai Zhu San is composed of ginseng, tuckahoe, atractylodes, baked licorice, coixenolide, Chinese yam, lotus seed, shrinkage fructus amomi, platycodon grandiflorum, white hyacinth bean, and dried orange peel. In Hou Gu Mi Xi, atractylodes and platycodon grandiflorum are removed from Shen Ling Bai Zhu San and perilla leaf is added. Upon oral administration, Hou Gu Mi Xi replenishes qi, and may improve spleen qi deficiency, gastrointestinal (GI) symptoms and GI function.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C14315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14315>	C187440	Canarypox Virus|Canarypox	A poxvirus of the genus Avipoxvirus.  Has been adapted as a cloning vector (canarypox vector) for use as a mammalian expression vector.			Virus	
C143160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143160>	C99547	Life Expectancy Greater than Six Months|Life Expectancy More than 6 Months	A response indicating that an individual expects to, or is expected to, live longer than six months.			Intellectual Product	
C143161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143161>	C17634	Prostate Specific Antigen Density|PSA Density|PSA Density|PSAD	The ratio of serum prostate specific antigen to prostate volume.	PSA Density		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C143162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143162>	C177899	Onvansertib|NMS-1286937|ONVANSERTIB|PCM 075|PCM-075|PLK-1 Inhibitor PCM-075|PLK1 Inhibitor PCM-075|Polo-like Kinase 1 Inhibitor NMS-1286937|Polo-like Kinase 1 Inhibitor PCM-075	An orally bioavailable, adenosine triphosphate (ATP) competitive inhibitor of polo-like kinase 1 (PLK1; PLK-1; STPK13), with potential antineoplastic activity. Upon administration, onvansertib selectively binds to and inhibits PLK1, which disrupts mitosis and induces selective G2/M cell-cycle arrest followed by apoptosis in PLK1-overexpressing tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase that is crucial for the regulation of mitosis, and plays a key role in tumor cell proliferation. PLK1 expression is upregulated in a variety of tumor cell types and high expression is associated with increased aggressiveness and poor prognosis.	Onvansertib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C143163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143163>	C192554	CTCAE 5.0 by Body System|Common Terminology Criteria for Adverse Events 5.0 by Body System				Finding	CTCAE Adverse Events Version 5.0 Terminology
C143164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143164>	C143163	Blood and Lymphatic System Disorders, CTCAE 5.0	Blood and Lymphatic System Disorders, CTCAE 5.0 captures adverse events effecting this System Organ Class as defined and used by MedDRA 20.1 and CTCAE 5.0.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C143165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143165>	C143163	Cardiac Disorders, CTCAE 5.0	Cardiac Disorders, CTCAE 5.0 captures adverse events effecting this System Organ Class as defined and used by MedDRA 20.1 and CTCAE 5.0.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C143166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143166>	C143163	Endocrine Disorders, CTCAE 5.0	Endocrine Disorders, CTCAE 5.0 captures adverse events effecting this System Organ Class as defined and used by MedDRA 20.1 and CTCAE 5.0.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C143167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143167>	C143163	Eye Disorders, CTCAE 5.0	Eye Disorders, CTCAE 5.0 captures adverse events effecting this System Organ Class as defined and used by MedDRA 20.1 and CTCAE 5.0.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C143169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143169>	C143163	General Disorders and Administration Site Conditions, CTCAE 5.0	General Disorders and Administration Site Conditions, CTCAE 5.0 captures adverse events effecting this System Organ Class as defined and used by MedDRA 20.1 and CTCAE 5.0.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C14316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14316>	C14376	Infectious Agent|Infectious Agents|Infective Agent|infectiousAgent	Any organism, such as a virus, parasite, or bacterium, that is capable of invading body tissues and multiplying.			Organism	BRIDG Attribute Terminology|BRIDG Terminology
C143170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143170>	C143163	Hepatobiliary Disorders, CTCAE 5.0	Hepatobiliary Disorders, CTCAE 5.0 captures adverse events effecting this System Organ Class as defined and used by MedDRA 20.1 and CTCAE 5.0.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C143171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143171>	C143163	Infections and Infestations, CTCAE 5.0	Infections and Infestations, CTCAE 5.0 captures adverse events effecting this System Organ Class as defined and used by MedDRA 20.1 and CTCAE 5.0.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C143172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143172>	C143163	Injury, Poisoning and Procedural Complications, CTCAE 5.0	Injury, Poisoning and Procedural Complications, CTCAE 5.0 captures adverse events effecting this System Organ Class as defined and used by MedDRA 20.1 and CTCAE 5.0.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C143173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143173>	C143163	Investigations, CTCAE 5.0	Investigations, CTCAE 5.0 captures adverse events effecting this System Organ Class as defined and used by MedDRA 20.1 and CTCAE 5.0.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C143174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143174>	C143163	Metabolism and Nutrition Disorders, CTCAE 5.0	Metabolism and Nutrition Disorders, CTCAE 5.0 captures adverse events effecting this System Organ Class as defined and used by MedDRA 20.1 and CTCAE 5.0.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C143175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143175>	C143163	Musculoskeletal and Connective Tissue Disorders, CTCAE 5.0	Musculoskeletal and Connective Tissue Disorders, CTCAE 5.0 captures adverse events effecting this System Organ Class as defined and used by MedDRA 20.1 and CTCAE 5.0.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C143176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143176>	C143163	Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps), CTCAE	Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps), CTCAE captures adverse events effecting this System Organ Class as defined and used by MedDRA 20.1 and CTCAE 5.0.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C143177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143177>	C143163	Nervous System Disorders, CTCAE 5.0	Nervous System Disorders, CTCAE 5.0 captures adverse events effecting this System Organ Class as defined and used by MedDRA 20.1 and CTCAE 5.0.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C143178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143178>	C143163	Pregnancy, Puerperium and Perinatal Conditions, CTCAE 5.0	Pregnancy, Puerperium and Perinatal Conditions, CTCAE 5.0 captures adverse events effecting this System Organ Class as defined and used by MedDRA 20.1 and CTCAE 5.0.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C143179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143179>	C143163	Renal and Urinary Disorders, CTCAE 5.0	Renal and Urinary Disorders, CTCAE 5.0 captures adverse events effecting this System Organ Class as defined and used by MedDRA 20.1 and CTCAE 5.0.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C14317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14317>	C14181	Human Virus|Viruses, Human	Viruses which routinely infect humans			Virus	
C143180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143180>	C143163	Reproductive System and Breast Disorders, CTCAE 5.0	Reproductive System and Breast Disorders, CTCAE 5.0 captures adverse events effecting this System Organ Class as defined and used by MedDRA 20.1 and CTCAE 5.0.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C143181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143181>	C143163	Respiratory, Thoracic and Mediastinal Disorders, CTCAE 5.0	Respiratory, Thoracic and Mediastinal Disorders, CTCAE 5.0 captures adverse events effecting this System Organ Class as defined and used by MedDRA 20.1 and CTCAE 5.0.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C143182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143182>	C143163	Skin and Subcutaneous Tissue Disorders, CTCAE 5.0	Skin and Subcutaneous Tissue Disorders, CTCAE 5.0 captures adverse events effecting this System Organ Class as defined and used by MedDRA 20.1 and CTCAE 5.0.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C143183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143183>	C143163	Vascular Disorders, CTCAE 5.0	Vascular Disorders, CTCAE 5.0 captures adverse events effecting this System Organ Class as defined and used by MedDRA 20.1 and CTCAE 5.0.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C143184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143184>	C143163	Congenital, Familial and Genetic Disorders, CTCAE 5.0	Congenital, Familial and Genetic Disorders, CTCAE 5.0 captures adverse events effecting this System Organ Class as defined and used by MedDRA 20.1 and CTCAE 5.0.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C143185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143185>	C143163	Ear and Labyrinth Disorders, CTCAE 5.0	Ear and Labyrinth Disorders, CTCAE 5.0 captures adverse events effecting this System Organ Class as defined and used by MedDRA 20.1 and CTCAE 5.0.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C143186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143186>	C143163	Immune System Disorders, CTCAE 5.0	Immune System Disorders, CTCAE 5.0 captures adverse events effecting this System Organ Class as defined and used by MedDRA 20.1 and CTCAE 5.0.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C143187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143187>	C143163	Psychiatric Disorders, CTCAE 5.0	Psychiatric Disorders, CTCAE 5.0 captures adverse events effecting this System Organ Class as defined and used by MedDRA 20.1 and CTCAE 5.0.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C143188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143188>	C143163	Social Circumstances, CTCAE 5.0	Social Circumstances, CTCAE 5.0 captures adverse events effecting this System Organ Class as defined and used by MedDRA 20.1 and CTCAE 5.0.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C143189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143189>	C143163	Surgical and Medical Procedures, CTCAE 5.0	Surgical and Medical Procedures, CTCAE 5.0 captures adverse events effecting this System Organ Class as defined and used by MedDRA 20.1 and CTCAE 5.0.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C14318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14318>	C14291	Ovine Jaagziekte Virus|JSRV|Jaagsiekte Sheep Retrovirus|Sheep Pulmonary Adenomatosis Virus	A betaretrovirus of sheep associated with transmissible ovine pulmonary adenocarcinoma.			Virus	
C143190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143190>	C220585|C143164	Eosinophilia, CTCAE|Eosinophilia|Eosinophilia	A disorder characterized by laboratory test results that indicate an increased number of eosinophils in the blood.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143191>	C220585|C143164	Methemoglobinemia, CTCAE|Methemoglobinemia|Methemoglobinemia	A disorder characterized by laboratory test results that indicate increased methemoglobin in the blood.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143192>	C220610|C143165	Cyanosis, CTCAE|Cyanosis|Cyanosis	A disorder characterized by a bluish discoloration of the skin and/or mucous membranes.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143193>	C220589|C143166	Hypophysitis, CTCAE|Hypophysitis|Hypophysitis	A disorder characterized by inflammation and cellular infiltration of the pituitary gland.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143194>	C220589|C143166	Hypopituitarism, CTCAE|Hypopituitarism|Hypopituitarism	A disorder characterized by a decrease in production of hormones from the pituitary gland.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143195>	C220589|C143166	Testosterone Deficiency, CTCAE|Testosterone Deficiency|Testosterone deficiency|Testosterone deficiency	A disorder characterized by low testosterone.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|HL Authorized Value Terminology|HL Late Effects Table
C143196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143196>	C220590|C143167	Vision Decreased, CTCAE|Vision decreased|Vision decreased	A disorder characterized by a decrease in visual acuity.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143197>	C220591|C146630	Anal Fissure, CTCAE|Anal fissure|Anal fissure	A disorder characterized by a tear in the lining of the anus.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143198>	C220591|C146630	Belching, CTCAE|Belching|Belching	To expel gas noisily from the mouth.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143199>	C220591|C146630	Chylous Ascites, CTCAE|Chylous ascites|Chylous ascites	A disorder characterized by accumulation of milky fluid in the peritoneal cavity.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14319>	C157254|C14226	Human Papillomavirus-6|HPV 6|HPV-6|HUMAN PAPILLOMAVIRUS TYPE 6|Human Papillomavirus Type 6	Genital warts caused by HPV 6 and 11 are the most common STD in the United States. Over a million cases are seen per year.	Human Papillomavirus-6		Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C1431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1431>	C129820	Imiquimod|1H-Imidazo(4,5-c)quinolin-4-amine, 1-(2-methylpropyl)-|4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline|Aldara|Aldara|IMIQUIMOD|R 837|S 26308|Zyclara|imiquimod	A synthetic agent with immune response modifying activity. As an immune response modifier (IRM), imiquimod stimulates cytokine production, especially interferon production, and exhibits antitumor activity, particularly against cutaneous cancers. Imiquimod's proapoptotic activity appears to be related to Bcl-2 overexpression in susceptible tumor cells. (NCI04)	Imiquimod		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C143200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143200>	C220591|C146630	Rectal Fissure, CTCAE|Rectal Fissure (Priority 2)|Rectal fissure|Rectal fissure	A disorder characterized by a tear in the lining of the rectum.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C143201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143201>	C220592|C143169	Disease Progression, CTCAE|Disease progression|Disease progression	Death due to disease progression that cannot be attributed to a CTCAE term associated with Grade 5.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143202>	C220592|C143169	Generalized Edema, CTCAE|Generalized edema|Generalized edema	A disorder characterized by fluid accumulation in the tissues of the body including the skin.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143203>	C220592|C143169	Vaccination Site Lymphadenopathy, CTCAE|Vaccination site lymphadenopathy|Vaccination site lymphadenopathy	A disorder characterized by lymph node enlargement after vaccination.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143204>	C220593|C143170	Budd-Chiari Syndrome, CTCAE|Budd-Chiari syndrome|Budd-Chiari syndrome	A disorder characterized by occlusion of the hepatic veins and typically presents with abdominal pain, ascites and hepatomegaly.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143205>	C220593|C143170	Sinusoidal Obstruction Syndrome, CTCAE|Sinusoidal obstruction syndrome|Sinusoidal obstruction syndrome	A disorder characterized by severe hepatic injury as a result of the blood vessels of the liver becoming inflamed and/or blocked.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143206>	C220595|C143171	Bacteremia, CTCAE|Bacteremia|Bacteremia	A disorder characterized by the presence of bacteria in the blood stream.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143207>	C220595|C143171	Cytomegalovirus Infection Reactivation, CTCAE|CMV Reactivation|Cytomegalovirus Reactivation|Cytomegalovirus infection reactivation|Cytomegalovirus infection reactivation	A disorder characterized by the reactivation of cytomegalovirus (CMV).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143208>	C220595|C143171	Epstein-Barr Virus Infection Reactivation, CTCAE|Epstein-Barr virus infection reactivation|Epstein-Barr virus infection reactivation	A disorder characterized by the reactivation of Epstein-Barr virus (EBV).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143209>	C220595|C143171	Folliculitis, CTCAE|Folliculitis|Folliculitis	A disorder characterized by inflammation or infection of the hair follicles.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14320>	C14376	Poikilotherms	Animals which have a body temperature which is largely controlled by external factors of the environment.			Animal	
C143210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143210>	C220595|C143171	Fungemia, CTCAE|Fungemia|Fungemia	A disorder characterized by the presence of fungus in the blood stream.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143211>	C220595|C143171	Hepatitis B Reactivation, CTCAE|Hepatitis B reactivation|Hepatitis B reactivation	A disorder characterized by the reactivation of hepatitis B virus.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143212>	C220595|C143171	Herpes Simplex Reactivation, CTCAE|Herpes simplex reactivation|Herpes simplex reactivation	A disorder characterized by the reactivation of Herpes simplex virus.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143213>	C220595|C143171	Shingles, CTCAE|Shingles|Shingles	A disorder characterized by the reactivation of herpes zoster virus.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143214>	C143171	Thrush, CTCAE|Thrush	A disorder characterized by a suspected candidal infection involving an oral mucosal surface.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C143215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143215>	C220595|C143171	Viremia, CTCAE|Viremia|Viremia	A disorder characterized by the presence of a virus in the blood stream.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143216>	C143172	Vaccination Complication, CTCAE|Vaccination complication	A disorder that occurs after the injection of a substance with antigenic properties, administered to activate the immune system.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C143217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143217>	C220597|C143173	Blood Bicarbonate Decreased, CTCAE|Blood bicarbonate decreased|Blood bicarbonate decreased	A finding based on laboratory test results that indicate a decrease in levels of bicarbonate in a venous blood specimen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143218>	C220597|C143173	Blood Lactate Dehydrogenase Increased, CTCAE|Blood lactate dehydrogenase increased|Blood lactate dehydrogenase increased	A finding based on laboratory test results that indicate increased levels of lactate dehydrogenase (LDH) in the blood specimen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143219>	C143173	Electrocardiogram T Wave Abnormal, CTCAE|Electrocardiogram T wave abnormal	A disorder characterized by Electrocardiogram T wave amplitude changes.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C14321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14321>	C79104	Felidae|Felid|Felids	Taxonomic family which includes domestic and wild cats such as lions and tigers.			Mammal	
C143220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143220>	C220597|C143173	Thyroid Stimulating Hormone Increased, CTCAE|Thyroid stimulating hormone increased|Thyroid stimulating hormone increased	A disorder characterized by an increase in thyroid stimulating hormone (TSH).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143221>	C220598|C143174	Hyperlipidemia, CTCAE|Hyperlipidemia|Hyperlipidemia	A disorder characterized by laboratory test results that indicate an elevation in the concentration of lipids in blood.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143222>	C220598|C143174	Hyperphosphatemia, CTCAE|Hyperphosphatemia|Hyperphosphatemia	A disorder characterized by laboratory test results that indicate an elevation in the concentration of phosphate in a blood.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143223>	C220599|C143175	Chest Wall Necrosis, CTCAE|Chest wall necrosis|Chest wall necrosis	A disorder characterized by a necrotic process occurring in the soft tissues of the chest wall including breast.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143224>	C220599|C143175	Muscle Cramp, CTCAE|Muscle cramp|Muscle cramp	A disorder characterized by marked cramping sensation originating from a muscle or group of muscles.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143225>	C220599|C143175	Osteonecrosis, CTCAE|Osteonecrosis|Osteonecrosis	A disorder characterized by necrotic changes in the bone tissue due to interruption of blood supply. Most often affecting the epiphysis of the long bones, the necrotic changes result in the collapse and the destruction of the bone structure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143226>	C220599|C143175	Rhabdomyolysis, CTCAE|Rhabdomyolysis|Rhabdomyolysis	A disorder characterized by the breakdown of muscle tissue resulting in the release of muscle fiber contents into the bloodstream.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143227>	C220599|C143175	Rotator Cuff Injury, CTCAE|Rotator cuff injury|Rotator cuff injury	A disorder characterized by an injury of the rotator cuff.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143228>	C220600|C143176	Skin Papilloma, CTCAE|Skin papilloma|Skin papilloma	A disorder characterized by the presence of one or more warts.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143229>	C220600|C143176	Tumor Hemorrhage, CTCAE|Tumor hemorrhage|Tumor hemorrhage	A disorder characterized by bleeding in a tumor.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14322>	C79105	Suidae|Suid|Suids	Taxonomic family which includes the domestic pig.			Mammal	
C143230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143230>	C220601|C143177	Anosmia, CTCAE|Anosmia|Anosmia	A disorder characterized by a change in the sense of smell.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143231>	C220601|C143177	Guillain-Barre Syndrome, CTCAE|Guillain-Barre syndrome|Guillain-Barre syndrome	A disorder characterized by the body's immune system attacking the peripheral nervous system causing ascending paralysis.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143232>	C220601|C143177	Myasthenia Gravis, CTCAE|Myasthenia gravis|Myasthenia gravis	A disorder characterized by weakness and rapid fatigue of any of the skeletal muscles.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143233>	C143177	Spinal Cord Compression, CTCAE|Spinal cord compression	A disorder characterized by pressure on the spinal cord.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C143234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143234>	C220601|C143177	Tendon Reflex Decreased, CTCAE|Tendon reflex decreased|Tendon reflex decreased	A disorder characterized by less than normal deep tendon reflexes.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143235>	C220601|C143177	Trochlear Nerve Disorder, CTCAE|IVth Nerve Disorder|Trochlear nerve disorder|Trochlear nerve disorder	A disorder characterized by dysfunction of the trochlear nerve (fourth cranial nerve).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143236>	C220602|C143178	Pregnancy Loss, CTCAE|Pregnancy loss|Pregnancy loss	Death in utero.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143237>	C220604|C143179	Dysuria, CTCAE|Dysuria|Dysuria|Dysuria (Priority 1)	A disorder characterized by painful urination.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C143238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143238>	C220604|C143179	Glucosuria, CTCAE|Glucosuria|Glucosuria	A disorder characterized by laboratory test results that indicate glucose in the urine.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143239>	C220604|C143179	Nephrotic Syndrome, CTCAE|Nephrotic syndrome|Nephrotic syndrome	A disorder characterized by symptoms that include severe edema, proteinuria, and hypoalbuminemia; it is indicative of renal dysfunction.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14323>	C79105	Bovidae|Bovid|Bovids	Taxonomic family which includes domestic cattle, goats, and sheep.			Mammal	
C143240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143240>	C220605|C143180	Amenorrhea, CTCAE|Amenorrhea|Amenorrhea	A disorder characterized by the abnormal absence of menses for at least three consecutive menstrual cycles.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143241>	C220606|C143181	Oropharyngeal Pain, CTCAE|Oropharyngeal pain|Oropharyngeal pain	A disorder characterized by a sensation of marked discomfort in the oropharynx or pain on swallowing.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143242>	C220606|C143181	Rhinorrhea, CTCAE|Rhinorrhea|Rhinorrhea	A disorder characterized by excessive mucous secretions draining from the nose.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143243>	C143182	Eczema, CTCAE|Eczema	A disorder characterized by skin which becomes itchy, red, inflamed, crusty, thick, scaly, and/or forms blisters.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C143244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143244>	C220607|C143182	Hair Color Changes, CTCAE|Hair color changes|Hair color changes	A disorder characterized by change in hair color or loss of normal pigmentation.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143245>	C220607|C143182	Hair Texture Abnormal, CTCAE|Hair texture abnormal|Hair texture abnormal	A disorder characterized by a change in the way the hair feels.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143246>	C220607|C143182	Hyperkeratosis, CTCAE|Hyperkeratosis|Hyperkeratosis	A disorder characterized by a thickening of the outer layer of the skin.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143247>	C220607|C143182	Nail Changes, CTCAE|Nail Changes, CTCAE 5.0|Nail changes|Nail changes	A disorder characterized by a change in the nails.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143248>	C220607|C143182	Subcutaneous Emphysema, CTCAE|Subcutaneous emphysema|Subcutaneous emphysema	A disorder characterized by air in the subcutaneous tissue.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143249>	C220610|C143183	Arterial Thromboembolism, CTCAE|Arterial thromboembolism|Arterial thromboembolism	A disorder characterized by occlusion of an arterial vessel by a blood clot that develops in an artery.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14324>	C17423	Virus-like Particle|VLP	Non-infectious particle(s) derived from viral structural proteins. These particles are used as vaccines to stimulate a host immune response against the virus that the particles were derived from.			Organism	
C143250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143250>	C141144	Immune Checkpoint Inhibitor|ICI	An agent that inhibits any of the immune checkpoint inhibitory proteins.	Immune Checkpoint Inhibitor		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C143253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143253>	C220591|C146630	Abdominal Distension, CTCAE|Abdominal Distension|Abdominal distension|Abdominal distension	A disorder characterized by swelling of the abdomen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143254>	C220595|C143171	Abdominal Infection, CTCAE|Abdominal Infection|Abdominal infection|Abdominal infection	A disorder characterized by an infectious process involving the abdominal cavity.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143255>	C220591|C146630	Abdominal Pain, CTCAE|Abdominal Pain|Abdominal pain|Abdominal pain	A disorder characterized by a sensation of marked discomfort in the abdominal region.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143256>	C220599|C143175	Abdominal Soft Tissue Necrosis, CTCAE|Abdominal Soft Tissue Necrosis|Abdominal soft tissue necrosis|Abdominal soft tissue necrosis	A disorder characterized by a necrotic process occurring in the soft tissues of the abdominal wall.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143257>	C220601|C143177	Abducens Nerve Disorder, CTCAE|Abducens Nerve Disorder|Abducens nerve disorder|Abducens nerve disorder	A disorder characterized by dysfunction of the abducens nerve (sixth cranial nerve).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143258>	C220601|C143177	Accessory Nerve Disorder, CTCAE|Accessory Nerve Disorder|Accessory nerve disorder|Accessory nerve disorder	A disorder characterized by dysfunction of the accessory nerve (eleventh cranial nerve).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143259>	C220598|C143174	Acidosis, CTCAE|Acidosis|Acidosis|Acidosis	A disorder characterized by abnormally high acidity (high hydrogen-ion concentration) of the blood and other body tissues.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14325>	C14256|C14216	Hepatitis A Virus|HAV|HEPATITIS A VIRUS|HEPATITIS A VIRUS|HHVA|Human Hepatitis A Virus|hepatitis A virus	A single stranded RNA virus.  A member of the picornaviridae family, subfamily hepatovirus.  The causative agent of Hepatitis A.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C143260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143260>	C220601|C143177	Acoustic Nerve Disorder NOS, CTCAE|Acoustic Nerve Disorder NOS|Acoustic nerve disorder NOS|Acoustic nerve disorder NOS	A disorder characterized by dysfunction of the acoustic nerve (eighth cranial nerve).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143261>	C220597|C143173	Activated Partial Thromboplastin Time Prolonged, CTCAE|Activated Partial Thromboplastin Time Prolonged|Activated partial thromboplastin time prolonged|Activated partial thromboplastin time prolonged	A finding based on laboratory test results in which the partial thromboplastin time is found to be greater than the control value. As a possible indicator of coagulopathy, a prolonged partial thromboplastin time (PTT) may occur in a variety of diseases and disorders, both primary and related to treatment.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143262>	C220604|C143179	Acute Kidney Injury, CTCAE|Acute Kidney Injury|Acute kidney injury|Acute kidney injury	A disorder characterized by the acute loss of renal function (within 2 weeks).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143266>	C220601|C143177	Akathisia, CTCAE|Akathisia|Akathisia|Akathisia	A disorder characterized by an uncomfortable feeling of inner restlessness and inability to stay still; this is a side effect of some psychotropic drugs.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143267>	C220597|C143173	Alanine Aminotransferase Increased, CTCAE|Alanine Aminotransferase Increased|Alanine aminotransferase increased|Alanine aminotransferase increased	A finding based on laboratory test results that indicate an increase in the level of alanine aminotransferase (ALT or SGPT) in the blood specimen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143268>	C220598|C143174	Alcohol Intolerance, CTCAE|Alcohol Intolerance|Alcohol intolerance|Alcohol intolerance	A disorder characterized by an increase in sensitivity to the adverse effects of alcohol, which can include nasal congestion, skin flushes, heart dysrhythmias, nausea, vomiting, indigestion and headaches.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143269>	C143173	Alkaline Phosphatase Increased, CTCAE|Alkaline Phosphatase Increased|Alkaline phosphatase increased	A finding based on laboratory test results that indicate an increase in the level of alkaline phosphatase in a blood specimen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C14326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14326>	C14307	Rubulavirus|RUBULAVIRUS	A genus of Paramyxovirinae which includes Mumps Virus			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C143270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143270>	C220598|C143174	Alkalosis, CTCAE|Alkalosis|Alkalosis|Alkalosis	A disorder characterized by abnormally high alkalinity (low hydrogen-ion concentration) of the blood and other body tissues.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143271>	C220594|C143186	Allergic Reaction, CTCAE|Allergic Reaction|Allergic reaction|Allergic reaction	A disorder characterized by an adverse general response from exposure to an allergen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143272>	C220606|C143181	Allergic Rhinitis, CTCAE|Allergic Rhinitis|Allergic rhinitis|Allergic rhinitis	A disorder characterized by an inflammation of the nasal mucous membranes caused by an IgE-mediated response to external allergens. The inflammation may also involve the mucous membranes of the sinuses, eyes, middle ear, and pharynx. Symptoms include sneezing, nasal congestion, rhinorrhea and itching.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143274>	C220601|C143177	Amnesia, CTCAE|Amnesia|Amnesia|Amnesia	A disorder characterized by systematic and extensive loss of memory.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143275>	C220591|C146630	Anal Fistula, CTCAE|Anal Fistula|Anal fistula|Anal fistula	A disorder characterized by an abnormal communication between the opening in the anal canal to the perianal skin.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143276>	C146630	Anal Hemorrhage, CTCAE|Anal Hemorrhage|Anal hemorrhage	A disorder characterized by bleeding from the anal region.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143277>	C220591|C146630	Anal Mucositis, CTCAE|Anal Mucositis|Anal mucositis|Anal mucositis	A disorder characterized by ulceration or inflammation of the mucous membrane of the anus.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143278>	C220591|C146630	Anal Necrosis, CTCAE|Anal Necrosis|Anal necrosis|Anal necrosis	A disorder characterized by a necrotic process occurring in the anal region.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143279>	C220591|C146630	Anal Pain, CTCAE|Anal Pain|Anal pain|Anal pain	A disorder characterized by a sensation of marked discomfort in the anal region.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14327>	C14217	Human Herpesvirus 8|HHV-8|HHV-8|HHV8|HHV8|HUMAN HERPESVIRUS 8|HUMAN HERPESVIRUS 8|Herpes Virus 8|Human Gammaherpesvirus 8|KSHV|KSHV|KSHV|Kaposi Sarcoma Herpes Virus|Kaposi Sarcoma-Associated Herpes Virus|Kaposi sarcoma-associated herpesvirus|Kaposi's Sarcoma-associated Herpesvirus|Virus-HHV8|human herpesvirus 8	A gammaherpesvirus that contributes to the development of Kaposi sarcoma.	Human Herpesvirus 8		Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C143280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143280>	C220591|C146630	Anal Stenosis, CTCAE|Anal Stenosis|Anal stenosis|Anal stenosis	A disorder characterized by a narrowing of the lumen of the anal canal.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143281>	C220591|C146630	Anal Ulcer, CTCAE|Anal Ulcer|Anal ulcer|Anal ulcer	A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the anal canal.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143282>	C220594|C143186	Anaphylaxis, CTCAE|Anaphylaxis|Anaphylaxis|Anaphylaxis	A disorder characterized by an acute inflammatory reaction resulting from the release of histamine and histamine-like substances from mast cells, causing a hypersensitivity immune response. Clinically, it presents with breathing difficulty, dizziness, hypotension, cyanosis and loss of consciousness and may lead to death.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143283>	C220585|C143164	Anemia, CTCAE|Anemia|Anemia|Anemia	A disorder characterized by a reduction in the amount of hemoglobin in 100 ml of blood. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143284>	C143172	Ankle Fracture, CTCAE|Ankle Fracture|Ankle fracture	A finding of damage to the ankle joint characterized by a break in the continuity of the ankle bone. Symptoms include marked discomfort, swelling and difficulty moving the affected leg and foot.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143285>	C220595|C143171	Anorectal Infection, CTCAE|Anorectal Infection|Anorectal infection|Anorectal infection	A disorder characterized by an infectious process involving the anal area and the rectum.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143287>	C220603|C143187	Anorgasmia, CTCAE|Anorgasmia|Anorgasmia|Anorgasmia	A disorder characterized by an inability to achieve orgasm.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143289>	C220596|C143172	Aortic Injury, CTCAE|Aortic Injury|Aortic injury|Aortic injury	A finding of damage to the aorta.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14328>	C14216|C113204	GB virus C|GB Virus C/ Hepatitis G Virus|GB virus C/HGV|GBV-C|GBV-C|GBV-C/G|GBV-HGV|HEPATITIS G VIRUS|HGV|HGV|HGV-1|Hepatitis G Virus|Hepatitis GB virus C|Hepatitis GB virus C/G|hepatitis G virus	A species of enveloped viruses in the Flaviviridae family and Pegivirus genus. The genome is composed of linear, single-stranded, positive-sense RNA. GB Virus C has been shown to infect human cells in vitro and in vivo but has not yet been shown to be the causative agent of disease.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C143290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143290>	C220586|C143165	Aortic Valve Disease, CTCAE|Aortic Valve Disease|Aortic valve disease|Aortic valve disease	A disorder characterized by a defect in aortic valve function or structure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143291>	C220606|C143177	Aphonia, CTCAE|Aphonia|Aphonia|Aphonia	A disorder characterized by the inability to speak. It may result from injuries to the vocal cords or may be functional (psychogenic).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143293>	C220595|C143171	Appendicitis Perforated, CTCAE|Appendicitis Perforated|Appendicitis perforated|Appendicitis perforated	A disorder characterized by acute inflammation to the vermiform appendix caused by a pathogenic agent with gangrenous changes resulting in the rupture of the appendiceal wall. The appendiceal wall rupture causes the release of inflammatory and bacterial contents from the appendiceal lumen into the abdominal cavity.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143294>	C220595|C143171	Appendicitis, CTCAE|Appendicitis|Appendicitis|Appendicitis	A disorder characterized by acute inflammation to the vermiform appendix caused by a pathogenic agent.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143295>	C220601|C143177	Arachnoiditis, CTCAE|Arachnoiditis|Arachnoiditis|Arachnoiditis	A disorder characterized by inflammation of the arachnoid membrane and adjacent subarachnoid space.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143296>	C220596|C143172	Arterial Injury, CTCAE|Arterial Injury|Arterial injury|Arterial injury	A finding of damage to an artery.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143297>	C220595|C143171	Arteritis Infective, CTCAE|Arteritis Infective|Arteritis infective|Arteritis infective	A disorder characterized by an infectious process involving an artery.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143298>	C220599|C143175	Arthralgia, CTCAE|Arthralgia|Arthralgia|Arthralgia	A disorder characterized by a sensation of marked discomfort in a joint.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143299>	C220599|C143175	Arthritis, CTCAE|Arthritis|Arthritis|Arthritis	A disorder characterized by inflammation involving a joint.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14329>	C14376	Microorganism|Micro-organism|Microbe|Microbe|Microbial|Microorganisms|Microorganisms, General|Single-Celled Organism|microorganism	A microscopic organism. The term microorganism may refer to a prokaryote or eukaryote, and may be a unicellular or multicellular organism. All taxonomic kingdoms contain microorganisms.	Microorganism		Organism	CTRP Biomarker Terminology|CTRP Terminology|NICHD Terminology|Pediatric Infectious Disease Terminology|PQ/CMC Source Type Terminology
C1432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1432>	C2186	Sulofenur|LY186641|SULOFENUR	A diarylsulfonylurea with potential antineoplastic activity. Sulofenur's antineoplastic mechanism of action is unknown. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C143300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143300>	C220591|C146630	Ascites, CTCAE|Ascites|Ascites|Ascites	A disorder characterized by accumulation of serous or hemorrhagic fluid in the peritoneal cavity.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143301>	C220597|C143173	Aspartate Aminotransferase Increased, CTCAE|Aspartate Aminotransferase Increased|Aspartate aminotransferase increased|Aspartate aminotransferase increased	A finding based on laboratory test results that indicate an increase in the level of aspartate aminotransferase (AST or SGOT) in a blood specimen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143308>	C220586|C143165	Atrioventricular Block Complete, CTCAE|Atrioventricular Block Complete|Atrioventricular block complete|Atrioventricular block complete	A disorder characterized by a dysrhythmia with complete failure of atrial electrical impulse conduction through the AV node to the ventricles.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143309>	C220586|C143165	Atrioventricular Block First Degree, CTCAE|Atrioventricular Block First Degree|Atrioventricular block first degree|Atrioventricular block first degree	A disorder characterized by a dysrhythmia with a delay in the time required for the conduction of an electrical impulse through the atrioventricular (AV) node beyond 0.2 seconds; prolongation of the PR interval greater than 200 milliseconds.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14330>	C14296	Helicobacter felis|H. felis|HELICOBACTER FELIS	A species of helix-shaped, Gram-negative Helicobacter in the phylum Proteobacteria that has been shown to be a human pathogen. H. felis infection induces chronic gastric inflammation.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C143310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143310>	C220594|C143186	Autoimmune Disorder, CTCAE|Autoimmune Disorder|Autoimmune disorder|Autoimmune disorder	A disorder characterized by loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to his own tissue constituents.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143311>	C143175	Avascular Necrosis, CTCAE|Avascular Necrosis|Avascular necrosis	A disorder characterized by necrotic changes in the bone tissue due to interruption of blood supply. Most often affecting the epiphysis of the long bones, the necrotic changes result in the collapse and the destruction of the bone structure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143312>	C220605|C143180	Azoospermia, CTCAE|Azoospermia|Azoospermia|Azoospermia	A disorder characterized by laboratory test results that indicate complete absence of spermatozoa in the semen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143314>	C220593|C143170	Bile Duct Stenosis, CTCAE|Bile Duct Stenosis|Bile duct stenosis|Bile duct stenosis	A disorder characterized by a narrowing of the lumen of the bile duct.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143315>	C220596|C143172	Biliary Anastomotic Leak, CTCAE|Biliary Anastomotic Leak|Biliary anastomotic leak|Biliary anastomotic leak	A finding of leakage of bile due to breakdown of a biliary anastomosis (surgical connection of two separate anatomic structures).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143316>	C220593|C143170	Biliary Fistula, CTCAE|Biliary Fistula|Biliary fistula|Biliary fistula	A disorder characterized by an abnormal communication between the bile ducts and another organ or anatomic site.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143317>	C220595|C143171	Biliary Tract Infection, CTCAE|Biliary Tract Infection|Biliary tract infection|Biliary tract infection	A disorder characterized by an infectious process involving the biliary tract.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143318>	C220596|C143172	Bladder Anastomotic Leak, CTCAE|Bladder Anastomotic Leak|Bladder anastomotic leak|Bladder anastomotic leak	A finding of leakage of urine due to breakdown of a bladder anastomosis (surgical connection of two separate anatomic structures).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143319>	C220595|C143171	Bladder Infection, CTCAE|Bladder Infection|Bladder infection|Bladder infection	A disorder characterized by an infectious process involving the bladder.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14331>	C79104	Canidae|Canid|Canids	Taxonomic family which includes the domestic dog, wolves and foxes.			Mammal	
C143322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143322>	C220591|C146630	Bloating, CTCAE|Bloating|Bloating|Bloating	A disorder characterized by subject-reported feeling of uncomfortable fullness of the abdomen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143323>	C220585|C143164	Blood and Lymphatic System Disorders - Other, Specify, CTCAE|Blood and Lymphatic System Disorders - Other|Blood and lymphatic system disorders - Other, specify|Blood and lymphatic system disorders - Other, specify	Other specified types of blood and lymphatic system disorders.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143324>	C220597|C143173	Blood Antidiuretic Hormone Abnormal, CTCAE|Blood Antidiuretic Hormone Abnormal|Blood antidiuretic hormone abnormal|Blood antidiuretic hormone abnormal	A finding based on laboratory test results that indicate abnormal levels of antidiuretic hormone (ADH) in the blood specimen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143325>	C143173	Blood Bilirubin Increased, CTCAE|Blood Bilirubin Increased|Blood bilirubin increased	A finding based on laboratory test results that indicate an abnormally high level of bilirubin in the blood. Excess bilirubin is associated with jaundice.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143326>	C220597|C143173	Blood Corticotrophin Decreased, CTCAE|Blood Corticotrophin Decreased|Blood corticotrophin decreased|Blood corticotrophin decreased	A finding based on laboratory test results that indicate a decrease in the expected levels of corticotrophin (ACTH) in a blood specimen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143327>	C143173	Blood Gonadotrophin Abnormal, CTCAE|Blood Gonadotrophin Abnormal|Blood gonadotrophin abnormal	A finding based on laboratory test results that indicate abnormal levels of gonadotrophin hormone in a blood specimen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143328>	C220597|C143173	Blood Prolactin Abnormal, CTCAE|Blood Prolactin Abnormal|Blood prolactin abnormal|Blood prolactin abnormal	A finding based on laboratory test results that indicate abnormal levels of prolactin hormone in a blood specimen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14332>	C14186	Avian Leukemia Sarcoma Virus|ALSV-A	A type C avian retrovirus			Virus	
C143330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143330>	C220607|C143182	Body Odor, CTCAE|Body Odor|Body odor|Body odor	A disorder characterized by an abnormal body smell resulting from the growth of bacteria on the body.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143331>	C220595|C143171	Bone Infection, CTCAE|Bone Infection|Bone infection|Bone infection	A disorder characterized by an infectious process involving the bones.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143332>	C220585|C143164	Bone Marrow Hypocellular, CTCAE|Bone Marrow Hypocellular|Bone marrow hypocellular|Bone marrow hypocellular	A disorder characterized by the inability of the bone marrow to produce hematopoietic elements.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143335>	C143180	Breast Atrophy, CTCAE|Breast Atrophy|Breast atrophy	A disorder characterized by underdevelopment of the breast.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143336>	C220595|C143171	Breast Infection, CTCAE|Breast Infection|Breast infection|Breast infection	A disorder characterized by an infectious process involving the breast.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143338>	C220606|C143181	Bronchial Fistula, CTCAE|Bronchial Fistula|Bronchial fistula|Bronchial fistula	A disorder characterized by an abnormal communication between the bronchus and another organ or anatomic site.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143339>	C220595|C143171	Bronchial Infection, CTCAE|Bronchial Infection|Bronchial infection|Bronchial infection	A disorder characterized by an infectious process involving the bronchi.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14333>	C14376	Marine Organism	Any organism that lives in the sea			Organism	
C143340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143340>	C220606|C143181	Bronchial Obstruction, CTCAE|Bronchial Obstruction|Bronchial obstruction|Bronchial obstruction	A disorder characterized by blockage of a bronchus passage, most often by bronchial secretions and exudates.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143341>	C220606|C143181	Bronchial Stricture, CTCAE|Bronchial Stricture|Bronchial stricture|Bronchial stricture	A disorder characterized by a narrowing of the bronchial tube.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143342>	C220606|C143181	Bronchopleural Fistula, CTCAE|Bronchopleural Fistula|Bronchopleural fistula|Bronchopleural fistula	A disorder characterized by an abnormal communication between a bronchus and the pleural cavity.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143343>	C220606|C143181	Bronchopulmonary Hemorrhage, CTCAE|Bronchopulmonary Hemorrhage|Bronchopulmonary hemorrhage|Bronchopulmonary hemorrhage	A disorder characterized by bleeding from the bronchial wall and/or lung parenchyma.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143344>	C220606|C143181	Bronchospasm, CTCAE|Bronchospasm|Bronchospasm|Bronchospasm	A disorder characterized by a sudden contraction of the smooth muscles of the bronchial wall or narrowing of the airway. May be manifested as wheezing.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143345>	C220596|C143172	Bruising, CTCAE|Bruising|Bruising|Bruising	A finding of injury of the soft tissues or bone characterized by leakage of blood into surrounding tissues.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143346>	C143182	Bullous Dermatitis, CTCAE|Bullous Dermatitis|Bullous dermatitis	A disorder characterized by inflammation of the skin characterized by the presence of bullae which are filled with fluid.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143349>	C220610|C143183	Capillary Leak Syndrome, CTCAE|Capillary Leak Syndrome|Capillary leak syndrome|Capillary leak syndrome	A disorder characterized by leakage of intravascular fluids into the extravascular space. This syndrome is observed in patients who demonstrate a state of generalized leaky capillaries following shock syndromes, low-flow states, ischemia-reperfusion injuries, toxemias, medications, or poisoning. It can lead to generalized edema and multiple organ failure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14334>	C14349	Endogenous Retrovirus|ENDOGENOUS RETROVIRUS|ERV	Genetic elements propagated primarily through the germline, with a proviral structure, i.e. the chromosomally-integrated form of retroviruses and regulated by cellular processes.  Could be involved in development and serve as progenitors to pathogenic retroviruses.  Classified as ecotropic or xenotropic.  Ecotropic viruses can be transmitted to cells of the same species and can produce malignancies. Xenotropic viruses cannot infect cells from their host species but are infectious in heterologous species.  Cycles of transcription and reverse transcription make the elements mobile and mutagenic.			Virus	CDISC SDTM Genomic Symbol Type Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C143350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143350>	C220597|C143173	Carbon Monoxide Diffusing Capacity Decreased, CTCAE|Carbon Monoxide Diffusing Capacity Decreased|Carbon monoxide diffusing capacity decreased|Carbon monoxide diffusing capacity decreased	A finding based on lung function test results that indicate a decrease in the lung capacity to absorb carbon monoxide (DLCO or TLCO).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143351>	C220586|C143165	Cardiac Arrest, CTCAE|Cardiac Arrest|Cardiac arrest|Cardiac arrest	A disorder characterized by cessation of the pumping function of the heart.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143352>	C220586|C143165	Cardiac Disorders - Other, Specify, CTCAE|Cardiac Disorders - Other|Cardiac disorders - Other, specify|Cardiac disorders - Other, specify	Other specified types of cardiac disorders.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143353>	C143173	Cardiac Troponin I Increased, CTCAE|Cardiac Troponin I Increased|Cardiac troponin I increased	A finding based on laboratory test results that indicate increased levels of cardiac troponin I in a biological specimen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143354>	C143173	Cardiac Troponin T Increased, CTCAE|Cardiac Troponin T Increased|Cardiac troponin T increased	A finding based on laboratory test results that indicate increased levels of cardiac troponin T in a biological specimen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143356>	C220595|C143171	Catheter Related Infection, CTCAE|Catheter Related Infection|Catheter related infection|Catheter related infection	A disorder characterized by an infectious process that involves a catheter or port.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143357>	C220597|C143173	CD4 Lymphocytes Decreased, CTCAE|CD4 Lymphocytes Decreased|CD4 lymphocytes decreased|CD4 lymphocytes decreased	A finding based on laboratory test results that indicate a decrease in levels of CD4 lymphocytes in a blood specimen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143358>	C220591|C146630	Cecal Hemorrhage, CTCAE|Cecal Hemorrhage|Cecal hemorrhage|Cecal hemorrhage	A disorder characterized by bleeding from the cecum.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143359>	C220595|C143171	Cecal Infection, CTCAE|Cecal Infection|Cecal infection|Cecal infection	A disorder characterized by an infectious process involving the cecum.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143360>	C220601|C143177	Central Nervous System Necrosis, CTCAE|Central Nervous System Necrosis|Central nervous system necrosis|Central nervous system necrosis	A disorder characterized by a necrotic process occurring in the brain and/or spinal cord.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143361>	C220601|C143177	Cerebrospinal Fluid Leakage, CTCAE|Cerebrospinal Fluid Leakage|Cerebrospinal fluid leakage|Cerebrospinal fluid leakage	A disorder characterized by loss of cerebrospinal fluid into the surrounding tissues.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143362>	C220595|C143171	Cervicitis Infection, CTCAE|Cervicitis Infection|Cervicitis infection|Cervicitis infection	A disorder characterized by an infectious process involving the uterine cervix.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143364>	C220586|C143165	Chest Pain - Cardiac, CTCAE|Chest Pain - Cardiac|Chest pain - cardiac|Chest pain - cardiac	A disorder characterized by substernal discomfort due to insufficient myocardial oxygenation e.g., angina pectoris.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143366>	C220592|C143169	Chills, CTCAE|Chills|Chills|Chills	A disorder characterized by a sensation of cold that often marks a physiologic response to sweating after a fever.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143368>	C220597|C143173	Cholesterol High, CTCAE|Cholesterol High|Cholesterol high|Cholesterol high	A finding based on laboratory test results that indicate higher than normal levels of cholesterol in a blood specimen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143369>	C143179	Chronic Kidney Disease, CTCAE|Chronic Kidney Disease|Chronic kidney disease	A disorder characterized by gradual and usually permanent loss of kidney function resulting in renal failure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C14336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14336>	C14258	Vascular Plant|Higher Plant|Plants, Vascular|Tracheobionta|Tracheophytes	The flowering herbs, shrubs, trees and ferns.  These plants have vascular tissue, consisting of xylem, which carries water and nutrients from the roots up the stem to the leaves, and the phloem, which carries sugar produced in the leaves to other parts of the plant.			Plant	
C143373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143373>	C220591|C146630	Colonic Fistula, CTCAE|Colonic Fistula|Colonic fistula|Colonic fistula	A disorder characterized by an abnormal communication between the large intestine and another organ or anatomic site.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143374>	C146630	Colonic Hemorrhage, CTCAE|Colonic Hemorrhage|Colonic hemorrhage	A disorder characterized by bleeding from the colon.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143375>	C220591|C146630	Colonic Obstruction, CTCAE|Colonic Obstruction|Colonic obstruction|Colonic obstruction	A disorder characterized by blockage of the normal flow of the intestinal contents in the colon.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143376>	C220591|C146630	Colonic Perforation, CTCAE|Colonic Perforation|Colonic perforation|Colonic perforation	A disorder characterized by a rupture in the colonic wall.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143377>	C220591|C146630	Colonic Stenosis, CTCAE|Colonic Stenosis|Colonic stenosis|Colonic stenosis	A disorder characterized by a narrowing of the lumen of the colon.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143378>	C220591|C146630	Colonic Ulcer, CTCAE|Colonic Ulcer|Colonic ulcer|Colonic ulcer	A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the colon.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143379>	C220601|C143177	Concentration Impairment, CTCAE|Concentration Impairment|Concentration impairment|Concentration impairment	A disorder characterized by a deterioration in the ability to concentrate.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14337>	C14190	Bovine Papillomavirus-1|BPV-1	A type of Bovine Papillomavirus.			Virus	
C143380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143380>	C143165	Conduction Disorder, CTCAE|Conduction Disorder|Conduction disorder	A disorder characterized by pathological irregularities in the cardiac conduction system.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143382>	C220587|C143184	Congenital, Familial and Genetic Disorders - Other, Specify, CTCAE|Congenital, Familial and Genetic Disorders - Other|Congenital, familial and genetic disorders - Other, specify|Congenital, familial and genetic disorders - Other, specify	Other specified types of congenital, familial and genetic disorders.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143383>	C220595|C143171	Conjunctivitis Infective, CTCAE|Conjunctivitis Infective|Conjunctivitis infective|Conjunctivitis infective	A disorder characterized by an infectious process involving the conjunctiva. Clinical manifestations include pink or red color in the eyes.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143384>	C220595|C143171	Conjunctivitis, CTCAE|Conjunctivitis|Conjunctivitis|Conjunctivitis	A disorder characterized by inflammation, swelling and redness to the conjunctiva of the eye.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143386>	C220595|C143171	Corneal Infection, CTCAE|Corneal Infection|Corneal infection|Corneal infection	A disorder characterized by an infectious process involving the cornea.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143387>	C220590|C143167	Corneal Ulcer, CTCAE|Corneal Ulcer|Corneal ulcer|Corneal ulcer	A disorder characterized by an area of epithelial tissue loss on the surface of the cornea. It is associated with inflammatory cells in the cornea and anterior chamber.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143389>	C143173	CPK Increased, CTCAE|CPK Increased|CPK increased	A finding based on laboratory test results that indicate an increase in levels of creatine phosphokinase in a blood specimen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C14338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14338>	C44391|C14226	Human Papillomavirus-16|16|HPV 16|HPV Genotype 16|HPV-16|HPV-16|HPV16|HPV16|HUMAN PAPILLOMAVIRUS TYPE 16|High-Risk Human Papillomavirus 16|High-Risk Human Papillomavirus Subtype 16|High-Risk Human Papillomavirus Subtype HPV16|High-Risk Human Papillomavirus-16|High-Risk Subtype HPV-16|High-Risk Subtype HPV16|Human Papillomavirus 16|Human Papillomavirus Genotype 16|Human Papillomavirus Type 16|Human Papillomavirus Type 16|hrHPV-16|hrHPV16	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce skin and mucosal epithelial lesions. Human papillomavirus-16 (HPV16) has been directly linked to cervical cancer and is significantly associated with invasiveness. Progression from low- to high-grade neoplasia is often associated with the integration of the HPV16 genome into the host chromosome.	Human Papillomavirus Type 16		Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|NICHD Terminology|Pediatric Immunization Terminology
C143390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143390>	C220595|C143171	Cranial Nerve Infection, CTCAE|Cranial Nerve Infection|Cranial nerve infection|Cranial nerve infection	A disorder characterized by an infectious process involving a cranial nerve.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143391>	C220597|C143173	Creatinine Increased, CTCAE|Creatinine Increased|Creatinine increased|Creatinine increased	A finding based on laboratory test results that indicate increased levels of creatinine in a biological specimen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143392>	C220589|C143166	Cushingoid, CTCAE|Cushingoid|Cushingoid|Cushingoid	A disorder characterized by signs and symptoms that resemble Cushing's disease or syndrome: buffalo hump obesity, striations, adiposity, hypertension, diabetes, and osteoporosis, usually due to exogenous corticosteroids.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143393>	C220604|C143179	Cystitis Noninfective, CTCAE|Cystitis Noninfective|Cystitis Noninfective (Priority 2)|Cystitis noninfective|Cystitis noninfective	A disorder characterized by inflammation of the bladder which is not caused by an infection of the urinary tract.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C143394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143394>	C220594|C143186	Cytokine Release Syndrome, CTCAE|Cytokine Release Syndrome|Cytokine release syndrome|Cytokine release syndrome	A disorder characterized by fever, tachypnea, headache, tachycardia, hypotension, rash, and/or hypoxia caused by the release of cytokines.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143395>	C220592|C143169	Death Neonatal, CTCAE|Death Neonatal|Death neonatal|Death neonatal	Newborn death occurring during the first 28 days after birth.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143396>	C220592|C143169	Death NOS, CTCAE|Death NOS|Death NOS|Death NOS	Death that cannot be attributed to a CTCAE term associated with Grade 5.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143398>	C220603|C143187	Delayed Orgasm, CTCAE|Delayed Orgasm|Delayed orgasm|Delayed orgasm	A disorder characterized by sexual dysfunction characterized by a delay in climax.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14339>	C14240	Knock-Out Mouse|Knockout Mouse|Mouse, Knockout|Null Mouse	Informal term for the generation of a mutant mouse in which the function of a particular gene has been completely eliminated, also called a null mouse.			Experimental Model of Disease	
C1433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1433>	C2018	Liarozole|1H-Benzimidazole, 5-((3-chlorophenyl)-1H-imidazol-1-ylmethyl)-|LIAROZOLE|Liazal|R 75251|R-61405|liarozole	An orally-active benzimidazole derivative with potential antineoplastic activity. As a retinoic acid metabolism blocking agent, liarozole inhibits cytochrome P450-dependent all-trans-retinoic acid (ATRA)-4-hydroxylase, resulting in an increase in endogenous ATRA production, inhibition of cell proliferation, and induction of cell differentiation. This agent also inhibits aromatase, the enzyme that catalyzes the final, rate-limiting step in estrogen biosynthesis.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C143400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143400>	C220603|C143187	Delirium, CTCAE|Delirium|Delirium|Delirium	A disorder characterized by the acute and sudden development of confusion, illusions, movement changes, inattentiveness, agitation, and hallucinations. Usually, it is a reversible condition.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143401>	C220603|C143187	Delusions, CTCAE|Delusions|Delusions|Delusions	A disorder characterized by false personal beliefs held contrary to reality, despite contradictory evidence and common sense.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143402>	C220591|C146630	Dental Caries, CTCAE|Dental Caries|Dental caries|Dental caries	A disorder characterized by the decay of a tooth, in which it becomes softened, discolored and/or porous.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143403>	C220601|C143177	Depressed Level of Consciousness, CTCAE|Depressed Level of Consciousness|Depressed level of consciousness|Depressed level of consciousness	A disorder characterized by a decrease in ability to perceive and respond.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143405>	C220596|C143172	Dermatitis Radiation, CTCAE|Dermatitis Radiation|Dermatitis radiation|Dermatitis radiation	A finding of cutaneous inflammatory reaction occurring as a result of exposure to biologically effective levels of ionizing radiation.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143406>	C220595|C143171	Device Related Infection, CTCAE|Device Related Infection|Device related infection|Device related infection	A disorder characterized by an infectious process involving the use of a medical device.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14340>	C14258	Non-Vascular Plant|Bryophyte|Non-tracheophytes|Plants, Non-Vascular	A plant that does not have vascular tubes/tissues to transport food and water.  It belongs to the division Bryophyta, which includes liverwort, and moss.			Plant	
C143410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143410>	C220590|C143167	Dry Eye, CTCAE|Dry Eye|Dry eye|Dry eye	A disorder characterized by dryness of the cornea and conjunctiva.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143411>	C220591|C146630	Dry Mouth, CTCAE|Dry Mouth|Dry mouth|Dry mouth	A disorder characterized by reduced salivary flow in the oral cavity.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143414>	C220591|C146630	Duodenal Hemorrhage, CTCAE|Duodenal Hemorrhage|Duodenal hemorrhage|Duodenal hemorrhage	A disorder characterized by bleeding from the duodenum.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143415>	C220595|C143171	Duodenal Infection, CTCAE|Duodenal Infection|Duodenal infection|Duodenal infection	A disorder characterized by an infectious process involving the duodenum.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143416>	C220591|C146630	Duodenal Obstruction, CTCAE|Duodenal Obstruction|Duodenal obstruction|Duodenal obstruction	A disorder characterized by blockage of the normal flow of stomach contents through the duodenum.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143417>	C220591|C146630	Duodenal Perforation, CTCAE|Duodenal Perforation|Duodenal perforation|Duodenal perforation	A disorder characterized by a rupture in the duodenal wall.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143418>	C220591|C146630	Duodenal Stenosis, CTCAE|Duodenal Stenosis|Duodenal stenosis|Duodenal stenosis	A disorder characterized by a narrowing of the lumen of the duodenum.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143419>	C220591|C146630	Duodenal Ulcer, CTCAE|Duodenal Ulcer|Duodenal ulcer|Duodenal ulcer	A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the duodenal wall.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14341>	C14181	Primate Retrovirus	An RNA containing virus infecting primates (SIV, STLV, SFV).			Virus	
C143420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143420>	C220601|C143177	Dysarthria, CTCAE|Dysarthria|Dysarthria|Dysarthria	A disorder characterized by slow and slurred speech resulting from an inability to coordinate the muscles used in speech.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143421>	C220601|C143177	Dysesthesia, CTCAE|Dysesthesia|Dysesthesia|Dysesthesia	A disorder characterized by distortion of sensory perception, resulting in an abnormal and unpleasant sensation.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143422>	C220601|C143177	Dysgeusia, CTCAE|Dysgeusia|Dysgeusia|Dysgeusia	A disorder characterized by abnormal sensual experience with the taste of foodstuffs; it can be related to a decrease in the sense of smell.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143423>	C220605|C143180	Dysmenorrhea, CTCAE|Dysmenorrhea|Dysmenorrhea|Dysmenorrhea	A disorder characterized by abnormally painful abdominal cramps during menses.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143424>	C220605|C143180	Dyspareunia, CTCAE|Dyspareunia|Dyspareunia|Dyspareunia	A disorder characterized by painful or difficult coitus.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143425>	C220591|C146630	Dyspepsia, CTCAE|Dyspepsia|Dyspepsia|Dyspepsia	A disorder characterized by an uncomfortable, often painful feeling in the stomach, resulting from impaired digestion. Symptoms include burning stomach, bloating, heartburn, nausea and vomiting.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143427>	C143177	Dysphasia, CTCAE|Dysphasia|Dysphasia	A disorder characterized by impairment of verbal communication skills, often resulting from brain damage.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143429>	C220588|C143185	Ear and Labyrinth Disorders - Other, Specify, CTCAE|Ear and Labyrinth Disorders - Other|Ear and labyrinth disorders - Other, specify|Ear and labyrinth disorders - Other, specify	Other specified types of ear and labyrinth disorders.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14342>	C14362	PVC-211 MuLV|Friend murine leukemia virus (ISOLATE PVC-211)	A murine leukemia virus (MuLV) variant cloned from rats infected with the Friend leukemia virus.  Neuropathogenic, causes hind limb paralysis in rats and mice, unlike the parent Friend virus which causes erythroleukemia.			Virus	
C143430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143430>	C220588|C143185	Ear Pain, CTCAE|Ear Pain|Ear pain|Ear pain	A disorder characterized by a sensation of marked discomfort in the ear.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143431>	C143177	Edema Cerebral, CTCAE|Edema Cerebral|Edema cerebral	A disorder characterized by swelling due to an excessive accumulation of fluid in the brain.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143432>	C220592|C143169	Edema Face, CTCAE|Edema Face|Edema face|Edema face	A disorder characterized by swelling due to excessive fluid accumulation in facial area tissues.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143433>	C143169	Edema Limbs, CTCAE|Edema Limbs|Edema limbs	A disorder characterized by swelling due to excessive fluid accumulation in the upper or lower extremities.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143434>	C143169	Edema Trunk, CTCAE|Edema Trunk|Edema trunk	A disorder characterized by swelling due to excessive fluid accumulation in the trunk area.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143435>	C220605|C143180	Ejaculation Disorder, CTCAE|Ejaculation Disorder|Ejaculation Disorder (Priority 2)|Ejaculation disorder|Ejaculation disorder	A disorder characterized by problems related to ejaculation. This category includes premature, delayed, retrograde and painful ejaculation.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C143436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143436>	C143173	Ejection Fraction Decreased, CTCAE|Ejection Fraction Decreased|Ejection fraction decreased	The percentage computed when the amount of blood ejected during a ventricular contraction of the heart is compared to the amount that was present prior to the contraction.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143437>	C220597|C143173	Electrocardiogram QT Corrected Interval Prolonged, CTCAE|Electrocardiogram QT Corrected Interval Prolonged|Electrocardiogram QT corrected interval prolonged|Electrocardiogram QT corrected interval prolonged	A finding of a cardiac dysrhythmia characterized by an abnormally long corrected QT interval.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143438>	C143171	Encephalitis Infection, CTCAE|Encephalitis Infection|Encephalitis infection	A disorder characterized by an infectious process involving the brain tissue.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143439>	C143171	Encephalomyelitis Infection, CTCAE|Encephalomyelitis Infection|Encephalomyelitis infection	A disorder characterized by an infectious process involving the brain and spinal cord tissues.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143441>	C220595|C143171	Endocarditis Infective, CTCAE|Endocarditis Infective|Endocarditis infective|Endocarditis infective	A disorder characterized by an infectious process involving the endocardial layer of the heart.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143442>	C220589|C143166	Endocrine Disorders - Other, Specify, CTCAE|Endocrine Disorders - Other|Endocrine disorders - Other, specify|Endocrine disorders - Other, specify	Other specified types of endocrine disorders.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143443>	C220595|C143171	Endophthalmitis, CTCAE|Endophthalmitis|Endophthalmitis|Endophthalmitis	A disorder characterized by an infectious process involving the internal structures of the eye.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143444>	C220595|C143171	Enterocolitis Infectious, CTCAE|Enterocolitis Infectious|Enterocolitis infectious|Enterocolitis infectious	A disorder characterized by an infectious process involving the small and/or large intestines.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143445>	C220591|C146630	Enterocolitis, CTCAE|Enterocolitis|Enterocolitis|Enterocolitis	A disorder characterized by inflammation of the small and large intestines.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143446>	C220591|C146630	Enterovesical Fistula, CTCAE|Enterovesical Fistula|Enterovesical fistula|Enterovesical fistula	A disorder characterized by an abnormal communication between the urinary bladder and the intestine.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143447>	C220606|C143181	Epistaxis, CTCAE|Epistaxis|Epistaxis|Epistaxis	A disorder characterized by bleeding from the nose.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143449>	C220607|C143182	Erythema Multiforme, CTCAE|Erythema Multiforme|Erythema multiforme|Erythema multiforme	A disorder characterized by target lesions (a pink-red ring around a pale center).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14344>	C14186	Sloan Kettering Virus|Avian erythroblastosis virus (strain Sloan-Kettering)|SKVS	The Sloan-Kettering viruses (SKVs) are a group of transforming retroviruses that were isolated from chicken embryo cells which had been infected with the avian leukosis virus transformation-defective Bratislava 77 (tdB77). (from Li et al.  J Virol 1986;57:1065-72)			Virus	
C143450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143450>	C220607|C143182	Erythroderma, CTCAE|Erythroderma|Erythroderma|Erythroderma	A disorder characterized by generalized inflammatory erythema and exfoliation. The inflammatory process involves >90% of the body surface area.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143451>	C220596|C143172	Esophageal Anastomotic Leak, CTCAE|Esophageal Anastomotic Leak|Esophageal anastomotic leak|Esophageal anastomotic leak	A finding of leakage due to breakdown of an esophageal anastomosis (surgical connection of two separate anatomic structures).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143453>	C220591|C146630	Esophageal Hemorrhage, CTCAE|Esophageal Hemorrhage|Esophageal hemorrhage|Esophageal hemorrhage	A disorder characterized by bleeding from the esophagus.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143454>	C220595|C143171	Esophageal Infection, CTCAE|Esophageal Infection|Esophageal infection|Esophageal infection	A disorder characterized by an infectious process involving the esophagus.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143455>	C220591|C146630	Esophageal Necrosis, CTCAE|Esophageal Necrosis|Esophageal necrosis|Esophageal necrosis	A disorder characterized by a necrotic process occurring in the esophageal wall.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143456>	C220591|C146630	Esophageal Obstruction, CTCAE|Esophageal Obstruction|Esophageal obstruction|Esophageal obstruction	A disorder characterized by blockage of the normal flow of the contents in the esophagus.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143457>	C220591|C146630	Esophageal Pain, CTCAE|Esophageal Pain|Esophageal pain|Esophageal pain	A disorder characterized by a sensation of marked discomfort in the esophageal region.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143458>	C220591|C146630	Esophageal Perforation, CTCAE|Esophageal Perforation|Esophageal perforation|Esophageal perforation	A disorder characterized by a rupture in the wall of the esophagus.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143459>	C220591|C146630	Esophageal Stenosis, CTCAE|Esophageal Stenosis|Esophageal stenosis|Esophageal stenosis	A disorder characterized by a narrowing of the lumen of the esophagus.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14345>	C14339	TGF-Beta-Null Mice				Mammal	
C143460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143460>	C220591|C146630	Esophageal Ulcer, CTCAE|Esophageal Ulcer|Esophageal ulcer|Esophageal ulcer	A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the esophageal wall.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143466>	C220590|C143167	Extraocular Muscle Paresis, CTCAE|Extraocular Muscle Paresis|Extraocular muscle paresis|Extraocular muscle paresis	A disorder characterized by incomplete paralysis of an extraocular muscle.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143467>	C220601|C143177	Extrapyramidal Disorder, CTCAE|Extrapyramidal Disorder|Extrapyramidal disorder|Extrapyramidal disorder	A disorder characterized by abnormal, repetitive, involuntary muscle movements, frenzied speech and extreme restlessness.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143468>	C220590|C143167	Eye Disorders - Other, Specify, CTCAE|Eye Disorders - Other|Eye disorders - Other, specify|Eye disorders - Other, specify	Other specified types of eye disorders.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143469>	C220595|C143171	Eye Infection, CTCAE|Eye Infection|Eye infection|Eye infection	A disorder characterized by an infectious process involving the eye.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14346>	C14269	Negative Sense ssRNA Virus|(-) Strand ssRNA Virus|Negative Strand ssRNA Virus|ssRNA Virus, (-) Strand	A single stranded RNA virus where the RNA strand is the complement of a mRNA.			Virus	
C143471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143471>	C220590|C143167	Eyelid Function Disorder, CTCAE|Eyelid Function Disorder|Eyelid function disorder|Eyelid function disorder	A disorder characterized by impaired eyelid function.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143472>	C220601|C143177	Facial Muscle Weakness, CTCAE|Facial Muscle Weakness|Facial muscle weakness|Facial muscle weakness	A disorder characterized by a reduction in the strength of the facial muscles.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143473>	C220601|C143177	Facial Nerve Disorder, CTCAE|Facial Nerve Disorder|Facial nerve disorder|Facial nerve disorder	A disorder characterized by dysfunction of the facial nerve (seventh cranial nerve).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143474>	C220592|C143169	Facial Pain, CTCAE|Facial Pain|Facial pain|Facial pain	A disorder characterized by a sensation of marked discomfort in the face.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143475>	C220596|C143172	Fall, CTCAE|Fall|Fall|Fall	A finding of sudden movement downward, usually resulting in injury.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143476>	C220596|C143172	Fallopian Tube Anastomotic Leak, CTCAE|Fallopian Tube Anastomotic Leak|Fallopian tube anastomotic leak|Fallopian tube anastomotic leak	A finding of leakage due to breakdown of a fallopian tube anastomosis (surgical connection of two separate anatomic structures).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143479>	C143182	Fat Atrophy, CTCAE|Fat Atrophy|Fat atrophy	A disorder characterized by shrinking of adipose tissue.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C14347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14347>	C14268	Deltaretrovirus|BLV-HTLV Retrovirus|DELTARETROVIRUS	A genus in the family retroviridae consisting of exogenous horizontally transmitted viruses found in mammals; associated with B or T cell leukemia/lymphoma with a long latency. Bovine Leukemia Virus is the type species. (from CRISP)			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C143481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143481>	C220585|C143164	Febrile Neutropenia, CTCAE|Febrile Neutropenia|Febrile neutropenia|Febrile neutropenia	A disorder characterized by an ANC <1000/mm3 and a single temperature of >38.3 degrees C (101 degrees F) or a sustained temperature of >=38 degrees C (100.4 degrees F) for more than one hour.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143482>	C220591|C146630	Fecal Incontinence, CTCAE|Fecal Incontinence|Fecal Incontinence (Priority 1)|Fecal incontinence|Fecal incontinence	A disorder characterized by inability to control the escape of stool from the rectum.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C143483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143483>	C220605|C143180	Feminization Acquired, CTCAE|Feminization Acquired|Feminization acquired|Feminization acquired	A disorder characterized by the development of secondary female sex characteristics in males due to extrinsic factors.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143484>	C220602|C143178	Fetal Growth Retardation, CTCAE|Fetal Growth Retardation|Fetal growth retardation|Fetal growth retardation	A disorder characterized by inhibition of fetal growth resulting in the inability of the fetus to achieve its potential weight.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143485>	C220592|C143169	Fever, CTCAE|Fever|Fever|Fever	A disorder characterized by elevation of the body's temperature above the upper limit of normal.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143486>	C220597|C143173	Fibrinogen Decreased, CTCAE|Fibrinogen Decreased|Fibrinogen decreased|Fibrinogen decreased	A finding based on laboratory test results that indicate an decrease in levels of fibrinogen in a blood specimen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143487>	C220599|C143175	Fibrosis Deep Connective Tissue, CTCAE|Fibrosis Deep Connective Tissue|Fibrosis deep connective tissue|Fibrosis deep connective tissue	A disorder characterized by fibrotic degeneration of the deep connective tissues.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143488>	C220599|C143175	Flank Pain, CTCAE|Flank Pain|Flank pain|Flank pain	A disorder characterized by a sensation of marked discomfort on the lateral side of the body in the region below the ribs and above the hip.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143489>	C220590|C143167	Flashing Lights, CTCAE|Flashing Lights|Flashing lights|Flashing lights	A disorder characterized by a sudden or brief burst of light.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14348>	C14200	Double Stranded DNA Virus|dsDNA Virus	A virus that has double stranded DNA as its genetic material.			Virus	
C143491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143491>	C220590|C143167	Floaters, CTCAE|Floaters|Floaters|Floaters	A disorder characterized by an individual seeing spots before their eyes. The spots are shadows of opaque cell fragments in the vitreous humor or lens.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143492>	C220592|C143169	Flu Like Symptoms, CTCAE|Flu Like Symptoms|Flu like symptoms|Flu like symptoms	A disorder characterized by a group of symptoms similar to those observed in patients with the flu. It includes fever, chills, body aches, malaise, loss of appetite and dry cough.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143494>	C143173	Forced Expiratory Volume Decreased, CTCAE|Forced Expiratory Volume Decreased|Forced expiratory volume decreased	A finding based on test results that indicate a relative decrease in the fraction of the forced vital capacity that is exhaled in a specific number of seconds.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143496>	C220592|C143169	Gait Disturbance, CTCAE|Gait Disturbance|Gait disturbance|Gait disturbance	A disorder characterized by walking difficulties.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143497>	C220595|C143171	Gallbladder Infection, CTCAE|Gallbladder Infection|Gallbladder infection|Gallbladder infection	A disorder characterized by an infectious process involving the gallbladder.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143498>	C220596|C143172	Gastric Anastomotic Leak, CTCAE|Gastric Anastomotic Leak|Gastric anastomotic leak|Gastric anastomotic leak	A finding of leakage due to breakdown of a gastric anastomosis (surgical connection of two separate anatomic structures).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143499>	C220591|C146630	Gastric Fistula, CTCAE|Gastric Fistula|Gastric fistula|Gastric fistula	A disorder characterized by an abnormal communication between the stomach and another organ or anatomic site.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14349>	C14283	Other Virus Grouping	A non-taxonomic grouping of viruses based on a shared characteristic.			Virus	
C1434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1434>	C1450	Lobaplatin|1,2-diammino-methy lcyclobutane-platinum (II) lactate|D 19466|D-19466|D19466|LOBAPLATIN|lobaplatin	A third-generation, water-soluble platinum compound with potential antineoplastic activity. Lobaplatin forms highly reactive, charged, platinum complexes that bind to nucleophilic groups such as GC- and AG-rich sites in DNA, inducing intrastrand DNA cross-links. These cross-links will ultimately result in induction of apoptosis and cell growth inhibition. Compared to first and second generation platinum compounds, lobaplatin appears to be more stable, less toxic, have a better therapeutic index and may overcome tumor resistance.			Inorganic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C143500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143500>	C220591|C146630	Gastric Hemorrhage, CTCAE|Gastric Hemorrhage|Gastric hemorrhage|Gastric hemorrhage	A disorder characterized by bleeding from the gastric wall.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143501>	C220591|C146630	Gastric Necrosis, CTCAE|Gastric Necrosis|Gastric necrosis|Gastric necrosis	A disorder characterized by a necrotic process occurring in the gastric wall.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143502>	C220591|C146630	Gastric Perforation, CTCAE|Gastric Perforation|Gastric perforation|Gastric perforation	A disorder characterized by a rupture in the stomach wall.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143503>	C220591|C146630	Gastric Stenosis, CTCAE|Gastric Stenosis|Gastric stenosis|Gastric stenosis	A disorder characterized by a narrowing of the lumen of the stomach.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143504>	C220591|C146630	Gastric Ulcer, CTCAE|Gastric Ulcer|Gastric ulcer|Gastric ulcer	A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the stomach.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143506>	C220591|C146630	Gastroesophageal Reflux Disease, CTCAE|Gastroesophageal Reflux Disease|Gastroesophageal reflux disease|Gastroesophageal reflux disease	A disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is chronic in nature and usually caused by incompetence of the lower esophageal sphincter, and may result in injury to the esophageal mucosal. Symptoms include heartburn and acid indigestion.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143507>	C220596|C143172	Gastrointestinal Anastomotic Leak, CTCAE|Gastrointestinal Anastomotic Leak|Gastrointestinal anastomotic leak|Gastrointestinal anastomotic leak	A finding of leakage due to breakdown of a gastrointestinal anastomosis (surgical connection of two separate anatomic structures).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143508>	C220591|C146630	Gastrointestinal Disorders - Other, Specify, CTCAE|Gastrointestinal Disorders - Other|Gastrointestinal disorders - Other, specify|Gastrointestinal disorders - Other, specify	Other specified types of gastrointestinal disorders.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14350>	C14200	Single Stranded DNA Virus|ssDNA Virus	A virus that has single stranded DNA as its genetic material.			Virus	
C143510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143510>	C220591|C146630	Gastrointestinal Pain, CTCAE|Gastrointestinal Pain|Gastrointestinal pain|Gastrointestinal pain	A disorder characterized by a sensation of marked discomfort in the gastrointestinal region.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143511>	C220596|C143172	Gastrointestinal Stoma Necrosis, CTCAE|Gastrointestinal Stoma Necrosis|Gastrointestinal stoma necrosis|Gastrointestinal stoma necrosis	A disorder characterized by a necrotic process occurring in the gastrointestinal tract stoma.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143512>	C220591|C146630	Gastroparesis, CTCAE|Gastroparesis|Gastroparesis|Gastroparesis	A disorder characterized by an incomplete paralysis of the muscles of the stomach wall resulting in delayed emptying of the gastric contents into the small intestine.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143513>	C220592|C143169	General Disorders and Administration Site Conditions - Other, Specify, CTCAE|General Disorders and Administration Site Conditions - Other|General disorders and administration site conditions - Other, specify|General disorders and administration site conditions - Other, specify	Other specified types of general disorders and administration site conditions.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143514>	C220599|C143175	Generalized Muscle Weakness, CTCAE|Generalized Muscle Weakness|Generalized muscle weakness|Generalized muscle weakness	A disorder characterized by a reduction in the strength of muscles in multiple anatomic sites.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143515>	C143180	Genital Edema, CTCAE|Genital Edema|Genital edema	A disorder characterized by swelling due to an excessive accumulation of fluid in the genitals.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143516>	C220597|C143173	GGT Increased, CTCAE|GGT Increased|GGT increased|GGT increased	A finding based on laboratory test results that indicate higher than normal levels of the enzyme gamma-glutamyltransferase in the blood specimen. GGT (gamma-glutamyltransferase ) catalyzes the transfer of a gamma glutamyl group from a gamma glutamyl peptide to another peptide, amino acids or water.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143518>	C220601|C143177	Glossopharyngeal Nerve Disorder, CTCAE|Glossopharyngeal Nerve Disorder|Glossopharyngeal nerve disorder|Glossopharyngeal nerve disorder	A disorder characterized by dysfunction of the glossopharyngeal nerve (ninth cranial nerve).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143519>	C143174	Glucose Intolerance, CTCAE|Glucose Intolerance|Glucose intolerance	A disorder characterized by an inability to properly metabolize glucose.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C14351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14351>	C14269	Positive Sense ssRNA Virus|+ Strand ssRNA Virus|Positive Strand ssRNA Virus|ssRNA Virus, (+) Strand	A single stranded RNA virus where the RNA strand has the same polarity as a mRNA.			Virus	
C143520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143520>	C220599|C143166	Growth Accelerated, CTCAE|Growth Accelerated|Growth accelerated|Growth accelerated	A disorder characterized by greater growth than expected for age.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143521>	C220597|C143173	Growth Hormone Abnormal, CTCAE|Growth Hormone Abnormal|Growth hormone abnormal|Growth hormone abnormal	A finding based on laboratory test results that indicate abnormal levels of growth hormone (GH) in a biological specimen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143522>	C220599|C143175	Growth Suppression, CTCAE|Growth Suppression|Growth suppression|Growth suppression	A disorder characterized by stature that is smaller than normal as expected for age.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143523>	C220595|C143171	Gum Infection, CTCAE|Gum Infection|Gum infection|Gum infection	A disorder characterized by an infectious process involving the gums.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143525>	C220603|C143187	Hallucinations, CTCAE|Hallucinations|Hallucinations|Hallucinations	A disorder characterized by a false sensory perception in the absence of an external stimulus.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143526>	C220597|C143173	Haptoglobin Decreased, CTCAE|Haptoglobin Decreased|Haptoglobin decreased|Haptoglobin decreased	A finding based on laboratory test results that indicate an decrease in levels of haptoglobin (HP) in a blood specimen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143527>	C220601|C143177	Headache, CTCAE|Headache|Headache|Headache	A disorder characterized by a sensation of marked discomfort in various parts of the head, not confined to the area of distribution of any nerve.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143528>	C220588|C143185	Hearing Impaired, CTCAE|Hearing Impaired|Hearing impaired|Hearing impaired	A disorder characterized by partial or complete loss of the ability to detect or understand sounds resulting from damage to ear structures.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143529>	C220586|C143165	Heart Failure, CTCAE|Heart Failure|Heart failure|Heart failure	A disorder characterized by the inability of the heart to pump blood at an adequate volume to meet tissue metabolic requirements, or, the ability to do so only at an elevation in the filling pressure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14352>	C14183	Consomic Strain|Chromosome Substitution Strain|Consomic Strain/Chromosome Substitution Strain	Strains derived by repeated backcrossing while maintaining one whole chromosome genetically different from the background strain. (JAX IMSR glossary)			Organism	
C143531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143531>	C220605|C143180	Hematosalpinx, CTCAE|Hematosalpinx|Hematosalpinx|Hematosalpinx	A disorder characterized by the presence of blood in a fallopian tube.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143532>	C220604|C143179	Hematuria, CTCAE|Hematuria|Hematuria|Hematuria|Hematuria (Priority 1)	A disorder characterized by laboratory test results that indicate blood in the urine.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C143533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143533>	C220597|C143173	Hemoglobin Increased, CTCAE|Hemoglobin Increased|Hemoglobin increased|Hemoglobin increased	A finding based on laboratory test results that indicate increased levels of hemoglobin (Hgb) above normal.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143536>	C220585|C143164	Hemolytic Uremic Syndrome, CTCAE|Hemolytic Uremic Syndrome|Hemolytic uremic syndrome|Hemolytic uremic syndrome	A disorder characterized by a form of thrombotic microangiopathy with renal failure, hemolytic anemia, and severe thrombocytopenia when the etiology is due to infections with shiga-toxin producing bacteria, such as E coli O157:H7.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143537>	C220591|C146630	Hemorrhoidal Hemorrhage, CTCAE|Hemorrhoidal Hemorrhage|Hemorrhoidal hemorrhage|Hemorrhoidal hemorrhage	A disorder characterized by bleeding from the hemorrhoids.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143539>	C220593|C143170	Hepatic Failure, CTCAE|Hepatic Failure|Hepatic failure|Hepatic failure	A disorder characterized by the inability of the liver to metabolize chemicals in the body. Laboratory test results reveal abnormal plasma levels of ammonia, bilirubin, lactic dehydrogenase, alkaline phosphatase, aminotransferase, and/or prolongation of prothrombin time (INR.) Drug-induced liver injury (DILI) as defined by Hy's Law.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14353>	C14354	Recombinants|recombinant	An individual cell or organisms which carries recombinant DNA			Organism	
C143540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143540>	C220593|C143170	Hepatic Hemorrhage, CTCAE|Hepatic Hemorrhage|Hepatic hemorrhage|Hepatic hemorrhage	A disorder characterized by bleeding from the liver.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143541>	C220595|C143171	Hepatic Infection, CTCAE|Hepatic Infection|Hepatic infection|Hepatic infection	A disorder characterized by an infectious process involving the liver.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143542>	C220593|C143170	Hepatic Pain, CTCAE|Hepatic Pain|Hepatic pain|Hepatic pain	A disorder characterized by a sensation of marked discomfort in the liver region.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143543>	C220595|C143171	Hepatitis Viral, CTCAE|Hepatitis Viral|Hepatitis viral|Hepatitis viral	A disorder characterized by a viral pathologic process involving the liver parenchyma.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143544>	C220593|C143170	Hepatobiliary Disorders - Other, Specify, CTCAE|Hepatobiliary Disorders - Other|Hepatobiliary disorders - Other, specify|Hepatobiliary disorders - Other, specify	Other specified types of hepatobiliary disorders.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143545>	C220606|C143181	Hiccups, CTCAE|Hiccups|Hiccups|Hiccups	A disorder characterized by repeated gulp sounds that result from an involuntary opening and closing of the glottis. This is attributed to a spasm of the diaphragm.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143546>	C143172	Hip Fracture, CTCAE|Hip Fracture|Hip fracture	A finding of traumatic injury to the hip in which the continuity of either the femoral head, femoral neck, intertrochanteric or subtrochanteric regions is broken.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143547>	C220607|C143182	Hirsutism, CTCAE|Hirsutism|Hirsutism|Hirsutism	A disorder characterized by the presence of excess hair growth in women in anatomic sites where growth is considered to be a secondary male characteristic and under androgen control (beard, moustache, chest, abdomen).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143548>	C220606|C143181	Hoarseness, CTCAE|Hoarseness|Hoarseness|Hoarseness	A disorder characterized by harsh and raspy voice arising from or spreading to the larynx.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143549>	C220610|C143183	Hot Flashes, CTCAE|Hot Flashes|Hot flashes|Hot flashes|Hot flashes (Priority 2)	A disorder characterized by an uncomfortable and temporary sensation of intense body warmth, flushing, sometimes accompanied by sweating upon cooling.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C14354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14354>	C14376	Laboratory Organism|Experimental Organism	A grouping of those organisms that are commonly used in laboratory research.			Organism	
C143551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143551>	C220598|C143174	Hypercalcemia, CTCAE|Hypercalcemia|Hypercalcemia|Hypercalcemia	A disorder characterized by laboratory test results that indicate an elevation in the concentration of calcium (corrected for albumin) in blood.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143552>	C143174	Hyperglycemia, CTCAE|Hyperglycemia|Hyperglycemia	A disorder characterized by laboratory test results that indicate an elevation in the concentration of blood sugar. It is usually an indication of diabetes mellitus or glucose intolerance.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143553>	C220607|C143182	Hyperhidrosis, CTCAE|Hyperhidrosis|Hyperhidrosis|Hyperhidrosis	A disorder characterized by excessive sweating.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143554>	C220598|C143174	Hyperkalemia, CTCAE|Hyperkalemia|Hyperkalemia|Hyperkalemia	A disorder characterized by laboratory test results that indicate an elevation in the concentration of potassium in the blood; associated with kidney failure or sometimes with the use of diuretic drugs.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143555>	C220598|C143174	Hypermagnesemia, CTCAE|Hypermagnesemia|Hypermagnesemia|Hypermagnesemia	A disorder characterized by laboratory test results that indicate an elevation in the concentration of magnesium in the blood.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143556>	C220598|C143174	Hypernatremia, CTCAE|Hypernatremia|Hypernatremia|Hypernatremia	A disorder characterized by laboratory test results that indicate an elevation in the concentration of sodium in the blood.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143557>	C220589|C143166	Hyperparathyroidism, CTCAE|Hyperparathyroidism|Hyperparathyroidism|Hyperparathyroidism	A disorder characterized by an increase in production of parathyroid hormone by the parathyroid glands. This results in hypercalcemia (abnormally high levels of calcium in the blood).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143558>	C220601|C143177	Hypersomnia, CTCAE|Hypersomnia|Hypersomnia|Hypersomnia	A disorder characterized by excessive sleepiness during the daytime.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14355>	C14316	Agents of Opportunistic Infection	Infectious agents, which while normally present but remaining benign under the control of the immune system, become virulent and pathogenic in immune-compromised hosts (i.e when they get the opportunity to become infectious).			Organism	
C143560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143560>	C220589|C143166	Hyperthyroidism, CTCAE|Hyperthyroidism|Hyperthyroidism|Hyperthyroidism	A disorder characterized by excessive levels of thyroid hormone in the body. Common causes include an overactive thyroid gland or thyroid hormone overdose.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143561>	C220607|C143182	Hypertrichosis, CTCAE|Hypertrichosis|Hypertrichosis|Hypertrichosis	A disorder characterized by hair density or length beyond the accepted limits of normal in a particular body region, for a particular age or race.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143562>	C220598|C143174	Hypertriglyceridemia, CTCAE|Hypertriglyceridemia|Hypertriglyceridemia|Hypertriglyceridemia	A disorder characterized by laboratory test results that indicate an elevation in the concentration of triglyceride concentration in the blood.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143563>	C220598|C143174	Hyperuricemia, CTCAE|Hyperuricemia|Hyperuricemia|Hyperuricemia	A disorder characterized by laboratory test results that indicate an elevation in the concentration of uric acid.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143564>	C220598|C143174	Hypoalbuminemia, CTCAE|Hypoalbuminemia|Hypoalbuminemia|Hypoalbuminemia	A disorder characterized by laboratory test results that indicate a low concentration of albumin in the blood.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143565>	C220598|C143174	Hypocalcemia, CTCAE|Hypocalcemia|Hypocalcemia|Hypocalcemia	A disorder characterized by laboratory test results that indicate a low concentration of calcium (corrected for albumin) in the blood.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143566>	C220601|C143177	Hypoglossal Nerve Disorder, CTCAE|Hypoglossal Nerve Disorder|Hypoglossal nerve disorder|Hypoglossal nerve disorder	A disorder characterized by dysfunction of the hypoglossal nerve (twelfth cranial nerve).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143567>	C220598|C143174	Hypoglycemia, CTCAE|Hypoglycemia|Hypoglycemia|Hypoglycemia	A condition characterized by laboratory test results that indicate a low concentration of glucose in the blood.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143568>	C220607|C143182	Hypohidrosis, CTCAE|Hypohidrosis|Hypohidrosis|Hypohidrosis	A disorder characterized by reduced sweating.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143569>	C220598|C143174	Hypokalemia, CTCAE|Hypokalemia|Hypokalemia|Hypokalemia	A disorder characterized by laboratory test results that indicate a low concentration of potassium in the blood.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14356>	C14316	Infectious Agent, Bacteria|Bacterial Infectious Agent				Bacterium	
C143570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143570>	C220598|C143174	Hypomagnesemia, CTCAE|Hypomagnesemia|Hypomagnesemia|Hypomagnesemia	A disorder characterized by laboratory test results that indicate a low concentration of magnesium in the blood.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143571>	C220598|C143174	Hyponatremia, CTCAE|Hyponatremia|Hyponatremia|Hyponatremia	A disorder characterized by laboratory test results that indicate a low concentration of sodium in the blood.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143572>	C220589|C143166	Hypoparathyroidism, CTCAE|Hypoparathyroidism|Hypoparathyroidism|Hypoparathyroidism	A disorder characterized by a decrease in production of parathyroid hormone by the parathyroid glands.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143573>	C220598|C143174	Hypophosphatemia, CTCAE|Hypophosphatemia|Hypophosphatemia|Hypophosphatemia	A disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143576>	C220589|C143166	Hypothyroidism, CTCAE|Hypothyroidism|Hypothyroidism|Hypothyroidism	A disorder characterized by a decrease in production of thyroid hormone by the thyroid gland.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143578>	C220591|C146630	Ileal Stenosis, CTCAE|Ileal Stenosis|Ileal stenosis|Ileal stenosis	A disorder characterized by a narrowing of the lumen of the ileum.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14357>	C14316	Infectious Agent, Virus|Viral Infectious Agent				Virus	
C143580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143580>	C220594|C143186	Immune System Disorders - Other, Specify, CTCAE|Immune System Disorders - Other|Immune system disorders - Other, specify|Immune system disorders - Other, specify	Other specified types of immune system disorders.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143581>	C220595|C143171	Infections and Infestations - Other, Specify, CTCAE|Infections and Infestations - Other|Infections and infestations - Other, specify|Infections and infestations - Other, specify	Other specified types of infections and infestations.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143582>	C220595|C143171	Infective Myositis, CTCAE|Infective Myositis|Infective myositis|Infective myositis	A disorder characterized by an infectious process involving the skeletal muscles.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143583>	C220596|C143172	Infusion Related Reaction, CTCAE|Infusion Related Reaction|Infusion related reaction|Infusion related reaction	A disorder characterized by adverse reaction to the infusion of pharmacological or biological substances.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143584>	C220592|C143169	Infusion Site Extravasation, CTCAE|Infusion Site Extravasation|Infusion site extravasation|Infusion site extravasation	A disorder characterized by leakage of the infusion into the surrounding tissue. Signs and symptoms may include induration, erythema, swelling, burning sensation and marked discomfort at the infusion site.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143585>	C220592|C143169	Injection Site Reaction, CTCAE|Injection Site Reaction|Injection site reaction|Injection site reaction	A disorder characterized by an intense adverse reaction (usually immunologic) developing at the site of an injection.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143586>	C220596|C143172	Injury To Carotid Artery, CTCAE|Injury to Carotid Artery|Injury to carotid artery|Injury to carotid artery	A finding of damage to the carotid artery.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143587>	C220596|C143172	Injury To Jugular Vein, CTCAE|Injury to Jugular Vein|Injury to jugular vein|Injury to jugular vein	A finding of damage to the jugular vein.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143588>	C220596|C143172	Injury To Superior Vena Cava, CTCAE|Injury to Superior Vena Cava|Injury to superior vena cava|Injury to superior vena cava	A finding of damage to the superior vena cava.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143589>	C220596|C143172	Injury, Poisoning and Procedural Complications - Other, Specify, CTCAE|Injury, Poisoning and Procedural Complications - Other|Injury, poisoning and procedural complications - Other, specify|Injury, poisoning and procedural complications - Other, specify	Other specified types of injury, poisoning and procedural complications.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14358>	C79106	Leporidae|Rabbits and Hares	Taxonomic family which includes rabbits and hares.			Mammal	
C143590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143590>	C220597|C143173	INR Increased, CTCAE|INR Increased|INR increased|INR increased	A finding based on laboratory test results that indicate an increase in the ratio of the patient's prothrombin time (PT) to a control sample in the blood.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143592>	C220596|C143172	Intestinal Stoma Leak, CTCAE|Intestinal Stoma Leak|Intestinal stoma leak|Intestinal stoma leak	A finding of leakage of contents from an intestinal stoma (surgically created opening on the surface of the body).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143593>	C220596|C143172	Intestinal Stoma Obstruction, CTCAE|Intestinal Stoma Obstruction|Intestinal stoma obstruction|Intestinal stoma obstruction	A disorder characterized by blockage of the normal flow of the contents of the intestinal stoma.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143594>	C220596|C143172	Intestinal Stoma Site Bleeding, CTCAE|Intestinal Stoma Site Bleeding|Intestinal stoma site bleeding|Intestinal stoma site bleeding	A disorder characterized by bleeding from the intestinal stoma.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143595>	C220591|C146630	Intra-Abdominal Hemorrhage, CTCAE|Intra-Abdominal Hemorrhage|Intra-abdominal hemorrhage|Intra-abdominal hemorrhage	A disorder characterized by bleeding in the abdominal cavity.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143596>	C143177	Intracranial Hemorrhage, CTCAE|Intracranial Hemorrhage|Intracranial hemorrhage	A disorder characterized by bleeding from the cranium.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143597>	C220596|C143172	Intraoperative Arterial Injury, CTCAE|Intraoperative Arterial Injury|Intraoperative arterial injury|Intraoperative arterial injury	A finding of damage to an artery during a surgical procedure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143598>	C220596|C143172	Intraoperative Breast Injury, CTCAE|Intraoperative Breast Injury|Intraoperative breast injury|Intraoperative breast injury	A finding of damage to the breast parenchyma during a surgical procedure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143599>	C220596|C143172	Intraoperative Cardiac Injury, CTCAE|Intraoperative Cardiac Injury|Intraoperative cardiac injury|Intraoperative cardiac injury	A finding of damage to the heart during a surgical procedure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14359>	C14228	Invertebrates, Land	Terrestrial animals without back bones			Eukaryote	
C1435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1435>	C798	Efaproxiral|2-(4-(((3,5-Dimethylanilino)Carbonyl)Methyl)Phenoxy)-2-Methylpropionic Acid|2-Dacmpp|EFAPROXIRAL|Efaproxyn|RSR-13|RSR13|RSR13|efaproxiral	A synthetic small molecule with radiosensitizing activity.  Efaproxiral increases oxygen levels in hypoxic tumor tissues by binding non-covalently to the hemoglobin tetramer and decreasing hemoglobin-oxygen binding affinity.  Increasing tumor oxygenation reduces tumor radioresistance. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C143600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143600>	C220596|C143172	Intraoperative Ear Injury, CTCAE|Intraoperative Ear Injury|Intraoperative ear injury|Intraoperative ear injury	A finding of damage to the ear during a surgical procedure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143601>	C220596|C143172	Intraoperative Endocrine Injury, CTCAE|Intraoperative Endocrine Injury|Intraoperative endocrine injury|Intraoperative endocrine injury	A finding of damage to the endocrine gland during a surgical procedure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143602>	C220596|C143172	Intraoperative Gastrointestinal Injury, CTCAE|Intraoperative Gastrointestinal Injury|Intraoperative gastrointestinal injury|Intraoperative gastrointestinal injury	A finding of damage to the gastrointestinal system during a surgical procedure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143603>	C220596|C143172	Intraoperative Head and Neck Injury, CTCAE|Intraoperative Head and Neck Injury|Intraoperative head and neck injury|Intraoperative head and neck injury	A finding of damage to the head and neck during a surgical procedure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143604>	C220596|C143172	Intraoperative Hemorrhage, CTCAE|Intraoperative Hemorrhage|Intraoperative hemorrhage|Intraoperative hemorrhage	A finding of uncontrolled bleeding during a surgical procedure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143605>	C220596|C143172	Intraoperative Hepatobiliary Injury, CTCAE|Intraoperative Hepatobiliary Injury|Intraoperative hepatobiliary injury|Intraoperative hepatobiliary injury	A finding of damage to the hepatic parenchyma and/or biliary tract during a surgical procedure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143606>	C220596|C143172	Intraoperative Musculoskeletal Injury, CTCAE|Intraoperative Musculoskeletal Injury|Intraoperative musculoskeletal injury|Intraoperative musculoskeletal injury	A finding of damage to the musculoskeletal system during a surgical procedure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143607>	C220596|C143172	Intraoperative Neurological Injury, CTCAE|Intraoperative Neurological Injury|Intraoperative neurological injury|Intraoperative neurological injury	A finding of damage to the nervous system during a surgical procedure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143608>	C220596|C143172	Intraoperative Ocular Injury, CTCAE|Intraoperative Ocular Injury|Intraoperative ocular injury|Intraoperative ocular injury	A finding of damage to the eye during a surgical procedure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143609>	C220596|C143172	Intraoperative Renal Injury, CTCAE|Intraoperative Renal Injury|Intraoperative renal injury|Intraoperative renal injury	A finding of damage to the kidney during a surgical procedure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14360>	C14333|C14228	Invertebrates, Marine	Animals without a backbone that live in the ocean			Eukaryote	
C143610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143610>	C220596|C143172	Intraoperative Reproductive Tract Injury, CTCAE|Intraoperative Reproductive Tract Injury|Intraoperative reproductive tract injury|Intraoperative reproductive tract injury	A finding of damage to the reproductive organs during a surgical procedure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143611>	C220596|C143172	Intraoperative Respiratory Injury, CTCAE|Intraoperative Respiratory Injury|Intraoperative respiratory injury|Intraoperative respiratory injury	A finding of damage to the respiratory system during a surgical procedure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143612>	C220596|C143172	Intraoperative Splenic Injury, CTCAE|Intraoperative Splenic Injury|Intraoperative splenic injury|Intraoperative splenic injury	A finding of damage to the spleen during a surgical procedure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143613>	C220596|C143172	Intraoperative Urinary Injury, CTCAE|Intraoperative Urinary Injury|Intraoperative urinary injury|Intraoperative urinary injury	A finding of damage to the urinary system during a surgical procedure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143614>	C220596|C143172	Intraoperative Venous Injury, CTCAE|Intraoperative Venous Injury|Intraoperative venous injury|Intraoperative venous injury	A finding of damage to a vein during a surgical procedure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143615>	C220597|C143173	Investigations - Other, Specify, CTCAE|Investigations - Other|Investigations - Other, specify|Investigations - Other, specify	Other specified types of investigations.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143617>	C220605|C143180	Irregular Menstruation, CTCAE|Irregular Menstruation|Irregular menstruation|Irregular menstruation	A disorder characterized by a change in cycle or duration of menses from baseline.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143618>	C220603|C143187	Irritability, CTCAE|Irritability|Irritability|Irritability	A disorder characterized by an abnormal responsiveness to stimuli or physiological arousal; may be in response to pain, fright, a drug, an emotional situation or a medical condition.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143619>	C143177	Ischemia Cerebrovascular, CTCAE|Ischemia Cerebrovascular|Ischemia cerebrovascular	A disorder characterized by a decrease or absence of blood supply to the brain caused by obstruction (thrombosis or embolism) of an artery resulting in neurological damage.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143622>	C220591|C146630	Jejunal Perforation, CTCAE|Jejunal Perforation|Jejunal perforation|Jejunal perforation	A disorder characterized by a rupture in the jejunal wall.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143623>	C220591|C146630	Jejunal Stenosis, CTCAE|Jejunal Stenosis|Jejunal stenosis|Jejunal stenosis	A disorder characterized by a narrowing of the lumen of the jejunum.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143626>	C220595|C143171	Joint Infection, CTCAE|Joint Infection|Joint infection|Joint infection	A disorder characterized by an infectious process involving a joint.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143627>	C220599|C143175	Joint Range of Motion Decreased Cervical Spine, CTCAE|Joint Range of Motion Decreased Cervical Spine|Joint range of motion decreased cervical spine|Joint range of motion decreased cervical spine	A disorder characterized by a decrease in flexibility of a cervical spine joint.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143628>	C220599|C143175	Joint Range of Motion Decreased Lumbar Spine, CTCAE|Joint Range of Motion Decreased Lumbar Spine|Joint range of motion decreased lumbar spine|Joint range of motion decreased lumbar spine	A disorder characterized by a decrease in flexibility of a lumbar spine joint.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143629>	C220599|C143175	Joint Range of Motion Decreased, CTCAE|Joint Range of Motion Decreased|Joint range of motion decreased|Joint range of motion decreased	A disorder characterized by a decrease in joint flexibility of any joint.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14362>	C14244	Friend Murine Leukemia Virus|CFV|Friend Leukemia Virus|Friend Leukemia Virus, Conventional	A murine leukemia virus producing leukemia of the reticulum-cell type with massive infiltration of liver, spleen, and bone marrow. It infects DBA/2 and Swiss mice.			Virus	
C143631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143631>	C220596|C143172	Kidney Anastomotic Leak, CTCAE|Kidney Anastomotic Leak|Kidney anastomotic leak|Kidney anastomotic leak	A finding of leakage of urine due to breakdown of a kidney anastomosis (surgical connection of two separate anatomic structures).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143632>	C220595|C143171	Kidney Infection, CTCAE|Kidney Infection|Kidney infection|Kidney infection	A disorder characterized by an infectious process involving the kidney.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143633>	C220599|C143175	Kyphosis, CTCAE|Kyphosis|Kyphosis|Kyphosis	A disorder characterized by an abnormal increase in the curvature of the thoracic portion of the spine.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143634>	C220605|C143180	Lactation Disorder, CTCAE|Lactation Disorder|Lactation disorder|Lactation disorder	A disorder characterized by disturbances of milk secretion. It is not necessarily related to pregnancy that is observed in females and can be observed in males.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143635>	C220596|C143172	Large Intestinal Anastomotic Leak, CTCAE|Large Intestinal Anastomotic Leak|Large intestinal anastomotic leak|Large intestinal anastomotic leak	A finding of leakage due to breakdown of an anastomosis (surgical connection of two separate anatomic structures) in the large intestine.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143636>	C220606|C143181	Laryngeal Edema, CTCAE|Laryngeal Edema|Laryngeal edema|Laryngeal edema	A disorder characterized by swelling due to an excessive accumulation of fluid in the larynx.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143637>	C220606|C143181	Laryngeal Inflammation, CTCAE|Laryngeal Inflammation|Laryngeal inflammation|Laryngeal inflammation	A disorder characterized by an inflammation involving the larynx.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143638>	C220606|C143181	Laryngeal Mucositis, CTCAE|Laryngeal Mucositis|Laryngeal mucositis|Laryngeal mucositis	A disorder characterized by ulceration or inflammation involving the mucous membrane of the larynx.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143639>	C220606|C143181	Laryngeal Obstruction, CTCAE|Laryngeal Obstruction|Laryngeal obstruction|Laryngeal obstruction	A disorder characterized by blockage of the laryngeal airway.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14363>	C14183	NSF/N Mice				Mammal	
C143640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143640>	C220606|C143181	Laryngeal Stenosis, CTCAE|Laryngeal Stenosis|Laryngeal stenosis|Laryngeal stenosis	A disorder characterized by a narrowing of the laryngeal airway.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143641>	C220595|C143171	Laryngitis, CTCAE|Laryngitis|Laryngitis|Laryngitis	A disorder characterized by an inflammatory process involving the larynx.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143642>	C220606|C143181	Laryngopharyngeal Dysesthesia, CTCAE|Laryngopharyngeal Dysesthesia|Laryngopharyngeal dysesthesia|Laryngopharyngeal dysesthesia	A disorder characterized by an uncomfortable persistent sensation in the area of the laryngopharynx.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143643>	C220606|C143181	Laryngospasm, CTCAE|Laryngospasm|Laryngospasm|Laryngospasm	A disorder characterized by paroxysmal spasmodic muscular contraction of the vocal cords.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143645>	C220601|C143177	Lethargy, CTCAE|Lethargy|Lethargy|Lethargy	A disorder characterized by a decrease in consciousness characterized by mental and physical inertness.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143646>	C220600|C143176	Leukemia Secondary To Oncology Chemotherapy, CTCAE|Leukemia Secondary to Oncology Chemotherapy|Leukemia secondary to oncology chemotherapy|Leukemia secondary to oncology chemotherapy	A disorder characterized by leukemia arising as a result of the mutagenic effect of chemotherapy agents.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143647>	C220585|C143164	Leukocytosis, CTCAE|Leukocytosis|Leukocytosis|Leukocytosis	A disorder characterized by laboratory test results that indicate an increased number of white blood cells in the blood.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143648>	C220601|C143177	Leukoencephalopathy, CTCAE|Leukoencephalopathy|Leukoencephalopathy|Leukoencephalopathy	A disorder characterized by diffuse reactive astrocytosis with multiple areas of necrotic foci without inflammation.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143649>	C220603|C143187	Libido Decreased, CTCAE|Libido Decrease (Priority 2)|Libido Decreased|Libido decreased|Libido decreased	A disorder characterized by a decrease in sexual desire.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C14364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14364>	C155871	Genital Herpes	Herpes simplex infection of the genitals, most commonly caused by the herpes simplex-2 virus.			Disease or Syndrome	NICHD Terminology|Pediatric Infectious Disease Terminology
C143650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143650>	C220603|C143187	Libido Increased, CTCAE|Libido Increased|Libido increased|Libido increased	A disorder characterized by an increase in sexual desire.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143651>	C220595|C143171	Lip Infection, CTCAE|Lip Infection|Lip infection|Lip infection	A disorder characterized by an infectious process involving the lips.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143652>	C220597|C143173	Lipase Increased, CTCAE|Lipase Increased|Lipase increased|Lipase increased	A finding based on laboratory test results that indicate an increase in the level of lipase in a biological specimen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143653>	C143182	Lipohypertrophy, CTCAE|Lipohypertrophy|Lipohypertrophy	A disorder characterized by hypertrophy of the subcutaneous adipose tissue at the site of multiple subcutaneous injections of insulin.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143654>	C220592|C143169	Localized Edema, CTCAE|Localized Edema|Localized edema|Localized edema	A disorder characterized by swelling due to excessive fluid accumulation at a specific anatomic site.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143655>	C220599|C143175	Lordosis, CTCAE|Lordosis|Lordosis|Lordosis	A disorder characterized by an abnormal increase in the curvature of the lumbar portion of the spine.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143656>	C146630	Lower Gastrointestinal Hemorrhage, CTCAE|Lower Gastrointestinal Hemorrhage|Lower gastrointestinal hemorrhage	A disorder characterized by bleeding from the lower gastrointestinal tract (small intestine, large intestine, and anus).			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143657>	C143171	Lung Infection, CTCAE|Lung Infection|Lung infection	A disorder characterized by an infectious process involving the lungs, including pneumonia.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143658>	C220595|C143171	Lymph Gland Infection, CTCAE|Lymph Gland Infection|Lymph gland infection|Lymph gland infection	A disorder characterized by an infectious process involving the lymph nodes.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143659>	C220610|C143183	Lymph Leakage, CTCAE|Lymph Leakage|Lymph leakage|Lymph leakage	A disorder characterized by the loss of lymph fluid into the surrounding tissue or body cavity.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14365>	C14183	Congenic Strain	Congenic strains are produced by transferring a mutation from one genetic background to a specific inbred strain through repeated backcrossing. The congenic strain and the inbred partner are expected to be identical at all loci except for the transferred locus and a linked segment of chromosome. The size of the segment and the possibility of transferred alleles on other chromosomes depend on the number of backcross generations. A strain is considered fully congenic after ten generations of backcrossing (N10). (from JAX Strain Information)			Organism	
C143660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143660>	C220610|C143183	Lymphedema, CTCAE|Lymphedema|Lymphedema|Lymphedema	A disorder characterized by excessive fluid collection in tissues that causes swelling.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143662>	C143173	Lymphocyte Count Decreased, CTCAE|Lymphocyte Count Decreased|Lymphocyte count decreased	A finding based on laboratory test results that indicate a decrease in number of lymphocytes in a blood specimen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143663>	C220597|C143173	Lymphocyte Count Increased, CTCAE|Lymphocyte Count Increased|Lymphocyte count increased|Lymphocyte count increased	A finding based on laboratory test results that indicate an abnormal increase in the number of lymphocytes in the blood, effusions or bone marrow.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143665>	C220592|C143169	Malaise, CTCAE|Malaise|Malaise|Malaise	A disorder characterized by a feeling of general discomfort or uneasiness, an out-of-sorts feeling.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143666>	C220603|C143187	Mania, CTCAE|Mania|Mania|Mania	A disorder characterized by excitement of psychotic proportions manifested by mental and physical hyperactivity, disorganization of behavior and elevation of mood.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143667>	C220595|C143171	Mediastinal Infection, CTCAE|Mediastinal Infection|Mediastinal infection|Mediastinal infection	A disorder characterized by an infectious process involving the mediastinum.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143669>	C220601|C143177	Meningismus, CTCAE|Meningismus|Meningismus|Meningismus	A disorder characterized by neck stiffness, headache, and photophobia resulting from irritation of the cerebral meninges.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14366>	C14225	Man|Human, Male	An adult, male human.			Population Group	
C143670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143670>	C220595|C143171	Meningitis, CTCAE|Meningitis|Meningitis|Meningitis	A disorder characterized by an infectious or inflammatory process of the meninges of the brain and/or spinal cord.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143671>	C220605|C143180	Menorrhagia, CTCAE|Menorrhagia|Menorrhagia|Menorrhagia	A disorder characterized by abnormally heavy vaginal bleeding during menses.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143672>	C220598|C143174	Metabolism and Nutrition Disorders - Other, Specify, CTCAE|Metabolism and Nutrition Disorders - Other|Metabolism and nutrition disorders - Other, specify|Metabolism and nutrition disorders - Other, specify	Other specified types of metabolism and nutrition disorders.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143673>	C220588|C143185	Middle Ear Inflammation, CTCAE|Middle Ear Inflammation|Middle ear inflammation|Middle ear inflammation	A disorder characterized by inflammation (physiologic response to irritation), swelling and redness to the middle ear.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143674>	C220586|C143165	Mitral Valve Disease, CTCAE|Mitral Valve Disease|Mitral valve disease|Mitral valve disease	A disorder characterized by a defect in mitral valve function or structure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143677>	C220601|C143177	Movements Involuntary, CTCAE|Movements Involuntary|Movements involuntary|Movements involuntary	A disorder characterized by uncontrolled and purposeless movements.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143678>	C220595|C143171	Mucosal Infection, CTCAE|Mucosal Infection|Mucosal infection|Mucosal infection	A disorder characterized by an infectious process involving a mucosal surface.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143679>	C220591|C146630	Mucositis Oral, CTCAE|Mucositis Oral|Mucositis oral|Mucositis oral	A disorder characterized by ulceration or inflammation of the oral mucosal.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14367>	C14349	Latent Virus	Virus integrated within host genome but inactive; may be reactivated by stress such as ultraviolet irradiation.			Virus	
C143680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143680>	C220592|C143169	Multi-Organ Failure, CTCAE|Multi-Organ Failure|Multi-organ failure|Multi-organ failure	A disorder characterized by progressive deterioration of the lungs, liver, kidney and clotting mechanisms.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143681>	C143177	Muscle Weakness Left-Sided, CTCAE|Muscle Weakness Left-Sided|Muscle weakness left-sided	A disorder characterized by a reduction in the strength of the muscles on the left side of the body.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143682>	C220599|C143175	Muscle Weakness Lower Limb, CTCAE|Muscle Weakness Lower Limb|Muscle weakness lower limb|Muscle weakness lower limb	A disorder characterized by a reduction in the strength of the lower limb muscles.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143683>	C143177	Muscle Weakness Right-Sided, CTCAE|Muscle Weakness Right-Sided|Muscle weakness right-sided	A disorder characterized by a reduction in the strength of the muscles on the right side of the body.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143684>	C220599|C143175	Muscle Weakness Trunk, CTCAE|Muscle Weakness Trunk|Muscle weakness trunk|Muscle weakness trunk	A disorder characterized by a reduction in the strength of the trunk muscles.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143685>	C220599|C143175	Muscle Weakness Upper Limb, CTCAE|Muscle Weakness Upper Limb|Muscle weakness upper limb|Muscle weakness upper limb	A disorder characterized by a reduction in the strength of the upper limb muscles.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143686>	C220599|C143175	Musculoskeletal and Connective Tissue Disorder - Other, Specify, CTCAE|Musculoskeletal and Connective Tissue Disorders - Other|Musculoskeletal and connective tissue disorder - Other, specify|Musculoskeletal and connective tissue disorder - Other, specify	Other specified types of musculoskeletal and connective tissue disorder.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143687>	C220599|C143175	Musculoskeletal Deformity, CTCAE|Musculoskeletal Deformity|Musculoskeletal deformity|Musculoskeletal deformity	A disorder characterized by an abnormality of the musculoskeletal system.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143688>	C220599|C143175	Myalgia, CTCAE|Myalgia|Myalgia|Myalgia	A disorder characterized by marked discomfort sensation originating from a muscle or group of muscles.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14368>	C14349	Lytic Virus	A virus which, as part of its life cycle, causes its host cells plasma membrane to rupture (to lyse).			Virus	
C143690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143690>	C220600|C143176	Myelodysplastic Syndrome, CTCAE|Myelodysplastic Syndrome|Myelodysplastic syndrome|Myelodysplastic syndrome	A disorder characterized by insufficiently healthy hematapoietic cell production by the bone marrow.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143691>	C143165	Myocardial Infarction, CTCAE|Myocardial Infarction|Myocardial infarction	A disorder characterized by gross necrosis of the myocardium; this is due to an interruption of blood supply to the area.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143694>	C220607|C143182	Nail Discoloration, CTCAE|Nail Discoloration|Nail discoloration|Nail discoloration	A disorder characterized by a change in the color of the nail plate.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143695>	C220595|C143171	Nail Infection, CTCAE|Nail Infection|Nail infection|Nail infection	A disorder characterized by an infectious process involving the nail.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143696>	C220607|C143182	Nail Loss, CTCAE|Nail Loss|Nail loss|Nail loss	A disorder characterized by loss of all or a portion of the nail.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143697>	C220607|C143182	Nail Ridging, CTCAE|Nail Ridging|Nail ridging|Nail ridging	A disorder characterized by vertical or horizontal ridges on the nails.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143698>	C220606|C143181	Nasal Congestion, CTCAE|Nasal Congestion|Nasal congestion|Nasal congestion	A disorder characterized by obstruction of the nasal passage due to mucosal edema.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14369>	C14376	Lower Organism|Lower Organisms	A subjective term that might be applied to any non-human organism.			Organism	
C1436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1436>	C67437|C1490	Baccatin III|BACCATIN III	A compound obtained from the needles of the Taxus baccata tree that is used as a precursor of paclitaxel.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C143700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143700>	C143169	Neck Edema, CTCAE|Neck Edema|Neck edema	A disorder characterized by swelling due to an accumulation of excessive fluid in the neck.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143701>	C220600|C143176	Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other, Specify, CTCAE|Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other|Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify|Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify	Other specified types of neoplasms benign, malignant and unspecified (incl cysts and polyps).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143702>	C220601|C143177	Nervous System Disorders - Other, Specify, CTCAE|Nervous System Disorders - Other|Nervous system disorders - Other, specify|Nervous system disorders - Other, specify	Other specified types of nervous system disorders.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143703>	C220601|C143177	Neuralgia, CTCAE|Neuralgia|Neuralgia|Neuralgia	A disorder characterized by intense painful sensation along a nerve or group of nerves.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143704>	C143173	Neutrophil Count Decreased, CTCAE|Neutrophil Count Decreased|Neutrophil count decreased	A finding based on laboratory test results that indicate a decrease in number of neutrophils in a blood specimen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143705>	C143167	Night Blindness, CTCAE|Night Blindness|Night blindness	A disorder characterized by an inability to see clearly in dim light.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143706>	C220605|C143180	Nipple Deformity, CTCAE|Nipple Deformity|Nipple deformity|Nipple deformity	A disorder characterized by an abnormality of the nipple.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143707>	C220592|C143169	Non-Cardiac Chest Pain, CTCAE|Non-Cardiac Chest Pain|Non-cardiac chest pain|Non-cardiac chest pain	A disorder characterized by a sensation of marked discomfort in the chest unrelated to a heart disorder.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14370>	C14316	Sexually Transmitted Agents				Organism	
C143710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143710>	C220591|C146630	Obstruction Gastric, CTCAE|Obstruction Gastric|Obstruction gastric|Obstruction gastric	A disorder characterized by blockage of the normal flow of the contents in the stomach.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143711>	C220601|C143177	Oculomotor Nerve Disorder, CTCAE|Oculomotor Nerve Disorder|Oculomotor nerve disorder|Oculomotor nerve disorder	A disorder characterized by dysfunction of the oculomotor nerve (third cranial nerve).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143712>	C220601|C143177	Olfactory Nerve Disorder, CTCAE|Olfactory Nerve Disorder|Olfactory nerve disorder|Olfactory nerve disorder	A disorder characterized by dysfunction of the olfactory nerve (first cranial nerve).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143713>	C220605|C143180	Oligospermia, CTCAE|Oligospermia|Oligospermia|Oligospermia	A disorder characterized by a decrease in the number of spermatozoa in the semen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143714>	C220590|C143167	Optic Nerve Disorder, CTCAE|Optic Nerve Disorder|Optic nerve disorder|Optic nerve disorder	A disorder characterized by involvement of the optic nerve (second cranial nerve).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143715>	C220591|C146630	Oral Cavity Fistula, CTCAE|Oral Cavity Fistula|Oral cavity fistula|Oral cavity fistula	A disorder characterized by an abnormal communication between the oral cavity and another organ or anatomic site.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143716>	C220591|C146630	Oral Dysesthesia, CTCAE|Oral Dysesthesia|Oral dysesthesia|Oral dysesthesia	A disorder characterized by a burning or tingling sensation on the lips, tongue or entire mouth.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143717>	C220599|C143175	Osteonecrosis of Jaw, CTCAE|Osteonecrosis of Jaw|Osteonecrosis of jaw|Osteonecrosis of jaw	A disorder characterized by a necrotic process occurring in the bone of the mandible.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143719>	C220595|C143171	Otitis Externa, CTCAE|Otitis Externa|Otitis externa|Otitis externa	A disorder characterized by an infectious process involving the outer ear and ear canal. Contributory factors include excessive water exposure (swimmer's ear infection) and cuts in the ear canal. Symptoms include fullness, itching, swelling and marked discomfort in the ear and ear drainage.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14371>	C14249	Oncornavirus|RNA Tumor Virus	An informal grouping of rna-containing viruses that are capable of inducing tumors.			Virus	
C143720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143720>	C220595|C143171	Otitis Media, CTCAE|Otitis Media|Otitis media|Otitis media	A disorder characterized by an infectious process involving the middle ear.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143721>	C220595|C143171	Ovarian Infection, CTCAE|Ovarian Infection|Ovarian infection|Ovarian infection	A disorder characterized by an infectious process involving the ovary.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143722>	C220605|C143180	Ovarian Rupture, CTCAE|Ovarian Rupture|Ovarian rupture|Ovarian rupture	A disorder characterized by tearing or disruption of the ovarian tissue.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143723>	C220599|C143175	Pain In Extremity, CTCAE|Pain in Extremity|Pain in extremity|Pain in extremity	A disorder characterized by a sensation of marked discomfort in the upper or lower extremities.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143724>	C220607|C143182	Pain of Skin, CTCAE|Pain of Skin|Pain of skin|Pain of skin	A disorder characterized by a sensation of marked discomfort in the skin.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143725>	C220592|C143169	Pain, CTCAE|Pain|Pain|Pain	A disorder characterized by the sensation of marked discomfort, distress or agony.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143726>	C220607|C143182	Palmar-Plantar Erythrodysesthesia Syndrome, CTCAE|Palmar-Plantar Erythrodysesthesia Syndrome|Palmar-plantar erythrodysesthesia syndrome|Palmar-plantar erythrodysesthesia syndrome	A disorder characterized by redness, marked discomfort, swelling, and tingling in the palms of the hands or the soles of the feet. Also known as Hand-Foot Syndrome.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143728>	C220595|C143171	Pancreas Infection, CTCAE|Pancreas Infection|Pancreas infection|Pancreas infection	A disorder characterized by an infectious process involving the pancreas.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143729>	C220596|C143172	Pancreatic Anastomotic Leak, CTCAE|Pancreatic Anastomotic Leak|Pancreatic anastomotic leak|Pancreatic anastomotic leak	A finding of leakage due to breakdown of a pancreatic anastomosis (surgical connection of two separate anatomic structures).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14372>	C14374|C14365	Inbred Recombinant Congenic Mouse Strains				Mammal	
C143730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143730>	C220591|C146630	Pancreatic Duct Stenosis, CTCAE|Pancreatic Duct Stenosis|Pancreatic duct stenosis|Pancreatic duct stenosis	A disorder characterized by a narrowing of the lumen of the pancreatic duct.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143731>	C143173	Pancreatic Enzymes Decreased, CTCAE|Pancreatic Enzymes Decreased|Pancreatic enzymes decreased	A finding based on laboratory test results that indicate an decrease in levels of pancreatic enzymes in a biological specimen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143732>	C220591|C146630	Pancreatic Necrosis, CTCAE|Pancreatic Necrosis|Pancreatic necrosis|Pancreatic necrosis	A disorder characterized by a necrotic process occurring in the pancreas.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143734>	C220590|C143167	Papilledema, CTCAE|Papilledema|Papilledema|Papilledema	A disorder characterized by swelling around the optic disc.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143735>	C143171	Papulopustular Rash, CTCAE|Papulopustular Rash|Papulopustular rash	A disorder characterized by an eruption consisting of papules (a small, raised pimple) and pustules (a small pus filled blister), typically appearing in face, scalp, and upper chest and back. Unlike acne, this rash does not present with whiteheads or blackheads, and can be symptomatic, with itchy or tender lesions.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143736>	C220601|C143177	Paresthesia, CTCAE|Paresthesia|Paresthesia|Paresthesia	A disorder characterized by functional disturbances of sensory neurons resulting in abnormal cutaneous sensations of tingling, numbness, pressure, cold, and/or warmth.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143737>	C220595|C143171	Paronychia, CTCAE|Paronychia|Paronychia|Paronychia	A disorder characterized by an infectious process involving the soft tissues around the nail.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143738>	C220586|C143165	Paroxysmal Atrial Tachycardia, CTCAE|Paroxysmal Atrial Tachycardia|Paroxysmal atrial tachycardia|Paroxysmal atrial tachycardia	A disorder characterized by a dysrhythmia with abrupt onset and sudden termination of atrial contractions with a rate of 150-250 beats per minute. The rhythm disturbance originates in the atria.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143739>	C220605|C143180	Pelvic Floor Muscle Weakness, CTCAE|Pelvic Floor Muscle Weakness|Pelvic floor muscle weakness|Pelvic floor muscle weakness	A disorder characterized by a reduction in the strength of the muscles of the pelvic floor.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14373>	C14352	Consomic Mouse Strain	Strains of mice derived by repeated backcrossing while maintaining one whole chromosome genetically different from the background strain. (JAX IMSR glossary)			Organism	
C143740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143740>	C220595|C143171	Pelvic Infection, CTCAE|Pelvic Infection|Pelvic infection|Pelvic infection	A disorder characterized by an infectious process involving the pelvic cavity.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143741>	C220595|C143171	Penile Infection, CTCAE|Penile Infection|Penile infection|Penile infection	A disorder characterized by an infectious process involving the penis.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143742>	C220593|C143170	Perforation Bile Duct, CTCAE|Perforation Bile Duct|Perforation bile duct|Perforation bile duct	A disorder characterized by a rupture in the wall of the extrahepatic or intrahepatic bile duct.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143743>	C220586|C143165	Pericardial Effusion, CTCAE|Pericardial Effusion|Pericardial effusion|Pericardial effusion	A disorder characterized by fluid collection within the pericardial sac, usually due to inflammation.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143744>	C220586|C143165	Pericardial Tamponade, CTCAE|Pericardial Tamponade|Pericardial tamponade|Pericardial tamponade	A disorder characterized by an increase in intrapericardial pressure due to the collection of blood or fluid in the pericardium.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143747>	C220590|C143167	Periorbital Edema, CTCAE|Periorbital Edema|Periorbital edema|Periorbital edema	A disorder characterized by swelling due to an excessive accumulation of fluid around the orbits of the face.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143748>	C220595|C143171	Periorbital Infection, CTCAE|Periorbital Infection|Periorbital infection|Periorbital infection	A disorder characterized by an infectious process near or around the orbit of the eye.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143749>	C220610|C143183	Peripheral Ischemia, CTCAE|Peripheral Ischemia|Peripheral ischemia|Peripheral ischemia	A disorder characterized by impaired circulation to an extremity.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14374>	C14183	Recombinant Inbred Strain	Recombinant inbred (RI) strains are derived by systematic inbreeding from the cross of two pre-existing progenitor strains. (from JAX Strain Information)			Organism	
C143750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143750>	C220601|C143177	Peripheral Motor Neuropathy, CTCAE|Peripheral Motor Neuropathy|Peripheral motor neuropathy|Peripheral motor neuropathy	A disorder characterized by damage or dysfunction of the peripheral motor nerves.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143751>	C220595|C143171	Peripheral Nerve Infection, CTCAE|Peripheral Nerve Infection|Peripheral nerve infection|Peripheral nerve infection	A disorder characterized by an infectious process involving the peripheral nerves.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143752>	C220601|C143177	Peripheral Sensory Neuropathy, CTCAE|Peripheral Sensory Neuropathy|Peripheral sensory neuropathy|Peripheral sensory neuropathy	A disorder characterized by damage or dysfunction of the peripheral sensory nerves.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143753>	C220595|C143171	Peritoneal Infection, CTCAE|Peritoneal Infection|Peritoneal infection|Peritoneal infection	A disorder characterized by an infectious process involving the peritoneum.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143754>	C220603|C143187	Personality Change, CTCAE|Personality Change|Personality change|Personality change	A disorder characterized by a conspicuous change in a person's behavior and thinking.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143755>	C220596|C143172	Pharyngeal Anastomotic Leak, CTCAE|Pharyngeal Anastomotic Leak|Pharyngeal anastomotic leak|Pharyngeal anastomotic leak	A finding of leakage due to breakdown of a pharyngeal anastomosis (surgical connection of two separate anatomic structures).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143756>	C220606|C143181	Pharyngeal Mucositis, CTCAE|Pharyngeal Mucositis|Pharyngeal mucositis|Pharyngeal mucositis	A disorder characterized by ulceration or inflammation involving the mucous membrane of the pharynx.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143757>	C220606|C143181	Pharyngeal Stenosis, CTCAE|Pharyngeal Stenosis|Pharyngeal stenosis|Pharyngeal stenosis	A disorder characterized by a narrowing of the pharyngeal airway.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143758>	C220595|C143171	Pharyngitis, CTCAE|Pharyngitis|Pharyngitis|Pharyngitis	A disorder characterized by inflammation of the throat.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143759>	C220606|C143181	Pharyngolaryngeal Pain, CTCAE|Pharyngolaryngeal Pain|Pharyngolaryngeal pain|Pharyngolaryngeal pain	A disorder characterized by a sensation of marked discomfort in the pharyngolaryngeal region.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14375>	C14349	Escape Mutant	HIV mutants which have overcome drug inhibition.			Virus	
C143760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143760>	C220595|C143171	Phlebitis Infective, CTCAE|Phlebitis Infective|Phlebitis infective|Phlebitis infective	A disorder characterized by an infectious process involving the vein. Clinical manifestations include erythema, marked discomfort, swelling, and induration along the course of the infected vein.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143761>	C220610|C143183	Phlebitis, CTCAE|Phlebitis|Phlebitis|Phlebitis	A disorder characterized by inflammation of the wall of a peripheral vein associated with an intravenous line.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143764>	C143173	Platelet Count Decreased, CTCAE|Platelet Count Decreased|Platelet count decreased	A finding based on laboratory test results that indicate a decrease in number of platelets in a blood specimen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143765>	C220606|C143181	Pleural Effusion, CTCAE|Pleural Effusion|Pleural effusion|Pleural effusion	A disorder characterized by an increase in amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough and marked chest discomfort.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143766>	C220595|C143171	Pleural Infection, CTCAE|Pleural Infection|Pleural infection|Pleural infection	A disorder characterized by an infectious process involving the pleura.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143767>	C220606|C143181	Pneumonitis, CTCAE|Pneumonitis|Pneumonitis|Pneumonitis	A disorder characterized by inflammation focally or diffusely affecting the lung parenchyma.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143769>	C220593|C143170	Portal Hypertension, CTCAE|Portal Hypertension|Portal hypertension|Portal hypertension	A disorder characterized by an increase in blood pressure in the portal venous system.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14376>	C14250	Other Organism Groupings	A non-taxonomic grouping of organisms based on a shared characteristic.			Classification	
C143770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143770>	C220593|C143170	Portal Vein Thrombosis, CTCAE|Portal Vein Thrombosis|Portal vein thrombosis|Portal vein thrombosis	A disorder characterized by the formation of a thrombus (blood clot) in the portal vein.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143771>	C220606|C143181	Postnasal Drip, CTCAE|Postnasal Drip|Postnasal drip|Postnasal drip	A disorder characterized by excessive mucous secretion in the back of the nasal cavity or throat, causing sore throat and/or coughing.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143772>	C220596|C143172	Postoperative Hemorrhage, CTCAE|Postoperative Hemorrhage|Postoperative hemorrhage|Postoperative hemorrhage	A disorder characterized by bleeding occurring after a surgical procedure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143773>	C220596|C143172	Postoperative Thoracic Procedure Complication, CTCAE|Postoperative Thoracic Procedure Complication|Postoperative thoracic procedure complication|Postoperative thoracic procedure complication	A finding of a previously undocumented problem that occurs after a thoracic procedure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143775>	C220602|C143178	Pregnancy, Puerperium and Perinatal Conditions - Other, Specify, CTCAE|Pregnancy, Puerperium and Perinatal Conditions - Other|Pregnancy, puerperium and perinatal conditions - Other, specify|Pregnancy, puerperium and perinatal conditions - Other, specify	Other specified types of pregnancy, puerperium and perinatal conditions.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143776>	C220602|C143178	Premature Delivery, CTCAE|Premature Delivery|Premature delivery|Premature delivery	A disorder characterized by delivery of a viable infant before the normal end of gestation. Typically, viability is achievable between the twentieth and thirty-seventh week of gestation.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143777>	C143180	Premature Menopause, CTCAE|Premature Menopause|Premature menopause	A disorder characterized by premature ovarian failure. Symptoms may include hot flashes, night sweats, mood swings, and a decrease in sex drive. Laboratory findings include elevated luteinizing hormone (LH) and follicle-stimulating hormone (FSH.)			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143778>	C220601|C143177	Presyncope, CTCAE|Presyncope|Presyncope|Presyncope	A disorder characterized by an episode of lightheadedness and dizziness which may precede an episode of syncope.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14377>	C44391|C14226	Human Papillomavirus-18|18|HPV 18|HPV Genotype 18|HPV-18|HPV-18|HPV18|HPV18|HUMAN PAPILLOMAVIRUS TYPE 18|Human Papillomavirus Genotype 18|Human Papillomavirus Type 18|Human Papillomavirus Type 18	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce skin and mucosal epithelial lesions. Human papillomavirus-18 (HPV18) has been directly linked to cervical cancer and plays a role in the pathogenesis of the disease. The virus integrates its DNA at specific chromosomal locations, such as 8q24 and 12q15. The use of molecular markers for HPV18 infection may allow the identification of patients with early stage cervical cancer and those at high risk for disease recurrence.	Human Papillomavirus Type 18		Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|NICHD Terminology|Pediatric Immunization Terminology
C143780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143780>	C220606|C143181	Productive Cough, CTCAE|Productive Cough|Productive cough|Productive cough	A disorder characterized by expectorated secretions upon coughing.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143781>	C220596|C143172	Prolapse of Intestinal Stoma, CTCAE|Prolapse of Intestinal Stoma|Prolapse of intestinal stoma|Prolapse of intestinal stoma	A finding of protrusion of the intestinal stoma (surgically created opening on the surface of the body) above the abdominal surface.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143782>	C220596|C143172	Prolapse of Urostomy, CTCAE|Prolapse of Urostomy|Prolapse of urostomy|Prolapse of urostomy	A finding of displacement of the urostomy.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143783>	C220595|C143171	Prostate Infection, CTCAE|Prostate Infection|Prostate infection|Prostate infection	A disorder characterized by an infectious process involving the prostate gland.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143784>	C220605|C143180	Prostatic Obstruction, CTCAE|Prostatic Obstruction|Prostatic obstruction|Prostatic obstruction	A disorder characterized by compression of the urethra secondary to enlargement of the prostate gland. This results in voiding difficulties (straining to void, slow urine stream, and incomplete emptying of the bladder).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143787>	C220603|C143187	Psychiatric Disorders - Other, Specify, CTCAE|Psychiatric Disorders - Other|Psychiatric disorders - Other, specify|Psychiatric disorders - Other, specify	Other specified types of psychiatric disorders.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143788>	C220603|C143187	Psychosis, CTCAE|Psychosis|Psychosis|Psychosis	A disorder characterized by personality change, impaired functioning, and loss of touch with reality. It may be a manifestation of schizophrenia, bipolar disorder or brain tumor.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143789>	C220606|C143181	Pulmonary Edema, CTCAE|Pulmonary Edema|Pulmonary edema|Pulmonary edema	A disorder characterized by accumulation of fluid in the lung tissues that causes a disturbance of the gas exchange that may lead to respiratory failure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14378>	C86013	Propionibacterium acnes|Bacillus acnes|Bacillus acnes|C. parvum|CP|CPAR|CPARV|CParv|Corynebacterium acnes|Corynebacterium acnes|Corynebacterium parvum|Corynebacterium parvum|Cutibacterium acnes|PROPIONIBACTERIUM ACNES|PROPIONIBACTERIUM ACNES	A species of relatively slow growing, typically aerotolerant, anaerobic Gram-positive bacteria in the phylum Actinobacteria.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C143790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143790>	C220606|C143181	Pulmonary Fibrosis, CTCAE|Pulmonary Fibrosis|Pulmonary fibrosis|Pulmonary fibrosis	A disorder characterized by the replacement of the lung tissue by connective tissue, leading to progressive dyspnea, respiratory failure or right heart failure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143791>	C220606|C143181	Pulmonary Fistula, CTCAE|Pulmonary Fistula|Pulmonary fistula|Pulmonary fistula	A disorder characterized by an abnormal communication between the lung and another organ or anatomic site.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143793>	C220586|C143165	Pulmonary Valve Disease, CTCAE|Pulmonary Valve Disease|Pulmonary valve disease|Pulmonary valve disease	A disorder characterized by a defect in pulmonary valve function or structure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143794>	C220607|C143182	Purpura, CTCAE|Purpura|Purpura|Purpura	A disorder characterized by hemorrhagic areas of the skin and mucous membrane. Newer lesions appear reddish in color. Older lesions are usually a darker purple color and eventually become a brownish-yellow color.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143795>	C220601|C143177	Pyramidal Tract Syndrome, CTCAE|Pyramidal Tract Syndrome|Pyramidal tract syndrome|Pyramidal tract syndrome	A disorder characterized by dysfunction of the corticospinal (pyramidal) tracts of the spinal cord. Symptoms include an increase in the muscle tone in the lower extremities, hyperreflexia, positive Babinski and a decrease in fine motor coordination.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143796>	C220596|C143172	Radiation Recall Reaction (Dermatologic), CTCAE|Radiation Recall Reaction (Dermatologic)|Radiation recall reaction (dermatologic)|Radiation recall reaction (dermatologic)	A finding of acute skin inflammatory reaction caused by drugs, especially chemotherapeutic agents, for weeks or months following radiotherapy. The inflammatory reaction is confined to the previously irradiated skin and the symptoms disappear after the removal of the pharmaceutical agent.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143797>	C220601|C143177	Radiculitis, CTCAE|Radiculitis|Radiculitis|Radiculitis	A disorder characterized by inflammation involving a nerve root. Patients experience marked discomfort radiating along a nerve path because of spinal pressure on the connecting nerve root.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143798>	C143182	Rash Acneiform, CTCAE|Rash Acneiform|Rash acneiform	A disorder characterized by an eruption of papules and pustules, typically appearing in face, scalp, upper chest and back.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143799>	C143182	Rash Maculo-Papular, CTCAE|Rash Maculo-Papular|Rash maculo-papular	A disorder characterized by the presence of macules (flat) and papules (elevated). Also known as morbillform rash, it is one of the most common cutaneous adverse events, frequently affecting the upper trunk, spreading centripetally and associated with pruritis.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C14379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14379>	C14336	Viscum album|European Mistletoe|Mistletoe|VISCUM ALBUM WHOLE|mistletoe	An evergreen parasitic plant, "European mistletoe", with waxy white berries and smooth-edged oval leaves in pairs along the woody stem.  The extract is being studied for its potential use in cancer treatment.			Plant	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C1437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1437>	C1941	Recombinant CD40-Ligand|CD154 antigen|CD40L|T-BAM|T-Cell Antigen gp39|TNF-Related Activation Protein|TRAP Ligand|gp39|rhu CD40L	A recombinant therapeutic agent which is chemically identical to or similar to CD40-ligand. CD40-ligand, also known as CD40L/TRAP and CD154, is a type II membrane protein which binds to CD40, a cell surface receptor that belongs to the tumor necrosis factor receptor family; CD40 is expressed on B lymphocytes, monocytes, dendritic cells (DC), hematopoietic progenitors, endothelial cells and epithelial cells. Recombinant CD40-ligand may be used to activate DC ex vivo via CD40 binding; CD40-ligand-activated DC may provide or augment a protective antitumor immunity when administered in dendritic cell cancer vaccines. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C143800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143800>	C220595|C143171	Rash Pustular, CTCAE|Rash Pustular|Rash pustular|Rash pustular	A disorder characterized by a circumscribed and elevated skin lesion filled with pus.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143801>	C220596|C143172	Rectal Anastomotic Leak, CTCAE|Rectal Anastomotic Leak|Rectal anastomotic leak|Rectal anastomotic leak	A finding of leakage due to breakdown of a rectal anastomosis (surgical connection of two separate anatomic structures).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143802>	C220591|C146630	Rectal Mucositis, CTCAE|Rectal Mucositis|Rectal Mucositis (Priority 2)|Rectal mucositis|Rectal mucositis	A disorder characterized by ulceration or inflammation of the mucous membrane of the rectum.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C143803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143803>	C220591|C146630	Rectal Stenosis, CTCAE|Rectal Stenosis|Rectal Stenosis (Priority 2)|Rectal stenosis|Rectal stenosis	A disorder characterized by a narrowing of the lumen of the rectum.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C143804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143804>	C220601|C143177	Recurrent Laryngeal Nerve Palsy, CTCAE|Recurrent Laryngeal Nerve Palsy|Recurrent laryngeal nerve palsy|Recurrent laryngeal nerve palsy	A disorder characterized by paralysis of the recurrent laryngeal nerve.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143805>	C220604|C143179	Renal and Urinary Disorders - Other, Specify, CTCAE|Renal and Urinary Disorders - Other|Renal and urinary disorders - Other, specify|Renal and urinary disorders - Other, specify	Other specified types of renal and urinary disorders.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143806>	C220604|C143179	Renal Calculi, CTCAE|Renal Calculi|Renal calculi|Renal calculi	A disorder characterized by the formation of crystals/kidney stones in the pelvis of the kidney.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143807>	C220604|C143179	Renal Colic, CTCAE|Renal Colic|Renal colic|Renal colic	A disorder characterized by paroxysmal and severe flank marked discomfort radiating to the inguinal area. Often, the cause is the passage of crystals/kidney stones.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143808>	C220605|C143180	Reproductive System and Breast Disorders - Other, Specify, CTCAE|Reproductive System and Breast Disorders - Other|Reproductive system and breast disorders - Other, specify|Reproductive system and breast disorders - Other, specify	Other specified types of reproductive system and breast disorders.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143809>	C220606|C143181	Respiratory Failure, CTCAE|Respiratory Failure|Respiratory failure|Respiratory failure	A disorder characterized by impaired gas exchange by the respiratory system resulting in hypoxia and a decrease in oxygenation of the tissues that may be associated with an increase in arterial levels of carbon dioxide.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14380>	C15172	WN, Rat Strain|WN	Anterior pituitary tumors nearly 100% in females over 18 months of age, pheochromocytomas or preneoplastic nodules in adrenal medulla about 40% in males, granulocytic leukemia 14% in animals over 18 months of age. Rarely show hyperplastic cortical nodules or adrenal cortical adenomas. High incidence of severe chronic nephritis. (Snell 1967). High 10-week body weight in males (19/23), and high relative heart weight in 10-week old males (19/23) (Tanase et al 1982).			Mammal	
C143810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143810>	C220606|C143181	Respiratory, Thoracic and Mediastinal Disorders - Other, Specify, CTCAE|Respiratory, Thoracic and Mediastinal Disorders - Other|Respiratory, thoracic and mediastinal disorders - Other, specify|Respiratory, thoracic and mediastinal disorders - Other, specify	Other specified types of respiratory, thoracic and mediastinal disorders.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143811>	C220603|C143187	Restlessness, CTCAE|Restlessness|Restlessness|Restlessness	A disorder characterized by an inability to rest, relax or be still.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143814>	C220590|C143167	Retinal Tear, CTCAE|Retinal Tear|Retinal tear|Retinal tear	A disorder characterized by a small laceration of the retina. Symptoms include flashes and floaters.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143815>	C220590|C143167	Retinal Vascular Disorder, CTCAE|Retinal Vascular Disorder|Retinal vascular disorder|Retinal vascular disorder	A disorder characterized by pathological retinal blood vessels that adversely affects vision.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143818>	C220601|C143177	Reversible Posterior Leukoencephalopathy Syndrome, CTCAE|Reversible Posterior Leukoencephalopathy Syndrome|Reversible posterior leukoencephalopathy syndrome|Reversible posterior leukoencephalopathy syndrome	A disorder characterized by headaches, mental status changes, visual disturbances, and/or seizures associated with imaging findings of posterior leukoencephalopathy. It has been observed in association with hypertensive encephalopathy, eclampsia, and immunosuppressive and cytotoxic drug treatment. It is an acute or subacute reversible condition. Also known as posterior reversible encephalopathy syndrome (PRES).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143819>	C220595|C143171	Rhinitis Infective, CTCAE|Rhinitis Infective|Rhinitis infective|Rhinitis infective	A disorder characterized by an infectious process involving the nasal mucosal.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14381>	C15172	SD/Rij, Rat Strain	Less sensitive to the induction of mammary tumors by DMBA than two samples of outbred Sprague-Dawley rats; mean life-span 743-22 days.			Mammal	
C143821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143821>	C220591|C146630	Salivary Duct Inflammation, CTCAE|Salivary Duct Inflammation|Salivary duct inflammation|Salivary duct inflammation	A disorder characterized by inflammation of the salivary duct.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143822>	C220595|C143171	Salivary Gland Infection, CTCAE|Salivary Gland Infection|Salivary gland infection|Salivary gland infection	A disorder characterized by an infectious process involving the salivary gland.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143823>	C220590|C143167	Scleral Disorder, CTCAE|Scleral Disorder|Scleral disorder|Scleral disorder	A disorder characterized by involvement of the sclera of the eye.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143824>	C220599|C143175	Scoliosis, CTCAE|Scoliosis|Scoliosis|Scoliosis	A disorder characterized by a lateral curvature of the spine.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143825>	C220595|C143171	Scrotal Infection, CTCAE|Scrotal Infection|Scrotal infection|Scrotal infection	A disorder characterized by an infectious process involving the scrotum.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143827>	C220595|C143171	Sepsis, CTCAE|Sepsis|Sepsis|Sepsis	A disorder characterized by the presence of pathogenic microorganisms in the blood stream that cause varying degrees of organ dysfunction due to a dysregulated host response to infection.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143829>	C220597|C143173	Serum Amylase Increased, CTCAE|Serum Amylase Increased|Serum amylase increased|Serum amylase increased	A finding based on laboratory test results that indicate an increase in the levels of amylase in a serum specimen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14382>	C15172	OM, Rat Strain	Spontaneous thyroid carcinoma 33% (Lindsey et al 1968). Adrenal cortical tumors 94% and pituitary tumors 8-18% at 18 months (Hansen et al 1973). In animals over 18 months Snell found adenomas or carcinomas of adrenal cortex 73% in males and 95% in females, pituitary tumors 25%, granulosa cell tumors of the ovary 33% in females. High blood pressure (3/23), reaching 154+/-1.0 (SEM) mmHg at 10 weeks of age (Tanase et al 1982). Mammary tumors 26-30%. High incidence of retinal degeneration in animals over 10 months (von Sallman and Grimes 1972, 1974). High systolic blood pressure (2/17) (Hansen et al 1973).			Mammal	
C143831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143831>	C220606|C143181	Sinus Disorder, CTCAE|Sinus Disorder|Sinus disorder|Sinus disorder	A disorder characterized by involvement of the paranasal sinuses.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143832>	C220595|C143171	Sinusitis, CTCAE|Sinusitis|Sinusitis|Sinusitis	A disorder characterized by an infectious process involving the mucous membranes of the paranasal sinuses.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143833>	C220607|C143182	Skin and Subcutaneous Tissue Disorders - Other, Specify, CTCAE|Skin and Subcutaneous Tissue Disorders - Other|Skin and subcutaneous tissue disorders - Other, specify|Skin and subcutaneous tissue disorders - Other, specify	Other specified types of skin and subcutaneous tissue disorders.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143835>	C220607|C143182	Skin Hyperpigmentation, CTCAE|Skin Hyperpigmentation|Skin hyperpigmentation|Skin hyperpigmentation	A disorder characterized by darkening of the skin due to excessive melanin deposition.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143836>	C220607|C143182	Skin Hypopigmentation, CTCAE|Skin Hypopigmentation|Skin hypopigmentation|Skin hypopigmentation	A disorder characterized by loss of skin pigment (e.g., vitiligo).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143837>	C220607|C143182	Skin Induration, CTCAE|Skin Induration|Skin induration|Skin induration	A disorder characterized by an area of hardness in the skin.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143838>	C220595|C143171	Skin Infection, CTCAE|Skin Infection|Skin infection|Skin infection	A disorder characterized by an infectious process involving the skin such as cellulitis.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143839>	C220607|C143182	Skin Ulceration, CTCAE|Skin Ulceration|Skin ulceration|Skin ulceration	A disorder characterized by a circumscribed, erosive lesion on the skin.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14383>	C15172	LOU/C, Rat Strain	Develop spontaneous plasmacytomas after about 8 months of age, with an incidence of about 30% in males and 16% in females. These develop rapidly, and may be detected by palpation. They usually develop in the ileocoecal lymph nodes, and about 60% of them synthesis monoclonal immunoglobulins (Bence-Jones proteins) of IgG1 (35%), IgE (36%) or IgA classes.			Mammal	
C143840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143840>	C220606|C143181	Sleep Apnea, CTCAE|Sleep Apnea|Sleep apnea|Sleep apnea	A disorder characterized by cessation of breathing for short periods during sleep.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143841>	C220596|C143172	Small Intestinal Anastomotic Leak, CTCAE|Small Intestinal Anastomotic Leak|Small intestinal anastomotic leak|Small intestinal anastomotic leak	A finding of leakage due to breakdown of an anastomosis (surgical connection of two separate anatomic structures) in the small bowel.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143842>	C220591|C146630	Small Intestinal Mucositis, CTCAE|Small Intestinal Mucositis|Small intestinal mucositis|Small intestinal mucositis	A disorder characterized by ulceration or inflammation of the mucous membrane of the small intestine.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143843>	C220591|C146630	Small Intestinal Obstruction, CTCAE|Small Intestinal Obstruction|Small intestinal obstruction|Small intestinal obstruction	A disorder characterized by blockage of the normal flow of the intestinal contents of the small intestine.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143844>	C220591|C146630	Small Intestinal Stenosis, CTCAE|Small Intestinal Stenosis|Small intestinal stenosis|Small intestinal stenosis	A disorder characterized by a narrowing of the lumen of the small intestine.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143845>	C220595|C143171	Small Intestine Infection, CTCAE|Small Intestine Infection|Small intestine infection|Small intestine infection	A disorder characterized by an infectious process involving the small intestine.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143846>	C220591|C146630	Small Intestine Ulcer, CTCAE|Small Intestine Ulcer|Small intestine ulcer|Small intestine ulcer	A disorder characterized by a circumscribed, erosive lesion on the mucosal surface of the small intestine.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143847>	C220606|C143181	Sneezing, CTCAE|Sneezing|Sneezing|Sneezing	A disorder characterized by the involuntary expulsion of air from the nose.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143848>	C220608|C143188	Social Circumstances - Other, Specify, CTCAE|Social Circumstances - Other|Social circumstances - Other, specify|Social circumstances - Other, specify	Other specified types of social circumstances.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143849>	C220595|C143171	Soft Tissue Infection, CTCAE|Soft Tissue Infection|Soft tissue infection|Soft tissue infection	A disorder characterized by an infectious process involving soft tissues.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14384>	C15172	HMT, Rat Strain	About 50% incidence of squamous-cell carcinoma of the mouth late in life. Mean life-span 27-30 months with or without mouth tumors (Hulse 1979, Buckley et al 1980).			Mammal	
C143850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143850>	C220599|C143175	Soft Tissue Necrosis Lower Limb, CTCAE|Soft Tissue Necrosis Lower Limb|Soft tissue necrosis lower limb|Soft tissue necrosis lower limb	A disorder characterized by a necrotic process occurring in the soft tissues of the lower extremity.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143851>	C220599|C143175	Soft Tissue Necrosis Upper Limb, CTCAE|Soft Tissue Necrosis Upper Limb|Soft tissue necrosis upper limb|Soft tissue necrosis upper limb	A disorder characterized by a necrotic process occurring in the soft tissues of the upper extremity.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143852>	C220601|C143177	Somnolence, CTCAE|Somnolence|Somnolence|Somnolence	A disorder characterized by characterized by excessive sleepiness and drowsiness.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143853>	C220606|C143181	Sore Throat, CTCAE|Sore Throat|Sore throat|Sore throat	A disorder characterized by marked discomfort in the throat.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143854>	C220601|C143177	Spasticity, CTCAE|Spasticity|Spasticity|Spasticity	A disorder characterized by increased involuntary muscle tone that affects the regions interfering with voluntary movement. It results in gait, movement, and speech disturbances.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143855>	C220596|C143172	Spermatic Cord Anastomotic Leak, CTCAE|Spermatic Cord Anastomotic Leak|Spermatic cord anastomotic leak|Spermatic cord anastomotic leak	A finding of leakage due to breakdown of a spermatic cord anastomosis (surgical connection of two separate anatomic structures).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143856>	C143172	Spinal Fracture, CTCAE|Spinal Fracture|Spinal fracture	A finding of traumatic injury to the spine in which the continuity of a vertebral bone is broken.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143857>	C220595|C143171	Splenic Infection, CTCAE|Splenic Infection|Splenic infection|Splenic infection	A disorder characterized by an infectious process involving the spleen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143858>	C220596|C143172	Stenosis of Gastrointestinal Stoma, CTCAE|Stenosis of Gastrointestinal Stoma|Stenosis of gastrointestinal stoma|Stenosis of gastrointestinal stoma	A finding of narrowing of the gastrointestinal stoma (surgically created opening on the surface of the body).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143859>	C220607|C143182	Stevens-Johnson Syndrome, CTCAE|Stevens-Johnson Syndrome|Stevens-Johnson syndrome|Stevens-Johnson syndrome	A disorder characterized by less than 10% total body skin area separation of dermis. The syndrome is thought to be a hypersensitivity complex affecting the skin and the mucous membranes.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14385>	C15172	DA, Rat Strain	DA: Urinary bladder tumors 54% in males and 14% in females, with a peak incidence at 25-30 months of age (Deerberg et al 1985). High incidence of hormone-dependent endometrial adenocarcinoma. A transplantable cell line (RUCA-I) derived from such a tumor in DA rats can produce these tumors in ectopic sites. The rate of proliferation is reduced by tamoxifen, and this cell line appears to be a suitable model for the study of molecular aspects of estrogen and tamoxifen-dependent gene expression.			Mammal	
C143860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143860>	C220595|C143171	Stoma Site Infection, CTCAE|Stoma Site Infection|Stoma site infection|Stoma site infection	A disorder characterized by an infectious process involving a stoma (surgically created opening on the surface of the body).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143861>	C220606|C143181	Stridor, CTCAE|Stridor|Stridor|Stridor	A disorder characterized by a high pitched breathing sound due to laryngeal or upper airway obstruction.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143862>	C220601|C143177	Stroke, CTCAE|Stroke|Stroke|Stroke	A disorder characterized by an interruption of blood supply to parts of the brain resulting in neurological damage.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143863>	C220592|C143169	Sudden Death NOS, CTCAE|Sudden Death NOS|Sudden death NOS|Sudden death NOS	An unexpected death that cannot be attributed to a CTCAE term associated with Grade 5.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143864>	C220603|C143187	Suicidal Ideation, CTCAE|Suicidal Ideation|Suicidal ideation|Suicidal ideation	A disorder characterized by thoughts of taking one's own life.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143865>	C220603|C143187	Suicide Attempt, CTCAE|Suicide Attempt|Suicide attempt|Suicide attempt	A disorder characterized by self-inflicted harm in an attempt to end one's own life.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143866>	C220599|C143175	Superficial Soft Tissue Fibrosis, CTCAE|Superficial Soft Tissue Fibrosis|Superficial soft tissue fibrosis|Superficial soft tissue fibrosis	A disorder characterized by fibrotic degeneration of the superficial soft tissues.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143867>	C220610|C143183	Superficial Thrombophlebitis, CTCAE|Superficial Thrombophlebitis|Superficial thrombophlebitis|Superficial thrombophlebitis	A disorder characterized by a blood clot and inflammation involving a superficial vein of the extremities.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143868>	C220610|C143183	Superior Vena Cava Syndrome, CTCAE|Superior Vena Cava Syndrome|Superior vena cava syndrome|Superior vena cava syndrome	A disorder characterized by obstruction of the blood flow in the superior vena cava. Signs and symptoms include swelling and cyanosis of the face, neck, and upper arms, cough, orthopnea and headache.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143869>	C220609|C143189	Surgical and Medical Procedures - Other, Specify, CTCAE|Surgical and Medical Procedures - Other|Surgical and medical procedures - Other, specify|Surgical and medical procedures - Other, specify	Other specified types of surgical and medical procedures.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14386>	C15172	BDVI, Rat Strain	About 4% of spontaneous peripheral nerve tumors, with cystic schwannomas being the most frequent type. 24 spontaneous and 28 ethylnitrosourea-induced tumors has been described by Turusov and Cabral, (1994).			Mammal	
C143872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143872>	C220605|C143180	Testicular Disorder, CTCAE|Testicular Disorder|Testicular disorder|Testicular disorder	A disorder characterized by abnormal function or appearance of the testis.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143873>	C143183	Thromboembolic Event, CTCAE|Thromboembolic Event|Thromboembolic event	A disorder characterized by occlusion of a vessel by a thrombus that has migrated from a distal site via the blood stream.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143874>	C220585|C143164	Thrombotic Thrombocytopenic Purpura, CTCAE|Thrombotic Thrombocytopenic Purpura|Thrombotic thrombocytopenic purpura|Thrombotic thrombocytopenic purpura	A disorder characterized by a deficiency of ADAMTS13 and the presence of microangiopathic hemolytic anemia, thrombocytopenic purpura, fever, renal abnormalities and neurological abnormalities such as seizures, hemiplegia, and visual disturbances. It is an acute or subacute condition.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143876>	C220591|C146630	Tooth Development Disorder, CTCAE|Tooth Development Disorder|Tooth development disorder|Tooth development disorder	A disorder characterized by a pathological process of the teeth occurring during tooth development.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143877>	C220591|C146630	Tooth Discoloration, CTCAE|Tooth Discoloration|Tooth discoloration|Tooth discoloration	A disorder characterized by a change in tooth hue or tint.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143878>	C220595|C143171	Tooth Infection, CTCAE|Tooth Infection|Tooth infection|Tooth infection	A disorder characterized by an infectious process involving a tooth.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143879>	C220591|C146630	Toothache, CTCAE|Toothache|Toothache|Toothache	A disorder characterized by a sensation of marked discomfort in the tooth.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14387>	C15172	BDIX, Rat Strain	Strain widely used in carcinogenesis and teratogenesis studies. Highly susceptible to the transplacental induction of malignant tumors of the central nervous system by ethyl nitrosourea (Druckrey et al 1970). A transplantable monocytic-myeloid leukemia L5222 induced by ethyl nitrosourea has been used as a model for chemotherapy (Ivankovic and Zeller 1974). Transplantable colon tumor PROb grows progressively and metastasizes, whereas REGb grows slowly and is then rejected (Blottiere et al 1992a,b).			Mammal	
C143880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143880>	C220607|C143182	Toxic Epidermal Necrolysis, CTCAE|Toxic Epidermal Necrolysis|Toxic epidermal necrolysis|Toxic epidermal necrolysis	A disorder characterized by greater than 30% total body skin area separation of dermis. The syndrome is thought to be a hypersensitivity complex affecting the skin and the mucous membranes.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143881>	C220606|C143181	Tracheal Mucositis, CTCAE|Tracheal Mucositis|Tracheal mucositis|Tracheal mucositis	A disorder characterized by an inflammation or ulceration involving the mucous membrane of the trachea.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143882>	C220596|C143172	Tracheal Obstruction, CTCAE|Tracheal Obstruction|Tracheal obstruction|Tracheal obstruction	A disorder characterized by blockage of the lumen of the trachea.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143883>	C220606|C143181	Tracheal Stenosis, CTCAE|Tracheal Stenosis|Tracheal stenosis|Tracheal stenosis	A disorder characterized by a narrowing of the trachea.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143884>	C220595|C143171	Tracheitis, CTCAE|Tracheitis|Tracheitis|Tracheitis	A disorder characterized by an infectious process involving the trachea.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143885>	C220596|C143172	Tracheostomy Site Bleeding, CTCAE|Tracheostomy Site Bleeding|Tracheostomy site bleeding|Tracheostomy site bleeding	A disorder characterized by bleeding from the tracheostomy site.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143886>	C220601|C143177	Transient Ischemic Attacks, CTCAE|Transient Ischemic Attacks|Transient ischemic attacks|Transient ischemic attacks	A disorder characterized by a brief attack (less than 24 hours) of cerebral dysfunction of vascular origin, with no persistent neurological deficit.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143887>	C220600|C143176	Treatment Related Secondary Malignancy, CTCAE|Treatment Related Secondary Malignancy|Treatment related secondary malignancy|Treatment related secondary malignancy	A disorder characterized by development of a malignancy most probably as a result of treatment for a previously existing malignancy.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143889>	C220586|C143165	Tricuspid Valve Disease, CTCAE|Tricuspid Valve Disease|Tricuspid valve disease|Tricuspid valve disease	A disorder characterized by a defect in tricuspid valve function or structure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14388>	C15172	BDII, Rat Strain	Frequent microphthalmia. Genetic markers described for sublines of this strain in the USA differ from those in Europe, suggesting that the US sublines were contaminated at some time in the past with LEW (Czerwinski and Crowell 1986). Mean life-span of BDII/Han 33.6 +/-4.7 months in males and 22.5+/-4.4 months in females, with 91% of females developing endometrial carcinomas, but with a more varied range of tumors in males. These include 26% adrenal pheochromocytomas, 23% histiocytic sarcomas, 18% pituitary tumors and 14% hemangiomas. About 12% of aged male BDII/Han develop diverticula of the stomach (Kaspareit-Rittinghausen and Deerberg 1987). High incidence of hormone-dependent endometrial adenocarcinoma.			Mammal	
C143890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143890>	C220601|C143177	Trigeminal Nerve Disorder, CTCAE|Trigeminal Nerve Disorder|Trigeminal nerve disorder|Trigeminal nerve disorder	A disorder characterized by dysfunction of the trigeminal nerve (fifth cranial nerve).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143894>	C220599|C143175	Unequal Limb Length, CTCAE|Unequal Limb Length|Unequal limb length|Unequal limb length	A disorder characterized by a discrepancy between the lengths of the lower or upper extremities.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143895>	C220591|C146630	Upper Gastrointestinal Hemorrhage, CTCAE|Upper Gastrointestinal Hemorrhage|Upper gastrointestinal hemorrhage|Upper gastrointestinal hemorrhage	A disorder characterized by bleeding from the upper gastrointestinal tract (oral cavity, pharynx, esophagus, and stomach).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143896>	C220595|C143171	Upper Respiratory Infection, CTCAE|Upper Respiratory Infection|Upper respiratory infection|Upper respiratory infection	A disorder characterized by an infectious process involving the upper respiratory tract (nose, paranasal sinuses, pharynx, larynx, or trachea).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143897>	C220596|C143172	Ureteric Anastomotic Leak, CTCAE|Ureteric Anastomotic Leak|Ureteric anastomotic leak|Ureteric anastomotic leak	A finding of leakage due to breakdown of a ureteral anastomosis (surgical connection of two separate anatomic structures).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143898>	C220596|C143172	Urethral Anastomotic Leak, CTCAE|Urethral Anastomotic Leak|Urethral anastomotic leak|Urethral anastomotic leak	A finding of leakage due to breakdown of a urethral anastomosis (surgical connection of two separate anatomic structures).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143899>	C220595|C143171	Urethral Infection, CTCAE|Urethral Infection|Urethral infection|Urethral infection	A disorder characterized by an infectious process involving the urethra.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14389>	C15172	A990, Rat Strain	Resistant to Cysticercus. Susceptible to estrogen-induced mammary and adrenal tumors. Good reproduction. High open-field defecation (2/12, males, 3/12 females) and low ambulation (11/12), Harrington (1972). Low wheel activity (12/12) (Harrington 1971b). Aggressive towards handlers (Harrington 1981).			Mammal	
C1438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1438>	C1557	Troxacitabine|2(1H)-Pyrimidinone, 4-amino-1-((2S,4S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)-|BCH-4556|L-Oddc|TROXACITABINE|Troxatyl|troxacitabine	A dioxolane derivative and a novel L-configuration deoxycytidine analogue with potent antineoplastic activity. When incorporated into growing chain during DNA replication, troxacitabine stops DNA polymerization due to its unnatural L-configuration, in contrast to the normal nucleotides with D-configuration. As a result, this agent terminates DNA synthesis upon incorporated into DNA molecules, and consequently interrupts tumor cell proliferation.	Troxacitabine		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C143900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143900>	C220604|C143179	Urinary Fistula, CTCAE|Urinary Fistula|Urinary Fistula (Priority 1)|Urinary fistula|Urinary fistula	A disorder characterized by an abnormal communication between any part of the urinary system and another organ or anatomic site.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C143901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143901>	C220604|C143179	Urinary Frequency, CTCAE|Urinary Frequency|Urinary Frequency (Priority 1)|Urinary frequency|Urinary frequency	A disorder characterized by urination at short intervals.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C143904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143904>	C220595|C143171	Urinary Tract Infection, CTCAE|Urinary Tract Infection|Urinary tract infection|Urinary tract infection	A disorder characterized by an infectious process involving the urinary tract, most commonly the bladder and the urethra.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143905>	C220604|C143179	Urinary Tract Obstruction, CTCAE|Urinary Tract Obstruction|Urinary Tract Obstruction (Priority 2)|Urinary tract obstruction|Urinary tract obstruction	A disorder characterized by blockage of the normal flow of contents of the urinary tract.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C143906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143906>	C220604|C143179	Urinary Tract Pain, CTCAE|Urinary Tract Pain|Urinary Tract Pain (Priority 2)|Urinary tract pain|Urinary tract pain	A disorder characterized by a sensation of marked discomfort in the urinary tract.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C143907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143907>	C220604|C143179	Urinary Urgency, CTCAE|Urinary Urgency|Urinary Urgency (Priority 1)|Urinary urgency|Urinary urgency	A disorder characterized by a sudden compelling urge to urinate.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C143908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143908>	C220604|C143179	Urine Discoloration, CTCAE|Urine Discoloration|Urine discoloration|Urine discoloration	A disorder characterized by a change in the color of the urine.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143909>	C220597|C143173	Urine Output Decreased, CTCAE|Urine Output Decreased|Urine output decreased|Urine output decreased	A finding based on test results that indicate urine production is less relative to previous output.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14390>	C15172	WF, Rat Strain|WF|WISTAR FURTH|Wistar Furth Rat	A Wistar substrain derived by Furth (1945), this inbred rat strain is a white albino with pink eyes, genotype c. The Wistar Furth rat carries a heteropyenotic Y chromosome that is used as a cellular marker. Leukemia develops in 15-22% of these rats, which is characterized by mononuclear cells with reddish granules. The Wistar Furth rat exhibits good reproductive performance and is docile, with an averages life span of 22 months.			Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C143910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143910>	C220596|C143172	Urostomy Leak, CTCAE|Urostomy Leak|Urostomy leak|Urostomy leak	A finding of leakage of contents from a urostomy.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143911>	C220596|C143172	Urostomy Obstruction, CTCAE|Urostomy Obstruction|Urostomy obstruction|Urostomy obstruction	A disorder characterized by blockage of the urostomy.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143912>	C220596|C143172	Urostomy Site Bleeding, CTCAE|Urostomy Site Bleeding|Urostomy site bleeding|Urostomy site bleeding	A disorder characterized by bleeding from the urostomy site.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143913>	C220596|C143172	Urostomy Stenosis, CTCAE|Urostomy Stenosis|Urostomy stenosis|Urostomy stenosis	A finding of narrowing of the opening of a urostomy.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143915>	C220596|C143172	Uterine Anastomotic Leak, CTCAE|Uterine Anastomotic Leak|Uterine anastomotic leak|Uterine anastomotic leak	A finding of leakage due to breakdown of a uterine anastomosis (surgical connection of two separate anatomic structures).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143916>	C220605|C143180	Uterine Fistula, CTCAE|Uterine Fistula|Uterine fistula|Uterine fistula	A disorder characterized by an abnormal communication between the uterus and another organ or anatomic site.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143917>	C220595|C143171	Uterine Infection, CTCAE|Uterine Infection|Uterine infection|Uterine infection	A disorder characterized by an infectious process involving the endometrium. It may extend to the myometrium and parametrial tissues.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143918>	C220605|C143180	Uterine Obstruction, CTCAE|Uterine Obstruction|Uterine obstruction|Uterine obstruction	A disorder characterized by blockage of the uterine outlet.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143919>	C220596|C143172	Uterine Perforation, CTCAE|Uterine Perforation|Uterine perforation|Uterine perforation	A disorder characterized by a rupture in the uterine wall.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14391>	C15172	W/Nhg, Rat Strain	High incidence (97% in females, 36% in males) of spontaneous thymomas starting from about one year of age. They sometimes caused dyspnea, and were occasionally the cause of death, but were not associated with any myopathies or autoimmune disease (Murray et al 1985).			Mammal	
C143921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143921>	C220596|C143172	Vaginal Anastomotic Leak, CTCAE|Vaginal Anastomotic Leak|Vaginal anastomotic leak|Vaginal anastomotic leak	A finding of leakage due to breakdown of a vaginal anastomosis (surgical connection of two separate anatomic structures).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143922>	C220605|C143180	Vaginal Discharge, CTCAE|Vaginal Discharge|Vaginal discharge|Vaginal discharge	A disorder characterized by vaginal secretions. Mucus produced by the cervical glands is discharged from the vagina naturally, especially during the childbearing years.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143924>	C220595|C143171	Vaginal Infection, CTCAE|Vaginal Infection|Vaginal infection|Vaginal infection	A disorder characterized by an infectious process involving the vagina.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143925>	C220605|C143180	Vaginal Inflammation, CTCAE|Vaginal Inflammation|Vaginal inflammation|Vaginal inflammation	A disorder characterized by inflammation involving the vagina. Symptoms may include redness, edema, marked discomfort and an increase in vaginal discharge.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143926>	C220605|C143180	Vaginal Stricture, CTCAE|Vaginal Stricture|Vaginal stricture|Vaginal stricture	A disorder characterized by a narrowing of the vaginal canal.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143927>	C220601|C143177	Vagus Nerve Disorder, CTCAE|Vagus Nerve Disorder|Vagus nerve disorder|Vagus nerve disorder	A disorder characterized by dysfunction of the vagus nerve (tenth cranial nerve).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143928>	C220596|C143172	Vas Deferens Anastomotic Leak, CTCAE|Vas Deferens Anastomotic Leak|Vas deferens anastomotic leak|Vas deferens anastomotic leak	A finding of leakage due to breakdown of a vas deferens anastomosis (surgical connection of two separate anatomic structures).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143929>	C220596|C143172	Vascular Access Complication, CTCAE|Vascular Access Complication|Vascular access complication|Vascular access complication	A finding of a previously undocumented problem related to the vascular access site.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14392>	C15172	ACI, Rat Strain|ACI	Median survival 113 weeks in males, 108 weeks in females. Spontaneous tumors 46% testes, 16% adrenal, 5% pituitary, 6% skin and ear duct and fewer of other types in males; 21% pituitary, 13% uterus, 11% mammary gland, 6% adrenal and fewer of other types in females.  Will grow transplantable Morris hepatomas 3924A which can be used as a model for the treatment of liver cancer (Yang et al 1995).			Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C143930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143930>	C220610|C143183	Vascular Disorders - Other, Specify, CTCAE|Vascular Disorders - Other|Vascular disorders - Other, specify|Vascular disorders - Other, specify	Other specified types of vascular disorders.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143932>	C143177	Vasovagal Reaction, CTCAE|Vasovagal Reaction|Vasovagal reaction	A disorder characterized by a sudden drop of the blood pressure, bradycardia, and peripheral vasodilation that may lead to loss of consciousness. It results from an increase in the stimulation of the vagus nerve.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143933>	C220596|C143172	Venous Injury, CTCAE|Venous Injury|Venous injury|Venous injury	A finding of damage to a vein.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143935>	C220588|C143185	Vertigo, CTCAE|Vertigo|Vertigo|Vertigo	A disorder characterized by a sensation as if the external world were revolving around the patient (objective vertigo) or as if he himself were revolving in space (subjective vertigo).			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143936>	C220588|C143185	Vestibular Disorder, CTCAE|Vestibular Disorder|Vestibular disorder|Vestibular disorder	A disorder characterized by dizziness, imbalance, nausea, and vision problems.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143937>	C220589|C143166	Virilization, CTCAE|Virilization|Virilization|Virilization	A disorder characterized by inappropriate masculinization occurring in a female or prepubertal male.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143938>	C220591|C146630	Visceral Arterial Ischemia, CTCAE|Visceral Arterial Ischemia|Visceral arterial ischemia|Visceral arterial ischemia	A disorder characterized by a decrease in blood supply due to narrowing or blockage of a visceral (mesenteric) artery.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143939>	C220597|C143173	Vital Capacity Abnormal, CTCAE|Vital Capacity Abnormal|Vital capacity abnormal|Vital capacity abnormal	A finding based on pulmonary function test results that indicate an abnormal vital capacity (VC) (amount of exhaled after a maximum inhalation) when compared to the predicted value.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14393>	C15172	A28807, Rat Strain	Very docile. Susceptible to the induction of autoimmune thyroiditis. Low and intermediate antibody responses to 1 and 10 g BSA, respectively. Low antibody response to streptococcal group A carbohydrate; not linked to the MHC. High relative heart weight in 10-week old males (20/23).			Mammal	
C143941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143941>	C220606|C143181	Voice Alteration, CTCAE|Voice Alteration|Voice alteration|Voice alteration	A disorder characterized by a change in the sound and/or speed of the voice.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143943>	C220595|C143171	Vulval Infection, CTCAE|Vulval Infection|Vulval infection|Vulval infection	A disorder characterized by an infectious process involving the vulva.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143944>	C220590|C143167	Watering Eyes, CTCAE|Watering Eyes|Watering eyes|Watering eyes	A disorder characterized by excessive tearing in the eyes; it can be caused by overproduction of tears or impaired drainage of the tear duct.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143947>	C143181	Wheezing, CTCAE|Wheezing|Wheezing	A disorder characterized by a high-pitched, whistling sound during breathing. It results from the narrowing or obstruction of the respiratory airways.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143948>	C220597|C143173	White Blood Cell Decreased, CTCAE|White Blood Cell Decreased|White blood cell decreased|White blood cell decreased	A finding based on laboratory test results that indicate a decrease in number of white blood cells (WBC) in a blood specimen.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143949>	C220596|C143172	Wound Complication, CTCAE|Wound Complication|Wound complication|Wound complication	A finding of development of a new problem at the site of an existing wound.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C14394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14394>	C15172	BB, Rat Strain	BB: The development of lymphocytic thyroiditis is not affected by iodine treatment according to Allen (1992), though Ebner et al (1992) found the opposite. Epitope specificities of collagen-induced arthritis studied by Cremer et al (1992). A lymphopenic, nondiabetic substrain BB-DR has very low T-cell numbers, depressed B-lymphocyte numbers and a complete absence of peripheral CD8+ T cells characteristics of the susceptible BB strain(Joseph et al 1993). Transfusing of BB-DR thymocytes into nude rats transfers the autoimmune insulin-dependent diabetes mellitus (Whalen et al 1995).			Mammal	
C143950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143950>	C220596|C143172	Wound Dehiscence, CTCAE|Wound Dehiscence|Wound dehiscence|Wound dehiscence	A finding of separation of the approximated margins of a surgical wound.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143951>	C220595|C143171	Wound Infection, CTCAE|Wound Infection|Wound infection|Wound infection	A disorder characterized by an infectious process involving the wound.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C143952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143952>	C143172	Wrist Fracture, CTCAE|Wrist Fracture|Wrist fracture	A finding of traumatic injury to the wrist joint in which the continuity of a wrist bone is broken.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C143953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143953>	C213431|C213309	Ad-RTS-hIL-12|Adenoviral- RheoSwitch Therapeutic System-Human Interleukin 12|INXN 2001|INXN-2001	An inducible adenoviral vector encoding human pro-inflammatory cytokine interleukin-12 (IL-12; IL12), which is under the transcriptional control of the RheoSwitch Therapeutic System (RTS) (Ad-RTS-hIL-12), with potential immunomodulating and antineoplastic activities. RTS consists of two fusion proteins: Gal4-EcR, which contains a modified ecdysone receptor (EcR) fused with the DNA binding domain of the yeast Gal4 transcription factor, and VP16-RXR, which contains a chimeric retinoid X receptor (RXR) fused with the transcription activation domain of the viral protein VP16 of herpes simplex virus type 1 (HSV1). Upon intratumoral administration of Ad-RTS-hIL-12, given in combination with the proprietary, diacylhydrazine-based activator ligand veledimex (INXN-1001), veledimex binds specifically to the EcR part of the RTS and stabilizes heterodimerization between the two fusion proteins, forming an active transcription factor, which induces the transcription of IL-12 under the control of an inducible promoter containing Gal4-binding sites. The expressed IL-12 activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma (IFN-g) and inducing cytotoxic T-lymphocyte (CTL)-mediated responses against tumor cells, which may result in immune-mediated tumor cell lysis and inhibition of tumor cell proliferation. In the presence of veledimex, the protein heterodimer changes to a stable conformation and can bind to the inducible promoter, while without veledimex the two fusion proteins form unstable heterodimers; this allows the controlled, regulated intratumoral expression of the IL-12 gene.	Ad-RTS-hIL-12		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C143954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143954>	C15301	Systematic Programmed Illumination|sPI	A type of light therapy that uses ambient exposure to bluish-white light in a programmed schedule for prevention and treatment of cancer-related fatigue.	Systematic Programmed Illumination		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C143955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143955>	C16342	Blood Inflammatory Marker	A substance detectable in the blood that can be used to assess levels of inflammation in the body.			Functional Concept	
C143956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143956>	C1663	eVLP CMV gB-pp65 Plus GM-CSF VBI-1901|Enveloped Virus-like Particles CMV gB-pp65 Plus GM-CSF VBI-1901|VBI 1901|VBI-1901|VBI-1901 Vaccine	A cancer vaccine composed of enveloped virus-like particles (eVLPs) containing the human cytomegalovirus (CMV) antigens glycoprotein B (gB) and phosphoprotein 65 (pp65; UL83) that are combined with the immunoadjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulatory and antineoplastic activities. Upon intradermal administration of VBI-1901, the eVLPs are taken up by and activate immune cells, such as dendritic cells (DCs), thereby stimulating the immune system to exert a cytotoxic T-lymphocyte (CTL) immune response against CMV gB and pp65-expressing tumor cells. This may lyse and inhibit the proliferation of CMV-infected cancer cells. eVLPs, derived from viral structural proteins, stimulate the immune system and promote CTL responses. CMV gB and pp65 are expressed in certain tumor cell types, such as glioblastoma multiforme (GBM). GM-CSF stimulates the immune system and potentiates the antitumor immune response.	eVLP CMV gB-pp65 Plus GM-CSF VBI-1901		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C143957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143957>	C200483|C124946	Tebotelimab|Anti-PD-1/Anti-LAG-3 DART Protein MGD013|Bispecific DART Protein MGD013|Dual-affinity Retargeting Protein MGD013|MGD 013|MGD-013|MGD013|PD-1 x LAG-3 Bispecific DART Molecule MGD013|PD-1 x LAG-3 DART Molecule MGD013|PD-1 x LAG-3 DART Protein MGD013|TEBOTELIMAB	An Fc-bearing, humanized antibody-like protein that specifically recognizes the immune checkpoint molecules programmed cell death 1 (PD-1; PD1; PDCD1; CD279; Programmed Death 1) and lymphocyte activation gene-3 (LAG-3; LAG3; CD223), with potential T-lymphocyte immunomodulatory and antineoplastic activities. Upon administration, tebotelimab specifically binds to both PD-1 and LAG-3, which are both expressed on T-cells. The dual blockade of the PD-1 and LAG-3 pathways enables potent activation of a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. PD-1 and LAG-3 play key roles in suppressing T-cell activation.	Tebotelimab		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C143958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143958>	C143253	Grade 1 Abdominal Distension, CTCAE|Grade 1 Abdominal distension|Grade 1 Abdominal distension	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143959>	C143255	Grade 1 Abdominal Pain, CTCAE|Grade 1 Abdominal pain|Grade 1 Abdominal pain	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14395>	C15172	BN, Rat Strain|BN|BROWN NORWAY|Brown Norway Rat	An inbred strain of Rattus norvegicus derived from Silvers and Billingham stock (1958), characterized by a non-agouti brown coat color and RT1n MHC haplotype.			Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C143960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143960>	C143257	Grade 1 Abducens Nerve Disorder, CTCAE|Grade 1 Abducens nerve disorder|Grade 1 Abducens nerve disorder	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143961>	C143258	Grade 1 Accessory Nerve Disorder, CTCAE|Grade 1 Accessory nerve disorder|Grade 1 Accessory nerve disorder	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143962>	C143259	Grade 1 Acidosis, CTCAE|Grade 1 Acidosis|Grade 1 Acidosis	pH <normal, but >=7.3			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143963>	C143260	Grade 1 Acoustic Nerve Disorder NOS, CTCAE|Grade 1 Acoustic nerve disorder NOS|Grade 1 Acoustic nerve disorder NOS	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143964>	C143261	Grade 1 Activated Partial Thromboplastin Time Prolonged, CTCAE|Grade 1 Activated partial thromboplastin time prolonged|Grade 1 Activated partial thromboplastin time prolonged	>ULN - 1.5 x ULN			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143965>	C143266	Grade 1 Akathisia, CTCAE|Grade 1 Akathisia|Grade 1 Akathisia	Mild restlessness or increased motor activity			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143966>	C143267	Grade 1 Alanine Aminotransferase Increased, CTCAE|Grade 1 Alanine aminotransferase increased|Grade 1 Alanine aminotransferase increased	>ULN - 3.0 x ULN if baseline was normal or less than normal; 1.0 - 1.5 x baseline if baseline was >ULN			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143967>	C143269	Grade 1 Alkaline Phosphatase Increased, CTCAE|Grade 1 Alkaline phosphatase increased	>ULN-2.5 x ULN if baseline was normal; 2.0-2.5 x baseline if baseline was abnormal			Finding	CTCAE Adverse Events Version 5.0 Terminology
C143968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143968>	C143270	Grade 1 Alkalosis, CTCAE|Grade 1 Alkalosis|Grade 1 Alkalosis	pH >normal, but <=7.5			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143969>	C143271	Grade 1 Allergic Reaction, CTCAE|Grade 1 Allergic reaction|Grade 1 Allergic reaction	Systemic intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14396>	C15172	BUF, Rat Strain|BUF|BUFFALO|Buffalo Rat	Derived from Buffalo stock of H. Morris to the NIH in 1950 and disseminated from Charles River since 1998, the Buffalo is a white albino rat, genotype c. The incidence of spontaneous tumor formation includes anterior pituitary and adrenal cortex in upwards of 30% of aged rats. The Buffalo rat is used most commonly in oncology and carcinogenesis research. Low incidence of dental caries. Spontaneous tumors of anterior pituitary 30%, and of adrenal cortex 25% in older animals. Survival 58% at 2 years of age with thyroid carcinoma in 25% (Lindsey et al 1968). Low incidence of renal neoplasms (Snell 1967). High incidence of tumors of the anterior pituitary, adrenal medulla and adrenal cortex in animals over 18 months old (Snell1965).			Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C143970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143970>	C143272	Grade 1 Allergic Rhinitis, CTCAE|Grade 1 Allergic rhinitis|Grade 1 Allergic rhinitis	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143971>	C143274	Grade 1 Amnesia, CTCAE|Grade 1 Amnesia|Grade 1 Amnesia	Mild; transient memory loss			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143972>	C143197	Grade 1 Anal Fissure, CTCAE|Grade 1 Anal fissure|Grade 1 Anal fissure	Asymptomatic			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143973>	C143275	Grade 1 Anal Fistula, CTCAE|Grade 1 Anal fistula|Grade 1 Anal fistula	Asymptomatic			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143974>	C143276	Grade 1 Anal Hemorrhage, CTCAE|Grade 1 Anal hemorrhage	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C143975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143975>	C143277	Grade 1 Anal Mucositis, CTCAE|Grade 1 Anal mucositis|Grade 1 Anal mucositis	Asymptomatic or mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143976>	C143279	Grade 1 Anal Pain, CTCAE|Grade 1 Anal pain|Grade 1 Anal pain	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143977>	C143280	Grade 1 Anal Stenosis, CTCAE|Grade 1 Anal stenosis|Grade 1 Anal stenosis	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143978>	C143281	Grade 1 Anal Ulcer, CTCAE|Grade 1 Anal ulcer|Grade 1 Anal ulcer	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143979>	C143283	Grade 1 Anemia, CTCAE|Grade 1 Anemia|Grade 1 Anemia	Hemoglobin (Hgb) <LLN - 10.0 g/dL; <LLN - 6.2 mmol/L; <LLN - 100 g/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14397>	C15172	COP, Rat Strain	Spontaneous tumors of the thymus (Dunning and Curtis 1946, Dunning et al 1947)			Mammal	
C143980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143980>	C143284	Grade 1 Ankle Fracture, CTCAE|Grade 1 Ankle fracture	Mild; non-operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C143981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143981>	C143285	Grade 1 Anorectal Infection, CTCAE|Grade 1 Anorectal infection|Grade 1 Anorectal infection	Localized, local intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143982>	C143287	Grade 1 Anorgasmia, CTCAE|Grade 1 Anorgasmia|Grade 1 Anorgasmia	Inability to achieve orgasm not adversely affecting relationship			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143983>	C143230	Grade 1 Anosmia, CTCAE|Grade 1 Anosmia|Grade 1 Anosmia	Present			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143984>	C143290	Grade 1 Aortic Valve Disease, CTCAE|Grade 1 Aortic valve disease|Grade 1 Aortic valve disease	Asymptomatic valvular thickening with or without mild valvular regurgitation or stenosis by imaging			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143985>	C143295	Grade 1 Arachnoiditis, CTCAE|Grade 1 Arachnoiditis|Grade 1 Arachnoiditis	Mild symptoms			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143986>	C143296	Grade 1 Arterial Injury, CTCAE|Grade 1 Arterial injury|Grade 1 Arterial injury	Asymptomatic diagnostic finding; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143987>	C143298	Grade 1 Arthralgia, CTCAE|Grade 1 Arthralgia|Grade 1 Arthralgia	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143988>	C143299	Grade 1 Arthritis, CTCAE|Grade 1 Arthritis|Grade 1 Arthritis	Mild pain with inflammation, erythema, or joint swelling			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143989>	C143300	Grade 1 Ascites, CTCAE|Grade 1 Ascites|Grade 1 Ascites	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14398>	C15172	CRDH, Rat Strain	Non-insulin-dependent overt diabetes: blood glucose 384+/- 134 mg/dl (plasma insulin at 60 min following intragastric glucose load 83.3 +/-10.2mU/mL) and hypertension blood pressure 176 +/-8mmHg. There was severe diffuse diabetic glomerulosclerosis and severe hypertensive changes in arteries and arterioles characterised by fibrinoid necrosis and/or onion skin lesions as well as smooth muscle hyperplasia. Myocardial changes were prominent, with foci of ischemic necrosis and hyperplastic vascular changes.			Mammal	
C143990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143990>	C143301	Grade 1 Aspartate Aminotransferase Increased, CTCAE|Grade 1 Aspartate aminotransferase increased|Grade 1 Aspartate aminotransferase increased	>ULN - 3.0 x ULN if baseline was normal or less than normal; 1.0 - 1.5 x baseline if baseline was >ULN			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143991>	C143309	Grade 1 Atrioventricular Block First Degree, CTCAE|Grade 1 Atrioventricular block first degree|Grade 1 Atrioventricular block first degree	Asymptomatic, intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143992>	C143310	Grade 1 Autoimmune Disorder, CTCAE|Grade 1 Autoimmune disorder|Grade 1 Autoimmune disorder	Asymptomatic; serologic or other evidence of autoimmune reaction, with normal organ function; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143993>	C143311	Grade 1 Avascular Necrosis, CTCAE|Grade 1 Avascular necrosis	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C143994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143994>	C143198	Grade 1 Belching, CTCAE|Grade 1 Belching|Grade 1 Belching	Increase from baseline			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143995>	C143314	Grade 1 Bile Duct Stenosis, CTCAE|Grade 1 Bile duct stenosis|Grade 1 Bile duct stenosis	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143996>	C143315	Grade 1 Biliary Anastomotic Leak, CTCAE|Grade 1 Biliary anastomotic leak|Grade 1 Biliary anastomotic leak	Asymptomatic diagnostic finding; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143997>	C143318	Grade 1 Bladder Anastomotic Leak, CTCAE|Grade 1 Bladder anastomotic leak|Grade 1 Bladder anastomotic leak	Asymptomatic diagnostic finding; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C143999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C143999>	C143322	Grade 1 Bloating, CTCAE|Grade 1 Bloating|Grade 1 Bloating	No change in bowel function or oral intake			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14399>	C15172	DONRYU, Rat Strain	DONRYU: Spontaneous tumors 74% in males at 120-weeks, mostly pituitary adenomas, pheochromocytomas and insulinomas. In females incidence 89%, mostly uterine adenocarcinomas, mammary fibroadenomas and pituitary adenomas.			Mammal	
C1439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1439>	C67422|C1893	Dolastatin 15|DOLASTATIN 15|L-Proline, 1-(1-(N-(N-(N,N-dimethyl-L-valyl)-L-valyl)-N-methyl-L-valyl)-L-prolyl)-, 1-((2,5-dihydro-3-methoxy-5-oxo-2-(phenylmethyl)-1H-pyrrol-1-yl)carbonyl)-2-methylpropyl ester, (S-(R*,R*))-	A depsipeptide originally isolated from the marine mollusk Dolabella auricularia with potential antineoplastic activity.  Less potent than the structurally-related compound dolastatin 10, dolastatin 15 binds weakly to tubulin and blocks microtubule assembly, thereby inhibiting mitosis.  Dolastatin 15 also induces tumor cell apoptosis through a mechanism involving bcl-2, an oncoprotein that is overexpressed in some cancers. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C144000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144000>	C143323	Grade 1 Blood and Lymphatic System Disorders - Other, Specify, CTCAE|Grade 1 Blood and lymphatic system disorders - Other, specify|Grade 1 Blood and lymphatic system disorders - Other, specify	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144001>	C143324	Grade 1 Blood Antidiuretic Hormone Abnormal, CTCAE|Grade 1 Blood antidiuretic hormone abnormal|Grade 1 Blood antidiuretic hormone abnormal	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144002>	C143217	Grade 1 Blood Bicarbonate Decreased, CTCAE|Grade 1 Blood bicarbonate decreased|Grade 1 Blood bicarbonate decreased	<LLN and no intervention initiated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144003>	C143325	Grade 1 Blood Bilirubin Increased, CTCAE|Grade 1 Blood bilirubin increased	>ULN-1.5 x ULN if baseline was normal; > 1.0-1.5 x baseline if baseline was abnormal			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144004>	C143326	Grade 1 Blood Corticotrophin Decreased, CTCAE|Grade 1 Blood corticotrophin decreased|Grade 1 Blood corticotrophin decreased	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144005>	C143327	Grade 1 Blood Gonadotrophin Abnormal, CTCAE|Grade 1 Blood gonadotrophin abnormal	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144006>	C143218	Grade 1 Blood Lactate Dehydrogenase Increased, CTCAE|Grade 1 Blood lactate dehydrogenase increased|Grade 1 Blood lactate dehydrogenase increased	>ULN			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144007>	C143328	Grade 1 Blood Prolactin Abnormal, CTCAE|Grade 1 Blood prolactin abnormal|Grade 1 Blood prolactin abnormal	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144008>	C143330	Grade 1 Body Odor, CTCAE|Grade 1 Body odor|Grade 1 Body odor	Mild odor; physician intervention not indicated; self care interventions			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144009>	C143332	Grade 1 Bone Marrow Hypocellular, CTCAE|Grade 1 Bone marrow hypocellular|Grade 1 Bone marrow hypocellular	Mildly hypocellular or <=25% reduction from normal cellularity for age			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14400>	C15172	E3, Rat Strain	Has platelet storage disease associated with the red-eyed yellow locus, as described by Raymond and Dodds (1975) for the FH strain.			Mammal	
C144010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144010>	C143335	Grade 1 Breast Atrophy, CTCAE|Grade 1 Breast atrophy	Minimal asymmetry; minimal atrophy			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144011>	C143338	Grade 1 Bronchial Fistula, CTCAE|Grade 1 Bronchial fistula|Grade 1 Bronchial fistula	Asymptomatic			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144012>	C143340	Grade 1 Bronchial Obstruction, CTCAE|Grade 1 Bronchial obstruction|Grade 1 Bronchial obstruction	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144013>	C143341	Grade 1 Bronchial Stricture, CTCAE|Grade 1 Bronchial stricture|Grade 1 Bronchial stricture	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144014>	C143342	Grade 1 Bronchopleural Fistula, CTCAE|Grade 1 Bronchopleural fistula|Grade 1 Bronchopleural fistula	Asymptomatic			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144015>	C143343	Grade 1 Bronchopulmonary Hemorrhage, CTCAE|Grade 1 Bronchopulmonary hemorrhage|Grade 1 Bronchopulmonary hemorrhage	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144016>	C143344	Grade 1 Bronchospasm, CTCAE|Grade 1 Bronchospasm|Grade 1 Bronchospasm	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144017>	C143345	Grade 1 Bruising, CTCAE|Grade 1 Bruising|Grade 1 Bruising	Localized or in a dependent area			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144018>	C143346	Grade 1 Bullous Dermatitis, CTCAE|Grade 1 Bullous dermatitis	Asymptomatic; blisters covering <10% BSA			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144019>	C143349	Grade 1 Capillary Leak Syndrome, CTCAE|Grade 1 Capillary leak syndrome|Grade 1 Capillary leak syndrome	Asymptomatic			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14401>	C15172	F344, Rat Strain|F344|F344|FISCHER 344|Fischer 344	Most animals older than 2 years exhibit small local areas of nephritis; less than 25% show severe nephritis (Snell 1967). Tumors: Mammary tumors 41% in females and 23% in males, pituitary adenomas 36% in females and 24% in males, testicular interstitial cell tumors 85% in males. Other tumor types less common (Sass et al 1975). Thyroid carcinoma 22% (Lindsey et al 1968). Interstitial cell testicular tumors 65%, mononuclear cell leukemia 24%, subcutaneous fibroadenoma 9% in females. Both sexes have a 5% incidence of nodular hyperplasia of the liver.			Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C144020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144020>	C143350	Grade 1 Carbon Monoxide Diffusing Capacity Decreased, CTCAE|Grade 1 Carbon monoxide diffusing capacity decreased|Grade 1 Carbon monoxide diffusing capacity decreased	3 - 5 units below LLN if no baseline available; for follow-up, a decrease of 3 - 5 units (ml/min/mmHg) below the baseline value; asymptomatic and intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144021>	C143352	Grade 1 Cardiac Disorders - Other, Specify, CTCAE|Grade 1 Cardiac disorders - Other, specify|Grade 1 Cardiac disorders - Other, specify	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144022>	C143353	Grade 1 Cardiac Troponin I Increased, CTCAE|Grade 1 Cardiac troponin I increased	Levels above the upper limit of normal and below the level of myocardial infarction as defined by the manufacturer			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144023>	C143354	Grade 1 Cardiac Troponin T Increased, CTCAE|Grade 1 Cardiac troponin T increased	Levels above the upper limit of normal and below the level of myocardial infarction as defined by the manufacturer			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144024>	C143357	Grade 1 CD4 Lymphocytes Decreased, CTCAE|Grade 1 CD4 lymphocytes decreased|Grade 1 CD4 lymphocytes decreased	<LLN - 500/mm3; <LLN - 0.5 x 10^9/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144025>	C143358	Grade 1 Cecal Hemorrhage, CTCAE|Grade 1 Cecal hemorrhage|Grade 1 Cecal hemorrhage	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144026>	C143360	Grade 1 Central Nervous System Necrosis, CTCAE|Grade 1 Central nervous system necrosis|Grade 1 Central nervous system necrosis	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144027>	C143361	Grade 1 Cerebrospinal Fluid Leakage, CTCAE|Grade 1 Cerebrospinal fluid leakage|Grade 1 Cerebrospinal fluid leakage	Post-craniotomy: asymptomatic; post-lumbar puncture: transient headache; postural care indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144028>	C143364	Grade 1 Chest Pain - Cardiac, CTCAE|Grade 1 Chest pain - cardiac|Grade 1 Chest pain - cardiac	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144029>	C143366	Grade 1 Chills, CTCAE|Grade 1 Chills|Grade 1 Chills	Mild sensation of cold; shivering; chattering of teeth			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14402>	C15172	FH, Rat Strain	It has been suggested that FH rats represent a genetic model of depression They have altered serotonergic function (Aulka et al, 1994a), they exhibit differential responses to serotonin agonists and antagonists compared with other strains (Meehan and Schechter, 1994), and long-term treatment with imipramine, clomipramine and clorgyline produced significant decreases in plasma corticosterone levels, supporting this suggestion (Aulka et al, 1993).			Mammal	
C144030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144030>	C143368	Grade 1 Cholesterol High, CTCAE|Grade 1 Cholesterol high|Grade 1 Cholesterol high	>ULN - 300 mg/dL; >ULN - 7.75 mmol/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144031>	C143369	Grade 1 Chronic Kidney Disease, CTCAE|Grade 1 Chronic kidney disease	eGFR (estimated Glomerular Filtration Rate) or CrCl (creatinine clearance) <LLN-60 ml/min/1.73 m2 or proteinuria 2+ present; urine protein/creatinine >0.5			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144032>	C143199	Grade 1 Chylous Ascites, CTCAE|Grade 1 Chylous ascites|Grade 1 Chylous ascites	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144033>	C143373	Grade 1 Colonic Fistula, CTCAE|Grade 1 Colonic fistula|Grade 1 Colonic fistula	Asymptomatic			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144034>	C143374	Grade 1 Colonic Hemorrhage, CTCAE|Grade 1 Colonic hemorrhage	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144035>	C143375	Grade 1 Colonic Obstruction, CTCAE|Grade 1 Colonic obstruction|Grade 1 Colonic obstruction	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144036>	C143377	Grade 1 Colonic Stenosis, CTCAE|Grade 1 Colonic stenosis|Grade 1 Colonic stenosis	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144037>	C143378	Grade 1 Colonic Ulcer, CTCAE|Grade 1 Colonic ulcer|Grade 1 Colonic ulcer	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144038>	C143379	Grade 1 Concentration Impairment, CTCAE|Grade 1 Concentration impairment|Grade 1 Concentration impairment	Mild inattention or decreased level of concentration			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144039>	C143380	Grade 1 Conduction Disorder, CTCAE|Grade 1 Conduction disorder	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C14403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14403>	C15172	FHH, Rat Strain|Fawn Hooded Hypertension	Origin: An outbred stock of fawn hooded rats introduced into Europe by Tschopp in the early 1970s. Maintained as an outbred stock until the mid-1980s, then brother x sister mating initiated by A.P. Provoost to produce two strains designated FHH (also known as FHR) and FHL, which differ in hypertension and proteinuria.  FHH develops focal and segmental glomerular sclerosis, systemic hypertension and proteinuria at a young age, but these effects are more marked in FHH than FHL (Simons et al, 1993). The renal disease and hypertension are under independent genetic control, and both appear to be independent of the red-eyed dilution gene which causes platelet storage disease (Brown et al,1996)			Mammal	
C144040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144040>	C143382	Grade 1 Congenital, Familial and Genetic Disorders - Other, Specify, CTCAE|Grade 1 Congenital, familial and genetic disorders - Other, specify|Grade 1 Congenital, familial and genetic disorders - Other, specify	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144041>	C143384	Grade 1 Conjunctivitis, CTCAE|Grade 1 Conjunctivitis|Grade 1 Conjunctivitis	Asymptomatic or mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144042>	C143389	Grade 1 CPK Increased, CTCAE|Grade 1 CPK increased	>ULN-2.5 x ULN			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144043>	C143391	Grade 1 Creatinine Increased, CTCAE|Grade 1 Creatinine increased|Grade 1 Creatinine increased	>ULN - 1.5 x ULN			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144044>	C143392	Grade 1 Cushingoid, CTCAE|Grade 1 Cushingoid|Grade 1 Cushingoid	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144045>	C143393	Grade 1 Cystitis Noninfective, CTCAE|Grade 1 Cystitis noninfective|Grade 1 Cystitis noninfective	Microscopic hematuria; minimal increase in frequency, urgency, dysuria, or nocturia; new onset of incontinence			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144046>	C143394	Grade 1 Cytokine Release Syndrome, CTCAE|Grade 1 Cytokine release syndrome|Grade 1 Cytokine release syndrome	Fever with or without constitutional symptoms			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144047>	C143207	Grade 1 Cytomegalovirus Infection Reactivation, CTCAE|Grade 1 Cytomegalovirus infection reactivation|Grade 1 Cytomegalovirus infection reactivation	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144048>	C143398	Grade 1 Delayed Orgasm, CTCAE|Grade 1 Delayed orgasm|Grade 1 Delayed orgasm	Delay in achieving orgasm not adversely affecting relationship			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144049>	C143400	Grade 1 Delirium, CTCAE|Grade 1 Delirium|Grade 1 Delirium	Mild acute confusional state			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14404>	C15172	GH, Rat Strain	GH: Develops hypertension, cardiac hypertrophy and vascular disease (Phelan 1968, Simpson and Phelan 1984, Simpson et al, 1994). Genetic hypertension in GH (but not SHR) may be associated with a defect in renal prostaglandin catabolism (Armstronag et al 1976).			Mammal	
C144050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144050>	C143402	Grade 1 Dental Caries, CTCAE|Grade 1 Dental caries|Grade 1 Dental caries	One or more dental caries, not involving the root			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144051>	C143403	Grade 1 Depressed Level of Consciousness, CTCAE|Grade 1 Depressed level of consciousness|Grade 1 Depressed level of consciousness	Decreased level of alertness			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144052>	C143405	Grade 1 Dermatitis Radiation, CTCAE|Grade 1 Dermatitis radiation|Grade 1 Dermatitis radiation	Faint erythema or dry desquamation			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144053>	C143410	Grade 1 Dry Eye, CTCAE|Grade 1 Dry eye|Grade 1 Dry eye	Clinical or diagnostic observations only; symptoms relieved by lubricants			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144054>	C143411	Grade 1 Dry Mouth, CTCAE|Grade 1 Dry mouth|Grade 1 Dry mouth	Symptomatic (e.g., dry or thick saliva) without significant dietary alteration; unstimulated saliva flow >0.2 ml/min			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144056>	C143414	Grade 1 Duodenal Hemorrhage, CTCAE|Grade 1 Duodenal hemorrhage|Grade 1 Duodenal hemorrhage	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144057>	C143416	Grade 1 Duodenal Obstruction, CTCAE|Grade 1 Duodenal obstruction|Grade 1 Duodenal obstruction	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144058>	C143418	Grade 1 Duodenal Stenosis, CTCAE|Grade 1 Duodenal stenosis|Grade 1 Duodenal stenosis	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144059>	C143419	Grade 1 Duodenal Ulcer, CTCAE|Grade 1 Duodenal ulcer|Grade 1 Duodenal ulcer	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14405>	C15172	IR, Rat Strain	Vigorous and healthy, but high incidence of physical abnormalities. Skulls of young fragile through weaning. High death rate from hemorrhage due to blood platelet disease (Harrington 1981). Long latency to emerge into familiar environment (12/12 males, 10/12 females) (Harrington 1971a). High open field exploration in females (3/12) (Harrington 1972). Low wheel activity (11/12 males10/12 females) (Harrington 1971b).			Mammal	
C144060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144060>	C143420	Grade 1 Dysarthria, CTCAE|Grade 1 Dysarthria|Grade 1 Dysarthria	Mild slurred speech			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144061>	C143421	Grade 1 Dysesthesia, CTCAE|Grade 1 Dysesthesia|Grade 1 Dysesthesia	Mild sensory alteration			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144062>	C143422	Grade 1 Dysgeusia, CTCAE|Grade 1 Dysgeusia|Grade 1 Dysgeusia	Altered taste but no change in diet			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144063>	C143423	Grade 1 Dysmenorrhea, CTCAE|Grade 1 Dysmenorrhea|Grade 1 Dysmenorrhea	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144064>	C143424	Grade 1 Dyspareunia, CTCAE|Grade 1 Dyspareunia|Grade 1 Dyspareunia	Mild discomfort or pain associated with vaginal penetration; discomfort relieved with use of vaginal lubricants or estrogen			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144065>	C143425	Grade 1 Dyspepsia, CTCAE|Grade 1 Dyspepsia|Grade 1 Dyspepsia	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144066>	C143427	Grade 1 Dysphasia, CTCAE|Grade 1 Dysphasia	Awareness of receptive or expressive characteristics; not impairing ability to communicate			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144067>	C143237	Grade 1 Dysuria, CTCAE|Grade 1 Dysuria|Grade 1 Dysuria	Present			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144068>	C143429	Grade 1 Ear and Labyrinth Disorders - Other, Specify, CTCAE|Grade 1 Ear and labyrinth disorders - Other, specify|Grade 1 Ear and labyrinth disorders - Other, specify	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144069>	C143430	Grade 1 Ear Pain, CTCAE|Grade 1 Ear pain|Grade 1 Ear pain	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14406>	C15172	LEC, Rat Strain	Carries a mutation causing fulminated hepatitis and jaundice at about four months of age. Clinical symptoms include severe jaundice, bleeding, oliguria, loss of body weight and elevation of serum levels of bilirubin and hepatic enzymes. About half the animals die within a week of onset, and in survivors hepatocellular carcinoma spontaneously appears after 1-1.5 years (Kasai et al 1990,Sasaki 1985, Wirth et al 1990).			Mammal	
C144070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144070>	C143243	Grade 1 Eczema, CTCAE|Grade 1 Eczema	Asymptomatic or mild symptoms; additional medical intervention over baseline not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144071>	C143432	Grade 1 Edema Face, CTCAE|Grade 1 Edema face|Grade 1 Edema face	Localized edema			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144072>	C143433	Grade 1 Edema Limbs, CTCAE|Grade 1 Edema limbs	5-10% inter-limb discrepancy in volume or circumference at point of greatest visible difference; swelling or obscuration of anatomic architecture on close inspection			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144073>	C143434	Grade 1 Edema Trunk, CTCAE|Grade 1 Edema trunk	Swelling or obscuration of anatomic architecture on close inspection			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144074>	C143435	Grade 1 Ejaculation Disorder, CTCAE|Grade 1 Ejaculation disorder|Grade 1 Ejaculation disorder	Diminished ejaculation			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144075>	C143437	Grade 1 Electrocardiogram QT Corrected Interval Prolonged, CTCAE|Grade 1 Electrocardiogram QT corrected interval prolonged|Grade 1 Electrocardiogram QT corrected interval prolonged	Average QTc 450 - 480 ms			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144076>	C143219	Grade 1 Electrocardiogram T Wave Abnormal, CTCAE|Grade 1 Electrocardiogram T wave abnormal	T wave flattening			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144077>	C146699	Grade 1 Encephalopathy, CTCAE|Grade 1 Encephalopathy|Grade 1 Encephalopathy	Mild symptoms			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144078>	C143442	Grade 1 Endocrine Disorders - Other, Specify, CTCAE|Grade 1 Endocrine disorders - Other, specify|Grade 1 Endocrine disorders - Other, specify	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144079>	C143445	Grade 1 Enterocolitis, CTCAE|Grade 1 Enterocolitis|Grade 1 Enterocolitis	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14407>	C15172	LEW, Rat Strain	Of the large spectrum of 52 histologically different types of tumors, the highest incidence was observed for adenomas of the pituitary and adenomas/adenocarcinomas of the adrenal cortex in both sexes, mammary gland tumors and endometrial carcinomas (45%) in females, and C-cell adenomas/adenocarcinomas of the thyroid gland and tumors of the hemopoietic system (28%) in males (Baum et al, 1995).			Mammal	
C144080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144080>	C143446	Grade 1 Enterovesical Fistula, CTCAE|Grade 1 Enterovesical fistula|Grade 1 Enterovesical fistula	Asymptomatic			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144081>	C143190	Grade 1 Eosinophilia, CTCAE|Grade 1 Eosinophilia|Grade 1 Eosinophilia	>ULN and >Baseline			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144082>	C143447	Grade 1 Epistaxis, CTCAE|Grade 1 Epistaxis|Grade 1 Epistaxis	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144083>	C143208	Grade 1 Epstein-Barr Virus Infection Reactivation, CTCAE|Grade 1 Epstein-Barr virus infection reactivation|Grade 1 Epstein-Barr virus infection reactivation	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144084>	C143449	Grade 1 Erythema Multiforme, CTCAE|Grade 1 Erythema multiforme|Grade 1 Erythema multiforme	Not associated with skin tenderness			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144085>	C143451	Grade 1 Esophageal Anastomotic Leak, CTCAE|Grade 1 Esophageal anastomotic leak|Grade 1 Esophageal anastomotic leak	Asymptomatic diagnostic finding; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144087>	C143453	Grade 1 Esophageal Hemorrhage, CTCAE|Grade 1 Esophageal hemorrhage|Grade 1 Esophageal hemorrhage	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144088>	C143456	Grade 1 Esophageal Obstruction, CTCAE|Grade 1 Esophageal obstruction|Grade 1 Esophageal obstruction	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144089>	C143457	Grade 1 Esophageal Pain, CTCAE|Grade 1 Esophageal pain|Grade 1 Esophageal pain	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14408>	C15172	LH, Rat Strain	LH: The strain exhibits mild hypertension (approx 165mmHg in males and 140mmHg in females at 14 weeks of age in 1984) with increased body weight and plasma lipids. There is reduced life-span (compared with LN and LL) with histopathological lesions characteristic of hypertensive disease in rats.			Mammal	
C144090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144090>	C143459	Grade 1 Esophageal Stenosis, CTCAE|Grade 1 Esophageal stenosis|Grade 1 Esophageal stenosis	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144091>	C143460	Grade 1 Esophageal Ulcer, CTCAE|Grade 1 Esophageal ulcer|Grade 1 Esophageal ulcer	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144092>	C143466	Grade 1 Extraocular Muscle Paresis, CTCAE|Grade 1 Extraocular muscle paresis|Grade 1 Extraocular muscle paresis	Asymptomatic; clinical or diagnostic observations only			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144093>	C143467	Grade 1 Extrapyramidal Disorder, CTCAE|Grade 1 Extrapyramidal disorder|Grade 1 Extrapyramidal disorder	Mild involuntary movements			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144094>	C143468	Grade 1 Eye Disorders - Other, Specify, CTCAE|Grade 1 Eye disorders - Other, specify|Grade 1 Eye disorders - Other, specify	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; no change in vision			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144095>	C143471	Grade 1 Eyelid Function Disorder, CTCAE|Grade 1 Eyelid function disorder|Grade 1 Eyelid function disorder	Clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144096>	C143472	Grade 1 Facial Muscle Weakness, CTCAE|Grade 1 Facial muscle weakness|Grade 1 Facial muscle weakness	Mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144097>	C143473	Grade 1 Facial Nerve Disorder, CTCAE|Grade 1 Facial nerve disorder|Grade 1 Facial nerve disorder	Mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144098>	C143474	Grade 1 Facial Pain, CTCAE|Grade 1 Facial pain|Grade 1 Facial pain	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144099>	C143475	Grade 1 Fall, CTCAE|Grade 1 Fall|Grade 1 Fall	Minor with no resultant injuries; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14409>	C15172	M520, Rat Strain	Low frequency of pancreatic exocrine tumors. By 12-15 months of age develop small local areas of nephritis that progress by 22-24 months to moderate to severe nephritis in 75% of animals (Snell 1967). About 33% of females over 18 months develop tumors of the uterus of endometrial origin. Adrenocortical adenomas (about 20% in males and 40% in females over 18 months of age), and phaeochromocytomas or preneoplastic nodules in adrenal medulla (about 67% of males over 21 months of age) (Snell 1965). Low blood pressure (21/23), reaching 121_1.2 (SEM) mmHg at 10 weeks of age. Resistant to development of methylcholanthrene -induced thyroiditis (Glover et al 1969).			Mammal	
C1440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1440>	C492|C1946	Sodium Phenylbutyrate|4-Phenylbutyric Acid, Sodium Salt|Buphenyl|Phenylbutyrate Sodium|SODIUM PHENYLBUTYRATE|SPB11|Sodium 4-Phenylbutyrate|Sodium 4-phenylbutyrate|phenylbutyrate	The sodium salt of phenylbutyrate, a derivative of the short-chain fatty acid butyrate, with potential antineoplastic activity. Phenylbutyrate reversibly inhibits class I and II histone deacetylases (HDACs), which may result in a global increase in gene expression, decreased cellular proliferation, increased cell differentiation, and the induction of apoptosis in susceptible tumor cell populations.	Sodium Phenylbutyrate		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C144100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144100>	C143476	Grade 1 Fallopian Tube Anastomotic Leak, CTCAE|Grade 1 Fallopian tube anastomotic leak|Grade 1 Fallopian tube anastomotic leak	Asymptomatic diagnostic finding; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144101>	C143479	Grade 1 Fat Atrophy, CTCAE|Grade 1 Fat atrophy	Covering <10% BSA and asymptomatic			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144102>	C143482	Grade 1 Fecal Incontinence, CTCAE|Grade 1 Fecal incontinence|Grade 1 Fecal incontinence	Occasional use of pads required			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144103>	C143483	Grade 1 Feminization Acquired, CTCAE|Grade 1 Feminization acquired|Grade 1 Feminization acquired	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144104>	C143485	Grade 1 Fever, CTCAE|Grade 1 Fever|Grade 1 Fever	38.0 - 39.0 degrees C (100.4 - 102.2 degrees F)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144105>	C143486	Grade 1 Fibrinogen Decreased, CTCAE|Grade 1 Fibrinogen decreased|Grade 1 Fibrinogen decreased	<1.0 - 0.75 x LLN; if abnormal, <25% decrease from baseline			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144106>	C143487	Grade 1 Fibrosis Deep Connective Tissue, CTCAE|Grade 1 Fibrosis deep connective tissue|Grade 1 Fibrosis deep connective tissue	Mild induration, able to move skin parallel to plane (sliding) and perpendicular to skin (pinching up)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144107>	C143488	Grade 1 Flank Pain, CTCAE|Grade 1 Flank pain|Grade 1 Flank pain	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144108>	C143489	Grade 1 Flashing Lights, CTCAE|Grade 1 Flashing lights|Grade 1 Flashing lights	Symptomatic			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144109>	C143491	Grade 1 Floaters, CTCAE|Grade 1 Floaters|Grade 1 Floaters	Symptomatic			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14410>	C15172	NBL, Rat Strain	Good reproductive performance. Hyperplasia and dysplasia of the dorsolateral prostate caused by implantation of testosterone and estradiol-17-filled silastic capsules. Prolonged implantation leads to prostatic carcinoma (Leav et al 1988, 1989).			Mammal	
C144110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144110>	C143492	Grade 1 Flu Like Symptoms, CTCAE|Grade 1 Flu like symptoms|Grade 1 Flu like symptoms	Mild flu-like symptoms present			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144111>	C143209	Grade 1 Folliculitis, CTCAE|Grade 1 Folliculitis|Grade 1 Folliculitis	No intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144112>	C143494	Grade 1 Forced Expiratory Volume Decreased, CTCAE|Grade 1 Forced expiratory volume decreased	FEV1% (percentages of observed FEV1 and FVC related to their respective predicted values) 99-70% predicted			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144113>	C143496	Grade 1 Gait Disturbance, CTCAE|Grade 1 Gait disturbance|Grade 1 Gait disturbance	Mild change in gait (e.g., wide-based, limping or hobbling)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144114>	C143498	Grade 1 Gastric Anastomotic Leak, CTCAE|Grade 1 Gastric anastomotic leak|Grade 1 Gastric anastomotic leak	Asymptomatic diagnostic finding; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144115>	C143499	Grade 1 Gastric Fistula, CTCAE|Grade 1 Gastric fistula|Grade 1 Gastric fistula	Asymptomatic			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144116>	C143500	Grade 1 Gastric Hemorrhage, CTCAE|Grade 1 Gastric hemorrhage|Grade 1 Gastric hemorrhage	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144117>	C143503	Grade 1 Gastric Stenosis, CTCAE|Grade 1 Gastric stenosis|Grade 1 Gastric stenosis	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144118>	C143504	Grade 1 Gastric Ulcer, CTCAE|Grade 1 Gastric ulcer|Grade 1 Gastric ulcer	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144119>	C143506	Grade 1 Gastroesophageal Reflux Disease, CTCAE|Grade 1 Gastroesophageal reflux disease|Grade 1 Gastroesophageal reflux disease	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14411>	C15172	NZR, Rat Strain	Tumors (atriocaval epithelial mesotheliomas) of right atrium or inferior vena cava occur in approximately 12-20% of animals of both sexes over 1 year. These tumors are slow growing, but apparently malignant, and closely resemble similar tumors found in humans (Goodall et al 1975). In a later study, most common neoplasms of animal over one year of age: atrioclaval mesotheliomas 12%, lung adenomas 10% (males), pituitary adenomas 23%, mammary tumors 7%, liver tumors 3%, cervical tumors 3% (in females) (Goodall and Doesburg 1981).			Mammal	
C144120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144120>	C143507	Grade 1 Gastrointestinal Anastomotic Leak, CTCAE|Grade 1 Gastrointestinal anastomotic leak|Grade 1 Gastrointestinal anastomotic leak	Asymptomatic diagnostic finding; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144121>	C143508	Grade 1 Gastrointestinal Disorders - Other, Specify, CTCAE|Grade 1 Gastrointestinal disorders - Other, specify|Grade 1 Gastrointestinal disorders - Other, specify	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144122>	C146637	Grade 1 Gastrointestinal Fistula, CTCAE|Grade 1 Gastrointestinal fistula|Grade 1 Gastrointestinal fistula	Asymptomatic			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144123>	C143510	Grade 1 Gastrointestinal Pain, CTCAE|Grade 1 Gastrointestinal pain|Grade 1 Gastrointestinal pain	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144124>	C143512	Grade 1 Gastroparesis, CTCAE|Grade 1 Gastroparesis|Grade 1 Gastroparesis	Mild nausea, early satiety and bloating, able to maintain caloric intake on regular diet			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144125>	C143513	Grade 1 General Disorders and Administration Site Conditions - Other, Specify, CTCAE|Grade 1 General disorders and administration site conditions - Other, specify|Grade 1 General disorders and administration site conditions - Other, specify	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144126>	C143202	Grade 1 Generalized Edema, CTCAE|Grade 1 Generalized edema|Grade 1 Generalized edema	Noted on exam; 1+ pitting edema			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144127>	C143514	Grade 1 Generalized Muscle Weakness, CTCAE|Grade 1 Generalized muscle weakness|Grade 1 Generalized muscle weakness	Symptomatic; perceived by patient but not evident on physical exam			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144128>	C143515	Grade 1 Genital Edema, CTCAE|Grade 1 Genital edema	Mild swelling or obscuration of anatomic architecture on close inspection			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144129>	C143516	Grade 1 GGT Increased, CTCAE|Grade 1 GGT increased|Grade 1 GGT increased	>ULN - 2.5 x ULN if baseline was normal or less than normal; 1.0 - 1.5 x baseline if baseline was >ULN			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14412>	C15172	SHR, Rat Strain|SHR	SHR: rats develop hypertension spontaneously without exception at the age of 7-15 weeks. There is a systolic blood pressure plateau of about 200 mmHg. The genetic basis is polygenic, with at least three major genes involved (Tanase and Suzuki 1971, Yen et al 1974). There is a high incidence of cardiovascular disease (Okamoto et al 1973), but a low incidence of stroke which can be increased to about 30% with chronic stress (Yamori 1984).			Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C144130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144130>	C146626	Grade 1 Gingival Pain, CTCAE|Grade 1 Gingival pain|Grade 1 Gingival pain	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144131>	C143518	Grade 1 Glossopharyngeal Nerve Disorder, CTCAE|Grade 1 Glossopharyngeal nerve disorder|Grade 1 Glossopharyngeal nerve disorder	Mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144132>	C143519	Grade 1 Glucose Intolerance, CTCAE|Grade 1 Glucose intolerance	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144133>	C143238	Grade 1 Glucosuria, CTCAE|Grade 1 Glucosuria|Grade 1 Glucosuria	Present			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144134>	C143521	Grade 1 Growth Hormone Abnormal, CTCAE|Grade 1 Growth hormone abnormal|Grade 1 Growth hormone abnormal	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144135>	C143522	Grade 1 Growth Suppression, CTCAE|Grade 1 Growth suppression|Grade 1 Growth suppression	Reduction in growth velocity by 10 - 29% ideally measured over the period of a year			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144136>	C143231	Grade 1 Guillain-Barre Syndrome, CTCAE|Grade 1 Guillain-Barre syndrome|Grade 1 Guillain-Barre syndrome	Mild symptoms			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144137>	C143523	Grade 1 Gum Infection, CTCAE|Grade 1 Gum infection|Grade 1 Gum infection	Local therapy indicated (swish and swallow)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144138>	C146685	Grade 1 Gynecomastia, CTCAE|Grade 1 Gynecomastia|Grade 1 Gynecomastia	Asymptomatic			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144139>	C143244	Grade 1 Hair Color Changes, CTCAE|Grade 1 Hair color changes|Grade 1 Hair color changes	Present			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14413>	C15172	OXYS, Rat Strain	Inherited overproduction of free radicals, high levels of lipid peroxidation, protein oxidation, DNA rearrangements, morbid conditions mimicking human degenerative diseases: cataract, emphysema, cardiomyopathy, carcinogenesis; short life-span and low fecundity. Intensive transport of monosaccharides into the cells (Salganik et al 1994).			Mammal	
C144140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144140>	C143245	Grade 1 Hair Texture Abnormal, CTCAE|Grade 1 Hair texture abnormal|Grade 1 Hair texture abnormal	Present			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144141>	C143525	Grade 1 Hallucinations, CTCAE|Grade 1 Hallucinations|Grade 1 Hallucinations	Mild hallucinations (e.g., perceptual distortions)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144142>	C143526	Grade 1 Haptoglobin Decreased, CTCAE|Grade 1 Haptoglobin decreased|Grade 1 Haptoglobin decreased	<LLN			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144143>	C143527	Grade 1 Headache, CTCAE|Grade 1 Headache|Grade 1 Headache	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144144>	C143528	Grade 1 Hearing Impaired, CTCAE|Grade 1 Hearing impaired|Grade 1 Hearing impaired	Adult: Subjective change in hearing in the absence of documented hearing loss; threshold shift of 15 - 25 dB averaged at 2 contiguous test frequencies in at least one ear (on a 1, 2, 4, 3, 6, and 8 kHz audiogram); Pediatric (on a 1, 2, 3, 4, 6, and 8 kHz audiogram): Threshold shift >20 dB hearing loss (HL) (i.e., 25 dB HL or greater); sensorineural hearing loss (SNHL) above 4 kHz (i.e., 6 or 8 kHz) in at least one ear			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144145>	C143529	Grade 1 Heart Failure, CTCAE|Grade 1 Heart failure|Grade 1 Heart failure	Mild symptoms; no initiation or intensification of treatment			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144146>	C143531	Grade 1 Hematosalpinx, CTCAE|Grade 1 Hematosalpinx|Grade 1 Hematosalpinx	Minimal bleeding identified on imaging study or laparoscopy; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144147>	C143532	Grade 1 Hematuria, CTCAE|Grade 1 Hematuria|Grade 1 Hematuria	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144148>	C143533	Grade 1 Hemoglobin Increased, CTCAE|Grade 1 Hemoglobin increased|Grade 1 Hemoglobin increased	Increase in >0 - 2 g/dL above ULN			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144149>	C143537	Grade 1 Hemorrhoidal Hemorrhage, CTCAE|Grade 1 Hemorrhoidal hemorrhage|Grade 1 Hemorrhoidal hemorrhage	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14414>	C15172	WAG, Rat Strain	Tumors: medullary thyroid carcinoma 27%, chromophobe adenoma of the pituitary 68%, adrenal cortical adenoma 29%, pheochromocytoma 2%, islet cell adenoma 1%. Mean life-span more than 31 months in females and 22 months in males (Boorman et al 1972). Mean life-span 31 months in females with pituitary tumors found in 69% of females. Other common tumors include medullary thyroid carcinoma 40%, adrenal cortical adenoma 29%, fibroadenoma of breast 21% with 19 other types of tumor found in 290 animals (Boorman and Hollander 1973).			Mammal	
C144150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144150>	C143540	Grade 1 Hepatic Hemorrhage, CTCAE|Grade 1 Hepatic hemorrhage|Grade 1 Hepatic hemorrhage	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144151>	C143542	Grade 1 Hepatic Pain, CTCAE|Grade 1 Hepatic pain|Grade 1 Hepatic pain	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144152>	C143211	Grade 1 Hepatitis B Reactivation, CTCAE|Grade 1 Hepatitis B reactivation|Grade 1 Hepatitis B reactivation	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144153>	C143543	Grade 1 Hepatitis Viral, CTCAE|Grade 1 Hepatitis viral|Grade 1 Hepatitis viral	Asymptomatic, intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144154>	C143544	Grade 1 Hepatobiliary Disorders - Other, Specify, CTCAE|Grade 1 Hepatobiliary disorders - Other, specify|Grade 1 Hepatobiliary disorders - Other, specify	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144155>	C143212	Grade 1 Herpes Simplex Reactivation, CTCAE|Grade 1 Herpes simplex reactivation|Grade 1 Herpes simplex reactivation	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144156>	C143545	Grade 1 Hiccups, CTCAE|Grade 1 Hiccups|Grade 1 Hiccups	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144157>	C143547	Grade 1 Hirsutism, CTCAE|Grade 1 Hirsutism|Grade 1 Hirsutism	In women, increase in length, thickness or density of hair in a male distribution that the patient is able to camouflage by periodic shaving, bleaching, or removal of hair			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144158>	C143548	Grade 1 Hoarseness, CTCAE|Grade 1 Hoarseness|Grade 1 Hoarseness	Mild or intermittent voice change; fully understandable; self-resolves			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144159>	C143549	Grade 1 Hot Flashes, CTCAE|Grade 1 Hot flashes|Grade 1 Hot flashes	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14415>	C14382	OM/N, substrain				Mammal	
C144160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144160>	C143551	Grade 1 Hypercalcemia, CTCAE|Grade 1 Hypercalcemia|Grade 1 Hypercalcemia	Corrected serum calcium of >ULN - 11.5 mg/dL; >ULN - 2.9 mmol/L; Ionized calcium >ULN - 1.5 mmol/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144161>	C143552	Grade 1 Hyperglycemia, CTCAE|Grade 1 Hyperglycemia	Abnormal glucose above baseline with no medical intervention			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144162>	C143553	Grade 1 Hyperhidrosis, CTCAE|Grade 1 Hyperhidrosis|Grade 1 Hyperhidrosis	Limited to one site (palms, soles, or axillae); self care interventions			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144163>	C143554	Grade 1 Hyperkalemia, CTCAE|Grade 1 Hyperkalemia|Grade 1 Hyperkalemia	>ULN - 5.5 mmol/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144164>	C143246	Grade 1 Hyperkeratosis, CTCAE|Grade 1 Hyperkeratosis|Grade 1 Hyperkeratosis	Present			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144165>	C143221	Grade 1 Hyperlipidemia, CTCAE|Grade 1 Hyperlipidemia|Grade 1 Hyperlipidemia	Requiring diet changes			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144166>	C143555	Grade 1 Hypermagnesemia, CTCAE|Grade 1 Hypermagnesemia|Grade 1 Hypermagnesemia	>ULN - 3.0 mg/dL; >ULN - 1.23 mmol/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144167>	C143556	Grade 1 Hypernatremia, CTCAE|Grade 1 Hypernatremia|Grade 1 Hypernatremia	>ULN - 150 mmol/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144168>	C143557	Grade 1 Hyperparathyroidism, CTCAE|Grade 1 Hyperparathyroidism|Grade 1 Hyperparathyroidism	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144169>	C143222	Grade 1 Hyperphosphatemia, CTCAE|Grade 1 Hyperphosphatemia|Grade 1 Hyperphosphatemia	Laboratory finding only and intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14416>	C14244	Abelson Murine Leukemia Virus|A-MuLV	A retrovirus that is associated with leukemia and induces in vitro transformation of certain mouse cells.			Virus	
C144170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144170>	C143558	Grade 1 Hypersomnia, CTCAE|Grade 1 Hypersomnia|Grade 1 Hypersomnia	Mild increased need for sleep			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144171>	C143560	Grade 1 Hyperthyroidism, CTCAE|Grade 1 Hyperthyroidism|Grade 1 Hyperthyroidism	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144172>	C143561	Grade 1 Hypertrichosis, CTCAE|Grade 1 Hypertrichosis|Grade 1 Hypertrichosis	Increase in length, thickness or density of hair that the patient is either able to camouflage by periodic shaving or removal of hairs or is not concerned enough about the overgrowth to use any form of hair removal			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144173>	C143562	Grade 1 Hypertriglyceridemia, CTCAE|Grade 1 Hypertriglyceridemia|Grade 1 Hypertriglyceridemia	150 mg/dL - 300 mg/dL; 1.71 mmol/L - 3.42 mmol/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144174>	C143563	Grade 1 Hyperuricemia, CTCAE|Grade 1 Hyperuricemia|Grade 1 Hyperuricemia	>ULN without physiologic consequences			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144175>	C143564	Grade 1 Hypoalbuminemia, CTCAE|Grade 1 Hypoalbuminemia|Grade 1 Hypoalbuminemia	<LLN - 3 g/dL; <LLN - 30 g/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144176>	C143565	Grade 1 Hypocalcemia, CTCAE|Grade 1 Hypocalcemia|Grade 1 Hypocalcemia	Corrected serum calcium of <LLN - 8.0 mg/dL; <LLN - 2.0 mmol/L; Ionized calcium <LLN - 1.0 mmol/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144177>	C143566	Grade 1 Hypoglossal Nerve Disorder, CTCAE|Grade 1 Hypoglossal nerve disorder|Grade 1 Hypoglossal nerve disorder	Mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144178>	C143567	Grade 1 Hypoglycemia, CTCAE|Grade 1 Hypoglycemia|Grade 1 Hypoglycemia	<LLN - 55 mg/dL; <LLN - 3.0 mmol/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144179>	C143569	Grade 1 Hypokalemia, CTCAE|Grade 1 Hypokalemia|Grade 1 Hypokalemia	<LLN - 3.0 mmol/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14417>	C160998	Rat Strains|Common Rat Strains	Breeds of rats utilized for biological research.	Rat Strains		Mammal	
C144180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144180>	C143570	Grade 1 Hypomagnesemia, CTCAE|Grade 1 Hypomagnesemia|Grade 1 Hypomagnesemia	<LLN - 1.2 mg/dL; <LLN - 0.5 mmol/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144181>	C143571	Grade 1 Hyponatremia, CTCAE|Grade 1 Hyponatremia|Grade 1 Hyponatremia	<LLN - 130 mmol/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144182>	C143572	Grade 1 Hypoparathyroidism, CTCAE|Grade 1 Hypoparathyroidism|Grade 1 Hypoparathyroidism	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144183>	C143573	Grade 1 Hypophosphatemia, CTCAE|Grade 1 Hypophosphatemia|Grade 1 Hypophosphatemia	Laboratory finding only and intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144184>	C143193	Grade 1 Hypophysitis, CTCAE|Grade 1 Hypophysitis|Grade 1 Hypophysitis	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144185>	C143194	Grade 1 Hypopituitarism, CTCAE|Grade 1 Hypopituitarism|Grade 1 Hypopituitarism	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144186>	C143576	Grade 1 Hypothyroidism, CTCAE|Grade 1 Hypothyroidism|Grade 1 Hypothyroidism	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14418>	C14420	Wild Type Mouse		Wild Type Mouse		Mammal	
C144190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144190>	C143578	Grade 1 Ileal Stenosis, CTCAE|Grade 1 Ileal stenosis|Grade 1 Ileal stenosis	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144193>	C143580	Grade 1 Immune System Disorders - Other, Specify, CTCAE|Grade 1 Immune system disorders - Other, specify|Grade 1 Immune system disorders - Other, specify	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144194>	C143581	Grade 1 Infections and Infestations - Other, Specify, CTCAE|Grade 1 Infections and infestations - Other, specify|Grade 1 Infections and infestations - Other, specify	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144195>	C143583	Grade 1 Infusion Related Reaction, CTCAE|Grade 1 Infusion related reaction|Grade 1 Infusion related reaction	Mild transient reaction; infusion interruption not indicated; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144196>	C143584	Grade 1 Infusion Site Extravasation, CTCAE|Grade 1 Infusion site extravasation|Grade 1 Infusion site extravasation	Painless edema			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144197>	C143585	Grade 1 Injection Site Reaction, CTCAE|Grade 1 Injection site reaction|Grade 1 Injection site reaction	Tenderness with or without associated symptoms (e.g., warmth, erythema, itching)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144199>	C143588	Grade 1 Injury To Superior Vena Cava, CTCAE|Grade 1 Injury to superior vena cava|Grade 1 Injury to superior vena cava	Asymptomatic diagnostic finding; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14419>	C14376	Organism Strain|STRAIN|Strain|Strain|Strain|Strain Number|strain|strain	A population or type of organisms that is genetically different from others of the same species and possessing a set of defined characteristics.	Organism Strains		Organism	BRIDG Attribute Terminology|BRIDG Terminology|CDISC SDTM Non-host Organism Identifiers Parameter Code Terminology|CDISC SDTM Non-host Organism Identifiers Parameter Long Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C1441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1441>	C2156	Carzelesin|2-Benzofurancarboxamide, N-(2-((1-(chloromethyl)-1,6-dihydro-8-methyl-5-(((phenylamino)carbonyl)oxy)benzo(1,2-b:4,3-b')dipyrrol-3(2H)-yl)carbonyl)-1H-indol-5-yl)-6-(diethylamino)-, (S)-|CARZELESIN|U-80244|carzelesin	A cyclopropylpyrroloindole prodrug analogue and DNA minor groove binding agent, with antineoplastic activity.  After hydrolysis, the cyclopropyl group of carzelesin alkylates N3-adenine in a sequence-selective fashion. This results in tumor growth inhibition.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C144200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144200>	C143589	Grade 1 Injury, Poisoning and Procedural Complications - Other, Specify, CTCAE|Grade 1 Injury, poisoning and procedural complications - Other, specify|Grade 1 Injury, poisoning and procedural complications - Other, specify	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144201>	C143590	Grade 1 INR Increased, CTCAE|Grade 1 INR increased|Grade 1 INR increased	>1.2 - 1.5; >1 - 1.5 x baseline if on anticoagulation; monitoring only indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144202>	C143592	Grade 1 Intestinal Stoma Leak, CTCAE|Grade 1 Intestinal stoma leak|Grade 1 Intestinal stoma leak	Asymptomatic diagnostic finding; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144203>	C143594	Grade 1 Intestinal Stoma Site Bleeding, CTCAE|Grade 1 Intestinal stoma site bleeding|Grade 1 Intestinal stoma site bleeding	Minimal bleeding identified on clinical exam; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144204>	C143596	Grade 1 Intracranial Hemorrhage, CTCAE|Grade 1 Intracranial hemorrhage	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144205>	C143597	Grade 1 Intraoperative Arterial Injury, CTCAE|Grade 1 Intraoperative arterial injury|Grade 1 Intraoperative arterial injury	Primary repair of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144206>	C143598	Grade 1 Intraoperative Breast Injury, CTCAE|Grade 1 Intraoperative breast injury|Grade 1 Intraoperative breast injury	Primary repair of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144207>	C143600	Grade 1 Intraoperative Ear Injury, CTCAE|Grade 1 Intraoperative ear injury|Grade 1 Intraoperative ear injury	Primary repair of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144208>	C143601	Grade 1 Intraoperative Endocrine Injury, CTCAE|Grade 1 Intraoperative endocrine injury|Grade 1 Intraoperative endocrine injury	Primary repair of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144209>	C143602	Grade 1 Intraoperative Gastrointestinal Injury, CTCAE|Grade 1 Intraoperative gastrointestinal injury|Grade 1 Intraoperative gastrointestinal injury	Primary repair of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14420>	C14238	Mouse Strains|Mouse Strain	Breeds of mice utilized for biological research.	Mouse Strains		Mammal	
C144210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144210>	C143603	Grade 1 Intraoperative Head and Neck Injury, CTCAE|Grade 1 Intraoperative head and neck injury|Grade 1 Intraoperative head and neck injury	Primary repair of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144211>	C143605	Grade 1 Intraoperative Hepatobiliary Injury, CTCAE|Grade 1 Intraoperative hepatobiliary injury|Grade 1 Intraoperative hepatobiliary injury	Primary repair of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144212>	C143606	Grade 1 Intraoperative Musculoskeletal Injury, CTCAE|Grade 1 Intraoperative musculoskeletal injury|Grade 1 Intraoperative musculoskeletal injury	Primary repair of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144213>	C143607	Grade 1 Intraoperative Neurological Injury, CTCAE|Grade 1 Intraoperative neurological injury|Grade 1 Intraoperative neurological injury	Primary repair of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144214>	C143608	Grade 1 Intraoperative Ocular Injury, CTCAE|Grade 1 Intraoperative ocular injury|Grade 1 Intraoperative ocular injury	Primary repair of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144215>	C143609	Grade 1 Intraoperative Renal Injury, CTCAE|Grade 1 Intraoperative renal injury|Grade 1 Intraoperative renal injury	Primary repair of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144216>	C143610	Grade 1 Intraoperative Reproductive Tract Injury, CTCAE|Grade 1 Intraoperative reproductive tract injury|Grade 1 Intraoperative reproductive tract injury	Primary repair of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144217>	C143611	Grade 1 Intraoperative Respiratory Injury, CTCAE|Grade 1 Intraoperative respiratory injury|Grade 1 Intraoperative respiratory injury	Primary repair of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144218>	C143613	Grade 1 Intraoperative Urinary Injury, CTCAE|Grade 1 Intraoperative urinary injury|Grade 1 Intraoperative urinary injury	Primary repair of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144219>	C143614	Grade 1 Intraoperative Venous Injury, CTCAE|Grade 1 Intraoperative venous injury|Grade 1 Intraoperative venous injury	Primary repair of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14421>	C14420	Inbred Mouse Strains	Any strain of mouse that is the product of a mating between close relatives. In biological research, inbreeding allows for the selection of specific genotypes or phenotypes that are of particular importance to the study being carried out.	Inbred Mouse		Mammal	
C144220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144220>	C143615	Grade 1 Investigations - Other, Specify, CTCAE|Grade 1 Investigations - Other, specify|Grade 1 Investigations - Other, specify	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144221>	C143617	Grade 1 Irregular Menstruation, CTCAE|Grade 1 Irregular menstruation|Grade 1 Irregular menstruation	Intermittent/irregular menses for <=3 consecutive menstrual cycles			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144222>	C143618	Grade 1 Irritability, CTCAE|Grade 1 Irritability|Grade 1 Irritability	Mild; easily consolable			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144223>	C143619	Grade 1 Ischemia Cerebrovascular, CTCAE|Grade 1 Ischemia cerebrovascular	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144227>	C143623	Grade 1 Jejunal Stenosis, CTCAE|Grade 1 Jejunal stenosis|Grade 1 Jejunal stenosis	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144229>	C143627	Grade 1 Joint Range of Motion Decreased Cervical Spine, CTCAE|Grade 1 Joint range of motion decreased cervical spine|Grade 1 Joint range of motion decreased cervical spine	Mild restriction of rotation or flexion between 60 - 70 degrees			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144230>	C143628	Grade 1 Joint Range of Motion Decreased Lumbar Spine, CTCAE|Grade 1 Joint range of motion decreased lumbar spine|Grade 1 Joint range of motion decreased lumbar spine	Stiffness; difficulty bending to the floor to pick up a very light object but able to do athletic activity			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144231>	C143629	Grade 1 Joint Range of Motion Decreased, CTCAE|Grade 1 Joint range of motion decreased|Grade 1 Joint range of motion decreased	<=25% loss of ROM (range of motion); decreased ROM limiting athletic activity			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144232>	C143631	Grade 1 Kidney Anastomotic Leak, CTCAE|Grade 1 Kidney anastomotic leak|Grade 1 Kidney anastomotic leak	Asymptomatic diagnostic finding; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144233>	C143633	Grade 1 Kyphosis, CTCAE|Grade 1 Kyphosis|Grade 1 Kyphosis	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144234>	C143634	Grade 1 Lactation Disorder, CTCAE|Grade 1 Lactation disorder|Grade 1 Lactation disorder	Mild changes in lactation, not significantly affecting production or expression of breast milk			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144235>	C143635	Grade 1 Large Intestinal Anastomotic Leak, CTCAE|Grade 1 Large intestinal anastomotic leak|Grade 1 Large intestinal anastomotic leak	Asymptomatic diagnostic finding; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144236>	C143636	Grade 1 Laryngeal Edema, CTCAE|Grade 1 Laryngeal edema|Grade 1 Laryngeal edema	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144239>	C143637	Grade 1 Laryngeal Inflammation, CTCAE|Grade 1 Laryngeal inflammation|Grade 1 Laryngeal inflammation	Mild sore throat; raspy voice			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144240>	C143638	Grade 1 Laryngeal Mucositis, CTCAE|Grade 1 Laryngeal mucositis|Grade 1 Laryngeal mucositis	Endoscopic findings only; mild discomfort with normal intake			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144241>	C143639	Grade 1 Laryngeal Obstruction, CTCAE|Grade 1 Laryngeal obstruction|Grade 1 Laryngeal obstruction	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144242>	C143640	Grade 1 Laryngeal Stenosis, CTCAE|Grade 1 Laryngeal stenosis|Grade 1 Laryngeal stenosis	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144243>	C143642	Grade 1 Laryngopharyngeal Dysesthesia, CTCAE|Grade 1 Laryngopharyngeal dysesthesia|Grade 1 Laryngopharyngeal dysesthesia	Mild symptoms; no anxiety; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144244>	C143645	Grade 1 Lethargy, CTCAE|Grade 1 Lethargy|Grade 1 Lethargy	Mild symptoms; reduced alertness and awareness			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144245>	C143648	Grade 1 Leukoencephalopathy, CTCAE|Grade 1 Leukoencephalopathy|Grade 1 Leukoencephalopathy	Asymptomatic; small focal T2/FLAIR hyperintensities; involving periventricular white matter or <1/3 of susceptible areas of cerebrum +/- mild increase in subarachnoid space (SAS) and/or mild ventriculomegaly			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144246>	C143649	Grade 1 Libido Decreased, CTCAE|Grade 1 Libido decreased|Grade 1 Libido decreased	Decrease in sexual interest not adversely affecting relationship			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144247>	C143650	Grade 1 Libido Increased, CTCAE|Grade 1 Libido increased|Grade 1 Libido increased	Present			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144248>	C143651	Grade 1 Lip Infection, CTCAE|Grade 1 Lip infection|Grade 1 Lip infection	Localized, local intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144249>	C143652	Grade 1 Lipase Increased, CTCAE|Grade 1 Lipase increased|Grade 1 Lipase increased	>ULN - 1.5 x ULN			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14424>	C14421	C57BL/6 Mouse|B6|C57BL/6|C57BL/6	Derived by Little (1921) from A Lathrop stocks and separated out before 1937, the C57BL/6 mouse has a black coat and is one of the most widely used inbred strains. It accounts for 14% of all mouse inbred strain laboratory usage. The strain carries a Y chromosome of Asian Mus musculus origin and a LINE-1 element from Mus spretus, suggesting that up to 6.5% of the genome is Mus spretus in origin. Substrain C57BL/6 differs from other substrains at multiple loci, including H9, Igh2 and Lv, on chromosome 4. This mouse model is prone to the development of fatty lesions in the aorta similar to atheromatous plaque in humans, as well as hyperglycemia, hyperinsulinemia, hypercholesterolemia and non-insulin-dependent diabetes mellitus in response to a high fat diet. The C57BL/6 strain exhibits good reproductive performance and hermaphroditism in this substrain has been shown to occur.	C57BL/6 Mouse		Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C144250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144250>	C143653	Grade 1 Lipohypertrophy, CTCAE|Grade 1 Lipohypertrophy	Asymptomatic and covering <10% BSA			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144251>	C143654	Grade 1 Localized Edema, CTCAE|Grade 1 Localized edema|Grade 1 Localized edema	Localized to dependent areas, no disability or functional impairment			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144252>	C143655	Grade 1 Lordosis, CTCAE|Grade 1 Lordosis|Grade 1 Lordosis	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144253>	C143656	Grade 1 Lower Gastrointestinal Hemorrhage, CTCAE|Grade 1 Lower gastrointestinal hemorrhage	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144254>	C143660	Grade 1 Lymphedema, CTCAE|Grade 1 Lymphedema|Grade 1 Lymphedema	Trace thickening or faint discoloration			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144255>	C143662	Grade 1 Lymphocyte Count Decreased, CTCAE|Grade 1 Lymphocyte count decreased	<LLN-800/mm3; <LLN-0.8 x 10e9/L			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144256>	C143665	Grade 1 Malaise, CTCAE|Grade 1 Malaise|Grade 1 Malaise	Uneasiness or lack of well being			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144257>	C143666	Grade 1 Mania, CTCAE|Grade 1 Mania|Grade 1 Mania	Mild manic symptoms (e.g., elevated mood, rapid thoughts, rapid speech, decreased need for sleep)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144259>	C143669	Grade 1 Meningismus, CTCAE|Grade 1 Meningismus|Grade 1 Meningismus	Mild symptoms			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144260>	C143671	Grade 1 Menorrhagia, CTCAE|Grade 1 Menorrhagia|Grade 1 Menorrhagia	Mild; iron supplements indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144261>	C143672	Grade 1 Metabolism and Nutrition Disorders - Other, Specify, CTCAE|Grade 1 Metabolism and nutrition disorders - Other, specify|Grade 1 Metabolism and nutrition disorders - Other, specify	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144262>	C143673	Grade 1 Middle Ear Inflammation, CTCAE|Grade 1 Middle ear inflammation|Grade 1 Middle ear inflammation	Serous otitis			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144263>	C143674	Grade 1 Mitral Valve Disease, CTCAE|Grade 1 Mitral valve disease|Grade 1 Mitral valve disease	Asymptomatic valvular thickening with or without mild valvular regurgitation or stenosis by imaging			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144266>	C143677	Grade 1 Movements Involuntary, CTCAE|Grade 1 Movements involuntary|Grade 1 Movements involuntary	Mild symptoms			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144267>	C143678	Grade 1 Mucosal Infection, CTCAE|Grade 1 Mucosal infection|Grade 1 Mucosal infection	Localized, local intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144268>	C143679	Grade 1 Mucositis Oral, CTCAE|Grade 1 Mucositis oral|Grade 1 Mucositis oral	Asymptomatic or mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144269>	C143224	Grade 1 Muscle Cramp, CTCAE|Grade 1 Muscle cramp|Grade 1 Muscle cramp	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144270>	C143681	Grade 1 Muscle Weakness Left-Sided, CTCAE|Grade 1 Muscle weakness left-sided	Symptomatic; perceived by patient but not evident on physical exam			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144271>	C143682	Grade 1 Muscle Weakness Lower Limb, CTCAE|Grade 1 Muscle weakness lower limb|Grade 1 Muscle weakness lower limb	Symptomatic; perceived by patient but not evident on physical exam			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144272>	C143683	Grade 1 Muscle Weakness Right-Sided, CTCAE|Grade 1 Muscle weakness right-sided	Symptomatic; perceived by patient but not evident on physical exam			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144273>	C143684	Grade 1 Muscle Weakness Trunk, CTCAE|Grade 1 Muscle weakness trunk|Grade 1 Muscle weakness trunk	Symptomatic; perceived by patient but not evident on physical exam			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144274>	C143685	Grade 1 Muscle Weakness Upper Limb, CTCAE|Grade 1 Muscle weakness upper limb|Grade 1 Muscle weakness upper limb	Symptomatic; perceived by patient but not evident on physical exam			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144275>	C143686	Grade 1 Musculoskeletal and Connective Tissue Disorder - Other, Specify, CTCAE|Grade 1 Musculoskeletal and connective tissue disorder - Other, specify|Grade 1 Musculoskeletal and connective tissue disorder - Other, specify	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144276>	C143687	Grade 1 Musculoskeletal Deformity, CTCAE|Grade 1 Musculoskeletal deformity|Grade 1 Musculoskeletal deformity	Cosmetically and functionally insignificant hypoplasia			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144277>	C143688	Grade 1 Myalgia, CTCAE|Grade 1 Myalgia|Grade 1 Myalgia	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144278>	C143232	Grade 1 Myasthenia Gravis, CTCAE|Grade 1 Myasthenia gravis|Grade 1 Myasthenia gravis	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14427>	C14421	SWR/J Mouse|SWR/J		SWR/J Mouse		Mammal	
C144280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144280>	C143694	Grade 1 Nail Discoloration, CTCAE|Grade 1 Nail discoloration|Grade 1 Nail discoloration	Present			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144281>	C143695	Grade 1 Nail Infection, CTCAE|Grade 1 Nail infection|Grade 1 Nail infection	Localized, local intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144282>	C143696	Grade 1 Nail Loss, CTCAE|Grade 1 Nail loss|Grade 1 Nail loss	Asymptomatic separation of the nail bed from the nail plate or nail loss			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144283>	C143697	Grade 1 Nail Ridging, CTCAE|Grade 1 Nail ridging|Grade 1 Nail ridging	Present			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144284>	C143698	Grade 1 Nasal Congestion, CTCAE|Grade 1 Nasal congestion|Grade 1 Nasal congestion	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144285>	C143700	Grade 1 Neck Edema, CTCAE|Grade 1 Neck edema	Asymptomatic localized neck edema			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144286>	C143701	Grade 1 Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other, Specify, CTCAE|Grade 1 Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify|Grade 1 Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144287>	C143702	Grade 1 Nervous System Disorders - Other, Specify, CTCAE|Grade 1 Nervous system disorders - Other, specify|Grade 1 Nervous system disorders - Other, specify	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144288>	C143703	Grade 1 Neuralgia, CTCAE|Grade 1 Neuralgia|Grade 1 Neuralgia	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144289>	C143704	Grade 1 Neutrophil Count Decreased, CTCAE|Grade 1 Neutrophil count decreased	<LLN-1500/mm3; <LLN-1.5 x 10e9/L			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144290>	C143705	Grade 1 Night Blindness, CTCAE|Grade 1 Night blindness	Symptomatic but not limiting ADL			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144291>	C143706	Grade 1 Nipple Deformity, CTCAE|Grade 1 Nipple deformity|Grade 1 Nipple deformity	Asymptomatic; asymmetry with slight retraction and/or thickening of the nipple areolar complex			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144292>	C143707	Grade 1 Non-Cardiac Chest Pain, CTCAE|Grade 1 Non-cardiac chest pain|Grade 1 Non-cardiac chest pain	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144293>	C143710	Grade 1 Obstruction Gastric, CTCAE|Grade 1 Obstruction gastric|Grade 1 Obstruction gastric	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144294>	C143711	Grade 1 Oculomotor Nerve Disorder, CTCAE|Grade 1 Oculomotor nerve disorder|Grade 1 Oculomotor nerve disorder	Mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144295>	C143713	Grade 1 Oligospermia, CTCAE|Grade 1 Oligospermia|Grade 1 Oligospermia	Sperm concentration >0 to <15 million/ml			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144296>	C143714	Grade 1 Optic Nerve Disorder, CTCAE|Grade 1 Optic nerve disorder|Grade 1 Optic nerve disorder	Asymptomatic; clinical or diagnostic observations only			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144297>	C143715	Grade 1 Oral Cavity Fistula, CTCAE|Grade 1 Oral cavity fistula|Grade 1 Oral cavity fistula	Asymptomatic			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144298>	C143716	Grade 1 Oral Dysesthesia, CTCAE|Grade 1 Oral dysesthesia|Grade 1 Oral dysesthesia	Mild discomfort; not interfering with oral intake			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C1442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1442>	C1594	Morpholinodoxorubicin|5,12-Naphthacenedione, 7, 8, 9, 10-tetrahydro-6, 8, 11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2, 3, 6-trideoxy-3-(4-morpholinyl)-alpha-L-lyxo-hexopyranosyl] oxy]-, hydrochloride, (8S-cis)-|MORPHOLINODOXORUBICIN|morpholino-ADR|morpholino-adriamycin	A semisynthetic derivative of the anthracycline antineoplastic antibiotic doxorubicin.  As an antineoplastic agent, morpholinodoxorubicin is more potent than doxorubicin.  Similar to doxorubicin, morpholinodoxorubicin intercalates into DNA and causes single- and double-strand breaks in DNA via inhibition of topoisomerase I and II.  Unlike doxorubicin, this agent is metabolized in vivo to a DNA-alkylating derivative that forms DNA interstrand cross-links, thereby potentiating its doxorubicin-like cytotoxicity. (NCI04)			Antibiotic|Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C144301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144301>	C143241	Grade 1 Oropharyngeal Pain, CTCAE|Grade 1 Oropharyngeal pain|Grade 1 Oropharyngeal pain	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144302>	C143717	Grade 1 Osteonecrosis of Jaw, CTCAE|Grade 1 Osteonecrosis of jaw|Grade 1 Osteonecrosis of jaw	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144303>	C143225	Grade 1 Osteonecrosis, CTCAE|Grade 1 Osteonecrosis|Grade 1 Osteonecrosis	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144304>	C143719	Grade 1 Otitis Externa, CTCAE|Grade 1 Otitis externa|Grade 1 Otitis externa	Localized, local intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144306>	C143722	Grade 1 Ovarian Rupture, CTCAE|Grade 1 Ovarian rupture|Grade 1 Ovarian rupture	Asymptomatic clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144307>	C143723	Grade 1 Pain In Extremity, CTCAE|Grade 1 Pain in extremity|Grade 1 Pain in extremity	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144308>	C143724	Grade 1 Pain of Skin, CTCAE|Grade 1 Pain of skin|Grade 1 Pain of skin	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144309>	C143725	Grade 1 Pain, CTCAE|Grade 1 Pain|Grade 1 Pain	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144310>	C143726	Grade 1 Palmar-Plantar Erythrodysesthesia Syndrome, CTCAE|Grade 1 Palmar-plantar erythrodysesthesia syndrome|Grade 1 Palmar-plantar erythrodysesthesia syndrome	Minimal skin changes or dermatitis (e.g., erythema, edema, or hyperkeratosis) without pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144311>	C143729	Grade 1 Pancreatic Anastomotic Leak, CTCAE|Grade 1 Pancreatic anastomotic leak|Grade 1 Pancreatic anastomotic leak	Asymptomatic diagnostic finding; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144312>	C143730	Grade 1 Pancreatic Duct Stenosis, CTCAE|Grade 1 Pancreatic duct stenosis|Grade 1 Pancreatic duct stenosis	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144313>	C143731	Grade 1 Pancreatic Enzymes Decreased, CTCAE|Grade 1 Pancreatic enzymes decreased	<LLN and asymptomatic			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144316>	C143734	Grade 1 Papilledema, CTCAE|Grade 1 Papilledema|Grade 1 Papilledema	Asymptomatic; no visual field deficit			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144317>	C143735	Grade 1 Papulopustular Rash, CTCAE|Grade 1 Papulopustular rash	Papules and/or pustules covering <10% BSA, which may or may not be associated with symptoms of pruritus or tenderness			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144318>	C143736	Grade 1 Paresthesia, CTCAE|Grade 1 Paresthesia|Grade 1 Paresthesia	Mild symptoms			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144319>	C143737	Grade 1 Paronychia, CTCAE|Grade 1 Paronychia|Grade 1 Paronychia	Nail fold edema or erythema; disruption of the cuticle			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144320>	C143738	Grade 1 Paroxysmal Atrial Tachycardia, CTCAE|Grade 1 Paroxysmal atrial tachycardia|Grade 1 Paroxysmal atrial tachycardia	Asymptomatic, intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144321>	C143739	Grade 1 Pelvic Floor Muscle Weakness, CTCAE|Grade 1 Pelvic floor muscle weakness|Grade 1 Pelvic floor muscle weakness	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144322>	C146679	Grade 1 Pelvic Pain, CTCAE|Grade 1 Pelvic pain|Grade 1 Pelvic pain	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144323>	C143741	Grade 1 Penile Infection, CTCAE|Grade 1 Penile infection|Grade 1 Penile infection	Localized, local intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144325>	C146681	Grade 1 Perineal Pain, CTCAE|Grade 1 Perineal pain|Grade 1 Perineal pain	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144326>	C143747	Grade 1 Periorbital Edema, CTCAE|Grade 1 Periorbital edema|Grade 1 Periorbital edema	Soft or non-pitting			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144327>	C143750	Grade 1 Peripheral Motor Neuropathy, CTCAE|Grade 1 Peripheral motor neuropathy|Grade 1 Peripheral motor neuropathy	Mild symptoms; clinical or diagnostic observations only			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144328>	C143752	Grade 1 Peripheral Sensory Neuropathy, CTCAE|Grade 1 Peripheral sensory neuropathy|Grade 1 Peripheral sensory neuropathy	Mild symptoms			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144329>	C143754	Grade 1 Personality Change, CTCAE|Grade 1 Personality change|Grade 1 Personality change	Mild personality change			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144330>	C146682	Grade 1 Phantom Pain, CTCAE|Grade 1 Phantom pain|Grade 1 Phantom pain	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144331>	C143755	Grade 1 Pharyngeal Anastomotic Leak, CTCAE|Grade 1 Pharyngeal anastomotic leak|Grade 1 Pharyngeal anastomotic leak	Asymptomatic diagnostic finding; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144334>	C143756	Grade 1 Pharyngeal Mucositis, CTCAE|Grade 1 Pharyngeal mucositis|Grade 1 Pharyngeal mucositis	Endoscopic findings only; minimal symptoms with normal oral intake; mild pain but analgesics not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144335>	C143757	Grade 1 Pharyngeal Stenosis, CTCAE|Grade 1 Pharyngeal stenosis|Grade 1 Pharyngeal stenosis	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144336>	C143759	Grade 1 Pharyngolaryngeal Pain, CTCAE|Grade 1 Pharyngolaryngeal pain|Grade 1 Pharyngolaryngeal pain	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144337>	C143760	Grade 1 Phlebitis Infective, CTCAE|Grade 1 Phlebitis infective|Grade 1 Phlebitis infective	Localized, local intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144338>	C143764	Grade 1 Platelet Count Decreased, CTCAE|Grade 1 Platelet count decreased	<LLN-75,000/mm3; <LLN-75.0 x 10e9/L			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144339>	C143765	Grade 1 Pleural Effusion, CTCAE|Grade 1 Pleural effusion|Grade 1 Pleural effusion	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144341>	C146663	Grade 1 Pleuritic Pain, CTCAE|Grade 1 Pleuritic pain|Grade 1 Pleuritic pain	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144342>	C143767	Grade 1 Pneumonitis, CTCAE|Grade 1 Pneumonitis|Grade 1 Pneumonitis	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144343>	C143771	Grade 1 Postnasal Drip, CTCAE|Grade 1 Postnasal drip|Grade 1 Postnasal drip	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144344>	C143772	Grade 1 Postoperative Hemorrhage, CTCAE|Grade 1 Postoperative hemorrhage|Grade 1 Postoperative hemorrhage	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144345>	C146645	Grade 1 Precocious Puberty, CTCAE|Grade 1 Precocious puberty|Grade 1 Precocious puberty	Physical signs of puberty with no biochemical markers for females <8 years and males <9 years			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144346>	C143775	Grade 1 Pregnancy, Puerperium and Perinatal Conditions - Other, Specify, CTCAE|Grade 1 Pregnancy, puerperium and perinatal conditions - Other, specify|Grade 1 Pregnancy, puerperium and perinatal conditions - Other, specify	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144347>	C143776	Grade 1 Premature Delivery, CTCAE|Grade 1 Premature delivery|Grade 1 Premature delivery	Delivery of a liveborn infant at >34 to 37 weeks gestation			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144348>	C143780	Grade 1 Productive Cough, CTCAE|Grade 1 Productive cough|Grade 1 Productive cough	Occasional/minimal production of sputum with cough			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144349>	C143781	Grade 1 Prolapse of Intestinal Stoma, CTCAE|Grade 1 Prolapse of intestinal stoma|Grade 1 Prolapse of intestinal stoma	Asymptomatic; reducible			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144350>	C143782	Grade 1 Prolapse of Urostomy, CTCAE|Grade 1 Prolapse of urostomy|Grade 1 Prolapse of urostomy	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144352>	C143784	Grade 1 Prostatic Obstruction, CTCAE|Grade 1 Prostatic obstruction|Grade 1 Prostatic obstruction	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144353>	C146664	Grade 1 Prostatic Pain, CTCAE|Grade 1 Prostatic pain|Grade 1 Prostatic pain	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144354>	C143787	Grade 1 Psychiatric Disorders - Other, Specify, CTCAE|Grade 1 Psychiatric disorders - Other, specify|Grade 1 Psychiatric disorders - Other, specify	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144355>	C143788	Grade 1 Psychosis, CTCAE|Grade 1 Psychosis|Grade 1 Psychosis	Mild psychotic symptoms			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144356>	C143789	Grade 1 Pulmonary Edema, CTCAE|Grade 1 Pulmonary edema|Grade 1 Pulmonary edema	Radiologic findings only; minimal dyspnea on exertion			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144357>	C143790	Grade 1 Pulmonary Fibrosis, CTCAE|Grade 1 Pulmonary fibrosis|Grade 1 Pulmonary fibrosis	Radiologic pulmonary fibrosis <25% of lung volume associated with hypoxia			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144358>	C143791	Grade 1 Pulmonary Fistula, CTCAE|Grade 1 Pulmonary fistula|Grade 1 Pulmonary fistula	Asymptomatic			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144359>	C143793	Grade 1 Pulmonary Valve Disease, CTCAE|Grade 1 Pulmonary valve disease|Grade 1 Pulmonary valve disease	Asymptomatic valvular thickening with or without mild valvular regurgitation or stenosis by imaging			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144360>	C143794	Grade 1 Purpura, CTCAE|Grade 1 Purpura|Grade 1 Purpura	Combined area of lesions covering <10% BSA			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144361>	C143795	Grade 1 Pyramidal Tract Syndrome, CTCAE|Grade 1 Pyramidal tract syndrome|Grade 1 Pyramidal tract syndrome	Mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144362>	C143796	Grade 1 Radiation Recall Reaction (Dermatologic), CTCAE|Grade 1 Radiation recall reaction (dermatologic)|Grade 1 Radiation recall reaction (dermatologic)	Faint erythema or dry desquamation			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144363>	C143797	Grade 1 Radiculitis, CTCAE|Grade 1 Radiculitis|Grade 1 Radiculitis	Mild symptoms			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144364>	C143798	Grade 1 Rash Acneiform, CTCAE|Grade 1 Rash acneiform	Papules and/or pustules covering <10% BSA, which may or may not be associated with symptoms of pruritus or tenderness			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144365>	C143799	Grade 1 Rash Maculo-Papular, CTCAE|Grade 1 Rash maculo-papular	Macules/papules covering <10% BSA with or without symptoms (e.g., pruritus, burning, tightness)			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144366>	C143801	Grade 1 Rectal Anastomotic Leak, CTCAE|Grade 1 Rectal anastomotic leak|Grade 1 Rectal anastomotic leak	Asymptomatic diagnostic finding; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144367>	C143200	Grade 1 Rectal Fissure, CTCAE|Grade 1 Rectal fissure|Grade 1 Rectal fissure	Asymptomatic			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144370>	C143802	Grade 1 Rectal Mucositis, CTCAE|Grade 1 Rectal mucositis|Grade 1 Rectal mucositis	Asymptomatic or mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144372>	C146631	Grade 1 Rectal Pain, CTCAE|Grade 1 Rectal pain|Grade 1 Rectal pain	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144373>	C143803	Grade 1 Rectal Stenosis, CTCAE|Grade 1 Rectal stenosis|Grade 1 Rectal stenosis	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144375>	C143804	Grade 1 Recurrent Laryngeal Nerve Palsy, CTCAE|Grade 1 Recurrent laryngeal nerve palsy|Grade 1 Recurrent laryngeal nerve palsy	Mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144376>	C143805	Grade 1 Renal and Urinary Disorders - Other, Specify, CTCAE|Grade 1 Renal and urinary disorders - Other, specify|Grade 1 Renal and urinary disorders - Other, specify	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144377>	C143806	Grade 1 Renal Calculi, CTCAE|Grade 1 Renal calculi|Grade 1 Renal calculi	Asymptomatic or mild symptoms; occasional use of nonprescription analgesics indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144378>	C143807	Grade 1 Renal Colic, CTCAE|Grade 1 Renal colic|Grade 1 Renal colic	Mild pain not interfering with activity; nonprescription medication indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144380>	C143808	Grade 1 Reproductive System and Breast Disorders - Other, Specify, CTCAE|Grade 1 Reproductive system and breast disorders - Other, specify|Grade 1 Reproductive system and breast disorders - Other, specify	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144381>	C143810	Grade 1 Respiratory, Thoracic and Mediastinal Disorders - Other, Specify, CTCAE|Grade 1 Respiratory, thoracic and mediastinal disorders - Other, specify|Grade 1 Respiratory, thoracic and mediastinal disorders - Other, specify	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144382>	C143811	Grade 1 Restlessness, CTCAE|Grade 1 Restlessness|Grade 1 Restlessness	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144383>	C143814	Grade 1 Retinal Tear, CTCAE|Grade 1 Retinal tear|Grade 1 Retinal tear	No retinal detachment and treatment not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144384>	C143226	Grade 1 Rhabdomyolysis, CTCAE|Grade 1 Rhabdomyolysis|Grade 1 Rhabdomyolysis	Asymptomatic, intervention not indicated; laboratory findings only			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144385>	C143242	Grade 1 Rhinorrhea, CTCAE|Grade 1 Rhinorrhea|Grade 1 Rhinorrhea	Present			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144386>	C143227	Grade 1 Rotator Cuff Injury, CTCAE|Grade 1 Rotator cuff injury|Grade 1 Rotator cuff injury	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144387>	C143821	Grade 1 Salivary Duct Inflammation, CTCAE|Grade 1 Salivary duct inflammation|Grade 1 Salivary duct inflammation	Slightly thickened saliva; slightly altered taste (e.g., metallic)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144388>	C143823	Grade 1 Scleral Disorder, CTCAE|Grade 1 Scleral disorder|Grade 1 Scleral disorder	No change in vision from baseline			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144389>	C143824	Grade 1 Scoliosis, CTCAE|Grade 1 Scoliosis|Grade 1 Scoliosis	<20 degrees; clinically undetectable			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144390>	C143825	Grade 1 Scrotal Infection, CTCAE|Grade 1 Scrotal infection|Grade 1 Scrotal infection	Localized, local intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144391>	C146665	Grade 1 Scrotal Pain, CTCAE|Grade 1 Scrotal pain|Grade 1 Scrotal pain	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144392>	C146700	Grade 1 Seizure, CTCAE|Grade 1 Seizure	Brief partial seizure and no loss of consciousness			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144393>	C143829	Grade 1 Serum Amylase Increased, CTCAE|Grade 1 Serum amylase increased|Grade 1 Serum amylase increased	>ULN - 1.5 x ULN			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144394>	C146642	Grade 1 Serum Sickness, CTCAE|Grade 1 Serum sickness|Grade 1 Serum sickness	Clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144395>	C143213	Grade 1 Shingles, CTCAE|Grade 1 Shingles|Grade 1 Shingles	Localized, local intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144396>	C143831	Grade 1 Sinus Disorder, CTCAE|Grade 1 Sinus disorder|Grade 1 Sinus disorder	Asymptomatic mucosal crusting; blood-tinged secretions			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144397>	C143833	Grade 1 Skin and Subcutaneous Tissue Disorders - Other, Specify, CTCAE|Grade 1 Skin and subcutaneous tissue disorders - Other, specify|Grade 1 Skin and subcutaneous tissue disorders - Other, specify	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144398>	C143835	Grade 1 Skin Hyperpigmentation, CTCAE|Grade 1 Skin hyperpigmentation|Grade 1 Skin hyperpigmentation	Present			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144399>	C143836	Grade 1 Skin Hypopigmentation, CTCAE|Grade 1 Skin hypopigmentation|Grade 1 Skin hypopigmentation	Present			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C1443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1443>	C718	Organochlorine Compound|Organochlorines	Organochlorines are a group of compounds belonging to the chlorinated hydrocarbon pesticides (as aldrin, DDT, or dieldrin).  These compounds are believed to associated with many cancers, especially with breast cancer.			Chemical Viewed Structurally|Organic Chemical	
C144400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144400>	C143837	Grade 1 Skin Induration, CTCAE|Grade 1 Skin induration|Grade 1 Skin induration	Mild induration, able to move skin parallel to plane (sliding) and perpendicular to skin (pinching up)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144401>	C143838	Grade 1 Skin Infection, CTCAE|Grade 1 Skin infection|Grade 1 Skin infection	Localized, local intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144402>	C143228	Grade 1 Skin Papilloma, CTCAE|Grade 1 Skin papilloma|Grade 1 Skin papilloma	Asymptomatic; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144403>	C143839	Grade 1 Skin Ulceration, CTCAE|Grade 1 Skin ulceration|Grade 1 Skin ulceration	Combined area of ulcers <1 cm; nonblanchable erythema of intact skin with associated warmth or edema			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144404>	C143840	Grade 1 Sleep Apnea, CTCAE|Grade 1 Sleep apnea|Grade 1 Sleep apnea	Snoring and nocturnal sleep arousal without apneic periods			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144405>	C143841	Grade 1 Small Intestinal Anastomotic Leak, CTCAE|Grade 1 Small intestinal anastomotic leak|Grade 1 Small intestinal anastomotic leak	Asymptomatic diagnostic finding; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144406>	C143842	Grade 1 Small Intestinal Mucositis, CTCAE|Grade 1 Small intestinal mucositis|Grade 1 Small intestinal mucositis	Asymptomatic or mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144407>	C143843	Grade 1 Small Intestinal Obstruction, CTCAE|Grade 1 Small intestinal obstruction|Grade 1 Small intestinal obstruction	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144408>	C143844	Grade 1 Small Intestinal Stenosis, CTCAE|Grade 1 Small intestinal stenosis|Grade 1 Small intestinal stenosis	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144409>	C143846	Grade 1 Small Intestine Ulcer, CTCAE|Grade 1 Small intestine ulcer|Grade 1 Small intestine ulcer	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144410>	C143847	Grade 1 Sneezing, CTCAE|Grade 1 Sneezing|Grade 1 Sneezing	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144411>	C143848	Grade 1 Social Circumstances - Other, Specify, CTCAE|Grade 1 Social circumstances - Other, specify|Grade 1 Social circumstances - Other, specify	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144412>	C143852	Grade 1 Somnolence, CTCAE|Grade 1 Somnolence|Grade 1 Somnolence	Mild but more than usual drowsiness or sleepiness			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144413>	C143853	Grade 1 Sore Throat, CTCAE|Grade 1 Sore throat|Grade 1 Sore throat	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144414>	C143854	Grade 1 Spasticity, CTCAE|Grade 1 Spasticity|Grade 1 Spasticity	Mild or slight increase in muscle tone			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144415>	C143855	Grade 1 Spermatic Cord Anastomotic Leak, CTCAE|Grade 1 Spermatic cord anastomotic leak|Grade 1 Spermatic cord anastomotic leak	Asymptomatic diagnostic finding; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144416>	C143856	Grade 1 Spinal Fracture, CTCAE|Grade 1 Spinal fracture	Mild back pain; nonprescription analgesics indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144417>	C143860	Grade 1 Stoma Site Infection, CTCAE|Grade 1 Stoma site infection|Grade 1 Stoma site infection	Localized, local intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144418>	C146694	Grade 1 Stomal Ulcer, CTCAE|Grade 1 Stomal ulcer|Grade 1 Stomal ulcer	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144419>	C143862	Grade 1 Stroke, CTCAE|Grade 1 Stroke|Grade 1 Stroke	Incidental radiographic findings only			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144420>	C143248	Grade 1 Subcutaneous Emphysema, CTCAE|Grade 1 Subcutaneous emphysema|Grade 1 Subcutaneous emphysema	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144421>	C143864	Grade 1 Suicidal Ideation, CTCAE|Grade 1 Suicidal ideation|Grade 1 Suicidal ideation	Increased thoughts of death but no wish to kill oneself			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144422>	C143866	Grade 1 Superficial Soft Tissue Fibrosis, CTCAE|Grade 1 Superficial soft tissue fibrosis|Grade 1 Superficial soft tissue fibrosis	Mild induration, able to move skin parallel to plane (sliding) and perpendicular to skin (pinching up)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144423>	C143868	Grade 1 Superior Vena Cava Syndrome, CTCAE|Grade 1 Superior vena cava syndrome|Grade 1 Superior vena cava syndrome	Asymptomatic; incidental finding of SVC thrombosis			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144424>	C143869	Grade 1 Surgical and Medical Procedures - Other, Specify, CTCAE|Grade 1 Surgical and medical procedures - Other, specify|Grade 1 Surgical and medical procedures - Other, specify	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144425>	C143234	Grade 1 Tendon Reflex Decreased, CTCAE|Grade 1 Tendon reflex decreased|Grade 1 Tendon reflex decreased	Ankle reflex reduced			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144426>	C143872	Grade 1 Testicular Disorder, CTCAE|Grade 1 Testicular disorder|Grade 1 Testicular disorder	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144428>	C146666	Grade 1 Testicular Pain, CTCAE|Grade 1 Testicular pain|Grade 1 Testicular pain	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144429>	C143195	Grade 1 Testosterone Deficiency, CTCAE|Grade 1 Testosterone deficiency|Grade 1 Testosterone deficiency	Asymptomatic; mild symptoms with no intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144430>	C143873	Grade 1 Thromboembolic Event, CTCAE|Grade 1 Thromboembolic event	Medical intervention not indicated (e.g., superficial thrombosis)			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144431>	C143214	Grade 1 Thrush, CTCAE|Grade 1 Thrush	Asymptomatic; local symptomatic management			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144432>	C143220	Grade 1 Thyroid Stimulating Hormone Increased, CTCAE|Grade 1 Thyroid stimulating hormone increased|Grade 1 Thyroid stimulating hormone increased	TSH increased and no intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144433>	C146690	Grade 1 Tinnitus, CTCAE|Grade 1 Tinnitus|Grade 1 Tinnitus	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144434>	C143876	Grade 1 Tooth Development Disorder, CTCAE|Grade 1 Tooth development disorder|Grade 1 Tooth development disorder	Asymptomatic; hypoplasia of tooth or enamel			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144435>	C143877	Grade 1 Tooth Discoloration, CTCAE|Grade 1 Tooth discoloration|Grade 1 Tooth discoloration	Surface stains			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144436>	C143879	Grade 1 Toothache, CTCAE|Grade 1 Toothache|Grade 1 Toothache	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144439>	C143881	Grade 1 Tracheal Mucositis, CTCAE|Grade 1 Tracheal mucositis|Grade 1 Tracheal mucositis	Endoscopic findings only; minimal hemoptysis, pain, or respiratory symptoms			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144440>	C143882	Grade 1 Tracheal Obstruction, CTCAE|Grade 1 Tracheal obstruction|Grade 1 Tracheal obstruction	Partial asymptomatic obstruction on examination (e.g., visual, radiologic or endoscopic)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144441>	C143883	Grade 1 Tracheal Stenosis, CTCAE|Grade 1 Tracheal stenosis|Grade 1 Tracheal stenosis	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144442>	C143885	Grade 1 Tracheostomy Site Bleeding, CTCAE|Grade 1 Tracheostomy site bleeding|Grade 1 Tracheostomy site bleeding	Minimal bleeding identified on clinical exam; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144443>	C143886	Grade 1 Transient Ischemic Attacks, CTCAE|Grade 1 Transient ischemic attacks|Grade 1 Transient ischemic attacks	Mild neurologic deficit with or without imaging confirmation			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144444>	C143889	Grade 1 Tricuspid Valve Disease, CTCAE|Grade 1 Tricuspid valve disease|Grade 1 Tricuspid valve disease	Asymptomatic valvular thickening with or without mild valvular regurgitation or stenosis			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144445>	C143890	Grade 1 Trigeminal Nerve Disorder, CTCAE|Grade 1 Trigeminal nerve disorder|Grade 1 Trigeminal nerve disorder	Mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144446>	C143235	Grade 1 Trochlear Nerve Disorder, CTCAE|Grade 1 Trochlear nerve disorder|Grade 1 Trochlear nerve disorder	Mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144447>	C143229	Grade 1 Tumor Hemorrhage, CTCAE|Grade 1 Tumor hemorrhage|Grade 1 Tumor hemorrhage	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144448>	C143894	Grade 1 Unequal Limb Length, CTCAE|Grade 1 Unequal limb length|Grade 1 Unequal limb length	Mild length discrepancy <2 cm			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144449>	C143895	Grade 1 Upper Gastrointestinal Hemorrhage, CTCAE|Grade 1 Upper gastrointestinal hemorrhage|Grade 1 Upper gastrointestinal hemorrhage	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144450>	C143897	Grade 1 Ureteric Anastomotic Leak, CTCAE|Grade 1 Ureteric anastomotic leak|Grade 1 Ureteric anastomotic leak	Asymptomatic diagnostic finding; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144451>	C143898	Grade 1 Urethral Anastomotic Leak, CTCAE|Grade 1 Urethral anastomotic leak|Grade 1 Urethral anastomotic leak	Asymptomatic diagnostic finding; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144452>	C143901	Grade 1 Urinary Frequency, CTCAE|Grade 1 Urinary frequency|Grade 1 Urinary frequency	Present			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144453>	C143905	Grade 1 Urinary Tract Obstruction, CTCAE|Grade 1 Urinary tract obstruction|Grade 1 Urinary tract obstruction	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144454>	C143906	Grade 1 Urinary Tract Pain, CTCAE|Grade 1 Urinary tract pain|Grade 1 Urinary tract pain	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144455>	C143907	Grade 1 Urinary Urgency, CTCAE|Grade 1 Urinary urgency|Grade 1 Urinary urgency	Present			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144456>	C143908	Grade 1 Urine Discoloration, CTCAE|Grade 1 Urine discoloration|Grade 1 Urine discoloration	Present			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144457>	C143910	Grade 1 Urostomy Leak, CTCAE|Grade 1 Urostomy leak|Grade 1 Urostomy leak	Asymptomatic diagnostic finding; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144458>	C143911	Grade 1 Urostomy Obstruction, CTCAE|Grade 1 Urostomy obstruction|Grade 1 Urostomy obstruction	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144459>	C143912	Grade 1 Urostomy Site Bleeding, CTCAE|Grade 1 Urostomy site bleeding|Grade 1 Urostomy site bleeding	Minimal bleeding identified on clinical exam; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144460>	C143915	Grade 1 Uterine Anastomotic Leak, CTCAE|Grade 1 Uterine anastomotic leak|Grade 1 Uterine anastomotic leak	Asymptomatic diagnostic finding; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144461>	C143916	Grade 1 Uterine Fistula, CTCAE|Grade 1 Uterine fistula|Grade 1 Uterine fistula	Asymptomatic			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144463>	C143918	Grade 1 Uterine Obstruction, CTCAE|Grade 1 Uterine obstruction|Grade 1 Uterine obstruction	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144464>	C146683	Grade 1 Uterine Pain, CTCAE|Grade 1 Uterine pain|Grade 1 Uterine pain	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144465>	C143216	Grade 1 Vaccination Complication, CTCAE|Grade 1 Vaccination complication	Mild pain; erythema 2.5-5cm; induration/swelling 2.5-5cm; does not interfere with activity			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144466>	C143203	Grade 1 Vaccination Site Lymphadenopathy, CTCAE|Grade 1 Vaccination site lymphadenopathy|Grade 1 Vaccination site lymphadenopathy	Local lymph node enlargement			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144467>	C143921	Grade 1 Vaginal Anastomotic Leak, CTCAE|Grade 1 Vaginal anastomotic leak|Grade 1 Vaginal anastomotic leak	Asymptomatic diagnostic finding; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144468>	C143922	Grade 1 Vaginal Discharge, CTCAE|Grade 1 Vaginal discharge|Grade 1 Vaginal discharge	Mild vaginal discharge (greater than baseline for patient)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144471>	C143924	Grade 1 Vaginal Infection, CTCAE|Grade 1 Vaginal infection|Grade 1 Vaginal infection	Localized, local intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144472>	C143925	Grade 1 Vaginal Inflammation, CTCAE|Grade 1 Vaginal inflammation|Grade 1 Vaginal inflammation	Mild discomfort or pain, edema, or redness			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144473>	C146696	Grade 1 Vaginal Obstruction, CTCAE|Grade 1 Vaginal obstruction|Grade 1 Vaginal obstruction	Asymptomatic; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144474>	C146684	Grade 1 Vaginal Pain, CTCAE|Grade 1 Vaginal pain|Grade 1 Vaginal pain	Mild pain			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144475>	C143926	Grade 1 Vaginal Stricture, CTCAE|Grade 1 Vaginal stricture|Grade 1 Vaginal stricture	Asymptomatic; mild vaginal shortening or narrowing			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144476>	C143927	Grade 1 Vagus Nerve Disorder, CTCAE|Grade 1 Vagus nerve disorder|Grade 1 Vagus nerve disorder	Mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144477>	C143928	Grade 1 Vas Deferens Anastomotic Leak, CTCAE|Grade 1 Vas deferens anastomotic leak|Grade 1 Vas deferens anastomotic leak	Asymptomatic diagnostic finding; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144478>	C143929	Grade 1 Vascular Access Complication, CTCAE|Grade 1 Vascular access complication|Grade 1 Vascular access complication	TPA administration into line with no intent for systemic therapy indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144479>	C143930	Grade 1 Vascular Disorders - Other, Specify, CTCAE|Grade 1 Vascular disorders - Other, specify|Grade 1 Vascular disorders - Other, specify	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144480>	C143933	Grade 1 Venous Injury, CTCAE|Grade 1 Venous injury|Grade 1 Venous injury	Asymptomatic diagnostic finding; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144481>	C146629	Grade 1 Ventricular Arrhythmia, CTCAE|Grade 1 Ventricular arrhythmia|Grade 1 Ventricular arrhythmia	Asymptomatic, intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144482>	C143935	Grade 1 Vertigo, CTCAE|Grade 1 Vertigo|Grade 1 Vertigo	Mild symptoms			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144483>	C143937	Grade 1 Virilization, CTCAE|Grade 1 Virilization|Grade 1 Virilization	Mild symptoms; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144484>	C143939	Grade 1 Vital Capacity Abnormal, CTCAE|Grade 1 Vital capacity abnormal|Grade 1 Vital capacity abnormal	90 - 75% of predicted value			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144485>	C143941	Grade 1 Voice Alteration, CTCAE|Grade 1 Voice alteration|Grade 1 Voice alteration	Mild or intermittent change from normal voice			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144486>	C143943	Grade 1 Vulval Infection, CTCAE|Grade 1 Vulval infection|Grade 1 Vulval infection	Localized, local intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144487>	C143944	Grade 1 Watering Eyes, CTCAE|Grade 1 Watering eyes|Grade 1 Watering eyes	Intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144488>	C143947	Grade 1 Wheezing, CTCAE|Grade 1 Wheezing	Detectable airway noise with minimal symptoms			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144489>	C143948	Grade 1 White Blood Cell Decreased, CTCAE|Grade 1 White blood cell decreased|Grade 1 White blood cell decreased	<LLN - 3000/mm3; <LLN - 3.0 x 10^9/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14448>	C14421	SJL/J Mouse|SJL/J		SJL/J Mouse		Mammal	
C144490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144490>	C143949	Grade 1 Wound Complication, CTCAE|Grade 1 Wound complication|Grade 1 Wound complication	Observation only; topical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144491>	C143950	Grade 1 Wound Dehiscence, CTCAE|Grade 1 Wound dehiscence|Grade 1 Wound dehiscence	Incisional separation, intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144492>	C143951	Grade 1 Wound Infection, CTCAE|Grade 1 Wound infection|Grade 1 Wound infection	Localized, local intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144493>	C143952	Grade 1 Wrist Fracture, CTCAE|Grade 1 Wrist fracture	Mild; non-operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144494>	C143253	Grade 2 Abdominal Distension, CTCAE|Grade 2 Abdominal distension|Grade 2 Abdominal distension	Symptomatic; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144495>	C143254	Grade 2 Abdominal Infection, CTCAE|Grade 2 Abdominal infection|Grade 2 Abdominal infection	Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144496>	C143255	Grade 2 Abdominal Pain, CTCAE|Grade 2 Abdominal pain|Grade 2 Abdominal pain	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144497>	C143256	Grade 2 Abdominal Soft Tissue Necrosis, CTCAE|Grade 2 Abdominal soft tissue necrosis|Grade 2 Abdominal soft tissue necrosis	Local wound care; medical intervention indicated (e.g., dressings or topical medications)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144498>	C143257	Grade 2 Abducens Nerve Disorder, CTCAE|Grade 2 Abducens nerve disorder|Grade 2 Abducens nerve disorder	Moderate symptoms; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144499>	C143258	Grade 2 Accessory Nerve Disorder, CTCAE|Grade 2 Accessory nerve disorder|Grade 2 Accessory nerve disorder	Moderate symptoms; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C1444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1444>	C45812	Folate|2-[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]aminopentanedioic acid|Vitamin B-11|folate	A cofactor for 1-carbon transfer involved with DNA synthesis.			Organic Chemical|Vitamin	
C144500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144500>	C143260	Grade 2 Acoustic Nerve Disorder NOS, CTCAE|Grade 2 Acoustic nerve disorder NOS|Grade 2 Acoustic nerve disorder NOS	Moderate symptoms; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144501>	C143261	Grade 2 Activated Partial Thromboplastin Time Prolonged, CTCAE|Grade 2 Activated partial thromboplastin time prolonged|Grade 2 Activated partial thromboplastin time prolonged	>1.5 - 2.5 x ULN			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144502>	C143266	Grade 2 Akathisia, CTCAE|Grade 2 Akathisia|Grade 2 Akathisia	Moderate restlessness or increased motor activity; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144503>	C143267	Grade 2 Alanine Aminotransferase Increased, CTCAE|Grade 2 Alanine aminotransferase increased|Grade 2 Alanine aminotransferase increased	>3.0 - 5.0 x ULN if baseline was normal or less than normal; >1.5 - 2.0 x baseline if baseline was >ULN			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144504>	C143268	Grade 2 Alcohol Intolerance, CTCAE|Grade 2 Alcohol intolerance|Grade 2 Alcohol intolerance	Present			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144505>	C143269	Grade 2 Alkaline Phosphatase Increased, CTCAE|Grade 2 Alkaline phosphatase increased	>2.5-5.0 x ULN if baseline was normal; >2.5-5.0 x baseline if baseline was abnormal			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144506>	C143271	Grade 2 Allergic Reaction, CTCAE|Grade 2 Allergic reaction|Grade 2 Allergic reaction	Oral intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144507>	C143272	Grade 2 Allergic Rhinitis, CTCAE|Grade 2 Allergic rhinitis|Grade 2 Allergic rhinitis	Moderate symptoms; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144508>	C143240	Grade 2 Amenorrhea, CTCAE|Grade 2 Amenorrhea|Grade 2 Amenorrhea	Present			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144509>	C143274	Grade 2 Amnesia, CTCAE|Grade 2 Amnesia|Grade 2 Amnesia	Moderate; short term memory loss; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144510>	C143197	Grade 2 Anal Fissure, CTCAE|Grade 2 Anal fissure|Grade 2 Anal fissure	Symptomatic			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144511>	C143275	Grade 2 Anal Fistula, CTCAE|Grade 2 Anal fistula|Grade 2 Anal fistula	Symptomatic, invasive intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144512>	C143276	Grade 2 Anal Hemorrhage, CTCAE|Grade 2 Anal hemorrhage	Moderate symptoms; intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144513>	C143277	Grade 2 Anal Mucositis, CTCAE|Grade 2 Anal mucositis|Grade 2 Anal mucositis	Moderate symptoms; medical intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144514>	C143279	Grade 2 Anal Pain, CTCAE|Grade 2 Anal pain|Grade 2 Anal pain	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144515>	C143280	Grade 2 Anal Stenosis, CTCAE|Grade 2 Anal stenosis|Grade 2 Anal stenosis	Symptomatic; altered GI function			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144516>	C143281	Grade 2 Anal Ulcer, CTCAE|Grade 2 Anal ulcer|Grade 2 Anal ulcer	Symptomatic; altered GI function			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144517>	C143283	Grade 2 Anemia, CTCAE|Grade 2 Anemia|Grade 2 Anemia	Hgb <10.0 - 8.0 g/dL; <6.2 - 4.9 mmol/L; <100 - 80 g/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144518>	C143284	Grade 2 Ankle Fracture, CTCAE|Grade 2 Ankle fracture	Limiting instrumental ADL; outpatient operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144519>	C143285	Grade 2 Anorectal Infection, CTCAE|Grade 2 Anorectal infection|Grade 2 Anorectal infection	Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144520>	C143287	Grade 2 Anorgasmia, CTCAE|Grade 2 Anorgasmia|Grade 2 Anorgasmia	Inability to achieve orgasm adversely affecting relationship			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144521>	C143289	Grade 2 Aortic Injury, CTCAE|Grade 2 Aortic injury|Grade 2 Aortic injury	Operative intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144522>	C143290	Grade 2 Aortic Valve Disease, CTCAE|Grade 2 Aortic valve disease|Grade 2 Aortic valve disease	Asymptomatic; moderate regurgitation or stenosis by imaging			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144523>	C143295	Grade 2 Arachnoiditis, CTCAE|Grade 2 Arachnoiditis|Grade 2 Arachnoiditis	Moderate symptoms; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144524>	C143296	Grade 2 Arterial Injury, CTCAE|Grade 2 Arterial injury|Grade 2 Arterial injury	Symptomatic; repair or revision not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144525>	C143298	Grade 2 Arthralgia, CTCAE|Grade 2 Arthralgia|Grade 2 Arthralgia	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144526>	C143299	Grade 2 Arthritis, CTCAE|Grade 2 Arthritis|Grade 2 Arthritis	Moderate pain associated with signs of inflammation, erythema, or joint swelling; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144527>	C143300	Grade 2 Ascites, CTCAE|Grade 2 Ascites|Grade 2 Ascites	Symptomatic; medical intervention or paracentesis indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144528>	C143301	Grade 2 Aspartate Aminotransferase Increased, CTCAE|Grade 2 Aspartate aminotransferase increased|Grade 2 Aspartate aminotransferase increased	>3.0 - 5.0 x ULN if baseline was normal or less than normal; >1.5 - 2.0 x baseline if baseline was >ULN			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144529>	C143308	Grade 2 Atrioventricular Block Complete, CTCAE|Grade 2 Atrioventricular block complete|Grade 2 Atrioventricular block complete	Non-urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144530>	C143309	Grade 2 Atrioventricular Block First Degree, CTCAE|Grade 2 Atrioventricular block first degree|Grade 2 Atrioventricular block first degree	Non-urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144531>	C143310	Grade 2 Autoimmune Disorder, CTCAE|Grade 2 Autoimmune disorder|Grade 2 Autoimmune disorder	Evidence of autoimmune reaction involving a non-essential organ or function (e.g., hypothyroidism)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144532>	C143311	Grade 2 Avascular Necrosis, CTCAE|Grade 2 Avascular necrosis	Symptomatic; limiting instrumental ADL			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144533>	C143312	Grade 2 Azoospermia, CTCAE|Grade 2 Azoospermia|Grade 2 Azoospermia	Absence of sperm in ejaculate			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144534>	C143206	Grade 2 Bacteremia, CTCAE|Grade 2 Bacteremia|Grade 2 Bacteremia	Blood culture positive with no signs or symptoms			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144535>	C143198	Grade 2 Belching, CTCAE|Grade 2 Belching|Grade 2 Belching	Intervention initiated (including over the counter medications)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144536>	C143314	Grade 2 Bile Duct Stenosis, CTCAE|Grade 2 Bile duct stenosis|Grade 2 Bile duct stenosis	Symptomatic; altered GI function; IV fluids indicated <24 hrs			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144537>	C143315	Grade 2 Biliary Anastomotic Leak, CTCAE|Grade 2 Biliary anastomotic leak|Grade 2 Biliary anastomotic leak	Symptomatic; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144538>	C143316	Grade 2 Biliary Fistula, CTCAE|Grade 2 Biliary fistula|Grade 2 Biliary fistula	Symptomatic, invasive intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144539>	C143317	Grade 2 Biliary Tract Infection, CTCAE|Grade 2 Biliary tract infection|Grade 2 Biliary tract infection	Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144540>	C143318	Grade 2 Bladder Anastomotic Leak, CTCAE|Grade 2 Bladder anastomotic leak|Grade 2 Bladder anastomotic leak	Symptomatic; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144541>	C143319	Grade 2 Bladder Infection, CTCAE|Grade 2 Bladder infection|Grade 2 Bladder infection	Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144543>	C143322	Grade 2 Bloating, CTCAE|Grade 2 Bloating|Grade 2 Bloating	Symptomatic, decreased oral intake; change in bowel function			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144544>	C143323	Grade 2 Blood and Lymphatic System Disorders - Other, Specify, CTCAE|Grade 2 Blood and lymphatic system disorders - Other, specify|Grade 2 Blood and lymphatic system disorders - Other, specify	Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144545>	C143324	Grade 2 Blood Antidiuretic Hormone Abnormal, CTCAE|Grade 2 Blood antidiuretic hormone abnormal|Grade 2 Blood antidiuretic hormone abnormal	Symptomatic; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144546>	C143325	Grade 2 Blood Bilirubin Increased, CTCAE|Grade 2 Blood bilirubin increased	>1.5-3.0 x ULN if baseline was normal; >1.5-3.0 x baseline if baseline was abnormal			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144547>	C143326	Grade 2 Blood Corticotrophin Decreased, CTCAE|Grade 2 Blood corticotrophin decreased|Grade 2 Blood corticotrophin decreased	Symptomatic; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144548>	C143327	Grade 2 Blood Gonadotrophin Abnormal, CTCAE|Grade 2 Blood gonadotrophin abnormal	Symptomatic; medical intervention indicated; limiting instrumental ADL			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144549>	C143328	Grade 2 Blood Prolactin Abnormal, CTCAE|Grade 2 Blood prolactin abnormal|Grade 2 Blood prolactin abnormal	Moderate symptoms; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144550>	C143330	Grade 2 Body Odor, CTCAE|Grade 2 Body odor|Grade 2 Body odor	Pronounced odor; psychosocial impact; patient seeks medical intervention			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144551>	C143331	Grade 2 Bone Infection, CTCAE|Grade 2 Bone infection|Grade 2 Bone infection	Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144552>	C143332	Grade 2 Bone Marrow Hypocellular, CTCAE|Grade 2 Bone marrow hypocellular|Grade 2 Bone marrow hypocellular	Moderately hypocellular or >25 - <50% reduction from normal cellularity for age			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144553>	C143335	Grade 2 Breast Atrophy, CTCAE|Grade 2 Breast atrophy	Moderate asymmetry; moderate atrophy			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144554>	C143336	Grade 2 Breast Infection, CTCAE|Grade 2 Breast infection|Grade 2 Breast infection	Local infection with moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144555>	C143338	Grade 2 Bronchial Fistula, CTCAE|Grade 2 Bronchial fistula|Grade 2 Bronchial fistula	Symptomatic, invasive intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144556>	C143339	Grade 2 Bronchial Infection, CTCAE|Grade 2 Bronchial infection|Grade 2 Bronchial infection	Moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144557>	C143340	Grade 2 Bronchial Obstruction, CTCAE|Grade 2 Bronchial obstruction|Grade 2 Bronchial obstruction	Symptomatic (e.g., mild wheezing); endoscopic evaluation indicated; radiographic evidence of atelectasis/lobar collapse; medical management indicated (e.g., steroids, bronchodilators)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144558>	C143341	Grade 2 Bronchial Stricture, CTCAE|Grade 2 Bronchial stricture|Grade 2 Bronchial stricture	Symptomatic (e.g., rhonchi or wheezing) but without respiratory distress; medical intervention indicated (e.g., steroids, bronchodilators)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144559>	C143342	Grade 2 Bronchopleural Fistula, CTCAE|Grade 2 Bronchopleural fistula|Grade 2 Bronchopleural fistula	Symptomatic, invasive intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144560>	C143343	Grade 2 Bronchopulmonary Hemorrhage, CTCAE|Grade 2 Bronchopulmonary hemorrhage|Grade 2 Bronchopulmonary hemorrhage	Moderate symptoms; invasive intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144561>	C143344	Grade 2 Bronchospasm, CTCAE|Grade 2 Bronchospasm|Grade 2 Bronchospasm	Symptomatic; medical intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144562>	C143345	Grade 2 Bruising, CTCAE|Grade 2 Bruising|Grade 2 Bruising	Generalized			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144563>	C143204	Grade 2 Budd-Chiari Syndrome, CTCAE|Grade 2 Budd-Chiari syndrome|Grade 2 Budd-Chiari syndrome	Medical management indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144564>	C143346	Grade 2 Bullous Dermatitis, CTCAE|Grade 2 Bullous dermatitis	Blisters covering 10-30% BSA; painful blisters; limiting instrumental ADL			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144565>	C143349	Grade 2 Capillary Leak Syndrome, CTCAE|Grade 2 Capillary leak syndrome|Grade 2 Capillary leak syndrome	Symptomatic; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144566>	C143350	Grade 2 Carbon Monoxide Diffusing Capacity Decreased, CTCAE|Grade 2 Carbon monoxide diffusing capacity decreased|Grade 2 Carbon monoxide diffusing capacity decreased	6 - 8 units below LLN if no baseline available; for follow-up, an asymptomatic decrease of >5 - 8 units (ml/min/mmHg) below the baseline value; symptomatic and intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144567>	C143352	Grade 2 Cardiac Disorders - Other, Specify, CTCAE|Grade 2 Cardiac disorders - Other, specify|Grade 2 Cardiac disorders - Other, specify	Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144568>	C143356	Grade 2 Catheter Related Infection, CTCAE|Grade 2 Catheter related infection|Grade 2 Catheter related infection	Localized; local intervention indicated; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144569>	C143357	Grade 2 CD4 Lymphocytes Decreased, CTCAE|Grade 2 CD4 lymphocytes decreased|Grade 2 CD4 lymphocytes decreased	<500 - 200/mm3; <0.5 - 0.2 x 10^9/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144570>	C143358	Grade 2 Cecal Hemorrhage, CTCAE|Grade 2 Cecal hemorrhage|Grade 2 Cecal hemorrhage	Moderate symptoms; intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144571>	C143359	Grade 2 Cecal Infection, CTCAE|Grade 2 Cecal infection|Grade 2 Cecal infection	Localized; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144572>	C143360	Grade 2 Central Nervous System Necrosis, CTCAE|Grade 2 Central nervous system necrosis|Grade 2 Central nervous system necrosis	Moderate symptoms; corticosteroids indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144573>	C143361	Grade 2 Cerebrospinal Fluid Leakage, CTCAE|Grade 2 Cerebrospinal fluid leakage|Grade 2 Cerebrospinal fluid leakage	Post-craniotomy: moderate symptoms; medical intervention indicated; post-lumbar puncture: persistent moderate symptoms; blood patch indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144574>	C143362	Grade 2 Cervicitis Infection, CTCAE|Grade 2 Cervicitis infection|Grade 2 Cervicitis infection	Localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144575>	C143364	Grade 2 Chest Pain - Cardiac, CTCAE|Grade 2 Chest pain - cardiac|Grade 2 Chest pain - cardiac	Moderate pain; pain on exertion; hemodynamically stable; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144576>	C143223	Grade 2 Chest Wall Necrosis, CTCAE|Grade 2 Chest wall necrosis|Grade 2 Chest wall necrosis	Local wound care; medical intervention indicated (e.g., dressings or topical medications)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144577>	C143366	Grade 2 Chills, CTCAE|Grade 2 Chills|Grade 2 Chills	Moderate tremor of the entire body; narcotics indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144578>	C143368	Grade 2 Cholesterol High, CTCAE|Grade 2 Cholesterol high|Grade 2 Cholesterol high	>300 - 400 mg/dL; >7.75 - 10.34 mmol/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144579>	C143369	Grade 2 Chronic Kidney Disease, CTCAE|Grade 2 Chronic kidney disease	eGFR or CrCl 59-30 ml/min/1.73 m2			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144580>	C143199	Grade 2 Chylous Ascites, CTCAE|Grade 2 Chylous ascites|Grade 2 Chylous ascites	Symptomatic; medical intervention indicated (e.g., fat-restricted diet); paracentesis or tube drainage indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144581>	C143373	Grade 2 Colonic Fistula, CTCAE|Grade 2 Colonic fistula|Grade 2 Colonic fistula	Symptomatic, invasive intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144582>	C143374	Grade 2 Colonic Hemorrhage, CTCAE|Grade 2 Colonic hemorrhage	Moderate symptoms; intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144583>	C143375	Grade 2 Colonic Obstruction, CTCAE|Grade 2 Colonic obstruction|Grade 2 Colonic obstruction	Symptomatic; altered GI function			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144584>	C143376	Grade 2 Colonic Perforation, CTCAE|Grade 2 Colonic perforation|Grade 2 Colonic perforation	Invasive intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144585>	C143377	Grade 2 Colonic Stenosis, CTCAE|Grade 2 Colonic stenosis|Grade 2 Colonic stenosis	Symptomatic; altered GI function			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144586>	C143378	Grade 2 Colonic Ulcer, CTCAE|Grade 2 Colonic ulcer|Grade 2 Colonic ulcer	Symptomatic; altered GI function			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144587>	C143379	Grade 2 Concentration Impairment, CTCAE|Grade 2 Concentration impairment|Grade 2 Concentration impairment	Moderate impairment in attention or decreased level of concentration; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144588>	C143380	Grade 2 Conduction Disorder, CTCAE|Grade 2 Conduction disorder	Non-urgent medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144589>	C143382	Grade 2 Congenital, Familial and Genetic Disorders - Other, Specify, CTCAE|Grade 2 Congenital, familial and genetic disorders - Other, specify|Grade 2 Congenital, familial and genetic disorders - Other, specify	Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144590>	C143383	Grade 2 Conjunctivitis Infective, CTCAE|Grade 2 Conjunctivitis infective|Grade 2 Conjunctivitis infective	Localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144591>	C143384	Grade 2 Conjunctivitis, CTCAE|Grade 2 Conjunctivitis|Grade 2 Conjunctivitis	Symptomatic; moderate decrease in visual acuity (best corrected visual acuity 20/40 and better or 3 lines or less decreased vision from known baseline)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144592>	C143386	Grade 2 Corneal Infection, CTCAE|Grade 2 Corneal infection|Grade 2 Corneal infection	Localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144593>	C143389	Grade 2 CPK Increased, CTCAE|Grade 2 CPK increased	>2.5 x ULN-5 x ULN			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144594>	C143391	Grade 2 Creatinine Increased, CTCAE|Grade 2 Creatinine increased|Grade 2 Creatinine increased	>1.5 - 3.0 x baseline if baseline is below LLN; >1.5 - 3.0 x ULN			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144595>	C143392	Grade 2 Cushingoid, CTCAE|Grade 2 Cushingoid|Grade 2 Cushingoid	Moderate symptoms; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144596>	C143192	Grade 2 Cyanosis, CTCAE|Grade 2 Cyanosis|Grade 2 Cyanosis	Present			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144597>	C143393	Grade 2 Cystitis Noninfective, CTCAE|Grade 2 Cystitis noninfective|Grade 2 Cystitis noninfective	Moderate hematuria; moderate increase in frequency, urgency, dysuria, nocturia or incontinence; urinary catheter placement or bladder irrigation indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144598>	C143394	Grade 2 Cytokine Release Syndrome, CTCAE|Grade 2 Cytokine release syndrome|Grade 2 Cytokine release syndrome	Hypotension responding to fluids; hypoxia requiring low-flow nasal cannula or blow-by			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144599>	C143207	Grade 2 Cytomegalovirus Infection Reactivation, CTCAE|Grade 2 Cytomegalovirus infection reactivation|Grade 2 Cytomegalovirus infection reactivation	Moderate symptoms; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C1445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1445>	C28153	Potassium Hyaluronate|Hyaluronate Potassium	The potassium salt form of hyaluronic acid, a glucosaminoglycan, a component of connective tissue, skin, vitreous humour, umbilical cord, synovial fluid and the capsule of certain microorganisms contributing to adhesion, elasticity, and viscosity of extracellular substances.			Biologically Active Substance|Organic Chemical	
C144600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144600>	C143398	Grade 2 Delayed Orgasm, CTCAE|Grade 2 Delayed orgasm|Grade 2 Delayed orgasm	Delay in achieving orgasm adversely affecting relationship			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144601>	C143400	Grade 2 Delirium, CTCAE|Grade 2 Delirium|Grade 2 Delirium	Moderate and acute confusional state; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144602>	C143401	Grade 2 Delusions, CTCAE|Grade 2 Delusions|Grade 2 Delusions	Moderate delusional symptoms			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144603>	C143402	Grade 2 Dental Caries, CTCAE|Grade 2 Dental caries|Grade 2 Dental caries	Dental caries involving the root			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144604>	C143403	Grade 2 Depressed Level of Consciousness, CTCAE|Grade 2 Depressed level of consciousness|Grade 2 Depressed level of consciousness	Sedation; slow response to stimuli; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144605>	C143405	Grade 2 Dermatitis Radiation, CTCAE|Grade 2 Dermatitis radiation|Grade 2 Dermatitis radiation	Moderate to brisk erythema; patchy moist desquamation, mostly confined to skin folds and creases; moderate edema			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144606>	C143406	Grade 2 Device Related Infection, CTCAE|Grade 2 Device related infection|Grade 2 Device related infection	Oral intervention indicated (e.g., antibiotic, antifungal)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144607>	C143410	Grade 2 Dry Eye, CTCAE|Grade 2 Dry eye|Grade 2 Dry eye	Symptomatic; moderate decrease in visual acuity (best corrected visual acuity 20/40 and better or 3 lines or less decreased vision from known baseline)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144608>	C143411	Grade 2 Dry Mouth, CTCAE|Grade 2 Dry mouth|Grade 2 Dry mouth	Moderate symptoms; oral intake alterations (e.g., copious water, other lubricants, diet limited to purees and/or soft, moist foods); unstimulated saliva 0.1 to 0.2 ml/min			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14460>	C14421	NON Mouse|NON		NON Mouse		Mammal	
C144610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144610>	C143414	Grade 2 Duodenal Hemorrhage, CTCAE|Grade 2 Duodenal hemorrhage|Grade 2 Duodenal hemorrhage	Moderate symptoms; intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144611>	C143415	Grade 2 Duodenal Infection, CTCAE|Grade 2 Duodenal infection|Grade 2 Duodenal infection	Moderate symptoms; medical intervention indicated (e.g., oral antibiotics)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144612>	C143416	Grade 2 Duodenal Obstruction, CTCAE|Grade 2 Duodenal obstruction|Grade 2 Duodenal obstruction	Symptomatic; altered GI function			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144613>	C143417	Grade 2 Duodenal Perforation, CTCAE|Grade 2 Duodenal perforation|Grade 2 Duodenal perforation	Invasive intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144614>	C143418	Grade 2 Duodenal Stenosis, CTCAE|Grade 2 Duodenal stenosis|Grade 2 Duodenal stenosis	Symptomatic; altered GI function			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144615>	C143419	Grade 2 Duodenal Ulcer, CTCAE|Grade 2 Duodenal ulcer|Grade 2 Duodenal ulcer	Symptomatic; medical intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144616>	C143420	Grade 2 Dysarthria, CTCAE|Grade 2 Dysarthria|Grade 2 Dysarthria	Moderate impairment of articulation or slurred speech			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144617>	C143421	Grade 2 Dysesthesia, CTCAE|Grade 2 Dysesthesia|Grade 2 Dysesthesia	Moderate sensory alteration; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144618>	C143422	Grade 2 Dysgeusia, CTCAE|Grade 2 Dysgeusia|Grade 2 Dysgeusia	Altered taste with change in diet (e.g., oral supplements); noxious or unpleasant taste; loss of taste			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144619>	C143423	Grade 2 Dysmenorrhea, CTCAE|Grade 2 Dysmenorrhea|Grade 2 Dysmenorrhea	Moderate symptoms; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144620>	C143424	Grade 2 Dyspareunia, CTCAE|Grade 2 Dyspareunia|Grade 2 Dyspareunia	Moderate discomfort or pain associated with vaginal penetration; discomfort or pain partially relieved with use of vaginal lubricants or estrogen			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144621>	C143425	Grade 2 Dyspepsia, CTCAE|Grade 2 Dyspepsia|Grade 2 Dyspepsia	Moderate symptoms; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144622>	C143427	Grade 2 Dysphasia, CTCAE|Grade 2 Dysphasia	Moderate receptive or expressive characteristics; impairing ability to communicate spontaneously			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144623>	C143429	Grade 2 Ear and Labyrinth Disorders - Other, Specify, CTCAE|Grade 2 Ear and labyrinth disorders - Other, specify|Grade 2 Ear and labyrinth disorders - Other, specify	Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144624>	C143430	Grade 2 Ear Pain, CTCAE|Grade 2 Ear pain|Grade 2 Ear pain	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144625>	C143243	Grade 2 Eczema, CTCAE|Grade 2 Eczema	Moderate; topical or oral intervention indicated; additional medical intervention over baseline indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144626>	C143432	Grade 2 Edema Face, CTCAE|Grade 2 Edema face|Grade 2 Edema face	Moderate localized edema; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144627>	C143433	Grade 2 Edema Limbs, CTCAE|Grade 2 Edema limbs	>10-30% inter-limb discrepancy in volume or circumference at point of greatest visible difference; readily apparent obscuration of anatomic architecture; obliteration of skin folds; readily apparent deviation from normal anatomic contour; limiting instrumental ADL			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144628>	C143434	Grade 2 Edema Trunk, CTCAE|Grade 2 Edema trunk	Readily apparent obscuration of anatomic architecture; obliteration of skin folds; readily apparent deviation from normal anatomic contour; limiting instrumental ADL			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144629>	C143435	Grade 2 Ejaculation Disorder, CTCAE|Grade 2 Ejaculation disorder|Grade 2 Ejaculation disorder	Anejaculation or retrograde ejaculation			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144630>	C143436	Grade 2 Ejection Fraction Decreased, CTCAE|Grade 2 Ejection fraction decreased	Resting ejection fraction (EF) 50-40%; 10-19% drop from baseline			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144631>	C143437	Grade 2 Electrocardiogram QT Corrected Interval Prolonged, CTCAE|Grade 2 Electrocardiogram QT corrected interval prolonged|Grade 2 Electrocardiogram QT corrected interval prolonged	Average QTc 481 - 500 ms			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144632>	C143219	Grade 2 Electrocardiogram T Wave Abnormal, CTCAE|Grade 2 Electrocardiogram T wave abnormal	Nonspecific ST segment change			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144633>	C143442	Grade 2 Endocrine Disorders - Other, Specify, CTCAE|Grade 2 Endocrine disorders - Other, specify|Grade 2 Endocrine disorders - Other, specify	Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144634>	C143443	Grade 2 Endophthalmitis, CTCAE|Grade 2 Endophthalmitis|Grade 2 Endophthalmitis	Local intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144635>	C143444	Grade 2 Enterocolitis Infectious, CTCAE|Grade 2 Enterocolitis infectious|Grade 2 Enterocolitis infectious	Passage of >3 unformed stools per 24 hrs or duration of illness >48 hrs; moderate abdominal pain; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144636>	C143445	Grade 2 Enterocolitis, CTCAE|Grade 2 Enterocolitis|Grade 2 Enterocolitis	Abdominal pain; mucus or blood in stool			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144637>	C143446	Grade 2 Enterovesical Fistula, CTCAE|Grade 2 Enterovesical fistula|Grade 2 Enterovesical fistula	Symptomatic, invasive intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144638>	C143447	Grade 2 Epistaxis, CTCAE|Grade 2 Epistaxis|Grade 2 Epistaxis	Moderate symptoms; medical intervention indicated (e.g., nasal packing, cauterization; topical vasoconstrictors)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144639>	C143208	Grade 2 Epstein-Barr Virus Infection Reactivation, CTCAE|Grade 2 Epstein-Barr virus infection reactivation|Grade 2 Epstein-Barr virus infection reactivation	Moderate symptoms; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144640>	C143449	Grade 2 Erythema Multiforme, CTCAE|Grade 2 Erythema multiforme|Grade 2 Erythema multiforme	Associated with skin tenderness			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144641>	C143450	Grade 2 Erythroderma, CTCAE|Grade 2 Erythroderma|Grade 2 Erythroderma	Erythema covering >90% BSA without associated symptoms; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144642>	C143451	Grade 2 Esophageal Anastomotic Leak, CTCAE|Grade 2 Esophageal anastomotic leak|Grade 2 Esophageal anastomotic leak	Symptomatic; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144644>	C143453	Grade 2 Esophageal Hemorrhage, CTCAE|Grade 2 Esophageal hemorrhage|Grade 2 Esophageal hemorrhage	Moderate symptoms; intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144645>	C143454	Grade 2 Esophageal Infection, CTCAE|Grade 2 Esophageal infection|Grade 2 Esophageal infection	Local intervention indicated (e.g., oral antibiotic, antifungal, antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144646>	C143456	Grade 2 Esophageal Obstruction, CTCAE|Grade 2 Esophageal obstruction|Grade 2 Esophageal obstruction	Symptomatic; altered GI function; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144647>	C143457	Grade 2 Esophageal Pain, CTCAE|Grade 2 Esophageal pain|Grade 2 Esophageal pain	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144648>	C143458	Grade 2 Esophageal Perforation, CTCAE|Grade 2 Esophageal perforation|Grade 2 Esophageal perforation	Invasive intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144649>	C143459	Grade 2 Esophageal Stenosis, CTCAE|Grade 2 Esophageal stenosis|Grade 2 Esophageal stenosis	Symptomatic; altered GI function			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144650>	C143460	Grade 2 Esophageal Ulcer, CTCAE|Grade 2 Esophageal ulcer|Grade 2 Esophageal ulcer	Symptomatic; altered GI function; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144651>	C143466	Grade 2 Extraocular Muscle Paresis, CTCAE|Grade 2 Extraocular muscle paresis|Grade 2 Extraocular muscle paresis	Unilateral paresis without double vision			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144652>	C143467	Grade 2 Extrapyramidal Disorder, CTCAE|Grade 2 Extrapyramidal disorder|Grade 2 Extrapyramidal disorder	Moderate involuntary movements; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144653>	C143468	Grade 2 Eye Disorders - Other, Specify, CTCAE|Grade 2 Eye disorders - Other, specify|Grade 2 Eye disorders - Other, specify	Moderate; minimal, local or noninvasive intervention indicated; best corrected visual acuity 20/40 and better or 3 lines or less decreased vision from known baseline; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144654>	C143469	Grade 2 Eye Infection, CTCAE|Grade 2 Eye infection|Grade 2 Eye infection	Localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144655>	C143471	Grade 2 Eyelid Function Disorder, CTCAE|Grade 2 Eyelid function disorder|Grade 2 Eyelid function disorder	Symptomatic; nonoperative intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144656>	C143472	Grade 2 Facial Muscle Weakness, CTCAE|Grade 2 Facial muscle weakness|Grade 2 Facial muscle weakness	Moderate symptoms; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144657>	C143473	Grade 2 Facial Nerve Disorder, CTCAE|Grade 2 Facial nerve disorder|Grade 2 Facial nerve disorder	Moderate symptoms; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144658>	C143474	Grade 2 Facial Pain, CTCAE|Grade 2 Facial pain|Grade 2 Facial pain	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144659>	C143475	Grade 2 Fall, CTCAE|Grade 2 Fall|Grade 2 Fall	Symptomatic; noninvasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144660>	C143476	Grade 2 Fallopian Tube Anastomotic Leak, CTCAE|Grade 2 Fallopian tube anastomotic leak|Grade 2 Fallopian tube anastomotic leak	Symptomatic; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144661>	C143479	Grade 2 Fat Atrophy, CTCAE|Grade 2 Fat atrophy	Covering 10-30% BSA and associated with erythema or tenderness; limiting instrumental ADL			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144662>	C143482	Grade 2 Fecal Incontinence, CTCAE|Grade 2 Fecal incontinence|Grade 2 Fecal incontinence	Daily use of pads required			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144663>	C143483	Grade 2 Feminization Acquired, CTCAE|Grade 2 Feminization acquired|Grade 2 Feminization acquired	Moderate symptoms; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144664>	C143484	Grade 2 Fetal Growth Retardation, CTCAE|Grade 2 Fetal growth retardation|Grade 2 Fetal growth retardation	5 - <10% percentile of weight for gestational age			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144665>	C143485	Grade 2 Fever, CTCAE|Grade 2 Fever|Grade 2 Fever	>39.0 - 40.0 degrees C (102.3 - 104.0 degrees F)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144666>	C143486	Grade 2 Fibrinogen Decreased, CTCAE|Grade 2 Fibrinogen decreased|Grade 2 Fibrinogen decreased	<0.75 - 0.5 x LLN; if abnormal, 25 - <50% decrease from baseline			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144667>	C143487	Grade 2 Fibrosis Deep Connective Tissue, CTCAE|Grade 2 Fibrosis deep connective tissue|Grade 2 Fibrosis deep connective tissue	Moderate induration, able to slide skin, unable to pinch skin; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144668>	C143488	Grade 2 Flank Pain, CTCAE|Grade 2 Flank pain|Grade 2 Flank pain	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144669>	C143489	Grade 2 Flashing Lights, CTCAE|Grade 2 Flashing lights|Grade 2 Flashing lights	Limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144670>	C143491	Grade 2 Floaters, CTCAE|Grade 2 Floaters|Grade 2 Floaters	Limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144671>	C143492	Grade 2 Flu Like Symptoms, CTCAE|Grade 2 Flu like symptoms|Grade 2 Flu like symptoms	Moderate symptoms; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144672>	C143209	Grade 2 Folliculitis, CTCAE|Grade 2 Folliculitis|Grade 2 Folliculitis	Topical intervention initiated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144673>	C143494	Grade 2 Forced Expiratory Volume Decreased, CTCAE|Grade 2 Forced expiratory volume decreased	FEV1 60-69%			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144674>	C143210	Grade 2 Fungemia, CTCAE|Grade 2 Fungemia|Grade 2 Fungemia	Moderate symptoms; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144675>	C143496	Grade 2 Gait Disturbance, CTCAE|Grade 2 Gait disturbance|Grade 2 Gait disturbance	Moderate change in gait (e.g., wide-based, limping or hobbling); assistive device indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144676>	C143497	Grade 2 Gallbladder Infection, CTCAE|Grade 2 Gallbladder infection|Grade 2 Gallbladder infection	Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144677>	C143498	Grade 2 Gastric Anastomotic Leak, CTCAE|Grade 2 Gastric anastomotic leak|Grade 2 Gastric anastomotic leak	Symptomatic; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144678>	C143499	Grade 2 Gastric Fistula, CTCAE|Grade 2 Gastric fistula|Grade 2 Gastric fistula	Symptomatic, invasive intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144679>	C143500	Grade 2 Gastric Hemorrhage, CTCAE|Grade 2 Gastric hemorrhage|Grade 2 Gastric hemorrhage	Moderate symptoms; intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144680>	C143502	Grade 2 Gastric Perforation, CTCAE|Grade 2 Gastric perforation|Grade 2 Gastric perforation	Invasive intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144681>	C143503	Grade 2 Gastric Stenosis, CTCAE|Grade 2 Gastric stenosis|Grade 2 Gastric stenosis	Symptomatic; altered GI function			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144682>	C143504	Grade 2 Gastric Ulcer, CTCAE|Grade 2 Gastric ulcer|Grade 2 Gastric ulcer	Symptomatic; altered GI function; medical intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144683>	C143506	Grade 2 Gastroesophageal Reflux Disease, CTCAE|Grade 2 Gastroesophageal reflux disease|Grade 2 Gastroesophageal reflux disease	Moderate symptoms; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144684>	C143507	Grade 2 Gastrointestinal Anastomotic Leak, CTCAE|Grade 2 Gastrointestinal anastomotic leak|Grade 2 Gastrointestinal anastomotic leak	Symptomatic; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144685>	C143508	Grade 2 Gastrointestinal Disorders - Other, Specify, CTCAE|Grade 2 Gastrointestinal disorders - Other, specify|Grade 2 Gastrointestinal disorders - Other, specify	Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144686>	C146637	Grade 2 Gastrointestinal Fistula, CTCAE|Grade 2 Gastrointestinal fistula|Grade 2 Gastrointestinal fistula	Symptomatic, invasive intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144687>	C143510	Grade 2 Gastrointestinal Pain, CTCAE|Grade 2 Gastrointestinal pain|Grade 2 Gastrointestinal pain	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144688>	C143511	Grade 2 Gastrointestinal Stoma Necrosis, CTCAE|Grade 2 Gastrointestinal stoma necrosis|Grade 2 Gastrointestinal stoma necrosis	Superficial necrosis; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144689>	C143512	Grade 2 Gastroparesis, CTCAE|Grade 2 Gastroparesis|Grade 2 Gastroparesis	Moderate symptoms; able to maintain nutrition with dietary and lifestyle modifications; may need pharmacologic intervention			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144690>	C143513	Grade 2 General Disorders and Administration Site Conditions - Other, Specify, CTCAE|Grade 2 General disorders and administration site conditions - Other, specify|Grade 2 General disorders and administration site conditions - Other, specify	Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144691>	C143202	Grade 2 Generalized Edema, CTCAE|Grade 2 Generalized edema|Grade 2 Generalized edema	Oral therapy initiated; interfering with instrumental ADLs or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144692>	C143514	Grade 2 Generalized Muscle Weakness, CTCAE|Grade 2 Generalized muscle weakness|Grade 2 Generalized muscle weakness	Symptomatic; evident on physical exam; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144693>	C143515	Grade 2 Genital Edema, CTCAE|Grade 2 Genital edema	Readily apparent obscuration of anatomic architecture; obliteration of skin folds; readily apparent deviation from normal anatomic contour			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144694>	C143516	Grade 2 GGT Increased, CTCAE|Grade 2 GGT increased|Grade 2 GGT increased	>2.5 - 5.0 x ULN if baseline was normal or less than normal; >1.5 - 3.0 x baseline if baseline was >ULN			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144695>	C146626	Grade 2 Gingival Pain, CTCAE|Grade 2 Gingival pain|Grade 2 Gingival pain	Moderate pain interfering with oral intake			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144696>	C143518	Grade 2 Glossopharyngeal Nerve Disorder, CTCAE|Grade 2 Glossopharyngeal nerve disorder|Grade 2 Glossopharyngeal nerve disorder	Moderate symptoms; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144697>	C143519	Grade 2 Glucose Intolerance, CTCAE|Grade 2 Glucose intolerance	Symptomatic; dietary modification or oral agent indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144698>	C143520	Grade 2 Growth Accelerated, CTCAE|Grade 2 Growth accelerated|Grade 2 Growth accelerated	>=+2 SD (standard deviation) above mid parental height or target height			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144699>	C143521	Grade 2 Growth Hormone Abnormal, CTCAE|Grade 2 Growth hormone abnormal|Grade 2 Growth hormone abnormal	Symptomatic; medical intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C1446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1446>	C1909	Radiopharmaceutical Compound|Radioactive Pharmaceutical|Radiochemical|Radiopharmaceutical|Radiopharmaceutical|Radiopharmaceuticals|radioactive drug|radiopharmaceutical	An agent that contains a radioactive isotope and is used for diagnostic or therapeutic purposes.	Radiopharmaceutical Compound		Chemical Viewed Functionally	BRIDG Class Terminology|BRIDG Terminology|CTRP Agent Terminology|CTRP Terminology
C144700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144700>	C143522	Grade 2 Growth Suppression, CTCAE|Grade 2 Growth suppression|Grade 2 Growth suppression	Reduction in growth velocity by 30 - 49% ideally measured over the period of a year or 0 - 49% reduction in growth from the baseline growth curve			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144701>	C143231	Grade 2 Guillain-Barre Syndrome, CTCAE|Grade 2 Guillain-Barre syndrome|Grade 2 Guillain-Barre syndrome	Moderate symptoms; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144702>	C143523	Grade 2 Gum Infection, CTCAE|Grade 2 Gum infection|Grade 2 Gum infection	Moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144703>	C143525	Grade 2 Hallucinations, CTCAE|Grade 2 Hallucinations|Grade 2 Hallucinations	Moderate hallucinations			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144704>	C143527	Grade 2 Headache, CTCAE|Grade 2 Headache|Grade 2 Headache	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144705>	C143528	Grade 2 Hearing Impaired, CTCAE|Grade 2 Hearing impaired|Grade 2 Hearing impaired	Adult: Hearing loss not requiring hearing aid; intervention not indicated; limiting instrumental ADL; threshold shift of >25 dB averaged at 2 contiguous test frequencies in at least one ear (on a 1, 2, 3, 4, 6, and 8 kHz audiogram); Pediatric (on a 1, 2, 3, 4, 6, and 8 kHz audiogram): Threshold shift >20 dB at 4 kHz in at least one ear; mild/moderate impact on age-appropriate normal daily activity			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144706>	C143529	Grade 2 Heart Failure, CTCAE|Grade 2 Heart failure|Grade 2 Heart failure	Outpatient initiation or intensification of treatment			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144707>	C143531	Grade 2 Hematosalpinx, CTCAE|Grade 2 Hematosalpinx|Grade 2 Hematosalpinx	Moderate bleeding; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144708>	C143532	Grade 2 Hematuria, CTCAE|Grade 2 Hematuria|Grade 2 Hematuria	Symptomatic; urinary catheter or bladder irrigation indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144709>	C143533	Grade 2 Hemoglobin Increased, CTCAE|Grade 2 Hemoglobin increased|Grade 2 Hemoglobin increased	Increase in >2 - 4 g/dL above ULN			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144710>	C143537	Grade 2 Hemorrhoidal Hemorrhage, CTCAE|Grade 2 Hemorrhoidal hemorrhage|Grade 2 Hemorrhoidal hemorrhage	Moderate symptoms; intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144711>	C143540	Grade 2 Hepatic Hemorrhage, CTCAE|Grade 2 Hepatic hemorrhage|Grade 2 Hepatic hemorrhage	Moderate symptoms; intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144712>	C143541	Grade 2 Hepatic Infection, CTCAE|Grade 2 Hepatic infection|Grade 2 Hepatic infection	Moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144713>	C143542	Grade 2 Hepatic Pain, CTCAE|Grade 2 Hepatic pain|Grade 2 Hepatic pain	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144714>	C143211	Grade 2 Hepatitis B Reactivation, CTCAE|Grade 2 Hepatitis B reactivation|Grade 2 Hepatitis B reactivation	Moderate symptoms; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144715>	C143543	Grade 2 Hepatitis Viral, CTCAE|Grade 2 Hepatitis viral|Grade 2 Hepatitis viral	Moderate symptoms; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144716>	C143544	Grade 2 Hepatobiliary Disorders - Other, Specify, CTCAE|Grade 2 Hepatobiliary disorders - Other, specify|Grade 2 Hepatobiliary disorders - Other, specify	Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144717>	C143212	Grade 2 Herpes Simplex Reactivation, CTCAE|Grade 2 Herpes simplex reactivation|Grade 2 Herpes simplex reactivation	Moderate symptoms; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144718>	C143545	Grade 2 Hiccups, CTCAE|Grade 2 Hiccups|Grade 2 Hiccups	Moderate symptoms; medical intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144719>	C143546	Grade 2 Hip Fracture, CTCAE|Grade 2 Hip fracture	Hairline fracture; mild pain; limiting instrumental ADL; non-operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144720>	C143547	Grade 2 Hirsutism, CTCAE|Grade 2 Hirsutism|Grade 2 Hirsutism	In women, increase in length, thickness or density of hair in a male distribution that requires daily shaving or consistent destructive means of hair removal to camouflage; associated with psychosocial impact			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144721>	C143548	Grade 2 Hoarseness, CTCAE|Grade 2 Hoarseness|Grade 2 Hoarseness	Moderate or persistent voice changes; may require occasional repetition but understandable on telephone; medical evaluation indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144722>	C143549	Grade 2 Hot Flashes, CTCAE|Grade 2 Hot flashes|Grade 2 Hot flashes	Moderate symptoms; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144723>	C143551	Grade 2 Hypercalcemia, CTCAE|Grade 2 Hypercalcemia|Grade 2 Hypercalcemia	Corrected serum calcium of >11.5 - 12.5 mg/dL; >2.9 - 3.1 mmol/L; Ionized calcium >1.5 - 1.6 mmol/L; symptomatic			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144724>	C143552	Grade 2 Hyperglycemia, CTCAE|Grade 2 Hyperglycemia	Change in daily management from baseline for a diabetic; oral antiglycemic agent initiated; workup for diabetes			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144725>	C143553	Grade 2 Hyperhidrosis, CTCAE|Grade 2 Hyperhidrosis|Grade 2 Hyperhidrosis	Involving >1 site; patient seeks medical intervention; associated with psychosocial impact			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144726>	C143554	Grade 2 Hyperkalemia, CTCAE|Grade 2 Hyperkalemia|Grade 2 Hyperkalemia	>5.5 - 6.0 mmol/L; intervention initiated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144727>	C143221	Grade 2 Hyperlipidemia, CTCAE|Grade 2 Hyperlipidemia|Grade 2 Hyperlipidemia	Requiring pharmaceutical intervention			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144728>	C143556	Grade 2 Hypernatremia, CTCAE|Grade 2 Hypernatremia|Grade 2 Hypernatremia	>150 - 155 mmol/L; intervention initiated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144729>	C143557	Grade 2 Hyperparathyroidism, CTCAE|Grade 2 Hyperparathyroidism|Grade 2 Hyperparathyroidism	Moderate symptoms; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144730>	C143222	Grade 2 Hyperphosphatemia, CTCAE|Grade 2 Hyperphosphatemia|Grade 2 Hyperphosphatemia	Noninvasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144731>	C143558	Grade 2 Hypersomnia, CTCAE|Grade 2 Hypersomnia|Grade 2 Hypersomnia	Moderate increased need for sleep			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144732>	C143560	Grade 2 Hyperthyroidism, CTCAE|Grade 2 Hyperthyroidism|Grade 2 Hyperthyroidism	Symptomatic; thyroid suppression therapy indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144733>	C143561	Grade 2 Hypertrichosis, CTCAE|Grade 2 Hypertrichosis|Grade 2 Hypertrichosis	Increase in length, thickness or density of hair at least on the usual exposed areas of the body [face (not limited to beard/moustache area) plus/minus arms] that requires frequent shaving or use of destructive means of hair removal to camouflage; associated with psychosocial impact			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144734>	C143562	Grade 2 Hypertriglyceridemia, CTCAE|Grade 2 Hypertriglyceridemia|Grade 2 Hypertriglyceridemia	>300 mg/dL - 500 mg/dL; >3.42 mmol/L - 5.7 mmol/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144735>	C143564	Grade 2 Hypoalbuminemia, CTCAE|Grade 2 Hypoalbuminemia|Grade 2 Hypoalbuminemia	<3 - 2 g/dL; <30 - 20 g/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144736>	C143565	Grade 2 Hypocalcemia, CTCAE|Grade 2 Hypocalcemia|Grade 2 Hypocalcemia	Corrected serum calcium of <8.0 - 7.0 mg/dL; <2.0 - 1.75 mmol/L; Ionized calcium <1.0 - 0.9 mmol/L; symptomatic			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144737>	C143566	Grade 2 Hypoglossal Nerve Disorder, CTCAE|Grade 2 Hypoglossal nerve disorder|Grade 2 Hypoglossal nerve disorder	Moderate symptoms; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144738>	C143567	Grade 2 Hypoglycemia, CTCAE|Grade 2 Hypoglycemia|Grade 2 Hypoglycemia	<55 - 40 mg/dL; <3.0 - 2.2 mmol/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144739>	C143568	Grade 2 Hypohidrosis, CTCAE|Grade 2 Hypohidrosis|Grade 2 Hypohidrosis	Symptomatic; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144740>	C143569	Grade 2 Hypokalemia, CTCAE|Grade 2 Hypokalemia|Grade 2 Hypokalemia	Symptomatic with <LLN - 3.0 mmol/L; intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144741>	C143570	Grade 2 Hypomagnesemia, CTCAE|Grade 2 Hypomagnesemia|Grade 2 Hypomagnesemia	<1.2 - 0.9 mg/dL; <0.5 - 0.4 mmol/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144742>	C143571	Grade 2 Hyponatremia, CTCAE|Grade 2 Hyponatremia|Grade 2 Hyponatremia	125 - <130 mmol/L and asymptomatic			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144743>	C143572	Grade 2 Hypoparathyroidism, CTCAE|Grade 2 Hypoparathyroidism|Grade 2 Hypoparathyroidism	Moderate symptoms; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144744>	C143573	Grade 2 Hypophosphatemia, CTCAE|Grade 2 Hypophosphatemia|Grade 2 Hypophosphatemia	Oral replacement therapy indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144745>	C143193	Grade 2 Hypophysitis, CTCAE|Grade 2 Hypophysitis|Grade 2 Hypophysitis	Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144746>	C143194	Grade 2 Hypopituitarism, CTCAE|Grade 2 Hypopituitarism|Grade 2 Hypopituitarism	Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144747>	C143576	Grade 2 Hypothyroidism, CTCAE|Grade 2 Hypothyroidism|Grade 2 Hypothyroidism	Symptomatic; thyroid replacement initiated; increase in current thyroid replacement therapy; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14474>	C14421	FVB/N Mouse|FVB/N|FVB/N	NIH general purpose Swiss mice were selected for resistance or sensitivity to histamine challenge following pertussis vaccination. The sensitive strain, HFSF/N, was subsequently found to have the Fv1b allele, which sensitizes the mice to B strain Friend Leukemia virus. The FVB/N strain has an albino coat with genotype A,B,c,D,P, and has a vigorous reproductive performance. This strain is commonly used in the generation of transgenic mice due to the fact that the pronuclei of FVB/N fertilized oocytes are prominent, which allows for ease of microinjection.			Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C144751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144751>	C146633	Grade 2 Ileal Perforation, CTCAE|Grade 2 Ileal perforation|Grade 2 Ileal perforation	Invasive intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144752>	C143578	Grade 2 Ileal Stenosis, CTCAE|Grade 2 Ileal stenosis|Grade 2 Ileal stenosis	Symptomatic; altered GI function			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144755>	C143580	Grade 2 Immune System Disorders - Other, Specify, CTCAE|Grade 2 Immune system disorders - Other, specify|Grade 2 Immune system disorders - Other, specify	Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144756>	C143581	Grade 2 Infections and Infestations - Other, Specify, CTCAE|Grade 2 Infections and infestations - Other, specify|Grade 2 Infections and infestations - Other, specify	Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144757>	C143582	Grade 2 Infective Myositis, CTCAE|Grade 2 Infective myositis|Grade 2 Infective myositis	Localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144758>	C143583	Grade 2 Infusion Related Reaction, CTCAE|Grade 2 Infusion related reaction|Grade 2 Infusion related reaction	Therapy or infusion interruption indicated but responds promptly to symptomatic treatment (e.g., antihistamines, NSAIDS, narcotics, IV fluids); prophylactic medications indicated for <=24 hrs			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144759>	C143584	Grade 2 Infusion Site Extravasation, CTCAE|Grade 2 Infusion site extravasation|Grade 2 Infusion site extravasation	Erythema with associated symptoms (e.g., edema, pain, induration, phlebitis)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144760>	C143585	Grade 2 Injection Site Reaction, CTCAE|Grade 2 Injection site reaction|Grade 2 Injection site reaction	Pain; lipodystrophy; edema; phlebitis			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144761>	C143586	Grade 2 Injury To Carotid Artery, CTCAE|Grade 2 Injury to carotid artery|Grade 2 Injury to carotid artery	Repair or revision not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144763>	C143587	Grade 2 Injury To Jugular Vein, CTCAE|Grade 2 Injury to jugular vein|Grade 2 Injury to jugular vein	Repair or revision not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144764>	C143588	Grade 2 Injury To Superior Vena Cava, CTCAE|Grade 2 Injury to superior vena cava|Grade 2 Injury to superior vena cava	Symptomatic; repair or revision not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144765>	C143589	Grade 2 Injury, Poisoning and Procedural Complications - Other, Specify, CTCAE|Grade 2 Injury, poisoning and procedural complications - Other, specify|Grade 2 Injury, poisoning and procedural complications - Other, specify	Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144766>	C143590	Grade 2 INR Increased, CTCAE|Grade 2 INR increased|Grade 2 INR increased	>1.5 - 2.5; >1.5 - 2.5 x baseline if on anticoagulation; dose adjustment indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144767>	C143592	Grade 2 Intestinal Stoma Leak, CTCAE|Grade 2 Intestinal stoma leak|Grade 2 Intestinal stoma leak	Symptomatic; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144768>	C143593	Grade 2 Intestinal Stoma Obstruction, CTCAE|Grade 2 Intestinal stoma obstruction|Grade 2 Intestinal stoma obstruction	Self-limited; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144769>	C143594	Grade 2 Intestinal Stoma Site Bleeding, CTCAE|Grade 2 Intestinal stoma site bleeding|Grade 2 Intestinal stoma site bleeding	Moderate bleeding; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14476>	C14421	NIH Mouse|NIH		NIH		Mammal	
C144770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144770>	C143595	Grade 2 Intra-Abdominal Hemorrhage, CTCAE|Grade 2 Intra-abdominal hemorrhage|Grade 2 Intra-abdominal hemorrhage	Moderate symptoms; intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144771>	C143596	Grade 2 Intracranial Hemorrhage, CTCAE|Grade 2 Intracranial hemorrhage	Moderate symptoms; intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144772>	C143597	Grade 2 Intraoperative Arterial Injury, CTCAE|Grade 2 Intraoperative arterial injury|Grade 2 Intraoperative arterial injury	Partial resection of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144773>	C143598	Grade 2 Intraoperative Breast Injury, CTCAE|Grade 2 Intraoperative breast injury|Grade 2 Intraoperative breast injury	Partial resection of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144774>	C143600	Grade 2 Intraoperative Ear Injury, CTCAE|Grade 2 Intraoperative ear injury|Grade 2 Intraoperative ear injury	Partial resection of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144775>	C143601	Grade 2 Intraoperative Endocrine Injury, CTCAE|Grade 2 Intraoperative endocrine injury|Grade 2 Intraoperative endocrine injury	Partial resection of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144776>	C143602	Grade 2 Intraoperative Gastrointestinal Injury, CTCAE|Grade 2 Intraoperative gastrointestinal injury|Grade 2 Intraoperative gastrointestinal injury	Partial resection of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144777>	C143603	Grade 2 Intraoperative Head and Neck Injury, CTCAE|Grade 2 Intraoperative head and neck injury|Grade 2 Intraoperative head and neck injury	Partial resection of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144778>	C143605	Grade 2 Intraoperative Hepatobiliary Injury, CTCAE|Grade 2 Intraoperative hepatobiliary injury|Grade 2 Intraoperative hepatobiliary injury	Partial resection of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144779>	C143606	Grade 2 Intraoperative Musculoskeletal Injury, CTCAE|Grade 2 Intraoperative musculoskeletal injury|Grade 2 Intraoperative musculoskeletal injury	Partial resection of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144780>	C143607	Grade 2 Intraoperative Neurological Injury, CTCAE|Grade 2 Intraoperative neurological injury|Grade 2 Intraoperative neurological injury	Partial resection of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144781>	C143608	Grade 2 Intraoperative Ocular Injury, CTCAE|Grade 2 Intraoperative ocular injury|Grade 2 Intraoperative ocular injury	Partial resection of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144782>	C143609	Grade 2 Intraoperative Renal Injury, CTCAE|Grade 2 Intraoperative renal injury|Grade 2 Intraoperative renal injury	Partial resection of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144783>	C143610	Grade 2 Intraoperative Reproductive Tract Injury, CTCAE|Grade 2 Intraoperative reproductive tract injury|Grade 2 Intraoperative reproductive tract injury	Partial resection of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144784>	C143611	Grade 2 Intraoperative Respiratory Injury, CTCAE|Grade 2 Intraoperative respiratory injury|Grade 2 Intraoperative respiratory injury	Partial resection of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144785>	C143612	Grade 2 Intraoperative Splenic Injury, CTCAE|Grade 2 Intraoperative splenic injury|Grade 2 Intraoperative splenic injury	Primary repair of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144786>	C143613	Grade 2 Intraoperative Urinary Injury, CTCAE|Grade 2 Intraoperative urinary injury|Grade 2 Intraoperative urinary injury	Partial resection of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144787>	C143614	Grade 2 Intraoperative Venous Injury, CTCAE|Grade 2 Intraoperative venous injury|Grade 2 Intraoperative venous injury	Partial resection of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144788>	C143615	Grade 2 Investigations - Other, Specify, CTCAE|Grade 2 Investigations - Other, specify|Grade 2 Investigations - Other, specify	Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144789>	C143617	Grade 2 Irregular Menstruation, CTCAE|Grade 2 Irregular menstruation|Grade 2 Irregular menstruation	Intermittent/irregular menses for >3 consecutive menstrual cycles			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144790>	C143618	Grade 2 Irritability, CTCAE|Grade 2 Irritability|Grade 2 Irritability	Moderate; increased attention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144791>	C143619	Grade 2 Ischemia Cerebrovascular, CTCAE|Grade 2 Ischemia cerebrovascular	Moderate symptoms			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144795>	C143622	Grade 2 Jejunal Perforation, CTCAE|Grade 2 Jejunal perforation|Grade 2 Jejunal perforation	Invasive intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144796>	C143623	Grade 2 Jejunal Stenosis, CTCAE|Grade 2 Jejunal stenosis|Grade 2 Jejunal stenosis	Symptomatic; altered GI function			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144798>	C143626	Grade 2 Joint Infection, CTCAE|Grade 2 Joint infection|Grade 2 Joint infection	Localized; local intervention indicated; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral); needle aspiration indicated (single or multiple)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144799>	C143627	Grade 2 Joint Range of Motion Decreased Cervical Spine, CTCAE|Grade 2 Joint range of motion decreased cervical spine|Grade 2 Joint range of motion decreased cervical spine	Rotation <60 degrees to right or left; <60 degrees of flexion			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C1447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1447>	C28148|C198259|C118849	Barium Enema Injection|Barium Enema|Lower GI Series|Lower Gastrointestinal Series|barium enema|lower GI series	Injection of a barium-containing contrast medium through the anus and into the lower gastrointestinal tract so that X-rays can be taken in order to identify lesions and other abnormal growths.	Barium Enema Injection		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C144800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144800>	C143628	Grade 2 Joint Range of Motion Decreased Lumbar Spine, CTCAE|Grade 2 Joint range of motion decreased lumbar spine|Grade 2 Joint range of motion decreased lumbar spine	Pain with range of motion (ROM) in lumbar spine; requires a reaching aid to pick up a very light object from the floor			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144801>	C143629	Grade 2 Joint Range of Motion Decreased, CTCAE|Grade 2 Joint range of motion decreased|Grade 2 Joint range of motion decreased	>25 - 50% decrease in ROM; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144802>	C143631	Grade 2 Kidney Anastomotic Leak, CTCAE|Grade 2 Kidney anastomotic leak|Grade 2 Kidney anastomotic leak	Symptomatic; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144803>	C143632	Grade 2 Kidney Infection, CTCAE|Grade 2 Kidney infection|Grade 2 Kidney infection	Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144804>	C143633	Grade 2 Kyphosis, CTCAE|Grade 2 Kyphosis|Grade 2 Kyphosis	Moderate accentuation; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144805>	C143634	Grade 2 Lactation Disorder, CTCAE|Grade 2 Lactation disorder|Grade 2 Lactation disorder	Changes in lactation, significantly affecting breast production or expression of breast milk			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144806>	C143635	Grade 2 Large Intestinal Anastomotic Leak, CTCAE|Grade 2 Large intestinal anastomotic leak|Grade 2 Large intestinal anastomotic leak	Symptomatic; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144807>	C143636	Grade 2 Laryngeal Edema, CTCAE|Grade 2 Laryngeal edema|Grade 2 Laryngeal edema	Symptomatic; medical intervention indicated (e.g., dexamethasone, epinephrine, antihistamines)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144810>	C143637	Grade 2 Laryngeal Inflammation, CTCAE|Grade 2 Laryngeal inflammation|Grade 2 Laryngeal inflammation	Moderate sore throat; analgesics indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144811>	C143638	Grade 2 Laryngeal Mucositis, CTCAE|Grade 2 Laryngeal mucositis|Grade 2 Laryngeal mucositis	Moderate pain, analgesics indicated; altered oral intake; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144812>	C143639	Grade 2 Laryngeal Obstruction, CTCAE|Grade 2 Laryngeal obstruction|Grade 2 Laryngeal obstruction	Symptomatic (e.g., noisy airway breathing), no respiratory distress; medical intervention indicated (e.g., steroids); limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144813>	C143640	Grade 2 Laryngeal Stenosis, CTCAE|Grade 2 Laryngeal stenosis|Grade 2 Laryngeal stenosis	Symptomatic (e.g., noisy airway breathing), no respiratory distress; medical intervention indicated (e.g., steroids); limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144814>	C143641	Grade 2 Laryngitis, CTCAE|Grade 2 Laryngitis|Grade 2 Laryngitis	Moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144815>	C143642	Grade 2 Laryngopharyngeal Dysesthesia, CTCAE|Grade 2 Laryngopharyngeal dysesthesia|Grade 2 Laryngopharyngeal dysesthesia	Moderate symptoms; mild anxiety, but no dyspnea; short duration of observation and/or anxiolytic indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144816>	C143643	Grade 2 Laryngospasm, CTCAE|Grade 2 Laryngospasm|Grade 2 Laryngospasm	Transient episode; intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144817>	C143645	Grade 2 Lethargy, CTCAE|Grade 2 Lethargy|Grade 2 Lethargy	Moderate symptoms; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144818>	C143648	Grade 2 Leukoencephalopathy, CTCAE|Grade 2 Leukoencephalopathy|Grade 2 Leukoencephalopathy	Moderate symptoms; focal T2/FLAIR hyperintensities, involving periventricular white matter extending into centrum semiovale or involving 1/3 to 2/3 of susceptible areas of cerebrum +/- moderate increase in SAS and/or moderate ventriculomegaly			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144819>	C143649	Grade 2 Libido Decreased, CTCAE|Grade 2 Libido decreased|Grade 2 Libido decreased	Decrease in sexual interest adversely affecting relationship			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144820>	C143651	Grade 2 Lip Infection, CTCAE|Grade 2 Lip infection|Grade 2 Lip infection	Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144821>	C143652	Grade 2 Lipase Increased, CTCAE|Grade 2 Lipase increased|Grade 2 Lipase increased	>1.5 - 3.0 x ULN; >3.0 - 5.0 x ULN and asymptomatic			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144822>	C143653	Grade 2 Lipohypertrophy, CTCAE|Grade 2 Lipohypertrophy	Covering 10-30% BSA and associated tenderness; limiting instrumental ADL			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144823>	C143654	Grade 2 Localized Edema, CTCAE|Grade 2 Localized edema|Grade 2 Localized edema	Moderate localized edema and intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144824>	C143655	Grade 2 Lordosis, CTCAE|Grade 2 Lordosis|Grade 2 Lordosis	Moderate accentuation; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144825>	C143656	Grade 2 Lower Gastrointestinal Hemorrhage, CTCAE|Grade 2 Lower gastrointestinal hemorrhage	Moderate symptoms; intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144826>	C143657	Grade 2 Lung Infection, CTCAE|Grade 2 Lung infection	Moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144827>	C143658	Grade 2 Lymph Gland Infection, CTCAE|Grade 2 Lymph gland infection|Grade 2 Lymph gland infection	Localized; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144828>	C143659	Grade 2 Lymph Leakage, CTCAE|Grade 2 Lymph leakage|Grade 2 Lymph leakage	Symptomatic; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144829>	C143660	Grade 2 Lymphedema, CTCAE|Grade 2 Lymphedema|Grade 2 Lymphedema	Marked discoloration; leathery skin texture; papillary formation; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144830>	C143662	Grade 2 Lymphocyte Count Decreased, CTCAE|Grade 2 Lymphocyte count decreased	<800-500/mm3; <0.8-0.5 x 10e9/L			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144831>	C143663	Grade 2 Lymphocyte Count Increased, CTCAE|Grade 2 Lymphocyte count increased|Grade 2 Lymphocyte count increased	>4000/mm3 - 20,000/mm3			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144832>	C143665	Grade 2 Malaise, CTCAE|Grade 2 Malaise|Grade 2 Malaise	Uneasiness or lack of well being limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144833>	C143666	Grade 2 Mania, CTCAE|Grade 2 Mania|Grade 2 Mania	Moderate manic symptoms (e.g., relationship and work difficulties; poor hygiene)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144835>	C143669	Grade 2 Meningismus, CTCAE|Grade 2 Meningismus|Grade 2 Meningismus	Moderate symptoms; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144836>	C143671	Grade 2 Menorrhagia, CTCAE|Grade 2 Menorrhagia|Grade 2 Menorrhagia	Moderate symptoms; medical intervention indicated (e.g., hormones)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144837>	C143672	Grade 2 Metabolism and Nutrition Disorders - Other, Specify, CTCAE|Grade 2 Metabolism and nutrition disorders - Other, specify|Grade 2 Metabolism and nutrition disorders - Other, specify	Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144838>	C143191	Grade 2 Methemoglobinemia, CTCAE|Grade 2 Methemoglobinemia|Grade 2 Methemoglobinemia	>ULN			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144839>	C143673	Grade 2 Middle Ear Inflammation, CTCAE|Grade 2 Middle ear inflammation|Grade 2 Middle ear inflammation	Serous otitis, medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144840>	C143674	Grade 2 Mitral Valve Disease, CTCAE|Grade 2 Mitral valve disease|Grade 2 Mitral valve disease	Asymptomatic; moderate regurgitation or stenosis by imaging			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144843>	C143677	Grade 2 Movements Involuntary, CTCAE|Grade 2 Movements involuntary|Grade 2 Movements involuntary	Moderate symptoms; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144844>	C143678	Grade 2 Mucosal Infection, CTCAE|Grade 2 Mucosal infection|Grade 2 Mucosal infection	Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144845>	C143679	Grade 2 Mucositis Oral, CTCAE|Grade 2 Mucositis oral|Grade 2 Mucositis oral	Moderate pain or ulcer that does not interfere with oral intake; modified diet indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144846>	C143224	Grade 2 Muscle Cramp, CTCAE|Grade 2 Muscle cramp|Grade 2 Muscle cramp	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144847>	C143681	Grade 2 Muscle Weakness Left-Sided, CTCAE|Grade 2 Muscle weakness left-sided	Symptomatic; evident on physical exam; limiting instrumental ADL			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144848>	C143682	Grade 2 Muscle Weakness Lower Limb, CTCAE|Grade 2 Muscle weakness lower limb|Grade 2 Muscle weakness lower limb	Symptomatic; evident on physical exam; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144849>	C143683	Grade 2 Muscle Weakness Right-Sided, CTCAE|Grade 2 Muscle weakness right-sided	Symptomatic; evident on physical exam; limiting instrumental ADL			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144850>	C143684	Grade 2 Muscle Weakness Trunk, CTCAE|Grade 2 Muscle weakness trunk|Grade 2 Muscle weakness trunk	Symptomatic; evident on physical exam; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144851>	C143685	Grade 2 Muscle Weakness Upper Limb, CTCAE|Grade 2 Muscle weakness upper limb|Grade 2 Muscle weakness upper limb	Symptomatic; evident on physical exam; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144852>	C143686	Grade 2 Musculoskeletal and Connective Tissue Disorder - Other, Specify, CTCAE|Grade 2 Musculoskeletal and connective tissue disorder - Other, specify|Grade 2 Musculoskeletal and connective tissue disorder - Other, specify	Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144853>	C143687	Grade 2 Musculoskeletal Deformity, CTCAE|Grade 2 Musculoskeletal deformity|Grade 2 Musculoskeletal deformity	Deformity, hypoplasia, or asymmetry able to be remediated by prosthesis (e.g., shoe insert) or covered by clothing			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144854>	C143688	Grade 2 Myalgia, CTCAE|Grade 2 Myalgia|Grade 2 Myalgia	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144855>	C143232	Grade 2 Myasthenia Gravis, CTCAE|Grade 2 Myasthenia gravis|Grade 2 Myasthenia gravis	Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144856>	C143691	Grade 2 Myocardial Infarction, CTCAE|Grade 2 Myocardial infarction	Asymptomatic and cardiac enzymes minimally abnormal and no evidence of ischemic ECG changes			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144857>	C146695	Grade 2 Myocarditis, CTCAE|Grade 2 Myocarditis	Symptoms with moderate activity or exertion			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144858>	C143695	Grade 2 Nail Infection, CTCAE|Grade 2 Nail infection|Grade 2 Nail infection	Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144859>	C143696	Grade 2 Nail Loss, CTCAE|Grade 2 Nail loss|Grade 2 Nail loss	Symptomatic separation of the nail bed from the nail plate or nail loss; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144860>	C143698	Grade 2 Nasal Congestion, CTCAE|Grade 2 Nasal congestion|Grade 2 Nasal congestion	Moderate symptoms; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144861>	C143700	Grade 2 Neck Edema, CTCAE|Grade 2 Neck edema	Moderate neck edema; slight obliteration of anatomic landmarks; limiting instrumental ADL			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144862>	C143701	Grade 2 Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other, Specify, CTCAE|Grade 2 Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify|Grade 2 Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify	Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144863>	C143702	Grade 2 Nervous System Disorders - Other, Specify, CTCAE|Grade 2 Nervous system disorders - Other, specify|Grade 2 Nervous system disorders - Other, specify	Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144864>	C143703	Grade 2 Neuralgia, CTCAE|Grade 2 Neuralgia|Grade 2 Neuralgia	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144865>	C143704	Grade 2 Neutrophil Count Decreased, CTCAE|Grade 2 Neutrophil count decreased	<1500-1000/mm3; <1.5-1.0 x 10e9/L			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144866>	C143705	Grade 2 Night Blindness, CTCAE|Grade 2 Night blindness	Symptomatic; moderate decrease in visual acuity (best corrected visual acuity 20/40 and better or 3 lines or less decreased vision from known baseline); limiting instrumental ADL			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144867>	C143706	Grade 2 Nipple Deformity, CTCAE|Grade 2 Nipple deformity|Grade 2 Nipple deformity	Symptomatic; asymmetry of nipple areolar complex with moderate retraction and/or thickening of the nipple areolar complex			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144868>	C143707	Grade 2 Non-Cardiac Chest Pain, CTCAE|Grade 2 Non-cardiac chest pain|Grade 2 Non-cardiac chest pain	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144869>	C143710	Grade 2 Obstruction Gastric, CTCAE|Grade 2 Obstruction gastric|Grade 2 Obstruction gastric	Symptomatic; altered GI function; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144870>	C143711	Grade 2 Oculomotor Nerve Disorder, CTCAE|Grade 2 Oculomotor nerve disorder|Grade 2 Oculomotor nerve disorder	Moderate symptoms; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144871>	C143712	Grade 2 Olfactory Nerve Disorder, CTCAE|Grade 2 Olfactory nerve disorder|Grade 2 Olfactory nerve disorder	Moderate symptoms; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144872>	C143714	Grade 2 Optic Nerve Disorder, CTCAE|Grade 2 Optic nerve disorder|Grade 2 Optic nerve disorder	Moderate decrease in visual acuity (best corrected visual acuity 20/40 and better or 3 lines or less decreased vision from known baseline)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144873>	C143715	Grade 2 Oral Cavity Fistula, CTCAE|Grade 2 Oral cavity fistula|Grade 2 Oral cavity fistula	Symptomatic, invasive intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144874>	C143716	Grade 2 Oral Dysesthesia, CTCAE|Grade 2 Oral dysesthesia|Grade 2 Oral dysesthesia	Moderate pain; interfering with oral intake			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144877>	C143241	Grade 2 Oropharyngeal Pain, CTCAE|Grade 2 Oropharyngeal pain|Grade 2 Oropharyngeal pain	Moderate pain; altered oral intake; non-narcotics initiated; topical analgesics initiated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144878>	C143717	Grade 2 Osteonecrosis of Jaw, CTCAE|Grade 2 Osteonecrosis of jaw|Grade 2 Osteonecrosis of jaw	Symptomatic; medical intervention indicated (e.g., topical agents); limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144879>	C143225	Grade 2 Osteonecrosis, CTCAE|Grade 2 Osteonecrosis|Grade 2 Osteonecrosis	Symptomatic; medical intervention indicated (e.g., analgesics or bisphosphonates); limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144880>	C143719	Grade 2 Otitis Externa, CTCAE|Grade 2 Otitis externa|Grade 2 Otitis externa	Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144881>	C143720	Grade 2 Otitis Media, CTCAE|Grade 2 Otitis media|Grade 2 Otitis media	Localized; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144883>	C143721	Grade 2 Ovarian Infection, CTCAE|Grade 2 Ovarian infection|Grade 2 Ovarian infection	Localized; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144884>	C143722	Grade 2 Ovarian Rupture, CTCAE|Grade 2 Ovarian rupture|Grade 2 Ovarian rupture	Symptomatic and intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144886>	C143723	Grade 2 Pain In Extremity, CTCAE|Grade 2 Pain in extremity|Grade 2 Pain in extremity	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144887>	C143724	Grade 2 Pain of Skin, CTCAE|Grade 2 Pain of skin|Grade 2 Pain of skin	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144888>	C143725	Grade 2 Pain, CTCAE|Grade 2 Pain|Grade 2 Pain	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144889>	C143726	Grade 2 Palmar-Plantar Erythrodysesthesia Syndrome, CTCAE|Grade 2 Palmar-plantar erythrodysesthesia syndrome|Grade 2 Palmar-plantar erythrodysesthesia syndrome	Skin changes (e.g., peeling, blisters, bleeding, fissures, edema, or hyperkeratosis) with pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144890>	C143729	Grade 2 Pancreatic Anastomotic Leak, CTCAE|Grade 2 Pancreatic anastomotic leak|Grade 2 Pancreatic anastomotic leak	Symptomatic; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144891>	C143730	Grade 2 Pancreatic Duct Stenosis, CTCAE|Grade 2 Pancreatic duct stenosis|Grade 2 Pancreatic duct stenosis	Symptomatic; altered GI function			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144892>	C143731	Grade 2 Pancreatic Enzymes Decreased, CTCAE|Grade 2 Pancreatic enzymes decreased	Increase in stool frequency, bulk, or odor; steatorrhea			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144895>	C143734	Grade 2 Papilledema, CTCAE|Grade 2 Papilledema|Grade 2 Papilledema	Symptomatic; moderate decrease in visual acuity (best corrected visual acuity 20/40 and better or 3 lines or less decreased vision from known baseline)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144896>	C143735	Grade 2 Papulopustular Rash, CTCAE|Grade 2 Papulopustular rash	Papules and/or pustules covering 10-30% BSA, which may or may not be associated with symptoms of pruritus or tenderness; associated with psychosocial impact; limiting instrumental ADL; papules and/or pustules covering > 30% BSA with or without mild symptoms			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144897>	C143736	Grade 2 Paresthesia, CTCAE|Grade 2 Paresthesia|Grade 2 Paresthesia	Moderate symptoms; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144898>	C143737	Grade 2 Paronychia, CTCAE|Grade 2 Paronychia|Grade 2 Paronychia	Local intervention indicated; oral intervention indicated (e.g., antibiotic, antifungal, antiviral); nail fold edema or erythema with pain; associated with discharge or nail plate separation; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144899>	C143738	Grade 2 Paroxysmal Atrial Tachycardia, CTCAE|Grade 2 Paroxysmal atrial tachycardia|Grade 2 Paroxysmal atrial tachycardia	Non-urgent medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C1448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1448>	C1971|C1821	Nafoxidine Hydrochloride|1-[2-[4-(3,4-Dihydro-6-methoxy-2-phenyl-1-naphthalenyl)phenoxy]ethyl]pyrrolidine Hydrochloride|1-[2-[4-(3,4-Dihydro-6-methoxy-2-phenyl-1-naphthalenyl)phenoxy]ethyl]pyrrolidine Hydrochloride|NAFOXIDINE HYDROCHLORIDE|U 11100A|U-11,000A	The hydrochloride salt of the partial estrogen antagonist nafoxidine.  Nafoxidine competes with endogenous estrogen for binding to specific estrogen receptors.  This agent also inhibits angiogenesis in some tissues by blocking the effects of fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF); paradoxically, it may enhance angiogenesis in uterine tissue.  Nafoxidine also induces oxidative stress, protein kinase C and calcium signaling. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C144900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144900>	C143739	Grade 2 Pelvic Floor Muscle Weakness, CTCAE|Grade 2 Pelvic floor muscle weakness|Grade 2 Pelvic floor muscle weakness	Symptomatic, not interfering with bladder, bowel, or vaginal function; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144901>	C143740	Grade 2 Pelvic Infection, CTCAE|Grade 2 Pelvic infection|Grade 2 Pelvic infection	Moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144902>	C146679	Grade 2 Pelvic Pain, CTCAE|Grade 2 Pelvic pain|Grade 2 Pelvic pain	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144903>	C143741	Grade 2 Penile Infection, CTCAE|Grade 2 Penile infection|Grade 2 Penile infection	Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144905>	C143743	Grade 2 Pericardial Effusion, CTCAE|Grade 2 Pericardial effusion|Grade 2 Pericardial effusion	Asymptomatic effusion size small to moderate			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144906>	C146681	Grade 2 Perineal Pain, CTCAE|Grade 2 Perineal pain|Grade 2 Perineal pain	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144907>	C143747	Grade 2 Periorbital Edema, CTCAE|Grade 2 Periorbital edema|Grade 2 Periorbital edema	Indurated or pitting edema; topical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144908>	C143748	Grade 2 Periorbital Infection, CTCAE|Grade 2 Periorbital infection|Grade 2 Periorbital infection	Localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144909>	C143749	Grade 2 Peripheral Ischemia, CTCAE|Grade 2 Peripheral ischemia|Grade 2 Peripheral ischemia	Brief (<24 hrs) episode of ischemia managed medically and without permanent deficit; claudication			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144910>	C143750	Grade 2 Peripheral Motor Neuropathy, CTCAE|Grade 2 Peripheral motor neuropathy|Grade 2 Peripheral motor neuropathy	Moderate symptoms; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144911>	C143751	Grade 2 Peripheral Nerve Infection, CTCAE|Grade 2 Peripheral nerve infection|Grade 2 Peripheral nerve infection	Localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144912>	C143752	Grade 2 Peripheral Sensory Neuropathy, CTCAE|Grade 2 Peripheral sensory neuropathy|Grade 2 Peripheral sensory neuropathy	Moderate symptoms; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144913>	C143754	Grade 2 Personality Change, CTCAE|Grade 2 Personality change|Grade 2 Personality change	Moderate personality change			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144914>	C146682	Grade 2 Phantom Pain, CTCAE|Grade 2 Phantom pain|Grade 2 Phantom pain	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144915>	C143755	Grade 2 Pharyngeal Anastomotic Leak, CTCAE|Grade 2 Pharyngeal anastomotic leak|Grade 2 Pharyngeal anastomotic leak	Symptomatic; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144918>	C143756	Grade 2 Pharyngeal Mucositis, CTCAE|Grade 2 Pharyngeal mucositis|Grade 2 Pharyngeal mucositis	Moderate pain, analgesics indicated; altered oral intake; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144919>	C143757	Grade 2 Pharyngeal Stenosis, CTCAE|Grade 2 Pharyngeal stenosis|Grade 2 Pharyngeal stenosis	Symptomatic (e.g., noisy airway breathing), no respiratory distress; medical intervention indicated (e.g., steroids); limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144920>	C143758	Grade 2 Pharyngitis, CTCAE|Grade 2 Pharyngitis|Grade 2 Pharyngitis	Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144921>	C143759	Grade 2 Pharyngolaryngeal Pain, CTCAE|Grade 2 Pharyngolaryngeal pain|Grade 2 Pharyngolaryngeal pain	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144922>	C143760	Grade 2 Phlebitis Infective, CTCAE|Grade 2 Phlebitis infective|Grade 2 Phlebitis infective	Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144923>	C143761	Grade 2 Phlebitis, CTCAE|Grade 2 Phlebitis|Grade 2 Phlebitis	Present			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144924>	C143764	Grade 2 Platelet Count Decreased, CTCAE|Grade 2 Platelet count decreased	<75,000-50,000/mm3; <75.0-50.0 x 10e9/L			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144925>	C143765	Grade 2 Pleural Effusion, CTCAE|Grade 2 Pleural effusion|Grade 2 Pleural effusion	Symptomatic; intervention indicated (e.g., diuretics or therapeutic thoracentesis)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144927>	C143766	Grade 2 Pleural Infection, CTCAE|Grade 2 Pleural infection|Grade 2 Pleural infection	Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144928>	C146663	Grade 2 Pleuritic Pain, CTCAE|Grade 2 Pleuritic pain|Grade 2 Pleuritic pain	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144929>	C143767	Grade 2 Pneumonitis, CTCAE|Grade 2 Pneumonitis|Grade 2 Pneumonitis	Symptomatic; medical intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144930>	C143769	Grade 2 Portal Hypertension, CTCAE|Grade 2 Portal hypertension|Grade 2 Portal hypertension	Decreased portal vein flow			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144931>	C143770	Grade 2 Portal Vein Thrombosis, CTCAE|Grade 2 Portal vein thrombosis|Grade 2 Portal vein thrombosis	Intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144932>	C143771	Grade 2 Postnasal Drip, CTCAE|Grade 2 Postnasal drip|Grade 2 Postnasal drip	Moderate symptoms; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144933>	C143772	Grade 2 Postoperative Hemorrhage, CTCAE|Grade 2 Postoperative hemorrhage|Grade 2 Postoperative hemorrhage	Moderate bleeding requiring transfusion <2 units (10 cc/kg for pediatrics) of pRBCs			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144934>	C143773	Grade 2 Postoperative Thoracic Procedure Complication, CTCAE|Grade 2 Postoperative thoracic procedure complication|Grade 2 Postoperative thoracic procedure complication	Extubated within 24 - 72 hrs postoperatively			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144935>	C143775	Grade 2 Pregnancy, Puerperium and Perinatal Conditions - Other, Specify, CTCAE|Grade 2 Pregnancy, puerperium and perinatal conditions - Other, specify|Grade 2 Pregnancy, puerperium and perinatal conditions - Other, specify	Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144936>	C143776	Grade 2 Premature Delivery, CTCAE|Grade 2 Premature delivery|Grade 2 Premature delivery	Delivery of a liveborn infant at >28 to 34 weeks gestation			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144937>	C143777	Grade 2 Premature Menopause, CTCAE|Grade 2 Premature menopause	Present			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144938>	C143778	Grade 2 Presyncope, CTCAE|Grade 2 Presyncope|Grade 2 Presyncope	Present (e.g., near fainting)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144939>	C143780	Grade 2 Productive Cough, CTCAE|Grade 2 Productive cough|Grade 2 Productive cough	Moderate sputum production; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144940>	C143781	Grade 2 Prolapse of Intestinal Stoma, CTCAE|Grade 2 Prolapse of intestinal stoma|Grade 2 Prolapse of intestinal stoma	Recurrent after manual reduction; local irritation or stool leakage; difficulty to fit appliance; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144941>	C143782	Grade 2 Prolapse of Urostomy, CTCAE|Grade 2 Prolapse of urostomy|Grade 2 Prolapse of urostomy	Local care or maintenance; minor revision indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144942>	C143783	Grade 2 Prostate Infection, CTCAE|Grade 2 Prostate infection|Grade 2 Prostate infection	Moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144944>	C143784	Grade 2 Prostatic Obstruction, CTCAE|Grade 2 Prostatic obstruction|Grade 2 Prostatic obstruction	Symptomatic; elective intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144945>	C146664	Grade 2 Prostatic Pain, CTCAE|Grade 2 Prostatic pain|Grade 2 Prostatic pain	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144946>	C143787	Grade 2 Psychiatric Disorders - Other, Specify, CTCAE|Grade 2 Psychiatric disorders - Other, specify|Grade 2 Psychiatric disorders - Other, specify	Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144947>	C143788	Grade 2 Psychosis, CTCAE|Grade 2 Psychosis|Grade 2 Psychosis	Moderate psychotic symptoms (e.g., disorganized speech; impaired reality testing)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144948>	C143789	Grade 2 Pulmonary Edema, CTCAE|Grade 2 Pulmonary edema|Grade 2 Pulmonary edema	Moderate dyspnea on exertion; medical intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144949>	C143790	Grade 2 Pulmonary Fibrosis, CTCAE|Grade 2 Pulmonary fibrosis|Grade 2 Pulmonary fibrosis	Evidence of pulmonary hypertension; radiographic pulmonary fibrosis 25 - 50% associated with hypoxia			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144950>	C143791	Grade 2 Pulmonary Fistula, CTCAE|Grade 2 Pulmonary fistula|Grade 2 Pulmonary fistula	Symptomatic, invasive intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144951>	C143793	Grade 2 Pulmonary Valve Disease, CTCAE|Grade 2 Pulmonary valve disease|Grade 2 Pulmonary valve disease	Asymptomatic; moderate regurgitation or stenosis by imaging			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144952>	C143794	Grade 2 Purpura, CTCAE|Grade 2 Purpura|Grade 2 Purpura	Combined area of lesions covering 10 - 30% BSA			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144953>	C143795	Grade 2 Pyramidal Tract Syndrome, CTCAE|Grade 2 Pyramidal tract syndrome|Grade 2 Pyramidal tract syndrome	Moderate symptoms; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144954>	C143796	Grade 2 Radiation Recall Reaction (Dermatologic), CTCAE|Grade 2 Radiation recall reaction (dermatologic)|Grade 2 Radiation recall reaction (dermatologic)	Moderate to brisk erythema; patchy moist desquamation, mostly confined to skin folds and creases; moderate edema			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144955>	C143797	Grade 2 Radiculitis, CTCAE|Grade 2 Radiculitis|Grade 2 Radiculitis	Moderate symptoms; medical intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144956>	C143798	Grade 2 Rash Acneiform, CTCAE|Grade 2 Rash acneiform	Papules and/or pustules covering 10-30% BSA, which may or may not be associated with symptoms of pruritus or tenderness; associated with psychosocial impact; limiting instrumental ADL; papules and/or pustules covering > 30% BSA with or without mild symptoms			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144957>	C143799	Grade 2 Rash Maculo-Papular, CTCAE|Grade 2 Rash maculo-papular	Macules/papules covering 10-30% BSA with or without symptoms (e.g., pruritus, burning, tightness); limiting instrumental ADL; rash covering > 30% BSA with or without mild symptoms			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144958>	C143800	Grade 2 Rash Pustular, CTCAE|Grade 2 Rash pustular|Grade 2 Rash pustular	Localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144959>	C143801	Grade 2 Rectal Anastomotic Leak, CTCAE|Grade 2 Rectal anastomotic leak|Grade 2 Rectal anastomotic leak	Symptomatic; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144960>	C143200	Grade 2 Rectal Fissure, CTCAE|Grade 2 Rectal fissure|Grade 2 Rectal fissure	Symptomatic			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144963>	C143802	Grade 2 Rectal Mucositis, CTCAE|Grade 2 Rectal mucositis|Grade 2 Rectal mucositis	Moderate symptoms; medical intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144965>	C146631	Grade 2 Rectal Pain, CTCAE|Grade 2 Rectal pain|Grade 2 Rectal pain	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144967>	C143803	Grade 2 Rectal Stenosis, CTCAE|Grade 2 Rectal stenosis|Grade 2 Rectal stenosis	Symptomatic; altered GI function			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144969>	C143804	Grade 2 Recurrent Laryngeal Nerve Palsy, CTCAE|Grade 2 Recurrent laryngeal nerve palsy|Grade 2 Recurrent laryngeal nerve palsy	Moderate symptoms			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144970>	C143805	Grade 2 Renal and Urinary Disorders - Other, Specify, CTCAE|Grade 2 Renal and urinary disorders - Other, specify|Grade 2 Renal and urinary disorders - Other, specify	Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144971>	C143806	Grade 2 Renal Calculi, CTCAE|Grade 2 Renal calculi|Grade 2 Renal calculi	Symptomatic; oral antiemetics indicated; around the clock nonprescription analgesics or any oral narcotic analgesics indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144972>	C143807	Grade 2 Renal Colic, CTCAE|Grade 2 Renal colic|Grade 2 Renal colic	Moderate pain; prescription medication indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144974>	C143808	Grade 2 Reproductive System and Breast Disorders - Other, Specify, CTCAE|Grade 2 Reproductive system and breast disorders - Other, specify|Grade 2 Reproductive system and breast disorders - Other, specify	Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144975>	C143810	Grade 2 Respiratory, Thoracic and Mediastinal Disorders - Other, Specify, CTCAE|Grade 2 Respiratory, thoracic and mediastinal disorders - Other, specify|Grade 2 Respiratory, thoracic and mediastinal disorders - Other, specify	Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144976>	C143811	Grade 2 Restlessness, CTCAE|Grade 2 Restlessness|Grade 2 Restlessness	Moderate symptoms; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144977>	C143814	Grade 2 Retinal Tear, CTCAE|Grade 2 Retinal tear|Grade 2 Retinal tear	No retinal detachment and treatment indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144978>	C143815	Grade 2 Retinal Vascular Disorder, CTCAE|Grade 2 Retinal vascular disorder|Grade 2 Retinal vascular disorder	Retinal vascular disorder without neovascularization			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144979>	C146632	Grade 2 Retroperitoneal Hemorrhage, CTCAE|Grade 2 Retroperitoneal hemorrhage	Self-limited; intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C144980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144980>	C143818	Grade 2 Reversible Posterior Leukoencephalopathy Syndrome, CTCAE|Grade 2 Reversible posterior leukoencephalopathy syndrome|Grade 2 Reversible posterior leukoencephalopathy syndrome	Moderate symptoms; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144981>	C143226	Grade 2 Rhabdomyolysis, CTCAE|Grade 2 Rhabdomyolysis|Grade 2 Rhabdomyolysis	Non-urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144982>	C143819	Grade 2 Rhinitis Infective, CTCAE|Grade 2 Rhinitis infective|Grade 2 Rhinitis infective	Localized; local intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144983>	C143227	Grade 2 Rotator Cuff Injury, CTCAE|Grade 2 Rotator cuff injury|Grade 2 Rotator cuff injury	Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental AD or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144984>	C143821	Grade 2 Salivary Duct Inflammation, CTCAE|Grade 2 Salivary duct inflammation|Grade 2 Salivary duct inflammation	Thick, ropy, sticky saliva; markedly altered taste; alteration in diet indicated; secretion-induced symptoms; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144985>	C143822	Grade 2 Salivary Gland Infection, CTCAE|Grade 2 Salivary gland infection|Grade 2 Salivary gland infection	Moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144986>	C143823	Grade 2 Scleral Disorder, CTCAE|Grade 2 Scleral disorder|Grade 2 Scleral disorder	Symptomatic; moderate decrease in visual acuity (best corrected visual acuity 20/40 and better or 3 lines or less decreased vision from known baseline); limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144987>	C143824	Grade 2 Scoliosis, CTCAE|Grade 2 Scoliosis|Grade 2 Scoliosis	>20 - 45 degrees; visible by forward flexion; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144988>	C143825	Grade 2 Scrotal Infection, CTCAE|Grade 2 Scrotal infection|Grade 2 Scrotal infection	Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144989>	C146665	Grade 2 Scrotal Pain, CTCAE|Grade 2 Scrotal pain|Grade 2 Scrotal pain	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144990>	C143829	Grade 2 Serum Amylase Increased, CTCAE|Grade 2 Serum amylase increased|Grade 2 Serum amylase increased	>1.5 - 2.0 x ULN; >2.0 - 5.0 x ULN and asymptomatic or with mild signs or symptoms			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144991>	C146642	Grade 2 Serum Sickness, CTCAE|Grade 2 Serum sickness|Grade 2 Serum sickness	Moderate arthralgia; fever, rash, urticaria, antihistamines indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144992>	C143213	Grade 2 Shingles, CTCAE|Grade 2 Shingles|Grade 2 Shingles	Local infection with moderate symptoms; oral intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144993>	C143831	Grade 2 Sinus Disorder, CTCAE|Grade 2 Sinus disorder|Grade 2 Sinus disorder	Symptomatic stenosis or edema/narrowing interfering with airflow; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144994>	C143832	Grade 2 Sinusitis, CTCAE|Grade 2 Sinusitis|Grade 2 Sinusitis	Localized; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144995>	C143205	Grade 2 Sinusoidal Obstruction Syndrome, CTCAE|Grade 2 Sinusoidal obstruction syndrome|Grade 2 Sinusoidal obstruction syndrome	Blood bilirubin 2 - 5 mg/dL; minor interventions required (i.e., blood product, diuretic, oxygen)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144996>	C143833	Grade 2 Skin and Subcutaneous Tissue Disorders - Other, Specify, CTCAE|Grade 2 Skin and subcutaneous tissue disorders - Other, specify|Grade 2 Skin and subcutaneous tissue disorders - Other, specify	Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144997>	C143835	Grade 2 Skin Hyperpigmentation, CTCAE|Grade 2 Skin hyperpigmentation|Grade 2 Skin hyperpigmentation	Associated with psychosocial impact			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144998>	C143836	Grade 2 Skin Hypopigmentation, CTCAE|Grade 2 Skin hypopigmentation|Grade 2 Skin hypopigmentation	Associated with psychosocial impact			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C144999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C144999>	C143837	Grade 2 Skin Induration, CTCAE|Grade 2 Skin induration|Grade 2 Skin induration	Moderate induration, able to slide skin, unable to pinch skin; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C1449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1449>	C390	Thorium Dioxide|THORIUM DIOXIDE|Thoria|Thorium Anhydride|Thorium Oxide|Thorium(IV) Oxide|Thorotrast|Thortrast|Umbrathor	A radioactive crystalline solid compound used in a broad range of industrial applications. Thorium dioxide was utilized as a radiographic contrast agent; however, it is no longer considered safe for use in human patients because it was found to be a carcinogen that can cause cholangiocarcinoma.			Hazardous or Poisonous Substance|Indicator, Reagent, or Diagnostic Aid|Inorganic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C145000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145000>	C143838	Grade 2 Skin Infection, CTCAE|Grade 2 Skin infection|Grade 2 Skin infection	Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145001>	C143228	Grade 2 Skin Papilloma, CTCAE|Grade 2 Skin papilloma|Grade 2 Skin papilloma	Intervention initiated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145002>	C143839	Grade 2 Skin Ulceration, CTCAE|Grade 2 Skin ulceration|Grade 2 Skin ulceration	Combined area of ulcers 1 - 2 cm; partial thickness skin loss involving skin or subcutaneous fat			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145003>	C143840	Grade 2 Sleep Apnea, CTCAE|Grade 2 Sleep apnea|Grade 2 Sleep apnea	Moderate apnea and oxygen desaturation; excessive daytime sleepiness; medical evaluation indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145004>	C143841	Grade 2 Small Intestinal Anastomotic Leak, CTCAE|Grade 2 Small intestinal anastomotic leak|Grade 2 Small intestinal anastomotic leak	Symptomatic; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145005>	C143842	Grade 2 Small Intestinal Mucositis, CTCAE|Grade 2 Small intestinal mucositis|Grade 2 Small intestinal mucositis	Moderate symptoms; medical intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145006>	C143843	Grade 2 Small Intestinal Obstruction, CTCAE|Grade 2 Small intestinal obstruction|Grade 2 Small intestinal obstruction	Symptomatic; altered GI function; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145007>	C146635	Grade 2 Small Intestinal Perforation, CTCAE|Grade 2 Small intestinal perforation|Grade 2 Small intestinal perforation	Invasive intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145008>	C143844	Grade 2 Small Intestinal Stenosis, CTCAE|Grade 2 Small intestinal stenosis|Grade 2 Small intestinal stenosis	Symptomatic; altered GI function			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145009>	C143845	Grade 2 Small Intestine Infection, CTCAE|Grade 2 Small intestine infection|Grade 2 Small intestine infection	Moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145010>	C143846	Grade 2 Small Intestine Ulcer, CTCAE|Grade 2 Small intestine ulcer|Grade 2 Small intestine ulcer	Symptomatic; altered GI function; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145011>	C143847	Grade 2 Sneezing, CTCAE|Grade 2 Sneezing|Grade 2 Sneezing	Moderate symptoms; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145012>	C143848	Grade 2 Social Circumstances - Other, Specify, CTCAE|Grade 2 Social circumstances - Other, specify|Grade 2 Social circumstances - Other, specify	Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145013>	C143849	Grade 2 Soft Tissue Infection, CTCAE|Grade 2 Soft tissue infection|Grade 2 Soft tissue infection	Localized; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145014>	C143850	Grade 2 Soft Tissue Necrosis Lower Limb, CTCAE|Grade 2 Soft tissue necrosis lower limb|Grade 2 Soft tissue necrosis lower limb	Local wound care; medical intervention indicated (e.g., dressings or topical medications)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145015>	C143851	Grade 2 Soft Tissue Necrosis Upper Limb, CTCAE|Grade 2 Soft tissue necrosis upper limb|Grade 2 Soft tissue necrosis upper limb	Local wound care; medical intervention indicated (e.g., dressings or topical medications)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145016>	C143852	Grade 2 Somnolence, CTCAE|Grade 2 Somnolence|Grade 2 Somnolence	Moderate sedation; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145017>	C143853	Grade 2 Sore Throat, CTCAE|Grade 2 Sore throat|Grade 2 Sore throat	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145018>	C143854	Grade 2 Spasticity, CTCAE|Grade 2 Spasticity|Grade 2 Spasticity	Moderate increase in muscle tone and increase in resistance through range of motion			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145019>	C143855	Grade 2 Spermatic Cord Anastomotic Leak, CTCAE|Grade 2 Spermatic cord anastomotic leak|Grade 2 Spermatic cord anastomotic leak	Symptomatic; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145020>	C143856	Grade 2 Spinal Fracture, CTCAE|Grade 2 Spinal fracture	Moderate back pain; prescription analgesics indicated; limiting instrumental ADL			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145021>	C143858	Grade 2 Stenosis of Gastrointestinal Stoma, CTCAE|Grade 2 Stenosis of gastrointestinal stoma|Grade 2 Stenosis of gastrointestinal stoma	Symptomatic; IV fluids indicated <24 hrs; manual dilation at bedside			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145022>	C143860	Grade 2 Stoma Site Infection, CTCAE|Grade 2 Stoma site infection|Grade 2 Stoma site infection	Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145023>	C146694	Grade 2 Stomal Ulcer, CTCAE|Grade 2 Stomal ulcer|Grade 2 Stomal ulcer	Symptomatic; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145024>	C143862	Grade 2 Stroke, CTCAE|Grade 2 Stroke|Grade 2 Stroke	Mild to moderate neurologic deficit; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145025>	C143248	Grade 2 Subcutaneous Emphysema, CTCAE|Grade 2 Subcutaneous emphysema|Grade 2 Subcutaneous emphysema	Moderate; minimal, local or noninvasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145026>	C143864	Grade 2 Suicidal Ideation, CTCAE|Grade 2 Suicidal ideation|Grade 2 Suicidal ideation	Suicidal ideation with no specific plan or intent			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145027>	C143866	Grade 2 Superficial Soft Tissue Fibrosis, CTCAE|Grade 2 Superficial soft tissue fibrosis|Grade 2 Superficial soft tissue fibrosis	Moderate induration, able to slide skin, unable to pinch skin; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145028>	C143867	Grade 2 Superficial Thrombophlebitis, CTCAE|Grade 2 Superficial thrombophlebitis|Grade 2 Superficial thrombophlebitis	Present			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145029>	C143868	Grade 2 Superior Vena Cava Syndrome, CTCAE|Grade 2 Superior vena cava syndrome|Grade 2 Superior vena cava syndrome	Symptomatic; medical intervention indicated (e.g., anticoagulation, radiation or chemotherapy)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145030>	C143869	Grade 2 Surgical and Medical Procedures - Other, Specify, CTCAE|Grade 2 Surgical and medical procedures - Other, specify|Grade 2 Surgical and medical procedures - Other, specify	Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145031>	C143234	Grade 2 Tendon Reflex Decreased, CTCAE|Grade 2 Tendon reflex decreased|Grade 2 Tendon reflex decreased	Ankle reflex absent; other reflexes reduced			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145032>	C143872	Grade 2 Testicular Disorder, CTCAE|Grade 2 Testicular disorder|Grade 2 Testicular disorder	Symptomatic but not interfering with sexual function; intervention not indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145034>	C146666	Grade 2 Testicular Pain, CTCAE|Grade 2 Testicular pain|Grade 2 Testicular pain	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145035>	C143195	Grade 2 Testosterone Deficiency, CTCAE|Grade 2 Testosterone deficiency|Grade 2 Testosterone deficiency	Replacement therapy initiated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145036>	C143873	Grade 2 Thromboembolic Event, CTCAE|Grade 2 Thromboembolic event	Medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145037>	C143214	Grade 2 Thrush, CTCAE|Grade 2 Thrush	Oral intervention indicated (e.g., antifungal)			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145038>	C143876	Grade 2 Tooth Development Disorder, CTCAE|Grade 2 Tooth development disorder|Grade 2 Tooth development disorder	Impairment correctable with oral surgery			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145039>	C143878	Grade 2 Tooth Infection, CTCAE|Grade 2 Tooth infection|Grade 2 Tooth infection	Localized; local intervention indicated (e.g., topical antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145040>	C143879	Grade 2 Toothache, CTCAE|Grade 2 Toothache|Grade 2 Toothache	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145043>	C143881	Grade 2 Tracheal Mucositis, CTCAE|Grade 2 Tracheal mucositis|Grade 2 Tracheal mucositis	Moderate symptoms; medical intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145044>	C143882	Grade 2 Tracheal Obstruction, CTCAE|Grade 2 Tracheal obstruction|Grade 2 Tracheal obstruction	Symptomatic (e.g., noisy airway breathing), no respiratory distress; medical intervention indicated (e.g., steroids); limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145045>	C143883	Grade 2 Tracheal Stenosis, CTCAE|Grade 2 Tracheal stenosis|Grade 2 Tracheal stenosis	Symptomatic (e.g., noisy airway breathing), no respiratory distress; medical intervention indicated (e.g., steroids); limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145046>	C143884	Grade 2 Tracheitis, CTCAE|Grade 2 Tracheitis|Grade 2 Tracheitis	Moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145047>	C143885	Grade 2 Tracheostomy Site Bleeding, CTCAE|Grade 2 Tracheostomy site bleeding|Grade 2 Tracheostomy site bleeding	Moderate bleeding; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145048>	C143886	Grade 2 Transient Ischemic Attacks, CTCAE|Grade 2 Transient ischemic attacks|Grade 2 Transient ischemic attacks	Moderate neurologic deficit with or without imaging confirmation			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145049>	C143889	Grade 2 Tricuspid Valve Disease, CTCAE|Grade 2 Tricuspid valve disease|Grade 2 Tricuspid valve disease	Asymptomatic; moderate regurgitation or stenosis by imaging			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145050>	C143890	Grade 2 Trigeminal Nerve Disorder, CTCAE|Grade 2 Trigeminal nerve disorder|Grade 2 Trigeminal nerve disorder	Moderate symptoms; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145051>	C143235	Grade 2 Trochlear Nerve Disorder, CTCAE|Grade 2 Trochlear nerve disorder|Grade 2 Trochlear nerve disorder	Moderate symptoms; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145052>	C143229	Grade 2 Tumor Hemorrhage, CTCAE|Grade 2 Tumor hemorrhage|Grade 2 Tumor hemorrhage	Moderate symptoms; intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145053>	C143894	Grade 2 Unequal Limb Length, CTCAE|Grade 2 Unequal limb length|Grade 2 Unequal limb length	Moderate length discrepancy 2 - 5 cm; shoe lift indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145054>	C143895	Grade 2 Upper Gastrointestinal Hemorrhage, CTCAE|Grade 2 Upper gastrointestinal hemorrhage|Grade 2 Upper gastrointestinal hemorrhage	Moderate symptoms; intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145055>	C143896	Grade 2 Upper Respiratory Infection, CTCAE|Grade 2 Upper respiratory infection|Grade 2 Upper respiratory infection	Moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145056>	C143897	Grade 2 Ureteric Anastomotic Leak, CTCAE|Grade 2 Ureteric anastomotic leak|Grade 2 Ureteric anastomotic leak	Symptomatic; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145057>	C143898	Grade 2 Urethral Anastomotic Leak, CTCAE|Grade 2 Urethral anastomotic leak|Grade 2 Urethral anastomotic leak	Symptomatic; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145058>	C143899	Grade 2 Urethral Infection, CTCAE|Grade 2 Urethral infection|Grade 2 Urethral infection	Localized; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145059>	C143900	Grade 2 Urinary Fistula, CTCAE|Grade 2 Urinary fistula|Grade 2 Urinary fistula	Symptomatic, invasive intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14505>	C14421	AKR/J Mouse|AKR/J|AKR/J	Originally disseminated by Detweiler and carried by Furth (1928-1936) and the Rockefeller Institute for subsequent generations. The AKR mouse has an albino coat (genotype a, B, c) and is highly susceptible to leukemias. The strain is viremic from birth in that all tissues express the AKV retrovirus and copies of the AKV genome are integrated in the mouse genome, which is associated with leukemia development. The AKR strain is also a source of the Thy1.1 thymocyte antigen, which is expressed on thymocyte, bone marrow and T cell progenitors and is used as a marker for a variety of stem cells. The strain has a low reproductive performance with small litter sizes at birth and weaning.	AKR/J Mouse		Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C145060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145060>	C143901	Grade 2 Urinary Frequency, CTCAE|Grade 2 Urinary frequency|Grade 2 Urinary frequency	Medical management indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145061>	C143904	Grade 2 Urinary Tract Infection, CTCAE|Grade 2 Urinary tract infection|Grade 2 Urinary tract infection	Localized; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145062>	C143905	Grade 2 Urinary Tract Obstruction, CTCAE|Grade 2 Urinary tract obstruction|Grade 2 Urinary tract obstruction	Symptomatic but no hydronephrosis, sepsis, or renal dysfunction; urethral dilation, urinary or suprapubic catheter indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145063>	C143906	Grade 2 Urinary Tract Pain, CTCAE|Grade 2 Urinary tract pain|Grade 2 Urinary tract pain	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145064>	C143907	Grade 2 Urinary Urgency, CTCAE|Grade 2 Urinary urgency|Grade 2 Urinary urgency	Medical management indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145065>	C143910	Grade 2 Urostomy Leak, CTCAE|Grade 2 Urostomy leak|Grade 2 Urostomy leak	Symptomatic; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145066>	C143911	Grade 2 Urostomy Obstruction, CTCAE|Grade 2 Urostomy obstruction|Grade 2 Urostomy obstruction	Symptomatic; dilation or endoscopic repair or stent placement indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145067>	C143912	Grade 2 Urostomy Site Bleeding, CTCAE|Grade 2 Urostomy site bleeding|Grade 2 Urostomy site bleeding	Moderate bleeding; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145068>	C143913	Grade 2 Urostomy Stenosis, CTCAE|Grade 2 Urostomy stenosis|Grade 2 Urostomy stenosis	Symptomatic but no hydronephrosis, sepsis, or renal dysfunction; dilation or endoscopic repair or stent placement indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145069>	C143915	Grade 2 Uterine Anastomotic Leak, CTCAE|Grade 2 Uterine anastomotic leak|Grade 2 Uterine anastomotic leak	Symptomatic; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145070>	C143916	Grade 2 Uterine Fistula, CTCAE|Grade 2 Uterine fistula|Grade 2 Uterine fistula	Symptomatic, invasive intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145072>	C143917	Grade 2 Uterine Infection, CTCAE|Grade 2 Uterine infection|Grade 2 Uterine infection	Moderate symptoms; oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145073>	C143918	Grade 2 Uterine Obstruction, CTCAE|Grade 2 Uterine obstruction|Grade 2 Uterine obstruction	Symptomatic; elective intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145074>	C146683	Grade 2 Uterine Pain, CTCAE|Grade 2 Uterine pain|Grade 2 Uterine pain	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145075>	C143919	Grade 2 Uterine Perforation, CTCAE|Grade 2 Uterine perforation|Grade 2 Uterine perforation	Invasive intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145076>	C143216	Grade 2 Vaccination Complication, CTCAE|Grade 2 Vaccination complication	Moderate pain; Erythema 5.1-10 cm; Induration/swelling 5.1-10 cm; lipodystrophy; limiting instrumental ADL			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145077>	C143203	Grade 2 Vaccination Site Lymphadenopathy, CTCAE|Grade 2 Vaccination site lymphadenopathy|Grade 2 Vaccination site lymphadenopathy	Localized ulceration; generalized lymph node enlargement			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145078>	C143921	Grade 2 Vaginal Anastomotic Leak, CTCAE|Grade 2 Vaginal anastomotic leak|Grade 2 Vaginal anastomotic leak	Symptomatic; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145079>	C143922	Grade 2 Vaginal Discharge, CTCAE|Grade 2 Vaginal discharge|Grade 2 Vaginal discharge	Moderate to heavy vaginal discharge; use of perineal pad or tampon indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145082>	C143924	Grade 2 Vaginal Infection, CTCAE|Grade 2 Vaginal infection|Grade 2 Vaginal infection	Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145083>	C143925	Grade 2 Vaginal Inflammation, CTCAE|Grade 2 Vaginal inflammation|Grade 2 Vaginal inflammation	Moderate discomfort or pain, edema, or redness; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145084>	C146696	Grade 2 Vaginal Obstruction, CTCAE|Grade 2 Vaginal obstruction|Grade 2 Vaginal obstruction	Symptomatic; elective intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145085>	C146684	Grade 2 Vaginal Pain, CTCAE|Grade 2 Vaginal pain|Grade 2 Vaginal pain	Moderate pain; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145086>	C146697	Grade 2 Vaginal Perforation, CTCAE|Grade 2 Vaginal perforation|Grade 2 Vaginal perforation	Invasive intervention not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145087>	C143926	Grade 2 Vaginal Stricture, CTCAE|Grade 2 Vaginal stricture|Grade 2 Vaginal stricture	Vaginal narrowing and/or shortening not interfering with physical examination			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145088>	C143927	Grade 2 Vagus Nerve Disorder, CTCAE|Grade 2 Vagus nerve disorder|Grade 2 Vagus nerve disorder	Moderate symptoms; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145089>	C143928	Grade 2 Vas Deferens Anastomotic Leak, CTCAE|Grade 2 Vas deferens anastomotic leak|Grade 2 Vas deferens anastomotic leak	Symptomatic; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145090>	C143929	Grade 2 Vascular Access Complication, CTCAE|Grade 2 Vascular access complication|Grade 2 Vascular access complication	Device dislodgement, blockage, leak, or malposition; device replacement indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145091>	C143930	Grade 2 Vascular Disorders - Other, Specify, CTCAE|Grade 2 Vascular disorders - Other, specify|Grade 2 Vascular disorders - Other, specify	Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145092>	C143933	Grade 2 Venous Injury, CTCAE|Grade 2 Venous injury|Grade 2 Venous injury	Symptomatic (e.g., claudication); repair or revision not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145093>	C146629	Grade 2 Ventricular Arrhythmia, CTCAE|Grade 2 Ventricular arrhythmia|Grade 2 Ventricular arrhythmia	Non-urgent medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145094>	C143935	Grade 2 Vertigo, CTCAE|Grade 2 Vertigo|Grade 2 Vertigo	Moderate symptoms; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145095>	C143936	Grade 2 Vestibular Disorder, CTCAE|Grade 2 Vestibular disorder|Grade 2 Vestibular disorder	Symptomatic; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145096>	C143215	Grade 2 Viremia, CTCAE|Grade 2 Viremia|Grade 2 Viremia	Moderate symptoms; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145097>	C143937	Grade 2 Virilization, CTCAE|Grade 2 Virilization|Grade 2 Virilization	Moderate symptoms; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145098>	C143938	Grade 2 Visceral Arterial Ischemia, CTCAE|Grade 2 Visceral arterial ischemia|Grade 2 Visceral arterial ischemia	Brief (<24 hrs) episode of ischemia managed medically and without permanent deficit			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145099>	C143196	Grade 2 Vision Decreased, CTCAE|Grade 2 Vision decreased|Grade 2 Vision decreased	Moderate decrease in visual acuity (best corrected visual acuity 20/40 and better or 3 lines or less decreased vision from known baseline)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C1450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1450>	C798|C2163|C1590	Platinum Compound|Platinum Agents|Platinum-Based Chemotherapeutic Agent	A chemotherapy compound that contains a platinum atom. Platinum compounds do not contain alkyl groups but do cause DNA crosslinks and adducts similar to alkylating agents. DNA crosslinks and adducts ultimately lead to the induction of apoptosis.	Platinum Compound		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology
C145100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145100>	C143939	Grade 2 Vital Capacity Abnormal, CTCAE|Grade 2 Vital capacity abnormal|Grade 2 Vital capacity abnormal	<75 - 50% of predicted value; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145101>	C143941	Grade 2 Voice Alteration, CTCAE|Grade 2 Voice alteration|Grade 2 Voice alteration	Moderate or persistent change from normal voice; still understandable			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145102>	C143943	Grade 2 Vulval Infection, CTCAE|Grade 2 Vulval infection|Grade 2 Vulval infection	Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145103>	C143944	Grade 2 Watering Eyes, CTCAE|Grade 2 Watering eyes|Grade 2 Watering eyes	Symptomatic; moderate decrease in visual acuity (best corrected visual acuity 20/40 and better or 3 lines or less decreased vision from known baseline)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145104>	C143947	Grade 2 Wheezing, CTCAE|Grade 2 Wheezing	Moderate symptoms; medical intervention indicated; limiting instrumental ADL			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145105>	C143948	Grade 2 White Blood Cell Decreased, CTCAE|Grade 2 White blood cell decreased|Grade 2 White blood cell decreased	<3000 - 2000/mm3; <3.0 - 2.0 x 10^9/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145106>	C143949	Grade 2 Wound Complication, CTCAE|Grade 2 Wound complication|Grade 2 Wound complication	Bedside local care indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145107>	C143950	Grade 2 Wound Dehiscence, CTCAE|Grade 2 Wound dehiscence|Grade 2 Wound dehiscence	Incisional separation, local care (e.g., suturing) or medical intervention indicated (e.g., analgesic)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145108>	C143951	Grade 2 Wound Infection, CTCAE|Grade 2 Wound infection|Grade 2 Wound infection	Oral intervention indicated (e.g., antibiotic, antifungal, or antiviral)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145109>	C143952	Grade 2 Wrist Fracture, CTCAE|Grade 2 Wrist fracture	Limiting instrumental ADL; outpatient operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C14510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14510>	C14421	YBR Mouse|YBR		YBR Mouse		Mammal	
C145110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145110>	C143253	Grade 3 Abdominal Distension, CTCAE|Grade 3 Abdominal distension|Grade 3 Abdominal distension	Severe discomfort; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145111>	C143254	Grade 3 Abdominal Infection, CTCAE|Grade 3 Abdominal infection|Grade 3 Abdominal infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145112>	C143255	Grade 3 Abdominal Pain, CTCAE|Grade 3 Abdominal pain|Grade 3 Abdominal pain	Severe pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145113>	C143256	Grade 3 Abdominal Soft Tissue Necrosis, CTCAE|Grade 3 Abdominal soft tissue necrosis|Grade 3 Abdominal soft tissue necrosis	Operative debridement or other invasive intervention indicated (e.g., tissue reconstruction, flap, or grafting)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145114>	C143257	Grade 3 Abducens Nerve Disorder, CTCAE|Grade 3 Abducens nerve disorder|Grade 3 Abducens nerve disorder	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145115>	C143258	Grade 3 Accessory Nerve Disorder, CTCAE|Grade 3 Accessory nerve disorder|Grade 3 Accessory nerve disorder	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145116>	C143259	Grade 3 Acidosis, CTCAE|Grade 3 Acidosis|Grade 3 Acidosis	pH <7.3			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145117>	C143260	Grade 3 Acoustic Nerve Disorder NOS, CTCAE|Grade 3 Acoustic nerve disorder NOS|Grade 3 Acoustic nerve disorder NOS	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145118>	C143261	Grade 3 Activated Partial Thromboplastin Time Prolonged, CTCAE|Grade 3 Activated partial thromboplastin time prolonged|Grade 3 Activated partial thromboplastin time prolonged	>2.5 x ULN; bleeding			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145119>	C143262	Grade 3 Acute Kidney Injury, CTCAE|Grade 3 Acute kidney injury|Grade 3 Acute kidney injury	Hospitalization indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145120>	C143266	Grade 3 Akathisia, CTCAE|Grade 3 Akathisia|Grade 3 Akathisia	Severe restlessness or increased motor activity; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145121>	C143267	Grade 3 Alanine Aminotransferase Increased, CTCAE|Grade 3 Alanine aminotransferase increased|Grade 3 Alanine aminotransferase increased	>5.0 - 20.0 x ULN if baseline was normal or less than normal; >2.0 - 4.0 x baseline if baseline was >ULN up to 5 x ULN			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145122>	C143268	Grade 3 Alcohol Intolerance, CTCAE|Grade 3 Alcohol intolerance|Grade 3 Alcohol intolerance	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145123>	C143269	Grade 3 Alkaline Phosphatase Increased, CTCAE|Grade 3 Alkaline phosphatase increased	>5.0-20.0 x ULN if baseline was normal; >5.0-20.0 x baseline if baseline was abnormal			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145124>	C143270	Grade 3 Alkalosis, CTCAE|Grade 3 Alkalosis|Grade 3 Alkalosis	pH >7.5			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145125>	C143271	Grade 3 Allergic Reaction, CTCAE|Grade 3 Allergic reaction|Grade 3 Allergic reaction	Bronchospasm; hospitalization indicated for clinical sequelae; IV intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145126>	C143274	Grade 3 Amnesia, CTCAE|Grade 3 Amnesia|Grade 3 Amnesia	Severe; long term memory loss; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145127>	C143197	Grade 3 Anal Fissure, CTCAE|Grade 3 Anal fissure|Grade 3 Anal fissure	Invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145128>	C143275	Grade 3 Anal Fistula, CTCAE|Grade 3 Anal fistula|Grade 3 Anal fistula	Invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145129>	C143276	Grade 3 Anal Hemorrhage, CTCAE|Grade 3 Anal hemorrhage	Transfusion indicated; invasive intervention indicated; hospitalization			Finding	CTCAE Adverse Events Version 5.0 Terminology
C14512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14512>	C14421	MA/MyJ Mouse|MA/MyJ		MA/MyJ Mouse		Mammal	
C145130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145130>	C143277	Grade 3 Anal Mucositis, CTCAE|Grade 3 Anal mucositis|Grade 3 Anal mucositis	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145131>	C143278	Grade 3 Anal Necrosis, CTCAE|Grade 3 Anal necrosis|Grade 3 Anal necrosis	TPN or hospitalization indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145132>	C143279	Grade 3 Anal Pain, CTCAE|Grade 3 Anal pain|Grade 3 Anal pain	Severe pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145133>	C143280	Grade 3 Anal Stenosis, CTCAE|Grade 3 Anal stenosis|Grade 3 Anal stenosis	Symptomatic and severely altered GI function; non-emergent operative intervention indicated; TPN or hospitalization indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145134>	C143281	Grade 3 Anal Ulcer, CTCAE|Grade 3 Anal ulcer|Grade 3 Anal ulcer	Severely altered GI function; TPN indicated; elective invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145135>	C143282	Grade 3 Anaphylaxis, CTCAE|Grade 3 Anaphylaxis|Grade 3 Anaphylaxis	Symptomatic bronchospasm, with or without urticaria; parenteral intervention indicated; allergy-related edema/angioedema; hypotension			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145136>	C143283	Grade 3 Anemia, CTCAE|Grade 3 Anemia|Grade 3 Anemia	Hgb <8.0 g/dL; <4.9 mmol/L; <80 g/L; transfusion indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145137>	C143284	Grade 3 Ankle Fracture, CTCAE|Grade 3 Ankle fracture	Limiting self care ADL; elective operative intervention indicated requiring hospitalization			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145138>	C143285	Grade 3 Anorectal Infection, CTCAE|Grade 3 Anorectal infection|Grade 3 Anorectal infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145139>	C143289	Grade 3 Aortic Injury, CTCAE|Grade 3 Aortic injury|Grade 3 Aortic injury	Severe symptoms; repair or revision indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145140>	C143290	Grade 3 Aortic Valve Disease, CTCAE|Grade 3 Aortic valve disease|Grade 3 Aortic valve disease	Symptomatic; severe regurgitation or stenosis by imaging; symptoms controlled with medical intervention			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145141>	C143291	Grade 3 Aphonia, CTCAE|Grade 3 Aphonia|Grade 3 Aphonia	Voicelessness; unable to speak			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145142>	C143293	Grade 3 Appendicitis Perforated, CTCAE|Grade 3 Appendicitis perforated|Grade 3 Appendicitis perforated	Medical intervention indicated; operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145143>	C143294	Grade 3 Appendicitis, CTCAE|Grade 3 Appendicitis|Grade 3 Appendicitis	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145144>	C143295	Grade 3 Arachnoiditis, CTCAE|Grade 3 Arachnoiditis|Grade 3 Arachnoiditis	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145145>	C143296	Grade 3 Arterial Injury, CTCAE|Grade 3 Arterial injury|Grade 3 Arterial injury	Severe symptoms; repair or revision indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145146>	C143249	Grade 3 Arterial Thromboembolism, CTCAE|Grade 3 Arterial thromboembolism|Grade 3 Arterial thromboembolism	Urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145147>	C143297	Grade 3 Arteritis Infective, CTCAE|Grade 3 Arteritis infective|Grade 3 Arteritis infective	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145148>	C143298	Grade 3 Arthralgia, CTCAE|Grade 3 Arthralgia|Grade 3 Arthralgia	Severe pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145149>	C143299	Grade 3 Arthritis, CTCAE|Grade 3 Arthritis|Grade 3 Arthritis	Severe pain associated with signs of inflammation, erythema, or joint swelling; irreversible joint damage; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145150>	C143300	Grade 3 Ascites, CTCAE|Grade 3 Ascites|Grade 3 Ascites	Severe symptoms; catheter placement indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145151>	C143301	Grade 3 Aspartate Aminotransferase Increased, CTCAE|Grade 3 Aspartate aminotransferase increased|Grade 3 Aspartate aminotransferase increased	>5.0 - 20.0 x ULN if baseline was normal or less than normal; >2.0 - 4.0 x baseline if baseline was >ULN up to 5 x ULN			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145152>	C143308	Grade 3 Atrioventricular Block Complete, CTCAE|Grade 3 Atrioventricular block complete|Grade 3 Atrioventricular block complete	Symptomatic and incompletely controlled medically, or controlled with device (e.g., pacemaker); new onset			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145153>	C143310	Grade 3 Autoimmune Disorder, CTCAE|Grade 3 Autoimmune disorder|Grade 3 Autoimmune disorder	Autoimmune reactions involving major organ (e.g., colitis, anemia, myocarditis, kidney)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145154>	C143311	Grade 3 Avascular Necrosis, CTCAE|Grade 3 Avascular necrosis	Severe symptoms; limiting self care ADL; elective operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145155>	C143314	Grade 3 Bile Duct Stenosis, CTCAE|Grade 3 Bile duct stenosis|Grade 3 Bile duct stenosis	Severely altered GI function; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145156>	C143315	Grade 3 Biliary Anastomotic Leak, CTCAE|Grade 3 Biliary anastomotic leak|Grade 3 Biliary anastomotic leak	Severe symptoms; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145157>	C143316	Grade 3 Biliary Fistula, CTCAE|Grade 3 Biliary fistula|Grade 3 Biliary fistula	Invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145158>	C143317	Grade 3 Biliary Tract Infection, CTCAE|Grade 3 Biliary tract infection|Grade 3 Biliary tract infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145159>	C143318	Grade 3 Bladder Anastomotic Leak, CTCAE|Grade 3 Bladder anastomotic leak|Grade 3 Bladder anastomotic leak	Severe symptoms; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14515>	C14421	C58/J Mouse|C58/J		C58/J Mouse		Mammal	
C145160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145160>	C143319	Grade 3 Bladder Infection, CTCAE|Grade 3 Bladder infection|Grade 3 Bladder infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145162>	C143323	Grade 3 Blood and Lymphatic System Disorders - Other, Specify, CTCAE|Grade 3 Blood and lymphatic system disorders - Other, specify|Grade 3 Blood and lymphatic system disorders - Other, specify	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145163>	C143324	Grade 3 Blood Antidiuretic Hormone Abnormal, CTCAE|Grade 3 Blood antidiuretic hormone abnormal|Grade 3 Blood antidiuretic hormone abnormal	Hospitalization indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145164>	C143325	Grade 3 Blood Bilirubin Increased, CTCAE|Grade 3 Blood bilirubin increased	>3.0-10.0 x ULN if baseline was normal; >3.0-10.0 x baseline if baseline was abnormal			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145165>	C143326	Grade 3 Blood Corticotrophin Decreased, CTCAE|Grade 3 Blood corticotrophin decreased|Grade 3 Blood corticotrophin decreased	Hospitalization indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145166>	C143327	Grade 3 Blood Gonadotrophin Abnormal, CTCAE|Grade 3 Blood gonadotrophin abnormal	Severe symptoms; limiting self care ADL			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145167>	C143331	Grade 3 Bone Infection, CTCAE|Grade 3 Bone infection|Grade 3 Bone infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145168>	C143332	Grade 3 Bone Marrow Hypocellular, CTCAE|Grade 3 Bone marrow hypocellular|Grade 3 Bone marrow hypocellular	Severely hypocellular or >50 - <=75% reduction cellularity from normal for age			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145169>	C143335	Grade 3 Breast Atrophy, CTCAE|Grade 3 Breast atrophy	Asymmetry >1/3 of breast volume; severe atrophy			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145170>	C143336	Grade 3 Breast Infection, CTCAE|Grade 3 Breast infection|Grade 3 Breast infection	IV antibiotic, antifungal, or antiviral intervention indicated; severe infection; axillary adenitis			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145171>	C143338	Grade 3 Bronchial Fistula, CTCAE|Grade 3 Bronchial fistula|Grade 3 Bronchial fistula	Invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145172>	C143339	Grade 3 Bronchial Infection, CTCAE|Grade 3 Bronchial infection|Grade 3 Bronchial infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145173>	C143340	Grade 3 Bronchial Obstruction, CTCAE|Grade 3 Bronchial obstruction|Grade 3 Bronchial obstruction	Shortness of breath with stridor; endoscopic intervention indicated (e.g., laser, stent placement)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145174>	C143341	Grade 3 Bronchial Stricture, CTCAE|Grade 3 Bronchial stricture|Grade 3 Bronchial stricture	Shortness of breath with stridor; endoscopic intervention indicated (e.g., laser, stent placement)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145175>	C143342	Grade 3 Bronchopleural Fistula, CTCAE|Grade 3 Bronchopleural fistula|Grade 3 Bronchopleural fistula	Hospitalization; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145176>	C143343	Grade 3 Bronchopulmonary Hemorrhage, CTCAE|Grade 3 Bronchopulmonary hemorrhage|Grade 3 Bronchopulmonary hemorrhage	Hospitalization			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145177>	C143344	Grade 3 Bronchospasm, CTCAE|Grade 3 Bronchospasm|Grade 3 Bronchospasm	Supplemental oxygen indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145178>	C143204	Grade 3 Budd-Chiari Syndrome, CTCAE|Grade 3 Budd-Chiari syndrome|Grade 3 Budd-Chiari syndrome	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; asterixis; mild encephalopathy			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145179>	C143346	Grade 3 Bullous Dermatitis, CTCAE|Grade 3 Bullous dermatitis	Blisters covering >30% BSA; limiting self care ADL			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145180>	C143349	Grade 3 Capillary Leak Syndrome, CTCAE|Grade 3 Capillary leak syndrome|Grade 3 Capillary leak syndrome	Severe symptoms			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145181>	C143350	Grade 3 Carbon Monoxide Diffusing Capacity Decreased, CTCAE|Grade 3 Carbon monoxide diffusing capacity decreased|Grade 3 Carbon monoxide diffusing capacity decreased	Asymptomatic decrease of >8 units drop; >5 units drop along with the presence of pulmonary symptoms (e.g., >Grade 2 hypoxia or >Grade 2 dyspnea); intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145182>	C143352	Grade 3 Cardiac Disorders - Other, Specify, CTCAE|Grade 3 Cardiac disorders - Other, specify|Grade 3 Cardiac disorders - Other, specify	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145183>	C143353	Grade 3 Cardiac Troponin I Increased, CTCAE|Grade 3 Cardiac troponin I increased	Levels consistent with myocardial infarction as defined by the manufacturer			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145184>	C143354	Grade 3 Cardiac Troponin T Increased, CTCAE|Grade 3 Cardiac troponin T increased	Levels consistent with myocardial infarction as defined by the manufacturer			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145185>	C143356	Grade 3 Catheter Related Infection, CTCAE|Grade 3 Catheter related infection|Grade 3 Catheter related infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145186>	C143357	Grade 3 CD4 Lymphocytes Decreased, CTCAE|Grade 3 CD4 lymphocytes decreased|Grade 3 CD4 lymphocytes decreased	<200 - 50/mm3; <0.2 - 0.05 x 10^9/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145187>	C143358	Grade 3 Cecal Hemorrhage, CTCAE|Grade 3 Cecal hemorrhage|Grade 3 Cecal hemorrhage	Hospitalization			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145188>	C143359	Grade 3 Cecal Infection, CTCAE|Grade 3 Cecal infection|Grade 3 Cecal infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145189>	C143360	Grade 3 Central Nervous System Necrosis, CTCAE|Grade 3 Central nervous system necrosis|Grade 3 Central nervous system necrosis	Severe symptoms; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145190>	C143361	Grade 3 Cerebrospinal Fluid Leakage, CTCAE|Grade 3 Cerebrospinal fluid leakage|Grade 3 Cerebrospinal fluid leakage	Severe symptoms; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145191>	C143362	Grade 3 Cervicitis Infection, CTCAE|Grade 3 Cervicitis infection|Grade 3 Cervicitis infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145192>	C143364	Grade 3 Chest Pain - Cardiac, CTCAE|Grade 3 Chest pain - cardiac|Grade 3 Chest pain - cardiac	Pain at rest; cardiac catheterization; new onset cardiac chest pain; unstable angina; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145193>	C143223	Grade 3 Chest Wall Necrosis, CTCAE|Grade 3 Chest wall necrosis|Grade 3 Chest wall necrosis	Operative debridement or other invasive intervention indicated (e.g., tissue reconstruction, flap, or grafting)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145194>	C143366	Grade 3 Chills, CTCAE|Grade 3 Chills|Grade 3 Chills	Severe or prolonged, not responsive to narcotics			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145195>	C143368	Grade 3 Cholesterol High, CTCAE|Grade 3 Cholesterol high|Grade 3 Cholesterol high	>400 - 500 mg/dL; >10.34 - 12.92 mmol/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145196>	C143369	Grade 3 Chronic Kidney Disease, CTCAE|Grade 3 Chronic kidney disease	eGFR or CrCl 29-15 ml/min/1.73 m2			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145197>	C143199	Grade 3 Chylous Ascites, CTCAE|Grade 3 Chylous ascites|Grade 3 Chylous ascites	Severe symptoms; elective operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145198>	C143373	Grade 3 Colonic Fistula, CTCAE|Grade 3 Colonic fistula|Grade 3 Colonic fistula	Invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145199>	C143374	Grade 3 Colonic Hemorrhage, CTCAE|Grade 3 Colonic hemorrhage	Transfusion indicated; invasive intervention indicated; hospitalization			Finding	CTCAE Adverse Events Version 5.0 Terminology
C14519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14519>	C14421	C57L/J Mouse|C57L/J		C57L/J Mouse		Mammal	
C1451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1451>	C713	Oligonucleotide Primer|Primer	Short DNA oligonucleotide chains used to prime DNA (and in some cases RNA) synthesis.			Nucleic Acid, Nucleoside, or Nucleotide	
C145200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145200>	C143375	Grade 3 Colonic Obstruction, CTCAE|Grade 3 Colonic obstruction|Grade 3 Colonic obstruction	Hospitalization indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145201>	C143376	Grade 3 Colonic Perforation, CTCAE|Grade 3 Colonic perforation|Grade 3 Colonic perforation	Invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145202>	C143377	Grade 3 Colonic Stenosis, CTCAE|Grade 3 Colonic stenosis|Grade 3 Colonic stenosis	Severely altered GI function; tube feeding or hospitalization indicated; elective operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145203>	C143378	Grade 3 Colonic Ulcer, CTCAE|Grade 3 Colonic ulcer|Grade 3 Colonic ulcer	Severely altered GI function; TPN indicated; elective invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145204>	C143379	Grade 3 Concentration Impairment, CTCAE|Grade 3 Concentration impairment|Grade 3 Concentration impairment	Severe impairment in attention or decreased level of concentration; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145205>	C143380	Grade 3 Conduction Disorder, CTCAE|Grade 3 Conduction disorder	Symptomatic, urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145206>	C143382	Grade 3 Congenital, Familial and Genetic Disorders - Other, Specify, CTCAE|Grade 3 Congenital, familial and genetic disorders - Other, specify|Grade 3 Congenital, familial and genetic disorders - Other, specify	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145207>	C143383	Grade 3 Conjunctivitis Infective, CTCAE|Grade 3 Conjunctivitis infective|Grade 3 Conjunctivitis infective	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145208>	C143384	Grade 3 Conjunctivitis, CTCAE|Grade 3 Conjunctivitis|Grade 3 Conjunctivitis	Symptomatic with marked decrease in visual acuity (best corrected visual acuity worse than 20/40 or more than 3 lines of decreased vision from known baseline, up to 20/200); limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145209>	C143386	Grade 3 Corneal Infection, CTCAE|Grade 3 Corneal infection|Grade 3 Corneal infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145210>	C143387	Grade 3 Corneal Ulcer, CTCAE|Grade 3 Corneal ulcer|Grade 3 Corneal ulcer	Corneal ulcer without perforation in the affected eye			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145211>	C143389	Grade 3 CPK Increased, CTCAE|Grade 3 CPK increased	>5 x ULN-10 x ULN			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145212>	C143390	Grade 3 Cranial Nerve Infection, CTCAE|Grade 3 Cranial nerve infection|Grade 3 Cranial nerve infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145213>	C143391	Grade 3 Creatinine Increased, CTCAE|Grade 3 Creatinine increased|Grade 3 Creatinine increased	>3.0 x baseline if baseline is below LLN; >3.0 - 6.0 x ULN			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145214>	C143392	Grade 3 Cushingoid, CTCAE|Grade 3 Cushingoid|Grade 3 Cushingoid	Severe symptoms, medical intervention or hospitalization indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145215>	C143393	Grade 3 Cystitis Noninfective, CTCAE|Grade 3 Cystitis noninfective|Grade 3 Cystitis noninfective	Gross hematuria; transfusion, IV medications, or hospitalization indicated; elective invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145216>	C143394	Grade 3 Cytokine Release Syndrome, CTCAE|Grade 3 Cytokine release syndrome|Grade 3 Cytokine release syndrome	Hypotension managed with one pressor; hypoxia requiring high-flow nasal cannula, facemask, nonrebreather mask, or Venturi mask			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145217>	C143207	Grade 3 Cytomegalovirus Infection Reactivation, CTCAE|Grade 3 Cytomegalovirus infection reactivation|Grade 3 Cytomegalovirus infection reactivation	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; IV intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145218>	C143400	Grade 3 Delirium, CTCAE|Grade 3 Delirium|Grade 3 Delirium	Severe and acute confusional state; hospitalization indicated; urgent intervention indicated; new onset; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145219>	C143401	Grade 3 Delusions, CTCAE|Grade 3 Delusions|Grade 3 Delusions	Severe delusional symptoms; outpatient management; new onset			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145220>	C143402	Grade 3 Dental Caries, CTCAE|Grade 3 Dental caries|Grade 3 Dental caries	Dental caries resulting in pulpitis or periapical abscess or resulting in tooth loss			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145221>	C143403	Grade 3 Depressed Level of Consciousness, CTCAE|Grade 3 Depressed level of consciousness|Grade 3 Depressed level of consciousness	Difficult to arouse			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145222>	C143405	Grade 3 Dermatitis Radiation, CTCAE|Grade 3 Dermatitis radiation|Grade 3 Dermatitis radiation	Moist desquamation in areas other than skin folds and creases; bleeding induced by minor trauma or abrasion			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145223>	C143406	Grade 3 Device Related Infection, CTCAE|Grade 3 Device related infection|Grade 3 Device related infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145224>	C143410	Grade 3 Dry Eye, CTCAE|Grade 3 Dry eye|Grade 3 Dry eye	Symptomatic with marked decrease in visual acuity (best corrected visual acuity worse than 20/40 or more than 3 lines of decreased vision from known baseline, up to 20/200); limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145225>	C143411	Grade 3 Dry Mouth, CTCAE|Grade 3 Dry mouth|Grade 3 Dry mouth	Inability to adequately aliment orally; tube feeding or TPN indicated; unstimulated saliva <0.1 ml/min			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145227>	C143414	Grade 3 Duodenal Hemorrhage, CTCAE|Grade 3 Duodenal hemorrhage|Grade 3 Duodenal hemorrhage	Hospitalization			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145228>	C143415	Grade 3 Duodenal Infection, CTCAE|Grade 3 Duodenal infection|Grade 3 Duodenal infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145229>	C143416	Grade 3 Duodenal Obstruction, CTCAE|Grade 3 Duodenal obstruction|Grade 3 Duodenal obstruction	Hospitalization indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145230>	C143417	Grade 3 Duodenal Perforation, CTCAE|Grade 3 Duodenal perforation|Grade 3 Duodenal perforation	Invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145231>	C143418	Grade 3 Duodenal Stenosis, CTCAE|Grade 3 Duodenal stenosis|Grade 3 Duodenal stenosis	Severely altered GI function; tube feeding or hospitalization indicated; elective operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145232>	C143419	Grade 3 Duodenal Ulcer, CTCAE|Grade 3 Duodenal ulcer|Grade 3 Duodenal ulcer	Severely altered GI function; TPN indicated; elective invasive intervention indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145233>	C143420	Grade 3 Dysarthria, CTCAE|Grade 3 Dysarthria|Grade 3 Dysarthria	Severe impairment of articulation or slurred speech			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145234>	C143421	Grade 3 Dysesthesia, CTCAE|Grade 3 Dysesthesia|Grade 3 Dysesthesia	Severe sensory alteration; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145235>	C143423	Grade 3 Dysmenorrhea, CTCAE|Grade 3 Dysmenorrhea|Grade 3 Dysmenorrhea	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145236>	C143424	Grade 3 Dyspareunia, CTCAE|Grade 3 Dyspareunia|Grade 3 Dyspareunia	Severe discomfort or pain associated with vaginal penetration; discomfort or pain unrelieved by vaginal lubricants or estrogen			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145237>	C143425	Grade 3 Dyspepsia, CTCAE|Grade 3 Dyspepsia|Grade 3 Dyspepsia	Severe symptoms; operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145238>	C143427	Grade 3 Dysphasia, CTCAE|Grade 3 Dysphasia	Severe receptive or expressive characteristics; impairing ability to read, write or communicate intelligibly			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145239>	C143429	Grade 3 Ear and Labyrinth Disorders - Other, Specify, CTCAE|Grade 3 Ear and labyrinth disorders - Other, specify|Grade 3 Ear and labyrinth disorders - Other, specify	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145240>	C143430	Grade 3 Ear Pain, CTCAE|Grade 3 Ear pain|Grade 3 Ear pain	Severe pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145241>	C143243	Grade 3 Eczema, CTCAE|Grade 3 Eczema	Severe or medically significant but not immediately life-threatening; IV intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145242>	C143431	Grade 3 Edema Cerebral, CTCAE|Grade 3 Edema cerebral	New onset; worsening from baseline			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145243>	C143432	Grade 3 Edema Face, CTCAE|Grade 3 Edema face|Grade 3 Edema face	Severe swelling; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145244>	C143433	Grade 3 Edema Limbs, CTCAE|Grade 3 Edema limbs	>30% inter-limb discrepancy in volume; gross deviation from normal anatomic contour; limiting self care ADL			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145245>	C143434	Grade 3 Edema Trunk, CTCAE|Grade 3 Edema trunk	Gross deviation from normal anatomic contour; limiting self care ADL			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145246>	C143436	Grade 3 Ejection Fraction Decreased, CTCAE|Grade 3 Ejection fraction decreased	Resting ejection fraction (EF) 39-20%; >=20% drop from baseline			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145247>	C143437	Grade 3 Electrocardiogram QT Corrected Interval Prolonged, CTCAE|Grade 3 Electrocardiogram QT corrected interval prolonged|Grade 3 Electrocardiogram QT corrected interval prolonged	Average QTc >500 ms; >60 ms change from baseline			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145248>	C143438	Grade 3 Encephalitis Infection, CTCAE|Grade 3 Encephalitis infection	IV antibiotic, antifungal, or antiviral intervention indicated; severe changes in mental status; self-limited seizure activity; focal neurologic abnormalities			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145249>	C143439	Grade 3 Encephalomyelitis Infection, CTCAE|Grade 3 Encephalomyelitis infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145250>	C143441	Grade 3 Endocarditis Infective, CTCAE|Grade 3 Endocarditis infective|Grade 3 Endocarditis infective	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145251>	C143442	Grade 3 Endocrine Disorders - Other, Specify, CTCAE|Grade 3 Endocrine disorders - Other, specify|Grade 3 Endocrine disorders - Other, specify	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145252>	C143443	Grade 3 Endophthalmitis, CTCAE|Grade 3 Endophthalmitis|Grade 3 Endophthalmitis	Systemic intervention; hospitalization indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145253>	C143444	Grade 3 Enterocolitis Infectious, CTCAE|Grade 3 Enterocolitis infectious|Grade 3 Enterocolitis infectious	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated; profuse watery diarrhea with signs of hypovolemia; bloody diarrhea; fever; severe abdominal pain; hospitalization indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145254>	C143445	Grade 3 Enterocolitis, CTCAE|Grade 3 Enterocolitis|Grade 3 Enterocolitis	Severe or persistent abdominal pain; fever; ileus; peritoneal signs			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145255>	C143446	Grade 3 Enterovesical Fistula, CTCAE|Grade 3 Enterovesical fistula|Grade 3 Enterovesical fistula	Invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145256>	C143190	Grade 3 Eosinophilia, CTCAE|Grade 3 Eosinophilia|Grade 3 Eosinophilia	Steroids initiated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145257>	C143447	Grade 3 Epistaxis, CTCAE|Grade 3 Epistaxis|Grade 3 Epistaxis	Transfusion; invasive intervention indicated (e.g., hemostasis of bleeding site)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145258>	C143208	Grade 3 Epstein-Barr Virus Infection Reactivation, CTCAE|Grade 3 Epstein-Barr virus infection reactivation|Grade 3 Epstein-Barr virus infection reactivation	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; IV intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145259>	C143449	Grade 3 Erythema Multiforme, CTCAE|Grade 3 Erythema multiforme|Grade 3 Erythema multiforme	Associated with oral or genital erosions			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145260>	C143450	Grade 3 Erythroderma, CTCAE|Grade 3 Erythroderma|Grade 3 Erythroderma	Erythema covering >90% BSA with associated symptoms (e.g., pruritus or tenderness); limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145261>	C143451	Grade 3 Esophageal Anastomotic Leak, CTCAE|Grade 3 Esophageal anastomotic leak|Grade 3 Esophageal anastomotic leak	Severe symptoms; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145263>	C143453	Grade 3 Esophageal Hemorrhage, CTCAE|Grade 3 Esophageal hemorrhage|Grade 3 Esophageal hemorrhage	Hospitalization			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145264>	C143454	Grade 3 Esophageal Infection, CTCAE|Grade 3 Esophageal infection|Grade 3 Esophageal infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145265>	C143455	Grade 3 Esophageal Necrosis, CTCAE|Grade 3 Esophageal necrosis|Grade 3 Esophageal necrosis	Inability to aliment adequately by GI tract; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145266>	C143456	Grade 3 Esophageal Obstruction, CTCAE|Grade 3 Esophageal obstruction|Grade 3 Esophageal obstruction	Hospitalization indicated; invasive intervention indicated; limiting self care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145267>	C143457	Grade 3 Esophageal Pain, CTCAE|Grade 3 Esophageal pain|Grade 3 Esophageal pain	Severe pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145268>	C143458	Grade 3 Esophageal Perforation, CTCAE|Grade 3 Esophageal perforation|Grade 3 Esophageal perforation	Invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145269>	C143459	Grade 3 Esophageal Stenosis, CTCAE|Grade 3 Esophageal stenosis|Grade 3 Esophageal stenosis	Severely altered GI function; tube feeding or hospitalization indicated; elective operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145270>	C143460	Grade 3 Esophageal Ulcer, CTCAE|Grade 3 Esophageal ulcer|Grade 3 Esophageal ulcer	Severely altered GI function; TPN indicated; elective invasive intervention indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145271>	C143466	Grade 3 Extraocular Muscle Paresis, CTCAE|Grade 3 Extraocular muscle paresis|Grade 3 Extraocular muscle paresis	Bilateral paresis or unilateral paresis causing double vision in peripheral gaze, but not in central gaze			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145272>	C143467	Grade 3 Extrapyramidal Disorder, CTCAE|Grade 3 Extrapyramidal disorder|Grade 3 Extrapyramidal disorder	Severe involuntary movements or torticollis; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145273>	C143468	Grade 3 Eye Disorders - Other, Specify, CTCAE|Grade 3 Eye disorders - Other, specify|Grade 3 Eye disorders - Other, specify	Severe or medically significant but not immediately sight-threatening; decrease in visual acuity (best corrected visual acuity worse than 20/40 or more than 3 lines of decreased vision from known baseline, up to 20/200); limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145274>	C143469	Grade 3 Eye Infection, CTCAE|Grade 3 Eye infection|Grade 3 Eye infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145275>	C143471	Grade 3 Eyelid Function Disorder, CTCAE|Grade 3 Eyelid function disorder|Grade 3 Eyelid function disorder	Operative intervention indicated requiring hospitalization; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145276>	C143472	Grade 3 Facial Muscle Weakness, CTCAE|Grade 3 Facial muscle weakness|Grade 3 Facial muscle weakness	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145277>	C143473	Grade 3 Facial Nerve Disorder, CTCAE|Grade 3 Facial nerve disorder|Grade 3 Facial nerve disorder	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145278>	C143474	Grade 3 Facial Pain, CTCAE|Grade 3 Facial pain|Grade 3 Facial pain	Severe pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145279>	C143475	Grade 3 Fall, CTCAE|Grade 3 Fall|Grade 3 Fall	Hospitalization indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145280>	C143476	Grade 3 Fallopian Tube Anastomotic Leak, CTCAE|Grade 3 Fallopian tube anastomotic leak|Grade 3 Fallopian tube anastomotic leak	Severe symptoms; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145281>	C143479	Grade 3 Fat Atrophy, CTCAE|Grade 3 Fat atrophy	Covering >30% BSA; associated with erythema or tenderness; limiting self-care ADL			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145283>	C143482	Grade 3 Fecal Incontinence, CTCAE|Grade 3 Fecal incontinence|Grade 3 Fecal incontinence	Severe symptoms; elective operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145284>	C143484	Grade 3 Fetal Growth Retardation, CTCAE|Grade 3 Fetal growth retardation|Grade 3 Fetal growth retardation	1 - <5% percentile of weight for gestational age			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145285>	C143485	Grade 3 Fever, CTCAE|Grade 3 Fever|Grade 3 Fever	>40.0 degrees C (>104.0 degrees F) for <=24 hrs			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145286>	C143486	Grade 3 Fibrinogen Decreased, CTCAE|Grade 3 Fibrinogen decreased|Grade 3 Fibrinogen decreased	<0.5 - 0.25 x LLN; if abnormal, 50 - <75% decrease from baseline			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145287>	C143487	Grade 3 Fibrosis Deep Connective Tissue, CTCAE|Grade 3 Fibrosis deep connective tissue|Grade 3 Fibrosis deep connective tissue	Severe induration; unable to slide or pinch skin; limiting joint or orifice movement (e.g., mouth, anus); limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145288>	C143488	Grade 3 Flank Pain, CTCAE|Grade 3 Flank pain|Grade 3 Flank pain	Severe pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145289>	C143489	Grade 3 Flashing Lights, CTCAE|Grade 3 Flashing lights|Grade 3 Flashing lights	Limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145290>	C143491	Grade 3 Floaters, CTCAE|Grade 3 Floaters|Grade 3 Floaters	Limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145291>	C143492	Grade 3 Flu Like Symptoms, CTCAE|Grade 3 Flu like symptoms|Grade 3 Flu like symptoms	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145292>	C146643	Grade 3 Flushing, CTCAE|Grade 3 Flushing	Symptomatic, associated with hypotension and/or tachycardia; limiting self care ADL			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145293>	C143209	Grade 3 Folliculitis, CTCAE|Grade 3 Folliculitis|Grade 3 Folliculitis	Systemic intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145294>	C143494	Grade 3 Forced Expiratory Volume Decreased, CTCAE|Grade 3 Forced expiratory volume decreased	50-59%			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145295>	C143210	Grade 3 Fungemia, CTCAE|Grade 3 Fungemia|Grade 3 Fungemia	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145296>	C143496	Grade 3 Gait Disturbance, CTCAE|Grade 3 Gait disturbance|Grade 3 Gait disturbance	Limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145297>	C143497	Grade 3 Gallbladder Infection, CTCAE|Grade 3 Gallbladder infection|Grade 3 Gallbladder infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145298>	C143498	Grade 3 Gastric Anastomotic Leak, CTCAE|Grade 3 Gastric anastomotic leak|Grade 3 Gastric anastomotic leak	Severe symptoms; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145299>	C143499	Grade 3 Gastric Fistula, CTCAE|Grade 3 Gastric fistula|Grade 3 Gastric fistula	Invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C1452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1452>	C2578	Enoxaparin|ENOXAPARIN|enoxaparin	A low molecular weight, synthetic heparin. As an anticoagulant/antithrombotic agent, enoxaprin's mechanism of action is similar to that of heparin, although it exhibits a higher ratio of anti-Factor Xa to anti-Factor IIa activity. This agent also has anti-inflammatory properties, inhibiting monocyte adhesion to tumor necrosis factor alpha- or lipopolysaccharide-activated endothelial cells.  Compared to unfractionated heparins, the use of enoxaparin is associated with lower incidences of osteoporosis and heparin-induced thrombocytopenia. (NCI04)	Enoxaparin		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C145300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145300>	C143500	Grade 3 Gastric Hemorrhage, CTCAE|Grade 3 Gastric hemorrhage|Grade 3 Gastric hemorrhage	Hospitalization			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145301>	C143501	Grade 3 Gastric Necrosis, CTCAE|Grade 3 Gastric necrosis|Grade 3 Gastric necrosis	Inability to aliment adequately by GI tract; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145302>	C143502	Grade 3 Gastric Perforation, CTCAE|Grade 3 Gastric perforation|Grade 3 Gastric perforation	Invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145303>	C143503	Grade 3 Gastric Stenosis, CTCAE|Grade 3 Gastric stenosis|Grade 3 Gastric stenosis	Severely altered GI function; tube feeding or hospitalization indicated; elective operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145304>	C143504	Grade 3 Gastric Ulcer, CTCAE|Grade 3 Gastric ulcer|Grade 3 Gastric ulcer	Severely altered GI function; TPN indicated; elective invasive intervention indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145305>	C143506	Grade 3 Gastroesophageal Reflux Disease, CTCAE|Grade 3 Gastroesophageal reflux disease|Grade 3 Gastroesophageal reflux disease	Severe symptoms; operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145306>	C143507	Grade 3 Gastrointestinal Anastomotic Leak, CTCAE|Grade 3 Gastrointestinal anastomotic leak|Grade 3 Gastrointestinal anastomotic leak	Severe symptoms; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145307>	C143508	Grade 3 Gastrointestinal Disorders - Other, Specify, CTCAE|Grade 3 Gastrointestinal disorders - Other, specify|Grade 3 Gastrointestinal disorders - Other, specify	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145308>	C146637	Grade 3 Gastrointestinal Fistula, CTCAE|Grade 3 Gastrointestinal fistula|Grade 3 Gastrointestinal fistula	Invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145309>	C143510	Grade 3 Gastrointestinal Pain, CTCAE|Grade 3 Gastrointestinal pain|Grade 3 Gastrointestinal pain	Severe pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145310>	C143511	Grade 3 Gastrointestinal Stoma Necrosis, CTCAE|Grade 3 Gastrointestinal stoma necrosis|Grade 3 Gastrointestinal stoma necrosis	Severe symptoms; hospitalization indicated; elective operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145311>	C143512	Grade 3 Gastroparesis, CTCAE|Grade 3 Gastroparesis|Grade 3 Gastroparesis	Weight loss >=20% from baseline; tube feeding or TPN indicated; elective operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145312>	C143513	Grade 3 General Disorders and Administration Site Conditions - Other, Specify, CTCAE|Grade 3 General disorders and administration site conditions - Other, specify|Grade 3 General disorders and administration site conditions - Other, specify	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145313>	C143202	Grade 3 Generalized Edema, CTCAE|Grade 3 Generalized edema|Grade 3 Generalized edema	Interferes with self-care ADL or severe impact on age-appropriate normal daily activity (pediatric); intravenous IV therapy indicated; skin breakdown			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145314>	C143514	Grade 3 Generalized Muscle Weakness, CTCAE|Grade 3 Generalized muscle weakness|Grade 3 Generalized muscle weakness	Limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145315>	C143515	Grade 3 Genital Edema, CTCAE|Grade 3 Genital edema	Lymphorrhea; gross deviation from normal anatomic contour; limiting self care ADL			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145316>	C143516	Grade 3 GGT Increased, CTCAE|Grade 3 GGT increased|Grade 3 GGT increased	>5.0 - 20.0 x ULN if baseline was normal or less than normal; >3.0 - 10.0 x baseline if baseline was >ULN			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145317>	C146626	Grade 3 Gingival Pain, CTCAE|Grade 3 Gingival pain|Grade 3 Gingival pain	Severe pain; inability to aliment orally			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145318>	C143518	Grade 3 Glossopharyngeal Nerve Disorder, CTCAE|Grade 3 Glossopharyngeal nerve disorder|Grade 3 Glossopharyngeal nerve disorder	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145319>	C143519	Grade 3 Glucose Intolerance, CTCAE|Grade 3 Glucose intolerance	Severe symptoms; insulin indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145320>	C143522	Grade 3 Growth Suppression, CTCAE|Grade 3 Growth suppression|Grade 3 Growth suppression	Reduction in growth velocity of >=50% ideally measured over the period of a year			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145321>	C143231	Grade 3 Guillain-Barre Syndrome, CTCAE|Grade 3 Guillain-Barre syndrome|Grade 3 Guillain-Barre syndrome	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145322>	C143523	Grade 3 Gum Infection, CTCAE|Grade 3 Gum infection|Grade 3 Gum infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145323>	C143525	Grade 3 Hallucinations, CTCAE|Grade 3 Hallucinations|Grade 3 Hallucinations	Severe hallucinations; hospitalization not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145324>	C143527	Grade 3 Headache, CTCAE|Grade 3 Headache|Grade 3 Headache	Severe pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145325>	C143528	Grade 3 Hearing Impaired, CTCAE|Grade 3 Hearing impaired|Grade 3 Hearing impaired	Adult: Hearing loss requiring hearing aid; intervention indicated; limiting self-care ADL; threshold shift of >25 dB averaged at 3 contiguous test frequencies in at least one ear(on a 1, 2, 3, 4, 6, and 8 kHz audiogram); Pediatric (on a 1, 2, 3, 4, 6, and 8 kHz audiogram): Hearing loss sufficient to indicate therapeutic intervention, including hearing aids; threshold shift >20 dB at 2 to <4 kHz in at least one ear; severe impact on age-appropriate normal daily activity			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145326>	C143529	Grade 3 Heart Failure, CTCAE|Grade 3 Heart failure|Grade 3 Heart failure	Hospitalization indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145327>	C143531	Grade 3 Hematosalpinx, CTCAE|Grade 3 Hematosalpinx|Grade 3 Hematosalpinx	Invasive intervention indicated; hospitalization			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145328>	C143532	Grade 3 Hematuria, CTCAE|Grade 3 Hematuria|Grade 3 Hematuria	Gross hematuria; transfusion, IV medications, or hospitalization indicated; elective invasive intervention indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145329>	C143533	Grade 3 Hemoglobin Increased, CTCAE|Grade 3 Hemoglobin increased|Grade 3 Hemoglobin increased	Increase in >4 g/dL above ULN			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145330>	C143536	Grade 3 Hemolytic Uremic Syndrome, CTCAE|Grade 3 Hemolytic uremic syndrome|Grade 3 Hemolytic uremic syndrome	Laboratory findings with clinical consequences (e.g., renal insufficiency, petechiae)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145331>	C143537	Grade 3 Hemorrhoidal Hemorrhage, CTCAE|Grade 3 Hemorrhoidal hemorrhage|Grade 3 Hemorrhoidal hemorrhage	Hospitalization			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145332>	C143539	Grade 3 Hepatic Failure, CTCAE|Grade 3 Hepatic failure|Grade 3 Hepatic failure	Asterixis; mild encephalopathy; drug-induced liver injury (DILI); limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145333>	C143540	Grade 3 Hepatic Hemorrhage, CTCAE|Grade 3 Hepatic hemorrhage|Grade 3 Hepatic hemorrhage	Hospitalization			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145334>	C143541	Grade 3 Hepatic Infection, CTCAE|Grade 3 Hepatic infection|Grade 3 Hepatic infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145335>	C143542	Grade 3 Hepatic Pain, CTCAE|Grade 3 Hepatic pain|Grade 3 Hepatic pain	Severe pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145336>	C143211	Grade 3 Hepatitis B Reactivation, CTCAE|Grade 3 Hepatitis B reactivation|Grade 3 Hepatitis B reactivation	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; IV intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145337>	C143543	Grade 3 Hepatitis Viral, CTCAE|Grade 3 Hepatitis viral|Grade 3 Hepatitis viral	Symptomatic liver dysfunction; fibrosis by biopsy; compensated cirrhosis; hospitalization or prolongation of existing hospitalization indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145338>	C143544	Grade 3 Hepatobiliary Disorders - Other, Specify, CTCAE|Grade 3 Hepatobiliary disorders - Other, specify|Grade 3 Hepatobiliary disorders - Other, specify	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145339>	C143212	Grade 3 Herpes Simplex Reactivation, CTCAE|Grade 3 Herpes simplex reactivation|Grade 3 Herpes simplex reactivation	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; IV intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145340>	C143545	Grade 3 Hiccups, CTCAE|Grade 3 Hiccups|Grade 3 Hiccups	Severe symptoms; interfering with sleep; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145341>	C143546	Grade 3 Hip Fracture, CTCAE|Grade 3 Hip fracture	Severe pain; hospitalization or intervention indicated for pain control (e.g., traction); operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145342>	C143548	Grade 3 Hoarseness, CTCAE|Grade 3 Hoarseness|Grade 3 Hoarseness	Severe voice changes including predominantly whispered speech			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145343>	C143549	Grade 3 Hot Flashes, CTCAE|Grade 3 Hot flashes|Grade 3 Hot flashes	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145344>	C143551	Grade 3 Hypercalcemia, CTCAE|Grade 3 Hypercalcemia|Grade 3 Hypercalcemia	Corrected serum calcium of >12.5 - 13.5 mg/dL; >3.1 - 3.4 mmol/L; Ionized calcium >1.6 - 1.8 mmol/L; hospitalization indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145345>	C143552	Grade 3 Hyperglycemia, CTCAE|Grade 3 Hyperglycemia	Insulin therapy initiated; hospitalization indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145346>	C143553	Grade 3 Hyperhidrosis, CTCAE|Grade 3 Hyperhidrosis|Grade 3 Hyperhidrosis	Associated with electrolyte/hemodynamic imbalance			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145347>	C143554	Grade 3 Hyperkalemia, CTCAE|Grade 3 Hyperkalemia|Grade 3 Hyperkalemia	>6.0 - 7.0 mmol/L; hospitalization indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145348>	C143246	Grade 3 Hyperkeratosis, CTCAE|Grade 3 Hyperkeratosis|Grade 3 Hyperkeratosis	Limiting self-care ADLs or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145349>	C143221	Grade 3 Hyperlipidemia, CTCAE|Grade 3 Hyperlipidemia|Grade 3 Hyperlipidemia	Hospitalization			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145350>	C143555	Grade 3 Hypermagnesemia, CTCAE|Grade 3 Hypermagnesemia|Grade 3 Hypermagnesemia	>3.0 - 8.0 mg/dL; >1.23 - 3.30 mmol/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145351>	C143556	Grade 3 Hypernatremia, CTCAE|Grade 3 Hypernatremia|Grade 3 Hypernatremia	>155 - 160 mmol/L; hospitalization indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145352>	C143222	Grade 3 Hyperphosphatemia, CTCAE|Grade 3 Hyperphosphatemia|Grade 3 Hyperphosphatemia	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145353>	C143558	Grade 3 Hypersomnia, CTCAE|Grade 3 Hypersomnia|Grade 3 Hypersomnia	Severe increased need for sleep			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145354>	C143560	Grade 3 Hyperthyroidism, CTCAE|Grade 3 Hyperthyroidism|Grade 3 Hyperthyroidism	Severe symptoms; hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145355>	C143562	Grade 3 Hypertriglyceridemia, CTCAE|Grade 3 Hypertriglyceridemia|Grade 3 Hypertriglyceridemia	>500 mg/dL - 1000 mg/dL; >5.7 mmol/L - 11.4 mmol/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145356>	C143563	Grade 3 Hyperuricemia, CTCAE|Grade 3 Hyperuricemia|Grade 3 Hyperuricemia	>ULN with physiologic consequences			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145357>	C143564	Grade 3 Hypoalbuminemia, CTCAE|Grade 3 Hypoalbuminemia|Grade 3 Hypoalbuminemia	<2 g/dL; <20 g/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145358>	C143565	Grade 3 Hypocalcemia, CTCAE|Grade 3 Hypocalcemia|Grade 3 Hypocalcemia	Corrected serum calcium of <7.0 - 6.0 mg/dL; <1.75 - 1.5 mmol/L; Ionized calcium <0.9 - 0.8 mmol/L; hospitalization indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145359>	C143566	Grade 3 Hypoglossal Nerve Disorder, CTCAE|Grade 3 Hypoglossal nerve disorder|Grade 3 Hypoglossal nerve disorder	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145360>	C143567	Grade 3 Hypoglycemia, CTCAE|Grade 3 Hypoglycemia|Grade 3 Hypoglycemia	<40 - 30 mg/dL; <2.2 - 1.7 mmol/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145361>	C143568	Grade 3 Hypohidrosis, CTCAE|Grade 3 Hypohidrosis|Grade 3 Hypohidrosis	Increase in body temperature; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145362>	C143569	Grade 3 Hypokalemia, CTCAE|Grade 3 Hypokalemia|Grade 3 Hypokalemia	<3.0 - 2.5 mmol/L; hospitalization indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145363>	C143570	Grade 3 Hypomagnesemia, CTCAE|Grade 3 Hypomagnesemia|Grade 3 Hypomagnesemia	<0.9 - 0.7 mg/dL; <0.4 - 0.3 mmol/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145364>	C143571	Grade 3 Hyponatremia, CTCAE|Grade 3 Hyponatremia|Grade 3 Hyponatremia	125 - <130 mmol/L symptomatic; 120 - <125 mmol/L regardless of symptoms			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145365>	C143572	Grade 3 Hypoparathyroidism, CTCAE|Grade 3 Hypoparathyroidism|Grade 3 Hypoparathyroidism	Severe symptoms; medical intervention or hospitalization indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145366>	C143573	Grade 3 Hypophosphatemia, CTCAE|Grade 3 Hypophosphatemia|Grade 3 Hypophosphatemia	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145367>	C143193	Grade 3 Hypophysitis, CTCAE|Grade 3 Hypophysitis|Grade 3 Hypophysitis	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145368>	C143194	Grade 3 Hypopituitarism, CTCAE|Grade 3 Hypopituitarism|Grade 3 Hypopituitarism	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145369>	C143576	Grade 3 Hypothyroidism, CTCAE|Grade 3 Hypothyroidism|Grade 3 Hypothyroidism	Severe symptoms; hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145373>	C146633	Grade 3 Ileal Perforation, CTCAE|Grade 3 Ileal perforation|Grade 3 Ileal perforation	Invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145374>	C143578	Grade 3 Ileal Stenosis, CTCAE|Grade 3 Ileal stenosis|Grade 3 Ileal stenosis	Severely altered GI function; tube feeding or hospitalization indicated; elective operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145377>	C143580	Grade 3 Immune System Disorders - Other, Specify, CTCAE|Grade 3 Immune system disorders - Other, specify|Grade 3 Immune system disorders - Other, specify	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145378>	C143581	Grade 3 Infections and Infestations - Other, Specify, CTCAE|Grade 3 Infections and infestations - Other, specify|Grade 3 Infections and infestations - Other, specify	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145379>	C143582	Grade 3 Infective Myositis, CTCAE|Grade 3 Infective myositis|Grade 3 Infective myositis	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145380>	C143583	Grade 3 Infusion Related Reaction, CTCAE|Grade 3 Infusion related reaction|Grade 3 Infusion related reaction	Prolonged (e.g., not rapidly responsive to symptomatic medication and/or brief interruption of infusion); recurrence of symptoms following initial improvement; hospitalization indicated for clinical sequelae			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145381>	C143584	Grade 3 Infusion Site Extravasation, CTCAE|Grade 3 Infusion site extravasation|Grade 3 Infusion site extravasation	Ulceration or necrosis; severe tissue damage; operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145382>	C143585	Grade 3 Injection Site Reaction, CTCAE|Grade 3 Injection site reaction|Grade 3 Injection site reaction	Ulceration or necrosis; severe tissue damage; operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145383>	C143586	Grade 3 Injury To Carotid Artery, CTCAE|Grade 3 Injury to carotid artery|Grade 3 Injury to carotid artery	Severe symptoms (e.g., transient cerebral ischemia); repair or revision indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145385>	C143587	Grade 3 Injury To Jugular Vein, CTCAE|Grade 3 Injury to jugular vein|Grade 3 Injury to jugular vein	Symptomatic; repair or revision indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145386>	C143588	Grade 3 Injury To Superior Vena Cava, CTCAE|Grade 3 Injury to superior vena cava|Grade 3 Injury to superior vena cava	Severe symptoms; repair or revision indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145387>	C143589	Grade 3 Injury, Poisoning and Procedural Complications - Other, Specify, CTCAE|Grade 3 Injury, poisoning and procedural complications - Other, specify|Grade 3 Injury, poisoning and procedural complications - Other, specify	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145388>	C143590	Grade 3 INR Increased, CTCAE|Grade 3 INR increased|Grade 3 INR increased	>2.5; >2.5 x baseline if on anticoagulation; bleeding			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145389>	C143592	Grade 3 Intestinal Stoma Leak, CTCAE|Grade 3 Intestinal stoma leak|Grade 3 Intestinal stoma leak	Severe symptoms; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145390>	C143593	Grade 3 Intestinal Stoma Obstruction, CTCAE|Grade 3 Intestinal stoma obstruction|Grade 3 Intestinal stoma obstruction	Severe symptoms; IV fluids, tube feeding, or TPN indicated >=24 hrs; elective operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145391>	C143594	Grade 3 Intestinal Stoma Site Bleeding, CTCAE|Grade 3 Intestinal stoma site bleeding|Grade 3 Intestinal stoma site bleeding	Invasive intervention indicated; hospitalization			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145392>	C143595	Grade 3 Intra-Abdominal Hemorrhage, CTCAE|Grade 3 Intra-abdominal hemorrhage|Grade 3 Intra-abdominal hemorrhage	Hospitalization			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145393>	C143596	Grade 3 Intracranial Hemorrhage, CTCAE|Grade 3 Intracranial hemorrhage	Ventriculostomy, ICP monitoring, intraventricular thrombolysis, or invasive intervention indicated; hospitalization			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145394>	C143597	Grade 3 Intraoperative Arterial Injury, CTCAE|Grade 3 Intraoperative arterial injury|Grade 3 Intraoperative arterial injury	Complete resection or reconstruction of injured organ/structure indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145395>	C143598	Grade 3 Intraoperative Breast Injury, CTCAE|Grade 3 Intraoperative breast injury|Grade 3 Intraoperative breast injury	Complete resection or reconstruction of injured organ/structure indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145396>	C143599	Grade 3 Intraoperative Cardiac Injury, CTCAE|Grade 3 Intraoperative cardiac injury|Grade 3 Intraoperative cardiac injury	Primary repair of injured organ/structure indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145397>	C143600	Grade 3 Intraoperative Ear Injury, CTCAE|Grade 3 Intraoperative ear injury|Grade 3 Intraoperative ear injury	Complete resection or reconstruction of injured organ/structure indicated; limiting self-care ADL (e.g., impaired hearing; impaired balance) or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145398>	C143601	Grade 3 Intraoperative Endocrine Injury, CTCAE|Grade 3 Intraoperative endocrine injury|Grade 3 Intraoperative endocrine injury	Complete resection or reconstruction of injured organ/structure indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145399>	C143602	Grade 3 Intraoperative Gastrointestinal Injury, CTCAE|Grade 3 Intraoperative gastrointestinal injury|Grade 3 Intraoperative gastrointestinal injury	Complete resection or reconstruction of injured organ/structure indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C1453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1453>	C2578	Dalteparin|DALTEPARIN|dalteparin	A low molecular weight, synthetic heparin. As an anticoagulant/antithrombotic agent, dalteparin binds to antithrombin and enhances the inhibition of Factor Xa. Compared to unfractionated heparins, the use of dalteparin is associated with lower incidences of osteoporosis and heparin-induced thrombocytopenia. (NCI04)	Dalteparin		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C145400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145400>	C143603	Grade 3 Intraoperative Head and Neck Injury, CTCAE|Grade 3 Intraoperative head and neck injury|Grade 3 Intraoperative head and neck injury	Complete resection or reconstruction of injured organ/structure indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145401>	C143604	Grade 3 Intraoperative Hemorrhage, CTCAE|Grade 3 Intraoperative hemorrhage|Grade 3 Intraoperative hemorrhage	Postoperative invasive intervention indicated; hospitalization			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145402>	C143605	Grade 3 Intraoperative Hepatobiliary Injury, CTCAE|Grade 3 Intraoperative hepatobiliary injury|Grade 3 Intraoperative hepatobiliary injury	Complete resection or reconstruction of injured organ/structure indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145403>	C143606	Grade 3 Intraoperative Musculoskeletal Injury, CTCAE|Grade 3 Intraoperative musculoskeletal injury|Grade 3 Intraoperative musculoskeletal injury	Complete resection or reconstruction of injured organ/structure indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145404>	C143607	Grade 3 Intraoperative Neurological Injury, CTCAE|Grade 3 Intraoperative neurological injury|Grade 3 Intraoperative neurological injury	Complete resection or reconstruction of injured organ/structure indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145405>	C143608	Grade 3 Intraoperative Ocular Injury, CTCAE|Grade 3 Intraoperative ocular injury|Grade 3 Intraoperative ocular injury	Complete resection or reconstruction of injured organ/structure indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145406>	C143609	Grade 3 Intraoperative Renal Injury, CTCAE|Grade 3 Intraoperative renal injury|Grade 3 Intraoperative renal injury	Complete resection or reconstruction of injured organ/structure indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145407>	C143610	Grade 3 Intraoperative Reproductive Tract Injury, CTCAE|Grade 3 Intraoperative reproductive tract injury|Grade 3 Intraoperative reproductive tract injury	Complete resection or reconstruction of injured organ/structure indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145408>	C143611	Grade 3 Intraoperative Respiratory Injury, CTCAE|Grade 3 Intraoperative respiratory injury|Grade 3 Intraoperative respiratory injury	Complete resection or reconstruction of injured organ/structure indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145409>	C143612	Grade 3 Intraoperative Splenic Injury, CTCAE|Grade 3 Intraoperative splenic injury|Grade 3 Intraoperative splenic injury	Resection or reconstruction of injured organ/structure indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145410>	C143613	Grade 3 Intraoperative Urinary Injury, CTCAE|Grade 3 Intraoperative urinary injury|Grade 3 Intraoperative urinary injury	Complete resection or reconstruction of injured organ/structure indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145411>	C143614	Grade 3 Intraoperative Venous Injury, CTCAE|Grade 3 Intraoperative venous injury|Grade 3 Intraoperative venous injury	Complete resection or reconstruction of injured organ/structure indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145412>	C143615	Grade 3 Investigations - Other, Specify, CTCAE|Grade 3 Investigations - Other, specify|Grade 3 Investigations - Other, specify	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145413>	C143618	Grade 3 Irritability, CTCAE|Grade 3 Irritability|Grade 3 Irritability	Severe abnormal or excessive response; inconsolable; medical or psychiatric intervention indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145417>	C143622	Grade 3 Jejunal Perforation, CTCAE|Grade 3 Jejunal perforation|Grade 3 Jejunal perforation	Invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145418>	C143623	Grade 3 Jejunal Stenosis, CTCAE|Grade 3 Jejunal stenosis|Grade 3 Jejunal stenosis	Severely altered GI function; tube feeding or hospitalization indicated; elective operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145420>	C143626	Grade 3 Joint Infection, CTCAE|Grade 3 Joint infection|Grade 3 Joint infection	Arthroscopic intervention indicated (e.g., drainage) or arthrotomy (e.g., open surgical drainage)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145421>	C143627	Grade 3 Joint Range of Motion Decreased Cervical Spine, CTCAE|Grade 3 Joint range of motion decreased cervical spine|Grade 3 Joint range of motion decreased cervical spine	Ankylosed/fused over multiple segments with no C-spine rotation			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145422>	C143628	Grade 3 Joint Range of Motion Decreased Lumbar Spine, CTCAE|Grade 3 Joint range of motion decreased lumbar spine|Grade 3 Joint range of motion decreased lumbar spine	<50% lumbar spine flexion; associated with symptoms of ankylosis or fused over multiple segments with no L-spine flexion (e.g., unable to reach to floor to pick up a very light object)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145423>	C143629	Grade 3 Joint Range of Motion Decreased, CTCAE|Grade 3 Joint range of motion decreased|Grade 3 Joint range of motion decreased	>50% decrease in ROM; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145424>	C143631	Grade 3 Kidney Anastomotic Leak, CTCAE|Grade 3 Kidney anastomotic leak|Grade 3 Kidney anastomotic leak	Severe symptoms; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145425>	C143632	Grade 3 Kidney Infection, CTCAE|Grade 3 Kidney infection|Grade 3 Kidney infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145426>	C143633	Grade 3 Kyphosis, CTCAE|Grade 3 Kyphosis|Grade 3 Kyphosis	Severe accentuation; operative intervention indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145427>	C143635	Grade 3 Large Intestinal Anastomotic Leak, CTCAE|Grade 3 Large intestinal anastomotic leak|Grade 3 Large intestinal anastomotic leak	Severe symptoms; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145428>	C143636	Grade 3 Laryngeal Edema, CTCAE|Grade 3 Laryngeal edema|Grade 3 Laryngeal edema	Stridor; respiratory distress; hospitalization indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145431>	C143637	Grade 3 Laryngeal Inflammation, CTCAE|Grade 3 Laryngeal inflammation|Grade 3 Laryngeal inflammation	Severe throat pain; endoscopic intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145432>	C143638	Grade 3 Laryngeal Mucositis, CTCAE|Grade 3 Laryngeal mucositis|Grade 3 Laryngeal mucositis	Severe pain; severely altered eating/swallowing; medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145433>	C143639	Grade 3 Laryngeal Obstruction, CTCAE|Grade 3 Laryngeal obstruction|Grade 3 Laryngeal obstruction	Stridor; endoscopic intervention indicated (e.g., stent, laser); limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145434>	C143640	Grade 3 Laryngeal Stenosis, CTCAE|Grade 3 Laryngeal stenosis|Grade 3 Laryngeal stenosis	Stridor; endoscopic intervention indicated (e.g., stent, laser); limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145435>	C143641	Grade 3 Laryngitis, CTCAE|Grade 3 Laryngitis|Grade 3 Laryngitis	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145436>	C143642	Grade 3 Laryngopharyngeal Dysesthesia, CTCAE|Grade 3 Laryngopharyngeal dysesthesia|Grade 3 Laryngopharyngeal dysesthesia	Severe symptoms; dyspnea and swallowing difficulty; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145437>	C143643	Grade 3 Laryngospasm, CTCAE|Grade 3 Laryngospasm|Grade 3 Laryngospasm	Recurrent episodes; noninvasive intervention indicated (e.g., breathing technique, pressure point massage)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145438>	C143647	Grade 3 Leukocytosis, CTCAE|Grade 3 Leukocytosis|Grade 3 Leukocytosis	>100,000/mm3			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145439>	C143648	Grade 3 Leukoencephalopathy, CTCAE|Grade 3 Leukoencephalopathy|Grade 3 Leukoencephalopathy	Severe symptoms; extensive T2/FLAIR hyperintensities, involving periventricular white matter involving 2/3 or more of susceptible areas of cerebrum +/- moderate to severe increase in SAS and/or moderate to severe ventriculomegaly			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145440>	C143651	Grade 3 Lip Infection, CTCAE|Grade 3 Lip infection|Grade 3 Lip infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145441>	C143652	Grade 3 Lipase Increased, CTCAE|Grade 3 Lipase increased|Grade 3 Lipase increased	>3.0 - 5.0 x ULN with signs or symptoms; >5.0 x ULN and asymptomatic			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145442>	C143653	Grade 3 Lipohypertrophy, CTCAE|Grade 3 Lipohypertrophy	Covering >30% BSA and associated tenderness and narcotics or NSAIDs indicated; lipohypertrophy; limiting self care ADL			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145443>	C143654	Grade 3 Localized Edema, CTCAE|Grade 3 Localized edema|Grade 3 Localized edema	Severe localized edema and intervention indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145444>	C143655	Grade 3 Lordosis, CTCAE|Grade 3 Lordosis|Grade 3 Lordosis	Severe accentuation; operative intervention indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145445>	C143656	Grade 3 Lower Gastrointestinal Hemorrhage, CTCAE|Grade 3 Lower gastrointestinal hemorrhage	Transfusion indicated; invasive intervention indicated; hospitalization			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145446>	C143657	Grade 3 Lung Infection, CTCAE|Grade 3 Lung infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145447>	C143658	Grade 3 Lymph Gland Infection, CTCAE|Grade 3 Lymph gland infection|Grade 3 Lymph gland infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145448>	C143659	Grade 3 Lymph Leakage, CTCAE|Grade 3 Lymph leakage|Grade 3 Lymph leakage	Severe symptoms; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145449>	C143660	Grade 3 Lymphedema, CTCAE|Grade 3 Lymphedema|Grade 3 Lymphedema	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145450>	C143662	Grade 3 Lymphocyte Count Decreased, CTCAE|Grade 3 Lymphocyte count decreased	<500-200/mm3; <0.5-0.2 x 10e9/L			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145451>	C143663	Grade 3 Lymphocyte Count Increased, CTCAE|Grade 3 Lymphocyte count increased|Grade 3 Lymphocyte count increased	>20,000/mm3			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145452>	C143665	Grade 3 Malaise, CTCAE|Grade 3 Malaise|Grade 3 Malaise	Uneasiness or lack of well being limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145453>	C143666	Grade 3 Mania, CTCAE|Grade 3 Mania|Grade 3 Mania	Severe manic symptoms (e.g., hypomania; major sexual or financial indiscretions); hospitalization not indicated; new onset			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145455>	C143667	Grade 3 Mediastinal Infection, CTCAE|Grade 3 Mediastinal infection|Grade 3 Mediastinal infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145456>	C143669	Grade 3 Meningismus, CTCAE|Grade 3 Meningismus|Grade 3 Meningismus	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145457>	C143670	Grade 3 Meningitis, CTCAE|Grade 3 Meningitis|Grade 3 Meningitis	IV antibiotic, antifungal, or antiviral intervention indicated; steroid therapy indicated; severe changes in mental status; self-limited seizure activity; neurologic abnormalities			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145458>	C143671	Grade 3 Menorrhagia, CTCAE|Grade 3 Menorrhagia|Grade 3 Menorrhagia	Hospitalization; operative intervention indicated (e.g., hysterectomy)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145459>	C143672	Grade 3 Metabolism and Nutrition Disorders - Other, Specify, CTCAE|Grade 3 Metabolism and nutrition disorders - Other, specify|Grade 3 Metabolism and nutrition disorders - Other, specify	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14545>	C14421	C57BLKS Mouse|C57BLKS		C57BLKS Mouse		Mammal	
C145460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145460>	C143191	Grade 3 Methemoglobinemia, CTCAE|Grade 3 Methemoglobinemia|Grade 3 Methemoglobinemia	Requiring urgent intervention			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145461>	C143673	Grade 3 Middle Ear Inflammation, CTCAE|Grade 3 Middle ear inflammation|Grade 3 Middle ear inflammation	Mastoiditis; necrosis of canal soft tissue or bone			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145462>	C143674	Grade 3 Mitral Valve Disease, CTCAE|Grade 3 Mitral valve disease|Grade 3 Mitral valve disease	Symptomatic; severe regurgitation or stenosis by imaging; symptoms controlled with medical intervention			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145465>	C143677	Grade 3 Movements Involuntary, CTCAE|Grade 3 Movements involuntary|Grade 3 Movements involuntary	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145466>	C143678	Grade 3 Mucosal Infection, CTCAE|Grade 3 Mucosal infection|Grade 3 Mucosal infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145467>	C143679	Grade 3 Mucositis Oral, CTCAE|Grade 3 Mucositis oral|Grade 3 Mucositis oral	Severe pain; interfering with oral intake			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145468>	C143680	Grade 3 Multi-Organ Failure, CTCAE|Grade 3 Multi-organ failure|Grade 3 Multi-organ failure	Shock with azotemia and acid-base disturbances; significant coagulation abnormalities			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145469>	C143224	Grade 3 Muscle Cramp, CTCAE|Grade 3 Muscle cramp|Grade 3 Muscle cramp	Severe pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145470>	C143681	Grade 3 Muscle Weakness Left-Sided, CTCAE|Grade 3 Muscle weakness left-sided	Limiting self care ADL			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145471>	C143682	Grade 3 Muscle Weakness Lower Limb, CTCAE|Grade 3 Muscle weakness lower limb|Grade 3 Muscle weakness lower limb	Limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145472>	C143683	Grade 3 Muscle Weakness Right-Sided, CTCAE|Grade 3 Muscle weakness right-sided	Limiting self care ADL			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145473>	C143684	Grade 3 Muscle Weakness Trunk, CTCAE|Grade 3 Muscle weakness trunk|Grade 3 Muscle weakness trunk	Limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145474>	C143685	Grade 3 Muscle Weakness Upper Limb, CTCAE|Grade 3 Muscle weakness upper limb|Grade 3 Muscle weakness upper limb	Limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145475>	C143686	Grade 3 Musculoskeletal and Connective Tissue Disorder - Other, Specify, CTCAE|Grade 3 Musculoskeletal and connective tissue disorder - Other, specify|Grade 3 Musculoskeletal and connective tissue disorder - Other, specify	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145476>	C143687	Grade 3 Musculoskeletal Deformity, CTCAE|Grade 3 Musculoskeletal deformity|Grade 3 Musculoskeletal deformity	Significant deformity, hypoplasia, or asymmetry, unable to be remediated by prosthesis or covered by clothing; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145477>	C143688	Grade 3 Myalgia, CTCAE|Grade 3 Myalgia|Grade 3 Myalgia	Severe pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145478>	C143232	Grade 3 Myasthenia Gravis, CTCAE|Grade 3 Myasthenia gravis|Grade 3 Myasthenia gravis	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145479>	C143691	Grade 3 Myocardial Infarction, CTCAE|Grade 3 Myocardial infarction	Severe symptoms; cardiac enzymes abnormal; hemodynamically stable; ECG changes consistent with infarction			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145480>	C143695	Grade 3 Nail Infection, CTCAE|Grade 3 Nail infection|Grade 3 Nail infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145481>	C143698	Grade 3 Nasal Congestion, CTCAE|Grade 3 Nasal congestion|Grade 3 Nasal congestion	Associated with bloody nasal discharge or epistaxis			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145482>	C143700	Grade 3 Neck Edema, CTCAE|Grade 3 Neck edema	Generalized neck edema (e.g., difficulty in turning neck); limiting self care ADL			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145483>	C143701	Grade 3 Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other, Specify, CTCAE|Grade 3 Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify|Grade 3 Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145484>	C143239	Grade 3 Nephrotic Syndrome, CTCAE|Grade 3 Nephrotic syndrome|Grade 3 Nephrotic syndrome	IV therapy indicated; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145485>	C143702	Grade 3 Nervous System Disorders - Other, Specify, CTCAE|Grade 3 Nervous system disorders - Other, specify|Grade 3 Nervous system disorders - Other, specify	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145486>	C143703	Grade 3 Neuralgia, CTCAE|Grade 3 Neuralgia|Grade 3 Neuralgia	Severe pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145487>	C143704	Grade 3 Neutrophil Count Decreased, CTCAE|Grade 3 Neutrophil count decreased	<1000-500/mm3; <1.0-0.5 x 10e9/L			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145488>	C143705	Grade 3 Night Blindness, CTCAE|Grade 3 Night blindness	Symptomatic with marked decrease in visual acuity (best corrected visual acuity worse than 20/40 or more than 3 lines of decreased vision from known baseline, up to 20/200); limiting self care ADL			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145489>	C143707	Grade 3 Non-Cardiac Chest Pain, CTCAE|Grade 3 Non-cardiac chest pain|Grade 3 Non-cardiac chest pain	Severe pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145490>	C143710	Grade 3 Obstruction Gastric, CTCAE|Grade 3 Obstruction gastric|Grade 3 Obstruction gastric	Hospitalization indicated; invasive intervention indicated; limiting self care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145491>	C143711	Grade 3 Oculomotor Nerve Disorder, CTCAE|Grade 3 Oculomotor nerve disorder|Grade 3 Oculomotor nerve disorder	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145492>	C143712	Grade 3 Olfactory Nerve Disorder, CTCAE|Grade 3 Olfactory nerve disorder|Grade 3 Olfactory nerve disorder	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145493>	C143714	Grade 3 Optic Nerve Disorder, CTCAE|Grade 3 Optic nerve disorder|Grade 3 Optic nerve disorder	Marked decrease in visual acuity (best corrected visual acuity worse than 20/40 or more than 3 lines of decreased vision from known baseline, up to 20/200)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145494>	C143715	Grade 3 Oral Cavity Fistula, CTCAE|Grade 3 Oral cavity fistula|Grade 3 Oral cavity fistula	Invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145495>	C143716	Grade 3 Oral Dysesthesia, CTCAE|Grade 3 Oral dysesthesia|Grade 3 Oral dysesthesia	Disabling pain; tube feeding or TPN indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145498>	C143241	Grade 3 Oropharyngeal Pain, CTCAE|Grade 3 Oropharyngeal pain|Grade 3 Oropharyngeal pain	Severe pain; severely altered eating/swallowing; narcotics initiated; requires parenteral nutrition			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145499>	C143717	Grade 3 Osteonecrosis of Jaw, CTCAE|Grade 3 Osteonecrosis of jaw|Grade 3 Osteonecrosis of jaw	Severe symptoms; elective operative intervention indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C1454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1454>	C308|C307	Bispecific Antibody|Bispecific Antibodies|bispecific antibody|bsAb				Chemical Viewed Functionally	
C145500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145500>	C143225	Grade 3 Osteonecrosis, CTCAE|Grade 3 Osteonecrosis|Grade 3 Osteonecrosis	Severe symptoms; elective operative intervention indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145501>	C143719	Grade 3 Otitis Externa, CTCAE|Grade 3 Otitis externa|Grade 3 Otitis externa	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145502>	C143720	Grade 3 Otitis Media, CTCAE|Grade 3 Otitis media|Grade 3 Otitis media	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145504>	C143721	Grade 3 Ovarian Infection, CTCAE|Grade 3 Ovarian infection|Grade 3 Ovarian infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145505>	C143722	Grade 3 Ovarian Rupture, CTCAE|Grade 3 Ovarian rupture|Grade 3 Ovarian rupture	Transfusion; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145506>	C143723	Grade 3 Pain In Extremity, CTCAE|Grade 3 Pain in extremity|Grade 3 Pain in extremity	Severe pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145507>	C143724	Grade 3 Pain of Skin, CTCAE|Grade 3 Pain of skin|Grade 3 Pain of skin	Severe pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145508>	C143725	Grade 3 Pain, CTCAE|Grade 3 Pain|Grade 3 Pain	Severe pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145509>	C143726	Grade 3 Palmar-Plantar Erythrodysesthesia Syndrome, CTCAE|Grade 3 Palmar-plantar erythrodysesthesia syndrome|Grade 3 Palmar-plantar erythrodysesthesia syndrome	Severe skin changes (e.g., peeling, blisters, bleeding, fissures, edema, or hyperkeratosis) with pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145510>	C143728	Grade 3 Pancreas Infection, CTCAE|Grade 3 Pancreas infection|Grade 3 Pancreas infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145511>	C143729	Grade 3 Pancreatic Anastomotic Leak, CTCAE|Grade 3 Pancreatic anastomotic leak|Grade 3 Pancreatic anastomotic leak	Severe symptoms; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145512>	C143730	Grade 3 Pancreatic Duct Stenosis, CTCAE|Grade 3 Pancreatic duct stenosis|Grade 3 Pancreatic duct stenosis	Severely altered GI function; tube feeding or hospitalization indicated; elective operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145513>	C143731	Grade 3 Pancreatic Enzymes Decreased, CTCAE|Grade 3 Pancreatic enzymes decreased	Sequelae of absorption deficiency			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145516>	C143732	Grade 3 Pancreatic Necrosis, CTCAE|Grade 3 Pancreatic necrosis|Grade 3 Pancreatic necrosis	Tube feeding or TPN indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145517>	C143734	Grade 3 Papilledema, CTCAE|Grade 3 Papilledema|Grade 3 Papilledema	Symptomatic with marked decrease in visual acuity (best corrected visual acuity worse than 20/40 or more than 3 lines of decreased vision from known baseline, up to 20/200)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145518>	C143735	Grade 3 Papulopustular Rash, CTCAE|Grade 3 Papulopustular rash	Papules and/or pustules covering >30% BSA with moderate or severe symptoms; limiting self-care ADL; IV antibiotics indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145519>	C143736	Grade 3 Paresthesia, CTCAE|Grade 3 Paresthesia|Grade 3 Paresthesia	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145520>	C143737	Grade 3 Paronychia, CTCAE|Grade 3 Paronychia|Grade 3 Paronychia	Operative intervention indicated; IV antibiotics indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145521>	C143738	Grade 3 Paroxysmal Atrial Tachycardia, CTCAE|Grade 3 Paroxysmal atrial tachycardia|Grade 3 Paroxysmal atrial tachycardia	Symptomatic, urgent intervention indicated; ablation			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145522>	C143739	Grade 3 Pelvic Floor Muscle Weakness, CTCAE|Grade 3 Pelvic floor muscle weakness|Grade 3 Pelvic floor muscle weakness	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145523>	C143740	Grade 3 Pelvic Infection, CTCAE|Grade 3 Pelvic infection|Grade 3 Pelvic infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145524>	C146679	Grade 3 Pelvic Pain, CTCAE|Grade 3 Pelvic pain|Grade 3 Pelvic pain	Severe pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145525>	C143741	Grade 3 Penile Infection, CTCAE|Grade 3 Penile infection|Grade 3 Penile infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145527>	C143742	Grade 3 Perforation Bile Duct, CTCAE|Grade 3 Perforation bile duct|Grade 3 Perforation bile duct	Invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145528>	C143743	Grade 3 Pericardial Effusion, CTCAE|Grade 3 Pericardial effusion|Grade 3 Pericardial effusion	Effusion with physiologic consequences			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145529>	C146681	Grade 3 Perineal Pain, CTCAE|Grade 3 Perineal pain|Grade 3 Perineal pain	Severe pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145530>	C143747	Grade 3 Periorbital Edema, CTCAE|Grade 3 Periorbital edema|Grade 3 Periorbital edema	Edema associated with visual disturbance; increased intraocular pressure, glaucoma or retinal hemorrhage; diuretics indicated; operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145531>	C143748	Grade 3 Periorbital Infection, CTCAE|Grade 3 Periorbital infection|Grade 3 Periorbital infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145532>	C143749	Grade 3 Peripheral Ischemia, CTCAE|Grade 3 Peripheral ischemia|Grade 3 Peripheral ischemia	Prolonged (>=24 hrs) or recurring symptoms and/or invasive intervention indicated; pain at rest			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145533>	C143750	Grade 3 Peripheral Motor Neuropathy, CTCAE|Grade 3 Peripheral motor neuropathy|Grade 3 Peripheral motor neuropathy	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145534>	C143751	Grade 3 Peripheral Nerve Infection, CTCAE|Grade 3 Peripheral nerve infection|Grade 3 Peripheral nerve infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145535>	C143752	Grade 3 Peripheral Sensory Neuropathy, CTCAE|Grade 3 Peripheral sensory neuropathy|Grade 3 Peripheral sensory neuropathy	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145536>	C143753	Grade 3 Peritoneal Infection, CTCAE|Grade 3 Peritoneal infection|Grade 3 Peritoneal infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145538>	C143754	Grade 3 Personality Change, CTCAE|Grade 3 Personality change|Grade 3 Personality change	Severe personality change; hospitalization not indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145539>	C146682	Grade 3 Phantom Pain, CTCAE|Grade 3 Phantom pain|Grade 3 Phantom pain	Severe pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145540>	C143755	Grade 3 Pharyngeal Anastomotic Leak, CTCAE|Grade 3 Pharyngeal anastomotic leak|Grade 3 Pharyngeal anastomotic leak	Severe symptoms; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145543>	C143756	Grade 3 Pharyngeal Mucositis, CTCAE|Grade 3 Pharyngeal mucositis|Grade 3 Pharyngeal mucositis	Severe pain; unable to adequately aliment or hydrate orally; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145545>	C143757	Grade 3 Pharyngeal Stenosis, CTCAE|Grade 3 Pharyngeal stenosis|Grade 3 Pharyngeal stenosis	Stridor; endoscopic intervention indicated (e.g., stent, laser); limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145546>	C143758	Grade 3 Pharyngitis, CTCAE|Grade 3 Pharyngitis|Grade 3 Pharyngitis	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145547>	C143759	Grade 3 Pharyngolaryngeal Pain, CTCAE|Grade 3 Pharyngolaryngeal pain|Grade 3 Pharyngolaryngeal pain	Severe pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145548>	C143760	Grade 3 Phlebitis Infective, CTCAE|Grade 3 Phlebitis infective|Grade 3 Phlebitis infective	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145549>	C143764	Grade 3 Platelet Count Decreased, CTCAE|Grade 3 Platelet count decreased	<50,000-25,000/mm3; <50.0-25.0 x 10e9/L			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145550>	C143765	Grade 3 Pleural Effusion, CTCAE|Grade 3 Pleural effusion|Grade 3 Pleural effusion	Symptomatic with respiratory distress and hypoxia; operative intervention including chest tube or pleurodesis indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145552>	C143766	Grade 3 Pleural Infection, CTCAE|Grade 3 Pleural infection|Grade 3 Pleural infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145553>	C146663	Grade 3 Pleuritic Pain, CTCAE|Grade 3 Pleuritic pain|Grade 3 Pleuritic pain	Severe pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145554>	C143767	Grade 3 Pneumonitis, CTCAE|Grade 3 Pneumonitis|Grade 3 Pneumonitis	Severe symptoms; oxygen indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145555>	C143769	Grade 3 Portal Hypertension, CTCAE|Grade 3 Portal hypertension|Grade 3 Portal hypertension	Reversal/retrograde portal vein flow; associated with varices and/or ascites			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145556>	C143770	Grade 3 Portal Vein Thrombosis, CTCAE|Grade 3 Portal vein thrombosis|Grade 3 Portal vein thrombosis	Medical intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145557>	C143772	Grade 3 Postoperative Hemorrhage, CTCAE|Grade 3 Postoperative hemorrhage|Grade 3 Postoperative hemorrhage	Transfusion indicated of >=2 units (10 cc/kg for pediatrics) pRBCs; invasive intervention indicated; hospitalization			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145558>	C143773	Grade 3 Postoperative Thoracic Procedure Complication, CTCAE|Grade 3 Postoperative thoracic procedure complication|Grade 3 Postoperative thoracic procedure complication	Extubated >72 hrs postoperatively, but before tracheostomy indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145559>	C143775	Grade 3 Pregnancy, Puerperium and Perinatal Conditions - Other, Specify, CTCAE|Grade 3 Pregnancy, puerperium and perinatal conditions - Other, specify|Grade 3 Pregnancy, puerperium and perinatal conditions - Other, specify	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145560>	C143776	Grade 3 Premature Delivery, CTCAE|Grade 3 Premature delivery|Grade 3 Premature delivery	Delivery of a liveborn infant at 24 to 28 weeks gestation			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145561>	C143780	Grade 3 Productive Cough, CTCAE|Grade 3 Productive cough|Grade 3 Productive cough	Persistent or copious production of sputum; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145562>	C143781	Grade 3 Prolapse of Intestinal Stoma, CTCAE|Grade 3 Prolapse of intestinal stoma|Grade 3 Prolapse of intestinal stoma	Severe symptoms; elective operative intervention indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145563>	C143782	Grade 3 Prolapse of Urostomy, CTCAE|Grade 3 Prolapse of urostomy|Grade 3 Prolapse of urostomy	Dysfunctional stoma; elective operative intervention or major stomal revision indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145564>	C143783	Grade 3 Prostate Infection, CTCAE|Grade 3 Prostate infection|Grade 3 Prostate infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145566>	C143784	Grade 3 Prostatic Obstruction, CTCAE|Grade 3 Prostatic obstruction|Grade 3 Prostatic obstruction	Severe symptoms; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145567>	C146664	Grade 3 Prostatic Pain, CTCAE|Grade 3 Prostatic pain|Grade 3 Prostatic pain	Severe pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145568>	C143787	Grade 3 Psychiatric Disorders - Other, Specify, CTCAE|Grade 3 Psychiatric disorders - Other, specify|Grade 3 Psychiatric disorders - Other, specify	Severe or medically significant but not immediately life-threatening; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145569>	C143788	Grade 3 Psychosis, CTCAE|Grade 3 Psychosis|Grade 3 Psychosis	Severe psychotic symptoms (e.g., paranoid, extreme disorganization); hospitalization not indicated; new onset			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145570>	C143789	Grade 3 Pulmonary Edema, CTCAE|Grade 3 Pulmonary edema|Grade 3 Pulmonary edema	Severe dyspnea or dyspnea at rest; oxygen indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145571>	C143790	Grade 3 Pulmonary Fibrosis, CTCAE|Grade 3 Pulmonary fibrosis|Grade 3 Pulmonary fibrosis	Severe hypoxia; evidence of right-sided heart failure; radiographic pulmonary fibrosis >50 - 75%			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145572>	C143791	Grade 3 Pulmonary Fistula, CTCAE|Grade 3 Pulmonary fistula|Grade 3 Pulmonary fistula	Invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145573>	C143793	Grade 3 Pulmonary Valve Disease, CTCAE|Grade 3 Pulmonary valve disease|Grade 3 Pulmonary valve disease	Symptomatic; severe regurgitation or stenosis by imaging; symptoms controlled with medical intervention			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145574>	C143794	Grade 3 Purpura, CTCAE|Grade 3 Purpura|Grade 3 Purpura	Combined area of lesions covering >30% BSA			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145575>	C143795	Grade 3 Pyramidal Tract Syndrome, CTCAE|Grade 3 Pyramidal tract syndrome|Grade 3 Pyramidal tract syndrome	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145576>	C143796	Grade 3 Radiation Recall Reaction (Dermatologic), CTCAE|Grade 3 Radiation recall reaction (dermatologic)|Grade 3 Radiation recall reaction (dermatologic)	Moist desquamation in areas other than skin folds and creases; bleeding induced by minor trauma or abrasion			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145577>	C143797	Grade 3 Radiculitis, CTCAE|Grade 3 Radiculitis|Grade 3 Radiculitis	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145578>	C143798	Grade 3 Rash Acneiform, CTCAE|Grade 3 Rash acneiform	Papules and/or pustules covering >30% BSA with moderate or severe symptoms; limiting self-care ADL; associated with local superinfection with oral antibiotics indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145579>	C143799	Grade 3 Rash Maculo-Papular, CTCAE|Grade 3 Rash maculo-papular	Macules/papules covering >30% BSA with moderate or severe symptoms; limiting self care ADL			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145580>	C143800	Grade 3 Rash Pustular, CTCAE|Grade 3 Rash pustular|Grade 3 Rash pustular	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145581>	C143801	Grade 3 Rectal Anastomotic Leak, CTCAE|Grade 3 Rectal anastomotic leak|Grade 3 Rectal anastomotic leak	Severe symptoms; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145582>	C143200	Grade 3 Rectal Fissure, CTCAE|Grade 3 Rectal fissure|Grade 3 Rectal fissure	Invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145585>	C143802	Grade 3 Rectal Mucositis, CTCAE|Grade 3 Rectal mucositis|Grade 3 Rectal mucositis	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145588>	C146631	Grade 3 Rectal Pain, CTCAE|Grade 3 Rectal pain|Grade 3 Rectal pain	Severe pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145590>	C143803	Grade 3 Rectal Stenosis, CTCAE|Grade 3 Rectal stenosis|Grade 3 Rectal stenosis	Severely altered GI function; tube feeding or hospitalization indicated; elective operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145592>	C143804	Grade 3 Recurrent Laryngeal Nerve Palsy, CTCAE|Grade 3 Recurrent laryngeal nerve palsy|Grade 3 Recurrent laryngeal nerve palsy	Severe symptoms; medical intervention indicated (e.g., thyroplasty, vocal cord injection)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145593>	C143805	Grade 3 Renal and Urinary Disorders - Other, Specify, CTCAE|Grade 3 Renal and urinary disorders - Other, specify|Grade 3 Renal and urinary disorders - Other, specify	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145594>	C143806	Grade 3 Renal Calculi, CTCAE|Grade 3 Renal calculi|Grade 3 Renal calculi	Hospitalization indicated; IV intervention (e.g., analgesics, antiemetics); elective invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145595>	C143807	Grade 3 Renal Colic, CTCAE|Grade 3 Renal colic|Grade 3 Renal colic	Hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145597>	C143808	Grade 3 Reproductive System and Breast Disorders - Other, Specify, CTCAE|Grade 3 Reproductive system and breast disorders - Other, specify|Grade 3 Reproductive system and breast disorders - Other, specify	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145598>	C143810	Grade 3 Respiratory, Thoracic and Mediastinal Disorders - Other, Specify, CTCAE|Grade 3 Respiratory, thoracic and mediastinal disorders - Other, specify|Grade 3 Respiratory, thoracic and mediastinal disorders - Other, specify	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145599>	C143811	Grade 3 Restlessness, CTCAE|Grade 3 Restlessness|Grade 3 Restlessness	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C1455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1455>	C923	Conjugate Vaccine	A category of vaccines created by covalently attaching an antigen from an organism to a carrier protein from the same organism to aid in the delivery of the immunogen.			Chemical Viewed Functionally	NICHD Terminology|Pediatric Immunization Terminology
C145600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145600>	C143815	Grade 3 Retinal Vascular Disorder, CTCAE|Grade 3 Retinal vascular disorder|Grade 3 Retinal vascular disorder	Retinal vascular disorder with neovascularization			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145601>	C146632	Grade 3 Retroperitoneal Hemorrhage, CTCAE|Grade 3 Retroperitoneal hemorrhage	Transfusion indicated; invasive intervention indicated; hospitalization			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145602>	C143818	Grade 3 Reversible Posterior Leukoencephalopathy Syndrome, CTCAE|Grade 3 Reversible posterior leukoencephalopathy syndrome|Grade 3 Reversible posterior leukoencephalopathy syndrome	Severe symptoms; hospitalization; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145603>	C143226	Grade 3 Rhabdomyolysis, CTCAE|Grade 3 Rhabdomyolysis|Grade 3 Rhabdomyolysis	Symptomatic, urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145604>	C143227	Grade 3 Rotator Cuff Injury, CTCAE|Grade 3 Rotator cuff injury|Grade 3 Rotator cuff injury	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145605>	C143821	Grade 3 Salivary Duct Inflammation, CTCAE|Grade 3 Salivary duct inflammation|Grade 3 Salivary duct inflammation	Acute salivary gland necrosis; severe secretion-induced symptoms (e.g., thick saliva/oral secretions or gagging); tube feeding or TPN indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145606>	C143822	Grade 3 Salivary Gland Infection, CTCAE|Grade 3 Salivary gland infection|Grade 3 Salivary gland infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145607>	C143823	Grade 3 Scleral Disorder, CTCAE|Grade 3 Scleral disorder|Grade 3 Scleral disorder	Symptomatic with marked decrease in visual acuity (best corrected visual acuity worse than 20/40 or more than 3 lines of decreased vision from known baseline, up to 20/200); limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145608>	C143824	Grade 3 Scoliosis, CTCAE|Grade 3 Scoliosis|Grade 3 Scoliosis	>45 degrees; scapular prominence in forward flexion; operative intervention indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145609>	C143825	Grade 3 Scrotal Infection, CTCAE|Grade 3 Scrotal infection|Grade 3 Scrotal infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145610>	C146665	Grade 3 Scrotal Pain, CTCAE|Grade 3 Scrotal pain|Grade 3 Scrotal pain	Severe pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145611>	C143827	Grade 3 Sepsis, CTCAE|Grade 3 Sepsis|Grade 3 Sepsis	IV intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145612>	C143829	Grade 3 Serum Amylase Increased, CTCAE|Grade 3 Serum amylase increased|Grade 3 Serum amylase increased	>2.0 - 5.0 x ULN with moderate or severe signs or symptoms; >5.0 x ULN and asymptomatic			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145613>	C143213	Grade 3 Shingles, CTCAE|Grade 3 Shingles|Grade 3 Shingles	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; IV intervention indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145614>	C143831	Grade 3 Sinus Disorder, CTCAE|Grade 3 Sinus disorder|Grade 3 Sinus disorder	Stenosis with significant nasal obstruction; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145615>	C143832	Grade 3 Sinusitis, CTCAE|Grade 3 Sinusitis|Grade 3 Sinusitis	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145616>	C143205	Grade 3 Sinusoidal Obstruction Syndrome, CTCAE|Grade 3 Sinusoidal obstruction syndrome|Grade 3 Sinusoidal obstruction syndrome	Blood bilirubin >5 mg/dL; coagulation modifier indicated (e.g., defibrotide); reversal of flow on ultrasound			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145617>	C143833	Grade 3 Skin and Subcutaneous Tissue Disorders - Other, Specify, CTCAE|Grade 3 Skin and subcutaneous tissue disorders - Other, specify|Grade 3 Skin and subcutaneous tissue disorders - Other, specify	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145618>	C146644	Grade 3 Skin Atrophy, CTCAE|Grade 3 Skin atrophy	Covering >30% BSA; associated with ulceration			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145619>	C143837	Grade 3 Skin Induration, CTCAE|Grade 3 Skin induration|Grade 3 Skin induration	Severe induration; unable to slide or pinch skin; limiting joint or orifice movement (e.g., mouth, anus); limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145620>	C143838	Grade 3 Skin Infection, CTCAE|Grade 3 Skin infection|Grade 3 Skin infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145621>	C143839	Grade 3 Skin Ulceration, CTCAE|Grade 3 Skin ulceration|Grade 3 Skin ulceration	Combined area of ulcers >2 cm; full-thickness skin loss involving damage to or necrosis of subcutaneous tissue that may extend down to fascia			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145622>	C143840	Grade 3 Sleep Apnea, CTCAE|Grade 3 Sleep apnea|Grade 3 Sleep apnea	Oxygen desaturation; associated with pulmonary hypertension; medical intervention indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145623>	C143841	Grade 3 Small Intestinal Anastomotic Leak, CTCAE|Grade 3 Small intestinal anastomotic leak|Grade 3 Small intestinal anastomotic leak	Severe symptoms; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145624>	C143842	Grade 3 Small Intestinal Mucositis, CTCAE|Grade 3 Small intestinal mucositis|Grade 3 Small intestinal mucositis	Severe pain; interfering with oral intake; tube feeding, TPN or hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145625>	C143843	Grade 3 Small Intestinal Obstruction, CTCAE|Grade 3 Small intestinal obstruction|Grade 3 Small intestinal obstruction	Hospitalization indicated; invasive intervention indicated; limiting self care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145626>	C146635	Grade 3 Small Intestinal Perforation, CTCAE|Grade 3 Small intestinal perforation|Grade 3 Small intestinal perforation	Invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145627>	C143844	Grade 3 Small Intestinal Stenosis, CTCAE|Grade 3 Small intestinal stenosis|Grade 3 Small intestinal stenosis	Symptomatic and severely altered GI function; tube feeding, TPN or hospitalization indicated; non-emergent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145628>	C143845	Grade 3 Small Intestine Infection, CTCAE|Grade 3 Small intestine infection|Grade 3 Small intestine infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145629>	C143846	Grade 3 Small Intestine Ulcer, CTCAE|Grade 3 Small intestine ulcer|Grade 3 Small intestine ulcer	Severely altered GI function; TPN indicated; elective invasive intervention indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145630>	C143848	Grade 3 Social Circumstances - Other, Specify, CTCAE|Grade 3 Social circumstances - Other, specify|Grade 3 Social circumstances - Other, specify	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145631>	C143849	Grade 3 Soft Tissue Infection, CTCAE|Grade 3 Soft tissue infection|Grade 3 Soft tissue infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145632>	C143850	Grade 3 Soft Tissue Necrosis Lower Limb, CTCAE|Grade 3 Soft tissue necrosis lower limb|Grade 3 Soft tissue necrosis lower limb	Operative debridement or other invasive intervention indicated (e.g., tissue reconstruction, flap, or grafting)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145633>	C143851	Grade 3 Soft Tissue Necrosis Upper Limb, CTCAE|Grade 3 Soft tissue necrosis upper limb|Grade 3 Soft tissue necrosis upper limb	Operative debridement or other invasive intervention indicated (e.g., tissue reconstruction, flap, or grafting)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145634>	C143852	Grade 3 Somnolence, CTCAE|Grade 3 Somnolence|Grade 3 Somnolence	Obtundation or stupor			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145635>	C143853	Grade 3 Sore Throat, CTCAE|Grade 3 Sore throat|Grade 3 Sore throat	Severe pain; limiting ability to swallow; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145636>	C143854	Grade 3 Spasticity, CTCAE|Grade 3 Spasticity|Grade 3 Spasticity	Severe increase in muscle tone and increase in resistance through range of motion			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145637>	C143855	Grade 3 Spermatic Cord Anastomotic Leak, CTCAE|Grade 3 Spermatic cord anastomotic leak|Grade 3 Spermatic cord anastomotic leak	Severe symptoms; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145638>	C143233	Grade 3 Spinal Cord Compression, CTCAE|Grade 3 Spinal cord compression	Severe symptoms; limiting self care ADL			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145639>	C143856	Grade 3 Spinal Fracture, CTCAE|Grade 3 Spinal fracture	Severe back pain; hospitalization or intervention indicated for pain control (e.g., vertebroplasty); limiting self care ADL; disability			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145640>	C143857	Grade 3 Splenic Infection, CTCAE|Grade 3 Splenic infection|Grade 3 Splenic infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145641>	C143858	Grade 3 Stenosis of Gastrointestinal Stoma, CTCAE|Grade 3 Stenosis of gastrointestinal stoma|Grade 3 Stenosis of gastrointestinal stoma	Severely altered GI function; tube feeding, TPN or hospitalization indicated; elective operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145642>	C143859	Grade 3 Stevens-Johnson Syndrome, CTCAE|Grade 3 Stevens-Johnson syndrome|Grade 3 Stevens-Johnson syndrome	Skin sloughing covering <10% BSA			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145643>	C143860	Grade 3 Stoma Site Infection, CTCAE|Grade 3 Stoma site infection|Grade 3 Stoma site infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145644>	C146694	Grade 3 Stomal Ulcer, CTCAE|Grade 3 Stomal ulcer|Grade 3 Stomal ulcer	Severe symptoms; elective operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145645>	C143861	Grade 3 Stridor, CTCAE|Grade 3 Stridor|Grade 3 Stridor	Respiratory distress; medical intervention indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145646>	C143862	Grade 3 Stroke, CTCAE|Grade 3 Stroke|Grade 3 Stroke	Severe neurologic deficit; hospitalization; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145647>	C143248	Grade 3 Subcutaneous Emphysema, CTCAE|Grade 3 Subcutaneous emphysema|Grade 3 Subcutaneous emphysema	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145648>	C143864	Grade 3 Suicidal Ideation, CTCAE|Grade 3 Suicidal ideation|Grade 3 Suicidal ideation	Specific plan to commit suicide without serious intent to die which may not require hospitalization			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145649>	C143865	Grade 3 Suicide Attempt, CTCAE|Grade 3 Suicide attempt|Grade 3 Suicide attempt	Suicide attempt or gesture without intent to die			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145650>	C143866	Grade 3 Superficial Soft Tissue Fibrosis, CTCAE|Grade 3 Superficial soft tissue fibrosis|Grade 3 Superficial soft tissue fibrosis	Severe induration; unable to slide or pinch skin; limiting joint or orifice movement (e.g., mouth, anus); limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145651>	C143868	Grade 3 Superior Vena Cava Syndrome, CTCAE|Grade 3 Superior vena cava syndrome|Grade 3 Superior vena cava syndrome	Severe symptoms; multi-modality intervention indicated (e.g., anticoagulation, chemotherapy, radiation, stenting)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145652>	C143869	Grade 3 Surgical and Medical Procedures - Other, Specify, CTCAE|Grade 3 Surgical and medical procedures - Other, specify|Grade 3 Surgical and medical procedures - Other, specify	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145653>	C143234	Grade 3 Tendon Reflex Decreased, CTCAE|Grade 3 Tendon reflex decreased|Grade 3 Tendon reflex decreased	Absence of all reflexes			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145654>	C143872	Grade 3 Testicular Disorder, CTCAE|Grade 3 Testicular disorder|Grade 3 Testicular disorder	Severe symptoms; interfering with sexual function; intervention indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145656>	C146666	Grade 3 Testicular Pain, CTCAE|Grade 3 Testicular pain|Grade 3 Testicular pain	Severe pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145657>	C143873	Grade 3 Thromboembolic Event, CTCAE|Grade 3 Thromboembolic event	Urgent medical intervention indicated (e.g., pulmonary embolism or intracardiac thrombus)			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145658>	C143874	Grade 3 Thrombotic Thrombocytopenic Purpura, CTCAE|Grade 3 Thrombotic thrombocytopenic purpura|Grade 3 Thrombotic thrombocytopenic purpura	Laboratory findings with clinical consequences (e.g., renal insufficiency, petechiae)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145659>	C143214	Grade 3 Thrush, CTCAE|Grade 3 Thrush	IV antifungal intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145660>	C143876	Grade 3 Tooth Development Disorder, CTCAE|Grade 3 Tooth development disorder|Grade 3 Tooth development disorder	Maldevelopment with impairment not surgically correctable; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145661>	C143878	Grade 3 Tooth Infection, CTCAE|Grade 3 Tooth infection|Grade 3 Tooth infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145662>	C143879	Grade 3 Toothache, CTCAE|Grade 3 Toothache|Grade 3 Toothache	Severe pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145665>	C143881	Grade 3 Tracheal Mucositis, CTCAE|Grade 3 Tracheal mucositis|Grade 3 Tracheal mucositis	Severe pain; hemorrhage or respiratory symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145666>	C143882	Grade 3 Tracheal Obstruction, CTCAE|Grade 3 Tracheal obstruction|Grade 3 Tracheal obstruction	Stridor or respiratory distress; invasive intervention indicated (e.g., stent, laser); limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145667>	C143883	Grade 3 Tracheal Stenosis, CTCAE|Grade 3 Tracheal stenosis|Grade 3 Tracheal stenosis	Stridor or respiratory distress; invasive intervention indicated (e.g., stent, laser); limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145668>	C143884	Grade 3 Tracheitis, CTCAE|Grade 3 Tracheitis|Grade 3 Tracheitis	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145669>	C143885	Grade 3 Tracheostomy Site Bleeding, CTCAE|Grade 3 Tracheostomy site bleeding|Grade 3 Tracheostomy site bleeding	Invasive intervention indicated; hospitalization			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145670>	C143887	Grade 3 Treatment Related Secondary Malignancy, CTCAE|Grade 3 Treatment related secondary malignancy|Grade 3 Treatment related secondary malignancy	Non life-threatening secondary malignancy			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145671>	C143889	Grade 3 Tricuspid Valve Disease, CTCAE|Grade 3 Tricuspid valve disease|Grade 3 Tricuspid valve disease	Symptomatic; severe regurgitation or stenosis; symptoms controlled with medical intervention			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145672>	C143890	Grade 3 Trigeminal Nerve Disorder, CTCAE|Grade 3 Trigeminal nerve disorder|Grade 3 Trigeminal nerve disorder	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145673>	C143235	Grade 3 Trochlear Nerve Disorder, CTCAE|Grade 3 Trochlear nerve disorder|Grade 3 Trochlear nerve disorder	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145674>	C143229	Grade 3 Tumor Hemorrhage, CTCAE|Grade 3 Tumor hemorrhage|Grade 3 Tumor hemorrhage	Hospitalization			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145675>	C143894	Grade 3 Unequal Limb Length, CTCAE|Grade 3 Unequal limb length|Grade 3 Unequal limb length	Severe length discrepancy >5 cm; operative intervention indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145676>	C143895	Grade 3 Upper Gastrointestinal Hemorrhage, CTCAE|Grade 3 Upper gastrointestinal hemorrhage|Grade 3 Upper gastrointestinal hemorrhage	Hospitalization			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145677>	C143896	Grade 3 Upper Respiratory Infection, CTCAE|Grade 3 Upper respiratory infection|Grade 3 Upper respiratory infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145678>	C143897	Grade 3 Ureteric Anastomotic Leak, CTCAE|Grade 3 Ureteric anastomotic leak|Grade 3 Ureteric anastomotic leak	Severe symptoms; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145679>	C143898	Grade 3 Urethral Anastomotic Leak, CTCAE|Grade 3 Urethral anastomotic leak|Grade 3 Urethral anastomotic leak	Severe symptoms; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14567>	C14421	101 Mouse|101	Inbr: 66. Genet: A^w. Origin: Dunn, 1936. (Jackson Labs/Festing)	101		Mammal	
C145680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145680>	C143899	Grade 3 Urethral Infection, CTCAE|Grade 3 Urethral infection|Grade 3 Urethral infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145681>	C143900	Grade 3 Urinary Fistula, CTCAE|Grade 3 Urinary fistula|Grade 3 Urinary fistula	Invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145682>	C143904	Grade 3 Urinary Tract Infection, CTCAE|Grade 3 Urinary tract infection|Grade 3 Urinary tract infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145683>	C143905	Grade 3 Urinary Tract Obstruction, CTCAE|Grade 3 Urinary tract obstruction|Grade 3 Urinary tract obstruction	Altered organ function (e.g., hydronephrosis or renal dysfunction); invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145684>	C143906	Grade 3 Urinary Tract Pain, CTCAE|Grade 3 Urinary tract pain|Grade 3 Urinary tract pain	Severe pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145685>	C143909	Grade 3 Urine Output Decreased, CTCAE|Grade 3 Urine output decreased|Grade 3 Urine output decreased	Adult: Oliguria (<80 ml in 8 hr); Infants: <1 ml/kg/hour; Children: <0.5 ml/kg/hour			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145686>	C143910	Grade 3 Urostomy Leak, CTCAE|Grade 3 Urostomy leak|Grade 3 Urostomy leak	Severe symptoms; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145687>	C143911	Grade 3 Urostomy Obstruction, CTCAE|Grade 3 Urostomy obstruction|Grade 3 Urostomy obstruction	Altered organ function (e.g., sepsis or hydronephrosis, or renal dysfunction); elective operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145688>	C143912	Grade 3 Urostomy Site Bleeding, CTCAE|Grade 3 Urostomy site bleeding|Grade 3 Urostomy site bleeding	Invasive intervention indicated; hospitalization			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145689>	C143913	Grade 3 Urostomy Stenosis, CTCAE|Grade 3 Urostomy stenosis|Grade 3 Urostomy stenosis	Symptomatic (e.g., hydronephrosis, or renal dysfunction); elective operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145690>	C143915	Grade 3 Uterine Anastomotic Leak, CTCAE|Grade 3 Uterine anastomotic leak|Grade 3 Uterine anastomotic leak	Severe symptoms; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145691>	C143916	Grade 3 Uterine Fistula, CTCAE|Grade 3 Uterine fistula|Grade 3 Uterine fistula	Invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145693>	C143917	Grade 3 Uterine Infection, CTCAE|Grade 3 Uterine infection|Grade 3 Uterine infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145694>	C143918	Grade 3 Uterine Obstruction, CTCAE|Grade 3 Uterine obstruction|Grade 3 Uterine obstruction	Severe symptoms; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145695>	C146683	Grade 3 Uterine Pain, CTCAE|Grade 3 Uterine pain|Grade 3 Uterine pain	Severe pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145696>	C143919	Grade 3 Uterine Perforation, CTCAE|Grade 3 Uterine perforation|Grade 3 Uterine perforation	Invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145697>	C143216	Grade 3 Vaccination Complication, CTCAE|Grade 3 Vaccination complication	Severe pain; Erythema > 10 cm; Induration/swelling > 10 cm; necrosis; limiting self care ADL			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145698>	C143921	Grade 3 Vaginal Anastomotic Leak, CTCAE|Grade 3 Vaginal anastomotic leak|Grade 3 Vaginal anastomotic leak	Severe symptoms; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145699>	C146687	Grade 3 Vaginal Dryness, CTCAE|Grade 3 Vaginal dryness|Grade 3 Vaginal dryness	Severe vaginal dryness resulting in dyspareunia or severe discomfort			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C1456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1456>	C894	Superantigen	An antigen produced by bacteria or viruses that cause non-specific activation of T-lymphocytes. Superantigens form crosslinks between either two major histocompatibility class (MHC) II molecules, which increases both cytokine expression and costimulatory receptor expression in antigen presenting cells, or one MHC class II molecule and the variable region of the T-cell receptor beta chain, which results in increased proliferation of and cytokine expression by T-lymphocytes. This non-specific release of cytokines and upregulation of immune cell activation can lead to rashes, fever, vomiting, anergy, and damage to tissues and organs. These symptoms can progress to autoimmunity, multi-organ failure, coma and death.			Chemical Viewed Functionally	
C145702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145702>	C143924	Grade 3 Vaginal Infection, CTCAE|Grade 3 Vaginal infection|Grade 3 Vaginal infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145703>	C143925	Grade 3 Vaginal Inflammation, CTCAE|Grade 3 Vaginal inflammation|Grade 3 Vaginal inflammation	Severe discomfort or pain, edema, or redness; small areas of mucosal ulceration; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145704>	C146696	Grade 3 Vaginal Obstruction, CTCAE|Grade 3 Vaginal obstruction|Grade 3 Vaginal obstruction	Severe symptoms; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145705>	C146684	Grade 3 Vaginal Pain, CTCAE|Grade 3 Vaginal pain|Grade 3 Vaginal pain	Severe pain; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145706>	C146697	Grade 3 Vaginal Perforation, CTCAE|Grade 3 Vaginal perforation|Grade 3 Vaginal perforation	Invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145707>	C143926	Grade 3 Vaginal Stricture, CTCAE|Grade 3 Vaginal stricture|Grade 3 Vaginal stricture	Vaginal narrowing and/or shortening interfering with the use of tampons, sexual activity or physical examination			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145708>	C143927	Grade 3 Vagus Nerve Disorder, CTCAE|Grade 3 Vagus nerve disorder|Grade 3 Vagus nerve disorder	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145709>	C143928	Grade 3 Vas Deferens Anastomotic Leak, CTCAE|Grade 3 Vas deferens anastomotic leak|Grade 3 Vas deferens anastomotic leak	Severe symptoms; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145710>	C143929	Grade 3 Vascular Access Complication, CTCAE|Grade 3 Vascular access complication|Grade 3 Vascular access complication	Pulmonary embolism, deep vein or cardiac thrombosis; intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145711>	C143930	Grade 3 Vascular Disorders - Other, Specify, CTCAE|Grade 3 Vascular disorders - Other, specify|Grade 3 Vascular disorders - Other, specify	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145712>	C143932	Grade 3 Vasovagal Reaction, CTCAE|Grade 3 Vasovagal reaction	Present			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145713>	C143933	Grade 3 Venous Injury, CTCAE|Grade 3 Venous injury|Grade 3 Venous injury	Severe symptoms; repair or revision indicated; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145714>	C146629	Grade 3 Ventricular Arrhythmia, CTCAE|Grade 3 Ventricular arrhythmia|Grade 3 Ventricular arrhythmia	Urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145715>	C143935	Grade 3 Vertigo, CTCAE|Grade 3 Vertigo|Grade 3 Vertigo	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145716>	C143936	Grade 3 Vestibular Disorder, CTCAE|Grade 3 Vestibular disorder|Grade 3 Vestibular disorder	Severe symptoms; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145717>	C143215	Grade 3 Viremia, CTCAE|Grade 3 Viremia|Grade 3 Viremia	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145718>	C143938	Grade 3 Visceral Arterial Ischemia, CTCAE|Grade 3 Visceral arterial ischemia|Grade 3 Visceral arterial ischemia	Prolonged (>=24 hrs) or recurring symptoms and/or invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145719>	C143196	Grade 3 Vision Decreased, CTCAE|Grade 3 Vision decreased|Grade 3 Vision decreased	Marked decrease in visual acuity (best corrected visual acuity worse than 20/40 or more than 3 lines of decreased vision from known baseline, up to 20/200)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145720>	C143939	Grade 3 Vital Capacity Abnormal, CTCAE|Grade 3 Vital capacity abnormal|Grade 3 Vital capacity abnormal	<50% of predicted value; limiting self-care ADL or severe impact on age-appropriate normal daily activity (pediatric)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145721>	C143941	Grade 3 Voice Alteration, CTCAE|Grade 3 Voice alteration|Grade 3 Voice alteration	Severe voice changes including predominantly whispered speech; may require frequent repetition or face-to-face contact for understandability; may require assistive technology			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145722>	C143943	Grade 3 Vulval Infection, CTCAE|Grade 3 Vulval infection|Grade 3 Vulval infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145723>	C143944	Grade 3 Watering Eyes, CTCAE|Grade 3 Watering eyes|Grade 3 Watering eyes	Marked decrease in visual acuity (best corrected visual acuity worse than 20/40 or more than 3 lines of decreased vision from known baseline, up to 20/200)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145724>	C143947	Grade 3 Wheezing, CTCAE|Grade 3 Wheezing	Severe respiratory symptoms limiting self care ADL; oxygen therapy or hospitalization indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145725>	C143948	Grade 3 White Blood Cell Decreased, CTCAE|Grade 3 White blood cell decreased|Grade 3 White blood cell decreased	<2000 - 1000/mm3; <2.0 - 1.0 x 10^9/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145726>	C143949	Grade 3 Wound Complication, CTCAE|Grade 3 Wound complication|Grade 3 Wound complication	Operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145727>	C143950	Grade 3 Wound Dehiscence, CTCAE|Grade 3 Wound dehiscence|Grade 3 Wound dehiscence	Fascial disruption or dehiscence without evisceration; revision by operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145728>	C143951	Grade 3 Wound Infection, CTCAE|Grade 3 Wound infection|Grade 3 Wound infection	IV antibiotic, antifungal, or antiviral intervention indicated; invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145729>	C143952	Grade 3 Wrist Fracture, CTCAE|Grade 3 Wrist fracture	Limiting self care ADL; elective operative intervention indicated requiring hospitalization			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145730>	C143254	Grade 4 Abdominal Infection, CTCAE|Grade 4 Abdominal infection|Grade 4 Abdominal infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145731>	C143256	Grade 4 Abdominal Soft Tissue Necrosis, CTCAE|Grade 4 Abdominal soft tissue necrosis|Grade 4 Abdominal soft tissue necrosis	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145732>	C143259	Grade 4 Acidosis, CTCAE|Grade 4 Acidosis|Grade 4 Acidosis	Life-threatening consequences			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145733>	C143262	Grade 4 Acute Kidney Injury, CTCAE|Grade 4 Acute kidney injury|Grade 4 Acute kidney injury	Life-threatening consequences; dialysis indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145734>	C143267	Grade 4 Alanine Aminotransferase Increased, CTCAE|Grade 4 Alanine aminotransferase increased|Grade 4 Alanine aminotransferase increased	>20.0 x ULN if baseline was normal or less than normal; >4.0 x baseline if baseline was >ULN			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145735>	C143268	Grade 4 Alcohol Intolerance, CTCAE|Grade 4 Alcohol intolerance|Grade 4 Alcohol intolerance	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145736>	C143269	Grade 4 Alkaline Phosphatase Increased, CTCAE|Grade 4 Alkaline phosphatase increased	>20.0 x ULN if baseline was normal; >20.0 x baseline if baseline was abnormal			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145737>	C143270	Grade 4 Alkalosis, CTCAE|Grade 4 Alkalosis|Grade 4 Alkalosis	Life-threatening consequences			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145738>	C143271	Grade 4 Allergic Reaction, CTCAE|Grade 4 Allergic reaction|Grade 4 Allergic reaction	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145739>	C143275	Grade 4 Anal Fistula, CTCAE|Grade 4 Anal fistula|Grade 4 Anal fistula	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145740>	C143276	Grade 4 Anal Hemorrhage, CTCAE|Grade 4 Anal hemorrhage	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145741>	C143278	Grade 4 Anal Necrosis, CTCAE|Grade 4 Anal necrosis|Grade 4 Anal necrosis	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145742>	C143280	Grade 4 Anal Stenosis, CTCAE|Grade 4 Anal stenosis|Grade 4 Anal stenosis	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145743>	C143281	Grade 4 Anal Ulcer, CTCAE|Grade 4 Anal ulcer|Grade 4 Anal ulcer	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145744>	C143282	Grade 4 Anaphylaxis, CTCAE|Grade 4 Anaphylaxis|Grade 4 Anaphylaxis	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145745>	C143283	Grade 4 Anemia, CTCAE|Grade 4 Anemia|Grade 4 Anemia	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145746>	C143285	Grade 4 Anorectal Infection, CTCAE|Grade 4 Anorectal infection|Grade 4 Anorectal infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145747>	C143289	Grade 4 Aortic Injury, CTCAE|Grade 4 Aortic injury|Grade 4 Aortic injury	Life-threatening consequences; evidence of end organ damage; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145748>	C143290	Grade 4 Aortic Valve Disease, CTCAE|Grade 4 Aortic valve disease|Grade 4 Aortic valve disease	Life-threatening consequences; urgent intervention indicated (e.g., valve replacement, valvuloplasty)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145749>	C143293	Grade 4 Appendicitis Perforated, CTCAE|Grade 4 Appendicitis perforated|Grade 4 Appendicitis perforated	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145750>	C143294	Grade 4 Appendicitis, CTCAE|Grade 4 Appendicitis|Grade 4 Appendicitis	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145751>	C143295	Grade 4 Arachnoiditis, CTCAE|Grade 4 Arachnoiditis|Grade 4 Arachnoiditis	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145752>	C143296	Grade 4 Arterial Injury, CTCAE|Grade 4 Arterial injury|Grade 4 Arterial injury	Life-threatening consequences; evidence of end organ damage; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145753>	C143249	Grade 4 Arterial Thromboembolism, CTCAE|Grade 4 Arterial thromboembolism|Grade 4 Arterial thromboembolism	Life-threatening consequences; hemodynamic or neurologic instability; organ damage; loss of extremity(ies)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145754>	C143297	Grade 4 Arteritis Infective, CTCAE|Grade 4 Arteritis infective|Grade 4 Arteritis infective	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145755>	C143300	Grade 4 Ascites, CTCAE|Grade 4 Ascites|Grade 4 Ascites	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145756>	C143301	Grade 4 Aspartate Aminotransferase Increased, CTCAE|Grade 4 Aspartate aminotransferase increased|Grade 4 Aspartate aminotransferase increased	>20.0 x ULN if baseline was normal or less than normal; >4.0 x baseline if baseline was >ULN			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145757>	C143308	Grade 4 Atrioventricular Block Complete, CTCAE|Grade 4 Atrioventricular block complete|Grade 4 Atrioventricular block complete	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145758>	C143310	Grade 4 Autoimmune Disorder, CTCAE|Grade 4 Autoimmune disorder|Grade 4 Autoimmune disorder	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145759>	C143311	Grade 4 Avascular Necrosis, CTCAE|Grade 4 Avascular necrosis	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145760>	C143314	Grade 4 Bile Duct Stenosis, CTCAE|Grade 4 Bile duct stenosis|Grade 4 Bile duct stenosis	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145761>	C143315	Grade 4 Biliary Anastomotic Leak, CTCAE|Grade 4 Biliary anastomotic leak|Grade 4 Biliary anastomotic leak	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145762>	C143316	Grade 4 Biliary Fistula, CTCAE|Grade 4 Biliary fistula|Grade 4 Biliary fistula	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145763>	C143317	Grade 4 Biliary Tract Infection, CTCAE|Grade 4 Biliary tract infection|Grade 4 Biliary tract infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145764>	C143318	Grade 4 Bladder Anastomotic Leak, CTCAE|Grade 4 Bladder anastomotic leak|Grade 4 Bladder anastomotic leak	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145765>	C143319	Grade 4 Bladder Infection, CTCAE|Grade 4 Bladder infection|Grade 4 Bladder infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145766>	C143323	Grade 4 Blood and Lymphatic System Disorders - Other, Specify, CTCAE|Grade 4 Blood and lymphatic system disorders - Other, specify|Grade 4 Blood and lymphatic system disorders - Other, specify	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145767>	C143325	Grade 4 Blood Bilirubin Increased, CTCAE|Grade 4 Blood bilirubin increased	>10.0 x ULN if baseline was normal; >10.0 x baseline if baseline was abnormal			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145768>	C143331	Grade 4 Bone Infection, CTCAE|Grade 4 Bone infection|Grade 4 Bone infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145769>	C143332	Grade 4 Bone Marrow Hypocellular, CTCAE|Grade 4 Bone marrow hypocellular|Grade 4 Bone marrow hypocellular	Aplastic persistent for longer than 2 weeks			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145770>	C143336	Grade 4 Breast Infection, CTCAE|Grade 4 Breast infection|Grade 4 Breast infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145771>	C143338	Grade 4 Bronchial Fistula, CTCAE|Grade 4 Bronchial fistula|Grade 4 Bronchial fistula	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145772>	C143339	Grade 4 Bronchial Infection, CTCAE|Grade 4 Bronchial infection|Grade 4 Bronchial infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145773>	C143340	Grade 4 Bronchial Obstruction, CTCAE|Grade 4 Bronchial obstruction|Grade 4 Bronchial obstruction	Life-threatening respiratory or hemodynamic compromise; intubation or urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145774>	C143341	Grade 4 Bronchial Stricture, CTCAE|Grade 4 Bronchial stricture|Grade 4 Bronchial stricture	Life-threatening respiratory or hemodynamic compromise; intubation or urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145775>	C143342	Grade 4 Bronchopleural Fistula, CTCAE|Grade 4 Bronchopleural fistula|Grade 4 Bronchopleural fistula	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145776>	C143343	Grade 4 Bronchopulmonary Hemorrhage, CTCAE|Grade 4 Bronchopulmonary hemorrhage|Grade 4 Bronchopulmonary hemorrhage	Life-threatening consequences; intubation or urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145777>	C143344	Grade 4 Bronchospasm, CTCAE|Grade 4 Bronchospasm|Grade 4 Bronchospasm	Life-threatening respiratory or hemodynamic compromise; intubation or urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145778>	C143204	Grade 4 Budd-Chiari Syndrome, CTCAE|Grade 4 Budd-Chiari syndrome|Grade 4 Budd-Chiari syndrome	Life-threatening consequences; moderate to severe encephalopathy; coma			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145779>	C143346	Grade 4 Bullous Dermatitis, CTCAE|Grade 4 Bullous dermatitis	Blisters covering >30% BSA; associated with fluid or electrolyte abnormalities; ICU care or burn unit indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145780>	C143349	Grade 4 Capillary Leak Syndrome, CTCAE|Grade 4 Capillary leak syndrome|Grade 4 Capillary leak syndrome	Life-threatening consequences			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145781>	C143351	Grade 4 Cardiac Arrest, CTCAE|Grade 4 Cardiac arrest|Grade 4 Cardiac arrest	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145782>	C143352	Grade 4 Cardiac Disorders - Other, Specify, CTCAE|Grade 4 Cardiac disorders - Other, specify|Grade 4 Cardiac disorders - Other, specify	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145783>	C146674	Grade 4 Cataract, CTCAE|Grade 4 Cataract|Grade 4 Cataract	Best corrected visual acuity of 20/200 or worse in the affected eye			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145784>	C143356	Grade 4 Catheter Related Infection, CTCAE|Grade 4 Catheter related infection|Grade 4 Catheter related infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145785>	C143357	Grade 4 CD4 Lymphocytes Decreased, CTCAE|Grade 4 CD4 lymphocytes decreased|Grade 4 CD4 lymphocytes decreased	<50/mm3; <0.05 x 10^9/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145786>	C143358	Grade 4 Cecal Hemorrhage, CTCAE|Grade 4 Cecal hemorrhage|Grade 4 Cecal hemorrhage	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145787>	C143359	Grade 4 Cecal Infection, CTCAE|Grade 4 Cecal infection|Grade 4 Cecal infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145788>	C143360	Grade 4 Central Nervous System Necrosis, CTCAE|Grade 4 Central nervous system necrosis|Grade 4 Central nervous system necrosis	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145789>	C143361	Grade 4 Cerebrospinal Fluid Leakage, CTCAE|Grade 4 Cerebrospinal fluid leakage|Grade 4 Cerebrospinal fluid leakage	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145790>	C143362	Grade 4 Cervicitis Infection, CTCAE|Grade 4 Cervicitis infection|Grade 4 Cervicitis infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145791>	C143223	Grade 4 Chest Wall Necrosis, CTCAE|Grade 4 Chest wall necrosis|Grade 4 Chest wall necrosis	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145792>	C143368	Grade 4 Cholesterol High, CTCAE|Grade 4 Cholesterol high|Grade 4 Cholesterol high	>500 mg/dL; >12.92 mmol/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145793>	C143369	Grade 4 Chronic Kidney Disease, CTCAE|Grade 4 Chronic kidney disease	eGFR or CrCl <15 ml/min/1.73 m2; dialysis or renal transplant indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145794>	C143199	Grade 4 Chylous Ascites, CTCAE|Grade 4 Chylous ascites|Grade 4 Chylous ascites	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145795>	C143373	Grade 4 Colonic Fistula, CTCAE|Grade 4 Colonic fistula|Grade 4 Colonic fistula	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145796>	C143374	Grade 4 Colonic Hemorrhage, CTCAE|Grade 4 Colonic hemorrhage	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145797>	C143375	Grade 4 Colonic Obstruction, CTCAE|Grade 4 Colonic obstruction|Grade 4 Colonic obstruction	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145798>	C143376	Grade 4 Colonic Perforation, CTCAE|Grade 4 Colonic perforation|Grade 4 Colonic perforation	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145799>	C143377	Grade 4 Colonic Stenosis, CTCAE|Grade 4 Colonic stenosis|Grade 4 Colonic stenosis	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14579>	C14421	129X1/SvJ Mouse|129X1/SvJ		129X1/SvJ Mouse		Mammal	
C1457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1457>	C1329	Yeast Artificial Chromosome|YAC|YAC Vector	A cloning vector based upon elements of yeast chromosomes.  At a minimum these include: yeast telomeres, a yeast centromere, and a yeast autonomously replicating sequence (ARS).  Such vectors are propagated in yeast and then transferred into a target eukaryotic cell where the yeast sequences can be recognized and will maintain the molecule through cell division.  These vectors can maintain extremely large amounts of foreign DNA.  YACs are maintained as linear molecules			Nucleic Acid, Nucleoside, or Nucleotide	
C145800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145800>	C143378	Grade 4 Colonic Ulcer, CTCAE|Grade 4 Colonic ulcer|Grade 4 Colonic ulcer	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145801>	C143380	Grade 4 Conduction Disorder, CTCAE|Grade 4 Conduction disorder	Life-threatening consequences			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145802>	C143382	Grade 4 Congenital, Familial and Genetic Disorders - Other, Specify, CTCAE|Grade 4 Congenital, familial and genetic disorders - Other, specify|Grade 4 Congenital, familial and genetic disorders - Other, specify	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145803>	C143383	Grade 4 Conjunctivitis Infective, CTCAE|Grade 4 Conjunctivitis infective|Grade 4 Conjunctivitis infective	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145804>	C143384	Grade 4 Conjunctivitis, CTCAE|Grade 4 Conjunctivitis|Grade 4 Conjunctivitis	Best corrected visual acuity of 20/200 or worse in the affected eye			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145805>	C143386	Grade 4 Corneal Infection, CTCAE|Grade 4 Corneal infection|Grade 4 Corneal infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145806>	C143387	Grade 4 Corneal Ulcer, CTCAE|Grade 4 Corneal ulcer|Grade 4 Corneal ulcer	Perforation in the affected eye			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145807>	C143389	Grade 4 CPK Increased, CTCAE|Grade 4 CPK increased	>10 x ULN			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145808>	C143390	Grade 4 Cranial Nerve Infection, CTCAE|Grade 4 Cranial nerve infection|Grade 4 Cranial nerve infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145809>	C143391	Grade 4 Creatinine Increased, CTCAE|Grade 4 Creatinine increased|Grade 4 Creatinine increased	>6.0 x ULN			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145810>	C143393	Grade 4 Cystitis Noninfective, CTCAE|Grade 4 Cystitis noninfective|Grade 4 Cystitis noninfective	Life-threatening consequences; urgent invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145811>	C143394	Grade 4 Cytokine Release Syndrome, CTCAE|Grade 4 Cytokine release syndrome|Grade 4 Cytokine release syndrome	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145812>	C143207	Grade 4 Cytomegalovirus Infection Reactivation, CTCAE|Grade 4 Cytomegalovirus infection reactivation|Grade 4 Cytomegalovirus infection reactivation	Life-threatening consequences; urgent intervention indicated; blindness			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145813>	C143395	Grade 4 Death Neonatal, CTCAE|Grade 4 Death neonatal|Grade 4 Death neonatal	Neonatal loss of life			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145814>	C143400	Grade 4 Delirium, CTCAE|Grade 4 Delirium|Grade 4 Delirium	Life-threatening consequences, threats of harm to self or others; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145815>	C143401	Grade 4 Delusions, CTCAE|Grade 4 Delusions|Grade 4 Delusions	Life-threatening consequences, threats of harm to self or others; hospitalization indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145816>	C143403	Grade 4 Depressed Level of Consciousness, CTCAE|Grade 4 Depressed level of consciousness|Grade 4 Depressed level of consciousness	Life-threatening consequences; coma; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145817>	C143405	Grade 4 Dermatitis Radiation, CTCAE|Grade 4 Dermatitis radiation|Grade 4 Dermatitis radiation	Life-threatening consequences; skin necrosis or ulceration of full thickness dermis; spontaneous bleeding from involved site; skin graft indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145818>	C143406	Grade 4 Device Related Infection, CTCAE|Grade 4 Device related infection|Grade 4 Device related infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145820>	C143414	Grade 4 Duodenal Hemorrhage, CTCAE|Grade 4 Duodenal hemorrhage|Grade 4 Duodenal hemorrhage	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145821>	C143415	Grade 4 Duodenal Infection, CTCAE|Grade 4 Duodenal infection|Grade 4 Duodenal infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145822>	C143416	Grade 4 Duodenal Obstruction, CTCAE|Grade 4 Duodenal obstruction|Grade 4 Duodenal obstruction	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145823>	C143417	Grade 4 Duodenal Perforation, CTCAE|Grade 4 Duodenal perforation|Grade 4 Duodenal perforation	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145824>	C143418	Grade 4 Duodenal Stenosis, CTCAE|Grade 4 Duodenal stenosis|Grade 4 Duodenal stenosis	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145825>	C143419	Grade 4 Duodenal Ulcer, CTCAE|Grade 4 Duodenal ulcer|Grade 4 Duodenal ulcer	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145826>	C143429	Grade 4 Ear and Labyrinth Disorders - Other, Specify, CTCAE|Grade 4 Ear and labyrinth disorders - Other, specify|Grade 4 Ear and labyrinth disorders - Other, specify	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145827>	C143431	Grade 4 Edema Cerebral, CTCAE|Grade 4 Edema cerebral	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145828>	C143436	Grade 4 Ejection Fraction Decreased, CTCAE|Grade 4 Ejection fraction decreased	Resting ejection fraction (EF) <20%			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145829>	C143437	Grade 4 Electrocardiogram QT Corrected Interval Prolonged, CTCAE|Grade 4 Electrocardiogram QT corrected interval prolonged|Grade 4 Electrocardiogram QT corrected interval prolonged	Life-threatening consequences; Torsade de pointes; polymorphic ventricular tachycardia			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145830>	C143438	Grade 4 Encephalitis Infection, CTCAE|Grade 4 Encephalitis infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145831>	C143439	Grade 4 Encephalomyelitis Infection, CTCAE|Grade 4 Encephalomyelitis infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145832>	C143441	Grade 4 Endocarditis Infective, CTCAE|Grade 4 Endocarditis infective|Grade 4 Endocarditis infective	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145833>	C143442	Grade 4 Endocrine Disorders - Other, Specify, CTCAE|Grade 4 Endocrine disorders - Other, specify|Grade 4 Endocrine disorders - Other, specify	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145834>	C143443	Grade 4 Endophthalmitis, CTCAE|Grade 4 Endophthalmitis|Grade 4 Endophthalmitis	Best corrected visual acuity of 20/200 or worse in the affected eye			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145835>	C143444	Grade 4 Enterocolitis Infectious, CTCAE|Grade 4 Enterocolitis infectious|Grade 4 Enterocolitis infectious	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145836>	C143445	Grade 4 Enterocolitis, CTCAE|Grade 4 Enterocolitis|Grade 4 Enterocolitis	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145837>	C143446	Grade 4 Enterovesical Fistula, CTCAE|Grade 4 Enterovesical fistula|Grade 4 Enterovesical fistula	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145838>	C143447	Grade 4 Epistaxis, CTCAE|Grade 4 Epistaxis|Grade 4 Epistaxis	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145839>	C143208	Grade 4 Epstein-Barr Virus Infection Reactivation, CTCAE|Grade 4 Epstein-Barr virus infection reactivation|Grade 4 Epstein-Barr virus infection reactivation	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145840>	C143449	Grade 4 Erythema Multiforme, CTCAE|Grade 4 Erythema multiforme|Grade 4 Erythema multiforme	Associated with fluid or electrolyte abnormalities; ICU care or burn unit indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145841>	C143450	Grade 4 Erythroderma, CTCAE|Grade 4 Erythroderma|Grade 4 Erythroderma	Erythema covering >90% BSA with associated fluid or electrolyte abnormalities; ICU care or burn unit indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145842>	C143451	Grade 4 Esophageal Anastomotic Leak, CTCAE|Grade 4 Esophageal anastomotic leak|Grade 4 Esophageal anastomotic leak	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145844>	C143453	Grade 4 Esophageal Hemorrhage, CTCAE|Grade 4 Esophageal hemorrhage|Grade 4 Esophageal hemorrhage	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145845>	C143454	Grade 4 Esophageal Infection, CTCAE|Grade 4 Esophageal infection|Grade 4 Esophageal infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145846>	C143455	Grade 4 Esophageal Necrosis, CTCAE|Grade 4 Esophageal necrosis|Grade 4 Esophageal necrosis	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145847>	C143456	Grade 4 Esophageal Obstruction, CTCAE|Grade 4 Esophageal obstruction|Grade 4 Esophageal obstruction	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145848>	C143458	Grade 4 Esophageal Perforation, CTCAE|Grade 4 Esophageal perforation|Grade 4 Esophageal perforation	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145849>	C143459	Grade 4 Esophageal Stenosis, CTCAE|Grade 4 Esophageal stenosis|Grade 4 Esophageal stenosis	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145850>	C143460	Grade 4 Esophageal Ulcer, CTCAE|Grade 4 Esophageal ulcer|Grade 4 Esophageal ulcer	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145851>	C143466	Grade 4 Extraocular Muscle Paresis, CTCAE|Grade 4 Extraocular muscle paresis|Grade 4 Extraocular muscle paresis	Bilateral paresis requiring head turning to see beyond central 60 degrees or double vision in central gaze			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145852>	C143467	Grade 4 Extrapyramidal Disorder, CTCAE|Grade 4 Extrapyramidal disorder|Grade 4 Extrapyramidal disorder	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145853>	C143468	Grade 4 Eye Disorders - Other, Specify, CTCAE|Grade 4 Eye disorders - Other, specify|Grade 4 Eye disorders - Other, specify	Sight-threatening consequences; urgent intervention indicated; best corrected visual acuity of 20/200 or worse in the affected eye			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145854>	C143469	Grade 4 Eye Infection, CTCAE|Grade 4 Eye infection|Grade 4 Eye infection	Life-threatening consequences; urgent intervention indicated; enucleation			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145855>	C143476	Grade 4 Fallopian Tube Anastomotic Leak, CTCAE|Grade 4 Fallopian tube anastomotic leak|Grade 4 Fallopian tube anastomotic leak	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145857>	C143484	Grade 4 Fetal Growth Retardation, CTCAE|Grade 4 Fetal growth retardation|Grade 4 Fetal growth retardation	<1% percentile of weight for gestational age			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145858>	C143485	Grade 4 Fever, CTCAE|Grade 4 Fever|Grade 4 Fever	>40.0 degrees C (>104.0 degrees F) for >24 hrs			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145859>	C143486	Grade 4 Fibrinogen Decreased, CTCAE|Grade 4 Fibrinogen decreased|Grade 4 Fibrinogen decreased	<0.25 x LLN; if abnormal, 75% decrease from baseline; absolute value <50 mg/dL			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145860>	C143487	Grade 4 Fibrosis Deep Connective Tissue, CTCAE|Grade 4 Fibrosis deep connective tissue|Grade 4 Fibrosis deep connective tissue	Generalized; associated with signs or symptoms of impaired breathing or feeding			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145861>	C143494	Grade 4 Forced Expiratory Volume Decreased, CTCAE|Grade 4 Forced expiratory volume decreased	<=49%			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145862>	C143497	Grade 4 Gallbladder Infection, CTCAE|Grade 4 Gallbladder infection|Grade 4 Gallbladder infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145863>	C143498	Grade 4 Gastric Anastomotic Leak, CTCAE|Grade 4 Gastric anastomotic leak|Grade 4 Gastric anastomotic leak	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145864>	C143499	Grade 4 Gastric Fistula, CTCAE|Grade 4 Gastric fistula|Grade 4 Gastric fistula	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145865>	C143500	Grade 4 Gastric Hemorrhage, CTCAE|Grade 4 Gastric hemorrhage|Grade 4 Gastric hemorrhage	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145866>	C143501	Grade 4 Gastric Necrosis, CTCAE|Grade 4 Gastric necrosis|Grade 4 Gastric necrosis	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145867>	C143502	Grade 4 Gastric Perforation, CTCAE|Grade 4 Gastric perforation|Grade 4 Gastric perforation	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145868>	C143503	Grade 4 Gastric Stenosis, CTCAE|Grade 4 Gastric stenosis|Grade 4 Gastric stenosis	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145869>	C143504	Grade 4 Gastric Ulcer, CTCAE|Grade 4 Gastric ulcer|Grade 4 Gastric ulcer	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145870>	C143507	Grade 4 Gastrointestinal Anastomotic Leak, CTCAE|Grade 4 Gastrointestinal anastomotic leak|Grade 4 Gastrointestinal anastomotic leak	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145871>	C143508	Grade 4 Gastrointestinal Disorders - Other, Specify, CTCAE|Grade 4 Gastrointestinal disorders - Other, specify|Grade 4 Gastrointestinal disorders - Other, specify	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145872>	C146637	Grade 4 Gastrointestinal Fistula, CTCAE|Grade 4 Gastrointestinal fistula|Grade 4 Gastrointestinal fistula	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145873>	C143511	Grade 4 Gastrointestinal Stoma Necrosis, CTCAE|Grade 4 Gastrointestinal stoma necrosis|Grade 4 Gastrointestinal stoma necrosis	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145874>	C143512	Grade 4 Gastroparesis, CTCAE|Grade 4 Gastroparesis|Grade 4 Gastroparesis	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145875>	C143513	Grade 4 General Disorders and Administration Site Conditions - Other, Specify, CTCAE|Grade 4 General disorders and administration site conditions - Other, specify|Grade 4 General disorders and administration site conditions - Other, specify	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145876>	C143202	Grade 4 Generalized Edema, CTCAE|Grade 4 Generalized edema|Grade 4 Generalized edema	Life-threatening consequences			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145877>	C143516	Grade 4 GGT Increased, CTCAE|Grade 4 GGT increased|Grade 4 GGT increased	>20.0 x ULN if baseline was normal or less than normal; >10.0 x baseline if baseline was >ULN			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145878>	C143518	Grade 4 Glossopharyngeal Nerve Disorder, CTCAE|Grade 4 Glossopharyngeal nerve disorder|Grade 4 Glossopharyngeal nerve disorder	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145879>	C143519	Grade 4 Glucose Intolerance, CTCAE|Grade 4 Glucose intolerance	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145880>	C143231	Grade 4 Guillain-Barre Syndrome, CTCAE|Grade 4 Guillain-Barre syndrome|Grade 4 Guillain-Barre syndrome	Life-threatening consequences; urgent intervention indicated; intubation			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145881>	C143523	Grade 4 Gum Infection, CTCAE|Grade 4 Gum infection|Grade 4 Gum infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145882>	C143525	Grade 4 Hallucinations, CTCAE|Grade 4 Hallucinations|Grade 4 Hallucinations	Life-threatening consequences, threats of harm to self or others; hospitalization indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145883>	C143528	Grade 4 Hearing Impaired, CTCAE|Grade 4 Hearing impaired|Grade 4 Hearing impaired	Adult: Nonservicable hearing; decrease in hearing to profound bilateral loss (absolute threshold >80 dB HL at 2 kHz and above); Pediatric: Audiologic indication for cochlear implant; >40 dB HL (i.e., 45 dB HL or more); SNHL at 2 kHz and above			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145884>	C143529	Grade 4 Heart Failure, CTCAE|Grade 4 Heart failure|Grade 4 Heart failure	Requiring inotropic support, mechanical circulatory support, or consideration of cardiac transplantation			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145885>	C143531	Grade 4 Hematosalpinx, CTCAE|Grade 4 Hematosalpinx|Grade 4 Hematosalpinx	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145886>	C143532	Grade 4 Hematuria, CTCAE|Grade 4 Hematuria|Grade 4 Hematuria	Life-threatening consequences; urgent invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145887>	C143536	Grade 4 Hemolytic Uremic Syndrome, CTCAE|Grade 4 Hemolytic uremic syndrome|Grade 4 Hemolytic uremic syndrome	Life-threatening consequences, (e.g., CNS hemorrhage or thrombosis/embolism or renal failure)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145888>	C143537	Grade 4 Hemorrhoidal Hemorrhage, CTCAE|Grade 4 Hemorrhoidal hemorrhage|Grade 4 Hemorrhoidal hemorrhage	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145889>	C143539	Grade 4 Hepatic Failure, CTCAE|Grade 4 Hepatic failure|Grade 4 Hepatic failure	Life-threatening consequences; moderate to severe encephalopathy; coma			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145890>	C143540	Grade 4 Hepatic Hemorrhage, CTCAE|Grade 4 Hepatic hemorrhage|Grade 4 Hepatic hemorrhage	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145891>	C143541	Grade 4 Hepatic Infection, CTCAE|Grade 4 Hepatic infection|Grade 4 Hepatic infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145892>	C143211	Grade 4 Hepatitis B Reactivation, CTCAE|Grade 4 Hepatitis B reactivation|Grade 4 Hepatitis B reactivation	Life-threatening consequences; urgent intervention indicated; severe decompensated liver function (e.g., coagulopathy, encephalopathy, coma)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145893>	C143543	Grade 4 Hepatitis Viral, CTCAE|Grade 4 Hepatitis viral|Grade 4 Hepatitis viral	Life-threatening consequences; severe decompensated liver function (e.g., coagulopathy, encephalopathy, coma)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145894>	C143544	Grade 4 Hepatobiliary Disorders - Other, Specify, CTCAE|Grade 4 Hepatobiliary disorders - Other, specify|Grade 4 Hepatobiliary disorders - Other, specify	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145895>	C143212	Grade 4 Herpes Simplex Reactivation, CTCAE|Grade 4 Herpes simplex reactivation|Grade 4 Herpes simplex reactivation	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145896>	C143546	Grade 4 Hip Fracture, CTCAE|Grade 4 Hip fracture	Life-threatening consequences; symptoms associated with neurovascular compromise			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145897>	C143551	Grade 4 Hypercalcemia, CTCAE|Grade 4 Hypercalcemia|Grade 4 Hypercalcemia	Corrected serum calcium of >13.5 mg/dL; >3.4 mmol/L; Ionized calcium >1.8 mmol/L; life-threatening consequences			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145898>	C143552	Grade 4 Hyperglycemia, CTCAE|Grade 4 Hyperglycemia	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145899>	C143554	Grade 4 Hyperkalemia, CTCAE|Grade 4 Hyperkalemia|Grade 4 Hyperkalemia	>7.0 mmol/L; life-threatening consequences			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C1458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1458>	C1594	Zorubicin Hydrochloride|(2S-cis)-Benzoic Acid[1-[4-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3-naphthacenyl]ethylidene]hydrazide|Benzoyl Hydrazone Daunorubicin|Daunorubicin Benzoylhydrazone Hydrochloride|RP 22,050 Hydrochloride|RP 22050|Rubidazone|Rubidazone|ZORUBICIN HYDROCHLORIDE|Zorubicin hydrochloride	A benzoyl-hydrazone derivative of the anthracycline antineoplastic antibiotic daunorubicin.  Zorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. (NCI04)			Antibiotic|Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C145900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145900>	C143221	Grade 4 Hyperlipidemia, CTCAE|Grade 4 Hyperlipidemia|Grade 4 Hyperlipidemia	Life-threatening consequences			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145901>	C143555	Grade 4 Hypermagnesemia, CTCAE|Grade 4 Hypermagnesemia|Grade 4 Hypermagnesemia	>8.0 mg/dL; >3.30 mmol/L; life-threatening consequences			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145902>	C143556	Grade 4 Hypernatremia, CTCAE|Grade 4 Hypernatremia|Grade 4 Hypernatremia	>160 mmol/L; life-threatening consequences			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145903>	C143222	Grade 4 Hyperphosphatemia, CTCAE|Grade 4 Hyperphosphatemia|Grade 4 Hyperphosphatemia	Life-threatening consequences; urgent intervention indicated (e.g., dialysis)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145904>	C143560	Grade 4 Hyperthyroidism, CTCAE|Grade 4 Hyperthyroidism|Grade 4 Hyperthyroidism	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145905>	C143562	Grade 4 Hypertriglyceridemia, CTCAE|Grade 4 Hypertriglyceridemia|Grade 4 Hypertriglyceridemia	>1000 mg/dL; >11.4 mmol/L; life-threatening consequences			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145906>	C143563	Grade 4 Hyperuricemia, CTCAE|Grade 4 Hyperuricemia|Grade 4 Hyperuricemia	Life-threatening consequences			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145907>	C143564	Grade 4 Hypoalbuminemia, CTCAE|Grade 4 Hypoalbuminemia|Grade 4 Hypoalbuminemia	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145908>	C143565	Grade 4 Hypocalcemia, CTCAE|Grade 4 Hypocalcemia|Grade 4 Hypocalcemia	Corrected serum calcium of <6.0 mg/dL; <1.5 mmol/L; Ionized calcium <0.8 mmol/L; life-threatening consequences			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145909>	C143567	Grade 4 Hypoglycemia, CTCAE|Grade 4 Hypoglycemia|Grade 4 Hypoglycemia	<30 mg/dL; <1.7 mmol/L; life-threatening consequences; seizures			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145910>	C143568	Grade 4 Hypohidrosis, CTCAE|Grade 4 Hypohidrosis|Grade 4 Hypohidrosis	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145911>	C143569	Grade 4 Hypokalemia, CTCAE|Grade 4 Hypokalemia|Grade 4 Hypokalemia	<2.5 mmol/L; life-threatening consequences			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145912>	C143570	Grade 4 Hypomagnesemia, CTCAE|Grade 4 Hypomagnesemia|Grade 4 Hypomagnesemia	<0.7 mg/dL; <0.3 mmol/L; life-threatening consequences			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145913>	C143571	Grade 4 Hyponatremia, CTCAE|Grade 4 Hyponatremia|Grade 4 Hyponatremia	<120 mmol/L; life-threatening consequences			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145914>	C143572	Grade 4 Hypoparathyroidism, CTCAE|Grade 4 Hypoparathyroidism|Grade 4 Hypoparathyroidism	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145915>	C143573	Grade 4 Hypophosphatemia, CTCAE|Grade 4 Hypophosphatemia|Grade 4 Hypophosphatemia	Life-threatening consequences			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145916>	C143193	Grade 4 Hypophysitis, CTCAE|Grade 4 Hypophysitis|Grade 4 Hypophysitis	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145917>	C143194	Grade 4 Hypopituitarism, CTCAE|Grade 4 Hypopituitarism|Grade 4 Hypopituitarism	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145918>	C143576	Grade 4 Hypothyroidism, CTCAE|Grade 4 Hypothyroidism|Grade 4 Hypothyroidism	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145922>	C146633	Grade 4 Ileal Perforation, CTCAE|Grade 4 Ileal perforation|Grade 4 Ileal perforation	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145923>	C143578	Grade 4 Ileal Stenosis, CTCAE|Grade 4 Ileal stenosis|Grade 4 Ileal stenosis	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145926>	C143580	Grade 4 Immune System Disorders - Other, Specify, CTCAE|Grade 4 Immune system disorders - Other, specify|Grade 4 Immune system disorders - Other, specify	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145927>	C143581	Grade 4 Infections and Infestations - Other, Specify, CTCAE|Grade 4 Infections and infestations - Other, specify|Grade 4 Infections and infestations - Other, specify	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145928>	C143582	Grade 4 Infective Myositis, CTCAE|Grade 4 Infective myositis|Grade 4 Infective myositis	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145929>	C143583	Grade 4 Infusion Related Reaction, CTCAE|Grade 4 Infusion related reaction|Grade 4 Infusion related reaction	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145930>	C143584	Grade 4 Infusion Site Extravasation, CTCAE|Grade 4 Infusion site extravasation|Grade 4 Infusion site extravasation	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145931>	C143585	Grade 4 Injection Site Reaction, CTCAE|Grade 4 Injection site reaction|Grade 4 Injection site reaction	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145932>	C143586	Grade 4 Injury To Carotid Artery, CTCAE|Grade 4 Injury to carotid artery|Grade 4 Injury to carotid artery	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145934>	C143587	Grade 4 Injury To Jugular Vein, CTCAE|Grade 4 Injury to jugular vein|Grade 4 Injury to jugular vein	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145935>	C143588	Grade 4 Injury To Superior Vena Cava, CTCAE|Grade 4 Injury to superior vena cava|Grade 4 Injury to superior vena cava	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145936>	C143589	Grade 4 Injury, Poisoning and Procedural Complications - Other, Specify, CTCAE|Grade 4 Injury, poisoning and procedural complications - Other, specify|Grade 4 Injury, poisoning and procedural complications - Other, specify	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145937>	C143592	Grade 4 Intestinal Stoma Leak, CTCAE|Grade 4 Intestinal stoma leak|Grade 4 Intestinal stoma leak	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145938>	C143593	Grade 4 Intestinal Stoma Obstruction, CTCAE|Grade 4 Intestinal stoma obstruction|Grade 4 Intestinal stoma obstruction	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145939>	C143594	Grade 4 Intestinal Stoma Site Bleeding, CTCAE|Grade 4 Intestinal stoma site bleeding|Grade 4 Intestinal stoma site bleeding	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145940>	C143595	Grade 4 Intra-Abdominal Hemorrhage, CTCAE|Grade 4 Intra-abdominal hemorrhage|Grade 4 Intra-abdominal hemorrhage	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145941>	C143596	Grade 4 Intracranial Hemorrhage, CTCAE|Grade 4 Intracranial hemorrhage	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145942>	C143597	Grade 4 Intraoperative Arterial Injury, CTCAE|Grade 4 Intraoperative arterial injury|Grade 4 Intraoperative arterial injury	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145943>	C143598	Grade 4 Intraoperative Breast Injury, CTCAE|Grade 4 Intraoperative breast injury|Grade 4 Intraoperative breast injury	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145944>	C143599	Grade 4 Intraoperative Cardiac Injury, CTCAE|Grade 4 Intraoperative cardiac injury|Grade 4 Intraoperative cardiac injury	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145945>	C143600	Grade 4 Intraoperative Ear Injury, CTCAE|Grade 4 Intraoperative ear injury|Grade 4 Intraoperative ear injury	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145946>	C143601	Grade 4 Intraoperative Endocrine Injury, CTCAE|Grade 4 Intraoperative endocrine injury|Grade 4 Intraoperative endocrine injury	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145947>	C143602	Grade 4 Intraoperative Gastrointestinal Injury, CTCAE|Grade 4 Intraoperative gastrointestinal injury|Grade 4 Intraoperative gastrointestinal injury	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145948>	C143603	Grade 4 Intraoperative Head and Neck Injury, CTCAE|Grade 4 Intraoperative head and neck injury|Grade 4 Intraoperative head and neck injury	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145949>	C143604	Grade 4 Intraoperative Hemorrhage, CTCAE|Grade 4 Intraoperative hemorrhage|Grade 4 Intraoperative hemorrhage	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14594>	C14421	I/LnJ Mouse|I/LnJ		I/LnJ Mouse		Mammal	
C145950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145950>	C143605	Grade 4 Intraoperative Hepatobiliary Injury, CTCAE|Grade 4 Intraoperative hepatobiliary injury|Grade 4 Intraoperative hepatobiliary injury	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145951>	C143606	Grade 4 Intraoperative Musculoskeletal Injury, CTCAE|Grade 4 Intraoperative musculoskeletal injury|Grade 4 Intraoperative musculoskeletal injury	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145952>	C143607	Grade 4 Intraoperative Neurological Injury, CTCAE|Grade 4 Intraoperative neurological injury|Grade 4 Intraoperative neurological injury	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145953>	C143608	Grade 4 Intraoperative Ocular Injury, CTCAE|Grade 4 Intraoperative ocular injury|Grade 4 Intraoperative ocular injury	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145954>	C143609	Grade 4 Intraoperative Renal Injury, CTCAE|Grade 4 Intraoperative renal injury|Grade 4 Intraoperative renal injury	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145955>	C143610	Grade 4 Intraoperative Reproductive Tract Injury, CTCAE|Grade 4 Intraoperative reproductive tract injury|Grade 4 Intraoperative reproductive tract injury	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145956>	C143611	Grade 4 Intraoperative Respiratory Injury, CTCAE|Grade 4 Intraoperative respiratory injury|Grade 4 Intraoperative respiratory injury	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145957>	C143612	Grade 4 Intraoperative Splenic Injury, CTCAE|Grade 4 Intraoperative splenic injury|Grade 4 Intraoperative splenic injury	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145958>	C143613	Grade 4 Intraoperative Urinary Injury, CTCAE|Grade 4 Intraoperative urinary injury|Grade 4 Intraoperative urinary injury	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145959>	C143614	Grade 4 Intraoperative Venous Injury, CTCAE|Grade 4 Intraoperative venous injury|Grade 4 Intraoperative venous injury	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14595>	C14421	BDP/J Mouse|BDP/J		BDP/J Mouse		Mammal	
C145960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145960>	C143615	Grade 4 Investigations - Other, Specify, CTCAE|Grade 4 Investigations - Other, specify|Grade 4 Investigations - Other, specify	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145964>	C143622	Grade 4 Jejunal Perforation, CTCAE|Grade 4 Jejunal perforation|Grade 4 Jejunal perforation	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145965>	C143623	Grade 4 Jejunal Stenosis, CTCAE|Grade 4 Jejunal stenosis|Grade 4 Jejunal stenosis	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145967>	C143626	Grade 4 Joint Infection, CTCAE|Grade 4 Joint infection|Grade 4 Joint infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145968>	C143631	Grade 4 Kidney Anastomotic Leak, CTCAE|Grade 4 Kidney anastomotic leak|Grade 4 Kidney anastomotic leak	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145969>	C143632	Grade 4 Kidney Infection, CTCAE|Grade 4 Kidney infection|Grade 4 Kidney infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145970>	C143635	Grade 4 Large Intestinal Anastomotic Leak, CTCAE|Grade 4 Large intestinal anastomotic leak|Grade 4 Large intestinal anastomotic leak	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145971>	C143636	Grade 4 Laryngeal Edema, CTCAE|Grade 4 Laryngeal edema|Grade 4 Laryngeal edema	Life-threatening airway compromise; urgent intervention indicated (e.g., tracheotomy or intubation)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145974>	C143638	Grade 4 Laryngeal Mucositis, CTCAE|Grade 4 Laryngeal mucositis|Grade 4 Laryngeal mucositis	Life-threatening airway compromise; urgent intervention indicated (e.g., tracheotomy or intubation)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145975>	C143639	Grade 4 Laryngeal Obstruction, CTCAE|Grade 4 Laryngeal obstruction|Grade 4 Laryngeal obstruction	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145976>	C143640	Grade 4 Laryngeal Stenosis, CTCAE|Grade 4 Laryngeal stenosis|Grade 4 Laryngeal stenosis	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145977>	C143641	Grade 4 Laryngitis, CTCAE|Grade 4 Laryngitis|Grade 4 Laryngitis	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145978>	C143642	Grade 4 Laryngopharyngeal Dysesthesia, CTCAE|Grade 4 Laryngopharyngeal dysesthesia|Grade 4 Laryngopharyngeal dysesthesia	Life-threatening consequences			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145979>	C143643	Grade 4 Laryngospasm, CTCAE|Grade 4 Laryngospasm|Grade 4 Laryngospasm	Persistent or severe episodes associated with syncope; urgent intervention indicated (e.g., fiberoptic laryngoscopy, intubation, botox injection)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145980>	C143646	Grade 4 Leukemia Secondary To Oncology Chemotherapy, CTCAE|Grade 4 Leukemia secondary to oncology chemotherapy|Grade 4 Leukemia secondary to oncology chemotherapy	Present			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145981>	C143647	Grade 4 Leukocytosis, CTCAE|Grade 4 Leukocytosis|Grade 4 Leukocytosis	Clinical manifestations of leucostasis; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145982>	C143648	Grade 4 Leukoencephalopathy, CTCAE|Grade 4 Leukoencephalopathy|Grade 4 Leukoencephalopathy	Life-threatening consequences; extensive T2/FLAIR hyperintensities, involving periventricular white matter involving most of susceptible areas of cerebrum +/- moderate to severe increase in SAS and/or moderate to severe ventriculomegaly			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145983>	C143652	Grade 4 Lipase Increased, CTCAE|Grade 4 Lipase increased|Grade 4 Lipase increased	>5.0 x ULN and with signs or symptoms			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145984>	C143656	Grade 4 Lower Gastrointestinal Hemorrhage, CTCAE|Grade 4 Lower gastrointestinal hemorrhage	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145985>	C143657	Grade 4 Lung Infection, CTCAE|Grade 4 Lung infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145986>	C143658	Grade 4 Lymph Gland Infection, CTCAE|Grade 4 Lymph gland infection|Grade 4 Lymph gland infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145987>	C143659	Grade 4 Lymph Leakage, CTCAE|Grade 4 Lymph leakage|Grade 4 Lymph leakage	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145988>	C143662	Grade 4 Lymphocyte Count Decreased, CTCAE|Grade 4 Lymphocyte count decreased	<200/mm3; <0.2 x 10e9/L			Finding	CTCAE Adverse Events Version 5.0 Terminology
C145989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145989>	C143666	Grade 4 Mania, CTCAE|Grade 4 Mania|Grade 4 Mania	Life-threatening consequences, threats of harm to self or others; hospitalization indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14598>	C14421	P/J Mouse|P/J		P/J Mouse		Mammal	
C145991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145991>	C143667	Grade 4 Mediastinal Infection, CTCAE|Grade 4 Mediastinal infection|Grade 4 Mediastinal infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145992>	C143669	Grade 4 Meningismus, CTCAE|Grade 4 Meningismus|Grade 4 Meningismus	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145993>	C143670	Grade 4 Meningitis, CTCAE|Grade 4 Meningitis|Grade 4 Meningitis	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145994>	C143671	Grade 4 Menorrhagia, CTCAE|Grade 4 Menorrhagia|Grade 4 Menorrhagia	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145995>	C143672	Grade 4 Metabolism and Nutrition Disorders - Other, Specify, CTCAE|Grade 4 Metabolism and nutrition disorders - Other, specify|Grade 4 Metabolism and nutrition disorders - Other, specify	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145996>	C143191	Grade 4 Methemoglobinemia, CTCAE|Grade 4 Methemoglobinemia|Grade 4 Methemoglobinemia	Life-threatening consequences			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145997>	C143673	Grade 4 Middle Ear Inflammation, CTCAE|Grade 4 Middle ear inflammation|Grade 4 Middle ear inflammation	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C145998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C145998>	C143674	Grade 4 Mitral Valve Disease, CTCAE|Grade 4 Mitral valve disease|Grade 4 Mitral valve disease	Life-threatening consequences; urgent intervention indicated (e.g., valve replacement, valvuloplasty)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C1459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1459>	C2259	Liatermin|GDNF|Glial Cell-Line Derived Neurotrophic Factor|LIATERMIN|Recombinant Glial Cell-Line Derived Neurotrophic Factor	A recombinant therapeutic agent which is chemically identical to or similar to endogenous glial cell line-derived neurotrophic factor (GDNF).  GDNF is a glycosylated, disulfide-bonded homodimer distantly related member of the transforming growth factor-beta superfamily.  This agent is important in the development and maintenance of dopamine neurons, has restorative effects in a wide variety of rodent and primate models of Parkinson disease, and may have utility in the treatment of Parkinson's disease, which is marked by progressive degeneration of midbrain dopaminergic neurons. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C146001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146001>	C143678	Grade 4 Mucosal Infection, CTCAE|Grade 4 Mucosal infection|Grade 4 Mucosal infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146002>	C143679	Grade 4 Mucositis Oral, CTCAE|Grade 4 Mucositis oral|Grade 4 Mucositis oral	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146003>	C143680	Grade 4 Multi-Organ Failure, CTCAE|Grade 4 Multi-organ failure|Grade 4 Multi-organ failure	Life-threatening consequences (e.g., vasopressor dependent and oliguric or anuric or ischemic colitis or lactic acidosis)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146004>	C143686	Grade 4 Musculoskeletal and Connective Tissue Disorder - Other, Specify, CTCAE|Grade 4 Musculoskeletal and connective tissue disorder - Other, specify|Grade 4 Musculoskeletal and connective tissue disorder - Other, specify	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146005>	C143232	Grade 4 Myasthenia Gravis, CTCAE|Grade 4 Myasthenia gravis|Grade 4 Myasthenia gravis	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146006>	C143690	Grade 4 Myelodysplastic Syndrome, CTCAE|Grade 4 Myelodysplastic syndrome|Grade 4 Myelodysplastic syndrome	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146007>	C143691	Grade 4 Myocardial Infarction, CTCAE|Grade 4 Myocardial infarction	Life-threatening consequences; hemodynamically unstable			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146008>	C143700	Grade 4 Neck Edema, CTCAE|Grade 4 Neck edema	Vascular or respiratory impairment requiring urgent intervention			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146009>	C143701	Grade 4 Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other, Specify, CTCAE|Grade 4 Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify|Grade 4 Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146010>	C143239	Grade 4 Nephrotic Syndrome, CTCAE|Grade 4 Nephrotic syndrome|Grade 4 Nephrotic syndrome	Life-threatening consequences; urgent intervention indicated; renal replacement therapy; anasarca			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146011>	C143702	Grade 4 Nervous System Disorders - Other, Specify, CTCAE|Grade 4 Nervous system disorders - Other, specify|Grade 4 Nervous system disorders - Other, specify	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146012>	C143704	Grade 4 Neutrophil Count Decreased, CTCAE|Grade 4 Neutrophil count decreased	<500/mm3; <0.5 x 10e9/L			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146013>	C143705	Grade 4 Night Blindness, CTCAE|Grade 4 Night blindness	Best corrected visual acuity of 20/200 or worse in the affected eye			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146014>	C143710	Grade 4 Obstruction Gastric, CTCAE|Grade 4 Obstruction gastric|Grade 4 Obstruction gastric	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146015>	C143714	Grade 4 Optic Nerve Disorder, CTCAE|Grade 4 Optic nerve disorder|Grade 4 Optic nerve disorder	Best corrected visual acuity of 20/200 or worse in the affected eye			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146016>	C143715	Grade 4 Oral Cavity Fistula, CTCAE|Grade 4 Oral cavity fistula|Grade 4 Oral cavity fistula	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146018>	C143717	Grade 4 Osteonecrosis of Jaw, CTCAE|Grade 4 Osteonecrosis of jaw|Grade 4 Osteonecrosis of jaw	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146019>	C143225	Grade 4 Osteonecrosis, CTCAE|Grade 4 Osteonecrosis|Grade 4 Osteonecrosis	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146020>	C143719	Grade 4 Otitis Externa, CTCAE|Grade 4 Otitis externa|Grade 4 Otitis externa	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146021>	C143720	Grade 4 Otitis Media, CTCAE|Grade 4 Otitis media|Grade 4 Otitis media	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146023>	C143721	Grade 4 Ovarian Infection, CTCAE|Grade 4 Ovarian infection|Grade 4 Ovarian infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146024>	C143722	Grade 4 Ovarian Rupture, CTCAE|Grade 4 Ovarian rupture|Grade 4 Ovarian rupture	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146025>	C143728	Grade 4 Pancreas Infection, CTCAE|Grade 4 Pancreas infection|Grade 4 Pancreas infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146026>	C143729	Grade 4 Pancreatic Anastomotic Leak, CTCAE|Grade 4 Pancreatic anastomotic leak|Grade 4 Pancreatic anastomotic leak	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146027>	C143730	Grade 4 Pancreatic Duct Stenosis, CTCAE|Grade 4 Pancreatic duct stenosis|Grade 4 Pancreatic duct stenosis	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146030>	C143732	Grade 4 Pancreatic Necrosis, CTCAE|Grade 4 Pancreatic necrosis|Grade 4 Pancreatic necrosis	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146031>	C143734	Grade 4 Papilledema, CTCAE|Grade 4 Papilledema|Grade 4 Papilledema	Best corrected visual acuity of 20/200 or worse in the affected eye			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146032>	C143735	Grade 4 Papulopustular Rash, CTCAE|Grade 4 Papulopustular rash	Life-threatening consequences			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146033>	C143738	Grade 4 Paroxysmal Atrial Tachycardia, CTCAE|Grade 4 Paroxysmal atrial tachycardia|Grade 4 Paroxysmal atrial tachycardia	Life-threatening consequences; incompletely controlled medically; cardioversion indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146034>	C143740	Grade 4 Pelvic Infection, CTCAE|Grade 4 Pelvic infection|Grade 4 Pelvic infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146035>	C143741	Grade 4 Penile Infection, CTCAE|Grade 4 Penile infection|Grade 4 Penile infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146036>	C143742	Grade 4 Perforation Bile Duct, CTCAE|Grade 4 Perforation bile duct|Grade 4 Perforation bile duct	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146037>	C143743	Grade 4 Pericardial Effusion, CTCAE|Grade 4 Pericardial effusion|Grade 4 Pericardial effusion	Life-threatening consequences; hospitalization			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146038>	C143744	Grade 4 Pericardial Tamponade, CTCAE|Grade 4 Pericardial tamponade|Grade 4 Pericardial tamponade	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146039>	C143748	Grade 4 Periorbital Infection, CTCAE|Grade 4 Periorbital infection|Grade 4 Periorbital infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146040>	C143749	Grade 4 Peripheral Ischemia, CTCAE|Grade 4 Peripheral ischemia|Grade 4 Peripheral ischemia	Life-threatening consequences; major tissue loss; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146041>	C143750	Grade 4 Peripheral Motor Neuropathy, CTCAE|Grade 4 Peripheral motor neuropathy|Grade 4 Peripheral motor neuropathy	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146042>	C143751	Grade 4 Peripheral Nerve Infection, CTCAE|Grade 4 Peripheral nerve infection|Grade 4 Peripheral nerve infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146043>	C143752	Grade 4 Peripheral Sensory Neuropathy, CTCAE|Grade 4 Peripheral sensory neuropathy|Grade 4 Peripheral sensory neuropathy	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146044>	C143753	Grade 4 Peritoneal Infection, CTCAE|Grade 4 Peritoneal infection|Grade 4 Peritoneal infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146046>	C143754	Grade 4 Personality Change, CTCAE|Grade 4 Personality change|Grade 4 Personality change	Life-threatening consequences, threats of harm to self or others; hospitalization indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146047>	C143755	Grade 4 Pharyngeal Anastomotic Leak, CTCAE|Grade 4 Pharyngeal anastomotic leak|Grade 4 Pharyngeal anastomotic leak	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14604>	C14421	DBA/2 Mouse|DBA/2|DBA/2	Derived from crosses made by Little in 1929-1930 between DBA progenitors. The DBA/2 mouse has a d H2 haplotype and carries the Cdh23ahl mutation that results in a progressive hearing loss beginning at 3-4 weeks of age and severe hearing loss after 3 months of age. Alleles GpnmbR150X and Tyrp1isa contribute to an eye phenotype that closely resembles human hereditary glaucoma. The DBA/2 mouse strain shows severe intolerance to alcohol and morphine and is naturally CD94 deficient.	DBA/2 Mouse		Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C146050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146050>	C143756	Grade 4 Pharyngeal Mucositis, CTCAE|Grade 4 Pharyngeal mucositis|Grade 4 Pharyngeal mucositis	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146052>	C143757	Grade 4 Pharyngeal Stenosis, CTCAE|Grade 4 Pharyngeal stenosis|Grade 4 Pharyngeal stenosis	Life-threatening airway compromise; urgent intervention indicated (e.g., tracheotomy or intubation)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146053>	C143758	Grade 4 Pharyngitis, CTCAE|Grade 4 Pharyngitis|Grade 4 Pharyngitis	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146054>	C143760	Grade 4 Phlebitis Infective, CTCAE|Grade 4 Phlebitis infective|Grade 4 Phlebitis infective	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146055>	C143764	Grade 4 Platelet Count Decreased, CTCAE|Grade 4 Platelet count decreased	<25,000/mm3; <25.0 x 10e9/L			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146056>	C143765	Grade 4 Pleural Effusion, CTCAE|Grade 4 Pleural effusion|Grade 4 Pleural effusion	Life-threatening respiratory or hemodynamic compromise; intubation or urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146058>	C143766	Grade 4 Pleural Infection, CTCAE|Grade 4 Pleural infection|Grade 4 Pleural infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146059>	C143767	Grade 4 Pneumonitis, CTCAE|Grade 4 Pneumonitis|Grade 4 Pneumonitis	Life-threatening respiratory compromise; urgent intervention indicated (e.g., tracheotomy or intubation)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146060>	C143769	Grade 4 Portal Hypertension, CTCAE|Grade 4 Portal hypertension|Grade 4 Portal hypertension	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146061>	C143770	Grade 4 Portal Vein Thrombosis, CTCAE|Grade 4 Portal vein thrombosis|Grade 4 Portal vein thrombosis	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146062>	C143772	Grade 4 Postoperative Hemorrhage, CTCAE|Grade 4 Postoperative hemorrhage|Grade 4 Postoperative hemorrhage	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146063>	C143773	Grade 4 Postoperative Thoracic Procedure Complication, CTCAE|Grade 4 Postoperative thoracic procedure complication|Grade 4 Postoperative thoracic procedure complication	Life-threatening airway compromise; urgent intervention indicated (e.g., tracheotomy or intubation)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146064>	C143236	Grade 4 Pregnancy Loss, CTCAE|Grade 4 Pregnancy loss|Grade 4 Pregnancy loss	Fetal loss at any gestational age			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146065>	C143775	Grade 4 Pregnancy, Puerperium and Perinatal Conditions - Other, Specify, CTCAE|Grade 4 Pregnancy, puerperium and perinatal conditions - Other, specify|Grade 4 Pregnancy, puerperium and perinatal conditions - Other, specify	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146066>	C143776	Grade 4 Premature Delivery, CTCAE|Grade 4 Premature delivery|Grade 4 Premature delivery	Delivery of a liveborn infant at 24 weeks of gestation or less			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146067>	C143781	Grade 4 Prolapse of Intestinal Stoma, CTCAE|Grade 4 Prolapse of intestinal stoma|Grade 4 Prolapse of intestinal stoma	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146068>	C143782	Grade 4 Prolapse of Urostomy, CTCAE|Grade 4 Prolapse of urostomy|Grade 4 Prolapse of urostomy	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146069>	C143783	Grade 4 Prostate Infection, CTCAE|Grade 4 Prostate infection|Grade 4 Prostate infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14606>	C14421	DBA/1 Mouse|DBA/1|DBA/1	Derived from crosses made by Little in 1929-1930 between DBA progenitors. The DBA/1 mouse has a q H2 haplotype and carries the Cdh23^ahl mutation that results in progressive hearing loss after 10 months of age. The DBA/1 and DBA/2 mice differ at loci Car2, Ce2, Hc, H2, If1, Lsh, Tla, and Qa3. The strain is commonly used as a model for rheumatoid arthritis as it mimics hallmarks of the human disease when immunized with type II collagen.	DBA/1 Mouse		Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C146071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146071>	C143787	Grade 4 Psychiatric Disorders - Other, Specify, CTCAE|Grade 4 Psychiatric disorders - Other, specify|Grade 4 Psychiatric disorders - Other, specify	Life-threatening consequences; hospitalization or urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146072>	C143788	Grade 4 Psychosis, CTCAE|Grade 4 Psychosis|Grade 4 Psychosis	Life-threatening consequences, threats of harm to self or others; hospitalization indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146073>	C143789	Grade 4 Pulmonary Edema, CTCAE|Grade 4 Pulmonary edema|Grade 4 Pulmonary edema	Life-threatening respiratory compromise; urgent intervention or intubation with ventilatory support indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146074>	C143790	Grade 4 Pulmonary Fibrosis, CTCAE|Grade 4 Pulmonary fibrosis|Grade 4 Pulmonary fibrosis	Life-threatening consequences (e.g., hemodynamic/pulmonary complications); intubation with ventilatory support indicated; radiographic pulmonary fibrosis >75% with severe honeycombing			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146075>	C143791	Grade 4 Pulmonary Fistula, CTCAE|Grade 4 Pulmonary fistula|Grade 4 Pulmonary fistula	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146076>	C143793	Grade 4 Pulmonary Valve Disease, CTCAE|Grade 4 Pulmonary valve disease|Grade 4 Pulmonary valve disease	Life-threatening consequences; urgent intervention indicated (e.g., valve replacement, valvuloplasty)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146077>	C143795	Grade 4 Pyramidal Tract Syndrome, CTCAE|Grade 4 Pyramidal tract syndrome|Grade 4 Pyramidal tract syndrome	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146078>	C143796	Grade 4 Radiation Recall Reaction (Dermatologic), CTCAE|Grade 4 Radiation recall reaction (dermatologic)|Grade 4 Radiation recall reaction (dermatologic)	Life-threatening consequences; skin necrosis or ulceration of full thickness dermis; spontaneous bleeding from involved site; skin graft indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146079>	C143797	Grade 4 Radiculitis, CTCAE|Grade 4 Radiculitis|Grade 4 Radiculitis	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146080>	C143798	Grade 4 Rash Acneiform, CTCAE|Grade 4 Rash acneiform	Life-threatening consequences; papules and/or pustules covering any % BSA, which may or may not be associated with symptoms of pruritus or tenderness and are associated with extensive superinfection with IV antibiotics indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146081>	C143801	Grade 4 Rectal Anastomotic Leak, CTCAE|Grade 4 Rectal anastomotic leak|Grade 4 Rectal anastomotic leak	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146084>	C143802	Grade 4 Rectal Mucositis, CTCAE|Grade 4 Rectal mucositis|Grade 4 Rectal mucositis	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146088>	C143803	Grade 4 Rectal Stenosis, CTCAE|Grade 4 Rectal stenosis|Grade 4 Rectal stenosis	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146090>	C143804	Grade 4 Recurrent Laryngeal Nerve Palsy, CTCAE|Grade 4 Recurrent laryngeal nerve palsy|Grade 4 Recurrent laryngeal nerve palsy	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146091>	C143805	Grade 4 Renal and Urinary Disorders - Other, Specify, CTCAE|Grade 4 Renal and urinary disorders - Other, specify|Grade 4 Renal and urinary disorders - Other, specify	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146092>	C143806	Grade 4 Renal Calculi, CTCAE|Grade 4 Renal calculi|Grade 4 Renal calculi	Life-threatening consequences; urgent invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146094>	C143808	Grade 4 Reproductive System and Breast Disorders - Other, Specify, CTCAE|Grade 4 Reproductive system and breast disorders - Other, specify|Grade 4 Reproductive system and breast disorders - Other, specify	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146095>	C143809	Grade 4 Respiratory Failure, CTCAE|Grade 4 Respiratory failure|Grade 4 Respiratory failure	Life-threatening consequences; urgent intervention, intubation, or ventilatory support indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146096>	C143810	Grade 4 Respiratory, Thoracic and Mediastinal Disorders - Other, Specify, CTCAE|Grade 4 Respiratory, thoracic and mediastinal disorders - Other, specify|Grade 4 Respiratory, thoracic and mediastinal disorders - Other, specify	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146097>	C146632	Grade 4 Retroperitoneal Hemorrhage, CTCAE|Grade 4 Retroperitoneal hemorrhage	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146098>	C143818	Grade 4 Reversible Posterior Leukoencephalopathy Syndrome, CTCAE|Grade 4 Reversible posterior leukoencephalopathy syndrome|Grade 4 Reversible posterior leukoencephalopathy syndrome	Life-threatening consequences			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146099>	C143226	Grade 4 Rhabdomyolysis, CTCAE|Grade 4 Rhabdomyolysis|Grade 4 Rhabdomyolysis	Life-threatening consequences; dialysis			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C1460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1460>	C281|C2019	Sorivudine|(+)-1-Beta-D-arabinofuranosyl-5-[(E)-2-bromovi- ny1] uracil|(E)-1-beta-D-arabinofuranosyl-5-(2-bromoethenyl)-2,4(1H,3H)-pyrimidinedione|1-Beta-D-arabinofuranosyl-(E)-5-(2-bromovinyl)uracil|2,4(1H,3H)-pyrimidinedione, 1-beta-D-arabinofuranosyl-5-(2-bromoethenyl)|5-(2-bromovinyl)-1-beta-D- arabinofuranosyluracil|5-Bromovinyl-araU|BV-araU|Bravavir|SORIVUDINE|SQ 32756|Usevir|YN-72|sorivudine	A synthetic thymidine analogue with potent antiviral activity against herpes simplex and varicella zoster viruses. Sorivudine is phosphorylated into triphosphate form within the cells; this metabolite interferes with viral DNA replication by inhibiting DNA polymerase activity without been incorporated into elongating viral DNA. Due to the dangerous effects of drug-drug interactions via its metabolite, sorivudine has been removed from the market.			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C146100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146100>	C143821	Grade 4 Salivary Duct Inflammation, CTCAE|Grade 4 Salivary duct inflammation|Grade 4 Salivary duct inflammation	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146101>	C143822	Grade 4 Salivary Gland Infection, CTCAE|Grade 4 Salivary gland infection|Grade 4 Salivary gland infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146102>	C143823	Grade 4 Scleral Disorder, CTCAE|Grade 4 Scleral disorder|Grade 4 Scleral disorder	Best corrected visual acuity of 20/200 or worse in the affected eye			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146103>	C143825	Grade 4 Scrotal Infection, CTCAE|Grade 4 Scrotal infection|Grade 4 Scrotal infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146104>	C143827	Grade 4 Sepsis, CTCAE|Grade 4 Sepsis|Grade 4 Sepsis	Life-threatening consequences			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146105>	C143829	Grade 4 Serum Amylase Increased, CTCAE|Grade 4 Serum amylase increased|Grade 4 Serum amylase increased	>5.0 x ULN and with signs or symptoms			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146106>	C146642	Grade 4 Serum Sickness, CTCAE|Grade 4 Serum sickness|Grade 4 Serum sickness	Life-threatening consequences; pressor or ventilatory support indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146107>	C143213	Grade 4 Shingles, CTCAE|Grade 4 Shingles|Grade 4 Shingles	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146108>	C143831	Grade 4 Sinus Disorder, CTCAE|Grade 4 Sinus disorder|Grade 4 Sinus disorder	Necrosis of soft tissue or bone; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146109>	C143832	Grade 4 Sinusitis, CTCAE|Grade 4 Sinusitis|Grade 4 Sinusitis	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146110>	C143205	Grade 4 Sinusoidal Obstruction Syndrome, CTCAE|Grade 4 Sinusoidal obstruction syndrome|Grade 4 Sinusoidal obstruction syndrome	Life-threatening consequences (e.g., ventilatory support, dialysis, plasmapheresis, peritoneal drainage)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146111>	C143833	Grade 4 Skin and Subcutaneous Tissue Disorders - Other, Specify, CTCAE|Grade 4 Skin and subcutaneous tissue disorders - Other, specify|Grade 4 Skin and subcutaneous tissue disorders - Other, specify	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146112>	C143837	Grade 4 Skin Induration, CTCAE|Grade 4 Skin induration|Grade 4 Skin induration	Generalized; associated with signs or symptoms of impaired breathing or feeding			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146113>	C143838	Grade 4 Skin Infection, CTCAE|Grade 4 Skin infection|Grade 4 Skin infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146114>	C143839	Grade 4 Skin Ulceration, CTCAE|Grade 4 Skin ulceration|Grade 4 Skin ulceration	Any size ulcer with extensive destruction, tissue necrosis, or damage to muscle, bone, or supporting structures with or without full thickness skin loss			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146115>	C143840	Grade 4 Sleep Apnea, CTCAE|Grade 4 Sleep apnea|Grade 4 Sleep apnea	Cardiovascular or neuropsychiatric symptoms; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146116>	C143841	Grade 4 Small Intestinal Anastomotic Leak, CTCAE|Grade 4 Small intestinal anastomotic leak|Grade 4 Small intestinal anastomotic leak	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146117>	C143842	Grade 4 Small Intestinal Mucositis, CTCAE|Grade 4 Small intestinal mucositis|Grade 4 Small intestinal mucositis	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146118>	C143843	Grade 4 Small Intestinal Obstruction, CTCAE|Grade 4 Small intestinal obstruction|Grade 4 Small intestinal obstruction	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146119>	C146635	Grade 4 Small Intestinal Perforation, CTCAE|Grade 4 Small intestinal perforation|Grade 4 Small intestinal perforation	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146120>	C143844	Grade 4 Small Intestinal Stenosis, CTCAE|Grade 4 Small intestinal stenosis|Grade 4 Small intestinal stenosis	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146121>	C143845	Grade 4 Small Intestine Infection, CTCAE|Grade 4 Small intestine infection|Grade 4 Small intestine infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146122>	C143846	Grade 4 Small Intestine Ulcer, CTCAE|Grade 4 Small intestine ulcer|Grade 4 Small intestine ulcer	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146123>	C143848	Grade 4 Social Circumstances - Other, Specify, CTCAE|Grade 4 Social circumstances - Other, specify|Grade 4 Social circumstances - Other, specify	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146124>	C143849	Grade 4 Soft Tissue Infection, CTCAE|Grade 4 Soft tissue infection|Grade 4 Soft tissue infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146125>	C143850	Grade 4 Soft Tissue Necrosis Lower Limb, CTCAE|Grade 4 Soft tissue necrosis lower limb|Grade 4 Soft tissue necrosis lower limb	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146126>	C143851	Grade 4 Soft Tissue Necrosis Upper Limb, CTCAE|Grade 4 Soft tissue necrosis upper limb|Grade 4 Soft tissue necrosis upper limb	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146127>	C143852	Grade 4 Somnolence, CTCAE|Grade 4 Somnolence|Grade 4 Somnolence	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146128>	C143854	Grade 4 Spasticity, CTCAE|Grade 4 Spasticity|Grade 4 Spasticity	Life-threatening consequences; unable to move active or passive range of motion			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146129>	C143855	Grade 4 Spermatic Cord Anastomotic Leak, CTCAE|Grade 4 Spermatic cord anastomotic leak|Grade 4 Spermatic cord anastomotic leak	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14612>	C14421	SM/J Mouse|SM/J		SM/J Mouse		Mammal	
C146130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146130>	C143233	Grade 4 Spinal Cord Compression, CTCAE|Grade 4 Spinal cord compression	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146131>	C143856	Grade 4 Spinal Fracture, CTCAE|Grade 4 Spinal fracture	Life-threatening consequences; symptoms associated with neurovascular compromise			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146132>	C143857	Grade 4 Splenic Infection, CTCAE|Grade 4 Splenic infection|Grade 4 Splenic infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146133>	C143858	Grade 4 Stenosis of Gastrointestinal Stoma, CTCAE|Grade 4 Stenosis of gastrointestinal stoma|Grade 4 Stenosis of gastrointestinal stoma	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146134>	C143859	Grade 4 Stevens-Johnson Syndrome, CTCAE|Grade 4 Stevens-Johnson syndrome|Grade 4 Stevens-Johnson syndrome	Skin sloughing covering >=10% BSA; life-threatening consequences			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146135>	C143860	Grade 4 Stoma Site Infection, CTCAE|Grade 4 Stoma site infection|Grade 4 Stoma site infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146136>	C143861	Grade 4 Stridor, CTCAE|Grade 4 Stridor|Grade 4 Stridor	Life-threatening airway compromise; urgent intervention indicated (e.g., tracheotomy or intubation)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146137>	C143862	Grade 4 Stroke, CTCAE|Grade 4 Stroke|Grade 4 Stroke	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146138>	C143864	Grade 4 Suicidal Ideation, CTCAE|Grade 4 Suicidal ideation|Grade 4 Suicidal ideation	Specific plan to commit suicide with serious intent to die which requires hospitalization			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146139>	C143865	Grade 4 Suicide Attempt, CTCAE|Grade 4 Suicide attempt|Grade 4 Suicide attempt	Suicide attempt with intent to die which requires hospitalization			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146140>	C143866	Grade 4 Superficial Soft Tissue Fibrosis, CTCAE|Grade 4 Superficial soft tissue fibrosis|Grade 4 Superficial soft tissue fibrosis	Generalized; associated with signs or symptoms of impaired breathing or feeding			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146141>	C143868	Grade 4 Superior Vena Cava Syndrome, CTCAE|Grade 4 Superior vena cava syndrome|Grade 4 Superior vena cava syndrome	Life-threatening consequences; urgent multi-modality intervention indicated (e.g., lysis, thrombectomy, surgery)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146142>	C143869	Grade 4 Surgical and Medical Procedures - Other, Specify, CTCAE|Grade 4 Surgical and medical procedures - Other, specify|Grade 4 Surgical and medical procedures - Other, specify	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146143>	C143872	Grade 4 Testicular Disorder, CTCAE|Grade 4 Testicular disorder|Grade 4 Testicular disorder	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146145>	C143873	Grade 4 Thromboembolic Event, CTCAE|Grade 4 Thromboembolic event	Life-threatening consequences with hemodynamic or neurologic instability			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146146>	C143874	Grade 4 Thrombotic Thrombocytopenic Purpura, CTCAE|Grade 4 Thrombotic thrombocytopenic purpura|Grade 4 Thrombotic thrombocytopenic purpura	Life-threatening consequences, (e.g., CNS hemorrhage or thrombosis/embolism or renal failure)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146147>	C143878	Grade 4 Tooth Infection, CTCAE|Grade 4 Tooth infection|Grade 4 Tooth infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146148>	C143880	Grade 4 Toxic Epidermal Necrolysis, CTCAE|Grade 4 Toxic epidermal necrolysis|Grade 4 Toxic epidermal necrolysis	Skin sloughing covering >=30% BSA with associated symptoms (e.g., erythema, purpura, or epidermal detachment); life-threatening consequences			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146151>	C143881	Grade 4 Tracheal Mucositis, CTCAE|Grade 4 Tracheal mucositis|Grade 4 Tracheal mucositis	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146152>	C143882	Grade 4 Tracheal Obstruction, CTCAE|Grade 4 Tracheal obstruction|Grade 4 Tracheal obstruction	Life-threatening airway compromise; urgent intervention indicated (e.g., tracheotomy or intubation)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146153>	C143883	Grade 4 Tracheal Stenosis, CTCAE|Grade 4 Tracheal stenosis|Grade 4 Tracheal stenosis	Life-threatening airway compromise; urgent intervention indicated (e.g., tracheotomy or intubation)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146154>	C143884	Grade 4 Tracheitis, CTCAE|Grade 4 Tracheitis|Grade 4 Tracheitis	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146155>	C143885	Grade 4 Tracheostomy Site Bleeding, CTCAE|Grade 4 Tracheostomy site bleeding|Grade 4 Tracheostomy site bleeding	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146156>	C143887	Grade 4 Treatment Related Secondary Malignancy, CTCAE|Grade 4 Treatment related secondary malignancy|Grade 4 Treatment related secondary malignancy	Acute life-threatening secondary malignancy; blast crisis in leukemia			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146157>	C143889	Grade 4 Tricuspid Valve Disease, CTCAE|Grade 4 Tricuspid valve disease|Grade 4 Tricuspid valve disease	Life-threatening consequences; urgent intervention indicated (e.g., valve replacement, valvuloplasty)			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146158>	C143229	Grade 4 Tumor Hemorrhage, CTCAE|Grade 4 Tumor hemorrhage|Grade 4 Tumor hemorrhage	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146159>	C146688	Grade 4 Tumor Lysis Syndrome, CTCAE|Grade 4 Tumor lysis syndrome	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146160>	C143895	Grade 4 Upper Gastrointestinal Hemorrhage, CTCAE|Grade 4 Upper gastrointestinal hemorrhage|Grade 4 Upper gastrointestinal hemorrhage	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146161>	C143896	Grade 4 Upper Respiratory Infection, CTCAE|Grade 4 Upper respiratory infection|Grade 4 Upper respiratory infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146162>	C143897	Grade 4 Ureteric Anastomotic Leak, CTCAE|Grade 4 Ureteric anastomotic leak|Grade 4 Ureteric anastomotic leak	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146163>	C143898	Grade 4 Urethral Anastomotic Leak, CTCAE|Grade 4 Urethral anastomotic leak|Grade 4 Urethral anastomotic leak	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146164>	C143899	Grade 4 Urethral Infection, CTCAE|Grade 4 Urethral infection|Grade 4 Urethral infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146165>	C143900	Grade 4 Urinary Fistula, CTCAE|Grade 4 Urinary fistula|Grade 4 Urinary fistula	Life-threatening consequences; urgent invasive intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146166>	C143904	Grade 4 Urinary Tract Infection, CTCAE|Grade 4 Urinary tract infection|Grade 4 Urinary tract infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146167>	C143905	Grade 4 Urinary Tract Obstruction, CTCAE|Grade 4 Urinary tract obstruction|Grade 4 Urinary tract obstruction	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146168>	C143909	Grade 4 Urine Output Decreased, CTCAE|Grade 4 Urine output decreased|Grade 4 Urine output decreased	Adult: Anuria (<240 ml in 24 hr); Pediatric: No urine output over 12 hours			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146169>	C143910	Grade 4 Urostomy Leak, CTCAE|Grade 4 Urostomy leak|Grade 4 Urostomy leak	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146170>	C143911	Grade 4 Urostomy Obstruction, CTCAE|Grade 4 Urostomy obstruction|Grade 4 Urostomy obstruction	Life-threatening consequences; organ failure; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146171>	C143912	Grade 4 Urostomy Site Bleeding, CTCAE|Grade 4 Urostomy site bleeding|Grade 4 Urostomy site bleeding	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146172>	C143913	Grade 4 Urostomy Stenosis, CTCAE|Grade 4 Urostomy stenosis|Grade 4 Urostomy stenosis	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146173>	C143915	Grade 4 Uterine Anastomotic Leak, CTCAE|Grade 4 Uterine anastomotic leak|Grade 4 Uterine anastomotic leak	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146174>	C143916	Grade 4 Uterine Fistula, CTCAE|Grade 4 Uterine fistula|Grade 4 Uterine fistula	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146176>	C143917	Grade 4 Uterine Infection, CTCAE|Grade 4 Uterine infection|Grade 4 Uterine infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146177>	C143919	Grade 4 Uterine Perforation, CTCAE|Grade 4 Uterine perforation|Grade 4 Uterine perforation	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146178>	C143216	Grade 4 Vaccination Complication, CTCAE|Grade 4 Vaccination complication	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146179>	C143921	Grade 4 Vaginal Anastomotic Leak, CTCAE|Grade 4 Vaginal anastomotic leak|Grade 4 Vaginal anastomotic leak	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146182>	C143924	Grade 4 Vaginal Infection, CTCAE|Grade 4 Vaginal infection|Grade 4 Vaginal infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146183>	C143925	Grade 4 Vaginal Inflammation, CTCAE|Grade 4 Vaginal inflammation|Grade 4 Vaginal inflammation	Life-threatening consequences; widespread areas of mucosal ulceration; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146184>	C146697	Grade 4 Vaginal Perforation, CTCAE|Grade 4 Vaginal perforation|Grade 4 Vaginal perforation	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146185>	C143927	Grade 4 Vagus Nerve Disorder, CTCAE|Grade 4 Vagus nerve disorder|Grade 4 Vagus nerve disorder	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146186>	C143928	Grade 4 Vas Deferens Anastomotic Leak, CTCAE|Grade 4 Vas deferens anastomotic leak|Grade 4 Vas deferens anastomotic leak	Life-threatening consequences; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146187>	C143929	Grade 4 Vascular Access Complication, CTCAE|Grade 4 Vascular access complication|Grade 4 Vascular access complication	Life-threatening consequences with hemodynamic or neurologic instability			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146188>	C143930	Grade 4 Vascular Disorders - Other, Specify, CTCAE|Grade 4 Vascular disorders - Other, specify|Grade 4 Vascular disorders - Other, specify	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146189>	C143932	Grade 4 Vasovagal Reaction, CTCAE|Grade 4 Vasovagal reaction	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146190>	C143933	Grade 4 Venous Injury, CTCAE|Grade 4 Venous injury|Grade 4 Venous injury	Life-threatening consequences; evidence of end organ damage; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146191>	C146629	Grade 4 Ventricular Arrhythmia, CTCAE|Grade 4 Ventricular arrhythmia|Grade 4 Ventricular arrhythmia	Life-threatening consequences; hemodynamic compromise			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146192>	C143938	Grade 4 Visceral Arterial Ischemia, CTCAE|Grade 4 Visceral arterial ischemia|Grade 4 Visceral arterial ischemia	Life-threatening consequences; evidence of end organ damage; urgent operative intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146193>	C143196	Grade 4 Vision Decreased, CTCAE|Grade 4 Vision decreased|Grade 4 Vision decreased	Best corrected visual acuity of 20/200 or worse in the affected eye			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146194>	C146677	Grade 4 Vitreous Hemorrhage, CTCAE|Grade 4 Vitreous hemorrhage|Grade 4 Vitreous hemorrhage	Best corrected visual acuity of 20/200 or worse in the affected eye			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146195>	C143943	Grade 4 Vulval Infection, CTCAE|Grade 4 Vulval infection|Grade 4 Vulval infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146196>	C143944	Grade 4 Watering Eyes, CTCAE|Grade 4 Watering eyes|Grade 4 Watering eyes	Best corrected visual acuity of 20/200 or worse in the affected eye			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146197>	C143947	Grade 4 Wheezing, CTCAE|Grade 4 Wheezing	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146198>	C143948	Grade 4 White Blood Cell Decreased, CTCAE|Grade 4 White blood cell decreased|Grade 4 White blood cell decreased	<1000/mm3; <1.0 x 10^9/L			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146199>	C143949	Grade 4 Wound Complication, CTCAE|Grade 4 Wound complication|Grade 4 Wound complication	Life-threatening consequences			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C1461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1461>	C68542|C2020	Perillyl Alcohol|(S)-(-)-Perillyl Alcohol|(S)-(-)-Perillyl alcohol|(S)-4-Isopropenyl-1-cyclohexenylmethanol|1-Cyclohexene-1-methanol|4-(1-Methylethenyl)|4-(1-Methylethenyl)-1-cyclohexene-1-methanol|4-Isopropenylcyclohex-1-ene-1-methanol|Dihydrocuminyl Alcohol|NEO100|PERILLYL ALCOHOL|POH|Perilla Alcohol|Perilla alcohol|Perillic Alcohol|Perillic alcohol|Perillol|Perillol|[(4S)-4-prop-1-en-2-yl-1-cyclohexenyl]methanol|p-Mentha-1,8-dien-7-ol|p-Mentha-1,8-dien-7-ol|perillyl alcohol	A naturally occurring monoterpene related to limonene with antineoplastic activity. Perillyl alcohol inhibits farnesyl transferase and geranylgeranyl transferase, thereby preventing post-translational protein farnesylation and isoprenylation and activation of oncoproteins such as p21-ras, and arresting tumor cells in the G1 phase of the cell cycle. (NCI04)	Perillyl Alcohol		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C146200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146200>	C143950	Grade 4 Wound Dehiscence, CTCAE|Grade 4 Wound dehiscence|Grade 4 Wound dehiscence	Life-threatening consequences; symptomatic hernia with evidence of strangulation; fascial disruption with evisceration; major reconstruction flap, grafting, resection, or amputation indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146201>	C143951	Grade 4 Wound Infection, CTCAE|Grade 4 Wound infection|Grade 4 Wound infection	Life-threatening consequences; urgent intervention indicated			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146202>	C143254	Grade 5 Abdominal Infection, CTCAE|Grade 5 Abdominal infection|Grade 5 Abdominal infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146203>	C143256	Grade 5 Abdominal Soft Tissue Necrosis, CTCAE|Grade 5 Abdominal soft tissue necrosis|Grade 5 Abdominal soft tissue necrosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146204>	C143259	Grade 5 Acidosis, CTCAE|Grade 5 Acidosis|Grade 5 Acidosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146205>	C143262	Grade 5 Acute Kidney Injury, CTCAE|Grade 5 Acute kidney injury|Grade 5 Acute kidney injury	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146206>	C143268	Grade 5 Alcohol Intolerance, CTCAE|Grade 5 Alcohol intolerance|Grade 5 Alcohol intolerance	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146207>	C143270	Grade 5 Alkalosis, CTCAE|Grade 5 Alkalosis|Grade 5 Alkalosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146208>	C143271	Grade 5 Allergic Reaction, CTCAE|Grade 5 Allergic reaction|Grade 5 Allergic reaction	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146209>	C143275	Grade 5 Anal Fistula, CTCAE|Grade 5 Anal fistula|Grade 5 Anal fistula	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146210>	C143276	Grade 5 Anal Hemorrhage, CTCAE|Grade 5 Anal hemorrhage	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146211>	C143278	Grade 5 Anal Necrosis, CTCAE|Grade 5 Anal necrosis|Grade 5 Anal necrosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146212>	C143280	Grade 5 Anal Stenosis, CTCAE|Grade 5 Anal stenosis|Grade 5 Anal stenosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146213>	C143281	Grade 5 Anal Ulcer, CTCAE|Grade 5 Anal ulcer|Grade 5 Anal ulcer	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146214>	C143282	Grade 5 Anaphylaxis, CTCAE|Grade 5 Anaphylaxis|Grade 5 Anaphylaxis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146215>	C143283	Grade 5 Anemia, CTCAE|Grade 5 Anemia|Grade 5 Anemia	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146216>	C143285	Grade 5 Anorectal Infection, CTCAE|Grade 5 Anorectal infection|Grade 5 Anorectal infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146217>	C143289	Grade 5 Aortic Injury, CTCAE|Grade 5 Aortic injury|Grade 5 Aortic injury	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146218>	C143290	Grade 5 Aortic Valve Disease, CTCAE|Grade 5 Aortic valve disease|Grade 5 Aortic valve disease	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146219>	C143293	Grade 5 Appendicitis Perforated, CTCAE|Grade 5 Appendicitis perforated|Grade 5 Appendicitis perforated	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146220>	C143294	Grade 5 Appendicitis, CTCAE|Grade 5 Appendicitis|Grade 5 Appendicitis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146221>	C143295	Grade 5 Arachnoiditis, CTCAE|Grade 5 Arachnoiditis|Grade 5 Arachnoiditis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146222>	C143296	Grade 5 Arterial Injury, CTCAE|Grade 5 Arterial injury|Grade 5 Arterial injury	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146223>	C143249	Grade 5 Arterial Thromboembolism, CTCAE|Grade 5 Arterial thromboembolism|Grade 5 Arterial thromboembolism	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146224>	C143297	Grade 5 Arteritis Infective, CTCAE|Grade 5 Arteritis infective|Grade 5 Arteritis infective	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146225>	C143300	Grade 5 Ascites, CTCAE|Grade 5 Ascites|Grade 5 Ascites	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146226>	C143308	Grade 5 Atrioventricular Block Complete, CTCAE|Grade 5 Atrioventricular block complete|Grade 5 Atrioventricular block complete	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146227>	C143310	Grade 5 Autoimmune Disorder, CTCAE|Grade 5 Autoimmune disorder|Grade 5 Autoimmune disorder	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146228>	C143311	Grade 5 Avascular Necrosis, CTCAE|Grade 5 Avascular necrosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146229>	C143314	Grade 5 Bile Duct Stenosis, CTCAE|Grade 5 Bile duct stenosis|Grade 5 Bile duct stenosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146230>	C143315	Grade 5 Biliary Anastomotic Leak, CTCAE|Grade 5 Biliary anastomotic leak|Grade 5 Biliary anastomotic leak	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146231>	C143316	Grade 5 Biliary Fistula, CTCAE|Grade 5 Biliary fistula|Grade 5 Biliary fistula	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146232>	C143317	Grade 5 Biliary Tract Infection, CTCAE|Grade 5 Biliary tract infection|Grade 5 Biliary tract infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146233>	C143318	Grade 5 Bladder Anastomotic Leak, CTCAE|Grade 5 Bladder anastomotic leak|Grade 5 Bladder anastomotic leak	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146234>	C143319	Grade 5 Bladder Infection, CTCAE|Grade 5 Bladder infection|Grade 5 Bladder infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146235>	C143323	Grade 5 Blood and Lymphatic System Disorders - Other, Specify, CTCAE|Grade 5 Blood and lymphatic system disorders - Other, specify|Grade 5 Blood and lymphatic system disorders - Other, specify	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146236>	C143331	Grade 5 Bone Infection, CTCAE|Grade 5 Bone infection|Grade 5 Bone infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146237>	C143332	Grade 5 Bone Marrow Hypocellular, CTCAE|Grade 5 Bone marrow hypocellular|Grade 5 Bone marrow hypocellular	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146238>	C143336	Grade 5 Breast Infection, CTCAE|Grade 5 Breast infection|Grade 5 Breast infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146239>	C143338	Grade 5 Bronchial Fistula, CTCAE|Grade 5 Bronchial fistula|Grade 5 Bronchial fistula	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146240>	C143339	Grade 5 Bronchial Infection, CTCAE|Grade 5 Bronchial infection|Grade 5 Bronchial infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146241>	C143340	Grade 5 Bronchial Obstruction, CTCAE|Grade 5 Bronchial obstruction|Grade 5 Bronchial obstruction	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146242>	C143341	Grade 5 Bronchial Stricture, CTCAE|Grade 5 Bronchial stricture|Grade 5 Bronchial stricture	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146243>	C143342	Grade 5 Bronchopleural Fistula, CTCAE|Grade 5 Bronchopleural fistula|Grade 5 Bronchopleural fistula	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146244>	C143343	Grade 5 Bronchopulmonary Hemorrhage, CTCAE|Grade 5 Bronchopulmonary hemorrhage|Grade 5 Bronchopulmonary hemorrhage	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146245>	C143344	Grade 5 Bronchospasm, CTCAE|Grade 5 Bronchospasm|Grade 5 Bronchospasm	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146246>	C143204	Grade 5 Budd-Chiari Syndrome, CTCAE|Grade 5 Budd-Chiari syndrome|Grade 5 Budd-Chiari syndrome	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146247>	C143346	Grade 5 Bullous Dermatitis, CTCAE|Grade 5 Bullous dermatitis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146248>	C143349	Grade 5 Capillary Leak Syndrome, CTCAE|Grade 5 Capillary leak syndrome|Grade 5 Capillary leak syndrome	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146249>	C143351	Grade 5 Cardiac Arrest, CTCAE|Grade 5 Cardiac arrest|Grade 5 Cardiac arrest	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146250>	C143352	Grade 5 Cardiac Disorders - Other, Specify, CTCAE|Grade 5 Cardiac disorders - Other, specify|Grade 5 Cardiac disorders - Other, specify	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146251>	C143356	Grade 5 Catheter Related Infection, CTCAE|Grade 5 Catheter related infection|Grade 5 Catheter related infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146252>	C143358	Grade 5 Cecal Hemorrhage, CTCAE|Grade 5 Cecal hemorrhage|Grade 5 Cecal hemorrhage	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146253>	C143359	Grade 5 Cecal Infection, CTCAE|Grade 5 Cecal infection|Grade 5 Cecal infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146254>	C143360	Grade 5 Central Nervous System Necrosis, CTCAE|Grade 5 Central nervous system necrosis|Grade 5 Central nervous system necrosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146255>	C143361	Grade 5 Cerebrospinal Fluid Leakage, CTCAE|Grade 5 Cerebrospinal fluid leakage|Grade 5 Cerebrospinal fluid leakage	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146256>	C143362	Grade 5 Cervicitis Infection, CTCAE|Grade 5 Cervicitis infection|Grade 5 Cervicitis infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146257>	C143223	Grade 5 Chest Wall Necrosis, CTCAE|Grade 5 Chest wall necrosis|Grade 5 Chest wall necrosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146258>	C143369	Grade 5 Chronic Kidney Disease, CTCAE|Grade 5 Chronic kidney disease	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146259>	C143199	Grade 5 Chylous Ascites, CTCAE|Grade 5 Chylous ascites|Grade 5 Chylous ascites	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146260>	C143373	Grade 5 Colonic Fistula, CTCAE|Grade 5 Colonic fistula|Grade 5 Colonic fistula	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146261>	C143374	Grade 5 Colonic Hemorrhage, CTCAE|Grade 5 Colonic hemorrhage	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146262>	C143375	Grade 5 Colonic Obstruction, CTCAE|Grade 5 Colonic obstruction|Grade 5 Colonic obstruction	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146263>	C143376	Grade 5 Colonic Perforation, CTCAE|Grade 5 Colonic perforation|Grade 5 Colonic perforation	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146264>	C143377	Grade 5 Colonic Stenosis, CTCAE|Grade 5 Colonic stenosis|Grade 5 Colonic stenosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146265>	C143378	Grade 5 Colonic Ulcer, CTCAE|Grade 5 Colonic ulcer|Grade 5 Colonic ulcer	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146266>	C143380	Grade 5 Conduction Disorder, CTCAE|Grade 5 Conduction disorder	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146267>	C143382	Grade 5 Congenital, Familial and Genetic Disorders - Other, Specify, CTCAE|Grade 5 Congenital, familial and genetic disorders - Other, specify|Grade 5 Congenital, familial and genetic disorders - Other, specify	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146268>	C143386	Grade 5 Corneal Infection, CTCAE|Grade 5 Corneal infection|Grade 5 Corneal infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146269>	C143390	Grade 5 Cranial Nerve Infection, CTCAE|Grade 5 Cranial nerve infection|Grade 5 Cranial nerve infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146270>	C143393	Grade 5 Cystitis Noninfective, CTCAE|Grade 5 Cystitis noninfective|Grade 5 Cystitis noninfective	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146271>	C143394	Grade 5 Cytokine Release Syndrome, CTCAE|Grade 5 Cytokine release syndrome|Grade 5 Cytokine release syndrome	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146272>	C143207	Grade 5 Cytomegalovirus Infection Reactivation, CTCAE|Grade 5 Cytomegalovirus infection reactivation|Grade 5 Cytomegalovirus infection reactivation	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146274>	C143400	Grade 5 Delirium, CTCAE|Grade 5 Delirium|Grade 5 Delirium	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146275>	C143401	Grade 5 Delusions, CTCAE|Grade 5 Delusions|Grade 5 Delusions	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146276>	C143403	Grade 5 Depressed Level of Consciousness, CTCAE|Grade 5 Depressed level of consciousness|Grade 5 Depressed level of consciousness	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146277>	C143405	Grade 5 Dermatitis Radiation, CTCAE|Grade 5 Dermatitis radiation|Grade 5 Dermatitis radiation	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146278>	C143406	Grade 5 Device Related Infection, CTCAE|Grade 5 Device related infection|Grade 5 Device related infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146279>	C143201	Grade 5 Disease Progression, CTCAE|Grade 5 Disease progression|Grade 5 Disease progression	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146281>	C143414	Grade 5 Duodenal Hemorrhage, CTCAE|Grade 5 Duodenal hemorrhage|Grade 5 Duodenal hemorrhage	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146282>	C143415	Grade 5 Duodenal Infection, CTCAE|Grade 5 Duodenal infection|Grade 5 Duodenal infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146283>	C143416	Grade 5 Duodenal Obstruction, CTCAE|Grade 5 Duodenal obstruction|Grade 5 Duodenal obstruction	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146284>	C143417	Grade 5 Duodenal Perforation, CTCAE|Grade 5 Duodenal perforation|Grade 5 Duodenal perforation	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146285>	C143418	Grade 5 Duodenal Stenosis, CTCAE|Grade 5 Duodenal stenosis|Grade 5 Duodenal stenosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146286>	C143419	Grade 5 Duodenal Ulcer, CTCAE|Grade 5 Duodenal ulcer|Grade 5 Duodenal ulcer	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146287>	C143429	Grade 5 Ear and Labyrinth Disorders - Other, Specify, CTCAE|Grade 5 Ear and labyrinth disorders - Other, specify|Grade 5 Ear and labyrinth disorders - Other, specify	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146288>	C143431	Grade 5 Edema Cerebral, CTCAE|Grade 5 Edema cerebral	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146289>	C143438	Grade 5 Encephalitis Infection, CTCAE|Grade 5 Encephalitis infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146290>	C143439	Grade 5 Encephalomyelitis Infection, CTCAE|Grade 5 Encephalomyelitis infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146291>	C143441	Grade 5 Endocarditis Infective, CTCAE|Grade 5 Endocarditis infective|Grade 5 Endocarditis infective	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146292>	C143442	Grade 5 Endocrine Disorders - Other, Specify, CTCAE|Grade 5 Endocrine disorders - Other, specify|Grade 5 Endocrine disorders - Other, specify	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146293>	C143444	Grade 5 Enterocolitis Infectious, CTCAE|Grade 5 Enterocolitis infectious|Grade 5 Enterocolitis infectious	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146294>	C143445	Grade 5 Enterocolitis, CTCAE|Grade 5 Enterocolitis|Grade 5 Enterocolitis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146295>	C143446	Grade 5 Enterovesical Fistula, CTCAE|Grade 5 Enterovesical fistula|Grade 5 Enterovesical fistula	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146296>	C143447	Grade 5 Epistaxis, CTCAE|Grade 5 Epistaxis|Grade 5 Epistaxis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146297>	C143208	Grade 5 Epstein-Barr Virus Infection Reactivation, CTCAE|Grade 5 Epstein-Barr virus infection reactivation|Grade 5 Epstein-Barr virus infection reactivation	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146298>	C143449	Grade 5 Erythema Multiforme, CTCAE|Grade 5 Erythema multiforme|Grade 5 Erythema multiforme	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146299>	C143450	Grade 5 Erythroderma, CTCAE|Grade 5 Erythroderma|Grade 5 Erythroderma	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C1462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1462>	C514|C156880	Radicicol|(1aR,2Z,4E,14R,15aR)-8-Chloro-1a,14,15,15a-Tetrahydro-9,11-dihydroxy-14-methyl-6H-oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione|(1aR,2Z,4E,14R,15aR)-8-Chloro-1a,14,15,15a-Tetrahydro-9,11-dihydroxy-14-methyl-6H-oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione|MONORDEN|Monorden|RDC	A macrocyclic antifungal antibiotic that inhibits signal-dependent transcriptional activation and induces differentiation in leukemia. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C146300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146300>	C143451	Grade 5 Esophageal Anastomotic Leak, CTCAE|Grade 5 Esophageal anastomotic leak|Grade 5 Esophageal anastomotic leak	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146302>	C143453	Grade 5 Esophageal Hemorrhage, CTCAE|Grade 5 Esophageal hemorrhage|Grade 5 Esophageal hemorrhage	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146303>	C143454	Grade 5 Esophageal Infection, CTCAE|Grade 5 Esophageal infection|Grade 5 Esophageal infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146304>	C143455	Grade 5 Esophageal Necrosis, CTCAE|Grade 5 Esophageal necrosis|Grade 5 Esophageal necrosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146305>	C143456	Grade 5 Esophageal Obstruction, CTCAE|Grade 5 Esophageal obstruction|Grade 5 Esophageal obstruction	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146306>	C143458	Grade 5 Esophageal Perforation, CTCAE|Grade 5 Esophageal perforation|Grade 5 Esophageal perforation	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146307>	C143459	Grade 5 Esophageal Stenosis, CTCAE|Grade 5 Esophageal stenosis|Grade 5 Esophageal stenosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146308>	C143460	Grade 5 Esophageal Ulcer, CTCAE|Grade 5 Esophageal ulcer|Grade 5 Esophageal ulcer	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146309>	C143467	Grade 5 Extrapyramidal Disorder, CTCAE|Grade 5 Extrapyramidal disorder|Grade 5 Extrapyramidal disorder	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146310>	C143469	Grade 5 Eye Infection, CTCAE|Grade 5 Eye infection|Grade 5 Eye infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146311>	C143476	Grade 5 Fallopian Tube Anastomotic Leak, CTCAE|Grade 5 Fallopian tube anastomotic leak|Grade 5 Fallopian tube anastomotic leak	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146313>	C143485	Grade 5 Fever, CTCAE|Grade 5 Fever|Grade 5 Fever	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146314>	C143487	Grade 5 Fibrosis Deep Connective Tissue, CTCAE|Grade 5 Fibrosis deep connective tissue|Grade 5 Fibrosis deep connective tissue	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146315>	C143497	Grade 5 Gallbladder Infection, CTCAE|Grade 5 Gallbladder infection|Grade 5 Gallbladder infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146316>	C143498	Grade 5 Gastric Anastomotic Leak, CTCAE|Grade 5 Gastric anastomotic leak|Grade 5 Gastric anastomotic leak	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146317>	C143499	Grade 5 Gastric Fistula, CTCAE|Grade 5 Gastric fistula|Grade 5 Gastric fistula	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146318>	C143500	Grade 5 Gastric Hemorrhage, CTCAE|Grade 5 Gastric hemorrhage|Grade 5 Gastric hemorrhage	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146319>	C143501	Grade 5 Gastric Necrosis, CTCAE|Grade 5 Gastric necrosis|Grade 5 Gastric necrosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146320>	C143502	Grade 5 Gastric Perforation, CTCAE|Grade 5 Gastric perforation|Grade 5 Gastric perforation	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146321>	C143503	Grade 5 Gastric Stenosis, CTCAE|Grade 5 Gastric stenosis|Grade 5 Gastric stenosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146322>	C143504	Grade 5 Gastric Ulcer, CTCAE|Grade 5 Gastric ulcer|Grade 5 Gastric ulcer	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146323>	C143507	Grade 5 Gastrointestinal Anastomotic Leak, CTCAE|Grade 5 Gastrointestinal anastomotic leak|Grade 5 Gastrointestinal anastomotic leak	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146324>	C143508	Grade 5 Gastrointestinal Disorders - Other, Specify, CTCAE|Grade 5 Gastrointestinal disorders - Other, specify|Grade 5 Gastrointestinal disorders - Other, specify	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146325>	C146637	Grade 5 Gastrointestinal Fistula, CTCAE|Grade 5 Gastrointestinal fistula|Grade 5 Gastrointestinal fistula	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146326>	C143511	Grade 5 Gastrointestinal Stoma Necrosis, CTCAE|Grade 5 Gastrointestinal stoma necrosis|Grade 5 Gastrointestinal stoma necrosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146327>	C143513	Grade 5 General Disorders and Administration Site Conditions - Other, Specify, CTCAE|Grade 5 General disorders and administration site conditions - Other, specify|Grade 5 General disorders and administration site conditions - Other, specify	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146328>	C143518	Grade 5 Glossopharyngeal Nerve Disorder, CTCAE|Grade 5 Glossopharyngeal nerve disorder|Grade 5 Glossopharyngeal nerve disorder	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146329>	C143519	Grade 5 Glucose Intolerance, CTCAE|Grade 5 Glucose intolerance	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146330>	C143231	Grade 5 Guillain-Barre Syndrome, CTCAE|Grade 5 Guillain-Barre syndrome|Grade 5 Guillain-Barre syndrome	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146331>	C143523	Grade 5 Gum Infection, CTCAE|Grade 5 Gum infection|Grade 5 Gum infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146332>	C143525	Grade 5 Hallucinations, CTCAE|Grade 5 Hallucinations|Grade 5 Hallucinations	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146333>	C143529	Grade 5 Heart Failure, CTCAE|Grade 5 Heart failure|Grade 5 Heart failure	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146334>	C143531	Grade 5 Hematosalpinx, CTCAE|Grade 5 Hematosalpinx|Grade 5 Hematosalpinx	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146335>	C143532	Grade 5 Hematuria, CTCAE|Grade 5 Hematuria|Grade 5 Hematuria	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146336>	C143536	Grade 5 Hemolytic Uremic Syndrome, CTCAE|Grade 5 Hemolytic uremic syndrome|Grade 5 Hemolytic uremic syndrome	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146337>	C143537	Grade 5 Hemorrhoidal Hemorrhage, CTCAE|Grade 5 Hemorrhoidal hemorrhage|Grade 5 Hemorrhoidal hemorrhage	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146338>	C143539	Grade 5 Hepatic Failure, CTCAE|Grade 5 Hepatic failure|Grade 5 Hepatic failure	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146339>	C143540	Grade 5 Hepatic Hemorrhage, CTCAE|Grade 5 Hepatic hemorrhage|Grade 5 Hepatic hemorrhage	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146340>	C143541	Grade 5 Hepatic Infection, CTCAE|Grade 5 Hepatic infection|Grade 5 Hepatic infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146341>	C143211	Grade 5 Hepatitis B Reactivation, CTCAE|Grade 5 Hepatitis B reactivation|Grade 5 Hepatitis B reactivation	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146342>	C143543	Grade 5 Hepatitis Viral, CTCAE|Grade 5 Hepatitis viral|Grade 5 Hepatitis viral	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146343>	C143544	Grade 5 Hepatobiliary Disorders - Other, Specify, CTCAE|Grade 5 Hepatobiliary disorders - Other, specify|Grade 5 Hepatobiliary disorders - Other, specify	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146344>	C143212	Grade 5 Herpes Simplex Reactivation, CTCAE|Grade 5 Herpes simplex reactivation|Grade 5 Herpes simplex reactivation	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146345>	C143551	Grade 5 Hypercalcemia, CTCAE|Grade 5 Hypercalcemia|Grade 5 Hypercalcemia	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146346>	C143552	Grade 5 Hyperglycemia, CTCAE|Grade 5 Hyperglycemia	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146347>	C143554	Grade 5 Hyperkalemia, CTCAE|Grade 5 Hyperkalemia|Grade 5 Hyperkalemia	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146348>	C143555	Grade 5 Hypermagnesemia, CTCAE|Grade 5 Hypermagnesemia|Grade 5 Hypermagnesemia	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146349>	C143556	Grade 5 Hypernatremia, CTCAE|Grade 5 Hypernatremia|Grade 5 Hypernatremia	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146350>	C143222	Grade 5 Hyperphosphatemia, CTCAE|Grade 5 Hyperphosphatemia|Grade 5 Hyperphosphatemia	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146351>	C143560	Grade 5 Hyperthyroidism, CTCAE|Grade 5 Hyperthyroidism|Grade 5 Hyperthyroidism	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146352>	C143562	Grade 5 Hypertriglyceridemia, CTCAE|Grade 5 Hypertriglyceridemia|Grade 5 Hypertriglyceridemia	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146353>	C143563	Grade 5 Hyperuricemia, CTCAE|Grade 5 Hyperuricemia|Grade 5 Hyperuricemia	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146354>	C143564	Grade 5 Hypoalbuminemia, CTCAE|Grade 5 Hypoalbuminemia|Grade 5 Hypoalbuminemia	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146355>	C143565	Grade 5 Hypocalcemia, CTCAE|Grade 5 Hypocalcemia|Grade 5 Hypocalcemia	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146356>	C143567	Grade 5 Hypoglycemia, CTCAE|Grade 5 Hypoglycemia|Grade 5 Hypoglycemia	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146357>	C143568	Grade 5 Hypohidrosis, CTCAE|Grade 5 Hypohidrosis|Grade 5 Hypohidrosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146358>	C143569	Grade 5 Hypokalemia, CTCAE|Grade 5 Hypokalemia|Grade 5 Hypokalemia	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146359>	C143570	Grade 5 Hypomagnesemia, CTCAE|Grade 5 Hypomagnesemia|Grade 5 Hypomagnesemia	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146360>	C143571	Grade 5 Hyponatremia, CTCAE|Grade 5 Hyponatremia|Grade 5 Hyponatremia	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146361>	C143572	Grade 5 Hypoparathyroidism, CTCAE|Grade 5 Hypoparathyroidism|Grade 5 Hypoparathyroidism	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146362>	C143573	Grade 5 Hypophosphatemia, CTCAE|Grade 5 Hypophosphatemia|Grade 5 Hypophosphatemia	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146363>	C143193	Grade 5 Hypophysitis, CTCAE|Grade 5 Hypophysitis|Grade 5 Hypophysitis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146364>	C143194	Grade 5 Hypopituitarism, CTCAE|Grade 5 Hypopituitarism|Grade 5 Hypopituitarism	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146365>	C143576	Grade 5 Hypothyroidism, CTCAE|Grade 5 Hypothyroidism|Grade 5 Hypothyroidism	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146369>	C146633	Grade 5 Ileal Perforation, CTCAE|Grade 5 Ileal perforation|Grade 5 Ileal perforation	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146370>	C143578	Grade 5 Ileal Stenosis, CTCAE|Grade 5 Ileal stenosis|Grade 5 Ileal stenosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146373>	C143580	Grade 5 Immune System Disorders - Other, Specify, CTCAE|Grade 5 Immune system disorders - Other, specify|Grade 5 Immune system disorders - Other, specify	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146374>	C143581	Grade 5 Infections and Infestations - Other, Specify, CTCAE|Grade 5 Infections and infestations - Other, specify|Grade 5 Infections and infestations - Other, specify	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146375>	C143582	Grade 5 Infective Myositis, CTCAE|Grade 5 Infective myositis|Grade 5 Infective myositis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146376>	C143583	Grade 5 Infusion Related Reaction, CTCAE|Grade 5 Infusion related reaction|Grade 5 Infusion related reaction	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146377>	C143584	Grade 5 Infusion Site Extravasation, CTCAE|Grade 5 Infusion site extravasation|Grade 5 Infusion site extravasation	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146378>	C143585	Grade 5 Injection Site Reaction, CTCAE|Grade 5 Injection site reaction|Grade 5 Injection site reaction	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146379>	C143586	Grade 5 Injury To Carotid Artery, CTCAE|Grade 5 Injury to carotid artery|Grade 5 Injury to carotid artery	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146381>	C143587	Grade 5 Injury To Jugular Vein, CTCAE|Grade 5 Injury to jugular vein|Grade 5 Injury to jugular vein	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146382>	C143588	Grade 5 Injury To Superior Vena Cava, CTCAE|Grade 5 Injury to superior vena cava|Grade 5 Injury to superior vena cava	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146383>	C143589	Grade 5 Injury, Poisoning and Procedural Complications - Other, Specify, CTCAE|Grade 5 Injury, poisoning and procedural complications - Other, specify|Grade 5 Injury, poisoning and procedural complications - Other, specify	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146384>	C143592	Grade 5 Intestinal Stoma Leak, CTCAE|Grade 5 Intestinal stoma leak|Grade 5 Intestinal stoma leak	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146385>	C143593	Grade 5 Intestinal Stoma Obstruction, CTCAE|Grade 5 Intestinal stoma obstruction|Grade 5 Intestinal stoma obstruction	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146386>	C143594	Grade 5 Intestinal Stoma Site Bleeding, CTCAE|Grade 5 Intestinal stoma site bleeding|Grade 5 Intestinal stoma site bleeding	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146387>	C143595	Grade 5 Intra-Abdominal Hemorrhage, CTCAE|Grade 5 Intra-abdominal hemorrhage|Grade 5 Intra-abdominal hemorrhage	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146388>	C143596	Grade 5 Intracranial Hemorrhage, CTCAE|Grade 5 Intracranial hemorrhage	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146389>	C143597	Grade 5 Intraoperative Arterial Injury, CTCAE|Grade 5 Intraoperative arterial injury|Grade 5 Intraoperative arterial injury	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146390>	C143598	Grade 5 Intraoperative Breast Injury, CTCAE|Grade 5 Intraoperative breast injury|Grade 5 Intraoperative breast injury	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146391>	C143599	Grade 5 Intraoperative Cardiac Injury, CTCAE|Grade 5 Intraoperative cardiac injury|Grade 5 Intraoperative cardiac injury	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146392>	C143600	Grade 5 Intraoperative Ear Injury, CTCAE|Grade 5 Intraoperative ear injury|Grade 5 Intraoperative ear injury	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146393>	C143601	Grade 5 Intraoperative Endocrine Injury, CTCAE|Grade 5 Intraoperative endocrine injury|Grade 5 Intraoperative endocrine injury	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146394>	C143602	Grade 5 Intraoperative Gastrointestinal Injury, CTCAE|Grade 5 Intraoperative gastrointestinal injury|Grade 5 Intraoperative gastrointestinal injury	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146395>	C143603	Grade 5 Intraoperative Head and Neck Injury, CTCAE|Grade 5 Intraoperative head and neck injury|Grade 5 Intraoperative head and neck injury	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146396>	C143604	Grade 5 Intraoperative Hemorrhage, CTCAE|Grade 5 Intraoperative hemorrhage|Grade 5 Intraoperative hemorrhage	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146397>	C143605	Grade 5 Intraoperative Hepatobiliary Injury, CTCAE|Grade 5 Intraoperative hepatobiliary injury|Grade 5 Intraoperative hepatobiliary injury	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146398>	C143606	Grade 5 Intraoperative Musculoskeletal Injury, CTCAE|Grade 5 Intraoperative musculoskeletal injury|Grade 5 Intraoperative musculoskeletal injury	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146399>	C143607	Grade 5 Intraoperative Neurological Injury, CTCAE|Grade 5 Intraoperative neurological injury|Grade 5 Intraoperative neurological injury	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14639>	C14421	AU/SsJ Mouse|AU/SsJ		AU/SsJ Mouse		Mammal	
C1463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1463>	C323|C274	Dihydrolenperone|1-Butanone, 1-(4-fluorophenyl)-4-[4-[(4-fluorophenyl)hydroxymethyl]-1-piperidi nyl]-|1-Butanone, 1-(4-fluorophenyl)-4-[4-[(4-fluorophenyl)hydroxymethyl]-1-piperidinyl]-|DIHYDROLENPERONE|Dihydro-lenperone|Dihydro-lenperone|RMI 11974	A butyrophenone that has been investigated for antineoplastic activity. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C146400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146400>	C143608	Grade 5 Intraoperative Ocular Injury, CTCAE|Grade 5 Intraoperative ocular injury|Grade 5 Intraoperative ocular injury	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146401>	C143609	Grade 5 Intraoperative Renal Injury, CTCAE|Grade 5 Intraoperative renal injury|Grade 5 Intraoperative renal injury	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146402>	C143610	Grade 5 Intraoperative Reproductive Tract Injury, CTCAE|Grade 5 Intraoperative reproductive tract injury|Grade 5 Intraoperative reproductive tract injury	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146403>	C143611	Grade 5 Intraoperative Respiratory Injury, CTCAE|Grade 5 Intraoperative respiratory injury|Grade 5 Intraoperative respiratory injury	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146404>	C143612	Grade 5 Intraoperative Splenic Injury, CTCAE|Grade 5 Intraoperative splenic injury|Grade 5 Intraoperative splenic injury	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146405>	C143613	Grade 5 Intraoperative Urinary Injury, CTCAE|Grade 5 Intraoperative urinary injury|Grade 5 Intraoperative urinary injury	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146406>	C143614	Grade 5 Intraoperative Venous Injury, CTCAE|Grade 5 Intraoperative venous injury|Grade 5 Intraoperative venous injury	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146407>	C143615	Grade 5 Investigations - Other, Specify, CTCAE|Grade 5 Investigations - Other, specify|Grade 5 Investigations - Other, specify	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146411>	C143622	Grade 5 Jejunal Perforation, CTCAE|Grade 5 Jejunal perforation|Grade 5 Jejunal perforation	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146412>	C143623	Grade 5 Jejunal Stenosis, CTCAE|Grade 5 Jejunal stenosis|Grade 5 Jejunal stenosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146414>	C143626	Grade 5 Joint Infection, CTCAE|Grade 5 Joint infection|Grade 5 Joint infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146415>	C143631	Grade 5 Kidney Anastomotic Leak, CTCAE|Grade 5 Kidney anastomotic leak|Grade 5 Kidney anastomotic leak	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146416>	C143632	Grade 5 Kidney Infection, CTCAE|Grade 5 Kidney infection|Grade 5 Kidney infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146417>	C143635	Grade 5 Large Intestinal Anastomotic Leak, CTCAE|Grade 5 Large intestinal anastomotic leak|Grade 5 Large intestinal anastomotic leak	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146418>	C143636	Grade 5 Laryngeal Edema, CTCAE|Grade 5 Laryngeal edema|Grade 5 Laryngeal edema	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146421>	C143638	Grade 5 Laryngeal Mucositis, CTCAE|Grade 5 Laryngeal mucositis|Grade 5 Laryngeal mucositis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146422>	C143639	Grade 5 Laryngeal Obstruction, CTCAE|Grade 5 Laryngeal obstruction|Grade 5 Laryngeal obstruction	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146423>	C143640	Grade 5 Laryngeal Stenosis, CTCAE|Grade 5 Laryngeal stenosis|Grade 5 Laryngeal stenosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146424>	C143641	Grade 5 Laryngitis, CTCAE|Grade 5 Laryngitis|Grade 5 Laryngitis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146425>	C143642	Grade 5 Laryngopharyngeal Dysesthesia, CTCAE|Grade 5 Laryngopharyngeal dysesthesia|Grade 5 Laryngopharyngeal dysesthesia	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146426>	C143643	Grade 5 Laryngospasm, CTCAE|Grade 5 Laryngospasm|Grade 5 Laryngospasm	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146427>	C143646	Grade 5 Leukemia Secondary To Oncology Chemotherapy, CTCAE|Grade 5 Leukemia secondary to oncology chemotherapy|Grade 5 Leukemia secondary to oncology chemotherapy	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146428>	C143647	Grade 5 Leukocytosis, CTCAE|Grade 5 Leukocytosis|Grade 5 Leukocytosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146429>	C143648	Grade 5 Leukoencephalopathy, CTCAE|Grade 5 Leukoencephalopathy|Grade 5 Leukoencephalopathy	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146430>	C143656	Grade 5 Lower Gastrointestinal Hemorrhage, CTCAE|Grade 5 Lower gastrointestinal hemorrhage	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146431>	C143657	Grade 5 Lung Infection, CTCAE|Grade 5 Lung infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146432>	C143658	Grade 5 Lymph Gland Infection, CTCAE|Grade 5 Lymph gland infection|Grade 5 Lymph gland infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146433>	C143659	Grade 5 Lymph Leakage, CTCAE|Grade 5 Lymph leakage|Grade 5 Lymph leakage	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146434>	C143666	Grade 5 Mania, CTCAE|Grade 5 Mania|Grade 5 Mania	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146436>	C143667	Grade 5 Mediastinal Infection, CTCAE|Grade 5 Mediastinal infection|Grade 5 Mediastinal infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146437>	C143669	Grade 5 Meningismus, CTCAE|Grade 5 Meningismus|Grade 5 Meningismus	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146438>	C143670	Grade 5 Meningitis, CTCAE|Grade 5 Meningitis|Grade 5 Meningitis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146439>	C143671	Grade 5 Menorrhagia, CTCAE|Grade 5 Menorrhagia|Grade 5 Menorrhagia	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146440>	C143672	Grade 5 Metabolism and Nutrition Disorders - Other, Specify, CTCAE|Grade 5 Metabolism and nutrition disorders - Other, specify|Grade 5 Metabolism and nutrition disorders - Other, specify	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146441>	C143191	Grade 5 Methemoglobinemia, CTCAE|Grade 5 Methemoglobinemia|Grade 5 Methemoglobinemia	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146442>	C143673	Grade 5 Middle Ear Inflammation, CTCAE|Grade 5 Middle ear inflammation|Grade 5 Middle ear inflammation	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146443>	C143674	Grade 5 Mitral Valve Disease, CTCAE|Grade 5 Mitral valve disease|Grade 5 Mitral valve disease	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146446>	C143678	Grade 5 Mucosal Infection, CTCAE|Grade 5 Mucosal infection|Grade 5 Mucosal infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146447>	C143679	Grade 5 Mucositis Oral, CTCAE|Grade 5 Mucositis oral|Grade 5 Mucositis oral	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146449>	C143686	Grade 5 Musculoskeletal and Connective Tissue Disorder - Other, Specify, CTCAE|Grade 5 Musculoskeletal and connective tissue disorder - Other, specify|Grade 5 Musculoskeletal and connective tissue disorder - Other, specify	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146450>	C143232	Grade 5 Myasthenia Gravis, CTCAE|Grade 5 Myasthenia gravis|Grade 5 Myasthenia gravis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146451>	C143690	Grade 5 Myelodysplastic Syndrome, CTCAE|Grade 5 Myelodysplastic syndrome|Grade 5 Myelodysplastic syndrome	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146452>	C143691	Grade 5 Myocardial Infarction, CTCAE|Grade 5 Myocardial infarction	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146453>	C143701	Grade 5 Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) - Other, Specify, CTCAE|Grade 5 Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify|Grade 5 Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146454>	C143239	Grade 5 Nephrotic Syndrome, CTCAE|Grade 5 Nephrotic syndrome|Grade 5 Nephrotic syndrome	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146455>	C143702	Grade 5 Nervous System Disorders - Other, Specify, CTCAE|Grade 5 Nervous system disorders - Other, specify|Grade 5 Nervous system disorders - Other, specify	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146456>	C143710	Grade 5 Obstruction Gastric, CTCAE|Grade 5 Obstruction gastric|Grade 5 Obstruction gastric	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146457>	C143715	Grade 5 Oral Cavity Fistula, CTCAE|Grade 5 Oral cavity fistula|Grade 5 Oral cavity fistula	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146459>	C143717	Grade 5 Osteonecrosis of Jaw, CTCAE|Grade 5 Osteonecrosis of jaw|Grade 5 Osteonecrosis of jaw	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146460>	C143225	Grade 5 Osteonecrosis, CTCAE|Grade 5 Osteonecrosis|Grade 5 Osteonecrosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146461>	C143719	Grade 5 Otitis Externa, CTCAE|Grade 5 Otitis externa|Grade 5 Otitis externa	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146462>	C143720	Grade 5 Otitis Media, CTCAE|Grade 5 Otitis media|Grade 5 Otitis media	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146464>	C143721	Grade 5 Ovarian Infection, CTCAE|Grade 5 Ovarian infection|Grade 5 Ovarian infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146465>	C143722	Grade 5 Ovarian Rupture, CTCAE|Grade 5 Ovarian rupture|Grade 5 Ovarian rupture	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146466>	C143728	Grade 5 Pancreas Infection, CTCAE|Grade 5 Pancreas infection|Grade 5 Pancreas infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146467>	C143729	Grade 5 Pancreatic Anastomotic Leak, CTCAE|Grade 5 Pancreatic anastomotic leak|Grade 5 Pancreatic anastomotic leak	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146468>	C143730	Grade 5 Pancreatic Duct Stenosis, CTCAE|Grade 5 Pancreatic duct stenosis|Grade 5 Pancreatic duct stenosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146471>	C143732	Grade 5 Pancreatic Necrosis, CTCAE|Grade 5 Pancreatic necrosis|Grade 5 Pancreatic necrosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146472>	C143735	Grade 5 Papulopustular Rash, CTCAE|Grade 5 Papulopustular rash	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146473>	C143738	Grade 5 Paroxysmal Atrial Tachycardia, CTCAE|Grade 5 Paroxysmal atrial tachycardia|Grade 5 Paroxysmal atrial tachycardia	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146474>	C143740	Grade 5 Pelvic Infection, CTCAE|Grade 5 Pelvic infection|Grade 5 Pelvic infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146475>	C143741	Grade 5 Penile Infection, CTCAE|Grade 5 Penile infection|Grade 5 Penile infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146476>	C143742	Grade 5 Perforation Bile Duct, CTCAE|Grade 5 Perforation bile duct|Grade 5 Perforation bile duct	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146477>	C143743	Grade 5 Pericardial Effusion, CTCAE|Grade 5 Pericardial effusion|Grade 5 Pericardial effusion	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146478>	C143744	Grade 5 Pericardial Tamponade, CTCAE|Grade 5 Pericardial tamponade|Grade 5 Pericardial tamponade	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146479>	C143748	Grade 5 Periorbital Infection, CTCAE|Grade 5 Periorbital infection|Grade 5 Periorbital infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14647>	C14421	A2G Mouse|A2G		A2G Mouse		Mammal	
C146480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146480>	C143749	Grade 5 Peripheral Ischemia, CTCAE|Grade 5 Peripheral ischemia|Grade 5 Peripheral ischemia	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146481>	C143750	Grade 5 Peripheral Motor Neuropathy, CTCAE|Grade 5 Peripheral motor neuropathy|Grade 5 Peripheral motor neuropathy	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146482>	C143751	Grade 5 Peripheral Nerve Infection, CTCAE|Grade 5 Peripheral nerve infection|Grade 5 Peripheral nerve infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146483>	C143753	Grade 5 Peritoneal Infection, CTCAE|Grade 5 Peritoneal infection|Grade 5 Peritoneal infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146485>	C143755	Grade 5 Pharyngeal Anastomotic Leak, CTCAE|Grade 5 Pharyngeal anastomotic leak|Grade 5 Pharyngeal anastomotic leak	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146488>	C143756	Grade 5 Pharyngeal Mucositis, CTCAE|Grade 5 Pharyngeal mucositis|Grade 5 Pharyngeal mucositis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146490>	C143757	Grade 5 Pharyngeal Stenosis, CTCAE|Grade 5 Pharyngeal stenosis|Grade 5 Pharyngeal stenosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146491>	C143758	Grade 5 Pharyngitis, CTCAE|Grade 5 Pharyngitis|Grade 5 Pharyngitis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146492>	C143760	Grade 5 Phlebitis Infective, CTCAE|Grade 5 Phlebitis infective|Grade 5 Phlebitis infective	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146493>	C143765	Grade 5 Pleural Effusion, CTCAE|Grade 5 Pleural effusion|Grade 5 Pleural effusion	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146495>	C143766	Grade 5 Pleural Infection, CTCAE|Grade 5 Pleural infection|Grade 5 Pleural infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146496>	C143767	Grade 5 Pneumonitis, CTCAE|Grade 5 Pneumonitis|Grade 5 Pneumonitis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146497>	C143769	Grade 5 Portal Hypertension, CTCAE|Grade 5 Portal hypertension|Grade 5 Portal hypertension	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146498>	C143770	Grade 5 Portal Vein Thrombosis, CTCAE|Grade 5 Portal vein thrombosis|Grade 5 Portal vein thrombosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146499>	C143772	Grade 5 Postoperative Hemorrhage, CTCAE|Grade 5 Postoperative hemorrhage|Grade 5 Postoperative hemorrhage	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C1464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1464>	C798|C2077	Tirapazamine|3-Amino-1,2,4-benzotriazine-1,4-dioxide|SR 4233|SR-4233|SR4233|TIRAPAZAMINE|Tirazone|WIN 59075|WIN-59075|WIN59075|tirapazamine	A benzotriazine di-N-oxide with potential antineoplastic activity.  Tirapazamine is selectively activated by multiple reductases to form free radicals in hypoxic cells, thereby inducing single-and double-strand breaks in DNA, base damage, and cell death.  This agent also sensitizes hypoxic cells to ionizing radiation and inhibits the repair of radiation-induced DNA strand breaks via inhibition of topoisomerase II. (NCI04)	Tirapazamine		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C146500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146500>	C143773	Grade 5 Postoperative Thoracic Procedure Complication, CTCAE|Grade 5 Postoperative thoracic procedure complication|Grade 5 Postoperative thoracic procedure complication	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146501>	C143775	Grade 5 Pregnancy, Puerperium and Perinatal Conditions - Other, Specify, CTCAE|Grade 5 Pregnancy, puerperium and perinatal conditions - Other, specify|Grade 5 Pregnancy, puerperium and perinatal conditions - Other, specify	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146502>	C143781	Grade 5 Prolapse of Intestinal Stoma, CTCAE|Grade 5 Prolapse of intestinal stoma|Grade 5 Prolapse of intestinal stoma	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146503>	C143782	Grade 5 Prolapse of Urostomy, CTCAE|Grade 5 Prolapse of urostomy|Grade 5 Prolapse of urostomy	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146504>	C143783	Grade 5 Prostate Infection, CTCAE|Grade 5 Prostate infection|Grade 5 Prostate infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146506>	C143787	Grade 5 Psychiatric Disorders - Other, Specify, CTCAE|Grade 5 Psychiatric disorders - Other, specify|Grade 5 Psychiatric disorders - Other, specify	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146507>	C143788	Grade 5 Psychosis, CTCAE|Grade 5 Psychosis|Grade 5 Psychosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146508>	C143789	Grade 5 Pulmonary Edema, CTCAE|Grade 5 Pulmonary edema|Grade 5 Pulmonary edema	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146509>	C143790	Grade 5 Pulmonary Fibrosis, CTCAE|Grade 5 Pulmonary fibrosis|Grade 5 Pulmonary fibrosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14650>	C14421	A/J Mouse|A/J|A/J	Derived by Strong (1921) from a cross between the Cold Spring harbor and Bagg Albino stocks. The A strain mouse has an albino coat (genotype a,b,c) and is susceptible to carcinogen-induced lung adenomas and cleft palate formation in response to cortisone. Also, the strain has defective macrophage function reminiscent of lps mutation common to other strains. The A strain has intermediate breeding performance with a high ratio of females at birth and a low litter size at weaning.	A/J Mouse		Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C146510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146510>	C143791	Grade 5 Pulmonary Fistula, CTCAE|Grade 5 Pulmonary fistula|Grade 5 Pulmonary fistula	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146511>	C143793	Grade 5 Pulmonary Valve Disease, CTCAE|Grade 5 Pulmonary valve disease|Grade 5 Pulmonary valve disease	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146512>	C143795	Grade 5 Pyramidal Tract Syndrome, CTCAE|Grade 5 Pyramidal tract syndrome|Grade 5 Pyramidal tract syndrome	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146513>	C143796	Grade 5 Radiation Recall Reaction (Dermatologic), CTCAE|Grade 5 Radiation recall reaction (dermatologic)|Grade 5 Radiation recall reaction (dermatologic)	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146514>	C143797	Grade 5 Radiculitis, CTCAE|Grade 5 Radiculitis|Grade 5 Radiculitis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146515>	C143798	Grade 5 Rash Acneiform, CTCAE|Grade 5 Rash acneiform	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146516>	C143801	Grade 5 Rectal Anastomotic Leak, CTCAE|Grade 5 Rectal anastomotic leak|Grade 5 Rectal anastomotic leak	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146519>	C143802	Grade 5 Rectal Mucositis, CTCAE|Grade 5 Rectal mucositis|Grade 5 Rectal mucositis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146523>	C143803	Grade 5 Rectal Stenosis, CTCAE|Grade 5 Rectal stenosis|Grade 5 Rectal stenosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146525>	C143804	Grade 5 Recurrent Laryngeal Nerve Palsy, CTCAE|Grade 5 Recurrent laryngeal nerve palsy|Grade 5 Recurrent laryngeal nerve palsy	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146526>	C143805	Grade 5 Renal and Urinary Disorders - Other, Specify, CTCAE|Grade 5 Renal and urinary disorders - Other, specify|Grade 5 Renal and urinary disorders - Other, specify	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146527>	C143806	Grade 5 Renal Calculi, CTCAE|Grade 5 Renal calculi|Grade 5 Renal calculi	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146529>	C143808	Grade 5 Reproductive System and Breast Disorders - Other, Specify, CTCAE|Grade 5 Reproductive system and breast disorders - Other, specify|Grade 5 Reproductive system and breast disorders - Other, specify	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14652>	C14421	A/He Mouse|A/He		A/He Mouse		Mammal	
C146530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146530>	C143809	Grade 5 Respiratory Failure, CTCAE|Grade 5 Respiratory failure|Grade 5 Respiratory failure	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146531>	C143810	Grade 5 Respiratory, Thoracic and Mediastinal Disorders - Other, Specify, CTCAE|Grade 5 Respiratory, thoracic and mediastinal disorders - Other, specify|Grade 5 Respiratory, thoracic and mediastinal disorders - Other, specify	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146532>	C146632	Grade 5 Retroperitoneal Hemorrhage, CTCAE|Grade 5 Retroperitoneal hemorrhage	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146533>	C143818	Grade 5 Reversible Posterior Leukoencephalopathy Syndrome, CTCAE|Grade 5 Reversible posterior leukoencephalopathy syndrome|Grade 5 Reversible posterior leukoencephalopathy syndrome	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146534>	C143226	Grade 5 Rhabdomyolysis, CTCAE|Grade 5 Rhabdomyolysis|Grade 5 Rhabdomyolysis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146535>	C143821	Grade 5 Salivary Duct Inflammation, CTCAE|Grade 5 Salivary duct inflammation|Grade 5 Salivary duct inflammation	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146536>	C143822	Grade 5 Salivary Gland Infection, CTCAE|Grade 5 Salivary gland infection|Grade 5 Salivary gland infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146537>	C143825	Grade 5 Scrotal Infection, CTCAE|Grade 5 Scrotal infection|Grade 5 Scrotal infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146538>	C143827	Grade 5 Sepsis, CTCAE|Grade 5 Sepsis|Grade 5 Sepsis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146539>	C143213	Grade 5 Shingles, CTCAE|Grade 5 Shingles|Grade 5 Shingles	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146540>	C143831	Grade 5 Sinus Disorder, CTCAE|Grade 5 Sinus disorder|Grade 5 Sinus disorder	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146541>	C143832	Grade 5 Sinusitis, CTCAE|Grade 5 Sinusitis|Grade 5 Sinusitis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146542>	C143205	Grade 5 Sinusoidal Obstruction Syndrome, CTCAE|Grade 5 Sinusoidal obstruction syndrome|Grade 5 Sinusoidal obstruction syndrome	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146543>	C143833	Grade 5 Skin and Subcutaneous Tissue Disorders - Other, Specify, CTCAE|Grade 5 Skin and subcutaneous tissue disorders - Other, specify|Grade 5 Skin and subcutaneous tissue disorders - Other, specify	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146544>	C143837	Grade 5 Skin Induration, CTCAE|Grade 5 Skin induration|Grade 5 Skin induration	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146545>	C143838	Grade 5 Skin Infection, CTCAE|Grade 5 Skin infection|Grade 5 Skin infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146546>	C143839	Grade 5 Skin Ulceration, CTCAE|Grade 5 Skin ulceration|Grade 5 Skin ulceration	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146547>	C143840	Grade 5 Sleep Apnea, CTCAE|Grade 5 Sleep apnea|Grade 5 Sleep apnea	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146548>	C143841	Grade 5 Small Intestinal Anastomotic Leak, CTCAE|Grade 5 Small intestinal anastomotic leak|Grade 5 Small intestinal anastomotic leak	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146549>	C143842	Grade 5 Small Intestinal Mucositis, CTCAE|Grade 5 Small intestinal mucositis|Grade 5 Small intestinal mucositis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146550>	C143843	Grade 5 Small Intestinal Obstruction, CTCAE|Grade 5 Small intestinal obstruction|Grade 5 Small intestinal obstruction	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146551>	C146635	Grade 5 Small Intestinal Perforation, CTCAE|Grade 5 Small intestinal perforation|Grade 5 Small intestinal perforation	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146552>	C143844	Grade 5 Small Intestinal Stenosis, CTCAE|Grade 5 Small intestinal stenosis|Grade 5 Small intestinal stenosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146553>	C143845	Grade 5 Small Intestine Infection, CTCAE|Grade 5 Small intestine infection|Grade 5 Small intestine infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146554>	C143846	Grade 5 Small Intestine Ulcer, CTCAE|Grade 5 Small intestine ulcer|Grade 5 Small intestine ulcer	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146555>	C143848	Grade 5 Social Circumstances - Other, Specify, CTCAE|Grade 5 Social circumstances - Other, specify|Grade 5 Social circumstances - Other, specify	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146556>	C143849	Grade 5 Soft Tissue Infection, CTCAE|Grade 5 Soft tissue infection|Grade 5 Soft tissue infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146557>	C143850	Grade 5 Soft Tissue Necrosis Lower Limb, CTCAE|Grade 5 Soft tissue necrosis lower limb|Grade 5 Soft tissue necrosis lower limb	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146558>	C143851	Grade 5 Soft Tissue Necrosis Upper Limb, CTCAE|Grade 5 Soft tissue necrosis upper limb|Grade 5 Soft tissue necrosis upper limb	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146559>	C143852	Grade 5 Somnolence, CTCAE|Grade 5 Somnolence|Grade 5 Somnolence	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146560>	C143854	Grade 5 Spasticity, CTCAE|Grade 5 Spasticity|Grade 5 Spasticity	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146561>	C143855	Grade 5 Spermatic Cord Anastomotic Leak, CTCAE|Grade 5 Spermatic cord anastomotic leak|Grade 5 Spermatic cord anastomotic leak	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146562>	C143233	Grade 5 Spinal Cord Compression, CTCAE|Grade 5 Spinal cord compression	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146563>	C143856	Grade 5 Spinal Fracture, CTCAE|Grade 5 Spinal fracture	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146564>	C143857	Grade 5 Splenic Infection, CTCAE|Grade 5 Splenic infection|Grade 5 Splenic infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146565>	C143858	Grade 5 Stenosis of Gastrointestinal Stoma, CTCAE|Grade 5 Stenosis of gastrointestinal stoma|Grade 5 Stenosis of gastrointestinal stoma	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146566>	C143859	Grade 5 Stevens-Johnson Syndrome, CTCAE|Grade 5 Stevens-Johnson syndrome|Grade 5 Stevens-Johnson syndrome	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146567>	C143860	Grade 5 Stoma Site Infection, CTCAE|Grade 5 Stoma site infection|Grade 5 Stoma site infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146568>	C143861	Grade 5 Stridor, CTCAE|Grade 5 Stridor|Grade 5 Stridor	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146569>	C143862	Grade 5 Stroke, CTCAE|Grade 5 Stroke|Grade 5 Stroke	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146570>	C143863	Grade 5 Sudden Death NOS, CTCAE|Grade 5 Sudden death NOS|Grade 5 Sudden death NOS	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146571>	C143865	Grade 5 Suicide Attempt, CTCAE|Grade 5 Suicide attempt|Grade 5 Suicide attempt	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146572>	C143866	Grade 5 Superficial Soft Tissue Fibrosis, CTCAE|Grade 5 Superficial soft tissue fibrosis|Grade 5 Superficial soft tissue fibrosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146573>	C143868	Grade 5 Superior Vena Cava Syndrome, CTCAE|Grade 5 Superior vena cava syndrome|Grade 5 Superior vena cava syndrome	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146574>	C143869	Grade 5 Surgical and Medical Procedures - Other, Specify, CTCAE|Grade 5 Surgical and medical procedures - Other, specify|Grade 5 Surgical and medical procedures - Other, specify	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146576>	C143873	Grade 5 Thromboembolic Event, CTCAE|Grade 5 Thromboembolic event	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146577>	C143874	Grade 5 Thrombotic Thrombocytopenic Purpura, CTCAE|Grade 5 Thrombotic thrombocytopenic purpura|Grade 5 Thrombotic thrombocytopenic purpura	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146578>	C143878	Grade 5 Tooth Infection, CTCAE|Grade 5 Tooth infection|Grade 5 Tooth infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146579>	C143880	Grade 5 Toxic Epidermal Necrolysis, CTCAE|Grade 5 Toxic epidermal necrolysis|Grade 5 Toxic epidermal necrolysis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C14657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14657>	C14421	BALB/cJ Mouse|BALB/cJ		BALB/cJ Mouse		Mammal	
C146582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146582>	C143881	Grade 5 Tracheal Mucositis, CTCAE|Grade 5 Tracheal mucositis|Grade 5 Tracheal mucositis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146583>	C143882	Grade 5 Tracheal Obstruction, CTCAE|Grade 5 Tracheal obstruction|Grade 5 Tracheal obstruction	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146584>	C143883	Grade 5 Tracheal Stenosis, CTCAE|Grade 5 Tracheal stenosis|Grade 5 Tracheal stenosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146585>	C143884	Grade 5 Tracheitis, CTCAE|Grade 5 Tracheitis|Grade 5 Tracheitis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146586>	C143885	Grade 5 Tracheostomy Site Bleeding, CTCAE|Grade 5 Tracheostomy site bleeding|Grade 5 Tracheostomy site bleeding	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146587>	C143887	Grade 5 Treatment Related Secondary Malignancy, CTCAE|Grade 5 Treatment related secondary malignancy|Grade 5 Treatment related secondary malignancy	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146588>	C143889	Grade 5 Tricuspid Valve Disease, CTCAE|Grade 5 Tricuspid valve disease|Grade 5 Tricuspid valve disease	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146589>	C143229	Grade 5 Tumor Hemorrhage, CTCAE|Grade 5 Tumor hemorrhage|Grade 5 Tumor hemorrhage	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146590>	C143895	Grade 5 Upper Gastrointestinal Hemorrhage, CTCAE|Grade 5 Upper gastrointestinal hemorrhage|Grade 5 Upper gastrointestinal hemorrhage	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146591>	C143896	Grade 5 Upper Respiratory Infection, CTCAE|Grade 5 Upper respiratory infection|Grade 5 Upper respiratory infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146592>	C143897	Grade 5 Ureteric Anastomotic Leak, CTCAE|Grade 5 Ureteric anastomotic leak|Grade 5 Ureteric anastomotic leak	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146593>	C143898	Grade 5 Urethral Anastomotic Leak, CTCAE|Grade 5 Urethral anastomotic leak|Grade 5 Urethral anastomotic leak	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146594>	C143899	Grade 5 Urethral Infection, CTCAE|Grade 5 Urethral infection|Grade 5 Urethral infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146595>	C143900	Grade 5 Urinary Fistula, CTCAE|Grade 5 Urinary fistula|Grade 5 Urinary fistula	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146596>	C143904	Grade 5 Urinary Tract Infection, CTCAE|Grade 5 Urinary tract infection|Grade 5 Urinary tract infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146597>	C143905	Grade 5 Urinary Tract Obstruction, CTCAE|Grade 5 Urinary tract obstruction|Grade 5 Urinary tract obstruction	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146598>	C143910	Grade 5 Urostomy Leak, CTCAE|Grade 5 Urostomy leak|Grade 5 Urostomy leak	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146599>	C143911	Grade 5 Urostomy Obstruction, CTCAE|Grade 5 Urostomy obstruction|Grade 5 Urostomy obstruction	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C1465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1465>	C333|C1744	Dexniguldipine|(+)-(R)-3-(4,4-Diphenylpiperidino)Propyl Methyl 1,4-Dihydro-2,6-Dimethyl-4-(M-Nitrophenyl)-3,5-Pyridinedicarboxylate|B 859-35 Base Form|B8509-035 Base Form|B859 35 Base Form|DEXNIGULDIPINE|DNIG	Dexniguldipine is the (+)-enantiomer of the dihydropyridine derivate niguldipine. Dexniguldipine showed a binding affinity to the P-glycoprotein and therefore it is to be assumed to block the P-glycoprotein pumping mechanism and to modulate multidrug resistance. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C146600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146600>	C143912	Grade 5 Urostomy Site Bleeding, CTCAE|Grade 5 Urostomy site bleeding|Grade 5 Urostomy site bleeding	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146601>	C143913	Grade 5 Urostomy Stenosis, CTCAE|Grade 5 Urostomy stenosis|Grade 5 Urostomy stenosis	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146602>	C143915	Grade 5 Uterine Anastomotic Leak, CTCAE|Grade 5 Uterine anastomotic leak|Grade 5 Uterine anastomotic leak	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146603>	C143916	Grade 5 Uterine Fistula, CTCAE|Grade 5 Uterine fistula|Grade 5 Uterine fistula	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146605>	C143917	Grade 5 Uterine Infection, CTCAE|Grade 5 Uterine infection|Grade 5 Uterine infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146606>	C143919	Grade 5 Uterine Perforation, CTCAE|Grade 5 Uterine perforation|Grade 5 Uterine perforation	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146607>	C143921	Grade 5 Vaginal Anastomotic Leak, CTCAE|Grade 5 Vaginal anastomotic leak|Grade 5 Vaginal anastomotic leak	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146610>	C143924	Grade 5 Vaginal Infection, CTCAE|Grade 5 Vaginal infection|Grade 5 Vaginal infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146611>	C146697	Grade 5 Vaginal Perforation, CTCAE|Grade 5 Vaginal perforation|Grade 5 Vaginal perforation	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146612>	C143926	Grade 5 Vaginal Stricture, CTCAE|Grade 5 Vaginal stricture|Grade 5 Vaginal stricture	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146613>	C143927	Grade 5 Vagus Nerve Disorder, CTCAE|Grade 5 Vagus nerve disorder|Grade 5 Vagus nerve disorder	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146614>	C143928	Grade 5 Vas Deferens Anastomotic Leak, CTCAE|Grade 5 Vas deferens anastomotic leak|Grade 5 Vas deferens anastomotic leak	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146615>	C143929	Grade 5 Vascular Access Complication, CTCAE|Grade 5 Vascular access complication|Grade 5 Vascular access complication	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146616>	C143930	Grade 5 Vascular Disorders - Other, Specify, CTCAE|Grade 5 Vascular disorders - Other, specify|Grade 5 Vascular disorders - Other, specify	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146617>	C143932	Grade 5 Vasovagal Reaction, CTCAE|Grade 5 Vasovagal reaction	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146618>	C143933	Grade 5 Venous Injury, CTCAE|Grade 5 Venous injury|Grade 5 Venous injury	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146619>	C146629	Grade 5 Ventricular Arrhythmia, CTCAE|Grade 5 Ventricular arrhythmia|Grade 5 Ventricular arrhythmia	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146620>	C143938	Grade 5 Visceral Arterial Ischemia, CTCAE|Grade 5 Visceral arterial ischemia|Grade 5 Visceral arterial ischemia	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146621>	C143943	Grade 5 Vulval Infection, CTCAE|Grade 5 Vulval infection|Grade 5 Vulval infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146622>	C143947	Grade 5 Wheezing, CTCAE|Grade 5 Wheezing	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146623>	C143949	Grade 5 Wound Complication, CTCAE|Grade 5 Wound complication|Grade 5 Wound complication	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146624>	C143950	Grade 5 Wound Dehiscence, CTCAE|Grade 5 Wound dehiscence|Grade 5 Wound dehiscence	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146625>	C143951	Grade 5 Wound Infection, CTCAE|Grade 5 Wound infection|Grade 5 Wound infection	Death			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology
C146626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146626>	C220591|C146630	Gingival Pain, CTCAE|Gingival Pain|Gingival pain|Gingival pain	A disorder characterized by a sensation of marked discomfort in the gingival region.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146627>	C220591|C146630	Oral Pain, CTCAE|Oral Pain|Oral Pain, CTCAE 5.0|Oral pain|Oral pain	A disorder characterized by a sensation of marked discomfort in the mouth, tongue or lips.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146629>	C220586|C143165	Ventricular Arrhythmia, CTCAE|Ventricular Arrhythmia|Ventricular Arrhythmia, CTCAE 5.0|Ventricular arrhythmia|Ventricular arrhythmia	A disorder characterized by a dysrhythmia that originates in the ventricles.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146630>	C143163	Gastrointestinal Disorders, CTCAE 5.0	Gastrointestinal Disorders, CTCAE 5.0 captures adverse events effecting this System Organ Class as defined and used by MedDRA 20.1 and CTCAE 5.0.			Finding	CTCAE Adverse Events Version 5.0 Terminology
C146631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146631>	C220591|C146630	Rectal Pain, CTCAE|Rectal Pain|Rectal Pain (Priority 2)|Rectal Pain, CTCAE 5.0|Rectal pain|Rectal pain	A disorder characterized by a sensation of marked discomfort in the rectal region.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C146632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146632>	C146630	Retroperitoneal Hemorrhage, CTCAE 5.0|Retroperitoneal Hemorrhage|Retroperitoneal hemorrhage	A disorder characterized by bleeding from the retroperitoneal area.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C146633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146633>	C220591|C146630	Ileal Perforation, CTCAE|Ileal Perforation|Ileal Perforation, CTCAE 5.0|Ileal perforation|Ileal perforation	A disorder characterized by a rupture in the ileal wall.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146634>	C220591|C146630	Rectal Perforation, CTCAE|Rectal Perforation|Rectal Perforation (Priority 1)|Rectal Perforation, CTCAE 5.0|Rectal perforation|Rectal perforation	A disorder characterized by a rupture in the rectal wall.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C146635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146635>	C220591|C146630	Small Intestinal Perforation, CTCAE|Small Intestinal Perforation|Small Intestinal Perforation, CTCAE 5.0|Small intestinal perforation|Small intestinal perforation	A disorder characterized by a rupture in the small intestine wall.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146636>	C308	IL-2/9/15 Gamma Chain Receptor Inhibitor BNZ-1|BNZ-1|BNZ132-1-40	A pegylated peptide antagonist that binds to the common gamma chain (gc; IL2RG; CD132) of the signaling receptor for the pro-inflammatory cytokines interleukin (IL)-2, IL-9, and IL-15, with potential immunomodulating and antineoplastic activities. Upon administration, IL-2/9/15 gc receptor inhibitor BNZ-1 specifically targets and binds to the IL binding site on the gc receptor and blocks IL-2, IL-9 and IL-15 binding, thereby inhibiting IL-2-, IL-9-, and IL-15-mediated signaling and downstream pathways. This may inhibit proliferation of tumor cells that are dependent on IL-2/9/15 signaling for their growth. IL-2/9/15 are upregulated in certain tumor cell types and play a key role in tumor progression and survival.	IL-2/9/15 Gamma Chain Receptor Inhibitor BNZ-1		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C146637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146637>	C220591|C146630	Gastrointestinal Fistula, CTCAE|Gastrointestinal Fistula|Gastrointestinal Fistula, CTCAE 5.0|Gastrointestinal fistula|Gastrointestinal fistula	A disorder characterized by an abnormal communication between any part of the gastrointestinal system and another organ or anatomic site.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146638>	C574	Calcineurin Inhibitor|CNI Inhibitor	Any agent that inhibits calcineurin (protein phosphatase 3; PPP3), a serine/threonine protein phosphatase dependent on calcium and calmodulin, with immunosuppressant activity. Inhibition of calcineurin prevents dephosphorylation of the transcription factor nuclear factor of activated T-cells, cytoplasmic (NFATc), which prevents its translocation to the nucleus and the subsequent induction of the expression of interleukin-2 (IL-2). This prevents IL-2-mediated proliferation and activation of T-cells, and T-lymphocyte-mediated immune responses.	Calcineurin Inhibitor		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C146639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146639>	C155747	Peroxisome Biogenesis Disorders in the Zellweger Spectrum|PBD-ZSD|Zellweger Spectrum Disorder	A group of conditions with overlapping signs and symptoms. It includes Zellweger syndrome, neonatal adrenoleukodystrophy, and infantile Refsum disease.			Disease or Syndrome	
C146640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146640>	C6454	Atypical Type A Thymoma|Atypical Type A Thymoma Variant	A rare type A thymoma displaying atypical features (hypercellularity, increased mitotic activity, and focal necrosis).			Neoplastic Process	
C146641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146641>	C132246	3p14 Loss of Heterozygosity|3p14 LOH	A molecular abnormality that results in monoallelic loss of function mutations located within 3p14.	3p14 Loss of Heterozygosity		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146642>	C220594|C143186	Serum Sickness, CTCAE|Serum Sickness|Serum Sickness, CTCAE 5.0|Serum sickness|Serum sickness	A disorder characterized by a delayed-type hypersensitivity reaction to foreign proteins derived from an animal serum. It occurs approximately six to twenty-one days following the administration of the foreign antigen. Symptoms include fever, arthralgias, myalgias, skin eruptions, lymphadenopathy, chest marked discomfort and dyspnea.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146643>	C143183	Flushing, CTCAE 5.0|Flushing|Flushing	A disorder characterized by episodic reddening of the skin, especially face, neck, or chest.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C146644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146644>	C143182	Skin Atrophy, CTCAE 5.0|Skin Atrophy|Skin atrophy	A disorder characterized by the degeneration and thinning of the epidermis and dermis.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C146645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146645>	C220589|C143166	Precocious Puberty, CTCAE|Precocious Puberty|Precocious Puberty, CTCAE 5.0|Precocious puberty|Precocious puberty	A disorder characterized by unusually early development of secondary sexual features; the onset of sexual maturation begins usually before age 8 for girls and before age 9 for boys.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146646>	C177686	KIR2DL1 Polymorphism Positive|CD158A Polymorphism Positive|KIR-K64 Polymorphism Positive|KIR221 Polymorphism Positive|KIR2DL1 Gene Polymorphism Positive|KIR2DL1 Polymorphism Present|KIR2DS5 Polymorphism Positive|Killer Cell Immunoglobulin Like Receptor, Two Ig Domains and Long Cytoplasmic Tail 1 Gene Polymorphism Positive|NKAT Polymorphism Positive|NKAT-1 Polymorphism Positive|NKAT1 Polymorphism Positive	An indication that polymorphism of the KIR2DL1 gene has been detected in a sample.	KIR2DL1 Polymorphism Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146647>	C35681	Helicobacter pylori Negative|H. pylori Negative|Negative	An indication that Helicobacter pylori was not detected in a sample.	Helicobacter pylori Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C146648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146648>	C180928|C177686	BRCA1 Polymorphism Positive|BRCA1 Gene Polymorphism Present|BRCA1 Polymorphism Present|BROVCA1 Gene Polymorphism Present|Breast Cancer Type 1 Susceptibility Gene Polymorphism Present	An indication that polymorphism of the BRCA1 gene has been detected in a sample.	BRCA1 Polymorphism Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146649>	C177686	BRCA2 Polymorphism Positive|BRCA2 Gene Polymorphism Present|BRCA2 Polymorphism Present|BROVCA2 Gene Polymorphism Present|Breast Cancer Type 2 Susceptibility Gene Polymorphism Present|FANCD1 Gene Polymorphism Present	An indication that polymorphism of the BRCA2 gene has been detected in a sample.	BRCA2 Polymorphism Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146650>	C35682	Clostridium difficile Positive|C. diff. Positive|C. difficile Positive	An indication that Clostridium difficile was detected in a sample.	Clostridium difficile Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C146651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146651>	C180750	AKT1 Gene Alteration Positive|AKT Gene Alteration Positive|PKB Gene Alteration Positive|PRKBA Gene Alteration Positive|RAC Gene Alteration Positive|RAC-ALPHA Gene Alteration Positive|RAC-PK-Alpha Gene Alteration Positive|v-akt Murine Thymoma Viral Oncogene Homolog 1 Gene Alteration Positive	A finding indicating that mutation, overexpression or rearrangement of the AKT1 gene has been detected in a sample.	AKT1 Gene Alteration Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146652>	C180750	AKT2 Gene Alteration Positive|AKT Serine/Threonine Kinase 2 Gene Alteration Positive|HIHGHH Gene Alteration Positive|PKBB Gene Alteration Positive|PKBBETA Gene Alteration Positive|PRKBB Gene Alteration Positive|RAC-BETA Gene Alteration Positive|RAC-PK-Beta Gene Alteration Positive|v-akt Murine Thymoma Viral Oncogene Homolog 2 Gene Alteration Positive	A finding indicating that mutation, overexpression or rearrangement of the AKT2 gene has been detected in a sample.	AKT2 Gene Alteration Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146653>	C180750	AKT3 Gene Alteration Positive|AKT Serine/Threonine Kinase 3 Gene Alteration Positive|PKB-GAMMA Alteration Positive|PKBG Gene Alteration Positive|PRKBG Gene Alteration Positive|RAC-GAMMA Gene Alteration Positive|RAC-PK-Gamma Gene Alteration Positive|STK-2 Alteration Positive|v-akt Murine Thymoma Viral Oncogene Homolog 3 Gene Alteration Positive	A finding indicating that mutation, overexpression or rearrangement of the AKT3 gene has been detected in a sample.	AKT3 Gene Alteration Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146654>	C171055|C16606	RB1 Gene Deletion|RB Gene Deletion|Retinoblastoma 1 Gene Deletion|Retinoblastoma Gene Deletion	A molecular abnormality referring to the loss of at least one copy of the RB1 gene.	RB1 Gene Deletion		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146655>	C94299|C177692	RARA Positive|NR1B1 Positive|Nuclear Receptor Subfamily 1 Group B Member 1 Positive|RAR Positive|RARalpha Positive|Retinoic Acid Receptor Alpha Positive	An indication that RARA expression has been detected in a sample.	RARA Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146656>	C141299	Blasts More Than 5 Percent of Peripheral Blood White Cells|Blasts Greater than 5 Percent of Peripheral Blood White Cells|Blasts Over 5 Percent of Peripheral Blood White Cells	A semi-quantitative microscopic finding indicating that more than 5 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.	Blasts More Than 5 Percent of Peripheral Blood White Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C146657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146657>	C177692	MLL Positive|ALL-1 Positive|Histone-Lysine N-Methyltransferase 2A Positive|Histone-Lysine N-Methyltransferase MLL Positive|KMT2A Positive|Lysine (K)-Specific Methyltransferase 2A Positive|Lysine N-Methyltransferase 2A Positive|Myeloid/Lymphoid or Mixed-Lineage Leukemia Positive|Zinc Finger Protein HRX Positive	An indication that MLL expression has been detected in a sample.	MLL Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146659>	C177692	MITF Positive|Class E Basic Helix-Loop-Helix Protein 32 Positive|MI Positive|Microphthalmia-Associated Transcription Factor Positive|bHLHe32 Positive	An indication that MITF expression has been detected in a sample.	MITF Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146660>	C574	Mezigdomide|BMS 986348|BMS-986348|BMS986348|CC 92480|CC-92480|CC92480|CELMoD CC-92480|Cereblon E3 Ligase Modulation Drug CC-92480|Cereblon E3 Ubiquitin Ligase Modulating Agent CC-92480|Cereblon Modulator CC-92480|MEZIGDOMIDE	A modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and antineoplastic activities. Upon administration, mezigdomide specifically binds to cereblon (CRBN), thereby affecting the ubiquitin E3 ligase activity, and targeting certain substrate proteins for ubiquitination. This induces proteasome-mediated degradation of certain transcription factors, some of which are transcriptional repressors in T-cells. This leads to modulation of the immune system, including activation of T-lymphocytes, and downregulation of the activity of other proteins, some of which play key roles in the proliferation of certain cancer cell types. CRBN, the substrate recognition component of the CRL4-CRBN E3 ubiquitin ligase complex, plays a key role in the ubiquitination of certain proteins.	Mezigdomide		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C146661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146661>	C36214|C190646	Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells|Lymphoblasts Greater than or Equal to 20 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that 20 percent or more of the nucleated cells in a bone marrow sample are immature mononuclear cells of lymphoid origin.	Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C146662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146662>	C36213|C190647	Lymphoblasts 20 Percent or More of Peripheral Blood White Cells|Lymphoblasts Greater than or Equal to 20 Percent of Peripheral Blood White Cells	A semi-quantitative microscopic finding indicating that 20 percent or more of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells of lymphoid origin.	Lymphoblasts 20 Percent or More of Peripheral Blood White Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C146663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146663>	C220606|C143181	Pleuritic Pain, CTCAE|Pleuritic Pain|Pleuritic Pain, CTCAE 5.0|Pleuritic pain|Pleuritic pain	A disorder characterized by a sensation of marked discomfort in the pleura.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146664>	C220605|C143180	Prostatic Pain, CTCAE|Prostatic Pain|Prostatic Pain, CTCAE 5.0|Prostatic pain|Prostatic pain	A disorder characterized by a sensation of marked discomfort in the prostate gland.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146665>	C220605|C143180	Scrotal Pain, CTCAE|Scrotal Pain|Scrotal Pain, CTCAE 5.0|Scrotal pain|Scrotal pain	A disorder characterized by a sensation of marked discomfort in the scrotal area.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146666>	C220605|C143180	Testicular Pain, CTCAE|Testicular Pain|Testicular Pain, CTCAE 5.0|Testicular pain|Testicular pain	A disorder characterized by a sensation of marked discomfort in the testis.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146667>	C201552	Anti-c-Met Antibody-drug Conjugate HTI-1066|ADC HTI-1066|HTI 1066|HTI-1066	An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the tumor-associated antigen (TAA) the proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of HTI-1066 targets and binds to c-Met expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the c-Met-expressing cancer cells, through an as of yet unknown mechanism of action. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis.	Anti-c-Met Antibody-drug Conjugate HTI-1066		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C146668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146668>	C177692	TP53 Positive|Antigen NY-CO-13 Positive|Cellular Tumor Antigen p53 Positive|TRP53 Positive|Transformation-Related Protein 53 Positive|Tumor Protein p53 Positive|Tumor Suppressor p53 Positive|p53 Positive	An indication that TP53 expression has been detected in a sample.	TP53 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146669>	C42776|C136411	Myeloblasts 5 Percent or More of Bone Marrow Nucleated Cells|Myeloblasts Greater than or Equal to 5 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that 5 percent or more of the nucleated cells in a bone marrow sample are immature mononuclear cells of myeloid origin.	Myeloblasts 5 Percent or More of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C146670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146670>	C177692|C128808	CEACAM5 Positive|CD66e Antigen Positive|CD66e Positive|CEA Positive|Carcinoembryonic Antigen CGM2 Positive|Carcinoembryonic Antigen Related Cell Adhesion Molecule 5 Positive|Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 Positive|Meconium Antigen 100 Positive	An indication that CEACAM5 expression has been detected in a sample.	CEACAM5 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146671>	C94299|C177692	FLT3 Positive|CD135 Positive|FLK-2 Positive|FLK2 Positive|FLT-3 Positive|FMS-Related Tyrosine Kinase 3 Positive|Fetal Liver Kinase-2 Positive|Receptor-Type Tyrosine-Protein Kinase FLT3 Positive|Stem Cell Tyrosine Kinase 1 Positive	An indication that FLT3 expression has been detected in a sample.	FLT3 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146672>	C35682	Human Herpesvirus 8 Positive|HHV-8 Positive|HHV8 Positive|Human Herpesvirus-8 Positive|KSHV Positive|Kaposi Sarcoma Herpes Virus Positive|Kaposi Sarcoma-Associated Herpes Virus Positive	An indication that human herpesvirus 8 has been detected in a sample.	Human Herpesvirus 8 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C146673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146673>	C35881	Blasts 30 Percent or Less of Peripheral Blood White Cells|Blasts Less than or Equal to 30 Percent of Peripheral Blood White Cells	A semi-quantitative microscopic finding indicating that 30 percent or less of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.	Blasts 30 Percent or Less of Peripheral Blood White Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C146674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146674>	C220590|C143167	Cataract, CTCAE|Cataract|Cataract|Cataract|Cataract, CTCAE 5.0	A disorder characterized by partial or complete opacity of the crystalline lens of one or both eyes. This results in a decrease in visual acuity and eventual blindness if untreated.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146675>	C93102|C121369	Deleterious PTEN Gene Mutation|Deleterious MMAC1 Gene Mutation|Deleterious Mutated in Multiple Advanced Cancers 1 Gene Mutation|Deleterious PTEN1 Gene Mutation|Deleterious Phosphatase and Tensin Homolog Gene Mutation|Deleterious TEP1 Gene Mutation|PTEN Deleterious Gene Mutation	A change in the nucleotide sequence of the PTEN gene that is associated with increased risk of disease.	Deleterious PTEN Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146676>	C93102|C118396	Deleterious TP53 Gene Mutation|Deleterious BCC7 Gene Mutation|Deleterious LFS1 Gene Mutation|Deleterious Li-Fraumeni Syndrome Gene Mutation|Deleterious TRP53 Gene Mutation|Deleterious Tumor Protein p53 Gene Mutation|Deleterious p53 Gene Mutation|TP53 Deleterious Gene Mutation	A change in the nucleotide sequence of the TP53 gene that is associated with increased risk of disease.	Deleterious TP53 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C146677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146677>	C220590|C143167	Vitreous Hemorrhage, CTCAE|Vitreous Hemorrhage|Vitreous Hemorrhage, CTCAE 5.0|Vitreous hemorrhage|Vitreous hemorrhage	A disorder characterized by bleeding into the vitreous humor.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146678>	C35682|C26683	Disseminated Tumor Cells Positive|DTC Positive|Disseminated Tumor Cells Present	An indication that single tumor cells or small clusters of tumor cells have been detected in a tissue sample.	Disseminated Tumor Cells Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C146679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146679>	C220605|C143180	Pelvic Pain, CTCAE|Pelvic Pain|Pelvic Pain, CTCAE 5.0|Pelvic pain|Pelvic pain	A disorder characterized by a sensation of marked discomfort in the pelvis.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146680>	C220605|C143180	Penile Pain, CTCAE|Penile Pain|Penile Pain, CTCAE 5.0|Penile pain|Penile pain	A disorder characterized by a sensation of marked discomfort in the penis.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146681>	C220605|C143180	Perineal Pain, CTCAE|Perineal Pain|Perineal Pain, CTCAE 5.0|Perineal pain|Perineal pain	A disorder characterized by a sensation of marked discomfort in the area between the genital organs and the anus.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146682>	C220601|C143177	Phantom Pain, CTCAE|Phantom Pain|Phantom Pain, CTCAE 5.0|Phantom pain|Phantom pain	A disorder characterized by a sensation of marked discomfort related to a limb or an organ that is removed from or is not physically part of the body.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146683>	C220605|C143180	Uterine Pain, CTCAE|Uterine Pain|Uterine Pain, CTCAE 5.0|Uterine pain|Uterine pain	A disorder characterized by a sensation of marked discomfort in the uterus.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146684>	C220605|C143180	Vaginal Pain, CTCAE|Vaginal Pain|Vaginal Pain, CTCAE 5.0|Vaginal pain|Vaginal pain	A disorder characterized by a sensation of marked discomfort in the vagina.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146685>	C220605|C143180	Gynecomastia, CTCAE|Gynecomastia|Gynecomastia|Gynecomastia|Gynecomastia (Priority 2)|Gynecomastia, CTCAE 5.0	A disorder characterized by excessive development of the breasts in males.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C146686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146686>	C177692	MKI67 Positive|Antigen Ki-67 Positive|KI67 Positive|Ki 67 Positive|Ki-67 Antigen Positive|Ki-67 Positive	An indication that MKI67 expression has been detected in a sample.	MKI67 Positive		Laboratory or Test Result	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146687>	C220605|C143180	Vaginal Dryness, CTCAE|Vaginal Dryness|Vaginal Dryness, CTCAE 5.0|Vaginal dryness|Vaginal dryness	A disorder characterized by an uncomfortable feeling of itching and burning in the vagina.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146688>	C143174	Tumor Lysis Syndrome, CTCAE 5.0|Tumor Lysis Syndrome|Tumor lysis syndrome	A disorder characterized by metabolic abnormalities that result from a spontaneous or therapy-related cytolysis of tumor cells.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C146689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146689>	C141297|C136411	Blasts 5-30 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that between 5 and 30 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts 5-30 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C146690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146690>	C220588|C143185	Tinnitus, CTCAE|Tinnitus|Tinnitus|Tinnitus|Tinnitus, CTCAE 5.0	A disorder characterized by noise in the ears, such as ringing, buzzing, roaring or clicking.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146691>	C35877|C35682	Circulating Tumor Cells Positive|CTC Positive|Circulating Tumor Cells Present	An indication that tumor cells have been detected in a peripheral blood sample.	Circulating Tumor Cells Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C146692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146692>	C18302	BRCA Mutation Analysis|BRCA Family Gene Mutation Analysis|BRCA Mutation Status	A procedure to test for the presence of mutations in BRCA family genes.	BRCA Mutation Analysis		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146693>	C2124	Fluorine F 18 Tetrafluoroborate|18F-TFB|18F-Tetrafluoroborate	A radioconjugate composed of the sodium-iodide symporter (NIS; SLC5A5) ligand tetrafluoroborate (TFB) labeled with the radionuclide fluorine F 18, with potential use as an imaging agent for NIS-expressing cells upon positron emission tomography (PET). Upon administration, fluorine F 18 tetrafluoroborate targets, binds to, and is taken up by NIS, which is expressed on the surface of cells in the normal thyroid gland, lactating mammary gland and various tumors. Then, NIS-expressing cells can be visualized and NIS expression levels can be assessed using PET. Since iodides are taken up by NIS, this agent may predict the uptake of radioactive iodine by thyroid cancer cells.	Fluorine F 18 Tetrafluoroborate		Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C146694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146694>	C220596|C143172	Stomal Ulcer, CTCAE|Stomal Ulcer|Stomal Ulcer, CTCAE 5.0|Stomal ulcer|Stomal ulcer	A disorder characterized by a circumscribed, erosive lesion on the jejunal mucosal surface close to the anastomosis site following a gastroenterostomy procedure.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146695>	C143165	Myocarditis, CTCAE|Myocarditis|Myocarditis|Myocarditis, CTCAE 5.0	A disorder characterized by inflammation of the muscle tissue of the heart.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C146696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146696>	C220605|C143180	Vaginal Obstruction, CTCAE|Vaginal Obstruction|Vaginal Obstruction, CTCAE 5.0|Vaginal obstruction|Vaginal obstruction	A disorder characterized by blockage of vaginal canal.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146697>	C220605|C143180	Vaginal Perforation, CTCAE|Vaginal Perforation|Vaginal Perforation, CTCAE 5.0|Vaginal perforation|Vaginal perforation	A disorder characterized by a rupture in the vaginal wall.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146698>	C220604|C143179	Bladder Spasm, CTCAE|Bladder Spasm|Bladder Spasm, CTCAE 5.0|Bladder Spasms (Priority 2)|Bladder spasm|Bladder spasm	A disorder characterized by a sudden and involuntary contraction of the bladder wall.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C146699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146699>	C220601|C143177	Encephalopathy, CTCAE|Encephalopathy|Encephalopathy|Encephalopathy|Encephalopathy, CTCAE 5.0	A disorder characterized by a pathologic process involving the brain.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C1466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1466>	C496	Recombinant Fibroblast Growth Factor 3|FGF3|Fibroblast Growth Factor 3|HBGF-3|Proto-Oncogene Protein Int-2	A recombinant agent which is chemically identical to or similar to endogenous fibroblast growth factor 3 (FGF-3). FGF-3 is a growth factor for epithelial cells, and is involved in the differentiation of mesodermal structures during embryonic development. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C146700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146700>	C143177	Seizure, CTCAE 5.0|Seizure|Seizure	A disorder characterized by a sudden, involuntary skeletal muscular contractions of cerebral or brain stem origin.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C146701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146701>	C140258	Enneking Stage IA|Stage IA	A stage for malignant musculoskeletal tumors characterized by low grade (G1), intracomparmental site (T1), and no metastasis (M0).			Classification	GDC Terminology|GDC Value Terminology
C146702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146702>	C140258	Enneking Stage IB|Stage IB	A stage for malignant musculoskeletal tumors characterized by low grade (G1), extracomparmental site (T2), and no metastasis (M0).			Classification	GDC Terminology|GDC Value Terminology
C146703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146703>	C140258	Enneking Stage IIA|Stage IIA	A stage for malignant musculoskeletal tumors characterized by high grade (G2), intracomparmental site (T1), and no metastasis (M0).			Classification	GDC Terminology|GDC Value Terminology
C146704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146704>	C140258	Enneking Stage IIB|Stage IIB	A stage for malignant musculoskeletal tumors characterized by high grade (G2), intracomparmental site (T2), and no metastasis (M0).			Classification	GDC Terminology|GDC Value Terminology
C146705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146705>	C140258	Enneking Stage III|Stage III	A stage for malignant musculoskeletal tumors characterized by any grade, any site, and regional or distant metastasis (M1).			Classification	GDC Terminology|GDC Value Terminology
C146706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146706>	C7569|C142781	Mediastinal/Thymus NUT Carcinoma|Mediastinal/Thymic NUT Carcinoma	A highly aggressive, poorly differentiated carcinoma that arises from the mediastinum/thymus. It is characterized by mutations and rearrangement of the NUT gene.			Neoplastic Process	
C146707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146707>	C220604|C143179	Bladder Perforation, CTCAE|Bladder Perforation|Bladder Perforation, CTCAE 5.0|Bladder perforation|Bladder perforation	A disorder characterized by a rupture in the bladder wall.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146708>	C220593|C143170	Gallbladder Perforation, CTCAE|Gallbladder Perforation|Gallbladder Perforation, CTCAE 5.0|Gallbladder perforation|Gallbladder perforation	A disorder characterized by a rupture in the gallbladder wall.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146709>	C156690|C136411	Blasts 5-25 Percent of Bone Marrow Nucleated Cells|M2 (5-25% blasts)	A semi-quantitative microscopic finding indicating that between 5 and 25 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts 5-25 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	ALL Authorized Value Terminology|ALL Lab Table|CTRP Biomarker Terminology|CTRP Terminology
C146710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146710>	C146630	Esophageal Varices Hemorrhage, CTCAE 5.0|Esophageal Varices Hemorrhage|Esophageal varices hemorrhage	A disorder characterized by bleeding from esophageal varices.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C146711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146711>	C1983|C154231	Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM|Breast Cancer Vaccine SV-BR-1-GM|Bria-IMT|GM-CSF Gene-transfected Breast Cancer Vaccine SV-BR-1-GM|SV-BR-1 Breast Cancer Cell Line Vaccine|SV-BR-1-GM|SV-BR-1-GM Vaccine	A vaccine consisting of irradiated allogeneic breast cancer cells, derived from the breast cancer cell line SV-BR-1 that are transfected with the immunostimulant granulocyte-macrophage colony-stimulating factor (GM-CSF; CSF2) gene, with potential immunostimulating and antineoplastic activities. Upon intradermal administration of the allogeneic GM-CSF-secreting breast cancer vaccine SV-BR-1-GM, the genetically-modified cells secrete GM-CSF. This potentiates a tumor-specific cytotoxic T-lymphocyte (CTL) immune response against breast cancer cells.	Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM		Cell|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C146712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146712>	C141297|C136411	Blasts 20-30 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that between 20 and 30 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts 20-30 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C146713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146713>	C141240	FGFR Gene Mutation|FGF Receptor Gene Family Mutation|FGF Receptor Gene Mutation|FGFR Family Gene Mutation|FGFR Family Mutation|FGFR Mutation|Fibroblast Growth Factor Receptor Family Gene Mutation|Fibroblast Growth Factor Receptor Gene Mutation	A change in the nucleotide sequence of an FGFR family gene.	FGFR Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C146714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146714>	C220596|C143172	Fallopian Tube Perforation, CTCAE|Fallopian Tube Perforation|Fallopian Tube Perforation, CTCAE 5.0|Fallopian tube perforation|Fallopian tube perforation	A disorder characterized by a rupture of the fallopian tube wall.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146716>	C131488	Human Papillomavirus-16 Negative|HPV-16 Negative|HPV16 Negative|Human Papilloma Virus 16 Negative|Human Papilloma Virus-16 Negative|Human Papillomavirus 16 Negative	An indication that human papillomavirus-16 has not been detected in a sample.	Human Papillomavirus-16 Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C146717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146717>	C66950|C6459	Thymus Hepatoid Adenocarcinoma|Thymic Hepatoid Adenocarcinoma|Thymic Hepatoid Carcinoma|Thymus Hepatoid Carcinoma	A very rare adenocarcinoma that arises from the thymus. It is characterized by the presence of malignant polygonal cells resembling hepatocytes.			Neoplastic Process	
C146718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146718>	C138961	PSA Doubling Time Less than or Equal to 6 Months|PSA Doubling Time Less than or Equal to Six Months|PSA-DT Less than or Equal to 6 Months|PSADT Less than or Equal to 6 Months	An indication that the number of months that a subject's blood concentration of prostate specific antigen took to double was six months or less.	PSA Doubling Time Less than or Equal to 6 Months		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146719>	C143165	Left Ventricular Systolic Dysfunction, CTCAE 5.0|Left Ventricular Systolic Dysfunction|Left ventricular systolic dysfunction	A disorder characterized by failure of the left ventricle to produce adequate output.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C146720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146720>	C267	Fosnetupitant/Palonosetron Hydrochloride|Fosnetupitant-Palonosetron HCl|Fosnetupitant/Palonosetron HCl Combination|IV NEPA FDC|Pro-netupitant/Palonosetron|Pronetupitant/Palonosetron	A combination formulation containing the prodrug of netupitant, fosnetupitant, a selective neurokinin 1 receptor (NK1R; TACR1) antagonist, and the hydrochloride salt form of palonosetron, a selective serotonin (5-hydroxytrytamine; 5-HT) receptor subtype 3 (5-HT3R) antagonist, with potential antiemetic activity. Upon intravenous administration, fosnetupitant is converted by phosphatases to its active form netupitant. Netupitant competitively binds to and blocks the activity of NK1Rs in the central nervous system (CNS), by inhibiting binding of the endogenous tachykinin-derived neuropeptide substance P (SP) to NK1R. This prevents delayed emesis, which is associated with SP secretion. Palonosetron competitively blocks the interaction of 5-HT with 5-HT3Rs located on vagal afferent nerves in the chemoreceptor trigger zone (CTZ). This inhibits acute emesis associated with 5-HT secretion and subsequent 5-HT3R activation. Altogether, this results in inhibition of acute and delayed nausea and vomiting, and may prevent chemotherapy-induced nausea and vomiting (CINV).	Fosnetupitant/Palonosetron Hydrochloride		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C146721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146721>	C25164	Index Date|index date|index_date	A date used as a reference point for ensuing events, often a diagnosis date, or a first visit date, or the date a patient enrolled in a study.			Temporal Concept	GDC Property Terminology|GDC Terminology
C146722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146722>	C81945|C178120	Activating ALK Gene Mutation|Activating ALK Mutation|Activating ALK Receptor Tyrosine Kinase Gene Mutation|Activating Anaplastic Lymphoma Kinase Receptor Gene Mutation|Activating Anaplastic Lymphoma Receptor Tyrosine Kinase Gene Mutation|Activating CD246 Gene Mutation	A change in the nucleotide sequence of the ALK gene that results in constitutive activation of both ALK tyrosine kinase receptor protein and its downstream signaling pathways.	Activating ALK Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146723>	C178120|C130952	Activating ROS1 Gene Mutation|Activating MCF3 Gene Mutation|Activating ROS Gene Mutation|Activating ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene Mutation|Activating c-ros-1 Gene Mutation	A change in the nucleotide sequence of the ROS1 gene that results in constitutive activation of both proto-oncogene tyrosine-protein kinase ROS and its downstream signaling pathways.	Activating ROS1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146724>	C177692	AG7 Antigen Positive|AG7 Positive	An indication that expression of the tumor-associated antigen AG7 has been detected in a sample.	AG7 Antigen Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C146725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146725>	C69179	HLA-DPB1*0401 Positive Cells Present|HLA-DPB1*0401 Positive|HLA-DPB1*04:01 Positive|HLA-DPB1*04:01 Positive Cells Present	An indication that cells expressing HLA-DPB1*0401 have been detected in a sample.	HLA-DPB1*0401 Positive Cells Present		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146726>	C97927	WT1 Gene Mutation|GUD Gene Mutation|WAGR Gene Mutation|WIT-2 Gene Mutation|WT1 mutation|WT33 Gene Mutation|Wilms Tumor 1 Gene Mutation	A change in the nucleotide sequence of the WT1 gene.	WT1 Gene Mutation		Cell or Molecular Dysfunction	AML Authorized Value Terminology|AML Minimal Residual Disease Table|AML Molecular Analysis Table|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146727>	C97927|C157554	PIK3CG Gene Mutation|PI3CG Gene Mutation|PI3Kgamma Gene Mutation|Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma Gene Mutation|p110gamma Gene Mutation	A change in the nucleotide sequence of the PIK3CG gene.	PIK3CG Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146728>	C97927|C157554	PIK3R5 Gene Mutation|FOAP-2 Gene Mutation|P101-PI3K Gene Mutation|Phosphoinositide-3-Kinase Regulatory Subunit 5 Gene Mutation|Phosphoinositide-3-Kinase, Regulatory Subunit 5 Gene Mutation|p101 Gene Mutation	A change in the nucleotide sequence of the PIK3R5 gene.	PIK3R5 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146729>	C220590|C143167	Retinal Detachment, CTCAE|Retinal Detachment|Retinal Detachment, CTCAE 5.0|Retinal detachment|Retinal detachment	A disorder characterized by the separation of the inner retina layers from the underlying pigment epithelium.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146730>	C220591|C146630	Typhlitis, CTCAE|Typhlitis|Typhlitis|Typhlitis|Typhlitis, CTCAE 5.0	A disorder characterized by necrotizing enterocolitis in neutropenic patients. Also referred to as neutropenic enterocolitis, ileocecal syndrome, or cecitis.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146731>	C143165	Asystole, CTCAE|Asystole|Asystole|Asystole, CTCAE 5.0	A disorder characterized by a dysrhythmia without cardiac electrical activity. Typically, this is accompanied by cessation of the pumping function of the heart.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C146732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146732>	C220586|C143165	Ventricular Fibrillation, CTCAE|Ventricular Fibrillation|Ventricular Fibrillation, CTCAE 5.0|Ventricular fibrillation|Ventricular fibrillation	A disorder characterized by a dysrhythmia without discernible QRS complexes due to rapid repetitive excitation of myocardial fibers without coordinated contraction of the ventricles.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146733>	C220586|C143165	Ventricular Tachycardia, CTCAE|Ventricular Tachycardia|Ventricular Tachycardia, CTCAE 5.0|Ventricular tachycardia|Ventricular tachycardia	A disorder characterized by a dysrhythmia with a heart rate greater than 100 beats per minute that originates distal to the bundle of His.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146734>	C3058|C216100|C203369	Refractory Glioblastoma	A glioblastoma that is resistant to treatment.	Refractory Glioblastoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C146735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146735>	C220593|C143170	Gallbladder Necrosis, CTCAE|Gallbladder Necrosis|Gallbladder Necrosis, CTCAE 5.0|Gallbladder necrosis|Gallbladder necrosis	A disorder characterized by a necrotic process occurring in the gallbladder.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146736>	C220593|C143170	Hepatic Necrosis, CTCAE|Hepatic Necrosis|Hepatic Necrosis, CTCAE 5.0|Hepatic necrosis|Hepatic necrosis	A disorder characterized by a necrotic process occurring in the hepatic parenchyma.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146737>	C143177	Ataxia, CTCAE 5.0|Ataxia|Ataxia	A disorder characterized by lack of coordination of muscle movements resulting in the impairment or inability to perform voluntary activities.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C146738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146738>	C220591|C146630	Hemorrhoids, CTCAE|Hemorrhoids|Hemorrhoids|Hemorrhoids|Hemorrhoids (Priority 2)|Hemorrhoids, CTCAE 5.0	A disorder characterized by the presence of dilated veins in the rectum and surrounding area.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C146739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146739>	C220599|C143175	Back Pain, CTCAE|Back Pain|Back Pain, CTCAE 5.0|Back pain|Back pain	A disorder characterized by a sensation of marked discomfort in the back region.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146740>	C143182	Telangiectasia, CTCAE 5.0|Telangiectasia|Telangiectasia	A disorder characterized by local dilatation of small vessels resulting in red discoloration of the skin or mucous membranes.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C146741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146741>	C220599|C143175	Bone Pain, CTCAE|Bone Pain|Bone Pain, CTCAE 5.0|Bone pain|Bone pain	A disorder characterized by a sensation of marked discomfort in the bones.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146742>	C220605|C143180	Breast Pain, CTCAE|Breast Pain|Breast Pain, CTCAE 5.0|Breast pain|Breast pain	A disorder characterized by a sensation of marked discomfort in the breast region.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146743>	C220599|C143175	Chest Wall Pain, CTCAE|Chest Wall Pain|Chest Wall Pain, CTCAE 5.0|Chest wall pain|Chest wall pain	A disorder characterized by a sensation of marked discomfort in the chest wall.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146744>	C220599|C143175	Buttock Pain, CTCAE|Buttock Pain|Buttock Pain, CTCAE 5.0|Buttock pain|Buttock pain	A disorder characterized by a sensation of marked discomfort in the buttocks.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146745>	C220588|C143185	External Ear Pain, CTCAE|External Ear Pain|External Ear Pain, CTCAE 5.0|External ear pain|External ear pain	A disorder characterized by a sensation of marked discomfort in the external ear region.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146746>	C220601|C143177	Cognitive Disturbance, CTCAE|Cognitive Disturbance|Cognitive Disturbance, CTCAE 5.0|Cognitive disturbance|Cognitive disturbance	A disorder characterized by a conspicuous change in cognitive function.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146747>	C220601|C143177	Dizziness, CTCAE|Dizziness|Dizziness|Dizziness|Dizziness, CTCAE 5.0	A disorder characterized by a disturbing sensation of lightheadedness, unsteadiness, giddiness, spinning or rocking.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146748>	C220603|C143187	Euphoria, CTCAE|Euphoria|Euphoria|Euphoria|Euphoria, CTCAE 5.0	A disorder characterized by an exaggerated feeling of well-being which is disproportionate to events and stimuli.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146749>	C220599|C143175	Exostosis, CTCAE|Exostosis|Exostosis|Exostosis|Exostosis, CTCAE 5.0	A disorder characterized by non-neoplastic overgrowth of bone.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146750>	C220601|C143177	Syncope, CTCAE|Syncope|Syncope|Syncope|Syncope, CTCAE 5.0	A disorder characterized by spontaneous loss of consciousness caused by insufficient blood supply to the brain.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146751>	C220590|C143167	Eye Pain, CTCAE|Eye Pain|Eye Pain, CTCAE 5.0|Eye pain|Eye pain	A disorder characterized by a sensation of marked discomfort in the eye.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146752>	C220605|C143180	Fallopian Tube Obstruction, CTCAE|Fallopian Tube Obstruction|Fallopian Tube Obstruction, CTCAE 5.0|Fallopian tube obstruction|Fallopian tube obstruction	A disorder characterized by blockage of the normal flow of the contents in the fallopian tube.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146753>	C220592|C143169	Fatigue, CTCAE|Fatigue|Fatigue|Fatigue|Fatigue (Priority 2)|Fatigue, CTCAE 5.0	A disorder characterized by a state of generalized weakness with a pronounced inability to summon sufficient energy to accomplish daily activities.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C146754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146754>	C143177	Brachial Plexopathy, CTCAE 5.0|Brachial Plexopathy|Brachial plexopathy	A disorder characterized by regional paresthesia of the brachial plexus, marked discomfort and muscle weakness, and limited movement in the arm or hand.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C146755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146755>	C220593|C143170	Gallbladder Pain, CTCAE|Gallbladder Pain|Gallbladder Pain, CTCAE 5.0|Gallbladder pain|Gallbladder pain	A disorder characterized by a sensation of marked discomfort in the gallbladder region.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146756>	C177692	ENPP3 Positive|CD203c Positive|Ectonucleotide Pyrophosphatase/Phosphodiesterase 3 Positive|Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 Positive|PD-Ibeta Positive|PDNP3 Positive	An indication that ENPP3 expression has been detected in a sample.	ENPP3 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146757>	C220605|C143180	Spermatic Cord Obstruction, CTCAE|Spermatic Cord Obstruction|Spermatic Cord Obstruction, CTCAE 5.0|Spermatic cord obstruction|Spermatic cord obstruction	A disorder characterized by blockage of the normal flow of the contents of the spermatic cord.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146758>	C143179	Proteinuria, CTCAE 5.0|Proteinuria|Proteinuria	A disorder characterized by laboratory test results that indicate the presence of excessive protein in the urine. It is predominantly albumin, but also globulin.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C146759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146759>	C220586|C143165	Sinus Tachycardia, CTCAE|Sinus Tachycardia|Sinus Tachycardia, CTCAE 5.0|Sinus tachycardia|Sinus tachycardia	A disorder characterized by a dysrhythmia with a heart rate greater than 100 beats per minute that originates in the sinus node.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146760>	C220599|C143175	Joint Effusion, CTCAE|Joint Effusion|Joint Effusion, CTCAE 5.0|Joint effusion|Joint effusion	A disorder characterized by excessive fluid in a joint, usually as a result of joint inflammation.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146761>	C220591|C146630	Lip Pain, CTCAE|Lip Pain|Lip Pain, CTCAE 5.0|Lip pain|Lip pain	A disorder characterized by a sensation of marked discomfort of the lip.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146762>	C141145|C129822	Anti-ICOS Agonist Monoclonal Antibody BMS-986226|Anti-ICOS BMS-986226|Anti-inducible T-cell Co-stimulator BMS-986226|BMS 986226|BMS-986226|BMS986226	An agonistic monoclonal antibody that recognizes inducible T-cell co-stimulator (ICOS; CD278), with potential immunomodulating and antineoplastic activities. Upon administration, anti-ICOS agonist monoclonal antibody BMS-986226 targets and binds to ICOS expressed on certain T-cells. This stimulates ICOS-mediated signaling, induces proliferation of ICOS-positive T-cells, enhances cytotoxic T-lymphocyte (CTL) survival and augments the CTL-mediated immune response against tumor cells. ICOS, a T-cell specific, CD28-superfamily co-stimulatory molecule and immune checkpoint protein, is normally expressed on certain activated T-cells and plays a key role in the proliferation and activation of T-cells.	Anti-ICOS Agonist Monoclonal Antibody BMS-986226		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C146763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146763>	C220601|C143177	Memory Impairment, CTCAE|Memory Impairment|Memory Impairment, CTCAE 5.0|Memory impairment|Memory impairment	A disorder characterized by a deterioration in memory function.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146764>	C146630	Nausea, CTCAE 5.0|Nausea|Nausea	A disorder characterized by a queasy sensation and/or the urge to vomit.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C146765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146765>	C191738|C129822	Sovipostobart|BMS 986249|BMS-986249|BMS986249|CTLA-4 Probody BMS-986249|CTLA-4-directed Probody BMS-986249|Protease-activated Anti-CTLA-4 Antibody Prodrug BMS-986249|SOVIPOSTOBART	A probody composed of ipilimumab, a recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), linked to a proprietary masking peptide that covers the active antigen-binding site of the antibody through a protease-cleavable linker, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of sovipostobart, the masking peptide is cleaved by tumor-associated proteases upon extravasation into the tumor microenvironment (TME). Protease-mediated removal of the linker enables binding of the unmasked monoclonal antibody moiety to CTLA-4, which is expressed on certain T-cells. This inhibits the CTLA4-mediated downregulation of T-cell activation, and leads to both activation of tumor infiltrating T-effector cells and a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily expressed on activated effector T-cells (Teffs) and regulatory T-cells (Tregs), plays a key role in the inhibition of T-cell activity and downregulation of the immune system. The peptide masking of BMS-986249 minimizes binding to CTLA-4 in normal tissues and may reduce systemic toxicity, when compared to ipilimumab. Tumor-associated proteases are present in high concentrations and aberrantly activated in the TME.	Sovipostobart		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C146766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146766>	C220599|C143175	Neck Pain, CTCAE|Neck Pain|Neck Pain, CTCAE 5.0|Neck pain|Neck pain	A disorder characterized by a sensation of marked discomfort in the neck area.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146767>	C220599|C143175	Osteoporosis, CTCAE|Osteoporosis|Osteoporosis|Osteoporosis|Osteoporosis, CTCAE 5.0	A disorder characterized by reduced bone mass, with a decrease in cortical thickness and in the number and size of the trabeculae of cancellous bone (but normal chemical composition), resulting in increased fracture incidence.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146768>	C220604|C143179	Hemoglobinuria, CTCAE|Hemoglobinuria|Hemoglobinuria|Hemoglobinuria|Hemoglobinuria, CTCAE 5.0	A disorder characterized by laboratory test results that indicate the presence of free hemoglobin in the urine.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146769>	C220605|C143180	Ovulation Pain, CTCAE|Ovulation Pain|Ovulation Pain, CTCAE 5.0|Ovulation pain|Ovulation pain	A disorder characterized by a sensation of marked discomfort in one side of the abdomen between menstrual cycles, around the time of the discharge of the ovum from the ovarian follicle.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146770>	C220590|C143167	Photophobia, CTCAE|Photophobia|Photophobia|Photophobia|Photophobia, CTCAE 5.0	A disorder characterized by fear and avoidance of light.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146771>	C220603|C143187	Insomnia, CTCAE|Insomnia|Insomnia|Insomnia|Insomnia, CTCAE 5.0	A disorder characterized by difficulty in falling asleep and/or remaining asleep.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146772>	C220607|C143182	Scalp Pain, CTCAE|Scalp Pain|Scalp Pain, CTCAE 5.0|Scalp pain|Scalp pain	A disorder characterized by a sensation of marked discomfort in the skin covering the top and the back of the head.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146773>	C220585|C143164	Lymph Node Pain, CTCAE|Lymph Node Pain|Lymph Node Pain, CTCAE 5.0|Lymph node pain|Lymph node pain	A disorder characterized by a sensation of marked discomfort in a lymph node.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146774>	C220591|C146630	Stomach Pain, CTCAE|Stomach Pain|Stomach Pain, CTCAE 5.0|Stomach pain|Stomach pain	A disorder characterized by a sensation of marked discomfort in the stomach.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146775>	C220601|C143177	Nystagmus, CTCAE|Nystagmus|Nystagmus|Nystagmus|Nystagmus, CTCAE 5.0	A disorder characterized by involuntary movements of the eyeballs.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146777>	C220603|C143187	Agitation, CTCAE|Agitation|Agitation|Agitation|Agitation, CTCAE 5.0	A disorder characterized by a state of restlessness associated with unpleasant feelings of irritability and tension.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146778>	C220603|C143187	Anxiety, CTCAE|Anxiety|Anxiety|Anxiety|Anxiety, CTCAE 5.0	A disorder characterized by apprehension of danger and dread accompanied by restlessness, tension, tachycardia, and dyspnea unattached to a clearly identifiable stimulus.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146779>	C28681|C138180|C129826	Autologous TCR-engineered T-cells IMA201|ACTengine IMA201|Autologous T-cell Receptor-engineered T-cells IMA201|IMA 201|IMA-201|IMA201|IMA201 Autologous T-lymphocytes|IMA201 T-cells	A preparation of autologous T-lymphocytes that are genetically modified with a lentiviral vector encoding a T-cell receptor (TCR) specific for an as of yet not identified tumor-associated antigen (TAA), with potential antineoplastic activity. Upon intravenous administration back into the patient, the autologous TCR-engineered T-cells IMA201 specifically recognize and bind to the TAA on cancer cells, which induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against the TAA-positive cancer cells.	Autologous TCR-engineered T-cells IMA201		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C146780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146780>	C220601|C143177	Tremor, CTCAE|Tremor|Tremor|Tremor|Tremor, CTCAE 5.0	A disorder characterized by the uncontrolled shaking movement of the whole body or individual parts.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146782>	C220600|C143176	Tumor Pain, CTCAE|Tumor Pain|Tumor Pain, CTCAE 5.0|Tumor pain|Tumor pain	A disorder characterized by a sensation of marked discomfort from a neoplasm that may be pressing on a nerve, blocking blood vessels, inflamed or fractured from metastasis.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146783>	C220606|C143181	Sinus Pain, CTCAE|Sinus Pain|Sinus Pain, CTCAE 5.0|Sinus pain|Sinus pain	A disorder characterized by a sensation of marked discomfort in the face, between the eyes, or upper teeth originating from the sinuses.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146785>	C220603|C143187	Confusion, CTCAE|Confusion|Confusion|Confusion|Confusion, CTCAE 5.0	A disorder characterized by a lack of clear and orderly thought and behavior.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146786>	C220604|C143179	Urinary Incontinence, CTCAE|Urinary Incontinence|Urinary Incontinence (Priority 1)|Urinary Incontinence, CTCAE 5.0|Urinary incontinence|Urinary incontinence	A disorder characterized by inability to control the flow of urine from the bladder.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C146787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146787>	C220599|C143175	Myositis, CTCAE|Myositis|Myositis|Myositis|Myositis, CTCAE 5.0	A disorder characterized by inflammation involving the skeletal muscles.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146788>	C220593|C146630	Cholecystitis, CTCAE|Cholecystitis|Cholecystitis|Cholecystitis|Cholecystitis, CTCAE 5.0	A disorder characterized by inflammation involving the gallbladder. It may be associated with the presence of gallstones.			Finding	CTCAE Adverse Events Version 5.0 Terminology|CTCAE Adverse Events Version 6.0 Terminology|GDC Terminology|GDC Value Terminology
C146789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146789>	C146630	Pancreatitis, CTCAE 5.0|Pancreatitis|Pancreatitis	A disorder characterized by inflammation of the pancreas with no documented pancreas infection.			Finding	CTCAE Adverse Events Version 5.0 Terminology|GDC Terminology|GDC Value Terminology
C146790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146790>	C113691	Child-Pugh Class A5|A5|Child-Pugh Grade A5	A total score of 5 for hepatic function, corresponding to class A in the Child-Pugh classification.			Intellectual Product	GDC Terminology|GDC Value Terminology
C146791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146791>	C113691	Child-Pugh Class A6|A6|Child-Pugh Grade A6	A total score of 6 for hepatic function, corresponding to class A in the Child-Pugh classification.			Intellectual Product	GDC Terminology|GDC Value Terminology
C146792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146792>	C113692	Child-Pugh Class B7|B7|Child-Pugh Grade B7	A total score of 7 for hepatic function, corresponding to class B in the Child-Pugh classification.			Intellectual Product	GDC Terminology|GDC Value Terminology
C146793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146793>	C113692	Child-Pugh Class B8|B8|Child-Pugh Grade B8	A total score of 8 for hepatic function, corresponding to class B in the Child-Pugh classification.			Intellectual Product	GDC Terminology|GDC Value Terminology
C146794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146794>	C113692	Child-Pugh Class B9|B9|Child-Pugh Grade B9	A total score of 9 for hepatic function, corresponding to class B in the Child-Pugh classification.			Intellectual Product	GDC Terminology|GDC Value Terminology
C146795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146795>	C113694	Child-Pugh Class C10|C10|Child-Pugh Grade C10	A total score of 10 for hepatic function, corresponding to class C in the Child-Pugh classification.			Intellectual Product	GDC Terminology|GDC Value Terminology
C146796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146796>	C113694	Child-Pugh Class C11|C11|Child-Pugh Grade C11	A total score of 11 for hepatic function, corresponding to class C in the Child-Pugh classification.			Intellectual Product	GDC Terminology|GDC Value Terminology
C146797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146797>	C113694	Child-Pugh Class C12|C12|Child-Pugh Grade C12	A total score of 12 for hepatic function, corresponding to class C in the Child-Pugh classification.			Intellectual Product	GDC Terminology|GDC Value Terminology
C146798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146798>	C113694	Child-Pugh Class C13|Child-Pugh Grade C13	A total score of 13 for hepatic function, corresponding to class C in the Child-Pugh classification.			Intellectual Product	
C146799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146799>	C113694	Child-Pugh Class C14|Child-Pugh Grade C14	A total score of 14 for hepatic function, corresponding to class C in the Child-Pugh classification.			Intellectual Product	
C1467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1467>	C1591	Recombinant Human Macrophage Inflammatory Protein-1 Beta|ACT-2|CCL4|H400is SIS gamma|HuMIP-1-Beta|HuMIP-1b|Human Macrophage Inflammatory Protein-1 Beta|MIP-1 Beta|MIP-1-b|MIP-1Beta|PAT 744|rHuMIP-1-Beta	The recombinant form of endogenous MIP-1 beta chemokine that chemoattracts both neutrophils and monocytes, stimulates macrophages, and stimulates myelopoietic cell growth.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C146801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146801>	C113694	Child-Pugh Class C15|Child-Pugh Grade C15	A total score of 15 for hepatic function, corresponding to class C in the Child-Pugh classification..			Intellectual Product	
C146802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146802>	C91102	Since First Time Questionnaire Was Answered Question|Since First Time Questionnaire Was Answered|Since Questionnaire Was First Answered|Since the first time I answered this questionnaire	A question about the status of an individual since the time when they first answered a questionnaire.			Intellectual Product	
C146803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146803>	C172727|C15749	Minimally Invasive Interval Debulking Surgery|Minimally Invasive	Endoscopic or robotic-assisted cytoreductive surgery performed after primary cytoreduction and between courses of chemotherapy.			Therapeutic or Preventive Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uveal Melanoma Baseline Form
C146804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146804>	C15334	Renorrhaphy	Surgical suturing of a kidney.			Therapeutic or Preventive Procedure	
C146805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146805>	C201688	Givosiran|ALN AS1|ALN-AS1|ESC-GalNAc-siRNA Conjugate ALN-AS1|GIVOSIRAN|RNA Interference Therapeutic ALN-AS1|RNAi ALN-AS1	A proprietary enhanced stabilization chemistry (ESC)-stabilized conjugate composed of the liver-targeted ligand N-acetylgalactosamine (GalNAc) conjugated to small-interfering RNAs (siRNAs) directed against the liver-expressed enzyme aminolevulinic acid synthase 1 (delta-aminolevulinate synthase 1; ALAS1; ALAS-1) that can potentially be used in the treatment of acute hepatic porphyrias (AHPs). Upon subcutaneous administration of givosiran, the GalNAc moiety targets and binds with high affinity to asialoglycoprotein receptors (ASGPRs) expressed on hepatocytes. Once inside the cell, the siRNAs bind to and silence ALAS1 mRNA and inhibit both the translation and expression of the ALAS1 protein. This prevents delta-aminolevulinic acid (ALA) formation, decreases 5-ALA levels and prevents the production of porphyrins and hemes, such as porphobilinogen (PBG). AHPs are a group of metabolic disorders caused by deficiencies of specific enzymes that are responsible for hemoglobulin biosynthesis within the liver, which leads to the accumulation of toxic intermediates, such as ALA and PBG. ALAS1, a liver-expressed, rate-limiting enzyme in the heme biosynthesis pathway, is responsible for the formation of ALA from succinyl-CoA and glycine. ESC enables the subcutaneous dosing of givosiran with increased efficacy, durability and a wide therapeutic index as compared to non-ESC GalNAc-siRNA conjugates.	Givosiran		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C146806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146806>	C201493|C200765	Allogeneic CD123-specific Universal CAR123-expressing T-lymphocytes|Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor|UCART123|UCART123 T Cells|Universal Chimeric Antigen Receptor T-cell 123|Universal Chimeric Antigen Receptor T-cells targeting CD123|Universal TALEN Gene-edited CART123 Cells	Allogeneic, off-the-shelf, universal transcription activator-like effector nuclease (TALEN)-engineered T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) human interleukin-3 receptor alpha chain (IL3RA; cluster of differentiation 123; CD123), with potential immunomodulating and antineoplastic activities.  Upon transfusion of allogeneic CD123-specific universal CAR123-expressing T-lymphocytes (UCART123), these cells target and bind to cancer cells expressing CD123. This induces selective toxicity in and causes lysis of CD123-expressing tumor cells. CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with both increased leukemic cell proliferation and aggressiveness. Using TALEN technology, the UCART123 cells no longer express the endogenous T-cell receptor (TCR) thereby abrogating the potential induction of graft-versus-host disease (GvHD) by the donor T-cells.	Allogeneic CD123-specific Universal CAR123-expressing T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C146807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146807>	C155926	Elimusertib|ATR Inhibitor BAY1895344|ATR Kinase Inhibitor BAY1895344|BAY 1895344|BAY-1895344|BAY1895344|ELIMUSERTIB	An orally available ataxia telangiectasia and Rad3-related (ATR)-specific kinase inhibitor, with potential antineoplastic activity. Upon oral administration, elimusertib selectively binds to and inhibits the activity of ATR, which prevents ATR-mediated signaling. This inhibits DNA damage checkpoint activation, disrupts DNA damage repair and induces apoptosis in ATR-overexpressing tumor cells. ATR, a serine/threonine protein kinase upregulated in a variety of cancer cell types, plays a key role in DNA repair, cell cycle progression and cell survival.	Elimusertib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C146808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146808>	C184322	Anti-IL17A Monoclonal Antibody CJM112|CJM 112|CJM-112|CJM112	A human immunoglobulin G1 (IgG1) monoclonal antibody against the pro-inflammatory cytokine interleukin 17A (IL-17A; IL-17), with potential anti-inflammatory activity. Upon subcutaneous administration, anti-IL17A monoclonal antibody CJM112 selectively targets and binds to IL-17A, thereby neutralizing the IL-17A protein. This prevents binding of IL-17A to the IL-17 receptor (IL-17R), and inhibits IL-17A/IL-17R-mediated signaling and inflammation mediated by this pathway. IL-17A is mainly produced by inflammatory T helper 17 cells (Th17), and certain lymphocytes. IL-17A production is upregulated in many immune-mediated inflammatory diseases, such as psoriasis and multiple sclerosis (MS), and plays a key role in the development of inflammation and the immune response.	Anti-IL17A Monoclonal Antibody CJM112		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C146809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146809>	C153598|C101293	454 Sequencing|454 Sequencing Technology|LS 454 Sequencing|LS454|LS454	A proprietary next-generation DNA sequencing system from 454 Life Sciences that used large-scale parallel pyrosequencing. The system relied on fixing nebulized and adapter-ligated DNA fragments to small DNA-capture beads in a water-in-oil emulsion.			Molecular Biology Research Technique	GDC Terminology|GDC Value Terminology
C146810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146810>	C159156	HER2 Inhibitor TAS0728|TAS 0728|TAS-0728|TAS0728|TPC-107	An orally available covalent inhibitor of human epidermal growth factor receptor 2 (HER2; ERBB2), with potential antineoplastic activity. Upon oral administration, HER2 inhibitor TAS0728 specifically and irreversibly binds to and inhibits the activity of HER2. This prevents HER2-mediated signaling and leads to cell death in HER2- and HER3 (ErbB3)-expressing tumor cells. HER2, a receptor tyrosine kinase mutated or overexpressed in many tumor cell types, play key roles in tumor cell proliferation and tumor vascularization. HER3 has no active kinase domain but is activated through heterodimerization with other members of the EGFR receptor family, such as HER2.	HER2 Inhibitor TAS0728		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C146811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146811>	C153598|C101293	ABI SOLiD Sequencing|ABI SOLiD|SOLiD|SOLiD Sequencing Technology|Sequencing of Oligonucleotides by Ligation/Detection	A proprietary next-generation DNA sequencing system from Applied Biosystems that utilizes DNA ligase. DNA fragments attached to beads are clonally amplified and ligated to fluorescently labeled "interrogation probes". Ligation frees the fluor, which is detected and identifies the specific probe. The marker of the attached probe is then removed and a 5'-phosphate group is regenerated. Multiple cycles of ligation, detection, and cleavage are performed.			Molecular Biology Research Technique	GDC Terminology|GDC Value Terminology
C146812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146812>	C153598|C101293	BGISEQ-500 Sequencing|BGISEQ|BGISEQ-500 Sequencing Technology	A proprietary next-generation DNA sequencing system from BGI Genomics using combinatorial Probe-Anchor Synthesis (cPAS) and improved DNA Nanoballs (DNB) technology. The cPAS chemistry works by incorporating a fluorescent probe to a DNA anchor on the DNB, followed by high-resolution digital imaging.			Molecular Biology Research Technique	
C146813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146813>	C181141	Intismeran Autogene|INTISMERAN AUTOGENE|PCV mRNA-4157|V 940|V-940|V940|mRNA 4157|mRNA-4157|mRNA-based PCV mRNA-4157|mRNA-based Personalized Cancer Vaccine mRNA-4157	An mRNA-based individualized, therapeutic personalized cancer vaccine (PCV) targeting thirty-four tumor-associated antigens (TAAs) that are specifically expressed by the patient's cancer cells and encapsulated in lipid nanoparticles, with potential immunostimulatory and antineoplastic activities. The cells from the patient's tumor are analyzed, and genetic sequencing is used to identify thirty-four neoantigen epitopes that may elicit the strongest immune response in the patient. The sequences encoding the patient-specific epitopes are transcribed and loaded onto a single mRNA strand. Upon administration, intismeran autogene is taken up and translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy the patient's cancer cells that express these neoantigens.	Intismeran Autogene		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C146814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146814>	C153598	Capillary Sequencing|Capillary Sequencing Technology	A DNA sequencing technology that uses a long, thin, acrylic-fiber capillary to size-separate fluorescence-labelled DNA fragments.			Molecular Biology Research Technique	
C146815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146815>	C153598|C101293	Complete Genomics Sequencing|Complete Genomics	A next-generation DNA sequencing service offered by Complete Genomics. Unamplified human genomic DNA is sheared into 500bp fragments and then amplified to create DNA nano-balls (DNBs). The DNBs are arrayed on a substrate and their sequence is determined by Combinatorial Probe-Anchor Ligation (cPAL) sequencing.			Molecular Biology Research Technique	GDC Terminology|GDC Value Terminology
C146816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146816>	C153598|C101293	Helicos Sequencing|HeliScope|Helicos|Helicos Sequencing Technology	A proprietary next-generation DNA sequencing system from Helicos BioSciences based on zero wave guide technology and using unamplified DNA templates that are anchored to the surface of a glass slide. For each nucleotide cycle, polymerases are bound to the immobilized templates, and both fluorescently labeled nucleotides and proprietary terminators, which kinetically inhibit the polymerase from incorporating more than a single base, are added. The slide surface is then imaged with a high-intensity laser and where the fluorescent signal detected indicates a base incorporation at that position in the fluorescing template sequence.			Molecular Biology Research Technique	
C146817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146817>	C153598|C101293	Illumina Sequencing|Illumina|Illumina Sequencing Technology	A proprietary next-generation DNA sequencing system from Solexa that uses reversible terminator nucleotides. The genomic DNA to be sequenced is fragmented and ligated to adapter molecules on both ends to construct an Illumina-specific adapter library. PCR amplification of the DNA fragments is then performed using the adapter sequence as primer. Sequencing is carried out by repeated cycles of adding reversible fluorescent-labelled nucleotide and incorporation of the nucleotides to the complementary strand. The fluorescence of the incorporated nucleotides is detected.			Molecular Biology Research Technique	GDC Terminology|GDC Value Terminology
C146818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146818>	C101293	Nanopore Sequencing|Oxford Nanopore|Oxford Nanopore Sequencing|Oxford Nanopore Sequencing|Oxford Nanopore Sequencing Technology	A proprietary next-generation DNA sequencing technology from Oxford Nanopore Technologies that can directly identify and sequence a DNA molecule as it passes through a nanopore, driven by electrophoresis.			Molecular Biology Research Technique	
C146819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146819>	C19645|C153598	SMRT Sequencing|PacBio|PacBio SMRT|SMRT Sequencing Technology|Single Molecule, Real-Time Sequencing	A proprietary third-generation DNA sequencing system from Pacific Biosciences that uses zero-mode waveguides (ZMWs) and phospholinked nucleotides. A single DNA polymerase enzyme is affixed at the bottom of a ZMW structure with a single molecule of DNA as a template. A fluorescent tag is cleaved off with each base addition and is detected to create the sequence.			Molecular Biology Research Technique	GDC Terminology|GDC Value Terminology
C146820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146820>	C201282|C129822	Tidutamab|Anti-SSTR2 x Anti-CD3 Monoclonal Antibody XmAb18087|TIDUTAMAB|XmAb 18087|XmAb-18087|XmAb18087	A humanized, Fc domain-containing, bispecific monoclonal antibody targeting human CD3, a T-cell surface antigen, and somatostatin receptor 2 (SSTR2), a tumor-associated antigen (TAA) expressed on certain cancer cells, with potential antineoplastic activity. Upon administration, tidutamab binds to both T-cells and SSTR2-expressing cancer cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the SSTR2-expressing cancer cells. The inclusion of an Fc domain on the antibody prolongs the half-life of the bispecific antibody.	Tidutamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C146821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146821>	C61078	Nanoparticle Paclitaxel Ointment SOR007|NanoPac Ointment|Nanopartcle Paclitaxel SOR007|SOR007|SOR007 Ointment|Topical Nanoparticle Paclitaxel Ointment|Uncoated Nanoparticle Paclitaxel Ointment	A topical ointment composed of the water-insoluble taxane paclitaxel that has been processed to form uncoated nanoparticles, with potential antineoplastic activity. Upon topical administration of nanoparticle paclitaxel ointment SOR007 to the affected area, and following epithelial and dermal penetration, paclitaxel binds to tubulin and inhibits the disassembly of microtubules, which leads to the inhibition of cell division, thereby halting the proliferation of rapidly-dividing tumor cells. The nanoparticles in the nanoparticle paclitaxel ointment are produced through a specific proprietary submicron particle production.	Nanoparticle Paclitaxel Ointment SOR007		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C146823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146823>	C200766|C176018	Autologous iCASP9-CD19-expressing T-Lymphocytes|ATLCAR.CD19|Autologous ATL-iC9-CAR-CD19|Autologous iC9-CAR19 Cells|Autologous iC9-CAR19 T-cells|Autologous iC9-CARCD19 T Cells|Autologous iC9-CART19 Cells	A preparation of autologous T-lymphocytes that are transduced with a retroviral vector encoding a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19 and the inducible suicide gene human caspase 9 (iCASP9 or iC9), that is linked to a drug binding domain, with potential immunomodulating and antineoplastic activities. The iCASP9 construct consists of the entire coding sequence for the human FK506-drug binding protein (FKBP12) with an F36V mutation (FKBP12-F36V) that is linked to the gene encoding iC9, which is a modified form of the CASP9 gene where the sequences encoding the endogenous caspase activation and recruitment domains have been deleted. Upon intravenous administration, autologous iCASP9-CD19-expressing T-lymphocytes (iC9-CAR19 T-cells) target and bind to CD19-expressing tumor cells, thereby selectively lysing these tumor cells. If the administered T-cells cause unacceptable side effects, the chemical homodimerizer AP1903, which binds to the FKBP12-F36V drug-binding domain, can be administered; this induces caspase 9 expression, and results in apoptosis of the administered iC9-CAR19 T-cells. The CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.	Autologous iCASP9-CD19-expressing T-Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C146824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146824>	C201282|C129822	Etevritamab|AMG 596|AMG-596|AMG596|Anti-EGFRvIII x Anti-CD3 Bi-specific T-cell Engager AMG 596|Anti-EGFRvIII/CD3 BiTE Antibody AMG 596|BiTE Antibody AMG 596|Bispecific BITE Antibody AMG 596|EGFRvIII specific BiTE Antibody AMG 596|ETEVRITAMAB	A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one that is directed against a tumor-associated antigen (TAA), the epidermal growth factor receptor (EGFR) deletion-mutant form, EGFR variant III (EGFRvIII), and one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of etevritamab, the bispecific antibody binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and EGFRvIII found on EGFRvIII-expressing tumor cells. This activates and crosslinks CTLs with EGFRvIII-expressing tumor cells, which results in the CTL-mediated cell death of EGFRvIII-expressing tumor cells. EGFRvIII, a mutation in the EGFR gene where exons 2-7 have been deleted, is overexpressed by a variety of cancers, but is absent in normal, healthy cells. It plays a key role in tumor cell proliferation, tumor angiogenesis and resistance to both radio- and chemotherapy.	Etevritamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C146825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146825>	C128462	BRD4 Inhibitor PLX2853|PLX 2853|PLX-2853|PLX2853	An orally bioavailable inhibitor of the bromodomain-containing protein 4 (BRD4), with potential antineoplastic activity. Upon oral administration, the BRD4 inhibitor PLX2853 binds to the acetylated lysine recognition motifs in the bromodomains of the BRD4 protein, thereby preventing the binding of BRD4 to acetylated lysines on histones. This disrupts chromatin remodeling and dyregulates gene expression. This may lead to the downregulation of the expression of certain growth-promoting genes, which may induce apoptosis and inhibit the proliferation of BRD4-overexpressing tumor cells. BRD4, a member of the human bromodomain and extra-terminal (BET) family of proteins, is a transcriptional regulator that is overexpressed in certain tumor cells and plays an important role in cellular proliferation.	BRD4 Inhibitor PLX2853		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C146826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146826>	C48233	Mediastinal Germ Cell Tumor TNM Finding|Thymic Germ Cell Tumor TNM Finding	A TNM finding about one or more characteristics of a mediastinal germ cell tumor. This is not an official UICC TNM classification. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)			Finding	
C146827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146827>	C146826	Mediastinal Germ Cell Tumor Distant Metastasis TNM Finding|Thymic Germ Cell Tumor Distant Metastasis TNM Finding	A TNM finding about one or more characteristics of a mediastinal germ cell tumor as they pertain to distant metastases. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)			Finding	
C146828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146828>	C146827	Mediastinal Germ Cell Tumor M0 TNM Finding|Thymic Germ Cell Tumor M0 TNM Finding	Mediastinal germ cell tumor without evidence of distant metastasis. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)			Finding	
C146829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146829>	C146827	Mediastinal Germ Cell Tumor M1 TNM Finding|Thymic Germ Cell Tumor M1 TNM Finding	Mediastinal germ cell tumor with distant metastasis. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)			Finding	
C146830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146830>	C146826	Mediastinal Germ Cell Tumor Primary Tumor TNM Finding|Thymic Germ Cell Tumor Primary Tumor TNM Finding	A TNM finding about one or more characteristics of a mediastinal germ cell tumor as they pertain to staging of the primary tumor. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)			Finding	
C146831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146831>	C146830	Mediastinal Germ Cell Tumor TX TNM Finding|Thymic Germ Cell Tumor TX TNM Finding	Primary tumor cannot be assessed. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)			Finding	
C146832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146832>	C146830	Mediastinal Germ Cell Tumor T0 TNM Finding|Thymic Germ Cell Tumor T0 TNM Finding	No evidence of primary tumor. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)			Finding	
C146833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146833>	C146830	Mediastinal Germ Cell Tumor T1 TNM Finding|Thymic Germ Cell Tumor T1 TNM Finding	Mediastinal germ cell tumor confined to the organ of origin (thymus and mediastinal fat). (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)			Finding	
C146834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146834>	C146833	Mediastinal Germ Cell Tumor T1a TNM Finding|Thymic Germ Cell Tumor T1a TNM Finding	Mediastinal germ cell tumor confined to the organ of origin (thymus and mediastinal fat) and measuring 5 cm or less. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)			Finding	
C146835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146835>	C146833	Mediastinal Germ Cell Tumor T1b TNM Finding|Thymic Germ Cell Tumor T1b TNM Finding	Mediastinal germ cell tumor confined to the organ of origin (thymus and mediastinal fat) and measuring more than 5 cm. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)			Finding	
C146836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146836>	C146830	Mediastinal Germ Cell Tumor T2 TNM Finding|Thymic Germ Cell Tumor T2 TNM Finding	Mediastinal germ cell tumor infiltrating contiguous organs or accompanied by malignant effusion. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)			Finding	
C146837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146837>	C146836	Mediastinal Germ Cell Tumor T2a TNM Finding|Thymic Germ Cell Tumor T2a TNM Finding	Mediastinal germ cell tumor infiltrating contiguous organs or accompanied by malignant effusion and measuring 5 cm or less. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)			Finding	
C146838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146838>	C146836	Mediastinal Germ Cell Tumor T2b TNM Finding|Thymic Germ Cell Tumor T2b TNM Finding	Mediastinal germ cell tumor infiltrating contiguous organs or accompanied by malignant effusion and measuring more than 5 cm. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)			Finding	
C146839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146839>	C146830	Mediastinal Germ Cell Tumor T3 TNM Finding|Thymic Germ Cell Tumor T3 TNM Finding	Mediastinal germ cell tumor invading into neighboring structures, such as pericardium, mediastinal pleura, thoracic wall, great vessels and lung. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)			Finding	
C14683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14683>	C14421	RF/J Mouse|RF/J		RF/J Mouse		Mammal	
C146840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146840>	C146830	Mediastinal Germ Cell Tumor T4 TNM Finding|Thymic Germ Cell Tumor T4 TNM Finding	Mediastinal germ cell tumor with pleural or pericardial dissemination. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)			Finding	
C146841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146841>	C146826	Mediastinal Germ Cell Tumor Regional Lymph Nodes TNM Finding|Thymic Germ Cell Tumor Regional Lymph Nodes TNM Finding	A TNM finding about one or more characteristics of a mediastinal germ cell tumor as they pertain to staging of regional lymph nodes. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)			Finding	
C146842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146842>	C146841	Mediastinal Germ Cell Tumor NX TNM Finding|Thymic Germ Cell Tumor NX TNM Finding	Regional lymph nodes cannot be assessed. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)			Finding	
C146843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146843>	C146841	Mediastinal Germ Cell Tumor N0 TNM Finding|Thymic Germ Cell Tumor N0 TNM Finding	Mediastinal germ cell tumor with no regional lymph node metastasis. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)			Finding	
C146844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146844>	C146841	Mediastinal Germ Cell Tumor N1 TNM Finding|Thymic Germ Cell Tumor N1 TNM Finding	Mediastinal germ cell tumor with metastasis in regional lymph nodes. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)			Finding	
C146845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146845>	C146841	Mediastinal Germ Cell Tumor N2 TNM Finding|Thymic Germ Cell Tumor N2 TNM Finding	Mediastinal germ cell tumor with metastasis in other intrathoracic lymph nodes excluding anterior mediastinal lymph nodes. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)			Finding	
C146846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146846>	C146841	Mediastinal Germ Cell Tumor N3 TNM Finding|Thymic Germ Cell Tumor N3 TNM Finding	Mediastinal germ cell tumor with metastasis in scalene and/or supraclavicular lymph nodes. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)			Finding	
C146847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146847>	C28108	Mediastinal Malignant Germ Cell Tumor Stage|Mediastinal Malignant Germ Cell Tumor Stage of the Pediatric Study Group|Thymic Malignant Germ Cell Tumor Stage|Thymic Malignant Germ Cell Tumor Stage of the Pediatric Study Group	A mediastinal malignant germ cell tumor stage defined according to the Pediatric Study Group classification criteria.			Classification	
C146848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146848>	C6446	Malignant Mediastinal Germ Cell Tumor Stage Grouping of the Pediatric Study Group|Malignant Thymic Germ Cell Tumor Stage Grouping of the Pediatric Study Group	A term that refers to the staging of mediastinal malignant germ cell tumors according to the Pediatric Study Group staging criteria. This staging system is not an official UICC TNM classification. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)			Neoplastic Process	
C146849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146849>	C146848	Stage I Malignant Mediastinal Germ Cell Tumor|Stage I Malignant Thymic Germ Cell Tumor	Locoregional tumor, non-metastatic, complete resection. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)			Neoplastic Process	
C146850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146850>	C146848	Stage II Malignant Mediastinal Germ Cell Tumor|Stage II Malignant Thymic Germ Cell Tumor	Locoregional tumor, non-metastatic, macroscopic complete resection but microscopic residual tumor. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)			Neoplastic Process	
C146851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146851>	C146848	Stage III Malignant Mediastinal Germ Cell Tumor|Stage III Malignant Thymic Germ Cell Tumor	Locoregional tumor, regional lymph nodes negative or positive; no distant metastasis; biopsy only or gross residual tumor after primary resection. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)			Neoplastic Process	
C146852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146852>	C146848	Stage IV Malignant Mediastinal Germ Cell Tumor|Stage IV Malignant Thymic Germ Cell Tumor	Tumor with distant metastasis. (WHO Classification of Tumors of the Lung, Pleura, Thymus and Heart, 2015)			Neoplastic Process	
C146853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146853>	C202063	Porcupine Inhibitor CGX1321|CGX 1321|CGX-1321|CGX1321|PORCN Inhibitor CGX1321|WNT Signaling Inhibitor CGX1321|WTN Inhibitor CGX1321	An orally bioavailable inhibitor of the membrane-bound O-acyltransferase (MBOAT) porcupine (PORCN), with potential antineoplastic, protective and regenerative activities. Upon oral administration, PORCN inhibitor CGX1321 specifically targets and binds to PORCN in the endoplasmic reticulum (ER), thereby inhibiting the post-translational palmitoylation and secretion of Wnt ligands, thus preventing the activation of Wnt-mediated signaling, and inhibiting cell growth in Wnt-driven tumors. In addition, by inhibiting the secretion of Wnt ligands and preventing Wnt-mediated signaling, CGX1321 may also limit fibrosis and promote regeneration of certain tissues upon cell injury. PORCN catalyzes the palmitoylation of Wnt ligands, and plays a key role in Wnt ligand secretion. Wnt signaling is dysregulated in a variety of cancers and plays a key role in tumor cell proliferation. It also plays a key role in tissue regeneration.	Porcupine Inhibitor CGX1321		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C146854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146854>	C214800|C129839	Eftozanermin Alfa|ABBV 621|ABBV-621|ABBV621|APG880|EFTOZANERMIN ALFA|HERA Ligand ABBV-621|Hexavalent TRAIL Receptor Agonist ABBV-621|TRAIL Receptor Agonist ABBV-621|TRAIL-Fc Protein ABBV-621|TRAIL-receptor Agonist Fusion Protein ABBV-621	A fusion protein composed of a tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor agonist consisting of six receptor binding domains (RBDs) of TRAIL fused to the Fc-domain of a human immunoglobulin G1 (IgG1) antibody, with potential pro-apoptotic and antineoplastic activities. Upon administration of eftozanermin alfa, this fusion protein binds to TRAIL-receptors, pro-apoptotic death receptors (DRs) TRAIL-R1 (death receptor 4; DR4) and TRAIL-R2 (death receptor 5; DR5), expressed on tumor cells, thereby inducing tumor cell apoptosis.  ABBV-621 is designed to maximize receptor clustering for optimal efficacy. TRAIL, a member of the TNF superfamily of cytokines, plays a key role in the induction of apoptosis through TRAIL-mediated death receptor pathways.	Eftozanermin Alfa		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C146855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146855>	C161601|C15359	Salvage Surgery|Rescue Surgery|Salvage Resection|Salvage Surgical Resection|Surgical Salvage	Surgical treatment undertaken after failure of initial surgery or failure of other modalities.	Salvage Surgery		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C146856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146856>	C8708|C153071	Locally Advanced Angiosarcoma	An angiosarcoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Angiosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C146857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146857>	C8524|C146858	Locally Advanced Epithelioid Hemangioendothelioma	An epithelioid hemangioendothelioma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Epithelioid Hemangioendothelioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C146858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146858>	C3800|C36263	Metastatic Epithelioid Hemangioendothelioma	An epithelioid hemangioendothelioma that has spread from its original site of growth to another anatomic site.	Metastatic Epithelioid Hemangioendothelioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C146860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146860>	C181114	Elranatamab|Anti-CD3/Anti-BCMA Bispecific Antibody PF-06863135|B-cell Maturation Antigen-CD3 Bispecific Antibody PF-06863135|BCMA x CD3 Bispecific Antibody PF-06863135|BCMA-CD3 Bispecific Ab PF-06863135|ELRANATAMAB|Elranatamab-bcmm|Elrexfio|PF 06863135|PF-06863135|PF06863135|RN 613|RN-613|RN613	A bispecific monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, with potential antineoplastic activity. Upon administration, elranatamab binds to both CD3 on T-cells and BCMA expressed on malignant plasma cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against BCMA-expressing plasma cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.	Elranatamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C146861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146861>	C6446|C4290|C3729	Mediastinal Mixed Germ Cell Tumor	A malignant germ cell tumor that arises from the mediastinum. It is characterized by the presence of at least two different germ cell tumor components. The different germ cell tumor components include choriocarcinoma, embryonal carcinoma, yolk sac tumor, teratoma, and seminoma.			Neoplastic Process	
C146862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146862>	C207757|C129822	Anti-TGF-beta Monoclonal Antibody SAR-439459|Anti-TGFb SAR-439459|Anti-transforming Growth Factor-beta mAb SAR439459|SAR 439459|SAR-439459|SAR-439459|SAR439459	A monoclonal antibody (mAb) directed against human transforming growth factor beta (TGF-beta; TGFb), with potential antineoplastic activity. Upon administration, anti-TGF-beta monoclonal antibody SAR-439459 specifically targets and binds to TGF-beta, thereby preventing the activation of TGF-beta-mediated signaling pathways. This may inhibit the proliferation of tumor cells in which TGF-beta is overactivated. TGF-beta, a pro-inflammatory mediator that is mutated and/or overexpressed in a variety of cancer cell types, is involved in cancer cell proliferation and migration, and in tumor progression.	Anti-TGF-beta Monoclonal Antibody SAR-439459		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C146863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146863>	C133465	ALK NP_004295.2:p.F1174L|ALK F1174L|ALK NP_004295.2:p.Phe1174Leu|ALK Phe1174Leu|ALK Tyrosine Kinase Receptor F1174L|ALK Tyrosine Kinase Receptor Phe1174Leu|ALK p.F1174L|ALK p.Phe1174Leu|Anaplastic Lymphoma Kinase F1174L|Anaplastic Lymphoma Kinase Phe1174Leu|CD246 Antigen F1174L|CD246 Antigen Phe1174Leu|NP_004295.2:p.F1174L|NP_004295.2:p.Phe1174Leu|p.F1174L	A change in the amino acid residue at position 1174 in the ALK tyrosine kinase receptor protein where phenylalanine has been replaced by leucine.			Cell or Molecular Dysfunction	
C146864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146864>	C137952	ALK NM_004304.4:c.3522C>G|ALK Receptor Tyrosine Kinase c.3522C>G|ALK c.3522C>G|Anaplastic Lymphoma Kinase (Ki-1) c.3522C>G|Anaplastic Lymphoma Receptor Tyrosine Kinase c.3522C>G|CD246 c.3522C>G|NM_004304.4:c.3522C>G	A nucleotide substitution at position 3522 of the coding sequence of the ALK gene where cytosine has been mutated to guanine.			Cell or Molecular Dysfunction	
C146865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146865>	C137952	ALK NM_004304.4:c.3522C>A|ALK Receptor Tyrosine Kinase c.3522C>A|ALK c.3522C>A|Anaplastic Lymphoma Kinase (Ki-1) c.3522C>A|Anaplastic Lymphoma Receptor Tyrosine Kinase c.3522C>A|CD246 c.3522C>A|NM_004304.4:c.3522C>A	A nucleotide substitution at position 3522 of the coding sequence of the ALK gene where cytosine has been mutated to adenine.			Cell or Molecular Dysfunction	
C146866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146866>	C137952	ALK NM_004304.4:c.3520T>C|ALK Receptor Tyrosine Kinase c.3520T>C|ALK c.3520T>C|Anaplastic Lymphoma Kinase (Ki-1) c.3520T>C|Anaplastic Lymphoma Receptor Tyrosine Kinase c.3520T>C|CD246 c.3520T>C|NM_004304.4:c.3520T>C	A nucleotide substitution at position 3520 of the coding sequence of the ALK gene where thymine has been mutated to cytosine.			Cell or Molecular Dysfunction	
C146867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146867>	C133465	ALK NP_004295.2:p.F1174C|ALK F1174C|ALK NP_004295.2:p.Phe1174Cy|ALK Phe1174Cys|ALK Tyrosine Kinase Receptor F1174C|ALK Tyrosine Kinase Receptor Phe1174Cys|ALK p.F1174C|ALK p.Phe1174Cys|Anaplastic Lymphoma Kinase F1174C|Anaplastic Lymphoma Kinase Phe1174Cys|CD246 Antigen F1174C|CD246 Antigen Phe1174Cys|NP_004295.2:p.F1174C|NP_004295.2:p.Phe1174Cys	A change in the amino acid residue at position 1174 in the ALK tyrosine kinase receptor protein where phenylalanine has been replaced by cysteine.			Cell or Molecular Dysfunction	
C146868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146868>	C137952	ALK NM_004304.4:c.3521T>G|ALK Receptor Tyrosine Kinase c.3521T>G|ALK c.3521T>G|Anaplastic Lymphoma Kinase (Ki-1) c.3521T>G|Anaplastic Lymphoma Receptor Tyrosine Kinase c.3521T>G|CD246 c.3521T>G|NM_004304.4:c.3521T>G	A nucleotide substitution at position 3521 of the coding sequence of the ALK gene where thymine has been mutated to guanine.			Cell or Molecular Dysfunction	
C146869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146869>	C133465	ALK NP_004295.2:p.F1174V|ALK F1174V|ALK NP_004295.2:p.Phe1174Val|ALK Phe1174Val|ALK Tyrosine Kinase Receptor F1174V|ALK Tyrosine Kinase Receptor Phe1174Val|ALK p.F1174V|ALK p.Phe1174Val|Anaplastic Lymphoma Kinase F1174V|Anaplastic Lymphoma Kinase Phe1174Val|CD246 Antigen F1174V|CD246 Antigen Phe1174Val|NP_004295.2:p.F1174V|NP_004295.2:p.Phe1174Val	A change in the amino acid residue at position 1174 in the ALK tyrosine kinase receptor protein where phenylalanine has been replaced by valine.			Cell or Molecular Dysfunction	
C146870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146870>	C137952	ALK NM_004304.4:c.3520T>G|ALK Receptor Tyrosine Kinase c.3520T>G|ALK c.3520T>G|Anaplastic Lymphoma Kinase (Ki-1) c.3520T>G|Anaplastic Lymphoma Receptor Tyrosine Kinase c.3520T>G|CD246 c.3520T>G|NM_004304.4:c.3520T>G	A nucleotide substitution at position 3520 of the coding sequence of the ALK gene where thymine has been mutated to guanine.			Cell or Molecular Dysfunction	
C146871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146871>	C137952	ALK NM_004304.4:c.3185A>T|ALK Receptor Tyrosine Kinase c.3185A>T|ALK c.3185A>T|Anaplastic Lymphoma Kinase (Ki-1) c.3185A>T|Anaplastic Lymphoma Receptor Tyrosine Kinase c.3185A>T|CD246 c.3185A>T|NM_004304.4:c.3185A>T	A nucleotide substitution at position 3185 of the coding sequence of the ALK gene where adenine has been mutated to thymine.			Cell or Molecular Dysfunction	
C146872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146872>	C133463	ALK NP_004295.2:p.K1062M|ALK K1062M|ALK Lys1062Met|ALK NP_004295.2:p.Lys1062Met|ALK Tyrosine Kinase Receptor K1062M|ALK Tyrosine Kinase Receptor Lys1062Met|ALK p.K1062M|ALK p.Lys1062Met|Anaplastic Lymphoma Kinase K1062M|Anaplastic Lymphoma Kinase Lys1062Met|CD246 Antigen K1062M|CD246 Antigen Lys1062Met|NP_004295.2:p.K1062M|NP_004295.2:p.Lys1062Met	A change in the amino acid residue at position 1062 in the ALK tyrosine kinase receptor protein where lysine has been replaced by methionine.			Cell or Molecular Dysfunction	
C146873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146873>	C137952	ALK NM_004304.4:c.3824G>A|ALK Receptor Tyrosine Kinase c.3824G>A|ALK c.3824G>A|Anaplastic Lymphoma Kinase (Ki-1) c.3824G>A|Anaplastic Lymphoma Receptor Tyrosine Kinase c.3824G>A|CD246 c.3824G>A|NM_004304.4:c.3824G>A	A nucleotide substitution at position 3824 of the coding sequence of the ALK gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C146874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146874>	C133464	ALK NP_004295.2:p.R1275Q|ALK Arg1275Gln|ALK NP_004295.2:p.Arg1275Gln|ALK R1275Q|ALK Tyrosine Kinase Receptor Arg1275Gln|ALK Tyrosine Kinase Receptor R1275Q|ALK p.Arg1275Gln|ALK p.R1275Q|Anaplastic Lymphoma Kinase Arg1275Gln|Anaplastic Lymphoma Kinase R1275Q|CD246 Antigen Arg1275Gln|CD246 Antigen R1275Q|NP_004295.2:p.Arg1275Gln|NP_004295.2:p.R1275Q	A change in the amino acid residue at position 1275 in the ALK tyrosine kinase receptor protein where arginine has been replaced by glutamine.			Cell or Molecular Dysfunction	
C146875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146875>	C133463	ALK NP_004295.2:p.T1087I|ALK NP_004295.2:p.Thr1087Ile|ALK T1087I|ALK Thr1087Ile|ALK Tyrosine Kinase Receptor T1087I|ALK Tyrosine Kinase Receptor Thr1087Ile|ALK p.T1087I|ALK p.Thr1087Ile|Anaplastic Lymphoma Kinase Thr1087Ile|CD246 Antigen T1087I|CD246 Antigen Thr1087Ile|NP_004295.2:p.T1087I|NP_004295.2:p.Thr1087Ile	A change in the amino acid residue at position 1087 in the ALK tyrosine kinase receptor protein where threonine has been replaced by isoleucine.			Cell or Molecular Dysfunction	
C146876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146876>	C133466	ALK NP_004295.2:p.F1245L|ALK F1245L|ALK NP_004295.2:p.Phe1245Leu|ALK Phe1245Leu|ALK Tyrosine Kinase Receptor F1245L|ALK Tyrosine Kinase Receptor Phe1245Leu|ALK p.F1245L|ALK p.Phe1245Leu|Anaplastic Lymphoma Kinase F1245L|Anaplastic Lymphoma Kinase Phe1245Leu|CD246 Antigen F1245L|CD246 Antigen Phe1245Leu|NP_004295.2:p.F1245L|NP_004295.2:p.Phe1245Leu	A change in the amino acid residue at position 1245 in the ALK tyrosine kinase receptor protein where phenylalanine has been replaced by leucine.			Cell or Molecular Dysfunction	
C146877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146877>	C137952	ALK NM_004304.4:c.3735C>G|ALK Receptor Tyrosine Kinase c.3735C>G|ALK c.3735C>G|Anaplastic Lymphoma Kinase (Ki-1) c.3735C>G|Anaplastic Lymphoma Receptor Tyrosine Kinase c.3735C>G|CD246 c.3735C>G|NM_004304.4:c.3735C>G	A nucleotide substitution at position 3735 of the coding sequence of the ALK gene where cytosine has been mutated to guanine.			Cell or Molecular Dysfunction	
C146878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146878>	C137952	ALK NM_004304.4:c.3735C>A|ALK Receptor Tyrosine Kinase c.3735C>A|ALK c.3735C>A|Anaplastic Lymphoma Kinase (Ki-1) c.3735C>A|Anaplastic Lymphoma Receptor Tyrosine Kinase c.3735C>A|CD246 c.3735C>A|NM_004304.4:c.3735C>A	A nucleotide substitution at position 3735 of the coding sequence of the ALK gene where cytosine has been mutated to adenine.			Cell or Molecular Dysfunction	
C146879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146879>	C137952	ALK NM_004304.4:c.3733T>C|ALK Receptor Tyrosine Kinase c.3733T>C|ALK c.3733T>C|Anaplastic Lymphoma Kinase (Ki-1) c.3733T>C|Anaplastic Lymphoma Receptor Tyrosine Kinase c.3733T>C|CD246 c.3733T>C|NM_004304.4:c.3733T>C	A nucleotide substitution at position 3733 of the coding sequence of the ALK gene where thymine has been mutated to cytosine.			Cell or Molecular Dysfunction	
C146880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146880>	C158854	BRAF NM_004333.4:c.1801A>G|B-RAF1 c.1801A>G|BRAF c.1801A>G|NM_004333.4:c.1801A>G|v-raf Murine Sarcoma Viral Oncogene Homolog B1 c.1801A>G	A nucleotide substitution at position 1801 of the coding sequence of the BRAF gene where adenine has been mutated to guanine.			Cell or Molecular Dysfunction	
C146881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146881>	C98307	BRAF NP_004324.2:p.K601E|BRAF K601E|BRAF Lys601Glu|BRAF NP_004324.2:p.Lys601Glu|BRAF p.K601E|BRAF p.Lys601Glu|NP_004324.2:p.K601E|NP_004324.2:p.Lys601Glu|Serine/Threonine-Protein Kinase B-raf K601E|Serine/Threonine-Protein Kinase B-raf Lys601Glu	A change in the amino acid residue at position 601 in the serine/threonine protein kinase B-raf protein where lysine has been replaced by glutamic acid.			Cell or Molecular Dysfunction	
C146882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146882>	C64860	Tumor Treating Fields Therapy|Alternating Electric Field Therapy|TTF|TTFields	A type of electromagnetic field therapy that uses low-intensity, intermediate-frequency alternating electrical fields to a target area to induce selective toxicity to proliferating cells.	Tumor Treating Fields Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C146883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146883>	C45741|C35815	Mediastinal Granulocytic Sarcoma	A malignant tumor that arises from the mediastinum and is composed of myeloblasts, neutrophils and neutrophil precursors. It is the most common type of myeloid sarcoma affecting the mediastinum.			Neoplastic Process	
C146884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146884>	C97928	TP53 Protein Variant|Antigen NY-CO-13 Protein Variant|Cellular Tumor Antigen p53 Protein Variant|Transformation-Related Protein 53 Protein Variant|Tumor Protein p53 Protein Variant|Tumor Suppressor p53 Protein Variant	A variation in the amino acid sequence for cellular tumor antigen p53.			Cell or Molecular Dysfunction	Pediatric Oncology Target Molecular Abnormalities Terminology
C146885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146885>	C175689	TP53 NM_000546.5:c.524G>A|LFS1 c.524G>A|Li-Fraumeni Syndrome c.524G>A|NM_000546.5:c.524G>A|P53 c.524G>A|TP53 c.524G>A|Tumor Protein p53 c.524G>A	A nucleotide substitution at position 524 of the coding sequence of the TP53 gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C146886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146886>	C146884	TP53 NP_000537.3:p.R175H|Antigen NY-CO-13 Arg175His|Antigen NY-CO-13 R175H|Cellular Tumor Antigen p53 Arg175His|Cellular Tumor Antigen p53 R175H|NP_000537.3:p.Arg175His|NP_000537.3:p.R175H|TP53 Arg175His|TP53 NP_000537.3:p.Arg175His|TP53 R175H|TP53 p.Arg175His|TP53 p.R175H|Transformation-Related Protein 53 Arg175His|Transformation-Related Protein 53 R175H|Tumor Protein p53 Arg175His|Tumor Protein p53 R175H|Tumor Suppressor p53 Arg175His|Tumor Suppressor p53 R175H	A change in the amino acid residue at position 175 in the cellular tumor antigen p53 protein where arginine has been replaced by histidine.	TP53 NP_000537.3:p.R175H		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146887>	C175689	TP53 NM_000546.5:c.638G>T|LFS1 c.638G>T|Li-Fraumeni Syndrome c.638G>T|NM_000546.5:c.638G>T|P53 c.638G>T|TP53 c.638G>T|Tumor Protein p53 c.638G>T	A nucleotide substitution at position 638 of the coding sequence of the TP53 gene where guanine has been mutated to thymine.	TP53 NM_000546.5:c.638G>T		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146888>	C146884	TP53 NP_000537.3:p.R213L|Antigen NY-CO-13 Arg213Leu|Antigen NY-CO-13 R213L|Cellular Tumor Antigen p53 Arg213Leu|Cellular Tumor Antigen p53 R213L|NP_000537.3:p.Arg213Leu|NP_000537.3:p.R213L|TP53 Arg213Leu|TP53 NP_000537.3:p.Arg213Leu|TP53 R213L|TP53 p.Arg213Leu|TP53 p.R213L|Transformation-Related Protein 53 Arg213Leu|Transformation-Related Protein 53 R213L|Tumor Protein p53 Arg213Leu|Tumor Protein p53 R213L|Tumor Suppressor p53 Arg213Leu|Tumor Suppressor p53 R213L	A change in the amino acid residue at position 213 in the cellular tumor antigen p53 protein where arginine has been replaced by leucine.	TP53 NP_000537.3:p.R213L		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146889>	C175689	TP53 NM_000546.5:c.659A>G|LFS1 c.659A>G|Li-Fraumeni Syndrome c.659A>G|NM_000546.5:c.659A>G|P53 c.659A>G|TP53 c.659A>G|Tumor Protein p53 c.659A>G	A nucleotide substitution at position 659 of the coding sequence of the TP53 gene where adenine has been mutated to guanine.	TP53 NM_000546.5:c.659A>G		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146890>	C146884	TP53 NP_000537.3:p.Y220C|Antigen NY-CO-13 Tyr220Cys|Antigen NY-CO-13 Y220C|Cellular Tumor Antigen p53 Tyr220Cys|Cellular Tumor Antigen p53 Y220C|NP_000537.3:p.Tyr220Cys|NP_000537.3:p.Y220C|TP53 NP_000537.3:p.Tyr220Cys|TP53 Tyr220Cys|TP53 Y220C|TP53 p.Tyr220Cys|TP53 p.Y220C|Transformation-Related Protein 53 Tyr220Cys|Transformation-Related Protein 53 Y220C|Tumor Protein p53 Tyr220Cys|Tumor Protein p53 Y220C|Tumor Suppressor p53 Tyr220Cys|Tumor Suppressor p53 Y220C|p53 Y220C Mutation	A change in the amino acid residue at position 220 in the cellular tumor antigen p53 protein where tyrosine has been replaced by cysteine.	TP53 NP_000537.3:p.Y220C		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146891>	C175689	TP53 NM_000546.5:c.713G>A|LFS1 c.713G>A|Li-Fraumeni Syndrome c.713G>A|NM_000546.5:c.713G>A|P53 c.713G>A|TP53 c.713G>A|Tumor Protein p53 c.713G>A	A nucleotide substitution at position 713 of the coding sequence of the TP53 gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C146892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146892>	C146884	TP53 NP_000537.3:p.C238Y|Antigen NY-CO-13 C238Y|Antigen NY-CO-13 Cys238Tyr|Cellular Tumor Antigen p53 C238Y|Cellular Tumor Antigen p53 Cys238Tyr|NP_000537.3:p.C238Y|NP_000537.3:p.Cys238Tyr|TP53 C238Y|TP53 Cys238Tyr|TP53 NP_000537.3:p.Cys238Tyr|TP53 p.C238Y|TP53 p.Cys238Tyr|Transformation-Related Protein 53 C238Y|Transformation-Related Protein 53 Cys238Tyr|Tumor Protein p53 C238Y|Tumor Protein p53 Cys238Tyr|Tumor Suppressor p53 C238Y|Tumor Suppressor p53 Cys238Tyr	A change in the amino acid residue at position 238 in the cellular tumor antigen p53 protein where cysteine has been replaced by tyrosine.			Cell or Molecular Dysfunction	
C146893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146893>	C3482|C164141|C157774	Metastatic Genitourinary System Carcinoma|Metastatic Genitourinary Cancer|Metastatic Genitourinary Carcinoma|Metastatic Urogenital Carcinoma	A carcinoma that arises from the genitourinary system and has metastasized to other anatomic sites.	Metastatic Genitourinary System Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C146894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146894>	C2866	Alzheimer's Disease 1|AD1|Familial Alzheimer's Disease, Type 1	Alzheimer's disease caused by mutation(s) in the APP gene, encoding amyloid-beta A4 protein. The onset of this condition typically occurs before age 65.			Mental or Behavioral Dysfunction	Cellosaurus Disease Terminology
C146895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146895>	C175689	TP53 NM_000546.5:c.733G>A|LFS1 c.733G>A|Li-Fraumeni Syndrome c.733G>A|NM_000546.5:c.733G>A|P53 c.733G>A|TP53 c.733G>A|Tumor Protein p53 c.733G>A	A nucleotide substitution at position 733 of the coding sequence of the TP53 gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C146896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146896>	C146884	TP53 NP_000537.3:p.G245S|Antigen NY-CO-13 G245S|Antigen NY-CO-13 Gly245Ser|Cellular Tumor Antigen p53 G245S|Cellular Tumor Antigen p53 Gly245Ser|NP_000537.3:p.G245S|NP_000537.3:p.Gly245Ser|TP53 G245S|TP53 Gly245Ser|TP53 NP_000537.3:p.Gly245Ser|TP53 p.G245S|TP53 p.Gly245Ser|Transformation-Related Protein 53 G245S|Transformation-Related Protein 53 Gly245Ser|Tumor Protein p53 G245S|Tumor Protein p53 Gly245Ser|Tumor Suppressor p53 G245S|Tumor Suppressor p53 Gly245Ser	A change in the amino acid residue at position 245 in the cellular tumor antigen p53 protein where glycine has been replaced by serine.			Cell or Molecular Dysfunction	
C146897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146897>	C137802	Chimpanzee Trisomy 22|Chimpanzee Down Syndrome	A condition resulting from the presence of an extra copy of chromosome 22 in chimpanzees. The condition is in many respects similar to Trisomy 21 in humans.			Disease or Syndrome	Cellosaurus Disease Terminology
C146898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146898>	C175689	TP53 NM_000546.5:c.734G>A|LFS1 c.734G>A|Li-Fraumeni Syndrome c.734G>A|NM_000546.5:c.734G>A|P53 c.734G>A|TP53 c.734G>A|Tumor Protein p53 c.734G>A	A nucleotide substitution at position 734 of the coding sequence of the TP53 gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C146899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146899>	C4924	Trichothiodystrophy 4, Nonphotosensitive	A subtype of trichothiodystrophy caused by mutation(s) in the MPLKIP gene, encoding M-phase-specific PLK1-interacting protein.			Disease or Syndrome	Cellosaurus Disease Terminology
C1468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1468>	C574|C2087	Mycophenolate Mofetil|CellCept|Cellcept|Cellcept|MMF|MYCOPHENOLATE MOFETIL|Mycophenolate mofetil|mycophenolate mofetil	The morpholinoethyl ester of mycophenolic acid (MPA) with potent immunosuppressive properties.  Mycophenolate stops T-cell and B-cell proliferation through selective inhibition of the de novo pathway of purine biosynthesis.  In vivo, the active metabolite, MPA, reversibly inhibits inosine 5'-monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of guanine nucleotides.  MPA displays high lymphocyte specificity and cytotoxicity due to the higher dependence of activated lymphocytes on both salvage and de novo synthesis of guanine nucleotides relative to other cell types. (NCI04)	Mycophenolate Mofetil		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C146900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146900>	C146884	TP53 NP_000537.3:p.G245D|Antigen NY-CO-13 G245D|Antigen NY-CO-13 Gly245Asp|Cellular Tumor Antigen p53 G245D|Cellular Tumor Antigen p53 Gly245Asp|NP_000537.3:p.G245D|NP_000537.3:p.Gly245Asp|TP53 G245D|TP53 Gly245Asp|TP53 NP_000537.3:p.Gly245Asp|TP53 p.G245D|TP53 p.Gly245Asp|Transformation-Related Protein 53 G245D|Transformation-Related Protein 53 Gly245Asp|Tumor Protein p53 G245D|Tumor Protein p53 Gly245Asp|Tumor Suppressor p53 G245D|Tumor Suppressor p53 Gly245Asp	A change in the amino acid residue at position 245 in the cellular tumor antigen p53 protein where glycine has been replaced by aspartic acid.			Cell or Molecular Dysfunction	
C146901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146901>	C175689	TP53 NM_000546.5:c.743G>A|LFS1 c.743G>A|Li-Fraumeni Syndrome c.743G>A|NM_000546.5:c.743G>A|P53 c.743G>A|TP53 c.743G>A|Tumor Protein p53 c.743G>A	A nucleotide substitution at position 743 of the coding sequence of the TP53 gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C146902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146902>	C175689	TP53 NM_000546.5:c.743_744delinsAA|LFS1 c.743_744GG>AA|LFS1 c.743_744delGGinsAA|Li-Fraumeni Syndrome c.743_744GG>AA|Li-Fraumeni Syndrome c.743_744delGGinsAA|NM_000546.5:c.743_744GG>AA|NM_000546.5:c.743_744delGGinsAA|NM_000546.5:c.743_744delinsAA|P53 c.743_744GG>AA|P53 c.743_744delGGinsAA|TP53 NM_000546.5:c.743_744GG>AA|TP53 NM_000546.5:c.743_744delGGinsAA|TP53 NM_000546.5:c.743_744delGGinsAA|TP53 c.743_744GG>AA|TP53 c.743_744delGGinsAA|Tumor Protein p53 c.743_744GG>AA|Tumor Protein p53 c.743_744delGGinsAA	A complex substitution where the nucleotide sequence at positions 743 and 744 of the coding sequence of the TP53 gene has changed from guanine-guanine to adenine-adenine.			Cell or Molecular Dysfunction	
C146903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146903>	C146884	TP53 NP_000537.3:p.R248Q|Antigen NY-CO-13 Arg248Gln|Antigen NY-CO-13 R248Q|Cellular Tumor Antigen p53 Arg248Gln|Cellular Tumor Antigen p53 R248Q|NP_000537.3:p.Arg248Gln|NP_000537.3:p.R248Q|TP53 Arg248Gln|TP53 NP_000537.3:p.Arg248Gln|TP53 R248Q|TP53 p.Arg248Gln|TP53 p.R248Q|Transformation-Related Protein 53 Arg248Gln|Transformation-Related Protein 53 R248Q|Tumor Protein p53 Arg248Gln|Tumor Protein p53 R248Q|Tumor Suppressor p53 Arg248Gln|Tumor Suppressor p53 R248Q	A change in the amino acid residue at position 248 in the cellular tumor antigen p53 protein where arginine has been replaced by glutamine.			Cell or Molecular Dysfunction	
C146904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146904>	C175689	TP53 NM_000546.5:c.742C>T|LFS1 c.742C>T|Li-Fraumeni Syndrome c.742C>T|NM_000546.5:c.742C>T|P53 c.742C>T|TP53 c.742C>T|Tumor Protein p53 c.742C>T	A nucleotide substitution at position 742 of the coding sequence of the TP53 gene where cytosine has been mutated to thymine.			Cell or Molecular Dysfunction	
C146905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146905>	C175689	TP53 NM_000546.5:c.741_742delinsTT|LFS1 c.741_742CC>TT|LFS1 c.741_742delCCinsTT|Li-Fraumeni Syndrome c.741_742CC>TT|Li-Fraumeni Syndrome c.741_742delCCinsTT|NM_000546.5:c.741_742CC>TT|NM_000546.5:c.741_742delCCinsTT|NM_000546.5:c.741_742delinsTT|P53 c.741_742CC>TT|P53 c.741_742delCCinsTT|TP53 NM_000546.5:c.741_742CC>TT|TP53 NM_000546.5:c.741_742delCCinsTT|TP53 NM_000546.5:c.741_742delCCinsTT|TP53 c.741_742CC>TT|TP53 c.741_742delCCinsTT|Tumor Protein p53 c.741_742CC>TT|Tumor Protein p53 c.741_742delCCinsTT	A complex substitution where the nucleotide sequence at positions 741 and 742 of the coding sequence of the TP53 gene has changed from cytosine-cytosine to thymine-thymine.			Cell or Molecular Dysfunction	
C146906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146906>	C146884	TP53 NP_000537.3:p.R248W|Antigen NY-CO-13 Arg248Trp|Antigen NY-CO-13 R248W|Cellular Tumor Antigen p53 Arg248Trp|Cellular Tumor Antigen p53 R248W|NP_000537.3:p.Arg248Trp|NP_000537.3:p.R248W|TP53 Arg248Trp|TP53 NP_000537.3:p.Arg248Trp|TP53 R248W|TP53 p.Arg248Trp|TP53 p.R248W|Transformation-Related Protein 53 Arg248Trp|Transformation-Related Protein 53 R248W|Tumor Protein p53 Arg248Trp|Tumor Protein p53 R248W|Tumor Suppressor p53 Arg248Trp|Tumor Suppressor p53 R248W	A change in the amino acid residue at position 248 in the cellular tumor antigen p53 protein where arginine has been replaced by tryptophan.	TP53 NP_000537.3:p.R248W		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146907>	C175689	TP53 NM_000546.5:c.797G>T|LFS1 c.797G>T|Li-Fraumeni Syndrome c.797G>T|NM_000546.5:c.797G>T|P53 c.797G>T|TP53 c.797G>T|Tumor Protein p53 c.797G>T	A nucleotide substitution at position 797 of the coding sequence of the TP53 gene where guanine has been mutated to thymine.			Cell or Molecular Dysfunction	
C146908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146908>	C146884	TP53 NP_000537.3:p.G266V|Antigen NY-CO-13 G266V|Antigen NY-CO-13 Gly266Val|Cellular Tumor Antigen p53 G266V|Cellular Tumor Antigen p53 Gly266Val|NP_000537.3:p.G266V|NP_000537.3:p.Gly266Val|TP53 G266V|TP53 Gly266Val|TP53 NP_000537.3:p.Gly266Val|TP53 p.G266V|TP53 p.Gly266Val|Transformation-Related Protein 53 G266V|Transformation-Related Protein 53 Gly266Val|Tumor Protein p53 G266V|Tumor Protein p53 Gly266Val|Tumor Suppressor p53 G266V|Tumor Suppressor p53 Gly266Val	A change in the amino acid residue at position 266 in the cellular tumor antigen p53 protein where glycine has been replaced by valine.			Cell or Molecular Dysfunction	
C146909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146909>	C175689	TP53 NM_000546.5:c.797G>A|LFS1 c.797G>A|Li-Fraumeni Syndrome c.797G>A|NM_000546.5:c.797G>A|P53 c.797G>A|TP53 c.797G>A|Tumor Protein p53 c.797G>A	A nucleotide substitution at position 797 of the coding sequence of the TP53 gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C146910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146910>	C146884	TP53 NP_000537.3:p.G266E|Antigen NY-CO-13 G266E|Antigen NY-CO-13 Gly266Glu|Cellular Tumor Antigen p53 G266E|Cellular Tumor Antigen p53 Gly266Glu|NP_000537.3:p.G266E|NP_000537.3:p.Gly266Glu|TP53 G266E|TP53 Gly266Glu|TP53 NP_000537.3:p.Gly266Glu|TP53 p.G266E|TP53 p.Gly266Glu|Transformation-Related Protein 53 G266E|Transformation-Related Protein 53 Gly266Glu|Tumor Protein p53 G266E|Tumor Protein p53 Gly266Glu|Tumor Suppressor p53 G266E|Tumor Suppressor p53 Gly266Glu	A change in the amino acid residue at position 266 in the cellular tumor antigen p53 protein where glycine has been replaced by glutamic acid.			Cell or Molecular Dysfunction	
C146912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146912>	C175689	TP53 NM_000546.5:c.814G>A|LFS1 c.814G>A|Li-Fraumeni Syndrome c.814G>A|NM_000546.5:c.814G>A|P53 c.814G>A|TP53 c.814G>A|Tumor Protein p53 c.814G>A	A nucleotide substitution at position 814 of the coding sequence of the TP53 gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C146913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146913>	C146884	TP53 NP_000537.3:p.V272M|Antigen NY-CO-13 V272M|Antigen NY-CO-13 Val272Met|Cellular Tumor Antigen p53 V272M|Cellular Tumor Antigen p53 Val272Met|NP_000537.3:p.V272M|NP_000537.3:p.Val272Met|TP53 NP_000537.3:p.Val272Met|TP53 V272M|TP53 Val272Met|TP53 p.V272M|TP53 p.Val272Met|Transformation-Related Protein 53 V272M|Transformation-Related Protein 53 Val272Met|Tumor Protein p53 V272M|Tumor Protein p53 Val272Met|Tumor Suppressor p53 V272M|Tumor Suppressor p53 Val272Met	A change in the amino acid residue at position 272 in the cellular tumor antigen p53 protein where valine has been replaced by methionine.			Cell or Molecular Dysfunction	
C146914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146914>	C175689	TP53 NM_000546.5:c.818G>A|LFS1 c.818G>A|Li-Fraumeni Syndrome c.818G>A|NM_000546.5:c.818G>A|P53 c.818G>A|TP53 c.818G>A|Tumor Protein p53 c.818G>A	A nucleotide substitution at position 818 of the coding sequence of the TP53 gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C146915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146915>	C146884	TP53 NP_000537.3:p.R273H|Antigen NY-CO-13 Arg273His|Antigen NY-CO-13 R273H|Cellular Tumor Antigen p53 Arg273His|Cellular Tumor Antigen p53 R273H|NP_000537.3:p.Arg273His|NP_000537.3:p.R273H|TP53 Arg273His|TP53 NP_000537.3:p.Arg273His|TP53 R273H|TP53 p.Arg273His|TP53 p.R273H|Transformation-Related Protein 53 Arg273His|Transformation-Related Protein 53 R273H|Tumor Protein p53 Arg273His|Tumor Protein p53 R273H|Tumor Suppressor p53 Arg273His|Tumor Suppressor p53 R273H	A change in the amino acid residue at position 273 in the cellular tumor antigen p53 protein where arginine has been replaced by histidine.			Cell or Molecular Dysfunction	
C146916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146916>	C175689	TP53 NM_000546.5:c.817C>T|LFS1 c.817C>T|Li-Fraumeni Syndrome c.817C>T|NM_000546.5:c.817C>T|P53 c.817C>T|TP53 c.817C>T|Tumor Protein p53 c.817C>T	A nucleotide substitution at position 817 of the coding sequence of the TP53 gene where cytosine has been mutated to thymine.			Cell or Molecular Dysfunction	
C146917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146917>	C146884	TP53 NP_000537.3:p.R273C|Antigen NY-CO-13 Arg273Cys|Antigen NY-CO-13 R273C|Cellular Tumor Antigen p53 Arg273Cys|Cellular Tumor Antigen p53 R273C|NP_000537.3:p.Arg273Cys|NP_000537.3:p.R273C|TP53 Arg273Cys|TP53 NP_000537.3:p.Arg273Cys|TP53 R273C|TP53 p.Arg273Cys|TP53 p.R273C|Transformation-Related Protein 53 Arg273Cys|Transformation-Related Protein 53 R273C|Tumor Protein p53 Arg273Cys|Tumor Protein p53 R273C|Tumor Suppressor p53 Arg273Cys|Tumor Suppressor p53 R273C	A change in the amino acid residue at position 273 in the cellular tumor antigen p53 protein where arginine has been replaced by cysteine.			Cell or Molecular Dysfunction	
C146918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146918>	C16205	Medical History Taking|Medical History Collection	The process of gathering information regarding a person's medical history.			Health Care Activity	
C146919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146919>	C175689	TP53 NM_000546.5:c.818G>T|LFS1 c.818G>T|Li-Fraumeni Syndrome c.818G>T|NM_000546.5:c.818G>T|P53 c.818G>T|TP53 c.818G>T|Tumor Protein p53 c.818G>T	A nucleotide substitution at position 818 of the coding sequence of the TP53 gene where guanine has been mutated to thymine.			Cell or Molecular Dysfunction	
C146920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146920>	C146884	TP53 NP_000537.3:p.R273L|Antigen NY-CO-13 Arg273Leu|Antigen NY-CO-13 R273L|Cellular Tumor Antigen p53 Arg273Leu|Cellular Tumor Antigen p53 R273L|NP_000537.3:p.Arg273Leu|NP_000537.3:p.R273L|TP53 Arg273Leu|TP53 NP_000537.3:p.Arg273Leu|TP53 R273L|TP53 p.Arg273Leu|TP53 p.R273L|Transformation-Related Protein 53 Arg273Leu|Transformation-Related Protein 53 R273L|Tumor Protein p53 Arg273Leu|Tumor Protein p53 R273L|Tumor Suppressor p53 Arg273Leu|Tumor Suppressor p53 R273L	A change in the amino acid residue at position 273 in the cellular tumor antigen p53 protein where arginine has been replaced by leucine.			Cell or Molecular Dysfunction	
C146921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146921>	C175689	TP53 NM_000546.5:c.844C>T|LFS1 c.844C>T|Li-Fraumeni Syndrome c.844C>T|NM_000546.5:c.844C>T|P53 c.844C>T|TP53 c.844C>T|Tumor Protein p53 c.844C>T	A nucleotide substitution at position 844 of the coding sequence of the TP53 gene where cytosine has been mutated to thymine.			Cell or Molecular Dysfunction	
C146922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146922>	C175689	TP53 NM_000546.5:c.843_844delinsTT|LFS1 c.843_844CC>TT|LFS1 c.843_844delCCinsTT|Li-Fraumeni Syndrome c.843_844CC>TT|Li-Fraumeni Syndrome c.843_844delCCinsTT|NM_000546.5:c.843_844CC>TT|NM_000546.5:c.843_844delCCinsTT|NM_000546.5:c.843_844delinsTT|P53 c.843_844CC>TT|P53 c.843_844delCCinsTT|TP53 NM_000546.5:c.843_844CC>TT|TP53 NM_000546.5:c.843_844delCCinsTT|TP53 NM_000546.5:c.843_844delCCinsTT|TP53 c.843_844CC>TT|TP53 c.843_844delCCinsTT|Tumor Protein p53 c.843_844CC>TT|Tumor Protein p53 c.843_844delCCinsTT	A complex substitution where the nucleotide sequence at positions 843 and 844 of the coding sequence of the TP53 gene has changed from cytosine-cytosine to thymine-thymine.			Cell or Molecular Dysfunction	
C146923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146923>	C146884	TP53 NP_000537.3:p.R282W|Antigen NY-CO-13 Arg282Trp|Antigen NY-CO-13 R282W|Cellular Tumor Antigen p53 Arg282Trp|Cellular Tumor Antigen p53 R282W|NP_000537.3:p.Arg282Trp|NP_000537.3:p.R282W|TP53 Arg282Trp|TP53 NP_000537.3:p.Arg282Trp|TP53 R282W|TP53 p.Arg282Trp|TP53 p.R282W|Transformation-Related Protein 53 Arg282Trp|Transformation-Related Protein 53 R282W|Tumor Protein p53 Arg282Trp|Tumor Protein p53 R282W|Tumor Suppressor p53 Arg282Trp|Tumor Suppressor p53 R282W	A change in the amino acid residue at position 282 in the cellular tumor antigen p53 protein where arginine has been replaced by tryptophan.			Cell or Molecular Dysfunction	
C146924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146924>	C175689	TP53 NM_000546.5:c.844C>G|LFS1 c.844C>G|Li-Fraumeni Syndrome c.844C>G|NM_000546.5:c.844C>G|P53 c.844C>G|TP53 c.844C>G|Tumor Protein p53 c.844C>G	A nucleotide substitution at position 844 of the coding sequence of the TP53 gene where cytosine has been mutated to guanine.			Cell or Molecular Dysfunction	
C146925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146925>	C146884	TP53 NP_000537.3:p.R282G|Antigen NY-CO-13 Arg282Gly|Antigen NY-CO-13 R282G|Cellular Tumor Antigen p53 Arg282Gly|Cellular Tumor Antigen p53 R282G|NP_000537.3:p.Arg282Gly|NP_000537.3:p.R282G|TP53 Arg282Gly|TP53 NP_000537.3:p.Arg282Gly|TP53 R282G|TP53 p.Arg282Gly|TP53 p.R282G|Transformation-Related Protein 53 Arg282Gly|Transformation-Related Protein 53 R282G|Tumor Protein p53 Arg282Gly|Tumor Protein p53 R282G|Tumor Suppressor p53 Arg282Gly|Tumor Suppressor p53 R282G	A change in the amino acid residue at position 282 in the cellular tumor antigen p53 protein where arginine has been replaced by glycine.			Cell or Molecular Dysfunction	
C146926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146926>	C97928	CDKN2A Protein Variant|CDK4I Protein Variant|Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant|Cyclin-Dependent Kinase Inhibitor 2A Protein Variant|Cyclin-Dependent Kinase Inhibitor p16 Protein Variant|p16(INK4a) Protein Variant|p16-INK4 Protein Variant|p16INK4A Protein Variant	A variation in the amino acid sequence for a protein encoded by the CDKN2A gene.	CDKN2A Protein Variant		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146927>	C128817	CDKN2A NM_000077.4:c.89C>T|CDK4I c.89C>T|CDKN2 c.89C>T|CDKN2A c.89C>T|Cyclin Dependent Kinase Inhibitor 2A c.89C>T|INK4A c.89C>T|MLM c.89C>T|MTS-1 c.89C>T|MTS1 c.89C>T|NM_000077.4:c.89C>T	A nucleotide substitution at position 89 of the coding sequence of the CDKN2A gene where cytosine has been mutated to thymine.			Cell or Molecular Dysfunction	
C146928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146928>	C146926	CDKN2A NP_000068.1:p.A30V|CDK4I Protein Variant A30V|CDK4I Protein Variant Ala30Val|CDKN2A A30V|CDKN2A Ala30Val|CDKN2A NP_000068.1:p.Ala30Val|CDKN2A p.A30V|CDKN2A p.Ala30Val|Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant A30V|Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant Ala30Val|Cyclin-Dependent Kinase Inhibitor 2A Protein Variant A30V|Cyclin-Dependent Kinase Inhibitor 2A Protein Variant Ala30Val|Cyclin-Dependent Kinase Inhibitor p16 Protein Variant A30V|Cyclin-Dependent Kinase Inhibitor p16 Protein Variant Ala30Val|NP_000068.1:p.A30V|NP_000068.1:p.Ala30Val|p16(INK4a) Protein Variant A30V|p16(INK4a) Protein Variant Ala30Val|p16-INK4 Protein Variant A30V|p16-INK4 Protein Variant Ala30Val|p16INK4A Protein Variant A30V|p16INK4A Protein Variant Ala30Val	A change in the amino acid residue at position 30 in the cyclin-dependent kinase inhibitor 2 protein where alanine has been replaced by valine.			Cell or Molecular Dysfunction	
C146929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146929>	C128817	CDKN2A NM_000077.4:c.152T>A|CDK4I c.152T>A|CDKN2 c.152T>A|CDKN2A c.152T>A|Cyclin Dependent Kinase Inhibitor 2A c.152T>A|INK4A c.152T>A|MLM c.152T>A|MTS-1 c.152T>A|MTS1 c.152T>A|NM_000077.4:c.152T>A	A nucleotide substitution at position 152 of the coding sequence of the CDKN2A gene where thymine has been mutated to adenine.			Cell or Molecular Dysfunction	
C146930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146930>	C146926	CDKN2A NP_000068.1:p.V51D|CDK4I Protein Variant V51D|CDK4I Protein Variant Val51Asp|CDKN2A NP_000068.1:p.Val51Asp|CDKN2A V51D|CDKN2A Val51Asp|CDKN2A p.V51D|CDKN2A p.Val51Asp|Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant V51D|Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant Val51Asp|Cyclin-Dependent Kinase Inhibitor 2A Protein Variant V51D|Cyclin-Dependent Kinase Inhibitor 2A Protein Variant Val51Asp|Cyclin-Dependent Kinase Inhibitor p16 Protein Variant V51D|Cyclin-Dependent Kinase Inhibitor p16 Protein Variant Val51Asp|NP_000068.1:p.V51D|NP_000068.1:p.Val51Asp|p16(INK4a) Protein Variant V51D|p16(INK4a) Protein Variant Val51Asp|p16-INK4 Protein Variant V51D|p16-INK4 Protein Variant Val51Asp|p16INK4A Protein Variant V51D|p16INK4A Protein Variant Val51Asp	A change in the amino acid residue at position 51 in the cyclin-dependent kinase inhibitor 2 protein where valine has been replaced by aspartic acid.			Cell or Molecular Dysfunction	
C146931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146931>	C128817	CDKN2A NM_000077.4:c.151G>A|CDK4I c.151G>A|CDKN2 c.151G>A|CDKN2A c.151G>A|Cyclin Dependent Kinase Inhibitor 2A c.151G>A|INK4A c.151G>A|MLM c.151G>A|MTS-1 c.151G>A|MTS1 c.151G>A|NM_000077.4:c.151G>A	A nucleotide substitution at position 151 of the coding sequence of the CDKN2A gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C146932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146932>	C146926	CDKN2A NP_000068.1:p.V51I|CDK4I Protein Variant V51I|CDK4I Protein Variant Val51Ile|CDKN2A NP_000068.1:p.Val51Ile|CDKN2A V51I|CDKN2A Val51Ile|CDKN2A p.V51I|CDKN2A p.Val51Ile|Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant V51I|Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant Val51Ile|Cyclin-Dependent Kinase Inhibitor 2A Protein Variant V51I|Cyclin-Dependent Kinase Inhibitor 2A Protein Variant Val51Ile|Cyclin-Dependent Kinase Inhibitor p16 Protein Variant V51I|Cyclin-Dependent Kinase Inhibitor p16 Protein Variant Val51Ile|NP_000068.1:p.V51I|NP_000068.1:p.Val51Ile|p16(INK4a) Protein Variant V51I|p16(INK4a) Protein Variant Val51Ile|p16-INK4 Protein Variant V51I|p16-INK4 Protein Variant Val51Ile|p16INK4A Protein Variant V51I|p16INK4A Protein Variant Val51Ile	A change in the amino acid residue at position 51 in the cyclin-dependent kinase inhibitor 2 protein where valine has been replaced by isoleucine.			Cell or Molecular Dysfunction	
C146933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146933>	C128817	CDKN2A NM_000077.4:c.247C>T|CDK4I c.247C>T|CDKN2 c.247C>T|CDKN2A c.247C>T|Cyclin Dependent Kinase Inhibitor 2A c.247C>T|INK4A c.247C>T|MLM c.247C>T|MTS-1 c.247C>T|MTS1 c.247C>T|NM_000077.4:c.247C>T	A nucleotide substitution at position 247 of the coding sequence of the CDKN2A gene where cytosine has been mutated to thymine.			Cell or Molecular Dysfunction	
C146934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146934>	C146926	CDKN2A NP_000068.1:p.H83Y|CDK4I Protein Variant H83Y|CDK4I Protein Variant His83Tyr|CDKN2A H83Y|CDKN2A His83Tyr|CDKN2A NP_000068.1:p.His83Tyr|CDKN2A p.H83Y|CDKN2A p.His83Tyr|Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant H83Y|Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant His83Tyr|Cyclin-Dependent Kinase Inhibitor 2A Protein Variant H83Y|Cyclin-Dependent Kinase Inhibitor 2A Protein Variant His83Tyr|Cyclin-Dependent Kinase Inhibitor p16 Protein Variant H83Y|Cyclin-Dependent Kinase Inhibitor p16 Protein Variant His83Tyr|NP_000068.1:p.H83Y|NP_000068.1:p.His83Tyr|p16(INK4a) Protein Variant H83Y|p16(INK4a) Protein Variant His83Tyr|p16-INK4 Protein Variant H83Y|p16-INK4 Protein Variant His83Tyr|p16INK4A Protein Variant H83Y|p16INK4A Protein Variant His83Tyr	A change in the amino acid residue at position 83 in the cyclin-dependent kinase inhibitor 2 protein where histidine has been replaced by tyrosine.			Cell or Molecular Dysfunction	
C146935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146935>	C128817	CDKN2A NM_000077.4:c.248A>C|CDK4I c.248A>C|CDKN2 c.248A>C|Cyclin Dependent Kinase Inhibitor 2A c.248A>C|INK4A c.248A>C|MLM c.248A>C|MTS-1 c.248A>C|MTS1 c.248A>C|NM_000077.4:c.248A>C	A nucleotide substitution at position 248 of the coding sequence of the CDKN2A gene where adenine has been mutated to cytosine.			Cell or Molecular Dysfunction	
C146936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146936>	C128817	CDKN2A NM_000077.4:c.248_249delinsCT|CDK4I c.248_249AC>CT|CDKN2 c.248_249AC>CT|CDKN2A NM_000077.4:c.248_249delACinsCT|CDKN2A NM_000077.4:c.248_249delACinsCT|CDKN2A c.248_249AC>CT|CDKN2A c.248_249delACinsCT|INK4A c.248_249AC>CT|MLM c.248_249AC>CT|MTS-1 c.248_249AC>CT|MTS1 c.248_249AC>CT|NM_000077.4:c.248_249AC>CT|NM_000077.4:c.248_249delACinsCT|NM_000077.4:c.248_249delinsCT	A complex substitution where the nucleotide sequence at positions 248 and 249 of the coding sequence of the CDKN2A gene has changed from adenine-cytosine to cytosine-thymine.			Cell or Molecular Dysfunction	
C146937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146937>	C28681|C138180|C129826	Autologous PBLs Retrovirally-transduced with TCRs Targeting Neoantigens|Autologous PBLs Expressing Mutated Neoantigen-specific T-Cell Receptors|Autologous Peripheral Blood Lymphocytes Retrovirally-transduced with TCRs Targeting Neoantigens|Neoantigen-reactive TCRs-transduced Autologous PBLs|Neoantigen-specific TCRs Gene-transduced Autologous PBLs	Autologous human peripheral blood lymphocytes (PBLs) transduced with a retroviral vector encoding T-cell receptors (TCRs) specific for a patient's individual and unique mutated antigens, with potential immunostimulating and antineoplastic activities. Tumor cells are analyzed to identify and isolate specific mutated tumor-associated antigens (TAAs) that are expressed by the patient's tumor cells; then T-cell receptor coding sequences are engineered to target the patient's TAAs and inserted into retroviral vectors. After transduction, expansion in culture, and reintroduction into the patient, neoantigen-specific TCRs retroviral vector-transduced autologous PBLs recognize and bind to tumor cells expressing the patient's neoantigens, which results in a specific cytotoxic T-lymphocyte (CTL)-mediated immune response against the patient's tumor cells.	Autologous PBLs Retrovirally-transduced with TCRs Targeting Neoantigens		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C146938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146938>	C146926	CDKN2A NP_000068.1:p.H83P|CDK4I Protein Variant H83P|CDK4I Protein Variant His83Pro|CDKN2A H83P|CDKN2A His83Pro|CDKN2A NP_000068.1:p.His83Pro|CDKN2A p.H83P|CDKN2A p.His83Pro|Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant H83P|Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant His83Pro|Cyclin-Dependent Kinase Inhibitor 2A Protein Variant H83P|Cyclin-Dependent Kinase Inhibitor 2A Protein Variant His83Pro|Cyclin-Dependent Kinase Inhibitor p16 Protein Variant H83P|Cyclin-Dependent Kinase Inhibitor p16 Protein Variant His83Pro|NP_000068.1:p.H83P|NP_000068.1:p.His83Pro|p16(INK4a) Protein Variant H83P|p16(INK4a) Protein Variant His83Pro|p16-INK4 Protein Variant H83P|p16-INK4 Protein Variant His83Pro|p16INK4A Protein Variant H83P|p16INK4A Protein Variant His83Pro	A change in the amino acid residue at position 83 in the cyclin-dependent kinase inhibitor 2 protein where histidine has been replaced by proline.			Cell or Molecular Dysfunction	
C146939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146939>	C138180|C129826	NY-ESO-1 TCR Retroviral Vector-transduced Autologous PBMCs|Autologous RV-NY-ESO-1 TCR PBMC|Autologous RV-NYESO TCR PBMC|Engineered Autologous PBMC Expressing NY-ESO-1 TCR|NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBMCs|NY-ESO-1 T-cell Receptor-engineered Peripheral Blood Mononuclear Cells|NY-ESO-1 TCR-transduced Autologous PBMCs	Human autologous peripheral blood mononuclear cells (PBMCs) transduced with a retroviral vector (RV) encoding a T-cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1, with potential immunostimulating and antineoplastic activities. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the NY-ESO-1 TCR RV-transduced autologous PBMCs recognize and bind to NY-ESO-1-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of NY-ESO-1-positive tumor cells. NY-ESO-1, a tumor associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types.			Cell|Pharmacologic Substance	
C146940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146940>	C201557|C129826	NY-ESO-1 TCR/sr39TK Lentiviral Vector-transduced Autologous PBSCs|Autologous LV-NY-ESO-1 TCR PBSC|Engineered Autologous PBSC Expressing NY-ESO-1 TCR/sr39TK|LV-NYESO TCR/sr39TK PBSC|NY-ESO-1 Reactive TCR/sr39TK LV-transduced Autologous PBSCs|NY-ESO-1 T-cell Receptor/sr39TK-engineered Peripheral Blood Stem Cells|NY-ESO-1 TCR/HSV-sr39TK LV-modified PBSCs|NY-ESO-1 TCR/sr39TK-modified Autologous PBSC	Human autologous peripheral blood stem cells (PBSCs) transduced with a lentiviral vector (LV) encoding a T-cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1, and carrying the positron emission tomography (PET) reporter/suicide gene sr39TK, a mutant form of the herpes simplex virus type 1 thymidine kinase gene (HSV-1 TK), with potential immunostimulating and antineoplastic activities. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the NY-ESO-1 TCR/sr39TK LV-transduced autologous PBSCs recognize and bind to NY-ESO-1-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of NY-ESO-1-positive tumor cells. NY-ESO-1, a tumor-associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types. The incorporation of sr39TK allows for the ganciclovir (GCV)-mediated cell killing of the gene-modified PBSCs if serious adverse effects occur. sr39TK converts the nucleoside prodrug GCV into GCV monophosphate (GCV-MP), which is in turn phosphorylated by cellular kinases to the cytotoxic nucleotide GCV-triphosphate (GCV-TP); the TP form competitively inhibits deoxyguanosine triphosphate (dGTP) incorporation into DNA and inhibits DNA synthesis, causing DNA damage and cell death in the sr39TK-expressing PBSCs. In addition, sr39TK allows for PET imaging of the gene-modified PBSCs upon subsequent administration of radio-labeled substrates, such as 9-(4-[18F]-fluoro-3-[hydroxymethyl]butyl)guanine ([18F]-FHBG). The monophosphorylation of [18 F]-FHBG is catalyzed by sr39TK; this promotes triphosphorylation and accumulation of [18F]-FHBG in the PBSCs, which allows in vivo imaging and tracking of the PBSCs upon PET. Compared to wild-type HSV-TK, the mutant form has increased prodrug phosphorylating capacity and enhances the cell killing by GCV.			Cell|Pharmacologic Substance	
C146941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146941>	C128817	CDKN2A NM_000077.4:c.322G>C|CDK4I c.322G>C|CDKN2 c.322G>C|CDKN2A c.322G>C|Cyclin Dependent Kinase Inhibitor 2A c.322G>C|INK4A c.322G>C|MLM c.322G>C|MTS-1 c.322G>C|MTS1 c.322G>C|NM_000077.4:c.322G>C	A nucleotide substitution at position 322 of the coding sequence of the CDKN2A gene where guanine has been mutated to cytosine.			Cell or Molecular Dysfunction	
C146942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146942>	C146926	CDKN2A NP_000068.1:p.D108H|CDK4I Protein Variant Asp108His|CDK4I Protein Variant D108H|CDKN2A Asp108His|CDKN2A D108H|CDKN2A NP_000068.1:p.Asp108His|CDKN2A p.Asp108His|CDKN2A p.D108H|Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant Asp108His|Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant D108H|Cyclin-Dependent Kinase Inhibitor 2A Protein Variant Asp108His|Cyclin-Dependent Kinase Inhibitor 2A Protein Variant D108H|Cyclin-Dependent Kinase Inhibitor p16 Protein Variant Asp108His|Cyclin-Dependent Kinase Inhibitor p16 Protein Variant D108H|NP_000068.1:p.Asp108His|NP_000068.1:p.D108H|p16(INK4a) Protein Variant Asp108His|p16(INK4a) Protein Variant D108H|p16-INK4 Protein Variant Asp108His|p16-INK4 Protein Variant D108H|p16INK4A Protein Variant Asp108His|p16INK4A Protein Variant D108H	A change in the amino acid residue at position 108 in the cyclin-dependent kinase inhibitor 2 protein where aspartic acid has been replaced by histidine.			Cell or Molecular Dysfunction	
C146943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146943>	C128817	CDKN2A NM_000077.4:c.322G>T|CDK4I c.322G>T|CDKN2 c.322G>T|CDKN2A c.322G>T|Cyclin Dependent Kinase Inhibitor 2A c.322G>T|INK4A c.322G>T|MLM c.322G>T|MTS-1 c.322G>T|MTS1 c.322G>T|NM_000077.4:c.322G>T	A nucleotide substitution at position 322 of the coding sequence of the CDKN2A gene where guanine has been mutated to thymine.			Cell or Molecular Dysfunction	
C146944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146944>	C146926	CDKN2A NP_000068.1:p.D108Y|CDK4I Protein Variant Asp108Tyr|CDK4I Protein Variant D108Y|CDKN2A Asp108Tyr|CDKN2A D108Y|CDKN2A NP_000068.1:p.Asp108Tyr|CDKN2A p.Asp108Tyr|CDKN2A p.D108Y|Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant Asp108Tyr|Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant D108Y|Cyclin-Dependent Kinase Inhibitor 2A Protein Variant Asp108Tyr|Cyclin-Dependent Kinase Inhibitor 2A Protein Variant D108Y|Cyclin-Dependent Kinase Inhibitor p16 Protein Variant Asp108Tyr|Cyclin-Dependent Kinase Inhibitor p16 Protein Variant D108Y|NP_000068.1:p.Asp108Tyr|NP_000068.1:p.D108Y|p16(INK4a) Protein Variant Asp108Tyr|p16(INK4a) Protein Variant D108Y|p16-INK4 Protein Variant Asp108Tyr|p16-INK4 Protein Variant D108Y|p16INK4A Protein Variant Asp108Tyr|p16INK4A Protein Variant D108Y	A change in the amino acid residue at position 108 in the cyclin-dependent kinase inhibitor 2 protein where aspartic acid has been replaced by tyrosine.			Cell or Molecular Dysfunction	
C146945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146945>	C128817	CDKN2A NM_000077.4:c.389T>A|CDK4I c.389T>A|CDKN2 c.389T>A|CDKN2A c.389T>A|Cyclin Dependent Kinase Inhibitor 2A c.389T>A|INK4A c.389T>A|MLM c.389T>A|MTS-1 c.389T>A|MTS1 c.389T>A|NM_000077.4:c.389T>A	A nucleotide substitution at position 389 of the coding sequence of the CDKN2A gene where thymine has been mutated to adenine.			Cell or Molecular Dysfunction	
C146946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146946>	C146926	CDKN2A NP_000068.1:p.L130Q|CDK4I Protein Variant L130Q|CDK4I Protein Variant Leu130Gln|CDKN2A L130Q|CDKN2A Leu130Gln|CDKN2A NP_000068.1:p.Leu130Gln|CDKN2A p.L130Q|CDKN2A p.Leu130Gln|Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant L130Q|Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant Leu130Gln|Cyclin-Dependent Kinase Inhibitor 2A Protein Variant L130Q|Cyclin-Dependent Kinase Inhibitor 2A Protein Variant Leu130Gln|Cyclin-Dependent Kinase Inhibitor p16 Protein Variant L130Q|Cyclin-Dependent Kinase Inhibitor p16 Protein Variant Leu130Gln|NP_000068.1:p.L130Q|NP_000068.1:p.Leu130Gln|p16(INK4a) Protein Variant L130Q|p16(INK4a) Protein Variant Leu130Gln|p16-INK4 Protein Variant L130Q|p16-INK4 Protein Variant Leu130Gln|p16INK4A Protein Variant L130Q|p16INK4A Protein Variant Leu130Gln	A change in the amino acid residue at position 130 in the cyclin-dependent kinase inhibitor 2 protein where leucine has been replaced by glutamine.			Cell or Molecular Dysfunction	
C146947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146947>	C128817	CDKN2A NM_000077.4:c.439G>A|CDK4I c.439G>A|CDKN2 c.439G>A|CDKN2A c.439G>A|Cyclin Dependent Kinase Inhibitor 2A c.439G>A|INK4A c.439G>A|MLM c.439G>A|MTS-1 c.439G>A|MTS1 c.439G>A|NM_000077.4:c.439G>A	A nucleotide substitution at position 439 of the coding sequence of the CDKN2A gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C146948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146948>	C146926	CDKN2A NP_000068.1:p.A147T|CDK4I Protein Variant A147T|CDK4I Protein Variant Ala147Thr|CDKN2A A147T|CDKN2A Ala147Thr|CDKN2A NP_000068.1:p.Ala147Thr|CDKN2A p.A147T|CDKN2A p.Ala147Thr|Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant A147T|Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant Ala147Thr|Cyclin-Dependent Kinase Inhibitor 2A Protein Variant A147T|Cyclin-Dependent Kinase Inhibitor 2A Protein Variant Ala147Thr|Cyclin-Dependent Kinase Inhibitor p16 Protein Variant A147T|Cyclin-Dependent Kinase Inhibitor p16 Protein Variant Ala147Thr|NP_000068.1:p.A147T|NP_000068.1:p.Ala147Thr|p16(INK4a) Protein Variant A147T|p16(INK4a) Protein Variant Ala147Thr|p16-INK4 Protein Variant A147T|p16-INK4 Protein Variant Ala147Thr|p16INK4A Protein Variant A147T|p16INK4A Protein Variant Ala147Thr	A change in the amino acid residue at position 147 in the cyclin-dependent kinase inhibitor 2 protein where alanine has been replaced by threonine.			Cell or Molecular Dysfunction	
C146949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146949>	C128817	CDKN2A NM_000077.4:c.442G>A|CDK4I c.442G>A|CDKN2 c.442G>A|CDKN2A c.442G>A|Cyclin Dependent Kinase Inhibitor 2A c.442G>A|INK4A c.442G>A|MLM c.442G>A|MTS-1 c.442G>A|MTS1 c.442G>A|NM_000077.4:c.442G>A	A nucleotide substitution at position 442 of the coding sequence of the CDKN2A gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C146950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146950>	C146926	CDKN2A NP_000068.1:p.A148T|CDK4I Protein Variant A148T|CDK4I Protein Variant Ala148Thr|CDKN2A A148T|CDKN2A Ala148Thr|CDKN2A NP_000068.1:p.Ala148Thr|CDKN2A p.A148T|CDKN2A p.Ala148Thr|Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant A148T|Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant Ala148Thr|Cyclin-Dependent Kinase Inhibitor 2A Protein Variant A148T|Cyclin-Dependent Kinase Inhibitor 2A Protein Variant Ala148Thr|Cyclin-Dependent Kinase Inhibitor p16 Protein Variant A148T|Cyclin-Dependent Kinase Inhibitor p16 Protein Variant Ala148Thr|NP_000068.1:p.A148T|NP_000068.1:p.Ala148Thr|p16(INK4a) Protein Variant A148T|p16(INK4a) Protein Variant Ala148Thr|p16-INK4 Protein Variant A148T|p16-INK4 Protein Variant Ala148Thr|p16INK4A Protein Variant A148T|p16INK4A Protein Variant Ala148Thr	A change in the amino acid residue at position 148 in the cyclin-dependent kinase inhibitor 2 protein where alanine has been replaced by threonine.			Cell or Molecular Dysfunction	
C146951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146951>	C97928	GNAS Protein Variant|GNAS Complex Locus Protein Variant	A variation in the amino acid sequence for a protein encoded by the GNAS gene.			Cell or Molecular Dysfunction	
C146952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146952>	C35682|C177693	TP53 Overexpression Positive|Antigen NY-CO-13 Overexpression|Cellular Tumor Antigen p53 Overexpression|TP53 Overexpression|TRP53 Overexpression|Transformation-Related Protein 53 Overexpression|Tumor Protein p53 Overexpression|Tumor Suppressor p53 Overexpression|p53 Overexpression	An indication that overexpression of TP53 has been detected in a sample.	TP53 Overexpression Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C146953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146953>	C45930	GNAS NM_000516.5:c.374A>G|GNAS Complex Locus Gene c.374A>G|GNAS c.374A>G|GNAS1 c.374A>G|GSA c.374A>G|GSP c.374A>G|NM_000516.5:c.374A>G	A nucleotide substitution at position 374 of the coding sequence of the GNAS gene where adenine has been mutated to guanine.			Cell or Molecular Dysfunction	
C146954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146954>	C146951	GNAS NP_000507.1:p.Q125R|Adenylate Cyclase-Stimulating G Alpha Protein Gln125Arg|Adenylate Cyclase-Stimulating G Alpha Protein Q125R|GNAS Gln125Arg|GNAS NP_000507.1:p.Gln125Arg|GNAS Q125R|GNAS p.Gln125Arg|GNAS p.Q125R|Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short Gln125Arg|Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short Q125R|NP_000507.1:p.Gln125Arg|NP_000507.1:p.Q125R	A change in the amino acid residue at position 125 in the guanine nucleotide-binding protein G(s) subunit alpha isoforms short protein where glutamine has been replaced by arginine.			Cell or Molecular Dysfunction	
C146955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146955>	C45930	GNAS NM_000516.5:c.478C>T|GNAS Complex Locus Gene c.478C>T|GNAS c.478C>T|GNAS1 c.478C>T|GSA c.478C>T|GSP c.478C>T|NM_000516.5:c.478C>T	A nucleotide substitution at position 478 of the coding sequence of the GNAS gene where cytosine has been mutated to thymine.			Cell or Molecular Dysfunction	
C146956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146956>	C146951	GNAS NP_000507.1:p.R160C|Adenylate Cyclase-Stimulating G Alpha Protein Arg160Cys|Adenylate Cyclase-Stimulating G Alpha Protein R160C|GNAS Arg160Cys|GNAS NP_000507.1:p.Arg160Cys|GNAS R160C|GNAS p.Arg160Cys|GNAS p.R160C|Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short Arg160Cys|Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short R160C|NP_000507.1:p.Arg160Cys|NP_000507.1:p.R160C	A change in the amino acid residue at position 160 in the guanine nucleotide-binding protein G(s) subunit alpha isoforms short protein where arginine has been replaced by cysteine.			Cell or Molecular Dysfunction	
C146957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146957>	C45930	GNAS NM_000516.5:c.602G>A|GNAS Complex Locus Gene c.602G>A|GNAS c.602G>A|GNAS1 c.602G>A|GSA c.602G>A|GSP c.602G>A|NM_000516.5:c.602G>A	A nucleotide substitution at position 602 of the coding sequence of the GNAS gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C146958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146958>	C146951	GNAS NP_000507.1:p.R201H|Adenylate Cyclase-Stimulating G Alpha Protein Arg201His|Adenylate Cyclase-Stimulating G Alpha Protein R201H|GNAS Arg201His|GNAS NP_000507.1:p.Arg201His|GNAS R201H|GNAS p.Arg201His|GNAS p.R201H|Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short Arg201His|Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short R201H|NP_000507.1:p.Arg201His|NP_000507.1:p.R201H	A change in the amino acid residue at position 201 in the guanine nucleotide-binding protein G(s) subunit alpha isoforms short protein where arginine has been replaced by histidine.			Cell or Molecular Dysfunction	
C146959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146959>	C45930	GNAS NM_000516.5:c.601C>T|GNAS Complex Locus Gene c.601C>T|GNAS c.601C>T|GNAS1 c.601C>T|GSA c.601C>T|GSP c.601C>T|NM_000516.5:c.601C>T	A nucleotide substitution at position 601 of the coding sequence of the GNAS gene where cytosine has been mutated to thymine.			Cell or Molecular Dysfunction	
C146960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146960>	C146951	GNAS NP_000507.1:p.R201C|Adenylate Cyclase-Stimulating G Alpha Protein Arg201Cys|Adenylate Cyclase-Stimulating G Alpha Protein R201C|GNAS Arg201Cys|GNAS NP_000507.1:p.Arg201Cys|GNAS R201C|GNAS p.Arg201Cys|GNAS p.R201C|Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short Arg201Cys|Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short R201C|NP_000507.1:p.Arg201Cys|NP_000507.1:p.R201C	A change in the amino acid residue at position 201 in the guanine nucleotide-binding protein G(s) subunit alpha isoforms short protein where arginine has been replaced by cysteine.			Cell or Molecular Dysfunction	
C146961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146961>	C45930	GNAS NM_000516.5:c.601C>A|GNAS Complex Locus Gene c.601C>A|GNAS c.601C>A|GNAS1 c.601C>A|GSA c.601C>A|GSP c.601C>A|NM_000516.5:c.601C>A	A nucleotide substitution at position 601 of the coding sequence of the GNAS gene where cytosine has been mutated to adenine.			Cell or Molecular Dysfunction	
C146962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146962>	C146951	GNAS NP_000507.1:p.R201S|Adenylate Cyclase-Stimulating G Alpha Protein Arg201Ser|Adenylate Cyclase-Stimulating G Alpha Protein R201S|GNAS Arg201Ser|GNAS NP_000507.1:p.Arg201Ser|GNAS R201S|GNAS p.Arg201Ser|GNAS p.R201S|Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short Arg201Ser|Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short R201S|NP_000507.1:p.Arg201Ser|NP_000507.1:p.R201S	A change in the amino acid residue at position 201 in the guanine nucleotide-binding protein G(s) subunit alpha isoforms short protein where arginine has been replaced by serine.			Cell or Molecular Dysfunction	
C146963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146963>	C45930	GNAS NM_000516.5:c.680A>G|GNAS Complex Locus Gene c.680A>G|GNAS c.680A>G|GNAS1 c.680A>G|GSA c.680A>G|GSP c.680A>G|NM_000516.5:c.680A>G	A nucleotide substitution at position 680 of the coding sequence of the GNAS gene where adenine has been mutated to guanine.			Cell or Molecular Dysfunction	
C146964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146964>	C146951	GNAS NP_000507.1:p.Q227R|Adenylate Cyclase-Stimulating G Alpha Protein Gln227Arg|Adenylate Cyclase-Stimulating G Alpha Protein Q227R|GNAS Gln227Arg|GNAS NP_000507.1:p.Gln227Arg|GNAS Q227R|GNAS p.Gln227Arg|GNAS p.Q227R|Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short Gln227Arg|Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short Q227R|NP_000507.1:p.Gln227Arg|NP_000507.1:p.Q227R	A change in the amino acid residue at position 227 in the guanine nucleotide-binding protein G(s) subunit alpha isoforms short protein where glutamine has been replaced by arginine.			Cell or Molecular Dysfunction	
C146965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146965>	C45930	GNAS NM_000516.5:c.680A>T|GNAS Complex Locus Gene c.680A>T|GNAS c.680A>T|GNAS1 c.680A>T|GSA c.680A>T|GSP c.680A>T|NM_000516.5:c.680A>T	A nucleotide substitution at position 680 of the coding sequence of the GNAS gene where adenine has been mutated to thymine.			Cell or Molecular Dysfunction	
C146966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146966>	C146951	GNAS NP_000507.1:p.Q227L|Adenylate Cyclase-Stimulating G Alpha Protein Gln227Leu|Adenylate Cyclase-Stimulating G Alpha Protein Q227L|GNAS Gln227Leu|GNAS NP_000507.1:p.Gln227Leu|GNAS Q227L|GNAS p.Gln227Leu|GNAS p.Q227L|Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short Gln227Leu|Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short Q227L|NP_000507.1:p.Gln227Leu|NP_000507.1:p.Q227L	A change in the amino acid residue at position 227 in the guanine nucleotide-binding protein G(s) subunit alpha isoforms short protein where glutamine has been replaced by leucine.			Cell or Molecular Dysfunction	
C146967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146967>	C146951	GNAS NP_000507.1:p.Q227P|Adenylate Cyclase-Stimulating G Alpha Protein Gln227Pro|Adenylate Cyclase-Stimulating G Alpha Protein Q227P|GNAS Gln227Pro|GNAS NP_000507.1:p.Gln227Pro|GNAS Q227P|GNAS p.Gln227Pro|GNAS p.Q227P|Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short Gln227Pro|Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short Q227P|NP_000507.1:p.Gln227Pro|NP_000507.1:p.Q227P	A change in the amino acid residue at position 227 in the guanine nucleotide-binding protein G(s) subunit alpha isoforms short protein where glutamine has been replaced by proline.			Cell or Molecular Dysfunction	
C146968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146968>	C45930	GNAS NM_000516.5:c.679C>G|GNAS Complex Locus Gene c.679C>G|GNAS c.679C>G|GNAS1 c.679C>G|GSA c.679C>G|GSP c.679C>G|NM_000516.5:c.679C>G	A nucleotide substitution at position 679 of the coding sequence of the GNAS gene where cytosine has been mutated to guanine.			Cell or Molecular Dysfunction	
C146969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146969>	C146951	GNAS NP_000507.1:p.Q227E|Adenylate Cyclase-Stimulating G Alpha Protein Gln227Glu|Adenylate Cyclase-Stimulating G Alpha Protein Q227E|GNAS Gln227Glu|GNAS NP_000507.1:p.Gln227Glu|GNAS Q227E|GNAS p.Gln227Glu|GNAS p.Q227E|Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short Gln227Glu|Guanine Nucleotide-Binding Protein G(s) Subunit Alpha Isoforms Short Q227E|NP_000507.1:p.Gln227Glu|NP_000507.1:p.Q227E	A change in the amino acid residue at position 227 in the guanine nucleotide-binding protein G(s) subunit alpha isoforms short protein where glutamine has been replaced by glutamic acid.			Cell or Molecular Dysfunction	
C146971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146971>	C97928	RNF43 Protein Variant|E3 Ubiquitin-Protein Ligase RNF43 Protein Variant|RING Finger Protein 124 Protein Variant|RING-Type E3 Ubiquitin Transferase RNF43 Protein Variant|Ring Finger Protein 43 Protein Variant	A variation in the amino acid sequence for E3 ubiquitin-protein ligase RNF43.			Cell or Molecular Dysfunction	
C146972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146972>	C141252	RNF43 NM_017763.5:c.380G>C|NM_017763.5:c.380G>C|RNF124 c.380G>C|RNF43 c.380G>C|Ring Finger Protein 43 Gene c.380G>C|URCC c.380G>C	A nucleotide substitution at position 380 of the coding sequence of the RNF453 gene where guanine has been mutated to cytosine.			Cell or Molecular Dysfunction	
C146973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146973>	C146971	RNF43 NP_060233.3:p.R127P|E3 Ubiquitin-Protein Ligase RNF43 Protein Variant Arg127Pro|E3 Ubiquitin-Protein Ligase RNF43 Protein Variant R127P|NP_060233.3:p.Arg127Pro|NP_060233.3:p.R127P|RING Finger Protein 124 Protein Variant Arg127Pro|RING Finger Protein 124 Protein Variant R127P|RING-Type E3 Ubiquitin Transferase RNF43 Protein Variant Arg127Pro|RING-Type E3 Ubiquitin Transferase RNF43 Protein Variant R127P|RNF43 Arg127Pro|RNF43 NP_060233.3:p.Arg127Pro|RNF43 R127P|RNF43 p.Arg127Pro|RNF43 p.R127P|Ring Finger Protein 43 Protein Variant Arg127Pro|Ring Finger Protein 43 Protein Variant R127P	A change in the amino acid residue at position 127 in the E3 ubiquitin-protein ligase RNF43 protein where arginine has been replaced by proline.			Cell or Molecular Dysfunction	
C146974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146974>	C141252	RNF43 NM_017763.5:c.420C>G|NM_017763.5:c.420C>G|RNF124 c.420C>G|RNF43 c.420C>G|Ring Finger Protein 43 Gene c.420C>G|URCC c.420C>G	A nucleotide substitution at position 420 of the coding sequence of the RNF453 gene where cytosine has been mutated to guanine.			Cell or Molecular Dysfunction	
C146975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146975>	C146971	RNF43 NP_060233.3:p.D140E|E3 Ubiquitin-Protein Ligase RNF43 Protein Variant Asp140Glu|E3 Ubiquitin-Protein Ligase RNF43 Protein Variant D140E|NP_060233.3:p.Asp140Glu|NP_060233.3:p.D140E|RING Finger Protein 124 Protein Variant Asp140Glu|RING Finger Protein 124 Protein Variant D140E|RING-Type E3 Ubiquitin Transferase RNF43 Protein Variant Asp140Glu|RING-Type E3 Ubiquitin Transferase RNF43 Protein Variant D140E|RNF43 Asp140Glu|RNF43 D140E|RNF43 NP_060233.3:p.Asp140Glu|RNF43 p.Asp140Glu|RNF43 p.D140E|Ring Finger Protein 43 Protein Variant Asp140Glu|Ring Finger Protein 43 Protein Variant D140E	A change in the amino acid residue at position 140 in the E3 ubiquitin-protein ligase RNF43 protein where aspartic acid has been replaced by glutamic acid.			Cell or Molecular Dysfunction	
C146976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146976>	C141252	RNF43 NM_017763.5:c.461C>T|NM_017763.5:c.461C>T|RNF124 c.461C>T|RNF43 c.461C>T|Ring Finger Protein 43 Gene c.461C>T|URCC c.461C>T	A nucleotide substitution at position 461 of the coding sequence of the RNF453 gene where cytosine has been mutated to thymine.			Cell or Molecular Dysfunction	
C146977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146977>	C146971	RNF43 NP_060233.3:p.P154L|E3 Ubiquitin-Protein Ligase RNF43 Protein Variant P154L|E3 Ubiquitin-Protein Ligase RNF43 Protein Variant Pro154Leu|NP_060233.3:p.P154L|NP_060233.3:p.Pro154Leu|RING Finger Protein 124 Protein Variant P154L|RING Finger Protein 124 Protein Variant Pro154Leu|RING-Type E3 Ubiquitin Transferase RNF43 Protein Variant P154L|RING-Type E3 Ubiquitin Transferase RNF43 Protein Variant Pro154Leu|RNF43 NP_060233.3:p.Pro154Leu|RNF43 P154L|RNF43 Pro154Leu|RNF43 p.P154L|RNF43 p.Pro154Leu|Ring Finger Protein 43 Protein Variant P154L|Ring Finger Protein 43 Protein Variant Pro154Leu	A change in the amino acid residue at position 154 in the E3 ubiquitin-protein ligase RNF43 protein where proline has been replaced by leucine.			Cell or Molecular Dysfunction	
C146978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146978>	C141252	RNF43 NM_017763.5:c.505G>A|NM_017763.5:c.505G>A|RNF124 c.505G>A|RNF43 c.505G>A|Ring Finger Protein 43 Gene c.505G>A|URCC c.505G>A	A nucleotide substitution at position 505 of the coding sequence of the RNF453 gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C146979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146979>	C146971	RNF43 NP_060233.3:p.A169T|E3 Ubiquitin-Protein Ligase RNF43 Protein Variant A169T|E3 Ubiquitin-Protein Ligase RNF43 Protein Variant Ala169Thr|NP_060233.3:p.A169T|NP_060233.3:p.Ala169Thr|RING Finger Protein 124 Protein Variant A169T|RING Finger Protein 124 Protein Variant Ala169Thr|RING-Type E3 Ubiquitin Transferase RNF43 Protein Variant A169T|RING-Type E3 Ubiquitin Transferase RNF43 Protein Variant Ala169Thr|RNF43 A169T|RNF43 Ala169Thr|RNF43 NP_060233.3:p.Ala169Thr|RNF43 p.A169T|RNF43 p.Ala169Thr|Ring Finger Protein 43 Protein Variant A169T|Ring Finger Protein 43 Protein Variant Ala169Thr	A change in the amino acid residue at position 169 in the E3 ubiquitin-protein ligase RNF43 protein where alanine has been replaced by threonine.			Cell or Molecular Dysfunction	
C146980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146980>	C141252	RNF43 NM_017763.5:c.954G>T|NM_017763.5:c.954G>T|RNF124 c.954G>T|RNF43 c.954G>T|Ring Finger Protein 43 Gene c.954G>T|URCC c.954G>T	A nucleotide substitution at position 954 of the coding sequence of the RNF453 gene where guanine has been mutated to thymine.			Cell or Molecular Dysfunction	
C146981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146981>	C146971	RNF43 NP_060233.3:p.E318D|E3 Ubiquitin-Protein Ligase RNF43 Protein Variant E318D|E3 Ubiquitin-Protein Ligase RNF43 Protein Variant Glu318Asp|NP_060233.3:p.E318D|NP_060233.3:p.Glu318Asp|RING Finger Protein 124 Protein Variant E318D|RING Finger Protein 124 Protein Variant Glu318Asp|RING-Type E3 Ubiquitin Transferase RNF43 Protein Variant E318D|RING-Type E3 Ubiquitin Transferase RNF43 Protein Variant Glu318Asp|RNF43 E318D|RNF43 Glu318Asp|RNF43 NP_060233.3:p.Glu318Asp|RNF43 p.E318D|RNF43 p.Glu318Asp|Ring Finger Protein 43 Protein Variant E318D|Ring Finger Protein 43 Protein Variant Glu318Asp	A change in the amino acid residue at position 318 in the E3 ubiquitin-protein ligase RNF43 protein where glutamic acid has been replaced by aspartic acid.			Cell or Molecular Dysfunction	
C146982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146982>	C96271	PIK3CA Exon 9 Mutation|PI3K-Alpha Exon 9 Mutation|PI3KCA Exon 9 Mutation|Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Exon 9 Mutation|p110-alpha Exon 9 Mutation	A change in the nucleotide sequence of exon 9 of the PIK3CA gene.			Cell or Molecular Dysfunction	
C146983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146983>	C96271	PIK3CA Exon 20 Mutation|PI3K-Alpha Exon 20 Mutation|PI3KCA Exon 20 Mutation|Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Exon 20 Mutation|p110-alpha Exon 20 Mutation	A change in the nucleotide sequence of exon 20 of the PIK3CA gene.			Cell or Molecular Dysfunction	
C146984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146984>	C260	Imipenem Anhydrous|(5R,6S)-3-((2-(Formimidoylamino)ethyl)thio)-6-((R)-1-hydroxyethyl)-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic Acid|IMIPENEM ANHYDROUS				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C146985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146985>	C177561	AJCC Cancer Staging Manual 8th Edition|8th|AJCC Ed. 8|AJCC Edition 8|AJCC V8|AJCC v8|AJCC2|AJCC8|American Joint Committee on Cancer Staging Manual, Edition 8|Eighth Edition (2017)	The 8th edition of the criteria developed by the American Joint Committee on Cancer (AJCC), implemented in 2018, used for the classification and staging of neoplastic diseases.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uveal Melanoma Baseline Form|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C146986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146986>	C153466	PTEN Coding Region Mutation Present|MMAC1 Coding Region Mutation Present|Mutated in Multiple Advanced Cancers 1 Gene Coding Region Mutation Present|PTEN Exon 1-9 Mutation Present|PTEN Exon Mutation Present|PTEN Gene Mutation in Exon|PTEN1 Coding Region Mutation Present|Phosphatase and Tensin Homolog Gene Coding Region Mutation Present|TEP1 Coding Region Mutation Present	A genetic finding indicating that a sample has one or more exon mutations in the PTEN gene.			Laboratory or Test Result	
C146987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146987>	C6593|C3085	Mediastinal Hemangioma	A hemangioma that arises from the mediastinum. It can be of the capillary or the cavernous type.			Neoplastic Process	
C146988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146988>	C6642|C3800	Mediastinal Epithelioid Hemangioendothelioma	An epithelioid hemangioendothelioma that arises from the mediastinum.			Neoplastic Process	
C146989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146989>	C8701|C212064|C138020	Refractory Central Nervous System Non-Hodgkin Lymphoma	A central nervous system non-Hodgkin lymphoma which does not respond to treatment.	Refractory Central Nervous System Non-Hodgkin Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C146990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146990>	C9251|C212064|C138019	Recurrent Central Nervous System Non-Hodgkin Lymphoma	The reemergence of central nervous system non-Hodgkin lymphoma after a period of remission.	Recurrent Central Nervous System Non-Hodgkin Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C146991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146991>	C16809	Fluorine-19 Magnetic Resonance Imaging|19F-MRI|Fluorine-19 MRI	Magnetic resonance imaging that uses a probe labeled with 19F. MR sensitivity of 19F is relatively high and no fluorine atoms exist in biological tissues, resulting in low endogenous background noise.			Diagnostic Procedure	
C146992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146992>	C203000	Dilanubicel|Allogeneic UCB-derived Hematopoietic Stem and Progenitor Cells NLA101|Allogeneic Umbilical Cord Blood-derived HSPCs NLA101|DILANUBICEL|NLA101	A preparation of universal, off-the-shelf, ex vivo expanded, allogeneic umbilical cord blood (UCB)-derived hematopoietic stem and progenitor cells (HSPCs) that can potentially be used to improve hematopoietic recovery after chemotherapy or hematopoietic cell transplantation (HCT).  Upon administration of dilanubicel, these cells increase and restore the number of HSPCs, which may prevent or decrease infection and other complications of chemotherapy-induced neutropenia (CIN) or cord blood transplantation.	Dilanubicel		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C146993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146993>	C242	Androgen Receptor Inhibitor|AR Antagonist|AR Inhibitor|Androgen Receptor Antagonist	Any agent that inhibits the activity of the androgen receptor (AR).	Androgen Receptor Inhibitor		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C146994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146994>	C35552	Observed Medical Device Type In Intended Location|OBMDILOC|Obs Med Device Type In Intended Loc|Obs Med Device Type In Intended Loc|Observed Medical Device In The Intended Location	A description of the type of medical device that is found in a subject and is present in its intended location within the body.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C146995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146995>	C25180	Adaptive Study Design Indicator|ADAPT|Adaptive Design|Adaptive Design|adaptiveDesignIndicator	An indication as to whether a study's design includes a prospectively planned opportunity for modification of one or more specified aspects of the study design and/or hypotheses based on analysis of data, usually interim data.			Research Activity	BRIDG Attribute Terminology|BRIDG Terminology|CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C146996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146996>	C142727	Supplemental Qualifiers Tabulation Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in a domain.			Idea or Concept	
C146997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146997>	C25634	Study Purpose|Purpose of Trial	The overall rationale, reason, or intention of the clinical study.			Idea or Concept	ICH M11 Protocol Section 2 Data Element Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C146998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146998>	C120648	Protoporphyrin Measurement	The determination of the amount of protoporphyrin present in a sample.			Laboratory Procedure	
C146999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C146999>	C54680	Mode of Action	The mechanism by which a pharmacologically active substance produces an effect on the cellular level of a living organism or in a biochemical system.			Functional Concept	
C1469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1469>	C1511	In 111 Satumomab Pendetide|INDIUM IN-111 SATUMOMAB PENDETIDE|Indium In 111 Satumomab Pendetide|Indium In-11 CYT-103|OncoScint CR/OV	An radioimmunoconjugate of the murine monoclonal antibody, Satumomab (MoAb B72.3), conjugated to the linker-chelator, glycyl-tyrosyl-(N,-diethylenetriaminepentaacetic acid)-lysine hydrochloride (GYK-DTPA-HCl; pendetide) labeled with indium 111 (In-111). Satumomab recognizes TAG-72, an antigen expressed by the majority of adenocarcinomas. In-111 Satumomab pendetide emits gamma radiation and X-Ray photons that can be captured by gamma camera allowing imaging of TAG-72 expressing tissues.			Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C147000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147000>	C107511	Worst Nausea Past 24 Hours Rating Question|Please rate your worst nausea over the past 24 hours|Worst Nausea Last 24 Hours Rating|Worst Nausea Past 24 Hours Rating	A question about the rating of an individual's nausea during the last 24 hours.			Intellectual Product	
C147001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147001>	C173398	Undesirable Sedation Troubles Past 24 Hours Rating Question|Please rate any undesired sedation trouble that you had over the past 24 hours|Undesirable Sedation Troubles Last 24 Hours Rating|Undesirable Sedation Troubles Past 24 Hours Rating	A question about the rating of an individual's undesirable sedation troubles during the last 24 hours.			Intellectual Product	
C147002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147002>	C91102	Undesirable Appetite Increase Past 24 Hours Rating Question|Please rate any undesired appetite increase that you had over the past 24 hours|Undesirable Appetite Increase Last 24 Hours Rating|Undesirable Appetite Increase Past 24 Hours Rating	A question about the rating of an individual's undesirable appetite increase during the last 24 hours.			Intellectual Product	
C147003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147003>	C8810|C7723	Cardiac Extraskeletal Osteosarcoma|Cardiac Osteogenic Sarcoma|Cardiac Osteosarcoma|Heart Extraskeletal Osteosarcoma	An extraskeletal osteosarcoma that arises from the heart. It produces osteoid and bone, and occasionally shows chondroblastic differentiation.			Neoplastic Process	
C147004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147004>	C6496|C5361	Cardiac Myxofibrosarcoma|Cardiac Myxoid Malignant Fibrous Histiocytoma|Heart Myxofibrosarcoma|Heart Myxoid Malignant Fibrous Histiocytoma	A low-grade sarcoma that arises from the heart. It is composed of spindle or rounded cells in a myxoid stroma. The most common location is the left atrium.			Neoplastic Process	
C147005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147005>	C3918|C3081	Cardiac Germ Cell Tumor|Heart Germ Cell Tumor	A germ cell tumor that arises within the myocardium or cardiac chambers. The reported cases have been teratomas and yolk sac tumors.			Neoplastic Process	
C147006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147006>	C5371|C3011	Cardiac Yolk Sac Tumor|Heart Yolk Sac Tumor	A yolk sac tumor that arises within the myocardium or cardiac chambers.			Neoplastic Process	
C147007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147007>	C189045|C147005	Cardiac Teratoma|Heart Teratoma	A teratoma that arises within the myocardium or cardiac chambers.			Neoplastic Process	
C147008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147008>	C19285	TNFRSF1A Gene Product	A protein encoded by the TNFRSF1A gene.			Amino Acid, Peptide, or Protein	
C147009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147009>	C222543|C163018	EGFR NM_005228.3:c.2389T>A|EGFR c.2389T>A|ERBB c.2389T>A|ERBB1 c.2389T>A|Epidermal Growth Factor Receptor Gene c.2389T>A|HER1 c.2389T>A|NM_005228.3:c.2389T>A	A nucleotide substitution at position 2389 of the coding sequence of the EGFR gene where thymine has been mutated to adenine.	EGFR NM_005228.3:c.2389T>A		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147010>	C222543|C163018	EGFR NM_005228.3:c.2390G>C|EGFR c.2390G>C|ERBB c.2390G>C|ERBB1 c.2390G>C|Epidermal Growth Factor Receptor Gene c.2390G>C|HER1 c.2390G>C|NM_005228.3:c.2390G>C	A nucleotide substitution at position 2390 of the coding sequence of the EGFR gene where guanine has been mutated to cytosine.	EGFR NM_005228.3:c.2390G>C		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147011>	C185938	EGFR NP_005219.2:p.C797S|EGFR C797S|EGFR Cys797Ser|EGFR NP_005219.2:p.Cys797Ser|EGFR p.C797S|EGFR p.Cys797Ser|Epidermal Growth Factor Receptor C797S|Epidermal Growth Factor Receptor Cys797Ser|NP_005219.2:p.C797S|NP_005219.2:p.Cys797Ser|Proto-Oncogene c-ErbB-1 C797S|Proto-Oncogene c-ErbB-1 Cys797Ser|Receptor Tyrosine-Protein Kinase erbB-1 C797S|Receptor Tyrosine-Protein Kinase erbB-1 Cys797Ser	A change in the amino acid residue at position 797 in the epidermal growth factor receptor protein where cysteine has been replaced by serine.	EGFR NP_005219.2:p.C797S		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147012>	C185938	EGFR NP_005219.2:p.C797A|EGFR C797A|EGFR Cys797Ala|EGFR NP_005219.2:p.Cys797Ala|EGFR p.C797A|EGFR p.Cys797Ala|Epidermal Growth Factor Receptor C797A|Epidermal Growth Factor Receptor Cys797Ala|NP_005219.2:p.C797A|NP_005219.2:p.Cys797Ala|Proto-Oncogene c-ErbB-1 C797A|Proto-Oncogene c-ErbB-1 Cys797Ala|Receptor Tyrosine-Protein Kinase erbB-1 C797A|Receptor Tyrosine-Protein Kinase erbB-1 Cys797Ala	A change in the amino acid residue at position 797 in the epidermal growth factor receptor protein where cysteine has been replaced by alanine.			Cell or Molecular Dysfunction	
C147013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147013>	C222543|C180953	EGFR NM_005228.3:c.2374C>T|EGFR c.2374C>T|ERBB c.2374C>T|ERBB1 c.2374C>T|Epidermal Growth Factor Receptor Gene c.2374C>T|HER1 c.2374C>T|NM_005228.3:c.2374C>T	A nucleotide substitution at position 2374 of the coding sequence of the EGFR gene where cytosine has been mutated to thymine.	EGFR NM_005228.3:c.2374C>T		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147014>	C147131	EGFR NP_005219.2:p.L792F|EGFR L792F|EGFR Leu792Phe|EGFR NP_005219.2:p.Leu792Phe|EGFR p.L792F|EGFR p.Leu792Phe|Epidermal Growth Factor Receptor L792F|Epidermal Growth Factor Receptor Leu792Phe|NP_005219.2:p.L792F|NP_005219.2:p.Leu792Phe|Proto-Oncogene c-ErbB-1 L792F|Proto-Oncogene c-ErbB-1 Leu792Phe|Receptor Tyrosine-Protein Kinase erbB-1 L792F|Receptor Tyrosine-Protein Kinase erbB-1 Leu792Phe	A change in the amino acid residue at position 792 in the epidermal growth factor receptor protein where leucine has been replaced by phenylalanine.	EGFR NP_005219.2:p.L792F		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147015>	C222543|C163018	EGFR NM_005228.3:c.2375T>A|EGFR c.2375T>A|ERBB c.2375T>A|ERBB1 c.2375T>A|Epidermal Growth Factor Receptor Gene c.2375T>A|HER1 c.2375T>A|NM_005228.3:c.2375T>A	A nucleotide substitution at position 2375 of the coding sequence of the EGFR gene where thymine has been mutated to adenine.	EGFR NM_005228.3:c.2375T>A		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147016>	C147131	EGFR NP_005219.2:p.L792H|EGFR L792H|EGFR Leu792His|EGFR NP_005219.2:p.Leu792His|EGFR p.L792H|EGFR p.Leu792His|Epidermal Growth Factor Receptor L792H|Epidermal Growth Factor Receptor Leu792His|NP_005219.2:p.L792H|NP_005219.2:p.Leu792His|Proto-Oncogene c-ErbB-1 L792H|Proto-Oncogene c-ErbB-1 Leu792His|Receptor Tyrosine-Protein Kinase erbB-1 L792H|Receptor Tyrosine-Protein Kinase erbB-1 Leu792His	A change in the amino acid residue at position 792 in the epidermal growth factor receptor protein where leucine has been replaced by histidine.	EGFR NP_005219.2:p.L792H		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147017>	C147131	EGFR NP_005219.2:p.L792Y|EGFR L792Y|EGFR Leu792Tyr|EGFR NP_005219.2:p.Leu792Tyr|EGFR p.L792Y|EGFR p.Leu792Tyr|Epidermal Growth Factor Receptor L792Y|Epidermal Growth Factor Receptor Leu792Tyr|NP_005219.2:p.L792Y|NP_005219.2:p.Leu792Tyr|Proto-Oncogene c-ErbB-1 L792Y|Proto-Oncogene c-ErbB-1 Leu792Tyr|Receptor Tyrosine-Protein Kinase erbB-1 L792Y|Receptor Tyrosine-Protein Kinase erbB-1 Leu792Tyr	A change in the amino acid residue at position 792 in the epidermal growth factor receptor protein where leucine has been replaced by tyrosine.	EGFR NP_005219.2:p.L792Y		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147018>	C147133	EGFR NP_005219.2:p.L718V|EGFR L718V|EGFR Leu718Val|EGFR NP_005219.2:p.Leu718Val|EGFR p.L718V|EGFR p.Leu718Val|Epidermal Growth Factor Receptor L718V|Epidermal Growth Factor Receptor Leu718Val|NP_005219.2:p.L718V|NP_005219.2:p.Leu718Val|Proto-Oncogene c-ErbB-1 L718V|Proto-Oncogene c-ErbB-1 Leu718Val|Receptor Tyrosine-Protein Kinase erbB-1 L718V|Receptor Tyrosine-Protein Kinase erbB-1 Leu718Val	A change in the amino acid residue at position 718 in the epidermal growth factor receptor protein where leucine has been replaced by valine.			Cell or Molecular Dysfunction	
C147019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147019>	C222543|C180951	EGFR NM_005228.3:c.2153T>A|EGFR c.2153T>A|ERBB c.2153T>A|ERBB1 c.2153T>A|Epidermal Growth Factor Receptor Gene c.2153T>A|HER1 c.2153T>A|NM_005228.3:c.2153T>A	A nucleotide substitution at position 2153 of the coding sequence of the EGFR gene where thymine has been mutated to adenine.	EGFR NM_005228.3:c.2153T>A		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147021>	C147133	EGFR NP_005219.2:p.L718Q|EGFR L718Q|EGFR Leu718Gln|EGFR NP_005219.2:p.Leu718Gln|EGFR p.L718Q|EGFR p.Leu718Gln|Epidermal Growth Factor Receptor L718Q|Epidermal Growth Factor Receptor Leu718Gln|NP_005219.2:p.L718Q|NP_005219.2:p.Leu718Gln|Proto-Oncogene c-ErbB-1 L718Q|Proto-Oncogene c-ErbB-1 Leu718Gln|Receptor Tyrosine-Protein Kinase erbB-1 L718Q|Receptor Tyrosine-Protein Kinase erbB-1 Leu718Gln	A change in the amino acid residue at position 718 in the epidermal growth factor receptor protein where leucine has been replaced by glutamine.			Cell or Molecular Dysfunction	
C147022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147022>	C128663	EGFR NM_005228.3:c.2386G>A|EGFR c.2386G>A|ERBB c.2386G>A|ERBB1 c.2386G>A|Epidermal Growth Factor Receptor Gene c.2386G>A|HER1 c.2386G>A|NM_005228.3:c.2386G>A	A nucleotide substitution at position 2386 of the coding sequence of the EGFR gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C147023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147023>	C147132	EGFR NP_005219.2:p.G796S|EGFR G796S|EGFR Gly796Ser|EGFR NP_005219.2:p.Gly796Ser|EGFR p.G796S|EGFR p.Gly796Ser|Epidermal Growth Factor Receptor G796S|Epidermal Growth Factor Receptor Gly796Ser|NP_005219.2:p.G796S|NP_005219.2:p.Gly796Ser|Proto-Oncogene c-ErbB-1 G796S|Proto-Oncogene c-ErbB-1 Gly796Ser|Receptor Tyrosine-Protein Kinase erbB-1 G796S|Receptor Tyrosine-Protein Kinase erbB-1 Gly796Ser	A change in the amino acid residue at position 796 in the epidermal growth factor receptor protein where glycine has been replaced by serine.			Cell or Molecular Dysfunction	
C147024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147024>	C128663	EGFR NM_005228.3:c.2386G>C|EGFR c.2386G>C|ERBB c.2386G>C|ERBB1 c.2386G>C|Epidermal Growth Factor Receptor Gene c.2386G>C|HER1 c.2386G>C|NM_005228.3:c.2386G>C	A nucleotide substitution at position 2386 of the coding sequence of the EGFR gene where guanine has been mutated to cytosine.			Cell or Molecular Dysfunction	
C147025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147025>	C147132	EGFR NP_005219.2:p.G796R|EGFR G796R|EGFR Gly796Arg|EGFR NP_005219.2:p.Gly796Arg|EGFR p.G796R|EGFR p.Gly796Arg|Epidermal Growth Factor Receptor G796R|Epidermal Growth Factor Receptor Gly796Arg|NP_005219.2:p.G796R|NP_005219.2:p.Gly796Arg|Proto-Oncogene c-ErbB-1 G796R|Proto-Oncogene c-ErbB-1 Gly796Arg|Receptor Tyrosine-Protein Kinase erbB-1 G796R|Receptor Tyrosine-Protein Kinase erbB-1 Gly796Arg	A change in the amino acid residue at position 796 in the epidermal growth factor receptor protein where glycine has been replaced by arginine.			Cell or Molecular Dysfunction	
C147028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147028>	C181114	Pavurutamab|AMG 701|AMG-701|AMG701|Anti-BCMA x Anti-CD3 BiTE AMG 701|Anti-BCMA/CD3 BiTE Antibody AMG 701|BCMA/CD3-directed Bispecific T-cell Engager Antibody AMG 701|BiTE Antibody AMG 701|Bispecific T-cell Engager Antibody AMG 701|PAVURUTAMAB	A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17), fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of pavurutamab, this bispecific antibody binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA found on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated cell death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.	Pavurutamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C147029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147029>	C1512	Antibody-drug Conjugate SC-007|ADC SC-007|SC-007|SC-007	An antibody-drug conjugate (ADC) composed of a monoclonal antibody against an undisclosed tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of SC-007 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.	Antibody-drug Conjugate SC-007		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C147030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147030>	C2116	Giredestrant|GDC 9545|GDC-49545|GIREDESTRANT|RG6171|SERD GDC-9545|Selective Estrogen Receptor Degrader GDC-9545|Selective Estrogen Receptor Downregulator GDC-9545	An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, giredestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.	Giredestrant		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C147031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147031>	C214964|C211912	Anti-MUC16/MMAE Antibody-drug Conjugate DMUC4064A|ADC DMUC4064A|DMUC-4064A|DMUC4064A|RG7882|THIOMAB-drug Conjugate DMUC4064A	An antibody-drug conjugate (ADC) composed of a monoclonal antibody against human mucin 16 (MUC16; cancer antigen 125; CA125; FLJ14303) conjugated to monomethyl auristatin E (MMAE), an auristatin derivative and potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration, anti-MUC16/MMAE ADC DMUC4064A binds to MUC16 located on the tumor cell surface. After internalization of the agent, the MMAE moiety is released and binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and apoptosis. MUC16, a member of the mucin family glycoproteins, is overexpressed in a variety of tumor cells and plays a key role in tumor cell proliferation.	Anti-MUC16/MMAE Antibody-drug Conjugate DMUC4064A		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C147032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147032>	C221052	Baseline Nausea and Vomiting Score 0|Nausea Score 0	A subjective score of 0 on a scale that ranges from 0: No nausea at all to 10: Nausea as bad as it can be.			Intellectual Product	
C147033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147033>	C217121	Baseline Nausea and Vomiting Scale|Nausea Scale|Nausea and Vomiting Scale	A scale for the subjective scoring of nausea that ranges from 0: No nausea at all to 10: Nausea as bad as it can be.			Intellectual Product	
C147034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147034>	C221052	Baseline Nausea and Vomiting Score 1|Nausea Score 1	A subjective score of 1 on a scale that ranges from 0: No nausea at all to 10: Nausea as bad as it can be.			Intellectual Product	
C147035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147035>	C221052	Baseline Nausea and Vomiting Score 2|Nausea Score 2	A subjective score of 2 on a scale that ranges from 0: No nausea at all to 10: Nausea as bad as it can be.			Intellectual Product	
C147036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147036>	C221052	Baseline Nausea and Vomiting Score 3|Nausea Score 3	A subjective score of 3 on a scale that ranges from 0: No nausea at all to 10: Nausea as bad as it can be.			Intellectual Product	
C147037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147037>	C221052	Baseline Nausea and Vomiting Score 4|Nausea Score 4	A subjective score of 4 on a scale that ranges from 0: No nausea at all to 10: Nausea as bad as it can be.			Intellectual Product	
C147038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147038>	C221052	Baseline Nausea and Vomiting Score 5|Nausea Score 5	A subjective score of 5 on a scale that ranges from 0: No nausea at all to 10: Nausea as bad as it can be.			Intellectual Product	
C147039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147039>	C221052	Baseline Nausea and Vomiting Score 6|Nausea Score 6	A subjective score of 6 on a scale that ranges from 0: No nausea at all to 10: Nausea as bad as it can be.			Intellectual Product	
C147040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147040>	C221052	Baseline Nausea and Vomiting Score 7|Nausea Score 7	A subjective score of 7 on a scale that ranges from 0: No nausea at all to 10: Nausea as bad as it can be.			Intellectual Product	
C147041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147041>	C221052	Baseline Nausea and Vomiting Score 8|Nausea Score 8	A subjective score of 8 on a scale that ranges from 0: No nausea at all to 10: Nausea as bad as it can be.			Intellectual Product	
C147042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147042>	C221052	Baseline Nausea and Vomiting Score 9|Nausea Score 9	A subjective score of 9 on a scale that ranges from 0: No nausea at all to 10: Nausea as bad as it can be.			Intellectual Product	
C147043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147043>	C221052	Baseline Nausea and Vomiting Score 10|Nausea Score 10	A subjective score of 10 on a scale that ranges from 0: No nausea at all to 10: Nausea as bad as it can be.			Intellectual Product	
C147044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147044>	C744	Apremilast|(+)-N-(2-((1S)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxo- 2,3-dihydro-1H-isoindol-4-yl)acetamide|APREMILAST|CC 10004|CC-10004|CC10004|Otezla	An orally bioavailable, small molecule inhibitor of phosphodiesterase 4 (PDE4), with potential anti-inflammatory activity. Upon oral administration, apremilast targets, binds to and inhibits the activity of PDE4, thereby blocking cyclic adenosine monophosphate (cAMP) degradation and increasing intracellular cAMP levels. This may decrease the production of the proinflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha). PDE4 is an enzyme that plays an important role in the degradation of cAMP and in cytokine production in inflammatory cells.	Apremilast		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C147045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147045>	C107528	Refractory Chemotherapy-Induced Nausea and Vomiting	Chemotherapy-induced nausea and vomiting that does not respond to treatment.	Refractory Chemotherapy-Induced Nausea and Vomiting		Finding	CTRP Disease Terminology|CTRP Terminology
C147046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147046>	C25952	ENPP3 Gene|ENPP3|ENPP3|Ectonucleotide Pyrophosphatase/Phosphodiesterase 3 Gene	This gene plays a role in phosphonucleotide metabolism.	ENPP3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C147047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147047>	C147046	ENPP3 wt Allele|B10|CD203c|DJ1005H11.3|DJ914N13.3|Ectonucleotide Pyrophosphatase/Phosphodiesterase 3 wt Allele|NPP3|PD-IBETA|PDNP3	Human ENPP3 wild-type allele is located in the vicinity of 6q23.2 and is approximately 119 kb in length. This allele, which encodes ectonucleotide pyrophosphatase/phosphodiesterase family member 3 protein, is involved in the hydrolysis of phosphodiester and phosphosulfate bonds.	ENPP3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147048>	C16561	Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3|CD203c|CD203c Antigen|E-NPP 3|ENPP3|PD-Ibeta|Phosphodiesterase I Beta|Phosphodiesterase I/Nucleotide Pyrophosphatase 3|Phosphodiesterase-I Beta	Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (875 aa, ~100 kDa) is encoded by the human ENPP3 gene. This protein plays a role in the cleavage of phosphodiester and phosphosulfate bonds.	Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147049>	C25997	PIK3AP1 Gene|PIK3AP1|PIK3AP1|Phosphoinositide-3-Kinase Adaptor Protein 1 Gene	This gene is involved in signaling from toll-like receptors and the B-cell receptor.	PIK3AP1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C147050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147050>	C147049	PIK3AP1 wt Allele|BCAP|FLJ35564|Phosphoinositide-3-Kinase Adaptor Protein 1 wt Allele	Human PIK3AP1 wild-type allele is located in the vicinity of 10q24.1 and is approximately 127 kb in length. This allele, which encodes phosphoinositide 3-kinase adapter protein 1, plays a role in B-cell receptor and toll-like receptor signaling.	PIK3AP1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147051>	C26231	Phosphoinositide 3-Kinase Adapter Protein 1|B Cell Adaptor Protein|B-Cell Adapter for Phosphoinositide 3-Kinase|B-Cell Adaptor Protein|B-Cell Phosphoinositide 3-Kinase Adapter Protein 1|PIK3 Adaptor Protein|PIK3AP1|Phosphoinositide-3-Kinase Adaptor Protein 1	Phosphoinositide 3-kinase adapter protein 1 (805 aa, ~90 kDa) is encoded by the human PIK3AP1 gene. This protein is involved in linking the B-cell receptor and toll-like receptors to the phosphoinositide 3-kinase (PI3K)-Akt signaling pathway.	Phosphoinositide 3-Kinase Adapter Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147052>	C97927|C157554	PIK3AP1 Gene Mutation|BCAP Gene Mutation|Phosphoinositide-3-Kinase Adaptor Protein 1 Gene Mutation	A change in the nucleotide sequence of the PIK3AP1 gene.	PIK3AP1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147053>	C147008	Soluble Tumor Necrosis Factor Receptor Superfamily Member 1A|Soluble Tumor Necrosis Factor Receptor Superfamily Member I|sTNF RI|sTNF-RI|sTNFRSF1A	Soluble tumor necrosis factor receptor superfamily member 1A (~18 kDa) is encoded by the human TNFRSF1A gene. This enzymatically processed protein may be involved in the inhibition of binding and downstream signaling associated with binding of either tumor necrosis factor or lymphotoxin-alpha to the membrane-bound form of tumor necrosis factor receptor superfamily member 1A.	Soluble Tumor Necrosis Factor Receptor Superfamily Member 1A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147054>	C180950|C158949	ROS1 Gene Rearrangement Negative|MCF3 Gene Rearrangement Negative|No rearrangement detected|ROS Gene Rearrangement Negative|ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene Rearrangement Negative|ROS1 Rearrangement Negative|c-ros-1 Gene Rearrangement Negative	A genetic finding indicating that rearrangement of the ROS1 gene has not been detected in a sample.	ROS1 Gene Rearrangement Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147055>	C35881	Blasts 1 Percent or More of Peripheral Blood White Cells|Blasts Greater than or Equal to 1 Percent of Peripheral Blood White Cells	A semi-quantitative microscopic finding indicating that 1 percent or more of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.	Blasts 1 Percent or More of Peripheral Blood White Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C147056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147056>	C41397	Blasts 6-19 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that between 6 and 19 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts 6-19 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C147057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147057>	C177692	CD44 Positive|CD44 Antigen Positive|CD44 Molecule Positive|CDw44 Positive	An indication that CD44 expression has been detected in a sample.	CD44 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147058>	C69408	HLA-A*0202 Positive Cells Present|HLA-A*0202 Positive|HLA-A*02:02 Positive|HLA-A*02:02 Positive Cells Present|HLA-A0202 Positive	An indication that cells expressing HLA-A*0202 have been detected in a sample.	HLA-A*0202 Positive Cells Present		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147059>	C177692	HLA-B*5103 Positive Cells Present|HLA-B*5103 Positive|HLA-B*51:03 Positive|HLA-B*51:03 Positive Cells Present|HLA-B5103 Positive	An indication that cells expressing HLA-B*5103 have been detected in a sample.	HLA-B*5103 Positive Cells Present		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147060>	C177692	HLA-C*0404 Positive Cells Present|HLA-C*0404 Positive|HLA-C*04:04 Positive|HLA-C*04:04 Positive Cells Present|HLA-C0404 Positive	An indication that cells expressing HLA-C*0404 have been detected in a sample.	HLA-C*0404 Positive Cells Present		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147061>	C97927	ARAF Gene Mutation|A-RAF Gene Mutation|A-Raf Proto-Oncogene, Serine/Threonine Kinase Gene Mutation|ARAF1 Gene Mutation|PKS2 Gene Mutation|RAFA1 Gene Mutation|v-Raf Murine Sarcoma 3611 Viral Oncogene Homolog 1 Gene Mutation	A change in the nucleotide sequence of the ARAF gene.	ARAF Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147062>	C97927|C136422	MAP2K1 Gene Mutation|MAPKK1 Gene Mutation|MEK1 Gene Mutation|MKK1 Gene Mutation|Mitogen-Activated Protein Kinase Kinase 1 Gene Mutation|PRKMK1 Gene Mutation	A change in the nucleotide sequence of the MAP2K1 gene.	MAP2K1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C147063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147063>	C140465|C103223	DLL3 Gene Positive|Delta Like Canonical Notch Ligand 3 Gene Positive|Delta, Drosophila, Homolog of, 3 Gene Positive|Delta-Like 3 (Drosophila) Gene Positive|Delta-Like 3 Gene Positive|Delta3 Gene Positive	An indication that the DLL3 gene has been detected in a sample.	DLL3 Gene Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147064>	C118376	FGF3 Gene Amplification|FGF-3 Gene Amplification|Fibroblast Growth Factor 3 Gene Amplification|HBGF-3 Gene Amplification|HBGF3 Gene Amplification|INT-2 Gene Amplification|INT2 Gene Amplification|Murine Mammary Tumor Virus Integration Site 2 Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the FGF3 gene.	FGF3 Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147065>	C188218|C156485	Metastatic Neuroendocrine Tumor|Metastatic Carcinoid Tumor|Metastatic Carcinoid Tumor|Metastatic Well Differentiated Neuroendocrine Neoplasm|Metastatic Well Differentiated Neuroendocrine Neoplasm|Secondary carcinoid tumors|Secondary carcinoid tumors, unspecified site|Secondary neuroendocrine tumors	A neuroendocrine tumor that has spread from its original site of growth to another anatomic site.			Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|mCode Cancer Disorder Value Set|mCode Elixhauser Metastatic Cancer Value Set|mCode Secondary Cancer Disorder Value Set|mCode Terminology
C147066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147066>	C103175	CDISC Protocol Entities Study Design Attribute Terminology|PROT-Att Study Design|Study Design Attribute Terminology|Study Design Attribute Terminology	Terminology associated with the protocol entity study design attribute codelist of the Clinical Data Interchange Standards Consortium (CDISC).			Intellectual Product	
C147067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147067>	C103175	CDISC Protocol Study Purpose Response Terminology|PROT-SPURPRS|Study Purpose Value Set|Study Purpose Value Set	Terminology associated with the study purpose response codelist of the Clinical Data Interchange Standards Consortium (CDISC) protocol entities.			Intellectual Product	
C147068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147068>	C103175	CDISC Protocol Subject Allocation Response Terminology|PROT-SUBALLRS|Participant Allocation Value Set|Participant Allocation Value Set	Terminology associated with the subject allocation response codelist of the Clinical Data Interchange Standards Consortium (CDISC) protocol entities.			Intellectual Product	
C147069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147069>	C103175	CDISC Protocol Randomization Type Response Terminology|PROT-RANDTYP|Randomization Type Value Set|Randomization Type Value Set	Terminology associated with the randomization type response codelist of the Clinical Data Interchange Standards Consortium (CDISC) protocol entities.			Intellectual Product	
C147070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147070>	C85865|C122814	Developmental and Epileptic Encephalopathy 2|CDKL5 Deficiency Disorder|Cyclin-Dependent Kinase-Like 5 Deficiency Disorder|Cyclin-Dependent Kinase-Like 5 Deficiency Disorder|DEE2|EIEE2|Early Infantile Epileptic Encephalopathy 2	An X-linked dominant form of early infantile epileptic encephalopathy, caused by mutation(s) in the CDKL5 gene, encoding cyclin-dependent kinase-like 5.			Disease or Syndrome	Cellosaurus Disease Terminology|mCode Elixhauser Neurological Seizure Disorder Value Set|mCode Terminology
C147071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147071>	C122814	Developmental and Epileptic Encephalopathy 6A|DEE6|Dravet Syndrome|EIEE6|Early Infantile Epileptic Encephalopathy 6	An autosomal dominant form of early infantile epileptic encephalopathy, caused by mutation(s) in the SCN1A gene, encoding sodium channel protein type 1 subunit alpha.			Disease or Syndrome	Cellosaurus Disease Terminology
C147072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147072>	C82342	Juvenile Huntington Disease	An early-onset form of Huntington disease (before age 20) caused by trinucleotide repeat expansion in the HTT gene, encoding huntingtin.			Disease or Syndrome	Cellosaurus Disease Terminology
C147073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147073>	C134526	Canine Mammary Adenoma	An adenoma arising from the mammary gland of a dog.			Neoplastic Process	Cellosaurus Disease Terminology
C147074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147074>	C81945|C190003	Sensitizing ALK Gene Mutation|ALK Sensitizing Mutation|Sensitizing Anaplastic Lymphoma Kinase (Ki-1) Gene Mutation|Sensitizing Anaplastic Lymphoma Receptor Tyrosine Kinase Gene Mutation|Sensitizing CD246 Gene Mutation	A molecular genetic abnormality indicating the presence of a sensitizing mutation in the ALK gene.	Sensitizing ALK Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147075>	C94299|C177692	PRLR Positive|PRL-R Positive|Prolactin Receptor Positive	An indication that PRLR expression has been detected in a sample.	PRLR Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147076>	C35682|C177693	KIT Overexpression Positive|CD117 Antigen Overexpression Positive|CD117 Overexpression Positive|Mast/Stem Cell Growth Factor Receptor Kit Overexpression Positive|Proto-Oncogene c-Kit Overexpression Positive|c-KIT Overexpression Positive	An indication that overexpression of KIT has been detected in a sample.	KIT Overexpression Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147077>	C158948	BRAF Fusion Positive|B-RAF Fusion Positive|BRAF Fusion|BRAF1 Fusion Positive|Serine/Threonine-Protein Kinase B-raf Fusion Positive|v-raf Murine Sarcoma Viral Oncogene Homolog B1 Fusion Positive	An indication that BRAF fusion expression has been detected in a sample.	BRAF Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147078>	C177692	MAGEA4 Positive|CT1.4 Positive|Cancer/Testis Antigen 1.4 Positive|MAGE A4 Positive|MAGE-41 Positive|MAGE-X2 Positive|MAGE4 Positive|MAGE4A Positive|MAGE4B Positive|Melanoma-Associated Antigen 4 Positive	An indication that MAGEA4 expression has been detected in a sample.	MAGEA4 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147079>	C177692	Chromogranin Positive|CHG Positive	An indication that expression of one or more chromogranin family proteins has been detected in a sample.	Chromogranin Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147080>	C40998|C147079	Chromogranin-Positive Neoplastic Cells Present|CHG-Positive Neoplastic Cells Present	An indication that expression of one or more chromogranin family proteins has been detected in a sample of neoplastic cells.	Chromogranin-Positive Neoplastic Cells Present		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147081>	C212830|C16606	MET Gene Deletion|HGFR Gene Deletion|Hepatocyte Growth Factor Receptor Gene Deletion|MET Proto-Oncogene, Receptor Tyrosine Kinase Gene Deletion|c-MET Gene Deletion	A molecular abnormality referring to the loss of at least one copy of the MET gene.	MET Gene Deletion		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C147082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147082>	C25993|C25873	TRPM6 Gene|TRPM6|TRPM6|Transient Receptor Potential Cation Channel Subfamily M Member 6 Gene	This gene plays a role in both magnesium ion transport and protein phosphorylation.	TRPM6 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C147083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147083>	C147082	TRPM6 wt Allele|CHAK2|FLJ22628|HMGX|HOMG|HOMG1|HSH|Hypomagnesemia, Secondary Hypocalcemia Gene|Transient Receptor Potential Cation Channel Subfamily M Member 6 wt Allele|Transient Receptor Potential Cation Channel, Subfamily M, Member 6 Gene	Human TRPM6 wild-type allele is located in the vicinity of 9q21.13 and is approximately 166 kb in length. This allele, which encodes transient receptor potential cation channel subfamily M member 6 protein, is involved in both magnesium homeostasis and protein phosphorylation. Mutation of the gene is associated with hypomagnesemia.	TRPM6 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147084>	C28505|C17325	Transient Receptor Potential Cation Channel Subfamily M Member 6|Channel Kinase 2|EC 2.7.11.1|Melastatin-Related TRP Cation Channel 6|TRPM6	Transient receptor potential cation channel subfamily M member 6 (2022 aa, ~232 kDa) is encoded by the human TRPM6 gene. This protein plays a role in serine/threonine phosphorylation and magnesium absorption in the gut and kidney.	Transient Receptor Potential Cation Channel Subfamily M Member 6		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147085>	C97139	Antigen-Presentation Machinery Expression Profile|APM Expression Profile|Antigen-Presentation Machinery Molecules Expression Profile	The identification and quantitation of all of the antigen-presentation machinery molecules expressed in a biological sample.	Antigen-Presentation Machinery Expression Profile		Qualitative Concept	CTRP Biomarker Terminology|CTRP Terminology
C147086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147086>	C64430	Protein Wnt-10b Activity Measurement|Protein Wnt-12 Activity Measurement|WNT10B Activity Measurement|Wingless-Type MMTV Integration Site Family Member 10B Protein Activity Measurement	A measurement of the protein Wnt-10b activity in a sample.	Protein Wnt-10b Activity Measurement		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147087>	C177692	CD38 Positive|ADP-Ribosyl Cyclase 1 Positive|ADPRC1 Positive|CD38 Antigen Positive|CD38 Molecule Positive|T10 Positive	An indication that CD38 expression has been detected in a sample.	CD38 Positive		Laboratory or Test Result	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147088>	C138961	PSA Level Greater than Four|PSA Level Greater than 4	A blood concentration of prostate specific antigen greater than 4 ng/mL.	PSA Level Greater than Four		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147089>	C165233	CCND1 Negative|BCL-1 Negative|BCL1 Negative|Cyclin D1 Negative|Cyclin-D1 Negative|PRAD1 Negative	Indicates that expression of CCND1 has not been detected in a sample.	CCND1 Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147090>	C165233	CD2 Negative|CD2 Antigen Negative|CD2 Molecule Negative|LFA-2 Negative|T11 Negative	Indicates that expression of C2 has not been detected in a sample.	CD2 Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147091>	C48777	Lymphovascular Invasion 0|LVI 0	Lymphovascular invasion is not present (absent) or is not identified. (AJCC 8th ed.)			Finding	
C147092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147092>	C48777	Lymphovascular Invasion 1|LVI 1	Lymphovascular invasion is present or identified. (AJCC 8th ed.)			Finding	
C147093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147093>	C48777	Lymphovascular Invasion 9|LVI 9	Presence of lymphovascular invasion unknown or indeterminate. (AJCC 8th ed.)			Finding	
C147094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147094>	C48777	Lymphovascular Invasion 2|LVI 2	Lymphatic and small vessel invasion only. (AJCC 8th ed.)			Finding	
C147095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147095>	C48777	Lymphovascular Invasion 3|LVI 3	Venous (large vessel) invasion only. (AJCC 8th ed.)			Finding	
C147096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147096>	C48777	Lymphovascular Invasion 4|LVI 4	Both lymphatic and small vessel and venous (large vessel) invasion. (AJCC 8th ed.)			Finding	
C147097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147097>	C7723|C171026	Cardiac Angiosarcoma|Heart Angiosarcoma	An angiosarcoma that arises from the heart. It most often arises in the right atrium near the atrioventricular groove. The prognosis is poor.			Neoplastic Process	
C147098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147098>	C9306|C4567	Pericardial Sarcoma	A rare sarcoma that arises from the pericardium. The two most common types are angiosarcoma and synovial sarcoma. Patients present with symptoms related to pericardial effusion.			Neoplastic Process	
C1470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1470>	C2554	Loxoribine|7-Allyl-8-oxoguanosine|LOXORIBINE	A guanine ribonucleotide derivative with immunostimulatory and immunomodulatory activity. Loxoribine undergoes facilitated transport across the plasma membrane into the cytoplasmic compartment of the cell and acts intracellularly, bypassing the biochemical steps involved in the membrane signal transduction pathway used by Ag or anti-IgM Abs to activate B cells. This agent activates the Toll-like receptor 7 (TLR7), a member of the TLR family of pathogen-associated molecular pattern recognition receptors thereby activating the innate immune system. This activation requires endosomal maturation and recognition is restricted to TLR7. As a result, loxoribine induces cycling B cells to proliferate and differentiate non-specifically and recruit antigen-reactive B cells to undergo differentiation to antibody production, markedly amplifying the underlying response in the process.			Immunologic Factor|Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C147101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147101>	C171026|C147098	Pericardial Angiosarcoma	A rare angiosarcoma that arises from the pericardium. Patients present with symptoms related to pericardial effusion.			Neoplastic Process	
C147102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147102>	C3400|C147098	Pericardial Synovial Sarcoma	A rare synovial sarcoma that arises from the pericardium. Patients present with symptoms related to pericardial effusion.			Neoplastic Process	
C147103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147103>	C45761|C189045	Pericardial Teratoma	A teratoma that arises within the pericardium.			Neoplastic Process	
C147104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147104>	C8881|C45761|C4567	Malignant Pericardial Germ Cell Tumor	A malignant germ cell tumor that arises within the pericardium.			Neoplastic Process	
C147105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147105>	C3011|C147104	Pericardial Yolk Sac Tumor	A yolk sac tumor that arises within the pericardium.			Neoplastic Process	
C147106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147106>	C8536|C6751|C45761	Benign Pericardial Germ Cell Tumor	A germ cell tumor that arises from the pericardium. There is no evidence of atypia or metastases.			Neoplastic Process	
C147107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147107>	C71701|C3059	Refractory Glioma	Glioma that does not respond to treatment.			Neoplastic Process	
C147108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147108>	C3017|C158104	Refractory Ependymoma	Ependymoma that does not respond to treatment.			Neoplastic Process	
C147109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147109>	C5588|C129441	Recurrent Medulloblastoma, SHH-Activated	The reemergence of SHH-activated medulloblastoma after a period of remission.			Neoplastic Process	
C147110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147110>	C142856|C129441	Refractory Medulloblastoma, SHH-Activated	SHH-activated medulloblastoma that does not respond to treatment.			Neoplastic Process	
C147111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147111>	C3222|C147113	Progressive Medulloblastoma	A medulloblastoma that is worsening in terms of extent or severity.			Neoplastic Process	
C147112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147112>	C3017|C219636	Progressive Ependymoma	An ependymoma that is worsening in terms of extent or severity.			Neoplastic Process	
C147113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147113>	C9293|C206692	Progressive Central Nervous System Neoplasm	A central nervous system neoplasm that is worsening in terms of extent or severity.			Neoplastic Process	
C147114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147114>	C3063	Steroid Refractory Graft Versus Host Disease|Steroid Refractory GVHD|Steroid Resistant GVHD|Steroid Resistant Graft Versus Host Disease	Graft versus host disease that does not respond to steroid treatment.			Disease or Syndrome	
C147115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147115>	C147111|C129441	Progressive Medulloblastoma, SHH-Activated	A medulloblastoma, SHH-activated that is worsening in terms of extent or severity.			Neoplastic Process	
C147117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147117>	C157605	Prophylactic Mastectomy Patient	An individual who is undergoing prophylactic mastectomy.	Prophylactic Mastectomy Patient		Patient or Disabled Group	CTRP Intervention Terminology|CTRP Terminology
C147118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147118>	C19896	Mutant Protein|Protein Variant	A protein with an amino acid sequence that differs from the wildtype, canonical sequence.			Classification	
C147119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147119>	C136286	MET NP_000236.2:p.D1010N|C-MET Asp1010Asn|C-MET D1010N|HGF Receptor Asp1010Asn|HGF Receptor D1010N|HGFR Asp1010Asn|HGFR D1010N|Hepatocyte Growth Factor Receptor Asp1010Asn|Hepatocyte Growth Factor Receptor D1010N|MET Asp1010Asn|MET D1010N|MET D1010N mutation detected|MET NP_000236.2:p.Asp1010Asn|MET NP_001120972.1:p.Asp1028Asn|MET NP_001120972.1:p.D1028N|MET p.Asp1010Asn|MET p.D1010N|NP_000236.2:p.Asp1010Asn|NP_000236.2:p.D1010N|NP_001120972.1:p.Asp1028Asn|NP_001120972.1:p.D1028N|Proto-Oncogene c-Met Asp1010Asn|Proto-Oncogene c-Met D1010N|Scatter Factor Receptor Asp1010Asn|Scatter Factor Receptor D1010N|Tyrosine-Protein Kinase Met Asp1010Asn|Tyrosine-Protein Kinase Met D1010N	A change in the amino acid residue at position 1010 in the hepatocyte growth factor receptor protein where aspartic acid has been replaced by asparagine.			Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C147120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147120>	C63429|C39788	MET Intron 13 Mutation|HGFR Intron 13 Mutation|MET Proto-Oncogene, Receptor Tyrosine Kinase Intron 13 Mutation|Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Intron 13 Mutation|c-Met Intron 13 Mutation	A molecular genetic abnormality indicating the presence of a mutation in intron 13 of the MET gene.			Cell or Molecular Dysfunction	
C147122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147122>	C63429|C39788	MET Intron 14 Mutation|HGFR Intron 14 Mutation|MET Proto-Oncogene, Receptor Tyrosine Kinase Intron 14 Mutation|Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Intron 14 Mutation|c-Met Intron 14 Mutation	A molecular genetic abnormality indicating the presence of a mutation in intron 14 of the MET gene.			Cell or Molecular Dysfunction	
C147123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147123>	C148639|C131179	MET Codon 963 Splice Mutation|HGFR Codon 963 Splice Mutation|MET Asp963 Splice Mutation|MET D963 Splice Mutation|MET D963_splice mutation detected|MET Proto-Oncogene, Receptor Tyrosine Kinase Codon 963 Splice Mutation|Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Codon 963 Splice Mutation|c-Met Codon 963 Splice Mutation	A change in the nucleotide sequence of MET gene that alters splicing at codon 963.			Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C147124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147124>	C148639|C131179	MET Codon 1010 Splice Mutation|HGFR Codon 1010 Splice Mutation|MET Asp1010 Splice Mutation|MET D1010 Splice Mutation|MET D1010_splice mutation detected|MET Proto-Oncogene, Receptor Tyrosine Kinase Codon 1010 Splice Mutation|Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Codon 1010 Splice Mutation|c-Met Codon 1010 Splice Mutation	A change in the nucleotide sequence of MET gene that alters splicing at codon 1010.			Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C147125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147125>	C2167|C129825	Abivertinib|ABIVERTINIB|AC 0010|AC-0010|AC0010	An orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. Upon oral administration, abivertinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the drug-resistant T790M EGFR mutant, which prevents signaling mediated by mutant forms of EGFR. This may both induce cell death and inhibit tumor growth in EGFR-mutated tumor cells. EGFR, a receptor tyrosine kinase that is mutated in a variety of cancers, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors, which also inhibit wild-type EGFR.	Abivertinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C147126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147126>	C25196	Adaptive Randomization	A type of randomization schema in which a subject's group assignment probability is adjusted based on the group assignments of those subjects already randomized in the trial.			Health Care Activity	
C147127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147127>	C147126	Block Randomization	A type of adaptive randomization schema in which a pre-specified number of subjects is assigned to a block containing the same pre-specified number of balanced group assignments in random order. This block is normally determined prior to the start of the study.			Health Care Activity	
C147128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147128>	C75385	Choriogonadotropin Measurement|Choriogonadotropin|Choriogonadotropin|HCGND|Human Chorionic Gonadotropin	The determination of the amount of choriogonadotropin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C147129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147129>	C67332	Centimeters of Mercury|Centimeter of Mercury|centimeter of mercury|cmHg|cmHg|cmHg|cm[Hg]|cm[Hg]|cm[Hg]	A unit of pressure equal to 0.001316 atmosphere and equal to the pressure indicated by one centimeter rise of mercury in a barometer at the Earth's surface.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit for Vital Sign Result Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C147130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147130>	C67456|C67365	Enzyme Unit per Liter|EU/L|Enzyme U/L|Enzyme U/L|Enzyme Unit/L|U/L|U/L|enzyme unit per liter|{Enzyme}.U/L|{Enzyme}.U/L|{Enzyme}.U/l|{Enzyme}.U/l	Unit of catalytic activity concentration defined as activity equal to one enzyme unit per one liter of system volume.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C147131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147131>	C98356	EGFR NP_005219.2:p.L792X|EGFR L792X|EGFR Leu792Xxx|EGFR NP_005219.2:p.Leu792Xxx|EGFR p.L792X|EGFR p.Leu792Xxx|Epidermal Growth Factor Receptor L792X|Epidermal Growth Factor Receptor Leu792Xxx|NP_005219.2:p.L792X|NP_005219.2:p.Leu792Xxx|Proto-Oncogene c-ErbB-1 L792X|Proto-Oncogene c-ErbB-1 Leu792Xxx|Receptor Tyrosine-Protein Kinase erbB-1 L792X|Receptor Tyrosine-Protein Kinase erbB-1 Leu792Xxx	A change in the amino acid residue at position 792 in the epidermal growth factor receptor protein where leucine has been replaced by another amino acid.	EGFR NP_005219.2:p.L792X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147132>	C98356	EGFR NP_005219.2:p.G796X|EGFR G796X|EGFR Gly796Xxx|EGFR NP_005219.2:p.Gly796Xxx|EGFR p.G796X|EGFR p.Gly796Xxx|Epidermal Growth Factor Receptor G796X|Epidermal Growth Factor Receptor Gly796Xxx|NP_005219.2:p.G796X|NP_005219.2:p.Gly796Xxx|Proto-Oncogene c-ErbB-1 G796X|Proto-Oncogene c-ErbB-1 Gly796Xxx|Receptor Tyrosine-Protein Kinase erbB-1 G796X|Receptor Tyrosine-Protein Kinase erbB-1 Gly796Xxx	A change in the amino acid residue at position 796 in the epidermal growth factor receptor protein where glycine has been replaced by another amino acid.			Cell or Molecular Dysfunction	
C147133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147133>	C98356	EGFR NP_005219.2:p.L718X|EGFR L718X|EGFR Leu718Xxx|EGFR NP_005219.2:p.Leu718Xxx|EGFR p.L718X|EGFR p.Leu718Xxx|Epidermal Growth Factor Receptor L718X|Epidermal Growth Factor Receptor Leu718Xxx|NP_005219.2:p.L718X|NP_005219.2:p.Leu718Xxx|Proto-Oncogene c-ErbB-1 L718X|Proto-Oncogene c-ErbB-1 Leu718Xxx|Receptor Tyrosine-Protein Kinase erbB-1 L718X|Receptor Tyrosine-Protein Kinase erbB-1 Leu718Xxx	A change in the amino acid residue at position 718 in the epidermal growth factor receptor protein where leucine has been replaced by another amino acid.			Cell or Molecular Dysfunction	
C147134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147134>	C28676|C129826	Allogeneic Double Negative T Cells|Allogeneic DNT Cells|DNT-UHN-1	A population of healthy, donor-derived CD4 and CD8 double-negative T-lymphocytes (DNTs), with potential immunomodulating and anti-leukemic activities. The DNTs are expanded ex vivo in order to enhance their tumor destroying potential. Upon administration of the allogeneic DNTs (DNT-UHN-1), the receptors NKG2-D type II integral membrane protein (KLRK1; NKG2D) and  DNAX accessory molecule 1 (cluster of differentiation 226; CD226; DNAM-1) expressed on the DNTs recognize and bind to their cognate ligands expressed on leukemia cells. Upon binding, the DNTs release interferon-gamma (IFN-g), thereby destroying the tumor cells. DNTs derived from peripheral blood of healthy donors appear to be effective against certain types of tumor cells, including leukemia cells, and do not attack normal hematopoietic cells. NKG2D, a member of the CD94/NKG2 family of C-type lectin-like receptors, and DNAM-1, a member of the immunoglobulin superfamily containing 2 Ig-like domains of the V-set, play a key role in natural killer cell (NK)-mediated tumor cell killing. Certain tumor cells express higher levels of NKG2D and DNAM-1 ligands on their surfaces, thereby increasing their susceptibility to DNT-mediated cell lysis.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology
C147135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147135>	C28681|C138180|C129826	Anti-NY-ESO-1 TCR LV-transduced Autologous T-Cells TAEST16001|Anti-NY-ESO-1 TCR Transduced Autologous T Cells TAEST16001|NY-ESO-1 Antigen Specific Affinity-enhanced TCR Transduced Autologous T Cells|TAEST 16001|TAEST16001	A preparation of human autologous T-lymphocytes that are transduced with a lentiviral vector (LV) encoding an affinity-enhanced T-cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1, with potential immunostimulating and antineoplastic activities. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the anti-NY-ESO-1 TCR LV-transduced autologous T-cells TAEST16001 recognize and bind to NY-ESO-1-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of NY-ESO-1-positive tumor cells. NY-ESO-1, a tumor-associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types, and is not, or is minimally, expressed in normal, healthy cells.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology
C147136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147136>	C16830	Harmonic Ace+7|Harmonic Ace 7|Harmonic Ace 7	A proprietary type of laparoscopic ultrasonic shears designed for secure sealing in vessel sizes up to and including 7mm diameter.	Harmonic Ace 7		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C147137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147137>	C126063	Planned Number of Cohorts	The anticipated number of groups or cohorts that are part of the study.			Quantitative Concept	
C147138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147138>	C15320	Observational Study Model|Observation Model|Observation Study Design Model Type|Observational Study Design	The study design developed to assess biomedical and/or health outcomes in pre-defined groups of individuals that are not assigned an intervention by the investigator.			Research Activity	CDISC DDF Observational Study Design Attribute Terminology|CDISC DDF Terminology|Clinical Data Interchange Standards Consortium Terminology
C147139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147139>	C25365	Study Design Description|Overall Description of Trial Design and Description of Intervention Model|Overall Design|Study Design Overview|Summary of Study Design	A summary of the components of study design employed for the study including, but not limited to, interventions, study populations, blinding, treatment assignment methods, etc.			Intellectual Product	CDISC DDF Study Design Attribute Terminology|CDISC DDF Terminology|Clinical Data Interchange Standards Consortium Terminology|ICH M11 Protocol Section 4 Data Element Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C147140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147140>	C71460	Randomization Method|Randomization Type	The type of randomization method used to assign subjects to treatment groups or cohorts.			Conceptual Entity	
C147141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147141>	C146997	Study Primary Purpose	The principal reason or intention for the execution of an interventional or non-interventional clinical study.			Idea or Concept	
C147142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147142>	C146997	Study Secondary Purpose	The ancillary reason or intention for the execution of an interventional or non-interventional clinical study.			Idea or Concept	
C147143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147143>	C147126	Minimization Randomization	A type of adaptive randomization schema in which the subject is assigned to the group that has the lowest imbalance score at the time of that particular subject's randomization. If all groups have low imbalance scores, then the subject is randomly assigned to one of the groups.			Health Care Activity	
C147144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147144>	C25196	Simple Randomization	A type of randomization schema in which each subject has the same chance of being randomized into any one group as all other subjects. The assignment of the previous subject has no bearing on how the current subject will be assigned.			Health Care Activity	
C147145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147145>	C147127	Stratified Randomization|Stratified Randomisation	A type of block randomization in which subjects are stratified into groups based on prognostic variables and then randomized into balanced treatment groups.			Health Care Activity	CDISC DDF Study Design Characteristics Value Set Terminology|CDISC DDF Terminology|Clinical Data Interchange Standards Consortium Terminology
C147146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147146>	C146997	Exploratory Research|exploratory research	Any action or process to perform research on a hypothetical or theoretical idea in order to determine whether the phenomena is new (which may lead to additional studies) or can be explained by an existing and well-substantiated theory.			Idea or Concept	CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C147147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147147>	C146997	Hypothesis Generation	Any action or process to create a tentative proposal to explain certain observations or facts, and which requires further investigation to be verified.			Idea or Concept	
C147148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147148>	C35552	Dimensionless Index|DIMSSNDX|Dimensionless Velocity Index	The ratio of the left ventricular outflow tract (LVOT) velocity to the maximum velocity of the aortic valve.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147149>	C35552	Effective Orifice Area|EOA	The minimal cross-sectional area of the flow jet downstream of a cardiac valve.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147150>	C35552	Effective Orifice Area Index|EOAINDEX	The ratio of the effective orifice area (EOA) to the body surface area (BSA).			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147151>	C25180	Observed Foreign Body Indicator|FBODYIND	An indication as to whether a foreign body is present in the body.			Conceptual Entity	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147152>	C35552	Mean Pressure Gradient|MGPRES	The arithmetic average of the quantitative measurement of the pressure gradient across a predetermined point.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147153>	C53265	Observed Medical Device Type Not Present In Intended Location Type|OBMDNLOC|Obs Med Device Type Not In Intended Loc|Obs Med Device Type Not In Intended Loc	A description of the type of medical device that is found in a subject but is not present in its intended location within the body.			Qualitative Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147154>	C53265	Observed Non-Medical Foreign Body Type|OBNMFBT	A description of the type of non-medical foreign body that is present in the body.			Qualitative Concept	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147155>	C35552	Peak Pressure Gradient|PGPRES	The quantitative measurement of the largest pressure gradient across a predetermined point.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147156>	C35552	Pressure Half Time|PRESHT	The amount of time required for the maximum transvalvular pressure gradient to decrease to one half of its initial value.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147157>	C35552	Valve Area Index|VAREANDX	The ratio of the valve area to the body surface area.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147158>	C35552	Valve Area|VLVAREA	The quantitative measurement of the surface area of a valve.			Finding	CDISC SDTM Cardiovascular Test Code Terminology|CDISC SDTM Cardiovascular Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147159>	C225418	Anteromedial|ANTEROMEDIAL	Denoting the front portion of the body towards the median plane.			Spatial Concept	CDISC SDTM Directionality Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147160>	C225418	Distal Volar|DISTAL VOLAR	Pertaining to the farthest portion from the palm side of a hand or the sole side of a foot.			Spatial Concept	CDISC SDTM Directionality Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147161>	C34022	Lower Extensor Surface|LOWER EXTENSOR SURFACE	Pertaining to the lower portion of the surface on the opposite side of the joint when it bends.			Anatomical Structure	CDISC SDTM Directionality Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147162>	C34022	Lower Flexor Surface|LOWER FLEXOR SURFACE	Pertaining to the lower portion of the surface on the same side of the joint when it bends.			Anatomical Structure	CDISC SDTM Directionality Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147163>	C225418	Lower Medial|LOWER MEDIAL	Denoting to the lower portion of the body towards the median plane.			Spatial Concept	CDISC SDTM Directionality Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147164>	C225418	Proximal Volar|PROXIMAL VOLAR	Pertaining to the nearest portion from the palm side of a hand or the sole side of a foot.			Spatial Concept	CDISC SDTM Directionality Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147165>	C34022	Upper Extensor Surface|UPPER EXTENSOR SURFACE	Pertaining to the upper portion of the surface on the opposite side of the joint when it bends.			Anatomical Structure	CDISC SDTM Directionality Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147166>	C34022	Upper Flexor Surface|UPPER FLEXOR SURFACE	Pertaining to the upper portion of the surface on the same side of the joint when it bends.			Anatomical Structure	CDISC SDTM Directionality Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147167>	C13442	Volar|VOLAR	Pertaining to the palm side of a hand or the sole side of a foot.			Spatial Concept	CDISC SDTM Directionality Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147168>	C117304	Associated Persons Adverse Events Domain	A domain utilized for the submission of adverse event records related to persons associated with the study subject.			Idea or Concept	
C147169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147169>	C117304	Associated Persons Biospecimen Domain	A domain utilized for the submission of biospecimen records related to persons associated with the study subject.			Idea or Concept	
C147170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147170>	C117304	Associated Persons Death Details Domain	A domain utilized for the submission of death details records related to persons associated with the study subject.			Idea or Concept	
C147171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147171>	C117304	Associated Persons Exposure Domain	A domain utilized for the submission of exposure records related to persons associated with the study subject.			Idea or Concept	
C147172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147172>	C117304	Associated Persons Laboratory Test Results Domain	A domain utilized for the submission of laboratory test records related to persons associated with the study subject.			Idea or Concept	
C147173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147173>	C117304	Associated Persons Medical History Domain	A domain utilized for the submission of medical history records related to persons associated with the study subject.			Idea or Concept	
C147174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147174>	C117304	Associated Persons Questionnaires Domain	A domain utilized for the submission of questionnaires records related to persons associated with the study subject.			Idea or Concept	
C147175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147175>	C117304	Relationship between Associated Persons and Subjects Domain|APRELSUB|Relationship between Associated Persons and Subjects	A domain utilized for the submission of relationship to subject records related to persons associated with the study subject.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147176>	C117304	Associated Persons Reproductive System Findings Domain	A domain utilized for the submission of reproductive system findings records related to persons associated with the study subject.			Idea or Concept	
C147177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147177>	C117304	Associated Persons Subject Characteristics Domain	A domain utilized for the submission of subject characteristics records related to persons associated with the study subject.			Idea or Concept	
C147178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147178>	C117304	Associated Persons Subject Status Domain	A domain utilized for the submission of subject status records related to persons associated with the study subject.			Idea or Concept	
C147179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147179>	C117304	Associated Persons Substance Use Domain	A domain utilized for the submission of substance use records related to persons associated with the study subject.			Idea or Concept	
C147180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147180>	C49556	Ophthalmic Examinations Domain|OE|Ophthalmic Examinations	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to ophthalmic examinations.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|CDISC SEND Domain Abbreviation Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147181>	C142727	Pool Definition Dataset|POOLDEF|Pool Definition|Pool Definition Domain	A dataset that identifies individual subjects included in a pool of subjects for which a single observation record (pool level) is captured. (CDISC)			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|CDISC SEND Domain Abbreviation Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147182>	C142727	Related Records Dataset|RELREC|Related Records|Related Records Domain	A dataset used to describe relationships between records for a subject within or across domains, and relationships of records across datasets. (CDISC)			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|CDISC SEND Domain Abbreviation Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147183>	C142727	Related Subjects Dataset|RELSUB|Related Subjects	A dataset used to represent relationships between study subjects. (CDISC)			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147184>	C49556	Subject Disease Milestones Domain|SM|Subject Disease Milestones	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to subject disease milestones.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147185>	C146996	Adverse Events Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the adverse events domain.			Idea or Concept	
C147186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147186>	C146996	Procedure Agents Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the procedure agents domain.			Idea or Concept	
C147187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147187>	C146996	Biospecimen Events Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the biospecimen events domain.			Idea or Concept	
C147188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147188>	C146996	Body Weight Gain Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the body weight gain domain.			Idea or Concept	
C147189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147189>	C146996	Biospecimen Findings Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the biospecimen findings domain.			Idea or Concept	
C147190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147190>	C146996	Body Weight Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the body weight domain.			Idea or Concept	
C147191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147191>	C146996	Clinical Events Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the clinical events domain.			Idea or Concept	
C147192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147192>	C146996	Clinical Observations Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the clinical observations domain.			Idea or Concept	
C147193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147193>	C146996	Concomitant and Prior Medications Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the concomitant and prior medications domain.			Idea or Concept	
C147194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147194>	C146996	Comments Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the comments domain.			Idea or Concept	
C147195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147195>	C146996	Cardiovascular System Findings Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the cardiovascular system findings domain.			Idea or Concept	
C147196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147196>	C146996	Drug Accountability Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the drug accountability domain.			Idea or Concept	
C147197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147197>	C146996	Death Details (human clinical trials) Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the death details (human clinical trials) domain.			Idea or Concept	
C147198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147198>	C146996	Device Events Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the device events domain.			Idea or Concept	
C147199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147199>	C146996	Device Identifiers Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the device identifiers domain.			Idea or Concept	
C1471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1471>	C97452	Lamivudine|(-)-BCH-189|2',3'-Dideoxy-3'-thiacytidine|3'-Thia-2',3'-dideoxycytidine|3TC|4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone|Epivir|GR109714X|LAM|LAMIVUDINE|lamivudine	A synthetic nucleoside analogue with activity against hepatitis B virus (HBV) and HIV. Intracellularly, lamivudine is phosphorylated to its active metabolites, lamiduvine triphosphate (L-TP) and lamiduvine monophosphate (L-MP).  In HIV, L-TP inhibits HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleoside analogue into viral DNA.  In HBV, incorporation of L-MP into viral DNA by HBV polymerase results in DNA chain termination. L-TP is a weak inhibitor of mammalian DNA polymerases alpha and beta, and mitochondrial DNA polymerase. (NCI04)	Lamivudine		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C147200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147200>	C146996	Demographics Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the demographics domain.			Idea or Concept	
C147201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147201>	C146996	Device Properties Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the device properties domain.			Idea or Concept	
C147202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147202>	C146996	Device Subject Relationships Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the device subject relationships domain.			Idea or Concept	
C147203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147203>	C146996	Disposition Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the disposition domain.			Idea or Concept	
C147204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147204>	C146996	Device Tracking and Disposition Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the device tracking and disposition domain.			Idea or Concept	
C147205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147205>	C146996	Device In-Use Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the device in-use domain.			Idea or Concept	
C147206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147206>	C146996	Protocol Deviations Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the protocol deviations domain.			Idea or Concept	
C147207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147207>	C146996	Device Exposure Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the device exposure domain.			Idea or Concept	
C147208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147208>	C146996	Exposure as Collected Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the exposure as collected domain.			Idea or Concept	
C147209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147209>	C146996	ECG Test Results Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the ECG test results domain.			Idea or Concept	
C147210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147210>	C146996	Environmental and Social Factors Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the environmental and social factors domain.			Idea or Concept	
C147211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147211>	C146996	Exposure Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the exposure domain.			Idea or Concept	
C147212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147212>	C146996	Findings About Events or Interventions Supplemental Qualifiers Dataset|SUPPFA|SUPPFA	A dataset containing supplemental information, specifically non-standard variables, to parent records in the findings about events or interventions domain.			Idea or Concept	
C147213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147213>	C146996	Fetal Measurements Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the fetal measurements domain.			Idea or Concept	
C147214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147214>	C146996	Food and Water Consumption Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the food and water consumption domain.			Idea or Concept	
C147215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147215>	C146996	Fetal Pathology Findings Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the fetal pathology findings domain.			Idea or Concept	
C147216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147216>	C146996	Healthcare Encounters Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the healthcare encounters domain.			Idea or Concept	
C147217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147217>	C146996	Implantation Classification Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the implantation classification domain.			Idea or Concept	
C147218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147218>	C146996	Inclusion/Exclusion Criteria Not Met Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the inclusion/exclusion criteria not met domain.			Idea or Concept	
C147219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147219>	C146996	Immunogenicity Specimen Assessments Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the immunogenicity specimen assessments domain.			Idea or Concept	
C147220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147220>	C146996	Laboratory Test Results Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the laboratory test results domain.			Idea or Concept	
C147221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147221>	C146996	Macroscopic Findings Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the macroscopic findings domain.			Idea or Concept	
C147222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147222>	C146996	Microbiology Specimen Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the microbiology specimen domain.			Idea or Concept	
C147223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147223>	C146996	Medical History Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the medical history domain.			Idea or Concept	
C147224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147224>	C146996	Microscopic Findings Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the microscopic findings domain.			Idea or Concept	
C147225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147225>	C146996	Musculoskeletal System Findings Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the musculoskeletal system findings domain.			Idea or Concept	
C147226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147226>	C146996	Meal Data Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the meal data domain.			Idea or Concept	
C147227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147227>	C146996	Microbiology Susceptibility Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the microbiology susceptibility domain.			Idea or Concept	
C147228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147228>	C146996	Nervous System Findings Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the nervous system findings domain.			Idea or Concept	
C147229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147229>	C146996	Ophthalmic Examinations Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the ophthalmic examinations domain.			Idea or Concept	
C147230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147230>	C146996	Non-Host Organism Identifiers Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the non-host organism identifiers domain.			Idea or Concept	
C147231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147231>	C146996	Organ Measurements Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the organ measurements domain.			Idea or Concept	
C147232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147232>	C146996	Pharmacogenomics/Genetics Biomarker Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the pharmacogenomics/genetics biomarker domain.			Idea or Concept	
C147233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147233>	C146996	Pharmacokinetics Concentrations Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the pharmacokinetics concentrations domain.			Idea or Concept	
C147234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147234>	C146996	Physical Examination Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the physical examination domain.			Idea or Concept	
C147235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147235>	C146996	Pharmacogenomics/Genetics Findings Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the pharmacogenomics/genetics findings domain.			Idea or Concept	
C147236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147236>	C146996	Pharmacogenomics/Genetics Methods and Supporting Information Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the pharmacogenomics/genetics methods and supporting information domain.			Idea or Concept	
C147237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147237>	C146996	Palpable Masses Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the palpable masses domain.			Idea or Concept	
C147238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147238>	C146996	Pharmacokinetic Parameters Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the pharmacokinetic parameters domain.			Idea or Concept	
C147239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147239>	C146996	Procedures Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the procedures domain.			Idea or Concept	
C147240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147240>	C146996	Questionnaires Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the questionnaires domain.			Idea or Concept	
C147241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147241>	C146996	ECG QT Correction Model Data Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the ECG QT correction model data domain.			Idea or Concept	
C147242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147242>	C146996	Respiratory Test Results Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the respiratory test results domain.			Idea or Concept	
C147243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147243>	C146996	Reproductive System Findings Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the reproductive system findings domain.			Idea or Concept	
C147244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147244>	C146996	Disease Response Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the disease response domain.			Idea or Concept	
C147245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147245>	C146996	Subject Biomarker Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the subject biomarker domain.			Idea or Concept	
C147246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147246>	C146996	Subject Characteristics Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the subject characteristics domain.			Idea or Concept	
C147247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147247>	C146996	Subject Elements Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the subject elements domain.			Idea or Concept	
C147248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147248>	C146996	Subject Stages Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the subject stages domain.			Idea or Concept	
C147249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147249>	C146996	Subject Disease Milestones Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the subject disease milestones domain.			Idea or Concept	
C147250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147250>	C146996	Skin Response Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the skin response domain.			Idea or Concept	
C147251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147251>	C146996	Subject Status Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the subject status domain.			Idea or Concept	
C147252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147252>	C146996	Substance Use Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the substance use domain.			Idea or Concept	
C147253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147253>	C146996	Subject Visits Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the subject visits domain.			Idea or Concept	
C147254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147254>	C146996	Trial Arms Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the trial arms domain.			Idea or Concept	
C147255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147255>	C146996	Trial Disease Assessments Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the trial disease assessments domain.			Idea or Concept	
C147256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147256>	C146996	Trial Elements Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the trial elements domain.			Idea or Concept	
C147257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147257>	C146996	Tumor Findings Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the tumor findings domain.			Idea or Concept	
C147258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147258>	C146996	Trial Inclusion and Exclusion Criteria Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the trial inclusion/exclusion criteria domain.			Idea or Concept	
C147259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147259>	C146996	Trial Disease Milestones Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the trial disease milestones domain.			Idea or Concept	
C147260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147260>	C146996	Trial Paths Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the trial paths domain.			Idea or Concept	
C147261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147261>	C146996	Tumor Response Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the tumor response domain.			Idea or Concept	
C147262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147262>	C146996	Trial Summary Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the trial summary domain.			Idea or Concept	
C147263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147263>	C146996	Trial Stages Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the trial stages domain.			Idea or Concept	
C147264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147264>	C146996	Tumor/Lesion Identification Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the tumor/lesion identification domain.			Idea or Concept	
C147265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147265>	C146996	Trial Visits Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the trial visits domain.			Idea or Concept	
C147266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147266>	C146996	Trial Sets Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the trial sets domain.			Idea or Concept	
C147267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147267>	C146996	Urinary System Findings Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the urinary system findings domain.			Idea or Concept	
C147268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147268>	C146996	Vital Signs Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the vital signs domain.			Idea or Concept	
C147269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147269>	C146996	Whole Body Findings Supplemental Qualifiers Dataset	A dataset containing supplemental information, specifically non-standard variables, to parent records in the whole body findings domain.			Idea or Concept	
C147270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147270>	C49556	Trial Disease Milestones Domain|TM|Trial Disease Milestones	A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to trial disease milestones.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147271>	C41079	CDISC Study Reference Class|STUDY REFERENCE|Study Reference	This special purpose SDTM class contains further descriptions of study-specific identifiers that will be used in subject based domains. (CDISC)			Conceptual Entity	CDISC Define-XML General Observation Class Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147272>	C210010	Binding Antidrug Antibody Measurement|ADA_BAB|Binding ADA Measurement|Binding Antidrug Antibody|Binding Antidrug Antibody	The determination of the binding antidrug antibody in a biological sample.			Laboratory Procedure	CDISC SDTM Immunogenicity Specimen Assessments Test Code Terminology|CDISC SDTM Immunogenicity Specimen Assessments Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147273>	C210010	Neutralizing Binding Antidrug Antibody Measurement|ADA_NAB|NADA Measurement|Neutralizing ADA Measurement|Neutralizing Binding Antidrug Antibody|Neutralizing Binding Antidrug Antibody	The determination of the neutralizing binding antidrug antibody in a biological sample.			Laboratory Procedure	CDISC SDTM Immunogenicity Specimen Assessments Test Code Terminology|CDISC SDTM Immunogenicity Specimen Assessments Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147274>	C210010	Neutralizing Cross-Reacting Binding Antidrug Antibody Measurement|ADA_NX|Cross-Reactive NADA Measurement|Neutraliz Cross-React Bind Antidrug AB|Neutraliz Cross-React Bind Antidrug AB|Neutralizing Cross-Reactive ADA Measurement|Neutralizing Cross-Reactive Binding Antidrug Antibody	The determination of the neutralizing cross-reactive binding antidrug antibody in a biological sample.			Laboratory Procedure	CDISC SDTM Immunogenicity Specimen Assessments Test Code Terminology|CDISC SDTM Immunogenicity Specimen Assessments Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147275>	C210010	Cross-Reactive Binding Antidrug Antibody Measurement|ADA_X|Cross-Reactive Binding ADA Measurement|Cross-Reactive Binding Antidrug Antibody|Cross-Reactive Binding Antidrug Antibody	The determination of the cross-reactive binding antidrug antibody in a biological sample.			Laboratory Procedure	CDISC SDTM Immunogenicity Specimen Assessments Test Code Terminology|CDISC SDTM Immunogenicity Specimen Assessments Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147276>	C181398	Arachis hypogaea Antigen IgE Antibody Measurement	The determination of the amount of Arachis hypogaea antigen IgE antibody present in a sample.			Laboratory Procedure	
C147277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147277>	C181398	Triticum aestivum Antigen IgE Antibody Measurement	The determination of the amount of Triticum aestivum antigen IgE antibody present in a sample.			Laboratory Procedure	
C147278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147278>	C181398	Glycine max Antigen IgE Antibody Measurement	The determination of the amount of Glycine max antigen IgE antibody present in a sample.			Laboratory Procedure	
C147279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147279>	C181398	Zea mays Antigen IgE Antibody Measurement	The determination of the amount of Zea mays antigen IgE antibody present in a sample.			Laboratory Procedure	
C147280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147280>	C181398	Cow Milk Protein Antigen IgE Antibody Measurement	The determination of the amount of cow milk protein antigen IgE antibody present in a sample.			Laboratory Procedure	
C147281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147281>	C181398	Egg White Antigen IgE Antibody Measurement	The determination of the amount of egg white antigen IgE antibody present in a sample.			Laboratory Procedure	
C147282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147282>	C181398	White Oak Pollen IgE Antibody Measurement	The determination of the amount of white oak pollen IgE antibody present in a sample.			Laboratory Procedure	
C147283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147283>	C81971|C182150	White Elm Pollen IgG Antibody Measurement	The determination of the amount of white elm pollen IgG antibody present in a sample.			Laboratory Procedure	
C147284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147284>	C181398	Boxelder Pollen IgE Antibody Measurement	The determination of the amount of boxelder pollen IgE antibody present in a sample.			Laboratory Procedure	
C147285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147285>	C181398	Common Ragweed Pollen IgE Antibody Measurement	The determination of the amount of common ragweed pollen IgE antibody present in a sample.			Laboratory Procedure	
C147286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147286>	C181398	Cladosporium herbarum IgE Antibody Measurement	The determination of the amount of Cladosporium herbarum IgE antibody present in a sample.			Laboratory Procedure	
C147287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147287>	C181398	Penicillium chrysogenum IgE Antibody Measurement|Penicillium chrysogenum IgE Antibody	The determination of the amount of Penicillium chrysogenum IgE antibody present in a sample.			Laboratory Procedure	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147288>	C49237	Acetone Measurement|ACETONE|ACETONE|Acetone|Acetone|Acetone	The determination of the amount of acetone present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SDTM Tobacco Product Testing Test Code Terminology|CDISC SDTM Tobacco Product Testing Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147289>	C81185|C156535	Acylcarnitine to Free Carnitine Ratio Measurement|ACRNCRNF|Acylcarnitine/Carnitine, Free|Acylcarnitine/Carnitine, Free	The determination of the ratio of acylcarnitine compared to free carnitine present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147290>	C64430	ADAM Metallopeptidase Domain 8 Measurement|A Disintegrin And Metalloproteinase Domain 8|ADAM Metallopeptidase Domain 8|ADAM Metallopeptidase Domain 8|ADAM8|ADAM8 Measurement|Soluble CD156a	The determination of the amount of ADAM metallopeptidase domain 8 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147291>	C74732	Alpha Fetoprotein Adjusted for Body Weight Measurement|AFPADJBW|Alpha Fetoprotein Adj for Body Weight|Alpha Fetoprotein Adj for Body Weight	The determination of the amount of alpha fetoprotein, adjusted for body weight, present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147292>	C64430	Apolipoprotein A1 to Apolipoprotein B Ratio Measurement|ALA1ALB|Apolipoprotein A1/Apolipoprotein B|Apolipoprotein A1/Apolipoprotein B	The determination of the ratio of apolipoprotein A1 compared to apolipoprotein B present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147293>	C75913	Albumin Clearance|ALBC	The determination of the clearance of endogenous albumin, used for evaluating the glomerular filtration rate.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147294>	C64432	Bone Alkaline Phosphatase to Total Alkaline Phosphatase Ratio Measurement|ALPBALP|Alk Phos, Bone/Total Alk Phos|Alk Phos, Bone/Total Alk Phos|Alkaline Phosphatase, Bone/Total Alkaline Phosphatase	The determination of the ratio of bone-specific alkaline phosphatase compared to total alkaline phosphatase present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147295>	C64432	Intestinal Alkaline Phosphatase to Total Alkaline Phosphatase Ratio Measurement|ALPIALP|Alk Phos, Intestinal/Total Alk Phos|Alk Phos, Intestinal/Total Alk Phos|Alkaline Phosphatase, Intestinal/Total Alkaline Phosphatase	The determination of the ratio of intestinal-specific alkaline phosphatase compared to total alkaline phosphatase present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147296>	C64432	Liver Alkaline Phosphatase to Total Alkaline Phosphatase Ratio Measurement|ALPLALP|Alk Phos, Liver/Total Alk Phos|Alk Phos, Liver/Total Alk Phos|Alkaline Phosphatase, Liver/Total Alkaline Phosphatase	The determination of the ratio of liver-specific alkaline phosphatase compared to total alkaline phosphatase present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147297>	C210010	Acetylcholine Receptor Modulation Antibody to Acetylcholine Receptor Antibody Ratio Measurement|ACH Receptor Modulation Antibody to ACH Receptor Antibody Ratio Measurement	The determination of the ratio of acetylcholine receptor modulation antibody compared to acetylcholine receptor antibody present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	
C147298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147298>	C49237	Anabasine Measurement|ANABASN|ANABASN|Anabasine|Anabasine|Anabasine	The determination of the amount of anabasine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SDTM Tobacco Product Testing Test Code Terminology|CDISC SDTM Tobacco Product Testing Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147299>	C64430	Alpha-N-acetylglucosaminidase Measurement|ANAG|Alpha-N-acetylglucosaminidase|Alpha-N-acetylglucosaminidase	The determination of the amount of alpha-N-acetylglucosaminidase present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C1472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1472>	C2156	Bizelesin|BIZELESIN|Benzo(1,2-b:4,3-b')dipyrrol-4-ol, 6,6'-(carbonylbis(imino-1H-indole-5,2-diylcarbonyl))bis(8-(chloromethyl)-3,6,7,8-tetrahydro-1-methyl-, (S-(R*,R*)))-|Benzo[1,2-b:4,3-b']dipyrrol-4-ol, 6, 6'-[carbonylbis(imino- 1H-indole-5, 2-diylcarbonyl)]bis[8-(chloromethyl)-3,6,7,8-tetrahydro-1-methyl-, (S-(R*,R*))]|U-77779|bizelesin	A synthetic cyclopropylpyrroloindole antineoplastic antibiotic.  Bizelesin binds to the minor groove of DNA and induces interstrand cross-linking of DNA, thereby inhibiting DNA replication and RNA synthesis.  Bizelesin also enhances p53 and p21 induction and triggers G2/M cell-cycle arrest, resulting in cell senescence without apoptosis. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C147300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147300>	C120626	Atypical Neutrophil Cytoplasmic Antibody Measurement|Atypical ANCA Measurement	The determination of the amount of atypical neutrophil cytoplasmic antibody present in a sample.			Laboratory Procedure	
C147301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147301>	C120626	Classic Neutrophil Cytoplasmic Antibody Measurement|Classical ANCA Measurement	The determination of the amount of classic neutrophil cytoplasmic antibody present in a sample.			Laboratory Procedure	
C147302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147302>	C210010	Perinuclear Neutrophil Cytoplasmic Antibody Measurement|Perinuclear ANCA Measurement|p-ANCA Measurement	The determination of the amount of perinuclear neutrophil cytoplasmic antibody present in a sample.			Laboratory Procedure	
C147303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147303>	C74685	Anion Gap 3 Measurement|ANIONG3|Anion Gap 3|Anion Gap 3	The determination of the amount of unmeasured anions (computed as sodium minus the chloride and bicarbonate) present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147304>	C74685	Anion Gap 4 Measurement|ANIONG4|Anion Gap 4|Anion Gap 4	The determination of the amount of unmeasured anions (computed as the difference between the sum of serum sodium and serum potassium, and the sum of the serum bicarbonate and chloride) present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147305>	C49237	Arsenic Measurement|ARSENIC|ARSENIC|Arsenic|Arsenic|Arsenic|As	The determination of the amount of arsenic present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SDTM Tobacco Product Testing Test Code Terminology|CDISC SDTM Tobacco Product Testing Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147306>	C81958	Antithrombin Activity Actual to Control Ratio Measurement|ATHMBAAC|Antithrombin Activity Actual/Antithrombin Activity Control|Antithrombin Activity Actual/Control|Antithrombin Activity Actual/Control|Antithrombin Activity Actual/Normal	The determination of the ratio of the biological activity of antithrombin in a subject's specimen when compared to the same activity in a control specimen. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147307>	C49237	Adenosine Triphosphate Measurement|ATP|Adenosine Triphosphate|Adenosine Triphosphate	The determination of the amount of adenosine triphosphate present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147308>	C81979|C81969	Beta-2 Glycoprotein 1 IgA Antibody Measurement	The determination of the amount of beta-2 glycoprotein 1 IgA antibody present in a sample.			Laboratory Procedure	
C147309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147309>	C74957	Base Deficit|BASEDEF	The determination of the amount of alkali required to return a biological specimen to a normal pH under standard conditions.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147310>	C178941|C122098	Borrelia burgdorferi IgG and IgM Antibody Measurement	The determination of the amount of Borrelia burgdorferi IgG and IgM antibody present in a sample.			Laboratory Procedure	
C147311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147311>	C48938	Basophilic Erythroblast Count|BLASTERY|Basophilic Erythroblast|Basophilic Erythroblast	The determination of the amount of basophilic erythroblasts present in a sample from an experimental organism.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147313>	C80160	Complement C1 Esterase Inhibitor Measurement|C1 Esterase Inhibitor Measurement|C1-Inh Measurement|C1-Inhibitor Measurement|C1INH|Complement C1 Esterase Inhibitor|Complement C1 Esterase Inhibitor|SERPING1 Measurement	The determination of the amount of complement C1 esterase inhibitor present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147314>	C119272	Calcium Corrected for Total Protein Measurement|CACRTP|Calcium Corrected for Total Protein|Calcium Corrected for Total Protein	The determination of the amount of calcium, which has been corrected for total protein, present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147315>	C81867	Chemokine (C-C Motif) Ligand 21 Measurement|6Ckine|CCL21|CCL21 Measurement|Chemokine (C-C Motif) Ligand 21|Chemokine (C-C Motif) Ligand 21|Secondary Lymphoid Tissue Chemokine	The determination of the amount of chemokine (C-C motif) ligand 21 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147316>	C81971	Cyclic Citrullinated Peptide IgG Antibody Measurement	The determination of the amount of cyclic citrullinated peptide IgG antibody present in a sample.			Laboratory Procedure	
C147317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147317>	C80160	Complement CH100 Measurement|CH100|CH100|Complement CH100|Complement CH100|Total Hemolytic Complement CH100	The determination of the amount of complement required to lyse 100 percent of red blood cells in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147318>	C210010	Chromatin Antibody Measurement	The determination of the amount of chromatin antibody present in a sample.			Laboratory Procedure	
C147319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147319>	C64489	Macromolecular Type 1 Creatine Kinase to Total Creatine Kinase Ratio Measurement|CK, Macromolecular Type 1/Total CK|CK, Macromolecular Type 1/Total CK|CKMT1CK|Creatine Kinase, Macromolecular Type 1/Total Creatine Kinase|Macro-CK Type 1 to Total Creatine Kinase Ratio Measurement	The determination of the ratio of macromolecular type 1 creatine kinase compared to total creatine kinase present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147320>	C64489	Macromolecular Type 2 Creatine Kinase to Total Creatine Kinase Ratio Measurement|CK, Macromolecular Type 2/Total CK|CK, Macromolecular Type 2/Total CK|CKMT2CK|Creatine Kinase, Macromolecular Type 2/Total Creatine Kinase|Macro-CK Type 2 to Total Creatine Kinase Ratio Measurement	The determination of the ratio of macromolecular type 2 creatine kinase compared to total creatine kinase present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147321>	C49237	Ubiquinone 10 Measurement|COQ10|Coenzyme Q10|Ubiquinone 10|Ubiquinone 10	The determination of the amount of ubiquinone 10 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147322>	C75340	Carbamazepine Measurement|CRBMZPN|Carbamazepine|Carbamazepine	The determination of the amount of carbamazepine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147323>	C81183	Carnitine Ester Measurement|CRNTESTR|Carnitine Esters|Carnitine Esters	The determination of the amount of carnitine ester present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147324>	C25747	Creatinine Clearance Adjusted for BSA|CRTCLRBS	The determination of the clearance of creatinine and whose result is adjusted for body surface area.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147325>	C61014	Cryoglobulin Volume to Serum Volume Ratio Measurement|CRYGLBSR|Cryoglobulin Volume/Serum Volume|Cryoglobulin Volume/Serum Volume	The determination of the ratio of cryoglobulin volume compared to serum volume present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147326>	C64430	Cryofibrinogen Measurement|CRYOFBRN|Cryofibrinogen|Cryofibrinogen	The determination of the amount of cryofibrinogen present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147327>	C74691	Citalopram Measurement|CTLPRM|Citalopram|Citalopram	The determination of the amount of citalopram present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147328>	C81867	Chemokine (C-X-C Motif) Ligand 13 Measurement|B Lymphocyte Chemoattractant|CXCL13|CXCL13 Measurement|Chemokine (C-X-C Motif) Ligand 13|Chemokine (C-X-C Motif) Ligand 13	The determination of the amount of chemokine (C-X-C motif) ligand 13 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147329>	C81867|C186057	Chemokine (C-X-C Motif) Ligand 3 Measurement|CCL3 Measurement|CXCL3|Chemokine (C-X-C Motif) Ligand 3|Chemokine (C-X-C Motif) Ligand 3|GRO Gamma|MIP2 Beta|MIP2B|Macrophage Inflammatory Protein 2-Beta	The determination of the amount of chemokine (C-X-C motif) ligand 3 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147330>	C81867	Chemokine (C-X-C Motif) Ligand 4 Measurement|CXCL4|CXCL4 Measurement|Chemokine (C-X-C Motif) Ligand 4|Chemokine (C-X-C Motif) Ligand 4|Oncostatin A|PLF4|Platelet Factor 4	The determination of the amount of chemokine (C-X-C mofitf) ligand 4 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147331>	C49237	Cystathionine Measurement|CYSTHION|Cystathionine|Cystathionine	The determination of the amount of cystathionine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147332>	C210012|C210010	Dengue Virus Antibody Measurement	The determination of the amount of Dengue virus antibody present in a sample.			Laboratory Procedure	
C147333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147333>	C74691	Desvenlafaxine Measurement|DSVLFXN|Desvenlafaxine|Desvenlafaxine|O-Desmethylvenlafaxine	The determination of the amount of desvenlafaxine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147334>	C81969|C163432	Endomysial IgA Antibody Measurement	The determination of the amount of endomysial IgA antibody present in a sample.			Laboratory Procedure	
C147335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147335>	C75345	Estrogen Measurement|ESTROGEN|Estrogen|Estrogen|Oestrogen	The determination of the amount of estrogen present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147336>	C98799	von Willebrand Factor Multimers Measurement|FACTVWMU|vWF Multimers Measurement|von Willebrand Factor Multimers|von Willebrand Factor Multimers	The determination of the amount of von Willebrand factor multimers present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147337>	C80157	Very Long Chain Fatty Acids Measurement|FATACVLC|Fatty Acids, Very Long Chain|Fatty Acids, Very Long Chain|VLCFA Measurement	The determination of the amount of very long chain fatty acids present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147338>	C74697	Fentanyl Measurement|FENTANYL|Fentanyl|Fentanyl	The determination of the amount of fentanyl present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147339>	C146998	Free Erythrocyte Protoporphyrin Measurement|Erythrocyte Protoporphyrin, Free|Erythrocyte Protoporphyrin, Free|FEP	The determination of the amount of free erythrocyte protoporphyrin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147340>	C74691	Fluvoxamine Measurement|FLUVOXAM|Fluvoxamine|Fluvoxamine	The determination of the amount of fluvoxamine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147341>	C146998	Free Protoporphyrin Measurement|FPP|Protoporphyrin, Free|Protoporphyrin, Free	The determination of the amount of free protoporphyrin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147342>	C49237	Fructose Measurement|FRUCTOSE|Fructose|Fructose	The determination of the amount of fructose present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147343>	C48938	Filamentous Fungi Count|FUNGIFIL|FUNGIFIL|Fungi, Filamentous|Fungi, Filamentous|Fungi, Filamentous	The determination of the amount of filamentous fungus present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147344>	C48938	Yeast-Like Fungi Count|FUNGYLK|FUNGYLK|Fungi, Yeast-Like|Fungi, Yeast-Like|Fungi, Yeast-Like	The determination of the amount of yeast-like fungus present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147345>	C103399	Factor VIII Activity Actual to Control Ratio Measurement|FVIIIAAC|Factor VIII Activity Actual/Control|Factor VIII Activity Actual/Control|Factor VIII Activity Actual/Factor VIII Activity Control|Factor VIII Activity Actual/Normal	The determination of the ratio of the biological activity of factor VIII dependent coagulation in a subject's specimen when compared to the same activity in a control specimen. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147346>	C105442	Factor XIV Activity Actual to Control Ratio Measurement|FXIVAAC|Factor XIV Activity Actual/Control|Factor XIV Activity Actual/Control|Factor XIV Activity Actual/Factor XIV Activity Control|Factor XIV Activity Actual/Normal|Protein C Activity Actual/Control	The determination of the ratio of the biological activity of factor XIV dependent coagulation in a subject's specimen when compared to the same activity in a control specimen. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147347>	C210010	Gliadin Antibody Measurement	The determination of the amount of gliadin antibody present in a sample.			Laboratory Procedure	
C147348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147348>	C81969	Gliadin IgA Antibody Measurement	The determination of the amount of gliadin IgA antibody present in a sample.			Laboratory Procedure	
C147349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147349>	C81971	Gliadin IgG Antibody Measurement	The determination of the amount of gliadin IgG antibody present in a sample.			Laboratory Procedure	
C147351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147351>	C67208	Granulocytes to Leukocytes Ratio Measurement|GRANLE|GRANLE|Gran/Leuk|Gran/Leuk|Granulocytes/Leukocytes|Granulocytes/Leukocytes|Polymorphonuclear Leukocytes/Leukocytes	The determination of the ratio of granulocytes compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Cell Phenotyping Test Code Terminology|CDISC SDTM Cell Phenotyping Test Name Terminology|CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147352>	C74692	Hydroxyalprazolam Measurement|HALPRZLM|Hydroxyalprazolam|Hydroxyalprazolam	The determination of the amount of hydroxyprazolam present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147353>	C64848	Hemoglobin A2 Prime to Total Hemoglobin Ratio Measurement|HBA2PHB|Hemoglobin A2 Prime/Total Hemoglobin|Hemoglobin A2 Prime/Total Hemoglobin	The determination of the ratio of hemoglobin A2 prime compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147354>	C64848	Hemoglobin Barts to Total Hemoglobin Ratio Measurement|HBBARTHB|Hemoglobin Barts/Total Hemoglobin|Hemoglobin Barts/Total Hemoglobin	The determination of the ratio of hemoglobin Barts compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147355>	C64848	Carboxyhemoglobin to Total Hemoglobin Ratio Measurement|Carboxyhemoglobin/Total Hemoglobin|Carboxyhemoglobin/Total Hemoglobin|HBCOHGB	The determination of the ratio of carboxyhemoglobin compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147356>	C64848	Hemoglobin G Coushatta to Total Hemoglobin Ratio Measurement|HBGCHTHB|Hemoglobin G Coushatta/Total Hemoglobin|Hemoglobin G Coushatta/Total Hemoglobin	The determination of the ratio of hemoglobin G compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147357>	C64848	Hemoglobin Lepore to Total Hemoglobin Ratio Measurement|HBLEPRHB|Hemoglobin Lepore/Total Hemoglobin|Hemoglobin Lepore/Total Hemoglobin	The determination of the ratio of hemoglobin Lepore compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147358>	C64848	Hemoglobin O-Arab to Total Hemoglobin Ratio Measurement|HBOARBHB|Hemoglobin O-Arab/Total Hemoglobin|Hemoglobin O-Arab/Total Hemoglobin	The determination of the ratio of hemoglobin O-Arab compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147359>	C64848	Oxyhemoglobin to Total Hemoglobin Ratio Measurement|FO2 Hb|Fractioned Oxyhemoglobin|HBOXHGB|Oxyhemoglobin/Total Hemoglobin|Oxyhemoglobin/Total Hemoglobin	The determination of the ratio of oxyhemoglobin compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147360>	C64851	Free Choriogonadotropin Beta Measurement|Choriogonadotropin Beta, Free|Choriogonadotropin Beta, Free|HCGFR	The determination of the amount of free choriogonadotropin beta present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147361>	C147128	Intact Choriogonadotropin Measurement|Choriogonadotropin, Intact|Choriogonadotropin, Intact|HCGNDI	The determination of the amount of intact choriogonadotropin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147362>	C74949	HDL Cholesterol to Total Cholesterol Ratio Measurement|HDL Cholesterol/Total Cholesterol|HDL Cholesterol/Total Cholesterol|HDLCCHOL	The determination of the ratio of HDL cholesterol compared to total cholesterol present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147363>	C64848	Hemoglobin A1 to Total Hemoglobin Ratio Measurement|HGBA1HGB|Hemoglobin A1/Total Hemoglobin|Hemoglobin A1/Total Hemoglobin	The determination of the ratio of hemoglobin A1 compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147364>	C64848	Hemoglobin D to Total Hemoglobin Ratio Measurement|HGBDHGB|Hemoglobin D/Total Hemoglobin|Hemoglobin D/Total Hemoglobin	The determination of the ratio of hemoglobin D compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147365>	C64848	Hemoglobin E to Total Hemoglobin Ratio Measurement|HGBEHGB|Hemoglobin E/Total Hemoglobin|Hemoglobin E/Total Hemoglobin	The determination of the ratio of hemoglobin E compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147366>	C64848	Hemoglobin F to Total Hemoglobin Ratio Measurement|HGBFHGB|Hemoglobin F/Total Hemoglobin|Hemoglobin F/Total Hemoglobin	The determination of the ratio of hemoglobin F compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147367>	C64848	Methemoglobin to Total Hemoglobin Ratio Measurement|FMET HB|Fractionated Methemoglobin|HGBMHGB|Methemoglobin/Total Hemoglobin|Methemoglobin/Total Hemoglobin	The determination of the ratio of methemoglobin compared to total hemoglobin present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147368>	C64430	Heat Shock Protein 70 Measurement|HSP70|HSP70 Measurement|Heat Shock Protein 70|Heat Shock Protein 70	The determination of the amount of heat shock protein 70 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147369>	C64430	Heat Shock Protein 90 Alpha Measurement|HSP90 Measurement|HSP90A|Heat Shock Protein 90 Alpha|Heat Shock Protein 90 Alpha	The determination of the amount of heat shock protein 90 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147370>	C74791	17-Hydroxyprogesterone Measurement|17-Hydroxyprogesterone|17-Hydroxyprogesterone|17-OHP|HYPGST17	The determination of the amount of 17-hydroxyprogesterone present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147371>	C74949	IDL Cholesterol and VLDL Cholesterol Subtype 3 Measurement|IDL Cholesterol and VLDL Cholesterol Subtype 3|IDL+VLDL Cholesterol Subtype 3|IDL+VLDL Cholesterol Subtype 3|IDLVLDL3	The determination of the amount of IDL cholesterol and VLDLD cholesterol subtype 3 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147372>	C81971	Immunoglobulin G to Albumin Ratio Measurement|IGGALB|IgG to Albumin Ratio Measurement|IgG/Albumin|Immunoglobulin G/Albumin|Immunoglobulin G/Albumin	The determination of the ratio of IgG compared to albumin present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147373>	C75913	IgG Clearance|IGGC	The determination of the clearance of endogenous IgG, used for evaluating the glomerular filtration rate.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147374>	C81971|C75913	IgG Clearance to Albumin Clearance Ratio Measurement|IGGCALBC|IgG Clearance/Albumin Clearance|IgG Clearance/Albumin Clearance	The determination of the ratio of IgG clearance compared to albumin clearance present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147375>	C81971	IgG Synthesis Rate|IGGSYNRT	The determination of the IgG synthesis rate in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147376>	C81869	Immunoglobulin Light Chain Measurement|IMMGLC|Immunoglobulin Light Chains|Immunoglobulin Light Chains|Serum Free Immunoglobulin Light Chain, NOS	The determination of the amount of immunoglobulin light chain present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C147377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147377>	C74788	Free Insulin Measurement|INSLNFR|Insulin, Free|Insulin, Free	The determination of the amount of free insulin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147378>	C210012|C210010	Japanese Encephalitis Virus Antibody Measurement	The determination of the amount of Japanese encephalitis virus antibody present in a sample.			Laboratory Procedure	
C147379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147379>	C147376	Kappa Light Chain Measurement|KAPPALC|Kappa Light Chain|Kappa Light Chain	The determination of the amount of kappa light chain present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147380>	C48938	Keratocyte Count|KERAT|Keratocyte|Keratocyte	The determination of the amount of keratocytes present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147381>	C74949	Lecithin to Sphingomyelin Ratio Measurement|LCTHSPGM|LS Ratio|Lecithin/Sphingomyelin|Lecithin/Sphingomyelin	The determination of the ratio of lecithin compared to sphingomyelin present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147382>	C49237	Lead Measurement|LEAD|LEAD|Lead|Lead|Lead|Pb	The determination of the amount of lead present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SDTM Tobacco Product Testing Test Code Terminology|CDISC SDTM Tobacco Product Testing Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147383>	C48938	Leukocytes Corrected for Nucleated Erythrocytes Count|LEUKCRBC|Leukocytes Corrected for Nucleated Erythrocytes|Leuks Corrected for Nucl Erythrocytes|Leuks Corrected for Nucl Erythrocytes	The determination of the amount of leukocytes, which has been corrected for nucleated erythrocytes, present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147384>	C147376	Lambda Light Chain Measurement|LMBDLC|Lambda Light Chain|Lambda Light Chain	The determination of the amount of lambda light chain present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147385>	C74957	Liver Fibrosis Score|LVFBRSC	The determination of the liver pathology through the assessment of multiple blood test parameters, taking into account the age and sex of the patient.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147386>	C75340	Levetiracetam Measurement|LVTRCTM|Levetiracetam|Levetiracetam	The determination of the amount of levetiracetam present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147387>	C51949	Clefted Lymphocytes Count|LYMCLF|Lymphocytes, Clefted|Lymphocytes, Clefted	The determination of the amount of clefted lymphocytes present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147388>	C67208	Clefted Lymphocytes to Leukocytes Ratio Measurement|LYMCLFLE|Lymphocytes, Clefted/Leukocytes|Lymphocytes, Clefted/Leukocytes	The determination of the ratio of clefted lymphocytes compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147389>	C67208	Lymphoma Cells to Leukocytes Ratio Measurement|LYMMCELE|Lymphoma Cells/Leukocytes|Lymphoma Cells/Leukocytes	The determination of the ratio of lymphoma cells compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147390>	C49237	Macroscopic Blood Measurement|MACROBLD|Macroscopic Blood|Macroscopic Blood|Visible Blood	The determination of the amount or presence of macroscopic blood present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147391>	C49237	Meconium Measurement|MECONIUM|Meconium|Meconium	The determination of the amount of meconium present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147392>	C74697	Meperidine Measurement|MEPRDN|Meperidine|Meperidine	The determination of the amount of meperidine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147393>	C49237	Mercury Measurement|Hg|MERCURY|MERCURY|Mercury|Mercury|Mercury	The determination of the amount of mercury present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SDTM Tobacco Product Testing Test Code Terminology|CDISC SDTM Tobacco Product Testing Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147394>	C49237	Methanol Measurement|METHANOL|Methanol|Methanol	The determination of the amount of methanol present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147395>	C210010	Mitochondrial M2 Antibody Measurement|AMA-M2 Measurement	The determination of the amount of mitochondrial M2 antibody present in a sample.			Laboratory Procedure	
C147396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147396>	C67208	Monocytes and Macrophages to Leukocytes Ratio Measurement|MONMPHLE|MONMPHLE|Monocytes and Macrophages/Leukocytes|Monocytes and Macrophages/Leukocytes|Monocytes and Macrophages/Leukocytes	The determination of the ratio of monocytes and macrophages compared to total leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Cell Phenotyping Test Code Terminology|CDISC SDTM Cell Phenotyping Test Name Terminology|CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147397>	C92291	Monoclonal Protein to Total Protein Ratio Measurement|M Protein to Total Protein Ratio Measurement|M Protein/Total Protein|M-Spike Protein/Total Protein|MONOPTPT|Monoclonal Protein Spike/Total Protein|Monoclonal Protein/Total Protein|Monoclonal Protein/Total Protein|Myeloma Protein/Total Protein	The determination of the ratio of monoclonal protein compared to total protein present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147398>	C48938	Mesothelial Cells Count|MSTHCE|Mesothelial Cells|Mesothelial Cells	The determination of the amount of mesothelial cells present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147399>	C67208	Mesothelial Cells to Leukocytes Ratio Measurement|MSTHCELE|Mesothelial Cells/Leukocytes|Mesothelial Cells/Leukocytes	The determination of the ratio of mesothelial cells compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C1473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1473>	C281	Recombinant Soluble T4	A recombinant form of CD4 antigen with anti-HIV application. Recombinant soluble T4 antigen (rsT4) is derived from cell surface antigen CD4 lacking its transmembrane and cytoplasmic domains, thereby the agent is mobile within tissues. rsT4 binds to the envelope glycoprotein gp110 of HIV and prevents the binding of virus to CD4 positive lymphocytes, resulting in an inhibition of virus infectivity.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	NCI Drug Dictionary Terminology
C147400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147400>	C116198	Free Metanephrine Measurement|MTNEPHFR|Metanephrine, Free|Metanephrine, Free	The determination of the amount of free metanephrine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147401>	C48938	Nonhematic Cells Count|NHMCE|Nonhematic Cells|Nonhematic Cells	The determination of the amount of nonhematic cells present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147402>	C67208	Nonhematic Cells to Leukocytes Ratio Measurement|NHMCELE|Nonhematic Cells/Leukocytes|Nonhematic Cells/Leukocytes	The determination of the ratio of nonhematic cells compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147403>	C75340	Nicotine Measurement|NICOTINE|NICOTINE|Nicotine|Nicotine|Nicotine	The determination of the amount of nicotine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SDTM Tobacco Product Testing Test Code Terminology|CDISC SDTM Tobacco Product Testing Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147404>	C49237	N-Methylhistamine Measurement|N-methylhistamine|N-methylhistamine|NMH	The determination of the amount of N-methylhistamine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147405>	C48938	Basophilic Normoblast Count|Basophilic Normoblast|Basophilic Normoblast|NORMBASO	The determination of the amount of basophilic normoblasts present in a sample from an experimental organism.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147406>	C209443	Nornicotine Measurement|NORNCTN|NORNCTN|Nornicotine|Nornicotine|Nornicotine	The determination of the amount of nornicotine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SDTM Tobacco Product Testing Test Code Terminology|CDISC SDTM Tobacco Product Testing Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147407>	C96648	Neutral Fats Measurement|NTRLFAT|Neutral Fats|Neutral Fats	The determination of the amount of neutral fats present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147408>	C74760	Type 1 Collagen X-link N-Telopeptides to Creatinine Ratio Measurement|NTXICRT|T1 Collagen X-link N-Telopeptides/Creat|T1 Collagen X-link N-Telopeptides/Creat|Type I Collagen X-linked N-Telopeptides/Creatinine	The determination of the ratio of the type 1 collagen X-link N-telopeptides compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147409>	C74697	Oxymorphone Measurement|OXMORPHN|Oxymorphone|Oxymorphone	The determination of the amount of oxymorphone present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147410>	C74691	Paroxetine Measurement|PAROXET|Paroxetine|Paroxetine	The determination of the amount of paroxetine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147411>	C82625	Partial Pressure of Carbon Dioxide Adjusted for Body Temperature Measurement|PCO2 Adjusted for Body Temperature|PCO2ADJT|Partial Pressure Carbon Dioxide Adj Temp|Partial Pressure Carbon Dioxide Adj Temp	The determination of the partial pressure of carbon dioxide, adjusted for body temperature, present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147412>	C210010	Platelet Factor 4-Heparin Complex Induced Antibody Measurement	The determination of the amount of platelet factor-4 heparin complex induced antibody present in a sample.			Laboratory Procedure	
C147413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147413>	C75340	Phenytoin Measurement|PHENYTN|Phenytoin|Phenytoin	The determination of the amount of phenytoin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147414>	C49237	Phenylketone Measurement|PHNKET|Phenyl Ketones|Phenylketones|Phenylketones	The determination of the amount of phenylketone present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147415>	C48938	Agranular Platelets Count|PLATAGRN|Platelets, Agranular|Platelets, Agranular	The determination of the amount of agranular platelets present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147416>	C67208	Immature Plasma Cells to Total Cells Ratio Measurement|Immature Plasma Cells/Total Cells|Immature Plasma Cells/Total Cells|PLSIMCCE	The determination of the ratio of immature plasma cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147417>	C71251	Partial Pressure of Oxygen Adjusted for Body Temperature Measurement|PO2 Adjusted for Body Temperature|PO2ADJT|Partial Pressure Oxygen Adj for Temp|Partial Pressure Oxygen Adj for Temp	The determination of the partial pressure of oxygen, adjusted for body temperature, present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147418>	C48938	Polychromatophilic Erythroblast Count|POLYERY|Polychromatophilic Erythroblast|Polychromatophilic Erythroblast	The determination of the amount of polychromatophilic erythroblasts present in a sample from an experimental organism.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147419>	C48938	Polychromatophilic Normoblast Count|POLYNORM|Polychromatophilic Normoblast|Polychromatophilic Normoblast	The determination of the amount of polychromatophilic normoblasts present in a sample from an experimental organism.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147420>	C49237	Phosphatidylcholine to Albumin Ratio Measurement|PPTDCALB|Phosphatidylcholine/Albumin|Phosphatidylcholine/Albumin	The determination of the ratio of phosphatidylcholine compared to albumin present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147421>	C75345	Pregnenolone Measurement|PRGNENLN|Pregnenolone|Pregnenolone	The determination of the amount of pregnenolone present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147422>	C64430	Protein Pattern Measurement|PROTPATN|Protein Pattern|Protein Pattern	An assessment of the protein band pattern present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147423>	C49237	Phosphatidylglycerol to Lung Surfactant Ratio Measurement|PSDGLSRF|Phosphatidylglycerol/Lung Surfactant|Phosphatidylglycerol/Lung Surfactant|Phosphatidylglycerol/Pulmonary Surfactant	The determination of the ratio of phosphatidylglycerol compared to lung surfactant present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147424>	C100436	Protein S Activity Actual to Control Ratio Measurement|PTSAAC|Protein S Activity Actual/Control|Protein S Activity Actual/Control|Protein S Activity Actual/Normal|Protein S Activity Actual/Protein S Activity Control	The determination of the ratio of the biological activity of protein S in a subject's specimen when compared to the same activity in a control specimen. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147425>	C147424|C122142	Free Protein S Activity Actual to Control Ratio Measurement|PTSFAAC|Protein S Free Activity Actual/Control|Protein S Free Activity Actual/Control|Protein S Free Activity Actual/Normal|Protein S Free Activity Actual/Protein S Free Activity Control	The determination of the ratio of the biological activity of free protein S in a subject's specimen when compared to the same activity in a control specimen. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147426>	C74760	Pyridinoline to Creatinine Ratio Measurement|PYDCREAT|Pyridinoline/Creatinine|Pyridinoline/Creatinine	The determination of the ratio of pyridinoline compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147427>	C49237	Pyruvate Measurement|PYRUVATE|Pyruvate|Pyruvate|Pyruvic Acid	The determination of the amount of pyruvate present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147428>	C49237	Reducing Substance Measurement|RDCSUB|Reducing Substances|Reducing Substances	The determination of the amount of reducing substances present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147429>	C49237	Reducing Sugar Measurement|RDCSUG|Reducing Sugars|Reducing Sugars	The determination of the amount of reducing sugars present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147430>	C62662	Reptilase Activity Actual to Control Ratio Measurement|RPTLAAC|Reptilase Activity Actual/Control|Reptilase Activity Actual/Control|Reptilase Activity Actual/Normal|Reptilase Activity Actual/Reptilase Activity Control	The determination of the ratio of the biological activity of reptilase dependent coagulation in a subject's specimen when compared to the same activity in a control specimen. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147431>	C74675	Salicylates Measurement|SALCYLT|Salicylates|Salicylates	The determination of the amount of salicylates present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147432>	C74691	Sertraline Measurement|SERTRAL|Sertraline|Sertraline	The determination of the amount of sertraline present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147433>	C48938	Motile Sperm to Total Sperm Ratio Measurement|Motile Sperm/Total Sperm|Motile Sperm/Total Sperm|SPMMSPM	The determination of the ratio of motile sperm compared to total sperm present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147434>	C74793	Weakly Bound Testosterone Measurement|TESTOSWB|Testosterone, Weakly Bound|Testosterone, Weakly Bound	The determination of the amount of weakly bound testosterone present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147435>	C103446	Thyroglobulin Recovery Rate|TGLOBRR	The determination of the thyroglobulin recovery rate present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147436>	C74689	Tetrahydrocannabinol Measurement|Delta-9-Tetrahydrocannabinol|THC|THC|Tetrahydrocannabinol|Tetrahydrocannabinol	The determination of the amount of tetrahydrocannabinol present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147437>	C92745|C62662	Thrombin Activity Actual to Control Ratio Measurement|THMBAAC|Thrombin Activity Actual/Control|Thrombin Activity Actual/Control|Thrombin Activity Actual/Normal|Thrombin Activity Actual/Thrombin Activity Control	The determination of the ratio of the biological activity of thrombin dependent coagulation in a subject's specimen when compared to the same activity in a control specimen. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147438>	C81869	Thyroid Stimulating Immunoglobulin Measurement	The determination of the amount of thyroid stimulating immunoglobulin present in a sample.			Laboratory Procedure	
C147439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147439>	C74793	Free Testosterone to Testosterone Ratio Measurement|TSTFTSTT|Testosterone, Free/Testosterone|Testosterone, Free/Testosterone	The determination of the ratio of free testosterone compared to total testosterone present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147440>	C74793	Free Testosterone and Weakly Bound to Total Testosterone Ratio Measurement|TSTFWTST|Testosterone Free+Weakly Bound/Testost|Testosterone Free+Weakly Bound/Testost|Testosterone, Free and Weakly Bound/Testosterone	The determination of the ratio of free and weakly bound testosterone compared to total testosterone present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147441>	C81969|C163969	Tissue Transglutaminase IgA Antibody Measurement	The determination of the amount of tissue transglutaminase IgA antibody present in a sample.			Laboratory Procedure	
C147442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147442>	C81972|C163969	Tissue Transglutaminase IgM Antibody Measurement	The determination of the amount of tissue transglutaminase IgM antibody present in a sample.			Laboratory Procedure	
C147443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147443>	C64430	Ubiquitin Protein Measurement|UBQN|Ubiquitin Protein|Ubiquitin Protein	The determination of the amount of ubiquitin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147444>	C74691	Venlafaxine Measurement|VENLAFAX|Venlafaxine|Venlafaxine	The determination of the amount of venlafaxine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147445>	C84818	Vitamin D2 and Vitamin D3 and 25-Hydroxy Vitamin D2 and 25-Hydroxy Vitamin D3 Measurement|VITD23OH|Vitamin D + Metabolites|Vitamin D + Metabolites|Vitamin D2 + Vitamin D3 + 25-Hydroxy Vitamin D2 + 25-Hydroxy Vitamin D3|Vitamin D2 + Vitamin D3 + 25-Hydroxy Vitamin D2 + 25-Hydroxy Vitamin D3|Vitamin D2 D3 25-OH|Vitamin D2 D3 25-OH	The determination of the amount of vitamin D2, vitamin D3, and 25-hydroxyvitamin D present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147446>	C84818	25-Hydroxyvitamin D2 and 25-Hydroxyvitamin D3 Measurement|25-Hydroxyvit D2 + 25-Hydroxyvit D3|25-Hydroxyvit D2 + 25-Hydroxyvit D3|VTD2D3IT	The determination of the amount of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147447>	C122117	von Willebrand Factor Activity Actual to Control Ratio Measurement|VWFAAC|von Will Factor Act Actual/Control|von Will Factor Act Actual/Control|von Willebrand Factor Activity Actual/Normal|von Willebrand Factor Activity Actual/von Willebrand Factor Activity Control	The determination of the ratio of the biological activity of von Willebrand factor dependent coagulation in a subject's specimen when compared to the same activity in a control specimen. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147448>	C210012|C210010	West Nile Virus Antibody Measurement	The determination of the amount of West Nile virus antibody present in a sample.			Laboratory Procedure	
C147449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147449>	C49237	Xanthochromia Measurement|XNTHCHR|Xanthochromia|Xanthochromia	The determination of the amount of xanthochromia present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147450>	C210012|C210010	Yellow Fever Virus Antibody Measurement	The determination of the amount of Yellow Fever virus antibody present in a sample.			Laboratory Procedure	
C147451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147451>	C210012|C210010	Zika Virus Antibody Measurement	The determination of the amount of Zika virus antibody present in a sample.			Laboratory Procedure	
C147452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147452>	C146998	Zinc Protoporphyrin Measurement|ZPP|Zinc Protoporphyrin|Zinc Protoporphyrin	The determination of the amount of zinc protoporphyrin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147453>	C12358	Paralaryngeal Lymph Node|PARALARYNGEAL LYMPH NODE	A lymph node located adjacent to the larynx, in the parapharyngeal space.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147454>	C12358	Prelaryngeal Lymph Node|PRELARYNGEAL LYMPH NODE	A lymph node located anterior to the larynx.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147455>	C12358	Pretracheal Lymph Node|PRETRACHEAL LYMPH NODE	A lymph node located anterior to the trachea, between the isthmus of the thyroid gland and the innominate vein.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147456>	C139113	Burkholderia cepacia Measurement|B. cepacia|BCEPACIA|Burkholderia cepacia|Burkholderia cepacia|Pseudomonas cepacia	The determination of the amount of the organism assigned to the Burkholderia cepacia species in a biological sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147457>	C147458	Haemophilus influenzae Measurement|H. influenzae|HAEMINF|Haemophilus influenzae|Haemophilus influenzae	The determination of the amount of the organism assigned to the Haemophilus influenzae species in a biological sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147458>	C49188	Haemophilus Measurement|HAEMOPH|Haemophilus|Haemophilus	The determination of the amount of the organism assigned to the Haemophilus genus in a biological sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147459>	C49188	Nontuberculous Mycobacteria Measurement|NTBMYCO|NTM|Non-tuberculous mycobacteria|Nontuberculous Mycobacteria|Nontuberculous Mycobacteria	The determination of the amount of organisms that are assigned to the Mycobacterium genus but are not tuberculosis or leprosy-causing in a biological sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147460>	C154811	Staphylococcus aureus Measurement|S. aureus|SAUREUS|Staphylococcus aureus|Staphylococcus aureus	The determination of the amount of the organism assigned to the Staphylococcus aureus species in a biological sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147461>	C83190	Developmental Behavioral Pediatrician|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Pediatrics Developmental -Behavioral Pediatrics	A pediatrician who specializes in diagnosing and treating developmental and behavioral disorders in children.			Professional or Occupational Group	CDISC SDTM Evaluator Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147462>	C28181	Developmental Psychologist|DEVELOPMENTAL PSYCHOLOGIST	A psychologist who specializes in diagnosing and treating emotional and behavioral problems associated with developmental delay or disability.			Professional or Occupational Group	CDISC SDTM Evaluator Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147463>	C17721	Pediatric Neurologist|PEDIATRIC NEUROLOGIST|Psychiatry and Neurology Neurology with Special Qualifications in Child Neurology	A neurologist with additional training/certification in child neurology.			Biomedical Occupation or Discipline	CDISC SDTM Evaluator Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147464>	C80405	Transesophageal Echocardiography With Contrast|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY	A cardiac ultrasound performed by passing a specialized probe containing a transducer into the patient's esophagus, with intravenous application of a contrast agent.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147465>	C80404	Transthoracic Echocardiography With Contrast|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY	A non-invasive cardiac ultrasound performed by placing the transducer on the chest, with intravenous application of a contrast agent.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147466>	C17455	Enzyme-Linked Lectin Assay|ELLA	An enzyme immunoassay that utilizes enzyme-lectin conjugates to detect specific carbohydrate end groups on immobilized glycoproteins on microtiter plates.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147467>	C190559	Eye Fundus Photography|FUNDUS PHOTOGRAPHY	A method of capturing images of the vitreous, retina, choroid, and optic nerve using a specialized low power microscope with an attached camera.	Eye Fundus Photography		Occupational Activity	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C147468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147468>	C179019	Multiplexed Opsonophagocytic Killing Assay|MOPA|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY	An assay technique that measures the opsonophagocytic killing activity of antibodies against multiple serotypes in a single serum assay.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147469>	C50921	Oxacillin Resistant Staphylococcus aureus|ORSA|Oxacillin-resistant Staphylococcus aureus|STAPHYLOCOCCUS AUREUS, OXACILLIN-RESISTANT	A species of Gram-positive coccus-shaped bacterium in the family Micrococcaceae that is resistant to oxacillin.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147470>	C64430	Phosphatase and Tensin Homolog Measurement|PTEN|PTEN Measurement|Phosphatase and Tensin Homolog|Phosphatase and Tensin Homolog	The determination of the amount of phosphatase and tensin homolog protein in a biological sample.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147471>	C25285	Antibiotic Susceptibility Zone Diameter|DIAZOINH|Diameter of the Kill Zone|Diameter of the Zone of Inhibition|Diameter of the Zone of Inhibition|Zone of Inhibition Diameter	The determination of the diameter of the circular region of bacteria growth inhibition that surrounds an antibiotic source on the surface of a cultured plate.			Spatial Concept	CDISC SDTM Microbiology Susceptibility Test Code Terminology|CDISC SDTM Microbiology Susceptibility Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147472>	C110937	Bone Mineral Content|BMC|Bone Mass|Bone Mineral Mass	An assessment of the quantity of minerals within a specific bone.			Finding	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147473>	C120401	Bone Mineral Density T-Score|BMDT	The standard deviation of the subject's bone mineral density score in comparison to the expected normal bone mineral density of a healthy 30-year old adult.			Quantitative Concept	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147474>	C48309	Eye Drop Comfort Grade|EYDCOMGR	The position on a scale of intensity, amount or quality of eye drop comfort.			Quantitative Concept	CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147475>	C25167	Actual Subject to Eye Chart Distance|SUBECADT|Subject to Eye Chart Actual Distance|Subject to Eye Chart Actual Distance	The actual distance between the subject and the eye chart during an eye assessment.			Quantitative Concept	CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147476>	C25167	Planned Subject to Eye Chart Distance|SUBECPDT|Subject to Eye Chart Planned Distance|Subject to Eye Chart Planned Distance	The planned distance between the subject and the eye chart during an eye assessment.			Quantitative Concept	CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147477>	C75389	Acuity Card Grating Frequency|VACGRFRQ|Visual Acuity Card Grating Frequency|Visual Acuity Card Grating Frequency	A measurement of the number of horizontal or vertical lines within a pre-determined unit of length on a visual acuity card.			Quantitative Concept	CDISC SDTM Ophthalmic Exam Test Code Terminology|CDISC SDTM Ophthalmic Exam Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147478>	C125997	Kumar IMWG 2016 Oncology Response Criteria|KUMAR IMWG 2016	A tumor response criterion published in 2016 by Kumar et al. entitled International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. (Kumar S, Paiva B, Anderson KC, Durie B, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016 Aug;17(8):e328-46.)			Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147479>	C85653	Lambda z Lower Limit TAU|LAMZLTAU	The lower limit on time for values to be included in the calculation of Lambda z, calculated within a dosing interval.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147480>	C25337	Number of Points for Lambda z TAU|LAMZNTAU	The number of time points used in computing Lambda z determined in a dosing interval.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147481>	C85652	Lambda z TAU|LAMZTAU	The first order rate constant associated with the terminal (log-linear) portion of the curve, calculated within a dosing interval.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147482>	C85654	Lambda z Upper Limit TAU|LAMZUTAU	The upper limit on time for values to be included in the calculation of Lambda z, calculated within a dosing interval.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147483>	C94856	Half-Life TAU|TAUHL	Half-life calculated within a dosing interval.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147484>	C38081	Expiratory Vital Capacity|EVC	The maximum volume of air an individual can exhale from the point of maximal inhalation.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147485>	C25180	Student Indicator|STDNTIND	An indication as to whether the subject or associated person is enrolled in school.			Conceptual Entity	CDISC SDTM Subject Characteristic Test Code Terminology|CDISC SDTM Subject Characteristic Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147486>	C25533	Diffusely Increased|DIFFUSELY INCREASED	An indication that the increase is widespread.			Qualitative Concept	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C147487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147487>	C25533	Focally Increased|FOCALLY INCREASED	An indication that the increase is limited to a specific area.			Qualitative Concept	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C147488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147488>	C103347	Absolute Change in Longest Diameter From Nadir Product of Perpendicular Diameters Timepoint|ACPPDNLD|Absolute Change From PPD Nadir in LDIAM|Absolute Change From PPD Nadir in LDIAM	The absolute change in the longest diameter of the lesion from the timepoint at which the product of perpendicular diameters of the lesion is the smallest.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C147489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147489>	C103347	Absolute Change in Longest Perpendicular from Nadir Product of Perpendicular Diameters Timepoint|ACPPDNLP|Absolute Change From PPD Nadir in LPERP|Absolute Change From PPD Nadir in LPERP	The absolute change in the longest perpendicular of the lesion from the timepoint at which the product of perpendicular diameters of the lesion is the smallest.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C147490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147490>	C62667	Bone Marrow Tracer Uptake|BMUPTAKE	A visually assessed combination of extent and intensity of tracer uptake within the bone marrow.			Diagnostic Procedure	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C147491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147491>	C19332	Energy Expenditure|ENRGEXP	A measurement of the amount of energy used to carry out a physiological or physical function.	Energy Expenditure		Organism Attribute	CDISC SDTM Terminology|CDISC SDTM Vital Sign Test Code Terminology|CDISC SDTM Vital Sign Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C147492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147492>	C49677	Maximum Predicted Heart Rate|MAXPREHR	The predicted upper limit for an individual's heart rate, which is calculated as 220 minus the subject's age for men, and 210 minus the subject's age for women.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Vital Sign Test Code Terminology|CDISC SDTM Vital Sign Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C147493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147493>	C18190	Qualitative Histopathologic Examination|GHISTXQL|GHISTXQL|General Histopathologic Exam, Qual|General Histopathologic Exam, Qual|General Histopathologic Examination, Qualitative|General Histopathological Exam, Qual	A general histopathologic examination, without a prespecified visual target, focused on qualitative or semi-quantitative findings.			Diagnostic Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Microscopic Findings Test Code Terminology|CDISC SEND Microscopic Findings Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147494>	C26683	Decreased Corpora Lutea|CORPORA LUTEA, DECREASED NUMBER	A decrease in the number of corpora lutea within the ovary.			Laboratory or Test Result	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147495>	C26683	Increased Corpora Lutea|CORPORA LUTEA, INCREASED NUMBER	An increase in the number of corpora lutea within the ovary.			Laboratory or Test Result	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147496>	C82547	Increased Eroded Surface|ERODED SURFACE, INCREASED	An increase in the amount of surface erosion.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147497>	C42076	Intrahepatocellular Erythrocytes|INTRAHEPATOCELLULAR ERYTHROCYTES	The presence of red blood cells within hepatocytes of the liver parenchyma.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147498>	C35867	Increased Osteoclasts|OSTEOCLASTS, INCREASED	An increase in the amount of osteoclasts.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147499>	C175281	Severity One Out of Three|1 OF 3|Severity 1 of 3	A severity result of one, on a three level scale.			Intellectual Product	CDISC SEND Severity Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C1474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1474>	C1287	Filgrastim|FILGRASTIM|Filgrastim Biosimilar Filgrastim-sndz|Filgrastim Biosimilar Tbo-filgrastim|Filgrastim XM02|Filgrastim-aafi|Filgrastim-aafi|Filgrastim-ayow|Filgrastim-ayow|Filgrastim-ayow|Filgrastim-sndz|Filgrastim-sndz|G-CSF|Granix|Neupogen|Neutroval|Nivestim|Nivestym|Recombinant Methionyl Human Granulocyte Colony Stimulating Factor|Releuko|Releuko|Tbo-filgrastim|Tbo-filgrastim|Tevagrastim|XM02|Zarxio|filgrastim|r-metHuG-CSF|rG-CSF	A recombinant, non-glycosylated cytokine which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF) isoform B, with immunomodulating activity. Filgrastim binds to and activates G-CSF receptors with the same biological activity and stability as the endogenous cytokine, thereby controlling the production, differentiation, and function of neutrophilic granulocyte progenitors.	Filgrastim		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|HL Authorized Value Terminology|HL Concomitant Medication Table|NCI Drug Dictionary Terminology
C147500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147500>	C175281	Severity One Out of Four|1 OF 4|Severity 1 of 4	A severity result of one, on a four level scale.			Intellectual Product	CDISC SEND Severity Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147501>	C175281	Severity One Out of Five|1 OF 5|Severity 1 of 5	A severity result of one, on a five level scale.			Intellectual Product	CDISC SEND Severity Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147502>	C175281	Severity Two Out of Three|2 OF 3|Severity 2 of 3	A severity result of two, on a three level scale.			Intellectual Product	CDISC SEND Severity Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147503>	C175281	Severity Two Out of Four|2 OF 4|Severity 2 of 4	A severity result of two, on a four level scale.			Intellectual Product	CDISC SEND Severity Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147504>	C175281	Severity Two Out of Five|2 OF 5|Severity 2 of 5	A severity result of two, on a five level scale.			Intellectual Product	CDISC SEND Severity Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147505>	C175281	Severity Three Out of Three|3 OF 3|Severity 3 of 3	A severity result of three, on a three level scale.			Intellectual Product	CDISC SEND Severity Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147506>	C175281	Severity Three Out of Four|3 OF 4|Severity 3 of 4	A severity result of three, on a four level scale.			Intellectual Product	CDISC SEND Severity Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147507>	C175281	Severity Three Out of Five|3 OF 5|Severity 3 of 5	A severity result of three, on a five level scale.			Intellectual Product	CDISC SEND Severity Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147508>	C175281	Severity Four Out of Four|4 OF 4|Severity 4 of 4	A severity result of four, on a four level scale.			Intellectual Product	CDISC SEND Severity Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147509>	C175281	Severity Four Out of Five|4 OF 5|Severity 4 of 5	A severity result of four, on a five level scale.			Intellectual Product	CDISC SEND Severity Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147510>	C175281	Severity Five Out of Five|5 OF 5|Severity 5 of 5	A severity result of five, on a five level scale.			Intellectual Product	CDISC SEND Severity Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147511>	C12768	Saphenous Nerve|NERVE, SAPHENOUS	A branch of the femoral nerve traveling the length of the leg/hindlimb, which innervates the sartorius and the skin of the medial aspect of the leg/hindlimb from the knee/stifle joint to the metatarsus.			Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147512>	C77678	Subcutaneous Port Site|SITE, SUBCUTANEOUS PORT	The anatomic site at which a subcutaneous port is implanted under the skin, allowing access to the vascular system or a body cavity.			Body Location or Region	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C147513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147513>	C89081	Planned Dose Frequency|PDOSFRQ	The intended number of times a substance is administered within a specific time period.			Functional Concept	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C147514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147514>	C164471	Planned Pharmacologic Target Common Name|PPTCNAM|Planned Pharm Target Common Name|Planned Pharm Target Common Name	The common name of disease, gene, or protein that is the target of the pharmaceutical intervention.			Conceptual Entity	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C147515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147515>	C70663	Planned Pharmacologic Target Entrez Gene Identifier|PPTEGID|Planned Pharm Target Entrez Gene ID|Planned Pharm Target Entrez Gene ID	The accession number maintained within the Entrez Gene database for the assumed gene target of the pharmacologic intervention.			Intellectual Product	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C147516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147516>	C43568	Planned Pharmacologic Target Entrez Gene Symbol|PPTEGSYM|Planned Pharm Target Entrez Gene Symbol|Planned Pharm Target Entrez Gene Symbol	The official alpha-numeric name maintained within the Entrez Gene database for the assumed gene target of the pharmacologic intervention.			Intellectual Product	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C147517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147517>	C146999	Planned Pharmacologic Target Mode of Action|PPTMDA|Planned Pharm Target Mode of Action|Planned Pharm Target Mode of Action	A description of the cellular functional or anatomic change for the assumed target of the pharmacologic intervention.			Conceptual Entity	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C147518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147518>	C26170|C199456	Zilucoplan|C5 Inhibitor RA101495|Complement C5 Inhibitor RA101495|RA 101495|RA101495|ZILUCOPLAN	A synthetic macrocyclic peptide inhibitor of the terminal complement protein C5, with potential anti-inflammatory and cell protective activities. Upon subcutaneous administration, complement zilucoplan binds to a unique site in terminal complement protein C5, which blocks C5 cleavage into C5a and C5b and prevents the C5b-dependent assembly of the membrane-attack complex (MAC).  Zilucoplan also inhibits the interaction between C5b and C6, thereby further blocking MAC assembly. This prevents MAC-mediated lysis and destruction of red blood cells (RBCs) that occurs in complement-mediated diseases, such as paroxysmal nocturnal hemoglobinuria (PNH), generalized myasthenia gravis (gMG) and lupus nephritis (LN). C5, a complement pathway protein, is expressed at high levels by the liver.	Zilucoplan		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C147519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147519>	C15620	Antibiotic Lock Therapy|ALT	The use of a highly concentrated antibiotic solution for the to treatment of catheter-related bloodstream infections.			Therapeutic or Preventive Procedure	
C147520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147520>	C147519	Mino-Lok Therapy|MLT|Mino-Lok	Administration of a proprietary solution of minocycline, disodium EDTA, and ethyl alcohol to a patient as a treatment for catheter-related bloodstream infections.	Mino-Lok Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C147521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147521>	C129821|C1291	cEt KRAS Antisense Oligonucleotide AZD4785|ASO AZD4785|AZD 4785|AZD-4785|AZD-4785|AZD4785|Generation 2.5 Drug AZD4785|IONIS-KRAS-2.5Rx|cEt KRAS ASO AZD4785	A proprietary formulation composed of a high affinity antisense oligonucleotide (ASO) that contains 2'-4' constrained ethyl residues (cEt) and targets KRAS (K-RAS) transcripts, with potential antineoplastic activity. Upon intravenous administration, cEt KRAS antisense oligonucleotide AZD4785 targets and binds, with high affinity, to a unique genetic sequence within KRAS messenger RNA (mRNA), thereby inhibiting translation of KRAS protein, including forms containing activating mutations. Inhibition of KRAS protein synthesis prevents KRAS-dependent signaling and inhibits the proliferation of KRAS-driven tumor cells. KRAS, a tumor-associated antigen (TAA), is mutated in a variety of tumor cell types. It plays a key role in tumor cell proliferation and survival and is associated with tumor initiation, metastasis and poor prognosis.	cEt KRAS Antisense Oligonucleotide AZD4785		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C147522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147522>	C26199	PSIP1 Gene Product	A protein encoded by the PSIP1 gene.			Amino Acid, Peptide, or Protein	
C147523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147523>	C200766|C176023	Orvacabtagene Autoleucel|Autologous Anti-BCMA CAR-T Cells JCARH 125|Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing CD4+/CD8+ T-lymphocytes JCARH125|Autologous BCMA 41BBz CAR-T Cell JCARH-125|Autologous BCMA-specific CAR-T Cells JCARH125|Autologous BCMA-specific CAR4-1BB-CD3zeta-expressing CD4+/CD8+ T Lymphocytes JCARH 125|JCARH 125|JCARH-125|JCARH125|ORVACABTAGENE AUTOLEUCEL	A preparation of autologous CD4- and CD8-positive T-lymphocytes that have been ex vivo transduced with a genetically-engineered lentiviral vector (LV) expressing a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) fused to the co-stimulatory domain of 4-1BB (CD137) and the CD3-zeta (CD3z) T-cell signaling domain, with potential immunostimulating and antineoplastic activities. Upon administration, orvacabtagene autoleucel specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.	Orvacabtagene Autoleucel		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C147524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147524>	C141480	HER2/Neu Expression by Immunohistochemistry 0|HER2/Neu IHC 0	An immunohistochemical result of 0 for HER2/Neu expression that is considered negative for expression.	HER2/Neu Expression by Immunohistochemistry 0		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147525>	C141480	HER2/Neu Expression by Immunohistochemistry 1+|HER2/Neu IHC 1+	An immunohistochemical result of 1+ for HER2/Neu expression that is considered negative for expression.	HER2/Neu Expression by Immunohistochemistry 1+		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147526>	C185751	HER2/Neu Expression by Immunohistochemistry 2+|HER2/Neu IHC 2+	An immunohistochemical result of 2+ for HER2/Neu expression that is considered equivocal for expression.	HER2/Neu Expression by Immunohistochemistry 2+		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147527>	C141481	HER2/Neu Expression by Immunohistochemistry 3+|HER2/Neu IHC 3+	An immunohistochemical result of 3+ for HER2/Neu expression that is considered positive for expression.	HER2/Neu Expression by Immunohistochemistry 3+		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147528>	C140266	Enneking Metastasis M0|M0|No Metastasis (M0)	No metastasis.			Classification	GDC Terminology|GDC Value Terminology
C147529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147529>	C140266	Enneking Metastasis M1|M1|Regional or Distant Metastasis (M1)	Regional or distant metastasis.			Classification	GDC Terminology|GDC Value Terminology
C147530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147530>	C28193	MIRAGE Syndrome|Myelodysplasia, Infection, Restriction of Growth, Adrenal Hypoplasia, Genital Phenotypes, and Enteropathy	An autosomal dominant condition caused by mutation(s) in the SAMD9 gene, encoding sterile alpha motif domain-containing protein 9A. It is a syndromic condition comprising myelodysplasia, infection, restriction of growth, adrenal hypoplasia, genital abnormalities, and enteropathy.			Disease or Syndrome	CCPS Disease Terminology|Cellosaurus Disease Terminology|Childhood Cancer Predisposition Study Terminology
C147532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147532>	C134533	Sheep Lung Adenocarcinoma	Adenocarcinoma arising from the lung of a sheep.			Neoplastic Process	Cellosaurus Disease Terminology
C147533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147533>	C36289	Myeloid Engraftment	Myeloid recovery after bone marrow transplantation. It manifests with the production of new blood cells. It takes approximately two to four weeks after the bone marrow is infused with the transplanted stem cells for the recovery to occur.			Finding	
C147535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147535>	C21176	Interleukin-23|IL-23|IL23|Interleukin 23	A heterodimeric cytokine composed of interleukin-12 subunit beta and interleukin-23 subunit alpha. This complex binds to the interleukin-23 receptor complex, which activates the JAK-STAT signaling pathway and modulates the proliferation, differentiation and effector functions of T-lymphocytes, natural killer cells and some myeloid lineage cells.	Interleukin-23		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147537>	C118970	CDISC Clinical Classification ATLAS Test Name Terminology|ATLAS Clinical Classification Test Name|ATLAS1TN|CC-ATLAS TEST	Test names of clinical classification questions associated with the ATLAS Score (ATLAS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147538>	C118970	CDISC Clinical Classification ATLAS Test Code Terminology|ATLAS Clinical Classification Test Code|ATLAS1TC|CC-ATLAS TESTCD	Test codes of clinical classification questions associated with the ATLAS Score (ATLAS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147539>	C100110	CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|FAC061TN|Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 Questionnaire Test Name|QS-FACT-BMT Version 4 TEST	Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147540>	C100110	CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|FAC061TC|Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 Questionnaire Test Code|QS-FACT-BMT Version 4 TESTCD	Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147541>	C100110	CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|FAC084TN|Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form Questionnaire Test Name|QS-FACIT-Dyspnea 10 Item Short Form TEST	Test names of questionnaire questions associated with the Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147542>	C100110	CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|FAC084TC|Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form Questionnaire Test Code|QS-FACIT-Dyspnea 10 Item Short Form TESTCD	Test codes of questionnaire questions associated with the Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147543>	C100110	CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Name Terminology|FAC070TN|Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 Questionnaire Test Name|QS-FACIT-Fatigue Version 4 TEST	Test names of questionnaire questions associated with the Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 (FACIT-Fatigue 13-Item Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147544>	C100110	CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Code Terminology|FAC070TC|Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 Questionnaire Test Code|QS-FACIT-Fatigue Version 4 TESTCD	Test codes of questionnaire questions associated with the Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 (FACIT-Fatigue 13-Item Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147545>	C100110	CDISC Questionnaire Peds-FACIT-F Test Name Terminology|FAC099TN|Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue Questionnaire Test Name|QS-Peds-FACIT-F TEST	Test names of questionnaire questions associated with the Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (Peds-FACIT-F) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147546>	C100110	CDISC Questionnaire Peds-FACIT-F Test Code Terminology|FAC099TC|Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue Questionnaire Test Code|QS-Peds-FACIT-F TESTCD	Test codes of questionnaire questions associated with the Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (Peds-FACIT-F) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147547>	C100110	CDISC Questionnaire TSCC Test Name Terminology|QS-TSCC TEST|TSCC01TN|Trauma Symptom Checklist for Children Questionnaire Test Name	Test names of questionnaire questions associated with the Trauma Symptom Checklist for Children (TSCC) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147548>	C100110	CDISC Questionnaire TSCC Test Code Terminology|QS-TSCC TESTCD|TSCC01TC|Trauma Symptom Checklist for Children Questionnaire Test Code	Test codes of questionnaire questions associated with the Trauma Symptom Checklist for Children (TSCC) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147549>	C100110	CDISC Questionnaire TSCYC Test Name Terminology|QS-TSCYC TEST|TSCYC1TN|Trauma Symptom Checklist for Young Children Questionnaire Test Name	Test names of questionnaire questions associated with the Trauma Symptom Checklist for Young Children (TSCYC) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147550>	C100110	CDISC Questionnaire TSCYC Test Code Terminology|QS-TSCYC TESTCD|TSCYC1TC|Trauma Symptom Checklist for Young Children Questionnaire Test Code	Test codes of questionnaire questions associated with the Trauma Symptom Checklist for Young Children (TSCYC) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147551>	C211913	ATLAS Clinical Classification Question	A question associated with the ATLAS clinical classification.			Intellectual Product	
C147552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147552>	C211913	FACT-BMT Version 4 Questionnaire Question	A question associated with the FACT-BMT Version 4 questionnaire.			Intellectual Product	
C147553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147553>	C211913	FACIT-Dyspnea 10 Item Short Form Questionnaire Question	A question associated with the FACIT-Dyspnea 10 Item Short Form questionnaire.			Intellectual Product	
C147554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147554>	C211913	FACIT-Fatigue 13-Item Version 4 Questionnaire Question	A question associated with the FACIT-Fatigue 13-Item Version 4 questionnaire.			Intellectual Product	
C147555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147555>	C211913	Peds-FACIT-F Questionnaire Question	A question associated with the Peds-FACIT-F questionnaire.			Intellectual Product	
C147556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147556>	C211913	TSCC Questionnaire Question	A question associated with the TSCC questionnaire.			Intellectual Product	
C147557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147557>	C211913	TSCYC Questionnaire Question	A question associated with the TSCYC questionnaire.			Intellectual Product	
C147558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147558>	C50995	Platinum-Resistant Disease|Platinum-Resistant|Platinum-resistant	A finding indicating that a cancer is resistant to platinum therapy. For non-gynecologic cancers, the terms "platinum-resistant" and "platinum-refractory" are used interchangeably. For gynecologic cancers, it refers to cancer progression between one and six months of completing the last platinum therapy.			Finding	GDC Terminology|GDC Value Terminology
C147560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147560>	C21176	Interleukin-23 Receptor Complex|IL-23 Receptor|IL-23R|IL23R|IL23R/IL12RB1 Complex|Interleukin 23 Receptor|Interleukin-23 Receptor	A heterodimeric complex composed of interleukin-12 receptor subunit beta-1 and interleukin-23 receptor. This receptor complex binds to interleukin-23, which activates the JAK-STAT signaling pathway and modulates the activation of T-lymphocytes, natural killer cells and some myeloid lineage cells.			Amino Acid, Peptide, or Protein|Receptor	
C147561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147561>	C4908|C169021	Platinum-Resistant Ovarian Carcinoma|Platinum-Resistant Ovarian Cancer|Platinum-Resistant Ovarian Cancer	Ovarian carcinoma that progresses between one and six months of completing platinum therapy.	Platinum-Resistant Ovarian Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C147562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147562>	C574|C2201	Synthetic Vaccine Particles-Rapamycin|SEL 110|SEL-110|SEL110|SVP-R|SVP-Rapa|SVP-Rapamycin	A proprietary, biodegradable, poly (lactic-co-glycolic acid) (PLGA) nanoparticle-based formulation composed of synthetic vaccine particles (SVP) encapsulating the macrolide antibiotic rapamycin (SVP-R), with immunosuppressant and drug-protective activities. Upon administration of SVP-R, the SVP moiety is selectively and preferentially taken up through endocytosis by antigen-presenting cells (APCs), located in the spleen and lymph nodes, specifically dendritic cells (DCs). Rapamycin, a mammalian target of rapamycin (mTOR) inhibitor, prevents DC maturation, induces tolerogenic DCs, induces regulatory T-cells (Tregs), blocks activation of effector T-cells, induces B-cell tolerance, reduces B-cell activation, and prevents antibody formation, thereby inducing immune tolerance. When co-administered with a biological immunogenic drug known to induce the production of anti-drug antibodies (ADA), SVP-R is able to prevent ADA formation, which prevents the unwanted neutralizing effects of ADAs, increases efficacy of the biological drug, and permits sustained therapeutic activity and repeated administration of the biological drug. In the presence of a specific target antigen, SVP-R is able to prevent an antigen-specific immune response and induces antigen-specific immune tolerance. Compared to the administration of free rapamycin, SVP-R induces long-lasting immunological tolerance.	Synthetic Vaccine Particles-Rapamycin		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology
C147563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147563>	C201282|C155321|C129822	Anti-CD38/CD3 Bispecific Monoclonal Antibody GBR 1342|Anti-CD38 x Anti-CD3 Bispecific Monoclonal Antibody GBR 1342|Anti-CD38/Anti-CD3 Bispecific Monoclonal Antibody GBR 1342|BEAT GBR 1342|CD38xCD3 BsAb GBR 1342|GBR 1342|GBR-1342|GBR-1342|GBR1342	A humanized, bispecific monoclonal antibody (BsAb) against human CD3, a T-cell surface antigen, and the human cell surface glycoprotein CD38, a tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, anti-CD38/anti-CD3 bispecific monoclonal antibody GBR 1342 binds to both CD3 on T-cells and CD38 expressed on certain tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis. GBR 1342 uses the proprietary bispecific engagement by antibodies based on the T-cell receptor (BEAT) platform.	Anti-CD38/CD3 Bispecific Monoclonal Antibody GBR 1342		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C147564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147564>	C36285	Hormone Resistance|Hormone Therapy Resistance	A finding indicating decreased tissue sensitivity to a hormone.			Finding	
C147565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147565>	C20921	ARHGEF10 Gene|ARHGEF10|ARHGEF10|Rho Guanine Nucleotide Exchange Factor 10 Gene	This gene plays a role in both GTPase activation and nerve myelination.			Gene or Genome	
C147566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147566>	C147565	ARHGEF10 wt Allele|GEF10|KIAA0294|Rho Guanine Nucleotide Exchange Factor (GEF) 10 Gene|Rho Guanine Nucleotide Exchange Factor 10 wt Allele|SNCV	Human ARHGEF10 wild-type allele is located in the vicinity of 8p23.3 and is approximately 135 kb in length. This allele, which encodes Rho guanine nucleotide exchange factor 10 protein, is involved in the regulation of GTPase-mediated signaling. Mutations in the gene are associated with autosomal dominant slowed nerve conduction velocity.			Gene or Genome	
C147568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147568>	C17494	Rho Guanine Nucleotide Exchange Factor 10|ARHGEF10|Gef10	Rho guanine nucleotide exchange factor 10 (1369 aa, ~152 kDa) is encoded by the human ARHGEF10 gene. This protein plays a role in guanine nucleotide exchange and peripheral nerve myelination.			Amino Acid, Peptide, or Protein	
C147569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147569>	C20921	ARHGEF10L Gene|ARHGEF10L|ARHGEF10L|Rho Guanine Nucleotide Exchange Factor 10 Like Gene	This gene is involved in guanine nucleotide exchange for Rho family GTPases.			Gene or Genome	
C147570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147570>	C147569	ARHGEF10L wt Allele|FLJ10521|GRINCHGEF|GrinchGEF|KIAA1626|Rho Guanine Nucleotide Exchange Factor (GEF) 10-Like Gene|Rho Guanine Nucleotide Exchange Factor 10 Like wt Allele	Human ARHGEF10L wild-type allele is located in the vicinity of 1p36.13 and is approximately 178 kb in length. This allele, which encodes Rho guanine nucleotide exchange factor 10-like protein, plays a role in the regulation of Rho family GTPases.			Gene or Genome	
C147571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147571>	C17494	Rho Guanine Nucleotide Exchange Factor 10-Like Protein|ARHGEF10L|GrinchGEF	Rho guanine nucleotide exchange factor 10-like protein (1279 aa, ~140 kDa) is encoded by the human ARHGEF10L gene. This protein is involved in the regulation of Rho family-mediated signaling.			Amino Acid, Peptide, or Protein	
C147572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147572>	C54362	BAZ1A Gene|BAZ1A|BAZ1A|Bromodomain Adjacent to Zinc Finger Domain 1A Gene	This gene plays a role in nucleosome spacing.			Gene or Genome	
C147573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147573>	C147572	BAZ1A wt Allele|ACF1|ACF1, Drosophila, Homolog of Gene|Bromodomain Adjacent to Zinc Finger Domain 1A wt Allele|Bromodomain Adjacent to Zinc Finger Domain, 1A Gene|HSPC317|WALp1|WCRF180|hACF1	Human BAZ1A wild-type allele is located within 14q13.1-q13.2 and is approximately 123 kb in length. This allele, which encodes bromodomain adjacent to zinc finger domain protein 1A, is involved in chromatin remodeling.			Gene or Genome	
C147574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147574>	C26199	Bromodomain Adjacent to Zinc Finger Domain Protein 1A|ATP-Dependent Chromatin Remodeling Protein|ATP-Dependent Chromatin-Remodeling Protein|ATP-Utilizing Chromatin Assembly and Remodeling Factor 1|BAZ1A|CHRAC Subunit ACF1|WCRF180|Williams Syndrome Transcription Factor-Related Chromatin-Remodeling Factor 180|hACF1|hWALp1	Bromodomain adjacent to zinc finger domain protein 1A (1556 aa, ~179 kDa) is encoded by the human BAZ1A gene. This protein plays a role in ATP-dependent chromatin remodeling.			Amino Acid, Peptide, or Protein	
C147575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147575>	C98362	KRAS NP_004976.2:p.A59X|GTPase KRas A59X|GTPase KRas Ala59Xxx|K-Ras 2 A59X|KRAS A59 Mutation|KRAS A59X|KRAS Ala59Xxx|KRAS NP_004976.2:p.Ala59Xxx|KRAS p.A59X|KRAS p.Ala59Xxx|Ki-Ras A59X|NP_004976.2:p.A59X|NP_004976.2:p.Ala59Xxx|c-K-ras A59X	A change in the amino acid residue at position 59 in the GTPase KRas protein where alanine has been replaced by another amino acid.	KRAS NP_004976.2:p.A59X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147576>	C98362	KRAS NP_004976.2:p.K117X|GTPase KRas K117X|GTPase KRas Lys117Xxx|K-Ras 2 K117X|KRAS K117 Mutation|KRAS K117X|KRAS Lys117Xxx|KRAS NP_004976.2:p.Lys117Xxx|KRAS p.K117X|KRAS p.Lys146Xxx|Ki-Ras K117X|NP_004976.2:p.K117X|NP_004976.2:p.Lys117Xxx|c-K-ras K117X	A change in the amino acid residue at position 117 in the GTPase KRas protein where lysine has been replaced by another amino acid.	KRAS NP_004976.2:p.K117X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147577>	C217337|C213143	Upinitatug Rilsodotin|ADC XMT-1536|Anti-NaPi2b ADC XMT-1536|Anti-NaPi2b/Auristatin F-HPA ADC XMT-1536|UPINITATUG RILSODOTIN|Upifitamab Rilsodotin|XMT 1536|XMT-1536|XMT1536	A proprietary antibody-drug conjugate (ADC) composed of upinitatug , a proprietary, humanized monoclonal antibody against human sodium-dependent phosphate transport protein 2B (SLC34A2; NaPi2b), site-specifically linked, via a protease cleavable linker, to the proprietary cytotoxic aurastatin derivative auristatin F-HPA (AF-HPA; auristatin F-hydroxypropylamide), with potential antineoplastic activity. Upinitatug rilsodotin is produced via the proprietary dolaflexin ADC conjugation platform, which promotes the conjugation of between 10 and 15 AF-HPA payload molecules to each XMT-1535 antibody. Upon administration of upinitatug rilsodotin, the antibody moiety targets and binds to NaPi2b expressed on tumor cells. Upon binding, internalization by endosomes/lysosomes, and enzymatic cleavage, the AF-HPA binds to tubulin and inhibits microtubule polymerization, which results in G2/M phase arrest and apoptosis of NaPi2b-expressing tumor cells. NaPi2b, a tumor-associated antigen (TAA), is overexpressed on a variety of cancer cells and plays a key role in the transport of inorganic phosphate (Pi) and the maintenance of phosphate homeostasis.	Upinitatug Rilsodotin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C147578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147578>	C222573|C20401|C129822	Upinitatug|Anti-NaPi2b MoAb XMT-1535|Anti-NaPi2b Monoclonal Antibody XMT-1535|MoAb XMT-1535|UPINITATUG|Upifitamab|XMT 1535|XMT-1535|XMT1535	A proprietary humanized monoclonal antibody against human sodium-dependent phosphate transport protein 2B (SLC34A2; NaPi2b), with potential antineoplastic activity. Upon administration of upinitatug, the antibody targets and binds to NaPi2b expressed on tumor cells. Although the tumor cell killing effects of upinitatug are not established, this binding may induce an antibody-dependent cellular cytotoxicity (ADCC)-mediated immune response against NaPi2b-expressing tumor cells, and/or may inhibit NaPi2b-mediated sodium and phosphate ion cotransport activity and ion-dependent tumor cell signaling. NaPi2b, a tumor-associated antigen (TAA), is overexpressed on a variety of tumor cells. It plays a key role in the transport of inorganic phosphate (Pi) and the maintenance of phosphate homeostasis.	Upinitatug		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C147579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147579>	C42998	Tablet with Sensor Dosage Form|Tablet with Sensor|Tablet with sensor	A solid dosage form containing medicinal substances, with or without suitable diluents, plus an ingestible sensor that communicates with medical devices that are usually located outside of the body.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology|FDA Structured Product Labeling Terminology|SPL Pharmaceutical Dosage Form Terminology
C147580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147580>	C21295	CPEB3 Gene|CPEB3|CPEB3|Cytoplasmic Polyadenylation Element Binding Protein 3 Gene	This gene is involved in RNA binding and translation regulation.			Gene or Genome	
C147581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147581>	C147580	CPEB3 wt Allele|Cytoplasmic Polyadenylation Element Binding Protein 3 wt Allele|KIAA0940	Human CPEB3 wild-type allele is located in the vicinity of 10q23.32 and is approximately 244 kb in length. This allele, which encodes cytoplasmic polyadenylation element-binding protein 3, plays a role in the modulation of translation.			Gene or Genome	
C147582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147582>	C21298	Cytoplasmic Polyadenylation Element-Binding Protein 3|CPE-BP3|CPE-Binding Protein 3|CPEB3|hCPEB-3	Cytoplasmic polyadenylation element-binding protein 3 (698 aa, ~76 kDa) is encoded by the human CPEB3 gene. This protein is involved in the regulation of mRNA synthesis.			Amino Acid, Peptide, or Protein	
C147583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147583>	C91105	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 Questionnaire|FAC061|FACT-BMT V4|FACT-BMT Version 4	A standardized, self-administered 12-item subscale, validated by McQuellen et al. in 1997 that, in combination with the general Functional Assessment of Cancer Therapy (FACT) instrument, utilizes a five-point Likert scale and covers four specific domains of well-being to measure quality of life in bone marrow transplantation patients.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147585>	C91105	Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 Questionnaire|FAC070|FACIT-FATIGUE 13-ITEM V4|FACIT-Fatigue 13-Item Version 4	A standardized 10-item self-report, interviewer, or telephone administered questionnaire, part of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System developed by Cella et al. in 1987, that utilizes a five-point Likert rating scale to evaluate shortness of breath across a range of functional activities over the past 7 days in individuals with chronic obstructive pulmonary disease.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147586>	C91105	Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue Questionnaire|FAC099|PEDS-FACIT-F|Peds-FACIT-F	A standardized 11-item self-report questionnaire, part of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System developed by Cella et al. in 1987, that utilizes a five-point Likert rating scale to evaluate fatigue over the past 7 days in children.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147587>	C91105	Trauma Symptom Checklist for Children Questionnaire|TSCC|TSCC|TSCC01	A standardized 54-item self-report questionnaire developed by Briere et al. in 1996, that utilizes a four-point Likert rating scale to evaluate severity of posttraumatic stress and related symptoms in children ages 10-17 years who have experienced traumatic events.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147588>	C91105	Trauma Symptom Checklist for Young Children Questionnaire|TSCYC|TSCYC|TSCYC1	A standardized 90-item caretaker-report questionnaire developed by Briere et al. in 1999, that utilizes a four-point Likert rating scale to evaluate severity of posttraumatic stress and related symptoms in children ages 3-12 years who have experienced traumatic events.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147589>	C118969	ATLAS Score Clinical Classification|ATLAS|ATLAS|ATLAS1	A standardized scoring system created by Miller et al. in 2013 that assesses age, treatment with systemic antibiotics, leukocyte count, albumin and serum creatinine to predict treatment response or mortality from Clostridium difficile infection.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147590>	C141679	4-Stair Ascend - Wear Orthoses|A4STR1-Wear Orthoses|A4STR1-Wear Orthoses|A4STR103	Four Stair Ascend Test (4 Stair Ascend) Did subject wear orthoses?			Intellectual Product	CDISC Functional Test 4-Stair Ascend Test Code Terminology|CDISC Functional Test 4-Stair Ascend Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147591>	C141678	4-Stair Descend - Wear Orthoses|D4STR1-Wear Orthoses|D4STR1-Wear Orthoses|D4STR103	Four Stair Descend Test (4 Stair Descend) Did subject wear orthoses?			Intellectual Product	CDISC Functional Test 4-Stair Descend Test Code Terminology|CDISC Functional Test 4-Stair Descend Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147592>	C141676	10-Meter Walk/Run - Wear Orthoses|TENMW1-Wear Orthoses|TENMW1-Wear Orthoses|TENMW103	Ten Meter Walk/Run Test (10 Meter Walk/Run) Did subject wear orthoses?			Intellectual Product	CDISC Functional Test 10-Meter Walk/Run Test Code Terminology|CDISC Functional Test 10-Meter Walk/Run Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147593>	C147552	FACT-BMT Version 4 - I Have a Lack of Energy|FAC061-I Have a Lack of Energy|FAC061-I Have a Lack of Energy|FAC06101	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I have a lack of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147594>	C147552	FACT-BMT Version 4 - I Have Nausea|FAC061-I Have Nausea|FAC061-I Have Nausea|FAC06102	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I have nausea.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147595>	C147552	FACT-BMT Version 4 - Trouble Meeting Needs of Family|FAC061-Trouble Meeting Needs of Family|FAC061-Trouble Meeting Needs of Family|FAC06103	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) Because of my physical condition, I have trouble meeting the needs of my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147596>	C147552	FACT-BMT Version 4 - I Have Pain|FAC061-I Have Pain|FAC061-I Have Pain|FAC06104	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I have pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147597>	C147552	FACT-BMT Version 4 - Bothered by Treatment Side Effect|FAC061-Bothered by Treatment Side Effect|FAC061-Bothered by Treatment Side Effect|FAC06105	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am bothered by side effects of treatment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147598>	C147552	FACT-BMT Version 4 - I Feel Ill|FAC061-I Feel Ill|FAC061-I Feel Ill|FAC06106	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I feel ill.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147599>	C147552	FACT-BMT Version 4 - I Am Forced to Spend Time in Bed|FAC061-I Am Forced to Spend Time in Bed|FAC061-I Am Forced to Spend Time in Bed|FAC06107	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am forced to spend time in bed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C1475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1475>	C2198	Ziconotide|Prialt|Prialt|SNX 111|SNX-111|ZICONOTIDE|ziconotide	A synthetic, nonopiod, twenty-five amino acid polybasic peptide analogue of an omega-conotoxin derived from the marine snail Conus magus with analgesic activity. Ziconotide appears to block neuronal N-type voltage-sensitive calcium channels (NCCB), inhibiting transmission from pain-sensing primary nociceptors. This agent may exhibit significant analgesic activity in refractory pain.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C147600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147600>	C147552	FACT-BMT Version 4 - I Feel Close to My Friends|FAC061-I Feel Close to My Friends|FAC061-I Feel Close to My Friends|FAC06108	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I feel close to my friends.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147601>	C147552	FACT-BMT Version 4 - Get Emotional Support From Family|FAC061-Get Emotional Support From Family|FAC061-Get Emotional Support From Family|FAC06109	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I get emotional support from my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147602>	C147552	FACT-BMT Version 4 - I Get Support From My Friends|FAC061-I Get Support From My Friends|FAC061-I Get Support From My Friends|FAC06110	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I get support from my friends.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147603>	C147552	FACT-BMT Version 4 - My Family Has Accepted My Illness|FAC061-My Family Has Accepted My Illness|FAC061-My Family Has Accepted My Illness|FAC06111	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) My family has accepted my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147604>	C147552	FACT-BMT Version 4 - Satisfied Communication Illness|FAC061-Satisfied Communication Illness|FAC061-Satisfied Communication Illness|FAC06112	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am satisfied with family communication about my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147605>	C147552	FACT-BMT Version 4 - I Feel Close to My Partner|FAC061-I Feel Close to My Partner|FAC061-I Feel Close to My Partner|FAC06113	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I feel close to my partner (or the person who is my main support).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147606>	C147552	FACT-BMT Version 4 - I Am Satisfied With My Sex Life|FAC061-I Am Satisfied With My Sex Life|FAC061-I Am Satisfied With My Sex Life|FAC06114	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am satisfied with my sex life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147607>	C147552	FACT-BMT Version 4 - I Feel Sad|FAC061-I Feel Sad|FAC061-I Feel Sad|FAC06115	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I feel sad.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147608>	C147552	FACT-BMT Version 4 - Satisfied With How I Am Coping|FAC061-Satisfied With How I Am Coping|FAC061-Satisfied With How I Am Coping|FAC06116	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am satisfied with how I am coping with my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147609>	C147552	FACT-BMT Version 4 - Losing Hope Against Illness|FAC061-Losing Hope Against Illness|FAC061-Losing Hope Against Illness|FAC06117	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am losing hope in the fight against my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147610>	C147552	FACT-BMT Version 4 - I Feel Nervous|FAC061-I Feel Nervous|FAC061-I Feel Nervous|FAC06118	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I feel nervous.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147611>	C147552	FACT-BMT Version 4 - I Worry About Dying|FAC061-I Worry About Dying|FAC061-I Worry About Dying|FAC06119	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I worry about dying.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147612>	C147552	FACT-BMT Version 4 - Worry My Condition Will Get Worse|FAC061-Worry My Condition Will Get Worse|FAC061-Worry My Condition Will Get Worse|FAC06120	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I worry that my condition will get worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147613>	C147552	FACT-BMT Version 4 - I Am Able to Work|FAC061-I Am Able to Work|FAC061-I Am Able to Work|FAC06121	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am able to work (include work at home).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147614>	C147552	FACT-BMT Version 4 - My Work Is Fulfilling|FAC061-My Work Is Fulfilling|FAC061-My Work Is Fulfilling|FAC06122	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) My work (include work at home) is fulfilling.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147615>	C147552	FACT-BMT Version 4 - I Am Able to Enjoy Life|FAC061-I Am Able to Enjoy Life|FAC061-I Am Able to Enjoy Life|FAC06123	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am able to enjoy life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147616>	C147552	FACT-BMT Version 4 - I Have Accepted My Illness|FAC061-I Have Accepted My Illness|FAC061-I Have Accepted My Illness|FAC06124	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I have accepted my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147617>	C147552	FACT-BMT Version 4 - I Am Sleeping Well|FAC061-I Am Sleeping Well|FAC061-I Am Sleeping Well|FAC06125	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am sleeping well.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147618>	C147552	FACT-BMT Version 4 - Enjoy Things I Usually Do for Fun|FAC061-Enjoy Things I Usually Do for Fun|FAC061-Enjoy Things I Usually Do for Fun|FAC06126	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am enjoying the things I usually do for fun.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147619>	C147552	FACT-BMT Version 4 - Content With Quality of My Life|FAC061-Content With Quality of My Life|FAC061-Content With Quality of My Life|FAC06127	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am content with the quality of my life right now.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147620>	C147552	FACT-BMT Version 4 - I Am Concerned About Keeping Job|FAC061-I Am Concerned About Keeping Job|FAC061-I Am Concerned About Keeping Job|FAC06128	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am concerned about keeping my job (include work at home).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147621>	C147552	FACT-BMT Version 4 - I Feel Distant From Other People|FAC061-I Feel Distant From Other People|FAC061-I Feel Distant From Other People|FAC06129	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I feel distant from other people.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147622>	C147552	FACT-BMT Version 4 - I Worry Transplant Will Not Work|FAC061-I Worry Transplant Will Not Work|FAC061-I Worry Transplant Will Not Work|FAC06130	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I worry that the transplant will not work.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147623>	C147552	FACT-BMT Version 4 - Side Effect of Treatment Worse|FAC061-Side Effect of Treatment Worse|FAC061-Side Effect of Treatment Worse|FAC06131	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) The side effects of treatment are worse than I had imagined.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147624>	C147552	FACT-BMT Version 4 - I Have a Good Appetite|FAC061-I Have a Good Appetite|FAC061-I Have a Good Appetite|FAC06132	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I have a good appetite.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147625>	C147552	FACT-BMT Version 4 - I Like the Appearance of My Body|FAC061-I Like the Appearance of My Body|FAC061-I Like the Appearance of My Body|FAC06133	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I like the appearance of my body.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147626>	C147552	FACT-BMT Version 4 - I Am Able to Get Around by Myself|FAC061-I Am Able to Get Around by Myself|FAC061-I Am Able to Get Around by Myself|FAC06134	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am able to get around by myself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147627>	C147552	FACT-BMT Version 4 - I Get Tired Easily|FAC061-I Get Tired Easily|FAC061-I Get Tired Easily|FAC06135	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I get tired easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147628>	C147552	FACT-BMT Version 4 - I Am Interested in Sex|FAC061-I Am Interested in Sex|FAC061-I Am Interested in Sex|FAC06136	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am interested in sex.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147629>	C147552	FACT-BMT Version 4 - Concerns Ability to Have Children|FAC061-Concerns Ability to Have Children|FAC061-Concerns Ability to Have Children|FAC06137	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I have concerns about my ability to have children.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147630>	C147552	FACT-BMT Version 4 - Confidence in My Nurse(s)|FAC061-Confidence in My Nurse(s)|FAC061-Confidence in My Nurse(s)|FAC06138	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I have confidence in my nurse(s).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147631>	C147552	FACT-BMT Version 4 - I Regret Bone Marrow Transplant|FAC061-I Regret Bone Marrow Transplant|FAC061-I Regret Bone Marrow Transplant|FAC06139	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I regret having the bone marrow transplant.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147632>	C147552	FACT-BMT Version 4 - I Can Remember Things|FAC061-I Can Remember Things|FAC061-I Can Remember Things|FAC06140	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I can remember things.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147633>	C147552	FACT-BMT Version 4 - I Am Able to Concentrate|FAC061-I Am Able to Concentrate|FAC061-I Am Able to Concentrate|FAC06141	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am able to concentrate.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147634>	C147552	FACT-BMT Version 4 - I Have Frequent Colds/Infections|FAC061-I Have Frequent Colds/Infections|FAC061-I Have Frequent Colds/Infections|FAC06142	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I have frequent colds/infections.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147635>	C147552	FACT-BMT Version 4 - My Eyesight Is Blurry|FAC061-My Eyesight Is Blurry|FAC061-My Eyesight Is Blurry|FAC06143	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) My eyesight is blurry.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147636>	C147552	FACT-BMT Version 4 - Bothered by Change in Food Tastes|FAC061-Bothered by Change in Food Tastes|FAC061-Bothered by Change in Food Tastes|FAC06144	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am bothered by a change in the way food tastes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147637>	C147552	FACT-BMT Version 4 - I Have Tremors|FAC061-I Have Tremors|FAC061-I Have Tremors|FAC06145	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I have tremors.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147638>	C147552	FACT-BMT Version 4 - I Have Been Short of Breath|FAC061-I Have Been Short of Breath|FAC061-I Have Been Short of Breath|FAC06146	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I have been short of breath.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147639>	C147552	FACT-BMT Version 4 - I Am Bothered by Skin Problems|FAC061-I Am Bothered by Skin Problems|FAC061-I Am Bothered by Skin Problems|FAC06147	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I am bothered by skin problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147640>	C147552	FACT-BMT Version 4 - I Have Trouble With My Bowels|FAC061-I Have Trouble With My Bowels|FAC061-I Have Trouble With My Bowels|FAC06148	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) I have trouble with my bowels.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147641>	C147552	FACT-BMT Version 4 - Illness Is Hardship for My Family|FAC061-Illness Is Hardship for My Family|FAC061-Illness Is Hardship for My Family|FAC06149	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) My illness is a personal hardship for my close family members.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147642>	C147552	FACT-BMT Version 4 - Cost of Treatment Is Burden on Me|FAC061-Cost of Treatment Is Burden on Me|FAC061-Cost of Treatment Is Burden on Me|FAC06150	Functional Assessment of Cancer Therapy-Bone Marrow Transplant Version 4 (FACT-BMT Version 4) The cost of my treatment is a burden on me or my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Code Terminology|CDISC Questionnaire FACT-BMT Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147643>	C147553	FACIT-Dyspnea 10 Item Short Form - Part I: Dressing Without Help|FAC084-Part I: Dressing Without Help|FAC084-Part I: Dressing Without Help|FAC08401	Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Dressing yourself without help.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147644>	C147553	FACIT-Dyspnea 10 Item Short Form - Part I: Dressing Why Not|FAC084-Part I: Dressing Why Not|FAC084-Part I: Dressing Why Not|FAC08402	Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Dressing yourself without help. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147645>	C147553	FACIT-Dyspnea 10 Item Short Form - Part I: Walk 50 Steps|FAC084-Part I: Walk 50 Steps|FAC084-Part I: Walk 50 Steps|FAC08403	Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Walking 50 steps/paces on flat ground at a normal speed without stopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147646>	C147553	FACIT-Dyspnea 10 Item Short Form - Part I: Walk 50 Steps Why Not|FAC084-Part I: Walk 50 Steps Why Not|FAC084-Part I: Walk 50 Steps Why Not|FAC08404	Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Walking 50 steps/paces on flat ground at a normal speed without stopping. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147647>	C147553	FACIT-Dyspnea 10 Item Short Form - Part I: Walk Up 20 Stairs|FAC084-Part I: Walk Up 20 Stairs|FAC084-Part I: Walk Up 20 Stairs|FAC08405	Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Walking up 20 stairs (2 flights) without stopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147648>	C147553	FACIT-Dyspnea 10 Item Short Form - Part I: Walk Up 20 Stairs Why Not|FAC084-Part I: Walk Up 20 Stairs Why Not|FAC084-Part I: Walk Up 20 Stairs Why Not|FAC08406	Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Walking up 20 stairs (2 flights) without stopping. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147649>	C147553	FACIT-Dyspnea 10 Item Short Form - Part I: Preparing Meals|FAC084-Part I: Preparing Meals|FAC084-Part I: Preparing Meals|FAC08407	Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Preparing Meals.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147650>	C147553	FACIT-Dyspnea 10 Item Short Form - Part I: Preparing Meals Why Not|FAC084-Part I: Preparing Meals Why Not|FAC084-Part I: Preparing Meals Why Not|FAC08408	Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Preparing Meals. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147651>	C147553	FACIT-Dyspnea 10 Item Short Form - Part I: Washing Dishes|FAC084-Part I: Washing Dishes|FAC084-Part I: Washing Dishes|FAC08409	Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Washing dishes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147652>	C147553	FACIT-Dyspnea 10 Item Short Form - Part I: Washing Dishes Why Not|FAC084-Part I: Washing Dishes Why Not|FAC084-Part I: Washing Dishes Why Not|FAC08410	Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Washing dishes. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147653>	C147553	FACIT-Dyspnea 10 Item Short Form - Part I: Sweeping/Mopping|FAC084-Part I: Sweeping/Mopping|FAC084-Part I: Sweeping/Mopping|FAC08411	Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Sweeping or mopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147654>	C147553	FACIT-Dyspnea 10 Item Short Form - Part I: Sweeping/Mopping Why Not|FAC084-Part I: Sweeping/Mopping Why Not|FAC084-Part I: Sweeping/Mopping Why Not|FAC08412	Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Sweeping or mopping. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147655>	C147553	FACIT-Dyspnea 10 Item Short Form - Part I: Making a Bed|FAC084-Part I: Making a Bed|FAC084-Part I: Making a Bed|FAC08413	Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Making a bed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147656>	C147553	FACIT-Dyspnea 10 Item Short Form - Part I: Making a Bed Why Not|FAC084-Part I: Making a Bed Why Not|FAC084-Part I: Making a Bed Why Not|FAC08414	Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Making a bed. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147657>	C147553	FACIT-Dyspnea 10 Item Short Form - Part I: Lifting 10-20 Lbs|FAC084-Part I: Lifting 10-20 Lbs|FAC084-Part I: Lifting 10-20 Lbs|FAC08415	Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Lifting something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147658>	C147553	FACIT-Dyspnea 10 Item Short Form - Part I: Lifting 10-20 Lbs Why Not|FAC084-Part I: Lifting 10-20 Lbs Why Not|FAC084-Part I: Lifting 10-20 Lbs Why Not|FAC08416	Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Lifting something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries). Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147659>	C147553	FACIT-Dyspnea 10 Item Short Form - Part I: Carry 10-20 Lbs|FAC084-Part I: Carry 10-20 Lbs|FAC084-Part I: Carry 10-20 Lbs|FAC08417	Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Carrying something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries) from one room to another.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147660>	C147553	FACIT-Dyspnea 10 Item Short Form - Part I: Carry 10-20 Lbs Why Not|FAC084-Part I: Carry 10-20 Lbs Why Not|FAC084-Part I: Carry 10-20 Lbs Why Not|FAC08418	Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Carrying something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries) from one room to another. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147661>	C147553	FACIT-Dyspnea 10 Item Short Form - Part I: Walk for 1/2 Mile|FAC084-Part I: Walk for 1/2 Mile|FAC084-Part I: Walk for 1/2 Mile|FAC08419	Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Walking (faster than your usual speed) for 1/2 mile (almost 1 km) without stopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147662>	C147553	FACIT-Dyspnea 10 Item Short Form - Part I: Walk for 1/2 Mile Why Not|FAC084-Part I: Walk for 1/2 Mile Why Not|FAC084-Part I: Walk for 1/2 Mile Why Not|FAC08420	Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part I. Over the past 7 days, how short of breath did you get with each of these activities?: Walking (faster than your usual speed) for 1/2 mile (almost 1 km) without stopping. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147663>	C147553	FACIT-Dyspnea 10 Item Short Form - Part II: Dressing Without Help|FAC084-Part II: Dressing Without Help|FAC084-Part II: Dressing Without Help|FAC08421	Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part II Functional Limitation. Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Dressing yourself without help.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147664>	C147553	FACIT-Dyspnea 10 Item Short Form - Part II: Walk 50 Steps|FAC084-Part II: Walk 50 Steps|FAC084-Part II: Walk 50 Steps|FAC08422	Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part II Functional Limitation. Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Walking 50 steps/paces on flat ground at a normal speed without stopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147665>	C147553	FACIT-Dyspnea 10 Item Short Form - Part II: Walk Up 20 Stairs|FAC084-Part II: Walk Up 20 Stairs|FAC084-Part II: Walk Up 20 Stairs|FAC08423	Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part II Functional Limitation. Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Walking up 20 stairs (2 flights) without stopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147666>	C147553	FACIT-Dyspnea 10 Item Short Form - Part II: Preparing Meals|FAC084-Part II: Preparing Meals|FAC084-Part II: Preparing Meals|FAC08424	Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part II Functional Limitation. Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Preparing meals.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147667>	C147553	FACIT-Dyspnea 10 Item Short Form - Part II: Washing Dishes|FAC084-Part II: Washing Dishes|FAC084-Part II: Washing Dishes|FAC08425	Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part II Functional Limitation. Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Washing dishes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147668>	C147553	FACIT-Dyspnea 10 Item Short Form - Part II: Sweeping/Mopping|FAC084-Part II: Sweeping/Mopping|FAC084-Part II: Sweeping/Mopping|FAC08426	Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part II Functional Limitation. Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Sweeping or mopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147669>	C147553	FACIT-Dyspnea 10 Item Short Form - Part II: Making a Bed|FAC084-Part II: Making a Bed|FAC084-Part II: Making a Bed|FAC08427	Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part II Functional Limitation. Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Making a bed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14766>	C14421	DDK Mouse|DDK		DDK Mouse		Mammal	
C147670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147670>	C147553	FACIT-Dyspnea 10 Item Short Form - Part II: Lifting 10-20 Lbs|FAC084-Part II: Lifting 10-20 Lbs|FAC084-Part II: Lifting 10-20 Lbs|FAC08428	Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part II Functional Limitation. Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Lifting something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147671>	C147553	FACIT-Dyspnea 10 Item Short Form - Part II: Carry 10-20 Lbs|FAC084-Part II: Carry 10-20 Lbs|FAC084-Part II: Carry 10-20 Lbs|FAC08429	Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part II Functional Limitation. Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Carrying something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries) from one room to another.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147672>	C147553	FACIT-Dyspnea 10 Item Short Form - Part II: Walk for 1/2 Mile|FAC084-Part II: Walk for 1/2 Mile|FAC084-Part II: Walk for 1/2 Mile|FAC08430	Functional Assessment of Chronic Illness Therapy-Dyspnea 10 Item Short Form (FACIT-Dyspnea 10 Item Short Form) Part II Functional Limitation. Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Walking (faster than your usual speed) for 1/2 mile (almost 1 km) without stopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea 10 Item Short Form Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147673>	C147554	FACIT-Fatigue 13-Item Version 4 - I Feel Fatigued|FAC070-I Feel Fatigued|FAC070-I Feel Fatigued|FAC07001	Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 (FACIT-Fatigue 13-Item Version 4) I feel fatigued.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Code Terminology|CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147674>	C147554	FACIT-Fatigue 13-Item Version 4 - I Feel Weak All Over|FAC070-I Feel Weak All Over|FAC070-I Feel Weak All Over|FAC07002	Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 (FACIT-Fatigue 13-Item Version 4) I feel weak all over.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Code Terminology|CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147675>	C147554	FACIT-Fatigue 13-Item Version 4 - I Feel Listless|FAC070-I Feel Listless|FAC070-I Feel Listless|FAC07003	Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 (FACIT-Fatigue 13-Item Version 4) I feel listless ("washed out").			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Code Terminology|CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147676>	C147554	FACIT-Fatigue 13-Item Version 4 - I Feel Tired|FAC070-I Feel Tired|FAC070-I Feel Tired|FAC07004	Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 (FACIT-Fatigue 13-Item Version 4) I feel tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Code Terminology|CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147677>	C147554	FACIT-Fatigue 13-Item Version 4 - Trouble Starting Things|FAC070-Trouble Starting Things|FAC070-Trouble Starting Things|FAC07005	Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 (FACIT-Fatigue 13-Item Version 4) I have trouble starting things because I am tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Code Terminology|CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147678>	C147554	FACIT-Fatigue 13-Item Version 4 - Trouble Finishing Things|FAC070-Trouble Finishing Things|FAC070-Trouble Finishing Things|FAC07006	Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 (FACIT-Fatigue 13-Item Version 4) I have trouble finishing things because I am tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Code Terminology|CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147679>	C147554	FACIT-Fatigue 13-Item Version 4 - I Have Energy|FAC070-I Have Energy|FAC070-I Have Energy|FAC07007	Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 (FACIT-Fatigue 13-Item Version 4) I have energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Code Terminology|CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147680>	C147554	FACIT-Fatigue 13-Item Version 4 - Able to Do My Usual Activities|FAC070-Able to Do My Usual Activities|FAC070-Able to Do My Usual Activities|FAC07008	Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 (FACIT-Fatigue 13-Item Version 4) I am able to do my usual activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Code Terminology|CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147681>	C147554	FACIT-Fatigue 13-Item Version 4 - I Need to Sleep During the Day|FAC070-I Need to Sleep During the Day|FAC070-I Need to Sleep During the Day|FAC07009	Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 (FACIT-Fatigue 13-Item Version 4) I need to sleep during the day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Code Terminology|CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147682>	C147554	FACIT-Fatigue 13-Item Version 4 - I Am Too Tired to Eat|FAC070-I Am Too Tired to Eat|FAC070-I Am Too Tired to Eat|FAC07010	Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 (FACIT-Fatigue 13-Item Version 4) I am too tired to eat.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Code Terminology|CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147683>	C147554	FACIT-Fatigue 13-Item Version 4 - Need Help Doing Usual Activities|FAC070-Need Help Doing Usual Activities|FAC070-Need Help Doing Usual Activities|FAC07011	Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 (FACIT-Fatigue 13-Item Version 4) I need help doing my usual activities.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Code Terminology|CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147684>	C147554	FACIT-Fatigue 13-Item Version 4 - Frustrated by Being Too Tired|FAC070-Frustrated by Being Too Tired|FAC070-Frustrated by Being Too Tired|FAC07012	Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 (FACIT-Fatigue 13-Item Version 4) I am frustrated by being too tired to do the things I want to do.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Code Terminology|CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147685>	C147554	FACIT-Fatigue 13-Item Version 4 - Limit Social Activity, I am Tired|FAC070-Limit Social Activity, I am Tired|FAC070-Limit Social Activity, I am Tired|FAC07013	Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 (FACIT-Fatigue 13-Item Version 4) I have to limit my social activity because I am tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Code Terminology|CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147686>	C147555	Peds-FACIT-F - I Feel Tired|FAC099-I Feel Tired|FAC099-I Feel Tired|FAC09901	Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (Peds-FACIT-F) I feel tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Peds-FACIT-F Test Code Terminology|CDISC Questionnaire Peds-FACIT-F Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147687>	C147555	Peds-FACIT-F - I Have Energy|FAC099-I Have Energy|FAC099-I Have Energy|FAC09902	Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (Peds-FACIT-F) I have energy (or strength).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Peds-FACIT-F Test Code Terminology|CDISC Questionnaire Peds-FACIT-F Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147688>	C147555	Peds-FACIT-F - Could Do My Usual Things at Home|FAC099-Could Do My Usual Things at Home|FAC099-Could Do My Usual Things at Home|FAC09903	Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (Peds-FACIT-F) I could do my usual things at home.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Peds-FACIT-F Test Code Terminology|CDISC Questionnaire Peds-FACIT-F Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147689>	C147555	Peds-FACIT-F - Trouble Starting Things|FAC099-Trouble Starting Things|FAC099-Trouble Starting Things|FAC09904	Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (Peds-FACIT-F) I had trouble starting things because I was too tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Peds-FACIT-F Test Code Terminology|CDISC Questionnaire Peds-FACIT-F Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147690>	C147555	Peds-FACIT-F - Trouble Finishing Things|FAC099-Trouble Finishing Things|FAC099-Trouble Finishing Things|FAC09905	Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (Peds-FACIT-F) I had trouble finishing things because I was too tired.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Peds-FACIT-F Test Code Terminology|CDISC Questionnaire Peds-FACIT-F Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147691>	C147555	Peds-FACIT-F - I Needed to Sleep During the Day|FAC099-I Needed to Sleep During the Day|FAC099-I Needed to Sleep During the Day|FAC09906	Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (Peds-FACIT-F) I needed to sleep during the day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Peds-FACIT-F Test Code Terminology|CDISC Questionnaire Peds-FACIT-F Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147692>	C147555	Peds-FACIT-F - Upset by Being Too Tired|FAC099-Upset by Being Too Tired|FAC099-Upset by Being Too Tired|FAC09907	Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (Peds-FACIT-F) I got upset by being too tired to do things I wanted to do.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Peds-FACIT-F Test Code Terminology|CDISC Questionnaire Peds-FACIT-F Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147693>	C147555	Peds-FACIT-F - Hard for Me to Play With Friends|FAC099-Hard for Me to Play With Friends|FAC099-Hard for Me to Play With Friends|FAC09908	Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (Peds-FACIT-F) Being tired made it hard for me to play or go out with my friends as much as I'd like.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Peds-FACIT-F Test Code Terminology|CDISC Questionnaire Peds-FACIT-F Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147694>	C147555	Peds-FACIT-F - Needed Help Doing Usual Things|FAC099-Needed Help Doing Usual Things|FAC099-Needed Help Doing Usual Things|FAC09909	Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (Peds-FACIT-F) I needed help doing my usual things at home.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Peds-FACIT-F Test Code Terminology|CDISC Questionnaire Peds-FACIT-F Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147695>	C147555	Peds-FACIT-F - I Feel Weak|FAC099-I Feel Weak|FAC099-I Feel Weak|FAC09910	Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (Peds-FACIT-F) I feel weak.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Peds-FACIT-F Test Code Terminology|CDISC Questionnaire Peds-FACIT-F Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147696>	C147555	Peds-FACIT-F - I Was Too Tired to Eat|FAC099-I Was Too Tired to Eat|FAC099-I Was Too Tired to Eat|FAC09911	Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (Peds-FACIT-F) I was too tired to eat.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Peds-FACIT-F Test Code Terminology|CDISC Questionnaire Peds-FACIT-F Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147697>	C147555	Peds-FACIT-F - Being Tired Made Me Sad|FAC099-Being Tired Made Me Sad|FAC099-Being Tired Made Me Sad|FAC09912	Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (Peds-FACIT-F) Being tired made me sad.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Peds-FACIT-F Test Code Terminology|CDISC Questionnaire Peds-FACIT-F Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147698>	C147555	Peds-FACIT-F - Being Tired Made Me Mad|FAC099-Being Tired Made Me Mad|FAC099-Being Tired Made Me Mad|FAC09913	Pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (Peds-FACIT-F) Being tired made me mad (angry).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Peds-FACIT-F Test Code Terminology|CDISC Questionnaire Peds-FACIT-F Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147699>	C147556	TSCC - Bad Dreams or Nightmares|TSCC01-Bad Dreams or Nightmares|TSCC01-Bad Dreams or Nightmares|TSCC0101	Trauma Symptom Checklist for Children (TSCC) Bad dreams or nightmares.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C1476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1476>	C575|C222318	Denileukin Diftitox|DAB(389)-Interleukin-2|DAB(389)IL-2|DAB-IL2|DAB389 Interleukin-2|DAB389 Interleukin-2 Immunotoxin|DAB389IL-2|DAB389IL2|DABIL2|DENILEUKIN DIFTITOX|Denileukin Diftitox-cxdl|Denileukin diftitox|Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein E7777|E7777|Interleukin-2 Fusion Protein|Interleukin-2 Fusion Toxin|LY 335348|LY-335348|LY335348|Lymphir|Ontak|Ontak|Remitoro|denileukin diftitox	A cytotoxic recombinant fusion protein consisting of the human cytokine interleukin-2 (IL-2) fused to diphtheria toxin fragments A and B, containing both the catalytic and translocation domains, with potential antineoplastic activity. Upon administration, the IL-2 moiety of denileukin difitox targets and binds to IL-2 receptors. After internalization by IL-2 receptor-expressing cells via endocytosis, denileukin difitox is proteolytically cleaved. This releases the catalytic domain of the toxin moiety, which catalyzes the transfer of the ADP-ribose moiety of NAD to a diphthamide residue of elongation factor 2 (EF-2). This covalent modification inactivates EF-2 and disrupts polypeptide chain elongation, resulting in an inhibition of translation and cell death.	Denileukin Diftitox		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C147700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147700>	C147556	TSCC - Afraid Something Bad Might Happen|TSCC01-Afraid Something Bad Might Happen|TSCC01-Afraid Something Bad Might Happen|TSCC0102	Trauma Symptom Checklist for Children (TSCC) Feeling afraid something bad might happen.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147701>	C147556	TSCC - Scary Ideas Just Pop Into My Head|TSCC01-Scary Ideas Just Pop Into My Head|TSCC01-Scary Ideas Just Pop Into My Head|TSCC0103	Trauma Symptom Checklist for Children (TSCC) Scary ideas or pictures just pop into my head.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147702>	C147556	TSCC - Wanting to Say Dirty Words|TSCC01-Wanting to Say Dirty Words|TSCC01-Wanting to Say Dirty Words|TSCC0104	Trauma Symptom Checklist for Children (TSCC) Wanting to say dirty words.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147703>	C147556	TSCC - Pretending I am Someone Else|TSCC01-Pretending I am Someone Else|TSCC01-Pretending I am Someone Else|TSCC0105	Trauma Symptom Checklist for Children (TSCC) Pretending I am someone else.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147704>	C147556	TSCC - Arguing Too Much|TSCC01-Arguing Too Much|TSCC01-Arguing Too Much|TSCC0106	Trauma Symptom Checklist for Children (TSCC) Arguing too much.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147705>	C147556	TSCC - Feeling Lonely|TSCC01-Feeling Lonely|TSCC01-Feeling Lonely|TSCC0107	Trauma Symptom Checklist for Children (TSCC) Feeling lonely.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147706>	C147556	TSCC - Touching Private Parts Too Much|TSCC01-Touching Private Parts Too Much|TSCC01-Touching Private Parts Too Much|TSCC0108	Trauma Symptom Checklist for Children (TSCC) Touching my private parts too much.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147707>	C147556	TSCC - Feeling Sad or Unhappy|TSCC01-Feeling Sad or Unhappy|TSCC01-Feeling Sad or Unhappy|TSCC0109	Trauma Symptom Checklist for Children (TSCC) Feeling sad or unhappy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147708>	C147556	TSCC - Remembering Things I Didn't Like|TSCC01-Remembering Things I Didn't Like|TSCC01-Remembering Things I Didn't Like|TSCC0110	Trauma Symptom Checklist for Children (TSCC) Remembering things that happened that I didn't like.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147709>	C147556	TSCC - Going Away in My Mind|TSCC01-Going Away in My Mind|TSCC01-Going Away in My Mind|TSCC0111	Trauma Symptom Checklist for Children (TSCC) Going away in my mind, trying not to think.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147710>	C147556	TSCC - Remembering Scary Things|TSCC01-Remembering Scary Things|TSCC01-Remembering Scary Things|TSCC0112	Trauma Symptom Checklist for Children (TSCC) Remembering scary things.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147711>	C147556	TSCC - Wanting to Yell and Break Things|TSCC01-Wanting to Yell and Break Things|TSCC01-Wanting to Yell and Break Things|TSCC0113	Trauma Symptom Checklist for Children (TSCC) Wanting to yell and break things.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147712>	C147556	TSCC - Crying|TSCC01-Crying|TSCC01-Crying|TSCC0114	Trauma Symptom Checklist for Children (TSCC) Crying.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147713>	C147556	TSCC - Getting Scared All of Sudden|TSCC01-Getting Scared All of Sudden|TSCC01-Getting Scared All of Sudden|TSCC0115	Trauma Symptom Checklist for Children (TSCC) Getting scared all of a sudden and don't know why.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147714>	C147556	TSCC - Getting Mad and Can't Calm Down|TSCC01-Getting Mad and Can't Calm Down|TSCC01-Getting Mad and Can't Calm Down|TSCC0116	Trauma Symptom Checklist for Children (TSCC) Getting mad and can't calm down.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147715>	C147556	TSCC - Thinking About Having Sex|TSCC01-Thinking About Having Sex|TSCC01-Thinking About Having Sex|TSCC0117	Trauma Symptom Checklist for Children (TSCC) Thinking about having sex.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147716>	C147556	TSCC - Feeling Dizzy|TSCC01-Feeling Dizzy|TSCC01-Feeling Dizzy|TSCC0118	Trauma Symptom Checklist for Children (TSCC) Feeling dizzy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147717>	C147556	TSCC - Wanting to Yell at People|TSCC01-Wanting to Yell at People|TSCC01-Wanting to Yell at People|TSCC0119	Trauma Symptom Checklist for Children (TSCC) Wanting to yell at people.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147718>	C147556	TSCC - Wanting to Hurt Myself|TSCC01-Wanting to Hurt Myself|TSCC01-Wanting to Hurt Myself|TSCC0120	Trauma Symptom Checklist for Children (TSCC) Wanting to hurt myself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147719>	C147556	TSCC - Wanting to Hurt Other People|TSCC01-Wanting to Hurt Other People|TSCC01-Wanting to Hurt Other People|TSCC0121	Trauma Symptom Checklist for Children (TSCC) Wanting to hurt other people.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147720>	C147556	TSCC - Think Touch People Private Parts|TSCC01-Think Touch People Private Parts|TSCC01-Think Touch People Private Parts|TSCC0122	Trauma Symptom Checklist for Children (TSCC) Thinking about touching other people's private parts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147721>	C147556	TSCC - Think About Sex When Don't Want|TSCC01-Think About Sex When Don't Want|TSCC01-Think About Sex When Don't Want|TSCC0123	Trauma Symptom Checklist for Children (TSCC) Thinking about sex when I don't want to.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147722>	C147556	TSCC - Feeling Scared of Men|TSCC01-Feeling Scared of Men|TSCC01-Feeling Scared of Men|TSCC0124	Trauma Symptom Checklist for Children (TSCC) Feeling scared of men.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147723>	C147556	TSCC - Feeling Scared of Women|TSCC01-Feeling Scared of Women|TSCC01-Feeling Scared of Women|TSCC0125	Trauma Symptom Checklist for Children (TSCC) Feeling scared of women.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147724>	C147556	TSCC - Washing Myself Because Feel Dirty|TSCC01-Washing Myself Because Feel Dirty|TSCC01-Washing Myself Because Feel Dirty|TSCC0126	Trauma Symptom Checklist for Children (TSCC) Washing myself because I feel dirty on the inside.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147725>	C147556	TSCC - Feeling Stupid or Bad|TSCC01-Feeling Stupid or Bad|TSCC01-Feeling Stupid or Bad|TSCC0127	Trauma Symptom Checklist for Children (TSCC) Feeling stupid or bad.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147726>	C147556	TSCC - Feeling Like Did Something Wrong|TSCC01-Feeling Like Did Something Wrong|TSCC01-Feeling Like Did Something Wrong|TSCC0128	Trauma Symptom Checklist for Children (TSCC) Feeling like I did something wrong.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147727>	C147556	TSCC - Feeling Like Things Aren't Real|TSCC01-Feeling Like Things Aren't Real|TSCC01-Feeling Like Things Aren't Real|TSCC0129	Trauma Symptom Checklist for Children (TSCC) Feeling like things aren't real.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147728>	C147556	TSCC - Forgetting Things|TSCC01-Forgetting Things|TSCC01-Forgetting Things|TSCC0130	Trauma Symptom Checklist for Children (TSCC) Forgetting things, can't remember things.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147729>	C147556	TSCC - Feeling Like I'm Not in My Body|TSCC01-Feeling Like I'm Not in My Body|TSCC01-Feeling Like I'm Not in My Body|TSCC0131	Trauma Symptom Checklist for Children (TSCC) Feeling like I'm not in my body.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147730>	C147556	TSCC - Feeling Nervous or Jumpy Inside|TSCC01-Feeling Nervous or Jumpy Inside|TSCC01-Feeling Nervous or Jumpy Inside|TSCC0132	Trauma Symptom Checklist for Children (TSCC) Feeling nervous or jumpy inside.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147731>	C147556	TSCC - Feeling Afraid|TSCC01-Feeling Afraid|TSCC01-Feeling Afraid|TSCC0133	Trauma Symptom Checklist for Children (TSCC) Feeling afraid.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147732>	C147556	TSCC - Not Trusting People Because Sex|TSCC01-Not Trusting People Because Sex|TSCC01-Not Trusting People Because Sex|TSCC0134	Trauma Symptom Checklist for Children (TSCC) Not trusting people because they might want sex.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147733>	C147556	TSCC - Can't Stop Thinking Something Bad|TSCC01-Can't Stop Thinking Something Bad|TSCC01-Can't Stop Thinking Something Bad|TSCC0135	Trauma Symptom Checklist for Children (TSCC) Can't stop thinking about something bad that happened to me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147734>	C147556	TSCC - Getting Into Fights|TSCC01-Getting Into Fights|TSCC01-Getting Into Fights|TSCC0136	Trauma Symptom Checklist for Children (TSCC) Getting into fights.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147735>	C147556	TSCC - Feeling Mean|TSCC01-Feeling Mean|TSCC01-Feeling Mean|TSCC0137	Trauma Symptom Checklist for Children (TSCC) Feeling mean.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147736>	C147556	TSCC - Pretending I'm Somewhere Else|TSCC01-Pretending I'm Somewhere Else|TSCC01-Pretending I'm Somewhere Else|TSCC0138	Trauma Symptom Checklist for Children (TSCC) Pretending I'm somewhere else.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147737>	C147556	TSCC - Being Afraid of the Dark|TSCC01-Being Afraid of the Dark|TSCC01-Being Afraid of the Dark|TSCC0139	Trauma Symptom Checklist for Children (TSCC) Being afraid of the dark.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147738>	C147556	TSCC - Scared When Think About Sex|TSCC01-Scared When Think About Sex|TSCC01-Scared When Think About Sex|TSCC0140	Trauma Symptom Checklist for Children (TSCC) Getting scared or upset when I think about sex.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147739>	C147556	TSCC - Worrying About Things|TSCC01-Worrying About Things|TSCC01-Worrying About Things|TSCC0141	Trauma Symptom Checklist for Children (TSCC) Worrying about things.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14773>	C15161	BALB/c-Hfh11nu X DD/1		BALB/c-Hfh11nu X DD/1		Mammal	
C147740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147740>	C147556	TSCC - Feeling Like Nobody Likes Me|TSCC01-Feeling Like Nobody Likes Me|TSCC01-Feeling Like Nobody Likes Me|TSCC0142	Trauma Symptom Checklist for Children (TSCC) Feeling like nobody likes me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147741>	C147556	TSCC - Remembering Things Don't Want To|TSCC01-Remembering Things Don't Want To|TSCC01-Remembering Things Don't Want To|TSCC0143	Trauma Symptom Checklist for Children (TSCC) Remembering things I don't want to remember.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147742>	C147556	TSCC - Having Sex Feelings in My Body|TSCC01-Having Sex Feelings in My Body|TSCC01-Having Sex Feelings in My Body|TSCC0144	Trauma Symptom Checklist for Children (TSCC) Having sex feelings in my body.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147743>	C147556	TSCC - My Mind Going Empty or Blank|TSCC01-My Mind Going Empty or Blank|TSCC01-My Mind Going Empty or Blank|TSCC0145	Trauma Symptom Checklist for Children (TSCC) My mind going empty or blank.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147744>	C147556	TSCC - Feeling Like I Hate People|TSCC01-Feeling Like I Hate People|TSCC01-Feeling Like I Hate People|TSCC0146	Trauma Symptom Checklist for Children (TSCC) Feeling like I hate people.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147745>	C147556	TSCC - Can't Stop Thinking About Sex|TSCC01-Can't Stop Thinking About Sex|TSCC01-Can't Stop Thinking About Sex|TSCC0147	Trauma Symptom Checklist for Children (TSCC) Can't stop thinking about sex.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147746>	C147556	TSCC - Trying Not to Have Any Feelings|TSCC01-Trying Not to Have Any Feelings|TSCC01-Trying Not to Have Any Feelings|TSCC0148	Trauma Symptom Checklist for Children (TSCC) Trying not to have any feelings.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147747>	C147556	TSCC - Feeling Mad|TSCC01-Feeling Mad|TSCC01-Feeling Mad|TSCC0149	Trauma Symptom Checklist for Children (TSCC) Feeling mad.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147748>	C147556	TSCC - Feeling Afraid Somebody Kill Me|TSCC01-Feeling Afraid Somebody Kill Me|TSCC01-Feeling Afraid Somebody Kill Me|TSCC0150	Trauma Symptom Checklist for Children (TSCC) Feeling afraid somebody will kill me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147749>	C147556	TSCC - Wishing Bad Things Never Happened|TSCC01-Wishing Bad Things Never Happened|TSCC01-Wishing Bad Things Never Happened|TSCC0151	Trauma Symptom Checklist for Children (TSCC) Wishing bad things had never happened.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14774>	C14773	KSN Mouse|KSN		KSN Mouse		Mammal	
C147750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147750>	C147556	TSCC - Wanting to Kill Myself|TSCC01-Wanting to Kill Myself|TSCC01-Wanting to Kill Myself|TSCC0152	Trauma Symptom Checklist for Children (TSCC) Wanting to kill myself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147751>	C147556	TSCC - Daydreaming|TSCC01-Daydreaming|TSCC01-Daydreaming|TSCC0153	Trauma Symptom Checklist for Children (TSCC) Daydreaming.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147752>	C147556	TSCC - Getting Upset People Talk Sex|TSCC01-Getting Upset People Talk Sex|TSCC01-Getting Upset People Talk Sex|TSCC0154	Trauma Symptom Checklist for Children (TSCC) Getting upset when people talk about sex.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCC Test Code Terminology|CDISC Questionnaire TSCC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147753>	C147557	TSCYC - Temper Tantrums|TSCYC1-Temper Tantrums|TSCYC1-Temper Tantrums|TSCYC101	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Temper tantrums.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147754>	C147557	TSCYC - Looking Sad|TSCYC1-Looking Sad|TSCYC1-Looking Sad|TSCYC102	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Looking sad.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147755>	C147557	TSCYC - Telling a Lie|TSCYC1-Telling a Lie|TSCYC1-Telling a Lie|TSCYC103	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Telling a lie.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147756>	C147557	TSCYC - Bad Dreams or Nightmares|TSCYC1-Bad Dreams or Nightmares|TSCYC1-Bad Dreams or Nightmares|TSCYC104	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Bad dreams or nightmares.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147757>	C147557	TSCYC - Living in a Fantasy World|TSCYC1-Living in a Fantasy World|TSCYC1-Living in a Fantasy World|TSCYC105	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Living in a fantasy world.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147758>	C147557	TSCYC - Seeming to Know More About Sex|TSCYC1-Seeming to Know More About Sex|TSCYC1-Seeming to Know More About Sex|TSCYC106	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Seeming to know more about sex than he or she should.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147759>	C147557	TSCYC - Being Easily Scared|TSCYC1-Being Easily Scared|TSCYC1-Being Easily Scared|TSCYC107	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Being easily scared.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147760>	C147557	TSCYC - Not Wanting to Go Somewhere|TSCYC1-Not Wanting to Go Somewhere|TSCYC1-Not Wanting to Go Somewhere|TSCYC108	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Not wanting to go somewhere that reminded him or her of a bad thing from the past.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147761>	C147557	TSCYC - Worrying Food Was Poisoned|TSCYC1-Worrying Food Was Poisoned|TSCYC1-Worrying Food Was Poisoned|TSCYC109	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Worrying that his or her food was poisoned.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147762>	C147557	TSCYC - Flinching When Someone Moved|TSCYC1-Flinching When Someone Moved|TSCYC1-Flinching When Someone Moved|TSCYC110	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Flinching or jumping when someone moved quickly or there was a loud noise.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147763>	C147557	TSCYC - Being Bothered by Memories|TSCYC1-Being Bothered by Memories|TSCYC1-Being Bothered by Memories|TSCYC111	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Being bothered by memories of something that happened to him or her.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147764>	C147557	TSCYC - Worrying Someone Might Be Sexual|TSCYC1-Worrying Someone Might Be Sexual|TSCYC1-Worrying Someone Might Be Sexual|TSCYC112	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Worrying that someone might be sexual with him or her.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147765>	C147557	TSCYC - Not Wanting to Talk|TSCYC1-Not Wanting to Talk|TSCYC1-Not Wanting to Talk|TSCYC113	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Not wanting to talk about something that happened to him or her.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147766>	C147557	TSCYC - Not Do Something Supposed to Do|TSCYC1-Not Do Something Supposed to Do|TSCYC1-Not Do Something Supposed to Do|TSCYC114	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Not doing something he or she was supposed to do.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147767>	C147557	TSCYC - Breaking Things on Purpose|TSCYC1-Breaking Things on Purpose|TSCYC1-Breaking Things on Purpose|TSCYC115	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Breaking things on purpose.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147768>	C147557	TSCYC - Talking About Sexual Things|TSCYC1-Talking About Sexual Things|TSCYC1-Talking About Sexual Things|TSCYC116	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Talking about sexual things.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147769>	C147557	TSCYC - Having Trouble Concentrating|TSCYC1-Having Trouble Concentrating|TSCYC1-Having Trouble Concentrating|TSCYC117	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Having trouble concentrating.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147770>	C147557	TSCYC - Blaming for Things Weren't Fault|TSCYC1-Blaming for Things Weren't Fault|TSCYC1-Blaming for Things Weren't Fault|TSCYC118	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Blaming himself or herself for things that weren't his or her fault.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147771>	C147557	TSCYC - Acting Frightened Reminded Past|TSCYC1-Acting Frightened Reminded Past|TSCYC1-Acting Frightened Reminded Past|TSCYC119	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Acting frightened when he or she was reminded of something that happened in the past.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147772>	C147557	TSCYC - Pretending to Have Sex|TSCYC1-Pretending to Have Sex|TSCYC1-Pretending to Have Sex|TSCYC120	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Pretending to have sex.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147773>	C147557	TSCYC - Worrying Bad Things in Future|TSCYC1-Worrying Bad Things in Future|TSCYC1-Worrying Bad Things in Future|TSCYC121	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Worrying that bad things would happen in the future.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147774>	C147557	TSCYC - Arguing|TSCYC1-Arguing|TSCYC1-Arguing|TSCYC122	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Arguing.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147775>	C147557	TSCYC - Getting Into Physical Fights|TSCYC1-Getting Into Physical Fights|TSCYC1-Getting Into Physical Fights|TSCYC123	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Getting into physical fights.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147776>	C147557	TSCYC - Drawing Pictures Upsetting Thing|TSCYC1-Drawing Pictures Upsetting Thing|TSCYC1-Drawing Pictures Upsetting Thing|TSCYC124	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Drawing pictures about an upsetting thing that happened to him or her.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147777>	C147557	TSCYC - Not Noticing What He or She Doing|TSCYC1-Not Noticing What He or She Doing|TSCYC1-Not Noticing What He or She Doing|TSCYC125	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Not noticing what he or she was doing.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147778>	C147557	TSCYC - Having Trouble Sitting Still|TSCYC1-Having Trouble Sitting Still|TSCYC1-Having Trouble Sitting Still|TSCYC126	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Having trouble sitting still.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147779>	C147557	TSCYC - Playing Games Something Bad Past|TSCYC1-Playing Games Something Bad Past|TSCYC1-Playing Games Something Bad Past|TSCYC127	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Playing games about something bad that actually happened to him or her in the past.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C14777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14777>	C14421	DDY Mouse|DDY		DDY Mouse		Mammal	
C147780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147780>	C147557	TSCYC - Seeming to Be in a Daze|TSCYC1-Seeming to Be in a Daze|TSCYC1-Seeming to Be in a Daze|TSCYC128	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Seeming to be in a daze.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147781>	C147557	TSCYC - Trouble Remember Upsetting Thing|TSCYC1-Trouble Remember Upsetting Thing|TSCYC1-Trouble Remember Upsetting Thing|TSCYC129	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Having trouble remembering an upsetting thing that happened in the past.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147782>	C147557	TSCYC - Using Drugs|TSCYC1-Using Drugs|TSCYC1-Using Drugs|TSCYC130	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Using drugs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147783>	C147557	TSCYC - Fear of the Dark|TSCYC1-Fear of the Dark|TSCYC1-Fear of the Dark|TSCYC131	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Fear of the dark.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147784>	C147557	TSCYC - Being Afraid to Be Alone|TSCYC1-Being Afraid to Be Alone|TSCYC1-Being Afraid to Be Alone|TSCYC132	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Being afraid to be alone.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147785>	C147557	TSCYC - Spacing Out|TSCYC1-Spacing Out|TSCYC1-Spacing Out|TSCYC133	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Spacing out.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147786>	C147557	TSCYC - Being Too Aggressive|TSCYC1-Being Too Aggressive|TSCYC1-Being Too Aggressive|TSCYC134	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Being too aggressive.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147787>	C147557	TSCYC - Touching Other Private Parts|TSCYC1-Touching Other Private Parts|TSCYC1-Touching Other Private Parts|TSCYC135	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often he or she has done, felt, or experienced each of the following things in the last month: Touching other children's or adults' private parts (under or over clothes).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147788>	C147557	TSCYC - Seeing Bad Happened in the Past|TSCYC1-Seeing Bad Happened in the Past|TSCYC1-Seeing Bad Happened in the Past|TSCYC136	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Suddenly seeing, feeling, or hearing something bad that happened in the past.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147789>	C147557	TSCYC - Hearing Voices to Hurt Someone|TSCYC1-Hearing Voices to Hurt Someone|TSCYC1-Hearing Voices to Hurt Someone|TSCYC137	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Hearing voices telling him or her to hurt someone.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147790>	C147557	TSCYC - Staring Off Into Space|TSCYC1-Staring Off Into Space|TSCYC1-Staring Off Into Space|TSCYC138	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Staring off into space.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147791>	C147557	TSCYC - Changing Subject About Bad Thing|TSCYC1-Changing Subject About Bad Thing|TSCYC1-Changing Subject About Bad Thing|TSCYC139	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Changing the subject or not answering when he or she was asked about a bad thing that happened to him or her.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147792>	C147557	TSCYC - Having a Nervous Breakdown|TSCYC1-Having a Nervous Breakdown|TSCYC1-Having a Nervous Breakdown|TSCYC140	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Having a nervous breakdown.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147793>	C147557	TSCYC - Not Happy Like Other Children|TSCYC1-Not Happy Like Other Children|TSCYC1-Not Happy Like Other Children|TSCYC141	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Not laughing or being happy like other children.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147794>	C147557	TSCYC - Crying at Night Frightened|TSCYC1-Crying at Night Frightened|TSCYC1-Crying at Night Frightened|TSCYC142	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Crying at night because he or she was frightened.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147795>	C147557	TSCYC - Hitting Adults|TSCYC1-Hitting Adults|TSCYC1-Hitting Adults|TSCYC143	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Hitting adults (including parents).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147796>	C147557	TSCYC - Being Frightened of Men|TSCYC1-Being Frightened of Men|TSCYC1-Being Frightened of Men|TSCYC144	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Being frightened of men.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147797>	C147557	TSCYC - Not Being Able to Pay Attention|TSCYC1-Not Being Able to Pay Attention|TSCYC1-Not Being Able to Pay Attention|TSCYC145	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Not being able to pay attention.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147798>	C147557	TSCYC - Seeming to Be Million Miles Away|TSCYC1-Seeming to Be Million Miles Away|TSCYC1-Seeming to Be Million Miles Away|TSCYC146	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Seeming to be a million miles away.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147799>	C147557	TSCYC - Being Easily Startled|TSCYC1-Being Easily Startled|TSCYC1-Being Easily Startled|TSCYC147	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Being easily startled.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C1477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1477>	C308	Milodistim|23-L-Leucine-27-L-aspartic acid-39-L-glutamic acid-colony-stimulating factor 2 (Human Clone pHG25 Protein Moiety Reduced), (127-9')-protein with 9-Glycine-10-glycine-11-glycine-12-glycine-13-L-serine-14-glycine-15-glycine-16-glycine-18-glycine-19-L-serine-34-L-aspartic acid-89-L-aspartic acid-9-152-interleukin 3 (human clone D11 Precursor Protein Moiety Reduced)|GM-CSF/IL-3 Fusion Protein|GM-CSF/IL3 Fusion Protein|Granulocyte-Macrophage Colony Stimulating Factor/Interleukin-3 Fusion Protein|MILODISTIM|PIXY321|Pixykine	A recombinant fusion protein derived from the coding sequences of two growth factors, interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF).  Milodistim exhibits greater receptor binding affinity and colony stimulating activity than its parent cytokines.  This agent stimulates proliferation of immature hematopoietic cells and allows the stimulation and expansion of multi-lineage hematopoiesis from immature bone marrow progenitor cells. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C147800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147800>	C147557	TSCYC - Watching Out for Possible Danger|TSCYC1-Watching Out for Possible Danger|TSCYC1-Watching Out for Possible Danger|TSCYC148	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Watching out everywhere for possible danger.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147801>	C147557	TSCYC - No Longer Doing Things Enjoy|TSCYC1-No Longer Doing Things Enjoy|TSCYC1-No Longer Doing Things Enjoy|TSCYC149	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: No longer doing things that he or she used to enjoy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147802>	C147557	TSCYC - Frightened Something Sexual Seen|TSCYC1-Frightened Something Sexual Seen|TSCYC1-Frightened Something Sexual Seen|TSCYC150	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Becoming frightened or disturbed when something sexual was mentioned or seen.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147803>	C147557	TSCYC - Not Sleeping for Two or More Days|TSCYC1-Not Sleeping for Two or More Days|TSCYC1-Not Sleeping for Two or More Days|TSCYC151	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Not sleeping for two or more days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147804>	C147557	TSCYC - Not Paying Attention in Own World|TSCYC1-Not Paying Attention in Own World|TSCYC1-Not Paying Attention in Own World|TSCYC152	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Not paying attention because he or she was in his or her own world.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147805>	C147557	TSCYC - Making Mistakes|TSCYC1-Making Mistakes|TSCYC1-Making Mistakes|TSCYC153	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Making mistakes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147806>	C147557	TSCYC - Crying for No Obvious Reason|TSCYC1-Crying for No Obvious Reason|TSCYC1-Crying for No Obvious Reason|TSCYC154	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Crying for no obvious reason.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147807>	C147557	TSCYC - Not Wanting to Be Around Someone|TSCYC1-Not Wanting to Be Around Someone|TSCYC1-Not Wanting to Be Around Someone|TSCYC155	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Not wanting to be around someone who did something bad to him or her or reminded him or her of something bad.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147808>	C147557	TSCYC - Being Tense|TSCYC1-Being Tense|TSCYC1-Being Tense|TSCYC156	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Being tense.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147809>	C147557	TSCYC - Worrying About People's Safety|TSCYC1-Worrying About People's Safety|TSCYC1-Worrying About People's Safety|TSCYC157	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Worrying about other people's safety.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147810>	C147557	TSCYC - Very Angry Over a Little Thing|TSCYC1-Very Angry Over a Little Thing|TSCYC1-Very Angry Over a Little Thing|TSCYC158	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Becoming very angry over a little thing.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147811>	C147557	TSCYC - Drawing Pictures About Sex Things|TSCYC1-Drawing Pictures About Sex Things|TSCYC1-Drawing Pictures About Sex Things|TSCYC159	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Drawing pictures about sexual things.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147812>	C147557	TSCYC - Pulling His or Her Hair Out|TSCYC1-Pulling His or Her Hair Out|TSCYC1-Pulling His or Her Hair Out|TSCYC160	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Pulling his or her hair out.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147813>	C147557	TSCYC - Calling Himself or Herself Bad|TSCYC1-Calling Himself or Herself Bad|TSCYC1-Calling Himself or Herself Bad|TSCYC161	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Calling himself or herself bad, stupid, or ugly.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147814>	C147557	TSCYC - Throwing Things at Friends/Family|TSCYC1-Throwing Things at Friends/Family|TSCYC1-Throwing Things at Friends/Family|TSCYC162	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Throwing things at friends or family members.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147815>	C147557	TSCYC - Getting Upset About the Past|TSCYC1-Getting Upset About the Past|TSCYC1-Getting Upset About the Past|TSCYC163	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Getting upset about something in the past.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147816>	C147557	TSCYC - Temporary Blindness or Paralysis|TSCYC1-Temporary Blindness or Paralysis|TSCYC1-Temporary Blindness or Paralysis|TSCYC164	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Temporary blindness or paralysis.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147817>	C147557	TSCYC - Getting Upset Something Sexual|TSCYC1-Getting Upset Something Sexual|TSCYC1-Getting Upset Something Sexual|TSCYC165	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Getting upset about something sexual.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147818>	C147557	TSCYC - Not Going to Bed First Time Asked|TSCYC1-Not Going to Bed First Time Asked|TSCYC1-Not Going to Bed First Time Asked|TSCYC166	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Not going to bed at night the first time he or she was asked.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147819>	C147557	TSCYC - Fear He or She Killed by Someone|TSCYC1-Fear He or She Killed by Someone|TSCYC1-Fear He or She Killed by Someone|TSCYC167	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Fear that he or she would be killed by someone.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147820>	C147557	TSCYC - Saying Nobody Liked Him or Her|TSCYC1-Saying Nobody Liked Him or Her|TSCYC1-Saying Nobody Liked Him or Her|TSCYC168	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Saying that nobody liked him or her.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147821>	C147557	TSCYC - Crying When Reminded From Past|TSCYC1-Crying When Reminded From Past|TSCYC1-Crying When Reminded From Past|TSCYC169	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Crying when he or she was reminded of something from the past.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147822>	C147557	TSCYC - Saying Bad Didn't Happen|TSCYC1-Saying Bad Didn't Happen|TSCYC1-Saying Bad Didn't Happen|TSCYC170	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Saying that something bad didn't happen to him or her even though it did happen.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147823>	C147557	TSCYC - Saying He or She Wanted to Die|TSCYC1-Saying He or She Wanted to Die|TSCYC1-Saying He or She Wanted to Die|TSCYC171	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Saying he or she wanted to die or be killed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147824>	C147557	TSCYC - Acting as If Didn't Have Feelings|TSCYC1-Acting as If Didn't Have Feelings|TSCYC1-Acting as If Didn't Have Feelings|TSCYC172	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Acting as if he or she didn't have any feelings about something bad that happened to him or her.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147825>	C147557	TSCYC - Whining|TSCYC1-Whining|TSCYC1-Whining|TSCYC173	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Whining.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147826>	C147557	TSCYC - Not Sleeping Well|TSCYC1-Not Sleeping Well|TSCYC1-Not Sleeping Well|TSCYC174	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Not sleeping well.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147827>	C147557	TSCYC - Worrying About Sexual Things|TSCYC1-Worrying About Sexual Things|TSCYC1-Worrying About Sexual Things|TSCYC175	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Worrying about sexual things.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147828>	C147557	TSCYC - Being Frightened by Things|TSCYC1-Being Frightened by Things|TSCYC1-Being Frightened by Things|TSCYC176	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Being frightened by things that didn't used to scare him or her.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147829>	C147557	TSCYC - Hallucinating|TSCYC1-Hallucinating|TSCYC1-Hallucinating|TSCYC177	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Hallucinating.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147830>	C147557	TSCYC - Acting Like He or She Was in Trance|TSCYC1-Acting Like He/She Was in Trance|TSCYC1-Acting Like He/She Was in Trance|TSCYC178	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Acting like he or she was in a trance.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147831>	C147557	TSCYC - Forgetting His or Her Own Name|TSCYC1-Forgetting His or Her Own Name|TSCYC1-Forgetting His or Her Own Name|TSCYC179	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Forgetting his or her own name.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147832>	C147557	TSCYC - Upset When Reminded Bad Happened|TSCYC1-Upset When Reminded Bad Happened|TSCYC1-Upset When Reminded Bad Happened|TSCYC180	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Getting upset when he or she was reminded of something bad that happened.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147833>	C147557	TSCYC - Avoiding Bad Happened in Past|TSCYC1-Avoiding Bad Happened in Past|TSCYC1-Avoiding Bad Happened in Past|TSCYC181	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Avoiding things that reminded him or her of a bad thing that had happened in the past.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147834>	C147557	TSCYC - Acting Jumpy|TSCYC1-Acting Jumpy|TSCYC1-Acting Jumpy|TSCYC182	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Acting jumpy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147835>	C147557	TSCYC - Making a Mess|TSCYC1-Making a Mess|TSCYC1-Making a Mess|TSCYC183	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Making a mess.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147836>	C147557	TSCYC - Acting Sad or Depressed|TSCYC1-Acting Sad or Depressed|TSCYC1-Acting Sad or Depressed|TSCYC184	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Acting sad or depressed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147837>	C147557	TSCYC - Being Absent-minded|TSCYC1-Being Absent-minded|TSCYC1-Being Absent-minded|TSCYC185	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Being so absent-minded that he or she didn't notice what was going on around him or her.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147838>	C147557	TSCYC - Not Wanting to Eat Certain Foods|TSCYC1-Not Wanting to Eat Certain Foods|TSCYC1-Not Wanting to Eat Certain Foods|TSCYC186	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Not wanting to eat certain foods.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147839>	C147557	TSCYC - Yelling at Family, Friends or Teachers|TSCYC1-Yelling at Family/Friend/Teachers|TSCYC1-Yelling at Family/Friend/Teachers|TSCYC187	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Yelling at family, friends, or teachers.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147840>	C147557	TSCYC - Not Playing Because Depressed|TSCYC1-Not Playing Because Depressed|TSCYC1-Not Playing Because Depressed|TSCYC188	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Not playing because he or she was depressed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147841>	C147557	TSCYC - Being Disobedient|TSCYC1-Being Disobedient|TSCYC1-Being Disobedient|TSCYC189	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Being disobedient.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147842>	C147557	TSCYC - Intentionally Hurt Other Children|TSCYC1-Intentionally Hurt Other Children|TSCYC1-Intentionally Hurt Other Children|TSCYC190	Trauma Symptom Checklist for Young Children (TSCYC) Please indicate how often the child has done, felt, or experienced each of the following things in the last month: Intentionally hurting other children or family members.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire TSCYC Test Code Terminology|CDISC Questionnaire TSCYC Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147843>	C147551	ATLAS - Age|ATLAS1-Age|ATLAS1-Age|ATLAS101	ATLAS Score (ATLAS) Age.			Intellectual Product	CDISC Clinical Classification ATLAS Test Code Terminology|CDISC Clinical Classification ATLAS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147844>	C147551	ATLAS - Treatment With Antibiotics|ATLAS1-Treatment With Antibiotics|ATLAS1-Treatment With Antibiotics|ATLAS102	ATLAS Score (ATLAS) Treatment with systemic antibiotics during CDI therapy (>= 1 day).			Intellectual Product	CDISC Clinical Classification ATLAS Test Code Terminology|CDISC Clinical Classification ATLAS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147845>	C147551	ATLAS - Leukocyte Count|ATLAS1-Leukocyte Count|ATLAS1-Leukocyte Count|ATLAS103	ATLAS Score (ATLAS) Leukocyte count (total).			Intellectual Product	CDISC Clinical Classification ATLAS Test Code Terminology|CDISC Clinical Classification ATLAS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147846>	C147551	ATLAS - Albumin|ATLAS1-Albumin|ATLAS1-Albumin|ATLAS104	ATLAS Score (ATLAS) Albumin (serum).			Intellectual Product	CDISC Clinical Classification ATLAS Test Code Terminology|CDISC Clinical Classification ATLAS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147847>	C147551	ATLAS - Serum Creatinine|ATLAS1-Serum Creatinine|ATLAS1-Serum Creatinine|ATLAS105	ATLAS Score (ATLAS) Serum creatinine (as a measure of renal function).			Intellectual Product	CDISC Clinical Classification ATLAS Test Code Terminology|CDISC Clinical Classification ATLAS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147848>	C147551	ATLAS - Score|ATLAS1-Score|ATLAS1-Score|ATLAS106	ATLAS Score (ATLAS) Score.			Intellectual Product	CDISC Clinical Classification ATLAS Test Code Terminology|CDISC Clinical Classification ATLAS Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C147849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147849>	C21295	IGF2BP2 Gene|IGF2BP2|IGF2BP2|Insulin-Like Growth Factor 2 mRNA Binding Protein 2 Gene	This gene plays a role in RNA transport and mRNA stability.			Gene or Genome	
C147850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147850>	C147849	IGF2BP2 wt Allele|IMP-2|IMP2|Insulin Like Growth Factor 2 mRNA Binding Protein 2 wt Allele|VICKZ2	Human IGF2BP2 wild-type allele is located in the vicinity of 3q27.2 and is approximately 182 kb in length. This allele, which encodes insulin-like growth factor 2 mRNA-binding protein 2, is involved in transport and stabilization of mRNA. Variation in the gene is associated with susceptibility to type 2 diabetes mellitus.			Gene or Genome	
C147851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147851>	C21298	Insulin-Like Growth Factor 2 mRNA Binding Protein 2|Hepatocellular Carcinoma Autoantigen p62|IGF II mRNA Binding Protein 2|IGF-II mRNA-Binding Protein 2|IGF2 mRNA-Binding Protein 2|IGF2BP2|IMP-2|VICKZ Family Member 2	Insulin-like growth factor 2 mRNA-binding protein 2 (599 aa, ~66 kDa) is encoded by the human IGF2BP2 gene. This protein plays a role in the translation, localization and stability of mRNA.			Amino Acid, Peptide, or Protein	
C147852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147852>	C15493	Estrogen Receptor Status 0|ER IHC 0|ER Status 0	An immunohistochemical result of 0 for estrogen receptor expression that is considered negative for expression.			Laboratory or Test Result	
C147853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147853>	C177694|C16150	Estrogen Receptor Status 1+|ER IHC 1+|ER Status 1+	An immunohistochemical result of 1 for estrogen receptor expression that is considered weak for expression.			Laboratory or Test Result	
C147854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147854>	C16150	Estrogen Receptor Status 2+|ER IHC 2+|ER Status 2+	An immunohistochemical result of 2 for estrogen receptor expression that is considered intermediate for expression.			Laboratory or Test Result	
C147855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147855>	C141465	Estrogen Receptor Status 3+|ER IHC 3+|ER Status 3+	An immunohistochemical result of 3 for estrogen receptor expression that is considered positive for expression.			Laboratory or Test Result	
C147856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147856>	C15497	Progesterone Receptor Status 0|PgR IHC 0|PgR Status 0	An immunohistochemical result of 0 for progesterone receptor expression that is considered negative for expression.			Laboratory or Test Result	
C147857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147857>	C16149	Progesterone Receptor Status 1+|PgR IHC 2+|PgR Status 2+	An immunohistochemical result of 1 for progesterone receptor expression that is considered intermediate for expression.			Laboratory or Test Result	
C147858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147858>	C16149	Progesterone Receptor Status 2+|PgR IHC 2+|PgR Status 2+	An immunohistochemical result of 2 for progesterone receptor expression that is considered intermediate for expression.			Laboratory or Test Result	
C147859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147859>	C141458	Progesterone Receptor Status 3+|PgR IHC 3+|PgR Status 3+	An immunohistochemical result of 3 for progesterone receptor expression that is considered positive for expression.			Laboratory or Test Result	
C147860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147860>	C116519	Computer-Based Cognitive Stimulation Intervention|Computer-Based General Cognitive Stimulation Intervention	Computer-based programs designed to improve thinking, concentration, memory, and communication.	Computer-Based Cognitive Stimulation Intervention		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C147861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147861>	C9308	Recurrent Lymphoproliferative Disorder	The reemergence of a lymphoproliferative disorder after a period of remission.	Recurrent Lymphoproliferative Disorder		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C147863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147863>	C27691|C134157	Recurrent EBV-Related Lymphoma|Recurrent EBV-Associated Lymphoma	The reemergence of EBV-related lymphoma after a period of remission.	Recurrent EBV-Related Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C147864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147864>	C20921	LEPROTL1 Gene|LEPROTL1|LEPROTL1|Leptin Receptor Overlapping Transcript Like 1 Gene	This gene is involved in the downregulation of growth hormone receptor (GHR) signaling.			Gene or Genome	
C147865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147865>	C147864	LEPROTL1 wt Allele|HSPC112|Leptin Receptor Overlapping Transcript Like 1 wt Allele|UNQ577/PRO1139|Vps55|my047	Human LEPROTL1 wild-type allele is located in the vicinity of 8p12 and is approximately 82 kb in length. This allele, which encodes leptin receptor overlapping transcript-like 1 protein, plays a role in the negative regulation of growth hormone receptor (GHR) signaling.			Gene or Genome	
C147866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147866>	C18515	Leptin Receptor Overlapping Transcript-Like 1|Endospanin-2|LEPROTL1	Leptin receptor overlapping transcript-like 1 (131 aa, ~14 kDa) is encoded by the human LEPROTL1 gene. This protein is involved in the modulation of growth hormone receptor (GHR) localization to the cell surface.			Amino Acid, Peptide, or Protein	
C147867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147867>	C25952|C25871	N4BP2 Gene|N4BP2|N4BP2|NEDD4 Binding Protein 2 Gene	This gene plays a role in 5'-polydeoxyribonucleotide kinase and nicking endonuclease activity.			Gene or Genome	
C147868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147868>	C147867	N4BP2 wt Allele|B3BP|KIAA1413|NEDD4 Binding Protein 2 wt Allele	Human N4BP2 wild-type allele is located in the vicinity of 4p14 and is approximately 130 kb in length. This allele, which encodes NEDD4-binding protein 2, is involved in DNA processing.			Gene or Genome	
C147869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147869>	C16984|C16499	NEDD4-Binding Protein 2|BCL-3 Binding Protein|BCL-3-Binding Protein|N4BP2	NEDD4-binding protein 2 (1770 aa, ~199 kDa) is encoded by the human N4BP2 gene. This protein plays a role in DNA modification.			Amino Acid, Peptide, or Protein|Enzyme	
C147870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147870>	C20420	SOX21 Gene|SOX21|SOX21|SRY-Box 21 Gene	This gene is involved in the promotion of cellular differentiation.			Gene or Genome	
C147871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147871>	C217121|C21154	Undesired Appetite Increase Scale	A scale for the subjective scoring of undesired appetite increase that ranges from 0: No undesired appetite increase at all to 10: Undesired appetite increase as bad as it can be.			Intellectual Product	
C147872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147872>	C221066	Undesired Appetite Increase Score 0	A subjective score of 0 on a scale that ranges from 0: No undesired appetite increase at all to 10: Undesired appetite increase as bad as it can be.			Intellectual Product	
C147873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147873>	C221066	Undesired Appetite Increase Score 1	A subjective score of 1 on a scale that ranges from 0: No undesired appetite increase at all to 10: Undesired appetite increase as bad as it can be.			Intellectual Product	
C147874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147874>	C221066	Undesired Appetite Increase Score 2	A subjective score of 2 on a scale that ranges from 0: No undesired appetite increase at all to 10: Undesired appetite increase as bad as it can be.			Intellectual Product	
C147875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147875>	C221066	Undesired Appetite Increase Score 3	A subjective score of 3 on a scale that ranges from 0: No undesired appetite increase at all to 10: Undesired appetite increase as bad as it can be.			Intellectual Product	
C147876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147876>	C221066	Undesired Appetite Increase Score 4	A subjective score of 4 on a scale that ranges from 0: No undesired appetite increase at all to 10: Undesired appetite increase as bad as it can be.			Intellectual Product	
C147877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147877>	C221066	Undesired Appetite Increase Score 5	A subjective score of 5 on a scale that ranges from 0: No undesired appetite increase at all to 10: Undesired appetite increase as bad as it can be.			Intellectual Product	
C147878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147878>	C147870	SOX21 wt Allele|SOX25|SOXA|SRY (Sex Determining Region Y)-Box 21 Gene|SRY Box 21 Gene|SRY-Box 21 wt Allele|SRY-Related HMG-Box Gene 21	Human SOX21 wild-type allele is located in the vicinity of 13q32.1 and is approximately 3 kb in length. This allele, which encodes transcription factor SOX-21 protein, plays a role in transcriptional regulation and cellular differentiation.			Gene or Genome	
C147879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147879>	C221066	Undesired Appetite Increase Score 6	A subjective score of 6 on a scale that ranges from 0: No undesired appetite increase at all to 10: Undesired appetite increase as bad as it can be.			Intellectual Product	
C147880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147880>	C221066	Undesired Appetite Increase Score 7	A subjective score of 7 on a scale that ranges from 0: No undesired appetite increase at all to 10: Undesired appetite increase as bad as it can be.			Intellectual Product	
C147881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147881>	C221066	Undesired Appetite Increase Score 8	A subjective score of 8 on a scale that ranges from 0: No undesired appetite increase at all to 10: Undesired appetite increase as bad as it can be.			Intellectual Product	
C147882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147882>	C221066	Undesired Appetite Increase Score 9	A subjective score of 9 on a scale that ranges from 0: No undesired appetite increase at all to 10: Undesired appetite increase as bad as it can be.			Intellectual Product	
C147883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147883>	C221066	Undesired Appetite Increase Score 10	A subjective score of 10 on a scale that ranges from 0: No undesired appetite increase at all to 10: Undesired appetite increase as bad as it can be.			Intellectual Product	
C147884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147884>	C17207	Transcription Factor SOX-21|SOX-A|SOX21	Transcription factor SOX-21 (276 aa, ~29 kDa) is encoded by the human SOX21 gene. This protein is involved in cellular differentiation and transcriptional regulation.			Amino Acid, Peptide, or Protein	
C147885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147885>	C217121|C21154	Undesired Sedation Scale	A scale for the subjective scoring of undesired sedation that ranges from 0: No undesired sedation at all to 10: Undesired sedation as bad as it can be.			Intellectual Product	
C147886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147886>	C221068	Undesired Sedation Score 0	A subjective score of 0 on a scale that ranges from 0: No undesired sedation at all to 10: Undesired sedation as bad as it can be.			Intellectual Product	
C147887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147887>	C221068	Undesired Sedation Score 1	A subjective score of 1 on a scale that ranges from 0: No undesired sedation at all to 10: undesired sedation as bad as it can be.			Intellectual Product	
C147888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147888>	C221068	Undesired Sedation Score 2	A subjective score of 2 on a scale that ranges from 0: No undesired sedation at all to 10: undesired sedation as bad as it can be.			Intellectual Product	
C147889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147889>	C221068	Undesired Sedation Score 3	A subjective score of 3 on a scale that ranges from 0: No undesired sedation at all to 10: undesired sedation as bad as it can be.			Intellectual Product	
C147890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147890>	C221068	Undesired Sedation Score 4	A subjective score of 4 on a scale that ranges from 0: No undesired sedation at all to 10: undesired sedation as bad as it can be.			Intellectual Product	
C147891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147891>	C221068	Undesired Sedation Score 5	A subjective score of 5 on a scale that ranges from 0: No undesired sedation at all to 10: undesired sedation as bad as it can be.			Intellectual Product	
C147892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147892>	C221068	Undesired Sedation Score 6	A subjective score of 6 on a scale that ranges from 0: No undesired sedation at all to 10: undesired sedation as bad as it can be.			Intellectual Product	
C147893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147893>	C20912	IL23R Gene|IL23R|IL23R|Interleukin 23 Receptor Gene	This gene plays a role in interleukin signaling, immunity and inflammation.			Gene or Genome	
C147894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147894>	C221068	Undesired Sedation Score 7	A subjective score of 7 on a scale that ranges from 0: No undesired sedation at all to 10: undesired sedation as bad as it can be.			Intellectual Product	
C147895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147895>	C221068	Undesired Sedation Score 8	A subjective score of 8 on a scale that ranges from 0: No undesired sedation at all to 10: undesired sedation as bad as it can be.			Intellectual Product	
C147896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147896>	C221068	Undesired Sedation Score 9	A subjective score of 9 on a scale that ranges from 0: No undesired sedation at all to 10: undesired sedation as bad as it can be.			Intellectual Product	
C147897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147897>	C221068	Undesired Sedation Score 10	A subjective score of 10 on a scale that ranges from 0: No undesired sedation at all to 10: undesired sedation as bad as it can be.			Intellectual Product	
C147898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147898>	C147893	IL23R wt Allele|Interleukin 23 Receptor wt Allele	Human IL23R wild-type allele is located in the vicinity of 1p31.3 and is approximately 121 kb in length. This allele, which encodes interleukin-23 receptor, is involved in immune cell activation.			Gene or Genome	
C1478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1478>	C2554	QS21|NIAID VEU 016|Purified Quillaja Saponin|QS-21|QS-21 Adjuvant|QUILLAJA SAPONIN (QS-21)|Stimulon QS-21 Adjuvant	A purified, natural saponin isolated from the soapbark tree Quillaja saponaria Molina with potential immunoadjuvant activity. When co-administered with vaccine peptides, QS21 may increase total antitumoral vaccine-specific antibody responses and cytotoxic T-cell responses.	QS21		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C147900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147900>	C17667	Interleukin-23 Receptor|IL-23 Receptor|IL-23R|IL23 Receptor|IL23R|Interleukin 23 Receptor	Interleukin-23 receptor (629 aa, ~72 kDa) is encoded by the human IL23R gene. This protein plays a role in JAK-STAT signaling and immune cell activation.			Amino Acid, Peptide, or Protein|Receptor	
C147901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147901>	C5136|C4642|C187207	Childhood Brain Glioblastoma|Brain Glioblastoma	A brain glioblastoma that occurs during childhood.	Childhood Brain Glioblastoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C147902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147902>	C97927	ABCD1 Gene Mutation|ABC42 Gene Mutation|ALD Gene Mutation|ALDP Gene Mutation|AMN Gene Mutation|ATP Binding Cassette Subfamily D Member 1 Gene Mutation|ATP-Binding Cassette, Subfamily D, Member 1 Gene Mutation	A change in the nucleotide sequence of the ABCD1 gene.	ABCD1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147903>	C124447	Number of Lymph Nodes with Micrometastases	The number of examined lymph nodes that were positive for micrometastases.			Quantitative Concept	
C147904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147904>	C124447	Number of Lymph Nodes with Macrometastases	The number of examined lymph nodes that were positive for macrometastases.			Quantitative Concept	
C147905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147905>	C17241	Urine Dipstick Test|Urine Test Strip	Use of a test strip designed to detect one or more specific substances in urine. Results are indicated by a color change and may be qualitative or semi-quantitative.			Laboratory Procedure	
C147906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147906>	C8181	Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma|Oropharyngeal Squamous Cell Carcinoma, p16INK4a Negative|p16INK4a Negative Oropharyngeal Squamous Cell Cancer|p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma	An oropharyngeal squamous cell carcinoma which is negative for p16INK4a by immunohistochemistry. This negative immunohistochemistry result does not exclude human papillomavirus infection.	p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C147908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147908>	C1909	Hormone Therapy Agent|Hormonal Therapy Agent|Hormone Therapy|Hormone Therapy Drug	Any agent that can alter hormone levels or modulate hormone effects.	Hormone Therapy Agent		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C147909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147909>	C20993	Vascular Thrombosis Response|RECIST Vascular Thrombosis Response	Guidelines for monitoring and reporting vascular thrombosis response. These guidelines are consistent with RECIST1.1 and consider thrombosis as a non-measurable disease.			Intellectual Product	
C147910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147910>	C147909	irCR Thrombosis|irCR	Complete resolution of thrombosis, with recanalization of vessel.			Intellectual Product	
C147911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147911>	C147909	irPR Thrombosis|irPR	Any of a) partial recanalization of thrombosis (if prior complete blockage), b) unequivocal reduction in the maximal girth of thrombosis, c) unequivocal reduction in the volume, or elimination, of arterial enhancing portion of thrombosis.			Intellectual Product	
C147912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147912>	C147909	irPD Thrombosis|irPD	Any unequivocal, unambiguous increase in the volume of new or existing enhancing thrombosis. Unequivocal progression of thrombosis corresponds to at least 73% increase in volume, which is similar to 20% increase in diameter, and at least a 5 mm absolute increase.			Intellectual Product	
C147913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147913>	C147909	irSD Thrombosis|irSD	Any of a) no change or small changes that do not meet the criteria for irPR or irPD, taking as reference the smallest sum diameters while on study, b) increase in the volume of non-enhancing thrombosis, c) new bland non-enhancing thrombosis.			Intellectual Product	
C147914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147914>	C20181	Strategy	A plan of action intended to accomplish a specific goal.			Activity	
C147915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147915>	C18000	Breast Carcinoma Grade|Breast Cancer Grade|Breast Cancer Modified Nottingham Grade|Modified Nottingham Grade|Modified Nottingham Grade for Breast Cancer	A modification of the Nottingham grading system for use in grading breast carcinoma.			Classification	
C147916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147916>	C28077|C147915	Breast Carcinoma Grade G1|Breast Cancer Grade G1|G1	A low combined histologic grade (favorable), SBR score of 3-5 points.			Classification	
C147917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147917>	C28078|C147915	Breast Carcinoma Grade G2|Breast Cancer Grade G2|G2	An intermediate combined histologic grade (moderately favorable), SBR score of 6-7 points.			Classification	
C147918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147918>	C28079|C147915	Breast Carcinoma Grade G3|Breast Cancer Grade G3|G3	A high combined histologic grade (unfavorable), SBR score of 8-9 points.			Classification	
C147919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147919>	C13717	Ill-Defined Anatomic Site|Ill-Defined Site	An anatomic site that is not specified or defined well enough to associate with a specific site.			Body Location or Region	
C147920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147920>	C243|C242	Selective Androgen Receptor Modulator|SARM				Chemical Viewed Functionally	
C147922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147922>	C39752	Ibrutinib Resistance	A finding indicating that chronic lymphocytic leukemia does not respond to treatment with Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib.	Ibrutinib Resistance		Finding	CTRP Biomarker Terminology|CTRP Terminology
C147923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147923>	C471|C242	CYP17A1 Inhibitor|17,20-lyase Inhibitor|CYP17 Inhibitor	Any agent that inhibits the activity of the enzyme CYP17A1.			Chemical Viewed Functionally	
C147924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147924>	C162158|C128798	Advanced Lung Non-Squamous Non-Small Cell Carcinoma|Advanced Non-Squamous Non-Small Cell Lung Cancer|Advanced Non-Squamous Non-Small Cell Lung Carcinoma	Non-squamous non-small cell lung carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Non-Squamous Non-Small Cell Lung Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C147925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147925>	C159662|C126836	Allogeneic Hematopoietic Stem Cell Transplant Recipient|Allogeneic Hematopoietic Stem Cell Transplantation Recipient|Allogeneic Hematopoietic Stem Cell Transplantation Recipient	A person receiving an allogeneic hematopoietic stem cell transplant.	Allogeneic Hematopoietic Stem Cell Transplantation Recipient		Human	CTRP Intervention Terminology|CTRP Terminology
C147926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147926>	C29921	AMHR2 Gene Product	A protein encoded by the AMHR2 gene.			Amino Acid, Peptide, or Protein	
C147927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147927>	C147926	Anti-Muellerian Hormone Type-2 Receptor Extracellular Domain|AMHR2-ED|Anti-Mullerian Hormone Receptor II Extracellular Domain|Anti-Müllerian Hormone Receptor II Extracellular Domain|Extracellular Domain of Anti-Mullerian Hormone Receptor II|Extracellular Domain of Anti-Müllerian Hormone Receptor II	Anti-Muellerian hormone type-2 receptor extracellular domain is encoded by the human AMHR2 gene. This protein may play a role in ovarian carcinogenesis.			Amino Acid, Peptide, or Protein|Enzyme	
C147928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147928>	C38187	CARTPT Gene|CART Prepropeptide Gene|CARTPT|CARTPT	This gene plays a role in the negative regulation of appetite.			Gene or Genome	
C147929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147929>	C147928	CARTPT wt Allele|CART|CART Prepropeptide wt Allele|Cocaine and Amphetamine Regulated Transcript Gene|Cocaine- and Amphetamine-Regulated Transcript Gene	Human CARTPT wild-type allele is located in the vicinity of 5q13.2 and is approximately 2 kb in length. This allele, which encodes cocaine- and amphetamine-regulated transcript protein, is involved in the regulation of appetite.			Gene or Genome	
C147930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147930>	C686	Cocaine- and Amphetamine-Regulated Transcript Protein|CART|CART Prepropeptide|CARTPT	Cocaine- and amphetamine-regulated transcript protein (116 aa, ~13 kDa) is encoded by the human CARTPT gene. This protein plays a role in the inhibition of appetite.			Amino Acid, Peptide, or Protein	
C147931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147931>	C16615	DUX4L2 Gene|DUX4L2|DUX4L2|Double Homeobox 4 Like 2 Gene	This gene may be involved in the regulation of gene expression.			Gene or Genome	
C147932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147932>	C147931	DUX4L2 wt Allele|DUX4|Double Homeobox 4 Like 2 wt Allele	Human DUX4L2 gene is located in the vicinity of 4q35.2 and is approximately 1 kb in length. This allele, which encodes double homeobox protein 4-like protein 2, may play a role in transcription. This gene is within a D4Z4 repeat array; contraction of this macrosatellite repeat is associated with facioscapulohumeral muscular dystrophy (FSHD).			Gene or Genome	
C147933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147933>	C17207	Double Homeobox Protein 4-Like Protein 2|DUX4L2	Double homeobox protein 4-like protein 2 (424 aa, ~45 kDa) is encoded by the human DUX4L2 gene. This protein may be involved in transcriptional regulation.			Amino Acid, Peptide, or Protein	
C147934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147934>	C20923	GPRC5D Gene|G Protein-Coupled Receptor Class C Group 5 Member D Gene|GPRC5D|GPRC5D	This gene plays a role in retinoid acid-independent G protein-coupled receptor signaling.	GPRC5D Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C147935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147935>	C147934	GPRC5D wt Allele|G Protein-Coupled Receptor Class C Group 5 Member D wt Allele|G Protein-Coupled Receptor, Class C, Group 5, Member D Gene|G Protein-Coupled Receptor, Family C, Group 5, Member D Gene	Human GPRC5D wild-type allele is located in the vicinity of 12p13.1 and is approximately 39 kb in length. This allele, which encodes G-protein coupled receptor family C group 5 member D, is involved in G protein-coupled receptor signaling.	GPRC5D wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147936>	C18239	G-Protein Coupled Receptor Family C Group 5 Member D|G Protein-Coupled Receptor Class C Group 5 Member D|G Protein-Coupled Receptor Family C Group 5 Member D|G-Protein Coupled Receptor Class C Group 5 Member D|GPRC5D	G-protein coupled receptor family C group 5 member D (39 aa, ~39 kDa) is encoded by the human GPRC5D gene. This protein plays a role in G protein-coupled receptor signaling.	G-Protein Coupled Receptor Family C Group 5 Member D		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147937>	C17118	Preschool|Nursery School	An educational institution for children that precedes kindergarten.			Organization	
C147938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147938>	C91105	Inventory of Callous-Unemotional Traits|ICU	A 24-item questionnaire designed to provide a comprehensive assessment of callous and unemotional traits. These traits have proven to be important for designating a distinct subgroup of antisocial and aggressive youth.			Intellectual Product	
C147939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147939>	C25997	SHANK2 Gene|SH3 and Multiple Ankyrin Repeat Domains 2 Gene|SHANK2|SHANK2	This gene is involved in linking the postsynaptic membrane to glutamate receptors.			Gene or Genome	
C147940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147940>	C63474|C16664	Outreach|Outreach Strategy	Education or intervention aimed at individuals outside of a medical care system, especially those who might not otherwise have access to medical services.	Outreach		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C147941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147941>	C147939	SHANK2 wt Allele|AUTS17|CORTBP1|CTTNBP1|KIAA1022|PROSAP1|ProSAP1|SH3 and Multiple Ankyrin Repeat Domains 2 wt Allele|SHANK|SPANK-3	Human SHANK2 wild-type allele is located within 11q13.3-q13.4 and is approximately 785 kb in length. This allele, which encodes SH3 and multiple ankyrin repeat domains protein 2, plays a role in postsynaptic signal transduction. Deletions and nonsense mutation of the gene may be associated with autism.			Gene or Genome	
C147942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147942>	C63474|C16664	Inreach|Inreach Strategy	Education or intervention aimed at individuals within a medical care system.	Inreach		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C147943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147943>	C63474|C16664	Outreach and Inreach|Both Outreach and Inreach Strategies	Education or intervention aimed at individuals both outside of, and within a medical care system.	Outreach and Inreach		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C147944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147944>	C26231	SH3 and Multiple Ankyrin Repeat Domains Protein 2|Cortactin Binding Protein 1|Cortactin SH3 Domain-Binding Protein|Cortactin-Binding Protein 1|GKAP/SAPAP Interacting Protein|Proline-Rich Synapse Associated Protein 1|Proline-Rich Synapse-Associated Protein 1|SHANK2	SH3 and multiple ankyrin repeat domains protein 2 (1470 aa, ~159 kDa) is encoded by the human SHANK2 gene. This protein is involved in organization of both the structure and function of the synaptic junction.			Amino Acid, Peptide, or Protein	
C147946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147946>	C20673	TOX Gene|TOX|TOX|Thymocyte Selection Associated High Mobility Group Box Gene	This gene plays a role in T-cell development.	TOX Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C147947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147947>	C147946	TOX wt Allele|KIAA0808|TOX Transcription Factor Gene|TOX1|Thymocyte Selection Associated High Mobility Group Box wt Allele|Thymus High Mobility Group Box Protein, Mouse, Homolog of Gene	Human TOX wild-type allele is located in the vicinity of 8q12.1 and is approximately 314 kb in length. This allele, which encodes thymocyte selection-associated high mobility group box protein TOX, is involved in DNA binding and T-cell development.	TOX wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147948>	C3457|C114779	Primary Central Nervous System B-Cell Non-Hodgkin Lymphoma	A B-cell non-Hodgkin lymphoma that arises from the brain, meninges, or spinal cord.	Primary Central Nervous System B-Cell Non-Hodgkin Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C147949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147949>	C91105	Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire|PQ-LES-Q	A version of the Quality of Life Enjoyment and Satisfaction Questionnaire designed to assess changes in quality of life associated with treatment, as perceived by children and adolescents in the context of life events that are more meaningful in this population.			Intellectual Product	
C147950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147950>	C26199	Thymocyte Selection-Associated High Mobility Group Box Protein TOX|TOX|Thymus High Mobility Group Box Protein TOX	Thymocyte selection-associated high mobility group box protein TOX (526 aa, ~58 kDa) is encoded by the human TOX gene. This protein plays a role in thymocyte development.	Thymocyte Selection-Associated High Mobility Group Box Protein TOX		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147951>	C17824	Interventional Radiologist|Radiology Vascular and Interventional Radiology	A radiologist that specializes in the use of minimally invasive image-guided procedures for the diagnosis and treatment of disease.			Professional or Occupational Group	
C147952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147952>	C20921	LEMD3 Gene|LEM Domain Containing 3 Gene|LEMD3|LEMD3	This gene is involved in inhibition of nuclear import of receptor-regulated SMADs (R-SMADs).			Gene or Genome	
C147953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147953>	C147952	LEMD3 wt Allele|LEM Domain Containing 3 wt Allele|MAN1	Human LEMD3 wild-type allele is located in the vicinity of 12q14.3 and is approximately 79 kb in length. This allele, which encodes inner nuclear membrane protein Man1, plays a role in the downregulation of transforming growth factor beta (TGF-B) receptor signaling. Mutations in the gene have been associated with osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis.			Gene or Genome	
C147954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147954>	C18515	Inner Nuclear Membrane Protein Man1|Integral Inner Nuclear Membrane Protein|LEM Domain-Containing Protein 3|LEMD3|MAN Antigen 1	Inner nuclear membrane protein Man1 (911 aa, ~100 kDa) is encoded by the human LEMD3 gene. This protein is involved in the negative regulation of transforming growth factor beta (TGF-B) receptor signaling.			Amino Acid, Peptide, or Protein	
C147955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147955>	C25873	MAP3K4 Gene|MAP3K4|MAP3K4|Mitogen-Activated Protein Kinase Kinase Kinase 4 Gene	This gene plays a role in environmental stress-activated signaling pathways.			Gene or Genome	
C147956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147956>	C147955	MAP3K4 wt Allele|DJ473J16.1 (Mitogen-Activated Protein Kinase Kinase Kinase 4) Gene|MAPKKK4|MEKK 4|MEKK4|MTK1|Mitogen-Activated Protein Kinase Kinase Kinase 4 wt Allele|PRO0412|SSK2/SSK22 MAP Kinase Kinase Kinase, Yeast, Homolog of Gene	Human MAP3K4 wild-type allele is located in the vicinity of 6q26 and is approximately 126 kb in length. This allele, which encodes mitogen-activated protein kinase kinase kinase 4 protein, is involved in signaling stimulated by environmental stressors.			Gene or Genome	
C147957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147957>	C17325	Mitogen-Activated Protein Kinase Kinase Kinase 4|EC 2.7.11.25|MAP Three Kinase 1|MAP/ERK Kinase Kinase 4|MAP3K4|MAPK/ERK Kinase Kinase 4|MEK Kinase 4|MEKK 4|Predicted Protein of HQ0412	Mitogen-activated protein kinase kinase kinase 4 (1608 aa, ~182 kDa) is encoded by the human MAP3K4 gene. This protein plays a role in stress induced signaling pathways.			Amino Acid, Peptide, or Protein|Enzyme	
C147958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147958>	C20993	The Screen for Child Anxiety Related Emotional Disorders|SCARED	A 41-item, self- or parent-report questionnaire designed to screen for childhood anxiety disorders, including general anxiety disorder, separation anxiety disorder, panic disorder, social phobia, and symptoms related to school phobias in children aged 8-17.			Intellectual Product	
C147959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147959>	C21154	Symptom Checklist 90|SCL-90	A 90-item self-report symptom inventory designed to measure psychological symptoms and psychological distress for individuals 13 years and older. It is intended to measure symptom intensity on nine different subscales.			Intellectual Product	
C147960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147960>	C91105	The Mood and Feelings Questionnaire|MFQ	A 13-item, self-administered questionnaire designed to meassure depressive symptoms. The MFQ consists of a series of descriptive phrases regarding how the subject has been feeling or acting recently and is a screening tool for depression in children and young people aged between 6 and 17 years.			Intellectual Product	
C147961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147961>	C20420	UBTF Gene|UBTF|UBTF|Upstream Binding Transcription Factor Gene	This gene is involved in the transcription of ribosomal RNA genes.	UBTF Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C147962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147962>	C147961	UBTF wt Allele|CONDBA|NOR-90|UBF|UBF-1|UBF1|UBF2|Upstream Binding Factor Gene|Upstream Binding Transcription Factor (RNA Polymerase I) Gene|Upstream Binding Transcription Factor wt Allele|Upstream Binding Transcription Factor, RNA Polymerase I Gene	Human UBTF wild-type allele is located in the vicinity of 17q21.31 and is approximately 17 kb in length. This allele, which encodes nucleolar transcription factor 1 protein, plays a role in ribosomal RNA synthesis. Mutation of the gene is associated with childhood-onset neurodegeneration with brain atrophy (CONDBA).	UBTF wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147963>	C17207	Nucleolar Transcription Factor 1|90-kDa Nucleolus Organizer Region Autoantigen|Autoantigen NOR-90|UBF-1|UBTF|Upstream Binding Factor 1|Upstream-Binding Factor 1	Nucleolar transcription factor 1 (764 aa, ~89 kDa) is encoded by the human UBTF gene. This protein is involved in the positive regulation of ribosomal RNA gene transcription.	Nucleolar Transcription Factor 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147964>	C16360	Diagnostic and Statistical Manual of Mental Disorders, 5th Edition|DSM-5|DSM-V	Published by the American Psychiatric Association, the DSM is a listing of currently recognized mental health disorders and their diagnostic criteria, for children and adults. It includes statistical information on etiology, incidence, prevalence, age of onset and prognosis. The 5th edition was published in 2013. As new information becomes available subsequent editions are published.			Manufactured Object	
C147965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147965>	C8511|C4872	Refractory Breast Carcinoma|Refractory Breast Cancer	Breast carcinoma that does not respond to treatment.	Refractory Breast Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C147966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147966>	C20194	TUSC7 Gene|TUSC7|TUSC7|Tumor Suppressor Candidate 7 (Non-Protein Coding) Gene	This gene plays a role in the negative regulation of cell proliferation.			Gene or Genome	
C147967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147967>	C147966	TUSC7 wt Allele|LINC00902|LOC285194|LSAMP Antisense RNA 3 (Non-Protein Coding) Gene|LSAMP Antisense RNA 3 Gene|LSAMP-AS1|LSAMP-AS3|LSAMPAS3|NCRNA00295|Non-Protein Coding RNA 295 Gene|Tumor Suppressor Candidate 7 (Non-Protein Coding) wt Allele|Tumor Suppressor Candidate 7 (Noncoding) Gene	Human TUSC7 wild-type allele is located in the vicinity of 3q13.31 and is approximately 14 kb in length. This allele, which encodes tumor suppressor candidate 7 long non-coding RNA, is involved in the modulation of cell proliferation.			Gene or Genome	
C147968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147968>	C88924	Tumor Suppressor Candidate 7|LINC00902|LSAMP Antisense RNA 3|LSAMP-AS3|LSAMPAS3|LncRNA LOC285194|Long Noncoding RNA LOC285194|NCRNA00295|Non-Protein Coding RNA 295|TUSC7	Tumor suppressor candidate 7 (~2 kb) is encoded by the human TUSC7 gene. This long non-coding RNA plays a role in the downregulation of cell proliferation.			Nucleic Acid, Nucleoside, or Nucleotide	
C147969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147969>	C25993|C20103	GABRA6 Gene|GABRA6|GABRA6|Gamma-Aminobutyric Acid Type A Receptor Alpha6 Subunit Gene	This gene is involved in neurotransmitter-dependent chloride transport.			Gene or Genome	
C147970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147970>	C147969	GABRA6 wt Allele|GABA(A) Receptor, Alpha 6 Gene|GABA-A Receptor, Alpha-6 Polypeptide Gene|Gamma-Aminobutyric Acid (GABA) A Receptor, Alpha 6 Gene|Gamma-Aminobutyric Acid Receptor, Alpha-6 Gene|Gamma-Aminobutyric Acid Type A Receptor Alpha6 Subunit wt Allele	Human GABRA6 wild-type allele is located in the vicinity of 5q34 and is approximately 156 kb in length. This allele, which encodes gamma-aminobutyric acid receptor subunit alpha-6 protein, plays a role in chloride conductance.			Gene or Genome	
C147971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147971>	C28505|C18106	Gamma-Aminobutyric Acid Receptor Subunit Alpha-6|GABA(A) Receptor Subunit Alpha-6|GABRA6	Gamma-aminobutyric acid receptor subunit alpha-6 (453 aa, ~51 kDa) is encoded by the human GABRA6 gene. This protein is involved in ligand-gated chloride transport.			Amino Acid, Peptide, or Protein|Receptor	
C147972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147972>	C20194	GID4 Gene|GID Complex Subunit 4 Homolog Gene|GID4|GID4	This gene plays a role in the ubiquitination of gluconeogenic enzymes.			Gene or Genome	
C147973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147973>	C147972	GID4 wt Allele|C17orf39|Chromosome 17 Open Reading Frame 39 Gene|GID Complex Subunit 4 Homolog wt Allele|GID Complex Subunit 4, VID24 Homolog (S. cerevisiae) Gene|GID Complex Subunit 4, VID24 Homolog Gene|Glucose-Induced Defradation-Deficient Protein 4, S cerevisiae, Homolog of Gene|VID2|VID24|Vacuolar Import and Degradation 24 Gene	Human GID4 wild-type allele is located in the vicinity of 17p11.2 and is approximately 29 kb in length. This allele, which encodes glucose-induced degradation protein 4 homolog, is involved in the degradation of gluconeogenic enzymes.			Gene or Genome	
C147974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147974>	C95242	Glucose-Induced Degradation Protein 4 Homolog|GID Complex Subunit 4|GID4|Vacuolar Import and Degradation Protein 24|Vacuolar Import and Degradation Protein 24 Homolog	Glucose-induced degradation protein 4 homolog (300 aa, ~34 kDa) is encoded by the human GID4 gene. This protein plays a role in the ubiquitination and proteasomal targeting of gluconeogenic enzymes.			Amino Acid, Peptide, or Protein	
C147975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147975>	C106409	PTPRO Gene|PTPRO|PTPRO|Protein Tyrosine Phosphatase, Receptor Type O Gene	This gene is involved in glomerulus development.	PTPRO Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C147976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147976>	C147975	PTPRO wt Allele|GLEPP1|NPHS6|PTP Phi|PTP-OC|PTP-U2|PTPROT|PTPU2|Protein Tyrosine Phosphatase, Receptor Type O wt Allele|Protein Tyrosine Phosphatase, Receptor Type, O Gene|R-PTP-O	Human PTPRO wild-type allele is located in the vicinity of 12p12.3 and is approximately 276 kb in length. This allele, which encodes receptor-type tyrosine-protein phosphatase O protein, plays a role in both glomerulus development and protein tyrosine phosphatase activity. Mutation of the gene may be associated with nephrotic syndrome.	PTPRO wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147977>	C17444	Receptor-Type Tyrosine-Protein Phosphatase O|EC 3.1.3.48|Osteoclastic Transmembrane Protein-Tyrosine Phosphatase|PTPRO|Phosphotyrosine Phosphatase U2|Protein Tyrosine Phosphatase PTP-U2|Protein Tyrosine Phosphatase U2|R-PTP-O	Receptor-type tyrosine-protein phosphatase O (1216 aa, ~138 kDa) is encoded by the human PTPRO gene. This protein is involved in tyrosine phosphatase activity and glomerular epithelium development.	Receptor-Type Tyrosine-Protein Phosphatase O		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147978>	C212943|C19676	PARP3 Gene|PARP3|PARP3|Poly(ADP-Ribose) Polymerase Family Member 3 Gene	This gene plays a role in the ADP-ribosylation of proteins involved in base excision repair.	PARP3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C147979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147979>	C147978	PARP3 wt Allele|ADP-Ribosyltransferase (NAD+; Poly (ADP-Ribose) Polymerase)-Like 2 Gene|ADP-Ribosyltransferase (NAD+; Poly (ADP-Ribose) Polymerase)-Like 3 Gene|ADPRT3|ADPRTL2|ADPRTL3|ARTD3|IRT1|PADPRT-3|Poly(ADP-Ribose) Polymerase Family Member 3 wt Allele|Poly(ADP-Ribose) Polymerase Family, Member 3 Gene	Human PARP3 wild-type allele is located in the vicinity of 3p21.2 and is approximately 7 kb in length. This allele, which encodes protein mono-ADP-ribosyltransferase PARP3 protein, is involved in the regulation of DNA base excision repair.	PARP3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147980>	C21170|C17434	Protein Mono-ADP-Ribosyltransferase PARP3|ADP-Ribosyltransferase 3|ADP-Ribosyltransferase Diphtheria Toxin-Like 3|ADP-Ribosyltransferase-Like 3|ADPRT-3|ARTD3|DNA ADP-Ribosyltransferase PARP3|EC 2.4.2.-|IRT1|NAD(+) ADP-Ribosyltransferase 3|NAD+ ADP-Ribosyltransferase 3|PARP-3|PARP3|Poly (ADP-Ribose) Polymerase 3|Poly (ADP-Ribosyl) Transferase-Like 3|Poly [ADP-Ribose] Polymerase 3|Poly [ADP-Ribose] Polymerase 3|Poly(ADP-Ribose) Polymerase 3|Poly(ADP-Ribose) Synthase 3|Poly(ADP-Ribose) Synthetase-3|Poly[ADP-Ribose] Synthase 3|Poly[ADP-Ribose] Synthetase 3|hPARP-3|pADPRT-3	Protein mono-ADP-ribosyltransferase PARP3 (533 aa, ~60 kDa) is encoded by the human PARP3 gene. This protein plays a role in DNA repair and mono-ADP-ribosylation of target proteins.	Poly [ADP-Ribose] Polymerase 3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147981>	C15747	Verbal Support|Verbal Support Therapy	Therapy in which a therapist, or other personnel, provides nondirective, supportive care by offering supportive, validating statements and reflective listening. Verbal support sessions are aimed at providing an empathic, therapeutic environment to facilitate emotional expression and sharing of worries and fears.	Verbal Support		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C147982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147982>	C2955|C151906	Refractory Colorectal Carcinoma|Refractory Colorectal Cancer	Colorectal carcinoma that does not respond to treatment.	Refractory Colorectal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C147983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147983>	C3224|C120186	Refractory Melanoma	A melanoma that does not respond to treatment.	Refractory Melanoma		Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C147984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147984>	C21275	KEL Gene|KEL|KEL|Kell Blood Group, Metallo-Endopeptidase Gene	This gene is involved in endothelin-converting enzyme activity.			Gene or Genome	
C147985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147985>	C147984	KEL wt Allele|CD238|ECE3|Kell Blood Group Gene|Kell Blood Group, Metallo-Endopeptidase wt Allele|Kell Blood Group, Metalloendopeptidase	Human KEL wild-type allele is located in the vicinity of 7q34 and is approximately 22 kb in length. This allele, which encodes Kell blood group glycoprotein, plays a role in peptide hormone-converting enzyme activity. Point mutations in the gene determine an individual's Kell blood group antigen profile.			Gene or Genome	
C147986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147986>	C16843	Kell Blood Group Glycoprotein|CD238|CD238 Antigen|EC 3.4.24.-|KEL|Kell Blood Group Antigen|Kell Glycoprotein	Kell blood group glycoprotein (732 aa, ~83 kDa) is encoded by the human KEL gene. This protein is involved in cleavage of endothelin-3.			Amino Acid, Peptide, or Protein|Enzyme	
C147987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147987>	C25873	IKBKE Gene|IKBKE|IKBKE|Inhibitor of Nuclear Factor Kappa B Kinase Subunit Epsilon Gene	This gene plays a role in the phosphorylation of both interferon regulatory factors-3 and -7 and proteins in the nuclear factor kappa-B signaling pathway.	IKBKE Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C147988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147988>	C147987	IKBKE wt Allele|IKK-E|IKK-I|IKKE|IKKI|Inhibitor of Kappa Light Polypeptide Gene Enhancer in B Cells, Kinase of, Epsilon Gene|Inhibitor of Kappa Light Polypeptide Gene Enhancer in B-Cells, Kinase Epsilon Gene|Inhibitor of Nuclear Factor Kappa B Kinase Subunit Epsilon wt Allele|KIAA0151	Human IKBKE wild-type allele is located in the vicinity of 1q32.1 and is approximately 27 kb in length. This allele, which encodes inhibitor of nuclear factor kappa-B kinase subunit epsilon, is involved in the modulation of both interferon expression and the nuclear factor kappa-B signaling pathway. Amplification and overexpression of the gene is associated with breast carcinoma.	IKBKE wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147989>	C17325	Inhibitor of Nuclear Factor Kappa-B Kinase Subunit Epsilon|EC 2.7.11.10|I-Kappa-B Kinase Epsilon|I-Kappa-B Kinase-Epsilon|IKBKE|IKK-E|IKK-Epsilon|IKK-I|IKK-Related Kinase Epsilon|IKKepsilon|IkBKE|Inducible I Kappa-B Kinase|Inducible I-Kappa-B Kinase|Inducible IkappaB Kinase	Inhibitor of nuclear factor kappa-B kinase subunit epsilon (716 aa, ~80 kDa) is encoded by the human IKBKE gene. This protein plays a role in the regulation of both nuclear factor kappa-B signaling and interferon expression.	Inhibitor of Nuclear Factor Kappa-B Kinase Subunit Epsilon		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C147990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147990>	C18568	FGF14 Gene|FGF14|FGF14|Fibroblast Growth Factor 14 Gene	This gene is involved in development and maintenance of the central nervous system.			Gene or Genome	
C147991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147991>	C18568	FGF12 Gene|FGF12|FGF12|Fibroblast Growth Factor 12 Gene	This gene plays a role in both nervous system development and neuronal excitation.			Gene or Genome	
C147992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147992>	C147990	FGF14 wt Allele|BA397O8.2|FGF-14|FHF-4|FHF4|Fibroblast Growth Factor 14 wt Allele|SCA27	Human FGF14 wild-type allele is located in the vicinity of 13q33.1 and is approximately 692 kb in length. This allele, which encodes fibroblast growth factor 14 protein, plays a role in nervous system development. Mutation of the gene is associated with spinocerebellar ataxia 27.			Gene or Genome	
C147993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147993>	C147991	FGF12 wt Allele|EIEE47|FGF-12|FGF12B|FHF-1|FHF1|Fibroblast Growth Factor 12 wt Allele|Fibroblast Growth Factor 12B Gene|Fibroblast Growth Factor FGF-12b Gene	Human FGF12 wild-type allele is located within 3q28-q29 and is approximately 329 kb in length. This allele, which encodes fibroblast growth factor 12 protein, is involved in the development and function of the nervous system. Mutation of the gene is associated with early infantile epileptic encephalopathy.			Gene or Genome	
C147995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147995>	C20426	Fibroblast Growth Factor 14|FGF-14|FGF14|FHF-4|Fibroblast Growth Factor Homologous Factor 4|Fibroblast Growth Factor-14	Fibroblast growth factor 14 (247 aa, ~28 kDa) is encoded by the human FGF14 gene. This protein is involved in signal transduction in central nervous system development.			Amino Acid, Peptide, or Protein	
C147996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147996>	C4911|C151906	Refractory Gastric Carcinoma|Refractory Gastric (Stomach) Cancer	A gastric carcinoma that is resistant to treatment.	Refractory Gastric Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C147997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147997>	C20426	Fibroblast Growth Factor 12|FGF-12|FGF12|FHF-1|Fibroblast Growth Factor Homologous Factor 1|Fibroblast Growth Factor-12|Myocyte-Activating Factor	Fibroblast growth factor 12 (243 aa, ~27 kDa) is encoded by the human FGF12 gene. This protein plays a role in both nervous system development and the promotion of voltage-gated sodium channel activity in neurons.			Amino Acid, Peptide, or Protein	
C147998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147998>	C25994	EDN3 Gene|EDN3|EDN3|Endothelin 3 Gene	This gene is involved in vasoconstriction.			Gene or Genome	
C147999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C147999>	C147998	EDN3 wt Allele|ET-3|ET3|Endothelin 3 wt Allele|HSCR4|PPET3|WS4B	Human EDN3 wild-type allele is located in the vicinity of 20q13.32 and is approximately 26 kb in length. This allele, which encodes endothelin-3 protein, plays a role in vasoconstriction. Mutation of the gene is associated with congenital central hyperventilation syndrome, Waardenburg syndrome type 4B and increased susceptibility to Hirschsprung disease (aganglionic megacolon).			Gene or Genome	
C1479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1479>	C1572	ALVAC Vaccine|ALVAC	A derivative of the Canarypox Virus, ALVAC can infect mammalian cells but it can't replicate.  Thus, it produces a self-limiting infection which does not produce symptoms or harm the host.  When carrying foreign genes it will cause transient expression of protein.			Chemical Viewed Functionally	
C148000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148000>	C1746	Endothelin-3|EDN3|ET-3|Endothelin 3|PPET3|Preproendothelin 3|Preproendothelin-3	Endothelin-3 (238 aa, ~26 kDa) is encoded by the human EDN3 gene. This protein is involved in vasoconstriction.			Amino Acid, Peptide, or Protein|Hormone	
C148001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148001>	C28533	XK Gene|X-Linked Kx Blood Group Gene|XK|XK	This gene may play a role in sodium-dependent transport of neutral amino acids or peptides.	XK Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C148002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148002>	C148001	XK wt Allele|KX|Kell Blood Group Precursor (McLeod Phenotype) Gene|Kell Blood Group Precursor Gene|McLeod Syndrome Gene|NA|NAC|Neuroacanthocytosis Gene|Neurocanthocytosis Gene|Precursor Substance, Kell Blood Group Gene|X-Linked Kx Blood Group wt Allele|X1k|XK Locus Gene|XK, Kell Blood Group Complex Subunit (McLeod Syndrome) Gene|XKR1	Human XK wild-type allele is located in the vicinity of Xp21.1 and is approximately 46 kb in length. This allele, which encodes membrane transport protein XK, may be involved in transmembrane transport of amino acids or peptides. Mutation or deletion of the gene is associated with the McLeod phenotype of the Kell blood group system.	XK wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148003>	C16386	Membrane Transport Protein XK|Kell Complex 37 kDa Component|Kell Complex, 37-kD Component|Kx Antigen|Kx Blood Group Antigen|XK|XK-Related Protein 1	Membrane transport protein XK (444 aa, ~51 kDa) is encoded by the human XK gene. This protein may play a role in amino acid transport.	Membrane Transport Protein XK		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148004>	C25804	GUSB Gene|GUSB|GUSB|Glucuronidase Beta Gene	This gene is involved in the degradation of glycosaminoglycans.	GUSB Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C148005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148005>	C148004	GUSB wt Allele|BG|GUS|Glucuronidase Beta wt Allele|Glucuronidase, Beta Gene|MPS7	Human GUSB wild-type allele is located in the vicinity of 7q11.21 and is approximately 22 kb in length. This allele, which encodes beta-glucuronidase protein, plays a role in the metabolism of glycosaminoglycans. Mutation of the gene is associated with mucopolysaccharidosis VII.	GUSB wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148006>	C16701	Beta-Glucuronidase|Beta-D-Glucuronidase|Beta-G1|EC 3.2.1.31|GUSB	Beta-glucuronidase (651 aa, ~75 kDa) is encoded by the human GUSB gene. This protein is involved in the catabolism of glycosaminoglycans.	Beta-Glucuronidase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148007>	C20845	RPLP0 Gene|RPLP0|RPLP0|Ribosomal Protein Lateral Stalk Subunit P0 Gene	This gene plays a role in the structure of the 60S ribosome subunit.	RPLP0 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C148008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148008>	C148007	RPLP0 wt Allele|L10E|LP0|P0|PRLP0|RPP0|Ribosomal Phosphoprotein, Acidic, P0 Gene|Ribosomal Phosphoprotein, Large, P0 Gene|Ribosomal Protein Lateral Stalk Subunit P0 wt Allele|Ribosomal Protein, Large, P0 Gene	Human RPLP0 wild-type allele is located in the vicinity of 12q24.23 and is approximately 5 kb in length. This allele, which encodes 60S acidic ribosomal protein P0, is involved in the structure of the ribosome.	RPLP0 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148009>	C21210	60S Acidic Ribosomal Protein P0|60S Ribosomal Protein L10E|Acidic Ribosomal Phosphoprotein P0|Large Ribosomal Subunit Protein uL10|Neutral Ribosomal Phosphoprotein P0|RPLP0	60S acidic ribosomal protein P0 (317 aa, ~34 kDa) is encoded by the human RPLP0 gene. This protein plays a role in ribosome structure.	60S Acidic Ribosomal Protein P0		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148010>	C18004	Intergroup Rhabdomyosarcoma Study Group Clinical Staging and Grouping System|Intergroup Rhabdomyosarcoma Clinical Grouping System|Rhabdomyosarcoma Clinical Group System	Staging and grouping for rhabdomyosarcoma that groups patients into low, intermediate, or high clinical risk groups based on: histologic type, tumor site, tumor size, and pathologic TNM. Note: this is not the TNM system described in AJCC.			Classification	
C148011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148011>	C148010	Intergroup Rhabdomyosarcoma Clinical Group Extent of Disease|Rhabdomyosarcoma Extent of Disease	An indication of whether rhabdomyosarcoma is confined to its primary location or has extended beyond the site of origin.			Classification	
C148012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148012>	C148011	Intergroup Rhabdomyosarcoma Group I|Group I|Group I|Rhabdomyosarcoma Group I	Localized disease, excised.			Classification	GDC Terminology|GDC Value Terminology
C148013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148013>	C148011	Intergroup Rhabdomyosarcoma Group Ia|Group Ia|Group Ia|Rhabdomyosarcoma Group Ia	Confined to site of origin.			Classification	GDC Terminology|GDC Value Terminology
C148014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148014>	C148011	Intergroup Rhabdomyosarcoma Group Ib|Group Ib|Group Ib|Rhabdomyosarcoma Group Ib	Infiltrative, beyond site of origin; negative lymph nodes.			Classification	GDC Terminology|GDC Value Terminology
C148015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148015>	C148011	Intergroup Rhabdomyosarcoma Group II|Group II|Group II|Rhabdomyosarcoma Group II	Total gross resection with regional disease spread.			Classification	GDC Terminology|GDC Value Terminology
C148016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148016>	C148011	Intergroup Rhabdomyosarcoma Group IIa|Group IIa|Group IIa|Rhabdomyosarcoma Group IIa	Localized tumor with microscopic residual disease.			Classification	GDC Terminology|GDC Value Terminology
C148017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148017>	C148011	Intergroup Rhabdomyosarcoma Group IIb|Group IIb|Group IIb|Rhabdomyosarcoma Group IIb	Regional disease with positive lymph nodes, excised.			Classification	GDC Terminology|GDC Value Terminology
C148018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148018>	C148011	Intergroup Rhabdomyosarcoma Group IIc|Group IIc|Group IIc|Rhabdomyosarcoma Group IIc	Regional disease with positive lymph nodes.			Classification	GDC Terminology|GDC Value Terminology
C148019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148019>	C148011	Intergroup Rhabdomyosarcoma Group III|Group III|Group III|Rhabdomyosarcoma Group III	Gross residual disease.	Intergroup Rhabdomyosarcoma Group III		Classification	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C148020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148020>	C148011	Intergroup Rhabdomyosarcoma Group IIIa|Group IIIa|Group IIIa|Rhabdomyosarcoma Group IIIa	Localized or regional disease; biopsy.	Intergroup Rhabdomyosarcoma Group IIIa		Classification	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C148021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148021>	C148011	Intergroup Rhabdomyosarcoma Group IIIb|Group IIIb|Group IIIb|Rhabdomyosarcoma Group IIIb	Localized or regional disease; resection (debulking of more than 50% of tumor).	Intergroup Rhabdomyosarcoma Group IIIb		Classification	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C148022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148022>	C148011	Intergroup Rhabdomyosarcoma Group IV|Group IV|Group IV|Rhabdomyosarcoma Group IV	Distant metastasis.			Classification	GDC Terminology|GDC Value Terminology
C148023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148023>	C35755	Sleep-Disordered Breathing|Breathing-related sleep disorder|SDB|Sleep Disordered Breathing	A group of breathing disorders characterized by abnormal respiratory patterns or insufficient ventilation during sleep.	Sleep-Disordered Breathing		Disease or Syndrome	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|CTRP Disease Terminology|CTRP Terminology
C148024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148024>	C36102	BRCA Hereditary Ovarian Carcinoma|BRCA Familial Ovarian Cancer|BRCA Familial Ovarian Carcinoma|BRCA Hereditary Ovarian Cancer|BRCA-Associated Ovarian Carcinoma|BRCA-Mutated Ovarian Carcinoma	Hereditary ovarian carcinoma caused by deleterious germline mutation in a gene of the BRCA family.			Neoplastic Process	
C148025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148025>	C7833|C148024	Recurrent BRCA Hereditary Ovarian Carcinoma|Recurrent BRCA Familial Ovarian Cancer|Recurrent BRCA Familial Ovarian Carcinoma|Recurrent BRCA Hereditary Ovarian Cancer|Recurrent BRCA- Associated Ovarian Carcinoma|Recurrent BRCA-Mutated Ovarian Cancer|Recurrent BRCA-Mutated Ovarian Carcinoma	The reemergence of BRCA hereditary ovarian carcinoma after a period of remission.	Recurrent BRCA-Mutated Ovarian Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148026>	C162702|C148029|C127153	Recurrent Childhood Malignant Solid Neoplasm|Childhood Recurrent Malignant Solid Neoplasm|Childhood Recurrent Malignant Solid Tumor	The reemergence of a childhood malignant solid neoplasm after a period of remission.	Childhood Recurrent Malignant Solid Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148027>	C162703|C148029|C133737	Refractory Childhood Malignant Solid Neoplasm|Childhood Refractory Malignant Solid Neoplasm|Childhood Refractory Malignant Solid Tumor	A childhood malignant solid neoplasm that does not respond to treatment.	Childhood Refractory Malignant Solid Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148028>	C170419|C126340	Activating PIK3CD Gene Mutation|Activating APDS Gene Mutation|Activating IMD14 Gene Mutation|Activating P110DELTA Gene Mutation|Activating PI3K mutation/PASLI|Activating PI3K-Delta Gene Mutation|Activating PIK3CD Mutation|Activating Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta Gene Mutation|Activating p110D Gene Mutation|PIK3CD (GOF)|PIK3CD Gain of Function|PIK3CD Gain of Function Gene Mutation	A mutation in PIK3CD, the gene encoding the p110delta catalytic subunit of PI3K, that results in induction of PI3K signaling. Mutations of this type are associated with immunodeficiency 14 (PASLI: activated PI3k-delta syndrome, p110-delta-activating mutation causing senescent T-cells, lymphadenopathy, and immunodeficiency).			Cell or Molecular Dysfunction	
C148029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148029>	C9107|C4005|C132146	Childhood Malignant Solid Neoplasm|Childhood Malignant Solid Tumor|Malignant Solid Tumor	A malignant solid neoplasm that occurs during childhood.	Childhood Malignant Solid Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148030>	C28681|C138180|C129826	Autologous Anti-CD19 T-cell Receptor T cells ET190L1|ET 190|ET190|ET190L1|ET190L1-ARTEMIS (TM)|ET190L1-ARTEMIS (TM) T Cells	Autologous human peripheral blood T-lymphocytes transduced with a lentivirus encoding a proprietary expression construct composed of a T-cell receptor (TCR)-like human antibody, which is synthesized by a proprietary phage display platform, targeting peptides derived from the tumor-associated antigen (TAA) CD19 that are presented in the context of major histocompatibility complex (MHC) molecules, with potential antineoplastic activity. Following leukapheresis, isolation of lymphocytes, expansion ex vivo, transduction, and re-introduction into the patient, the autologous anti-CD19 TCR T-cells ET190L1 target and bind to tumor cells expressing CD19 peptide/MHC complexes. This results in cytotoxic T-lymphocyte (CTL)-mediated elimination of CD19-positive tumor cells. CD19, cluster of differentiation antigen 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage malignancies. ET190L1 is able to match the anticancer activity of chimeric antigen receptor (CAR) T-cells; however, ET190L1 is less likely to stimulate cytokine release syndrome (CRS) and does not cause CAR T-cell-triggered neurotoxicity.	Autologous Anti-CD19 T-cell Receptor T cells ET190L1		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148031>	C263	S-warfarin|2H-1-Benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)-, (S)-|WARFARIN, (S)-		S-warfarin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C148032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148032>	C18842	Low Density Array|LDA|Low-Density Array	A card containing 384 wells that can be loaded with cDNA probe sets and cDNA reverse transcribed from samples of interest. The card is designed to be placed into a thermocycler to perform quantitative reverse transcriptase-based PCR (QRT-PCR) analysis.			Research Device	
C148034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148034>	C37930	Opioid-Induced Constipation|OIC	Constipation that results from, or follows, treatment with an opioid or opioid-containing medication.			Finding	
C148035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148035>	C153464|C150123	PSMA-Positive Tumor|FOLH1-Positive Tumor|Folate Hydrolase 1-Positive Tumor|Glutamate Carboxypeptidase 2-Positive Tumor|Prostate-Specific Membrane Antigen Positive Tumor	An indication that prostate-specific membrane antigen (PSMA) expression has been detected in a tumor sample.			Laboratory or Test Result	
C148036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148036>	C27359|C132146|C127156	Unresectable Malignant Solid Neoplasm|Unresectable Malignant Solid Tumor|Unresectable Malignant Solid Tumor	A malignant solid neoplasm that is not amenable to surgical resection.	Unresectable Malignant Solid Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148037>	C177794|C132505	Recurrent WHO Grade 2 Glioma|Recurrent Grade 2 Glioma|Recurrent Grade II Glioma|Recurrent Grade II Glioma|Recurrent WHO Grade II Glioma	The reemergence of WHO grade 2 glioma after a period of remission.	Recurrent WHO Grade II Glioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148038>	C142848|C127816	Recurrent WHO Grade 3 Glioma|Recurrent Grade III Glioma|Recurrent Grade III Glioma|Recurrent WHO Grade III Glioma	The reemergence of a WHO grade 3 glioma after a period of remission.	Recurrent WHO Grade III Glioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148039>	C201170	Imaradenant|A2AR Antagonist AZD4635|AZD-4635|AZD4635|Adenosine A2A Receptor Antagonist AZD4635|HTL-1071|IMARADENANT	An orally bioavailable antagonist of the adenosine A2A receptor (A2AR; ADORA2A), with potential immunomodulating and antineoplastic activities. Upon administration, imaradenant selectively binds to and inhibits A2AR expressed on T-lymphocytes. This blocks tumor-released adenosine from interacting with A2AR and prevents the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes, and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits T-cell proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression.	Imaradenant		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148040>	C19498	Medical Clearance	Written permission from a medical professional stating that an individual is healthy enough to participate in a specific activity.			Intellectual Product	
C148041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148041>	C97927	ATRX Gene Mutation|ATRX|ATRX, Chromatin Remodeler Gene Mutation|Alpha Thalassemia/Mental Retardation Syndrome X-Linked Gene Mutation|Positive|RAD54 Gene Mutation|RAD54 Homolog Gene Mutation|RAD54L Gene Mutation|XH2 Gene Mutation|XNP Gene Mutation|Yes|ZNF-HX Gene Mutation	A change in the nucleotide sequence of the ATRX gene.	ATRX Gene Mutation		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology|CRF8 Pathology Review Targeted Genomics Table|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148042>	C141146	Anti-TIM-3 Antibody BMS-986258|Anti-TIM3 Antibody BMS-986258|BMS 986258|BMS-986258|BMS-986258	An antibody against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Following administration, anti-TIM-3 antibody BMS-986258 binds to TIM-3 that is expressed on certain T-cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which together result in decreased tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.	Anti-TIM-3 Antibody BMS-986258		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148063>	C45824	Nullizygosity|Homozygous Null|Nullizygous|Nullizygous	Having no copies, or nonfunctional copies, of a particular gene or genetic region.			Functional Concept	GDC Terminology|GDC Value Terminology
C148064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148064>	C16830	Skin Staple	A type of surgical staple designed to close skin wounds.	Skin Staple		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C148065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148065>	C9270|C188021	Advanced B-Cell Malignant Neoplasm|Advanced B-Cell Malignancy|Advanced B-Cell Neoplasm|Advanced B-Cell Neoplasm	A B-cell malignant neoplasm that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced B-Cell Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148066>	C213143	Bezetabart Debotansine|ADC STRO-001|Anti-CD74 ADC STRO-001|Anti-CD74 Antibody-drug Conjugate BN301|Anti-CD74 Antibody-drug Conjugate STRO-001|BEZETABART DEBOTANSINE|BN 301|BN-301|BN301|SP7675|STRO-001	An antibody-drug conjugate (ADC) comprised of bezetabart, an aglycosylated human anti-CD74 IgG1 antibody (SP7219) that has been genetically modified to incorporate the non-natural amino acid (nnAA) para-azidomethyl-L-phenylalanine (pAMF), which is site-specifically conjugated to a non-cleavable dibenzocyclooctyne (DBCO)-maytansinoid linker-warhead, with potential antineoplastic activity. Upon administration, the antibody moiety of bezetabart debotansine targets and binds to the CD74 expressed on tumor cells; upon internalization, the maytansinoid linker-warhead moiety binds to tubulin and disrupts microtubule assembly/disassembly dynamics, which results in the inhibition of both cell division and cell growth of CD74-expressing tumor cells. CD74, a transmembrane glycoprotein and tumor-associated antigen (TAA) involved in major histocompatibility complex (MHC) class II protein formation and localization, is a receptor for macrophage migration inhibitory factor (MIF; MMIF). MIF binding induces intramembrane cleavage of CD74, which liberates the cytosolic intracellular domain (ICD) of CD74 and regulates the expression of genes involved in promoting cell survival. CD74 is overexpressed on cells from hematologic B-lineage malignancies.	Bezetabart Debotansine		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148067>	C16685	Histone H3.2|H3.2|Histone H3/m|Histone H3/o	Histone H3.2 (136 aa, ~15 kDa) is encoded by the human H3C13, H3C14 and H3C15 genes. This protein plays a role in nucleosome remodeling and chromosomal structure.			Amino Acid, Peptide, or Protein	GDC Terminology|GDC Value Terminology
C148068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148068>	C177692	CD34 Positive|CD34 Antigen Positive|CD34 Molecule Positive|HPCA1 Positive|Hematopoietic Progenitor Cell Antigen CD34 Positive	An indication that CD34 expression has been detected in a sample.	CD34 Positive		Laboratory or Test Result	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148069>	C20194	HSATII DNA|HSAT-II DNA|Human Satellite II Repeat DNA	Human HSATII is comprised of an approximately 26 bp tandem repeat sequence that is the main component of pericentromeric heterochromatin located on chromosomes 2, 5, 7, 10, 13, 14, 15, 17, 21, 22, and Y; additionally large (5-6 Mb) blocks of this repeat are located at 1q12 and on chromosome 16. This satellite DNA is not expressed in normal cells. Aberrant expression and translation of HSATII RNA, which occurs when the sequence is demethylated, is associated with various cancers and may result in sequestration of transcription regulation proteins.	HSATII DNA		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C148070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148070>	C88924	HSATII RNA|HSAT-II RNA|Human Satellite II Repeat RNA	A 30 base to 800 base ribonucleic acid derived from transcription of demethlyated human satellite II (HSATII) DNA sequences. This ribonucleotide may sequester chromatin regulatory proteins and may be a biomarker for various cancers.	HSATII RNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148071>	C153117	Blasts Under 20,000 in Peripheral Blood White Cells|Absolute Blasts in Peripheral Blood Less Than 20,000|Absolute Blasts in Peripheral Blood Less Than 20000|Blasts Less than 20,000 of Peripheral Blood White Cells|Blasts Less than 20000 of Peripheral Blood White Cells|Blasts Under 20000 in Peripheral Blood White Cells	A quantitative microscopic finding indicating that less than 20,000 of the total number of nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.	Blasts Under 20,000 in Peripheral Blood White Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C148072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148072>	C48182	Low Density Array Gene Signature|LDA Gene Signature|Low-Density Array Gene Signature	A gene expression profile determined using quantitative reverse transcriptase-based PCR (QRT-PCR) and low-density array technology.	Low Density Array Gene Signature		Functional Concept	CTRP Biomarker Terminology|CTRP Terminology
C148073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148073>	C16223	Sequencing Library	A collection of double stranded DNA fragments flanked by oligonucleotide sequence adapters to enable their analysis by high-throughput sequencing.			Body Substance	
C148074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148074>	C35136	Peripheral Vascular Insufficiency|PVI	A condition in which there is inadequate blood flow through the peripheral blood vessels due to intrinsic disease of the vasculature.			Disease or Syndrome	
C148075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148075>	C49803|C202126	Septal Defect Repair|Closure of Septal Defect|Repair of Septal Defect	Any surgical repair of a septal defect.			Therapeutic or Preventive Procedure	
C148076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148076>	C2964|C203309	Unresectable Craniopharyngioma	A craniopharyngioma that is not amenable to surgical resection.	Unresectable Craniopharyngioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148077>	C71698|C2964	Recurrent Craniopharyngioma	The reemergence of a craniopharyngioma after a period of remission.	Recurrent Craniopharyngioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148078>	C155321|C129822	Mezagitamab|Anti-CD38 MAb TAK-079|MEZAGITAMAB|TAK 079|TAK-079|TAK079	A human, non-agonistic immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface glycoprotein ADP-ribosyl cyclase 1 (CD38) with potential immunomodulating and antineoplastic activities. Mezagitamab specifically binds to CD38 that is expressed on human plasmablasts, plasma cells, NK cells and activated T- and B-cells. This may trigger antibody-dependent cellular cytotoxicity (ADCC), cell lysis and depletion of CD38-expressing cells. Additionally, TAK-079 does not induce CD38-dependent signaling and does not promote cytokine activation in peripheral blood mononuclear cells (PMBCs). CD38, a type II transmembrane glycoprotein, is overexpressed on cells associated with autoimmune diseases and hematologic malignancies.	Mezagitamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148079>	C93202|C103514	F-18 Sodium Fluoride Positron Emission Tomography and Magnetic Resonance Imaging|F-18 Sodium Fluoride PET/MRI|F-18 Sodium Fluoride PET/MRI Scan	An imaging procedure that combines F-18 sodium fluoride PET with an MRI scan to overlay activity data onto detailed anatomic images.			Diagnostic Procedure	
C148080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148080>	C192560|C103514	C-11 Choline Positron Emission Tomography and Magnetic Resonance Imaging|C-11 Choline PET/MRI|C-11 Choline PET/MRI Scan	An imaging procedure that combines C-11 choline PET with an MRI scan to overlay activity data onto detailed anatomic images.			Diagnostic Procedure	
C148081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148081>	C177696	PIK3CA Gene Mutation Negative|PI3KCA Mutation Negative|PIK3CA Mutation Negative|PIK3CA Wildtype|PIK3CA wt|Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Gene Mutation Negative|p110-alpha Gene Mutation Negative	A genetic finding indicating that PIK3CA gene mutations have not been detected in a sample.	PIK3CA Gene Mutation Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148082>	C177696	FLT3 Gene Mutation Negative|CD135 Gene Mutation Negative|FLK2 Gene Mutation Negative|FLT3 Mutation Negative|FLT3 Wild Type|FLT3 Wildtype|FLT3 wt|FMS-Related Tyrosine Kinase 3 Gene Mutation Negative	A genetic finding indicating that FLT3 gene mutations have not been detected in a sample.	FLT3 Gene Mutation Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148083>	C177696	CDKN2A Gene Mutation Negative|CDK4I Gene Mutation Negative|CDKN2A Mutation Negative|CDKN2A Wildtype|CDKN2A wt|Cyclin-Dependent Kinase Inhibitor 2A Gene Mutation Negative|p14ARF Gene Mutation Negative|p16 Gene Mutation Negative|p16-INK4A Gene Mutation Negative|p16INK4 Gene Mutation Negative|p16INK4a Gene Mutation Negative|p19ARF Gene Mutation Negative	A genetic finding indicating that CDKN2A gene mutations have not been detected in a sample.	CDKN2A Gene Mutation Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148084>	C159778	BRCA1 Gene Mutation Negative|BRCA1 Mutation Negative|BRCA1 Wildtype|BRCA1 wt|BROVCA1 Gene Mutation Negative|Breast Cancer 1 Gene Mutation Negative|Breast Cancer 1, Early Onset Gene Mutation Negative|Breast Cancer Type 1 Susceptibility Gene Mutation Negative	A genetic finding indicating that BRCA1 gene mutations have not been detected in a sample.	BRCA1 Gene Mutation Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148085>	C159778	BRCA2 Gene Mutation Negative|BRCA2 Mutation Negative|BRCA2 Wildtype|BRCA2 wt|BRCC2 Gene Mutation Negative|BROVCA2 Gene Mutation Negative|Breast Cancer 2 Gene Mutation Negative|Breast Cancer 2, Early Onset Gene Mutation Negative|Breast Cancer Type 2 Susceptibility Gene Mutation Negative|FANCD1 Gene Mutation Negative	A genetic finding indicating that BRCA2 gene mutations have not been detected in a sample.	BRCA2 Gene Mutation Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148086>	C136567	IDH1 Gene Mutation Negative|HEL-216 Gene Mutation Negative|HEL-S-26 Gene Mutation Negative|IDCD Gene Mutation Negative|IDH1 Mutation Negative|IDH1 Wild Type|IDH1 Wildtype|IDH1 wt|IDPC Gene Mutation Negative|Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic Gene Mutation Negative|Isocitrate Dehydrogenase 1 (NADP+), Soluble Gene Mutation Negative|PICD Gene Mutation Negative	A genetic finding indicating that IDH1 gene mutations have not been detected in a sample.	IDH1 Gene Mutation Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148087>	C136567	IDH2 Gene Mutation Negative|D2HGA2 Gene Mutation Negative|ICD-M Gene Mutation Negative|IDH2 Mutation Negative|IDH2 Wildtype|IDH2 wt|IDHM Gene Mutation Negative|IDPM Gene Mutation Negative|Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial Gene Mutation Negative|Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial Gene Mutation Negative|mNADP-IDH Gene Mutation Negative	A genetic finding indicating that IDH2 gene mutations have not been detected in a sample.	IDH2 Gene Mutation Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148088>	C47911	Sequencing Run	The valid and completed operation of a high-throughput sequencing instrument for a single sequencing process.			Activity	
C148089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148089>	C180944|C132848	BRAF Gene Mutation Negative|B-RAF Gene Mutation Negative|B-RAF1 Gene Mutation Negative|BRAF Mutation Negative|BRAF Wild Type|BRAF Wildtype|BRAF wt|Negative|No mutation detected|v-raf Murine Sarcoma Viral Oncogene Homolog B1 Gene Mutation Negative	A genetic finding indicating that BRAF gene mutations have not been detected in a sample.	BRAF Gene Mutation Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148090>	C189831|C177696	ALK Gene Mutation Negative|ALK Mutation Negative|ALK Wildtype|ALK wt|Anaplastic Lymphoma Kinase (Ki-1) Gene Mutation Negative|Anaplastic Lymphoma Receptor Tyrosine Kinase Gene Mutation Negative|CD246 Gene Mutation Negative	A genetic finding indicating that ALK gene mutations have not been detected in a sample.	ALK Gene Mutation Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148091>	C190823|C177696	EGFR Gene Mutation Negative|EGFR Mutation Negative|EGFR Wildtype|EGFR wt|ERBB Gene Mutation Negative|ERBB1 Gene Mutation Negative|Epidermal Growth Factor Receptor Gene Mutation Negative|HER1 Gene Mutation Negative|No mutation detected|c-erbB1 Gene Mutation Negative	A genetic finding indicating that EGFR gene mutations have not been detected in a sample.	EGFR Gene Mutation Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148092>	C177696	TP53 Gene Mutation Negative|BCC7 Gene Mutation Negative|LFS1 Gene Mutation Negative|Li-Fraumeni Syndrome Gene Mutation Negative|Negative|No|Normal|TP53 Mutation Negative|TP53 Wild Type|TP53 Wildtype|TP53 wt|TRP53 Gene Mutation Negative|Tumor Protein p53 Gene Mutation Negative|p53 Gene Mutation Negative	A genetic finding indicating that TP53 gene mutations have not been detected in a sample.	TP53 Gene Mutation Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148093>	C132847	NRAS Gene Mutation Negative|N-RAS Gene Mutation Negative|NRAS Mutation Negative|NRAS Wild-Type|NRAS Wildtype|NRAS wt|Negative|Neuroblastoma RAS Viral Oncogene Homolog Gene Mutation Negative|No mutation detected	A genetic finding indicating that NRAS gene mutations have not been detected in a sample.	NRAS Gene Mutation Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148094>	C177696	MYD88 Gene Mutation Negative|MYD88 Mutation Negative|MYD88 Wildtype|MYD88 wt|Myeloid Differentiation Primary Response 88 Gene Mutation Negative	A genetic finding indicating that MYD88 gene mutations have not been detected in a sample.	MYD88 Gene Mutation Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148095>	C156028|C150479	EGFR Gene Rearrangement|ERBB Gene Rearrangement|ERBB1 Gene Rearrangement|Epidermal Growth Factor Receptor Gene Rearrangement|HER1 Gene Rearrangement|c-erbB1 Gene Rearrangement	A molecular abnormality indicating rearrangement of the EGFR gene.	EGFR Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C148096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148096>	C129310	H3.3 K27M Variant|H3.3 K27M Mutation|H3.3 K27M Mutation|H3.3 K28M Mutation|H3.3 Lys27Met Mutation|H3.3 Lys28Met Mutation|H3.3 NP_002098.1:p.K28M|H3.3 NP_002098.1:p.Lys28Met|H3.3 p.K28M|H3.3 p.Lys28Met|H3.3K27M Mutation|Histone H3.3 K27M Mutation|Histone H3.3 K28M Mutation|Histone H3.3 Lys27Met Mutation|Histone H3.3 Lys28Met Mutation|NP_002098.1:p.K28M|NP_002098.1:p.Lys28Met	A change in the amino acid residue at position 27 in histone H3.3 protein where lysine has been replaced by methionine.	H3.3 K27M Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148097>	C150618|C132244	FGFR3 Gene Fusion Positive|CD333 Gene Fusion Positive|FGFR-3 Gene Fusion Positive|FGFR3 Fusion|Fibroblast Growth Factor Receptor 3 Gene Fusion Positive|JTK4 Gene Mutation Fusion Positive	An indication that a FGFR3 fusion gene has been detected in a sample.	FGFR3 Gene Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148098>	C15184	NOURISH-T|NOURISH for Healthy Transitions|Nourishing Our Understanding of Role Modeling to Improve Support and Health for Healthy Transitions	A program for behavior modification that focusing on caregivers as agents for change. In NOURISH-T, caregivers are educated about the importance of modeling healthy eating and physical activity behaviors to promote positive health behavior change and healthy weight management in pediatric cancer survivors.			Therapeutic or Preventive Procedure	
C148099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148099>	C7612|C120186	Refractory Malignant Thymoma	Malignant thymoma that does not respond to treatment.	Refractory Malignant Thymoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C1480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1480>	C1967	Damnacanthal	An alkaloid phytochemical found in the Morinda Citrifolia (Noni) that inhibits the growth of RAS cancer cells. The exact mechanism is unknown but may involve the inhibition of tyrosine kinase. (NCI)			Organic Chemical|Pharmacologic Substance	
C148100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148100>	C130236	ROS1 Gene Inversion|MCF3 Gene Inversion|ROS Gene Inversion|ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene Inversion|ROS1 Inversion|ROS1 Inversion Mutation|c-ros-1 Gene Inversion	A genetic rearrangement that refers to any inversion involving the ROS1 gene.	ROS1 Gene Inversion		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C148101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148101>	C36327	Hedgehog Pathway Mutation|Hedgehog Pathway Gene Mutation|Hedgehog Signaling Mutation|Hedgehog Signaling Pathway Gene Mutation|Hedgehog Signaling Pathway Mutation	A change in the sequence of one or more genes that are involved in the hedgehog signaling pathway.			Cell or Molecular Dysfunction	
C148102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148102>	C29629	Dextromethorphan/Bupropion Tablet AXS-05|AXS 05|AXS-05|DM + BUP	A tablet composed of the non-opioid derivative of morphine dextromethorphan (DM) and the aminoketone bupropion, with potential analgesic, antidepressant and anti-agitation activities. Upon oral administration, the DM component may act as a weak N-methyl-D-aspartate (NMDA) receptor antagonist, a sigma-1 receptor agonist and an inhibitor of the serotonin and norepinephrine transporters, which together may alleviate pain, agitation, anxiety and depression. While the bupropion component acts as a norepinephrine and dopamine reuptake inhibitor and a central nicotinic acetylcholine receptor antagonist, which is beneficial in the treatment of depression. Additionally, bupropion may increase the bioavailability of DM, thus prolonging the therapeutic effects of DM.	Dextromethorphan/Bupropion Tablet AXS-05		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology
C148103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148103>	C211912	Anti-CD48/MMAE Antibody-drug Conjugate SGN-CD48A|Anti-CD48 ADC SGN-CD48A|SGN CD48A|SGN-CD48A|SGNCD48A	An antibody-drug conjugate (ADC) composed of an antibody targeting the cell surface antigen CD48 that is conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), via a proprietary next-generation PEGylated glucuronide linker, with potential antineoplastic activity. Following intravenous administration, the antibody moiety of anti-CD48 ADC SGN-CD48A binds to CD48 on the surface of tumor cells. Following internalization of the ADC, the MMAE binds to tubulin and inhibits microtubule polymerization, which may result in G2/M phase cell cycle arrest and apoptosis in CD48-expressing tumor cells. CD48, a member of the signaling lymphocyte activation molecule (SLAM) family of immune cell receptors, is involved in T-cell activation and leukocyte trafficking. Additionally, CD48 is expressed on the surface of multiple myeloma cells at significantly higher levels than it is expressed on normal lymphocytes and monocytes. The linkage system in SGN-CD48A improves stability, reduces off-target uptake, and enables conjugation of larger numbers of MMAE/antibody than other systems, resulting in increased specificity against CD48-positive cells.	Anti-CD48/MMAE Antibody-drug Conjugate SGN-CD48A		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148104>	C97927|C141240	DDR2 Gene Mutation|DDR2 Mutation|Discoidin Domain Receptor Family Member 2 Gene Mutation|Discoidin Domain Receptor Family, Member 2 Gene Mutation|MIG20a Gene Mutation|NTRKR3 Gene Mutation|TKT Gene Mutation|TYRO10 Gene Mutation	A change in the nucleotide sequence of the DDR2 gene.			Cell or Molecular Dysfunction	
C148105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148105>	C36327	GNAI Family Gene Mutation|G Protein Subunit Alpha I Gene Mutation|G(i) Alpha Gene Mutation|GNAI Gene Mutation|Guanine Nucleotide Binding Protein (G Protein), Alpha Inhibiting Activity Gene Mutation|Guanine Nucleotide Binding Protein Alpha Inhibiting Activity Gene Mutation|Guanine Nucleotide-Binding Protein G(i), Alpha Gene Mutation	A change in the nucleotide sequence of a GNAI family gene.			Cell or Molecular Dysfunction	
C148106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148106>	C96866|C178119	Inactivating ERBB2 Gene Mutation|CD340 Inactivating Mutation|HER-2 Inactivating Mutation|HER2 Inactivating Mutation|HER2/Neu Inactivating Mutation|Inactivating HER2 Mutation|Loss of Function ERBB2 Mutation|Loss of Function HER2 Mutation	A change in the nucleotide sequence of the ERBB2 gene that either inhibits expression of the receptor tyrosine-protein kinase erbB-2 protein or results in the translation of an inactive receptor tyrosine-protein kinase erbB-2 protein.			Cell or Molecular Dysfunction	
C148107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148107>	C39712|C18060	Somatic KIT Gene Mutation|C-KIT Somatic Mutation|CD117 Somatic Mutation|KIT Proto-Oncogene Tyrosine Protein Kinase Gene Somatic Mutation|KIT Somatic Mutation|Somatic c-KIT Gene Mutation|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Gene Somatic Mutation	A change in the nucleotide sequence of the KIT gene that originated in non-germline cells.	Somatic KIT Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148109>	C177683|C133704	FGF1 Gene Fusion Positive|AFGF Gene Fusion Positive|ECGF Gene Fusion Positive|ECGF-alpha Gene Fusion Positive|ECGF-beta Gene Fusion Positive|ECGFA Gene Fusion Positive|ECGFB Gene Fusion Positive|FGF-1 Gene Fusion Positive|FGF1 Fusion|FGF1 Fusion Mutation|FGFA Gene Fusion Positive|Fibroblast Growth Factor 1 (Acidic) Gene Fusion Positive|Fibroblast Growth Factor 1 Gene Fusion Positive|Fibroblast Growth Factor 1, Acidic Gene Fusion Positive|HBGF-1 Gene Fusion Positive|HBGF1 Gene Fusion Positive	An indication that a FGF1 fusion gene has been detected in a sample.	FGF1 Gene Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148110>	C177683|C133704	FGF3 Gene Fusion Positive|FGF-3 Gene Fusion Positive|FGF3 Fusion|FGF3 Fusion Mutation|FGF3 Fusion Positive|Fibroblast Growth Factor 3 Gene Fusion Positive|HBGF-3 Gene Fusion Positive|HBGF3 Gene Fusion Positive|INT-2 Gene Fusion Positive|INT2 Gene Fusion Positive|Murine Mammary Tumor Virus Integration Site 2 Gene Fusion Positive	An indication that a FGF3 fusion gene has been detected in a sample.	FGF3 Gene Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148111>	C97927	FGF1 Gene Mutation|AFGF Gene Mutation|ECGF Gene Mutation|ECGF-alpha Gene Mutation|ECGF-beta Gene Mutation|ECGFA Gene Mutation|ECGFB Gene Mutation|FGF-1 Gene Mutation|FGFA Gene Mutation|Fibroblast Growth Factor 1 (Acidic) Gene Mutation|Fibroblast Growth Factor 1 Gene Mutation|Fibroblast Growth Factor 1, Acidic Gene Mutation|HBGF-1 Gene Mutation|HBGF1 Gene Mutation	A change in the nucleotide sequence of the FGF1 gene.	FGF1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148112>	C118376	FGF1 Gene Amplification|AFGF Gene Amplification|ECGF Gene Amplification|ECGF-alpha Gene Amplification|ECGF-beta Gene Amplification|ECGFA Gene Amplification|ECGFB Gene Amplification|FGF-1 Gene Amplification|FGFA Gene Amplification|Fibroblast Growth Factor 1 (Acidic) Gene Amplification|Fibroblast Growth Factor 1 Gene Amplification|Fibroblast Growth Factor 1, Acidic Gene Amplification|HBGF-1 Gene Amplification|HBGF1 Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the FGF1 gene.	FGF1 Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148113>	C97927	FGF3 Gene Mutation|FGF-3 Gene Mutation|Fibroblast Growth Factor 3 Gene Mutation|HBGF-3 Gene Mutation|HBGF3 Gene Mutation|INT-2 Gene Mutation|INT2 Gene Mutation|Murine Mammary Tumor Virus Integration Site 2 Gene Mutation	A change in the nucleotide sequence of the FGF3 gene.	FGF3 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148114>	C150614|C132244	FGFR1 Gene Fusion Positive|BFGFR Gene Fusion Positive|CD331 Gene Fusion Positive|CEK Gene Fusion Positive|FGFBR Gene Fusion Positive|FGFR-1 Gene Fusion Positive|FGFR1 Fusion|FGFR1 Fusion Mutation|FLG Gene Fusion Positive|FLT-2 Gene Fusion Positive|FLT2 Gene Fusion Positive|FMS-Like Tyrosine Kinase 2 Gene Fusion Positive|Fibroblast Growth Factor Receptor 1 Gene Fusion Positive|KAL2 Gene Fusion Positive|N-SAM Gene Fusion Positive|OGD Gene Fusion Positive	An indication that a FGFR1 fusion gene has been detected in a sample.	FGFR1 Gene Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148115>	C177683	PDGFA Gene Fusion Positive|PDGF-A Fusion|PDGF-A Fusion Mutation|PDGF-A Gene Fusion Positive|PDGF1 Gene Fusion Positive|PDGFA Fusion|Platelet Derived Growth Factor Subunit A Gene Fusion Positive|Platelet-Derived Growth Factor Alpha Polypeptide Gene Fusion Positive	An indication that a PDGFA fusion gene has been detected in a sample.	PDGFA Gene Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148116>	C177683	PDGFB Gene Fusion Positive|IBGC5 Gene Fusion Positive|PDGF-2 Gene Fusion Positive|PDGF-B Fusion|PDGF-B Fusion Mutation|PDGF2 Gene Fusion Positive|PDGFB Fusion|Platelet Derived Growth Factor Subunit B Gene Fusion Positive|Platelet-Derived Growth Factor Beta Polypeptide Gene Fusion Positive|SIS Gene Fusion Positive|SSV Gene Fusion Positive|c-sis Gene Fusion Positive	An indication that a PDGFB fusion gene has been detected in a sample.	PDGFB Gene Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148117>	C212872	PDGFRA Gene Fusion Positive|CD140A Gene Fusion Positive|PDGFR-2 Gene Fusion Positive|PDGFR-A Fusion|PDGFR-A Fusion Mutation|PDGFR2 Gene Fusion Positive|PDGFRA Fusion|PDGFRalpha Gene Fusion Positive|Platelet-Derived Growth Factor Receptor Alpha Gene Fusion Positive|RHEPDGFRA Gene Fusion Positive	An indication that a PDGFRA fusion gene has been detected in a sample.	PDGFRA Gene Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148118>	C212872	PDGFRB Gene Fusion Positive|CD140b Gene Fusion Positive|JTK12 Gene Fusion Positive|PDGFR-1 Gene Fusion Positive|PDGFR-B Fusion|PDGFR-B Fusion Mutation|PDGFR1 Gene Fusion Positive|PDGFRB Fusion|PDGFRbeta Gene Fusion Positive|Platelet-Derived Growth Factor Receptor Beta Gene Fusion Positive	An indication that a PDGFRB fusion gene has been detected in a sample.	PDGFRB Gene Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148119>	C45581	PDGFA Gene Amplification|PDGF-1 Gene Amplification|PDGF-A Gene Amplification|PDGF1 Gene Amplification|Platelet Derived Growth Factor Subunit A Gene Amplification|Platelet-Derived Growth Factor Alpha Polypeptide Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the PDGFA gene.	PDGFA Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148120>	C45581	PDGFB Gene Amplification|IBGC5 Gene Amplification|PDGF-2 Gene Amplification|PDGF-B Gene Amplification|PDGF2 Gene Amplification|Platelet Derived Growth Factor Subunit B Gene Amplification|Platelet-Derived Growth Factor Beta Polypeptide Gene Amplification|SIS Gene Amplification|SSV Gene Amplification|c-sis Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the PDGFB gene.	PDGFB Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148121>	C97927	PDGFA Gene Mutation|PDGF-1 Gene Mutation|PDGF-A Gene Mutation|PDGF1 Gene Mutation|Platelet Derived Growth Factor Subunit A Gene Mutation|Platelet-Derived Growth Factor Alpha Polypeptide Gene Mutation	A change in the nucleotide sequence of the PDGFA gene.	PDGFA Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148122>	C97927	PDGFB Gene Mutation|IBGC5 Gene Mutation|PDGF-2 Gene Mutation|PDGF-B Gene Mutation|PDGF2 Gene Mutation|Platelet Derived Growth Factor Subunit B Gene Mutation|Platelet-Derived Growth Factor Beta Polypeptide Gene Mutation|SIS Gene Mutation|SSV Gene Mutation|c-sis Gene Mutation	A change in the nucleotide sequence of the PDGFB gene.	PDGFB Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148123>	C1927	Esperamicin Antibiotic|Esperamicin|Esperamicin Antineoplastic Antibiotic|Esperamicins|Esperamycin	Any agent belonging to the esperamicins, a class of bacterium-derived chromoprotein enediyne antibiotics with antineoplastic activity. Esperamicins bind to the minor groove of DNA, cleave DNA and induce apoptosis of tumor cells.			Chemical Viewed Functionally	
C148124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148124>	C2916|C27359	Unresectable Carcinoma	A carcinoma that is not amenable to surgical resection.	Unresectable Carcinoma		Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C148125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148125>	C7569|C179420|C148124	Unresectable Thymus Carcinoma|Unresectable Thymic Carcinoma|Unresectable Thymic Carcinoma	A thymus carcinoma that is not amenable to surgical resection.	Unresectable Thymic Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148126>	C148130|C148128	Locally Advanced Thymus Carcinoma|Locally Advanced Thymic Carcinoma|Locally Advanced Thymic Carcinoma	A thymus carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Thymic Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148127>	C7619|C7569	Recurrent Thymus Carcinoma|Recurrent Thymic Carcinoma|Recurrent Thymic Carcinoma	A thymus carcinoma that has recurred after a period of remission.	Recurrent Thymic Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148128>	C7569|C3482|C176862	Metastatic Thymus Carcinoma|Metastatic Thymic Carcinoma|Metastatic Thymic Carcinoma	A carcinoma that arises from the thymus and has spread from its original site of growth to another anatomic site.	Metastatic Thymic Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148129>	C9265|C8689	Refractory Mycosis Fungoides and Sezary Syndrome	Mycosis fungoides and Sezary syndrome resistant to treatment.	Refractory Mycosis Fungoides and Sezary Syndrome		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148130>	C8524|C3482	Locally Advanced Carcinoma	A carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.			Neoplastic Process	
C148131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148131>	C78283|C1742|C1291	Aganirsen|AGANIRSEN|GS-101	A 25-mer antisense oligonucleotide (ASO) that targets the mRNA transcript for insulin receptor substrate (IRS-1), a protein required for the formation and growth of new blood vessels, that can be used to reduce corneal angiogenesis and neovascularization. Upon ocular administration, aganirsen binds to IRS-1 mRNA and blocks the synthesis of IRS-1. By blocking the expression of IRS-1 in pro-angiogenic conditions, such as those seen in corneal grafts and other inflammatory-based ocular diseases, aganirsen blocks the corneal neovascularization pathway, inhibits vascular endothelial growth factor (VEGF) production, which is a key component of neovascularization, and prevents the production of various pro-inflammatory cytokines, which together decrease the risk of corneal neovascularization. Additionally, upon corneal transplantation, neovascularization induces an immune response that can lead to immunological corneal graft rejection; therefore, by inhibiting neovascularization this agent can decrease the risk of corneal graft rejection. IRS-1, overexpressed in endothelial cells during corneal neovascularization, plays a key role in the regulation of angiogenesis.			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C148132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148132>	C171165	MR-Compatible Sectioning and Localization Device	A device designed to facilitate lesion detection and improve direct comparison of histopathologic specimens with prior in vivo imaging, consisting of an MRI compatible localization device, with MR-visible fiducial marks for ex vivo imaging to facilitate radiographic-pathologic correlation.	MR-Compatible Sectioning and Localization Device		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C148133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148133>	C201275|C200766	Autologous PD-1 Antibody-expressing Mesothelin-specific CAR-T Cells|Autologous PD-1 Antibody expressing Mesothelin Specific CAR-T Cells|Autologous PD-1 Antibody-expressing Mesothelin-specific CAR T-cells	Genetically modified, autologous T-lymphocytes that express an antibody that targets the negative immunoregulatory human cell surface receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and are transduced with a gene encoding a chimeric antigen receptor (CAR) specific for the human tumor-associated antigen (TAA) mesothelin, with potential immunomodulating and antineoplastic activities. After isolation, transduction, expansion in culture, and reintroduction into the patient, the autologous PD-1 antibody expressing mesothelin specific CAR-T cells specifically target and kill mesothelin-expressing tumor cells. The anti-PD-1 expressed on the CAR-T cells binds to PD-1 expressed on T-cells and prevents the interaction of PD-1 with its ligand programmed cell death 1 ligand 1 (PD-L1, PD-1L1; CD274) expressed on cancer cells, which prevents PD-1-mediated signaling and T-cell exhaustion, enhances T-cell activation, and results in enhanced toxicity in mesothelin-expressing tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation and overexpression within the tumor microenvironment and inhibits T-cell function. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148134>	C168618	Safusidenib|AB 218|AB-218|AB218|DS 1001|DS-1001|DS-1001b|Mutant Isocitrate Dehydrogenase Type 1 Inhibitor DS-1001|SAFUSIDENIB	An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1; IDH-1; IDH1 [NADP+] soluble) mutant forms, including substitution mutations at the arginine in position 132, IDH1(R132) (IDH1-R132), with potential antineoplastic activity. Upon oral administration, safusidenib specifically binds to and inhibits certain mutant forms of IDH1, thereby inhibiting the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing IDH1 mutations. IDH1(R132) mutations are highly expressed in certain malignancies, including gliomas; they initiate and drive cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG. Safusidenib minimally targets and affects wild-type IDH1, which is expressed in normal, healthy cells.	Safusidenib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148135>	C201491|C200766	iC9-GD2-CAR-CD28-OX40-expressing Autologous NKT Cells|GD2-CAR NKT Cells|GD2-CAR-expressing Autologous Natural Killer T-Cells|GINAKIT Cells|GINAKIT-cells|iC9-GD2.CD28.OX40.zeta Natural Killer T Cells	A preparation of autologous interleukin-15 (IL-15)-expressing natural killer T-cells (NKT) transduced with a retroviral vector encoding a chimeric antigen receptor (CAR) derived from the antibody 14G2a that recognizes disialoganglioside GD2 (GD2-CAR) that is coupled to the co-stimulatory domains of CD28 and OX40 (CD134), and to the zeta chain of the TCR/CD3 complex (CD3-zeta), and linked to the suicide gene inducible caspase 9 (iCasp9 or iC9), with potential immunomodulating and antineoplastic activities. Upon transfusion, the iC9-GD2-CAR-CD28-OX40-expressing autologous NKT cells recognize, bind to and induce selective cytotoxicity in GD2-expressing tumor cells. The tumor-associated antigen (TAA) GD2 is overexpressed on the surface of neuroblastoma cells and by other neuroectoderm-derived neoplasms, while it is minimally expressed on normal, healthy cells. The iCasp9 safety switch consists of a full-length caspase 9, including its caspase recruitment domain, linked to a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V). If the administered NKT cells lead to unacceptable side effects, the chemical homodimerizer AP1903, which binds to the FKBP12-F36V drug-binding domain, activates caspase 9, and results in apoptosis of the administered NKT cells, can be administered.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology
C148136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148136>	C1505	Nutritious Semisolid Food Gel|Nutri-jelly	A proprietary, flavored, semisolid food gel-based nutritional supplement containing a variety of vitamins, iron, calcium, protein, fat and carbohydrates, that can be consumed for nutritional support. Upon oral intake, the nutritious semisolid food gel may prevent malnutrition and weight loss. The food gel has a semisolid texture and is specifically formulated for patients who have difficulty chewing and swallowing.			Food|Pharmacologic Substance	NCI Drug Dictionary Terminology
C148137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148137>	C1505	Nutritious Semisolid Food Gel with Phenethyl Isothiocyanate|Nutri-jelly with PEITC|Semisolid Food Gel with PEITC	A proprietary, flavored, semisolid food gel-based nutritional supplement containing a variety of vitamins, iron, calcium, protein, fat and carbohydrates, in combination with the phytochemical phenethyl isothiocyanate (PEITC), that can be consumed for nutritional support, and with chemopreventive and anti-cancer activities. Upon oral intake, the nutritious semisolid food gel may aid in the prevention of malnutrition and weight loss. The food gel has a semisolid texture and is specifically formulated for patients who have difficulty chewing and swallowing. PEITC may delay cancer growth, and inhibit cancer cell migration and invasion.			Food|Pharmacologic Substance	NCI Drug Dictionary Terminology
C148138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148138>	C128462	BET-bromodomain Inhibitor ODM-207|BET Inhibitor ODM-207|Bromodomain and Extraterminal Domain Protein Inhibitor ODM-207|ODM 207|ODM-207|ODM-207|ODM207	An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, the BET inhibitor ODM-207 binds to the acetylated lysine recognition motifs in the bromodomains of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression of oncogenic drivers that are important for cell proliferation and survival. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of proliferation in BET-overexpressing tumor cells. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that bind to acetylated lysine residues in histones and play an important role during development and cellular growth. In tumor cells, BET proteins play a key role in the regulation of oncogene transcription and tumor cell proliferation.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148139>	C26170	Oral Moisturizing Jelly|Gel-based Artificial Saliva|OMJ	An edible, gel-based formulation containing an artificial saliva substitute, composed of water, electrolytes and buffering agents, with potential anti-xerostomia and protective activities. Upon application of the oral moisturizing jelly (OMJ), the natural electrolyte and pH balance of human saliva is restored, which increases moisture of mucosal tissues of the mouth, tongue and oropharynx. This relieves dryness, enhances lubrication, and increases salivary flow. OMJ makes it easier to chew, swallow and talk, and also prevents xerostomia-induced infections, as well as tooth decay.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C148140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148140>	C129825	Karonudib|Karolinska MTH1 Inhibitor TH1579|Karolinska NUDT1 Inhibitor TH1579|TH1579	An orally available inhibitor of Karolinska nudt1 (MTH1; MutT homologue 1; NUDT1), with potential antineoplastic activity. Upon administration, karonudib targets and binds to the active site of MTH1, thereby preventing the activity of MTH1. This leads to the incorporation of oxidized deoxynucleoside triphosphates (dNTPs) into the DNA of cancer cells, which causes DNA damage, introduces double strand breaks (DSBs), and induces apoptosis in cancer cells. MTH1, a member of the Nudix phosphohydrolase superfamily hydrolyzes oxidized purine nucleoside triphosphates, including 8-oxo-dGTP and 2-OH-dATP, converts them into their corresponding monophosphate forms, and prevents their incorporation into DNA, which allows MTH1-expressing cells to evade cell death. Compared to normal, healthy cells, cancer cells overexpress MTH1, which leads to dysregulation of the cellular redox system and increased reactive oxygen species (ROS) production, which together prevents the incorporation of damaged and oxidized nucleotides into DNA.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C148141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148141>	C214984|C201282|C129822	Tepoditamab|Anti-CLEC12A x CD3 Bispecific Antibody MCLA117|Anti-CLEC12A/Anti-CD3 Bispecific Antibody MCLA117|Bispecific Antibody MCLA-117|Immunoglobulin G1, Bispecific, Anti-(C-type lectin CLEC12A and CD3 Antigen) (Human Monoclonal MCLA-117 Gamma1-chain), Disulfide with Human Monoclonal MCLA-117 Kappa-chain, Dimer|MCLA 117|MCLA-117|MCLA117|TEPODITAMAB	An immunoglobulin G1 (IgG1) bispecific human monoclonal antibody against human CD3, a T-cell surface antigen, and human C-type lectin domain family 12 member A (CLEC12A), a tumor-associated antigen (TAA) overexpressed on certain tumor cells, with potential antineoplastic activity. Upon administration, tepoditamab binds to both CD3 on T-cells and CLEC12A expressed on malignant cells, such as myeloid blasts, atypical progenitor cells and leukemic stem cells (LSCs). This results in the cross-linking of T-cells with tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against CLEC12A-expressing tumor cells. CLEC12A, a myeloid differentiation antigen and member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily, is overexpressed on myeloid leukemia cells, but not on normal early hematopoietic progenitors, including hematopoietic stem cells (HSCs).	Tepoditamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148142>	C49146|C1663	Adenoviral PSA Vaccine ETBX-071|Adenoviral PSA Prostate Cancer Vaccine ETBX-071|ETBX-071|ETBX-071	A cancer vaccine composed of a genetically engineered, replication-deficient adenovirus carrying the gene encoding human prostate-specific antigen (PSA), with potential immunostimulating and antineoplastic activities. Upon vaccination with the adenoviral-PSA vaccine ETBX-071, the adenovirus infects cells and expresses PSA. In turn, PSA activates the immune system and induces a cytotoxic T-lymphocyte (CTL) response against PSA-expressing tumor cells. PSA, a tumor associated antigen (TAA), is expressed by prostate epithelial cells and is overexpressed in prostate cancer.			Immunologic Factor|Pharmacologic Substance|Virus	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology
C148143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148143>	C177174	Resiquimod Gel CD11301|CD 11301|CD11301|CD11301 Topical Gel	A topical gel containing the Toll-like receptor (TLR) agonist resiquimod, an imidazoquinolinamine, with potential immunomodulating activity. Upon topical application, the resiquimod gel CD11301 binds to TLR7 and 8, which are found mainly on dendritic cells (DCs), macrophages, and B-lymphocytes, and activates the TLR signaling pathway, which results in the induction of the nuclear translocation of transcription activator nuclear factor kappa-B (NF-kB) and activation of other transcription factors. Subsequently, NF-kB-dependent gene expression is induced and cytokine production increases, especially interferon-alpha (INF-a), which results in the enhancement of T-helper 1 (Th1) immune responses. In addition, topical application of resiquimod appears to activate epidermal Langerhans cells, leading to enhanced activation of T-lymphocytes.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C148144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148144>	C1663	Oral Therapeutic Vaccine V3-X|CA19-9 Oral Vaccine V3-X|V3 X|V3-X|V3-X Vaccine	An orally bioavailable therapeutic vaccine consisting of the tumor-associated antigen (TAA) oligosaccharide antigen sialyl Lewis A (CA19-9; sialylated Lewis A antigen; carbohydrate antigen 19-9; cancer antigen 19-9), with potential immunostimulating and antineoplastic activities. Upon oral administration, oral therapeutic vaccine V3-X induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing CA19-9. CA19-9 is an antigen that is overexpressed in a variety of cancer cell types, and plays a key role in tumor cell survival and metastasis.			Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology
C148145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148145>	C216199	Lutetium Lu 177 Vipivotide Tetraxetan|177Lu-PSMA-617|177Lu-labeled PSMA-617|AAA 617|AAA-617|AAA617|LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN|Lu177-PSMA-617|Lutetium Lu 177 vipivotide tetraxetan|Lutetium Lu 177-PSMA-617|Lutetium-177-PSMA-617|Pluvicto	A radioconjugate composed of PSMA-617, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of lutetium Lu 177  vipivotide tetraxetan, vipivotide tetraxetan targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.	Lutetium Lu 177 Vipivotide Tetraxetan		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148146>	C1752|C1663	PD-L1 Peptide Vaccine|PD-L1 Peptide	A vaccine composed of a peptide derived from the tumor-associated antigen (TAA) and immune checkpoint molecule programmed cell death-1 ligand 1 (PD-L1) combined with the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Vaccination with PD-L1 peptide vaccine may activate the immune system to induce an immune response against PD-L1-expressing cells. This may increase and restore the proliferation and activation of various immune cells, including cytotoxic T-lymphocytes (CTLs), and may eradicate PD-L1-expressing tumor cells. PD-L1 is overexpressed on many human cancer cell types as well as on antigen presenting cells (APCs) and immunosuppressive cells in the tumor micro-environment (TME), such as regulatory T-cells (Tregs). PD-L1 binding to its cognate receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) on T-cells suppresses the immune system and results in increased immune evasion and decreased CTL activation. Montanide ISA-51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148147>	C2167|C129825	Lazertinib|GNS 1480|GNS-1480|GNS1480|LAZERTINIB|N-{5-[(4-{4-[(dimethylamino)methyl]-3-phenyl-1H-pyrazol-1-yl}pyrimidin-2-yl)amino]-4-methoxy-2-(morpholin-4-yl)phenyl}prop-2-enamide|YH 25448|YH-25448|YH25448	An orally available third-generation, selective inhibitor of certain forms of the epidermal growth factor receptor (EGFR) with activating mutations, including the resistance mutation T790M, exon 19 deletions (Del19), and the L858R mutation, with potential antineoplastic activity. Upon administration, lazertinib specifically and irreversibly binds to and inhibits selective EGFR mutants, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Lazertinib may inhibit programmed cell death-1 ligand 1 (PD-L1) and inflammatory cytokines in specific cancer cells harboring certain EGFR mutations. Compared to some other EGFR inhibitors, lazertinib may have therapeutic benefits in tumors with T790M- or L858R-mediated drug resistance. In addition, lazertinib penetrates the blood-brain barrier (BBB). This agent shows minimal activity against wild-type EGFR (wtEGFR), and does not cause dose-limiting toxicities, which occur during the use of non-selective EGFR inhibitors and inhibit wtEGFR. EGFR, a receptor tyrosine kinase (RTK) mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.	Lazertinib		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCIt Antineoplastic Agent Terminology
C148148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148148>	C93144	Lactobacillus reuteri Probiotic Tablet|L. reuteri Probiotic|Lactobacillus reuteri Probiotic	A tablet containing a strain of the probiotic Gram-positive, naturally-occurring bacterium Lactobacillus reuteri (L. reuteri), with potential antimicrobial, immunomodulatory and protective activities. Upon oral administration of the L. reuteri probiotic tablet, the Lactobacillus strain may improve digestion and help maintain adequate colonization of the gastrointestinal (GI) tract by modulating the composition of the normal microflora. During colonization of the GI tract, this bacterium adheres to human intestinal epithelial cells, and activates intestinal epithelial proliferation; both of these processes promote the formation and maintenance of a protective barrier, thereby preventing the attachment of harmful pathogens. L. reuteri produces lactic acid and other substances during fermentation, and creates an acidic environment that is unfavorable for pathogens, thereby further protecting the intestinal mucosa against pathogen-induced damage and loss of integrity of the intestinal mucosal barrier. Dietary supplementation with this bacterium has been shown to decrease intestinal inflammation and enhance innate and acquired immunity. Lactobacillus reuteri is naturally found in the GI tract.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C148149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148149>	C201557	Allogeneic TCR alpha/beta-positive T-lymphocyte-depleted Peripheral Blood Stem Cells|Allogeneic TCR a/b T cell-depleted PBSCs|Allogeneic TCR alpha/beta T Cell-depleted PBSCs	A preparation of allogeneic T-cell receptor (TCR) alpha/beta-positive T cell-depleted peripheral blood stem cells (PBSCs), that can potentially be used for hematopoietic stem cell transplantation (HSCT). Allogeneic PBMCs are processed, using the proprietary CliniMACS device, to remove TCRalpha/beta T-cells, while retaining other cells, such as donor-derived natural killer (NK) cells and gamma/delta T-cells. As TCR alpha/beta-positive T-cells appear to be related to the development of graft versus host disease (GvHD), depletion of these cells may lower the risk of the recipient developing GvHD. Upon infusion of the TCR alpha/beta-positive T-cell-depleted PBSCs for allogeneic stem cell transplantation (allo SCT), the alpha/beta-positive T-cell depletion as well as the presence of allogeneic NK cells, and other cells, may facilitate engraftment, exert graft-versus-leukemia effects, enhance post-transplant immune recovery, and reduce the risk of infections and GvHD.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148150>	C28681|C138180|C129826	Autologous NY-ESO-1 TCR-targeted T Lymphocytes|NY-ESO-1 T Cell Receptor Genetically Modified Autologous T Cells	A preparation of human autologous T-lymphocytes that are transduced with a gene encoding a T-cell receptor (TCR) specific for the cancer-testis antigen NY-ESO-1, with potential immunostimulating and antineoplastic activities. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the anti-NY-ESO-1 TCR-transduced autologous T-cells recognize and bind to NY-ESO-1-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of NY-ESO-1-positive tumor cells. NY-ESO-1, a tumor-associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types, and is not, or is minimally, expressed in normal, healthy cells.	Autologous NY-ESO-1 TCR-targeted T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148151>	C121007	Child-Pugh A-B7 Cirrhosis|Child-Pugh A-B7	An indication that Child-Pugh scores ranging from A (scores 5 or 6) to B7 (score 7) for liver cirrhosis will be considered for trial inclusion.			Intellectual Product	
C148152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148152>	C34447|C171605|C151907	Refractory Head and Neck Squamous Cell Carcinoma|Refractory Head and Neck Squamous Cell Cancer|Refractory Squamous Cell Carcinoma of the Head and Neck	A head and neck squamous cell carcinoma that does not respond to treatment.	Refractory Head and Neck Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148153>	C4104|C34447|C126465	Metastatic Head and Neck Squamous Cell Carcinoma|Metastatic Head and Neck Squamous Cell Cancer	A head and neck squamous cell carcinoma which has spread from the original site of growth to another anatomic site.	Metastatic Head and Neck Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148154>	C1752|C1663	PD-L1/IDO Peptide Vaccine IO102-103|IDO/PD-L1 Peptide Vaccine IO 102 IO 103|IO102 and IO103|IO102-103|IO102-IO103|IO102-IO103 Peptide Vaccine|IO102/IO103|IO103/IO102 Peptide Vaccine|Peptide Vaccine IO102-IO103|Peptide Vaccine IO103/IO102	A peptide vaccine composed of IO103, a peptide vaccine derived from the tumor-associated antigen (TAA) programmed cell death-1 ligand 1 (PD-L1), IO102, the 21-mer peptide vaccine derived from the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO), and the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Vaccination with the PD-L1/IDO peptide vaccine IO102-103 may activate the immune system to induce an immune response against PD-L1 and IDO-expressing cells. This may increase and restore the proliferation and activation of various immune cells, including cytotoxic T-lymphocytes (CTLs), and may eradicate PD-L1 and IDO-expressing tumor cells through a CTL-mediated immune response. PD-L1 is overexpressed on many human cancer cell types. PD-L1 binding to its cognate receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) on T-cells suppresses the immune system and results in increased immune evasion and decreased CTL activation. IDO, a cytosolic enzyme responsible for tryptophan catabolism and conversion of tryptophan into kynurenine, is overexpressed by a variety of tumor cell types and antigen presenting cells (APCs) and plays an important role in immunosuppression mainly through suppression of CTL activation; tryptophan depletion inhibits T-lymphocyte proliferation and activation, and suppresses the immune system. Montanide ISA-51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens.	PD-L1/IDO Peptide Vaccine IO102-103		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148155>	C129822|C128037	Prolgolimab|BCD 100|BCD-100|BCD100|PROLGOLIMAB	A monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, prolgolimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148156>	C200766|C176018	Autologous CD19CAR-CD28-CD137/CD27/CD3zeta-iCasp9-expressing T-lymphocytes|4S-CAR-T19|4SCAR19|4SCAR19 Cells|Autologous Anti-CD19 CAR-T cells 4SCAR19|Autologous CD19- scFv/CD28/CD137/CD27/CD3z-iCasp9 4SCAR-19 T-cells|Autologous CD19-scFv/CD28/CD137/CD27/CD3z-iCasp9 CAR-T-cells	Autologous T-lymphocytes that have been transduced with a fourth generation-lentiviral vector to express the 4SCAR19 gene composed of a chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) of anti-CD19 coupled to the co-stimulatory molecules CD28, 4-1BB (CD137), and CD27, and to the cytoplasmic portion of the zeta chain of the human T-cell receptor (CD3zeta), and containing the apoptosis-inducible suicide gene human caspase 9 (iCASP9 or iC9), that is linked to a drug binding domain, with potential immunostimulating and antineoplastic activities. The iCASP9 construct consists of the entire coding sequence for the human FK506-drug binding protein (FKBP12) with an F36V mutation (FKBP12-F36V) that is linked to the gene encoding iC9, which is a modified form of the CASP9 gene where the sequences encoding the endogenous caspase activation and recruitment domains have been deleted. Upon transfusion, anti-CD19-CAR-CD28/CD137/CD27/CD3zeta-iCasp9-expressing autologous T-lymphocytes target and bind to CD19-expressing neoplastic B-cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells, and causes tumor cell lysis. If the administered T-cells cause unacceptable side effects, the chemical homodimerizer AP1903, which binds to the FKBP12-F36V drug-binding domain, can be administered; this induces caspase 9 expression, and results in apoptosis of the administered 4SCAR19 T-cells. CD19, cluster of differentiation 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. Incorporation of the costimulatory signaling domains increases human T-cell function, expansion, and survival.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148159>	C129822|C128037	Geptanolimab|APL-501|CBT 501|CBT-501|CBT501|GB-226|GEPTANOLIMAB|Genolimzumab	An immunoglobulin G4 (IgG4) humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PD1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, geptanolimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C148160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148160>	C201275|C200766	Autologous Mesothelin-specific CAR-T Cells|Autologous CART-meso|Hu-CART Meso Cells	Genetically modified, autologous T-lymphocytes transduced with a gene encoding a chimeric antigen receptor (CAR) specific for the human tumor-associated antigen (TAA) mesothelin, with potential immunomodulating and antineoplastic activities. After isolation, transduction, expansion in culture, and reintroduction into the patient, the autologous mesothelin-specific CAR-T cells specifically target and kill mesothelin-expressing tumor cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types.	Autologous Mesothelin-specific CAR-T Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148161>	C2124	Carbon C 14 Pevonedistat|Carbon C 14-pevonedistat|[14 C]-pevonedistat	An orally bioavailable radioconjugate composed of pevonedistat, a small molecule inhibitor of NEDD8-activating enzyme (NAE), radiolabeled with the radioisotope carbon C 14, with potential use for evaluating the pharmacokinetic profile of pevonedistat. Pevonedistat binds to and inhibits NAE, which results in the inhibition of tumor cell proliferation and survival. Labeling of pevonedistat with the radioactive tracer carbon C 14 allows for the evaluation of pevonedistat's pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME).			Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	NCI Drug Dictionary Terminology
C148162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148162>	C141215	Rituximab Conjugate CON-4619|Aurixim|Aurixim Antibody Conjugate|CON-4619	A proprietary conjugate of rituximab, a recombinant chimeric murine/human antibody directed against the CD20 antigen, with potential antineoplastic activity. Upon administration of the rituximab conjugate CON-4619, the rituximab moiety targets and binds to CD20, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148163>	C1511	Zirconium Zr 89 Anti-EGFR Monoclonal Antibody ABT-806|89Zr-ABT806|89Zr-labeled ABT-806	A radioimmunoconjugate composed of ABT-806, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the epidermal growth factor receptor (EGFR), labeled with the radioisotope zirconium Zr 89, with potential use as an imaging agent upon positron emission tomography (PET). Upon administration of zirconium Zr 89 anti-EGFR monoclonal antibody ABT-806, the antibody moiety binds to a specific EGFR epitope of either the wild-type or the variant III mutant (EGFRvIII; de2-7 EGFR; DEGFR) on tumor cells. Upon PET imaging, EGFR-expressing tumor cells can be visualized and assessed. This may result in the quantification of EGFR-expressing tumor cells, an assessment of the expected response to treatment with ABT-806 and the selection of patients that would respond to ABT-806. ABT-806 is the humanized version of chimeric monoclonal antibody 806. EGFR, a receptor tyrosine kinase overexpressed on the cell surfaces of many tumor cell types, plays a key role in tumor cell proliferation.			Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	NCI Drug Dictionary Terminology
C148164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148164>	C200766	Autologous mRNA-modified Anti-cMET CAR-T Cells|Autologous cMET Redirected CAR-T Cells|Autologous mRNA CART-cMET|cMET CAR-mRNA-electroporated Autologous T lymphocytes	A preparation of autologous, genetically-engineered T-lymphocytes that have been electroporated with an mRNA encoding a chimeric antigen receptor (CAR) consisting of an anti-human hepatocyte growth factor receptor (HGFR or cMET) single chain variable fragment (scFv), with potential antineoplastic activities. Upon administration, autologous mRNA-modified anti-cMET CAR-T cells direct T-cells to cMET-expressing tumor cells, which induces selective toxicity against cMET-expressing tumor cells and causes tumor cell lysis. cMET, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148165>	C155712	Trastuzumab Conjugate BI-CON-02|BI-CON-02	A conjugated form of trastuzumab, a humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2; ERBB2), with potential immunomodulating and antineoplastic activities. Upon administration, the trastuzumab conjugate BI-CON-02 targets and binds to HER2 on the tumor cell surface, thereby inducing both cytotoxic T-lymphocyte (CTL) and antibody-dependent cell-mediated cytotoxicity (ADCC) responses against tumor cells that overexpress HER2. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148166>	C2185	Cyclin-dependent Kinase 8/19 Inhibitor BCD 115|BCD 115|BCD-115|BCD115|CDK 8/19 Inhibitor BCD 115|SENEXIN B	An orally bioavailable inhibitor of cyclin dependent kinases 8 and 19 (CDK8/19), with potential antineoplastic and chemoprotective activities. Upon oral administration, CDK8/19 inhibitor BCD 115 binds to and inhibits the activity of CDK8/19, which prevents activation of CDK8/19-mediated oncogenic signaling pathways, blocks selective transcription of certain tumor promoting genes, and inhibits proliferation of CDK8/19-overexpressing tumor cells. CDKs are serine/threonine kinases involved in the regulation of the cell cycle and may be overexpressed in certain cancer cell types. CDK8 plays a key role in transcription regulation and is an important oncogenic driver in a variety of cancer cell types.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148167>	C1511	Zirconium Zr 89 Pembrolizumab|89Zr-labeled Pembrolizumab|89Zr-pembrolizumab|PEMBROLIZUMAB DESFERRIOXAMINE ZIRCONIUM ZR-89	A radioimmunoconjugate composed of pembrolizumab, a humanized monoclonal antibody immunoglobulin (Ig) G4 antibody directed against the human cell surface receptor programmed cell death 1 (PD-1; PDCD1; CD279; programmed cell death-1), labeled with the radioisotope zirconium Zr 89, with potential use as an imaging agent upon positron emission tomography (PET). Upon administration of zirconium Zr 89 pembrolizumab, the antibody moiety binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T-cells, and blocks the binding to and activation of PD-1 by its ligands. Upon PET imaging, PD-1-expressing T-cells, as well as pembrolizumab biodistribution, can be visualized and the expected response to treatment with pembrolizumab, as well as selection of patients that would respond to pembrolizumab, can be assessed. The ligands for PD-1 include programmed cell death-1 ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death-1 ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C148168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148168>	C200766|C176023	Autologous EGFRt/BCMA-41BBz-targeted CAR T Cells|Autologous EGFRt/BCMA-41BBz CAR T Cell|B-cell Maturation Antigen-Targeted EGFRt/BCMA-41BBz CAR-modified T Cells	A preparation of autologous T-lymphocytes transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) fused to the co-stimulatory domain of 4-1BB (CD137) and the CD3-zeta (CD3z) T-cell signaling domain, and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous EGFRt/BCMA-41BBz-targeted CAR T cells are directed to, and induce selective toxicity in, BCMA-expressing tumor cells. Devoid of both ligand-binding domains and tyrosine kinase activity, the expressed EGFRt facilitates in vivo detection of the administered, transduced T-cells and, if the administered T-cells cause unacceptable side effects, can promote elimination of those cells through a cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) response. The 4-1BB costimulatory signaling domain enhances both proliferation of T-cells and antitumor activity. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and is overexpressed on malignant plasma cells.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology
C148169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148169>	C1966	Fluorescein-conjugated Wisteria floribunda Lectin|Fluorescein-labeled WFA|Fluorescein-labeled WFL|Fluorescein-labeled Wisteria floribunda Lectin	A fluorescein conjugated to a preparation of lectin(s) extracted from the seeds of Wisteria floribunda (Japanese wisteria), with potential use as a diagnostic agent. Upon administration of fluorescein-conjugated Wisteria floribunda lectin, the lectin moiety preferentially targets and binds to carbohydrate structures containing N-acetylgalactosamine and galactose residues overexpressed on certain tumor cell surfaces. Using white and fluorescent light,  tumor cells with increased lectin-binding affinity can be visualized or imaged.			Indicator, Reagent, or Diagnostic Aid	NCI Drug Dictionary Terminology
C148170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148170>	C2021	Raltitrexed Disodium|L-glutamic Acid, N-((5-(((3,4-Dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl)methylamino)-2-thienyl)carbonyl)-, Disodium Salt|RALTITREXED DISODIUM|Tomudex	The disodium salt form of raltitrexed, a quinazoline folate analogue, with potential antineoplastic activity.  Upon administration of raltitrexed, this agent is taken up by cells via the reduced folate carrier, undergoes intracellular polyglutamation, and blocks the folate-binding site of thymidylate synthase (TS). This inhibits the conversion of deoxyuridine monophosphate (dUMP) into deoxythymidine monophosphate (dTMP) and thus increases dUMP levels and decreases the amount of deoxythymidine triphosphate (dTTP) available for DNA synthesis. This prevents DNA replication and repair, and leads to DNA fragmentation and cell death, and results in reduced tumor cell 'proliferation.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C148171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148171>	C1752|C1663	MUC1 SP Vaccine|IMMUCIN|ImMucin|MUC1-SP-L Vaccine|Mucin 1 Signal Peptide Vaccine|SP MUC1 Vaccine|VXL-100|VXL100	A therapeutic cancer vaccine comprised of a synthetic, 21-mer long peptide (LP) derived from the entire signal peptide (SP) domain of the tumor-associated antigen (TAA) mucin 1 (MUC1), with potential immunomodulating and antineoplastic activities. Upon intradermal administration, MUC1 SP vaccine may stimulate the host immune system to mount robust cytotoxic T-lymphocyte (CTL) and B-cell responses against MUC1-expressing tumor cells, resulting in tumor cell apoptosis and decreased tumor growth. MUC1 is overexpressed on many tumor cell types.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C148172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148172>	C35682|C103223	SLCO1B3 Gene Positive|LST2 Gene Positive|LST3 Gene Positive|OATP-8 Gene Positive|OATP1B3 Gene Positive|OATP8 Gene Positive|SLC21A8 Gene Positive|Solute Carrier Organic Anion Transporter Family Member 1B3 Gene Positive	An indication that the SLCO1B3 gene has been detected in a sample.	SLCO1B3 Gene Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148173>	C8511|C7569	Refractory Thymus Carcinoma|Refractory Thymic Carcinoma|Refractory Thymic Carcinoma	A thymus carcinoma that does not respond to treatment.	Refractory Thymic Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148174>	C20744	Histone Gene	A gene encoding a histone protein.			Gene or Genome	
C148175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148175>	C8491|C173046	Refractory Indolent Adult Non-Hodgkin Lymphoma	An indolent adult non-Hodgkin lymphoma that is resistant to treatment.	Refractory Indolent Adult Non-Hodgkin Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148176>	C181113	Anti-BCMA Antibody SEA-BCMA|Anti-BCMA Afucosylated Monoclonal Antibody SEA-BCMA|SEA-BCMA|SEA-BCMA	A humanized, afucosylated monoclonal antibody created using the proprietary, sugar-engineered antibody (SEA) platform and directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17), with potential immunoadjuvant activity. Upon administration, the anti-BCMA antibody SEA-BCMA targets and binds to BCMA expressed on tumor cells.  When administered with antibody-coupled T-cell receptor (ACTR)-expressing T-cells, the ACTR-expressing T-cells bind, with high affinity, to the anti-BCMA antibody SEA-BCMA. This activates the ACTR T-cells and the T-cells induce specific cytotoxic T-lymphocyte (CTL)-mediated cytotoxicity toward BCMA-expressing tumor cells. BCMA, a cell surface protein and member of the tumor necrosis factor (TNF) receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.	Anti-BCMA Antibody SEA-BCMA		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148177>	C200766|C176023	Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes|Anti-BCMA-CAR-4-1BB-CD3zeta-EGFRt SIN Lentiviral Vector-transduced Autologous CD4+/CD8+ T-lymphocytes|Autologous BCMA-specific CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T Lymphocytes	A preparation of an approximately equal ratio of autologous CD4- and CD8-positive T-lymphocytes that have been ex vivo transduced with a genetically-engineered self-inactivating (SIN) lentiviral vector (LV) expressing a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) specific for the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) fused to the co-stimulatory domain of 4-1BB (CD137), the CD3-zeta (CD3z) T-cell signaling domain, and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-BCMA-CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes specifically recognize and induce selective toxicity against BCMA-expressing tumor cells. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt facilitates both in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) response. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and is overexpressed on malignant plasma cells.	Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148178>	C213381	Oncolytic Vaccinia Virus TG6002|Oncolytic FCU1-expressing TK-RR-deleted Vaccinia Virus TG6002|T 601|T-601|T601|TG 6002|TG-6002|TG6002|Vaccinia Virus TG6002	A modified, replicative oncolytic vaccinia virus (VV), deleted of the genes for tyrosine kinase (TK) and ribonucleotide reductase (RR), and expressing the yeast-originated, bifunctional cytosine deaminase/uracil phosphoribosyltransferase gene (FCU1), with potential immunomodulating and antineoplastic activities. Upon intravenous administration of the oncolytic vaccinia virus TG6002, the virus preferentially targets and infects tumor cells, causing oncolysis. In turn, the lysed tumor cells release various tumor-associated antigens (TAAs), which induce an immune response against the tumor cells. Upon concomitant administration of the non-cytotoxic prodrug flucytosine (5-fluorocytosine; 5-FC), the FCU1 expressed in the infected cancer cells produce the enzymes cytosine deaminase and uracil phosphoribosyltransferase which catalyze the conversion of 5-FC into the cytotoxic forms 5-fluorouracil (5-FU) and 5-fluoro-uridilyl monophosphate (5-FUMP); 5-FU and 5-FUMP exert a cytotoxic effect in the infected tumor cells. Double gene deletion (TK-RR-) restricts the propagation of TG6002 to the tumor cells, thereby reducing toxicity to normal cells.			Pharmacologic Substance|Virus	NCI Drug Dictionary Terminology
C148179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148179>	C2189	Licochalcone A|2-Propen-1-one, 3-(5-(1,1-Dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl)-1-(4-hydroxyphenyl)-, (E)-|3-Dimethylallyl-4,4'-dihydroxy-6-methoxychalcone|LICOCHALCONE A	A derivative of the phenol chalconoid, found in and extracted from the roots of Glycyrrhiza species G. glabra and inflata, with potential anti-inflammatory, antibacterial, and anticancer activities. Upon administration, licochalcone A inhibits the phosphatidylinositol-3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway and inhibits the activity of c-Jun N-terminal kinase 1 (JNK-1), a member of the mitogen-activated protein kinase (MAPK) family that plays a role in the MAPK-mediated signaling pathway. Inhibition of the PI3K/Akt/mTOR- and MAPK-signaling pathways induces cell cycle arrest and apoptosis, decreases migration and invasion of cancer cells, and inhibits tumor cell proliferation. Licochalcone A also prevents the production of reactive oxygen species (ROS), and reduces oxidative stress through the nuclear factor-erythroid 2-related factor 2 (Nrf2) pathway.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C148180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148180>	C129826	PD-1 knockout EBV-specific Cytotoxic T Lymphocytes|PD-1 knockout EBV-CTLs|PD-1 knockout EBV-reactive CTLs|PD-1 knockout Epstein-Barr Virus-Cytotoxic T-lymphocytes	A preparation of Epstein-Barr virus (EBV) reactive cytotoxic T-lymphocytes (CTLs) in which the programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1) gene is deleted, with potential immunomodulating activity. Upon administration of the PD-1 knockout EBV-specific CTLs, these CTLs target and induce selective toxicity in EBV-positive cancer cells. This results in cell lysis and inhibition of cancer cell proliferation. Expression of PD-1, an inhibitory receptor expressed on activated T-cells, plays a key role in CTL suppression, T-cell exhaustion and CTL apoptosis. PD-1 knockout abrogates T-cell exhaustion and increases T-cell activity and cytotoxicity. EBV, a ubiquitous human herpesvirus, is associated with various cancer cell types.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology
C148181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148181>	C308	Danicopan|ACH 4471|ACH-0144471|ACH-4471|ACH4471|ALXN 2040|ALXN-2040|ALXN2040|DANICOPAN|Factor D Inhibitor ACH-4471	An orally bioavailable inhibitor of complement factor D (FD; CFD), a serine protease that cleaves complement factor B, with potential complement system inhibiting activity. Upon administration, danicopan targets, binds to and blocks the activity of FD, and thereby inhibits cleavage of complement factor B into Ba and Bb in the alternative pathway of the complement cascade. This inhibits FD-mediated signaling and activation of the alternative complement pathway (ACP), blocks complement-mediated hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and prevents ACP-induced tissue damage. FD plays a key role in the activation of the ACP.	Danicopan		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C148182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148182>	C1420	Ruthenium-based Photosensitizer TLD1411|PS TLD1411|TLD 1411|TLD-1411|TLD1411	A ruthenium-based photosensitizer (PS), that can potentially be used for photodynamic therapy (PDT). Upon intratumoral administration, the ruthenium-based PS TLD1411 targets mitochondria in tumor cells. Upon PDT, TLD1411 produces singlet molecular oxygen (O2), and induces a reactive oxygen species (ROS)-mediated tumor cell apoptosis.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C148184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148184>	C137864	Amorphous Calcium Carbonate|ACC	A nutritional supplement composed of a proprietary synthetic and amorphous form of calcium carbonate, that can potentially be used to replenish calcium. Upon administration of amorphous calcium carbonate (ACC), the mineral calcium may give calcium supplementary support, improve bone, muscle and heart strength, improve performance and decrease bone-associated pain.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C148185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148185>	C213366	CRISPR/Cas9-edited HPV16/18 E6/E7 Plasmid|CRISPR/Cas9 targeting HPV16/18 E6 and E7 Genes|CRISPR/Cas9-HPV16 E6/E7T1 Plus CRISPR/Cas9-HPV18 E6/ E7T2	A plasmid encoding for clustered regularly interspaced short palindromic repeats (CRISPR) targeting the promoters for the human papillomavirus (HPV) type 16 (HPV16) and 18 (HPV18) epitopes E6 and E7, and coupled to the endonuclease cas9, with potential antineoplastic activities. Upon administration and transfection of the CRISPR/Cas9-edited HPV16/18 E6/E7 plasmid, the guide RNA (gRNA) of the CRISPR moiety specifically targets and binds to complementary sites on the HPV 16/18 promoter regions for E6 and E7. Cas9 cleaves these specific DNA sites, thereby disrupting HPV16/18 E6/E7 transcription. Decreased expression of E6 and E7 induces apoptosis and decreases tumor cell proliferation in HPV-driven tumor cells. This induces the expression of certain tumor suppressor genes, such as p53 and retinoblastoma 1 (RB1), which induces tumor cell apoptosis and inhibits tumor cell proliferation.			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	NCI Drug Dictionary Terminology
C148186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148186>	C2842|C213366	TALEN-edited HPV16/18 E6/E7 Plasmid|Plasmid HPV16/18 E6E7-targeting TALEN|TALEN-HPV16 E6/E7/TALEN-HPV18 E6/E7|TALEN-HPV16 E6/E7/TALEN-HPV18 E6/E7 Plasmid|TALEN-mediated HPV16/18 E6/7 Editing	A transcription activator-like effector nuclease (TALEN)-edited plasmid targeting human papillomavirus (HPV) types 16 (HPV16) and 18 (HPV18) epitopes E6 and E7, with potential antineoplastic activity. Upon administration of TALEN-edited HPV16/18 E6/E7, the TALEN targets and binds to specific sites on genomic HPV16 and 18 E6 and E7, and cleaves the DNA sequences encoding E6 and E7. This causes double-strand DNA (dsDNA) breaks, which prevents the transcription and translation of E6 and E7. In addition, inhibition of HPV16/18 E6/E7 increases the expression of tumor suppressor genes, such as p53 and retinoblastoma 1 (RB1). Altogether, TALEN-based HPV editing increases apoptosis and inhibits tumor cell proliferation of HPV-driven cancer cells. HPV16/18 E6 and E7 are oncogenes vital to viral function and carcinogenesis.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C148187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148187>	C308|C129821	RIG-I selective Ligand RGT100|RGT 100|RGT-100|RGT100	A synthetic RNA oligonucleotide and agonist of the retinoic acid-inducible gene I protein (RIG-I; DDX58), with potential antineoplastic activity. Upon intratumoral/intralesional administration, the RIG-I selective ligand RGT100 targets and binds to the cytosolic RNA receptor RIG-I. This induces RIG-I-mediated signaling, upregulates interferon (IFN)-alfa (IFN-a) and beta (IFN-b), and induces a potent IFN-mediated innate immune response against the tumor cells. This induces the activation of natural killer (NK) cells and cytotoxic T-lymphocytes (CTL) and induces apoptosis in cancer cells.			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	NCI Drug Dictionary Terminology
C148188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148188>	C2594	Neo-multiple TAA-loaded Dendritic Cell Vaccine|Neo-multiple TAA-loaded DC Vaccine|Neoantigen-loaded Dendritic Cell Vaccine|neo-MASCT	An autologous dendritic cell (DC) vaccine composed of DCs loaded with multiple distinct neoantigens, with potential immunomodulating and antineoplastic activities. Upon administration, the neo-multiple tumor-associated antigens (TAA)-loaded DC vaccine may stimulate a cytotoxic T-lymphocyte (CTL)-mediated immune response against the tumor cells expressing these neoantigens.			Cell|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology
C148189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148189>	C201556	Autologous Mesenchymal Stem Cells-Poly Lactic-co-glycolic Acid|Autologous Bone Marrow-derived MSCs-PLGA|Autologous MSC-PLGA	A preparation of autologous bone marrow derived mesenchymal stem cells (MSC) that are seeded on biodegradable poly lactic-co-glycolic acid (PLGA)-containing polymer scaffolds, that can potentially be used for bone marrow engraftment. When administered into the bone lesion of the patient, the autologous MSC-PLGA can be used for bone marrow engraftment.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology
C148190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148190>	C16830	Surgical Clip|Clip Closure|Clip Closure Device	A type of surgical staple designed to close wounds and control bleeding from blood vessels.	Surgical Clip		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C148191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148191>	C103514	F-18 Fluciclovine Positron Emission Tomography and Magnetic Resonance Imaging|F-18 Fluciclovine PET/MRI|F-18 Fluciclovine PET/MRI Scan	An imaging procedure that combines fluciclovine F18 PET with an MRI scan to overlay activity data onto detailed anatomic images.			Diagnostic Procedure	
C148192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148192>	C49164	Immune-Related Response Criteria|irRC|irRC	A set of response criteria designed to capture additional response patterns observed with immune therapy beyond those described by Response Evaluation Criteria in Solid Tumors (RECIST) or WHO criteria.			Intellectual Product	
C148193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148193>	C148192	Immune-Related Response Criteria Complete Response|Complete Response|irCR|irCR (Immune-Related Response Criteria)|irRC Complete Response	Complete disappearance of all lesions (whether measurable or not, and no new lesions); confirmation by a repeat, consecutive assessment no less than 4 weeks from the date first documented.			Intellectual Product	
C148194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148194>	C148192	Immune-Related Response Criteria Partial Response|Partial Response|irPR|irPR (Immune-Related Response Criteria)|irRC Criteria Partial Response	Decrease in tumor burden greater than or equal to 50 percent relative to baseline confirmed by a consecutive assessment at least 4 weeks after first documentation.			Intellectual Product	
C148195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148195>	C148192	Immune-Related Response Criteria Stable Disease|Stable Disease|irRC Stable Disease|irSD|irSD (Immune-Related Response Criteria)	Not meeting criteria for irCR or irPR, in absence of irPD.			Intellectual Product	
C148196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148196>	C148192	Immune-Related Response Criteria Progressive Disease|Progressive Disease|irPD|irPD (Immune-Related Response Criteria)|irRC Progressive Disease	Increase in tumor burden greater than or equal to 25 percent relative to nadir (minimum recorded tumor burden); confirmation by a repeat, consecutive assessment no less than 4 weeks from the date first documented.			Intellectual Product	
C148197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148197>	C91105	Arm and Breast Questionnaire|Arm and Breast	A questionnaire developed by the Canadian Cancer Trials Group, Queens University, using questions from other validated questionnaires, for use in-house.			Intellectual Product	
C148198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148198>	C173562	How Difficult to Push or Pull Large Objects with Affected Arm Question|How Difficult to Push or Pull Large Objects with Affected Arm|Push or pull large objects, like a living room chair, with your affected arm	A question about how difficult is is or was for an individual to push or pull objects with their affected arem.			Intellectual Product	Arm and Breast Questionnaire
C148199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148199>	C173562	How Difficult to Lift Items over 10 Pounds with Affected Arm Question|How Difficult to Lift Items over 10 Pounds with Affected Arm|Lift items over 10 pounds, like a heavy bag or groceries with your affected arm	A question about how difficult it is for an individual to lift items over 10 pounds with their affected arm.			Intellectual Product	Arm and Breast Questionnaire
C148200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148200>	C173562	How Difficult to Reach or Extend Affected Arm Above Shoulder Level Question|Reach or extend your affected arm above shoulder level	A question about how difficult it is for an individual to reach or extend their affected arm above shoulder level.			Intellectual Product	Arm and Breast Questionnaire
C148201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148201>	C173562	How Difficult to Wash Back with Affected Arm Question|How Difficult to Wash Back with Affected Arm|Wash your back with your affected arm	A question about how difficult it is for an individual to wash their back with their affected arm.			Intellectual Product	Arm and Breast Questionnaire
C148202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148202>	C173562	How Difficult to Bend and Straighten Affected Arm Question|Bend and straighten your affected arm|How Difficult to Bend and Straighten Affected Arm	A question about how difficult it is for an individual to bend or straighten their affected arm.			Intellectual Product	Arm and Breast Questionnaire
C148203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148203>	C173561	How Much Bothered by Tenderness in Affected Underarm, Arm, or Hand Question|How Much Bothered by Tenderness in Affected Underarm, Arm, or Hand|Tenderness in the underarm, arm or hand	A question about how bothered an individual is by tenderness in their affected underarm, arm, or hand.			Intellectual Product	Arm and Breast Questionnaire
C148204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148204>	C173593|C173561	How Much Bothered by Swelling in Affected Underarm, Arm, or Hand Question|How Much Bothered by Swelling in Affected Underarm, Arm, or Hand|Swelling in the underarm, arm or hand	A question about how bothered an individual is by swelling in their affected underarm, arm, or hand.			Intellectual Product	Arm and Breast Questionnaire
C148205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148205>	C173734|C173561	How Much Bothered by Numbness in Affected Underarm, Arm, or Hand Question|How Much Bothered by Numbness in Affected Underarm, Arm, or Hand|Numbness in the underarm, arm or hand	A question about how bothered an individual is by numbness in their affected underarm, arm, or hand.			Intellectual Product	Arm and Breast Questionnaire
C148206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148206>	C173734|C173561	How Much Bothered by Tingling in Affected Underarm, Arm, or Hand Question|How Much Bothered by Tingling in Affected Underarm, Arm, or Hand|Tingling sensation ("pins and needles") in the underarm, arm or hand	A question about how bothered an individual is by tingling sensation in their affected underarm, arm, or hand.			Intellectual Product	Arm and Breast Questionnaire
C148207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148207>	C173561	How Much Bothered by Increased Skin Sensitivity in Affected Underarm, Arm, or Hand Question|How Much Bothered by Increased Skin Sensitivity in Affected Underarm, Arm, or Hand|Increased skin sensitivity in the underarm, arm or hand	A question about how bothered an individual is by increased skin sensitivity in their affected underarm, arm, or hand.			Intellectual Product	Arm and Breast Questionnaire
C148208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148208>	C173561	How Much Bothered by Tightness, Pulling, or Stretching in Affected Underarm, Arm, or Hand Question|How Much Bothered by Tightness, Pulling, or Stretching in Affected Underarm, Arm, or Hand|Tightness, pulling, or stretching in the underarm, arm or hand	A question about how bothered an individual is by tenderness in their affected underarm, arm, or hand.			Intellectual Product	Arm and Breast Questionnaire
C148209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148209>	C173561|C156140	How Much Bothered by Discomfort or Pain in Affected Underarm, Arm, or Hand Question|Discomfort or pain in the underarm, arm or hand|How Much Bothered by Discomfort or Pain in Affected Underarm, Arm, or Hand	A question about how bothered an individual is by discomfort or pain in their affected underarm, arm, or hand.			Intellectual Product	Arm and Breast Questionnaire
C148210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148210>	C173561	How Much Bothered by Arm Weakness in Affected Arm Question|Arm weakness|How Much Bothered by Arm Weakness in Affected Arm	A question about how bothered an individual is by arm weakness in their affected arm.			Intellectual Product	Arm and Breast Questionnaire
C148211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148211>	C173561	How Much Bothered by Arm Heaviness in Affected Arm Question|Arm heaviness|How Much Bothered by Arm Heaviness in Affected Arm	A question about how bothered an individual is by arm heaviness in their affected arm.			Intellectual Product	Arm and Breast Questionnaire
C148212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148212>	C173561	How Much Bothered by Shoulder Stiffness in Affected Arm Question|How Much Bothered by Shoulder Stiffness in Affected Arm|Shoulder stiffness	A question about how bothered an individual is by shoulder stiffness in their affected arm.			Intellectual Product	Arm and Breast Questionnaire
C148213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148213>	C28676|C201545	Donor-derived Cytokine-induced Memory-like Natural Killer Cells|Allogeneic CIML NK Cells|Allogeneic CIML NKs|Allogeneic Cytokine-induced Memory-like NK Cell	A population of donor-derived cytokine-induced, memory-like, cytotoxic natural killer (NK) cells (CIML NKs), with potential antitumor activity. Allogeneic NK cells are pre-activated ex vivo with various cytokines, which induces the differentiation of the NK cells into CIML NK cells. The pretreated NK cells exhibit enhanced activation and interferon-gamma (IFN-g) responses, and may exert enhanced cytotoxicity against tumor cells. Upon administration, the CIML NKs may induce an anti-tumor immune response and kill tumor cells.	Donor-derived Cytokine-induced Memory-like Natural Killer Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C148214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148214>	C28310	Autologous AML/Dendritic Cell Fusion Vaccine|Autologous AML/DC Fusion Vaccine|Autologous DC/AML Fusion Vaccine|Autologous Dendritic Cell/AML Fusion Vaccine|DC/AML Fusion Cell Vaccine	A therapeutic cell-based cancer vaccine consisting of autologous dendritic cells (DCs) fused with autologous acute myeloid leukemia (AML) cells, with potential immunostimulatory and antineoplastic activities. The autologous AML/DC fusion vaccine is generated in vitro by mixing DCs and irradiated AML cells harvested from individual patients, in the presence of polyethylene glycol (PEG), to produce hybrid DC-leukemia fusion cells. Upon re-administration, the autologous AML/DC fusion vaccine may elicit a cytotoxic T-lymphocyte (CTL)-mediated antitumor immune response against a broad array of AML-associated antigens, which may lead to AML cell lysis.	Autologous AML/Dendritic Cell Fusion Vaccine		Cell|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148216>	C200766	Autologous PD-L1/CD80/CD86-targeted CAR-T Cells|Autologous CAR-T Cells Targeting PD-L1 and CD80/CD86|Z-CTLs|Zeushield CTLs|Zeushield Cytotoxic T Lymphocytes	A preparation of autologous human T-lymphocytes engineered to express a chimeric antigen receptor (CAR) composed of a modified from of the human inhibitory receptor programmed cell death protein 1 (PD-1; PDCD1), in which the intracellular signal domain of PD-1 is transformed to allow for stimulatory signaling but with an intact extracellular ligand binding domain that specifically binds the tumor-associated antigen (TAA) programmed cell death-1 ligand 1 (PD-L1), and a modified form of the T-cell inhibitory receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with a transformed intracellular signal domain to allow for stimulatory signaling, which specifically binds the B7 proteins CD80 (B7-1) and CD86 (B7-2), with potential immunostimulating and antineoplastic activities. Usually, ligand binding to PD-1 and CTLA-4 inhibits T-cell activity; however, these modified forms of PD-1 and CTLA-4 promote T-cell stimulatory signaling. Upon administration, the autologous PD-L1/CD80/CD86-targeted CAR-T cells target and bind to PD-L1 expressed on certain tumor cells and to CD80/CD86 expressed on antigen-presenting cells (APCs). This stimulates T-cell activation, T-cell proliferation and enhanced cytokine production, which induces selective toxicity in tumor cells expressing PD-L1. PD-1, found on activated T-cells, negatively regulates T-cell activity; it plays a key role in immune evasion and prevents tumor cell lysis. PD-L1 is often overexpressed on tumor cell types and plays a key role in immune evasion. The co-stimulatory molecules CD80 and CD86 play a key role in T-lymphocyte activation upon binding to CD28 upon antigen recognition; however, binding of CD80 and CD86 to wild-type CTLA-4 inhibits T-cell activity and results in T-cell exhaustion.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148217>	C173791|C173561	How Much Bothered by Tenderness in Affected Breast or Chest Area Question|How Much Bothered by Tenderness in Affected Breast or Chest Area|Tenderness in the breast or chest area	A question about how bothered an individual is by tenderness in their breast or chest area.			Intellectual Product	Arm and Breast Questionnaire
C148218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148218>	C173791|C173593|C173561	How Much Bothered by Swelling in Affected Breast or Chest Area Question|How Much Bothered by Swelling in Affected Breast or Chest Area|Swelling in the breast or chest area	A question about how bothered an individual is by swelling in their breast or chest area.			Intellectual Product	Arm and Breast Questionnaire
C148219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148219>	C173791|C173734|C173561	How Much Bothered by Numbness in Affected Breast or Chest Area Question|How Much Bothered by Numbness in Affected Breast or Chest Area|Numbness in the breast or chest area	A question about how bothered an individual is by numbness in their breast or chest area .			Intellectual Product	Arm and Breast Questionnaire
C148220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148220>	C173791|C173734|C173561	How Much Bothered by Tingling in Affected Breast or Chest Area Question|How Much Bothered by Tingling in Affected Breast or Chest Area|Tingling sensation ("pins and needles") in the breast or chest area	A question about how bothered an individual is by tingling sensation in their breast or chest area.			Intellectual Product	Arm and Breast Questionnaire
C148221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148221>	C173791|C173561	How Much Bothered by Increased Skin Sensitivity in Affected Breast or Chest Area Question|How Much Bothered by Increased Skin Sensitivity in Affected Breast or Chest Area|Increased skin sensitivity in the breast or chest area	A question about how bothered an individual is by increased skin sensitivity in their breast or chest area.			Intellectual Product	Arm and Breast Questionnaire
C148222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148222>	C173791|C173561	How Much Bothered by Tightness, Pulling, or Stretching in Affected Breast or Chest Area Question|How Much Bothered by Tightness, Pulling, or Stretching in Affected Breast or Chest Area|Tightness, pulling, or stretching in the breast or chest area	A question about how bothered an individual is by tightness, pulling, or stretching in their breast or chest area.			Intellectual Product	Arm and Breast Questionnaire
C148223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148223>	C173791|C173561|C156140	How Much Bothered by Discomfort or Pain in Affected Breast or Chest Area Question|Discomfort or pain in the breast or chest area|How Much Bothered by Discomfort or Pain in Affected Breast or Chest Area	A question about how bothered an individual is by discomfort or pain in their breast or chest area.			Intellectual Product	Arm and Breast Questionnaire
C148224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148224>	C173806|C173151|C173150	Extent Breast Cancer Treatment Disrupted Social Activities with Family and Friends Question|Extent Breast Cancer Treatment Disrupted Social Activities with Family and Friends|Social activities with family and friends	A question about to what extent an individual's breast cancer treatment has disrupted their social activities with family and friends.			Intellectual Product	Arm and Breast Questionnaire
C148225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148225>	C173924|C173806|C173150	Extent Breast Cancer Treatment Disrupted Work Question|Extent Breast Cancer Treatment Disrupted Work|Work (including housework)	A question about to what extent an individual's breast cancer treatment has disrupted their work .			Intellectual Product	Arm and Breast Questionnaire
C148226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148226>	C173806|C173150	Extent Breast Cancer Treatment Disrupted Recreational Activities Question|Extent Breast Cancer Treatment Disrupted Recreational Activities|Recreational activities	A question about to what extent an individual's breast cancer treatment has disrupted their recreational activities.			Intellectual Product	Arm and Breast Questionnaire
C148227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148227>	C173806|C173150	Extent Breast Cancer Treatment Disrupted Self-care Question|Extent Breast Cancer Treatment Disrupted Self-care|Self-care (bathing, dressing)	A question about to what extent an individual's breast cancer treatment has disrupted their self-care.			Intellectual Product	Arm and Breast Questionnaire
C148228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148228>	C173925|C173806|C173150	Extent Breast Cancer Treatment Disrupted Normal Sleep Question|Extent Breast Cancer Treatment Disrupted Normal Sleep|Normal sleep	A question about to what extent an individual's breast cancer treatment has disrupted their normal sleep.			Intellectual Product	Arm and Breast Questionnaire
C148229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148229>	C2152|C128462	PI3K/BET Inhibitor LY294002|2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one|2-Morpholin-4-yl-8-phenylchromen-4-one|4H-1-Benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl-|LY 294002|LY-294002|LY-294002|LY294002	A morpholine-based inhibitor of phosphatidylinositol 3-kinase (PI3K) and the bromodomain and extra-terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, the PI3K/BET inhibitor LY294002 specifically targets and binds to both PI3K and the acetylated lysine recognition motifs in the bromodomains of BET proteins. Inhibition of PI3K activity inhibits the PI3K/AKT kinase signaling pathway. This may result in inhibition of growth and survival for tumor cells in which the PI3K-mediated signaling pathway is overactivated. Inhibition of BET proteins prevents their interaction with acetylated histones, disrupts chromatin remodeling and inhibits the expression of oncogenic drivers that are important for cell proliferation and survival, which together may lead to an inhibition of proliferation in BET-overexpressing tumor cells. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators and play an important role during development and cellular growth. In tumor cells, BET proteins play a key role in the regulation of oncogene transcription and tumor cell proliferation.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C148230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148230>	C192561|C103512	F-18 Fluciclovine Positron Emission Tomography and Computed Tomography|F-18 Fluciclovine PET/CT|F-18 Fluciclovine PET/CT Scan|PET-CT (F-18 fluciclovine)	An imaging procedure that combines fluciclovine F18 PET with an computed tomography to overlay activity data onto detailed anatomic images.	F-18 Fluciclovine Positron Emission Tomography and Computed Tomography		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C148231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148231>	C41187	Patient Preference for Care Action	The patient's decision about an intervention or a procedure offered.			Functional Concept	
C148232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148232>	C166244	Surgery Declined|Declined Surgery|Refused Surgery|Surgery Refused	An indication that an individual was offered surgical intervention but decline to undergo surgery.			Qualitative Concept	
C148233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148233>	C138961	PSA Level Less than or Equal to Two|PSA Level 2 or Less|PSA Level Less than or Equal to 2|PSA Level Two or Less	A blood concentration of prostate specific antigen less than or equal to 2 ng/mL.	PSA Level Less than or Equal to Two		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148234>	C138961	PSA Level 0.2 to Two|PSA Level 0.2 to 2|PSA Level Between 0.2 and 2|PSA Level Between 0.2 and Two	A blood concentration of prostate specific antigen between 0.2 and 2 ng/mL.	PSA Level 0.2 to Two		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148235>	C141137|C129820	IDO1 Inhibitor MK-7162|Indoleamine-2,3-dioxygenase-1 Inhibitor MK-7162|MK 7162|MK-7162|MK7162	An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1 inhibitor MK-7162 specifically targets and binds to IDO1, a cytosolic enzyme responsible for the oxidation of the amino acid tryptophan into the immunosuppressive metabolite kynurenine. By inhibiting IDO1 and decreasing kynurenine in tumor cells, MK-7162 restores and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells and T-lymphocytes. This agent may also induce increased interferon (IFN) production, which may lead to a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL) response against and inhibit the growth of the IDO1-expressing tumor cells. IDO1, an enzyme overexpressed by multiple tumor cell types, plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and suppresses the immune system.	IDO1 Inhibitor MK-7162		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C148236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148236>	C91105	Quality of Life Questionnaire BR-23|QLQ-BR23	A questionnaire developed by the European Organisation for Research and Treatment of Cancer (EORTC) consisting of 23 questions designed to assess the quality of life of breast cancer patients participating in international clinical trials.			Intellectual Product	
C148237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148237>	C173346	Painful, Irritated, or Watery Eyes Question|Painful, Irritated, or Watery Eyes|Painful, Irritated, or Watery Eyes	A question about whether an individual's eyes are or were painful, irritated, or watery.			Intellectual Product	
C148238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148238>	C226655	Very Much Disrupted|Disrupted very much	A response indicating that aspects of an individual's life are or were very much disrupted.			Intellectual Product	
C148239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148239>	C181141	mRNA-based Personalized Cancer Vaccine NCI-4650|NCI 4650|NCI-4650|mRNA-based PCV NCI-4650	An mRNA-based therapeutic personalized cancer vaccine (PCV) targeting up to fifteen tumor-associated antigens (TAAs) that are specifically expressed by a patient's cancer cells, with potential immunostimulatory and antineoplastic activities. The cells from the patient's tumor are analyzed and subjected to RNA sequencing to identify mutant and immunogenic epitopes. The neoantigen epitopes are screened to select those that induce a strong immune response in tumor- infiltrating lymphocytes (TILs) isolated from the patient. The selected mRNA sequences encoding up to fifteen neoantigen epitopes are incorporated in a proprietary formulation designed to maximize mRNA delivery and minimize mRNA-triggered immune responses. Upon administration, the mRNA-based PCV NCI-4650 is taken up and the mRNAs are translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This induces both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy the patient's cancer cells that express these neoantigens.	mRNA-based Personalized Cancer Vaccine NCI-4650		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148240>	C203001|C119988	Autologous CD34-positive BCL11A-disrupted Hematopoietic Progenitor Cells ST-400|Autologous BCL11A-disrupted HPCs ST-400|Autologous BCL11A-disrupted Hematopoietic Progenitor Cells ST-400|Autologous CD34-positive BCL11A-disrupted HPCs ST-400|ST 400|ST-400	A population of autologous CD34-positive, B-cell lymphoma/leukemia 11A (BCL11A)-disrupted hematopoietic progenitor cells (HPCs) that may be used for bone marrow autotransplantation. CD34-positive HPCs are isolated from human blood upon apheresis and are genetically modified in vitro using a proprietary zinc finger nuclease (ZFN) technology to specifically disrupt the transcriptional enhancer sequence for the BCL11A gene. Upon infusion into the patient following conditioning chemotherapy, the autologous CD34-positive BCL11A-disrupted HPCs ST-400 can populate the bone marrow and differentiate into a variety of blood cell types including lymphoid cells, myeloid cells and erythroblasts. BCL11A is a suppressor of fetal hemoglobin (HbF) expression. Therefore, disruption of the BCL11A enhancer decreases the expression of BCL11A and stimulates the expression of HbF in erythrocytes that differentiate from ST-400. HbF may compensate for reduced or absent expression of adult hemoglobin in patients, including those with transfusion-dependent beta-thalassemia.	Autologous CD34-positive BCL11A-disrupted Hematopoietic Progenitor Cells ST-400		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology
C148241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148241>	C28310	Autologous Dendritic Cells Transduced with Wild-type p53 Adenovirus Vaccine|Ad.p53-DC|Autologous DCs Transduced with Ad.p53 Vaccine|Autologous DCs Transduced with wt p53 Ad Vaccine|Dendritic Cell Based p53 Vaccine|Dendritic Cell-based p53 Vaccine	A cancer vaccine consisting of autologous dendritic cells (DCs) transduced with a recombinant replication-defective adenoviral (Ad) vector encoding the full-length wild-type (wt) cancer tumor antigen p53 protein (TP53; p53), with potential immunomodulating activity. Intradermal vaccination with the autologous DCs transduced with wt p53 Ad vaccine may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells overexpressing wt and mutant forms of p53, resulting in tumor cell lysis. p53, a tumor suppressor gene, is overexpressed and/or mutated in many tumor cells, resulting in the loss of apoptosis regulation and abnormal cell proliferation.	Autologous Dendritic Cells Transduced with Wild-type p53 Adenovirus Vaccine		Cell|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148242>	C38114	Veterinary Route of Administration	Methods of administraion of pharmaceutical preparations that are used in the veterinary setting.			Functional Concept	
C148243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148243>	C42636	Veterinary Dosage Form	Pharmaceutical preparations intended for veterinary use.			Biomedical or Dental Material	
C148244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148244>	C8158|C7191	Recurrent Grade 3a Follicular Lymphoma	The reemergence of grade 3a follicular lymphoma after a period of remission.	Recurrent Grade 3a Follicular Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148245>	C3510|C148517	Unresectable Cutaneous Melanoma|Unresectable Cutaneous (Skin) Melanoma|Unresectable Melanoma of Skin|Unresectable Skin Melanoma	A skin melanoma that is not amenable to surgical resection.	Unresectable Cutaneous Melanoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148246>	C25193	Primary Industry of Employment|Primary Industry	The main category of employment for an individual.			Occupation or Discipline	
C148247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148247>	C19160	Natural and Applied Sciences|Basic and Applied Science	A grouping of sciences including those concerned with the description, prediction, and understanding of natural phenomena, based on empirical evidence from observation and experimentation, as well as those focused on the use of scientific processes and knowledge as the means to achieve a particular practical or useful result.			Occupation or Discipline	
C148248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148248>	C25193	Trades, Transport, or Construction|Trades/Transport/Construction	Occupations that include tradesmen, laborers, or professional employed in the physical construction of the built environment and its infrastructure, as well as professional or vocational positions of employment that involve transportation or material moving.			Occupation or Discipline	
C148249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148249>	C25193	Processing, Manufacturing, or Utilities|Processing/Manufacturing/Utilities	Occupations involved in refining of raw materials, creation of finished goods, and distribution of materials or services.			Occupation or Discipline	
C148250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148250>	C70680	Out of Pocket Payment|Out of Pocket|Out-of-Pocket|Out-of-Pocket Payment|Self Pay|Self-pay	A payment made from personal funds.			Functional Concept	
C148251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148251>	C172444	Sick Leave|On sick leave from full- or part-time work	A leave of absence granted because of illness.			Functional Concept	
C148252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148252>	C172444	Disability Leave|On disability leave from full- or part-time work	A leave of absence granted because of physical or mental disability.			Functional Concept	
C148253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148253>	C75560	Stay at Home Parent|Stay-at-Home Parent	A homemaker whose work includes caring for children.			Occupation or Discipline	
C148254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148254>	C177166	Working Full Time Hours|Yes, started working full time hours (> 30 hours per week)	A response indicating that an individual is working full time.			Intellectual Product	
C148255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148255>	C177166	Working Part Time Hours|Yes, started working part time hours (< 30 hours per week)	A response indicating that an individual is working part time.			Intellectual Product	
C148256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148256>	C226564	On Sick or Disability Leave|Yes, started sick or disability leave	A response indicating that an individual is on sick or disability leave from work.			Intellectual Product	
C148257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148257>	C177166	Unemployed or Retired|Yes, quit work/ became unemployed or retired	A response indicating that an individual is unemployed due to quitting, being fired, or retirement.			Intellectual Product	
C148258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148258>	C177166	Not Currently Working|Not applicable - not currently working	A response indicating that an individual does not currently work.			Intellectual Product	
C148259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148259>	C74996	Joubert Syndrome 3|JBTS3	An autosomal recessive subtype of Joubert syndrome caused by mutation(s) in the AHI1 gene, encoding Jouberin.			Disease or Syndrome	Cellosaurus Disease Terminology
C148260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148260>	C150251	Primary Congenital Glaucoma 3A|GLC3A	An autosomal recessive form of congenital glaucoma caused by mutation(s) in the CYP1B1 gene, encoding cytochrome P450 1B1.			Disease or Syndrome	Cellosaurus Disease Terminology
C148261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148261>	C84683	Ectrodactyly-Ectodermal Dysplasia-Cleft Syndrome|EEC Syndrome	A rare form of ectodermal dysplasia, inherited in an autosomal dominant fashion, manifesting with varying degrees of severity, ectrodactyly and cleft lip/palate.			Disease or Syndrome	Cellosaurus Disease Terminology
C148262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148262>	C38291	Administration via Dialysis				Functional Concept	
C148263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148263>	C15184	System Support Mapping|MAP|MAP Intervention|System Support Mapping Intervention	A method by which trained facilitators guide participants to create a visual diagram of their self-management activities within their broader life context. MAP helps participants tangibly see complex self-management activities on paper, facilitating self-awareness and patient-driven engagement which makes them more actionable.	System Support Mapping		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C148264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148264>	C113003	CliniMACS CD34 Reagent System	A proprietary flow cytometry system that uses anti-CD34 antibodies to isolate CD34+ cells from apheresis specimens.	CliniMACS CD34 Reagent System		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C148266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148266>	C138961	PSA Level Two to Ten|PSA Level 2 to 10|PSA Level Between 2 and 10|PSA Level Between Two and Ten	A blood concentration of prostate specific antigen between 2 and 10 ng/mL.	PSA Level Two to Ten		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148267>	C265	Bupropion Hydrochloride Controlled-release|Bupropion HCl Controlled-release|Bupropion HCl Extended Release|Bupropion Hydrochloride Extended-Release|Forfivo XL|Wellbutrin SR|Wellbutrin XL|Zyban|Zyban	A controlled-release tablet formulation containing the hydrochloride salt of the aminoketone bupropion, with antidepressant activity and for potential use in promoting smoking cessation, improving sexual desire, and improving cancer-related fatigue. Bupropion is a weak blocker of the neuronal uptake of serotonin, dopamine and norepinephrine and is a central nicotinic acetylcholine receptor antagonist. Bupropion may also reduce circulating levels of tumor necrosis factor (TNF) and normalize hypothalamic-pituitary-adrenal (HPA) axis functioning, which is dysregulated in certain cases of cancer-related fatigue.  The controlled-release formulation results in a higher concentration of the drug in the body over an extended period, thereby permitting a reduction in the frequency of dosing.	Bupropion Hydrochloride Controlled-release		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C148268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148268>	C87836	Combined Dosage Form				Biomedical or Dental Material	
C148269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148269>	C173593	Have Swollen Arm or Hand Question|Arm or Hand is Swollen|Did you have a swollen arm or hand|Have Swollen Arm or Hand	A question about whether an individual has or had a swollen arm or hand.			Intellectual Product	Quality of Life Questionnaire BR-23
C148270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148270>	C173398	Have Difficulty Raising Arm or Moving Arm Sideways Question|Have Difficulty Raising Arm or Moving Arm Sideways|Was it difficult to raise your arm or to move it sideways	A question about whether an individual had or has difficulty raising their arm or to move it sideways.			Intellectual Product	Quality of Life Questionnaire BR-23
C148271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148271>	C91126|C173791	Have Pain in Area of Affected Breast Question|Have Pain in Area of Affected Breast|Have you had any pain in the area of your affected breast	A question about whether an individual has or had any pain in the area of their affected breast.			Intellectual Product	Quality of Life Questionnaire BR-23
C148272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148272>	C173791|C173593	Area of Affected Breast Swollen Question|Area of Affected Breast Swollen|Was the area of your affected breast swollen	A question about whether the area of an individual's affected breast is or was swollen.			Intellectual Product	Quality of Life Questionnaire BR-23
C148273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148273>	C173791	Area of Affected Breast Oversensitive Question|Area of Affected Breast Overly Sensitive|Area of Affected Breast Oversensitive|Was the area of your affected breast oversensitive	A question about whether the area of an individual's affected breast is or was oversensitive.			Intellectual Product	Quality of Life Questionnaire BR-23
C148274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148274>	C173791	Have Skin Problem On or In Area of Affected Breast Question|Have Skin Problem On or In Area of Affected Breast|Have you had skin problems on or in the area of your affected breast (e.g., itchy, dry, flaky)	A question about whether an individual has or had skin problems on or in the area of their affected breast.			Intellectual Product	Quality of Life Questionnaire BR-23
C148275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148275>	C42636	Dosage Form and Package Type				Biomedical or Dental Material	
C148276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148276>	C97452	Tenofovir Alafenamide|GS 7340|GS-7340|L-Alanine, N-((S)-(((1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)phenoxyphosphinyl)-, 1-Methylethyl Ester|TENOFOVIR ALAFENAMIDE|TFV Alafenamide	A lipophilic phosphonamidate prodrug of tenofovir, a synthetic antiviral acyclic nucleotide analog of adenosine 5-monophosphate and a nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity against hepatitis B virus (HBV) and potentially against human immunodeficiency virus (HIV). Upon oral administration, tenofovir alafenamide is taken up by hepatocytes through passive diffusion and through the hepatic uptake transporters organic anion transporting polypeptides 1B1 (OATP1B1) and 1B3 (OATP1B3). Inside the hepatocytes, tenofovir alafenamide is hydrolyzed and converted to tenofovir by carboxylesterase 1 (CES1). Intracellular tenofovir is phosphorylated by cellular kinases to its pharmacologically active form, tenofovir diphosphate. Tenofovir diphosphate is incorporated into viral DNA instead of the natural substrate deoxyadenosine 5-triphosphate, and inhibits HBV reverse transcriptase, resulting in DNA chain-termination and inhibition of HBV replication. In addition, tenofovir diphosphate is incorporated into HIV DNA instead of the natural substrate deoxyadenosine 5-triphosphate, thereby inhibiting HIV-1 reverse transcriptase (RT) and resulting in DNA chain termination and impairment of HIV replication.	Tenofovir Alafenamide		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C148277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148277>	C127787	Total Number of Prostate Tissue Cores|Number Of Cores|Total Number of Prostate Cores	An indication of the total number of prostate core specimens collected during a biopsy procedure.			Quantitative Concept	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C148278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148278>	C25337	Number of Prostate Tissue Cores Positive for Carcinoma|Number Of Positive Cores|Number of Prostate Cores Positive for Carcinoma	An indication of the number of prostate core specimens that are identified as positive for carcinoma.			Quantitative Concept	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C148279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148279>	C48570	Greatest Percentage of Core Involvement by Cancer in Any Core	An indication of the percentage of cancerous cells present in the tissue core with the greatest amount of tumor involvement.			Finding	
C148280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148280>	C798	MOF Compound RiMO-301|RiMO-301	A nanoparticle-based metal-organic framework (MOF) compound composed of proprietary X-ray-absorbing metals, with potential radiosensitizing properties. Upon intratumoral administration and subsequent irradiation of the tumor site, RiMO-301 absorbs the X-ray photons and produces reactive oxygen species (ROS), such as hydroxyl radicals and singlet oxygen, which induces ROS-mediated DNA damage in the irradiated cancer cells leading to tumor cell lysis. In addition, RiMO-301 may also contain an as of yet unidentified immunomodulating agent loaded into the channels/pores of the construct that may induce an immune response against the tumor-associated antigens (TAAs) released by the lysed tumor cells, thereby locally killing additional tumor and non-tumor cells. MOFs, porous crystalline materials composed of metal clusters and organic linkers, generate ROS at much lower X-ray dosages than used in standard radiotherapy, which results in reduced radiation exposure and X-ray damage to normal, healthy cells.	MOF Compound RiMO-301		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148281>	C17230	Contrast-Enhanced Ultrasound|CEUS	Ultrasound imaging following the administration of a microbubble contrast agent.	Contrast-Enhanced Ultrasound		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C148282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148282>	C158737	Hepatitis B Virus Core Antibody Positive|Anti-HBc Antibody Positive|Anti-HBc Positive|Anti-HBcAb Positive|Anti-Hepatitis B Core Antibody Positive|Anti-Hepatitis B Virus Core Antibody Positive|HBcAb Positive|Hepatitis B Core Antibody Positive|Positive	An indication that antibodies that recognize a hepatitis B virus core protein have been detected in a sample.	Hepatitis B Virus Core Antibody Positive		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C148283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148283>	C97927	TET2 Gene Mutation|KIAA1546 Gene Mutation|Tet Methylcytosine Dioxygenase 2 Gene Mutation|Tet Oncogene Family Member 2 Gene Mutation	A change in the nucleotide sequence of the TET2 gene.	TET2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148284>	C67297	VAC Alternating with VI Regimen|VAC Alternating with VI|VAC Plus VI|VAC-VI|VAC-VI Regimen|VAC/VI|Vincristine/Actinomycin-D/Cyclophosphamide Alternating with Vincristine/Irinotecan|Vincristine/Actinomycin-D/Cyclophosphamide-Vincristine/Irinotecan|Vincristine/Dactinomycin/Cyclophosphamide Alternating With Vincristine/Irinotecan|Vincristine/Dactinomycin/Cyclophosphamide-Vincristine/Irinotecan	A regimen consisting of vincristine, dactinomycin and cyclophosphamide, alternating with vincristine and irinotecan that can be used for the treatment of rhabdomyosarcoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C148285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148285>	C67297|C67229	VIT Regimen|Irinotecan/Temozolomide/Vincristine|VIT|Vincristine-Irinotecan-Temozolomide|Vincristine/Irinotecan/Temozolomide	A regimen consisting of vincristine, irinotecan and temozolomide that can be used for the treatment of Ewing sarcoma and nonpleomorphic rhabdomyosarcoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C148286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148286>	C7895|C150316	Refractory Stage 0 Bladder Cancer AJCC v6 and v7|Refractory Bladder Carcinoma In Situ AJCC v6 and v7|Refractory Stage 0 Bladder Cancer	Stage 0 bladder cancer defined according to the AJCC v6 and v7 criteria that is resistant to treatment.	Refractory Stage 0 Bladder Cancer AJCC v6 and v7		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148287>	C140330	Blasts More than 25 Percent of Bone Marrow Nucleated Cells|Blasts Greater than 25 Percent of Bone Marrow Nucleated Cells|Blasts Over 25 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that more than 25 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts More than 25 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C148288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148288>	C93327	Online Mindfulness Meditation|Online MBSR|Online Mindful Meditation|Online Mindfullness Meditation|Online Mindfulness Relaxation|Online Mindfulness-Based Stress Reduction|Web-Based Mindfulness Meditation	Online, guided sessions designed to improve psychological well-being through reduced anxiety, depressive symptoms, and distress, and improved mood.	Online Mindfullness Meditation		Mental Process	CTRP Intervention Terminology|CTRP Terminology
C148290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148290>	C69040	Otic Emulsion Dosage Form|Ear emulsion	An emulsion intended for application to the ear.			Biomedical or Dental Material	
C148291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148291>	C25499	Holiday	A day set aside by custom or by law on which normal activities, especially business, work, or school, are suspended or reduced.			Event	
C148292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148292>	C148291	Statutory Holiday|Legal Holiday|Public Holiday	Cultural, nationalistic, and religious holidays that are legislated by the government.			Event	
C148293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148293>	C91752	Patient Did Not Keep Appointment	Failure of a patient to go to a scheduled appointment.			Individual Behavior	
C148294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148294>	C3158|C148301	Refractory Leiomyosarcoma	Leiomyosarcoma that does not respond to treatment.	Refractory Leiomyosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148295>	C4247|C139001	Refractory Undifferentiated Pleomorphic Sarcoma	Undifferentiated pleomorphic sarcoma that does not respond to treatment.	Refractory Undifferentiated Pleomorphic Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148296>	C3400|C139001	Refractory Synovial Sarcoma	Synovial sarcoma that does not respond to treatment.	Refractory Synovial Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148297>	C27781|C150594	Refractory Myxoid Liposarcoma|Refractory Myxoid/Round Cell Liposarcoma	Myxoid liposarcoma that does not respond to treatment.	Refractory Myxoid Liposarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148298>	C8816|C27781	Metastatic Myxoid Liposarcoma|Metastatic Myxoid/Round Cell Liposarcoma	Myxoid liposarcoma that has spread to other anatomic sites.	Metastatic Myxoid Liposarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148299>	C4252	Refractory Round Cell Liposarcoma	Round cell liposarcoma that does not respond to treatment.	Refractory Round Cell Liposarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C1482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1482>	C843|C2143	Squalamine Lactate|3beta-N-1-(N-(3-(4-Aminobutyl))-1,3-diaminopropane)-7alpha,24-dihydroxy-5alpha-cholestane 24-sulfate|MSI-1256F|SQUALAMINE LACTATE|Squalamine|squalamine lactate	The lactate salt form of squalamine, an aminosterol isolated from tissues of the dogfish shark Squalus acanthias.  Possessing anti-angiogenic properties, squalamine inhibits the sodium-hydrogen exchanger NHE3, resulting in suppression of endothelial cell proliferation and migration.  This agent also has broad-spectrum antimicrobial properties. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148300>	C4252	Metastatic Round Cell Liposarcoma	Round cell liposarcoma that has spread to other anatomic sites.	Metastatic Round Cell Liposarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148301>	C9118|C120186	Refractory Sarcoma	A sarcoma that does not respond to treatment.			Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology
C148302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148302>	C9118|C4813	Recurrent Sarcoma	The reemergence of sarcoma after a period of remission.			Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology
C148303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148303>	C54362	INSM2 Gene|INSM Transcriptional Repressor 2 Gene|INSM2|INSM2	This gene may play a role in the repression of genes involved in cell growth.			Gene or Genome	
C148304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148304>	C148303	INSM2 wt Allele|IA-6|IA6|INSM Transcriptional Repressor 2 wt Allele|Insulinoma-Associated 2 Gene|Insulinoma-Associated Gene 6|Nbla106	Human INSM2 wild-type allele is located in the vicinity of 14q13.2 and is approximately 3 kb in length. This allele, which encodes insulinoma-associated protein 2, is involved in transcriptional repression, cell growth regulation and tumor suppression.			Gene or Genome	
C148305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148305>	C26199	Insulinoma-Associated Protein 2|IA-2|INSM2|INSM2|INSULINOMA-ASSOCIATED PROTEIN 2|Insulinoma-Associated Protein IA-6|Zinc Finger Protein IA-6|Zinc Finger Protein IA-6	Insulinoma-associated protein 2 (566 aa, ~59 kDa) is encoded by the human INSM2 gene. This protein plays a role in cell growth regulation and tumor suppression.			Amino Acid, Peptide, or Protein	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C148306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148306>	C106409	PTPRN Gene|PTPRN|PTPRN|Protein Tyrosine Phosphatase Receptor Type N Gene	This gene is involved in the regulation of neurotransmitter, pituitary hormone and insulin secretion.	PTPRN Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C148307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148307>	C148306	PTPRN wt Allele|IA-2|IA-2/PTP|IA2|ICA3|ICA512|Protein Tyrosine Phosphatase Receptor Type N wt Allele|Protein Tyrosine Phosphatase, Receptor Type N Gene|Protein-Tyrosine Phosphatase, Receptor-Type, N Gene|R-PTP-N	Human PTPRN wild-type allele is located in the vicinity of 2q35 and is approximately 20 kb in length. This allele, which encodes receptor-type tyrosine-protein phosphatase-like N protein, plays a role in processes that regulate secretory vesicle functions.	PTPRN wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148308>	C17444	Receptor-Type Tyrosine-Protein Phosphatase-Like N|IA-2|IA-2|ICA 512|ICA512|ISLET CELL ANTIGEN 512|Insulinoma-Associated Protein 2|Insulinoma-Associated Tyrosine-Phosphatase-Like Protein|Islet Antigen 2|Islet Antigen 2|Islet Cell Antigen 2|Islet Cell Antigen 512|Islet Cell Autoantigen 3|Islet Cell Autoantigen 3|PTP IA-2|PTP-IA2|PTPRN|Protein Tyrosine Phosphatase Receptor Type-N|Protein Tyrosine Phosphatase-Like N|R-PTP-N|Receptor Type Protein Tyrosine Phosphatase N|Receptor-type Tyrosine-protein Phosphatase-like N	Receptor-Type Tyrosine-Protein Phosphatase-Like N (979 aa, ~106 kDa) is encoded by the human PTPRN gene. This protein is involved in neurotransmitter and hormone secretion.	Receptor-Type Tyrosine-Protein Phosphatase-Like N		Amino Acid, Peptide, or Protein|Enzyme|Receptor	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148309>	C8510	Unresectable Metastasis	A finding indicating that a metastatic tumor is not amenable to surgical resection.	Unresectable Metastasis		Finding	CTRP Disease Terminology|CTRP Terminology
C148310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148310>	C25994	SCT Gene|SCT|SCT|Secretin Gene	This gene plays a role in the formation of pancreatic juice and bile.			Gene or Genome	
C148311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148311>	C148310	SCT wt Allele|Secretin wt Allele	Human SCT wild-type allele is located in the vicinity of 11p15.5 and is approximately 2 kb in length. This allele, which encodes prepro-secretin, is involved in the production of digestive juices.			Gene or Genome	
C148312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148312>	C1746	SCT Gene Product	A protein encoded by the SCT gene.			Amino Acid, Peptide, or Protein	
C148313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148313>	C148312	Prepro-Secretin|PreproSCT|Preprosecretin|SCT|Secretin	Prepro-secretin (121 aa, ~13 kDa) is encoded by the human SCT gene. This protein plays a role in the production of bicarbonate-rich digestive juices.			Amino Acid, Peptide, or Protein	
C148314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148314>	C148312	Secretin|SCT	Secretin (27 aa, ~3 kDa) is encoded by the human SCT gene. This protein is involved in the secretion of bile and bicarbonate in the duodenum and in the pancreatic and biliary ducts.			Amino Acid, Peptide, or Protein|Hormone	
C148315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148315>	C82341|C176696	Spinocerebellar Ataxia Type 2|OPCA2|Olivopontocerebellar Atrophy 2|SCA2|Wadia-Swami Syndrome	An autosomal dominant condition caused by mutation(s) in the ATXN2 gene, encoding ataxin-2. Specifically, the mutation is an expanded CAG trinucleotide repeat in the gene. It is a progressive cerebellar ataxia associated supranuclear ophthalmoplegia, mild dementia and peripheral neuropathy.			Disease or Syndrome	Cellosaurus Disease Terminology
C148316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148316>	C82341|C176696	Spinocerebellar Ataxia Type 36|SCA36	An autosomal dominant condition caused by mutation(s) in the NOP56 gene, encoding nucleolar protein 56. It is characterized by slowly progressive adult-onset gait ataxia, associated with eye movement abnormalities, tongue fasciculations and variable upper motor neuron signs.			Disease or Syndrome	Cellosaurus Disease Terminology
C148317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148317>	C140267	Spastic Paraplegia 11|HSP-TCC|Spastic Paraplegia, Autosomal Recessive, Complicated, with Thin Corpus Callosum	An autosomal recessive condition caused by mutation(s) in the SPG11 gene, encoding spatacsin. It is a complicated sub-type of hereditary spastic paraplegia that has varying neurologic manifestations in addition to spasticity.			Disease or Syndrome	Cellosaurus Disease Terminology
C148318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148318>	C84828	Limb-Girdle Muscular Dystrophy Type 1C|LGMD1C	A sub-type of limb-girdle muscular dystrophy caused by mutation(s) in the CAV3 gene, encoding caveolin-3.			Disease or Syndrome	Cellosaurus Disease Terminology
C148319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148319>	C29936	SERPINB3 Gene|SERPINB3|SERPINB3|Serpin Family B Member 3 Gene	This gene is involved in the inhibition of protease activity.	SERPINB3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C148320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148320>	C148319	SERPINB3 wt Allele|HsT1196|SCC|SCCA|SCCA-1|SCCA-PD|SCCA1|SSCA1|Serine (Or Cysteine) Proteinase Inhibitor, Clade B (Ovalbumin), Member 3 Gene|Serpin Family B Member 3 wt Allele|Serpin Peptidase Inhibitor, Clade B (Ovalbumin), Member 3 Gene|T4-A	Human SERPINB3 wild-type allele is located in the vicinity of 18q21.33 and is approximately 7 kb in length. This allele, which encodes serpin B3 protein, plays a role in proteinase inhibition.	SERPINB3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148321>	C53543|C27644	Mitochondrially Inherited Nonsyndromic Sensorineural Deafness	A maternally inherited form of nonsyndromic sensorineural deafness that is caused by a mutation in any of several mitochondrial genes.			Disease or Syndrome	Cellosaurus Disease Terminology
C148322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148322>	C17122	Serpin B3|Protein T4-A|SCCA-1|SERPINB3|Squamous Cell Carcinoma Antigen 1	Serpin B3 (390 aa, ~45 kDa) is encoded by the human SERPINB3 gene. This protein is involved in the inhibition of serine- and cysteine-type proteinases.	Serpin B3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148323>	C29936	SERPINB4 Gene|SERPINB4|SERPINB4|Serpin Family B Member 4 Gene	This gene plays a role in the inhibition of protease activity.	SERPINB4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C148324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148324>	C148323	SERPINB4 wt Allele|LEUPIN|PI11|Protease Inhibitor (Leucine-Serpin) Gene|SCCA-2|SCCA1|SCCA2|Serine (Or Cysteine) Proteinase Inhibitor, Clade B (Ovalbumin), Member 4 Gene|Serpin Family B Member 4 wt Allele|Serpin Peptidase Inhibitor, Clade B (Ovalbumin), Member 4 Gene	Human SERPINB4 wild-type allele is located in the vicinity of 18q21.33 and is approximately 7 kb in length. This allele, which encodes serpin B4 protein, is involved in the inhibition of serine proteinases.	SERPINB4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148325>	C53543	Rippling Muscle Disease 2|RMD2	An autosomal dominant condition caused by mutation(s) in the CAV3 gene, encoding caveolin-3. It is characterized by mechanically triggered contractions of skeletal muscles. Limb-girdle muscular dystrophy type 1C is an allelic disorder with an overlapping phenotype.			Disease or Syndrome	Cellosaurus Disease Terminology
C148326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148326>	C17122	Serpin B4|Leupin|PI-11|Peptidase Inhibitor 11|SCCA-2|SERPINB4|Squamous Cell Carcinoma Antigen 2	Serpin B4 (390 aa, ~45 kDa) is encoded by the human SERPINB4 gene. This protein plays a role in the inhibition of protease activity for enzymes such as granzyme M.	Serpin B4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148327>	C53543	HyperCKmia|Isolated HyperCKemia	A condition characterized by elevated concentrations of creatine kinase in the blood. It is one of a group of conditions caused by mutation(s) in the CAV3 gene, encoding caveolin-3. Isolated hyperCKmia has no other associated manifestations.			Disease or Syndrome	Cellosaurus Disease Terminology
C148328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148328>	C26003	GZMM Gene|GZMM|GZMM|Granzyme M Gene	This gene is involved in peptide cleavage.			Gene or Genome	
C148329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148329>	C148328	GZMM wt Allele|Granzyme M (Lymphocyte Met-Ase 1) Gene|Granzyme M wt Allele|LMET1|MET1|Protease, Serine, Natural Killer Cell, Met-Ase Gene	Human GZMM wild-type allele is located in the vicinity of 19p13.3 and is approximately 6 kb in length. This allele, which encodes granzyme M protein, plays a role in the cleavage of peptide substrates.			Gene or Genome	
C148330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148330>	C17123	Granzyme M|EC 3.4.21.-|GZMM|Hu-Met-1|Lymphocyte Met-Ase 1|Met-1 Serine Protease|Met-Ase|Natural Killer Cell Granular Protease	Granzyme M (257 aa, ~28 kDa) is encoded by the human GZMM gene. This protein is involved in the cleavage of protein and peptide substrates.			Amino Acid, Peptide, or Protein|Enzyme	
C148331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148331>	C9118|C27359	Unresectable Sarcoma	A sarcoma which is not amenable to surgical resection.			Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology
C148332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148332>	C25871	GALT Gene|GALT|GALT|Galactose-1-Phosphate Uridylyltransferase Gene	This gene plays a role in galactose metabolism.			Gene or Genome	
C148333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148333>	C148332	GALT wt Allele|Galactose-1-Phosphate Uridylyltransferase wt Allele	Human GALT wild-type allele is located in the vicinity of 9p13.3 and is approximately 13 kb in length. This allele, which encodes galactose-1-phosphate uridylyltransferase protein, is involved in carbohydrate metabolism. Mutation of the gene is associated with galactosemia.			Gene or Genome	
C148334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148334>	C16925	Galactose-1-Phosphate Uridylyltransferase|EC 2.7.7.12|GALT|Gal-1-P Uridylyltransferase|UDP-Glucose--Hexose-1-Phosphate Uridylyltransferase	Galactose-1-phosphate uridylyltransferase (379 aa, ~43 kDa) is encoded by the human GALT gene. This protein plays a role in the metabolism of galactose.			Amino Acid, Peptide, or Protein|Enzyme	
C148335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148335>	C33904	Other and Ill Defined Digestive Organs ICD-O-3|Other and Ill Defined Digestive Organs|Other and ill-defined digestive organs	Digestive organs that are referenced in topographic category C26 of ICD-O-3.			Conceptual Entity	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C148336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148336>	C33904	Other and Ill-Defined Sites ICD-O-3|Other and Ill-Defined Sites|Other and ill-defined sites|Other ill-defined sites	Other anatomic sites that are referenced in topographic category C76 of ICD-O-3.			Conceptual Entity	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C148337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148337>	C33904	Other and Ill-Defined Sites in Lip, Oral Cavity and Pharynx ICD-O-3|Other and Ill-Defined Sites in Lip, Oral Cavity and Pharynx|Other and ill-defined sites in lip, oral cavity and pharynx	Anatomic sites in the lip, oral cavity and pharynx that are referenced in topographic category C14 of ICD-O-3.			Conceptual Entity	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C148338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148338>	C33904	Other and Ill-Defined Sites within Respiratory System and Intrathoracic Organs ICD-O-3|Ill-defined sites within respiratory system|Other and Ill-Defined Sites within Respiratory System and Intrathoracic Organs|Other and ill-defined sites within respiratory system and intrathoracic organs	Anatomic sites within the respiratory system and intrathoracic organs that are referenced in topographic category C39 of ICD-O-3.			Conceptual Entity	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C148339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148339>	C33904	Other and Unspecified Female Genital Organs ICD-O-3|Other and Unspecified Female Genital Organs|Other and unspecified female genital organs|Other specified parts of female genital organs	Female genital organs that are referenced in topographic category C57 of ICD-O-3.			Conceptual Entity	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C148340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148340>	C33904	Other and Unspecified Major Salivary Glands ICD-O-3|Other and Unspecified Major Salivary Glands|Other and unspecified major salivary glands	Major salivary glands that are referenced in topographic category C08 of ICD-O-3.			Conceptual Entity	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C148341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148341>	C33904	Other and Unspecified Male Genital Organs ICD-O-3|Other and Unspecified Male Genital Organs|Other and unspecified male genital organs|Other specified parts of male genital organs	Male genital organs that are referenced in topographic category C63 of ICD-O-3.			Conceptual Entity	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C148342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148342>	C33904	Other and Unspecified Parts of Biliary Tract ICD-O-3|Other and Unspecified Parts of Biliary Tract|Other and unspecified parts of biliary tract	Components of the biliary tract that are referenced in topographic category C24 of ICD-O-3.			Conceptual Entity	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C148343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148343>	C33904	Other and Unspecified Parts of Mouth ICD-O-3|Other and Unspecified Parts of Mouth|Other and unspecified parts of mouth	Components of the mouth that are referenced in topographic category C06 of ICD-O-3.			Conceptual Entity	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C148344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148344>	C33904	Other and Unspecified Parts of Tongue ICD-O-3|Other and Unspecified Parts of Tongue|Other and unspecified parts of tongue	Components of the tongue that are referenced in topographic category C02 of ICD-O-3.			Conceptual Entity	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C148345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148345>	C33904	Other and Unspecified Urinary Organs ICD-O-3|Other and Unspecified Urinary Organs|Other and unspecified urinary organs	Urinary organs that are referenced in topographic category C68 of ICD-O-3.			Conceptual Entity	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C148346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148346>	C33904	Other Endocrine Glands and Related Structures ICD-O-3|Other Endocrine Glands and Related Structures|Other endocrine glands and related structures	Endocrine glands and related structures that are referenced in topographic category C75 of ICD-O-3.			Conceptual Entity	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C148347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148347>	C25994	GAL Gene|GAL|GAL|Galanin and GMAP Prepropeptide Gene	This gene is involved in neuropeptide activity.			Gene or Genome	
C148348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148348>	C148347	GAL wt Allele|ETL8|GAL-GMAP|GALN|GLNN|GMAP|Galanin and GMAP Prepropeptide wt Allele|Galanin-Related Peptide Gene	Human GAL wild-type allele is located in the vicinity of 11q13.2 and is approximately 7 kb in length. This allele, which encodes galanin peptides protein, plays a role in neuropeptide signaling. Mutation of the gene may be associated with familial temporal lobe epilepsy 8.			Gene or Genome	
C148349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148349>	C1746	GAL Gene Product	A protein encoded by the GAL gene.			Amino Acid, Peptide, or Protein|Hormone	
C148350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148350>	C148349	Galanin Peptides|GAL|Galanin Prepropeptide|Galanin and GMAP Prepropeptide|Galanin/GMAP Prepropeptide	Galanin peptides (123 aa, ~13 kDa) is encoded by the human GAL gene. This protein plays a role in both G protein-coupled receptor signaling and innate immunity.			Amino Acid, Peptide, or Protein	
C148351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148351>	C148349	Galanin|GAL	Galanin (30 aa, ~3 kDa) is encoded by the human GAL gene. This protein is involved in nociception, secretion of cortisol, growth hormone and insulin, hair follicle development and contraction of smooth muscle cells of the gastrointestinal and genitourinary tracts.			Amino Acid, Peptide, or Protein|Hormone	
C148352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148352>	C148349	Galanin Message-Associated Peptide|GAL|GMAP|Galanin-Message-Associated Peptide	Galanin message-associated peptide (59 aa, ~7 kDa) is encoded by the human GAL gene. This protein may play a role in innate immunity.			Amino Acid, Peptide, or Protein	
C148353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148353>	C26068	GDF11 Gene|GDF11|GDF11|Growth Differentiation Factor 11 Gene	This gene plays a role in anterior/posterior axis development.	GDF11 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C148354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148354>	C148353	GDF11 wt Allele|BMP-11|BMP11|Bone Morphogenetic Protein 11 Gene|Growth Differentiation Factor 11 wt Allele|VHO	Human GDF11 wild-type allele is located in the vicinity of 12q13.2 and is approximately 14 kb in length. This allele, which encodes growth/differentiation factor 11 protein, is involved in embryological pattern formation during development.	GDF11 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148355>	C17274	Growth/Differentiation Factor 11|BMP-11|Bone Morphogenetic Protein 11|Bone Morphogenetic Protein-11|GDF-11|GDF11|Growth/Differentiation Factor-11	Growth/differentiation factor 11 (407 aa, ~45 kDa) is encoded by the human GDF11 gene. This protein plays a role in patterning of mesodermal, neural and skeletal tissues during development.	Growth/Differentiation Factor 11		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148356>	C25939	KDM4C Gene|KDM4C|KDM4C|Lysine Demethylase 4C Gene	This gene is involved in histone H3 demethylation.			Gene or Genome	
C148357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148357>	C148356	KDM4C wt Allele|GASC1|Gene Amplified in Squamous Cell Carcinoma 1|JHDM3C|JMJD2C|Jumonji Domain Containing 2C Gene|KIAA0780|Lysine (K)-Specific Demethylase 4C Gene|Lysine Demethylase 4C wt Allele|TDRD14C|Tudor Domain Containing 14C Gene	Human KDM4C wild-type allele is located in the vicinity of 9p24.1 and is approximately 455 kb in length. This allele, which encodes lysine-specific demethylase 4C protein, plays a role in the demethylation of histone H3. Chromosomal aberrations involving the gene and aberrant expression of this gene may be associated with esophageal squamous cell carcinoma and other neoplastic diseases.			Gene or Genome	
C148358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148358>	C16946	Lysine-Specific Demethylase 4C|EC 1.14.11.-|GASC-1 Protein|Gene Amplified In Squamous Cell Carcinoma 1 Protein|JmjC Domain-Containing Histone Demethylation Protein 3C|Jumonji Domain-Containing Protein 2C|KDM4C|Lysine (K)-Specific Demethylase 4C|Lysine Demethylase 4C|[Histone H3]-Trimethyl-L-Lysine(9) Demethylase 4C	Lysine-specific demethylase 4C (1056 aa, ~120 kDa) is encoded by the human KDM4C gene. This protein is involved in the demethylation of trimethylated lysine-9 and -36 in histone H3.			Amino Acid, Peptide, or Protein|Enzyme	
C148359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148359>	C25952|C25871	PFKFB4 Gene|6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 4 Gene|PFKFB4|PFKFB4	This gene plays a role in the metabolism of fructose-2,6-bisphosphate and ATP.			Gene or Genome	
C148360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148360>	C148359	PFKFB4 wt Allele|6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 4 wt Allele	Human PFKFB4 wild-type allele is located in the vicinity of 3p21.31 and is approximately 45 kb in length. This allele, which encodes 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 protein, is involved in the regulation of glycolysis. Expression of the gene by hypoxic cancer cells is essential to their survival.			Gene or Genome	
C148361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148361>	C16984|C16981	6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 4|6PF-2-K/Fru-2,6-P2ase 4|6PF-2-K/Fru-2,6-P2ase Testis-Type Isozyme|PFK/FBPase 4|PFKFB4	6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (469 aa, ~54 kDa) is encoded by the human PFKFB4 gene. This protein plays a role in the biosynthesis and catabolism of fructose-2,6-bisphosphate and ATP.			Amino Acid, Peptide, or Protein|Enzyme	
C148362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148362>	C3247|C172281	Refractory Myelodysplastic Syndrome	A myelodysplastic syndrome that does not respond to treatment.	Refractory Myelodysplastic Syndrome		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148363>	C3247|C172132	Recurrent Myelodysplastic Syndrome	The reemergence of myelodysplastic syndrome after a period of remission.	Recurrent Myelodysplastic Syndrome		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148364>	C20985	Percutaneous Local Ablation|PLA	Any ablation procedure where a needle or probe is passed through the skin.	Percutaneous Local Ablation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C148365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148365>	C45246	Ophthalmic/Otic Dosage Form				Functional Concept	
C148366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148366>	C98986	Methylmalonic Aciduria Due to Methylmalonyl-CoA Mutase Deficiency|Methylmalonic Aciduria, Mut Type	An autosomal recessive form of methylmalonic aciduria caused by mutation(s) in the MUT gene, encoding methylmalonyl-CoA mutase, mitochondrial.			Disease or Syndrome	Cellosaurus Disease Terminology
C148367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148367>	C116936	Bilateral Frontoparietal Polymicrogyria|BFPP	An autosomal recessive condition caused by mutation(s) in the ADGRG1 gene, encoding adhesion G-protein coupled receptor G1. It is characterized by motor and cognitive developmental delay, pyramidal signs, and seizures.			Disease or Syndrome	Cellosaurus Disease Terminology
C148368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148368>	C111648	Catecholaminergic Polymorphic Ventricular Tachycardia Type 2|CPVT2	An autosomal recessive condition caused by mutation(s) in the CASQ2 gene, encoding calsequestrin-2. It is characterized by a relative resting bradycardia and a slight prolongation of the QTc interval. Polymorphic ventricular tachycardia may be induced with exercise stress testing or isoproterenol infusion.			Disease or Syndrome	Cellosaurus Disease Terminology
C148369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148369>	C84910	Muscular Dystrophy Congenital, LMNA-Related|MDCL	An autosomal recessive muscular dystrophy caused by mutation(s) in the LMNA gene, encoding prelamin-A/C. Limb-girdle muscular dystrophy type 1B and Emery-Dreifuss muscular dystrophy-2 are allelic disorders with overlapping phenotypes.			Disease or Syndrome	Cellosaurus Disease Terminology
C148370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148370>	C84638	Primary Ciliary Dyskinesia 14|CILD14	An autosomal recessive primary ciliary motility defect caused by mutation(s) in the CCDC39 gene, encoding coiled-coil domain-containing protein 39.			Disease or Syndrome	
C148371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148371>	C28193	Temtamy Syndrome|TEMTYS	An extremely rare autosomal recessive condition caused by mutation(s) in the C12orf57 gene, encoding protein C10. It is characterized by agenesis/hypoplasia of the corpus callosum, associated with developmental delay, and variable craniofacial and skeletal abnormalities.			Disease or Syndrome	Cellosaurus Disease Terminology
C148372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148372>	C20194	DNMT3L Gene|DNA Methyltransferase 3 Like Gene|DNMT3L|DNMT3L	This gene is involved in the regulation of DNA methyltransferase activity.	DNMT3L Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C148373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148373>	C148372	DNMT3L wt Allele|DNA Methyltransferase 3 Like wt Allele	Human DNMT3L wild-type allele is located in the vicinity of 21q22.3 and is approximately 21 kb in length. This allele, which encodes DNA (cytosine-5)-methyltransferase 3-like protein, plays a role in the regulation of DNA methylation and gene transcription.	DNMT3L wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148374>	C18466	DNA (Cytosine-5)-Methyltransferase 3-Like|Cytosine-5-Methyltransferase 3-Like Protein|DNA (Cytosine-5-)-Methyltransferase 3-Like|DNA Cytosine-5-Methyltransferase 3-Like Protein|DNA Methyltransferase 3-Like Protein|DNMT3L	DNA (cytosine-5)-methyltransferase 3-like (386 aa, ~44 kDa) is encoded by the human DNMT3L gene. This protein is involved in the modulation of DNA methyltransferase activity.	DNA (Cytosine-5)-Methyltransferase 3-Like		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148375>	C20921	DEPDC5 Gene|DEP Domain Containing 5 Gene|DEPDC5|DEPDC5	This gene plays a role in the regulation of Ras-related GTP-binding protein-mediated signaling.			Gene or Genome	
C148376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148376>	C148375	DEPDC5 wt Allele|DEP Domain Containing 5 wt Allele|DEP.5|FFEVF|FFEVF1|KIAA0645	Human DEPDC5 wild-type allele is located within 22q12.2-q12.3 and is approximately 153 kb in length. This allele, which encodes GATOR complex protein DEPDC5, is involved in the modulation of signaling by Ras-related GTP-binding proteins. Mutations in this gene are associated with autosomal dominant familial focal epilepsy with variable foci and with an increased risk of hepatocellular carcinoma in individuals with chronic hepatitis C virus infection.			Gene or Genome	
C148377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148377>	C17298	GATOR Complex Protein DEPDC5|DEP Domain-Containing Protein 5|DEPDC5	GATOR complex protein DEPDC5 (1603 aa, ~181 kDa) is encoded by the human DEPDC5 gene. This protein plays a role in the inhibition of Ras-related GTP-binding protein-mediated signaling.			Amino Acid, Peptide, or Protein	
C148378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148378>	C45246	Endocervical Dosage Form				Functional Concept	
C148379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148379>	C129660	Cytomegalovirus DNA|CMV DNA|HHV-5 DNA|HHV5 DNA|Human Herpes Virus 5 DNA|Human Herpes Virus-5 DNA|Human Herpesvirus 5 DNA|Human Herpesvirus-5 DNA	The viral DNA that originates from cytomegalovirus.	Cytomegalovirus DNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Terminology
C148380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148380>	C1663	Lm-tLLO-neoantigens Vaccine ADXS-NEO|ADXS NEO|ADXS-NEO|Neoepitope-based Immunotherapeutic ADXS-NEO	A proprietary, personalized plasmid DNA-based cancer vaccine composed of a live-attenuated strain of the Gram-positive bacterium Listeria monocytogenes (Lm) carrying a proprietary plasmid vector encoding multiple, patient-specific, immunogenic neoepitopes fused to a truncated form of the immunostimulant listeriolysin O (tLLO), with potential immunostimulatory and antineoplastic activities. Upon administration of the Lm-tLLO-neoantigens vaccine ADXS-NEO, the ADXS-NEO is taken up by antigen presenting cells (APCs), such as dendritic cells (DCs), and the expressed tLLO-neoantigens fusion protein is processed and presented to the immune system by both major histocompatibility complex (MHC) I and II molecules. This activates the immune system to exert both innate and adaptive immune responses involving the recruitment and activation of T-lymphocytes against the tumor-associated antigens (TAAs) specifically expressed by the patient's tumor cells, and inhibits the immunosuppressive tumor-infiltrating T-regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSCs) within the tumor microenvironment (TME). This results in tumor cell lysis. The various unique mutation-derived TAAs that are used in ADXS-NEO are identified from a biopsy of the patient's tumor.	Lm-tLLO-neoantigens Vaccine ADXS-NEO		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148381>	C35682	MUC16 Ectodomain Antigen Positive|MUC16 ecto Antigen Positive|Mucin 16 Ectodomain Antigen Positive|Mucin-16 Ectodomain Antigen Positive	An indication that a soluble form of the extracellular domain of the mucin-16 protein has been detected in a sample. This is a marker for intramembrane cleavage of mucin-16.	MUC16 Ectodomain Antigen Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148382>	C4043|C214957	Refractory Hypopharyngeal Squamous Cell Carcinoma|Refractory Hypopharyngeal Throat Squamous Cell Cancer	A hypopharyngeal squamous cell carcinoma that does not respond to treatment.	Refractory Hypopharyngeal Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148383>	C4044|C214956	Refractory Laryngeal Squamous Cell Carcinoma|Refractory Laryngeal Throat Squamous Cell Cancer	Laryngeal squamous cell carcinoma that does not respond to treatment.	Refractory Laryngeal Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148384>	C4833|C214956|C150530	Refractory Oral Cavity Squamous Cell Carcinoma|Refractory Oral Cavity Squamous Cell Cancer	Oral cavity squamous cell carcinoma that does not respond to treatment.	Refractory Oral Cavity Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148385>	C8181|C214957	Refractory Oropharyngeal Squamous Cell Carcinoma|Refractory Oropharyngeal Throat Squamous Cell Cancer	An oropharyngeal squamous cell carcinoma that does not respond to treatment.	Refractory Oropharyngeal Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148386>	C8193|C148401	Refractory Paranasal Sinus Squamous Cell Carcinoma|Refractory Paranasal Sinus Squamous Cell Cancer	Paranasal sinus squamous cell carcinoma that does not respond to treatment.	Refractory Paranasal Sinus Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148387>	C8193|C115443	Recurrent Paranasal Sinus Squamous Cell Carcinoma|Recurrent Paranasal Sinus Squamous Cell Cancer	The reemergence of paranasal sinus squamous cell carcinoma after a period of remission.	Recurrent Paranasal Sinus Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148388>	C45584	BCL6 Gene Fusion|B-Cell CLL/Lymphoma 6 Gene Fusion|BCL5 Gene Fusion|Bcl-6 Gene Fusion|LAZ3 Gene Fusion|ZBTB27 Gene Fusion|ZNF51 Gene Fusion|Zinc Finger Protein 51 Gene Fusion	A molecular genetic abnormality indicating the presence of a fusion gene involving sequences derived from the BCL6 gene.			Cell or Molecular Dysfunction	
C148389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148389>	C97927|C136644	NOTCH2 Gene Mutation|AGS2 Gene Mutation|HJCYS Gene Mutation|Notch 2 Gene Mutation|Notch Homolog 2 Gene Mutation|hN2 Gene Mutation	A change in the nucleotide sequence of the NOTCH2 gene.	NOTCH2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148390>	C97927	CD79B Gene Mutation|AGM6 Gene Mutation|B29 Gene Mutation|CD79b Antigen Gene Mutation|CD79b Molecule Gene Mutation|IGB Gene Mutation	A change in the nucleotide sequence of the CD79B gene.	CD79B Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148391>	C42944	Inhalation Vapor Dosage Form				Biomedical or Dental Material	
C148392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148392>	C80280	Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Molecular Subtypes|DLBCL, NOS Genetic Subtypes|DLBCL, NOS Molecular Subtypes|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Genetic Subtypes	Molecular subtyping of diffuse large B-cell lymphomas (DLBCL) based on structural genomic abnormalities and gene expression data obtained from biopsy samples. The molecular analysis revealed four subtypes of DLBCL (MCD, BN2, N1, and EZB) which have distinct genotypic, epigenetic, and clinical characteristics. (NEJM 2018; 378: 1396-407)			Neoplastic Process	
C148393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148393>	C28681	MDS Neoantigen-specific Autologous T-lymphocytes|Autologous T-lymphocytes Targeting Patient-specific MDS Stem Cell Neoantigens|MDS Neoantigen-specific Autologous T-cells|MDS Neoantigen-specific Immunized Autologous T-cells|MDS-specific PACTN Agent|Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens Agent|Personalized MDS Neoantigen-specific Autologous T-lymphocytes	A preparation of autologous T-lymphocytes that are exposed, ex vivo, to multiple, patient-specific myelodysplastic syndrome (MDS) stem cell neoantigens, with potential immunostimulating and antineoplastic activities. Upon infusion of the MDS neoantigen-specific autologous T-lymphocytes, the immunized T-cells specifically target and lyse cells expressing the MDS neoantigens.	MDS Neoantigen-specific Autologous T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCIt Antineoplastic Agent Terminology
C148394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148394>	C148392	MCD Diffuse Large B-Cell Lymphoma|MCD DLBCL	A diffuse large B-cell lymphoma molecular subtype characterized by the co-occurrence of MYD88 and CD79B gene mutations. Patients who belong in this subtype have an inferior outcome. (NEJM 2018; 378: 1396-407)			Neoplastic Process	
C148395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148395>	C148392	BN2 Diffuse Large B-Cell Lymphoma|BN2 DLBCL	A diffuse large B-cell lymphoma molecular subtype characterized by the presence of BCL6 gene fusions and NOTCH2 gene mutations. Patients who belong in this subtype have a favorable outcome. (NEJM 2018; 378: 1396-407)			Neoplastic Process	
C148396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148396>	C148392	N1 Diffuse Large B-Cell Lymphoma|N1 DLBCL	A diffuse large B-cell lymphoma molecular subtype characterized by the presence of NOTCH1 gene mutations. Patients who belong in this subtype have an inferior outcome. (NEJM 2018; 378: 1396-407)			Neoplastic Process	
C148397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148397>	C148243	Intramammary Dosage Form				Biomedical or Dental Material	
C148398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148398>	C148392	EZB Diffuse Large B-Cell Lymphoma|EZB DLBCL	A diffuse large B-cell lymphoma molecular subtype characterized by the presence of EZH2 gene mutations and BCL2 gene translocations. Patients who belong in this subtype have a favorable outcome. (NEJM 2018; 378: 1396-407)			Neoplastic Process	
C148399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148399>	C148243	Beehive Dosage Form				Biomedical or Dental Material	
C1483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1483>	C1504	Recombinant Betacellulin|Beta Cellulin	A recombinant form of the endogenous Betacellulin, a member of the Epidermal Growth Factor family that is expressed primarily in the pancreas and induces differentiation of a pancreatic acinar cell line.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C148400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148400>	C2685	MVA-BN-Brachyury-TRICOM Vaccine|MVA-BN-BRACHYURY-TRICOM VACCINE|MVA-BN-Brachyury|MVA-BN-Brachyury Prime Vaccine	A cancer priming vaccine consisting of a proprietary version of the recombinant vaccinia viral vector, modified vaccinia Ankara-Bavarian Nordic (MVA-BN), encoding the human transcription factor and tumor-associated antigen (TAA) brachyury, and a triad of T-cell co-stimulatory molecules (TRICOM), which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration of MVA-BN-brachyury vaccine, the vector expresses the brachyury protein. The expressed brachyury protein may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing brachyury. The MVA-BN-brachyury vaccine, which is a priming vaccine, is followed by multiple boosting doses of the fowlpox virus (FPV)-brachyury vaccine. The expression of brachyury, a member of the T-box family of transcription factors that is overexpressed in numerous cancer cell types, is correlated with increased epithelial-mesenchymal transition (EMT), cancer resistance, cancer progression and metastasis. TRICOM enhances antigen-specific T-cell activation.	MVA-BN-Brachyury-TRICOM Vaccine		Immunologic Factor|Pharmacologic Substance|Virus	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148401>	C68611|C214956	Refractory Sinonasal Squamous Cell Carcinoma|Refractory Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma	Nasal cavity and paranasal sinus squamous cell carcinoma that does not respond to treatment.			Neoplastic Process	
C148402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148402>	C2521	FPV-Brachyury-TRICOM Vaccine|FPV-Brachyury|FPV-Brachyury Boost Vaccine	A cancer vaccine consisting of a recombinant fowlpox viral (FPV) vector encoding the human transcription factor and tumor-associated antigen (TAA) brachyury, and a triad of T-cell co-stimulatory molecules (TRICOM), which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3, with potential immunostimulatory and antineoplastic activities. Upon subcutaneous administration occurring after the administration of a proprietary modified vaccinia Ankara developed by Bavarian Nordic-based prime vaccine (MVA-BN-brachyury), the booster vaccine FPV-brachyury vaccine potentiates a cytotoxic T-lymphocyte (CTL) response against brachyury-expressing tumor cells. The expression of brachyury, a member of the T-box family of transcription factors that is overexpressed in numerous cancer cell types, is correlated with increased epithelial-mesenchymal transition (EMT), cancer resistance, cancer progression and metastasis. TRICOM enhances antigen-specific T-cell activation.	FPV-Brachyury-TRICOM Vaccine		Immunologic Factor|Pharmacologic Substance|Virus	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C148403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148403>	C94299|C35682|C177693	MET Overexpression Positive|HGFR Overexpression Positive|Hepatocyte Growth Factor Receptor Overexpression Positive|MET Proto-Oncogene, Receptor Tyrosine Kinase Overexpression Positive|Met Proto-Oncogene Overexpression Positive|c-met Overexpression Positive	An indication that overexpression of MET has been detected in a sample.	MET Overexpression Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148404>	C156029	PDGFR Gene Amplification|PDGF Receptor Gene Amplification|PDGFR Family Gene Amplification|Platelet Derived Growth Factor Receptor Gene Amplification|Platelet-Derived Growth Factor Receptor Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of a PDGFR family gene.	PDGFR Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C148405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148405>	C36345	PDGFR Protein Overexpression|PDGF Receptor Protein Overexpression|PDGFR Family Protein Overexpression|Platelet Derived Growth Factor Receptor Protein Overexpression|Platelet-Derived Growth Factor Receptor Protein Overexpression	A molecular abnormality indicating the presence of an abnormally high level of a platelet-derived growth factor receptor family protein.	PDGFR Protein Overexpression		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148406>	C94299|C35682|C177693	AXL Overexpression Positive|ARK Overexpression Positive|AXL Receptor Tyrosine Kinase Overexpression Positive|JTK11 Overexpression Positive|Tyro7 Overexpression Positive|Tyrosine-Protein Kinase Receptor UFO Overexpression Positive|UFO Overexpression Positive	An indication that overexpression of AXL has been detected in a sample.	AXL Overexpression Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148407>	C42076	Unspecified Atypical Cells Present|Atypical Cells Present|Indeterminate Abnormal Cells Present|Unspecified Abnormal Cells Present	A finding indicating that abnormal cells with indeterminate morphological features are present in a sample.	Unspecified Atypical Cells Present		Finding	CTRP Biomarker Terminology|CTRP Terminology
C148408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148408>	C157401	Dolutegravir Sodium|DOLUTEGRAVIR SODIUM|Tivicay	The sodium salt form of dolutegravir, an orally bioavailable integrase strand-transfer inhibitor (INSTI), with activity against human immunodeficiency virus type 1 (HIV-1) infection. Upon oral administration, dolutegravir binds to the active site of integrase, an HIV enzyme that catalyzes the transfer of viral genetic material into human chromosomes. This prevents integrase from binding to retroviral deoxyribonucleic acid (DNA), and blocks the strand transfer step, which is essential for the HIV replication cycle. This prevents HIV-1 replication.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C148409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148409>	C42944	Nebulizer Dosage Form				Biomedical or Dental Material	
C148410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148410>	C2185|C213865|C200052|C192741|C155765	Milciclib|1H-Pyrazolo(4,3-h)quinazoline-3-carboxamide, 4,5-dihydro-N,1,4,4-tetramethyl-8-((4-(4-methyl-1-piperazinyl)phenyl)amino)-|MILCICLIB|N,1,4,4-Tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide|PHA 848125|PHA-848125	An orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and tropomyosin receptor kinase A (TRKA), with potential antineoplastic activity. CDK2/TRKA inhibitor PHA-848125 AC potently inhibits cyclin-dependent kinase 2 (CDK2) and exhibits activity against other CDKs including CDK1 and CDK4, in addition to TRKA. Inhibition of these kinases may result in cell cycle arrest and apoptosis of tumor cells that express these kinases. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some cancer cell types. The neurotrophin receptor TRKA is mutated in a variety of cancer cell types.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C148411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148411>	C48724	T2d TNM Finding|T2d|T2d|T2d Primary Tumor Finding|T2d Tumor Finding	A TNM stage finding term that refers to choroidal and ciliary body melanoma or conjunctival melanoma TNM staging. For choroidal and ciliary body melanoma it means tumor size category 2 with ciliary body involvement and extraocular extension 5 mm or less in largest diameter. For conjunctival melanoma it means caruncular tumor, and more than 1 quadrant of the nonbulbar conjunctiva involved. (from AJCC 8th Ed.)			Finding	GDC Terminology|GDC Value Terminology
C148412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148412>	C48728	T3d TNM Finding|T3d|T3d|T3d Primary Tumor Finding|T3d Tumor Finding	A TNM finding term that refers to choroidal and ciliary body melanoma, conjunctival melanoma, or retinoblastoma TNM staging. For choroidal and ciliary body melanoma it means tumor size category 3 with ciliary body involvement and extraocular extension 5 mm or less in largest diameter. For conjunctival melanoma it means tumor of any size invading the nasolacrimal duct and/or lacrimal sac and/or paranasal sinuses. For retinoblastoma it means hyphema and/or massive vitreous hemorrhage (clinical) or full-thickness invasion into the outer third of the sclera and/or invasion into or around emissary channels (pathologic). (from AJCC 8th Ed.)			Finding	GDC Terminology|GDC Value Terminology
C148413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148413>	C42744	Oral Solid Dosage Form				Biomedical or Dental Material	
C148414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148414>	C42744	Oromucosal Dosage Form	A medication designed to have its effects in the oral cavity.			Biomedical or Dental Material	
C148415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148415>	C128462	BET Inhibitor ABBV-744|1H-Pyrrolo(2,3-C)pyridine-2-carboxamide, N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(1-hydroxy-1-methylethyl)phenyl)-6,7-dihydro-6-methyl-7-oxo-|ABBV 744|ABBV-744|ABBV-744|ABBV744|BD2-selective BET Inhibitor ABBV-744	An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, the BET inhibitor ABBV-744 preferentially binds to the second bromodomain (BD2) of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of proliferation in BET-overexpressing tumor cells. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that contain two homologous bromodomains, the BD1 and BD2 domains. They play an important role during development and cellular growth.	BET Inhibitor ABBV-744		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148416>	C208255|C1941	CD40L-Fc Fusion Protein MEDI5083|MEDI 5083|MEDI-5083|MEDI-5083|MEDI5083	A fusion protein composed of CD40 ligand (CD40L; CD154; TRAP; TNFSF5) fused to a modified immunoglobulin (Ig) Fc fragment, with potential immunostimulating activity. Upon administration of the CD40L-Fc fusion protein MEDI5083, the CD40L moiety specifically targets, binds to, and activates CD40, a cell surface receptor that belongs to the tumor necrosis factor (TNF) receptor family and is expressed on various immune cells, such as B-lymphocytes, monocytes, and dendritic cells (DCs). Activation of CD40 induces proliferation and activation of B-lymphocytes, shifts the induction of suppressive macrophages towards immunostimulatory macrophages, activates monocyte-derived DCs (moDCs), and leads to the secretion of inflammatory cytokines, which activates the immune system to induce the proliferation and activation of cytotoxic T-lymphocytes (CTLs) against tumor cells. Altogether, this may cause tumor cell lysis.	CD40L-Fc Fusion Protein MEDI5083		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C148417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148417>	C20993	Adult Comorbidity Evaluation-27|ACE-27|ACE27	A 27-item comorbidity index for patients with cancer. ACE27 includes comorbid conditions of various organ systems, as well as malignancy, substance abuse, and body weight.			Intellectual Product	
C148418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148418>	C13442	Neuromuscular	Pertaining to muscles and nerves.			Spatial Concept	
C148419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148419>	C28676	Partially HLA-matched Adenovirus-specific T Lymphocytes|Partially HLA-matched Ad-specific CTLs|Partially HLA-matched Viralym-A Cells	A population of frozen, off-the-shelf, ready to administer, allogeneic, partially or closely human leukocyte antigen (HLA) matched cytotoxic T-lymphocytes (CTLs) specifically reactive to human adenovirus (Ad; AdV), with potential immunomodulating and anti-adenoviral activities. Ex vivo, Ad-derived peptides were mixed with peripheral blood mononuclear cells (PBMCs) from healthy donors and the Ad-reactive CTLs were selected, grown and frozen. Upon thawing and infusion, the partially HLA-matched Ad-specific CTLs may help reconstitute Ad-specific CTL responses in patients at risk of developing Ad infections after allogeneic stem cell transplant (HSCT) or in Ad-infected immunocompromised hosts. This may induce killing of Ad-infected cells and may prevent or reduce severity of Ad infection.	Partially HLA-matched Adenovirus-specific T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology
C148420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148420>	C141245	Moderate Hepatic Insufficiency|Moderate Hepatic Impairment	Findings indicating moderate impairment of liver function.			Finding	
C148421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148421>	C49165	Compartectomy	A limb-sparing surgical tumor resection procedure in which the entire lesion is removed and the plane of dissection is outside the limiting fascia or bone.			Therapeutic or Preventive Procedure	
C148422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148422>	C2089	PKC-beta Inhibitor MS-553|MS 553|MS-553|MS553|PKC-b Inhibitor MS-553	An orally available inhibitor of the beta-isoform of protein kinase C (PKC), with potential immunosuppressive and antineoplastic activities. Upon oral administration, PKC-beta inhibitor MS-553 selectively binds to and inhibits PKC-beta, which prevents the activation of PKC-beta-mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells. PKC-beta, a serine/threonine protein kinase overexpressed in certain types of cancer cells, is involved in tumor cell differentiation, proliferation, invasion and survival.	PKC-beta Inhibitor MS-553		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148423>	C82179|C172626	Recurrent Mixed Phenotype Acute Leukemia	The reemergence of mixed phenotype acute leukemia after a period of remission.	Recurrent Mixed Phenotype Acute Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148425>	C3161|C27358	Recurrent Leukemia|Leukemia, unspecified, in relapse	The reemergence of leukemia after a period of remission.			Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|mCode Cancer Disorder Value Set|mCode Elixhauser Leukemia Value Set|mCode Primary Cancer Disorder Value Set|mCode Primary Malignant Neoplasm Disorder Value Set|mCode Terminology
C148426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148426>	C3161|C27357	Refractory Leukemia|Advanced Leukemia|Advanced Leukemia	A leukemia that is resistant to treatment.	Advanced Leukemia		Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C148427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148427>	C3171|C193431|C148429	Recurrent Acute Myeloid Leukemia|Acute myeloblastic leukemia, in relapse|Recurrent Acute Myeloid Leukemia (AML)	The reemergence of acute myeloid leukemia after a period of remission.	Recurrent Acute Myeloid Leukemia		Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology|mCode Cancer Disorder Value Set|mCode Elixhauser Leukemia Value Set|mCode Primary Cancer Disorder Value Set|mCode Primary Malignant Neoplasm Disorder Value Set|mCode Terminology
C148429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148429>	C9300|C148425	Recurrent Acute Leukemia|Acute leukemia of unspecified cell type, in relapse	The reemergence of acute leukemia after a period of remission.			Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|mCode Cancer Disorder Value Set|mCode Elixhauser Leukemia Value Set|mCode Primary Cancer Disorder Value Set|mCode Primary Malignant Neoplasm Disorder Value Set|mCode Terminology
C148430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148430>	C82179|C172630	Refractory Mixed Phenotype Acute Leukemia	A mixed phenotype acute leukemia that does not respond to treatment.	Refractory Mixed Phenotype Acute Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148431>	C9300|C148426	Refractory Acute Leukemia	An acute leukemia that does not respond to treatment.			Neoplastic Process	
C148432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148432>	C35417|C27324|C165171	Unresectable Intrahepatic Cholangiocarcinoma|Unresectable Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)	An intrahepatic cholangiocarcinoma that is not amenable to surgical removal.	Unresectable Intrahepatic Cholangiocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148433>	C15686	Percutaneous Hepatic Perfusion	A minimally invasive procedure in which high dose chemotherapy is delivered directly to the liver via a catheter placed in the hepatic artery, and the effluent blood returning through the hepatic veins is filtered via an extracorporeal system before being returned through a sheath in the internal jugular vein.	Percutaneous Hepatic Perfusion		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C148434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148434>	C3871|C214958|C150532	Refractory Nasopharyngeal Carcinoma|Refractory Nasopharyngeal Throat Cancer	A nasopharyngeal carcinoma that is resistant to treatment.	Refractory Nasopharyngeal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148435>	C201171	Adenosine A2B Receptor Antagonist PBF-1129|A2BR Antagonist PBF-1129|PBF 1129|PBF-1129|PBF1129	An orally bioavailable antagonist of the immunomodulatory checkpoint molecule adenosine A2B receptor (A2BR; ADORA2B), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon administration, A2BR antagonist PBF-1129 competes with adenosine for binding to A2BR expressed on various cancer cell types and numerous immune cells, such as dendritic cells (DCs), mast cells, macrophages and lymphocytes. This inhibits A2BR activity and prevents adenosine/A2BR-mediated signaling. The inhibition of A2BR in cancer cells prevents activation of downstream oncogenic pathways, which leads to an inhibition of cell proliferation and metastasis. A2BR inhibition also prevents the release of various growth factors, cytokines and chemokines, such as vascular endothelial growth factor (VEGF), interleukin-8 (IL-8) and angiopoietin-2 (Ang2) from immune cells, which may abrogate the adenosine-mediated immunosuppression in the tumor microenvironment (TME) and activate the immune system to exert anti-tumor immune responses against cancer cells leading to tumor cell killing. In addition, under non-cancerous inflammatory conditions, inhibition of A2BR leads to reduced activation and proliferation of various immune cells, which results in decreased pro-inflammatory cytokine production and may prevent inflammation. A2BR, a G protein-coupled signaling receptor, is expressed on the cell surfaces of numerous immune cells and is often overexpressed on a variety of cancer cell types; it plays a key role in their proliferation, progression and metastasis. Adenosine is overproduced under inflammatory conditions and plays a key role in pro-inflammatory actions. Adenosine is often overproduced by tumor cells and plays a key role in immunosuppression and tumor cell proliferation. The pro- and anti-inflammatory effects of adenosine and A2BR are cell type-specific and dependent on the extracellular microenvironment.	Adenosine A2B Receptor Antagonist PBF-1129		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148436>	C122940	Free Tissue Transfer	The transplantation of autologous tissue that is completely detached from its original blood supply from one location to another using microvascular reconstruction techniques to reestablish circulation.			Therapeutic or Preventive Procedure	
C148437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148437>	C16546	Hysteroscopy	Endoscopic examination of the uterine cavity through the vagina and cervix.	Hysteroscopy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C148438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148438>	C15454	Mandibulotomy	A surgical incision through the mandible to access the mouth or throat.			Therapeutic or Preventive Procedure	
C148439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148439>	C42636	Impregnated Dosage Form				Biomedical or Dental Material	
C148440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148440>	C97927	CD274 Gene Mutation|B7-H Gene Mutation|B7H1 Gene Mutation|CD274 Antigen Gene Mutation|CD274 Molecule Gene Mutation|PD-L1 Gene Mutation|PDCD1L1 Gene Mutation|PDCD1LG1 Gene Mutation|PDL1 Gene Mutation|Programmed Cell Death 1 Ligand 1 Gene Mutation	A change in the nucleotide sequence of the CD274 gene.	CD274 Gene Mutation		Cell or Molecular Dysfunction	CTRP Disease Terminology|CTRP Terminology
C148441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148441>	C91105	BRIEF Health Literacy Screening Tool|BRIEF|BRIEF Health Literacy Screening Tool (BRIEF)	A standardized four-item questionnaire developed by Haun et al. in 2009 that utilizes a five-point Likert rating scale to assess the adequacy of an individual's health literacy.			Intellectual Product	
C148442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148442>	C176426	Require Help to Read Hospital Materials Question|How often do you have someone help you read hospital materials|Require Help to Read Hospital Materials	A question about whether an individual has or had someone help them read hospital materials.			Intellectual Product	BRIEF Health Literacy Screening Tool
C148443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148443>	C154551	Dispersion Dosage Form Category|Dispersion	A type of liquid pharmaceutical dose form consisting of one or more substances, excluding solid particles and large liquid droplets, that are dispersed in an appropriate liquid vehicle.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C148444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148444>	C45246	Gastrointestinal Dosage Form	A preparation intended for administration to the stomach or duodenum.			Functional Concept	
C148445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148445>	C42744	Gingival Dosage Form				Biomedical or Dental Material	
C148446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148446>	C176537|C173398|C118873	Have Problems Learning About Medical Condition Due to Difficulty Understanding Written Information Question|Have Problems Learning About Medical Condition Due to Difficulty Understanding Written Information|How often do you have problems learning about your medical condition because of difficulty understanding written information	A question about whether an individual has or had problems learning about their medical condition because of difficulty understanding written information.			Intellectual Product	BRIEF Health Literacy Screening Tool
C148447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148447>	C118873	Have Problem Understanding What is Told About Medical Condition Question|Have Problem Understanding What is Told About Medical Condition|How often do you have a problem understanding what is told to you about your medical condition	A question about whether an individual has or had a problem understanding what is told to them about their medical condition.			Intellectual Product	BRIEF Health Literacy Screening Tool
C148448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148448>	C42636	Herbal Dosage Form				Biomedical or Dental Material	
C148449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148449>	C45246	Uterine Dosage Form				Functional Concept	
C148450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148450>	C173086	Confident Filling Out Medical Forms Question|Confident Filling Out Medical Forms|How confident are you filling out medical forms by yourself	A question about how confident an individual is filling out medical forms by themselves.			Intellectual Product	BRIEF Health Literacy Screening Tool
C148451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148451>	C42744	Laryngopharyngeal Dosage Form				Biomedical or Dental Material	
C148452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148452>	C150386	Medicinal Gas Dosage Form Category|Medicinal gas	A type of gaseous pharmaceutical dose form consisting of a pure substance or mixture of substances that exist in the form of a gas at normal atmospheric pressure and room temperature.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C148453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148453>	C43186	Multi-dose Container|Multidose container	A container holding a quantity of the preparation suitable for 2 or more doses.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Container Terminology
C148454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148454>	C69064|C42972	Nasal Powder Dosage Form|Nasal powder	Solid, usually multidose preparation consisting of one or more powders of solid active substance(s) intended for nasal use by insufflation into the nasal cavity.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C148455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148455>	C184956	Emavusertib|AU 4948|AU-4948|CA 4948|CA-4948|CA4948|EMAVUSERTIB|IRAK4 Inhibitor CA-4948|Interleukin-1 Receptor-associated Kinase 4 Inhibitor CA-4948	An orally bioavailable, reversible inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), with potential antineoplastic, immunomodulating and anti-inflammatory activities. Upon oral administration, emavusertib targets, binds to, and blocks the kinase activity of IRAK4. This inhibits IRAK4-mediated signaling, prevents the activation of IRAK4-mediated nuclear factor-kappa B (NF-kB) signaling and decreases the expression of inflammatory cytokines and certain pro-survival factors. This inhibits proliferation of IRAK4-overactivated tumor cells, which are found in cells harboring MYD88 activating mutations or those with overactivated toll-like receptor (TLR) pathways. In addition, emavusertib may inhibit inflammation and immune-mediated cell destruction in inflammatory and auto-immune diseases where TLR or interleukin 1 receptor (IL-1R) signaling is overactivated and MYD88 is dysregulated. IRAK4, a serine/threonine-protein kinase that plays a key role in both the TLR and IL-1R signaling pathways, is activated though the adaptor protein MYD88 and links the TLR and IL-1R signaling pathway to the NF-kB pathway.	Emavusertib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology
C148456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148456>	C42744	Sublingual Dosage Form				Biomedical or Dental Material	
C148457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148457>	C110937	Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma	A finding indicating the presence of a sarcoma arising from the soft tissue, other than rhabdomyosarcoma.			Finding	
C148458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148458>	C148457	Recurrent Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma	A finding indicating the reemergence of a sarcoma arising from the soft tissue, other than rhabdomyosarcoma, after a period of remission.			Finding	
C148459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148459>	C148457	Refractory Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma	A finding indicating the presence of a sarcoma arising from the soft tissue, other than rhabdomyosarcoma, that is resistant to treatment.			Finding	
C148461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148461>	C84640	Lissencephaly 3|LIS3	An autosomal dominant sub-type of lissencephaly caused by mutation(s) in the TUBA1A gene, encoding adhesion tubulin alpha-1A chain.			Disease or Syndrome	Cellosaurus Disease Terminology
C148462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148462>	C717|C213309|C204256	Delolimogene Mupadenorepvec|DELOLIMOGENE MUPADENOREPVEC|LOAd 703|LOAd-703|LOAd703|Oncolytic Adenovirus LOAd703	A double-armed oncolytic adenovirus composed of a recombinant genetically modified E1/E3-deleted, adenoviral serotype 5 (Ad5) vector, with the L5 segment of the Ad5 fiber replaced by the shaft and knob from the Ad35 serotype (Ad5/35), which expresses a trimerized (TMZ) form of the membrane-bound immunostimulator CD40 ligand (CD40L; TNFSF5) and the ligand for the signaling domain 4-1BB (4-1BBL; CD137L; TNFSF9), under the control of a CMV promoter, with potential immunostimulating and antineoplastic activities. Upon intratumoral administration of delolimogene mupadenorepvec, the virus infects and selectively replicates in tumor cells. This causes direct oncolysis and the release of a plethora of tumor-associated antigens (TAAs) from the tumor cells. The released TAAs stimulate the immune system and activate anti-tumor cytotoxic T-lymphocytes (CTLs), thereby further killing tumor cells. In addition, infected tumor cells and tumor stroma cells, including stellate cells and infiltrating immune cells, express the immunostimulants CD40L and 4-1BBL. The expressed CD40L and 4-1BBL proteins activate the CD40L- and 4-1BBL-mediated signaling pathways, respectively. This activates antigen-presenting cells (APCs), such as dendritic cells (DCs) and M1 macrophages. The DCs produce various cytokines, including interleukin-12 (IL12), IL21, tumor necrosis factor-alpha (TNFa), and interferon-gamma (IFNg), which leads to the activation and expansion of both T-cells and natural killer (NK) cells. Altogether, this modulates immune suppression in the tumor microenvironment (TME), disrupts tumor stroma, and causes additional immune stimulation against tumor cells, thereby inducing further tumor cell lysis. In addition, CD40L reduces myeloid suppressor cells in the TME. Inclusion of the chimeric Ad5/35 fiber targets CD46 and increases viral uptake in cells. Transgene expression is driven by a separate promoter to allow for efficient expression in both tumor cells and tumor stroma. Replication is restricted to tumor cells by the presence of the delta24 mutation in the E1A gene, which deletes the retinoplastoma protein (pRb)-binding domain and forces viral replication to be conditional on hyperphosphorylated pRb and a dysfunctional Rb pathway.	Double-armed TMZ-CD40L/4-1BBL Oncolytic Ad5/35 Adenovirus LOAd703		Pharmacologic Substance|Virus	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148463>	C15655	Tube Thoracostomy|Chest Tube Placement|Chest Tube Thoracostomy	A surgical procedure in which a chest tube is inserted between the ribs to drain fluid or air from the pleural cavity.			Therapeutic or Preventive Procedure	
C148464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148464>	C91105	Patient Satisfaction with Cancer Care Questionnaire|PSCC|Patient Satisfaction with Cancer Care|Patient Satisfaction with Cancer Care (PSCC)|Patient Satisfaction with Cancer Care Measure	A questionnaire designed measure patient satisfaction with cancer care. It is designed to address: 1) satisfaction with care during screening and treatment, 2) challenges of poor and minority individuals receiving cancer-related care, and 3) relevance for evaluation of care for both navigated and un-navigated patients. The questionnaire is usually administered within 3 months of screening and again 3 months after the initiation of treatment.			Intellectual Product	
C148465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148465>	C25616	During Most Recent Visit	Happening during a patient's most recent visit.			Temporal Concept	Patient Satisfaction with Cancer Care Questionnaire
C148466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148466>	C25616	After Most Recent Visit	Happening after a patient's most recent visit.			Temporal Concept	Patient Satisfaction with Cancer Care Questionnaire
C148467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148467>	C226920|C226742	Health Concerns Were Understood|Felt Health Concerns Were Understood|I felt that my health concerns were understood	A response indicating that an individual feels or felt that their health concerns were understood.			Intellectual Product	Patient Satisfaction with Cancer Care Questionnaire
C148468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148468>	C226668|C176250	Treated with Courtesy and Respect|Felt Treated with Courtesy and Respect|I felt that I was treated with courtesy and respect	A response indicating that an individual feels or felt that they were treated with courtesy and respect.			Intellectual Product	Patient Satisfaction with Cancer Care Questionnaire
C148469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148469>	C226911	Included in Decisions About Health|Felt Included in Decisions About Health|I felt included in decisions about my health	A response indicating that an individual feels or felt included in decisions about their health.			Intellectual Product	Patient Satisfaction with Cancer Care Questionnaire
C148470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148470>	C226644	Told How to Take Care of Myself|I was told how to take care of myself	A response indicating that an individual was told how to take care of themselves.			Intellectual Product	Patient Satisfaction with Cancer Care Questionnaire
C148471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148471>	C226920	Encouraged to Talk About Personal Health Concerns|Felt Encouraged to Talk About Personal Health Concerns|I felt encouraged to talk about my personal health concerns	A response indicating that an individual feels or felt encouraged to talk about their personal health concerns.			Intellectual Product	Patient Satisfaction with Cancer Care Questionnaire
C148472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148472>	C226920|C176242	Had Enough Time With Doctor|Felt I Had Enough Time with Doctor|I felt I had enough time with my doctor	A response indicating that an individual feels or felt that they had enough time with their doctor.			Intellectual Product	Patient Satisfaction with Cancer Care Questionnaire
C148473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148473>	C176250	My Questions Were Answered to My Satisfaction|My questions were answered to my satisfaction	A response indicating that an individual feels or felt that their questions were answered to their satisfaction.			Intellectual Product	Patient Satisfaction with Cancer Care Questionnaire
C148474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148474>	C176250	Making Appointment was Easy|Making an appointment was easy	A response indicating that an individual feels or felt that making an appointment was easy.			Intellectual Product	Patient Satisfaction with Cancer Care Questionnaire
C148475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148475>	C226644	Knew What Next Steps of Care Would Be|I knew what the next step in my care would be	A response indicating that an individual knew what the next steps in their care would be.			Intellectual Product	Patient Satisfaction with Cancer Care Questionnaire
C148476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148476>	C213556	Confident in How I Dealt with Health Care System|I felt confident in how I dealt with the health care system	A response indicating that an individual feels or felt confident in how they dealt with the health care system.			Intellectual Product	Patient Satisfaction with Cancer Care Questionnaire
C148477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148477>	C226920|C175322	Able to Get Advice Needed About Health Issues|Able to Get Advice I Needed About My Health Issues|I was able to get the advice I needed about my health issues	A response indicating that an individual was able to get the advice they needed about their health issues.			Intellectual Product	Patient Satisfaction with Cancer Care Questionnaire
C148478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148478>	C226920|C226742	Know Who to Contact for Questions|I knew who to contact when I had a question|Knew Whom to Contact for Questions	A response indicating that an individual knows who to contact when they have a question.			Intellectual Product	Patient Satisfaction with Cancer Care Questionnaire
C148479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148479>	C2092	Linzagolix|KLH 2109|KLH-2109|KLH2109|LINZAGOLIX|OBE2109|Thieno(3,4-d)pyrimidine-5-carboxylic acid, 3-(5-((2,3-Difluoro-6-methoxyphenyl)methoxy)-2-fluoro-4-methoxyphenyl)-1,2,3,4-tetrahydro-2,4-dioxo-	An orally bioavailable gonadotropin-releasing hormone (GnRH or LHRH) receptor antagonist, with potential hormone production inhibitory activity. Upon oral administration of linzagolix, this agent competes with GnRH for receptor binding and inhibits GnRH receptor signaling in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. As a result, this may relieve symptoms associated with hormonally dependent disease states such as hormone-dependent prostate cancer. In women, this prevents the production of estrogen by the ovaries and may relieve symptoms from sex-hormone dependent diseases, such as pain associated with endometriosis, heavy menstrual bleeding or uterine fibroids.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C148480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148480>	C39619|C1663	WT1/PSMA/hTERT-encoding Plasmid DNA INO-5401|INO 5401|INO-5401|INO5401	A preparation composed of three separate DNA plasmids encoding the tumor-associated antigens (TAAs) Wilms tumor gene-1 (WT1), prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT), with potential immunostimulating and antineoplastic activites. Upon intramuscular delivery and electroporation of the WT1/PSMA/hTERT-encoding plasmid DNA INO-5401, the genes are translated into their respective proteins inside the cell. The expressed proteins activate the immune system and induce a cytotoxic T-lymphocyte (CTL)-mediated response against cells expressing the WT1, PSMA and hTERT antigens, causing tumor cell lysis. hTERT, WT1 and PSMA are upregulated in many cancer cell types.	WT1/PSMA/hTERT-encoding Plasmid DNA INO-5401		Immunologic Factor|Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148481>	C93144	Bifidobacterium lactis/Lactobacillus acidophilus/Inulin Probiotic Supplement|B. lactis/L. acidophilus/Inulin Probiotic Supplement|ProBion Clinica	A tablet probiotic supplement containing the polysaccharide inulin and the non-pathogenic microorganisms Bifidobacterium lactis and Lactobacillus acidophilus, with potential anti-inflammatory, immunomodulating and protective activities. Upon oral administration of B. lactis/L. acidophilus/inulin probiotic supplement, the bacterial components in this dietary supplement may improve digestion and promote adequate colonization of the gastrointestinal (GI) tract by modulating the composition of the normal microflora. During colonization in the GI tract, the bacteria may form a protective intestinal barrier that may prevent both damage to the mucosal epithelia caused by toxins and attachment of potential pathogens, which protects against bacterial translocation and infection. In addition, this agent may both reduce the secretion of pro-inflammatory cytokines, including interleukin-10, and potentiate natural and acquired immunity. In colon cancer patients, these probiotic bacteria may favorably modulate the composition of the colon cancer-associated microbiota and may increase expression of tumor-suppressing genes. Inulin promotes growth and activity of beneficial GI bacteria, thereby altering the endogenous flora further.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C148484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148484>	C2124	Gallium Ga 68-P16-093|Ga-68 P16-093|Ga-68 PSMA-093|Ga-68 PSMA-93|Gallium-68-P16 093|[68Ga] HBED-CC-PHENOXY-PSMA|[68Ga]P16-093	A radioconjugate composed of a human prostate specific membrane antigen (PSMA)-targeting ligand (P16-093) conjugated to the radioisotope gallium Ga 68, via the acyclic radiometal chelator N,N'-bis [2-hydroxy-5-(carboxyethyl)benzyl] ethylenediamine-N,N'-diacetic acid (HBED-CC), with potential use as a tracer for PSMA-expressing tumors during positron emission tomography (PET). Upon intravenous administration of the gallium Ga 68 P16-093, the P16-093 moiety targets and binds to PSMA-expressing tumor cells. During PET imaging, PSMA-expressing tumor cells can be detected. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.	Gallium Ga 68-P16-093		Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C148485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148485>	C146993	Androgen Receptor Antagonist ONC1-0013B|(R)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-4-oxo-2-thioxo-7-oxa-1,3-diazaspiro[4.4]nonan-1-yl)-2-fluoro-N-methylbenzamide|AR Antagonist ONC1-0013B|ONC 10013B|ONC 113B|ONC-10013B|ONC1-0013B|ONC1-13B|ONC1-13B|ONC10013B	An orally bioavailable antagonist of the androgen receptor (AR), with potential antineoplastic activity. Upon oral administration, AR antagonist ONC1-13B specifically binds to AR, prevents AR activation, downregulates AR expression and prevents AR-mediated signaling. This inhibits cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in proliferation, survival and chemoresistance of tumor cells.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C148486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148486>	C200711	Glofitamab|Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody RO7082859|Columvi|GLOFITAMAB|Glofitamab-gxbm|RO 7082859|RO-7082859|RO7082859	A bispecific monoclonal antibody, with potential antineoplastic activity. Glofitamab contains two antigen-recognition sites: one for human CD3, a T cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, glofitamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells.	Glofitamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C148487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148487>	C129820	Polyamine Transport Inhibitor AMXT-1501 Dicaprate|AMX 513 Dicaprate|AMX513 Dicaprate|AMXT 1501 Dicaprate|AMXT-1501 DICAPRATE|AMXT-1501 Dicaprate	The dicaprate salt form of AMXT-1501, an orally bioavailable polyamine transport inhibitor, with immunostimulating and antineoplastic activities.  Upon administration, AMXT-1501 targets, binds to and blocks polyamine transport from the bloodstream into the tumor microenvironment (TME), thereby preventing cancer cell uptake. This decreases polyamine concentrations inside the TME and tumor cell, inhibits tumor cell proliferation and induces apoptosis. In addition, AMXT-1501 may abrogate polyamine-mediated immune suppression in the TME. Polyamines, naturally found in normal, heathy cells, are required for normal cell growth and division. In cancer cells, polyamines play key roles in tumor cell proliferation and tumor-induced suppression of the patient's immune system.	Polyamine Transport Inhibitor AMXT-1501 Dicaprate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148488>	C204154|C159200	Pelcitoclax|APG 1252|APG-1252|APG1252|Bcl-2/Bcl-XL Inhibitor APG-1252|PELCITOCLAX	A Bcl-2 homology (BH)-3 mimetic and selective inhibitor of the anti-apoptotic proteins B-cell lymphoma 2 (Bcl-2) and Bcl-XL, with potential pro-apoptotic and antineoplastic activities. Upon administration, pelcitoclax specifically binds to and inhibits the activity of the pro-survival proteins Bcl-2 and Bcl-XL. This restores apoptotic processes and inhibits cell proliferation in Bcl-2/Bcl-XL-dependent tumor cells. Bcl-2 and Bcl-XL, proteins belonging to the Bcl-2 family that are overexpressed in many cancers, play an important role in the negative regulation of apoptosis; tumor expression is associated with increased drug resistance and cancer cell survival.	Pelcitoclax		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C148489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148489>	C2189|C1742	Astragalus membranaceus/Angelica gigas/Trichosanthes kirilowii Maximowicz Mixed Herbal Extract SH003|Am/Ag/Tk Herbal Extract SH003|SH003	A traditional Chinese medicine (TCM)-based herbal extract composed of Astragalus membranaceus (Am), Angelica gigas (Ag) and Trichosanthes kirilowii Maximowicz (Tk), with potential anti-angiogenic and antineoplastic activities. Upon administration, the active ingredients in Am/Ag/Tk mixed herbal extract SH003 work synergistically to exert a number of activities through various mechanisms of action (MOA); although, not all of the MOAs are fully elucidated. SH003 blocks the binding of vascular endothelial growth factor (VEGF) to its receptor VEGF receptor 2 (VEGFR2; KDR), thereby inhibiting VEGF/VEGFR2-mediated signaling and VEGF-induced tumor endothelial cell migration, invasion and tube formation. This inhibits tumor angiogenesis. In addition, SH003 inhibits signal transducer and activator of transcription 3 (STAT3) activation and STAT3-mediated signaling, decreases the production of the pro-inflammatory cytokine interleukin-6 (IL-6), and the expression of STAT3 target genes. This induces apoptosis in, and reduces proliferation and metastasis of, cancer cells in which STAT3 signaling is overactivated. STAT3 activation contributes to inflammation in the cancer environment and tumor cell proliferation.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C148490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148490>	C200766	Autologous CD5-specific CAR-28 zeta CAR T-cells|Autologous CD5-specific CAR-28 zeta CAR T-lymphocytes|Autologous CD5.CAR/28zeta CAR T Cells|CD5.CAR/28zeta CAR T Cells	Autologous T-lymphocytes transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD5 single chain variable fragment (scFv) coupled to the costimulatory signaling domain CD28 and the zeta chain of the T-cell receptor (TCR), with potential immunomodulating and antineoplastic activities. Upon transfusion, the autologous CD5-specific CAR-28 zeta CAR T-cells are directed to and induce selective toxicity in CD5-expressing tumor cells. The tumor-associated antigen (TAA) CD5 is a T-cell surface glycoprotein expressed on the surface of normal T-cells, and is overexpressed on various B- and T-cell malignancies; its expression is associated with poor prognosis.	Autologous CD5-specific CAR-28 zeta CAR T-cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148491>	C129824	HER2-targeted DARPin MP0274|DARPin MP0274|HER-2-targeting DARPin MP0274|HER2-targeting DARPin Drug MP0274|MP 0274|MP0274	A proprietary, designed ankyrin repeat proteins (DARPin)-based agent targeting the tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2), with potential antineoplastic activity. Compared to antibodies, DARPins are small in size, have favorable pharmacokinetics and allow for both high affinity binding and efficacy. Upon administration, the HER2-targeted DARPin MP0274 binds to two distinct non-overlapping epitopes on HER2, thereby inhibiting the activity of HER2 and promoting HER2 internalization. This prevents HER2-mediated signaling, induces apoptosis and inhibits the growth of HER2-overexpressing tumor cells. DARPin also binds to human serum albumin, which extends the half-life of MP0274. HER2 is overexpressed in a variety of cancer cell types and is associated with increased tumor cell proliferation.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148492>	C25616	During Hospital or Clinic Visits after Abnormal Screening or Diagnosis|During All Hospital or Clinic Visits after Abnormal Screening or Diagnosis|Thinking about all the visits you have had to a clinic or hospital, after receiving a diagnosis/abnormal screening	The time period during a hospital or clinic visit and after when an individual received an abnormal screening or diagnosis.			Temporal Concept	
C148493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148493>	C213708|C172091|C126109	Advanced Urothelial Carcinoma|Advanced Urothelial Cancer	A urothelial carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Urothelial Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148494>	C8925|C8524	Locally Advanced Melanoma	Melanoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Melanoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148495>	C2594	Hepatitis B Virus Antigen Peptides/Hepatitis G2 Cell Protein Lysate-activated Dendritic Cells|HBV Antigen Peptides/HepG2 Cell Protein Lysate-activated DCs|HBV Antigen Peptides/HepG2 Cell Protein Lysate-activated Dendritic Cells	A cell-based cancer vaccine composed of autologous dendritic cells (DCs) ex vivo activated with the hepatitis B virus (HBV)-specific tumor-associated antigen (TAA) peptides derived from the patient's tumor and cell lysate proteins harvested from the immortalized human liver cancer cell line HepG2, with potential immunostimulatory and antineoplastic activities. Upon administration, the HBV peptides/HepG2 cell protein lysate-activated DCs expose the immune system to the HBV epitopes and an undefined amount of other TAAs from the HepG2 cell lysate, which may result in the induction of a specific anti-tumor cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing the HBV/HepG2 TAAs. HBV TAAs are found on HBV-positive cells and on HBV-induced hepatocellular carcinoma (HBV-HCC).			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology
C148496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148496>	C201178|C200766	Autologous PSMA-specific TGFb-resistant CAR T Cells|Autologous CART-PSMA-TGFbRDN Cells|Autologous CART-PSMA-TGFbRDN T-cells|PSMA-specific/TGFb-resistant CAR-modified Autologous T Cells	Autologous T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-prostate specific membrane antigen (PSMA) single chain variable fragment (scFv) and expressing a dominant negative (DN) form of transforming growth factor-beta (TGF-beta; TGFb) receptor, with potential immunomodulating and antineoplastic activities. Upon transfusion, the autologous PSMA-specific TGFb-resistant CAR T cells are directed to and induce selective toxicity in PSMA-expressing tumor cells. The tumor-associated antigen (TAA) PSMA is overexpressed by prostate cancers; its expression is associated with poor prognosis and metastasis. The inclusion of the DN TGFb receptor blocks signaling of the immunosuppressive cytokine TGFb in the tumor microenvironment (TME) and makes the CAR T cells resistant to TGFb. TGFb negatively regulates T-cell proliferation and activation and plays a key role in tumor immune suppression.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148497>	C2124	Carbon C 11-JNJ-63779586|11C-JNJ-63779586	A radioconjugate composed of JNJ-63779586 labeled with the positron-emitting isotope carbon C 11, with potential use in imaging via positron emission tomography (PET).  Upon administration of carbon C 11-JNJ-63779586, the JNJ-63779586 moiety acts as a substrate for the efflux transporter P-glycoprotein (P-gp) and the breast cancer resistance protein (BCRP). Upon PET imaging, this radioligand may allow for the assessment of P-gp and BCRP function and expression in tumors. As P-gp and BCRP activity may influence response to therapy, measuring P-gp and BCRP activity may be beneficial when choosing chemotherapy. P-gp and BCRP, efflux transporters, are overexpressed by certain tumor cells and may contribute to multidrug resistance to chemotherapy.			Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	NCI Drug Dictionary Terminology
C148498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148498>	C200766|C176023	Ciltacabtagene Autoleucel|Autologous Anti-BCMA CAR-T Cells JNJ-68284528|Autologous Bi-epitope BCMA-targeted CAR T-cells JNJ-68284528|Autologous Bi-epitope CAR T-cells JNJ-68284528|CARVYKTI|CILTACABTAGENE AUTOLEUCEL|Cilta-cel|Ciltacabtagene autoleucel|JNJ 68284528|JNJ-68284528|JNJ68284528|LCAR B38M|LCAR-B38M|LCAR-B38M-transduced CAR-T Cells JNJ-68284528|LCAR-B38M-transduced Car-T Cells JNJ-68284528|LCARB38M	A preparation of autologous T-lymphocytes that are transduced, ex vivo, with LCAR-B38M, a lentiviral vector expressing a chimeric antigen receptor (CAR) containing two bispecific anti-B-cell maturation antigen (BCMA) variable fragments of llama heavy-chain murine antibodies fused to the signaling domain of 4-1BB (CD137), with potential immunostimulating and antineoplastic activities. The antigen-binding region of the CAR is a non-scFv structure targeting two distinct regions of BCMA. Upon intravenous administration back into the patient, ciltacabtagene autoleucel are directed to cells expressing BCMA, bind to two different epitopes on BCMA and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-associated antigen (TAA) and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is overexpressed on malignant plasma cells.	Ciltacabtagene Autoleucel		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148499>	C28676	Allogeneic interleukin-17-producing CD8-positive T-cells	A preparation of allogeneic human cytotoxic T-lymphocytes that express the pro-inflammatory cytokine interleukin-17 (IL-17; IL17), with potential immunomodulating and anti-tumor activities. Upon ex vivo stimulation, the IL-17-producing CD8-positive T-cells (Tc17) convert to interferon-gamma (IFNg; IFN-g)-producing CD8-positive T-cells (Tc1). Tc1 cells exert enhanced anti-tumor cytotoxicity. Human Tc17 cells may contribute to a number of human inflammatory and malignant diseases.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology
C1484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1484>	C1757	Tyrphostin A25|4,5-Trihydroxybenzylidene malononitrile|AG 82	A member of the tyrphostin family of tyrosine kinase inhibitors that competitively binds and inhibits epidermal growth factor receptor and GTPase activity of transducin and induces apoptosis in human leukemic cell lines. (NCI)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C148500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148500>	C28676|C129826	Anti-minor Histocompatibility Complex Donor T-Lymphocytes|Anti-MiHA Donor T-lymphocytes|Anti-MiHA T Cells|GLIDE|GLIDE Cells|GLIDE T-lymphocytes|Guided Lymphocyte Immunopeptide Derived Expansion Against MiHAs Cells|Guided Lymphocyte Immunopeptide Derived Expansion Cells|MiHA T-lympocytes|MiHA-specific T Cells	A preparation of allogeneic, donor-derived T-lymphocytes that are specific for a unique set of minor histocompatibility complex antigens (MiHA) exclusively found on the surface of malignant cells, with potential immunomodulating and antineoplastic activities. T-lymphocytes are derived from an allogeneic hematopoietic cell transplant (AHCT) donor. Ex vivo, these T-cells are exposed to and primed against a select set of host-specific hematopoietic tissue-restricted MiHAs that are expressed on leukemic cells. Then the cells are subsequently expanded. After AHCT and infusion of the anti-MiHA T-lymphocytes, these cells target and bind to MiHA antigens expressed on the host's leukemia cells, thereby killing these cancer cells. MiHA are small, cell-surface peptides that are associated with graft-versus-host disease (GvHD). The selected set of MiHAs is expressed mainly, or only, by hematopoietic cells, and overexpressed on leukemic cells.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148501>	C209713	Aurora A Kinase Inhibitor LY3295668|AK 01|AK-01|AK-01|LY 3295668|LY-3295668|LY3295668	An orally bioavailable inhibitor of the serine/threonine protein kinase aurora A, with potential antimitotic and antineoplastic activities. Upon administration, aurora A kinase inhibitor LY3295668 targets, binds to and inhibits the activity of aurora A kinase. This may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, inhibition of cell division and the induction of apoptosis in cells overexpressing aurora A kinase. Aurora A kinase, overexpressed in a wide variety of cancers, plays an essential role in the regulation of spindle assembly and mitosis.	Aurora A Kinase Inhibitor LY3295668		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148502>	C21295	MBD1 Gene|MBD1|MBD1|Methyl-CpG Binding Domain Protein 1 Gene	This gene plays a role in transcriptional repression through binding to methylated CpG islands.			Gene or Genome	
C148503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148503>	C148502	MBD1 wt Allele|CXXC3|Methyl-CpG Binding Domain Protein 1 wt Allele|PCM1|RFT|The Regulator of Fibroblast Growth Factor 2 (FGF-2) Transcription Gene	Human MBD1 wild-type allele is located in the vicinity of 18q21.1 and is approximately 15 kb in length. This allele, which encodes methyl-CpG-binding domain protein 1, is involved in the inhibition of gene expression.			Gene or Genome	
C148504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148504>	C16518	Methyl-CpG-Binding Domain Protein 1|CXXC Finger Protein 3|CXXC-Type Zinc Finger Protein 3|MBD1|Methyl-CpG Binding Domain Protein 1|Methyl-CpG-Binding Protein MBD1|Protein Containing Methyl-CpG-Binding Domain 1	Methyl-CpG-binding domain protein 1 (605 aa, ~67 kDa) is encoded by the human MBD1 gene. This protein plays a role in the repression of gene expression.			Amino Acid, Peptide, or Protein	
C148505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148505>	C1891|C129818	Vilaprisan|(8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-11-(4-methylsulfonylphenyl)-17-(1,1,2,2,2-pentafluoroethyl)-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one|BAY 1002670|BAY-1002670|BAY1002670|VILAPRISAN	An orally available progestin and selective progesterone receptor modulator (SPRM), with potential anti-progesterone and antineoplastic activities. Upon oral administration, vilaprisan competitively binds to the progesterone receptor (PR) in progesterone-responsive tissue and inhibits PR-mediated gene expression. This interferes with progesterone activity in the reproductive system and may inhibit PR-mediated proliferative effects in cells overexpressing PRs. As a result, this agent may suppress ovulation and inhibit proliferation of endometrial tissue or uterine fibroid formation.	Vilaprisan		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148506>	C200766|C176023	Autologous BCMA-4-1BBz-targeted CAR T-cells|Autologous Anti-BCMA CAR4-1BBz T Cells|Autologous Anti-BCMA:TCRz-4-1-BB CAR-T Cells	A preparation of autologous T-lymphocytes that have been ex vivo transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) specific for the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) fused to the co-stimulatory domain of 4-1BB (CD137), and the CD3-zeta (CD3z) T-cell signaling domain (4-1BBz), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous BCMA-4-1BBz-targeted CAR T-cells specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells; it is overexpressed on malignant plasma cells, and plays a key role in plasma cell survival.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148507>	C214992|C201551	Anti-EGFR/DM1 Antibody-drug Conjugate AVID100|ADC AVID100|AVID-100|AVID100|Antibody-drug Conjugate AVID100	A targeted antibody drug conjugate (ADC) consisting of a human monoclonal antibody directed against the epidermal growth factor receptor (EGFR) conjugated to the cytotoxic agent maytansinoid mertansine (DM1), with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of AVID100 binds to  EGFR on tumor cell surfaces. Following receptor internalization, the mertansine moiety binds to tubulin and interferes with microtubule assembly/disassembly dynamics. This inhibits both cell division and proliferation of cancer cells that express EGFR. EGFR, overexpressed by a variety of cancers, plays a key role in tumor cell proliferation and survival.	Anti-EGFR/DM1 Antibody-drug Conjugate AVID100		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148508>	C2124	Fluorine F 18-Al-NOTA-MATBBN|18F-Al-NOTA-MATBBN	A radioconjugate containing a bombesin (BBN) peptide analog, derived from an unspecified GRPR antagonist (MATBBN) that targets the gastrin-releasing peptide receptor (GRPR), and is linked to the radionuclide fluorine F 18 (18F), by the macrocyclic chelating agent, 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA), through a method that first couples 18F to aluminum (Al), with potential use in diagnostic imaging using positron emission tomography/computed tomography (PET/CT). Upon administration of fluorine F 18-Al-NOTA-MATBBN, the peptide moiety targets and binds to GRPR. Upon PET/CT, GRPR-expressing tumor cells can then be visualized. GRPR, also called bombesin receptor 2 (BB2), is a seven-transmembrane G protein-coupled receptor belonging to the bombesin receptor family. It is overexpressed in certain types of cancers. Bombesin is a peptide exhibiting high affinity for the gastrin-releasing peptide receptor (GRPR).			Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	NCI Drug Dictionary Terminology
C148509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148509>	C210988	CDC7 Kinase Inhibitor LY3143921 Hydrate|LY-3143921 Hydrate|LY-3143921 MONOHYDRATE|LY3143921 Hydrate|LY3143921 Monohydrate	The hydrated form of an orally bioavailable inhibitor of cell division cycle 7 (CDC7) kinase, with potential antineoplastic activity. Upon administration of CDC7 kinase inhibitor LY3143921 hydrate, LY3143921 targets, binds to and inhibits the activity of CDC7, which may result in the inhibition of DNA replication and mitosis, the induction of tumor cell apoptosis, and the inhibition of tumor cell proliferation in CDC7-overexpressing tumor cells. The serine-threonine kinase CDC7 plays a key role in DNA replication by binding to and  phosphorylating serine (Ser)-40 and 53 of MCM2 (minichromosome maintenance complex component 2), which is required for the initiation of DNA replication. Although expressed at low levels in healthy, normal cells, CDC7 is expressed at much higher levels in cancer cells.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148510>	C4813|C27718	Recurrent Human Papillomavirus-Related Malignant Neoplasm	The reemergence of human papillomavirus-related malignant neoplasm after a period of remission.	Recurrent Human Papillomavirus-Related Malignant Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148511>	C1904	Nanoparticle SN-38-encapsulated Micelle Formulation IT-141|IT-141|IT141|Nanoparticle SN-38 Formulation IT141	A nanoparticle-based formulation consisting of polymeric micelles, composed of triblock copolymers, loaded with the bioactive hydrophobic irinotecan metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38), with potential antineoplastic activity. Upon administration, nanoparticle SN-38-encapsulated micelle formulation IT141 diffuses into the tumor site and the SN-38 moiety binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, which results in DNA breaks, inhibition of DNA replication, and apoptosis. Compared to SN-38 alone, this formulation increases the water solubility of SN-38 and allows the delivery of higher doses of SN-38. IT-141 also has a much longer circulation time and reduces toxicity to normal, healthy tissues.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C148512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148512>	C27718|C120186	Refractory Human Papillomavirus-Related Malignant Neoplasm	Human papillomavirus-related malignant neoplasm that does not respond to treatment.	Refractory Human Papillomavirus-Related Malignant Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148513>	C143099|C141136|C129825	ALK/c-Met Inhibitor TQ-B3139|TQ B3139|TQ-B3139	An orally available, small molecule inhibitor of the receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and hepatocyte growth factor receptor (c-Met; HGFR), with potential antineoplastic activity. Upon oral administration, TQ-B3139 binds to and inhibits the activity of ALK and c-Met, which leads to the disruption of ALK- and c-Met-mediated signaling and the inhibition of cell growth in ALK- and c-Met-expressing tumor cells. ALK and c-Met, overexpressed or mutated in many tumor cell types, play key roles in tumor cell proliferation, survival, invasion and metastasis.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148514>	C7712|C171295	Metastatic Uveal Melanoma	A uveal melanoma that has spread from its primary site to another anatomic site.	Metastatic Uveal Melanoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148515>	C190137|C148514	Advanced Uveal Melanoma	A uveal melanoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Uveal Melanoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C148516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148516>	C471	11beta-hydroxysteroid Dehydrogenase Type 1 Inhibitor AZD4017|11-beta-hydroxysteroid Dehydrogenase Type 1 Inhibitor AZD4017|11b-HSD1 inhibitor AZD4017|11bHSD1 Inhibitor AZD4017|AZD 4017|AZD-4017|AZD-4017|AZD4017	A selective, orally bioavailable inhibitor of the enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11b-HSD1; 11bHSD1; HSD11B1), with potential protective activity. Upon administration, AZD4017 selectively binds to and inhibits the activity of 11b-HSD1. This prevents the conversion of cortisone to the active hormone cortisol that activates glucocorticoid receptors. By blocking cortisol production in metabolic tissues, AZD4017 may inhibit the adverse metabolic effects, such as glucose intolerance, hyperinsulinemia, systolic hypertension, increased adiposity, myoatrophy and dermal atrophy, caused by exogenous administration of glucocorticoids in these tissues. 11bHSD1 is highly expressed in metabolic tissues, such as liver, skeletal muscle, and adipose tissue. It plays a crucial role in regenerating active glucocorticoid from circulating glucocorticoids and regulates the production of cortisol to activate the glucocorticoid receptors. AZD4017 does not inhibit the anti-inflammatory activity of the administered glucocorticoids.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C148517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148517>	C3224|C27359	Unresectable Melanoma	A melanoma that is not amenable to surgical resection.	Unresectable Melanoma		Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C148518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148518>	C129826	EPS8 Peptide-specific Dendritic Cells|EPS8 Peptide-specific DCs	A preparation of dendritic cells (DCs) pulsed with peptides derived from epidermal growth factor receptor (EGFR) pathway substrate 8 (EPS8), with potential immunostimulating and antineoplastic activities. Upon administration of the EPS8 peptide-specific DCs, the immune system is exposed to the EPS8 antigens. This results in the induction of a specific cytotoxic T-lymphocyte (CTL) response against EPS8-expressing tumor cells and tumor cell lysis. EPS8, a tumor-associated antigen (TAA), is overexpressed in a variety of tumor cell types but rarely in normal tissues. As a substrate for the EGFR kinase, it plays a key role in tumor progression through the EGFR-dependent pathway. Its expression is correlated with a poor prognosis.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148519>	C80509|C226473	Topical Celecoxib|Celecoxib Cream|Celecoxib Topical|DFD-07|DFD07	A topical cream formulation containing celecoxib, a nonsteroidal anti-inflammatory drug (NSAID), with anti-inflammatory and potential keratolytic, chemopreventive and antineoplastic activities. Upon topical application to the affected area, celecoxib selectively binds to and inhibits cyclooxygenase-2 activity (COX-2), which may result in localized keratinocyte apoptosis. The breakdown of keratinocytes prevents their proliferation locally and may reduce tumor cell proliferation.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148520>	C146993	Androgen Receptor Antagonist BAY 1161116|AR Antagonist BAY 1161116|BAY 1161116|BAY-1161116|BAY1161116	An orally bioavailable antagonist of the androgen receptor (AR), with potential antineoplastic activity. Upon oral administration, AR antagonist BAY 1161116 specifically binds to AR, inhibits AR activation, and prevents AR-mediated signaling. This inhibits cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in proliferation, survival and chemoresistance of tumor cells.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148521>	C263|C129839	Amblyomin-X	A recombinant form of a toxic protein derived from the salivary glands of the Amblyomma cajennense tick that inhibits Factor Xa and induces apoptosis, with potential antithrombotic and antineoplastic activities.  Upon administration, amblyomin-X promotes endoplasmic reticulum (ER) stress, mitochondrial dysfunction, cytochrome-c release, poly(ADP-ribose) polymerase (PARP) cleavage, and activation of caspase. Additionally, this agent selectively induces apoptosis in tumor cells. It also affects endothelial cell functions, such as adhesion, and may inhibit angiogenesis. Amblyomin-X targets and binds to factor Xa, inhibits its activity and interrupts the blood coagulation cascade, thereby preventing thrombin formation and thrombus development. As cancer is associated with thrombosis, amblyomin-X could potentially exert its antineoplastic and antithrombotic effects in the cancer patient at the same time.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148522>	C1663	HAAH Lambda phage Vaccine SNS-301|Bacteriophage Cancer Vaccine SNS-301|HAAH-1/2/3 Lambda Phage Vaccine SNS-301|Nanoparticle HAAH Vaccine SNS-301|PAN 301-1|PAN-301-1|SNS 301|SNS-301|SNS301	A nanoparticle-based cancer vaccine composed of a neutralized bacteriophage Lambda construct that is genetically engineered to contain peptide fragments of human aspartyl/asparaginyl beta-hydroxylase (HAAH; ASPH) on its surface and are fused to the C-terminus of the head protein of phage lambda gpD, with potential immunostimulating and antineoplastic activities. HAAH lambda phage vaccine SNS-301 also contains DNA fragments representing the phage CpG motif that activate the MHC class II pathway. Upon intradermal administration of the HAAH lambda phage vaccine SNS-301, the bacteriophage exposes the immune system to HAAH, producing a HAAH-specific antibody response, and may activate the immune system to induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against HAAH-expressing tumor cells. HAAH is a transmembrane protein and highly conserved enzyme that catalyzes the hydroxylation of aspartyl and asparaginyl residues in epidermal growth factor-like domains of substrate proteins. HAAH is normally expressed in fetal development and is upregulated in a variety of cancer cell types, while its expression is nearly absent in healthy, normal cells. HAAH plays a key role in cancer cell growth, cell motility and invasiveness. Its expression is associated with a poor prognosis.	HAAH Lambda phage Vaccine SNS-301		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148523>	C201510|C200766	Autologous CD38-4SCAR-expressing T-cells 4SCAR38|4S-CD38-CAR-T Cell|4SCAR38|4SCAR38 T-cells|Anti-CD38 CAR-T Cells 4SCAR38|Anti-CD38-CD28-CD137-CD27-CD3z-iCasp9 CAR T-cells 4SCAR38|CD38-4SCAR-expressing T Lymphocytes|CD38-scFv/CD28/CD137/CD27/CD3z-iCasp9 T-cells|CD38-specific 4th Generation Chimeric Antigen Receptor-modified T Cells	A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a fourth generation chimeric antigen receptor (4SCAR) consisting of an anti-CD38 single chain variable fragment (scFv) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (TCR), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous CD38-4SCAR-expressing T-cells 4SCAR38 are directed to and induce selective toxicity in CD38-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.			Cell|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148524>	C201173|C200766	Autologous CD22-4SCAR-expressing T-cells 4SCAR22|4S-CD22-CAR-T Cell|4SCAR22|4SCAR22 T-cells|Anti-CD22 CAR-T Cells 4SCAR22|Anti-CD22-CD28-CD137-CD27-CD3z-iCasp9 CAR T-cells 4SCAR22|CD22-4SCAR-expressing T Lymphocytes|CD22-scFv/CD28/CD137/CD27/CD3z-iCasp9 T-cells|CD22-specific 4th Generation Chimeric Antigen Receptor-modified T Cells	A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a  fourth generation chimeric antigen receptor (4SCAR) consisting of an anti-CD22 single chain variable fragment (scFv) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (TCR), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous CD22-4SCAR-expressing T-cells 4SCAR22 are directed to and induce selective toxicity in CD22-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. CD22, a B-lineage-restricted, transmembrane phosphoglycoprotein, is expressed on malignant B cells. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.			Cell|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148525>	C201174|C200766	Autologous CD20-4SCAR-expressing T-cells 4SCAR20|4S-CD20-CAR-T Cell|4SCAR20|4SCAR20 T-cells|Anti-CD20 CAR-T Cells 4SCAR20|Anti-CD20-CD28-CD137-CD27-CD3z-iCasp9 CAR T-cells 4SCAR20|CD20-4SCAR-expressing T Lymphocytes|CD20-scFv/CD28/CD137/CD27/CD3z-iCasp9 T-cells|CD20-specific 4th Generation Chimeric Antigen Receptor-modified T Cells	A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a  fourth generation chimeric antigen receptor (4SCAR) consisting of an anti-CD20 single chain variable fragment (scFv) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (TCR), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous CD20-4SCAR-expressing T-cells 4SCAR20 are directed to and induce selective toxicity in CD20-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.			Cell|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148526>	C201493|C200766	Autologous CD123-4SCAR-expressing T-cells 4SCAR123|4S-CD123-CAR-T Cell|4SCAR123|4SCAR123 T-cells|Anti-CD123 CAR-T Cells 4SCAR123|Anti-CD123-CD28-CD137-CD27-CD3z-iCasp9 CAR T-cells 4SCAR123|CD123-4SCAR-expressing T Lymphocytes|CD123-scFv/CD28/CD137/CD27/CD3z-iCasp9 T-cells|CD123-specific 4th Generation Chimeric Antigen Receptor-modified T Cells	A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a  fourth generation chimeric antigen receptor (4SCAR) consisting of an anti-CD123 (interleukin-3 receptor alpha chain or IL3RA) single chain variable fragment (scFv) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (TCR), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon administration, autologous CD123-4SCAR-expressing T-cells 4SCAR123 are directed to and induce selective toxicity in CD123-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with increased leukemic cell proliferation and aggressiveness. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.			Cell|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148527>	C15643	Bilateral Modified Radical Neck Dissection|Functional (Limited) Neck Dissection|Functional (Limited) Neck Dissection|Functional Bilateral Neck Dissection	A surgical procedure in which all the bilateral cervical lymph node groups of the neck are removed but the internal jugular veins, sternocleidomastoid muscles, and/or spinal accessory nerves are preserved.			Therapeutic or Preventive Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C148528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148528>	C129825	mTORC 1/2 Inhibitor LXI-15029|LXI-15029|LXI15029|MTI-31|MTI-31|SCC-31	An orally bioavailable inhibitor of raptor-mammalian target of rapamycin (mTOR) complex 1 (mTOR complex 1; mTORC1) and rictor-mTOR complex 2 (mTOR complex 2; mTORC2), with potential antineoplastic activity. Upon oral administration, mTORC1/2 inhibitor LXI-15029 binds to the kinase domain of mTOR and inhibits both mTORC1 and mTORC2, in an ATP-competitive manner. This inhibits mTOR-mediated signaling and leads to both an induction of apoptosis and a decrease in the proliferation of mTORC1/2-expressing tumor cells. mTOR is a serine/threonine kinase that is upregulated in certain tumor cell types. It plays an important role in the PI3K/Akt/mTOR signaling pathway, which is often deregulated in cancer cells and promotes cell growth, survival, and resistance to chemotherapy and radiotherapy.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148529>	C213472|C129825	Ningetinib Tosylate|CT-053 Tosylate|CT-053-PTSA|CT-053PTSA|NINGETINIB TOSYLATE	The tosylate salt form of ningetinib, an orally available inhibitor of the receptor tyrosine kinases c-MET/hepatocyte growth factor receptor (HGFR), vascular endothelial growth factor receptor 2 (VEGFR2 KDR), Axl (UFO), Mer, and Fms-like tyrosine kinase 3 (Flt3; CD135; STK1; FLK2), with antineoplastic activity. Upon administration, ningetinib binds to a variety of kinases, including c-Met, VEGFR2, Axl, Mer and Flt3, thereby inhibiting their signaling pathways. This inhibits growth, angiogenesis and metastasis of tumor cells that overexpress these kinases. c-Met, VEGFR2, Axl, Mer and Flt3 are overexpressed by many tumor cell types and play key roles in tumor cell proliferation, survival, invasion and metastasis.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148530>	C201495|C200766	CD33-specific CAR Lentiviral Vector-transduced Autologous T-lymphocytes|Autologous Anti-CD33 CAR-T Cells|Autologous Anti-CD33 Chimeric Antigen Receptor T Cells|Autologous CD33-CAR-T Cells	Autologous T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) specific for the CD33 antigen, with potential immunomodulating and antineoplastic activities. Upon transfusion, CD33-specific CAR lentiviral vector-transduced autologous T-lymphocytes target and induce selective toxicity in CD33-expressing tumor cells. CD33 is expressed on normal non-pluripotent hematopoietic stem cells and on myeloid leukemia cells.	CD33-specific CAR Lentiviral Vector-transduced Autologous T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148531>	C61078	Paclitaxel Polymeric Micelle Formulation NANT-008|Cynviloq|Genexol-PM|IG-001|Micellar Nanoparticle-encapsulated NANT-008|NANT 008|NANT-008|NANT008|Nant-paclitaxel|Paclitaxel-loaded Micellar Diblock Copolymer NANT-008|Paclitaxel-loaded Polymeric Micelle NANT-008	A nanoparticle-based formulation consisting of polymeric micelles encapsulating the taxane paclitaxel, with potential antineoplastic activity. Paclitaxel is covalently bound to polyethylene glycol (PEG)-based block copolymers which forms a micellar structure with an outer hydrophilic PEG shell surrounding the hydrophobic paclitaxel. Upon administration of the paclitaxel polymeric micelle formulation NANT-008, the nanoparticles are stable in the bloodstream and specifically accumulate in the tumor tissue. Due to the acidic conditions in the tumor and the pH-responsive nature of the micelles, paclitaxel is released in the tumor environment. Paclitaxel binds to microtubules, promotes microtubule assembly, and prevents depolymerization, thus interfering with normal mitosis. Compared to the administration of paclitaxel alone, this formulation increases the solubility of paclitaxel, enhances its specific retention in cancer tissue, and increases its therapeutic effect, while decreasing its toxicity. In addition, the micellar formulation allows the delivery of higher doses of paclitaxel to target tissues while minimizing systemic toxicity.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148532>	C2152|C129825	Amdizalisib|AMDIZALISIB|HMPL 689|HMPL-689|HMPL689|PI3K-d Inhibitor HMPL 689|PI3K-delta Inhibitor HMPL 689	An orally bioavailable selective inhibitor of the delta isoform of phosphatidylinositide 3-kinase (phosphoinositide 3'-kinase delta; PI3Kd; PI3K-d), with potential antineoplastic activity. Upon oral administration, amdizalisib selectively binds to and inhibits PI3Kd, and prevents the activation of the PI3Kd/AKT signaling pathway, and B-cell activation. This both decreases proliferation and induces cell death in PI3Kd-overexpressing tumor cells. PI3Kd plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of hematologic cancer cells. The targeted inhibition of PI3Kd is designed to preserve PI3K signaling in normal, non-neoplastic cells and thereby to minimize serious side effects. PI3Kd, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.	Amdizalisib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148533>	C141136|C129825	ALK Inhibitor PLB 1003|PLB 1003|PLB-1003|PLB1003	An orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon oral administration, PLB1003 selectively binds to and inhibits wild-type ALK, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to the disruption of ALK-mediated signaling and inhibits tumor cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors. ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148534>	C96404|C1663	Polyinosinic-polycytidylic Acid/Inactivated Rabies Virus Vaccine YS-ON-001|Poly IC/Inactivated RV-V YS-ON-001|YS ON 001|YS-ON-001	A cancer vaccine composed of inactivated rabies vaccine (RV-V) and polyinosinic-polycytidylic acid (poly IC; poly I-C), an immunostimulant and Toll-like receptor 3 (TLR3) agonist, with potential immunostimulating and antineoplastic activities. Upon administration of the poly IC/inactivated RV-V YS-ON-001, the RV-V stimulates the immune system in various ways, such as promoting the activation and proliferation of T helper type 1 (Th1) cells, dendritic cells (DCs), B cells and natural killer cells (NKs), promoting macrophage M1 polarization, downregulating regulatory T-cells (Tregs), and inducing the production of anti-tumor cytokines. This re-activates immune responses in the suppressed tumor microenvironment (TME), leading to an induction of cytotoxic T-lymphocyte (CTL)-mediated immune response against the tumor cells, which cause tumor cell apoptosis and a reduction of tumor cell proliferation. Poly IC, a synthetic double-stranded RNA with one strand composed of a inosinic acid polymer and the other strand a cytidylic acid polymer, binds to TLR3 and stimulates the release of cytotoxic cytokines, such as interferon-gamma (IFNg). This may boost the immune response against the tumor cells.			Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology
C148535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148535>	C129822|C128057	Adebrelimab|ADEBRELIMAB|HTI 1088|HTI-1088|HTI1088|SHR 1316|SHR-1316|SHR1316	An immunoglobulin G4 (IgG4), humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, adebrelimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148536>	C8946	Castration-Naive Prostate Carcinoma|CNPC|Castration-Naive Prostate Cancer	Advanced prostatic carcinoma which was not previously treated with androgen-deprivation therapy.			Neoplastic Process	
C148537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148537>	C143099|C129825	MET Kinase Inhibitor OMO-1|JNJ 38877618|JNJ-38877618|JNJ-38877618|JNJ38877618|OMO-1|OMO1	An inhibitor of the proto-oncogene and receptor tyrosine kinase (RTK) hepatocyte growth factor receptor (c-Met; HGFR; MET) with potential antineoplastic activity. Upon administration, OMO-1 selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148538>	C471	Elcubragistat|ABX-1431|ABX1431|ELCUBRAGISTAT|MGLL Inhibitor ABX-1431|Serine Hydrolase Monoacylglycerol Lipase Inhibitor ABX-1431	An orally bioavailable inhibitor of the serine hydrolase monoacylglycerol lipase (MGLL), with potential use for the treatment of various central nervous system (CNS) diseases and with potential analgesic and anti-neuroinflammatory activities. Upon oral administration, elcubragistat targets and binds to MGLL, thereby inhibiting MGLL activity and preventing the breakdown and inactivation of endogenous 2-arachidonoylglycerol (2-AG). Increased 2-AG levels results in enhanced activation of the cannabinoid receptor 1 (CB1) in the CNS and enhanced CB1 endocannabinoid signaling in active neural circuits. Activation of CB1 helps modulate the endocannabinoid system and reduce neurotransmitter release, thereby decreasing overactive neural signaling. This induces analgesic, anti-inflammatory and various neurological effects that are caused by dysregulation of the endocannabinoid system and overactive neural signaling, including anxiolytic effects, reduced spasticity and decreased neurodegenerative effects. In addition, MGLL inhibition by elcubragistat depletes the supply of the inflammatory signaling molecule arachidonic acid, thereby further alleviating pain and inflammation. CB1 plays a key role in the regulation of neurotransmission; increased CB1 activation decreases overactive neural signaling. MGLL, an enzyme that catalyzes the breakdown of 2-AG, regulates the activation of CB1 and CB2 to modulate neurotransmission and inflammatory signaling, respectively.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C148539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148539>	C1951|C1663	HPV E6/E7-encoding Semliki Forest Virus Vaccine Vvax001|HPV E6/7 Semliki Forest Virus Based Cancer Vaccine|SFVeE6,7|Vvax-001|Vvax001|Vvax001 Therapeutic Cancer Vaccine|rSFVeE6,7	A vaccine consisting of a recombinant, attenuated, replication-incompetent form of the Semliki Forest Virus (SFV) vector encoding the viral oncoproteins E6 and E7 derived from the human papillomavirus (HPV), with potential immunomodulating and antineoplastic activities. Upon intramuscular administration, HPV E6/E7-encoding SFV vaccine Vvax001 induces expression of the E6/E7 proteins and stimulates both the innate and the adaptive immune system, resulting in a potent cytotoxic T-lymphocyte (CTL) response against and lysis of tumor cells expressing HPV E6 and E7. Oncoproteins E6 and E7 play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.			Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology
C148540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148540>	C117719	Castration-Naive	A finding indicating that an advanced prostate carcinoma was not previously treated with androgen-deprivation therapy.			Finding	
C148541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148541>	C308	Triclosan/Copolymer/Fluoride Toothpaste|Triclosan/Copolymer/Fluoride Dentifrice	A fluoride-based toothpaste containing the anti-inflammatory and broad-spectrum antibacterial agent triclosan and polyvinylmethyl ether maleic acid copolymer (PVM/MA), with potential antibacterial, anti-inflammatory, and protective activities. Upon application of the triclosan/copolymer/fluoride toothpaste to the teeth, the toothpaste helps remove plaque accumulation. The fluoride protects the teeth against cavities while the triclosan prevents inflammation and may protect against gingivitis and mucositis. The copolymer in the toothpaste enhances the uptake of triclosan by enamel and buccal epithelial cells, thereby prolonging its protective effect and enhancing its activity.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C148542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148542>	C210674	Magnesium-rich Mineral Water|Rozana	Carbonated, iron-depleted mineral water from the French springs of Beauregard-Vendon (Rouzat) containing very high amounts of the mineral magnesium as well as sodium, calcium, potassium, bicarbonate, sulfate, chloride and nitrate, that can be used for supplemental purposes and can potentially be used to treat hypomagnesemia. Magnesium, an electrolyte, plays a key role as a cofactor in multiple enzymatic reactions and for muscle and nervous system functioning. Hypomagnesemia may manifest as asthenia, cramps, muscle weakness, fatigue, and mood disorders.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C148543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148543>	C28676|C129826	Anti-CD3/MUC1 Antibody-armed PD-1 Inhibitor-induced Cytokine-induced Killer Cells|Anti-CD3/MUC1-armed PD-1 Inhibitor-induced CIK Cells|PD-1 Activated CIK Armed With Anti-CD3/Anti-MUC1 Bispecific Antibody	A preparation of cytokine-induced killer cells (CIKs), which have been exposed, ex vivo, to a specific set of cytokines and a programmed cell death protein 1 (PD-1) inhibitor, mixed with a bispecific anti-cluster of differentiation 3 (CD3)/anti-mucin-1 (MUC1) antibody, with potential anti-tumor cytotoxic activity. Upon administration of the anti-CD3/MUC1 antibody-armed PD-1 inhibitor-induced CIKs, the antibody moiety binds to both CD3 on the CIKs and MUC1 on cancer cells. This crosslinks the CIKs and tumor cells, which allows the CIKs to target and lyse MUC1-expressing cancer cells. PD-1 blockade activates the CIKs. The cytokines used, usually interferon-gamma (IFNg), interleukin 1 (IL-1), and IL-2, stimulate the proliferation and maturation of peripheral blood mononuclear cells (PBMCs) into CIK cells. Anti-CD3 stimulation allows for the CIKs' improved lytic activity.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148544>	C35880|C131063	CD5-Positive Blast Cells Greater than 50 Percent|>50% CD5 Positive Blasts|>50% CD5-Positive Blasts|CD5 Positive Blast Cells Greater than 50 Percent|Greater than 50 Percent CD5 Positive Blasts|Greater than 50 Percent CD5-Positive Blasts|Greater than 50% CD5 Positive Blasts|Greater than 50% CD5-Positive Blasts	A semi-quantitative microscopic finding indicating that more than 50% of the immature blood cells in a sample express CD5.	CD5-Positive Blast Cells Greater than 50 Percent		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148545>	C205055	Cytomegalovirus Reactivation Finding|CMV Reactivation|Cytomegalovirus Reactivation	A laboratory test result indicating that a previously latent cytomegalovirus infection has become an active infection.	Cytomegalovirus Reactivation		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C148546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148546>	C47793	Ivabradine Hydrochloride|(7,8-Dimethoxy 3-(3-(((1S)-(4,5-dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-2H-benzazepin-2-one Hydrochloride|2H-3-Benzazepin-2-one, 3-(3-((((7S)-3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-, Monohydrochloride|Corlanor|IVABRADINE HYDROCHLORIDE|Ivabradine HCl	The hydrochloride salt form of ivabradine, an orally bioavailable, hyperpolarization-activated, cyclic nucleotide-gated (HCN) channel blocker, with negative chronotropic activity. Upon administration, ivabradine selectively binds to the intracellular portion of the HCN channel pore and blocks HCN channels in the pacemaker cells within the sinoatrial (SA) node. This inhibits the If (funny) pacemaker ion current, prevents the inward flow and intracellular accumulation of positively charged ions, reduces pacemaker activity and slows diastolic depolarization. This decreases heart rate, reduces myocardial oxygen demand and allows more time for blood to flow to the myocardium without affecting cardiac contractility. HCN channels, mixed sodium (Na+) and potassium (K+) channels that carry the inward If current, play a key role in the regulation of pacemaker firing rate in the SA node. The If pacemaker current, the inward flow of positively charged Na+-K+ ions, initiates the spontaneous diastolic depolarization phase and modulating heart rate.	Ivabradine Hydrochloride		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C148547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148547>	C69039	Ophthalmic Powder Dosage Form				Biomedical or Dental Material	
C148548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148548>	C150386	Radiopharmaceutical Dosage Form Category|Radiopharmaceutical	A type of specialized pharmaceutical dose form that is used in the preparation of radiopharmaceuticals.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C148549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148549>	C154551	Solvent Dosage Form Category|Solvent	A type of liquid pharmaceutical dose form consisting of a vehicle that contains no active ingredient itself, and is used to dissolve, disperse or dilute another product.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C148550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148550>	C148399	Beehive Dispersion Dosage Form|Bee-hive dispersion	Liquid preparation intended for in-hive use, consisting of two or more phases, at least one of which is dispersed in the liquid phase, from which the active substance(s) are released by vaporization or physical contact usually over an extended period of time. The precise method of administration of the dispersion is described in the product information.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C148551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148551>	C42938	Coated Granules Dosage Form|Coated granules|GRANULE, COATED	A granule whose outer shell is covered with a substance.			Biomedical or Dental Material	CDISC SDTM Dosage Form Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C148552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148552>	C171282	Lyophilized Dosage Form Category|Lyophilisate	A type of solid pharmaceutical dose form consisting of a powder or disc formed by freeze-drying of a liquid or semi-solid preparation. When referring to a powder, the use of this term is restricted to veterinary medicines.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C148553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148553>	C38617	Parotid Bed	The structures that surround and contact the parotid gland, forming the boundaries of the parotid space.			Body Part, Organ, or Organ Component	
C148554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148554>	C21295	OSBPL10 Gene|OSBPL10|OSBPL10|Oxysterol Binding Protein Like 10 Gene	This gene plays a role in binding to cholesterol and acidic phospholipids.			Gene or Genome	
C148555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148555>	C148554	OSBPL10 wt Allele|ORP10|OSBP9|Oxysterol Binding Protein Like 10 wt Allele	Human OSBPL10 wild-type allele is located in the vicinity of 3p23 and is approximately 420 kb in length. This allele, which encodes oxysterol-binding protein-related protein 10, is involved in sterol binding and phospholipid transport.			Gene or Genome	
C148556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148556>	C17728	Oxysterol-Binding Protein-Related Protein 10|ORP-10|OSBP-Related Protein 10|OSBPL10|Oxysterol Binding Protein-Like 10|Oxysterol-Binding Protein-Like Protein 10	Oxysterol-binding protein-related protein 10 (764 aa, ~84 kDa) is encoded by the human OSBPL10 gene. This protein plays a role in subcellular phospholipid localization and cholesterol binding.			Amino Acid, Peptide, or Protein	
C148557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148557>	C28681|C129826	Therapeutic Invariant Natural Killer T-cells|Therapeutic Invariant NK T-cells|Therapeutic iNK T-cells|Therapeutic iNKT Cells|Therapeutic iNKTs	A preparation of natural killer T-cells (NKTs) expressing an invariant (alpha, beta) T-cell receptor (iNKTs), with potential immunomodulating and antineoplastic activities. Upon infusion of the therapeutic iNKTs, these cells recognize CD1d-restricted lipid ligands, which are expressed on certain tumor cells, and secrete large amounts of various cytokines. This may activate the immune system against tumor cells. Additionally, iNKTs directly target and lyse tumor cells.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148558>	C91105	Components of Primary Care Instrument|CPCI|Components of Primary Care Instrument (CPCI)	A questionnaire designed to measure key aspects of the delivery of primary care from the perspective of patients visiting their family physician, and to report the association of these aspects with patient satisfaction.			Intellectual Product	
C148559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148559>	C173145	Go to This Doctor for Almost All Medical Care Question|Go to This Doctor for Almost All Medical Care|I go to this doctor for almost all of my medical care	A question about whether an individual sees a particular doctor for almost all of their medical care.			Intellectual Product	Components of Primary Care Instrument
C148560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148560>	C173145	This Doctor Handles Emergencies Question|This Doctor Handles Emergencies|This doctor handles emergencies	A question about whether an individual's doctor handles emergencies.			Intellectual Product	Components of Primary Care Instrument
C148561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148561>	C173145	This Doctor Can Take Care of Almost Any Medical Problem I Might Have Question|This Doctor Can Take Care of Almost Any Medical Problem I Might Have|This doctor can take care of almost any medical problem I might have	A question about whether an individual's doctor can take care of almost any problem the individual might have.			Intellectual Product	Components of Primary Care Instrument
C148562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148562>	C173145	I Could Go to This Doctor for Help with Personal or Emotional Problem Question|I Could Go to This Doctor for Help with Personal or Emotional Problem|I could go to this doctor for help with a personal or emotional problem	A question about whether an individual could see a particular doctor for help with a personal or emotional problem.			Intellectual Product	Components of Primary Care Instrument
C148563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148563>	C173145	I Could Go to This Doctor for Care of Ongoing Problem Question|I Could Go to This Doctor for Care of Ongoing Problem|I could go to this doctor for care of an ongoing problem such as high blood pressure	A question about whether an individual could see a particular doctor for an ongoing problem.			Intellectual Product	Components of Primary Care Instrument
C148564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148564>	C173145	This Doctor Knows a Lot About My Family Medical History Question|This Doctor Knows a Lot About My Family Medical History|This doctor knows a lot about my family medical history	A question about whether an individual's doctor knows a lot about the individual's family medical history.			Intellectual Product	Components of Primary Care Instrument
C148565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148565>	C173145	This Doctor Clearly Understands My Health Needs Question|This Doctor Clearly Understands My Health Needs|This doctor clearly understands my health needs	A question about whether an individual's doctor understands the individual's health needs.			Intellectual Product	Components of Primary Care Instrument
C148566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148566>	C173145	This Doctor and I Have Been Through a Lot Together Question|This Doctor and I Have Been Through a Lot Together|This doctor and I have been through a lot together	A question about whether an individual has been through a lot with their doctor.			Intellectual Product	Components of Primary Care Instrument
C148567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148567>	C173145	This Doctor Understands What is Important to Me Regarding My Health Question|This Doctor Understands What is Important to Me Regarding My Health|This doctor understands what is important to me regarding my health	A question about whether an individual's doctor understands what is important to the individual regarding their health.			Intellectual Product	Components of Primary Care Instrument
C148568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148568>	C173145	This Doctor Does Not Know My Medical History Very Well Question|This Doctor Does Not Know My Medical History Very Well|This doctor does not know my medical history very well	A question about whether an individual's doctor doesn't know the individual's medical history well.			Intellectual Product	Components of Primary Care Instrument
C148569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148569>	C173145	I Could Go to This Doctor for Check-Up to Prevent Illness Question|I Could Go to This Doctor for Check-Up to Prevent Illness|I could go to this doctor for a check-up to prevent illness	A question about whether an individual could see a particular doctor for checkups to prevent illness.			Intellectual Product	Components of Primary Care Instrument
C148570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148570>	C173145	This Doctor Always Takes My Beliefs and Wishes into Account in Caring for Me Question|This Doctor Always Takes My Beliefs and Wishes into Account in Caring for Me|This doctor always takes my beliefs and wishes into account in caring for me	A question about whether an individual's doctor takes the individual's beliefs and wishes into account in caring for them.			Intellectual Product	Components of Primary Care Instrument
C148571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148571>	C173703|C173145	This Doctor Knows Whether I Exercise, Eat Right, Smoke, or Drink Alcohol Question|This Doctor Knows Whether I Exercise, Eat Right, Smoke, or Drink Alcohol|This doctor knows whether or not I exercise, eat right, smoke, or drink alcohol	A question about whether an individual's doctor knows whether the individual exercises, eats right, smokes, or drinks alcohol.			Intellectual Product	Components of Primary Care Instrument
C148572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148572>	C25790	MPEG1 Gene|MPEG1|MPEG1|Macrophage Expressed 1 Gene	This gene may be involved in antimicrobial activity.			Gene or Genome	
C148573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148573>	C148572	MPEG1 wt Allele|MPG1|MPS1|Macrophage Expressed 1 wt Allele|Macrophage Expressed Gene 1|Mpg-1	Human MPEG1 wild-type allele is located in the vicinity of 11q12.1 and is approximately 5 kb in length. This allele, which encodes macrophage-expressed gene 1 protein, may play a role in perforin-like activity.			Gene or Genome	
C148574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148574>	C16725	Macrophage-Expressed Gene 1 Protein|MPEG1|Macrophage Gene 1 Protein|Mpg-1|Perforin 2|Perforin-2	Macrophage-expressed gene 1 protein (716 aa, ~79 kDa) is encoded by the human MPEG1 gene. This protein may be involved in host defense.			Immunologic Factor	
C148575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148575>	C173145	This Doctor Knows Me Well as a Person Question|This Doctor Knows Me Well as a Person|This doctor knows me well as a person (such as my hobbies, job, etc.)	A question about whether an individual's doctor knows the individual well as a person.			Intellectual Product	Components of Primary Care Instrument
C148576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148576>	C135578	I Can Easily Talk About Personal Things with This Doctor Question|I Can Easily Talk About Personal Things with This Doctor|I can easily talk about personal things with this doctor	A question about whether an individual could talk about personal things with their doctor.			Intellectual Product	Components of Primary Care Instrument
C148577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148577>	C135578	Sometimes This Doctor Does Not Listen to Me Question|Sometimes This Doctor Does Not Listen to Me|Sometimes, this doctor does not listen to me	A question about whether an individual's doctor sometimes does not listen to them.			Intellectual Product	Components of Primary Care Instrument
C148578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148578>	C173792|C173145	This Doctor Always Explains Things to My Satisfaction Question|This Doctor Always Explains Things to My Satisfaction|This doctor always explains things to my satisfaction	A question about whether an individual's doctor always explains things to the individual's satisfaction.			Intellectual Product	Components of Primary Care Instrument
C148579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148579>	C173934|C135578	Sometimes with This Doctor I Don't Bring Up Things That I'm Worried About Question|Sometimes with This Doctor I Don't Bring Up Things That I'm Worried About|Sometimes, with this doctor, I don't bring up things that I'm worried about	A question about whether an individual sometimes does not bring up things they are worried about with their doctor.			Intellectual Product	Components of Primary Care Instrument
C148580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148580>	C25871	ITPKB Gene|ITPKB|ITPKB|Inositol-Trisphosphate 3-Kinase B Gene	This gene plays a role in the phosphorylation of inositol trisphosphate (IP3).			Gene or Genome	
C148581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148581>	C135578	I Don't Always Feel Comfortable Asking Questions of This Doctor Question|I Don't Always Feel Comfortable Asking Questions of This Doctor|I don't always feel comfortable asking questions of this doctor	A question about whether an individual does not always feel comfortable asking questions of their doctor.			Intellectual Product	Components of Primary Care Instrument
C148582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148582>	C148580	ITPKB wt Allele|IP3-3KB|IP3K|IP3K-B|IP3KB|Inositol-Trisphosphate 3-Kinase B wt Allele|PIG37	Human ITPKB wild-type allele is located in the vicinity of 1q42.12 and is approximately 108 kb in length. This allele, which encodes inositol-trisphosphate 3-kinase B protein, is involved in second messenger metabolism.			Gene or Genome	
C148583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148583>	C173160|C173145	Sometimes I Feel Like This Doctor Ignores My Concerns Question|Sometimes I Feel Like This Doctor Ignores My Concerns|Sometimes, I feel like this doctor ignores my concerns	A question about whether an individual sometimes feels that their doctor ignores the individual's concerns.			Intellectual Product	Components of Primary Care Instrument
C148584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148584>	C173145	If I am Sick I Would Always Contact a Doctor in This Office First Question|If I am Sick I Would Always Contact a Doctor in This Office First|If I am sick, I would always contact a doctor in this office first	A question about whether an individual would contact a doctor in a particular office first when sick.			Intellectual Product	Components of Primary Care Instrument
C148585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148585>	C176545|C173145	My Medical Care Improves When I See the Same Doctor that I Have Seen Before Question|My Medical Care Improves When I See the Same Doctor that I Have Seen Before|My medical care improves when I see the same doctor that I have seen before	A question about whether an individual feels that their medical care improves when they see the same doctor that they have seen before.			Intellectual Product	Components of Primary Care Instrument
C148586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148586>	C16984	Inositol-Trisphosphate 3-Kinase B|EC 2.7.1.127|IP3 3-Kinase B|IP3K B|ITPKB|Inositol 1,4,5-Trisphosphate 3-Kinase B|InsP 3 Kinase B|InsP 3-Kinase B|Proliferation-Inducing Protein 37	Inositol-trisphosphate 3-kinase B (946 aa, ~102 kDa) is encoded by the human ITPKB gene. This protein plays a role in the conversion of inositol trisphosphate (IP3) to inositol tetrakisphosphate (IP4).			Amino Acid, Peptide, or Protein|Enzyme	
C148587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148587>	C173145	It is Very Important to Me to See My Regular Doctor Question|It is Very Important to Me to See My Regular Doctor|It is very important to me to see my regular doctor	A question about whether it is very important for an individual to see the same doctor that they have seen before.			Intellectual Product	Components of Primary Care Instrument
C148588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148588>	C176545|C173145	I Rarely See the Same Doctor When I Go for Medical Care Question|I Rarely See the Same Doctor When I Go for Medical Care|I rarely see the same doctor when I go for medical care	A question about whether an individual rarely sees the same doctor then they go for medical care.			Intellectual Product	Components of Primary Care Instrument
C148589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148589>	C135578	I Can Call This Doctor if I Have Concern and am Not Sure I Need to See a Doctor Question|I Can Call This Doctor if I Have Concern and am Not Sure I Need to See a Doctor|I can call this doctor if I have a concern and am not sure I need to see a doctor	A question about whether an individual can call a particular doctor if they have a concern and are not sure they need to see a doctor.			Intellectual Product	Components of Primary Care Instrument
C148590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148590>	C173145	I Have Tremendous Trust in This Doctor Question|I Have Tremendous Trust in This Doctor|I have tremendous trust in this doctor	A question about whether an individual has tremendous trust in a particular doctor.			Intellectual Product	Components of Primary Care Instrument
C148591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148591>	C173145	This Doctor Knows When I'm Due for Checkup Question|This Doctor Knows When I'm Due for Checkup|This doctor knows when I'm due for a checkup	A question about whether an individual's doctor knows when the individual is due for a checkup.			Intellectual Product	Components of Primary Care Instrument
C148592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148592>	C176545|C173145	I Want One Doctor to Coordinate All of the Health Care I Receive Question|I Want One Doctor to Coordinate All of the Health Care I Receive|I want one doctor to coordinate all of the health care I receive	A question about whether an individual wants one doctor to coordinate all of the individual's health care.			Intellectual Product	Components of Primary Care Instrument
C148593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148593>	C176545|C173145	This Doctor Keeps Track of All My Health Care Question|This Doctor Keeps Track of All My Health Care|This doctor keeps track of all my health care	A question about whether an individual's doctor tracks all of the individual's health care.			Intellectual Product	Components of Primary Care Instrument
C148594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148594>	C91102	Follows Up on a Problem I've Had Either at the Next Visit or By Phone Question|Follows Up on a Problem I've Had Either at the Next Visit or By Phone|This doctor always follows up on a problem I've had, either at the next visit or by phone	A question about whether an individual's doctor always follows up on the individual's problem on the phone or at the next visit.			Intellectual Product	Components of Primary Care Instrument
C148595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148595>	C25954	ZC3H12A Gene|ZC3H12A|ZC3H12A|Zinc Finger CCCH-Type Containing 12A Gene	This gene is involved in ribonuclease activity and transcriptional regulation.			Gene or Genome	
C148596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148596>	C173145	I Would Recommend This Doctor to Friends and Family Question|I Would Recommend This Doctor to Friends and Family|I would recommend this doctor to friends and family	A question about whether an individual would recommend their doctor to friends and family.			Intellectual Product	Components of Primary Care Instrument
C148597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148597>	C173145	This Doctor Always Has My Best Interests at Heart Question|This Doctor Always Has My Best Interests at Heart|This doctor always has my best interests at heart	A question about whether an individual's doctor always has the individual's best interests at heart.			Intellectual Product	Components of Primary Care Instrument
C148598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148598>	C176545|C173145	This Doctor Takes Responsibility for Helping Me Get All the Health Care I Need Question|This Doctor Takes Responsibility for Helping Me Get All the Health Care I Need|This doctor takes responsibility for helping me get all the health care I need	A question about whether an individual's doctor takes responsibility for helping the individual get all the health care they need.			Intellectual Product	Components of Primary Care Instrument
C148599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148599>	C173145|C173086	I am Confident This Doctor Will Act as My Advocate Question|I am Confident This Doctor Will Act as My Advocate|I am confident this doctor will act as my advocate	A question about whether an individual is confident that their doctor will act as the individual's health advocate.			Intellectual Product	Components of Primary Care Instrument
C1485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1485>	C2843	Rubitecan|9-NC|9-Nitro-20(S)-camptothecin|9-nitrocamptothecin|Camptogen|Nitrocamptothecin|Orathecin|RFS 2000|RUBITECAN|nitrocamptothecin	A semisynthetic agent related to camptothecin with potent antitumor and antiviral properties.  Rubitecan binds to and inhibits the enzyme topoisomerase I and induces protein-linked DNA single-strand breaks, thereby blocking DNA and RNA synthesis in dividing cells; this agent also prevents repair of reversible single-strand DNA breaks. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148600>	C148595	ZC3H12A wt Allele|FLJ23231|MCPIP|MCPIP-1|MCPIP1|Reg1|Zinc Finger CCCH-Type Containing 12A wt Allele|dJ423B22.1	Human ZC3H12A wild-type allele is located in the vicinity of 1p34.3 and is approximately 11 kb in length. This allele, which encodes endoribonuclease ZC3H12A protein, plays a role in transcription regulation and RNA metabolism.			Gene or Genome	
C148601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148601>	C173145	This Doctor Looks Out for My Interests in Dealing with My Health Insurance Question|This Doctor Looks Out for My Interests in Dealing with My Health Insurance|This doctor looks out for my interests in dealing with my health insurance	A question about whether an individual's doctor looks out for the individual's interests in dealing with their health insurer.			Intellectual Product	Components of Primary Care Instrument
C148602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148602>	C176545|C173145	I Wonder if This Doctor is Cutting Corners on My Health Care Question|I Wonder if This Doctor is Cutting Corners on My Health Care|I wonder if this doctor is cutting corners on my health care	A question about whether an individual wonders if their doctor is cutting corners on the individual's health care.			Intellectual Product	Components of Primary Care Instrument
C148603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148603>	C25959	Endoribonuclease ZC3H12A|Bifunctional Endoribonuclease and Deubiquitinase ZC3H12A|EC 3.1.-.-|MCP Induced Protein 1|MCP-1 Treatment-Induced Protein|MCP-Induced Protein 1|MCP1-Induced Protein|MCPIP-1|Monocyte Chemotactic Protein-Induced Protein 1|Reg1|Regnase 1|Regnase-1|Ribonuclease ZC3H12A|ZC3H12A|Zinc Finger CCCH Domain-Containing Protein 12A	Endoribonuclease ZC3H12A (599 aa, ~66 kDa) is encoded by the human ZC3H12A gene. This protein is involved in the modulation of both RNA metabolism and transcription.			Amino Acid, Peptide, or Protein|Enzyme	
C148604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148604>	C174127|C173145	This Doctor Helps Me Weigh the Pros and Cons of My Health Care Decisions Question|This Doctor Helps Me Weigh the Pros and Cons of My Health Care Decisions|This doctor helps me weigh the pros and cons of my health care decisions	A question about whether an individual's doctor helps the individual to weight the pros and cons of their health care decisions.			Intellectual Product	Components of Primary Care Instrument
C148605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148605>	C173145	This Doctor Guides Me Through the Steps I Need to Deal with My Insurance Plan Question|This Doctor Guides Me Through the Steps I Need to Deal with My Insurance Plan|This doctor guides me through the steps I need to take to deal with my insurance plan	A question about whether an individual's doctor guides the individual through the steps needed to deal with the individual's insurance plan.			Intellectual Product	Components of Primary Care Instrument
C148606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148606>	C173145	Other Members of My Family See This Doctor Question|Other Members of My Family See This Doctor|Other members of my family see this doctor	A question about whether members of an individual's family see the same doctor.			Intellectual Product	Components of Primary Care Instrument
C148607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148607>	C173145	This Doctor Knows a Lot About My Family Question|This Doctor Knows a Lot About My Family|This doctor knows a lot about my family	A question about whether an individual's doctor knows a lot about the individual's family.			Intellectual Product	Components of Primary Care Instrument
C148608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148608>	C173145	This Doctor Understands How My Family Affects My Health Question|This Doctor Understands How My Family Affects My Health|This doctor understands how my family affects my health	A question about if a doctor understands how an individual's family affects the individual's health.			Intellectual Product	Components of Primary Care Instrument
C148609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148609>	C173145	This Doctor Knows a Lot About My Community Question|This Doctor Knows a Lot About My Community|This doctor knows a lot about my community	A question about whether an individual's doctor knows a lot about the individual's community.			Intellectual Product	Components of Primary Care Instrument
C148610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148610>	C173145	This Doctor Uses Knowledge of My Community to Take Care of Me Question|This Doctor Uses Knowledge of My Community to Take Care of Me|This doctor uses her/his knowledge of my community to take care of me	A question about whether an individual's doctor uses their knowledge about the individual's community to take care of the individual..			Intellectual Product	Components of Primary Care Instrument
C148611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148611>	C176545|C173145	This Doctor Always Follows Up on My Visits to Other Health Care Providers Question|This Doctor Always Follows Up on My Visits to Other Health Care Providers|This doctor always follows up on my visits to other health care providers	A question about whether an individual's doctor always follows up on the individual's visits to other health care providers.			Intellectual Product	Components of Primary Care Instrument
C148612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148612>	C173145	This Doctor Helps Me Interpret My Lab Tests, X-Rays, or Visits to Other Doctors Question|This Doctor Helps Me Interpret My Lab Tests, X-Rays, or Visits to Other Doctors|This doctor helps me interpret my lab tests, x-rays or visits to other doctors	A question about whether an individual's doctor helps the individual's to interpret lab results, x-rays, or visits to other health care providers.			Intellectual Product	Components of Primary Care Instrument
C148613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148613>	C173145	This Doctor Communicates with the Other Health Providers I See Question|This Doctor Communicates with the Other Health Providers I See|This doctor communicates with the other health providers I see	A question about whether an individual's doctor communicates with the individual's other health care providers.			Intellectual Product	Components of Primary Care Instrument
C148614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148614>	C173145	This Doctor Does Not Always Know About Care I Have Received at Other Places Question|This Doctor Does Not Always Know About Care I Have Received at Other Places|This doctor does not always know about care I have received at other places	A question about whether an individual's doctor does not always know about the care the individual received from other health care providers.			Intellectual Product	Components of Primary Care Instrument
C148615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148615>	C173145	How Long Been a Patient of This Doctor Question|Have you been a patient of this doctor|How Long Been a Patient of This Doctor	A question about how long an individual has been a patient of a specific doctor.			Intellectual Product	Components of Primary Care Instrument
C148616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148616>	C91102	How Long Been a Patient of This Practice Question|Have you been a patient of this practice|How Long Been a Patient of This Practice	A question about how long an individual has been a patient of a specific medical practice.			Intellectual Product	Components of Primary Care Instrument
C148617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148617>	C20194	PCNX2 Gene|PCNX2|PCNX2|Pecanex Homolog 2 Gene	This gene may play a role in Notch signaling, cell cycle regulation and tumorigenesis.			Gene or Genome	
C148618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148618>	C91102	Number of Visits to This Doctor Question|Number of Visits to This Doctor|Visits have you had to this doctor	A question about the number of times an individual has been to a specific doctor.			Intellectual Product	Components of Primary Care Instrument
C148619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148619>	C148617	PCNX2 wt Allele|FLJ11383|KIAA0435|PCNXL2|Pecanex Homolog 2 (Drosophila) Gene|Pecanex Homolog 2 wt Allele|Pecanex, Drosophila, Homolog of, 2 Gene|Pecanex-Like 2 (Drosophila) Gene	Human PCNX2 wild-type allele is located in the vicinity of 1q42.2 and is approximately 312 kb in length. This allele, which encodes pecanex-like protein 2, may be involved in cell cycle regulation and tumorigenesis. Mutation of the gene is associated with colorectal carcinomas.			Gene or Genome	
C148620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148620>	C173145	Number of Visits to Other Doctors in This Office Question|Number of Visits to Other Doctors in This Office|Visits have you had to other doctors in this office	A question about how many visits an individual has had with other doctors at a specific medical office.			Intellectual Product	Components of Primary Care Instrument
C148621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148621>	C173145	Number of Visits to Doctors Outside of This Office Question|Number of Visits to Doctors Outside of This Office|Visits have you had to doctors outside of this office|Visits to Doctors Outside of This Office	A question about how many visits an individual has had with other doctors outside of a specific medical office.			Intellectual Product	Components of Primary Care Instrument
C148622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148622>	C18466	Pecanex-Like Protein 2|PCNX2|Pecanex Homolog Protein 2	Pecanex-like protein 2 (2137 aa, ~237 kDa) is encoded by the human PCNX2 gene. This protein may play a role in tumorigenesis, Notch signaling and cell cycle regulation.			Amino Acid, Peptide, or Protein	
C148623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148623>	C217121	Agreement Rating Scale|6 Point Agreement Scale	A subjective scale for the scoring of agreement that ranges from 1: Strongly Disagree to 6: Strongly Agree.			Intellectual Product	Components of Primary Care Instrument
C148624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148624>	C221053	Agreement Rating Score 1	A subjective score of 1 on a scale that ranges from 1: Strongly Disagree to 6: Strongly Agree.			Intellectual Product	Components of Primary Care Instrument
C148625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148625>	C221053	Agreement Rating Score 2	A subjective score of 2 on a scale that ranges from 1: Strongly Disagree to 6: Strongly Agree.			Intellectual Product	
C148626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148626>	C25939	GRHPR Gene|GRHPR|GRHPR|Glyoxylate and Hydroxypyruvate Reductase Gene	This gene is involved in the metabolism of glyoxylate and hydroxypyruvate.			Gene or Genome	
C148627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148627>	C221053	Agreement Rating Score 3	A subjective score of 3 on a scale that ranges from 1: Strongly Disagree to 6: Strongly Agree.			Intellectual Product	Components of Primary Care Instrument
C148628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148628>	C221053	Agreement Rating Score 4	A subjective score of 4 on a scale that ranges from 1: Strongly Disagree to 6: Strongly Agree.			Intellectual Product	Components of Primary Care Instrument
C148629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148629>	C148626	GRHPR wt Allele|GLXR|GLYD|Glycerate-2-Dehydrogenase Gene|Glyoxylate and Hydroxypyruvate Reductase wt Allele|MSTP035|PH2|Primary Hyperoxaluria Type 2 Gene	Human GRHPR wild-type allele is located in the vicinity of 9p13.2 and is approximately 14 kb in length. This allele, which encodes glyoxylate reductase/hydroxypyruvate reductase protein, plays a role in hydroxypyruvate and glyoxylate metabolism. Mutation of the gene is associated with type II primary hyperoxaluria.			Gene or Genome	
C148630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148630>	C221053	Agreement Rating Score 5	A subjective score of 5 on a scale that ranges from 1: Strongly Disagree to 6: Strongly Agree.			Intellectual Product	Components of Primary Care Instrument
C148631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148631>	C221053	Agreement Rating Score 6	A subjective score of 6 on a scale that ranges from 1: Strongly Disagree to 6: Strongly Agree.			Intellectual Product	Components of Primary Care Instrument
C148632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148632>	C16946	Glyoxylate Reductase/Hydroxypyruvate Reductase|EC 1.1.1.79|EC 1.1.1.81|GRHPR|Glyoxylate Reductase and Hydroxypyruvate Reductase	Glyoxylate reductase/hydroxypyruvate reductase (328 aa, ~36 kDa) is encoded by the human GRHPR gene. This protein is involved in the metabolism of hydroxypyruvate and glyoxylate.			Amino Acid, Peptide, or Protein|Enzyme	
C148633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148633>	C50713	Acute Pulmonary Embolism	An acute embolism to the pulmonary vasculature.			Finding	
C148634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148634>	C148633	Acute Submassive Pulmonary Embolism	Acute pulmonary embolism with evidence of right ventricular dysfunction, but not associated with systemic hypotension.			Finding	
C148635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148635>	C61078	PEOX-based Polymer Encapsulated Paclitaxel FID-007|FID 007|FID-007|FID007|Nanoencapsulated Paclitaxel FID-007|Paclitaxel in Polyethyloxazoline Polymer	A nanoparticle-based formulation composed of the poorly water-soluble paclitaxel encapsulated within branched polymers composed of polyethyloxazoline (PEOX), with potential antineoplastic activity. Upon injection of the PEOX-based polymer encapsulated paclitaxel FID-007, the nanoparticles accumulate at the tumor site, due to the unique characteristics of the tumor vasculature, while avoiding normal, healthy tissue. Once the paclitaxel is released, it binds to tubulin inside tumor cells and inhibits the disassembly-assembly dynamics of microtubules, resulting in cell cycle arrest and cell death. Compared to the administration of paclitaxel alone, this formulation increases paclitaxel's solubility and enhances its tumor tissue penetration and efficacy, while avoiding systemic exposure, which minimizes its toxicity.	PEOX-based Polymer Encapsulated Paclitaxel FID-007		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C148636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148636>	C54443	EDQM Health Care Terminology|EDQM HC|EDQM HealthCare Controlled Vocabularies|European Directorate for the Quality of Medicines and HealthCare Controlled Vocabularies	A terminology developed by the European Directorate for the Quality of Medicines and HealthCare to provide the basis for global harmonization of pharmaceutical products in marketing authorization applications, labelling, and electronic communications in pharmacovigilance and adverse reporting. For more information, please visit: https://standardterms.edqm.eu			Intellectual Product	
C148637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148637>	C263	TAFIa Inhibitor DS-1040b|(2S)-5-amino-2-[[1-(4-methylcyclohexyl)imidazol-4-yl]methyl]pentanoic Acid|CPB2 Inhibitor DS-1040b|Carboxypeptidase B2 Inhibitor DS-1040b|Carboxypeptidase U Inhibitor DS-1040b|DS 1040|DS-1040|DS-1040|DS-1040b|DS1040|Inhibitor of Activated Thrombin Activatable Fibrinolysis Inhibitor DS-1040b	An inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa; carboxypeptidase B2; CPB2), with potential fibrinolytic activity. Upon DS-1040 infusion, this agent binds to and inhibits TAFIa. This abrogates TAFIa-mediated inhibition of fibrinolysis. This induces fibrinolysis, degrades fibrin clots and prevents thrombus formation. TAFIa, a carboxypeptidase that is activated by thrombin, cleaves C-terminal amino acid residues from fibrin, which prevents binding and activation of plasminogen and inhibits plasmin-mediated fibrinolysis.	TAFIa Inhibitor DS-1040b		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C148638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148638>	C177692	SSX2 Positive|CT5.2 Positive|Cancer/Testis Antigen 5.2 Positive|SSX Family Member 2 Positive|SSX2A Positive|SSX2B Positive|Synovial Sarcoma, X Breakpoint 2 Positive|Tumor Antigen HOM-MEL-40 Positive	An indication that SSX2 expression has been detected in a sample.	SSX2 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C148639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148639>	C18093	Exon Mutation|Coding Region Mutation|Coding Sequence Variant|Coding Sequence Variant|Exon Variant	A change in the nucleotide sequence of an exon in a gene.			Cell or Molecular Dysfunction	GDC Terminology|GDC Value Terminology
C148640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148640>	C45576	Elongation Mutation|Feature Elongation|Feature Elongation	The mutation of either a splice site or stop codon that leads to an extended transcript.			Cell or Molecular Dysfunction	GDC Terminology|GDC Value Terminology
C148641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148641>	C45576	Truncation Mutation|Feature Truncation|Feature Truncation	The mutation of either a splice site or stop codon that leads to a truncated transcript.			Cell or Molecular Dysfunction	GDC Terminology|GDC Value Terminology
C148642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148642>	C45576	Intergenic Mutation|Intergenic Variant|Intergenic Variant	A change in the nucleotide sequence of a region between gene loci.			Cell or Molecular Dysfunction	GDC Terminology|GDC Value Terminology
C148643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148643>	C45576	Non-Sense Mediated Decay Mutation|NMD Mutation|NMD Transcript Variant|NMD Transcript Variant|NONSENSE MEDIATED DECAY	A mutation occurring in a sequence that regulates non-sense mediated mRNA decay.			Cell or Molecular Dysfunction	CDISC SDTM Genomic Symbol Type Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C148644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148644>	C18093	Non-Coding Gene Mutation|Non-Coding Transcript Variant|Noncoding Gene Mutation|Untranslated Gene Mutation	A change in the nucleotide sequence of a non-coding gene.			Cell or Molecular Dysfunction	GDC Terminology|GDC Value Terminology
C148645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148645>	C148644|C148639	Non-Coding Gene Exon Mutation|Non-Coding Transcript Exon Variant|Noncoding Gene Exon Mutation|Untranslated Gene Exon Mutation	A change in the nucleotide sequence of an exon in a non-coding gene.			Cell or Molecular Dysfunction	GDC Terminology|GDC Value Terminology
C148646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148646>	C45576	Regulatory Region Mutation|Regulatory Region Variant|Regulatory Region Variant	A change in the nucleotide sequence of a regulatory region for a gene.			Cell or Molecular Dysfunction	GDC Terminology|GDC Value Terminology
C148647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148647>	C148646	Regulatory Region Deletion|Regulatory Region Ablation|Regulatory Region Ablation	A deletion mutation where the deleted sequence includes a regulatory region for a gene.			Cell or Molecular Dysfunction	GDC Terminology|GDC Value Terminology
C148648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148648>	C148646	Regulatory Region Amplification	An increase in the copy number of a region containing a regulatory sequence for a gene.			Cell or Molecular Dysfunction	GDC Terminology|GDC Value Terminology
C148649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148649>	C18133	Start Lost Mutation|Start Lost|Start Lost	A mutation occurring within the start codon of a gene that results in a sequence that no longer encodes a start codon. This can result in a gene deletion or gene transcription may start from an alternative start site.			Cell or Molecular Dysfunction	GDC Terminology|GDC Value Terminology
C148650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148650>	C18133|C179437	Nonstop Mutation|Read-Through Mutation|Stop Lost|Stop Lost	A mutation occurring within the stop codon of a gene that results in a sequence that no longer encodes a stop codon and results in the transcription of non-coding regions downstream of the gene.			Cell or Molecular Dysfunction	GDC Terminology|GDC Value Terminology
C148651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148651>	C20629	Silent Stop Codon Mutation|Stop Retained Variant|Stop Retained Variant	A mutation occurring within the stop codon of a gene, which still encodes a stop codon.			Cell or Molecular Dysfunction	GDC Terminology|GDC Value Terminology
C148652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148652>	C45576	Transcription Factor Binding Site Mutation|TF Binding Site Variant|TF Binding Site Variant|TFBS Variant	A change in the nucleotide sequence of a transcription factor binding site for a gene.			Cell or Molecular Dysfunction	GDC Terminology|GDC Value Terminology
C148653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148653>	C19296|C148652	Transcription Factor Binding Site Deletion Mutation|TFBS Ablation|TFBS Ablation	A deletion mutation where the deleted sequence includes a transcription factor binding site for a gene.			Cell or Molecular Dysfunction	GDC Terminology|GDC Value Terminology
C148654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148654>	C148652	Transcription Factor Binding Site Amplification|TFBS Amplification|TFBS Amplification	An increase in the copy number of a region containing a transcription factor binding site for a gene.			Cell or Molecular Dysfunction	GDC Terminology|GDC Value Terminology
C148655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148655>	C25616	Less Than One Year|Less than 1 Year|Less than one year	An indication that something has lasted, or occurred during, less than one year.			Temporal Concept	Components of Primary Care Instrument
C148656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148656>	C25616	One to Two Years|1 to 2 Years|One to two years	An indication that something has lasted, or occurred during, one to two years.			Temporal Concept	Components of Primary Care Instrument
C148657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148657>	C25616	Three to Five Years|3 to 5 Years|Three to five years	An indication that something has lasted, or occurred during, three to five years.			Temporal Concept	Components of Primary Care Instrument
C148658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148658>	C25616	Six to Ten Years|6 to 10 Years|Six to ten years	An indication that something has lasted, or occurred during, six to ten years.			Temporal Concept	Components of Primary Care Instrument
C148659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148659>	C25616	Eleven to Fifteen Years|11 to 15 Years|Eleven to 15 years	An indication that something has lasted, or occurred during, 11 to 15 years.			Temporal Concept	Components of Primary Care Instrument
C148660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148660>	C25616	Sixteen to Twenty Years|16 to 20 Years|Sixteen to 20 years	An indication that something has lasted, or occurred during, 16 to 20 years.			Temporal Concept	Components of Primary Care Instrument
C148661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C148661>	C25616	Twenty Years or More|Greater than or Equal to 20 Years|Twenty years or more	An indication that something has lasted, or occurred during, 20 years or more.			Temporal Concept	Components of Primary Care Instrument
C14867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14867>	C14421	CAST/Ei Mouse|CAST/Ei		CAST/Ei Mouse		Mammal	
C1486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1486>	C2165|C1660	Trecovirsen|Deoxyribonucleic acid d(P-thio)(T-C-T-T-C-C-T-C-T-C-T-C-T-A-C-C-C-A-C-G-C-T-C-T-C)|GEM 91|GEM91|Gene Expression Modulator 91|TRECOVIRSEN	A 25-mer antisense oligodeoxynucleotide phosphorothioate.  GEM-91 is complementary to the gag mRNA of human immunodeficiency virus type 1 (HIV-1), resulting in HIV-1 replication inhibition. (NCI)			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C1487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1487>	C1967	Lavendustin C|LAVENDUSTIN C	A compound that inhibits calmodulin kinase II and p60. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C1488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1488>	C2843	Aminocamptothecin|9-AC|9-AC|9-AMINOCAMPTOTHECIN|9-Amino-20-(S)-camptothecin|9-amino-20(S)-camptothecin|9-amino-20-camptothecin|9-amino-CPT|9-amino-camptothecin|9-aminocamptothecin|aminocamptothecin	A water-insoluble camptothecin derivative.  Aminocamptothecin binds to the nuclear enzyme topoisomerase I, thereby inhibiting repair of single-strand DNA breakages.  Because the terminal lactone ring of aminocamptothecin required for the agent's antitumor activity spontaneously opens under physiological conditions to an inactive carboxy form, the drug must be administered over an extended period of time to achieve effective cytotoxicity. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C1489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1489>	C593	Recombinant Interleukin-13|IL-13|Interleukin 13	The recombinant analogue of an endogenous cytokine interleukin 13 with potential antineoplastic activity. Produced by lymphocytes and exhibiting a variety of functions, interleukin-13 (therapeutic) inhibits DNA synthesis and regulates inflammatory and immune responses. In animal models, this agent has been shown to kill tumor cells both directly and indirectly by activating the host immune system at the tumor site. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C1490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1490>	C860	Taxane Compound|Taxanes|taxane				Chemical Viewed Structurally	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology
C1491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1491>	C1757	Tyrphostin AG 879|AG 879|a-Cyano-(3,5-Di-T-Butyl-4-Hydroxy) Thiocinnamide	A compound that selectively inhibits protein tyrosine kinase and nerve growth factor-dependent tyrosine phosphorylation. (NCI)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C1492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1492>	C1288	Sargramostim|23-L-Leucinecolony-Stimulating Factor 2|DRG-0012|Leukine|Prokine|SARGRAMOSTIM|Sagramostim|Sargramostatin|rhu GM-CFS|sargramostim	A recombinant therapeutic agent chemically identical to endogenous human GM-CSF except a leucine substitution in position 23.  Binding to specific cell surface receptors, sargramostim modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production and may reverse treatment-induced neutropenias. This agent also promotes antigen presentation, up-regulates antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function; it may also augment host antitumoral immunity.	Sargramostim		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C149344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149344>	C20420	HIVEP1 Gene|HIVEP1|HIVEP1|Human Immunodeficiency Virus Type I Enhancer Binding Protein 1 Gene	This gene plays a role in the transcriptional regulation of both viral and cellular genes.			Gene or Genome	
C149345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149345>	C149344	HIVEP1 wt Allele|CIRIP|CRYBP1|GAAP|Human Immunodeficiency Virus Type I Enhancer Binding Protein 1 wt Allele|MBP-1|PRDII-BF1|Schnurri-1|ZAS Family, Member 1 Gene|ZAS1|ZNF40|ZNF40A	Human HIVEP1 wild-type allele is located in the vicinity of 6p24.1 and is approximately 157 kb in length. This allele, which encodes zinc finger protein 40, is involved in the modulation of viral and cellular gene expression.			Gene or Genome	
C149346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149346>	C150386	Additive Dosage Form Category|Additive (unspecified)	A type of pharmaceutical dose form that may be liquid, semi-solid or solid, to be added to a large volume of diluent, such as in a bath.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C149347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149347>	C42636	Anticoagulant and Preservative Solution for Blood Dosage Form|Anticoagulant and preservative solution for blood	Sterile aqueous liquid preparation intended to be mixed with extracorporeal blood to preserve the blood and prevent coagulation.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149348>	C70962	Application Method of Administration|Application	The technique of administration of a pharmaceutical product by placing or spreading it onto the affected area.			Activity	EDQM Health Care Terminology|EDQM-HC Administration Method Terminology
C149349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149349>	C16830	Balling Gun Delivery Device|Balling gun	Device for delivery of a solid dose into the throat of the animal.			Medical Device	EDQM Health Care Terminology|EDQM-HC Administration Device Terminology
C149350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149350>	C48470	Barrel Dosing Unit|Barrel|[bbl_us]|[bbl_us]|barrel|barrel|bbl_us	A unit of presentation used to represent the quantity of product that is found in a single barrel container.			Quantitative Concept	EDQM Health Care Terminology|EDQM-HC Units of Presentation Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology|UCUM Terminology
C149351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149351>	C42636	Bath Additive Dosage Form|Bath additive	A pharmaceutical dose form that is added to a bath.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149352>	C70962	Bathing Method of Administration|Bathing	The technique of administration of a pharmaceutical product by immersing all or part of the affected area in the product, sometimes for an extended period of time.			Activity	EDQM Health Care Terminology|EDQM-HC Administration Method Terminology
C149353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149353>	C148242	Beak Dipping Route of Administration|Beak dipping	Administration of a veterinary medicinal product by dipping the beak of birds into an aqueous solution of the medicinal product.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Routes and Methods of Administration Terminology
C149354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149354>	C148243	Bee Smoke Paper Dosage Form|Bee smoke paper	Pharmaceutical impregnated strips that deliver the active substance(s) when lit. This is used to treat bee hives and nests.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149355>	C148243	Bee Smoke Stick Dosage Form|Bee smoke stick	Pharmaceutical impregnated sticks that deliver the active substance(s) when lit. This is used to treat bee hives and nests.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149356>	C148399	Beehive Dispersion in Sachet Dosage Form|Bee-hive dispersion in sachet	Medicinal product consisting of a bee-hive dispersion presented in a sachet.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149357>	C148399	Beehive Gel Dosage Form|Bee-hive gel	Semi-solid multidose preparation intended for veterinary use, consisting of a gel from which the active substance(s) are released by vaporization or physical contact over an extended period of time.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149358>	C148399	Beehive Solution Dosage Form|Bee-hive solution	Liquid preparation intended for in-hive use, consisting of a solution from which the active substance(s) are released by vaporization or physical contact usually over an extended period of time. The precise method of administration of the solution is described in the product information.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149359>	C148399	Beehive Strip Dosage Form|Bee-hive strip	Solid preparation for veterinary use consisting of a matrix impregnated with active substance(s) that are released by vaporization or physical contact over an extended period of time. Any specific requirements for the placing of the bee-hive strip are described in the product information.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149360>	C42953	Bladder Irrigation Solution Dosage Form|Bladder irrigation	Sterile liquid preparation intended for irrigation of the urinary bladder.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149361>	C50341	Pharmaceutical Brush Device|Brush	Administration device fitted with a fine brush used for the application of liquid pharmaceutical forms.			Medical Device	EDQM Health Care Terminology|EDQM-HC Administration Device Terminology
C149362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149362>	C96112	Brush Closure Device|Brush applicator	A closure with a brush device.			Intellectual Product	EDQM Health Care Terminology|EDQM-HC Closure Terminology
C149363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149363>	C70962	Smoking Method of Administration|Burning	The technique of administration of a pharmaceutical product by lighting it in order to evolve smoke that is taken in by the subject.			Activity	EDQM Health Care Terminology|EDQM-HC Administration Method Terminology
C149364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149364>	C48470	Cachet Dosing Unit|Cachet	A unit of presentation used to represent the quantity of product that is found in a single discrete entity where the pharmaceutical dose form is a type of cachet.			Quantitative Concept	EDQM Health Care Terminology|EDQM-HC Units of Presentation Terminology
C149365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149365>	C64878	Oral Cachet Dosage Form|Cachet	Solid discoid preparation consisting of a wafer enclosing a unit dose intended for oral use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149366>	C148268	Hard Capsule plus Tablet Dosage Form|Capsule, hard + tablet	Combination package consisting of a hard capsule and a tablet.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pack Terminology
C149367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149367>	C148268	Soft Capsule plus Tablet Dosage Form|Capsule, soft + tablet	Combination package consisting of a soft capsule and a tablet.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pack Terminology
C149368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149368>	C64876	Chewable Soft Capsule Dosage Form|Chewable capsule, soft	A soft tablet that must be chewed to release the active and/or inert ingredient(s).			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149369>	C42893	Chewable-Dispersible Tablet Dosage Form|Chewable/dispersible tablet	An uncoated tablet intended either to be chewed before being swallowed, or to be dispersed in the specified liquid before being swallowed.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149370>	C70962	Chewing Method of Administration|Chewing	The technique of administration of a pharmaceutical product by crushing or grinding it with the teeth; after chewing, some products are intended to be swallowed, some are intended to be spat out.			Activity	EDQM Health Care Terminology|EDQM-HC Administration Method Terminology
C149371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149371>	C96112	Child-Resistant Closure|Child-resistant closure	A closure which is difficult for young children to open but which is not difficult for adults to open properly.			Intellectual Product	EDQM Health Care Terminology|EDQM-HC Closure Terminology
C149372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149372>	C148275	Coated Granules in Sachet Dosage Form|Coated granules in sachet	Medicinal product consisting of coated granules presented in a sachet.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149373>	C42986	Collodion Dosage Form|Collodion	Liquid preparation usually containing pyroxylin in a mixture of ether and ethanol. When applied to the skin, the preparation forms a flexible film on the site of application.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149374>	C42955	Compressed Lozenge Dosage Form|Compressed lozenge	Solid single-dose preparation intended to be sucked to obtain a local or systemic effect. It is prepared by compression and is often rhomboid in shape. Compressed lozenges usually contain flavoring and sweetening agents. They dissolve or disintegrate slowly when sucked.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149375>	C148268	Concentrate and Solvent for Concentrate for Oral Spray, Suspension Dosage Form|Concentrate and solvent for concentrate for oral spray, suspension	A concentrate and a solvent intended for the preparation of a concentrate for oral spray, suspension by diluting the concentrate with the solvent; the resulting concentrate for oral spray, suspension must subsequently be diluted again before administration as an oral spray, suspension.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149376>	C148268	Concentrate and Solvent for Concentrate for Solution for Infusion Dosage Form|Concentrate and solvent for concentrate for solution for infusion	Sterile concentrate and sterile solvent intended for the preparation of a concentrate for solution for infusion by diluting the concentrate with the solvent; the resulting concentrate for solution for infusion must subsequently be diluted again before administration as a solution for infusion.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149377>	C148268	Concentrate and Solvent for Cutaneous Solution Dosage Form|Concentrate and solvent for cutaneous solution	Concentrate and solvent intended for the preparation of a cutaneous solution by diluting the concentrate with the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149378>	C148268	Concentrate and Solvent for Solution for Infusion Dosage Form|Concentrate and solvent for solution for infusion	Sterile concentrate and sterile solvent intended for the preparation of a solution for infusion by diluting the concentrate with the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149379>	C148268	Concentrate and Solvent for Solution for Injection Dosage Form|Concentrate and solvent for solution for injection	Sterile concentrate and sterile solvent intended for the preparation of a solution for injection by diluting the concentrate with the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149380>	C148268	Concentrate and Solvent for Solution for Injection/Infusion Dosage Form|Concentrate and solvent for solution for injection/infusion	Sterile concentrate and sterile solvent intended for the preparation of a solution for injection/infusion by diluting the concentrate with the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149381>	C148268	Concentrate and Solvent for Suspension for Injection Dosage Form|Concentrate and solvent for suspension for injection	Sterile concentrate and sterile solvent intended for the preparation of a suspension for injection by diluting the concentrate with the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149382>	C42898	Concentrate for Concentrate for Oral Spray, Suspension Dosage Form|Concentrate for concentrate for oral spray, suspension	Liquid preparation for veterinary use intended to be diluted in the specified liquid to obtain a concentrate for oral spray, suspension, which in turn is intended to be diluted in the specified liquid to obtain an oral spray, suspension.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149383>	C42898	Concentrate for Concentrate for Solution for Infusion Dosage Form|Concentrate for concentrate for solution for infusion	Liquid sterile preparation intended to be diluted in the specified liquid to obtain a concentrate for solution for infusion, which in turn is intended to be diluted in the specified liquid to obtain a solution for infusion.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149384>	C42898	Concentrate for Cutaneous Solution Dosage Form|Concentrate for cutaneous solution	Liquid preparation intended to be diluted in the specified liquid to obtain a cutaneous solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149385>	C42898	Concentrate for Cutaneous Spray, Emulsion Dosage Form|Concentrate for cutaneous spray, emulsion	Liquid preparation intended to be diluted in the specified liquid to obtain a cutaneous spray emulsion.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149386>	C42898	Concentrate for Dip Emulsion Dosage Form|Concentrate for dip emulsion	Liquid preparation intended to be diluted in the specified liquid to obtain a dip emulsion.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149387>	C42898	Concentrate for Dip Solution Dosage Form|Concentrate for dip solution	Liquid preparation intended to be diluted in the specified liquid to obtain a dip solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149388>	C42898	Concentrate for Dip Suspension Dosage Form|Concentrate for dip suspension	Liquid preparation intended to be diluted in the specified liquid to obtain a dip suspension.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149389>	C42898	Concentrate for Dispersion for Infusion Dosage Form|Concentrate for dispersion for infusion	Liquid sterile preparation intended to be diluted in the specified liquid to obtain a dispersion for infusion.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149390>	C42898	Concentrate for Emulsion for Infusion Dosage Form|Concentrate for emulsion for infusion	Liquid sterile preparation intended to be diluted in the specified liquid to obtain an emulsion for infusion.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149391>	C42898	Concentrate for Gargle Dosage Form|Concentrate for gargle	Liquid preparation consisting of an aqueous solution intended to be diluted in water to obtain a gargle.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149392>	C42898	Concentrate for Intravesical Solution Dosage Form|Concentrate for intravesical solution	Liquid preparation intended to be diluted in the specified liquid to obtain an intravesical solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149393>	C42898	Concentrate for Nebulizer Solution Dosage Form|Concentrate for nebuliser solution	Liquid preparation intended to be diluted in the specified liquid to obtain a nebulizer solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149394>	C42898	Concentrate for Oral Solution Dosage Form|Concentrate for oral solution	Liquid preparation intended to be diluted in the specified liquid to obtain an oral solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149395>	C42898	Concentrate for Oral Suspension Dosage Form|Concentrate for oral suspension	Liquid preparation intended to be diluted in the specified liquid to obtain an oral suspension.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149396>	C42898	Concentrate for Oral/Rectal Solution Dosage Form|Concentrate for oral/rectal solution	Liquid preparation intended to be diluted in the specified liquid to obtain an oral/rectal solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149397>	C42898	Concentrate for Oromucosal Solution Dosage Form|Concentrate for oromucosal solution	Liquid preparation intended to be diluted in the specified liquid to obtain an oromucosal solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149398>	C42898	Concentrate for Rectal Solution Dosage Form|Concentrate for rectal solution	Liquid preparation intended to be diluted in the specified liquid to obtain a rectal solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149399>	C42898	Concentrate for Solution for Fish Treatment Dosage Form|Concentrate for solution for fish treatment	Liquid preparation intended to be diluted in the specified liquid to obtain a solution for fish treatment by immersion.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C1493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1493>	C1450	Satraplatin|(OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum|(OC-6-43)-bis(acetato-O)amminedichloro(cyclohexanamine)platinum|BMS-182751|BMY-45594|JM 216|JM-216|Orplatna|SATRAPLATIN|platinum,bis(acetato-O)amminedichloro(cyclohexanamine)-,(OC-6-43)|satraplatin	An orally administered third generation platinum compound with potential antineoplastic activity. Satraplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in cell growth inhibition and apoptosis.	Satraplatin		Inorganic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C149400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149400>	C42898	Concentrate for Solution for Hemodialysis Dosage Form|Concentrate for solution for haemodialysis	Liquid preparation consisting of an aqueous solution of electrolytes intended to be diluted with water of a suitable quality to obtain a solution for hemodialysis.C80			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149401>	C42898	Concentrate for Solution for Infusion Dosage Form|Concentrate for solution for infusion	Liquid sterile preparation intended to be diluted in the specified liquid to obtain a solution for infusion.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149402>	C42899	Concentrate for Solution for Injection Dosage Form|Concentrate for solution for injection	Liquid sterile preparation intended to be diluted in the specified liquid to obtain a solution for injection.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149403>	C42898	Concentrate for Solution for Injection/Infusion Dosage Form|Concentrate for solution for injection/infusion	Sterile liquid preparation intended to be diluted in the specified liquid to obtain a solution for injection/infusion.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149404>	C42898	Concentrate for Solution for Intraocular Irrigation Dosage Form|Concentrate for solution for intraocular irrigation	Liquid sterile preparation intended to be diluted in the specified liquid to obtain a solution for intraocular irrigation.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149405>	C42898	Concentrate for Solution for Peritoneal Dialysis Dosage Form|Concentrate for solution for peritoneal dialysis	Liquid sterile preparation intended to be diluted in the specified liquid to obtain a solution for peritoneal dialysis.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149406>	C42898	Concentrate for Spray Emulsion Dosage Form|Concentrate for spray emulsion	Liquid sterile preparation intended to be diluted in the specified liquid to obtain an emulsion for spray.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149407>	C42899	Concentrate for Suspension for Injection Dosage Form|Concentrate for suspension for injection	Liquid sterile preparation intended to be diluted in the specified liquid to obtain a suspension for injection.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149408>	C42744	Continuous Release Intraruminal Device Dosage Form|Continuous-release intraruminal device	Solid single-dose preparation intended for oral use in ruminant animals. It is designed to be retained in the rumen to deliver the active substance(s) in a continuous manner at a defined rate over a defined period of time. This may be achieved by erosion, corrosion, diffusion, osmotic pressure or any other suitable chemical, physical or physico-chemical means.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149409>	C54680	Conventional Release Mechanism of Action|Conventional	Release of the substance(s) in a way that is not deliberately modified by a special formulation design and/or manufacturing method.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Release Characteristics Terminology
C149410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149410>	C148268	Cream plus Pessary Dosage Form|Cream + pessary	Combination package consisting of a cream and a pessary.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pack Terminology
C149411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149411>	C148268	Cream plus Soft Vaginal Capsule Dosage Form|Cream + vaginal capsule, soft	Combination package consisting of a cream and a soft vaginal capsule.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pack Terminology
C149412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149412>	C148268	Cream plus Vaginal Tablet Dosage Form|Cream + vaginal tablet	Combination package consisting of a cream and a vaginal tablet.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pack Terminology
C149413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149413>	C42913	Cutaneous Emulsion Dosage Form|Cutaneous emulsion	Liquid, usually multidose preparation consisting of an emulsion intended for cutaneous use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149414>	C42967	Topical Paste Dosage Form|Cutaneous paste	Semi-solid single-dose or multidose preparation containing a large proportion of finely divided solids dispersed in the basis, intended for cutaneous use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149415>	C148268	Cutaneous Solution plus Medicated Sponge Dosage Form|Cutaneous solution + medicated sponge	Combination package consisting of a cutaneous solution and a medicated sponge.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pack Terminology
C149416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149416>	C148275	Cutaneous Solution in Single-dose Container Dosage Form|Cutaneous solution in single-dose container	Medicinal product consisting of a cutaneous solution presented in a single-dose container.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149417>	C64905	Topical Solution/Concentrate for Oromucosal Solution Dosage Form|Cutaneous solution/concentrate for oromucosal solution	Liquid preparation consisting of a solution intended for cutaneous use or intended to be diluted in the specified liquid to obtain an oromucosal solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149418>	C91194	Topical Emulsion Spray Dosage Form|Cutaneous spray, emulsion|Cutaneous suspension spray	Liquid preparation, usually multidose, consisting of an emulsion in a pressurized container with a spray valve or in a container equipped with a spray pump, intended for cutaneous use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149419>	C91194	Topical Ointment Spray Dosage Form|Cutaneous spray, ointment	Ointment formed at the time of administration from a liquid preparation in a pressurized container with a spray valve or in a container equipped with a spray pump.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149420>	C42990	Topical Suspension Spray Dosage Form|Cutaneous spray, suspension	Liquid, usually multidose preparation consisting of a suspension in a pressurized container with a spray valve or in a container equipped with a spray pump, intended for cutaneous use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149421>	C42991	Topical Stick Dosage Form|Cutaneous stick	Solid preparation, usually rod-shaped or conical, intended for application to the skin to obtain a local effect. Cutaneous sticks may consist of the active substance(s) alone or dissolved or dispersed in a suitable basis.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149422>	C42966	Cutaneous/Nasal Ointment Dosage Form|Cutaneous/nasal ointment	Semi-solid preparation consisting of an ointment intended for cutaneous or nasal use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149423>	C13442	Cutaneous/Transdermal	Relating to the skin and its layers or its appendages (e.g. hair, nails).			Spatial Concept	
C149424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149424>	C50341	Dabbing Applicator Device|Dabbing applicator	Closure with dabbing device.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Administration Device Terminology
C149425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149425>	C50341	Dart Device|Dart	A pointed missile which on contact with an animal delivers its medicinal content.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Container Terminology
C149426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149426>	C48470	Dart Dosing Unit|Dart	A unit of presentation used to represent the quantity of product that is found in a single dart device.			Quantitative Concept	EDQM Health Care Terminology|EDQM-HC Units of Presentation Terminology
C149427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149427>	C54680	Delayed Release Mechanism of Action|Delayed	Release of the substance(s) at a later time than would be achieved with a conventional-release product, achieved by a special formulation design and/or manufacturing method; enteric-coated and other gastro-resistant products are included.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Release Characteristics Terminology
C149428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149428>	C69059	Dental Emulsion Dosage Form|Dental emulsion	Liquid, usually multidose preparation consisting of an emulsion intended for administration on to the teeth and the gums.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149429>	C69059|C42986	Dental Solution Dosage Form|Dental solution	Liquid, usually multidose preparation consisting of a solution intended for administration on teeth and gums.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149430>	C69059	Dental Stick Dosage Form|Dental stick	Solid single-dose preparation, rod-shaped and usually prepared by compression or molding, intended for dental use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149431>	C69059	Dental Suspension Dosage Form|Dental suspension	Liquid, usually multidose preparation consisting of a suspension intended for administration on teeth and gums.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149432>	C69059	Denture Lacquer Dosage Form|Denture lacquer	Liquid preparation to be applied to dentures to form a lacquer by evaporation of the volatile solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149433>	C70962	Dialysis Method of Administration|Dialysis	The technique of administration of a pharmaceutical product by inclusion in a dialysis system as a dialysis or substitution product.			Activity	EDQM Health Care Terminology|EDQM-HC Administration Method Terminology
C149434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149434>	C42913	Dip Emulsion Dosage Form|Dip emulsion	Liquid preparation consisting of an emulsion intended for veterinary use by dipping.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149435>	C42986	Dip Solution Dosage Form|Dip solution	Liquid preparation consisting of a solution intended for veterinary use by dipping.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149436>	C42994	Dip Suspension Dosage Form|Dip suspension	Liquid preparation consisting of a suspension intended for veterinary use by dipping.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149437>	C148242	Dipping Route of Administration|Dipping	Administration of a veterinary medicinal product by immersing the animal into a bath or plunge pool containing the medicinal product.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Routes and Methods of Administration Terminology
C149438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149438>	C42998	Dispersible Tablet for Dose Dispenser Dosage Form|Dispersible tablets for dose dispenser	Solid preparation consisting of small, dispersible tablets that are designed to be used in a dose dispenser, each tablet usually consisting of a small fraction of a dose, with multiple tablets being automatically counted and administered as a single dose.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149439>	C42746	Dispersion for Concentrate for Dispersion for Infusion Dosage Form|Dispersion for concentrate for dispersion for infusion	Liquid sterile preparation consisting of a dispersion intended for use in the preparation of a concentrate for dispersion for infusion, which in turn is intended to be diluted in the specified liquid to obtain a dispersion for infusion.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149440>	C202489	Dispersion for Infusion Dosage Form|Dispersion for infusion	Liquid sterile preparation consisting of two or more phases of which at least one is dispersed in the liquid phase, intended to be introduced, usually in large volumes, usually into the circulating blood stream.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149441>	C42746|C202489	Dispersion for Injection Dosage Form|Dispersion for injection	Liquid sterile preparation consisting of two or more phases of which at least one is dispersed in the liquid phase, intended for administration by injection.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149442>	C42746|C202489	Dispersion for Injection/Infusion Dosage Form|Dispersion for injection/infusion	Sterile liquid preparation consisting of two or more phases of which at least one is dispersed in the liquid phase, intended for administration by injection or infusion.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149443>	C69095	Dose Dispenser Cartridge|Dose-dispenser cartridge	Container intended for use in a dose dispenser, usually pre-filled with a medicinal product.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Container Terminology
C149444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149444>	C50341	Dredging Applicator Device|Dredging applicator	Closure with dredging device.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Administration Device Terminology
C149445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149445>	C43186	Dredging Container|Dredging container	Container for a pharmaceutical form to be applied by dredging.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Container Terminology
C149446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149446>	C16830	Drench Gun|Drench gun	Device for administering an oral liquid to an animal.			Medical Device	EDQM Health Care Terminology|EDQM-HC Administration Device Terminology
C149447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149447>	C48470	Dressing Dosing Unit|Dressing	A unit of presentation used to represent the quantity of product that is found in a single discrete entity where the pharmaceutical dose form is a type of dressing.			Quantitative Concept	EDQM Health Care Terminology|EDQM-HC Units of Presentation Terminology
C149448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149448>	C50341	Dropper with Screw Cap Device|Dropper applicator	Screw cap with dropper.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Administration Device Terminology
C149449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149449>	C43186	Dropper Container|Dropper container	A container, usually a bottle, fitted with a dropper applicator.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Container Terminology
C149450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149450>	C148290	Ear Drops Emulsion Dosage Form|Ear drops, emulsion	Liquid single-dose or multidose preparation consisting of an emulsion intended for application to the external auditory meatus. Multidose containers may be dropper containers or containers provided with a dropper applicator, or the dropper may be supplied separately. Drops are not necessarily administered dropwise, but may also be administered as a small volume.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149451>	C148268	Ear drops, Powder for Suspension Dosage Form|Ear drops, powder and solvent for suspension	Powder and solvent intended for the preparation of ear drops, suspension, by dispersing the powder in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149452>	C91177	Ear Drops Powder for Suspension Dosage Form|Ear drops, powder for suspension	Solid preparation consisting of one or more powder intended to be dispersed in the specified liquid to obtain an ear drops suspension.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149453>	C91176	Ear Drops Solution Dosage Form|Ear drops, solution	Liquid single-dose or multidose preparation consisting of an aqueous or oily solution intended for application to the external auditory meatus. Multidose containers may be dropper containers or containers provided with a dropper applicator, or the dropper may be supplied separately. Drops are not necessarily administered dropwise, but may also be administered as a small volume.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149454>	C148275	Ear Gel Dosage Form|Ear gel	Semi-solid single-dose or multidose preparation consisting of a gel intended for application to the external auditory meatus, if necessary by means of a tampon impregnated with the preparation.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149455>	C91177	Ear Drops Suspension Dosage Form|Ear drops, suspension	Liquid single-dose or multidose preparation consisting of an aqueous or oily suspension intended for application to the external auditory meatus. Multidose containers may be dropper containers or containers provided with a dropper applicator, or the dropper may be supplied separately. Drops are not necessarily administered dropwise, but may also be administered as a small volume.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149456>	C148275	Ear Drops, Suspension in Single-dose Container Dosage Form|Ear drops, suspension in single-dose container	Medicinal product consisting of an ear drops suspension presented in a single-dose container.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149457>	C91175	Ear Ointment Dosage Form|Ear ointment	Semi-solid single-dose or multidose preparation consisting of an ointment intended for application to the external auditory meatus, if necessary by means of a tampon impregnated with the preparation.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149458>	C69040	Ear Powder Dosage Form|Ear powder	Solid, usually multidose preparation consisting of one or more powders consisting of (a) solid active substance(s) intended for application to the external auditory meatus. Ear powders are presented in containers fitted with a suitable applicator or device for insufflation.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149459>	C148290	Ear Spray Emulsion Dosage Form|Ear spray, emulsion	Liquid, usually multidose preparation consisting of an emulsion intended for application to the external auditory meatus by spraying to obtain local effect. Ear sprays are presented in containers with a spray pump or in pressurized containers fitted with a spray valve.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149460>	C91176	Ear Spray Solution Dosage Form|Ear spray, solution	Liquid, usually multidose preparation consisting of a solution intended for application to the external auditory meatus by spraying to obtain a local effect. Ear sprays are presented in containers with a spray pump or in pressurized containers fitted with a spray valve.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149461>	C91177	Ear Spray Suspension Dosage Form|Ear spray, suspension	Liquid, usually multidose preparation consisting of a suspension intended for application to the external auditory meatus by spraying to obtain a local effect. Ear sprays are presented in containers with a spray pump or in pressurized containers fitted with a spray valve.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149462>	C69040	Ear Stick Dosage Form|Ear stick	Solid single-dose preparation of usually conical shape intended to be inserted in the external auditory meatus where it melts or dissolves.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149464>	C69040	Ear Tampon Dosage Form|Ear tampon	Solid single-dose preparation intended to be inserted into the external auditory meatus for a limited period of time, consisting of a suitable material impregnated with active substance(s).			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149465>	C148290	Ear Wash Emulsion Dosage Form|Ear wash, emulsion	Liquid single-dose or multidose preparation consisting usually of an oil-in-water emulsion with a pH within physiological limits. Ear washes are intended to clean the external auditory meatus.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149466>	C91176	Ear Wash Solution Dosage Form|Ear wash, solution	Liquid single-dose or multidose preparation consisting usually of an aqueous solution with a pH within physiological limits. Ear washes are intended to clean the external auditory meatus.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149467>	C219590	Ear/Eye Drops, Solution Dosage Form|Ear/eye drops, solution	Liquid sterile preparation consisting of a solution intended for use as ear drops or eye drops.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149468>	C219590	Ear/Eye Drops, Suspension Dosage Form|Ear/eye drops, suspension	Liquid sterile preparation consisting of a suspension intended for use as ear drops or eye drops.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149469>	C148365	Ear/Eye Ointment Dosage Form|Ear/eye ointment	Semi-solid preparation consisting of an ointment intended for auricular or ocular use.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149470>	C219578	Ear/Eye/Nasal Drops, Solution Dosage Form|Ear/eye/nasal drops, solution	Liquid sterile preparation consisting of a solution intended for use as ear drops, eye drops or nasal drops.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149471>	C219578	Ear/Nasal Drops, Suspension Dosage Form|Ear/nasal drops, suspension	Liquid preparation consisting of a suspension intended for use as ear drops or nasal drops.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149472>	C148268	Effervescent Granules plus Film-Coated Tablet Dosage Form|Effervescent granules + film-coated tablet	Combination package consisting of effervescent granules and a film-coated tablet.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pack Terminology
C149473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149473>	C42909	Effervescent Granules for Oral Suspension Dosage Form|Effervescent granules for oral suspension	Solid preparation consisting of effervescent granules intended to be dispersed or dissolved in the specified liquid, which is supplied in the same packaging, to obtain an oral suspension.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149474>	C148268	Effervescent Tablet plus Film-Coated Tablet Dosage Form|Effervescent tablet + film-coated tablet	Combination package consisting of an effervescent tablet and a film-coated tablet.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pack Terminology
C149475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149475>	C42910	Effervescent Vaginal Tablet Dosage Form|Effervescent vaginal tablet	Solid single-dose preparation consisting of a vaginal tablet usually containing acid substances and carbonates or hydrogen carbonates that react rapidly in the presence of aqueous liquid to release carbon dioxide.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149476>	C148268	Emulsion and Lyophilisate for Suspension for Injection Dosage Form|Emulsion and lyophilisate for suspension for injection	Sterile emulsion and sterile lyophilisate (freeze-dried powder) intended for the preparation of a suspension for injection, for veterinary use, by dispersing the lyophilisate in the emulsion. The emulsion contains active ingredient(s); the lyophilisate may or may not contain active ingredient(s).			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149477>	C148268	Emulsion and Suspension for Emulsion for Injection Dosage Form|Emulsion and suspension for emulsion for injection	Sterile emulsion and sterile suspension, both of which contain active substance(s), intended for the preparation of an emulsion for injection by mixing the emulsion and the suspension.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149478>	C42913	Emulsion for Emulsion for Injection Dosage Form|Emulsion for emulsion for injection	Liquid sterile preparation consisting of an emulsion intended for use in the preparation of an emulsion for injection.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149479>	C42913	Emulsion for Infusion Dosage Form|Emulsion for infusion	Liquid sterile preparation consisting of an oil-in-water emulsion intended to be introduced, usually in large volumes, usually into the circulating blood stream.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149480>	C148275	Emulsion for Infusion in Administration System Dosage Form|Emulsion for infusion in administration system	Medicinal product consisting of an emulsion for infusion presented in an administration system.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149481>	C42913	Emulsion for Injection/Infusion Dosage Form|Emulsion for injection/infusion	Liquid sterile single-dose or multidose preparation consisting of an emulsion intended for administration by injection or infusion.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149482>	C148275	Emulsion for Injection/Infusion in Pre-filled Syringe Dosage Form|Emulsion for injection/infusion in pre-filled syringe	Medicinal product consisting of an emulsion for injection/infusion presented in a pre-filled syringe.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149483>	C42913	Emulsion for Suspension for Injection Dosage Form|Emulsion for suspension for injection	Liquid sterile preparation consisting of an emulsion intended for use in the preparation of a suspension for injection.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149484>	C225418	Endocervical	Relating to the cervix uteri as the intended site of administration.			Spatial Concept	EDQM Health Care Terminology|EDQM-HC Intended Site of Administration Terminology
C149485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149485>	C148378	Endocervical Gel Dosage Form|Endocervical gel|Endocervical gel	Semi-solid preparation consisting of a gel intended for endocervical use by means of a suitable applicator.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149486>	C69064	Endosinusial Solution Dosage Form|Endosinusial solution	Liquid preparation consisting of a solution intended to be administered to the sinuses to obtain a local effect.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149487>	C69064	Endosinusial Suspension Wash Dosage Form|Endosinusial wash, suspension	Liquid preparation consisting of a suspension intended for cleaning the sinuses.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149488>	C148268	Endotracheopulmonary Instillation, Powder and Solvent for Solution Dosage Form|Endotracheopulmonary instillation, powder and solvent for solution	Powder and aqueous solvent intended for the preparation of an endotracheopulmonary instillation solution by dissolving the powder in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149489>	C148268	Endotracheopulmonary Instillation, Powder and Solvent for Suspension Dosage Form|Endotracheopulmonary instillation, powder and solvent for suspension	Powder and aqueous solvent intended for the preparation of an endotracheopulmonary instillation suspension by dispersing the powder in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149490>	C42972	Endotracheopulmonary Instillation, Powder for Solution Dosage Form|Endotracheopulmonary instillation, powder for solution|Powder for endotracheopulmonary instillation solution	Solid preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain an endotracheopulmonary instillation solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149491>	C42972	Endotracheopulmonary Instillation, Powder for Suspension Dosage Form|Endotracheopulmonary instillation, powder for suspension	Solid preparation consisting of one or more powders intended to be dispersed in the specified liquid to obtain an endotracheopulmonary instillation suspension.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149492>	C42986	Endotracheopulmonary Instillation, Solution Dosage Form|Endotracheopulmonary instillation, solution	Liquid preparation consisting of an aqueous solution intended for instillation to the trachea and/or bronchi.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149493>	C42994	Endotracheopulmonary Instillation, Suspension Dosage Form|Endotracheopulmonary instillation, suspension	Liquid preparation consisting of an aqueous suspension intended for instillation to the trachea and/or bronchi. Preparations for inhalation use are excluded.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149494>	C27993	Environmental	Relating to the surroundings in which the target of the pharmaceutical product is found, as the intended site of administration, e.g. an enclosed volume of water or air; usually the product disperses in the area and is subsequently taken up by the subject.			Qualitative Concept	EDQM Health Care Terminology|EDQM-HC Intended Site of Administration Terminology
C149495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149495>	C42747	Epilesional Solution Dosage Form|Epilesional solution	Liquid sterile preparation consisting of a solution intended to be administered onto a lesion.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149496>	C38114	Epilesional Route of Administration|Epilesional use	Administration of a medicinal product onto a lesion.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Routes and Methods of Administration Terminology
C149497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149497>	C225418	Extracorporeal	Relating to a body substance or tissue as the intended site of administration, after being removed from the body in order to be treated with the pharmaceutical product and then subsequently returned to the body.			Spatial Concept	EDQM Health Care Terminology|EDQM-HC Intended Site of Administration Terminology
C149498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149498>	C219588	Emulsion Eye Drops Dosage Form|Eye drops, emulsion	Liquid sterile single-dose or multidose preparation consisting of an emulsion intended for ocular use. Multidose preparations are presented in containers that allow successive drops to be administered.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149499>	C148275	Eye Drops, Emulsion in Single-dose Container Dosage Form|Eye drops, emulsion in single-dose container	Medicinal product consisting of an eye drops emulsion presented in a single-dose container.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C1494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1494>	C2456	Arcitumomab|ARCITUMOMAB|CEA-Scan|IMMU-4|Immunoglobulin G 1 (mouse monoclonal IMMU-4 Fab' fragment gamma-chain anti-human antigen CEA), disulfide with mouse Monoclonal IMMU-4 Light Chain	A murine IgG monoclonal Fab' fragment antibody directed against carcinoembryonic antigen (CEA), a protein that is overexpressed by many tumor cell types. For tumors that overexpress CEA, technetium-99m labeled arcitumomab may be used as an adjunct diagnostic imaging tool to obtain prognostic information following resection and to monitor for recurrent disease. (NCI04)			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C149500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149500>	C148268	Eye Drops, Powder and Solvent for Solution Dosage Form|Eye drops, powder and solvent for solution	Sterile powder and sterile solvent intended for the preparation of eye drops, solution, by dissolving the powder in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149501>	C148268	Eye Drops, Powder and Solvent for Suspension Dosage Form|Eye drops, powder and solvent for suspension	Sterile powder and sterile solvent intended for the preparation of eye drops, suspension, by dispersing the powder in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149502>	C148547	Eye Drops, Powder for Solution Dosage Form|Eye drops, powder for solution|Powder for eye drops|Powder for ophthalmic solution	Solid sterile preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain an eye drops solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149503>	C148547	Eye Drops, Powder for Suspension Dosage Form|Eye drops, powder for suspension|Powder for ophthalmic suspension	Solid preparation consisting of one or more powders intended to be dispersed in the specified liquid to obtain an eye drops suspension.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149504>	C91163	Eye Drops, Prolonged Release Dosage Form	Liquid sterile single-dose or multidose preparation intended for ocular use. The active substance is released over an extended period of time.			Biomedical or Dental Material	
C149505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149505>	C148275	Eye Drops, Prolonged-Release Solution in Single-dose Container Dosage Form|Eye drops, prolonged-release solution in single-dose container	Medicinal product consisting of a prolonged-release eye drops solution presented in a single-dose container.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149506>	C148275	Eye Drops, Solution in Single-dose Container Dosage Form|Eye drops, solution in single-dose container	Medicinal product consisting of an eye drops solution presented in a single-dose container.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149507>	C69038	Eye Drops Solvent for Reconstitution Dosage Form|Eye drops, solvent for reconstitution	Liquid preparation consisting of a sterile solvent containing no active substances, intended for reconstitution of a usually freeze-dried powder for eye drops.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149508>	C91164|C60995	Ophthalmic Suspension Drops Dosage Form|Eye Drop Suspension Dosage Form|Eye drops suspension|Eye drops, suspension|Eye suspension	Liquid sterile single-dose or multidose preparation consisting of an aqueous or oily suspension intended for ocular use. Multidose preparations are presented in containers that allow successive drops to be administered. The containers contain usually at most 10 mL of the preparation.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149509>	C148275	Eye Drops, Suspension in Single-dose Container Dosage Form|Eye drops, suspension in single-dose container	Medicinal product consisting of an eye drops suspension presented in a single-dose container.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149510>	C148275	Eye Gel in Single-dose Container Dosage Form|Eye gel in single-dose container	Medicinal product consisting of an eye gel presented in a single-dose container.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149511>	C69039	Eye Lotion Dosage Form|Eye lotion	Liquid sterile single-dose or multidose preparation consisting of an aqueous solution intended for washing or bathing the eye.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149512>	C69038	Eye Lotion Solvent for Reconstitution Dosage Form|Eye lotion, solvent for reconstitution	Liquid preparation consisting of a sterile solvent containing no active substances, intended for reconstitution of a usually freeze-dried powder for eye lotion.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149513>	C148275	Eye Ointment in Single-dose Container Dosage Form|Eye ointment in single-dose container	Medicinal product consisting of an eye ointment presented in a single-dose container.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149514>	C148268	Film-Coated Tablet plus Pessary Dosage Form|Film-coated tablet + pessary	Combination package consisting of a film-coated tablet and a pessary.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pack Terminology
C149515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149515>	C148268	Film-Coated Tablet plus Tablet Dosage Form|Film-coated tablet + tablet	Combination package consisting of a film-coated tablet and a tablet.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pack Terminology
C149516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149516>	C148275	Film-Coated Tablet and Gastro-Resistant Granules in Sachet Dosage Form|Film-coated tablet and gastro-resistant granules in sachet	Medicinal product consisting of a film-coated tablet and gastro-resistant granules presented together in a sachet and intended to be swallowed together as a single dose.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149517>	C43186	Fixed Cryogenic Vessel|Fixed cryogenic vessel	A static thermally insulated container designed to maintain the contents in the liquid state.			Medical Device	EDQM Health Care Terminology|EDQM-HC Container Terminology
C149518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149518>	C148242	Foot-stab Route of Administration|Foot-stab use	Administration of a veterinary medicinal product into the foot of birds.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Routes and Methods of Administration Terminology
C149519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149519>	C42972	Gargle, Powder for Solution Dosage Form|Gargle, powder for solution	Solid preparation consisting of one or more powders intended to be dissolved in water to obtain a gargle.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149520>	C42998	Gargle, Tablet for Solution Dosage Form|Gargle, tablet for solution	Solid preparation consisting of a tablet intended to be dissolved in water to obtain a gargle.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149521>	C42986	Gargle/Mouthwash Dosage Form|Gargle/mouthwash	Liquid preparation consisting of a solution intended for use as a gargle or a mouthwash.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149522>	C42986	Gargle/Nasal Wash Dosage Form|Gargle/nasal wash	Liquid preparation consisting of a solution intended for use as a gargle or a nasal wash.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149523>	C70962	Gargling Method of Administration|Gargling	The technique of administration of a pharmaceutical product by rinsing the throat and/or mouth with it, holding it in the throat and keeping it in motion by releasing a stream of air from the lungs; after gargling, the product is usually intended to be spat out.			Activity	EDQM Health Care Terminology|EDQM-HC Administration Method Terminology
C149524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149524>	C148268	Gas and Solvent for dispersion for Injection/Infusion Dosage Form|Gas and solvent for dispersion for injection/infusion	Sterile gas and sterile solvent, either in the same compartment or in different compartments, intended for the preparation of a dispersion for injection/infusion by dispersing the gas in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149525>	C42933	Gas for Dispersion for Infusion Dosage Form|Gas for dispersion for infusion	Sterile preparation consisting of a gas that is intended to be mixed with the specified liquid to obtain a dispersion of the gas in the liquid, which is intended for administration by infusion.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149526>	C42933	Gas for Dispersion for Injection Dosage Form|Gas for dispersion for injection	Sterile preparation consisting of a gas that is intended to be mixed with the specified liquid to obtain a dispersion of the gas in the liquid, which is intended for administration by injection.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149527>	C42933	Gas for Dispersion for Injection/Infusion Dosage Form|Gas for dispersion for injection/infusion	Sterile preparation consisting of a gas that is intended to be mixed with the specified liquid to obtain a dispersion of the gas in the liquid, which is intended for administration by injection or infusion.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149528>	C148444	Gastrointestinal Emulsion Dosage Form|Gastroenteral emulsion	Liquid preparation consisting of an emulsion intended for administration to the stomach or duodenum by means of a suitable applicator.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149529>	C148444	Gastroenteral Solution Dosage Form|Gastroenteral solution	Liquid preparation consisting of a solution intended for administration to the stomach or duodenum by means of a suitable applicator.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149530>	C148444	Gastroenteral Suspension Dosage Form|Gastroenteral suspension	Liquid preparation consisting of a suspension intended for administration to the stomach or duodenum by means of a suitable applicator.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149531>	C42902	Gastro-resistant Capsule, Hard Dosage Form|Gastro-resistant capsule, hard	Solid single-dose, delayed-release preparation contained in a hard shell. The preparation is intended to resist the gastric fluid and to release the active substance(s) in the intestinal fluid. Hard gastro-resistant capsules are usually made by filling hard capsules with gastro-resistant granules or solid particles made gastro-resistant by coating or, in certain cases, by providing hard capsules with a gastro-resistant shell. They are intended for oral use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149532>	C42902	Gastro-resistant Capsule, Soft Dosage Form|Gastro-resistant capsule, soft	Solid single-dose, delayed-release preparation contained in a soft shell. The preparation is intended to resist the gastric fluid and to release the active substance(s) in the intestinal fluid. Soft gastro-resistant capsules are usually formed, filled and sealed in one operation. They may contain a liquid or semi-solid preparation in the gastro-resistant shell. Soft gastro-resistant capsules are intended for oral use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149533>	C42903	Delayed Release Granule for Oral Suspension Dosage Form	Solid preparation consisting of gastro-resistant granules intended to be dispersed in the specified liquid to obtain an oral suspension.			Biomedical or Dental Material	
C149534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149534>	C219569|C148275	Gastro-Resistant Granules for Oral Suspension in Sachet Dosage Form	Medicinal product consisting of gastro-resistant granules for oral suspension presented in a sachet.			Biomedical or Dental Material	
C149535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149535>	C148268	Gastro-Resistant Tablet plus Rectal Suspension Dosage Form|Gastro-resistant tablet + rectal suspension	Combination package consisting of a gastro-resistant tablet and a rectal suspension.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pack Terminology
C149536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149536>	C42934	Gel for Gel Dosage Form|Gel for gel	Semi-solid preparation consisting of a gel intended for use in the preparation of a gel for cutaneous use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149537>	C42934	Gel for Injection Dosage Form|Gel for injection	Sterile single-dose preparation consisting of a hydrophilic gel intended for injection into a specific tissue or organ.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149538>	C148275	Gel in Pressurized Container Dosage Form|Gel in pressurised container	Medicinal product consisting of a gel presented in a pressurized container.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149539>	C148275	Gel in Sachet Dosage Form|Gel in sachet	Medicinal product consisting of a gel presented in a sachet.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149540>	C148445	Gingival Gel Dosage Form|Gingival gel	Semi-solid single-dose or multidose preparation consisting of a gel intended for gingival use to obtain a local effect.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149541>	C148445	Gingival Paste Dosage Form|Gingival paste	Semi-solid single-dose or multidose preparation consisting of a paste of solid particles finely dispersed in a hydrophilic basis intended for gingival use to obtain a local effect.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149542>	C148445	Gingival Solution Dosage Form|Gingival solution	Liquid, usually multidose preparation consisting of a solution intended for gingival use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149543>	C38197	Gingival Route of Administration|Gingival use	Administration of a medicinal product to the gingivae.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Routes and Methods of Administration Terminology
C149544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149544>	C148268	Granule and Solvent for Oral Suspension Dosage Form|Granules and solvent for oral suspension	Granules and solvent intended for the preparation of an oral suspension by dispersing the granules in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149545>	C148268	Granule and Solvent for Suspension for Injection Dosage Form|Granules and solvent for suspension for injection	Sterile granules and sterile solvent intended for the preparation of a suspension for injection by dispersing the granules in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149546>	C42939	Granules for Oral Solution Dosage Form|Granules for oral solution	Solid preparation consisting of aggregated particles that may include excipients to facilitate wetting and dissolution, intended to be dissolved in the specified liquid to obtain an oral solution, which is usually prepared just before administration to the patient.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149547>	C148275	Granules for Oral Solution in Sachet Dosage Form|Granules for oral solution in sachet	Medicinal product consisting of granules for oral solution presented in a sachet.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149548>	C42940	Granules for Oral Suspension Dosage Form|Granules for oral suspension	Solid preparation consisting of aggregated particles that may include excipients to facilitate wetting and dispersion, intended to be dispersed in the specified liquid to obtain an oral suspension, which is usually prepared just before administration to the patient.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149549>	C148275	Granules for Oral Suspension in Sachet Dosage Form|Granules for oral suspension in sachet	Medicinal product consisting of granules for oral suspension presented in a sachet.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149550>	C42940	Granules for Oral/Rectal Suspension Dosage Form|Granules for oral/rectal suspension	Solid preparation consisting of granules intended to be dispersed in the specified liquid to obtain an oral/rectal suspension.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149551>	C42940	Granules for Rectal Suspension Dosage Form|Granules for rectal suspension	Solid preparation consisting of aggregated particles that may include excipients to facilitate wetting and dispersion, intended to be dispersed in the specified liquid to obtain a rectal suspension, which is usually prepared just before administration to the patient.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149552>	C42940	Granules for Suspension for Injection Dosage Form|Granules for suspension for injection	Solid sterile preparation consisting of granules intended to be dispersed in the specified liquid to obtain a suspension for injection.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149553>	C42938	Granules for Syrup Dosage Form|Granules for syrup	Solid preparation consisting of aggregated particles that may include excipients to facilitate wetting and dissolution and to obtain the characteristics of a syrup, intended to be dissolved in water to obtain a syrup.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149554>	C42938	Granules for Use in Drinking Water Dosage Form|Granules for use in drinking water	Solid preparation for veterinary use consisting of granules intended to be dissolved in the animal drinking water.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149555>	C42939	Granules for Vaginal Solution Dosage Form|Granules for vaginal solution	Solid preparation consisting of aggregated particles that may include excipients to facilitate wetting and dissolution, intended to be dissolved in the specified liquid to obtain a vaginal solution, which is usually prepared just before administration to the patient.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149556>	C148275	Granules in Sachet Dosage Form|Granules in sachet	Medicinal product consisting of granules presented in a sachet, the entire contents of which are intended for oral administration as a single dose.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149557>	C148275	Granules in Single-dose Container Dosage Form|Granules in single-dose container	Medicinal product consisting of granules presented in a single-dose container.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149558>	C171282	Herbal Material (Unprocessed) Dosage Form Category|Herbal material (unprocessed)	A type of solid pharmaceutical dose form consisting of whole, broken or fragmented plants or parts of plants (including algae, fungi, lichen) in an unprocessed state, and which may be dried or fresh.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C149559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149559>	C148448	Herbal Tea Dosage Form|Herbal tea	Solid preparation consisting exclusively of one or more herbal drugs intended for the preparation of an oral aqueous preparation by means of decoction, infusion or maceration. Herbal teas are usually presented in bulk form or in bags. The tea is prepared immediately before oral intake.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149560>	C148275	Herbal Tea in Bag Dosage Form|Herbal tea in bag	Medicinal product consisting of a herbal tea enclosed in a porous bag (a tea bag) intended to be placed in water for the preparation of an oral aqueous preparation on one occasion only.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149561>	C148275	Implant in Pre-filled Syringe Dosage Form|Implant in pre-filled syringe	Medicinal product consisting of an implant presented in a pre-filled syringe.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149562>	C70962	Implantation Method of Administration|Implantation	The technique of administration of a pharmaceutical product by placing it within a tissue of the body, usually as part of a surgical procedure.			Activity	EDQM Health Care Terminology|EDQM-HC Administration Method Terminology
C149563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149563>	C42942	Implantation Chain Dosage Form|Implantation chain	Solid sterile preparation consisting of small spheres mounted on a non-degradable thread to form a chain that allows withdrawal of the remainder of the chain after a certain period of action. Each implantation chain is presented in a sterile container. The implantation chain is intended for release over an extended period of time in order to obtain local or systemic effect.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149564>	C42942	Implantation Matrix Dosage Form|Implantation matrix	Solid sterile preparation consisting of a usually pliable, absorbent piece of material (e.g. collagen), usually impregnated with a liquid preparation, intended for implantation in the body. The material may be cut into smaller pieces before implantation, and may be shaped around a tissue (e.g. a bone) or inserted into a medical device that is then implanted. Implantation matrices are intended for release over an extended period of time, usually in order to obtain a local effect. Usually the matrix disappears with time.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149565>	C42942	Implantation Paste Dosage Form|Implantation paste	Semi-solid sterile preparation containing large proportions of solids finely dispersed in the basis, intended to be implanted in the body for release of the active substance(s) over an extended period of time, usually to obtain a systemic effect.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149566>	C42942	Implantation Suspension Dosage Form|Implantation suspension	Liquid sterile preparation consisting of a suspension intended for implantation in the body; the active substance(s) are released over an extended period of time to obtain a local or systemic effect.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149567>	C42942	Implantation Tablet Dosage Form|Implantation tablet	Solid sterile preparation prepared by compression of a solid active substance as such or of a formulation thereof into an implant of a size and shape suitable for implantation, usually subcutaneously. Each implantation tablet is presented in a sterile container. Implantation tablets are intended for release over an extended period of time in order to obtain local or systemic effect.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149568>	C16830	Implanter Device|Implanter	Device for administering implants.			Medical Device	EDQM Health Care Terminology|EDQM-HC Administration Device Terminology
C149569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149569>	C148439	Impregnated Dressing Dosage Form|Impregnated dressing	Solid preparation consisting of a piece or strip of gauze or other suitable fabric impregnated with a liquid or semi-solid preparation intended for cutaneous use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149570>	C171282	Impregnated Material Dosage Form Category|Impregnated material	A type of solid pharmaceutical dose form consisting of a material onto or into which active substance(s) are absorbed for subsequent release after administration, often over an extended period of time.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C149571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149571>	C148439	Impregnated Pad Dosage Form|Impregnated pad	Solid preparation consisting of a piece of absorbent material impregnated with a liquid preparation.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149572>	C148439	Impregnated Plug Dosage Form|Impregnated plug	Solid preparation consisting of a piece of material (e.g. polyethylene), usually porous, in which a liquid, semi-solid or solid preparation is impregnated.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149573>	C148242	In Drinking Water Use Route of Administration|In drinking water use	Administration of a veterinary medicinal product by incorporation into the animal drinking water.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Routes and Methods of Administration Terminology
C149574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149574>	C148242	In Drinking Water/Milk Use Route of Administration|In drinking water/milk use	Administration of a veterinary medicinal product by incorporation into the animal drinking water, milk or milk replacer.C238			Functional Concept	EDQM Health Care Terminology|EDQM-HC Routes and Methods of Administration Terminology
C149575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149575>	C148242	In Ovo Route of Administration|In Ovo|In ovo|In-Ovo|In-Ovo Route of Administration	Administration of a veterinary medicinal product through the shell into an embryonated egg.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Routes and Methods of Administration Terminology
C149576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149576>	C148242	In-feed Use Route of Administration|In-feed use	Administration of a veterinary medicinal product by incorporation into the animal feed.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Routes and Methods of Administration Terminology
C149577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149577>	C70962	Infusion Method of Administration|Infusion	The technique of administration of a pharmaceutical product, usually slowly and in larger volumes than for an injection, by introducing it into the body, usually after puncturing the skin; it is usually administered intravenously, but occasionally by other routes, e.g. subcutaneously.			Activity	EDQM Health Care Terminology|EDQM-HC Administration Method Terminology
C149578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149578>	C70962	Inhalation Method of Administration|Inhalation	The technique of administration of a pharmaceutical product by breathing it into the lungs, usually via the mouth.			Activity	EDQM Health Care Terminology|EDQM-HC Administration Method Terminology
C149579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149579>	C91142	Inhalation Powder, Hard Capsule Dosage Form|Hard capsule inhalation powder|Inhalation powder, hard capsule	Solid single-dose preparation intended for inhalation use, consisting of one or more powders of solid active substance(s) enclosed in a hard capsule. The capsule is loaded into a dry-powder inhaler to generate an aerosol.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149580>	C91142	Pre-dispensed Inhalation Powder Dosage Form|Inhalation powder, pre-dispensed	Solid preparation intended for inhalation use, consisting of one or more powders of solid active substance(s) presented in a suitable pharmaceutical form other than a hard capsule, either in the form of a single dose or divided into multiple single doses. The preparation is loaded into a dry-powder inhaler to generate an aerosol.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149581>	C91142	Inhalation Powder, Tablet Dosage Form|Inhalation powder, tablet	Solid multidose preparation intended for inhalation use. The dose of inhalation powder is generated from the tablet by a metering mechanism within the inhaler, for example by scraping off a small amount of powder from the tablet.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149582>	C148391	Inhalation Vapor, Capsule Dosage Form|Capsule for Inhalation|INHALATION VAPOR, CAPSULE|Inhalation vapour, capsule	Solid preparation consisting of a capsule formulation intended for generation of vapor to be inhaled to obtain a local effect. The vapor is usually generated by adding the whole capsule or the capsule contents to hot water.			Biomedical or Dental Material	CDISC SDTM Dosage Form Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149583>	C42910	Effervescent Tablet Inhalation Vapor Dosage Form|Inhalation vapour, effervescent tablet	Solid preparation consisting of a tablet usually containing acid substances and carbonates or hydrogen carbonates that react rapidly in the presence of aqueous liquid to release carbon dioxide, intended for generation of vapor to be inhaled to obtain a local effect. The vapor may be generated by adding the tablet to hot water.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149584>	C148391	Emulsion Inhalation Vapor Dosage Form|Emulsion for inhalation|Inhalation vapour, emulsion	Liquid preparation consisting of an emulsion intended for generation of vapor to be inhaled to obtain a local effect. The vapor may be generated by adding the emulsion to hot water.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149585>	C148391	Inhalation Vapor from Impregnated Pad Dosage Form|Inhalation vapour, impregnated pad	Solid preparation consisting of a piece of absorbent material impregnated usually with a liquid or semi-solid preparation, intended for generation of vapor to be inhaled to obtain a local effect.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149586>	C148391	Inhalation Vapor from Impregnated Plug Dosage Form|Inhalation vapour, impregnated plug	Solid preparation consisting of an impregnated plug that generates a vapor to be inhaled, for example by the patient inhaling through a device containing the plug, thereby drawing air through or over it and vaporizing the active ingredient(s) impregnated therein.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149587>	C148391	Inhalation Vapor, Liquid Dosage Form|Inhalation vapour, liquid	Liquid preparation consisting of a liquid active substance per se, such as an essential oil or a volatile anesthetic, intended for generation of vapor to be inhaled. The vapor may be generated by adding the liquid to hot water or by the use of a vaporizing device.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149588>	C148391	Inhalation Vapor, Ointment Dosage Form|Inhalation vapour, ointment	Semi-solid preparation consisting of an ointment intended for generation of vapor to be inhaled to obtain a local effect. The vapor may be generated by adding the ointment to hot water.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149589>	C148391	Inhalation Vapor, Powder Dosage Form|Inhalation vapour, powder	Solid preparation consisting of one or more powders of solid active substance(s) intended for generation of vapor to be inhaled to obtain a local effect. The vapor is usually generated by adding the powder to hot water.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149590>	C148391	Inhalation Vapor, Solution Dosage Form|Inhalation vapour, solution	Liquid preparation consisting of a solution intended for generation of vapor to be inhaled to obtain a local effect. The vapor is usually generated by adding the solution to hot water.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149591>	C148391	Inhalation Vapor, Tablet Dosage Form|Inhalation vapour, tablet	Solid preparation consisting of a tablet intended for generation of vapor to be inhaled to obtain a local effect. The vapor is usually generated by adding the tablet to hot water.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149592>	C70962	Injection Method of Administration|Injection	Administration by any method which pierces the skin, such as but not limited to intravenous, intramuscular, intraosseous, or subcutaneous injection.			Activity	EDQM Health Care Terminology|EDQM-HC Administration Method Terminology
C149593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149593>	C16830	In-ovo Injection Device|In-ovo injection device	Device for automatic injection into embryonated eggs.			Medical Device	EDQM Health Care Terminology|EDQM-HC Administration Device Terminology
C149594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149594>	C70962	Insertion Method of Administration|Insertion	The technique of administration of a pharmaceutical product by placing it into a body cavity, lesion, wound etc.			Activity	EDQM Health Care Terminology|EDQM-HC Administration Method Terminology
C149595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149595>	C149559	Instant Herbal Tea Dosage Form|Instant herbal tea	Solid preparation consisting of a lyophilized herbal drug extract intended to be dissolved in water before oral use. Instant herbal teas are supplied in bulk form (multidose) or in sachets (single-dose).			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149596>	C70962	Drop Instillation Method of Administration|Instillation	The technique of administration of a pharmaceutical product drop by drop onto or into the affected area.			Activity	EDQM Health Care Terminology|EDQM-HC Administration Method Terminology
C149597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149597>	C16830	Internal Graduated Calibration Chamber|Internal graduated calibration chamber	Graduated device for connection to a container for administering a cutaneous liquid to an animal.			Medical Device	EDQM Health Care Terminology|EDQM-HC Administration Device Terminology
C149598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149598>	C148444	Intestinal Gel Dosage Form|Intestinal gel	Semi-solid preparation consisting of a gel intended for intestinal use.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149599>	C38114	Intestinal Route of Administration|Intestinal use	Administration of a medicinal product to the intestine (duodenum, jejunum, ileum and colon) by means of an appropriate device.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Routes and Methods of Administration Terminology
C1495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1495>	C582|C1748	Intoplicine|7H-benzo(e)pyrido(4,3-b)indol-3-ol, 11-((3-(dimethylamino)propyl)amino)-8-methyl|INTOPLICINE|intoplicine	A benzopyridoindole derivative with antineoplastic property. Intoplicine inhibits activities of both topoisomerase I and II via intercalating DNA helix, thereby hindering the movements of enzymes along DNA molecules during DNA transcription and replication, respectively. Furthermore, this agent stabilizes DNA-enzyme complexes during unwinding processes by both topoisomerases, leading to double- and single-stranded DNA breaks. Consequently, these effects bring about cell growth inhibition and apoptosis of tumor cells.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C149600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149600>	C38232	Intracerebroventricular Route of Administration|Intracerebroventricular use	Administration of a medicinal product into the cerebral ventricles (cerebral ventricular system) of the brain.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Routes and Methods of Administration Terminology
C149601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149601>	C38114	Intracholangiopancreatic Route of Administration|Intracholangiopancreatic use	Injection of a medicinal product into the bile duct and the pancreatic duct, for example via a cannula introduced into the ampulla of Vater, usually for the administration of a contrast medium for techniques such as endoscopic retrograde cholangiopancreatography (ERCP).			Functional Concept	EDQM Health Care Terminology|EDQM-HC Routes and Methods of Administration Terminology
C149602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149602>	C38114	Intraglandular Route of Administration|Intraglandular use	Administration of a medicinal product directly into a gland, usually by injection.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Routes and Methods of Administration Terminology
C149603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149603>	C225418	Intramammary	Relating to the milk-producing organs (mammae) of a female mammal as the intended site of administration, to describe veterinary-only pharmaceutical products that are administered via the teat canal.			Spatial Concept	EDQM Health Care Terminology|EDQM-HC Intended Site of Administration Terminology
C149604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149604>	C148397	Intramammary Emulsion Dosage Form|Intramammary emulsion	Liquid sterile preparation for veterinary use consisting of an emulsion intended for intramammary use. Intramammary emulsions are presented in intramammary syringes for use on one occasion only to introduce the emulsion into a single teat canal.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149605>	C148397	Intramammary Gel Dosage Form|Intramammary gel	Semi-solid preparation for veterinary use consisting of a gel containing dissolved or dispersed active substance(s) intended for intramammary use. Intramammary gels are presented in intramammary syringes for use on one occasion only to introduce the gel into a single teat canal.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149606>	C42966|C148397	Intramammary Ointment Dosage Form|Intramammary ointment	Semi-solid sterile preparation for veterinary use consisting of an ointment containing dissolved or dispersed active substance(s) intended for intramammary use. Intramammary ointments are presented in intramammary syringes for use on one occasion only to introduce the ointment into a single teat canal.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149607>	C148397	Intramammary Solution Dosage Form|Intramammary solution	Liquid sterile preparation for veterinary use consisting of a solution intended for intramammary use. Intramammary solutions are presented in intramammary syringes for use on one occasion only to introduce the solution into a single teat canal.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149608>	C148397	Intramammary Suspension Dosage Form|Intramammary suspension	Liquid sterile preparation for veterinary use consisting of a suspension intended for intramammary use. Intramammary suspensions are presented in intramammary syringes for use on one occasion only to introduce the suspension into a single teat canal.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149609>	C43202	Intramammary Syringe|Intramammary syringe	Device for introducing a pharmaceutical form through the teat canal.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Administration Device Terminology
C149610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149610>	C91163	Intraocular Instillation Solution Dosage Form|Intraocular instillation solution|Intraocular solution	Liquid sterile preparation consisting of a solution intended to be instilled as drops into an internal part of the eye.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149611>	C38291	Intraportal Route of Administration|Intraportal use	Injection/infusion of a medicinal product into the hepatic portal vein for local delivery to the liver.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Routes and Methods of Administration Terminology
C149612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149612>	C171282	Intraruminal Device Dosage Form Category|Intraruminal device	A type of solid pharmaceutical dose form intended for administration to ruminant animals where it is retained in the rumen for release of the active substance(s), usually over an extended period of time.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C149613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149613>	C148449	Intrauterine Capsule Dosage Form|Intrauterine capsule	Solid single-dose preparation for veterinary use consisting of a soft capsule containing a liquid or semi-solid preparation intended for intrauterine use, including preparations releasing their contents over an extended period of time.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149614>	C45235|C17423	Intrauterine Delivery System Dosage Form|INTRAUTERINE SYSTEM|Intrauterine delivery system	Solid single-dose delivery system intended for intrauterine use that releases its contents of active substance(s) over an extended period of time.			Medical Device	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149615>	C148449	Intrauterine Emulsion Dosage Form|Intrauterine emulsion	Liquid preparation for veterinary use consisting of an emulsion intended for intrauterine use.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149616>	C148449	Intrauterine Foam Dosage Form|Intrauterine foam	Liquid preparation for veterinary use, usually presented in a pressurized container provided with an applicator suitable for delivery to the uterus of foam containing large volumes of gas dispersed in a liquid containing the active substance(s).			Functional Concept	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149617>	C148449	Intrauterine Solution Dosage Form|Intrauterine solution	Liquid preparation for veterinary use consisting of a solution intended for intrauterine use.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149618>	C148449	Intrauterine Suspension Dosage Form|Intrauterine suspension	Liquid preparation for veterinary use consisting of a suspension intended for intrauterine use.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149619>	C148449	Intrauterine Tablet Dosage Form|Intrauterine tablet	Solid single-dose preparation for veterinary use prepared by compression or molding into tablets of a size and shape suited for administration to the uterus, including preparations releasing their contents over an extended period of time.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149620>	C45246	Intravesical Solution Dosage Form|Intravesical solution	Liquid preparation consisting of an aqueous solution intended for intravesical use by means of a suitable applicator.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149621>	C45246	Intravesical Solution/Solution for Injection Dosage Form|Intravesical solution/solution for injection	Liquid sterile preparation consisting of a solution intended for intravesical use or for administration by injection.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149622>	C45246	Intravesical Suspension Dosage Form|Intravesical suspension	Liquid preparation consisting of a small-volume suspension intended for intravesical use by means of a suitable applicator.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149623>	C225418	Intravesical/Uretheral	Relating to the urinary bladder or the urethra.			Spatial Concept	
C149624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149624>	C148275	Intravitreal Implant in Applicator Dosage Form|Intravitreal implant in applicator	Medicinal product consisting of an intravitreal implant presented in an applicator.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149625>	C47916	Radiopharmaceutical Preparation Kit Dosage Form|Kit for radiopharmaceutical preparation	A preparation to be reconstituted or combined with radionuclides in the final radiopharmaceutical, usually prior to its administration.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149626>	C154551	Lacquer Dosage Form Category|Lacquer	A type of liquid pharmaceutical dose form consisting of one or more substances dissolved or suspended in a volatile solvent that evaporates to leave a hard coating.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C149627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149627>	C148451	Laryngopharyngeal Solution Dosage Form|Laryngopharyngeal solution	Liquid preparation consisting of a solution intended for administration to the laryngopharynx for a local effect, other than by spraying.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149628>	C148451	Laryngopharyngeal Spray, Solution Dosage Form|Laryngopharyngeal spray, solution	Liquid preparation consisting of a solution intended for spraying onto the laryngopharynx for a local effect.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149629>	C148243	Lick Block Dosage Form|Lick block	Solid block containing active substance(s) intended for veterinary use. It is formed by pressing. Administration takes place when the animal is licking the block.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149630>	C87836	Living Tissue Equivalent Dosage Form|Living tissue equivalent	Cultured, living tissue used for the reconstruction of parts of the body. The tissue may consist of ex vivo expanded cells with an extracellular matrix.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149631>	C48470	Lyophilisate Dosing Unit|Lyophilisate	A unit of presentation used to represent the quantity of product that is found in a single discrete entity where the pharmaceutical dose form is a type of lyophilisate.			Quantitative Concept	EDQM Health Care Terminology|EDQM-HC Units of Presentation Terminology
C149632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149632>	C148268	Lyophilisate and Solvent for Oculonasal Suspension Dosage Form|Lyophilisate and solvent for oculonasal suspension	Lyophilisate and solvent intended for the preparation of an oculonasal suspension, for veterinary use, by dispersing the lyophilisate in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149633>	C148268	Lyophilisate and Solvent for Oral Suspension Dosage Form|Lyophilisate and solvent for oral suspension	Lyophilisate and solvent intended for the preparation of an oral suspension, for veterinary use, by dispersing the lyophilisate in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149634>	C148268	Lyophilisate and Solvent for Solution for Injection Dosage Form|Lyophilisate and solvent for solution for injection	Sterile lyophilisate and sterile solvent intended for the preparation of a solution for injection, for veterinary use, by dissolving the lyophilisate in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149635>	C148268	Lyophilisate and Solvent for Suspension for Injection Dosage Form|Lyophilisate and solvent for suspension for injection	Sterile lyophilisate and sterile solvent intended for the preparation of a suspension for injection, for veterinary use, by dispersing the lyophilisate in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149636>	C148268	Lyophilisate and Suspension for Suspension for Injection Dosage Form|Lyophilisate and suspension for suspension for injection	Sterile lyophilisate and sterile suspension, both of which contain active substance(s), intended for the preparation of a suspension for injection, for veterinary use, by dispersing the lyophilisate in the suspension.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149637>	C87541	Lyophilisate for Oculonasal Suspension Dosage Form|Lyophilisate for oculonasal suspension	Solid preparation for veterinary use consisting of a freeze-dried powder intended to be dispersed in the specified liquid to create a suspension for oculonasal use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149638>	C87541	Lyophilisate for Oculonasal Suspension/Use in Drinking Water Dosage Form|Lyophilisate for oculonasal suspension/use in drinking water	Solid preparation for veterinary use consisting of a freeze-dried powder intended to be dispersed in the specified liquid to create a suspension for oculonasal use, or to be dispersed in the animal drinking water.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149639>	C87541	Lyophilisate for Oral Spray, Suspension Dosage Form|Lyophilisate for oral spray, suspension	Solid preparation for veterinary use consisting of a freeze-dried powder intended to be dispersed in the specified liquid to obtain an oral spray, suspension.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149640>	C87541	Lyophilisate for Oral Suspension Dosage Form|Lyophilisate for oral suspension	Solid preparation for veterinary use consisting of a freeze-dried powder intended to be dispersed in the specified liquid to create an oral suspension.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149641>	C87541	Lyophilisate for Solution for Infusion Dosage Form|Lyophilisate for solution for infusion	Solid sterile preparation for veterinary use consisting of a freeze-dried powder intended to be dissolved in the specified liquid to obtain a solution for infusion.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149642>	C87541	Lyophilisate for Solution for Injection Dosage Form|Lyophilisate for solution for injection	Solid sterile preparation for veterinary use consisting of a freeze-dried powder intended to be dissolved in the specified liquid to obtain a solution for injection.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149643>	C87541	Lyophilisate for Suspension for Injection Dosage Form|Lyophilisate for suspension for injection	Solid sterile preparation for veterinary use consisting of a freeze-dried powder intended to be dispersed in the specified liquid to obtain a suspension for injection.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149644>	C87541	Lyophilisate for Use in Drinking Water Dosage Form|Lyophilisate for use in drinking water	Solid preparation for veterinary use consisting of a freeze-dried powder intended to be dissolved in the animal drinking water. If alternative methods of administration to individual animals are also authorized, the method of administration is clearly described in the product information.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149645>	C48470	Matrix Dosing Unit|Matrix	A unit of presentation used to represent the quantity of product that is found in a single discrete entity where the pharmaceutical dose form is a type of matrix.			Quantitative Concept	EDQM Health Care Terminology|EDQM-HC Units of Presentation Terminology
C149646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149646>	C45235	Matrix for Implantation Matrix Dosage Form|Matrix for implantation matrix	Solid sterile preparation consisting of a usually pliable, absorbent piece of material (e.g. collagen) intended to be used in the preparation of an implantation matrix.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149647>	C81182	Measuring Spoon|Measuring spoon	Spoon for the administration of liquid and multidose solid pharmaceutical forms.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Administration Device Terminology
C149648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149648>	C42894	Oral Gum Dosage Form|Oral gum	Solid single-dose preparation with a gum-like consistency, intended to be sucked or chewed before being swallowed. Medicated chewing gum is excluded.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149649>	C148243	Medicated Collar Dosage Form|Medicated collar	Solid preparation for veterinary use consisting of a matrix impregnated with active substance(s), which is worn around the animal's neck. The active substance(s) are released by diffusion, by mechanical means or by vaporization over a period of time.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149650>	C42953	Medicated Nail Lacquer Dosage Form|Medicated nail lacquer	Liquid preparation to be applied to the nails to form a lacquer by evaporation of the volatile solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149651>	C148243	Medicated Pellets Dosage Form|Medicated pellets	Solid single-dose or multidose preparation intended for veterinary use, consisting of large granules, usually formed by extrusion, intended for oral use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149652>	C148243	Medicated Pendant Dosage Form|Medicated pendant	Solid preparation for veterinary use consisting of a matrix impregnated with active substance(s), which is fixed to a device to be worn around the animal's neck. The active substance(s) are released by diffusion, by mechanical means or by vaporization over a period of time.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149653>	C42970	Medicated Plaster Dosage Form|Medicated plaster	Flexible single-dose preparation intended to be applied to the skin to obtain, usually, a local effect. Medicated plasters consist of an adhesive basis containing the active substance and spread as a uniform layer on an appropriate support made of natural or synthetic material. The adhesive layer is covered by a suitable protective liner, which is removed before applying the plaster to the skin. Medicated plasters are presented in a range of sizes or as larger sheets to be cut before use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149654>	C47889	Medicated Thread Dosage Form|Medicated thread	Solid preparation consisting of a biodegradable or non-degradable thread impregnated with active substance(s).			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149655>	C69048	Medicated Vaginal Tampon Dosage Form|Medicated vaginal tampon	Solid single-dose preparation consisting of a suitable material impregnated with active substance(s) intended to be inserted in the vagina for a limited period of time.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149656>	C42933	Compressed Medicinal Gas Dosage Form|Medicinal gas, compressed	A gas packaged under pressure which is entirely gaseous at -50 degrees C.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149657>	C42933	Cryogenic Medicinal Gas Dosage Form|Medicinal gas, cryogenic	A gas which liquefies at 1.013 bar at a temperature below -150 degrees C.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149658>	C42933	Liquefied Medicinal Gas Dosage Form|LIQUEFIED GAS|Medicinal gas, liquefied	A gas packaged under pressure, which is partially liquid (gas over liquid) at -50 degrees C.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149659>	C96112	Metered Actuation Pump Device|Metering pump	Closure whereby a measured quantity of the contents is released by mechanical actuation of the pump.			Intellectual Product	EDQM Health Care Terminology|EDQM-HC Closure Terminology
C149660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149660>	C96112	Metered Actuation Valve Device|Metering valve	Closure whereby a measured quantity of the contents is released by actuation of the valve.			Intellectual Product	EDQM Health Care Terminology|EDQM-HC Closure Terminology
C149661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149661>	C16830	Mobile Cryogenic Vessel|Mobile cryogenic vessel	A mobile thermally insulated container designed to maintain the contents in a liquid state.			Medical Device	EDQM Health Care Terminology|EDQM-HC Container Terminology
C149662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149662>	C54680	Modified-release Mechanism of Action|Modified	Release of the substance(s) in a way that differs from that which would be achieved with a conventional-release product, which is achieved by a special formulation design and/or manufacturing method, but which is not classified as delayed-release or prolonged-release; pulsatile-release products are included.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Release Characteristics Terminology
C149663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149663>	C64904	Modified-release Hard Capsule Dosage Form|Modified-release capsule, hard	Solid single-dose preparation consisting of a hard shell containing a solid or semi-solid formulation, showing a rate, a place and/or a time of release different from that of a conventional-release capsule. This deliberate modification is achieved by a special formulation design and/or manufacturing method.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149664>	C64909	Modified-release Soft Capsule Dosage Form|Modified-release capsule, soft	Solid single-dose preparation consisting of a soft shell containing a semi-solid or liquid formulation, showing a rate, a place and/or a time of release different from that of a conventional-release capsule. This deliberate modification is achieved by a special formulation design and/or manufacturing method.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149665>	C42938	Modified-release Granule Dosage Form|Modified-release granules|Modified-release granules	Solid preparation consisting of granules showing a rate and/or place of release different from that of conventional-release granules. This deliberate modification is achieved by a special formulation design and/or manufacturing method. Modified-release granules are usually single-dose preparations intended for oral use, and include prolonged-release, delayed release and pulsatile-release granules.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149666>	C42938	Modified-release Granule for Oral Suspension Dosage Form	Solid preparation consisting of modified-release granules intended to be dispersed in the specified liquid to obtain an oral suspension.			Biomedical or Dental Material	
C149667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149667>	C16830	Mouthpiece	Aid used for the administration or inhalation of a medicinal product by mouth.			Medical Device	EDQM Health Care Terminology|EDQM-HC Administration Device Terminology
C149668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149668>	C29269	Mouthwash, Powder for Solution Dosage Form|Mouthwash, powder for solution	Solid preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain a mouthwash.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149669>	C29269	Mouthwash, Tablet for Solution Dosage Form|Mouthwash, tablet for solution	Solid preparation consisting of an uncoated tablet intended to be dissolved in water to obtain a mouthwash.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149670>	C42755	Muco-adhesive Buccal Tablet Dosage Form|Muco-adhesive buccal tablet	Solid single-dose preparation to be applied to the buccal mucosa to obtain a systemic delivery over an extended period of time. Mucoadhesive buccal tablets are usually prepared by compression of mixtures of powders or granulations into tablets with a shape suited for the intended use. They usually contain hydrophilic polymers, which on wetting with saliva produce a flexible hydrogel that adheres to the buccal mucosa.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149671>	C148453	Multidose Container with Airless Pump|Multidose container with airless pump	Multidose container with an integral pump designed to protect the contents against in use-contamination.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Container Terminology
C149672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149672>	C148453	Multidose Container with Metering Pump|Multidose container with metering pump	Multidose container with integral metering pump.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Container Terminology
C149673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149673>	C148453	Multidose Container with Pump|Multidose container with pump	Multidose container with an integral pump. Metering pump, spray pump, and multidose container with airless pump are excluded.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Container Terminology
C149674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149674>	C16830	Multipuncturer	Device for puncturing the skin, normally used for immunological products, especially diagnostics.			Medical Device	EDQM Health Care Terminology|EDQM-HC Administration Device Terminology
C149675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149675>	C50341	Nasal Applicator Device|Nasal applicator	Aid used for the administration of a drug by nose.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Administration Device Terminology
C149676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149676>	C219579|C219573	Emulsion Nasal Drops Dosage Form|Nasal drops emulsion|Nasal drops, emulsion	Liquid single-dose or multidose preparation consisting of an emulsion intended for nasal use by means of a suitable applicator.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149677>	C148268	Nasal Drops, Lyophilisate and Solvent for Suspension Dosage Form|Nasal drops, lyophilisate and solvent for suspension	Lyophilisate and solvent intended for the preparation of nasal drops, suspension, for veterinary use, by dispersing the lyophilisate in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149678>	C87541	Nasal Drops, Lyophilisate for Suspension Dosage Form|Nasal drops, lyophilisate for suspension	Solid preparation for veterinary use consisting of a freeze-dried powder intended to be dispersed in the specified liquid to obtain a suspension for use as nasal drops.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149679>	C148268	Nasal Drops, Powder and Solvent for Solution Dosage Form|Nasal drops, powder and solvent for solution	Powder and solvent intended for the preparation of nasal drops, solution, by dissolving the powder in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149680>	C148454	Nasal Drops, Powder for Solution Dosage Form|Nasal drops, powder for solution|Powder for nasal drops	Solid preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain a nasal drops solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149681>	C148275	Nasal Drops, Solution in Single-dose Container Dosage Form|Nasal drops, solution in single-dose container	Medicinal product consisting of a nasal drops solution presented in a single-dose container.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149682>	C91157|C219579	Emulsion Nasal Spray Dosage Form|Nasal spray emulsion|Nasal spray, emulsion	Liquid single-dose or multidose preparation consisting of an emulsion in a container with or without a metering dose valve or in a container with a spray pump or equivalent device to create a spray, intended for nasal use.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149683>	C148268	Nasal Spray, Lyophilisate and Solvent for Suspension Dosage Form|Nasal spray, lyophilisate and solvent for suspension	Lyophilisate and solvent intended for the preparation of a nasal spray, suspension, for veterinary use, by dispersing the lyophilisate in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149684>	C87541	Nasal Spray, Lyophilisate for Suspension Dosage Form|Nasal spray, lyophilisate for suspension	Solid preparation consisting of a freeze-dried powder intended to be dispersed in the specified liquid to obtain a nasal spray, suspension.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149685>	C148454	Nasal Spray, Powder for Solution Dosage Form|Nasal spray, powder for solution	Solid preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain a nasal spray solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149686>	C69064	Nasal Spray, Solution Dosage Form|Nasal spray, solution	Liquid single-dose or multidose preparation consisting of a solution in a container with or without a metering dose valve or in a container with a spray pump or equivalent device to create a spray, intended for nasal use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149687>	C148275	Nasal Spray, Solution in Single-dose Container Dosage Form|Nasal spray, solution in single-dose container	Medicinal product consisting of a nasal spray solution presented in a single-dose container.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149688>	C69064	Nasal Spray, Solution/Oromucosal Solution Dosage Form|Nasal spray, solution/oromucosal solution	Liquid preparation consisting of a solution intended for use as a nasal spray or an oromucosal solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149689>	C69064	Nasal Spray, Suspension Dosage Form|Nasal spray, suspension	Liquid single-dose or multidose preparation consisting of a suspension in a container with or without a metering dose valve or in a container with a spray pump or equivalent device to create a spray, intended for nasal use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149690>	C69064	Nasal Stick Dosage Form|Nasal stick	Solid single-dose preparation, usually rod-shaped or conical, intended for nasal use to obtain a local effect.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149691>	C69064	Nasal Wash Dosage Form|Nasal wash	Liquid single-dose or multidose preparation consisting of usually an aqueous isotonic solution intended for cleansing the nasal cavities.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149692>	C69064	Nasal/Oromucosal Solution Dosage Form|Nasal/oromucosal solution	Liquid preparation consisting of a solution intended for nasal or oromucosal application.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149693>	C69064	Nasal/Oromucosal Spray Solution Dosage Form|Nasal/oromucosal spray, solution	Liquid preparation consisting of a solution in a container with or without a metering dose valve or in a container with a spray pump, intended for nasal or oromucosal use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149694>	C42986|C148243	Nebulization Solution Dosage Form|Nebulisation solution	Liquid preparation consisting of a solution intended for conversion by nebulizers into an aerosol.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149695>	C38216	Nebulizer Route of Administration|Nebulisation use	Administration of medicinal product converted into an aerosol.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Routes and Methods of Administration Terminology
C149696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149696>	C219598	Nebulizer Emulsion Dosage Form|Nebuliser emulsion	Liquid preparation consisting of an emulsion intended for inhalation to obtain local effect or systemic delivery. The emulsion is converted into an aerosol by a continuously operating nebulizer or a metered-dose nebulizer.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149697>	C219598	Nebulizer Solution Dosage Form|Neb|Nebs|Nebuliser solution|Nebulizer Solution	Liquid preparation consisting of a solution intended for inhalation use. The solution is converted into an aerosol by a continuously operating nebulizer or a metered-dose nebulizer.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149698>	C219598	Nebulizer Suspension Dosage Form|Nebuliser suspension	Liquid preparation consisting of a suspension intended for inhalation use. The suspension is converted into an aerosol by a continuously operating nebulizer or a metered-dose nebulizer.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149699>	C16830	Needle-free Injector|Needle-free injector	Device for injecting a medicinal product, usually a liquid, by means of high pressure without a needle, through the skin barrier.			Medical Device	EDQM Health Care Terminology|EDQM-HC Administration Device Terminology
C1496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1496>	C360	DOTMP|(1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrayltetrakis(methylene))tetrakisphosphonic Acid|1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetramethylene-Phosphonic Acid	A bone-seeking chelating agent.  Has been used as a radiopharmaceutical in complexes with radioactive metals for bone marrow ablation.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C149700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149700>	C64925	No Transformation|No transformation	No transformation of the product takes place.			Activity	EDQM Health Care Terminology|EDQM-HC Transformation Terminology
C149701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149701>	C70962	Unspecified Method of Administration|Not specified	The technique of administration of a pharmaceutical product by an unspecified method.			Activity	EDQM Health Care Terminology|EDQM-HC Administration Method Terminology
C149702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149702>	C13442	Oculonasal	Relating to the eyes and nares of a bird as the intended site of administration.			Spatial Concept	EDQM Health Care Terminology|EDQM-HC Intended Site of Administration Terminology
C149703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149703>	C148243	Oculonasal Suspension Dosage Form|Oculonasal suspension	Liquid, usually multidose preparation for veterinary use consisting of a suspension intended for oculonasal use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149704>	C69039	Ophthalmic Insert Dosage Form|Ophthalmic insert	Solid sterile preparation of suitable size and shape, designed to be inserted in the conjunctival sac to produce a local or ocular effect by the release of active substance(s) over a determined period of time. Ophthalmic inserts generally consist of a reservoir of active substance(s) embedded in a matrix or bounded by a rate-controlling membrane. They are presented individually in sterile containers.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149705>	C69039	Ophthalmic Strip Dosage Form|Ophthalmic strip	Solid sterile single-dose preparation consisting of a strip made of a suitable material usually impregnated with active substance(s) intended for use on the eyeball.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149706>	C50341	Oral Applicator Device|Oral applicator	Administration device for administering a liquid or semi-solid pharmaceutical form to the oral cavity.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Administration Device Terminology
C149707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149707>	C219574	Oral Drops, Emulsion Dosage Form|Oral drops, emulsion	Liquid, usually multidose preparation consisting of an emulsion intended for oral use. The preparation is administered in small volumes as drops by means of a suitable device such as a dropper. The measured dose may be diluted in water or another suitable liquid before swallowing.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149708>	C42744	Oral Drops, Granules for Solution Dosage Form|Oral drops, granules for solution	Solid preparation consisting of granules intended to be dissolved in the specified liquid to obtain an oral drops solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149709>	C219574	Oral Drops, Liquid Dosage Form|Oral drops, liquid	Liquid, usually multidose preparation consisting of a liquid active substance per se, intended for oral use. The preparation is administered in small volumes as drops by means of a suitable device such as a dropper. The measured dose may be diluted in water or another suitable liquid before swallowing.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149710>	C42744	Oral Drops, Powder for Suspension Dosage Form|Oral drops, powder for suspension	Solid preparation consisting of one or more powders intended to be dispersed in the specified liquid to obtain an oral drops suspension.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149711>	C219574	Oral Drops, Solution Dosage Form|Oral drops, solution	Liquid, usually multidose preparation consisting of a solution intended for oral use. The preparation is administered in small volumes as drops by means of a suitable device such as a dropper. The measured dose may be diluted in water or another suitable liquid before swallowing.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149712>	C219574	Oral Drops, Suspension Dosage Form|Oral drops, suspension	Liquid, usually multidose preparation consisting of a suspension intended for oral use. The preparation is administered in small volumes as drops by means of a suitable device such as a dropper. The measured dose may be diluted in water or another suitable liquid before swallowing.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149713>	C38288	Oral Emulsion Dosage Form|Oral emulsion	Liquid, single-dose or multidose preparation consisting of an emulsion intended for oral use. Each dose from a multidose container is administered by means of a device suitable for measuring the prescribed volume. The device is usually a spoon or a cup for volumes of 5 mL or multiples thereof or an oral syringe for other volumes.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149714>	C148275	Oral Emulsion in Sachet Dosage Form|Oral emulsion in sachet	Medicinal product consisting of an oral emulsion presented in a sachet.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149715>	C148413	Oral Herbal Material Dosage Form|Oral herbal material	Solid preparation consisting of whole, broken or fragmented plants or parts of plants in an unprocessed state (herbal drug), intended for oral use without requiring transformation (e.g. dissolution or dispersion in water); the material may be dried or fresh, and may be chewed before being swallowed. The word 'plant' is used in the broader sense to include also algae, fungi and lichens.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149716>	C68996	Oral Liquid Dosage Form|Oral liquid	Liquid, single-dose or multidose preparation consisting of a liquid active substance per se, intended for oral use. Each dose from a multidose container is administered by means of a device suitable for measuring the prescribed volume. The device is usually a spoon or a cup for volumes of 5 mL or multiples thereof or an oral syringe for other volumes.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149717>	C148413	Oral Lyophilisate Dosage Form|Oral lyophilisate	Solid single-dose preparation made by freeze-drying of a liquid or semi-solid preparation. This fast-releasing preparation is intended to be placed in the mouth where its contents are released in saliva and swallowed or, alternatively, to be dissolved in water before oral administration.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149718>	C148275	Oral Paste in Sachet Dosage Form|Oral paste in sachet	Medicinal product consisting of an oral paste presented in a sachet.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149719>	C148275	Oral Powder in Sachet Dosage Form|Oral powder in sachet	Medicinal product consisting of an oral powder presented in a sachet.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149720>	C148275	Oral Solution in Sachet Dosage Form|Oral solution in sachet	Medicinal product consisting of an oral solution presented in a sachet.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149721>	C148275	Oral Solution in Single-dose Container Dosage Form|Oral solution in single-dose container	Medicinal product consisting of an oral solution presented in a single-dose container.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149722>	C68996	Oral Solution/Concentrate for Nebulizer Solution Dosage Form|Oral solution/concentrate for nebuliser solution	Liquid preparation consisting of a solution intended for oral use or intended to be diluted in the specified liquid to obtain a nebulizer solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149723>	C68992	Oral Spray, Suspension Dosage Form|Oral spray, suspension	Liquid, usually multidose preparation for veterinary use consisting of a suspension intended for oral use. It is administered by spraying, including by spraying as coarse droplets over the animal(s), which then consume the product, for example during preening.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149724>	C148275	Oral Suspension in Pre-filled Oral Applicator Dosage Form|Oral suspension in pre-filled oral applicator	Medicinal product consisting of an oral suspension presented in a pre-filled oral applicator.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149725>	C148275	Oral Suspension in Sachet Dosage Form|Oral suspension in sachet	Medicinal product consisting of an oral suspension presented in a sachet.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149726>	C43202	Oral Syringe|Oral syringe	Administration device for administering a liquid or semi-solid pharmaceutical form to the oral cavity.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Administration Device Terminology
C149727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149727>	C68996	Oral/Rectal Solution Dosage Form|Oral/rectal solution	Liquid preparation consisting of a solution intended for oral or rectal use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149728>	C68992	Oral/Rectal Suspension Dosage Form|Oral/rectal suspension	Liquid preparation consisting of a suspension intended for oral or rectal use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149729>	C42932	Orally Disintegrating Film Dosage Form|Orodispersible film	Solid preparation consisting of a single- or multilayer sheet of suitable material(s) intended to be placed in the mouth where it disperses rapidly before being swallowed.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149730>	C70962	Oral Disintegration Method of Administration|Orodispersion	The technique of administration of a pharmaceutical product by placing it in the mouth and allowing it to dissipate; the product is usually then swallowed.			Activity	EDQM Health Care Terminology|EDQM-HC Administration Method Terminology
C149731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149731>	C13442	Oromucosal	Relating to the mouth as the intended site of administration, where the pharmaceutical product is administered with the intention of acting on the mucosa of the mouth, whether for local or systemic use after application to the mouth.			Spatial Concept	EDQM Health Care Terminology|EDQM-HC Intended Site of Administration Terminology
C149732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149732>	C148414	Oromucosal Capsule Dosage Form|Oromucosal capsule	Solid single-dose preparation contained in a soft shell to be chewed or sucked to obtain a local effect in the oral cavity.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149733>	C148414	Oromucosal Cream Dosage Form|Oromucosal cream	Semi-solid, usually multidose preparation consisting of an oil-in-water emulsion intended for oromucosal use. Oromucosal creams are applied to the oral cavity or onto a specific part of the oral cavity, other than the gingivae, to obtain a local effect.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149734>	C148414	Oromucosal Drops Dosage Form	Liquid, usually multidose preparation consisting of a solution, suspension or emulsion intended for oromucosal use. Oromucosal drops are administered by instillation into the oral cavity or onto a specific part of the oral cavity.			Biomedical or Dental Material	
C149735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149735>	C148414	Oromucosal Gel Dosage Form|Oromucosal gel	Semi-solid single-dose or multidose preparation consisting of a hydrophilic gel intended for oromucosal use. It is applied to the oral cavity or onto a specific part of the oral cavity, to obtain a local effect.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149736>	C148414	Oromucosal Ointment Dosage Form|Oromucosal ointment	Semi-solid multidose preparation consisting of an ointment intended for oromucosal use. It is applied to the oral cavity or onto a specific part of the oral cavity, to obtain a local effect			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149737>	C148414	Oromucosal Paste Dosage Form|Oromucosal paste	Semi-solid single-dose or multidose preparation consisting of a paste of solid particles finely dispersed in a hydrophilic basis intended for oromucosal use. Oromucosal pastes are applied to the oral cavity or onto a specific part of the oral cavity, to obtain a local effect.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149738>	C148414	Oromucosal Patch Dosage Form|Oromucosal patch	Flexible single-dose preparation intended to be applied to the oral cavity to obtain either a systemic or a local effect by delivering the active substance(s) over a certain period of time, after which it is then removed.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149739>	C148275	Oromucosal Powder in Pouch Dosage Form	Medicinal product consisting of an oromucosal powder presented in a pouch.			Biomedical or Dental Material	
C149740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149740>	C219596	Oromucosal Solution Dosage Form|Oromucosal solution	Liquid single-dose or multidose preparation consisting of a solution intended for oromucosal use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149741>	C219607	Oromucosal Spray, Emulsion Dosage Form|Oromucosal spray, emulsion	Liquid, usually multidose preparation consisting of an emulsion intended for oromucosal use. It is administered by spraying into the oral cavity or onto a specific part of the oral cavity or the throat. It is presented in a container with a spray pump or in a pressurized container with or without a metering valve.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149742>	C219607	Oromucosal Spray, Solution Dosage Form|Oromucosal spray, solution	Liquid, usually multidose preparation consisting of a solution intended for oromucosal use. It is administered by spraying into the oral cavity or onto a specific part of the oral cavity or the throat. It is presented in a container with a spray pump or in a pressurized container with or without a metering valve.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149743>	C219607	Oromucosal Spray, Suspension Dosage Form|Oromucosal spray, suspension	Liquid, usually multidose preparation consisting of a suspension intended for oromucosal use. It is administered by spraying into the oral cavity or onto a specific part of the oral cavity or the throat. It is presented in a container with a spray pump or in a pressurized container with or without a metering valve.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149744>	C219596	Oromucosal Suspension Dosage Form|Oromucosal suspension	Liquid single-dose or multidose preparation consisting of a suspension intended for oromucosal use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149745>	C148414	Oromucosal/Laryngopharyngeal Solution Dosage Form|Oromucosal/laryngopharyngeal solution	Liquid preparation consisting of a solution intended for oromucosal or laryngopharyngeal use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149747>	C48470	Pastille Dosing Unit|Pastille	A unit of presentation used to represent the quantity of product that is found in a single discrete entity where the pharmaceutical dose form is a type of pastille.			Quantitative Concept	EDQM Health Care Terminology|EDQM-HC Units of Presentation Terminology
C149748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149748>	C48470	Pen Dosing Unit|Pen	A unit of presentation used to represent the quantity of product that is found in a single pen container.			Quantitative Concept	EDQM Health Care Terminology|EDQM-HC Units of Presentation Terminology
C149749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149749>	C48470	Pendant Dosing Unit|Pendant	A unit of presentation used to represent the quantity of product that is found in a single discrete entity where the pharmaceutical dose form is a type of pendant.			Quantitative Concept	EDQM Health Care Terminology|EDQM-HC Units of Presentation Terminology
C149750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149750>	C42934	Periodontal Gel Dosage Form|Periodontal gel	Semi-solid preparation consisting of a gel intended to be placed in the pouch between the tooth and the gingiva.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149751>	C69059	Periodontal Insert Dosage Form|Dental insert|Periodontal insert	Solid single-dose preparation consisting of a medicated insert to be placed within the tooth socket/periodontal membrane. The biodegradable insert is a sheet which slowly releases active substance(s).			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149752>	C69059	Periodontal Powder Dosage Form|Periodontal powder	Solid preparation consisting of one or more powders intended for administration within the tooth socket/periodontal membrane.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149753>	C38291	Periosseous Route of Administration|Periosseous use	Administration of a medicinal product on or around the bone			Functional Concept	EDQM Health Care Terminology|EDQM-HC Routes and Methods of Administration Terminology
C149754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149754>	C38291	Peritumoral Route of Administration|Peritumoral use	Administration of a medicinal product directly into the region surrounding a tumor.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Routes and Methods of Administration Terminology
C149755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149755>	C69048	Pessary Dosage Form|Pessary|Vaginal insert	Solid, single-dose preparation usually prepared by molding, of various shapes, usually ovoid, with a volume and consistency suitable for insertion into the vagina to obtain a local effect. It contains one or more active substances dispersed or dissolved in a suitable basis that may be soluble or dispersible in water or may melt at body temperature.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149756>	C48470	Pessary Dosage Unit|Pessary	A unit of presentation used to represent the quantity of product that is found in a single discrete entity where the pharmaceutical dose form is a type of pessary.			Quantitative Concept	EDQM Health Care Terminology|EDQM-HC Units of Presentation Terminology
C149757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149757>	C48470	Pillule Dosage Unit|Pillule	A unit of presentation used to represent the quantity of product that is found in a single discrete entity where the pharmaceutical dose form is a type of pillule.			Quantitative Concept	EDQM Health Care Terminology|EDQM-HC Units of Presentation Terminology
C149758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149758>	C45235	Pillule Dosage Form|Pillules	Solid preparation for homeopathic use, obtained from sucrose, lactose or other suitable excipients. Pillules may be prepared by impregnation of preformed pillules with a dilution or dilutions of homeopathic stocks or by progressive addition of these excipients and the addition of a dilution or dilutions of homeopathic stocks. Pillules are intended for oral or sublingual use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149759>	C148275	Pillules in Single-dose Container Dosage Form|Pillules in single-dose container	Medicinal product consisting of pillules presented in a single-dose container.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149760>	C48470	Pipette Dosage Unit|Pipette	A unit of presentation used to represent the quantity of product that is found in a single pipette administration device.			Quantitative Concept	EDQM Health Care Terminology|EDQM-HC Units of Presentation Terminology
C149761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149761>	C48470	Plaster Dosing Unit|Plaster	A unit of presentation used to represent the quantity of product that is found in a single discrete entity where the pharmaceutical dose form is a type of plaster.			Quantitative Concept	EDQM Health Care Terminology|EDQM-HC Units of Presentation Terminology
C149762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149762>	C45235	Plaster for Provocation Test Dosage Form|Plaster for provocation test	Solid flexible preparation containing an allergen product intended for provocation testing by application to the skin.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149763>	C48470	Plug Dosing Unit|PLUG|Plug|{PLUG}|{PLUG}	A unit of presentation used to represent the quantity of product that is found in a single discrete entity where the pharmaceutical dose form is a type of plug.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|EDQM Health Care Terminology|EDQM-HC Units of Presentation Terminology
C149764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149764>	C183495	Posterior Juxtascleral Route of Administration|Posterior juxtascleral use	Administration of a medicinal product beneath the sub-tenon membrane of the sclera (i.e. in the episcleral space), adjacent to the macula.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Routes and Methods of Administration Terminology
C149765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149765>	C87836	Pouch Dosage Form				Biomedical or Dental Material	
C149766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149766>	C43186	Pour-on Container|Pour-on container	Container with built-in applicator for pouring-on use.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Container Terminology
C149767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149767>	C42953	Pour-on Emulsion Dosage Form|Pour-on emulsion	Liquid preparation consisting of an emulsion intended for pour-on use for the prevention and treatment of ectoparasitic and/or endoparasitic infestations of animals. Pour-on emulsions are applied in volumes that are usually greater than 5 mL.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149768>	C42986	Pour-on Solution Dosage Form|Pour-on solution	Liquid preparation consisting of a solution intended for pour-on use for the prevention and treatment of ectoparasitic and/or endoparasitic infestations of animals. Pour-on solutions are applied in volumes that are usually greater than 5 mL.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149769>	C42986	Pour-on Suspension Dosage Form|Pour-on suspension	Liquid preparation consisting of a suspension intended for pour-on use for the prevention and treatment of ectoparasitic and/or endoparasitic infestations of animals. Pour-on suspensions are applied in volumes that are usually greater than 5 mL.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149770>	C38304	Pour-on Route of Administration|Pour-on use	Administration of a veterinary medicinal product by pouring onto the dorsal midline of the animal or to the top of the head and around the base of the horns.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Routes and Methods of Administration Terminology
C149771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149771>	C148268	Powder and Gel for Gel Dosage Form|Powder and gel for gel	Powder and gel intended for the preparation of a gel (for cutaneous use) by mixing the powder in the gel. The powder contains active ingredient(s); the gel does not contain active ingredient(s).			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149772>	C148268	Powder and Solution for Beehive Dispersion Dosage Form|Powder and solution for bee-hive dispersion	Powder and solution, both of which contain active ingredient(s), intended for the preparation of a bee-hive dispersion by mixing the powder with the solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149773>	C148268	Powder and Solution for Beehive Solution Dosage Form|Powder and solution for bee-hive solution	Powder and solution, both of which contain active ingredient(s), intended for the preparation of a bee-hive solution by dissolving the powder in the solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149774>	C148268	Powder and Solution for Dental Cement Dosage Form|Powder and solution for dental cement	Powder and solution, both containing active substance(s), intended for the preparation of a dental cement by mixing the powder and the solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149775>	C148268	Powder and Solution for Solution for Injection Dosage Form|Powder and solution for solution for injection	Sterile powder and sterile solution, both containing active substance(s), intended for the preparation of a solution for injection by dissolving the powder in the solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149776>	C148268	Powder and Solvent for Concentrate for Solution for Infusion Dosage Form|Powder and solvent for concentrate for solution for infusion	Sterile powder and sterile solvent intended for the preparation of a concentrate for solution for infusion by dissolving the powder in the solvent; the resulting concentrate for solution for infusion must subsequently be diluted before administration as a solution for infusion.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149777>	C148268	Powder and Solvent for Topical Solution Dosage Form|Powder and solvent for cutaneous solution	Powder and solvent intended for the preparation of a cutaneous solution by dissolving the powder in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149778>	C148268	Powder and Solvent for Dental Gel Dosage Form|Powder and solvent for dental gel	Powder and solvent intended for the preparation of a dental gel by mixing the powder and the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149779>	C148268	Powder and Solvent for Emulsion for Injection Dosage Form|Powder and solvent for emulsion for injection	Sterile powder and sterile solvent intended for the preparation of an emulsion for injection by mixing the powder and the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149780>	C148268	Powder and Solvent for Endocervical Gel Dosage Form|Powder and solvent for endocervical gel	Powder and solvent intended for the preparation of an endocervical gel by mixing the powder and the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149781>	C148268	Powder and Solvent for Endosinusial Solution Dosage Form|Powder and solvent for endosinusial solution	Powder and solvent intended for the preparation of an endosinusial solution by dissolving the powder in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149782>	C148268	Powder and Solvent for Epilesional Solution Dosage Form|Powder and solvent for epilesional solution	Sterile powder and sterile solvent intended for the preparation of an epilesional solution by dissolving the powder in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149783>	C148268	Powder and Solvent for Gingival Gel Dosage Form|Powder and solvent for gingival gel	Powder and solvent intended for the preparation of a gingival gel by mixing the powder and the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149784>	C148268	Powder and Solvent for Implantation Paste Dosage Form|Powder and solvent for implantation paste	Sterile powder and sterile solvent intended for the preparation of an implantation paste by dispersing the powder in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149785>	C148268	Powder and Solvent for Intraocular Instillation Solution Dosage Form|Powder and solvent for intraocular instillation solution	Sterile powder and sterile solvent intended for the preparation of an intraocular instillation solution by dissolving the powder in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149786>	C148268	Powder and Solvent for Intravesical Solution Dosage Form|Powder and solvent for intravesical solution	Powder and solvent intended for the preparation of an intravesical solution by dissolving the powder in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149787>	C148268	Powder and Solvent for Intravesical Suspension Dosage Form|Powder and solvent for intravesical suspension	Powder and solvent intended for the preparation of an intravesical suspension by dispersing the powder in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149788>	C148268	Powder and Solvent for Nebulizer Solution Dosage Form|Powder and solvent for nebuliser solution	Powder and solvent intended for the preparation of a nebulizer solution by dissolving the powder in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149789>	C148268	Powder and Solvent for Oral Solution Dosage Form|Powder and solvent for oral solution	Powder and solvent intended for the preparation of an oral solution by dissolving the powder in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149790>	C148268	Powder and Solvent for Oral Suspension Dosage Form|Powder and solvent for oral suspension	Powder and solvent intended for the preparation of an oral suspension by dispersing the powder in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149791>	C148268	Powder and Solvent for Prolonged-Release Suspension for Injection Dosage Form|Powder and solvent for prolonged-release suspension for injection	Sterile powder and sterile solvent intended for the preparation of a prolonged-release suspension for injection by dispersing the powder in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149792>	C148275	Powder and Solvent for Prolonged-Release Suspension for Injection in Pre-filled Pen Dosage Form|Powder and solvent for prolonged-release suspension for injection in pre-filled pen	Medicinal product consisting of a powder and solvent for prolonged-release suspension for injection presented in a pre-filled pen. The powder and solvent are contained in different compartments of the pre-filled pen, which contains all of the components necessary to prepare the prolonged-release suspension for injection.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149793>	C148275	Powder and Solvent for Prolonged-Release Suspension for Injection in Pre-filled Syringe Dosage Form|Powder and solvent for prolonged-release suspension for injection in pre-filled syringe	Medicinal product consisting of a powder and solvent for prolonged-release suspension for injection presented in a pre-filled syringe. The powder and solvent are contained in different compartments of the pre-filled syringe, which contains all of the components necessary to prepare the prolonged-release suspension for injection.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149794>	C148268	Powder and Solvent for Sealant Dosage Form|Powder and solvent for sealant	Sterile powder and sterile solvent intended for the preparation of a sealant by dissolving the powder in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149795>	C148268	Powder and Solvent for Solution for Infusion Dosage Form|Powder and solvent for solution for infusion	Sterile powder and sterile solvent intended for the preparation of a solution for infusion by dissolving the powder in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149796>	C148268	Powder and Solvent for Solution for Injection Dosage Form|Powder and solvent for solution for injection	Sterile powder and sterile solvent intended for the preparation of a solution for injection by dissolving the powder in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149797>	C148275	Powder and Solvent for Solution for Injection in Cartridge Dosage Form|Powder and solvent for solution for injection in cartridge	Medicinal product consisting of a powder and solvent for solution for injection presented in a cartridge. The powder and solvent are contained in different compartments of the cartridge, which contains all of the components necessary to prepare the solution for injection.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149798>	C148275	Powder and Solvent for Solution for Injection in Pre-filled Pen Dosage Form|Powder and solvent for solution for injection in pre-filled pen	Medicinal product consisting of a powder and solvent for solution for injection presented in a pre-filled pen. The powder and solvent are contained in different compartments of the pre-filled pen, which contains all of the components necessary to prepare the solution for injection.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149799>	C148275	Powder and Solvent for Solution for Injection in Pre-filled Syringe Dosage Form|Powder and solvent for solution for injection in pre-filled syringe	Medicinal product consisting of a powder and solvent for solution for injection presented in a pre-filled syringe. The powder and solvent are contained in different compartments of the pre-filled syringe, which contains all of the components necessary to prepare the solution for injection.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C1497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1497>	C2180	Relcovaptan|1-(5-Chloro-3-(2-chlorophenyl)-1-(3,4-dimethoxybenzenesulfonyl)-3-hydroxy-2,3-dihydro-1H-indole-2-carbonyl)pyrrolidine-2-carboxamide|RELCOVAPTAN|SR-49059|SR49059				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C149800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149800>	C148268	Powder and Solvent for Solution for Injection/Infusion Dosage Form|Powder and solvent for solution for injection/infusion	Sterile powder and sterile solvent intended for the preparation of a solution for injection/infusion by dissolving the powder in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149801>	C148268	Powder and Solvent for Solution for Injection/Skin-Prick Test Dosage Form|Powder and solvent for solution for injection/skin-prick test	Sterile powder and sterile solvent intended for the preparation of a solution for injection/skin-prick test by dissolving the powder in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149802>	C148268	Powder and Solvent for Suspension for Injection Dosage Form|Powder and solvent for suspension for injection	Sterile powder and sterile solvent intended for the preparation of a suspension for injection by dispersing the powder in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149803>	C148275	Powder and Solvent for Suspension for Injection in Pre-filled Syringe Dosage Form|Powder and solvent for suspension for injection in pre-filled syringe	Medicinal product consisting of a powder and solvent for suspension for injection presented in a pre-filled syringe. The powder and solvent are contained in different compartments of the pre-filled syringe, which contains all of the components necessary to prepare the suspension for injection.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149804>	C148268	Powder and Solvent for Syrup Dosage Form|Powder and solvent for syrup	Powder and solvent intended for the preparation of a syrup by dissolving the powder in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149805>	C148268	Powder and Suspension for Suspension for Injection Dosage Form|Powder and suspension for suspension for injection	Sterile powder and sterile suspension, both of which contain active substance(s), intended for the preparation of a suspension for injection by dispersing the powder in the suspension.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149806>	C148399	Powder for Beehive Dispersion Dosage Form|Powder for bee-hive dispersion	Solid preparation consisting of one or more powders intended to be mixed with the specified liquid to obtain a bee-hive dispersion.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149807>	C148399	Powder for Beehive Solution Dosage Form|Powder for bee-hive solution	Solid preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain a bee-hive solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149808>	C42947	Powder for Bladder Irrigation Dosage Form|Powder for bladder irrigation	Solid sterile preparation consisting of one or more powders intended to be dissolved in sterile water to obtain a bladder irrigation.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149809>	C148268	Powder for Concentrate and Solution for Solution for Infusion Dosage Form|Powder for concentrate and solution for solution for infusion	Medicinal product consisting of a powder for concentrate for solution for infusion and a solution for solution for infusion, intended for the preparation of a solution for infusion.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149810>	C42973	Powder for Concentrate for Dispersion for Infusion Dosage Form|Powder for concentrate for dispersion for infusion	Solid sterile preparation consisting of one or more powders intended to be dispersed in the specified liquid to obtain a concentrate for dispersion for infusion, which must subsequently be diluted before administration as a dispersion for infusion.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149811>	C42973	Powder for Concentrate for Intravesical Suspension Dosage Form|Powder for concentrate for intravesical suspension	Solid sterile preparation consisting of one or more powders intended to be dispersed in the specified liquid to obtain a concentrate for intravesical suspension, which must subsequently be diluted before administration as an intravesical suspension.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149812>	C69070	Powder for Concentrate for Solution for Hemodialysis Dosage Form|Powder for concentrate for solution for haemodialysis	Solid sterile preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain a concentrate for solution for hemodialysis, which must subsequently be diluted before use as a solution for hemodialysis.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149813>	C42973	Powder for Concentrate for Solution for Infusion Dosage Form|Powder for concentrate for solution for infusion	Solid sterile preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain a concentrate for solution for infusion, which must subsequently be diluted before administration as a solution for infusion.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149814>	C42973	Powder for Concentrate for Solution for Injection/Infusion Dosage Form|Powder for concentrate for solution for injection/infusion	Solid sterile preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain a concentrate for solution for injection/infusion, which must subsequently be diluted before administration as a solution for injection/infusion.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149815>	C91193	Powder for Topical Solution Dosage Form|Powder for cutaneous solution	Solid preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain a cutaneous solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149816>	C42908	Powder for Dental Cement Dosage Form|Powder for dental cement	Solid preparation consisting of one or more powders intended for use in the preparation of a dental cement.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149817>	C42934	Powder for Dental Gel Dosage Form|Powder for dental gel	Solid preparation consisting of one or more powders intended to be mixed with the specified liquid or gel to obtain a dental gel.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149818>	C42908	Powder for Dental Solution Dosage Form|Powder for dental solution	Solid preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain a dental solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149819>	C42973	Powder for Dip Solution Dosage Form|Powder for dip solution	Solid preparation for veterinary use consisting of one or more powders intended to be dissolved in the specified liquid to obtain a dip solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149820>	C42973	Powder for Dispersion for Infusion Dosage Form|Powder for dispersion for infusion	Solid sterile preparation consisting of one or more powders intended to be dispersed in the specified liquid to obtain a dispersion for infusion.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149821>	C42973	Powder for Dispersion for Injection Dosage Form|Powder for dispersion for injection	Solid sterile preparation consisting of one or more powders intended to be dispersed in the specified liquid to obtain a dispersion for injection.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149822>	C42974	Powder for Emulsion for Injection Dosage Form|Powder for emulsion for injection	Solid sterile preparation consisting of one or more powders intended to be mixed with the specified liquid to obtain an emulsion for injection.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149823>	C42934	Powder for Endocervical Gel Dosage Form|Powder for endocervical gel	Solid preparation consisting of one or more powders intended to be mixed with the specified liquid or gel to obtain an endocervical gel.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149824>	C42973	Powder for Endosinusial Solution Dosage Form|Powder for endosinusial solution	Solid preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain an endosinusial solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149825>	C42973	Powder for Epilesional Solution Dosage Form|Powder for epilesional solution	Solid sterile preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain an epilesional solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149826>	C42934	Powder for Gel Dosage Form|Powder for gel	Solid preparation consisting of one or more powders intended to be mixed with the specified liquid or gel to obtain a gel (for cutaneous use).			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149827>	C42934	Powder for Gingival Gel Dosage Form|Powder for gingival gel	Solid preparation consisting of one or more powders intended to be mixed with the specified liquid or gel to obtain a gingival gel.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149828>	C42972	Powder for Implantation Matrix Dosage Form|Powder for implantation matrix	Solid sterile preparation consisting of one or more powders intended to be used in the preparation of an implantation matrix, e.g. by dissolving in the specified liquid to prepare the solution used to impregnate the matrix.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149829>	C42972	Powder for Implantation Paste Dosage Form|Powder for implantation paste	Solid sterile preparation consisting of one or more powders intended to be mixed with the specified liquid or paste to obtain an implantation paste.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149830>	C42975	Powder for Implantation Suspension Dosage Form|Powder for implantation suspension	Solid sterile preparation consisting of one or more powder intended to be dispersed in the specified liquid to obtain an implantation suspension.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149831>	C42973	Powder for Intraocular Instillation Solution Dosage Form|Powder for intraocular instillation solution	Solid sterile preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain an intraocular instillation solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149832>	C42973	Powder for Intravesical Solution Dosage Form|Powder for intravesical solution	Solid preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain an intravesical solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149833>	C42973	Powder for Intravesical Solution/Solution for Injection Dosage Form|Powder for intravesical solution/solution for injection	Solid sterile preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain an intravesical solution/solution for injection.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149834>	C42975	Powder for Intravesical Suspension Dosage Form|Powder for intravesical suspension	Solid preparation consisting of one or more powders intended to be dispersed in the specified liquid to obtain an intravesical suspension.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149835>	C42973	Powder for Nebulizer Solution Dosage Form|Powder for nebuliser solution	Solid preparation consisting of one or more powders, intended to be dissolved in the specified liquid to obtain a nebulizer solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149836>	C42975	Powder for Nebulizer Suspension Dosage Form|Powder for nebuliser suspension	Solid preparation consisting of one or more powders, intended to be dispersed in the specified liquid to obtain a nebulizer suspension.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149838>	C148275	Powder for Oral Solution in Sachet Dosage Form|Powder for oral solution in sachet	Medicinal product consisting of a powder for oral solution presented in a sachet.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C14983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14983>	C14421	ABH Mouse|ABH		ABH Mouse		Mammal	
C149840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149840>	C42975	Powder for Oral/Rectal Suspension Dosage Form|Powder for oral/rectal suspension	Solid preparation consisting of one or more powders, intended to be dissolved in the specified liquid to obtain an oral/rectal solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149841>	C148275	Powder for Oral/Rectal Suspension in Sachet Dosage Form|Powder for oral/rectal suspension in sachet	Medicinal product consisting of a powder for oral/rectal suspension presented in a sachet.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149842>	C42975	Powder for Prolonged-release Suspension for Injection Dosage Form|Powder for prolonged-release suspension for injection	Solid sterile preparation consisting of one or more powders, intended to be dispersed in the specified liquid to obtain a prolonged-release suspension for injection.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149843>	C42973	Powder for Rectal Solution Dosage Form|Powder for rectal solution	Solid preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain a rectal solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149844>	C42975	Powder for Rectal Suspension Dosage Form|Powder for rectal suspension	Solid preparation consisting of one or more powders intended to be dispersed in the specified liquid to obtain a rectal suspension.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149845>	C42972	Powder for Sealant Dosage Form|Powder for sealant	Solid sterile preparation consisting of one or more powder intended to be dissolved in the specified liquid to obtain a sealant.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149846>	C42973	Powder for Solution for Fish Treatment Dosage Form|Powder for solution for fish treatment	Powder to be used to produce a solution intended for the treatment of fish by immersion.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149847>	C42973	Powder for Solution for Infusion Dosage Form|Powder for infusion solution|Powder for solution for infusion	Solid sterile preparation consisting of one or more powders intended to be dissolved in the specified aqueous liquid to obtain a solution for infusion.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149848>	C42973	Powder for Solution for Injection/Infusion Dosage Form|Powder for solution for injection/infusion	Solid sterile preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain a solution for injection/infusion.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149849>	C42973	Powder for Solution for Injection/Skin-Prick Test Dosage Form|Powder for solution for injection/skin-prick test	Solid sterile preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain a solution for injection/skin-prick test.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149850>	C42947	Powder for Solution for Intraocular Irrigation Dosage Form|Powder for solution for intraocular irrigation	Solid sterile preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain a solution for intraocular irrigation.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149851>	C42973	Powder for Solution for Iontophoresis Dosage Form|Powder for solution for iontophoresis	Solid preparation consisting of one or more powders intended to be dissolved in the specified liquid to obtain a solution for iontophoresis.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149852>	C42973	Powder for Solution for Skin-Prick Test Dosage Form|Powder for solution for skin-prick test	Solid sterile preparation consisting of one or more powder intended to be dissolved in the specified liquid to obtain a solution for skin-prick test.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149853>	C42975	Powder for Suspension for Fish Treatment Dosage Form|Powder for suspension for fish treatment	Solid preparation for veterinary use consisting of one or more powders intended to be dispersed in the specified liquid to obtain a suspension for fish treatment by immersion.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149854>	C42972	Powder for Syrup Dosage Form|Powder for syrup	Solid preparation consisting of one or more powders that may include excipients to facilitate dissolution in water and to obtain the characteristics of a syrup, intended to be dissolved in water to obtain a syrup.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149855>	C42973	Powder for Use in Drinking Water Dosage Form|Powder for use in drinking water	Solid preparation for veterinary use consisting of one or more powder intended to be dissolved in the animal drinking water.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149856>	C42973	Powder for Use in Drinking Water/Milk Dosage Form|Powder for use in drinking water/milk	Solid preparation for veterinary use consisting of one or more powders intended to be dissolved in the animal drinking water, milk or milk replacer.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149857>	C148268	Powder, Dispersion and Solvent for Concentrate for Dispersion for Infusion Dosage Form	Sterile powder and sterile dispersion, both of which contain active substance(s), and sterile solvent intended for the preparation of a concentrate for dispersion for infusion; it is prepared as specified in the packaging information; the resulting concentrate for dispersion for infusion must subsequently be diluted before administration as a dispersion for infusion.			Biomedical or Dental Material	
C149858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149858>	C148268	Powder, Solvent and Matrix for Implantation Matrix Dosage Form|Powder, solvent and matrix for implantation matrix	Sterile powder (including freeze-dried powder), sterile solvent and sterile matrix intended for the preparation of an implantation matrix, for example by dissolving the powder in the solvent and using the resulting solution to impregnate the matrix. The powder contains active ingredient(s); the matrix does not contain active ingredient(s).			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149859>	C43207	Pre-filled Gastroenteral Tube|Pre-filled gastroenteral tube	Pre-filled tube for the administration of a medicinal product to the gastroenteral tract.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Container Terminology
C149860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149860>	C43164	Pre-filled Injector|Pre-filled injector	Filled container, usually fitted with an injection needle, containing a sterile, single-dose parenteral preparation.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Container Terminology
C149861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149861>	C43166	Pre-filled Oral Applicator|Pre-filled oral applicator	Filled container for administering a liquid or semi-solid pharmaceutical form to the oral cavity, containing the final preparation in one compartment, or the components necessary for its preparation in different compartments.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Container Terminology
C149862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149862>	C97716	Pre-filled Oral Syringe|Pre-filled oral syringe	Filled container for administering a liquid or semi-solid pharmaceutical form to the oral cavity, containing the final preparation in one compartment, or the components necessary for its preparation in different compartments.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Container Terminology
C149863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149863>	C150386	Unspecified Premix Dosage Form Category|Premix (unspecified)	A type of specialized pharmaceutical dose form that is used in the preparation of products such as medicated feeding stuffs.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C149864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149864>	C148243	Premix for Medicated Feeding Stuff Dosage Form|Premix for medicated feeding stuff	Liquid, semi-solid or solid preparation intended to facilitate oral administration of active substances to animals. Premixes for medicated feeding stuff are used exclusively in the preparation of medicated feeding stuffs. Used as powders or granules, they are free-flowing and homogeneous. Used in liquid form, they are homogeneous suspensions or solutions which may be obtained from thixotropic gels or structured liquids. The particle size and other properties are such as to ensure uniform distribution of the active substance(s) in the final feeding stuff.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149865>	C43186	Pressurized Container|Pressurised container	Container suited for compressed, liquefied or dissolved gas fitted with a device to enable, after its actuation, a controlled spontaneous release of the contents at atmospheric pressure and room temperature.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Container Terminology
C149866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149866>	C91148|C219583	Pressurized Inhalation Emulsion Dosage Form|Pressurised inhalation, emulsion	Liquid, usually multidose preparation consisting of an emulsion intended for inhalation use. The preparation is presented in a pressurized container fitted with a metering dose valve.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149867>	C91148|C219583	Pressurized Inhalation, Solution Dosage Form|Pressurised inhalation, solution	Liquid, usually multidose preparation consisting of a solution intended for inhalation use. The preparation is presented in a pressurized container usually fitted with a metering dose valve.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149868>	C91148|C219583	Pressurized Inhalation, Suspension Dosage Form|Pressurised inhalation, suspension	Liquid, usually multidose preparation consisting of a suspension intended for inhalation use. The preparation is presented in a pressurized container fitted with a metering dose valve.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149869>	C50341	Prick Test Applicator|Prick test applicator	Device for prick testing of allergen products.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Administration Device Terminology
C149870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149870>	C54680	Prolonged Release Mechanism of Action|Prolonged	Release of the substance(s) over a longer duration than would be achieved with a conventional-release product, achieved by a special formulation design and/or manufacturing method.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Release Characteristics Terminology
C149871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149871>	C42902	Prolonged-Release Capsule, Hard Dosage Form|Prolonged-release capsule, hard	Solid single-dose preparation consisting of a hard shell containing a solid or semi-solid formulation, showing a slower release of the active substance(s) than that of a conventional-release capsule. Prolonged release is achieved by a special formulation design and/or manufacturing method. Hard prolonged-release capsules are intended for oral use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149872>	C42902	Prolonged-Release Capsule, Soft Dosage Form|Prolonged-release capsule, soft	Solid single-dose preparation consisting of a soft shell containing a semi-solid or liquid formulation, showing a slower release of the active substance(s) than that of a conventional-release capsule. Prolonged release is achieved by a special formulation design and/or manufacturing method. Soft prolonged-release capsules are intended for oral use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149873>	C69067	Extended Release Granule for Oral Suspension Dosage Form	Solid preparation consisting of prolonged-release granules intended to be dispersed in the specified liquid to obtain an oral suspension.			Biomedical or Dental Material	
C149874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149874>	C148275	Prolonged-Release Granules for Oral Suspension in Sachet Dosage Form	Medicinal product consisting of prolonged-release granules for oral suspension presented in a sachet.			Biomedical or Dental Material	
C149875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149875>	C148275	Prolonged-Release Granules in Sachet Dosage Form|Prolonged-release granules in sachet	Medicinal product consisting of prolonged-release granules presented in a sachet.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149876>	C42730	Prolonged-Release Solution for Injection Dosage Form|Prolonged-release solution for injection	Liquid sterile preparation consisting of a solution intended for administration by injection; the active substance(s) are released over an extended period of time.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149877>	C42730	Prolonged-Release Suspension for Injection Dosage Form|Prolonged-release suspension for injection	Liquid sterile preparation consisting of a suspension intended for administration by injection; the active substance(s) are released over an extended period of time.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149878>	C148275	Prolonged-Release Suspension for Injection in Pre-filled Syringe Dosage Form|Prolonged-release suspension for injection in pre-filled syringe	Medicinal product consisting of a prolonged-release suspension for injection presented in a pre-filled syringe.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149879>	C42744	Pulsatile Release Intraruminal Device Dosage Form|Pulsatile-release intraruminal device	Solid single-dose preparation intended for oral use in ruminant animals. It is designed to be retained in the rumen to deliver the active substance(s) in a pulsatile manner by the release of a specific quantity of active substance(s) at one or several defined intermediate intervals. This may be achieved by corrosion by ruminal fluids of the metallic elements of the intraruminal device which leads to sequential release of the constituent units which are usually in the form of tablets.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C14987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C14987>	C14421	BUB/BnJ Mouse|BUB/BnJ				Mammal	
C149880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149880>	C149625	Precursor Radiopharmaceutical Dosage Form|Radiopharmaceutical precursor	A radionuclide produced for the radio-labelling of another substance prior to administration.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149881>	C149625	Precursor Radiopharmaceutical Solution Dosage Form|Radiopharmaceutical precursor, solution	Liquid preparation consisting of a solution containing a radionuclide produced for the radio-labelling of another substance prior to administration.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149882>	C69046	Rectal Capsule Dosage Form|Rectal capsule	Solid single-dose preparation consisting of a soft capsule of elongated shape suitable for rectal use, containing a liquid or semi-solid formulation, and which may have a lubricating coating.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149883>	C69046	Rectal Emulsion Dosage Form|Rectal emulsion	Liquid preparation consisting of an emulsion intended for rectal use or for diagnostic purposes. Rectal emulsions are usually presented in containers with a volume in the range of 2.5 mL to 2000 mL. The container is fitted with an applicator or an applicator is provided separately.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149884>	C69046	Rectal Solution Dosage Form|Rectal solution	Liquid preparation consisting of a solution intended for rectal use or for diagnostic purposes. Rectal solutions are usually presented in containers with a volume in the range of 2.5 mL to 2000 mL. The container is fitted with an applicator or an applicator is provided separately.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149885>	C69046	Rectal Suspension Dosage Form|Rectal suspension	Liquid preparation consisting of a suspension intended for rectal use or for diagnostic purposes. Rectal suspension are usually presented in containers with a volume in the range of 2.5 mL to 2000 mL. The container is fitted with an applicator or an applicator is provided separately.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149886>	C69046	Rectal Tampon Dosage Form|Rectal tampon	Solid single-dose preparation consisting of a suitable material impregnated with active substance(s) intended to be inserted in the rectum for a limited period of time usually for a local effect.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149887>	C70962	Rinsing/Washing Method of Administration|Rinsing/washing	The technique of administration of a pharmaceutical product by bringing it into contact with the affected area for a short period of time, e.g. by pouring it over the area and allowing it to drain away, or swilling it around the area and then removing it.			Activity	EDQM Health Care Terminology|EDQM-HC Administration Method Terminology
C149888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149888>	C43186	Roll-on Container|Roll-on container	A container, usually a bottle, fitted with a roll-on applicator			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Container Terminology
C149889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149889>	C43186	Sachet Container|Sachet	Container consisting of two surfaces made of flexible material to be closed only by sealing or folding over. The contents are intended for single use.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Container Terminology
C149890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149890>	C16830	Scarifier Device|Scarifier	Device for scratching the skin.			Medical Device	EDQM Health Care Terminology|EDQM-HC Administration Device Terminology
C149891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149891>	C49861	Screw Cap Device|Screw cap	Hollow cylindrical object with screw thread, meant to close a container.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Closure Terminology
C149892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149892>	C42953	Sealant Dosage Form|Sealant	Liquid, more or less viscous, sterile preparation intended for use as tissue glue.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149893>	C45235	Sealant Matrix Dosage Form|Sealant matrix	Solid sterile preparation consisting of a pliable piece of material impregnated or coated with a sealant or with a powder that forms a sealant after contact with an appropriate fluid (e.g. blood). It may act as a hemostatic agent and/or tissue glue. The matrix may itself form part of the seal, and is usually absorbed by the body over time.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149894>	C42972	Sealant Powder Dosage Form|Sealant powder	Solid sterile preparation consisting of one or more powders intended to be applied directly onto the intended site (e.g. a lesion) to form a hemostatic agent and/or tissue glue after contact with an appropriate fluid (e.g. blood).			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149895>	C45306	Semi-solid	A state of matter consisting of molecules in a non-rigid structure that can retain its shape and volume but that is not resistant to such change.			Substance	EDQM Health Care Terminology|EDQM-HC State of Matter Terminology|PQ/CMC State of Matter Terminology
C149896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149896>	C43186	Single-dose Container|Single-dose container	A container that holds a quantity of the preparation intended for total or partial use on one occasion only.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Container Terminology
C149897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149897>	C38304	Skin Scarification Route of Administration|Skin scarification	Administration of a medicinal product by scratching the skin.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Routes and Methods of Administration Terminology
C149898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149898>	C148275	Solution and Suspension for Suspension for Injection in Pre-filled Syringe Dosage Form|Solution and suspension for suspension for injection in pre-filled syringe	Medicinal product consisting of a solution and suspension for suspension for injection presented in a pre-filled syringe. The solution and suspension are contained in different compartments of the pre-filled syringe, which contains all of the components necessary to prepare the suspension for injection.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149899>	C148399	Solution for Beehive Dispersion Dosage Form|Solution for bee-hive dispersion	Liquid preparation consisting of a solution intended for use in the preparation of a bee-hive dispersion.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C1498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1498>	C587	Aldesleukin|125-L-Serine-2-133-interleukin 2|ALDESLEUKIN|Proleukin|Proleukin|Recombinant Human IL-2|Recombinant Human Interleukin-2|aldesleukin|r-serHuIL-2|recombinant human interleukin-2	A recombinant analog of the endogenous cytokine interleukin-2 (IL-2) with immunoregulatory and antineoplastic activities. Aldesleukin binds to and activates the IL-2 receptor, followed by heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains; activation of the tyrosine kinase Jak3; and phosphorylation of tyrosine residues on the IL-2R beta chain, resulting in an activated receptor complex. Various cytoplasmic signaling molecules are recruited to the activated receptor complex and become substrates for regulatory enzymes that are associated with the receptor complex. This agent enhances lymphocyte mitogenesis; stimulates long-term growth of human IL-2 dependent cell lines; enhances lymphocyte cytotoxicity; induces lymphokine-activated killer (LAK) cell and natural killer (NK) cell activities; and induces expression of interferon-gamma. Aldesleukin may induce T cell-mediated tumor regression in some tumor types.	Aldesleukin		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C149900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149900>	C148399	Solution for Beehive Solution Dosage Form|Solution for bee-hive solution	Liquid preparation consisting of a solution intended for use in the preparation of a bee-hive solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149901>	C148399	Solution for Beehive Strip Dosage Form|Solution for bee-hive strip	Liquid preparation consisting of a solution intended for use in the preparation of a bee-hive strip by application to an absorbent matrix; the bee-hive strip is usually used immediately after preparation.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149902>	C42986	Solution for Blood Fraction Modification Dosage Form|Solution for blood fraction modification	Liquid sterile preparation consisting of a solution intended for use in extracorporeal modification of a blood fraction that is returned to the patient following modification.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149903>	C42986	Solution for Cardioplegia Dosage Form|Solution for cardioplegia	Liquid sterile preparation consisting of an aqueous solution intended for use in inducing cardiac arrest during heart surgery. Some preparations may require mixing with other preparations prior to administration, for example to adjust the pH.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149904>	C42986	Solution for Cardioplegia/Organ Preservation Dosage Form|Solution for cardioplegia/organ preservation	Liquid sterile preparation consisting of an aqueous solution of electrolytes typically at a concentration close to the intracellular electrolyte composition, intended for inducing cardiac arrest during heart surgery, and for storage, protection and/or perfusion of mammalian body organs that are in particular destined for transplantation.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149905>	C69059	Solution for Dental Cement Dosage Form|Solution for dental cement	Liquid preparation consisting of a solution intended for use in the preparation of a dental cement.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149906>	C42986	Solution for Hemodiafiltration Dosage Form|Solution for haemodiafiltration	Liquid sterile preparation consisting of an aqueous solution containing electrolytes with a concentration close to the electrolytic composition of plasma, intended for parenteral use in hemodiafiltration. Glucose may be included.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149907>	C42986	Solution for Hemodialysis Dosage Form|Solution for haemodialysis	Liquid preparation consisting of an aqueous solution containing electrolytes with a concentration close to the electrolytic composition of plasma, intended for use in hemodialysis. Glucose may be included.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149908>	C42986	Solution for Hemodialysis/Hemofiltration Dosage Form|Solution for haemodialysis/haemofiltration	Liquid sterile preparation consisting of a solution intended for use as a solution for hemodialysis or a solution for hemofiltration.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149909>	C42986	Solution for Hemofiltration Dosage Form|Solution for haemofiltration	Liquid sterile preparation consisting of an aqueous solution containing electrolytes with a concentration close to the electrolytic composition of plasma, intended for parenteral use in hemofiltration. Glucose may be included.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149910>	C42945	Solution for Infusion Dosage Form|Infusion solution|Solution for infusion	Liquid sterile preparation consisting of an aqueous solution intended to be introduced, usually in large volumes, usually into the circulating blood stream.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149911>	C148275	Solution for Infusion in Administration System Dosage Form|Solution for infusion in administration system	Medicinal product consisting of a solution for infusion presented in an administration system.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149912>	C148275	Solution for Infusion in Pre-filled Syringe Dosage Form|Solution for infusion in pre-filled syringe	Medicinal product consisting of a solution for infusion presented in a pre-filled syringe.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149913>	C148275	Solution for Injection in Administration System Dosage Form|Solution for injection in administration system	Medicinal product consisting of a solution for injection presented in an administration system.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149914>	C148275	Solution for Injection in Cartridge Dosage Form|Solution for injection in cartridge	Medicinal product consisting of a solution for injection presented in a cartridge.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149915>	C148275	Solution for Injection in Dose-Dispenser Cartridge Dosage Form|Solution for injection in dose-dispenser cartridge	Medicinal product consisting of a solution for injection presented in a dose-dispenser cartridge.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149916>	C148275	Solution for Injection in Needle-Free Injector Dosage Form|Solution for injection in needle-free injector	Medicinal product consisting of a solution for injection presented in a needle-free injector.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149917>	C148275	Solution for Injection in Pre-filled Injector Dosage Form|Solution for injection in pre-filled injector	Medicinal product consisting of a solution for injection presented in a pre-filled injector.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149918>	C148275	Solution for Injection in Pre-filled Pen Dosage Form|Solution for injection in pre-filled pen	Medicinal product consisting of a solution for injection presented in a pre-filled pen.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149919>	C148275	Solution for Injection in Pre-filled Syringe Dosage Form|Solution for injection in pre-filled syringe	Medicinal product consisting of a solution for injection presented in a pre-filled syringe.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149920>	C42945	Solution for Injection/Infusion Dosage Form|Solution for injection/infusion	Liquid sterile single-dose or multidose preparation consisting of a solution intended for administration by injection or infusion.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149921>	C148275	Solution for Injection/Infusion in Pre-filled Syringe Dosage Form|Solution for injection/infusion in pre-filled syringe	Medicinal product consisting of a solution for injection/infusion presented in a pre-filled syringe.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149922>	C42945	Solution for Injection/Skin-prick Test Dosage Form|Solution for injection/skin-prick test	Liquid sterile preparation consisting of a solution containing an allergen product intended for diagnostic use in a skin-prick test or as an injection (usually intraepidermal); it may also be licensed for immunotherapy treatment by injection (usually subcutaneous).			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149923>	C42947	Solution for Intraocular Irrigation Dosage Form|Solution for intraocular irrigation	Liquid sterile preparation consisting of a solution intended for irrigation of one or more internal structures of the eye, for example during surgical procedures.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149924>	C42986	Solution for Iontophoresis Dosage Form|Solution for iontophoresis	Liquid preparation consisting of an aqueous solution intended for transdermal delivery by means of iontophoresis.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149925>	C42986	Solution for Organ Preservation Dosage Form|Solution for organ preservation	Liquid sterile preparation consisting of an aqueous solution of electrolytes typically at a concentration close to the intracellular electrolyte composition, intended for storage, protection and/or perfusion of mammalian body organs that are in particular destined for transplantation.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149926>	C42986	Solution for Peritoneal Dialysis Dosage Form|Solution for peritoneal dialysis	Liquid sterile preparation consisting of an aqueous solution containing electrolytes with a concentration close to the electrolytic composition of plasma and glucose in varying concentrations or other suitable osmotic agents, intended for intraperitoneal use as a dialysis solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149927>	C42986	Solution for Provocation Test Dosage Form|Solution for provocation test	Liquid preparation consisting of a solution containing an allergen intended for provocation testing by the nasal, ocular or bronchial routes.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149928>	C42986	Solution for Sealant Dosage Form|Solution for sealant	Liquid sterile preparation consisting of a solution intended for the preparation of a sealant.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149929>	C42986	Solution for Skin-prick Test Dosage Form|Solution for skin-prick test	Liquid sterile preparation consisting of a solution containing an allergen product intended for diagnostic use in a skin-prick test.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149930>	C42986	Solution for Skin-scratch Test Dosage Form|Solution for skin-scratch test	Liquid sterile preparation consisting of a solution containing an allergen product intended for diagnostic use in a skin-scratch test.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149931>	C42986	Solution for Solution for Infusion Dosage Form|Solution for solution for infusion	Liquid sterile preparation consisting of a solution intended for use in the preparation of a solution for infusion.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149932>	C42986	Solution for Solution for Injection Dosage Form|Solution for solution for injection	Liquid sterile preparation consisting of a solution intended for use in the preparation of a solution for injection.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149933>	C42986	Solution for Spray Dosage Form|Solution for Spray	Liquid preparation consisting of a solution intended for use in the preparation of a spray.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149934>	C42986	Solution for Suspension for Injection Dosage Form|Solution for suspension for injection	Liquid sterile preparation consisting of a solution intended for use in the preparation of a suspension for injection.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149935>	C42986	Solution for Use in Drinking Water Dosage Form|Solution for use in drinking water	Liquid preparation for veterinary use consisting of a solution intended for administration by incorporation into the animal drinking water. If direct oral administration to individual animals is also authorized, the method of administration, including any necessary dilution, is clearly described in the product information.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149936>	C42986	Solution for Use in Drinking Water/Milk Dosage Form|Solution for use in drinking water/milk	Solution for veterinary use, intended for administration by incorporation into the animal drinking water, milk or milk replacer. If direct oral administration to individual animals is also authorized, the method of administration, including any necessary dilution, is clearly described in the product information.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149937>	C171428	Solvent for Parenteral Use Dosage Form|Solvent for parenteral use	Liquid sterile preparation consisting of a solvent containing no active substances, intended for use in the preparation of a product for parenteral use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149938>	C171428	Solvent for Solution for Infusion Dosage Form|Solvent for solution for infusion	Liquid sterile preparation consisting of a solvent containing no active substances, intended for use in the preparation of a solution for infusion.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149939>	C42947	Solvent for Solution for Intraocular Irrigation Dosage Form|Solvent for solution for intraocular irrigation	Liquid sterile preparation consisting of a solvent containing no active substances, intended for use in the preparation of a solution for intraocular irrigation.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149940>	C171428	Solvent for [Product Name] Dosage Form|Solvent for...	Liquid preparation consisting of an excipient that contains no active substances itself but is intended to be used in the preparation of a pharmaceutical product, e.g. for diluting/dissolving/dispersing the item(s) containing the active substance(s).			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149941>	C16830	Spatula Device|Spatula	Administration device with a flattened side used for the application of semi-solid pharmaceutical forms.			Medical Device	EDQM Health Care Terminology|EDQM-HC Administration Device Terminology
C149942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149942>	C48470	Spoonful Dosing Unit|Spoonful	A unit of presentation used to represent the quantity of product that is administered by filling a single spoon administration device.			Quantitative Concept	EDQM Health Care Terminology|EDQM-HC Units of Presentation Terminology
C149943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149943>	C50341	Spot-on Applicator|Spot-on applicator	Device for administration by spot-on use.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Administration Device Terminology
C149944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149944>	C42913	Spot-on Emulsion Dosage Form|Spot-on emulsion	Liquid preparation consisting of an emulsion intended for spot-on use for the prevention and treatment of ectoparasitic and/or endoparasitic infestations of animals. Spot-on-emulsions are applied in volumes that are usually less than 10 mL.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149945>	C42986	Spot-on Solution Dosage Form|Spot-on solution	Liquid preparation consisting of a solution intended for spot-on use for the prevention and treatment of ectoparasitic and/or endoparasitic infestations of animals. Spot-on-solutions are applied in volumes that are usually less than 10 mL.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149946>	C42994	Spot-on Suspension Dosage Form|Spot-on suspension	Liquid preparation consisting of a suspension intended for spot-on use for the prevention and treatment of ectoparasitic and/or endoparasitic infestations of animals. Spot-on-suspensions are applied in volumes that are usually less than 10 mL.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149947>	C38304	Spot-on Route of Administration|Spot-on use	Administration of a veterinary medicinal product to a single site on the back of the animal or the base of the poll of the head.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Routes and Methods of Administration Terminology
C149948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149948>	C43186	Spray Container|Spray container	Container for a liquid pharmaceutical form to be converted into a spray by mechanical means.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Container Terminology
C149949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149949>	C96112	Actuation Spray Valve Device|Spray valve	A valve device on a container that delivers a precise spray dose of contents by actuation.			Intellectual Product	EDQM Health Care Terminology|EDQM-HC Closure Terminology
C149950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149950>	C70962	Spraying Method of Administration|Spraying	The technique of administration of a pharmaceutical product by atomizing or otherwise dissipating it into a fine dispersion of particles in air, directing it such that it comes into contact with the affected area.			Activity	EDQM Health Care Terminology|EDQM-HC Administration Method Terminology
C149951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149951>	C16830	Stab Vaccinator|Stab vaccinator	Device for administering a product by stabbing the bird.			Medical Device	EDQM Health Care Terminology|EDQM-HC Administration Device Terminology
C149952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149952>	C42947	Stomach Irrigation Dosage Form|Stomach irrigation	Liquid sterile preparation consisting of an aqueous solution intended for irrigation of the stomach.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149953>	C43164	Straw	Hollow tube containing a single dose of a medicinal product for oral administration by sucking.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Container Terminology
C149954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149954>	C48470	Straw Dosing Unit|Straw	A unit of presentation used to represent the quantity of product that is found in a single straw container.			Quantitative Concept	EDQM Health Care Terminology|EDQM-HC Units of Presentation Terminology
C149955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149955>	C148456	Sublingual Film Dosage Form|Sublingual film	Solid preparation consisting of a single- or multilayer sheet of suitable material(s) intended for sublingual use to obtain a systemic effect.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149956>	C148456	Sublingual Powder Dosage Form|Sublingual powder	Solid preparation consisting of a powder intended for sublingual use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149957>	C219648	Sublingual Spray, Emulsion Dosage Form|Sublingual spray, emulsion	Liquid, usually multidose preparation consisting of an emulsion intended for sublingual use. Sublingual sprays are usually presented in pressurized containers with a metering valve.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149958>	C219648	Sublingual Spray, Solution Dosage Form|Sublingual spray, solution	Liquid, usually multidose preparation consisting of a solution intended for sublingual use. Sublingual sprays are usually presented in pressurized containers with a metering valve.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149959>	C219648	Sublingual Spray, Suspension Dosage Form|Sublingual spray, suspension	Liquid, usually multidose preparation consisting of a suspension intended for sublingual use. Sublingual sprays are usually presented in pressurized containers with a metering valve.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149961>	C70962	Sucking Method of Administration|Sucking	The technique of administration of a pharmaceutical product by placing it in the mouth and encouraging it to dissolve in the saliva, usually by moving the tongue.			Activity	EDQM Health Care Terminology|EDQM-HC Administration Method Terminology
C149962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149962>	C148268	Suspension and Effervescent Granules for Oral Suspension Dosage Form|Suspension and effervescent granules for oral suspension	Suspension and effervescent granules intended for the preparation of an oral suspension by dissolving or dispersing the effervescent granules in the suspension, or by dissolving or dispersing the effervescent granules in the specified liquid and mixing it with the suspension. The suspension contains active ingredient(s); the effervescent granules do not contain active ingredient(s).			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149963>	C148268	Suspension and Solution for Spray Dosage Form|Suspension and solution for spray	Suspension and solution intended for use as a spray by mixing the suspension into the solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149964>	C42995	Injectable Suspension for Emulsion Dosage Form|Suspension for emulsion for injection	Liquid sterile preparation consisting of a suspension intended for use in the preparation of an emulsion for injection.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149966>	C148275	Suspension for Injection in Cartridge Dosage Form|Suspension for injection in cartridge	Medicinal product consisting of a suspension for injection presented in a cartridge.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149967>	C148275	Suspension for Injection in Pre-filled Injector Dosage Form|Suspension for injection in pre-filled injector	Medicinal product consisting of a suspension for injection presented in a pre-filled injector.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149968>	C148275	Suspension for Injection in Pre-filled Pen Dosage Form|Suspension for injection in pre-filled pen	Medicinal product consisting of a suspension for injection presented in a pre-filled pen.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149969>	C148275	Suspension for Injection in Pre-filled Syringe Dosage Form|Suspension for injection in pre-filled syringe	Medicinal product consisting of a suspension for injection presented in a pre-filled syringe.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149970>	C42994	Suspension for Oral Suspension Dosage Form|Suspension for oral suspension	Liquid preparation consisting of a suspension intended for use in the preparation of an oral suspension.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149971>	C42994	Suspension for Suspension for Injection Dosage Form|Suspension for suspension for injection	Liquid sterile preparation consisting of a suspension intended for use in the preparation of a suspension for injection.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149972>	C42994	Suspension for Use in Drinking Water Dosage Form|Suspension for use in drinking water	Liquid preparation for veterinary use consisting of a suspension intended for administration by incorporation into the animal drinking water. If direct oral administration to individual animals is also authorized, the method of administration, including any necessary dilution, is clearly described in the product information.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149973>	C70962	Swallowing Method of Administration|Swallowing	The technique of administration of a pharmaceutical product by introducing it into the stomach via the mouth and esophagus with a voluntary muscular action.			Activity	EDQM Health Care Terminology|EDQM-HC Administration Method Terminology
C149974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149974>	C148275	Syrup in Sachet Dosage Form|Syrup in sachet	Medicinal product consisting of a syrup in a sachet.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C149975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149975>	C48470	System Dosing Unit|System	A unit of presentation used to represent the quantity of product that is found in a single discrete entity where the pharmaceutical dose form is a type of system.			Quantitative Concept	EDQM Health Care Terminology|EDQM-HC Units of Presentation Terminology
C149976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149976>	C148268	Tablet plus Vaginal Tablet Dosage Form|Tablet + vaginal tablet	Combination package consisting of a tablet and a vaginal tablet.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pack Terminology
C149977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149977>	C148268	Tablet and Powder for Oral Solution Dosage Form|Tablet and powder for oral solution	Tablet and powder intended for the preparation of an oral solution by dissolving the tablet and the powder in the specified liquid. The tablet contains active ingredient(s); the powder does not contain active ingredient(s).			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149978>	C148268	Tablet and Solvent for Rectal Suspension Dosage Form|Tablet and solvent for rectal suspension	Tablet and solvent intended for the preparation of a rectal suspension by dispersing the tablet in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C149979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149979>	C43186	Tablet Container|Tablet container	Container without neck and with a flat bottom, suited for tablets, capsules, etc., can be re-closed well.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Container Terminology
C149980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149980>	C42998	Tablet for Topical Solution Dosage Form|Tablet for cutaneous solution	Solid, usually single-dose preparation consisting of a tablet, usually uncoated, intended to be dissolved in the specified liquid to obtain a cutaneous solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149981>	C42998	Tablet for Rectal Solution Dosage Form|Tablet for rectal solution	Solid, usually single-dose preparation consisting of a tablet, usually uncoated, intended to be dissolved in the specified liquid to obtain a rectal solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149982>	C42998	Tablet for Rectal Suspension Dosage Form|Tablet for rectal suspension	Solid, usually single-dose preparation consisting of a tablet, usually uncoated, intended to be dispersed in the specified liquid to obtain a rectal suspension.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149983>	C69048	Tablet for Vaginal Solution Dosage Form|Tablet for vaginal solution	Solid, usually single-dose preparation consisting of a tablet, usually uncoated, intended to be dissolved in the specified liquid to obtain a vaginal solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149984>	C171282	Tea Dosage Form Category|Tea	A type of solid pharmaceutical dose form consisting of one or more herbal drugs intended for preparation of a solution by decoction or maceration, or a lyophilized preparation of such a solution.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C149985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149985>	C148243	Teat Dip Emulsion Dosage Form|Teat dip emulsion	Liquid preparation consisting of an emulsion intended for teat use. The teats of an animal are dipped pre- and, where necessary, post-milking to reduce the population of pathogenic micro-organisms on the surfaces.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149986>	C42986	Teat Dip Solution Dosage Form|Teat dip solution	Liquid preparation consisting of a solution intended for teat use. The teats of an animal are dipped pre- and, where necessary, post-milking to reduce the population of pathogenic micro-organisms on the surfaces.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149987>	C42986	Teat Dip Suspension Dosage Form|Teat dip suspension	Liquid preparation consisting of a suspension intended for teat use. The teats of an animal are dipped pre- and, where necessary, post-milking to reduce the population of pathogenic micro-organisms on the surfaces.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149988>	C42986	Teat Dip/Spray Solution Dosage Form|Teat dip/spray solution	Liquid preparation intended for use as a teat dip solution or as a teat spray solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149989>	C42986	Teat Spray Solution Dosage Form|Teat spray solution	Liquid preparation consisting of a solution intended to be sprayed onto the teats of an animal pre-, and where necessary, post-milking to reduce the population of pathogenic micro-organisms on the surfaces.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149990>	C148243	Teat Stick Dosage Form|Teat stick	Solid single-dose preparation for veterinary use, usually rod shaped, intended to be inserted into the teat canal of an animal where it melts or dissolves.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149991>	C148242	Teat Route of Administration|Teat use	Administration of a veterinary medicinal product to the surface of teat(s).			Functional Concept	EDQM Health Care Terminology|EDQM-HC Routes and Methods of Administration Terminology
C149992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149992>	C48470	Thread Dosing Unit|Thread	A unit of presentation used to represent the quantity of product that is found in a single discrete entity where the pharmaceutical dose form is a type of thread.			Quantitative Concept	EDQM Health Care Terminology|EDQM-HC Units of Presentation Terminology
C149993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149993>	C148242	Top-dressing Route of Administration|Top-dressing use	Administration of a veterinary medicinal product by application onto the surface of the feed immediately prior to feeding.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Routes and Methods of Administration Terminology
C149994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149994>	C42934	Transdermal Gel Dosage Form|Transdermal gel	Semi-solid single-dose or multidose preparation consisting of a single-phase basis of liquids gelled by a suitable gelling agent. Active substance(s) is (are) dissolved or dispersed in the basis, which may be hydrophilic or hydrophobic. Transdermal gels are intended for transdermal use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149995>	C42747	Transdermal Ointment Dosage Form|Transdermal ointment	Semi-solid single-dose or multidose preparation consisting of a single-phase basis in which solids or liquids may be dispersed. Active substance(s) are dissolved or dispersed in the basis, which may be hydrophilic, hydrophobic or water-emulsifying. Transdermal ointments are intended for transdermal use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149996>	C42968	Transdermal Patch Dosage Form|Transdermal patch	Flexible single-dose preparation intended to be applied to the unbroken skin to obtain a systemic delivery over an extended period of time. Transdermal patches consist of a backing sheet supporting a reservoir or a matrix containing the active substance(s) and on the top a pressure-sensitive adhesive, which assures the adhesion of the preparation to the skin. The backing sheet is impermeable to the active substance(s) and normally impermeable to water. In reservoir systems the active substance may be dissolved or dispersed in a semi-solid basis or in a solid polymer matrix, which is separated from the skin by a rate-controlling membrane. The pressure-sensitive adhesive may, in this case, be applied to some or all parts of the membrane, or only around the border of the membrane and the backing sheet. Matrix systems contain the active substance in a solid or semi-solid matrix, the properties of which control the diffusion pattern to the skin. The matrix system may also be a solution or dispersion of the active substance in the pressure-sensitive adhesive. The releasing surface of the patch is covered by a protective liner to be removed before applying the patch to the skin.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149997>	C42986	Transdermal Solution Dosage Form|Transdermal solution	Liquid single-dose or multidose preparation consisting of a solution intended for transdermal use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149998>	C42986	Transdermal Spray, Solution Dosage Form|Transdermal spray, solution	Liquid, usually multidose preparation consisting of a solution in a pressurized container with a spray valve or a container equipped with a spray pump, intended for transdermal use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C149999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C149999>	C45246|C17423	Transdermal System Dosage Form|Transdermal drug delivery system|Transdermal system	Assembly of components intended for transdermal delivery driven by external forces (e.g., electrical current, chemical reaction).			Medical Device	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C1499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1499>	C97452|C1556	Lodenosine|2'-Beta-Fluoro-2',3'-Dideoxyadenosine|2'-F-dd-ara-A|2'-F-dd-araA|2'-FddA|2'-FddA|2'-Fluoro-2',3'-Dideoxyadenosine|2'-beta-fluoro-2',3'-dideoxyadenosine|9-(2,3-Dideoxy-2-fluoro-beta-D-threo-pentofuranosyl) Adenine|9-(2,3-Dideoxy-2-fluoro-beta-D-threo-pentofuranosyl)-9H-purin-6-amine|DRG-0246|F-ddA|LODENOSINE	A nucleoside reverse transcriptase inhibitor analog of adenosine. Lodenosine is a synthetic purine fluoro-dideoxyadenosine derivative that was rationally designed to have improved chemical and enzymatic stability. It has shown activity against clinical isolates and cell lines that are resistant to AZT, dideoxyinosine, and dideoxycytosine.			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C150000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150000>	C73487	Unclear State of Matter|Unclear	A state of matter of unknown, unspecified or variable physical characteristics.			Conceptual Entity	EDQM Health Care Terminology|EDQM-HC State of Matter Terminology
C150001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150001>	C150386	Unknown Dosage Form Category|UNKNOWN|Unknown	The type of pharmaceutical dose form is unknown, or has unspecified or variable physical characteristics.			Classification	CDISC SDTM Dosage Form Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C150002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150002>	C54680	Unknown Release Mechanism of Action|Unknown	Release of the substance(s) in a way that is unknown or not specified.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Release Characteristics Terminology
C150003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150003>	C17998	Unknown Transformation|Unknown	It is unknown whether any transformation of the product takes place.			Idea or Concept	EDQM Health Care Terminology|EDQM-HC Transformation Terminology
C150004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150004>	C13442	Unknown/Miscellaneous Anatomical Location|Unknown/Miscellaneous	Relating to various unspecified parts of the body as the intended site of administration, or where the intended site of administration is unknown or not specified.			Spatial Concept	EDQM Health Care Terminology|EDQM-HC Intended Site of Administration Terminology
C150005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150005>	C69052	Urethral Emulsion Dosage Form|Urethral emulsion	Liquid preparation consisting of an emulsion intended for urethral use by means of a suitable applicator.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C150006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150006>	C42991	Urethral Stick Dosage Form|Urethral stick	Solid sterile single-dose preparation, usually rod-shaped and of a size adapted to the dimensions of the urethra, intended for insertion into the urethra. They may be prepared by compression or molding.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C150007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150007>	C219587	Hard Vaginal Capsule Dosage Form|Vaginal capsule, hard	Solid single-dose preparation consisting of a hard capsule of a size and shape suited for vaginal use, containing a liquid or semi-solid formulation, intended for a local effect.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C150008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150008>	C219587	Soft Vaginal Capsule Dosage Form|Vaginal capsule, soft	Solid single-dose preparation consisting of a soft capsule of a size and shape suited for vaginal use, containing a liquid or semi-solid formulation, intended for a local effect.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C150009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150009>	C148268	Soft Vaginal Capsule plus Vaginal Cream Dosage Form|Vaginal capsule, soft + vaginal cream	Combination package consisting of a soft vaginal capsule and a vaginal cream.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pack Terminology
C150010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150010>	C148268	Vaginal Cream plus Vaginal Tablet Dosage Form|Vaginal cream + vaginal tablet	Combination package consisting of a vaginal cream and a vaginal tablet.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pack Terminology
C150011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150011>	C42636|C17423	Vaginal Delivery System Dosage Form|SYSTEM|Vaginal delivery system	Drug delivery system intended to be inserted in the vagina where it releases its contents over an extended period of time.			Medical Device	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C150012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150012>	C219597	Vaginal Emulsion Dosage Form|Vaginal emulsion	Liquid preparation consisting of an emulsion intended for vaginal use by means of a suitable applicator in order to obtain a local effect.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C150014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150014>	C219597	Vaginal Solution Dosage Form|Vaginal solution	Liquid preparation consisting of a solution intended for vaginal use by means of a suitable applicator in order to obtain a local effect.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C150015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150015>	C50341	Vaginal Sponge Applicator|Vaginal sponge applicator	Device for introducing a sponge into the vagina of an animal.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Administration Device Terminology
C150016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150016>	C219597	Vaginal Suspension Dosage Form|Vaginal suspension	Liquid preparation consisting of a suspension intended for vaginal use by means of a suitable applicator in order to obtain a local effect.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C150017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150017>	C48470	Vessel Dosing Unit|Vessel	A unit of presentation used to represent the quantity of product that is found in a single vessel-type container.			Quantitative Concept	EDQM Health Care Terminology|EDQM-HC Units of Presentation Terminology
C150018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150018>	C148242	Water-borne Use Route of Administration|Water-borne use	Administration of a veterinary medicinal product to aquatic (marine or fresh water) species by medication of the water environment.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Routes and Methods of Administration Terminology
C150019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150019>	C148242	Wing-web-stab Use Route of Administration|Wing-web-stab use	Administration of a veterinary medicinal product into the wing-web of a bird.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Routes and Methods of Administration Terminology
C150020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150020>	C17207	Zinc Finger Protein 40|CIRIP|Cirhin Interaction Protein|GAAP|Gate Keeper of Apoptosis-Activating Protein|HIV-EP1|HIVEP1|Human Immunodeficiency Virus Type I Enhancer Binding Protein 1|Human Immunodeficiency Virus Type I Enhancer-Binding Protein 1|MBP-1|Major Histocompatibility Complex Binding Protein 1|Major Histocompatibility Complex-Binding Protein 1|PRDII-BF1|Positive Regulatory Domain II Binding Factor 1|Positive Regulatory Domain II-Binding Factor 1|Schnurri-1	Zinc finger protein 40 (2718 aa, ~297 kDa) is encoded by the human HIVEP1 gene. This protein plays a role in the regulation of viral and cellular gene expression.			Amino Acid, Peptide, or Protein	
C150021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150021>	C133708	UBE2O Gene|UBE2O|UBE2O|Ubiquitin Conjugating Enzyme E2 O Gene	This gene is involved in the monoubiquitination of substrate proteins.			Gene or Genome	
C150022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150022>	C150021	UBE2O wt Allele|E2-230K|KIAA1734|Ubiquitin Conjugating Enzyme E2 O wt Allele|Ubiquitin-Conjugating Enzyme E2, 230-kD Gene	Human UBE2O wild-type allele is located in the vicinity of 17q25.1 and is approximately 64 kb in length. This allele, which encodes (E3-independent) E2 ubiquitin-conjugating enzyme protein, plays a role in protein monoubiquitination.			Gene or Genome	
C150023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150023>	C133711	(E3-Independent) E2 Ubiquitin-Conjugating Enzyme|E2/E3 Hybrid Ubiquitin-Protein Ligase UBE2O|EC 2.3.2.24|UBE2O|Ubiquitin Carrier Protein O|Ubiquitin Conjugating Enzyme E2O|Ubiquitin-Conjugating Enzyme E2 O|Ubiquitin-Conjugating Enzyme E2 of 230 kDa|Ubiquitin-Conjugating Enzyme E2-230K|Ubiquitin-Conjugating Enzyme E2O|Ubiquitin-Protein Ligase O	(E3-independent) E2 ubiquitin-conjugating enzyme (1292 aa, ~141 kDa) is encoded by the human UBE2O gene. This protein is involved in the monoubiquitination of target proteins.			Amino Acid, Peptide, or Protein|Enzyme	
C150024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150024>	C357	Ceftolozane|(6R,7R)-3-((5-Amino-4-(((2-aminoethyl)carbamoyl)amino)-1-methyl-1H-pyrazol-2-ium-2- yl)methyl)-7-(((2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-((1-carboxy-1- methylethoxy)imino)acetyl)amino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- Carboxylate|5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic Acid, 3-((4-((((2- Aminoethyl)amino)carbonyl)amino)-2,3-dihydro-3-imino-2-methyl-1H-pyrazol-1- yl)methyl)-7-(((2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-((1-carboxy-1- methylethoxy)imino)acetyl)amino)-8-oxo-, (6R,7R)-|CEFTOLOZANE|CXA-101	A semi-synthetic, broad-spectrum, fifth-generation cephalosporin antibiotic with bactericidal activity against certain Gram-negative and Gram-positive bacteria. Upon administration, ceftolozane binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. This interferes with the final transpeptidation step required to form peptidoglycan chain cross-links, which are a key component of and provide strength and rigidity to the bacterial cell wall. This inhibits bacterial cell wall synthesis and reduces cell wall stability, which weakens the bacterial cell wall and causes bacterial cell lysis.	Ceftolozane		Antibiotic|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C150025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150025>	C20921	NFKBIZ Gene|NFKB Inhibitor Zeta Gene|NFKBIZ|NFKBIZ	This gene plays a role in the regulation of nuclear factor kappa-B-mediated gene transcription.			Gene or Genome	
C150026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150026>	C150025	NFKBIZ wt Allele|FLJ34463|IKBZ|INAP|MAIL|NFKB Inhibitor Zeta wt Allele|Nuclear Factor of Kappa Light Polypeptide Gene Enhancer in B-Cells Inhibitor, Zeta Gene	Human NFKBIZ wild-type allele is located in the vicinity of 3q12.3 and is approximately 33 kb in length. This allele, which encodes NF-kappa-B inhibitor zeta protein, is involved in the modulation of nuclear factor kappa-B-mediated gene transcription.			Gene or Genome	
C150027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150027>	C4025|C3532	Thoracic Esophagus Adenocarcinoma	An adenocarcinoma that arises from the thoracic esophagus.			Neoplastic Process	
C150028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150028>	C43186	Barrel Container|Barrel	A large, cylindrical container, suited for liquid, solid and semi-solid pharmaceutical forms.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Container Terminology
C150029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150029>	C4024|C3532	Thoracic Esophagus Squamous Cell Carcinoma	A squamous cell carcinoma that arises from the thoracic esophagus.			Neoplastic Process	
C150031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150031>	C4763|C4025	Cervical Esophagus Adenocarcinoma	An adenocarcinoma that arises from the cervical esophagus.			Neoplastic Process	
C150032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150032>	C4763|C4024	Cervical Esophagus Squamous Cell Carcinoma	A squamous cell carcinoma that arises from the cervical esophagus.			Neoplastic Process	
C150034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150034>	C6794|C5475	Gastric Cardia Squamous Cell Carcinoma	A squamous cell carcinoma that arises from the gastric cardia.			Neoplastic Process	
C150035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150035>	C172299	Dispersion Activity|Dispersion	Transformation of a solid or gas into a dispersion or suspension by mixing it with a specified liquid.			Phenomenon or Process	EDQM Health Care Terminology|EDQM-HC Transformation Terminology
C150036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150036>	C18515	NF-Kappa-B Inhibitor Zeta|I-Kappa-B-Zeta|IL-1 Inducible Nuclear Ankyrin-Repeat Protein|IL1-Induced Nuclear Ankyrin Repeat Protein|INAP|IkB-Zeta|IkappaB-Zeta|IkappaBzeta|Interleukin 1-Induced Nuclear Ankyrin Repeat Protein|MAIL|Molecule Possessing Ankyrin Repeats Induced by Lipopolysaccharide|NFKBIZ|Nuclear Factor of Kappa Light Polypeptide Gene Enhancer in B-Cells Inhibitor Zeta	NF-kappa-B inhibitor zeta (718 aa, ~78 kDa) is encoded by the human NFKBIZ gene. This protein plays a role in the inhibition of nuclear factor kappa-B-mediated gene transcription.			Amino Acid, Peptide, or Protein|Immunologic Factor	
C150037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150037>	C4024|C3535	Distal Esophagus Squamous Cell Carcinoma|Squamous Cell Carcinoma of the Distal Esophagus|Squamous Cell Carcinoma of the Lower Third of the Esophagus	A squamous cell carcinoma that arises from the distal esophagus.	Distal Esophagus Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150038>	C20194	KLHL42 Gene|KLHL42|KLHL42|Kelch Like Family Member 42 Gene	This gene is involved in the regulation of both ubiquitination and microtubule dynamics.			Gene or Genome	
C150039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150039>	C148414	Oromucosal/Laryngopharyngeal Solution/Spray, Solution Dosage Form|Oromucosal/laryngopharyngeal solution/spray, solution	Liquid preparation consisting of a solution intended for oromucosal or laryngopharyngeal use, presented in a container with an optional spray device to allow administration as a spray.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C150040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150040>	C150038	KLHL42 wt Allele|Ctb9|KIAA1340|KLHDC5|Kelch Domain Containing 5 Gene|Kelch Like Family 42 Gene|Kelch Like Family Member 42 wt Allele|Kelch Like Family, Member 42 Gene	Human KLHL42 wild-type allele is located in the vicinity of 12p11.22 and is approximately 23 kb in length. This allele, which encodes kelch-like protein 42, plays a role in the modulation of microtubule dynamics and the regulation of protein ubiquitination.			Gene or Genome	
C150042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150042>	C95242	Kelch-Like Protein 42|Ctb9|Cullin 3-Binding Protein 9|Cullin-3-Binding Protein 9|KLHL42|Kelch Domain-Containing Protein 5	Kelch-like protein 42 (505 aa, ~57 kDa) is encoded by the human KLHL42 gene. This protein is involved in microtubule dynamics and protein ubiquitination.			Amino Acid, Peptide, or Protein	
C150043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150043>	C3483|C148425	Recurrent Chronic Leukemia|Chronic leukemia of unspecified cell type, in relapse	The reemergence of chronic leukemia after a period of remission.			Neoplastic Process	mCode Cancer Disorder Value Set|mCode Elixhauser Leukemia Value Set|mCode Primary Cancer Disorder Value Set|mCode Primary Malignant Neoplasm Disorder Value Set|mCode Terminology
C150044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150044>	C3483|C148426	Refractory Chronic Leukemia	A chronic leukemia that is resistant to treatment.			Neoplastic Process	
C150045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150045>	C19683	Parenting	The act or activities involved in being a parent and raising children.			Individual Behavior	
C150046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150046>	C19332	Physical Function	An individual's capacity to undertake physical activities, such as everyday tasks.			Organism Attribute	
C150047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150047>	C20181	Decompensation	The inability of an organ or organ system to maintain homeostasis due to functional overload, often caused by the presence of disease intrinsic to the organ or organ system, or dysfunction in other organ systems.			Classification	
C150048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150048>	C3178|C166143|C150043	Recurrent Chronic Myelomonocytic Leukemia|Chronic myelomonocytic leukemia, in relapse	The reemergence of chronic myelomonocytic leukemia after a period of remission.	Recurrent Chronic Myelomonocytic Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|mCode Cancer Disorder Value Set|mCode Elixhauser Leukemia Value Set|mCode Primary Cancer Disorder Value Set|mCode Primary Malignant Neoplasm Disorder Value Set|mCode Terminology
C150049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150049>	C3178|C171339|C150044	Refractory Chronic Myelomonocytic Leukemia|Refractory Chronic Myelomonocytic Leukemia (CMML)	A chronic myelomonocytic leukemia that is resistant to treatment.	Refractory Chronic Myelomonocytic Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150050>	C217122	Overall Comorbidity Score|ACE-27 Overall Comorbidity Score|ACE-27 Overall Score	Represents the severity grade of organ decompensation for the highest-ranked single comorbid ailment or, in the case in which there are two comorbid ailments in 2 different organ systems each rated as moderate organ decompensation, the overall score is severe.			Intellectual Product	
C150051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150051>	C26147	UGGT2 Gene|UDP-Glucose Glycoprotein Glucosyltransferase 2 Gene|UGGT2|UGGT2	This gene plays a role in protein folding and glycosylation.			Gene or Genome	
C150052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150052>	C150051	UGGT2 wt Allele|FLJ10873|FLJ11485|HUGT2|MGC117360|MGC150689|MGC87276|UDP-Glucose Glycoprotein Glucosyltransferase 2 wt Allele|UGCGL2|UGT2	Human UGGT2 wild-type allele is located in the vicinity of 13q32.1 and is approximately 252 kb in length. This allele, which encodes UDP-glucose:glycoprotein glucosyltransferase 2 protein, is involved in protein folding quality control.			Gene or Genome	
C150053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150053>	C17434	UDP-Glucose:Glycoprotein Glucosyltransferase 2|EC 2.4.1.-|UDP--Glc:Glycoprotein Glucosyltransferase 2|UDP-Glc:Glycoprotein Glucosyltransferase 2|UDP-Glucose Ceramide Glucosyltransferase-Like 1|UDP-Glucose Ceramide Glucosyltransferase-Like 2|UGGT2|UGT2|hUGT2	UDP-glucose:glycoprotein glucosyltransferase 2 (1516 aa, ~175 kDa) is encoded by the human UGGT2 gene. This protein plays a role in the glucosylation of proteins with folding defects.			Amino Acid, Peptide, or Protein|Enzyme	
C150054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150054>	C16616	HLA-DMB Gene|HLA-DMB|HLA-DMB|Major Histocompatibility Complex, Class II, DM Beta Gene	This gene is involved in the post-translational modification of class II major histocompatibility protein complexes.			Gene or Genome	
C150055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150055>	C150054	HLA-DMB wt Allele|D6S221E|DMB|HLADMB|Major Histocompatibility Complex, Class II, DM Beta wt Allele|RING7|Really Interesting New Gene 7	Human HLA-DMB wild-type allele is located in the vicinity of 6p21.32 and is approximately 6 kb in length. This allele, which encodes HLA class II histocompatibility antigen, DM beta chain protein, plays a role in facilitating the presentation of antigenic peptides.			Gene or Genome	
C150056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150056>	C20705	HLA Class II Histocompatibility Antigen, DM Beta Chain|Class II Histocompatibility Antigen, M Beta Chain|HLA-DM Histocompatibility Type, Beta Chain|HLA-DMB|MHC Class II Antigen DMB|MHC Class II Antigen HLA-DM Beta Chain|MHC Class II HLA-DMB|Really Interesting New Gene 7 Protein	HLA class II histocompatibility antigen, DM beta chain (263 aa, ~29 kDa) is encoded by the human HLA-DMB gene. This protein is involved in removing the class II-associated invariant chain peptide (CLIP) from newly synthesized class II major histocompatibility protein complexes.			Amino Acid, Peptide, or Protein	
C150057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150057>	C20194	SEL1L3 Gene|SEL1L Family Member 3 Gene|SEL1L3|SEL1L3	This gene may play a role in calcium binding and signal transduction.			Gene or Genome	
C150058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150058>	C150057	SEL1L3 wt Allele|KIAA0746|SEL1L Family Member 3 wt Allele|Sel-1 Suppressor of Lin-12-Like 3 (C. elegans) Gene|Sel-1 Suppressor of Lin-12-Like 3 Gene|Sel-1L3	Human SEL1L3 wild-type allele is located in the vicinity of 4p15.2 and is approximately 142 kb in length. This allele, which encodes protein sel-1 homolog 3 protein, may be involved in signal transduction and calcium binding.			Gene or Genome	
C150059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150059>	C18466	Protein Sel-1 Homolog 3|KIAA0746 Protein|SEL1L3|Sel-1L3|Suppressor of Lin-12-Like Protein 3	Protein sel-1 homolog 3 (1132 aa, ~129 kDa) is encoded by the human SEL1L3 gene. This protein may play a role in calcium binding and signal transduction.			Amino Acid, Peptide, or Protein	
C150060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150060>	C20921	NFKBID Gene|NFKB Inhibitor Delta Gene|NFKBID|NFKBID	This gene may be involved in the regulation of nuclear factor-kappa-B activity and cytokine gene expression.			Gene or Genome	
C150061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150061>	C150060	NFKBID wt Allele|IKBNS|IkappaBNS|NF-Kappa-B Inhibitor, Delta Gene|NFKB Inhibitor Delta wt Allele|NFKB Inhibitor, Delta Gene|Nuclear Factor of Kappa Light Polypeptide Gene Enhancer in B-Cells Inhibitor, Delta Gene|TA-NFKBH	Human NFKBID wild-type allele is located in the vicinity of 19q13.12 and is approximately 15 kb in length. This allele, which encodes NF-kappa-B inhibitor delta protein, may play a role in the regulation of cytokine gene expression.			Gene or Genome	
C150062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150062>	C18515	NF-Kappa-B Inhibitor Delta|I-Kappa-B-Delta|IkB-Delta|IkappaBNS|IkappaBdelta|NFKBID|Nuclear Factor of Kappa Light Polypeptide Gene Enhancer in B-Cells Inhibitor Delta|T-Cell Activation NFKB-Like Protein|TA-NFKBH	NF-kappa-B inhibitor delta (313 aa, ~33 kDa) is encoded by the human NFKBID gene. This protein may be involved in the regulation of nuclear factor-kappa-B signaling-dependent cytokine gene expression.			Amino Acid, Peptide, or Protein|Immunologic Factor	
C150063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150063>	C20194	SPATA2 Gene|SPATA2|SPATA2|Spermatogenesis Associated 2 Gene	This gene plays a role in sperm formation.			Gene or Genome	
C150064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150064>	C150063	SPATA2 wt Allele|KIAA0757|PD1|PPP1R145|Protein Phosphatase 1, Regulatory Subunit 145 Gene|Spermatogenesis Associated 2 wt Allele|tamo	Human SPATA2 wild-type allele is located in the vicinity of 20q13.13 and is approximately 12 kb in length. This allele, which encodes spermatogenesis-associated protein 2, is involved in spermatogenesis.			Gene or Genome	
C150065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150065>	C18466	Spermatogenesis-Associated Protein 2|SPATA2|Spermatogenesis Associated PD1|Spermatogenesis-Associated Protein PD1	Spermatogenesis-associated protein 2 (520 aa, ~58 kDa) is encoded by the human SPATA2 gene. This protein plays a role in spermatogenesis.			Amino Acid, Peptide, or Protein	
C150066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150066>	C148275	Ear Drops, Solution in Single-dose Container Dosage Form|Ear drops, solution in single-dose container	Medicinal product consisting of an ear drops solution presented in a single-dose container.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C150067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150067>	C20194	TNIP1 Gene|TNFAIP3 Interacting Protein 1 Gene|TNIP1|TNIP1	This gene is involved in the positive regulation of tumor necrosis factor alpha-induced protein 3 (TNFAIP3)-mediated deubiquitination activity.			Gene or Genome	
C150068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150068>	C69064|C219573	Nasal Drops, Solution Dosage Form|Nasal drops, solution	Liquid single-dose or multidose preparation consisting of a solution intended for nasal use by means of a suitable applicator.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C150069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150069>	C150067	TNIP1 wt Allele|ABIN-1|KIAA0113|NAF1|Nef-Associated Factor 1 SNP Gene|TNFAIP3 Interacting Protein 1 wt Allele|VAN|nip40-1	Human TNIP1 wild-type allele is located in the vicinity of 5q33.1 and is approximately 64 kb in length. This allele, which encodes TNFAIP3-interacting protein 1, plays a role in the modulation of tumor necrosis factor alpha-induced protein 3 (TNFAIP3)-mediated deubiquitination activity.			Gene or Genome	
C150070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150070>	C18466	TNFAIP3-Interacting Protein 1|A20-Binding Inhibitor of NFKB 1|ABIN-1|HIV-1 Nef-Interacting Protein|Naf1|Nef-Associated Factor 1|Nip40-1|TNIP1|VAN|Virion-Associated Nuclear Shuttling Protein|Virion-Associated Nuclear-Shuttling Protein|hVAN	TNFAIP3-interacting protein 1 (636 aa, ~72 kDa) is encoded by the human TNIP1 gene. This protein is involved in the regulation of tumor necrosis factor alpha-induced protein 3 (TNFAIP3)-mediated deubiquitination activity.			Amino Acid, Peptide, or Protein	
C150071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150071>	C16616	HLA-DMA Gene|HLA-DMA|HLA-DMA|Major Histocompatibility Complex, Class II, DM Alpha Gene	This gene plays a role in removing the class II-associated invariant chain peptide (CLIP) from newly synthesized class II major histocompatibility protein complexes.			Gene or Genome	
C150072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150072>	C150071	HLA-DMA wt Allele|D6S222E|DMA|HLADM|HLADMA|Major Histocompatibility Complex, Class II, DM Alpha wt Allele|RING6|Really Interesting New Gene 6	Human HLA-DMA wild-type allele is located in the vicinity of 6p21.32 and is approximately 20 kb in length. This allele, which encodes HLA class II histocompatibility antigen, DM alpha chain protein, is involved in the post-translational modification of class II major histocompatibility protein complexes.			Gene or Genome	
C150073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150073>	C20705	HLA Class II Histocompatibility Antigen, DM Alpha Chain|Class II Histocompatibility Antigen, M Alpha Chain|HLA-DM Histocompatibility Type, Alpha Chain|HLA-DMA|MHC Class II Antigen DMA|MHC Class II Antigen HLA-DM Alpha Chain|MHC Class II HLA-DMA|Really Interesting New Gene 6 Protein	HLA class II histocompatibility antigen, DM alpha chain (261 aa, ~29 kDa) is encoded by the human HLA-DMA gene. This protein plays a role in facilitating the presentation of antigenic peptides.			Amino Acid, Peptide, or Protein	
C150074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150074>	C148268	Powder and Solvent for Dispersion for Injection Dosage Form|Powder and solvent for dispersion for injection	Sterile powder and sterile solvent intended for the preparation of a dispersion for injection by dispersing the powder in the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C150075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150075>	C25997	SLA Gene|SLA|SLA|Src Like Adaptor Gene	This gene is involved in the regulation of T-cell receptor and B-cell receptor signaling.			Gene or Genome	
C150076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150076>	C150075	SLA wt Allele|SLA1|SLAP|SLAP1|Src Like Adaptor wt Allele	Human SLA wild-type allele is located in the vicinity of 8q24.22 and is approximately 66 kb in length. This allele, which encodes Src-like-adapter protein, plays a role in the modulation of signaling from both the B-cell receptor and the T-cell receptor.			Gene or Genome	
C150077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150077>	C26231	Src-Like-Adapter|SLA|SLAP-1|Src-Like Adaptor|Src-Like-Adapter Protein 1|Src-Like-Adaptor|hSLAP	Src-like-adapter (276 aa, ~31 kDa) is encoded by the human SLA gene. This protein is involved in the regulation of B-cell receptor and T-cell receptor signaling.			Amino Acid, Peptide, or Protein	
C150078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150078>	C25873	MAP4K1 Gene|MAP4K1|MAP4K1|Mitogen-Activated Protein Kinase Kinase Kinase Kinase 1 Gene	This gene plays a role in hematopoiesis.			Gene or Genome	
C150079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150079>	C150078	MAP4K1 wt Allele|HPK1|MEKKK1|Mitogen-Activated Protein Kinase Kinase Kinase Kinase 1 wt Allele	Human MAP4K1 wild-type allele is located in the vicinity of 19q13.2 and is approximately 31 kb in length. This allele, which encodes mitogen-activated protein kinase kinase kinase kinase 1 protein, is involved in protein kinase-dependent signaling.			Gene or Genome	
C150080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150080>	C17325	Mitogen-Activated Protein Kinase Kinase Kinase Kinase 1|EC 2.7.11.1|Hematopoietic Progenitor Kinase|Hematopoietic Progenitor Kinase 1|MAP4K1|MAPK/ERK Kinase Kinase Kinase 1|MEK Kinase Kinase 1|MEKKK 1	Mitogen-activated protein kinase kinase kinase kinase 1 (833 aa, ~91 kDa) is encoded by the human MAP4K1 gene. This protein plays a role in the modulation of serine/threonine kinase-dependent signaling pathways.			Amino Acid, Peptide, or Protein|Enzyme	
C150081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150081>	C20103	LAPTM5 Gene|LAPTM5|LAPTM5|Lysosomal Protein Transmembrane 5 Gene	This gene is involved in hematopoietic cell differentiation and embryogenesis.			Gene or Genome	
C150082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150082>	C150081	LAPTM5 wt Allele|CD40-Ligand-Activated Specific Transcripts Gene|CLAST6|E3|KIAA0085|Lysosomal Protein Transmembrane 5 wt Allele|Lysosome-Associated Protein, Transmembrane 5 Gene|Retinoic Acid-Inducible Gene E3	Human LAPTM5 wild-type allele is located in the vicinity of 1p35.2 and is approximately 25 kb in length. This allele, which encodes lysosomal-associated transmembrane protein 5, plays a role in the modulation of both embryogenesis and hematopoietic cell differentiation.			Gene or Genome	
C150083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150083>	C18106	Lysosomal-Associated Transmembrane Protein 5|E3 Protein|Human Retinoic Acid-Inducible E3 Protein|LAPTM5|Lysosomal Associated Multispanning Membrane Protein 5|Lysosomal Multispanning Membrane Protein 5|Lysosomal-Associated Multitransmembrane Protein 5|Lysosome-Associated Multispanning Transmembrane Protein 5|Retinoic Acid-Inducible E3 Protein	Lysosomal-associated transmembrane protein 5 (262 aa, ~30 kDa) is encoded by the human LAPTM5 gene. This protein is involved in the regulation of both hematopoietic cell differentiation and embryogenesis.			Amino Acid, Peptide, or Protein|Receptor	
C150084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150084>	C91106	Undecided	A response indicating that a decision has or had not been made.			Intellectual Product	Patient Satisfaction with Cancer Care Questionnaire
C150085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150085>	C226644	Received All the Services Needed|I received all the services I needed|Received All the Services I Needed	A response indicating that an individual feels or felt that they received all the services they needed.			Intellectual Product	Patient Satisfaction with Cancer Care Questionnaire
C150086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150086>	C226644|C176250	Satisfied With the Care Received|I was satisfied with the care I received|Satisfied With the Care I Received	A response indicating that an individual feels or felt that they are satisfied with the care they received.			Intellectual Product	Patient Satisfaction with Cancer Care Questionnaire
C150087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150087>	C226920|C226644	Doctors Seemed to Communicate Well About Care|Doctors Seemed to Communicate Well About My Care|The doctors seemed to communicate well about my care	A response indicating that an individual feels or felt that doctors seemed to communicate well about their care.			Intellectual Product	Patient Satisfaction with Cancer Care Questionnaire
C150088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150088>	C226644	Received High Quality Care From Regular Doctor|I received high quality care from my regular doctor|Received High Quality Care From My Regular Doctor	A response indicating that an individual feels or felt that they received high quality care from their regular doctor.			Intellectual Product	Patient Satisfaction with Cancer Care Questionnaire
C150089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150089>	C226644	Received High Quality Care From Specialists|I received high quality care from my specialists|Received High Quality Care From My Specialists	A response indicating that an individual feels or felt that they received high quality care from their specialists.			Intellectual Product	Patient Satisfaction with Cancer Care Questionnaire
C150090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150090>	C226696	Regular Doctor was Informed About the Results of Test|My Regular Doctor was Informed About the Results of the Test I Got|My regular doctor was informed about the results of the test I got	A response indicating that an individual feels or felt that their regular doctor was informed about the results of the test they got.			Intellectual Product	Patient Satisfaction with Cancer Care Questionnaire
C150091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150091>	C4908|C152048	Refractory Ovarian Carcinoma	Ovarian carcinoma that is resistant to treatment.			Neoplastic Process	
C150092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150092>	C61574|C150527	Refractory Malignant Uterine Corpus Neoplasm|Refractory Uterine Corpus Cancer	Malignant uterine corpus neoplasm that is resistant to treatment.			Neoplastic Process	
C150093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150093>	C7558|C152048|C150092	Refractory Endometrial Carcinoma	An endometrial carcinoma that is resistant to treatment			Neoplastic Process	
C150094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150094>	C9072|C7620|C7558	Recurrent Endometrial Carcinoma	The reemergence of endometrial carcinoma after a period of remission.			Neoplastic Process	
C150095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150095>	C7979|C158421|C153614	Recurrent Ovarian Endometrioid Adenocarcinoma|Recurrent Ovarian Endometrioid Carcinoma	The reemergence of ovarian endometrioid adenocarcinoma after a period of remission.			Neoplastic Process	
C150096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150096>	C7979|C170968	Refractory Ovarian Endometrioid Adenocarcinoma	Ovarian endometrioid adenocarcinoma that is resistant to treatment.			Neoplastic Process	
C150097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150097>	C6287|C158437|C158421	Recurrent Endometrial Endometrioid Adenocarcinoma	The reemergence of endometrial endometrioid adenocarcinoma after a period of remission.			Neoplastic Process	
C150098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150098>	C6287|C165289	Refractory Endometrial Endometrioid Adenocarcinoma	An endometrial endometrioid adenocarcinoma that is resistant to treatment.			Neoplastic Process	
C150099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150099>	C138961	PSA Level Less than 0.5	An indication that a blood concentration of prostate specific antigen below 0.5 ng/mL was detected in a sample.	PSA Level Less than 0.5		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C1500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1500>	C260	Penicillin Antibiotic|penicillin	Any beta-lactam antibiotic derived from Penicillium fungi with bactericidal activity. Penicillin antibiotics bind to and inactivate penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall, eventually causing cell lysis.			Chemical Viewed Functionally	
C150100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150100>	C25871	DGKZ Gene|DGKZ|DGKZ|Diacylglycerol Kinase Zeta Gene	This gene is involved in the phosphorylation of diacylglycerols.	DGKZ Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C150101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150101>	C150100	DGKZ wt Allele|DAGK5|DAGK6|DGK-ZETA|Diacylglycerol Kinase Zeta wt Allele|Diacylglycerol Kinase, Zeta 104kDa Gene|Diacylglycerol Kinase, Zeta, 104-kD Gene|hDGKzeta	Human DGKZ wild-type allele is located in the vicinity of 11p11.2 and is approximately 48 kb in length. This allele, which encodes diacylglycerol kinase zeta protein, plays a role in the modulation of second messenger signaling.	DGKZ wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150102>	C16984	Diacylglycerol Kinase Zeta|DAG Kinase Zeta|DGK-Zeta|Diglyceride Kinase Zeta|EC 2.7.1.107	Diacylglycerol kinase zeta (1117 aa, ~124 kDa) is encoded by the human DGKZ gene. This protein is involved in the phosphorylation of the second messenger molecule diacylglycerol.	Diacylglycerol Kinase Zeta		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150103>	C148636	EDQM-HC Pharmaceutical Dosage Form Terminology|Dosage Form|European Directorate for the Quality of Medicines and HealthCare Pharmaceutical Dosage Form|PDF|Pharmaceutical Dosage Form	Terminology subset about the physical manifestation of a product that contains the active ingredient(s) and/or inactive ingredient(s) that are intended to be delivered to the patient. Note: 'Pharmaceutical dose form' and 'Dosage form' are synonyms. 'Pharmaceutical dose form' can refer to the administrable dose form or the manufactured dose form, depending on the product that it is describing.			Intellectual Product	EDQM Health Care Terminology
C150104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150104>	C148636	EDQM-HC Combined Pharmaceutical Dose Form Terminology|CDF|Combined Pharmaceutical Dose Form|European Directorate for the Quality of Medicines and HealthCare Combined Pharmaceutical Dose Form	Terminology subset about single terms to describe two or more manufactured items that are intended to be combined in a specific way to produce a single pharmaceutical product, and which includes information on the manufactured dose form of each manufactured item and the administrable dose form of the pharmaceutical product. Note: in the example 'Powder and solvent for solution for injection', the medicinal product contains two manufactured items: (i) a powder for solution for injection, and (ii) a solvent; the pharmaceutical product that is prepared form the two manufactured items is a solution for injection; the combined pharmaceutical dose form for the medicinal product is therefore 'powder and solvent for solution for injection'.			Intellectual Product	EDQM Health Care Terminology
C150105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150105>	C148636	EDQM-HC Combined Term Terminology|CMT|Combined Term|European Directorate for the Quality of Medicines and HealthCare Combined Term	Terminology subset about single terms to describe a pharmaceutical dose form (or combined pharmaceutical dose for) and an item of packaging, either for the purpose of distinguishing between marketed products that differ only in the container or administration device, or where the item of packaging has special characteristics that are relevant to the use of the medicinal product.			Intellectual Product	EDQM Health Care Terminology
C150106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150106>	C148636	EDQM-HC Combined Pack Terminology|CMP|Combined Pack|European Directorate for the Quality of Medicines and HealthCare Combined Pack	Terminology subset about single terms to describe two or more medicinal products that are packaged together and marketed under a single license, and which are intended to be administered independently, as separate pharmaceutical products.			Intellectual Product	EDQM Health Care Terminology
C150107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150107>	C148636	EDQM-HC Routes and Methods of Administration Terminology|European Directorate for the Quality of Medicines and HealthCare Routes and Methods of Administration|ROA|Routes and Methods of Administration	Terminology subset about the paths by which the pharmaceutical product is taken into or makes contact with the body.			Intellectual Product	EDQM Health Care Terminology
C150108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150108>	C148636	EDQM-HC Closure Terminology|CLO|Closure|European Directorate for the Quality of Medicines and HealthCare Closures	Terminology subset about items used to close a container for the purpose of the correct storage and (where appropriate) use of the product.			Intellectual Product	EDQM Health Care Terminology
C150109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150109>	C148636	EDQM-HC Container Terminology|CON|Container|European Directorate for the Quality of Medicines and HealthCare Containers	Terminology subset about items of packaging that is part of a medicinal product and is used for storage, identification and/or transport of the components of the medicinal product. Note: 'Container' is a general concept that groups together the concepts of immediate container, intermediate packaging and outer packaging.			Intellectual Product	EDQM Health Care Terminology
C150110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150110>	C148636	EDQM-HC Administration Device Terminology|Administration Device|DEV|European Directorate for the Quality of Medicines and HealthCare Administration Device	Terminology subset about devices that are used to administer a pharmaceutical product.			Intellectual Product	EDQM Health Care Terminology
C150111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150111>	C148636	EDQM-HC Units of Presentation Terminology|European Directorate for the Quality of Medicines and HealthCare Units of Presentation|UOP|Units of Presentation	Terminology subset about qualitative terms describing the discrete countable entity in which a pharmaceutical product or manufactured item is presented, in cases where strength or quantity is expressed referring to one instance of this countable entity. Note: A unit of presentation will often have the same name as a concept in another controlled vocabulary list, such as a basic dose form or a container, but the two concepts are not equivalent, and each has its own definition and identifier.			Intellectual Product	EDQM Health Care Terminology
C150112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150112>	C148636	EDQM-HC Administration Method Terminology|AME|Administration Method|European Directorate for the Quality of Medicines and HealthCare Administration Method	Terminology subset about general methods by which a pharmaceutical product is intended to be administered to the patient.			Intellectual Product	EDQM Health Care Terminology
C150113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150113>	C148636	EDQM-HC Basic Dose Form Terminology|BDF|Basic Dose Form|European Directorate for the Quality of Medicines and HealthCare Basic Dose Form	Terminology subset about generalized versions of the pharmaceutical dose form, used to group together related pharmaceutical dose forms.			Intellectual Product	EDQM Health Care Terminology
C150114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150114>	C148636	EDQM-HC Intended Site of Administration Terminology|European Directorate for the Quality of Medicines and HealthCare Intended Site of Administration|ISI|Intended Site of Administration	Terminology subset about general body sites at which a pharmaceutical product is intended to be administered.			Intellectual Product	EDQM Health Care Terminology
C150115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150115>	C148636	EDQM-HC Release Characteristics Terminology|European Directorate for the Quality of Medicines and HealthCare Release Characteristics|RCA|Release Characteristics	Terminology subset about descriptions of the timing by which an active ingredient is made available in the body after administration of the pharmaceutical product, in comparison with a conventional, direct release of the active ingredient.			Intellectual Product	EDQM Health Care Terminology
C150116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150116>	C148636	EDQM-HC State of Matter Terminology|European Directorate for the Quality of Medicines and HealthCare State of Matter|SOM|State of Matter	Terminology subset about physical conditions describing the molecular form of a product. Note: State of matter is used to group basic dose forms according to their physical properties.			Intellectual Product	EDQM Health Care Terminology
C150117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150117>	C148636	EDQM-HC Transformation Terminology|European Directorate for the Quality of Medicines and HealthCare Transformation|TRA|Transformation	Terminology subset about procedures that are carried out in order to convert a manufactured item that requires such a procedure into a pharmaceutical product, i.e., from its manufactured dose form to its administrable dose form. Note: A transformation is not required when the manufactured item is equal to the pharmaceutical product.			Intellectual Product	EDQM Health Care Terminology
C150118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150118>	C25873	PRKCD Gene|PRKCD|PRKCD|Protein Kinase C Delta Gene	This gene plays a role in the regulation of both cell death and cell survival.			Gene or Genome	
C150119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150119>	C150118	PRKCD wt Allele|ALPS3|CVID9|MAY1|PKCD|Protein Kinase C Delta wt Allele|Protein Kinase C, Delta Gene|SDK1|Sphingosine-Dependent Protein Kinase-1 Gene|nPKC-delta	Human PRKCD wild-type allele is located in the vicinity of 3p21.1 and is approximately 37 kb in length. This allele, which encodes protein kinase C delta type protein, is involved in both cell death and cell survival. Mutation of the gene is associated with autoimmune lymphoproliferative syndrome 3.			Gene or Genome	
C150120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150120>	C17325	Protein Kinase C Delta Type|EC 2.7.10.2|EC 2.7.11.13|PRKCD|Tyrosine-Protein Kinase PRKCD|nPKC-Delta	Protein kinase C delta type (676 aa, ~78 kDa) is encoded by the human PRKCD gene. This protein plays a role in the regulation of apoptosis.			Amino Acid, Peptide, or Protein|Enzyme	
C150121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150121>	C50052	Radiation Dosimeter Device|Dosimeter	A device that is used to measure the amount of ionizing radiation exposure or absorption.	Radiation Dosimeter Device		Manufactured Object	CTRP Terminology
C150122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150122>	C167434	High Grade Myeloid Neoplasm|High-Grade Myeloid Neoplasm|High-Grade Myeloid Neoplasm	A finding indicating that a myeloproliferative process has high-grade pathologic and/or clinical features.	High-Grade Myeloid Neoplasm		Finding	CTRP Disease Terminology|CTRP Terminology
C150123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150123>	C35682	Biomarker Positive Malignant Neoplasm|Biomarker Positive Cancer|Positive Biomarker in Cancer|Positive Biomarker in Malignant Neoplasm|Positive Biomarker(s)|Positive Biomarker(s)	A finding indicating the presence of a biomarker in a tumor sample from a patient with a malignant neoplasm.	Biomarker Positive Malignant Neoplasm		Laboratory or Test Result	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C150124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150124>	C177686|C150123	EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma|EGFR NP_005219.2:p.T790M Positive NSCLC|EGFR NP_005219.2:p.Thr790Met Positive NSCLC|EGFR T790M Mutation Positive NSCLC|EGFR T790M Mutation Positive Non-Small Cell Lung Cancer|EGFR T790M Mutation Positive Non-Small Cell Lung Cancer|EGFR Thr790Met Mutation Positive NSCLC|EGFR Thr790Met Mutation Positive Non-Small Cell Lung Cancer|EGFR Thr790Met Mutation Positive Non-Small Cell Lung Carcinoma|NSCLC with EGFR T790M Mutation|NSCLC with EGFR Thr790Met Mutation	A finding indicating the presence of the epidermal growth factor receptor T790M amino acid substitution mutation in a tumor sample from a patient with non-small cell lung carcinoma.	EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150125>	C35681|C175007	Thyroglobulin Antibody Negative|Anti-TG Antibody Negative|Anti-Thyroglobulin Antibody Negative|TG Antibody Negative	An indication that antibodies that recognize thyroglobulin have not been detected in a sample.	Thyroglobulin Antibody Negative		Finding	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150126>	C217485	Telotristat Ethyl|LX 1032|LX 1606|LX-1032|LX-1606|LX1032|LX1606|TELOTRISTAT ETHYL	The ethyl ester form of telotristat, a tryptophan hydroxylase (TPH) inhibitor, with potential anti-serotonergic activity. Upon administration, telotristat binds to and inhibits the activity of TPH. This may result in a reduction in peripheral serotonin (5-HT) production and improvement of serotonin-mediated gastrointestinal effects such as severe diarrhea. TPH, the rate-limiting enzyme in serotonin biosynthesis, is overexpressed in carcinoid tumor cells.	Telotristat Ethyl		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C150127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150127>	C181108	Anti-BCMA/PBD ADC MEDI2228|ADC MEDI2228|Anti-BCMA ADC MEDI2228|Anti-BCMA/PBD MEDI2228|Antibody-drug Conjugate MEDI2228|MEDI 2228|MEDI-2228|MEDI-2228|MEDI2228	An antibody-drug conjugate (ADC) consisting of a fully human monoclonal antibody against the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA, TNFRSF17) that is site-specifically conjugated, via a protease-cleavable linker, to a cytotoxic, DNA minor groove crosslinking agent and pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of anti-BCMA/PBD ADC MEDI2228, the antibody moiety targets the cell surface antigen BCMA expressed on certain cancer cells. Upon antibody/antigen binding, internalization and lysosome-mediated cleavage, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of BCMA-overexpressing tumor cells. BCMA, a receptor for a proliferation-inducing ligand (APRIL; tumor necrosis factor ligand superfamily member 13; TNFSF13), and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in plasma survival; it is found on the surfaces of plasma cells and is overexpressed on malignant plasma cells.	Anti-BCMA/PBD ADC MEDI2228		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150128>	C68753|C17220	Tumor Mutation Burden|MUTATED_ALLELE|Mutated Allele|TMB|Tumor Mutational Burden|Tumor Mutational Burden	The total number of genomic alterations found in the cells of a cancer.	Tumor Mutation Burden|Tumor Mutational Burden		Indicator, Reagent, or Diagnostic Aid	CTRP Biomarker Terminology|CTRP Terminology
C150129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150129>	C20031	Circulating Protein	Protein found in the peripheral blood.	Circulating Protein		Amino Acid, Peptide, or Protein	
C150130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150130>	C4758|C148515	Uveal Melanoma Metastatic in the Liver|Metastatic Uveal Melanoma in the Liver	A melanoma that originates from melanocytes of the uveal tract and has spread to the liver.	Uveal Melanoma Metastatic in the Liver		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150131>	C8695|C3183|C142810	Recurrent T Acute Lymphoblastic Leukemia|Recurrent T-Acute Lymphoblastic Leukemia	The reemergence of T acute lymphoblastic leukemia after a period of remission.	Recurrent T Acute Lymphoblastic Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150132>	C96058|C8688|C206293|C178554	Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma	The reemergence of monomorphic epitheliotropic intestinal T-cell lymphoma after a period of remission.	Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150133>	C4752|C193424|C173409|C150043	Recurrent T-Cell Prolymphocytic Leukemia|Prolymphocytic leukemia of T-cell type, in relapse	The reemergence of T-cell prolymphocytic leukemia after a period of remission.	Recurrent T-Cell Prolymphocytic Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|mCode Cancer Disorder Value Set|mCode Elixhauser Leukemia Value Set|mCode Primary Cancer Disorder Value Set|mCode Primary Malignant Neoplasm Disorder Value Set|mCode Terminology
C150134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150134>	C99107	Splanchnic Vein Thrombosis	Thrombosis within the hepatic portal system.	Splanchnic Vein Thrombosis		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C150135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150135>	C201554	Expanded Cord Blood Stem Cells Mixed with Engineered Human Endothelial Cells AB-110|AB 110|AB-110|AB-110 Cell Product|CD34+ Cord-Blood Derived Hematopoietic Stem Cells Co-Cultured and Co-Infused with Genetically Modified Endothelial Cells AB-110|CD34-positive Enriched HPCs Mixed with Engineered Human ECs AB-110|Cord Blood-derived HPCs Co-cultured and Expanded with E-CEL UVEC Cells AB-110|Genetically-modified Endothelial Cells Plus Expanded Cord Blood Hematopoietic Stem Cells AB-110	A population of ex vivo expanded, CD34-positive-enriched hematopoietic progenitor cells (HPCs), which are derived from allogeneic human umbilical cord blood (UCB), and are co-cultured and expanded with a proprietary preparation of human endothelial cells (ECs), which are genetically modified with an adenovirus (Ad) vector that includes the Ad E4 region that encodes the ORF1 (E4ORF1) gene, that can be used for transplantation. Upon transplantation of the expanded cord blood stem cells mixed with engineered human ECs AB-110, the UCB-derived cells can differentiate into a variety of cell types and promote blood cell recovery. Compared to bone marrow transplants, these HPCs demonstrate a decreased risk of causing graft-versus-host disease (GvHD), increase survival and enhance the potential for transplant and engraftment in any given patient as there is no need for a matched donor. Compared to HPCs alone, inclusion of the ECs increases blood stem cell count, enhances engraftment potential and increases the chances for blood cell recovery, thereby further increasing the potential for a successful cord blood transplantation. Insertion of the Ad E4ORF1 gene enhances survival and replication of the ECs ex vivo, preserves the ECs' vascular functions and improves the ability of the ECs to secrete angiocrines, which promotes stem cell proliferation and increases engraftment.	Expanded Cord Blood Stem Cells Mixed with Engineered Human Endothelial Cells AB-110		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C150136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150136>	C183489	Intracervical Route of Administration|Intracervical use	Injection of a medicinal product into the cervix uteri.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Routes and Methods of Administration Terminology
C150137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150137>	C186493	Abbreviated Breast MRI Protocol|AB-MRI|Abbreviated Breast MRI	Protocols aimed at reducing the cost of breast MRI to improve access to it as a supplemental screening method. Shorter protocols and shorter acquisition times can be achieved with maintenance of diagnostic accuracy comparable to that obtained with conventional MRI protocols. Use of these abbreviated MRI protocols could result in lower cost and faster throughput, thus increasing availability.	Abbreviated Breast MRI Protocol		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C150138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150138>	C43164	Unit-dose Blister|Unit-dose blister	Container consisting of two layers of which one is shaped to contain the individual unit, usually provided with perforations, the intention being to allow each individual unit to be separated for single unit administration. All the information required for blister packs must appear on each unit dose presentation.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Container Terminology
C150139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150139>	C3858	Clinically Significant Anxiety Symptoms	An indication that an individual's anxiety symptoms are or were clinically significant.			Finding	
C150140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150140>	C3858	Clinically Significant Depressive Symptoms	An indication that an individual's depressive symptoms are or were clinically significant.			Finding	
C150141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150141>	C193375	Partial Brain Radiation Therapy|PBRT|Partial Brain Irradiation|Partial Brain Radiotherapy	Radiation therapy that limits external beam radiation to a portion of the brain in order to reduce the total radiation exposure and decrease side effects.	Partial Brain Radiation Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C150142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150142>	C150143	Balloon Catheter Shaft Length|Shaft length	The length of the balloon catheter tube that extends from the catheter handle to the distal end of the catheter.			Quantitative Concept	FDA CDRH GUDID Terminology
C150143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150143>	C53450	Balloon Catheter Characteristics				Conceptual Entity	
C150144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150144>	C150143	Introducer Sheath Compatibility|Introducer Size|Sheath Compatibility|Sheath Size	The size of the device that would fit through an introducer sheath.			Quantitative Concept	FDA CDRH GUDID Terminology
C150145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150145>	C150143	Catheter Balloon Diameter|Balloon Diameter|Nominal Diameter	The nominal diameter of the balloon per manufacturer specification.			Quantitative Concept	FDA CDRH GUDID Terminology
C150146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150146>	C150143	Catheter Balloon Length|Balloon Length|Nominal Length	The nominal length of the balloon per manufacturer specification.			Quantitative Concept	FDA CDRH GUDID Terminology
C150147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150147>	C150143	Balloon Catheter Nominal Inflation Pressure|Nominal (Inflation) Pressure	Balloon pressure at balloon nominal diameter condition.			Quantitative Concept	FDA CDRH GUDID Terminology
C150148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150148>	C93102|C131479	Deleterious ATR Gene Mutation|Deleterious ATR Serine/Threonine Kinase Gene Mutation|Deleterious Ataxia Telangiectasia and Rad3 Related Gene Mutation|Deleterious FRP1 Gene Mutation|Deleterious MEC1 Gene Mutation	A change in the nucleotide sequence of the ATR gene that is associated with increased risk of disease.	Deleterious ATR Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150149>	C93102|C131794	Deleterious FANCA Gene Mutation|Deleterious FA Gene Mutation|Deleterious FA-H Gene Mutation|Deleterious FA1 Gene Mutation|Deleterious FAA Gene Mutation|Deleterious FACA Gene Mutation|Deleterious FAH Gene Mutation|Deleterious FANCH Gene Mutation|Deleterious Fanconi Anemia Complementation Group A Gene Mutation|Deleterious Fanconi Anemia, Complementation Group A Gene Mutation|Deleterious Fanconi Anemia, Complementation Group H Gene Mutation|Deleterious Fanconi Anemia, Type 1 Gene Mutation	A change in the nucleotide sequence of the FANCA gene that is associated with increased risk of disease.	Deleterious FANCA Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150150>	C93102|C131792	Deleterious FANCC Gene Mutation|Deleterious FA3 Gene Mutation|Deleterious FAC Gene Mutation|Deleterious FACC Gene Mutation|Deleterious Fanconi Anemia Complementation Group C Gene Mutation|Deleterious Fanconi Anemia, Complementation Group C Gene Mutation|Deleterious Fanconi Anemia, Type 3 Gene Mutation	A change in the nucleotide sequence of the FANCC gene that is associated with increased risk of disease.	Deleterious FANCC Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150151>	C93102|C131790	Deleterious FANCD2 Gene Mutation|Deleterious FA-D2 Gene Mutation|Deleterious FA4 Gene Mutation|Deleterious FACD Gene Mutation|Deleterious FAD Gene Mutation|Deleterious FAD2 Gene Mutation|Deleterious FANCD Gene Mutation|Deleterious Fanconi Anemia Complementation Group D2 Gene Mutation|Deleterious Fanconi Anemia, Complementation Group D2 Gene Mutation|Deleterious Fanconi Anemia, Type 4 Gene Mutation	A change in the nucleotide sequence of the FANCD2 gene that is associated with increased risk of disease.	Deleterious FANCD2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150152>	C93102|C131791	Deleterious FANCE Gene Mutation|Deleterious FACE Gene Mutation|Deleterious FAE Gene Mutation|Deleterious Fanconi Anemia Complementation Group E Gene Mutation|Deleterious Fanconi Anemia, Complementation Group E Gene Mutation	A change in the nucleotide sequence of the FANCE gene that is associated with increased risk of disease.	Deleterious FANCE Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150153>	C93102|C132003	Deleterious FANCF Gene Mutation|Deleterious FAF Gene Mutation|Deleterious Fanconi Anemia Complementation Group F Gene Mutation|Deleterious Fanconi Anemia, Complementation Group F Gene Mutation	A change in the nucleotide sequence of the FANCF gene that is associated with increased risk of disease.	Deleterious FANCF Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150154>	C93102|C132004	Deleterious FANCM Gene Mutation|Deleterious FAAP250 Gene Mutation|Deleterious Fanconi Anemia Complementation Group M Gene Mutation|Deleterious Fanconi Anemia, Complementation Group M Gene Mutation	A change in the nucleotide sequence of the FANCM gene that is associated with increased risk of disease.	Deleterious FANCM Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150155>	C141248|C131805	Deleterious MRE11 Gene Mutation|Deleterious ATLD Gene Mutation|Deleterious HNGS1 Gene Mutation|Deleterious MRE11 Homolog A, Double Strand Break Repair Nuclease Gene Mutation|Deleterious MRE11 Homolog, Double Strand Break Repair Nuclease Gene Mutation|Deleterious MRE11 Meiotic Recombination 11 Homolog A (S. cerevisiae) Gene Mutation|Deleterious MRE11A Gene Mutation|Deleterious MRE11B Gene Mutation|Deleterious Meiotic Recombination (S. cerevisiae) 11 Homolog A Gene Mutation|Deleterious Meiotic Recombination 11, S. cerevisiae, Homolog of, A Gene Mutation	A change in the nucleotide sequence of the MRE11 gene that is associated with increased risk of disease.	Deleterious MRE11 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150157>	C141248|C131806	Deleterious NBN Gene Mutation|Deleterious AT-V1 Gene Mutation|Deleterious AT-V2 Gene Mutation|Deleterious ATV Gene Mutation|Deleterious NBS Gene Mutation|Deleterious NBS1 Gene Mutation|Deleterious Nibrin Gene Mutation|Deleterious Nijmegen Breakage Syndrome 1 Gene Mutation|Deleterious P95 Gene Mutation	A change in the nucleotide sequence of the NBN gene that is associated with increased risk of disease.	Deleterious NBN Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150158>	C141248|C131793	Deleterious RAD50 Gene Mutation|Deleterious NBSLD Gene Mutation|Deleterious RAD50 (S. cerevisiae) Homolog Gene Mutation|Deleterious RAD50 Double Strand Break Repair Protein Gene Mutation|Deleterious RAD50 Homolog (S. cerevisiae) Gene Mutation|Deleterious RAD50 Homolog, Double Strand Break Repair Protein Gene Mutation|Deleterious RAD50, S. cerevisiae, Homolog of Gene Mutation|Deleterious RAD50-2 Gene Mutation|Deleterious RAD502 Gene Mutation|Deleterious hRad50 Gene Mutation	A change in the nucleotide sequence of the RAD50 gene that is associated with increased risk of disease.	Deleterious RAD50 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150159>	C20746	ACTG1 Gene|ACTG1|ACTG1|Actin Gamma 1 Gene	This gene plays a role in cell motility.			Gene or Genome	
C150160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150160>	C150159	ACTG1 wt Allele|ACT|ACTG|Actin Gamma 1 wt Allele|Actin, Cytoplasmic, 2 Gene|Actin, Gamma Gene|DFNA20|DFNA26|Deafness, Autosomal Dominant 20 Gene|Deafness, Autosomal Dominant 20/26 Gene|Deafness, Autosomal Dominant 26 Gene|HEL-176	Human ACTG1 wild-type allele is located in the vicinity of 17q25.3 and is approximately 44 kb in length. This allele, which encodes actin, cytoplasmic 2 protein, is involved in cell motility. Mutation of the gene is associated with autosomal dominant non-syndromic sensorineural progressive hearing loss and Baraitser-Winter syndrome.			Gene or Genome	
C150161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150161>	C150143	Balloon Catheter Nominal Outer Diameter|Crossing Profile|Distal Outer Diameter (OD)|Outer Diameter (OD)|Proximal Outer Diameter (OD)	The nominal measure of the outer diameter of the the balloon.			Quantitative Concept	FDA CDRH GUDID Terminology
C150162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150162>	C16258	Actin, Cytoplasmic 2|ACTG1|Cytoskeletal Gamma-Actin|Epididymis Luminal Protein 176|Gamma-Actin	Actin, cytoplasmic 2 (375 aa, ~42 kDa) is encoded by the human ACTG1 gene. This protein plays a role in cytoskeletal structure.			Amino Acid, Peptide, or Protein	
C150163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150163>	C150143	Balloon Catheter Tip Length	The length of the distal end of the catheter to the distal end of the balloon.			Quantitative Concept	FDA CDRH GUDID Terminology
C150164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150164>	C150143	Balloon Catheter Rated Burst Pressure|RBP|Rated Burst Pressure	Calculated pressure at which a balloon would not be expected to burst. Based on an appropriate confidence and reliability from measured burst pressures.			Quantitative Concept	FDA CDRH GUDID Terminology
C150165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150165>	C21275	ADAMTS20 Gene|ADAM Metallopeptidase with Thrombospondin Type 1 Motif 20 Gene|ADAMTS20|ADAMTS20	This gene is involved in both tissue-remodeling and proteolysis.			Gene or Genome	
C150166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150166>	C150165	ADAMTS20 wt Allele|A Disintegrin-Like and Metalloprotease (Reprolysin Type) with Thrombospondin Type 1 Motif, 20 Gene|A Disintegrin-Like and Metalloproteinase with Thrombospondin Type 1 Motif, 20 Gene|ADAM Metallopeptidase with Thrombospondin Type 1 Motif 20 wt Allele|ADAM-TS20|ADAMTS-20|GON-1	Human ADAMTS20 wild-type allele is located in the vicinity of 12q12 and is approximately 199 kb in length. This allele, which encodes a disintegrin and metalloproteinase with thrombospondin motifs 20 protein, plays a role in extracellular proteolysis.			Gene or Genome	
C150167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150167>	C201666	ATM Kinase Inhibitor AZD1390|7-Fluoro-1-isopropyl-3-methyl-8-(6-(3-(piperidin-1-yl)propoxy)pyridin-3-yl)-1H-imidazo[4,5-c]quinolin-2(3H)-one|AZD-1390|AZD-1390|AZD1390	An orally bioavailable inhibitor of ataxia telangiectasia mutated (ATM) kinase, with potential antineoplastic activity. Upon oral administration, AZD1390 targets and binds to ATM, thereby inhibiting the kinase activity of ATM and ATM-mediated signaling. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, induces tumor cell apoptosis, and leads to cell death in ATM-overexpressing tumor cells. AZD1390 hypersensitizes tumors to chemo/radiotherapy. In addition, AZD1390 is able to cross the blood-brain barrier (BBB). ATM, a serine/threonine protein kinase belonging to the phosphatidylinositol 3-kinase-related kinase (PIKK) family of protein kinases, is upregulated in a variety of cancer cell types. It is activated in response to DNA double-strand breaks (DSB) and plays a key role in DNA repair.	ATM Kinase Inhibitor AZD1390		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150168>	C16843	A Disintegrin and Metalloproteinase with Thrombospondin Motifs 20|A Disintegrin and Metalloprotease with Thrombospondin Motifs 20|A Disintegrin and Metalloprotease with Thrombospondin Motifs-20|ADAM-TS 20|ADAM-TS20|ADAMTS-20|ADAMTS20|EC 3.4.24.-	A disintegrin and metalloproteinase with thrombospondin motifs 20 (1910 aa, ~215 kDa) is encoded by the human ADAMTS20 gene. This protein is involved in remodeling of tissues and the extracellular matrix.			Amino Acid, Peptide, or Protein|Enzyme	
C150169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150169>	C21295	ANKRD24 Gene|ANKRD24|ANKRD24|Ankyrin Repeat Domain 24 Gene	This gene plays a role in the modulation of protein-protein interactions.			Gene or Genome	
C150170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150170>	C150169	ANKRD24 wt Allele|Ankyrin Repeat Domain 24 wt Allele|KIAA1981	Human ANKRD24 wild-type allele is located in the vicinity of 19p13.3 and is approximately 42 kb in length. This allele, which encodes ankyrin repeat domain-containing protein 24, is involved in protein-protein interactions.			Gene or Genome	
C150171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150171>	C17728	Ankyrin Repeat Domain-Containing Protein 24|ANKRD24	Ankyrin repeat domain-containing protein 24 (1146 aa, ~124 kDa) is encoded by the human ANKRD24 gene. This protein plays a role in protein-protein interactions.			Amino Acid, Peptide, or Protein	
C150172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150172>	C20921	ARFGAP3 Gene|ADP Ribosylation Factor GTPase Activating Protein 3 Gene|ARFGAP3|ARFGAP3	This gene is involved in the modulation of ADP-ribosylation factor 1-mediated signaling.			Gene or Genome	
C150173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150173>	C150172	ARFGAP3 wt Allele|ADP Ribosylation Factor GTPase Activating Protein 3 wt Allele|ADP-Ribosylation Factor GTPase Activating Protein 1 Gene|ARFGAP1	Human ARFGAP3 wild-type allele is located in the vicinity of 22q13.2 and is approximately 62 kb in length. This allele, which encodes ADP-ribosylation factor GTPase-activating protein 3, plays a role in the modulation of ADP-ribosylation factor 1-dependent secretory pathways.			Gene or Genome	
C150174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150174>	C17298	ADP-Ribosylation Factor GTPase-Activating Protein 3|ARF GAP 3|ARFGAP3	ADP-ribosylation factor GTPase-activating protein 3 (516 aa, ~57 kDa) is encoded by the human ARFGAP3 gene. This protein is involved in the promotion of ADP-ribosylation factor 1 GTPase activity.			Amino Acid, Peptide, or Protein	
C150175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150175>	C19771	Prolaris Prostate Cancer Testing|Prolaris|Prolaris|Prolaris Testing	A proprietary prognostic test which directly measures tumor cell growth characteristics for stratifying the risk of disease progression in prostate cancer patients. It provides a measure of the aggressiveness of an individual's prostate cancer and predicts disease-specific mortality.	Prolaris Prostate Cancer Testing		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C150176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150176>	C19676	BOD1L1 Gene|BOD1L1|BOD1L1|Biorientation of Chromosomes in Cell Division 1 Like 1 Gene	This gene plays a role in the protection of DNA replication forks.			Gene or Genome	
C150177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150177>	C150176	BOD1L1 wt Allele|BOD1L|Biorientation of Chromosomes in Cell Division 1 Like 1 wt Allele|Biorientation of Chromosomes in Cell Division 1-Like Gene|FAM44A|FLJ33215|Family with Sequence Similarity 44, Member A Gene|KIAA1327	Human BOD1L1 wild-type allele is located in the vicinity of 4p15.33 and is approximately 59 kb in length. This allele, which encodes biorientation of chromosomes in cell division protein 1-like 1 protein, is involved in replication fork maintenance.			Gene or Genome	
C150178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150178>	C21170	Biorientation of Chromosomes in Cell Division Protein 1-Like 1|BOD1-Like Protein 1|BOD1L1	Biorientation of chromosomes in cell division protein 1-like 1 (3051 aa, ~330 kDa) is encoded by the human BOD1L1 gene. This protein plays a role in promoting the repair of damaged replication forks.			Amino Acid, Peptide, or Protein	
C150179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150179>	C79698|C27588	Non-Neoplastic Optic Nerve Disorder	A non-neoplastic disorder that affects the optic nerve.	Non-Neoplastic Optic Nerve Disorder		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C150180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150180>	C25993	CACNA1E Gene|CACNA1E|CACNA1E|Calcium Voltage-Gated Channel Subunit Alpha1 E Gene	This gene is involved in depolarization of neuronal membranes.			Gene or Genome	
C150181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150181>	C150180	CACNA1E wt Allele|BII|CACH6|CACNL1A6|Calcium Channel, L Type, Alpha-1 Polypeptide Gene|Calcium Channel, L Type, Alpha-1 Polypeptide, Isoform 6 Gene|Calcium Channel, R Type, Alpha-1 Polypeptide Gene|Calcium Channel, Voltage-Dependent, Alpha-1E Subunit Gene|Calcium Channel, Voltage-Dependent, R Type, Alpha 1E Subunit Gene|Calcium Voltage-Gated Channel Subunit Alpha1 E wt Allele|Cav2.3|gm139	Human CACNA1E wild-type allele is located in the vicinity of 1q25.3 and is approximately 395 kb in length. This allele, which encodes voltage-dependent R-type calcium channel subunit alpha-1E protein, plays a role in membrane depolarization.			Gene or Genome	
C150182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150182>	C28505	Voltage-Dependent R-Type Calcium Channel Subunit Alpha-1E|BII|Brain Calcium Channel II|CACNA1E|Calcium Channel, L Type, Alpha-1 Polypeptide, Isoform 6|Calcium Channel, Voltage-Dependent, R Type, Alpha 1E Subunit|Calcium Voltage-Gated Channel Subunit Alpha1 Subunit E|Voltage-Dependent Calcium Channel Alpha 1E Subunit|Voltage-Gated Calcium Channel Alpha Subunit Cav2.3|Voltage-Gated Calcium Channel Subunit Alpha Cav2.3	Voltage-dependent R-type calcium channel subunit alpha-1E (2313 aa, ~262 kDa) is encoded by the human CACNA1E gene. This protein is involved in voltage-dependent calcium transport.			Amino Acid, Peptide, or Protein	
C150183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150183>	C53450	Catheter Characteristics				Clinical Attribute	
C150184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150184>	C150183	Catheter Length	The length of the catheter.			Quantitative Concept	FDA CDRH GUDID Terminology
C150185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150185>	C150183	Guidewire Compatibility|Inner Lumen Dimension|Maximum Guidewire Size	The size of the guidewires that will fit through the inner lumen of the device.			Quantitative Concept	FDA CDRH GUDID Terminology
C150186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150186>	C150183	Catheter Working Length|Effective Length|Working Length	The length of the catheter that can be inserted into the body or the working/functional measurement from the beginning to the end of delivery system.			Quantitative Concept	FDA CDRH GUDID Terminology
C150187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150187>	C150183	Tip Bend Radius	The radius of an imaginary circle drawn inside of a curve of a curved catheter or guidewire.			Quantitative Concept	FDA CDRH GUDID Terminology
C150188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150188>	C53450	Stent Characteristics				Clinical Attribute	
C150189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150189>	C150188	Nominal Stent Diameter|Stent Diameter	Deployed stent diameter, as marked on packaging.			Quantitative Concept	FDA CDRH GUDID Terminology
C150190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150190>	C150188	Nominal Stent Length|Stent Length	Deployed stent length, as marked on the packaging.			Quantitative Concept	FDA CDRH GUDID Terminology
C150192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150192>	C150188	Tapered Stent Smaller Diameter|Distal Stent|Tapered Stent Smallest Diameter	The diameter of the portion of the tapered end of the stent that is the smaller of the two tapered ends.			Quantitative Concept	FDA CDRH GUDID Terminology
C150193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150193>	C25993	CACNA1S Gene|CACNA1S|CACNA1S|Calcium Voltage-Gated Channel Subunit Alpha1 S Gene	This gene plays a role in muscle cell membrane depolarization.			Gene or Genome	
C150194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150194>	C150188	Tapered Stent Larger Diameter	The diameter of the portion of the tapered end of the stent that is the larger of the two tapered ends.			Quantitative Concept	FDA CDRH GUDID Terminology
C150195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150195>	C150193	CACNA1S wt Allele|CACH1|CACN1|CACNL1A3|CCHL1A3|Calcium Channel, L Type, Alpha 1 Polypeptide, Isoform 3 (Skeletal Muscle, Hypokalemic Periodic Paralysis) Gene|Calcium Channel, L Type, Alpha-1 Polypeptide, Isoform 3, Skeletal Muscle Gene|Calcium Channel, Skeletal Muscle Dihydropyridine-Sensitive, Alpha-1 Subunit Gene|Calcium Channel, Voltage-Dependent, L Type, Alpha 1S Subunit Gene|Calcium Channel, Voltage-Dependent, L Type, Alpha-1S Subunit Gene|Calcium Voltage-Gated Channel Subunit Alpha1 S wt Allele|Cav1.1|HOKPP|HOKPP1|MHS5|TTPP1|hypoPP	Human CACNA1S wild-type allele is located in the vicinity of 1q32.1 and is approximately 73 kb in length. This allele, which encodes voltage-dependent L-type calcium channel subunit alpha-1S protein, is involved in skeletal muscle contraction. Mutation of the gene is associated with susceptibility to hypothermia and to two types of periodic paralysis, hypokalemic and thyrotoxic.			Gene or Genome	
C150196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150196>	C150188	Tapered Stent Length	The length of the tapered portion of the stent.			Quantitative Concept	FDA CDRH GUDID Terminology
C150197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150197>	C150188	Maximum Inflated Stent Diameter|Maximum Stent Diameter	Maximum diameter to which a stent can be distended.			Quantitative Concept	FDA CDRH GUDID Terminology
C150198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150198>	C28505	Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1S|CACNA1S|Calcium Channel, L Type, Alpha-1 Polypeptide, Isoform 3, Skeletal Muscle|Dihydropyridine Receptor Alpha 1 Subunit|Dihydropyridine-Sensitive L-Type Calcium Channel Alpha-1 Subunit|Voltage-Gated Calcium Channel Alpha 1 Subunit|Voltage-Gated Calcium Channel Subunit Alpha Cav1.1	Voltage-dependent L-type calcium channel subunit alpha-1S (1873 aa, ~212 kDa) is encoded by the human CACNA1S gene. This protein plays a role in voltage-dependent calcium transport in muscle cells.			Amino Acid, Peptide, or Protein	
C150199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150199>	C53450	Atherectomy Device Characteristics	The notable properties of the atherectomy device.			Clinical Attribute	
C1501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1501>	C1934	Phenyl Acetate|Acetic Acid Phenyl Ester|Acetylphenol|Acetylphenol|PHENYL ACETATE|Phenyl acetate|phenylacetate	An aromatic fatty acid metabolite of phenylalanine with potential antineoplastic activity.  Naturally occurring in mammals, phenylacetate induces differentiation, growth inhibition, and apoptosis in tumor cells.  Implicated mechanisms of action include decreased protein prenylation, activation of the peroxisome proliferation-activated receptors, inhibition of DNA methylation, and depletion of glutamine. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150200>	C150199	Atherectomy Device Tip Length	The length of the tip of the atherectomy device, if present.			Quantitative Concept	FDA CDRH GUDID Terminology
C150201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150201>	C173694|C170783|C150202	Advanced Oropharyngeal Squamous Cell Carcinoma|Advanced Oropharyngeal Throat Squamous Cell Cancer|Advanced Squamous Cell Carcinoma of the Oropharynx	A squamous cell carcinoma of the oropharynx that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Squamous Cell Carcinoma of the Oropharynx		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150202>	C8181|C173685|C156082	Metastatic Oropharyngeal Squamous Cell Carcinoma|Metastatic Oropharyngeal Throat Squamous Cell Cancer|Metastatic Squamous Cell Carcinoma of the Oropharynx	A squamous cell carcinoma of the oropharynx which has spread from the original site of growth to another anatomic site.	Metastatic Squamous Cell Carcinoma of the Oropharynx		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150203>	C20988	CDH20 Gene|CDH20|CDH20|Cadherin 20 Gene	This gene is involved in calcium-dependent cell-cell adhesion.			Gene or Genome	
C150204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150204>	C150206|C139291	Advanced Oral Cavity Squamous Cell Carcinoma|Advanced Oral Cavity Squamous Cell Cancer|Advanced Squamous Cell Carcinoma of the Oral Cavity	A squamous cell carcinoma of the oral cavity that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Squamous Cell Carcinoma of the Oral Cavity		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150205>	C150203	CDH20 wt Allele|CDH7L3|Cadherin 20 wt Allele|Cadherin 20, Type 2 Gene|Cdh7	Human CDH20 wild-type allele is located in the vicinity of 18q21.33 and is approximately 222 kb in length. This allele, which encodes cadherin-20 protein, plays a role in cell-cell adhesion.			Gene or Genome	
C150206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150206>	C4833|C156087|C148153	Metastatic Oral Cavity Squamous Cell Carcinoma|Metastatic Oral Cavity Squamous Cell Cancer|Metastatic Squamous Cell Carcinoma of the Oral Cavity	A squamous cell carcinoma of the oral cavity which has spread from the original site of growth to another anatomic site.	Metastatic Squamous Cell Carcinoma of the Oral Cavity		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150207>	C175491|C173694|C150209	Advanced Nasopharyngeal Squamous Cell Carcinoma|Advanced Nasopharyngeal Throat Squamous Cell Cancer|Advanced Squamous Cell Carcinoma of the Nasopharynx	A squamous cell carcinoma of the nasopharynx that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Squamous Cell Carcinoma of the Nasopharynx		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150208>	C16373	Cadherin-20|CDH20|Cadherin 20	Cadherin-20 (801 aa, ~89 kDa) is encoded by the human CDH20 gene. This protein is involved in the mediation of cell-cell adhesion.			Amino Acid, Peptide, or Protein	
C150209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150209>	C173685|C167265|C156079	Metastatic Nasopharyngeal Squamous Cell Carcinoma|Metastatic Nasopharyngeal Throat Squamous Cell Cancer|Metastatic Squamous Cell Carcinoma of the Nasopharynx	A squamous cell carcinoma of the nasopharynx which has spread from the original site of growth to another anatomic site.	Metastatic Squamous Cell Carcinoma of the Nasopharynx		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150210>	C173694|C150212	Advanced Hypopharyngeal Squamous Cell Carcinoma|Advanced Hypopharyngeal Throat Squamous Cell Cancer|Advanced Squamous Cell Carcinoma of the Hypopharynx	A squamous cell carcinoma of the hypopharynx that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Squamous Cell Carcinoma of the Hypopharynx		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150211>	C150213|C139291	Advanced Laryngeal Squamous Cell Carcinoma|Advanced Laryngeal Throat Squamous Cell Cancer|Advanced Squamous Cell Carcinoma of the Larynx	A squamous cell carcinoma of the larynx that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Squamous Cell Carcinoma of the Larynx		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150212>	C4043|C173685|C156081	Metastatic Hypopharyngeal Squamous Cell Carcinoma|Metastatic Hypopharyngeal Throat Squamous Cell Cancer|Metastatic Squamous Cell Carcinoma of the Hypopharynx	A squamous cell carcinoma of the hypopharynx that has spread from the original site of growth to another anatomic site.	Metastatic Squamous Cell Carcinoma of the Hypopharynx		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150213>	C4044|C156085|C148153	Metastatic Laryngeal Squamous Cell Carcinoma|Metastatic Laryngeal Throat Squamous Cell Cancer|Metastatic Squamous Cell Carcinoma of the Larynx	A squamous cell carcinoma of the larynx that has spread from the original site of growth to another anatomic site.	Metastatic Squamous Cell Carcinoma of the Larynx		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150214>	C25871	CMPK1 Gene|CMPK1|CMPK1|Cytidine/Uridine Monophosphate Kinase 1 Gene	This gene plays a role in the synthesis of pyrimidine nucleoside diphosphates.			Gene or Genome	
C150215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150215>	C150214	CMPK1 wt Allele|CK|CMK|CMPK|Cytidine Monophosphate (UMP-CMP) Kinase 1, Cytosolic Gene|Cytidine/Uridine Monophosphate Kinase 1 wt Allele|UCK|UMK|UMP-CMPK|UMPK	Human CMPK1 wild-type allele is located in the vicinity of 1p33 and is approximately 45 kb in length. This allele, which encodes UMP-CMP kinase protein, is involved in pyrimidine nucleoside monophosphate metabolism.			Gene or Genome	
C150216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150216>	C1742|C129824	Erenapurstat|APE1/Ref-1 Inhibitor APX3330|APE1/Ref-1 Redox Inhibitor APX3330|APX 3330|APX-3330|APX3330|E 3330|E3330|ERENAPURSTAT|[(2E)-2-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methylene]-undecanoic Acid	An orally bioavailable inhibitor of apurinic/apyrimidinic endonuclease 1/reduction-oxidation (redox) effector factor-1 (APE1/Ref-1; APEX1), with potential anti-angiogenic and antineoplastic activities. Upon administration, erenapurstat selectively targets and binds to APE1/Ref-1. This inhibits the redox-dependent signaling activity of APE1/Ref-1, by preventing the reduction and activation of numerous APE1/Ref-1-dependent oncogenic transcription factors (TFs), such as nuclear factor kappa B (NF-kB), AP-1, STAT3, p53, NRF2 and HIF-1alpha, that are involved in signaling, cell proliferation, tumor progression and survival of cancer cells. Therefore, this agent inhibits the activation of multiple TF-mediated signaling pathways and inhibits tumor cell proliferation and survival.  APE1/Ref-1, a multifunctional protein overexpressed in many cancer cell types, plays a key role as a redox regulator of transcription factor activation and in base excision repair upon DNA damage. It drives cancer cell proliferation, migration, drug resistance, angiogenesis and inflammation and its expression level correlates with increased tumor aggressiveness and decreased patient survival. Erenapurstat specifically blocks the redox activity of APE1/Ref-1 and does not affect its ability to act as a DNA repair endonuclease.	Erenapurstat		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150217>	C16984	UMP-CMP Kinase|CK|CMPK1|Cytidine Monophosphate Kinase|Cytidine/Uridine Monophosphate Kinase 1|Cytidylate Kinase|Deoxycytidylate Kinase|EC 2.7.4.14|EC 2.7.4.6|Nucleoside-Diphosphate Kinase|UMP/CMP Kinase|UMP/CMPK|Uridine Monophosphate Kinase|Uridine Monophosphate/Cytidine Monophosphate Kinase|dCMP Kinase	UMP-CMP kinase (196 aa, ~22 kDa) is encoded by the human CMPK1 gene. This protein plays a role in catalyzing the synthesis of cytidine and uridine diphosphate.			Amino Acid, Peptide, or Protein|Enzyme	
C150218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150218>	C20745	DNAH9 Gene|DNAH9|DNAH9|Dynein Axonemal Heavy Chain 9 Gene	This gene is involved in cilium movement.			Gene or Genome	
C150220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150220>	C150218	DNAH9 wt Allele|DNAH17L|DNEL1|DYH9|Dnahc9|Dynein Axonemal Heavy Chain 9 wt Allele|Dynein, Axonemal, Heavy Chain 17-Like Gene|Dynein, Axonemal, Heavy Chain 9 Gene|Dynein, Axonemal, Heavy Polypeptide 17-Like Gene|Dynein, Axonemal, Heavy Polypeptide 9 Gene|Dynein, Axonemal, Light Intermediate Chain 1 Gene|HL-20|HL20|KIAA0357	Human DNAH9 wild-type allele is located in the vicinity of 17p12 and is approximately 372 kb in length. This allele, which encodes dynein heavy chain 9, axonemal protein, plays a role in the regulation of the movement of cilia and flagella.			Gene or Genome	
C150221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150221>	C16861	Dynein Heavy Chain 9, Axonemal|Axonemal Beta Dynein Heavy Chain 9|Ciliary Dynein Heavy Chain 9|DNAH9	Dynein heavy chain 9, axonemal (4486 aa, ~512 kDa) is encoded by the human DNAH9 gene. This protein is involved in the mediation of ciliary and flagellar movement.			Amino Acid, Peptide, or Protein|Enzyme	
C150223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150223>	C20103	EPHB6 Gene|EPH Receptor B6 Gene|EPHB6|EPHB6	This gene plays a role in ephrin-B signal transduction.			Gene or Genome	
C150224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150224>	C150223	EPHB6 wt Allele|EPH Receptor B6 wt Allele|HEP	Human EPHB6 wild-type allele is located in the vicinity of 7q34 and is approximately 16 kb in length. This allele, which encodes ephrin type-B receptor 6, is involved in the modulation of ephrin-B signaling.			Gene or Genome	
C150225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150225>	C18106	Ephrin Type-B Receptor 6|EPHB6|Ephrin Receptor EphB6|HEP|Human Kinase-Defective Eph-Family Receptor Protein|Tyrosine-Protein Kinase-Defective Receptor EPH-6	Ephrin type-B receptor 6 (1021 aa, ~111 kDa) is encoded by the human EPHB6 gene. This protein plays a role in the regulation of ephrin-B signaling pathways.			Amino Acid, Peptide, or Protein|Receptor	
C150226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150226>	C150183	Catheter Inner Diameter|Inner Diameter	The measurement of the diameter of the inner catheter tubing which goes over the guidewire.			Quantitative Concept	FDA CDRH GUDID Terminology
C150227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150227>	C26000	FGA Gene|FGA|FGA|Fibrinogen Alpha Chain Gene	This gene is involved in fibrin formation.			Gene or Genome	
C150228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150228>	C150227	FGA wt Allele|Fib2|Fibrinogen Alpha Chain wt Allele|Fibrinogen, A Alpha Polypeptide Gene|Fibrinogen--Alpha Polypeptide Chain Gene	Human FGA wild-type allele is located in the vicinity of 4q31.3 and is approximately 8 kb in length. This allele, which encodes fibrinogen alpha chain protein, plays a role in blood clotting. Mutation of the gene is associated with congenital afibrinogenemia, familial visceral amyloidosis, congenital dysfibrinogenemia and congenital hypodysfibrinogenemia.			Gene or Genome	
C150229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150229>	C150188	Crossing Profile|Catheter Gauge|Catheter Size	A linear measure of the maximum breadth of the stent/delivery system over the distal most region of the delivery system.			Quantitative Concept	FDA CDRH GUDID Terminology
C150230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150230>	C150199	Atherectomy Cutter Length|Cutter Length	The length of the cutter component for atherectomy devices that are used to cut plaque/thrombus.			Quantitative Concept	FDA CDRH GUDID Terminology
C150231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150231>	C17351	Fibrinogen Alpha Chain|FGA	Fibrinogen alpha chain (866 aa, ~95 kDa) is encoded by the human FGA gene. This protein is involved in blood clot formation.			Amino Acid, Peptide, or Protein	
C150232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150232>	C20420	FOXP4 Gene|FOXP4|FOXP4|Forkhead Box P4 Gene	This gene plays a role in the tissue-specific repression of gene transcription.			Gene or Genome	
C150233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150233>	C150199	Atherectomy Cutter Diameter|Cutter Diameter	The diameter of the cutter component for atherectomy devices that is used to cut the plaque/thrombus.			Quantitative Concept	FDA CDRH GUDID Terminology
C150234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150234>	C150232	FOXP4 wt Allele|FKHLA|Forkhead Box P4 wt Allele|hFKHLA	Human FOXP4 wild-type allele is located in the vicinity of 6p21.1 and is approximately 56 kb in length. This allele, which encodes forkhead box protein P4, is involved in transcriptional repression.			Gene or Genome	
C150235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150235>	C17207	Forkhead Box Protein P4|FOXP4|Fork Head-Related Protein Like A|Fork Head-Related Protein-Like A|Winged-Helix Repressor FOXP4	Forkhead box protein P4 (680 aa, ~73 kDa) is encoded by the human FOXP4 gene. This protein plays a role in the tissue-specific regulation of transcription.			Amino Acid, Peptide, or Protein	
C150236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150236>	C20917|C20194	FZR1 Gene|FZR1|FZR1|Fizzy and Cell Division Cycle 20 Related 1 Gene	This gene is involved in the regulation of protein ubiquitination and the cell cycle.			Gene or Genome	
C150237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150237>	C150236	FZR1 wt Allele|CDC20 Homolog 1 Gene|CDC20-Like 1b Gene|CDC20C|CDH1|CDH1/HCT1, S. cerevisiae, Homolog of Gene|FZR|FZR, Drosophila, Homolog of, 1 Gene|FZR2|Fizzy and Cell Division Cycle 20 Related 1 wt Allele|Fizzy-Related Protein, Drosophila, Homolog of, 1 Gene|Fizzy/Cell Division Cycle 20 Related 1 (Drosophila) Gene|Fizzy/Cell Division Cycle 20 Related 1 Gene|HCDH|HCDH1|KIAA1242	Human FZR1 wild-type allele is located in the vicinity of 19p13.3 and is approximately 32 kb in length. This allele, which encodes fizzy-related protein homolog protein, plays a role in cell cycle-specific ubiquitination.			Gene or Genome	
C150238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150238>	C95242|C17761	Fizzy-Related Protein Homolog|CDC20-Like Protein 1|Cdh1/Hct1 Homolog|FZR1|Fzr|hCDH1	Fizzy-related protein homolog (496 aa, ~55 kDa) is encoded by the human FZR1 gene. This protein is involved in the positive regulation of protein ubiquitination during anaphase.			Amino Acid, Peptide, or Protein	
C150239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150239>	C20923	ADGRA2 Gene|ADGRA2|ADGRA2|Adhesion G Protein-Coupled Receptor A2 Gene|GPR124	This gene plays a role in endothelial cell migration.			Gene or Genome	
C150240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150240>	C150239	ADGRA2 wt Allele|Adhesion G Protein-Coupled Receptor A2 wt Allele|DKFZp434C211|DKFZp434J0911|FLJ14390|GPR124|KIAA1531|TEM5	Human ADGRA2 wild-type allele is located in the vicinity of 8p11.23 and is approximately 61 kb in length. This allele, which encodes adhesion G protein-coupled receptor A2 protein, is involved in endothelial cell migration and central nervous system development.			Gene or Genome	
C150241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150241>	C18239	Adhesion G Protein-Coupled Receptor A2|ADGRA2|G Protein-Coupled Receptor 124|G-Protein Coupled Receptor 124|Tumor Endothelial Marker 5	Adhesion G protein-coupled receptor A2 (1338 aa, ~143 kDa) is encoded by the human ADGRA2 gene. This protein plays a role in central nervous system development and endothelial cell migration.			Amino Acid, Peptide, or Protein|Receptor	
C150243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150243>	C150199	Atherectomy Rotating Component Length|Rotating Component Length	The length of the rotating component of an atherectomy device.			Quantitative Concept	FDA CDRH GUDID Terminology
C150244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150244>	C150199	Atherectomy Rotating Component Diameter|Rotating Component Diameter	The diameter of the rotating component of an atherectomy device.			Quantitative Concept	FDA CDRH GUDID Terminology
C150245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150245>	C17647	Hepatic Perfusion Imaging|Hepatic Perfusion Scan|Hepatic Perfusion Study	Any imaging procedure designed to assess the state of fluid flow through the liver.	Hepatic Perfusion Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C150246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150246>	C19988	Perfusion	The passage of fluid through the vessels of a specific organ or tissue.			Organism Function	
C150247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150247>	C16737	Hepatic Artery Infusion Pump|HAI Pump|HAIP	A pump designed to adminster chemotherapy directly to the liver via the hepatic artery.			Medical Device	
C150248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150248>	C174048	ERK1/2 Inhibitor ERAS-007|ASN 007|ASN-007|ASN-007|ASN007|ERAS 007|ERAS-007|ERAS007|ERK Inhibitor ASN007|ERK Inhibitor ERAS-007|ERK1/2 Inhibitor ASN007	An orally bioavailable inhibitor of the extracellular signal-regulated kinases 1 (ERK1) and 2 (ERK2), with potential antineoplastic activity. Upon oral administration, ERAS-007 specifically binds to and inhibits the serine/threonine-protein kinase activities of both ERK1 and ERK2, thereby preventing the phosphorylation of ERK1/2 substrates and the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent proliferation and survival of tumor cells. The MAPK/ERK pathway, also known as the RAS/RAF/MEK/ERK pathway, is hyperactivated in a variety of tumor cell types due to mutations in upstream targets. It plays a key role in the proliferation, differentiation and survival of tumor cells.	ERK1/2 Inhibitor ERAS-007		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150249>	C20745	GSN Gene|GSN|GSN|Gelsolin Gene	This gene is involved in the regulation of actin filament polymerization.			Gene or Genome	
C150250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150250>	C82341	Spinocerebellar Ataxia Type 16|SCAR16	An autosomal recessive form of spinocerebellar ataxia caused by mutation(s) in the STUB1 gene, encoding E3 ubiquitin-protein ligase CHIP.	Spinocerebellar Ataxia Type 16		Disease or Syndrome	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology
C150251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150251>	C50648	Primary Congenital Glaucoma	Congenital glaucoma that arises independent of another pathologic process, disease, or injury.	Primary Congenital Glaucoma		Disease or Syndrome	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology
C150252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150252>	C150249	GSN wt Allele|ADF|AGEL|Amyloidosis, Finnish Type Gene|DKFZp313L0718|Gelsolin (Amyloidosis, Finnish Type) Gene|Gelsolin wt Allele	Human GSN wild-type allele is located in the vicinity of 9q33.2 and is approximately 125 kb in length. This allele, which encodes gelsolin protein, plays a role in both assembly and disassembly of actin filaments. Mutation of the gene is associated with Finnish type familial amyloidosis (amyloidosis V).			Gene or Genome	
C150253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150253>	C16492	Gelsolin|ADF|AGEL|Actin-Depolymerizing Factor|Brevin|GELSOLIN|GSN	Gelsolin (782 aa, ~86 kDa) is encoded by the human GSN gene. This protein is involved in the modulation of actin filament polymerization.			Amino Acid, Peptide, or Protein	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C150254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150254>	C15679	Local Consolidation Therapy|LCT|Local Consolidative Therapy	Any of various localized therapies designed to kill cancer cells left after initial treatment.	Local Consolidation Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C150255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150255>	C20923	HCAR1 Gene|HCAR1|HCAR1|Hydroxycarboxylic Acid Receptor 1 Gene	This gene plays a role in lactate-dependent signaling.			Gene or Genome	
C150256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150256>	C150255	HCAR1 wt Allele|FKSG80|GPR104|GPR81|HCA1|Hydroxycarboxylic Acid Receptor 1 wt Allele|LACR1|TA-GPCR|TAGPCR	Human HCAR1 wild-type allele is located in the vicinity of 12q24.31 and is approximately 5 kb in length. This allele, which encodes hydroxycarboxylic acid receptor 1 protein, is involved in lactate-mediated signaling.			Gene or Genome	
C150257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150257>	C18239	Hydroxycarboxylic Acid Receptor 1|G Protein-Coupled Receptor 104|G Protein-Coupled Receptor 81|G-Protein Coupled Receptor 104|G-Protein Coupled Receptor 81|HCAR1|Hydroxy-Carboxylic Acid Receptor 1|Lactate Receptor 1|T-Cell Activation G Protein-Coupled Receptor	Hydroxycarboxylic acid receptor 1 (346 aa, ~39 kDa) is encoded by the human HCAR1 gene. This protein plays a role in lactate-dependent G protein-coupled receptor signaling.			Amino Acid, Peptide, or Protein|Receptor	
C150258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150258>	C21295	HNRNPK Gene|HNRNPK|HNRNPK|Heterogeneous Nuclear Ribonucleoprotein K Gene	This gene is involved in binding to poly-cytidine sequences in pre-mRNA and single-stranded DNA.			Gene or Genome	
C150259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150259>	C150258	HNRNPK wt Allele|AUKS|CSBP|HNRPK|Heterogeneous Nuclear Ribonucleoprotein K wt Allele|TUNP	Human HNRNPK wild-type allele is located in the vicinity of 9q21.32 and is approximately 13 kb in length. This allele, which encodes Heterogeneous nuclear ribonucleoprotein K, plays a role in pre-mRNA binding, single-stranded DNA binding and transcriptional regulation. Mutation of the gene is associated with Au-Kline syndrome.			Gene or Genome	
C150260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150260>	C21298	Heterogeneous Nuclear Ribonucleoprotein K|HNRNPK|HnRNP K|TUNP|Transformation Up-Regulated Nuclear Protein|Transformation Upregulated Nuclear Protein|dC-Stretch Binding Protein	Heterogeneous nuclear ribonucleoprotein K (463 aa, ~51 kDa) is encoded by the human HNRNPK gene. This protein is involved in the regulation of transcription and binding to poly-cytidine sequences in mRNA and single-stranded DNA.			Amino Acid, Peptide, or Protein	
C150261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150261>	C25873	CILK1 Gene|CILK1|CILK1|Ciliogenesis Associated Kinase 1 Gene|ICK	This gene plays a role in ciliogenesis and intraflagellar transport.			Gene or Genome	
C150262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150262>	C150261	CILK1 wt Allele|Ciliogenesis Associated Kinase 1 wt Allele|ECO|EJM10|ICK|Iciliogenesis Associated Kinase 1 Gene|Intestinal Cell (MAK-Like) Kinase Gene|Intestinal Cell Kinase Gene|KIAA0936|LCK2|MGC46090|MRK|hICK	Human CILK1 wild-type allele is located in the vicinity of 6p12.1 and is approximately 61 kb in length. This allele, which encodes serine/threonine-protein kinase ICK protein, is involved in intraflagellar transport and ciliogenesis. Mutation of the gene is associated with endocrine-cerebroosteodysplasia and susceptibility to juvenile myoclonic epilepsy.			Gene or Genome	
C150263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150263>	C17325	Serine/Threonine-Protein Kinase ICK|CILK1|Ciliogenesis Associated Kinase 1|EC 2.7.11.1|ICK|Intestinal Cell Kinase|LCK2|Laryngeal Cancer Kinase 2|MAK-Related Kinase|MRK|Serine/Threonine Protein Kinase ICK|hICK	Serine/threonine-protein kinase ICK (632 aa, ~71 kDa) is encoded by the human CILK1 gene. This protein plays a role in serine/threonine-protein kinase activity, ciliogenesis and intraflagellar transport.			Amino Acid, Peptide, or Protein|Enzyme	
C150264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150264>	C20194	ING4 Gene|ING4|ING4|Inhibitor of Growth Family Member 4 Gene	This gene is involved in acetylation of histone H3 and histone H4.			Gene or Genome	
C150265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150265>	C150264	ING4 wt Allele|Candidate Tumor Suppressor p33 ING1 Homolog Gene|Inhibitor of Growth 4 Gene|Inhibitor of Growth Family Member 4 wt Allele|my036|p29ING4	Human ING4 wild-type allele is located in the vicinity of 12p13.31 and is approximately 13 kb in length. This allele, which encodes inhibitor of growth protein 4, plays a role in chromatin remodeling.			Gene or Genome	
C150266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150266>	C18466	Inhibitor of Growth Protein 4|Brain My036 Protein|ING4|p29ING4	Inhibitor of growth protein 4 (249 aa, ~29 kDa) is encoded by the human ING4 gene. This protein is involved in chromatin acetylation.			Amino Acid, Peptide, or Protein	
C150267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150267>	C20988	ITGA10 Gene|ITGA10|ITGA10|Integrin Subunit Alpha 10 Gene	This gene plays a role in collagen binding.			Gene or Genome	
C150268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150268>	C150267	ITGA10 wt Allele|Integrin Subunit Alpha 10 wt Allele|Integrin, Alpha 10 Gene|Integrin, Alpha-10 Gene|PRO827|UNQ468/PRO827	Human ITGA10 wild-type allele is located in the vicinity of 1q21.1 and is approximately 19 kb in length. This allele, which encodes integrin alpha-10 protein, is involved in cell-matrix adhesion.			Gene or Genome	
C150269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150269>	C16393	Integrin Alpha-10|ITGA10|Integrin Subunit Alpha 10	Integrin alpha-10 (1167 aa, ~128 kDa) is encoded by the human ITGA10 gene. This protein plays a role in cell adhesion to collagen in the extracellular matrix.			Amino Acid, Peptide, or Protein	
C150270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150270>	C20988	ITGA9 Gene|ITGA9|ITGA9|Integrin Subunit Alpha 9 Gene	This gene is involved in cell-matrix adhesion-dependent signaling.			Gene or Genome	
C150271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150271>	C150270	ITGA9 wt Allele|ALPHA-RLC|Alpha Related to the Development of Lung Cancer Gene|ITGA4L|Integrin Subunit Alpha 9 wt Allele|Integrin, Alpha 4-Like Gene|Integrin, Alpha 9 Gene|Integrin, Alpha-9 Gene|RLC	Human ITGA9 wild-type allele is located in the vicinity of 3p22.2 and is approximately 371 kb in length. This allele, which encodes integrin alpha-9 protein, plays a role in cell adhesion-regulated signaling. Aberrant expression is associated with small cell lung cancers.			Gene or Genome	
C150272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150272>	C16393	Integrin Alpha-9|ITGA9|Integrin Alpha-RLC|Integrin Subunit Alpha 9	Integrin alpha-9 (1035 aa, ~114 kDa) is encoded by the human ITGA9 gene. This protein is involved in cell-matrix binding and cell adhesion-dependent signaling.			Amino Acid, Peptide, or Protein	
C150273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150273>	C20923	ADGRL3 Gene|ADGRL3|ADGRL3|Adhesion G Protein-Coupled Receptor L3 Gene|LPHN3	This gene plays a role in cell-cell adhesion, G protein-coupled receptor signaling and neuronal migration.			Gene or Genome	
C150274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150274>	C150273	ADGRL3 wt Allele|Adhesion G Protein-Coupled Receptor L3 wt Allele|CIRL3|CL3|KIAA0768|LEC3|LPHN3|Latrophilin Homolog 3 (Cow) Gene	Human ADGRL3 wild-type allele is located in the vicinity of 4q13.1 and is approximately 877 kb in length. This allele, which encodes adhesion G protein-coupled receptor L3 protein, is involved in neuronal migration, cell-cell adhesion and G protein-coupled receptor signaling.			Gene or Genome	
C150275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150275>	C18239	Adhesion G Protein-Coupled Receptor L3|ADGRL3|CIRL-3|Calcium-Independent Alpha-Latrotoxin Receptor 3|Latrophilin 3|Latrophilin-3|Lectomedin 3|Lectomedin-3	Adhesion G protein-coupled receptor L3 (1447 aa, ~162 kDa) is encoded by the human ADGRL3 gene. This protein plays a role in G protein-coupled receptor signaling, neuronal migration and cell-cell adhesion.			Amino Acid, Peptide, or Protein|Receptor	
C150276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150276>	C25804	LYZ Gene|LYZ|LYZ|Lysozyme Gene	This gene is involved in bacterial cell wall peptidoglycan metabolism.			Gene or Genome	
C150277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150277>	C150276	LYZ wt Allele|LYZF1|LZM|Lysozyme (Renal Amyloidosis) Gene|Lysozyme wt Allele|Renal Amyloidosis Gene	Human LYZ wild-type allele is located in the vicinity of 12q15 and is approximately 6 kb in length. This allele, which encodes lysozyme C protein, plays a role in antimicrobial activity. Missense mutations in this gene are associated with hereditary renal amyloidosis.			Gene or Genome	
C150278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150278>	C16701	Lysozyme C|1,4-Beta-N-Acetylmuramidase C|C-Type Lysozyme|EC 3.2.1.17|LYZ|Lysozyme F1	Lysozyme C (148 aa, ~17 kDa) is encoded by the human LYZ gene. This protein is involved in the proteolytic degradation of bacterial peptidoglycans.			Amino Acid, Peptide, or Protein|Enzyme	
C150279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150279>	C25873	MARK1 Gene|MARK1|MARK1|Microtubule Affinity Regulating Kinase 1 Gene	This gene plays a role in both cell polarity and microtubule dynamics.			Gene or Genome	
C150280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150280>	C150279	MARK1 wt Allele|KIAA1477|MARK|Microtubule Affinity Regulating Kinase 1 wt Allele|Par-1c|Par1c	Human MARK1 wild-type allele is located in the vicinity of 1q41 and is approximately 136 kb in length. This allele, which encodes serine/threonine-protein kinase MARK1 protein, is involved in both microtubule dynamics and protein phosphorylation.			Gene or Genome	
C150281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150281>	C3270	High Risk Neuroblastoma|High-Risk Neuroblastoma|High-Risk Neuroblastoma	Neuroblastoma usually presenting with metastatic disease and MYCN gene amplifications.	High-Risk Neuroblastoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150283>	C17325	Serine/Threonine-Protein Kinase MARK1|EC 2.7.11.1|EC 2.7.11.26|MAP/Microtubule Affinity-Regulating Kinase 1|MARK1|PAR1 Homolog C|Par-1c|Par1c	Serine/threonine-protein kinase MARK1 (795 aa, ~89 kDa) is encoded by the human MARK1 gene. This protein plays a role in the phosphorylation of microtubule-associated proteins (MAPs), which results in microtubule disassembly.			Amino Acid, Peptide, or Protein|Enzyme	
C150284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150284>	C20819	NUP93 Gene|NUP93|NUP93|Nucleoporin 93 Gene	This gene is involved in both nuclear pore formation and nuclear import.			Gene or Genome	
C150285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150285>	C150284	NUP93 wt Allele|KIAA0095|NIC96|NIC96. S cerevisiae, Homolog of Gene|Nucleoporin 93 wt Allele|Nucleoporin, 93-kD Gene	Human NUP93 wild-type allele is located in the vicinity of 16q13 and is approximately 120 kb in length. This allele, which encodes nuclear pore complex protein Nup93, plays a role in nuclear import.			Gene or Genome	
C150286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150286>	C21183	Nuclear Pore Complex Protein Nup93|93 kDa Nucleoporin|NUP93|Nucleoporin 93kDa|Nucleoporin Nup93	Nuclear pore complex protein Nup93 (819 aa, ~93 kDa) is encoded by the human NUP93 gene. This protein is involved in nuclear pore functions.			Amino Acid, Peptide, or Protein	NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C150287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150287>	C110937	Refractory Osteomedullary Disease	A finding indicating that a disease has affected the medullary bone and is resistant to treatment.			Finding	
C150288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150288>	C20988	PCDHAC2 Gene|PCDHAC2|PCDHAC2|Protocadherin Alpha Subfamily C, 2 Gene	This gene plays a role in homophilic cell adhesion.			Gene or Genome	
C150289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150289>	C150288	PCDHAC2 wt Allele|PCDH-ALPHA-C2|Protocadherin Alpha Subfamily C, 2 wt Allele|Protocadherin-Alpha, Subfamily C, Member 2 Gene	Human PCDHAC2 wild-type allele is located in the vicinity of 5q31.3 and is approximately 46 kb in length. This allele, which encodes protocadherin alpha-C2 protein, is involved in cell-cell adhesion.			Gene or Genome	
C150290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150290>	C16393	Protocadherin Alpha-C2|PCDH-Alpha-C2|PCDHAC2	Protocadherin alpha-C2 (1007 aa, ~109 kDa) is encoded by the human PCDHAC2 gene. This protein plays a role in calcium-dependent cell-cell adhesion.			Amino Acid, Peptide, or Protein	
C150291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150291>	C20194	PGAP3 Gene|PGAP3|PGAP3|Post-GPI Attachment to Proteins 3 Gene	This gene is involved in lipid remodeling of glycophosphoinositol anchors.			Gene or Genome	
C150292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150292>	C150291	PGAP3 wt Allele|AGLA546|CAB2|Gene Coamplified wth ERBB2|MGC9753|PERLD1|PP1498|Post-GPI Attachment to Proteins 3 wt Allele|UNQ546/PRO1100|hCOS16	Human PGAP3 wild-type allele is located in the vicinity of 17q21.2 and is approximately 26 kb in length. This allele, which encodes post-GPI attachment to proteins factor 3 protein, plays a role in posttranslational protein modifications. Mutations in this gene are associated with autosomal recessive neurologic hyperphosphatasia with cognitive disability type 4 (HPMRS4).			Gene or Genome	
C150293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150293>	C18466	Post-GPI Attachment to Proteins Factor 3|COS16 Homolog|Gene Coamplified with ERBB2 Protein|PGAP3|Per1-Like Domain Containing 1|hCOS16	Post-GPI attachment to proteins factor 3 (320 aa, ~36 kDa) is encoded by the human PGAP3 gene. This protein is involved in the maturation of glycophosphoinositol anchoring lipids.			Amino Acid, Peptide, or Protein	
C150294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150294>	C241	Methylene Blue Oral Rinse|MB Oral Rinse	An oral rinse composed of the diaminophenothiazine dye methylene blue (MB), an inhibitor of nitric oxide (NO) synthase (NOS) and soluble guanylate cyclase (sGC), with potential local analgesic and antioxidant activities. Although the exact mechanism by which MB exerts its analgesic effect has yet to be fully elucidated, upon rinsing with the MB oral rinse, the MB preferentially targets and binds to nerve cells and blocks the electrical conductivity of nerve fibers, thereby blocking neuronal excitability. This inhibits pain signaling and produces an anti-nociceptive effect. In addition, MB inhibits the production of oxygen, NO, oxygen free radicals and superoxides by NOS, and prevents the accumulation of cyclic guanosine monophosphate (cGMP) by directly inhibiting sGC and by constraining NO-dependent sGC activity. This prevents the activation of the NO-cGMP signal pathway, which plays a role in neuropathic pain, and promotes an analgesic effect. Administration of the MB oral rinse may improve the intractable pain of oral mucositis.	Methylene Blue Oral Rinse		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology
C150295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150295>	C20194	PKD1L2 Gene|PKD1L2|PKD1L2|Polycystin 1 Like 2 (Gene/Pseudogene) Gene	This gene may play a role in calcium channel regulation and G protein-coupled receptor activity.			Gene or Genome	
C150296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150296>	C150295	PKD1L2 wt Allele|KIAA1879|PC1L2|Polycystic Kidney Disease 1-Like 2 Gene|Polycystin 1 Like 2 (Gene/Pseudogene) wt Allele|Polycystin 1-Like 2 Gene	Human PKD1L2 wild-type allele is located in the vicinity of 16q23.2 and is approximately 119 kb in length. This allele, which encodes polycystin-1-like protein 2, may be involved in G protein-coupled receptor signaling and the regulation of calcium transport.			Gene or Genome	
C150297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150297>	C18466	Polycystic Kidney Disease 1-Like 2|PC1-Like 2 Protein|PKD1L2|Polycystic Kidney Disease Protein 1-Like 2|Polycystin-1L2	Polycystin-1-like protein 2 (2459 aa, ~273 kDa) is encoded by the human PKD1L2 gene. This protein may play a role in calcium transport and receptor signaling.			Amino Acid, Peptide, or Protein	
C150298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150298>	C20194	PKHD1 Gene|PKHD1|PKHD1|PKHD1, Fibrocystin/Polyductin Gene	This gene may be involved in signaling and differentiation of the collecting duct and biliary system.			Gene or Genome	
C150299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150299>	C150298	PKHD1 wt Allele|ARPKD|FCYT|FPC|Fibrocystin/Polyductin Complex Gene|PKD4|PKHD1, Fibrocystin/Polyductin wt Allele|Polycystic Kidney and Hepatic Disease 1 (Autosomal Recessive) Gene|Polycystic Kidney and Hepatic Disease 1 Gene|TIG Multiple Domains 1 Gene|TIGM1	Human PKHD1 wild-type allele is located within 6p12.3-p12.2 and is approximately 473 kb in length. This allele, which encodes fibrocystin protein, may play a role in kidney and biliary development and in receptor signaling. Mutations in this gene are associated with autosomal recessive polycystic kidney disease (polycystic kidney and hepatic disease 1; polycystic kidney disease 4).			Gene or Genome	
C1502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1502>	C79611	Fiber|Fibra				Plant	
C150300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150300>	C18466	Fibrocystin|PKHD1|Polycystic Kidney and Hepatic Disease 1 Protein|Polyductin|Tigmin	Fibrocystin (4074 aa, ~447 kDa) is encoded by the human PKHD1 gene. This protein may be involved in receptor signaling that promotes differentiation of the kidney and biliary system.			Amino Acid, Peptide, or Protein	
C150301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150301>	C20921	PLEKHG5 Gene|PLEKHG5|PLEKHG5|Pleckstrin Homology and RhoGEF Domain Containing G5 Gene	This gene plays a role in transforming protein RhoA- and nuclear factor kappa B-dependent signaling.			Gene or Genome	
C150302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150302>	C150301	PLEKHG5 wt Allele|CMTRIC|DSMA4|GEF720|KIAA0720|Pleckstrin Homology Domain Containing, Family G (with RhoGef Domain) Member 5 Gene|Pleckstrin Homology Domain-Containing Protein, Family G. Member 5 Gene|Pleckstrin Homology and RhoGEF Domain Containing G5 wt Allele|Syx|Tech	Human PLEKHG5 wild-type allele is located in the vicinity of 1p36.31 and is approximately 54 kb in length. This allele, which encodes pleckstrin homology domain-containing family G member 5 protein, is involved in the regulation of nuclear factor kappa B and transforming protein RhoA signaling pathways. Mutation of the gene is associated with recessive intermediate Charcot-Marie-Tooth disease type C and autosomal recessive distal spinal muscular atrophy.			Gene or Genome	
C150303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150303>	C17494	Pleckstrin Homology Domain-Containing Family G Member 5|GEF720|Guanine Nucleotide Exchange Factor 720|PH Domain-Containing Family G Member 5|PLEKHG5|Pleckstrin Homology Domain- and RhoGEF Domain-Containing Protein G5|Pleckstrin Homology Domain-Containing Protein, Family G. Member 5|Synectin-Binding Guanine Exchange Factor	Pleckstrin homology domain-containing family G member 5 (1062 aa, ~117 kDa) is encoded by the human PLEKHG5 gene. This protein plays a role in the activation of transforming protein RhoA and nuclear factor kappa B signaling pathways.			Amino Acid, Peptide, or Protein|Enzyme	
C150304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150304>	C133710	RNF2 Gene|RNF2|RNF2|Ring Finger Protein 2 Gene	This gene is involved in monoubiquitination of lysine-119 of histone H2A and transcriptional repression.			Gene or Genome	
C150305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150305>	C150304	RNF2 wt Allele|BAP-1|BAP1|DING|HIPI3|RING1B|RING2|Ring Finger Protein 2 wt Allele	Human RNF2 wild-type allele is located in the vicinity of 1q25.3 and is approximately 57 kb in length. This allele, which encodes E3 ubiquitin-protein ligase RING2 protein, plays a role in histone ubiquitination and the repression of gene transcription.			Gene or Genome	
C150306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150306>	C21254	E3 Ubiquitin-Protein Ligase RING2|EC 2.3.2.27|HIP2-Interacting Protein 3|Huntingtin-Interacting Protein 2-Interacting Protein 3|Protein DinG|RING Finger Protein 1B|RING Finger Protein 2|RING Finger Protein BAP-1|RING-Type E3 Ubiquitin Transferase RING2|RING1b|RNF2	E3 ubiquitin-protein ligase RING2 (336 aa, ~38 kDa) is encoded by the human RNF2 gene. This protein is involved in both transcriptional repression and the monoubiquitination of lysine-119 of histone H2A.			Amino Acid, Peptide, or Protein|Enzyme	
C150307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150307>	C25873	RPS6KA2 Gene|RPS6KA2|RPS6KA2|Ribosomal Protein S6 Kinase A2 Gene	This gene plays a role in the regulation of transcription, cellular proliferation, differentiation, and survival.			Gene or Genome	
C150308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150308>	C150307	RPS6KA2 wt Allele|HU-2|MAPKAPK1C|RSK|RSK3|Ribosomal Protein S6 Kinase A2 wt Allele|Ribosomal Protein S6 Kinase, 90-kD, 2 Gene|Ribosomal Protein S6 Kinase, 90kD, Polypeptide 2 Gene|Ribosomal Protein S6 Kinase, 90kDa, Polypeptide 2 Gene|S6K-alpha|S6K-alpha2|p90-RSK3|p90RSK2|pp90RSK3	Human RPS6KA2 wild-type allele is located in the vicinity of 6q27 and is approximately 497 kb in length. This allele, which encodes ribosomal protein S6 kinase alpha-2 protein, is involved in mitogen activated protein kinase (MAPK) signaling.			Gene or Genome	
C150309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150309>	C17325	Ribosomal Protein S6 Kinase Alpha-2|EC 2.7.11.1|MAP Kinase-Activated Protein Kinase 1c|MAPK-Activated Protein Kinase 1c|MAPKAP Kinase 1c|MAPKAPK-1c|Mitogen-Activated Protein Kinase-Activated Protein Kinase 1c|RPS6KA2|RSK-3|Ribosomal S6 Kinase 3|S6K-Alpha-2|p90-RSK 2|p90RSK2	Ribosomal protein S6 kinase alpha-2 (733 aa, ~83 kDa) is encoded by the human RPS6KA2 gene. This protein plays a role in the modulation of transcription, cellular proliferation, differentiation, and survival.			Amino Acid, Peptide, or Protein|Enzyme	
C150310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150310>	C122516	Grade 3 or 4 Elevation of AST, ALT, and/or Bilirubin|Grade 3 or 4 Elevation of Aspartate Aminotransferase, Alanine Aminotransferase, and/or Bilirubin	A finding of grade 3 or 4 AST, Grade 3 or 4 ALT, and/or grade 3 or 4 bilirubin.			Laboratory or Test Result	
C150311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150311>	C25993	RYR1 Gene|RYR1|RYR1|Ryanodine Receptor 1 Gene	This gene is involved in the release of calcium ions from the sarcoplasmic reticulum and from intracellular stores in neurons.	RYR1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C150312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150312>	C150311	RYR1 wt Allele|CCO|Central Core Disease of Muscle Gene|MHS|MHS1|PPP1R137|Protein Phosphatase 1, Regulatory Subunit 137 Gene|RYDR|RYR|RYR-1|Ryanodine Receptor 1 (Skeletal) Gene|SKRR	Human RYR1 wild-type allele is located in the vicinity of 19q13.2 and is approximately 154 kb in length. This allele, which encodes ryanodine receptor 1 protein, plays a role in skeletal muscle contraction and neuronal signaling. Mutation of the gene is associated with central core disease, King-Denborough syndrome, minicore myopathy with external ophthalmoplegia, congenital neuromuscular disease with uniform type 1 fiber and susceptibility to malignant hyperthermia type 1.	RYR1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150313>	C28505	Ryanodine Receptor 1|RYR-1|RYR1|RyR1|Sarcoplasmic Reticulum Calcium Release Channel|Skeletal Muscle Calcium Release Channel|Skeletal Muscle Ryanodine Receptor|Skeletal Muscle-Type Ryanodine Receptor|Type 1 Ryanodine Receptor|Type 1-Like Ryanodine Receptor	Ryanodine receptor 1 (5038 aa, ~565 kDa) is encoded by the human RYR1 gene. This protein is involved in the transport of calcium ions from the sarcoplasmic reticulum and neurons.	Ryanodine Receptor 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150314>	C20194	SAMD9 Gene|SAMD9|SAMD9|SAMD9|Sterile Alpha Motif Domain Containing 9 Gene	This gene may play a role in endosomal vesicle fusion, extra-osseous calcification and inflammatory responses.	SAMD9 Gene		Gene or Genome	CCPS Genetics Terminology|Childhood Cancer Predisposition Study Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C150315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150315>	C150314	SAMD9 wt Allele|C7orf5|Chromosome 7 Open Reading Frame 5 Gene|DRIF1|Expressed in Aggressive Fibromatosis Gene|FLJ20073|KIAA2004|M7MLS2|MIRAGE|NFTC|OEF1|OEF2|Sterile Alpha Motif Domain Containing 9 wt Allele	Human SAMD9 wild-type allele is located in the vicinity of 7q21.2 and is approximately 19 kb in length. This allele, which encodes sterile alpha motif domain-containing protein 9, may be involved in extra-osseous calcification, inflammatory responses and endosomal vesicle fusion. Mutation of the gene is associated with normophosphatemic familial tumoral calcinosis and MIRAGE syndrome.	SAMD9 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150316>	C4912|C162719	Refractory Bladder Carcinoma|Refractory Bladder Cancer	Bladder carcinoma that does not respond to treatment.	Refractory Bladder Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150317>	C18466	Sterile Alpha Motif Domain-Containing Protein 9|SAM Domain-Containing Protein 9|SAMD9	Sterile alpha motif domain-containing protein 9 (1589 aa, ~184 kDa) is encoded by the human SAMD9 gene. This protein may play a role in inflammatory responses, endosomal vesicle fusion and extra-osseous calcification.	Sterile Alpha Motif Domain-Containing Protein 9		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150318>	C21170|C16701	Single-Strand Selective Monofunctional Uracil DNA Glycosylase|EC 3.2.2.-|SMUG1	Single-strand selective monofunctional uracil DNA glycosylase (270 aa, ~30 kDa) is encoded by the human SMUG1 gene. This protein is involved in DNA repair.			Amino Acid, Peptide, or Protein|Enzyme	
C150319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150319>	C25804|C19676	SMUG1 Gene|SMUG1|SMUG1|Single-Strand-Selective Monofunctional Uracil-DNA Glycosylase 1 Gene	This gene is involved in the initiation of DNA base excision repair.			Gene or Genome	
C15031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15031>	C14421	DW/J Mouse|DW/J		DW/J Mouse		Mammal	
C150320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150320>	C150319	SMUG1 wt Allele|FDG|HMUDG|Single-Strand-Selective Monofunctional Uracil-DNA Glycosylase 1 wt Allele|UNG3	Human SMUG1 wild-type allele is located in the vicinity of 12q13.13 and is approximately 68 kb in length. This allele, which encodes single-strand selective monofunctional uracil DNA glycosylase protein, plays a role in base excision repair of DNA.			Gene or Genome	
C150321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150321>	C54362	SP140 Gene|SP140|SP140|SP140 Nuclear Body Protein Gene	This gene may play a role in transcriptional activation in leukocytes.			Gene or Genome	
C150322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150322>	C150321	SP140 wt Allele|LYSP100|LYSP100-A|LYSP100-B|SP140 Nuclear Body Protein wt Allele|Speckled, 140-kD Gene	Human SP140 wild-type allele is located in the vicinity of 2q37.1 and is approximately 114 kb in length. This allele, which encodes nuclear body protein SP140, may be involved in the promotion of gene expression in leukocytes. Variation of this gene is associated with multiple sclerosis, Crohn disease, and chronic lymphocytic leukemia.			Gene or Genome	
C150323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150323>	C26199	Nuclear Body Protein SP140|LYSp100|Lymphoid-Restricted Homolog of Sp100|Lymphoid-Restricted SP100 Homolog|Nuclear Autoantigen Sp-140|SP140|Speckled 140 kDa	Nuclear body protein SP140 (867 aa, ~98 kDa) is encoded by the human SP140 gene. This protein may play a role in the activation of gene expression in leukocytes.			Amino Acid, Peptide, or Protein	
C150324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150324>	C25873	STK36 Gene|STK36|STK36|Serine/Threonine Kinase 36 Gene	This gene is involved in the regulation of GLI zinc-finger transcription factor family activity.			Gene or Genome	
C150325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150325>	C150324	STK36 wt Allele|FU|Fused Homolog (Drosophila) Gene|Fused, Drosophila, Homolog of Gene|KIAA1278|Serine/Threonine Kinase 36 (Fused Homolog, Drosophila) Gene|Serine/Threonine Kinase 36 wt Allele	Human STK36 wild-type allele is located in the vicinity of 2q35 and is approximately 31 kb in length. This allele, which encodes serine/threonine-protein kinase 36 protein plays a role in the modulation of GLI family transcription factor activity.			Gene or Genome	
C150326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150326>	C17325	Serine/Threonine-Protein Kinase 36|EC 2.7.11.1|Fused Homolog|STK36|Serine/Threonine Kinase 36|Testicular Tissue Protein Li 188	Serine/threonine-protein kinase 36 (1315 aa, ~144 kDa) is encoded by the human STK36 gene. This protein is involved in the induction of GLI zinc-finger family transcription factor activity.			Amino Acid, Peptide, or Protein|Enzyme	
C150327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150327>	C20744	SYNE1 Gene|SYNE1|SYNE1|Spectrin Repeat Containing Nuclear Envelope Protein 1 Gene	This gene plays a role in subcellular spatial organization.			Gene or Genome	
C150328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150328>	C150327	SYNE1 wt Allele|8B|ARCA1|C6orf98|CPG2|CPG2 Full Length Gene|Chromosome 6 Open Reading Frame 98 Gene|EDMD4|KASH1|KIAA0796|KIAA1262|KIAA1756|MYNE1|Nesp1|Nuclear Envelope Spectrin Repeat-1 Gene|SCAR8|Spectrin Repeat Containing Nuclear Envelope Protein 1 wt Allele|Spectrin Repeat Containing, Nuclear Envelope 1 Gene|Synaptic Nuclei Expressed Gene 1|dJ45H2.2	Human SYNE1 wild-type allele is located in the vicinity of 6q25.2 and is approximately 516 kb in length. This allele, which encodes nesprin-1 protein, is involved in the subcellular position of the nucleus. Mutation of the gene is associated with autosomal recessive spinocerebellar ataxia 8.			Gene or Genome	
C150329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150329>	C18073	Nesprin-1|Enaptin|KASH Domain-Containing Protein 1|KASH1|Myne-1|Myocyte Nuclear Envelope Protein 1|Nesprin 1|Nuclear Envelope Spectrin Repeat Protein 1|SYNE1|Spectrin Repeat Containing Nuclear Envelope Protein 1|Spectrin Repeat-Containing Nuclear Envelope Protein 1|Synaptic Nuclear Envelope Protein 1|Syne-1	Nesprin-1 (8797 aa, ~1011 kDa) is encoded by the human SYNE1 gene. This protein plays a role in linking the nuclear lamina and the cytoskeleton.			Amino Acid, Peptide, or Protein	
C150330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150330>	C26006	SYT1 Gene|SYT1|SYT1|Synaptotagmin 1 Gene	This gene is involved in synaptic vesicle trafficking.			Gene or Genome	
C150331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150331>	C150330	SYT1 wt Allele|P65|SVP65|SYT|Synaptotagmin 1 wt Allele	Human SYT1 wild-type allele is located in the vicinity of 12q21.2 and is approximately 588 kb in length. This allele, which encodes synaptotagmin-1 protein, plays a role in localization and exocytosis of synaptic vesicles.			Gene or Genome	
C150332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150332>	C16386	Synaptotagmin-1|SYT1|Synaptotagmin 1|Synaptotagmin I|SytI|p65	Synaptotagmin-1 (422 aa, ~48 kDa) is encoded by the human SYT1 gene. This protein is involved in trafficking and exocytosis of synaptic vesicles.			Amino Acid, Peptide, or Protein	
C150333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150333>	C20539	TAF1L Gene|TAF1L|TAF1L|TATA-Box Binding Protein Associated Factor 1 Like Gene	This gene plays a role in transcription initiation during male meiosis.			Gene or Genome	
C150334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150334>	C150333	TAF1L wt Allele|TAF(II)210|TAF1 RNA Polymerase II, TATA Box Binding Protein (TBP)-Associated Factor, 210kDa-Like Gene|TAF1 RNA Polymerase II-Like Gene|TAF1-Like RNA Polymerase II, TATA Box Binding Protein (TBP)-Associated Factor, 210kDa Gene|TAF2A2|TATA-Box Binding Protein Associated Factor 1 Like wt Allele	Human TAF1L wild-type allele is located in the vicinity of 9p21.1 and is approximately 6 kb in length. This allele, which encodes transcription initiation factor TFIID subunit 1-like protein, is involved in the modulation of transcription during male meiosis.			Gene or Genome	
C150335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150335>	C19851	Transcription Initiation Factor TFIID Subunit 1-Like|TAF(II)210|TAF1L|TATA Box-Binding Protein-Associated Factor 1-Like|TBP-Associated Factor 1-Like|TBP-Associated Factor 210 kDa|TBP-Associated Factor RNA Polymerase 1-Like|Transcription Initiation Factor TFIID 210 kDa Subunit	Transcription initiation factor TFIID subunit 1-like (1826 aa, ~207 kDa) is encoded by the human TAF1L gene. This protein plays a role in the initiation of transcription and the regulation of gene expression during male meiosis.			Amino Acid, Peptide, or Protein	
C150336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150336>	C20420	TBX22 Gene|T-Box 22 Gene|TBX22|TBX22	This gene is involved in transcriptional regulation and development of the palate.			Gene or Genome	
C150337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150337>	C150336	TBX22 wt Allele|ABERS|CLPA|CPX|Cleft Palate and/or Ankyloglossia Gene|T-Box 22 wt Allele|TBXX|dJ795G23.1	Human TBX22 wild-type allele is located in the vicinity of Xq21.1 and is approximately 21 kb in length. This allele, which encodes T-box transcription factor TBX22 protein, plays a role in palate development. Mutation of the gene is associated with X-linked cleft palate and ankyloglossia.			Gene or Genome	
C150338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150338>	C17207	T-Box Transcription Factor TBX22|T-Box Protein 22|TBOX22|TBX22	T-box transcription factor TBX22 (520 aa, ~58 kDa) is encoded by the human TBX22 gene. This protein is involved in palate development and transcriptional regulation.			Amino Acid, Peptide, or Protein	
C150339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150339>	C20420	TCF7L1 Gene|TCF7L1|TCF7L1|Transcription Factor 7 Like 1 Gene	This gene plays a role in catenin beta-1-dependent transcriptional regulation.			Gene or Genome	
C150340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150340>	C150339	TCF7L1 wt Allele|TCF-3|TCF3|Transcription Factor 3, Formerly Gene|Transcription Factor 7 Like 1 wt Allele|Transcription Factor 7-Like 1 (T-Cell Specific, HMG-Box) Gene	Human TCF7L1 wild-type allele is located in the vicinity of 2p11.2 and is approximately 177 kb in length. This allele, which encodes transcription factor 7-like 1 protein, is involved in Wnt pathway-dependent transcriptional regulation.			Gene or Genome	
C150341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150341>	C17207	Transcription Factor 7-Like 1|HMG Box Transcription Factor 3|TCF-3|TCF7L1|Transcription Factor 7 Like 1	Transcription factor 7-like 1 (588 aa, ~63 kDa) is encoded by the human TCF7L1 gene. This protein plays a role in transcriptional regulation that is modulated by the Wnt signaling pathway.			Amino Acid, Peptide, or Protein	
C150342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150342>	C25870	TGM7 Gene|TGM7|TGM7|Transglutaminase 7 Gene	This gene is involved in the conjugation of polyamines to and cross-linking of proteins.			Gene or Genome	
C150343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150343>	C94625	Local Skin Heating	The application of heat to a limited portion of the body.	Local Skin Heating		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C150344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150344>	C150342	TGM7 wt Allele|TGMZ|Transglutaminase 7 wt Allele	Human TGM7 wild-type allele is located 15q15.2 and is approximately 26 kb in length. This allele, which encodes protein-glutamine gamma-glutamyltransferase Z protein, plays a role in post-translational protein modification.			Gene or Genome	
C150345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150345>	C16259	Protein-Glutamine Gamma-Glutamyltransferase Z|EC 2.3.2.13|TG(Z)|TGM7|TGZ|TGase Z|TGase-7|Transglutaminase 7|Transglutaminase Z|Transglutaminase-7	Protein-glutamine gamma-glutamyltransferase Z (710 aa, ~80 kDa) is encoded by the human TGM7 gene. This protein is involved in protein cross-linking and conjugation of polyamines to proteins.			Amino Acid, Peptide, or Protein|Enzyme	
C150346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150346>	C21295	UMODL1 Gene|UMODL1|UMODL1|Uromodulin Like 1 Gene	This gene may play a role in development of visual and olfactory pathways.			Gene or Genome	
C150347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150347>	C150346	UMODL1 wt Allele|Uromodulin Like 1 wt Allele	Human UMODL1 wild-type allele is located in the vicinity of 21q22.3 and is approximately 112 kb in length. This allele, which encodes uromodulin-like 1 protein, is involved in calcium binding.			Gene or Genome	
C150348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150348>	C21214	Uromodulin-Like 1|Olfactorin|UMODL1|Uromodulin Like 1	Uromodulin-like 1 (1318 aa, ~144 kDa) is encoded by the human UMODL1 gene. This protein plays a role in calcium binding.			Amino Acid, Peptide, or Protein	
C150349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150349>	C20923	VIPR2 Gene|VIPR2|VIPR2|Vasoactive Intestinal Peptide Receptor 2 Gene	This gene is involved in the regulation of vasoactive intestinal peptide (VIP)- and pituitary adenylate cyclase-activating peptide (PACAP)-mediated signaling.	VIPR2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C150350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150350>	C150349	VIPR2 wt Allele|C16DUPq36.3|DUP7q36.3|PACAP-R-3|PACAP-R3|VIP-R-2|VPAC2|VPAC2R|VPCAP2R|Vasoactive Intestinal Peptide Receptor 2 wt Allele	Human VIPR2 wild-type allele is located in the vicinity of 7q36.3 and is approximately 117 kb in length. This allele, which encodes vasoactive intestinal polypeptide receptor 2 protein, plays a role in G protein-coupled receptor signaling.	VIPR2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150351>	C18239	Vasoactive Intestinal Polypeptide Receptor 2|Helodermin-Preferring VIP Receptor|PACAP Type III Receptor|PACAP-R-3|PACAP-R3|Pituitary Adenylate Cyclase Activating Polypeptide Type III Receptor|Pituitary Adenylate Cyclase-Activating Polypeptide Type III Receptor|VIP and PACAP Receptor 2|VIP-R-2|VIPR2|VPAC2|Vasoactive Intestinal Peptide Receptor 2	Vasoactive intestinal polypeptide receptor 2 (438 aa, ~49 kDa) is encoded by the human VIPR2 gene. This protein is involved in neuroendocrine hormone-dependent G protein-coupled receptor signaling.	Vasoactive Intestinal Polypeptide Receptor 2		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150352>	C20420	ZBTB7B Gene|ZBTB7B|ZBTB7B|Zinc Finger and BTB Domain Containing 7B Gene	This gene plays a role in the regulation of T-cell lineage commitment and the repression of collagen gene expression.			Gene or Genome	
C150353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150353>	C150352	ZBTB7B wt Allele|CKROX|THPOK|ZBTB15|ZFP-67|ZFP67|ZNF857B|Zinc Finger Protein 67 Homolog (Mouse) Gene|Zinc Finger Protein 67, Mouse, Homolog of Gene|Zinc Finger and BTB Domain Containing 7B wt Allele|c-KROX|hcKROX	Human ZBTB7B wild-type allele is located in the vicinity of 1q21.3 and is approximately 16 kb in length. This allele, which encodes zinc finger and BTB domain-containing protein 7B, is involved in the repression of type I collagen gene expression and the promotion of CD4-positive T-cell differentiation.			Gene or Genome	
C150354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150354>	C17207	Zinc Finger and BTB Domain-Containing Protein 7B|Collagen Krox Protein|Krueppel-Related Zinc Finger Protein cKrox|T Helper-Inducing POZ/Kruppel-Like Factor|T-Helper-Inducing POZ/Krueppel-Like Factor|ZBTB7B|ZBTB7B|Zfp-67|Zinc Finger Protein 67 Homolog|Zinc Finger Protein 857B|Zinc Finger Protein Th-POK|Zinc Finger and BTB Domain Containing 15|Zinc Finger and BTB Domain-Containing Protein 15|hcKrox	Zinc finger and BTB domain-containing protein 7B (539 aa, ~58 kDa) is encoded by the human ZBTB7B gene. This protein plays a role in the regulation of both T-cell differentiation and collagen gene expression.			Amino Acid, Peptide, or Protein	
C150355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150355>	C21295	ZSWIM4 Gene|ZSWIM4|ZSWIM4|Zinc Finger SWIM-Type Containing 4 Gene	This gene is involved in zinc binding.			Gene or Genome	
C150356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150356>	C150355	ZSWIM4 wt Allele|FLJ00044|FLJ12221|Zinc Finger SWIM-Type Containing 4 wt Allele	Human ZSWIM4 wild-type allele is located in the vicinity of 19p13.13 and is approximately 37 kb in length. This allele, which encodes zinc finger SWIM domain-containing protein 4, plays a role in zinc binding.			Gene or Genome	
C150357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150357>	C17728	Zinc Finger SWIM Domain-Containing Protein 4|ZSWIM4|Zinc Finger SWIM-Type Containing 4	Zinc finger SWIM domain-containing protein 4 (989 aa, ~110 kDa) is encoded by the human ZSWIM4 gene. This protein may be involved in zinc-dependent protein-protein or protein-DNA interactions.			Amino Acid, Peptide, or Protein	
C150358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150358>	C16742	Oculus Rift Headset	A proprietary virtual reality headset.	Oculus Rift Headset		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C150359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150359>	C9385|C8500	Bilateral Synchronous Sporadic Renal Cell Carcinoma|BSSRCC|Bilateral Synchronous Sporadic Renal Cell Cancer	Non-hereditary renal cell carcinoma arising from a kidney and detected in the other kidney within six months of the first primary. The majority are clear cell renal cell carcinomas.	Bilateral Synchronous Sporadic Renal Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150360>	C36279	Pre-existing Chronic Kidney Disease, Stage 3|Preexisting Chronic Kidney Disease, Stage 3	Stage 3 chronic kidney disease that was diagnosed or treated before a specific date.	Pre-existing Chronic Kidney Disease, Stage 3		Finding	CTRP Disease Terminology|CTRP Terminology
C150362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150362>	C12372	Gastroduodenal Artery	A small artery located in the abdomen that arises from the common, left, or right hepatic artery, and supplies blood to the pylorus of the stomach, the proximal duodenum, and the head of the pancreas.			Body Part, Organ, or Organ Component	
C150363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150363>	C483	Selective Human Estrogen-receptor Alpha Partial Agonist TTC-352|3-(4-Fluorophenyl)-2-(4-hydroxyphenoxy)benzo[b]thiophen-6-ol|ERa Partial Agonist TTC-352|SEM TTC-352|Selective Estrogen Mimic TTC-352|Selective Estrogen Modulator TTC-352|ShERPA TTC-352|TTC 352|TTC-352|TTC-352	A benzothiophene and orally bioavailable selective human estrogen receptor alpha (ERalpha; ESR1; ERa) partial agonist (ShERPA), with potential antineoplastic activity. Upon administration, TTC-352 mimics the naturally-occurring 17beta-estradiol (E2) and targets and binds to ERa located in the nucleus. This causes translocation of ERa to extranuclear sites. Nuclear export of ERa prevents normal ER-mediated signaling and inhibits proliferation of ER-positive tumor cells. TTC-352 causes tumor regression of tamoxifen (TAM)-resistant (TR) tumor cells which often overexpress protein kinase C alpha (PKCalpha; PKCa). PKCa expression is associated with poor patient survival and breast cancer aggressiveness and may predict tumor responses to E2, E2-like compounds and ShERPAs. Unlike E2 and E2-like compounds, TTC-352 does not cause endometrial proliferation.	Selective Human Estrogen-receptor Alpha Partial Agonist TTC-352		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150364>	C4030|C162719	Refractory Urothelial Carcinoma	A urothelial carcinoma that does not respond to treatment.	Refractory Urothelial Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150365>	C150364	Platinum-Resistant Urothelial Carcinoma	Urothelial carcinoma that is resistant to platinum therapy.			Neoplastic Process	
C150366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150366>	C48570	Percent of Prostate Cores Positive for Carcinoma|Number of Prostate Cores Positive for Carcinoma/Total Number of Prostate Cores	The number of prostate core biopsy samples positive for carcinoma divided by the total number of prostate core samples.			Finding	
C150367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150367>	C37261	Hermansky-Pudlak Syndrome 1|HPS1	An autosomal recessive sub-type of Hermansky-Pudlak syndrome caused by mutation(s) in the HPS1 gene, encoding Hermansky-Pudlak syndrome 1 protein. This sub-type is associated with pulmonary fibrosis.	Hermansky-Pudlak Syndrome 1		Disease or Syndrome	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology
C150368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150368>	C37261	Hermansky-Pudlak Syndrome 2|HPS2	An autosomal recessive sub-type of Hermansky-Pudlak syndrome caused by mutation(s) in the AP3B1 gene, encoding AP-3 complex subunit beta-1. Immunodeficiency due to neutropenia is a characteristic of this sub-type.	Hermansky-Pudlak Syndrome 2		Disease or Syndrome	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology
C150369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150369>	C37261	Hermansky-Pudlak Syndrome 6|HPS6	An autosomal recessive sub-type of Hermansky-Pudlak syndrome caused by mutation(s) in the HPS6 gene, encoding Hermansky-Pudlak syndrome 6 protein. Individuals with this type of syndrome, as well as with types 3 or 5, have the mildest symptoms.	Hermansky-Pudlak Syndrome 6		Disease or Syndrome	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology
C150370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150370>	C49236	Cavernous Nerve Electrical Stimulation|Cavernosal Nerve Electrical Stimulation|Cavernosal Nerve Stimulation|Cavernous Nerve Stimulation	Stimulation of the cavernous nerve with an electrical current for the purpose of treating neurogenic cases of erectile dysfunction.	Cavernous Nerve Electrical Stimulation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C150371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150371>	C53450	Guidewire Length	The length of the guidewire.			Quantitative Concept	FDA CDRH GUDID Terminology
C150372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150372>	C53450	Guidewire Diameter	The diameter of the guidewire.			Quantitative Concept	FDA CDRH GUDID Terminology
C150373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150373>	C390	Imaging Agent QRH-882260 Heptapeptide|Fluorescence Peptide QRH-882260|Fluorescently-labeled Peptide QRH-882260|Gln-Arg-His-Lys-Pro-Arg-Glu-Gly-Gly-Gly-Ser-Lys(Cy5)-NH2|QRH-882260|QRH-882260|QRH-882260 Cy-5-labeled Heptapeptide|QRHKPRE-GGGSK-(Cy5)-NH2	An orally bioavailable fluorescent imaging agent composed of the near-infrared (NIR) fluorophore cyanine 5 (Cy5) linked to a seven-amino acid long peptide that specifically binds to the tumor-associated antigen (TAA) epithelial growth factor receptor (epidermal growth factor receptor; EGFR), that can potentially be used for the imaging of EGFR-expressing tumor cells. Upon oral administration of the fluorescent imaging agent QRH-882260 heptapeptide, the peptide moiety selectively binds to EGFR expressed on tumor cells in the gastrointestinal (GI) tract. Upon fluorescence imaging, EGFR-expressing tumor cells can be visualized. EGFR, a member of the epidermal growth factor receptor family, is overexpressed on the surfaces of various tumors cells.			Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C150374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150374>	C226473	A-101 Topical Solution|A-101|A-101 Solution	A proprietary topical formulation consisting of a high-concentration of hydrogen peroxide (H2O2), with potential keratolytic activity. Upon administration of the A-101 topical solution to an affected area of skin, the hydrogen peroxide penetrates into the cells, increases oxygen content, produces reactive oxygen species (ROS), causes oxidative stress and induces apoptosis through oxidative damage. This may clear the affected skin cells and remove common warts (verruca vulgaris) or seborrheic keratosis (SK).			Pharmacologic Substance	NCI Drug Dictionary Terminology
C150375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150375>	C98083	Licogliflozin|D-Glucitol, 1,5-Anhydro-1-C-(3-((2,3-dihydro-1,4-benzodioxin-6-yl)methyl)-4-ethylphenyl)-, (1S)-|LICOGLIFLOZIN|LIK 066|LIK-066|LIK066	An inhibitor of the sodium-dependent glucose co-transporter (sodium-glucose transporter; sodium-glucose transport protein; sodium-glucose linked transporter; SGLT) family members 1 and 2 (SGLT1/2) with antihyperglycemic activity. By binding to and blocking SGLT1/2, licogliflozin suppresses the reabsorption of glucose in the proximal tubule within the kidneys and enhances urinary excretion of glucose. This normalizes blood glucose levels. SGLT1/2, parts of a transport system expressed in the proximal renal tubules, mediate the majority of renal glucose reabsorption from tubular fluid.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C150376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150376>	C192825	EP4 Antagonist ONO-4578|BMS 986310|BMS-986310|BMS-986310|BMS986310|ONO 4578|ONO-4578|ONO4578|PGE2 Receptor Antagonist ONO-4578|Prostaglandin E2 Receptor Antagonist ONO-4578|Selective PGE2 Receptor 4 Antagonist ONO-4578	An orally bioavailable antagonist of the prostaglandin E2 receptor subtype 4 (PTGER4; EP4), with potential analgesic, immunomodulating and antineoplastic activities. Upon administration, the EP4 antagonist ONO-4578 selectively targets and binds to EP4, inhibiting the binding of the immunosuppressive prostaglandin E2 (PGE2) to EP4. This prevents the activation of EP4 and inhibits PGE2-EP4-mediated signaling, thereby inhibiting proliferation of tumor cells in which the PGE2-EP4 signaling pathway is over-activated. In addition, EP4 inhibition prevents the activity of tumor-associated myeloid cells (TAMCs) in the tumor microenvironment (TME) by inhibiting interleukin-23 (IL-23) production and the IL-23-mediated expansion of Th17 cells. EP4, a prostanoid receptor, is a G protein-coupled receptor that is expressed in certain types of cancers; it promotes tumor cell proliferation and invasion.	EP4 Antagonist ONO-4578		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150377>	C200766|C176018	Autologous Anti-CD19 CAR-T Cells TBI-1501|Anti-CD19-CAR T-cells TBI-1501|Autologous Anti-CD19 Chimeric Antigen Receptor T Cells TBI-1501|CAR19 T-lymphocytes TBI-1501|TBI-1501	Autologous T-lymphocytes that have been transduced, via a proprietary technology involving a recombinant human fibronectin fragment to enhance transduction efficiency, with a retroviral vector to express a chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) of anti-CD19 coupled to co-stimulatory molecules, with potential immunostimulating and antineoplastic activities. Upon transfusion, anti-CD19-CAR-expressing autologous T-lymphocytes TBI-1501 target and bind to CD19-expressing neoplastic B-cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells, the release of cytotoxic molecules and the induction of tumor cell lysis. CD19, cluster of differentiation 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. Incorporation of the costimulatory signaling domains increase proliferation and activation of T-cells.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology
C150378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150378>	C200766|C176018	Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T Lymphocytes BinD19|Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T-cells BinD19|BinD 19|BinD19	Autologous T-lymphocytes that have been transduced with a lentiviral vector to express a T-cell receptor (TCR) consisting of a single chain variable fragment (scFv) of anti-CD19 coupled to the co-stimulatory molecule 4-1BB (CD137) and to the cytoplasmic portion of the zeta chain of the human T-cell receptor (CD3zeta), with potential immunostimulating and antineoplastic activities. Upon transfusion, the autologous anti-CD19 CAR TCR-zeta/4-1BB-transduced T-lymphocytes BinD19 target and bind to CD19-expressing neoplastic B-cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells, the release of cytotoxic molecules and tumor cell lysis. CD19, cluster of differentiation 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. Incorporation of the costimulatory signaling domains increases human T-cell function, expansion, and survival.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology
C150379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150379>	C308	Candida albicans Antigen Injection|Candida albicans Skin Test Antigen|Candida albicans Test Antigen Injection|Candin	An injectable formulation composed of antigens derived from the culture filtrate and cells of two different strains of Candida albicans (C. albicans), with immunomodulatory activity. Upon intralesional administration into the cutaneous human papilloma virus (HPV)-infected warts, the C. albicans antigens stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL)-mediated immune response against the injected antigens and cause a delayed type hypersensitivity response against other local antigens, including antigens within the wart tissue. This leads to the production of Th1 cytokines, and the activation of natural killer (NK) cell- and CTL- mediated killing of HPV-infected cells. This causes clearing of both local and distant warts, and prevents both HPV infection and wart formation that results from HPV infection.	Candida albicans Antigen Injection		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C150380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150380>	C308	East Indian Sandalwood Oil Cream|EISO Cream|SAN 007|Santalum album Oil Cream|VIR 003|VIR 007	A cream containing an essential oil derived from the East Indian sandalwood tree (Santalum album), containing alpha- and beta-santalols, with potential anti-inflammatory, anti-proliferative, anti-bacterial, anti-viral and immunomodulating activities. Upon topical application of the East Indian sandalwood oil (EISO) cream to an affected area of skin, the active ingredients in the cream may suppress various enzymes, such as cyclooxygenase (COX) and cyclic adenosine monophosphate (cAMP) phosphodiesterases (PDEs), prevent the production of pro-inflammatory cytokines and chemokines and directly cause apoptosis in susceptible cell types, including certain cancer cells and virally-infected cells.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C150381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150381>	C129826	CMV/EBV/ADV/BKV-specific Cytotoxic T Lymphocytes|CMV/EBV/ADV/BKV specific Cytotoxic T-lymphocytes	A population of cytotoxic T-lymphocytes (CTLs) specifically reactive to cytomegalovirus (CMV), Epstein-Barr virus (EBV), adenovirus (ADV) and BK virus (BKV), with potential antiviral and protective activities. T-cells derived from peripheral blood mononuclear cells (PBMCs) are exposed to and activated by dendritic cells (DCs) that are loaded with specific peptides from CMV, EBV, ADV and BKV. Upon infusion of the CMV/EBV/ADV/BKV-specific CTLs, these lymphocytes target and cause lysis of CMV-, EBV-, ADV- and/or BKV-infected cells and may prevent infection and complications from CMV-, EBV-, ADV- and BKV-driven viral diseases. Opportunistic infections caused by these viruses are often seen in immunosuppressed patients.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology
C150382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150382>	C200766	Satricabtagene Autoleucel|Autologous Anti-Claudin18.2 CAR-T Cells|Autologous Anti-Claudin18.2-transduced T Lymphocytes CT041|Autologous CAR-CLD18 T Cells|Autologous CAR-CLD18.2 T Cells|CT 041|CT-041|CT041|Claudin18.2-redirected Autologous Cells|SATRICABTAGENE AUTOLEUCEL	A preparation of autologous T-lymphocytes ex vivo transduced with a lentiviral vector encoding for a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), with potential immunostimulating and antineoplastic activities. Upon administration, satricabtagene autoleucel specifically recognize and induce selective toxicity in CLDN18.2-expressing tumor cells. CLDN18.2, a tight junction protein, is expressed on a variety of tumor cells, but its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.	Satricabtagene Autoleucel		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C150383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150383>	C155727	Fanregratinib|FANREGRATINIB|FGFR Inhibitor HMPL-453|FGFR1/2/3 Inhibitor HMPL-453|HMPL 453|HMPL-453|HMPL453	An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), with potential antineoplastic activity. Upon administration, fanregratinib binds to and inhibits FGFR1/2/3, which may result in the inhibition of FGFR1/2/3-related signal transduction pathways. This inhibits proliferation in FGFR1/2/3-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases (RTKs) upregulated in many tumor cell types, plays a key role in cellular proliferation, migration and survival.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150384>	C93259|C213472|C129825	Vandetanib-eluting Radiopaque Bead BTG-002814|BTG-002814|VERB|VERB BTG-002814|VTB-loaded Beads|Vandetanib-eluting Radiopaque Embolic Beads	Radiopaque drug-eluting beads (DEBs) that are loaded with vandetanib, a dual inhibitor of both vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR), with potential antineoplastic, anti-angiogenic and imaging activities. Upon intra-arterial hepatic artery administration of vandetanib (VTB)-eluting Radiopaque beads (VERBs) BTG-002814, the DEBs occlude the tumor blood vessels and deprive tumor cells of oxygen and nutrients, thereby causing hepatic arterial embolization and direct tumor cell death. The VERBs release vandetanib from the beads in a sustained manner. Vandetanib selectively inhibits the tyrosine kinase activity of both VEGFR and EGFR, thereby blocking both VEGF/VEGFR- and EGF/EGFR-stimulated signaling and inhibiting cell proliferation, migration and angiogenesis in VEGFR/EGFR-expressing hepatic tumor cells. The DEBs, controlled release microspherical devices, cause low systemic exposure and prevent systemic toxicity of vandetanib. DEBs also deliver high concentrations of vandetanib in the tumor for a controlled and extended period of time. Use of radiopaque DEBs allows for visualization of both the bead location and the degree of embolization upon imaging.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150385>	C81234	Ecological Momentary Assessment|EMA	A method for assessment in clinical psychology that involves repeated sampling of subjects' current behaviors and experiences in real time, in a subjects' natural environments. EMA aims to minimize recall bias, maximize ecological validity, and allow study of microprocesses that influence behavior in real-world contexts.	Ecological Momentary Assessment		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C150386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150386>	C25372	Basic Dosage Form Category	A category of terms used to group together pharmaceutical dose forms.			Classification	
C150387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150387>	C165181|C116509	Robot-assisted Laparoscopic Partial Nephrectomy|RPN|Robot-assisted Partial Nephrectomy|Robotic-assisted Partial Nephrectomy	A surgical procedure where a partial nephrectomy is done using a laparoscopic robot.	Robot-assisted Laparoscopic Partial Nephrectomy		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C150388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150388>	C1512	IRDye800CW-labeled Heptapeptide KSP-910638G|KSP Heptapeptide|KSP-910638G|KSP-910638G|KSP-910638G Heptapeptide	An imaging agent composed of a heptapeptide targeting human epithelial growth factor receptor type 2 (EGFR2; HER2; ErbB2) conjugated, via a five-amino acid linker, to the near-infrared (NIR) fluorescent dye IRDye800CW, that can potentially be used for the imaging of HER2-expressing tumors. Upon oral administration of the IRDye800CW-labeled heptapeptide KSP-910638G, the peptide moiety targets and binds to HER2 expressed on tumor cells in the gastrointestinal (GI) tract. Upon fluorescence imaging of the fluorophore IRDye800CW, the tumor cells can be detected.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C150389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150389>	C107589	CXCR1/2 Inhibitor SX-682|(2-(((5-((4-Fluorophenyl)carbamoyl)pyrimidin-2-yl)thio)methyl)-4-(trifluoromethoxy)phenyl)boronic Acid|SX 682|SX-682|SX-682|SX682	An orally bioavailable, selective and reversible antagonist of C-X-C motif chemokine receptors 1 (CXCR1) and 2 (CXCR2), with potential anti-inflammatory and antineoplastic activities. Upon administration CXCR1/2 inhibitor SX-682 selectively and allosterically binds to CXCR 1 and 2 and inhibits their activation by tumor-secreted chemokines. This inhibits CXCR1/2-mediated signaling, reduces both recruitment and migration of immunosuppressive myeloid-derived suppressor cells (MDSCs) and neutrophils in the tumor microenvironment (TME), inhibits inflammatory processes and abrogates the immunosuppressive-induced nature of the TME. This allows effector cells, such as natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs), to kill and eliminate cancer cells. This inhibits tumor cell migration, metastasis, angiogenesis and tumor cell proliferation. CXCR1 and 2, G protein-coupled receptor proteins located on myeloid cells and certain tumor cells, play key roles in the immunosuppressive nature of the TME, tumor metastasis, therapy-resistance and myeloid cell suppression. They play a key role in inflammation and their expression is elevated in several inflammatory-driven diseases.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150390>	C20401|C129822	Guselkumab|CNTO 1959|GUSELKUMAB|Tremfya	An orally available, human, immunoglobulin G1 (IgG1) kappa, monoclonal antibody directed against the p19 protein subunit of interleukin-23 (IL-23), with immunomodulating activity. Upon administration, guselkumab binds to the p19 subunit of IL-23, thereby blocking the binding of IL-23 to the IL-23 receptor. This inhibits IL-23-mediated signaling and the differentiation of CD4-positive T-cells into Th1 and Th17 cells. This prevents Th1- and Th17-mediated immune responses and inhibits the production of pro-inflammatory cytokines. This may prevent or reduce symptoms and severity of immune-mediated inflammatory disorders. IL-23 plays a key role in the regulation of inflammation and the immune system, and modulates the release of various pro-inflammatory cytokines and chemokines. It is upregulated in various immune-mediated inflammatory disorders.	Guselkumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150392>	C2124	Fluorine F 18 Integrin Alpha v Beta 6-targeted Peptide|18F-aVb6-BP|18F-aVb6-Binding-Peptide|18F-alphavbeta6-binding Peptide	A radiotracer composed of an integrin alphaVbeta6 (aVb6) binding peptide (BP) radiolabeled with the radionuclide fluorine F 18, with potential integrin aVb6 imaging activity using positron emission tomography (PET). Upon administration, the fluorine F 18 integrin aVb6-targeted peptide selectively binds to integrin aVb6-positive cancer cells. During PET, aVb6-expressing tumor cells can be visualized and the degree of tumor growth can be determined. Integrin aVb6, a cell adhesion and signaling receptor, is upregulated in certain cancer cell types and has been associated with increased proliferation, migration and invasion of tumor cells.			Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C150393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150393>	C141137	Indoximod Prodrug NLG802|ETHYL LEUCYL-1-METHYL-D-TRYPTOPHANATE|IDO1 Inhibitor NLG802|Indoleamine 2,3-Dioxygenase (IDO) Inhibitor|NLG 802|NLG-1564|NLG-802|NLG802	An orally bioavailable prodrug of indoximod, a methylated tryptophan, with immune checkpoint inhibitory and antineoplastic activities. Upon oral administration, the indoximod prodrug NLG802 is converted to indoximod. Indoximod targets, binds to and inhibits the enzyme indoleamine 2,3-dioxygenase (IDO; IDO1), which converts the essential amino acid tryptophan into the immunosuppressive metabolite kynurenine. By increasing tryptophan levels and decreasing kynurenine levels, indoximod restores and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells, and T-lymphocytes, and causes a reduction in tumor-associated regulatory T-cells (Tregs). Activation of the immune system, which is suppressed in many cancers, may induce a cytotoxic T-lymphocyte (CTL) response against IDO1-expressing tumor cells, thereby inhibiting their growth. IDO1, overexpressed by multiple tumor cell types, plays an important role in immunosuppression. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system. NLG802 elicits increased plasma concentrations of indoximod and improves its efficacy, compared to the direct administration of indoximod.	Indoximod Prodrug NLG802		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150394>	C82547	Fibrinous Material Present	A finding indicating the presence of fibrinous material in a surgical pathology specimen.			Finding	
C150395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150395>	C42076	Small Aggregates of Tumor Cells Present	A morphologic finding indicating the presence of small aggregates of tumor cells in a tissue sample.			Finding	
C150396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150396>	C80289	Fibrin-Associated Diffuse Large B-Cell Lymphoma|FA-DLBCL|Fibrin-Associated EBV-Positive Large B-Cell Lymphoma	An unusual form of diffuse large B-cell lymphoma. It is not mass-forming and does not directly produce symptoms, but it is discovered incidentally on histological examination of surgical pathology specimens, excised for various pathologies other than lymphoma. The specimens typically contain fibrinous materials. Single and small aggregates of large lymphoma cells are found in only small foci within the fibrinous or amorphous material. EBV is positive, with type III latency. The clinical outcome is highly favorable, even with surgical excision alone. (WHO 2017)	Fibrin-Associated Diffuse Large B-Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150397>	C2124	Gallium Ga 68-NOTA-RM26|68Ga-NOTA-RM26	A radioconjugate containing RM26, a synthetic bombesin analogue and antagonist of the gastrin-releasing peptide receptor (GRPR), that is linked, through the macrocyclic chelating agent 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA) to the radionuclide gallium (Ga) 68, with potential use in diagnostic imaging using positron emission tomography/computed tomography (PET/CT). Upon administration of gallium Ga 68-NOTA-RM26, the peptide moiety targets and binds to GRPR. Upon PET/CT, GRPR-expressing tumor cells can then be visualized. GRPR, also called bombesin receptor subtype 2 (BB2), is a G protein-coupled seven-transmembrane receptor belonging to the bombesin receptor family. It is overexpressed in certain types of cancers.			Organic Chemical|Pharmacologic Substance	NCI Drug Dictionary Terminology
C150398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150398>	C26170	Hydrocortisone Sodium Succinate/Aluminum Phosphate Gel|Hydrocortisone Sodium Succinate Mixed with Aluminum Phosphate Gel	A gel composed of the sodium succinate form of the glucocorticoid hydrocortisone mixed with aluminum phosphate, with potential protective activity. Upon oral administration of the hydrocortisone sodium succinate/aluminum phosphate gel, the gel forms a layer over the esophageal mucosa, which may restore and protect the esophageal membrane against damage. Hydrocortisone exerts anti-inflammatory effects locally, may reduce or prevent infection, may reduce the formation of connective tissue in order to prevent postoperative esophageal stenosis and stricture, and may reduce symptoms of dysphagia or choking, after endoscopic submucosal dissection (ESD). The aluminum phosphate acts as a buffer and may protect the local mucosal membrane from the acidic environment.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C150399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150399>	C9308	HHV8-Related Lymphoproliferative Disorder|HHV8-Associated Lymphoproliferative Disorder|HHV8-Associated Lymphoproliferative Disorder|KSHV/HHV8-Related Lymphoproliferative Disorder	A lymphoproliferative disorder caused by the human herpesvirus 8 (HHV8). This category includes the following: HHV8-positive multicentric Castleman disease; HHV8-positive diffuse large B-cell lymphoma, not otherwise specified; primary effusion lymphoma; and germinotropic lymphoproliferative disorders.	HHV8-Associated Lymphoproliferative Disorder		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C1503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1503>	C707	2'-deoxyadenosine|2'-DEOXYADENOSINE|9-(2-Deoxy-Beta-D-Erythro-Pentofuranosyl)Adenine|Deoxyadenosine|Deoxyadenosine|Desoxyadenosine	A purine nucleoside component of DNA comprised of adenosine linked by its N9 nitrogen to the C1 carbon of deoxyribose.			Nucleic Acid, Nucleoside, or Nucleotide	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C150400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150400>	C39619|C1663	Oral Pancreatic Cancer Vaccine V3-P|Cancer Vaccine V3-P|Oral Tableted Therapeutic Vaccine V3-P|V3 P|V3-P|V3-P Cancer Vaccine|V3P	An orally bioavailable, therapeutic cancer vaccine composed of the carbohydrate antigen sialyl-Lewis A (carbohydrate antigen 19-9; CA19.9; CA19-9) that is derived from pooled blood of pancreatic cancer patients, with potential immunomodulating activity. Upon oral administration of the oral pancreatic cancer vaccine V3-P, the CA19.9 antigens may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL)-mediated immune response against pancreatic cancer cells expressing the CA19.9 antigen. CA19.9 is overexpressed on a number of different tumor cell types and plays a key role in tumor cell survival and metastasis.			Immunologic Factor|Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150401>	C129820	ssRNA-based Immunomodulator CV8102|CV 8102|CV-8102|CV-8102|CV8102|RNA-based Adjuvant CV8102|RNAdjuvant	A 547 nucleotide (nt), noncoding, uncapped single-stranded RNA (ssRNA) containing several polyU-repeats complexed with a polymeric carrier formed by disulfide-crosslinked cationic peptides, with potential immunostimulating activity. Upon intratumoral injection, the ssRNA in CV8102 activates toll-like receptors (TLRs) and retinoic acid-inducible gene I (RIG I; RIG-I; DDX58). This stimulates a T-helper type 1 cell (Th1) response, the production of a variety of pro-inflammatory cytokines and chemokines, and activates a systemic cytotoxic-T-lymphocyte (CTL)-mediated immune response against the tumor cells when simultaneously exposed to tumor-associated antigens (TAAs). The cationic carrier peptides protect the ssRNA from RNase degradation.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150402>	C93144	Lactobacillus rhamnosus/Lactobacillus reuteri Probiotic Supplement|L. rhamnosus and L. reuteri Probiotic Supplement|RepHresh Pro-B	A probiotic supplement containing the bacteria Lactobacillus (L.) rhamnosus and L. reuteri, with potential restorative and protective activities. Upon oral administration of the L. rhamnosus and L. reuteri probiotic supplement, the bacteria may restore and provide balance to the microbiota in the breast tissue. This may reduce or prevent inflammation, and may protect against the invasion of harmful bacteria and infection in the breast. In addition, the bacteria may restore the natural balance of the vaginal flora. This may prevent the invasion of harmful bacteria and yeast, and may prevent bacterial and yeast infections. This supplement may also relieve symptoms such as vaginal itching, odor and discharge, and may improve vaginal discomfort.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C150403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150403>	C134305	Miptenalimab|Anti-LAG3 Monoclonal Antibody BI 754111|Anti-Lymphocyte Activation Gene 3 Protein Monoclonal Antibody BI 754111|BI 754111|BI-754111|BI754111|MIPTENALIMAB	A monoclonal antibody directed against the inhibitory receptor lymphocyte activation gene 3 protein (LAG3; LAG-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration,miptenalimab binds to LAG3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks its binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells, and negatively regulates both proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.	Miptenalimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150404>	C27855|C150399	HHV8-Positive Multicentric Castleman Disease|KSHV-Associated Multicentric Castleman Disease|KSHV/HHV8-Associated Multicentric Castleman Disease|KSHV/HHV8-MCD|KSHV/HHV8-Positive Multicentric Castleman Disease|Kaposi Sarcoma HHV-Associated Multicentric Castleman Disease|Kaposi Sarcoma Virus-Associated Multicentric Castleman Disease	Multicentric Castleman disease associated with HHV8 infection.	HHV8-Positive Multicentric Castleman Disease		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150405>	C159717|C150399	HHV8-Positive Germinotropic Lymphoproliferative Disorder|GLPD|HHV8+ GLPD|KSHV/HHV8-Positive Germinotropic Lymphoproliferative Disorder|KSVH/HHV8+ GLPD	A monotypic HHV8-positive lymphoproliferative disorder that usually occurs in HIV-negative individuals. It is characterized by the presence of HHV8-positive plasmablasts partially or completely replacing germinal centers. Coinfection with EBV is characteristic. In most cases, there is a favorable response to chemotherapy or radiation. (WHO 2017)	HHV8-Positive Germinotropic Lymphoproliferative Disorder		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150406>	C6915	Extracavitary Primary Effusion Lymphoma|Extracavitary PEL	A rare HHV8-positive B-cell lymphoma indistinguishable from primary effusion lymphoma presenting as solid tumor mass. (WHO 2017)	Extracavitary Primary Effusion Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150407>	C6915	Body Cavity Primary Effusion Lymphoma|Body Cavity PEL	A large B-cell lymphoma presenting as a serous effusion without detectable tumor masses. It is universally associated with human herpes virus 8 (HHV8), also called Kaposi sarcoma-associated herpesvirus.  It mostly occurs in the setting of immunodeficiency. The most common sites of involvement are the pleural, pericardial, and peritoneal cavities. (WHO 2017)	Body Cavity Primary Effusion Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150408>	C20988|C20744	CLDN18 Gene|CLDN18|CLDN18|Claudin 18 Gene	This gene plays a role in tight junction assembly.	CLDN18 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C150409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150409>	C150408	CLDN18 wt Allele|Claudin 18 wt Allele|SFTA5|SFTPJ|Surfactant Associated 5 Gene|Surfactant, Pulmonary Associated Protein J Gene|UNQ778/PRO1572	Human CLDN18 wild-type allele is located in the vicinity of 3q22.3 and is approximately 35 kb in length. This allele, which encodes claudin-18 protein, is involved in tight junction assembly. Aberrant expression may be associated with gastric, pancreatic, esophageal, ovarian and lung neoplasms.	CLDN18 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150410>	C18073|C16393	CLDN18 Gene Product	A protein encoded by the CLDN18 gene.			Amino Acid, Peptide, or Protein	
C150411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150411>	C150410	Claudin-18|CLDN-18|CLDN-18.1|CLDN18|CLDN18.1|Claudin 18|Claudin 18 Isoform 1|Claudin 18 Isoform A1|Claudin 18.1|Claudin-18 Isoform 1|Claudin-18 Isoform A1|Surfactant Associated Protein J	Claudin-18 (261 aa, ~28 kDa) is encoded by the human CLDN18 gene. This protein plays a role in tight junction formation in the epithelium of the lung.	Claudin-18		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150412>	C150410	Claudin-18 Isoform A2|CLDN-18.2|CLDN18.2|Claudin 18 Isoform 2|Claudin 18 Isoform A2|Claudin 18.2|Claudin-18 Isoform 2|Claudin-18.2	Claudin-18 isoform A2 (261 aa, ~28 kDa) is encoded by the human CLDN18 gene. This protein is involved in tight junction formation in the epithelium of the gastric mucosa.	Claudin-18 Isoform A2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150413>	C223184	Telaglenastat Hydrochloride|2-Pyridineacetamide, N-(5-(4-(6-((2-(3-(trifluoromethoxy)phenyl)acetyl)amino)-3-pyridazinyl)butyl)-1,3,4-thiadiazol-2-yl)-, Hydrochloride (1:1)|CB-839 HCl|Glutaminase Inhibitor CB-839 Hydrochloride|TELAGLENASTAT HYDROCHLORIDE	The hydrochloride salt form of CB-839, an orally bioavailable inhibitor of glutaminase, with potential antineoplastic and immunostimulating activities. Upon oral administration, CB-839 selectively and reversibly binds to and inhibits human glutaminase, an enzyme that is essential for the conversion of the amino acid glutamine into glutamate. Blocking glutamine metabolism inhibits proliferation in rapidly growing tumor cells and leads to an induction of cell death. Unlike normal healthy cells, glutamine-dependent tumors heavily rely on the intracellular conversion of exogenous glutamine into glutamate and glutamate metabolites to both provide energy and generate building blocks for the production of macromolecules, which are needed for cellular growth and survival. In addition, CB-839 causes accumulation of glutamine in tumor cells and increases glutamine concentration in the tumor microenvironment (TME) upon cell death. As glutamine is essential for T-cell generation, CB-839 may also enhance T-cell proliferation and activation in the TME, which may lead to further killing of tumor cells.	Telaglenastat Hydrochloride		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150414>	C13442	Parenteral	Relating to the internal body as the intended site of administration, other than the natural openings and cavities such as the gastrointestinal tract, auditory canal, nasal cavity, lungs, etc.; the pharmaceutical product is usually administered by breaking the skin, such as by injection, infusion, and implantation.			Spatial Concept	EDQM Health Care Terminology|EDQM-HC Intended Site of Administration Terminology
C150415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150415>	C67450	Million Tissue Culture Infectious Dose 50%|10*6.[TCID_50]/{dose}|10*6.[TCID_50]/{dose}|10^6 50 Percent Tissue Culture Infective Dose per Dose|10^6 TCID 50/dose|10^6.[TCID_50]/{dose}|10^6.[TCID_50]/{dose}|10^6{TCID50}|Million Tissue Culture Infectious Dose 50 Percent	A potency unit equal to the potency at which one dose of preparation contains one million (10^6) 50 percent tissue culture infective doses.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150416>	C67450	Ten Million Tissue Culture Infectious Dose 50%|10^7 50 Percent Tissue Culture Infective Dose per Dose|10^7 TCID 50/dose|10^7.[TCID50]|10^7.[TCID50]|10^7{TCID50}|Ten Million Tissue Culture Infectious Dose 50 Percent	A unit of potency equal to ten million tissue culture infectious dose 50% units.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150417>	C67450	Hundred Million Tissue Culture Infectious Dose 50%|10*8.[TCID_50]/{dose}|10*8.[TCID_50]/{dose}|10^8 50 Percent Tissue Culture Infective Dose per Dose|10^8 TCID 50/dose|10^8.[TCID_50]/{dose}|10^8.[TCID_50]/{dose}|10^8{TCID50}|Hundred Million Tissue Culture Infectious Dose 50 Percent	A potency unit equal to the potency at which one dose of preparation contains one million (10^8) 50 percent tissue culture infective doses.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150418>	C2124	Fluorine F 18 DASA-23|1-((2-Fluoro-6-[18F]fluorophenyl)sulfonyl)-4-((4-methoxyphenyl)sulfonyl)piperazine|18F-DASA-23|F18-labeled PKM2 Inhibitor DASA-23|F18-labeled Pyruvate Kinase M2 Inhibitor DASA-23|[18F]DASA-23|[18F]DASA23	A radiotracer composed of DASA-23, a pyruvate kinase isoform M2 (PKM2) ligand, conjugated to the radioisotope fluorine F 18, with potential use for imaging of PKM2-expressing tumor cells upon positron emission tomography (PET). Upon administration of fluorine F 18 DASA-23, the DASA-23 moiety selectively targets and is taken up by tumor cells that express PKM2. Upon binding to PKM2 and following PET, PKM2-expressing tumor cells can be visualized and the metabolic activity of the tumor cells can be assessed through the quantitation of PKM2 expression levels. PKM2, an enzyme that plays a key role in the glycolytic reprogramming, metabolic activity and rapid proliferation of tumor cells, is selectively overexpressed in various tumor cell types. Tumor uptake of fluorine F 18 DASA-23 is positively correlated with PKM2 expression.	Fluorine F 18 DASA-23		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C150419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150419>	C156897	Bluetooth-enabled Activity Monitor|Bluetooth-enabled Activity Tracker|Bluetooth-enabled Activity Tracking Device	A consumer, wearable device that is designed to collect and display information about an individual's activities and is able to transfer that information to another device or system over a Bluetooth connection. Information collected may include steps, stairs climbed, distance traveled, calories used, heart rate, sleep quality, or other metrics.	Bluetooth-enabled Activity Monitor		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C150420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150420>	C16830	Robotic Uterine Manipulator|BAUM|Barakat Automated Uterine Manipulator	A robotic device designed to assist a surgeon in moving the uterus into an optimal position during laparoscopic procedures.	Robotic Uterine Manipulator		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C150421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150421>	C41024	Neoplastic Plasma Cells Under 5 Percent of Bone Marrow Nucleated Cells|Neoplastic Plasma Cells Less than 5 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that less than 5 percent of the nucleated cells in a bone marrow sample are neoplastic plasma cells.	Neoplastic Plasma Cells Under 5 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C150422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150422>	C142779	Deep Inspiration Breath Hold|DIBH	A type of active breathing control where a breath is held during a procedure while the lungs are fully expanded. It is typically used during radiation therapy to help limit radiation to underlying organs.	Deep Inspiration Breath Hold		Activity	CTRP Intervention Terminology|CTRP Terminology
C150423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150423>	C153598	Paired-End Sequencing|Paired End|Paired-end Reads	A DNA sequencing strategy where a single read is initiated from each end of a DNA fragment.			Molecular Biology Research Technique	
C150424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150424>	C62714|C138187	Non-myeloablative TCR alpha/beta-depleted Haploidentical Hematopoietic Stem Cell Transplantation|Non-myeloablative TCR alpha/beta-depleted Haploidentical HSCT|Nonmyeloablative T-cell Receptor-alpha-beta-depleted Haploidentical Hematopoietic Cell Transplantation	An allogeneic hematopoietic stem cell transplantation (HSCT) in a recipient that was not pre-treated with a conditioning regimen of high doses of chemotherapy or radiation, using cells depleted of T-cell receptors (TCR) alpha and beta as Graft-versus-Host Disease (GvHD) prophylaxis, from a related donor who is a partial human leukocyte antigen (HLA) tissue type match.	Non-myeloablative TCR alpha/beta-depleted Haploidentical Hematopoietic Stem Cell Transplantation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C150425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150425>	C40998|C153405	HMB45-Positive Cells Present|HMB-45 Positive|HMB-45 Positive Cells Present|HMB-45-Positive Cells Present|HMB45 Positive|HMB45 Positive Cells Present|HMB45 Positive Cells Present|Human Melanoma Black 45 Positive Cells Present|Melanoma (gp100) Antibody (HMB45) Positive Cells Present|Monoclonal Mouse Anti-Human Melanocyte Protein PMEL Positive Cells Present|Monoclonal Mouse Anti-Human Melanosome, Clone HMB-45-Positive Cells Present	An immunohistochemical finding that the monoclonal antibody HMB-45 binds to a the cells in a biosample.	HMB45 Positive Cells Present		Finding	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150426>	C18881	Second-strand Library Sequencing|Second-strand|Second-strand Library|Second-strand Sequencing|Second_Stranded	Directional sequencing, where the first read of the read pair (or in case of single end reads, the only read) is from the transcript strand.			Molecular Biology Research Technique	GDC Terminology|GDC Value Terminology
C150427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150427>	C18881	Unstranded Library Sequencing|Unstranded|Unstranded|Unstranded Library|Unstranded Sequencing	Non-directional sequencing, where the reads can map from either the transcript strand or its complement.			Molecular Biology Research Technique	GDC Terminology|GDC Value Terminology
C150428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150428>	C18881	First-strand Library Sequencing|First-strand|First-strand Library|First-strand Sequencing|First_Stranded	Directional sequencing, where the first read (or the only read in case of single end reads) is from the complement strand.			Molecular Biology Research Technique	GDC Terminology|GDC Value Terminology
C150429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150429>	C1511	Copper Cu-64-DOTA-alendronate|64Cu-DOTA-alendronate|[64Cu]-DOTA-alendronate	A radioconjugate containing the biphosphonate alendronate conjugated with the bifunctional, macrocyclic chelating agent 1,4,7,10-tetra-azacyclododecane-1,4,7,10-tetra-acetic acid (DOTA) and labeled with the radioisotope copper Cu 64, with potential use as an imaging agent for microcalcifications in mammary tumors using positron emission tomography (PET). Upon administration of the copper Cu-64 alendronate, the alendronate moiety targets and binds to hydroxyapatite crystals found in malignant tumors. Upon binding and PET imaging, the radioisotope moiety is detected, thereby allowing differentiation between malignant tumors, benign tumors and normal tissue, as the highest uptake of 64Cu-DOTA-alendronate occurs in malignant tumors while the lowest uptake occurs in benign tumors and normal mammary tissue.	Copper Cu-64-DOTA-alendronate		Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C150430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150430>	C1557	Radgocitabine Hydrochloride|2'-Cyano-2'-deoxy-1-(beta-D-arabinofuranosyl)cytosine Monohydrochloride|CNDAC Hydrochloride|Deoxycytidine Analogue TAS-109 Hydrochloride|RADGOCITABINE HYDROCHLORIDE	The hydrochloride salt form of radgocitabine, an analogue of the nucleoside deoxycytidine with potential antineoplastic activity. Upon administration, radgocitabine is incorporated into DNA and directly inhibits the activity of DNA polymerase, which may result in inhibition of DNA replication and cell cycle arrest in the S and G2/M phases, DNA fragmentation, and tumor cell apoptosis.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C150431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150431>	C132247	9p21 Loss of Heterozygosity|9p21 LOH	A molecular abnormality that results in monoallelic loss of function mutations located within 9p21.	9p21 Loss of Heterozygosity		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150432>	C97927	ABL2 Gene Mutation|ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase Gene Mutation|ABLL Gene Mutation|ARG Gene Mutation|Abelson-Related Gene Mutation|v-Abl Abelson Murine Leukemia Viral Oncogene Homolog 2 Gene Mutation	A change in the nucleotide sequence of the ABL2 gene.	ABL2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C150433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150433>	C97927	CD79A Gene Mutation|CD79a Molecule Gene Mutation|CD79a Molecule, Immunoglobulin-Associated Alpha Gene Mutation|IGA Gene Mutation|MB-1 Gene Mutation|MB1 Gene Mutation	A change in the nucleotide sequence of the CD79A gene.	CD79A Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150434>	C178120|C150433	Activating CD79A Gene Mutation|Activating CD79A Mutation|Activating CD79a Molecule Gene Mutation|Activating CD79a Molecule, Immunoglobulin-Associated Alpha Gene Mutation|Activating IGA Gene Mutation|Activating MB-1 Gene Mutation|Activating MB1 Gene Mutation	A change in the nucleotide sequence of the CD79A gene that results in constitutive activation of B-cell antigen receptor complex-associated protein alpha chain and its downstream signaling pathways.	Activating CD79A Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150435>	C178120|C148390	Activating CD79B Gene Mutation|Activating AGM6 Gene Mutation|Activating B29 Gene Mutation|Activating CD79B Mutation|Activating CD79b Antigen Gene Mutation|Activating CD79b Molecule Gene Mutation|Activating IGB Gene Mutation	A change in the nucleotide sequence of the CD79B gene that results in constitutive activation of B-cell antigen receptor complex-associated protein beta chain and its downstream signaling pathways.	Activating CD79B Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150436>	C178120	Activating EML4/ALK Gene Mutation|Activating EML4-ALK Fusion Gene Mutation|Activating EML4-ALK Gene Mutation|Activating EML4-ALK Mutation|Activating EML4/ALK Fusion Gene Mutation|Activating EML4/ALK Mutation	A change in the nucleotide sequence of the ALK portion of the EML4/ALK fusion gene that results in constitutive activation of the EML4/ALK fusion protein and its downstream signaling pathways. These mutations are associated with increased oncogenic potential.	Activating EML4/ALK Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150437>	C141240	NTRK Family Gene Mutation|NTRK Gene Mutation|TRK Family Gene Mutation|TRK Gene Mutation|TRK Receptor Family Gene Mutation|TRK Receptor Gene Mutation	A change in the nucleotide sequence of an NTRK family gene.	NTRK Family Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C150438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150438>	C198558|C176689	Activating NTRK Family Fusion Gene Mutation|Activating NTRK Fusion Gene Mutation|Activating TRK Family Fusion Gene Mutation|Activating TRK Fusion Gene Mutation|Activating TRK Receptor Family Fusion Gene Mutation|Activating TRK Receptor Fusion Gene Mutation	A fusion mutation involving an NTRK family gene that causes the encoded receptor tyrosine kinase and its downstream pathways to be constitutively activated.	Activating NTRK Family Fusion Gene Mutation		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150439>	C62200|C176689	Activating NTRK Family Point Mutation|Activating NTRK Point Mutation|Activating TRK Family Gene Point Mutation|Activating TRK Gene Point Mutation|Activating TRK Receptor Family Gene Point Mutation|Activating TRK Receptor Gene Point Mutation	A point mutation in an NTRK family gene that causes the encoded receptor tyrosine kinase and its downstream pathways to be constitutively activated.	Activating NTRK Family Point Mutation		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15043>	C14421	LG/J Mouse|LG/J		LG/J Mouse		Mammal	
C150440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150440>	C97927	ACVR1B Gene Mutation|ACTRIB Gene Mutation|ACVRLK4 Gene Mutation|ALK4 Gene Mutation|Activin A Receptor, Type IB Gene Mutation|Activin A Receptor, Type II-Like Kinase 4 Gene Mutation|Activin Receptor-Like Kinase 4 Gene Mutation|SKR2 Gene Mutation	A change in the nucleotide sequence of the ACVR1B gene.	ACVR1B Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150441>	C185933|C133155	AKT1 Gene Rearrangement|AKT Gene Rearrangement|PKB Gene Rearrangement|PRKBA Gene Rearrangement|RAC Gene Rearrangement|RAC-ALPHA Gene Rearrangement|RAC-PK-Alpha Gene Rearrangement|v-akt Murine Thymoma Viral Oncogene Homolog 1 Gene Rearrangement	A molecular abnormality indicating rearrangement of the AKT1 gene.	AKT1 Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150442>	C97927|C96865	AKT3 Gene Mutation|AKT Serine/Threonine Kinase 3 Gene Mutation|PKB-GAMMA Gene Mutation|PKBG Gene Mutation|PRKBG Gene Mutation|RAC-Gamma Gene Mutation|RAC-PK-Gamma Gene Mutation|STK-2 Gene Mutation|v-akt Murine Thymoma Viral Oncogene Homolog 3 Gene Mutation	A change in the nucleotide sequence of the AKT3 gene.	AKT3 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150443>	C38184	ALKATI Allele|ALK ATI|ALK Alternative Transcription Initiation Allele|ALK Intron 19 ATI Isoform Gene|ALK(ATI)|ALK-ATI|ALKATI|ALKATI Alteration|Anaplastic Lymphoma Kinase (Ki-1) Alternative Transcription Initiation Gene|Anaplastic Lymphoma Receptor Tyrosine Kinase Alternative Transcription Initiation Gene|CD246 Alternative Transcription Initiation Gene	Human ALKATI allele is located within 2p23 and is approximately 3 kb in length. This allele, which encodes ALKATI protein, plays a role in tumor formation.	ALKATI Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150444>	C17020	ALK Gene Product	A protein encoded by the ALK gene.	ALK Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150445>	C150444	ALKATI Protein|ALK ATI|ALK Alternative Transcription Initiation Protein|ALK Intron 19 ATI Isoform Protein|ALK(ATI)|ALK-ATI|ALKATI|Anaplastic Lymphoma Kinase Alternative Transcription Initiation Protein|Anaplastic Lymphoma Receptor Tyrosine Kinase Alternative Transcription Initiation Protein|CD246 Alternative Transcription Initiation Protein|CD246 Antigen Alternative Transcription Initiation Protein	ALKATI protein (~60 kDa) is encoded by the ALKATI allele of the human ALK gene. This protein is involved in tyrosine phosphorylation, signal transduction and tumorigenesis.	ALKATI Protein		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150446>	C177686	ALKATI Positive|ALK ATI Positive|ALK Alternative Transcription Initiation Positive|ALK Intron 19 ATI Isoform Positive|ALK(ATI) Positive|ALK-ATI Positive|ALKATI Alteration Positive|Anaplastic Lymphoma Kinase Alternative Transcription Initiation Positive|Anaplastic Lymphoma Receptor Tyrosine Kinase Alternative Transcription Initiation Positive|CD246 Alternative Transcription Initiation Positive|CD246 Antigen Alternative Transcription Initiation Positive	An indication that expression of ALKATI has been detected in a sample.	ALKATI Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150447>	C35681	ATM Deficient Tumor|A-T Mutated Deficient Tumor|AT Mutated Deficient Tumor|ATM Serine/Threonine Kinase Deficient Tumor|Ataxia Telangiectasia Mutated Deficient Tumor|Serine-Protein Kinase ATM Deficient Tumor	A finding indicating that the expression of ATM in a tumor sample is aberrantly low or undetectable.	ATM Deficient Tumor		Finding	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150448>	C178119|C128813	BAP1 Loss of Function Gene Mutation|Inactivating BAP1 Gene Mutation|Inactivating BAP1 Mutation|Inactivating BRCA1 Associated Protein 1 Gene Mutation|Inactivating BRCA1-Associated Protein 1 Gene Mutation|Inactivating UCHL2 Gene Mutation	A change in the nucleotide sequence of the BAP1 gene that either inhibits expression or results in the translation of an inactive ubiquitin carboxyl-terminal hydrolase BAP1 protein.	BAP1 Loss of Function Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150449>	C177686	BAP1 Loss of Function Mutation Positive|Inactivating BAP1 Mutation Positive|Inactivating BRCA1 Associated Protein 1 Mutation Positive|Inactivating BRCA1-Associated Protein 1 Mutation Positive|Inactivating UCHL2 Mutation Positive	An indication that expression of BAP1 with a loss of function mutation has been detected in a sample.			Laboratory or Test Result	
C150450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150450>	C35682|C177693	BCL6 Overexpression Positive|B-Cell CLL/Lymphoma 6 Overexpression Positive|B-Cell Lymphoma 6 Overexpression Positive|BCL5 Overexpression Positive|BCL6 Overexpression|LAZ-3 Overexpression Positive|LAZ3 Overexpression Positive|ZBTB27 Overexpression Positive|ZNF51 Overexpression Positive	An indication that overexpression of BCL6 has been detected in a sample.	BCL6 Overexpression Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150451>	C35682	Bence Jones Protein Present|Bence Jones Protein Positive|Bence-Jones Protein Positive|Bence-Jones Protein Present	An indication that Bence Jones protein has been detected in a sample.	Bence Jones Protein Present		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C150452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150452>	C36213	Blasts 20-30 Percent of Peripheral Blood White Cells|Blasts Between 20 and 30 Percent of Peripheral Blood White Cells	A semi-quantitative microscopic finding indicating that between 20 and 30 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.	Blasts 20-30 Percent of Peripheral Blood White Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C150453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150453>	C140330	Blasts 30 Percent or More of Bone Marrow Nucleated Cells|Blasts Greater than or Equal to 30 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that 30 percent or more of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts 30 Percent or More of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C150454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150454>	C41241	Blasts 5 Percent or Less of Peripheral Blood White Cells|Blasts Less than or Equal to 5 Percent of Peripheral Blood White Cells	A semi-quantitative microscopic finding indicating that 5 percent or less of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.	Blasts 5 Percent or Less of Peripheral Blood White Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C150455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150455>	C136411	Blasts 5-19 Percent of Bone Marrow Nucleated Cells|Blasts Between 5 and 19 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that between 5 and 19 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts 5-19 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C150456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150456>	C35880	Blasts Less than or Equal to 10000/mm3|Blasts Less than or Equal to 10,000 per Cubic Millimeter|Blasts Less than or Equal to 10,000/mm3|Blasts Less than or Equal to 10000 per Cubic Millimeter|Blasts Less than or Equal to 10000 per Cubic mm|Blasts Less than or Equal to 10000 per Microliter|Blasts Less than or Equal to 10000 per uL|Blasts Less than or Equal to 10000/Cubic mm|Blasts Less than or Equal to 10000/uL	A quantitative microscopic finding indicating that immature mononuclear cells are found at less than or equal to 10000 per cubic millimeter field in a sample.	Blasts Less than or Equal to 10000/mm3		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C150457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150457>	C136648	Blasts More than 10 Percent of Bone Marrow Nucleated Cells|Blasts Greater than 10 Percent of Bone Marrow Nucleated Cells|Blasts Over 10 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that more than 10 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts More than 10 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C150458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150458>	C138056	Blasts More than 10 Percent of Peripheral Blood White Cells|Blasts Greater than 10 Percent of Peripheral Blood White Cells|Blasts Over 10 Percent of Peripheral Blood White Cells	A semi-quantitative microscopic finding indicating that more than 10 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.	Blasts More than 10 Percent of Peripheral Blood White Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C150459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150459>	C35881	Blasts More than 10000 of Peripheral Blood White Cells|Absolute Blasts in Peripheral Blood Greater than 10,000|Absolute Blasts in Peripheral Blood Greater than 10000|Absolute Blasts in Peripheral Blood More than 10,000|Absolute Blasts in Peripheral Blood More than 10000|Blasts Greater than 10,000 in Peripheral Blood White Cells|Blasts Greater than 10000 in Peripheral Blood White Cells|Blasts More than 10,000 in Peripheral Blood White Cells	A quantitative microscopic finding indicating that more than 10000 of the total number of nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.	Blasts More than 10000 of Peripheral Blood White Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C150460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150460>	C36214	Blasts More than 20 Percent of Bone Marrow Nucleated Cells|Blasts Greater than 20 Percent of Bone Marrow Nucleated Cells|Blasts Over 20 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that more than 20 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts More than 20 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C150461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150461>	C36213	Blasts More than 20 Percent of Peripheral Blood White Cells|Blasts Greater than 20 Percent of Peripheral Blood White Cells|Blasts Over 20 Percent of Peripheral Blood White Cells	A semi-quantitative microscopic finding indicating that more than 20 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.	Blasts More than 20 Percent of Peripheral Blood White Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C150462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150462>	C163007	Blasts More than 60 Percent of Peripheral Blood White Cells|Blasts Greater than 60 Percent of Peripheral Blood White Cells|Blasts Over 60 Percent of Peripheral Blood White Cells	A semi-quantitative microscopic finding indicating that more than 60 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.	Blasts More than 60 Percent of Peripheral Blood White Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C150463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150463>	C28227|C129822|C128037|C128036	Vudalimab|Anti-PD-1/Anti-CTLA-4 XmAb20717|Anti-PD1/CTLA4 Bispecific Antibody XmAb20717|PD-1 x CTLA-4 Bispecific Antibody XmAb20717|PD-1 x CTLA-4 Dual Checkpoint Inhibitor XmAb20717|VUDALIMAB|XmAb 20717|XmAb20717	A Fc-engineered bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, vudalimab targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T-lymphocytes (TILs) and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD1 and CTLA4 with XmAb20717 may enhance T cell activation and proliferation more than the blockade of either immune checkpoint receptor alone. The engineered Fc domain increases the stability and half-life of the antibody.	Vudalimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150464>	C181911	CCND1 Splice Variant Positive|BCL-1 Splice Variant Positive|BCL1 Splice Variant Positive|CCND1 Splice Variant|CCND1 Splice Variant Present|Cyclin D1 Splice Variant Positive|Cyclin-D1 Splice Variant Positive|PRAD1 Splice Variant Positive	An indication that expression of a splice variant of CCND1 has been detected in a sample.	CCND1 Splice Variant Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150465>	C177692	CD28 Positive|Antigen CD28 Positive|CD28 Antigen Positive|CD28 Molecule Positive|T-Cell Antigen CD28 Positive|T-Cell Specific Surface Glycoprotein CD28 Positive|T44 Positive|T90/44 Positive|Tp44 Positive	An indication that expression of CD28 has been detected in a sample.	CD28 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150466>	C165233	CD34 Negative|Antigen CD34 Negative|CD34 Antigen Negative|CD34 Molecule Negative|HPCA1 Negative|Hematopoietic Progenitor Cell Antigen CD34 Negative	An indication that expression of CD34 has not been detected in a sample.	CD34 Negative		Laboratory or Test Result	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150467>	C216199	Lutetium Lu-177 PSMA-R2|177Lu-PSMA-R2|177LuPSMA-R2|LUTETIUM LU-177 PSMA-R2|Lu177-PSMA-R2|Lutetium-177 PSMA-R2	A radioconjugate composed of PSMA-R2, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of 177Lu-PSMA-R2, the PSMA-R2 moiety targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on the majority of prostate tumor cells.	Lutetium Lu-177 PSMA-R2		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150468>	C177692	SPN Positive|Antigen CD43 Positive|CD43 Antigen Positive|CD43 Positive|CD43 Positive|GALGP Positive|LSN Positive|Leukocyte Large Sialoglycoprotein Positive|Leukocyte Sialoglycoprotein Positive|Leukosialin Positive|SPN-Positive|Sialophorin Positive|gpL115 Positive	An indication that expression of SPN has been detected in a sample.	SPN Positive		Laboratory or Test Result	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150469>	C177692	CD7 Positive|Antigen CD7 Positive|CD7 Antigen Positive|CD7 Molecule Positive|GP40 Positive|LEU9 Positive|Leu-9 Positive|T-Cell Antigen CD7 Positive|T-Cell Leukemia Antigen Positive|TP40 Positive|TP41 Positive	An indication that expression of CD7 has been detected in a sample.	CD7 Positive		Laboratory or Test Result	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150470>	C69408	HLA-A*02:642 Positive Cells Present|HLA-A*02:642 Positive|HLA-A*02:642 Positive Cells	A laboratory test result indicating the presence of HLA-A*02:642 positive cells in a tissue sample.	HLA-A*02:642 Positive Cells Present		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150471>	C1752|C1663	Personalized Synthetic Long Peptide Vaccine|Personalized SLP Vaccine|TSMA-based SLP Vaccine|TSMA-based Synthetic Long Peptide Vaccine|Tumor Specific Mutant Antigen-based Synthetic Long Peptide Vaccine	A personalized peptide vaccine consisting of synthetic long peptides (SLPs), ranging from 20-35 amino acids in size, that are derived from two or more of the patient's tumor-specific mutant antigens (TSMAs), with potential immunostimulatory and antitumor activities. A patient's tumor is isolated, TSMAs are identified, assessed and prioritized, and two or more TSMAs are selected to be further processed into SLPs. Upon administration, personalized SLP vaccine may stimulate the host immune system to mount a cytotoxic T-cell lymphocyte (CTL)-mediated immune response against the TSMAs expressed by the tumor cells.	Personalized Synthetic Long Peptide Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150472>	C94299|C177692	CD86 Positive|Activation B7-2 Antigen Positive|Antigen CD86 Positive|B-Lymphocyte Activation Antigen B7-2 Positive|B-Lymphocyte Antigen B7-2 Positive|B7-2 Positive|B7.2 Positive|CD28LG2 Positive|CD86 Antigen Positive|CD86 Molecule Positive|CTLA-4 Counter-Receptor B7.2 Positive|FUN-1 Positive|LAB7-2 Positive|LAB72 Positive|T-Lymphocyte Activation Antigen CD86 Positive	An indication that expression of CD86 has been detected in a sample.	CD86 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150473>	C97927	CDH1 Gene Mutation|Arc-1 Gene Mutation|CD324 Gene Mutation|CDHE Gene Mutation|Cadherin 1 Gene Mutation|Cadherin 1, Type 1, E-Cadherin (Epithelial) Gene Mutation|Cadherin, Epithelial Gene Mutation|Calcium-Dependent Adhesion Protein, Epithelial Gene Mutation|E-Cadherin Gene Mutation|ECAD Gene Mutation|LCAM Gene Mutation|Positive|UVO Gene Mutation	A change in the nucleotide sequence of the CDH1 gene.	CDH1 Gene Mutation		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150474>	C97927|C157553	CDK4 Gene Mutation|CDK4 mutation|Cell Division Kinase 4 Gene Mutation|Cyclin Dependent Kinase 4 Gene Mutation	A change in the nucleotide sequence of the CDK4 gene.	CDK4 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150475>	C97927	CDKN1A Gene Mutation|CDKN1 Gene Mutation|CIP1 Gene Mutation|Cyclin Dependent Kinase Inhibitor 1A Gene Mutation|MDA-6 Gene Mutation|MDA6 Gene Mutation|P21 Gene Mutation|PIC1 Gene Mutation|SDI1 Gene Mutation|WAF1 Gene Mutation|p21CIP1 Gene Mutation	A change in the nucleotide sequence of the CDKN1A gene.	CDKN1A Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150476>	C97927	CDKN1B Gene Mutation|CDKN4 Gene Mutation|Cyclin Dependent Kinase Inhibitor 1B Gene Mutation|KIP1 Gene Mutation|p27Kip1 Gene Mutation	A change in the nucleotide sequence of the CDKN1B gene.	CDKN1B Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150477>	C97927	CHD4 Gene Mutation|CHD-4 Gene Mutation|Chromodomain Helicase DNA Binding Protein 4 Gene Mutation|Mi-2b Gene Mutation|Mi2-BETA Gene Mutation	A change in the nucleotide sequence of the CHD4 gene.	CHD4 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150478>	C36541|C159452	Chromosome 5 Rearrangement|Rearrangement of Chromosome 5	A rearrangement of genomic material involving chromosome 5.	Chromosome 5 Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150479>	C36541|C159455	Chromosome 7 Rearrangement|Rearrangement of Chromosome 7	A rearrangement of genomic material involving chromosome 7.	Chromosome 7 Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150480>	C121659	Salty|Saltiness|Salty Taste	Tasting of or like salt.			Conceptual Entity	
C150481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150481>	C121659	Bitter|Bitter Taste|Bitterness	Having a sharp, pungent taste.			Conceptual Entity	
C150482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150482>	C121659	Sour|Sour Taste|Sourness	Having a sharp, acidic taste.			Conceptual Entity	
C150483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150483>	C28676|C201545	Cord Blood-derived Expanded Allogeneic Natural Killer Cells|Allogeneic CB-derived Ex vivo-expanded NK Cells|CB-derived Expanded Allogeneic NK Cells|UCB-derived Expanded Allogeneic NK Cells|Umbilical Cord Blood-derived Expanded Allogeneic Natural Killer Cells	A preparation of human umbilical cord blood (UCB)-derived and ex vivo-expanded allogeneic natural killer (NK) cells, with immunomodulating and cytotoxic activities. Upon infusion of the cord blood-derived expanded allogeneic NK cells, these cells recognize and bind to tumor cells, and secrete perforins, granzymes, and cytokines, which cause cancer cell lysis.	Cord Blood-derived Expanded Allogeneic Natural Killer Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150484>	C121659	Umami|Savoriness|Savory Taste|Umami Taste	Having a meaty, broth-like taste.			Conceptual Entity	
C150485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150485>	C94299|C177692	EGFRvIII Positive|EGFR Variant III Positive|Epidermal Growth Factor Receptor Class III Variant Positive|Epidermal Growth Factor Receptor Variant III Positive|Epidermal Growth Factor Receptor vIII Positive	An indication that expression of EGFRvIII has been detected in a sample.	EGFRvIII Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150486>	C19821	High CpG Island Methylator Phenotype|CIMP High|CIMP-High|CIMP-High Phenotype Positive|CIMP-High Phenotype Present	A phenotype characterized by hypermethylation of a high number of promoter-associated CpG islands.	High CpG Island Methylator Phenotype		Clinical Attribute	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C150487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150487>	C35682	Clostridium difficile Toxin Positive|C. diff. Toxin Positive|C. difficile Toxin Positive	An indication that Clostridium difficile toxin was detected in a sample.	Clostridium difficile Toxin Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C150489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150489>	C190402	Severe Mosquito Bite Allergy	An EBV-positive NK-cell lymphoproliferative disorder characterized by high fever and intense local skin symptoms, including erythema, bullae, ulcers, skin necrosis, and deep scarring following mosquito bites. Patients have NK-cell lymphocytosis in the peripheral blood and an increased risk of developing hemophagocytic syndrome and progressing into overt NK/T-cell lymphoma or aggressive NK-cell leukemia in the longstanding clinical course. (WHO 2017)	Severe Mosquito Bite Allergy		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C150490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150490>	C177692	COX2 Positive|COX-2 Positive|Cyclo-Oxygenase-2 Positive|Cyclooxygenase 2 Positive|Cyclooxygenase-2 Positive|PTGS2 Positive|Prostaglandin G/H Synthase 2 Positive|Prostaglandin-Endoperoxide Synthase 2 Positive	An indication that COX2 expression has been detected in a sample.	COX2 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150491>	C97927	CRLF2 Gene Mutation|CRLF2 Mutation|Cytokine Receptor Crl2 Gene Mutation|Cytokine Receptor Like Factor 2 Gene Mutation|Cytokine Receptor-Like Factor 2 Gene Mutation|TSLPR Gene Mutation|Thymic Stromal-Derived Lymphopoietin Receptor Gene Mutation	A change in the nucleotide sequence of the CRLF2 gene.	CRLF2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150492>	C26683	CRP Level Greater than or Equal to 3 mg/L|C-Reactive Protein Level Greater than or Equal to 3 Milligrams per Liter|C-Reactive Protein Level Greater than or Equal to 3 Milligrams/Liter|CRP Level Greater than or Equal to 3|CRP Level Greater than or Equal to 3 Milligrams per Liter|CRP Level Greater than or Equal to 3 Milligrams/Liter|CRP Level Greater than or Equal to Three	A laboratory test result indicating that C-reactive protein is present in a sample at concentrations of 3 mg/L or more.	CRP Level Greater than or Equal to 3 mg/L		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150493>	C97927	CXCR4 Gene Mutation|C-X-C Chemokine Receptor Type 4 Gene Mutation|CD184 Gene Mutation|CXC-R4 Gene Mutation|CXCR-4 Gene Mutation|Chemokine (C-X-C Motif) Receptor 4 Gene Mutation|LAP3 Gene Mutation	A change in the nucleotide sequence of the CXCR4 gene.	CXCR4 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150494>	C97927	CYLD Gene Mutation|CDMT Gene Mutation|CYLD Lysine 63 Deubiquitinase Gene Mutation|CYLD1 Gene Mutation|CYLDI Gene Mutation|Cylindromatosis (Turban Tumor Syndrome) Gene Mutation|EAC Gene Mutation|USPL2 Gene Mutation|Ubiquitin Specific Peptidase Like 2 Gene Mutation	A change in the nucleotide sequence of the CYLD gene.	CYLD Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150495>	C3468|C213746|C178547	Intestinal T-Cell Lymphoma	A mature T-cell and NK-cell non-Hodgkin lymphoma that arises from the small or large intestine. This group includes enteropathy-associated T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, and intestinal T-cell lymphoma, not otherwise specified. Most of these lymphomas arise from the small intestine and a minority from the large intestine or stomach.	Intestinal T-Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Morphology PT Terminology|Mapped ICDO3.1 Morphology Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C150496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150496>	C93102|C79425	Deleterious IKZF1 Gene Mutation|Deleterious IK1 Gene Mutation|Deleterious IKAROS Family Zinc Finger 1 Gene Mutation|Deleterious IKAROS Gene Mutation|Deleterious LYF1 Gene Mutation|Deleterious LyF-1 Gene Mutation|Deleterious ZNFN1A1 Gene Mutation|Deleterious hIk-1 Gene Mutation	A change in the nucleotide sequence of the IKZF1 gene that is associated with increased risk of disease.	Deleterious IKZF1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150497>	C97927	DNMT3A Gene Mutation|DNA Methyltransferase 3 Alpha Gene Mutation|DNA Methyltransferase 3A Gene Mutation	A change in the nucleotide sequence of the DNMT3A gene.	DNMT3A Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150498>	C165233	DPYD Negative|DHP Negative|DHPDHASE Negative|DPD Negative|Dihydropyrimidine Dehydrogenase Negative	An indication that expression of DPYD has not been detected in a sample.	DPYD Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150499>	C35682|C175007	Epstein-Barr Virus Antibody Positive|Anti-EBV Antibody Positive|EBV Antibody Positive|Epstein Barr Virus Antibody Positive|HHV-4 Antibody Positive|HHV4 Antibody Positive|Human Herpesvirus 4 Antibody Positive|Human Herpesvirus-4 Antibody Positive	An indication that antibodies that recognize the Epstein-Barr virus have been detected in a sample.	Epstein-Barr Virus Antibody Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C15049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15049>	C14421	PL/J Mouse|PL/J		PL/J Mouse		Mammal	
C1504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1504>	C530	Recombinant Epidermal Growth Factor	A recombinant therapeutic agent which is chemically identical to or similar to endogenous epidermal growth factor (EGF).  As a mitogen, EGF stimulates the proliferation of epidermal, epithelial, and embryonic cells.  This agent is also a strong chemoattractant for fibroblasts and epithelial cells and is an important factor mediating angiogenesis and wound healing.  EGF and EGF-like factors have been shown to promote regeneration of the epidermis and the generation of granulation tissues following severe burns and, when locally administered, may improve healing of injured corneal tissues. (NCI04)			Chemical Viewed Functionally	
C150500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150500>	C98357|C93102	Deleterious EGFR Gene Mutation|Deleterious EGFR Mutation|Deleterious ERBB Gene Mutation|Deleterious ERBB1 Gene Mutation|Deleterious Epidermal Growth Factor Receptor Gene Mutation|Deleterious HER1 Gene Mutation|EGFR Driver Mutation	A change in the nucleotide sequence of the EGFR gene that is associated with increased risk of disease.	Deleterious EGFR Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C150501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150501>	C94299|C165233	EGFR Negative|ERBB Negative|ERBB1 Negative|Epidermal Growth Factor Receptor Negative|HER1 Negative|c-erbB1 Negative	An indication that EGFR expression has not been detected in a sample.	EGFR Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150502>	C97927	EP300 Gene Mutation|E1A Binding Protein p300 Gene Mutation|KAT3B Gene Mutation|p300 Gene Mutation	A change in the nucleotide sequence of the EP300 gene.	EP300 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150503>	C141465	Estrogen Receptor Positive by Immunohistochemistry 1-9 Percent|ER Positive by Immunohistochemistry 1-9 Percent|ESR1 Positive by Immunohistochemistry 1-9 Percent	An immunohistochemical staining finding indicating that between 1 and 9 percent of the cells in a tissue sample are expressing estrogen receptor.	Estrogen Receptor Positive by Immunohistochemistry 1-9 Percent		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150504>	C96058|C96054	Small Intestinal Monomorphic Epitheliotropic T-Cell Lymphoma	A monomorphic epitheliotropic intestinal T-cell lymphoma that arises from the small intestine and is characterized by the presence of a monomorphic cellular infiltrate of small to medium-sized T-lymphocytes that are cytotoxic and express CD56. It is not associated with celiac disease.	Small Intestinal Monomorphic Epitheliotropic T-Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150505>	C150495	Intestinal T-Cell Lymphoma, Not Otherwise Specified|Intestinal T-Cell Lymphoma, NOS|Intestinal T-Cell Lymphoma, NOS	A T-cell lymphoma that arises from the small or large intestine and infrequently other sites in the gastrointestinal tract and is characterized by the absence of the morphologic characteristics of either classic enteropathy-associated T-cell lymphoma or monomorphic epitheliotropic intestinal T-cell lymphoma.	Intestinal T-Cell Lymphoma, Not Otherwise Specified		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150507>	C129839	SMAC Mimetic BI 891065|BI 891065|PROPANAMIDE, N-(5-(2-(2-METHOXY-3-PYRIDINYL)-7-METHYLIMIDAZO(1,2-A)PYRIDIN-3-YL)-6-(2-(1-METHYL-6-ISOQUINOLINYL)ETHYNYL)-2-PYRIDINYL)-2-(METHYLAMINO)-, (2S)-	A mimetic of second mitochondrial-derived activator of caspases (Smac/DIABLO) and inhibitor of IAPs (Inhibitor of Apoptosis Proteins), with potential antineoplastic activity. Upon administration, Smac mimetic BI 891065 targets and binds to the Smac binding groove on IAPs, including the caspase inhibitor X chromosome-linked IAP (XIAP) and the cellular IAPs 1 and 2. This inhibits the activities of these IAPs and promotes the induction of apoptosis through apoptotic signaling pathways. IAPs are overexpressed by many cancer cell types and suppress apoptosis by binding to and inhibiting certain caspases.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150508>	C275	Polymer-encapsulated Luteolin Nanoparticle|3',4',5,7-Tetrahydroxyflavone-encapsulated Polymer Nanoparticles|Nano-luteolin|Nanoluteolin|Nanoparticle-based Luteolin	A nanoparticle formulation containing the poorly water-soluble naturally-occurring flavonoid luteolin encapsulated within a water-soluble polymer, with potential anti-oxidant, anti-inflammatory, apoptosis-inducing and chemopreventive activities. Upon administration of the polymer-encapsulated luteolin nanoparticle, luteolin scavenges free radicals, protects cells from reactive oxygen species (ROS)-induced damage and induces direct tumor cell cycle arrest and apoptosis in tumor cells. This inhibits tumor cell proliferation and suppresses metastasis. Compared to luteolin alone, encapsulation increases the delivery of luteolin to the tumor cells by protecting the drug against clearance and degradation, increases blood circulation time and enhances delivery into the tumor through the leaky vasculature.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150509>	C200766|C176023	Autologous BCMA/TACI-targeted CAR T Cells AUTO2|APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI|APRIL CAR T Cells Targeting BCMA and TACI|AUTO 2|AUTO2|Autologous APRIL CAR T Cells|Autologous CAR T Product AUTO2|SUB-96123	A preparation of autologous T-lymphocytes that are genetically engineered to contain a dual-targeted chimeric antigen receptor (CAR), which includes the natural protein a proliferation-inducing ligand (APRIL; TNFSF13), that targets the tumor-associated antigens (TAAs) B-cell maturation antigen (BCMA; TNFRSF17) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI; TNFRSF13B), with potential immunomodulating and antineoplastic activities. Upon administration, the autologous BCMA/TACI-targeted CAR T-cells AUTO2 bind to BCMA and TACI expressed on tumor cells and induce selective cytotoxicity in those cells. In addition, AUTO2 carries the universal RQR8 safety "off" switch, which allows selective removal of the T-cells through both complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) following administration of rituximab if unacceptable side-effects occur.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology
C150510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150510>	C8696|C3183|C136488	Refractory T Acute Lymphoblastic Leukemia|Refractory T-Acute Lymphoblastic Leukemia	A T acute lymphoblastic leukemia that does not respond to treatment.	Refractory T Acute Lymphoblastic Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150511>	C28676|C138180|C129826	Allogeneic T-lymphocytes Expressing NY-ESO-1-C259-specific TCR|Allogeneic NY-ESO-1-C259 T-cells|NY-ESO-1 c259 T Cells	Genetically engineered human allogeneic T-lymphocytes that are transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the cancer/testis antigen NY-ESO-1, with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo and introduction into the patient, the allogeneic T-lymphocytes expressing NY-ESO-1-C259-specific TCR specifically target and bind to NY-ESO-1-overexpressing tumor cells. This may result in the specific cytotoxic T-lymphocyte (CTL) killing of NY-ESO-1-positive cancer cells. NY-ESO-1, a tumor-associated antigen (TAA), is expressed in normal testis and on the surface of various tumor cell types.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150512>	C6166|C27819|C126109	Metastatic Urethral Urothelial Carcinoma|Metastatic Urethral Urothelial Cancer	A urethral urothelial carcinoma that has spread to another anatomical site.	Metastatic Urethral Urothelial Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150513>	C39851|C156062|C126109	Metastatic Bladder Urothelial Carcinoma|Metastatic Bladder Urothelial Cancer	A bladder urothelial carcinoma that has spread to another anatomical site.	Metastatic Bladder Urothelial Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150514>	C8064|C7355|C163965	Metastatic Renal Pelvis Urothelial Carcinoma|Metastatic Renal Pelvis Urothelial Cancer	A renal pelvis urothelial carcinoma that has spread to another anatomical site.	Metastatic Renal Pelvis Urothelial Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150515>	C8064|C4830|C27818	Metastatic Ureter Urothelial Carcinoma|Metastatic Ureter Urothelial Cancer	A ureter urothelial carcinoma that has spread to another anatomical site.	Metastatic Ureter Urothelial Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150516>	C9255|C8254|C4830	Recurrent Ureter Urothelial Carcinoma|Recurrent Ureter Urothelial Cancer	The reemergence of ureter urothelial carcinoma after a period of remission.	Recurrent Ureter Urothelial Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150517>	C49146|C204256|C1663	Ad5 [E1-, E2b-]-HER2/Neu Vaccine ETBX-021|Ad5 [E1-, E2b-]-HER2/neu Vaccine|Adenovirus Type 5 E1/E2b-deleted HER2/neu Vaccine ETBX-021|ETBX-021|ETBX-021	A cancer vaccine composed of a genetically engineered, replication-defective oncolytic adenovirus serotype 5 (Ad5) vector, in which the E1, E2b and E3 genes are deleted, that encodes a modified version of the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (HER2/neu; ErbB-2; ERBB2), with potential antineoplastic activity. Upon administration of Ad5 [E1-, E2b-]-HER2/neu ETBX-021, the vector expresses HER2/neu and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing the HER2/neu antigen. This results in the immune-mediated induction of death in and inhibition of proliferation of HER2/neu-expressing tumor cells. HER2/neu, a member of the epidermal growth factor receptor (EGFR) family of tyrosine kinases, is overexpressed in various tumor cell types while expression is restricted and minimal in certain normal healthy cells. It plays a key role in cancer cell proliferation and survival. The gene deletions in Ad5 may circumvent pre-existing anti-adenovirus immunity, allow HER2 gene insertion and expression and induce a strong immune response.			Immunologic Factor|Pharmacologic Substance|Virus	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C150518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150518>	C201175|C200766	Autologous Anti-EGFRvIII 4SCAR-IgT Cells|Anti-PD-1/PD-L1-Antibodies-expressing Autologous GBM-specific CAR-T Cells|Autologous Anti-PD-1/Anti-PD-L1 Antibodies-expressing Anti-EGFRvIII CAR T Cells|Autologous EGFRvIII-4SCAR-IgT|EGFRvIII-4SCAR-IgT Cells-producing PD1 and PD-L1 Antibodies|PD-1/PD-L1 Antibody-producing T cells (IgT)	A preparation of autologous T-cells that are genetically modified to express immunoglobulins (Igs) that target the negative immunoregulatory human cell surface receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and programmed death-ligand 1 (PD-L1; CD274) and are transduced with a replication incompetent, self-inactivating lentiviral vector expressing a fourth generation chimeric antigen receptor (4SCAR) consisting of a single chain variable fragment (scFv) targeting anti-epidermal growth factor receptor variant III (EGFRvIII) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (TCR), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-EGFRvIII 4SCAR-IgT cells are directed to and induce selective toxicity in EGFRvIII-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. EGFRvIII, a tumor-associated antigen (TAA) encoded by an in-frame deletion of exons 2-7 in the EGFR gene, is overexpressed by a variety of cancer cell types and is not expressed by normal, healthy cells. It plays a key role in tumor cell proliferation, tumor angiogenesis and resistance to both radio- and chemotherapy. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity. The anti-PD-1 and anti-PD-L1 antibodies produced by the T-cells (IgT) bind to PD-1, expressed on T-cells, and its ligand PD-L1 expressed on cancer cells, respectively. This inhibits PD-1/PD-L1-mediated signaling, prevents T-cell inhibition and exhaustion, enhances T-cell activation within the tumor microenvironment (TME) and results in an enhanced T-cell-mediated immune response against and toxicity in the EGFRvIII-expressing tumor cells.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150519>	C8254|C7355|C172622	Recurrent Renal Pelvis Urothelial Carcinoma|Recurrent Renal Pelvis Urothelial Cancer	The reemergence of renal pelvis urothelial carcinoma after a period of remission.	Recurrent Renal Pelvis Urothelial Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150520>	C36327	DNA Damage Response Gene Mutation|DDR Gene Alteration|DDR Gene Mutation|DNA Damage Response Gene Alteration|DNA Damage Response Gene Alteration	Any change in the nucleotide sequence of a gene involved in DNA damage response pathways.	DNA Damage Response Gene Alteration		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150521>	C4030|C224632|C129827	Unresectable Urothelial Carcinoma	Urothelial carcinoma that is not amenable to surgical resection.	Unresectable Urothelial Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150522>	C66897|C116437	Proton Beam Craniospinal Irradiation|Craniospinal Proton Beam Radiation Therapy|Proton Craniospinal Irradiation|Proton Craniospinal Radiation Therapy|p-CSI	The use of proton beam radiation therapy to treat central nervous system malignancies of the cerebrospinal space.	Proton Beam Craniospinal Irradiation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C150523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150523>	C116518	Physical Performance Testing|Physical Fitness Testing|Physical Function Testing	Any of various activities and tests designed to assess an individual's physical fitness.	Physical Performance Testing		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C150524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150524>	C4813|C4016	Recurrent Malignant Bone Neoplasm	The reemergence of a malignant bone neoplasm after a period of remission.	Recurrent Malignant Bone Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150525>	C4016|C120186	Refractory Malignant Bone Neoplasm	Malignant bone neoplasm that is resistant to treatment.	Refractory Malignant Bone Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150526>	C4913|C177724	Recurrent Malignant Female Reproductive System Neoplasm	The reemergence of a malignant female reproductive system neoplasm after a period of remission.	Recurrent Malignant Female Reproductive System Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150527>	C4913|C120186	Refractory Malignant Female Reproductive System Neoplasm	Malignant female reproductive system neoplasm that is resistant to treatment.	Refractory Malignant Female Reproductive System Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150528>	C131500	Recurrent Malignant Neoplasm of Multiple Primary Sites	Reemergence of a malignant neoplasm of multiple primary sites after a period of remission.	Recurrent Malignant Neoplasm of Multiple Primary Sites		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150529>	C120186	Refractory Malignant Neoplasm of Multiple Primary Sites	Malignant neoplasm of multiple primary sites that is resistant to treatment.	Refractory Malignant Neoplasm of Multiple Primary Sites		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150530>	C9316|C152078	Refractory Malignant Oral Neoplasm|Refractory Malignant Lip and Oral Cavity Neoplasm	Lip or oral cavity malignant neoplasm that is resistant to treatment.	Refractory Malignant Oral Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150531>	C7545|C152077	Recurrent Malignant Pharyngeal Neoplasm	Reemergence of a malignant pharyngeal neoplasm after a period of remission.	Recurrent Malignant Pharyngeal Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150532>	C7545|C152078	Refractory Malignant Pharyngeal Neoplasm|Refractory Malignant Pharyngeal Throat Neoplasm	Malignant pharyngeal neoplasm that is resistant to treatment.	Refractory Malignant Pharyngeal Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150533>	C8561|C177724	Recurrent Malignant Male Reproductive System Neoplasm	The reemergence of a malignant male reproductive system neoplasm after a period of remission.	Recurrent Malignant Male Reproductive System Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150534>	C8561|C120186	Refractory Malignant Male Reproductive System Neoplasm	Malignant male reproductive system neoplasm that is resistant to treatment.	Refractory Malignant Male Reproductive System Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150535>	C4456|C120186	Refractory Malignant Mesothelioma	Malignant mesothelioma that is resistant to treatment.	Refractory Malignant Mesothelioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150536>	C4867|C4813	Recurrent Malignant Soft Tissue Neoplasm	Reemergence of a malignant soft tissue neoplasm after a period of remission.	Recurrent Malignant Soft Tissue Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150537>	C4867|C120186	Refractory Malignant Soft Tissue Neoplasm	Malignant soft tissue neoplasm that is resistant to treatment.	Refractory Malignant Soft Tissue Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150538>	C7510|C152077	Recurrent Malignant Thyroid Gland Neoplasm	The reemergence of malignant thyroid gland neoplasm after a period of remission.	Recurrent Malignant Thyroid Gland Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150539>	C7510|C152078	Refractory Malignant Thyroid Gland Neoplasm	Malignant thyroid gland neoplasm that is resistant to treatment.	Refractory Malignant Thyroid Gland Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150540>	C7619|C215715	Recurrent Endocrine Carcinoma|Recurrent Malignant Endocrine Neoplasm	The reemergence of endocrine carcinoma after a period of remission.	Recurrent Endocrine Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150541>	C8511|C215715	Refractory Endocrine Carcinoma|Refractory Malignant Endocrine Neoplasm	An endocrine carcinoma that is resistant to treatment.	Refractory Endocrine Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150542>	C9297|C177724	Recurrent Malignant Urinary System Neoplasm	Reemergence of a malignant urinary system neoplasm after a period of remission.	Recurrent Malignant Urinary System Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150543>	C9297|C120186	Refractory Malignant Urinary System Neoplasm	Malignant urinary system neoplasm that is resistant to treatment.	Refractory Malignant Urinary System Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150544>	C3510|C150546|C147983	Refractory Cutaneous Melanoma|Refractory Cutaneous (Skin) Melanoma|Refractory Melanoma of the Skin	A melanoma of the skin that is resistant to treatment.	Refractory Melanoma of the Skin		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150545>	C4813|C2920	Recurrent Malignant Skin Neoplasm	Reemergence of a malignant skin neoplasm after a period of remission.	Recurrent Malignant Skin Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150546>	C2920|C120186	Refractory Malignant Skin Neoplasm	Malignant skin neoplasm that is resistant to treatment.	Refractory Malignant Skin Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150547>	C54179	Ann Arbor Stage IE	An Ann Arbor classification lymphoma stage term that refers to the involvement of a single extranodal organ or site in the absence of any lymph node involvement.			Classification	
C150548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150548>	C54179	Ann Arbor Stage IIE	An Ann Arbor classification lymphoma stage term that refers to the involvement of a single extranodal organ or site plus its regional lymph nodes with or without other lymph nodes involvement on the same side of the diaphragm.			Classification	
C150549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150549>	C54179	Ann Arbor Stage IIIE	An Ann Arbor classification lymphoma stage term that refers to extralymphatic organ or site involvement plus involvement of lymph nodes on both sides of the diaphragm.			Classification	
C150550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150550>	C54179	Ann Arbor Stage IIIS	An Ann Arbor classification lymphoma stage term that refers to the involvement of lymph nodes on both sides of the diaphragm plus involvement of the spleen.			Classification	
C150551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150551>	C54179	Ann Arbor Stage IIIE and IIIS	An Ann Arbor classification lymphoma stage term that refers to extralymphatic organ or site involvement plus involvement of lymph nodes on both sides of the diaphragm or involvement of lymph nodes on both sides of the diaphragm plus involvement of the spleen.			Classification	
C150553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150553>	C28676	Allogeneic Most Closely HLA-matched Adenovirus-specific Cytotoxic T Lymphocytes|Most Closely HLA Matched Third-Party Donor Adenovirus Specific CTLs|Most Closely HLA Matched Third-Party Donor Adenovirus Specific T Cells	A population of off the shelf, closely human leukocyte antigen (HLA)-matched allogeneic, ex vivo-expanded cytotoxic T-lymphocytes (CTLs) specifically reactive to human adenovirus (Ad), with potential immunomodulating and anti-adenoviral activities. Upon administration, the allogeneic most closely HLA-matched Ad-specific CTLs may reconstitute Ad-specific CTL responses in patients at risk of developing Ad infections either following allogeneic stem cell transplantation or in Ad-infected immunocompromised hosts. The anti-adenoviral CTLs are provided by a third party donor and not by the allogeneic stem cell transplant donor.	Allogeneic Most Closely HLA-matched Adenovirus-specific Cytotoxic T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C150554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150554>	C177692	F3 Positive|CD142 Antigen Positive|CD142 Positive|Coagulation Factor III Positive|Factor III Positive|TF Positive|Tissue Factor Positive	An indication that expression of F3 has been detected in a sample.	F3 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150555>	C28193	Schuurs-Hoeijmakers Syndrome	An autosomal dominant condition caused by mutation(s) in the PACS1 gene, encoding phosphofurin acidic cluster sorting protein 1. It is characterized by intellectual developmental delay, craniofacial abnormalities, as well as other variable congenital abnormalities.	Schuurs-Hoeijmakers Syndrome		Disease or Syndrome	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology
C150556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150556>	C129733	Autosomal Recessive Osteopetrosis 8|OPTB8	A sub-type of autosomal recessive osteopetrosis caused by mutation(s) in the SNX10 gene, encoding sorting nexin-10.	Autosomal Recessive Osteopetrosis 8		Congenital Abnormality	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology
C150557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150557>	C2919	Prostate Adenocarcinoma without Neuroendocrine Differentiation|Prostate Adenocarcinoma without Evidence of Neuroendocrine Differentiation|Prostate Adenocarcinoma without Evidence of Neuroendocrine Differentiation	A prostate adenocarcinoma characterized by the absence of focal or diffuse neuroendocrine differentiation.	Prostate Adenocarcinoma Without Evidence of Neuroendocrine Differentiation		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150558>	C133877	Anti-CD40 Agonist Monoclonal Antibody CDX-1140|Agonist CD40 Antibody CDX-1140|Anti-CD40 Agonistic Monoclonal Antibody CDX-1140|CDX 1140|CDX-1140|CDX-1140	A fully human immunoglobulin G2 (IgG2) agonistic monoclonal antibody targeting the B-cell surface antigen CD40, with potential immunostimulatory and antineoplastic activities. Upon administration, CDX-1140 targets and binds to CD40 on a variety of immune cell types. This induces CD40-dependent signaling pathways, triggers the proliferation and activation of antigen-presenting cells (APCs) and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells, such as dendritic cells (DCs), macrophages and B-cells, and plays a key role in the activation of the immune system.	Anti-CD40 Agonist Monoclonal Antibody CDX-1140		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150559>	C210737	Avatrombopag|4-Piperidinecarboxylic Acid, 1-(3-Chloro-5-(((4-(4-chloro-2-thienyl)-5-(4-cyclohexyl-1-piperazinyl)-2-thiazolyl)amino)carbonyl)-2-pyridinyl)-|AKR 501|AKR-501|AKR501|AS 1670542|AVATROMBOPAG|Doptelet|E 5501|E-5501|E5501|YM 477|YM-477|YM477	An orally available platelet thrombopoietin receptor (TPOR; MPL) agonist, with potential megakaryopoiesis stimulating activity. Upon administration, avatrombopag binds to and stimulates TPOR, which may lead to the proliferation and differentiation of megakaryocytes from bone marrow progenitor cells. This increases the production of platelets and may prevent chemotherapy-induced thrombocytopenia (CIT). TPOR is a cytokine receptor and member of the hematopoietin receptor superfamily.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology
C150560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150560>	C141146|C129820	Anti-TIM-3 Monoclonal Antibody S095018|Anti-TIM-3 Monoclonal Antibody Sym023|Anti-TIM3 Monoclonal Antibody Sym023|S 095018|S-095018|S095018|SYM-023|Sym 023|Sym-023|Sym023	A recombinant, fully human monoclonal antibody against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, the anti-TIM-3 monoclonal antibody S095018 binds to TIM-3 expressed on certain T-cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor cell proliferation. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.	Anti-TIM-3 Monoclonal Antibody S095018		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150562>	C50995	Incomplete Response/Stable Disease|IR/SD|Incomplete Response/Stable Disease (IR/SD)	Persistence of one or more non-target lesions.			Finding	
C150563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150563>	C40998|C134701	CD2-Positive Neoplastic Cells Present	An indication that expression of CD2 has been detected in a sample of neoplastic cells.			Finding	
C150564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150564>	C165233	B-Cell Markers Negative	A finding indicating that expression of B-lymphocyte lineage markers have not been detected in a sample.			Finding	
C150565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150565>	C165233	Myeloid Markers Negative	A finding indicating that expression of myeloid lineage markers have not been detected in a sample.			Finding	
C150566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150566>	C3996	IgM Monoclonal Gammopathy of Undetermined Significance|IgM MGUS	Monoclonal gammopathy of undetermined significance defined by a serum IgM paraprotein concentration less than 30g/L; bone marrow lymphoplasmacytic infiltration of less than 10%; and no evidence of anemia, constitutional symptoms, hyperviscocity, lymphadenopathy, hepatosplenomegaly, or other end-organ damage that can be attributed to the underlying lymphoproliferative disorder. It is a precursor condition that may progress to lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia, other B-cell neoplasms, or primary amyloidosis. Progression to plasma cell myeloma occurs rarely, if at all. (WHO 2017)	IgM Monoclonal Gammopathy of Undetermined Significance		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C150567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150567>	C128812	Serum IgM Monoclonal Gammopathy of Less than 30g/L	An abnormal laboratory test result indicating that a serum IgM paraprotein concentration is less than 30g/L.	Serum IgM Monoclonal Gammopathy of Less than 30g/L		Laboratory or Test Result	CTRP Disease Terminology|CTRP Terminology
C150568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150568>	C42076	Bone Marrow Lymphoplasmacytic Infiltration of Less than 10%	A morphologic finding indicating the presence of a lymphoplasmacytic infiltrate in the bone marrow, comprising less than 10% of the cellular population.			Finding	
C150569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150569>	C154271	Radial Probe Endobronchial Ultrasound|RP-EBUS|Radial EBUS|Radial Endobronchial Ultrasound|Radial Probe EBUS|Radial-Probe Endobronchial Ultrasound	Endobronchial ultrasound that employs a flexible catheter housing a rotating ultrasound transducer to produces a 360 degree (radial) ultrasound image.	Radial Probe Endobronchial Ultrasound		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C150570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150570>	C9480|C4912	Invasive Bladder Carcinoma|Infiltrating Bladder Cancer|Infiltrating Bladder Carcinoma	A carcinoma that arises from the bladder mucosa and invades the bladder wall.	Infiltrating Bladder Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150571>	C35867	Muscle Invasion	A morphologic finding indicating the presence of a malignant cellular infiltrate invading muscle in a tissue sample.			Finding	
C150572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150572>	C150570	Muscle Invasive Bladder Carcinoma|Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall|Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall|Muscle-Invasive Bladder Carcinoma	A carcinoma that arises from the bladder mucosa and invades the muscle of the bladder wall.	Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150573>	C4952|C4874	Localized Cerebral Neoplasm|Non-Metastatic Cerebral Neoplasm	A cerebral neoplasm that is confined to a specific site without evidence of spread to other anatomic sites.			Neoplastic Process	
C150574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150574>	C15642	Thoracic Epidural Analgesia|TEA|Thoracic Epidural	Epidural analgesia administered to the thoracic spine to treat pain in the thoracic and upper abdominal areas during surgery.	Thoracic Epidural Analgesia		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C150575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150575>	C16809	Advanced Magnetic Resonance Imaging|AMRI	Any of various magnetic resonance (MR) imaging techniques with predictive power beyond that achievable with conventional contrast-enhanced MR, such as diffusion MRI, perfusion MRI, functional MRI, dynamic susceptibility contrast MRI, dynamic contrast enhancement MRI, higher order diffusion techniques such as diffusion tensor imaging, and MR spectroscopy.	Advanced Magnetic Resonance Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C150576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150576>	C64381	Four Quadrants Transverse Abdominis Plane Block|4 Quadrant TAP Block|4Q-TAP Block	A peripheral nerve block that involves performing bilateral subcostal as well as posterior transverse abdominis plane blocks.	Four Quadrants Transverse Abdominis Plane Block		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C150577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150577>	C9296|C4124|C206534	Metastatic Gastroesophageal Junction Adenocarcinoma	Gastroesophageal junction adenocarcinoma which has spread from its original site of growth to another anatomic site.	Metastatic Gastroesophageal Junction Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150578>	C9296|C206533|C129654	Unresectable Gastroesophageal Junction Adenocarcinoma	A gastroesophageal junction adenocarcinoma that is not amenable to surgical resection.			Neoplastic Process	
C150579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150579>	C8818|C27781	Recurrent Myxoid Liposarcoma|Recurrent Myxoid/Round Cell Liposarcoma	The reemergence of myxoid liposarcoma after a period of remission.			Neoplastic Process	
C150580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150580>	C9325|C224629	Unresectable Adrenal Cortical Carcinoma|Unresectable Adrenal Cortex Carcinoma	Adrenal cortical carcinoma that is not amenable to surgical resection.			Neoplastic Process	
C150581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150581>	C4917|C191853|C141076	Refractory Lung Small Cell Carcinoma|Refractory Small Cell Lung Carcinoma	Small cell lung carcinoma that does not respond to treatment.			Neoplastic Process	
C150582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150582>	C175398|C129829	PALB2 Biallelic Inactivation|FANCN Biallelic Gene Inactivation|Fanconi Anemia, Complementation Group N Biallelic Gene Inactivation|PALB2 Biallelic Gene Inactivation|PNCA3 Biallelic Gene Inactivation|Partner and Localizer of BRCA2 Biallelic Gene Inactivation	The presence of mutations in both alleles of the PALB2 gene that either lead to loss of expression of the PALB2 protein or result in the translation of an inactive PALB2 protein.	PALB2 Biallelic Inactivation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150583>	C131794|C129829	FANCA Biallelic Inactivation|FA Biallelic Gene Inactivation|FA-H Biallelic Gene Inactivation|FA1 Biallelic Gene Inactivation|FAA Biallelic Gene Inactivation|FACA Biallelic Gene Inactivation|FAH Biallelic Gene Inactivation|FANCA Biallelic Gene Inactivation|FANCH Biallelic Gene Inactivation|Fanconi Anemia Complementation Group A Biallelic Gene Inactivation|Fanconi Anemia, Complementation Group A Biallelic Gene Inactivation|Fanconi Anemia, Complementation Group H Biallelic Gene Inactivation|Fanconi Anemia, Type 1 Biallelic Gene Inactivation	The presence of mutations in both alleles of the FANCA gene that either lead to loss of expression of the FANCA protein or result in the translation of an inactive FANCA protein.	FANCA Biallelic Inactivation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150584>	C162040|C157641|C129830	ATM Monoallelic Inactivation|A-T Mutated Monoallelic Gene Inactivation|AT Mutated Monoallelic Gene Inactivation|ATM Gene LOH|ATM Gene Loss of Heterozygosity|ATM LOH|ATM Loss of Heterozygosity|ATM Monoallelic Gene Inactivation|ATM Serine/Threonine Kinase Monoallelic Gene Inactivation|Ataxia Telangiectasia Mutated Monoallelic Gene Inactivation	The presence of mutations in only one allele of the ATM gene that either lead to decreased of expression of the ATM protein or result in the translation of an inactive and potentially dominant-negative form of the ATM protein.	ATM Monoallelic Inactivation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150585>	C129825	TAM/c-Met Inhibitor RXDX-106|CEP 40783|CEP-40783|CEP-40783|CEP40783|N-[4-(6,7-Dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-3-(4-fluorophenyl)-2,4-dioxo-1-propan-2-ylpyrimidine-5-carboxamide|RXDX 106|RXDX-106|RXDX106|TYRO3/AXL/MER/c-Met Inhibitor RXDX-106	An orally available and selective inhibitor of the receptor tyrosine kinase (RTK) activity of both hepatocyte growth factor receptor (c-Met; HGFR) and receptors in the TYRO3, AXL, and MER (TAM) family, with potential immunomodulating and antineoplastic activities. Upon oral administration of TAM/c-Met inhibitor RXDX-106, this agent selectively targets and binds to TYRO3, AXL, MER and c-Met, and prevents their RTK activity. This blocks TYRO3/AXL/MER/c-Met-mediated signal transduction pathways, and inhibits the proliferation and migration of TYRO3-, AXL-, MER- and c-Met-overexpressing tumor cells. Inhibition of the TAM family in the tumor microenvironment (TME) activates the immune system in the TME, reverses TAM mediated immunosuppression and enhances the anti-tumor immune response, which lead to immune-mediated tumor cell killing. TYRO3, AXL and MER, members of the TAM family of RTKs, are overexpressed in many tumor cell types. TAMs play key roles in tumor cell proliferation, survival, invasion, angiogenesis and metastasis, and their expression is associated with drug resistance and poor prognosis. c-Met, also overexpressed in many tumor cell types, plays a critical role in tumor formation, proliferation, invasion and metastasis, and contributes to tumor resistance. In the TME, TAM expression on immune cells contributes to tumor cell evasion of immune surveillance and to the negative regulation of immune responses.	TAM/c-Met Inhibitor RXDX-106		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150586>	C226930|C200766	Autologous Anti-DLL3 CAR T-Cells AMG 119|AMG 119|AMG 119 CAR-T Cells|AMG-119|AMG119|CAR T-Cells AMG 119|CAR-T Cells AMG 119	A preparation of autologous T-lymphocytes that are genetically engineered to express a chimeric antigen receptor (CAR) that targets the tumor-associated antigen (TAA) delta-like ligand 3 (DLL3), with potential immunomodulatory and antineoplastic activities. Upon administration of the autologous anti-DLL3 CAR T-cells AMG 119, the T-cells target, bind to and induce selective cytotoxicity in tumor cells expressing DLL3. DLL3, an inhibitory Notch ligand, is expressed on the surface of some cancer cell types but is minimally expressed in normal tissues.	Autologous Anti-DLL3 CAR T-Cells AMG 119		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150587>	C178716	Complete Remission in Leukemia with Incomplete Hematologic Recovery|Complete Remission in Leukemia with Incomplete Hematological Recovery|Complete Remission with Incomplete Hematological Recovery|Complete Remission with Incomplete Hematological Recovery|Complete Remission with Incomplete Hematological Recovery (CRi)	The disappearance of all signs of leukemia in response to treatment with residual neutropenia (less than 1,000 per microliter), with or without complete platelet recovery.	Complete Remission with Incomplete Hematological Recovery		Finding	CTRP Biomarker Terminology|CTRP Terminology
C150588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150588>	C3996	Non-IgM Monoclonal Gammopathy of Undetermined Significance|Non-IgM MGUS	Monoclonal gammopathy of undetermined significance defined by the presence in the serum of an IgG, IgA, or (rarely) IgD paraprotein at a concentration of less than 30g/L; clonal bone marrow plasma cells less than 10%; and absence of end-organ damage such as hypercalcemia, renal insufficiency, anemia, bone marrow lesions, and amyloidosis attributable to the plasma cell proliferative disorder. The risk of progression to plasma cell myeloma, light-chain amyloidosis, or a related disorder is 1% per year. (WHO 2017)	Non-IgM Monoclonal Gammopathy of Undetermined Significance		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150589>	C6810|C3209	Testicular Follicular Lymphoma|PFLT	A distinctive variant of follicular lymphoma arising from the testis. It has been reported with higher frequency in children, but is also seen rarely in adults. It differs biologically from nodal follicular lymphoma because it lacks evidence of the BCL2 translocation. It is usually of high cytological grade, usually grade 3A, but has a good prognosis, even without additional therapy beyond surgical excision. (WHO 2017)	Testicular Follicular Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150590>	C201551	Serclutamab Talirine|ABBV 321|ABBV-321|ABBV321|ADC ABBV-321|Anti-EGFR/PBD ADC ABBV-321|SERCLUTAMAB TALIRINE	A antibody drug conjugate (ADC) consisting of serclutamab, an affinity-matured humanized monoclonal antibody directed against the epidermal growth factor receptor (EGFR) conjugated to a talirine, a cytotoxic, DNA minor groove crosslinking agent and pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon intravenous administration of serclutamab talirine, the serclutamab moiety targets and binds to EGFR on tumor cell surfaces. Following receptor internalization and lysosome-mediated cleavage, talirine is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase (RTK) that is overexpressed by a variety of cancers, plays a key role in tumor cell proliferation and survival.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150592>	C8818|C3704	Recurrent Dedifferentiated Liposarcoma	The reemergence of dedifferentiated liposarcoma after a period of remission.	Recurrent Dedifferentiated Liposarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150593>	C3704|C150594	Refractory Dedifferentiated Liposarcoma	Dedifferentiated liposarcoma that does not respond to treatment.	Refractory Dedifferentiated Liposarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150594>	C3194|C148301	Refractory Liposarcoma	Liposarcoma that does not respond to treatment.	Refractory Liposarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150595>	C9385|C4124|C27806	Metastatic Renal Cell Carcinoma|Metastatic Renal Cell Cancer	A renal cell carcinoma that has spread from the kidney to other anatomic sites.	Metastatic Renal Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150596>	C36185	Hepatic Steatosis|Fatty (change of) liver, not elsewhere classified|Fatty Liver Change|Liver Steatosis	A morphologic finding indicating intracytoplasmic fat accumulation in the liver parenchyma.	Hepatic Steatosis		Disease or Syndrome	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology|mCode Elixhauser Mild Liver Disease Value Set|mCode Terminology
C150597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150597>	C36263	Metastatic Malignant Neoplasm in the Viscera|Secondary Malignant Neoplasm of Viscera|Visceral Metastases	A malignant neoplasm which has spread from its original site of growth to any visceral site.	Metastatic Malignant Neoplasm in the Viscera		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150598>	C3704|C132148	Unresectable Dedifferentiated Liposarcoma	Dedifferentiated liposarcoma that is not amenable to surgical resection.	Unresectable Dedifferentiated Liposarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150599>	C177692	MECOM Positive|EVI-1 Positive|EVI1 Positive|Ecotropic Virus Integration 1 Site Positive|Ecotropic Virus Integration Site 1 Positive|MDS1 Positive|MDS1 and EVI1 Complex Positive|MDS1-EVI1 Positive	An indication that expression of MECOM has been detected in a sample.	MECOM Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C1505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1505>	C1908	Dietary Supplement|DIETARY SUPPLEMENT|Dietary Supplements|Nutritional Supplement|Supplement|Supplements|dietary supplement|nutritional supplement|supplemental nutrition	Oral preparations containing dietary ingredient(s) intended to supplement the diet.  Dietary ingredients include vitamins, minerals, herbs, amino acids, extracts and metabolites.	Dietary Supplement		Food	CDISC SDTM Intervention Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology|CTRP Agent Terminology|CTRP Terminology|ICH M11 Intervention Type Value Set Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C150601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150601>	C84639	Citrullinemia Type I|Argininosuccinate Synthetase Deficiency|CTLN1	An autosomal recessive sub-type of citrullinemia caused by mutation(s) in the ASS1 gene, encoding argininosuccinate synthetase.	Citrullinemia Type I		Disease or Syndrome	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology
C150602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150602>	C9305|C211531	Resectable Malignant Neoplasm	A malignant neoplasm that is amenable to surgical resection.	Resectable Malignant Neoplasm		Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C150603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150603>	C84639	Citrullinemia Type II|CTLN2	An autosomal recessive sub-type of citrullinemia caused by mutation(s) in the SLC25A13 gene, encoding calcium-binding mitochondrial carrier protein Aralar2.	Citrullinemia Type II		Disease or Syndrome	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology
C150604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150604>	C2916|C150602	Resectable Carcinoma	A carcinoma that is amenable to surgical resection.	Resectable Carcinoma		Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C150605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150605>	C9118|C150602	Resectable Sarcoma	Sarcoma that is amenable to surgical resection.	Resectable Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150606>	C3194|C150605	Resectable Liposarcoma	Liposarcoma that is amenable to surgical resection.	Resectable Liposarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150607>	C3704|C150606	Resectable Dedifferentiated Liposarcoma	Dedifferentiated liposarcoma that is amenable to surgical resection.	Resectable Dedifferentiated Liposarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150608>	C53543	Minicore Myopathy with External Ophthalmoplegia	An autosomal recessive condition caused by mutation(s) in the RYR1 gene, encoding ryanodine receptor 1. It may be characterized clinically by neonatal hypotonia, delayed motor development, and generalized muscle weakness, and amyotrophy. Pathologically, the absence of mitochondria and focal disorganization of the sarcomere appear as "minicores" on ATPase staining as a result of focal defects in oxidative activity.	Minicore Myopathy with External Ophthalmoplegia		Disease or Syndrome	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology
C150609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150609>	C75467	Charcot-Marie-Tooth Disease Type 2A1|CMT2A1	An autosomal dominant sub-type of Charcot-Marie-Tooth disease caused by mutation(s) in the KIF1B gene, encoding kinesin-like protein KIF1B.	Charcot-Marie-Tooth Disease Type 2A1		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C150610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150610>	C4247|C153068	Unresectable Undifferentiated Pleomorphic Sarcoma	An undifferentiated pleomorphic sarcoma that is not amenable to surgical resection.	Unresectable Undifferentiated Pleomorphic Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150611>	C4247|C153086	Resectable Undifferentiated Pleomorphic Sarcoma	An undifferentiated pleomorphic sarcoma that is amenable to surgical resection.	Resectable Undifferentiated Pleomorphic Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150612>	C118376	FGF19 Gene Amplification|FGF-19 Gene Amplification|FGF19 Amplification|Fibroblast Growth Factor 19 Gene Amplification|Fibroblast Growth Factor-19 Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the FGF19 gene.	FGF19 Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150613>	C35681	FGFR Family Alteration Negative|FGF Receptor Alteration Negative|FGF Receptor Family Alteration Negative|FGFR Alteration Negative|Fibroblast Growth Factor Receptor Alteration Negative|Fibroblast Growth Factor Receptor Family Alteration Negative	An indication that mutation, overexpression, fusion or rearrangement of an FGFR family member has not been detected in a sample.	FGFR Family Alteration Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150614>	C133705	FGFR1 Gene Alteration Positive|BFGFR Gene Alteration Positive|CD331 Gene Alteration Positive|CEK Gene Alteration Positive|FGFBR Gene Alteration Positive|FGFR-1 Gene Alteration Positive|FGFR1 Gene Aberration|FGFR1 Gene Aberration Positive|FGFR1 Gene Alteration|FLG Gene Alteration Positive|FLT-2 Gene Alteration Positive|FLT2 Gene Alteration Positive|FMS-Like Tyrosine Kinase 2 Gene Alteration Positive|Fibroblast Growth Factor Receptor 1 Gene Alteration Positive|KAL2 Gene Alteration Positive|N-SAM Gene Alteration Positive|OGD Gene Alteration Positive	An indication that mutation, overexpression, fusion or rearrangement involving the FGFR1 gene has been detected in a sample.	FGFR1 Gene Alteration Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150615>	C84273|C118377	FGFR1 Gene Translocation|BFGFR Gene Translocation|CD331 Gene Translocation|CEK Gene Translocation|FGFBR Gene Translocation|FGFR-1 Gene Translocation|FLG Gene Translocation|FLT-2 Gene Translocation|FLT2 Gene Translocation|FMS-Like Tyrosine Kinase 2 Gene Translocation|Fibroblast Growth Factor Receptor 1 Gene Translocation|KAL2 Gene Translocation|N-SAM Gene Translocation|OGD Gene Translocation	A cytogenetic abnormality that refers to any translocation involving the FGFR1 gene.	FGFR1 Gene Translocation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150616>	C158948|C133705	FGFR2 Fusion Positive|BEK Fusion Positive|CD332 Antigen Fusion Positive|CD332 Fusion Positive|ECT1 Fusion Positive|FGFR-2 Fusion Positive|FGFR2 Fusion|Fibroblast Growth Factor Receptor 2 Fusion Positive|K-SAM Fusion Positive|KGFR Fusion Positive|Keratinocyte Growth Factor Receptor Fusion Positive	An indication that expression of a fusion containing sequences from FGFR2 has been detected in a sample.	FGFR2 Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150617>	C133705	FGFR2 Gene Alteration Positive|BEK Gene Alteration Positive|CD332 Gene Alteration Positive|ECT1 Gene Alteration Positive|FGFR-2 Gene Alteration Positive|FGFR2 Alteration Positive|FGFR2 Gene Aberration|FGFR2 Gene Aberration Positive|FGFR2 Gene Alteration|Fibroblast Growth Factor Receptor 2 Gene Alteration Positive|K-SAM Gene Alteration Positive|KGFR Gene Alteration Positive|Keratinocyte Growth Factor Receptor Gene Alteration Positive	An indication that mutation, overexpression, fusion or rearrangement involving the FGFR2 gene has been detected in a sample.	FGFR2 Gene Alteration Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150618>	C133705	FGFR3 Gene Alteration Positive|CD333 Gene Alteration Positive|FGFR-3 Gene Alteration Positive|FGFR3 Alteration Positive|FGFR3 Gene Aberration|FGFR3 Gene Aberration Positive|FGFR3 Gene Alteration|Fibroblast Growth Factor Receptor 3 Gene Alteration Positive|JTK4 Gene Alteration Positive	An indication that mutation, overexpression, fusion or rearrangement involving the FGFR3 gene has been detected in a sample.	FGFR3 Gene Alteration Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150619>	C158072|C118377	FGFR3 Gene Translocation|CD333 Gene Translocation|FGFR-3 Gene Translocation|Fibroblast Growth Factor Receptor 3 Gene Translocation|JTK4 Gene Translocation	A cytogenetic abnormality that refers to any translocation involving the FGFR3 gene.	FGFR3 Gene Translocation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150620>	C3270|C150602	Resectable Neuroblastoma	Neuroblastoma that is amenable to surgical resection.	Resectable Neuroblastoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150621>	C133705	FGFR4 Alteration Positive|CD334 Alteration Positive|FGFR-4 Alteration Positive|Fibroblast Growth Factor Receptor 4 Alteration Positive|JTK2 Alteration Positive|TKF Alteration Positive	An indication that mutation, overexpression, fusion or rearrangement involving FGFR4 has been detected in a sample.	FGFR4 Alteration Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150622>	C3270|C27359	Unresectable Neuroblastoma	Neuroblastoma which is not amenable to surgical resection.	Unresectable Neuroblastoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150623>	C178120|C128919	Activating FLT3 Gene Mutation|Activating CD135 Gene Mutation|Activating FLK2 Gene Mutation|Activating FLT3 Gene Mutant|Activating FMS-Related Tyrosine Kinase 3 Gene Mutation|FLT3 Activating Mutation	A change in the nucleotide sequence of the FLT3 gene that results in constitutive activation of receptor-type tyrosine-protein kinase FLT3 and its downstream signaling pathways.	Activating FLT3 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150624>	C156029	FLT3 Gene Amplification|CD135 Gene Amplification|FLK2 Gene Amplification|FLT3 Amplification|FMS-Related Tyrosine Kinase 3 Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the FLT3 gene.	FLT3 Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C150625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150625>	C177687	FLT3 Internal Tandem Duplication Negative|FLT3-ITD Mutation Negative|FLT3-ITD Negative|FLT3/ITD Mutation Negative|FLT3/ITD Negative	An indication that internal tandem duplication within the FLT3 gene has not been detected in a sample.	FLT3 Internal Tandem Duplication Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150626>	C177686	FLT3 Internal Tandem Duplication Positive|FLT3-ITD Mutation Positive|FLT3-ITD Positive|FLT3/ITD Mutation Positive|FLT3/ITD Positive	An indication that internal tandem duplication within the FLT3 gene has been detected in a sample.	FLT3 Internal Tandem Duplication Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150627>	C158948	FOXO1 Fusion Positive|FKH1 Fusion Positive|FKHR Fusion Positive|FOXO1 Fusion Mutation|FOXO1A Fusion Positive|Forkhead Box O1 Fusion Positive|Forkhead Box O1A Fusion Positive|Forkhead in Rhabdomyosarcoma Fusion Positive	An indication that expression of a fusion containing sequences from FOXO1 has been detected in a sample.	FOXO1 Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150628>	C97927	GATA3 Gene Mutation|GATA Binding Protein 3 Gene Mutation	A change in the nucleotide sequence of the GATA3 gene.	GATA3 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150629>	C19635|C17666	Germline BRCA1 Gene Mutation|Germline BRCA1 Mutation|Germline BROVCA1 Gene Mutation|Germline Breast Cancer Type 1 Susceptibility Gene Mutation	A change in the nucleotide sequence of the BRCA1 gene that originates in the gametes.	Germline BRCA1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15062>	C14421	SWV Mouse|SWV		SWV Mouse		Mammal	
C150630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150630>	C19636|C17666	Germline BRCA2 Gene Mutation|Germline BRCA2 Mutation|Germline Breast Cancer Type 2 Susceptibility Gene Mutation|Germline FANCD1 Gene Mutation|Germline XRCC11 Gene Mutation	A change in the nucleotide sequence of the BRCA2 gene that originates in the gametes.	Germline BRCA2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150631>	C35682|C175007	Human Anti-Chimeric Antibody Positive|HACA Positive	An indication that antibodies directed against chimeric therapeutic antibodies have been detected in a human sample.	Human Anti-Chimeric Antibody Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C150632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150632>	C96866	ERBB2 Exon 20 Mutation|CD340 Exon 20 Mutation|Erb-B2 Receptor Tyrosine Kinase 2 Exon 20 Mutation|HER-2 Exon 20 Mutation|HER2 Exon 20 Mutation|HER2/Neu Exon 20 Mutation|Neu Exon 20 Mutation|Other ERBB2 exon 20 mutation, specify|c-erbB2 Exon 20 Mutation|v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 Exon 20 Mutation	A molecular genetic abnormality indicating the presence of a mutation in exon 20 of the ERBB2 gene.	ERBB2 Exon 20 Mutation		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150633>	C150632	ERBB2 Exon 20 Insertion Mutation|CD340 Exon 20 Insertion Mutation|Erb-B2 Receptor Tyrosine Kinase 2 Exon 20 Insertion Mutation|HER-2 Exon 20 Insertion Mutation|HER2 Exon 20 Insertion Mutation|HER2/Neu Exon 20 Insertion Mutation|Neu Exon 20 Insertion Mutation|c-erbB2 Exon 20 Insertion Mutation|v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 Exon 20 Insertion Mutation	A molecular genetic abnormality indicating the presence of an in-frame insertion mutation occurring within exon 20 of the ERBB2 gene.	ERBB2 Exon 20 Insertion Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150634>	C68748|C177693	ERBB2 Overexpression|Erb-B2 Receptor Tyrosine Kinase Overexpression|HER2 Overexpression|HER2/neu Overexpression|NEU Overexpression|Proto-Oncogene Neu Overexpression|Receptor Tyrosine-Protein Kinase erbB-2 Protein Variant Overexpression|Tyrosine Kinase-Type Cell Surface Receptor HER2 Overexpression|v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 Overexpression	An indication that overexpression of ERBB2 has been detected in a sample.	ERBB2 Overexpression		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150636>	C94299|C177692	ERBB3 Positive|ERBB3 Receptor Protein-Tyrosine Kinase Positive|ErbB-3 Positive|HER-3 Positive|HER3 Positive|Receptor Tyrosine-Protein Kinase erbB-3 Positive|Tyrosine Kinase-Type Cell Surface Receptor HER3 Positive|c-erbB-3 Positive|c-erbB3 Positive	An indication that expression of ERBB3 has been detected in a sample.	ERBB3 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150637>	C154811	Clostridium difficile Measurement|CDF|Clostridium difficile|Clostridium difficile	The determination of the amount of Clostridium difficile species in a biological sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150638>	C97927	HGF Gene Mutation|F-TCF Gene Mutation|HGF/SF Gene Mutation|HPTA Gene Mutation|Hepatocyte Growth Factor Gene Mutation|SF Gene Mutation|Scatter Factor Gene Mutation	A change in the nucleotide sequence of the HGF gene.	HGF Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150639>	C150637	Clostridium difficile 027/NAP1/BI Measurement|C150639|Clostridium difficile 027/NAP1/BI|Clostridium difficile 027/NAP1/BI	The determination of the amount of the 027/NAP1/BI strain of Clostridium difficile species in a biological specimen.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150640>	C165233	HLA-A*0201 Negative|HLA-A*02:01 Negative	An indication that cells expressing HLA-A*0201 have not been detected in a tissue sample.	HLA-A*0201 Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150641>	C178119|C133695|C129829|C120465	Homologous Recombination Repair Biallelic Inactivation|HHR Biallelic Inactivation|HRR Biallelic Inactivation|Homologous Recombination Pathway Biallelic Inactivation|Recombination Repair Biallelic Inactivation	The presence of mutations in both alleles of a gene involved in homologous recombination-type DNA repair that lead to defects in DNA repair pathways.	Homologous Recombination Repair Biallelic Inactivation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150642>	C177692	HOXA10 Positive|HOX1.8 Positive|HOX1H Positive|Homeo Box A10 Positive|Homeobox 1.8 Positive|Homeobox 1H Positive|Homeobox A10 Positive|Hox-1.8 Positive|Hox-1H Positive|Hox-A10 Positive	An indication that expression of HOXA10 has been detected in a sample.	HOXA10 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150643>	C177692	HOXA9 Positive|HOX1.7 Positive|HOX1G Positive|Homeo Box A9 Positive|Homeobox 1.7 Positive|Homeobox 1G Positive|Homeobox A9 Positive|Hox-1.7 Positive|Hox-1G Positive|Hox-A9 Positive	An indication that expression of HOXA9 has been detected in a sample.	HOXA9 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150644>	C94299|C165233	IGF1R Negative|CD221 Negative|IGF-1R Negative|IGFR Negative|Insulin Like Growth Factor 1 Receptor Negative	An indication that expression of IGF1R has not been detected in a sample.	IGF1R Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150645>	C165233	SMARCB1 Negative|BAF47 Negative|INI1-Negative|SNF5 Negative|SWI/SNF-Related Matrix-Associated Actin Dependent Regulator of Chromatin Subfamily B Member 1 Negative	An indication that expression of SMARCB1 has not been detected in a sample.	SMARCB1 Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150646>	C134952	Charcot-Marie-Tooth Disease Type 2A2A|Axonal Charcot-Marie-Tooth Disease Type 2A2A|CMT2A2|CMT2A2A	Charcot-Marie-Tooth Disease Type 2A that is inherited in an autosomal dominant manner.	Charcot-Marie-Tooth Disease Type 2A2A		Disease or Syndrome	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology
C150647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150647>	C134952	Charcot-Marie-Tooth Disease Type 2A2B|Axonal Charcot-Marie-Tooth Disease Type 2A2B|CMT2A2B	An autosomal recessive sub-type of Charcot-Marie-Tooth disease caused by compound heterozygous or homozygous mutation(s) in the MFN2 gene, encoding mitofusin-2. This condition is more severe and has an earlier onset as compared to Charcot-Marie-Tooth disease type 2A2A.	Charcot-Marie-Tooth Disease Type 2A2B		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C150648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150648>	C177692	ISG15 Positive|G1P2 Positive|IFI15 Positive|IP17 Positive|ISG15 Ubiquitin-Like Modifier Positive|UCRP Positive|Ubiquitin Cross-Reactive Protein Positive|Ubiquitin-Like Protein ISG15 Positive|hUCRP Positive	An indication that expression of ISG15 has been detected in a sample.	ISG15 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150649>	C97927	KDM6A Gene Mutation|KABUK2 Gene Mutation|Lysine (K)-Specific Demethylase 6A Gene Mutation|Lysine Demethylase 6A Gene Mutation|UTX Gene Mutation	A change in the nucleotide sequence of the KDM6A gene.	KDM6A Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150650>	C165233	KIR Ligand Negative|Killer-Cell Immunoglobulin-Like Receptor Ligand Negative	An indication that expression of ligands for the killer-cell immunoglobulin-like receptors have not been detected in a sample.	KIR Ligand Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150651>	C97927	KMT2D Gene Mutation|ALR Gene Mutation|CAGL114 Gene Mutation|KABUK1 Gene Mutation|KMS Gene Mutation|Lysine (K)-Specific Methyltransferase 2D Gene Mutation|Lysine Methyltransferase 2D Gene Mutation|MLL2 Gene Mutation|MLL4 Gene Mutation|Myeloid/Lymphoid or Mixed-Lineage Leukemia 2 Gene Mutation|TNRC21 Gene Mutation	A change in the nucleotide sequence of the KMT2D gene.	KMT2D Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150652>	C97927	KRT5 Gene Mutation|CK-5 Gene Mutation|CK5 Gene Mutation|EBS2 Gene Mutation|K5 Gene Mutation|KRT5A Gene Mutation|Keratin 5 Gene Mutation|Keratin 5, Type II Gene Mutation	A change in the nucleotide sequence of the KRT5 gene.	KRT5 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150653>	C97927	KRT72 Gene Mutation|CK6 Gene Mutation|K6IRS2 Gene Mutation|K6irs Gene Mutation|KB35 Gene Mutation|KRT6 Gene Mutation|KRT6IRS2 Gene Mutation|Keratin 72 Gene Mutation|Keratin 72, Type II Gene Mutation	A change in the nucleotide sequence of the KRT72 gene.	KRT72 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150654>	C94299|C177692	GNRHR Positive|GNRHR1 Positive|GRHR Positive|Gonadotropin Releasing Hormone Receptor Positive|Gonadotropin-Releasing Hormone Receptor Positive|LHRH Receptor Positive|LHRHR Positive|LRHR Positive|Luteinizing Releasing Hormone Receptor Positive|Luteinizing-Releasing Hormone (LHRH) Receptor Positive|Luteinizing-Releasing Hormone Receptor Positive	An indication that expression of GNRHR has been detected in a sample.	GNRHR Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150655>	C40998	Surface Immunoglobulin-Positive Cells Present|Cells with Surface Ig|Cells with Surface Immunoglobulins Present|Presence of Surface Immunoglobulin|Surface Ig Present|Surface Immunoglobulin Positive Cells Present|Surface Immunoglobulin Positive Cells Present	A microscopic finding indicating that immunoglobulins are bound to or expressed on the surface of cells in a sample.	Surface Immunoglobulin Positive Cells Present		Finding	CTRP Biomarker Terminology|CTRP Terminology
C150656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150656>	C35880|C150655	Lymphoblasts with Surface Immunoglobulin Present|Lymphoblasts with Surface Ig|Surface Immunoglobulin Positive Lymphoblasts Present	A microscopic finding indicating that immunoglobulins are bound to or expressed on the surface of the immature lymphoid cells in a sample.	Lymphoblasts with Surface Immunoglobulin Present		Finding	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C150657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150657>	C40971	Endoscopy Under Anesthesia|Examination Under Anesthesia with Endoscopy	Any endoscopic procedure done while the patient is sedated.			Diagnostic Procedure	
C150658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150658>	C61547	Alcoholism Counseling|Alcohol Counseling	Counseling designed to guide and support an individual to overcome alcohol dependence.			Health Care Activity	
C150659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150659>	C124351	Preanesthetic Evaluation|Preanesthesia Assessment|Preanesthesia Evaluation|Preanesthesia Study|Preanesthetic Assessment	A medical examination by an anesthesiologist before an operation, to assess the patient's physical condition and identify medical conditions or diseases that could significantly increase the risk of complications.			Diagnostic Procedure	
C150660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150660>	C15454	Laryngopharyngectomy	Surgery involving the complete or partial excision of the larynx and pharynx.	Laryngopharyngectomy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C150661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150661>	C150660	Total Laryngopharyngectomy	Surgical removal of the entire larynx and pharynx.	Total Laryngopharyngectomy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C150662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150662>	C150660	Partial Laryngopharyngectomy|PLP	Laryngopharyngectomy in which one side of the larynx is spared from surgery.	Partial Laryngopharyngectomy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C150663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150663>	C190548	Orthopantomogram|OPG|Orthopantogram|PX|Panoramic Dental X-ray|Panoramic Radiograph|Panoramic X-Ray|Panorex	A panoramic or wide-view x-ray of the upper and lower jaw and teeth.			Diagnostic Procedure	
C150664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150664>	C17369	Videostroboscopy|Videostrobe	An imaging technique used to assess the function of the larynx. It uses a strobe light to illuminate the larynx and records the results, allowing the function of the larynx to be viewed in slow motion.	Videostroboscopy		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C150665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150665>	C26001	COL6A3 Gene|COL6A3|COL6A3|Collagen Type VI Alpha 3 Chain Gene	This gene plays a role in both cell-matrix adhesion and the organization of the extracellular matrix in connective tissues.	COL6A3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C150666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150666>	C150665	COL6A3 wt Allele|BTHLM1|Collagen Type VI Alpha 3 Chain wt Allele|Collagen, Type VI, Alpha 3 Gene|Collagen, Type VI, Alpha-3 Gene|DYT27|UCMD1	Human COL6A3 wild-type allele is located in the vicinity of 2q37.3 and is approximately 90 kb in length. This allele, which encodes collagen alpha-3(VI) chain protein, is involved in beaded filament collagen formation. Mutation of the gene is associated with Bethlem myopathy, type 27 dystonia and Ullrich congenital muscular dystrophy.	COL6A3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150667>	C180395	Collagen Alpha-3(VI) Chain|COL6A3|Collagen Type VI Alpha 3 Chain|Collagen Type VI Alpha 3 Polypeptide|Collagen VI, Alpha-3 Polypeptide|Type VI Collagen Alpha 3 Chain	Collagen alpha-3(VI) chain (3177 aa, ~344 kDa) is encoded by the human COL6A3 gene. This protein plays a role in extracellular matrix formation and cell-matrix adhesion in connective tissues.	Collagen Alpha-3(VI) Chain		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150668>	C177692	COL6A3 Positive|Collagen Alpha-3(VI) Chain Positive|Collagen Type VI Alpha 3 Chain Positive|Type VI Collagen Alpha 3 Chain Positive	An indication that expression of COL6A3 has been detected in a sample.	COL6A3 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150669>	C3231	Chemically-Induced Menopause|CIM|Chemical Menopause|Chemically Induced Menopause	Menopause caused by chemotherapy or other chemicals or medications.	Chemically-Induced Menopause		Organism Attribute	CTRP Disease Terminology|CTRP Terminology
C150671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150671>	C200766|C176018	Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells|Autologous CD19CAR-CD3zeta-4-1BB-expressing T-lymphocytes|Autologous CD3zeta-4-1BB-expressing CART-19 Cells	A preparation of autologous T-lymphocytes that are engineered to express a chimeric antigen receptor (CAR) composed of an anti-cluster of differentiation 19 (CD19) single chain variable fragment (scFv) linked to the intracellular signaling domains of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), with potential immunomodulating and antineoplastic activities. Upon administration of the autologous anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells, these cells target, bind to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.	Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150672>	C9308|C35686	Immunodeficiency-Related Lymphoproliferative Disorder|Immunodeficiency-Associated Lymphoproliferative Disorder|Lymphoid Hyperplasia Arising in Setting of Immune Deficiency/Dysregulation	A lymphoproliferative disorder that occurs in a patient with immunodeficiency.			Disease or Syndrome	
C150673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150673>	C150672	Lymphoproliferative Disease Associated with Primary Immune Disorder|Lymphoproliferative Disease Associated with PID	A lymphoid proliferation that arises in the setting of immune deficiency due to a primary immunodeficiency or immunoregulatory disorder. The primary immune disorders most frequently associated with lymphoproliferative disorders are ataxia-telangiectasia, Wiskott-Aldrich syndrome, common variable immunodeficiency, severe combined immunodeficiency, X-linked lymphoproliferative disease, Nijmegen breakage syndrome, hyper-IgM syndrome, and autoimmune lymphoproliferative syndrome. (WHO 2017)			Disease or Syndrome	
C150676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150676>	C28681|C129826	Autologous GPC3/NY-ESO-1/AFP specific CD8-positive T-lymphocytes|Autologous HCC Antigens-specific CD8+ T lymphocytes|Autologous HCC Antigens-specific CD8-positive T-lymphocytes|Autologous Specific HCC Antigens CD8+ T Cells	A preparation of autologous CD8-positive T-lymphocytes that are exposed, ex vivo, to multiple specific hepatocellular carcinoma (HCC) antigens, including glypican (GPC)-3, New York esophageal squamous cell carcinoma-1 (NY-ESO-1) and alpha-fetoprotein (AFP), with potential immunostimulating and antineoplastic activities. Upon infusion of the GPC3/NY-ESO-1/AFP-specific CD8-positive T lymphocytes, the T-cells specifically target and lyse cells expressing the targeted HCC neoantigens.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150677>	C20401|C129822	Anti-CD26 Monoclonal Antibody YS110|YS110	A humanized, immunoglobulin G1 (IgG1) monoclonal antibody directed against the extracellular domain of dipeptidyl peptidase 4 (CD26; DPP4; DPP IV), with potential antineoplastic activity. Upon administration of anti-CD26 monoclonal antibody YS110, this antibody targets and binds to CD26 expressed on tumor cells. This inhibits CD26 activity and causes internalization of CD26-YS110. This leads to cell cycle arrest, lysis and inhibition of growth in CD26-positive tumor cells. YS110 also induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against CD26-expressing tumor cells. CD26, a 110-kDa, type II transmembrane glycoprotein, is overexpressed in a variety of cancer cell types while absent in normal, healthy cells and plays a key role in tumor cell growth, migration, invasion and survival. It also plays a major role in the regulation of T-cell activity.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150678>	C7184|C4969|C3208|C27770	Methotrexate-Associated Lymphoma	A non-Hodgkin or Hodgkin lymphoma that develops in patients who are immunosuppressed with methotrexate.			Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology
C150679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150679>	C129822|C128036	Quavonlimab|Anti-CTLA-4 Monoclonal Antibody MK-1308|MK 1308|MK-1308|MK1308|QUAVONLIMAB	A monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, quavonlimab targets and binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.	Quavonlimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150680>	C69145|C129825	MEK Inhibitor SHR 7390|MAP2K Inhibitor SHR 7390|MAPK Kinase Inhibitor SHR 7390|MEKi SHR 7390|SHR 7390|SHR-7390|SHR7390	An orally available small molecule inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK), with potential antineoplastic activity. Upon administration, MEK inhibitor SHR 7390 selectively binds to and inhibits the activity of MEK. This prevents the activation of MEK-dependent effector proteins, which results in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a dual-specificity threonine/tyrosine kinase family that plays a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway, is frequently upregulated in a variety of tumor cell types.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150681>	C177692	MAGEA12 Positive|CT1.12 Positive|Cancer/Testis Antigen 1.12 Positive|MAGE A12 Positive|MAGE-12 Antigen Positive|MAGE12 Positive|MAGE12F Antigen Positive|Melanoma Antigen Family A 12 Positive|Melanoma Antigen Family A, 12 Positive|Melanoma-Associated Antigen 12 Positive	An indication that MAGEA12 expression has been detected in a sample.	MAGEA12 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150682>	C201275|C200766	Autologous Mesothelin-specific CAR-T-Cells Expressing Anti-PD-1/CTLA-4 Antibodies|Autologous Anti-MG7 CAR-T Cells|Autologous Anti-MG7-CAR T Lymphocytes|Autologous MG7-CART|Autologous MG7-CART Cells|MG7-targeted Chimeric Antigen Receptor T Cells	A preparation of autologous, engineered T-lymphocytes that express both a second-generation chimeric antigen receptor (CAR) specific for the human gastric carcinoma-associated antigen MG7, and the co-stimulatory molecule 4-1BB (CD137), with potential antineoplastic activity. Upon intratumoral injection, the autologous anti-MG7-CAR T-lymphocytes target and attach to cancer cells expressing MG7. This induces selective toxicity in and causes lysis of MG7-expressing tumor cells. MG7, a glycosylated protein sequence from the tumor-associated antigen (TAA) carcinoembryonic antigen (CEA), plays a key role in the development of certain tumor cell types. 4-1BB enhances T-cell activation and signaling after recognition of MG7.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150683>	C97927	MAGI2 Gene Mutation|ACVRINP1 Gene Mutation|ACVRIP1 Gene Mutation|AIP-1 Gene Mutation|AIP1 Gene Mutation|ARIP1 Gene Mutation|MAGI-2 Gene Mutation|Membrane Associated Guanylate Kinase, WW and PDZ Domain Containing 2 Gene Mutation|SSCAM Gene Mutation	A change in the nucleotide sequence of the MAGI2 gene.	MAGI2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150684>	C150672	Other Iatrogenic Immunodeficiency-Related Lymphoproliferative Disorders|Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders	Lymphoid proliferations or lymphomas that arise in patients treated with immunosuppressive drugs for autoimmune diseases or conditions other than in the post-transplant setting. (WHO 2017)			Disease or Syndrome	
C150685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150685>	C97927	MAP3K1 Gene Mutation|MAPKKK1 Gene Mutation|MEKK Gene Mutation|MEKK1 Gene Mutation|Mitogen-Activated Protein Kinase Kinase Kinase 1 Gene Mutation	A change in the nucleotide sequence of the MAP3K1 gene.	MAP3K1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150686>	C63587	Carboplatin/Cetuximab/Fluorouracil Regimen|Carboplatin, Fluorouracil, Cetuximab|Carboplatin-Fluorouracil-Cetuximab|Carboplatin-Fluorouracil-Cetuximab Regimen|Carboplatin/5-FU/Cetuximab|Carboplatin/5-FU/Cetuximab Regimen|Carboplatin/5-Fluorouracil/Cetuximab|Carboplatin/Fluorouracil Plus Cetuximab|Carboplatin/Fluorouracil/Cetuximab|Carboplatin/Fluorouracil/Cetuximab Regimen|Cetuximab-Carboplatin-5-Fluorouracil	A regimen consisting of carboplatin, fluorouracil (5-FU) and cetuximab that can be used for the treatment of head and neck cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C150687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150687>	C63587	Carboplatin/Cetuximab Regimen|Carboplatin-Cetuximab|Carboplatin-Cetuximab Regimen|Carboplatin/Cetuximab	A regimen consisting of carboplatin and cetuximab that can be used for the treatment of head and neck cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C150688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150688>	C124351	Medical Evaluation of Speech, Language, and Hearing Problems	A medical evaluation of speech, language, and hearing problems.	Medical Evaluation of Speech, Language, and Hearing Problems		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C150689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150689>	C97927	MED12 Gene Mutation|ARC240 Gene Mutation|CAGH45 Gene Mutation|HOPA Gene Mutation|Human Opposite Paired Gene Mutation|Mediator Complex Subunit 12 Gene Mutation|TNRC11 Gene Mutation|TRAP230 Gene Mutation|Trinucleotide Repeat-Containing Gene 11 Gene Mutation	A change in the nucleotide sequence of the MED12 gene.	MED12 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150690>	C63587	Carboplatin/Cetuximab/Docetaxel Regimen|Carboplatin and Docetaxel (DCb) and Cetuximab|Carboplatin-Docetaxel-Cetuximab|Carboplatin-Docetaxel-Cetuximab Regimen|Carboplatin/Docetaxel/Cetuximab|Carboplatin/Docetaxel/Cetuximab Regimen	A regimen consisting of carboplatin, docetaxel and cetuximab that can be used for the treatment of head and neck cancer and non-small cell lung cancer (NSCLC).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C150691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150691>	C63587	Cetuximab/Cisplatin/Fluorouracil Regimen|Cisplatin and Fluorouracil (CF) and Cetuximab|Cisplatin-Fluorouracil-Cetuximab|Cisplatin-Fluorouracil-Cetuximab Regimen|Cisplatin/5-FU/Cetuximab|Cisplatin/5-FU/Cetuximab Regimen|Cisplatin/5-Fluorouracil/Cetuximab|Cisplatin/Fluorouracil Plus Cetuximab|Cisplatin/Fluorouracil/Cetuximab|Cisplatin/Fluorouracil/Cetuximab Regimen|PFE|Platinol/Fluorouracil/Erbitux	A regimen consisting of cisplatin, fluorouracil (5-FU) and cetuximab used for the treatment of various types of head and neck cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C150692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150692>	C9294	Tumors Derived from Langerhans Cells	This category includes two main sub-groups, according to the degree of cytological atypia and clinical aggressiveness: Langerhans cell histiocytosis and Langerhans cell sarcoma. (WHO 2017)			Neoplastic Process	
C150693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150693>	C63587	Cisplatin/Paclitaxel/Cetuximab Regimen|Cisplatin-Paclitaxel-Cetuximab|Cisplatin-Paclitaxel-Cetuximab Regimen|Cisplatin/Paclitaxel/Cetuximab	A regimen consisting of cisplatin, paclitaxel and cetuximab that can be used for the treatment of head and neck cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C150694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150694>	C177692	MPO Positive|Myeloperoxidase Positive	An indication that expression of MPO has been detected in a sample.	MPO Positive		Laboratory or Test Result	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150695>	C201175|C200766	Autologous EGFR-specific CAR-T-Cells Expressing Anti-PD-1/CTLA-4 Antibodies|Autologous Anti-CTLA-4/PD-1 Expressing EGFR-CAR-T Cells|Autologous Anti-CTLA-4/PD-1-expressing EGFR-CAR-T|Autologous Anti-PD-1/CTLA4-targeting Antibodies-expressing EGFR-specific CAR-T Cells|Autologous CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells	A preparation of autologous T-lymphocytes that have been activated and genetically modified to express immune checkpoint antibodies against the negative immunoregulatory receptors human cell surface receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), and are transduced with a gene encoding a chimeric antigen receptor (CAR) specific for the human tumor-associated antigen (TAA) epidermal growth factor receptor (EGFR), with potential immunomodulating and antineoplastic activities. After isolation, activation, transduction, expansion in culture and reintroduction into the patient, the T-cells in the autologous EGFR specific CAR-T-cells expressing anti-PD-1/CTLA4 antibodies  specifically target and kill EGFR-expressing tumor cells. The anti-PD-1 antibody secreted from the CAR-T cells binds to PD-1 expressed on T-cells and prevents the interaction of PD-1 with its ligand programmed cell death 1 ligand 1 (PD-L1, PD-1L1; CD274) expressed on cancer cells, which prevents PD-1-mediated signaling and T-cell exhaustion. The anti-CTLA4 expressed by the CAR-T cells targets and binds to CTLA4 expressed on T-cells, and inhibits the CTLA4-mediated downregulation of T-cell activation. Both antibodies enhance T-cell activation, improve immunosuppression in the tumor microenvironment (TME) and improve the T-cell mediated immune response against and toxicity in EGFR-expressing tumor cells. Both PD-1 and CTLA-4 negatively regulate T-cell activation and proliferation, and play a key role in immunosuppression within the TME. EGFR, a receptor tyrosine kinase that is overexpressed in a variety of cancer cell types, plays a key role in tumor cell proliferation.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150696>	C28681|C129826	Autologous Ovarian Cancer Immunogene-modified T Lymphocytes|Autologous Human OC-IgT Cells|OC-IgT Cells	A preparation of autologous immunogene modified T-lymphocytes (IgT) that have been genetically engineered to be specifically reactive to ovarian cancer (OC) cells, with potential antineoplastic and immunostimulating activities. Upon administration of the autologous OC-IgT cells, the T-cells recognize and induce specific toxicity in the OC cells.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150697>	C28310|C129826	Autologous Tumor-specific Antigen-loaded Dendritic Cells|Autologous TSA-DC|Autologous TSA-DC Vaccine|Autologous TSA-DCs|Autologous TSA-loaded Dendritic Cells|Tumor Specific Antigen-loaded Autologous Dendritic Cells	A cell-based cancer vaccine composed of autologous dendritic cells (DCs) loaded with tumor-specific antigen(s) (TSAs), with potential immunostimulatory and antineoplastic activities. Upon administration of the autologous TSA-loaded DCs, the DCs stimulate a specific cytotoxic T-lymphocyte (CTL)-mediated immune response against the tumor cells expressing the TSA(s), resulting in tumor cell lysis.			Cell|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150698>	C200766	Autologous FRa-4SCAR-expressing T-cells 4SCAR-FRa|4SCAR-FRa|Autologous 4S-FRa-CAR-T Cells|Autologous Anti-FRa-CD28-CD137-CD27-CD3z-iCasp9 CAR T-cells 4SCAR-FRa|Chimeric Antigen Receptor T Cells 4SCAR-FRa|FRa-specific 4th Generation CART Cells	A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a fourth generation chimeric antigen receptor (4SCAR) consisting of an anti-folate receptor alpha (FRa; folate receptor 1; FOLR1) single chain variable fragment (scFv) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (CD3zeta; CD3z), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon administration, autologous FRa-4SCAR-expressing T-cells 4SCAR-FRa are directed to and induce selective toxicity in FRa-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. FRa is overexpressed in various tumor cell types, and is associated with increased leukemic cell proliferation and aggressiveness. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.			Cell|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150699>	C201178|C200766	Autologous PSMA-4SCAR-expressing T-cells 4SCAR-PSMA|4SCAR-PSMA|Autologous 4S-PSMA-CAR-T Cells|Autologous Anti-PSMA-CD28-CD137-CD27-CD3z-iCasp9 CAR T-cells 4SCAR-PSMA|Chimeric Antigen Receptor T Cells 4SCAR-PSMA|PSMA-specific 4th Generation CART Cells	A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating lentiviral vector expressing a fourth generation chimeric antigen receptor (4SCAR) consisting of an anti-prostate-specific membrane antigen (PSMA) single chain variable fragment (scFv) that is coupled to the costimulatory signaling domains CD28, CD137, CD27 and the zeta chain of the T-cell receptor (CD3zeta; CD3z), and is fused with the suicide gene inducible caspase 9 (iCasp9), with potential immunostimulating and antineoplastic activities. Upon administration, autologous PSMA-4SCAR-expressing T-cells 4SCAR-PSMA are directed to and induce selective toxicity in PSMA-expressing tumor cells. iCasp9 consists of a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V) linked to human caspase 9. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered. AP1903 binds to the drug binding FKBP12-F36V domain and induces activation of caspase 9, which results in the apoptosis of the administered T-cells and enhances safety of this agent. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C1506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1506>	C221	Opioid|Narcotic|narcotic|opioid	A class of synthetic chemicals/drugs similar to opiates (opium derivatives) with analgesic properties.  Due to binding to opiate receptors, opioids mimic opiate activity on neurons, various cells (i.e. lymphocytes), pain suppression and other neurobehavioral activity. (NCI)			Classification|Organic Chemical	
C150700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150700>	C514	Encochleated Amphotericin B|CAMB|Cochleate Lipid-crystal Nano-particles-containing Amphotericin B|Cochleate-Amphotericin B|Lipid-crystal Nano-particle Formulation of Amphotericin B|Lipid-crystal Nanoparticle-based Amphotericin B Formulation|MAT2203|Nano-cochleated-particles containing Amphotericin B|Oral Encochleated Amphotericin B	A proprietary, orally bioavailable, nanoparticle-based encochleated formulation composed of amphotericin B, a polyene antifungal antibiotic produced by Streptomyces nodosus, encochleated within lipid-based crystals, which are composed of multi-layered, rolled-up sheets of soy-derived phosphatidylserine (PS) bilayers and calcium, with broad-spectrum antifungal activity. Upon oral administration, the cochleate crystal structure protects amphotericin B from degradation within the gastrointestinal (GI) tract. The lipid structure facilitates uptake into the bloodstream where the nanoparticles are taken up by macrophages and fungal cells though phagocytosis. Amphotericin B is released from the cochleate due to the calcium differential between the inside of the cell, which has low calcium levels, and the outside of the cell, which has high calcium levels. This delivers amphotericin B directly to the fungal-infected site and to its target cells. In turn, amphotericin B binds to ergosterol, an essential component of the fungal cell membrane. This results in depolarization of the cell membrane, alterations in cell membrane permeability, leakage of important intracellular components, and cell rupture. This causes fungal cell death and prevents fungal infections. Compared to amphotericin B alone, which can only be administered intravenously (IV), this formulation permits oral administration and reduces treatment-limiting side effects that are seen with IV amphotericin B, particularly nephro- and hepato-toxicity.			Antibiotic|Organic Chemical|Pharmacologic Substance	NCI Drug Dictionary Terminology
C150701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150701>	C3107	Langerhans Cell Histiocytosis, Monostotic|Langerhans cell histiocytosis, mono-ostotic	Langerhans cell histiocytosis presenting as a solitary lesion.			Neoplastic Process	GDC Terminology|GDC Value Terminology
C150702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150702>	C3107	Langerhans Cell Histiocytosis, Polyostotic|Langerhans cell histiocytosis, poly-ostotic	Langerhans cell histiocytosis presenting with multiple sites of involvement.			Neoplastic Process	GDC Terminology|GDC Value Terminology
C150703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150703>	C3107	Langerhans Cell Histiocytosis, Disseminated|Langerhans cell histiocytosis, disseminated	Langerhans cell histiocytosis presenting with disseminated disease.			Neoplastic Process	GDC Terminology|GDC Value Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C150704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150704>	C213904|C172847	EBV-Positive Inflammatory Follicular Dendritic Cell/Fibroblastic Reticular Cell Tumor of the Digestive System|EBV-Positive Inflammatory Follicular Dendritic Cell Sarcoma of the Digestive System|EBV-Positive Inflammatory Follicular Dendritic Cell Tumor of the Digestive System|Epstein-Barr Virus Positive Inflammatory Follicular Dendritic Cell Sarcoma of the Digestive System|Epstein-Barr Virus-Positive Inflammatory Follicular Dendritic Cell Sarcoma of the Digestive System|Inflammatory Pseudotumor-Like Follicular/Fibroblastic Dendritic Cell Sarcoma of the Digestive System	EBV-positive inflammatory follicular dendritic cell/fibroblastic reticular cell tumor that arises from the digestive system.			Neoplastic Process	
C150705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150705>	C36386|C133155	MTOR Gene Rearrangement|FK506 Binding Protein 12-Rapamycin Associated Protein 1 Gene Rearrangement|FRAP1 Gene Rearrangement|Mammalian Target of Rapamycin Gene Rearrangement|Mechanistic Target of Rapamycin Gene Rearrangement	A molecular abnormality indicating rearrangement of the MTOR gene.	MTOR Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C150706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150706>	C177692	MUC1 Positive|CD227 Antigen Positive|CD227 Positive|Carcinoma-Associated Mucin Positive|EMA Positive|Epithelial Membrane Antigen Positive|H23 Antigen Positive|H23AG Positive|KL-6 Positive|MAM6 Positive|MCD Positive|MUC-1 Antigen Positive|MUC-1 Positive|Mucin 1 Positive|Mucin-1 Positive|PEM Positive|PEMT Positive|PUM Positive|Peanut-Reactive Urinary Mucin Positive|Polymorphic Epithelial Mucin Positive|Tumor-Associated Epithelial Membrane Antigen Positive	An indication that expression of MUC1 has been detected in a sample.	MUC1 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150707>	C63587	Cetuximab/Cisplatin/Docetaxel Regimen|Cisplatin and Docetaxel (DC) and Cetuximab|Cisplatin-Docetaxel-Cetuximab|Cisplatin-Docetaxel-Cetuximab Regimen|Cisplatin/Docetaxel/Cetuximab|Cisplatin/Docetaxel/Cetuximab Regimen|Docetaxel/Cisplatin/Cetuximab|TPE|TPEx|Taxotere/Platinol/Erbitux	A regimen consisting of cisplatin, docetaxel and cetuximab that can be used for the treatment of head and neck cancer and non-small cell lung cancer (NSCLC).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C150708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150708>	C97927	XK Gene Mutation|KX Gene Mutation|Kell Blood Group Precursor Gene Mutation|McLeod Syndrome Gene Mutation|NA Gene Mutation|NAC Gene Mutation|Neuroacanthocytosis Gene Mutation|Neurocanthocytosis Gene Mutation|Precursor Substance, Kell Blood Group Gene Mutation|X-Linked Kx Blood Group Gene Mutation|X1k Gene Mutation|XK Locus Gene Mutation|XKR1 Gene Mutation	A change in the nucleotide sequence of the XK gene.	XK Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150709>	C138182	Neoplastic Plasma Cells 20 Percent or Less of Bone Marrow Nucleated Cells|Neoplastic Plasma Cells Less than or Equal to 20 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that 20 percent or less of the nucleated cells in a bone marrow sample are neoplastic plasma cells.	Neoplastic Plasma Cells 20 Percent or Less of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C150710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150710>	C41036	Neoplastic Plasma Cells 60 Percent or More of Bone Marrow Nucleated Cells|Neoplastic Plasma Cells Greater than or Equal to 60 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that 60 percent or more of the nucleated cells in a bone marrow sample are neoplastic plasma cells.	Neoplastic Plasma Cells 60 Percent or More of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C150711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150711>	C41031	Neoplastic Plasma Cells 10-60 Percent of Bone Marrow Nucleated Cells|Neoplastic Plasma Cells Between 10 and 60 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that between 10 and 60 percent of the nucleated cells in a bone marrow sample are neoplastic plasma cells.	Neoplastic Plasma Cells 10-60 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C150712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150712>	C171053|C133155	NF1 Gene Rearrangement|NF-1 Gene Rearrangement|NFNS Gene Rearrangement|Neurofibromin 1 Gene Rearrangement|Neurofibromin Gene Rearrangement	A molecular abnormality indicating rearrangement of the NF1 gene.	NF1 Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C150713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150713>	C177692	NF1 Positive|NF-1 Positive|Neurofibromin 1 Positive|Neurofibromin Positive	An indication that expression of NF1 has been detected in a sample.	NF1 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150714>	C133155	NF2 Gene Rearrangement|ACN Gene Rearrangement|BANF Gene Rearrangement|Merlin Gene Rearrangement|NF-2 Gene Rearrangement|Neurofibromin 2 Gene Rearrangement|SCH Gene Rearrangement	A molecular abnormality indicating rearrangement of the NF2 gene.	NF2 Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150715>	C177686|C150123	Mutation-Positive Lynch Syndrome	A finding of Lynch syndrome in which one is identified as a carrier or obligate carrier of a pathogenic mutation(s) in one of several DNA mismatch repair genes, including MLH1, MSH2/EPCAM, MSH6 or PMS2.			Finding	
C150716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150716>	C177687|C173902	Mutation-Negative Lynch Syndrome|Lynch-Like Syndrome|Lynch-Like Syndrome	A finding of Lynch syndrome in which one is identified as having a "non-sporadic" DNA mismatch repair (MMR) deficient premalignant lesion or "non-sporadic" MMR deficient malignant tumor, but germline MMR genetic testing did not demonstrate a recognized pathogenic mutation in the genes responsible for DNA mismatch repair.	Mutation-Negative Lynch Syndrome		Finding	CTRP Disease Terminology|CTRP Terminology
C150717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150717>	C1946|C129825	Panobinostat Nanoparticle Formulation MTX110|MTX 110|MTX-110|MTX110	A gold nanoparticle (GNP)-based formulation containing panobinostat, a pan histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon intra-tumoral injection of MTX110, panobinostat is released from the formulation and selectively targets, binds to and inhibits histone deacetylase (HDAC), which induces hyperacetylation of core histone proteins. The accumulation of highly acetylated histones leads to chromatin remodeling, an altered pattern of gene expression, inhibition of tumor oncogene transcription and the selective transcription of tumor suppressor genes. This results in the inhibition of tumor cell division and the induction of tumor cell apoptosis. HDAC, upregulated in many tumor cell types, is an enzyme family that deacetylates histone proteins. Panobinostat is water insoluble and does not cross the blood-brain barrier (BBB) when administered orally or intravenously. MTX110 solubilizes panobinostat and can be directly injected into the brain, which bypasses the BBB and delivers high concentrations of panobinostat to the tumor, while minimizing systemic toxicity.	Panobinostat Nanoparticle Formulation MTX110		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150718>	C54153	Tissue Procurement	The removal of tissues from a donor for the purpose of transplantation.			Activity	
C150719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150719>	C25188	Eloped|Elope				Organism Attribute	
C150720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150720>	C25188	Engaged|Engaged to be married|Engagement	In a formal agreement for marriage.			Organism Attribute	
C150721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150721>	C51774|C210448	Single|Single Person	Never married.			Organism Attribute	
C150722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150722>	C198996	Widow	A woman who has lost her spouse by death and has not remarried.			Human	
C150723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150723>	C198996	Widowed or Surviving Civil Partner|Widowed/surviving civil partner	An individual who has lost their spouse by death, has not remarried, and who has legal rights related to the estate of the deceased spouse.			Organism Attribute	
C150724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150724>	C198996	Widower	A man who has lost his spouse by death and has not remarried.			Human	
C150725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150725>	C198996	Bachelor	A man who is not, and has never been, married.			Organism Attribute	
C150727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150727>	C150720	Broken Engagement|Broken engagement	A formal agreement or promise to marry that is ended before the marriage takes place.			Organism Attribute	
C150728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150728>	C25188	Broken with Partner|Broken with partner	The ending of a social partnership.			Organism Attribute	
C150729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150729>	C94852	Cohabitee Left Home|Cohabitee left home	An indication that an individual who is or was living with another person left their shared home.			Organism Attribute	
C150730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150730>	C150729	Spouse Left Home|Spouse left home	An indication that a married individual who is or was living with another person left their shared home.			Organism Attribute	
C150731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150731>	C150730	Husband Left Home|Husband left home	An indication that a male, married individual who is or was living with another person left their shared home.			Organism Attribute	
C150732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150732>	C150730	Wife Left Home|Wife left home	An indication that a female, married individual who is or was living with another person left their shared home.			Organism Attribute	
C150733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150733>	C92454	Cohabitating	Living together as if married, usually without legal or religious sanction.			Organism Attribute	
C150734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150734>	C28227|C134305|C128057	Anti-LAG-3/PD-L1 Bispecific Antibody FS118|FS118|LAG-3/PD-L1 Bispecific Antibody FS118|LAG-3/PD-L1 Mab2 FS118|Mab2 FS118	A bispecific antibody directed against two immune checkpoint proteins, the inhibitory receptor lymphocyte activation gene 3 protein (LAG3; LAG-3) and the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. FS118 is generated by incorporating an anti-LAG-3 Fc-region with antigen binding (Fcab) into a PD-L1-specific antibody. Upon administration, FS118 simultaneously targets and binds to LAG3 expressed on T-cells in the tumor microenvironment (TME) and PD-L1 expressed on tumor cells. This prevents LAG3- and PD-L1-mediated signaling, reverses T-cell inactivation, activates the immune system and enhances cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses against PD-L1-expressing tumor cells, which together lead to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF) negatively regulates both proliferation and activation of T-cells. Its expression is associated with tumor-mediated immune suppression. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to its receptor programmed death 1 (PD-1; PDCD1; CD279) on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.	Anti-LAG-3/PD-L1 Bispecific Antibody FS118		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150735>	C25188	Common Law Partnership|Common Law Marriage|Common law partnership	A legal status where individuals are living in a continuous, conjugal relationship for a period of time defined by law.			Organism Attribute	
C150736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150736>	C25188	Civil Partnership Dissolved|Divorced/person whose civil partnership has been dissolved	Indicates that a civil partnership has been legally dissolved.			Organism Attribute	
C150738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150738>	C53999|C153069	Metastatic Gastrointestinal Stromal Tumor|Metastatic Gastrointestinal Stromal Tumor (GIST)	A gastrointestinal stromal tumor that has spread from its original site of growth to another anatomic site.	Metastatic Gastrointestinal Stromal Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150739>	C153066|C150738	Locally Advanced Gastrointestinal Stromal Tumor|Locally Advanced Gastrointestinal Stromal Tumor (GIST)	A gastrointestinal stromal tumor that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Gastrointestinal Stromal Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150741>	C53999|C153068	Unresectable Malignant Gastrointestinal Stromal Tumor|Unresectable Gastrointestinal Stromal Tumor|Unresectable Gastrointestinal Stromal Tumor (GIST)	A malignant gastrointestinal stromal tumor that is not amenable to surgical resection.	Unresectable Gastrointestinal Stromal Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C150742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150742>	C25188	Marital or Civil Status Not Disclosed|Marital/civil state not disclosed	An indication that the marital or civil status of a relationship has not been disclosed.			Organism Attribute	
C150743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150743>	C198996	Married or Civil Partner|Married/civil partner	An indication that an individual is in a legally recognized relationship with another person, with the same rights and responsibilities as a marriage.			Organism Attribute	
C150744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150744>	C25188	Monogamous	An indication that an individual is or was married to single individual at a given time.			Organism Attribute	
C150745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150745>	C25188	Newly Wed|Newly wed|Newlywed	An indication that an individual has recently married.			Organism Attribute	
C150746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150746>	C25188	Purposely Unmarried and Sexually Abstinent|Purposely unmarried and sexually abstinent	An indication that an individual is intentionally not married and abstains from engaging in sexual activities.			Organism Attribute	
C150747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150747>	C25188	Remarried	An indication that an individual has married, after already having been married at least once.			Organism Attribute	
C150748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150748>	C51777	Separated from Cohabitee|Separated from cohabitee	An indication that an individual is separated from the person with whom they were sharing a home.			Organism Attribute	
C150749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150749>	C198996	Spinster	An unmarried, older woman, beyond the usual age for marriage.			Organism Attribute	
C150750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150750>	C51777	Trial Separation|Trial separation	An indication that a couple has informally separated.			Organism Attribute	
C150751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150751>	C29696|C265	Venlafaxine Hydrochloride Extended Release|Effexor XR|Venlafaxine HCl ER	An extended-release (ER) formulation composed of the hydrochloride salt form of venlafaxine, a synthetic phenethylamine bicyclic derivative and serotonin (5-hydroxytryptamine; 5-HT) and norepinephrine (NE) reuptake inhibitor (SNRI), with antidepressant and anti-anxiety activities and with potential use in the treatment of neuropathic pain. Upon administration, venlafaxine is released from the formulation in a controlled manner for an extended period of time. Venlafaxine, and its main active metabolite, O-desmethylvenlafaxine (ODV), selectively bind to the pre-synaptic 5-HT and NE transporters in the synaptic cleft and inhibit the re-uptake of 5-HT and NE, and to a lesser extent dopamine, thereby prolonging and potentiating the activities and signaling mediated by these neurotransmitters in the central nervous system (CNS). This relieves depressive and anxious states. Additionally, venlafaxine may exert analgesic effects through blockade of neuronal NE reuptake and inhibition of nociceptive pathways, or through its potential to regulate monoaminergic and opioidergic systems.	Venlafaxine Hydrochloride Extended Release		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C150752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150752>	C154624	Home Health Encounter|HH|Home|Home Care Visit|Home Health	A patient encounter that takes place in a private home.	Home Health Encounter		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C150753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150753>	C154624	Inpatient Encounter|IMP|In Patient|Inpatient|Inpatient Visit	A patient encounter where a patient is admitted to a hospital or equivalent facility.			Conceptual Entity	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C150754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150754>	C150753	Inpatient Acute Care Encounter|ACUTE|Acute Inpatient Care|Inpatient Acute|Inpatient Acute Care|Inpatient Acute Care Visit	An inpatient encounter for short-term treatment of a severe injury or episode of illness, or other urgent medical condition.			Conceptual Entity	
C150755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150755>	C150753	Inpatient Non-acute Care Encounter|Inpatient Non-acute|Inpatient Non-acute Care|Inpatient Non-acute Care Visit|NONAC|Non-Acute Inpatient Care|Non-Acute Institutional Stay	An inpatient encounter for a non-acute condition.			Conceptual Entity	
C150756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150756>	C208255|C192655|C141144|C129820	Maplirpacept|MAPLIRPACEPT|PF 07901801|PF-07901801|PF07901801|SIRPa-IgG4 Fc|SIRPa-IgG4 Fc TTI-622|SIRPa-IgG4-Fc Fusion Protein TTI-622|TTI 622|TTI-622|TTI622	A soluble recombinant antibody-like fusion protein composed of the N-terminal CD47 binding domain of human signal-regulatory protein alpha (SIRPa; CD172a) linked to an Fc domain derived from human immunoglobulin G subtype 4 (IgG4), with potential immune checkpoint inhibitory, phagocytosis-inducing and antineoplastic activities. Upon administration, maplirpacept selectively targets and binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with endogenous SIRPa, a cell surface protein expressed on macrophages. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation. This induces pro-phagocytic signaling resulting from the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1) expressed on macrophages, and results in macrophage activation and the specific phagocytosis of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSC) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects tumor cells from phagocytosis, thereby allowing these cells to proliferate and survive.	Maplirpacept		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150757>	C62143	Pre-admission Encounter|PRENC|Pre-admission|Pre-admission	A patient encounter that takes place before the planned date for a medical service.			Conceptual Entity	
C150758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150758>	C62143	Short Stay|SS|Short Stay Encounter	A patient encounter where the patient is admitted to a health care facility for a predetermined length of time, usually less than 24 hours.			Conceptual Entity	
C150759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150759>	C39564	Virtual Patient Encounter|VIRTUAL VISIT|VR|Virtual|Virtual Encounter|Virtual Visit	A patient encounter where the patient and the practitioner(s) are not in the same physical location and the interaction takes place by electronic means.	Virtual Patient Encounter		Conceptual Entity	CDISC SDTM Health Care Encounters Dictionary Derived Term Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C150760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150760>	C62143	Emergency Department Admit to Inpatient Hospital Stay|EI	A patient encounter that begins in an emergency department and the patient is subsequently admitted to a hospital as an inpatient.			Conceptual Entity	
C150761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150761>	C62143	Observation Stay|OS	A patient encounter where the patient receives short-term treatment in a hospital but is not admitted and remains classified as an outpatient.			Conceptual Entity	
C150762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150762>	C62143	Institutional Professional Consultation|IC	A patient encounter with a healthcare professional for a medical consultation.			Conceptual Entity	
C150763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150763>	C21541	General Medical Unit|General Medical Ward|General Ward	The part or unit of a hospital that provides care to adult patients with a variety of general medical needs.			Health Care Related Organization	
C150764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150764>	C21541	Oncology Unit|Oncology Department|Oncology Ward	The part or unit of a hospital that provides specialized care for patients undergoing treatment for cancer.			Health Care Related Organization	
C150765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150765>	C115302	CDISC Functional Test COWAT Test Name Terminology|COWAT1TN|Controlled Oral Word Association Test Functional Test Test Name|FT-COWAT TEST	Test names of functional test questions associated with the Controlled Oral Word Association Test (COWAT) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150766>	C115302	CDISC Functional Test COWAT Test Code Terminology|COWAT1TC|Controlled Oral Word Association Test Functional Test Test Code|FT-COWAT TESTCD	Test codes of functional test questions associated with the Controlled Oral Word Association Test (COWAT) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150767>	C115302	CDISC Functional Test ERT Test Name Terminology|EMO1TN|Emotion Recognition Functional Test Test Name|FT-ERT TEST	Test names of functional test questions associated with the Emotion Recognition Test (ERT) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150768>	C115302	CDISC Functional Test ERT Test Code Terminology|EMO1TC|Emotion Recognition Functional Test Test Code|FT-ERT TESTCD	Test codes of functional test questions associated with the Emotion Recognition Test (ERT) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150769>	C115302	CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|FT-MMSE-2 Standard Version TEST|MMS2TN|Mini-Mental State Examination 2 Standard Version Functional Test Test Name	Test names of functional test questions associated with the Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150770>	C115302	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|FT-MMSE-2 Standard Version TESTCD|MMS2TC|Mini-Mental State Examination 2 Standard Version Functional Test Test Code	Test codes of functional test questions associated with the Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150771>	C115302	CDISC Functional Test Paced Tapping Test Name Terminology|FT-Paced Tapping TEST|PTAP1TN|Paced Tapping Functional Test Test Name	Test names of functional test questions associated with the Paced Tapping Test (Paced Tapping) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150772>	C115302	CDISC Functional Test Paced Tapping Test Code Terminology|FT-Paced Tapping TESTCD|PTAP1TC|Paced Tapping Functional Test Test Code	Test codes of functional test questions associated with the Paced Tapping Test (Paced Tapping) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150773>	C100110	CDISC Questionnaire FACT-C Version 4 Test Name Terminology|FAC008TN|Functional Assessment of Cancer Therapy-Colorectal Version 4 Questionnaire Test Name|QS-FACT-C Version 4 TEST	Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150774>	C100110	CDISC Questionnaire FACT-C Version 4 Test Code Terminology|FAC008TC|Functional Assessment of Cancer Therapy-Colorectal Version 4 Questionnaire Test Code|QS-FACT-C Version 4 TESTCD	Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150775>	C100110	CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|FAC063TN|Functional Assessment of Cancer Therapy-Taxane Version 4 Questionnaire Test Name|QS-FACT-Taxane Version 4 TEST	Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150776>	C100110	CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|FAC063TC|Functional Assessment of Cancer Therapy-Taxane Version 4 Questionnaire Test Code|QS-FACT-Taxane Version 4 TESTCD	Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150777>	C100110	CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|FAC062TN|Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 Questionnaire Test Name|QS-FACT-BRM Version 4 TEST	Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150778>	C100110	CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|FAC062TC|Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 Questionnaire Test Code|QS-FACT-BRM Version 4 TESTCD	Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150779>	C100110	CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|FAC057TN|Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 Questionnaire Test Name|QS-FACT/GOG-NTX Version 4 TEST	Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150780>	C100110	CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|FAC057TC|Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 Questionnaire Test Code|QS-FACT/GOG-NTX Version 4 TESTCD	Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150781>	C100110	CDISC Questionnaire FACT-L Version 4 Test Name Terminology|FAC016TN|Functional Assessment of Cancer Therapy-Lung Version 4 Questionnaire Test Name|QS-FACT-L Version 4 TEST	Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150782>	C100110	CDISC Questionnaire FACT-L Version 4 Test Code Terminology|FAC016TC|Functional Assessment of Cancer Therapy-Lung Version 4 Questionnaire Test Code|QS-FACT-L Version 4 TESTCD	Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150783>	C100110	CDISC Questionnaire FKSI-DRS Version 4 Test Name Terminology|FAC041TN|Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms Version 4 Questionnaire Test Name|QS-FKSI-DRS Version 4 TEST	Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms Version 4 (FKSI-DRS Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150784>	C100110	CDISC Questionnaire FKSI-DRS Version 4 Test Code Terminology|FAC041TC|Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms Version 4 Questionnaire Test Code|QS-FKSI-DRS Version 4 TESTCD	Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms Version 4 (FKSI-DRS Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150785>	C100110	CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Name Terminology|FAC030TN|National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 Questionnaire Test Name|QS-NCCN-FACT FBRSI-24 Version 2 TEST	Test names of questionnaire questions associated with the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150786>	C100110	CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Code Terminology|FAC030TC|National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 Questionnaire Test Code|QS-NCCN-FACT FBRSI-24 Version 2 TESTCD	Test codes of questionnaire questions associated with the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150787>	C100110	CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Name Terminology|FAC036TN|National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 Questionnaire Test Name|QS-NCCN-FACT FHNSI-22 Version 2 TEST	Test names of questionnaire questions associated with the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150788>	C100110	CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Code Terminology|FAC036TC|National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 Questionnaire Test Code|QS-NCCN-FACT FHNSI-22 Version 2 TESTCD	Test codes of questionnaire questions associated with the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150789>	C100110	CDISC Questionnaire SIQ Test Name Terminology|QS-SIQ TEST|SIQ01TN|Suicidal Ideation Questionnaire Test Name	Test names of questionnaire questions associated with the Suicidal Ideation Questionnaire (SIQ) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150790>	C100110	CDISC Questionnaire SIQ Test Code Terminology|QS-SIQ TESTCD|SIQ01TC|Suicidal Ideation Questionnaire Test Code	Test codes of questionnaire questions associated with the Suicidal Ideation Questionnaire (SIQ) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150791>	C100110	CDISC Questionnaire SIQ-JR Test Name Terminology|QS-SIQ-JR TEST|SIQ02TN|Suicidal Ideation Questionnaire-JR Questionnaire Test Name	Test names of questionnaire questions associated with the Suicidal Ideation Questionnaire-Junior (SIQ-JR) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150792>	C100110	CDISC Questionnaire SIQ-JR Test Code Terminology|QS-SIQ-JR TESTCD|SIQ02TC|Suicidal Ideation Questionnaire-JR Questionnaire Test Code	Test codes of questionnaire questions associated with the Suicidal Ideation Questionnaire-Junior (SIQ-JR) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150793>	C211913	COWAT Functional Test Question	A question associated with the COWAT functional test.			Intellectual Product	
C150794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150794>	C211913	MMSE-2 Standard Version Functional Test Question	A question associated with the MMSE-2 functional test.			Intellectual Product	
C150795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150795>	C211913	ERT Functional Test Question	A question associated with the ERT functional test.			Intellectual Product	
C150796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150796>	C211913	Paced Tapping Functional Test Question	A question associated with the Paced Tapping functional test.			Intellectual Product	
C150797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150797>	C211913	FACT-C Version 4 Questionnaire Question	A question associated with the FACT-C Version 4 questionnaire.			Intellectual Product	
C150798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150798>	C211913	FACT-Taxane Version 4 Questionnaire Question	A question associated with the FACT-Taxane Version 4 questionnaire.			Intellectual Product	
C150799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150799>	C211913	FACT-BRM Version 4 Questionnaire Question	A question associated with the FACT-BRM Version 4 questionnaire.			Intellectual Product	
C1507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1507>	C29713|C270	Prazosin Hydrochloride|Alpress LP|CP-12299-1|Duramipress|Eurex|Hypovase|Minipress|Minipress|PRAZOSIN HYDROCHLORIDE|Peripress|Prazosin hydrochloride|Sinetens	A synthetic piperazine derivative with hypotensive antiadrenergic properties, Prazosin Hydrochloride reduces peripheral resistance and relaxes vascular smooth muscles as a selective adrenergic alpha-1 antagonist by a mechanism not completely known. It is used in the treatment of heart failure, hypertension, pheochromocytoma, Raynaud's syndrome, prostatic hypertrophy, and urinary retention. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C150800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150800>	C211913	FACT/GOG-NTX Version 4 Questionnaire Question	A question associated with the FACT/GOG-NTX Version 4 questionnaire.			Intellectual Product	
C150801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150801>	C211913	FACT-L Version 4 Questionnaire Question	A question associated with the FACT-L Version 4 questionnaire.			Intellectual Product	
C150802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150802>	C211913	FKSI-DRS Version 4 Questionnaire Question	A question associated with the FKSI-DRS Version 4 questionnaire.			Intellectual Product	
C150803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150803>	C211913	NCCN-FACT FBRSI-24 Version 2 Questionnaire Question	A question associated with the NCCN-FACT FBRSI-24 Version 2 questionnaire.			Intellectual Product	
C150804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150804>	C211913	NCCN-FACT FHNSI-22 Version 2 Questionnaire Question	A question associated with the NCCN-FACT FHNSI-22 Version 2 questionnaire.			Intellectual Product	
C150805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150805>	C211913	SIQ Questionnaire Question	A question associated with the SIQ questionnaire.			Intellectual Product	
C150806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150806>	C211913	SIQ-JR Questionnaire Question	A question associated with the SIQ-JR questionnaire.			Intellectual Product	
C150807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150807>	C2150|C1557	Gemcitabine-Releasing Intravesical System|GemRIS|Inlexzo|TAR 200|TAR-200	A controlled-release intravesical system consisting of a small flexible tube-like device with a solid core composed of gemcitabine, a broad-spectrum antimetabolite and deoxycytidine analogue, with antineoplastic activity. Upon placement of the gemcitabine-releasing intravesical system (GemRIS) into the bladder, gemcitabine is gradually and continuously released from the system over an extended period of time before being removed from the bladder. Upon release, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA, resulting in premature termination of DNA replication and the induction of apoptosis of bladder tumor cells. In addition, dFdCDP inhibits ribonucleotide reductase (RNR) and reduces the deoxynucleotide pool available for DNA synthesis.	Gemcitabine-Releasing Intravesical System		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150808>	C62727	Magnetic Resonance-Guided Radiotherapy|MRGRT|MRgRT|Magnetic-Resonance Guided Radiotherapy	A therapeutic procedure that utilizes magnetic resonance imaging for detailed anatomic visualization immediately before or during radiation treatment.	Magnetic Resonance-Guided Radiotherapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C150809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150809>	C1752|C1663	Synthetic Long HPV16 E6/E7 Peptides Vaccine ISA101b|HPV16 E6/E7-SLP ISA101b|ISA 101b|ISA-101b|ISA101b	A therapeutic peptide vaccine consisting of nine overlapping synthetic long peptides (SLPs), 25 to 32 amino acids in size, derived from the human papillomavirus (HPV) type 16 (HPV16) oncoprotein E6 and three SLPs, each 35 amino acids in size, derived from HPV16 E7, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the synthetic long HPV16 E6/E7 peptides vaccine ISA101b is taken up and the long peptides are proteolytically degraded to form shorter peptide epitopes by dendritic cells (DCs). The processed viral epitopes are presented by DCs, which stimulate the host immune system to mount helper T-cell and cytotoxic T-lymphocyte (CTL) responses against HPV16 E6/E7-expressing tumor cells. This results in the destruction of tumor cells and leads to decreased tumor growth. The HPV16 E6 and E7 oncoproteins are implicated in the tumorigenesis of a variety of cancers. The SLPs allow optimal presentation by antigen-presenting cells (APCs). Compared to ISA101, the E6 SLPs in ISA101b are identical, overlap by ten to eighteen residues and cover the complete sequence of HPV16 E6. However, ISA101 has four overlapping SLPs E7 peptides while ISA101b has three E7 SLPs, which leaves seven amino acids of the E7 SLPs uncovered in ISA101b but this modification is not likely to alter the immunogenicity of ISA101b.	Synthetic Long HPV16 E6/E7 Peptides Vaccine ISA101b		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150810>	C77526	CDISC SEND Null Flavor Reason Terminology|NULLFLAV|Null Flavor Reason|SEND-NULLFLAV	The terminology that includes concepts relevant to the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND) null flavor.			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150811>	C66830	CDISC SDTM Other Disposition Event Response Terminology|OTHEVENT|Other Disposition Event Response|SDTM-OTHEVENT	Terminology associated with the other event codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150812>	C66830	CDISC SDTM CDAD Findings About Test Code Terminology|CDAD Findings About Test Code|CDFATSCD|SDTM-CDFATSCD	Terminology associated with the Clostridium difficile-associated diarrhea findings about test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150813>	C66830	CDISC SDTM CDAD Findings About Test Name Terminology|CDAD Findings About Test Name|CDFATS|SDTM-CDFATS	Terminology associated with the Clostridium difficile-associated diarrhea findings about test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150814>	C85534	Albumin Excretion Rate|ALBEXR	A determination of the amount of albumin being excreted in a biological specimen over a defined period of time.			Quantitative Concept	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150815>	C85534	Calcium Excretion Rate|CAEXR	A determination of the amount of calcium being excreted in a biological specimen over a defined period of time.			Quantitative Concept	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150816>	C85534	Chloride Excretion Rate|CLEXR	A determination of the amount of chloride being excreted in a biological specimen over a defined period of time.			Quantitative Concept	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150817>	C85534	Creatinine Excretion Rate|CREATEXR	A determination of the amount of creatinine being excreted in a biological specimen over a defined period of time.			Quantitative Concept	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150818>	C85534	Glucose Excretion Rate|GLUCEXR	A determination of the amount of glucose being excreted in a biological specimen over a defined period of time.			Quantitative Concept	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150819>	C85534	Iron Excretion Rate|IRONEXR	A determination of the amount of iron being excreted in a biological specimen over a defined period of time.			Quantitative Concept	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150820>	C85534	Potassium Excretion Rate|KEXR	A determination of the amount of potassium being excreted in a biological specimen over a defined period of time.			Quantitative Concept	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150821>	C85534	Phosphorus Excretion Rate|PHOSEXR	A determination of the amount of phosphorus being excreted in a biological specimen over a defined period of time.			Quantitative Concept	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150822>	C85534	Protein Excretion Rate|PROTEXR|Total Protein Excretion Rate	A determination of the amount of total protein being excreted in a biological specimen over a defined period of time.			Quantitative Concept	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150823>	C85534	Sodium Excretion Rate|SODMEXR	A determination of the amount of sodium being excreted in a biological specimen over a defined period of time.			Quantitative Concept	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150824>	C74589	Non-Protocol Disposition Event|OTHER EVENT|Other Event	The group of incidents that are not driven by the protocol but that may occur during a clinical trial and describe whether a subject completed the study epoch or the reason this event did not occur.			Intellectual Product	CDISC SDTM Category For Disposition Event Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150825>	C97927	BRD4 Gene Mutation|Bromodomain Containing 4 Gene Mutation|Bromodomain-Containing 4 Gene Mutation|CAP Gene Mutation|Chromosome-Associated Protein Gene Mutation|HUNK1 Gene Mutation|HUNKI Gene Mutation|MCAP Gene Mutation	A change in the nucleotide sequence of the BRD4 gene.	BRD4 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150826>	C49499	Dose Rate Reduced|DOSE RATE REDUCED	An indication that the administration of a medication was modified by reducing the rate at which the dose was given.			Activity	CDISC SDTM Action Taken with Study Treatment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150827>	C25337	Number of Occurrences	The number of times something happened.			Quantitative Concept	
C150828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150828>	C85504	Cycloserine-Cefoxitin Fructose Agar|CCFA|CYCLOSERINE-CEFOXITIN FRUCTOSE AGAR	A solid growth medium mainly consisting of proteose peptone, fructose, cycloserine, cefoxitin, fructose, and egg yolk, which is used primarily for the isolation and cultivation of Clostridium difficile.			Indicator, Reagent, or Diagnostic Aid	CDISC SDTM Culture Medium Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150829>	C85504	Chromogenic Selective Medium|CHROMOGENIC SELECTIVE MEDIUM	A solid growth medium mainly consisting of various peptones, taurocholate and a chromogenic substrate which is used primarily for the isolation and cultivation of Clostridium difficile.			Indicator, Reagent, or Diagnostic Aid	CDISC SDTM Culture Medium Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150830>	C42614	Mononucleotide Marker Name|MONTMKNM|Mononucleotide Marker Names|Mononucleotide Marker Names	The literal identifier of the mononucleotide marker of interest.			Conceptual Entity	CDISC SDTM Device Properties Test Code Terminology|CDISC SDTM Device Properties Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|Mercaptopurine/Methotrexate/Tretinoin
C150831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150831>	C42614	Pentanucleotide Marker Name|PENTMKNM|Pentanucleotide Marker Names|Pentanucleotide Marker Names	The literal identifier of the pentanucleotide marker of interest.			Conceptual Entity	CDISC SDTM Device Properties Test Code Terminology|CDISC SDTM Device Properties Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|Mercaptopurine/Methotrexate/Tretinoin
C150832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150832>	C42614	Software Name|SFTWRNAM	The literal identifier of the software program.			Conceptual Entity	CDISC SDTM Device Properties Test Code Terminology|CDISC SDTM Device Properties Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|Mercaptopurine/Methotrexate/Tretinoin
C150833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150833>	C75345	6 Beta-Hydroxycortisol Measurement|6 Beta-Hydrocortisol|6 Beta-Hydroxycortisol|6 Beta-Hydroxycortisol|6 beta-OHF|6-Beta-Hydrocortisol Measurement|OHF6B	The determination of the amount of 6 beta-hydroxycortisol present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150834>	C67208	Abnormal Cells to Leukocytes Ratio Measurement|ABNCELE|Abnormal Cells/Leukocytes|Abnormal Cells/Leukocytes	The determination of the ratio of abnormal cells compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150835>	C48938	Abnormal Cells to Total Cells Ratio Measurement|ABNCECE|Abnormal Cells/Total Cells|Abnormal Cells/Total Cells	The determination of the ratio of abnormal cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150836>	C67208	Blasts to Total Cells Ratio Measurement|BLASTCE|BLASTCE|Blasts to Nucleated Cells Ratio Measurement|Blasts/Total Cells|Blasts/Total Cells|Blasts/Total Cells	The determination of the ratio of blasts compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150837>	C74760	C-peptide to Creatinine Ratio Measurement|C Peptide to Creatinine Ratio Measurement|C-peptide/Creatinine|C-peptide/Creatinine|CPEPCRT	The determination of the ratio of C-peptide compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150838>	C74722	Cylindroid Cast Measurement|CSCYL|Cylindroid Casts|Cylindroid Casts|Cylindroid Pseudocasts	The determination of the amount of cylindroid casts present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150839>	C67208	Dysmorphic Erythrocytes to Erythrocytes Ratio Measurement|Dysmorphic Erythrocytes/Erythrocytes|Dysmorphic Erythrocytes/Erythrocytes|RBCDYRBC	The determination of the ratio of dysmorphic erythrocytes compared to total erythrocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150840>	C67208	Eosinophils to Nucleated Cells Ratio Measurement|EOSNUCCE|Eosinophils/Nucleated Cells|Eosinophils/Nucleated Cells	The determination of the ratio of eosinophils compared to nucleated cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Cell Phenotyping Test Code Terminology|CDISC SDTM Cell Phenotyping Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150841>	C48938	Nucleated Cell Count|NUCCE|NUCCE|Nucleated Cells|Nucleated Cells|Total Nucleated Cells	The determination of the amount of nucleated cells present in a sample.			Laboratory Procedure	CDISC SDTM Cell Phenotyping Test Code Terminology|CDISC SDTM Cell Phenotyping Test Name Terminology|CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150842>	C74782	Free Estradiol Measurement|ESTFR|Estradiol, Free|Estradiol, Free	The determination of the amount of free estradiol present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150843>	C74782	Free Estradiol to Estradiol Ratio Measurement|ESTFREST|Estradiol, Free/Estradiol|Estradiol, Free/Estradiol	The determination of the ratio of free estradiol compared to total estradiol present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150844>	C48938	Glitter Cell Count|GLTRCE|Glitter Cells|Glitter Cells	The determination of the amount of glitter cells present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150845>	C64430	Guanine Deaminase Measurement|GDA|Guanase|Guanine Aminohydrolase|Guanine Deaminase|Guanine Deaminase	The determination of the amount of guanine deaminase present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150846>	C64430	Protein Induced by Vitamin K Absence-II Measurement|DCP|DCP Measurement|Des-Gamma Carboxyprothrombin Measurement|Des-Gammacarboxyprothrombin|Des-Gammacarboxyprothrombin Measurement|PIVKA-II|PIVKA-II Measurement|PIVKAII|Protein Induced by Vitamin K Absence-II|Protein Induced by Vitamin K Absence-II|Protein Induced by Vitamin K Absence/Antagonist-II|Protein Induced by Vitamin K Absence/Antagonist-II Measurement	The determination of the amount of protein induced by vitamin K absence-II present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150847>	C25747	Estimated Creatinine Clearance|CRTCLRE|Creatinine Clearance, Estimated|Creatinine Clearance, Estimated	An estimate of the clearance of endogenous creatinine, used for evaluating the glomerular filtration rate.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150848>	C52786	Hand Digit 1 Proximal Phalanx|PROXIMAL PHALANX 1 OF THE HAND	The long bone in the first finger, as counted from the thenar side of the hand; it is located between, and articulates with, the first metacarpal and the distal phalanx.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150849>	C13056	Brachioradialis Muscle|BRACHIORADIALIS MUSCLE	A muscle that originates from the proximal two-thirds of the lateral supracondylar ridge of the humerus and inserts into the styloid process of the radius; it enables flexion of the elbow and assists with pronation and supination of the forearm.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150850>	C13056	Flexor Digitorum Superficialis Muscle|FLEXOR DIGITORUM SUPERFICIALIS MUSCLE	A muscle that originates in the humeroulnar and radial heads of the forearm and inserts in the middle phalanges of the second through fifth digits of the hand; it is primarily involved in the flexion of the fingers at the proximal interphalangeal joints and is supplied by the median nerve and the ulnar artery.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150851>	C13056	Flexor Pollicis Longus Muscle|FLEXOR POLLICIS LONGUS MUSCLE	A muscle that originates on the anterior surface of the radius and interosseous membrane and inserts into the palmar aspect of the base of the distal phalanx of the thumb; It is involved in flexion of the thumb and is supplied by the anterior interosseous branch of the median nerve and the radial and anterior interosseous arteries.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150852>	C13056	Lumbrical Muscle|LUMBRICAL MUSCLES OF THE HAND	One of a group of four short muscles in the hand that originate on the radial and ulnar sides of the tendons of the flexor digitorum profundus and insert in the radial lateral band of the extensor expansion tendon; they are involved in the extension of the proximal and distal interphalangeal joints, and are supplied by the median and ulnar nerves and the palmar metacarpal arteries.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150853>	C13056	Opponens Pollicis Muscle|OPPONENS POLLICIS MUSCLE	A muscle that originates on the distal border of the flexor retinaculum and the tubercles of the scaphoid and trapezium, and inserts into the lateral aspect of the first metacarpal; it is involved in the rotation and flexion of the thumb and is supplied by the recurrent branch of the medial nerve and the superficial palmar branch of the radial artery.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150854>	C13056	Pronator Quadratus Muscle|PRONATOR QUADRATUS MUSCLE	A muscle that originates on the distal anteriomedial surface of the ulna and inserts in the distal anteriolateral surface of the radius; it is involved in the pronation of the forearm and is supplied by the anterior interosseous nerve and artery.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150855>	C12470	Skin of the Buttock|SKIN OF THE BUTTOCK	The skin or integument covering the buttocks.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150856>	C52376	Skin of the Thigh|SKIN OF THE THIGH	The skin or integument covering the thigh.			Gene or Genome	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150857>	C79448|C150637	C. difficile Glutamate Dehydrogenase Measurement|C. difficile Glutamate Dehydrogenase|C. difficile Glutamate Dehydrogenase|CDFGDH|Clostridium difficile Glutamate Dehydrogenase	The determination of the amount of glutamate dehydrogenase produced by Clostridium difficile present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150858>	C103381	Clostridium difficile A and/or B Toxin Measurement|CDFABTOX|Clostridium difficile A/B Toxin|Clostridium difficile A/B Toxin	The determination of the amount of A and/or B toxin produced by Clostridium difficile present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150859>	C198307	Clostridium difficile tcdA DNA Measurement|CDFTCDAD|Clostridium difficile Toxin A DNA Measurement|Clostridium difficile tcdA DNA|Clostridium difficile tcdA DNA	The determination of the amount of tcdA DNA produced by Clostridium difficile present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150860>	C198307	Clostridium difficile tcdB DNA Measurement|CDFTCDBD|Clostridium difficile Toxin B DNA Measurement|Clostridium difficile tcdB DNA|Clostridium difficile tcdB DNA	The determination of the amount of tcdB DNA produced by Clostridium difficile present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150861>	C198307	Clostridium difficile tcdC DNA Measurement|CDFTCDCD|Clostridium difficile Regulatory Protein DNA Measurement|Clostridium difficile tcdC DNA|Clostridium difficile tcdC DNA	The determination of the amount of tcdC DNA produced by Clostridium difficile present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150862>	C150637	Toxigenic Clostridium difficile Measurement|TOXCDF|Toxigenic Clostridium difficile|Toxigenic Clostridium difficile	The determination of the amount of the Clostridium difficile species that is considered toxigenic in a biological sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150863>	C103381	Clostridium difficile A Toxin Measurement|CDFATOX|Clostridium difficile A Toxin|Clostridium difficile A Toxin	The determination of the amount of A toxin produced by Clostridium difficile present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150864>	C103381	Clostridium difficile B Toxin Measurement|CDFBTOX|Clostridium difficile B Toxin|Clostridium difficile B Toxin	The determination of the amount of B toxin produced by Clostridium difficile present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150865>	C150637	Toxin B-Producing Clostridium difficile Measurement|TOXBPCDF|Toxin B-Producing Clostridium difficile|Toxin B-Producing Clostridium difficile	The determination of the amount of the strain of Clostridium difficile species that produces Toxin B in a biological sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150866>	C198307	Clostridium difficile cdt DNA Measurement|CDFCDTD|Clostridium difficile Binary Toxin DNA Measurement|Clostridium difficile cdt DNA|Clostridium difficile cdt DNA	The determination of the amount of cdt DNA produced by Clostridium difficile present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150867>	C96561	Adjudicator 1|ADJUDICATOR 1	An adjudicator performing the assessment that is given the designation of one.			Professional or Occupational Group	CDISC SDTM Medical Evaluator Identifier Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150868>	C96561	Adjudicator 2|ADJUDICATOR 2	An adjudicator performing the assessment that is given the designation of two.			Professional or Occupational Group	CDISC SDTM Medical Evaluator Identifier Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150869>	C96561	Adjudicator 3|ADJUDICATOR 3	An adjudicator performing the assessment that is given the designation of three.			Professional or Occupational Group	CDISC SDTM Medical Evaluator Identifier Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150870>	C16094	Cardiac Output Thermodilution Method|CARDIAC THERMODILUTION	A technique for calculating cardiac output using a Swan-Ganz catheter that is inserted into the pulmonary artery through a peripheral vein to measure the change in right ventricular outflow blood temperature after a cold saline solution is injected into the right atrium from a proximal catheter port.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150871>	C215114	Electrogastrography|ELECTROGASTROGRAPHY	A non-invasive technique that utilizes abdominal skin electrodes and computerized spectral analysis to assess gastric myoelectrical activity.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150872>	C86063	Microdensitometry|MICRODENSITOMETRY	A technique for measuring microscopic optical density on exposed film or photographic images through the detection of faint spectral lines.			Occupational Activity	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150873>	C17230	Quantitative Ultrasound|QUANTITATIVE ULTRASOUND	A method of empirically measuring the velocity and attenuation of ultrasonic sound waves as they pass through tissue.			Health Care Activity	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150874>	C38101	Single Energy X-Ray Absorptiometry|SXA|SXA SCAN	A technique for measuring anatomical densities in which a single X-ray beam, whose low and high energy is separated, is aimed at the bone or tissue of interest and x-ray absorption is assessed. This technique has multiple applications including the measurement of bone mineral density and bone mineral content and more novel applications such as breast density.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150875>	C17137	Ballpoint Pen Technique|BALLPOINT PEN TECHNIQUE	A technique used to measure the skin induration diameter of intradermal tuberculin tests based on resistance to the movement of a ballpoint pen across the skin.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150876>	C18640|C15959	Cell Based Bioassay|CELL BASED BIOASSAY	An in vitro assay that utilizes live cells to test the biological activity or potency of a drug substance or product.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150877>	C77180	Aspergillus niveus|ASPERGILLUS NIVEUS	A species of mold fungus in the phylum Ascomycota that is commonly found in soil. This species is a rare opportunistic pathogen in humans.			Fungus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150878>	C86752	Staphylococcus capitis Subspecies urealyticus|STAPHYLOCOCCUS CAPITIS SUBSP. UREALYTICUS|Staphylococcus capitis Subspecies ureolyticus	A subspecies of Staphylococcus capitis that is positive for urease activity and is able to produce acid from maltose aerobically.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150879>	C76200	Carbapenem Resistant Acinetobacter|ACINETOBACTER, CARBAPENEM-RESISTANT|Carbapenem-resistant Acinetobacter	Any species, subspecies, or strain of Acinetobacter that is able to grow in the presence of carbapenem.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150880>	C76369	Mycobacterium malmoense|MYCOBACTERIUM MALMOENSE	A species of slow-growing non-photochromogenic bacteria in the genus Mycobacterium. This species is a frequent cause of nontuberculous lung infections in norther Europe.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150881>	C76369	Mycobacterium xenopi|MYCOBACTERIUM XENOPI	A species of slow-growing, nontuberculous bacteria in the genus Mycobacterium. This species is able to cause opportunistic lung infections and extrapulmonary or disseminated disease in immunocompromised individuals.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150882>	C86533	Mycobacterium abscessus Subspecies massiliense|MYCOBACTERIUM ABSCESSUS SUBSP. MASSILIENSE|Mycobacterium massiliense|Mycobacterium massiliense	A subspecies of Mycobacterium abscessus. M. abcessus subsp. massiliense has a truncated erm(41) gene and is susceptible to clarithromycin.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150883>	C86533	Mycobacterium abscessus Subspecies bolletii|MYCOBACTERIUM ABSCESSUS SUBSP. BOLLETII|Mycobacterium bolletii|Mycobacterium bolletii	A subspecies of Mycobacterium abscessus. M. abscessus subsp. bolletii is recognized as a rare pathogen with a functional inducible erythromycin ribosome methyltransferase (erm) (41) gene and macrolide resistance.			Bacterium	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150884>	C74590	Subject Met Eligibility Criteria But Was Not Needed|MET ELIGIBILITY CRITERIA BUT NOT NEEDED|Passed Screening But Not Needed|Qualified But Not Needed|Reserve, Not Used	An indication that the individual met inclusion and exclusion criteria but was ultimately not utilized as a trial subject.			Intellectual Product	CDISC SDTM Reason for Non-Completion Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150885>	C62164	Sitting With Legs Dependent|SITTING, LEGS DEPENDENT|Sitting With Legs Dangling	A dependent position where the legs of a subject dangle or hang down while sitting.			Spatial Concept	CDISC SDTM Body Position Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150886>	C21480	Child Relation|CHILD|Child	An individual's biological or non-biological first generation offspring, including but not limited to biological children (including those born outside of marriage), adopted children, step children, and foster children.			Human	CDISC SDTM Evaluator Terminology|CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C150887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150887>	C42708|C25165	Biological Daughter|DAUGHTER, BIOLOGICAL|Daughter	A female progeny with genetic makeup inherited from the parent.			Human	CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|HL Authorized Value Terminology|HL Family Medical History Table
C150888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150888>	C42708|C25205	Biological Son|Natural Son|SON, BIOLOGICAL|Son	A male progeny with genetic makeup inherited from the parent.			Human	CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Family Medical History Table
C150889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150889>	C38114	Microdialysis Route of Administration|MICRODIALYSIS	Administration through perfusion liquid.			Functional Concept	CDISC SDTM Route of Administration Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150890>	C13236	Abscess Fluid|ABSCESS FLUID	The fluid that is abnormally collected in localized areas of damaged tissue within the body, usually composed of living and dead white blood cells, bacteria, and dead tissue.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150891>	C94552	Alveolar Air|ALVEOLAR AIR	The gas located in the alveolus of the lungs, which takes part in gas exchange with the blood in the pulmonary capillaries.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150892>	C32589	Cervicovaginal Secretion|CERVICOVAGINAL SECRETION	The watery fluid, consisting of vulvar gland, endometrium, and oviduct secretions, cervical mucus, vaginal wall plasma transudate, exfoliated cells, and bacterial and immune cell products, that hydrates and forms an antimicrobial barrier for the mucosa of the lower female genital tract.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150893>	C106485	Serum or Plasma Supernatant|SUPERNATANT, SERUM OR PLASMA	The liquid lying above a liquid, solid or semi-solid residue, which is separated by crystallization, precipitation or centrifugation of a serum or plasma sample.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150894>	C106485	Cerebrospinal Fluid Supernatant|SUPERNATANT, CEREBROSPINAL FLUID	The liquid lying above a liquid, solid or semi-solid residue, which is separated by crystallization, precipitation or centrifugation of a cerebrospinal fluid sample.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150895>	C70699	Swabbed Material|SWABBED MATERIAL	A heterogeneous and variable aggregate of body fluids, tissues, cells, microorganisms, and other materials that are collected from a swab biospecimen collection procedure.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150896>	C62667	Overall Tracer Uptake Compared to Nadir|OTRCUPCN	A visually assessed combination of extent and intensity of tracer uptake, as compared to nadir.			Diagnostic Procedure	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Code Terminology|CDISC SDTM Tumor or Lesion Properties Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C150897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150897>	C25737	Organ of Interest|OOI|Organ Under Study	The identification of an organ that may contain a tumor, lesion or site of disease, and may be part of the objective assessment of the response to the therapeutic intervention.			Qualitative Concept	
C150898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150898>	C48572	Millimeters of Aluminum Equivalents|mmAI|mmAL|mmAL|{mmAL}|{mmAL}	A unit defined as the thickness, in millimeters, of aluminum that has the equivalent degree of attenuation, under specified conditions, as the actual material in use within the procedure.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150899>	C42574	Seconds Per Hour|Seconds per Hour|s/h|s/h|s/h|sec/hr|sec/hr	A rate unit expressed in seconds per period of time equal to sixty minutes.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C1508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1508>	C95942	Retrotransposon|Transposon	Retrotransposons are transposable DNA elements (transposons) that employ retroviral-like reverse transcription during the process of transposition: retrotransposon DNA is first transcribed into an RNA template, then reverse transcribed into DNA, and then inserted into a new genomic site.			Nucleic Acid, Nucleoside, or Nucleotide	
C150900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150900>	C67332	Hybrid Resistance Units|Wood Unit|Wood Units|Wood unit|Wood units|[wood'U]|mmHg*min/L|mmHg*min/L|mm[Hg].min/L|mm[Hg].min/L|mm[Hg].min/l|mm[Hg].min/l	A unit of resistance equal to the number of millimeters of mercury times minutes, per unit of volume equal to one liter.			Quantitative Concept	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 7: Diagnostic Procedures Terminology|CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|UCUM Terminology
C150901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150901>	C48572	Event Unit|EVENTS|{EVENTS}|{EVENTS}	A unit of measure for the number of happenings at a given place or time.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150902>	C48655	Unencoded Data	The source or original information exists but has not yet been translated by an encoding system.			Qualitative Concept	
C150903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150903>	C48655	Temporarily Unavailable|NAV|TEMPORARILY UNAVAILABLE|Temporarily Unknown|Temporarily Unknown	Information is not available currently but expected to be made available in the near future.			Qualitative Concept	CDISC SEND Null Flavor Reason Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150904>	C48655	Masked Data|MASKED|MSK	Information exists but is not provided due to security or privacy concerns.			Qualitative Concept	CDISC SEND Null Flavor Reason Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150905>	C49018	Draining Lymph Node|LYMPH NODE, DRAINING	The lymph node or group of lymph nodes that drain a particular anatomic site or organ.			Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C150906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150906>	C222322|C200766|C176018	Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells|Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-EGFRt T Cells|CD19-CD8CD28zCAR-specific-mbIL15-HER1t T-lymphocytes	A preparation of autologous, genetically modified T-lymphocytes, that have been electroporated ex vivo with sleeping beauty (SB)-derived DNA plasmids, expressing a second-generation chimeric antigen receptor (CAR) composed of a mouse single-chain variable fragment (scFv) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19) that is linked to the co-stimulatory molecules T-cell surface glycoproteins CD8 and CD28 and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3-zeta) and co-expressed with a chimeric membrane-bound fusion protein comprised of interleukin-15 (IL-15) fused to IL-15 receptor (mbIL15) and a safety/kill switch composed of a truncated form of the human epidermal growth factor receptor (ErbB1t; EGFR) (HER1t), with potential immunostimulating and antineoplastic activities. Upon reintroduction of the autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells into the patient, the T-cells target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.  HER1t can promote selective elimination of the CAR-T cells through cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). IL-15 is a pro-survival cytokine that is required for the maintenance of long-lived CD8+ memory T-cells and use of mbIL15 preserves T stem-cell memory (TSCM) through sustained IL-15 signaling, improves T-cell persistence and potentiates the immune response against tumor cells. The SB system permits electroporation of the CAR, the IL-15 fusion variant and safety switch transgenes into T-cells without the need for viral vectors and accelerates the manufacturing process.	Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C150907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150907>	C97927	DOT1L Gene Mutation|DOT1 Gene Mutation|DOT1 Like Histone Lysine Methyltransferase Gene Mutation|DOT1-like, Histone H3 Methyltransferase (S. cerevisiae) Gene Mutation|Histone Methyltransferase DOT1L Gene Mutation|KMT4 Gene Mutation	A change in the nucleotide sequence of the DOT1L gene.	DOT1L Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150908>	C97927	IKBKE Gene Mutation|IKK-E Gene Mutation|IKK-I Gene Mutation|IKKE Gene Mutation|IKKI Gene Mutation|Inhibitor of Kappa Light Polypeptide Gene Enhancer in B-Cells, Kinase Epsilon Gene Mutation|Inhibitor of Nuclear Factor Kappa B Kinase Subunit Epsilon Gene Mutation	A change in the nucleotide sequence of the IKBKE gene.	IKBKE Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C150909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150909>	C222260	Emotion Recognition Test Functional Test|EMO1|EMOTION RECOGNITION|ERT	A standardized method for measuring visibly different facial movements that was developed by Ekman et al in 1976.			Intellectual Product	CDISC Functional Test Category Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150910>	C222259	Mini-Mental State Examination 2 Standard Version Functional Test|MMS2|MMSE-2 STANDARD VERSION|MMSE-2 Standard Version	An updated version of the Mini-Mental State Examination, a brief, quantitative measure of cognitive status in adults, that was originally developed by Marshal Folstein, Susan Folstein and Paul McHugh (Journal of Psychiatric Research, 1975), where the overall difficulty and raw score range remain the same despite modifications to some tasks and replacement of some items.			Intellectual Product	CDISC Functional Test Category Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150911>	C222260	Paced Tapping Test Functional Test|PACED TAPPING|PTAP1|Paced Tapping	A cognitive test that is used to assess sensorimotor synchronization and timing of movement, where a subject produces a series of finger taps, at first in time with an external pacing stimulus and then continuing after the stimulus has ended.			Intellectual Product	CDISC Functional Test Category Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150912>	C91105	Functional Assessment of Cancer Therapy-Colorectal Version 4 Questionnaire|FAC008|FACT-C V4|FACT-C Version 4	A standardized 36-item self-report rating scale to measure quality of life in patients with colorectal cancer that is divided into five subscales: physical, social/family, emotional, and functional well-being, as well as a colorectal cancer specific subscale. Originally developed by Cella, et al. in 1997, it combines the Functional Assessment of Cancer Therapy - General (FACT-G), and the Colorectal Cancer Subscale (CCS).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150913>	C91105	Functional Assessment of Cancer Therapy-Taxane Version 4 Questionnaire|FAC063|FACT-TAXANE V4|FACT-Taxane Version 4	A standardized 43-item self-report rating scale to measure the health related quality of life in patients receiving taxane containing chemotherapy. Originally developed by Cella, et al. in 1997, it combines the 27-item Functional Assessment of Cancer Therapy - General (FACT-G), which is divided into five subscales: physical, social/family, emotional, and functional well-being, with a Taxane subscale that combines the 11-item Neurotoxicity subscale and 5 additional questions assessing symptoms related to arthralgia, myalgia, and skin discoloration.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150914>	C91105	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 Questionnaire|FAC062|FACT-BRM V4|FACT-BRM Version 4	A standardized 40-item self-report rating scale to measure quality of life in cancer patients receiving treatment with biologic response modifiers that is divided into six subscales: physical, social/family, emotional, and functional well-being, as well as two subscales related to physical and mental symptoms common to treatment with biologic response modifiers. Originally developed by Cella, et al. in 1997, it combines the Functional Assessment of Cancer Therapy - General (FACT-G), and two Biologic Response Modifier (BRM) subscales.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150915>	C91105	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 Questionnaire|FAC057|FACT/GOG-NTX V4|FACT/GOG-NTX Version 4	A standardized 38-item self-report rating scale to measure the effects of chemotherapy-induced neuropathy on the quality of life of cancer patients that is divided into five subscales: physical, social/family, emotional, and functional well-being, as well as a subscale to evaluate symptoms and concerns associated with chemotherapy-induced neuropathy. Originally developed by Cella, et al. in 1997, it combines the Functional Assessment of Cancer Therapy - General (FACT-G), and the Gynecologic Oncology Group - Neurotoxicity (GOG-Ntx) subscale.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150916>	C91105	Functional Assessment of Cancer Therapy-Lung Version 4 Questionnaire|FAC016|FACT-L V4|FACT-L Version 4	A standardized 34-item self-report rating scale to measure quality of life in patients with lung cancer that is divided into five subscales: physical, social/family, emotional, and functional well-being, as well as a subscale that is specific to issues faced by lung cancer patients. Originally developed by Cella, et al. in 1997, it combines the Functional Assessment of Cancer Therapy - General (FACT-G), and the Lung Cancer Subscale (LCS).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150917>	C91105	Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms Version 4 Questionnaire|FAC041|FKSI-DRS V4|FKSI-DRS Version 4	A standardized 9-item self-report rating scale developed by Cella, et al. in 2007 to assess disease-related symptoms in patients with kidney cancer.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150918>	C91105	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 Questionnaire|FAC030|NCCN-FACT FBRSI-24 V2|NCCN-FACT FBRSI-24 Version 2	A standardized 24-item self-report rating scale that utilizes a five-point rating scale and a seven-day time frame to assess the symptoms in advanced brain tumors perceived as most important by patients and clinicians. Originally developed by Cella et al. in 2014, it is a modified version of the Functional Assessment of Cancer Therapy-Brain questionnaire (FACT-Br).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150919>	C91105	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 Questionnaire|FAC036|NCCN-FACT FHNSI-22 V2|NCCN-FACT FHNSI-22 Version 2	A standardized 22-item self-report rating scale to assess quality of life for patients diagnosed with head and neck cancers. Originally developed by Cella et al. in 2013, it is a modified version of the Functional Assessment of Cancer Therapy-Head and Neck questionnaire (FACT-HN) and is broken down into disease-related symptoms, treatment side effects, and general function and well-being.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150920>	C91105	Suicidal Ideation Questionnaire|SIQ|SIQ|SIQ01	A standardized 30-item self-report questionnaire developed by William M. Reynolds in 1987 that utilizes a seven-point rating scale to assess the frequency of suicidal thoughts in adolescents grades 10 to 12.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150921>	C91105	Suicidal Ideation Questionnaire-Junior|SIQ-JR|SIQ-JR|SIQ02	A standardized 15-item self-report questionnaire developed by William M. Reynolds in 1987 that utilizes a seven-point rating scale to assess the frequency of suicidal thoughts in adolescents grades 7 to 9.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150922>	C150793	COWAT - Another Word That Begins With R|COWAT1-Another Word That Begins With R|COWAT1-Another Word That Begins With R|COWAT101	Controlled Oral Word Association Test (COWAT) Can you tell me another word that begins with R?			Intellectual Product	CDISC Functional Test COWAT Test Code Terminology|CDISC Functional Test COWAT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150923>	C150793	COWAT - Number Correct Words: C|COWAT1-Number Correct Words: C|COWAT1-Number Correct Words: C|COWAT102	Controlled Oral Word Association Test (COWAT) Number correct words: Now I'm going to give you another letter, and again, say all words beginning with that letter that you can think of. You will have a minute for each one. The first letter is C.			Intellectual Product	CDISC Functional Test COWAT Test Code Terminology|CDISC Functional Test COWAT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150924>	C150793	COWAT - Number Correct Words: F|COWAT1-Number Correct Words: F|COWAT1-Number Correct Words: F|COWAT103	Controlled Oral Word Association Test (COWAT) Number correct words: Now I am going to give another letter. Tell me as many words as you can that begin with F. Tell me as many words as quickly as you can that begin with F.			Intellectual Product	CDISC Functional Test COWAT Test Code Terminology|CDISC Functional Test COWAT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150925>	C150793	COWAT - Number Correct Words: L|COWAT1-Number Correct Words: L|COWAT1-Number Correct Words: L|COWAT104	Controlled Oral Word Association Test (COWAT) Number correct words: Now I am going to give another letter. Tell me as many words as you can that begin with L. Tell me as many words as quickly as you can that begin with L.			Intellectual Product	CDISC Functional Test COWAT Test Code Terminology|CDISC Functional Test COWAT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150926>	C150795	ERT - Total Stimuli Expected|EMO1-Total Stimuli Expected|EMO1-Total Stimuli Expected|EMO101	Emotion Recognition Test (ERT) Total number of stimuli (face images) expected to be administered in the task.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150927>	C150795	ERT - Total Stimuli Administered|EMO1-Total Stimuli Administered|EMO1-Total Stimuli Administered|EMO102	Emotion Recognition Test (ERT) Total number of stimuli (face images) actually administered in the task.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150928>	C150795	ERT - Total Stimuli Completed|EMO1-Total Stimuli Completed|EMO1-Total Stimuli Completed|EMO103	Emotion Recognition Test (ERT) Total number of stimuli (face images) actually completed in the task.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150929>	C150795	ERT - Total Stimuli Response Correct|EMO1-Total Stimuli Response Correct|EMO1-Total Stimuli Response Correct|EMO103A	Emotion Recognition Test (ERT) Total number of stimuli (face images) for which the participant's response was correct.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150930>	C150795	ERT - Total Stimuli Response Incorrect|EMO1-Total Stimuli Response Incorrect|EMO1-Total Stimuli Response Incorrect|EMO103B	Emotion Recognition Test (ERT) Total number of stimuli (face images) for which the participant's response was incorrect.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150931>	C150795	ERT - Total Stimuli Not Responded|EMO1-Total Stimuli Not Responded|EMO1-Total Stimuli Not Responded|EMO103C	Emotion Recognition Test (ERT) Total number of stimuli (face images) for which the participant has not responded.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150932>	C150795	ERT - Total Negative Stimuli Expected|EMO1-Total Negative Stimuli Expected|EMO1-Total Negative Stimuli Expected|EMO104	Emotion Recognition Test (ERT) Total number of negative emotion stimuli (face images) expected to be administered in the task.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150933>	C150795	ERT - Total Negative Stimuli Administered|EMO1-Total Negative Stimuli Administered|EMO1-Total Negative Stimuli Administered|EMO105	Emotion Recognition Test (ERT) Total number of negative emotion stimuli (face images) actually administered in the task.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150934>	C150795	ERT - Total Negative Stimuli Completed|EMO1-Total Negative Stimuli Completed|EMO1-Total Negative Stimuli Completed|EMO106	Emotion Recognition Test (ERT) Total number of negative emotion stimuli (face images) actually completed in the task.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150935>	C150795	ERT - Total Negative Stimuli Correct|EMO1-Total Negative Stimuli Correct|EMO1-Total Negative Stimuli Correct|EMO106A	Emotion Recognition Test (ERT) Total number of negative emotion stimuli (face images) for which the participant's response was correct.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150936>	C150795	ERT - Total Negative Stimuli Incorrect|EMO1-Total Negative Stimuli Incorrect|EMO1-Total Negative Stimuli Incorrect|EMO106B	Emotion Recognition Test (ERT) Total number of negative emotion stimuli (face images) for which the participant's response was incorrect.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150937>	C150795	ERT - Total Negative Stimuli Not Respond|EMO1-Total Negative Stimuli Not Respond|EMO1-Total Negative Stimuli Not Respond|EMO106C	Emotion Recognition Test (ERT) Total number of negative emotion stimuli (face images) for which the participant has not responded.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150938>	C150795	ERT - Number Stimuli Portraying Anger|EMO1-Number Stimuli Portraying Anger|EMO1-Number Stimuli Portraying Anger|EMO107	Emotion Recognition Test (ERT) Number of stimuli defined as portraying anger.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150939>	C150795	ERT - Anger Responded as Anger|EMO1-Anger Responded as Anger|EMO1-Anger Responded as Anger|EMO107A	Emotion Recognition Test (ERT) Number of anger stimuli responded to as anger.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150940>	C150795	ERT - Anger Responded as Disgust|EMO1-Anger Responded as Disgust|EMO1-Anger Responded as Disgust|EMO107B	Emotion Recognition Test (ERT) Number of anger stimuli responded to as disgust.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150941>	C150795	ERT - Anger Responded as Fear|EMO1-Anger Responded as Fear|EMO1-Anger Responded as Fear|EMO107C	Emotion Recognition Test (ERT) Number of anger stimuli responded to as fear.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150942>	C150795	ERT - Anger Responded as Happiness|EMO1-Anger Responded as Happiness|EMO1-Anger Responded as Happiness|EMO107D	Emotion Recognition Test (ERT) Number of anger stimuli responded to as happiness.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150943>	C150795	ERT - Anger Responded as Neutral|EMO1-Anger Responded as Neutral|EMO1-Anger Responded as Neutral|EMO107E	Emotion Recognition Test (ERT) Number of anger stimuli responded to as neutral.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150944>	C150795	ERT - Anger Responded as Sadness|EMO1-Anger Responded as Sadness|EMO1-Anger Responded as Sadness|EMO107F	Emotion Recognition Test (ERT) Number of anger stimuli responded to as sadness.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150945>	C150795	ERT - Anger Responded as Surprise|EMO1-Anger Responded as Surprise|EMO1-Anger Responded as Surprise|EMO107G	Emotion Recognition Test (ERT) Number of anger stimuli responded to as surprise.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150946>	C150795	ERT - Number Stimuli Portraying Disgust|EMO1-Number Stimuli Portraying Disgust|EMO1-Number Stimuli Portraying Disgust|EMO108	Emotion Recognition Test (ERT) Number of stimuli defined as portraying disgust.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150947>	C150795	ERT - Disgust Responded as Anger|EMO1-Disgust Responded as Anger|EMO1-Disgust Responded as Anger|EMO108A	Emotion Recognition Test (ERT) Number of disgust stimuli responded to as anger.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150948>	C150795	ERT - Disgust Responded as Disgust|EMO1-Disgust Responded as Disgust|EMO1-Disgust Responded as Disgust|EMO108B	Emotion Recognition Test (ERT) Number of disgust stimuli responded to as disgust.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150949>	C150795	ERT - Disgust Responded as Fear|EMO1-Disgust Responded as Fear|EMO1-Disgust Responded as Fear|EMO108C	Emotion Recognition Test (ERT) Number of disgust stimuli responded to as fear.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150950>	C150795	ERT - Disgust Responded as Happiness|EMO1-Disgust Responded as Happiness|EMO1-Disgust Responded as Happiness|EMO108D	Emotion Recognition Test (ERT) Number of disgust stimuli responded to as happiness.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150951>	C150795	ERT - Disgust Responded as Neutral|EMO1-Disgust Responded as Neutral|EMO1-Disgust Responded as Neutral|EMO108E	Emotion Recognition Test (ERT) Number of disgust stimuli responded to as neutral.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150952>	C150795	ERT - Disgust Responded as Sadness|EMO1-Disgust Responded as Sadness|EMO1-Disgust Responded as Sadness|EMO108F	Emotion Recognition Test (ERT) Number of disgust stimuli responded to as sadness.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150953>	C150795	ERT - Disgust Responded as Surprise|EMO1-Disgust Responded as Surprise|EMO1-Disgust Responded as Surprise|EMO108G	Emotion Recognition Test (ERT) Number of disgust stimuli responded to as surprise.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150954>	C150795	ERT - Number Stimuli Portraying Fear|EMO1-Number Stimuli Portraying Fear|EMO1-Number Stimuli Portraying Fear|EMO109	Emotion Recognition Test (ERT) Number of stimuli defined as portraying fear.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150955>	C150795	ERT - Fear Responded as Anger|EMO1-Fear Responded as Anger|EMO1-Fear Responded as Anger|EMO109A	Emotion Recognition Test (ERT) Number of fear stimuli responded to as anger.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150956>	C150795	ERT - Fear Responded as Disgust|EMO1-Fear Responded as Disgust|EMO1-Fear Responded as Disgust|EMO109B	Emotion Recognition Test (ERT) Number of fear stimuli responded to as disgust.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150957>	C150795	ERT - Fear Responded as Fear|EMO1-Fear Responded as Fear|EMO1-Fear Responded as Fear|EMO109C	Emotion Recognition Test (ERT) Number of fear stimuli responded to as fear.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150958>	C150795	ERT - Fear Responded as Happiness|EMO1-Fear Responded as Happiness|EMO1-Fear Responded as Happiness|EMO109D	Emotion Recognition Test (ERT) Number of fear stimuli responded to as happiness.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150959>	C150795	ERT - Fear Responded as Neutral|EMO1-Fear Responded as Neutral|EMO1-Fear Responded as Neutral|EMO109E	Emotion Recognition Test (ERT) Number of fear stimuli responded to as neutral.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150960>	C150795	ERT - Fear Responded as Sadness|EMO1-Fear Responded as Sadness|EMO1-Fear Responded as Sadness|EMO109F	Emotion Recognition Test (ERT) Number of fear stimuli responded to as sadness.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150961>	C150795	ERT - Fear Responded as Surprise|EMO1-Fear Responded as Surprise|EMO1-Fear Responded as Surprise|EMO109G	Emotion Recognition Test (ERT) Number of fear stimuli responded to as surprise.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150962>	C150795	ERT - Number Stimuli Portraying Happiness|EMO1-Number Stimuli Portraying Happiness|EMO1-Number Stimuli Portraying Happiness|EMO110	Emotion Recognition Test (ERT) Number of stimuli defined as portraying happiness.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150963>	C150795	ERT - Happiness Responded as Anger|EMO1-Happiness Responded as Anger|EMO1-Happiness Responded as Anger|EMO110A	Emotion Recognition Test (ERT) Number of happiness stimuli responded to as anger.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150964>	C150795	ERT - Happiness Responded as Disgust|EMO1-Happiness Responded as Disgust|EMO1-Happiness Responded as Disgust|EMO110B	Emotion Recognition Test (ERT) Number of happiness stimuli responded to as disgust.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150965>	C150795	ERT - Happiness Responded as Fear|EMO1-Happiness Responded as Fear|EMO1-Happiness Responded as Fear|EMO110C	Emotion Recognition Test (ERT) Number of happiness stimuli responded to as fear.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150966>	C150795	ERT - Happiness Responded as Happiness|EMO1-Happiness Responded as Happiness|EMO1-Happiness Responded as Happiness|EMO110D	Emotion Recognition Test (ERT) Number of happiness stimuli responded to as happiness.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150967>	C150795	ERT - Happiness Responded as Neutral|EMO1-Happiness Responded as Neutral|EMO1-Happiness Responded as Neutral|EMO110E	Emotion Recognition Test (ERT) Number of happiness stimuli responded to as neutral.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150968>	C150795	ERT - Happiness Responded as Sadness|EMO1-Happiness Responded as Sadness|EMO1-Happiness Responded as Sadness|EMO110F	Emotion Recognition Test (ERT) Number of happiness stimuli responded to as sadness.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150969>	C150795	ERT - Happiness Responded as Surprise|EMO1-Happiness Responded as Surprise|EMO1-Happiness Responded as Surprise|EMO110G	Emotion Recognition Test (ERT) Number of happiness stimuli responded to as surprise.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150970>	C150795	ERT - Number Stimuli Portraying Neutral|EMO1-Number Stimuli Portraying Neutral|EMO1-Number Stimuli Portraying Neutral|EMO111	Emotion Recognition Test (ERT) Number of stimuli defined as portraying a neutral expression.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150971>	C150795	ERT - Neutral Responded as Anger|EMO1-Neutral Responded as Anger|EMO1-Neutral Responded as Anger|EMO111A	Emotion Recognition Test (ERT) Number of neutral stimuli responded to as anger.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150972>	C150795	ERT - Neutral Responded as Disgust|EMO1-Neutral Responded as Disgust|EMO1-Neutral Responded as Disgust|EMO111B	Emotion Recognition Test (ERT) Number of neutral stimuli responded to as disgust.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150973>	C150795	ERT - Neutral Responded as Fear|EMO1-Neutral Responded as Fear|EMO1-Neutral Responded as Fear|EMO111C	Emotion Recognition Test (ERT) Number of neutral stimuli responded to as fear.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150974>	C150795	ERT - Neutral Responded as Happiness|EMO1-Neutral Responded as Happiness|EMO1-Neutral Responded as Happiness|EMO111D	Emotion Recognition Test (ERT) Number of neutral stimuli responded to as happiness.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150975>	C150795	ERT - Neutral Responded as Neutral|EMO1-Neutral Responded as Neutral|EMO1-Neutral Responded as Neutral|EMO111E	Emotion Recognition Test (ERT) Number of neutral stimuli responded to as neutral.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150976>	C150795	ERT - Neutral Responded as Sadness|EMO1-Neutral Responded as Sadness|EMO1-Neutral Responded as Sadness|EMO111F	Emotion Recognition Test (ERT) Number of neutral stimuli responded to as sadness.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150977>	C150795	ERT - Neutral Responded as Surprise|EMO1-Neutral Responded as Surprise|EMO1-Neutral Responded as Surprise|EMO111G	Emotion Recognition Test (ERT) Number of neutral stimuli responded to as surprise.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150978>	C150795	ERT - Number Stimuli Portraying Sadness|EMO1-Number Stimuli Portraying Sadness|EMO1-Number Stimuli Portraying Sadness|EMO112	Emotion Recognition Test (ERT) Number of stimuli defined as portraying sadness.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150979>	C150795	ERT - Sadness Responded as Anger|EMO1-Sadness Responded as Anger|EMO1-Sadness Responded as Anger|EMO112A	Emotion Recognition Test (ERT) Number of sadness stimuli responded to as anger.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150980>	C150795	ERT - Sadness Responded as Disgust|EMO1-Sadness Responded as Disgust|EMO1-Sadness Responded as Disgust|EMO112B	Emotion Recognition Test (ERT) Number of sadness stimuli responded to as disgust.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150981>	C150795	ERT - Sadness Responded as Fear|EMO1-Sadness Responded as Fear|EMO1-Sadness Responded as Fear|EMO112C	Emotion Recognition Test (ERT) Number of sadness stimuli responded to as fear.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150982>	C150795	ERT - Sadness Responded as Happiness|EMO1-Sadness Responded as Happiness|EMO1-Sadness Responded as Happiness|EMO112D	Emotion Recognition Test (ERT) Number of sadness stimuli responded to as happiness.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150983>	C150795	ERT - Sadness Responded as Neutral|EMO1-Sadness Responded as Neutral|EMO1-Sadness Responded as Neutral|EMO112E	Emotion Recognition Test (ERT) Number of sadness stimuli responded to as neutral.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150984>	C150795	ERT - Sadness Responded as Sadness|EMO1-Sadness Responded as Sadness|EMO1-Sadness Responded as Sadness|EMO112F	Emotion Recognition Test (ERT) Number of sadness stimuli responded to as sadness.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150985>	C150795	ERT - Sadness Responded as Surprise|EMO1-Sadness Responded as Surprise|EMO1-Sadness Responded as Surprise|EMO112G	Emotion Recognition Test (ERT) Number of sadness stimuli responded to as surprise.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150986>	C150795	ERT - Number Stimuli Portraying Surprise|EMO1-Number Stimuli Portraying Surprise|EMO1-Number Stimuli Portraying Surprise|EMO113	Emotion Recognition Test (ERT) Number of stimuli defined as portraying surprise.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150987>	C150795	ERT - Surprise Responded as Anger|EMO1-Surprise Responded as Anger|EMO1-Surprise Responded as Anger|EMO113A	Emotion Recognition Test (ERT) Number of surprise stimuli responded to as anger.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150988>	C150795	ERT - Surprise Responded as Disgust|EMO1-Surprise Responded as Disgust|EMO1-Surprise Responded as Disgust|EMO113B	Emotion Recognition Test (ERT) Number of surprise stimuli responded to as disgust.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150989>	C150795	ERT - Surprise Responded as Fear|EMO1-Surprise Responded as Fear|EMO1-Surprise Responded as Fear|EMO113C	Emotion Recognition Test (ERT) Number of surprise stimuli responded to as fear.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150990>	C150795	ERT - Surprise Responded as Happiness|EMO1-Surprise Responded as Happiness|EMO1-Surprise Responded as Happiness|EMO113D	Emotion Recognition Test (ERT) Number of surprise stimuli responded to as happiness.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150991>	C150795	ERT - Surprise Responded as Neutral|EMO1-Surprise Responded as Neutral|EMO1-Surprise Responded as Neutral|EMO113E	Emotion Recognition Test (ERT) Number of surprise stimuli responded to as neutral.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150992>	C150795	ERT - Surprise Responded as Sadness|EMO1-Surprise Responded as Sadness|EMO1-Surprise Responded as Sadness|EMO113F	Emotion Recognition Test (ERT) Number of surprise stimuli responded to as sadness.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150993>	C150795	ERT - Surprise Responded as Surprise|EMO1-Surprise Responded as Surprise|EMO1-Surprise Responded as Surprise|EMO113G	Emotion Recognition Test (ERT) Number of surprise stimuli responded to as surprise.			Intellectual Product	CDISC Functional Test ERT Test Code Terminology|CDISC Functional Test ERT Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150994>	C150794	MMSE-2 Standard Version - Repeat Word 1|MMS2-Repeat Word 1|MMS2-Repeat Word 1|MMS201A	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Now repeat those words back to me: Word 1.			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150995>	C150794	MMSE-2 Standard Version - Repeat Word 2|MMS2-Repeat Word 2|MMS2-Repeat Word 2|MMS201B	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Now repeat those words back to me: Word 2.			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150996>	C150794	MMSE-2 Standard Version - Repeat Word 3|MMS2-Repeat Word 3|MMS2-Repeat Word 3|MMS201C	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Now repeat those words back to me: Word 3.			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150997>	C150794	MMSE-2 Standard Version - What Is the Year|MMS2-What Is the Year|MMS2-What Is the Year|MMS202A	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) What is the year?			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150998>	C150794	MMSE-2 Standard Version - What Is the Season|MMS2-What Is the Season|MMS2-What Is the Season|MMS202B	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) What is the season?			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C150999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C150999>	C150794	MMSE-2 Standard Version - What Is the Month of Year|MMS2-What Is the Month of Year|MMS2-What Is the Month of Year|MMS202C	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) What is the month of the year?			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C1509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1509>	C26170	Neuroprotective Agent|Neuroprotectants|Neuroprotective Drugs	A pharmacological agent that protects the central nervous system from damage caused by acute ischemia or chronic neurodegenerative diseases.			Chemical Viewed Functionally	
C151000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151000>	C150794	MMSE-2 Standard Version - What Is the Day of Week|MMS2-What Is the Day of Week|MMS2-What Is the Day of Week|MMS202D	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) What is the day of the week?			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151001>	C150794	MMSE-2 Standard Version - What Is the Date|MMS2-What Is the Date|MMS2-What Is the Date|MMS202E	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) What is the date?			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151002>	C150794	MMSE-2 Standard Version - What Is the State|MMS2-What Is the State|MMS2-What Is the State|MMS203A	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Where are we now? What is the state (or province)?			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151003>	C150794	MMSE-2 Standard Version - What Is the County|MMS2-What Is the County|MMS2-What Is the County|MMS203B	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Where are we now? What is the county (or city/town)?			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151004>	C150794	MMSE-2 Standard Version - What Is the City/Town|MMS2-What Is the City/Town|MMS2-What Is the City/Town|MMS203C	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Where are we now? What is the city/town (or part of city/neighborhood)?			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151005>	C150794	MMSE-2 Standard Version - What Is the Building|MMS2-What Is the Building|MMS2-What Is the Building|MMS203D	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Where are we now? What is the building (name or type)?			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151006>	C150794	MMSE-2 Standard Version - What Is the Floor|MMS2-What Is the Floor|MMS2-What Is the Floor|MMS203E	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Where are we now? What is the floor of the building (room number or address)?			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151007>	C150794	MMSE-2 Standard Version - Recall Word 1|MMS2-Recall Word 1|MMS2-Recall Word 1|MMS204A	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) What were those three words I asked you to remember: Word 1?			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151008>	C150794	MMSE-2 Standard Version - Recall Word 2|MMS2-Recall Word 2|MMS2-Recall Word 2|MMS204B	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) What were those three words I asked you to remember: Word 2?			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151009>	C150794	MMSE-2 Standard Version - Recall Word 3|MMS2-Recall Word 3|MMS2-Recall Word 3|MMS204C	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) What were those three words I asked you to remember: Word 3?			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151010>	C150794	MMSE-2 Standard Version - What is 100 Take Away 7|MMS2-What is 100 Take Away 7|MMS2-What is 100 Take Away 7|MMS205A	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) What is 100 take away 7 [93]?			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151011>	C150794	MMSE-2 Standard Version - Keep Subtracting 7 Step 2|MMS2-Keep Subtracting 7 Step 2|MMS2-Keep Subtracting 7 Step 2|MMS205B	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Keep going [86].			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151012>	C150794	MMSE-2 Standard Version - Keep Subtracting 7 Step 3|MMS2-Keep Subtracting 7 Step 3|MMS2-Keep Subtracting 7 Step 3|MMS205C	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Keep going [79].			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151013>	C150794	MMSE-2 Standard Version - Keep Subtracting 7 Step 4|MMS2-Keep Subtracting 7 Step 4|MMS2-Keep Subtracting 7 Step 4|MMS205D	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Keep going [72].			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151014>	C150794	MMSE-2 Standard Version - Keep Subtracting 7 Step 5|MMS2-Keep Subtracting 7 Step 5|MMS2-Keep Subtracting 7 Step 5|MMS205E	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Keep going [65].			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151015>	C150794	MMSE-2 Standard Version - Naming Object 1|MMS2-Naming Object 1|MMS2-Naming Object 1|MMS206A	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) What is this: Object 1?			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151016>	C150794	MMSE-2 Standard Version - Naming Object 2|MMS2-Naming Object 2|MMS2-Naming Object 2|MMS206B	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) What is this: Object 2?			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151017>	C150794	MMSE-2 Standard Version - Repeat What I Say|MMS2-Repeat What I Say|MMS2-Repeat What I Say|MMS207	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Now I am going to ask you to repeat what I say. Ready? "It is a lovely, sunny day but too warm." Now you say that.			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151018>	C150794	MMSE-2 Standard Version - Point to the Circle|MMS2-Point to the Circle|MMS2-Point to the Circle|MMS208A	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Look at these pictures and point to the circle.			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151019>	C150794	MMSE-2 Standard Version - Point to the Square|MMS2-Point to the Square|MMS2-Point to the Square|MMS208B	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Then point to the square.			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151020>	C150794	MMSE-2 Standard Version - Point to the Triangle|MMS2-Point to the Triangle|MMS2-Point to the Triangle|MMS208C	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Then point to the triangle.			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151021>	C150794	MMSE-2 Standard Version - Do What This Says to Do|MMS2-Do What This Says to Do|MMS2-Do What This Says to Do|MMS209	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Please do what this says to do.			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151022>	C150794	MMSE-2 Standard Version - Write a Sentence|MMS2-Write a Sentence|MMS2-Write a Sentence|MMS210	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Please write a sentence.			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151023>	C150794	MMSE-2 Standard Version - Copy This Design|MMS2-Copy This Design|MMS2-Copy This Design|MMS211	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Please copy this design.			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151024>	C150794	MMSE-2 Standard Version - BV Total Raw Score|MMS2-BV Total Raw Score|MMS2-BV Total Raw Score|MMS212	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) BV (Brief Version) total raw score.			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151025>	C150794	MMSE-2 Standard Version - SV Total Raw Score|MMS2-SV Total Raw Score|MMS2-SV Total Raw Score|MMS213	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) SV (Standard Version) total raw score.			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151026>	C150794	MMSE-2 Standard Version - Level of Consciousness|MMS2-Level of Consciousness|MMS2-Level of Consciousness|MMS214	Mini-Mental State Examination 2 Standard Version (MMSE-2 Standard Version) Assessment of level of consciousness.			Intellectual Product	CDISC Functional Test MMSE-2 Standard Version Test Code Terminology|CDISC Functional Test MMSE-2 Standard Version Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151027>	C150796	Paced Tapping - Total Trials Expected|PTAP1-Total Trials Expected|PTAP1-Total Trials Expected|PTAP101	Paced Tapping Test (Paced Tapping) Total number of trials expected to be administered in the task.			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151028>	C150796	Paced Tapping - Total Trials Administered|PTAP1-Total Trials Administered|PTAP1-Total Trials Administered|PTAP102	Paced Tapping Test (Paced Tapping) Total number of trials actually administered in the task.			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151029>	C150796	Paced Tapping - Total Trials Completed|PTAP1-Total Trials Completed|PTAP1-Total Trials Completed|PTAP103	Paced Tapping Test (Paced Tapping) Total number of trials actually completed in the task.			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151030>	C150796	Paced Tapping - Total Interval Tone Admin All|PTAP1-Total Interval Tone Admin All|PTAP1-Total Interval Tone Admin All|PTAP104	Paced Tapping Test (Paced Tapping) Total number of intertap intervals across all 4 toned tapping phases of each trial administered.			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151031>	C150796	Paced Tapping - Total Interval Tone Trim All|PTAP1-Total Interval Tone Trim All|PTAP1-Total Interval Tone Trim All|PTAP105	Paced Tapping Test (Paced Tapping) Total number of intertap intervals across the 4 toned tapping phases of each trial, that were trimmed before analysis.			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151032>	C150796	Paced Tapping - Minimum Interval Tone All|PTAP1-Minimum Interval Tone All|PTAP1-Minimum Interval Tone All|PTAP105A	Paced Tapping Test (Paced Tapping) The minimum intertap interval within the tone-paced tapping phase across all trials (in milliseconds).			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151033>	C150796	Paced Tapping - Maximum Interval Tone All|PTAP1-Maximum Interval Tone All|PTAP1-Maximum Interval Tone All|PTAP105B	Paced Tapping Test (Paced Tapping) The maximum intertap interval within the tone-paced tapping phase across all trials (in milliseconds).			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151034>	C150796	Paced Tapping - Mean Interval Tone All|PTAP1-Mean Interval Tone All|PTAP1-Mean Interval Tone All|PTAP105C	Paced Tapping Test (Paced Tapping) The mean intertap interval within the tone-paced tapping phase across all trials (in milliseconds).			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151035>	C150796	Paced Tapping - Median Interval Tone All|PTAP1-Median Interval Tone All|PTAP1-Median Interval Tone All|PTAP105D	Paced Tapping Test (Paced Tapping) The median intertap interval within the tone-paced tapping phase across all trials (in milliseconds).			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151036>	C150796	Paced Tapping - Variance Interval Tone All|PTAP1-Variance Interval Tone All|PTAP1-Variance Interval Tone All|PTAP105E	Paced Tapping Test (Paced Tapping) The variance of the intertap interval within the tone-paced tapping phase across all trials (in milliseconds).			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151037>	C150796	Paced Tapping - Deviation Interval Tone All|PTAP1-Deviation Interval Tone All|PTAP1-Deviation Interval Tone All|PTAP105F	Paced Tapping Test (Paced Tapping) The standard deviation of the intertap intervals within the tone-paced tapping phase across all trials.			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151038>	C150796	Paced Tapping - Reciprocal Interval Tone All|PTAP1-Reciprocal Interval Tone All|PTAP1-Reciprocal Interval Tone All|PTAP105G	Paced Tapping Test (Paced Tapping) The reciprocal of the standard deviation of the intertap intervals within the tone-paced tapping phase across all trials.			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151039>	C150796	Paced Tapping - Avg Sign Dev Interval Tone All|PTAP1-Avg Sign Dev Interval Tone All|PTAP1-Avg Sign Dev Interval Tone All|PTAP105H	Paced Tapping Test (Paced Tapping) The average signed deviation of the intertap intervals within the tone-paced tapping phase across all trials.			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151040>	C150796	Paced Tapping - Total Interval Self Admin All|PTAP1-Total Interval Self Admin All|PTAP1-Total Interval Self Admin All|PTAP106	Paced Tapping Test (Paced Tapping) Total number of interlap intervals across all 4 trials administered (self-paced tapping phases).			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151041>	C150796	Paced Tapping - Total Interval Self Trim All|PTAP1-Total Interval Self Trim All|PTAP1-Total Interval Self Trim All|PTAP107	Paced Tapping Test (Paced Tapping) Total number of intertap intervals across all 4 trials that were trimmed before analysis (self-paced tapping phases).			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151042>	C150796	Paced Tapping - Minimum Interval Self All|PTAP1-Minimum Interval Self All|PTAP1-Minimum Interval Self All|PTAP107A	Paced Tapping Test (Paced Tapping) The minimum intertap interval within the self-paced tapping phase across all trials (in milliseconds).			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151043>	C150796	Paced Tapping - Maximum Interval Self All|PTAP1-Maximum Interval Self All|PTAP1-Maximum Interval Self All|PTAP107B	Paced Tapping Test (Paced Tapping) The maximum intertap interval within the self-paced tapping phase across all trials (in milliseconds).			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151044>	C150796	Paced Tapping - Mean Interval Self All|PTAP1-Mean Interval Self All|PTAP1-Mean Interval Self All|PTAP107C	Paced Tapping Test (Paced Tapping) The mean intertap interval within the self-paced tapping phase across all trials (in milliseconds).			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151045>	C150796	Paced Tapping - Median Interval Self All|PTAP1-Median Interval Self All|PTAP1-Median Interval Self All|PTAP107D	Paced Tapping Test (Paced Tapping) The median intertap interval within the self-paced tapping phase across all trials (in milliseconds).			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151046>	C150796	Paced Tapping - Variance Interval Self All|PTAP1-Variance Interval Self All|PTAP1-Variance Interval Self All|PTAP107E	Paced Tapping Test (Paced Tapping) The variance of the intertap interval within the self-paced tapping phase across all trials (in milliseconds).			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151047>	C150796	Paced Tapping - Deviation Interval Self All|PTAP1-Deviation Interval Self All|PTAP1-Deviation Interval Self All|PTAP107F	Paced Tapping Test (Paced Tapping) The standard deviation of the intertap intervals within the self-paced tapping phase across all trials.			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151048>	C150796	Paced Tapping - Reciprocal Interval Self All|PTAP1-Reciprocal Interval Self All|PTAP1-Reciprocal Interval Self All|PTAP107G	Paced Tapping Test (Paced Tapping) The reciprocal of the standard deviation of the intertap intervals within the self-paced tapping phase across all trials.			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151049>	C150796	Paced Tapping - Avg Sign Dev Interval Self All|PTAP1-Avg Sign Dev Interval Self All|PTAP1-Avg Sign Dev Interval Self All|PTAP107H	Paced Tapping Test (Paced Tapping) The average signed deviation of the intertap intervals within the self-paced tapping phase across all trials.			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151050>	C150796	Paced Tapping - Trials Expected in Trial|PTAP1-Trials Expected in Trial|PTAP1-Trials Expected in Trial|PTAP108	Paced Tapping Test (Paced Tapping) Number of trials expected to be administered in Trial n.			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151051>	C150796	Paced Tapping - Trials Administered in Trial|PTAP1-Trials Administered in Trial|PTAP1-Trials Administered in Trial|PTAP109	Paced Tapping Test (Paced Tapping) Number of trials actually administered in Trial n.			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151052>	C150796	Paced Tapping - Trials Completed in Trial|PTAP1-Trials Completed in Trial|PTAP1-Trials Completed in Trial|PTAP110	Paced Tapping Test (Paced Tapping) Number of trials actually completed in Trial n.			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151053>	C150796	Paced Tapping - Num Intervals Expected Tone Trial|PTAP1-Num Intervals Expected Tone Trial|PTAP1-Num Intervals Expected Tone Trial|PTAP111	Paced Tapping Test (Paced Tapping) Total number of intertap intervals expected for the tone-tapping phase of Trial n.			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151054>	C150796	Paced Tapping - Num Intervals Trim Tone Trial|PTAP1-Num Intervals Trim Tone Trial|PTAP1-Num Intervals Trim Tone Trial|PTAP112	Paced Tapping Test (Paced Tapping) Total number of intertap intervals within the tone-tapping phase of Trial n, that were trimmed before analysis.			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151055>	C150796	Paced Tapping - Minimum Interval Tone Trial|PTAP1-Minimum Interval Tone Trial|PTAP1-Minimum Interval Tone Trial|PTAP112A	Paced Tapping Test (Paced Tapping) The minimum intertap interval within the tone-tapping phase of Trial n (in milliseconds).			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151056>	C150796	Paced Tapping - Maximum Interval Tone Trial|PTAP1-Maximum Interval Tone Trial|PTAP1-Maximum Interval Tone Trial|PTAP112B	Paced Tapping Test (Paced Tapping) The maximum intertap interval within the tone-tapping phase of Trial n (in milliseconds).			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151057>	C150796	Paced Tapping - Mean Interval Tone Trial|PTAP1-Mean Interval Tone Trial|PTAP1-Mean Interval Tone Trial|PTAP112C	Paced Tapping Test (Paced Tapping) The mean intertap interval within the tone-tapping phase of Trial n (in milliseconds).			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151058>	C150796	Paced Tapping - Median Interval Tone Trial|PTAP1-Median Interval Tone Trial|PTAP1-Median Interval Tone Trial|PTAP112D	Paced Tapping Test (Paced Tapping) The median intertap interval within the tone-tapping phase of Trial n (in milliseconds).			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151059>	C150796	Paced Tapping - Variance Interval Tone Trial|PTAP1-Variance Interval Tone Trial|PTAP1-Variance Interval Tone Trial|PTAP112E	Paced Tapping Test (Paced Tapping) The variance of the intertap interval within the tone-tapping phase of Trial n (in milliseconds).			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151060>	C150796	Paced Tapping - Deviation Interval Tone Trial|PTAP1-Deviation Interval Tone Trial|PTAP1-Deviation Interval Tone Trial|PTAP112F	Paced Tapping Test (Paced Tapping) The standard deviation of the intertap intervals within the tone-tapping phase of Trial n.			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151061>	C150796	Paced Tapping - Reciprocal Interval ToneTrial|PTAP1-Reciprocal Interval ToneTrial|PTAP1-Reciprocal Interval ToneTrial|PTAP112G	Paced Tapping Test (Paced Tapping) The reciprocal of the standard deviation of the intertap intervals within the tone-tapping phase of Trial n.			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151062>	C150796	Paced Tapping - Avg Sign Dev Interval Tone Trial|PTAP1-Avg Sign Dev Interval Tone Trial|PTAP1-Avg Sign Dev Interval Tone Trial|PTAP112H	Paced Tapping Test (Paced Tapping) The average signed deviation of the intertap intervals within the tone-tapping phase of Trial n.			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151063>	C150796	Paced Tapping - Num Intervals Expected Self Trial|PTAP1-Num Intervals Expected Self Trial|PTAP1-Num Intervals Expected Self Trial|PTAP113	Paced Tapping Test (Paced Tapping) Total number of intertap intervals expected for the self-paced tapping phase of Trial n.			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151064>	C150796	Paced Tapping - Num Intervals Trim Self Trial|PTAP1-Num Intervals Trim Self Trial|PTAP1-Num Intervals Trim Self Trial|PTAP114	Paced Tapping Test (Paced Tapping) Total number of intertap intervals within the self-paced tapping phase of Trial n, that were trimmed before analysis.			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151065>	C150796	Paced Tapping - Minimum Interval Self Trial|PTAP1-Minimum Interval Self Trial|PTAP1-Minimum Interval Self Trial|PTAP114A	Paced Tapping Test (Paced Tapping) The minimum intertap interval within the self-paced tapping phase of Trial n (in milliseconds).			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151066>	C150796	Paced Tapping - Maximum Interval Self Trial|PTAP1-Maximum Interval Self Trial|PTAP1-Maximum Interval Self Trial|PTAP114B	Paced Tapping Test (Paced Tapping) The maximum intertap interval within the self-paced tapping phase of Trial n (in milliseconds).			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151067>	C150796	Paced Tapping - Mean Interval Self Trial|PTAP1-Mean Interval Self Trial|PTAP1-Mean Interval Self Trial|PTAP114C	Paced Tapping Test (Paced Tapping) The mean intertap interval within the self-paced tapping phase of Trial n (in milliseconds).			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151068>	C150796	Paced Tapping - Median Interval Self Trial|PTAP1-Median Interval Self Trial|PTAP1-Median Interval Self Trial|PTAP114D	Paced Tapping Test (Paced Tapping) The median intertap interval within the self-paced tapping phase of Trial n (in milliseconds).			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151069>	C150796	Paced Tapping - Variance Interval Self Trial|PTAP1-Variance Interval Self Trial|PTAP1-Variance Interval Self Trial|PTAP114E	Paced Tapping Test (Paced Tapping) The variance of the intertap interval within the self-paced tapping phase of Trial n (in milliseconds).			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151070>	C150796	Paced Tapping - Deviation Interval Self Trial|PTAP1-Deviation Interval Self Trial|PTAP1-Deviation Interval Self Trial|PTAP114F	Paced Tapping Test (Paced Tapping) The standard deviation of the intertap intervals within the self-paced tapping phase of Trial n.			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151071>	C150796	Paced Tapping - Reciprocal Interval Self Trial|PTAP1-Reciprocal Interval Self Trial|PTAP1-Reciprocal Interval Self Trial|PTAP114G	Paced Tapping Test (Paced Tapping) The reciprocal of the standard deviation of the intertap intervals within the self-paced tapping phase of Trial n.			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151072>	C150796	Paced Tapping - Avg Sign Dev Interval Self Trial|PTAP1-Avg Sign Dev Interval Self Trial|PTAP1-Avg Sign Dev Interval Self Trial|PTAP114H	Paced Tapping Test (Paced Tapping) The average signed deviation of the intertap intervals within the self-paced tapping phase of Trial n.			Intellectual Product	CDISC Functional Test Paced Tapping Test Code Terminology|CDISC Functional Test Paced Tapping Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151073>	C141677	Rising From Floor - Wear Orthoses|RISEF1-Wear Orthoses|RISEF1-Wear Orthoses|RISEF103	Rising From Floor Test (Rising From Floor) Did subject wear orthoses?			Intellectual Product	CDISC Functional Test Rising From Floor Test Code Terminology|CDISC Functional Test Rising From Floor Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151074>	C115414	T25FW - Did Patient Wear AFO|T25FW1-Did Patient Wear AFO|T25FW1-Did Patient Wear AFO|T25FW103	Timed 25-Foot Walk (T25FW) Did patient wear an AFO?			Intellectual Product	CDISC Functional Test T25FW Test Code Terminology|CDISC Functional Test T25FW Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151075>	C115414	T25FW - Was Assistive Device Used|T25FW1-Was Assistive Device Used|T25FW1-Was Assistive Device Used|T25FW104	Timed 25-Foot Walk (T25FW) Was assistive device used?			Intellectual Product	CDISC Functional Test T25FW Test Code Terminology|CDISC Functional Test T25FW Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151076>	C150797	FACT-C Version 4 - I Have a Lack of Energy|FAC008-I Have a Lack of Energy|FAC008-I Have a Lack of Energy|FAC00801	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Physical Well-Being: I have a lack of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151077>	C150797	FACT-C Version 4 - I Have Nausea|FAC008-I Have Nausea|FAC008-I Have Nausea|FAC00802	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Physical Well-Being: I have nausea.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151078>	C150797	FACT-C Version 4 - Trouble Meeting Needs of Family|FAC008-Trouble Meeting Needs of Family|FAC008-Trouble Meeting Needs of Family|FAC00803	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Physical Well-Being: Because of my physical condition, I have trouble meeting the needs of my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151079>	C150797	FACT-C Version 4 - I Have Pain|FAC008-I Have Pain|FAC008-I Have Pain|FAC00804	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Physical Well-Being: I have pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151080>	C150797	FACT-C Version 4 - Bothered by Treatment Side Effect|FAC008-Bothered by Treatment Side Effect|FAC008-Bothered by Treatment Side Effect|FAC00805	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Physical Well-Being: I am bothered by side effects of treatment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151081>	C150797	FACT-C Version 4 - I Feel Ill|FAC008-I Feel Ill|FAC008-I Feel Ill|FAC00806	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Physical Well-Being: I feel ill.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151082>	C150797	FACT-C Version 4 - I Am Forced to Spend Time in Bed|FAC008-I Am Forced to Spend Time in Bed|FAC008-I Am Forced to Spend Time in Bed|FAC00807	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Physical Well-Being: I am forced to spend time in bed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151083>	C150797	FACT-C Version 4 - I Feel Close to My Friends|FAC008-I Feel Close to My Friends|FAC008-I Feel Close to My Friends|FAC00808	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Social/Family Well-Being: I feel close to my friends.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151084>	C150797	FACT-C Version 4 - Get Emotional Support From Family|FAC008-Get Emotional Support From Family|FAC008-Get Emotional Support From Family|FAC00809	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Social/Family Well-Being: I get emotional support from my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151085>	C150797	FACT-C Version 4 - I Get Support From My Friends|FAC008-I Get Support From My Friends|FAC008-I Get Support From My Friends|FAC00810	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Social/Family Well-Being: I get support from my friends.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151086>	C150797	FACT-C Version 4 - My Family Has Accepted My Illness|FAC008-My Family Has Accepted My Illness|FAC008-My Family Has Accepted My Illness|FAC00811	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Social/Family Well-Being: My family has accepted my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151087>	C150797	FACT-C Version 4 - Satisfied Communication Illness|FAC008-Satisfied Communication Illness|FAC008-Satisfied Communication Illness|FAC00812	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Social/Family Well-Being: I am satisfied with family communication about my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151088>	C150797	FACT-C Version 4 - I Feel Close to My Partner|FAC008-I Feel Close to My Partner|FAC008-I Feel Close to My Partner|FAC00813	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Social/Family Well-Being: I feel close to my partner (or the person who is my main support).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151089>	C150797	FACT-C Version 4 - I Am Satisfied With My Sex Life|FAC008-I Am Satisfied With My Sex Life|FAC008-I Am Satisfied With My Sex Life|FAC00814	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Social/Family Well-Being: I am satisfied with my sex life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151090>	C150797	FACT-C Version 4 - I Feel Sad|FAC008-I Feel Sad|FAC008-I Feel Sad|FAC00815	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Emotional Well-Being: I feel sad.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151091>	C150797	FACT-C Version 4 - Satisfied With How I Am Coping|FAC008-Satisfied With How I Am Coping|FAC008-Satisfied With How I Am Coping|FAC00816	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Emotional Well-Being: I am satisfied with how I am coping with my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151092>	C150797	FACT-C Version 4 - Losing Hope Against Illness|FAC008-Losing Hope Against Illness|FAC008-Losing Hope Against Illness|FAC00817	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Emotional Well-Being: I am losing hope in the fight against my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151093>	C150797	FACT-C Version 4 - I Feel Nervous|FAC008-I Feel Nervous|FAC008-I Feel Nervous|FAC00818	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Emotional Well-Being: I feel nervous.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151094>	C150797	FACT-C Version 4 - I Worry About Dying|FAC008-I Worry About Dying|FAC008-I Worry About Dying|FAC00819	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Emotional Well-Being: I worry about dying.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151095>	C150797	FACT-C Version 4 - Worry My Condition Will Get Worse|FAC008-Worry My Condition Will Get Worse|FAC008-Worry My Condition Will Get Worse|FAC00820	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Emotional Well-Being: I worry that my condition will get worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151096>	C150797	FACT-C Version 4 - I Am Able to Work|FAC008-I Am Able to Work|FAC008-I Am Able to Work|FAC00821	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Functional Well-Being: I am able to work (include work at home).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151097>	C150797	FACT-C Version 4 - My Work Is Fulfilling|FAC008-My Work Is Fulfilling|FAC008-My Work Is Fulfilling|FAC00822	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Functional Well-Being: My work (include work at home) is fulfilling.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151098>	C150797	FACT-C Version 4 - I Am Able to Enjoy Life|FAC008-I Am Able to Enjoy Life|FAC008-I Am Able to Enjoy Life|FAC00823	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Functional Well-Being: I am able to enjoy life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151099>	C150797	FACT-C Version 4 - I Have Accepted My Illness|FAC008-I Have Accepted My Illness|FAC008-I Have Accepted My Illness|FAC00824	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Functional Well-Being: I have accepted my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15109>	C14421	CE/J Mouse|CE/J		CE/J Mouse		Mammal	
C1510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1510>	C672	DNA Adduct|Carcinogen-DNA Adducts|Drug-DNA Adduct	A structure formed when a chemical is attached to DNA by a covalent bond.	DNA Adduct		Hazardous or Poisonous Substance	CTRP Biomarker Terminology|CTRP Terminology
C151100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151100>	C150797	FACT-C Version 4 - I Am Sleeping Well|FAC008-I Am Sleeping Well|FAC008-I Am Sleeping Well|FAC00825	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Functional Well-Being: I am sleeping well.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151101>	C150797	FACT-C Version 4 - Enjoy Things I Usually Do for Fun|FAC008-Enjoy Things I Usually Do for Fun|FAC008-Enjoy Things I Usually Do for Fun|FAC00826	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Functional Well-Being: I am enjoying the things I usually do for fun.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151102>	C150797	FACT-C Version 4 - Content With Quality of My Life|FAC008-Content With Quality of My Life|FAC008-Content With Quality of My Life|FAC00827	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Functional Well-Being: I am content with the quality of my life right now.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151103>	C150797	FACT-C Version 4 - Swelling/Cramps in Stomach Area|FAC008-Swelling/Cramps in Stomach Area|FAC008-Swelling/Cramps in Stomach Area|FAC00828	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Additional Concerns: I have swelling or cramps in my stomach area.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151104>	C150797	FACT-C Version 4 - I Am Losing Weight|FAC008-I Am Losing Weight|FAC008-I Am Losing Weight|FAC00829	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Additional Concerns: I am losing weight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151105>	C150797	FACT-C Version 4 - I Have Control of My Bowels|FAC008-I Have Control of My Bowels|FAC008-I Have Control of My Bowels|FAC00830	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Additional Concerns: I have control of my bowels.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151106>	C150797	FACT-C Version 4 - I Can Digest My Food Well|FAC008-I Can Digest My Food Well|FAC008-I Can Digest My Food Well|FAC00831	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Additional Concerns: I can digest my food well.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151107>	C150797	FACT-C Version 4 - I Have Diarrhea|FAC008-I Have Diarrhea|FAC008-I Have Diarrhea|FAC00832	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Additional Concerns: I have diarrhea (diarrhoea).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151108>	C150797	FACT-C Version 4 - I Have a Good Appetite|FAC008-I Have a Good Appetite|FAC008-I Have a Good Appetite|FAC00833	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Additional Concerns: I have a good appetite.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151109>	C150797	FACT-C Version 4 - I Like the Appearance of My Body|FAC008-I Like the Appearance of My Body|FAC008-I Like the Appearance of My Body|FAC00834	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Additional Concerns: I like the appearance of my body.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151110>	C150797	FACT-C Version 4 - Do You Have an Ostomy Appliance|FAC008-Do You Have an Ostomy Appliance|FAC008-Do You Have an Ostomy Appliance|FAC00835	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Additional Concerns: Do you have an ostomy appliance?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151111>	C150797	FACT-C Version 4 - Embarrassed by Ostomy Appliance|FAC008-Embarrassed by Ostomy Appliance|FAC008-Embarrassed by Ostomy Appliance|FAC00836	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Additional Concerns: I am embarrassed by my ostomy appliance.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151112>	C150797	FACT-C Version 4 - Caring for Ostomy Is Difficult|FAC008-Caring for Ostomy Is Difficult|FAC008-Caring for Ostomy Is Difficult|FAC00837	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Additional Concerns: Caring for my ostomy appliance is difficult.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151113>	C150798	FACT-Taxane Version 4 - I Have a Lack of Energy|FAC063-I Have a Lack of Energy|FAC063-I Have a Lack of Energy|FAC06301	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Physical Well-Being: I have a lack of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151114>	C150798	FACT-Taxane Version 4 - I Have Nausea|FAC063-I Have Nausea|FAC063-I Have Nausea|FAC06302	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Physical Well-Being: I have nausea.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151115>	C150798	FACT-Taxane Version 4 - Trouble Meeting Needs of Family|FAC063-Trouble Meeting Needs of Family|FAC063-Trouble Meeting Needs of Family|FAC06303	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Physical Well-Being: Because of my physical condition, I have trouble meeting the needs of my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151116>	C150798	FACT-Taxane Version 4 - I Have Pain|FAC063-I Have Pain|FAC063-I Have Pain|FAC06304	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Physical Well-Being: I have pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151117>	C150798	FACT-Taxane Version 4 - Bothered by Treatment Side Effect|FAC063-Bothered by Treatment Side Effect|FAC063-Bothered by Treatment Side Effect|FAC06305	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Physical Well-Being: I am bothered by side effects of treatment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151118>	C150798	FACT-Taxane Version 4 - I Feel Ill|FAC063-I Feel Ill|FAC063-I Feel Ill|FAC06306	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Physical Well-Being: I feel ill.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151119>	C150798	FACT-Taxane Version 4 - I Am Forced to Spend Time in Bed|FAC063-I Am Forced to Spend Time in Bed|FAC063-I Am Forced to Spend Time in Bed|FAC06307	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Physical Well-Being: I am forced to spend time in bed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151120>	C150798	FACT-Taxane Version 4 - I Feel Close to My Friends|FAC063-I Feel Close to My Friends|FAC063-I Feel Close to My Friends|FAC06308	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Social/Family Well-Being: I feel close to my friends.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151121>	C150798	FACT-Taxane Version 4 - Get Emotional Support From Family|FAC063-Get Emotional Support From Family|FAC063-Get Emotional Support From Family|FAC06309	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Social/Family Well-Being: I get emotional support from my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151122>	C150798	FACT-Taxane Version 4 - I Get Support From My Friends|FAC063-I Get Support From My Friends|FAC063-I Get Support From My Friends|FAC06310	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Social/Family Well-Being: I get support from my friends.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151123>	C150798	FACT-Taxane Version 4 - My Family Has Accepted My Illness|FAC063-My Family Has Accepted My Illness|FAC063-My Family Has Accepted My Illness|FAC06311	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Social/Family Well-Being: My family has accepted my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151124>	C150798	FACT-Taxane Version 4 - Satisfied Communication Illness|FAC063-Satisfied Communication Illness|FAC063-Satisfied Communication Illness|FAC06312	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Social/Family Well-Being: I am satisfied with family communication about my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151125>	C150798	FACT-Taxane Version 4 - I Feel Close to My Partner|FAC063-I Feel Close to My Partner|FAC063-I Feel Close to My Partner|FAC06313	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Social/Family Well-Being: I feel close to my partner (or the person who is my main support).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151126>	C150798	FACT-Taxane Version 4 - I Am Satisfied With My Sex Life|FAC063-I Am Satisfied With My Sex Life|FAC063-I Am Satisfied With My Sex Life|FAC06314	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Social/Family Well-Being: I am satisfied with my sex life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151127>	C150798	FACT-Taxane Version 4 - I Feel Sad|FAC063-I Feel Sad|FAC063-I Feel Sad|FAC06315	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Emotional Well-Being: I feel sad.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151128>	C150798	FACT-Taxane Version 4 - Satisfied With How I Am Coping|FAC063-Satisfied With How I Am Coping|FAC063-Satisfied With How I Am Coping|FAC06316	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Emotional Well-Being: I am satisfied with how I am coping with my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151129>	C150798	FACT-Taxane Version 4 - Losing Hope Against Illness|FAC063-Losing Hope Against Illness|FAC063-Losing Hope Against Illness|FAC06317	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Emotional Well-Being: I am losing hope in the fight against my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151130>	C150798	FACT-Taxane Version 4 - I Feel Nervous|FAC063-I Feel Nervous|FAC063-I Feel Nervous|FAC06318	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Emotional Well-Being: I feel nervous.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151131>	C150798	FACT-Taxane Version 4 - I Worry About Dying|FAC063-I Worry About Dying|FAC063-I Worry About Dying|FAC06319	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Emotional Well-Being: I worry about dying.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151132>	C150798	FACT-Taxane Version 4 - Worry My Condition Will Get Worse|FAC063-Worry My Condition Will Get Worse|FAC063-Worry My Condition Will Get Worse|FAC06320	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Emotional Well-Being: I worry that my condition will get worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151133>	C150798	FACT-Taxane Version 4 - I Am Able to Work|FAC063-I Am Able to Work|FAC063-I Am Able to Work|FAC06321	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Functional Well-Being: I am able to work (include work at home).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151134>	C150798	FACT-Taxane Version 4 - My Work Is Fulfilling|FAC063-My Work Is Fulfilling|FAC063-My Work Is Fulfilling|FAC06322	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Functional Well-Being: My work (include work at home) is fulfilling.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151135>	C150798	FACT-Taxane Version 4 - I Am Able to Enjoy Life|FAC063-I Am Able to Enjoy Life|FAC063-I Am Able to Enjoy Life|FAC06323	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Functional Well-Being: I am able to enjoy life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151136>	C150798	FACT-Taxane Version 4 - I Have Accepted My Illness|FAC063-I Have Accepted My Illness|FAC063-I Have Accepted My Illness|FAC06324	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Functional Well-Being: I have accepted my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151137>	C150798	FACT-Taxane Version 4 - I Am Sleeping Well|FAC063-I Am Sleeping Well|FAC063-I Am Sleeping Well|FAC06325	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Functional Well-Being: I am sleeping well.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151138>	C150798	FACT-Taxane Version 4 - Enjoy Things I Usually Do for Fun|FAC063-Enjoy Things I Usually Do for Fun|FAC063-Enjoy Things I Usually Do for Fun|FAC06326	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Functional Well-Being: I am enjoying the things I usually do for fun.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151139>	C150798	FACT-Taxane Version 4 - Content With Quality of My Life|FAC063-Content With Quality of My Life|FAC063-Content With Quality of My Life|FAC06327	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Functional Well-Being: I am content with the quality of my life right now.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151140>	C150798	FACT-Taxane Version 4 - Numbness or Tingling in My Hands|FAC063-Numbness or Tingling in My Hands|FAC063-Numbness or Tingling in My Hands|FAC06328	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: I have numbness or tingling in my hands.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151141>	C150798	FACT-Taxane Version 4 - Numbness or Tingling in My Feet|FAC063-Numbness or Tingling in My Feet|FAC063-Numbness or Tingling in My Feet|FAC06329	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: I have numbness or tingling in my feet.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151142>	C150798	FACT-Taxane Version 4 - I Feel Discomfort in My Hands|FAC063-I Feel Discomfort in My Hands|FAC063-I Feel Discomfort in My Hands|FAC06330	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: I feel discomfort in my hands.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151143>	C150798	FACT-Taxane Version 4 - I Feel Discomfort in My Feet|FAC063-I Feel Discomfort in My Feet|FAC063-I Feel Discomfort in My Feet|FAC06331	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: I feel discomfort in my feet.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151144>	C150798	FACT-Taxane Version 4 - Have Joint Pain or Muscle Cramps|FAC063-Have Joint Pain or Muscle Cramps|FAC063-Have Joint Pain or Muscle Cramps|FAC06332	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: I have joint pain or muscle cramps.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151145>	C150798	FACT-Taxane Version 4 - I Feel Weak All Over|FAC063-I Feel Weak All Over|FAC063-I Feel Weak All Over|FAC06333	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: I feel weak all over.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151146>	C150798	FACT-Taxane Version 4 - I Have Trouble Hearing|FAC063-I Have Trouble Hearing|FAC063-I Have Trouble Hearing|FAC06334	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: I have trouble hearing.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151147>	C150798	FACT-Taxane Version 4 - Get Ringing or Buzzing in My Ears|FAC063-Get Ringing or Buzzing in My Ears|FAC063-Get Ringing or Buzzing in My Ears|FAC06335	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: I get a ringing or buzzing in my ears.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151148>	C150798	FACT-Taxane Version 4 - I Have Trouble Buttoning Buttons|FAC063-I Have Trouble Buttoning Buttons|FAC063-I Have Trouble Buttoning Buttons|FAC06336	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: I have trouble buttoning buttons.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151149>	C150798	FACT-Taxane Version 4 - Trouble Feeling Shape of Objects|FAC063-Trouble Feeling Shape of Objects|FAC063-Trouble Feeling Shape of Objects|FAC06337	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: I have trouble feeling the shape of small objects when they are in my hand.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151150>	C150798	FACT-Taxane Version 4 - I Have Trouble Walking|FAC063-I Have Trouble Walking|FAC063-I Have Trouble Walking|FAC06338	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: I have trouble walking.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151151>	C150798	FACT-Taxane Version 4 - I Feel Bloated|FAC063-I Feel Bloated|FAC063-I Feel Bloated|FAC06339	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: I feel bloated.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151152>	C150798	FACT-Taxane Version 4 - My Hands Are Swollen|FAC063-My Hands Are Swollen|FAC063-My Hands Are Swollen|FAC06340	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: My hands are swollen.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151153>	C150798	FACT-Taxane Version 4 - My Legs or Feet Are Swollen|FAC063-My Legs or Feet Are Swollen|FAC063-My Legs or Feet Are Swollen|FAC06341	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: My legs or feet are swollen.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151154>	C150798	FACT-Taxane Version 4 - I Have Pain in My Fingertips|FAC063-I Have Pain in My Fingertips|FAC063-I Have Pain in My Fingertips|FAC06342	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: I have pain in my fingertips.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151155>	C150798	FACT-Taxane Version 4 - Bothered by My Hands/Nails Look|FAC063-Bothered by My Hands/Nails Look|FAC063-Bothered by My Hands/Nails Look|FAC06343	Functional Assessment of Cancer Therapy-Taxane Version 4 (FACT-Taxane Version 4) Additional Concerns: I am bothered by the way my hands or nails look.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Code Terminology|CDISC Questionnaire FACT-Taxane Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151156>	C150799	FACT-BRM Version 4 - I Have a Lack of Energy|FAC062-I Have a Lack of Energy|FAC062-I Have a Lack of Energy|FAC06201	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Physical Well-Being: I have a lack of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151157>	C150799	FACT-BRM Version 4 - I Have Nausea|FAC062-I Have Nausea|FAC062-I Have Nausea|FAC06202	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Physical Well-Being: I have nausea.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151158>	C150799	FACT-BRM Version 4 - Trouble Meeting Needs of Family|FAC062-Trouble Meeting Needs of Family|FAC062-Trouble Meeting Needs of Family|FAC06203	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Physical Well-Being: Because of my physical condition, I have trouble meeting the needs of my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151159>	C150799	FACT-BRM Version 4 - I Have Pain|FAC062-I Have Pain|FAC062-I Have Pain|FAC06204	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Physical Well-Being: I have pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151160>	C150799	FACT-BRM Version 4 - Bothered by Treatment Side Effect|FAC062-Bothered by Treatment Side Effect|FAC062-Bothered by Treatment Side Effect|FAC06205	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Physical Well-Being: I am bothered by side effects of treatment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151161>	C150799	FACT-BRM Version 4 - I Feel Ill|FAC062-I Feel Ill|FAC062-I Feel Ill|FAC06206	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Physical Well-Being: I feel ill.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151162>	C150799	FACT-BRM Version 4 - I Am Forced to Spend Time in Bed|FAC062-I Am Forced to Spend Time in Bed|FAC062-I Am Forced to Spend Time in Bed|FAC06207	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Physical Well-Being: I am forced to spend time in bed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151163>	C150799	FACT-BRM Version 4 - I Feel Close to My Friends|FAC062-I Feel Close to My Friends|FAC062-I Feel Close to My Friends|FAC06208	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Social/Family Well-Being: I feel close to my friends.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151164>	C150799	FACT-BRM Version 4 - Get Emotional Support From Family|FAC062-Get Emotional Support From Family|FAC062-Get Emotional Support From Family|FAC06209	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Social/Family Well-Being: I get emotional support from my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151165>	C150799	FACT-BRM Version 4 - I Get Support From My Friends|FAC062-I Get Support From My Friends|FAC062-I Get Support From My Friends|FAC06210	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Social/Family Well-Being: I get support from my friends.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151166>	C150799	FACT-BRM Version 4 - My Family Has Accepted My Illness|FAC062-My Family Has Accepted My Illness|FAC062-My Family Has Accepted My Illness|FAC06211	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Social/Family Well-Being: My family has accepted my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151167>	C150799	FACT-BRM Version 4 - Satisfied Communication Illness|FAC062-Satisfied Communication Illness|FAC062-Satisfied Communication Illness|FAC06212	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Social/Family Well-Being: I am satisfied with family communication about my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151168>	C150799	FACT-BRM Version 4 - I Feel Close to My Partner|FAC062-I Feel Close to My Partner|FAC062-I Feel Close to My Partner|FAC06213	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Social/Family Well-Being: I feel close to my partner (or the person who is my main support).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151169>	C150799	FACT-BRM Version 4 - I Am Satisfied With My Sex Life|FAC062-I Am Satisfied With My Sex Life|FAC062-I Am Satisfied With My Sex Life|FAC06214	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Social/Family Well-Being: I am satisfied with my sex life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151170>	C150799	FACT-BRM Version 4 - I Feel Sad|FAC062-I Feel Sad|FAC062-I Feel Sad|FAC06215	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Emotional Well-Being: I feel sad.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151171>	C150799	FACT-BRM Version 4 - Satisfied With How I Am Coping|FAC062-Satisfied With How I Am Coping|FAC062-Satisfied With How I Am Coping|FAC06216	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Emotional Well-Being: I am satisfied with how I am coping with my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151172>	C150799	FACT-BRM Version 4 - Losing Hope Against Illness|FAC062-Losing Hope Against Illness|FAC062-Losing Hope Against Illness|FAC06217	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Emotional Well-Being: I am losing hope in the fight against my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151173>	C150799	FACT-BRM Version 4 - I Feel Nervous|FAC062-I Feel Nervous|FAC062-I Feel Nervous|FAC06218	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Emotional Well-Being: I feel nervous.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151174>	C150799	FACT-BRM Version 4 - I Worry About Dying|FAC062-I Worry About Dying|FAC062-I Worry About Dying|FAC06219	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Emotional Well-Being: I worry about dying.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151175>	C150799	FACT-BRM Version 4 - Worry My Condition Will Get Worse|FAC062-Worry My Condition Will Get Worse|FAC062-Worry My Condition Will Get Worse|FAC06220	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Emotional Well-Being: I worry that my condition will get worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151176>	C150799	FACT-BRM Version 4 - I Am Able to Work|FAC062-I Am Able to Work|FAC062-I Am Able to Work|FAC06221	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Functional Well-Being: I am able to work (include work at home).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151177>	C150799	FACT-BRM Version 4 - My Work Is Fulfilling|FAC062-My Work Is Fulfilling|FAC062-My Work Is Fulfilling|FAC06222	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Functional Well-Being: My work (include work at home) is fulfilling.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151178>	C150799	FACT-BRM Version 4 - I Am Able to Enjoy Life|FAC062-I Am Able to Enjoy Life|FAC062-I Am Able to Enjoy Life|FAC06223	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Functional Well-Being: I am able to enjoy life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151179>	C150799	FACT-BRM Version 4 - I Have Accepted My Illness|FAC062-I Have Accepted My Illness|FAC062-I Have Accepted My Illness|FAC06224	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Functional Well-Being: I have accepted my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151180>	C150799	FACT-BRM Version 4 - I Am Sleeping Well|FAC062-I Am Sleeping Well|FAC062-I Am Sleeping Well|FAC06225	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Functional Well-Being: I am sleeping well.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151181>	C150799	FACT-BRM Version 4 - Enjoy Things I Usually Do for Fun|FAC062-Enjoy Things I Usually Do for Fun|FAC062-Enjoy Things I Usually Do for Fun|FAC06226	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Functional Well-Being: I am enjoying the things I usually do for fun.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151182>	C150799	FACT-BRM Version 4 - Content With Quality of My Life|FAC062-Content With Quality of My Life|FAC062-Content With Quality of My Life|FAC06227	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Functional Well-Being: I am content with the quality of my life right now.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151183>	C150799	FACT-BRM Version 4 - I Get Tired Easily|FAC062-I Get Tired Easily|FAC062-I Get Tired Easily|FAC06228	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Additional Concerns-Physical: I get tired easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151184>	C150799	FACT-BRM Version 4 - I Feel Weak All Over|FAC062-I Feel Weak All Over|FAC062-I Feel Weak All Over|FAC06229	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Additional Concerns-Physical: I feel weak all over.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151185>	C150799	FACT-BRM Version 4 - I Have a Good Appetite|FAC062-I Have a Good Appetite|FAC062-I Have a Good Appetite|FAC06230	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Additional Concerns-Physical: I have a good appetite.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151186>	C150799	FACT-BRM Version 4 - I Have Pain in My Joints|FAC062-I Have Pain in My Joints|FAC062-I Have Pain in My Joints|FAC06231	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Additional Concerns-Physical: I have pain in my joints.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151187>	C150799	FACT-BRM Version 4 - I Am Bothered by the Chills|FAC062-I Am Bothered by the Chills|FAC062-I Am Bothered by the Chills|FAC06232	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Additional Concerns-Physical: I am bothered by the chills.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151188>	C150799	FACT-BRM Version 4 - I Am Bothered by Fevers|FAC062-I Am Bothered by Fevers|FAC062-I Am Bothered by Fevers|FAC06233	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Additional Concerns-Physical: I am bothered by fevers (episodes of high body temperature).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151189>	C150799	FACT-BRM Version 4 - I Am Bothered by Sweating|FAC062-I Am Bothered by Sweating|FAC062-I Am Bothered by Sweating|FAC06234	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Additional Concerns-Physical: I am bothered by sweating.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151190>	C150799	FACT-BRM Version 4 - I Have Trouble Concentrating|FAC062-I Have Trouble Concentrating|FAC062-I Have Trouble Concentrating|FAC06235	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Additional Concerns-Mental: I have trouble concentrating.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151191>	C150799	FACT-BRM Version 4 - I Have Trouble Remembering Things|FAC062-I Have Trouble Remembering Things|FAC062-I Have Trouble Remembering Things|FAC06236	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Additional Concerns-Mental: I have trouble remembering things.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151192>	C150799	FACT-BRM Version 4 - I Get Depressed Easily|FAC062-I Get Depressed Easily|FAC062-I Get Depressed Easily|FAC06237	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Additional Concerns-Mental: I get depressed easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151193>	C150799	FACT-BRM Version 4 - I Get Annoyed Easily|FAC062-I Get Annoyed Easily|FAC062-I Get Annoyed Easily|FAC06238	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Additional Concerns-Mental: I get annoyed easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151194>	C150799	FACT-BRM Version 4 - I Have Emotional Ups and Downs|FAC062-I Have Emotional Ups and Downs|FAC062-I Have Emotional Ups and Downs|FAC06239	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Additional Concerns-Mental: I have emotional ups and downs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151195>	C150799	FACT-BRM Version 4 - I Feel Motivated to Do Things|FAC062-I Feel Motivated to Do Things|FAC062-I Feel Motivated to Do Things|FAC06240	Functional Assessment of Cancer Therapy-Biologic Response Modifiers Version 4 (FACT-BRM Version 4) Additional Concerns-Mental: I feel motivated to do things.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Code Terminology|CDISC Questionnaire FACT-BRM Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151196>	C150800	FACT/GOG-NTX Version 4 - I Have a Lack of Energy|FAC057-I Have a Lack of Energy|FAC057-I Have a Lack of Energy|FAC05701	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Physical Well-Being: I have a lack of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151197>	C150800	FACT/GOG-NTX Version 4 - I Have Nausea|FAC057-I Have Nausea|FAC057-I Have Nausea|FAC05702	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Physical Well-Being: I have nausea.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151198>	C150800	FACT/GOG-NTX Version 4 - Trouble Meeting Needs of Family|FAC057-Trouble Meeting Needs of Family|FAC057-Trouble Meeting Needs of Family|FAC05703	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Physical Well-Being: Because of my physical condition, I have trouble meeting the needs of my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151199>	C150800	FACT/GOG-NTX Version 4 - I Have Pain|FAC057-I Have Pain|FAC057-I Have Pain|FAC05704	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Physical Well-Being: I have pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C1511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1511>	C2124|C1512	Radioimmunoconjugate|Radiolabeled Antibodies	Monoclonal antibodies (MoAb) conjugated with radioisotopes, i.e., I-131, Y-90, T-99, or In-111. Using radioimmunoconjugates in radiotherapy or radioimaging has the advantage of targeting cells carrying specific antigens, thereby limiting toxic effects on normal cells. Tumor eradication can be achieved by either the antibody-mediated immune response or by only the cytotoxic activity of the radiation.			Chemical Viewed Functionally	
C151200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151200>	C150800	FACT/GOG-NTX Version 4 - Bothered by Treatment Side Effect|FAC057-Bothered by Treatment Side Effect|FAC057-Bothered by Treatment Side Effect|FAC05705	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Physical Well-Being: I am bothered by side effects of treatment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151201>	C150800	FACT/GOG-NTX Version 4 - I Feel Ill|FAC057-I Feel Ill|FAC057-I Feel Ill|FAC05706	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Physical Well-Being: I feel ill.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151202>	C150800	FACT/GOG-NTX Version 4 - I Am Forced to Spend Time in Bed|FAC057-I Am Forced to Spend Time in Bed|FAC057-I Am Forced to Spend Time in Bed|FAC05707	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Physical Well-Being: I am forced to spend time in bed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151203>	C150800	FACT/GOG-NTX Version 4 - I Feel Close to My Friends|FAC057-I Feel Close to My Friends|FAC057-I Feel Close to My Friends|FAC05708	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Social/Family Well-Being: I feel close to my friends.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151204>	C150800	FACT/GOG-NTX Version 4 - Get Emotional Support From Family|FAC057-Get Emotional Support From Family|FAC057-Get Emotional Support From Family|FAC05709	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Social/Family Well-Being: I get emotional support from my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151205>	C150800	FACT/GOG-NTX Version 4 - I Get Support From My Friends|FAC057-I Get Support From My Friends|FAC057-I Get Support From My Friends|FAC05710	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Social/Family Well-Being: I get support from my friends.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151206>	C150800	FACT/GOG-NTX Version 4 - My Family Has Accepted My Illness|FAC057-My Family Has Accepted My Illness|FAC057-My Family Has Accepted My Illness|FAC05711	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Social/Family Well-Being: My family has accepted my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151207>	C150800	FACT/GOG-NTX Version 4 - Satisfied Communication Illness|FAC057-Satisfied Communication Illness|FAC057-Satisfied Communication Illness|FAC05712	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Social/Family Well-Being: I am satisfied with family communication about my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151208>	C150800	FACT/GOG-NTX Version 4 - I Feel Close to My Partner|FAC057-I Feel Close to My Partner|FAC057-I Feel Close to My Partner|FAC05713	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Social/Family Well-Being: I feel close to my partner (or the person who is my main support).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151209>	C150800	FACT/GOG-NTX Version 4 - I Am Satisfied With My Sex Life|FAC057-I Am Satisfied With My Sex Life|FAC057-I Am Satisfied With My Sex Life|FAC05714	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Social/Family Well-Being: I am satisfied with my sex life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151210>	C150800	FACT/GOG-NTX Version 4 - I Feel Sad|FAC057-I Feel Sad|FAC057-I Feel Sad|FAC05715	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Emotional Well-Being: I feel sad.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151211>	C150800	FACT/GOG-NTX Version 4 - Satisfied With How I Am Coping|FAC057-Satisfied With How I Am Coping|FAC057-Satisfied With How I Am Coping|FAC05716	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Emotional Well-Being: I am satisfied with how I am coping with my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151212>	C150800	FACT/GOG-NTX Version 4 - Losing Hope Against Illness|FAC057-Losing Hope Against Illness|FAC057-Losing Hope Against Illness|FAC05717	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Emotional Well-Being: I am losing hope in the fight against my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151213>	C150800	FACT/GOG-NTX Version 4 - I Feel Nervous|FAC057-I Feel Nervous|FAC057-I Feel Nervous|FAC05718	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Emotional Well-Being: I feel nervous.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151214>	C150800	FACT/GOG-NTX Version 4 - I Worry About Dying|FAC057-I Worry About Dying|FAC057-I Worry About Dying|FAC05719	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Emotional Well-Being: I worry about dying.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151215>	C150800	FACT/GOG-NTX Version 4 - Worry My Condition Will Get Worse|FAC057-Worry My Condition Will Get Worse|FAC057-Worry My Condition Will Get Worse|FAC05720	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Emotional Well-Being: I worry that my condition will get worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151216>	C150800	FACT/GOG-NTX Version 4 - I Am Able to Work|FAC057-I Am Able to Work|FAC057-I Am Able to Work|FAC05721	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Functional Well-Being: I am able to work (include work at home).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151217>	C150800	FACT/GOG-NTX Version 4 - My Work Is Fulfilling|FAC057-My Work Is Fulfilling|FAC057-My Work Is Fulfilling|FAC05722	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Functional Well-Being: My work (include work at home) is fulfilling.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151218>	C150800	FACT/GOG-NTX Version 4 - I Am Able to Enjoy Life|FAC057-I Am Able to Enjoy Life|FAC057-I Am Able to Enjoy Life|FAC05723	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Functional Well-Being: I am able to enjoy life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151219>	C150800	FACT/GOG-NTX Version 4 - I Have Accepted My Illness|FAC057-I Have Accepted My Illness|FAC057-I Have Accepted My Illness|FAC05724	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Functional Well-Being: I have accepted my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151220>	C150800	FACT/GOG-NTX Version 4 - I Am Sleeping Well|FAC057-I Am Sleeping Well|FAC057-I Am Sleeping Well|FAC05725	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Functional Well-Being: I am sleeping well.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151221>	C150800	FACT/GOG-NTX Version 4 - Enjoy Things I Usually Do for Fun|FAC057-Enjoy Things I Usually Do for Fun|FAC057-Enjoy Things I Usually Do for Fun|FAC05726	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Functional Well-Being: I am enjoying the things I usually do for fun.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151222>	C150800	FACT/GOG-NTX Version 4 - Content With Quality of My Life|FAC057-Content With Quality of My Life|FAC057-Content With Quality of My Life|FAC05727	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Functional Well-Being: I am content with the quality of my life right now.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151223>	C150800	FACT/GOG-NTX Version 4 - Numbness or Tingling in My Hands|FAC057-Numbness or Tingling in My Hands|FAC057-Numbness or Tingling in My Hands|FAC05728	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Additional Concerns: I have numbness or tingling in my hands.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151224>	C150800	FACT/GOG-NTX Version 4 - Numbness or Tingling in My Feet|FAC057-Numbness or Tingling in My Feet|FAC057-Numbness or Tingling in My Feet|FAC05729	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Additional Concerns: I have numbness or tingling in my feet.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151225>	C150800	FACT/GOG-NTX Version 4 - I Feel Discomfort in My Hands|FAC057-I Feel Discomfort in My Hands|FAC057-I Feel Discomfort in My Hands|FAC05730	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Additional Concerns: I feel discomfort in my hands.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151226>	C150800	FACT/GOG-NTX Version 4 - I Feel Discomfort in My Feet|FAC057-I Feel Discomfort in My Feet|FAC057-I Feel Discomfort in My Feet|FAC05731	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Additional Concerns: I feel discomfort in my feet.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151227>	C150800	FACT/GOG-NTX Version 4 - Have Joint Pain or Muscle Cramps|FAC057-Have Joint Pain or Muscle Cramps|FAC057-Have Joint Pain or Muscle Cramps|FAC05732	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Additional Concerns: I have joint pain or muscle cramps.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151228>	C150800	FACT/GOG-NTX Version 4 - I Feel Weak All Over|FAC057-I Feel Weak All Over|FAC057-I Feel Weak All Over|FAC05733	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Additional Concerns: I feel weak all over.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151229>	C150800	FACT/GOG-NTX Version 4 - I Have Trouble Hearing|FAC057-I Have Trouble Hearing|FAC057-I Have Trouble Hearing|FAC05734	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Additional Concerns: I have trouble hearing.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151230>	C150800	FACT/GOG-NTX Version 4 - Get Ringing or Buzzing in My Ears|FAC057-Get Ringing or Buzzing in My Ears|FAC057-Get Ringing or Buzzing in My Ears|FAC05735	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Additional Concerns: I get a ringing or buzzing in my ears.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151231>	C150800	FACT/GOG-NTX Version 4 - I Have Trouble Buttoning Buttons|FAC057-I Have Trouble Buttoning Buttons|FAC057-I Have Trouble Buttoning Buttons|FAC05736	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Additional Concerns: I have trouble buttoning buttons.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151232>	C150800	FACT/GOG-NTX Version 4 - Trouble Feeling Shape of Objects|FAC057-Trouble Feeling Shape of Objects|FAC057-Trouble Feeling Shape of Objects|FAC05737	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Additional Concerns: I have trouble feeling the shape of small objects when they are in my hand.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151233>	C150800	FACT/GOG-NTX Version 4 - I Have Trouble Walking|FAC057-I Have Trouble Walking|FAC057-I Have Trouble Walking|FAC05738	Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity Version 4 (FACT/GOG-NTX Version 4) Additional Concerns: I have trouble walking.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Code Terminology|CDISC Questionnaire FACT/GOG-NTX Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151234>	C150801	FACT-L Version 4 - I Have a Lack of Energy|FAC016-I Have a Lack of Energy|FAC016-I Have a Lack of Energy|FAC01601	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Physical Well-Being: I have a lack of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151235>	C150801	FACT-L Version 4 - I Have Nausea|FAC016-I Have Nausea|FAC016-I Have Nausea|FAC01602	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Physical Well-Being: I have nausea.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151236>	C150801	FACT-L Version 4 - Trouble Meeting Needs of Family|FAC016-Trouble Meeting Needs of Family|FAC016-Trouble Meeting Needs of Family|FAC01603	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Physical Well-Being: Because of my physical condition, I have trouble meeting the needs of my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151237>	C150801	FACT-L Version 4 - I Have Pain|FAC016-I Have Pain|FAC016-I Have Pain|FAC01604	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Physical Well-Being: I have pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151238>	C150801	FACT-L Version 4 - Bothered by Treatment Side Effect|FAC016-Bothered by Treatment Side Effect|FAC016-Bothered by Treatment Side Effect|FAC01605	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Physical Well-Being: I am bothered by side effects of treatment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151239>	C150801	FACT-L Version 4 - I Feel Ill|FAC016-I Feel Ill|FAC016-I Feel Ill|FAC01606	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Physical Well-Being: I feel ill.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151240>	C150801	FACT-L Version 4 - I am Forced to Spend Time in Bed|FAC016-I am Forced to Spend Time in Bed|FAC016-I am Forced to Spend Time in Bed|FAC01607	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Physical Well-Being: I am forced to spend time in bed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151241>	C150801	FACT-L Version 4 - I Feel Close to My Friends|FAC016-I Feel Close to My Friends|FAC016-I Feel Close to My Friends|FAC01608	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Social/Family Well-Being: I feel close to my friends.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151242>	C150801	FACT-L Version 4 - Get Emotional Support From Family|FAC016-Get Emotional Support From Family|FAC016-Get Emotional Support From Family|FAC01609	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Social/Family Well-Being: I get emotional support from my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151243>	C150801	FACT-L Version 4 - I Get Support From My Friends|FAC016-I Get Support From My Friends|FAC016-I Get Support From My Friends|FAC01610	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Social/Family Well-Being: I get support from my friends.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151244>	C150801	FACT-L Version 4 - My Family Has Accepted My Illness|FAC016-My Family Has Accepted My Illness|FAC016-My Family Has Accepted My Illness|FAC01611	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Social/Family Well-Being: My family has accepted my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151245>	C150801	FACT-L Version 4 - Satisfied Communication Illness|FAC016-Satisfied Communication Illness|FAC016-Satisfied Communication Illness|FAC01612	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Social/Family Well-Being: I am satisfied with family communication about my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151246>	C150801	FACT-L Version 4 - I Feel Close to My Partner|FAC016-I Feel Close to My Partner|FAC016-I Feel Close to My Partner|FAC01613	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Social/Family Well-Being: I feel close to my partner (or the person who is my main support).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151247>	C150801	FACT-L Version 4 - I Am Satisfied With My Sex Life|FAC016-I Am Satisfied With My Sex Life|FAC016-I Am Satisfied With My Sex Life|FAC01614	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Social/Family Well-Being: I am satisfied with my sex life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151248>	C150801	FACT-L Version 4 - I Feel Sad|FAC016-I Feel Sad|FAC016-I Feel Sad|FAC01615	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Emotional Well-Being: I feel sad.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151249>	C150801	FACT-L Version 4 - Satisfied With How I Am Coping|FAC016-Satisfied With How I Am Coping|FAC016-Satisfied With How I Am Coping|FAC01616	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Emotional Well-Being: I am satisfied with how I am coping with my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151250>	C150801	FACT-L Version 4 - Losing Hope Against Illness|FAC016-Losing Hope Against Illness|FAC016-Losing Hope Against Illness|FAC01617	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Emotional Well-Being: I am losing hope in the fight against my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151251>	C150801	FACT-L Version 4 - I Feel Nervous|FAC016-I Feel Nervous|FAC016-I Feel Nervous|FAC01618	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Emotional Well-Being: I feel nervous.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151252>	C150801	FACT-L Version 4 - I Worry About Dying|FAC016-I Worry About Dying|FAC016-I Worry About Dying|FAC01619	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Emotional Well-Being: I worry about dying.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151253>	C150801	FACT-L Version 4 - Worry My Condition Will Get Worse|FAC016-Worry My Condition Will Get Worse|FAC016-Worry My Condition Will Get Worse|FAC01620	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Emotional Well-Being: I worry that my condition will get worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151254>	C150801	FACT-L Version 4 - I Am Able to Work|FAC016-I Am Able to Work|FAC016-I Am Able to Work|FAC01621	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Functional Well-Being: I am able to work (include work at home).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151255>	C150801	FACT-L Version 4 - My Work Is Fulfilling|FAC016-My Work Is Fulfilling|FAC016-My Work Is Fulfilling|FAC01622	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Functional Well-Being: My work (include work at home) is fulfilling.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151256>	C150801	FACT-L Version 4 - I Am Able to Enjoy Life|FAC016-I Am Able to Enjoy Life|FAC016-I Am Able to Enjoy Life|FAC01623	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Functional Well-Being: I am able to enjoy life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151257>	C150801	FACT-L Version 4 - I Have Accepted My Illness|FAC016-I Have Accepted My Illness|FAC016-I Have Accepted My Illness|FAC01624	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Functional Well-Being: I have accepted my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151258>	C150801	FACT-L Version 4 - I Am Sleeping Well|FAC016-I Am Sleeping Well|FAC016-I Am Sleeping Well|FAC01625	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Functional Well-Being: I am sleeping well.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151259>	C150801	FACT-L Version 4 - Enjoy Things I Usually Do for Fun|FAC016-Enjoy Things I Usually Do for Fun|FAC016-Enjoy Things I Usually Do for Fun|FAC01626	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Functional Well-Being: I am enjoying the things I usually do for fun.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151260>	C150801	FACT-L Version 4 - Content With Quality of My Life|FAC016-Content With Quality of My Life|FAC016-Content With Quality of My Life|FAC01627	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Functional Well-Being: I am content with the quality of my life right now.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151261>	C150801	FACT-L Version 4 - I Have Been Short of Breath|FAC016-I Have Been Short of Breath|FAC016-I Have Been Short of Breath|FAC01628	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Additional Concerns: I have been short of breath.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151262>	C150801	FACT-L Version 4 - I Am Losing Weight|FAC016-I Am Losing Weight|FAC016-I Am Losing Weight|FAC01629	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Additional Concerns: I am losing weight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151263>	C150801	FACT-L Version 4 - My Thinking Is Clear|FAC016-My Thinking Is Clear|FAC016-My Thinking Is Clear|FAC01630	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Additional Concerns: My thinking is clear.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151264>	C150801	FACT-L Version 4 - I Have Been Coughing|FAC016-I Have Been Coughing|FAC016-I Have Been Coughing|FAC01631	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Additional Concerns: I have been coughing.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151265>	C150801	FACT-L Version 4 - I Am Bothered by Hair Loss|FAC016-I Am Bothered by Hair Loss|FAC016-I Am Bothered by Hair Loss|FAC01632	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Additional Concerns: I am bothered by hair loss.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151266>	C150801	FACT-L Version 4 - I Have a Good Appetite|FAC016-I Have a Good Appetite|FAC016-I Have a Good Appetite|FAC01633	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Additional Concerns: I have a good appetite.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151267>	C150801	FACT-L Version 4 - I Feel Tightness in My Chest|FAC016-I Feel Tightness in My Chest|FAC016-I Feel Tightness in My Chest|FAC01634	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Additional Concerns: I feel tightness in my chest.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151268>	C150801	FACT-L Version 4 - Breathing Is Easy for Me|FAC016-Breathing Is Easy for Me|FAC016-Breathing Is Easy for Me|FAC01635	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Additional Concerns: Breathing is easy for me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151269>	C150801	FACT-L Version 4 - Have You Ever Smoked|FAC016-Have You Ever Smoked|FAC016-Have You Ever Smoked|FAC01636	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Additional Concerns: Have you ever smoked?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151270>	C150801	FACT-L Version 4 - I Regret My Smoking|FAC016-I Regret My Smoking|FAC016-I Regret My Smoking|FAC01637	Functional Assessment of Cancer Therapy-Lung Version 4 (FACT-L Version 4) Additional Concerns: I regret my smoking.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-L Version 4 Test Code Terminology|CDISC Questionnaire FACT-L Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151271>	C150802	FKSI-DRS Version 4 - I Have a Lack of Energy|FAC041-I Have a Lack of Energy|FAC041-I Have a Lack of Energy|FAC04101	Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms Version 4 (FKSI-DRS Version 4) I have a lack of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FKSI-DRS Version 4 Test Code Terminology|CDISC Questionnaire FKSI-DRS Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151272>	C150802	FKSI-DRS Version 4 - I Have Pain|FAC041-I Have Pain|FAC041-I Have Pain|FAC04102	Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms Version 4 (FKSI-DRS Version 4) I have pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FKSI-DRS Version 4 Test Code Terminology|CDISC Questionnaire FKSI-DRS Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151273>	C150802	FKSI-DRS Version 4 - I Am Losing Weight|FAC041-I Am Losing Weight|FAC041-I Am Losing Weight|FAC04103	Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms Version 4 (FKSI-DRS Version 4) I am losing weight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FKSI-DRS Version 4 Test Code Terminology|CDISC Questionnaire FKSI-DRS Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151274>	C150802	FKSI-DRS Version 4 - I Have Bone Pain|FAC041-I Have Bone Pain|FAC041-I Have Bone Pain|FAC04104	Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms Version 4 (FKSI-DRS Version 4) I have bone pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FKSI-DRS Version 4 Test Code Terminology|CDISC Questionnaire FKSI-DRS Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151275>	C150802	FKSI-DRS Version 4 - I Feel Fatigued|FAC041-I Feel Fatigued|FAC041-I Feel Fatigued|FAC04105	Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms Version 4 (FKSI-DRS Version 4) I feel fatigued.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FKSI-DRS Version 4 Test Code Terminology|CDISC Questionnaire FKSI-DRS Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151276>	C150802	FKSI-DRS Version 4 - I Have Been Short of Breath|FAC041-I Have Been Short of Breath|FAC041-I Have Been Short of Breath|FAC04106	Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms Version 4 (FKSI-DRS Version 4) I have been short of breath.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FKSI-DRS Version 4 Test Code Terminology|CDISC Questionnaire FKSI-DRS Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151277>	C150802	FKSI-DRS Version 4 - I Have Been Coughing|FAC041-I Have Been Coughing|FAC041-I Have Been Coughing|FAC04107	Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms Version 4 (FKSI-DRS Version 4) I have been coughing.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FKSI-DRS Version 4 Test Code Terminology|CDISC Questionnaire FKSI-DRS Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151278>	C150802	FKSI-DRS Version 4 - I Am Bothered by Fevers|FAC041-I Am Bothered by Fevers|FAC041-I Am Bothered by Fevers|FAC04108	Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms Version 4 (FKSI-DRS Version 4) I am bothered by fevers (episodes of high body temperature).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FKSI-DRS Version 4 Test Code Terminology|CDISC Questionnaire FKSI-DRS Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151279>	C150802	FKSI-DRS Version 4 - I Have Had Blood in My Urine|FAC041-I Have Had Blood in My Urine|FAC041-I Have Had Blood in My Urine|FAC04109	Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-Related Symptoms Version 4 (FKSI-DRS Version 4) I have had blood in my urine.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FKSI-DRS Version 4 Test Code Terminology|CDISC Questionnaire FKSI-DRS Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151280>	C150803	NCCN-FACT FBRSI-24 Version 2 - I Get Headaches|FAC030-I Get Headaches|FAC030-I Get Headaches|FAC03001	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I get headaches.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151281>	C150803	NCCN-FACT FBRSI-24 Version 2 - I Have Trouble With Coordination|FAC030-I Have Trouble With Coordination|FAC030-I Have Trouble With Coordination|FAC03002	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I have trouble with coordination.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151282>	C150803	NCCN-FACT FBRSI-24 Version 2 - I Have Had Seizures|FAC030-I Have Had Seizures|FAC030-I Have Had Seizures|FAC03003	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I have had seizures (convulsions).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151283>	C150803	NCCN-FACT FBRSI-24 Version 2 - I Need Help in Caring for Myself|FAC030-I Need Help in Caring for Myself|FAC030-I Need Help in Caring for Myself|FAC03004	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I need help in caring for myself (bathing, dressing, eating, etc.).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151284>	C150803	NCCN-FACT FBRSI-24 Version 2 - Have Weakness in My Arms or Legs|FAC030-Have Weakness in My Arms or Legs|FAC030-Have Weakness in My Arms or Legs|FAC03005	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I have weakness in my arms or legs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151285>	C150803	NCCN-FACT FBRSI-24 Version 2 - I Am Losing Weight|FAC030-I Am Losing Weight|FAC030-I Am Losing Weight|FAC03006	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I am losing weight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151286>	C150803	NCCN-FACT FBRSI-24 Version 2 - Trouble Meeting Needs of Family|FAC030-Trouble Meeting Needs of Family|FAC030-Trouble Meeting Needs of Family|FAC03007	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) Because of my physical condition, I have trouble meeting the needs of my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151287>	C150803	NCCN-FACT FBRSI-24 Version 2 - Difficulty Expressing My Thoughts|FAC030-Difficulty Expressing My Thoughts|FAC030-Difficulty Expressing My Thoughts|FAC03008	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I have difficulty expressing my thoughts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151288>	C150803	NCCN-FACT FBRSI-24 Version 2 - I Am Sleeping Well|FAC030-I Am Sleeping Well|FAC030-I Am Sleeping Well|FAC03009	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I am sleeping well.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151289>	C150803	NCCN-FACT FBRSI-24 Version 2 - I Am Able to Concentrate|FAC030-I Am Able to Concentrate|FAC030-I Am Able to Concentrate|FAC03010	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I am able to concentrate.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151290>	C150803	NCCN-FACT FBRSI-24 Version 2 - I Can Remember New Things|FAC030-I Can Remember New Things|FAC030-I Can Remember New Things|FAC03011	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I can remember new things.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151291>	C150803	NCCN-FACT FBRSI-24 Version 2 - Able to Find the Right Words|FAC030-Able to Find the Right Words|FAC030-Able to Find the Right Words|FAC03012	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I am able to find the right word(s) to say what I mean.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151292>	C150803	NCCN-FACT FBRSI-24 Version 2 - Bothered by Change in Personality|FAC030-Bothered by Change in Personality|FAC030-Bothered by Change in Personality|FAC03013	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I am bothered by the change in my personality.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151293>	C150803	NCCN-FACT FBRSI-24 Version 2 - Worry My Condition Will Get Worse|FAC030-Worry My Condition Will Get Worse|FAC030-Worry My Condition Will Get Worse|FAC03014	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I worry that my condition will get worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151294>	C150803	NCCN-FACT FBRSI-24 Version 2 - I Am Afraid of Having a Seizure|FAC030-I Am Afraid of Having a Seizure|FAC030-I Am Afraid of Having a Seizure|FAC03015	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I am afraid of having a seizure (convulsion).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151295>	C150803	NCCN-FACT FBRSI-24 Version 2 - Frustrated I Cannot Do Things|FAC030-Frustrated I Cannot Do Things|FAC030-Frustrated I Cannot Do Things|FAC03016	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I get frustrated that I cannot do things I used to.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151296>	C150803	NCCN-FACT FBRSI-24 Version 2 - Losing Hope Against Illness|FAC030-Losing Hope Against Illness|FAC030-Losing Hope Against Illness|FAC03017	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I am losing hope in the fight against my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151297>	C150803	NCCN-FACT FBRSI-24 Version 2 - I Have a Lack of Energy|FAC030-I Have a Lack of Energy|FAC030-I Have a Lack of Energy|FAC03018	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I have a lack of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151298>	C150803	NCCN-FACT FBRSI-24 Version 2 - I Have Nausea|FAC030-I Have Nausea|FAC030-I Have Nausea|FAC03019	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I have nausea.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151299>	C150803	NCCN-FACT FBRSI-24 Version 2 - Bothered by Treatment Side Effect|FAC030-Bothered by Treatment Side Effect|FAC030-Bothered by Treatment Side Effect|FAC03020	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I am bothered by side effects of treatment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C1512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1512>	C308|C307	Immunoconjugate|Icon	An agent that consists of an immune substance, such as a monoclonal antibody, antigen or an immunoglobulin, and covalently bound to other molecule(s), usually either a toxin, a radioisotope, or a cytotoxic agent. Immunoconjugates allow for specific delivery of certain substances to specific cells or tissues for diagnostic or therapeutic purposes.			Chemical Viewed Functionally	
C151300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151300>	C150803	NCCN-FACT FBRSI-24 Version 2 - I Feel Fatigued|FAC030-I Feel Fatigued|FAC030-I Feel Fatigued|FAC03021	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I feel fatigued.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151301>	C150803	NCCN-FACT FBRSI-24 Version 2 - I Have a Good Appetite|FAC030-I Have a Good Appetite|FAC030-I Have a Good Appetite|FAC03022	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I have a good appetite.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151302>	C150803	NCCN-FACT FBRSI-24 Version 2 - I Am Able to Enjoy Life|FAC030-I Am Able to Enjoy Life|FAC030-I Am Able to Enjoy Life|FAC03023	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I am able to enjoy life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151303>	C150803	NCCN-FACT FBRSI-24 Version 2 - Content With Quality of My Life|FAC030-Content With Quality of My Life|FAC030-Content With Quality of My Life|FAC03024	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Brain Symptom Index-24 Version 2 (NCCN-FACT FBRSI-24 Version 2) I am content with the quality of my life right now.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FBRSI-24 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151304>	C150804	NCCN-FACT FHNSI-22 Version 2 - I Have Pain|FAC036-I Have Pain|FAC036-I Have Pain|FAC03601	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I have pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151305>	C150804	NCCN-FACT FHNSI-22 Version 2 - I Am Losing Weight|FAC036-I Am Losing Weight|FAC036-I Am Losing Weight|FAC03602	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I am losing weight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151306>	C150804	NCCN-FACT FHNSI-22 Version 2 - I Have Trouble Breathing|FAC036-I Have Trouble Breathing|FAC036-I Have Trouble Breathing|FAC03603	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I have trouble breathing.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151307>	C150804	NCCN-FACT FHNSI-22 Version 2 - I Feel Ill|FAC036-I Feel Ill|FAC036-I Feel Ill|FAC03604	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I feel ill.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151308>	C150804	NCCN-FACT FHNSI-22 Version 2 - Pain in My Mouth, Throat or Neck|FAC036-Pain in My Mouth, Throat or Neck|FAC036-Pain in My Mouth, Throat or Neck|FAC03605	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I have pain in my mouth, throat or neck.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151309>	C150804	NCCN-FACT FHNSI-22 Version 2 - Trouble Meeting Needs of Family|FAC036-Trouble Meeting Needs of Family|FAC036-Trouble Meeting Needs of Family|FAC03606	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) Because of my physical condition, I have trouble meeting the needs of my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151310>	C150804	NCCN-FACT FHNSI-22 Version 2 - Can Swallow Naturally and Easily|FAC036-Can Swallow Naturally and Easily|FAC036-Can Swallow Naturally and Easily|FAC03607	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I can swallow naturally and easily.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151311>	C150804	NCCN-FACT FHNSI-22 Version 2 - Able to Eat the Foods That I Like|FAC036-Able to Eat the Foods That I Like|FAC036-Able to Eat the Foods That I Like|FAC03608	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I am able to eat the foods that I like.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151312>	C150804	NCCN-FACT FHNSI-22 Version 2 - Able to Communicate With Others|FAC036-Able to Communicate With Others|FAC036-Able to Communicate With Others|FAC03609	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I am able to communicate with others.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151313>	C150804	NCCN-FACT FHNSI-22 Version 2 - I Can Eat Solid Foods|FAC036-I Can Eat Solid Foods|FAC036-I Can Eat Solid Foods|FAC03610	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I can eat solid foods.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151314>	C150804	NCCN-FACT FHNSI-22 Version 2 - I Am Sleeping Well|FAC036-I Am Sleeping Well|FAC036-I Am Sleeping Well|FAC03611	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I am sleeping well.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151315>	C150804	NCCN-FACT FHNSI-22 Version 2 - Worry My Condition Will Get Worse|FAC036-Worry My Condition Will Get Worse|FAC036-Worry My Condition Will Get Worse|FAC03612	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I worry that my condition will get worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151316>	C150804	NCCN-FACT FHNSI-22 Version 2 - I Have a Lack of Energy|FAC036-I Have a Lack of Energy|FAC036-I Have a Lack of Energy|FAC03613	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I have a lack of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151317>	C150804	NCCN-FACT FHNSI-22 Version 2 - I Have Nausea|FAC036-I Have Nausea|FAC036-I Have Nausea|FAC03614	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I have nausea.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151318>	C150804	NCCN-FACT FHNSI-22 Version 2 - Had Change in the Way Food Tastes|FAC036-Had Change in the Way Food Tastes|FAC036-Had Change in the Way Food Tastes|FAC03615	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I have had a change in the way food tastes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151319>	C150804	NCCN-FACT FHNSI-22 Version 2 - I Have Mouth Sores|FAC036-I Have Mouth Sores|FAC036-I Have Mouth Sores|FAC03616	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I have mouth sores.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151320>	C150804	NCCN-FACT FHNSI-22 Version 2 - I Am Bothered by Hair Loss|FAC036-I Am Bothered by Hair Loss|FAC036-I Am Bothered by Hair Loss|FAC03617	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I am bothered by hair loss.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151321>	C150804	NCCN-FACT FHNSI-22 Version 2 - Bothered by Treatment Side Effect|FAC036-Bothered by Treatment Side Effect|FAC036-Bothered by Treatment Side Effect|FAC03618	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I am bothered by side effects of treatment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151322>	C150804	NCCN-FACT FHNSI-22 Version 2 - I Have a Good Appetite|FAC036-I Have a Good Appetite|FAC036-I Have a Good Appetite|FAC03619	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I have a good appetite.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151323>	C150804	NCCN-FACT FHNSI-22 Version 2 - I Am Able to Work|FAC036-I Am Able to Work|FAC036-I Am Able to Work|FAC03620	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I am able to work (include work at home).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151324>	C150804	NCCN-FACT FHNSI-22 Version 2 - I Am Able to Enjoy Life|FAC036-I Am Able to Enjoy Life|FAC036-I Am Able to Enjoy Life|FAC03621	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I am able to enjoy life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151325>	C150804	NCCN-FACT FHNSI-22 Version 2 - Content With Quality of My Life|FAC036-Content With Quality of My Life|FAC036-Content With Quality of My Life|FAC03622	National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Head & Neck Symptom Index-22 Version 2 (NCCN-FACT FHNSI-22 Version 2) I am content with the quality of my life right now.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Code Terminology|CDISC Questionnaire NCCN-FACT FHNSI-22 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151326>	C150805	SIQ - Would Be Better If I Was Not Alive|SIQ01-Would Be Better If I Was Not Alive|SIQ01-Would Be Better If I Was Not Alive|SIQ0101	Suicidal Ideation Questionnaire (SIQ) I thought it would be better if I was not alive.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151327>	C150805	SIQ - I Thought About Killing Myself|SIQ01-I Thought About Killing Myself|SIQ01-I Thought About Killing Myself|SIQ0102	Suicidal Ideation Questionnaire (SIQ) I thought about killing myself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151328>	C150805	SIQ - I Thought How I Would Kill Myself|SIQ01-I Thought How I Would Kill Myself|SIQ01-I Thought How I Would Kill Myself|SIQ0103	Suicidal Ideation Questionnaire (SIQ) I thought about how I would kill myself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151329>	C150805	SIQ - I Thought When I Would Kill Myself|SIQ01-I Thought When I Would Kill Myself|SIQ01-I Thought When I Would Kill Myself|SIQ0104	Suicidal Ideation Questionnaire (SIQ) I thought about when I would kill myself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151330>	C150805	SIQ - I Thought About People Dying|SIQ01-I Thought About People Dying|SIQ01-I Thought About People Dying|SIQ0105	Suicidal Ideation Questionnaire (SIQ) I thought about people dying.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151331>	C150805	SIQ - I Thought About Death|SIQ01-I Thought About Death|SIQ01-I Thought About Death|SIQ0106	Suicidal Ideation Questionnaire (SIQ) I thought about death.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151332>	C150805	SIQ - What to Write in a Suicide Note|SIQ01-What to Write in a Suicide Note|SIQ01-What to Write in a Suicide Note|SIQ0107	Suicidal Ideation Questionnaire (SIQ) I thought about what to write in a suicide note.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151333>	C150805	SIQ - I Thought About Writing a Will|SIQ01-I Thought About Writing a Will|SIQ01-I Thought About Writing a Will|SIQ0108	Suicidal Ideation Questionnaire (SIQ) I thought about writing a will.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151334>	C150805	SIQ - Tell People I Plan to Kill Myself|SIQ01-Tell People I Plan to Kill Myself|SIQ01-Tell People I Plan to Kill Myself|SIQ0109	Suicidal Ideation Questionnaire (SIQ) I thought about telling people I plan to kill myself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151335>	C150805	SIQ - People Happier If Not Around|SIQ01-People Happier If Not Around|SIQ01-People Happier If Not Around|SIQ0110	Suicidal Ideation Questionnaire (SIQ) I thought that people would be happier if I were not around.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151336>	C150805	SIQ - How People Feel If I Killed Myself|SIQ01-How People Feel If I Killed Myself|SIQ01-How People Feel If I Killed Myself|SIQ0111	Suicidal Ideation Questionnaire (SIQ) I thought about how people would feel if I killed myself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151337>	C150805	SIQ - I Wished I Were Dead|SIQ01-I Wished I Were Dead|SIQ01-I Wished I Were Dead|SIQ0112	Suicidal Ideation Questionnaire (SIQ) I wished I were dead.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151338>	C150805	SIQ - How Easy It Would Be to End It All|SIQ01-How Easy It Would Be to End It All|SIQ01-How Easy It Would Be to End It All|SIQ0113	Suicidal Ideation Questionnaire (SIQ) I thought about how easy it would be to end it all.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151339>	C150805	SIQ - Killing Myself Would Solve Problem|SIQ01-Killing Myself Would Solve Problem|SIQ01-Killing Myself Would Solve Problem|SIQ0114	Suicidal Ideation Questionnaire (SIQ) I thought that killing myself would solve my problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151340>	C150805	SIQ - Others Better Off If I Was Dead|SIQ01-Others Better Off If I Was Dead|SIQ01-Others Better Off If I Was Dead|SIQ0115	Suicidal Ideation Questionnaire (SIQ) I thought others would be better off if I was dead.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151341>	C150805	SIQ - Wished I Had the Nerve Kill Myself|SIQ01-Wished I Had the Nerve Kill Myself|SIQ01-Wished I Had the Nerve Kill Myself|SIQ0116	Suicidal Ideation Questionnaire (SIQ) I wished I had the nerve to kill myself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151342>	C150805	SIQ - Wished I Had Never Been Born|SIQ01-Wished I Had Never Been Born|SIQ01-Wished I Had Never Been Born|SIQ0117	Suicidal Ideation Questionnaire (SIQ) I wished that I had never been born.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151343>	C150805	SIQ - If Had Chance I Would Kill Myself|SIQ01-If Had Chance I Would Kill Myself|SIQ01-If Had Chance I Would Kill Myself|SIQ0118	Suicidal Ideation Questionnaire (SIQ) I thought if I had the chance I would kill myself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151344>	C150805	SIQ - Thought Way People Kill Themselves|SIQ01-Thought Way People Kill Themselves|SIQ01-Thought Way People Kill Themselves|SIQ0119	Suicidal Ideation Questionnaire (SIQ) I thought about ways people kill themselves.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151345>	C150805	SIQ - Thought Killing Myself Not Do It|SIQ01-Thought Killing Myself Not Do It|SIQ01-Thought Killing Myself Not Do It|SIQ0120	Suicidal Ideation Questionnaire (SIQ) I thought about killing myself, but would not do it.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151346>	C150805	SIQ - Thought About Having Bad Accident|SIQ01-Thought About Having Bad Accident|SIQ01-Thought About Having Bad Accident|SIQ0121	Suicidal Ideation Questionnaire (SIQ) I thought about having a bad accident.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151347>	C150805	SIQ - Thought Life Was Not Worth Living|SIQ01-Thought Life Was Not Worth Living|SIQ01-Thought Life Was Not Worth Living|SIQ0122	Suicidal Ideation Questionnaire (SIQ) I thought that life was not worth living.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151348>	C150805	SIQ - My Life Was Too Rotten to Continue|SIQ01-My Life Was Too Rotten to Continue|SIQ01-My Life Was Too Rotten to Continue|SIQ0123	Suicidal Ideation Questionnaire (SIQ) I thought that my life was too rotten to continue.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151349>	C150805	SIQ - Only Way Be Noticed Is Kill Myself|SIQ01-Only Way Be Noticed Is Kill Myself|SIQ01-Only Way Be Noticed Is Kill Myself|SIQ0124	Suicidal Ideation Questionnaire (SIQ) I thought that the only way to be noticed is to kill myself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151350>	C150805	SIQ - People Realize Worth Caring About|SIQ01-People Realize Worth Caring About|SIQ01-People Realize Worth Caring About|SIQ0125	Suicidal Ideation Questionnaire (SIQ) I thought that if I killed myself people would realize I was worth caring about.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151351>	C150805	SIQ - No One Cared If I Lived or Died|SIQ01-No One Cared If I Lived or Died|SIQ01-No One Cared If I Lived or Died|SIQ0126	Suicidal Ideation Questionnaire (SIQ) I thought that no one cared if I lived or died.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151352>	C150805	SIQ - Hurting Myself but Not Kill Myself|SIQ01-Hurting Myself but Not Kill Myself|SIQ01-Hurting Myself but Not Kill Myself|SIQ0127	Suicidal Ideation Questionnaire (SIQ) I thought about hurting myself but not really killing myself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151353>	C150805	SIQ - Wondered If Had Nerve Kill Myself|SIQ01-Wondered If Had Nerve Kill Myself|SIQ01-Wondered If Had Nerve Kill Myself|SIQ0128	Suicidal Ideation Questionnaire (SIQ) I wondered if I had the nerve to kill myself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151354>	C150805	SIQ - If Things Not Better I Kill Myself|SIQ01-If Things Not Better I Kill Myself|SIQ01-If Things Not Better I Kill Myself|SIQ0129	Suicidal Ideation Questionnaire (SIQ) I thought that if things did not get better I would kill myself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151355>	C150805	SIQ - Wished I Had Right to Kill Myself|SIQ01-Wished I Had Right to Kill Myself|SIQ01-Wished I Had Right to Kill Myself|SIQ0130	Suicidal Ideation Questionnaire (SIQ) I wished that I had the right to kill myself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151356>	C150805	SIQ - TS|SIQ01-TS|SIQ01-TS|SIQ0131	Suicidal Ideation Questionnaire (SIQ) TS (total raw score).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151357>	C150805	SIQ - Total %|SIQ01-Total %|SIQ01-Total %|SIQ0132	Suicidal Ideation Questionnaire (SIQ) Total standardization sample %.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151358>	C150805	SIQ - Specific %: Standard Sample 1|SIQ01-Specific %: Standard Sample 1|SIQ01-Specific %: Standard Sample 1|SIQ0133	Suicidal Ideation Questionnaire (SIQ) Specific standardization %: Sample 1.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151359>	C150805	SIQ - Specific %: Standard Sample 2|SIQ01-Specific %: Standard Sample 2|SIQ01-Specific %: Standard Sample 2|SIQ0134	Suicidal Ideation Questionnaire (SIQ) Specific standardization %: Sample 2.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151360>	C150805	SIQ - Specific %: Standard Sample 3|SIQ01-Specific %: Standard Sample 3|SIQ01-Specific %: Standard Sample 3|SIQ0135	Suicidal Ideation Questionnaire (SIQ) Specific standardization %: Sample 3.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151361>	C150805	SIQ - Critical Item 1|SIQ01-Critical Item 1|SIQ01-Critical Item 1|SIQ0136	Suicidal Ideation Questionnaire (SIQ) Critical item 1.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151362>	C150805	SIQ - Critical Item 2|SIQ01-Critical Item 2|SIQ01-Critical Item 2|SIQ0137	Suicidal Ideation Questionnaire (SIQ) Critical item 2.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151363>	C150805	SIQ - Critical Item 3|SIQ01-Critical Item 3|SIQ01-Critical Item 3|SIQ0138	Suicidal Ideation Questionnaire (SIQ) Critical item 3.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151364>	C150805	SIQ - Critical Item 4|SIQ01-Critical Item 4|SIQ01-Critical Item 4|SIQ0139	Suicidal Ideation Questionnaire (SIQ) Critical item 4.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151365>	C150805	SIQ - Critical Item 5|SIQ01-Critical Item 5|SIQ01-Critical Item 5|SIQ0140	Suicidal Ideation Questionnaire (SIQ) Critical item 5.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151366>	C150805	SIQ - Critical Item 6|SIQ01-Critical Item 6|SIQ01-Critical Item 6|SIQ0141	Suicidal Ideation Questionnaire (SIQ) Critical item 6.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151367>	C150805	SIQ - Critical Item 7|SIQ01-Critical Item 7|SIQ01-Critical Item 7|SIQ0142	Suicidal Ideation Questionnaire (SIQ) Critical item 7.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151368>	C150805	SIQ - Critical Item 8|SIQ01-Critical Item 8|SIQ01-Critical Item 8|SIQ0143	Suicidal Ideation Questionnaire (SIQ) Critical item 8.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ Test Code Terminology|CDISC Questionnaire SIQ Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151369>	C150806	SIQ-JR - Would Be Better If I Was Not Alive|SIQ02-Would Be Better If I Was Not Alive|SIQ02-Would Be Better If I Was Not Alive|SIQ0201	Suicidal Ideation Questionnaire-Junior (SIQ-JR) I thought it would be better if I was not live.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ-JR Test Code Terminology|CDISC Questionnaire SIQ-JR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151370>	C150806	SIQ-JR - I Thought About Killing Myself|SIQ02-I Thought About Killing Myself|SIQ02-I Thought About Killing Myself|SIQ0202	Suicidal Ideation Questionnaire-Junior (SIQ-JR) I thought about killing myself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ-JR Test Code Terminology|CDISC Questionnaire SIQ-JR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151371>	C150806	SIQ-JR - I Thought How I Would Kill Myself|SIQ02-I Thought How I Would Kill Myself|SIQ02-I Thought How I Would Kill Myself|SIQ0203	Suicidal Ideation Questionnaire-Junior (SIQ-JR) I thought about how I would kill myself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ-JR Test Code Terminology|CDISC Questionnaire SIQ-JR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151372>	C150806	SIQ-JR - I Thought When I Would Kill Myself|SIQ02-I Thought When I Would Kill Myself|SIQ02-I Thought When I Would Kill Myself|SIQ0204	Suicidal Ideation Questionnaire-Junior (SIQ-JR) I thought about when I would kill myself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ-JR Test Code Terminology|CDISC Questionnaire SIQ-JR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151373>	C150806	SIQ-JR - I Thought About People Dying|SIQ02-I Thought About People Dying|SIQ02-I Thought About People Dying|SIQ0205	Suicidal Ideation Questionnaire-Junior (SIQ-JR) I thought about people dying.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ-JR Test Code Terminology|CDISC Questionnaire SIQ-JR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151374>	C150806	SIQ-JR - I Thought About Death|SIQ02-I Thought About Death|SIQ02-I Thought About Death|SIQ0206	Suicidal Ideation Questionnaire-Junior (SIQ-JR) I thought about death.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ-JR Test Code Terminology|CDISC Questionnaire SIQ-JR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151375>	C150806	SIQ-JR - What to Write in a Suicide Note|SIQ02-What to Write in a Suicide Note|SIQ02-What to Write in a Suicide Note|SIQ0207	Suicidal Ideation Questionnaire-Junior (SIQ-JR) I thought about what to write in a suicide note.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ-JR Test Code Terminology|CDISC Questionnaire SIQ-JR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151376>	C150806	SIQ-JR - I Thought About Writing a Will|SIQ02-I Thought About Writing a Will|SIQ02-I Thought About Writing a Will|SIQ0208	Suicidal Ideation Questionnaire-Junior (SIQ-JR) I thought about writing a will.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ-JR Test Code Terminology|CDISC Questionnaire SIQ-JR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151377>	C150806	SIQ-JR - Tell People I Plan to Kill Myself|SIQ02-Tell People I Plan to Kill Myself|SIQ02-Tell People I Plan to Kill Myself|SIQ0209	Suicidal Ideation Questionnaire-Junior (SIQ-JR) I thought about telling people I plan to kill myself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ-JR Test Code Terminology|CDISC Questionnaire SIQ-JR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151378>	C150806	SIQ-JR - How People Feel If I Killed Myself|SIQ02-How People Feel If I Killed Myself|SIQ02-How People Feel If I Killed Myself|SIQ0210	Suicidal Ideation Questionnaire-Junior (SIQ-JR) I thought about how people would feel if I killed myself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ-JR Test Code Terminology|CDISC Questionnaire SIQ-JR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151379>	C150806	SIQ-JR - I Wished I Were Dead|SIQ02-I Wished I Were Dead|SIQ02-I Wished I Were Dead|SIQ0211	Suicidal Ideation Questionnaire-Junior (SIQ-JR) I wished I were dead.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ-JR Test Code Terminology|CDISC Questionnaire SIQ-JR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151380>	C150806	SIQ-JR - Killing Myself Would Solve Problem|SIQ02-Killing Myself Would Solve Problem|SIQ02-Killing Myself Would Solve Problem|SIQ0212	Suicidal Ideation Questionnaire-Junior (SIQ-JR) I thought that killing myself would solve my problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ-JR Test Code Terminology|CDISC Questionnaire SIQ-JR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151381>	C150806	SIQ-JR - Others Be Happier If I Was Dead|SIQ02-Others Be Happier If I Was Dead|SIQ02-Others Be Happier If I Was Dead|SIQ0213	Suicidal Ideation Questionnaire-Junior (SIQ-JR) I thought that others would be happier if I was dead.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ-JR Test Code Terminology|CDISC Questionnaire SIQ-JR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151382>	C150806	SIQ-JR - Wished I Had Never Been Born|SIQ02-Wished I Had Never Been Born|SIQ02-Wished I Had Never Been Born|SIQ0214	Suicidal Ideation Questionnaire-Junior (SIQ-JR) I wished that I had never been born.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ-JR Test Code Terminology|CDISC Questionnaire SIQ-JR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151383>	C150806	SIQ-JR - No One Cared If I Lived or Died|SIQ02-No One Cared If I Lived or Died|SIQ02-No One Cared If I Lived or Died|SIQ0215	Suicidal Ideation Questionnaire-Junior (SIQ-JR) I thought that no one cared if I lived or died.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ-JR Test Code Terminology|CDISC Questionnaire SIQ-JR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151384>	C150806	SIQ-JR - TS|SIQ02-TS|SIQ02-TS|SIQ0216	Suicidal Ideation Questionnaire-Junior (SIQ-JR) TS (total raw score).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ-JR Test Code Terminology|CDISC Questionnaire SIQ-JR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151385>	C150806	SIQ-JR - Total %|SIQ02-Total %|SIQ02-Total %|SIQ0217	Suicidal Ideation Questionnaire-Junior (SIQ-JR) Total standardization sample %.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ-JR Test Code Terminology|CDISC Questionnaire SIQ-JR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151386>	C150806	SIQ-JR - Specific %: Standard Sample 1|SIQ02-Specific %: Standard Sample 1|SIQ02-Specific %: Standard Sample 1|SIQ0218	Suicidal Ideation Questionnaire-Junior (SIQ-JR) Specific standardization %: Sample 1.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ-JR Test Code Terminology|CDISC Questionnaire SIQ-JR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151387>	C150806	SIQ-JR - Specific %: Standard Sample 2|SIQ02-Specific %: Standard Sample 2|SIQ02-Specific %: Standard Sample 2|SIQ0219	Suicidal Ideation Questionnaire-Junior (SIQ-JR) Specific standardization %: Sample 2.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ-JR Test Code Terminology|CDISC Questionnaire SIQ-JR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151388>	C150806	SIQ-JR - Specific %: Standard Sample 3|SIQ02-Specific %: Standard Sample 3|SIQ02-Specific %: Standard Sample 3|SIQ0220	Suicidal Ideation Questionnaire-Junior (SIQ-JR) Specific standardization %: Sample 3.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ-JR Test Code Terminology|CDISC Questionnaire SIQ-JR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151389>	C150806	SIQ-JR - Critical Item 1|SIQ02-Critical Item 1|SIQ02-Critical Item 1|SIQ0221	Suicidal Ideation Questionnaire-Junior (SIQ-JR) Critical item 1.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ-JR Test Code Terminology|CDISC Questionnaire SIQ-JR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151390>	C150806	SIQ-JR - Critical Item 2|SIQ02-Critical Item 2|SIQ02-Critical Item 2|SIQ0222	Suicidal Ideation Questionnaire-Junior (SIQ-JR) Critical item 2.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ-JR Test Code Terminology|CDISC Questionnaire SIQ-JR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151391>	C150806	SIQ-JR - Critical Item 3|SIQ02-Critical Item 3|SIQ02-Critical Item 3|SIQ0223	Suicidal Ideation Questionnaire-Junior (SIQ-JR) Critical item 3.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ-JR Test Code Terminology|CDISC Questionnaire SIQ-JR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151392>	C150806	SIQ-JR - Critical Item 4|SIQ02-Critical Item 4|SIQ02-Critical Item 4|SIQ0224	Suicidal Ideation Questionnaire-Junior (SIQ-JR) Critical item 4.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ-JR Test Code Terminology|CDISC Questionnaire SIQ-JR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151393>	C150806	SIQ-JR - Critical Item 5|SIQ02-Critical Item 5|SIQ02-Critical Item 5|SIQ0225	Suicidal Ideation Questionnaire-Junior (SIQ-JR) Critical item 5.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ-JR Test Code Terminology|CDISC Questionnaire SIQ-JR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151394>	C150806	SIQ-JR - Critical Item 6|SIQ02-Critical Item 6|SIQ02-Critical Item 6|SIQ0226	Suicidal Ideation Questionnaire-Junior (SIQ-JR) Critical item 6.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SIQ-JR Test Code Terminology|CDISC Questionnaire SIQ-JR Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C151395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151395>	C81182	Aqueous Volumeter	A device that measures the volume of an object or body part by capturing the equivalent water displaced from a vessel.	Aqueous Volumeter		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C151396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151396>	C62398|C16180	Transanal Total Mesorectal Excision|TaTME	A surgical procedure for rectal cancer that involves the removal of the rectum by combining abdominal and transanal endoscopic approaches to overcome limitations of standard laparoscopic total mesorectal excision.	Transanal Total Mesorectal Excision		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C151397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151397>	C139562	Left Upper Quadrant of Abdomen|ABDOMINAL QUADRANT, LEFT UPPER|LUQ|Left Upper Quadrant|left upper quadrant of abdomen	The region of the abdomen that extends from the median plane to the left of the patient, and from the umbilical plane to the left ribcage.			Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C151398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151398>	C139562	Right Upper Quadrant of Abdomen|ABDOMINAL QUADRANT, RIGHT UPPER|RUQ|Right Upper Quadrant|right upper quadrant of abdomen	The region of the abdomen that extends from the median plane to the right of the patient, and from the umbilical plane to the right ribcage.			Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C151399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151399>	C12664	Left Lower Quadrant of Abdomen|ABDOMINAL QUADRANT, LEFT LOWER|LLQ|Left Lower Quadrant	The region of the abdomen that extends from the median plane to the left of the patient, and below the umbilicus.			Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C1513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1513>	C20181	Analog|Analogue|analog	A synthetic chemical which structurally or functionally resembles a naturally occurring compound.			Chemical Viewed Structurally	
C151400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151400>	C12664	Right Lower Quadrant of Abdomen|ABDOMINAL QUADRANT, RIGHT LOWER|RLQ|Right Lower Quadrant	The region of the abdomen that extends from the median plane to the right of the patient, and from the umbilical plane to the right inguinal ligament.			Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C151401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151401>	C27993	Definable|Defined	Able to concisely explain of the meaning of a word or phrase or symbol.			Conceptual Entity	
C151402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151402>	C21124	Septation	The formation of a division between cavities or parts of an organism.			Organ or Tissue Function	
C151403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151403>	C40557	Tumor Implant	A nodular tumor that develops at a site in a body cavity or the surface of an organ, at a distance from the primary tumor.			Finding	
C151404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151404>	C25972	PTP4A3 Gene|PTP4A3|PTP4A3|Protein Tyrosine Phosphatase Type IVA, Member 3 Gene	This gene plays a role in cell cycle progression, cell proliferation, cell motility and cellular invasiveness.	PTP4A3 Gene		Gene or Genome	CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C151405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151405>	C151404	PTP4A3 wt Allele|PRL-3|PRL-R|PRL3|Protein Tyrosine Phosphatase Type IVA, Member 3 wt Allele|Protein Tyrosine Phosphatase, Type 4A, 3 Gene|Protein-Tyrosine Phosphatase, Type 4A, 3 Gene	Human PTP4A3 wild-type allele is located in the vicinity of 8q24.3 and is approximately 40 kb in length. This allele, which encodes protein tyrosine phosphatase type IVA 3 protein, is involved in protein phosphatase activity, progression of the cell cycle and promotion of cell proliferation and cell motility. Aberrant expression of the gene is associated with tumor metastasis.	PTP4A3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C151406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151406>	C106408	Protein Tyrosine Phosphatase Type IVA 3|EC 3.1.3.48|PRL-3|PRL-R|PTP4A3|Phosphatase of Regenerating Liver 3|Potentially Prenylated Protein Tyrosine Phosphatase|Protein-Tyrosine Phosphatase 4a3|Protein-Tyrosine Phosphatase of Regenerating Liver 3	Protein tyrosine phosphatase type IVA 3 (173 aa, ~20 kDa) is encoded by the human PTP4A3 gene. This protein plays a role in tyrosine phosphatase activity that promotes cell cycle progression.	Protein Tyrosine Phosphatase Type IVA 3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C151407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151407>	C124800	Flt3/MerTK Inhibitor MRX-2843|MRX 2843|MRX-2843|MRX-2843|MRX2843|UNC-2371A	An orally bioavailable inhibitor of two receptor tyrosine kinases (RTKs), FMS-like tyrosine kinase-3 (Flt3; CD135; fetal liver kinase-2; Flk2) and tyrosine-protein kinase Mer (MerTK; proto-oncogene c-Mer; Mer), with potential antineoplastic activity. Upon administration, MRX-2843 targets and binds to both Flt3 and MerTK. This prevents ligand-dependent phosphorylation and activation of Flt3 and MerTK, which inhibits the activation of their downstream signaling pathways. This induces apoptosis and inhibits proliferation of Flt3- and/or MerTK-overexpressing tumor cells. Flt3 and MerTK, are overexpressed in certain tumor cell types and play key roles in tumor cell proliferation and survival.	Flt3/MerTK Inhibitor MRX-2843		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C151408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151408>	C27993	Beyond	Past a place or outside an area.			Qualitative Concept	
C1514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1514>	C1708	Agonist|RECEPTOR AGONIST|Receptor Agonist|agonist	An agent that has affinity for a receptor and intrinsic activity at that receptor.			Chemical Viewed Functionally	CDISC SEND Planned Pharmacologic Target Mode of Action Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15151>	C14421	129 Mouse|129	Inbr and colour depends on substrain (see below). Origin: Dunn 1928 from crosses of coat colour stocks from English fanciers and a chinchilla stock from Castle. This strain has a common origin with strain 101. Most substrains carry the white-bellied agouti gene AW though only a subset have the agouti pattern as many carry albino or chinchilla and/or the pink-eyed dilution gene, p, which is derived from Asian mice of the Mus musculus type (see also strains SJL, P/J and FS/Ei). (Jackson Labs/Festing)	129 Mouse		Mammal	
C15152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15152>	C14239	CD-1 Nude Mouse|CD-1 Nude|CD1 NU|Cr1:CD-1 -nuBR	An inbred strain of athymic, nude mouse developed by transferring the Foxn1nu gene to a CD1 mouse.	CD-1 Nude Mouse		Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15153>	C14239	BALB/c Nude Mouse|BALB/c Nude|BALB/cAnNCr1-nuBR		BALB/c Nude Mouse		Mammal	
C15154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15154>	C15156	NIH-III Mouse|N:NIH-bg-nu-xidBR|NIH-III		NIH-III Mouse		Mammal	
C15155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15155>	C14239	NU/NU Mouse|Crl:NU/NU-nuBR|NU/NU		NU/NU Mouse		Mammal	
C15156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15156>	C14420	Immunodeficient Mouse	Any mouse strain with a faulty immune system such that its ability to fight infectious disease is compromised or ablated. Immunodeficient mice may be derived by inbreeding or genetic engineering. Immunodeficiency may also be induced by some chemicals, heavy metals, alkylating agents, radiation, and thymectomy.	Immunodeficient Mouse		Mammal	
C15157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15157>	C15156	Rag1 Mouse|Rag1		Rag1 Mouse		Mammal	
C15158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15158>	C14294	Fox Chase SCID Mouse|C.B-17/IcrCrl-scid-BR|CB17 SCID|CB17 SCID Mouse|Fox Chase SCID	Discovered by Bosma (1980) at Fox Chase Cancer Center, the CB17 SCID mouse has an autosomal recessive mutation in the Prkdc gene which causes a severe combined immunodeficiency affecting B and T lymphocytes.	Fox Chase SCID Mouse		Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15159>	C14294	SCID Beige Mouse|C.B-17/IcrCrl-scid-bgBR|CB-17/IcrCrl-scid-bgBR|SCID Beige		SCID Beige Mouse		Mammal	
C1515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1515>	C699	Ranimustine|Cymer|Cymerin|MCNU|MCNU|RANIMUSTINE|Ranomustine|alpha-D-glucopyranoside, methyl 6-((((2-chloroethyl)nitrosoamino)carbonyl)amino)-6-deoxy-|methyl 6-((((2-chloroethyl)nitrosoamino)carbonyl) amino)-6-deoxy-alpha-D-glucopyranoside|methyl 6-(3-(2-chloroethyl)-3-nitrosoiureido)-6-deoxy-alpha-D-glucopyranoside|methyl 6-(3-(2-chloroethyl)-3-nitrosoureido)-6-deoxy-alpha-D-glucopyranoside	A chloroethylnitrosourea derivative that inhibits proliferation and growth of tumor cells by alkylation and cross-linkage of DNA strands of tumor cells. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15160>	C14239	B6.Cg-Foxn1-nu Mouse|B6.Cg-Foxn1-nu|C57BL/6J-Hfh1l-nu		B6.Cg-Foxn1-nu Mouse		Mammal	
C15161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15161>	C14239	CBy.Cg-Foxn1-nu|BALB/cByJ-Hfh1l-nu		CBy.Cg-Foxn1-nu		Mammal	
C15162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15162>	C14239	CByB6F1/J-Foxn1-nu Mouse|CByB6F1/J-Foxn1-nu|CByB6F1/J-Hfh1l-nu		CByB6F1/J-Foxn1-nu Mouse		Mammal	
C15163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15163>	C14239	NU/J Foxn1-nu Mouse|NU/J Foxn1-nu|NU/J Hfh1l-nu		NU/J Foxn1-nu Mouse		Mammal	
C15164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15164>	C14294	CBySmn.CB17-Prkdc-scid/J Mouse|BALB/cBySmn-Prkdc-scid/J|CBySmn.CB17-Prkdc-scid/J		CBySmn.CB17-Prkdc-scid/J Mouse		Mammal	
C15165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15165>	C14294	C3Smn.CB17-Prkdc-scid/J Mouse|C3Smn.C-Prkdc-scid/J|C3Smn.CB17-Prkdc-scid/J		C3Smn.CB17-Prkdc-scid/J Mouse		Mammal	
C15166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15166>	C14294	B6.CB17-Prkdc-scid/SzJ Mouse|C57BL/6J-Prkdc-scid/SzJ		B6.CB17-Prkdc-scid/SzJ Mouse		Mammal	
C15167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15167>	C14294	NOD.CB17-Prkdc-scid/J Mouse|NOD SCID|NOD.CB17-Prkdc-scid/J|NOD.SCID|NOD/LtSz-Prkdc-scid/J		NOD.CB17-Prkdc-scid/J Mouse		Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15168>	C15157	NOD.129S7(B6)-Rag1-tm1Mom Mouse|NOD.129S7(B6)-Rag1-tm1Mom|NOD/LtSz-Rag1-tm1Mom		NOD.129S7(B6)-Rag1-tm1Mom Mouse		Mammal	
C15169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15169>	C15157	C.129S7-Rag1-tm1Mom Mouse|BALB/c-Rag1-tm1Mom|C.129S7-Rag1-tm1Mom		C.129S7-Rag1-tm1Mom Mouse		Mammal	
C1516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1516>	C744	Lisofylline|CT 1501R|CT-1501R|LISOFYLLINE|Lisofenicol|lisofylline				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C15170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15170>	C15157	B6;129-Rag1-tm1Mom Mouse|B6,129-Rag1-tm1Mom|B6;129-Rag1-tm1Mom		B6;129-Rag1-tm1Mom Mouse		Mammal	
C15171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15171>	C15157	B6.129S7-Rag1-tm1Mom Mouse|B6.129S7-Rag1-tm1Mom|C57BL/6J-Rag1-tm1Mom		B6.129S7-Rag1-tm1Mom Mouse		Mammal	
C15172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15172>	C14266	Common Rattus Norvegicus Strains	Rat breeds, belonging to the species Rattus norvegicus, that are commonly used as experimental organisms.	Common Rattus Norvegicus Strains		Mammal	
C15173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15173>	C16393	T-Lymphocyte Activation Antigen CD80|Activation B7-1 Antigen|B-lymphocyte Activation Antigen B7-1|B7|B7-1|B71 Antigen|BB1|CD28 Antigen Ligand 1|CD28LG|CD28LG1|CD80|CD80 Antigen|CTLA-4 Counter-Receptor B7.1|LAB7	T-lymphocyte activation antigen CD80 (288 aa, ~33 kDa) is encoded by the human CD80 gene. This protein is involved in the regulation of T-cell activation.	T-Lymphocyte Activation Antigen CD80		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15174>	C16393	T-Cell Surface Antigen CD2|CD2|CD2 Antigen|CD2R|E-Rosette Receptor|Erythrocyte Receptor|LFA-2|LFA-3 Receptor|Lymphocyte-Function Antigen-2|Rosette Receptor|Sheep Erythrocyte Receptor|Sheep Red Blood Cell Receptor|T-Cell Surface Antigen T11/Leu-5|T-Lymphocyte Surface CD2 Antigen	T-cell surface antigen CD2 (351 aa, ~39 kDa) is encoded by the human CD2 gene. This protein plays a role in both T-cell activation and T-cell adhesion to other cells.	T-Cell Surface Antigen CD2		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15175>	C35682|C35553	Human Immunodeficiency Virus Positive|HIV Positive|HIV Positivity|HIV positive|HIV test positive|Positive	A laboratory test result indicating the presence of the human immunodeficiency virus (HIV) in a sample.	Human Immunodeficiency Virus Positive		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Terminology|NCI CTEP SDC AIDS-related Malignancy and Condition, Miscellaneous Sub-Category Terminology|NCI CTEP Simplified Disease Classification Terminology
C15176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15176>	C64386	Acupuncture Therapy|Acupuncture|Acupuncture|Acupuncture|acupuncture	The practice of piercing specific points on the body with very thin sterile needles in order to relieve pain or induce regional anesthesia.	Acupuncture Therapy		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CRF4 Treatment Complementary Table|CTRP Intervention Terminology|CTRP Terminology
C15177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15177>	C16120|C15467	Adrenalectomy|Adrenal Gland Excision|Excision of Adrenal Gland|adrenalectomy	Surgical removal of part or all of the adrenal gland.	Adrenalectomy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C15178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15178>	C19160	Complementary and Alternative Medicine|Alternative Therapy|CAM|CAM|Complementary and Integrative Health|alternative medicine|complementary and alternative medicine|complementary medicine	A group of diverse medical and health care systems, practices, and products that are not presently considered to be part of conventional medicine. Complementary medicine as being used together with conventional medicine, whereas alternative medicine is used in place of conventional medicine. The National Center for Complementary and Alternative Medicine (NCCAM) groups CAM practices into four domains, recognizing there can be some overlap: mind-body medicine; biologically based practices, manipulative and body-based practices, and energy medicine. In addition, NCCAM studies CAM whole medical systems, which cut across all domains.			Biomedical Occupation or Discipline	
C15179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15179>	C49165	Amputation|AMPUTATION_TYPE|AMPUTATION_TYPE|amputation	The surgical removal of all or part of a limb or other appendage.			Therapeutic or Preventive Procedure	CDRH Health Effects - Health Impact Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Variable Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Variable Terminology
C1517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1517>	C446|C2115	Stallimycin|DISTAMYCIN A|Distamycin 3|Distamycin A|Herperetin|STALLIMYCIN	An oligopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces distallicus.  Distamycin preferentially binds to adenine-thymine (A-T) rich sequences in the minor groove of DNA, thereby inhibiting DNA replication and RNA transcription.  In addition to antitumor effects, distamycin also possesses antiviral and antiprotozoal activities and is used as a chromosome dye. (NCI04)			Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C15180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15180>	C15747	Pain Therapy|Analgesia|Pain Control|Pain Management|Pain, Pain Management|analgesia	(i) the systematic study of clinical and basic science and its application for the reduction of pain and suffering; (ii) the blending of tools, techniques and principles taken from the discrete healing art disciplines and reformulated as a holistic application for the reduction of pain and suffering; and (iii) a newly emerging discipline emphasizing an interdisciplinary approach with a goal of reduction of pain and suffering. (AAPM)	Pain Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C15181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15181>	C71314	Anesthesia Procedure|Anesthesia|anesthesia	Treatment with a pharmacological substance that produces a loss of feeling.	Anesthesia Procedure		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|Newborn Screening Terminology|NICHD Terminology
C15182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15182>	C15336	Animal Testing Alternative|Animal Alternative	Any method or technique that eliminates the use of animals in experiments, research, and testing.			Research Activity	
C15183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15183>	C15986|C15632	Antimetabolite Chemotherapy|Chemotherapy, Antimetabolites|Chemotherapy, Cancer, Antimetabolites	Treatment of cancer that utilizes antimetabolite substances to disrupt DNA, RNA, or protein synthesis.			Therapeutic or Preventive Procedure	
C15184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15184>	C63474	Behavioral Intervention|BEHAVIORAL THERAPY|Behavior Conditioning Therapy|Behavior Modification|Behavior Therapy|Behavior or Life Style Modifications|Behavioral Interventions|Behavioral Modification|Behavioral Therapy|Behavioral Treatment|Behavioral Treatments|Behavioural|behavior modification	The use of operant conditioning, including rewards and punishments, in helping a person create an atmosphere where he or she does not contribute to painful stimuli.	Behavioral Intervention		Therapeutic or Preventive Procedure	CDISC SDTM Intervention Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|ICH M11 Intervention Type Value Set Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C15185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15185>	C15429	Behavioral Research	Studies of the motivating factors that influence health practices as well as efforts to modify these practices.			Research Activity	
C15186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15186>	C15436	Biofeedback|biofeedback	A training technique in which various bodily functions, such as heart rate, skin temperature, muscle tension, and brain activity are monitored so that people can learn to control them voluntarily so as to improve their health and physical performance.	Biofeedback		Mental Process	CTRP Intervention Terminology|CTRP Terminology
C15187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15187>	C49236	Biological Therapy|BRM therapy|Biological Agent Therapy|Biological Agents|Biological Response Modifier Therapy|Biological Response Modifiers Therapy|Biologics Therapies|Biotherapy|biological response modifier therapy|biological therapy|biotherapy	A type of treatment that uses substances derived from or made by living organisms to treat disease; this includes both naturally occurring and synthetic products.	Biological Therapy		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology
C15188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15188>	C15429	Biomedical Research	Research concerned with the application of biological and physiological principles to clinical medicine.			Research Activity	
C151895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151895>	C127514	Cerenkov Luminescence Imaging|CLI|Cerenkov Imaging|Cherenkov Imaging	An imaging modality to study charged particles in tissue by detecting the Cerenkov luminescence produced, allowing the imaging of beta-emitting nuclear medicine probes by optical methods.	Cerenkov Luminescence Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C151896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151896>	C27993	Other Than|Except	Distinct from those already mentioned, listed, or considered.			Qualitative Concept	
C151897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151897>	C130038	Hematologic Neoplasm with Germline Predisposition without a Constitutional Disorder Affecting Multiple Organ Systems|Hematologic Neoplasm with Germline Predisposition without a Preexisting Disorder or Organ Dysfunction|Myeloid Neoplasm with Germline Predisposition without a Preexisting Disorder or Organ Dysfunction	Familial hematologic neoplasms associated with germline mutations without a preexisting disorder or organ dysfunction.			Neoplastic Process	
C151898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151898>	C151897	Acute Myeloid Leukemia with Germline CEBPA Mutation|Acute Myeloid Leukemia with Germline Biallelic CEBPA Mutations|CEBPA-Associated Familial AML|CEBPA-Associated Familial Acute Myeloid Leukemia|Familial Acute Myeloid Leukemia with Mutated CEBPA	A familial acute myeloid leukemia caused by germline CEBPA mutations that typically affects children or young adults. Its morphological and immunophenotypic features are similar to those of sporadic acute myeloid leukemia with CEBPA mutations and it usually has a favorable prognosis.			Neoplastic Process	
C151899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151899>	C27993	Unplanned	Not expected or scheduled.			Qualitative Concept	
C15189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15189>	C18020	Biopsy Procedure|BIOPSY|BIOPSY_TYPE|BIOPSY_TYPE|BIOPSY_TYPE|Biopsy|Biopsy|Biopsy|Biopsy|Biopsy|Biopsy|Biopsy|Biopsy|Biopsy|Biopsy|Bx|biopsy	The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis.	Biopsy		Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Procedure Terminology|CDISC SDTM Specimen Collection Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|CDRH Health Effects - Health Impact Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF7 Pathology Review Table|CRF8 Pathology Review Table|CTRP Intervention Terminology|CTRP Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Variable Terminology|GCT Authorized Value Terminology|GCT Biopsy/Surgical Procedures Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Biopsy/Surgical Procedures Table|HL Disease Characteristics Table|HL Lesion Characteristics Table|HL Variable Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Variable Terminology
C1518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1518>	C1821	Raloxifene|Keoxifene|LY 139481|RALOXIFENE|[6-Hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone|raloxifene	A selective benzothiophene estrogen receptor modulator (SERM).  Raloxifene binds to estrogen receptors (ER) as a mixed estrogen agonist/antagonist; it displays both an ER-alpha-selective partial agonist/antagonist effect and a pure ER-beta-selective antagonist effect.  This agent functions as an estrogen agonist in some tissues (bones, lipid metabolism) and as an estrogen antagonist in others (endometrium and breasts), with the potential for producing some of estrogen's beneficial effects without producing its adverse effects. (NCI04)	Raloxifene		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C151900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151900>	C97927	DDX41 Gene Mutation|ABS Gene Mutation|DEAD-Box Helicase 41 Gene Mutation|DEAD/H Box 41 Gene Mutation|Drosophila Abstrakt Homolog Gene Mutation	A change in the nucleotide sequence of the DDX41 gene.	DDX41 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C151901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151901>	C151897	Hematologic Neoplasm with Germline DDX41 Mutation	An autosomal dominant familial myelodysplastic syndrome/acute myeloid leukemia syndrome characterized by inherited mutations in the gene on chromosome 5 encoding the DEAD box RNA helicase DDX41. Patients usually present with leukopenia, hypocellular bone marrow with prominent erythroid dysplasia and a normal karyotype, often leading to erythroleukemia. The prognosis is generally poor. (WHO 2017)			Neoplastic Process	
C151902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151902>	C130038	Hematologic Neoplasm with Germline Predisposition Associated with a Constitutional Platelet Disorder|Hematologic Neoplasm with Germline Predisposition and Preexisting Platelet Disorder|Myeloid Neoplasm with Germline Predisposition and Preexisting Platelet Disorder	Hematologic neoplasms associated with germline mutations and familial platelet disorders.			Neoplastic Process	
C151903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151903>	C151902	Hematologic Neoplasm with Germline RUNX1 Mutation	An autosomal dominant syndrome characterized by abnormalities in platelet number and function and enhanced risk of developing myelodysplastic syndrome/acute myeloid leukemia at a young age. Patients have germline monoallelic mutations in RUNX1 gene. The clinical presentation is variable, even within the same family. Most affected individuals have a mild to moderate bleeding tendency. Platelet counts are normal or mildly reduced, with normal platelet morphology and variable degrees of platelet dysfunction. Distinct families with germline RUNX1 mutations exhibit varying risks of development of myeloid neoplasms with 11-100% (median: 44%) of family members affected. (WHO 2017)			Neoplastic Process	
C151904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151904>	C151906|C133839	Refractory Metastatic Digestive System Carcinoma|Refractory Metastatic Gastrointestinal System Carcinoma	A digestive system carcinoma that has metastasized to another anatomic site and is resistant to treatment.	Refractory Metastatic Digestive System Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C151905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151905>	C7622|C154608|C133839	Recurrent Metastatic Digestive System Carcinoma|Recurrent Metastatic Gastrointestinal System Carcinoma	The reemergence of metastatic digestive system carcinoma after a period of remission.	Recurrent Metastatic Digestive System Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C151906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151906>	C96963|C8511	Refractory Digestive System Carcinoma|Refractory Gastrointestinal System Carcinoma	A carcinoma hat arises from any part of the digestive system and is resistant to treatment.	Refractory Digestive System Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C151907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151907>	C8511|C35850|C152078	Refractory Head and Neck Carcinoma	A head and neck carcinoma that does not respond to treatment.			Neoplastic Process	
C151908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151908>	C151902	Hematologic Neoplasm with Germline ANKRD26 Mutation|Myeloid Neoplasm with Germline ANKRD26 Mutation	An autosomal dominant disorder characterized by moderate thrombocytopenia and increased risk of developing myelodysplastic syndrome/acute myeloid leukemia. This disorder is characterized by germline mutations in ANKRD26, located on chromosome band 10p12.1. (WHO 2017)			Neoplastic Process	
C151909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151909>	C97927	ANKRD26 Gene Mutation|Ankyrin Repeat Domain 26 Gene Mutation	A change in the nucleotide sequence of the ANKRD26 gene.	ANKRD26 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15190>	C15189	Needle Biopsy|Aspiration Biopsy|Puncture Biopsy|needle biopsy	The removal of a tissue sample using a needle, for microscopic examination.	Needle Biopsy		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C151910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151910>	C130038	Hematologic Neoplasm with Germline Predisposition Associated with a Constitutional Disorder Affecting Multiple Organ Systems|Hematologic Neoplasm with Germline Predisposition Associated with Other Organ Dysfunction|Myeloid Neoplasm with Germline Predisposition Associated with Other Organ Dysfunction	Familial hematologic neoplasms associated with germline mutations and a preexisting disorder or organ dysfunction other than a platelet disorder.			Neoplastic Process	
C151911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151911>	C151902	Hematologic Neoplasm with Germline ETV6 Mutation	Autosomal dominant familial thrombocytopenia associated with germline ETV6 mutation and hematologic malignancies. The hematologic malignancies reported are diverse, including myelodysplastic syndrome, acute myeloid leukemia, chronic myelomonocytic leukemia, B lymphoblastic leukemia, and plasma cell myeloma. Non-hematological neoplasms, including colorectal adenocarcinoma, have been also reported in affected families. (WHO 2017)			Neoplastic Process	
C151912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151912>	C151910	Hematologic Neoplasm with Germline GATA2 Mutation|Myeloid Neoplasm with Germline GATA2 Mutation	Myelodysplastic syndromes/acute myeloid leukemias associated with germline GATA2 mutation.			Neoplastic Process	
C151913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151913>	C26057	DDX41 Gene|DDX41|DDX41|DDX41|DEAD-Box Helicase 41 Gene	This gene may play a role in RNA splicing and tumor suppression.	DDX41 Gene		Gene or Genome	CCPS Genetics Terminology|Childhood Cancer Predisposition Study Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C151914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151914>	C151913	DDX41 wt Allele|ABS|Abstrakt, Drosophila, Homolog of Gene|DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 41 Gene|DEAD-Box Helicase 41 wt Allele|DEAD/H Box 41 Gene|Drosophila Abstrakt Homolog Gene|MGC8828|MPLPF	Human DDX41 wild-type allele is located in the vicinity of 5q35.3 and is approximately 6 kb in length. This allele, which encodes probable ATP-dependent RNA helicase DDX41 protein, may be involved in the functionality of the spliceosome. Heterozygous mutation of the gene may be associated with susceptibility to multiple types of familial myeloproliferative and lymphoproliferative neoplasms.	DDX41 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C151915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151915>	C17417	Probable ATP-Dependent RNA Helicase DDX41|DDX41|DEAD Box Protein 41|DEAD Box Protein Abstrakt Homolog|DEAD-Box Protein Abstrakt|EC 3.6.4.13	Probable ATP-dependent RNA helicase DDX41 (622 aa, ~70 kDa) is encoded by the human DDX41 gene. This protein may play a role in gene splicing.	Probable ATP-Dependent RNA Helicase DDX41		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C151918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151918>	C47885	Non-Research Project	A project that does not have a specific hypothesis or discovery objective and typically supports research projects. Supporting projects can be one-time or ongoing operations.			Research Activity	
C151919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151919>	C36327	Telomere Maintenance Gene Mutation	A change in the nucleotide sequence of a gene involved in telomere synthesis and maintenance.			Cell or Molecular Dysfunction	
C15191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15191>	C15657	Pheresis|Apheresed|Apheresis|Apheresis|Blood Component Removal|Collection, Apheresis/Leukapheresis|Hemapheresis|Hemapheresis|apheresis|pheresis	A procedure that collects a component of the peripheral blood while returning the rest to the donor.	Pheresis		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology|FDA eManufacturing Terminology|HL Authorized Value Terminology|HL Transfusion Medicine Procedures Table|NICHD Terminology|Pediatric Rheumatology Terminology
C151920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151920>	C17564	Biosafety Level|BSL|Biosafety Containment Level|Laboratory Biosafety Level	Guidelines for the four levels of protective measures required for handling potentially dangerous biological agents. Each level is defined by the potential of an agent to cause disease, the severity of the disease and the mode of transmission. These guidelines consist of recommendations for best practices, safety equipment, laboratory techniques, and facility design features to achieve appropriate biosafety and biocontainment. They also include safeguards designed to protect laboratory personnel, the surrounding environment and the community.			Intellectual Product	
C151921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151921>	C151922	Hematologic Neoplasm with Germline Predisposition Associated with Telomerase Biology Disorder|Myeloid Neoplasm with Germline Predisposition Associated with Telomerase Biology Disorder	Familial myelodysplastic syndromes/ acute myeloid leukemias associated with telomerase biology disorders.			Neoplastic Process	
C151922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151922>	C151910	Hematologic Neoplasm with Germline Predisposition Associated with Inherited Bone Marrow Failure Syndrome|Hematologic Neoplasm Associated with Inherited Bone Marrow Failure Syndrome|Myeloid Neoplasm Associated with Inherited Bone Marrow Failure Syndrome|Myeloid Neoplasm with Germline Predisposition Associated with Inherited Bone Marrow Failure Syndrome	Familial myelodysplastic syndromes/ acute myeloid leukemias associated with inherited bone marrow failure syndromes.			Neoplastic Process	
C151924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151924>	C20194	ANKRD26 Gene|ANKRD26|ANKRD26|ANKRD26|Ankyrin Repeat Domain 26 Gene	This gene plays a role in platelet functions, adipogenesis and appetite.	ANKRD26 Gene		Gene or Genome	CCPS Genetics Terminology|Childhood Cancer Predisposition Study Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C151925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151925>	C151924	ANKRD26 wt Allele|Ankyrin Repeat Domain 26 wt Allele|KIAA1074|THC2|Thrombocytopenia 2 (Autosomal Dominant) Gene|bA145E8.1	Human ANKRD26 wild-type allele is located in the vicinity of 10p12.1 and is approximately 134 kb in length. This allele, which encodes ankyrin repeat domain-containing protein 26, is involved in adipogenesis, appetite and platelet functions. Mutations in the 5' promoter region of this gene that result in increased expression are associated with autosomal dominant thrombocytopenia 2.	ANKRD26 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C151926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151926>	C28681|C213868|C201547	Autologous CISH-inactivated TILs|Autologous CISH-inactivated T-lymphocytes|Autologous CISH-inactivated TIL|Autologous CISH-inactivated Tumor-infiltrating Lymphocytes|Autologous CRISPR/Cas 9-CISH Knockout TILs	A preparation of autologous tumor-infiltrating lymphocytes (TILs) where the cytokine-inducible SH2-containing protein gene (CISH) has been inactivated using the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR associated protein 9 (Cas9) editing system, containing guide RNA (gRNA) coupled to a recombinant form of the DNA endonuclease Cas9, with potential immunomodulating and antineoplastic activities. Using the CRISPR/Cas9 system, the autologous TILs are transfected, ex vivo, with a plasmid encoding for a gRNA that site-specifically targets and binds to the human CISH gene. Cas9 cleaves these specific DNA sites, which causes double strand breaks, disrupts the gene encoding CISH and prevents transcription. Upon intravenous administration, the autologous CISH-inactivated TILs are able to induce a T-cell-mediated immune response against tumor cells. CISH, a member of the suppressor of cytokine signaling family (SOCS; cytokine-induced STAT inhibitor; STAT-induced STAT inhibitor; SSI), is induced by T-cell receptor (TCR) stimulation. CISH plays a key role in the negative regulation of both T-cell signaling and CTL-mediated tumor cell eradication. The knockout of the CISH gene enhances the expansion and anti-tumor activities of effector T-cells.	Autologous CISH-inactivated TILs		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C151927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151927>	C592	Efineptakin alfa|EFINEPTAKIN ALFA|GX-I7|Hyleukin-7 (TM)|IL-7-hyFc|Il-7 Hybrid Fc|NT-I7|NT-I7 Recombinant Human Interleukin-7-hyFc|NT-I7 Recombinant Human Interleukin-7-hyFc|TJ 107|TJ-107|TJ107|rhIL-7-hyFc	A long-acting immunoglobulin (Ig) fusion protein composed of a recombinant form of the endogenous human protein interleukin-7 (rhIL-7) and fused to a hybrid Fc (hyFc) region of a human antibody, with hematopoietic and immunopotentiating activities. Upon administration of efineptakin alfa, IL-7 stimulates the proliferation, differentiation, trafficking and survival of a variety of T-cell subsets, including naive, central memory (CM), effector memory (EM), terminally differentiated effector memory (TEMRA) and natural killer (NK) T-cells, and enhances T-cell-mediated anti-tumor immune responses. Compared to rhIL-7 alone, fusion to the hyFc region enhances the half-life of IL-7. The hyFc region is composed of the hinge and N-terminal portion of heavy chain constant (CH) region 2 (hinge-CH2) of human IgD, which is fused to the C-terminal region of CH2 and the entire CH3 region of human IgG4.	Efineptakin alfa		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C151928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151928>	C18466	Ankyrin Repeat Domain-Containing Protein 26|ANKRD26|Ankyrin Repeat Domain 26	Ankyrin repeat domain-containing protein 26 (1709 aa, ~196 kDa) is encoded by the human ANKRD26 gene. This protein plays a role in appetite, platelet functions and adipogenesis.	Ankyrin Repeat Domain-Containing Protein 26		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C151929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151929>	C129986	Cinobufotalin|14,15b-Epoxy-3b,5a,16b-trihydroxy-5b,20(22)-bufadienolide 16-Acetate|5-Beta-bufa-20,22-dienolide, 14,15-beta-epoxy-3-beta,5,16-beta-trihydroxy-, 16-Acetate|5b,20(22)-Bufadienolide-14,15b-epoxy-3b,5a,16b-triol 16-Acetate|CB|CINOBUFOTALIN	A bufadienolide isolated from toad venom and utilized in traditional Chinese medicine (TCM) for its cardiotonic, diuretic and hemostatic effects, with potential cytotoxic and antineoplastic activities. Upon administration and although the exact mechanism of action(s) (MoAs) through which this agent exerts its effects have yet to be fully discovered, cinobufotalin causes DNA fragmentation, decreases mitochondrial membrane potential (MMP), increases intracellular calcium (Ca2+) ion concentrations and reactive oxygen species (ROS) production, upregulates Fas protein and activates cytochrome C, various caspases, Bid and Bax. This causes cell cycle arrest, induces apoptosis and inhibits tumor cell growth and survival. In addition, cinobufotalin inhibits the activity of sphingosine kinase 1 (SphK1) and induces pro-apoptotic ceramide production, which further promotes tumor cell apoptosis. Cinobufotalin also induces mitochondrial protein cyclophilin D (Cyp-D)-dependent opening of the mitochondrial permeability transition pore (mPTP), which may contribute to cinobufotalin-induced non-apoptotic death of certain tumor cells.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15192>	C15657|C15388	Blood Transfusion|BLOOD TRANSFUSION|Blood Component Transfusion|Transfusion|Transfusion of Blood Products|blood transfusion|transfusion	The injection of whole blood or a blood component directly into the bloodstream.	Blood Transfusion		Therapeutic or Preventive Procedure	CDISC SDTM Mode of Disease Transmission Terminology|CDISC SDTM Terminology|CDRH Health Effects - Health Impact Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|Newborn Screening Terminology|NICHD Terminology
C151930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151930>	C129986	Bushen-Jianpi Decoction|BJD|BJHD|BSJPD|JPBS|Jianpi Bushen|Jianpi Bushen Decoction	A traditional Chinese medicine (TCM) that is used for Yin deficiency of the liver, kidney and spleen, with potential immunomodulating and antineoplastic activities. Bushen-Jianpi decoction (BSJPD; BJD) consists of various herbs, including, but not limited to, Radix Codonopsis (Dang Shen), Fructus Lycii (the fruit of Chinese wolfberry), Rhizoma Atractylodis Macrocephalae (Baishu; Bai Zhu), Fructus Ligustri Lucidi, Cuscuta chinensis (Chinese dodder) seed, and Psoralea corylifolia Linn. As a TCM, Bushen-Jianpi is used as an antineoplastic agent as it is thought to invigorate the spleen and tonify the kidney, which presumably prevents or treats a variety of cancers. Upon administration of Bushen-Jianpi decoction, the ingredients in the decoction may affect signaling pathways involved in carcinogenesis and enhance the immune system by increasing the levels of numerous cytokines and a variety of immune cells, such as cytotoxic T-lymphocytes (CTLs), natural killer cells (NKs) and macrophages. It may also reduce the expression of various proteins involved in tumorigenesis.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C151931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151931>	C20401|C129822	Anti-PRL-3 Monoclonal Antibody PRL3-zumab|PRL3 Zumab|PRL3-zumab	A humanized monoclonal antibody against  phosphatase of regenerating liver 3 (PRL-3; PTP4A3), with potential immunomodulating and antineoplastic activities. Upon administration, anti-PRL-3 monoclonal antibody PRL3-zumab targets, binds to and blocks PRL-3 expressed on tumor cells. Although the exact mechanism of action through which this antibody kills tumor cells has yet to be fully elucidated, PRL3-zumab binds to PRL-3. This prevents PRL-3-mediated signaling in, inhibits the proliferation of and induces apoptosis in PRL-3-expressing tumor cells. PRL-3, a member of the PRL family of protein tyrosine kinases, is upregulated in a variety of tumor cells. Its expression is associated with increased invasiveness, higher metastatic potential, increased tumor cell survival and poor prognosis.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C151932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151932>	C200712	STAT3 Inhibitor C-188-9|C188-9|STAT3 Inhibitor TTI-101|STAT3 Inhibitor XIII|TTI 101|TTI-101|TTI-101|TTI101	An orally bioavailable, binaphthol-sulfonamide-based inhibitor of signal transducer and activator of transcription 3 (STAT3), with potential antineoplastic activity. Upon oral administration, the STAT3 inhibitor C-188-9 specifically targets and binds to the phosphotyrosyl peptide binding site within the Src homology 2 (SH2) domain of STAT3. This inhibits the Janus kinase (JAK)-mediated tyrosine phosphorylation and activation of STAT3. This impedes nuclear translocation of STAT3, prevents STAT3 binding to responsive gene promoters and blocks STAT3-mediated regulation of gene expression. STAT3 regulates the transcription of genes involved in several cellular functions. STAT3 is constitutively activated in a variety of human cancers and plays a key role in neoplastic transformation, uncontrolled tumor cell proliferation, resistance to apoptosis, metastasis, immune evasion, tumor angiogenesis, epithelial-mesenchymal transition (EMT) and the Warburg effect.	STAT3 Inhibitor C-188-9		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C151933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151933>	C273	Hec1/Nek2 Inhibitor T-1101 Tosylate|T 1101 Tosylate|T1101 Tosylate|TAI-95	The tosylate salt form of T-1101, an orally bioavailable inhibitor of highly expressed in cancer 1 (Hec1) and NIMA-related kinase 2 (Nek2), with potential antineoplastic activity. Upon oral administration, T-1101 specifically targets, binds to and inhibits the interaction of Hec1 with Nek2. This prevents Hec1/Nek2-mediated signal transduction pathways, inhibits mitosis, induces apoptosis and tumor cell proliferation. Hec1, overexpressed in some cancers, is located at the centromere during cell mitosis and plays an essential role in the pathway of spindle checkpoint. It is correlated with cancer formation, progression, and survival. Phosphorylation of Hec1 by Nek2 kinase is essential for its mitotic function.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C151934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151934>	C135727	Serial Liquid Biopsy	Multiple liquid biopsies made over time.	Serial Liquid Biopsy		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C151935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151935>	C201513|C201174|C201173|C176018	Anti-CD19/CD20/CD22/CD30 CAR-T Cells|Anti-CD19/CD20/CD22/CD30 Chimeric Antigen Receptor-T Cells|CAR-T CD19/CD20/CD22/CD30	A preparation of human T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19), CD20, CD22 and CD30, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD19/CD20/CD22/CD30 CAR-T cells target and bind to CD19, CD20, CD22 and CD30 expressed on the surface of certain tumor cells. This induces selective toxicity in tumor cells expressing these TAAs. The TAAs are overexpressed in certain hematologic malignancies.			Cell|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|NCI Drug Dictionary Terminology
C151936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151936>	C28681|C138180|C129826	Autologous E6 T Cell Receptor Genetically-modified T Cells|Autologous Anti-HPV-16 E6 TCR T Cells|Autologous E6 TCR T Cells|Autologous E6 TCR T-cells|Autologous HPV-16 E6 TCR T Cells	A preparation of human autologous peripheral blood lymphocytes (PBLs) that have been genetically engineered to express a T-cell receptor (TCR) that specifically targets the viral oncoprotein human papillomavirus type 16 (HPV-16) E6, with potential antineoplastic activity. Upon administration, the HPV E6 TCR genetically-modified T-cells target and bind to HPV-16 E6-expressing tumor cells, which leads to specific cytotoxic T-lymphocyte (CTL)-mediated killing of HPV-16 E6-positive tumor cells. HPV-16 E6, a cell surface glycoprotein, plays a key role in the tumorigenesis of various HPV-associated tumors and is absent from healthy human tissues.	Autologous E6 T Cell Receptor Genetically-modified T Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C151937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151937>	C1752	Onilcamotide|ONILCAMOTIDE|RV 001|RV 001V|RV001 Vaccine|RV001V|RhoC Peptide Vaccine RV001V	A cancer vaccine composed of an immunogenic peptide derived from the Ras homolog family member C (RhoC; Rho-related GTP-binding protein RhoC) that is emulsified in the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, onilcamotide may stimulate the host immune system to mount a humoral and cytotoxic T-lymphocyte (CTL) response against tumor cells expressing RhoC, which results in tumor cell lysis. RhoC, a tumor-associated antigen (TAA) that is overexpressed in a variety of tumor cell types, is associated with increased metastatic potential.			Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C151938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151938>	C34808	Pelvic Mass	A benign or malignant tumor-like pathologic process involving the organs and structures in the pelvis.	Pelvic Mass		Finding	CTRP Disease Terminology|CTRP Terminology
C151939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151939>	C1966	Fluorescence Imaging Agent IC2000|IC 2000|IC2000	A fluorescent imaging agent that can potentially be used as a diagnostic imaging agent.			Indicator, Reagent, or Diagnostic Aid	NCI Drug Dictionary Terminology
C15193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15193>	C217124	Bone Marrow Biopsy|Biopsy of Bone Marrow|Biopsy, Bone Marrow|bone marrow biopsy	A biopsy involving the removal of a core tissue containing bone spicules and hematopoietic elements embedded in the marrow stroma.  This procedure is done in the hip area mainly for the diagnosis and evaluation of neoplastic and non-neoplastic hematopoietic disorders (e.g. anemias, leukemias, lymphomas) and the evaluation of the spread of solid tumors (e.g. carcinomas, sarcomas) and lymphomas for therapeutic purposes.			Diagnostic Procedure	HL Authorized Value Terminology|HL Subject Response Table
C151940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151940>	C9292	Extracranial Solid Neoplasm|Extracranial Solid Tumor|Extracranial Solid Tumor	A solid neoplasm involving any anatomic site other than the brain.	Extracranial Solid Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C151941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151941>	C281	Acyclic Nucleoside Phosphonate Prodrug ABI-1968|ABI-1968|ABI1968|HTI 1968	A prodrug of an acyclic nucleoside phosphonate, with potential anti-viral and antineoplastic activities. Upon administration, acyclic nucleoside phosphonate prodrug ABI-1968 is taken up by viral-infected cells and converted to its active metabolite. The metabolite is incorporated into DNA chains by DNA polymerases, which results in the termination of DNA synthesis, inhibits viral replication and induces apoptosis and inhibits the proliferation of susceptible virally-infected tumor cells.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C151942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151942>	C1752|C1663	Therapeutic Liver Cancer Peptide Vaccine IMA970A|HCC Vaccine IMA970A|IMA970A	An off-the-shelf hepatocellular cancer (HCC) multi-peptide-based therapeutic vaccine composed of sixteen peptides derived from tumor-associated antigens (TAAs) expressed by hepatic tumor cells, of which seven are restricted to human leukocyte antigen (HLA)-A2 (HLA-A*02), five to HLA-A*24 and four to HLA class II, with potential immunomodulating and antineoplastic activities. Upon intradermal administration of the therapeutic liver cancer peptide vaccine IMA970A, the liver-specific peptides in the vaccine activate the immune system to exert both CD4+ T-helper and CD8+ cytotoxic T-lymphocyte (CTL)-mediated immune responses against liver cancer cells.			Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C151943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151943>	C128462	Bivalent BRD4 Inhibitor AZD5153|(R)-4-(2-(4-(1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl)phenoxy)ethyl)-1,3-dimethylpiperazin-2-one|AZD 5153|AZD-5153|AZD5153|BET Inhibitor AZD5153|BRD4/BET Bromodomain Antagonist AZD5153|Bivalent BET Bromodomain Inhibitor AZD5153	An orally bioavailable bivalent inhibitor of  bromodomain-containing protein 4 (BRD4), with potential antineoplastic activity. Upon oral administration, the BRD4 inhibitor AZD5153 selectively binds to the acetylated lysine recognition motifs in two bromodomains in the BRD4 protein, thereby preventing the binding of BRD4 to acetylated lysines on histones. This disrupts chromatin remodeling and dysregulates expression of target genes, which leads to the downregulation of the expression of certain growth-promoting genes, induces apoptosis and inhibits the proliferation of BRD4-overexpressing tumor cells. BRD4, a member of the human bromodomain and extra-terminal (BET) family of proteins, is a transcriptional regulator that is overexpressed in certain tumor cells and plays an important role in cellular proliferation.	Bivalent BRD4 Inhibitor AZD5153		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C151944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151944>	C200766|C176018	Autologous PD1-inhibiting Anti-CD19 4-1BB CAR T Cells|Autologous iPD1 CD19 eCAR T Cells	A preparation of autologous T-lymphocytes that are transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19) linked to the intracellular signaling domain of 4-1BB (CD137) that also encodes a cell-intrinsic programmed cell death 1 (PD1; PDCD1; CD279; programmed death-1) short/small hairpin RNA (shRNA)-expressing cassette, with potential immunomodulating and antineoplastic activities. Upon administration of the autologous PD1-inhibiting anti-CD19 4-1BB CAR T-cells, these cells target, bind to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. The shRNA silences expression of PD1, abrogates T-cell exhaustion, increases CAR T-cell activity and enhances tumor cytotoxicity. Expression of PD-1, an inhibitory receptor expressed on activated T-cells, plays a key role in CTL suppression, T-cell exhaustion and CTL apoptosis.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C151945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151945>	C141137|C129820	IDO/TDO Inhibitor HTI-1090|HTI 1090|HTI-1090|SHR9146	An orally available inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1; IDO-1) and the kynurenine-producing hepatic enzyme tryptophan 2,3-dioxygenase (TDO), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1/TDO inhibitor HTI-1090 specifically targets and binds to both IDO1, a cytosolic enzyme responsible for the oxidation of the amino acid tryptophan into the immunosuppressive metabolite kynurenine, and TDO, a hepatic enzyme catalyzing the first step of tryptophan degradation. By inhibiting IDO1 and TDO, HTI-1090 decreases kynurenine levels in tumor cells, restores tryptophan and promotes the proliferation and activation of various immune cells, including dendritic cells (DCs), natural killer (NK) cells and T-lymphocytes. This reduces the number of tumor-associated regulatory T-cells (Tregs) and activates the immune system to induce a cytotoxic T-lymphocyte (CTL) response against the IDO1/TDO-expressing tumor cells, thereby inhibiting the growth of the tumor cells. IDO1 and TDO, both overexpressed by multiple tumor cell types, play important roles in immunosuppression and the promotion of tumor cell survival and proliferation. Tryptophan depletion inhibits T-lymphocyte proliferation and activation, and subsequently suppresses the immune system.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C151946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151946>	C129824	Topical Potassium Dobesilate|AM-001	A topical formulation composed of an inhibitor of fibroblast growth factor (FGF), with potential antineoplastic activity. Upon topical administration potassium dobesilate selectively binds to and blocks the activity of FGF, interferes with the binding of FGF to FGFR and prevents FGFR-mediated signaling. This inhibits angiogenesis and tumor cell proliferation, and induces cell death in FGFR-overexpressing tumor cells. FGF plays a key role in angiogenesis, tumor cell proliferation, survival and invasiveness, and is upregulated in many tumor cell types.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C151947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151947>	C129822|C128057	Cosibelimab|Anti-PD-L1 Monoclonal Antibody TG-1501|Anti-PDL1 Monoclonal Antibody TG-1501|CK 301|CK-301|COSIBELIMAB|Cosibelimab-ipdl|TG 1501|TG-1501|TG1501|Unloxcyt	An immunoglobulin G1 (IgG1), human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, cosibelimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death protein 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.	Cosibelimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C151948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151948>	C223354|C222322|C129820	CD16/IL15/CD33 Trispecific Killer Cell Engager OXS-3550|161533|161533 TRIKE|CD16/IL-15/CD33 161533 Tri-Specific Killer Engagers|CD16/IL15/CD33 TriKE OXS-3550|OXIS3550|OXS 3550|OXS-3550|OXS-3550|OXS3550	A trispecific killer engager (TriKE) molecule containing an anti-cluster of differentiation 16 (CD16; FcgammaRIII) single-chain variable fragment (scFv) to engage natural killer (NK) cells, an anti-CD33 scFv to engage myeloid cells and a human modified interleukin-15 (IL-15) linker, that links the two scFv, with potential immunomodulating and antineoplastic activities against CD33-expressing tumor cells. Upon administration of the CD16/IL15/CD33 TriKE OXS-3550, the simultaneous binding to CD16 on NK cells and CD33 on tumor cells will induce NK cell cytotoxicity specifically against CD33-expressing tumor cells. The cytokine  IL-15 linker promotes NK cell proliferation, activity, survival and expansion. CD33 is expressed on normal non-pluripotent hematopoietic stem cells and is overexpressed on myeloid leukemia cells.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C151949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151949>	C224110|C2080	Vonoprazan Fumarate|1H-Pyrrole-3-methanamine, 5-(2-Fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl)-, (2E)-2-Butenedioate (1:1)|TAK-438|Takecab|VONOPRAZAN FUMARATE|Voquezna	The fumarate salt form of vonoprazan, a pyrrole derivative and reversible potassium-competitive acid blocker (P-CAB), with potential antacid activity. Upon administration, vonoprazan specifically and competitively binds to the gastric hydrogen-potassium ATPase (H+/K+ ATPase) proton pump at or, more likely, near its potassium ion (K+) binding site and sterically inhibits K+ binding. This blocks the activation of the H+/K+ ATPase by K+, inhibits the proton pump and prevents gastric acid secretion, thereby lowering gastric acid levels.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C15194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15194>	C15342	Bone Marrow Transplantation|BMT|BMT|BMT|BONE MARROW TRANSPLANT|Blood and Bone Marrow Transplant|Bone Marrow|Bone Marrow Grafting|Bone Marrow Transplant|Bone marrow transplant|Marrow Transplantation|bone marrow transplantation	A procedure to replace diseased bone marrow with transplanted healthy bone marrow cells.	Bone Marrow Transplantation		Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology|HL Authorized Value Terminology|HL Stem Cell Transplant Table|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C151950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151950>	C225418	Supradiaphragmatic	Located or performed from above the diaphragm.			Spatial Concept	
C151951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151951>	C128462	Trotabresib|4-(2-(Cyclopropylmethoxy)-5-methylsulfonylphenyl)-2-methylisoquinolin-1-one|BET Inhibitor CC-90010|CC 90010|CC-90010|CC90010|TROTABRESIB	An orally bioavailable inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon oral administration, trotabresib preferentially binds to the second bromodomain (BD2) of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of proliferation in BET-overexpressing tumor cells. BET proteins (BRD2, BRD3, BRD4 and BRDT) are transcriptional regulators that contain two homologous bromodomains, the BD1 and BD2 domains. They play an important role during development and cellular growth.	Trotabresib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C151952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151952>	C141215|C129822	Glyco-engineered Anti-CD20 Monoclonal Antibody CHO H01|CHO H01|CHO-H01|CHO-H01	A glyco-engineered monoclonal antibody directed against the human B-cell-specific cell surface antigen CD20, with potential antineoplastic and immunomodulating activities. Upon administration of glyco-engineered anti-CD20 monoclonal antibody CHO H01, the antibody specifically targets and binds to CD20. This induces antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B-cells, which leads to B-cell apoptosis and the inhibition of tumor cell proliferation. In addition, CHO H01 inhibits CD20-mediated signaling which further induces apoptosis in and inhibits proliferation of CD20-expressing tumor cells. CD20, a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B-cells during most stages of B-cell development, is often overexpressed in B-cell malignancies. The Fc-glycans are homogenously engineered onto the antibody and increase ADCC, anti-tumor activity and the half-life of the antibody.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C151953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151953>	C1904	Locnartecan|HDC SN-38|HSP90-targeted SN-38 Conjugate PEN-866|LOCNARTECAN|PEN 866|PEN-866|PEN866|STA-12-8666|STA-8666	A miniature drug conjugate composed of the irinotecan metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) conjugated, through a cleavable linker, to a ligand of chaperone protein heat shock protein 90 (Hsp90), with potential antineoplastic activity. Upon administration of locnartecan, the HSP90 ligand moiety targets HSP90, which allows the conjugate to penetrate, accumulate and be retained in the tumor cell. Once the linker is cleaved, the SN-38 moiety is released in a sustained manner. SN-38 then binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, which results in DNA breaks, inhibition of DNA replication and apoptosis. Compared to SN-38 alone, locnartecan preferentially targets, accumulates  and is retained in the tumor cells due to its binding to Hsp90, which results in increased concentrations of SN-38 at the tumor site. This allows sustained release of SN-38 and leads to increased and prolonged efficacy while reducing toxicity to normal, healthy tissues. Hsp90, a chaperone protein upregulated and activated in a variety of tumor cells compared to normal healthy tissue, regulates the folding, stability and degradation of many oncogenic signaling proteins.	Locnartecan		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C151954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151954>	C201495|C201493|C200766	Autologous Anti-Muc1/CD33/CD38/CD56/CD123 Gene-engineered CAR-T Cells|Autologous Muc1/CD33/CD38/CD56/CD123-specific Gene-engineered CAR-T Cells	A preparation of genetically modified autologous T-cells transduced with lentiviral vectors expressing chimeric antigen receptors (CARs) specific for the tumor-associated antigens (TAAs) mucin 1 (Muc1; MUC1), cluster of differentiation 33 (CD33), CD38, CD56 and CD123 (interleukin-3 receptor alpha chain or IL3RA), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous anti-Muc1/CD33/CD38/CD56/CD123 gene-engineered CAR-T cells are directed to and induce selective toxicity in Muc1/CD33/CD38/CD56/CD123-expressing tumor cells. Muc1/CD33/CD38/CD56/CD123 are present on certain tumor cell types and are minimally expressed on normal, healthy cells. Expression of these TAAs are correlated with poor prognosis. CD28, CD137 and CD27, T-cell surface-associated co-stimulatory molecules included in the CARs, are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C151955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151955>	C78281	Upacicalcet Sodium Hydrate|AJT-240|AJT240|CaSR Agonist SK 1403|Calcium-sensing Receptor Agonist SK 1403|PLS 240|PLS-240|PLS240|SK1403|UPACICALCET SODIUM HYDRATE|UPASITA	The sodium hydrate form of upacicalcet, an agonist of calcium-sensing receptors (CaSR), with potential use in the treatment of secondary hyperparathyroidism (SHPT). Upon administration, upacicalcet targets and binds to CaSRs expressed on the membranes of cells in the parathyroid glands, which suppresses osteoclast activity and reduces the excessive secretion of parathyroid hormone (PTH). This prevents the excessive PTH-mediated efflux of phosphorus and calcium from bone into the blood and normalizes serum calcium and phosphorus levels. Upacicalcet may decrease the risk of bone fracture, may lower depositions of phosphorus and calcium salts in non-bone tissues, may reduce bone and joint pain and may slow the progression of other diseases related to increased levels of PTH. CaSR controls calcium homeostasis and regulates the release of PTH.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C151956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151956>	C2842	HPV16-E6-T27|HPV16-targeting TALEN T27|T27	A transcription activator-like effector nucleases (TALEN)-edited plasmid targeting the human papillomavirus (HPV) type 16 (HPV16) epitope E6, with potential antineoplastic activity. Upon administration of TALEN-edited HPV16 E6 T27, the TALEN targets and binds to a specific site on genomic HPV16 E6 and cleaves the DNA sequences encoding E6. This causes double-strand DNA (dsDNA) breaks within the viral DNA, which prevents the transcription and translation of E6. Inhibition of E6 expression restores and increases the expression of tumor suppressor genes, such as p53, and proapoptotic protein BAK, and promotes downstream signaling. Altogether, TALEN-based HPV editing increases apoptosis, reduces viral replication and viral load, eliminates HPV and inhibits tumor cell proliferation of HPV-driven cancer cells. HPV16 E6 is an oncogene vital to viral function and HPV infection, and promotes carcinogenesis.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C151957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151957>	C3211	Transformed Non-Hodgkin Lymphoma	Histologic transformation of a usually indolent non-Hodgkin lymphoma to an aggressive non-Hodgkin lymphoma.	Transformed Non-Hodgkin Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C151958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151958>	C2842	HPV16-E7-T512|HPV16-targeting TALEN T512|T512	A transcription activator-like effector nucleases (TALEN)-edited plasmid targeting human papillomavirus (HPV) type 16 (HPV16) epitope E7, with potential antineoplastic activity. Upon administration of TALEN-edited HPV16 E7 T512, the TALEN targets and binds to a specific site on genomic HPV16 E7, and cleaves the DNA sequences encoding E7. This causes double-strand DNA (dsDNA) breaks within the viral DNA, which prevents the transcription and translation of E7. Inhibition of E7 expression restores and increases the expression of tumor suppressor genes, such as retinoblastoma 1 (RB1), and promotes downstream signaling. Altogether, TALEN-based HPV editing increases cell cycle arrest, induces apoptosis, reduces viral replication and load, eliminates HPV and inhibits tumor cell proliferation of HPV-driven cancer cells. HPV16 E7 is an oncogene that is vital to viral function and HPV infection, and promotes carcinogenesis.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C151959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151959>	C225418	Suprarenal	Located above the upper pole of the kidney.			Spatial Concept	
C15195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15195>	C15687|C15313	Brachytherapy|BRACHYTHERAPY|Brachytherapy, NOS|Internal Radiation|Internal Radiation|Internal Radiation Brachytherapy|Internal Radiation Therapy|Internal Radiation Therapy|Internal Radiation Therapy|Radiation Brachytherapy|Radiation, Internal|brachytherapy|internal radiation|radiation brachytherapy	A type of radiation therapy in which radioactive material is placed inside the body, into a tumor or body cavity.	Internal Radiation Therapy		Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|HemOnc Agent Terminology
C151960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151960>	C27993	Generic	General; lacking specificity.			Qualitative Concept	
C151961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151961>	C50995	Less than Partial Clinical Response|Less than Partial Response	A change towards improvement from the pretreatment baseline, but not meeting the criteria for complete response or partial response.			Finding	
C151962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151962>	C158424	Magnetic Field	The region around a magnetic material or a moving electric charge within which the force of magnetism acts.			Phenomenon or Process	
C151963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151963>	C40429	Atomic Nucleus|Nucleus	The region of an atom that contains the protons and neutrons.			Element, Ion, or Isotope	
C151964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151964>	C106562	Saturation Recovery Pulse Sequence|SR|Saturation Recovery Sequence	A sequence of multiple 90 degree radio frequency pulses spaced at repetition times that allow the recovery of all the longitudinal magnetization before the next pulse.			Spatial Concept	
C151965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151965>	C17369	Tissue Suppression|Signal Suppression|Tissue Signal Suppression	Any of various techniques that allow the imaging of a body part while suppressing signals coming from a selected tissue.			Diagnostic Procedure	
C151966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151966>	C158424	Steady-State|Steady State	Having reached equilibrium for the measurement or phenomenon concerned.			Phenomenon or Process	
C151967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151967>	C215224|C200106	Datopotamab Deruxtecan|ADC DS-1062a|Anti-TROP2/DXd Antibody-drug Conjugate DS-1062a|DATOPOTAMAB DERUXTECAN|DS-1062|DS-1062a|Dato-DXd|Datopotamab Deruxtecan-dlnk|Datroway	An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against tumor-associated antigen (TAA) trophoblast cell surface protein 2 (calcium signal transducer 2; TROP2; TROP-2; TACSTD2) conjugated, via an enzymatically cleavable tetrapeptide-based  linker, to the cytotoxic DNA topoisomerase I inhibitor and exatecan (DX-8951) derivative DXd (MAAA-1181a; MAAA-1181), with potential antineoplastic activity. Upon administration of the datopotamab deruxtecan, the anti-TROP2 antibody targets and binds to TROP2 expressed on tumor cells. Upon cellular uptake and lysosomal degradation of the linker, DXd targets and binds to DNA topoisomerase I, thereby stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication and apoptosis. This inhibits tumor cell proliferation of TROP2-expressing tumor cells. TROP2 is a transmembrane protein overexpressed in various tumors while its expression is low and/or restricted in normal, healthy tissues. Its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival. The ADC allows for reduced systemic exposure and enhanced delivery of the cytotoxic agent DXd.	Datopotamab Deruxtecan		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C151968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151968>	C203000	Sizavaleucel|Donor-derived CD34+ HPCs/CD3+ T-cells MDR-101|Donor-derived CD34+ Hematopoietic Stem and Progenitor Cells Plus CD3+ T-cells MDR-101|MDR 101|MDR-101|SIZAVALEUCEL	A preparation of allogeneic, organ donor-derived CD34-positive hematopoietic stem and progenitor cells (HPCs) and CD3-positive T-cells that can be used after organ transplantation to potentially prevent organ rejection. Upon infusion of sizavaleucel after organ transplantation, these cells mix and co-exist with the recipient's blood and immune cells, thereby inducing hematologic mixed chimerism and enabling the recipient's immune system to become immune tolerant to the donor cells. This increases acceptance of the transplanted organ, decreases the risk of organ transplant rejection, increases organ survival and may decrease the need for additional immunosuppressive agents. Sizavaleucel is ex vivo processed in a specific and unique way which has yet to be fully elucidated. Cell doses are dependent on the degree of human leukocyte antigen (HLA)-match/HLA-mismatch between the recipient and donor.	Sizavaleucel		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C151969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151969>	C1511	Indium In 111 Rosopatamab Tetraxetan|111In-J591|In111-HuJ591|In111-J591|Indium In 111 Monoclonal Antibody HuJ591	A radioimmunoconjugate containing the recombinant humanized monoclonal antibody rosopatamab directed against the extracellular domain of prostate-specific membrane antigen (PSMA) and labeled with the gamma-emitting isotope indium 111 (In 111; 111In), with potential radioimaging application. Upon administration, indium In 111 rosopatamab tetraxetan targets and binds to PSMA expressed on tumor cells. The use of gamma scintigraphy allows for the detection and imaging of the radioactive In 111, which can be used to determine the distribution and tumor localization of PSMA. PSMA is a transmembrane peptidase that is highly expressed on prostate tumor cells.	Indium In 111 Rosopatamab Tetraxetan		Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C15196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15196>	C213421	Carcinogenicity Test	An assay, usually performed on in vitro systems, in which the propensity of an agent to cause tumors is measured.			Research Activity	
C151970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151970>	C48470	Bowl Dosing Unit|BOWL|Bowl|Bowl Dosage Unit|{BOWL}|{BOWL}	A dosing unit equal to the amount of smokable material in a pipe bowl.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C151971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151971>	C168981|C142869	Locally Advanced Bile Duct Carcinoma|Locally Advanced Bile Duct Cancer	A bile duct carcinoma that has spread to nearby tissues or lymph nodes.	Locally Advanced Bile Duct Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C151972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151972>	C48442	Spiral Pitch|Helical Pitch|Pitch	The distance between sucessive turns of a spiral helix.			Qualitative Concept	
C151973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151973>	C17369	Cardiac Synchronization	Techniques to coordinate imaging data to the movement of the heart during the cardiac cycle.			Diagnostic Procedure	
C151974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151974>	C25515|C21514	Occasionally|From time to time, occasionally|Only occasionally	Not frequently or regularly.			Quantitative Concept	Female Sexual Function Index|GDC Terminology|GDC Value Terminology|Hospital Anxiety and Depression Scale Questionnaire|Oral Health Impact Profile|Patient Reported Outcomes Version of CTCAE|PRO-CTCAE Attribute Value Terminology|PRO-CTCAE Version 1.0 Questionnaire Terminology|Revised Dyadic Adjustment Scale|Sexual Health Inventory for Men
C151975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151975>	C7464	Acute Leukemia of Ambiguous Lineage, Not Otherwise Specified|Acute Leukemia of Ambiguous Lineage, NOS	Acute leukemia of ambiguous lineage, expressing combinations of markers that do not allow for its classification as either acute undifferentiated leukemia or mixed phenotype acute leukemia, and definitive classification along a single lineage is difficult. (WHO 2017)			Neoplastic Process	
C151976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151976>	C7400|C204124|C193424|C148429	Recurrent Burkitt Leukemia|Mature B-cell leukemia Burkitt-type, in relapse	The reemergence of Burkitt leukemia after a period of remission.	Recurrent Burkitt Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|mCode Cancer Disorder Value Set|mCode Elixhauser Leukemia Value Set|mCode Primary Cancer Disorder Value Set|mCode Primary Malignant Neoplasm Disorder Value Set|mCode Terminology
C151977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151977>	C7400|C204126|C148431	Refractory Burkitt Leukemia	A Burkitt leukemia that is resistant to treatment.	Refractory Burkitt Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C151978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151978>	C9360|C8701	Refractory Lymphoblastic Lymphoma	A lymphoblastic lymphoma that is resistant to treatment.	Refractory Lymphoblastic Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C151979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151979>	C160233|C125904	Refractory High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements|Refractory Double-Hit Lymphoma|Refractory Double-Hit Lymphoma|Refractory High-Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements	A high-grade B-cell lymphoma with MYC and BCL2 or BCL6 rearrangements that is resistant to treatment.	Refractory High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C15197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15197>	C16084	Case-Control Study|CASE CONTROL|case-control study|case-control study|case-control study	A study that compares two groups of people: those with the disease or condition under study (cases) and a very similar group of people who do not have the disease or condition (controls). Researchers study the medical and lifestyle histories of the people in each group to learn what factors may be associated with the disease or condition. For example, one group may have been exposed to a particular substance that the other was not. Also called retrospective study.			Research Activity	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|CDISC SDTM Observational Study Model Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|SeroNet Authorized Values|SeroNet Study Descriptors
C151980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151980>	C160229|C125904	Recurrent High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements|Recurrent Double-Hit Lymphoma|Recurrent Double-Hit Lymphoma|Recurrent High-Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements	The reemergence of high-grade B-cell lymphoma with MYC and BCL2 or BCL6 rearrangements after a period of remission.	Recurrent High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C151981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151981>	C214845|C210654	Pelvic Rhabdomyosarcoma	Rhabdomyosarcoma involving the organs and structures in the pelvis.	Pelvic Rhabdomyosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C151982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151982>	C214845|C210658	Abdominal Rhabdomyosarcoma	Rhabdomyosarcoma involving the organs and structures in the abdomen.	Abdominal Rhabdomyosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C151983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151983>	C3359|C153068	Unresectable Rhabdomyosarcoma	A rhabdomyosarcoma that is not amenable to surgical resection.	Unresectable Rhabdomyosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C151984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151984>	C8563|C210655	Pelvic Undifferentiated High Grade Pleomorphic Sarcoma|Undifferentiated High Grade Pleomorphic Sarcoma of the Pelvis|Undifferentiated Pelvic Pleomorphic Sarcoma	Undifferentiated high grade pleomorphic sarcoma  involving the bones of the pelvis.	Pelvic Undifferentiated Pleomorphic Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C151985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151985>	C4247|C210658	Abdominal Undifferentiated Pleomorphic Sarcoma|Undifferentiated Abdominal Pleomorphic Sarcoma	Undifferentiated pleomorphic sarcoma involving the organs and structures in the abdomen.	Abdominal Undifferentiated Pleomorphic Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C151986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151986>	C82180	Blasts Expressing B-Lymphoid, T-Lymphoid, and Myeloid Markers Present	A finding indicating the presence of blasts with evidence of trilineage (B-cell, T-cell, and myeloid lineage) assignment.			Laboratory or Test Result	
C151987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151987>	C82180	Blasts Expressing B-Lymphoid and T-Lymphoid Markers Present	A finding indicating the presence of blasts with evidence of both B-cell and T-cell lineage assignment.			Laboratory or Test Result	
C151988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151988>	C200052|C192742|C192741	Ebvaciclib|CDK Inhibitor PF-06873600|EBVACICLIB|PF 06873600|PF-06873600	An orally bioavailable, cyclin dependent kinase (CDK) inhibitor, with potential antineoplastic activity. Upon administration, ebvaciclib selectively targets, binds to and inhibits the activity of CDKs. Inhibition of these kinases leads to cell cycle arrest, an induction of apoptosis, and inhibition of tumor cell proliferation. CDKs are ATP-dependent serine/threonine kinases that are important regulators of cell cycle progression and proliferation and are frequently overexpressed in tumor cells.	Ebvaciclib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C151989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151989>	C19238	Ice Pack	A container filled with frozen material that retains its temperature for an extended period.			Manufactured Object	
C15198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15198>	C15467|C15333	Surgical Castration|Castration|castration|surgical castration	Surgical removal of the ovaries or testes.	Surgical Castration		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C151990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151990>	C82179	Mixed Phenotype Acute Leukemia, Rare Types|Mixed Phenotype Acute Leukemia, NOS, Rare Subtypes|Mixed Phenotype Acute Leukemia, NOS, Rare Subtypes|Mixed Phenotype Acute Leukemia, Not Otherwise Specified, Rare Subtypes|Mixed Phenotype Acute Leukemia, Rare Subtypes	A very rare mixed phenotype acute leukemia in which the blasts express combinations of B, T, myeloid, and megakaryocytic lineage markers but are negative for KMT2A rearrangement and t(9;22)(q34;q11.2) translocation. The prognosis is usually unfavorable.	Mixed Phenotype Acute Leukemia, Not Otherwise Specified, Rare Subtypes		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C151991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151991>	C151990	Mixed Phenotype Acute Leukemia, B/T/Myeloid|MPAL-B/T/M|Mixed Phenotype Acute Leukemia, B/T/Myeloid, NOS|Mixed Phenotype Acute Leukemia, B/T/Myeloid, NOS|Mixed Phenotype Acute Leukemia, B/T/Myeloid, Not Otherwise Specified|Mixed Phenotype Acute Leukemia, B/T/Myeloid, Not Otherwise Specified	A very rare mixed phenotype acute leukemia in which the blasts show evidence of B-cell, T-cell, and myeloid lineage but are negative for KMT2A rearrangement and t(9;22)(q34;q11.2) translocation.	Mixed Phenotype Acute Leukemia, B/T/Myeloid, Not Otherwise Specified		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C151992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151992>	C151990	Mixed Phenotype Acute Leukemia, B/T|MPAL-B/T|Mixed Phenotype Acute Leukemia, B/T, NOS|Mixed Phenotype Acute Leukemia, B/T, NOS|Mixed Phenotype Acute Leukemia, B/T, Not Otherwise Specified|Mixed Phenotype Acute Leukemia, B/T, Not Otherwise Specified	A very rare mixed phenotype acute leukemia in which the blasts show clear-cut evidence of both B-cell and T-cell lineage but are negative for KMT2A rearrangement and t(9;22)(q34;q11.2) translocation.	Mixed Phenotype Acute Leukemia, B/T, Not Otherwise Specified		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C151993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151993>	C158960|C156269	Locally Advanced Pancreatic Ductal Adenocarcinoma	A pancreatic ductal adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advance Pancreatic Ductal Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C151994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151994>	C200712	STAT3 Inhibitor DSP-0337|Cancer Stemness Inhibitor DSP-0337|DSP 0337|DSP-0337|Napabucasin Prodrug DSP-0337	An orally administered prodrug of napabucasin, a small molecule cancer stemness inhibitor with potential antineoplastic activity. Upon administration, DSP-0337 is converted to its active form, napabucasin. Napabucasin targets and inhibits signal transducer and activator of transcription 3 (STAT3), thereby preventing STAT-3-mediated signaling. The STAT3 pathway is overly active in many cancer types and is implicated in cancer stem cell-mediated growth, recurrence and resistance to conventional chemotherapies.	STAT3 Inhibitor DSP-0337		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C151995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151995>	C9120|C156906	Resectable Pancreatic Ductal Adenocarcinoma	Pancreatic ductal adenocarcinoma amenable to surgical resection.	Resectable Pancreatic Ductal Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C151996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151996>	C26147	GALNT12 Gene|GALNT12|GALNT12|Polypeptide N-Acetylgalactosaminyltransferase 12 Gene	This gene plays a role in O-linked protein glycosylation.			Gene or Genome	
C151997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151997>	C151996	GALNT12 wt Allele|CRCS1|Colorectal Cancer, Susceptibility To 1 Gene|GalNAc-T12|Polypeptide N-Acetylgalactosaminyltransferase 12 wt Allele|UDP-N-Acetyl-Alpha-D-Galactosamine:Polypeptide N-Acetylgalactosaminyltransferase 12 (GalNAc-T12) Gene	Human GALNT12 wild-type allele is located in the vicinity of 9q22.33 and is approximately 42 kb in length. This allele, which encodes polypeptide N-acetylgalactosaminyltransferase 12 protein, is involved in O-linked glycosylation of protein substrates. Mutation of the gene is associated with an increased risk of colorectal cancer.			Gene or Genome	
C151998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151998>	C17434	Polypeptide N-Acetylgalactosaminyltransferase 12|EC 2.4.1.41|GALNT12|GalNAc-T12|Polypeptide GalNAc Transferase 12|Protein-UDP Acetylgalactosaminyltransferase 12|UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase 12|UDP-N-Acetyl-Alpha-D-Galactosamine:Polypeptide N-Acetylgalactosaminyltransferase 12|pp-GaNTase 12	Polypeptide N-acetylgalactosaminyltransferase 12 (581 aa, ~67 kDa) is encoded by the human GALNT12 gene. This protein plays a role in catalyzing the transfer of an N-acetyl-D-galactosamine (GalNAc) residue to a serine or threonine residue on a protein substrate.			Amino Acid, Peptide, or Protein|Enzyme	
C151999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C151999>	C21550	GREM1 Gene|GREM1|GREM1|Gremlin 1, DAN Family BMP Antagonist Gene	This gene is involved in the downregulation of bone morphogenetic protein signaling.	GREM1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C15199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15199>	C49165	Cauterization|Cauterize|cauterize|cautery	To destroy tissue using a hot or cold instrument, an electrical current, or a chemical that burns or dissolves the tissue. This process may be used to kill certain types of small tumors or to seal off blood vessels to stop bleeding.			Therapeutic or Preventive Procedure	
C1519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1519>	C2139|C1971	Roquinimex|1,2-Dihydro-4-hydroxy-N,1-dimethyl-2-oxo-3-quinolinecarboxanilide|1,2-Dihydro-4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide|1,2-Dihydro-4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide|FCF 89|LS 2616|Linomide|N-Phenyl-N-methyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxamide|ROQUINIMEX	A quinoline-3-carboxamide with potential antineoplastic activity.  Roquinimex inhibits endothelial cell proliferation, migration, and basement membrane invasion; reduces the secretion of the angiogenic factor tumor necrosis factor alpha by tumor-associated macrophages (TAMs); and inhibits angiogenesis.  This agent is also an immune modulator that appears to alter cytokine profiles and enhance the activity of T cells, natural killer cells, and macrophages. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C152000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152000>	C151999	GREM1 wt Allele|C15DUPq|CKTSF1B1|CRAC1|CRCS4|Cell Proliferation-Inducing Gene 2|Colorectal Adenoma and Carcinoma 1 Gene|Cystine Knot Superfamily 1, BMP Antagonist 1 Gene|DAND2|DRM|DUP15q|GREMLIN|Gremlin 1 Homolog, Cysteine Knot Superfamily Gene|Gremlin 1, Cysteine Knot Superfamily, Homolog (Xenopus laevis) Gene|Gremlin 1, Cysteine Knot Superfamily, Homolog Gene|Gremlin 1, DAN Family BMP Antagonist wt Allele|HMPS|HMPS1|IHG-2|MPSH|PIG2	Human GREM1 wild-type allele is located in the vicinity of 15q13.3 and is approximately 27 kb in length. This allele, which encodes gremlin-1 protein, plays a role in antagonizing bone morphogenetic protein signaling pathways. Mutation of the gene is associated with hereditary mixed polyposis syndrome 1.	GREM1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C152001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152001>	C20464	Gremlin-1|Cell Proliferation-Inducing Gene 2 Protein|Cysteine Knot Superfamily 1, BMP Antagonist 1|DAN Domain Family Member 2|Down-Regulated in Mos-Transformed Cells Protein|GREM1|Gremlin 1|IHG-2|Increased In High Glucose Protein 2|Increased In High Glucose-2	Gremlin-1 (184 aa, ~21 kDa) is encoded by the human GREM1 gene. This protein is involved in the modulation of signaling by bone morphogenetic proteins.	Gremlin-1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C152002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152002>	C28533	KIF1B Gene|KIF1B|KIF1B|Kinesin Family Member 1B Gene	This gene plays a role in localization of mitochondria and transport of synaptic vesicles.			Gene or Genome	
C152003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152003>	C152002	KIF1B wt Allele|CMT2|CMT2A|CMT2A1|HMSNII|KIAA0591|KIAA1448|KLP|Kinesin Family Member 1B wt Allele|NBLST1	Human KIF1B wild-type allele is located in the vicinity of 1p36.22 and is approximately 171 kb in length. This allele, which encodes kinesin-like protein KIF1B, is involved in the transport of synaptic vesicles and mitochondria. Mutation of the gene is associated with pheochromocytoma, increased susceptibility to neuroblastoma and Charcot-Marie-Tooth disease type 2A1.			Gene or Genome	
C152004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152004>	C16386	Kinesin-Like Protein KIF1B|KIF1B|Kinesin Family Member 1B|Kinesin Superfamily Protein KIF1B|Klp	Kinesin-like protein KIF1B (1816 aa, ~204 kDa) is encoded by the human KIF1B gene. This protein plays a role in intercellular transport of organelles and vesicles.			Amino Acid, Peptide, or Protein	
C152005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152005>	C20845	RPS20 Gene|RPS20|RPS20|Ribosomal Protein S20 Gene	This gene is involved in both translation and nonsense-mediated mRNA decay.	RPS20 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C152006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152006>	C152005	RPS20 wt Allele|Ribosomal Protein S20 wt Allele|S20|uS10	Human RPS20 wild-type allele is located in the vicinity of 8q12.1 and is approximately 7 kb in length. This allele, which encodes 40S ribosomal protein S20, plays a role in mRNA decay and translation.	RPS20 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C152007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152007>	C21210	40S Ribosomal Protein S20|RPS20|Small Ribosomal Subunit Protein uS10	40S ribosomal protein S20 (119 aa, ~13 kDa) is encoded by the human RPS20 gene. This protein is involved in mRNA catabolism and protein synthesis.	40S Ribosomal Protein S20		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C152008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152008>	C25869|C20194	TMEM45B Gene|TMEM45B|TMEM45B|Transmembrane Protein 45B Gene	This gene may play a role in cell proliferation and migration.			Gene or Genome	
C152009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152009>	C152008	TMEM45B wt Allele|BC016153|FLJ40787|Transmembrane Protein 45B wt Allele	Human TMEM45B wild-type allele is located in the vicinity of 11q24.3 and is approximately 44 kb in length. This allele, which encodes transmembrane protein 45B, may be involved in cell migration and cellular proliferation.			Gene or Genome	
C15200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15200>	C52005|C201126	Cecostomy	Surgical creation of an opening in the cecum.			Therapeutic or Preventive Procedure	
C152010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152010>	C18466	Transmembrane Protein 45B|TMEM45B	Transmembrane protein 45B (275 aa, ~32 kDa) is encoded by the human TMEM45B gene. This protein may play a role in the modulation of cell proliferation and cell migration.			Amino Acid, Peptide, or Protein	
C152011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152011>	C26006	MLPH Gene|MLPH|MLPH|Melanophilin Gene	This gene is involved in melanosome transport.			Gene or Genome	
C152012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152012>	C152011	MLPH wt Allele|Melanophilin wt Allele|SLAC2-A|SLAC2A	Human MLPH wild-type allele is located in the vicinity of 2q37.3 and is approximately 70 kb in length. This allele, which encodes melanophilin protein, plays a role in melanosome transport. Mutation of the gene is associated with hypopigmentation in type 3 Griscelli syndrome.			Gene or Genome	
C152013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152013>	C16386	Melanophilin|Exophilin 3|Exophilin-3|MLPH|SlaC2-a|Slp Homolog Lacking C2 Domains A|Synaptotagmin-Like Protein 2a|Synaptotagmin-Like Protein Lacking C2 Domains A	Melanophilin (600 aa, ~66 kDa) is encoded by the human MLPH gene. This protein is involved in melanin transport.			Amino Acid, Peptide, or Protein	
C152014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152014>	C20917	NDC80 Gene|NDC80|NDC80|NDC80 Kinetochore Complex Component Gene	This gene plays a role in kinetochore assembly and microtubule organization.	NDC80 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C152015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152015>	C152014	NDC80 wt Allele|HEC|HEC1|Highly Expressed In Cancer, Rich In Leucine Heptad Repeats Gene|Highly Expressed in Cancer Gene|Highly Expressed in Cancer, Rich in Leucine Heptad Repeats (Yeast) Gene|HsHec1|KNTC2|Kinetochore Associated 2 Gene|NDC80 Homolog, Kinetochore Complex Component Gene|NDC80 Kinetochore Complex Component Homolog (S. cerevisiae) Gene|NDC80 Kinetochore Complex Component wt Allele|NDC80, Kinetochore Complex Component Gene|NDC80, S. cerevisiae, Homolog of Gene|TID3|hsNDC80	Human NDC80 wild-type allele is located in the vicinity of 18p11.32 and is approximately 45 kb in length. This allele, which encodes kinetochore protein NDC80 homolog protein, is involved in chromosome segregation and mitotic spindle checkpoint activity.	NDC80 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C152016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152016>	C17761	Kinetochore Protein NDC80 Homolog|Hec1|Highly Expressed in Cancer Protein|HsHec1|Kinetochore Protein Hec1|Kinetochore-Associated Protein 2|NDC80|NDC80 Kinetochore Complex Component Homolog|Retinoblastoma-Associated Protein HEC	Kinetochore protein NDC80 homolog (642 aa, ~74 kDa) is encoded by the human NDC80 gene. This protein plays a role in the attachment of mitotic spindle microtubules to the kinetochore.	Kinetochore Protein NDC80 Homolog		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C152017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152017>	C20923	GPR160 Gene|G Protein-Coupled Receptor 160 Gene|GPR160|GPR160	This gene may be involved in G protein-coupled receptor signaling.			Gene or Genome	
C152018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152018>	C152017	GPR160 wt Allele|G Protein-Coupled Receptor 160 wt Allele|GPCR1|GPCR150	Human GPR160 wild-type allele is located in the vicinity of 3q26.2 and is approximately 48 kb in length. This allele, which encodes probable G-protein coupled receptor 160 protein, may play a role in G protein-coupled receptor signaling.			Gene or Genome	
C15201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15201>	C15958	Cell-free System	An in vitro biosystem created through the mixing of isolated subcellular fractions and/or purified enzymes and coenzymes. Cell-free systems can be used for studying biological reactions or in biomanufacturing.			Research Device	
C152020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152020>	C18239	Probable G-Protein Coupled Receptor 160|G Protein-Coupled Receptor 160|G-Protein Coupled Receptor GPCR1|GPR160|hGPCR1	Probable G-protein coupled receptor 160 (338 aa, ~40 kDa) is encoded by the human GPR160 gene. This protein may be involved in G protein-coupled receptor signaling.			Amino Acid, Peptide, or Protein|Receptor	
C152021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152021>	C16275	Analgesic Quantification Algorithm|AQA	An algorithm designed to categorize  analgesic medication use, and capture changes in the dosing, frequency, and/or type of analgesic medications administered.			Intellectual Product	
C152022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152022>	C226700	No Analgesic	A response that indicates the patient did not use any analgesic.			Intellectual Product	Analgesic Quantification Algorithm
C152023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152023>	C226700	Non-Opioid Analgesic	A response that indicates the patient used a non-opioid analgesic.			Intellectual Product	Analgesic Quantification Algorithm
C152024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152024>	C226700	Weak Opioids	A response that indicates the patient used weak opioids.			Intellectual Product	Analgesic Quantification Algorithm
C152025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152025>	C175312	Strong Opioids Less than or Equal to 75 mg Oral Morphine Equivalent per Day	A response that indicates the patient used strong opioids at less than or equal to 75 mg oral morphine equivalents (OME) per day.			Intellectual Product	Analgesic Quantification Algorithm
C152026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152026>	C175312	Strong Opioids Greater than 75-150 mg Oral Morphine Equivalent per Day	A response that indicates the patient used strong opioids at greater than 75 mg to a maximum of 150 mg oral morphine equivalents (OME) per day.			Intellectual Product	Analgesic Quantification Algorithm
C152027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152027>	C175312	Strong Opioids Greater than 150-300 mg Oral Morphine Equivalent per Day	A response that indicates the patient used strong opioids at greater than 150 mg to a maximum of 300 mg oral morphine equivalents (OME) per day.			Intellectual Product	Analgesic Quantification Algorithm
C152028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152028>	C175312	Strong Opioids Greater than 300-600 mg Oral Morphine Equivalent per Day	A response that indicates the patient used strong opioids at greater than 300 mg to a maximum of 600 mg oral morphine equivalents (OME) per day.			Intellectual Product	Analgesic Quantification Algorithm
C152029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152029>	C175312	Strong Opioids Greater than 600 mg Oral Morphine Equivalent per Day	A response that indicates the patient used strong opioids at greater than 600 mg oral morphine equivalents (OME) per day.			Intellectual Product	Analgesic Quantification Algorithm
C15202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15202>	C15203	Child Development Study	A type of research study that uses methods such as longitudinal studies, cross-sectional studies, observational studies, and experimental design  to focus on the cognitive, social, and emotional development of individuals from conception through early adulthood.			Research Activity	
C152030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152030>	C20420	CXXC5 Gene|CXXC Finger Protein 5 Gene|CXXC5|CXXC5	This gene plays a role in the regulation of apoptosis, signaling pathways and gene expression.			Gene or Genome	
C152031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152031>	C152030	CXXC5 wt Allele|CF5|CXXC Finger Protein 5 wt Allele|HSPC195|RINF|WID	Human CXXC5 wild-type allele is located in the vicinity of 5q31.2 and is approximately 7 kb in length. This allele, which encodes CXXC-type zinc finger protein 5, is involved in the modulation of signaling, the regulation of apoptosis and transcriptional regulation.			Gene or Genome	
C152032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152032>	C17207	CXXC-Type Zinc Finger Protein 5|CF5|CXXC Finger 5 Protein|CXXC Finger Protein 5|CXXC5|Putative MAPK-Activating Protein PM08|Putative NF-Kappa-B-Activating Protein 102|RINF|Retinoid-Inducible Nuclear Factor|WT1-Induced Inhibitor of Dishevelled	CXXC-type zinc finger protein 5 (322 aa, ~33 kDa) is encoded by the human CXXC5 gene. This protein plays a role in transcriptional regulation.			Amino Acid, Peptide, or Protein	
C152033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152033>	C15848	Intensity-Modulated Radiotherapy Inverse Planning|IMRT Reverse Planned|Inverse-Planned Intensity-Modulated Radiation Therapy	A procedure that utilizes a computerized algorithm to directly determine aperture intensities for optimal radiation dose distributions associated with intensity-modulated radiotherapy (IMRT).			Health Care Activity	
C152034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152034>	C15848	Intensity-Modulated Radiotherapy Forward Planning|Forward-Planned Intensity-Modulated Radiation Therapy|IMRT Forward Planning	A procedure that utilizes manual determinations of beam angles and aperture exposure time to optimize radiation dose distributions associated with intensity-modulated radiotherapy (IMRT).			Health Care Activity	
C152035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152035>	C54648	Tangential Fields|Tangential Field|Tangents|TgF	A two-dimensional (2D) array of opposing, oblique beams of external radiation. This approach is most often used in the adjuvant radiotherapy of breast malignancies.			Body Location or Region	
C152036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152036>	C4025|C3535	Distal Esophagus Adenocarcinoma|Adenocarcinoma of the Lower Third of the Esophagus	An adenocarcinoma arising from the lower third of the esophagus. The vast majority of esophageal adenocarcinomas involve the lower third of the esophagus.	Distal Esophagus Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C152037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152037>	C25939	BLVRA Gene|BLVRA|BLVRA|Biliverdin Reductase A Gene	This gene is involved in the conversion of biliverdin to bilirubin.			Gene or Genome	
C152038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152038>	C152037	BLVRA wt Allele|BLVR|BVR|BVRA|Biliverdin Reductase A wt Allele	Human BLVRA wild-type allele is located in the vicinity of 7p13 and is approximately 49 kb in length. This allele, which encodes biliverdin reductase A protein, plays a role in protoheme degradation. Truncation mutations in the gene are associated with hyperbiliverdinemia.			Gene or Genome	
C152039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152039>	C16946	Biliverdin Reductase A|BLVRA|BVR A|Biliverdin-IX Alpha-Reductase|EC 1.3.1.24|Testis Tissue Sperm-Binding Protein Li 61n	Biliverdin reductase A (296 aa, ~33 kDa) is encoded by the human BLVRA gene. This protein is involved in the reduction of biliverdin IX alpha.			Amino Acid, Peptide, or Protein|Enzyme	
C15203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15203>	C15878	Child Health Study	A study that focuses on the health and well-being of individuals between 2 and 18 years of age. It may cover aspects such as physical health, mental health, social development (family and school interactions), and access to healthcare.			Research Activity	
C152040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152040>	C20744	ACTR3B Gene|ACTR3B|ACTR3B|ARP3 Actin Related Protein 3 Homolog B Gene	This gene may play a role in actin binding and organization of the cytoskeleton.			Gene or Genome	
C152041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152041>	C152040	ACTR3B wt Allele|ARP11|ARP3 Actin Related Protein 3 Homolog B wt Allele|ARP3 Actin-Related Protein 3 Homolog B (Yeast) Gene|ARP3BETA|ARP4	Human ACTR3B wild-type allele is located within 7q36.1-q36.2 and is approximately 128 kb in length. This allele, which encodes actin-related protein 3B, is involved in cytoskeletal organization.			Gene or Genome	
C152042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152042>	C18073	Actin-Related Protein 3B|ACTR3B|ARP3 Actin Related Protein 3 Homolog B|ARP3-Beta|Actin-Like Protein 3B|Actin-Related Protein 3-Beta|Actin-Related Protein ARP4|Actin-Related Protein Arp11	Actin-related protein 3B (418 aa, ~48 kDa) is encoded by the human ACTR3B gene. This protein plays a role in actin binding and organization of the cytoskeleton.			Amino Acid, Peptide, or Protein	
C152043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152043>	C25939	ALDH4A1 Gene|ALDH4A1|ALDH4A1|Aldehyde Dehydrogenase 4 Family Member A1 Gene	This gene is involved in the conversion of proline and ornithine to glutamate.			Gene or Genome	
C152044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152044>	C152043	ALDH4A1 wt Allele|ALDH4|Aldehyde Dehydrogenase 4 Family Member A1 wt Allele|Aldehyde Dehydrogenase 4 Family, Member A1 Gene|P5CD|P5CDH|P5CDh	Human ALDH4A1 wild-type allele is located in the vicinity of 1p36.13 and is approximately 31 kb in length. This allele, which encodes delta-1-pyrroline-5-carboxylate dehydrogenase protein, mitochondrial, plays a role in glutamate synthesis. Mutation of the gene is associated with type II hyperprolinemia.			Gene or Genome	
C152045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152045>	C16946	Delta-1-Pyrroline-5-Carboxylate Dehydrogenase, Mitochondrial|ALDH4A1|Aldehyde Dehydrogenase 4|Aldehyde Dehydrogenase 4 Family Member A1|Aldehyde Dehydrogenase Family 4 Member A1|EC 1.2.1.88|L-Glutamate Gamma-Semialdehyde Dehydrogenase|Mitochondrial Delta-1-Pyrroline 5-Carboxylate Dehydrogenase|P5C Dehydrogenase|Pyrroline-5-Carboxylate Dehydrogenase	Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial (563 aa, ~62 kDa) is encoded by the human ALDH4A1 gene. This protein is involved in the conversion of proline pyrroline-5-carboxylate to glutamate.			Amino Acid, Peptide, or Protein|Enzyme	
C152046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152046>	C8511|C40022	Refractory Primary Peritoneal Carcinoma|Refractory Primary Peritoneal Cancer|Refractory Primary Peritoneal Cancer	Primary peritoneal carcinoma that is resistant to treatment.	Refractory Primary Peritoneal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C152047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152047>	C3867|C152048	Refractory Fallopian Tube Carcinoma|Refractory Fallopian Tube Cancer|Refractory Fallopian Tube Cancer	Fallopian tube carcinoma that is resistant to treatment.	Refractory Fallopian Tube Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C152048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152048>	C8511|C150527	Refractory Female Reproductive System Carcinoma|Refractory Female Reproductive System Cancer	Female reproductive system carcinoma that is resistant to treatment.			Neoplastic Process	
C152049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152049>	C26006	AP2B1 Gene|AP2B1|AP2B1|Adaptor Related Protein Complex 2 Beta 1 Subunit Gene	This gene plays a role in protein transport via clathrin-coated vesicles.			Gene or Genome	
C15204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15204>	C15908	Chiropractic Therapy|Chiropractic|Chiropractic Medicine	An alternative medical system that focuses on the relationship between bodily structure (primarily that of the spine) and function, and how that relationship affects the preservation and restoration of health. Chiropractors use manipulative therapy as an integral treatment tool.			Therapeutic or Preventive Procedure	
C152050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152050>	C152049	AP2B1 wt Allele|ADTB2|AP105B|AP2-BETA|Adaptin, Beta 2 (Beta) Gene|Adaptin, Beta 2 Gene|Adaptin, Beta-2 Gene|Adaptor Related Protein Complex 2 Beta 1 Subunit wt Allele|Adaptor-Related Protein Complex 2, Beta 1 Subunit Gene|CLAPB1|Clathrin Adaptor Complex AP2, Beta Subunit Gene|Clathrin-Associated/Assembly/Adaptor Protein, Large, Beta 1 Gene	Human AP2B1 wild-type allele is located in the vicinity of 17q12 and is approximately 148 kb in length. This allele, which encodes AP-2 complex subunit beta protein, is involved in endocytosis mediated by clathrin-coated vesicles.			Gene or Genome	
C152051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152051>	C16386	AP-2 Complex Subunit Beta|AP105B|AP2B1|Adapter-Related Protein Complex 2 Beta Subunit|Adapter-Related Protein Complex 2 Subunit Beta|Adaptor Protein Complex AP-2 Subunit Beta|Adaptor-Related Protein Complex 2 Subunit Beta|Beta-2-Adaptin|Beta-Adaptin|Clathrin Assembly Protein Complex 2 Beta Large Chain|Plasma Membrane Adaptor HA2/AP2 Adaptin Beta Subunit|Testicular Tissue Protein Li 22	AP-2 complex subunit beta (937 aa, ~105 kDa) is encoded by the human AP2B1 gene. This protein plays a role in formation of and cargo selection for clathrin-coated vesicles.			Amino Acid, Peptide, or Protein	
C152052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152052>	C54648	Direct Field	A radiation therapy technique where treatment is emitted along the central axis of an external radiation beam.			Therapeutic or Preventive Procedure	
C152053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152053>	C54648	Modified Wide Tangent Field	A radiation therapy technique used to treat breast malignancies where the treatment fields are wide superiorly to include the internal mammary nodes, but narrow inferiorly to reduce radiation exposure to the heart and lung.			Therapeutic or Preventive Procedure	
C152054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152054>	C152052	Direct Electron Field	A radiation therapy technique where external electron beams are used to deliver treatment to superficial malignancies while sparing underlying organs at risk.			Therapeutic or Preventive Procedure	
C152055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152055>	C152052	Direct Mixed Photon and Electron Field|Mixed|Radiation, Mixed Photon Beam	A radiation therapy technique where external photon and electron beams are used to deliver treatment of superficial and deep-seated malignancies, respectively, while sparing underlying organs at risk.			Therapeutic or Preventive Procedure	GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C152056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152056>	C67322|C42534	Megavolt|MV|Megavolts	A SI derived unit of electric potential and electromotive force that is equal to one million volts.			Quantitative Concept	
C152057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152057>	C67275	Megaelectronvolt|10^6 Electronvolts|10^6 eV|MeV|MeV|MeV|MeV|Megaelectron Volt|Megaelectronvolts	A unit of energy that is equal to one million electron volts.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C152058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152058>	C25870	LPCAT1 Gene|LPCAT1|LPCAT1|Lysophosphatidylcholine Acyltransferase 1 Gene	This gene is involved in the conversion of lysophosphatidylcholine to phosphatidylcholine.			Gene or Genome	
C152059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152059>	C152058	LPCAT1 wt Allele|AGPAT10|AGPAT9|AYTL2|Acyltransferase Like 2 Gene|FLJ12443|LPCAT|LPCAT-1|Lysophosphatidylcholine Acyltransferase 1 wt Allele|PFAAP3|lpcat|lysoPAFAT	Human LPCAT1 wild-type allele is located in the vicinity of 5p15.33 and is approximately 69 kb in length. This allele, which encodes lysophosphatidylcholine acyltransferase 1 protein, plays a role in phosphatidylcholine biosynthesis.			Gene or Genome	
C15205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15205>	C15824	Nutrition Research, Cholesterol|Lipid Nutrition, Cholesterol	The study of the role of cholesterol in cancer causation or prevention and in general health.			Research Activity	
C152060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152060>	C16259	Lysophosphatidylcholine Acyltransferase 1|1-Acylglycerophosphocholine O-Acyltransferase|1-Alkylglycerophosphocholine O-Acetyltransferase|Acetyl-CoA:Lyso-PAF Acetyltransferase|Acetyl-CoA:Lyso-Platelet-Activating Factor Acetyltransferase|Acyltransferase-Like 2|EC 2.3.1.23|EC 2.3.1.67|LPC Acyltransferase 1|LPCAT-1|LPCAT1|Lyso-PAF Acetyltransferase|LysoPAFAT|LysoPC Acyltransferase 1|Lysophosphatidylcholine Acyltransferase|Phosphonoformate Immuno-Associated Protein 3	Lysophosphatidylcholine acyltransferase 1 (534 aa, ~59 kDa) is encoded by the human LPCAT1 gene. This protein is involved in the synthesis of phosphatidylcholine from lysophosphatidylcholine.			Amino Acid, Peptide, or Protein|Enzyme	
C152061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152061>	C25873	CDC42BPA Gene|CDC42 Binding Protein Kinase Alpha Gene|CDC42BPA|CDC42BPA	This gene plays a role in protein phosphorylation, cytoskeleton reorganization and cell migration.			Gene or Genome	
C152062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152062>	C152061	CDC42BPA wt Allele|CDC42 Binding Protein Kinase Alpha (DMPK-Like) Gene|CDC42 Binding Protein Kinase Alpha wt Allele|CDC42-Binding Protein Kinase Alpha (DMPK-Like) Gene|FLJ23347|KIAA0451|MRCK|MRCKA|PK428|Protein Kinase, Serine/Threonine, Related to the Myotonic Dystrophy Protein Kinase Gene	Human CDC42BPA wild-type allele is located in the vicinity of 1q42.13 and is approximately 329 kb in length. This allele, which encodes serine/threonine-protein kinase MRCK alpha protein, is involved in signal transduction downstream of CDC42.			Gene or Genome	
C152063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152063>	C17325	Serine/Threonine-Protein Kinase MRCK Alpha|CDC42-Binding Protein Kinase Alpha|CDC42BPA|DMPK-Like Alpha|EC 2.7.11.1|MRCK Alpha|Myotonic Dystrophy Kinase-Related CDC42-Binding Kinase Alpha|Myotonic Dystrophy Kinase-Related CDC42-Binding Protein Kinase Alpha|Myotonic Dystrophy Kinase-Related Cdc42-Binding Kinase|Myotonic Dystrophy Protein Kinase-Like Alpha|Ser-Thr Protein Kinase PK428|Ser-Thr Protein Kinase Related To The Myotonic Dystrophy Protein Kinase	Serine/threonine-protein kinase MRCK alpha (1732 aa, ~197 kDa) is encoded by the human CDC42BPA gene. This protein plays a role in cytoskeleton reorganization and cell migration.			Amino Acid, Peptide, or Protein|Enzyme	
C152064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152064>	C111802	Revesz Syndrome|DKCA5|Dyskeratosis Congenita, Autosomal Dominant, 5|Exudative Retinopathy with Bone Marrow Failure	An autosomal dominant form of dyskeratosis congenita, caused by mutation(s) in the TINF2 gene, encoding TERF1-interacting nuclear factor 2. It is a fatal disease associated with exudative retinopathy and bone marrow failure.			Disease or Syndrome	
C152065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152065>	C28193	Telomere Syndrome|Telomere Biology Disorders|Telomere Disease	A group of disorders caused by mutation(s) that disrupt the maintenance of telomeres, resulting in the short telomere defect.	Telomere Syndrome		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C152066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152066>	C62667	Hepatobiliary Iminodiacetic Acid Scan|HIDA Scan	Radionuclide imaging of the liver, gallbladder, and bile ducts using the radioactive tracer 99mTc-hepatic iminodiacetic acid.	Hepatobiliary Iminodiacetic Acid Scan		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C152067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152067>	C492	Oxylipin	A family of bioactive lipid metabolites that are produced when polyunsaturated fatty acids (PUFAs) undergo at least one round of dioxygen-dependent oxidation, which is catalyzed by cyclooxygenase (COX), lipoxygenase (LOX) or cytochrome P450 (CYP) epoxygenase family enzymes Oxylipins play an important role in the modulation of the tumor microenvironment (TME) and facilitate tumor cell proliferation, migration and invasion.	Oxylipin		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C152068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152068>	C782	6-Ketoprostaglandin F1alpha|(13E,15S)-9alpha,11alpha,15-trihydroxy-6-oxoprost-13-en-1-oic acid|6-Keto-PGF1alpha|6-Keto-Prostaglandin F1-Alpha|6-Keto-Prostaglandin F1a|6-Keto-Prostaglandin F1alpha|6-KetoPGF1a|6-Ketoprostaglandin F1-Alpha|6-Oxo-PGF1a|6-Oxo-PGF1alpha|6-Oxoprostaglandin F1a|6-Oxoprostaglandin F1alpha|Prost-13-en-1-oic acid, 9,11,15-trihydroxy-6-oxo-, (9alpha,11alpha,13E,15S)-	A form of prostaglandin F1alpha that has been modified with a keto group at position 6. 6-Ketoprostaglandin F1alpha (6-ketoPGF1a) is an inactive metabolite derived from prostaglandin I2 (PGI2). The concentration of 6-ketoPGF1a in a sample may be correlated with the levels of PGI2 synthesis. 6-KetoPGF1a levels are elevated in certain types of cancers.	6-Ketoprostaglandin F1alpha		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C152069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152069>	C782	9alpha,11beta-Prostaglandin F2alpha|9a11b-PGF2a|9alpha,11beta-PGF2alpha	A form of prostaglandin F2alpha derived from prostaglandin D2 (PGD2). The concentration of 9alpha,11beta-prostaglandin F2alpha (9a11b-PGF2a) in a sample may be correlated with the levels of PGD2 synthesis. 9a11b-PGF2a levels are elevated in certain types of cancers.	9alpha,11beta-Prostaglandin F2alpha		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C15206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15206>	C63536	Clinical Study|CLINICAL STUDY|Clinical Research|Clinical Research|Clinical Studies|Study|clinical study|clinical study|study	Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research.			Research Activity	CDISC DDF Entities Terminology|CDISC DDF Terminology|CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Individual Case Safety Report Terminology|ICDC Node Terminology|ICDC Terminology|Report Source ICSR Terminology|SeroNet Authorized Values|SeroNet Study Descriptors
C152070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152070>	C782	Prostaglandin F2alpha|(5Z,13E,15S)-9alpha,11alpha,15-trihydroxyprosta-5,13-dien-1-oic acid|PGF2|PGF2a|PGF2alpha|Prostaglandin F2a|Prostaglandin-F2alpha	A naturally occurring prostaglandin that stimulates myometrial activity, relaxes the cervix, inhibits corpus luteal steroidogenesis, and induces luteolysis by direct action on the corpus luteum. Expression of prostaglandin F2alpha (PGF2) is elevated in certain types of cancers.	Prostaglandin F2alpha		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C152071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152071>	C45678	Bisphenol A|2, 2-Bis(4-hydroxyphenyl)propane|2,2-Bis(4'-hydroxyphenyl)propane|2,2-Bis(4-Hydroxyphenyl)propane|2,2-Bis(p-hydroxyphenyl)propane|2,2-Di(4-hydroxyphenyl)propane|2,2-Di(4-phenylol)propane|4,4' Isopropylidinediphenol|4,4'-(1-Methylethane-1,1-diyl)diphenol|4,4'-(1-Methylethylidene)bisphenol|4,4'-(Propane-2,2-diyl)diphenol|4,4'-Isopropylidenediphenol|BISPHENOL A|BPA|Phenol, 4,4'-(1-methylethylidene)bis-|Phenol, 4,4'-isopropylidenedi-	A diphenylmethane derivative with two hydroxyphenyl groups. Bisphenol A (BPA) is a colorless solid that is used in the synthesis of commercial plastics, including polycarbonates and epoxy resins, which are incorporated into a wide variety of consumer goods. Ingested BPA may exhibit estrogenic effects. Exposure to BPA may increase the risk of certain cancers.	Bisphenol A		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152072>	C55826	Phthalate|Phthalic Acid Ester	A family of benzene derivatives that are formed by esterification of phthalic acid. Phthalates are added to increase the flexibility and softness of commercial plastics, which are incorporated into a wide variety of consumer goods. Ingested phthalates may exhibit estrogenic or antiandrogenic effects or they may act as endocrine disruptors. Exposure to phthalate may increase the risk of certain cancers.	Phthalate		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C152073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152073>	C73539	Indican|1H-Indol-3-yl Hydrogen Sulfate|3-Indolyl Hydrogen Sulfate|3-Indolyl Sulfate|3-Indoxyl Sulfate|3-Indoxylsulfuric Acid|INDICAN|Indol-3-yl Hydrogen Sulfate|Indol-3-yl Sulfate|Indoxyl Sulfate|Indoxylsulfuric Acid|Uindoxyl Sulfate	A toxic metabolite derived from dietary proteins and tryptophan. In the intestine, proteins and tryptophan are converted to indole by tryptophanase-expressing organisms. In the liver, indole is hydroxylated to form indoxyl and indoxyl is sufated to produce indican. Overproduction of indican is associated with glomerular sclerosis, interstitial fibrosis and renal failure.	Indican		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152074>	C153279|C152076|C148331	Metastatic Unresectable Sarcoma	A metastatic sarcoma that is not amenable to surgical resection.	Metastatic Unresectable Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C152075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152075>	C133878|C129822	Modotuximab|1024 DS|1024-DS|Immunoglobulin G1, Anti-(human epidermal growth factor receptor extracellular domain III) (human-mus musculus monoclonal 1024 DS heavy chain), Disulfide with human-mus musculus monoclonal 1024 DS light chain, Dimer|MODOTUXIMAB|Zatuximab	A recombinant immunoglobulin G1 (IgG1) monoclonal antibody directed against the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, modotuximab targets and binds to an epitope located in the extracellular domain (ECD) of EGFR, which causes internalization and degradation of EGFR, including the mutated EGFR variant III (EGFRvIII). This prevents EGFR-mediated signaling, thereby inhibiting EGFR-dependent tumor cell proliferation. EGFR, a receptor tyrosine kinase, is often overexpressed on the cell surfaces of various solid tumor cell types.	Modotuximab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C152076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152076>	C9118|C36263	Metastatic Sarcoma	A sarcoma that has spread from its original site of growth to another anatomic site.			Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology
C152077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152077>	C4813|C4013	Recurrent Malignant Head and Neck Neoplasm|Recurrent Head and Neck Cancer	The reemergence of a malignant head and neck neoplasm after a period of remission.			Neoplastic Process	
C152078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152078>	C4013|C120186	Refractory Malignant Head and Neck Neoplasm|Refractory Head and Neck Cancer	A malignant head and neck neoplasm that is resistant to treatment.			Neoplastic Process	
C152079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152079>	C97927|C151919	DKC1 Gene Mutation|CBF5 Gene Mutation|DKC Gene Mutation|DKCX Gene Mutation|Dyskerin Pseudouridine Synthase 1 Gene Mutation|NAP57 Gene Mutation|NOLA4 Gene Mutation|XAP101 Gene Mutation	A change in the nucleotide sequence of the DKC1 gene.	DKC1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C152080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152080>	C97927|C151919	TERC Gene Mutation|DKCA1 Gene Mutation|SCARNA19 Gene Mutation|Small Cajal Body-Specific RNA 19 Gene Mutation|TR Gene Mutation|TRC3 Gene Mutation|Telomerase RNA Component Gene Mutation|hTR Gene Mutation	A change in the nucleotide sequence of the TERC gene.	TERC Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C152081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152081>	C97927|C151919	NOP10 Gene Mutation|DKCB1 Gene Mutation|NOLA3 Gene Mutation|NOP10 Ribonucleoprotein Gene Mutation|NOP10P Gene Mutation|Nucleolar Protein Family A, Member 3 Gene Mutation	A change in the nucleotide sequence of the NOP10 gene.	NOP10 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C152082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152082>	C97927|C151919	NHP2 Gene Mutation|DKCB2 Gene Mutation|NHP2 Ribonucleoprotein Gene Mutation|NHP2P Gene Mutation|NOLA2 Gene Mutation|Nucleolar Protein Family A, Member 2 Gene Mutation	A change in the nucleotide sequence of the NHP2 gene.	NHP2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C152083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152083>	C97927|C151919	WRAP53 Gene Mutation|DKCB3 Gene Mutation|TCAB1 Gene Mutation|Telomerase Cajal Body Protein 1 Gene Mutation|WD Repeat Containing, Antisense to TP53 Gene Mutation|WD Repeat Domain 79 Gene Mutation|WDR79 Gene Mutation	A change in the nucleotide sequence of the WRAP53 gene.	WRAP53 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C152084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152084>	C97927|C151919|C131783	TINF2 Gene Mutation|DKCA3 Gene Mutation|TERF1 Interacting Nuclear Factor 2 Gene Mutation|TIN2 Gene Mutation	A change in the nucleotide sequence of the TINF2 gene.	TINF2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C152085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152085>	C97927|C151919	CTC1 Gene Mutation|AAF-132 Gene Mutation|AAF132 Gene Mutation|C17orf68 Gene Mutation|CST Telomere Replication Complex Component 1 Gene Mutation	A change in the nucleotide sequence of the CTC1 gene.	CTC1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C152086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152086>	C97927|C151919	PARN Gene Mutation|DAN Gene Mutation|DKCB6 Gene Mutation|Deadenylation Nuclease Gene Mutation|Poly(A)-Specific Ribonuclease (Deadenylation Nuclease) Gene Mutation|Poly(A)-Specific Ribonuclease Gene Mutation	A change in the nucleotide sequence of the PARN gene.	PARN Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C152087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152087>	C97927|C151919	RTEL1 Gene Mutation|C20orf41 Gene Mutation|DKCA4 Gene Mutation|DKCB5 Gene Mutation|NHL Gene Mutation|RTEL Gene Mutation|Regulator of Telomere Elongation Helicase 1 Gene Mutation	A change in the nucleotide sequence of the RTEL1 gene.	RTEL1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C152088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152088>	C97927|C151919	ACD Gene Mutation|ACD, Shelterin Complex Subunit and Telomerase Recruitment Factor Gene Mutation|Adrenocortical Dysplasia Homolog (Mouse) Gene Mutation|PIP1 Gene Mutation|PTOP Gene Mutation|TINT1 Gene Mutation|TPP1 Gene Mutation	A change in the nucleotide sequence of the ACD gene.	ACD Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C152089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152089>	C78275	Voxelotor|Benzaldehyde, 2-Hydroxy-6-((2-(1-(1-methylethyl)-1H-pyrazol-5-yl)-3-pyridinyl)methoxy)-|GBT 440|GBT-440|GBT440|GTX 011|GTX-011|GTX011|Oxbryta|VOXELOTOR	An orally bioavailable modulator and stabilizer of sickle cell hemoglobin (HbS), with potential use in the treatment of sickle cell disease (SCD).  Upon administration, voxelotor targets and covalently binds to the N-terminal valine of the alpha chain of HbS. This stabilizes HbS, thereby improving oxygen binding affinity. The binding of voxelotor to HbS prevents HbS polymerization, reduces sickling, decreases red blood cell (RBC) damage and increases the half-life of RBCs. This improves blood flow and decreases hemolytic anemia.	Voxelotor		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C15208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15208>	C16084|C15273	Cohort Study|COHORT|cohort study|cohort study	A research study that compares a particular outcome (such as lung cancer) in groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke compared with those who do not smoke).			Research Activity	CDISC Glossary Terminology|CDISC SDTM Observational Study Model Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C152090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152090>	C20338	NOP10 Gene|NOP10|NOP10|NOP10|NOP10 Ribonucleoprotein Gene	This gene plays a role in both ribosome biogenesis and telomere maintenance.	NOP10 Gene		Gene or Genome	CCPS Genetics Terminology|Childhood Cancer Predisposition Study Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C152091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152091>	C152090	NOP10 wt Allele|DKCB1|Homolog of Yeast Nop10p Gene|NOLA3|NOP10 Ribonucleoprotein Homolog (Yeast) Gene|NOP10 Ribonucleoprotein wt Allele|NOP10, S. cerevisiae, Homolog of Gene|NOP10P|Nucleolar Protein Family A, Member 3 (H/ACA Small Nucleolar RNPs) Gene|Nucleolar Protein Family A, Member 3 Gene	Human NOP10 wild-type allele is located in the vicinity of 15q14 and is approximately 1 kb in length. This allele, which encodes H/ACA ribonucleoprotein complex subunit 3 protein, is involved in both telomere maintenance and ribosome stability. Mutation of the gene is associated with autosomal recessive dyskeratosis congenita type 1.	NOP10 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C152092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152092>	C21298	H/ACA Ribonucleoprotein Complex Subunit 3|NOP10|NOP10 Ribonucleoprotein Homolog|Nucleolar Protein 10|Nucleolar Protein Family A Member 3|SnoRNP Protein NOP10	H/ACA ribonucleoprotein complex subunit 3 (64 aa, ~8 kDa) is encoded by the human NOP10 gene. This protein plays a role in ribosomal RNA (rRNA) stability and telomere maintenance.	H/ACA Ribonucleoprotein Complex Subunit 3		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C152093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152093>	C20338	NHP2 Gene|NHP2|NHP2|NHP2|NHP2 Ribonucleoprotein Gene	This gene is involved in both telomere maintenance and ribosomal RNA (rRNA) stability.	NHP2 Gene		Gene or Genome	CCPS Genetics Terminology|Childhood Cancer Predisposition Study Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C152094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152094>	C48058	Radiation Therapy Beam Energy	Energy in the form of ionizing radiation delivered to precise anatomic locations for therapeutic purposes.			Natural Phenomenon or Process	
C152095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152095>	C152093	NHP2 wt Allele|DKCB2|FLJ20479|HSPC286|NHP2 Ribonucleoprotein Homolog (Yeast) Gene|NHP2 Ribonucleoprotein wt Allele|NHP2, S. cerevisiae, Homolog of Gene|NHP2P|NOLA2|Nucleolar Protein Family A, Member 2 (H/ACA Small Nucleolar RNPs) Gene|Nucleolar Protein Family A, Member 2 Gene	Human NHP2 wild-type allele is located in the vicinity of 5q35.3 and is approximately 5 kb in length. This allele, which encodes H/ACA ribonucleoprotein complex subunit 2 protein, plays a role in both ribosome biogenesis and telomere maintenance. Mutation of the gene is associated with autosomal recessive dyskeratosis congenita type 2.	NHP2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C152096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152096>	C21298	H/ACA Ribonucleoprotein Complex Subunit 2|NHP2|NHP2 Ribonucleoprotein Homolog|NHP2-Like Protein|Nucleolar Protein Family A Member 2|SnoRNP Protein NHP2	H/ACA ribonucleoprotein complex subunit 2 (153 aa, ~17 kDa) is encoded by the human NHP2 gene. This protein is involved in both ribosome stability and telomere maintenance.	H/ACA Ribonucleoprotein Complex Subunit 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C152097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152097>	C19233	Lung Inhomogeneity Correction	Adjustment of radiation therapy measurements for the effects of increased transmission through lung tissue in the treatment of thoracic malignancies.			Activity	
C152098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152098>	C20338	CTC1 Gene|CST Telomere Replication Complex Component 1 Gene|CTC1|CTC1	This gene plays a role in telomere replication.	CTC1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C152099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152099>	C152098	CTC1 wt Allele|AAF-132|AAF132|C17orf68|CRMCC|CST Telomere Replication Complex Component 1 wt Allele|Chromosome 17 Open Reading Frame 68 Gene|FLJ22170|tmp494178	Human CTC1 wild-type allele is located in the vicinity of 17p13.1 and is approximately 23 kb in length. This allele, which encodes CST complex subunit CTC1 protein, is involved in the replication of telomeric DNA. Mutation of the gene is associated with cerebroretinal microangiopathy with calcifications and cysts.	CTC1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15209>	C15210	Colectomy|Colon Resection|Colon Resection|colectomy	Surgical removal of part or all of the colon.	Colectomy		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology
C1520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1520>	C2107	Teloxantrone|Anthra(1,9-cd)pyrazol-6(2H)-one,7,10-dihydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)-5-((2-(methylamino)ethyl)amino)-|CI-937|Moxantrazole|TELOXANTRONE	An anthrapyrazole antineoplastic antibiotic. Teloxantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair, as well as RNA and protein synthesis.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C152100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152100>	C16518	CST Complex Subunit CTC1|Alpha Accessory Factor 132|Alpha Accessory Factor, 132-kD Subunit|CST Telomere Maintenance Complex Component 1|CST Telomere Replication Complex Component 1|CTC1|CTS Telomere Maintenance Complex Component 1|Conserved Telomere Capping Protein 1|Conserved Telomere Maintenance Component 1|HBV DNAPTP1-Transactivated Protein B	CST complex subunit CTC1 (1217 aa, ~135 kDa) is encoded by the human CTC1 gene. This protein plays a role in the regulation of telomeric DNA replication.	CST Complex Subunit CTC1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C152101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152101>	C25953|C20338	PARN Gene|PARN|PARN|PARN|Poly(A)-Specific Ribonuclease Gene	This gene is involved in exonucleolytic degradation of mRNA poly(A) tails and maturation of the telomerase RNA component (TERC).	PARN Gene		Gene or Genome	CCPS Genetics Terminology|Childhood Cancer Predisposition Study Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C152102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152102>	C152101	PARN wt Allele|DAN|DKCB6|Deadenylation Nuclease Gene|PFBMFT4|Poly(A)-Specific Ribonuclease (Deadenylation Nuclease) Gene|Poly(A)-Specific Ribonuclease wt Allele	Human PARN wild-type allele is located in the vicinity of 16p13.12 and is approximately 197 kb in length. This allele, which encodes poly(A)-specific ribonuclease PARN protein, plays a role in the positive regulation of mRNA decay and telomere synthesis. Mutation of the gene is associated with telomere-related pulmonary fibrosis and/or bone marrow failure type 4 and autosomal recessive dyskeratosis congenita type 6.	PARN wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C152103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152103>	C17100	Poly(A)-Specific Ribonuclease PARN|Deadenylating Nuclease|Deadenylation Nuclease|EC 3.1.13.4|PARN|Poly(A)-Specific Ribonuclease|Polyadenylate-Specific Ribonuclease	Poly(A)-specific ribonuclease PARN (639 aa, ~73 kDa) is encoded by the human PARN gene. This protein is involved in both telomere synthesis and mRNA decay.	Poly(A)-Specific Ribonuclease PARN		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C152104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152104>	C49236	Drug Preload|Preload	The administration of an additional aliquot of an agent ahead of a standard dose, with the intent of raising the concentration of the agent in the compartment to which it is administered.			Therapeutic or Preventive Procedure	
C152105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152105>	C3507	Inborn Error of Immunity|IEI|PID|Primary Immune Deficiency Disorder|Primary Immunodeficiency|Primary Immunodeficiency Disorder|Primary Immunodeficiency Syndrome|Primary Immunodeficiency Syndrome	A group of immunodeficiencies caused by damaging germline mutations in single genes. Patients are at an increased risk to develop infections, autoimmunity, bone marrow failure, and malignancies, usually lymphomas.	Primary Immunodeficiency Syndrome		Disease or Syndrome	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology
C152106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152106>	C81123	Rurioctocog Alfa Pegol|Adynovate|Adynovi|Antihemophilic Factor, Pegylated (MW 20000) Human Sequence Recombinant|RURIOCTOCOG ALFA PEGOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152107>	C28394	Chloramine-T Anhydrous|CHLORAMINE-T ANHYDROUS				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152109>	C1937	Sodium Aurotiosulfate|Gold Sodium Thiosulfate|Gold Sodium Thiosulfate Dihydrate|SODIUM AUROTIOSULFATE|Sodium Aurotiosulfate Dihydrate				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15210>	C51652	Colon and Rectal Surgery|colon and rectum surgery|colorectal surgery	Surgical removal of part or all of the colon and/or rectum.			Therapeutic or Preventive Procedure	
C152110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152110>	C83486	Morrhuate Sodium|MORRHUATE SODIUM				Biomedical or Dental Material	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152111>	C29698	Proxazole Citrate|PROXAZOLE CITRATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152112>	C47794	Prucalopride Succinate|Motegrity|PRUCALOPRIDE SUCCINATE|Resolor	The succinate salt form of prucalopride, an orally bioavailable dihydro-benzofuran-carboxamide and selective serotonin (5-HT4) receptor agonist, with gastrointestinal (GI) prokinetic activity. Upon oral administration, prucalopride specifically targets, binds to and stimulates the 5-HT4 receptor. This alters colonic motility patterns and stimulates colonic mass movements. This may normalize bowel movements and may relief chronic constipation. In addition, by increasing esophageal and gastric motility, prucalopride may also provide relief for aspiration-associated symptoms.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C152113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152113>	C29697	Psyllium Hemicellulose|PSYLLIUM HEMICELLULOSE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152114>	C29703	Pyricarbate|PYRICARBATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152115>	C82130	Pyroxylin|PYROXYLIN				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152116>	C29712|C20401	Quilizumab|QUILIZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152117>	C514	Quilseconazole|QUILSECONAZOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152118>	C258	Quindecamine|QUINDECAMINE				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152119>	C258	Quindecamine Acetate|QUINDECAMINE ACETATE				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15211>	C52005|C15210	Colostomy|colostomy	The surgical creation of an opening between the colon and the surface of the body.			Therapeutic or Preventive Procedure	
C152120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152120>	C78274	Quindonium Bromide|QUINDONIUM BROMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152121>	C66884	Quinelorane|QUINELORANE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152122>	C66884	Quinelorane Hydrochloride|QUINELORANE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152123>	C29712	Quinetolate|QUINETOLATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152124>	C776	Quingestanol|QUINGESTANOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152125>	C776	Quingestanol Acetate|19-Nor-17-alpha-pregna-3,5-dien-20-yn-17-ol, 3-(Cyclopentyloxy)-, Acetate|19-Nor-17-alpha-pregna-3,5-dien-20-yn-17-ol, 3-(Cyclopentyloxy)-, Acetate (Ester)|3-Cyclopentyl Enol Ether of Norethindrone Acetate|BRN 2186975|QUINGESTANOL ACETATE|W 4540|W-4540|W4540				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152126>	C776|C389	Quingestrone|3-(Cyclopentyloxy)pregna-3,5-dien-20-one|3-Cyclopentyloxy-3,5-pregnadien-20-on|QUINGESTRONE|W-3399				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152127>	C271	Quinine Ascorbate|QUININE ASCORBATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152128>	C66884	Quinpirole|QUINPIROLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152129>	C66884	Quinpirole Hydrochloride|QUINPIROLE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15212>	C49236	Multimodality Therapy|Combination Therapy|Combined Modality Therapy|Combined Modality Treatment|Combined Treatment|Combined Treatment Modalities|Multimodal Therapy|Multimodal Treatment|Multimodality Treatment|concurrent therapy|multimodality treatment	Use of two or more simultaneous or consecutive treatment modalities; e.g., surgery + radiation, or radiation + immunotherapy. Does not refer to use of two or more chemotherapeutic agents.			Therapeutic or Preventive Procedure	
C152130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152130>	C319	Quinterenol|QUINTERENOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152131>	C319	Quinterenol Sulfate|QUINTERENOL SULFATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152132>	C94727	Quinupramine|QUINUPRAMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152133>	C1946	Quisinostat Hydrochloride|QUISINOSTAT HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152134>	C29575|C129825	Rabacfosadine|RABACFOSADINE	An acyclic nucleotide phosphonate prodrug and polymerase inhibitor that can potentially be used for its antineoplastic activity in the treatment of lymphoma in dogs. Upon administration, rabacfosadine is hydrolyzed intracellularly to 9-(2-phosphonylmethoxyethyl)-N6-cyclopropyl-2, 6-diaminopurine (cPrPMEDAP) and subsequently deaminated to 9-(2-phosphonylmethoxyethyl) guanine (PMEG) and phosphorylated to PMEG diphosphate (PMEGpp). PMEGpp binds to and inhibits DNA polymerases. This inhibits DNA synthesis, resulting in S phase arrest and induction of apoptosis.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152135>	C29575|C129825	Rabacfosadine Succinate|RABACFOSADINE SUCCINATE	The succinate form of rabacfosadine, an acyclic nucleotide phosphonate prodrug and polymerase inhibitor that can potentially be used for its antineoplastic activity in the treatment of lymphoma in dogs. Upon administration, rabacfosadine is hydrolyzed intracellularly to 9-(2-phosphonylmethoxyethyl)-N6-cyclopropyl-2, 6-diaminopurine (cPrPMEDAP) and subsequently deaminated to 9-(2-phosphonylmethoxyethyl) guanine (PMEG) and phosphorylated to PMEG diphosphate (PMEGpp). PMEGpp binds to and inhibits DNA polymerases. This inhibits DNA synthesis, resulting in S phase arrest and induction of apoptosis.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152136>	C308	Rabeximod|RABEXIMOD				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152137>	C241	Racemethorphan|RACEMETHORPHAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152138>	C241	Racemorphan|RACEMORPHAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152139>	C66883	Raclopride|RACLOPRIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15213>	C15785	Community Health Service	Diagnostic, therapeutic and preventive health service provided for individuals in the community.	Community Health Service		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C152140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152140>	C2124	Raclopride C-11|RACLOPRIDE C-11				Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152141>	C281	Radalbuvir|RADALBUVIR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152142>	C281|C1291	Radavirsen|RADAVIRSEN				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152143>	C241	Radiprodil|RADIPRODIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152144>	C20401	Radretumab|RADRETUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152145>	C1327	Rafigrelide|RAFIGRELIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152146>	C250	Rafoxanide|RAFOXANIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152147>	C242	Ralaniten|RALANITEN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152148>	C29707	Ralinepag|RALINEPAG				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152149>	C20401	Ralpancizumab|RALPANCIZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15214>	C15656|C15454|C126391	Craniotomy|Open Craniotomy|craniotomy|incision of the skull	Surgical creation of an opening of the skull.	Craniotomy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C152150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152150>	C97452	Raluridine|RALURIDINE				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152151>	C208255	Ramatercept|RAMATERCEPT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152152>	C61101	Ramoplanin|RAMOPLANIN				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152153>	C2092	Ramorelix|RAMORELIX				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152154>	C20401	Ranevetmab|RANEVETMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152155>	C261	Ranimycin|RANIMYCIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152156>	C265	Rapastinel|RAPASTINEL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152157>	C241	Raseglurant|RASEGLURANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152158>	C217549	Ravidasvir|RAVIDASVIR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152159>	C217549	Ravidasvir Hydrochloride|RAVIDASVIR HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15215>	C64982|C49165|C20985	Cryosurgery|Ablation, Cryo|CRYOABLATION|Cryoablation|cryoablation|cryosurgery|cryosurgical ablation	The use of extreme cold to damage or destroy a body part, pathway, or function. The procedure is performed using small cryogenic probes during surgery, and has recently been applied to solitary sporadic renal tumor lesions.	Cryosurgery		Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C152160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152160>	C52588|C20401	Raxibacumab|RAXIBACUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152161>	C471	Razuprotafib|AKB 9778|AKB-9778|AKB9778|RAZUPROTAFIB	A small molecule inhibitor of vascular endothelial protein tyrosine phosphatase (VE-PTP), with potential vasculature stabilizing activity. Upon administration, razuprotafib targets, binds to and inhibits VE-PTP, which is a negative regulator of the endothelial cell (EC)-specific receptor tyrosine kinase (RTK) Tie2. This restores Tie2 activation, which may improve endothelial function and stabilize blood vessels. VE-PTP is upregulated in stressed endothelium associated with a variety of diseases. Tie2 plays an important role in endothelial function and vascular stability. A decrease in Tie2 activation leads to vascular leakage and inflammation.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C152162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152162>	C213472|C155700	Rebastinib|DCC-2036|REBASTINIB	An orally bioavailable small-molecule inhibitor of multiple tyrosine kinases with potential antineoplastic activity. Upon oral administration, rebastinib binds to and inhibits the Bcr-Abl fusion oncoprotein by changing the conformation of the folded protein to disallow ligand-dependent and ligand-independent activation; in addition, this agent binds to and inhibits Src family kinases LYN, HCK and FGR and the receptor tyrosine kinases TIE-2 and VEGFR-2. Rebastinib may exhibit more potent activity against T315I Bcr-Abl gatekeeper mutant kinases than other Bcr-Abl kinase inhibitors. The TIE-2 and VEGFR-2 receptor tyrosine kinases regulate angiogenesis, respectively, while the Src family kinases Abl, LYN, and HCK Src regulate a variety of cellular responses including differentiation, division, adhesion, and the stress response.	Rebastinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152163>	C265|C185721	Reboxetine Mesylate|REBOXETINE MESYLATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152164>	C47793	Recainam|RECAINAM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152165>	C47793	Recainam Hydrochloride|RECAINAM HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152166>	C47793	Recainam Tosylate|RECAINAM TOSYLATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152167>	C78276	Recanaclotide|RECANACLOTIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152168>	C797	Recilisib|RECILISIB				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152169>	C797	Recilisib Sodium|RECILISIB SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15216>	C49165	Curettage Procedure|CURETTAGE|Curettage|curettage	The removal of tissue with a curette device, a spoon-shaped instrument with a sharp edge.	Curettage Procedure		Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Specimen Collection Method Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C152170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152170>	C1745	Recoflavone|RECOFLAVONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152171>	C26170	Redasemtide|REDASEMTIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152172>	C20401|C1509	Refanezumab|REFANEZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152173>	C82130	Regenerated Cellulose|REGENERATED CELLULOSE				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152174>	C84868	Relamorelin|RELAMORELIN				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152175>	C183118	Relebactam Anhydrous|RELEBACTAM ANHYDROUS				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152176>	C183118	Relebactam Monohydrate|RELEBACTAM	The monohydrate form of relebactam, a beta-lactamase inhibitor, that can be used to inhibit the breakdown of certain drugs, such as the broad spectrum beta-lactam carbapenem antibiotic imipenem. Upon administration of relebactam monohydrate, relebactam targets, binds to and inhibits beta-lactamase. This reduces the breakdown  of drugs, such as imipenem, and thereby increases the activity and therapeutic effect of such drugs that would otherwise be inactivated by beta-lactamase.			Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C152177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152177>	C47794	Relenopride|RELENOPRIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152178>	C47794	Relenopride Hydrochloride|RELENOPRIDE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152179>	C1937	Relmapirazin|APC-2|Lumitrace|Lumtrace|MB-102|N,N'-((3,6-diamino-2,5-pyrazinediyl)dicarbonyl)bis(D-serine)|RELMAPIRAZIN				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15217>	C15334	Cystectomy|cystectomy	The surgical removal of the urinary bladder; or the surgical removal of a cyst..	Cystectomy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C152180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152180>	C29726	Reloxaliase|RELOXALIASE				Amino Acid, Peptide, or Protein|Enzyme|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152181>	C308	Reltecimod|RELTECIMOD				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152182>	C308	Reltecimod Sodium|RELTECIMOD SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152183>	C78272	Remacemide|REMACEMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152184>	C78272	Remacemide Hydrochloride|REMACEMIDE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152185>	C190794	Remdesivir|2-Ethylbutyl (2S)-2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate|GS-5734|L-Alanine, N-((S)-hydroxyphenoxyphosphinyl)-, 2-Ethylbutyl Ester, 6-Ester with 2-C-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-2,5-anhydro-D-altrononitrile|RDV|REMDESIVIR|SARS-CoV-2 antiviral agents: remdesivir|Veklury|Veklury	A prodrug of an adenosine triphosphate (ATP) analog, with potential antiviral activity against a variety of RNA viruses. Upon administration, remdesivir, being a prodrug, is metabolized into its active form GS-441524. As an ATP analog, GS-441524 competes with ATP for incorporation into RNA and inhibits the action of viral RNA-dependent RNA polymerase. This results in the termination of RNA transcription and decreases viral RNA production.	Remdesivir		Pharmacologic Substance	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|Appendix 8: Pharmacological Therapy Terminology|CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology|Therapies for COVID-19 Terminology
C152186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152186>	C38149	Remeglurant|REMEGLURANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152187>	C1012	Remimazolam|CNS 7056|CNS-7056|CNS7056|REMIMAZOLAM	A short-acting benzodiazepine derivative that is structurally related to midazolam, with sedative-hypnotic activity. Upon administration, remimazolam targets and binds to a specific site on the gamma-aminobutyric acid (GABA)-A-chloride ionophore receptor complex located on the neuronal membrane. Binding causes an allosteric modification of the receptor thereby enhancing the affinity of GABA to the receptor leading to an increase in the frequency of chloride-channel opening events, which leads to an increase in chloride ion conductance, neuronal hyperpolarization, inhibition of the action potential, and a decrease in neuronal excitability.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C152188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152188>	C78568	Remiprostol|REMIPROSTOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152189>	C28227	Remtolumab|REMTOLUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15218>	C15334|C15290	Cystostomy|Vesicostomy	Surgical creation of an external opening into the anterior bladder wall.			Therapeutic or Preventive Procedure	
C152190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152190>	C78281|C1291	Renapersen|RENADIRSEN				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152191>	C267	Renzapride|RENZAPRIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152192>	C2080	Repifermin|REPIFERMIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152193>	C52588	Repromicin|REPROMICIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152194>	C48149|C319	Reproterol|REPROTEROL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152195>	C48149|C319	Reproterol Hydrochloride|REPROTEROL HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152196>	C257	Reproxalap|REPROXALAP				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152197>	C29712|C20401	Reslizumab|RESLIZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152198>	C521	Resocortol|RESOCORTOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152199>	C521	Resocortol Butyrate|RESOCORTOL BUTYRATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15219>	C16205	Health Care Delivery|Care Delivery|Health Services Delivery, Other|Healthcare Delivery	The provision of medical care.			Health Care Activity	
C1521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1521>	C2107	Losoxantrone|Biantrazole|Biantrazole|CI-941|CI-941|DuP 941|LOSOXANTRONE|losoxantrone	An anthrapyrazole-based antineoplastic antibiotic. Losoxantrone intercalates into DNA, induces single- and double-stranded DNA breaks and inhibits topoisomerase II, thereby inhibiting DNA replication and repair as well as RNA and protein synthesis. Losoxantrone is less cardiotoxic than doxorubicin.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C152200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152200>	C29704	Revefenacin|REVEFENACIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152201>	C29726	Reveglucosidase Alfa|REVEGLUCOSIDASE ALFA				Amino Acid, Peptide, or Protein|Enzyme|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152202>	C47794	Revexepride|REVEXEPRIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152203>	C2578	Reviparin Sodium|REVIPARIN SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152204>	C201688	Revusiran|REVUSIRAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152205>	C514	Rezafungin|REZAFUNGIN	A next-generation, semi-synthetic, cyclic lipopeptide and echinocandin derivative, with potential antifungal activity. Upon administration, rezafungin inhibits the fungal specific enzyme 1,3-beta-D-glucan synthase, which is essential for fungal cell wall synthesis, and results in decreased synthesis of beta(1,3)-D-glucan. This weakens the fungal cell wall thereby causing osmotic lysis, fungal cell wall rupture and fungal cell death.	Rezafungin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C152206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152206>	C514	Rezafungin Acetate|REZAFUNGIN ACETATE	The acetate form of rezafungin, a next-generation, semi-synthetic, cyclic lipopeptide and echinocandin derivative, with potential antifungal activity. Upon administration, rezafungin inhibits the fungal specific enzyme 1,3-beta-D-glucan synthase, which is essential for fungal cell wall synthesis, and results in decreased synthesis of beta(1,3)-D-glucan. This weakens the fungal cell wall thereby causing osmotic lysis, fungal cell wall rupture and fungal cell death.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152207>	C29713	Rezatomidine|REZATOMIDINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152208>	C217648	Riamilovir|RIAMILOVIR|TZV|Triazavirin	A synthetic guanine derivative, with potential broad-spectrum antiviral activity. Upon administration, riamilovir inhibits viral RNA synthesis, thereby preventing viral transcription and replication. Riamilovir may also bind to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and human angiotensin-converting enzyme 2 (ACE2). This may block the entry of SARS-CoV-2 into human host cells.			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C152209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152209>	C78276|C26170	Ribaxamase|RIBAXAMASE|SYN 004|SYN-004|SYN004	An orally administered recombinant beta-lactamase that can be used to protect the gut microbiome from disruption caused by intravenous (IV) administered beta-lactam antibiotics. Upon administration, ribaxamase hydrolyzes the beta-lactam ring of susceptible antibiotics that were administered intravenously and are excreted into the intestines. This degrades the beta-lactam antibiotic, may prevent antibiotic-mediated damage in the gastrointestinal (GI) tract and may protect the gut microbiome. This may also prevent the overgrowth and associated infection with Clostridioides difficile and antibiotic-associated diarrhea. Ribaxamase is not systemically absorbed and does not interfere with the efficacy of IV beta-lactam antibiotics.	Ribaxamase		Amino Acid, Peptide, or Protein|Enzyme|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15220>	C18020	Diagnosis Assessment|DIAGNOS|DIAGNOSIS|DIAGNOSIS|Diagnosed|Diagnosis|Diagnosis|Diagnosis|Diagnosis|Diagnostic|Diagnostic|Diagnostic intent|Dx|diagnose|diagnosis|diagnosis	The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.			Diagnostic Procedure	CDISC Glossary Terminology|CDISC SDTM Medical History Event Date Type Terminology|CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Electrocardiogram Category Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF6 DIPG Imaging Assessment Table|CRF6 DMG Imaging Assessment Table|ICDC Node Terminology|ICDC Terminology|mCode Procedure Intent Value Set|mCode Terminology|Newborn Screening Terminology|NICHD Terminology
C152210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152210>	C192742|C192741	Ribociclib Succinate|Kisqali|RIBOCICLIB SUCCINATE	The succinate salt form of ribociclib, an orally available inhibitor of the cyclin-dependent kinases (CDKs) 4 and 6, with antineoplastic activity. Upon oral administration, ribociclib specifically targets, binds to and inhibits CDK4 and CDK6. This inhibits the cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, which inhibits phosphorylation of the retinoblastoma (Rb) protein. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle dysregulation.	Ribociclib Succinate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C152211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152211>	C2180	Ribuvaptan|RIBUVAPTAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152212>	C258	Ridinilazole|5,5'-Bi-1H-benzimidazole, 2,2'-Di-4-pyridinyl-|RIDINILAZOLE|SMT-19969|SMT19969|WHO 10075	A narrow-spectrum antibiotic with potential activity against Clostridioides difficile infection (CDI). Upon oral administration, ridinilazole exerts its bactericidal activity against C. difficile through inhibition of cell division. This suppresses bacterial toxin production and inhibits the associated inflammatory response. Compared to other antibiotics that treat C. difficile, ridinilazole does not deplete intestinal bacteria and preserves the intestinal bacterial activity and the associated bile acid metabolome.	Ridinilazole		Antibiotic|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152213>	C258	Rifalazil|RIFALAZIL				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152214>	C258	Rifamexil|RIFAMEXIL				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152215>	C258	Rifamide|RIFAMIDE				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152216>	C1404|C129825	Rigosertib|Glycine, N-(2-methoxy-5-((((1E)-2-(2,4,6-trimethoxyphenyl)ethenyl)sulfonyl) methyl)phenyl)-|N-(2-Methoxy-5-((((1E)-2-(2,4,6-trimethoxyphenyl)ethenyl)sulfonyl)methyl) phenyl)glycine|ON 01910|RIGOSERTIB	A synthetic benzyl styryl sulfone analogue and Ras mimetic, with potential antineoplastic activity. Upon administration, rigosertib targets and binds to Ras-binding domain (RBD) found in many Ras effector proteins, including Raf kinase and phosphatidylinositol 3-kinase (PI3K). This prevents Ras from binding to its targets and inhibits Ras-mediated signaling pathways, including Ras/Raf/Erk, Ras/CRAF/polo-like kinase1 (Plk1), and Ras/ PI3K/Akt signaling pathways. This induces cell cycle arrest and apoptosis and inhibits proliferation in a variety of susceptible tumor cells.	Rigosertib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology
C152217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152217>	C97453	Rilpivirine Hydrochloride|RILPIVIRINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152218>	C29710	Rimcazole|RIMCAZOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152219>	C29710	Rimcazole Hydrochloride|RIMCAZOLE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15221>	C15657	Dialysis|Dialysis Procedure|Dialysis Therapy|dialysis	A procedure to remove toxic substances from the blood that is used in patients with end-stage chronic kidney disease or acute kidney failure. This includes hemodialysis and peritoneal dialysis.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C152220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152220>	C212891	Rimegepant|RIMEGEPANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152221>	C212891	Rimegepant Sulfate|RIMEGEPANT SULFATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152222>	C78281|C1291	Rimigorsen|RIMIGORSEN				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152223>	C835	Rinfabate|RINFABATE				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152224>	C2496	Rinucumab|RINUCUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152225>	C210759	Riociguat|Adempas|BAY 63-2521|BAY-63-2521|BAY63-2521|RIOCIGUAT	An orally bioavailable stimulator of soluble guanylate cyclase (sGC), with vasodilating activity.  Upon oral administration, riociguat directly stimulates the catalytic activity of sGC. In addition, riociguat stabilizes the binding of nitric oxide (NO) to sGC. Altogether this stimulates the NO-sGC-cyclic guanosine monophosphate (cGMP) pathway and increases the formation of the intracellular second messenger cGMP, which results in smooth muscle relaxation and vasodilation. sGC, a heme-containing cytoplasmic signaling enzyme, catalyzes the formation of cGMP from guanosine triphosphate (GTP) in response to NO binding to heme. Riociguat stimulates sGC independently of and synergistically with NO.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152226>	C29705|C1404	Ripasudil|RIPASUDIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152227>	C574|C20401	Risankizumab|ABBV-066|BI-655066|RISANKIZUMAB|Risankizumab-rzaa|Skyrizi	A humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the p19 subunit of human interleukin 23 (IL-23) cytokine, with anti-inflammatory activity. Upon administration, risankizumab targets and binds to the p19 subunit of human IL-23, inhibiting the interaction of IL-23 with the IL-23 receptor complex. This inhibits IL-23/IL-23 receptor-mediated signaling and inhibits the release of pro-inflammatory cytokines and chemokines. IL-23 plays an important role in the development, maintenance and activation of Th17 cells, which produce pro-inflammatory cytokines including IL-17A, IL-17F, and IL-22. It is upregulated in various inflammatory and autoimmune diseases.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C152228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152228>	C265	Rislenemdaz|RISLENEMDAZ				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152229>	C84868	Rismorelin|RISMORELIN				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15222>	C49236	Diet|Dietary|diet	The customary allowance of food and drink taken by a person or an animal from day to day, particularly one especially planned to meet specific requirements of the individual, including or excluding certain items of food; a prescribed course of eating and drinking in which the amount and kind of food, as well as the times at which it is to be taken, are regulated for therapeutic purposes or selected with reference to a particular state of health.			Therapeutic or Preventive Procedure	GDC Terminology|GDC Value Terminology
C152230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152230>	C47793	Risotilide|RISOTILIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152231>	C47793	Risotilide Hydrochloride|RISOTILIDE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152232>	C2139	Ristianol|RISTIANOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152233>	C2139	Ristianol Phosphate|RISTIANOL PHOSPHATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152234>	C1937	Ristocetin|RISTOCETIN				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152235>	C52588|C20401	Rivabazumab|RIVABAZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152236>	C52588|C20401	Rivabazumab Pegol|RIVABAZUMAB PEGOL				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152237>	C93259|C213472|C129825	Rivoceranib|-Pyridinecarboxamide, N-(4-(1-cyanocyclopentyl)phenyl)-2-((4-pyridinylmethyl)amino)-|Apatinib|Apatinib|Apatinib Free Base|RIVOCERANIB|YN968D1 Free Base	An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Upon administration, rivoceranib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.	Rivoceranib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology
C152238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152238>	C29726	Rizolipase|RIZOLIPASE				Amino Acid, Peptide, or Protein|Enzyme|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152239>	C245	Roflurane|ROFLURANE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15223>	C15824	Nutrition Research, Carbohydrates|Carbohydrate Nutrition	The study of the role of carbohydrates in cancer causation or prevention and in general health.			Research Activity	
C152240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152240>	C261	Rokitamycin|ROKITAMYCIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152241>	C574|C20401	Roledumab|ROLEDUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152242>	C29756	Roletamide|ROLETAMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152243>	C308	Rolipoltide|ROLIPOLTIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152244>	C1595	Rolitetracycline Nitrate|ROLITETRACYCLINE NITRATE				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152245>	C29696	Rolodine|ROLODINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152246>	C78281|C20401	Romosozumab|Evenity|ROMOSOZUMAB|Romosozumab-aqqg	A recombinant humanized immunoglobulin G2 (IgG2) monoclonal antibody directed against sclerostin, with anti-osteoporotic activity. Upon administration, romosozumab targets, binds to and inhibits the activity of sclerostin, a regulatory factor in bone metabolism. This stimulates osteoblastic activity, increases bone formation and, to a lesser extent, decreases bone resorption This may increase trabecular and cortical bone mass and improve bone structure and strength. Altogether, this may decrease the risk of fractures. Sclerostin, a negative regulator of bone formation secreted by osteocytes, inhibits Wnt signaling and suppresses osteoblast development and function.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C152247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152247>	C201	Romurtide|ROMURTIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152248>	C277	Ronidazole|RONIDAZOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152249>	C29574	Ronopterin|4-Aminotetrahydrobiopterin|RONOPTERIN|VAS 203|VAS-203|VAS203				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15224>	C15824	Nutrition Research, Fats|Dietary Fat|Lipid Nutrition, Fats	The study of the role of dietary fats in cancer causation or prevention and in general health.			Research Activity	
C152251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152251>	C47793	Ropitoin|ROPITOIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152252>	C47793	Ropitoin Hydrochloride|ROPITOIN HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152253>	C78568	Rosaprostol|ROSAPROSTOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152254>	C261	Rosaramicin|ROSARAMICIN				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152255>	C261	Rosaramicin Propionate|ROSARAMICIN PROPIONATE				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152256>	C261	Rosaramicin Sodium Phosphate|ROSARAMICIN SODIUM PHOSPHATE				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152257>	C261	Rosaramicin Stearate|ROSARAMICIN STEARATE				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152258>	C1404	Rosiptor|ROSIPTOR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152259>	C1404	Rosiptor Acetate|ROSIPTOR ACETATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15225>	C15824	Nutrition Research, Fiber	The study of the role of dietary fiber in cancer causation or prevention and in general health.			Research Activity	
C152260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152260>	C47793	Rotigaptide|ROTIGAPTIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152261>	C20401	Rovalpituzumab|ROVALPITUZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152262>	C76367	Rovatirelin|ROVATIRELIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152263>	C257	Rovazolac|ROVAZOLAC				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152264>	C574|C20401	Rovelizumab|ROVELIZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152265>	C29702	Roxatidine|ROXATIDINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152266>	C29702	Roxatidine Acetate Hydrochloride|ROXATIDINE ACETATE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152267>	C101256	Roxifiban|ROXIFIBAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152268>	C101256	Roxifiban Acetate|ROXIFIBAN ACETATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152269>	C29701	Roxolonium Metilsulfate|ROXOLONIUM METILSULFATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15226>	C15216	Dilation and Curettage|D and C|D and C|D&C|Dilation and Curettage Procedure|Dilation and Curettage of the Uterus|dilatation and curettage|dilation and curettage	A surgical scraping and removal of the inner lining of the uterus through direct dilation of the uterine cervix.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|GDC Terminology|GDC Value Terminology
C152270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152270>	C574|C224821	Rozanolixizumab|ROZANOLIXIZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152271>	C574|C20401	Rozrolimupab|ROZROLIMUPAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152272>	C574	Ruclosporin|RUCLOSPORIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152273>	C574|C20401	Ruplizumab|RUPLIZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152274>	C78311	Rusalatide|RUSALATIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152275>	C78311	Rusalatide Acetate|RUSALATIDE ACETATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152276>	C261	Rutamycin|RUTAMYCIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152277>	C217549	Ruzasvir|RUZASVIR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152278>	C47796	Sabcomeline|SABCOMELINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152279>	C47796	Sabcomeline Hydrochloride|SABCOMELINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15227>	C49165	Dissection	The process of cutting apart or separating tissue as, for example, in the study of anatomy or in the course of a surgical procedure.			Health Care Activity	
C152280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152280>	C20401	Sacituzumab|Immunoglobulin G1, Anti-(Human Tumor-associated Calcium Signal Transducer 2) (Human-mus musculus Monoclonal HRS7 Heavy Chain), Disulfide with Human-mus musculus Monoclonal HRS7 kappa-chain, Dimer|RS7|SACITUZUMAB|hRS7				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152281>	C270	Sacubitril|(2R,4S)-5-(biphenyl-4-yl)-4-((3-carboxypropionyl)amino)-2-methylpentanoic acid ethyl ester|AHU 377|AHU-377|AHU377|SACUBITRIL	A neprilysn (NEP) inhibitor prodrug with natriuretic activity. Upon administration, sacubitril is metabolized by esterases to its active metabolite, sacubitrilat, which inhibits NEP, a neutral endopeptidase that cleaves natriuretic peptides such as atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and c-type natriuretic peptide (CNP), as well as certain vasoconstricting peptides including as angiotensin I and II, and endothelin-1. Additionally, sacubitrilat may inhibit NEP-mediated catabolism of certain peptide-based agents, thereby improving their in vivo stability and increasing tumor cell exposure.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C152282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152282>	C270	Sacubitrilat|SACUBITRILAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152283>	C190412	Safotibant|SAFOTIBANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152284>	C257	Salcolex|SALCOLEX				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152285>	C257	Salethamide|SALETHAMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152286>	C257	Salethamide Maleate|SALETHAMIDE MALEATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152287>	C257	Salicylate Meglumine|SALICYLATE MEGLUMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152288>	C280	Salinazid|SALINAZID				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152289>	C275	Salnacedin|SALNACEDIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15228>	C49658	Double Blind Study|DOUBLE BLIND|Double Blind|Double Masked|Double-Blinded|Double-Masked|double-blind study|double-blind study|double-blinded	A study method in which neither the subjects nor the investigators are permitted to know which subject is receiving which treatment.			Research Activity	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|CDISC SDTM Terminology|CDISC SDTM Trial Blinding Schema Terminology|Clinical Data Interchange Standards Consortium Terminology|ICH M11 Terminology|ICH M11 Trial Blind Schema Value Set Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C152290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152290>	C257	Salprotoside|SALPROTOSIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152291>	C2124	Samarium Sm-153 Lexidronam|153Sm-EDTMP|SAMARIUM SM-153 LEXIDRONAM|Samarium (153SM) Lexidronam|Samarium SM 153 Lexidronam|Samarium Sm-153 EDTMP|Samarium, SM-153 Lexidronam|Samarium-153 EDTMP|Samarium-153 Ethylenediaminetetramethylenephosphonate|Samarium-153 Ethylenediaminetetramethylenephosphonic Acid|Sm-153 EDTMP				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152292>	C217549	Samatasvir|SAMATASVIR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152293>	C681	Samidorphan|SAMIDORPHAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152294>	C681	Samidorphan L-Malate|SAMIDORPHAN L-MALATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152295>	C1823	Sampeginterferon Beta-1A|SAMPEGINTERFERON BETA-1A				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152296>	C260	Sanfetrinem Cilexetil|SANFETRINEM CILEXETIL				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152297>	C66930	Saprisartan|SAPRISARTAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152298>	C66930	Saprisartan Potassium|SAPRISARTAN POTASSIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152299>	C1595	Sarecycline|SARECYCLINE				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15229>	C204844	Anti-Tumor Efficacy Assessment|Anti-Tumor Efficacy|Antitumor Drug Screening Assay|Drug Screening Assays, Antitumor	A technique used for assessment of the effectiveness of a potential antineoplastic agent.	Antitumor Drug Screening Assay		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C1522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1522>	C98241|C1934	Troglitazone|5-((4-((3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy)phenyl)methyl)-2,4-Thiazolidinedione|5-[4-[(6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione|CI-991|CS-045|Prelay|Rezulin|Romozin|TROGLITAZONE	An orally-active thiazolidinedione with antidiabetic and hepatotoxic properties and potential antineoplastic activity.  Troglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor, thereby inducing cell differentiation and inhibiting cell growth and angiogenesis.  This agent also modulates the transcription of insulin-responsive genes, inhibits macrophage and monocyte activation, and stimulates adipocyte differentiation. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C152300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152300>	C1595	Sarecycline Hydrochloride|SARECYCLINE HYDROCHLORIDE				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152301>	C265	Saredutant|SAREDUTANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152302>	C574|C190830	Sarilumab|IL-6 receptor monoclonal antibodies: sarilumab|Immunoglobulin G1, Anti-Human Interleukin 6 Receptor alpha) (Human REGN88 Heavy Chain), Disulfide with Human REGN88 Light Chain, Dimer|Kevzara|REGN88|SAR153191|SARILUMAB	A recombinant, human immunoglobulin (IgG) monoclonal antibody targeting the interleukin 6 receptor (IL-6R), with potential anti-inflammatory activity. Upon intravenous administration of sarilumab, this agent targets and binds to both soluble IL-6 receptor (sIL-6R) and membrane-bound IL-6 receptor (mIL-6R). This inhibits the binding of the pro-inﬂammatory cytokine IL-6 to the IL-6 receptor (IL-6R), which results in the blockade of the IL-6/IL-6R-mediated signal transduction pathway. This may inhibit IL-6/IL-6R-mediated inflammation.	Sarilumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|Appendix 8: Pharmacological Therapy Terminology|CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology|Therapies for COVID-19 Terminology
C152303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152303>	C98233	Saroglitazar|SAROGLITAZAR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152304>	C276	Sarolaner|SAROLANER				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152305>	C823	Sarsagenin|SARSAGENIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152306>	C29750	Saruplase|SARUPLASE				Amino Acid, Peptide, or Protein|Enzyme|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152307>	C574|C20401	Satralizumab|SATRALIZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152308>	C20401|C1937	Satumomab|SATUMOMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152309>	C29723	Saviprazole|SAVIPRAZOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15230>	C15687	Embolization Therapy|Embolization|embolization|therapy, embolization	A procedure in which substances are injected into blood vessels adjacent to a tumor for the purpose of interrupting the blood flow to the cancer cells.	Embolization Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C152310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152310>	C66883	Savoxepin|SAVOXEPIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152311>	C514	Scopafungin|SCOPAFUNGIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152312>	C29726	Sebelipase Alfa|SEBELIPASE ALFA				Amino Acid, Peptide, or Protein|Enzyme|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152313>	C1450	Sebriplatin|SEBRIPLATIN				Inorganic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152314>	C39713	Secalciferol|SECALCIFEROL				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152315>	C574|C184322	Secukinumab|AIN457|Cosentyx|SECUKINUMAB	A recombinant human immunoglobulin G1 (IgG1) monoclonal antibody against the pro-inflammatory cytokine interleukin 17A (IL-17A; IL-17), with potential anti-inflammatory activity. Upon subcutaneous administration, secukinumab selectively targets and binds to IL-17A, thereby neutralizing the IL-17A protein. This prevents binding of IL-17A to the IL-17 receptor (IL-17R), and inhibits IL-17A/IL-17R-mediated signaling and inflammation mediated by this pathway. IL-17A is mainly produced by inflammatory T helper 17 cells (Th17), and certain lymphocytes. IL-17A production is upregulated in many immune-mediated inflammatory diseases and plays a key role in the development of inflammation and the immune response.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C152316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152316>	C776	Segesterone Acetate|SEGESTERONE ACETATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152317>	C62799	Seglitide|SEGLITIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152318>	C62799	Seglitide Acetate|SEGLITIDE ACETATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152319>	C80212	Selepressin|SELEPRESSIN				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15231>	C15483|C15251	Estrogen Replacement Therapy|ERT|ERT|Estrogen Replacement|estrogen replacement therapy	The administration of estrogen, especially in postmenopausal women, to relieve menopausal symptoms and to protect against osteoporosis and heart disease. (Bartleby.com)			Therapeutic or Preventive Procedure	
C152320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152320>	C1404	Seletalisib|SELETALISIB				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152321>	C78568	Selexipag|SELEXIPAG				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152322>	C1509	Selfotel|SELFOTEL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152324>	C308	Seliforant|SELIFORANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152325>	C1509	Selisistat|SELISISTAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152326>	C265	Seltorexant|SELTOREXANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152327>	C264	Selurampanel|SELURAMPANEL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152328>	C98085	Semaglutide|Ozempic|Rybelsus|SEMAGLUTIDE|Wegovy	A glucagon-like peptide-1 (GLP-1) receptor agonist that is 94% homologous to human GLP-1 (7-37), with antihyperglycemic and appetite regulating activities. Upon administration, semaglutide binds to and activates GLP-1 receptor. In pancreatic beta cells, this increases glucose-dependent insulin release. Semaglutide also reduces the elevated glucagon secretion by inhibiting alpha cells of the pancreas and slows gastric emptying. Altogether this lowers the postprandial glucose level. In the brain, the binding to and activation of GLP-1 receptor suppresses appetite, which decreases caloric intake and lowers body weight. GLP-1 is normally secreted by L cells of the gastrointestinal (GI) mucosa in response to a meal to normalize blood glucose levels. It also plays an important role in the regulation of appetite and caloric intake.	Semaglutide		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C152329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152329>	C47793	Sematilide|SEMATILIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15232>	C49165	Excision|Abscission|EXCISION|Excisional|Extirpation|Surgical Removal|excision	The surgical removal of a lesion, often with healthy margins.	Excision		Health Care Activity	CDISC SDTM Procedure Terminology|CDISC SDTM Specimen Collection Method Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table
C152330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152330>	C47793	Sematilide Hydrochloride|SEMATILIDE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152331>	C667	Sembragiline|SEMBRAGILINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152332>	C1185	Semparatide|SEMPARATIDE				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152333>	C1185	Semparatide Acetate|SEMPARATIDE ACETATE				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152334>	C29726	Senrebotase|SENREBOTASE				Amino Acid, Peptide, or Protein|Enzyme|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152335>	C129824	Sepantronium|SEPANTRONIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152336>	C29710	Seperidol Hydrochloride|SEPERIDOL HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152337>	C78568|C29705	Sepetaprost|SEPETAPROST				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152338>	C776	Sepranolone|SEPRANOLONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152339>	C344	Seprilose|SEPRILOSE				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15233>	C15224	Nutrition Research, Fats, Unsaturated|Lipid Nutrition, Unsaturated	The study of the role of unsaturated fats in cancer causation or prevention and in general health.			Research Activity	
C152340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152340>	C28197	Serazapine|SERAZAPINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152341>	C28197	Serazapine Hydrochloride|SERAZAPINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152342>	C29707	Serelaxin|SERELAXIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152343>	C66885	Sergolexole|SERGOLEXOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152344>	C66885	Sergolexole Maleate|SERGOLEXOLE MALEATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152345>	C38149	Seridopidine|SERIDOPIDINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152346>	C29726	Serrapeptase|SERRAPEPTASE				Amino Acid, Peptide, or Protein|Enzyme|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152347>	C1322	Setileuton|SETILEUTON				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152348>	C574|C177182	Setipiprant|SETIPIPRANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152349>	C29711	Setmelanotide|SETMELANOTIDE				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15234>	C70821	Follow-Up Study	Study in which persons exposed to risk or given a designated preventive or therapeutic regimen are observed over a period or at intervals to determine the outcome of the exposure or regimen.			Research Activity	
C152350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152350>	C52588|C20401	Setoxaximab|SETOXAXIMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152351>	C281	Setrobuvir|SETROBUVIR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152352>	C78281|C20401	Setrusumab|SETRUSUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152353>	C1633	Seviprotimut-L|SEVIPROTIMUT-L				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152354>	C319	Sevitropium Mesilate|SEVITROPIUM MESILATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152355>	C78275	Sevuparin Sodium|SEVUPARIN SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152356>	C74536	Sfericase|SFERICASE				Amino Acid, Peptide, or Protein|Enzyme|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152357>	C518	Siagoside|SIAGOSIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152358>	C101256	Sibrafiban|SIBRAFIBAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152359>	C2081|C1745	Silibinin|SILIBININ		Silibinin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C15235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15235>	C15824	Nutrition Research, Food Additives	The study of the role of food additives in cancer causation or prevention and in general health.			Research Activity	
C152360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152360>	C2081|C1745	Silidianin|SILIDIANIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152361>	C78276	Silodrate|SILODRATE				Inorganic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152362>	C29705	Simenepag|SIMENEPAG				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152363>	C29705	Simenepag Isopropyl|SIMENEPAG ISOPROPYL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152364>	C81123	Simoctocog Alfa|SIMOCTOCOG ALFA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152365>	C212865	Sinapultide|SINAPULTIDE				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152366>	C29698	Sintropium Bromide|SINTROPIUM BROMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152367>	C1509	Sipatrigine|SIPATRIGINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152368>	C208296	Siponimod|1-((4-((1E)-1-(((4-Cyclohexyl-3-(trifluoromethyl)phenyl)methoxy)imino)ethyl)- 2-ethylphenyl)methyl)azetidine-3-carboxylic Acid|3-Azetidinecarboxylic Acid, 1-((4-((1E)-1-(((4-Cyclohexyl-3-(trifluoromethyl)phenyl)methoxy)imino)ethyl)-2-ethylphenyl)methyl)-|BAF 312|BAF-312|BAF312|SIPONIMOD	An orally bioavailable sphingosine 1-phosphate (S1P) receptor modulator, with potential anti-inflammatory and immunomodulating activities. Upon oral administration, siponimod targets and binds to S1P receptors 1 and 5 on lymphocytes. This prevents the egress of lymphocytes from lymph nodes, thereby reducing both the number of circulating peripheral lymphocytes and the infiltration of lymphocytes into target tissues, such as the central nervous system (CNS). This prevents lymphocyte-mediated immune response and may reduce inflammation. S1P plays a key role in lymphocyte migration from lymphoid tissues. Siponimod does not target S1P receptor 3, the activation of which may be responsible for adverse effects such as bradycardia associated with other S1P receptor modulators.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152369>	C20401	Sirtratumab|SIRTRATUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15236>	C16120|C15330	Gastrectomy|Gastric Resection|gastrectomy	Surgical removal of part or all of the stomach.	Gastrectomy		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Procedures Codelist|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology
C152370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152370>	C211912	Sirtratumab Vedotin|AGS-15E|AGS15E|ASG-15ME|Anti-SLITRK6 ADC AGS15E|Anti-SLITRK6 Antibody-drug Conjugate AGS15E|Anti-SLITRK6 Monoclonal Antibody-MMAE Conjugate AGS15E|SIRTRATUMAB VEDOTIN	An antibody-drug conjugate (ADC) composed of sirtratumab, a monoclonal antibody directed against SLIT and NTRK-like protein 6 (SLITRK6), covalently linked to the cytotoxic agent monomethyl auristatin E (MMAE), an auristatin derivative and a potent inhibitor of microtubule polymerization, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of sirtratumab vedotin binds to SLITRK6 expressed on tumor cells, which facilitates both the internalization of the ADC and the intracellular delivery of MMAE. Upon cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and tumor cell apoptosis.  SLITRK6, a member of the Slitrk family of leucine-rich repeat (LRR) neuronal transmembrane proteins, is minimally expressed in normal tissue but overexpressed in a variety of cancers, including bladder cancer, some forms of lung cancer, breast cancer and glioblastoma.	Sirtratumab Vedotin		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C152371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152371>	C574|C163951	Sirukumab|CNTO 136|CNTO-136|Plivensia (TM)|SIRUKUMAB	A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the pro-inflammatory cytokine interleukin-6 (IL-6), with potential immunomodulating and anti-inflammatory activities. Upon administration, sirukumab targets, binds to and blocks the activity of IL-6, which may inhibit the binding of IL-6 to its receptor interleukin-6 receptor (IL-6R). This may inhibit the IL-6/IL-6R-mediated signal transduction pathway and the associated inflammatory response.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C152372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152372>	C276	Sisapronil|SISAPRONIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152373>	C28334	Sitaxentan Sodium|SITAXENTAN SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152374>	C29711	Smilagenin|SMILAGENIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152375>	C29701	Sodium Amylosulfate|SODIUM AMYLOSULFATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152376>	C1937	Sodium Arsenate As-74|SODIUM ARSENATE AS-74				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152377>	C83486	Sodium Ethasulfate|SODIUM ETHASULFATE				Biomedical or Dental Material	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152378>	C45678	Sodium Glucaspaldrate|SODIUM GLUCASPALDRATE				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152379>	C276	Sodium Stibocaptate|SODIUM STIBOCAPTATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15237>	C16223	Gene Bank	A stored copy of genetic information of a species in a preferred environment for conservation purposes. (biology-online.org)			Manufactured Object	
C152380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152380>	C1937	Sodium Sulfate S-35|SODIUM SULFATE S-35				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152381>	C78275	Sodium Zirconium Cyclosilicate|Lokelma|Lokelma|SODIUM ZIRCONIUM CYCLOSILICATE	An insoluble, non-absorbed inorganic material used as a potassium binder and a treatment for hyperkalemia. Upon administration as an oral suspension, sodium zirconium cyclosilicate selectively targets and binds to potassium in the gastrointestinal (GI) tract, exchanging its sodium ions for potassium ions. This increases fecal potassium excretion, decreases the concentration of free potassium in the GI lumen, and lowers serum potassium levels.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152382>	C263	Sofigatran|SOFIGATRAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152383>	C214964|C20401	Sofituzumab|SOFITUZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152384>	C66880	Sofpironium Bromide|SOFPIRONIUM BROMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152385>	C574|C1967	Solcitinib|SOLCITINIB				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152386>	C261	Solithromycin|SOLITHROMYCIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152387>	C78273	Solnatide|SOLNATIDE				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152388>	C47793	Solpecainol|SOLPECAINOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152389>	C78272	Solriamfetol|SOLRIAMFETOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15238>	C15187	Gene Therapy|DNA Therapy|GENETIC|Gene Transfer Procedure|Gene transfer|Genetic|Intervention, Genetic|Molecular Biology, Gene Therapy|gene therapy|gene therapy	Application of genetic material (usually DNA) into cells in order to permanently correct an inherited disease or acquired disease.	Gene Therapy		Therapeutic or Preventive Procedure	CDISC Glossary Terminology|CDISC SDTM Intervention Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|ICH M11 Intervention Type Value Set Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C152390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152390>	C66883|C29710	Solypertine|SOLYPERTINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152391>	C66883|C29710	Solypertine Tartrate|SOLYPERTINE TARTRATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152392>	C164163	Somagrebove|SOMAGREBOVE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152393>	C164163	Somalapor|SOMALAPOR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152394>	C164163	Somapacitan|SOMAPACITAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152395>	C164163	Somatosalm|SOMATOSALM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152396>	C164163	Somatrogon|SOMATROGON				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152397>	C164163	Somatropin Pegol|SOMATROPIN PEGOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152398>	C164163	Somavaratan|SOMAVARATAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152399>	C164163	Somavubove|SOMAVUBOVE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15239>	C16205	Patient Care|Patient Care Delivery	Any of the services rendered for the benefit of a patient.			Health Care Activity	
C1523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1523>	C62799	Lanreotide|Angiopeptin|Angiopeptin|BIM-23014|DC 13116|Dermopeptin|Ipstyl|L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7)-disulfide|LANREOTIDE|Nal-cyclo(cys-tyr-trp-lys-val-cys)-thr-NH2|Somatulina|Somatuline	A synthetic cyclic octapeptide analogue of somatostatin. Lanreotide binds to somatostatin receptors (SSTR), specifically SSTR-2 and also to SSTR-5 with a lesser affinity. However, compare with octreotide, this agent is less potent in inhibiting the release of growth hormone from the pituitary gland. Furthermore, lanreotide has an acute effect on decreasing circulating total and free insulin-like growth factor 1 (IGF-I).  This agent is usually given as a prolonged-release microparticle or Autogel formulation for the treatment of acromegaly and to relieve the symptoms of neuroendocrine tumors.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology
C152400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152400>	C164163	Somenopor|SOMENOPOR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152401>	C164163	Sometripor|SOMETRIPOR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152402>	C164163	Somfasepor|SOMFASEPOR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152403>	C164163	Somidobove|SOMIDOBOVE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152404>	C45678	Soneclosan|SONECLOSAN				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152405>	C155725	Sonidegib Phosphate|SONIDEGIB PHOSPHATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152406>	C29703	Sorbinicate|SORBINICATE				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152407>	C83486	Sorbitan Sesquioleate|SORBITAN SESQUIOLEATE				Biomedical or Dental Material	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152408>	C264	Soretolide|SORETOLIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152409>	C319	Soterenol|SOTERENOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15240>	C61547	Genetic Counseling|genetic counseling	The process whereby an expert in hereditary disorders provides information about risk and clinical burden of a disorder or disorders to patients or relatives in families with genetic disorders as an aid to making informed and responsible decisions about marriage, children, early diagnosis, and handling disability.	Genetic Counseling		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C152410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152410>	C319	Soterenol Hydrochloride|SOTERENOL HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152411>	C281	Sovaprevir|SOVAPREVIR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152412>	C66930|C28334	Sparsentan|SPARSENTAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152413>	C259	Sparsomycin|SPARSOMYCIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152414>	C47793	Sparteine|SPARTEINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152415>	C47793	Sparteine Sulfate|SPARTEINE SULFATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152416>	C45678	Spiclamine|SPICLAMINE				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152417>	C67413|C241	Spiradoline|SPIRADOLINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152418>	C67413|C241	Spiradoline Mesylate|SPIRADOLINE MESYLATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152419>	C247	Spiraprilat|SPIRAPRILAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15241>	C16223	Genomic Library	A collection of DNA molecules, derived from restriction fragments that have been cloned in vectors, that includes all or part of the genetic material of an organism.			Manufactured Object	
C152420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152420>	C101255	Spirorenone|SPIRORENONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152421>	C101255	Spiroxasone|SPIROXASONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152422>	C496	Sprifermin|SPRIFERMIN				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152423>	C446|C2115	Stallimycin Hydrochloride|STALLIMYCIN HYDROCHLORIDE				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152424>	C471	Stannsoporfin|STANNSOPORFIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152425>	C281	Statolon|STATOLON				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152426>	C1594	Steffimycin|STEFFIMYCIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152427>	C2360	Stenbolone|STENBOLONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152428>	C2360	Stenbolone Acetate|STENBOLONE ACETATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152429>	C276	Stibamine Glucoside|STIBAMINE GLUCOSIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15242>	C70694	Health Maintenance Organization|HMO	A type of managed health care that requires enrollees to see health care providers that are part in the plan's network; exceptions are made for emergency care.			Health Care Related Organization	
C152430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152430>	C276	Stibosamine|STIBOSAMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152431>	C276	Stilbamidine Isethionate|STILBAMIDINE ISETHIONATE|Stilbamidine Isetionate	A compound of the diamidine stilbenedicarboxamidine and hydroxyethanesulfonic acid, with potential activity against various protozoans. Upon administration, stilbamidine isethionate targets and binds to DNA. This inhibits cell division and reproduction in protozoans. It is also taken up in the lysosomes.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152432>	C250	Stilbazium Iodide|STILBAZIUM IODIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152433>	C264	Stiripentol|STIRIPENTOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152434>	C737	Stirofos|STIROFOS|TCVP|TETRACHLORVINPHOS|Tetrachlorvinphos	A synthetic alkenyl phosphate, dialkyl phosphate, trichlorobenzene compound, and organophosphate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a colorless or off-white crystalline solid, and exposure occurs by inhalation, ingestion, or contact.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152435>	C29750	Streptodornase|STREPTODORNASE				Amino Acid, Peptide, or Protein|Enzyme|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152436>	C29750	Streptokinase|STREPTOKINASE				Amino Acid, Peptide, or Protein|Enzyme|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152437>	C280	Streptoniazid|STREPTONIAZID				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152438>	C280	Streptonicozid|STREPTONICOZID				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152439>	C261	Streptovarycin|STREPTOVARYCIN				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15243>	C15898	Health Promotion|Health Promotion (Salutogenesis)|Health Promotion and Wellness|Mindfulness Health Promotion|Salutogenesis	The realization that individual behavior plays a key role in health and disease prevention. Health promotion encourages individuals to adopt and maintain healthy behaviors (e.g., good eating habits and regular physical exercise) and modify unhealthy behaviors (e.g., quitting smoking) to foster healing and reduce the risks of major chronic diseases.	Health Promotion		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C152440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152440>	C1446	Strontium Chloride Sr-85|STRONTIUM CHLORIDE SR-85				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152441>	C1446	Strontium Nitrate Sr-85|STRONTIUM NITRATE SR-85				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152442>	C29696|C264	Styramate|STYRAMATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152443>	C29739	Succinylsulfathiazole|SUCCINYLSULFATHIAZOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152444>	C802	Sucrosofate|SUCROSOFATE				Biomedical or Dental Material|Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152445>	C802	Sucrosofate Potassium|SUCROSOFATE POTASSIUM				Biomedical or Dental Material|Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152446>	C275	Sudismase|SUDISMASE				Amino Acid, Peptide, or Protein|Enzyme|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152447>	C257	Sudoxicam|SUDOXICAM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152448>	C66885	Sulamserod|SULAMSEROD				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152449>	C66885	Sulamserod Hydrochloride|SULAMSEROD HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15244>	C25396	Access to Care|Health Care Access	The ability of individuals or a population to utilize and obtain care from the health care system.			Conceptual Entity	
C152450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152450>	C45812	Sulbutiamine|SULBUTIAMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152451>	C20401|C1937	Sulesomab|SULESOMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152452>	C29739	Sulfabenz|SULFABENZ				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152453>	C97936	Sulfacarbamide|SULFACARBAMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152454>	C29739	Sulfadicramide|SULFADICRAMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152455>	C29739	Sulfaethidole|SULFAETHIDOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152456>	C29739	Sulfamoxole|SULFAMOXOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152457>	C29739	Sulfanilate Zinc|SULFANILATE ZINC				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152458>	C29739	Sulfasymazine|SULFASYMAZINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152459>	C29739	Sulfatroxazole|SULFATROXAZOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15245>	C15829	Health Services Research|HEALTH SERVICES RESEARCH	A multidisciplinary field of inquiry that examines the costs, quality, accessibility, delivery, organization, and financing of health care services.			Research Activity	CDISC SDTM Terminology|CDISC SDTM Trial Indication Type Terminology|Clinical Data Interchange Standards Consortium Terminology
C152460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152460>	C29739	Sulfazamet|SULFAZAMET				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152461>	C29576	Sulfinalol|SULFINALOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152462>	C29576	Sulfinalol Hydrochloride|SULFINALOL HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152463>	C29739	Sulfisomidine|SULFISOMIDINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152464>	C78160	Sulfomyxin|SULFOMYXIN				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152465>	C29701	Sulglicotide|SULGLICOTIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152466>	C29707	Suloctidil|SULOCTIDIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152467>	C263	Sulodexide|SULODEXIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152469>	C264	Sulthiame|SULTHIAME				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15246>	C80430|C49803|C191377	Heart Transplantation|CARDIAC TRANSPLANT|Cardiac Transplantation|Heart Grafting|Heart Transplant|Heart Transplant|Heart Transplant	A surgical procedure in which a damaged heart is removed and replaced by another heart from a suitable donor.			Therapeutic or Preventive Procedure	AML Adverse Events Table|AML Authorized Value Terminology|CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C152470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152470>	C281	Sultimotide Alfa|SULTIMOTIDE ALFA				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152471>	C1500	Suncillin|SUNCILLIN				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152472>	C1500	Suncillin Sodium|SUNCILLIN SODIUM				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152473>	C47794|C29713	Sunepitron|SUNEPITRON				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152474>	C47794|C29713	Sunepitron Hydrochloride|SUNEPITRON HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152475>	C574	Suplatast Tosilate|SUPLATAST TOSILATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152476>	C281|C20401	Suptavumab|SUPTAVUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152477>	C47793	Suricainide|SURICAINIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152478>	C47793	Suricainide Maleate|SURICAINIDE MALEATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152479>	C78272	Suritozole|SURITOZOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15247>	C191377	Heart and Lung Transplantation|Heart Lung Grafting|Heart Lung Transplantation|Heart-Lung Grafting|Heart-Lung Transplantation	The surgical transfer of a heart and one or both lungs from one individual to another.			Therapeutic or Preventive Procedure	
C152480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152480>	C258	Surotomycin|SUROTOMYCIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152481>	C78311	Susoctocog Alfa|SUSOCTOCOG ALFA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152482>	C280	Sutezolid|SUTEZOLID				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152483>	C281|C20401	Suvizumab|SUVIZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152484>	C52588|C20401	Suvratoxumab|SUVRATOXUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152485>	C270	Syrosingopine|SYROSINGOPINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152486>	C29756	Taclamine|TACLAMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152487>	C29756	Taclamine Hydrochloride|TACLAMINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152488>	C574	Tadekinig Alfa|TADEKINIG ALFA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152489>	C271	Tafenoquine Succinate|Arakoda|Krintafel|TAFENOQUINE SUCCINATE	The succinate salt form of tafenoquine, an orally bioavailable 8-aminoquinoline derivative, with antimalarial activity. Although the mechanism is not completely understood, upon administration, tafenoquine inhibits the parasitic enzyme heme polymerase in the blood stages of the parasites. This inhibits the conversion of the toxic heme into non-toxic hemazoin, thereby resulting in the accumulation of toxic heme within the parasite. Tafenoquine is active against all the stages of Plasmodium species and is also active against the pre-erythrocytic liver stages of the parasites. This prevents the development of the erythrocytic forms of the parasite which are responsible for relapses in P. vivax malaria.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C15248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15248>	C15221	Hemodialysis|Artificial Kidney Dialysis|Extracorporeal Dialysis|HEMODIALYSIS|Kidney Dialysis|Renal Dialysis|Renal Dialysis	A therapeutic procedure used in patients with kidney failure.  It involves the extracorporeal removal of harmful wastes and fluids from the blood using a dialysis machine.  Following the dialysis, the blood is returned to the body.			Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C152490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152490>	C1331	Tafluposide|TAFLUPOSIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152491>	C29756	Taglutimide|TAGLUTIMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152492>	C1500	Talampicillin|TALAMPICILLIN				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152493>	C1500	Talampicillin Hydrochloride|TALAMPICILLIN HYDROCHLORIDE				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152494>	C62554	Talazoparib Tosylate|TALAZOPARIB TOSYLATE|Talzenna	The tosylate salt form of talazoparib, an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. Upon administration, talazoparib selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.	Talazoparib Tosylate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C152495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152495>	C82130	Talinexomer|TALINEXOMER				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152496>	C66884	Talipexole|TALIPEXOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152497>	C2311	Talisomycin|BU 2231A|BU-2231A|BU2231A|TALISOMYCIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152498>	C29698|C142789	Talnetant Hydrochloride|TALNETANT HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152499>	C319	Taloximine|TALOXIMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15249>	C217456|C16120	Hepatectomy|Liver Resection|hepatectomy	Surgical removal of all or part of the liver.	Hepatectomy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C1524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1524>	C2018	Liarozole Fumarate|(+-)-5-(m-Chloro-alpha-imidazol-1-ylbenzyl)benzimidazole Fumarate (2:3)|1H-Benzimidazole, 5-((3-chlorophenyl)-1H-imidazol-1-ylmethyl)-, (+-)-, (E)-2-butenedioate (2:3)|LIAROZOLE FUMARATE|R85246	The orally active fumarate salt of the benzimidazole derivative liarozole with potential antineoplastic activity. As a retinoic acid metabolism blocking agent (RAMBA), liarozole inhibits cytochrome P450-dependent all-trans-retinoic acid (ATRA)-4-hydroxylase, resulting in an increase in endogenous ATRA production, inhibition of cell proliferation, and induction of cell differentiation. This agent also inhibits aromatase, the enzyme that catalyzes the final, rate-limiting step in estrogen biosynthesis.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C152500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152500>	C47796	Talsaclidine Fumarate|TALSACLIDINE FUMARATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152501>	C265	Tametraline|TAMETRALINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152502>	C265	Tametraline Hydrochloride|TAMETRALINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152503>	C94727	Tampramine|TAMPRAMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152504>	C94727	Tampramine Fumarate|TAMPRAMINE FUMARATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152505>	C20401	Tamtuvetmab|TAMTUVETMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152506>	C265|C185721	Tandamine|TANDAMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152507>	C265|C185721	Tandamine Hydrochloride|TANDAMINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152508>	C263	Taneptacogin Alfa|TANEPTACOGIN ALFA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152509>	C308	Tanurmotide|TANURMOTIDE				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15250>	C61370	Botanical Therapy|Herbal Medicine / Botanical Therapy|Herbal Therapy|Phytotherapy or Herbalism|herbal medicine	Therapy based on plant-derived preparations which include the following: Individual herbs - Ginkgo biloba, Hypericum, Garlic, Ginseng, Echinacea, Saw palmetto, Urtica diocia (nettle), Kava kava, Hawthorne, Witch Hazel, Bilberry, Ginger, Aloe vera, Capsicum, Feverfew, Green tea, Tee Tree oil, Licorice root, Yohimbe, Valerian, Bee Pollen, Cat's Claw, Evening Primrose, Dong Quai, Fenugreek, Marshmallow, Psyllium, Turmeric. Combinations include: Padma 28, Hoxey, Essiac, Saw palmetto, Pygeum africanum.			Therapeutic or Preventive Procedure	
C152510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152510>	C1404	Tanzisertib|TANZISERTIB				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152511>	C257	Tapinarof|TAPINAROF				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152512>	C78568	Taprenepag|TAPRENEPAG				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152513>	C78568	Taprenepag Isopropyl|TAPRENEPAG ISOPROPYL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152514>	C1967|C129825	Tarloxotinib Bromide|TARLOXOTINIB BROMIDE		Tarloxotinib Bromide		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152515>	C47795	Tasimelteon|TASIMELTEON				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152516>	C29709	Tasipimidine|TASIPIMIDINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152517>	C66930	Tasosartan|TASOSARTAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152518>	C98085	Taspoglutide|TASPOGLUTIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152519>	C1446	Tauroselcholic Acid|TAUROSELCHOLIC ACID				Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15251>	C15599	Postmenopausal Hormone Replacement Therapy	The administration of hormones, usually estrogen and/or progesterone, to postmenopausal women, to relieve menopausal symptoms and to protect against osteoporosis and heart disease.			Therapeutic or Preventive Procedure	
C152520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152520>	C2198	Tazadolene|TAZADOLENE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152521>	C2198	Tazadolene Succinate|TAZADOLENE SUCCINATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152522>	C257	Tebufelone|TEBUFELONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152523>	C173064	Tecarfarin|TECARFARIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152524>	C173064	Tecarfarin Sodium|TECARFARIN SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152525>	C2124	Technetium Tc-99M Etarfolatide|TECHNETIUM TC-99M ETARFOLATIDE|Technetium (99MTc) Etarfolatide				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152526>	C2124	Technetium Tc-99M Fanolesomab|TECHNETIUM TC-99M FANOLESOMAB|Technetium (99mTc) Fanolesomab				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152527>	C2124	Technetium Tc-99M Furifosmin|TECHNETIUM TC-99M FURIFOSMIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152528>	C2124	Technetium Tc-99M Medronate Disodium|TECHNETIUM TC-99M MEDRONATE DISODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152529>	C2124	Technetium Tc-99M Nitridocade|TECHNETIUM TC-99M NITRIDOCADE|Technetium (99mTc) Nitridocade				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15252>	C15292	Hospice Care|End of Life Care|End of Life Care|Hospice|hospice	The active total care of patients whose disease is not responsive to curative treatment. The goal of palliative care is achievement of the best possible quality of life for patients and their families. Control of pain, of other symptoms, and of psychological, social, and spiritual problems is paramount. Palliative care affirms life and regards dying as a normal process, neither hastens nor postpones death, provides relief from pain and other distressing symptoms, integrates the psychological and spiritual aspects of patient care, offers a support system to help patients live as actively as possible until death, and offers a support system to help the family cope during the patient's illness and in their own bereavement. (World Health Organization)	Hospice Care		Health Care Activity	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology
C152530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152530>	C2124	Technetium Tc-99M Pentetate Calcium Trisodium|TECHNETIUM TC-99M PENTETATE CALCIUM TRISODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152531>	C2124	Technetium Tc-99M Siboroxime|TECHNETIUM TC-99M SIBOROXIME|Technetium (99mTc) Siboroxime				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152532>	C2124	Technetium Tc-99M Trofolastat Chloride|TECHNETIUM TC-99M TROFOLASTAT CHLORIDE|Technetium (99mTc) Trofolastat Chloride	The chloride salt form of a radioconjugate composed of an urea-based human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the gamma-emitting radioisotope technetium Tc 99m, with potential use as a tracer for PSMA-expressing tumors using single photon emission computed tomography/computed tomography (SPECT/CT). Upon intravenous administration of the technetium Tc 99m trofolastat, the trofolastat moiety targets and binds to PSMA-expressing tumor cells. Upon internalization, PSMA-expressing tumor cells can be detected during SPECT/CT imaging. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152533>	C277	Teclozan|TECLOZAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152534>	C257	Tedalinab|TEDALINAB				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152535>	C265	Tedatioxetine|TEDATIOXETINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152536>	C265	Tedatioxetine Hydrobromide|TEDATIOXETINE HYDROBROMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152537>	C258	Tedizolid Phosphate|Sivextro|TEDIZOLID PHOSPHATE	The phosphate salt form of tedizolid, an antibacterial agent of the oxazolidinone class, that is used for the treatment of acute bacterial skin and skin structure infections caused by certain Gram-positive microorganisms. Upon intravenous administration, tedizolid targets and binds to the 50S subunit of the bacterial ribosome. This inhibits bacterial protein synthesis.			Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152538>	C52588|C20401	Tefibazumab|TEFIBAZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152539>	C1946|C129825	Tefinostat|CHR 2845|CHR-2845|CHR2845|TEFINOSTAT	A hydroxamic acid-derived histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Tefinostat inhibits HDAC leading to an accumulation of highly acetylated histones, which may result in chromatin remodeling, inhibition of tumor oncogene transcription, inhibition of tumor cell division, and the induction of tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins; this agent may specifically target HDACs in cells of the monocyte-macrophage lineage.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15253>	C49235	Hospital Administration|Hospital Administration / HMO|Hospital Management	General management of a hospital, or the more specific processes involved in the management of an individual department.			Health Care Activity	
C152540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152540>	C245	Teflurane|TEFLURANE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152541>	C783|C281	Tegobuvir|TEGOBUVIR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152542>	C224110	Tegoprazan|TEGOPRAZAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152543>	C280	Telacebec|TELACEBEC				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152544>	C1272	Telbermin|TELBERMIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152545>	C212891	Telcagepant|TELCAGEPANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152546>	C212891	Telcagepant Potassium|TELCAGEPANT POTASSIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152548>	C211679	Telmapitant|TELMAPITANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152549>	C266|C217485	Telotristat|TELOTRISTAT	A tryptophan hydroxylase (TPH) inhibitor, with potential anti-serotonergic activity. Upon administration, telotristat binds to and inhibits the activity of TPH. This may result in a reduction in peripheral serotonin (5-HT) production and improvement of serotonin-mediated gastrointestinal effects such as severe diarrhea. TPH, the rate-limiting enzyme in serotonin biosynthesis, is overexpressed in carcinoid tumor cells.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology
C15254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15254>	C213308	Human Genome Project	An international, collaborative research project to determine the complete sequence of human DNA, and to identify and map all of the genes from both a physical and functional standpoint.			Research Activity	
C152550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152550>	C66880	Tematropium Methylsulfate|TEMATROPIUM METHYLSULFATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152551>	C281	Temavirsen|TEMAVIRSEN				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152552>	C281	Temavirsen Sodium|TEMAVIRSEN SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152553>	C157400	Temsavir|TEMSAVIR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152554>	C210	Temurtide|TEMURTIDE				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152555>	C78276	Tenapanor|TENAPANOR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152556>	C78276	Tenapanor Hydrochloride|TENAPANOR HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152557>	C471	Tendamistat|TENDAMISTAT				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152558>	C257	Tenidap|TENIDAP				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152559>	C97452	Tenofovir Alafenamide Fumarate|TENOFOVIR ALAFENAMIDE FUMARATE				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15255>	C15467|C15454	Hypophysectomy|Excision of the Hypophysis|Excision of the Pituitary Gland|Excision of the Pituitary Gland+B3297|Hypophysis Cerebri Excision|Hypophysis Excision|Pituitary Gland Excision|Pituitectomy	Surgical removal of part or all of the pituitary gland.			Therapeutic or Preventive Procedure	
C152560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152560>	C97452	Tenofovir Exalidex|TENOFOVIR EXALIDEX				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152561>	C277	Tenonitrozole|TENONITROZOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152562>	C78276	Tenylidone|TENYLIDONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152563>	C29576	Teoprolol|TEOPROLOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152564>	C308	Tepilamide Fumarate|TEPILAMIDE FUMARATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152565>	C78274	Teprasiran|TEPRASIRAN				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152566>	C247	Teprotide|TEPROTIDE				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152567>	C66885|C66884	Terguride|TERGURIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152568>	C270	Terlakiren|TERLAKIREN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152569>	C29698|C29696	Terodiline|TERODILINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15256>	C15332	Hysterectomy|Hysterectomy NOS|hysterectomy|hysterectomy type|hysterectomy_type	A surgical procedure to remove the uterine body (partial hysterectomy) or the uterine body and cervix (total hysterectomy).	Hysterectomy		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Procedures Codelist|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology|GDC Property Terminology|GDC Terminology|GDC Value Terminology
C152570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152570>	C29698|C29696	Terodiline Hydrochloride|TERODILINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152571>	C250	Teroxalene|TEROXALENE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152572>	C250	Teroxalene Hydrochloride|TEROXALENE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152573>	C213472|C129825	Tesevatinib Tosylate|TESEVATINIB TOSYLATE	The tosylate salt form of tesevatinib, an orally bioavailable small-molecule receptor tyrosine kinase (RTK) inhibitor, with potential antineoplastic activity. Upon administration, tesevatinib binds to and inhibits several tyrosine receptor kinases that play major roles in tumor cell proliferation and tumor vascularization, including epidermal growth factor receptor (EGFR; ERBB1), epidermal growth factor receptor 2 (HER2; ERBB2), vascular endothelial growth factor receptor (VEGFR), and ephrin B4 (EphB4). This may result in the inhibition of tumor growth and angiogenesis, and tumor regression.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152574>	C257	Tesicam|TESICAM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152575>	C281	Teslexivir|TESLEXIVIR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152576>	C862	Testosterone Ketolaurate|TESTOSTERONE KETOLAURATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152577>	C45678	Tetraethylammonium Bromide|TETRAETHYLAMMONIUM BROMIDE				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152578>	C47796|C2141	Tetramisole Hydrochloride|TETRAMISOLE HYDROCHLORIDE				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152579>	C796	Tetroquinone|TETROQUINONE				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15257>	C52005	Ileostomy|ileostomy	Surgical creation of an external opening into the ileum for fecal diversion or drainage. Loop or tube procedures are most often employed.	Ileostomy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C152580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152580>	C257	Tetrydamine|TETRYDAMINE				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152581>	C87006	Tezacaftor|TEZACAFTOR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152582>	C29712|C20401	Tezepelumab|TEZEPELUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152583>	C98150	Theofibrate|THEOFIBRATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152584>	C319|C29635	Theophylline Ephedrine|THEOPHYLLINE EPHEDRINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152585>	C265	Thiazesim|THIAZESIM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152586>	C265	Thiazesim Hydrochloride|THIAZESIM HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152587>	C849	Thiazosulfone|THIAZOSULFONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152588>	C45678|C28394	Thimerfonate Sodium|THIMERFONATE SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152589>	C29696	Thiocolchicoside|THIOCOLCHICOSIDE				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15258>	C15306	Immunization|immunization	Inoculating an individual with either killed or live agents to prevent contraction of a disease.			Therapeutic or Preventive Procedure	NICHD Terminology|Pediatric Immunization Terminology
C152590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152590>	C740|C29710	Thiopropazate|THIOPROPAZATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152591>	C45678|C28394	Thiosalan|THIOSALAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152592>	C47795	Thozalinone|THOZALINONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152593>	C308	Thymoctonan|THYMOCTONAN				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152594>	C29703|C1553	Thyropropic Acid|THYROPROPIC ACID				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152595>	C2124|C1553	Thyroxine I-125|THYROXINE I-125				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152596>	C2124|C1553	Thyroxine I-131|THYROXINE I-131				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152597>	C29703	Tiadenol|TIADENOL				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152598>	C98150	Tiafibrate|TIAFIBRATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152599>	C28197|C265	Tianeptine|TIANEPTINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C15259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15259>	C15258	Passive Immunization|Adoptive Transfer	The conference of active humoral immunity from one individual to another via the transfer of formed antibodies.			Therapeutic or Preventive Procedure	
C1525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1525>	C94726	RG 12915|RG-12915|RG-12915|RG12915	A 5-hydroxytryptamine-3 (5-HT3) receptor antagonist with antiemetic activity. RG 12915 binds to and antagonizes the action of serotonin on the 5-HT-3 receptor located on vagal afferents in the chemoreceptor trigger zone (CTZ), resulting in suppression of chemotherapy-induced nausea and vomiting.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C152600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152600>	C333	Tiapamil|TIAPAMIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152601>	C333	Tiapamil Hydrochloride|TIAPAMIL HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152602>	C66883	Tiapride|TIAPRIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152603>	C319	Tiaramide|TIARAMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152604>	C319	Tiaramide Hydrochloride|TIARAMIDE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152605>	C78274	Tiazotic Acid|TIAZOTIC ACID				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152606>	C29703	Tibric Acid|TIBRIC ACID				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152607>	C45678|C28394	Tibrofan|TIBROFAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152608>	C20401	Tibulizumab|TIBULIZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152609>	C521	Ticabesone|TICABESONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15260>	C18020|C16723	Immunodiagnostic Procedure|Immunodiagnosis|Immunodiagnostics|Immunological Diagnostic Method	Method used to identify disease using laboratory techniques involving interaction of antigens with specific antibodies.			Laboratory Procedure	
C152610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152610>	C521	Ticabesone Propionate|TICABESONE PROPIONATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152611>	C1558	Ticarcillin Cresyl Sodium|TICARCILLIN CRESYL SODIUM				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152612>	C514	Ticlatone|TICLATONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152613>	C921|C49184	Ticrynafen|TICRYNAFEN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152614>	C263	Tifacogin|TIFACOGIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152615>	C257	Tiflamizole|TIFLAMIZOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152616>	C98234	Tiformin|TIFORMIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152617>	C157400	Tifuvirtide|TIFUVIRTIDE				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152618>	C1742	Tigapotide Triflutate|TIGAPOTIDE TRIFLUTATE				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152619>	C260	Tigemonam|TIGEMONAM				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15261>	C116540	Immunosuppressive Therapy|Anti-Rejection Therapy|Immunosuppression|immunosuppression|immunosuppressive therapy	Immunomodulation therapy designed to reduce the body's immune response.	Immunosuppressive Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C152620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152620>	C260	Tigemonam Dicholine|TIGEMONAM DICHOLINE				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152621>	C776	Tigestol|19-Nor-17alpha-pregn-5(10)-en-20-yn-17-ol|19-Norpregn-5(10)-en-20-yn-17-ol, (17alpha)-|TIGESTOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152622>	C177298	Tigilanol Tiglate|EBC-46|EBI-46|TIGILANOL TIGLATE	A short-chain diterpene ester isolated from the seed of Fontainea picrosperma, with potential antineoplastic activity. Upon intratumoral administration, tigilanol tiglate disrupts mitochondrial functioning and induces mitochondrial swelling, which leads to oncolysis of tumor cells that are in direct contact of the agent. In addition, tigilanol tiglate activates protein kinase C (PKC) signaling cascade, which leads to an acute inflammatory response. This results in hypoxia and activates innate immune cells including neutrophils and macrophages, thereby further killing tumor cells. The activation of the beta-II isoform of PKC (PKC beta II ) also increases tumor vasculature permeability, which leads to the destruction of tumor vasculature.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C152623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152623>	C29704	Tigloidine|TIGLOIDINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152624>	C276	Tigolaner|TIGOLANER				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152625>	C29710	Tilapertin|TILAPERTIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152626>	C261	Tildipirosin|TILDIPIROSIN				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152627>	C20401	Tildrakizumab|Immunoglobulin G1, Anti-(Human Interleukin 23) (Human-Mus Musculus Monoclonal Heavy Chain), Disulfide with Human-Mus Musculus Monoclonal Light Chain, Dimer|Immunoglobulin G1, Anti-(Human Interleukin-23); Humanized Mouse Monoclonal Gamma1 Heavy Chain (219-214')-Disulfide with Humanized Mouse Monoclonal Kappa Light Chain Dimer (225-225'':228-228'')-Bisdisulfide|MK-3222|TILDRAKIZUMAB	A humanized monoclonal antibody directed against the p19 protein subunit of interleukin-23 (IL-23), with immunomodulating activity. Upon subcutaneous administration, tildrakizumab targets and binds to the p19 subunit of IL-23, thereby neutralizing IL-23 and preventing the binding of IL-23 to its receptor. This inhibits IL-23-mediated signaling and inhibits differentiation of CD4 positive T-cells into Th1 and Th17 cells. This prevents Th1- and Th17-mediated responses and cytokine production. This may prevent or reduce symptoms and severity of graft versus host disease (GVHD). IL-23, a pro-inflammatory cytokine that play a key role in the regulation of the immune system, is upregulated in immune-mediated inflammatory disorders. Both Th1 and Th17 cells play a crucial role in GVHD.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C152628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152628>	C67413|C241	Tilidine|TILIDINE	A synthetic opioid and a prodrug form of nortilidine, that can be used to treat moderate to severe acute and chronic pain. Upon administration, tilidine is metabolized to its active metabolite nortilidine, which crosses the blood-brain barrier (BBB), and binds to and activates the mu-opioid receptor. This induces anti-nociception responses mediated through inhibiting the release of various neurotransmitters such as substance P, gamma-aminobutyric acid (GABA), dopamine, acetylcholine, noradrenaline, vasopressin, and somatostatin.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152629>	C67413|C241	Tilidine Hydrochloride|TILIDINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15262>	C15187	Immunotherapy|IMMUNOTHERAPY|Immunological|Immunological Therapy|Immunologically Directed Therapy|immunotherapy	Therapy designed to induce changes in a patient's immune status in order to treat disease.	Immunotherapy		Therapeutic or Preventive Procedure	ALL Authorized Value Terminology|ALL Non-protocol Therapy Table|AML Authorized Value Terminology|AML Survival Characteristics Table|CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Codelists Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Medical History Form|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|HL Adverse Events Table|HL Authorized Value Terminology|HL Biopsy/Surgical Procedures Table|HL Concomitant Medication Table|HL Course Timing Table|HL Function Test Table|HL Histology Table|HL Imaging Table|HL Immunohistochemistry Table|HL Lab Table|HL Lesion Characteristics Table|HL Non-protocol Therapy Table|HL Off Protocol Therapy/Study Table|HL Protocol Treatment Modifications Table|HL Radiation Therapy Table|HL Secondary Malignant Neoplasm Table|HL Staging Table|HL Stem Cell Transplant Table|HL Subject Response Table|HL Survival Characteristics Table|HL Total Dose Table|HL Transfusion Medicine Procedures Table|HL Vitals Table|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C152630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152630>	C744	Tilivapram|TILIVAPRAM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152631>	C129820	Tilomisole|TILOMISOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152632>	C177175	Tilsotolimod|TILSOTOLIMOD	A proprietary synthetic oligonucleotide-based agonist of toll-like receptor 9 (TLR9), with potential immunostimulating activity. Upon administration, tilsotolimod binds to and activates TLR9 expressed by plasmacytoid dendritic cells (pDCs) and B-cells. This initiates immune signaling pathways, activates B-cells and pDCs, and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.	Tilsotolimod		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152633>	C574|C177182	Timapiprant|TIMAPIPRANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152634>	C29703	Timefurone|TIMEFURONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152635>	C20401|C129822	Timigutuzumab|TIMIGUTUZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152636>	C521	Timobesone|TIMOBESONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152637>	C280	Tiocarlide|TIOCARLIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152638>	C28394	Tiodonium Chloride|TIODONIUM CHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152639>	C66884	Tiomergine|TIOMERGINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15263>	C27993	In Vitro|in vitro	In the laboratory; literally, "in glass".			Functional Concept	
C152640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152640>	C29710	Tioperidone|TIOPERIDONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152641>	C29710	Tioperidone Hydrochloride|TIOPERIDONE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152642>	C257	Tiopinac|TIOPINAC				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152643>	C29702	Tiotidine|TIOTIDINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152644>	C270	Tipentosin|TIPENTOSIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152645>	C270	Tipentosin Hydrochloride|TIPENTOSIN HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152646>	C129825	Tipiracil|TIPIRACIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology
C152647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152647>	C129825	Tipiracil Hydrochloride|TIPIRACIL HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology
C152648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152648>	C308	Tiplimotide|TIPLIMOTIDE				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152649>	C521	Tipredane|TIPREDANE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15264>	C15820|C15447	Infant Nutrition Research|Lactation / Infant Nutrition	Nutritional studies with a focus on the specific nutritional needs of children under the age of 2.			Organism Function	
C152650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152650>	C214840	Tiprelestat|TIPRELESTAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152651>	C29576	Tiprenolol|TIPRENOLOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152652>	C29576	Tiprenolol Hydrochloride|TIPRENOLOL HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152653>	C308	Tiprinast|TIPRINAST				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152654>	C78568	Tiprostanide|TIPROSTANIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152655>	C823|C29703	Tiqueside|TIQUESIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152657>	C78272	Tirasemtiv|TIRASEMTIV				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152658>	C211	Tirilazad|TIRILAZAD				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152659>	C211	Tirilazad Mesylate|TIRILAZAD MESYLATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15265>	C191377|C15334	Kidney Transplantation|Kidney Grafting|Kidney Transplant|Kidney Transplant|Renal Transplantation	The transfer of a healthy kidney from a donor to a patient for the purpose of replacing one of the failing kidneys of the patient.	Kidney Transplantation		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology
C152660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152660>	C29698	Tiropramide|TIROPRAMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152662>	C797	Tisocromide|TISOCROMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152663>	C45678	Tisoquone|TISOQUONE				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152664>	C20401	Tisotumab|TISOTUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152665>	C201688	Tivanisiran|TIVANISIRAN				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152666>	C93259	Tivozanib Hydrochloride|Fotivda|TIVOZANIB HYDROCHLORIDE|Tivozanib Hydrochloride Hydrate|Tivozanib Monohydrochloride Monohydrate	The hydrochloride salt of tivozanib, an orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death. VEGFR tyrosine kinases, frequently overexpressed by a variety of tumor cell types, play a key role in angiogenesis.	Tivozanib Hydrochloride		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C152667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152667>	C211	Tixocortol|TIXOCORTOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152668>	C211	Tixocortol Pivalate|TIXOCORTOL PIVALATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152669>	C263	Tizabrin|TIZABRIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15266>	C16120	Laparotomy|laparotomy	Creation of a surgical opening into the abdominal cavity.	Laparotomy		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C152670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152670>	C744|C29707	Toborinone|TOBORINONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152671>	C66913	Tocamphyl|TOCAMPHYL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152672>	C942	Tocofenoxate|TOCOFENOXATE				Pharmacologic Substance|Vitamin	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152673>	C98150	Tocofibrate|TOCOFIBRATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152674>	C241	Tofetridine|TOFETRIDINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152675>	C98083	Tofogliflozin|TOFOGLIFLOZIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152676>	C98083	Tofogliflozin Anhydrous|TOFOGLIFLOZIN ANHYDROUS				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152677>	C744	Tolafentrine|TOLAFENTRINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152678>	C29576	Tolamolol|TOLAMOLOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152679>	C514	Tolciclate|TOLCICLATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15267>	C15454	Laryngectomy|laryngectomy	Surgery to remove part or all of the larynx.			Therapeutic or Preventive Procedure	
C152680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152680>	C78276	Toldimfos|TOLDIMFOS				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152681>	C82130	Tolevamer|TOLEVAMER				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152682>	C82130	Tolevamer Potassium Sodium|TOLEVAMER POTASSIUM SODIUM				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152683>	C29711	Tolimidone|TOLIMIDONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152684>	C29707|C270	Tolmesoxide|TOLMESOXIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152685>	C270	Tolnapersine|TOLNAPERSINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152686>	C45678|C28394	Toloconium Metilsulfate|TOLOCONIUM METILSULFATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152687>	C29756	Toloxychlorinol|TOLOXYCHLORINOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152688>	C241	Tolpadol|TOLPADOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152689>	C265	Tolquinzole|TOLQUINZOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15268>	C64982|C49165|C15466	Laser Surgery|Clinical, Surgery, Laser|Conventional Laser Therapy|Laser|laser surgery	A type of operation using the cutting powers of laser beams from various sources. The use of a laser either to vaporize surface lesions or to make bloodless cuts in tissue.	Laser Surgery		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C152690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152690>	C281	Tomeglovir|TOMEGLOVIR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152691>	C257	Tomicorat|TOMICORAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152692>	C133878	Tomuzotuximab|TOMUZOTUXIMAB	A glycoengineered second-generation antibody of cetuximab with potential antineoplastic activities. Upon intravenous administration, tomuzotuximab selectively binds to the extracellular domain of the epidermal growth factor receptor (EGFR), thereby preventing the activation and subsequent dimerization of the receptor. This may prevent EGFR-mediated signaling and inhibit EGFR-dependent tumor cell proliferation.  Further, tomuzotuximab has a fully human glycosylation pattern and is glyco-optimized at its Fc domain to promote antibody-dependent cell-mediated cytotoxicity (ADCC). EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surfaces of certain tumor types.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C152693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152693>	C52588	Tonabacase|TONABACASE				Amino Acid, Peptide, or Protein|Enzyme|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152694>	C62712	Tonogenchoncel-L|TONOGENCHONCEL-L				Cell|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152695>	C29704|C29701	Toquizine|TOQUIZINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152696>	C20401	Toralizumab|TORALIZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152697>	C78275	Torapsel|TORAPSEL				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152698>	C29708	Toreforant|TOREFORANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152699>	C29708	Toreforant Tartrate|TOREFORANT TARTRATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15269>	C15191	Leukapheresis|LEUKAPHERESIS|Leukocyte Adsorptive Apheresis|Leukocytopheresis|Leukocytopheresis|Therapeutic Leukopheresis|White Blood Cell Reduction Apheresis|leukapheresis	A procedure that collects white blood cells from the peripheral blood while returning the rest to the donor.	Leukapheresis		Therapeutic or Preventive Procedure	CDISC SDTM Specimen Collection Method Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C1526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1526>	C67437|C1490	Docetaxel|DOCETAXEL|Docecad|N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol|RP 56976|RP-56976|RP56976|Taxotere|Taxotere|Taxotere|Taxotere Injection Concentrate|[2aR-[2a alphaa,4beta,4a beta,6beta,9alpha,(alphaR*,betaS*),-11alpha,12alpha,12a alpha,12b alpha]]-beta-[[(1,1-dimethylethoxy)carbonyl]-amino]-alpha-hydroxybenzemepropanoic Acid 12b-(Acetyloxy)-12(benzyloxy)-2a,3,4,4a,5,6,8,10,11,12,12a,12b-dodecahydeo-4,-6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester|docetaxel	A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)	Docetaxel		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology|OS Authorized Value Terminology|OS Total Dose Table
C152700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152700>	C212	Tosactide|TOSACTIDE				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152701>	C52588|C20401	Tosatoxumab|TOSATOXUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152702>	C78274	Tosifen|TOSIFEN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152703>	C2459|C210737	Totrombopag|LGD-4665|TOTROMBOPAG|TPO Mimetic LGD-4665|Thrombopoietin Receptor Agonist LGD-4665	An orally available small molecule agonist of the platelet thrombopoietin (TPO) receptor (TPOR; MPL), with potential megakaryopoiesis stimulating activity. Upon administration, totrombopag mimics TPO and binds to TPOR. This stimulates TPOR and leads to the proliferation and differentiation of megakaryocytes in the bone marrow. This increases the production of blood platelets and decreases bleeding in thrombocytopenic patients. TPOR is a cytokine receptor and member of the hematopoietin receptor superfamily.	Totrombopag		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C152704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152704>	C38149	Tozadenant|TOZADENANT		Tozadenant		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152705>	C29707|C29705	Trabodenoson|TRABODENOSON				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152706>	C28197|C264	Tracazolate|TRACAZOLATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152707>	C267|C211679	Tradipitant|LY-686017|LY686017|TRADIPITANT|VLY-686	An orally bioavailable, centrally-acting, selective, neurokinin 1 receptor (NK1-receptor; NK1R; NK-1R) antagonist with potential anti-emetic, anti-pruritic and anti-inflammatory activities. Upon oral administration, tradipitant competitively binds to and blocks the activity of the NK1R in the central nervous system (CNS), thereby inhibiting the binding of the endogenous ligand and neuropeptide, substance P (SP; neurokinin-1; NK1). This inhibits SP/NK1-mediated signal transduction and may prevent both SP-induced emesis and pruritis. In addition, inhibition of SP/NK1R signaling also reduces neurogenic inflammation which is triggered by the release of neuropeptides, such as substance P, from nerve cells. NK1R is a G protein-coupled receptor (GPCR) that preferentially binds to SP, a neuropeptide secreted by neuronal cells and inflammatory cells.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C152708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152708>	C496	Trafermin|TRAFERMIN				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152709>	C29726	Tralesinidase Alfa|TRALESINIDASE ALFA				Amino Acid, Peptide, or Protein|Enzyme|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15270>	C49165	Ligation|Closure by Ligation|ligation	The process of tying off vessels.			Therapeutic or Preventive Procedure	
C152710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152710>	C20401	Tralokinumab|TRALOKINUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152711>	C69145|C129825	Trametinib Dimethyl Sulfoxide|Mekinist|Meqsel|Spexotras|TRAMETINIB DIMETHYL SULFOXIDE	A dimethyl sulfoxide (DMSO) solvated form of trametinib, an orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration, trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity serine/threonine and tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.	Trametinib Dimethyl Sulfoxide		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C152712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152712>	C574	Tranilast|TRANILAST				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152713>	C68303	Transcrocetin|TRANSCROCETIN|Transcrocetinate				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152714>	C575	Transferrin Aldifitox|Diphtheria Toxin CRM107 (Corynebacterium Diphtheriae Precursor) Conjugate With Transferrin (Human)|HN-66000|TRANSFERRIN ALDIFITOX|Tf-CRM107|Transferrin-CRM107|transferrin-CRM107	A synthetic targeted protein toxin which consists of human transferrin (Tf) conjugated to a diphtheria toxin that contains a point mutation (CRM107). After binding to the transferrin receptor expressed on the tumor cell surface, transferrin-CRM107 is internalized, where the diphtheria toxin moiety exerts its cytotoxic effect intracellularly by inhibiting protein synthesis through ADP-ribosylation of elongation factor. (NCI04)			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology
C152715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152715>	C29701	Trantelinium Bromide|TRANTELINIUM BROMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152717>	C29710	Trebenzomine|TREBENZOMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152718>	C29710	Trebenzomine Hydrochloride|TREBENZOMINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152719>	C2165|C1660	Trecovirsen Sodium|TRECOVIRSEN SODIUM				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15271>	C217456|C191377	Liver Transplantation|Hepatic Transplantation|Liver Grafting|Liver Transplant|Liver Transplant|Transplantation of Liver	The transfer of a healthy liver allograft from a donor to a patient.	Liver Transplantation		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology
C152720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152720>	C67413|C241	Trefentanil|TREFENTANIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152721>	C67413|C241	Trefentanil Hydrochloride|TREFENTANIL HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152722>	C20401	Tregalizumab|TREGALIZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152723>	C98086	Trelagliptin|TRELAGLIPTIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152724>	C98086	Trelagliptin Succinate|TRELAGLIPTIN SUCCINATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152725>	C281	Tremacamra|TREMACAMRA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152726>	C1752|C1663	Trempamotide|TREMPAMOTIDE				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152727>	C78311	Trenonacog Alfa|TRENONACOG ALFA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152728>	C66884	Trepipam|TREPIPAM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152729>	C66884	Trepipam Maleate|TREPIPAM MALEATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15272>	C158758	Lobectomy|LOBECTOMY|lobectomy	Surgical removal of a lobe of an organ.	Lobectomy		Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table
C152730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152730>	C78568|C29707	Treprostinil Diolamine|TREPROSTINIL DIOLAMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152731>	C744	Trequinsin|TREQUINSIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152732>	C492	Trethocanoic Acid|TRETHOCANOIC ACID				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152733>	C20401	Trevogrumab|TREVOGRUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152734>	C521	Triamcinolone Acetonide Sodium Phosphate|CL-106359|CL-61965|Pregna-1,4-diene-3,20-dione, 9-Fluoro-11-hydroxy-16,17-((1-methylethylidene)bis(oxy))-21-(phosphonooxy)-, Disodium Salt, (11beta,16alpha)-|TRIAMCINOLONE ACETONIDE SODIUM PHOSPHATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152735>	C123418	Tribenoside|TRIBENOSIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152736>	C28394	Triclobisonium Chloride|TRICLOBISONIUM CHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152737>	C250	Triclofenol Piperazine|TRICLOFENOL PIPERAZINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152738>	C212	Tricosactide|TRICOSACTIDE				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152739>	C29701	Tricyclamol Chloride|TRICYCLAMOL CHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15273>	C70821	Longitudinal Study|PROSPECTIVE|longitudinal study|longitudinal study|prospective	A study in which participants are followed and repeatedly evaluated over a period of time.			Research Activity	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|CDISC SDTM Observational Study Time Perspective Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|SeroNet Authorized Values|SeroNet Study Descriptors
C152740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152740>	C212	Tridecactide|ACTH (1-13)|EK-12|TRIDECACTIDE|alpha-1-13-Corticotropin, HumanL-seryl-L-tyrosyl-L-seryl-L-methionyl-L-glutamyl-L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophylglycyl-L-lysyl-L-prolyl-L-valine|alpha-Corticotropin 1-13|alpha1-13-Corticotropin	A synthetic 13-amino acid peptide analogue of the naturally occurring alpha-melanocyte stimulating hormone (a-MSH) and derived from proteolytic cleavage of adrenocorticotropic hormone (ACTH), with potential analgesia, antipyretic, antioxidative, cytoprotective, anti-inflammatory and immunomodulating activities. Upon administration, tridecactide mimics the action of a-MSH, binds to melanocortin receptors (MC-Rs) and stimulates melanocytes to increase the production and release of melanin. In addition, tridecactide's anti-inflammatory effects are through the activation of MC-Rs that are expressed in a number of tissues, such as peripheral immune cells and hypothalamic neurons, and affects various pathways regulating inflammatory responses. Specifically, tridecactide inhibits the activation of nuclear factor-kappa B (NF-κB), inhibits the expression of pro-inflammatory cytokines and adhesion molecule expression, prevents T-cell proliferation and inflammatory cell migration. This agent may also suppress pro-inflammatory non-cytokine regulators such as nitric oxide (NO), prostaglandin E (PGE), and reactive oxygen species (ROS), and induces the expression of interleukin (IL) 10.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C152741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152741>	C29704	Tridihexethyl Iodide|TRIDIHEXETHYL IODIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152742>	C2119|C2080	Tridolgosir|TRIDOLGOSIR				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152743>	C29756|C28197	Triflubazam|TRIFLUBAZAM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152744>	C29701	Triletide|TRILETIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152745>	C66880	Trimedoxime Bromide|TRIMEDOXIME BROMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152746>	C776|C389	Trimegestone|TRIMEGESTONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152747>	C29707|C270	Trimethidinium Methosulfate|TRIMETHIDINIUM METHOSULFATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152748>	C78568|C29701	Trimoprostil|TRIMOPROSTIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152749>	C270	Trimoxamine|TRIMOXAMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15274>	C191377|C15655	Lung Transplantation|Lung Transplant|lung grafting	The surgical transfer of one or both lungs from one individual to another.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C152750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152750>	C270	Trimoxamine Hydrochloride|TRIMOXAMINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152751>	C448	Tripamide|TRIPAMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152752>	C29703	Triparanol|TRIPARANOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152753>	C29707|C29698	Trixolane|TRIXOLANE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152754>	C265	Trizoxime|TRIZOXIME				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152755>	C265	Trocimine|TROCIMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152756>	C28394	Troclosene Potassium|TROCLOSENE POTASSIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152757>	C78272	Trofinetide|TROFINETIDE				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152758>	C1937	Trofolastat|TROFOLASTAT				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152759>	C29707	Trolnitrate|TROLNITRATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15275>	C49163|C15227	Lymphadenectomy|LYMPHADENECTOMY|Lymph Node Dissection|Lymph Node Dissection|Lymph Node Dissection|Lymph Node Dissection|Lymph Node Dissection|Lymph Node Excision|excision of the lymph node|lymph node dissection|lymph node excision|lymphadenectomy	Surgical removal of lymph nodes, usually done to assess the spread of cancer.	Lymphadenectomy		Health Care Activity	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C152760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152760>	C29756	Tropabazate|TROPABAZATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152761>	C29710	Tropapride|TROPAPRIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152762>	C38149|C29698	Tropatepine|TROPATEPINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152763>	C66880|C29698	Tropenziline Bromide|TROPENZILINE BROMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152764>	C212879|C2081	Tropifexor|TROPIFEXOR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152765>	C66880|C38149	Tropigline|TROPIGLINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152766>	C66880	Tropirine|TROPIRINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152767>	C29750	Troplasminogen Alfa|TROPLASMINOGEN ALFA				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152768>	C29713	Tropodifene|TROPODIFENE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152769>	C2363	Trospectomycin|TROSPECTOMYCIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15276>	C15908	Massage Therapy|Massage|massage therapy	A therapeutic method of manipulation, methodical pressure, friction, and kneading of the body. (from Taber's)	Massage Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C152770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152770>	C2363	Trospectomycin Sulfate|TROSPECTOMYCIN SULFATE|Trospectinomycin|U-63366				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152771>	C29701	Troxipide|TROXIPIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152772>	C390	Troxolamide|TROXOLAMIDE				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152773>	C270	Troxonium Tosilate|TROXONIUM TOSILATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152774>	C66880|C270	Troxypyrrolium Tosilate|TROXYPYRROLIUM TOSILATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152775>	C66886	Truxicurium Iodide|TRUXICURIUM IODIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152776>	C66886	Truxipicurium Iodide|TRUXIPICURIUM IODIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152777>	C29747	Tuaminoheptane|TUAMINOHEPTANE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152778>	C25974	Tubulozole|TUBULOZOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152779>	C25974	Tubulozole Hydrochloride|TUBULOZOLE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15277>	C157802|C15774	Mastectomy|Mammectomy|mastectomy	Surgical removal of the breast.	Mastectomy		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology
C152780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152780>	C78275	Tucaresol|TUCARESOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152781>	C261	Tulathromycin|TULATHROMYCIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152782>	C308|C208255	Tulinercept|TULINERCEPT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152783>	C48149|C319	Tulobuterol|TULOBUTEROL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152784>	C265|C1509	Tulrampator|TULRAMPATOR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152785>	C81123	Turoctocog Alfa|TUROCTOCOG ALFA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152786>	C81123	Turoctocog Alfa Pegol|TUROCTOCOG ALFA PEGOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152787>	C261	Tylvalosin|TYLVALOSIN				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152788>	C261	Tylvalosin Tartrate|TYLVALOSIN TARTRATE				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152789>	C258	Tyrothricin|TYROTHRICIN				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15278>	C15277	Modified Radical Mastectomy|MODIFIED RADICAL MASTECTOMY|Modified Mastectomy|modified radical mastectomy	The surgical removal of one or both breasts, including the areola, nipple, and the majority of the axillary lymph nodes, but sparing the pectoralis major muscle.	Modified Radical Mastectomy		Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C152790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152790>	C212891	Ubrogepant|MK-1602|UBROGEPANT|Ubrelvy|Ubrelvy	An orally bioavailable calcitonin gene-related peptide (CGRP) receptor antagonist that can be used in the acute treatment of migraines. Upon oral administration, ubrogepant targets, binds to and blocks the activity of CGRP receptor. This prevents CGRP-mediated signaling. By blocking the CGRP-mediated pathways, ubrogepant is able to ease migraine symptoms, especially migraine headache pain. CGRP-mediated signaling plays a key role in migraine pathogenesis.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152791>	C257	Ufenamate|UFENAMATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152792>	C84868	Ulimorelin|ULIMORELIN				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152793>	C2151	Ulodesine|ULODESINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152794>	C2151	Ulodesine Succinate|ULODESINE SUCCINATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152795>	C2152|C129825	Umbralisib Tosylate|UMBRALISIB TOSYLATE|Ukoniq	The tosylate form of umbralisib, an orally bioavailable, selective inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinases (PI3K) with potential antineoplastic activity.  umbralisib inhibits PI3K and prevents the activation of the PI3K/AKT kinase signaling pathway. This decreases proliferation and induces cell death in susceptible tumor cells.  Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in tumor cells and cells of the hematopoietic lineage. The targeted inhibition of PI3K-delta allows for PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.	Umbralisib Tosylate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C152796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152796>	C29704	Umeclidinium|UMECLIDINIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152797>	C29704	Umeclidinium Bromide|GSK 573719A|GSK-573719A|GSK573719A|Incruse|UMECLIDINIUM BROMIDE	The bromide salt form of umeclidinium, a muscarinic receptor antagonist, with bronchodilator activity. Although it does not display selectivity for specific muscarinic receptors, on topical application, umeclidinium acts mainly on M3 muscarinic receptors located on smooth muscle cells, thereby preventing smooth muscle contraction and resulting in bronchodilatory effect.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C152798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152798>	C29710|C28197	Umespirone|UMESPIRONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152799>	C281	Umifenovir|Arbidol|UMIFENOVIR	An orally bioavailable indole derivative, with broad-spectrum antiviral and potential anti-inflammatory activities. Upon oral administration, umifenovir inhibits the fusion of the viral envelope with host cell membrane, thereby blocking the entry of virus into host cells and preventing viral infection and replication. Umifenovir may also suppress the expression of the cytokines interleukin-1beta (IL-1b), IL-6, IL-12 and tumor necrosis factor-alpha (TNF-a) and promote the expression of IL-10. This may reduce inflammation.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C15279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15279>	C15277	Radical Mastectomy|Halsted Radical Mastectomy|Halsted radical mastectomy|RADICAL MASTECTOMY|radical mastectomy	The surgical removal of one or both breasts, including the areola, nipple, axillary lymph nodes, and pectoral muscles.	Radical Mastectomy		Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C1527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1527>	C2018	Letrozole|4,4'-(1H-1,2,4triazol-1-ylmethylene)dibenzonitrile|CGS 20267|CGS-20267|CGS20267|Femara|Femara|Femara|Fempro|LETROZOLE|letrozole	A nonsteroidal inhibitor of estrogen synthesis with antineoplastic activity. As a third-generation aromatase inhibitor, letrozole selectively and reversibly inhibits aromatase, which may result in growth inhibition of estrogen-dependent breast cancer cells. Aromatase, a cytochrome P-450 enzyme localized to the endoplasmic reticulum of the cell and found in many tissues including those of the premenopausal ovary, liver, and breast, catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.	Letrozole		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C152800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152800>	C574|C2201	Umirolimus|UMIROLIMUS				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152801>	C514	Undecanoic Acid|UNDECANOIC ACID				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152802>	C1967	Upadacitinib|UPADACITINIB				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152803>	C1967	Upadacitinib Tartrate|UPADACITINIB TARTRATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152804>	C1937	Upenazime|UPENAZIME				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152805>	C217652	Uprifosbuvir|UPRIFOSBUVIR				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152806>	C29713|C270	Urapidil|URAPIDIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152807>	C66913	Ursulcholic Acid|URSULCHOLIC ACID				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152808>	C20401	Urtoxazumab|URTOXAZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152809>	C29728|C29711	Usistapide|USISTAPIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15280>	C157802|C15774	Breast Conservation Treatment|BCS|BCT|Breast Conserving Surgery/Lumpectomy|Breast-Conserving Surgery|breast-conserving surgery|breast-sparing surgery	Breast conservation treatment is defined as excision of the primary tumor and adjacent breast tissue, followed by radiation therapy.  This procedure is also referred to as lumpectomy, segmental mastectomy, or partial mastectomy. (from Consensus Statements: Treatment of Early-stage Breast Cancer, 1990)	Breast Conservation Treatment		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology
C152810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152810>	C183118	Vaborbactam|VABORBACTAM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152811>	C210736	Vadadustat|AKB 6548|AKB-6548|AKB6548|VADADUSTAT	An orally bioavailable, hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor (HIF-PHI), with potential anti-anemic and anti-inflammatory activities. Upon administration, vadadustat binds to and inhibits HIF-PH, an enzyme responsible for the degradation of transcription factors in the HIF family under normal oxygen conditions. This prevents HIF breakdown and promotes HIF activity. Increased HIF activity leads to an increase in endogenous erythropoietin production, thereby enhancing erythropoiesis. It also reduces the expression of the peptide hormone hepcidin, improves iron availability, and boosts hemoglobin (Hb) levels. HIF regulates the expression of genes in response to reduced oxygen levels, including genes required for erythropoiesis and iron metabolism. In addition, HIF 1-alpha (HIF1A) may play a role in reducing inflammation during acute lung injury (ALI) through HIF-dependent control of glucose metabolism in the alveolar epithelium.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C152812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152812>	C20401	Vadastuximab|VADASTUXIMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152813>	C345	Valactate|VALACTATE				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152814>	C29712|C2144	Valategrast|VALATEGRAST				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152815>	C78272	Valbenazine|Ingressa|VALBENAZINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152816>	C78272	Valbenazine Ditosylate|VALBENAZINE TOSYLATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152817>	C281	Valnivudine|VALNIVUDINE				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152818>	C29756	Valnoctamide|VALNOCTAMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152819>	C78311|C213309	Valoctocogene Roxaparvovec|VALOCTOCOGENE ROXAPARVOVEC				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15281>	C15277	Total Mastectomy|Simple Mastectomy|Simple Mastectomy|simple mastectomy|total mastectomy	A surgical procedure involving the removal of the entire breast tissue, nipple and a portion of the overlying skin, while leaving the axillary contents intact.	Total Mastectomy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C152820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152820>	C217648	Valomaciclovir Stearate|VALOMACICLOVIR STEARATE				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152821>	C333	Valperinol|VALPERINOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152822>	C264	Valpromide|VALPROMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152823>	C29756	Valtrate|VALTRATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152824>	C308	Valziflocept|VALZIFLOCEPT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152825>	C521	Vamorolone|VAMOROLONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152826>	C20401	Vandortuzumab|VANDORTUZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152827>	C29633	Vangatalcite|VANGATALCITE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152828>	C217517	Vaniprevir|VANIPREVIR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152829>	C1752	Vanutide Cridificar|VANUTIDE CRIDIFICAR				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152830>	C20401	Vapaliximab|VAPALIXIMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152831>	C281	Vapendavir|VAPENDAVIR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152832>	C257	Varespladib|VARESPLADIB				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152833>	C471|C257	Varespladib Methyl|VARESPLADIB METHYL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152834>	C1822	Varfollitropin Alfa|VARFOLLITROPIN ALFA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152835>	C2496	Varisacumab|VARISACUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152836>	C1291	Varodarsen|VARODARSEN				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152837>	C333	Vatanidipine|VATANIDIPINE|Watanidipine				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152838>	C20401	Vatelizumab|VATELIZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152839>	C29713	Vatinoxan|VATINOXAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15283>	C64386	Naturopathy Therapy|Naturopathic|Naturopathic Therapy|Naturopathy|naturopathy	A system of therapy based on preventative care, and on the use of heat, water, light, air, and massage as primary therapies for disease. Some naturopaths use no medications, either pharmaceutical or herbal. Some recommend herbal remedies only. A few who are licensed to prescribe may recommend pharmaceuticals in those cases where they feel their use is warranted. (MedicineNet.com)			Therapeutic or Preventive Procedure	
C152840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152840>	C942	Vatiquinone|VATIQUINONE				Pharmacologic Substance|Vitamin	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152841>	C78311	Vatreptacog Alfa|VATREPTACOG ALFA				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152842>	C67422	Vedotin Fragment|VEDOTIN FRAGMENT				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152843>	C217517	Vedroprevir|VEDROPREVIR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152844>	C98083	Velagliflozin|VELAGLIFLOZIN				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152845>	C797|C78275	Velaresol|VELARESOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152846>	C62799	Veldoreotide|VELDOREOTIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152847>	C2141	Veledimex|Benzoic Acid, 2-Ethyl-3-methoxy-, 2-(3,5-Dimethylbenzoyl)-2-((1R)-1-(1,1-dimethylethyl)butyl)hydrazide|INXN-1001|RG-115932|VELEDIMEX	An orally bioavailable, small molecule diacylhydrazine-based activator ligand, that can be used to activate certain genes using the ecdysone receptor (EcR)-based inducible gene regulation system, the RheoSwitch Therapeutic System (RTS). Upon administration of veledimex, this agent specifically binds to the EcR located on the separately administered RTS, which includes two fusions proteins: Gal4-EcR, which contains a modified ecdysone receptor (EcR) fused with the DNA binding domain of the yeast Gal4 transcription factor, and VP16-RXR, which contains a chimeric retinoid X receptor (RXR) fused with the transcription activation domain of the viral protein VP16 of herpes simplex virus type 1 (HSV1). The fusion proteins form inactive, unstable and unproductive heterodimers in the absence of veledimex. In the presence of veledimex, the protein heterodimer changes to a stable conformation, forming an active transcription factor complex, which can bind to the inducible promoter, thereby allowing the induction of controlled transcription of the target gene.	Veledimex		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C152848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152848>	C78274	Veliflapon|VELIFLAPON				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152849>	C29726	Velmanase Alfa|VELMANASE ALFA				Amino Acid, Peptide, or Protein|Enzyme|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15284>	C15334	Nephrectomy|nephrectomy	A surgical procedure to completely or partially remove a kidney. With a complete nephrectomy, the attached adrenal gland, perinephric fat, and regional lymph nodes are often removed as well. With a partial nephrectomy, the removed tissue contains the tumor and a rim of normal renal parenchyma only.	Nephrectomy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C152850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152850>	C29728	Velneperit|VELNEPERIT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152851>	C217549	Velpatasvir|GS 5816|GS-5816|GS5816|VELPATASVIR	An orally available inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex, with potential activity against HCV genotypes 1-6. Although the exact mechanism of action of velpatasvir has not yet been completely determined, upon oral administration and intracellular uptake, it appears to bind to domain I of the NS5A protein. This inhibits the activity of the NS5A protein and results in the disruption of the viral RNA replication complex, blockage of viral HCV RNA production, and inhibition of viral replication. NS5A, a zinc-binding and proline-rich hydrophilic phosphoprotein, plays a crucial role in HCV RNA replication. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family.	Velpatasvir		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C152852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152852>	C210976	Venglustat|VENGLUSTAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152853>	C29702	Venritidine|VENRITIDINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152854>	C20401	Vepalimomab|VEPALIMOMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152855>	C241	Veradoline|VERADOLINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152856>	C241	Veradoline Hydrochloride|VERADOLINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152857>	C66883	Veralipride|VERALIPRIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152858>	C63817	Vercirnon|VERCIRNON				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152859>	C63817	Vercirnon Sodium|VERCIRNON SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15285>	C15429	Nursing Research	Clinical research carried out by nurses.			Research Activity	
C152860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152860>	C281	Verdinexor|VERDINEXOR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152861>	C471|C1509	Verdiperstat|VERDIPERSTAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152862>	C210759	Vericiguat|BAY-1021189|MK-1242|VERICIGUAT|Verquvo	An orally bioavailable stimulator of soluble guanylate cyclase (sGC), with vasodilating activity.  Upon oral administration, vericiguat directly stimulates the catalytic activity of sGC and increases the formation of the intracellular second messenger cyclic guanosine monophosphate (cGMP), which is derived from guanosine triphosphate (GTP). This results in smooth muscle relaxation and vasodilation. sGC, a heme-containing cytoplasmic signaling enzyme, catalyzes the formation of cGMP from GTP in response to nitric oxide (NO) binding to heme. Vericiguat stimulates sGC independently of and synergistically with NO.	Vericiguat		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C152863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152863>	C921	Verinurad|VERINURAD				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152864>	C93038|C47793	Vernakalant|VERNAKALANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152865>	C93038|C47793	Vernakalant Hydrochloride|VERNAKALANT HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152866>	C29705|C1404	Verosudil|VEROSUDIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152867>	C29705|C1404	Verosudil Hydrochloride|VEROSUDIL HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152868>	C210975	Verubecestat|VERUBECESTAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152869>	C2355	Verucerfont|VERUCERFONT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15286>	C16205	Nutritional Assessment|Dietary Assessment|dietary counseling|nutritional counseling	An in-depth evaluation of an individual's food and nutrient intake, lifestyle, and medical history designed to help the individual either maintain their health status or attain a healthier status.	Nutritional Assessment		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C152870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152870>	C281|C2139	Vesatolimod|VESATOLIMOD				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152871>	C29726	Vestronidase Alfa|VESTRONIDASE ALFA				Amino Acid, Peptide, or Protein|Enzyme|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152872>	C48149	Vibegron|Gemtesa|Gemtesa|VIBEGRON	An orally bioavailable agonist of the human beta-3 adrenergic receptor (ADRB3), with muscle relaxing activity. Upon oral administration, vibegron targets, binds to and activates ADRB3, which leads to relaxation of the detrusor smooth muscle during bladder filling. This increases bladder capacity and provides symptomatic relief, including urge urinary incontinence, urgency, and urinary frequency, for overactive bladder.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152873>	C574|C2169	Vidofludimus|2-(N-(3-Fluoro-3'-methoxy(1,1'-biphenyl)-4-yl)carbamoyl)cyclopent-1-ene-1-carboxylic acid|VIDOFLUDIMUS	An orally bioavailable inhibitor of dihydroorotate dehydrogenase (DHODH), with potential anti-inflammatory, immunomodulating and anti-viral activities. Upon administration, vidofludimus specifically targets, binds to and prevents the activation of DHODH. This prevents the fourth enzymatic step in de novo pyrimidine synthesis, leading to inhibition of transcriptional elongation, cell cycle arrest, and apoptosis in activated lymphocytes. DHODH inhibition also leads to metabolic stress in activated lymphocytes and inhibition of the release of proinflammatory cytokines including interleukin (IL)-17 (IL-17A and IL-17F) and interferon-gamma (IFNg), thereby reducing inflammation. In addition, DHODH inhibition may lead to host-based anti-viral activity against many viruses. DHODH, a mitochondrial enzyme that catalyzes the conversion of dihydroorotate (DHO) to orotate, is a key enzyme in pyrimidine de novo biosynthesis. Metabolically highly activated and rapidly proliferating lymphocytes and various virus infected cells require de novo synthesis to meet their needs for pyrimidines.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C152874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152874>	C574|C29712|C177182	Vidupiprant|VIDUPIPRANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152875>	C48149|C319	Vilanterol|GW 642444|GW-642444|GW642444|VILANTEROL	A long-acting beta-2 adrenergic agonist, with bronchodilator activity. Upon administration, vilanterol stimulates beta-2 adrenergic receptors in the lungs, thereby activating the enzyme adenylate cyclase that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increased cAMP concentrations relax bronchial smooth muscle, relieve bronchospasms, and reduce inflammatory cell mediator release, especially from mast cells.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C152876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152876>	C48149|C319	Vilanterol Trifenatate|VILANTEROL TRIFENATATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152877>	C265|C185721	Viloxazine|VILOXAZINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152878>	C265|C185721	Viloxazine Hydrochloride|VILOXAZINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152879>	C66917|C1506	Viminol|VIMINOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15287>	C16011	Nutritional Requirements Research	Studies on the components within food, including proteins, carbohydrates, fats, vitamins, minerals, and other factors, required to maintain a healthy body.			Functional Concept	
C152880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152880>	C932|C29707	Vinburnine|VINBURNINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152881>	C250	Vincofos|VINCOFOS				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152882>	C932|C67422	Vinepidine Sulfate|(4'S)-4'-Deoxyleurocristine Sulfate (1:1)|LY 119863|LY-119863|LY119863|VINEPIDINE SULFATE|Vincaleukoblastine, 4'-Deoxy-22-oxo-, (4'alpha)-, Sulfate (1:1) (Salt)				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152883>	C932|C67422	Vinformide|VINFORMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152884>	C932|C67422	Vinleurosine|VINLEUROSINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152885>	C932|C67422	Vinleurosine Sulfate|VINLEUROSINE SULFATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152886>	C744|C29708	Vinmegallate|VINMEGALLATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152887>	C932|C29707	Vinpocetine|VINPOCETINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152888>	C932|C67422	Vinrosidine|VINROSIDINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152889>	C932|C67422	Vinrosidine Sulfate|(4'-alpha)Vincaleukoblastine Sulfate|VINROSIDINE SULFATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15288>	C15198	Orchiectomy|Castration|Male Castration|Male Gonadectomy|Testis Removed|orchidectomy|orchiectomy	Surgical removal of one or both testicles.	Orchiectomy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C152890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152890>	C45812|C241	Vintiamol|VINTIAMOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152891>	C932|C67422	Vintriptol|VINTRIPTOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152892>	C38149|C2139	Vipadenant|VIPADENANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152893>	C78568	Viprostol|VIPROSTOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152894>	C94725|C265	Viqualine|VIQUALINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152895>	C471|C258	Viquidacin|VIQUIDACIN				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152896>	C47793|C29707	Viquidil|VIQUIDIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152897>	C514	Viridofulvin|VIRIDOFULVIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152898>	C281	Viroxime|VIROXIME				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152899>	C241	Vixotrigine|VIXOTRIGINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15289>	C64982|C49163|C15342	Organ Transplantation|Anatomical Gift|Clinical, Transplantation, Organ|Organ Donation|Organ Donation Procedure|Organ Transplants|organ grafting	The transfer of an organ, organ part, or tissue from one body to another, for the purpose of replacing the recipient's damaged or failing organ with a working one from the donor. Donors can be living, or cadaveric (dead).	Organ Transplantation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C1528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1528>	C67439|C443	Risedronate Sodium|Actonel|Monosodium (1-hydroxy-2-(3-pyridinyl)ethylidene)bisphosphonate|NE-58095|RISEDRONATE SODIUM|Risedronate|Risendronate Sodium|risedronate	The sodium salt of risedronic acid, a synthetic pyridinyl bisphosphonate. Risedronic acid binds to hydroxyapatite crystals in bone and inhibits osteoclast-dependent bone resorption.	Risedronate Sodium		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C152900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152900>	C241	Vixotrigine Hydrochloride|VIXOTRIGINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152901>	C20401	Vobarilizumab|VOBARILIZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152902>	C574	Voclosporin|VOCLOSPORIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152903>	C211679	Vofopitant Dihydrochloride|VOFOPITANT DIHYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152904>	C29703|C1291	Volanesorsen|VOLANESORSEN				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152905>	C29703|C1291	Volanesorsen Sodium|VOLANESORSEN SODIUM				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152906>	C177899	Volasertib Trihydrochloride|VOLASERTIB TRIHYDROCHLORIDE	The trihydrochloride form of volasertib, a dihydropteridinone Polo-like kinase 1 (Plk1) inhibitor, with potential antineoplastic activity. Volasertib selectively inhibits Plk1, inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152907>	C2081|C177170	Volixibat|VOLIXIBAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152908>	C2081|C177170	Volixibat Potassium|VOLIXIBAT POTASSIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152909>	C29726|C29707	Vonapanitase|VONAPANITASE				Amino Acid, Peptide, or Protein|Enzyme|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15290>	C49165	Ostomy|ostomy|surgical construction of a stoma	Surgical creation of an opening in an organ.			Therapeutic or Preventive Procedure	
C152910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152910>	C78311	Vonicog Alfa|VONICOG ALFA				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152911>	C224110|C2080	Vonoprazan|VONOPRAZAN	A potassium-competitive acid blocker (P-CAB), with acid suppressing activity. Upon oral administration, vonoprazan concentrates in the gastric parietal cells and competitively and reversibly binds to the potassium binding site of the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase), thereby inhibiting the pump's activity and the parietal cell secretion of H+ ions into the gastric lumen, the final step in gastric acid production. By inhibiting gastric acid secretion, vonoprazan provides relief and healing in the treatment of various conditions, such as gastroduodenal ulcers and reflux esophagitis.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology
C152912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152912>	C210771	Vorapaxar|VORAPAXAR	An orally bioavailable protease-activated receptor-1 (PAR-1) antagonist, with antiplatelet activity. Upon oral administration, vorapaxar binds to PAR-1 expressed on platelets, and inhibits PAR-1-mediated platelet aggregation. Vorapaxar inhibits thrombin-induced and thrombin receptor agonist peptide (TRAP)-induced platelet aggregation, and does not inhibit platelet aggregation induced by adenosine diphosphate (ADP), collagen or a thromboxane mimetic.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology
C152913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152913>	C210771	Vorapaxar Sulfate|SCH 530348|VORAPAXAR SULFATE|Zontivity	The sulfate salt form of vorapaxar, an orally bioavailable protease-activated receptor-1 (PAR-1) antagonist, with antiplatelet activity. Upon oral administration, vorapaxar binds to PAR-1 expressed on platelets, and inhibits PAR-1-mediated platelet aggregation. Vorapaxar inhibits thrombin-induced and thrombin receptor agonist peptide (TRAP)-induced platelet aggregation, and does not inhibit platelet aggregation induced by adenosine diphosphate (ADP), collagen or a thromboxane mimetic.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152914>	C137826|C129825	Vorasidenib|AG 881|AG-881|AG881|VORASIDENIB	An orally available inhibitor of mutated forms of both isocitrate dehydrogenase type 1 (IDH1, IDH1 [NADP+] soluble) in the cytoplasm and type 2 (IDH2, isocitrate dehydrogenase [NADP+], mitochondrial) in the mitochondria, with potential antineoplastic activity. Upon administration, vorasidenib specifically inhibits mutant forms of IDH1 and IDH2, thereby inhibiting the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing IDH mutations. In addition, vorasidenib is able to penetrate the blood-brain barrier (BBB). IDH1 and 2, metabolic enzymes that catalyze the conversion of isocitrate into a-KG, play key roles in energy production and are mutated in a variety of cancer cell types. In addition, mutant forms of IDH1 and 2 catalyze the formation of 2HG and drive cancer growth by blocking cellular differentiation and inducing cellular proliferation.	Vorasidenib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCIt Antineoplastic Agent Terminology
C152915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152915>	C213309	Voretigene Neparvovec|VORETIGENE NEPARVOVEC				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152916>	C192643	Vorsetuzumab|VORSETUZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152917>	C265	Vortioxetine|VORTIOXETINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152918>	C307	Vosoritide|VOSORITIDE				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152919>	C201688	Vutrisiran|ALN 65492|ALN-65492|ALN-TTRSC02 Free Acid|ALN65492|VUTRISIRAN	A N-acetylgalactosamine (GalNAc)-conjugated small-interfering RNA (siRNA) directed against transthyretin (TTR), that can be used in the treatment of TTR-mediated amyloidosis (ATTR). Upon subcutaneous administration of vutrisiran, the GalNAc moiety targets and binds with high affinity to asialoglycoprotein receptors (ASGPRs) expressed on hepatocytes. Once inside the cells, the siRNAs bind to and silence TTR mRNAs, and inhibit both the translation and expression of the TTR protein. ATTR is caused by mutations in the TTR gene and results in the formation of abnormal amyloid proteins that accumulate in and cause damage to various body organs and tissues.			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15291>	C15691|C15332|C15198	Oophorectomy|Female Castration|Ovariectomy|oophorectomy	Partial or complete removal of one or both of the ovaries.	Oophorectomy		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Procedures Codelist|CPTAC Terminology|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C152920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152920>	C308	Votucalis|VOTUCALIS				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152922>	C217517	Voxilaprevir|GS 9857|GS-9857|GS9857|VOXILAPREVIR	An orally bioavailable inhibitor of the hepatitis C virus (HCV) non-structural protein 3/non-structural protein 4A (NS3/NS4A) serine protease, with antiviral activity. Upon administration, voxilaprevir binds to the HCV NS3/NS4A serine protease and prevents NS3/NS4A protease-mediated polyprotein maturation. This disrupts both the processing of viral proteins and the formation of the viral replication complex, thereby preventing viral replication and function. NS3, a serine protease, is essential for the proteolytic cleavage of multiple sites within the HCV polyprotein and plays a key role during HCV ribonucleic acid (RNA) replication. NS4A is an activating factor for NS3. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family; HCV infection is associated with the development of hepatocellular carcinoma (HCC).	Voxilaprevir		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C152923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152923>	C29708|C20401	Vunakizumab|VUNAKIZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152924>	C1509	Xaliproden|XALIPRODEN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152925>	C78322|C48149	Xamoterol Fumarate|XAMOTEROL FUMARATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152926>	C47796	Xanomeline|XANOMELINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152927>	C47796	Xanomeline Tartrate|XANOMELINE TARTRATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152928>	C29707	Xanthinol Niacinate|XANTHINOL NIACINATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152929>	C29707	Xanthiol|XANTHIOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15292>	C15747	Palliative Therapy|Comfort Care|PA-Palliative Therapy|Palliative|Palliative|Palliative Care|Palliative Treatment|Palliative Treatment|Symptom Management|Symptoms Management|comfort care|palliation|palliative care|palliative therapy|palliative therapy|symptom management	The patient- and family-centered active holistic care of patients with advanced, progressive disease. Essential components of palliative care are: pain and symptom control, communication regarding treatment and alternatives, prognosis, and available services, rehabilitation services, care that addresses treatment and palliative concerns, intellectual, emotional, social, and spiritual needs, terminal care, support in bereavement. The goal of palliative care is an achievement of the best quality of life for patients and their families.	Palliative Therapy		Therapeutic or Preventive Procedure	AML Adverse Events Table|AML Authorized Value Terminology|AML Cellular Immunotherapy Table|AML Concomitant Medication Table|AML Course Timing Table|AML Function Test Table|AML Lab Table|AML Minimal Residual Disease Table|AML Molecular Analysis Table|AML Myeloid Sarcoma Involvement Table|AML Off Protocol Therapy/Study Table|AML Radiation Therapy Table|AML Secondary Malignant Neoplasm Table|AML Stem Cell Transplant Table|AML Subject Response Table|AML Survival Characteristics Table|AML Total Dose Table|AML Transfusion Medicine Procedures Table|AML Vitals Table|CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C152930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152930>	C101256	Xemilofiban|XEMILOFIBAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152931>	C29703	Xenalipin|XENALIPIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152932>	C258	Xibornol|XIBORNOL				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152933>	C29696	Xilobam|XILOBAM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152934>	C257	Ximoprofen|XIMOPROFEN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152935>	C241|C1506	Xorphanol|XORPHANOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152936>	C241|C1506	Xorphanol Mesylate|XORPHANOL MESYLATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152937>	C66885	Xylamidine Tosylate Anhydrous|XYLAMIDINE TOSYLATE ANHYDROUS				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152938>	C1511|C129819	Yttrium Y-90 Epratuzumab|YTTRIUM Y-90 EPRATUZUMAB				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152939>	C1511|C129819	Yttrium Y-90 Labetuzumab|YTTRIUM Y-90 LABETUZUMAB				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15293>	C191377	Pancreas Transplantation|pancreas grafting	The surgical transfer of a pancreas from one individual to another.			Therapeutic or Preventive Procedure	
C152940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152940>	C1511|C129819	Yttrium Y-90 Labetuzumab Tetraxetan|YTTRIUM Y-90 LABETUZUMAB TETRAXETAN				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152941>	C1511|C129819	Yttrium Y-90 Tacatuzumab|YTTRIUM Y-90 TACATUZUMAB				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152942>	C28197|C267	Zacopride|ZACOPRIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152943>	C28197|C267	Zacopride Hydrochloride|ZACOPRIDE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152944>	C28197|C265	Zalospirone|ZALOSPIRONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152945>	C29702	Zaltidine|ZALTIDINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152946>	C29702	Zaltidine Hydrochloride|ZALTIDINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152947>	C270|C217487	Zamicastat|ZAMICASTAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152948>	C28227|C199386|C155711	Zenocutuzumab|Anti-HER2 x Anti-HER3 Bispecific Monoclonal Antibody MCLA-128|Anti-HER2/Anti-HER3 Bispecific Monoclonal Antibody MCLA-128|Bizengri|MCLA 128|MCLA-128|MCLA128|ZENOCUTUZUMAB|Zenocutuzumab-zbco	A full-length IgG1 bispecific antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) directed against human epidermal growth factor receptor 2 (HER2; EGFR2, ERBB2) and human epidermal growth factor receptor 3 (HER3; ErbB3), with potential antineoplastic activity. Upon intravenous administration of zenocutuzumab, the bispecific antibody docks on HER2, and subsequently blocks heregulin-stimulated proliferation of tumor cells by binding HER3. In addition to inhibiting HER3-dependent signaling, simultaneous targeting of HER2 and HER3 by zenocutuzumab may overcome a common resistance mechanism driven by heregulin-mediated dimerization of HER2 and HER3. Zenocutuzumab is expected to eliminate tumor cells by recruiting natural killer (NK) cells to tumor cells coated with the bispecific antibody.	Zenocutuzumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C152949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152949>	C258	Zibrofusidic Acid|ZIBROFUSIDIC ACID				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15294>	C116653	Pancreatectomy|Excision of the Pancreas|Pancreas Excision|pancreatectomy	Surgical removal of part or all of the pancreas.	Pancreatectomy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C152950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152950>	C29710	Zicronapine|ZICRONAPINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152951>	C29710	Zicronapine Succinate|ZICRONAPINE SUCCINATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152952>	C258	Zidebactam|ZIDEBACTAM				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152953>	C784|C275	Zilascorb (2H)|ZILASCORB (2H)				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152954>	C94725|C265	Zimeldine|ZIMELDINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152955>	C94725|C265	Zimeldine Hydrochloride|ZIMELDINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152956>	C210653	Zinc Acetate, Basic|ZINC ACETATE, BASIC				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152957>	C1446	Zinc Chloride Zn-65|ZINC CHLORIDE ZN-65				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152958>	C48149	Zinterol|ZINTEROL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152959>	C48149	Zinterol Hydrochloride|ZINTEROL HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15295>	C15912	Chemotherapeutic Perfusion|Perfusion|perfusion	The process of flooding fluid through the artery to saturate the surrounding tissue. In regional perfusion, a specific area of the body (usually an arm or a leg) is targeted and high doses of anticancer drugs are flooded through the artery to reach the surrounding tissue and kill as many cancer cells as possible. Such a procedure is performed in cases where the cancer is not thought to have spread past a localized area.	Chemotherapeutic Perfusion		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C152961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152961>	C29576	Zoleprodolol|ZOLEPRODOLOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152962>	C258	Zoliflodacin|ZOLIFLODACIN				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152963>	C47795|C1509	Zonampanel|ZONAMPANEL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152964>	C47795|C1509	Zonampanel Anhydrous|ZONAMPANEL ANHYDROUS				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152965>	C2311	Zorbamycin|ZORBAMYCIN				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152966>	C921|C29696	Zoxazolamine|ZOXAZOLAMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152967>	C804	Zuretinol Acetate|ZURETINOL ACETATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C152968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152968>	C20917	CDCA7 Gene|CDCA7|CDCA7|Cell Division Cycle Associated 7 Gene	This gene is involved in MYC-dependent cell proliferation.			Gene or Genome	
C152969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152969>	C152968	CDCA7 wt Allele|Cell Division Cycle Associated 7 wt Allele|FLJ14736|ICF3|JPO1	Human CDCA7 wild-type allele is located in the vicinity of 2q31.1 and is approximately 15 kb in length. This allele, which encodes cell division cycle-associated protein 7, plays a role in the regulation of cell proliferation. Mutation of the gene is associated with immunodeficiency-centromeric instability-facial anomalies syndrome 3.			Gene or Genome	
C15296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15296>	C15295	Isolated Chemotherapeutic Perfusion|perfusion, isolated	The delivery of chemotherapy to a specific tissue area that is excluded from the general circulation during the period of infusion, which allows for a high concentration of the drug in the tumour area as well as sparing of the rest of the body from the side effects of the drug.			Therapeutic or Preventive Procedure	
C152970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152970>	C17761	Cell Division Cycle-Associated Protein 7|CDCA7|Protein JPO1|c-Myc Target JPO1	Cell division cycle-associated protein 7 (371 aa, ~43 kDa) is encoded by the human CDCA7 gene. This protein is involved in the modulation of cell proliferation.			Amino Acid, Peptide, or Protein	
C152971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152971>	C133878|C129822	Futuximab|992 DS|992-DS|992DS|FUTUXIMAB|Immunoglobulin G1, Anti-(Human Epidermal Growth Factor Receptor Extracellular Domain III) (Human-Mus Musculus Monoclonal 992 DS Heavy Chain), Disulfide with Human-Mus Musculus Monoclonal 992 DS Light Chain, Dimer	A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor receptor (EGFR; ErbB1; HER1), with potential antineoplastic activity. Upon administration, futuximab targets and binds to an epitope located in the extracellular domain (ECD) of EGFR, which causes internalization and degradation of EGFR, including the mutated EGFR variant III (EGFRvIII). This prevents EGFR-mediated signaling, thereby inhibiting EGFR-dependent tumor cell proliferation. EGFR, a receptor tyrosine kinase, is overexpressed on the cell surfaces of various solid tumor cell types.	Futuximab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C152972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152972>	C20917|C154302	CENPA Gene|CENPA|CENPA|Centromere Protein A Gene	This gene plays a role in kinetochore assembly and cell cycle progression.			Gene or Genome	
C152973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152973>	C152972	CENPA wt Allele|CENP-A|CenH3|Centromere Protein A (17kD) Gene|Centromere Protein A wt Allele|Centromere Protein A, 17kDa Gene	Human CENPA wild-type allele is located in the vicinity of 2p23.3 and is approximately 40 kb in length. This allele, which encodes histone H3-like centromeric protein A, is involved in cell division and centromeric nucleosome structure.			Gene or Genome	
C152974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152974>	C17761|C16685	Histone H3-Like Centromeric Protein A|CENP-A|CENP-A|CENP-A|CENPA|CENTROMERE A|Centromere Autoantigen A|Centromere Autoantigen A|Centromere Protein A|Centromere Protein A|Centromere-Specific Histone|Centromeric Protein A|Histone cenH3	Histone H3-like centromeric protein A (140 aa, ~16 kDa) is encoded by the human CENPA gene. This protein plays a role in cell cycle progression, cell division and centromeric nucleosome assembly.			Amino Acid, Peptide, or Protein	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C152975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152975>	C20194	CMC2 Gene|C-X9-C Motif Containing 2 Gene|CMC2|CMC2	This gene may be involved in cytochrome c oxidase assembly.			Gene or Genome	
C152976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152976>	C200418	AXL Inhibitor DS-1205c|DS 1205c|DS-1205c|DS1205c	An orally available and selective inhibitor of the receptor tyrosine kinase AXL (UFO), with potential antineoplastic activity. Upon administration, DS-1205c targets, binds to and prevents the activation of AXL. This blocks AXL-mediated signal transduction pathways and inhibits tumor cell proliferation and migration. AXL, a member of the Tyro3, AXL and Mer (TAM) family of receptor tyrosine kinases, is overexpressed by many tumor cell types. It plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance and poor prognosis.	AXL Inhibitor DS-1205c		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C152977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152977>	C152975	CMC2 wt Allele|2310061C15Rik|C-X(9)-C Motif Containing 2 Gene|C-X9-C Motif Containing 2 wt Allele|C16orf61|COX Assembly Mitochondrial Protein 2 Homolog (S. cerevisiae) Gene|Chromosome 16 Open Reading Frame 61 Gene|DC13|MGC45036	Human CMC2 wild-type allele is located in the vicinity of 16q23.2 and is approximately 54 kb in length. This allele, which encodes COX assembly mitochondrial protein 2 homolog, may play a role in cytochrome c oxidase localization.			Gene or Genome	
C152978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152978>	C18466	COX Assembly Mitochondrial Protein 2 Homolog|C-X(9)-C Motif Containing 2|C-X9-C Motif Containing Protein 2|CMC2|Cx9C Motif-Containing Protein 2	COX assembly mitochondrial protein 2 homolog (79 aa, ~9 kDa) is encoded by the human CMC2 gene. This protein may be involved in localization and assembly of complex IV of the mitochondrial electron transport chain.			Amino Acid, Peptide, or Protein	
C152979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152979>	C156880	Hsp90 Inhibitor LAM-003|LAM 003|LAM-003|LAM-003A Prodrug LAM-003|LAM003|Prodrug LAM-003	An L-alanine ester prodrug of LAM-003A, an orally bioavailable, synthetic, second-generation small-molecule inhibitor of heat shock protein 90 (Hsp90), with potential antineoplastic activity. Upon oral administration, LAM-003 is converted to LAM-003A. LAM-003A selectively targets and binds to Hsp90, thereby inhibiting its chaperone function and promoting the degradation of oncogenic signaling proteins involved in tumor cell proliferation and survival. This may inhibit the growth and survival of a wide variety of cancer cell types. Hsp90, a chaperone protein upregulated in a variety of tumor cells, regulates the folding, stability, and degradation of many oncogenic signaling proteins.	Hsp90 Inhibitor LAM-003		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15297>	C15221	Peritoneal Dialysis	A form of dialysis that uses the peritoneum as a membrane across which the infused diasylate exchanges nutrients for waste products that are removed when the fluid is exchanged.			Therapeutic or Preventive Procedure	
C152980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152980>	C28676	Related Donor Adenovirus-specific Cytotoxic T Cells|Related Donor Ad-specific CTLs	A population of allogeneic related donor cytotoxic T-lymphocytes (CTLs) specifically reactive to human adenovirus (Ad) with potential immunomodulating and anti-adenoviral activities. Upon infusion of related donor Ad-specific CTLs, these cells help reconstitute Ad-specific CTL responses in patients at risk of developing Ad infections after allogeneic stem cell transplant or in Ad-infected immunocompromised hosts. These related donor Ad-specific CTLs are manufactured with the CliniMACS Prodigy Cytokine Capture System which facilitates production of the Ad-specific CTLs.	Related Donor Adenovirus-specific Cytotoxic T Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C152981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152981>	C26001	COL4A2 Gene|COL4A2|COL4A2|Collagen Type IV Alpha 2 Chain Gene	This gene plays a role in the formation of basement membrane collagen structures.			Gene or Genome	
C152982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152982>	C152981	COL4A2 wt Allele|COL4A2|Collagen Type IV Alpha 2 Chain wt Allele|Collagen of Basement Membrane, Alpha-2 Gene|Collagen, Type IV, Alpha-2 Gene|DKFZp686I14213|FLJ22259|ICH|POREN2	Human COL4A2 wild-type allele is located in the vicinity of 13q34 and is approximately 207 kb in length. This allele, which encodes collagen alpha-2(IV) chain protein, is involved in basement membrane collagen structures. Mutation of the gene is associated with porencephaly 2 and increased susceptibility for intracerebral hemorrhage.			Gene or Genome	
C152983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152983>	C16447	COL4A2 Gene Product	A protein encoded by the COL4A2 gene.			Amino Acid, Peptide, or Protein	
C152984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152984>	C152983	Collagen Alpha-2(IV) Chain|COL4A2|Collagen Type 4 Alpha-2 Chain|Collagen Type IV Alpha 2|Collagen Type IV Alpha 2 Chain|Collagen Type IV Alpha-2 Chain	Collagen alpha-2(IV) chain (1712 aa, ~168 kDa) is encoded by the human COL4A2 gene. This protein is involved in basement membrane formation.			Amino Acid, Peptide, or Protein	
C152985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152985>	C152983	Canstatin|COL4A2 C-Terminal NC1 Peptide|Collagen Alpha-2(IV) Chain C-Terminal NC1 Peptide	Canstatin (227 aa, ~25 kDa) is encoded by the human COL4A2 gene. This protein plays a role in the inhibition of angiogenesis.			Amino Acid, Peptide, or Protein	
C152986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152986>	C20420	EBF4 Gene|EBF4|EBF4|Early B-Cell Factor 4 Gene	This gene is involved in neural development and B-cell maturation.			Gene or Genome	
C152987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152987>	C152986	EBF4 wt Allele|COE4|Early B Cell Factor 4 wt Allele|KIAA1442|O/E-4|RP5-860F19.3	Human EBF4 wild-type allele is located in the vicinity of 20p13 and is approximately 67 kb in length. This allele, which encodes transcription factor COE4 protein, plays a role in transcriptional regulation.			Gene or Genome	
C152988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C152988>	C17207	Transcription Factor COE4|EBF4|Early B-Cell Factor 4|O/E-4|OE-4|Olf-1/EBF-Like 4	Transcription factor COE4 (602 aa, ~64 kDa) is encoded by the human EBF4 gene. This protein is involved in transcriptional regulation, B-cell maturation and neural development.			Amino Acid, Peptide, or Protein	
C15299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15299>	C16974	Pharmacokinetics|PK|PK|Pharmacokinetic (PK) study|pharmacokinetics|pharmacokinetics	The quantitative analysis of the characteristic processes of a drug within biological systems, as affected by absorption, distribution, binding, biotransformation, elimination, and excretion that determine the time course of drug action in response to an administered drug dose.			Research Activity	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|CDISC SEND Study Category Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C1529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1529>	C1970	Batimastat|(2R,3S)-N{4}-Hydroxy-N{1}-[(1S)-2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-2-(2-methylpropyl)-3-[(2-thienylthio)methyl]butanediamide|(2R,3S)-N{4}-Hydroxy-N{1}-[(1S)-2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-2-(2-methylpropyl)-3-[(2-thienylthio)methyl]butanediamide|BATIMASTAT|BB-94|BB94|Butanediamide, N4-hydroxy-N1-(2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl)-2-(2-methylpropyl)-3-((2-thienylthio)methyl)-, (2R-(1(S*),2R*,3S*))-|[4-(N-Hydroxyamino)-2R-isobutyl-3S-(2-thienylthiomethyl)-succinyl]-L-phenylalanine-N-methylamide|[4-(N-Hydroxyamino)-2R-isobutyl-3S-(thiophen-2-ylthiomethyl)-succinyl]-L-phenylalanine-N-methylamide|batimastat	A synthetic hydroxamate with potential antineoplastic activity.  Batimastat binds covalently to the zinc ion in the active site of matrix metalloproteinases (MMPs), thereby inhibiting the action of MMPs, inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C15300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15300>	C15986|C15632	Photodynamic Therapy|PDT|PDT|PHOTODYNAMIC THERAPY|Photoradiation Therapy|photodynamic therapy	Use of light activated drugs (photosensitizing agents) to treat cancer and other conditions.	Photodynamic Therapy		Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C15301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15301>	C49236	Phototherapy|Actinotherapy|Bright Light Therapy|PHOTOTHERAPY|light therapy|phototherapy	The treatment of a disorder by exposure to light, including ultraviolet and infrared radiation. (Bartleby.com)	Phototherapy		Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology
C15302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15302>	C15747	Physical Therapy|PT|PT|Physiatric Procedure|Physical Medicine Procedure|Physical Therapeutics|Physical Therapy Procedure|Physiotherapy|Physiotherapy|Physiotherapy Procedure|physical therapy	The treatment of deformity or disease through mechanical force and movement, including both active and passive exercises, intended to ameliorate injury, increase mobility, and improve overall function.	Physical Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|NICHD Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology|Pediatric Rheumatology Terminology
C15303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15303>	C208216	Pilot Study|Pilot|pilot study|pilot study	The initial study examining a new method or treatment.			Research Activity	CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology|HL Authorized Value Terminology|HL Subject Characteristics Table
C153044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153044>	C20194	FBXO31 Gene|F-Box Protein 31 Gene|FBXO31|FBXO31	This gene plays a role in protein ubiquitination and cell cycle arrest.	FBXO31 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C153045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153045>	C153044	FBXO31 wt Allele|F-Box Protein 31 wt Allele|FBX14|FBXO14|Fbx31|MGC15419|MRT45|Putative Breast Cancer Tumor-Suppressor Gene|pp2386	Human FBXO31 wild-type allele is located in the vicinity of 16q24.2 and is approximately 65 kb in length. This allele, which encodes F-box only protein 31, is involved in G1 arrest and protein ubiquitination. Mutation of the gene is associated with autosomal recessive mental retardation type 45.	FBXO31 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153046>	C95242	F-Box Only Protein 31|F-Box Protein 31|FBXO31|SCF Ubiquitin Ligase Specificity Factor	F-box only protein 31 (539 aa, ~61 kDa) is encoded by the human FBXO31 gene. This protein plays a role in ubiquitination of phosphorylated cyclin-D1.	F-Box Only Protein 31		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153047>	C18568	FGF18 Gene|FGF18|FGF18|Fibroblast Growth Factor 18 Gene	This gene is involved in bone development and cell proliferation in the liver and small intestine.			Gene or Genome	
C153048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153048>	C153047	FGF18 wt Allele|FGF-18|Fibroblast Growth Factor 18 wt Allele|UNQ420/PRO856|ZFGF5	Human FGF18 wild-type allele is located in the vicinity of 5q35.1 and is approximately 38 kb in length. This allele, which encodes fibroblast growth factor 18 protein, plays a role in promoting cell proliferation in the small intestine and liver.			Gene or Genome	
C153049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153049>	C20426	Fibroblast Growth Factor 18|FGF-18|FGF18|Fibroblast Growth Factor-18|zFGF5	Fibroblast growth factor 18 (207 aa, ~24 kDa) is encoded by the human FGF18 gene. This protein is involved in ossification and the positive regulation of cell proliferation.			Amino Acid, Peptide, or Protein	
C15304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15304>	C15191	Plasmapheresis|Plasma Exchange|Plasma Exchange|Therapeutic Plasma Exchange|Therapeutic Plasmapheresis|plasmapheresis	A procedure that collects plasma from the peripheral blood while returning the rest to the donor.	Plasmapheresis		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|NICHD Terminology|Pediatric Rheumatology Terminology
C153050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153050>	C20923	ADGRG6 Gene|ADGRG6|ADGRG6|Adhesion G Protein-Coupled Receptor G6 Gene	This gene plays a role in development of the heart and nervous system and in stature.			Gene or Genome	
C153051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153051>	C153050	ADGRG6 wt Allele|APG1|DREG|FLJ14937|GPR126|LCCS9|PR126|PS1TP2|VIGR	Human ADGRG6 wild-type allele is located in the vicinity of 6q24.2 and is approximately 144 kb in length. This allele, which encodes adhesion G-protein coupled receptor G6 protein, is involved in axon myelination, heart development and stature. Mutation of the gene is associated with lethal congenital contracture syndrome type 9.			Gene or Genome	
C153052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153052>	C18239	Adhesion G-Protein Coupled Receptor G6|ADGRG6|Adhesion G Protein-Coupled Receptor G6|Developmentally Regulated G-Protein-Coupled Receptor|G Protein-Coupled Receptor 126|G-Protein Coupled Receptor 126|HBV PreS1-Transactivated Protein|Vascular Inducible G Protein-Coupled Receptor|Vascular-Inducible G Protein-Coupled Receptor	Adhesion G-protein coupled receptor G6 (1221 aa, ~137 kDa) is encoded by the human ADGRG6 gene. This protein plays a role in heart development, stature and myelin sheath formation.			Amino Acid, Peptide, or Protein|Receptor	
C153053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153053>	C20923	GPR180 Gene|G Protein-Coupled Receptor 180 Gene|GPR180|GPR180	This gene may be involved in signaling and vascular remodeling.			Gene or Genome	
C153054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153054>	C153053	GPR180 wt Allele|G Protein-Coupled Receptor 180 wt Allele|ITR	Human GPR180 wild-type allele is located in the vicinity of 13q32.1 and is approximately 33 kb in length. This allele, which encodes integral membrane protein GPR180, may play a role in vascular remodeling and receptor signaling.			Gene or Genome	
C153055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153055>	C18239	Integral Membrane Protein GPR180|G Protein-Coupled Receptor 180|G-Protein Coupled Receptor 180|GPR180|Intimal Thickness Related Receptor|Intimal Thickness-Related Receptor	Integral membrane protein GPR180 (440 aa, ~49 kDa) is encoded by the human GPR180 gene. This protein may be involved in G protein-receptor-mediated signaling and remodeling of the vasculature.			Amino Acid, Peptide, or Protein|Receptor	
C153056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153056>	C25952|C25870	PLAAT1 Gene|HRASLS|PLAAT1|PLAAT1|Phospholipase A and Acyltransferase 1 Gene	This gene plays a role in lipid acetylation and phospholipase activity.			Gene or Genome	
C153057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153057>	C153056	PLAAT1 wt Allele|A-C1|H-REV107|HRAS Like Suppressor Gene|HRAS-Like Suppressor Gene|HRASLS|HRASLS1|HRSL1|HSD28|PLA/AT1|PLAAT-1|Phospholipase A and Acyltransferase 1 wt Allele	Human PLAAT1 wild-type allele is located in the vicinity of 3q29 and is approximately 60 kb in length. This allele, which encodes phospholipid A and acyltransferase 1 protein, is involved in lipid metabolism.			Gene or Genome	
C153058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153058>	C16980|C16259	Phospholipase A and Acyltransferase 1|EC 2.3.1.-|EC 3.1.1.-|H-REV107 Protein-Related Protein|HRAS-Like Suppressor|HRAS-Like Suppressor 1|HRASLS|HRSL1|PLAAT1|Phospholipase A-C1|Phospholipid-Metabolizing Enzyme A-C1	Phospholipid A and acyltransferase 1 (168 aa, ~19 kDa) is encoded by the human PLAAT1 gene. This protein plays a role in phosphate removal from and acetylation of lipids.			Amino Acid, Peptide, or Protein|Enzyme	
C153059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153059>	C97927|C150437	NTRK1 Gene Mutation|MTC Gene Mutation|NTRK1 Mutation|Neurotrophic Receptor Tyrosine Kinase 1 Gene Mutation|Neurotrophic Tyrosine Kinase, Receptor, Type 1 Gene Mutation|TRK Gene Mutation|TRK Mutation|TRK1 Gene Mutation|TRKA Gene Mutation|TRKA Mutation|Trk-A Gene Mutation|TrkA Gene Mutation|p140-TrkA Gene Mutation	A change in the nucleotide sequence of the NTRK1 gene.	NTRK1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15305>	C15655	Pneumonectomy|pneumonectomy	The excision of part or all of a lung.			Therapeutic or Preventive Procedure	GDC Terminology|GDC Value Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table
C153060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153060>	C94299|C177693|C138155	NTRK1 Overexpression Positive|High Affinity Nerve Growth Factor Receptor Overexpression Positive|NTRK1 Overexpression|Neurotrophic Receptor Tyrosine Kinase 1 Overexpression Positive|TRK1 Overexpression Positive|TRKA Overexpression Positive|Trk-A Overexpression Positive|Tropomyosin-Related Kinase A Overexpression Positive	An indication that overexpression of NTRK1 has been detected in a sample.	NTRK1 Overexpression Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153061>	C46006|C3420	NTRK1 Gene Translocation|MTC Gene Translocation|NTRK1 Translocation|Neurotrophic Receptor Tyrosine Kinase 1 Gene Translocation|Neurotrophic Tyrosine Kinase, Receptor, Type 1 Gene Translocation|TRK Gene Translocation|TRK Translocation|TRK1 Gene Translocation|TRKA Gene Translocation|TRKA Translocation|Trk-A Gene Translocation|p140-TrkA Gene Translocation	A cytogenetic abnormality that refers to any translocation involving the NTRK1 gene.	NTRK1 Gene Translocation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153062>	C183567	NTRK1 Gene Amplification|MTC Gene Amplification|NTRK1 Amplification|Neurotrophic Receptor Tyrosine Kinase 1 Gene Amplification|Neurotrophic Tyrosine Kinase, Receptor, Type 1 Gene Amplification|TRK Amplification|TRK Gene Amplification|TRK1 Gene Amplification|TRKA Amplification|TRKA Gene Amplification|Trk-A Gene Amplification|p140-TrkA Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the NTRK1 gene.	NTRK1 Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153063>	C81974	Polyspecific Direct Antiglobulin Test	A nonspecific screening test to detect the presence of antibody and complement-coated erythrocytes in a blood specimen in vivo.	Polyspecific Direct Antiglobulin Test		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C153064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153064>	C37965	Chronic Hemolysis	Persisting and longstanding disruption of erythrocyte membrane integrity and the resulting release of hemoglobin.	Chronic Hemolysis		Laboratory or Test Result	CTRP Disease Terminology|CTRP Terminology
C153066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153066>	C153071|C153069	Locally Advanced Soft Tissue Sarcoma	Soft tissue sarcoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Soft Tissue Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153067>	C514	Antifungal Agent VL-2397|ASP 2397|ASP-2397|ASP2397|VL 2397|VL-2397|VL-2397|VL2397	A cyclic hexapeptide and natural compound isolated from the Malaysian leaf litter fungus, Acremonium persicinium MF-347833, with potential antifungal activity against various invasive fungal infections including invasive aspergillosis (IA). Upon administration, VL-2397, by resembling the siderophore ferrichrome, is specifically taken up by fungal cells through the membrane-bound transporter siderophore iron transporter 1 (Sit; Sit1). Upon fungal cell entry, VL-2397 targets and binds to an as of yet undisclosed intracellular site, thereby killing fungal cells. Since mammalian cells lack the Sit1 transporter, VL-2397 is not taken up by human cells.	Antifungal Agent VL-2397		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C153068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153068>	C9306|C148331	Unresectable Soft Tissue Sarcoma	A soft tissue sarcoma that is not amenable to surgical resection.	Unresectable Soft Tissue Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153069>	C9306|C219038|C152076	Metastatic Soft Tissue Sarcoma	A soft tissue sarcoma that has spread from the original site of growth to another anatomic site.	Metastatic Soft Tissue Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C15306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15306>	C15843	Primary Prevention|PRIMARY PREVENTION|Prevention, Primary	Prevention of disease or mental disorders in susceptible individuals or populations through promotion of health, including mental health, and specific protection, as in immunization, as distinguished from the prevention of complications or after-effects of existing disease.			Therapeutic or Preventive Procedure	CDISC SDTM Cardiac Procedure Indication Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C153070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153070>	C153073|C153071	Locally Advanced Bone Sarcoma	Bone sarcoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Bone Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153071>	C8524|C152076	Locally Advanced Sarcoma	Sarcoma that has spread from its original site of growth to nearby tissues or lymph nodes.			Neoplastic Process	
C153072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153072>	C9312|C148331	Unresectable Bone Sarcoma	Bone sarcoma that is not amenable to surgical resection.	Unresectable Bone Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153073>	C9312|C152076	Metastatic Bone Sarcoma	Bone sarcoma that has spread from the original site of growth to another anatomic site.	Metastatic Bone Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153074>	C3400|C153068	Unresectable Synovial Sarcoma	A synovial sarcoma that is not amenable to surgical resection.	Unresectable Synovial Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153075>	C3770|C165447|C156069|C155936	Metastatic Pancreatic Neuroendocrine Carcinoma|Metastatic Pancreatic Neuroendocrine Cancer	A pancreatic neuroendocrine carcinoma that has spread from the original site of growth to another anatomic site.	Metastatic Pancreatic Neuroendocrine Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153076>	C210660	IGHV4-34 Gene|IGHV4-34|IGHV4-34|Immunoglobulin Heavy Variable 4-34 Gene	This gene plays a role in the specificity of antigen recognition by immunoglobulins.	IGHV4-34 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C153077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153077>	C153076	IGHV4-34 wt Allele|Homo sapiens Immunoglobulin Heavy Variable 4-34 Gene|IGHV434|Ig Heavy Chain V-II Region ARH-77 Gene|Immunogloblin Heavy Chain Variable Region 4-34 Gene|Immunoglobulin Heavy Variable 4-34 wt Allele|VH	Human IGHV4-34 wild-type allele is located in the vicinity of 14q32.33 and is approximately 1 kb in length. This allele, which encodes immunoglobulin heavy variable 4-34, is involved in antigen recognition.	IGHV4-34 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153078>	C210663	Immunoglobulin Heavy Variable 4-34|IGHV4-34|Ig Heavy Chain V-II Region ARH-77|Immunogloblin Heavy Chain Variable Region 4-34|Protein IGHV4-34	Immunoglobulin heavy variable 4-34 (123 aa, ~14 kDa) is encoded by the human IGHV4-34 gene. This protein plays a role in antigen recognition variability.	Immunoglobulin Heavy Variable 4-34		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153079>	C5018|C3770|C165456|C155935	Unresectable Pancreatic Neuroendocrine Carcinoma|Unresectable Pancreatic Neuroendocrine Cancer	A pancreatic neuroendocrine carcinoma that is not amenable to surgical resection.	Unresectable Pancreatic Neuroendocrine Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C15307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15307>	C15334	Prostatectomy|prostatectomy	Surgical removal of part or all of the prostate.	Prostatectomy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C153080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153080>	C203250|C165453	Unresectable Neuroendocrine Tumor G1|Unresectable Carcinoid Tumor|Unresectable Carcinoid Tumor	Neuroendocrine tumor grade 1 that is not amenable to surgical resection.	Unresectable Carcinoid Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153081>	C2926|C141076	Refractory Lung Non-Small Cell Carcinoma|Refractory Non-Small Cell Lung Cancer|Refractory Non-Small Cell Lung Carcinoma	Non-small cell lung carcinoma that does not respond to treatment.	Refractory Non-Small Cell Lung Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153083>	C28681	Autologous CD8+ SLC45A2-specific T Lymphocytes|Autologous SLC45A2-specific CTLs|Autologous SLC45A2-specific Cytotoxic T Lymphocytes	A preparation of autologous CD8+ T lymphocytes targeting SLC45A2, a melanoma-associated antigen, with potential immunomodulating and antineoplastic activities. Following peripheral blood mononuclear cell (PBMC) collection and ex vivo expansion of SLC45A2-specific cytotoxic T-lymphocytes (CTLs), the autologous CD8+ SLC45A2-specific CTLs are re-infused into the patient, where they target and lyse SLC45A2-expressing tumor cells. While SLC45A2 is expressed by approximately 80% of cutaneous melanomas, its expression is limited in mature normal melanocytes, allowing high tumor selectivity and reduced potential for autoimmune toxicity.	Autologous CD8+ SLC45A2-specific T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153084>	C20401	Bezlotoxumab|BEZLOTOXUMAB|MK 6072|MK-6072|MK6072|Zinplava	A human monoclonal antibody directed against Clostridium difficile Toxin B (TcdB), with anti-toxin activity. Upon intravenous infusion, the two Fab regions of bezlotoxumab bind to two distinct epitopes within the N-terminal half of the TcdB combined repetitive oligopeptide (CROP) domain, blocking the carbohydrate binding pockets of the toxin and preventing binding of the toxin to target host cells. TcdB is one of two exotoxins responsible for the symptoms of Clostridium difficile infections.	Bezlotoxumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C153086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153086>	C9306|C150605	Resectable Soft Tissue Sarcoma	A soft tissue sarcoma that is amenable to surgical resection.			Neoplastic Process	
C153087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153087>	C21295	MUC20 Gene|MUC20|MUC20|Mucin 20, Cell Surface Associated Gene	This gene is involved in regulation of hepatocyte growth factor (HGF)/HGF receptor (c-Met) signaling.	MUC20 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C153088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153088>	C153087	MUC20 wt Allele|FLJ14408|KIAA1359|MUC-20|Mucin 20, Cell Surface Associated wt Allele|Mucin 20, Cell Surface-Associated Gene|UNQ2782/PRO7170	Human MUC20 wild-type allele is located in the vicinity of 3q29 and is approximately 20 kb in length. This allele, which encodes mucin-20 protein, plays a role in modulation of the hepatocyte growth factor (HGF)/HGF receptor (c-Met) signaling pathway.	MUC20 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153089>	C16883	Mucin-20|MUC-20|MUC20|Mucin 20|Transmembrane Mucin MUC20S	Mucin-20 (709 aa, ~72 kDa) is encoded by the human MUC20 gene. This protein is involved in suppression of hepatocyte growth factor (HGF)/HGF receptor (c-Met) signaling.	Mucin-20		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15308>	C49236	Psychotherapy|psychotherapy|talk therapy	A method of treating disease, esp. psychic disorders, by mental rather than pharmacological means (e.g., suggestion, re-education, hypnotism, and psychoanalysis). (Taber's)	Psychotherapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C153090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153090>	C94411|C18194	Guardant360 Profiling System|Guardant360|Guardant360|Guardant360|Guardant360 Genomic Profiling	A proprietary epigenomic and genomic profiling system for the identification of disease and treatment response biomarkers in cell-free circulating tumor DNA (ctDNA) found in liquid biopsy (blood) samples. This system uses next-generation digital sequencing technology to assist in the diagnosis of multiple solid tumor types, facilitate the selection of diagnosis-specific targeted therapeutics based on markers for treatment sensitivity or resistance and identification of new markers of disease progression, minimal residual disease and recurrence.	Guardant360		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C153091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153091>	C177696	ERBB2 Gene Mutation Negative|ERBB2 Mutation Negative|ERBB2 Wild-Type|ERBB2 Wildtype|ERBB2 wt|Erb-B2 Receptor Tyrosine Kinase 2 Gene Mutation Negative|HER-2 Gene Mutation Negative|HER2 Gene Mutation Negative|HER2 Wild-Type|HER2 Wildtype|HER2 wt|HER2/neu Gene Mutation Negative|NEU Gene Mutation Negative|Negative|No mutation detected|v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 Gene Mutation Negative	A genetic finding indicating that ERBB2 gene mutations have not been detected in a sample.	ERBB2 Gene Mutation Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153093>	C20401|C199456	Sutimlimab|BIVV 009|BIVV-009|BIVV009|Enjaymo|IPN 009|IPN-009|IPN009|Immunoglobulin G4, Anti-(Human Complement C1S) (Humanized Mouse Monoclonal TNT009 Gamma4-chain), Disulfide with Humanized Mouse Monoclonal TNT009 Kappa-chain, Dimer|SUTIMLIMAB|Sutimlimab-jome|TNT009|WHO 10757	A humanized monoclonal immunoglobulin G4 (IgG4) antibody directed against human compliment factor C1s, with potential immunomodulatory activity. Upon intravenous administration, sutimlimab targets, binds to and blocks the activity of C1s, a portion of the C1 complex, preventing enzymatic action on its substrates, C4 and C2, and inhibiting the formation of C3 convertase. By selectively targeting the classical complement pathway (CP), the function of both the alternative and lectin pathways are preserved. C1s, a serine protease, is responsible for the propagation of the classical complement pathway of the immune system; dysregulation of the classical compliment cascade plays a key role in a variety of complement-mediated disorders.	Sutimlimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C153094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153094>	C39619|C1663	TetMYB DNA Vaccine|DNA Vaccine TetMYB|DNA-based TetMYB Vaccine|TetMYB|TetMYB Vaccine	A therapeutic engineered DNA vaccine composed of DNA sequences encoding for one or more tetanus toxoid peptides and the oncoprotein MYB, with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, TetMYB is taken up and processed by dendritic cells (DCs), which present the processed antigen to the immune system. This activates cytotoxic T-lymphocytes (CTLs) and causes a CTL-mediated immune response against MYB-expressing tumor cells. MYB, an oncoprotein and transcription factor, is overexpressed in a variety of cancer types and is essential for tumor cell growth, inhibition of differentiation, and protection from apoptosis. Its expression is correlated with lower T-cell infiltration and poorer prognosis. As MYB is only weakly immunogenic, the tetanus toxoid peptides enhance the T-cell mediated immune responses against the MYB-expressing tumor cells.			Immunologic Factor|Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153095>	C2167|C129825	Epitinib Succinate|EPITINIB SUCCINATE|HMPL 813|HMPL-813|HMPL813	The succinate salt form of epitinib, an orally available epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon administration, epitinib inhibits the activity of EGFR, thereby preventing EGFR-mediated signaling. This may lead to induction of cell death and inhibition of tumor growth in EGFR-overexpressing tumor cells. EGFR is a receptor tyrosine kinase (RTK) that is overexpressed in certain tumor types and plays a key role in tumor cell proliferation and vascularization.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153096>	C66884|C38149	Carbidopa/Levodopa|Carbidopa Levodopa|Carbidopa-Levodopa|Sinemet	An orally available combination of carbidopa, an inhibitor of aromatic amino acid decarboxylation, and levodopa, an inert, metabolic precursor to dopamine, with dopaminergic and antiparkinsonian properties. Upon oral administration, levodopa crosses the blood-brain barrier (BBB) and is decarboxylated to dopamine via dopa decarboxylase in the brain, promoting increased activation of dopamine receptors. Carbidopa inhibits dopa decarboxylase in the periphery, thereby preventing decarboxylation of levodopa in extracerebral tissues and increasing the delivery of dopamine to the central nervous system (CNS). As carbidopa does not cross the BBB, it does not interfere with CNS levodopa metabolism.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C153097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153097>	C2594	CD137L/Epstein-Barr Virus-Targeting Autologous Dendritic Cell Vaccine|CD137L-DC-EBV-VAX|CD137L/Epstein-Barr Virus-Targeting Autologous DC Vaccine	A cell-based cancer vaccine composed of in vitro generated, highly potent, CD137 ligand (CD137L)-dendritic cells (CD137L-DCs), pulsed with Epstein-Bar Virus (EBV) antigen peptides, with potential antineoplastic and immunostimulatory activities. Upon administration, CD137L-DCs induce potent CD8+ T-cell responses against EBV+ target cells. DCs stimulated with CD137L enhance cytotoxic T-lymphocyte proliferation and activation to a greater extent compared to non-CD137L-stimulated DCs.			Cell|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153099>	C158949|C103223	1p/19q Codeletion Negative|1p/19q Co-deletion Negative|1p/19q Intact|Negative|del(1p/19q) Negative	A finding indicating that concurrent deletion of chromosome arms 1p and 19q is not detected in a sample.	1p/19q Codeletion Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15309>	C49235	Public Health Administration	A health profession that focusses on community-wide disease prevention and health promotion. Public health administrators run the organizations that promote health and disseminate information about health.			Health Care Activity	
C1530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1530>	C1558	Piperacillin-Tazobactam|PIPER/TAZO|Piperacillin/Tazobactam|Zosyn|piperacillin-tazobactam	A combination formulation of the antibiotic piperacillin and the beta-lactamase inhibitor tazobactam with antibacterial activity. Piperacillin, a broad-spectrum, semisynthetic penicillin, binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall, thereby interfering with the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. As a result, the cell wall is weakened and the cell lyses. Tazobactam, a penicillanic acid sulfone derivative, irreversibly binds to and inhibits bacterial beta-lactamase at or near its active site, thereby preventing the destruction of the beta-lactamase susceptible piperacillin by this bacterial enzyme.	Piperacillin-Tazobactam		Antibiotic|Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C153100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153100>	C97927	ABL1 Gene Mutation|ABL Gene Mutation|ABL Proto-Oncogene 1, Non-Receptor Tyrosine Kinase Gene Mutation|JTK7 Gene Mutation|c-ABL1 Gene Mutation|v-Abl Abelson Murine Leukemia Viral Oncogene Homolog 1 Gene Mutation	A change in the nucleotide sequence of the ABL1 gene.	ABL1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C153101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153101>	C40998|C153383	Activated PI3K-Positive Cells Present|Activated PI3K Present|Cells with Activated 1-Phosphatidylinositol 3-Kinase Present|Cells with Activated PI3 Kinase Present|Cells with Activated PI3-Kinase Present|Cells with Activated PI3K Family Present|Cells with Activated PI3K Present|Cells with Activated PIK3 Present|Cells with Activated Phosphatidylinositide 3-Kinase Present|Cells with Activated Phosphatidylinositol 3 Kinase Present|Cells with Activated Phosphatidylinositol 3-Kinase Present|Cells with Activated Phosphatidylinositol-3-Kinase Present|Cells with Activated Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Present	An indication that cells expressing the active form of a phosphatidylinositol 3-kinase (PI3K) family protein has been detected in a sample.	Activated PI3K-Positive Cells Present		Finding	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153102>	C211912|C155712	HM2/MMAE Antibody-Drug Conjugate ALT-P7|ADC ALT-P7|ALT-P7|HER2ALT-P7|HM2-MMAE|HM2/MMAE ADC ALT-P7	An antibody-drug conjugate (ADC) composed of the trastuzumab biobetter HM2 conjugated, in a site-specific manner, to monomethyl auristatin E (MMAE), an auristatin derivative and potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration of ALT-P7, the antibody moiety targets and binds to human epidermal growth factor receptor 2 (HER2) on tumor cells. Upon antibody/antigen binding and internalization, the MMAE moiety is released, binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and apoptosis. HER2 is a receptor tyrosine kinase (RTK) that is overexpressed by many cancer cell types.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153103>	C178120|C146713	Activating FGFR Gene Mutation|Activating FGF Receptor Gene Family Mutation|Activating FGF Receptor Gene Mutation|Activating FGFR Family Gene Mutation|Activating FGFR Family Mutation|Activating FGFR Mutation|Activating Fibroblast Growth Factor Receptor Family Gene Mutation|Activating Fibroblast Growth Factor Receptor Gene Mutation|Gain-of-Function FGFR Gene Mutation	A change in the nucleotide sequence of an FGFR family gene that results in constitutive activation the encoded fibroblast growth factor receptor protein and its downstream signaling pathways.	Activating FGFR Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153104>	C199268	CD45RO Antibody|Anti-CD45R0 Antibody|Anti-CD45R0 Antigen Antibody|Anti-CD45RO|Anti-CD45RO Antigen Antibody|Anti-PTPRC Isoform CD45RO|Anti-PTPRC Isoform CD45RO Antibody|Anti-Receptor-Type Tyrosine-Protein Phosphatase C Isoform CD45RO Antibody|CD45R0 Antigen Antibody|CD45RO Antigen Antibody|PTPRC Isoform CD45RO Antibody|Receptor-Type Tyrosine-Protein Phosphatase C Isoform CD45RO Antibody	Any immunoglobulin that recognizes CD45RO protein.	CD45RO Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153105>	C2136	Evocalcet|EVOCALCET|KHK7580|MT-4580|Orkedia|benzeneacetic Acid, 4-((3S)-3-(((1R)-1-(1-naphthalenyl)ethyl)amino)-1-pyrrolidinyl)-	An orally available calcium receptor (CaR) modulator, with potential calcimimetic activity. Upon administration, evocalcet allosterically binds to and inhibits the activity of CaR, thereby suppressing the production of serum parathyroid hormone (PTH) and prevents the PTH-mediated efflux of calcium from bone and normalizes calcium levels.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C153106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153106>	C25619	Integrated Statistical Analysis Plan|IntegratedStatisticalAnalysisPlan	A type of statistical analysis plan that is intended to draw conclusions across multiple studies.			Intellectual Product	BRIDG Class Terminology|BRIDG Terminology
C153107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153107>	C25162	Priority at Discharge Code|PriorityAtDischargeCode|priorityAtDischargeCode	A coded value specifying the degree to which a condition is established to be chiefly responsible for occasioning the admission of the patient.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C153108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153108>	C25648	Performed Composition Relationship|PerformedCompositionRelationship	A relationship between a composite activity and a component activity that comprises it, i.e. parent and child activities where all activities have occurred in the context of a particular study or experiment.			Conceptual Entity	BRIDG Class Terminology|BRIDG Terminology
C153109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153109>	C20130	BCL-2 Family Protein|BCL-2 Family|BCL-2 Family Proteins|BCL2 Family|BCL2 Family Protein	A family of proteins that all contain at least one of four Bcl-2 homology domains (BH). These proteins are involved in the regulation of apoptosis.	BCL-2 Family Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Biomarkers/Targets Associated with Other Relevant Evidence
C15310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15310>	C15631	Paracentesis|paracentesis	The removal of excess fluid via needle puncture from any body cavity.	Paracentesis		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C153110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153110>	C25648	Assessed Activity Relationship|AssessedActivityRelationship	Specifies the link between an assessment (performed observation) and the performed activity that the assessment is based on.			Conceptual Entity	BRIDG Class Terminology|BRIDG Terminology
C153111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153111>	C35682|C177693	BCL2 Overexpression Positive|Apoptosis Regulator Bcl-2 Overexpression Positive|B-Cell CLL/Lymphoma 2 Overexpression Positive|B-Cell Leukemia/Lymphoma 2 Overexpression Positive|B-Cell Lymphoma 2 Overexpression Positive|BCL-2 Overexpression|BCL-2 Overexpression Positive|BCL2 Overexpression	An indication that overexpression of BCL2 has been detected in a sample.	BCL2 Overexpression Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153112>	C25162	Target Anatomic Site Directionality Code|TargetAnatomicSite.directionalityCode|TargetAnatomicSiteDirectionalityCode|targetAnatomicSiteDirectionalityCode	A coded value specifying the directional portion of the anatomic site that is a target site for a procedure.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Class and Attribute Terminology|BRIDG Terminology
C153113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153113>	C97927	BCOR Gene Mutation|ANOP2 Gene Mutation|BCL6 Co-Repressor Gene Mutation|BCL6 Corepressor Gene Mutation|BCOR mutation|MAA2 Gene Mutation|MCOPS2 Gene Mutation	A change in the nucleotide sequence of the BCOR gene.	BCOR Gene Mutation		Cell or Molecular Dysfunction	CRF8 Pathology Review Targeted Genomics Table|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153114>	C97927	BCORL1 Gene Mutation|BCL6 Corepressor-Like 1 Gene Mutation|BCORL1 mutation|BCoR-L1 Gene Mutation|CXorf10 Gene Mutation|Chromosome X Open Reading Frame 10 Gene Mutation	A change in the nucleotide sequence of the BCORL1 gene.	BCORL1 Gene Mutation		Cell or Molecular Dysfunction	CRF8 Pathology Review Targeted Genomics Table|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153115>	C16325	BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.T315A|BCR-ABL T315A Mutation|BCR-ABL Thr315Ala Mutation|BCR-ABL1 T315A Mutation|BCR-ABL1 Thr315IAla Mutation|BCR/ABL Fusion Protein with T315A|BCR/ABL Fusion Protein with Thr315Ala|BCR/ABL T315A Mutation|BCR/ABL Thr315Ala Mutation|BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.Thr315Ala|BCR/ABL1 Fusion Protein with NP_005148.2:p.T315A|BCR/ABL1 Fusion Protein with NP_005148.2:p.Thr315Ala|BCR/ABL1 T315A Mutation|BCR/ABL1 Thr315Ala Mutation|BCR::ABL1 Fusion Protein with ABL1 NP_005148.2:p.T315A	A fusion protein encoded by the BCR/ABL1 fusion gene with a mutation in codon 315 of the ABL1 gene. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein where the threonine at position 315 of the ABL1 protein has been replaced by alanine.	BCR/ABL1 Fusion Protein with ABL1 NP_005148.2:p.T315A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153116>	C155765	TrkA Inhibitor VMD-928|NTRK1 Inhibitor VMD-928|VMD 928|VMD-928|VMD-928|VMD928	An orally bioavailable, selective inhibitor of tropomyosin receptor kinase A (TrkA; neurotrophic tyrosine receptor kinase (NTRK) type 1; NTRK1; TRK1-transforming tyrosine kinase protein), with potential antineoplastic activity. Upon oral administration, VMD-928 specifically targets and binds to TrkA, inhibits neurotrophin-TrkA interaction and prevents TrkA activation. This prevents the activation of downstream signaling pathways and inhibits cell growth in tumors that overexpress TrkA. Uncontrolled TrkA signaling plays an important role in tumor cell growth, survival, invasion and treatment resistance.	TrkA Inhibitor VMD-928		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153117>	C35881	Blasts 30,000 or Less of Peripheral Blood White Cells|Absolute Blasts 30,000 or Less of Peripheral Blood White Cells|Absolute Blasts 30000 or Less of Peripheral Blood White Cells|Absolute Blasts in Peripheral Blood Less Than or Equal to 30,000|Absolute Blasts in Peripheral Blood Less Than or Equal to 30000|Blasts 30000 or Less of Peripheral Blood White Cells|Blasts Less than or Equal to 30,000 in Peripheral Blood White Cells|Blasts Less than or Equal to 30000 in Peripheral Blood White Cells	A quantitative microscopic finding indicating that 30,000 or fewer nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.	Blasts 30,000 or Less of Peripheral Blood White Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C153118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153118>	C200766|C176018	Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells PZ01|Autologous CD19-specific CAR-T cells PZ01|Autologous PZ01 CAR-T Cells|PZ01	A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) of anti-CD19, coupled to the costimulatory domains of 4-1BB (CD137) and the zeta chain of the human T-cell receptor (CD3zeta), with potential immunostimulating and antineoplastic activities. Upon transfusion, the autologous anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells PZ01 target, bind to, and induce selective toxicity in CD19-expressing B cells. The CD19 antigen is a B-cell-specific cell surface antigen expressed in all B-cell lineage malignancies.			Cell|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153119>	C41398	Blasts 9 Percent or Less of Bone Marrow Nucleated Cells|Blasts Less than or Equal to 9 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that 9 percent or less of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts 9 Percent or Less of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C15311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15311>	C15381	Quality Control|QA Report|QC|quality control (QC)	Set of measurements and inspections taken to verify that performance of equipment and procedures remains within specified limits.			Activity	CDISC Glossary Terminology|ORCHESTRA Terminology
C153120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153120>	C41241	Blasts 9 Percent or Less of Peripheral Blood White Cells|Blasts Less than or Equal to 9 Percent of Peripheral Blood White Cells	A semi-quantitative microscopic finding indicating that 9 percent or less of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.	Blasts 9 Percent or Less of Peripheral Blood White Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C153121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153121>	C35883	Blasts Increased by Greater than or Equal to 50 Percent|Increase in Blasts by Greater than or Equal to 50	A semi-quantitative microscopic finding indicating that the amount of immature mononuclear cells in a sample from a certain subject has increased by at least 50 percent over a prior sample from the same subject.	Blasts Increased by Greater than or Equal to 50 Percent		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C153122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153122>	C213472|C200418	Axl/Mer Inhibitor INCB081776|5-PYRIMIDINECARBOXAMIDE, N-(4-(4-AMINO-7-(1-(2-METHYL-1-OXOPROPYL)-4-PIPERIDINYL)PYRROLO(2,1-F)(1,2,4)TRIAZIN-5-YL)PHENYL)-1,2,3,4-TETRAHYDRO-1-(1-METHYLETHYL)-2,4-DIOXO-3-(2-PYRIDINYL)-|INCB 081776|INCB 81776|INCB-081776|INCB-81776|INCB081776|INCB81776	An orally available and selective inhibitor of the receptor tyrosine kinases (RTKs) Axl (UFO) and Mer, with potential antineoplastic activity. Upon administration, INCB081776 targets and binds to both Axl and Mer, and prevents their activity. This blocks Axl- and Mer-mediated signal transduction pathways, and inhibits proliferation and migration of Axl- and Mer-overexpressing tumor cells. Axl and Mer, both members of the TAM (Tyro3, Axl and Mer) family of RTKs, are overexpressed by many tumor cell types. They play key roles in tumor cell proliferation, survival, invasion, angiogenesis and metastasis, and their expression is associated with enhanced immunosuppression, drug resistance and poor prognosis.	Axl/Mer Inhibitor INCB081776		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153123>	C54672	CTAG2 Gene Product	A protein encoded by the CTAG2 gene.			Amino Acid, Peptide, or Protein	
C153124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153124>	C51811	Study Research Coordinator|StudyResearchCoordinator	A person who handles the administrative responsibilities of a study on behalf of the study investigator, acts as a liaison between study site and study sponsor, and reviews all data and records before a monitor's visit.			Professional or Occupational Group	BRIDG Class Terminology|BRIDG Terminology
C153125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153125>	C153123	Cancer/Testis Antigen 2 Isoform LAGE-1A|CT6.2a|Cancer/Testis Antigen 6.2a|Isoform LAGE-1A|L Antigen Family Member 1 Isoform A|LAGE-1A|LAGE-1S|LAGE-1a Protein	Cancer/testis antigen 2 (180 aa, ~18 kDa) is encoded by the human CTAG2 gene. This protein may play a role in tumorigenesis of several tissues.	Cancer/Testis Antigen 2 Isoform LAGE-1A		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153126>	C138947	LAGE-1A Positive|CT6.2a Positive|Cancer/Testis Antigen 2 Isoform LAGE-1A Positive|Cancer/Testis Antigen 6.2a Positive|Isoform LAGE-1A Positive|L Antigen Family Member 1 Isoform A Positive|LAGE-1S Positive|LAGE-1a Protein Positive	An indication that expression of the LAGE-1A isoform of the cancer/testis antigen 2 protein has been detected in a sample.	LAGE-1A Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153127>	C25162	Last Follow-up Source Type Code|LastFollowUpSourceTypeCode|lastFollowUpSourceTypeCode	A coded value specifying the kind of medical record that provided the latest vital status information about this person.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C153129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153129>	C214964|C201282	Ubamatamab|Anti-MUC16 x Anti-CD3 REGN4018|Anti-MUC16/CD3 Bispecific Antibody REGN4018|REGN 4018|REGN-4018|REGN4018|UBAMATAMAB	A bispecific, human monoclonal antibody with potential antineoplastic activity. REGN4018 contains two antigen-recognition sites: one for human CD3, a T cell surface antigen that is part of the T cell receptor complex, and one for human mucin 16 (MUC16, cancer antigen 125; CA125; FLJ14303), a member of the mucin family of glycoproteins that is overexpressed by several epithelial cancers, including ovarian cancer. Upon administration, ubamatamab binds to both T-cells and MUC16-expressing tumor cells, which cross-links the T-cells to the tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against the MUC16-expressing tumor cells.	Ubamatamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15312>	C16847	Radiation Dosimetry|Dosimetry|RADIATION DOSIMETRY|dosimetry	Any of a number of techniques used to measure radiation exposure.	Radiation Dosimetry		Activity	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C153130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153130>	C213678|C129820	Anti-NY-ESO1/LAGE-1A TCR/scFv Anti-CD3 IMCnyeso|Bispecific NY-ESO-1- and LAGE-1A-specific TCR/Anti-CD3|HLA- A*0201-Restricted NY-ESO-1- and LAGE-1A-specific Soluble TCR/Anti-CD3 Bispecific Molecule|IMCNYESO|IMCnyeso	A bispecific molecule composed of a soluble, affinity-enhanced T-cell receptor (TCR) specific for human leukocyte antigen A2 (HLA-A2)-restricted cancer-testis antigens (CTAs) NY-ESO-1 and L antigen family member 1 isoform A (LAGE-1A; LAGE-A1; CT6.2a), fused to a single-chain variable fragment (scFv) specific for the T-cell surface antigen CD3, with potential immunomodulating and antineoplastic activities. Upon infusion, anti-NY-ESO1/LAGE-1A TCR/scFv anti-CD3 IMCnyeso specifically targets and binds with its TCR moiety to NY-ESO-1 and/or LAGE-1A expressed on tumor cells and with its scFv moiety to CD3 expressed on T-cells. This crosslinks tumor cells and T-cells, re-directs and activates T-cells, and results in a cytotoxic T-lymphocyte (CTL)-mediated destruction of NY-ESO-1 and/or LAGE-1A-positive tumor cells. NY-ESO-1 and LAGE-1A, members of the cancer-testis antigen (CTA) family, are overexpressed on the surface of various tumor cell types; they share a specific HLA-A*0201 epitope, 157-165, which is expressed on certain tumor cell types while its expression is not found on normal, healthy cells.	Anti-NY-ESO1/LAGE-1A TCR/scFv Anti-CD3 IMCnyeso		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153131>	C70900	Performed Experiment Unit Allocation|PerformedExperimentUnitAllocation	The completed action that is the assignment of an experimental unit to a portion of the study, such as an arm or a portion of an arm (when secondary allocations may occur).			Occupational Activity	BRIDG Class Terminology|BRIDG Terminology
C153132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153132>	C95349	Occurrence Study Day Range|OccurrenceStudyDayRange|occurrenceStudyDayRange	The relative timing for a medical condition expressed as the number of days offset from the study-defined reference activity (e.g., date of registration, start of treatment) for this particular experimental unit.			Temporal Concept	BRIDG Attribute Terminology|BRIDG Terminology
C153133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153133>	C2150|C1557	Aerosol Gemcitabine|Aerosolized GCB|Aerosolized Gemcitabine	An aerosol inhalation formulation containing gemcitabine (GCB), a broad-spectrum antimetabolite and deoxycytidine analogue, with potential antineoplastic activity. Upon inhalation via a nebulizer, GCB is converted intracellularly by deoxycytidine kinase to its active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP). dFdCDP inhibits ribonucleotide reductase (RNR), thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA, resulting in DNA strand termination and the induction of apoptosis of lung tumor cells. GCB administration directly into the lungs via aerosol yields higher concentrations of GCB locally than can be achieved by systemic GCB administration, potentially reducing systemic toxicity.	Aerosol Gemcitabine		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153134>	C16632	Study Country|StudyCountry|StudyCountry	A country in which a study takes or took place.			Geographic Area	BRIDG Class Terminology|BRIDG Terminology
C153135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153135>	C93484	Study Subject Experience Document Version|StudySubjectExperienceDocumentVersion	A document capturing the actual end-to-end (or beginning to point-in-time) experience of a single study subject within the context of a particular study.			Intellectual Product	BRIDG Class Terminology|BRIDG Terminology
C153137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153137>	C574|C2169	Orludodstat|BAY 2402234|BAY-2402234|BAY2402234|DHODH Inhibitor BAY2402234|Dihydroorotate Dehydrogenase Inhibitor BAY2402234|ORLUDODSTAT	An orally available inhibitor of dihydroorotate dehydrogenase (DHODH), with potential antineoplastic activity. Upon administration, orludodstat specifically targets, binds to and prevents the activation of DHODH, thereby preventing the fourth enzymatic step in de novo pyrimidine synthesis. This prevents uridine monophosphate (UMP) formation, DNA synthesis, cell division and cellular proliferation, causes reactive oxygen species (ROS) production, enables differentiation and induces apoptosis in susceptible tumor cells. DHODH, a mitochondrial enzyme, catalyzes the conversion of dihydroorotate (DHO) to orotate in the endogenous synthesis of UMP.	Orludodstat		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153138>	C25162	Information Source Type Code|InformationSourceTypeCode|informationSourceTypeCode	A coded value specifying the kind of system or data collection from which the record of the activity was derived.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C153139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153139>	C25162	Order Care Setting Type Code|OrderCareSettingTypeCode|orderCareSettingTypeCode	A coded value specifying the level of healthcare (care setting) the patient was in when the order was given.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C15313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15313>	C49236|C221766	Radiation Therapy|Cancer Radiotherapy|ENERGY_TYPE|ENERGY_TYPE|ENERGY_TYPE|ENERGY_TYPE|Energy Type|Irradiate|Irradiated|Irradiation|RADIATION|RADIOTHERAPY|RT|Radiation|Radiation|Radiation|Radiation|Radiation Therapy, NOS|Radiotherapeutics|Radiotherapy|Radiotherapy|Therapy, Radiation|irradiated|irradiation|radiation therapy|radiotherapy	Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.	Radiation Therapy		Therapeutic or Preventive Procedure	ALL Authorized Value Terminology|ALL Non-protocol Therapy Table|CDISC SDTM Intervention Type Terminology|CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|CDRH Health Effects - Health Impact Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Codelists Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Medical History Form|CPTAC Terminology|CPTAC Treatments Codelist|CRF5 Response Evaluation Clinical Evaluation Table|CTRP Intervention Terminology|CTRP Terminology|EWS Authorized Value Terminology|EWS Non-Protocol Therapy Table|EWS Radiation Therapy Table|EWS Variable Terminology|GCT Radiation Therapy Table|GCT Variable Terminology|GDC Terminology|GDC Value Terminology|HL Adverse Events Table|HL Authorized Value Terminology|HL Biopsy/Surgical Procedures Table|HL Concomitant Medication Table|HL Course Timing Table|HL Function Test Table|HL Histology Table|HL Imaging Table|HL Immunohistochemistry Table|HL Lab Table|HL Lesion Characteristics Table|HL Non-protocol Therapy Table|HL Off Protocol Therapy/Study Table|HL Protocol Treatment Modifications Table|HL Radiation Therapy Table|HL Secondary Malignant Neoplasm Table|HL Staging Table|HL Stem Cell Transplant Table|HL Subject Response Table|HL Survival Characteristics Table|HL Total Dose Table|HL Transfusion Medicine Procedures Table|HL Variable Terminology|HL Vitals Table|ICH M11 Intervention Type Value Set Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology|OS Radiation Therapy Table|OS Variable Terminology
C153140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153140>	C20189	Urgency|Immediacy|Urgent|Urgent	The pressing importance of something.			Conceptual Entity	
C153141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153141>	C25168	Bone Marrow Donor	Someone from whom bone marrow is removed for transplantation or other purpose.	Bone Marrow Donor		Human	CTRP Intervention Terminology|CTRP Terminology
C153142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153142>	C25168	Cornea Donor	Someone from whom a cornea is removed for transplantation or other purpose.	Cornea Donor		Human	CTRP Intervention Terminology|CTRP Terminology
C153143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153143>	C25161	Result Classification|ResultClassification|ResultClassification	A category describing the result as distinguished by anatomical or physiological system, etiology, or purpose.			Classification	BRIDG Class Terminology|BRIDG Terminology
C153144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153144>	C60778	Study Conduct|StudyConduct|StudyConduct|conduct|conduct	An ongoing and/or past performance of a formal investigation as specified in a study protocol.			Activity	BRIDG Class Terminology|BRIDG Sub-Domain Terminology|BRIDG Terminology|CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C153145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153145>	C25337	Enrolled Study Subject Number|enrolledStudySubjectNumber|enrolledStudySubjectNumber	An integer specifying the quantity of study subjects enrolled in the study at the current time.			Quantitative Concept	BRIDG Attribute Terminology|BRIDG Terminology
C153146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153146>	C21097	Hypnosedation|Hypnoanesthesia	A sedation technique that combines hypnosis, local anesthesia, and conscious sedation.	Hypnosedation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C153147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153147>	C201282|C155321|C129822	Anti-CD3/CD38 Bispecific Monoclonal Antibody AMG 424|AMG 424|AMG-424|AMG424|Anti-CD3 x Anti-CD38 Bispecific Monoclonal Antibody AMG 424|Anti-CD3/Anti-CD38 Bispecific Monoclonal Antibody AMG 424|CD3xCD38 BsAb AMG 424	A humanized, bispecific monoclonal antibody (BsAb) targeting CD3, a T-cell surface antigen, and CD38, a human cell surface glycoprotein and tumor-associated antigen (TAA), with potential antineoplastic activity. Upon intravenous administration, anti-CD3/CD38 bispecific monoclonal antibody AMG 424 binds to both CD3 on T-cells and CD38 expressed on tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis.	Anti-CD3/CD38 Bispecific Monoclonal Antibody AMG 424		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153148>	C210759	Olinciguat|IW 1701|IW-1701|IW1701|OLINCIGUAT|Soluble Guanylate Cyclase Stimulator IW-1701|Stimulator of Soluble Guanylate Cyclase IW-1701|sGC Stimulator IW-1701	An orally bioavailable stimulator of soluble guanylate cyclase (sGC), with potential anti-inflammatory and vasodilating activities.  Upon oral administration, olinciguat targets, allosterically binds to and enhances the nitric oxide (NO)-dependent catalytic activity of sGC. This enhances NO-sGC signaling and increases the formation of the intracellular second messenger cyclic guanosine monophosphate (cGMP), which is derived from guanosine triphosphate (GTP). This enhances NO/cGMP-mediated muscle relaxation, suppresses leukocyte-endothelial interactions and promotes vascular anti-inflammatory effects. The NO/sGC/cGMP signaling pathway plays an important role in vasodilation, blood flow and inflammatory processes. sGC, a heme-containing cytoplasmic signaling enzyme, catalyzes the formation of cGMP from GTP in response to NO binding to heme.	Olinciguat		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C153149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153149>	C129822|C128037	Lipustobart|Anti-PD-1 Monoclonal Antibody LZM009|LIPUSTOBART|LZM 009|LZM-009|LZM009	A recombinant, humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor, programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, lipustobart binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands, programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways, leading to the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1 is a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells that negatively regulates T-cell activation and effector function when activated by its ligands. PD-1 plays an important role in tumor evasion from host immunity.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15314>	C69035	Diagnostic Reagents and Test Kits	A diagnostic test kit that includes the necessary reagents.			Indicator, Reagent, or Diagnostic Aid|Manufactured Object	
C153150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153150>	C177692	CLDN18.2 Positive|Claudin 18 Isoform A2 Positive|Claudin 18.2 Positive|Claudin-18 Isoform A2 Positive	An indication that expression of Claudin-18 Isoform A2 has been detected in a sample.	CLDN18.2 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153151>	C63817	CXCR2 Antagonist QBM076|QBM 076|QBM-076|QBM076	An orally available small molecule antagonist of the G protein-coupled receptor, C-X-C motif chemokine receptor 2 (CXCR2), with potential immunomodulating and antineoplastic activities. Upon administration, QBM076 binds to and inhibits the activation of CXCR2, resulting in reduced neutrophil recruitment, myeloid-derived suppressor cell (MDSC) accumulation, and may potentially slow tumorigenesis and metastatic processes. CXCR2 is upregulated in a variety of cancer types, predominately in neutrophils/MDSCs rather than tumor cells, and is thought to contribute to tumor cell proliferation, invasion, and metastasis.	CXCR2 Antagonist QBM076		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153152>	C125932	Lymphoma Response to Immunomodulatory Therapy Criteria|LYRIC	A tumor response criteria for immunomodulatory therapies designed to account for tumor flares.			Intellectual Product	
C153153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153153>	C153152	Lymphoma Response to Immunomodulatory Therapy Criteria Indeterminate Response 1|IR1|Indeterminate Response 1|LYRIC IR1|LYRIC Indeterminate Response 1|LYRIC Intermediate Response 1|LYRIC1	An increase in overall tumor burden of greater than or equal to 50 percent of up to six measurable lesions in the first 12 weeks of therapy, without clinical deterioration.			Intellectual Product	
C153154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153154>	C153152	Lymphoma Response to Immunomodulatory Therapy Criteria Indeterminate Response 2|IR2|Indeterminate Response 2|LYRIC IR2|LYRIC Indeterminate Response 2|LYRIC Intermediate Response 2|LYRIC2	The appearance of new lesions or growth of one or more existing lesions greater than or equal to 50 percent at any time during treatment occurring in the context of lack of overall progression of overall tumor burden.			Intellectual Product	
C153155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153155>	C153152	Lymphoma Response to Immunomodulatory Therapy Criteria Indeterminate Response 3|IR3|Indeterminate Response 3|LYRIC IR3|LYRIC Indeterminate Response 3|LYRIC Intermediate Response 3|LYRIC3	An increase in F-fluorodeoxyglucose (FDG) uptake of one or more lesions without a concomitant increase in lesion size or number.			Intellectual Product	
C153156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153156>	C123589	LYRIC Indeterminate Response|IR|Indeterminate Lymphoma Response|Indeterminate Response|Intermediate Response	A lymphoma response that cannot be distinguished between flare/pseudo-progression and true progressive disease.			Finding	
C153159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153159>	C213967|C1511	Actinium Ac 225 Rosopatamab Tetraxetan|225Ac-J591|Ac 225 MOAB J591|Ac 225 Monoclonal Antibody J591|Actinium Ac-225 Anti-PSMA Monoclonal Antibody J591|Actinium Ac-225 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591	A radioimmunoconjugate consisting of a humanized monoclonal antibody directed against prostate specific membrane antigen (PSMA) labeled with the alpha particle-emitting radioisotope actinium Ac-225, with potential antineoplastic activity. Upon administration, actinium Ac 225 rosopatamab tetraxetan binds to the extracellular domain of PSMA with high affinity, thereby delivering alpha radiation to PSMA expressing cells. PSMA, a type II membrane protein expressed in all types of prostatic tissues, is often overexpressed in tumor cells.	Actinium Ac 225 Rosopatamab Tetraxetan		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15315>	C15747	Rehabilitation|Physical Health Services / Rehabilitation|Rehabilitation, Medical|rehabilitation|rehabilitation therapy	Restoration of the ability to function in a normal or near normal manner following disease, illness, or injury.	Rehabilitation		Therapeutic or Preventive Procedure	CDRH Health Effects - Health Impact Terminology|CTRP Intervention Terminology|CTRP Terminology
C153160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153160>	C8688|C8459|C206293|C178554	Recurrent Hepatosplenic T-Cell Lymphoma	The reemergence of hepatosplenic T-cell lymphoma after a period of remission.			Neoplastic Process	
C153161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153161>	C8689|C8459|C178556	Refractory Hepatosplenic T-Cell Lymphoma	A hepatosplenic T-cell lymphoma that is resistant to treatment.			Neoplastic Process	
C153162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153162>	C165233	H3 K27M Negative|H3 K27M Mutation Negative|H3 K28M Mutation Negative|H3 K28M Negative|H3 Lys27Met Negative|H3 Lys28Met Negative|H3 p.K28M Negative|H3 p.Lys28Met Negative|Histone 3 K27M Mutation Negative|Histone H3 K28M Negative|Histone H3 Lys27Met Negative|Histone H3 Lys28Met Negative	An indication that expression of the histone H3 K27M mutation has not been detected in a sample.	H3 K27M Negative		Finding	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153163>	C180944|C177687|C165233	BRAF V600E Negative|BRAF NP_004324.2:p.V600E Negative|BRAF NP_004324.2:p.Val600Glu Negative|BRAF Non-V600E Gene Mutation|BRAF V600E Mutation Negative|BRAF Val600Glu Negative|BRAF p.V600E Negative|BRAF p.Val600Glu Negative|NP_004324.2:p.V600E Negative|NP_004324.2:p.Val600Glu Negative|Non-BRAF V600E Gene Mutation|Serine/Threonine-Protein Kinase B-raf V600E Negative	An indication that expression of the BRAF V600E mutation has not been detected in a sample.	BRAF V600E Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153164>	C210018	Macy Catheter	A catheter designed for drug administration through a rectal route of delivery. It is specifically designed for rectal administration of liquid medication, especially when a patient is unable to take medications orally.	Macy Catheter		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C153165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153165>	C34070	Extracellular Vesicle|Plasma Extracellular Vesicle	Bilayer membrane fragments present in the blood plasma that are released by different cell types upon activation or death. Extracellular vesicles are usually classified as either exosomes (formed by the membranes of intracellular compartments, 50-100 nm in diameter) and ectosomes (also called microparticles or microvesicles, formed from plasma membrane, 100-1000 nm in diameter).			Body Part, Organ, or Organ Component	
C153166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153166>	C113392|C113124	Cell Preparation Tube|CPT	An evacuated blood collection tube that contains sodium heparin, intended for the collection of whole blood and the separation of mononuclear cells.			Manufactured Object	
C153167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153167>	C113392|C113124	Plasma Preparation Tube|PPT	An evacuated blood collection tube that contains an inert gel and spray-dried K2EDTA anticoagulant, intended for the collection of whole blood and the separation of plasma.			Manufactured Object	
C153169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153169>	C9270|C8925	Advanced Melanoma	A melanoma that has spread extensively to other anatomic sites or is no longer responding to treatment.			Neoplastic Process	
C15316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15316>	C15436	Relaxation Therapy	A therapeutic regimen in which the patient is guided by the therapist into alternate relaxation and flexing of muscles throughout the body as a method of pain control.  It is related to guided imagery and distraction and attention therapies.	Relaxation Therapy		Mental Process	CTRP Intervention Terminology|CTRP Terminology
C153170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153170>	C172617|C159556|C150595	Advanced Renal Cell Carcinoma	A renal cell carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.			Neoplastic Process	
C153171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153171>	C9270|C3482	Advanced Carcinoma	Carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153172>	C9270|C3208	Advanced Lymphoma	A lymphoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Lymphoma		Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C153173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153173>	C2167|C129825	EGFR Mutant-specific Inhibitor ZN-e4|KP-673|ZN e4|ZN-e4|ZNe4	An orally available selective inhibitor of certain epidermal growth factor receptor (EGFR) activating mutations, including the resistance mutation T790M, with potential antineoplastic activity. Upon administration, the EGFR mutant-specific inhibitor ZN-e4 specifically binds to and inhibits selective EGFR mutations, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Compared to other EGFR inhibitors, ZN-e4 may offer therapeutic benefits in tumors with T790M-mediated drug resistance and may limit toxicities associated with non-selective EGFR inhibitors. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.	EGFR Mutant-specific Inhibitor ZN-e4		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153174>	C126328	Usher Syndrome Type 2C|USH2C	An autosomal recessive sub-type of Usher syndrome caused by homozygous or compound heterozygous mutation(s) in the ADGRV1 gene, encoding adhesion G protein-coupled receptor V1. It may also result from biallelic digenic mutation(s) in ADGRV1 and PDZD7, which encodes PDZ domain-containing protein 7.			Disease or Syndrome	Cellosaurus Disease Terminology
C153175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153175>	C6633|C134157	Recurrent Mediastinal Lymphoma|Recurrent Primary Mediastinal Lymphoma	The reemergence of a mediastinal lymphoma after a period of remission.			Neoplastic Process	
C153176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153176>	C120271	Intracranial Extension|Extension|Intracranial Tumor Extension	The direct spread of a malignant tumor from an adjacent site into the cranium.	Intracranial Extension		Pathologic Function	CRF6 DIPG Imaging Assessment Table|CTRP Disease Terminology|CTRP Terminology
C153177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153177>	C6633|C134154	Refractory Mediastinal Lymphoma|Refractory Primary Mediastinal Lymphoma	A mediastinal lymphoma that is resistant to treatment.			Neoplastic Process	
C153178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153178>	C7757	Nijmegen Breakage Syndrome-Like Disorder|NBSLD|RAD50 Deficiency	A condition caused by mutation(s) in the RAD50 gene, encoding DNA repair protein RAD50. It is characterized by microcephaly and chromosomal instability.			Disease or Syndrome	Cellosaurus Disease Terminology
C153179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153179>	C84392|C53543	Intellectual Developmental Disorder, Autosomal Recessive 34|MRT34|Mental Retardation, Autosomal Recessive 34|Mental Retardation, Autosomal Recessive 34, with Variant Lissencephaly	An autosomal recessive condition caused by mutation(s) in the CRADD gene, encoding death domain-containing protein CRADD. It is characterized by mild to moderate intellectual disability and lissencephaly with anterior-predominant pachygyria.			Disease or Syndrome	Cellosaurus Disease Terminology
C15317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15317>	C64979	Second-Look Surgery|Reoperation|Repeat Surgery|Second Look|Surgical Revision|second-look surgery	Surgery performed after cancer treatment to assess the results of prior treatment and to plan possible future treatment.	Second-Look Surgery		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C153180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153180>	C201154	MAT2A Inhibitor AG-270|AG 270|AG-270|AG-270|AG270	An orally available small molecule inhibitor of methionine adenosyltransferase II alpha (MAT2A) with potential antineoplastic activity. Upon administration, AG-270 inhibits the activity of MAT2A, a metabolic enzyme responsible for the production of S-Adenosyl-L-methionine (SAM), a primary donor of methyl groups in cellular transmethylation reactions that regulate gene expression, cell growth, and differentiation. MAT2A activity is selectively essential in cancer cells deficient in methylthioadenosine phosphorylase (MTAP), a critical enzyme in the methionine salvage pathway, that is deleted in some human cancers. Inhibition of MAT2A may potentially inhibit tumor cell growth in MTAP-deleted cancers that rely heavily on SAM synthesis.	MAT2A Inhibitor AG-270		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153181>	C16818	Contrast-Enhanced Mammography|CEM	A mammography technique that incorporates the administration of an iodinated contrast agent to enhance lesions that are not visible on standard mammograms. CEM provides low-energy 2D mammographic images analogous to digital mammography and contrast-enhanced recombined images that allow assessment of neovascularity similar to that offered by MRI.	Contrast-Enhanced Mammography		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C153182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153182>	C171284|C154321|C143013	Locally Advanced Skin Squamous Cell Carcinoma|Locally Advanced Cutaneous Squamous Cell Carcinoma	A squamous cell carcinoma of the skin that has spread from its original site of growth to nearby tissues or lymph nodes.			Neoplastic Process	
C153184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153184>	C8825|C162194	Advanced Synovial Sarcoma	A synovial sarcoma that has spread extensively to other anatomic sites or is no longer responding to treatment.			Neoplastic Process	
C153185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153185>	C9270|C152076	Advanced Sarcoma	A sarcoma that has spread extensively to other anatomic sites or is no longer responding to treatment.			Neoplastic Process	
C153187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153187>	C15301	Systematic Light Exposure|sLE	A type of light therapy that uses exposure to bright white light (BWL) from a proprietary LED light source for treatment of cancer-related fatigue.	Systematic Light Exposure		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C153188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153188>	C16830	Litebook|Litebook 1.2|Litebook Edge	A proprietary light source that uses white light emitting diodes (LED) to mimic the visible spectrum of sunlight (full spectrum white light), with minimum glare and maximum eye comfort.			Medical Device	
C153189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153189>	C205365	Transcriptomics|Transcriptome Profiling	A study of the complete set of RNA transcripts that are produced by the genome, under specific circumstances or in a specific cell.			Biomedical Occupation or Discipline	GDC Terminology|GDC Value Terminology|pFDA Bioinformatics/Genomics Terminology|precisionFDA Terminology
C15318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15318>	C92722	Reproducibility	The ability to yield similar results given a set of constraints.			Qualitative Concept	
C153190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153190>	C84343	Epigenomics	A study of the complete set of epigenetic modifications on the genetic material of a cell.			Biomedical Occupation or Discipline	
C153191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153191>	C84343	Metagenomics	The direct study of genetic material recovered from environmental samples, largely dominated by microbial organisms.			Biomedical Occupation or Discipline	pFDA Bioinformatics/Genomics Terminology|precisionFDA Terminology
C153192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153192>	C205365|C18816	Glycomics	A study of the complete set of glycans produced in a given cell or organism under specific conditions.			Biomedical Occupation or Discipline	
C153193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153193>	C205365	Lipidomics	A study of the complete set of lipids produced in a given cell or organism under specific conditions.			Biomedical Occupation or Discipline	
C153194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153194>	C19896	Transcriptome	The complete set of RNA transcripts that are produced by the genome, under specific circumstances or in a specific cell.			Classification	
C153195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153195>	C16629	Epigenome	The complete set of epigenetic modifications on the genome of a cell.			Gene or Genome	
C153196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153196>	C16629	Metagenome	The total genetic material recovered from an environmental sample.			Gene or Genome	
C153197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153197>	C19896	Lipidome	The complete set of lipids produced in a given cell or organism under specific conditions.			Conceptual Entity	
C153198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153198>	C217121	Morisky Medication Adherence Scale|MMAS	A structured, self-reported measure designed to estimate the risk of medication non-adherence. It was originally developed with 4 questions (MMAS-4), but was later expanded to 8 questions (MMAS-8).	Morisky Medication Adherence Scale		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C153199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153199>	C19975	Primary Immune Deficiency Treatment Consortium|PIDTC	A consortium of 42 centers in North America whose shared goal is to improve the outcome of patients with rare, life threatening, inherited disorders of the immune system.			Professional or Occupational Group	
C1531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1531>	C1591	Recombinant Eotaxin|Eotaxin	A recombinant therapeutic agent which is chemically identical to or similar to the endogenous chemokine eotaxin, a member of the C-C cytokine family which is chemotactic for eosinophils.  The early increase in eotaxin paralleled eosinophil infiltration in the asthmatic lung tissue in animal models hinted a potential role for eotaxin in immunotherapy.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C153200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153200>	C160783|C128798	Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma|Locally Advanced Non-Squamous Non-Small Cell Lung Cancer|Locally Advanced Non-Squamous Non-Small Cell Lung Carcinoma	Non-squamous non-small cell lung carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Non-Squamous Non-Small Cell Lung Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153201>	C173330|C162158|C157364	Advanced Lung Non-Small Cell Squamous Carcinoma|Advanced Non-Small Cell Squamous Lung Cancer|Advanced Non-Small Cell Squamous Lung Carcinoma|Advanced Squamous Non-Small Cell Lung Carcinoma	A non-small cell squamous lung carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Non-Small Cell Squamous Lung Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153202>	C4878|C3482|C176862	Metastatic Lung Carcinoma	A carcinoma that arises from the lung and has metastasized to another anatomic site.			Neoplastic Process	
C153203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153203>	C176863|C153202|C153171	Advanced Lung Carcinoma	A lung carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.			Neoplastic Process	
C153205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153205>	C116540	Chemokine Modulation Therapy|Chemokine Targeted Therapy	Therapy used to modulate the activity of chemokine receptors or their ligands, potentially modifying immune response and tumor-related processes, including tumor cell growth, angiogenesis, and metastasis.	Chemokine Modulation Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C153206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153206>	C153202|C148130	Locally Advanced Lung Carcinoma	A lung carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.			Neoplastic Process	
C153207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153207>	C25404	Obscure|Obscured	Make less clear or visible.			Activity	
C153208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153208>	C25404	Coalesce|Coalesced	Join together or fuse.			Activity	
C153209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153209>	C78275	Miridesap|(2R)-1-[6-[(2R)-2-carboxypyrrolidin-1-yl]-6-oxohexanoyl]pyrrolidine-2-carboxylic acid|CPHPC|CPHPC|GSK 2315698|GSK-2315698|GSK2315698|MIRIDESAP	A small molecule compound that depletes serum amyloid P component (SAP), with potential anti-amyloid activity. Upon injection, miridesap binds to circulating SAP, forming complexes that are rapidly cleared in the liver. SAP bound to amyloid deposits is in equilibrium with plasma SAP, and depletion of the latter should lead to the eventual removal of SAP from amyloid deposits as well. SAP is a universal component of amyloid deposits and contributes to the pathogenesis of amyloidosis.	Miridesap		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C15320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15320>	C15429	Study Design|Experiment Design|Experimental Design|Research Design|designType|study design|study design	A plan detailing how a study will be performed in order to represent the phenomenon under examination, to answer the research questions that have been asked, and defining the methods of data analysis. Study design is driven by research hypothesis being posed, study subject/population/sample available, logistics/resources: technology, support, networking, collaborative support, etc.			Research Activity	BRIDG Attribute Terminology|BRIDG Terminology|CDISC DDF Entities Terminology|CDISC DDF Terminology|CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology|SeroNet Study Descriptors|SeroNet Variables
C153210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153210>	C20401	Dezamizumab|Anti-SAP Monoclonal Antibody|Anti-SAP mAb|DEZAMIZUMAB|GSK-2398852|GSK2398852	A fully humanized monoclonal IgG1 anti-serum amyloid P component (SAP) antibody, with potential anti-amyloid activity. Upon intravenous administration, dezamizumab binds to SAP in amyloid deposits, thereby activating compliment and triggering the rapid clearance of amyloid by macrophage-derived multinucleated giant cells. SAP is a universal component of amyloid deposits and contributes to the pathogenesis of amyloidosis.	Dezamizumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C153213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153213>	C170470|C148130|C126465	Locally Advanced Head and Neck Carcinoma	A head and neck carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.			Neoplastic Process	
C153214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153214>	C129821	Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA|KrasG12D siRNA-loaded Mesenchymal Stromal Cells-derived Exosomes|MSC-derived Exosomes with KrasG12D siRNA	Exosomes derived from mesenchymal stromal cells (MSCs) that have been engineered to carry short interfering RNA (siRNA) specific to the KRAS G12D mutation subtype. Upon administration, the KRAS G12D siRNA-loaded exosomes deliver siRNA to tumor cells expressing the mutant form of KRAS, potentially silencing its activity. The KRAS G12D mutation is thought to drive tumorigenesis and progression in some cancers.	Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153215>	C201282|C112889	Anti-CD19/CD3 BiTE Antibody AMG 562|AMG 562|AMG-562|AMG562|BiTE Antibody AMG 562|Bispecific T-cell Engager Antibody AMG 562|CD19/CD3-directed Bispecific T-cell Engager Antibody AMG 562	A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the B-cell-specific membrane protein CD19, and another that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19/CD3 BiTE antibody AMG 562 binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD19 antigen expressed on malignant B-cells. This activates and redirects CTLs to CD19-expressing tumor cells, resulting in CTL-mediated killing of tumor cells. CD19 is a membrane antigen that is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.	Anti-CD19/CD3 BiTE Antibody AMG 562		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153216>	C171256	Smart Device	An electronic device that is capable of connecting to a network and can make use of the network for more complex services.			Manufactured Object	
C153217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153217>	C2868	Cardiac Amyloidosis	The accumulation of amyloid protein in the heart. Cardiac amyloidosis is irreversible and may lead to conductive dysfunction as well as heart failure secondary to restrictive cardiomyopathy.	Cardiac Amyloidosis		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C153218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153218>	C28681|C138180|C129826	Autologous TCR-engineered T-cells IMA202|ACTengine IMA202|IMA 202|IMA-202|IMA202|IMA202 T-cell Product|IMA202 T-cells	A preparation of autologous T-lymphocytes that are genetically modified with a lentiviral vector encoding a T-cell receptor (TCR) targeting patient-specific tumor associated antigens (TAAs), with potential antineoplastic activity. Upon intravenous administration back into the patient, the autologous TCR-engineered T-cells IMA202 specifically recognize and bind to the TAA on cancer cells, which induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against the TAA-positive cancer cells.	Autologous TCR-engineered T-cells IMA202		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153219>	C97927	CBLB Gene Mutation|Cas-Br-M Ecotropic Retroviral Transforming Sequence B Gene Mutation|Cbl Proto-Oncogene B Gene Mutation|Cbl-B Gene Mutation|RNF56 Gene Mutation	A change in the nucleotide sequence of the CBLB gene.	CBLB Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15321>	C20181	Research Resource|Resource|Resource|Resource|Resources	The funding, research facilities, and materials available for research			Idea or Concept	BRIDG Class Terminology|BRIDG Terminology
C153220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153220>	C177692	CD4 Positive|CD4 Antigen Positive|CD4 Molecule Positive|CD4-Positive|OKT4 Antigen Positive|T-Cell Antigen T4/Leu3 Positive|T-Cell Surface Glycoprotein CD4 Positive|T4/Leu-3 Positive	An indication that CD4 expression has been detected in a sample.	CD4 Positive		Laboratory or Test Result	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153221>	C177692	CD52 Positive|CAMPATH-1 Antigen Positive|CD52 Antigen Positive|CD52 Molecule Positive|CD52-Positive|CDw52 Positive	An indication that CD52 expression has been detected in a sample.	CD52 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153222>	C165233	NCAM1 Negative|CD56 Antigen Negative|CD56 Negative|CD56 Negative|Neural Cell Adhesion Molecule 1 Negative	Indicates that NCAM1 expression has not been detected in a sample.	NCAM1 Negative		Laboratory or Test Result	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153223>	C165233	Chromogranin Negative|CHG Negative	An indication that the expression of chromogranin family proteins have not been detected in a sample,	Chromogranin Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153224>	C27408|C156096	Colorectal Carcinoma Metastatic in the Lung|Metastatic Colorectal Cancer in the Lung	A carcinoma that originates from the wall of the colon or rectum and has spread to the lungs.	Colorectal Carcinoma Metastatic in the Lung		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153225>	C97927	CSF3R Gene Mutation|CD114 Gene Mutation|Colony Stimulating Factor 3 Receptor (Granulocyte) Gene Mutation|Colony Stimulating Factor 3 Receptor Gene Mutation|Colony-Stimulating Factor 3 Receptor, Granulocyte Gene Mutation|GCSF-R Gene Mutation|GCSFR Gene Mutation	A change in the nucleotide sequence of the CSF3R gene.	CSF3R Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153226>	C4881|C36303	Metastatic Breast Carcinoma in the Spine|Breast Carcinoma Metastatic in the Spine|Metastatic Breast Cancer in the Spine	A carcinoma that arises from the breast and has spread to the spine.	Breast Carcinoma Metastatic in the Spine		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153227>	C213275|C153238	Metastatic Breast Carcinoma in the Lymph Nodes|Breast Carcinoma Metastatic in Lymph Node|Breast Carcinoma Metastatic in the Lymph Nodes|Metastatic Breast Cancer in the Lymph Nodes	A carcinoma that arises from the breast and has spread to the lymph nodes.	Breast Carcinoma Metastatic in the Lymph Nodes		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153228>	C35880	Decrease in Blasts|Blast Cells Decreased|Blasts Decreased	A semi-quantitative microscopic finding indicating that the amount of immature mononuclear cells in a sample from a certain subject has decreased when compared to a prior sample from the same subject.	Decrease in Blasts		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C153229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153229>	C97927	ACKR1 Gene Mutation|Atypical Chemokine Receptor 1 (Duffy Blood Group) Gene Mutation|CCBP1 Gene Mutation|CD234 Gene Mutation|DARC Gene Mutation|DARC/ACKR1 Gene Mutation|Dfy Gene Mutation|Duffy Blood Group, Chemokine Receptor Gene Mutation|FY Gene Mutation|GPD Gene Mutation|GpFy Gene Mutation|WBCQ1 Gene Mutation	A change in the nucleotide sequence of the ACKR1 gene.	ACKR1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15322>	C15315	Respiratory Therapy|respiratory therapy	Any form of treatment that acts to improve or assist with respiratory function.	Respiratory Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C153230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153230>	C190205|C153229	ACKR1 NM_002036.3:c.-67T>C|ACKR1 c.-67T>C|Atypical Chemokine Receptor 1 (Duffy Blood Group) Gene c.-67T>C|CCBP1 c.-67T>C|CD234 c.-67T>C|DARC -46T>C|DARC c.-46T>C|DARC c.-67T>C|DARC/ACKR1 c.-67T>C|Dfy c.-67T>C|Duffy Blood Group, Chemokine Receptor Gene c.-67T>C|FY c.-67T>C|FYB-ES Allele|FYB-Erythroid Silent Allele|GPD c.-67T>C|GpFy c.-67T>C|WBCQ1 c.-67T>C	A nucleotide substitution at position -67 in the upstream promoter region of the ACKR1 gene where thymine has been mutated to cytosine.	ACKR1 NM_002036.3:c.-67T>C		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153231>	C165233	Duffy Null Polymorphism|ACKR1 Negative|DARC Negative|Duffy Negative|Duffy Null|Duffy-Null State|Fy(a-b-)|Fy(a-b-) Phenotype	A finding indicating that expression of atypical chemokine receptor 1 protein (ACKR1; DARC; Duffy antigen/chemokine receptor) is not detected on a subject's red blood cells. The Duffy null state is associated with leukopenia and neutropenia, decreased rate of HIV disease progression and with resistance to infection by the malarial parasite Plasmodium vivax. (Blood. 2009; 114:2783-2792.)	Duffy Null Polymorphism		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153232>	C98357|C190003	Sensitizing EGFR Gene Mutation|EGFR Sensitizing Mutation|ERBB1 Sensitizing Mutation|Epidermal Growth Factor Receptor Sensitizing Gene Mutation|HER1 Sensitizing Mutation|c-erbB1 Sensitizing Mutation	A change in the sequence of the EGFR gene that results in increased sensitivity to EGFR targeted agents.	Sensitizing EGFR Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153233>	C81326	Elevated Alpha-Hydroxyglutarate|Elevated 2-HG|Elevated 2-Hydroxy-Pentanedioic Acid|Elevated 2-Hydroxyglutarate|Elevated 2-Hydroxyglutaric Acid|Elevated 2-Hydroxypentanedioic Acid|Elevated 2HG|Elevated Alpha-Hydroxyglutaric Acid	A finding indicating elevated concentrations of alpha-hydroxyglutarate in a sample.	Elevated Alpha-Hydroxyglutarate		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C153235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153235>	C81326	Elevated WT1|Elevated Wilms Tumor 1|WT1 Elevated	A finding indicating elevated concentrations of WT1 in a sample.	Elevated WT1		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153236>	C118376	FGF9 Gene Amplification|FGF-9 Gene Amplification|FGF9 Amplification|Fibroblast Growth Factor 9 (Glia-Activating Factor) Gene Amplification|Fibroblast Growth Factor 9 Gene Amplification|Fibroblast Growth Factor-9 Gene Amplification|GAF Gene Amplification|Glia-Activating Factor Gene Amplification|HBFG-9 Gene Amplification|SYNS3 Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the FGF9 gene.	FGF9 Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153237>	C150617|C150616|C132244	FGFR2 Gene Fusion Positive|BEK Gene Fusion Positive|CD332 Gene Fusion Positive|ECT1 Gene Fusion Positive|FGFR-2 Gene Fusion Positive|FGFR2 Fusion|FGFR2 Fusion Gene|Fibroblast Growth Factor Receptor 2 Gene Fusion Positive|K-SAM Gene Fusion Positive|KGFR Gene Fusion Positive|Keratinocyte Growth Factor Receptor Gene Fusion Positive	An indication that a FGFR2 fusion gene has been detected in a sample.	FGFR2 Gene Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153238>	C4872|C3482|C170728	Metastatic Breast Carcinoma	A carcinoma that arises from the breast and has metastasized to another anatomic site.			Neoplastic Process	
C153239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153239>	C199141	International Myeloma Working Group|IMWG	A working group established to conduct basic, clinical and translational research in a collaborative manner to improve outcomes in myeloma and to provide scientifically valid and critically appraised consensus opinions on the diagnosis and treatment of myeloma and related disorders.			Population Group	
C15323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15323>	C15691|C15332	Salpingo-Oophorectomy|Destructive procedure on ovaries and fallopian tubes|salpingo-oophorectomy	Surgical removal of the fallopian tube(s) and ovary(ies).	Salpingo-Oophorectomy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C153240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153240>	C156028	FGFR Gene Rearrangement|FGF Receptor Gene Family Rearrangement|FGF Receptor Gene Rearrangement|FGFR Family Gene Rearrangement|FGFR Family Rearrangement|Fibroblast Growth Factor Receptor Family Gene Rearrangement|Fibroblast Growth Factor Receptor Gene Rearrangement	A molecular abnormality indicating rearrangement of an FGFR family gene.	FGFR Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C153241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153241>	C219858|C153240	FGFR2 Gene Rearrangement|BEK Gene Rearrangement|CD332 Gene Rearrangement|ECT1 Gene Rearrangement|FGFR-2 Gene Rearrangement|Fibroblast Growth Factor Receptor 2 Gene Rearrangement|K-SAM Gene Rearrangement|KGFR Gene Rearrangement|Keratinocyte Growth Factor Receptor Gene Rearrangement|Positive	A molecular abnormality indicating rearrangement of the FGFR2 gene.	FGFR2 Gene Rearrangement		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153242>	C94299|C177692	Folate Receptor Family Positive|Folate Binding Protein Positive|Folate Receptor Positive|Folate-Binding Protein Positive	An indication that expression of a member of the folate receptor family has been detected in a sample.	Folate Receptor Family Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153243>	C158737	Hepatitis B Surface Antibody Positive|Anti-HBs Antibody Positive|Anti-HBs Positive|Anti-HBsAb Positive|Anti-Hepatitis B Virus Surface Antibody Positive|HBsAb Positive|Hepatitis B Virus Surface Antibody Positive|Positive	An indication that antibodies that recognize a hepatitis B virus surface protein have been detected in a sample.	Hepatitis B Surface Antibody Positive		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Terminology
C153244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153244>	C35681|C175007	Hepatitis B Surface Antibody Negative|Anti-HBs Antibody Negative|Anti-HBs Negative|Anti-HBsAb Negative|Anti-Hepatitis B Virus Surface Antibody Negative|HBsAb Negative|Hepatitis B Virus Surface Antibody Negative|Negative	An indication that antibodies that recognize a hepatitis B virus surface protein have not been detected in a sample.	Hepatitis B Surface Antibody Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Terminology
C153245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153245>	C132890	Hematopoietic Immune Cell	A population of cells involved in the formation of blood cells and in host defense.	Hematopoietic Immune Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C153246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153246>	C19676	Homologous Recombination Repair Gene|HHR Gene|HRR Gene|Recombination Repair Gene	A gene involved in homologous recombination repair of DNA double-strand breaks.	Homologous Recombination Repair Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153247>	C97927	KDM2B Gene Mutation|CXXC2 Gene Mutation|F-Box and Leucine-Rich Repeat Protein 10 Gene Mutation|FBXL10 Gene Mutation|Fbl10 Gene Mutation|JEMMA (Jumonji Domain, EMSY-Interactor, Methyltransferase Motif) Protein Gene Mutation|JHDM1B Gene Mutation|Lysine (K)-Specific Demethylase 2B Gene Mutation|Lysine Specific Demethylase 2B Gene Mutation|PCCX2 Gene Mutation	A change in the nucleotide sequence of the KDM2B gene.	KDM2B Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153248>	C164049	Sequence Alignment Map|SAM|Sequence Alignment/Map	A tab-delimited, text-based format for storing biological sequences aligned to a reference sequence. A SAM file includes an optional header section and an alignment section. Each alignment line has 11 mandatory fields for essential alignment information, such as mapping position, and a variable number of optional fields.			Qualitative Concept	pFDA Bioinformatics/Genomics Terminology|precisionFDA Terminology
C153249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153249>	C171252	Binary Alignment Map|BAM|BAM|Binary Alignment/Map|Binary Sequence Alignment Map	A binary representation of a sequence alignment map (SAM), a compact and indexable representation of nucleotide sequence alignments, compressed by the BGZF (Blocked GNU Zip Format) library.			Qualitative Concept	GDC Terminology|GDC Value Terminology|pFDA Bioinformatics/Genomics Terminology|precisionFDA Terminology
C15324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15324>	C25404	Self Care|Self-care|Selfcare	Personal performance of activities or tasks traditionally performed by professional health care providers.			Health Care Activity	
C153250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153250>	C42761	FASTQ Format|FASTQ|FASTQ|FASTQ|FASTQ	A text-based format for storing a biological sequence that encodes the nucleotide calls as well as their quality scores. It is an extension of the FASTA format.			Qualitative Concept	GDC Terminology|GDC Value Terminology|pFDA Bioinformatics/Genomics Terminology|precisionFDA Terminology
C153251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153251>	C202673	KIT Exon 18 Mutation|CD117 Exon 18 Mutation|KIT Proto-Oncogene Tyrosine Protein Kinase Gene Exon 18 Mutation|c-KIT Exon 18 Mutation|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Gene Exon 18 Mutation	A change in the nucleotide sequence in exon 18 of the KIT gene.	KIT Exon 18 Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153252>	C97927	KMT2C Gene Mutation|HALR Gene Mutation|Lysine (K)-Specific Methyltransferase 2C Gene Mutation|Lysine Methyltransferase 2C Gene Mutation|MLL3 Gene Mutation|Myeloid/Lymphoid or Mixed-Lineage Leukemia 3 Gene Mutation	A change in the nucleotide sequence of the KMT2C gene.	KMT2C Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153253>	C45581	MAP2K1 Gene Amplification|MAPKK1 Gene Amplification|MEK1 Gene Amplification|MKK1 Gene Amplification|Mitogen-Activated Protein Kinase Kinase 1 Gene Amplification|PRKMK1 Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the MAP2K1 gene.	MAP2K1 Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C153254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153254>	C133155	MAP2K1 Gene Rearrangement|MAPKK1 Gene Rearrangement|MEK1 Gene Rearrangement|MKK1 Gene Rearrangement|Mitogen-Activated Protein Kinase Kinase 1 Gene Rearrangement|PRKMK1 Gene Rearrangement	A molecular abnormality indicating rearrangement of the MAP2K1 gene.	MAP2K1 Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C153255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153255>	C45581	MAP2K2 Gene Amplification|MAPKK2 Gene Amplification|MEK2 Gene Amplification|MKK2 Gene Amplification|Mitogen-Activated Protein Kinase Kinase 2 Gene Amplification|PRKMK2 Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the MAP2K2 gene.	MAP2K2 Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C153256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153256>	C97927|C136422	MAP2K2 Gene Mutation|MAPKK2 Gene Mutation|MEK2 Gene Mutation|MKK2 Gene Mutation|Mitogen-Activated Protein Kinase Kinase 2 Gene Mutation|PRKMK2 Gene Mutation	A change in the nucleotide sequence of the MAP2K2 gene.	MAP2K2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C153257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153257>	C133155	MAP2K2 Gene Rearrangement|MAPKK2 Gene Rearrangement|MEK2 Gene Rearrangement|MKK2 Gene Rearrangement|Mitogen-Activated Protein Kinase Kinase 2 Gene Rearrangement|PRKMK2 Gene Rearrangement	A molecular abnormality indicating rearrangement of the MAP2K2 gene.	MAP2K2 Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C153258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153258>	C63474	Problem-Solving Skills Training|PSST	Cognitive-behavioral interventions designed to adapt to the needs of patients to improve their problem-solving skills and alleviate stress.	Problem-Solving Skills Training		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C153259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153259>	C214800|C129822	Tilogotamab|DR5 HexaBody Agonist GEN1029|GEN 1029|GEN1029|HexaBody-DR5-01/DR5-05|HexaBody-DR5/DR5|Hx-DR5-01/05|TILOGOTAMAB	An agonistic hexamer formation-enhanced mixture of two antibodies (HexaBody) that target two separate epitopes on death receptor type 5 (DR5; TNFRSF10B; tumor necrosis factor-related apoptosis-inducing ligand receptor 2; TRAILR2), with potential antineoplastic activity. Upon administration, tilogotamab specifically binds to and activates DR5. This results in the activation of caspase cascades and the induction of apoptosis in DR5-expressing tumor cells. DR5, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is involved in the promotion of caspase-dependent apoptosis. Compared to other DR5 antibody-based agonists, the antibodies in GEN1029 (DR5-01 and DR5-05) elicit increased receptor activation because they exhibit enhanced formation of antibody hexamers and receptor clusters at the cell surface due to E430G mutations in the Fc domains of both antibodies.	Tilogotamab		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15325>	C15289	Skin Transplantation|dermatoplasty|skin grafting	The grafting of skin from one location to another in an attempt to replace a segment that is lost or damaged beyond repair.	Skin Transplantation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C153260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153260>	C48463|C117055	Milligram Morphine Equivalent|MEU|MME|Morphine Equivalent Units|Morphine Milligram Equivalent	A value assigned to opioids to represent their relative potencies. It is determined by using an equivalency factor to calculate a dose of morphine that is equivalent to the ordered opioid.			Quantitative Concept	
C153261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153261>	C20401|C1742|C129822	Anti-Globo H Monoclonal Antibody OBI-888|OBI 888|OBI-888|OBI-888|OBI888	A monoclonal antibody targeting the hexasaccharide glycosphingolipid antigen Globo H with potential immunostimulating, anti-angiogenic and antineoplastic activities. Upon infusion, anti-Globo H monoclonal antibody OBI-888 may induce tumor cell destruction via the activation of antibody dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC), and may reduce immunosuppression. Globo H is a tumor-associated antigen (TAA) expressed on the surface of various types of cancer cells.	Anti-Globo H Monoclonal Antibody OBI-888		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153262>	C61074	Tinodasertib|AUM-001|AUM001|ETC 1907206|ETC 206|ETC-1907206|ETC-206|ETC1907206|ETC206|MNK1/2 Inhibitor ETC-1907206|TINODASERTIB	A selective mitogen-activated protein kinase (MAPK)-interacting protein kinase (MNK) types 1/2 inhibitor with potential antineoplastic activity. Upon administration, tinodasertib may inhibit MNK1/2-dependent phosphorylation of eukaryotic initiation factor 4E (eIF4E) and interfere with its role in mRNA translation. eIF4E is an oncoprotein that must be phosphorylated before it can promote the proliferation and progression of tumor cells. MNKs are a family of serine/threonine kinases that have been implicated in oncogenic transformation and tumor progression.	Tinodasertib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153263>	C177692	MUC16 Positive|CA125 Antigen Positive|CA125 Positive|MUC-16 Positive|MUC16 Antigen Positive|Mucin 16 Positive|Mucin-16 Positive|Ovarian Cancer-Related Tumor Marker CA125 Positive|Ovarian Carcinoma Antigen CA125 Positive	An indication that MUC16 expression has been detected in a sample.	MUC16 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153264>	C16606|C150712	NF1 Gene Deletion|NF1 Deletion|NFNS Gene Deletion|Neurofibromin 1 Gene Deletion	A molecular abnormality referring to the loss of at least one copy of the NF1 gene.	NF1 Gene Deletion		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C153265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153265>	C177692	SLC5A5 Positive|NIS Positive|Sodium-Iodide Symporter Positive|Sodium/Iodide Cotransporter Positive|Solute Carrier Family 5 Member 5 Positive|TDH1 Positive	An indication that SLC5A5 expression has been detected in a sample.	SLC5A5 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153266>	C97927	NLRP1 Gene Mutation|CARD7 Gene Mutation|CIDED Gene Mutation|CLR17.1 Gene Mutation|DEFCAP Gene Mutation|NAC Gene Mutation|NALP1 Gene Mutation|NLR Family Pyrin Domain Containing 1 Gene Mutation|PP1044 Gene Mutation	A change in the nucleotide sequence of the NLRP1 gene.	NLRP1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153267>	C97927	NSD1 Gene Mutation|ARA267 Gene Mutation|KMT3B Gene Mutation|Nuclear Receptor Binding SET Domain Protein 1 Gene Mutation|Nuclear Receptor-Binding Su-Var, Enhancer of Zeste, and Trithorax Domain Protein 1 Gene Mutation|SOTOS Gene Mutation|SOTOS1 Gene Mutation|STO Gene Mutation	A change in the nucleotide sequence of the NSD1 gene.	NSD1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153268>	C97927	NUP98 Gene Mutation|ADAR2 Gene Mutation|ADIR2 Gene Mutation|NUP196 Gene Mutation|NUP96 Gene Mutation|Nucleoporin 98 Gene Mutation	A change in the nucleotide sequence of the NUP98 gene.	NUP98 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153269>	C133155	NUTM1 Gene Rearrangement|C15orf55 Gene Rearrangement|FAM22H Gene Rearrangement|NUT Gene Rearrangement|NUT Midline Carcinoma, Family Member 1 Gene Rearrangement|NUT Rearrangement|Nuclear Protein in Testis Gene Rearrangement	A molecular abnormality indicating rearrangement of the NUTM1 gene.	NUTM1 Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C15326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15326>	C15747	Sperm Banking|sperm banking	Freezing sperm for use in the future. This procedure can allow men to father children after loss of fertility.			Health Care Activity	
C153270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153270>	C97927	PHF6 Gene Mutation|BFLS Gene Mutation|BORJ Gene Mutation|CENP-31 Gene Mutation|CENP31 Gene Mutation|Centromere Protein 31 Gene Mutation|PHD Finger Protein 6 Gene Mutation	A change in the nucleotide sequence of the PHF6 gene.	PHF6 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153271>	C177683	RSPO Gene Fusion Positive|R-Spondin Family Gene Fusion Positive|R-Spondin Gene Fusion Positive|R-Spondin Homolog Gene Fusion Positive|RSPO Family Gene Fusion Positive|RSPO Fusion|RSPO Gene Fusion	Indicates that a fusion containing RSPO family gene sequences has been detected in a sample.	RSPO Gene Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153272>	C154495|C153560|C133697	TFE3 Gene Translocation|RCCP2 Gene Translocation|RCCX1 Gene Translocation|TFE3 Translocation|TFEA Gene Translocation|Transcription Factor Binding to IGHM Enhancer 3 Gene Translocation|Transcription Factor E3 Gene Translocation|bHLHe33 Gene Translocation	A cytogenetic abnormality that refers to a translocation involving the TFE3 gene.	TFE3 Gene Translocation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153273>	C223890|C154495	TFEB Gene Translocation|BHLHE35 Gene Translocation|TCFEB Gene Translocation|TFEB Translocation|Transcription Factor EB Gene Translocation	A cytogenetic abnormality that refers to a translocation involving the TFEB gene.	TFEB Gene Translocation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153274>	C20130	DNMT3 Family|DNA (Cytosine-5)-Methyltransferase 3|DNA (Cytosine-5)-Methyltransferase 3 Family|DNMT3	A family of proteins involved in methylation of DNA. There are three proteins in this family. DNA (cytosine-5)-methyltransferase (DNMT) 3A and DNMT3B are DNA methyltransferases that catalyze the methylation of hemimethylated and unmethylated CpG at the same rate. DNMT3-like (DNMT3L) has no enzymatic activity; instead this protein interacts with other members of the family and regulates their enzymatic activity.	DNMT3 Family		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153275>	C21344	CRIPTO Gene|CRIPTO|CRIPTO|Cripto, EGF-CFC Family Member Gene|TDGF1|TDGF1 Gene	This gene plays a role in the modulation of signaling by the growth factor Nodal homolog.	TDGF1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C153276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153276>	C153275	CRIPTO wt Allele|CR|CR-1|CRGF|Cripto, EGF-CFC Family Member wt Allele|Cripto-1|TDGF1|TDGF1 wt Allele|Teratocarcinoma-Derived Growth Factor 1 Gene	Human CRIPTO wild-type allele is located in the vicinity of 3p21.31 and is approximately 8 kb in length. This allele, which encodes protein Cripto, is involved in regulation of signaling by Nodal homolog. Mutation of the gene is associated with defects in forebrain development.	TDGF1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153277>	C20424	Protein Cripto|CR-1|CRGF|CRIPTO|CRIPTO-1|Cripto Growth Factor|Cripto, EGF-CFC Family Member|Cripto-1|Cripto-1 Growth Factor|Epidermal Growth Factor-Like Cripto Protein CR1|TDGF-1|TDGF1|Teratocarcinoma-Derived Growth Factor 1|Teratocarcinoma-Derived Growth Factor 1	Protein Cripto (188 aa, ~21 kDa) is encoded by the human CRIPTO gene. This protein plays a role in growth factor signaling pathways mediated by Nodal homolog.	Teratocarcinoma-Derived Growth Factor 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153278>	C8524|C153279	Locally Advanced Unresectable Malignant Neoplasm|Locally Advanced Unresectable Malignant Tumor	A malignant neoplasm that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.			Neoplastic Process	
C153279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153279>	C36263|C27359	Metastatic Unresectable Malignant Neoplasm|Metastatic Unresectable Malignant Tumor	A malignant neoplasm that has spread from its original site of growth to another anatomic site and is not amenable to surgical resection.			Neoplastic Process	
C15327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15327>	C15631	Lumbar Puncture|LP|Spinal Tap|lumbar puncture|spinal tap	An invasive procedure in which a hollow needle is introduced through an intervertebral space in the lower back to access the subarachnoid space in order to sample cerebrospinal fluid or to administer medication.			Diagnostic Procedure	
C153280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153280>	C21295	FCN2 Gene|FCN2|FCN2|Ficolin 2 Gene	This gene is involved in carbohydrate binding and the lectin complement pathway.	FCN2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C153281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153281>	C153280	FCN2 wt Allele|EBP-37|FCNL|Ficolin (Collagen/Fibrinogen Domain Containing Lectin) 2 (Hucolin) Gene|Ficolin (Collagen/Fibrinogen Domain Containing Lectin) 2 Gene|Ficolin (Collagen/Fibrinogen Domain-Containing Lectin) 2 (Hucolin) Gene|Ficolin 2 wt Allele|Ficolin-2 Gene|P35	Human FCN2 wild-type allele is located in the vicinity of 9q34.3 and is approximately 25 kb in length. This allele, which encodes ficolin-2 protein, plays a role in lectin activity.	FCN2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153282>	C17728	Ficolin-2|37 kDa Elastin-Binding Protein|Collagen/Fibrinogen Domain-Containing Protein 2|EBP-37|FCN2|Ficolin 2|Ficolin B|Ficolin-B|Ficolin-Beta|Hucolin|L-Ficolin|Serum Lectin p35	Ficolin-2 (313 aa, ~34 kDa) is encoded by the human FCN2 gene. This protein is involved in calcuim-dependent binding to carbohydrates.	Ficolin-2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153283>	C25993	TRPA1 Gene|TRPA1|TRPA1|Transient Receptor Potential Cation Channel Subfamily A Member 1 Gene	This gene plays a role in the perception of pain and cation transport.	TRPA1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C153284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153284>	C153283	TRPA1 wt Allele|ANKTM1|Ankyrin-Like with Transmembrane Domains 1 Gene|FEPS|FEPS1|Transient Receptor Potential Cation Channel Subfamily A Member 1 wt Allele|Transient Receptor Potential Cation Channel, Subfamily A, Member 1 Gene	Human TRPA1 wild-type allele is located in the vicinity of 8q21.11 and is approximately 70 kb in length. This allele, which encodes transient receptor potential cation channel subfamily A member 1 protein, is involved in cation transport and pain responses. Mutation of the gene is associated with familial episodic pain syndrome type 1.	TRPA1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153285>	C28505	Transient Receptor Potential Cation Channel Subfamily A Member 1|Ankyrin-Like Protein with Transmembrane Domains 1|Ankyrin-Like with Transmembrane Domains 1|Ankyrin-Like with Transmembrane Domains Protein 1|TRPA1|Transformation-Sensitive Protein p120	Transient receptor potential cation channel subfamily A member 1 (1119 aa, ~128 kDa) is encoded by the human TRPA1 gene. This protein plays a role in ion transport and the detection of pain.	Transient Receptor Potential Cation Channel Subfamily A Member 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153286>	C27291|C120186	Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor	A malignant small round cell tumor with or without neural differentiation that is resistant to treatment.			Neoplastic Process	
C153287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153287>	C211912	Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029|Anti-CD71 Probody/vcMMAE Drug Conjugate CX-2029|Antibody Prodrug-drug Conjugate CX-2029|CD71-Directed Probody Therapeutic CX-2029|CD71-directed PDC CX-2029|CX 2029|CX-2029|CX2029|PBC CX-2029|PDC-targeting CD71 CX-2029	A probody-drug conjugate (PDC) composed of a monoclonal antibody directed against the transferrin receptor 1 (TFR1;TRP1; CD71), linked to a proprietary masking peptide that covers the active antigen-binding site of the antibody through a protease-cleavable linker, and conjugated, via a valine-citrulline (VC) peptide linker, to the potent cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of the anti-CD71/vcMMAE PDC CX-2029, the anti-CD71 moiety is unable to bind to CD71 antigen, which is highly expressed on both tumor and healthy dividing cells, until the masking peptide that is attached to the anti-CD71 probody is cleaved by tumor-associated proteases upon extravasation into the tumor microenvironment (TME). Local protease-mediated removal of the linker and masking peptide enables specific binding of the unmasked anti-CD71 moiety to CD71 expressed on tumor cells. Upon internalization and proteolytic cleavage, MMAE is released into the cytosol of CD71-expressing tumor cells, binds to tubulin, and inhibits microtubule polymerization, which induces both G2/M phase arrest and tumor cell apoptosis. CD71, a transmembrane glycoprotein, is a highly expressed protein present in a number of solid and hematologic cancers, but is also expressed on normal, healthy tissues. The peptide masking of CX-2029 minimizes binding of the anti-CD71 antibody moiety to normal, healthy cells and may minimize systemic toxicity, when compared to other anti-CD71 antibody-drug conjugates (ADCs). Tumor-associated proteases are present in high concentrations and aberrantly activated in the TME.	Anti-CD71/vcMMAE Probody-drug Conjugate CX-2029		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153288>	C67413|C1506	Extended-release Microsphere Capsule-based Oxycodone|Oxycodone ER Microsphere Capsule|Xtampza ER	A wax microsphere capsule formulation of oxycodone, a semi-synthetic, morphine-like opioid alkaloid, with analgesic activity. Upon administration, oxycodone exerts its analgesic activity by binding to the mu-receptors in the central nervous system (CNS), thereby mimicking the effects of endogenous opioids. Due to the unique formulation, extended-release microsphere capsule-based oxycodone may provide an identical pharmacokinetic profile regardless of whether the capsule is intact when ingested or if ingested via enteral feeding tube, leading to a predictable level of analgesia in patients that must be transitioned from oral to enteral administration.	Extended-release Microsphere Capsule-based Oxycodone		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C153289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153289>	C27059	Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia|ALSP|HDLS|Hereditary Diffuse Leukoencephalopathy with Spheroids|POLD|Pigmentary Orthochromatic Leukodystrophy	A rapidly progressive neurodegenerative disorder, caused by mutations in the colony-stimulating factor 1 receptor (CSF1R) gene, that presents in adulthood with a variety of neuropsychiatric and motor disturbances. Hallmark features include diffuse myelin loss and axonal destruction, neuroaxonal spheroids, and pigmented macrophages and other glia.			Disease or Syndrome	Cellosaurus Disease Terminology
C15328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15328>	C16120	Splenectomy|splenectomy	Surgical removal of part or all of the spleen.			Therapeutic or Preventive Procedure	
C153290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153290>	C75466	Rubinstein-Taybi Syndrome Type 1|RSTS1	The most common form of Rubinstein-Taybi syndrome, caused by a mutation in the CREB binding protein (CREBBP) gene.			Disease or Syndrome	Cellosaurus Disease Terminology
C153291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153291>	C75466	Rubinstein-Taybi Syndrome Type 2|RSTS2	Rubinstein-Taybi syndrome caused by a mutation in the EP300 gene on chromosome 22q13, which presents with a mild phenotype associated with less severe facial dysmorphism and better cognitive function.			Disease or Syndrome	Cellosaurus Disease Terminology
C153292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153292>	C19771	Caris Molecular Intelligence Tumor Profiling|Caris Molecular Intelligence	A proprietary genomic profiling system that assesses DNA, RNA and proteins to establish a molecular profile for use, along with any relevant pathology data, in guiding individualized treatment decisions.	Caris Molecular Intelligence Tumor Profiling		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C153293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153293>	C2870	Recurrent Aplastic Anemia	The reemergence of aplastic anemia after a period of remission.	Recurrent Aplastic Anemia		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C153294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153294>	C61229|C153293	Recurrent Severe Aplastic Anemia|Relapsed Severe Aplastic Anemia	The reemergence of severe aplastic anemia after a period of remission.	Recurrent Severe Aplastic Anemia		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C153295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153295>	C61229	Refractory Severe Aplastic Anemia	Severe aplastic anemia that is resistant to treatment.	Refractory Severe Aplastic Anemia		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C153296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153296>	C34792	Recurrent Hemophagocytic Lymphohistiocytosis	The reemergence of hemophagocytic lymphohistiocytosis after a period of remission.	Recurrent Hemophagocytic Lymphohistiocytosis		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C153297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153297>	C34792	Refractory Hemophagocytic Lymphohistiocytosis	Hemophagocytic lymphohistiocytosis that is resistant to treatment.	Refractory Hemophagocytic Lymphohistiocytosis		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C153298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153298>	C171083	Longevity|Lifespan	The length or duration of life or viability.			Conceptual Entity	
C153299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153299>	C217122	Knee Injury and Osteoarthritis Outcome Score|KOOS|Knee Injury and Osteoarthritis Outcome Score (KOOS)	A self-reported instrument to assess a patient's opinion about their knee and associated problems. It consists of 5 subscales: Pain, Function in Daily Living, Function in Sport and Recreation, Other Symptoms, and Knee Related Quality of Life.			Intellectual Product	
C15329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15329>	C25218	Surgical Procedure|Operation|SURGERY|SURGERY|Surgery|Surgery|Surgery|Surgery|Surgery|Surgery|Surgery|Surgery|Surgery|Surgery Type|Surgery, NOS|Surgical|Surgical|Surgical Intervention|Surgical Interventions|Surgical Procedures|Surgically|Type of Surgery|surgery	A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.	Surgical Procedure		Health Care Activity	ALL Authorized Value Terminology|ALL Non-protocol Therapy Table|CDISC SDTM Intervention Type Terminology|CDISC SDTM Terminology|CDRH Health Effects - Health Impact Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Medical History Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Surgery-Anesthesia Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uveal Melanoma Baseline Form|CRF4 Treatment Additional Surgeries Table|CRF4 Treatment Surgery Table|CRF5 Response Evaluation Clinical Evaluation Table|CTRP Intervention Terminology|CTRP Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Non-Protocol Therapy Table|GCT Authorized Value Terminology|GCT Biopsy/Surgical Procedures Table|GCT Growing Teratoma Syndrome Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Non-protocol Therapy Table|ICH M11 Intervention Type Value Set Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology|NICHD Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Variable Terminology
C1532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1532>	C1974	Gutolactone	A quassinoid phytochemical isolated from the plant Simaba guianensis with potential antineoplastic and antimalarial activities. (NCI04)			Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C153300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153300>	C91105|C222259	Informant Questionnaire on Cognitive Decline in the Elderly|IQCODE|Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)	A questionnaire designed to assess whether an individual had a decline in cognitive functioning. This questionnaire is answered by a friend or family member of the individual and each situation is rated by the informant for the amount of change over the previous 10 years.			Intellectual Product	
C153301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153301>	C20993	Framingham Foot Assessment Clinical Tool	A research tool designed to assess foot pain and relate it to footwear.			Intellectual Product	
C153302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153302>	C217122	Study of Osteoporotic Fractures Frailty Index|SOF|Study of Osteoporotic Fractures (SOF) Frailty Index|Study of Osteoporotic Fractures Index|Study of Osteoporotic Fractures [SOF] Index	A frailty index consisting of 3 components: weight loss, the subject's inability to rise from a chair 5 times without using their arms, and reduced energy level.			Intellectual Product	
C153303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153303>	C91105	Life Space Questionnaire|LSQ	A questionnaire instrument designed to assess how much an individual gets out and about and the spatial extent of the person's typical life space, i.e., what is the usual range of places in which the person engages in activities.			Intellectual Product	
C153304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153304>	C217121	Brief Resilience Scale|BRS|Brief Resilience Scale (BRS)	A scale developed by Smith, et al, designed to assess an individual's ability to recover from stressful circumstances.			Intellectual Product	
C153305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153305>	C91105	Taste and Smell Questionnaire|NHANES Taste and Smell Questionnaire|NHANES Taste and Smell Section	A section of the National Health and Nutrition Examination Survey (NHANES) pertaining to taste and smell ability and related health conditions.			Intellectual Product	
C153306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153306>	C20993	Oral Health and Dental History Questions	The questions in the Health, Aging, and Body Composition Study that assess an individual's oral health and dental history.			Intellectual Product	
C153307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153307>	C18772	Weight History	A summary of an individual's weight over time.			Clinical Attribute	
C153308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153308>	C20993	Family History of Dementia and Longevity	The section and questions of the University of Michigan Health and Retirement Study (HRS) that explores psychosocial and cognitive predictors of an individual's perceived threat of Alzheimer's disease.			Intellectual Product	
C153309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153309>	C183052|C129818	Exicorilant|CORT 125281|CORT-1252|CORT125281|EXICORILANT|Glucocorticoid Receptor Antagonist CORT125281|Methanone, ((4aR,8aS)-1-(4-Fluorophenyl)-1,4,5,6,7,8,8a,9-octahydro-6-((2-methyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4ah-pyrazolo(3,4-g)isoquinolin-4a-yl)(4-(trifluoromethyl)-2-pyridinyl)-|WHO 10854	An orally available, selective glucocorticoid receptor (GR) antagonist, with potential antineoplastic activity. Upon oral administration, exicorilant competitively and selectively binds to GRs, inhibiting the activation of GR-mediated proliferative and anti-apoptotic gene expression pathways. The GR, a member of the nuclear receptor superfamily of ligand-dependent transcription factors, is overexpressed in certain tumor types and may be associated with tumor cell proliferation and treatment resistance. Inhibition of GR activity may potentially slow tumor cell growth and disease progression in certain cancers.	Exicorilant		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15330>	C49163	Digestive System Surgery|OR Gastrointestinal Therapeutic Procedure|Surgery, Digestive System|Surgery, Gastrointestinal|digestive system operative procedure|digestive system surgical procedure|gastrointestinal surgical procedure|gastrointestinal system operative procedure|operative procedure on the digestive system|operative procedure on the gastrointestinal system	Surgery performed on any part of the digestive system.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Procedures Codelist|CPTAC Terminology
C153310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153310>	C15313	Involved-site Radiation Therapy|ISRT	A type of conformal radiation therapy in which the prechemotherapy gross tumor volume determines the clinical target volume, resulting in an irradiated volume that is significantly smaller than with involved-field radiation therapy.	Involved-site Radiation Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C153312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153312>	C28681|C201547	Autologous Tumor Infiltrating Lymphocytes MDA-TIL|MDA Autologous TILs|MDA Autologous Tumor Infiltrating Lymphocytes|MDA-TILs	A preparation of autologous tumor infiltrating lymphocytes (TILs) with potential antineoplastic activity. TILs are isolated from a patient's tumor tissue, then cultured and expanded in vitro in the presence of interleukin-2 (IL-2) and an agonistic anti-4-1BB (CD137) antibody. Upon infusion of the autologous expanded TILs back into the patient, the cells specifically recognize, target, and kill the patient's tumor cells.	Autologous Tumor Infiltrating Lymphocytes MDA-TIL		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153313>	C63442	RIVAC Regimen|IVAC-R|IVAC-Rituximab|R-IVAC Regimen|RIVAC|Rituximab + Ifosfamide + Cytarabine + Etoposide|Rituximab-Ifosfamide-Cytarabine-Etoposide|Rituximab/Ifosfamide/Cytarabine/Etoposide|Rituximab/Ifosfamide/VP-16/ARA-C	A regimen consisting of rituximab, ifosfamide, high-dose cytarabine and etoposide that can be used in the treatment of non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|NCI Drug Dictionary Terminology|Pharmacotherapy Regimens
C153314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153314>	C177176	Guretolimod|(((4-((2-Amino-4-(((3s)-1-hydroxyhexan-3-yl)amino)-6-methylpyrimidin-5-yl)methyl)-3- methoxyphenyl)methyl)(2,2,2-trifluoroethyl)amino)acetic Acid|DSP 0509|DSP-0509|DSP0509|GURETOLIMOD|TLR7 Agonist DSP-0509|Toll-like Receptor 7 Agonist DSP-0509	A synthetic, small molecule, toll-like receptor (TLR) 7 agonist, with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, guretolimod activates TLR7, resulting in type I interferon secretion and activation of  cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses. TLR7 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.	Guretolimod		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153315>	C3482|C153279|C148124	Metastatic Unresectable Carcinoma	A carcinoma that has spread from its original site of growth to another anatomic site and is not amenable to surgical resection.			Neoplastic Process	
C153316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153316>	C154221|C153319|C153315	Metastatic Unresectable Gastric Adenocarcinoma|Metastatic Unresectable Gastric (Stomach) Adenocarcinoma	A gastric adenocarcinoma that has spread from its original site of growth to another anatomic site and is not amenable to surgical resection.	Metastatic Unresectable Gastric Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153319>	C4124|C4004|C153320	Metastatic Gastric Adenocarcinoma	A gastric adenocarcinoma that has spread from its original site of growth to another anatomic site.			Neoplastic Process	
C15331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15331>	C49163	Ophthalmologic Surgical Procedure|Eye Surgical Procedure|Ocular Surgical Procedure|Surgery, Ophthalmological|eye surgery|ophthalmological surgical procedure	Surgery involving the eyes.			Therapeutic or Preventive Procedure	
C153320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153320>	C4911|C133839	Metastatic Gastric Carcinoma	A gastric carcinoma that has spread from its original site of growth to another anatomic site.			Neoplastic Process	
C153321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153321>	C49236	Manual Therapy|MT	A physical treatment primarily used to treat musculoskeletal pain and disability through physical manipulation of the body.	Manual Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C153323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153323>	C36263|C2947	Metastatic Chordoma	A chordoma that has spread from its original site of growth to other anatomic sites.	Metastatic Chordoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153324>	C8524|C153323	Locally Advanced Chordoma	A chordoma that has spread from its original site of growth to nearby tissues.	Locally Advanced Chordoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153325>	C2947|C27359	Unresectable Chordoma	A chordoma which is not amenable to surgical resection.	Unresectable Chordoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153327>	C1557	Aspacytarabine|ASPACYTARABINE|Ara-C Asparagine Conjugate|Asparagine Ara-C Conjugate|Asparagine Cytarabine Conjugate|Astarabine|BST 236|BST-236|BST236|Cytarabine Asparagine Conjugate	A small molecule pro-drug consisting of cytarabine, an antimetabolite analog of cytidine with a modified arabinose sugar moiety, covalently bonded to asparagine, with potential antineoplastic activity. Upon intravenous administration, aspacytarabine targets cancer cells, which often lack asparagine synthetase and are dependent on an external source of amino acids due to their high metabolic rate. Once the prodrug is inside target cells, the cytarabine component is cleaved and competes with cytidine for incorporation into DNA. The arabinose sugar moiety of cytarabine sterically hinders the rotation of the molecule within DNA, resulting in cell cycle arrest, specifically during the S phase of replication. Cytarabine also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Because BST-236 specifically targets cancer cells, it may spare normal tissues from cytarabine-related toxicities.	Aspacytarabine		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153328>	C161844	Sinhalese Language|SIN|Sinhala|Sinhalese	An Indo-European language of the Indo-Aryan branch that is the native language of the Sinhalese people, who make up the largest ethnic group in Sri Lanka.			Language	
C153329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153329>	C25474	Sequencing Data|Sequence Data	A collection of digital nucleic acid sequences, protein sequences, or other polymer sequences stored on a computer.			Idea or Concept	GDC Terminology|GDC Value Terminology
C15332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15332>	C15333	Gynecological Surgical Procedure|Gynecologic Surgical Procedure|gynecologic surgery|gynecologic surgical procedures|gynecological surgery	Surgery performed on the female reproductive system.	Gynecological Surgical Procedure		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|NICHD Terminology
C153331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153331>	C8852|C80281|C147863	Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, NOS	The reemergence of EBV-positive diffuse large B-cell lymphoma, not otherwise specified after a period of remission.	Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153332>	C8853|C80281|C160149	Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, NOS	An EBV-positive diffuse large B-cell lymphoma, not otherwise specified that is resistant to treatment.	Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153333>	C35877	Reticulocytosis	A laboratory test result indicating an increased number of reticulocytes in the peripheral blood.			Laboratory or Test Result	
C153334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153334>	C1978	Allogeneic GM-CSF-secreting Lethally Irradiated Pancreatic Tumor Cell Vaccine|GVAX Allogeneic Irradiated Pancreatic Tumor Cell Vaccine|Irradiated Allogeneic GM-CSF-secreting Pancreatic Tumor Cell Vaccine	An allogeneic tumor vaccine composed of lethally irradiated allogeneic pancreatic tumor cells that are genetically modified to secrete the immunostimulatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Upon intradermal injection, allogeneic GM-CSF-secreting lethally irradiated pancreatic tumor cell vaccine secretes GM-CSF at the injection site. In turn, GM-CSF may stimulate the body's immune system against tumor cells by attracting and enhancing the activation of antigen-presenting cells (APCs), such as dendritic cells (DCs). This promotes antigen presentation to T-lymphocytes and induces a cytotoxic T-lymphocyte (CTL) response against the pancreatic tumor cells expressing the pancreatic tumor-associated antigens (TAAs).	Allogeneic GM-CSF-secreting Lethally Irradiated Pancreatic Tumor Cell Vaccine		Cell|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153335>	C117719	Castration-Sensitive	A finding indicating that a metastatic prostate carcinoma is sensitive to androgen-deprivation therapy.			Finding	
C153336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153336>	C4863	Castration-Sensitive Prostate Carcinoma|CSPC|Hormone-Sensitive Prostate Carcinoma	A prostate carcinoma that is sensitive to castration therapy.	Castration-Sensitive Prostate Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153337>	C129826	Cytokine-treated Veto Cells|Activated Veto Cells|Activated Veto T-cells|Veto CD8-positive T-cells|Veto Cell|Veto Cells|Veto-enhanced CTL|Veto-enhanced Cytotoxic T-cell	A preparation of activated veto cells, with potential immunostimulating and antineoplastic activities. White blood cells (WBCs), taken from either the patient or a healthy third-party donor, are processed and ex-vivo treated with an as of yet not disclosed mix of cytokines to activate specific cytotoxic veto cells. Upon administration, the veto cells specifically target and bind to tumor or foreign cells, thereby inducing apoptosis. Veto cells are able to selectively activate the immune system to only attack and kill tumor or foreign cells upon transplantation to prevent graft-versus-host disease (GvHD).	Cytokine-treated Veto Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153338>	C16742	ClariCore Optical Biopsy System|ClariCore	A proprietary system for prostate cancer biopsy collection. The system uses an optical fiber "needle", spectral analysis, and a proprietary algorithm to distinguish normal tissue from suspicious tissue. It then guides the collection of biopsy samples when suspicious tissue is identified.	ClariCore Optical Biopsy System		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C153339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153339>	C160966	Arabic Language|ARA|Arabic|Arabic	A Central Semitic language native to countries of the Arab League, minorities in neighboring countries, and some parts of Asia, Africa, Europe.			Language	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C15333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15333>	C49163	Urogenital Surgical Procedure|Genitourinary System Surgical Procedure|Surgery, Genitourinary|Urogenital Surgery	Any surgery to the reproductive or urinary system or its parts.			Therapeutic or Preventive Procedure	
C153340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153340>	C113210	Recurrent Cushing Disease	The reemergence of Cushing disease after a period of remission.			Disease or Syndrome	
C153341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153341>	C15330	Transabdominal Resection	Surgery comprising either abdominoperineal resection, low anterior resection, or coloanal anastomosis with total mesorectal excision.			Therapeutic or Preventive Procedure	
C153342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153342>	C41260	Northeastern Asian|Northeastern Asian Ancestry|Northeastern Asian Descent	Denotes a person whose ancestry is in any of the Asian countries bordering the Pacific Ocean: China, Japan, Mongolia, North Korea, and South Korea.			Population Group	
C153343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153343>	C41260	Western Asian|WEST ASIAN|Western Asian Ancestry|Western Asian Descent	Denotes a person whose ancestry is in any of the Asian countries bordering Africa, such as Afghanistan, Armenia, Azerbaijan, Bahrain, Cyprus, Gaza Strip, Georgia, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Syrian Arab Republic, Turkey, United Arab Emirates, West Bank, and Yemen.			Population Group	CDISC CDASH Terminology|CDISC SDTM Collected Race Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C153344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153344>	C43851	Southeastern European|Southeastern European Ancestry|Southeastern European Descent	Denotes a person whose ancestry is in any of the European countries of the Balkan peninsula: Turkey, Albania, Bosnia and Herzegovina, Bulgaria, Republic of Macedonia, Romania, Serbia, Greece, Croatia, Moldova and Montenegro.			Population Group	
C153346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153346>	C42331	Sub-Saharan African|SUB-SAHARAN AFRICAN|Sub-Saharan African Ancestry|Sub-Saharan African Descent	Denotes a person whose ancestral origins are in any of the African countries that are fully or partially located south of the Sahara desert.			Population Group	CDISC SDTM Collected Race Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C153347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153347>	C9192|C207060	Recurrent Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor	The reemergence of ovarian malignant mixed mesodermal (Mullerian) tumor after a period of remission.	Recurrent Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153348>	C71732|C165698	Metastatic Triple-Negative Breast Carcinoma	A triple-negative breast carcinoma that has spread from its original site of growth to another anatomic site.	Metastatic Triple-Negative Breast Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153349>	C17565	Nucleotide Sequence Read|Nucleotide Sequencing Read|Read|Sequence Read|Sequencing Read|Sequencing Reads|Sequencing read	The manual or automated determination of the nucleotide order in a nucleic acid fragment obtained after the completion of a sequencing process.			Laboratory Procedure	GDC Terminology|GDC Value Terminology|pFDA Bioinformatics/Genomics Terminology|precisionFDA Terminology
C15334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15334>	C15333	Urologic Surgical Procedure|Urinary Tract Surgery|Urologic Surgery|Urological Surgical Procedure	Any surgery performed on any part of the urinary tract or on any part of the male genitalia.	Urologic Surgical Procedure		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C153350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153350>	C159661|C126836	Autologous Hematopoietic Stem Cell Transplant Recipient|Autologous Hematopoietic Stem Cell Transplantation Recipient|Autologous Hematopoietic Stem Cell Transplantation Recipient	A person receiving an autologous hematopoietic stem cell transplant.	Autologous Hematopoietic Stem Cell Transplantation Recipient		Human	CTRP Intervention Terminology|CTRP Terminology
C153351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153351>	C4910|C147982	Refractory Colon Carcinoma	Colon carcinoma that is resistant to treatment.	Refractory Colon Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153352>	C7927|C151906	Refractory Liver Carcinoma	Liver carcinoma that is resistant to treatment.	Refractory Liver Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153353>	C275	Pterostilbene|3',5'-Dimethoxy-4-stilbenol|3,5-Dimethoxy-4'-hydroxystilbene|PTEROSTILBENE|Phenol, 4-(2-(3,5-Dimethoxyphenyl)ethenyl)-, (E)-|Trans-3,5-dimethoxy-4-hydroxystilbene	A naturally-derived stilbenoid structurally related to resveratrol, with potential antioxidant, anti-inflammatory, pro-apoptotic, antineoplastic and cytoprotective activities. Upon administration, pterostilbene exerts its anti-oxidant activity by scavenging reactive oxygen species (ROS), thereby preventing oxidative stress and ROS-induced cell damage. It may also activate the nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated pathway and increase the expression of various antioxidant enzymes, such as superoxide dismutase (SOD).  In addition, pterostilbene is able to inhibit inflammation by reducing the expression of various inflammatory mediators, such as interleukin (IL) 1beta, tumor necrosis factor alpha (TNF-a), inducible nitric oxide synthase (iNOS), cyclooxygenases (COX), and nuclear factor kappa B (NF-kB). It also inhibits or prevents the activation of many signaling pathways involved in carcinogenesis, and increases expression of various tumor suppressor genes while decreasing expression of certain tumor promoting genes. It also directly induces apoptosis in tumor cells.	Pterostilbene		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153354>	C177430	Ompenaclid|OMPENACLID|RGX 202|RGX-202|RGX-202-01|RGX202|SLC6A8 Inhibitor RGX-202	An orally available, small molecule inhibitor of the creatine transporter, solute carrier family 6, member 8 (SLC6a8), with potential antineoplastic activity. Upon oral administration, ompenaclid inhibits phosphocreatine uptake by SLC6a8, thereby reducing intracellular levels of phosphocreatine available for ATP synthesis in tumor cells. SLC6a8 is overexpressed in some cancer types and inhibition of its activity may potentially limit tumor cell growth and metastasis.	Ompenaclid		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153355>	C27814|C162750	Refractory Bile Duct Carcinoma	Bile duct carcinoma that is resistant to treatment.	Refractory Bile Duct Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153356>	C7724|C151906	Refractory Small Intestinal Carcinoma	A small intestinal carcinoma that is resistant to treatment.	Refractory Small Intestinal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153357>	C8637|C153358	Locally Advanced Small Intestinal Carcinoma	A small intestinal carcinoma that has spread to nearby tissues or lymph nodes.	Locally Advanced Small Intestinal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153358>	C179181|C148130|C133839	Locally Advanced Digestive System Carcinoma	Digestive system carcinoma that has spread to nearby tissues or lymph nodes.			Neoplastic Process	
C153359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153359>	C9296|C210258|C159565	Recurrent Gastroesophageal Junction Adenocarcinoma	The reemergence of gastroesophageal junction adenocarcinoma after a period of remission.	Recurrent Gastroesophageal Junction Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C15335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15335>	C25217	Technology Assessment	Technology assessment (TA) arose in the mid-1960s from an appreciation of the critical role of technology in modern society and its potential for unintended, and sometimes harmful, consequences. TA was conceived as a way to identify the desirable first-order, intended effects of technologies as well as the higher-order, unintended social, economic and environmental effects.  TA methodology draws upon a variety of analytical, evaluative and planning techniques. Among these are systems analysis, cost-benefit analysis, consensus methods (e.g., Delphi method), engineering feasibility studies, clinical trials, market research, technological forecasting, and others. TA practitioners and policy makers recognized that TA is evolving, flexible, and should be tailored to the task (Brooks and Bowers 1970 and U.S. Congress, Office of Technology Assessment 1977).			Activity	
C153360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153360>	C27814|C156782	Recurrent Bile Duct Carcinoma	The reemergence of bile duct carcinoma after a period of remission.	Recurrent Bile Duct Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153361>	C110937	Soft Tissue Sarcoma, Excluding Liposarcoma	A finding indicating the presence of a sarcoma arising from the soft tissue, other than liposarcoma.	Soft Tissue Sarcoma, Excluding Liposarcoma		Finding	CTRP Disease Terminology|CTRP Terminology
C153362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153362>	C135487	Read Length|Sequence Read Length|Sequencing Read Length|read length|read_length	The number of nucleotides successfully ordered from each side of a nucleic acid fragment obtained after the completion of a sequencing process.			Laboratory Procedure	GDC Property Terminology|GDC Terminology|ORCHESTRA Terminology
C153363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153363>	C713	Sequencing Adapter|Adapter	A short single-stranded or double-stranded oligonucleotide that is ligated/added to each fragment of a sequencing library to permit its amplification and subsequent sequencing.			Nucleic Acid, Nucleoside, or Nucleotide	
C153364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153364>	C19238	Nucleotide Sequencing Flow Cell|Flow Cell	An optical slide with microliter or picoliter sized wells that each hold a single nucleotide sequencing template. Sequencing reagents flow over the wells and nucleotide incorporation is separately determined for each well after each round of nucleotide elongation.			Manufactured Object	
C153365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153365>	C38013	Sequencing Size Selection Range|Size Selection Range|size selection range|size_selection_range	The minimum and maximum lengths of the DNA fragments selected for inclusion in a sequencing library.			Quantitative Concept	GDC Property Terminology|GDC Terminology
C153366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153366>	C47853	Sequencing Target Region|Target Region	A specific region in the genome or in a gene of interest that is chosen for sequencing by the use of appropriate primers.			Molecular Sequence	
C153367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153367>	C164049	BED Format|BED File Format|Browser Extensible Data|Browser Extensible Data Format	A tab-delimited text file format that allows the specification of the sequence data that is displayed in an annotation track. The minimum required information is chromosome, start position, and end position.			Qualitative Concept	pFDA Bioinformatics/Genomics Terminology|precisionFDA Terminology
C153368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153368>	C138935	Body Mass Index Greater Than 25|BMI Greater than 25	Indicates a body mass index measurement greater than 25.	Body Mass Index Greater Than 25		Finding	CTRP Disease Terminology|CTRP Terminology
C153369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153369>	C70663	Global Registration Identifier for Donors|GRID	A unique identifier assigned to a hematopoietic progenitor cell donor, potential donor, or a cord blood product that is listed in a registry.			Intellectual Product	
C15336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15336>	C15429	Testing	A procedure for critical evaluation.			Occupational Activity	
C153370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153370>	C153361	Metastatic Soft Tissue Sarcoma, Excluding Liposarcoma	A finding indicating that a soft tissue sarcoma other than liposarcoma has spread from its original site of growth to another anatomic site.	Metastatic Soft Tissue Sarcoma, Excluding Liposarcoma		Finding	CTRP Disease Terminology|CTRP Terminology
C153371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153371>	C153370	Locally Advanced Soft Tissue Sarcoma, Excluding Liposarcoma	A finding indicating that a soft tissue sarcoma other than liposarcoma has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Soft Tissue Sarcoma, Excluding Liposarcoma		Finding	CTRP Disease Terminology|CTRP Terminology
C153372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153372>	C177285	Lixumistat Acetate|HL271 Acetate|IM 156|IM-156|IM156|LIXUMISTAT ACETATE|Mitochondrial Oxidative Phosphorylation Inhibitor IM156|OxPhos Inhibitor IM156|Oxidative Phosphorylation Inhibitor IM156	The acetate salt form of lixumistat, an orally bioavailable biguanide compound and mitochondrial oxidative phosphorylation (OxPhos) inhibitor, with potential antineoplastic activity. Upon administration, lixumistat inhibits oxidative phosphorylation, decreases mitochondrial function, prevents tumor cell metabolism and deprives tumor cells of energy, thereby preventing tumor cell proliferation. Mitochondrial OxPhos is overactivated in cancer cells and plays a key role in tumor cell proliferation. Drug resistant tumor cells are very susceptible to decreased mitochondrial OxPhos as they cannot easily compensate for the decrease in mitochondrial function by increasing glycolysis.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153373>	C241|C2092	Elagolix|ABT-620|Butanoic Acid, 4-(((1R)-2-(5-(2-fluoro-3-methoxyphenyl)-3-((2-fluoro-6-(trifluoromethyl)phenyl)methyl)-3,6-dihydro-4-methyl-2,6-dioxo-1(2H)-pyrimidinyl)-1-phenylethyl)amino)-|ELAGOLIX|NBI 56418|NBI-56418|Orilissa	An orally bioavailable, second-generation, non-peptide based, small molecule compound and selective gonadotropin-releasing hormone (GnRH; LHRH) receptor antagonist, with potential hormone production inhibitory activity. Upon oral administration, elagolix competes with GnRH for receptor binding and inhibits GnRH receptor signaling in the anterior pituitary gland. This inhibits the secretion of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. In women, inhibition of FSH and LH prevents the production of estrogen by the ovaries. Inhibition of GnRH signaling may treat or prevent symptoms of sex hormone-dependent disease states.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153374>	C1752	Helicobacter pylori Therapeutic Vaccine IMX101|H. pylori Therapeutic Vaccine IMX101|IMX 101|IMX-101|IMX101|IMX101 Vaccine	A Helicobacter pylori (H. pylori) therapeutic vaccine comprised of three components: two antigens, the immunosuppressive antigen, gamma-glutamyl transpeptidase (GGT), and an as of yet not disclosed H. pylori outer membrane protein and mucosal adjuvant, which consists of a fusion protein containing two domains, with potential immunostimulating and H. pylori-eradicating activities. Upon administration of the H. pylori therapeutic vaccine IMX101, the GGT antigen, which is an immune evasion factor, elicits a strong B-cell-mediated immune response against the GGT antigen, thereby generating neutralizing antibodies that bind to and inhibit GGT. This inhibits H. pylori's central immune evasion mechanism and enables the immune system to elicit a strong cytotoxic T-lymphocyte (CTL)-mediated immune response against the second outer membrane protein antigen, thereby killing H. pylori. The third component contains a domain that targets immune cells present near the site of H. pylori infection in the stomach. Once taken up by immune cells, the second domain is able to activate and enhance the immune response against H. pylori antigens. H. pylori infections may lead to gastritis and in some cases gastric cancer. GGT plays a key role in H. pylori's immune evasion mechanisms.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology
C153375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153375>	C20401|C129822	Nidanilimab|CAN 04|CAN-04|CAN04|NIDANILIMAB|Nadunolimab	A low fucose, fully humanized monoclonal immunoglobulin G1 (IgG1) antibody (hmAb) against the interleukin 1 receptor accessory protein (interleukin-1 receptor associated protein; IL1RAP), with potential immunomodulating, anti-inflammatory and antineoplastic activities. Upon intravenous administration, nidanilimab targets and binds to IL1RAP, thereby preventing IL1RAP-mediated signaling, and disrupting IL-1 and IL-33 mediated nuclear factor kappa beta (NFkB) activation. This prevents the secretion of tumor stimulating cytokines, decreases tumor inflammation and inhibits tumor cell proliferation. In addition, nidanilimab induces antibody-dependent cellular cytotoxicity (ADCC), and stimulates natural killer (NK) cells to attack tumor cells, thereby killing the IL1RAP-poisitive tumor cells. IL1RAP, a co-receptor of the IL-1 receptor (IL1R1) and the IL-33 receptor (ST2), is upregulated in certain tumor cells, and plays a key role in tumor cell proliferation.	Nidanilimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153376>	C202064	CBP/beta-catenin Modulator E7386|E 7386|E-7386|E-7386|E7386	An orally bioavailable, specific inhibitor of the canonical Wnt/beta-catenin signaling pathway, with potential antineoplastic activity. Upon oral administration, CBP/beta-catenin modulator E7386 inhibits beta-catenin and prevents the interaction of beta-catenin with its transcriptional coactivator, CREB (cAMP response element-binding) binding protein (CBP). This prevents binding of beta-catenin/CBP to WRE (Wnt-responsive element), and inhibits the activation of transcription of a wide range of target genes of Wnt/beta-catenin signaling, thereby preventing gene expression of many Wnt-related, pro-survival proteins and suppressing tumor cell growth. The Wnt/beta-catenin signaling pathway regulates cell morphology, motility, and proliferation; aberrant regulation of this pathway leads to neoplastic proliferation. Beta-catenin is frequently mutated in various tumors.	CBP/beta-catenin Modulator E7386		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153377>	C200258	Zemirciclib|AZD 4573|AZD-4573|AZD4573|CDK9 Inhibitor AZD4573|ZEMIRCICLIB	A selective, short-acting inhibitor of the serine/threonine cyclin-dependent kinase 9 (CDK9), the catalytic subunit of the RNA polymerase II (RNA Pol II) elongation factor positive transcription elongation factor b (PTEF-b; PTEFb), with potential antineoplastic activity. Upon intravenous administration, zemirciclib binds to and blocks the phosphorylation and kinase activity of CDK9, thereby preventing PTEFb-mediated activation of RNA Pol II, leading to the inhibition of gene transcription of various anti-apoptotic proteins. This induces cell cycle arrest and apoptosis, and leads to a reduction in tumor cell proliferation. CDK9 regulates elongation of transcription through phosphorylation of RNA polymerase II at serine 2 (p-Ser2-RNAPII). It is upregulated in various tumor cell types and plays a key role in the regulation of Pol II-mediated transcription of anti-apoptotic proteins. Tumor cells are dependent on anti-apoptotic proteins for their survival.	Zemirciclib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153378>	C217652|C217549	Ledipasvir/Sofosbuvir|Harvoni|Ledipasvir Mixture with Sofosbuvir|Ledipasvir and Sofosbuvir|Ledipasvir-Sofosbuvir|Ledipasvir/Sofosbuvir Tablet	A tablet containing a fixed dose combination of ledipasvir, an inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex, and the prodrug sofosbuvir, an inhibitor of HCV NS5B polymerase, with activity against HCV. Upon oral administration of ledipasvir/sofosbuvir and intracellular uptake, ledipasvir binds to and blocks the activity of the NS5A protein. This results in the disruption of the viral RNA replication complex, blockage of HCV RNA production, and inhibition of viral replication. Sofosbuvir is converted to its active triphosphate form, and competes with uridine triphosphate for incorporation into RNA, thereby inhibiting NS5B polymerase and preventing viral replication. This may eradicate HCV and prevent HCV-mediated tumorigenesis. NS5A, a zinc-binding and proline-rich hydrophilic phosphoprotein, plays a crucial role in HCV RNA replication. The HCV NS5B protein, an RNA-dependent RNA polymerase, is essential for the replication of the viral HCV RNA genome. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family; HCV infection is associated with the development of certain tumors.			Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C153379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153379>	C28227|C129822|C128037|C128036	Cadonilimab|AK 104|AK-104|AK104|Anti-PD-1 x CTLA-4 Bispecific Antibody AK104|Anti-PD-1/CTLA-4 Bispecific Antibody AK104|Anti-PD1/Anti-CTLA4 Bispecific Antibody AK104|CADONILIMAB|PD-1 x CTLA-4 Dual Checkpoint Inhibitor AK104	A bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, cadonilimab targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T lymphocytes (TILs), and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a sustained cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD1 and CTLA4 with cadonilimab may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15337>	C15655	Thoracotomy|Incision of Thorax|incision of Chest Wall|thoracotomy	A surgical procedure in which an large incision is made into the chest wall, for the purpose of accessing organs inside the thoracic cavity.	Thoracotomy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table
C153380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153380>	C93221|C129820	Milled Seed Mix|Milled Flax/Sesame/Pumpkin Seed Mix|Milled Mix of Flax/Sesame/Pumpkin Seeds in Sour Milk|Milled Sesame/Pumpkin/Flax Seed Mixture	A nutritional supplement composed of a milled seed mixture, including milled flax, sesame and pumpkin seeds, in sour milk, with potential anti-inflammatory and lipid regulating activities. The seeds contain high levels of fatty acids, including omega-3 and omega-6 polyunsaturated fatty acids (PUFAs), such as dihomo-gamma-linolenic acid (DGLA), alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA). Upon administration of the milled seed mix, the intake of PUFAs improves PUFA levels and may favorably change the n-6/n-3 PUFA ratio, decrease triglyceride (TG) levels, and improve body weight. In addition, the active ingredients in the milled seed mix may change the expression of inflammatory markers, such as C-reactive protein (CRP) and pro-inflammatory cytokines, including interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-a), thereby decreasing inflammation. The milled seed mix may also prevent oxidative stress and affect glycemic control. Tumors cause inflammatory states and unfavorably affect lipid and fatty acid metabolism.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C153382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153382>	C18520	Phosphorylated EIF4E|Phospho-EIF4E|Phosphorylated Eukaryotic Initiation Factor 4E	A post-translationally modified form of eukaryotic translation initiation factor 4E where either the threonine at residue 22 or the serine at residue 209 are phosphorylated. Phosphorylation of eukaryotic translation initiation factor 4E increases its binding to 7-methylguanosine-containing mRNA caps and may promote the translation of mRNAs involved in epithelial mesenchymal transition (EMT), tumorigenesis and metastasis.	Phosphorylated EIF4E		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153383>	C35682	PI3K Alteration Positive|1-Phosphatidylinositol 3-Kinase Alteration Positive|PI3 Kinase Alteration Positive|PI3-Kinase Alteration Positive|Phosphatidylinositide 3-Kinase Alteration Positive|Phosphatidylinositol 3 Kinase Alteration Positive|Phosphatidylinositol 3-Kinase Alteration Positive|Phosphatidylinositol-3-Kinase Alteration Positive|Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Alteration Positive	An indication that mutation, overexpression, fusion or rearrangement of a PI3K family member has been detected in a sample.	PI3K Alteration Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153384>	C97927	PIGA Gene Mutation|GPI3 Gene Mutation|MCAHS2 Gene Mutation|PIG-A Gene Mutation|PNH1 Gene Mutation|Paroxysmal Nocturnal Hemoglobinuria Gene Mutation|Phosphatidylinositol Glycan Anchor Biosynthesis Class A Gene Mutation	A change in the nucleotide sequence of the PIGA gene.	PIGA Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153385>	C97927|C157554	PIK3C2B Gene Mutation|C2-PI3K Gene Mutation|PI3K-C2beta Gene Mutation|Phosphatidylinositol-4-Phosphate 3-Kinase, Catalytic Subunit Type 2 Beta Gene Mutation	A change in the nucleotide sequence of the PIK3C2B gene.	PIK3C2B Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153386>	C41022	Neoplastic Plasma Cells Under 50 Percent of Bone Marrow Nucleated Cells|Neoplastic Plasma Cells Less than 50 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that less than 50 percent of the nucleated cells in a bone marrow sample are neoplastic plasma cells.	Neoplastic Plasma Cells Under 50 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C153387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153387>	C9039|C213702	Metastatic Cervical Carcinoma	A carcinoma of the cervix that has spread to another anatomic site.			Neoplastic Process	
C153388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153388>	C4104|C4028|C153387	Metastatic Cervical Squamous Cell Carcinoma	A cervical squamous cell carcinoma that has spread to another anatomic site.	Metastatic Cervical Squamous Cell Carcinoma, Not Otherwise Specified		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153389>	C4124|C4029|C206195	Metastatic Cervical Adenocarcinoma	A cervical adenocarcinoma that has spread to another anatomic site.	Metastatic Cervical Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C15338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15338>	C15388	Thrombolytic Therapy|fibrinolytic therapy	Any pharmacologic intervention used to destroy or dissolve a clot in a blood vessel or graft.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C153390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153390>	C4519|C153387	Metastatic Cervical Adenosquamous Carcinoma	A cervical adenosquamous carcinoma that has spread to another anatomic site.	Metastatic Cervical Adenosquamous Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153393>	C153383	PIK3CA Gene Alteration Positive|PI3K-Alpha Gene Alteration|PI3KCA Gene Alteration|PIK3-Alpha Gene Alteration|PIK3CA Gene Alteration|Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Gene Alteration|p110-alpha Gene Alteration	An indication that mutation, overexpression, fusion or rearrangement involving the PIK3CA gene has been detected in a sample.	PIK3CA Gene Alteration Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153394>	C79086|C133155	PIK3CA Gene Rearrangement|PI3K-Alpha Gene Rearrangement|PI3KCA Gene Rearrangement|PIK3-Alpha Gene Rearrangement|Phosphatidylinositol 3-Kinase, Catalytic Subunit Gene Rearrangement|Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha Gene Rearrangement|Phosphoinositide-3-Kinase, Catalytic, Alpha Polypeptide Gene Rearrangement|p110-Alpha Gene Rearrangement	A molecular abnormality indicating rearrangement of the PIK3CA gene.	PIK3CA Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C153395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153395>	C141340|C126340	Activating PIK3CB Gene Mutation|P110BETA Activating Gene Mutation|PI3KBETA Activating Gene Mutation|PIK3C1 Activating Gene Mutation|PIK3CB Activating Gene Mutation|PIK3CB Activating Mutation|PIK3CB Gain|PIK3CB Gain of Function|PIK3CB Gain of Function Mutation|Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta Activating Gene Mutation|p110-Beta Activating Gene Mutation	A change in the nucleotide sequence of the PIK3CB gene that results in constitutive activation of phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform and its downstream signaling pathways.	Activating PIK3CB Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153396>	C97927	PLCG2 Gene Mutation|APLAID Gene Mutation|FCAS3 Gene Mutation|PLC-IV Gene Mutation|PLC-gamma-2 Gene Mutation|PLCgamma2 Gene Mutation|Phospholipase C Gamma 2 Gene Mutation	A change in the nucleotide sequence of the PLCG2 gene.	PLCG2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153397>	C15958	In Vitro Kinase Inhibitor Assay|In Vitro Kinase Inhibition Assay	Any of various laboratory assay methods designed to measure the kinase inhibition activity of a test compound.	In Vitro Kinase Inhibitor Assay		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C15339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15339>	C48800	Tissue Collection|Tissue Bank|Tissue Repository|Tissue/Specimen Collection	A repository of the tissue specimen, cells or cell lines, for experimental purpose. It can be from different diseases or different parts of the body.	Tissue Collection		Physical Object	CTRP Intervention Terminology|CTRP Terminology
C1533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1533>	C511|C2021	Pemetrexed Disodium|Alimta|Alimta|Almita|LY231514|LY231514|N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt|N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt|PEMETREXED DISODIUM|pemetrexed disodium	The disodium salt of a synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS) which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.	Pemetrexed Disodium		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153401>	C129310	H3.1 K27M Variant|H3.1 K27M Mutation|H3.1 K27M Mutation|H3.1 K28M Mutation|H3.1 Lys27Met Mutation|H3.1 Lys28Met Mutation|H3.1 NP_003521.2:p.K28M|H3.1 NP_003521.2:p.Lys28Met|H3.1 NP_003522.1:p.K28M|H3.1 NP_003522.1:p.Lys28Met|H3.1 NP_003528.1:p.K28M|H3.1 NP_003528.1:p.Lys28Met|H3.1 p.K28M|H3.1 p.Lys28Met|Histone H3.1 K27M Mutation|Histone H3.1 K28M Mutation|Histone H3.1 Lys27Met Mutation|Histone H3.1 Lys28Met Mutation|NP_003521.2:p.K28M|NP_003521.2:p.Lys28Met|NP_003522.1:p.K28M|NP_003522.1:p.Lys28Met|NP_003528.1:p.K28M|NP_003528.1:p.Lys28Met	A change in the amino acid residue at position 27 in histone H3.1 protein where lysine has been replaced by methionine.	H3.1 K27M Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153402>	C16742	Centrifuge	A machine that uses centrifugal force to separate heavier substances from lighter ones, for removing moisture, or for simulating gravitational effects.			Manufactured Object	
C153403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153403>	C225418	Subfacial	Situated, occurring, or performed below a fascia.			Spatial Concept	
C153404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153404>	C36294|C173902	Spread of Lymphoma|Lymphoma Spread	A finding indicating the spread of a lymphoma from a nodal or extranodal primary site.	Spread of Lymphoma		Finding	CTRP Disease Terminology|CTRP Terminology
C153405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153405>	C177692	PMEL Positive|ME20 Positive|ME20-M Positive|ME20M Positive|Melanocyte Protein PMEL Positive|P1 Positive|PMEL17 Positive|Premelanosome Protein Positive|SIL Positive|SILV Positive|Silver Homolog Positive|gp100 Positive	An indication that expression of PMEL has been detected in a sample.	PMEL Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153406>	C150634|C146678	Presence of ERBB2 Overexpressing Disseminated Tumor Cells|ERBB2 Overexpressing DTCs Positive|ERBB2 Overexpressing DTCs Present|ERBB2 Overexpressing Disseminated Tumor Cells Positive|ERBB2 Overexpressing Disseminated Tumor Cells Present|Erb-B2 Receptor Tyrosine Kinase 2 Overexpressing Disseminated Tumor Cells Present|HER2 Overexpressing Disseminated Tumor Cells Present|HER2/neu Overexpressing Disseminated Tumor Cells Positive|HER2/neu Overexpressing Disseminated Tumor Cells Present|NEU Overexpressing Disseminated Tumor Cells Present|Presence of ERBB2 Overexpressing DTCs|Proto-Oncogene Neu Overexpressing Disseminated Tumor Cells Present|Receptor Tyrosine-Protein Kinase erbB-2 Protein Variant Overexpressing Disseminated Tumor Cells Present|Tyrosine Kinase-Type Cell Surface Receptor HER2 Overexpressing Disseminated Tumor Cells Present|v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 Overexpressing Disseminated Tumor Cells Present	An indication that single tumor cells or small clusters of tumor cells that are overexpressing ERBB2 are present in a tissue sample.	Presence of ERBB2 Overexpressing Disseminated Tumor Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153407>	C141458	Progesterone Receptor Positive by Immunohistochemistry 1-9 Percent	An immunohistochemical staining finding indicating that between 1 and 9 percent of the cells in a tissue sample are expressing progesterone receptor.	Progesterone Receptor Positive by Immunohistochemistry 1-9 Percent		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153408>	C123611	PSA 50 Percent or Greater than Nadir|PSA 50% or Greater than Nadir|PSA Fifty Percent or Greater than Nadir|PSA Greater than or Equal to 50 Percent Above Nadir	A finding indicating that the blood concentration of prostate specific antigen in a subject's sample has increased by 50 percent or more over the lowest value recorded for a sample from that subject.	PSA 50 Percent or Greater than Nadir		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153409>	C138961	PSA Decline Greater than 75 Percent|PSA Decline Greater than Seventy Five Percent|PSA Decline Greater than Seventy-Five Percent|PSA Decline More than 75 Percent|PSA Decreased Greater than 75 Percent|PSA Decreased Greater than Seventy Five Percent|PSA Decreased Greater than Seventy-Five Percent|PSA Decreased More than 75 Percent|PSA Decreased More than Seventy Five Percent|PSA Decreased More than Seventy-Five Percent	A finding indicating that the blood concentration of prostate specific antigen in a subject's sample has decreased by more than 75 percent compared to the value recorded for a previous sample from that subject.	PSA Decline Greater than 75 Percent		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15340>	C15294	Total Pancreatectomy|TOTAL PANCREATECTOMY|Total Excision of the Pancreas|total pancreatectomy	Surgical removal of the entire pancreas.	Total Pancreatectomy		Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C153410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153410>	C138961	PSA Level Zero to Two|PSA Level 0 to 2|PSA Level Between 0 and 2|PSA Level Between Zero and Two	A blood concentration of prostate specific antigen between 0 ng/mL and 2 ng/mL.	PSA Level Zero to Two		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153411>	C138961	PSA Level 0.2 to Four|PSA Level 0.2 to 4|PSA Level 0.2 to 4.0|PSA Level Between 0.2 and 4|PSA Level Between 0.2 and 4.0|PSA Level Between 0.2 and Four	A blood concentration of prostate specific antigen between 0.2 ng/mL and 4 ng/mL.	PSA Level 0.2 to Four		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153412>	C138961	PSA Level Greater than or Equal to 0.4|PSA Level 0.4 or Greater	A blood concentration of prostate specific antigen greater than or equal to 0.4 ng/mL.	PSA Level Greater than or Equal to 0.4		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153413>	C138961	PSA Level Less than or Equal to Eleven|PSA Level 11 or Less|PSA Level Eleven or Less|PSA Level Less than or Equal to 11	A blood concentration of prostate specific antigen less than or equal to 11 ng/mL.	PSA Level Less than or Equal to Eleven		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153414>	C138961	PSA Level Four to Ten|PSA Level 4 to 10|PSA Level Between 4 and 10|PSA Level Between Four and Ten	A blood concentration of prostate specific antigen between 4 ng/mL and 10 ng/mL.	PSA Level Four to Ten		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153415>	C138961	PSA Level Greater than 0.4	A blood concentration of prostate specific antigen greater than 0.4 ng/mL.	PSA Level Greater than 0.4		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153416>	C138961	PSA Level Greater than or Equal to Fifteen|PSA Level 15 or Greater|PSA Level Fifteen or Greater|PSA Level Greater than or Equal to 15	A blood concentration of prostate specific antigen greater than or equal to 15 ng/mL.	PSA Level Greater than or Equal to Fifteen		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153417>	C281	Furosemide Topical Gel CLS006|CLS 006|CLS-006|CLS006|Furosemide Topical Gel CLS 006|Furosemide Topical Gel CLS-006	A sulfamoylanthranilic acid derivative and loop diuretic, with potential antiviral activity. Upon topical administration, furosemide gel inhibits potassium influx by interacting with cell membrane ion co-transporter,  Na+-K+-2Cl-co-transporter-1(NKCC1; SLC12A2). This may inhibit potassium influx and prevent the replication of DNA viruses, such as human papillomavirus (HPV), that rely on potassium for replication.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C153418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153418>	C138961	PSA Level Greater than or Equal to Three|PSA Level 3 or Greater|PSA Level Greater than or Equal to 3|PSA Level Three or Greater	A blood concentration of prostate specific antigen greater than or equal to 3 ng/mL.	PSA Level Greater than or Equal to Three		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153419>	C1931	Botanical Agent BEL-X-HG|BEL X HG|BEL-X-HG|BELXHG|Botanical Agent BEL X HG	An orally available botanically-based agent with potential antineoplastic activity. Upon oral administration, the components in BEL-X-HG may exert cytotoxic effects against cancer cells.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15341>	C15454|C15290	Tracheotomy|TRACHEOSTOMY|Tracheostomy|Tracheostomy Procedure|tracheostomy	Creation of a surgical opening into the trachea.			Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C153420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153420>	C138961	PSA Level Less than Four|PSA Level Less than 4	A blood concentration of prostate specific antigen less than 4 ng/mL.	PSA Level Less than Four		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153421>	C138961	PSA Level Less than One|PSA Level Less than 1	A blood concentration of prostate specific antigen less than 1 ng/mL.	PSA Level Less than One		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153422>	C138961	PSA Level Less than One Hundred|PSA Level Less than 100	A blood concentration of prostate specific antigen less than 100 ng/mL.	PSA Level Less than One Hundred		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153423>	C138961	PSA Level Less than or Equal to One Hundred Fifty|PSA Level 150 or Less|PSA Level Less than or Equal to 150|PSA Level One Hundred Fifty or Less	A blood concentration of prostate specific antigen less than or equal to 150 ng/mL.	PSA Level Less than or Equal to One Hundred Fifty		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153424>	C242	Tricaprin|Capric Acid Triglyceride|Glycerol Tricaprin|Glycerol Tridecanoate|TRICAPRIN|Tricapric Glyceride|Tridecanoin	An orally available precursor of decanoic acid (DA), a 10-carbon fatty acid and major component of medium chain triglyceride oils, with potential antiandrogen and antihyperglycemic properties. Upon oral administration, tricaprin is hydrolyzed to DA, which binds to and partially activates peroxisome proliferator-activated receptor (PPAR)-gamma, as well as PPAR-alpha and PPAR-beta/delta, without inducing adipogenesis. Additionally, tricaprin may improve insulin sensitivity and decrease androgen production.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C153425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153425>	C1450	Platinum Acetylacetonate-Titanium Dioxide Nanoparticles|NPt|NPt Nanomaterial|NPt Nanoparticles|NPt-Ca|Sol-gel NPt Nanomaterial|Sol-gel NPt Nanoparticles	A preparation of platinum acetylacetonate supported by sol-gel technology functionalized titania, with potential antineoplastic activity. Upon intravenous administration, the platinum moiety forms complexes with nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links, resulting in apoptosis and cell growth inhibition. Compared to platinum alone, the nanoparticle formulation allows increased delivery of platinum to the tumor site, thereby increasing efficacy while reducing systemic toxicity.			Inorganic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153426>	C521	Triamcinolone Acetonide Transdermal System SUN-131|SUN 131|SUN-131|SUN-131 TDS|SUN131|Triamcinolone Acetonide Transdermal Patch SUN-131	A transdermal system (TDS) containing triamcinolone acetonide, a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. Upon application of the TDS to the eyelid, triamcinolone acetonide binds to intracellular glucocorticoid receptors, ultimately inducing the expression of glucocorticoid-responsive genes and lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both mediators of inflammation. In addition, pro-inflammatory cytokine production, including interleukin (IL)-1and IL-6, and the activation of cytotoxic T-lymphocytes is also inhibited. Triamcinolone acetonide also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis through increasing Ikappa-B expression and curtailing activation of nuclear factor (NF)kappa-B.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C153427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153427>	C2167|C213472|C159156	Gozanertinib|ABT 101|ABT-101|ABT101|DBPR 112|DBPR-112|DBPR112|EGFR/HER2 Inhibitor ABT-101|GOZANERTINIB	An orally bioavailable dual kinase inhibitor of epidermal growth factor receptor (EGFR; ErbB1) and human epidermal growth factor receptor 2 (HER2; EGFR2; ErbB2), including EGFR L858R, EGFR T790M and HER2 exon 20 insertion (Ex20ins) mutations, with potential antineoplastic activity. Upon oral administration, gozanertinib targets, binds to and inhibits the activity of EGFR or HER2 insertions or mutations. This prevents EGFR/HER2-mediated signaling, which may induce cell death and inhibit tumor growth in EGFR/HER2-overexpressing tumor cells. The ErbB receptor tyrosine kinase family is involved in key cellular functions, including cell growth and survival. EGFR and HER2 alterations constitutively upregulate kinase activity.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153428>	C2124	Indium In 111 Minigastrin Analog CP04|111-Indium CP04|111In-CP04|Indium In 111 CP04|PPF11	A radioconjugate consisting of the minigastrin analog, CP04, labeled with the gamma-emitting radioisotope indium-111, with radioimaging potential. Upon intravenous administration, 111In-CP04 binds to and is subsequently internalized by cells expressing cholecystokinin receptor subtype 2 (CCK2R), which is overexpressed in certain tumor types. 111In-CP04 emits gamma radiation and X-ray photons that allow detection of tumor localization and distribution using gamma scintigraphy.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C153429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153429>	C2099	Colloidal Modified Fluid Gelatin Plasma Substitute|Colloidal Succinylated Gelatine Plasma Substitute|Gelaspan	A colloidal, isotonic, physiologically balanced, plasma volume substitute containing succinylated gelatine and electrolytes, with potential nephroprotective properties. Upon intravenous administration, colloidal modified fluid gelatin plasma substitute expands the blood volume, restores intravascular volume and increases blood flow, thereby preventing hypovolemia, hypotension and shock and may decrease the accumulation of nephrotoxic agents in the kidneys.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C15342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15342>	C201922	Transplantation|Grafting|Grafting Procedure|Surgery, Transplantation|Transplant|Transplant Procedure|Transplantation Surgery|transplantation	Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.	Transplantation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C153430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153430>	C28533	SLC6A8 Gene|SLC6A8|SLC6A8|Solute Carrier Family 6 Member 8 Gene	This gene plays a role in the transmembrane transport of creatine and phosphocreatine.	SLC6A8 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C153431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153431>	C153430	SLC6A8 wt Allele|CCDS1|CRT|CRTR|CT1|CTR5|Solute Carrier Family 6 (Neurotransmitter Transporter), Member 8 Gene|Solute Carrier Family 6 (Neurotransmitter Transporter, Creatine), Member 8 Gene|Solute Carrier Family 6 Member 8 wt Allele	Human SLC6A8 wild-type allele is located in the vicinity of Xq28 and is approximately 8 kb in length. This allele, which encodes sodium- and chloride-dependent creatine transporter 1 protein, is involved in muscle cell physiology and creatine/phosphocreatine transport. Alterations of the gene are associated with X-linked creatine deficiency syndrome.	SLC6A8 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153432>	C16386	Sodium- and Chloride-Dependent Creatine Transporter 1|CT1|Creatine Transporter|Creatine Transporter 1|Creatine Transporter SLC6A8|SLC6A8|Solute Carrier Family 6 Member 8	Sodium- and chloride-dependent creatine transporter 1 (635 aa, ~71 kDa) is encoded by the human SLC6A8 gene. This protein plays a role in sodium and chloride ion-dependent transmembrane transport of creatine and phosphocreatine.	Sodium- and Chloride-Dependent Creatine Transporter 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153433>	C177692	SLC6A8 Positive|CRTR Positive|CT1 Positive|Creatine Transporter Positive|Solute Carrier Family 6 Member 8 Positive	An indication that expression of SLC6A8 has been detected in a sample.	SLC6A8 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153434>	C91105	The Health Care Climate Questionnaire|HCCQ|The Health Care Climate Questionnaire (HCCQ)	A questionnaire designed to assess a patient's perceptions of the degree to which their specific doctor supports the patient's autonomy.			Intellectual Product	
C153435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153435>	C173160|C173145	Feel Physician Provided Choices and Options Question|Feel Physician Provided Choices and Options|I feel that my physician has provided me choices and options	A question about whether an individual feels that their physician has provided choices and options.			Intellectual Product	The Health Care Climate Questionnaire
C153436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153436>	C173160|C173145	Feel Understood by Physician Question|Feel Understood by Physician|I feel understood by my physician	A question about whether an individual feels understood by their physician.			Intellectual Product	The Health Care Climate Questionnaire
C153437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153437>	C173145|C173045	Able to be Open with Physician at Meetings Question|Able to be Open with Physician at Meetings|I am able to be open with my physician at our meetings	A question about whether an individual feels able to be open with their physician at their meetings.			Intellectual Product	The Health Care Climate Questionnaire
C153438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153438>	C173145	Physician Conveys Confidence in My Ability to Make Choices Question|My physician conveys confidence in my ability to make changes|Physician Conveys Confidence in My Ability to Make Choices	A question about whether an individual's physician conveys confidence in their ability to make choices.			Intellectual Product	The Health Care Climate Questionnaire
C153439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153439>	C173160|C173145	Feel My Physician Accepts Me Question|Feel My Physician Accepts Me|I feel that my physician accepts me	A question about whether an individual feels that their physician accepts them.			Intellectual Product	The Health Care Climate Questionnaire
C15343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15343>	C15705|C15307	Transurethral Prostatic Resection|Prostate Transurethral Resection|TURP|TURP|TURP|Transurethral Prostatectomy|Transurethral Resection (TURP)|Transurethral Resection of Prostate|Transurethral Resection of the Prostate|transurethral resection of the prostate	Prostate tissue removal via a cystoscope.			Therapeutic or Preventive Procedure	GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C153440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153440>	C173145	Physician Made Sure I Understood about My Condition and what I Need to Do Question|My physician has made sure I really understand about my condition and what I need to do|Physician Made Sure I Understood about My Condition and what I Need to Do	A question about whether an individual's physician has made sure they really understand about their condition and what they need to do.			Intellectual Product	The Health Care Climate Questionnaire
C153441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153441>	C135578	Physician Encourages Me to Ask Questions Question|My physician encourages me to ask questions|Physician Encourages Me to Ask Questions	A question about whether an individual's physician encourages them to ask questions.			Intellectual Product	The Health Care Climate Questionnaire
C153442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153442>	C173160|C173145	Feel Lot of Trust in Physician Question|Feel Lot of Trust in Physician|I feel a lot of trust in my physician	A question about whether an individual feels a lot of trust in their physician.			Intellectual Product	The Health Care Climate Questionnaire
C153443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153443>	C135578	Physician Answers Questions Fully and Carefully Question|My physician answers my questions fully and carefully|Physician Answers Questions Fully and Carefully	A question about whether an individual's physician answers their questions fully and carefully.			Intellectual Product	The Health Care Climate Questionnaire
C153444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153444>	C135578	Physician Listens to How I Would Like to do Things Question|My physician listens to how I would like to do things|Physician Listens to How I Would Like to do Things	A question about whether an individual's physician listens to how they would like to do things.			Intellectual Product	The Health Care Climate Questionnaire
C153445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153445>	C173145	Physician Handles People's Emotions Very Well Question|My physician handles people's emotions very well|Physician Handles People's Emotions Very Well	A question about whether an individual's physician handles people's emotions very well.			Intellectual Product	The Health Care Climate Questionnaire
C153446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153446>	C173160|C173145	Physician Cares about Me as a Person Question|I feel that my physician cares about me as a person|Physician Cares about Me as a Person	A question about whether an individual feels that their physician cares about them as  person.			Intellectual Product	The Health Care Climate Questionnaire
C153447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153447>	C173160|C135578	Don't Feel Very Good About the Way My Physician Talks to Me Question|Don't Feel Very Good About the Way My Physician Talks to Me|I don't feel very good about the way my physician talks to me	A question about whether an individual doesn't feel very good about the way their physician talks to them.			Intellectual Product	The Health Care Climate Questionnaire
C153448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153448>	C173145	Physician Tries to Understand how I See Things before Suggesting New Way to Do Things Question|My physician tries to understand how I see things before suggesting a new way to do things|Physician Tries to Understand how I See Things before Suggesting New Way to Do Things	A question about whether an individual's physician tries to understand how they see things before suggesting a new way to do things.			Intellectual Product	The Health Care Climate Questionnaire
C153449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153449>	C173160|C173145|C173045	Able to Share My Feelings with My Physician Question|Able to Share My Feelings with My Physician|I feel able to share my feelings with my physician	A question about whether an individual feels able to share their feelings with their physician.			Intellectual Product	The Health Care Climate Questionnaire
C15344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15344>	C15301	UV Light Therapy|Light Therapy, UV|Therapy, UV Light|UV Phototherapy|Ultraviolet Radiation Therapy|ultraviolet radiation therapy	A form of treatment, mainly used for skin disorders, in which the skin is irradiated with ultraviolet light.	UV Light Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C153450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153450>	C217121	7 Point Agreement Rating Scale|7 Point Agreement Scale|Agreement Rating Scale	A subjective scale for the scoring of agreement that ranges from 1: Strongly Disagree to 7: Strongly Agree, with 4: Neutral.			Intellectual Product	The Health Care Climate Questionnaire
C153451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153451>	C221054	Agreement Rating 1|Agreement Rating Score 1	A subjective score of 1 on a scale that ranges from 1: Strongly Disagree to 7: Strongly Agree, with 4: Neutral.			Intellectual Product	The Health Care Climate Questionnaire
C153452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153452>	C221054	Agreement Rating 2|Agreement Rating Score 2	A subjective score of 2 on a scale that ranges from 1: Strongly Disagree to 7: Strongly Agree, with 4: Neutral.			Intellectual Product	The Health Care Climate Questionnaire
C153453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153453>	C221054	Agreement Rating 3|Agreement Rating Score 3	A subjective score of 3 on a scale that ranges from 1: Strongly Disagree to 7: Strongly Agree, with 4: Neutral.			Intellectual Product	The Health Care Climate Questionnaire
C153454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153454>	C221054	Agreement Rating 4|Agreement Rating Score 4	A subjective score of 4 (neutral) on a scale that ranges from 1: Strongly Disagree to 7: Strongly Agree, with 4: Neutral.			Intellectual Product	The Health Care Climate Questionnaire
C153455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153455>	C221054	Agreement Rating 5|Agreement Rating Score 5	A subjective score of 5 on a scale that ranges from 1: Strongly Disagree to 7: Strongly Agree, with 4: Neutral.			Intellectual Product	The Health Care Climate Questionnaire
C153456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153456>	C221054	Agreement Rating 6|Agreement Rating Score 6	A subjective score of 6 on a scale that ranges from 1: Strongly Disagree to 7: Strongly Agree, with 4: Neutral.			Intellectual Product	The Health Care Climate Questionnaire
C153457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153457>	C221054	Agreement Rating 7|Agreement Rating Score 7	A subjective score of 7 on a scale that ranges from 1: Strongly Disagree to 7: Strongly Agree, with 4: Neutral.			Intellectual Product	The Health Care Climate Questionnaire
C153458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153458>	C91105	Preparation for Decision Making Scale|PrepDM|Preparation for Decision Making	A questionnaire designed to assess a patient's perception of how useful a decision aid, or other decision-support intervention, is in preparing them to communicate with their physician to make a healthcare decision.			Intellectual Product	
C153459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153459>	C174127	Helped Recognize that Decision Needs to be Made Question|Help you recognize that a decision needs to be made|Helped Recognize that Decision Needs to be Made	A question about whether an individual was helped to recognize that a decision needs to be made.			Intellectual Product	Preparation for Decision Making Scale
C15345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15345>	C15334|C15290	Ureterostomy	A surgically created connection between the ureter and the skin, which drains urine from the ureter in individuals with urinary obstruction or other issues that prevent normal urination.			Therapeutic or Preventive Procedure	
C153460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153460>	C174127	Prepared to Make Better Decision Question|Prepare you to make a better decision|Prepared to Make Better Decision	A question about whether an individual was prepared to make a better decision.			Intellectual Product	Preparation for Decision Making Scale
C153461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153461>	C173597	Helped Think About Pros and Cons of Each Option Question|Help you think about the pros and cons of each option|Helped Think About Pros and Cons of Each Option	A question about whether an individual was helped to think about the pros and cons of each option.			Intellectual Product	Preparation for Decision Making Scale
C153462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153462>	C173597	Helped Think About which Pros and Cons are Most Important Question|Help you think about which pros and cons are most important|Helped Think About which Pros and Cons are Most Important	A question about whether an individual was helped to think about which pros and cons are most important.			Intellectual Product	Preparation for Decision Making Scale
C153463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153463>	C174127	Helped to Know that Decision Depends on What Matters Most to You Question|Help you know that the decision depends on what matters most to you|Helped to Know that Decision Depends on What Matters Most to You	A question about whether an individual was helped to know that the decision depends on what matters most to them.			Intellectual Product	Preparation for Decision Making Scale
C153464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153464>	C177692	FOLH1 Positive|FGCP Positive|FOLH Positive|Folate Hydrolase 1 Positive|Folylpoly-Gamma-Glutamate Carboxypeptidase Positive|GCP2 Positive|GCPII Positive|Glutamate Carboxypeptidase 2 Positive|NAALAD1 Positive|NAALAdase Positive|PSM Positive|PSMA Positive|PSMA Positive|Prostate-Specific Membrane Antigen Positive|mGCP Positive	An indication that FOLH1 expression has been detected in a sample.	FOLH1 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153465>	C35682	PTEN Alteration Positive|MMAC1 Alteration Positive|Mutated in Multiple Advanced Cancers 1 Alteration Positive|PTEN Alteration|PTEN Tyrosine Phosphatase Alteration Positive|PTEN1 Alteration Positive|Phosphatase and Tensin Homolog Alteration Positive|Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN Alteration Positive|TEP1 Alteration Positive	An indication that mutation, overexpression, fusion or rearrangement involving PTEN has been detected in a sample.	PTEN Alteration Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153466>	C153465|C103223	PTEN Gene Alteration Positive|MMAC1 Gene Alteration Positive|Mutated in Multiple Advanced Cancers 1 Gene Alteration Positive|PTEN Gene Alteration|PTEN1 Gene Alteration Positive|Phosphatase and Tensin Homolog Gene Alteration Positive|TEP1 Gene Alteration Positive	An indication that mutation, overexpression, fusion or rearrangement involving the PTEN gene has been detected in a sample.	PTEN Gene Alteration Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153467>	C3101	PTEN Deficiency|MMAC1 Deficiency|Mutated in Multiple Advanced Cancers 1 Deficiency|PTEN Tyrosine Phosphatase Deficiency|PTEN1 Deficiency|Phosphatase and Tensin Homolog Deficiency|Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN Deficiency|TEP1 Deficiency	A condition of decreased or absent presence or activity of phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN, which is associated with multiple hamartoma syndrome (Cowden syndrome) and increased risk for development of several types of malignant cancers, including head and neck, breast, lung and prostate cancer and glioblastoma.	PTEN Deficiency		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153468>	C174127|C173597	Helped Organize Your Thoughts About Decision Question|Help you organize your own thoughts about the decision|Helped Organize Your Thoughts About Decision	A question about whether an individual was helped to organize their own thoughts about their decision.			Intellectual Product	Preparation for Decision Making Scale
C153469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153469>	C174127|C173597	Helped Think About How Involved You Want to be in Decision Question|Help you think about how involved you want to be in this decision|Helped Think About How Involved You Want to be in Decision	A question about whether an individual was helped to think about how involved they want to be in this decision.			Intellectual Product	Preparation for Decision Making Scale
C15346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15346>	C15416	Vaccination|vaccination	Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis or treatment.			Therapeutic or Preventive Procedure	
C153470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153470>	C135578	Helped Identify Questions You Want to Ask Your Doctor Question|Help you identify questions you want to ask your doctor|Helped Identify Questions You Want to Ask Your Doctor	A question about whether an individual was helped to identify questions they want to ask their doctor.			Intellectual Product	Preparation for Decision Making Scale
C153471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153471>	C135578	Prepared You to Talk to Your Doctor About What Matters Most to You Question|Prepare you to talk to your doctor about what matters most to you|Prepared You to Talk to Your Doctor About What Matters Most to You	A question about whether an individual was prepared to talk to their doctor about what matters most to them.			Intellectual Product	Preparation for Decision Making Scale
C153472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153472>	C173145	Prepared You for Follow-up Visit with Your Doctor Question|Prepare you for a follow-up visit with your doctor|Prepared You for Follow-up Visit with Your Doctor	A question about whether an individual was prepared for a follow-up visit with their doctor.			Intellectual Product	Preparation for Decision Making Scale
C153473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153473>	C19238	Compress	Cloth or another material applied to an area of the skin for application of pressure or medication to a restricted area, or for local applications of heat or cold, and held in place for a period of time.			Manufactured Object	
C153474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153474>	C153473	Cold Compress	A chilled cloth or similar dressing applied to the skin.	Cold Compress		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C153475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153475>	C153477|C153072|C153070	Locally Advanced Unresectable Bone Sarcoma	A bone sarcoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.	Locally Advanced Unresectable Bone Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153476>	C153477|C153068|C153066	Locally Advanced Unresectable Soft Tissue Sarcoma	A soft tissue sarcoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.	Locally Advanced Unresectable Soft Tissue Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153477>	C153278|C153071|C152074	Locally Advanced Unresectable Sarcoma	A sarcoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.			Neoplastic Process	
C153478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153478>	C308	Dolcanatide|D-Leucine, D-asparaginyl-L-alpha-aspartyl-L-alpha-glutamyl-L-cysteinyl-L-alpha-glutamyl-L-leucyl-L-cysteinyl-L-valyl-L-asparaginyl-L-valyl-L-alanyl-L-cysteinyl-L-threonylglycyl-L-cysteinyl-, Cyclic (4->12),(7->15)-bis(disulfide)|DOLCANATIDE|SP 333|SP-333|SP333	An orally administered analog of the human endogenous natriuretic hormone uroguanylin and guanylate cyclase C (GC-C) agonist, with potential laxative, anti-nociceptive and anti-inflammatory activities. Upon administration, dolcanatide, by mimicking uroguanylin, binds to and activates GC-C locally on endothelial cells in the gastrointestinal (GI) tract, without entering the systemic circulation. Activation of GC-C results in an increase in cyclic guanosine monophosphate (cGMP). Increased concentrations of cGMP lead to the activation of the anion channel cystic fibrosis transmembrane conductance regulator (CFTR). CFTR activation increases the secretion of negatively charged ions, particularly chloride and bicarbonate, into the GI tract lumen, which further drives sodium ions and then water into the lumen. This leads to increased fluid secretion in the GI tract, accelerated transit and changes in stool consistency. In addition, ion channel modulation may decrease muscle contractions and the activity of pain-sensing nerves, thereby decreasing intestinal pain. Also, GC-C may inhibit the secretion of pro-inflammatory cytokines, which may ameliorate GI inflammation. Uroguanylin, a naturally occurring human GI peptide, is a ligand for GC-C and plays a key role in anti-inflammatory processes in the GI tract.	Dolcanatide		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C153479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153479>	C1557	5-Aza-4'-thio-2'-deoxycytidine|5-AZA-4'-THIO-2'-DEOXYCYTIDINE|5-Aza-4-thio-2-deoxycytidine|5-Aza-TdCyd|Aza-TdC|Aza-TdCyd	An orally bioavailable, nucleoside analog and DNA methyltransferase I (DNMT1) inhibitor, with potential DNA hypomethylating and antineoplastic activities. Upon administration, 5-aza-4'-thio-2'-deoxycytidine (Aza-TdC) gets incorporated into DNA, where it binds to the active site of DNMT1, a maintenance methyltransferase that contributes to the hypermethylation and silencing of tumor suppressor genes. The formation of covalent DNMT1-DNA complexes inhibits DNMT1, prevents DNA methylation of CpG sites, causes CpG demethylation, and results in the re-expression and re-activation of silenced tumor suppressor genes. This inhibits tumor cell proliferation. DNMT1, overactivated in tumor cells, plays a key role in tumor cell proliferation.	5-Aza-4'-thio-2'-deoxycytidine		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15347>	C15262	Vaccine Therapy|vaccine therapy	Immunotherapy using a preparation that usually contains a complex mixture of disease-related antigens, immunopotentiating agents, and immunomodulators, which stimulate the immune system to destroy pathogenic microorganisms or tumor cells.	Vaccine Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C153480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153480>	C63586	Cetuximab/Irinotecan/Vemurafenib Regimen|Cetuximab-Irinotecan-Vemurafenib|Cetuximab-Irinotecan-Vemurafenib Regimen|Cetuximab/Irinotecan/Vemurafenib|Irinotecan + Cetuximab + Vemurafenib|Irinotecan + Cetuximab + Vemurafenib Regimen|Irinotecan, Vemurafenib, Cetuximab|Irinotecan/Cetuximab/Vemurafenib|Irinotecan/Cetuximab/Vemurafenib Regimen	A regimen consisting of cetuximab, irinotecan and vemurafenib that can be used for the treatment of colon cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C153481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153481>	C63586|C191676	Irinotecan/Panitumumab Regimen|Irinotecan + Panitumumab Regimen|Irinotecan-Panitumumab|Irinotecan-Panitumumab Regimen|Irinotecan/Panitumumab|Panitumumab/Irinotecan	A regimen consisting of irinotecan and panitumumab that can be used for the treatment of colorectal cancer and appendiceal cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C153482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153482>	C63586	Irinotecan/Panitumumab/Vemurafenib Regimen|Irinotecan + Panitumumab + Vemurafenib|Irinotecan + Panitumumab + Vemurafenib Regimen|Irinotecan + Panitumumab Regimen|Irinotecan-Panitumumab-Vemurafenib|Irinotecan-Panitumumab-Vemurafenib Regimen|Irinotecan/Panitumumab/Vemurafenib	A regimen consisting of irinotecan, panitumumab and vemurafenib that can be used for the treatment of colon cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C153483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153483>	C63586|C191676	IROX-Bevacizumab Regimen|Bevacizumab-Irinotecan-Oxaliplatin Regimen|Bevacizumab/Irinotecan/Oxaliplatin Regimen|IROX (Irinotecan/Oxaliplatin) + Bevacizumab|IROX + Bevacizumab|IROX + Bevacizumab Regimen|IROX Plus Bevacizumab|IROX/Bev|Oxaliplatin/Irinotecan + Bevacizumab	A regimen consisting of bevacizumab, irinotecan and oxaliplatin that can be used for the treatment of appendiceal adenocarcinoma and colorectal cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C153484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153484>	C20993	Perceived Efficacy in Patient-Physician Interactions|PEPPI|Perceived Efficacy in Patient-Physician Interactions (PEPPI)	A 10-item questionnaire, or 5-item subset, designed to assess a patient's confidence in obtaining medical information and attention to their medical concerns from physicians.			Intellectual Product	
C153485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153485>	C173145|C173086	How Confident in Ability to Know What Questions to Ask Doctor Question|How Confident in Ability to Know What Questions to Ask Doctor|How confident are you in your ability to know what questions to ask a doctor	A question about how confident an individual is in their ability to know what questions to ask a doctor.			Intellectual Product	Perceived Efficacy in Patient-Physician Interactions
C153486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153486>	C173145|C173086	How Confident in Ability to get Doctor to Answer All Questions Question|How Confident in Ability to get Doctor to Answer All Questions|How confident are you in your ability to get a doctor to answer all of your questions	A question about how confident an individual is in their ability to get a doctor to answer all of their questions.			Intellectual Product	Perceived Efficacy in Patient-Physician Interactions
C153487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153487>	C173145|C173086	How Confident in Ability to Make Most of Visit with Doctor Question|How Confident in Ability to Make Most of Visit with Doctor|How confident are you in your ability to make the most of your visit with a doctor	A question about how confident an individual is in their ability to make the most of their visit with a doctor.			Intellectual Product	Perceived Efficacy in Patient-Physician Interactions
C153488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153488>	C173145|C173086	How Confident in Ability to Get Doctor to Take Chief Health Concern Seriously Question|How Confident in Ability to Get Doctor to Take Chief Health Concern Seriously|How confident are you in your ability to get a doctor to take your chief health concern seriously	A question about how confident an individual is in their ability to get a doctor to take their chief health concern seriously.			Intellectual Product	Perceived Efficacy in Patient-Physician Interactions
C153489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153489>	C173145|C173086	How Confident in Ability to Get Doctor to do Something About Chief Health Concern Question|How Confident in Ability to Get Doctor to do Something About Chief Health Concern|How confident are you in your ability to get a doctor to do something about your chief health concern	A question about how confident an individual is in their ability to get a doctor to do something about their chief health concern.			Intellectual Product	Perceived Efficacy in Patient-Physician Interactions
C15348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15348>	C37932|C15333	Vasectomy|vasectomy	Surgical removal of part or all of the vas deferens.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C153490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153490>	C217121	5-Point Confidence Scale|Confidence Scale	A subjective scale for the scoring of confidence that ranges from 1: Not at all confident 5: Very confident.			Intellectual Product	Perceived Efficacy in Patient-Physician Interactions
C153491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153491>	C221055	Confidence 1|Confidence Score 1	A subjective score of 1 on a confidence scale that ranges from 1: Not at all confident to 5: Very confident.			Intellectual Product	Perceived Efficacy in Patient-Physician Interactions
C153492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153492>	C221055	Confidence 2|Confidence Score 2	A subjective score of 2 on a confidence scale that ranges from 1: Not at all confident to 5: Very confident.			Intellectual Product	Perceived Efficacy in Patient-Physician Interactions
C153493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153493>	C221055	Confidence 3|Confidence Score 3	A subjective score of 3 on a confidence scale that ranges from 1: Not at all confident to 5: Very confident.			Intellectual Product	Perceived Efficacy in Patient-Physician Interactions
C153494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153494>	C221055	Confidence 4|Confidence Score 4	A subjective score of 4 on a confidence scale that ranges from 1: Not at all confident to 5: Very confident.			Intellectual Product	Perceived Efficacy in Patient-Physician Interactions
C153495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153495>	C221055	Confidence 5|Confidence Score 5	A subjective score of 5 on a confidence scale that ranges from 1: Not at all confident to 5: Very confident.			Intellectual Product	Perceived Efficacy in Patient-Physician Interactions
C153496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153496>	C177696	RB1 Gene Mutation Negative|RB Gene Mutation Negative|RB Mutation Negative|RB1 Mutation Negative|RB1 Wildtype|RB1 wt|Retinoblastoma 1 Gene Mutation Negative|Retinoblastoma Gene Mutation Negative	A genetic finding indicating that RB1 gene mutations have not been detected in a sample.	RB1 Gene Mutation Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153497>	C150479|C133155	RHEB Gene Rearrangement|RHEB Rearrangement|RHEB2 Gene Rearrangement|Ras Homolog Enriched In Brain 2 Gene Rearrangement|Ras Homolog Enriched In Brain Gene Rearrangement|Ras Homolog, mTORC1 Binding Gene Rearrangement	A molecular abnormality indicating rearrangement of the RHEB gene.	RHEB Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153498>	C165233	ROS1 Negative|MCF3 Negative|Proto-Oncogene Tyrosine-Protein Kinase ROS Negative|Proto-Oncogene c-Ros Negative|Proto-Oncogene c-Ros-1 Negative|ROS Negative|ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Negative|Receptor Tyrosine Kinase c-Ros Oncogene 1 Negative|c-Ros-1 Negative	An indication that expression of ROS1 has not been detected in a sample.	ROS1 Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153499>	C177692	S100B Positive|NEF Positive|Protein S100-B Positive|S-100 Protein Beta Chain Positive|S-100 Protein Subunit Beta Positive|S100 Calcium Binding Protein B Positive|S100 Calcium-Binding Protein B Positive|S100-B Positive|S100beta Positive	An indication that expression of S100B has been detected in a sample.	S100B Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15349>	C15824	Nutrition Research, Water	The study of the role of water in cancer causation or prevention and in general health.			Research Activity	
C1534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1534>	C1446	Methionine C 11|Methionine C11	A synthetic amino acid radiolabeled with carbon-11. Acting as a methyl donor, methionine C 11 is incorporated into macromolecules, where it serves as a positron emission tomography (PET) imaging agent for detecting tumors with high rates of protein synthesis.	Methionine C 11		Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C153500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153500>	C19285	TNFRSF9 Gene Product	A protein encoded by the TNFRSF9 gene.			Amino Acid, Peptide, or Protein	
C153501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153501>	C153500	Soluble Tumor Necrosis Factor Receptor Superfamily Member 9|Soluble 4-1BB|Soluble 4-1BB Ligand Receptor|Soluble CD137|Soluble CD137 Antigen|Soluble Receptor Protein 4-1BB|Soluble T-Cell Antigen 4-1BB Homolog|Soluble T-Cell Antigen ILA|Soluble TNFRSF9|s4-1BB|sCD137|sILA|sTNFRSF9	Soluble tumor necrosis factor receptor superfamily member 9 is encoded by the human TNFRSF9 gene. This protein plays a role in both activation-induced cell death (AICD) of T-lymphocytes and negative feedback control of inflammation.	Soluble Tumor Necrosis Factor Receptor Superfamily Member 9		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153502>	C131071	Sensitizing ROS1 Fusion Positive|Sensitizing MCF3 Fusion Positive|Sensitizing Proto-Oncogene Tyrosine-Protein Kinase ROS Fusion Positive|Sensitizing Proto-Oncogene c-Ros Fusion Positive|Sensitizing Proto-Oncogene c-Ros-1 Fusion Positive|Sensitizing ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Fusion Positive|Sensitizing ROS-1 Fusion|Sensitizing ROS1 Fusion|Sensitizing Receptor Tyrosine Kinase c-Ros Oncogene 1 Fusion Positive|Sensitizing c-Ros-1 Fusion Positive	An indication that expression of ROS1 fusion containing a ROS1 alteration that causes increased sensitivity to ROS1 inhibitory agents has been detected in a sample.	Sensitizing ROS1 Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153503>	C97927	SETBP1 Gene Mutation|SEB Gene Mutation|SET Binding Protein 1 Gene Mutation	A change in the nucleotide sequence of the SETBP1 gene.	SETBP1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153504>	C97927	SETD2 Gene Mutation|HBP231 Gene Mutation|HIF-1 Gene Mutation|HIP-1 Gene Mutation|HYPB Gene Mutation|KMT3A Gene Mutation|LLS Gene Mutation|SET Domain Containing 2 Gene Mutation|SET2 Gene Mutation|p231HBP Gene Mutation	A change in the nucleotide sequence of the SETD2 gene.	SETD2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153505>	C97927	SH2D1A Gene Mutation|DSHP Gene Mutation|EBVS Gene Mutation|IMD5 Gene Mutation|LYP Gene Mutation|MTCP1 Gene Mutation|SAP Gene Mutation|SH2 Domain Containing 1A Gene Mutation|XLP Gene Mutation|XLPD Gene Mutation|XLPD1 Gene Mutation	A change in the nucleotide sequence of the SH2D1A gene.	SH2D1A Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153506>	C91105	SURE Test|SURE|SURE Test for Clinical Practice	A 4-item questionnaire designed to assess the probability that a patient experiences clinically-significant decisional conflict.			Intellectual Product	
C153507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153507>	C173160	Feel Sure About Best Choice Question|Do you feel SURE about the best choice for you|Feel Sure About Best Choice	A question about whether an individual feels sure about the best choice for them.			Intellectual Product	SURE Test
C153508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153508>	C177743	Know Benefits and Risk of Each Option Question|Do you know the benefits and risks of each option|Know Benefits and Risk of Each Option	A question about whether an individual knows the benefits and risks of each option.			Intellectual Product	SURE Test
C153509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153509>	C173081	Clear About Which Benefits and Risks Matter Most Question|Are you clear about which benefits and risks matter most to you|Clear About Which Benefits and Risks Matter Most	A question about whether an individual is clear about which benefits and risks matter most to them.			Intellectual Product	SURE Test
C15350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15350>	C16230|C15569	Total-Body Irradiation|SCT_TBI|SCT_TBI|TBI|TOTAL BODY IRRADIATION|Total Body Irradiation|Whole Body|Whole Body Irradiation|Whole-Body Irradiation|total-body irradiation	A therapeutic procedure that involves the irradiation of the whole body with ionizing or non-ionizing radiation.	Total-Body Irradiation		Therapeutic or Preventive Procedure	ALL Stem Cell Transplant Table|ALL Variable Terminology|AML Stem Cell Transplant Table|AML Variable Terminology|CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Body Irradiation Model Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C153510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153510>	C91102	Have Enough Support and Advice to Make Choice Question|Do you have enough support and advice to make a choice|Have Enough Support and Advice to Make Choice	A question about whether an individual has enough support and advice to make a choice.			Intellectual Product	SURE Test
C153511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153511>	C177692	SMARCB1 Positive|BAF47 Positive|INI1 Positive|SMARCB Positive|SNF5 Positive|SWI/SNF-Related Matrix-Associated Actin Dependent Regulator of Chromatin Subfamily B Member 1 Positive	An indication that expression of SMARCB1 has been detected in a sample.	SMARCB1 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153512>	C97927	SOX9 Gene Mutation|CMD1 Gene Mutation|CMPD1 Gene Mutation|SRA1 Gene Mutation|SRY (Sex Determining Region Y)-Box 9 (Campomelic Dysplasia, Autosomal Sex-Reversal) Gene Mutation|SRY-Box 9 Gene Mutation|SRY-Related HMG-Box Gene 9 Mutation	A change in the nucleotide sequence of the SOX9 gene.	SOX9 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153513>	C97927	STAG2 Gene Mutation|SA-2 Gene Mutation|SA2 Gene Mutation|SCC3B Gene Mutation|STAG2|Stromal Antigen 2 Gene Mutation	A change in the nucleotide sequence of the STAG2 gene.	STAG2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|EWS Authorized Value Terminology|EWS Molecular Analysis Table
C153514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153514>	C97927|C136421	STAT3 Gene Mutation|ADMIO Gene Mutation|ADMIO1 Gene Mutation|APRF Gene Mutation|HIES Gene Mutation|Signal Transducer and Activator of Transcription 3 (Acute-Phase Response Factor) Gene Mutation|Signal Transducer and Activator of Transcription 3 Gene Mutation	A change in the nucleotide sequence of the STAT3 gene.	STAT3 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C153515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153515>	C2517	6 Melanoma Helper Peptide Vaccine|6MHP|6MHP Vaccine	A multi-epitope vaccine containing the following six class II MHC-restricted peptides: gp100, MelanA/MART-1, two tyrosinase peptides, and the cancer/testis antigens MAGE-A3 and MAGE-A1,2,3,6, with potential antineoplastic activity. Upon administration, melanoma helper peptides induce an antigen-specific, Th1-dominant, CD4+ T-cell response, potentially augmenting cytotoxic T-cell (CTL) responses and maintaining immunologic memory against tumor cells expressing melanoma-specific antigens. The 6MHP vaccine may also induce a CD8+ T-cell response through epitope spreading, potentially priming subsequent immune responses against tumor cells.	6 Melanoma Helper Peptide Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153516>	C133155	STK11 Gene Rearrangement|LKB1 Gene Rearrangement|Liver Kinase B1 Gene Rearrangement|STK11 Rearrangement|Serine/Threonine Kinase 11 Gene Rearrangement	A molecular abnormality indicating rearrangement of the STK11 gene.	STK11 Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153517>	C133155	T-Cell Receptor Gene Rearrangement|T Cell Receptor Family Gene Rearrangement|T Cell Receptor Gene Rearrangement|T-Cell Receptor Family Gene Rearrangement|T-Cell Receptor Rearrangement|TCR Family Gene Rearrangement|TCR Gene Rearrangement|TCR Rearrangement	A molecular abnormality indicating rearrangement of a T-cell receptor (TCR) family gene.	T-Cell Receptor Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153518>	C158948	t(15;17) Positive	A cytogenetic finding indicating that the translocation t(15;17) has been detected in a sample.	t(15;17) Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153519>	C97927	TAF1 Gene Mutation|BA2R Gene Mutation|CCG1 Gene Mutation|CCGS Gene Mutation|Cell Cycle Gene 1 Mutation|DYT3 Gene Mutation|KAT4 Gene Mutation|N-TAF1 Gene Mutation|NSCL2 Gene Mutation|OF Gene Mutation|P250 Gene Mutation|TAF2A Gene Mutation|TAFII250 Gene Mutation|TATA-Box Binding Protein Associated Factor 1 Gene Mutation|XDP Gene Mutation	A change in the nucleotide sequence of the TAF1 gene.	TAF1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15351>	C70601|C15262	Adoptive Immunotherapy|ACT|ACT Therapy|Adoptive Cell Immunotherapy|Adoptive Cell Transfer|Adoptive Cell Transfer Immunotherapy|Adoptive Cell Transfer Therapy|adoptive cellular immunotherapy|adoptive cellular therapy|cellular adoptive immunotherapy	A technique for enhancing cell-mediated immunity by: 1) artificially increasing the number of specific immunocompetent cells through inoculation of either ex-vivo expanded primarily activated cytotoxic lymphocytes or genetically engineered lymphocytes with enhanced cytotoxic ability or 2) by altering tumor cells to make them more immunogenic.	Adoptive Immunotherapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C153520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153520>	C97927	TBX3 Gene Mutation|T-Box 3 Gene Mutation|TBX3-ISO Gene Mutation|UMS Gene Mutation|XHL Gene Mutation	A change in the nucleotide sequence of the TBX3 gene.	TBX3 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153521>	C157377	Testosterone Greater than or Equal to 100 ng/dL|Testosterone Greater or Equal to 100|Testosterone Greater than or Equal to 100|Testosterone Greater than or Equal to 100 Nanograms per Deciliter|Testosterone Greater than or Equal to 100 Nanograms/Deciliter	A semiquantitative finding indicating that the concentration of testosterone in a sample is greater than or equal to 100 ng/dL.	Testosterone Greater than or Equal to 100 ng/dL		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C153522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153522>	C157377	Testosterone Greater than 100 ng/dL|Testosterone Greater than 100|Testosterone Greater than 100 Nanograms per Deciliter|Testosterone Greater than 100 Nanograms/Deciliter|Testosterone Level Greater than 100	A semiquantitative finding indicating that the concentration of testosterone in a sample is greater than 100 ng/dL.	Testosterone Greater than 100 ng/dL		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C153523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153523>	C177696	TNFSF9 Gene Mutation Negative|4-1BB-L Gene Mutation Negative|4-1BB-L Wildtype|4-1BB-L wt|CD137L Gene Mutation Negative|CD137L Wildtype|CD137L wt|TNFSF9 Wildtype|TNFSF9 wt|TNLG5A Gene Mutation Negative|Tumor Necrosis Factor Ligand Superfamily, Member 9 Gene Mutation Negative|Tumor Necrosis Factor Superfamily Member 9 Gene Mutation Negative	A genetic finding indicating that TNFSF9 gene mutations have not been detected in a sample.	TNFSF9 Gene Mutation Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153524>	C97927	TTR Gene Mutation|ATTR Gene Mutation|PALB Gene Mutation|Prealbumin, Thyroxine-Binding Gene Mutation|TBPA Gene Mutation|TTR Mutation|Transthyretin Gene Mutation	A change in the nucleotide sequence of the TTR gene.	TTR Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153525>	C180942|C133155	TSC1 Gene Rearrangement|Hamartin Gene Rearrangement|TSC Gene Rearrangement|TSC1 Rearrangement|Tuberous Sclerosis 1 Gene Rearrangement	A molecular abnormality indicating rearrangement of the TSC1 gene.	TSC1 Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C153526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153526>	C133155	TSC2 Gene Rearrangement|TSC2 Rearrangement|Tuberin Gene Rearrangement|Tuberous Sclerosis 2 Gene Rearrangement	A molecular abnormality indicating rearrangement of the TSC2 gene.	TSC2 Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C153527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153527>	C91105	Patient Provider Orientation Scale|PPOS|Patient Provider Orientation Scale (PPOS)	A questionnaire designed to assess beliefs that people have concerning doctors, patients, and medical care.			Intellectual Product	
C153528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153528>	C173145	Doctor Should Decide What Gets Talked About During Visit Question|Doctor Should Decide What Gets Talked About During Visit|The doctor is the one who should decide what gets talked about during a visit	A question about whether the doctor is the one who should decide what gets talked about during a visit.			Intellectual Product	Patient Provider Orientation Scale
C153529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153529>	C176545	Health Care is Less Personal but Pays for Medical Advances Question|Although health care is less personal these days, this is a small price to pay for medical advances|Health Care is Less Personal but Pays for Medical Advances	A question about whether health care is less personal these days, but a small price to pay for medical advances.			Intellectual Product	Patient Provider Orientation Scale
C15352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15352>	C191377	Pancreatic Islet Transplantation|islets of Langerhans transplantation	The surgical transfer of pancreatic islet cells from one individual to another.			Therapeutic or Preventive Procedure	
C153530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153530>	C91102	Most Important Part of Standard Medical Visit is Physical Exam Question|Most Important Part of Standard Medical Visit is Physical Exam|The most important part of the standard medical visit is the physical exam	A question about whether the most important part of a standard medical visit is the physical exam.			Intellectual Product	Patient Provider Orientation Scale
C153531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153531>	C91102	Often Best for Patients to Not Have Full Explanation of Medical Condition Question|It is often best for patients if they do not have a full explanation of their medical condition|Often Best for Patients to Not Have Full Explanation of Medical Condition	A question about whether it is often best for patients if they do not have a full explanation of their medical condition.			Intellectual Product	Patient Provider Orientation Scale
C153532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153532>	C173145	Patient Should Rely on Doctor's Knowledge and Not Find Out About Their Conditions Question|Patient Should Rely on Doctor's Knowledge and Not Find Out About Their Conditions|Patients should rely on their doctors' knowledge and not try to find out about their conditions on their own	A question about whether patients should rely on their doctor's knowledge and not try to find out about their conditions on their own.			Intellectual Product	Patient Provider Orientation Scale
C153533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153533>	C173145	Doctors Asking Lots of Questions About Patient's Background is Prying into Personal Matters Question|Doctors Asking Lots of Questions About Patient's Background is Prying into Personal Matters|When doctors ask a lot of questions about a patient's background, they are prying too much into personal matters	A question about whether when doctors ask a lot of questions about patient's background, they are prying too much into personal matters.			Intellectual Product	Patient Provider Orientation Scale
C153534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153534>	C173812|C173145	If Doctors are Good at Diagnosis and Treatment then their Relations with Patients Not Important Question|If Doctors are Good at Diagnosis and Treatment then their Relations with Patients Not Important|If doctors are truly good at diagnosis and treatment, the way they relate to patients is not that important	A question about if doctors are truly good at diagnosis and treatment, the way they relate to patients is not that important.			Intellectual Product	Patient Provider Orientation Scale
C153535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153535>	C91102	Many Patients Continue Asking Questions When Not Learning Anything New Question|Many Patients Continue Asking Questions When Not Learning Anything New|Many patients continue asking questions even though they are not learning anything new	A question about whether many patients continue asking questions even though they are not learning anything new.			Intellectual Product	Patient Provider Orientation Scale
C153536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153536>	C173145	Patients Should be Treated as Equal Partners with Doctor Question|Patients Should be Treated as Equal Partners with Doctor|Patients should be treated as if they were partners with the doctor, equal in power and status	A question about whether patients should be treated as if they were partners with their doctor, equal in power and status.			Intellectual Product	Patient Provider Orientation Scale
C153537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153537>	C176537	Patients Generally Want Reassurance Rather than Information about Health Question|Patients Generally Want Reassurance Rather than Information about Health|Patients generally want reassurance rather than information about their health	A question about whether patients generally want reassurance rather than information about their health.			Intellectual Product	Patient Provider Orientation Scale
C153538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153538>	C173145	If Doctor's Primary Tools are being Open and Warm, Doctor Will Not Have Success Question|If Doctor's Primary Tools are being Open and Warm, Doctor Will Not Have Success|If a doctor's primary tools are being open and warm, the doctor will not have a lot of success	A question about if a doctor's primary tools are being open and warm, the doctor will not have a lot of success.			Intellectual Product	Patient Provider Orientation Scale
C153539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153539>	C173145	Disagreement is Sign that Doctor Does Not Have Patient's Respect and Trust Question|Disagreement is Sign that Doctor Does Not Have Patient's Respect and Trust|When patients disagree with their doctor, this is a sign that the doctor does not have the patient's respect and trust	A question about whether when patients disagree with their doctor, this is a sign that the doctor does not have the patient's respect and trust.			Intellectual Product	Patient Provider Orientation Scale
C15353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15353>	C15324	Self-Examination|Self-Surveillance	The inspection of one's own body, usually for signs of disease.	Self-Examination		Individual Behavior	CTRP Intervention Terminology|CTRP Terminology
C153540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153540>	C173812	Treatment Plan Cannot Succeed if in Conflict with Patient's Lifestyle or Values Question|A treatment plan cannot succeed if it is in conflict with a patient's lifestyle or values|Treatment Plan Cannot Succeed if in Conflict with Patient's Lifestyle or Values	A question about whether a treatment plan cannot succeed if it is in conflict with a patient's lifestyle or values.			Intellectual Product	Patient Provider Orientation Scale
C153541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153541>	C173145	Most Patients Want to Get in and Out of Doctor's Office as Quickly as Possible Question|Most Patients Want to Get in and Out of Doctor's Office as Quickly as Possible|Most patients want to get in and get out of the doctor's office as quickly as possible	A question about whether most patients want to get in and get out of the doctor's office as quickly as possible.			Intellectual Product	Patient Provider Orientation Scale
C153542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153542>	C173145	Patient Must Always be Aware that Doctor is in Charge Question|Patient Must Always be Aware that Doctor is in Charge|The patient must always be aware that the doctor is in charge	A question about whether the patient must always be aware that the doctor is in charge.			Intellectual Product	Patient Provider Orientation Scale
C153543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153543>	C91102	Not Important to Know Patient's Culture and Background to Treat their Illness Question|It is not that important to know a patient's culture and background in order to treat the person's illness|Not Important to Know Patient's Culture and Background to Treat their Illness	A question about whether it is not important that a doctor know a patient's culture and background in order to treat the person's illness.			Intellectual Product	Patient Provider Orientation Scale
C153544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153544>	C173812|C173145	Humor is Major Ingredient in Doctor's Treatment of Patient Question|Humor is Major Ingredient in Doctor's Treatment of Patient|Humor is a major ingredient in the doctor's treatment of the patient	A question about whether humor is a major ingredient in the doctor's treatment of the patient.			Intellectual Product	Patient Provider Orientation Scale
C153545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153545>	C176537	When Patients Look up Medical Information This Confuses More than Helps Question|When Patients Look up Medical Information This Confuses More than Helps|When patients look up medical information on their own, this usually confuses more than it helps.	A question about whether when patients look up medical information on their own, it usually confuses more than it helps.			Intellectual Product	Patient Provider Orientation Scale
C153546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153546>	C226653	Moderately Disagree|Moderate Disagreement|Moderately disagree	A response indicating moderate disagreement.			Intellectual Product	Patient Provider Orientation Scale
C153547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153547>	C176244	Moderately Agree|Moderate Agreement|Moderately agree	A response indicating moderate agreement.			Intellectual Product	Patient Provider Orientation Scale
C153548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153548>	C132890	Tumor-Infiltrating Immune Cell|Tumor-Infiltrating Immune Cells	Immune cells that have left the bloodstream and migrated into a tumor.	Tumor-Infiltrating Immune Cell		Cell	CTRP Biomarker Terminology|CTRP Terminology
C153549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153549>	C64548	Ultra High Sensitivity C-Reactive Protein Measurement|Ultra High Sensitivity CRP Measurement|uhs-CRP|uhsCRP	The determination of the amount of C-reactive protein (CRP) present in a sample, usually serum from a blood draw from a subject that does not have a chronic inflammatory condition, through the use of an enhanced particle-enhanced immunoturbidimetric assay. This test is optimized to measure lower concentrations of CRP than a conventional CRP test. Accuracy is enhanced to ultra high levels through the use of a proprietary set of calibrated CRP samples.	Ultra High Sensitivity C-Reactive Protein Measurement		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15354>	C157969|C157802	Mammoplasty|Breast Reconstruction|Breast Reconstruction|breast reconstruction	Surgical reconstruction of the breast.	Mammoplasty		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology
C153550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153550>	C68564	Urinary Microbiome|Urinary Microbiome Profile|Urinary Microbiota	The collection of microorganisms existing in the urinary tract and/or urine of an organism.	Urinary Microbiome		Organism	CTRP Biomarker Terminology|CTRP Terminology
C153551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153551>	C70922	25-Hydroxyvitamin D Less than 66 ng/ml|25(OH)D Less than 66 Nanograms per Milliliter|25(OH)D Less than 66 Nanograms/Milliliter|25(OH)D Less than 66 ng/mL|25-Hydroxyvitamin D Less than 66 Nanograms per Milliliter|25-Hydroxyvitamin D Less than 66 Nanograms/Milliliter|25-OH-VitD Less than 66 Nanograms per Milliliter|25-OH-VitD Less than 66 Nanograms/Milliliter|25-OH-VitD Less than 66 ng/mL|25-OH-Vitamin D Less than 66 Nanograms per Milliliter|25-OH-Vitamin D Less than 66 Nanograms/Milliliter|25-OH-Vitamin D Less than 66 ng/mL|Calcidiol Less than 66 Nanograms per Milliliter|Calcidiol Less than 66 Nanograms/Milliliter|Calcidiol Less than 66 ng/mL|Calcifediol Less than 66 Nanograms per Milliliter|Calcifediol Less than 66 ng/mL|Vitamin D Less than 66 ng/ml	A semiquantitative finding indicating that the concentration of 25-hydroxyvitamin D2 plus 25-hydroxyvitamin D3 is less than 66 ng/mL.	25-Hydroxyvitamin D Less than 66 ng/ml		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C153552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153552>	C70922	25-Hydroxyvitamin D Less than 30 ng/ml|25(OH)D Less than 30 Nanograms per Milliliter|25(OH)D Less than 30 Nanograms/Milliliter|25(OH)D Less than 30 ng/mL|25-Hydroxyvitamin D Less than 30 Nanograms per Milliliter|25-Hydroxyvitamin D Less than 30 Nanograms/Milliliter|25-OH-VitD Less than 30 Nanograms per Milliliter|25-OH-VitD Less than 30 Nanograms/Milliliter|25-OH-VitD Less than 30 ng/mL|25-OH-Vitamin D Less than 30 Nanograms per Milliliter|25-OH-Vitamin D Less than 30 Nanograms/Milliliter|25-OH-Vitamin D Less than 30 ng/mL|Calcidiol Less than 30 Nanograms per Milliliter|Calcidiol Less than 30 Nanograms/Milliliter|Calcidiol Less than 30 ng/mL|Calcifediol Less than 30 Nanograms per Milliliter|Calcifediol Less than 30 Nanograms/Milliliter|Calcifediol Less than 30 ng/mL|Vitamin D Less than 30 ng/ml	A semiquantitative finding indicating that the concentration of 25-hydroxyvitamin D2 plus 25-hydroxyvitamin D3 is less than 30 ng/mL.	25-Hydroxyvitamin D Less than 30 ng/ml		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C153553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153553>	C45233	Peak Oxygen Consumption|Oxygen Consumption Peak|V'O2 Peak|VO2 Peak|VO2peak	The highest rate of oxygen consumption a subject reaches during an aerobic capacity test.	Peak Oxygen Consumption		Finding	CTRP Biomarker Terminology|CTRP Terminology
C153554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153554>	C63474	Promoting Resilience in Stress Management|PRISM	A resilience-building intervention program for adolescents and young adults with serious illness. It focuses of 4 disease-non-specific skills: stress management, goal-setting and problem-solving, positive re-appraisals of stressors, and meaning-making or benefit-finding.	Promoting Resilience in Stress Management		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C153555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153555>	C165233	WT1 Negative|Wilms Tumor 1 Negative	Indicates that expression of WT1 has not been detected in a sample.	WT1 Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153556>	C97927	XPO1 Gene Mutation|CRM1 Gene Mutation|Exportin 1 Gene Mutation|Exportin-1 Gene Mutation|Required For Chromosome Region Maintenance Gene Mutation|emb Gene Mutation|exp1 Gene Mutation	A change in the nucleotide sequence of the XPO1 gene.	XPO1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153557>	C153228	Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level|Decrease of Pretreatment Bone Marrow Blast Percentage by at Least 50|Decrease of Pretreatment Bone Marrow Blast Percentage by at Least 50 Percent	A semiquantitative finding indicating that the amount of immature mononuclear cells in a subject's sample of nucleated cells from bone marrow has decreased by 50 percent or more over the value recorded for a pretreatment sample from that subject.	Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C153558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153558>	C18520	Phosphorylated-FAK Y397|FAK (Phospho Tyr397)|FAK (Phospho Y397)|FAK (pY397)|Focal Adhesion Kinase 1 Y397 Phosphorylated|Phospho-FAK (Y397)|Phospho-PTK2 (Tyr397)|Phospho-PTK2 (Y397)|Phosphorylated FAK Y397|Phosphorylated-Focal Adhesion Kinase 1 Y397	A post-translationally modified form of focal adhesion kinase 1 (FAK; FAK1; PTK2) where the tyrosine (Y; Tyr) at residue 397 is phosphorylated. Cell adhesion-signaling promotes the association of FAK with Src family kinases, which stimulates autophosphorylation of FAK Y397 and creates a SH2-binding site on FAK to promote Src family kinase- and integrin-mediated signaling.	Phosphorylated-FAK Y397		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153559>	C27992	Androgen-sensitive|Androgen-sensitivity	Describes cells, tissues, conditions, or diseases that are responsive to or dependent on any of the androgen hormones.	Androgen-sensitive		Qualitative Concept	CTRP Disease Terminology|CTRP Terminology
C15355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15355>	C15542|C15470|C15438	Radioimmunotherapy|Immunoradiotherapy|Immunotherapy, Cancer, Radioisotope|radioimmunotherapeutics|radioimmunotherapy	Treatment with a radioactive substance that is linked to an antibody so that it will attach to a tumor when injected into the body.	Radioimmunotherapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C153560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153560>	C3420	Xp11.2 Translocation|t(V;X)(v;p11.2)|t(X;V)(p11.2;v)|t(v;Xp11.2)	A cytogenetic abnormality that refers to any translocation involving Xp11.2 on the short arm of the X chromosome.	Xp11.2 Translocation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153561>	C190823|C177681	EGFR Gene Amplification Negative|EGFR Amplification Negative|EGFR Non-Amplification|ERBB1 Gene Amplification Negative|Epidermal Growth Factor Receptor Gene Amplification Negative|HER1 Gene Amplification Negative|No|Unamplified|c-erbB1 Gene Amplification Negative	An indication that amplification of the EGFR gene was not detected in a sample.	EGFR Gene Amplification Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153562>	C103223	MGMT Gene Promoter Methylation|MGMT Gene Methylation|MGMT Methylation|Methylated MGMT|Methylated MGMT Gene Promoter|Methylated MGMT Promoter|Methylguanine-DNA Methyltransferase Gene Promoter Methylation|O-6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation|Positive|Present	A genetic finding indicating that DNA methylation in the promoter region of the MGMT gene has been detected in a sample.	Methylated MGMT Gene Promoter		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C153563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153563>	C217121	Control Preference Scale|CPS|Control Preferences Scale (CPS)	A tool designed to assess the degree of control an individual wants to assume when decisions are being made about medical treatment.			Intellectual Product	
C153564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153564>	C176545|C174127|C173507	Preference for Making Decisions about Health Care Question|Preference for Making Decisions about Health Care|What is your preference for making decisions about your health care	A question about an individual's preference for making decisions about their healthcare.			Intellectual Product	
C153566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153566>	C16338	Magnesium-based Bone Void Filler|Magnesium-based BVF|Osteocrete	An injectable magnesium oxide-based bone void filler (BVF) with potential osteoconductive properties. Upon injection into bony voids or defects, the magnesium-based BVF mimics cancellous bone and provides a supportive scaffold to facilitate the bone healing process. Magnesium contributes to the structural development of bone and may potentially increase proliferation of bone marrow stromal cells and improve attachment and growth of osteoblasts.	Magnesium-based Bone Void Filler		Biomedical or Dental Material	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C153568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153568>	C40367|C175588	Recurrent Breast Acinic Cell Carcinoma|Recurrent Acinic Cell Breast Carcinoma	The reemergence of acinic cell breast carcinoma after a period of remission.			Neoplastic Process	
C153569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153569>	C7977|C155742	Recurrent Pancreatic Acinar Cell Carcinoma	The reemergence of pancreatic acinar cell carcinoma after a period of remission.			Neoplastic Process	
C15356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15356>	C16120|C15330	Whipple Procedure|Kausch-Whipple Procedure|PANCREATICODUODENECTOMY|Pancreatoduodenectomy|Whipple|Whipple procedure	Surgical removal of part of the pancreas, duodenum, and distal part of the bile duct.  Sometimes, the lower portion of the stomach and the gallbladder are also removed.  This procedure is performed for pancreatic, ampullary, duodenal and distal bile duct cancers.	Whipple Procedure		Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C153570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153570>	C5596|C171012	Recurrent Prostate Acinar Adenocarcinoma	The reemergence of prostate acinar adenocarcinoma after a period of remission.			Neoplastic Process	
C153571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153571>	C5933|C199666|C153800	Recurrent Parotid Gland Acinic Cell Carcinoma	The reemergence of parotid gland acinic cell carcinoma after a period of remission.			Neoplastic Process	
C153572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153572>	C5934|C199666|C153801	Recurrent Submandibular Gland Acinic Cell Carcinoma	The reemergence of submandibular gland acinic cell carcinoma after a period of remission.			Neoplastic Process	
C153573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153573>	C148510|C136651|C127907	Recurrent Endocervical Adenocarcinoma, Usual-Type|Recurrent Cervical Adenocarcinoma, Usual Type|Recurrent Cervical Adenocarcinoma, Usual-Type|Recurrent Endocervical Adenocarcinoma, Usual Type	The reemergence of endocervical adenocarcinoma, usual-type after a period of remission.			Neoplastic Process	
C153574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153574>	C6650|C224862|C159565	Recurrent Ampulla of Vater Adenocarcinoma|Recurrent Ampullary Adenocarcinoma	The reemergence of ampulla of Vater adenocarcinoma after a period of remission.			Neoplastic Process	
C153575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153575>	C5600|C208295|C159565	Recurrent Anal Adenocarcinoma	The reemergence of anal adenocarcinoma after a period of remission.			Neoplastic Process	
C153576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153576>	C7793|C5606|C153575	Recurrent Anal Mucinous Adenocarcinoma	The reemergence of anal mucinous adenocarcinoma after a period of remission.			Neoplastic Process	
C153577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153577>	C7793|C7477|C200069|C153575	Recurrent Paget Disease of the Anal Canal|Recurrent Paget's Disease of the Anal Canal	The reemergence of Paget disease of the anal canal after a period of remission.			Neoplastic Process	
C153578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153578>	C148268	Powder and Solvent for Suspension for Injection in Multidose Container Dosage Form|Powder and solvent for suspension for injection in multidose container	Medicinal product consisting of a powder and solvent for suspension for injection presented in a multidose container; usually the powder is presented in the multidose container while the solvent is presented in a separate container, and is added to the powder in order to prepare the suspension for injection in the multidose container.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C153579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153579>	C43558|C179174	Recurrent Appendix Mucinous Adenocarcinoma|Recurrent Appendiceal Mucinous Adenocarcinoma	The reemergence of appendix mucinous adenocarcinoma after a period of remission.			Neoplastic Process	
C15357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15357>	C15330	Esophagectomy|esophagectomy|excision of the esophagus	Surgical removal of part or all of the esophagus.	Esophagectomy		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology
C153580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153580>	C25638	Incomplete, Incorrect or Alternative Diagnosis Code Assigned	A diagnosis code was assigned based on incomplete, incorrect or non-ideal (an alternative diagnosis may be more appropriate) supporting information.	Incomplete, Incorrect or Alternative Diagnosis Code Assigned		Finding	CTRP Disease Terminology|CTRP Terminology
C153581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153581>	C91105	Decision Quality Instruments - Breast Surgery|DQI-Breast|Decision Quality Instruments (DQI) - Breast Surgery|Decision Quality Instruments - Breast	A questionnaire designed to assess what it is like for an individual to make decisions about surgery for early-stage breast cancer.			Intellectual Product	
C153582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153582>	C173791|C173564	How Important to Keep Breast Question|How Important to Keep Breast|How important is it to you to keep your breast	A question about how important it is to an individual that they keep their breast.			Intellectual Product	Decision Quality Instruments - Breast Surgery
C153583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153583>	C173791|C173564	How Important to Remove Entire Breast for Peace of Mind Question|How Important to Remove Entire Breast for Peace of Mind|How important is it to you remove your entire breast to gain peace of mind	A question about how important it is to an individual to have their entire breast removed for peace of mind.			Intellectual Product	Decision Quality Instruments - Breast Surgery
C153584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153584>	C7950|C175588	Recurrent Invasive Breast Lobular Carcinoma|Recurrent Invasive Lobular Carcinoma	The reemergence of invasive breast lobular carcinoma after a period of remission.			Neoplastic Process	
C153585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153585>	C175989|C173564	How Important to Avoid Having Radiation Question|How Important to Avoid Having Radiation|How important is it to you avoid having radiation	A question about how important it is to an individual to avoid having radiation therapy.			Intellectual Product	Decision Quality Instruments - Breast Surgery
C153586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153586>	C173806	Which Treatment Wanted to Treat Early Stage Breast Cancer Question|Which Treatment Wanted to Treat Early Stage Breast Cancer|Which treatment do you want to do to treat your early stage breast cancer	A question about which treatment an individual prefers for treating their early-stage breast cancer.			Intellectual Product	Decision Quality Instruments - Breast Surgery
C153587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153587>	C4194|C175588	Recurrent Invasive Breast Carcinoma of No Special Type|Recurrent Invasive Breast Ductal Carcinoma|Recurrent Invasive Ductal Breast Carcinoma|Recurrent Invasive Ductal Carcinoma of the Breast	The reemergence of invasive breast carcinoma of no special type after a period of remission.			Neoplastic Process	
C153588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153588>	C47857|C175588	Recurrent Breast Paget Disease|Recurrent Paget Disease of the Breast|Recurrent Paget's Disease of the Breast	The reemergence of Paget disease of the breast after a period of remission.			Neoplastic Process	
C153589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153589>	C174127|C173806	How Much Does Waiting Few Weeks for Treatment Decision Affects Chances of Survival Question|For most women with early breast cancer, how much would waiting a few weeks to make a treatment decision affect their chances of survival|How Much Does Waiting Few Weeks for Treatment Decision Affects Chances of Survival	A question about how much waiting a few weeks to make a treatment decision would affect an individual's chances of survival.			Intellectual Product	Decision Quality Instruments - Breast Surgery
C15358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15358>	C15751|C15696	Stereotactic Radiosurgery|SRS|Stereotactic External Beam Irradiation|Stereotactic Radiation Therapy|Stereotactic Radiotherapy|stereotactic external-beam radiation therapy|stereotactic radiation therapy|stereotactic radiosurgery|stereotaxic radiation therapy|stereotaxic radiosurgery	A non-surgical procedure that was developed to deliver one or several maximum dose targeted radiation treatments for cancers in the brain or spine.	Stereotactic Radiosurgery		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C153590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153590>	C7825|C4033	Recurrent Clear Cell Renal Cell Carcinoma	The reemergence of clear cell renal cell carcinoma after a period of remission.			Neoplastic Process	
C153591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153591>	C173806	With Treatment How Many Women Diagnosed with Early Breast Cancer Eventually Die of Breast Cancer Question|With Treatment How Many Women Diagnosed with Early Breast Cancer Eventually Die of Breast Cancer|With treatment, about how many women diagnosed with early breast cancer will eventually die of breast cancer	A question about how many women diagnosed with early breast cancer eventually die of breast cancer following treatment.			Intellectual Product	Decision Quality Instruments - Breast Surgery
C153592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153592>	C173812	Which Treatment More Likely Needs Another Operation to Remove Tumor Cells Question|After which treatment is it more likely that women will need to have another operation to remove more tumor cells|Which Treatment More Likely Needs Another Operation to Remove Tumor Cells	A question about which treatment is more likely to need another operation to remove more tumor cells.			Intellectual Product	Decision Quality Instruments - Breast Surgery
C153593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153593>	C91102	Which Women with Early Breast Cancer Live Longer on Average Question|On average, which women with early breast cancer live longer|Which Women with Early Breast Cancer Live Longer on Average	A question about which women with early breast cancer live longer on average, based on treatment type.			Intellectual Product	Decision Quality Instruments - Breast Surgery
C153594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153594>	C91102	Which Women Have Higher Chance of Cancer Coming Back in Treated Breast on Average Question|On average, which women have a higher chance of having cancer come back in the breast that has been treated|Which Women Have Higher Chance of Cancer Coming Back in Treated Breast on Average	A question about which women with early breast cancer have a higher chance of cancer returning in the treated breast, on average, based on treatment type.			Intellectual Product	Decision Quality Instruments - Breast Surgery
C153595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153595>	C7825|C4146	Recurrent Chromophobe Renal Cell Carcinoma	The reemergence of chromophobe renal cell carcinoma after a period of remission.			Neoplastic Process	
C153596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153596>	C217121	10-Point Importance Scale|Importance Scale	A scale for the subjective scoring of importance that ranges from 0: Not at all important to 10: Extremely important.			Intellectual Product	
C153597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153597>	C221057	Importance Score 0	A subjective score of 0 on a scale that ranges from 0: Not at all important to 10: Extremely important.			Intellectual Product	Decision Quality Instruments - Breast Surgery
C153598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153598>	C18881|C17632	DNA Sequencing|DNA Sequence Analysis|DNA-Seq|Deoxyribonucleic Acid Sequencing	The determination of the sequence of purines and pyrimidines in deoxyribonucleic acid (DNA).	DNA Sequencing		Molecular Biology Research Technique	CTRP Biomarker Terminology|CTRP Terminology
C153599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153599>	C221057	Importance Score 1	A subjective score of 1 on a scale that ranges from 0: Not at all important to 10: Extremely important.			Intellectual Product	Decision Quality Instruments - Breast Surgery
C15359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15359>	C49236	Salvage Therapy|SALVAGE|Salvage|Salvage|salvage therapy	Performing a salvage procedure is the last resort. The clinical situation involves either ongoing life support measures, life support measures for more than 60 seconds during the prior 10 minutes, or unanticipated institution of extracorporeal circulatory support. (ACC)	Salvage Therapy		Therapeutic or Preventive Procedure	CDISC SDTM Procedure Urgency Status Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Terminology|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C1535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1535>	C1975	Bruceanol D|Picras-3-en-21-oic Acid, 15-((3,4-dimethyl-1-oxo-2-pentenyl)oxy)-13,20-epoxy-1,11,12-trihydroxy-2,16-dioxo-, Methyl Ester, (1beta,11beta,12alpha,15beta(E))-	A quassinoid phytochemical isolated form the plant Brucea antidysenterica with potential antineoplastic activity. (NCI04)			Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C153600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153600>	C221057	Importance Score 2	A subjective score of 2 on a scale that ranges from 0: Not at all important to 10: Extremely important.			Intellectual Product	Decision Quality Instruments - Breast Surgery
C153601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153601>	C221057	Importance Score 3	A subjective score of 3 on a scale that ranges from 0: Not at all important to 10: Extremely important.			Intellectual Product	Decision Quality Instruments - Breast Surgery
C153602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153602>	C221057	Importance Score 4	A subjective score of 4 on a scale that ranges from 0: Not at all important to 10: Extremely important.			Intellectual Product	Decision Quality Instruments - Breast Surgery
C153603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153603>	C221057	Importance Score 5	A subjective score of 5 on a scale that ranges from 0: Not at all important to 10: Extremely important.			Intellectual Product	Decision Quality Instruments - Breast Surgery
C153604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153604>	C221057	Importance Score 6	A subjective score of 6 on a scale that ranges from 0: Not at all important to 10: Extremely important.			Intellectual Product	Decision Quality Instruments - Breast Surgery
C153605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153605>	C221057	Importance Score 7	A subjective score of 7 on a scale that ranges from 0: Not at all important to 10: Extremely important.			Intellectual Product	Decision Quality Instruments - Breast Surgery
C153606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153606>	C221057	Importance Score 8	A subjective score of 8 on a scale that ranges from 0: Not at all important to 10: Extremely important.			Intellectual Product	Decision Quality Instruments - Breast Surgery
C153607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153607>	C221057	Importance Score 9	A subjective score of 9 on a scale that ranges from 0: Not at all important to 10: Extremely important.			Intellectual Product	Decision Quality Instruments - Breast Surgery
C153608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153608>	C221057	Importance Score 10	A subjective score of 10 on a scale that ranges from 0: Not at all important to 10: Extremely important.			Intellectual Product	Decision Quality Instruments - Breast Surgery
C153609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153609>	C226690	Equally Likely for Both|Equally Likely	A response indicating that 2 things are equally likely.			Intellectual Product	Decision Quality Instruments - Breast Surgery
C15360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15360>	C15675	Adjuvant Chemotherapy|Adjuvant|Adjuvant	Chemotherapy that is administered subsequent to the main treatment plan to minimize or prevent disease recurrence.	Adjuvant Chemotherapy		Therapeutic or Preventive Procedure	CRF4 Treatment Chemotherapy Table|CRF4 Treatment Complementary Table|CTRP Intervention Terminology|CTRP Terminology|OS Authorized Value Terminology|OS Course Timing Table
C153610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153610>	C226690	No Difference in Likelihood|No difference	A response indicating no difference in likelihood.			Intellectual Product	Decision Quality Instruments - Breast Surgery
C153611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153611>	C5904|C199666	Recurrent Salivary Duct Carcinoma	The reemergence of salivary duct carcinoma after a period of remission.			Neoplastic Process	
C153612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153612>	C5948|C199666	Recurrent Minor Salivary Gland Adenocarcinoma	The reemergence of minor salivary gland adenocarcinoma after a period of remission.			Neoplastic Process	
C153614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153614>	C7833|C7700|C159565	Recurrent Ovarian Adenocarcinoma	The reemergence of ovarian adenocarcinoma after a period of remission.			Neoplastic Process	
C153615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153615>	C7550|C153614	Recurrent Ovarian Serous Adenocarcinoma	The reemergence of ovarian serous adenocarcinoma after a period of remission.			Neoplastic Process	
C153616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153616>	C5243|C153614	Recurrent Ovarian Mucinous Adenocarcinoma	The reemergence of ovarian mucinous adenocarcinoma after a period of remission.			Neoplastic Process	
C153617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153617>	C5228|C153614	Recurrent Ovarian Cystadenocarcinoma	The reemergence of ovarian cystadenocarcinoma after a period of remission.			Neoplastic Process	
C153618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153618>	C40078|C222817|C153614	Recurrent Ovarian Clear Cell Adenocarcinoma	The reemergence of ovarian clear cell adenocarcinoma after a period of remission.	Recurrent Ovarian Clear Cell Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153619>	C9120|C155742	Recurrent Pancreatic Ductal Adenocarcinoma	The reemergence of pancreatic ductal adenocarcinoma after a period of remission.			Neoplastic Process	
C15361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15361>	C15190	Fine-Needle Aspiration|Aspirate, Fine Needle|FINE NEEDLE ASPIRATION|FNA|FNA biopsy|Fine Needle Aspiration|Fine Needle Aspiration|Fine Needle Aspiration|Fine Needle Biopsy|fine-needle aspiration biopsy	The removal of tissue or fluid with a thin needle for examination under a microscope.	Fine-Needle Aspiration		Diagnostic Procedure	CDISC SDTM Specimen Collection Method Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Biopsy/Surgical Procedures Table
C153620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153620>	C3874|C155742	Recurrent Pancreatic Cystadenocarcinoma	The reemergence of pancreatic cystadenocarcinoma after a period of remission.			Neoplastic Process	
C153621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153621>	C4035|C165611	Recurrent Thyroid Gland Papillary Carcinoma	The reemergence of thyroid gland papillary carcinoma after a period of remission.			Neoplastic Process	
C153622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153622>	C8054|C165611	Recurrent Thyroid Gland Follicular Carcinoma	The reemergence of thyroid gland follicular carcinoma after a period of remission.			Neoplastic Process	
C153623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153623>	C7908|C3879|C191978	Recurrent Thyroid Gland Medullary Carcinoma	The reemergence of thyroid gland medullary carcinoma after a period of remission.			Neoplastic Process	
C153624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153624>	C7908|C3878	Recurrent Thyroid Gland Anaplastic Carcinoma|Recurrent Thyroid Gland Undifferentiated (Anaplastic) Carcinoma	The reemergence of thyroid gland anaplastic carcinoma after a period of remission.			Neoplastic Process	
C153625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153625>	C148275	Solution for Injection in Multidose Container Dosage Form|Solution for injection in multidose container	Medicinal product consisting of a solution for injection presented in a multidose container.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C153626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153626>	C5384|C4489|C150545|C139002	Recurrent Skin Angiosarcoma	The reemergence of skin angiosarcoma after a period of remission.			Neoplastic Process	
C153627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153627>	C148275	Suspension for Injection in Multidose Container Dosage Form|Suspension for injection in multidose container	Medicinal product consisting of a suspension for injection presented in a multidose container.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C15362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15362>	C16084	Case Study|CASE ONLY|Case Report|Case Report|case report	An uncontrolled observational study containing a detailed report of the diagnosis, treatment, and follow-up of an individual patient. Case reports also contain some demographic information about the patient (for example, age, sex, ethnic origin).			Research Activity	CDISC SDTM Observational Study Model Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|SeroNet Authorized Values|SeroNet Study Descriptors
C15364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15364>	C15239	Managed Care	An arrangement whereby a third-party payer (e.g., insurance company, federal government, or corporation) mediates between physicians and patients, negotiating fees for service and overseeing the types of treatment given.  Managed care has virtually replaced unmanaged indemnity plans, where payment is automatic and oversight procedures are minimal.  Whereas 96% of American workers had unmanaged indemnity in 1984, only 28% did in 1988.  Typically, in managed care, the third-party payer requires second opinions and pre-certification review for patients requiring hospital admission.  They obtain wholesale prices from doctors, and carry out cost-containment measures, including auditing hospitals and reviewing claims.  Managed care has figured heavily in the national debate over health care.			Health Care Activity	
C15365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15365>	C15829	Outcomes Research|Health Outcomes Research|outcomes research	The study of the end results of health services, with the intention of providing scientific evidence relating to the value of the decisions made by all who participate in the health care process.			Research Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C15366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15366>	C15192	Platelet Transfusion|Blood Platelet Transfusion	The infusion of platelets into the bloodstream.	Platelet Transfusion		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C15367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15367>	C16205	Health Risk Assessment|Risk Assessment|Risk Assessment|risk assessment	An estimated probability that one or more adverse event(s) will occur as a result of exposure to an actual or potential hazardous situation or chemical.	Risk Assessment		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C15369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15369>	C15194	Allogeneic Bone Marrow Transplantation|Allo BMT|Allogeneic BMT|Allogeneic Blood and Marrow Transplantation|allogeneic bone marrow transplantation	A clinical treatment in which a patient receives bone marrow from a compatible, but not genetically identical, donor.	Allogeneic Bone Marrow Transplantation		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology
C1536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1536>	C1975	Bruceanol E|Picrasan-21-oic Acid, 15-((3,4-dimethyl-1-oxo-2-pentenyl)oxy)-13,20-epoxy-1,11,12-trihydroxy-2,16-dioxo-, Methyl Ester, (1beta,11beta,12alpha,15beta(E))-	A quassinoid phytochemical isolated from the plant Brucea antidysenterica with potential antineoplastic activity. (NCI04)			Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C15370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15370>	C63475	Steroid Therapy|steroid therapy	The use of exogenous steroids for the treatment of any disease or disorder.	Steroid Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C15371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15371>	C211883	Cerebral Edema Management|management of cerebral edema	Any activity related to the care and/or treatment of cerebral edema.			Therapeutic or Preventive Procedure	
C15372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15372>	C15843	Smoking Cessation Intervention|Smoking and Tobacco Use Cessation Interventions	Any intervention designed to reduce and eliminate an individual's smoking.	Smoking Cessation Intervention		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C15373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15373>	C15910	Therapeutic Touch|Healing Touch|healing touch|therapeutic touch	An energy (biofield) therapy that encompasses a group of non-invasive techniques that utilize the hands to clear, energize, and balance the human and environmental energy fields.  Healing Touch interventions may be used to restore, energize, and balance an energy field disturbance. (HTA)	Therapeutic Touch		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C15374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15374>	C49236	Douche|douche	A procedure in which a stream of liquid is introduced into a body cavity, most commonly the vagina, for medical or hygienic reasons.			Therapeutic or Preventive Procedure	
C15375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15375>	C15436	Imagery Therapy|Guided Imagery|Imagery|imagery	A therapeutic exercise used in treatment of pain, hyperventilation, panic, and other conditions.  The practitioner guides the patient into a semi-hypnotic state by verbally introducing positive and soothing images.  It is as a form of distraction and attention therapy.	Imagery Therapy		Mental Process	CTRP Intervention Terminology|CTRP Terminology
C15376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15376>	C51975	Transcendental Meditation Therapy|TM|Transcendental Meditation|transcendental meditation	A mental technique used to promote relaxation, reduce stress, and improve quality of life. Transcendental Meditation is the registered trademark of the Maharishi Foundation Ltd.	Transcendental Meditation Therapy		Mental Process	CTRP Intervention Terminology|CTRP Terminology
C15377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15377>	C155788|C116540	Immunologic Desensitization|Desensitization|Desensitization, Immunologic|Hyposensitization Therapy	Treatment or therapy to reduce or eliminate a patient's allergic response to an allergen (NCI/OSP)			Therapeutic or Preventive Procedure	
C15378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15378>	C15313	Boron Neutron Capture Therapy|BNCT|Neutron capture therapy (procedure)|boron neutron capture therapy	A type of radiation therapy in which the patient is given an intravenous boron infusion that is absorbed by tumor cells. Radiation is then directed at the boron, killing the tumor cells but not the surrounding normal tissue.			Therapeutic or Preventive Procedure	mCode Neutron Beam Technique Value Set|mCode Radiotherapy Technique Value Set|mCode Teleradiotherapy Technique Value Set|mCode Terminology
C153798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153798>	C199143	Ochsner Medical Center	A medical center located in New Orleans, LA. It includes acute and sub-acute facilities and centers of excellence: Ochsner Cancer Institute, Ochsner Multi-Organ Transplant Center, and Ochsner Heart and Vascular Institute.			Professional or Occupational Group	
C15379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15379>	C15380	Teleradiology	The transmission of radiology images by electronic means to facilitate collaborative interpretation.			Conceptual Entity	
C1537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1537>	C1975	Bruceanol F|Picras-2-en-21-oic Acid, 15-((3,4-dimethyl-1-oxo-2-pentenyl)oxy)-13,20-epoxy-2,11,12-trihydroxy-1,16-dioxo-, Methyl Ester, (11beta,12alpha,15beta(E))-	A quassinoid phytochemical isolated from the plant Brucea antidysenterica with potential antineoplastic activity. (NCI04)			Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C153800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153800>	C7926|C6791	Recurrent Parotid Gland Carcinoma	The reemergence of parotid gland carcinoma after a period of remission.			Neoplastic Process	
C153801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153801>	C8396|C7926	Recurrent Submandibular Gland Carcinoma	The reemergence of submandibular gland carcinoma after a period of remission.			Neoplastic Process	
C153802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153802>	C9330|C7622	Recurrent Appendix Carcinoma|Recurrent Appendiceal Carcinoma	The reemergence of appendix carcinoma after a period of remission.			Neoplastic Process	
C153804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153804>	C5937|C157639|C153800	Recurrent Parotid Gland Adenoid Cystic Carcinoma	The reemergence of parotid gland adenoid cystic carcinoma after a period of remission.			Neoplastic Process	
C153805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153805>	C5974|C153800	Recurrent Parotid Gland Carcinoma ex Pleomorphic Adenoma	The reemergence of parotid gland carcinoma ex pleomorphic adenoma after a period of remission.			Neoplastic Process	
C153806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153806>	C5938|C203381|C153800	Recurrent Parotid Gland Mucoepidermoid Carcinoma	The reemergence of parotid gland mucoepidermoid carcinoma after a period of remission.			Neoplastic Process	
C153807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153807>	C5939|C203381|C153801	Recurrent Submandibular Gland Mucoepidermoid Carcinoma	The reemergence of submandibular gland mucoepidermoid carcinoma after a period of remission.			Neoplastic Process	
C153808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153808>	C5977|C153801	Recurrent Submandibular Gland Carcinoma ex Pleomorphic Adenoma	The reemergence of submandibular gland carcinoma ex pleomorphic adenoma after a period of remission.			Neoplastic Process	
C153809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153809>	C5935|C157639|C153801	Recurrent Submandibular Gland Adenoid Cystic Carcinoma	The reemergence of submandibular gland adenoid cystic carcinoma after a period of remission.			Neoplastic Process	
C15380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15380>	C15219	Telemedicine|Telehealth|telemedicine	The use of telecommunications technology to provide, enhance, or expedite health care services, as by accessing off-site databases, linking clinics or physicians' offices to central hospitals, or transmitting x-rays or other diagnostic images for examination at another site. (Bartleby.com)	Telemedicine		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C153810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153810>	C5942|C172650|C153800	Recurrent Parotid Gland Squamous Cell Carcinoma	The reemergence of parotid gland squamous cell carcinoma after a period of remission.			Neoplastic Process	
C153811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153811>	C5943|C172650|C153801	Recurrent Submandibular Gland Squamous Cell Carcinoma	The reemergence of submandibular gland squamous cell carcinoma after a period of remission.			Neoplastic Process	
C153812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153812>	C5947|C153801	Recurrent Submandibular Gland Undifferentiated Carcinoma	The reemergence of submandibular gland undifferentiated carcinoma after a period of remission.			Neoplastic Process	
C153813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153813>	C5946|C153800	Recurrent Parotid Gland Undifferentiated Carcinoma	The reemergence of parotid gland undifferentiated carcinoma after a period of remission.			Neoplastic Process	
C153815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153815>	C3044	Bridging Fibrosis	A morphologic finding indicating the presence of fibrous bands connecting portal tracts, portal tracts and centrilobular spaces, or centrilobular spaces in a liver tissue sample in a patient with evolving cirrhosis.			Finding	
C153818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153818>	C7833|C4270	Recurrent Malignant Ovarian Brenner Tumor|Recurrent Malignant Ovarian Transitional Cell Tumor	The reemergence of malignant ovarian Brenner tumor after a period of remission.			Neoplastic Process	
C153819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153819>	C7833|C5240	Recurrent Ovarian Transitional Cell Carcinoma	The reemergence of ovarian transitional cell carcinoma after a period of remission.			Neoplastic Process	
C15381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15381>	C25404	Quality Assurance|QA|QA|Qaulity Assurance Activity|quality assurance|quality assurance (QA)	Programs of regular assessment of medical and nursing activities to evaluate the quality of medical care including all actions taken to ensure that standards and procedures are adhered to and that delivered products or services meet performance requirements.			Activity	CDISC Glossary Terminology
C153820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153820>	C17647	FerriScan|FerriScan R2-MRI	A proprietary method to determine liver iron concentration through an MRI-based imaging technology that uses R2-MRI relaxometry.			Diagnostic Procedure	
C153821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153821>	C160955	Afar Language|AAR	An Afroasiatic language belonging to the Cushitic branch, spoken by the Afar people inhabiting Djibouti, Eritrea and Ethiopia.			Language	
C153822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153822>	C160954	Abkhazian Language|ABK|Abkhaz|Abkhazian|Abxaz	A Northwest Caucasian language spoken mostly by the Abkhaz people. It is one of the official languages of Abkhazia.			Language	
C153823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153823>	C71700|C4627|C131500	Recurrent Primary Malignant Central Nervous System Neoplasm|Recurrent Malignant Central Nervous System Neoplasm|Recurrent Malignant Central Nervous System Neoplasm	The reemergence of a primary malignant central nervous system neoplasm after a period of remission.	Recurrent Malignant Central Nervous System Neoplasm		Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C153824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153824>	C160953	Achinese Language|ACE|Acehnese|Achinese	A Malayo-Polynesian language spoken by the Acehnese people natively in Aceh, Sumatra, Indonesia.			Language	
C153825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153825>	C154012	Acoli Language|ACH|Acholi|Acoli|Acooli|Akoli|Atscholi|Dok Acoli|Gang|Lok Acoli|Lwo|Lwoo|Shuli	A Southern Luo dialect spoken by the Acoli people in the districts of Gulu, Kitgum and Pader in northern Uganda. It is also spoken in southern Sudan in Magwi County of Eastern Equatoria state.			Language	
C153826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153826>	C161852	Adangme Language|ADA|Adan|Adangme|Adantonwi|Agotime|Dangbe	A Ghana-Togo Mountain language of the Kwa family, spoken by the Adan and Agotime people of Ghana and Togo.			Language	
C153827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153827>	C160954	Adyghe Language|ADY|Adygei|Adyghe|West Circassian	A Northwest Caucasian language that is the official language of the Republic of Adygea in the Russian Federation, spoken by various tribes of the Adyghe people.			Language	
C153828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153828>	C160956	Afrikaans Language|AFR|Afrikaans	A West Germanic language, evolved from Dutch, spoken in South Africa, Namibia and, to a lesser extent, Botswana and Zimbabwe.			Language	
C153829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153829>	C51277	Ainu Language|AIN|Ainu	A language spoken by members of the Ainu ethnic group on the northern Japanese island of Hokkaido. It has no generally accepted genealogical relationship to any other language family.			Language	
C15382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15382>	C15696	Gamma Knife|Gamma Knife Radiosurgery|Gamma Knife therapy	A treatment using gamma rays that are tightly focused on small tumors or other lesions in the head or neck, so very little normal tissue receives radiation. The gamma rays are aimed at the tumor from many different angles at once, and deliver a large dose of radiation exactly to the tumor in one treatment session.			Therapeutic or Preventive Procedure	GDC Terminology|GDC Value Terminology
C153830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153830>	C160958	Akan Language|AKA|Akan	A Central Tano language that is the principal native language of the Akan people of Ghana, spoken over much of the southern half of that country and among some of the population of Ivory Coast.			Language	
C153831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153831>	C158073	Aleut Language|ALE|Aleut	The sole language in the Aleut branch of the Eskimo-Aleut language family. It is spoken by the Aleut people living in the Aleutian Islands, Pribilof Islands, Commander Islands, and the Alaskan Peninsula.			Language	
C153832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153832>	C161847	Southern Altai Language|ALT|Gorno-Altai|Gorno-Altay|Southern Altai	A Turkic language, spoken officially in the Altai Republic of Russia.			Language	
C153833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153833>	C160966	Amharic Language|AMH|Amharic	A Semitic language spoken as a first language by the Amharas ethnic group and which serves as the official working language of Ethiopia.			Language	
C153834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153834>	C161843	Angika Language|ANP|Angika|Chhika-Chhiki	An Eastern Indo-Aryan language spoken primarily in the Bihar and Jharkhand states of India and the Terai region of Nepal.			Language	
C153835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153835>	C161845	Aragonese Language|ARG|Aragonese	A Romance language spoken in several dialects by people in the Pyrenees valleys of Aragon Spain.			Language	
C153836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153836>	C51277	Mapuche Language|ARN|Mapudungun|Mapuzugun	A language isolate spoken in south-central Chile and west central Argentina by the Mapuche people.			Language	
C153837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153837>	C71698|C3568|C153823	Recurrent Malignant Brain Neoplasm	The reemergence of a malignant brain neoplasm after a period of remission.	Recurrent Malignant Brain Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153838>	C158073	Arapaho Language|ARP|Arapaho	A Plains Algonquian language spoken by the Arapaho of Wyoming and Oklahoma.			Language	
C153839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153839>	C161912	Lokono Language|ARW|Arawak|Lokono	An Arawak language spoken by the Lokono people of South America in eastern Venezuela, Guyana, Suriname, and French Guiana.			Language	
C15383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15383>	C15447	Special Diet Therapy|DIET	A form of therapy which includes dietary approaches and special diets that are applied as alternative therapies for risk factors or chronic disease in general.	Special Diet Therapy		Therapeutic or Preventive Procedure	CDISC SDTM Diabetes Therapy Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C153840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153840>	C161843	Assamese Language|ASM|Asamiya|Assamese	An Eastern Indo-Aryan language spoken mainly in the Indian state of Assam.			Language	
C153841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153841>	C161845	Asturian Language|AST|Asturian|Asturleonese|Bable|Leonese	A West Iberian Romance language spoken in the Principality of Asturias, Spain.			Language	
C153842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153842>	C71701|C4627|C120186	Refractory Primary Malignant Central Nervous System Neoplasm|Refractory Malignant Central Nervous System Neoplasm|Refractory Malignant Central Nervous System Neoplasm	A primary malignant central nervous system neoplasm that is resistant to treatment.	Refractory Malignant Central Nervous System Neoplasm		Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C153843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153843>	C161846	Avar Language|AVA|Avar|Avaric	A language that belongs to the Avar-Andic group of the Northeast Caucasian family. It is spoken mainly in the western and southern parts of the Russian Caucasus republic of Dagestan, and the Balaken, Zaqatala regions of north-western Azerbaijan.			Language	
C153844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153844>	C161844	Awadhi Language|AWA|Awadhi	An Indo-Aryan language spoken primarily in the Awadh region of Uttar Pradesh and Terai belt of Nepal.			Language	
C153845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153845>	C71702|C3568|C153842	Refractory Malignant Brain Neoplasm	A malignant brain neoplasm that is resistant to treatment.	Refractory Malignant Brain Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153846>	C51277	Aymara Language|AYM|Aymara	An Aymaran language spoken by the Aymara people of the Andes and by some communities in northern Chile.			Language	
C153847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153847>	C161847	Azerbaijani Language|AZE|Azerbaijani|Azeri|Azeri Turkic|Azeri Turkish	A Turkic language spoken primarily by the Azerbaijanis, mainly in Transcaucasia and Iranian Azerbaijan.			Language	
C153848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153848>	C161847	Bashkir Language|BAK|Bashkir	A Turkic language belonging to the Kipchak branch, mostly spoken in the Republic of Bashkortostan, Russia.			Language	
C153849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153849>	C160962	Balochi Language|BAL|Balochi|Baluchi	An Indo-European language that is the principal language of the Baloch people, spoken primarily in Iran, Pakistan and Afghanistan.			Language	
C15384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15384>	C49165	Surgical Incision|Incision|Incisional|Otomy|incision	An intentional cut made to an individual's body with the intent of performing a diagnostic or therapeutic intervention.			Health Care Activity	
C153850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153850>	C161851	Bambara Language|BAM|Bambara	A variety of the Manding language spoken as the national language of Mali.			Language	
C153851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153851>	C160953	Balinese Language|BAN|Balinese	A Malayo-Polynesian language spoken on the Indonesian island of Bali as well as northern Nusa Penida, western Lombok and eastern Java.			Language	
C153852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153852>	C161852	Basa Language|BAS|Basa	A cluster of Kainji languages spoken in scattered areas across Nigeria.			Language	
C153853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153853>	C160955	Beja Language|BEJ|Bedawiyet|Beja	An Afroasiatic language of the Cushitic branch spoken on the western coast of the Red Sea by the Beja people.			Language	
C153854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153854>	C161857	Belarusian Language|BEL|Belarusian	An East Slavic language spoken as the official language of Belarus.			Language	
C153855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153855>	C161853	Bemba Language|BEM|Bemba	A Niger-Congo Bantu language spoken primarily in north-eastern Zambia by the Bemba people.			Language	
C153856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153856>	C161844	Bengali Language|BEN|Bangla|Bengali|Bengali	An Indo-Aryan language spoken in South Asia. It is the official and most widely spoken language of Bangladesh.			Language	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C153857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153857>	C161844	Bhojpuri Language|BHO|Bhojpuri	An Indo-Aryan language spoken in the Northern-Eastern part of India and the Terai region of Nepal.			Language	
C153858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153858>	C160953	Bikol Language|BIK|Bikol	A group of Central Philippine languages spoken mostly in the Bicol Peninsula in the island of Luzon, the neighboring island province of Catanduanes, and the island of Burias of Masbate.			Language	
C153859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153859>	C161852	Edo Language|BIN|Bini|Edo	A Volta-Niger language spoken primarily in the Edo State of Nigeria by the Edo people.			Language	
C15385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15385>	C64979|C15232|C15189	Excisional Biopsy|BIOPSY, EXCISIONAL|Biopsy, Excisional|Excision Biopsy|Excisional biopsy|Excisional biopsy|excisional biopsy|surgical biopsy	A surgical procedure in which an entire lesion is removed for microscopic examination.			Diagnostic Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Specimen Collection Method Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|GDC Terminology|GDC Value Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table
C153860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153860>	C51277	Bislama Language|BIS|Bislama	A creole language, one of the official languages of Vanuatu.			Language	
C153861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153861>	C158073	Blackfoot Language|BLA|Blackfoot|Siksika	An Algonquian language spoken by the Niitsitapi people, who currently live in the northwestern plains of North America.			Language	
C153862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153862>	C161862	Standard Tibetan Language|BOD|Standard Tibetan|Tibetan	A Sino-Tibetan language that is an official language of the Tibet Autonomous Region of the People's Republic of China.			Language	
C153863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153863>	C161855	Bosnian Language|BOS|Bosnian	An Indo-European, Balto-Slavic variety of Serbo-Croatian spoken mainly by the Bosniak ethnic group of Bosnia and Herzegovina.			Language	
C153864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153864>	C161844	Braj Language|BRA|Braj|Braj Bhasha	A Western Hindi language mostly spoken in the Indian Braj region.			Language	
C153865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153865>	C142855|C127816	Refractory WHO Grade 3 Glioma|Refractory WHO Grade III Glioma|Refractory WHO Grade III Glioma	A WHO grade 3 glioma that is resistant to treatment.	Refractory WHO Grade III Glioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C153866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153866>	C161860	Breton Language|BRE|Breton	A Southwestern Brittonic Celtic language spoken in the Brittany area of France.			Language	
C153867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153867>	C161861	Buriat Language|BUA|Buriat|Buryat	A variety of Mongolic spoken by the Buryats people of Russia and Mongolia.			Language	
C153868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153868>	C160953	Buginese Language|BUG|Buginese	A Malayo-Polynesian language spoken by the Austronesian people of the island nations of Southeast Asia and the Pacific Ocean.			Language	
C153869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153869>	C161858	Bulgarian Language|BUL|Bulgarian	An Indo-European language, a member of the Southern branch of the Slavic language family.			Language	
C15386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15386>	C15189	Incisional Biopsy|BIOPSY, INCISIONAL|Biopsy, Incisional|Open Biopsy|incisional biopsy|open biopsy	A surgical procedure in which part of a lesion is removed for microscopic examination.	Incisional Biopsy		Diagnostic Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CTRP Intervention Terminology|CTRP Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Biopsy/Surgical Procedures Table|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table
C153870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153870>	C160955	Bilen Language|BYN|Bilen|Bilin|Blin	An Afro-Asiatic language spoken by the Bilen people in Eritrea and eastern Sudan.			Language	
C153871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153871>	C158073	Caddo Language|CAD|Caddo	A Native American language which is the traditional language of the Caddo Nation in Oklahoma.			Language	
C153872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153872>	C51277	Carib Language|CAR|Galibi Carib|Kari'nja	A Cariban language spoken by the Kalina people of South America.			Language	
C153873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153873>	C161845	Catalan Language|CAT|Catalan|Valencian|Valencian Language	A Western Romance language native to parts of Andorra, France, Italy, and Spain.			Language	
C153874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153874>	C161901	Cebuano Language|CEB|Cebuan|Cebuano	An Austronesian language spoken in the Philippines mainly in Central Visayas, western parts of Eastern Visayas, and most parts of Mindanao.			Language	
C153875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153875>	C161859	Czech Language|CES|Czech	A West Slavic language that serves as the official language of the Czech Republic.			Language	
C153876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153876>	C161901	Chamorro Language|CHA|Chamorran|Chamorran Language|Chamorro	An Austronesian language spoken by the Chamorro people of Guam and the Northern Mariana Islands.			Language	
C153877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153877>	C161846	Chechen Language|CHE|Chechen	A Northeast Caucasian language spoken mostly in the Chechen Republic.			Language	
C153878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153878>	C161901	Chuukese Language|CHK|Chuukese|Trukese	A Trukic language of the Austronesian language family spoken primarily on the islands of Chuuk in the Caroline Islands in Micronesia.			Language	
C153879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153879>	C210937	Mari Language|CHM|Mari	A language in the Uralic language family spoken primarily in the Mari Republic of the Russian Federation.			Language	
C15387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15387>	C51692	Shave Biopsy|shave biopsy	Removal skin tissue, for microscopic examination, using a blade oriented in the horizontal plane of the skin surface.	Shave Biopsy		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C153880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153880>	C158073	Chinook Jargon Language|CHN|Chinook Jargon|Chinook Wawa|Chinuk Wawa	An American indigenous language originating as a pidgin trade language in the Pacific Northwest.			Language	
C153881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153881>	C158073	Choctaw Language|CHO|Choctaw	A Native American language, traditionally spoken by the Native American Choctaw people of the southeastern United States.			Language	
C153882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153882>	C153897	Chipewyan Language|CHP|Chipewyan|Dene Suline|Denesuline	A language in the Northern Athabaskan language family spoken by the Chipewyan people of northwestern Canada.			Language	
C153883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153883>	C158073	Cherokee Language|CHR|Cherokee	An Iroquoian language spoken by the Cherokee people.			Language	
C153884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153884>	C161847	Chuvash Language|CHV|Chuvash	A Turkic language spoken in European Russia, primarily in the Chuvash Republic and adjacent areas.			Language	
C153885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153885>	C201557	Allogeneic CD34-positive E-rosetted T-cell Depleted Peripheral Blood Stem Cells	A preparation of CD34+ selected peripheral blood stem cells (PBSCs) that are depleted of T-cells via erythrocyte rosetting (E-rosetting) and intended for allogeneic stem cell transplant. Administration of this particular preparation of CD34+E- T-cell depleted PBSCs may potentially reduce the occurrence of graft-versus-host disease (GvHD) without increasing the risk of graft failure or poor graft function	Allogeneic CD34-positive E-rosetted T-cell Depleted Peripheral Blood Stem Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C153886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153886>	C158073	Cheyenne Language|CHY|Cheyenne	A Native American language of the Algonquian language family spoken by the Cheyenne people.			Language	
C153887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153887>	C161860	Cornish Language|COR|Cornish	A Southwestern Brittonic Celtic language that is native to Cornwall in south-west England.			Language	
C153888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153888>	C161845	Corsican Language|COS|Corsican	A Romance language within the Italo-Dalmatian subfamily spoken mainly in Corsica and northern Sardinia.			Language	
C153889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153889>	C158073	Cree Language|CRE|Cree	A dialect continuum of Algonquian languages native to areas of Canada and the United States.			Language	
C15388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15388>	C49236	Infusion Procedure|Infused|Infusion|infusion|infusion|infusion	Any form of treatment that is introduced into the body via a blood vessel, a muscle, or the spinal cord.	Infusion Procedure		Therapeutic or Preventive Procedure	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C153890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153890>	C161847	Crimean Tatar Language|CRH|Crimean|Crimean Tatar|Crimean Turkish	A Kipchak Turkic language spoken mainly in Crimea, as well as small communities in the United States and Canada.			Language	
C153891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153891>	C161859	Kashubian Language|CSB|Cassubian|Kashubian	A West Slavic language belonging to the Lechitic subgroup that is native to Poland.			Language	
C153892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153892>	C161860	Welsh Language|CYM|Welsh	A member of the Brittonic branch of the Celtic languages spoken natively in Wales.			Language	
C153893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153893>	C158073	Dakota Language|DAK|Dakhota|Dakota	A Siouan language spoken by the Dakota people of the Sioux tribes.			Language	
C153894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153894>	C161904	Danish Language|DAN|Danish	A North Germanic language spoken principally in Denmark and in the region of Southern Schleswig in northern Germany.			Language	
C153895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153895>	C161846	Dargwa Language|DAR|Dargin|Dargwa	A Northeast Caucasian language spoken by the Dargin people in the Russian republic of Dagestan.			Language	
C153896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153896>	C158073	Delaware Language|DEL|Delaware|Lenape	An Eastern Algonquian language spoken by the native Lenape people of the New York City area.			Language	
C153897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153897>	C161913	Athabascan Language|ATH|Athabaskan|Dene	A large family of indigenous languages of western North America.			Language	
C153898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153898>	C153897	Slavey Language|DEN|Dene K'e|Slave	An Athabaskan language spoken among the Slavey and Sahtu people of Canada in the Northwest Territories			Language	
C153899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153899>	C153897	Dogrib Language|DGR|Dogrib	A Northern Athabaskan language spoken by the Dogrib people of the Canadian Northwest Territories.			Language	
C15389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15389>	C64940|C15189	Endoscopic Biopsy|Endoscopy and Biopsy	The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis. In the case of an endoscopic biopsy, an endoscope is used to obtain the sample.	Endoscopic Biopsy		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C1538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1538>	C1941	Recombinant Fas Ligand|FAS-Ligand|Fas Ligand|Fas-L	A recombinant agent, which is chemically identical to or similar to the endogenous protein Fas ligand, a protein related to tumor necrosis factor (TNF) with potential antineoplastic activity.  Fas ligand binds to the Fas receptor, thereby activating caspases and inducing apoptosis. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C153900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153900>	C161905	Dinka Language|DIN|Dinka	An Eastern Sudanic Nilotic dialect cluster spoken by the Dinka people of South Sudan.			Language	
C153901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153901>	C161844	Maldivian Language|DIV|Dhivehi|Divehi|Maldivian	An Indo-Aryan language spoken in the South Asian island country of Maldives.			Language	
C153902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153902>	C161844	Dogri Language|DOI|Dogri	An Indo-Aryan language spoken in India and Pakistan, chiefly in the Jammu region.			Language	
C153903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153903>	C161856	Lower Sorbian Language|DSB|Lower Sorbian	A Slavic minority language spoken in eastern Germany in the historical province of Lower Lusatia.			Language	
C153904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153904>	C161853	Duala Language|DUA|Diwala|Douala|Duala|Dualla|Dwala|Dwela	A dialect cluster of the Bantu language family spoken by the Duala and Mungo peoples of Cameroon.			Language	
C153905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153905>	C161854	Dyula Language|DYU|Dioula|Dyula|Jula	A Mande language spoken in Burkina Faso, Ivory Coast and Mali.			Language	
C153906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153906>	C161862	Dzongkha Language|Bhutanese|DZO|Dzongkha	A Sino-Tibetan language that is the official and national language of Bhutan.			Language	
C153907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153907>	C161852	Efik Language|EFI|Efik	A Niger-Congo language that is the native language of the Efik people of Nigeria.			Language	
C153908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153908>	C161852	Ekajuk Language|Akajo|Akajuk|EKA|Ekajuk	An Ekoid language of the Niger-Congo family spoken in the Cross River State and some surrounding regions of Nigeria.			Language	
C153909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153909>	C160962	Modern Greek Language|ELL|Modern Greek	Refers to the dialects and varieties of the Greek language spoken in the modern era.			Language	
C15390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15390>	C49165	Fulguration|electrofulguration|fulguration	A procedure that uses a high-frequency current for the purpose of destroying living tissue, most commonly malignant tumors.			Therapeutic or Preventive Procedure	
C153910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153910>	C210937	Estonian Language|EST|Estonian	A Uralic language of the Finnic branch, spoken as the official language of Estonia.			Language	
C153911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153911>	C51277	Basque Language|Basque|EUS	A language isolate spoken in the Basque country of Spain and France. Basque is unrelated to the other languages of Europe or to any other known living language.			Language	
C153912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153912>	C161852	Ewe Language|EWE|Ewe	A Niger-Congo language spoken in southeastern Ghana, part of a cluster of related languages commonly called Gbe.			Language	
C153913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153913>	C161852	Ewondo Language|EWO|Ewondo	A Niger-Congo language spoken by the Ewondo people of Cameroon.			Language	
C153914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153914>	C161853	Fang Language|FAN|Fang	A Niger-Congo, Bantu language spoken in Cameroon, Gabon, Equatorial Guinea, Sao Tome and Principe, and the Congo Republic.			Language	
C153915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153915>	C161904	Faroese Language|FAO|Faroese	An Indo-European, North Germanic language spoken mainly on the Faroe Islands and parts of Denmark.			Language	
C153916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153916>	C160962	Persian Language|FAS|Persian	A Western Iranian language within the Indo-Iranian branch of the Indo-European language family primarily spoken in Iran, Afghanistan, and Tajikistan.			Language	
C153917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153917>	C153830	Fantse Language|FAT|Fante|Fanti|Fantse	One of the three formal literary dialects of the Akan language. It is the major local dialect in the Central Region of Ghana, as well as in other regions from mid to southern Ghana.			Language	
C153918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153918>	C160953	Fijian Language|FIJ|Fijian	An Austronesian language of the Malayo-Polynesian family spoken by ethnic Fijians as a native language.			Language	
C153919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153919>	C210937	Finnish Language|FIN|Finnish	A Finnic language spoken by a majority of the population in Finland and by ethnic Finns outside Finland.			Language	
C15391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15391>	C15687|C15390	Electrodesiccation|electrodesiccation	A procedure in which tissue desiccation is achieved via employment of a moderately damped alternating electrical current.			Therapeutic or Preventive Procedure	
C153920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153920>	C161852	Fon Language|FON|Fon	A Niger-Congo language, part of the Eastern Gbe language cluster, spoken mainly in Benin.			Language	
C153921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153921>	C160956	Northern Frisian Language|FRR|Northern Frisian	A part of the larger group of the West Germanic Frisian languages, spoken in the North Frisia area of Germany.			Language	
C153922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153922>	C154050	East Frisian Low Saxon Language|East Frisian Low German|East Frisian Low Saxon|Eastern Frisian|FRS	A West Low German, Friso-Saxon dialect spoken in the East Frisian peninsula of northwestern Lower Saxony state of Germany.			Language	
C153923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153923>	C160956	Western Frisian Language|FRY|Western Frisian	A West Germanic language spoken mostly in the province of Friesland in the north of the Netherlands.			Language	
C153924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153924>	C161852	Fula Language|FUL|Fula|Fulah|Fulani	A Niger-Congo language spoken as a set of various dialects in a continuum that stretches across 20 countries in West and Central Africa.			Language	
C153925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153925>	C161845	Friulian Language|FUR|Friulian	An Indo-European Romance language spoken in the Friuli region of northeastern Italy.			Language	
C153926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153926>	C161852	Ga Language|GAA|Ga	A Niger-Congo Kwa language spoken in the capital area of Ghana.			Language	
C153927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153927>	C161901	Gayo Language|GAY|Gayo	An Austronesian language spoken in the mountainous region of Aceh, Central Aceh, Bener Meriah, and Gayo Lues regencies of Indonesia.			Language	
C153928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153928>	C161852	Gbaya Language|GBA|Gbaya|Gbaya-Manza-Ngbaka	A family of languages spoken mainly in the Central African Republic, Cameroon, the Democratic Republic of the Congo, and the Republic of the Congo.			Language	
C153929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153929>	C161901	Gilbertese Language|GIL|Gilbertese|Kiribati|Taetae ni Kiribati	A Micronesian language of the Austronesian language family native to the island of Kiribati.			Language	
C15392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15392>	C15655|C15310	Thoracentesis|Chest Aspiration|Pleural Cavity Tap|Pleural Tap|Pleurocentesis|Puncture of Pleural Cavity for Aspiration|THORACENTESIS|Thoracic Paracentesis|thoracentesis	The removal of excess fluid via needle puncture from the thoracic cavity.	Thoracentesis		Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C153930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153930>	C161860	Scottish Gaelic Language|GLA|Gaelic|Scots Gaelic|Scottish Gaelic	An Indo-European Celtic language native to the Gaels of Scotland.			Language	
C153931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153931>	C161860	Irish Language|GLE|Irish	An Indo-European Celtic language originating in Ireland and historically spoken by the Irish people.			Language	
C153932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153932>	C161845	Galician Language|GLG|Galician	An Indo-European language of the Western Ibero-Romance branch spoken in the Galicia community of northwestern Spain.			Language	
C153933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153933>	C161860	Manx Language|GLV|Manx|Manx Gaelic	An Indo-European Celtic language spoken as a first language by the Manx people on the Isle of Man.			Language	
C153934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153934>	C161909	Gondi Language|GON|Gondi	A South-Central Dravidian language, spoken chiefly in the Indian states of Madhya Pradesh, Gujarat, Telangana, Maharashtra, Chhattisgarh, and Andhra Pradesh.			Language	
C153935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153935>	C161901	Gorontalo Language|GOR|Gorontalo|Hulontalo	An Austronesian language spoken in the Gorontalo Province of Indonesia by the Gorontaloan people.			Language	
C153936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153936>	C161852	Grebo Language|GRB|Grebo	A Niger-Congo Kru language spoken in Liberia.			Language	
C153937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153937>	C51277	Guarani Language|GRN|Guarani	A language in the Tupí-Guarani branch of the Tupi linguistic family that is an indigenous language in Latin America.			Language	
C153938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153938>	C160956	Swiss German Language|Alemannic|Alsatian|GSW|Swiss German	Any of the Alemannic dialects spoken in the German-speaking part of Switzerland and in some Alpine communities in Northern Italy bordering Switzerland.			Language	
C153939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153939>	C161844	Gujarati Language|GUJ|Gujarati	An Indo-Aryan language native to the Indian state of Gujarat.			Language	
C15393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15393>	C15296	Isolated Chemotherapeutic Limb Perfusion|Isolated Limb Perfusion (ILP)|Limb Perfusion|isolated limb infusion|isolated limb perfusion|limb perfusion	A profusion procedure used to deliver antineoplastic agents directly to an affected arm or leg while its circulation is isolated from rest of the body.	Isolated Chemotherapeutic Limb Perfusion		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C153940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153940>	C153897	Gwich'in Language|GWI|Gwich'in|Gwichin Language	An Athabaskan language spoken by the Gwich'in First Nation in Canada and the Alaska Native People of the United States.			Language	
C153941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153941>	C51277	Haida Language|HAI|Haida	A language isolate that is the language of the Haida people, spoken in the Haida Gwaii archipelago off the northern Pacific coast of Canada and on Prince of Wales Island in Alaska.			Language	
C153942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153942>	C51277	Haitian Creole Language|HAT|Haitian|Haitian Creole	A French-based creole language native to Haiti.			Language	
C153943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153943>	C160955	Hausa Language|HAU|Hausa	An Afro-Asiatic Chadic language native to Niger, Nigeria, Ghana, Benin, Cameroon, Ivory Coast, Togo and Sudan.			Language	
C153944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153944>	C161903	Hawaiian Language|HAW|Hawaiian	A Polynesian language native to the Hawaiian islands of the United States.			Language	
C153945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153945>	C160966	Hebrew Language|HEB|Hebrew	A Northwest Semitic language native to Israel.			Language	
C153946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153946>	C161853	Herero Language|HER|Herero	A Niger-Congo Bantu language spoken by the Herero and Mbanderu peoples in Namibia and Botswana.			Language	
C153947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153947>	C161901	Hiligaynon Language|HIL|Hiligaynon	An Austronesian regional language spoken in the Philippines.			Language	
C153948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153948>	C161844	Hindi Language|HIN|Hindi|Hindi	A standardized and Sanskritized register of the Hindustani language.			Language	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C153949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153949>	C161901	Hiri Motu Language|HMO|Hiri|Hiri Motu	A simplified version of Motu that is an official language of Papua New Guinea.			Language	
C15394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15394>	C158758|C15249	Partial Hepatectomy|partial excision of liver|subtotal hepatectomy	Partial removal of the liver			Therapeutic or Preventive Procedure	GDC Terminology|GDC Value Terminology
C153950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153950>	C161858	Croatian Language|Croatian|HRV	The standardized variety of the Serbo-Croatian language used by Croats, principally in Croatia, Bosnia and Herzegovina.			Language	
C153951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153951>	C160962	Upper Sorbian Language|HSB|Upper Sorbian	An Indo-European language spoken by Sorbs in the province of Upper Lusatia in Germany.			Language	
C153952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153952>	C153897	Hupa Language|HUP|Hupa	An Athabaskan language spoken along the lower course of the Trinity River in Northwestern California by the Hupa people.			Language	
C153953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153953>	C160962	Armenian Language|Armenian|HYE	An Indo-European language spoken as the official language of Armenia.			Language	
C153954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153954>	C161901	Iban Language|IBA|Iban	An Austronesian language spoken by the Iban people of the Malaysian state of Sarawak, the Indonesian province of West Kalimantan, and in Brunei.			Language	
C153955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153955>	C161852	Igbo Language|IBO|Igbo	A Niger-Congo language of the Igbo people of southeastern Nigeria.			Language	
C153956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153956>	C161862	Nuosu Language|III|Liangshan Yi|Northern Yi|Nosu|Nuosu|Sichuan Yi	A Sino-Tibetan language of the Yi people of Southern Sichuan and northern Yunnan provinces of China.			Language	
C153957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153957>	C158073	Inuvialuktun Language|IKU|Inuktitut|Inuvialuktun|Western Canadian Inuit|Western Canadian Inuktitut|Western Canadian Inuktun	An Eskimo-Aleut language spoken in the northern Northwest Territories and Nunavut Territory of Canada.			Language	
C153958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153958>	C161901	Ilocano Language|ILO|Ilocano|Ilokano|Iloko	An Austronesian language spoken in the Phillipines in northwest Luzon, the Babuyan Islands, Cordillera Administrative Region, Cagayan Valley, parts of Central Luzon, and scattered areas in Mindanao.			Language	
C153959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153959>	C161901	Indonesian Language|IND|Indonesian	An Austronesian language that is a standardized register of Malay and the official language of Indonesia.			Language	
C15395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15395>	C15194|C142985	Autologous Bone Marrow Transplantation|ABMT|Autologous Blood and Marrow Transplantation|Autologous Bone Marrow Transplant|Autologous Marrow Transplantation|autologous bone marrow transplantation	Bone marrow transfer in which the patient is his own donor.  Bone marrow is removed prior to bone marrow ablation treatment and then returned to reconstitute the hematopoietic system. Prior to reinfusion the bone marrow is often treated to purge it of residual tumor cells.	Autologous Bone Marrow Transplantation		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology
C153960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153960>	C161846	Ingush Language|INH|Ingush	A Northeast Caucasian language spoken by the Ingush people in the the Russian republics of Ingushetia and Chechnya.			Language	
C153961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153961>	C158073	Inupiaq Language|IPK|Inupiaq	A group of dialects of the Inuit languages, spoken by the Inupiat people in northern and northwestern Alaska, and part of the Northwest Territories.			Language	
C153962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153962>	C160953	Javanese Language|JAV|Javanese	An Austronesian language spoken by the Javanese people from the central and eastern parts of the island of Java, Indonesia.			Language	
C153963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153963>	C160962	Judeo-Persian Language|JPR|Jidi|Judeo-Persian	A group of Jewish dialects spoken by the Jews living in Iran.			Language	
C153964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153964>	C160955	Judeo-Arabic Language|JRB|Judeo-Arabic	A continuum of specifically Jewish varieties of Arabic formerly spoken by Arab Jews.			Language	
C153965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153965>	C161847	Kara-Kalpak Language|KAA|Kara-Kalpak	A Turkic language spoken by the Karakalpak people in the Karakalpakstan republic of Uzbekistan.			Language	
C153966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153966>	C160955	Kabyle Language|KAB|Kabyle	An Afro-Asiatic Berber language spoken by the Kabyle people in the north and northeast of Algeria.			Language	
C153967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153967>	C161862	Jingpho Language|Jingpho|KAC|Kachin	A Tibeto-Burman language of the Sal branch mainly spoken in the Kachin State of Myanmar and the Yunnan Province of China.			Language	
C153968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153968>	C158073	Greenlandic Language|Greenlandic|KAL|Kalaallisut	An Eskimo-Aleut language spoken by Greenlandic Inuit in Greenland.			Language	
C153969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153969>	C161853	Kamba Language|KAM|Kamba	A Niger-Congo Bantu language spoken by the Kamba people of Kenya.			Language	
C15396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15396>	C15217	Radical Cystectomy|Complete Cystectomy|RADICAL CYSTECTOMY|radical cystectomy	The surgical removal of the entire bladder, a portion of the urethra, adjacent lymph nodes, and additional genitourinary structures, including the prostate and a portion of the vas deferens in men, and the ovaries, fallopian tubes, uterus, and a portion of the vagina in women.	Radical Cystectomy		Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C153970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153970>	C161909	Kannada Language|KAN|Kannada	A Dravidian language spoken predominantly by the Kannada people in India, mainly in the state of Karnataka.			Language	
C153971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153971>	C161844	Kashmiri Language|KAS|Kashmiri	A language from the Dardic subgroup of Indo-Aryan languages spoken primarily in the Kashmir Valley and Chenab Valley of the Jammu and Kashmir state in India.			Language	
C153972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153972>	C51277	Georgian Language|Georgian|KAT	A Kartvelian language spoken by the Georgian people in Georgia.			Language	
C153973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153973>	C51277	Kanuri Language|KAU|Kanuri	A dialect continuum of the Saharan language spoken mainly in Nigeria, Niger, Chad and Cameroon.			Language	
C153974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153974>	C161847	Kazakh Language|KAZ|Kazakh	A Turkic language that is the official language of the Republic of Kazakhstan.			Language	
C153975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153975>	C160954	Kabardian Language|East Circassian|KBD|Kabardian|Kabardino-Cherkess	A Northwest Caucasian language spoken mainly in parts of the North Caucasus republics of Kabardino-Balkaria and Karachay-Cherkessia and in Turkey, Jordan and Syria.			Language	
C153976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153976>	C160955	Khasi Language|KHA|Khasi	An Austroasiatic language spoken primarily in the Meghalaya state of India by the Khasi people.			Language	
C153977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153977>	C161902	Central Khmer Language|Cambodian|Central Khmer|KHM	An Austroasiatic language that is spoken by the the Khmer people and is the official language of Cambodia.			Language	
C153978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153978>	C161853	Kikuyu Language|Gikuyu|KIK|Kikuyu	A Niger-Congo Bantu language spoken primarily by the Kikuyu people of Kenya.			Language	
C153979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153979>	C161852	Kinyarwanda Language|KIN|Kinyarwanda	A Niger-Congo language that is the official language of Rwanda.			Language	
C15397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15397>	C49236	Bladder Irrigation|irrigation of urinary bladder|simple bladder irrigation	Instillation of a solution into the bladder to provide cleansing or medication.	Bladder Irrigation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C153980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153980>	C161847	Kyrgyz Language|KIR|Kirghiz|Kyrgyz	A Turkic language spoken in Kyrgyzstan, as well as China, Afghanistan, Kazakhstan, Tajikistan, Turkey, Uzbekistan, Pakistan, and Russia.			Language	
C153981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153981>	C161853	Kimbundu Language|KMB|Kimbundu|North Mbundu	A Niger-Congo Bantu language spoken by the Ambundu people of Angola.			Language	
C153982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153982>	C161844	Konkani Language|KOK|Konkani	An Indo-Aryan language belonging to the Indo-European family of languages that is spoken along the western coast of India.			Language	
C153983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153983>	C210937	Komi Language|KOM|Komi	A Uralic macrolanguage spoken by the Komi peoples in the northeastern European part of Russia.			Language	
C153984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153984>	C161853	Kongo Language|KON|Kongo	A Niger-Congo Bantu language spoken by the Kongo and Ndundu people living in the tropical forests of the Democratic Republic of the Congo, the Republic of the Congo, and Angola.			Language	
C153985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153985>	C161902	Kosraean Language|KOS|Kosraean|Kusaiean	An Austroasiatic language spoken on the Kosrae and Caroline Islands of Micronesia, and Nauru.			Language	
C153986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153986>	C161854	Kpelle Language|KPE|Kpelle	A Mande language spoken by the Kpelle people of Liberia and Guinea.			Language	
C153987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153987>	C161847	Karachay-Balkar Language|KRC|Karachay-Balkar	A Turkic language spoken by the Karachay and Balkar people in the Kabardino-Balkaria and Karachay-Cherkessia republics of Russia.			Language	
C153988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153988>	C210937	Karelian Language|KRL|Karelian	A Uralic language spoken mainly in the Russian Republic of Karelia.			Language	
C153989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153989>	C161909	Kurukh Language|KRU|Kurukh|Kurux|Oraon|Uranw	A Dravidian language spoken by the Oraon and Kisan tribespeople of  India, Bangladesh, Nepal, and Bhutan.			Language	
C15398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15398>	C15334|C15290	Urethrostomy	A surgical procedure that creates a permanent opening in the urethra.			Therapeutic or Preventive Procedure	
C153990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153990>	C161852	Kwanyama Language|KUA|Kuanyama|Kwanyama|Oshikwanyama	A Niger-Congo language that is the national language of Angola and Namibia.			Language	
C153991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153991>	C161847	Kumyk Language|KUM|Kumyk	A Turkic language spoken by the Kumyk people of the Dagestan, North Ossetia, and Chechen republics of the Russian Federation.			Language	
C153992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153992>	C160962	Kurdish Language|KUR|Kurdish	A continuum of Northwestern Iranian languages spoken by the Kurdish people in Western Asia.			Language	
C153993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153993>	C158073	Kutenai Language|KUT|Kootenai|Kootenay|Ksanka|Ktunaxa|Kutenai	A language isolate that is the native language of the Kutenai people of Montana and Idaho in the United States and British Columbia in Canada.			Language	
C153994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153994>	C161845	Ladino Language|Judeo-Spanish|LAD|Ladino	A Romance language derived from Old Spanish, originally spoken in the former territories of the Ottoman Empire.			Language	
C153995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153995>	C161844	Lahnda Language|LAH|Lahnda|Lahndi|Western Punjabi	A group of north-western Indo-Aryan language varieties spoken in Pakistani Punjab and in parts of the neighboring Azad Kashmir and Khyber Pakhtunkhwa.			Language	
C153996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153996>	C161853	Lamba Language|LAM|Lamba	A Niger-Congo Bantu language spoken in Zambia and the Democratic Republic of the Congo.			Language	
C153997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153997>	C210880	Lao Language|LAO|Lao|Laotian	A Kra-Dai language that is the official language of Laos.			Language	
C153998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153998>	C160962	Latvian Language|LAV|Latvian	An Indo-European Baltic language that is the official language of Latvia.			Language	
C153999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C153999>	C161846	Lezghian Language|LEZ|Lezghian|Lezgi|Lezgin	A Northeast Caucasian language that is spoken mainly by the Lezgin people of Russia.			Language	
C15399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15399>	C15307	Radical Prostatectomy|Prostatovesiculectomy|radical prostatectomy	The surgical removal of all of the prostate as well as some surrounding tissue, including lymph nodes.	Radical Prostatectomy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C1539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1539>	C2150|C1557	Tezacitabine|2'-Deoxy-2'-(fluoromethylene)cytidine|FMdC|MDL 101,731|MDL 101,731|TEZACITABINE	A synthetic pyrimidine nucleoside analogue with potential antineoplastic activity. Phosphorylated by cellular kinases, tezacitabine is converted into its active diphosphate and triphosphate metabolites. Tezacitabine diphosphate binds to and irreversibly inhibits the activity of the enzyme ribonucleotide reductase (RNR), which may result in the inhibition of DNA synthesis in tumor cells and tumor cell apoptosis. Tezacitabine triphosphate acts as a substrate for DNA polymerase, further compromising DNA replication. This agent is relatively resistant to metabolic deactivation by cytidine deaminase. RNR catalyzes the conversion of ribonucleoside 5'-diphosphates to deoxyribonucleoside 5'-diphosphates necessary for DNA synthesis and is overexpressed in many tumor types.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C154000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154000>	C160956	Limburgish Language|LIM|Limburgan|Limburger|Limburgish	A group of East Low Franconian language varieties spoken in the Belgian and Dutch provinces both named Limburg and some neighboring areas of Germany.			Language	
C154001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154001>	C122592	Surefire Antireflux Microcatheter	A proprietary catheter with an expandable tip designed to increase infusion pressure while maintaining antegrade blood flow in order to deliver a higher concentration of agents to a target.	Surefire Antireflux Microcatheter		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C154002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154002>	C161853	Lingala Language|LIN|Lingala	A Niger-Congo Bantu language spoken throughout the northwestern part of the Democratic Republic of the Congo and a large part of the Republic of the Congo.			Language	
C154003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154003>	C160962	Lithuanian Language|LIT|Lithuanian	An Indo-European Baltic language that is the official language of Lithuania.			Language	
C154004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154004>	C161853	Mongo Language|LOL|Mongo|Mongo-Nkundu|Nkundo	A Niger-Congo Bantu language spoken by several of the Mongo peoples in the Democratic Republic of the Congo.			Language	
C154005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154005>	C161853	Lozi Language|LOZ|Lozi|Rozi|siLozi	A Niger-Congo Bantu language spoken by the Lozi people, primarily in southwestern Zambia and in surrounding countries.			Language	
C154006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154006>	C160956	Luxembourgish Language|LTZ|Letzeburgesch|Luxembourgish|Luxemburgish	A West Germanic language that is the national language of Luxembourg.			Language	
C154007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154007>	C161853	Luba-Kasai Language|LUA|Luba-Kasai|Luba-Lulua|Western Luba	A Niger-Congo Bantu language that is spoken in Central Africa and is an official language of the Democratic Republic of the Congo.			Language	
C154008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154008>	C161853	Luba-Katanga Language|Kiluba|LUB|Luba-Katanga|Luba-Shaba	A Niger-Congo Bantu language spoken by the Luba people in the Democratic Republic of the Congo.			Language	
C154009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154009>	C161853	Ganda Language|Ganda|LUG	A Niger-Congo Bantu language spoken mainly by the Baganda people in central Uganda.			Language	
C15400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15400>	C15307	Perineal Prostatectomy|perineal prostatectomy	Surgery to remove the prostate through an incision made between the scrotum and the anus.			Therapeutic or Preventive Procedure	
C154010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154010>	C51277	Luiseno Language|LUI|Luiseno	A Uto-Aztecan language spoken by the Luiseno Native American people of California.			Language	
C154011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154011>	C161853	Lunda Language|Chilunda|LUN|Lunda	A Niger-Congo Bantu language spoken in Zambia and the Democratic Republic of the Congo.			Language	
C154012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154012>	C161905	Luo Language|LUO|Luo|Luo (Kenya and Tanzania)	A Nilotic language spoken by the Luo people of Kenya and Tanzania.			Language	
C154013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154013>	C161862	Lushai Language|LUS|Lushai|Mizo	A Sino-Tibetan language spoken by the Mizo people in the Mizoram state of India and Chin State in Burma.			Language	
C154014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154014>	C161901	Madurese Language|MAD|Madurese	An Austronesian language spoken by the Madurese people of Madura Island, eastern Java, and surrounding islands of Indonesia.			Language	
C154015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154015>	C160962	Magahi Language|MAG|Magadhi|Magahi	An Indo-European language spoken in the Bihar, Jharkhand, and West Bengal states of eastern India.			Language	
C154016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154016>	C160953	Marshallese Language|Ebon|MAH|Marshallese	A Micronesian language spoken in the Marshall Islands.			Language	
C154017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154017>	C161844	Maithili Language|MAI|Maithili	An Indo-Aryan language spoken in the Bihar and Jharkhand states of India.			Language	
C154018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154018>	C161901	Makassarese Language|MAK|Macassar|Makasar|Makassar|Makassarese	An Austronesian language spoken by the Makassarese people in the South Sulawesi province of Indonesia.			Language	
C154019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154019>	C161909	Malayalam Language|MAL|Malayalam	A Dravidian language spoken across the Indian state of Kerala by the Malayali people.			Language	
C15401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15401>	C15307	Retropubic Prostatectomy|retropubic prostatectomy	The surgical removal of all or part of the prostate gland through a lower abdominal (retropubic) incision.			Therapeutic or Preventive Procedure	
C154020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154020>	C161851	Mandinka Language|MAN|MNK|Mandingo|Mandinka	A Niger-Congo Mande language spoken by the Mandinka people of the Casamance region of Senegal, the Gambia, and northern Guinea-Bissau.			Language	
C154021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154021>	C161844	Marathi Language|MAR|Marathi	An Indo-Aryan language spoken predominantly by the Marathi people of Maharashtra, India.			Language	
C154022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154022>	C161905	Maasai Language|MAS|Maa|Maasai|Masai	An Eastern Nilotic language spoken in Southern Kenya and Northern Tanzania by the Maasai people.			Language	
C154023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154023>	C210937	Moksha Language|MDF|Moksha	A member of the Mordvinic branch of the Uralic languages spoken mainly in the western part of the Mordovia Republic of Russia.			Language	
C154024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154024>	C161901	Mandar Language|Andian|MDR|Mandar|Mandharsche|Manjar	An Austronesian language spoken by the Mandar people of the West Sulawesi province of Indonesia,			Language	
C154025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154025>	C161854	Mende Language|MEN|Mende	A Niger-Congo Mande language spoken mainly by the Mende people of Sierra Leone.			Language	
C154026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154026>	C158073	Mi'kmaq Language|MIC|Mi'kmaq|Micmac|Migmaw|Mikmaq Language|Mikmaw	An Eastern Algonquian language spoken by the Mi'kmaq people in Canada and the United States.			Language	
C154027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154027>	C161901	Minangkabau Language|MIN|Minangkabau	An Austronesian language spoken by the Minangkabau people of the Indonesian province of West Sumatra, the western part of Riau Province, South Aceh Regency, and the northern part of Bengkulu and Jambi Provinces.			Language	
C154028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154028>	C161858	Macedonian Language|MKD|Macedonian	A South Slavic language spoken principally in the Republic of Macedonia and by the Macedonian diaspora.			Language	
C154029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154029>	C161901	Malagasy Language|MLG|Malagasy	An Austronesian language that is the national language of Madagascar.			Language	
C15402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15402>	C51628|C15332	Conization|Cone Biopsy of Cervix|Conization of Cervix|Conization of Uterine Cervix|cone biopsy|conization	Surgical removal of a cone-shaped portion of tissue from the uterine cervix.	Conization		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C154030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154030>	C160966	Maltese Language|MLT|Maltese	An Afro-Asiatic Semitic language that is the national language of Malta.			Language	
C154031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154031>	C51277	Manchu Language|MNC|Manchu	A Tungusic language spoken in Manchuria, China.			Language	
C154032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154032>	C161862	Meitei Language|MNI|Manipuri|Meetei|Meitei|Meithei	A Sino-Tibetan language that is the predominant language in the southeastern Himalayan state of Manipur, in northeastern India.			Language	
C154033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154033>	C158073	Mohawk Language|MOH|Mohawk	An Iroquoian language spoken by people of the Mohawk Nation of Canada and the United States.			Language	
C154034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154034>	C161861	Mongolian Language|MON|Mongolian	A Mongolic language that is the official language of Mongolia.			Language	
C154035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154035>	C161852	Mossi Language|MOS|Mossi	A Niger-Congo Gur language that is an official regional language of Burkina Faso.			Language	
C154036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154036>	C161903	Maori Language|MRI|Maori	An Eastern Polynesian language spoken by the Maori people of New Zealand.			Language	
C154037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154037>	C161901	Malay Language|MSA|Malay	An Austronesian language spoken in Brunei, Indonesia, Malaysia and Singapore.			Language	
C154038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154038>	C158073	Muscogee Language|Creek|Creek Language|MUS|Muscogee	A Muskogean language spoken by Muscogee (Creek) and Seminole people, primarily in the U.S. states of Oklahoma and Florida.			Language	
C154039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154039>	C160962	Mirandese Language|MWL|Mirandese	An Indo-European language spoken in the northeastern municipalities of Miranda do Douro, Mogadouro, and Vimioso in Portugal.			Language	
C15403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15403>	C15216	Endocervical Curettage|endocervical curettage	A procedure in which the mucous membrane of the cervical canal is scraped using a curette.			Diagnostic Procedure	
C154040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154040>	C160962	Marwari Language|MWR|Marwari	An Indo-European language spoken in the Indian state of Rajasthan.			Language	
C154041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154041>	C161862	Burmese Language|Burmese|MYA	A Sino-Tibetan language spoken in Myanmar where it is an official language and the language of the Bamar people.			Language	
C154042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154042>	C210937	Erzya Language|Erzya|MYV	A Uralic language spoken in the northern, eastern, and north-western parts of the Republic of Mordovia and adjacent regions of Nizhny Novgorod, Chuvashia, Penza, Samara, Saratov, Orenburg, Ulyanovsk, Tatarstan, and Bashkortostan in Russia.			Language	
C154043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154043>	C161845	Neapolitan Language|NAP|Neapolitan	A Romance language of the Italo-Dalmatian group spoken across much of southern Italy.			Language	
C154044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154044>	C161901	Nauru Language|NAU|Nauru|Nauruan	An Austronesian language spoken in the country of Nauru.			Language	
C154045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154045>	C153897	Navajo Language|NAV|Navaho|Navajo	A Southern Athabaskan language of the Na-Dene family spoken primarily in the Southwestern United States, especially in the Navajo Nation.			Language	
C154046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154046>	C161853	South Ndebele Language|NBL|South Ndebele	A Niger-Congo Bantu language spoken by the Ndebele people of South Africa.			Language	
C154047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154047>	C161853	North Ndebele Language|Matabele|NDE|North Ndebele	A Niger-Congo Bantu language spoken by the Northern Ndebele people of Zimbabwe.			Language	
C154048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154048>	C161853	Ndonga Language|NDO|Ndonga|Oshindonga	A Niger-Congo Bantu language spoken in Namibia and parts of Angola.			Language	
C154049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154049>	C177692	CD1A Positive|Antigen CD1a Positive|CD1a Antigen Positive|CD1a Molecule Positive|T-Cell Surface Glycoprotein CD1a Positive|T6/Leu-6 Positive|Thymocyte Antigen CD1A Positive|hTa1 Thymocyte Antigen Positive	An indication that CD1A expression has been detected in a sample.	CD1A Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15404>	C15337	Mediastinotomy|incision of the mediastinum	A surgical procedure in which an opening is made into the mediastinum.			Therapeutic or Preventive Procedure	
C154050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154050>	C160956	Low German Language|Low German|Low Saxon|NDS	A West Germanic language spoken mainly in northern Germany and the eastern part of the Netherlands.			Language	
C154051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154051>	C161844	Nepali Language|NEP|Nepali	An Indo-Aryan language that is the official language of Nepal.			Language	
C154052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154052>	C161862	Newar Language|NEW|Nepal Bhasa|Newari	A Sino-Tibetan language spoken by the Newar people of Nepal.			Language	
C154053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154053>	C161901	Nias Language|NIA|Nias	An Austronesian language spoken on Nias Island and the Batu Islands of Indonesia.			Language	
C154054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154054>	C161901	Niuean Language|NIU|Niuean	An Austronesian language native to Niue Island.			Language	
C154055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154055>	C160956	Flemish Language|Dutch|Flemish|NLD	A West Germanic language native to Netherlands and Flanders.			Language	
C154056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154056>	C51276	Nynorsk Language|NNO|Norwegian Nynorsk|Nynorsk	One of the two written standards of the Norwegian language.			Language	
C154057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154057>	C51276	Bokmal Language|Bokmal|NOB|Norwegian Bokmal	The preferred written standard for the Norwegian language.			Language	
C154058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154058>	C161847	Nogai Language|NOG|Nogai	A Turkic language spoken in southwestern European Russia.			Language	
C154059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154059>	C161904	Norwegian Language|NOR|Norwegian	A North Germanic language that is the official language of Norway.			Language	
C154060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154060>	C51276|C161851	N'Ko Language|N'Ko|NKo Language|NQO	A script devised as a writing system for the Manding languages of West Africa, and the name of the literary language written in that script.			Language	
C154061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154061>	C161853	Northern Sotho Language|NSO|Northern Sotho|Pedi|Sepedi	A Niger-Congo Bantu language spoken primarily in South Africa.			Language	
C154062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154062>	C161853	Chewa Language|Chewa|Chichewa|NYA|Nyanja	A Niger-Congo Bantu language native to Zambia, Malawi, Mozambique, and Zimbabwe.			Language	
C154063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154063>	C161853	Nyamwezi Language|NYM|Nyamwezi	A Niger-Congo Bantu language spoken in central Tanzania.			Language	
C154064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154064>	C161853	Nkore Language|NYN|Nkole|Nkore|Nyankole|Nyankore|Orunyankole|Orunyankore|Runyankole|Runyankore	A Niger-Congo Bantu language spoken by the Nkore and Hima peoples of south-western Uganda.			Language	
C154065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154065>	C161853	Nyoro Language|NYO|Nyoro	A Niger-Congo Bantu language spoken by the Nyoro people of Uganda.			Language	
C154066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154066>	C160958	Nzema Language|NZI|Nzema|Nzima	A Central Tano language spoken by the Nzema people of southwestern Ghana and southeast Ivory Coast.			Language	
C154067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154067>	C161845	Occitan Language|OCI|Occitan|Occitan (post 1500)	A Romance language spoken in southern France, Italy's Occitan Valleys, Monaco, and Spain's Val d'Aran.			Language	
C154068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154068>	C158073	Ojibwe Language|Chippewa|OJI|Ojibwa|Ojibwe|Otchipwe	An indigenous language in the Algonquian language family spoken by the Ojubwe people in Canada and the United States.			Language	
C154069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154069>	C161843	Odia Language|ORI|Odia|Oriya	An Indo-Aryan language that is spoken mostly in eastern India.			Language	
C15406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15406>	C15419	Cancer Screening|Cancer Screening for Patients|Early Cancer Detection|Screening|Screening of Cancer|cancer screening	The use of any device, marker, or other means for the purpose of detecting the presence of a tumor, usually before there are any symptoms.	Cancer Screening		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C154070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154070>	C160955	Oromo Language|ORM|Oromo	An Afroasiatic language spoken in the Horn of Africa.			Language	
C154071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154071>	C158073	Osage Language|OSA|Osage	A Siouan language spoken by the Osage people of Oklahoma.			Language	
C154072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154072>	C160962	Ossetian Language|OSS|Ossete|Ossetian|Ossetic	An Eastern Iranian language spoken in the Ossetia region of Russia.			Language	
C154073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154073>	C161901	Pangasinan Language|PAG|Pangasinan|Salitan Pangasinan	An Austronesian language of the Phillipines spoken in the province of Pangasinan.			Language	
C154074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154074>	C161901	Pampanga Language|Kapampangan|PAM|Pampanga	An Austronesian language of the Phillipines spoken in the provinces of Pampanga, Tarlac, and Bataan.			Language	
C154075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154075>	C161843	Punjabi Language|PAN|Panjabi|Punjabi	An Indo-Aryan language spoken by the Punjabi people of northwest India and eastern Pakistan.			Language	
C154076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154076>	C51277	Papiamento Language|PAP|Papiamento	A Portuguese-based creole language spoken in the Dutch West Indies.			Language	
C154077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154077>	C161901	Palauan Language|PAU|Palauan	An Austronesian language that is an official language of the Republic of Palau.			Language	
C154078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154078>	C4131|C154091	Metastatic Fibrolamellar Carcinoma|Metastatic FLC|Metastatic Fibrolamellar Hepatocellular Carcinoma	A fibrolamellar carcinoma that has spread from the liver to another anatomic site.	Metastatic Fibrolamellar Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C154079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154079>	C161859	Polish Language|POL|Polish	An Indo-European West Slavic language spoken primarily in Poland as the native language of the Poles.			Language	
C15407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15407>	C15716	Family Study|FAMILY BASED|Familial Study|Family Based Study|Family-Based Study	Research conducted on related or non-related members of families, examining the affects of genetics, the environment, or twin offspring.			Research Activity	CDISC SDTM Observational Study Model Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154080>	C161901	Pohnpeian Language|PON|Pohnpeian	An Austronesian Micronesian language spoken as the indigenous language of the island of Pohnpei in the Caroline Islands.			Language	
C154081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154081>	C160962	Pashto Language|PUS|Pashto|Pushto	An Indo-European language spoken by the Pashtun people of Afghanistan and Pakistan.			Language	
C154082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154082>	C9264|C4131	Recurrent Fibrolamellar Carcinoma|Recurrent FLC|Recurrent Fibrolamellar Hepatocellular Carcinoma|Relapsed FLC|Relapsed Fibrolamellar Carcinoma|Relapsed Fibrolamellar Hepatocellular Carcinoma	The reemergence of fibrolamellar carcinoma after a period of remission.	Recurrent Fibrolamellar Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C154083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154083>	C51277	Quechuan Language|QUE|Quechua|Quechuan	An indigenous, primary language family spoken by the Quechua peoples, primarily living in the Andes and highlands of South America.			Language	
C154084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154084>	C161844	Rajasthani Language|RAJ|Rajasthani	A group of Indo-Aryan languages spoken primarily in the state of Rajasthan and adjacent areas of Haryana, Punjab, Gujarat, and Madhya Pradesh in India.			Language	
C154085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154085>	C161903	Rapa Nui Language|Pascuan|RAP|Rapa Nui|Rapanui	An Eastern Polynesian language spoken on the island of Rapa Nui (Easter Island).			Language	
C154086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154086>	C161903	Cook Islands Maori Language|Cook Islands Maori|RAR|Rarotongan	An Eastern Polynesian language spoken as the official language of the Cook Islands.			Language	
C154087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154087>	C161845	Romansh Language|ROH|Romansh	A Romance language spoken predominantly in the southeastern Swiss canton of Grisons.			Language	
C154088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154088>	C7927|C217201|C214987	Metastatic Liver Carcinoma	A carcinoma that arises from the liver and has spread to another anatomic site.			Neoplastic Process	
C154089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154089>	C161844	Romani Language|ROM|Romani|Romany	Any of several languages of the Romani people belonging to the Indo-Aryan branch of the Indo-European language family.			Language	
C154090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154090>	C161842	Romanian Language|Moldavian|Moldovan|RON|Romanian	An Eastern Romance language spoken as a native language, primarily in Romania and Moldova.			Language	
C154091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154091>	C4124|C3099|C154088	Metastatic Hepatocellular Carcinoma	A hepatocellular carcinoma that has spread to another anatomic site.			Neoplastic Process	
C154092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154092>	C177696	TTR Gene Mutation Negative|ATTR Gene Mutation Negative|ATTR Wild Type|ATTR Wildtype|ATTR wt|PALB Gene Mutation Negative|Prealbumin, Thyroxine-Binding Gene Mutation Negative|TBPA Gene Mutation Negative|TTR Wild Type|TTR Wildtype|TTR wt|Transthyretin Gene Mutation Negative	A genetic finding indicating that TTR gene mutations have not been detected in a sample.	TTR Gene Mutation Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154093>	C215107	Blasts 0 Percent of Peripheral Blood White Cells|Absence of Circulating Blasts|Blast Cells Not Detected in Peripheral Blood White Cells|Circulating Blasts 0 Percent|Circulating Blasts 0 Percent of Peripheral White Blood Cells	A semi-quantitative microscopic finding indicating that immature mononuclear cells are not detected when the nucleated cells in a peripheral leukocyte sample were examined.	Blasts 0 Percent of Peripheral Blood White Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C154094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154094>	C143154	Blasts 20 Percent or Less of Peripheral Blood White Cells|Blasts Less than or Equal to 20 Percent of Peripheral Blood White Cells	A semi-quantitative microscopic finding indicating that 20 percent or less of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.	Blasts 20 Percent or Less of Peripheral Blood White Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C154095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154095>	C142112	Blasts 6-25 Percent of Bone Marrow Nucleated Cells|Blasts Between 6 and 25 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that between 6 and 25 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts 6-25 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C154096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154096>	C148071	Blasts Under 10,000 of Peripheral Blood White Cells|Absolute Blasts in Peripheral Blood Less Than 10,000|Absolute Blasts in Peripheral Blood Less Than 10000|Blasts Less than 10,000 of Peripheral Blood White Cells|Blasts Less than 10000 of Peripheral Blood White Cells|Blasts Under 10,000 in Peripheral Blood White Cells|Blasts Under 10000 in Peripheral Blood White Cells	A quantitative microscopic finding indicating that less than 10,000 of the total number of nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.	Blasts Under 10,000 in Peripheral Blood White Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C154097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154097>	C163008	Blasts More than 60 Percent of Bone Marrow Nucleated Cells|Blasts Greater than 60 Percent of Bone Marrow Nucleated Cells|Blasts Over 60 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that more than 60 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts More than 60 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C154098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154098>	C21523	C3 Gene Product	A protein encoded by the C3 gene.	C3 Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154099>	C154098	Complement C3d|C3d|COMPLEMENT C3D|Complement C3d Fragment	Complement C3d (302 aa, ~34 kDa) is encoded by the human C3 gene. This protein is involved in the promotion of B-cell and complement activation.	Complement C3d		Amino Acid, Peptide, or Protein	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15409>	C15192	Packed Red Blood Cell Transfusion|PRBC Transfusion	The intravenous administration of red blood cells (whole blood without the plasma) into an individual.	Packed Red Blood Cell Transfusion		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C1540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1540>	C1757	Tyrphostin A46|AG 99|TYRPHOSTIN A46	A protein tyrosine kinase inhibitor that selectively inhibits EGFR kinase, involved in signaling pathways. (NCI)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C154100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154100>	C4086	Squamous Dysplasia	A morphologic finding indicating the presence of dysplasia in the squamous epithelium of a tissue sample.	Squamous Dysplasia		Finding	CTRP Disease Terminology|CTRP Terminology
C154101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154101>	C161853	Kirundi Language|Kirundi|RUN|Rundi	A Niger-Congo Bantu language spoken in Burundi, adjacent parts of Tanzania, and the Democratic Republic of the Congo.			Language	
C154102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154102>	C161842	Aromanian Language|Aromanian|Arumanian|Macedo-Romanian|RUP	An Eastern Romance language spoken in Southeastern Europe.			Language	
C154103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154103>	C51277	Sandawe Language|SAD|Sandawe	A click language spoken by the Sandawe people in the Dodoma region of Tanzania.			Language	
C154104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154104>	C51277	Sango Language|SAG|Sango	A creole language spoken as an official language of the Central African Republic.			Language	
C154105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154105>	C161847	Yakut Language|SAH	A Turkic language spoken by the Yakut people in the Sakha Republic in the Russian Federation.			Language	
C154106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154106>	C177692	C3d Positive|Complement C3d Fragment Positive|Complement C3d Positive	An indication that C3d expression has been detected in a sample.	C3d Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154107>	C161901	Sasak Language|SAS|Sasak	An Austronesian language spoken by the Sasak people on the island of Lombok, Indonesia.			Language	
C154108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154108>	C161902	Santali Language|SAT|Santali	An Austroasiatic language spoken mainly in the Indian states of Jharkhand, West Bengal, and Chhattisgarh.			Language	
C154109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154109>	C161845	Sicilian Language|SCN|Sicilian	A Romance language spoken on the island of Sicily and its satellite islands.			Language	
C154110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154110>	C161904	Scots Language|SCO|Scots	A Germanic language variety spoken in Lowland Scotland and parts of Ulster, Ireland			Language	
C154111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154111>	C210937	Selkup Language|SEL|Selkup	A Uralic language spoken by the Selkup people of Russia.			Language	
C154112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154112>	C177692	HLA-B*1501 Positive Cells Present|HLA-B*1501 Positive|HLA-B*15:01 Positive|HLA-B*15:01 Positive Cells Present|HLA-B1501 Positive	An indication that cells expressing HLA-B*1501 have been detected in a sample.	HLA-B*1501 Positive Cells Present		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154113>	C177692	HLA-B*4601 Positive Cells Present|HLA-B*4601 Positive|HLA-B*46:01 Positive|HLA-B*46:01 Positive Cells Present|HLA-B4601 Positive	An indication that cells expressing HLA-B*4601 have been detected in a sample.	HLA-B*4601 Positive Cells Present		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154114>	C210880	Shan Language|SHN|Shan	A Kra-Dai language that is spoken by the Shan people, mostly in the Shan State of Myanmar.			Language	
C154115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154115>	C160955	Sidamo Language|SID|Sidaama|Sidaamu Afoo|Sidamo	An Afro-Asiatic language, belonging to the Highland East Cushitic branch of the Cushitic family spoken in parts of southern Ethiopia by the Sidama people.			Language	
C154116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154116>	C161859	Slovak Language|SLK|Slovak	An Indo-European West Slavic language that is the official language of Slovakia.			Language	
C154117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154117>	C161858	Slovenian Language|SLV|Slovenian	An Indo-European Western South Slavic language that is spoken in Slovenia.			Language	
C154118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154118>	C161908	Southern Sami Language|SMA|Southern Sami	A Uralic Sami language spoken mostly in Snasa, Royrvik, Roros, and Hattfjelldal in Norway.			Language	
C154119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154119>	C161908	Northern Sami Language|North Sami|Northern Sami|SME	A Uralic Sami language spoken in the northern parts of Norway, Sweden, and Finland.			Language	
C15411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15411>	C15262	Cytokine Therapy	The use of cytokines in the treatment of any disease or disorder.	Cytokine Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C154120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154120>	C161908	Lule Sami Language|Lule Sami|SMJ	A Uralic Sami language spoken in Lule Lappmark, Sweden and in the northern parts of Nordland county in Norway.			Language	
C154121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154121>	C161908	Inari Sami Language|Inari Sami|SMN	A Uralic Sami language spoken by the Inari Sami people of Finland.			Language	
C154122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154122>	C161901	Samoan Language|SMO|Samoan	An Austronesian language spoken mainly in the Samoan islands.			Language	
C154123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154123>	C161908	Skolt Sami Language|SMS|Skolt Sami	A Uralic Sami language that is spoken by the Skolts people in Finland.			Language	
C154124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154124>	C161853	Shona Language|SNA|Shona	A Niger-Congo Bantu language spoken by the Shona people of Zimbabwe.			Language	
C154125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154125>	C161844	Sindhi Language|SND|Sindhi	An Indo-Aryan language spoken by the Sindhi people of the Pakistani province of Sindh.			Language	
C154126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154126>	C161854	Soninke Language|SNK|Soninke	A Niger-Congo Mande language spoken by the Soninke people of Africa.			Language	
C154127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154127>	C161853	Sesotho Language|SOT|Sesotho|Sotho|Southern Sotho	A Niger-Congo Bantu language spoken in South Africa and in Lesotho, where it is the national language.			Language	
C154128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154128>	C160962	Albanian Language|Albanian|SQI	An Indo-European language that is an official language in Albania and Kosovo.			Language	
C154129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154129>	C161845	Sardinian Language|SRD|Sardinian	An Indo-European Romance language spoken mainly on the island of Sardinia, Italy.			Language	
C15412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15412>	C15545	Lymphokine-Activated Killer Cell Therapy|LAK cell therapy	The use of lymphokine-activated killer cells in the treatment of any disease or disorder.			Therapeutic or Preventive Procedure	
C154130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154130>	C51277	Sranan Tongo Language|SRN|Sranan|Sranan Tongo|Sranantongo|Surinaams|Surinamese|Surinamese Creole|Taki Taki	An English-based creole spoken in Suriname.			Language	
C154131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154131>	C161856	Serbian Language|SRP|Serbian	An Indo-European Slavic language spoken mainly by the Serbs as the official language of Serbia.			Language	
C154132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154132>	C161852	Serer Language|SRR|Serer	A Niger-Congo language spoken by the Serer people of Senegal and Gambia.			Language	
C154133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154133>	C161853	Swati Language|SSW|Swati	A Niger-Congo Bantu language spoken by the Swazi people in Swaziland and South Africa.			Language	
C154134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154134>	C21295	BST2 Gene|BST2|BST2|Bone Marrow Stromal Cell Antigen 2 Gene	This gene is involved in interferon-dependent antiviral responses.	BST2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C154135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154135>	C154134	BST2 wt Allele|Bone Marrow Stromal Cell Antigen 2 wt Allele|CD317|NPC-A-7|PDCA-1|TETHERIN	Human BST2 wild-type allele is located in the vicinity of 19p13.11 and is approximately 3 kb in length. This allele, which encodes bone marrow stromal antigen 2, plays a role in the negative regulation of viral infectivity.	BST2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154136>	C17728	Bone Marrow Stromal Antigen 2|BST2|Bone Marrow Stromal Cell Antigen 2|CD317|CD317 Antigen|HM1.24 Antigen|NPC-A-7|PDCA-1|Tetherin	Bone marrow stromal antigen 2 (180 aa, ~20 kDa) is encoded by the human BST2 gene. This protein is involved in preventing the release of virions from infected cells.	Bone Marrow Stromal Antigen 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C154137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154137>	C177692	BST2 Positive|BST-2 Positive|Bone Marrow Stromal Antigen 2 Positive|Bone Marrow Stromal Cell Antigen 2 Positive|CD317 Antigen Positive|CD317 Positive|HM1.24 Antigen Positive|HM1.24 Positive|Tetherin Positive	An indication that BST2 expression has been detected in a sample.	BST2 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154138>	C126416	Type-Specific HPV Antibody|HPV Type-Specific Antibody|HPV Type-Specific IgG Antibody|HPV Vaccine-Type-Specific Antibody	Any immunoglobulin that recognizes the human papillomavirus serotype(s) in a vaccine following inoculation.	Type-Specific HPV Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154139>	C188219	CCND1/IGHG1 Fusion Negative|BCL1-IGHG1 Fusion Negative|BCL1/IGHG1 Fusion Negative|CCND1-IGHG1 Fusion Negative|IGHG1-CCND1 Fusion Negative|IGHG1/CCND1 Fusion Negative	An indication that CCND1/IGHG1 fusion expression has not been detected in a sample.	CCND1/IGHG1 Fusion Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15413>	C15878	Fertility Study	Research to investigate issues regarding reproductive processes.			Research Activity	
C154140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154140>	C36219|C137698	Myeloblasts 5 Percent or Less of Bone Marrow Nucleated Cells|Myeloblasts Less than or Equal to 5 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that 5 percent or less of the nucleated cells in a bone marrow sample are immature mononuclear cells of myeloid origin.	Myeloblasts 5 Percent or Less of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C154141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154141>	C161853	Sukuma Language|SUK|Sukuma	A Niger-Congo Bantu language spoken in Tanzania.			Language	
C154142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154142>	C161901	Sundanese Language|SUN|Sundanese	An Austronesian language spoken by the Sudanese people of Indonesia.			Language	
C154143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154143>	C161854	Susu Language|SUS|Susu	A Niger-Congo Mande language spoken by the Susu people of Guinea and Sierra Leone, West Africa.			Language	
C154144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154144>	C97927	PARP1 Gene Mutation|ADPRT 1 Gene Mutation|ADPRT Gene Mutation|ADPRT1 Gene Mutation|ARTD1 Gene Mutation|PARP Gene Mutation|PARP-1 Gene Mutation|PPOL Gene Mutation|Poly (ADP Ribose) Polymerase 1 Gene Mutation|Poly (ADP-Ribose) Polymerase 1 Gene Mutation|Poly (ADP-Ribose) Polymerase Gene Mutation|Poly(ADP-Ribose) Polymerase 1 Gene Mutation|Poly(ADP-Ribose) Polymerase Gene Mutation|pADPRT-1 Gene Mutation	A change in the nucleotide sequence of the PARP1 gene.	PARP1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154145>	C161853	Swahili Language|SWA|Swahili	A Niger-Congo Bantu language spoken by the Swahili people throughout eastern and south-eastern Africa.			Language	
C154146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154146>	C161904	Swedish Language|SWE|Swedish	A North Germanic language spoken as the official language of Sweden.			Language	
C154147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154147>	C160966	Syriac Language|SYR|Syriac|Syriac Aramaic	An Afro-Asiatic language dialect of Middle Aramaic.			Language	
C154148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154148>	C97927	PARP2 Gene Mutation|ADPRT 2 Gene Mutation|ADPRT2 Gene Mutation|ADPRTL2 Gene Mutation|ADPRTL3 Gene Mutation|ARTD2 Gene Mutation|PARP-2 Gene Mutation|Poly (ADP Ribose) Polymerase 2 Gene Mutation|Poly (ADP-Ribose) Polymerase 2 Gene Mutation|Poly(ADP-Ribose) Polymerase 2 Gene Mutation|pADPRT-2 Gene Mutation	A change in the nucleotide sequence of the PARP2 gene.	PARP2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154149>	C161903	Tahitian Language|TAH|Tahitian	A Polynesian language, spoken mainly on the Society Islands in French Polynesia.			Language	
C154150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154150>	C161909	Tamil Language|TAM|Tamil	A Dravidian language predominantly spoken by the Tamil people of India and Sri Lanka.			Language	
C154151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154151>	C161847	Tatar Language|TAT|Tatar	A Turkic language spoken by Tatar people in the Russian republics of Tartarstan and  ashkortostan, as well as Siberia.			Language	
C154152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154152>	C177692	PTEN Positive|MMAC1 Positive|Mutated in Multiple Advanced Cancers 1 Positive|PTEN Tyrosine Phosphatase Positive|PTEN1 Positive|Phosphatase and Tensin Homolog Positive|Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN Positive	An indication that PTEN expression has been detected in a sample.	PTEN Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154153>	C161909	Telugu Language|TEL|Telugu	A South-central Dravidian language native to India, where it is the primary language in the states of Andhra Pradesh, Telangana, and the union territory of Puducherry.			Language	
C154154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154154>	C165233	PTEN Negative|MMAC1 Negative|Mutated in Multiple Advanced Cancers 1 Negative|PTEN Loss|PTEN Tyrosine Phosphatase Negative|PTEN1 Negative|Phosphatase and Tensin Homolog Negative|Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN Negative	An indication that PTEN expression or activity has not been detected in a sample.	PTEN Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154155>	C40998|C177692	Tumor-Associated Peptide Antigens Present|TAPA Positive|Tumor Associated Peptide Antigens Positive|Tumor Associated Peptide Antigens Present|Tumor-Associated Peptide Antigens Positive	An indication that expression of part or all of a study-specific panel of tumor-associated peptide antigens has been detected in a sample.	Tumor-Associated Peptide Antigens Present		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C154156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154156>	C157377	Testosterone Greater than 150 ng/dL|Testosterone Greater than 150|Testosterone Greater than 150 Nanograms per Deciliter|Testosterone Greater than 150 Nanograms/Deciliter|Testosterone Level Greater than 150	A semiquantitative finding indicating that the concentration of testosterone in a sample is greater than 150 ng/dL.	Testosterone Greater than 150 ng/dL		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C154157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154157>	C35682	HLA Phenotype Positive|HLA Positive|Human Leukocyte Antigen Phenotype Positive|Human Leukocyte Antigen Positive	An indication that a subject's human leukocyte antigen (HLA) complex expression profile is appropriate for inclusion in a study.	HLA Phenotype Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C154158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154158>	C94299|C177692	FGFR1 Positive|BFGFR Positive|CD331 Positive|CEK Positive|FGFBR Positive|FGFR-1 Positive|FLG Positive|FLT-2 Positive|FLT2 Positive|FMS-Like Tyrosine Kinase 2 Positive|Fibroblast Growth Factor Receptor 1 Positive|KAL2 Positive|N-SAM Positive|OGD Positive	An indication that FGFR1 expression has been detected in a sample.	FGFR1 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154159>	C150479|C133155	BRAF Gene Rearrangement|B-RAF Gene Rearrangement|B-RAF1 Gene Rearrangement|BRAF Rearrangement|Rearrangement identified|v-raf Murine Sarcoma Viral Oncogene Homolog B1 Gene Rearrangement	A molecular abnormality indicating rearrangement of the BRAF gene.	BRAF Gene Rearrangement		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C15415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15415>	C94625	Hyperthermia Treatment|Clinical Hyperthermia|Diathermy|Hyperthermia|Hyperthermia Therapy|diathermy|hyperthermia therapy	A type of treatment in which body tissue is exposed to high temperatures to damage and kill cancer cells or to make cancer cells more sensitive to the effects of radiation and certain anticancer drugs.	Hyperthermia Treatment		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C154160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154160>	C161852	Timne Language|TEM|Timne	A Niger-Congo language spoken in Sierra Leone.			Language	
C154161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154161>	C161912	Terena Language|Etelena|TER|Terena|Tereno	An Arawakan language spoken by the Terena people of Brazil.			Language	
C154162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154162>	C161901	Tetum Language|TET|Tetum|Tetun	An Austronesian language spoken on the island of Timor.			Language	
C154163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154163>	C160962	Tajik Language|TGK|Tajik	An Indo-European language variety of Persian spoken in Tajikistan and Uzbekistan.			Language	
C154164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154164>	C161901	Tagalog Language|TGL|Tagalog	An Austronesian language spoken as a first language by a quarter of the population of the Philippines and as a second language by the majority.			Language	
C154165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154165>	C210880	Thai Language|Central Thai|Siamese|THA|Thai	A Kra-Dai language that is spoken as the official and national language of Thailand.			Language	
C154166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154166>	C160955	Tigre Language|TIG|Tigre	An Afroasiatic language spoken in Northeast Africa, primarily by the Tigre people in Eritrea.			Language	
C154167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154167>	C160966	Tigrinya Language|TIR|Tigrinya	An Afroasiatic language of the Semitic branch mainly spoken by the Tigrayan people in the highlands of Eritrea and in the Tigray Region of northern Ethiopia.			Language	
C154168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154168>	C161852	Tiv Language|TIV|Tiv	A Niger-Congo Southern Bantoid language spoken in Nigeria, mainly in the Benue State.			Language	
C154169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154169>	C161903	Tokelau Language|TKL|Tokelau	A Polynesian language spoken in Tokelau and on Swains Island in American Samoa.			Language	
C15416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15416>	C15258	Active Immunization	Deliberate stimulation of a host's immune response via administration of antigens or immunologic adjuvants.			Therapeutic or Preventive Procedure	
C154170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154170>	C161913	Tlingit Language|TLI|Tlingit	A Na-Dene language spoken by the Tlingit people of Southeast Alaska and Western Canada.			Language	
C154171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154171>	C160955	Tamasheq Language|TMH|Tamashek|Tamasheq	An Afro-Asiatic language spoken by the Tuareg people, principally in the Timbuktu area of Mali.			Language	
C154172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154172>	C161853	Tonga Language (Nyasa)|TOG|Tonga|Tonga (Nyasa)	A Niger-Congo Bantu language spoken mainly in the Nkhata Bay District of Malawi.			Language	
C154173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154173>	C161903	Tonga Language (Tonga Islands)|TON|Tonga|Tonga (Tonga Islands)	An Austronesian language of the Polynesian branch spoken as a national language in Tonga.			Language	
C154174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154174>	C51277	Tok Pisin Language|TPI|Tok Pisin	An English Creole language spoken as an official language in Papua New Guinea.			Language	
C154175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154175>	C51277	Tsimshian Language|Coast Tsimshian|Sm'algyax|TSI|Tsimshian	A dialect of the Tsimshian language spoken in northwestern British Columbia and southeastern Alaska.			Language	
C154176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154176>	C161853	Tswana Language|TSN|Tswana	A Niger-Congo Bantu language spoken in Southern Africa and as an official language of Botswana.			Language	
C154177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154177>	C161853	Tsonga Language|TSO|Tsonga|Xitsonga	A Niger-Congo Bantu language spoken by the Tsonga people of southern Africa and native to Mozambique, South Africa, Swaziland, and Zimbabwe.			Language	
C154178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154178>	C161847	Turkmen Language|TUK|Turkmen	A Turkic language spoken as an official language of Turkmenistan.			Language	
C154179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154179>	C161853	Tumbuka Language|TUM	A Niger-Congo Bantu language spoken in the Northern Region of Malawi and also in the Lundazi district of Zambia.			Language	
C15417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15417>	C208219	Randomized Clinical Trial|Randomized|Randomized Clinical Trials|randomized clinical trial	Assignment of subjects by chance to groups that receive different treatments.			Research Activity	OS Authorized Value Terminology|OS Subject Characteristics Table
C154180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154180>	C161847	Turkish Language|Istanbul Turkish|TUR|Turkish	The most widely spoken of the Turkic languages, spoken as an official language in Turkey, Northern Cyprus, and Cyprus.			Language	
C154181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154181>	C161903	Tuvalua Language|TVL|Tuvalua	A Polynesian language spoken as the official language of Tuvalu.			Language	
C154182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154182>	C153830	Twi Language|Akan Kasa|TWI|Twi	A dialect of the Niger-Congo Akan language spoken by the Ashanti people in southern and central Ghana.			Language	
C154183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154183>	C161847	Tuvinian Language|TYV|Tuvinian	A Turkic language spoken in the Republic of Tuva in south-central Siberia in Russia.			Language	
C154184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154184>	C210937	Udmurt Language|UDM|Udmurt	A Uralic language spoken by the Udmurt people of the Russian constituent republic of Udmurtia.			Language	
C154185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154185>	C161847	Uyghur Language|UIG|Uighur|Uyghur	A Turkic language spoken primarily by the Uyghur people in the Xinjiang Uyghur Autonomous Region of Western China.			Language	
C154186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154186>	C160962	Ukrainian Language|UKR|Ukrainian	An Indo-European East Slavic language that is the official state language of the Ukraine.			Language	
C154187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154187>	C161853	Umbundu Language|South Mbundu|UMB|Umbundu	A Niger-Congo Bantu language spoken by the Ovimbundu people of Angola.			Language	
C154188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154188>	C161844	Urdu Language|URD|Urdu|Urdu	A Persianized standard register of the Hindustani language that is the official national language of Pakistan.			Language	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C154189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154189>	C161847	Uzbek Language|UZB|Uzbek	A Turkic language that is the sole official language of Uzbekistan.			Language	
C15418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15418>	C61007	Sargramostim/Thiotepa|GM-CSF/TSPA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C154190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154190>	C161854	Vai Language|Gallinas|VAI|Vai|Vy	A Niger-Congo Mande language spoken by the Vai people in Liberia and Sierra Leone.			Language	
C154191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154191>	C161853	Venda Language|Tshivenda|VEN|Venda	A Niger-Congo Bantu language mainly spoken by the Venda people in the northern part of South Africa's Limpopo Province, as well as by some Lemba people in Zimbabwe.			Language	
C154193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154193>	C210937	Votic Language|VOT|Votian|Votic	A Uralic language spoken by the Vote people of the Ingria area of Finland.			Language	
C154194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154194>	C160955	Wolaytta Language|WAL|Wolaitta|Wolaytta	An Afro-Asiatic language spoken in the Wolayita Zone and some other parts of the Southern Nations, Nationalities, and People's Region of Ethiopia.			Language	
C154195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154195>	C161901	Waray Language|WAR|Waray	An Austronesian language native to Eastern Visayas of the Philippines.			Language	
C154196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154196>	C158073	Washo Language|WAS|Washo|Washoe	A Native American language isolate spoken by the Washo people in the area of the California-Nevada border, especially around Lake Tahoe.			Language	
C154197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154197>	C161845	Walloon Language|WLN|Walloon	A Romance language that is spoken in the Wallonia region in Belgium and some villages of Northern France.			Language	
C154198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154198>	C161852	Wolof Language|WOL|Wolof	A Niger-Congo language spoken by the Wolof people of Senegal, the Gambia, and Mauritania.			Language	
C154199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154199>	C161861	Oirat Language|Kalmyk|Oirat|XAL	A Mongolic language that is regarded as either a dialect of Mongolian or a distinct language.			Language	
C15419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15419>	C25218	Disease Screening|Disease Screening Procedure|Screening|Screening Intervention|screening	The use of any device, marker, or other means for the purpose of detecting the presence of disease, usually in asymptomatic individuals.	Disease Screening		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C1541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1541>	C1291	C-myb Antisense Oligonucleotide G4460|G4460|INX-3001|LR-3001|c-MYB Antisense|c-MYB Antisense Oligodeoxynucleotide|c-Myb Antisense OND|c-Myb LR-3001	A 24-base phosphorothiolate antisense oligodeoxynucleotide (ODN) for the proto-oncogene c-myb with potential antineoplastic activity. C-myb antisense oligonucleotide G4460 binds to codon sequences 2 to 9 of c-myb mRNA, inhibiting translation of the transcript. Suppression of c-myb expression with this agent may result in the restoration of normal differentiation pathways, increased antiproliferative effects, and the induction of apoptosis in early progenitor hematopoietic cells and in tumor cells that overexpress c-myb. Tumor-cell overexpression of c-myb blocks differentiation, promotes proliferation, and inhibits apoptosis.			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C154200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154200>	C161853	Xhosa Language|XHO|Xhosa	A Niger-Congo Bantu language spoken as an official language in South Africa and Zimbabwe.			Language	
C154201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154201>	C161853	Yao Language|YAO|Yao	A Niger-Congo Bantu language spoken mainly in Malawi, Tanzania, and Mozambique.			Language	
C154202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154202>	C161901	Yapese Language|YAP|Yapese	An Austronesian language spoken by the people on the island of Yap, Federated States of Micronesia.			Language	
C154203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154203>	C160956	Yiddish Language|YID|Yiddish	A High German-based vernacular fused with elements taken from Hebrew and Aramaic as well as from Slavic languages and traces of Romance languages.			Language	
C154204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154204>	C161852	Yoruba Language|YOR|Yoruba	A Niger-Congo language spoken in West Africa.			Language	
C154205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154205>	C158071	Zapotec Language|ZAP|Zapotec	A group of around 50 closely related indigenous Mesoamerican languages spoken by the Zapotec people from the southwestern-central highlands of Mexico.			Language	
C154206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154206>	C160955	Zenaga Language|ZEN|Zenaga	An Afro-Asiatic Berber language spoken from the town of Mederdra in southwestern Mauritania to the Atlantic coast and in Senegal.			Language	
C154207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154207>	C160955	Standard Moroccan Berber Language|Standard Moroccan Berber|Standard Moroccan Tamazight|ZGH	The standardized national variety of Berber spoken in Morocco.			Language	
C154208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154208>	C210880	Zhuang Language|Chuang|ZHA|Zhuang	Any of more than a dozen Tai languages spoken by the Zhuang people of southern China in the province of Guangxi and adjacent parts of Yunnan and Guangdong.			Language	
C154209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154209>	C161853	Zulu Language|ZUL|Zulu	A Niger-Congo Bantu language spoken by the Zulu people of South Africa.			Language	
C15420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15420>	C15436	Hypnotherapy|Clinical Hypnosis|Hypnosis|Hypnosis	Therapeutic use of hypnotism by a clinical professional.	Hypnotherapy		Mental Process	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology
C154210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154210>	C158073	Zuni Language|ZUN|Zuni	A language of the Zuni people, indigenous to western New Mexico and eastern Arizona in the United States.			Language	
C154211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154211>	C160962	Zaza Language|Dimili|Dimli|Kirdki|Kirmanjki|ZZA|Zaza|Zazaki	An Indo-European language spoken primarily in eastern Turkey by the Zaza people.			Language	
C154212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154212>	C63443|C63442	Bendamustine/Obinutuzumab Regimen|Bendamustine + Obinutuzumab|Bendamustine and Obinutuzumab|Bendamustine-Obinutuzumab|Bendamustine-Obinutuzumab Regimen|Bendamustine/Obinutuzumab|Obinutuzumab Plus Bendamustine|Obinutuzumab-Bendamustine	A regimen consisting of bendamustine and obinutuzumab that can be used in the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C154213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154213>	C63442	G-CHOP Regimen|CHOP + Obinutuzumab|CHOP + Obinutuzumab Regimen|CHOP Plus Obinutuzumab|CHOP Plus Obinutuzumab Regimen|CHOP-Obinutuzumab Regimen|G-CHOP|G-CHOP|GCHOP|Gazyva Plus CHOP|Obinutuzumab Plus Cyclophosphamide/Doxorubicin/Vincristine/Prednisone|Obinutuzumab-Cyclophosphamide-Doxorubicin-Prednisone-Vincristine|Obinutuzumab-Cyclophosphamide-Doxorubicin-Prednisone-Vincristine Regimen|Obinutuzumab-Cyclophosphamide-Hydroxydaunorubicin-Oncovin-Prednisone|Obinutuzumab-Cyclophosphamide-Hydroxydaunorubicin-Oncovin-Prednisone Regimen|Obinutuzumab/Cyclophosphamide/Doxorubicin/Prednisone/Vincristine|Obinutuzumab/Cyclophosphamide/Doxorubicin/Prednisone/Vincristine Regimen	A regimen consisting of cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and obinutuzumab that can be used in the treatment of some forms of non-Hodgkin lymphoma (NHL), including follicular lymphoma, gastric and nongastric MALT lymphomas, nodal marginal zone lymphoma (NMZL) and splenic marginal zone lymphoma (SMZL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C154214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154214>	C63442	R-CEPP Regimen|CEPP + Rituximab Regimen|CEPP Plus Rituximab Regimen|CEPP-Rituximab Regimen|Cyclophosphamide/Etoposide/Prednisone/Procarbazine + Rituximab|Cyclophosphamide/Etoposide/Prednisone/Procarbazine Plus Rituximab|Cyclophosphamide/Etoposide/Prednisone/Procarbazine Plus Rituximab Regimen|R-CEPP|RCEPP|Rituximab-Cyclophosphamide-Etoposide-Prednisone-Procarbazine|Rituximab-Cyclophosphamide-Etoposide-Prednisone-Procarbazine Regimen|Rituximab/Cyclophosphamide/Etoposide/Prednisone/Procarbazine|Rituximab/Cyclophosphamide/Etoposide/Prednisone/Procarbazine Regimen	A regimen consisting of cyclophosphamide, etoposide, prednisone, procarbazine (CEPP) and rituximab that can be used in the treatment of some forms of non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), and post-transplant lymphoproliferative disorders.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C154215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154215>	C63442	R-CDOP Regimen|R-CDOP|R-CDOP|R-CDOP (rituximab-abbs)|R-CDOP (rituximab-arrx)|R-CDOP (rituximab-blit)|R-CDOP (rituximab-pvvr)|R-CDOP (rituximab-rite)|R-CDOP (rituximab-rixa)|R-CDOP (rituximab-rixi)|RCDOP|Rituximab-Cyclophosphamide-Doxil-Oncovin-Prednisone Regimen|Rituximab-Cyclophosphamide-Liposomal Doxorubicin-Vincristine-Prednisone|Rituximab-Cyclophosphamide-Liposomal Doxorubicin-Vincristine-Prednisone Regimen|Rituximab/Cyclophosphamide/Doxil/Oncovin/Prednisone Regimen|Rituximab/Cyclophosphamide/Liposomal Doxorubicin/Vincristine/Prednisone|Rituximab/Cyclophosphamide/Liposomal Doxorubicin/Vincristine/Prednisone Regimen	A regimen consisting of rituximab, cyclophosphamide, liposomal doxorubicin, vincristine and prednisone (R-CDOP) that can be used in the treatment of some forms of non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C154216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154216>	C51944	Immunohistochemical Panel for Burkitt Lymphoma|IHC Panel for Burkitt Lymphoma	An immunohistochemical screening panel for Burkitt lymphoma consisting of reagents that identify the cell-surface presence of: CD3, CD10, CD20, CD45, Ki-67, BCL2, BCL6, and TdT (terminal deoxynucleotide transferase).			Occupational Activity	
C154217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154217>	C113003	Flow Cytometry Panel for Burkitt Lymphoma	A flow cytometry screening panel for Burkitt lymphoma consisting of reagents that identify the cell-surface presence of: CD3, CD5, CD10, CD19, CD20, CD45, TdT (terminal deoxynucleotide transferase), and kappa or lambda light chains.			Laboratory Procedure	
C154218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154218>	C63443|C63442	Chlorambucil/Rituximab Regimen|Chlorambucil + Rituximab|Chlorambucil Plus Rituximab|Chlorambucil and Rituximab (RClb)|Chlorambucil and Rituximab-abbs (RClb)|Chlorambucil and Rituximab-arrx (RClb)|Chlorambucil and Rituximab-blit (RClb)|Chlorambucil and Rituximab-pvvr (RClb)|Chlorambucil and Rituximab-rite (RClb)|Chlorambucil and Rituximab-rixa (RClb)|Chlorambucil and Rituximab-rixi (RClb)|Chlorambucil-Rituximab|Chlorambucil-Rituximab Regimen|Chlorambucil/Rituximab|Rituximab + Chlorambucil|Rituximab/Chlorambucil Regimen	A regimen consisting of chlorambucil and rituximab that can be used in the treatment of some forms of non-Hodgkin lymphoma (NHL), including follicular lymphoma, gastric and nongastric mucosa-associated lymphoid tissue (MALT) lymphoma, nodal and splenic marginal zone lymphoma, and chronic lymphocytic leukemia (CLL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C154219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154219>	C17708	Resistance Training|Strength Training	Physical exercise that uses weight, or other forms of resistance, to induce muscle contraction and build strength, anaerobic endurance, and size of skeletal muscles. Typical exercises include leg and chest press, knee extension, leg curl, row, abdominal crunch, and bicep curl.	Resistance Training		Daily or Recreational Activity	CTRP Intervention Terminology|CTRP Terminology
C15421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15421>	C106541	Postmenopausal|POSTMENOPAUSAL|postmenopausal	After menopause.			Clinical Attribute	CDISC SDTM Menopause Status Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C154220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154220>	C17705	Cognitively-Based Compassion Training|CBCT	Classes consisting of didactics, class discussion, and guided meditation practice designed to challenge unexamined assumptions regarding feelings and actions toward others with a focus on generating spontaneous empathy and compassion for self and others.	Cognitively-Based Compassion Training		Educational Activity	CTRP Intervention Terminology|CTRP Terminology
C154221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154221>	C4004|C159775|C129654	Unresectable Gastric Adenocarcinoma	A gastric adenocarcinoma that is not amenable to surgical resection.			Neoplastic Process	
C154222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154222>	C3113|C27567	Pituitary Hyperplasia|Pituitary Gland Hyperplasia	A rare condition characterized by hyperplasia and hypertrophy of the pituitary gland. It is caused by hypersecretion of hypothalamic stimulating hormones.			Disease or Syndrome	
C154223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154223>	C159659	Cord Blood Transplant Recipient|CBT Recipient|Cord Blood Transplantation Recipient	An individual receiving a cord blood transplant.	Cord Blood Transplant Recipient		Human	CTRP Intervention Terminology|CTRP Terminology
C154224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154224>	C21072	Pectoral Nerve Block|PECS 1|PECS-1|Pectoralis Nerve Block	A peripheral neural block of the medial and lateral pectoral nerves.	Pectoral Nerve Block		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C154225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154225>	C17708	Stretching	A physical exercise in which a specific muscle or tendon is deliberately flexed or stretched in order to improve the muscle's elasticity.	Stretching		Daily or Recreational Activity	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|CTRP Intervention Terminology|CTRP Terminology
C154226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154226>	C43432	Waiting List|Waitlist	A list of people waiting for inclusion in some activity, vacancy, or service.	Waiting List		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C154227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154227>	C97927|C174168	ERCC3 Gene Mutation|BTF2 Gene Mutation|ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit Gene Mutation|Excision Repair Cross-Complementation Group 3 Gene Mutation|Excision Repair Cross-Complementing Rodent Repair Deficiency, Complementation Group 3 Gene Mutation|Excision-Repair, Complementing Defective, in Chinese Hamster, 3 Gene Mutation|GTF2H Gene Mutation|RAD25 Gene Mutation|TTD2 Gene Mutation|XPB Gene Mutation|Xeroderma Pigmentosum Group B Complementing Gene Mutation	A change in the nucleotide sequence of the ERCC3 gene.	ERCC3 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154228>	C97927|C131783	ABRAXAS1 Gene Mutation|ABRA1 Gene Mutation|ABRAXAS Gene Mutation|Abraxas 1, BRCA1 A Complex Subunit Gene Mutation|CCDC98 Gene Mutation|FAM175A Gene Mutation|Family with Sequence Similarity 175 Member A Gene Mutation	A change in the nucleotide sequence of the ABRAXAS1 gene.	ABRAXAS1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154229>	C97927|C131783	GEN1 Gene Mutation|GEN1 Holliday Junction 5' Flap Endonuclease Gene Mutation|Gen Gene Mutation|Gen Homolog 1, Endonuclease Gene Mutation	A change in the nucleotide sequence of the GEN1 gene.	GEN1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15422>	C50651	Human Migration|Human Migration / Distribution	Movement of residence from one place to another. Includes nomadism; labor or seasonal migration; patterns of rural, urban, or suburban migration; or voluntary or forced relocation. (PSY94)			Social Behavior	
C154230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154230>	C97927	HDAC2 Gene Mutation|HD2 Gene Mutation|Histone Deacetylase 2 Gene Mutation|RPD3 Gene Mutation|YAF1 Gene Mutation	A change in the nucleotide sequence of the HDAC2 gene.	HDAC2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154231>	C1962|C142078	Genetically-engineered Cell|Cell-based Gene Therapy Agent|Genetically-altered Cell|Genetically-modified Cell	Autologous or allogeneic cells that have been genetically modified.	Genetically-engineered Cell		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C154232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154232>	C199141	Women who Have Lumpectomy and Radiation Therapy|Women who have a lumpectomy and radiation	The group of women who treat their breast cancer with lumpectomy and radiation therapy.			Population Group	Decision Quality Instruments - Breast Surgery
C154233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154233>	C199141	Women who Have Mastectomy|Women who have a mastectomy	The group women who treat their breast cancer with mastectomy.			Population Group	Decision Quality Instruments - Breast Surgery
C154234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154234>	C226634	Most Will Die of Something Else|Most will die of something else	A response indicating the belief that most breast cancer patients will die of something else.			Intellectual Product	Decision Quality Instruments - Breast Surgery
C154235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154235>	C226634	About Half Will Die of Breast Cancer|About half will die of breast cancer	A response indicating the belief that about half of breast cancer patients will die of breast cancer.			Intellectual Product	Decision Quality Instruments - Breast Surgery
C154236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154236>	C226634	Most Will Die of Breast Cancer|Most will die of breast cancer	A response indicating the belief that most breast cancer patients will die of breast cancer.			Intellectual Product	Decision Quality Instruments - Breast Surgery
C154237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154237>	C226692	A Little or Not at All|A little or not at all|Little or None|Little or Not at All	A response indicating little to no agreement, interest, or importance.			Intellectual Product	Decision Quality Instruments - Breast Surgery
C154238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154238>	C91105	Brief Appraisal Inventory|BAI|Brief Appraisal Inventory (BAI)	A questionnaire designed to account for quality-of-life issues and assess their impact on responses in patient-reported outcome surveys.			Intellectual Product	
C154239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154239>	C173597|C118873	How Often Did You Think About Question|During today's interview, how often did you think about|How Often Did You Think About	A question about the frequency that a person thought about a particular thing.			Intellectual Product	Brief Appraisal Inventory
C15423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15423>	C15315|C126880	Psychosocial Rehabilitation	Programs, techniques, or processes of treatment by which individuals acquire psychological and social skills and attitudes which facilitate community interaction.  (from PSY94)			Therapeutic or Preventive Procedure	
C154240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154240>	C91102	Maintain Positive Outlook, Even When Things are Going Badly Question|Maintain Positive Outlook, Even When Things are Going Badly|Maintaining a positive outlook, even when things are going badly	A question about how often a person thought about maintaining a positive outlook, even when things are going badly.			Intellectual Product	Brief Appraisal Inventory
C154241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154241>	C173597	Achieve Calmer, More Peaceful, or Healthier Lifestyle Question|Achieve Calmer, More Peaceful, or Healthier Lifestyle|Achieving a calmer, more peaceful or healthier lifestyle	A question about how often a person thought about achieving a calmer, more peaceful, or healthier lifestyle.			Intellectual Product	Brief Appraisal Inventory
C154242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154242>	C176545	Solve Problems with Health Care or Health Care System Question|Solve Problems with Health Care or Health Care System|Solving problems that you have with health care or the health care system	A question about how often a person thought about solving problems that they have with health care or the health care system.			Intellectual Product	Brief Appraisal Inventory
C154243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154243>	C91102	Impressions and Assumptions Others Have About You Because of Your Health Question|Impressions and Assumptions Others Have About You Because of Your Health|Impressions and assumptions that others have about you because of your health	A question about how often a person thought about impressions and assumptions that others have about them because of their health.			Intellectual Product	Brief Appraisal Inventory
C154244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154244>	C91102	Comparison to Others Whose Health Does not Limit Them Question|Comparison to Others Whose Health Does not Limit Them|Comparison to Others Whose Health Does not Limit Them|How you compare to others whose health does not limit them	A question about how often a person thought about how they compare to others whose health does not limit them.			Intellectual Product	Brief Appraisal Inventory
C154245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154245>	C187306	Free of Money Problems Question|Being free of money problems|Free of Money Problems	A question about how often a person thought about being free of money problems.			Intellectual Product	Brief Appraisal Inventory
C154246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154246>	C91102	Increase Volunteer Work to Help Others in Community Question|Increase Volunteer Work to Help Others in Community|Increasing your volunteer work to help others in your community	A question about how often a person thought about increasing their volunteer work to help others in the community.			Intellectual Product	Brief Appraisal Inventory
C154247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154247>	C91102	Grow Spiritually Question|Grow Spiritually|Growing spiritually	A question about how often a person thought about growing spiritually.			Intellectual Product	Brief Appraisal Inventory
C154248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154248>	C173597	Stay Active and Productive Question|Stay Active and Productive|Staying active and productive	A question about how often a person thought about staying active and productive.			Intellectual Product	Brief Appraisal Inventory
C154249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154249>	C91102	Resolve Problems in Living Situation Question|Resolve Problems in Living Situation|Resolving problems in your living situation	A question about how often a person thought about resolving problems in their living situation.			Intellectual Product	Brief Appraisal Inventory
C15424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15424>	C15716	Record Linkage Study|Data Linkage|Data Linkage Study|Registry Linkage Study|Registry Linkage Study	A study in which data from different sources are "linked".  Usually used to compile epidemiological data.  The logic of record linkage is that two or more items of information about a person recorded at different times, and perhaps in different places, may be of greater value when considered together than when either is considered alone.			Research Activity	
C154250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154250>	C173151	Prepare Family for Ups and Downs of Health Condition Question|Prepare Family for Ups and Downs of Health Condition|Preparing your family for the ups and downs of your health condition	A question about how often a person thought about preparing their family for the ups and downs of the person's health condition.			Intellectual Product	Brief Appraisal Inventory
C154251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154251>	C91102	Settle Conflicts with People in Life Question|Settle Conflicts with People in Life|Settling conflicts with people in your life	A question about how often a person thought about settling conflicts with the people in their life.			Intellectual Product	Brief Appraisal Inventory
C154252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154252>	C118873	Find Romance Question|Find Romance|Finding romance	A question about how often a person thought about finding romance.			Intellectual Product	Brief Appraisal Inventory
C154253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154253>	C91102	Learn to Accept Yourself as You Are Question|Learn to Accept Yourself as You Are|Learn to Accept Yourself as You Are|Learning to accept yourself as you are	A question about how often a person thought about learning to accept themselves as they are.			Intellectual Product	Brief Appraisal Inventory
C154254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154254>	C91102	Things that Usually Don't Come to Mind, Except Because of Survey Question|Things that Usually Don't Come to Mind, Except Because of Survey|Things that do not usually come to mind, except because of this survey	A question about how often a person thought about things that do not usually come to mind, except because of this survey.			Intellectual Product	Brief Appraisal Inventory
C154255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154255>	C91102	Have Dreams and Goals Different From Most People Own Age Question|Have Dreams and Goals Different From Most People Own Age|Having dreams and goals that are different from most people your own age	A question about how often a person thought about having dreams and goals that are different from most people their age.			Intellectual Product	Brief Appraisal Inventory
C154256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154256>	C173151	Spend More Time with Family Before Health Worsens Question|Spend More Time with Family Before Health Worsens|Spending more time with your family before your health worsens	A question about how often a person thought about spending more time with their family before the person's health worsens.			Intellectual Product	Brief Appraisal Inventory
C154257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154257>	C173045	Remain Independent and Be Able to Get Around on Your Own Question|Remain Independent and Be Able to Get Around on Your Own|Remaining independent and being able to get around on your own	A question about how often a person thought about remaining independent and being able to get around on their own.			Intellectual Product	Brief Appraisal Inventory
C154258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154258>	C173597	Be Rid of Obligations and Responsibilities Question|Be Rid of Obligations and Responsibilities|Being rid of obligations and responsibilities	A question about how often a person thought about being rid of obligations and responsibilities.			Intellectual Product	Brief Appraisal Inventory
C154259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154259>	C91102	Try Not to Complain About Health to Others Question|Try Not to Complain About Health to Others|Trying not to complain about your health to others	A question about how often a person thought about trying not to complain about their health to others.			Intellectual Product	Brief Appraisal Inventory
C15425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15425>	C67022	Nutritional Supplementation|Supplementation|supplementation	The addition of one or more elements and/or chemical compounds that are either absent or deficient in an individual's daily diet.	Nutritional Supplementation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C154260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154260>	C91102	Comparison to Others Facing Similar Health Issues Question|Comparison to Others Facing Similar Health Issues|How you compare to others facing similar health issues	A question about how often a person thought about how they compare to others with similar health issues.			Intellectual Product	Brief Appraisal Inventory
C154261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154261>	C91102	Increase Travel for Leisure or Visit with People Question|Increase Travel for Leisure or Visit with People|Increasing your travel for leisure or for visiting with people	A question about how often a person thought about increasing their travel for leisure or for visiting with people.			Intellectual Product	Brief Appraisal Inventory
C154262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154262>	C173924	Accomplish New Goals at Work Question|Accomplish New Goals at Work|Accomplishing new goals at work	A question about how often a person thought about accomplishing new goals at work.			Intellectual Product	Brief Appraisal Inventory
C154263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154263>	C93098	External Qigong Therapy|EQT|External Qi Therapy	A form of traditional Chinese energy therapy that involves the use of hand movements, acupressure, focused attention, and other mind healing techniques to direct the therapist's emitted Qi into a patient to regulate the patient's Qi activity.	External Qigong Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C154264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154264>	C117720	Vulvovaginal Atrophy|VVA	A condition associated with decreased estrogen production, characterized by dryness, inflammation, and itching of the vulva and vaginal tissues. It may also be associated with dysuria and dyspareunia.	Vulvovaginal Atrophy		Finding	CTRP Disease Terminology|CTRP Terminology
C154265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154265>	C16782	Carbon Dioxide Fractional Laser|CO2 Fractional Laser|CO2RE	A carbon dioxide gas laser device that uses continuous or short-pulsed light beams to target and remove thin layers of skin in precise areas without damaging the surrounding skin.	Carbon Dioxide Fractional Laser		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C154266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154266>	C20993	Electronic Patient Visit Assessment|ePVA	A web-based instrument that is used capture a patient's self-assessments prior to a healthcare encounter.	Electronic Patient Visit Assessment		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C154267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154267>	C148174	Histone H1 Gene|H1 Gene|H1 Histone Family Gene	A gene encoding the linker histone protein histone H1.			Gene or Genome	
C154268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154268>	C15656	Brain Surgery	Surgery performed on any part of the brain.	Brain Surgery		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C154269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154269>	C67290|C140180	Bevacizumab/Everolimus Regimen|Bevacizumab + Everolimus|Bevacizumab Plus Everolimus|Bevacizumab-Everolimus|Bevacizumab-Everolimus Regimen|Bevacizumab/Everolimus|Everolimus/Bevacizumab	A regimen consisting of bevacizumab and everolimus that can be used for the treatment of kidney cancer and meningioma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C15426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15426>	C16048	Database|DB|Data Bank|Database, Electronic|database	An information set with a regular structure.  Although it can be applied to any set of information the term was invented to refer to computerized data, and is used almost exclusively in computing.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C154270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154270>	C67290	Everolimus/Lenvatinib Regimen|Everolimus and Lenvatinib|Everolimus/Lenvatinib|Lenvatinib + Everolimus|Lenvatinib Plus Everolimus|Lenvatinib-Everolimus|Lenvatinib-Everolimus Regimen|Lenvatinib/Everolimus|Lenvatinib/Everolimus Regimen	A regimen consisting of lenvatinib and everolimus that can be used for the treatment of kidney cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C154271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154271>	C64952|C46078	Endobronchial Ultrasound Bronchoscopy|EBUS|Endobronchial Ultrasound	A minimally invasive technique that uses endoscopic ultrasound to produce an image of the endobronchial passages.	Endobronchial Ultrasound Bronchoscopy		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C154272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154272>	C67338|C67290|C65070|C63787|C63719|C63587|C63586|C63524|C63522|C63510|C63502|C63360|C210232|C159901|C159900|C159462|C159457|C159454|C159449|C159440|C156290	Ipilimumab/Nivolumab Regimen|Ipilimumab + Nivolumab|Ipilimumab Plus Nivolumab|Ipilimumab and Nivolumab|Ipilimumab-Nivolumab|Ipilimumab-Nivolumab Regimen|Ipilimumab/Nivolumab|Nivolumab/Ipilimumab	A regimen consisting of ipilimumab and nivolumab that can be used for the treatment of bone, cervical, kidney, colorectal, esophageal and esophagogastric junction, head and neck, hepatocellular, biliary tract, ovarian, fallopian tube, primary peritoneal, vulvar, and vaginal cancers, melanoma, non-small cell lung cancer (NSCLC), malignant pleural/peritoneal mesothelioma, soft tissue sarcoma, gastrointestinal stromal tumor (GIST), uterine sarcoma, pancreatic adenocarcinoma, Kaposi sarcoma, angiosarcoma, Merkel cell carcinoma, and adrenal gland tumors.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C154273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154273>	C3280	Non-Malignant Nodule	A usually circumscribed and non-metastasizing nodular mass.	Non-Malignant Nodule		Finding	CTRP Disease Terminology|CTRP Terminology
C154274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154274>	C2517|C181141	mRNA-based TriMix Melanoma Vaccine ECI-006|ECI 006|ECI-006|ECI006	A melanoma vaccine consisting of mRNAs encoding five different melanoma tumor-associated antigens (TAAs) and a TriMix platform comprised of three mRNAs encoding for constitutively activated toll-like receptor 4 (caTLR4), CD40 ligand (CD40L), and CD70, with potential immunomodulatory and antineoplastic activities. Upon intranodal injection, mRNA based TriMix vaccine ECI-006 may stimulate the immune system to mount both humoral and cellular responses against tumor cells expressing the five TAAs specific to the vaccine, potentially decreasing cellular proliferation of cells expressing these antigens. The TriMix adjuvants CD40L and caTLR4 promote the generation of mature and active dendritic cells (DCs), and CD70 provides a costimulatory signal to CD27+ naive T-cells, thereby supporting T-cell proliferation and inhibiting T-cell apoptosis.			Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C154275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154275>	C1287	Recombinant HSA/Filgrastim Fusion Protein|Fusion Protein rHSA/GCSF|Human Serum Albumin GCSF|rHSA/G-CSF|rHSA/GCSF Fusion Protein	A long-acting recombinant fusion protein composed of human serum albumin (HSA) fused to granulocyte colony stimulating factor (G-CSF), with potential granulopoietic activity. Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, thereby stimulating the proliferation, differentiation, function, and survival of neutrophil precursors and mature neutrophils. This may prevent granulocytopenia. HSA fusion increases the molecular weight of G-CSF, prolongs its half-life and masks G-CSF, thereby preventing G-CSF degradation which further increases the half-life and bioavailability of G-CSF.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	NCI Drug Dictionary Terminology
C154276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154276>	C200766	Autologous AXL-targeted CAR T-cells CCT301-38|Autologous Anti-AXL CAR T Cells CCT30138|Autologous CAR T-cells Targeting AXL CCT301-38|CCT301 38|CCT301-38|CCT30138 CAR T Cells	A preparation of genetically modified autologous T-lymphocytes transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) targeting the receptor tyrosine kinase (RTK) AXL, with potential immunomodulatory and antineoplastic activities. After isolation, transduction, and expansion in culture, the CCT301-38 cells are reintroduced into the patient and are activated within the tumor microenvironment (TME) using proprietary Conditionally Active Biologic (CAB) technology. Upon activation, CAB antibodies bind to a proprietary T-cell signaling domain, promoting T-cell recognition and killing of AXL-expressing tumor cells. AXL is a RTK and oncogene that is overexpressed in many cancer types and is involved in the stimulation of tumor cell proliferation.			Cell|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C154277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154277>	C28681|C138180|C129826	Autologous ROR2-targeted CAR T-cells CCT301-59|Autologous Anti-ROR2 CAR T Cells CCT301-59|Autologous CAR T-cells Targeting ROR2 CCT301-59|Autologous CCT301-59 CAR T Cells|CCT301 59|CCT301-59	A preparation of genetically modified autologous T-lymphocytes transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) targeting the receptor tyrosine kinase-like orphan receptor 2 (ROR2), with potential immunomodulatory and antineoplastic activities. After isolation, transduction, and expansion in culture, CCT301-59 cells are reintroduced into the patient and are activated within the tumor microenvironment (TME) using proprietary Conditionally Active Biologic (CAB) technology. Upon activation, CAB antibodies bind to a proprietary T-cell signaling domain, promoting T-cell recognition and killing of ROR2-expressing tumor cells. ROR2 is involved in Wnt signal transduction and is involved in tumorigenesis and progression. ROR2 expression is upregulated in certain tumor types and high levels of ROR2 expression often correlates with poor prognosis.			Cell|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C154278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154278>	C1752	Colorectal Cancer Peptide Vaccine PolyPEPI1018|PolyPEPI 1018|PolyPEPI-1018|PolyPEPI1018|PolyPEPI1018 CRC Peptide Vaccine|PolyPEPI1018 CRC Vaccine	A peptide cancer vaccine consisting of a combination of six synthetic polypeptides directed against cancer testis antigens (CTAs) frequently expressed in colorectal cancers, with potential antineoplastic and immunostimulatory activities. Colorectal cancer peptide vaccine PolyPEPI1018 potentially elicits a cytotoxic T-lymphocyte response against colorectal tumors expressing the CTAs associated with the vaccine, which may result in a reduction in tumor cell proliferation.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C154279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154279>	C141136|C129825	Iruplinalkib|ALK Inhibitor WX-0593|FL 006|FL-006|FL006|IRUPLINALKIB|WX 0593|WX-0593|WX0593	An orally available, small molecule inhibitor of the receptor tyrosine kinase (RTK) anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon oral administration, iruplinalkib binds to and inhibits ALK tyrosine kinase, ALK fusion proteins, ALK point mutation variants ALK L1196M, ALK C1156Y, and EGFR L858R/T790M. Inhibition of ALK leads to the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors. Additionally, ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C154280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154280>	C200766	Therapeutic Ex-vivo-treated Autologous Central Memory T Cells|Autologous Tcm Cells	A preparation of autologous ex-vivo treated central memory T (Tcm) cells with potential immunostimulatory activity. Upon isolation and ex-vivo treatment through as an of yet not elucidated method, the therapeutic ex-vivo-treated autologous Tcm cells, upon reintroduction into the patient, can activate an antitumor immune response which may eradicate tumor cells.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C154281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154281>	C201497|C200766	Autologous Anti-HER2-CAR-4-1BB-CD3zeta-CD19t+-expressing Tcm-enriched T-lymphocytes|Autologous HER2(EQ) BBz/CD19t+ Tcm Cells|Autologous Memory Enriched HER2(EQ)BBzeta/CD19t+-expressing T-cells	A preparation of genetically modified autologous central memory (Tcm) enriched T-cells transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-human epidermal growth factor receptor 2 (HER2) single chain variable fragment (scFv) derived from trastuzumab, with a 4-1BB (CD137) costimulatory domain that is linked to the signaling domain of the T-cell antigen receptor complex zeta chain (CD3-zeta) (BBz), and truncated CD19 (CD19t), with potential immunostimulatory and antineoplastic activities. Upon intravenous infusion, Anti-HER2-CAR-4-1BB-CD19t+-expressing Tcm-enriched T-lymphocytes are directed against HER2-expressing cells, thereby inducing selective toxicity in HER2-expressing tumor cells. HER2, a receptor tyrosine kinase, is mutated or overexpressed in many tumor cell types, plays a significant role in tumor cell proliferation and tumor vascularization. The BBz costimulatory signaling domain enhances proliferation of T-cells and antitumor activity, while CD19t, a marker for transduction, is utilized to calculate CAR T-cell dosing and for CAR-expressing cell tracking. Tcm cells have the capacity for long-lived persistence and retain their ability to proliferate upon antigen re-encounter. The immunoglobulin G4 (IgG4) extracellular spacer contains a double mutation, (L235E;N297Q) (EQ) within the CH2 region to reduce Fc receptor recognition.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C154282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154282>	C2124	Fluorine F 18 Azafol|3'-Aza-2'-[(18)F]fluorofolic Acid|[18F]-azafol	A radioconjugate containing a folic acid receptor (FR; folate receptor) tracer labeled with fluorine F 18, with potential use for FR-expressing tumor imaging using positron emission tomography (PET). Upon administration of fluorine F 18 azafol, the azafol moiety selectively targets and binds to FR. This allows the visualization of tumor cells expressing FR using PET. FR is overexpressed on certain tumor cell types.			Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	NCI Drug Dictionary Terminology
C154283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154283>	C29639|C226473	Topical Ammonia-oxidizing Bacteria-based Probiotic Solution|AO Bacteria-containing Mist|AO+ Mist|AOB-based Probiotic Spray|Ammonia Oxidizing Bacteria-containing Probiotic Mist|Topical Probiotic Solution|Topical Probiotic Spray	A probiotic spray containing a live-cultured strain of ammonia-oxidizing bacteria (AOB), with potential skin restorative activity. Upon topical application of the AOB-based probiotic solution, the AOBs within the solution oxidize ammonia, thereby converting ammonia on your skin into nitric oxide and nitrite. AOB may potentially protect and restore the skin by preventing ammonia-mediated skin damage. AOB are a naturally-occurring bacteria found in ammonia-rich soil and water.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C154284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154284>	C28676|C129826	Allogeneic CD19CAR-transfected Cytokine-induced Killer Cells|Allogeneic CARCIK-CD19 (SY)|Allogeneic CARCIK-CD19 Cells|Transposon-manipulated Allogeneic CARCIK-CD19 Cells	A preparation of allogeneic cytokine-induced killer (CIK) cells derived from peripheral blood mononuclear cells (PBMCs) transfected with the Sleeping Beauty (SB) transposon, CD19CAR (CARCIK-CD19), with potential immunomodulatory and antineoplastic activities. CIK cells are CD3- and CD56-positive, non-major histocompatibility complex (MHC)-restricted, natural killer (NK)-like T-lymphocytes. Upon infusion following an allogeneic stem cell transplantation, the CARCIK-CD19 cells bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CIK cells may have enhanced cytotoxic activity compared to lymphokine-activated killer (LAK) cells. CD19 is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C154285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154285>	C28681|C129826	Autologous TAAs-loaded Autologous Dendritic Cells AV-GBM-1|AV GBM 1|AV-GBM-1|Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens|Autologous TAAs-loaded Autologous DCs AV-GBM-1|Neoantigen-loaded Autologous Dendritic Cells AV-GBM-1	A preparation of autologous dendritic cells (DCs) loaded with immunogenic tumor-associated antigens (TAAs) derived from cultured autologous glioblastoma multiforme (GBM) tumor cells, with potential immunostimulatory and antineoplastic activities. Upon administration, the autologous TAA-loaded DCs AV-GBM-1 expose the immune system to the GBM neoantigens, which results in a cytotoxic T-lymphocyte (CTL)-mediated immune response against the autologous GBM cells leading to GBM cell lysis.			Cell|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C154286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154286>	C2167|C129825	Rezivertinib|BPI 7711|BPI-7711|BPI7711|EGFR Mutant-specific Inhibitor BPI-7711|REZIVERTINIB	An orally available third-generation and selective inhibitor of certain epidermal growth factor receptor (EGFR) activating mutations, including the resistance mutations T790M and L858R, as well as exon 19 deletion, with potential antineoplastic activity. Upon administration, rezivertinib specifically and covalently binds to and inhibits selective EGFR mutations, with particularly high selectivity against the T790M mutation, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Compared to some other EGFR inhibitors, BPI-7711 may have therapeutic benefits in tumors with T790M-mediated drug resistance. This agent shows minimal activity against wild-type EGFR (wt EGFR), and does not cause dose-limiting toxicities that occur during the use of non-selective EGFR inhibitors, which also inhibit wt EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C154287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154287>	C201853	Sotorasib|AMG 510|AMG-510|AMG510|Lumakras|Lumykras|SOTORASIB	An orally available inhibitor of the specific KRAS mutation, p.G12C, with potential antineoplastic activity. Upon oral administration, sotorasib selectively targets, binds to and inhibits the activity of the KRAS p.G12C mutant. This may inhibit growth in KRAS p.G12C-expressing tumor cells. The KRAS p.G12C mutation is seen in some tumor cell types and plays a key role in tumor cell proliferation.	Sotorasib		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C154288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154288>	C200766	Autologous NY-ESO-1-redirected CRISPR-edited T Cells|Autologous NY-ESO-1 TCR-expressing CRISPR-edited (TCR and PD-1) T Cells|Autologous NY-ESO-1 Transgenic TCR-expressing Endogenous TCR-PD-1 Gene-edited T-cells|Autologous NYCE Cells|Autologous NYCE T Cells|Autologous NYCE T-cells|NY-ESO-1 TCR-PD-1-CRISPR-gene-edited Autologous T-lymphocytes|NY-ESO-1-redirected Autologous T Cells with CRISPR Edited Endogenous TCR and PD-1|NY-ESO-1-redirected Autologous T-cells with CRISPR-edited Endogenous TCR and PD-1|NY-ESO-1-redirected CRISPR Edited T Cells|NY-ESO-1-redirected CRISPR-TCRendo/PD1-edited T Cells	A preparation of human autologous T-lymphocytes that are transduced with a lentiviral vector (LV) encoding a T-cell receptor (TCR) specific for the tumor-associated antigen (TAA) cancer-testis antigen NY-ESO-1 and gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to eliminate endogenous TCR and programmed cell death 1 (PD-1) expression, with potential immunostimulating and antineoplastic activities. The CRISPR guide RNA (gRNA) specifically targets and binds to complementary sites on TCRalpha, TCRbeta and PD-1. In turn, Cas9 cleaves these specific DNA sites, thereby disrupting transcription. Upon isolation, transduction, electroporation with TCRalpha, TCRbeta and PD-1 gRNAs which are complexed to Cas9 RNA to disrupt expression of endogenous TCRalpha, TCRbeta and PD-1, expansion ex vivo, and reintroduction into the patient, the anti-NY-ESO-1 TCR LV-transduced CRISPR-edited autologous T-cells recognize and bind to NY-ESO-1-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of NY-ESO-1-positive tumor cells. NY-ESO-1, a tumor-associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types, and is not, or is minimally, expressed in normal, healthy cells. PD-1, an immune checkpoint receptor expressed on T-cells, plays a key role in tumor immune evasion by binding to its ligand programmed cell death ligand 1 (PD-L1) expressed on tumor cells. By removing PD-1 from T-cells, PD-1-mediated signaling is halted which may decrease T-cell exhaustion and may enhance T-cell activity against the NY-ESO-1-expressing tumor cells. Removal of endogenous TCR reduces TCR competition for expression, increases the persistence and function of the expressed transgenic TCR, enhances resistance to T-cell exhaustion and increases T-cell activity.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C154289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154289>	C275|C226473|C1892	Coffea arabica Extract|Coffee Bean Extract|Green Coffee Bean Extract|Green Coffee Beans Extract	An orally bioavailable dietary supplement composed of an extract from the beans of green coffee (Coffea arabica), which are unprocessed and unroasted, with potential anti-inflammatory, antioxidant and chemopreventive activities. Coffea arabica extract contain high amounts of phenolic compounds and their derivatives, such as chlorogenic acid (CGA), and alkaloids, such as caffeine. As many of the active components in the Coffea arabica are antioxidant compounds, upon administration, they scavenge free radicals, protect against oxidation of low-density lipoprotein (LDL), and inhibit cell damage due to reactive oxygen species (ROS). This inhibits oxidative stress and protects against DNA damage. The components in the extract also inhibit enzymes involved in inflammation, cell replication and DNA synthesis, and induce the expression of antioxidant enzymes. They also induce anti-inflammatory-mediated pathways, decrease nuclear factor Kappa-B (NF-kB) activation and decrease the expression of pro-inflammatory cytokines. This may inhibit growth and induce apoptosis of cancer cells. In addition, Coffea arabica extract upregulates the expression of anti-inflammatory adipokines (adipocytokines), such as adiponectin, and reduces the expression of pro-inflammatory adipokines, such as tumor necrosis factor-alpha (TNF-a), leptin and interleukin 6 (IL-6), thereby further preventing inflammation and inflammation-induced cancer. Adipokines are normally secreted by adipose tissue and play a key role in the regulation of glucose and fat metabolism, insulin sensitivity and inflammation.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C15428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15428>	C15429	Interdisciplinary Research|Interdisciplinary Studies|Multidisciplinary Collaboration|Multidisciplinary Research	Studies that bring together multiple scientific disciplines to address specific issues.			Research Activity	
C154290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154290>	C547	Somatostatin Antagonist|Somatostatin Receptor Antagonist	Any agent that binds to and antagonizes somatostatin receptors.			Chemical Viewed Functionally	
C154291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154291>	C29711	Peroxisome Proliferator-Activated Receptor Agonist|PPAR Agonist	Any agent that binds to and activates the peroxisome proliferator-activated (PPAR) receptor.			Chemical Viewed Functionally	
C154292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154292>	C78272	Nerve Growth Factor Mimetic	Any agent that mimics nerve growth factor (NGF).			Chemical Viewed Functionally	
C154293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154293>	C103514	Ga-68 NeoBOMB1 PET/MRI Positron Emission Tomography and Magnetic Resonance Imaging|68Ga NeoBOMB1 PET/MRI|Ga-68 NeoBOMB1 PET/MRI|Gallium Ga 68-NeoB PET/MRI|Gallium Ga-68 NeoBOMB1 PET/MRI	An imaging procedure that combines gallium-68-labelled NeoBomb1 PET with an MRI scan to overlay activity data onto detailed anatomic images.	Ga-68 NeoBOMB1 PET/MRI Positron Emission Tomography and Magnetic Resonance Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C154294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154294>	C103514	Ga-68 PSMA-R2 Positron Emission Tomography and Magnetic Resonance Imaging|68Ga PSMA-R2 PET/MRI|Ga-68 PSMA-R2 PET/MRI|Gallium Ga-68 PMSA-R2 PET/MRI	An imaging procedure that combines gallium-68-labelled PSMA-R2 with an MRI scan to overlay activity data onto detailed anatomic images.	Ga-68 PSMA-R2 Positron Emission Tomography and Magnetic Resonance Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C154295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154295>	C78272	Abrineurin|ABRINEURIN|N-L-Methionylneurotrophic Factor (Human Brain-derived)Dimer|Neurotrophic Factor (Human Brain-derived), N-L-methionyl-, Dimer				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C154296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154296>	C98083	Dapagliflozin Propanediol|D-Glucitol, 1,5-Anhydro-1-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-, (1S)-, Compd. with (2S)-1,2-propanediol, Hydrate (1:1:1)|DAPAGLIFLOZIN PROPANEDIOL|Dapagliflozin Propylene Glycol Hydrate|Dapagliflozin S-propylene Glycol Monohydrate|Farxiga	The propanediol form of dapagliflozin, a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. Upon administration, dapagliflozin selectively targets and inhibits SGLT2, thereby preventing the reabsorption of glucose by the kidneys.	Dapagliflozin Propanediol		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C154298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154298>	C148174	Histone H2 Gene|H2 Gene|H2 Histone Family Gene	A gene encoding the core histone protein histone H2.			Gene or Genome	
C154299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154299>	C154298	Histone H2A Gene|H2A Gene|H2A Histone Family Gene	A gene encoding the core histone protein histone H2A.			Gene or Genome	
C15429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15429>	C16203	Research Activity|Research|research study	Systematic investigation into a subject in order to discover facts, establish or revise a theory, or develop a plan of action based on the facts discovered.			Research Activity	
C1542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1542>	C2156	Pibrozelesin|Benzo(1,2-b:4,3-b')dipyrrole-1-carboxylic Acid, 8-(bromomethyl)-3,6,7,8-tetrahydro-2-methy-4-(((4-methyl-1-piperazinyl)carbonyl)oxy)-6-((5,6,7,-trimethoxy-1H-indol-2-yl)carbonyl)-, Methyl Ester (S)|Duocamycin B2 Analog|KW 2189|KW-2189|KW2189|PIBROZELESIN	A semisynthetic water-soluble derivative of the antineoplastic antibiotic duocarmycin B2.  Activated by carboxyl esterase, pibrozelesin alkylates DNA by binding to adenine-thymine (A-T)-rich sequences in the minor groove of DNA, thereby inhibiting DNA replication and inducing apoptosis.			Antibiotic|Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C154300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154300>	C154298	Histone H2B Gene|H2B Gene|H2B Histone Family Gene	A gene encoding the core histone protein histone H2B.			Gene or Genome	
C154301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154301>	C66883	Clopenthixol|1-Piperazineethanol, 4-(3-(2-Chloro-9H-thioxanthen-9-ylidene)propyl)-|4-(3-(2-Chlorothioxanthen-9-ylidene)propyl)-1-piperazineethanol|CLOPENTHIXOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C154302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154302>	C148174	Histone H3 Gene|H3 Gene|H3 Histone Family Gene	A gene encoding the core histone protein histone H3.	Histone H3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Genes/Proteins Terminology
C154303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154303>	C148174	Histone H4 Gene|H4 Gene|H4 Histone Family Gene	A gene encoding the core histone protein histone H4.			Gene or Genome	
C154305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154305>	C36327	Histone Gene Mutation	A change in the sequence of a histone family gene.	Histone Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154306>	C154305	Histone H3 Gene Mutation|H3 Gene Mutation|H3 Histone Family Gene Mutation|H3 Mutation|Histone H3 Mutation	A change in the sequence of a histone H3 family gene.	Histone H3 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154307>	C70700	Enrichment|Enrich	Any of various techniques designed to select or increase a target item in a mixed sample.			Laboratory Procedure	
C154308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154308>	C27993	en Masse	As a group; all together.			Qualitative Concept	
C154309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154309>	C105758	Do Not Process	An indication that a biospecimen should not be subjected to any treatment.			Qualitative Concept	
C15430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15430>	C15431	Peripheral Blood Stem Cell Transplantation|PBPC transplantation|PBSCT|PBSCT|PERIPHERAL BLOOD STEM CELL TRANSPLANT|Peripheral Blood|Peripheral Blood Progenitor Cell Transplantation|Peripheral Stem Cell Support|Peripheral Stem Cell Transplant|Peripheral Stem Cell Transplantation|peripheral stem cell support|peripheral stem cell transplantation	A method of hematopoietic reconstitution utilizing stem cells harvested from the circulating blood of a patient or donor. Peripheral blood stem cell transplantation (PBSCT) is used for the treatment of certain blood disorders, following partial or complete bone marrow ablation, or following high dose chemotherapy or radiation treatment for cancer. Immature circulating blood cells, similar to stem cells in the bone marrow, are removed before treatment. The cells are then given to the patient after treatment to help the bone marrow recover and continue producing healthy blood cells. Transplantation may be autologous (the patient's own blood cells are used), allogeneic (blood cells are donated by someone else), or syngeneic (blood cells are donated by an identical twin).	Peripheral Blood Stem Cell Transplantation		Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|HL Authorized Value Terminology|HL Stem Cell Transplant Table|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C154310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154310>	C97927|C154306	H3C2 Gene Mutation|H3 Clustered Histone 2 Gene Mutation|H3/l Gene Mutation|H3FL Gene Mutation|H3b Gene Mutation|HIST1H3B Gene Mutation|HIST1H3B Gene Mutation|Histone Cluster 1 H3 Family Member B Gene Mutation	A change in the sequence of the HIST1H3B gene.	HIST1H3B Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154311>	C219646|C154310	H3C2 NM_003537.3:c.83A>T|H3 Clustered Histone 2 c.83A>T|H3/l c.83A>T|H3C2 c.83A>T|H3FL c.83A>T|H3b c.83A>T|HIST1H3B NM_003537.3:c.83A>T|HIST1H3B NM_003537.3:c.83A>T|HIST1H3B c.83A>T|Histone Cluster 1 H3 Family Member B Gene c.83A>T|NM_003537.3:c.83A>T	A nucleotide substitution at position 83 of the coding sequence of the HIST1H3B gene where adenine has been mutated to thymine.	HIST1H3B NM_003537.3:c.83A>T		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154312>	C97927|C154306	H3C3 Gene Mutation|H3 Clustered Histone 3 Gene Mutation|H3/c Gene Mutation|H3FC Gene Mutation|H3c Gene Mutation|HIST1H3C Gene Mutation|HIST1H3C Gene Mutation|Histone Cluster 1 H3 Family Member C Gene Mutation	A change in the sequence of the HIST1H3C gene.	HIST1H3C Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154313>	C219646|C154312	H3C3 NM_003531.2:c.83A>T|H3 Clustered Histone 3 c.83A>T|H3/c c.83A>T|H3C3 c.83A>T|H3FC c.83A>T|H3c c.83A>T|HIST1H3C NM_003531.2:c.83A>T|HIST1H3C NM_003531.2:c.83A>T|HIST1H3C c.83A>T|Histone Cluster 1 H3 Family Member C Gene c.83A>T|NM_003531.2:c.83A>T	A nucleotide substitution at position 83 of the coding sequence of the HIST1H3C gene where adenine has been mutated to thymine.	HIST1H3C NM_003531.2:c.83A>T		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154314>	C26788	Autosomal Recessive Cytochrome B-Positive Chronic Granulomatous Disease Type I|CDG1|Chronic Granulomatous Disease due to Deficiency of NCF-1	An autosomal recessive form of chronic granulomatous disease caused by mutation(s) in the NCF1 gene, encoding neutrophil cytosol factor 1.			Disease or Syndrome	Cellosaurus Disease Terminology
C154315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154315>	C85865|C26788	X-linked Chronic Granulomatous Disease|CDGX	An X-linked recessive form of chronic granulomatous disease caused by mutation(s) in the CYBB gene, encoding cytochrome b-245 beta chain.			Disease or Syndrome	Cellosaurus Disease Terminology
C154316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154316>	C82341|C176696	Spinocerebellar Ataxia Type 12|SCA12	An autosomal dominant sub-type of spinocerebellar ataxia caused by mutation(s) in the PPP2R2B gene, encoding serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B beta isoform. It presents with characteristic action tremors in the upper limbs, followed by other movement abnormalities.			Disease or Syndrome	Cellosaurus Disease Terminology
C154317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154317>	C97927|C154306	H3C4 Gene Mutation|H3 Clustered Histone 4 Gene Mutation|H3/b Gene Mutation|H3FB Gene Mutation|H3d Gene Mutation|HIST1H3D Gene Mutation|HIST1H3D Gene Mutation|Histone Cluster 1 H3 Family Member D Gene Mutation	A change in the sequence of the HIST1H3D gene.	HIST1H3D Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154318>	C219646|C154317	H2C4 NM_003530.4:c.83A>T|H3 Clustered Histone 4 c.83A>T|H3/b c.83A>T|H3C4 c.83A>T|H3FB c.83A>T|H3d c.83A>T|HIST1H3D NM_003530.4:c.83A>T|HIST1H3D NM_003530.4:c.83A>T|HIST1H3D c.83A>T|Histone Cluster 1 H3 Family Member D Gene c.83A>T|NM_003530.4:c.83A>T	A nucleotide substitution at position 83 of the coding sequence of the HIST1H3D gene where adenine has been mutated to thymine.	HIST1H3D NM_003530.4:c.83A>T		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154319>	C97927|C154306	H3-3A Gene Mutation|H3 Histone Family Member 3A Gene Mutation|H3.3 Histone A Gene Mutation|H3.3A Gene Mutation|H3F3 Gene Mutation|H3F3A|H3F3A Gene Mutation	A change in the sequence of the H3-3A gene.	H3F3A Gene Mutation		Cell or Molecular Dysfunction	CRF8 Pathology Review Targeted Genomics Table|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15431>	C165194|C15388|C15342	Hematopoietic Cell Transplantation|HCT|HEMATOPOIETIC STEM CELL TRANSPLANT|HSCT|HSCT|Hematopoietic Stem Cell Infusion|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Transplantation|SCT|Stem Cell Transplant|Stem Cell Transplant|Stem Cell Transplant|Stem Cell Transplant|Stem Cell Transplant|Stem Cell Transplantation, NOS|stem cell transplantation	A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases.	Hematopoietic Cell Transplantation		Therapeutic or Preventive Procedure	ALL Authorized Value Terminology|ALL Non-protocol Therapy Table|ALL Survival Characteristics Table|AML Authorized Value Terminology|AML Survival Characteristics Table|CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology|EWS Authorized Value Terminology|EWS Non-Protocol Therapy Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Non-protocol Therapy Table|HL Survival Characteristics Table|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C154320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154320>	C219646|C154319	H3-3A NM_002107.4:c.83A>T|H3 Histone Family Member 3A c.83A>T|H3-3A c.83A>T|H3.3 Histone A c.83A>T|H3.3A c.83A>T|H3F3 c.83A>T|H3F3A NM_002107.4:c.83A>T|H3F3A NM_002107.4:c.83A>T|H3F3A c.83A>T|NM_002107.4:c.83A>T	A nucleotide substitution at position 83 of the coding sequence of the H3-3A gene where adenine has been mutated to thymine.	H3F3A NM_002107.4:c.83A>T		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154321>	C4104|C148130	Locally Advanced Squamous Cell Carcinoma	A squamous cell carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C154322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154322>	C203515|C162882|C162758	Locally Advanced Sinonasal Squamous Cell Carcinoma|Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Locally Advanced Squamous Cell Carcinoma of the Nasal Cavity and Paranasal Sinus|Locally Advanced Squamous Cell Carcinoma of the Nasal Cavity and/or Paranasal Sinuses	A squamous cell carcinoma that arises from the nasal cavity and/or paranasal sinuses and has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C154324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154324>	C54293	Sinonasal Poorly Differentiated Carcinoma|Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma|Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma|Poorly Differentiated Carcinoma of the Nasal Cavity and/or Paranasal Sinuses	A poorly differentiated carcinoma that arises from the nasal cavity and/or paranasal sinuses.	Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C154325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154325>	C63719|C63524|C63522|C63502|C63361|C63360|C203473|C191713|C173974|C159901|C159900|C159893|C159462|C159458|C159454|C156290|C140180	Dabrafenib/Trametinib Regimen|Dabrafenib + Trametinib|Dabrafenib Plus Trametinib|Dabrafenib and Trametinib|Dabrafenib-Trametinib Regimen|Dabrafenib/Trametinib|Tafinlar-Mekinist|Tafinlar/Mekinist	A regimen consisting of dabrafenib and trametinib that can be used in the treatment of cutaneous melanomas, non-small cell lung cancers (NSCLCs), anaplastic carcinoma, central nervous system (CNS), esophageal and esophagogastric junction and gastric cancers, ovarian, fallopian tube and primary peritoneal cancers, follicular, papillary and Hurthle cell thyroid carcinomas, and gallbladder or cholangiocarcinoma, ampullary, small bowel, and pancreatic adenocarcinomas, occult primary adenocarcinoma and squamous cell carcinoma, extrapulmonary poorly differentiated neuroendocrine carcinoma/large or small cell carcinoma/mixed neuroendocrine-non-neuroendocrine neoplasm, salivary gland tumors, gastrointestinal stromal tumors (GIST), and hairy cell leukemia.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C154326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154326>	C63524|C63360	Binimetinib/Encorafenib Regimen|Binimetinib and Encorafenib|Binimetinib/Encorafenib|Braftovi/Mektovi|Encorafenib + Binimetinib|Encorafenib Plus Binimetinib|Encorafenib-Binimetinib|Encorafenib-Binimetinib Regimen|Encorafenib/Binimetinib|Encorafenib/Binimetinib Regimen	A regimen consisting of binimetinib and encorafenib that can be used for the treatment of melanoma and non-small cell lung cancer (NSCLC).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C154327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154327>	C63524|C140180	Cobimetinib/Vemurafenib Regimen|Cobimetinib and Vemurafenib|Cobimetinib/Vemurafenib|Vemurafenib + Cobimetinib|Vemurafenib Plus Cobimetinib|Vemurafenib-Cobimetinib|Vemurafenib-Cobimetinib Regimen|Vemurafenib/Cobimetinib Regimen	A regimen consisting of vemurafenib and cobimetinib that can be used for the treatment of melanoma and central nervous system (CNS) cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C154328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154328>	C214440	Seclidemstat|LSD1 Inhibitor SP-2577|SECLIDEMSTAT|SP 2577|SP-2577|SP2577	An orally available, reversible, noncompetitive inhibitor of lysine-specific demethylase 1 (LSD1, or KDM1A), with potential antineoplastic activity. Upon oral administration, seclidemstat reversibly inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the di- and mono-methylated forms of lysine at position 4 of histone 3 (H3K4) to mono- and unmethylated H3K4, respectively. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. In addition, LSD1 demethylates mono- or di-methylated H3K9 which increases gene expression of tumor promoting genes; inhibition of LSD1 promotes H3K9 methylation and decreases transcription of these genes.	Seclidemstat		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C154329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154329>	C19683	Smoking	The act of puffing and/or inhaling the combustion products of a substance so as to be tasted and absorbed into the bloodstream.	Smoking		Individual Behavior	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology|GDC Deprecated Terminology|GDC Terminology
C15432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15432>	C20161	Surveillance, Epidemiology, and End Results Program|SEER|SEER-Surveillance, Epidemiology, and End Results|Surveillance, Epidemiology, and End Results Program (SEER)	A program of the National Cancer Institute that provides information on cancer statistics in an effort to reduce the cancer burden among the U.S. population.			Governmental or Regulatory Activity	
C154330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154330>	C16144	Biochemotherapy|Biotherapy and Chemotherapy|Combined Biotherapy and Chemotherapy	A drug treatment regime that combines chemotherapy drugs with biological or immunological agents.			Therapeutic or Preventive Procedure	
C154331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154331>	C25161	Anatomical Therapeutic Chemical Classification System|ATC|ATC System|WHO ATC CLASSIFICATION SYSTEM	A World Health Organization (WHO) classification system for medicinal substances where active substances are divided into different groups according to the organ or system on which they act and their therapeutic, pharmacological, and chemical properties. Drugs are classified in groups at five different levels.			Classification	CDISC Dictionary Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154332>	C1966	Near Infrared Imaging Agent HS-196|HS 196|HS-196|HS196|HSP90 Inhibitor-linked NIR Probe HS-196|NIR-tethered Hsp90 Inhibitor HS-196	An imaging agent containing a human heat shock protein 90 (Hsp90) inhibitor connected by a linker to a near infrared (NIR) fluorescent dye. Upon intravenous administration, HS-196 selectively and competitively binds to Hsp90 in cells. As Hsp90 is upregulated in a variety of tumor cells, the accumulation of the NIR-tethered imaging agent allows for in vivo detection due to enhanced uptake of HS-196. Hsp90 is a molecular chaperone that plays a key role in the conformational maturation, stability and function of oncogenic signaling proteins, such as HER2/ERBB2, AKT, RAF1, BCR-ABL and mutated p53, as well as many other molecules that are important in cell cycle regulation and/or immune responses.	Near Infrared Imaging Agent HS-196		Indicator, Reagent, or Diagnostic Aid	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C154333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154333>	C8688|C4340|C178554	Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified	The reemergence of peripheral T-cell lymphoma, not otherwise specified after a period of remission.	Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C154335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154335>	C39750	MGMT-Methylated Glioblastoma|Methylated MGMT Glioblastoma	A glioblastoma characterized by the presence of DNA methylation in the promoter region of the MGMT gene. It is associated with improved survival.	MGMT-Methylated Glioblastoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C154336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154336>	C27993	Firm	Having a structure or consistency that strongly resists stress or pressure.			Qualitative Concept	
C154337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154337>	C36920	Neoplastic Corticotroph Cell with Abundant Secretory Granules	A neoplastic basophilic PAS-positive and ACTH-positive cell with an abundance of secretory granules seen at the ultrastructural level.			Cell	
C154338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154338>	C36920	Neoplastic Corticotroph Cell with Scarce Secretory Granules	A neoplastic faintly basophilic or chromophobic PAS-positive and weakly ACTH-positive cell with scant and small secretory granules seen at the ultrastructural level.			Cell	
C154339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154339>	C7462	Densely Granulated Corticotroph Pituitary Neuroendocrine Tumor|Densely Granulated Corticotroph PitNET/Adenoma|Densely Granulated Corticotroph Pituitary Neuroendocrine Tumor/Adenoma	A corticotroph pituitary neuroendocrine tumor composed of basophilic PAS-positive cells that are diffusely and strongly positive for ACTH, consistent with the abundance of secretory granules seen at the ultrastructural level. (WHO)			Neoplastic Process	
C15433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15433>	C15747	Nutritional Support|Nutrition Therapy|Nutritional Care|Nutritional Therapy	Administration of essential nutrients to a patient utilizing methods other than oral feedings.	Nutritional Support		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C154340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154340>	C7462	Sparsely Granulated Corticotroph Pituitary Neuroendocrine Tumor|Sparsely Granulated Corticotroph PitNET/Adenoma|Sparsely Granulated Corticotroph Pituitary Neuroendocrine Tumor/Adenoma	A corticotroph pituitary neuroendocrine tumor composed of faintly basophilic or chromophobic PAS-positive cells with weak or patchy positivity for ACTH, consistent with the scant, small secretory granules seen ultrastructurally. (WHO)			Neoplastic Process	
C154341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154341>	C35867	Crooke Hyaline Change	Intracytoplasmic accumulation of cytokeratin.			Finding	
C154342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154342>	C7462	Crooke Cell Tumor|Crooke Cell Adenoma	A corticotroph pituitary tumor composed of cells with Crooke hyaline change. Ring-like cytokeratin expression is typical of these neoplasms. ACTH expression is dislocated to the cell periphery and juxtanuclear region. Ultrastructurally, intermediate filaments are arranged in a ring-like pattern. (WHO)			Neoplastic Process	
C154343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154343>	C97927	USP8 Gene Mutation|HumORF8 Gene Mutation|UBPY Gene Mutation|Ubiquitin Specific Protease 8 Gene Mutation	A change in the nucleotide sequence of the USP8 gene.			Cell or Molecular Dysfunction	
C15434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15434>	C15664	Technology Transfer	The process of converting scientific findings from research laboratories into useful products by the commercial sector.			Phenomenon or Process	
C15435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15435>	C15411	Transfer Factor Therapy|therapy, transfer factor	The administation of therapeutic factors from an immune individual to a usually immunocompromised individual.			Therapeutic or Preventive Procedure	
C15436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15436>	C51976	Mind-Body Intervention Procedure|Mind-Body Interventions|Mind-Body Medicine	A complementary health intervention that manipulates the body or uses mindfullness practices.	Mind-Body Intervention Procedure		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C15437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15437>	C15824	Nutrition Research, Food and Water Contaminants	The study of the role of food and water contaminants in cancer causation or prevention and in general health.			Research Activity	
C154381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154381>	C2124	Gallium Ga 68-NeoB|68Ga-NeoB|Gallium Ga 68 DOTA-NeoBOMB1|Gallium Ga 68 NeoBOMB1|[68Ga]-NeoB	A radioconjugate consisting of the gastrin-releasing peptide receptor (GRPR) antagonist, NeoBOMB1, linked via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope gallium Ga 68, with potential imaging activity during positron emission topography/computed tomography (PET/CT). Upon administration, gallium Ga 68-DOTA-NeoBOMB1 binds to GRPRs present on cancer cells. Upon binding, this radioconjugate can be used to quantify tumor uptake of NeoBOMB1 using PET/CT. GRPR, also known as bombesin receptor subtype 2, is a G-protein-coupled receptor that is overexpressed in some cancer types.	Gallium Ga 68-NeoB		Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C154382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154382>	C2124	Gallium Ga 68 PSMA-R2|68Ga-PSMA-R2|68GaPSMA-R2|Gallium-68 PSMA-R2|PSMA-R2 GALLIUM GA-68	A radioconjugate composed of PSMA-R2, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the beta-emitting radioisotope gallium Ga 68, with potential imaging activity during positron emission topography/computed tomography (PET/CT). Upon administration of gallium Ga 68 PSMA-R2, the PSMA-R2 moiety targets and binds to PSMA-expressing tumor cells. This allows for visualization of PSMA-expressing cells upon imaging. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on the majority of prostate tumor cells.	Gallium Ga 68 PSMA-R2		Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C154383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154383>	C171283	Aerosol Foam Dosage Form Category|Foam	A type of semi-solid pharmaceutical dose form consisting of a large volume of gas dispersed in a liquid or sometimes a solid phase.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C154384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154384>	C171282	Block Dosage Form Category|Block	A type of solid pharmaceutical dose form consisting of a large, compact mass, usually formed by compression of the component material into a cuboid or similar shape.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C15438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15438>	C15986|C15632|C15262	Cancer Immunotherapy|Immuno-Chemotherapy|Immunotherapy, Cancer, General|immunotherapy for cancer	Use of techniques, biologically active substances, and procedures to enhance or restore the ability of the host immune system to fight cancer. Also used to lessen adverse effects that may be caused by some cancer treatments.			Therapeutic or Preventive Procedure	
C15439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15439>	C15426	PDQ Information System|PDQ|PDQ|Physician Data Query|Physician Data Query				Intellectual Product	
C1543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1543>	C1906	Peptide 946|peptide 946				Amino Acid, Peptide, or Protein|Immunologic Factor	
C154403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154403>	C43432	Healthcare Problem List	A list of health problems or conditions compiled through healthcare encounters.			Intellectual Product	
C154404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154404>	C16275	PCORnet-defined Condition Algorithm	An algorithm designed to identify health conditions as defined by the National Patient-Centered Clinical Research Network.			Intellectual Product	
C154405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154405>	C25687	Active State|Active	Being in a state of progress or motion.			Qualitative Concept	
C154406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154406>	C171282	Cachet Dosage Form Category|Cachet	A type of solid pharmaceutical dose form consisting of a disc inside which a single dose of the active substance(s) is enclosed. Capsule is excluded.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C154407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154407>	C25687	Inactive|Inactive State	Not progressing or moving.			Qualitative Concept	FDA CDRH GUDID Terminology
C154408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154408>	C49474	ICD-9-CM/PCS|ICD-9-PCS|International Classification of Diseases, Ninth Revision, Clinical Modification/Procedure Coding System	The International Classification of Diseases, Ninth Revision, Clinical Modification/Procedure Coding System is the U.S. health system's adaptation of international ICD-9 standard list of six-character alphanumeric codes used in hospital inpatient settings for inpatient procedure coding.			Classification	
C15440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15440>	C15849	High-LET Neutron Therapy|NEUTRON Therapy|fast-neutron beam radiation|neutron therapy|therapy, high-LET neutron|therapy, neutron	A type of radiation therapy that utilizes cyclotron-generated neutrons to destroy tumor cells via direct interaction.	High-LET Neutron Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C154410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154410>	C49474	ICD-10-CM/PCS|ICD-10-PCS|International Classification of Diseases, Tenth Revision, Clinical Modification/Procedure Coding System	The International Classification of Diseases, Tenth Revision, Clinical Modification/Procedure Coding System is the U.S. health system's adaptation of international ICD-10 standard list of six-character alphanumeric codes used in hospital inpatient settings for inpatient procedure coding.			Classification	
C154412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154412>	C49474	ICD-11-CM/PCS|ICD-11-PCS|International Classification of Diseases, Eleventh Revision, Clinical Modification/Procedure Coding System	The International Classification of Diseases, Eleventh Revision, Clinical Modification/Procedure Coding System is the U.S. health system's adaptation of international ICD11 standard list of six-character alphanumeric codes used in hospital inpatient settings for inpatient procedure coding.			Classification	
C154413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154413>	C49474	International Classification of Diseases, Eleventh Revision, Clinical Modification|ICD-11-CM	An extension of the ICD-11 created by the U.S. National Center for Health Statistics so that the system could be used to capture more morbidity data.			Classification	
C154414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154414>	C21270	Human Phenotype Ontology|HPO	A standardized vocabulary of phenotypic abnormalities encountered in human disease.			Intellectual Product	
C154415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154415>	C20181	Revenue	The income that a government or company receives regularly.			Classification	
C154416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154416>	C16048	Global Medical Device Nomenclature|GMDN	A system of internationally agreed generic descriptors used to identify all medical device products.			Intellectual Product	
C154417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154417>	C27993	Underlying	Situated beneath, or the basic or root cause of something.			Qualitative Concept	
C154418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154418>	C81195	Month Imputed	An imputed date that includes the month of observation.			Temporal Concept	
C154419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154419>	C17357	Genderqueer|GENDER QUEER|Gender Expansive|Gender Non-conforming|Queer	An individual who does not subscribe to conventional gender distinctions but identifies with neither, both, or a combination of male and female genders. IMPORTANT NOTICE: The NCI Thesaurus contains biomedical terminologies that NCI does not own or control. This concept contains gender-related content that does not comply with Executive Order 14168.			Organism Attribute	CDISC SDTM Gender Identity Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15441>	C61063	Interleukin-2/Poly ICLC|IL-2/Poly ICLC			Obsolete_Concept	Therapeutic or Preventive Procedure	
C154420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154420>	C198618	Other Gender|Gender Something Else|Other|Other gender|Something Else	A response indicating that an individual identifies with a gender category not included in the existing list of values. IMPORTANT NOTICE: The NCI Thesaurus contains biomedical terminologies that NCI does not own or control. This concept contains gender-related content that does not comply with Executive Order 14168.			Organism Attribute	Operational Ontology for Radiation Oncology Prostate Cancer Terminology|SeroNet Authorized Values|SeroNet Research Participant Metadata|SeroNet Study Descriptors
C154422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154422>	C48312	Insurance Claim|Claim	Notification to an insurance company requesting payment of an amount due under the terms of the policy.			Conceptual Entity	
C154423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154423>	C25404	Unable to Classify	An inability to assign something to the existing classifications or categories.			Activity	
C154424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154424>	C19696	Adult Foster Home	A private home or other facility that provides care to persons of adult age in a home-like environment.			Functional Concept	
C154425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154425>	C21541	Assisted Living Facility	A residence facility for individuals who are able to attend to most of their personal and medical care, but who need oversight and support services, including some on-sight medical services.			Health Care Related Organization	
C154426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154426>	C203704|C201881	Other Acute Inpatient Hospital	An inpatient acute-care hospital not elsewhere specified.			Health Care Related Organization	
C154427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154427>	C21541	Residential Care Facility|Board and Care Home|Residential Facility|Residential Institution	A residential group facility for individuals who are able to attend to most of their personal and medical care. Generally, residents receive personal care and meals and have staff available around the clock, but nursing and medical care usually are not provided on site.			Health Care Related Organization	
C154428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154428>	C21541	Skilled Nursing Facility|Nursing Facility	A specialized, short-term care facility, that offers care (often including rehab) for a previously hospitalized patient as they transition back to their home or maybe eventually a nursing home.			Health Care Related Organization	
C154429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154429>	C7462|C4348	Non-Functioning Corticotroph Pituitary Neuroendocrine Tumor|Nonfunctional Corticotroph Adenoma|Nonfunctioning Corticotroph Adenoma|Silent Corticotroph Adenoma	Corticotroph pituitary neuroendocrine tumor not associated with a hormonal syndrome.			Neoplastic Process	
C15442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15442>	C61063	Interleukin-2/Zidovudine|IL-2/ZDV			Obsolete_Concept	Therapeutic or Preventive Procedure	
C154430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154430>	C94601|C64982	Definitive Surgical Resection	Surgical resection that has been chosen as the best alternative for treatment, considering all available therapeutic options.			Therapeutic or Preventive Procedure	
C154431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154431>	C154429|C154339	Non-Functioning Densely Granulated Corticotroph Pituitary Neuroendocrine Tumor|Densely Granulated Nonfunctional Corticotroph Adenoma|Densely Granulated Silent Corticotroph Adenoma|Non-Functioning Densely Granulated Corticotroph Adenoma|Nonfunctional Corticotroph Adenoma Type 1|Silent Corticotroph Adenoma Type 1	A densely granulated corticotroph pituitary neuroendocrine tumor not associated with a hormonal syndrome.			Neoplastic Process	
C154432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154432>	C154429|C154340	Non-Functioning Sparsely Granulated Corticotroph Pituitary Neuroendocrine Tumor|Non-Functioning Sparsely Granulated Corticotroph Adenoma|Nonfunctional Corticotroph Adenoma Type 2|Silent Corticotroph Adenoma Type 2|Sparsely Granulated Nonfunctional Corticotroph Adenoma|Sparsely Granulated Silent Corticotroph Adenoma	A sparsely granulated corticotroph pituitary neuroendocrine tumor not associated with a hormonal syndrome.			Neoplastic Process	
C154433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154433>	C171282	Capsule Dose Form Category|Capsule|Capsule	A type of solid pharmaceutical dose form consisting of a shell inside which a single dose of the active substance(s) is enclosed. Cachet is excluded.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology|PQ/CMC Basic Solid Dose Form Terminology
C154434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154434>	C171283	Cement Dosage Form Category|Cement	A type of semi-solid pharmaceutical dose form that hardens after application to form a seal or bond.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C154435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154435>	C154551	Collodion Dosage Form Category|Collodion	A type of liquid pharmaceutical dose form usually consisting of a solution of pyroxylin in ether and ethanol.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C154437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154437>	C154551	Concentrated Solution Dosage Form Category|Concentrate	A type of liquid pharmaceutical dose form consisting of a concentrated preparation that must be diluted before administration.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C154438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154438>	C171283	Cream Dosage Form Category|Cream	A type of semi-solid pharmaceutical dose form consisting of an oil-in-water or water-in-oil emulsion.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C15443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15443>	C15850|C104919	Low-LET Cobalt-60 Gamma Ray Therapy	Radiation therapy using low energy cobalt-60 gamma rays.	Low-LET Cobalt-60 Gamma Ray Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C154440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154440>	C213472|C212990|C155700	Bosutinib Monohydrate|3-Quinolinecarbonitrile, 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-, Hydrate (1:1)|BOSUTINIB MONOHYDRATE|Bosulif|Bosulif|SKI-606 Monohydrate	The monohydrate form of bosutinib, a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype.	Bosutinib Monohydrate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C154441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154441>	C7376|C154442	Resectable Pleural Malignant Mesothelioma|Resectable Malignant Pleural Mesothelioma	A malignant mesothelioma of the pleura that is amenable to surgical resection.	Resectable Malignant Pleural Mesothelioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C154442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154442>	C4456|C150602	Resectable Malignant Mesothelioma	Malignant mesothelioma that is amenable to surgical resection.			Neoplastic Process	
C154443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154443>	C4456|C27359	Unresectable Malignant Mesothelioma	Malignant mesothelioma that is not amenable to surgical resection.			Neoplastic Process	
C154444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154444>	C7376|C179420|C154443	Unresectable Pleural Malignant Mesothelioma	Malignant mesothelioma of the pleura that is not amenable to surgical resection.	Unresectable Pleural Malignant Mesothelioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C154445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154445>	C78275|C123418	Rivipansel Sodium|PF-06460031-02|RIVIPANSEL SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C154446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154446>	C118970	CDISC Clinical Classification CDRS-R Test Name Terminology|CC-CDRS-R TEST|CDRS1TN|Children's Depression Rating Scale, Revised Clinical Classification Test Name	Test names of clinical classification questions associated with the Children's Depression Rating Scale, Revised (CDRS-R) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154447>	C118970	CDISC Clinical Classification CDRS-R Test Code Terminology|CC-CDRS-R TESTCD|CDRS1TC|Children's Depression Rating Scale, Revised Clinical Classification Test Code	Test codes of clinical classification questions associated with the Children's Depression Rating Scale, Revised (CDRS-R) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154448>	C118970	CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CC-UHDRS 1999 Version TEST|UHDR1TN|Unified Huntington's Disease Rating Scale '99 Clinical Classification Test Name	Test names of clinical classification questions associated with the Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154449>	C118970	CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CC-UHDRS 1999 Version TESTCD|UHDR1TC|Unified Huntington's Disease Rating Scale '99 Clinical Classification Test Code	Test codes of clinical classification questions associated with the Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15444>	C15313	Low-LET Photon Therapy	Radiation therapy using low energy photons.	Low-LET Photon Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C154450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154450>	C100110	CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|FAC100TN|Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank Questionnaire Test Name|QS-FACIT-Dyspnea Scale 33 Item Bank Version TEST	Test names of questionnaire questions associated with the Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154451>	C100110	CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|FAC100TC|Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank Questionnaire Test Code|QS-FACIT-Dyspnea Scale 33 Item Bank Version TESTCD	Test codes of questionnaire questions associated with the Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154452>	C100110	CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|FAC006TN|Functional Assessment of Cancer Therapy-Bladder Version 4 Questionnaire Test Name|QS-FACT-BL Version 4 TEST	Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154453>	C100110	CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|FAC006TC|Functional Assessment of Cancer Therapy-Bladder Version 4 Questionnaire Test Code|QS-FACT-BL Version 4 TESTCD	Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154454>	C100110	CDISC Questionnaire NSCLC-SAQ Version 1.0 Test Name Terminology|NSCLC1TN|Non-Small Cell Lung Cancer Symptom Assessment Questionnaire v1.0 Questionnaire Test Name|QS-NSCLC-SAQ Version 1.0 TEST	Test names of questionnaire questions associated with the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire v1.0 (NSCLC-SAQ Version 1.0) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154455>	C100110	CDISC Questionnaire NSCLC-SAQ Version 1.0 Test Code Terminology|NSCLC1TC|Non-Small Cell Lung Cancer Symptom Assessment Questionnaire v1.0 Questionnaire Test Code|QS-NSCLC-SAQ Version 1.0 TESTCD	Test codes of questionnaire questions associated with the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire v1.0 (NSCLC-SAQ Version 1.0) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154456>	C100110	CDISC Questionnaire SMDDS Version 1.0 Test Name Terminology|QS-SMDDS Version 1.0 TEST|SMDDS1TN|Symptoms of Major Depressive Disorder Scale v1.0 Questionnaire Test Name	Test names of questionnaire questions associated with the Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154457>	C100110	CDISC Questionnaire SMDDS Version 1.0 Test Code Terminology|QS-SMDDS Version 1.0 TESTCD|SMDDS1TC|Symptoms of Major Depressive Disorder Scale v1.0 Questionnaire Test Code	Test codes of questionnaire questions associated with the Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154458>	C211913	CDRS-R Clinical Classification Question	A question associated with the CDRS-R clinical classification.			Intellectual Product	
C154459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154459>	C211913	UHDRS 1999 Version Clinical Classification Question	A question associated with the UHDRS 1999 Version clinical classification.			Intellectual Product	
C15445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15445>	C49236	Hormone Therapy|Chemotherapy-Hormones/Steroids|Endocrine Therapy|Hormonal|Hormonal Therapy|Hormonal Treatment|Hormonal therapy|Hormones|endocrine therapy|hormonal therapy|hormone therapy|hormone treatment	Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level.	Hormone Therapy		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C154460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154460>	C211913	FACIT-Dyspnea Scale 33 Item Bank Version Questionnaire Question	A question associated with the FACIT-Dyspnea Scale 33 Item Bank Version questionnaire.			Intellectual Product	
C154461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154461>	C211913	FACT-BL Version 4 Questionnaire Question	A question associated with the FACT-BL Version 4 questionnaire.			Intellectual Product	
C154462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154462>	C211913	NSCLC-SAQ Version 1.0 Questionnaire Question	A question associated with the NSCLC-SAQ Version 1.0 questionnaire.			Intellectual Product	
C154463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154463>	C211913	SMDDS Version 1.0 Questionnaire Question	A question associated with the SMDDS Version 1.0 questionnaire.			Intellectual Product	
C154464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154464>	C154551	Drop Dosage Form Category	A type of liquid pharmaceutical dose form that may be a dispersion, an emulsion, a solution or a suspension, and that is administered in small volumes by instillation; to be used only when further details of the specific form (e.g. dispersion, emulsion, solution, suspension) are unknown.			Classification	
C154465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154465>	C150386	Drug Delivery System Category|System	A type of pharmaceutical dose form consisting of one or more components that are used to deliver active substance(s) in a specified manner, usually with a modified release mechanism, after administration to a specified location on or in the body; to be used only where more specific terms are not applicable.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C154466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154466>	C154551	Emulsion Dosage Form Category|Emulsion	A type of liquid pharmaceutical dose form consisting of a stable dispersion of non-miscible liquids; it consists either of oil droplets in an aqueous continuous phase (oil-in-water emulsion) or aqueous droplets in an oily continuous phase (water-in-oil emulsion); for colloidal dispersions (droplets with a nominal diameter less than approximately 1 micrometre in size), see 'Dispersion'.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C154467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154467>	C171282	Film Dosage Form Category|Film	A type of solid pharmaceutical dose form consisting of a thin, single- or multilayer sheet of material, which usually dissolves or otherwise dissipates in an aqueous environment.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C154468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154468>	C171283	Gel Dosage Form Category|Gel	A type of semi-solid pharmaceutical dose form consisting of a colloidal dispersion of a liquid in a solid; lipophilic gels (oleogels) usually consist of liquid paraffin with polyethylene or fatty oils gelled with colloidal silica or aluminium or zinc soaps; hydrophilic gels (hydrogels) usually consists of water, glycerol or propylene glycol gelled with suitable gelling agents such as poloxamers, starch, cellulose derivatives, carbomers and magnesium-aluminium silicates.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C15446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15446>	C49652	Adjuvant Study|Adjuvant Protocol|Adjuvant Trial|Adjuvant Trials	A study performed secondary to and in support of a primary or base study in order to support, enhance, or expand upon its results or findings.			Research Activity	
C154471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154471>	C15300	Vascular-Targeted Photodynamic Therapy|VTP|Vascular Targeted Photodynamic Therapy|Vascular Targeted Phototherapy|Vascular-Targeted Phototherapy	A type of photodynamic therapy for localized treatment of tumors. It makes use of photosensitizers that are limited to the vascular bed and are rapidly cleared from the circulation.	Vascular-Targeted Photodynamic Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C154472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154472>	C18194	ExoDx Prostate Intelliscore|ExoDx Prostate (IntelliScore)|Intelliscore|Prostate Intelliscore	A proprietary non-invasive, urine-based, liquid biopsy for high-grade prostate cancer. It uses an exosomal RNA (exoRNA)-based assay.	ExoDx Prostate Intelliscore		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C154473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154473>	C8925|C8566	Melanoma of Unknown Primary|Melanoma of Unknown Primary Origin	A melanoma which has metastasized from an unknown primary anatomic site.	Melanoma of Unknown Primary		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C154474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154474>	C25716|C171440	Ambulatory Visit|Ambulatory Care Clinic Visit|Ambulatory Care Facility Visit|Ambulatory Center Visit|OUTPATIENT CLINIC VISIT|Outpatient Visit	A visit to an ambulatory care facility.			Individual Behavior	CDISC SDTM Health Care Encounters Dictionary Derived Term Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154475>	C25166	Discharged Alive	An indication that a patient left an in-patient facility while alive.			Health Care Activity	
C154476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154476>	C41205	Absent without Leave|AW	An indication that a patient is missing from an in-patient facility.			Finding	
C154477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154477>	C41205	Still in Hospital	An indication that a patient remains in an in-patient hospital.			Finding	
C154478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154478>	C70950	No Higher Limit|No Higher Limit of Normal	A higher limit of the normal range does not exist.			Intellectual Product	
C154479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154479>	C19696	Point-of-Care	Services designed to be administered at the patient's bedside or other patient location.			Functional Concept	
C15447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15447>	C67022	Dietary Intervention|Dietary Modification|Nutrition Intervention|Nutrition Interventions|Nutritional Interventions|intervention, dietary	Any alteration or treatment in an individual's diet with a planned goal, usually designed to improve the individual's overall health.	Dietary Intervention		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C154480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154480>	C171282	Granule Dosage Form Category|Granules	A type of solid pharmaceutical dose form consisting of dry aggregates of powder particles that are sufficiently resistant to withstand handling.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C154481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154481>	C20993	Adult Sickle Cell Quality of Life Measurement Information System|ASCQ-Me	A patient-reported outcome measurement system designed to evaluate and monitor the physical, mental, and social well-being of adults with sickle cell disease.			Intellectual Product	
C154482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154482>	C20993	NIH Toolbox	A comprehensive set of neuro-behavioral measures that assess cognitive, emotional, sensory, and motor functions, designed to be run on an iPad.			Intellectual Product	
C154483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154483>	C17176	Hospital Consumer Assessment of Healthcare Providers and Systems|CAHPS Hospital Survey|HCAHPS	A national, standardized, publicly reported satisfaction survey of a patients' perspectives of their hospital experience. It is required by the Centers for Medicare and Medicaid Services for all hospitals in the United States.			Research Device	
C154484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154484>	C64493	Every Afternoon|EVERY AFTERNOON	Scheduled or occurring each afternoon.			Quantitative Concept	CDISC SDTM Frequency Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154485>	C19464	Paper Form|Paper Format	A questionnaire or measure that is printed on a paper medium and filled out with a writing device.			Intellectual Product	
C154486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154486>	C19464	Electronic Form|Electronic Administration|Electronic Format	A questionnaire or measure that is administered on an electronic device, such as a computer, tablet, or smartphone.	Electronic Form		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C154487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154487>	C154302	H3C1 Gene|H3 Clustered Histone 1 Gene|H3C1|H3C1|HIST1H3A|HIST1H3A Gene	This gene plays a role in DNA compartmentalization.	HIST1H3A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C154488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154488>	C154487	H3C1 wt Allele|H3 Clustered Histone 1 wt Allele|H3 Histone Family, Member A Gene|H3/A|H3FA|H3a|HIST1 Cluster, H3A Gene|HIST1H3A|HIST1H3A wt Allele|Histone 1, H3a Gene|Histone Cluster 1 H3 Family Member A Gene|Histone Cluster 1, H3a Gene|Histone Gene Cluster 1, H3 Histone Family, Member A Gene|Histone Gene Cluster 1, H3a Gene	Human H3C1 wild-type allele is located in the vicinity of 6p22.2 and is approximately 1 kb in length. This allele, which encodes histone H3.1 protein, is involved in the formation of complex DNA structures.	HIST1H3A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154489>	C154302	H3C3 Gene|H3 Clustered Histone 3 Gene|H3C3|H3C3|HIST1H3C|HIST1H3C Gene	This gene is involved in the regulation of chromosome dynamics.	HIST1H3C Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C15448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15448>	C15262	Graft Versus Host Disease Prophylaxis/Therapy|GVHD prophylaxis/therapy	Therapy to prevent or treat graft vs host disease.	Graft Versus Host Disease Prophylaxis/Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C154490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154490>	C154489	H3C3 wt Allele|H3 Clustered Histone 3 wt Allele|H3 Histone Family, Member C Gene|H3/c|H3FC|H3c|HIST1 Cluster, H3C Gene|HIST1H3C|HIST1H3C wt Allele|Histone 1, H3c Gene|Histone Cluster 1 H3 Family Member C Gene|Histone Cluster 1, H3c Gene|Histone Gene Cluster 1, H3 Histone Family, Member C Gene|Histone Gene Cluster 1, H3c Gene	Human H3C3 wild-type allele is located in the vicinity of 6p22.2 and is approximately 1 kb in length. This allele, which encodes histone H3.1 protein, plays a role in the formation of nucleosomes.	HIST1H3C wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154491>	C45235	Gum Dosage Form Category|Gum	A type of solid pharmaceutical dose form consisting of a basis composed of gum(s) or with a gum-like consistency.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C154492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154492>	C36345	TFEB Protein Overexpression|Class E Basic Helix-Loop-Helix Protein 35 Overexpression|T-Cell Transcription Factor EB Overexpression|Transcription Factor EB Overexpression|bHLHe35 Protein Overexpression	Overexpression of TFEB protein that results from a t(6;11)(p21;q12) translocation, which involves the human genes MALAT1 and TFEB and is associated with renal cell carcinoma with t(6;11)(p21;q12); MALAT1-TFEB.			Cell or Molecular Dysfunction	
C154494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154494>	C9385|C189241	Renal Cell Carcinoma with MiT Translocations|MiT Family Translocation-Associated Renal Cell Carcinoma|MiT family translocation renal cell carcinoma	A renal cell carcinoma usually seen in children or young adults. It is characterized by papillary, alveolar and nested growth patterns with clear and eosinophilic cells. The carcinomas range from microscopic lesions to clinically symptomatic tumors. It is associated with translocations/gene fusions involving members of the MiT family of transcription factors. There are two subtypes: TFE3-rearranged renal cell carcinoma [Xp11 translocation renal cell carcinoma] and TFEB-rearranged renal cell carcinoma [t(6;11) renal cell carcinoma].			Neoplastic Process	GDC Terminology|GDC Value Terminology
C154495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154495>	C3420	MiT Family Translocation	Translocations/gene fusions in the MiT family transcription factors TFE3 or TFEB.			Cell or Molecular Dysfunction	
C154496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154496>	C4525|C36025	Anaplastic Sarcoma of the Kidney|ASK	A rare tumor, usually occurring in young adults (mean age 12 years) with slight female predominance. It is characterized by a proliferation of anaplastic spindle cells with bizarre, pleomorphic nuclei and atypical mitotic figures. Most cases show chondroid differentiation.			Neoplastic Process	
C154497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154497>	C171282	Implant Dosage Form Category|Implant	A type of solid pharmaceutical dose form consisting of a mass with a size and shape suitable for implantation, allowing release of active substance(s) over an extended period of time.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C154498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154498>	C17048	Telephonic Format|Telephone Administration|Telephonic	A questionnaire or measure that is administered via telephone.			Intellectual Product	
C154499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154499>	C154498	Telephonic Format with Interactive Voice Response Technology	A questionnaire or measure that is administered via telephone, using interactive voice response technology.			Intellectual Product	
C15449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15449>	C63475	Somatostatin Analog Therapy|Somatostatin Analogue Therapy	Endocrine drug therapy that uses analogs of somatostatin to treat neuroendocrine tumors.	Somatostatin Analog Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C1544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1544>	C1976|C1946	Romidepsin|Antibiotic FR 901228|Depsipeptide|FK 228|FK-228|FK228|FR 901228|FR-901228|FR901228|FR901228|Istodax|L-Valine, N- (3-hydroxy-7-mercapto-1-oxo-4-heptenyl)valyl- cysteinyl-2, 3-didehydro-2-aminobutanoyl-,xi-lactone, cyclic (1-2)-disulfide|L-Valine, N-(3-Hydroxy-7-Mercapto-1-Oxo-4-Heptenyl)-D-Valyl-D-Cysteinyl-(Z)-2,3 -Didehydro-2-Aminobutanoyl-, xi-Lactone, Cyclic (1-2)-Disulfide, (S-(E))-|N-[(3S,4E)-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4-1) Lactone, Cyclic|N-[(3S,4E)-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4->1) Lactone, Cyclic|ROMIDEPSIN|depsipeptide|romidepsin	A bicyclic depsipeptide antibiotic isolated from the bacterium Chromobacterium violaceum with antineoplastic activity. After intracellular activation, romidepsin binds to and inhibits histone deacetylase (HDAC), resulting in alterations in gene expression and the induction of cell differentiation, cell cycle arrest, and apoptosis. This agent also inhibits hypoxia-induced angiogenesis and depletes several heat shock protein 90 (Hsp90)-dependent oncoproteins.	Romidepsin		Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C154500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154500>	C154302	H3C4 Gene|H3 Clustered Histone 4 Gene|H3C4|H3C4|HIST1H3D|HIST1H3D Gene	This gene plays a role in chromosome dynamics.	HIST1H3D Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C154501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154501>	C154500	H3C4 wt Allele|H3 Clustered Histone 4 wt Allele|H3 Histone Family, Member B Gene|H3 Histone Family, Member D Gene|H3/b|H3FB|H3d|HIST1 Cluster, H3D Gene|HIST1H3D|HIST1H3D wt Allele|Histone 1, H3d Gene|Histone Cluster 1 H3 Family Member D Gene|Histone Cluster 1, H3d Gene|Histone Gene Cluster 1, H3 Histone Family, Member D Gene|Histone Gene Cluster 1, H3d Gene	Human H3C4 wild-type allele is located in the vicinity of 6p22.2 and is approximately 2 kb in length. This allele, which encodes histone H3.1 protein, is involved in DNA compaction.	HIST1H3D wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154502>	C45962	Multihormonal Immunoreactivity Present in a Single Cell Type	A finding indicating that neoplastic cells of a single cell type have detectable immunoreactivity for two or more hormones in a tissue sample.			Finding	
C154503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154503>	C45962	Multihormonal Immunoreactivity Present in Two or More Cell Types	A finding indicating that neoplastic cells of two or more cell types have detectable immunoreactivity for different hormones in a tissue sample.			Finding	
C154504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154504>	C45916	Monomorphous Plurihormonal Pituitary Neuroendocrine Tumor	A plurihormonal pituitary neuroendocrine tumor consisting of a single cell type producing two (or rarely more) hormones. (WHO)			Neoplastic Process	
C154505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154505>	C45916	Plurimorphous Plurihormonal Pituitary Neuroendocrine Tumor	A plurihormonal pituitary neuroendocrine tumor consisting of two or more different cell lineages. (WHO)			Neoplastic Process	
C154506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154506>	C227075	Self Without Assistance	An indication that an individual completed a questionnaire or measure by themselves, without assistance.			Intellectual Product	
C154507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154507>	C227075	Self With Assistance	An indication that an individual completed a questionnaire or measure by themselves, but required some assistance.			Intellectual Product	
C154508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154508>	C227075	Proxy Without Assistance	An indication that a questionnaire or measure was completed by someone on behalf of an individual, without input from the individual.			Intellectual Product	
C154509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154509>	C227075	Proxy With Assistance	An indication that a questionnaire or measure was completed by someone on behalf of an individual, with input from the individual.			Intellectual Product	
C15450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15450>	C16171	Prior Chemotherapy for Advanced Disease	An individual with advanced disease has had prior chemotherapy.			Clinical Attribute	
C154510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154510>	C68751	Heavy Smoker|Heavy Tobacco Smoker|Heavy tobacco smoker	A smoker who smokes more than 10 cigarettes per day, or an equivalent quantity of cigar or pipe smoke.			Organism Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C154511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154511>	C68751	Light Smoker|Light Tobacco Smoker|Light tobacco smoker	A smoker who smokes less than 10 cigarettes per day, or an equivalent quantity of cigar or pipe smoke.			Organism Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C154512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154512>	C154302	H3C6 Gene|H3 Clustered Histone 6 Gene|H3C6|H3C6|HIST1H3E|HIST1H3E Gene	This gene is involved in the modulation of DNA compartmentalization.	HIST1H3E Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C154513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154513>	C18059	Smoked Tobacco Only	An indication that individual used only tobacco products that are smoked.			Individual Behavior	
C154514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154514>	C137998	Non-Smoked Tobacco Only	An indication that individual used only smokeless tobacco products.			Individual Behavior	
C154515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154515>	C18059	Use of both Smoked and Non-smoked Tobacco Products	An indication that individual only used both smoked and smokeless tobacco products.			Individual Behavior	
C154516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154516>	C154512	H3C6 wt Allele|H3 Clustered Histone 6 wt Allele|H3 Histone Family, Member D Gene|H3 Histone Family, Member E Gene|H3/d|H3FD|H3e|HIST1 Cluster, H3e Gene|HIST1H3E|HIST1H3E wt Allele|Histone 1, H3e Gene|Histone Cluster 1 H3 Family Member E Gene|Histone Cluster 1, H3e Gene|Histone Gene Cluster 1, H3 Histone Family, Member E Gene|Histone Gene Cluster 1, H3e Gene	Human H3C6 wild-type allele is located in the vicinity of 6p22.2 and is approximately 3 kb in length. This allele, which encodes histone H3.1 protein, plays a role in chromosome dynamics.	HIST1H3E wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154517>	C18059	Use of Smoked Tobacco but no Information about Non-smoked Tobacco Use	An indication that it is known that an individual used smoked tobacco products, but it is unknown if they also used smokeless tobacco products.			Individual Behavior	
C154518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154518>	C171282	Insert Dosage Form Category|Insert	A type of solid pharmaceutical dose form consisting of a material of an appropriate shape and size to be placed inside an orifice of the body, and which dissolves or disintegrates over time. Pessaries and suppositories are excluded.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C154519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154519>	C154520	Double Pituitary Neuroendocrine Tumors of Distinct Lineages|Double PitNET/Adenomas of Distinct Lineages|Double Pituitary Neuroendocrine Tumors/Adenomas of Distinct Lineages|Pituitary Gland Double Adenomas	Pituitary neuroendocrine tumors composed of adenohypopheseal cells of two lineages or a null cell tumor in combination with a lineage-specific pituitary neuroendocrine tumor in the same gland.			Neoplastic Process	
C15451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15451>	C16124	Prior Anthracycline Therapy|Prior Anthracycline|Prior Anthracycline Usage	Having received prior anthracycline therapy.			Clinical Attribute	
C154520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154520>	C3329	Multiple Synchronous Pituitary Neuroendocrine Tumors of Distinct Lineages|Multiple Synchronous PitNET/Adenomas of Distinct Lineages|Multiple Synchronous Pituitary Neuroendocrine Tumors/Adenomas of Distinct Lineages|Pituitary Gland Multiple Adenomas	Multiple pituitary neuroendocrine tumors composed of adenohypopheseal cells of two or more lineages or a null cell tumor in combination with a lineage-specific pituitary neuroendocrine tumor in the same gland.			Neoplastic Process	
C154521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154521>	C98275	Two Separate Tumor Masses Present in the Same Organ	A finding indicating the presence of two separate tumor masses in the same organ.			Finding	
C154522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154522>	C98275	More Than Two Separate Tumor Masses Present in the Same Organ	A finding indicating the presence of more than two separate tumor masses in the same organ.			Finding	
C154523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154523>	C27993	Patient-Reported|Patient Reporting	An indication that the patient provides information about their vital signs, status, or subjective feelings. Some systems also consider information reported by the patient's family or guardian as patient-reported.			Qualitative Concept	
C154524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154524>	C25651	Patient Device Direct Feed Reporting|Patient device direct feed	An indication that vital sign data came from a device in direct contact with the patient.			Activity	
C154525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154525>	C25651	Healthcare Delivery Setting Reporting|Healthcare delivery setting	An indication that vital sign data came from an individual or record within a healthcare delivery setting.			Activity	
C154526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154526>	C25161	Centers for Medicare and Medicaid Services System for Diagnosis-Related Groups|CMS-DRG	A system developed by the Centers for Medicare and Medicaid Services to classify hospital cases into diagnosis-related groups to facilitate Medicare reimbursement. This system was used until 2007.			Classification	
C154527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154527>	C17146	Medicare Severity Diagnosis-Related Groups|MS-DRG|Medicare Severity-Diagnosis Related Group	A system developed by the Centers for Medicare and Medicaid Services to classify hospital cases into diagnosis-related groups to facilitate Medicare reimbursement. Compared to the CMS-DRG, the MS-DRG adds 300 diagnosis-related groups and factors in the severity of illness for establishing reimbursement levels.			Manufactured Object	
C154528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154528>	C25616	Period of Medical Insurance Coverage for Enrollment Basis|Medical insurance coverage|Period of Medical Insurance Coverage	A time period of care where the start and stop dates are based on when the patient's costs are covered by their personal medical insurance plan.			Temporal Concept	
C154529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154529>	C25616	Period of Outpatient Prescription Drug Coverage for Enrollment Basis|Outpatient prescription drug coverage|Period of Outpatient Prescription Drug Coverage	A time period of care where the start and stop dates are based on when the patient's outpatient drug costs are covered by their personal medical insurance plan.			Temporal Concept	
C15452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15452>	C16124	Prior Biologic Therapy	Previous biologic therapy administered as treatment.			Clinical Attribute	
C154530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154530>	C25616	Period of Care, Encounter-Based|Encounter-Based Enrollment Period|Encounter-based	A time period of care where the start and stop dates are populated from the earliest observed encounter and latest observed encounter.			Temporal Concept	
C154531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154531>	C29302	Topical Fibrinogen-depleted Human Standardized Platelet Lysate CAM-101|CAM 101|CAM-101|FD hPL CAM-101|Ophthalmic Fibrinogen Depleted Allogeneic Standardized Human Platelet Lysate|Topical Fibrinogen Depleted Human Platelet Lysate	A topical ophthalmic drop formulation containing fibrinogen-depleted, standardized human platelet lysate which is derived from pooled human platelet lysates (phPL) collected from healthy human donors, that can potentially be used to treat dry eye disease (DED). Upon ophthalmic administration of the topical fibrinogen-depleted human platelet lysate CAM-101, CAM-101 serves as artificial tears to relieve ocular dryness. In addition, as CAM-101 is rich in various growth factors and contains numerous nutritive, anti-inflammatory and pro-regenerative components, the components in CAM-101 may abrogate the underlying processes, such as inflammation, that contribute to DED. Compared to autologous serum drops that are used as artificial tears, CAM-101 is a more shelf-stable, convenient and standardized formulation.	Topical Fibrinogen-depleted Human Standardized Platelet Lysate CAM-101		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C154532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154532>	C37948	Geography-Based Enrollment|Enrollment Basis Geography|Geography	An assertion of complete data capture between the start and end dates based upon geographic characteristics, such as regional isolation.			Health Care Activity	
C154533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154533>	C37948	Algorithm-Based Enrollment|Algorithmic|Algorithmic Enrollment Basis|Enrollment Basis Algorithmic	An assertion of complete data capture between the start and end dates, based on a locally developed or applied algorithm, often using multiple criteria.			Health Care Activity	
C154534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154534>	C48906	Order to Dispense	A prescription drug order that specifies outpatient dispensing of the drug.			Activity	
C154535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154535>	C48906	Order to Administer|Medication Order	A prescription drug order that orders administration of the drug by a healthcare professional.			Activity	
C154536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154536>	C154302	H3C7 Gene|H3 Clustered Histone 7 Gene|H3C7|H3C7|HIST1H3F|HIST1H3F Gene	This gene plays a role in the formation of higher order chromosome structures.	HIST1H3F Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C154537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154537>	C154536	H3C7 wt Allele|H3 Clustered Histone 7 wt Allele|H3 Histone Family, Member F Gene|H3 Histone Family, Member I Gene|H3/i|H3FI|H3f|HIST1 Cluster, H3f Gene|HIST1H3F|HIST1H3F wt Allele|Histone 1, H3f Gene|Histone Cluster 1 H3 Family Member F Gene|Histone Cluster 1, H3f Gene|Histone Gene Cluster 1, H3 Histone Family, Member F Gene|Histone Gene Cluster 1, H3f Gene	Human H3C7 wild-type allele is located in the vicinity of 6p22.2 and is approximately 1 kb in length. This allele, which encodes histone H3.1 protein, is involved in DNA compartmentalization.	HIST1H3F wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154538>	C154302	H3C8 Gene|H3 Clustered Histone 8 Gene|H3C8|H3C8|HIST1H3G|HIST1H3G Gene	This gene is involved in the formation of higher order nucleosome structures.	HIST1H3G Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C154539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154539>	C154538	H3C8 wt Allele|H3 Clustered Histone 8 wt Allele|H3 Histone Family, Member G Gene|H3 Histone Family, Member H Gene|H3/h|H3FH|H3g|HIST1 Cluster, H3g Gene|HIST1H3G|HIST1H3G wt Allele|Histone 1, H3g Gene|Histone Cluster 1 H3 Family Member G Gene|Histone Cluster 1, H3g Gene|Histone Gene Cluster 1, H3 Histone Family, Member G Gene|Histone Gene Cluster 1, H3g Gene	Human H3C8 wild-type allele is located in the vicinity of 6p22.2 and is approximately 2 kb in length. This allele, which encodes histone H3.1 protein, plays a role in the formation of higher order chromosome structures.	HIST1H3G wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15453>	C15452	Prior Interferon Therapy	Having received prior interferon therapy.			Clinical Attribute	
C154540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154540>	C154302	H3C10 Gene|H3 Clustered Histone 10 Gene|H3C10|H3C10|HIST1H3H|HIST1H3H Gene	This gene plays a role in nucleosome formation.	HIST1H3H Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C154541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154541>	C154540	H3C10 wt Allele|H3 Clustered Histone 10 wt Allele|H3 Histone Family, Member H Gene|H3 Histone Family, Member K Gene|H3/k|H3FK|H3h|HIST1 Cluster, H3h Gene|HIST1H3H|HIST1H3H wt Allele|Histone 1, H3h Gene|Histone Cluster 1 H3 Family Member H Gene|Histone Cluster 1, H3h Gene|Histone Gene Cluster 1, H3 Histone Family, Member H Gene|Histone Gene Cluster 1, H3h Gene	Human H3C10 wild-type allele is located in the vicinity of 6p22.1 and is approximately 1 kb in length. This allele, which encodes histone H3.1 protein, is involved in the formation of higher order nucleosome structures.	HIST1H3H wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154542>	C16809	Gradient Echo MRI|GRE|GRE MRI|Gradient Echo Magnetic Resonance Imaging|Gradient Recalled Echo Imaging	An application of magnetic resonance imaging that uses spin refocusing and spin echo generation, resulting in shorter repetition times and faster imaging.	Gradient Echo MRI		Diagnostic Procedure	CRF6 DIPG Imaging Assessment Signal Characteristics Table|CRF6 DMG Imaging Assessment Signal Characteristics Table|CTRP Intervention Terminology|CTRP Terminology
C154543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154543>	C154302	H3C11 Gene|H3 Clustered Histone 11 Gene|H3C11|H3C11|HIST1H3I|HIST1H3I Gene	This gene is involved in the structure of nucleosomes.	HIST1H3I Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C154544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154544>	C154543	H3C11 wt Allele|H3 Clustered Histone 11 Gene|H3 Histone Family, Member F Gene|H3 Histone Family, Member I Gene|H3/f|H3FF|H3i|HIST1 Cluster, H3i Gene|HIST1H3I|HIST1H3I wt Allele|Histone 1, H3i Gene|Histone Cluster 1 H3 Family Member I Gene|Histone Cluster 1, H3i Gene|Histone Gene Cluster 1, H3 Histone Family, Member I Gene|Histone Gene Cluster 1, H3i Gene	Human H3C11 wild-type allele is located in the vicinity of 6p22.1 and is approximately 1 kb in length. This allele, which encodes histone H3.1 protein, plays a role in nucleosome formation.	HIST1H3I wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154545>	C9385|C224633|C174565	Unresectable Renal Cell Carcinoma	A renal cell carcinoma that is not amenable to surgical resection.			Neoplastic Process	
C154546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154546>	C154302	H3C12 Gene|H3 Clustered Histone 12 Gene|H3C12|HIST1H3J|HIST1H3J Gene	This gene plays a role in chromatin structure.	HIST1H3J Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C154547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154547>	C9385|C210816|C210619	Resectable Renal Cell Carcinoma	Renal cell carcinoma that is amenable to surgical resection.			Neoplastic Process	
C154548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154548>	C154546	H3C12 wt Allele|H3 Clustered Histone 12 wt Allele|H3 Histone Family, Member J Gene|H3/j|H3FJ|H3j|HIST1 Cluster, H3j Gene|HIST1H3J|HIST1H3J wt Allele|Histone 1, H3j Gene|Histone Cluster 1 H3 Family Member J Gene|Histone Cluster 1, H3j Gene|Histone Gene Cluster 1, H3 Histone Family, Member J Gene|Histone Gene Cluster 1, H3j Gene	Human H3C12 wild-type allele is located in the vicinity of 6p22.1 and is approximately 3 kb in length. This allele, which encodes histone H3.1 protein, is involved in the structure of nucleosomes.	HIST1H3J wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154549>	C2124|C129819	Lutetium Lu 177-DOTA-EB-TATE|(177)Lu-DOTA-EB-TATE|177 Lu-DOTA-EB-TATE|177Lu-DOTA-EB-TATE|177Lu-DOTA0-EB-Tyr3-Octreotate|Lutetium Lu 177 DOTA(0)-EB-Tyr(3)-Octreotate|Lutetium Lu 177-DOTA-EB-Tyr3-Octreotate|Lutetium-177-1, 4, 7, 10-tetra-azacyclododecane-1, 4, 7, 10-tetraacetic acid-Evans blue-octreotate|Lutetium-177-DOTA-EB-TATE	A radioconjugate consisting of Evans blue (EB) modified, tyrosine-containing somatostatin analog, Tyr3-octreotate (TATE), conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecane tetraacetic acid (DOTA), and radiolabeled with the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon intravenous administration, lutetium Lu 177-DOTA-EB-TATE binds to somatostatin receptors (SSTRs), specifically with high affinity to type 2 SSTRs (SSTR2s), present on the cell membranes of many neuroendocrine tumor (NET) cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR2-positive cells. The incorporation of an albumin-binding moiety through EB modification allows lutetium Lu 177-DOTA-EB-TATE to reversibly bind to endogenous albumin, potentially extending half-life and increasing targeted accumulation of the drug in tumors. SSTRs, especially SSTR2s, are expressed at relatively higher levels in many tumor cell types and tumor blood vessels, compared to normal tissues.	Lutetium Lu 177-DOTA-EB-TATE		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15454>	C49163	Head and Neck Surgery|Head and Neck Surgical Procedure	Any surgery involving a structure in the head and neck region.	Head and Neck Surgery		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C154550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154550>	C129822|C128057	Sugemalimab|Anti-PD-L1 Monoclonal Antibody CS1001|Anti-PD-L1 Monoclonal Antibody WBP 3155|CS 1001|CS-1001|CS1001|Cejemly|SUGEMALIMAB|WBP 315|WBP-315|WBP315	A fully human monoclonal antibody directed against the immunosuppressive ligand, programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sugemalimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor, programmed cell death 1 (PD-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells. Anti-PD-L1 monoclonal antibody CS1001 mirrors natural immunoglobulin G4 (IgG4), potentially reducing immunogenicity and other toxicities.	Sugemalimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C154551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154551>	C150386	Liquid Dose Form Category|Liquid	A type of liquid pharmaceutical dose form consisting of a pure substance in a liquid state.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C154552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154552>	C93170|C129822	Gentuximab	A recombinant, humanized monoclonal antibody directed against the vascular endothelial growth factor receptor 2 (VEGFR-2), with potential anti-angiogenic and antineoplastic activities. Upon intravenous injection, gentuximab specifically binds to VEGFR-2, preventing the binding of its ligand, vascular endothelial growth factor (VEGF). Inhibition of VEGFR-2 signaling may potentially inhibit tumor angiogenesis and decrease nutrient supply to tumor cells, resulting in tumor cell death. VEGFR-2 is a type V receptor tyrosine kinase (RTK) expressed on endothelial cells and some tumor cells that regulates endothelial migration and proliferation.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C154554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154554>	C171282	Lozenge Dosage Form Category|Lozenge	A type of solid pharmaceutical dose form consisting of a hard mass formed by moulding or compression, intended to dissolve or disintegrate slowly in the oral cavity when sucked.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C154555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154555>	C15222	Methionine-Restricted Diet	A diet which is limited in the amino acid methionine. Methionine depletion inhibits cell cycle progression and induces apoptosis in many transformed cells, but not normal cells. Dietary methionine restriction inhibits tumor growth in diverse cancer models and is in trial as part of clinical cancer treatments.	Methionine-Restricted Diet		Food	CTRP Intervention Terminology|CTRP Terminology
C154557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154557>	C171283	Ointment Dosage Form Category|Ointment	A type of semi-solid pharmaceutical dose form consisting of a single-phase basis in which solids or liquids may be dispersed; ointments may be composed of a variety of bases including hydrocarbons, emulsifiers, vegetable oils and animal fats; they may be hydrophobic (bases made from substances such as hard, liquid, or light liquid paraffins, vegetable oils, animal fats, synthetic glycerides, waxes and liquid polyalkylsiloxanes, and which are only able to absorb a small amount of water), hydrophilic (with a water-miscible basis, usually a mixture of liquid and solid macrogols) or water-emulsifying (capable of absorbing larger amounts of water and forming emulsions, with bases containing water-in-oil emulsifiers such as wool alcohols, sorbitan esters, monoglycerides and fatty alcohols, or oil-in-water emulsifiers such as sulfated fatty alcohols, polysorbates, macrogol cetostearyl ether, esters of fatty acids with macrogols).			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C154558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154558>	C1512	Antibody-drug Conjugate SC-005|SC 005|SC 005|SC-005|SC-005	An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against a tumor-associated antigen (TAA) linked to a currently undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of SC-005 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an unknown mechanism of action.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C154559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154559>	C171283	Paste Dosage Form Category|Paste	A type of semi-solid pharmaceutical dose form consisting of a large proportion of solid particles dispersed in a hydrophobic or hydrophilic basis.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C15455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15455>	C15892|C15419	Evaluation of Cancer Risk Factors|cancer risk factors evaluation	A study designed to identify risk factors that contribute to a neoplasic disease or disorder and determine the strength of their contributuon.	Evaluation of Cancer Risk Factors		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C154560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154560>	C62554	PARP 1/2 Inhibitor NOV1401	An orally available small molecule inhibitor of the nuclear enzymes poly (ADP-ribose) polymerase (PARP) 1 and 2, with potential antineoplastic activity. Upon administration, NOV1401 selectively binds to PARP-1 and -2, thereby preventing PARP-1 and -2-mediated DNA repair. This promotes genetic instability and enhances the accumulation of single and double strand DNA breaks, ultimately leading to apoptosis. The PARP family of proteins catalyzes post-translational ADP-ribosylation of nuclear proteins and is activated by single-strand DNA (ssDNA) breaks.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C154562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154562>	C171282	Pastille Dosage Form Category|Pastille	A type of solid pharmaceutical dose form consisting of a soft, flexible mass formed by moulding, intended to dissolve or disintegrate slowly in the oral cavity when sucked.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C154563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154563>	C1752|C1663	PD-L2 Peptide-Montanide Vaccine|PD-L2 Peptide Plus Montanide ISA-51 Vaccine|PD-L2 Peptide Plus Montanide Vaccine|Programmed Death Ligand 2 Peptide Vaccine	A vaccine composed of a peptide derived from the immune checkpoint molecule programmed death ligand 2 (PD-L2) combined with the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Vaccination with PD-L2 peptide-montanide vaccine may mount an immune response against PD-L2 expressing cells. This may enhance T-cell proliferation, cytokine production, and T-cell mediated cytolysis. PD-L2 binding to its cognate receptor, programmed cell death protein 1 (PD-1; PDCD1; CD279), downregulates T-cell responses and enhances immune evasion. Montanide ISA-51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C154564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154564>	C1752|C1663	PD-L1/PD-L2 Peptide-Montanide Vaccine|PD-L1/PD-L2 Peptide Plus Montanide ISA-51 Vaccine|PD-L1/PD-L2 Peptide Plus Montanide Vaccine	A vaccine composed of peptides derived from the immune checkpoint molecules, programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2), combined with the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Vaccination with PD-L1/PD-L2 peptide-montanide vaccine may stimulate an immune response against PD-L1 and PD-L2 expressing cells. This may enhance T-cell proliferation, cytokine production, and T-cell mediated cytolysis. Binding of programmed cell death protein 1 (PD-1; PDCD1; CD279) by its ligands, PD-L1 and PD-L2, results in downregulation of T-cell responses and enhanced immune evasion. Montanide ISA-51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C154565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154565>	C142078	Autologous TBX-4000-treated Peripheral Blood Mononuclear Cells TBX-3400|Autologous PBMCs TBX-3400|Autologous TBX-4000-treated Human PBMCs|TBX 3400|TBX-3400|TBX-3400 Cells	An autologous cell preparation in which the autologous peripheral blood mononuclear cells (PBMCs) are treated ex vivo with TBX-4000, a recombinant TAT-MYC fusion protein, with potential antineoplastic and immunomodulating activities. Upon reintroduction of the TBX-3400 cells into the patient, the generated T-cells may activate the immune system and exert a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. The TBX-4000 recombinant fusion protein consists of the N-terminal 9 amino acid segment of the HIV TAT protein transduction domain (PTD) fused to the MYC protein. TBX-4000 TAT-MYC rapidly localizes to the nucleus and transiently provides signals to drive proliferation and survival of T-cells.	Autologous TBX-4000-treated Peripheral Blood Mononuclear Cells TBX-3400		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C154566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154566>	C2124	Gallium Ga 68-NOTA-Sgc8|68Ga Labeled ssDNA Aptamer Sgc8|68Ga-Sgc8|[68Ga]-Sgc8	A radioconjugate containing a derivative of the androgen testosterone, 16-beta-fluoro-5-alpha-dihydrotestosterone (FDHT), labeled with the radioisotope fluorine F18 (18F-FDHT), with potential use as an imaging agent for positron emission tomography (PET). Upon administration, 18F-FDHT binds to the androgen receptor (AR). Upon PET imaging, AR-expressing prostate tumor cells can be imaged and assessed.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C154567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154567>	C66917	Maekmoondong-tang|Bakumondo-to|MMDT|Maekgeuron Granules|Mai-men-dong-tang|Ophiopogonis tuber/Pinelliae tuber/Glycyrrhizae radix/Zizyphi fructus/Ginseng radix/Oryzae semen Herbal Formulation|TJ-29	A traditional East Asian herbal medicine composed of six herbs, including Ophiopogonis tuber, Pinelliae tuber, Glycyrrhizae radix, Zizyphi fructus, Ginseng radix, and Oryzae semen, with potential anti-tussive activity. Maekmoondong-tang is traditionally prescribed for respiratory symptoms to direct the qi downwards and compensate for lung-yin deficiency or dry lung by tonifying yin and moistening the lung. Although the exact mechanisms through which Maekmoondong-tang exerts its effects have yet to be fully elucidated, this agent may, upon administration, improve the severity of chronic cough, reduce airway hyper-responsiveness possibly by reducing the cough reflex and bronchodilation, and airway inflammation possibly through anti-inflammatory and immunomodulatory effects.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C154568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154568>	C201933	Genetically-modified Anti-HER2-CAR-CD28zeta-expressing Allogeneic NK-92/5.28.z Cells|Anti-HER2-CAR-CD28zeta NK-92 Cells|Anti-HER2-CAR-engineered NK-92/5.28.z Cells|HER2.taNK|HER2.taNK Cells|NK-92/5.28.z|NK-92/5.28.z Cells	A preparation of genetically-modified natural killer (NK) cells derived from the allogeneic NK-92 cell line that are transduced with a lentiviral vector expressing a codon-optimized chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) of the anti-human epidermal growth factor 2 (HER2; ErbB2) monoclonal antibody FRP5, and fused, via hinge and transmembrane regions, to the intracellular domain of the costimulatory molecule CD28, and the intracellular signaling domain of the T-cell antigen receptor complex zeta chain (CD3-zeta), with potential cytolytic, immunomodulating and antineoplastic activities. Upon infusion of the genetically modified anti-HER2-CAR-CD28zeta-expressing allogeneic NK-92/5.28.z cells, the NK cells recognize and bind to HER2 expressed on tumor cells. This leads to the secretion and release of perforins, granzymes, cytokines and chemokines, which results in selective tumor cell lysis in HER2-expressing tumor cells. HER2, a receptor tyrosine kinase (RTK) mutated or overexpressed in many tumor cell types, plays a significant role in tumor cell proliferation and tumor vascularization. The NK-92 cells are derived from a human cytotoxic cell line composed of allogeneic, activated, interleukin-2-(IL-2) dependent-NK cells from a 50-year old male patient with rapidly progressive non-Hodgkin's lymphoma. As NK-92 cells are devoid of killer inhibitory receptors (KIRs; also called killer cell immunoglobulin-like receptors), which are negative regulators of NK cell activity, cancer cells are unable to suppress the cancer cell killing ability of the NK-92 cells.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C154569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154569>	C67502	Curcumin/Doxorubicin-encapsulating Nanoparticle IMX-110|IMX 110|IMX-110|IMX110|Stat3/NF-kB/poly-tyrosine Kinase Inhibitor/Doxorubicin-encapsulating Nanoparticle IMX-110	A water-soluble, nano-sized formulation composed of nanoparticles encapsulating the poorly water-soluble curcumin, a signal transducer and activator of transcription 3 (Stat3), nuclear factor Kappa B (NF-kB) and poly-tyrosine kinase inhibitor (TKI), and the antineoplastic anthracycline antibiotic doxorubicin, with potential antineoplastic activity. Upon administration of the curcumin/doxorubicin-encapsulating nanoparticle IMX-110, the curcumin moiety targets and inhibits the activation of STAT3 and NF-kB and prevents STAT3- and NF-kB-mediated signaling pathways, both of which are activated in a variety of human cancers and plays a key role in neoplastic transformation, uncontrolled tumor cell proliferation, tumor resistance to apoptosis, metastasis and immune evasion. The doxorubicin moiety intercalates into DNA and interferes with topoisomerase II activity. This inhibits DNA replication and RNA synthesis, leading to tumor cell growth inhibition and apoptosis. This agent also interacts with cell membrane lipids causing lipid peroxidation. Delivery of doxorubicin in nanoparticles may improve drug penetration into tumors and curcumin, by inhibiting NFkB and STAT3 activity, may circumvent the tumor cells multidrug resistance mechanisms and may therefore be effective in chemoresistant tumor cells. Chemotherapeutic agents, such as doxorubicin, upregulate the expression of NF-kB in tumor cells which generates chemotherapy-resistant tumor cells.	Doxorubicin-loaded EGFR-targeting Nanocells		Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15456>	C15313	Low-LET Implant Therapy	Radiation therapy using low-energy-emitting implanted radiation sources.			Therapeutic or Preventive Procedure	
C154570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154570>	C1742|C155727	Nintedanib Esylate|Methyl (3Z)-3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino) (phenyl)methylidene)-2-oxo-2,3-dihydro-1H-indole-6-carboxylate Ethanesulfonate|NINTEDANIB ESYLATE|Nintedanib Ethanesulfonate|Ofev	The esylate salt form of nintedanib, an orally bioavailable, indolinone-derived inhibitor of multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs), with potential antiangiogenic, antifibrotic and antineoplastic activities. Upon administration, nintedanib selectively binds to and inhibits vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), and colony stimulating factor 1 receptor (CSF1R) tyrosine kinases, which may result in the induction of endothelial cell apoptosis, the reduction in tumor vasculature, the inhibition of tumor cell proliferation and migration, and antifibrotic activity in pulmonary fibrosis. In addition, nintedanib also binds to and inhibits members of the Src family of tyrosine kinases, including Src, Lck and Lyn, and fms-like tyrosine kinase 3 (FLT-3). VEGFR, FGFR, PDGFR and CSF1R RTKs play key roles in tumor angiogenesis, tumor cell proliferation and metastasis, as well as pulmonary fibrosis.			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C154571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154571>	C91105	Adherence Starts With Knowledge 12 Questionnaire|ASK-12	A 12 question patient-report measure designed to identify factors that influence medication adherence and adherence-related behavior. It was derived from the ASK-20 questionnaire.			Intellectual Product	
C154572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154572>	C25616	More than 3 Months Ago|More than 3 months ago	A period of time more than 3 months before the present.			Temporal Concept	Adherence Starts With Knowledge 12 Questionnaire
C154573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154573>	C91106	Neutral	A response indicating that a person has a neutral opinion.			Intellectual Product	Adherence Starts With Knowledge 12 Questionnaire
C154574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154574>	C176020	Forgot to Take Medicines Some of the Time Question|Forgot to Take Medicines Some of the Time|I just forget to take my medicines some of the time	A question about whether a person sometimes just forgets to take their medicines.			Intellectual Product	Adherence Starts With Knowledge 12 Questionnaire
C154575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154575>	C91102	Run Out of Medicine Because Do Not Get Refills on Time Question|I run out of my medicine because I don't get refills on time|Run Out of Medicine Because Do Not Get Refills on Time	A question about whether a person runs out of medicine because they do not get refills in time.			Intellectual Product	Adherence Starts With Knowledge 12 Questionnaire
C154576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154576>	C173984	Taking Medicines More than Once a Day is Inconvenient Question|Taking Medicines More than Once a Day is Inconvenient|Taking medicines more than once a day is inconvenient	A question about whether a person feels that taking medicines more than once a day is inconvenient.			Intellectual Product	Adherence Starts With Knowledge 12 Questionnaire
C154577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154577>	C173086	Feel Confident Each Medicine Will Help Question|Feel Confident Each Medicine Will Help|I feel confident that each one of my medicines will help me	A question about whether a person feels confident that each of their medicines will help them.			Intellectual Product	Adherence Starts With Knowledge 12 Questionnaire
C154578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154578>	C177743	Know if Reaching Health Goals Question|I know if I am reaching my health goals|Know if Reaching Health Goals	A question about whether a person knows if they are reaching their health goals.			Intellectual Product	Adherence Starts With Knowledge 12 Questionnaire
C154579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154579>	C172728	Have Someone to Call with Questions about Medicines Question|Have Someone to Call with Questions about Medicines|I have someone I can call with questions about my medicines	A question about whether a person has someone to call with questions about their medicines.			Intellectual Product	Adherence Starts With Knowledge 12 Questionnaire
C15457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15457>	C15313	Low-LET Electron Therapy	Radiation therapy using low energy electrons.	Low-LET Electron Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C154580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154580>	C174127|C173145	Work Together with Doctor or Nurse to Make Decisions Question|My doctor/nurse and I work together to make decisions|Work Together with Doctor or Nurse to Make Decisions	A question about whether a person works together with their doctor or nurse to make decisions.			Intellectual Product	Adherence Starts With Knowledge 12 Questionnaire
C154581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154581>	C173984	Have Taken a Medicine More or Less Often than Prescribed Question|Have Taken a Medicine More or Less Often than Prescribed|Have you taken a medicine more or less often than prescribed	A question about whether a person has taken a medicine more or less often than prescribed.			Intellectual Product	Adherence Starts With Knowledge 12 Questionnaire
C154582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154582>	C173597	Have Skipped or Stopped Medicine Because Didn't Think it was Working Question|Have Skipped or Stopped Medicine Because Didn't Think it was Working|Have you skipped or stopped taking a medicine because you didn't think it was working	A question about whether a person has skipped or stopped taking a medicine because they didn't think it was working.			Intellectual Product	Adherence Starts With Knowledge 12 Questionnaire
C154583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154583>	C173219	Have Skipped or Stopped Medicine Because it Made You Feel Bad Question|Have Skipped or Stopped Medicine Because it Made You Feel Bad|Have you skipped or stopped taking a medicine because it made you feel bad	A question about whether a person has skipped or stopped taking a medicine because it made them feel bad.			Intellectual Product	Adherence Starts With Knowledge 12 Questionnaire
C154584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154584>	C173984	Have Skipped, Stopped, Not Refilled, or Taken Less Medicine Because of Cost Question|Have Skipped, Stopped, Not Refilled, or Taken Less Medicine Because of Cost|Have you skipped, stopped, not refilled, or taken less medicine because of the cost	A question about whether a person has skipped, stopped, took less, or did not refill a medicine because of the cost.			Intellectual Product	Adherence Starts With Knowledge 12 Questionnaire
C154585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154585>	C91102	Did not Have Medicine When Time to Take it Question|Did not Have Medicine When Time to Take it|Have you not had medicine with you when it was time to take it	A question about whether a person did not have their medicine with them when it was time to take it.			Intellectual Product	Adherence Starts With Knowledge 12 Questionnaire
C154586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154586>	C16742	Dermatoscope	An instrument that employs light and magnification to evaluate skin lesions.	Dermatoscope		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C154587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154587>	C171282	Patch Dosage Form Category|Patch	A type of solid pharmaceutical dose form consisting of a flexible preparation, with an adhesive layer and a reservoir of active substance(s) that is usually behind a semi-permeable membrane. Plasters are excluded.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C154588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154588>	C154586	Melanoma Advanced Imaging Dermatoscope|mAID	A dermatoscope designed to use hyperspectral imaging and software algorithms to identify early-stage skin melanomas with high specificity.	Melanoma Advanced Imaging Dermatoscope		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C154589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154589>	C199142|C161324	Focus Group|focus group	A small, usually diverse group of people whose response to something is studied to determine the response that can be expected from a larger population. It is used especially in market research and political analysis.	Focus Group		Group	CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C15458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15458>	C15849	High-LET Heavy Ion Therapy|Heavy Ion Radiation|Therapy, High-LET Heavy Ion	Radiation therapy using high energy charged particles.			Therapeutic or Preventive Procedure	
C154590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154590>	C171282	Pellet Dosage Form Category|Pellets	A type of solid pharmaceutical dose form consisting of usually cylindrical masses, usually formed by extrusion.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C154591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154591>	C171282	Pessary Dosage Form Category|Pessary	A type of solid pharmaceutical dose form consisting of a material that is usually ovoid and formed by moulding, of a suitable volume and consistency for insertion into the vagina where it dissolves, disperses or melts.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C154592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154592>	C171282	Pillule Dosage Form Category|Pillules	A type of solid pharmaceutical dose form consisting of small spheroids that are sufficiently resistant to withstand handling, used for homeopathic medicine.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C154593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154593>	C171282	Plaster Dosage Form Category|Plaster	A type of solid pharmaceutical dose form consisting of a flexible preparation with an adhesive layer containing active substance(s). Patches are excluded.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C154594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154594>	C171282	Pouch Dosage Form Category|Pouch	A type of solid pharmaceutical dose form that consists of a small bag that is intended to be placed in a body cavity for release of the active substance(s) contained within.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C154595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154595>	C171283	Poultice Dosage Form Category|Poultice	A type of semi-solid pharmaceutical dose form consisting of a moist mass, such as meal, herbs, seeds, etc., usually held within or spread upon an appropriate permeable material or dressing.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C154596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154596>	C171282	Powder Dosage Form Category|Powder	A type of solid pharmaceutical dose form consisting of dry, finely divided, loose particles, or freeze-dried preparations thereof.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C154597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154597>	C154551	Shampoo Dosage Form Category|Shampoo	A type of liquid (or occasionally semi-solid) pharmaceutical dose form that contains surface-active agents and usually forms a foam after rubbing on the scalp with water.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C154598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154598>	C154551	Solution Dosage Form Category|Solution|Solution	A type of liquid pharmaceutical dose form consisting of one or more substances dissolved in, or miscible with, an appropriate solvent, forming a single-phase liquid.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology|PQ/CMC Basic Liquid Dose Form Terminology
C154599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154599>	C150386	Spray Dosage Form Category	A type of pharmaceutical dose form that may be liquid, semi-solid or solid, administered as a dispersion in air; to be used only when further details of the specific form (e.g. solution, suspension, powder) are unknown.			Classification	
C15459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15459>	C15849	High-LET Pion Therapy|therapy, high-LET pion	Radiation therapy using high energy pions.			Therapeutic or Preventive Procedure	
C1545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1545>	C593|C222322	Recombinant Human Interleukin-15|IL15|Interleukin 15|RECOMBINANT HUMAN INTERLEUKIN-15|rIL15|rhIL-15	A recombinant agent that is chemically identical or similar to the endogenous form of the human cytokine interleukin-15 (IL-15) with immunomodulating activity. IL-15, secreted by mononuclear phagocytes (and some other cell types) following viral infection, regulates T and natural killer cell activation and proliferation. This cytokine induces activation of transcription activators STAT3, STAT5, and STAT6 via JAK kinase signal transduction pathways in mast cells, T cells, and dendritic epidermal T cells. IL-15 and interleukin-2 (IL-2) are structurally similar and share many biological activities; both may bind to common hematopoietin receptor subunits, negatively regulating each other's activity. CD8+ memory T cell number has been shown to be regulated by a balance between IL-15 and IL-2.	Recombinant Human Interleukin-15		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C154600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154600>	C171282	Stick Dosage Form Category|Stick	A type of solid pharmaceutical dose form consisting of a preparation usually in a cylindrical or conical shape, usually prepared by compression or moulding, intended for insertion in or application to a specific area of the body.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C154601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154601>	C171282	Suppository Dosage Form Category|Suppository	A type of solid pharmaceutical dose form consisting of a material that is usually formed by moulding, of a suitable shape, volume and consistency for insertion into the rectum where it dissolves, disperses or melts.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C154602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154602>	C154551	Suspension Dosage Form Category|Suspension	A type of liquid pharmaceutical dose form consisting of one or more substances dispersed in a liquid vehicle; the dispersed substance(s) are solid particles that are practically insoluble in the vehicle.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C154604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154604>	C154551	Syrup Dosage Form Category|Syrup	A type of liquid pharmaceutical dose form consisting of a viscous liquid usually with a high concentration of sugar or other sweetening agent.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C154605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154605>	C171282	Tablet Dosage Form Category|Tablet|Tablet	A type of solid pharmaceutical dose form consisting of a mass that is formed by compression of uniform volumes of particulate solids, or by other means such as extrusion or moulding.			Classification	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology|PQ/CMC Basic Solid Dose Form Terminology
C154606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154606>	C15195	Endoesophageal Brachytherapy|Esophageal Brachytherapy	The use of localized, internal radiation therapy for the treatment of esophageal cancer.	Endoesophageal Brachytherapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C154607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154607>	C17423	6-Channel Balloon Repositioning, Multichannel Applicator|E-App|Esophageal Applicator	A five-balloon self-centering applicator with one treatment catheter. The five balloons center and anchor the catheter within the esophagus and the catheter is used to deliver localized therapy.	6-Channel Balloon Repositioning, Multichannel Applicator		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C154608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154608>	C4813|C36263	Recurrent Metastatic Malignant Neoplasm	The reemergence of a metastatic malignant neoplasm after a period of remission.	Recurrent Metastatic Malignant Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C154609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154609>	C174459	Siewert Classification|Siewert Classification of Adenocarcinoma of the Esophagogastric Junction|Siewert-Stein Classification	A system of anatomical classification used for adenocarcinomas of the esophagogastric junction.	Siewert Classification		Classification	CTRP Disease Terminology|CTRP Terminology
C15460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15460>	C15687|C15313	Mixed High-Low LET Therapy	Radiation therapy using a mixture of low and high energy-emitting materials.			Therapeutic or Preventive Procedure	
C154610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154610>	C154609	Siewert Type I	An adenocarcinoma of the lower esophagus with the center located 1 cm to 5 cm above the esophagogastric junction.	Siewert Type I		Classification	CTRP Disease Terminology|CTRP Terminology
C154611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154611>	C154609	Siewert Type II	A true carcinoma of the cardia with the tumor center within 1 cm above and 2 cm below the esophagogastric junction.	Siewert Type II		Classification	CTRP Disease Terminology|CTRP Terminology
C154612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154612>	C154609	Siewert Type III	A subcardial carcinoma with the tumor center between 2 and 5 cm below the esophagogastric junction, with infiltration of the esophagogastric junction and lower esophagus from below.	Siewert Type III		Classification	CTRP Disease Terminology|CTRP Terminology
C154613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154613>	C16684	Histone H2A-Bbd|H2A Barr Body Deficient|H2A Barr Body-Deficient|H2A-Bbd|H2A.B|H2A.Bbd	A variant form of histone H2A found in chromatin structures that are transcriptionally active.			Amino Acid, Peptide, or Protein	GDC Terminology|GDC Value Terminology
C154614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154614>	C26702	Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay|ARSACS|SPAX6|Spastic Ataxia 6	An autosomal recessive condition caused by mutation(s) in the SACS gene, encoding sacsin. It is characterized by  early onset cerebellar ataxia, pyramidal tract signs and peripheral neuropathy.			Disease or Syndrome	Cellosaurus Disease Terminology
C154615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154615>	C27874	Leukocyte Adhesion Deficiency Type 3|LAD-3|LAD-III	An autosomal recessive condition caused by mutation(s) in the FERMT3 gene, encoding fermitin family homolog 3. It is characterized by a defect in activation of all beta integrins. It manifests clinically as severe infections with marked leukocytosis, accompanied by life-threatening bleeding episodes.			Disease or Syndrome	Cellosaurus Disease Terminology
C154617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154617>	C95405|C191984	Digestive System Large Cell Neuroendocrine Carcinoma|Gastrointestinal System Large Cell Neuroendocrine Carcinoma	An aggressive high-grade carcinoma with neuroendocrine differentiation that arises from the digestive system and is composed of malignant large cells. The mitotic count is more than 20 per 2 mm2 and/or the Ki-67 index is more than 20% (often more than 70%).			Neoplastic Process	
C154618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154618>	C53543	Lethal Neonatal Rigidity and Multifocal Seizure Syndrome|RMFSL	A rare, autosomal recessive genetic disorder caused by mutations in the BRAT1 gene that is characterized by microcephaly, neonatal onset of multifocal epilepsy, developmental arrest, and early death.			Disease or Syndrome	Cellosaurus Disease Terminology
C154619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154619>	C77140	Prior Invasive Malignancy|Prior Invasive Cancer	A finding indicating the presence of a previously diagnosed invasive malignant neoplasm.			Finding	
C15461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15461>	C15262	Non-Specific Immune-Modulator Therapy|Non-specific Immunotherapy|nonspecific immune stimulation	The use of immune system modulators to enhance immunity in a general, non-specific way.			Therapeutic or Preventive Procedure	
C154620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154620>	C154619	Prior Invasive Malignancy of Other Sites|Prior Invasive Cancer of Other Sites	A finding indicating the presence of a previously diagnosed malignant neoplasm infiltrating other, non-specified anatomic sites.			Finding	
C154621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154621>	C156486|C147065	Advanced Neuroendocrine Tumor|Advanced Carcinoid Tumor|Advanced Carcinoid Tumor|Advanced Well Differentiated Neuroendocrine Neoplasm|Advanced Well Differentiated Neuroendocrine Neoplasm	A neuroendocrine tumor that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Carcinoid Tumor|Advanced Well Differentiated Neuroendocrine Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C154622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154622>	C9237|C4004|C159565	Recurrent Gastric Adenocarcinoma	The reemergence of gastric adenocarcinoma after a period of remission.	Recurrent Gastric Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C154623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154623>	C25616	Enrollment Period|ENROLLMENT|Enrollment Table	A period of time during which a person is expected to have complete data capture. This concept is often insurance-based, but other methods of defining enrollment are possible.			Temporal Concept	
C154624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154624>	C62143	Healthcare Encounter|ENCOUNTER|Encounter Table	Interactions between patients and providers within the context of healthcare delivery.			Conceptual Entity	
C154625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154625>	C25162	Diagnosis Code|DIAGNOSIS|Diagnosis Table	Diagnosis codes indicate the results of diagnostic processes and medical coding within healthcare delivery. Data in this table are expected to be from healthcare-mediated processes and reimbursement drivers.			Intellectual Product	
C154626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154626>	C25162	Procedure Code|PROCEDURES|Procedure Table	Procedure codes indicate the discrete medical interventions and diagnostic testing, such as surgical procedures and lab orders, delivered within a healthcare context.			Intellectual Product	CDISC DDF Procedure Attribute Terminology|CDISC DDF Terminology|Clinical Data Interchange Standards Consortium Terminology
C154627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154627>	C222318|C210686	Daromun|Darleukin and Fibromun|Darleukin/Fibromun|L19-IL2 and L19-TNF-alpha|L19-IL2/L19-TNF-alpha|L19IL2/L19TNF	A combination of darleukin (L19-IL2), an immunocytokine consisting of the recombinant form of interleukin-2 (IL-2), fused to a human single-chain variable fragment (scFv) directed against the extra-domain B (ED-B) of fibronectin (L19), and fibromun (L19-TNFalpha), an immunocytokine consisting of human tumor necrosis factor alpha (TNFalpha) fused to a human scFv antibody fragment directed against the ED-B of L19, with potential antineoplastic and immunostimulating activities. Upon administration, the L-19 moieties of each immunocytokine bind to the ED-B domain of fibronectin on tumor cells in the tumor neovasculature. In turn, the IL-2 and TNF-alpha moieties of darleukin and fibromun, respectively, may locally induce an immune response against ED-B fibronectin-expressing tumor cells. ED-B is predominantly expressed during angiogenesis and tumor growth.	Daromun		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C154628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154628>	C100104	Vital Signs|AGE_AT_VITALS|VITAL|Vital Sign|vital signs|vital_signs	Vital signs (such as height, weight, and blood pressure) directly measure an individual's current state of attributes.			Finding	ICDC Node Terminology|ICDC Terminology|ICH M11 Protocol Section 8 Data Element Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology|OS Variable Terminology|OS Vitals Table
C154629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154629>	C128533	Dispensing|DISPENSING	Prescriptions filled through a community, mail-order or hospital pharmacy. Outpatient dispensing may not be directly captured within healthcare systems.			Therapeutic or Preventive Procedure	
C15462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15462>	C15194	In Vitro-Treated Bone Marrow Transplantation|antibody treated bone marrow transplant|antibody treated bone marrow transplantation|in vitro-treated bone marrow transplant|monoclonal antibody treated bone marrow transplant|monoclonal antibody treated bone marrow transplantation	Bone marrow transplantation where the marrow is manipulated outside the body before administration to a recipient.	In Vitro-Treated Bone Marrow Transplantation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C154630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154630>	C62289	Lab Result CM Domain|LAB_RESULT_CM|LAB_RESULT_CM Table	This table is used to store quantitative and qualitative measurements from blood and other body specimens.			Functional Concept	
C154631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154631>	C62289	Condition Domain|CONDITION|Condition Table	A condition represents a patient's diagnosed and self-reported health conditions and diseases. The patient's medical history and current state may both be represented.			Functional Concept	
C154632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154632>	C62289	Patient-Reported Outcomes CM Domain|PRO_CM|PRO_CM Table	This table is used to store responses to patient-reported outcome measures (PROs) or questionnaires. This table can be used to store item-level responses as well as the overall score for each measure.			Functional Concept	
C154633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154633>	C62289	Prescribing Domain|PRESCRIBING|Prescribing Table	Provider orders for medication dispensing and/or administration. These orders may take place in any setting, including the inpatient or outpatient basis.			Functional Concept	
C154634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154634>	C62289	PCORNet Trial Domain|PCORNET_TRIAL|PCORnet Trial Table	Patients who are enrolled in PCORnet clinical trials and PCORnet studies.			Functional Concept	
C154635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154635>	C62289	Death Domain|DEATH|Death Table	Reported mortality information for patients.			Functional Concept	
C154636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154636>	C62289	Death Cause Domain|DEATH_CAUSE|Death Cause Table	The individual causes associated with a reported death.			Functional Concept	
C154637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154637>	C62289	Medication Administered Domain|MED_ADMIN|MED_ADMIN Table	Records of medications administered to patients by healthcare providers. These administrations may take place in any setting, including inpatient, outpatient or home health encounters.			Functional Concept	
C154638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154638>	C62289	Provider Domain|PROVIDER|Provider Table	Data about the providers who are involved in the care processes documented in the CDM.			Functional Concept	
C154639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154639>	C62289	General Observation Domain|OB|OBS_GEN|OBS_GEN Table	A subject domain that is used for storing standardized qualitative and quantitative general observations that are not stored elsewhere.			Functional Concept	
C15463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15463>	C54708	Chemosensitization|Chemosensitization/Potentiation|Potentiation|potentiation	The synergistic action of two drugs, being greater than the sum of the effects of each used alone.			Phenomenon or Process	
C154640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154640>	C62289	Clinical Observation Domain|Clin Obs Domain|OBS_CLIN|OBS_CLIN Table|OC	A subject domain that is used for storing standardized qualitative and quantitative clinical observations about a patient, including vital signs.			Functional Concept	
C154641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154641>	C95405|C156457	Digestive System Small Cell Neuroendocrine Carcinoma|Digestive System Small Cell Carcinoma|Gastrointestinal System Small Cell Neuroendocrine Carcinoma	An aggressive high-grade carcinoma with neuroendocrine differentiation that arises from the digestive system and is composed of malignant small cells. The mitotic count is more than 20 per 2 mm2 and/or the Ki-67 index is more than 20% (often more than 70%).			Neoplastic Process	
C154642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154642>	C49755	Pipette Closure Device|Pipette applicator	Closure with pipette.			Manufactured Object	EDQM Health Care Terminology|EDQM-HC Closure Terminology
C154643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154643>	C154302	H3C15 Gene|H3 Clustered Histone 15 Gene|H3C15|H3C15|HIST2H3A	This gene is involved in the formation of complex DNA-containing structures.			Gene or Genome	
C154644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154644>	C154643	H3C15 wt Allele|H3 Clustered Histone 15 wt Allele|H3 Histone Family, Member N Gene|H3 Histone Family, Member O Gene|H3/n|H3/o|H3FN|HIST2H3A|Histone 2, H3a Gene|Histone Cluster 2 H3 Family Member A Gene|Histone Cluster 2, H3a Gene	Human H3C15 wild-type allele is located in the vicinity of 1q21.2 and is approximately 2 kb in length. This allele, which encodes histone H3.2 protein, plays a role in chromatin structure.			Gene or Genome	
C154645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154645>	C154302	H3C14 Gene|H3 Clustered Histone 14 Gene|H3C14|H3C14|HIST2H3C	This gene plays a role in the incorporation of DNA into nucleosomes.			Gene or Genome	
C154646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154646>	C154645	H3C14 wt Allele|H3 Clustered Histone 14 wt Allele|H3 Histone Family, Member M Gene|H3 Histone Family, Member N Gene|H3 Histone, Family 2 Gene|H3/M|H3/m|H3F2|H3FM|HIST2 Cluster, H3C Gene|HIST2H3C|Histone 2, H3c Gene|Histone Cluster 2 H3 Family Member C Gene|Histone Cluster 2, H3c Gene|Histone Gene Cluster 2, H3 Family, Member C Gene|Histone Gene Cluster 2, H3c Gene|MGC9629	Human H3C14 wild-type allele is located in the vicinity of 1q21.2 and is approximately 2 kb in length. This allele, which encodes histone H3.2 protein, is involved in the formation of complex DNA-containing structures.			Gene or Genome	
C154647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154647>	C154302	H3C13 Gene|H3 Clustered Histone 13 Gene|H3C13|H3C13|HIST2H3D	This gene is involved in DNA compaction.			Gene or Genome	
C154648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154648>	C154647	H3C13 wt Allele|H3 Clustered Histone 13 wt Allele|HIST2H3D|Histone 2, H3d Gene|Histone Cluster 2 H3 Family Member D Gene|Histone Cluster 2, H3d Gene	Human H3C13 wild-type allele is located in the vicinity of 1q21.2 and is approximately 1 kb in length. This allele, which encodes histone H3.2 protein, plays a role in the incorporation of DNA into nucleosomes.			Gene or Genome	
C154649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154649>	C154299	H2AB1 Gene|H2A.B Variant Histone 1 Gene|H2AB1|H2AB1|H2AFB1	This gene plays a role in DNA compaction, gene transcription and mRNA processing.			Gene or Genome	
C15464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15464>	C49236	Radiosensitization|RADIOSENSITIZATION|radiosensitization	Any action that serves to increase the toxic or lethal effect of radiation therapy on cells, through physical, chemical, or pharmaceutical intervention.			Therapeutic or Preventive Procedure	CDISC SDTM Terminology|CDISC SDTM Treatment Setting Terminology|Clinical Data Interchange Standards Consortium Terminology
C154650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154650>	C154649	H2AB1 wt Allele|H2A Histone Family Member B1 Gene|H2A Histone Family, Member B1 Gene|H2A.B|H2A.B Variant Histone 1 wt Allele|H2A.Bbd|H2AFB1	Human H2AB1 wild-type allele is located in the vicinity of Xq28 and is approximately 1 kb in length. This allele, which encodes histone H2A-Bbd type 1 protein, is involved in the modulation of DNA compaction, which regulates gene transcription and mRNA processing.			Gene or Genome	
C154651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154651>	C154613	Histone H2A-Bbd Type 1|H2A Barr Body-Deficient|H2A.B|H2A.Bbd|H2AB1|H2AFB1	Histone H2A-Bbd type 1 (115 aa, ~13 kDa) is encoded by the human H2AB1 gene. This protein plays a role in chromatin structures that are associated with active gene expression.			Amino Acid, Peptide, or Protein	
C154652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154652>	C154299	H2AB2 Gene|H2A.B Variant Histone 2 Gene|H2AB2|H2AB2|H2AFB2	This gene plays a role in chromatin compaction, transcriptional activation and mRNA processing.			Gene or Genome	
C154653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154653>	C154652	H2AB2 wt Allele|H2A Histone Family Member B2 Gene|H2A Histone Family, Member B2 Gene|H2A.B Variant Histone 2 wt Allele|H2A.Bbd|H2AFB2	Human H2AB2 wild-type allele is located in the vicinity of Xq28 and is approximately 1 kb in length. This allele, which encodes histone H2A-Bbd type 2/3 protein, plays a role in the modulation of both gene transcription and mRNA processing.			Gene or Genome	
C154654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154654>	C154299	H2AB3 Gene|H2A.B Variant Histone 3 Gene|H2AB3|H2AB3|H2AFB3	This gene plays a role in the modulation of chromatin structure.			Gene or Genome	
C154655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154655>	C154654	H2AB3 wt Allele|H2A Histone Family Member B3 Gene|H2A Histone Family, Member B3 Gene|H2A.B Variant Histone 3 wt Allele|H2ABBD|H2AFB|H2AFB3|Histone Variant H2A, Barr-Body Deficient Gene	Human H2AB3 wild-type allele is located in the vicinity of Xq28 and is approximately 1 kb in length. This allele, which encodes histone H2A-Bbd type 2/3 protein, is involved in the modulation of DNA compaction, which regulates gene transcription and mRNA processing.			Gene or Genome	
C154656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154656>	C154613	Histone H2A-Bbd Type 2/3|H2A Barr Body Deficient|H2A Barr Body-Deficient|H2A.B|H2A.Bbd|H2AB2/3	Histone H2A-Bbd type 2/3 (115 aa, ~13 kDa) is encoded by the human H2AB2 and H2AB3 genes. This protein plays a role in the promotion of gene expression.			Amino Acid, Peptide, or Protein	
C154657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154657>	C154299	MACROH2A2 Gene|H2AFY2|MACROH2A2|MACROH2A2|MacroH2A.1 Histone Gene	This gene plays a role in the formation of chromatin structures that repress gene transcription.			Gene or Genome	
C154658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154658>	C154657	MACROH2A2 wt Allele|H2A Histone Family Member Y2 Gene|H2A Histone Family, Member Y2 Gene|H2AFY2|Macro H2A2 Gene|MacroH2A.1 Histone wt Allele|macroH2A2	Human MACROH2A2 wild-type allele is located in the vicinity of 10q22.1 and is approximately 60 kb in length. This allele, which encodes core histone macro-H2A.2 protein, is involved in transcriptional repression.			Gene or Genome	
C154659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154659>	C95407	Core Histone Macro-H2A.2|Core Histone MacroH2A2.2|H2A2.2|H2AFY2|Histone MacroH2A2|MACROH2A2|mH2A.2|mH2A2	Core histone macro-H2A.2 (372 aa, ~40 kDa) is encoded by the human MACROH2A2 gene. This protein plays a role in nucleosome formation and transcriptional repression.			Amino Acid, Peptide, or Protein	GDC Terminology|GDC Value Terminology
C15465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15465>	C15194	Syngeneic Bone Marrow Transplantation|syngeneic bone marrow transplantation	Bone marrow transplantation in which the donor and recipient are genetically identical.	Syngeneic Bone Marrow Transplantation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C154660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154660>	C27993	Unstable|Unstable Condition|Unstable Status	Subject to change; variable.			Qualitative Concept	
C154661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154661>	C27993	Impossible	Not able to occur, exist, or be done.			Qualitative Concept	
C154662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154662>	C71470	Off Observation	No longer subject to surveillance.			Qualitative Concept	
C154663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154663>	C42972	Powder for Vaginal Solution Dosage Form|Powder for vaginal solution	Solid preparation consisting of one or more powders, including freeze-dried powders, intended to be dissolved in the specified liquid to obtain a vaginal solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C154664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154664>	C49236	Repetitive Transcranial Magnetic Stimulation|rTMS	A form of brain stimulation therapy that has been studied as a treatment for depression, psychosis, anxiety, and other disorders.	Repetitive Transcranial Magnetic Stimulation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C154665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154665>	C45373	Variant Allele Frequency|VAF|allele frequency|allele_frequency	The relative rate of occurrence of a specific variant allele within a population.	Variant Allele Frequency		Quantitative Concept	CTDC Property Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154666>	C154302	H3-5 Gene|H3-5|H3-5|H3.5 Histone Gene|H3F3C	This gene is involved in the regulation of DNA accessibility.			Gene or Genome	
C154667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154667>	C154666	H3-5 wt Allele|H3 Histone Family Member 3C Gene|H3 Histone, Family 3C Gene|H3.3C|H3.5|H3.5 Histone wt Allele|H3F3C|Histone Variant H3.5 Gene	Human H3-5 wild-type allele is located in the vicinity of 12p11.21 and is approximately 1 kb in length. This allele, which encodes histone H3.3C protein, plays a role in the regulation of gene transcription.			Gene or Genome	
C154668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154668>	C16685	Histone H3.3C|H3-5|H3.3C|H3.5|H3.5|H3F3C|Histone H3.5	Histone H3.3C (135 aa, ~15 kDa) is encoded by the human H3-5 gene. This protein is involved in the modulation of DNA accessibility to the transcriptional machinery.			Amino Acid, Peptide, or Protein	GDC Terminology|GDC Value Terminology
C154669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154669>	C154302	H3-4 Gene|H3-4|H3-4|H3.4 Histone Gene|HIST3H3	This gene is involved in the packaging of DNA into nucleosomes.			Gene or Genome	
C15466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15466>	C15301	Laser Therapy|Laser Therapy and Laser Surgery|Therapy, Laser|laser therapy	Any procedure in which an intense beam of light is used to cut, burn, or destroy tissue.	Laser Therapy		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology
C154670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154670>	C154669	H3-4 wt Allele|H3 Histone Family, Member T Gene|H3.4|H3.4 Histone wt Allele|H3/g|H3FT|H3t|HIST3 Cluster, H3 Gene|HIST3H3|Histone 3, H3 Gene|Histone Cluster 3 H3 Gene|Histone Cluster 3, H3 Gene|Histone Gene Cluster 3, H3 Gene|Histone Gene Cluster 3, H3 Histone Gene	Human H3-4 wild-type allele is located in the vicinity of 1q42.13 and is approximately 1 kb in length. This allele, which encodes histone H3.1t protein, plays a role in DNA sequestration.			Gene or Genome	
C154671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154671>	C16685	Histone H3.1t|H3-4|H3.4|H3/g|H3/t|H3t|H3t (H3.4)|HIST3H3|Histone H3.4	Histone H3.1t (136 aa, ~16 kDa) is encoded by the human H3-4 gene. This protein is involved in formation of higher order chromatin structures.			Amino Acid, Peptide, or Protein	GDC Terminology|GDC Value Terminology
C154672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154672>	C25162	Reporting Source Type Code|reportingSourceTypeCode|reportingSourceTypeCode	A coded value specifying the kind of medical record that provided the best information when abstracting the relevant healthcare data.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C154673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154673>	C222259	BrainCheck Cognitive Assessment|BrainCheck	A proprietary set of cognitive assessments designed to aid in diagnosing mild cognitive impairment, dementia, traumatic brain injuries, and sports-related head injuries. The tests are designed to be taken through an app on a mobile device.	BrainCheck Cognitive Assessment		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C154674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154674>	C93144	Clostridium butyricum CBM 588 Probiotic Strain|C. butyricum CBM 588 Probiotic Strain|C. butyricum MIYAIRI Strain|C. butyricum Strain MIYAIRI 588|CBM 588|CBM588|CLOSTRIDIUM BUTYRICUM MIYAIRI 588 STRAIN|Clostridium butyricum MIYAIRI 588|Clostridium butyricum MIYAIRI 588 Probiotic Strain|MIYAIRI 588|MIYAIRI 588 Strain of C. butyricum	A probiotic containing a specific strain of the anaerobic, butyric acid-forming Gram-positive bacterium Clostridium butyricum (C. butyricum), with potential immunomodulatory, anti-inflammatory and antineoplastic activities. Clostridium butyricum MIYAIRI (CBM) 588 is the 588th MIYAIRI strain, isolated from a soil sample in Japan in 1963. Upon oral administration of C. butyricum CBM 588 probiotic strain, C. butyricum modulates the composition of the normal gastrointestinal (GI) microflora, by increasing the beneficial bacteria and decreasing the harmful bacteria, and helps maintain adequate colonization of the GI tract, thereby improving digestion and preventing GI disturbances. These bacteria and the butyric acid produced by them create an environment unfavorable to pathogens by adhering to human epithelial cells and forming a protective mucosal barrier. This prevents attachment of pathogens and reduces the risk of infection. By restoring gut microbiota, these bacteria may restore or enhance intestinal immune responses. C. butyricum induces interleukin-10-producing macrophages in inflamed mucosa via the Toll-like receptor 2 (TLR2)/myeloid differentiation primary response gene 88 (MyD88) pathway, thereby decreasing inflammatory responses. In addition, CBM588 may exert antineoplastic activity by inducing the release of the endogenous cytokine tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) from intracellular stores in polymorphonuclear neutrophils (PMNs), most likely involving matrix metalloproteinase 8 (MMP-8) and the Toll-like receptors (TLR)2/4 signaling pathways. This results in TRAIL-mediated induction of apoptosis in susceptible tumor cells.	Clostridium butyricum CBM 588 Probiotic Strain		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C154675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154675>	C192742|C192741|C1740	Ribociclib/Letrozole|Kisqali Femara Co-pack|Kisqali and Femara Co-pack|Kisqali/Femara|Ribociclib + Letrozole|Ribociclib Plus Letrozole|Ribociclib Succinate/Letrozole|Ribociclib and Letrozole Co-pack|Ribociclib-Letrozole|Ribociclib-Letrozole Regimen	An orally available co-packaged agent combination of the succinate salt form of ribociclib, a cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6, and letrozole, a nonsteroidal inhibitor of estrogen synthesis, with antineoplastic activity. Upon oral administration, ribociclib specifically inhibits CDK4 and CDK6, thereby inhibiting retinoblastoma (Rb) phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Letrozole selectively and reversibly inhibits aromatase, which may result in growth inhibition of estrogen-dependent cancer cells.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C154677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154677>	C2181	Esterified Estrogens|ESTROGENS, ESTERIFIED|Estrogens, Esterified|Menest (BR)	A mixture of the sodium salts of the sulfate esters of estrogen including sodium estrone sulfate, sodium equilin sulfate and the concomitant component, 17 alpha-estradiol, that is used for estrogen replacement. Estrogens bind to nuclear receptors in estrogen-responsive tissues and modulate the secretion of the gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), stimulate skeletal growth, and have a widespread effect on metabolic processes including protein transport and electrolyte balance.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology
C154678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154678>	C41331	Adverse Event by Type	An adverse event that is categorized based on characteristics.			Finding	
C15467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15467>	C52011|C20985	Ablative Endocrine Surgery	Destructive or removal of any part of the endocrine system by surgical means, including the use of lasers or electrical current.			Therapeutic or Preventive Procedure	
C154680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154680>	C163045	Normalized Fluorescence Intensity Unit|NFIU|NFIU|NIU|Normalized Intensity Unit|{NIU}|{NIU}	A relative fluorescence intensity unit that is adjusted to a reference standard.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154681>	C103175	CDISC Protocol Entities Protocol Contact Role Response Terminology|PROT-PROTCRRS|Protocol Contact Role Value Set|Protocol Contact Role Value Set	Terminology associated with the protocol contact role response codelist of the Clinical Data Interchange Standards Consortium (CDISC) protocol entities.			Intellectual Product	
C154682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154682>	C103175	CDISC Protocol Entities Study Contact Information Attribute Terminology|PROT-Att Study Contact Information|Study Contact Information Attribute Terminology|Study Contact Information Attribute Terminology	Terminology associated with the protocol entity study contact information attribute codelist of the Clinical Data Interchange Standards Consortium (CDISC).			Intellectual Product	
C154683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154683>	C103175	CDISC SEND Test Article Physical Substance Classification Response Terminology|SEND-TAPHSCLS	Terminology associated with the test article physical substance classification response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	
C154684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154684>	C77526	CDISC SEND Planned Pharmacologic Target Mode of Action Response Terminology|PPTMDARS|Planned Pharmacologic Target Mode of Action Response|SEND-PPTMDARS	Terminology associated with the planned pharmacologic target mode of action response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154685>	C66830	CDISC SDTM Nutrition Findings About Test Code Terminology|NTFATSCD|Nutrition Findings About Test Code|SDTM-NTFATSCD	Terminology associated with the nutrition findings about test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154686>	C66830	CDISC SDTM Nutrition Findings About Test Name Terminology|NTFATS|Nutrition Findings About Test Name|SDTM-NTFATS	Terminology associated with the nutrition findings about test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154687>	C66830	CDISC SDTM Lung Cancer Findings About Test Code Terminology|LUFATSCD|Lung Cancer Findings About Test Code|SDTM-LUFATSCD	Terminology associated with the lung cancer findings about test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154688>	C66830	CDISC SDTM Lung Cancer Findings About Test Name Terminology|LUFATS|Lung Cancer Findings About Test Name|SDTM-LUFATS	Terminology associated with the lung cancer findings about test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154689>	C17127	Sexual Contact|SEXUAL CONTACT	Sexual interaction between individuals.			Individual Behavior	CDISC SDTM Mode of Disease Transmission Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15468>	C49236	Depigmentation Therapy	A medical treatment that removes skin pigmentation.			Therapeutic or Preventive Procedure	
C154699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154699>	C12948	Main Pancreatic and Accessory Ducts|DUCT, PANCREATIC	Any of the ducts that conveys pancreatic secretions from the pancreas to the duodenum.			Body Part, Organ, or Organ Component	CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15469>	C15411	Interferon Therapy	The use of any form of interferon in the treatment of any disease or disorder.	Interferon Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C1546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1546>	C67422	Cryptophycin|10-((3-Chloro-4-methoxyphenyl)methyl)-6-methyl-3-(2-methylpropyl)-16-(1-(3-phenyloxiranyl)ethyl)-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone|CRYPTOPHYCIN 1|Cryptophycin 1	The cryptophycins are a family of 16-membered macrolide antimitotic agents isolated from the cyanobacteria Nostoc sp. The mechanism of anticancer activity of the cryptophycins has been associated with their destabilization of microtubules and induction of bcl-2 phosphorylation leading to apoptosis. Cryptophycins demonstrated activity against the wide spectrum of solid tumors including those that overexpress the multidrug resistance efflux pump P-glycoprotein. (NCI)			Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C154700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154700>	C2929|C27633	Transplant-Related Squamous Cell Carcinoma|Transplant-Associated Squamous Cell Carcinoma	A squamous cell carcinoma that arises in a patient with a history of organ transplantation.	Transplant-Related Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C154701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154701>	C70914	Apparent Total Body Clearance Rate	The apparent total body clearance for intravascular administration.			Quantitative Concept	
C154702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154702>	C20993	SAE Battery	A series of evaluations designed to learn whether cancer treatment changes emotions, attention span, or behavior, or the way the brain processes and filters information.	SAE Battery		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C154703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154703>	C12814	Calf Muscular Vein|CALF MUSCULAR VEIN	Any of the superficial veins located within the muscles of the posterior lower leg, including the gastrocnemial and soleal veins.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154704>	C93874	Organizational Affiliation Name	The name of the organization or entity that the person or group has an established relationship with.			Intellectual Product	
C154705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154705>	C60776	Study Contact Information	Information regarding the means of contacting a person or group associated with the clinical study.			Conceptual Entity	
C154706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154706>	C51818	National Coordinating Investigator	In the case of a multinational study, a person who has the responsibilities of the sponsor of the study in his/her country and will be responsible for the coordination of the principal investigators at different sites within that member state. (EMA)			Professional or Occupational Group	
C154707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154707>	C60758	Technical Lead	An individual who is responsible for the delivery of technical aspects of a project.			Professional or Occupational Group	
C154708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154708>	C60758	Clinical Informaticist	An individual that designs, implements, evaluates and/or analyzes information technology in a healthcare or research setting.			Professional or Occupational Group	
C154709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154709>	C51877	Biostatistician	A person who is responsible for the statistical aspects of the clinical or pre-clinical study.			Professional or Occupational Group	
C15470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15470>	C15313	Isotope Therapy|Radiation, Radioisotope|Radioactive Isotope Therapy|Radioisotope Therapy|therapy, isotope, radioactive	Treatment of a disease by means of exposure of the target to radioisotopes.			Therapeutic or Preventive Procedure	GDC Terminology|GDC Value Terminology
C154710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154710>	C70700	Archive Sample Retrieval|ARCHIVE RETRIEVING	The act of removing a biological specimen from a biobank or other biorepository for further use.	Archive Sample Retrieval		Laboratory Procedure	CDISC SDTM Biospecimen Events Dictionary Derived Term Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C154711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154711>	C25244	Internal Orifice Area|IORFAREA	The extent of a 2-dimensional surface enclosed within the boundary of an internal orifice.			Spatial Concept	CDISC SDTM Device Properties Test Code Terminology|CDISC SDTM Device Properties Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|Mercaptopurine/Methotrexate/Tretinoin
C154712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154712>	C42614	Dinucleotide Marker Name|DINTMKNM|Dinucleotide Marker Names|Dinucleotide Marker Names	The literal identifier of the dinucleotide markers.			Conceptual Entity	CDISC SDTM Device Properties Test Code Terminology|CDISC SDTM Device Properties Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|Mercaptopurine/Methotrexate/Tretinoin
C154713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154713>	C25337	Number of Electroencephalogram Electrodes|EEGELCTN|Number of EEG Electrodes|Number of EEG Electrodes|Number of EEG Electrodes	The number of electroencephalogram electrodes used in the assessment.			Quantitative Concept	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154716>	C41195	Reference Equation|REFEQU	A calculation based upon a set of normalized data or values that are derived from a specified population.			Intellectual Product	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154717>	C83089	Continuous Surface ECG Recording for Non-human Species|CONTINUOUS SURFACE ECG RECORDING FOR NON-HUMAN SPECIES	A continuous electrocardiographic (ECG) recording utilizing one or more surface leads in a non-human species. (CDISC)			Activity	CDISC SDTM ECG Test Method Terminology|CDISC SDTM Terminology|CDISC SEND ECG Method Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154718>	C83089	Continuous ECG Recording for Non-human Species Using Implanted Leads|CONTINUOUS ECG RECORDING FOR NON-HUMAN SPECIES USING IMPLANTED LEADS	A continuous electrocardiographic (ECG) recording utilizing one or more implanted leads in a non-human species. (CDISC)			Activity	CDISC SDTM ECG Test Method Terminology|CDISC SDTM Terminology|CDISC SEND ECG Method Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154719>	C67208	Erythroid Cells to Total Cells Ratio Measurement|ERCECE|Erythroid Cells/Total Cells|Erythroid Cells/Total Cells	The determination of the ratio of erythroid cells compared to total cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15471>	C15187	Replacement Therapy	Administration of a body substance to compensate for the loss, as from disease or surgery, of a gland or tissue that would normally produce the substance.			Therapeutic or Preventive Procedure	
C154720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154720>	C67208	Erythroid Cells to Nucleated Cells Ratio Measurement|ERCENC|Erythroid Cells/Nucleated Cells|Erythroid Cells/Nucleated Cells	The determination of the ratio of erythroid cells compared to nucleated cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154721>	C119270	Standard Base Excess Measurement|STBSEXCS|Standard Base Excess|Standard Base Excess	A calculated measurement of the amount of acid required to return blood with hemoglobin at 5g/dL, which is used as a surrogate for extracellular fluid, to a normal pH under standard conditions.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154722>	C67208	Megakaryocytes to Leukocytes Ratio Measurement|KRCYMGLE|KRCYMGLE|Megakaryocytes/Leukocytes|Megakaryocytes/Leukocytes|Megakaryocytes/Leukocytes	The determination of the ratio of megakaryocytes compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Cell Phenotyping Test Code Terminology|CDISC SDTM Cell Phenotyping Test Name Terminology|CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154723>	C51951	Immature Platelet Count|Immature Platelets|Immature Platelets|PLATIM|Reticulated Platelets	The determination of the amount of immature platelets present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154724>	C64430|C209976	Krebs von den Lungen-6 Measurement|KL-6|KL-6 Measurement|KL6|Krebs von den Lungen-6|Krebs von den Lungen-6 Antigen	The determination of the amount of Krebs von den Lungen-6 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154725>	C210010	Islet Cell Antibody Measurement	The determination of the amount of islet cell antibody present in a sample.			Laboratory Procedure	
C154726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154726>	C74949	Atherogenic Index of Plasma|AIP|ATHPIDX|Atherogenic Index	The determination of the base 10 logarithm of the ratio of molar concentration of plasma triglyceride to high density lipoprotein cholesterol present in a sample			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154727>	C64430	Fibroblast Growth Factor 19 Measurement|FGF 19|FGF19|FGF19 Measurement|Fibroblast Growth Factor 19|Fibroblast Growth Factor 19	The determination of the amount of fibroblast growth factor 19 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154728>	C64430	Scavenger Receptor Cysteine-Rich Type 1 Protein M130 Measurement|M130|Scavenger Rcpt Cys-Rich Type1 Prot M130|Scavenger Rcpt Cys-Rich Type1 Prot M130|Scavenger Receptor Cysteine-Rich Type 1 Protein M130|Soluble CD163|Soluble CD163a	The determination of the amount of scavenger receptor cysteine-rich type 1 protein M130 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154729>	C64430	Retinol Binding Protein to Creatinine Ratio Measurement|RBPCREAT|Retinol Binding Protein/Creatinine|Retinol Binding Protein/Creatinine	The determination of the ratio of retinol binding protein compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15472>	C63475	Adrenal Blockade	Treatment to block production of adrenal hormones.			Therapeutic or Preventive Procedure	
C154730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154730>	C202425	S100 Calcium Binding Protein A8 Measurement|S100 Calcium Binding Protein A8|S100 Calcium Binding Protein A8|S100A8|S100A8 Measurement	The determination of the amount of S100 calcium binding protein A8 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154731>	C139083	4-Hydroxymidazolam Measurement|4-Hydroxymidazolam|4-Hydroxymidazolam|HYDMDZ4	The determination of the amount of 4-hydroxymidazolam present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154732>	C139083	1-Hydroxymidazolam Measurement|1'-Hydroxymidazolam|1-Hydroxymidazolam|1-Hydroxymidazolam|Alpha-Hydroxymidazolam|HYDMDZ1	The determination of the amount of 1-hydroxymidazolam present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154733>	C51951	Bizarre Platelet Count|Bizarre Platelets|Bizarre Platelets|PLATBIZ	The determination of the amount of bizarre platelets present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154734>	C64431	Albumin Index|ALBIDX	A relative measurement (ratio) of the albumin in cerebrospinal fluid to albumin in serum in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154735>	C81971	IgG Index|CSF IgG Index|CSF IgG Index|CSF Index|CSFIGIDX	A relative measurement (ratio) of the IgG in cerebrospinal fluid to IgG in serum in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154736>	C64430	E-selectin Measurement|E-Selectin|E-Selectin|ESELECT|SELE Measurement	The determination of the amount of E-selectin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154737>	C81869	Immunoglobulin Heavy Constant Gamma 2 Measurement|IGHG2|Immunoglobulin Heavy Constant Gamma 2|Immunoglobulin Heavy Constant Gamma 2	The determination of the amount of immunoglobulin heavy constant gamma 2 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154738>	C81869	Immunoglobulin Heavy Constant Gamma 4 Measurement|IGHG4|Immunoglobulin Heavy Constant Gamma 4|Immunoglobulin Heavy Constant Gamma 4	The determination of the amount of immunoglobulin heavy constant gamma 4 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154739>	C81183	Tryptophan Measurement|TRP|Tryptophan|Tryptophan	The determination of the amount of tryptophan present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15473>	C62740	Nausea and Vomiting Therapy|antiemetic support|management of nausea and vomiting|nausea and vomiting management|vomiting and nausea management	Therapies designed to reduce the frequency and intensity of nausea and vomiting.	Nausea and Vomiting Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C154740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154740>	C81183	Kynurenine Measurement|KYNURNN|Kynurenine|Kynurenine	The determination of the amount of kynurenine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154741>	C49237	Lactulose Measurement|LACTULOS|Lactulose|Lactulose	The determination of the amount of lactulose present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154742>	C49237	Mannitol Measurement|MANNITOL|Mannitol|Mannitol	The determination of the amount of mannitol present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154743>	C64430	Aldrin Epoxidase Measurement|ALDEPX|Aldrin Epoxidase|Aldrin Epoxidase	The determination of the amount of aldrin epoxidase present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154744>	C64430	Nociceptin Measurement|NCCPTN|Nociceptin|Nociceptin|Orphanin FQ	The determination of the amount of nociceptin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154745>	C49237	Thiocyanate Measurement|SCN|Thiocyanate|Thiocyanate	The determination of the amount of thiocyanate present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154746>	C213867	HLA Class IA Histocompatibility Antigen Measurement|HLA Class IA Antigen|HLA Class IA Antigen|HLA-A Antigen Measurement|HLAA	The determination of the amount of HLA class IA histocompatibility antigen present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154747>	C213867	HLA Class IB Histocompatibility Antigen Measurement|HLA Class IB Antigen|HLA Class IB Antigen|HLA-B Antigen Measurement|HLAB	The determination of the amount of HLA class IB histocompatibility antigen present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154748>	C213867	HLA Class IC Histocompatibility Antigen Measurement|HLA Class IC Antigen|HLA Class IC Antigen|HLA-C Antigen Measurement|HLAC	The determination of the amount of HLA class IC histocompatibility antigen present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154749>	C181192	HLA DR Beta1 Histocompatibility Antigen Measurement|HLA DR Beta1 Antigen|HLA DR Beta1 Antigen|HLA-DRB1 Antigen Measurement|HLADRB1	The determination of the amount of HLA DR beta1 histocompatibility antigen present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15474>	C16051	Hematologic Toxicity Attenuation|neutropenia attenuation	A treatment designed to reduce or prevent damage to the hematologic system due to adverse events from other drug therapies.	Hematologic Toxicity Attenuation		Therapeutic or Preventive Procedure	CTRP Disease Terminology|CTRP Terminology
C154750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154750>	C213867	HLA DQ Beta1 Histocompatibility Antigen Measurement|HLA DQ Beta1 Antigen|HLA DQ Beta1 Antigen|HLA-DQB1 Antigen Measurement|HLADQB1	The determination of the amount of HLA DQ beta1 histocompatibility antigen present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154751>	C213867	HLA DP Beta1 Histocompatibility Antigen Measurement|HLA DP Beta1 Antigen|HLA DP Beta1 Antigen|HLA-DPB1 Antigen Measurement|HLADPB1	The determination of the amount of HLA DP beta1 histocompatibility antigen present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154752>	C62662|C214530	Factor VIII Inhibitor Measurement|Alloantibody, Factor VIII Inhibitor|FCT8INH|Factor VIII Antibody|Factor VIII Inhibitor	The determination of the amount of factor VIII inhibitor present in a sample.			Laboratory Procedure	CDISC SDTM Immunogenicity Specimen Assessments Test Code Terminology|CDISC SDTM Immunogenicity Specimen Assessments Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154753>	C64488	Albumin Corrected Calcium Measurement|CACRALB|Calcium Corrected for Albumin|Calcium Corrected for Albumin	The determination of the amount of calcium in a sample, which has been corrected for albumin.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154755>	C51950	Segmented and Band Form Neutrophils Measurement|NEUTSGB|Neutrophils, Segmented + Band Form|Neutrophils, Segmented + Band Form	The determination of the amount of segmented and band form neutrophils present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154756>	C51950	Segmented, Band Form and Precursor Neutrophils Measurement|NEUTSGBP|Neutrophils + Immature Neutrophils|Neutrophils, Seg + Band Form + Precursor|Neutrophils, Seg + Band Form + Precursor|Neutrophils, Segmented + Band Form + Precursors	The determination of the amount of segmented, band form, and precursor neutrophils present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154757>	C28133	Mononuclear Cell Count|MNC|MNC|MNC|Mononuclear Cells|Mononuclear Cells|Mononuclear Cells|Mononuclear Cells|Mononucleated Cells	The determination of the amount of mononuclear cells present in a sample.			Laboratory Procedure	CDISC SDTM Biospecimen Characteristics Test Code Terminology|CDISC SDTM Biospecimen Characteristics Test Name Terminology|CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154758>	C81183	Homocitrulline Measurement|HOMOCIT|Homocitrulline|Homocitrulline	The determination of the amount of homocitrulline present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154759>	C81183	Alpha-Aminobutyric Acid Measurement|AAMBTAC|Alpha-Aminobutyric Acid|Alpha-Aminobutyric Acid|Alpha-aminobutyrate|Homoalanine|Homoalanine Measurement	The determination of the amount of alpha-aminobutyric acid present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15475>	C49236	Radioprotection|Radiation Protection|Radiological Protection	Methods for reducing radiation exposure or radiation effects to non-target tissues.	Radioprotection		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C154760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154760>	C81183	Sarcosine Measurement|N-Methylglycine|SARCOSIN|Sarcosine|Sarcosine	The determination of the amount of sarcosine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154761>	C81183	Alpha-Aminoadipic Acid Measurement|AAMAPAC|Alpha-Aminoadipate|Alpha-Aminoadipic Acid|Alpha-Aminoadipic Acid	The determination of the amount of alpha-aminoadipic acid present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154762>	C81183	Alloisoleucine Measurement|ALLOILE|Alloisoleucine|Alloisoleucine	The determination of the amount of alloisoleucine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154763>	C81183	Argininosuccinic Acid Measurement|ARGSAC|Argininosuccinate|Argininosuccinic Acid|Argininosuccinic Acid	The determination of the amount of argininosuccinic acid present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154764>	C81183	Beta Alanine Measurement|BALA|Beta Alanine|Beta Alanine	The determination of the amount of beta alanine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154765>	C81183	Beta-Aminobutyric Acid Measurement|BABA|BAMBTAC|Beta-Aminobutyric Acid|Beta-Aminobutyric Acid|Beta-aminobutyrate	The determination of the amount of beta-aminobutyric acid present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154766>	C81183	Gamma-Aminobutyric Acid Measurement|GABA|GAMBTAC|Gamma-Aminobutyric Acid|Gamma-Aminobutyric Acid|Gamma-aminobutyrate	The determination of the amount of gamma-aminobutyric acid present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154767>	C81183	Hydroxylysine Measurement|HYXLYS|Hydroxylysine|Hydroxylysine	The determination of the amount of hydroxylysine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154768>	C80183	Inactive Glucagon-Like Peptide-1 Measurement|GLP1IAC|Glucagon-Like Peptide-1, Inactive Form|Glucagon-Like Peptide-1, Inactive Form	The determination of the amount of inactive glucagon-like peptide-1 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154769>	C81971|C74913	Anti-Double Stranded DNA IgG Measurement|Anti-Double Stranded DNA IgG|Anti-Double Stranded DNA IgG|DDNAIGAB	The determination of the amount of anti-double stranded DNA IgG antibodies present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15476>	C211883	Management of Therapy Complications	Therapies for treating adverse events related to treatment.	Management of Therapy Complications		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C154770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154770>	C33027	Buccal Lymph Node|BUCCAL LYMPH NODE|Buccinator Lymph Node	A lymph node that is located superficial to the buccinator muscle.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154771>	C12716	Common Femoral Vein|COMMON FEMORAL VEIN	A vein that accompanies the common femoral artery and is formed by the confluence of the femoral vein and the deep femoral vein.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154772>	C12814	Fibular Vein|FIBULAR VEIN	A vein that arises from the plantar veins of the foot, accompanies the peroneal artery, and travels up the back of the leg to join the anterior and posterior tibial veins in forming the popliteal vein on the posterior surface of the knee.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154773>	C33027	Gastric Curvature Lymph Node|GASTRIC CURVATURE LYMPH NODE	A lymph node that is located between the two layers of the greater omentum, either superiorly along the cardiac half of the lesser curvature of the stomach or inferiorly along the pyloric half of the greater curvature of the stomach.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154774>	C33027	Perirectal Lymph Node|PERIRECTAL LYMPH NODE	A lymph node that is located in the connective tissue adjacent to the rectum.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154775>	C33027	Presacral Lymph Node|PRESACRAL LYMPH NODE|Presacral lymph node group (body structure)	A lymph node that is located in the mesorectum, between the rectum and the sacrum.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C154776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154776>	C12716	Deep Femoral Vein|PROFUNDA FEMORIS VEIN	A vein located in the upper thigh that connects, through tributaries, to the popliteal and inferior gluteal veins, and joins the superficial femoral vein at the groin to form the common femoral vein.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154777>	C13031	Sensorimotor Cortex|SENSORIMOTOR CORTEX	The region of the brain that consists of the precentral and postcentral gyri and is involved in somatosensory and motor functions.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154778>	C13031	Posterior Cingulate Cortex|POSTERIOR CINGULATE CORTEX	The caudal region of the cingulate cortex, located within the medial part of the inferior parietal lobule, that is thought to function as an interface between emotion and cognition.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154779>	C49333	Prefrontal Cortex|PREFRONTAL CORTEX	The grey matter on the medial, lateral, and orbital surfaces of the anterior part of the frontal cortex, which play a role in complex cognitive control, emotion, and social behavior.			Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15477>	C16124	Prior Radiation Therapy|Prior RT|Prior Radiation|Prior Radiotherapy|previously irradiated|previously_irradiated	An indicator that a person previously received radiation treatment for the same condition.			Clinical Attribute	ICDC Property Terminology|ICDC Terminology
C154780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154780>	C38629	Shin|SHIN	The front part of the leg from below the knee to the ankle.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154781>	C33904	L5-S1 Intervertebral Space|L5-S1 INTERVERTEBRAL SPACE	The space between the L5 and S1 vertebrae.			Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154782>	C23044	Congo Red Staining Method|CONGO RED STAIN	A microscopy staining method that utilizes the Congo Red stain, a benzidine derivative dye that has applications in staining biological structures, such as amyloid, as well as a pH indicator.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154783>	C38101	Contrast Enhanced X-ray|CONTRAST ENHANCED X-RAY	An x-ray technique that incorporates the administration of an iodinated contrast agent to enhance lesions that are not visible on standard x-rays.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154784>	C88502	Electroneurography|ELECTRONEUROGRAPHY	A nerve conduction study technique where a brief electrical stimulation is delivered under the skin, and the resulting electrical activity is recorded to assess the conductivity of peripheral nerve impulses.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154785>	C116701	Enzymatic Spectrophotometry|ENZYMATIC SPECTROPHOTOMETRY	A spectrophotometry technique that measures the changes in the intensity of the light absorbed or scattered in response to an enzymatic reaction.			Occupational Activity	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154786>	C16856	Fluorescence Lifetime Imaging Microscopy|FLUORESCENT LIFETIME IMAGING MICROSCOPY	An imaging technique that produces spatially resolved images based on the differences in the excited state decay rates of fluorescent compounds in a sample.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154787>	C168189	Knemometry|KNEMOMETRY	A technique which measures lower limb length using a knemometer, for the assessment of short-term growth and development in childhood.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154788>	C19236	Oscillometry|OSCILLOMETRY	A technique to measure a motion that repeats itself in a regular cycle around an equilibrium point or mean value.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154789>	C20080	Pulmonary Angiography|PULMONARY ANGIOGRAPHY	An x-ray imaging technique that involves visualization of the pulmonary vasculature after fluoroscopy-guided catheter placement and injection of an iodinated contrast medium into the pulmonary circulation.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15478>	C42651	Group C/Treatment IND Protocol|Treatment IND Protocol, Group C	A means for providing compassionate use of investigational agents between the time that an agent has been shown to have anti-tumor activity and the time that drug becomes available on the market.  Investigational agents that have been given Group C/Treatment IND designation by the FDA have reproducible efficacy in one or more specific tumor types. Such an agent is likely to alter the pattern of treatment of the disease and can be safely administered by properly trained physicians without specialized supportive care facilities. If a drug meets these criteria CTEP may initiate a formal application to the FDA to authorize Group C distribution for a specific indication. Such approval is not equivalent to formal FDA approval of effectiveness for this indication. Any registered investigator may receive a Group C agent.			Intellectual Product	
C154790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154790>	C17156	Secondary Ion Mass Spectrometry|SECONDARY ION MASS SPECTROMETRY	An analytical technique in which a mass spectrometer is used to detect sputtered ionized atoms (secondary ions) that are ejected from a solid surface after application of a beam of high energy primary ions.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154791>	C17204	Single Photon Tomography and Computed Tomography Scan|SPECT/CT|SPECT/CT SCAN	A dual-modality imaging technique that merges data from single-photon emission computed tomography (SPECT) and computed tomography (CT) to provide structural and functional information.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154792>	C16431	Immunochromatography|ICA|IMMUNOCHROMATOGRAPHY|Immunochromatography Assay	A type of chromatography assay in which an antibody-conjugate is passed over an immobilized antigen, giving a visual indication of positive or negative result.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154793>	C68645	Palm Method|PALM METHOD	A method for estimating body surface area, in which the individual's palm, excluding fingers and wrist, accounts for about 0.5% of the total body surface area of that individual. The entire palmar surface (including fingers) accounts for about 1% of the individuals total body surface area.			Occupational Activity	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154794>	C20368	Automated Count|AUTOMATED COUNT	A technique to determine the number of entities, that employs a machine or device to automatically detect cells as they pass through the instrument's light path.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154795>	C20368	Manual Count|MANUAL COUNT	A technique to determine the number of entities, which is performed by visual inspection.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154796>	C19236	Westergren Tube Method|WESTERGREN	A method that measures the sedimentation rate of an entity in an aqueous solution using a Westergren tube.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154797>	C19236	Impedance Conductivity|IMPEDANCE CONDUCTIVITY	A method that measures impedance of conductivity which corrects for the concentrations of conducting ions in the sample.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154798>	C15958	Flocculation Assay|FLOCCULATION	A process in which microscopic particles in suspension aggregate to form loosely clumped masses that are often macroscopically observable.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154799>	C15958	Complement Fixation Assay|COMPLEMENT FIXATION	An in vitro immunoassay that measures the binding of complement to antigen-antibody complexes in serum, leading to the depletion of free complement and the reduction of hemolytic activity.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15479>	C61063	Immune Globulin/Zidovudine|immune globulin/ZDV	A combination of agents containing immune globulin and zidovudine.		Obsolete_Concept	Therapeutic or Preventive Procedure	
C1547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1547>	C1967	Compound 32|4-(3'-bromoanilino)-6,7-dimethoxyquinazoline|PD 153035|ZM 252868	A protein tyrosine kinase inhibitor that has specific activity for the epidermal growth factor receptor. (NCI)			Organic Chemical|Pharmacologic Substance	
C154800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154800>	C48938	Transitional Cell to Tumor Cell Ratio Measurement|TRCETMCE|Transitional Cells/Tumor Cells|Transitional Cells/Tumor Cells	The determination of the ratio of transitional cells compared to tumor cells present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154801>	C48938	Tumor Cell Count|NEOCE|Neoplastic Cells|Neoplastic Cells	The determination of the amount of tumor cells present in a sample.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154802>	C18190	Histologic Type of Cancer|HISTTYPC	The determination of the histologic type of cancer in a sample.			Diagnostic Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154803>	C18190	Myelofibrosis Assessment|MYFIBROS|Myelofibrosis|Myelofibrosis	An evaluation of myelofibrosis in a sample.			Diagnostic Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154804>	C64430	ROS1 Protein Measurement|Proto-Oncogene Tyrosine-Protein Kinase ROS Measurement|ROS Proto-oncogene 1 Protein|ROS1|ROS1 Protein|ROS1 Protein	The determination of the amount of ROS1 protein present in a sample.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154805>	C64430	ALK Protein Measurement|ALK|ALK Protein|ALK Protein|ALK Tyrosine Kinase Receptor Measurement	The determination of the amount of ALK protein present in a sample.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154806>	C112273	EGFR Variant Protein Measurement|EGFR Variant Protein|EGFR Variant Protein|EGFRVP	The determination of the amount of EGFR variant protein present in a sample.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154807>	C64430	Programmed Death Ligand 1 Measurement|CD274|CD274 Measurement|PD-L1|PD-L1 Measurement|PDL1|PDL1 Measurement|Programmed Cell Death 1 Ligand 1|Programmed Death Ligand 1|Programmed Death Ligand 1	The determination of the amount of PD-L1 protein present in a sample.	Programmed Death Ligand 1 Measurement		Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154808>	C28076	Bauermeister Score|BAUERMEISTER SCORE	A score based on the Bauermeister scale, a 5-point grading system used to rate the extent of myelofibrosis in potential myeloproliferative neoplasms, based on the amount of reticulin and collagen fibers present in the bone marrow. (Bauermeister DE. Quantitation of bone marrow reticulin-a normal range. Am J Clin Pathol. 1971 Jul;56(1):24-31.)			Classification	CDISC SDTM Microscopic Findings Test Detail Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154809>	C28076	European Consensus Score For Bone Marrow Fibrosis|EUROPEAN CONSENSUS SCORE	A score based on the European Consensus scale, a grading system for the qualitative and quantitative evaluation of bone marrow fibrosis with a score ranging from zero (normal bone marrow) to three (coarse bundles of collagen fibrosis, usually associated with significant osteosclerosis). (Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005 Aug;90(8):1128-32.)			Classification	CDISC SDTM Microscopic Findings Test Detail Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15480>	C61063	Sargramostim/Zidovudine|GM-CSF/ZDV			Obsolete_Concept	Therapeutic or Preventive Procedure	
C154810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154810>	C48938	Tumor Proportion Score|TPS|TPS|TUMOR PROPORTION SCORE|Tumor Proportional Score	The percentage of viable tumor cells with partial or complete cell membrane staining.	Tumor Proportion Score		Laboratory Procedure	CDISC SDTM Microscopic Findings Test Detail Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154811>	C49188	Gram Positive Bacteria Measurement|GMPBAC|Gram Positive Bacteria|Gram Positive Bacteria	The determination of the gram-positive bacteria present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154812>	C49188	Gram Negative Bacteria Measurement|GMNBAC|Gram Negative Bacteria|Gram Negative Bacteria	The determination of the gram-negative bacteria present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154813>	C49188	Fungi Measurement|FUNGI|FUNGI|Fungi|Fungi|Fungi|Fungus	The determination of the fungi present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154814>	C210011|C187873	Streptococcus pyogenes Antigen Measurement|SPYAG|Streptococcus pyogenes Antigen|Streptococcus pyogenes Antigen	The determination of the Streptococcus pyogenes antigen present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154815>	C49188|C210012	Rubeola Antigen Measurement|Measles Virus Antigen|RBOAG|Rubeola Antigen	The determination of the Rubeola antigen present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154816>	C49188|C210011	Histoplasma capsulatum Antigen Measurement|HCPAG|Histoplasma capsulatum Antigen|Histoplasma capsulatum Antigen	The determination of the Histoplasma capsulatum antigen present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154817>	C49188	Galactomannan Antigen Measurement|GLTAG|Galactomannan Antigen|Galactomannan Antigen	The determination of the galactomannan antigen present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154818>	C210011|C172538	Escherichia coli Shiga-like Toxin Measurement|ECLSLTXN|Escherichia coli Shiga-like Toxin|Escherichia coli Shiga-like Toxin	The determination of the Escherichia coli shiga-like toxin present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154819>	C210011|C189536	Helicobacter pylori Antigen Measurement|HPYAG|Helicobacter pylori Antigen|Helicobacter pylori Antigen	The determination of the Helicobacter pylori antigen present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15481>	C15676	Antiandrogen Therapy|ADT|Androgen Deprivation Therapy|Androgen Deprivation Therapy (ADT)|Androgen Deprivation Therapy (ADT)|Anti-androgen Therapy|Anti-androgen Treatment|Antiandrogen Treatment|Hormone Deprivation Therapy|Hormone-Deprivation Therapy|antiandrogen therapy	A therapeutic regimen that utilizes pharmaceuticals to reduce serum levels of male sex hormones.	Antiandrogen Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C154820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154820>	C64430|C49188|C210011	Bacterial Sialidase Measurement|BCTSILDS|Bacterial Sialidase|Bacterial Sialidase	The determination of the bacterial sialidase present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154821>	C210012|C161395	HIV-1 Antigen Measurement|HIV-1 Antigen|HIV-1 Antigen|HIV1AG	The determination of the HIV-1 antigen present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154822>	C189542	Giardia lamblia Antigen Measurement|GLAAG|Giardia lamblia Antigen|Giardia lamblia Antigen	The determination of the Giardia lamblia antigen present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154823>	C210012|C171526	Respiratory Syncytial Virus Antigen Measurement|RSV Antigen|RSVAG|Respiratory Syncytial Virus Antigen|Respiratory Syncytial Virus Antigen	The determination of the Respiratory Syncytial Virus antigen present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154824>	C210011|C179762	Streptococcus agalactiae Antigen Measurement|SAGAG|Streptococcus Group B Antigen|Streptococcus agalactiae Antigen|Streptococcus agalactiae Antigen	The determination of the Streptococcus agalactiae antigen present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154825>	C64430|C49188	Urease Measurement|UREASE|Urease|Urease	The determination of the urease present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154826>	C92275	Legionella pneumophila Serogroup 1 Antigen Measurement|LPNS1AG|Legionella pneumophila Serogroup 1 Antigen|Legionella pneumophila Sg 1 Antigen|Legionella pneumophila Sg 1 Antigen	The determination of the Legionella pneumophila serogroup 1 antigen present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154827>	C210012|C172549	Rotavirus Antigen Measurement|ROTAG|Rotavirus Antigen|Rotavirus Antigen	The determination of the rotavirus antigen present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154828>	C210012|C184672	Cytomegalovirus Antigen Measurement|CMVAG|Cytomegalovirus Antigen|Cytomegalovirus Antigen	The determination of the cytomegalovirus antigen present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154829>	C49188|C210011	Cryptococcus Antigen Measurement|CRYPTCAG|Cryptococcus Antigen|Cryptococcus Antigen	The determination of the Cryptococcus antigen present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15482>	C15599	Androgen Therapy	Administration of male hormones to produce a clinical effect.			Therapeutic or Preventive Procedure	
C154830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154830>	C210012|C171498	Adenovirus Antigen Measurement|ADENOVAG|Adenovirus Antigen|Adenovirus Antigen	The determination of the adenovirus antigen present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154831>	C49188|C210011	Cryptosporidium parvum Antigen Measurement|CPAAG|Cryptosporidium parvum Antigen|Cryptosporidium parvum Antigen	The determination of the Cryptosporidium parvum antigen present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154832>	C210011|C179756	Bordetella pertussis Antigen Measurement|BPEAG|Bordetella pertussis Antigen|Bordetella pertussis Antigen	The determination of the Bordetella pertussis antigen present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154833>	C49188|C210012	Human Parainfluenza Antigen Measurement|HPIVAG|Human Parainfluenza Antigen|Human Parainfluenza Antigen	The determination of the human parainfluenza antigen present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154834>	C186162|C154833	Human Parainfluenza Type 1 Antigen Measurement|HPIV1AG|Human Parainfluenza Virus 1 Antigen|Human Parainfluenza Virus 1 Antigen|Human Respirovirus 1 Antigen	The determination of the human parainfluenza type 1 antigen present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154835>	C210011|C184659	Chlamydia Trachomatis Antigen Measurement|CTRAG|Chlamydia trachomatis Antigen|Chlamydia trachomatis Antigen	The determination of the Chlamydia trachomatis antigen present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154836>	C17723	Pathologist 1|PATHOLOGIST 1	A pathologist performing the assessment that is given the designation of one.			Biomedical Occupation or Discipline	CDISC SDTM Medical Evaluator Identifier Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154837>	C17723	Pathologist 2|PATHOLOGIST 2	A pathologist performing the assessment that is given the designation of two.			Biomedical Occupation or Discipline	CDISC SDTM Medical Evaluator Identifier Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154838>	C70913	Absolute Bioavailability|FABS	The fraction of the treatment dose that reaches the systemic circulation; this is the ratio of the amount of drug in the system after administration of a test formulation divided by the drug in the system after IV administration.			Qualitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154839>	C70913	Relative Bioavailability|FREL	The ratio of the amount of drug in the system after administration of a test formulation divided by the drug in the system after reference formulation.			Qualitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15483>	C63475	Estrogen Therapy	The use of estrogen in the treatment of any disease or disorder.			Therapeutic or Preventive Procedure	
C154840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154840>	C43242	Fraction Bound|FB	The ratio of bound drug concentration to the total concentration.			Conceptual Entity	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154841>	C85797	Total Clearance Predicted for Unbound Drug|CLPUB|Total CL Pred for Unbound Drug|Total CL Pred for Unbound Drug	The total body clearance for extravascular administration divided by the fraction of drug unbound, calculated using the predicted value of the last non-zero concentration.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154842>	C85773	Total Clearance Observed for Unbound Drug|CLOUB|Total CL Obs for Unbound Drug|Total CL Obs for Unbound Drug	The total body clearance for extravascular administration divided by the fraction of drug unbound, calculated using the observed value of the last non-zero concentration.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154843>	C75913	Renal Clearance for Unbound Drug|RNCLUB|Renal CL for Unbound Drug|Renal CL for Unbound Drug	The unbound fraction of drug within the portion of total clearance attributed to the kidneys.			Laboratory Procedure	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154844>	C154701	Apparent Clearance for Unbound Drug|Apparent CL for Unbound Drug|Apparent CL for Unbound Drug|CLFUB	The total apparent clearance of the unbound fraction of drug, adjusted for bioavailability.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154845>	C85761	Observed Area Under the Curve Infinity of Unbound Drug|AUC Infinity Obs, Unbound Drug|AUC Infinity Obs, Unbound Drug|AUCIFOUB	The portion of observed AUC to infinity, represented by the unbound fraction of drug. (CDISC)			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154846>	C85785	Predicted Area Under the Curve Infinity of Unbound Drug|AUC Infinity Pred, Unbound Drug|AUC Infinity Pred, Unbound Drug|AUCIFPUB	The portion of predicted AUC to infinity, represented by the unbound fraction of drug. (CDISC)			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154847>	C85565	Area Under the Curve From Dosing to Last Concentration of Unbound Drug|AUC to Last Nonzero Conc, Unbound Drug|AUC to Last Nonzero Conc, Unbound Drug|AUCLSTUB	The portion of the area under the curve (AUC) from the time of dosing to the last measurable concentration, represented by the unbound fraction of drug. (CDISC)			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154848>	C70918	Maximum Concentration of Unbound Drug|CMAXUB|Max Conc, Unbound Drug|Max Conc, Unbound Drug	The maximum concentration represented by the unbound fraction of drug, occurring at Tmax. (CDISC)			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154849>	C75913	Renal Clearance to Total Clearance Ratio Measurement After Oral Dosing|CLRPCLEV|Renal CL as Pct CL EV|Renal CL as Pct CL EV	The portion of total clearance attributed to the kidneys expressed as a percentage, following an oral dosing.			Laboratory Procedure	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15484>	C63475	Progestin Therapy	The use of progestogens in the treatment of any disease or disorder.			Therapeutic or Preventive Procedure	
C154850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154850>	C75913	Renal Clearance to Total Clearance Ratio Measurement After Intravenous Dosing|CLRPCLIV|Renal CL as Pct CL IV|Renal CL as Pct CL IV	The portion of total clearance attributed to the kidneys expressed as a percentage, following an intravenous dosing.			Laboratory Procedure	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154851>	C25174|C166116	Step Father|FATHER, STEP|Stepfather|Stepfather	A male that is related to a child or children through marriage to their biological parent.			Human	CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C154852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154852>	C106515	Peritoneal Dialysis Fluid|DIALYSIS FLUID, PERITONEAL|PD Fluid|Peritoneal Dialysate	The dialysis fluid which is collected from the peritoneal space and captures, for discard or analysis, the excess water and waste from the blood stream through diffusion and ultrafiltration. (NCI)			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154853>	C181043	Metastatic Tumor Site Indicator|METIND	An indication as to whether an anatomical location contains metastases.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Tumor Identification Test Code Terminology|CDISC SDTM Tumor Identification Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C154854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154854>	C67313	Hertz Per Second|Hz/s|Hz/s|Hz/s|Hz/sec	A unit of frequency rate change defined as the number of Hertz per unit of time equal to one second.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154855>	C73757	Milliliter per 100 Grams per Minute|mL/10*2.g/min|mL/10*2.g/min|mL/100g/min|mL/100g/min|ml/10*2.g/min|ml/10*2.g/min	A unit of flow rate expressed as the number of milliliters per 100g of material per minute.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154856>	C70564	Enzyme Unit per Gram Hemoglobin|EU/g Hb|Enzyme U/g Hb|Enzyme U/g Hb|Enzyme Unit per Gram of Hemoglobin|{Enzyme}.U/g{HGB}|{Enzyme}.U/g{HGB}	A unit of concentration (biologic activity) equal to one enzyme unit of substance per gram of hemoglobin.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154857>	C69090	Poise|P|P|P|P|P|P	A unit of dynamic viscosity equal to one pascal-second.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology|UCUM Terminology
C154858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154858>	C48564	Micrometer per Second|Micrometers per Second|micrometer per second|micron/sec|um/s|um/s|um/s|um/s|um/s|um/sec	A unit of both speed (scalar) and velocity (vector), defined as the distance of one micrometer travelled per unit time equal to one second.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C154859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154859>	C68785	Microsiemens|micromho|micromhos|uS|uS|uS|uSiemens|uSiemens|umho	A unit of electrical conductance, admittance, and susceptance equal to one millionth of a Siemens (10E-6 Siemens).			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|PQ/CMC Units of Measure Terminology
C15485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15485>	C16051	Neurotoxicity Attenuation	Therapies designed to reduce neurotoxicity during treatment exposure.			Therapeutic or Preventive Procedure	
C154860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154860>	C181043	Cancer Primary Site Known Indicator|ORCANIND|ORCANIND|Origin of Cancer Known Ind|Origin of Cancer Known Ind|Origin of Cancer Known Ind|Origin of Cancer Known Indicator	An indication as to whether the primary site of cancer is known.			Conceptual Entity	CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Lung Cancer Findings About Test Code Terminology|CDISC SDTM Lung Cancer Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154861>	C25180	Tumor Resected Indicator|RESCTIND|RESCTIND|Resected Tumor Ind|Resected Tumor Ind|Resected Tumor Ind|Resected Tumor Indicator	An indication as to whether the tumor has been resected.			Conceptual Entity	CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Lung Cancer Findings About Test Code Terminology|CDISC SDTM Lung Cancer Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154862>	C154689	Heterosexual Contact|OPPOSITE-SEX SEXUAL CONTACT	Sexual contact with someone of the opposite sex.			Individual Behavior	CDISC SDTM Mode of Disease Transmission Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C154863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154863>	C154689	Homosexual Contact|SAME-SEX SEXUAL CONTACT	Sexual contact with someone of the same sex.			Individual Behavior	CDISC SDTM Mode of Disease Transmission Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C154864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154864>	C17941	Intrauterine Exposure|INTRAUTERINE EXPOSURE	The exposure to agents that occurs during in utero development.			Phenomenon or Process	CDISC SDTM Mode of Disease Transmission Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154865>	C158028	Cerebral Blood Flow Assessment	An evaluation of the perfusion of blood through the brain.			Diagnostic Procedure	
C154866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154866>	C25447	Skin Conductance|SKNCUDNC	The degree to which the skin can conduct electricity.			Quantitative Concept	CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154867>	C99553	Sleep Onset Latency|SOL|SOL	The duration of time between when the lights are turned off and when the individual falls asleep.			Research Activity	CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154868>	C99553	N1 Sleep Phase Duration|N1 Sleep Duration|N1 Sleep Duration|N1SLPDUR|Stage 1 Sleep Duration	The length of time of N1 sleep.			Research Activity	CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154869>	C99553	N2 Sleep Phase Duration|N2 Sleep Duration|N2 Sleep Duration|N2SLPDUR|Stage 2 Sleep Duration	The length of time of N2 sleep.			Research Activity	CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15486>	C15187	Prostaglandin Inhibition	Therapies designed to reduce the production of prostaglandins.			Therapeutic or Preventive Procedure	
C154870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154870>	C99553	N3 Sleep Phase Duration|N3 Sleep Duration|N3 Sleep Duration|N3SLPDUR|Stage 3 Sleep Duration	The length of time of N3 sleep.			Research Activity	CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154871>	C99553	Rapid Eye Movement Sleep Phase Duration|REM Duration|REM Duration|REM Duration|REMDUR	The total amount of time an individual spends in rapid eye movement (REM) sleep.			Research Activity	CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154872>	C99553	Rapid Eye Movement Sleep Phase Latency|REM Latency|REM Latency|REM Latency|REMLAT	The time between the onset of sleep and the onset of the first rapid eye movement (REM) cycle.			Research Activity	CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154873>	C51625	Thorascopic Wedge Resection of the Lung|THORACOSCOPIC WEDGE RESECTION|TWR	A minimally invasive surgical procedure in which video-assisted thoracoscopy is used to remove of a portion of the lung.			Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154874>	C42331	Khoisan|KHOISAN	A name used for the non-Bantu indigenous peoples of Southern Africa.			Population Group	CDISC CDASH Terminology|CDISC SDTM Collected Race Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154875>	C126535	Aboriginal Australian|ABORIGINAL AUSTRALIAN	The native people of Australia.			Population Group	CDISC CDASH Terminology|CDISC SDTM Collected Race Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154876>	C25347	Fundal Height|FUNDHT	A measurement of the distance between the pubic symphysis and the top of the palpable uterus.			Quantitative Concept	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154877>	C119241	Erythema Indicator|ERYTHIND|Redness Indicator	An indication as to whether erythema is present.			Conceptual Entity	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154878>	C119241	Rash Indicator|RASHIND	An indication as to whether rash is present.			Conceptual Entity	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154879>	C93491|C181043	Skene's Gland Abnormality Indicator|SKGLAIND	An indication as to whether the Skene's gland is abnormal.			Conceptual Entity	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15487>	C15747	Hypercalcemia Therapy|bone resorption/hypercalcemia control|hypercalcemia control/bone resorption	Any care or treatment provided for the resolution of an abnormally high blood calcium concentration.			Therapeutic or Preventive Procedure	
C154880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154880>	C93491|C181043	Bartholin's Gland Abnormality Indicator|BTHGLIND	An indication as to whether the Bartholin's gland is abnormal.			Conceptual Entity	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154881>	C119241	Ulcer Indicator|ULCERIND|ulceration indicator|ulceration_indicator	An indication as to whether an ulcer is present.			Conceptual Entity	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Property Terminology|GDC Terminology
C154882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154882>	C119241	Pustule Indicator|PUSTIND	An indication as to whether a pustule is present.			Conceptual Entity	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154883>	C119241	Peeling Indicator|PEELIND	An indication as to whether there is the presence of peeling.			Conceptual Entity	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154884>	C119241	Ecchymosis Indicator|ECCHYIND	An indication as to whether ecchymosis is present.			Conceptual Entity	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154885>	C119241	Edema Indicator|EDEMAIND	An indication as to whether edema is present.			Conceptual Entity	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154886>	C181043	Mass Indicator|MASSIND	An indication as to whether a mass is present.			Conceptual Entity	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154887>	C25180	Motion Tenderness Indicator|MTENDIND	An indication as to whether there are symptoms of motion tenderness.			Conceptual Entity	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154888>	C25180	Discharge Indicator|DSCHGIND	An indication as to whether there is the presence of discharge.			Conceptual Entity	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154889>	C93491|C181043	Abnormal Bleeding Indicator|BLEEDIND	An indication as to whether there is the presence of abnormal bleeding.			Conceptual Entity	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154890>	C41150	Income Level|INCMLVL	An indication of the position on a scale measuring compensation or monetary support.			Group Attribute	CDISC SDTM Subject Characteristic Test Code Terminology|CDISC SDTM Subject Characteristic Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C154891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154891>	C172255	Neck Circumference|NECKCIR	A circumferential measurement of the neck, just below the larynx.			Spatial Concept	CDISC SDTM Terminology|CDISC SDTM Vital Sign Test Code Terminology|CDISC SDTM Vital Sign Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C154892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154892>	C134576	Experimental Organism Adenocarcinoma Arising in Fibroadenoma|ADENOCARCINOMA ARISING IN FIBROADENOMA, MALIGNANT	A malignant glandular neoplasm that arises from a pre-existing benign fibroadenoma.			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C154893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154893>	C110937	Growth Plate Open|GROWTH PLATE OPEN|Physis Open	An indication that the epiphyseal plate is made of hyaline cartilage and is not yet fused by bone.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154894>	C35552	Squamous Plaque/Cyst|SQUAMOUS PLAQUE/CYST	A focus of squamous epithelium in or near the surface of the heart, generally believed to be an embryonic rest.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154895>	C35867	Cytoplasmic Alteration|CYTOPLASMIC ALTERATION	A microscopic finding indicating the presence of intracytoplasmic changes in reactive, atypical, dysplastic, or neoplastic cells.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154896>	C25346	Test Article Physical Class|TAPHSCLS|Test Article Physical Substance Class|Test Article Physical Substance Class|Test Article Physical Substance Classification	The physicochemical category that a test article belongs to based on the composition and properties of that article.			Group	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C154897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154897>	C1708	Activator|ACTIVATOR	A class of substances that binds to, activates and increases the activity of a target.			Chemical Viewed Functionally	CDISC SEND Planned Pharmacologic Target Mode of Action Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154898>	C1708	Inhibitor|INHIBITOR	A class of substances that binds to and inhibits the function or activity of a target.			Chemical Viewed Functionally	CDISC SEND Planned Pharmacologic Target Mode of Action Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154899>	C1514	Full Receptor Agonist|FULL RECEPTOR AGONIST	A class of substances that binds to and activates a receptor and induces the maximal biological response.			Chemical Viewed Functionally	CDISC SEND Planned Pharmacologic Target Mode of Action Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15489>	C63475	Releasing Hormone Agonist Therapy|Releasing Factor Agonist Therapy	The use of releasing hormone agonists to bind to specific receptors and ultimately downregulate the activity of its specific hormone.	Releasing Hormone Agonist Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C1548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1548>	C1941	Recombinant OX40 Ligand|OX40 ligand|OX40L	A recombinant agent, which is chemically identical to or similar to the endogenous protein Fas ligand OX40, a member of the tumor necrosis factor (TNF) family.  Expressed by antigen presenting cells (APC), OX40 ligand binds to the OX40 receptor on CD4 T-cells, thereby priming antigen-specific activation of CD4 T-cells and inducing CD4 T-cell secretion of interleukin 4 (IL-4). (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C154900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154900>	C1514	Partial Receptor Agonist|PARTIAL RECEPTOR AGONIST	A class of substances that binds to and activates a receptor with less efficacy, and produces submaximal receptor activation relative to a full agonist.			Chemical Viewed Functionally	CDISC SEND Planned Pharmacologic Target Mode of Action Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154901>	C1514	Inverse Receptor Agonist|INVERSE RECEPTOR AGONIST	A class of substances that binds to a receptor at the same binding site as an agonist, but induces a biological response opposite to that agonist.			Chemical Viewed Functionally	CDISC SEND Planned Pharmacologic Target Mode of Action Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154902>	C1708	Mixed Agonist/Antagonist|AGONIST-ANTAGONIST|Mixed Agonist-Antagonist	A class of substances that binds to and acts as a full agonist or partial agonist at one receptor and an antagonist at another.			Chemical Viewed Functionally	CDISC SEND Planned Pharmacologic Target Mode of Action Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154903>	C1708	Allosteric Potentiator|ALLOSTERIC POTENTIATOR	A class of substances that binds to a target allosterically and induces a conformational change in the target. This leads to an enhanced binding affinity of the target to its substrate, and thereby amplifies the effect of the substrate on that target.			Chemical Viewed Functionally	CDISC SEND Planned Pharmacologic Target Mode of Action Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154904>	C1708	Allosteric Modulator|ALLOSTERIC MODULATOR	A class of substances that binds to a target allosterically and induces a conformational change in the target. This leads to an altered binding affinity of the target to its substrate.			Chemical Viewed Functionally	CDISC SEND Planned Pharmacologic Target Mode of Action Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154905>	C1708	RNA-based Molecule	Any compound that contains a polymeric ribonucleic acid molecule.			Chemical Viewed Functionally	
C154906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154906>	C25337	Number of Electrocardiogram Electrodes|ECGELCTN|Number of ECG Electrodes|Number of ECG Electrodes|Number of ECG Electrodes|Number of EKG Electrodes	The number of electrocardiogram electrodes used in the assessment.			Quantitative Concept	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154907>	C25337	Number of Electrooculogram Electrodes|EOGELCTN|Number of EOG Electrodes|Number of EOG Electrodes|Number of EOG Electrodes	The number of electrooculogram electrodes used in the assessment.			Quantitative Concept	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154908>	C25337	Number of Electromyogram Electrodes|EMGELCTN|Number of EMG Electrodes|Number of EMG Electrodes|Number of EMG Electrodes	The number of electromyogram electrodes used in the assessment.			Quantitative Concept	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C154909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154909>	C181043	Fontanelle Closure Indicator|FOCLOIND	An indication as to whether the fontanelle is closed.			Conceptual Entity	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15490>	C15542	Monoclonal Antibody Therapy	The use of monoclonal antibodies in the treatment of any disease or disorder.	Monoclonal Antibody Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C154910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154910>	C16502	Targeted Imaging|Targeted Molecular Imaging	Imaging that uses tagged molecules that are specific for a target molecule or biomarker.			Diagnostic Procedure	
C154913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154913>	C41331	Neonatal Adverse Event	Findings suggesting an adverse event in a neonate or newborn.			Finding	
C154914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154914>	C155946	INC-MedDRA Neonatal Adverse Events Terminology	A neonatal adverse event severity scale developed by NCIt EVS and the Clinical Pharmacology workgroup of INC to help researchers use a common approach when reporting adverse events (AEs).  This work will enhance regulatory science for neonates by providing standardized terminology for adverse event reporting.			Intellectual Product	INC Terminology
C154915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154915>	C93102|C150520	Deleterious DNA Damage Response Gene Mutation|DDR Deleterious Gene Alteration|DDR Gene Deleterious Alteration|Deleterious DDR Gene Mutation|Deleterious DNA Damage Response (DDR) Gene Alteration|Deleterious DNA Damage Response Gene Alteration	A change in the nucleotide sequence of a gene involved in any DNA damage response pathway that is associated with increased risk of disease.	Deleterious DNA Damage Response Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154916>	C97927	C5 Gene Mutation|CPAMD4 Gene Mutation|Complement Component 5 Gene Mutation|Component 5 Gene Mutation|ECLZB Gene Mutation	A change in the nucleotide sequence of the C5 gene.	C5 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154917>	C116468	Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation	The removal of naive T-cells from the donor's hematopoietic stem cell specimen prior to its transfusion into the recipient.	Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C154918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154918>	C165233	ARID1A Negative|ARID Domain-Containing Protein 1A Negative|AT Rich Interactive Domain 1A Negative|AT-Rich Interactive Domain-Containing Protein 1A Negative|B120 Negative|BAF250a Negative|BM029 Negative|BRG1-Associated Factor 250a Negative|Brain Protein 120 Negative|ELD Negative|OSA1 Negative|Osa Homolog 1 Negative|SMARCF1 Negative|SWI/SNF-Related, Matrix-Associated, Actin-Dependent Regulator of Chromatin Subfamily F Member 1 Negative	An indication that ARID1A expression has not been detected in a sample.	ARID1A Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154919>	C154913	Bronchopulmonary Dysplasia, AE|BPD, AE|Bronchopulmonary Dysplasia|Bronchopulmonary Dysplasia, Adverse Event|Bronchopulmonary dysplasia	An adverse event in a newborn characterized by a lung disorder associated with pulmonary maldevelopment, scarring, and/or inflammation that develops in preterm neonates. The condition is defined based on treatment with supplemental oxygen for at least 28 days adjusted for the degree of prematurity.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C15491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15491>	C106541	Premenopausal|PREMENOPAUSAL|premenopausal	Prior to menopause.			Clinical Attribute	CDISC SDTM Menopause Status Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C154920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154920>	C154913	Neonatal Pneumothorax, AE|Neonatal Pneumothorax|Neonatal Pneumothorax, Adverse Event|Neonatal pneumothorax	An adverse event in a newborn characterized by a collection of air or other gas between the visceral and parietal pleura.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154921>	C154913	Neonatal Coagulation Disorder, AE|Coagulation Disorder Neonatal|Coagulation disorder neonatal|Neonatal Coagulation Disorder, Adverse Event	An adverse event in a newborn characterized by abnormal blood clotting or bleeding.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154922>	C154913	Necrotizing Enterocolitis, AE|Necrotizing Enterocolitis|Necrotizing Enterocolitis, Adverse Event|Necrotizing enterocolitis neonatal	An adverse event in newborns characterized by extensive mucosal ulceration, pseudomembrane formation, submucosal hemorrhage, and necrosis in the intestines .			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154923>	C154913	Periventricular Leukomalacia, AE|Periventricular Leukomalacia|Periventricular Leukomalacia, Adverse Event|Periventricular leukomalacia	An adverse event in a newborn characterized by a form of cerebral white matter injury usually seen in preterm infants that is characterized by necrotic degeneration or gliosis of white matter adjacent to the cerebral ventricles that may evolve into focal cysts.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154924>	C154913	Neonatal Spontaneous Intestinal Perforation, AE|Neonatal SIP, AE|Neonatal Spontaneous Intestinal Perforation|Neonatal Spontaneous Intestinal Perforation, Adverse Event|Neonatal spontaneous intestinal perforation	An adverse event in a newborn characterized by a perforation in the gastrointestinal tract of a newborn with no demonstrable cause.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154925>	C154913	Retinopathy of Prematurity, AE|Retinopathy of Prematurity|Retinopathy of Prematurity, Adverse Event|Retinopathy of prematurity|RoP, AE	An adverse event characterized by a retinal condition of very immature infants that may be characterized by non-vascularized retinae that may lead to neovascularization, scarring, retinal detachment, and blindness.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154926>	C154913	Infant Sedation, AE|Infant Sedation|Infant Sedation, Adverse Event|Infant sedation	An adverse event in a newborn characterized by a state of a lowered level of consciousness.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154927>	C154913	Neonatal Culture Positive Sepsis, AE|Culture Positive Neonatal Sepsis|Culture positive neonatal sepsis|Neonatal Culture Positive Sepsis, Adverse Event	An adverse event in a newborn characterized by a systemic inflammatory response to an infection with an identifiable cause.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154928>	C154913	Neonatal Culture Negative Sepsis, AE|Culture Negative Neonatal Sepsis|Culture negative neonatal sepsis|Neonatal Culture Negative Sepsis, Adverse Event	An adverse event in a newborn characterized by a systemic inflammatory response without identifiable cause.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154929>	C154913	Neonatal Hypertension, AE|Hypertension neonatal|Neonatal Hypertension|Neonatal Hypertension, Adverse Event	An adverse event in a newborn characterized by abnormally high blood pressure.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C15492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15492>	C16150|C101267	Estrogen Receptor Positive|ER Alpha Positive|ER Positive|ER+|ER+|ER-Alpha Positive|ERA Positive|ESR Positive|ESR1 Positive|ESRA Positive|ESTRR Positive|Estrogen Receptor 1 Positive|Estrogen Receptor Alpha Positive|NR3A1 Positive|Nuclear Receptor Subfamily 3 Group A Member 1 Positive|Positive|Positive Estrogen Receptor|estrogen receptor positive	An indication that estrogen receptor alpha expression has been detected in a sample.	Estrogen Receptor Positive		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154930>	C154913	Neonatal Hypotension, AE|Neonatal Hypotension|Neonatal Hypotension, Adverse Event|Neonatal hypotension	An adverse event in a newborn characterized by abnormally low blood pressure, which is usually symptomatic.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154931>	C154913	Neonatal Edema, AE|Edema Neonatal|Edema neonatal|Neonatal Edema, Adverse Event	An adverse event in a newborn characterized by accumulation of an excessive amount of fluid in cells or intercellular tissues.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154932>	C154913	Neonatal Sinus Tachycardia, AE|Neonatal Sinus Tachycardia|Neonatal Sinus Tachycardia, Adverse Event|Neonatal sinus tachycardia	An adverse event in a newborn characterized by an abnormally high heart rate for age.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154933>	C154913	Neonatal Sinus Bradycardia, AE|Neonatal Sinus Bradycardia|Neonatal Sinus Bradycardia, Adverse Event|Neonatal sinus bradycardia	An adverse event in a newborn characterized by an abnormally low heart rate for age.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154934>	C154913	Neonatal Epileptic Seizure, AE|Neonatal Epileptic Seizure|Neonatal Epileptic Seizure, Adverse Event|Neonatal epileptic seizure	An adverse event in a newborn characterized by an electroencephalogram (EEG) confirmed paroxysmal surge of electrical activity in the brain that may result in physical or behavioral changes.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154935>	C154913	Neonatal Rash, AE|Neonatal Rash, Adverse Event|Rash Neonatal|Rash neonatal	An adverse event in a newborn characterized by an eruption in the skin which affects its appearance and/or texture.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154936>	C154913	Neonatal Pulmonary Hemorrhage, AE|Neonatal Pulmonary Hemorrhage|Neonatal Pulmonary Hemorrhage, Adverse Event|Neonatal pulmonary hemorrhage	An adverse event in a newborn characterized by bleeding in the respiratory tract of a neonate.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154937>	C154913	Neonatal Intraventricular Hemorrhage, AE|Intraventricular Hemorrhage neonatal|Intraventricular hemorrhage neonatal|Neonatal Intraventricular Hemorrhage, Adverse Event	An adverse event in a newborn characterized by bleeding into the lateral cerebral ventricles.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154938>	C154913	Infantile Apnea, AE|Infantile Apnea|Infantile Apnea, Adverse Event|Infantile apnea	An adverse event in a newborn characterized by cessation of air flow.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154939>	C154913	Infant Irritability, AE|Infant Irritability|Infant Irritability, Adverse Event|Infant irritability	An adverse event in a newborn characterized by crying easily and difficulty consoling.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C15493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15493>	C165744|C16150	Estrogen Receptor Negative|ER Alpha Negative|ER Negative|ER-|ER-|ER-Alpha Negative|ERA Negative|ESR Negative|ESR1 Negative|ESRA Negative|ESTRR Negative|Estrogen Receptor 1 Negative|Estrogen Receptor Alpha Negative|NR3A1 Negative|Negative|Negative Estrogen Receptor|Nuclear Receptor Subfamily 3 Group A Member 1 Negative|estrogen receptor negative	The absence of detectable estrogen receptor alpha in a tissue sample.	Estrogen Receptor Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C154940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154940>	C154913	Persistent Pulmonary Hypertension of the Newborn, AE|Persistent Pulmonary Hypertension of the Newborn|Persistent Pulmonary Hypertension of the Newborn, Adverse Event|Persistent pulmonary hypertension of the newborn	An adverse event in a newborn characterized by elevated pulmonary vascular pressure in a neonate.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154941>	C154913	Neonatal Fever, AE|Fever Neonatal|Fever neonatal|Neonatal Fever, Adverse Event	An adverse event in a newborn characterized by elevation of body temperature above normal due to the production of more heat than the body is able to dissipate.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154942>	C154913	Infantile Vomiting, AE|Infantile Vomiting|Infantile Vomiting, Adverse Event|Infantile vomiting	An adverse event in a newborn characterized by expulsion of the contents of the stomach through the mouth.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154943>	C154913	Neonatal Gastrointestinal Bleeding, AE|Gastro-intestinal Bleeding Neonatal|Gastrointestinal bleeding neonatal|Neonatal Gastrointestinal Bleeding, Adverse Event	An adverse event in a newborn characterized by hemorrhage originating at any site located within the gastrointestinal tract.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154944>	C154913	Feeding Intolerance, AE|Feeding Intolerance|Feeding Intolerance, Adverse Event|Feeding intolerance	An adverse event in a newborn characterized by inability to achieve a full feeding volume.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154945>	C154913	Hypoxic Ischemic Encephalopathy, AE|HIE, AE|Hypoxic Ischemic Encephalopathy|Hypoxic Ischemic Encephalopathy, Adverse Event|Hypoxic-ischemic encephalopathy	An adverse event in a newborn characterized by injury to the central nervous system that occurs when there is insufficient delivery of oxygen to all or part of the brain.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154946>	C154913	Neonatal Constipation, AE|Constipation Neonatal|Constipation neonatal|Neonatal Constipation, Adverse Event	An adverse event in a newborn characterized by irregular and infrequent or difficult evacuation of the bowels.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154947>	C154913	Neonatal Administration Site Complication, AE|Administration Site Complication Neonatal|Administration site reaction neonatal|Neonatal Administration Site Complication, Adverse Event	An adverse event in a newborn characterized by local irritation or a complication at the administration site of a drug.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154948>	C154913	Neonatal Tachyarrhythmia, AE|Neonatal Tachyarrhythmia|Neonatal Tachyarrhythmia, Adverse Event|Neonatal tachyarrhythmia	An adverse event in a newborn characterized by non-sinus rhythm with an abnormally high heart rate for age.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154949>	C154913	Neonatal Bradyarrhythmia, AE|Neonatal Bradyarrhythmia|Neonatal Bradyarrhythmia, Adverse Event|Neonatal bradyarrhythmia	An adverse event in a newborn characterized by non-sinus rhythm with an abnormally low heart rate for age.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C15494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15494>	C211883	Fatigue Assessment and Management	Methods for determining the level of an individual's existing fatigue and strategies for lessening it or living with it.	Fatigue Assessment and Management		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C154950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154950>	C154913	Neonatal Respiratory Distress Syndrome, AE|Neonatal Respiratory Distress Syndrome|Neonatal Respiratory Distress Syndrome, Adverse Event|Neonatal respiratory distress syndrome	An adverse event in a newborn characterized by progressive alveolar atelectasis from birth due to an abnormality of synthesis, function or metabolism of surfactant, characterized by respiratory failure and an abnormal chest radiograph showing diffuse reticulogranular densities and air bronchograms.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154951>	C154913	Neonatal Respiratory Insufficiency, AE|Neonatal Respiratory Insufficiency|Neonatal Respiratory Insufficiency, Adverse Event|Neonatal respiratory insufficiency	An adverse event in a newborn characterized by significant impairment of gas exchange resulting in compensatory breathing efforts and eventually hypoxia and/or hypercarbia. Note: Consider this adverse event for any patient whose respiratory condition deteriorates from baseline. If any specific diagnosis is identified: use diagnosis-specific scale (e.g. respiratory distress syndrome (RDS), pulmonary hemorrhage).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154952>	C154913	Neonatal Convulsion, AE|Neonatal Convulsion|Neonatal Convulsion, Adverse Event|Neonatal convulsion	An adverse event in a newborn characterized by sudden, involuntary, rapid rhythmic or stereotyped skeletal muscular contraction.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154953>	C154913	Neonatal Diarrhea, AE|Diarrhea Neonatal|Diarrhea neonatal|Neonatal Diarrhea, Adverse Event	An adverse event in a newborn characterized by watery bowel movements.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C154954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C154954>	C177692	ARID1A Positive|ARID Domain-Containing Protein 1A Positive|AT Rich Interactive Domain 1A Positive|AT-Rich Interactive Domain-Containing Protein 1A Positive|B120 Positive|BAF250a Positive|BM029 Positive|BRG1-Associated Factor 250a Positive|Brain Protein 120 Positive|ELD Positive|OSA1 Positive|Osa Homolog 1 Positive|SMARCF1 Positive|SWI/SNF-Related, Matrix-Associated, Actin-Dependent Regulator of Chromatin Subfamily F Member 1 Positive	An indication that ARID1A expression has been detected in a sample.	ARID1A Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15495>	C16150	Estrogen Receptor Status Unknown|Unknown Status, Estrogen Receptor|Unknown: Could not be determined or unsure	Indicates that the test result for estrogen receptor alpha is unknown or the test has not been performed.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C15496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15496>	C16149|C101267	Progesterone Receptor Positive|PGR Positive|PR Positive|PR+|Positive|progesterone receptor positive	An indication that progesterone receptor (PRG; PR) expression has been detected in a sample.	Progesterone Receptor Positive		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15497>	C165744|C16149	Progesterone Receptor Negative|Negative|PGR Negative|PR Negative|PR-|progesterone receptor negative	An indication that progesterone receptor (PRG; PR) expression has not been detected in a sample.	Progesterone Receptor Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15498>	C16149	Progesterone Receptor Status Unknown|PGR Unknown	An indication that progesterone receptor expression in a sample is not known or the assay has not been performed.			Laboratory or Test Result	
C15499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15499>	C16169	Prior Oophorectomy	Having had an oophorectomy in the past.			Clinical Attribute	
C1549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1549>	C78532	BR96 sFv-PE40|SGN-10	A single-chain immunotoxin consisting of Fv fragments of the BR96 monoclonal antibody (MoAb) and a truncated Pseudomonas exotoxin (PE40) that lacking the binding domain. MoAb BR96 specifically binds to Lewis Y-related carbohydrate antigen, a cell surface antigen overexpressed in many carcinomas.  After internalization, PE40 causes ADP-ribosylation of transcription elongation factor 2, thereby inactivating elongation factor 2 and inhibiting protein synthesis in the cancer cells.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C15500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15500>	C16175	Prior Estrogen Therapy	Having received prior estrogen therapy.			Clinical Attribute	
C15501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15501>	C16175	Prior Antiestrogen Therapy	Having received prior antiestrogen therapy.			Clinical Attribute	
C15502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15502>	C16175	Prior Progestin Therapy	Having received prior progestin therapy.			Clinical Attribute	
C15503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15503>	C15489	Prior LHRH Agonist Therapy	Having received prior leutenizing hormone-releasing hormone (LHRH) agonist therapy.			Clinical Attribute	
C15504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15504>	C16175	Prior Androgen Therapy	Having received prior androgen therapy.			Clinical Attribute	
C15505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15505>	C15545	Peripheral Blood Lymphocyte Therapy|peripheral blood lymphocyte therapy	A treatment for Epstein-Barr virus infection or overgrowth of lymphocytes after an organ or bone marrow transplant. Specific lymphocytes from a sibling donor are infused into the patient to try and reverse these conditions.	Peripheral Blood Lymphocyte Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C15506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15506>	C15747	Anticachectic Therapy	Treatment to manage or alleviate the fatigue and weight loss often associated with cancer.			Therapeutic or Preventive Procedure	
C15507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15507>	C15411	Tumor Necrosis Factor Therapy	A biological therapy that involves the use of anti-tumor necrosis factor antagonists. It results in the inhibition of tumor necrosis factor and the decrease of the inflammatory response in autoimmune disorders.			Therapeutic or Preventive Procedure	
C15508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15508>	C15542	Antibody-Drug Conjugate Therapy	Treatment with injections of therapeutic substances linked with specific antibodies in order to directly destroy specific, usually cancerous, cells or to stimulate the immune system to destroy those cells.			Therapeutic or Preventive Procedure	
C15509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15509>	C15433	Amino Acid Injection|RenAmin|Travasol	A concentrated dietary supplement for injection containing the essential amino acids leucine, isoleucine, lysine, valine, phenylalanine, histidine, threonine, methionine and tryptophan as well as the non-essential amino acids alanine, arginine, glycine, proline, serine and tyrosine, with potential anabolic and anti-catabolic activities. Upon dilution and intravenous infusion of the amino acid nutritional supplement, the amino acids serve as protein building blocks, promote protein synthesis in muscle cells and prevent protein breakdown.			Therapeutic or Preventive Procedure	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology
C1550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1550>	C944	Fat-Soluble Vitamin|Fat Soluble Vitamin|fat-soluble vitamin	A vitamin that is soluble in fat solvents and oils (lipo-soluble). Fat-soluble vitamins include vitamins A, D, E, K, F. Absorbed with ingested dietary fat, fat-soluble vitamins are stored in moderate amounts from the gastrointestinal tract. Present in minute amounts in various foods, these vitamins are essential to maintaining normal metabolism and biochemical functions; fat malabsorption may result in fat-soluble vitamin deficiencies. Fat-soluble vitamins are found in many types of foods and may be supplemented with pharmaceutical formulations. (NCI04)			Vitamin	
C15510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15510>	C15262	Growth Factor Antagonist Therapy	Therapies designed to inhibit the action of growth factors.			Therapeutic or Preventive Procedure	
C15511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15511>	C15986	Infection Prophylaxis and Management|Infectious Diseases / Treatment, General|Treatment of Infectious Disease|infectious diseases treatment|management, infection prophylaxis	Treat infections with antibacterial, antifungal, antiparasite or antiviral drugs	Infection Prophylaxis and Management		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C155121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155121>	C154952	Grade 1 Neonatal Convulsion, AE|Grade 1 Neonatal Convulsion|Grade 1 Neonatal Convulsion, Adverse Event	An adverse event in a newborn characterized by a single, self-limited suspected seizure requiring no treatment.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155122>	C154952	Grade 2 Neonatal Convulsion, AE|Grade 2 Neonatal Convulsion|Grade 2 Neonatal Convulsion, Adverse Event	An adverse event in a newborn characterized by suspected seizures controlled with one anti-seizure drug (no recurrence within three days after treatment).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155123>	C154952	Grade 3 Neonatal Convulsion, AE|Grade 3 Neonatal Convulsion|Grade 3 Neonatal Convulsion, Adverse Event	An adverse event in a newborn characterized by suspected seizures uncontrolled with one anti-seizure drug (recurrence within three days after treatment or requiring two or more anti-seizure drugs).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155124>	C154952	Grade 4 Neonatal Convulsion, AE|Grade 4 Neonatal Convulsion|Grade 4 Neonatal Convulsion, Adverse Event	An adverse event in a newborn characterized by suspected seizures with life-threatening consequences (e.g. need for ventilation); suspected status epilepticus (greater than 30 minutes of convulsions within any 60 minute period) despite multiple anti-seizure drugs.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155125>	C154952	Grade 5 Neonatal Convulsion, AE|Grade 5 Neonatal Convulsion|Grade 5 Neonatal Convulsion, Adverse Event	An adverse event in a newborn characterized by death related to suspected seizures.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155126>	C154934	Grade 1 Neonatal Epileptic Seizure, AE|Grade 1 Neonatal Epileptic Seizure|Grade 1 Neonatal Epileptic Seizure, Adverse Event	An adverse event in a newborn characterized by a single, self-limited electroencephalogram (EEG)-proven seizure requiring no treatment.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155127>	C154934	Grade 2 Neonatal Epileptic Seizure, AE|Grade 2 Neonatal Epileptic Seizure|Grade 2 Neonatal Epileptic Seizure, Adverse Event	An adverse event in a newborn characterized by electroencephalogram (EEG)-proven seizures that are controlled with one anti-seizure drug (no recurrence within three days after treatment).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155128>	C154934	Grade 3 Neonatal Epileptic Seizure, AE|Grade 3 Neonatal Epileptic Seizure|Grade 3 Neonatal Epileptic Seizure, Adverse Event	An adverse event in a newborn characterized by electroencephalogram (EEG)-proven seizures uncontrolled with one anti-seizure drug (recurrence within three days after treatment or requiring two or more anti-seizure drugs).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155129>	C154934	Grade 4 Neonatal Epileptic Seizure, AE|Grade 4 Neonatal Epileptic Seizure|Grade 4 Neonatal Epileptic Seizure, Adverse Event	An adverse event in a newborn characterized by electroencephalogram (EEG)- proven seizures with life-threatening consequences (e.g. need for ventilation); status epilepticus (greater than 30 minutes of seizure activity within any 60 minute period) despite multiple anti-seizure drugs.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C15512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15512>	C16175	Prior Endocrine Therapy for Advanced Disease	Having received prior endocrine therapy for advanced disease.			Clinical Attribute	
C155130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155130>	C154934	Grade 5 Neonatal Epileptic Seizure, AE|Grade 5 Neonatal Epileptic Seizure|Grade 5 Neonatal Epileptic Seizure, Adverse Event	An adverse event in a newborn characterized by death related to electroencephalogram (EEG)-proven seizures.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155131>	C154937	Grade 1 Neonatal Intraventricular Hemorrhage, AE|Grade 1 Intraventricular Hemorrhage neonatal|Grade 1 Neonatal Intraventricular Hemorrhage, Adverse Event	An adverse event in a newborn characterized by asymptomatic hemorrhage confined to the germinal matrix; minimal hemorrhage within the ventricle (less than 10% on parasagittal view).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155132>	C154937	Grade 2 Neonatal Intraventricular Hemorrhage, AE|Grade 2 Intraventricular Hemorrhage neonatal|Grade 2 Neonatal Intraventricular Hemorrhage, Adverse Event	An adverse event in a newborn characterized by hemorrhage occupying less than 50% of ventricular volume without ventricular dilatation greater than 4mm above the 97th percentile.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155133>	C154937	Grade 3 Neonatal Intraventricular Hemorrhage, AE|Grade 3 Intraventricular Hemorrhage neonatal|Grade 3 Neonatal Intraventricular Hemorrhage, Adverse Event	An adverse event in a newborn characterized by hemorrhage occupying greater than 50% of the ventricle volume; ventricular dilatation greater than 4mm above the 97th percentile; parenchymal venous infarction; requiring temporizing neurosurgical procedure (drain, shunt or reservoir).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155134>	C154937	Grade 4 Neonatal Intraventricular Hemorrhage, AE|Grade 4 Intraventricular Hemorrhage neonatal|Grade 4 Neonatal Intraventricular Hemorrhage, Adverse Event	An adverse event in a newborn characterized by intraventricular hemorrhage with parenchymal venous infarction; resulting in life threatening consequences (e.g. refractory seizures, hypotension, respiratory depression); requiring urgent stabilization or surgical decompression.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155135>	C154937	Grade 5 Neonatal Intraventricular Hemorrhage, AE|Grade 5 Intraventricular Hemorrhage neonatal|Grade 5 Neonatal Intraventricular Hemorrhage, Adverse Event	An intraventricular hemorrhage adverse event in a newborn which results in death.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155136>	C154925	Grade 1 Retinopathy of Prematurity, AE|Grade 1 Retinopathy of Prematurity|Grade 1 Retinopathy of Prematurity, Adverse Event	An adverse event in a newborn characterized by zone 2 International Classification of Retinopathy of Prematurity (ICROP) stage 1 with or without plus disease; zone 2 ICROP stage 2 without plus disease; zone 3 any ICROP stage; no care changes indicated.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155137>	C154925	Grade 2 Retinopathy of Prematurity, AE|Grade 2 Retinopathy of Prematurity|Grade 2 Retinopathy of Prematurity, Adverse Event|Grade 2 RoP, AE	An adverse event in a newborn characterized by type 2 prethreshold retinopathy of prematurity (ROP) (zone 1 International Classification of Retinopathy of Prematurity (ICROP) stage 1 or 2 without plus disease; zone 2 ICROP stage 3 without plus disease); requiring more frequent ophthalmic monitoring.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155138>	C154925	Grade 3 Retinopathy of Prematurity, AE|Grade 3 Retinopathy of Prematurity|Grade 3 Retinopathy of Prematurity, Adverse Event|Grade 3 RoP, AE	An adverse event in a newborn characterized by type 1 prethreshold retinopathy of prematurity (ROP) (zone 1 any stage with plus disease; zone 1 International Classification of Retinopathy of Prematurity (ICROP) stage 3 without plus disease; zone 2 ICROP stage 2 or 3 with plus disease); threshold ROP; requiring major care changes (e.g. laser intervention, intravitreal anti-VEGF therapy or operative management).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155139>	C154925	Grade 4 Retinopathy of Prematurity, AE|Grade 4 Retinopathy of Prematurity|Grade 4 Retinopathy of Prematurity, Adverse Event|Grade 4 RoP, AE	An adverse event in a newborn characterized by unilateral retinal detachment.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C15513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15513>	C15747	Drug Extravasation Therapy|drug extravasation management	Therapies designed to treat drug extravasation.			Therapeutic or Preventive Procedure	
C155140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155140>	C154925	Grade 5 Retinopathy of Prematurity, AE|Grade 5 Retinopathy of Prematurity|Grade 5 Retinopathy of Prematurity, Adverse Event|Grade 5 RoP, AE	An adverse event in a newborn characterized by bilateral retinal detachment and blindness.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155141>	C154945	Grade 1 Hypoxic Ischemic Encephalopathy, AE|Grade 1 HIE, AE|Grade 1 Hypoxic Ischemic Encephalopathy|Grade 1 Hypoxic Ischemic Encephalopathy, Adverse Event	An adverse event in a newborn clinically classified as perinatal asphyxia, but not resulting in encephalopathy.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155142>	C154945	Grade 2 Hypoxic Ischemic Encephalopathy, AE|Grade 2 HIE, AE|Grade 2 Hypoxic Ischemic Encephalopathy|Grade 2 Hypoxic Ischemic Encephalopathy, Adverse Event	An adverse event in a newborn characterized by mild transient clinical signs (see Sarnat stages for further guidance on mild, moderate and severe clinical signs of encephalopathy) of encephalopathy resulting from a perinatal asphyxia event;  necessitating observation and additional care.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155143>	C154945	Grade 3 Hypoxic Ischemic Encephalopathy, AE|Grade 3 HIE, AE|Grade 3 Hypoxic Ischemic Encephalopathy|Grade 3 Hypoxic Ischemic Encephalopathy, Adverse Event	An adverse event in a newborn characterized by moderate clinical signs (see Sarnat stages for further guidance on mild, moderate and severe clinical signs of encephalopathy) of encephalopathy resulting from a perinatal asphyxia event; meeting criteria for therapeutic hypothermia.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155144>	C154945	Grade 4 Hypoxic Ischemic Encephalopathy, AE|Grade 4 HIE, AE|Grade 4 Hypoxic Ischemic Encephalopathy|Grade 4 Hypoxic Ischemic Encephalopathy, Adverse Event	An adverse event in a newborn characterized by severe clinical signs (see Sarnat stages for further guidance on mild, moderate and severe clinical signs of encephalopathy) of encephalopathy resulting from a perinatal asphyxia event with life-threatening consequences (e.g. respiratory depression, refractory seizures).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155145>	C154945	Grade 5 Hypoxic Ischemic Encephalopathy, AE|Grade 5 HIE, AE|Grade 5 Hypoxic Ischemic Encephalopathy|Grade 5 Hypoxic Ischemic Encephalopathy, Adverse Event	An hypoxic ischemic encephalopathy adverse event in a newborn which results in death.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155146>	C154923	Grade 1 Periventricular Leukomalacia, AE|Grade 1 Periventricular Leukomalacia|Grade 1 Periventricular Leukomalacia, Adverse Event	An adverse event in a newborn characterized by transient periventricular echodensities persisting greater than seven days and resolving completely.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155147>	C154923	Grade 2 Periventricular Leukomalacia, AE|Grade 2 Periventricular Leukomalacia|Grade 2 Periventricular Leukomalacia, Adverse Event	An adverse event in a newborn characterized by transient periventricular echodensities evolving in to small localized fronto-parietal cysts or persistent diffuse echodensities.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155148>	C154923	Grade 3 Periventricular Leukomalacia, AE|Grade 3 Periventricular Leukomalacia|Grade 3 Periventricular Leukomalacia, Adverse Event	An adverse event in a newborn characterized by periventricular echodensities, evolving in to extensive cystic periventricular lesions; or densities extending in to the deep white matter.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155149>	C154939	Grade 1 Infant Irritability, AE|Grade 1 Infant Irritability|Grade 1 Infant Irritability, Adverse Event	An adverse event in a newborn characterized by mild, self-limiting, irritability, not affecting feeding and sleeping.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C15514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15514>	C15747	Psychosocial Assessment and Care|Psychosocial Care/Assessment	The act of determining, usually through interviews and observation, the state of an individual's psychological state and social environment, and subsequently providing assistance to the individual based on their needs.	Psychosocial Assessment and Care		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C155150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155150>	C154939	Grade 2 Infant Irritability, AE|Grade 2 Infant Irritability|Grade 2 Infant Irritability, Adverse Event	An adverse event in a newborn characterized by moderate irritability, minor changes in feeding and sleeping behavior, requiring minor additional care (e.g. occasional analgesics).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155151>	C154939	Grade 3 Infant Irritability, AE|Grade 3 Infant Irritability|Grade 3 Infant Irritability, Adverse Event	An adverse event in a newborn characterized by severe irritability, major changes in feeding behavior, requiring support other than oral feeding; requiring long term medical treatment (e.g. sedatives).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155152>	C154939	Grade 4 Infant Irritability, AE|Grade 4 Infant Irritability|Grade 4 Infant Irritability, Adverse Event	An adverse event in a newborn characterized by life threatening irritability, with loss of autonomic control of temperature or heart rate; requiring urgent care change.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155153>	C154926	Grade 1 Infant Sedation, AE|Grade 1 Infant Sedation|Grade 1 Infant Sedation, Adverse Event	An adverse event in a newborn characterized by mild, self-limiting or transient sedation or sleepiness; transient loss of interactions; not requiring care change.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155154>	C154926	Grade 2 Infant Sedation, AE|Grade 2 Infant Sedation|Grade 2 Infant Sedation, Adverse Event	An adverse event in a newborn characterized by moderate sedation; limiting interactions and minor changes in feeding behavior; requiring increased monitoring.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155155>	C154926	Grade 3 Infant Sedation, AE|Grade 3 Infant Sedation|Grade 3 Infant Sedation, Adverse Event	An adverse event in a newborn characterized by severe sedation, major changes in feeding behavior; requiring support other than oral feeding (e.g. tube feeding).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155156>	C154926	Grade 4 Infant Sedation, AE|Grade 4 Infant Sedation|Grade 4 Infant Sedation, Adverse Event	An adverse event in a newborn characterized by life-threatening sedation with cardiorespiratory instability; requiring urgent care change.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155157>	C154930	Grade 1 Neonatal Hypotension, AE|Grade 1 Neonatal Hypotension|Grade 1 Neonatal Hypotension, Adverse Event	An adverse event in a newborn characterized by transient (less than 60 minutes), asymptomatic hypotension; not affecting perfusion; not requiring intervention.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155158>	C154930	Grade 2 Neonatal Hypotension, AE|Grade 2 Neonatal Hypotension|Grade 2 Neonatal Hypotension, Adverse Event	An adverse event in a newborn characterized by persistent (greater than 60 minutes) hypotension; not affecting perfusion; requiring minor care changes (e.g. additional fluids).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155159>	C154930	Grade 3 Neonatal Hypotension, AE|Grade 3 Neonatal Hypotension|Grade 3 Neonatal Hypotension, Adverse Event	An adverse event in a newborn characterized by persistent hypotension affecting perfusion; requiring major care change (e.g. vaso-active drugs or hydrocortisone).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C15515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15515>	C15411	Colony-Stimulating Factor Therapy	The use of colony-stimulating factor to increase leukocyte production in the treatment of any disease or disorder.			Therapeutic or Preventive Procedure	
C155160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155160>	C154930	Grade 4 Neonatal Hypotension, AE|Grade 4 Neonatal Hypotension|Grade 4 Neonatal Hypotension, Adverse Event	A hypotensive adverse event in a newborn characterized by life-threatening consequences (e.g. shock, organ failure).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155161>	C154930	Grade 5 Neonatal Hypotension, AE|Grade 5 Neonatal Hypotension|Grade 5 Neonatal Hypotension, Adverse Event	A hypotensive adverse event in a newborn which results in death.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155162>	C154929	Grade 1 Neonatal Hypertension, AE|Grade 1 Neonatal Hypertension|Grade 1 Neonatal Hypertension, Adverse Event	An adverse event in a newborn characterized by systolic or diastolic blood pressure above the 90th percentile but below the 95th percentile; self-limiting.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155163>	C154929	Grade 2 Neonatal Hypertension, AE|Grade 2 Neonatal Hypertension|Grade 2 Neonatal Hypertension, Adverse Event	An adverse event in a newborn characterized by persistent or recurrent hypertension, with systolic or diastolic blood pressure between the 95th percentile and the 99th percentile.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155164>	C154929	Grade 3 Neonatal Hypertension, AE|Grade 3 Neonatal Hypertension|Grade 3 Neonatal Hypertension, Adverse Event	An adverse event in a newborn characterized by persistent or recurrent hypertension, with systolic or diastolic blood pressure above the 99th percentile; need for antihypertensive medication.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155165>	C154929	Grade 4 Neonatal Hypertension, AE|Grade 4 Neonatal Hypertension|Grade 4 Neonatal Hypertension, Adverse Event	A hypertensive adverse event in a newborn characterized by life-threatening consequences (e.g. malignant hypertension: shock, cardiac failure or neonatal encephalopathy).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155166>	C154929	Grade 5 Neonatal Hypertension, AE|Grade 5 Neonatal Hypertension|Grade 5 Neonatal Hypertension, Adverse Event	A hypertensive adverse event in a newborn which results in death.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155167>	C154932	Grade 1 Neonatal Sinus Tachycardia, AE|Grade 1 Neonatal Sinus Tachycardia|Grade 1 Neonatal Sinus Tachycardia, Adverse Event	An adverse event in a newborn characterized by brief, self-limiting, episodes of sinus tachycardia; no care changes.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155168>	C154932	Grade 2 Neonatal Sinus Tachycardia, AE|Grade 2 Neonatal Sinus Tachycardia|Grade 2 Neonatal Sinus Tachycardia, Adverse Event	An adverse event in a newborn characterized by persistent sinus tachycardia; no change in age appropriate behavior; requiring minor care changes (e.g. concomitant medication changed).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155169>	C154932	Grade 3 Neonatal Sinus Tachycardia, AE|Grade 3 Neonatal Sinus Tachycardia|Grade 3 Neonatal Sinus Tachycardia, Adverse Event	An adverse event in a newborn characterized by persistent sinus tachycardia; resulting in non-life threatening hemodynamic compromise; requiring major care changes (e.g. new medication or intervention).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C15516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15516>	C209812	Fertility Assessment and Management|fertility management/assessment	Evaluations used to determine reproductive status and potential, and the treatments that will be required to maintain a pregnancy.	Fertility Assessment and Management		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C155170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155170>	C154932	Grade 4 Neonatal Sinus Tachycardia, AE|Grade 4 Neonatal Sinus Tachycardia|Grade 4 Neonatal Sinus Tachycardia, Adverse Event	A sinus tachycardia adverse event in a newborn characterized by life-threatening consequences; requiring urgent major care changes.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155171>	C154932	Grade 5 Neonatal Sinus Tachycardia, AE|Grade 5 Neonatal Sinus Tachycardia|Grade 5 Neonatal Sinus Tachycardia, Adverse Event	A sinus tachycardia adverse event in a newborn which results in death.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155172>	C154933	Grade 1 Neonatal Sinus Bradycardia, AE|Grade 1 Neonatal Sinus Bradycardia|Grade 1 Neonatal Sinus Bradycardia, Adverse Event	An adverse event in a newborn characterized by brief, self-limiting, episodes of sinus bradycardia; no care changes.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155173>	C154933	Grade 2 Neonatal Sinus Bradycardia, AE|Grade 2 Neonatal Sinus Bradycardia|Grade 2 Neonatal Sinus Bradycardia, Adverse Event	An adverse event in a newborn characterized by persistent sinus bradycardia; no change in age-appropriate behavior; requiring minor care changes (e.g. concomitant medication adapted, intermittent increase of fraction of inspired oxygen (FiO2)).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155174>	C154933	Grade 3 Neonatal Sinus Bradycardia, AE|Grade 3 Neonatal Sinus Bradycardia|Grade 3 Neonatal Sinus Bradycardia, Adverse Event	An adverse event in a newborn characterized by persistent sinus bradycardia; resulting in non-life threatening hemodynamic compromise; requiring major care changes (e.g. new medication or intervention).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155175>	C154933	Grade 4 Neonatal Sinus Bradycardia, AE|Grade 4 Neonatal Sinus Bradycardia|Grade 4 Neonatal Sinus Bradycardia, Adverse Event	A sinus bradycardia adverse event in a newborn characterized by life-threatening consequences (e.g. shock); requiring urgent major care changes.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155176>	C154933	Grade 5 Neonatal Sinus Bradycardia, AE|Grade 5 Neonatal Sinus Bradycardia|Grade 5 Neonatal Sinus Bradycardia, Adverse Event	A sinus bradycardia adverse event in a newborn which results in death.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155177>	C154948	Grade 1 Neonatal Tachyarrhythmia, AE|Grade 1 Neonatal Tachyarrhythmia|Grade 1 Neonatal Tachyarrhythmia, Adverse Event	An adverse event in a newborn characterized by brief, self-limiting, episodes of asymptomatic tachyarrhythmia (e.g. extra-systolic beats); no care changes.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155178>	C154948	Grade 2 Neonatal Tachyarrhythmia, AE|Grade 2 Neonatal Tachyarrhythmia|Grade 2 Neonatal Tachyarrhythmia, Adverse Event	A tachyarrhythmia adverse event in a newborn characterized by no change in age-appropriate behavior; requiring minor care changes (e.g. increased monitoring).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155179>	C154948	Grade 3 Neonatal Tachyarrhythmia, AE|Grade 3 Neonatal Tachyarrhythmia|Grade 3 Neonatal Tachyarrhythmia, Adverse Event	A tachyarrhythmia adverse event in a newborn resulting in non-life threatening hemodynamic compromise or changes in age-appropriate behavior; requiring major care changes (e.g. new medication or intervention).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C15517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15517>	C211883	Catheter Management|management of catheter	Any activity related to the care and supervision of any type of catheter.	Catheter Management		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C155180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155180>	C154948	Grade 4 Neonatal Tachyarrhythmia, AE|Grade 4 Neonatal Tachyarrhythmia|Grade 4 Neonatal Tachyarrhythmia, Adverse Event	A tachyarrhythmia adverse event in a newborn characterized by life-threatening consequences (e.g. shock); requiring urgent major care changes.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155181>	C154948	Grade 5 Neonatal Tachyarrhythmia, AE|Grade 5 Neonatal Tachyarrhythmia|Grade 5 Neonatal Tachyarrhythmia, Adverse Event	A tachyarrhythmia adverse event in a newborn which results in death.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155182>	C154949	Grade 1 Neonatal Bradyarrhythmia, AE|Grade 1 Neonatal Bradyarrhythmia|Grade 1 Neonatal Bradyarrhythmia, Adverse Event	An adverse event in a newborn characterized by brief, self-limiting, episodes of asymptomatic bradyarrhythmia; no care changes.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155183>	C154949	Grade 2 Neonatal Bradyarrhythmia, AE|Grade 2 Neonatal Bradyarrhythmia|Grade 2 Neonatal Bradyarrhythmia, Adverse Event	A bradyarrhythmia adverse event in a newborn characterized by no change in age-appropriate behavior; requiring minor care changes (e.g. increased monitoring).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155184>	C154949	Grade 3 Neonatal Bradyarrhythmia, AE|Grade 3 Neonatal Bradyarrhythmia|Grade 3 Neonatal Bradyarrhythmia, Adverse Event	A bradyarrhythmia adverse event in a newborn resulting in non-life threatening hemodynamic compromise; requiring major care changes (e.g. new medication or intervention).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155185>	C154949	Grade 4 Neonatal Bradyarrhythmia, AE|Grade 4 Neonatal Bradyarrhythmia|Grade 4 Neonatal Bradyarrhythmia, Adverse Event	A bradyarrhythmia adverse event in a newborn characterized by life-threatening consequences (e.g. shock); requiring urgent major care changes.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155186>	C154949	Grade 5 Neonatal Bradyarrhythmia, AE|Grade 5 Neonatal Bradyarrhythmia|Grade 5 Neonatal Bradyarrhythmia, Adverse Event	A bradyarrhythmia adverse event in a newborn which results in death.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155187>	C154931	Grade 1 Neonatal Edema, AE|Grade 1 Edema Neonatal|Grade 1 Neonatal Edema, Adverse Event	An adverse event in a newborn characterized by mild edema; no change in age appropriate behavior; no care changes indicated.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155188>	C154931	Grade 2 Neonatal Edema, AE|Grade 2 Edema Neonatal|Grade 2 Neonatal Edema, Adverse Event	An adverse event in a newborn characterized by moderate edema; no change in age appropriate behavior; requiring minor care changes (e.g. alteration in fluid management).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155189>	C154931	Grade 3 Neonatal Edema, AE|Grade 3 Edema Neonatal|Grade 3 Neonatal Edema, Adverse Event	An adverse event in a newborn characterized by severe edema; limiting age appropriate behavior; requiring major care changes (e.g. diuretics).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C15518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15518>	C15439	Clinical Trials Information for Patients				Intellectual Product	
C155190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155190>	C154931	Grade 4 Neonatal Edema, AE|Grade 4 Edema Neonatal|Grade 4 Neonatal Edema, Adverse Event	An edema adverse event in a newborn characterized by life threatening consequences (e.g. respiratory failure, shock); requiring urgent major care changes (e.g. intubation, dialysis).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155191>	C154931	Grade 5 Neonatal Edema, AE|Grade 5 Edema Neonatal|Grade 5 Neonatal Edema, Adverse Event	An edema adverse event in a newborn which results in death.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155192>	C154921	Grade 1 Neonatal Coagulation Disorder, AE|Grade 1 Coagulation Disorder Neonatal|Grade 1 Neonatal Coagulation Disorder, Adverse Event	An adverse event in a newborn characterized by minor biochemical coagulation abnormalities without clinical signs; no care changes indicated.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155193>	C154921	Grade 2 Neonatal Coagulation Disorder, AE|Grade 2 Coagulation Disorder Neonatal|Grade 2 Neonatal Coagulation Disorder, Adverse Event	An adverse event in a newborn characterized by biochemical coagulation abnormalities with clinical signs; requiring increased monitoring.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155194>	C154921	Grade 3 Neonatal Coagulation Disorder, AE|Grade 3 Coagulation Disorder Neonatal|Grade 3 Neonatal Coagulation Disorder, Adverse Event	An adverse event in a newborn characterized by biochemical or clinical coagulation abnormalities; requiring intervention.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155195>	C154921	Grade 4 Neonatal Coagulation Disorder, AE|Grade 4 Coagulation Disorder Neonatal|Grade 4 Neonatal Coagulation Disorder, Adverse Event	A coagulation disorder adverse event in a newborn characterized by life threatening consequences (e.g. severe pulmonary embolism, limb ischemia, hemorrhagic shock, disseminated intravascular coagulation (DIC)); requiring urgent major care changes.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155196>	C154921	Grade 5 Neonatal Coagulation Disorder, AE|Grade 5 Coagulation Disorder Neonatal|Grade 5 Neonatal Coagulation Disorder, Adverse Event	A coagulation disorder adverse event in a newborn which results in death.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155197>	C154938	Grade 1 Infantile Apnea, AE|Grade 1 Infantile Apnea|Grade 1 Infantile Apnea, Adverse Event	An adverse event in a newborn characterized by self-limiting apnea.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155198>	C154938	Grade 2 Infantile Apnea, AE|Grade 2 Infantile Apnea|Grade 2 Infantile Apnea, Adverse Event	An adverse event in a newborn characterized by apnea responsive to stimulation or intermittent fraction of inspired oxygen (FiO2) increase.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155199>	C154938	Grade 3 Infantile Apnea, AE|Grade 3 Infantile Apnea|Grade 3 Infantile Apnea, Adverse Event	An adverse event in a newborn characterized by apnea requiring stimulation and sustained fraction of inspired oxygen (FiO2) increase; requiring non-invasive ventilation; reoccurrences requiring start of or relevant increase in dose of respiratory stimulants or other major care changes.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C15519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15519>	C15439	Clinical Trials Information for Physicians				Intellectual Product	
C1551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1551>	C944	Water-Soluble Vitamin|Water Soluble Vitamin|water-soluble vitamin	Vitamins that are freely soluble in water.			Chemical Viewed Functionally	
C155200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155200>	C154938	Grade 4 Infantile Apnea, AE|Grade 4 Infantile Apnea|Grade 4 Infantile Apnea, Adverse Event	An apneic adverse event in a newborn characterized by life-threatening respiratory and/or hemodynamic compromise; (semi-)urgent intubation required.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155201>	C154938	Grade 5 Infantile Apnea, AE|Grade 5 Infantile Apnea|Grade 5 Infantile Apnea, Adverse Event	An apneic adverse event in a newborn which results in death.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155202>	C154951	Grade 1 Neonatal Respiratory Insufficiency, AE|Grade 1 Neonatal Respiratory Insufficiency|Grade 1 Neonatal Respiratory Insufficiency, Adverse Event	An adverse event in a newborn characterized by clinical evidence of mildly increased respiratory distress (e.g. increased work of breathing) without significant deterioration in gas exchange (increase in partial pressure of carbon dioxide (pCO2) or decrease in oxygenation); no change in baseline functioning; no care changes required.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155203>	C154951	Grade 2 Neonatal Respiratory Insufficiency, AE|Grade 2 Neonatal Respiratory Insufficiency|Grade 2 Neonatal Respiratory Insufficiency, Adverse Event	An adverse event in a newborn characterized by clinical evidence of increased respiratory distress without significant deterioration in gas exchange (increase in partial pressure of carbon dioxide (pCO2) or decrease in oxygenation); corrected by minor adjustments in current ventilatory support, supplemental oxygen or non-invasive support.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155204>	C154951	Grade 3 Neonatal Respiratory Insufficiency, AE|Grade 3 Neonatal Respiratory Insufficiency|Grade 3 Neonatal Respiratory Insufficiency, Adverse Event	An adverse event in a newborn characterized by clinical evidence of increased respiratory distress with relevant deterioration in gas exchange (increase in partial pressure of carbon dioxide (pCO2) or decrease in oxygenation); requiring major care change (e.g. starting invasive support).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155205>	C154951	Grade 4 Neonatal Respiratory Insufficiency, AE|Grade 4 Neonatal Respiratory Insufficiency|Grade 4 Neonatal Respiratory Insufficiency, Adverse Event	A respiratory insufficiency adverse event in a newborn characterized by life-threatening respiratory and/or hemodynamic compromise; requiring urgent care change (e.g. urgent intubation).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155206>	C154951	Grade 5 Neonatal Respiratory Insufficiency, AE|Grade 5 Neonatal Respiratory Insufficiency|Grade 5 Neonatal Respiratory Insufficiency, Adverse Event	A respiratory insufficiency adverse event in a newborn which results in death.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155207>	C154950	Grade 1 Neonatal Respiratory Distress Syndrome, AE|Grade 1 Neonatal Respiratory Distress Syndrome|Grade 1 Neonatal Respiratory Distress Syndrome, Adverse Event	An adverse event in a newborn characterized by radiological evidence without clinical signs; clinical evidence of mildly increased respiratory distress (e.g. increased work of breathing) without significant deterioration in gas exchange (increase in partial pressure of carbon dioxide (pCO2) or decrease in oxygenation); no supportive care required.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155208>	C154950	Grade 2 Neonatal Respiratory Distress Syndrome, AE|Grade 2 Neonatal Respiratory Distress Syndrome|Grade 2 Neonatal Respiratory Distress Syndrome, Adverse Event	An adverse event in a newborn characterized by clinical evidence of increased respiratory distress without significant deterioration in gas exchange (increase in partial pressure of carbon dioxide (pCO2) or decrease in oxygenation); corrected by minor adjustments in current ventilatory support, supplemental oxygen or non-invasive support.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155209>	C154950	Grade 3 Neonatal Respiratory Distress Syndrome, AE|Grade 3 Neonatal Respiratory Distress Syndrome|Grade 3 Neonatal Respiratory Distress Syndrome, Adverse Event	An adverse event in a newborn characterized by clinical evidence of increased respiratory distress with relevant deterioration in gas exchange (increase in partial pressure of carbon dioxide (pCO2) or decrease in oxygenation); requiring major care change (e.g. starting invasive support).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C15520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15520>	C61063	Flavone Acetic Acid/Interleukin-2|FAA/IL-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C155210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155210>	C154950	Grade 4 Neonatal Respiratory Distress Syndrome, AE|Grade 4 Neonatal Respiratory Distress Syndrome|Grade 4 Neonatal Respiratory Distress Syndrome, Adverse Event	A respiratory distress adverse event in a newborn characterized by life-threatening respiratory and/or hemodynamic compromise; requiring urgent care change (e.g. urgent intubation).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155211>	C154950	Grade 5 Neonatal Respiratory Distress Syndrome, AE|Grade 5 Neonatal Respiratory Distress Syndrome|Grade 5 Neonatal Respiratory Distress Syndrome, Adverse Event	A respiratory distress adverse event in a newborn which results in death.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155212>	C154936	Grade 1 Neonatal Pulmonary Hemorrhage, AE|Grade 1 Neonatal Pulmonary Hemorrhage|Grade 1 Neonatal Pulmonary Hemorrhage, Adverse Event	An adverse event in a newborn characterized by limited hemorrhagic secretion in an endotracheal (ET) tube.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155213>	C154936	Grade 2 Neonatal Pulmonary Hemorrhage, AE|Grade 2 Neonatal Pulmonary Hemorrhage|Grade 2 Neonatal Pulmonary Hemorrhage, Adverse Event	An adverse event in a newborn characterized by hemorrhagic secretion in an endotracheal (ET) tube; without relevant increase in partial pressure of carbon dioxide (pCO2) or decrease in oxygenation; requiring minor changes in care (e.g. increase in positive end-expiration pressure (PEEP)).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155214>	C154936	Grade 3 Neonatal Pulmonary Hemorrhage, AE|Grade 3 Neonatal Pulmonary Hemorrhage|Grade 3 Neonatal Pulmonary Hemorrhage, Adverse Event	An adverse event in a newborn characterized by hemorrhagic secretion in an endotracheal (ET) tube; with relevant increase in partial pressure of carbon dioxide (pCO2) or decrease in oxygenation; requiring major change in ventilatory support or transfusion.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155215>	C154936	Grade 4 Neonatal Pulmonary Hemorrhage, AE|Grade 4 Neonatal Pulmonary Hemorrhage|Grade 4 Neonatal Pulmonary Hemorrhage, Adverse Event	A pulmonary hemorrhage adverse event in a newborn characterized by life-threatening respiratory and/or hemodynamic compromise.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155216>	C154936	Grade 5 Neonatal Pulmonary Hemorrhage, AE|Grade 5 Neonatal Pulmonary Hemorrhage|Grade 5 Neonatal Pulmonary Hemorrhage, Adverse Event	A pulmonary hemorrhage adverse event in a newborn which results in death.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155217>	C154940	Grade 1 Persistent Pulmonary Hypertension of the Newborn, AE|Grade 1 PPHN, AE|Grade 1 Persistent Pulmonary Hypertension of the Newborn|Grade 1 Persistent Pulmonary Hypertension of the Newborn, Adverse Event	An adverse event in a newborn characterized by technical evidence of increased right ventricular pressures; no clinical symptoms.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155218>	C154940	Grade 2 Persistent Pulmonary Hypertension of the Newborn, AE|Grade 2 PPHN, AE|Grade 2 Persistent Pulmonary Hypertension of the Newborn|Grade 2 Persistent Pulmonary Hypertension of the Newborn, Adverse Event	An adverse event in a newborn characterized by increased estimated right ventricular pressures; with moderate clinical symptoms; oxygenation index less than 25; minor care changes required.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155219>	C154940	Grade 3 Persistent Pulmonary Hypertension of the Newborn, AE|Grade 3 PPHN, AE|Grade 3 Persistent Pulmonary Hypertension of the Newborn|Grade 3 Persistent Pulmonary Hypertension of the Newborn, Adverse Event	An adverse event in a newborn characterized by Increased estimated right ventricular pressures; with severe clinical symptoms; oxygenation index greater than 25; major care changes required (e.g. inhaled nitric oxide (iNO)).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C15521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15521>	C94632	Antiprogesterone Therapy|Antiprogestational Therapy	Drug treatment to block the action of the female hormone progesterone.			Therapeutic or Preventive Procedure	
C155220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155220>	C154940	Grade 4 Persistent Pulmonary Hypertension of the Newborn, AE|Grade 4 PPHN, AE|Grade 4 Persistent Pulmonary Hypertension of the Newborn|Grade 4 Persistent Pulmonary Hypertension of the Newborn, Adverse Event	A persistent pulmonary hypertension adverse event in a newborn characterized by life-threatening respiratory and/or hemodynamic compromise; extracorporeal membrane oxygenation (ECMO) required; oxygenation index greater than 40.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155221>	C154940	Grade 5 Persistent Pulmonary Hypertension of the Newborn, AE|Grade 5 PPHN, AE|Grade 5 Persistent Pulmonary Hypertension of the Newborn|Grade 5 Persistent Pulmonary Hypertension of the Newborn, Adverse Event	A persistent pulmonary hypertension adverse event in a newborn which results in death.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155222>	C154920	Grade 1 Neonatal Pneumothorax, AE|Grade 1 Neonatal Pneumothorax|Grade 1 Neonatal Pneumothorax, Adverse Event	An adverse event in a newborn characterized by radiological evidence of pneumothorax; no clinical signs; no care change required.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155223>	C154920	Grade 2 Neonatal Pneumothorax, AE|Grade 2 Neonatal Pneumothorax|Grade 2 Neonatal Pneumothorax, Adverse Event	An adverse event in a newborn characterized by radiological evidence of pneumothorax; minor clinical signs; minor care change required (e.g. oxygen, increased monitoring).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155224>	C154920	Grade 3 Neonatal Pneumothorax, AE|Grade 3 Neonatal Pneumothorax|Grade 3 Neonatal Pneumothorax, Adverse Event	An adverse event in a newborn characterized by radiological evidence of pneumothorax; with clinical signs; major care change required (e.g. chest drainage).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155225>	C154920	Grade 4 Neonatal Pneumothorax, AE|Grade 4 Neonatal Pneumothorax|Grade 4 Neonatal Pneumothorax, Adverse Event	A pneumothorax adverse event in a newborn characterized by life-threatening respiratory and/or hemodynamic compromise (e.g. tension pneumothorax); urgent major care change required.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155226>	C154920	Grade 5 Neonatal Pneumothorax, AE|Grade 5 Neonatal Pneumothorax|Grade 5 Neonatal Pneumothorax, Adverse Event	A pneumothorax adverse event in a newborn which results in death.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155227>	C154919	Grade 1 Bronchopulmonary Dysplasia, AE|Grade 1 BPD, AE|Grade 1 Bronchopulmonary Dysplasia|Grade 1 Bronchopulmonary Dysplasia, Adverse Event	An adverse event in a newborn characterized by the need for supplemental oxygen at 28 days AND breathing room air at 36 weeks postmenstrual age (PMA) in infants born less than 32 weeks' gestation; breathing room air by 56 days postnatal age in infants born greater than 32 weeks' gestation; breathing room air at discharge. Note: For conversion of oxygen administered by different modalities to fraction of inspired oxygen (FiO2): see http://nicutools.org/MediCalcs/ActualO2.php3.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155228>	C154919	Grade 2 Bronchopulmonary Dysplasia, AE|Grade 2 BPD, AE|Grade 2 Bronchopulmonary Dysplasia|Grade 2 Bronchopulmonary Dysplasia, Adverse Event	An adverse event in a newborn characterized by the need for supplemental oxygen at 28 days AND need for 22-30% oxygen at 36 weeks postmenstrual age (PMA) in infants born less than 32 weeks' gestation; need for 22-30% oxygen by 56 days postnatal age in infants born greater than 32 weeks' gestation; need for 22-30% oxygen at discharge. Note: For conversion of oxygen administered by different modalities to fraction of inspired oxygen (FiO2): see http://nicutools.org/MediCalcs/ActualO2.php3.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155229>	C154919	Grade 3 Bronchopulmonary Dysplasia, AE|Grade 3 BPD, AE|Grade 3 Bronchopulmonary Dysplasia|Grade 3 Bronchopulmonary Dysplasia, Adverse Event	An adverse event in a newborn characterized by the need for supplemental oxygen at 28 days AND need for greater than 30% oxygen or positive pressure at 36 weeks postmenstrual age (PMA) in infants born less than 32 weeks' gestation; need for greater than 30% oxygen or positive pressure by 56 days postnatal age in infants born greater than 32 weeks' gestation; need for greater than 30% oxygen and/or positive pressure at discharge. Note: For conversion of oxygen administered by different modalities to fraction of inspired oxygen (FiO2): see http://nicutools.org/MediCalcs/ActualO2.php3.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C15522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15522>	C61063	Interleukin-2/Tumor Necrosis Factor|IL-2/TNF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C155230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155230>	C154919	Grade 4 Bronchopulmonary Dysplasia, AE|Grade 4 BPD, AE|Grade 4 Bronchopulmonary Dysplasia|Grade 4 Bronchopulmonary Dysplasia, Adverse Event	An adverse event in a newborn characterized by the need for supplemental oxygen at 28 days AND need for greater than 30% oxygen AND positive pressure at 36 weeks postmenstrual age (PMA) in infants born less than 32 weeks' gestation; need for greater than 30% oxygen AND positive pressure by 56 days postnatal age in infants born greater than 32 weeks' gestation; need for greater than 30% oxygen AND positive pressure at discharge. Note: For conversion of oxygen administered by different modalities to fraction of inspired oxygen (FiO2): see http://nicutools.org/MediCalcs/ActualO2.php3.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155231>	C154919	Grade 5 Bronchopulmonary Dysplasia, AE|Grade 5 BPD, AE|Grade 5 Bronchopulmonary Dysplasia|Grade 5 Bronchopulmonary Dysplasia, Adverse Event	A bronchopulmonary dysplasia adverse event in a newborn which results in death.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155232>	C154922	Grade 3 Necrotizing Enterocolitis, AE|Grade 3 Necrotizing Enterocolitis|Grade 3 Necrotizing Enterocolitis, Adverse Event	An adverse event in a newborn characterized by confirmed necrotizing enterocolitis; major care change indicated (e.g. NPO, antibiotics, non-urgent surgery).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155233>	C154922	Grade 4 Necrotizing Enterocolitis, AE|Grade 4 Necrotizing Enterocolitis|Grade 4 Necrotizing Enterocolitis, Adverse Event	A necrotizing enterocolitis adverse event in a newborn characterized by bowel perforation (pneumoperitoneum)(modified Bell stage IIIB); shock, disseminated intravascular coagulation (DIC), combined respiratory and metabolic acidosis (modified Bell stage IIIA); urgent major care change indicated.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155234>	C154922	Grade 5 Necrotizing Enterocolitis, AE|Grade 5 Necrotizing Enterocolitis|Grade 5 Necrotizing Enterocolitis, Adverse Event	A necrotizing enterocolitis adverse event in a newborn which results in death.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155235>	C154953	Grade 1 Neonatal Diarrhea, AE|Grade 1 Diarrhea Neonatal|Grade 1 Neonatal Diarrhea, Adverse Event	An adverse event in a newborn characterized by an increase of 2-4 stools per day over baseline; mild increase in ostomy output compared to baseline.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155236>	C154953	Grade 2 Neonatal Diarrhea, AE|Grade 2 Diarrhea Neonatal|Grade 2 Neonatal Diarrhea, Adverse Event	An adverse event in a newborn characterized by an increase of 4 - 6 stools per day over baseline; moderate increase in ostomy output compared to baseline.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155237>	C154953	Grade 3 Neonatal Diarrhea, AE|Grade 3 Diarrhea Neonatal|Grade 3 Neonatal Diarrhea, Adverse Event	An adverse event in a newborn characterized by an increase of 7 stools or more per day over baseline; severe increase in ostomy output compared to baseline; signs of dehydration.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155238>	C154953	Grade 4 Neonatal Diarrhea, AE|Grade 4 Diarrhea Neonatal|Grade 4 Neonatal Diarrhea, Adverse Event	A diarrhea adverse event in a newborn characterized by life-threatening consequences (e.g. severe dehydration).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155239>	C154953	Grade 5 Neonatal Diarrhea, AE|Grade 5 Diarrhea Neonatal|Grade 5 Neonatal Diarrhea, Adverse Event	A diarrhea adverse event in a newborn which results in death.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C15523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15523>	C61007	Interleukin-2/Tumor Infiltrating Lymphocytes|IL-2/TIL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C155240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155240>	C154942	Grade 1 Infantile Vomiting, AE|Grade 1 Infantile Vomiting|Grade 1 Infantile Vomiting, Adverse Event	An adverse event in a newborn characterized by an increase in vomiting over baseline, self limiting.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155241>	C154942	Grade 2 Infantile Vomiting, AE|Grade 2 Infantile Vomiting|Grade 2 Infantile Vomiting, Adverse Event	An adverse event in a newborn characterized by a persistent increase in vomiting over baseline; no dehydration; minor changes in feeding support indicated.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155242>	C154942	Grade 3 Infantile Vomiting, AE|Grade 3 Infantile Vomiting|Grade 3 Infantile Vomiting, Adverse Event	An adverse event in a newborn characterized by a persistent increase in vomiting over baseline; signs of dehydration; major changes in feeding support indicated (e.g. change to total parenteral nutrition (TPN) or gavage).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155243>	C154942	Grade 4 Infantile Vomiting, AE|Grade 4 Infantile Vomiting|Grade 4 Infantile Vomiting, Adverse Event	A vomiting adverse event in a newborn characterized by life-threatening consequences (e. g. severe dehydration).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155244>	C154942	Grade 5 Infantile Vomiting, AE|Grade 5 Infantile Vomiting|Grade 5 Infantile Vomiting, Adverse Event	A vomiting adverse event in a newborn which results in death.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155245>	C154944	Grade 1 Feeding Intolerance, AE|Grade 1 Feeding Intolerance|Grade 1 Feeding Intolerance, Adverse Event	An adverse event in a newborn characterized by mild feeding intolerance (e.g. increased gastric residual volume or abdominal distension); without discomfort; no change in care indicated.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155246>	C154944	Grade 2 Feeding Intolerance, AE|Grade 2 Feeding Intolerance|Grade 2 Feeding Intolerance, Adverse Event	An adverse event in a newborn characterized by moderate feeding intolerance; resulting in minor discomfort or alteration of drinking behavior; minor care changes indicated (e.g. feeds withheld).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155247>	C154944	Grade 3 Feeding Intolerance, AE|Grade 3 Feeding Intolerance|Grade 3 Feeding Intolerance, Adverse Event	An adverse event in a newborn characterized by severe feeding intolerance; requiring major changes in feeding support indicated (e.g. change to total parenteral nutrition (TPN) or gavage).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155248>	C154944	Grade 4 Feeding Intolerance, AE|Grade 4 Feeding Intolerance|Grade 4 Feeding Intolerance, Adverse Event	A feeding intolerance adverse event in a newborn characterized by life-threatening consequences.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155249>	C154944	Grade 5 Feeding Intolerance, AE|Grade 5 Feeding Intolerance|Grade 5 Feeding Intolerance, Adverse Event	A feeding intolerance adverse event in a newborn which results in death.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C15524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15524>	C15545	Tumor Infiltrating Lymphocyte Therapy	A form of adoptive cell transfer in which lymphocytes are isolated from a patient's tumor, grown in vitro, and then infused into the patient in combination with interleukin 2.	Tumor Infiltrating Lymphocyte Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C155250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155250>	C154943	Grade 1 Neonatal Gastrointestinal Bleeding, AE|Grade 1 Gastro-intestinal Bleeding Neonatal|Grade 1 Neonatal Gastrointestinal Bleeding, Adverse Event	A gastrointestinal bleeding adverse event in a newborn characterized by mild, self-limiting, bleeding; no change in care required.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155251>	C154943	Grade 2 Neonatal Gastrointestinal Bleeding, AE|Grade 2 Gastro-intestinal Bleeding Neonatal|Grade 2 Neonatal Gastrointestinal Bleeding, Adverse Event	A gastrointestinal bleeding adverse event in a newborn characterized by moderate bleeding; minor change in care or monitoring required.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155252>	C154943	Grade 3 Neonatal Gastrointestinal Bleeding, AE|Grade 3 Gastro-intestinal Bleeding Neonatal|Grade 3 Neonatal Gastrointestinal Bleeding, Adverse Event	A gastrointestinal bleeding adverse event in a newborn characterized by severe bleeding; non-life threatening hemodynamic consequences; major care change required (e.g. invasive intervention, transfusion, long term medical treatment).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155253>	C154943	Grade 4 Neonatal Gastrointestinal Bleeding, AE|Grade 4 Gastro-intestinal Bleeding Neonatal|Grade 4 Neonatal Gastrointestinal Bleeding, Adverse Event	A gastrointestinal bleeding adverse event in a newborn characterized by life-threatening consequences (e.g. hemorrhagic shock); urgent major care change required.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155254>	C154943	Grade 5 Neonatal Gastrointestinal Bleeding, AE|Grade 5 Gastro-intestinal Bleeding Neonatal|Grade 5 Neonatal Gastrointestinal Bleeding, Adverse Event	A gastrointestinal bleeding adverse event in a newborn which results in death.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155255>	C154924	Grade 3 Neonatal Spontaneous Intestinal Perforation, AE|Grade 3 Neonatal SIP, AE|Grade 3 Neonatal Spontaneous Intestinal Perforation|Grade 3 Neonatal Spontaneous Intestinal Perforation, Adverse Event	An adverse event in a newborn characterized by presence of spontaneous intestinal perforation (SIP), non-urgent medical stabilization and surgical intervention indicated.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155256>	C154924	Grade 4 Neonatal Spontaneous Intestinal Perforation, AE|Grade 4 Neonatal SIP, AE|Grade 4 Neonatal Spontaneous Intestinal Perforation|Grade 4 Neonatal Spontaneous Intestinal Perforation, Adverse Event	A spontaneous intestinal perforation (SIP) adverse event in a newborn characterized by life-threatening consequences (e.g. shock, organ failure); urgent intervention indicated.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155257>	C154924	Grade 5 Neonatal Spontaneous Intestinal Perforation, AE|Grade 5 Neonatal SIP, AE|Grade 5 Neonatal Spontaneous Intestinal Perforation|Grade 5 Neonatal Spontaneous Intestinal Perforation, Adverse Event	A spontaneous intestinal perforation (SIP) adverse event in a newborn which results in death.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155258>	C154946	Grade 1 Neonatal Constipation, AE|Grade 1 Constipation Neonatal|Grade 1 Neonatal Constipation, Adverse Event	An adverse event in a newborn characterized by reduced number of stools or hard stools; no apparent discomfort.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155259>	C154946	Grade 2 Neonatal Constipation, AE|Grade 2 Constipation Neonatal|Grade 2 Neonatal Constipation, Adverse Event	An adverse event in a newborn characterized by reduced number of stools or hard stools; apparent discomfort; minor care changes indicated.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C15525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15525>	C15757	Aromatase Inhibition Therapy|Aromatase Inhibition	Drug treatment to block the action of aromatases, thereby reducing estrogen biosynthesis.	Aromatase Inhibition Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C155260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155260>	C154946	Grade 3 Neonatal Constipation, AE|Grade 3 Constipation Neonatal|Grade 3 Neonatal Constipation, Adverse Event	An adverse event in a newborn characterized by reduced number of stools or hard stools; signs of obstruction; apparent discomfort or affecting feeding; major care changes indicated (e.g. long term medical treatment, enema).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155261>	C154946	Grade 4 Neonatal Constipation, AE|Grade 4 Constipation Neonatal|Grade 4 Neonatal Constipation, Adverse Event	A constipation adverse event in a newborn characterized by life-threatening consequences.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155262>	C154946	Grade 5 Neonatal Constipation, AE|Grade 5 Constipation Neonatal|Grade 5 Neonatal Constipation, Adverse Event	A constipation adverse event in a newborn which results in death.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155263>	C154928	Grade 2 Neonatal Culture Negative Sepsis, AE|Grade 2 Culture Negative Neonatal Sepsis|Grade 2 Neonatal Culture Negative Sepsis, Adverse Event	An adverse event in a newborn characterized by suspected sepsis with mild or ambiguous signs; anti-infectives initiated.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155264>	C154928	Grade 3 Neonatal Culture Negative Sepsis, AE|Grade 3 Culture Negative Neonatal Sepsis|Grade 3 Neonatal Culture Negative Sepsis, Adverse Event	An adverse event in a newborn characterized by suspected sepsis with severe signs (e.g. fever, grunting); supportive treatment escalated or initiated.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155265>	C154928	Grade 4 Neonatal Culture Negative Sepsis, AE|Grade 4 Culture Negative Neonatal Sepsis|Grade 4 Neonatal Culture Negative Sepsis, Adverse Event	A culture negative neonatal sepsis adverse event in a newborn characterized by life-threatening consequences (e.g. shock, disseminated intravascular coagulation (DIC)); urgent major care change required.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155266>	C154928	Grade 5 Neonatal Culture Negative Sepsis, AE|Grade 5 Culture Negative Neonatal Sepsis|Grade 5 Neonatal Culture Negative Sepsis, Adverse Event	A culture negative neonatal sepsis adverse event in a newborn which results in death.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155267>	C154927	Grade 1 Neonatal Culture Positive Sepsis, AE|Grade 1 Culture Positive Neonatal Sepsis|Grade 1 Neonatal Culture Positive Sepsis, Adverse Event	An adverse event in a newborn characterized by a positive blood culture positive; no care change indicated (e.g. contamination suspected).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155268>	C154927	Grade 2 Neonatal Culture Positive Sepsis, AE|Grade 2 Culture Positive Neonatal Sepsis|Grade 2 Neonatal Culture Positive Sepsis, Adverse Event	An adverse event in a newborn characterized by a positive blood culture positive with mild or ambiguous signs; anti-infectives initiated.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155269>	C154927	Grade 3 Neonatal Culture Positive Sepsis, AE|Grade 3 Culture Positive Neonatal Sepsis|Grade 3 Neonatal Culture Positive Sepsis, Adverse Event	An adverse event in a newborn characterized by a positive blood culture positive with severe signs; supportive treatment escalated or initiated.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C15526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15526>	C15481	5a-Reductase Inhibition	Treatment with a 5a-reductase inhibitor with the goal of suppressing the conversion of testosterone to dihydrotestosterone.			Therapeutic or Preventive Procedure	
C155270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155270>	C154927	Grade 4 Neonatal Culture Positive Sepsis, AE|Grade 4 Culture Positive Neonatal Sepsis|Grade 4 Neonatal Culture Positive Sepsis, Adverse Event	A culture positive sepsis adverse event in a newborn characterized by life-threatening consequences (e. g. shock, disseminated intravascular coagulation (DIC)); urgent major care change required.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155271>	C154927	Grade 5 Neonatal Culture Positive Sepsis, AE|Grade 5 Culture Positive Neonatal Sepsis|Grade 5 Neonatal Culture Positive Sepsis, Adverse Event	A culture positive sepsis adverse event in a newborn which results in death.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155272>	C154935	Grade 1 Neonatal Rash, AE|Grade 1 Neonatal Rash, Adverse Event|Grade 1 Rash Neonatal	An adverse event in a newborn characterized by localized rash.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155273>	C154935	Grade 2 Neonatal Rash, AE|Grade 2 Neonatal Rash, Adverse Event|Grade 2 Rash Neonatal	An adverse event in a newborn characterized by diffuse rash or target lesions.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155274>	C154935	Grade 3 Neonatal Rash, AE|Grade 3 Neonatal Rash, Adverse Event|Grade 3 Rash Neonatal	An adverse event in a newborn characterized by diffuse rash and vesicles or limited number of bullae or superficial ulcerations of mucous membranes limited to one site.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155275>	C154935	Grade 4 Neonatal Rash, AE|Grade 4 Neonatal Rash, Adverse Event|Grade 4 Rash Neonatal	An adverse event in a newborn characterized by extensive or generalized bullous lesions or ulceration of mucous membranes involving two or more distinct mucosal sites or Stevens-Johnson syndrome or toxic epidermal necrosis.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155276>	C154935	Grade 5 Neonatal Rash, AE|Grade 5 Neonatal Rash, Adverse Event|Grade 5 Rash Neonatal	A rash adverse event in a newborn which results in death.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155277>	C154947	Grade 1 Neonatal Administration Site Complication, AE|Grade 1 Administration Site Complication Neonatal|Grade 1 Neonatal Administration Site Complication, Adverse Event	An administration site complication adverse event in a newborn characterized by painless edema.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155278>	C154947	Grade 2 Neonatal Administration Site Complication, AE|Grade 2 Administration Site Complication Neonatal|Grade 2 Neonatal Administration Site Complication, Adverse Event	An administration site complication adverse event in a newborn characterized by erythema with associated symptoms (e.g., edema, pain, induration, phlebitis).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155279>	C154947	Grade 3 Neonatal Administration Site Complication, AE|Grade 3 Administration Site Complication Neonatal|Grade 3 Neonatal Administration Site Complication, Adverse Event	An administration site complication adverse event in a newborn characterized by ulceration or necrosis; severe tissue damage; operative intervention indicated.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C15527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15527>	C61063	Interleukin-2/Sargramostim|GM-CSF/IL-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C155280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155280>	C154947	Grade 4 Neonatal Administration Site Complication, AE|Grade 4 Administration Site Complication Neonatal|Grade 4 Neonatal Administration Site Complication, Adverse Event	An administration site complication adverse event in a newborn characterized by life-threatening consequences; urgent intervention indicated.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155281>	C154947	Grade 5 Neonatal Administration Site Complication, AE|Grade 5 Administration Site Complication Neonatal|Grade 5 Neonatal Administration Site Complication, Adverse Event	An administration site complication adverse event in a newborn which results in death.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155282>	C154941	Grade 1 Neonatal Fever, AE|Grade 1 Fever Neonatal|Grade 1 Neonatal Fever, Adverse Event	An adverse event in a newborn characterized by isolated, not sustained fever, no change in baseline age-appropriate behavior.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155283>	C154941	Grade 2 Neonatal Fever, AE|Grade 2 Fever Neonatal|Grade 2 Neonatal Fever, Adverse Event	An adverse event in a newborn characterized by fever, minor change in baseline age-appropriate behavior; minor changes in care (e.g. environmental settings, symptomatic treatment).			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155284>	C154941	Grade 3 Neonatal Fever, AE|Grade 3 Fever Neonatal|Grade 3 Neonatal Fever, Adverse Event	An adverse event in a newborn characterized by fever, major change in baseline age-appropriate behavior and without resolution to symptomatic treatment.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155285>	C154941	Grade 4 Neonatal Fever, AE|Grade 4 Fever Neonatal|Grade 4 Neonatal Fever, Adverse Event	A febrile adverse event in a newborn characterized by life-threatening consequences.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155286>	C154941	Grade 5 Neonatal Fever, AE|Grade 5 Fever Neonatal|Grade 5 Neonatal Fever, Adverse Event	A febrile adverse event in a newborn which results in death.			Finding	INC Terminology|INC-MedDRA Neonatal Adverse Events Terminology
C155287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155287>	C136411	Blasts 5-9 Percent of Bone Marrow Nucleated Cells|Blasts Between 5 and 9 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that between 5 and 9 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts 5-9 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C155288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155288>	C155993	Blasts 2-4 Percent of Peripheral Blood White Cells|Blasts Between 2 and 4 Percent of Peripheral Blood White Cells	A semi-quantitative microscopic finding indicating that between 2 and 4 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.	Blasts 2-4 Percent of Peripheral Blood White Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C155289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155289>	C116508	Robot-Assisted Esophagectomy|RAMIE|Robotic Assisted Minimally Invasive Esophagectomy	A minimally-invasive surgical technique that uses a robot is aid in the partial or complete removal of the esophagus.	Robot-Assisted Esophagectomy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C15528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15528>	C61007	Interleukin-2/Monoclonal Antibody Lym-1|IL-2/MOAB Lym-1			Obsolete_Concept	Therapeutic or Preventive Procedure	
C155290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155290>	C2962	Complex Partial Seizure|Focal Impaired Awareness Seizure	A seizure that originates in one area of the brain that affects consciousness.			Finding	
C155291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155291>	C2962	Non-Convulsive Status Epilepticus	Status epilepticus without prominent motor symptoms, the duration of which is at least ten minutes.			Finding	
C155292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155292>	C2124	Fluorine F 18 PARP Inhibitor|18F Fluorinated PARP1-targeted Probe|18F-1(2H)phthalazinone-based PARPi Imaging Agent|18F-radiolabeled 1(2H)phthalazinone PARPi|Fluorine F 18 PARPi|Fluorine F 18 Poly(ADP-ribose) Polymerase Inhibitor|[18F]PARP1-targeted Probe|[18F]PARPi|[18F]PARPi Imaging Agent	A radiotracer consisting of a 1(2H)phthalazinone-based poly(ADP-ribose) polymerase 1 (PARP1) inhibitor (PARPi) radiolabeled with the positron emitting isotope fluorine F 18, which can potentially be used for the imaging of PARP1 expression using positron emission tomography (PET). Upon administration, fluorine F 18 PARPi targets and binds to PARP1. Upon PET, PARP1-expressing tumor cells can be visualized. PARP1, which is overexpressed in many cancer cell types, catalyzes post-translational ADP-ribosylation of nuclear proteins and plays a key role in the repair of DNA strand breaks.	Fluorine F 18 PARP Inhibitor		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C155293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155293>	C201513|C200766	Autologous CCR4-CD30CAR-CD28-CD3zeta-expressing T-Lymphocytes|ATLCAR.CD30-CD28zeta-CCR4 Cells|ATLCAR.CD30.CCR4 Cells|ATLs Co-expressing CD30-CARCD28zeta and CCR4|Anti-CD30-CAR/CD28z-CCR4 Retroviral Vector-transduced Autologous T-Cells|Autologous CCR4-CAR-CD19-CD28-zeta-transduced T-lymphocytes|CCR4-CAR-CD30-28zeta-specific Autologous T-cells|SFG.CCR4-CAR.CD30 Autologous T-lymphocytes	A preparation of autologous T-lymphocytes (ATL) that have been transduced with the retroviral vector SFG, a Moloney murine leukemia (Mo-MuLV) virus-based vector, encoding human C-C chemokine receptor 4 (CCR4), linked via an internal ribosome entry site (IRES), to a chimeric antigen receptor (CAR) composed of a single chain single-chain variable fragment (scFv) directed against the CD30 antigen (CAR.CD30) and linked, via the spacer human IgG1 immunoglobulin heavy constant region (hinge-CH2CH3 region), to the co-stimulatory domains of CD28 and the zeta chain of the TCR/CD3 complex (CD3-zeta) (CD28zeta), with potential immunostimulating and antineoplastic activities. Upon administration of the autologous CCR4-CD30CAR-CD28-CD3zeta-expressing T-lymphocytes, the expressed CCR4 on the T-cells allows for enhanced migration of the cells to chemokine-secreting tumor cells. The expressed CAR.CD30 moiety specifically recognizes and binds to CD30-expressing tumor cells, resulting in specific T-cell-mediated tumor cell lysis. CD30, a cell surface receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is transiently expressed on activated lymphocytes and is constitutively expressed in hematologic malignancies. CCR4, a G-coupled-protein receptor for C-C chemokines normally expressed on regulatory T-cells (Tregs) but not on cytotoxic T-lymphocytes (CTLs), is involved in chemokine-mediated cellular migration. The co-expression of CCR4 on these CTLs may enhance their anti-tumor activity compared to T-lymphocytes expressing the same CAR-CD30 receptor but without CCR4 expression.	Autologous CCR4-CD30CAR-CD28-CD3zeta-expressing T-Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155294>	C201513|C200766	Autologous CD30CAR-CD28-CD3zeta-expressing T-Lymphocytes|ATL-expressing CD30-CAR-CD28zeta|ATLCAR.CD30 Cells|ATLCAR.CD30-CD28zeta Cells|Anti-CD30-CAR/CD28z Retroviral Vector-transduced Autologous T-Cells|Autologous CAR-CD19-CD28-zeta-transduced T-lymphocytes|CAR-CD30-28zeta-specific Autologous T-cells|SFG.CAR.CD30 Autologous T-lymphocytes	A preparation of autologous T-lymphocytes (ATL) that have been transduced with the retroviral vector SFG, a Moloney murine leukemia (Mo-MuLV) virus-based vector, encoding a chimeric antigen receptor (CAR) composed of a single chain single-chain variable fragment (scFv) directed against the CD30 antigen (CAR.CD30) and linked, via the spacer human IgG1 immunoglobulin heavy constant region (hinge-CH2CH3 region), to the co-stimulatory domains of CD28 and the zeta chain of the TCR/CD3 complex (CD3-zeta) (CD28zeta), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous CD30CAR-CD28-CD3zeta-expressing T-lymphocytes specifically recognize and bind to CD30-expressing tumor cells, resulting in specific T-cell-mediated tumor cell lysis. CD30, a cell surface receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is transiently expressed on activated lymphocytes and is constitutively expressed in hematologic malignancies.	Autologous CD30CAR-CD28-CD3zeta-expressing T-Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155295>	C20993	CARTOX 10 Point Neurological Assessment|CARTOX-10|CARTOX-10 Neurological Assessment	A test to monitor for neurotoxicity related to CAR T therapy: orientation to year, month, city, hospital, and President; ability to name 3 specified objects; ability to write a standard sentence; ability to count backwards from 100 by 10.			Intellectual Product	
C155296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155296>	C222044	CARTOX Grade 1|CARTOX Mild Neurological Impairment|CARTOX Score 7-9	A score of 7-9 on the CARTOX-10 assessment, indicating mild neurotoxicity.			Intellectual Product	
C155297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155297>	C222044	CARTOX Grade 2|CARTOX Moderate Neurological Impairment|CARTOX Score 3-6	A score of 3-6 on the CARTOX-10 assessment, indicating moderate neurotoxicity.			Intellectual Product	
C155298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155298>	C222044	CARTOX Grade 3|CARTOX Score 0-2|CARTOX Severe Neurological Impairment	A score of 0-2 on the CARTOX-10 assessment, indicating severe neurotoxicity.			Intellectual Product	
C155299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155299>	C187198|C167151	ERBB2 NM_004448.3:c.2305G>T|ERBB2 c.2305G>T|HER-2 c.2305G>T|HER-2/neu c.2305G>T|HER2 c.2305G>T|NEU c.2305G>T|NM_004448.3:c.2305G>T|v-erb-b2 Erythroblastic Leukemia Viral Oncogene Homolog 2, Neuro/Glioblastoma Derived Oncogene Homolog (Avian) c.2305G>T	A nucleotide substitution at position 2305 of the coding sequence of the ERBB2 gene where guanine has been mutated to thymine.	ERBB2 NM_004448.3:c.2305G>T		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15529>	C15669	Bone Metastases Prevention|Prevention of Bone Metastases	Methods used to prevent the spread of cancer from a primary tumor site to the bone.	Bone Metastases Prevention		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C1552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1552>	C80212	Vasopressin Tannate in Oil	An oil based formulation of Vasopressin, which could be administered intramuscularly. (NCI)			Pharmacologic Substance	
C155300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155300>	C98358	ERBB2 NP_004439.2:p.D769Y|Activating D769Y Mutation|ERBB2 Asp769Tyr|ERBB2 D769Y|ERBB2 NP_004439.2:p.Asp769Tyr|ERBB2 p.Asp769Tyr|ERBB2 p.D769Y|HER2 Asp769Tyr|HER2 D769Y|HER2 D769Y Mutation|NP_004439.2:p.Asp769Tyr|NP_004439.2:p.D769Y|Proto-Oncogene Neu Asp769Tyr|Proto-Oncogene Neu D769Y|Receptor Tyrosine-Protein Kinase erbB-2 Asp769Tyr|Receptor Tyrosine-Protein Kinase erbB-2 D769Y|Tyrosine Kinase-Type Cell Surface Receptor HER2 Asp769Tyr|Tyrosine Kinase-Type Cell Surface Receptor HER2 D769Y	A change in the amino acid residue at position 769 in the receptor tyrosine-protein kinase erbB-2 protein where aspartic acid has been replaced by tyrosine.	ERBB2 NP_004439.2:p.D769Y		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C155301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155301>	C187198|C167151	ERBB2 NM_004448.3:c.2305G>C|ERBB2 c.2305G>C|HER-2 c.2305G>C|HER-2/neu c.2305G>C|HER2 c.2305G>C|NEU c.2305G>C|NM_004448.3:c.2305G>C|v-erb-b2 Erythroblastic Leukemia Viral Oncogene Homolog 2, Neuro/Glioblastoma Derived Oncogene Homolog (Avian) c.2305G>C	A nucleotide substitution at position 2305 of the coding sequence of the ERBB2 gene where guanine has been mutated to cytosine.	ERBB2 NM_004448.3:c.2305G>C		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C155302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155302>	C98358	ERBB2 NP_004439.2:p.D769H|Activating D769H Mutation|ERBB2 Asp769His|ERBB2 D769H|ERBB2 NP_004439.2:p.Asp769His|ERBB2 p.Asp769His|ERBB2 p.D769H|HER2 Asp769His|HER2 D769H|HER2 D769H Mutation|NP_004439.2:p.Asp769His|NP_004439.2:p.D769H|Proto-Oncogene Neu Asp769His|Proto-Oncogene Neu D769H|Receptor Tyrosine-Protein Kinase erbB-2 Asp769His|Receptor Tyrosine-Protein Kinase erbB-2 D769H|Tyrosine Kinase-Type Cell Surface Receptor HER2 Asp769His|Tyrosine Kinase-Type Cell Surface Receptor HER2 D769H	A change in the amino acid residue at position 769 in the receptor tyrosine-protein kinase erbB-2 protein where aspartic acid has been replaced by histidine.	ERBB2 NP_004439.2:p.D769H		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C155303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155303>	C36438|C185933	Gain of Chromosome 14q	A cytogenetic abnormality that refers to allelic gain within the chromosomal region 14q.			Cell or Molecular Dysfunction	
C155304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155304>	C8997|C4769|C45921	Pituitary Gland Blastoma|Pituitary Blastoma|Pituitary Embryoma|Pituitary Gland Embryoma	A rare developmental early childhood neoplasm, arising within the fetal anterior pituitary. It is associated with DICER1 mutations. Patients present with features of Cushing disease, with elevated blood ACTH levels and hypercortisolism. Ophthalmoplegia is a frequent symptom. The overall prognosis is poor. (WHO)	Pituitary Gland Blastoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C155305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155305>	C3510	Cutaneous Melanoma of the Extremity|Primary Cutaneous Melanoma of the Extremity|Primary Extremity Melanoma|Primary Melanoma of the Extremity	A cutaneous melanoma that arises from the upper or lower extremity.	Cutaneous Melanoma of the Extremity		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155306>	C9097|C155305	Recurrent Cutaneous Melanoma of the Extremity|Recurrent Extremity Melanoma|Recurrent Melanoma of the Extremity	A cutaneous melanoma of the upper or lower extremity that has recurred after a period of remission.	Recurrent Cutaneous Melanoma of the Extremity		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155307>	C3092	Sickle Cell-Hemoglobin E Disease|Hemoglobin SE Disease	A variant of sickle cell disease due to heterozygosity for hemoglobin S and hemoglobin E mutations. Patients present with the symptoms of sickle cell disease but the symptoms are less frequent and severe compared to patients with hemoglobin SS disease.			Disease or Syndrome	
C155308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155308>	C167151	ERBB2 NM_004448.3:c.962A>G|ERBB2 c.962A>G|HER-2 c.962A>G|HER-2/neu c.962A>G|HER2 c.962A>G|NEU c.962A>G|NM_004448.3:c.962A>G|v-erb-b2 Erythroblastic Leukemia Viral Oncogene Homolog 2, Neuro/Glioblastoma Derived Oncogene Homolog (Avian) c.962A>G	A nucleotide substitution at position 962 of the coding sequence of the ERBB2 gene where adenine has been mutated to guanine.			Cell or Molecular Dysfunction	
C155309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155309>	C98358	ERBB2 NP_004439.2:p.E321G|ERBB2 E321G|ERBB2 Glu321Gly|ERBB2 NP_004439.2:p.Glu321Gly|ERBB2 p.E321G|ERBB2 p.Glu321Gly|NP_004439.2:p.E321G|NP_004439.2:p.Glu321Gly|Proto-Oncogene Neu E321G|Proto-Oncogene Neu Glu321Gly|Receptor Tyrosine-Protein Kinase erbB-2 E321G|Receptor Tyrosine-Protein Kinase erbB-2 Glu321Gly|Tyrosine Kinase-Type Cell Surface Receptor HER2 E321G|Tyrosine Kinase-Type Cell Surface Receptor HER2 Glu321Gly	A change in the amino acid residue at position 321 in the receptor tyrosine-protein kinase erbB-2 protein where glutamic acid has been replaced by glycine.			Cell or Molecular Dysfunction	
C15530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15530>	C61063	Interleukin-2/Monoclonal Antibody R24|IL-2/MOAB R24			Obsolete_Concept	Therapeutic or Preventive Procedure	
C155310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155310>	C3092	Sickle Cell-Hemoglobin D Disease|Hemoglobin SD Disease	A variant of sickle cell disease due to heterozygosity for hemoglobin S and hemoglobin D mutations. Patients present with the symptoms of sickle cell disease but the symptoms are less frequent and severe compared to patients with hemoglobin SS disease.			Disease or Syndrome	
C155311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155311>	C212038|C171572	Advanced Cutaneous Melanoma of the Extremity|Advanced Extremity Melanoma|Advanced Melanoma of the Extremity	A cutaneous melanoma of the upper or lower extremity that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Cutaneous Melanoma of the Extremity		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155312>	C98541	Sickle Cell Chronic Lung Disease	A pulmonary complication of sickle cell disease characterized by radiographic interstitial abnormalities and impaired pulmonary function. In severe cases, pulmonary hypertension is present.			Disease or Syndrome	
C155313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155313>	C62601	Proliferative Retinopathy	Retinopathy characterized by the formation of new vessels in the retina. The new vessels are abnormal and fragile. If hemorrhage occurs due to the vascular fragility, there is increased risk of vision loss or blindness.			Disease or Syndrome	
C155315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155315>	C91102	How Recently Question|How Recently|How recently have you	A question about how recently an individual experienced something.			Intellectual Product	Adherence Starts With Knowledge 12 Questionnaire
C155316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155316>	C155313	Bilateral Proliferative Retinopathy	Proliferative retinopathy occurring in both eyes.			Disease or Syndrome	
C155317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155317>	C20744	PDHX Gene|PDHX|PDHX|Pyruvate Dehydrogenase Complex Component X Gene	This gene plays a role in the localization of the pyruvate dehydrogenase complex.			Gene or Genome	
C155318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155318>	C155317	PDHX wt Allele|DLDBP|E3BP|OPDX|PDHXD|PDX1|Pyruvate Dehydrogenase Complex Component X wt Allele|Pyruvate Dehydrogenase Complex, Component X Gene|proX	Human PDHX wild-type allele is located in the vicinity of 11p13 and is approximately 105 kb in length. This allele, which encodes pyruvate dehydrogenase protein X component, mitochondrial protein, is involved in the regulation of pyruvate dehydrogenase activity. Mutation of the gene is associated with lactic acidosis due to pyruvate dehydrogenase E3-binding protein deficiency.			Gene or Genome	
C155319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155319>	C18073	Pyruvate Dehydrogenase Protein X Component, Mitochondrial|Dihydrolipoamide Dehydrogenase-Binding Protein of Pyruvate Dehydrogenase Complex|E3-Binding Protein|E3BP|Lipoyl-Containing Pyruvate Dehydrogenase Complex Component X|PDHX|Pyruvate Dehydrogenase Complex, E3-Binding Protein Subunit|Pyruvate Dehydrogenase Complex, Lipoyl-Containing Component X|proX	Pyruvate dehydrogenase protein X component, mitochondrial (501 aa, ~54 kDa) is encoded by the human PDHX gene. This protein plays a role in anchoring dihydrolipoamide dehydrogenase (E3) to the dihydrolipoamide transacetylase (E2) core of the pyruvate dehydrogenase complex.			Amino Acid, Peptide, or Protein	
C15531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15531>	C61063	Monoclonal Antibody R24/Sargramostim|GM-CSF/MOAB R24			Obsolete_Concept	Therapeutic or Preventive Procedure	
C155320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155320>	C70766	Read Depth|Depth of Coverage|Depth of Coverage|READ DEPTH|Sequence Coverage|Sequence Read Coverage|Sequencing Coverage|Sequencing Depth|Total Mapped Reads|Total Mapped Reads|Total Read Depth|Total Read Depth|mean coverage|mean_coverage	The number of times a particular locus (site, nucleotide, amplicon, region) was sequenced.			Conceptual Entity	CDISC SDTM Genomic Findings Test Detail Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Property Terminology|GDC Terminology
C155321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155321>	C20401|C164008	Anti-CD38 Monoclonal Antibody	Any monoclonal antibody that is directed against the CD38 antigen.	Anti-CD38 Monoclonal Antibody		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C155322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155322>	C2336	BRAF Inhibitor|B-RAF Inhibitor	Any agent that inhibits the serine/threonine-protein kinase BRAF(B-RAF).	BRAF Inhibitor		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology
C155323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155323>	C118969	Children's Depression Rating Scale, Revised Clinical Classification|CDRS-R|CDRS-R|CDRS1	A standardized 17-item clinician rating scale for the assessment of depressive symptomology in children and adolescents. The instrument, which is based on the adult Hamilton Depression Rating Scale developed by Max Hamilton at the University of Leeds in 1960, was published by Poznanski and Mokros in 1996 as a rating scale for children 6 - 12 years of age. In 2010, Mayes et al. demonstrated its use in adolescents.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155324>	C118969	Unified Huntington's Disease Rating Scale 1999 Version Clinical Classification|UHDR1|UHDRS 1999|UHDRS 1999 Version	An updated and expanded version of the standardized clinician rating scale developed by the Huntington Study Group in 1996 for the assessment of motor function, cognitive function, behavioral abnormalities, and functional capacity in Huntington's Disease.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155325>	C91105	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank Questionnaire|FAC100|FACIT-DYSPNEA 33 ITEM BANK|FACIT-Dyspnea Scale 33 Item Bank Version	A standardized 33-item repository of test questions developed by Choi et al. in 2011 as part of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System developed by Cella et al. in 1987, from which a subset may be administered to evaluate dyspnea severity and limitations in function caused by dyspnea in people with COPD.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155326>	C91105	Functional Assessment of Cancer Therapy-Bladder Version 4 Questionnaire|FAC006|FACT-BL V4|FACT-BL Version 4	A standardized 39-item self-report rating scale to measure quality of life in patients with bladder cancer that is divided into five subscales: physical, social/family, emotional, and functional well-being, as well as a bladder cancer subscale to assess urinary tract, intestinal and sexual symptoms. Originally developed by Cella, et al. in 1997, it combines the Functional Assessment of Cancer Therapy - General (FACT-G), and the Bladder Cancer Subscale (BICS).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155327>	C91105	Non-Small Cell Lung Cancer Symptom Assessment Questionnaire v1.0|NSCLC-SAQ V1.0|NSCLC-SAQ Version 1.0|NSCLC1	A standardized 7-item patient-reported outcome instrument, created by McCarrier et al. in 2016, that utilizes a 7-day recall period and a five-point verbal rating scale to assess symptoms of non-small cell lung cancer.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155328>	C91105	Symptoms of Major Depressive Disorder Scale v1.0 Questionnaire|SMDDS V1.0|SMDDS Version 1.0|SMDDS1	A standardized 35-item patient-reported outcome instrument, created by McCarrier et al. in 2015, that utilizes a 7-day recall period and a five-point verbal rating scale to assess symptoms of major depressive disorder.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155329>	C154458	CDRS-R - Impaired Schoolwork|CDRS1-Impaired Schoolwork|CDRS1-Impaired Schoolwork|CDRS101	Children's Depression Rating Scale, Revised (CDRS-R) Impaired schoolwork.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15532>	C15430	In Vitro-Treated Peripheral Blood Stem Cell Transplantation|in vitro-treated PBPC transplantation|in vitro-treated peripheral blood progenitor cell transplantation	Peripheral blood stem cell transplantation that uses cells that have been manipulated outside the body.	In Vitro-Treated Peripheral Blood Stem Cell Transplantation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C155330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155330>	C154458	CDRS-R - Impaired Schoolwork Comment|CDRS1-Impaired Schoolwork Comment|CDRS1-Impaired Schoolwork Comment|CDRS101A	Children's Depression Rating Scale, Revised (CDRS-R) Impaired schoolwork comment.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155331>	C154458	CDRS-R - Difficulty Having Fun|CDRS1-Difficulty Having Fun|CDRS1-Difficulty Having Fun|CDRS102	Children's Depression Rating Scale, Revised (CDRS-R) Difficulty having fun.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155332>	C154458	CDRS-R - Difficulty Having Fun Comment|CDRS1-Difficulty Having Fun Comment|CDRS1-Difficulty Having Fun Comment|CDRS102A	Children's Depression Rating Scale, Revised (CDRS-R) Difficulty having fun comment.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155333>	C154458	CDRS-R - Social Withdrawal|CDRS1-Social Withdrawal|CDRS1-Social Withdrawal|CDRS103	Children's Depression Rating Scale, Revised (CDRS-R) Social withdrawal.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155334>	C154458	CDRS-R - Social Withdrawal Comment|CDRS1-Social Withdrawal Comment|CDRS1-Social Withdrawal Comment|CDRS103A	Children's Depression Rating Scale, Revised (CDRS-R) Social withdrawal comment.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155335>	C154458	CDRS-R - Sleep Disturbance|CDRS1-Sleep Disturbance|CDRS1-Sleep Disturbance|CDRS104	Children's Depression Rating Scale, Revised (CDRS-R) Sleep disturbance.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155336>	C154458	CDRS-R - Sleep Disturbance Comment|CDRS1-Sleep Disturbance Comment|CDRS1-Sleep Disturbance Comment|CDRS104A	Children's Depression Rating Scale, Revised (CDRS-R) Sleep disturbance comment.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155337>	C154458	CDRS-R - Appetite Disturbance|CDRS1-Appetite Disturbance|CDRS1-Appetite Disturbance|CDRS105	Children's Depression Rating Scale, Revised (CDRS-R) Appetite disturbance.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155338>	C154458	CDRS-R - Appetite Disturbance Comment|CDRS1-Appetite Disturbance Comment|CDRS1-Appetite Disturbance Comment|CDRS105A	Children's Depression Rating Scale, Revised (CDRS-R) Appetite disturbance comment.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155339>	C154458	CDRS-R - Excessive Fatigue|CDRS1-Excessive Fatigue|CDRS1-Excessive Fatigue|CDRS106	Children's Depression Rating Scale, Revised (CDRS-R) Excessive fatigue.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15533>	C49236	Chemoprotection	The use of drugs to protect normal tissue from damage by cancer therapy agents.			Therapeutic or Preventive Procedure	GDC Terminology|GDC Value Terminology
C155340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155340>	C154458	CDRS-R - Excessive Fatigue Comment|CDRS1-Excessive Fatigue Comment|CDRS1-Excessive Fatigue Comment|CDRS106A	Children's Depression Rating Scale, Revised (CDRS-R) Excessive fatigue comment.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155341>	C154458	CDRS-R - Physical Complaints|CDRS1-Physical Complaints|CDRS1-Physical Complaints|CDRS107	Children's Depression Rating Scale, Revised (CDRS-R) Physical complaints.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155342>	C154458	CDRS-R - Physical Complaints Comment|CDRS1-Physical Complaints Comment|CDRS1-Physical Complaints Comment|CDRS107A	Children's Depression Rating Scale, Revised (CDRS-R) Physical complaints comment.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155343>	C154458	CDRS-R - Irritability|CDRS1-Irritability|CDRS1-Irritability|CDRS108	Children's Depression Rating Scale, Revised (CDRS-R) Irritability.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155344>	C154458	CDRS-R - Irritability Comment|CDRS1-Irritability Comment|CDRS1-Irritability Comment|CDRS108A	Children's Depression Rating Scale, Revised (CDRS-R) Irritability comment.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155345>	C154458	CDRS-R - Excessive Guilt|CDRS1-Excessive Guilt|CDRS1-Excessive Guilt|CDRS109	Children's Depression Rating Scale, Revised (CDRS-R) Excessive guilt.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155346>	C154458	CDRS-R - Excessive Guilt Comment|CDRS1-Excessive Guilt Comment|CDRS1-Excessive Guilt Comment|CDRS109A	Children's Depression Rating Scale, Revised (CDRS-R) Excessive guilt comment.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155347>	C154458	CDRS-R - Low Self-esteem|CDRS1-Low Self-esteem|CDRS1-Low Self-esteem|CDRS110	Children's Depression Rating Scale, Revised (CDRS-R) Low self-esteem.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155348>	C154458	CDRS-R - Low Self-esteem Comment|CDRS1-Low Self-esteem Comment|CDRS1-Low Self-esteem Comment|CDRS110A	Children's Depression Rating Scale, Revised (CDRS-R) Low self-esteem comment.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155349>	C154458	CDRS-R - Depressed Feelings|CDRS1-Depressed Feelings|CDRS1-Depressed Feelings|CDRS111	Children's Depression Rating Scale, Revised (CDRS-R) Depressed feelings.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15534>	C16051	Cardiotoxicity Attenuation	Therapy designed to reduce cardiotoxicity during treatment exposure.			Therapeutic or Preventive Procedure	
C155350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155350>	C154458	CDRS-R - Depressed Feelings Comment|CDRS1-Depressed Feelings Comment|CDRS1-Depressed Feelings Comment|CDRS111A	Children's Depression Rating Scale, Revised (CDRS-R) Depressed feelings comment.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155351>	C154458	CDRS-R - Morbid Ideation|CDRS1-Morbid Ideation|CDRS1-Morbid Ideation|CDRS112	Children's Depression Rating Scale, Revised (CDRS-R) Morbid ideation.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155352>	C154458	CDRS-R - Morbid Ideation Comment|CDRS1-Morbid Ideation Comment|CDRS1-Morbid Ideation Comment|CDRS112A	Children's Depression Rating Scale, Revised (CDRS-R) Morbid ideation comment.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155353>	C154458	CDRS-R - Suicidal Ideation|CDRS1-Suicidal Ideation|CDRS1-Suicidal Ideation|CDRS113	Children's Depression Rating Scale, Revised (CDRS-R) Suicidal ideation.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155354>	C154458	CDRS-R - Suicidal Ideation Comment|CDRS1-Suicidal Ideation Comment|CDRS1-Suicidal Ideation Comment|CDRS113A	Children's Depression Rating Scale, Revised (CDRS-R) Suicidal ideation comment.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155355>	C154458	CDRS-R - Excessive Weeping|CDRS1-Excessive Weeping|CDRS1-Excessive Weeping|CDRS114	Children's Depression Rating Scale, Revised (CDRS-R) Excessive weeping.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155356>	C154458	CDRS-R - Excessive Weeping Comment|CDRS1-Excessive Weeping Comment|CDRS1-Excessive Weeping Comment|CDRS114A	Children's Depression Rating Scale, Revised (CDRS-R) Excessive weeping comment.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155357>	C154458	CDRS-R - Depressed Facial Affect|CDRS1-Depressed Facial Affect|CDRS1-Depressed Facial Affect|CDRS115	Children's Depression Rating Scale, Revised (CDRS-R) Depressed facial affect.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155358>	C154458	CDRS-R - Depressed Facial Affect Comment|CDRS1-Depressed Facial Affect Comment|CDRS1-Depressed Facial Affect Comment|CDRS115A	Children's Depression Rating Scale, Revised (CDRS-R) Depressed facial affect comment.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155359>	C154458	CDRS-R - Listless Speech|CDRS1-Listless Speech|CDRS1-Listless Speech|CDRS116	Children's Depression Rating Scale, Revised (CDRS-R) Listless speech.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15535>	C16051	Urothelial Toxicity Attenuation	Therapy designed to reduce toxicity to the urothelium during treatment exposure.			Therapeutic or Preventive Procedure	
C155360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155360>	C154458	CDRS-R - Listless Speech Comment|CDRS1-Listless Speech Comment|CDRS1-Listless Speech Comment|CDRS116A	Children's Depression Rating Scale, Revised (CDRS-R) Listless speech comment.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155361>	C154458	CDRS-R - Hypoactivity|CDRS1-Hypoactivity|CDRS1-Hypoactivity|CDRS117	Children's Depression Rating Scale, Revised (CDRS-R) Hypoactivity.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155362>	C154458	CDRS-R - Hypoactivity Comment|CDRS1-Hypoactivity Comment|CDRS1-Hypoactivity Comment|CDRS117A	Children's Depression Rating Scale, Revised (CDRS-R) Hypoactivity comment.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155363>	C154458	CDRS-R - Subtotal 1|CDRS1-Subtotal 1|CDRS1-Subtotal 1|CDRS118	Children's Depression Rating Scale, Revised (CDRS-R) Subtotal 1 - sum of questions 1 to 6.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155364>	C154458	CDRS-R - Subtotal 2|CDRS1-Subtotal 2|CDRS1-Subtotal 2|CDRS119	Children's Depression Rating Scale, Revised (CDRS-R) Subtotal 2 - sum of questions 7 to 14.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155365>	C154458	CDRS-R - Subtotal 3|CDRS1-Subtotal 3|CDRS1-Subtotal 3|CDRS120	Children's Depression Rating Scale, Revised (CDRS-R) Subtotal 3 - sum of questions 15 to 17.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155366>	C154458	CDRS-R - CDRS-R Raw Summary Score|CDRS1-CDRS-R Raw Summary Score|CDRS1-CDRS-R Raw Summary Score|CDRS121	Children's Depression Rating Scale, Revised (CDRS-R) CDRS-R raw summary score.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155367>	C154458	CDRS-R - CDRS-R T-Score|CDRS1-CDRS-R T-Score|CDRS1-CDRS-R T-Score|CDRS122	Children's Depression Rating Scale, Revised (CDRS-R) CDRS-R T-score.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155368>	C154458	CDRS-R - CDRS-R Percentile|CDRS1-CDRS-R Percentile|CDRS1-CDRS-R Percentile|CDRS123	Children's Depression Rating Scale, Revised (CDRS-R) CDRS-R Percentile.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155369>	C154458	CDRS-R - CDRS-R T-Score Range|CDRS1-CDRS-R T-Score Range|CDRS1-CDRS-R T-Score Range|CDRS124	Children's Depression Rating Scale, Revised (CDRS-R) CDRS-R T-score range.			Intellectual Product	CDISC Clinical Classification CDRS-R Test Code Terminology|CDISC Clinical Classification CDRS-R Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15536>	C15690	Therapeutic Bone Marrow Suppression	Induction of bone marrow suppression for the treatment of disease, especially myeloproliferative disease.			Therapeutic or Preventive Procedure	
C155370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155370>	C154459	UHDRS 1999 Version - Ocular Pursuit: Horizontal|UHDR1-Ocular Pursuit: Horizontal|UHDR1-Ocular Pursuit: Horizontal|UHDR101A	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Ocular pursuit, horizontal.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155371>	C154459	UHDRS 1999 Version - Ocular Pursuit: Vertical|UHDR1-Ocular Pursuit: Vertical|UHDR1-Ocular Pursuit: Vertical|UHDR101B	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Ocular pursuit, vertical.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155372>	C154459	UHDRS 1999 Version - Saccade Initiation: Horizontal|UHDR1-Saccade Initiation: Horizontal|UHDR1-Saccade Initiation: Horizontal|UHDR102A	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Saccade initiation, horizontal.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155373>	C154459	UHDRS 1999 Version - Saccade Initiation: Vertical|UHDR1-Saccade Initiation: Vertical|UHDR1-Saccade Initiation: Vertical|UHDR102B	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Saccade initiation, vertical.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155374>	C154459	UHDRS 1999 Version - Saccade Velocity: Horizontal|UHDR1-Saccade Velocity: Horizontal|UHDR1-Saccade Velocity: Horizontal|UHDR103A	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Saccade velocity, horizontal.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155375>	C154459	UHDRS 1999 Version - Saccade Velocity: Vertical|UHDR1-Saccade Velocity: Vertical|UHDR1-Saccade Velocity: Vertical|UHDR103B	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Saccade velocity, vertical.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155376>	C154459	UHDRS 1999 Version - Dysarthria|UHDR1-Dysarthria|UHDR1-Dysarthria|UHDR104	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Dysarthria.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155377>	C154459	UHDRS 1999 Version - Tongue Protrusion|UHDR1-Tongue Protrusion|UHDR1-Tongue Protrusion|UHDR105	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Tongue protrusion.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155378>	C154459	UHDRS 1999 Version - Finger Taps: Right|UHDR1-Finger Taps: Right|UHDR1-Finger Taps: Right|UHDR106A	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Finger taps, right.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155379>	C154459	UHDRS 1999 Version - Finger Taps: Left|UHDR1-Finger Taps: Left|UHDR1-Finger Taps: Left|UHDR106B	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Finger taps, left.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15537>	C20401	Macrophage Colony-Stimulating Factor/Monoclonal Antibody R24|M-CSF/MOAB R24				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	
C155380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155380>	C154459	UHDRS 1999 Version - Pronate/Supinate: Hands: Right|UHDR1-Pronate/Supinate: Hands: Right|UHDR1-Pronate/Supinate: Hands: Right|UHDR107A	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Pronate/supinate-hands, right.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155381>	C154459	UHDRS 1999 Version - Pronate/Supinate: Hands: Left|UHDR1-Pronate/Supinate: Hands: Left|UHDR1-Pronate/Supinate: Hands: Left|UHDR107B	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Pronate/supinate-hands, left.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155382>	C154459	UHDRS 1999 Version - Luria|UHDR1-Luria|UHDR1-Luria|UHDR108	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Luria (fist-hand palm test).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155383>	C154459	UHDRS 1999 Version - Rigidity: Arms: Right|UHDR1-Rigidity: Arms: Right|UHDR1-Rigidity: Arms: Right|UHDR109A	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Rigidity-arms, right.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155384>	C154459	UHDRS 1999 Version - Rigidity: Arms: Left|UHDR1-Rigidity: Arms: Left|UHDR1-Rigidity: Arms: Left|UHDR109B	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Rigidity-arms, left.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155385>	C154459	UHDRS 1999 Version - Bradykinesia: Body|UHDR1-Bradykinesia: Body|UHDR1-Bradykinesia: Body|UHDR110	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Bradykinesia-body.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155386>	C154459	UHDRS 1999 Version - Maximal Dystonia: Trunk|UHDR1-Maximal Dystonia: Trunk|UHDR1-Maximal Dystonia: Trunk|UHDR111A	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Maximal dystonia-Trunk.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155387>	C154459	UHDRS 1999 Version - Maximal Dystonia: RUE|UHDR1-Maximal Dystonia: RUE|UHDR1-Maximal Dystonia: RUE|UHDR111B	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Maximal dystonia-RUE.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155388>	C154459	UHDRS 1999 Version - Maximal Dystonia: LUE|UHDR1-Maximal Dystonia: LUE|UHDR1-Maximal Dystonia: LUE|UHDR111C	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Maximal dystonia-LUE.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155389>	C154459	UHDRS 1999 Version - Maximal Dystonia: RLE|UHDR1-Maximal Dystonia: RLE|UHDR1-Maximal Dystonia: RLE|UHDR111D	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Maximal dystonia-RLE.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15538>	C174447	Protocol Treatment Arm|Arm|Arm|Arm|Planned Arm|Protocol Arm|TREATMENT_ARM|TREATMENT_ARM|TREATMENT_ARM|TREATMENT_ARM|TREATMENT_ARM|TREATMENT_ARM|Treatment Arm|Treatment Arm|arm|arm|study arm|study_arm|treatment arm|treatment_arm	A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.			Research Activity	ALL Subject Characteristics Table|ALL Variable Terminology|AML Subject Characteristics Table|AML Variable Terminology|BRIDG Class Terminology|BRIDG Terminology|CDISC DDF Study Arm Type Value Set Terminology|CDISC DDF Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology|CTDC Node Terminology|EWS Subject Characteristics Table|EWS Variable Terminology|GCT Subject Characteristics Table|GCT Variable Terminology|GDC Property Terminology|GDC Terminology|HL Subject Characteristics Table|HL Variable Terminology|ICDC Node Terminology|ICDC Terminology|OS Subject Characteristics Table|OS Variable Terminology
C155390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155390>	C154459	UHDRS 1999 Version - Maximal Dystonia: LLE|UHDR1-Maximal Dystonia: LLE|UHDR1-Maximal Dystonia: LLE|UHDR111E	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Maximal dystonia-LLE.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155391>	C154459	UHDRS 1999 Version - Maximal Chorea: Face|UHDR1-Maximal Chorea: Face|UHDR1-Maximal Chorea: Face|UHDR112A	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Maximal chorea-Face.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155392>	C154459	UHDRS 1999 Version - Maximal Chorea: BOL|UHDR1-Maximal Chorea: BOL|UHDR1-Maximal Chorea: BOL|UHDR112B	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Maximal chorea-BOL.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155393>	C154459	UHDRS 1999 Version - Maximal Chorea: Trunk|UHDR1-Maximal Chorea: Trunk|UHDR1-Maximal Chorea: Trunk|UHDR112C	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Maximal chorea-Trunk.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155394>	C154459	UHDRS 1999 Version - Maximal Chorea: RUE|UHDR1-Maximal Chorea: RUE|UHDR1-Maximal Chorea: RUE|UHDR112D	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Maximal chorea-RUE.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155395>	C154459	UHDRS 1999 Version - Maximal Chorea: LUE|UHDR1-Maximal Chorea: LUE|UHDR1-Maximal Chorea: LUE|UHDR112E	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Maximal chorea-LUE.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155396>	C154459	UHDRS 1999 Version - Maximal Chorea: RLE|UHDR1-Maximal Chorea: RLE|UHDR1-Maximal Chorea: RLE|UHDR112F	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Maximal chorea-RLE.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155397>	C154459	UHDRS 1999 Version - Maximal Chorea: LLE|UHDR1-Maximal Chorea: LLE|UHDR1-Maximal Chorea: LLE|UHDR112G	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Maximal chorea-LLE.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155398>	C154459	UHDRS 1999 Version - Gait|UHDR1-Gait|UHDR1-Gait|UHDR113	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Gait.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155399>	C154459	UHDRS 1999 Version - Tandem Walking|UHDR1-Tandem Walking|UHDR1-Tandem Walking|UHDR114	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Tandem walking.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15539>	C15697	Treatment Referral Center Protocol	A plan designed for operating a treatment referral center.			Health Care Activity	
C1553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1553>	C548	Thyroid Agent	Compounds that influence the function of the thyroid hormone through replacement, inhibition or stimulation. (NCI)			Chemical Viewed Functionally	
C155400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155400>	C154459	UHDRS 1999 Version - Retropulsion Pull Test|UHDR1-Retropulsion Pull Test|UHDR1-Retropulsion Pull Test|UHDR115	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Retropulsion pull test.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155401>	C154459	UHDRS 1999 Version - Diagnosis Confidence Level|UHDR1-Diagnosis Confidence Level|UHDR1-Diagnosis Confidence Level|UHDR117	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Diagnosis confidence level: To what degree are you confident that this person meets the operational definition of the unequivocal presence of an otherwise unexplained extrapyramidal movement disorder (e.g., chorea, dystonia, bradykinesia, rigidity) in a subject at risk of HD?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155402>	C154459	UHDRS 1999 Version - Verbal Fluency Test|UHDR1-Verbal Fluency Test|UHDR1-Verbal Fluency Test|UHDR119	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Verbal fluency test (raw score).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155403>	C154459	UHDRS 1999 Version - Symbol Digit Modalities Test|UHDR1-Symbol Digit Modalities Test|UHDR1-Symbol Digit Modalities Test|UHDR120	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Symbol digit modalities test (raw score).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155404>	C154459	UHDRS 1999 Version - Depressed Mood: Frequency|UHDR1-Depressed Mood: Frequency|UHDR1-Depressed Mood: Frequency|UHDR125A	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Depressed mood: Frequency: Within the past month, how often have you been feeling sad, down or "blue"?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155405>	C154459	UHDRS 1999 Version - Depressed Mood: Severity|UHDR1-Depressed Mood: Severity|UHDR1-Depressed Mood: Severity|UHDR125B	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Depressed mood: Severity: How has your mood affected your daily activities? [Evidence of sad mood from behavioral observation includes sad voice or expression, tearfulness.].			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155406>	C154459	UHDRS 1999 Version - Apathy: Frequency|UHDR1-Apathy: Frequency|UHDR1-Apathy: Frequency|UHDR126A	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Apathy: Frequency: Within the past month, how often have you found that you have lost interest in things that used to be important to you?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155407>	C154459	UHDRS 1999 Version - Apathy: Severity|UHDR1-Apathy: Severity|UHDR1-Apathy: Severity|UHDR126B	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Apathy: Severity: How has apathy impacted your ability to carry out daily activities?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155408>	C154459	UHDRS 1999 Version - Self-esteem/Guilt: Frequency|UHDR1-Self-esteem/Guilt: Frequency|UHDR1-Self-esteem/Guilt: Frequency|UHDR127A	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Self-esteem/guilt: Frequency: Within the past month, how often have you been feeling badly about yourself?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155409>	C154459	UHDRS 1999 Version - Self-esteem/Guilt: Severity|UHDR1-Self-esteem/Guilt: Severity|UHDR1-Self-esteem/Guilt: Severity|UHDR127B	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Self-esteem/guilt: Severity: How have these feelings affected your daily activities?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15540>	C94632	Antiprolactin Therapy	Drug treatment to block the action of the female hormone prolactin.			Therapeutic or Preventive Procedure	
C155410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155410>	C154459	UHDRS 1999 Version - Suicidal Thoughts: Frequency|UHDR1-Suicidal Thoughts: Frequency|UHDR1-Suicidal Thoughts: Frequency|UHDR128A	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Suicidal thoughts: Frequency: Within the past month, how often have you thought about hurting yourself or ending it all?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155411>	C154459	UHDRS 1999 Version - Suicidal Thoughts: Severity|UHDR1-Suicidal Thoughts: Severity|UHDR1-Suicidal Thoughts: Severity|UHDR128B	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Suicidal thoughts: Severity: Do you have a plan in mind to end it all? Have you taken any steps toward carrying out your plan?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155412>	C154459	UHDRS 1999 Version - Anxiety: Frequency|UHDR1-Anxiety: Frequency|UHDR1-Anxiety: Frequency|UHDR129A	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Anxiety: Frequency: Within the past month, how often have you found yourself worrying about things?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155413>	C154459	UHDRS 1999 Version - Anxiety: Severity|UHDR1-Anxiety: Severity|UHDR1-Anxiety: Severity|UHDR129B	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Anxiety: Severity: How much has nervousness or worry affected your daily activities?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155414>	C154459	UHDRS 1999 Version - Irritable Behavior: Frequency|UHDR1-Irritable Behavior: Frequency|UHDR1-Irritable Behavior: Frequency|UHDR130A	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Irritable behavior: Frequency: In the past month, how often have you felt impatient, irritable, or "cranky"?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155415>	C154459	UHDRS 1999 Version - Irritable Behavior: Severity|UHDR1-Irritable Behavior: Severity|UHDR1-Irritable Behavior: Severity|UHDR130B	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Irritable behavior: Severity: How has irritability impacted your ability to get along with others?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155416>	C154459	UHDRS 1999 Version - Disruptive Behavior: Frequency|UHDR1-Disruptive Behavior: Frequency|UHDR1-Disruptive Behavior: Frequency|UHDR131A	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Disruptive or aggressive behavior: Frequency: Within the past month, how often have you had emotional or temper outbursts? How often have you had times when you lost control of yourself?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155417>	C154459	UHDRS 1999 Version - UDHR1-Disruptive Behavior: Severity|UDHR1-Disruptive Behavior: Severity|UDHR1-Disruptive Behavior: Severity|UHDR131B	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Disruptive or aggressive behavior: Severity: Have you used threats or hostile words? Have you hit or shoved or thrown things or expressed your temper in a physical way?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155418>	C154459	UHDRS 1999 Version - Perseverative Thinking: Frequency|UHDR1-Perseverative Thinking: Frequency|UHDR1-Perseverative Thinking: Frequency|UHDR132A	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Perseverative/obsessional thinking: Frequency: Within the past month, how often have you found yourself getting stuck on certain ideas? How often have you been bothered by thoughts, images, or fears that keep coming back even if you try not to have them?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155419>	C154459	UHDRS 1999 Version - UDHR1-Perseverative Thinking: Severity|UDHR1-Perseverative Thinking: Severity|UDHR1-Perseverative Thinking: Severity|UHDR132B	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Perseverative/obsessional thinking: Severity: Have do repeated thoughts impact your daily life?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15541>	C15747	Sleep Disorder Therapy|Sleep Disorders	Any treatment that is undertaken with the purpose of alleviating any form of sleep disorder.	Sleep Disorder Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C155420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155420>	C154459	UHDRS 1999 Version - Compulsive Behavior: Frequency|UHDR1-Compulsive Behavior: Frequency|UHDR1-Compulsive Behavior: Frequency|UHDR133A	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Compulsive behavior: Frequency: Within the past month, how often have you found yourself doing certain things over and over again (counting, washing, checking)?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155421>	C154459	UHDRS 1999 Version - UDHR1-Compulsive Behavior: Severity|UDHR1-Compulsive Behavior: Severity|UDHR1-Compulsive Behavior: Severity|UHDR133B	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Compulsive behavior: Severity: Are you unable to resist doing some of these things?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155422>	C154459	UHDRS 1999 Version - Delusions: Frequency|UHDR1-Delusions: Frequency|UHDR1-Delusions: Frequency|UHDR134A	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Delusions: Frequency: How often does it seem like people are out to get you, people are controlling you, or you are very suspicious of others? Do you have special powers or importance?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155423>	C154459	UHDRS 1999 Version - UDHR1-Delusions: Severity|UDHR1-Delusions: Severity|UDHR1-Delusions: Severity|UHDR134B	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Delusions: Severity: When you feel suspicious (insert delusion here), are you able to convince yourself that it is not rational? [Severity should reflect the behavior's impact on the individual's ability to carry out daily activities as indicated by response choices.].			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155424>	C154459	UHDRS 1999 Version - Hallucinations: Frequency|UHDR1-Hallucinations: Frequency|UHDR1-Hallucinations: Frequency|UHDR135A	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Hallucinations: Frequency: How often have you heard things that other people couldn't hear, or seen things that other people couldn't see?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155425>	C154459	UHDRS 1999 Version - UDHR1-Hallucinations: Severity|UDHR1-Hallucinations: Severity|UDHR1-Hallucinations: Severity|UHDR135B	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Hallucinations: Severity: When you see or hear things (insert hallucination here), are you able to convince yourself that it is not rational? [Severity should reflect the behavior's impact on the individual's ability to carry out daily activities as indicated by response choices.].			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155426>	C154459	UHDRS 1999 Version - UDHR1-Examiner Believe Subject Confused|UDHR1-Examiner Believe Subject Confused|UDHR1-Examiner Believe Subject Confused|UHDR136	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Confusion is defined as intermittent or persistent disorganized thinking, perceptual disturbances or disorientation to time, place, or person. Does the examiner believe the subject is confused?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155427>	C154459	UHDRS 1999 Version - UDHR1-Confusion Altered Performance|UDHR1-Confusion Altered Performance|UDHR1-Confusion Altered Performance|UHDR136A	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) If yes: Does the examiner believe that this has altered the performance on the UHDRS?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155428>	C154459	UHDRS 1999 Version - UDHR1-Examiner Believe Signs of Dementia|UDHR1-Examiner Believe Signs of Dementia|UDHR1-Examiner Believe Signs of Dementia|UHDR137	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Unified Huntington's Disease Rating Scale '99 - Dementia is defined as progressive impairment in memory, abstract thinking or judgment that interferes with work or usual social activities and relationships. Does the examiner believe that the participant is showing signs of dementia?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155429>	C154459	UHDRS 1999 Version - UDHR1-Dementia Altered Performance|UDHR1-Dementia Altered Performance|UDHR1-Dementia Altered Performance|UHDR137A	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) If yes: Does the examiner believe that this has altered the performance on the UHDRS?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15542>	C15262	Antibody Therapy|antibody therapy|passive antibody therapy	Treatment with injections of antibodies to directly destroy specific, usually cancerous, cells or to stimulate the immune system to destroy those cells.			Therapeutic or Preventive Procedure	
C155430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155430>	C154459	UHDRS 1999 Version - UDHR1-Examiner Believe Signs Depression|UDHR1-Examiner Believe Signs Depression|UDHR1-Examiner Believe Signs Depression|UHDR138	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Unified Huntington's Disease Rating Scale '99 - Depression is defined as persistent depressed mood, anhedonia, or vegetative signs sufficient to interfere with daily functioning. Does the examiner believe that the participant is showing signs of depression?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155431>	C154459	UHDRS 1999 Version - Pharmacotherapy of Depression|UHDR1-Pharmacotherapy of Depression|UHDR1-Pharmacotherapy of Depression|UHDR139	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) In the opinion of the examiner, is a clinical evaluation or follow up warranted for possible pharmacotherapy of depression?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155432>	C154459	UHDRS 1999 Version - Pharmacotherapy of Irritability|UHDR1-Pharmacotherapy of Irritability|UHDR1-Pharmacotherapy of Irritability|UHDR140	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) In the opinion of the examiner, is a clinical evaluation or follow up warranted for possible pharmacotherapy of irritability?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155433>	C154459	UHDRS 1999 Version - Behavior Assessment Obtained From|UHDR1-Behavior Assessment Obtained From|UHDR1-Behavior Assessment Obtained From|UHDR141	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Was the Behavioral Assessment information obtained from.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155434>	C154459	UHDRS 1999 Version - Gainful Employment Accustomed Work|UHDR1-Gainful Employment Accustomed Work|UHDR1-Gainful Employment Accustomed Work|UHDR143	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject engage in gainful employment in his/her accustomed work?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155435>	C154459	UHDRS 1999 Version - Any Gainful Employment|UHDR1-Any Gainful Employment|UHDR1-Any Gainful Employment|UHDR144	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject engage in any kind of gainful employment?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155436>	C154459	UHDRS 1999 Version - Volunteer or Non Gainful Work|UHDR1-Volunteer or Non Gainful Work|UHDR1-Volunteer or Non Gainful Work|UHDR145	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject engage in any kind of volunteer or non gainful work?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155437>	C154459	UHDRS 1999 Version - Manage Finances Without Help|UHDR1-Manage Finances Without Help|UHDR1-Manage Finances Without Help|UHDR146	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject manage his/her finances (monthly) without any help?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155438>	C154459	UHDRS 1999 Version - Shop for Groceries Without Help|UHDR1-Shop for Groceries Without Help|UHDR1-Shop for Groceries Without Help|UHDR147	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject shop for groceries without help?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155439>	C154459	UHDRS 1999 Version - Handle Money as Purchaser|UHDR1-Handle Money as Purchaser|UHDR1-Handle Money as Purchaser|UHDR148	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject handle money as a purchaser in a simple cash (store) transaction?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15543>	C15411	Interleukin Therapy	The use of interleukin in the treatment of any disease or disorder.			Therapeutic or Preventive Procedure	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology
C155440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155440>	C154459	UHDRS 1999 Version - Supervise Children Without Help|UHDR1-Supervise Children Without Help|UHDR1-Supervise Children Without Help|UHDR149	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject supervise children without help?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155441>	C154459	UHDRS 1999 Version - Operate Automobile Safely|UHDR1-Operate Automobile Safely|UHDR1-Operate Automobile Safely|UHDR150	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject operate an automobile safely and independently?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155442>	C154459	UHDRS 1999 Version - Do Housework Without Help|UHDR1-Do Housework Without Help|UHDR1-Do Housework Without Help|UHDR151	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject do his/her own housework without help?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155443>	C154459	UHDRS 1999 Version - Do Laundry Without Help|UHDR1-Do Laundry Without Help|UHDR1-Do Laundry Without Help|UHDR152	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject do his/her own laundry (wash/dry) without help?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155444>	C154459	UHDRS 1999 Version - Prepare Own Meals Without Help|UHDR1-Prepare Own Meals Without Help|UHDR1-Prepare Own Meals Without Help|UHDR153	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject prepare his/her own meals without help?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155445>	C154459	UHDRS 1999 Version - Use Telephone Without Help|UHDR1-Use Telephone Without Help|UHDR1-Use Telephone Without Help|UHDR154	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject use the telephone without help?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155446>	C154459	UHDRS 1999 Version - Take Medications Without Help|UHDR1-Take Medications Without Help|UHDR1-Take Medications Without Help|UHDR155	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject take his/her own medications without help?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155447>	C154459	UHDRS 1999 Version - Feed Himself/Herself Without Help|UHDR1-Feed Himself/Herself Without Help|UHDR1-Feed Himself/Herself Without Help|UHDR156	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject feed himself/herself without help?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155448>	C154459	UHDRS 1999 Version - Dress Himself/Herself Without Help|UHDR1-Dress Himself/Herself Without Help|UHDR1-Dress Himself/Herself Without Help|UHDR157	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject dress himself/herself without help?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155449>	C154459	UHDRS 1999 Version - Bathe Himself/Herself Without Help|UHDR1-Bathe Himself/Herself Without Help|UHDR1-Bathe Himself/Herself Without Help|UHDR158	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject bathe himself/herself without help?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15544>	C15262	Anti-Cytokine Therapy|Anticytokine Therapy	Drug treatment to reduce the activity of cytokines, particulary to control inflammation in disease modalities.			Therapeutic or Preventive Procedure	
C155450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155450>	C154459	UHDRS 1999 Version - Public Transportation Without Help|UHDR1-Public Transportation Without Help|UHDR1-Public Transportation Without Help|UHDR159	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject use public transportation to get places without help?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155451>	C154459	UHDRS 1999 Version - Walk Own Neighborhood Without Help|UHDR1-Walk Own Neighborhood Without Help|UHDR1-Walk Own Neighborhood Without Help|UHDR160	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject walk to places in his/her own neighborhood without help?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155452>	C154459	UHDRS 1999 Version - Walk Without Falling|UHDR1-Walk Without Falling|UHDR1-Walk Without Falling|UHDR161	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject walk without falling?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155453>	C154459	UHDRS 1999 Version - Walk Without Help|UHDR1-Walk Without Help|UHDR1-Walk Without Help|UHDR162	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject walk without help?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155454>	C154459	UHDRS 1999 Version - Comb Hair Without Help|UHDR1-Comb Hair Without Help|UHDR1-Comb Hair Without Help|UHDR163	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject comb hair without help?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155455>	C154459	UHDRS 1999 Version - Transfer Chair Without Help|UHDR1-Transfer Chair Without Help|UHDR1-Transfer Chair Without Help|UHDR164	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject transfer between chairs without help?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155456>	C154459	UHDRS 1999 Version - Get in and Out of Bed Without Help|UHDR1-Get in and Out of Bed Without Help|UHDR1-Get in and Out of Bed Without Help|UHDR165	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject get in and out of bed without help?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155457>	C154459	UHDRS 1999 Version - Use Toilet/Commode Without Help|UHDR1-Use Toilet/Commode Without Help|UHDR1-Use Toilet/Commode Without Help|UHDR166	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject use the toilet/commode without help?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155458>	C154459	UHDRS 1999 Version - Care Provided at Home|UHDR1-Care Provided at Home|UHDR1-Care Provided at Home|UHDR167	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Could the subject's care still be provided at home?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155459>	C154459	UHDRS 1999 Version - Functional Assess Obtained From|UHDR1-Functional Assess Obtained From|UHDR1-Functional Assess Obtained From|UHDR168	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Was the Functional Assessment information obtained from.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15545>	C15351	Leukocyte Therapy	Adoptive immunotherapy that uses donor leukocytes.	Leukocyte Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C155460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155460>	C154459	UHDRS 1999 Version - Current Level Subject Independence|UHDR1-Current Level Subject Independence|UHDR1-Current Level Subject Independence|UHDR169	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Please indicate the most accurate current level of subject's independence (only increments of 5 are acceptable).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155461>	C154459	UHDRS 1999 Version - Occupation|UHDR1-Occupation|UHDR1-Occupation|UHDR170	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Occupation.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155462>	C154459	UHDRS 1999 Version - Finances|UHDR1-Finances|UHDR1-Finances|UHDR171	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Finances.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155463>	C154459	UHDRS 1999 Version - Domestic Chores|UHDR1-Domestic Chores|UHDR1-Domestic Chores|UHDR172	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Domestic Chores.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155464>	C154459	UHDRS 1999 Version - ADL|UHDR1-ADL|UHDR1-ADL|UHDR173	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) ADL.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155465>	C154459	UHDRS 1999 Version - Care Level|UHDR1-Care Level|UHDR1-Care Level|UHDR174	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Care Level.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155466>	C154459	UHDRS 1999 Version - Functional Capacity Obtained From|UHDR1-Functional Capacity Obtained From|UHDR1-Functional Capacity Obtained From|UHDR175	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Was the Functional Capacity information obtained from.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155467>	C154459	UHDRS 1999 Version - Purpose of This Visit|UHDR1-Purpose of This Visit|UHDR1-Purpose of This Visit|UHDR177	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) What was the purpose of this visit?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155468>	C154459	UHDRS 1999 Version - Since Last Assessment Opinion|UHDR1-Since Last Assessment Opinion|UHDR1-Since Last Assessment Opinion|UHDR178	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Since your last assessment of the subject, in your opinion, has the subject.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155469>	C154459	UHDRS 1999 Version - Since Last Assessment Feel|UHDR1-Since Last Assessment Feel|UHDR1-Since Last Assessment Feel|UHDR179	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Since your last assessment does the subject feel.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15546>	C15406	Breast Cancer Screening|Screening for Breast Cancer	Early detection of breast cancer involving asymptomatic women. Generally done in the population with higher risk, due to environmental or genetic factors.	Breast Cancer Screening		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C155470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155470>	C154459	UHDRS 1999 Version - Believe Subject Has Manifest HD|UHDR1-Believe Subject Has Manifest HD|UHDR1-Believe Subject Has Manifest HD|UHDR180	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Based on the entire UHDRS (Motor, Cognitive, Behavioral and Functional components) do you believe with a confidence level >= 99% that this subject has manifest HD?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155471>	C154459	UHDRS 1999 Version - Permanently Institutionalized|UHDR1-Permanently Institutionalized|UHDR1-Permanently Institutionalized|UHDR183A	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Since the last visit, has the subject been permanently institutionalized?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155472>	C154459	UHDRS 1999 Version - Continue to Be Assessed for Study|UHDR1-Continue to Be Assessed for Study|UHDR1-Continue to Be Assessed for Study|UHDR183B	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) If the subject was institutionalized will the subject continue to be assessed for this study?			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155473>	C154459	UHDRS 1999 Version - Total Motor Score|UHDR1-Total Motor Score|UHDR1-Total Motor Score|UHDR184	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Total Motor score.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155474>	C154459	UHDRS 1999 Version - Total Behavior Score|UHDR1-Total Behavior Score|UHDR1-Total Behavior Score|UHDR185	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Total Behavior score.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155475>	C154459	UHDRS 1999 Version - Mood Subscale Score|UHDR1-Mood Subscale Score|UHDR1-Mood Subscale Score|UHDR186	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Mood subscale score of the total behavior score.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155476>	C154459	UHDRS 1999 Version - Behavior Subscale Score|UHDR1-Behavior Subscale Score|UHDR1-Behavior Subscale Score|UHDR187	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Behavior subscale score of the total behavior score.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155477>	C154459	UHDRS 1999 Version - Psychosis Subscale Score|UHDR1-Psychosis Subscale Score|UHDR1-Psychosis Subscale Score|UHDR188	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Psychosis subscale score of the total behavior score.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155478>	C154459	UHDRS 1999 Version - Obsessive Subscale Score|UHDR1-Obsessive Subscale Score|UHDR1-Obsessive Subscale Score|UHDR189	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Obsessive subscale score of the total behavior score.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155479>	C154459	UHDRS 1999 Version - Total Functional Capacity Score|UHDR1-Total Functional Capacity Score|UHDR1-Total Functional Capacity Score|UHDR190	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Total functional capacity score.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15547>	C15406	Screening for Skin Cancer|early detection of skin cancer|skin cancer early detection|skin cancer screening	Checking an individual for the presence or absence of skin cancer.			Diagnostic Procedure	
C155480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155480>	C154459	UHDRS 1999 Version - Independence Scale Score|UHDR1-Independence Scale Score|UHDR1-Independence Scale Score|UHDR191	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Independence scale score.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155481>	C154459	UHDRS 1999 Version - Functional Checklist Score|UHDR1-Functional Checklist Score|UHDR1-Functional Checklist Score|UHDR192	Unified Huntington's Disease Rating Scale 1999 Version (UHDRS 1999 Version) Functional checklist score.			Intellectual Product	CDISC Clinical Classification Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Code Terminology|CDISC Clinical Classification UHDRS 1999 Version Test Name Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155482>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Dressing Without Help|FAC100-Sev: Dressing Without Help|FAC100-Sev: Dressing Without Help|FAC10001	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Dressing yourself without help.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155483>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Dressing Why Not|FAC100-Sev: Dressing Why Not|FAC100-Sev: Dressing Why Not|FAC10002	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Dressing yourself without help. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155484>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walk 50 Steps|FAC100-Sev: Walk 50 Steps|FAC100-Sev: Walk 50 Steps|FAC10003	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking 50 steps/paces on flat ground at a normal speed without stopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155485>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walk 50 Steps Why Not|FAC100-Sev: Walk 50 Steps Why Not|FAC100-Sev: Walk 50 Steps Why Not|FAC10004	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking 50 steps/paces on flat ground at a normal speed without stopping. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155486>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walk Up 20 Stairs|FAC100-Sev: Walk Up 20 Stairs|FAC100-Sev: Walk Up 20 Stairs|FAC10005	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking up 20 stairs (2 flights) without stopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155487>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walk Up 20 Stairs Why Not|FAC100-Sev: Walk Up 20 Stairs Why Not|FAC100-Sev: Walk Up 20 Stairs Why Not|FAC10006	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking up 20 stairs (2 flights) without stopping. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155488>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Preparing Meals|FAC100-Sev: Preparing Meals|FAC100-Sev: Preparing Meals|FAC10007	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Preparing meals.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155489>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Preparing Meals Why Not|FAC100-Sev: Preparing Meals Why Not|FAC100-Sev: Preparing Meals Why Not|FAC10008	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Preparing meals. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15548>	C15406	Screening for Oral Cancer|early detection for oral cancer|oral cancer early detection|oral cancer screening	Checking an individual for the presence or absence of oral cancer.	Screening for Oral Cancer		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C155490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155490>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Washing Dishes|FAC100-Sev: Washing Dishes|FAC100-Sev: Washing Dishes|FAC10009	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Washing dishes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155491>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Washing Dishes Why Not|FAC100-Sev: Washing Dishes Why Not|FAC100-Sev: Washing Dishes Why Not|FAC10010	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Washing dishes. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155492>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Sweeping/Mopping|FAC100-Sev: Sweeping/Mopping|FAC100-Sev: Sweeping/Mopping|FAC10011	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Sweeping or mopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155493>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Sweeping/Mopping Why Not|FAC100-Sev: Sweeping/Mopping Why Not|FAC100-Sev: Sweeping/Mopping Why Not|FAC10012	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Sweeping or mopping. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155494>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Making a Bed|FAC100-Sev: Making a Bed|FAC100-Sev: Making a Bed|FAC10013	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Making a bed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155495>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Making a Bed Why Not|FAC100-Sev: Making a Bed Why Not|FAC100-Sev: Making a Bed Why Not|FAC10014	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Making a bed. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155496>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Lifting 10-20 Lbs|FAC100-Sev: Lifting 10-20 Lbs|FAC100-Sev: Lifting 10-20 Lbs|FAC10015	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Lifting something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155497>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Lifting 10-20 Lbs Why Not|FAC100-Sev: Lifting 10-20 Lbs Why Not|FAC100-Sev: Lifting 10-20 Lbs Why Not|FAC10016	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Lifting something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries). Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155498>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Carry 10-20 Lbs|FAC100-Sev: Carry 10-20 Lbs|FAC100-Sev: Carry 10-20 Lbs|FAC10017	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Carrying something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries) from one room to another.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155499>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Carry 10-20 Lbs Why Not|FAC100-Sev: Carry 10-20 Lbs Why Not|FAC100-Sev: Carry 10-20 Lbs Why Not|FAC10018	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Carrying something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries) from one room to another. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15549>	C15406	Screening for Colorectal Cancer|colorectal cancer early detection|colorectal cancer screening|early detection of colorectal cancer	Checking an individual for the presence or absence of colorectal cancer.			Diagnostic Procedure	
C1554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1554>	C201523|C129822	Edrecolomab|EDRECOLOMAB|Immunoglobulin G2A (Mouse Monoclonal 17-1A Gamma-Chain Anti-Human Colon Cancer Tumor-Associated Antigen), Disulfide With Mouse Monoclonal 17-1A Light Chain, Dimer|MOAB 17-1A|Monoclonal Antibody 17-1A|Panorex|edrecolomab	A murine monoclonal IgG2a antibody to tumor-associated epithelial cell adhesion molecule (EpCAM, or 17-1A) antigen. Edrecolomab attaches to EpCAM, a human cell surface glycoprotein that is found on normal epithelial cells and some tumor cells, such as those of colon and breast carcinomas. Upon binding, this agent recruits the body's immune effector cells, which may exhibit antitumor cytotoxicity. (NCI04)	Edrecolomab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155500>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walk for 1/2 Mile|FAC100-Sev: Walk for 1/2 Mile|FAC100-Sev: Walk for 1/2 Mile|FAC10019	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking (faster than your usual speed) for 1/2 mile (almost 1 km) without stopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155501>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walk for 1/2 Mile Why Not|FAC100-Sev: Walk for 1/2 Mile Why Not|FAC100-Sev: Walk for 1/2 Mile Why Not|FAC10020	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking (faster than your usual speed) for 1/2 mile (almost 1 km) without stopping. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155502>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Bath Without Help|FAC100-Sev: Bath Without Help|FAC100-Sev: Bath Without Help|FAC10021	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Taking a bath without help.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155503>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Bath Without Help Why Not|FAC100-Sev: Bath Without Help Why Not|FAC100-Sev: Bath Without Help Why Not|FAC10022	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Taking a bath without help. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155504>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Taking a Shower|FAC100-Sev: Taking a Shower|FAC100-Sev: Taking a Shower|FAC10023	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Taking a shower.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155505>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Taking a Shower Why Not|FAC100-Sev: Taking a Shower Why Not|FAC100-Sev: Taking a Shower Why Not|FAC10024	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Taking a shower. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155506>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Putting on Socks|FAC100-Sev: Putting on Socks|FAC100-Sev: Putting on Socks|FAC10025	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Putting on socks or stockings.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155507>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Putting on Socks Why Not|FAC100-Sev: Putting on Socks Why Not|FAC100-Sev: Putting on Socks Why Not|FAC10026	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Putting on socks or stockings. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155508>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Standing 5 Minutes|FAC100-Sev: Standing 5 Minutes|FAC100-Sev: Standing 5 Minutes|FAC10027	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Standing for at least 5 minutes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155509>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Standing 5 Minutes Why Not|FAC100-Sev: Standing 5 Minutes Why Not|FAC100-Sev: Standing 5 Minutes Why Not|FAC10028	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Standing for at least 5 minutes. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15550>	C15406	Screening for Prostate Cancer|early detection of prostate cancer|prostate cancer early detection|prostate cancer screening	Checking an individual for the presence or absence of prostate cancer.			Diagnostic Procedure	
C155510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155510>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking 10 Steps|FAC100-Sev: Walking 10 Steps|FAC100-Sev: Walking 10 Steps|FAC10029	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking 10 steps/paces on flat ground at a normal speed without stopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155511>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking 10 Steps Why Not|FAC100-Sev: Walking 10 Steps Why Not|FAC100-Sev: Walking 10 Steps Why Not|FAC10030	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking 10 steps/paces on flat ground at a normal speed without stopping. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155512>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking 1/2 Mile|FAC100-Sev: Walking 1/2 Mile|FAC100-Sev: Walking 1/2 Mile|FAC10031	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking 1/2 mile (almost 1 km) on flat ground at a normal speed without stopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155513>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking 1/2 Mile Why Not|FAC100-Sev: Walking 1/2 Mile Why Not|FAC100-Sev: Walking 1/2 Mile Why Not|FAC10032	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking 1/2 mile (almost 1 km) on flat ground at a normal speed without stopping. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155514>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking Up 5 Stairs|FAC100-Sev: Walking Up 5 Stairs|FAC100-Sev: Walking Up 5 Stairs|FAC10033	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking up 5 stairs without stopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155515>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking Up 5 Stairs Why Not|FAC100-Sev: Walking Up 5 Stairs Why Not|FAC100-Sev: Walking Up 5 Stairs Why Not|FAC10034	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking up 5 stairs without stopping. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155516>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking Up 10 Stairs|FAC100-Sev: Walking Up 10 Stairs|FAC100-Sev: Walking Up 10 Stairs|FAC10035	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking up 10 stairs (1 flight) without stopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155517>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking Up 10 Stairs Why Not|FAC100-Sev: Walking Up 10 Stairs Why Not|FAC100-Sev: Walking Up 10 Stairs Why Not|FAC10036	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking up 10 stairs (1 flight) without stopping. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155518>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking Up 30 Stairs|FAC100-Sev: Walking Up 30 Stairs|FAC100-Sev: Walking Up 30 Stairs|FAC10037	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking up 30 stairs (3 flights) without stopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155519>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking Up 30 Stairs Why Not|FAC100-Sev: Walking Up 30 Stairs Why Not|FAC100-Sev: Walking Up 30 Stairs Why Not|FAC10038	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking up 30 stairs (3 flights) without stopping. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15551>	C15406	Cervical Cancer Screening|Cervical Cancer Early Detection|Early Detection of Cervical Cancer|Screening for Cervical Cancer	The use of any device, marker, or other means for the purpose of detecting the presence of cervical cancer, usually before there are symptoms.	Cervical Cancer Screening		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C155520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155520>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Lift Less Than 5 Lbs|FAC100-Sev: Lift Less Than 5 Lbs|FAC100-Sev: Lift Less Than 5 Lbs|FAC10039	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Lifting something weighing less than 5 lbs (about 2 kg, like a houseplant).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155521>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Lift Less Than 5 Lbs Why Not|FAC100-Sev: Lift Less Than 5 Lbs Why Not|FAC100-Sev: Lift Less Than 5 Lbs Why Not|FAC10040	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Lifting something weighing less than 5 lbs (about 2 kg, like a houseplant). Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155522>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Lifting 5-10 Lbs|FAC100-Sev: Lifting 5-10 Lbs|FAC100-Sev: Lifting 5-10 Lbs|FAC10041	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Lifting something weighing 5-10 lbs (about 2-4.5 kg, like a basket of clothes).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155523>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Lifting 5-10 Lbs Why Not|FAC100-Sev: Lifting 5-10 Lbs Why Not|FAC100-Sev: Lifting 5-10 Lbs Why Not|FAC10042	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Lifting something weighing 5-10 lbs (about 2-4.5 kg, like a basket of clothes). Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155524>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Lift More Than 20 Lbs|FAC100-Sev: Lift More Than 20 Lbs|FAC100-Sev: Lift More Than 20 Lbs|FAC10043	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Lifting something weighing more than 20 lbs (about 9 kg, like a medium-sized suitcase).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155525>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Lift More Than 20 Lbs Why Not|FAC100-Sev: Lift More Than 20 Lb Why Not|FAC100-Sev: Lift More Than 20 Lb Why Not|FAC10044	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Lifting something weighing more than 20 lbs (about 9 kg, like a medium-sized suitcase). Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155526>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Carrying Less Than 5 Lbs|FAC100-Sev: Carrying Less Than 5 Lbs|FAC100-Sev: Carrying Less Than 5 Lbs|FAC10045	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Carrying something weighing less than 5 lbs (about 2 kg, like a houseplant) from one room to another.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155527>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Carrying Less Than 5 Why Not|FAC100-Sev: Carrying Less Than 5 Why Not|FAC100-Sev: Carrying Less Than 5 Why Not|FAC10046	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Carrying something weighing less than 5 lbs (about 2 kg, like a houseplant) from one room to another. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155528>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Carrying 5-10 Lbs|FAC100-Sev: Carrying 5-10 Lbs|FAC100-Sev: Carrying 5-10 Lbs|FAC10047	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Carrying something weighing 5-10 lbs (about 2-4.5 kg, like a basket of clothes) from one room to another.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155529>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Carrying 5-10 Lbs Why Not|FAC100-Sev: Carrying 5-10 Lbs Why Not|FAC100-Sev: Carrying 5-10 Lbs Why Not|FAC10048	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Carrying something weighing 5-10 lbs (about 2-4.5 kg, like a basket of clothes) from one room to another. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15552>	C15406	Screening for Testicular Cancer|early detection of testicular cancer|testicular cancer early detection|testicular cancer screening	Checking an individual for the presence or absence of testicular cancer.			Diagnostic Procedure	
C155530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155530>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Get In/Out of a Car|FAC100-Sev: Get In/Out of a Car|FAC100-Sev: Get In/Out of a Car|FAC10049	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Getting in or out of a car.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155531>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Get In/Out of a Car Why Not|FAC100-Sev: Get In/Out of a Car Why Not|FAC100-Sev: Get In/Out of a Car Why Not|FAC10050	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Getting in or out of a car. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155532>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Dining Out|FAC100-Sev: Dining Out|FAC100-Sev: Dining Out|FAC10051	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Dining out.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155533>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Dining Out Why Not|FAC100-Sev: Dining Out Why Not|FAC100-Sev: Dining Out Why Not|FAC10052	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Dining out. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155534>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Low-intensity Activity|FAC100-Sev: Low-intensity Activ|FAC100-Sev: Low-intensity Activ|FAC10053	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Low-intensity leisure activity (gardening, etc.).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155535>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Low-intensity Activity Why Not|FAC100-Sev: Low-intensity Activ Why Not|FAC100-Sev: Low-intensity Activ Why Not|FAC10054	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Low-intensity leisure activity (gardening, etc.). Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155536>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Moderate Activity|FAC100-Sev: Moderate Activity|FAC100-Sev: Moderate Activity|FAC10055	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Moderate-intensity leisure activity (bicycling on level terrain, etc.).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155537>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Moderate Activity Why Not|FAC100-Sev: Moderate Activity Why Not|FAC100-Sev: Moderate Activity Why Not|FAC10056	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Moderate-intensity leisure activity (bicycling on level terrain, etc.). Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155538>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walk Fast 50 Steps|FAC100-Sev: Walk Fast 50 Steps|FAC100-Sev: Walk Fast 50 Steps|FAC10057	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking (faster than your usual speed) for 50 steps without stopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155539>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walk Fast 50 Steps Why Not|FAC100-Sev: Walk Fast 50 Steps Why Not|FAC100-Sev: Walk Fast 50 Steps Why Not|FAC10058	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking (faster than your usual speed) for 50 steps without stopping. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15553>	C15669	Breast Cancer Prevention|Prevention of Breast Cancer	Anything, such as drug administration or lifestyle changes, designed to inhibit the onset of breast cancer.			Therapeutic or Preventive Procedure	
C155540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155540>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking Fast 1 Mile|FAC100-Sev: Walking Fast 1 Mile|FAC100-Sev: Walking Fast 1 Mile|FAC10059	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking (faster than your usual speed) for at least 1 mile ( a little more than 1.5 km) without stopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155541>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Walking Fast 1 Mile Why Not|FAC100-Sev: Walking Fast 1 Mile Why Not|FAC100-Sev: Walking Fast 1 Mile Why Not|FAC10060	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Walking (faster than your usual speed) for at least 1 mile ( a little more than 1.5 km) without stopping. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155542>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Singing or Humming|FAC100-Sev: Singing or Humming|FAC100-Sev: Singing or Humming|FAC10061	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Singing or humming.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155543>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Singing or Humming Why Not|FAC100-Sev: Singing or Humming Why Not|FAC100-Sev: Singing or Humming Why Not|FAC10062	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Singing or humming. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155544>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Talking While Walking|FAC100-Sev: Talking While Walking|FAC100-Sev: Talking While Walking|FAC10063	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Talking while walking.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155545>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Talking While Walk Why Not|FAC100-Sev: Talking While Walk Why Not|FAC100-Sev: Talking While Walk Why Not|FAC10064	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Talking while walking. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155546>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Scrubbing the Floor|FAC100-Sev: Scrubbing the Floor|FAC100-Sev: Scrubbing the Floor|FAC10065	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Scrubbing the floor or counter.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155547>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Severity: Scrubbing the Floor Why Not|FAC100-Sev: Scrubbing the Floor Why Not|FAC100-Sev: Scrubbing the Floor Why Not|FAC10066	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Dyspnea Severity: Over the past 7 days, how short of breath did you get with each of these activities?: Scrubbing the floor or counter. Please indicate why you did not do this in the past 7 days.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155548>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Dressing Without Help|FAC100-Limit: Dressing Without Help|FAC100-Limit: Dressing Without Help|FAC10067	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Dressing yourself without help.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155549>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Walk 50 Steps|FAC100-Limit: Walk 50 Steps|FAC100-Limit: Walk 50 Steps|FAC10068	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Walking 50 steps/paces on flat ground at a normal speed without stopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15554>	C15669	Prevention of Colorectal Cancer|Colorectal Cancer Prevention	Any method of preventing colon cancer including limiting of exposure to carcinogens and infectious agents, diet, education, or lifestyle.			Therapeutic or Preventive Procedure	
C155550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155550>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Walk Up 20 Stairs|FAC100-Limit: Walk Up 20 Stairs|FAC100-Limit: Walk Up 20 Stairs|FAC10069	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Walking up 20 stairs (2 flights) without stopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155551>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Preparing Meals|FAC100-Limit: Preparing Meals|FAC100-Limit: Preparing Meals|FAC10070	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Preparing meals.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155552>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Washing Dishes|FAC100-Limit: Washing Dishes|FAC100-Limit: Washing Dishes|FAC10071	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Washing dishes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155553>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Sweeping/Mopping|FAC100-Limit: Sweeping/Mopping|FAC100-Limit: Sweeping/Mopping|FAC10072	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Sweeping or mopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155554>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Making a Bed|FAC100-Limit: Making a Bed|FAC100-Limit: Making a Bed|FAC10073	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Making a bed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155555>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Lifting 10-20 Lbs|FAC100-Limit: Lifting 10-20 Lbs|FAC100-Limit: Lifting 10-20 Lbs|FAC10074	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Lifting something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155556>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Carry 10-20 Lbs|FAC100-Limit: Carry 10-20 Lbs|FAC100-Limit: Carry 10-20 Lbs|FAC10075	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Carrying something weighing 10-20 lbs (about 4.5-9kg, like a large bag of groceries) from one room to another.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155557>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Walk for 1/2 Mile|FAC100-Limit: Walk for 1/2 Mile|FAC100-Limit: Walk for 1/2 Mile|FAC10076	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Walking (faster than your usual speed) for 1/2 mile (almost 1 km) without stopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155558>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Taking a Bath Without Help|FAC100-Limit: Taking a Bath Without Help|FAC100-Limit: Taking a Bath Without Help|FAC10077	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Taking a bath without help.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155559>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Taking a Shower|FAC100-Limit: Taking a Shower|FAC100-Limit: Taking a Shower|FAC10078	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Taking a shower.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15555>	C15669	Prevention of Head and Neck Cancer|Head and Neck Cancer Prevention	Any method of preventing head and neck cancer including limiting of exposure to carcinogens and infectious agents, diet, education, or lifestyle.			Therapeutic or Preventive Procedure	
C155560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155560>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Putting on Socks|FAC100-Limit: Putting on Socks|FAC100-Limit: Putting on Socks|FAC10079	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Putting on socks or stockings.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155561>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Standing 5 Minutes|FAC100-Limit: Standing 5 Minutes|FAC100-Limit: Standing 5 Minutes|FAC10080	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Standing for at least 5 minutes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155562>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Walking 10 Steps|FAC100-Limit: Walking 10 Steps|FAC100-Limit: Walking 10 Steps|FAC10081	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Walking 10 steps/paces on flat ground at a normal speed without stopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155563>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Walking 1/2 Mile|FAC100-Limit: Walking 1/2 Mile|FAC100-Limit: Walking 1/2 Mile|FAC10082	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Walking 1/2 mile (almost 1 km) on flat ground at a normal speed without stopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155564>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Walking Up 5 Stairs|FAC100-Limit: Walking Up 5 Stairs|FAC100-Limit: Walking Up 5 Stairs|FAC10083	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Walking up 5 stairs without stopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155565>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Walking Up 10 Stairs|FAC100-Limit: Walking Up 10 Stairs|FAC100-Limit: Walking Up 10 Stairs|FAC10084	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Walking up 10 stairs (1 flight) without stopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155566>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Walking Up 30 Stairs|FAC100-Limit: Walking Up 30 Stairs|FAC100-Limit: Walking Up 30 Stairs|FAC10085	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Walking up 30 stairs (3 flights) without stopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155567>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Scrubbing the Floor|FAC100-Limit: Scrubbing the Floor|FAC100-Limit: Scrubbing the Floor|FAC10086	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Scrubbing the floor or counter.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155568>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Lifting Less Than 5 Lbs|FAC100-Limit: Lifting Less Than 5 Lbs|FAC100-Limit: Lifting Less Than 5 Lbs|FAC10087	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Lifting something weighing less than 5 lbs (about 2 kg, like a houseplant).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155569>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Lifting 5-10 Lbs|FAC100-Limit: Lifting 5-10 Lbs|FAC100-Limit: Lifting 5-10 Lbs|FAC10088	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Lifting something weighing 5-10 lbs (about 2-4.5 kg, like a basket of clothes).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15556>	C15669	Prevention of Skin Cancer|Skin Cancer Prevention	Any method of preventing skin cancer including limiting of exposure to carcinogens and infectious agents, diet, education, or lifestyle.			Therapeutic or Preventive Procedure	
C155570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155570>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Lifting More Than 20 Lbs|FAC100-Limit: Lifting More Than 20 Lbs|FAC100-Limit: Lifting More Than 20 Lbs|FAC10089	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Lifting something weighing more than 20 lbs (about 9 kg, like a medium-sized suitcase).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155571>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Carrying Less Than 5 Lbs|FAC100-Limit: Carrying Less Than 5 Lbs|FAC100-Limit: Carrying Less Than 5 Lbs|FAC10090	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Carrying something weighing less than 5 lbs (about 2 kg, like a houseplant) from one room to another.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155572>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Carrying 5-10 Lbs|FAC100-Limit: Carrying 5-10 Lbs|FAC100-Limit: Carrying 5-10 Lbs|FAC10091	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Carrying something weighing 5-10 lbs (about 2-4.5 kg, like a basket of clothes) from one room to another.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155573>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Get In/Out of a Car|FAC100-Limit: Get In/Out of a Car|FAC100-Limit: Get In/Out of a Car|FAC10092	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Getting in or out of a car.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155574>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Dining Out|FAC100-Limit: Dining Out|FAC100-Limit: Dining Out|FAC10093	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Dining out.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155575>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Low-intensity Activity|FAC100-Limit: Low-intensity Activity|FAC100-Limit: Low-intensity Activity|FAC10094	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Low-intensity leisure activity (gardening, etc.).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155576>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Moderate Activity|FAC100-Limit: Moderate Activity|FAC100-Limit: Moderate Activity|FAC10095	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Moderate-intensity leisure activity (bicycling on level terrain, etc.).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155577>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Walk Fast 50 Steps|FAC100-Limit: Walk Fast 50 Steps|FAC100-Limit: Walk Fast 50 Steps|FAC10096	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Walking (faster than your usual speed) for 50 steps without stopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155578>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Walking Fast 1 Mile|FAC100-Limit: Walking Fast 1 Mile|FAC100-Limit: Walking Fast 1 Mile|FAC10097	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Walking (faster than your usual speed) for at least 1 mile (a little more than 1.5 km) without stopping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155579>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Singing or Humming|FAC100-Limit: Singing or Humming|FAC100-Limit: Singing or Humming|FAC10098	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Singing or humming.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15557>	C15669	Prevention of Cervical Cancer|Cervical Cancer Prevention	Any method of preventing cervical cancer including limiting of exposure to carcinogens and infectious agents, diet, education, or lifestyle.			Therapeutic or Preventive Procedure	
C155580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155580>	C154460	FACIT-Dyspnea Scale 33 Item Bank Version - Limit: Talking While Walking|FAC100-Limit: Talking While Walking|FAC100-Limit: Talking While Walking|FAC10099	Functional Assessment of Chronic Illness Therapy-Dyspnea Scale 33 Item Bank (FACIT-Dyspnea Scale 33 Item Bank Version) Functional Limitation: Considering your shortness of breath over the past 7 days, rate the amount of difficulty you had when doing the following activities: Talking while walking.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Code Terminology|CDISC Questionnaire FACIT-Dyspnea Scale 33 Item Bank Version Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155581>	C154461	FACT-BL Version 4 - I Have a Lack of Energy|FAC006-I Have a Lack of Energy|FAC006-I Have a Lack of Energy|FAC00601	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Physical Well-Being: I have a lack of energy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155582>	C154461	FACT-BL Version 4 - I Have Nausea|FAC006-I Have Nausea|FAC006-I Have Nausea|FAC00602	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Physical Well-Being: I have nausea.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155583>	C154461	FACT-BL Version 4 - Trouble Meeting Needs of Family|FAC006-Trouble Meeting Needs of Family|FAC006-Trouble Meeting Needs of Family|FAC00603	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Physical Well-Being: Because of my physical condition, I have trouble meeting the needs of my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155584>	C154461	FACT-BL Version 4 - I Have Pain|FAC006-I Have Pain|FAC006-I Have Pain|FAC00604	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Physical Well-Being: I have pain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155585>	C154461	FACT-BL Version 4 - Bothered by Treatment Side Effect|FAC006-Bothered by Treatment Side Effect|FAC006-Bothered by Treatment Side Effect|FAC00605	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Physical Well-Being: I am bothered by side effects of treatment.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155586>	C154461	FACT-BL Version 4 - I Feel Ill|FAC006-I Feel Ill|FAC006-I Feel Ill|FAC00606	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Physical Well-Being: I feel ill.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155587>	C154461	FACT-BL Version 4 - I Am Forced to Spend Time in Bed|FAC006-I Am Forced to Spend Time in Bed|FAC006-I Am Forced to Spend Time in Bed|FAC00607	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Physical Well-Being: I am forced to spend time in bed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155588>	C154461	FACT-BL Version 4 - I Feel Close to My Friends|FAC006-I Feel Close to My Friends|FAC006-I Feel Close to My Friends|FAC00608	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Social/Family Well-Being: I feel close to my friends.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155589>	C154461	FACT-BL Version 4 - Get Emotional Support From Family|FAC006-Get Emotional Support From Family|FAC006-Get Emotional Support From Family|FAC00609	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Social/Family Well-Being: I get emotional support from my family.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15558>	C15669	Prevention of Lung Cancer|Lung Cancer Prevention	Any method of preventing lung cancer including limiting of exposure to carcinogens and infectious agents, diet, education, or lifestyle.			Therapeutic or Preventive Procedure	
C155590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155590>	C154461	FACT-BL Version 4 - I Get Support From My Friends|FAC006-I Get Support From My Friends|FAC006-I Get Support From My Friends|FAC00610	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Social/Family Well-Being: I get support from my friends.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155591>	C154461	FACT-BL Version 4 - My Family Has Accepted My Illness|FAC006-My Family Has Accepted My Illness|FAC006-My Family Has Accepted My Illness|FAC00611	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Social/Family Well-Being: My family has accepted my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155592>	C154461	FACT-BL Version 4 - Satisfied Communication Illness|FAC006-Satisfied Communication Illness|FAC006-Satisfied Communication Illness|FAC00612	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Social/Family Well-Being: I am satisfied with family communication about my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155593>	C154461	FACT-BL Version 4 - I Feel Close to My Partner|FAC006-I Feel Close to My Partner|FAC006-I Feel Close to My Partner|FAC00613	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Social/Family Well-Being: I feel close to my partner (or the person who is my main support).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155594>	C154461	FACT-BL Version 4 - I Am Satisfied With My Sex Life|FAC006-I Am Satisfied With My Sex Life|FAC006-I Am Satisfied With My Sex Life|FAC00614	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Social/Family Well-Being: I am satisfied with my sex life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155595>	C154461	FACT-BL Version 4 - I Feel Sad|FAC006-I Feel Sad|FAC006-I Feel Sad|FAC00615	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Emotional Well-Being: I feel sad.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155596>	C154461	FACT-BL Version 4 - Satisfied With How I Am Coping|FAC006-Satisfied With How I Am Coping|FAC006-Satisfied With How I Am Coping|FAC00616	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Emotional Well-Being: I am satisfied with how I am coping with my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155597>	C154461	FACT-BL Version 4 - Losing Hope Against Illness|FAC006-Losing Hope Against Illness|FAC006-Losing Hope Against Illness|FAC00617	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Emotional Well-Being: I am losing hope in the fight against my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155598>	C154461	FACT-BL Version 4 - I Feel Nervous|FAC006-I Feel Nervous|FAC006-I Feel Nervous|FAC00618	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Emotional Well-Being: I feel nervous.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155599>	C154461	FACT-BL Version 4 - I Worry About Dying|FAC006-I Worry About Dying|FAC006-I Worry About Dying|FAC00619	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Emotional Well-Being: I worry about dying.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15559>	C15669	Prevention of Esophageal Cancer|Esophageal Cancer Prevention	Any method of preventing esophageal cancer including limiting of exposure to carcinogens and infectious agents, diet, education, or lifestyle.			Therapeutic or Preventive Procedure	
C1555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1555>	C67502|C203332	Pegylated Liposomal Doxorubicin Hydrochloride|(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-tri-hydroxy-1-methoxy-5,12-naphthacenedione Hydrochloride|ATI-0918|Caelyx|DOX-SL|DOXIL|Dox-SL|Doxil|Doxil|Doxilen|Doxorubicin HCl Liposomal|Doxorubicin HCl Liposome|Doxorubicin Hydrochloride Liposome|Doxorubicin Liposomal|Doxorubicin Liposomal|Duomeisu|Evacet|Evacet|LipoDox|LipoDox|Lipodox 50|Liposomal Adriamycin|Liposomal Doxorubicin Hydrochloride|Liposomal-Encapsulated Doxorubicin|Pegylated Doxorubicin HCl Liposome|Pegylated Liposomal Doxorubicin|Pegylated liposomal doxorubicin|S-Liposomal Doxorubicin|Stealth Liposomal Doxorubicin|TLC D-99|doxorubicin hydrochloride liposome|liposomal doxorubicin hydrochloride	A liposome-encapsulated preparation of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin. Doxorubicin intercalates between DNA base pairs, thereby hinders the movement of replication machinery along DNA strands, as well as blocks the activity of topoisomerase II during replication. As a result, this agent causes DNA adducts formation, renders single- and double-stranded DNA breakages that induce DNA repair and or apoptotic processes. Doxorubicin also generates reactive oxygen species that leads to cytotoxicity secondary to lipid peroxidation of cell membrane lipids. Liposomal delivery of doxorubicin HCl improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects. A liposomal formulation of doxorubicin also modulates toxicity, specifically the cardiac effects commonly seen with anthracycline antitumor drugs.	Pegylated Liposomal Doxorubicin Hydrochloride		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155600>	C154461	FACT-BL Version 4 - Worry My Condition Will Get Worse|FAC006-Worry My Condition Will Get Worse|FAC006-Worry My Condition Will Get Worse|FAC00620	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Emotional Well-Being: I worry that my condition will get worse.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155601>	C154461	FACT-BL Version 4 - I Am Able to Work|FAC006-I Am Able to Work|FAC006-I Am Able to Work|FAC00621	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Functional Well-Being: I am able to work (include work at home).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155602>	C154461	FACT-BL Version 4 - My Work Is Fulfilling|FAC006-My Work Is Fulfilling|FAC006-My Work Is Fulfilling|FAC00622	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Functional Well-Being: My work (include work at home) is fulfilling.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155603>	C154461	FACT-BL Version 4 - I Am Able to Enjoy Life|FAC006-I Am Able to Enjoy Life|FAC006-I Am Able to Enjoy Life|FAC00623	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Functional Well-Being: I am able to enjoy life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155604>	C154461	FACT-BL Version 4 - I Have Accepted My Illness|FAC006-I Have Accepted My Illness|FAC006-I Have Accepted My Illness|FAC00624	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Functional Well-Being: I have accepted my illness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155605>	C154461	FACT-BL Version 4 - I Am Sleeping Well|FAC006-I Am Sleeping Well|FAC006-I Am Sleeping Well|FAC00625	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Functional Well-Being: I am sleeping well.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155606>	C154461	FACT-BL Version 4 - Enjoy Things I Usually Do for Fun|FAC006-Enjoy Things I Usually Do for Fun|FAC006-Enjoy Things I Usually Do for Fun|FAC00626	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Functional Well-Being: I am enjoying the things I usually do for fun.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155607>	C154461	FACT-BL Version 4 - Content With Quality of My Life|FAC006-Content With Quality of My Life|FAC006-Content With Quality of My Life|FAC00627	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Functional Well-Being: I am content with the quality of my life right now.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155608>	C154461	FACT-BL Version 4 - Trouble Controlling My Urine|FAC006-Trouble Controlling My Urine|FAC006-Trouble Controlling My Urine|FAC00628	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Additional Concerns: I have trouble controlling my urine.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155609>	C154461	FACT-BL Version 4 - I Am Losing Weight|FAC006-I Am Losing Weight|FAC006-I Am Losing Weight|FAC00629	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Additional Concerns: I am losing weight.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15560>	C61063	Interleukin-3/Thiotepa|IL-3/TSPA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C155610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155610>	C154461	FACT-BL Version 4 - I Have Control of My Bowels|FAC006-I Have Control of My Bowels|FAC006-I Have Control of My Bowels|FAC00630	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Additional Concerns: I have control of my bowels.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155611>	C154461	FACT-BL Version 4 - I Urinate More Frequently|FAC006-I Urinate More Frequently|FAC006-I Urinate More Frequently|FAC00631	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Additional Concerns: I urinate more frequently than usual.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155612>	C154461	FACT-BL Version 4 - I Have Diarrhea|FAC006-I Have Diarrhea|FAC006-I Have Diarrhea|FAC00632	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Additional Concerns: I have diarrhea (diarrhoea).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155613>	C154461	FACT-BL Version 4 - I Have a Good Appetite|FAC006-I Have a Good Appetite|FAC006-I Have a Good Appetite|FAC00633	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Additional Concerns: I have a good appetite.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155614>	C154461	FACT-BL Version 4 - I Like the Appearance of My Body|FAC006-I Like the Appearance of My Body|FAC006-I Like the Appearance of My Body|FAC00634	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Additional Concerns: I like the appearance of my body.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155615>	C154461	FACT-BL Version 4 - It Burns When I Urinate|FAC006-It Burns When I Urinate|FAC006-It Burns When I Urinate|FAC00635	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Additional Concerns: It burns when I urinate.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155616>	C154461	FACT-BL Version 4 - I Am Interested in Sex|FAC006-I Am Interested in Sex|FAC006-I Am Interested in Sex|FAC00636	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Additional Concerns: I am interested in sex.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155617>	C154461	FACT-BL Version 4 - Able to Have/Maintain Erection|FAC006-Able to Have/Maintain Erection|FAC006-Able to Have/Maintain Erection|FAC00637	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Additional Concerns: (For men only) I am able to have and maintain an erection.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155618>	C154461	FACT-BL Version 4 - Do You Have an Ostomy Appliance|FAC006-Do You Have an Ostomy Appliance|FAC006-Do You Have an Ostomy Appliance|FAC00638	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Additional Concerns: Do you have an ostomy appliance?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155619>	C154461	FACT-BL Version 4 - Embarrassed by Ostomy Appliance|FAC006-Embarrassed by Ostomy Appliance|FAC006-Embarrassed by Ostomy Appliance|FAC00639	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Additional Concerns: I am embarrassed by my ostomy appliance.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15561>	C15669	Cancer Prevention Intervention	Any intervention designed to lessen an individual's cancer risk.			Therapeutic or Preventive Procedure	
C155620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155620>	C154461	FACT-BL Version 4 - Caring for Ostomy Appliance Is Difficult|FAC006-Caring for Ostomy Is Difficult|FAC006-Caring for Ostomy Is Difficult|FAC00640	Functional Assessment of Cancer Therapy-Bladder Version 4 (FACT-BL Version 4) Additional Concerns: Caring for my ostomy appliance is difficult.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-BL Version 4 Test Code Terminology|CDISC Questionnaire FACT-BL Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155621>	C154462	NSCLC-SAQ Version 1.0 - Rate Coughing at Worst|NSCLC1-Rate Coughing at Worst|NSCLC1-Rate Coughing at Worst|NSCLC101	Non-Small Cell Lung Cancer Symptom Assessment Questionnaire v1.0 (NSCLC-SAQ Version 1.0) How would you rate your coughing at its worst over the last 7 days?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NSCLC-SAQ Version 1.0 Test Code Terminology|CDISC Questionnaire NSCLC-SAQ Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155622>	C154462	NSCLC-SAQ Version 1.0 - Rate Worst Pain in Chest|NSCLC1-Rate Worst Pain in Chest|NSCLC1-Rate Worst Pain in Chest|NSCLC102	Non-Small Cell Lung Cancer Symptom Assessment Questionnaire v1.0 (NSCLC-SAQ Version 1.0) How would you rate the worst pain in your chest over the last 7 days?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NSCLC-SAQ Version 1.0 Test Code Terminology|CDISC Questionnaire NSCLC-SAQ Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155623>	C154462	NSCLC-SAQ Version 1.0 - Rate Worst Pain Other Than Chest|NSCLC1-Rate Worst Pain Other Than Chest|NSCLC1-Rate Worst Pain Other Than Chest|NSCLC103	Non-Small Cell Lung Cancer Symptom Assessment Questionnaire v1.0 (NSCLC-SAQ Version 1.0) How would you rate the worst pain in areas other than your chest over the last 7 days?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NSCLC-SAQ Version 1.0 Test Code Terminology|CDISC Questionnaire NSCLC-SAQ Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155624>	C154462	NSCLC-SAQ Version 1.0 - Short of Breath Usual Activities|NSCLC1-Short of Breath Usual Activities|NSCLC1-Short of Breath Usual Activities|NSCLC104	Non-Small Cell Lung Cancer Symptom Assessment Questionnaire v1.0 (NSCLC-SAQ Version 1.0) How often did you feel short of breath during usual activities over the last 7 days?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NSCLC-SAQ Version 1.0 Test Code Terminology|CDISC Questionnaire NSCLC-SAQ Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155625>	C154462	NSCLC-SAQ Version 1.0 - How Often Low Energy|NSCLC1-How Often Low Energy|NSCLC1-How Often Low Energy|NSCLC105	Non-Small Cell Lung Cancer Symptom Assessment Questionnaire v1.0 (NSCLC-SAQ Version 1.0) How often did you have low energy over the last 7 days?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NSCLC-SAQ Version 1.0 Test Code Terminology|CDISC Questionnaire NSCLC-SAQ Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155626>	C154462	NSCLC-SAQ Version 1.0 - How Often Tire Easily|NSCLC1-How Often Tire Easily|NSCLC1-How Often Tire Easily|NSCLC106	Non-Small Cell Lung Cancer Symptom Assessment Questionnaire v1.0 (NSCLC-SAQ Version 1.0) How often did you tire easily over the last 7 days?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NSCLC-SAQ Version 1.0 Test Code Terminology|CDISC Questionnaire NSCLC-SAQ Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155627>	C154462	NSCLC-SAQ Version 1.0 - How Often Poor Appetite|NSCLC1-How Often Poor Appetite|NSCLC1-How Often Poor Appetite|NSCLC107	Non-Small Cell Lung Cancer Symptom Assessment Questionnaire v1.0 (NSCLC-SAQ Version 1.0) How often did you have a poor appetite over the last 7 days?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NSCLC-SAQ Version 1.0 Test Code Terminology|CDISC Questionnaire NSCLC-SAQ Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155628>	C154462	NSCLC-SAQ Version 1.0 - Total Score|NSCLC1-Total Score|NSCLC1-Total Score|NSCLC113	Non-Small Cell Lung Cancer Symptom Assessment Questionnaire v1.0 (NSCLC-SAQ Version 1.0) Total score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire NSCLC-SAQ Version 1.0 Test Code Terminology|CDISC Questionnaire NSCLC-SAQ Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155629>	C154463	SMDDS Version 1.0 - How Sad Have You Felt|SMDDS1-How Sad Have You Felt|SMDDS1-How Sad Have You Felt|SMDDS101	Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how sad have you felt?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Code Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15562>	C61007	Interleukin-3/Melphalan|IL-3/L-PAM			Obsolete_Concept	Therapeutic or Preventive Procedure	
C155630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155630>	C154463	SMDDS Version 1.0 - How Hopeless Have You Felt|SMDDS1-How Hopeless Have You Felt|SMDDS1-How Hopeless Have You Felt|SMDDS102	Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how hopeless have you felt?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Code Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155631>	C154463	SMDDS Version 1.0 - How Irritable Have You Felt|SMDDS1-How Irritable Have You Felt|SMDDS1-How Irritable Have You Felt|SMDDS103	Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how irritable have you felt?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Code Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155632>	C154463	SMDDS Version 1.0 - How Overwhelmed Have You Felt|SMDDS1-How Overwhelmed Have You Felt|SMDDS1-How Overwhelmed Have You Felt|SMDDS104	Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how overwhelmed have you felt?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Code Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155633>	C154463	SMDDS Version 1.0 - How Worried Have You Felt|SMDDS1-How Worried Have You Felt|SMDDS1-How Worried Have You Felt|SMDDS105	Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how worried have you felt?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Code Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155634>	C154463	SMDDS Version 1.0 - How Tired Have You Felt|SMDDS1-How Tired Have You Felt|SMDDS1-How Tired Have You Felt|SMDDS106	Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how tired have you felt?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Code Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155635>	C154463	SMDDS Version 1.0 - How Difficult Stop Think Problems|SMDDS1-How Difficult Stop Think Problems|SMDDS1-How Difficult Stop Think Problems|SMDDS107	Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how difficult was it for you to stop thinking about your problems?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Code Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155636>	C154463	SMDDS Version 1.0 - How Difficult to Concentrate|SMDDS1-How Difficult to Concentrate|SMDDS1-How Difficult to Concentrate|SMDDS108	Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how difficult was it for you to concentrate?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Code Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155637>	C154463	SMDDS Version 1.0 - How Difficult to Enjoy Daily Life|SMDDS1-How Difficult to Enjoy Daily Life|SMDDS1-How Difficult to Enjoy Daily Life|SMDDS109	Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how difficult was it for you to enjoy your daily life?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Code Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155638>	C154463	SMDDS Version 1.0 - How Often Problem With Sleep|SMDDS1-How Often Problem With Sleep|SMDDS1-How Often Problem With Sleep|SMDDS110	Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how often did you have a problem with your sleep (falling asleep, staying asleep, or sleeping too much)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Code Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155639>	C154463	SMDDS Version 1.0 - How Often Have Poor Appetite|SMDDS1-How Often Have Poor Appetite|SMDDS1-How Often Have Poor Appetite|SMDDS111	Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how often did you have a poor appetite?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Code Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15563>	C61063	Interleukin-3/Zidovudine|IL-3/ZDV			Obsolete_Concept	Therapeutic or Preventive Procedure	
C155640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155640>	C154463	SMDDS Version 1.0 - How Often Did You Over Eat|SMDDS1-How Often Did You Over Eat|SMDDS1-How Often Did You Over Eat|SMDDS112	Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how often did you over eat?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Code Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155641>	C154463	SMDDS Version 1.0 - How Much Push Yourself Do Things|SMDDS1-How Much Push Yourself Do Things|SMDDS1-How Much Push Yourself Do Things|SMDDS113	Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how much of the time did you have to push yourself to do things?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Code Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155642>	C154463	SMDDS Version 1.0 - How Much Feel Like Doing Nothing|SMDDS1-How Much Feel Like Doing Nothing|SMDDS1-How Much Feel Like Doing Nothing|SMDDS114	Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how much of the time did you feel like doing nothing?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Code Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155643>	C154463	SMDDS Version 1.0 - How Much Blame Yourself Bad Thing|SMDDS1-How Much Blame Yourself Bad Thing|SMDDS1-How Much Blame Yourself Bad Thing|SMDDS115	Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how much of the time did you blame yourself when bad things happened?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Code Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155644>	C154463	SMDDS Version 1.0 - How Much Feel Not Worth Living|SMDDS1-How Much Feel Not Worth Living|SMDDS1-How Much Feel Not Worth Living|SMDDS116	Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Over the past 7 days, how much of the time did you feel that life is not worth living?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Code Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155645>	C154463	SMDDS Version 1.0 - Total Score|SMDDS1-Total Score|SMDDS1-Total Score|SMDDS126	Symptoms of Major Depressive Disorder Scale v1.0 (SMDDS Version 1.0) Total score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Code Terminology|CDISC Questionnaire SMDDS Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155646>	C101876	HAMA - Total Score|HAMA1-Total Score|HAMA1-Total Score|HAMA115	Hamilton Anxiety Rating Scale (HAMA) Total score.			Intellectual Product	CDISC Clinical Classification HAMA Test Code Terminology|CDISC Clinical Classification HAMA Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155647>	C9118	Sarcoma of the Extremity|Extremity Sarcoma|Primary Extremity Sarcoma|Primary Sarcoma of the Extremity	A sarcoma that arises from the soft tissues or bones of the upper or lower extremity.	Sarcoma of the Extremity		Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C155648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155648>	C155647|C148302	Recurrent Sarcoma of the Extremity|Recurrent Extremity Sarcoma	A sarcoma of the soft tissues or bones of the upper or lower extremity that has recurred after a period of remission.	Recurrent Sarcoma of the Extremity		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155649>	C155647|C153185	Advanced Sarcoma of the Extremity|Advanced Extremity Sarcoma	A sarcoma of the soft tissues or bones of the upper or lower extremity that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Sarcoma of the Extremity		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C15564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15564>	C15452	Prior Adjuvant Chemotherapy	Having received prior adjuvant chemotherapy.			Clinical Attribute	
C155651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155651>	C35996	Primitive Mesenchymal Stroma Formation	A morphologic finding indicating the presence of a primitive mesenchymal stroma in a tumor sample.			Finding	
C155652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155652>	C129825	Samuraciclib|CDK7 Inhibitor CT7001|CT 7001|CT-7001|CT7001|SAMURACICLIB	An orally available, selective inhibitor of cyclin-dependent kinase 7 (CDK7) with potential antineoplastic activity. Upon oral administration, samuraciclib selectively and competitively binds to the CDK7 ATP binding site, thereby inhibiting CDK7-mediated signaling. CDK7, a serine/threonine kinase, plays a role in controlling cell cycle progression, transcriptional regulation, and promotes the expression of key oncogenes such as c-Myc through the phosphorylation of RNA polymerase II. Inhibition of CDK7 may inhibit tumor cell proliferation in certain cancers that are dependent on CDK7-mediated transcriptional regulation and signaling.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155653>	C20401|C129822	Anti-GD2 Monoclonal Antibody|Anti-GD-2 Monoclonal Antibody	Any monoclonal antibody that is directed against the GD2 (GD-2) antigen.			Chemical Viewed Functionally	
C155654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155654>	C129822|C128057	Garivulimab|Anti-PD-L1 Monoclonal Antibody BGB-A333|BGB A333|BGB-A333|BGBA333|GARIVULIMAB	A humanized immunoglobulin G1 (IgG1)-variant monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, garivulimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. In addition, BGB-A333 blocks the interaction between PD-L1 and its other receptor, the immunostimulatory molecule cluster of differentiation 80 (CD80; B7-1). This prevents PD-L1/CD80 signaling and inhibits the induction of PD-L1-induced apoptosis of activated CD8+ T-cells and increases T-cell proliferation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on activated T-cells suppresses the immune system and results in immune evasion. PD-1 negatively regulates T-cell activation.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155655>	C142078	Plasmodium vivax-infected Red Blood Cell|P. vivax-infected RBCs|P. vivax-infected Red Blood Cells|Plasmodium vivax RBC Immunotherapy Agent	A preparation of red blood cells (RBCs) that have been infected with the malaria parasite Plasmodium vivax (P. vivax), with potential immunomodulating and antineoplastic activities. Upon administration of the P. vivax-infected RBCs, the P. vivax infection stimulates host immune responses against the P. vivax-infected RBCs. This also stimulates both innate and adaptive anti-tumor immune responses. This leads to the production of cytokines, including interferon-gamma (IFN-g) and tumor-necrosis factor alpha (TNF-a), the proliferation and activation of natural killer (NK) cells, dendritic cells (DCs), CD4-positive T-lymphocytes, and cytotoxic T-lymphocytes (CTLs). This results in the inhibition of tumor cell proliferation, induction of tumor cell apoptosis, and prevents angiogenesis.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology
C155656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155656>	C48181	Diagnostic DNA Methylation Signature|DDMS	A DNA methylation profile that indicates that the subject has a neoplastic disease. The profile also serves to identify the type and predict the severity of the disease.	Diagnostic DNA Methylation Signature		Functional Concept	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C155657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155657>	C28681|C154231|C129826	Autologous Cervical Cancer-specific Engineered Immune Effector Cells|Autologous CC-EIE Cells|Autologous CC-EIEs	A preparation of autologous immune effector cells genetically modified to target a not yet disclosed cervical cancer-specific tumor-associated antigen (TAA), with potential immunomodulating and antineoplastic activities. After isolation, transduction, expansion in culture, and reintroduction into the patient, the autologous cervical cancer-specific engineered immune effector (CC-EIE) cells bind to and induce selective toxicity in tumor cells expressing the TAA.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15565>	C16175	Prior Adjuvant Endocrine Therapy|Prior Adjuvant Endocrine/Hormonal Therapy|Prior Adjuvant Hormonal Therapy	An indication that an individual has been previously treated with endocrine/hormonal therapy following surgery.			Clinical Attribute	
C155664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155664>	C28681|C213868|C129826	Autologous Ovarian Cancer-specific Cytotoxic T-Lymphocytes|Autologous OC-CTLs|Autologous Ovarian Cancer-specific CTLs|OC-CTLs	A preparation of autologous cytotoxic T-lymphocytes (CTLs) genetically modified to target a not yet disclosed ovarian cancer-specific tumor-associated antigen (TAA), with potential immunomodulating and antineoplastic activities. After isolation, transduction, expansion in culture, and reintroduction into the patient, the autologous ovarian cancer-specific cytotoxic T-lymphocytes (OC-CTLs) bind to and induce selective toxicity in tumor cells expressing the TAA.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155665>	C80699	MIR27B Gene|MIR27B|MIR27B|MicroRNA 27b Gene	This gene may be involved in the negative regulation of CYP1B1 gene expression.			Gene or Genome	
C155666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155666>	C155665	MIR27B wt Allele|MIR-27b|MIRN27B|Micro RNA 27B Gene|MicroRNA 27b wt Allele|hsa-miR-27b|miRNA27B	Human MIR27B wild-type allele is located in the vicinity of 9q22.32 and is approximately 97 bases in length. This allele, which encodes MIR27B pre-miRNA, plays a role in the regulation of target gene expression. Downregulation of this gene may be associated with breast cancer and chronic lymphocytic leukemia.			Gene or Genome	
C155667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155667>	C25968	MIR27B Pre-miRNA|Pre-MIR27B|Pre-MicroRNA 27B|Pre-miRNA 27B|Pre-miRNA MIR27B|Pre-miRNA27B	MIR27B pre-miRNA (97 bases) is encoded by the human MIR27B gene. This ribonucleotide may be involved in the regulation of CYP1B1 gene transcription.			Nucleic Acid, Nucleoside, or Nucleotide	
C155668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155668>	C135718	NRAS NM_002524.4:c.34G>T|N-ras c.34G>T|NM_002524.4:c.34G>T|NRAS c.34G>T|NRAS1 c.34G>T|Neuroblastoma RAS Viral (v-ras) Oncogene Homolog c.34G>T	A nucleotide substitution at position 34 of the coding sequence of the NRAS gene where guanine has been mutated to thymine.	NRAS NM_002524.4:c.34G>T		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C155669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155669>	C107483	NRAS NP_002515.1:p.G12C|GTPase NRas G12C|GTPase NRas Gly12Cys|NP_002515.1:p.G12C|NP_002515.1:p.Gly12Cys|NRAS G12C|NRAS Gly12Cys|NRAS NP_002515.1:p.Gly12Cys|NRAS p.G12C|NRAS p.Gly12Cys|Transforming Protein N-Ras G12C|Transforming Protein N-Ras Gly12Cys	A change in the amino acid residue at position 12 in the GTPase NRas protein where glycine has been replaced by cysteine.	NRAS NP_002515.1:p.G12C		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15566>	C15446	Neoadjuvant Study	A study that focuses on evaluating treatments that are given as a first step to shrink a tumor before the main treatment, usually surgery, is given. Examples of neoadjuvant therapies studied include chemotherapy, radiation therapy, and hormone therapy.			Research Activity	
C155670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155670>	C135718	NRAS NM_002524.4:c.35G>A|N-ras c.35G>A|NM_002524.4:c.35G>A|NRAS G12D (c.35G>A) mutation|NRAS c.35G>A|NRAS1 c.35G>A|Neuroblastoma RAS Viral (v-ras) Oncogene Homolog c.35G>A	A nucleotide substitution at position 35 of the coding sequence of the NRAS gene where guanine has been mutated to adenine.	NRAS NM_002524.4:c.35G>A		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C155671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155671>	C107483	NRAS NP_002515.1:p.G12D|GTPase NRas G12D|GTPase NRas Gly12Asp|NP_002515.1:p.G12D|NP_002515.1:p.Gly12Asp|NRAS G12D|NRAS Gly12Asp|NRAS NP_002515.1:p.Gly12Asp|NRAS p.G12D|NRAS p.Gly12Asp|Transforming Protein N-Ras G12D|Transforming Protein N-Ras Gly12Asp	A change in the amino acid residue at position 12 in the GTPase NRas protein where glycine has been replaced by aspartic acid.	NRAS NP_002515.1:p.G12D		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C155672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155672>	C135718	NRAS NM_002524.4:c.34G>A|N-ras c.34G>A|NM_002524.4:c.34G>A|NRAS G12S (c.34G>A) mutation|NRAS c.34G>A|NRAS1 c.34G>A|Neuroblastoma RAS Viral (v-ras) Oncogene Homolog c.34G>A	A nucleotide substitution at position 34 of the coding sequence of the NRAS gene where guanine has been mutated to adenine.	NRAS NM_002524.4:c.34G>A		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C155673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155673>	C107483	NRAS NP_002515.1:p.G12S|GTPase NRas G12S|GTPase NRas Gly12Ser|NP_002515.1:p.G12S|NP_002515.1:p.Gly12Ser|NRAS G12S|NRAS G12S Mutation|NRAS Gly12Ser|NRAS NP_002515.1:p.Gly12Ser|NRAS p.G12S|NRAS p.Gly12Ser|Transforming Protein N-Ras G12S|Transforming Protein N-Ras Gly12Ser	A change in the amino acid residue at position 12 in the GTPase NRas protein where glycine has been replaced by serine.	NRAS NP_002515.1:p.G12S		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C155674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155674>	C135718	NRAS NM_002524.4:c.37G>C|N-ras c.37G>C|NM_002524.4:c.37G>C|NRAS G13R (c.37G>C) mutation|NRAS c.37G>C|NRAS1 c.37G>C|Neuroblastoma RAS Viral (v-ras) Oncogene Homolog c.37G>C	A nucleotide substitution at position 37 of the coding sequence of the NRAS gene where guanine has been mutated to cytosine.			Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C155675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155675>	C107484	NRAS NP_002515.1:p.G13R|GTPase NRas G13R|GTPase NRas Gly13Arg|NP_002515.1:p.G13R|NP_002515.1:p.Gly13Arg|NRAS G13R|NRAS Gly13Arg|NRAS NP_002515.1:p.Gly13Arg|NRAS p.G13R|NRAS p.Gly13Arg|Transforming Protein N-Ras G13R|Transforming Protein N-Ras Gly13Arg	A change in the amino acid residue at position 13 in the GTPase NRas protein where glycine has been replaced by arginine.			Cell or Molecular Dysfunction	
C155676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155676>	C135718	NRAS NM_002524.4:c.38G>T|N-ras c.38G>T|NM_002524.4:c.38G>T|NRAS c.38G>T|NRAS1 c.38G>T|Neuroblastoma RAS Viral (v-ras) Oncogene Homolog c.38G>T	A nucleotide substitution at position 38 of the coding sequence of the NRAS gene where guanine has been mutated to thymine.			Cell or Molecular Dysfunction	
C155677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155677>	C107484	NRAS NP_002515.1:p.G13V|GTPase NRas G13V|GTPase NRas Gly13Val|NP_002515.1:p.G13V|NP_002515.1:p.Gly13Val|NRAS G13V|NRAS Gly13Val|NRAS NP_002515.1:p.Gly13Val|NRAS p.G13V|NRAS p.Gly13Val|Transforming Protein N-Ras G13V|Transforming Protein N-Ras Gly13Val	A change in the amino acid residue at position 13 in the GTPase NRas protein where glycine has been replaced by valine.			Cell or Molecular Dysfunction	
C155678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155678>	C49236	Cytoreduction Treatment|Cytoreduction|Cytoreductive Effect	Any therapy designed to reduce the number of cells of a particular type or in a particular location.			Therapeutic or Preventive Procedure	
C155679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155679>	C155678	Cytoreductive Chemotherapy	Drug therapy designed to reduce the number of target cells.			Therapeutic or Preventive Procedure	
C15567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15567>	C15406	Screening for Gastric Cancer|early detection of gastric cancer|early detection of stomach cancer|gastric cancer early detection|gastric cancer screening|screening for stomach cancer|stomach cancer early detection|stomach cancer screening	Checking an individual for the presence or absence of gastric cancer.			Diagnostic Procedure	
C155680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155680>	C136635|C104673	KIT NM_000222.2:c.1924A>G|CD117 c.1924A>G|KIT K642E (c.1942A>G) mutation|KIT Proto-Oncogene Tyrosine Protein Kinase c.1924A>G|KIT c.1924A>G|NM_000222.2:c.1924A>G|c-KIT c.1924A>G|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.1924A>G	A nucleotide substitution at position 1924 of the coding sequence of the KIT gene where adenine has been mutated to guanine.	KIT NM_000222.2:c.1924A>G		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C155681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155681>	C126819	KIT NP_000213.1:p.K642E|CD117 Antigen K642E|CD117 Antigen Lys642Glu|KIT K642E|KIT Lys642Glu|KIT NP_000213.1:p.Lys642Glu|KIT p.K642E|KIT p.Lys642Glu|Mast/Stem Cell Growth Factor Receptor Kit K642E|Mast/Stem Cell Growth Factor Receptor Kit Lys642Glu|NP_000213.1:p.K642E|NP_000213.1:p.Lys642Glu|Proto-Oncogene Tyrosine-Protein Kinase Kit K642E|Proto-Oncogene Tyrosine-Protein Kinase Kit Lys642Glu|Proto-Oncogene c-Kit K642E|Proto-Oncogene c-Kit Lys642Glu|Stem Cell Factor Receptor K642E|Stem Cell Factor Receptor Lys642Glu|Tyrosine-Protein Kinase Kit K642E|Tyrosine-Protein Kinase Kit Lys642Glu|c-KIT K642E|c-KIT Lys642Glu|c-KIT p.K642E|c-KIT p.Lys642Glu	A change in the amino acid residue at position 642 in the mast/stem cell growth factor receptor Kit protein where lysine has been replaced by glutamic acid.	KIT NP_000213.1:p.K642E		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C155682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155682>	C136635|C104673	KIT NM_000222.2:c.1939C>T|CD117 c.1939C>T|KIT Proto-Oncogene Tyrosine Protein Kinase c.1939C>T|KIT c.1939C>T|NM_000222.2:c.1939C>T|c-KIT c.1939C>T|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.1939C>T	A nucleotide substitution at position 1939 of the coding sequence of the KIT gene where cytosine has been mutated to thymine.			Cell or Molecular Dysfunction	
C155683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155683>	C126819	KIT NP_000213.1:p.L647F|CD117 Antigen L647F|CD117 Antigen Leu647Phe|KIT L647F|KIT Leu647Phe|KIT NP_000213.1:p.Leu647Phe|KIT p.L647F|KIT p.Leu647Phe|Mast/Stem Cell Growth Factor Receptor Kit L647F|Mast/Stem Cell Growth Factor Receptor Kit Leu647Phe|NP_000213.1:p.L647F|NP_000213.1:p.Leu647Phe|Proto-Oncogene Tyrosine-Protein Kinase Kit L647F|Proto-Oncogene Tyrosine-Protein Kinase Kit Leu647Phe|Proto-Oncogene c-Kit L647F|Proto-Oncogene c-Kit Leu647Phe|Stem Cell Factor Receptor L647F|Stem Cell Factor Receptor Leu647Phe|Tyrosine-Protein Kinase Kit L647F|Tyrosine-Protein Kinase Kit Leu647Phe|c-KIT L647F|c-KIT Leu647Phe|c-KIT p.L647F|c-KIT p.Leu647Phe	A change in the amino acid residue at position 647 in the mast/stem cell growth factor receptor Kit protein where leucine has been replaced by phenylalanine.			Cell or Molecular Dysfunction	
C155684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155684>	C126819	KIT NP_000213.1:p.G648D|CD117 Antigen G648D|CD117 Antigen Gly648Asp|KIT G648D|KIT Gly648Asp|KIT NP_000213.1:p.Gly648Asp|KIT p.G648D|KIT p.Gly648Asp|Mast/Stem Cell Growth Factor Receptor Kit G648D|Mast/Stem Cell Growth Factor Receptor Kit Gly648Asp|NP_000213.1:p.G648D|NP_000213.1:p.Gly648Asp|Proto-Oncogene Tyrosine-Protein Kinase Kit G648D|Proto-Oncogene Tyrosine-Protein Kinase Kit Gly648Asp|Proto-Oncogene c-Kit G648D|Proto-Oncogene c-Kit Gly648Asp|Stem Cell Factor Receptor G648D|Stem Cell Factor Receptor Gly648Asp|Tyrosine-Protein Kinase Kit G648D|Tyrosine-Protein Kinase Kit Gly648Asp|c-KIT G648D|c-KIT Gly648Asp|c-KIT p.G648D|c-KIT p.Gly648Asp	A change in the amino acid residue at position 648 in the mast/stem cell growth factor receptor Kit protein where glycine has been replaced by aspartic acid.			Cell or Molecular Dysfunction	
C155685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155685>	C136635|C104673	KIT NM_000222.2:c.1958T>C|CD117 c.1958T>C|KIT Proto-Oncogene Tyrosine Protein Kinase c.1958T>C|KIT c.1958T>C|NM_000222.2:c.1958T>C|c-KIT c.1958T>C|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.1958T>C	A nucleotide substitution at position 1958 of the coding sequence of the KIT gene where thymine has been mutated to cytosine.			Cell or Molecular Dysfunction	
C155686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155686>	C126819	KIT NP_000213.1:p.I653T|CD117 Antigen I653T|CD117 Antigen Ile653Thr|KIT I653T|KIT Ile653Thr|KIT NP_000213.1:p.Ile653Thr|KIT p.I653T|KIT p.Ile653Thr|Mast/Stem Cell Growth Factor Receptor Kit I653T|Mast/Stem Cell Growth Factor Receptor Kit Ile653Thr|NP_000213.1:p.I653T|NP_000213.1:p.Ile653Thr|Proto-Oncogene Tyrosine-Protein Kinase Kit I653T|Proto-Oncogene Tyrosine-Protein Kinase Kit Ile653Thr|Proto-Oncogene c-Kit I653T|Proto-Oncogene c-Kit Ile653Thr|Stem Cell Factor Receptor I653T|Stem Cell Factor Receptor Ile653Thr|Tyrosine-Protein Kinase Kit I653T|Tyrosine-Protein Kinase Kit Ile653Thr|c-KIT I653T|c-KIT Ile653Thr|c-KIT p.I653T|c-KIT p.Ile653Thr	A change in the amino acid residue at position 653 in the mast/stem cell growth factor receptor Kit protein where isoleucine has been replaced by threonine.			Cell or Molecular Dysfunction	
C155687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155687>	C210950|C104673	KIT NM_000222.2:c.1961T>C|CD117 c.1961T>C|KIT Proto-Oncogene Tyrosine Protein Kinase c.1961T>C|KIT c.1961T>C|NM_000222.2:c.1961T>C|c-KIT c.1961T>C|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.1961T>C	A nucleotide substitution at position 1961 of the coding sequence of the KIT gene where thymine has been mutated to cytosine.	KIT NM_000222.2:c.1961T>C		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C155688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155688>	C126819	KIT NP_000213.1:p.V654A|CD117 Antigen V654A|CD117 Antigen Val654Ala|KIT NP_000213.1:p.Val654Ala|KIT V654A|KIT Val654Ala|KIT p.V654A|KIT p.Val654Ala|Mast/Stem Cell Growth Factor Receptor Kit V654A|Mast/Stem Cell Growth Factor Receptor Kit Val654Ala|NP_000213.1:p.V654A|NP_000213.1:p.Val654Ala|Proto-Oncogene Tyrosine-Protein Kinase Kit V654A|Proto-Oncogene Tyrosine-Protein Kinase Kit Val654Ala|Proto-Oncogene c-Kit V654A|Proto-Oncogene c-Kit Val654Ala|Stem Cell Factor Receptor V654A|Stem Cell Factor Receptor Val654Ala|Tyrosine-Protein Kinase Kit V654A|Tyrosine-Protein Kinase Kit Val654Ala|c-KIT V654A|c-KIT Val654Ala|c-KIT p.V654A|c-KIT p.Val654Ala	A change in the amino acid residue at position 654 in the mast/stem cell growth factor receptor Kit protein where valine has been replaced by alanine.	KIT NP_000213.1:p.V654A		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15568>	C15510	Antiangiogenesis Therapy|Angiogenesis Inhibition|Anti-Angiogenesis|Antiangiogenesis|antiangiogenesis	A therapeutic regimen that uses synthetic compounds or natural substances to prevent the development of new blood vessels.			Therapeutic or Preventive Procedure	
C155690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155690>	C126819	KIT NP_000213.1:p.L813P|CD117 Antigen L813P|CD117 Antigen Leu813Pro|KIT L813P|KIT Leu813Pro|KIT NP_000213.1:p.Leu813Pro|KIT p.L813P|KIT p.Leu813Pro|Mast/Stem Cell Growth Factor Receptor Kit L813P|Mast/Stem Cell Growth Factor Receptor Kit Leu813Pro|NP_000213.1:p.L813P|NP_000213.1:p.Leu813Pro|Proto-Oncogene Tyrosine-Protein Kinase Kit L813P|Proto-Oncogene Tyrosine-Protein Kinase Kit Leu813Pro|Proto-Oncogene c-Kit L813P|Proto-Oncogene c-Kit Leu813Pro|Stem Cell Factor Receptor L813P|Stem Cell Factor Receptor Leu813Pro|Tyrosine-Protein Kinase Kit L813P|Tyrosine-Protein Kinase Kit Leu813Pro|c-KIT L813P|c-KIT Leu813Pro|c-KIT p.L813P|c-KIT p.Leu813Pro	A change in the amino acid residue at position 813 in the mast/stem cell growth factor receptor Kit protein where leucine has been replaced by proline.			Cell or Molecular Dysfunction	
C155691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155691>	C84361	Queer|QUEER	Used to describe a sexual orientation that is not exclusively homosexual or heterosexual. IMPORTANT NOTICE: The NCI Thesaurus contains biomedical terminologies that NCI does not own or control. This concept contains gender-related content that does not comply with Executive Order 14168.			Organism Attribute	CDISC SDTM Sexual Orientation Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155692>	C84361	Questioning	Used to describe an individual who is unsure of their sexual orientation.			Organism Attribute	
C155693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155693>	C126819	KIT NP_000213.1:p.K818Q|CD117 Antigen K818Q|CD117 Antigen Lys818Gln|KIT K818Q|KIT Lys818Gln|KIT NP_000213.1:p.Lys818Gln|KIT p.K818Q|KIT p.Lys818Gln|Mast/Stem Cell Growth Factor Receptor Kit K818Q|Mast/Stem Cell Growth Factor Receptor Kit Lys818Gln|NP_000213.1:p.K818Q|NP_000213.1:p.Lys818Gln|Proto-Oncogene Tyrosine-Protein Kinase Kit K818Q|Proto-Oncogene Tyrosine-Protein Kinase Kit Lys818Gln|Proto-Oncogene c-Kit K818Q|Proto-Oncogene c-Kit Lys818Gln|Stem Cell Factor Receptor K818Q|Stem Cell Factor Receptor Lys818Gln|Tyrosine-Protein Kinase Kit K818Q|Tyrosine-Protein Kinase Kit Lys818Gln|c-KIT K818Q|c-KIT Lys818Gln|c-KIT p.K818Q|c-KIT p.Lys818Gln	A change in the amino acid residue at position 818 in the mast/stem cell growth factor receptor Kit protein where lysine has been replaced by glutamine.			Cell or Molecular Dysfunction	
C155694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155694>	C84363	Lesbian|Female Homosexual|LESBIAN	A woman whose physical, emotional, or romantic attraction is to other women.			Organism Attribute	CDISC SDTM Sexual Orientation Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155696>	C84361	Asexual|ASEXUAL|Asexuality|Sexually attracted to neither male nor female sex	Used to describe an individual who does not experience sexual attraction.			Organism Attribute	CDISC SDTM Sexual Orientation Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C155697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155697>	C28398|C122441	Counselor	A person with training to provide advice or instruction.			Occupation or Discipline	
C155698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155698>	C153315|C153278|C148130	Locally Advanced Unresectable Carcinoma	A carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.			Neoplastic Process	
C155699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155699>	C213704|C168995|C154545	Locally Advanced Unresectable Renal Cell Carcinoma	A renal cell carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.			Neoplastic Process	
C15569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15569>	C20985|C15536	Bone Marrow Ablation|bone marrow ablation	The destruction of bone marrow using radiation or drugs.			Therapeutic or Preventive Procedure	
C1556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1556>	C272	Purine Antagonist|Purine Inhibitors	An antimetabolite that affects the metabolism and utilization of purines.			Chemical Viewed Functionally	
C155700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155700>	C1967|C129825	BCR-ABL Inhibitor|BCR-ABL Tyrosine Kinase Inhibitor	Any agent that inhibits the tyrosine kinase BCR-ABL.	BCR-ABL Inhibitor		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C155701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155701>	C136635|C116396	KIT NM_000222.2:c.2458G>T|CD117 c.2458G>T|KIT Proto-Oncogene Tyrosine Protein Kinase c.2458G>T|KIT c.2458G>T|NM_000222.2:c.2458G>T|c-KIT c.2458G>T|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.2458G>T	A nucleotide substitution at position 2458 of the coding sequence of the KIT gene where guanine has been mutated to thymine.			Cell or Molecular Dysfunction	
C155702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155702>	C126819	KIT NP_000213.1:p.D820Y|CD117 Antigen Asp820Tyr|CD117 Antigen D820Y|KIT Asp820Tyr|KIT D820Y|KIT NP_000213.1:p.Asp820Tyr|KIT p.Asp820Tyr|KIT p.D820Y|Mast/Stem Cell Growth Factor Receptor Kit Asp820Tyr|Mast/Stem Cell Growth Factor Receptor Kit D820Y|NP_000213.1:p.Asp820Tyr|NP_000213.1:p.D820Y|Proto-Oncogene Tyrosine-Protein Kinase Kit Asp820Tyr|Proto-Oncogene Tyrosine-Protein Kinase Kit D820Y|Proto-Oncogene c-Kit Asp820Tyr|Proto-Oncogene c-Kit D820Y|Stem Cell Factor Receptor Asp820Tyr|Stem Cell Factor Receptor D820Y|Tyrosine-Protein Kinase Kit Asp820Tyr|Tyrosine-Protein Kinase Kit D820Y|c-KIT Asp820Tyr|c-KIT D820Y|c-KIT p.Asp820Tyr|c-KIT p.D820Y	A change in the amino acid residue at position 820 in the mast/stem cell growth factor receptor Kit protein where aspartic acid has been replaced by tyrosine.			Cell or Molecular Dysfunction	
C155703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155703>	C136635|C116396	KIT NM_000222.2:c.2466T>R|CD117 c.2466T>R|KIT Proto-Oncogene Tyrosine Protein Kinase c.2466T>R|KIT c.2466T>R|NM_000222.2:c.2466T>R|c-KIT c.2466T>R|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.2466T>R	A nucleotide substitution at position 2466 of the coding sequence of the KIT gene where thymine has been mutated to any purine (adenine or guanine).			Cell or Molecular Dysfunction	
C155704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155704>	C126819	KIT NP_000213.1:p.N822K|CD117 Antigen Asn822Lys|CD117 Antigen N822K|KIT Asn822Lys|KIT N822K|KIT NP_000213.1:p.Asn822Lys|KIT p.Asn822Lys|KIT p.N822K|Mast/Stem Cell Growth Factor Receptor Kit Asn822Lys|Mast/Stem Cell Growth Factor Receptor Kit N822K|NP_000213.1:p.Asn822Lys|NP_000213.1:p.N822K|Proto-Oncogene Tyrosine-Protein Kinase Kit Asn822Lys|Proto-Oncogene Tyrosine-Protein Kinase Kit N822K|Proto-Oncogene c-Kit Asn822Lys|Proto-Oncogene c-Kit N822K|Stem Cell Factor Receptor Asn822Lys|Stem Cell Factor Receptor N822K|Tyrosine-Protein Kinase Kit Asn822Lys|Tyrosine-Protein Kinase Kit N822K|c-KIT Asn822Lys|c-KIT N822K|c-KIT p.Asn822Lys|c-KIT p.N822K	A change in the amino acid residue at position 822 in the mast/stem cell growth factor receptor Kit protein where asparagine has been replaced by lysine.			Cell or Molecular Dysfunction	
C155705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155705>	C155703	KIT NM_000222.2:c.2466T>G|CD117 c.2466T>G|KIT Proto-Oncogene Tyrosine Protein Kinase c.2466T>G|KIT c.2466T>G|NM_000222.2:c.2466T>G|c-KIT c.2466T>G|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.2466T>G	A nucleotide substitution at position 2466 of the coding sequence of the KIT gene where thymine has been mutated to guanine.			Cell or Molecular Dysfunction	
C155706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155706>	C155703	KIT NM_000222.2:c.2466T>A|CD117 c.2466T>A|KIT Proto-Oncogene Tyrosine Protein Kinase c.2466T>A|KIT c.2466T>A|NM_000222.2:c.2466T>A|c-KIT c.2466T>A|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.2466T>A	A nucleotide substitution at position 2466 of the coding sequence of the KIT gene where thymine has been mutated to adenine.			Cell or Molecular Dysfunction	
C155707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155707>	C136635|C116396	KIT NM_000222.2:c.2464A>T|CD117 c.2464A>T|KIT Proto-Oncogene Tyrosine Protein Kinase c.2464A>T|KIT c.2464A>T|NM_000222.2:c.2464A>T|c-KIT c.2464A>T|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.2464A>T	A nucleotide substitution at position 2464 of the coding sequence of the KIT gene where adenine has been mutated to thymine.			Cell or Molecular Dysfunction	
C155708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155708>	C126819	KIT NP_000213.1:p.N822Y|CD117 Antigen Asn822Tyr|CD117 Antigen N822Y|KIT Asn822Tyr|KIT N822Y|KIT NP_000213.1:p.Asn822Tyr|KIT p.Asn822Tyr|KIT p.N822Y|Mast/Stem Cell Growth Factor Receptor Kit Asn822Tyr|Mast/Stem Cell Growth Factor Receptor Kit N822Y|NP_000213.1:p.Asn822Tyr|NP_000213.1:p.N822Y|Proto-Oncogene Tyrosine-Protein Kinase Kit Asn822Tyr|Proto-Oncogene Tyrosine-Protein Kinase Kit N822Y|Proto-Oncogene c-Kit Asn822Tyr|Proto-Oncogene c-Kit N822Y|Stem Cell Factor Receptor Asn822Tyr|Stem Cell Factor Receptor N822Y|Tyrosine-Protein Kinase Kit Asn822Tyr|Tyrosine-Protein Kinase Kit N822Y|c-KIT Asn822Tyr|c-KIT N822Y|c-KIT p.Asn822Tyr|c-KIT p.N822Y	A change in the amino acid residue at position 822 in the mast/stem cell growth factor receptor Kit protein where asparagine has been replaced by tyrosine.			Cell or Molecular Dysfunction	
C155709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155709>	C153251|C136635	KIT NM_000222.2:c.2485G>C|CD117 c.2485G>C|KIT Proto-Oncogene Tyrosine Protein Kinase c.2485G>C|KIT c.2485G>C|NM_000222.2:c.2485G>C|c-KIT c.2485G>C|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.2485G>C	A nucleotide substitution at position 2485 of the coding sequence of the KIT gene where guanine has been mutated to cytosine.			Cell or Molecular Dysfunction	
C15570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15570>	C15747	Pressor Support	The use of vasopressor agents to elevate arterial blood pressure.			Therapeutic or Preventive Procedure	
C155710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155710>	C126819	KIT NP_000213.1:p.A829P|CD117 Antigen A829P|CD117 Antigen Ala829Pro|KIT A829P|KIT Ala829Pro|KIT NP_000213.1:p.Ala829Pro|KIT p.A829P|KIT p.Ala829Pro|Mast/Stem Cell Growth Factor Receptor Kit A829P|Mast/Stem Cell Growth Factor Receptor Kit Ala829Pro|NP_000213.1:p.A829P|NP_000213.1:p.Ala829Pro|Proto-Oncogene Tyrosine-Protein Kinase Kit A829P|Proto-Oncogene Tyrosine-Protein Kinase Kit Ala829Pro|Proto-Oncogene c-Kit A829P|Proto-Oncogene c-Kit Ala829Pro|Stem Cell Factor Receptor A829P|Stem Cell Factor Receptor Ala829Pro|Tyrosine-Protein Kinase Kit A829P|Tyrosine-Protein Kinase Kit Ala829Pro|c-KIT A829P|c-KIT Ala829Pro|c-KIT p.A829P|c-KIT p.Ala829Pro	A change in the amino acid residue at position 829 in the mast/stem cell growth factor receptor Kit protein where alanine has been replaced by proline.			Cell or Molecular Dysfunction	
C155711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155711>	C20401|C163760|C129822	Anti-HER2 Monoclonal Antibody|Anti-ErbB2 Monoclonal Antibody|Anti-HER-2 Monoclonal Antibody	Any monoclonal antibody that is directed against human epidermal growth factor receptor 2 (HER2; HER-2; ERBB2).	Anti-HER2 Monoclonal Antibody		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155712>	C163760|C129823	Anti-HER2 Antibody-drug Conjugate|Anti-ErbB2 ADC|Anti-HER-2 ADC|Anti-HER2 ADC	Any antibody-drug conjugate (ADC) that is directed against the human epidermal growth factor receptor 2 (HER2; HER-2; ERBB2).	Anti-HER2 Antibody-drug Conjugate		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C155713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155713>	C129823	Anti-CD22 Antibody-drug Conjugate	An antibody-drug conjugate (ADC) directed against the CD22 antigen.			Chemical Viewed Functionally	
C155714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155714>	C153251|C136635	KIT NM_000222.2:c.2492T>C|CD117 c.2492T>C|KIT Proto-Oncogene Tyrosine Protein Kinase c.2492T>C|KIT c.2492T>C|NM_000222.2:c.2492T>C|c-KIT c.2492T>C|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.2492T>C	A nucleotide substitution at position 2492 of the coding sequence of the KIT gene where thymine has been mutated to cytosine.			Cell or Molecular Dysfunction	
C155715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155715>	C126819	KIT NP_000213.1:p.L831P|CD117 Antigen L831P|CD117 Antigen Leu831Pro|KIT L831P|KIT Leu831Pro|KIT NP_000213.1:p.Leu831Pro|KIT p.L831P|KIT p.Leu831Pro|Mast/Stem Cell Growth Factor Receptor Kit L831P|Mast/Stem Cell Growth Factor Receptor Kit Leu831Pro|NP_000213.1:p.L831P|NP_000213.1:p.Leu831Pro|Proto-Oncogene Tyrosine-Protein Kinase Kit L831P|Proto-Oncogene Tyrosine-Protein Kinase Kit Leu831Pro|Proto-Oncogene c-Kit L831P|Proto-Oncogene c-Kit Leu831Pro|Stem Cell Factor Receptor L831P|Stem Cell Factor Receptor Leu831Pro|Tyrosine-Protein Kinase Kit L831P|Tyrosine-Protein Kinase Kit Leu831Pro|c-KIT L831P|c-KIT Leu831Pro|c-KIT p.L831P|c-KIT p.Leu831Pro	A change in the amino acid residue at position 831 in the mast/stem cell growth factor receptor Kit protein where leucine has been replaced by proline.			Cell or Molecular Dysfunction	
C155716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155716>	C126819	KIT NP_000213.1:p.S840I|CD117 Antigen S840I|CD117 Antigen Ser840Ile|KIT NP_000213.1:p.Ser840Ile|KIT S840I|KIT Ser840Ile|KIT p.S840I|KIT p.Ser840Ile|Mast/Stem Cell Growth Factor Receptor Kit S840I|Mast/Stem Cell Growth Factor Receptor Kit Ser840Ile|NP_000213.1:p.S840I|NP_000213.1:p.Ser840Ile|Proto-Oncogene Tyrosine-Protein Kinase Kit S840I|Proto-Oncogene Tyrosine-Protein Kinase Kit Ser840Ile|Proto-Oncogene c-Kit S840I|Proto-Oncogene c-Kit Ser840Ile|Stem Cell Factor Receptor S840I|Stem Cell Factor Receptor Ser840Ile|Tyrosine-Protein Kinase Kit S840I|Tyrosine-Protein Kinase Kit Ser840Ile|c-KIT S840I|c-KIT Ser840Ile|c-KIT p.S840I|c-KIT p.Ser840Ile	A change in the amino acid residue at position 840 in the mast/stem cell growth factor receptor Kit protein where serine has been replaced by isoleucine.			Cell or Molecular Dysfunction	
C155717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155717>	C153251|C136635	KIT NM_000222.2:c.2537A>G|CD117 c.2537A>G|KIT Proto-Oncogene Tyrosine Protein Kinase c.2537A>G|KIT c.2537A>G|NM_000222.2:c.2537A>G|c-KIT c.2537A>G|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.2537A>G	A nucleotide substitution at position 2537 of the coding sequence of the KIT gene where adenine has been mutated to guanine.			Cell or Molecular Dysfunction	
C155718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155718>	C126819	KIT NP_000213.1:p.Y846C|CD117 Antigen Tyr846Cys|CD117 Antigen Y846C|KIT NP_000213.1:p.Tyr846Cys|KIT Tyr846Cys|KIT Y846C|KIT p.Tyr846Cys|KIT p.Y846C|Mast/Stem Cell Growth Factor Receptor Kit Tyr846Cys|Mast/Stem Cell Growth Factor Receptor Kit Y846C|NP_000213.1:p.Tyr846Cys|NP_000213.1:p.Y846C|Proto-Oncogene Tyrosine-Protein Kinase Kit Tyr846Cys|Proto-Oncogene Tyrosine-Protein Kinase Kit Y846C|Proto-Oncogene c-Kit Tyr846Cys|Proto-Oncogene c-Kit Y846C|Stem Cell Factor Receptor Tyr846Cys|Stem Cell Factor Receptor Y846C|Tyrosine-Protein Kinase Kit Tyr846Cys|Tyrosine-Protein Kinase Kit Y846C|c-KIT Tyr846Cys|c-KIT Y846C|c-KIT p.Tyr846Cys|c-KIT p.Y846C	A change in the amino acid residue at position 846 in the mast/stem cell growth factor receptor Kit protein where tyrosine has been replaced by cysteine.			Cell or Molecular Dysfunction	
C155719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155719>	C126819	KIT NP_000213.1:p.S850G|CD117 Antigen S850G|CD117 Antigen Ser850Gly|KIT NP_000213.1:p.Ser850Gly|KIT S850G|KIT Ser850Gly|KIT p.S850G|KIT p.Ser850Gly|Mast/Stem Cell Growth Factor Receptor Kit S850G|Mast/Stem Cell Growth Factor Receptor Kit Ser850Gly|NP_000213.1:p.S850G|NP_000213.1:p.Ser850Gly|Proto-Oncogene Tyrosine-Protein Kinase Kit S850G|Proto-Oncogene Tyrosine-Protein Kinase Kit Ser850Gly|Proto-Oncogene c-Kit S850G|Proto-Oncogene c-Kit Ser850Gly|Stem Cell Factor Receptor S850G|Stem Cell Factor Receptor Ser850Gly|Tyrosine-Protein Kinase Kit S850G|Tyrosine-Protein Kinase Kit Ser850Gly|c-KIT S850G|c-KIT Ser850Gly|c-KIT p.S850G|c-KIT p.Ser850Gly	A change in the amino acid residue at position 850 in the mast/stem cell growth factor receptor Kit protein where serine has been replaced by glycine.			Cell or Molecular Dysfunction	
C15571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15571>	C49236	Differentiation Therapy|therapy, differentiation	Drug therapy aimed at forcing cancer cells to resume the process of maturation and therefore to induce tumor to a more differentiated, less aggressive state. Differentiation therapy restrains cancer cells growth and facilitates the application of more conventional therapies.			Therapeutic or Preventive Procedure	
C155720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155720>	C153251|C136635	KIT NM_000222.2:c.2554G>A|CD117 c.2554G>A|KIT Proto-Oncogene Tyrosine Protein Kinase c.2554G>A|KIT c.2554G>A|NM_000222.2:c.2554G>A|c-KIT c.2554G>A|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.2554G>A	A nucleotide substitution at position 2554 of the coding sequence of the KIT gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C155721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155721>	C126819	KIT NP_000213.1:p.V852I|CD117 Antigen V852I|CD117 Antigen Val852Ile|KIT NP_000213.1:p.Val852Ile|KIT V852I|KIT Val852Ile|KIT p.V852I|KIT p.Val852Ile|Mast/Stem Cell Growth Factor Receptor Kit V852I|Mast/Stem Cell Growth Factor Receptor Kit Val852Ile|NP_000213.1:p.V852I|NP_000213.1:p.Val852Ile|Proto-Oncogene Tyrosine-Protein Kinase Kit V852I|Proto-Oncogene Tyrosine-Protein Kinase Kit Val852Ile|Proto-Oncogene c-Kit V852I|Proto-Oncogene c-Kit Val852Ile|Stem Cell Factor Receptor V852I|Stem Cell Factor Receptor Val852Ile|Tyrosine-Protein Kinase Kit V852I|Tyrosine-Protein Kinase Kit Val852Ile|c-KIT V852I|c-KIT Val852Ile|c-KIT p.V852I|c-KIT p.Val852Ile	A change in the amino acid residue at position 852 in the mast/stem cell growth factor receptor Kit protein where valine has been replaced by isoleucine.			Cell or Molecular Dysfunction	
C155722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155722>	C153251|C136635	KIT NM_000222.2:c.2576T>C|CD117 c.2576T>C|KIT Proto-Oncogene Tyrosine Protein Kinase c.2576T>C|KIT c.2576T>C|NM_000222.2:c.2576T>C|c-KIT c.2576T>C|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.2576T>C	A nucleotide substitution at position 2576 of the coding sequence of the KIT gene where thymine has been mutated to cytosine.			Cell or Molecular Dysfunction	
C155723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155723>	C126819	KIT NP_000213.1:p.L859P|CD117 Antigen L859P|CD117 Antigen Leu859Pro|KIT L859P|KIT Leu859Pro|KIT NP_000213.1:p.Leu859Pro|KIT p.L859P|KIT p.Leu859Pro|Mast/Stem Cell Growth Factor Receptor Kit L859P|Mast/Stem Cell Growth Factor Receptor Kit Leu859Pro|NP_000213.1:p.L859P|NP_000213.1:p.Leu859Pro|Proto-Oncogene Tyrosine-Protein Kinase Kit L859P|Proto-Oncogene Tyrosine-Protein Kinase Kit Leu859Pro|Proto-Oncogene c-Kit L859P|Proto-Oncogene c-Kit Leu859Pro|Stem Cell Factor Receptor L859P|Stem Cell Factor Receptor Leu859Pro|Tyrosine-Protein Kinase Kit L859P|Tyrosine-Protein Kinase Kit Leu859Pro|c-KIT L859P|c-KIT Leu859Pro|c-KIT p.L859P|c-KIT p.Leu859Pro	A change in the amino acid residue at position 859 in the mast/stem cell growth factor receptor Kit protein where leucine has been replaced by proline.			Cell or Molecular Dysfunction	
C155724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155724>	C126819	KIT NP_000213.1:p.L862P|CD117 Antigen L862P|CD117 Antigen Leu862Pro|KIT L862P|KIT Leu862Pro|KIT NP_000213.1:p.Leu862Pro|KIT p.L862P|KIT p.Leu862Pro|Mast/Stem Cell Growth Factor Receptor Kit L862P|Mast/Stem Cell Growth Factor Receptor Kit Leu862Pro|NP_000213.1:p.L862P|NP_000213.1:p.Leu862Pro|Proto-Oncogene Tyrosine-Protein Kinase Kit L862P|Proto-Oncogene Tyrosine-Protein Kinase Kit Leu862Pro|Proto-Oncogene c-Kit L862P|Proto-Oncogene c-Kit Leu862Pro|Stem Cell Factor Receptor L862P|Stem Cell Factor Receptor Leu862Pro|Tyrosine-Protein Kinase Kit L862P|Tyrosine-Protein Kinase Kit Leu862Pro|c-KIT L862P|c-KIT Leu862Pro|c-KIT p.L862P|c-KIT p.Leu862Pro	A change in the amino acid residue at position 862 in the mast/stem cell growth factor receptor Kit protein where leucine has been replaced by proline.			Cell or Molecular Dysfunction	
C155725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155725>	C188731	Smoothened Antagonist|SMO Antagonist|Smoothened Receptor Antagonist	Any agent that is an antagonist at the Smoothened (SMO) receptor.			Chemical Viewed Functionally	Pediatric Oncology Target Genes/Proteins Terminology
C155726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155726>	C3824	Lesion of the Cervix Uteri|Cervical Lesion	A localized pathological or traumatic structural change, damage, deformity, or discontinuity of the cervix uteri.			Finding	
C155727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155727>	C1967|C164035|C129825	FGFR Inhibitor|Fibroblast Growth Factor Receptor Inhibitor	Any agent that inhibits the fibroblast growth factor receptor (FGFR).			Chemical Viewed Functionally	
C155729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155729>	C20420	ZBTB33 Gene|ZBTB33|ZBTB33|Zinc Finger And BTB Domain Containing 33 Gene	This gene plays a role in the regulation of both gene transcription and signal transduction.			Gene or Genome	
C15572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15572>	C15669	Prevention of Prostate Cancer|Prostate Cancer Prevention	Any method of preventing prostate cancer including limiting of exposure to carcinogens and infectious agents, diet, education, or lifestyle.			Therapeutic or Preventive Procedure	
C155730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155730>	C155729	ZBTB33 wt Allele|KAISO|WUGSC:H_DJ525N14.1|ZNF-kaiso|ZNF348|Zinc Finger And BTB Domain Containing 33 wt Allele	Human ZBTB33 wild-type allele is located in the vicinity of Xq24 and is approximately 8 kb in length. This allele, which encodes transcriptional regulator Kaiso protein, is involved in transcriptional regulation, signaling and DNA binding.			Gene or Genome	
C155731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155731>	C17207	Transcriptional Regulator Kaiso|Kaiso Transcription Factor|ZBTB33|Zinc Finger and BTB Domain-Containing Protein 33|Zinc Finger- and BTB Domain-Containing Protein 33	Transcriptional regulator Kaiso (672 aa, ~74 kDa) is encoded by the human ZBTB33 gene. This protein plays a role in DNA binding, transcriptional regulation, chromatin modification and signal pathway regulation.			Amino Acid, Peptide, or Protein	
C155732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155732>	C20194	LINC00598 Gene|LINC00598|LINC00598|Long Intergenic Non-Protein Coding RNA 598 Gene	This gene may be involved in breast cancer and leukemia.			Gene or Genome	
C155733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155733>	C155732	LINC00598 wt Allele|FLJ21437|LIN00598|LOC646982|LncFOXO1|Long Intergenic Non-Protein Coding RNA 598 wt Allele|TTL|TTL-B1|TTL-B2|TTL-T|Twelve-Thirteen Translocation Leukemia Transcript (Non-Protein Coding) Gene	Human LINC00598 wild-type allele is located in the vicinity of 13q14.11 and is approximately 457 kb in length. This allele, which encodes long intergenic non-protein coding RNA 598, may play a role in tumorigenesis. A translocation t(12;13)(p13;q14) involving this gene and the ETV6 gene is associated with B-cell acute lymphoblastic leukemia.			Gene or Genome	
C155734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155734>	C88924	Long Intergenic Non-Protein Coding RNA 598|LINC00598|LncFOXO1|TTL|Twelve-Thirteen Translocation Leukemia Transcript	Long intergenic non-protein coding RNA 598 (~2-4 kb) is encoded by the human LINC00598 gene. This non-coding RNA may be involved in tumorigenesis.			Nucleic Acid, Nucleoside, or Nucleotide	
C155735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155735>	C154302	H3Y2 Gene|H3.X|H3.Y Histone 2 Gene|H3Y2	This gene may play a role in chromatin structure and transcriptional regulation.			Gene or Genome	
C155736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155736>	C154302	H3Y1 Gene|H3.Y|H3.Y Histone 1 Gene|H3Y1	This gene may be involved in both nucleosome formation and transcriptional regulation.			Gene or Genome	
C155737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155737>	C155736	H3Y1 wt Allele|H3 Histone, Family 3B (H3.3B) Pseudogene Gene|H3.Y|H3.Y Histone 1 wt Allele|H3.Y.1|Histone Cluster 2, H3c Pseudogene Gene|LOC391769	Human H3Y1 wild-type allele is located in the vicinity of 5p15.1 and is approximately 0.9 kb in length. This allele, which encodes histone H3.Y protein, may play a role in the chromatin structure and transcriptional regulation.			Gene or Genome	
C155738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155738>	C16685	Histone H3.Y|H3.Y|H3.Y|H3.Y.1|H3Y1|Histone H3.Y.1|Histone H3.Y1|Histone H3.y	Histone H3.Y (136 aa, ~15 kDa) is encoded by the human H3Y1 gene. This protein may be involved in both the positive regulation of transcription and the formation of higher order chromatin structures.			Amino Acid, Peptide, or Protein	GDC Terminology|GDC Value Terminology
C155739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155739>	C70950	No Lower Limit|No Lower Limit of Normal	A lower limit of the normal range does not exist.			Intellectual Product	
C15573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15573>	C15545	Tumor-Draining Lymph Node Lymphocyte Therapy|TDLN-LCT	The use of lymphocytes isolated from tumor-draining lymph nodes for adoptive cell therapy.			Therapeutic or Preventive Procedure	
C155740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155740>	C25162	CPT Category III Codes|CPT Category III|Temporary Current Procedural Terminology Codes	Codes for tracking the use of emerging technology, services, and procedures provided by the American Medical Association as part of their Current Procedural Terminology.			Intellectual Product	
C155741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155741>	C43361	Codabar|Code-a-bar	A linear barcode symbology developed in 1972 by Pitney Bowes Corp.			Intellectual Product	
C155742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155742>	C8294|C7626|C159565	Recurrent Pancreatic Adenocarcinoma	The reemergence of pancreatic adenocarcinoma after a period of remission.	Recurrent Pancreatic Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155743>	C202500|C162016|C156269	Locally Advanced Unresectable Pancreatic Adenocarcinoma	A pancreatic adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.	Locally Advanced Unresectable Pancreatic Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155744>	C42761	Range Start-End Unit Format|Range Start End Unit|Range Start-End Unit	A format for representation of a range of values along with their associated units where start is the low value of the range and end is the high value, delimited by a vertical bar.			Qualitative Concept	
C155745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155745>	C20401|C192997	Anti-CD137 Monoclonal Antibody|Anti-4-1BB Monoclonal Antibody	Any monoclonal antibody directed against the co-stimulatory immune checkpoint molecule CD137 (tumor necrosis factor receptor superfamily member 9; TNFRSF9; 4-1BB; induced by lymphocyte activation; ILA).	Anti-CD137 Monoclonal Antibody		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C155746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155746>	C67290|C63719|C63586|C63502|C63467|C63361|C191676|C159893|C159439|C156290	Modified FOLFOX6 Regimen|Modified FOLFOX-6|Modified FOLFOX6|Modified Folinic Acid-Fluorouracil-Oxaliplatin-6 Regimen|mFOLFOX-6|mFOLFOX-6 Regimen|mFOLFOX6|mFOLFOX6|mFOLFOX6 (L-Leucovorin)	A regimen consisting of leucovorin, infusional fluorouracil and oxaliplatin used for the treatment of anal carcinoma, esophageal and esophagogastric junction, gastric, occult primary, colorectal cancers, and appendiceal, small bowel, non-urothelial and urothelial bladder cancer, well-differentiated grade 3 neuroendocrine tumors (NETs), NETs of the pancreas, and extrapulmonary poorly differentiated neuroendocrine carcinoma/large or small cell carcinoma/mixed neuroendocrine-non-neuroendocrine neoplasm. This modified version differs from the FOLFOX6 regimen in that the dose of oxaliplatin is lower.	Modified FOLFOX6 Regimen		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C155747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155747>	C61253	Peroxisome Biogenesis Disorder|PBD	A group of conditions characterized by impairment of peroxisome assembly and metabolic pathways confined to this organelle, caused by mutation(s) in the peroxin (PEX) gene family. Phenotypically, they manifest as Zellweger syndrome (ZS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and rhizomelic chondrodysplasia punctata (RCDP1), the latter a distinct peroxisome biogenesis disorder phenotype. ZS, NALD, and IRD have multiple complementation groups and form a spectrum of diseases with overlapping features.			Disease or Syndrome	
C155748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155748>	C155747	Peroxisome Biogenesis Disorder 1A|PBD1A	An autosomal recessive condition caused by mutation(s) in the PEX1 gene, encoding peroxisome biogenesis factor 1. Peroxisome biogenesis disorder 1A manifests phenotypically as Zellweger syndrome.			Disease or Syndrome	Cellosaurus Disease Terminology
C155749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155749>	C155747	Peroxisome Biogenesis Disorder 1B|PBD1B	An autosomal recessive condition caused by mutation(s) in the PEX1 gene, encoding peroxisome biogenesis factor 1. Peroxisome biogenesis disorder 1B is characterized by overlapping phenotypes of neonatal adrenoleukodystrophy and infantile Refsum disease.			Disease or Syndrome	
C15574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15574>	C61063	interleukin-3/interleukin-6|IL-3/IL-6			Obsolete_Concept	Therapeutic or Preventive Procedure	
C155750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155750>	C155747	Peroxisome Biogenesis Disorder 2A|PBD2A	An autosomal recessive condition caused by mutation(s) in the PEX5 gene, encoding peroxisomal targeting signal 1 receptor. Peroxisome biogenesis disorder 2A manifests phenotypically as Zellweger syndrome.			Disease or Syndrome	Cellosaurus Disease Terminology
C155751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155751>	C155747	Peroxisome Biogenesis Disorder 2B|PBD2B	An autosomal recessive condition caused by mutation(s) in the PEX5 gene, encoding peroxisomal targeting signal 1 receptor. Peroxisome biogenesis disorder 2B is characterized by overlapping phenotypes of neonatal adrenoleukodystrophy and infantile Refsum disease.			Disease or Syndrome	Cellosaurus Disease Terminology
C155752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155752>	C155747	Peroxisome Biogenesis Disorder 3A|PBD3A	An autosomal recessive condition caused by mutation(s) in the PEX12 gene, encoding peroxisome assembly protein 12. Peroxisome biogenesis disorder 3A manifests phenotypically as Zellweger syndrome.			Disease or Syndrome	Cellosaurus Disease Terminology
C155753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155753>	C155747	Peroxisome Biogenesis Disorder 3B|PBD3B	An autosomal recessive condition caused by mutation(s) in the PEX12 gene, encoding peroxisome assembly protein 12. Peroxisome biogenesis disorder 3B is characterized by overlapping phenotypes of neonatal adrenoleukodystrophy and infantile Refsum disease.			Disease or Syndrome	
C155754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155754>	C155747	Peroxisome Biogenesis Disorder 4A|PBD4A	An autosomal recessive condition caused by mutation(s) in the PEX6 gene, peroxisome assembly factor 2. Peroxisome biogenesis disorder 4A manifests phenotypically as Zellweger syndrome.			Disease or Syndrome	
C155755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155755>	C155747	Peroxisome Biogenesis Disorder 4B|PBD4B	An autosomal recessive condition caused by mutation(s) in the PEX6 gene, peroxisome assembly factor 2, Peroxisome biogenesis disorder 4B is characterized by overlapping phenotypes of neonatal adrenoleukodystrophy and infantile Refsum disease.			Disease or Syndrome	
C155756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155756>	C155747	Peroxisome Biogenesis Disorder 5A|PBD5A	An autosomal recessive condition caused by mutation(s) in the PEX2 gene, encoding peroxisome biogenesis factor 2. Peroxisome biogenesis disorder 5A manifests phenotypically as Zellweger syndrome.			Disease or Syndrome	
C155757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155757>	C155747	Peroxisome Biogenesis Disorder 5B|PBD5B	An autosomal recessive condition caused by mutation(s) in the PEX2 gene, encoding peroxisome biogenesis factor 2. Peroxisome biogenesis disorder 5B is characterized by overlapping phenotypes of neonatal adrenoleukodystrophy and infantile Refsum disease.			Disease or Syndrome	
C155758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155758>	C155747	Peroxisome Biogenesis Disorder 6A|PBD6A	An autosomal recessive condition caused by mutation(s) in the PEX10 gene, encoding peroxisome biogenesis factor 10. Peroxisome biogenesis disorder 6A manifests phenotypically as Zellweger syndrome.			Disease or Syndrome	
C155759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155759>	C155747	Peroxisome Biogenesis Disorder 6B|PBD6B	An autosomal recessive condition caused by mutation(s) in the PEX10 gene, encoding peroxisome biogenesis factor 10. Peroxisome biogenesis disorder 6B is characterized by overlapping phenotypes of neonatal adrenoleukodystrophy and infantile Refsum disease.			Disease or Syndrome	
C15575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15575>	C15406	Screening for Lung Cancer|early detection of lung cancer|lung cancer early detection|lung cancer screening	Checking an individual for the presence or absence of lung cancer.			Diagnostic Procedure	
C155760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155760>	C155747	Peroxisome Biogenesis Disorder 7A|PBD7A	An autosomal recessive condition caused by mutation(s) in the PEX26 gene, encoding peroxisome assembly protein 26. Peroxisome biogenesis disorder 7A manifests phenotypically as Zellweger syndrome.			Disease or Syndrome	Cellosaurus Disease Terminology
C155761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155761>	C155747	Peroxisome Biogenesis Disorder 7B|PBD7B	An autosomal recessive condition caused by mutation(s) in the PEX26 gene, encoding peroxisome assembly protein 26. Peroxisome biogenesis disorder 7B is characterized by overlapping phenotypes of neonatal adrenoleukodystrophy and infantile Refsum disease.			Disease or Syndrome	Cellosaurus Disease Terminology
C155762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155762>	C155747	Peroxisome Biogenesis Disorder 8A|PBD8A	An autosomal recessive condition caused by mutation(s) in the PEX16 gene, encoding peroxisomal membrane protein PEX16. Peroxisome biogenesis disorder 8A manifests phenotypically as Zellweger syndrome.			Disease or Syndrome	Cellosaurus Disease Terminology
C155763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155763>	C155747	Peroxisome Biogenesis Disorder 8B|PBD8B	An autosomal recessive condition caused by mutation(s) in the PEX16 gene, encoding peroxisomal membrane protein PEX16. Peroxisome biogenesis disorder 8B is characterized by overlapping phenotypes of neonatal adrenoleukodystrophy and infantile Refsum disease.			Disease or Syndrome	
C155764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155764>	C61074|C1742|C129825	AKT Inhibitor|Akt Inhibitor|Protein Kinase B Inhibitor	Any agent that inhibits protein kinase B (AKT).	Akt Inhibitor		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C155765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155765>	C1967|C129825	TRK Inhibitor|Tropomyosin-related-kinase Inhibitor	Any agent that inhibits tropomyosin-related-kinase (TRK;  tropomyosin receptor kinase).	TRK Inhibitor		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C155766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155766>	C45233|C188283	Acute Lung Injury|ALI	A finding of acute onset of bilateral pulmonary infiltrates by chest radiograph and a PaO2/FiO2 of less than or equal to 300, in the absence of heart failure. The infiltrate may be rich in neutrophils. This syndrome represents a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).			Finding	
C155767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155767>	C6930|C3329	Mixed Gangliocytoma-Pituitary Neuroendocrine Tumor|Mixed Gangliocytoma-PitNET|Mixed Gangliocytoma-PitNET/Adenoma|Mixed Gangliocytoma-Pituitary Neuroendocrine Tumor/Adenoma|Pituitary Gland Adenoma with Gangliocytic Component|Pituitary Gland Adenoma-Neuronal Choristoma|Pituitary Gland Mixed Gangliocytoma-Adenoma	A pituitary neoplasm composed of mature ganglionic cells admixed with pituitary neoplastic neuroendocrine cells.			Neoplastic Process	
C155768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155768>	C4944	Sellar Neurocytoma|Extraventricular Neurocytoma of the Sellar Region|Extraventricular Neurocytoma of the Sellar Region (WHO Grade 2)|Extraventricular Neurocytoma of the Sellar Region (WHO Grade II)|Sellar Neurocytoma (WHO Grade 2)|Sellar Neurocytoma (WHO Grade II)	A rare extraventricular neurocytoma (WHO grade 2) of the hypothalamic-pituitary area. (WHO 2017)			Neoplastic Process	
C155769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155769>	C5466|C4944	Sellar Paraganglioma	An extremely rare paraganglioma arising from chief cells of the dispersed paraganglia of the sellar region. (WHO)			Neoplastic Process	
C15576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15576>	C15406	Screening for Ovarian Cancer|early detection of ovarian cancer|ovarian cancer early detection|ovarian cancer screening	The use of any device, marker, or other means for the purpose of detecting the presence of ovarian cancer, usually before there are symptoms.			Diagnostic Procedure	
C155770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155770>	C12471	Fibroadipose Tissue	Soft tissue composed of fibrous tissue admixed with adipose tissue.			Tissue	
C155772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155772>	C4944|C3789|C3568	Sellar Olfactory Neuroblastoma|Primary Sellar Neuroblastoma|Primary Sellar Olfactory Neuroblastoma|Sellar Esthesioneuroblastoma|Sellar Neuroblastoma	An extremely rare ectopic olfactory neuroblastoma that arises from the sellar region.			Neoplastic Process	
C155773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155773>	C124800	Denfivontinib Hydrochloride|DENFIVONTINIB HYDROCHLORIDE|FLT3 Inhibitor SKI-G-801|FLT3 Kinase Inhibitor SKI-G-801|FLT3 Tyrosine Kinase Inhibitor SKI-G-801|G-749 HCl Salt|G-749 Hydrochloride|G-801|SKI-G-801	The hydrochloride salt form of denfivontinib, an orally bioavailable inhibitor of both wild type and mutant forms of FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon administration, denfivontinib binds to and inhibits the activity of FLT3, including FLT3-ITD (internal tandem duplications), FLT3-D835Y as well as other mutants. This inhibits uncontrolled FLT3 signaling and results in the inhibition of proliferation in tumor cells overexpressing FLT3. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B lineage neoplasms and in acute myeloid leukemias, and plays a key role in tumor cell proliferation. In addition, denfivontinib also inhibits, to a lesser degree, the receptor tyrosine kinases AXL (UFO), Mer, Ret, vascular endothelial growth factor receptor 1 (VEGFR1), Fms, fibroblast growth factor receptors (FGFR) 1 and 3, and the serine/threonine kinases Aurora B and C.	Denfivontinib Hydrochloride		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155774>	C7157	Ependymal Pituicytoma|Sellar Ependymoma	A very rare, low-grade neoplasm that arises from the posterior pituitary. It is composed of epithelioid and oncocytic cells forming sheets and fascicles. It shows histopathological features reminiscent of ependymomas, including perivascular pseudorosettes and true rosettes. There is no evidence of necrosis or increased mitotic activity. Despite the presence of ependymal histopathological features, these neoplasms probably are not related to ependymomas. Their prognosis is unknown.			Neoplastic Process	Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C155775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155775>	C142078	Autologous Mesothelin-specific Human mRNA CAR-transfected PBMCs MCY-M11|Anti-mesothelin mRNA-transfected Autologous PBMCs MCY-M11|MCY-M11|MCY-M11	Autologous peripheral blood mononuclear cells (PBMCs) transfected with anti-mesothelin chimeric antigen receptor (CAR) mRNA, with potential antineoplastic activity. Upon intraperitoneal (IP) administration, the autologous mesothelin-specific human mRNA CAR-transfected PBMCs MCY-M11 recognize, bind to, phagocytose and directly kill cancer cells expressing mesothelin. In addition, MCY-M11 stimulates the immune system to induce a cytotoxic T-lymphocyte response against the mesothelin-expressing cancer cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in many epithelial-derived cancers.	Autologous Mesothelin-specific Human mRNA CAR-transfected PBMCs MCY-M11		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155776>	C4944|C4656	Sellar Meningioma	A rare meningioma that arises from the sellar region.			Neoplastic Process	
C155777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155777>	C12680	Sellar Region	The area inside or around the sella turcica.			Body Location or Region	
C155778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155778>	C155776	Intrasellar Meningioma	A rare meningioma arising from the intrasellar region.			Neoplastic Process	
C155779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155779>	C155777	Intrasellar Region	The area inside the sella turcica.			Body Location or Region	
C15577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15577>	C15544	Anti-Tumor Necrosis Factor Therapy|Anti-TNF Therapy|anti-TNF therapy|anti-TNF-alpha therapy	Drug treatment to reduce the activity of tumor necrosis factor, particulary to control inflammation in disease modalities.			Therapeutic or Preventive Procedure	GDC Terminology|GDC Value Terminology
C155780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155780>	C4944|C3269	Sellar Schwannoma|Sellar Neurilemmoma|Sellar Neurinoma	An extremely rare schwannoma that arises from the sellar region.			Neoplastic Process	
C155781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155781>	C4944|C3568|C2947	Sellar Chordoma	A chordoma that arises from the sellar region.			Neoplastic Process	
C155782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155782>	C6902|C155781	Sellar Chondroid Chordoma	A chondroid chordoma that arises from the sellar region.			Neoplastic Process	
C155783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155783>	C48876|C155781	Sellar Dedifferentiated Chordoma	A dedifferentiated chordoma that arises from the sellar region.			Neoplastic Process	
C155784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155784>	C4944|C4660	Sellar Solitary Fibrous Tumor|Sellar Hemangiopericytoma/ Solitary Fibrous Tumor|Sellar Solitary Fibrous Tumor/Hemangiopericytoma	An extremely rare meningeal solitary fibrous tumor that arises from the sellar region.			Neoplastic Process	
C155785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155785>	C174048	Beroterkib Anhydrous|ASTX 029|ASTX-029|ASTX029|AT-35029|AT35029|BEROTERKIB ANHYDROUS|ERK 1/2 Inhibitor ASTX029|ERK Inhibitor ASTX029|Extracellular Signal-regulated Kinase 1/2 Inhibitor ASTX029|Extracellular Signal-regulated Kinase Inhibitor ASTX029	The anhydrous form of beroterkib, an orally bioavailable inhibitor of the extracellular signal-regulated kinases (ERK) 1 and 2, with potential antineoplastic activity. Upon administration, beroterkib specifically binds to and inhibits both ERK 1 and 2, thereby preventing the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The MAPK/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in the proliferation, differentiation and survival of tumor cells.	Beroterkib Anhydrous		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155786>	C4944|C3813	Metastatic Malignant Neoplasm in the Sellar Region	A malignant neoplasm that has metastasized to the sellar region from another anatomic site.			Neoplastic Process	
C155788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155788>	C49236	Desensitization	Any of various methods to reduce or eliminate an organism's negative reaction to a substance or stimulus.			Therapeutic or Preventive Procedure	
C155789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155789>	C27993	Pure	Involving or containing nothing else.			Qualitative Concept	
C15578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15578>	C15986|C15632	In Vitro Sensitivity-Directed Chemotherapy	Uses the results of a chemosensitivity testing assay to tailor the treatment to the individual.	In Vitro Sensitivity-Directed Chemotherapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C155790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155790>	C4016|C3375	Malignant Skull Neoplasm	A primary or metastatic malignant neoplasm that affects the bones and structures of the skull.			Neoplastic Process	
C155791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155791>	C4676|C155790	Malignant Skull Base Neoplasm|Skull Base Cancer	A primary or metastatic malignant neoplasm that affects the skull base.			Neoplastic Process	
C155792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155792>	C4880|C3375	Benign Skull Neoplasm	A neoplasm that arises from the bones and structures of skull and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.			Neoplastic Process	
C155793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155793>	C4676|C155792	Benign Skull Base Neoplasm	A neoplasm that arises from the skull base and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.	Benign Skull Base Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155794>	C155713	Epratuzumab-cys-tesirine|ADC ADCT-602|ADCT-602|ADCT602|Anti-CD22/PBD ADC ADCT-602|Antibody-drug Conjugate ADCT-602|EPRATUZUMAB-CYS-TESIRINE|Epratuzumab-cys-SG3249|hLL2-cys-PBD|hLL2-cys-SG3249	An antibody-drug conjugate (ADC) composed of a cysteine-engineered version of epratuzumab (hLL2), a humanized anti-CD22 monoclonal antibody derived from the murine immunoglobulin (Ig) G2a monoclonal antibody LL2 (EPB-2), site-specifically conjugated to the cross-linking cytotoxic agent tesirine (SG3249), a cathepsin B-cleavable valine-alanine pyrrolobenzodiazepine dimer (PBD), with potential antineoplastic activity. Upon administration of epratuzumab-cys-tesirine, the epratuzumab moiety targets and binds to the B cell-specific CD22 receptor and is rapidly internalized. Upon cleavage, the imine groups of tesirine target and bind to the N2 positions of guanines on opposite strands of DNA. This induces interstrand cross-links in the minor groove of DNA and inhibits DNA replication, which inhibits the proliferation of CD22-overexpressing tumor cells. CD22, a cell surface glycoprotein, is expressed on mature B-cells and on most malignant B-cells.	Epratuzumab-cys-tesirine		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155795>	C15699	Ex-vivo T-Cell Depletion|Ex vivo TCD	Treatment that reduces or removes T cells from a graft before administration to the recipient.			Therapeutic or Preventive Procedure	
C155796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155796>	C4769|C202923|C114779	Primary Pituitary Gland Non-Hodgkin Lymphoma	A rare non-Hodgkin lymphoma that arises from the pituitary gland. The majority are diffuse large B-cell lymphomas.			Neoplastic Process	
C155797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155797>	C71720|C202930|C155796	Primary Pituitary Gland Diffuse Large B-Cell Lymphoma	A rare diffuse large B-cell lymphoma that arises from the pituitary gland.			Neoplastic Process	
C155799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155799>	C129650	Filgotinib|FILGOTINIB|GLPG 0634|GLPG0634|GS-6034	An orally bioavailable inhibitor of the tyrosine kinase Janus kinase 1 (JAK1), with potential anti-inflammatory and immunomodulating activities. Upon oral administration, filgotinib specifically targets, binds to, and inhibits the phosphorylation of JAK1, which interferes with JAK/STAT (signal transducer and activator of transcription)-dependent signaling. As JAK1 mediates signaling of many pro-inflammatory cytokines, JAK1 inhibition prevents cytokine signaling and activity in many inflammatory and immune-mediated processes and leads to a decrease in inflammation and activation of certain immune cells. JAK1 plays a key role in the signaling and activity of many cytokines and growth factors and is often dysregulated in a variety of autoimmune and inflammatory diseases, as well as some malignancies.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C15579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15579>	C61063	Interleukin-2/Tumor Necrosis Factor Receptor IgG Chimera|IL-2/TNFR:Fc			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1557>	C272	Pyrimidine Antagonist	An antimetabolite that affects the metabolism and utilization of pyrimidines.			Chemical Viewed Functionally	
C155800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155800>	C126102	CS1-CAR T Therapy|CS1-CAR T Infusion|CS1-CAR T-cell Therapy	Treatment with CAR T cells that are directed against the CS1 surface glycoprotein on multiple myeloma cells.	CS1-CAR T Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C155801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155801>	C5461|C4944	Sellar Germ Cell Tumor|Germ Cell Tumor of the Sellar Region	A germ cell tumor that arises from or adjacent to the sellar region.			Neoplastic Process	
C155802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155802>	C6284|C214899	Sellar Germinoma|Germinoma of the Sellar Region	A germinoma that arises from or adjacent to the sellar region.			Neoplastic Process	
C155803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155803>	C177769|C155802	Suprasellar Germinoma|Germinoma of the Suprasellar Region	A germinoma that arises from the suprasellar region.			Neoplastic Process	
C155804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155804>	C7011|C214899	Sellar Yolk Sac Tumor|Yolk Sac Tumor of the Sellar Region	A yolk sac tumor that arises from or adjacent to the sellar region.			Neoplastic Process	
C155805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155805>	C7010|C214899	Sellar Embryonal Carcinoma|Embryonal Carcinoma of the Sellar Region	An embryonal carcinoma that arises from or adjacent to the sellar region.			Neoplastic Process	
C155806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155806>	C7012|C214899	Sellar Choriocarcinoma|Choriocarcinoma of the Sellar Region	A choriocarcinoma that arises from or adjacent to the sellar region.			Neoplastic Process	
C155807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155807>	C5441|C155801	Sellar Teratoma|Teratoma of the Sellar Region	A teratoma that arises from or adjacent to the sellar region.			Neoplastic Process	
C155808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155808>	C7013|C155807	Sellar Mature Teratoma|Mature Teratoma of the Sellar Region	A mature teratoma that arises from or adjacent to the sellar region.			Neoplastic Process	
C155809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155809>	C7014|C155807	Sellar Immature Teratoma|Immature Teratoma of the Sellar Region	An immature teratoma that arises from or adjacent to the sellar region.			Neoplastic Process	
C15580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15580>	C50870	Intra-Operative Blood Salvage Autotransfusion|Cell Salvage|IOS|Intra-Operative Blood Salvage|Intraoperative Blood Salvage	A procedure that recovers blood lost during surgery and re-infuses it into the patient.			Therapeutic or Preventive Procedure	
C155810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155810>	C7015|C214899|C155807	Sellar Teratoma with Malignant Transformation|Teratoma with Malignant Transformation of the Sellar Region	A teratoma with malignant transformation that arises from or adjacent to the sellar region.			Neoplastic Process	
C155811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155811>	C7016|C214899	Sellar Mixed Germ Cell Tumor|Mixed Germ Cell Tumor of the Sellar Region	A mixed germ cell tumor that arises from or adjacent to the sellar region.			Neoplastic Process	
C155812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155812>	C211912	Ozuriftamab Vedotin|ADC BA3021|Anti-ROR2 CAB ADC|Antibody-drug Conjugate BA3021|BA 3021|BA3021|CAB Anti-ROR2 ADC BA3021|CAB-ROR2-ADC|CAB-ROR2-ADC BA3021|Conditionally Active Biologic Anti-ROR2 Antibody-drug Conjugate|OZURIFTAMAB VEDOTIN|ROR2-targeted ADC BA3021	An antibody-drug conjugate (ADC) composed of ozuriftamab, a conditionally active biologic (CAB) antibody against receptor tyrosine kinase-like orphan receptor 2 (ROR2) conjugated to monomethyl auristatin E, with potential antineoplastic activity. Upon administration of ozuriftamab vedotin, the anti-ROR2 antibody becomes activated through an as of yet not fully elucidated process, only under the unique microphysical conditions that are present in the tumor microenvironment (TME) as a result of the glycolytic metabolism of cancer cells and not in the microenvironment of normal, healthy tissues. Upon binding to ROR2-expressing cancer cells and internalization, the cytotoxic agent kills the cancer cells. ROR2, highly expressed during embryonic development while only minimally expressed on certain normal, healthy cells, is involved in Wnt signal transduction and is overexpressed on certain cancer cells. It plays a key role in cancer cell proliferation, migration and invasion. High levels of ROR2 expression often correlates with poor prognosis. The CAB antibody allows for efficient binding to ROR2-expressing cancer cells only, thereby maximizing efficacy while minimizing toxicity by avoiding activation and thus binding of the antibody to normal, healthy ROR2-expressing cells under normal conditions.	Ozuriftamab Vedotin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155813>	C198645	Axatilimab|AXATILIMAB|Anti-M-CSFR Monoclonal Antibody SNDX-6352|Axatilimab-csfr|INCA 034176|INCA 34176|INCA-034176|INCA-34176|INCA034176|INCA34176|Niktimvo|SNDX 6352|SNDX-6352|SNDX6352|UCB6352	A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against colony-stimulating factor 1 receptor (CSF-1R; CSF1R; macrophage-CSFR; M-CSFR; CD115; c-fms), with potential antineoplastic activity and anti-inflammatory, immunomodulating and anti-fibrotic activities. Upon intravenous administration, axatilimab binds to the ligand binding domain of CSF-1R expressed on monocytes and macrophages, thereby preventing binding and consequent activation by its natural ligands, interleukin-34 (IL-34) and colony-stimulating factor 1 (CSF-1). Inhibition of CSF-1R activation and CSF1R-mediated signaling may reduce the levels of these circulating pro-inflammatory and pro-fibrotic monocytes and monocyte-derived macrophages. This prevents the secretion of a variety of pro-inflammatory cytokines by monocytes and macrophages, reduces inflammation, and inhibits the tumor necrosis factor-beta (TGF-b) secretion by profibrotic (M2) macrophages. This inhibits the TGF-b-mediated development of fibrosis and may treat chronic graft-versus-host disease (cGVHD). In addition, by blocking CSF-1R activation and CSF-1R-mediated signaling in tumor-associated macrophages (TAMs), axatilimab may abrogate the TAMs-mediated immunosuppression in the tumor microenvironment (TME) and may enhance T-cell infiltration and antitumor T-cell immune responses. This may inhibit the proliferation of tumor cells. TAMs play key roles in immune suppression and promoting inflammation, tumor cell proliferation and survival. CSF-1R is a tyrosine protein kinase that plays an essential role in the regulation, proliferation, survival and differentiation of tissue macrophages as well as TAMs.	Axatilimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C155814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155814>	C25162	PCORnet Reserved	A code used for PCORNet network-wide activities related to general observation data.			Qualitative Concept	
C155815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155815>	C19347	Influenza Virus-Specific Culture|Influenza-Specific Culture|Organism-specific Culture	Cell culture conditions that are specific for the growth and identification of influenza virus.			Laboratory Procedure	
C155816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155816>	C8028|C222817|C158437	Recurrent Endometrial Clear Cell Adenocarcinoma	The reemergence of endometrial clear cell adenocarcinoma after a period of remission.	Recurrent Endometrial Clear Cell Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155817>	C40156|C150094	Recurrent Endometrial Undifferentiated Carcinoma	The reemergence of endometrial undifferentiated carcinoma after a period of remission.	Recurrent Endometrial Undifferentiated Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155818>	C9180|C226957|C207060	Recurrent Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor	The reemergence of uterine corpus malignant mixed mesodermal (Mullerian) tumor after a period of remission.	Recurrent Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155819>	C40153|C158437	Recurrent Endometrial Mixed Cell Adenocarcinoma|Recurrent Endometrial Mixed Epithelial Carcinoma|Recurrent Endometrial Mixed Epithelial Carcinoma	The reemergence of endometrial mixed cell adenocarcinoma after a period of remission.	Recurrent Endometrial Mixed Epithelial Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C15581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15581>	C15912	Intraperitoneal Chemotherapy|Intraperitoneal Therapy|intraperitoneal chemotherapy	The administration of pharmaceutical agents directly into the abdominal or peritoneal cavity. This technique is widely utilized for the chemotherapeutic treatment of advanced ovarian cancer.	Intraperitoneal Chemotherapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C155820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155820>	C98275	Aerodigestive Invasive Malignancy	A finding indicating the presence of an invasive malignant neoplasm involving the respiratory tract and the upper digestive tract.	Aerodigestive Invasive Malignancy		Finding	CTRP Disease Terminology|CTRP Terminology
C155821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155821>	C162188	Age-Related Clonal Hematopoiesis|ARCH	The gradual, clonal expansion of hematopoietic stem and progenitor cells carrying specific, disruptive, and recurrent genetic variants, in individuals without clear diagnosis of hematological malignancies. It is associated with an increased risk of developing hematologic cancers.	Age-Related Clonal Hematopoiesis		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C155822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155822>	C16135	Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy|LET-Optimized IMPT|LET-Optimized Intensity Modulated Proton Therapy|Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT)	Techniques for maximizing LET in target volumes and minimizing LET in critical structures and normal tissues during proton beam radiation therapy.	Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C155823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155823>	C156877	Kegel Nation App|Kegel Nation	A smartphone-based application designed to help monitor the frequency, progress and quality of a Kegel exercise regimen in both men and women. It allows patients to measure the duration of the pelvic muscle contraction and relaxation by touching the phone's screen during each exercise phase. The app then archives and charts the measured times with a time and date stamp. Patients can also use the app to track other indicators of bladder function recovery, such as urinary urgency and incontinence episodes, pad use, and voiding events.	Kegel Nation App		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C155824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155824>	C25162	CPT Category II Codes|CPT Category II	A set of supplemental tracking codes that can be used for performance measurement provided by the American Medical Association as part of their Current Procedural Terminology.			Intellectual Product	
C155825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155825>	C132306	HCPCS Level I|CPT-4|Healthcare Financing Administration Common Procedure Coding System Level I	Codes used to report medical procedures and professional services provided by the American Medical Association as part of their Current Procedural Terminology.			Intellectual Product	
C155826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155826>	C132306	HCPCS Level II|Healthcare Financing Administration Common Procedure Coding System Level II	Codes used to report products, supplies, and services not described by CPT-4 codes.			Intellectual Product	
C155827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155827>	C132306	HCPCS Level III|HCPCS Local Codes|Healthcare Financing Administration Common Procedure Coding System Level III	Codes developed by state Medicaid agencies, contractors and private insurers for use in specific programs and jurisdictions.			Intellectual Product	
C155828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155828>	C49235	Rooming	Placing a patient in a room.			Activity	
C155829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155829>	C176889|C132067	Unresectable Low Grade Glioma|Unresectable Low-Grade Glioma	Low grade glioma that is not amenable to surgical removal.			Neoplastic Process	
C15582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15582>	C15669	Prevention of Aerodigestive Tract Cancer|aerodigestive tract cancer prevention	Any method of preventing aerodigestive tract cancer including limit of exposure to carcinogens and infectious agents, diet, education, or lifestyle.			Therapeutic or Preventive Procedure	
C155830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155830>	C18202	Bronchoalveolar Biopsy Specimen|BALBX|Bronchoalveolar Biopsy	Tissue removed from the bronchi and alveoli for microscopic examination.			Body Substance	
C155831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155831>	C150895	Nasopharyngeal Swab Specimen|NPH|Nasopharyngeal Swab	A biospecimen collected from the back of the throat by swabbing.			Body Substance	
C155832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155832>	C103411	Nasopharyngeal Wash Specimen|NPWASH|Nasopharyngeal Wash	A biospecimen collected from the back of the throat by washing.			Body Substance	
C155833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155833>	C150895	Nasal Swab or Nose Specimen|NSWAB|Nasal Swab|Nasal Swab|Nose Swab	A biospecimen collected from the nasal passages by swabbing.			Body Substance	SeroNet Authorized Values|SeroNet Biospecimen Metadata|SeroNet Study Descriptors
C155834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155834>	C103411	Nasal Wash Specimen|NWASH|Nasal Wash	A biospecimen collected from the nasal passages by washing.			Body Substance	
C155835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155835>	C150895	Oropharyngeal Swab Specimen|Oropharyngeal Swab|THRT|Throat Swab	A biospecimen collected from the oropharynx by swabbing.			Body Substance	
C155837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155837>	C70769	National Drug Code Unit of Measure	A unit of measure that is required when submitting a national drug code for billing purposes.			Classification	
C155838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155838>	C155837	NDC ME (Milligram)|ME|ME|ME|National Drug Code Milligram	A recognized billing qualifier that may be used to identify milligrams as the NDC unit of measure.			Quantitative Concept	
C155839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155839>	C155837	NDC UN (Unit)|National Drug Code Unit|UN|UN|UN	A recognized billing qualifier that may be used to identify a unit as the NDC unit of measure. This is often used when describing a powder for injection (needs to be reconstituted), pellet, kit, patch, tablet or device.			Quantitative Concept	
C15583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15583>	C61063	Sargramostim/Tumor Necrosis Factor|GM-CSF/TNF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C155840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155840>	C155837	NDC ML (Milliliter)|ML|ML|ML|National Drug Code Milliliter	A recognized billing qualifier that may be used to identify a milliliter as the NDC unit of measure. This is often used when describing a liquid, solution, or suspension.			Quantitative Concept	
C155841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155841>	C155837	NDC GR (Gram)|GR|GR|National Drug Code Gram	A recognized billing qualifier that may be used to identify a unit as the NDC unit of measure. This is often used when describing ointments, creams, inhalers or bulk powder in a jar.			Quantitative Concept	
C155842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155842>	C217122	Hematopoietic Cell Transplantation-Comorbidity Index|HCT-CI|Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI)	A tool that predicts overall mortality risk, as well as non-relapse mortality risk, for patients with hematologic malignancies following hematopoietic stem cell transplantation. The index considers 17 categories of organ dysfunction.			Intellectual Product	
C155843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155843>	C20993	International Metastatic Renal Cell Carcinoma Database Consortium Criteria|Heng Criteria|IMDC|IMDC Criteria|IMDC Risk|International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Criteria	A validated risk prediction tool for patients with metastatic renal cell carcinoma (mRCC) receiving first-line targeted therapy. The model considers: Karnofsky performance status less than 80%, time from diagnosis to first-line targeted therapy less than 1 year, hemoglobin concentration less than lower limit of normal, neutrophil count greater than upper limit of normal, platelet count greater than upper limit of normal, and serum calcium concentration greater than upper limit of normal.			Intellectual Product	
C155844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155844>	C155843	International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Criteria - Favorable-Risk Group|Favorable|IMDC Favorable|IMDC Favorable Risk|IMDC Favorable Risk Group	A patient with 0 IMDC risk factors.			Intellectual Product	
C155845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155845>	C155843	International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Criteria - Intermediate-Risk Group|IMDC Intermediate|IMDC Intermediate Risk|IMDC Intermediate Risk Group|Intermediate	A patient with 1-2 IMDC risk factors.			Intellectual Product	
C155846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155846>	C155843	International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Criteria - Poor-Risk Group|IMDC Poor|IMDC Poor Risk|IMDC Poor Risk Group|Poor	A patient with 3-6 IMDC risk factors.			Intellectual Product	
C155847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155847>	C16567	Kegel Exercise|Kegel	An exercise to strengthen the pelvic floor muscles, in which the levator muscles are squeezed and held, then released, for a number of repetitions.	Kegel Exercise		Daily or Recreational Activity	CTRP Intervention Terminology|CTRP Terminology
C155848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155848>	C50134	Circadian Biometric Recorder|CBR System|Cyrcadia Health Circadian Biometric Recorder	A proprietary device that uses a thermal differential detection system to detect and record abnormal circadian cellular temperature changes, including those associated with breast cancer tumor infusion.	Circadian Biometric Recorder		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C155849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155849>	C17146	mySmartCheck	An online program for skin self-examination (SSE) designed to introduce users to melanoma risk factors and the importance of SSE behaviors; review past experiences doing skin self-checks, teach how to identify potentially suspicious moles, enhance confidence, address skin self-check barriers, and help users to create a monthly skin self-check action plan; take the user through the process of conducting a thorough skin self-check and record moles and other growths using an online body mole map.	mySmartCheck		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C15584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15584>	C15747	Quality-of-Life Assessment|Quality of Life Assessment	A determination of an individual's sense of well-being and ability to enjoy life.	Quality-of-Life Assessment		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C155850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155850>	C185612	Vociprotafib|(6-((2-Amino-3-chloropyridin-4-yl)sulfanyl)-3-((3S,4S)-4-amino- 3-methyl-2-oxa-8-azaspiro(4.5)decan-8-yl)- 5-methylpyrazin-2-yl)methanol|2-Pyrazinemethanol, 6-((2-amino-3-chloro-4-pyridinyl)thio)-3-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro(4.5)dec-8-yl)-5-methyl-|PTPN11 Inhibitor RMC-4630|RMC 4630|RMC-4630|RMC4630|SAR 442720|SAR-442720|SAR442720|SHP2 Inhibitor RMC-4630|VOCIPROTAFIB	An orally bioavailable inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; Src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic activity. Upon oral administration, vociprotafib targets, binds to and inhibits the activity of SHP2. This prevents SHP2-mediated signaling, inhibits MAPK signaling and prevents growth of SHP2-expressing tumor cells. SHP2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the RAS-RAF-MEK-ERK signaling pathway. The RAS-MAPK pathway is often hyperactivated in cancer cells due to specific mutations and rearrangements and are dependent on SHP2 for their oncogenic signaling. SHP2 also regulates programmed cell death 1 (PD-1)-mediated signal transduction and is involved in immune checkpoint modulation.	Vociprotafib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155851>	C155837	NDC F2 (International Unit)|F2|F2|F2|National Drug Code F2	A recognized billing qualifier that may be used to identify International Units as the NDC unit of measure. This is often used when describing IU/vial or micrograms.			Quantitative Concept	
C155852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155852>	C9005|C36263	Metastatic Malignant Pancreatic Neoplasm	A malignant neoplasm that arises from the pancreas and has metastasized to another anatomic site.			Neoplastic Process	
C155853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155853>	C173458	Able to Run 5 Miles Question|'Able to Run 5 Miles'|Are you able to run five miles (8 km)	A question about whether an individual is or was able to run 5 miles (8km).			Intellectual Product	PROMIS Adult Physical Health Domain
C155854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155854>	C173458	Able to Remove a Heavy Suitcase Question|Able to Remove a Heavy Suitcase|Are you able to remove a heavy suitcase (50 lbs/25 kg) from an overhead bin on an airplane or bus	A question about whether an individual is or was able to remove a heavy suitcase from an overhead location.			Intellectual Product	PROMIS Adult Physical Health Domain
C155855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155855>	C173398	Have Trouble Multitasking Question|Have Difficulty Multitasking|Have Trouble Multitasking|I have had difficulty multi-tasking	A question about whether an individual has or had trouble multitasking.			Intellectual Product	PROMIS Adult Mental Health Domain
C155856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155856>	C156877	MyPatientPal	A smartphone-based application designed to track of cancer symptoms, manage medications, develop charts to share with a doctor, and receive alerts about when to call the doctor's office or when to seek immediate medical attention. Features include a daily symptom log and a daily medication log.	MyPatientPal		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C155857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155857>	C118619|C102743	Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy|EBUS-TBN IPDT|EBUS-TBN Interstitial Photodynamic Therapy|Endobronchial Ultrasound Transbronchial Needle-Guided Interstitial Photodynamic Therapy|Endobronchial Ultrasound with Transbronchial Needle (EBUS-TBN) Guided Interstitial PDT (IPDT)|Ultrasound-Guided Transbronchial Needle-Guided Interstitial Photodynamic Therapy	Photodynamic treatment of deep-seated solid tumors using a light source that is placed by a transbronchial needle, using ultrasound guidance.	Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C155858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155858>	C120842	Gardasil Immunogenicity with Needle-Free Injection|GINI	A study to determine if immunogenicity to human papillomavirus will develop following needle-free vaccine delivery of Gardasil.	Gardasil Immunogenicity with Needle-Free Injection		Research Activity	CTRP Intervention Terminology|CTRP Terminology
C155859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155859>	C16782	Diode Laser Fiber Type Selective Stimulator|DLss	A device designed to use a diode laser to stimulate peripheral nerves. It is being tested to help predict whether a patient will develop peripheral neuropathy.	Diode Laser Fiber Type Selective Stimulator		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C15585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15585>	C93352|C15187	Targeted Fusion Protein Therapy	Drug therapy in which the drug is a fusion protein generated by molecular biology procedures.  The fusion protein combines a cell targeting moiety, such as an antibody fragment, with an effector moiety, like a bacterial toxin.	Targeted Fusion Protein Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C155860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155860>	C215116	Quantitative Sensory Testing|QST	A non-invasive method for diagnosing peripheral nervous system disorders. It determines an individual's sensation and pain thresholds for cold and warm temperatures, and vibration sensation threshold by stimulating the skin and comparing the results to standard values.	Quantitative Sensory Testing		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C155861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155861>	C36133	Well Differentiated Neuroendocrine Lesion|Neuroendocrine tumor, well differentiated	A neoplastic lesion with neuroendocrine differentiation and well differentiated histological features.			Finding	GDC Terminology|GDC Value Terminology
C155862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155862>	C36141	Intermediate Grade Neuroendocrine Lesion	A neoplastic lesion with neuroendocrine differentiation and histological features of intermediate grade.			Finding	
C155863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155863>	C36132	Poorly Differentiated Neuroendocrine Lesion	A neoplastic lesion with neuroendocrine differentiation and poorly differentiated histological features.			Finding	GDC Terminology|GDC Value Terminology
C155864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155864>	C36130	Low Grade Neuroendocrine Lesion	A neoplastic lesion with neuroendocrine differentiation and histological features of low grade.			Finding	
C155865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155865>	C26006	MIA2 Gene|MIA SH3 Domain ER Export Factor 2 Gene|MIA2|MIA2	This gene is involved in intracellular lipoprotein transport.	MIA2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C155866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155866>	C155865	MIA2 wt Allele|CTAGE5|FLJ22404|MEA11|MEA6|MGEA|MGEA11|MGEA6|MIA SH3 Domain ER Export Factor 2 wt Allele|Melanoma Inhibitory Activity 2 Gene|Meningioma Expressed Antigen 11 Gene|Meningioma Expressed Antigen 6 (Coiled-Coil Proline-Rich) Gene|Meningioma Expressed Antigen Gene|Meningioma-Expressed Antigen 6/11 Gene|TALI|TANGO1-Like Gene	Human MIA2 wild-type allele is located in the vicinity of 14q21.1 and is approximately 158 kb in length. This allele, which encodes melanoma inhibitory activity protein 2, plays a role in lipoprotein transport.	MIA2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C155867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155867>	C16386	Melanoma Inhibitory Activity Protein 2|MIA SH3 Domain ER Export Factor 2|MIA2|TALI|TANGO-Like Protein	Melanoma inhibitory activity protein 2 (1412 aa, ~160 kDa) is encoded by the human MIA2 gene. This protein is involved in ER-to-Golgi transport of lipoproteins.	Melanoma Inhibitory Activity Protein 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C155868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155868>	C70663	Device Unique Identifier|UDI|Unique Device Identifier|Universal Device Identifier	A globally-unique identifier for a device.			Intellectual Product	
C155869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155869>	C3773|C215187|C156485	Metastatic Neuroendocrine Carcinoma	A neuroendocrine carcinoma that has spread from its original site of growth to another anatomic site.	Metastatic Neuroendocrine Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C15586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15586>	C61063	Bispecific Antibody 520C9XH22/Interferon Gamma|BsAb 520C9xH22/IFN-G			Obsolete_Concept	Therapeutic or Preventive Procedure	
C155870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155870>	C156486|C155869|C153171	Advanced Neuroendocrine Carcinoma	A neuroendocrine carcinoma that has metastasized from its original site of growth to distal anatomic sites or is no longer responding to treatment.	Advanced Neuroendocrine Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155871>	C172342	Herpes Simplex Virus Infection|HSV Infection|Herpes|Herpes Simplex Virus	An infection that is caused by herpes simplex virus.	Herpes Simplex Virus Infection		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C155872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155872>	C3439	Molluscum Contagiosum|Molluscum Contagiosum Virus Infection|Molluscum Contagiosum Virus Infection	A self-limited viral skin infection caused by the molluscum contagiosum virus that belongs to the Poxviridae family and transmitted by direct skin contact. It presents with multiple epidermal nodules that are depressed in the middle. The nodular skin lesions can occur anywhere on the body, but more often they affect the head and neck, trunk, axillae, groin, and flexural areas of the extremities. Morphologically, the lesions are characterized by the presence of crateriform endophytic lobules of acanthotic epidermis. The lobules contain large, eosinophilic intracytoplasmic inclusion bodies that compress the nucleus to the periphery of the cell. The inclusion bodies are called molluscum bodies or Henderson-Paterson bodies.	Molluscum Contagiosum Virus Infection		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C155873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155873>	C9118|C4580	Chest Wall Sarcoma|Primary Thoracic Sarcoma	A sarcoma that arises from the anatomic structures that surround the lungs and the pleura.	Chest Wall Sarcoma		Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C155874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155874>	C202500|C162767|C153316	Locally Advanced Unresectable Gastric Adenocarcinoma	A gastric adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.	Locally Advanced Unresectable Gastric Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155875>	C9182|C4798	Recurrent Desmoid Fibromatosis|Recurrent Desmoid Tumor|Recurrent Desmoid-Type Fibromatosis|Recurrent Desmoid-Type Fibromatosis	Desmoid fibromatosis that has recurred after a period of remission.	Recurrent Desmoid-Type Fibromatosis		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155876>	C133878|C129822	Anti-EGFR Monoclonal Antibody CPGJ 602|CPGJ 602|CPGJ-602|CPGJ602	A recombinant, human-mouse chimeric monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Upon intravenous administration, anti-EGFR monoclonal antibody CPGJ 602 targets and binds to EGFR, which prevents receptor dimerization and activation. This leads to an inhibition of EGFR-dependent downstream pathways and EGFR-dependent tumor cell proliferation and metastasis. EGFR, a receptor tyrosine kinase, may be overexpressed on the surfaces of various tumor cell types.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155877>	C9182	Unresectable Desmoid Fibromatosis|Unresectable Desmoid Tumor|Unresectable Desmoid-Type Fibromatosis	Desmoid fibromatosis that is not amenable to surgical resection.			Neoplastic Process	
C155878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155878>	C200766|C176018	Relmacabtagene Autoleucel|Autologous Anti-CD19 CAR T-cells JWCAR029|Autologous CD19-targeted CAR T Cells JWCAR029|JWCAR 029|JWCAR-029|JWCAR029|RELMACABTAGENE AUTOLEUCEL|Relma-cel	A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed, costimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, relmacabtagene autoleucel target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.			Cell|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155879>	C129822|C128037	Penpulimab|AK 105|AK-105|AK105|Anike|Anniko|Anti-PD-1 Monoclonal Antibody AK105|PENPULIMAB|Penpulimab-kcqx	A monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, penpulimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.	Penpulimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15587>	C165194|C15569	Bone Marrow Ablation with Stem Cell Support	Bone marrow ablation followed by replacement of stem cells in the circulating blood to help the bone marrow recover and continue producing healthy blood cells.	Bone Marrow Ablation with Stem Cell Support		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C155880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155880>	C28681|C129826	Autologous HPV-specific Cytotoxic T Lymphocytes|Autologous HPV Specific Immune Lymphocytes|Autologous HPV-CTLs	A population of autologous cytotoxic T-lymphocytes (CTLs) that are specifically reactive to human papillomavirus (HPV), with potential antiviral and antineoplastic activities activities. Upon infusion of the autologous HPV-specific CTLs, these CTLs induce selective toxicity in HPV-positive cancer cells and other HPV-infected cells. HPV is associated with various cancer cell types.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155881>	C28676|C129826	Allogeneic HPV-specific Cytotoxic T Lymphocytes|Allogeneic HPV Specific Immune Lymphocytes|Allogeneic HPV-CTLs	A population of allogeneic cytotoxic T-lymphocytes (CTLs) that are specifically reactive to human papillomavirus (HPV), with potential antiviral and antineoplastic activities. Upon infusion of the allogeneic HPV-specific CTLs, these CTLs induce selective toxicity in HPV-positive cancer cells and other HPV-infected cells. HPV is associated with various cancer cell types.	Allodepleted T Cell Immunotherapeutic ATIR101		Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155882>	C308	Qilisheng Immunoregulatory Oral Solution|Qilisheng|Qilisheng Solution	An oral solution containing Spondias axillaris, Panax ginseng, schisandra berry, hawthorn, soybean and an as of yet not elucidated bacterium, with potential immunomodulating activity. Upon oral administration of the qilisheng immunoregulatory oral solution, the ingredients in qilisheng may modulate the immune system.			Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155883>	C200766|C176023	Autologous Anti-BCMA CAR-transduced T-cells KITE-585|Autologous Genetically Modified Anti-BCMA CAR-T Cells KITE-585|Autologous Genetically-modified Anti-BCMA CAR-transduced T-cells KITE-585|Autologous T-cells KITE-585|KITE 585|KITE-585|KITE585	A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) derived from a human monoclonal antibody specific for the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) fused, via an as of yet unknown linker, to the co-stimulatory domain of CD28, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-BCMA CAR transduced T-cells KITE-585 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma cells and plays a key role in plasma cell proliferation and survival. The CD28 co-stimulatory domain optimizes T-cell expansion and function.	Autologous Anti-BCMA CAR-transduced T-cells KITE-585		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155884>	C200766	Autologous Anti-HLA-A*0201/AFP CAR T-cells ET1402L1|Autologous AFP-CAR T-cells|Autologous AFP-CAR-transduced T-cells ET1402L1|Autologous ET1402L1-CAR T Cells|Autologous ET1402L1-CAR T-cells|Autologous T-cells Transduced with ET1402L1-CAR|ET1402L1-CAR T-cells	A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) derived from a human monoclonal antibody specific for an immunogenic human tumor-associated antigen (TAA) alpha-fetoprotein (AFP) epitope, AFP158-166, complexed with human leukocyte antigen (HLA)-A*02:01 (HLA-A*0201/AFP), fused to the co-stimulatory domains of CD28 and CD3zeta, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-HLA-A*0201/AFP CAR T-cells ET1402L1 specifically recognize and selectively bind to the AFP158-166 peptide presented by HLA-A*0201. Upon binding to the AFP-MHC complex, the T-cells release cytokines and induce selective toxicity in HLA-A*0201/AFP-positive tumor cells. AFP, an intracellularly expressed fetal glycoprotein rarely expressed in adult tissues, is overexpressed in certain tumors of endodermal origin and plays a key role in tumor cell proliferation and survival. AFP is processed into peptides and presented by class I major histocompatibility complexes (MHCs) on the surface of tumor cells.			Cell|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155885>	C202064	Tegavivint|9,10-Anthracenedione, 2,7-bis(((3R,5S)-3,5-dimethyl-1-piperidinyl)sulfonyl)-, 9,10-dioxime, rel-|BC 2059|BC-2059|BC2059|TEGAVIVINT|Tegatrabetan	A small molecule inhibitor of the Wnt/beta-catenin pathway with potential antineoplastic activity. Upon intravenous administration, tegavivint binds to transducin beta-like protein 1 (TBL1) and disrupts the binding of beta-catenin to TBL1. This promotes beta-catenin degradation, attenuates nuclear and cytoplasmic levels of beta-catenin, and reduces transcriptional activity of transcription factor 4 (TCF4) and expression of its target genes, cyclin D1, c-Myc and survivin. The Wnt/beta-catenin signaling pathway regulates cell morphology, motility, and proliferation; aberrant regulation of this pathway leads to neoplastic proliferation. Beta-catenin is frequently mutated in various tumors.	Tegavivint		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155887>	C226455	Gum Arabic Solution|Acacia Gum Solution|Acacia Resin Solution|Acacia Senegal Solution|Acacia Solution|Gum Acacia Solution	A solution containing the polymer gum acacia (gum Arabic), exuded from various Acacia trees, especially from Acacia senegal (Leguminosae), with potential protective and anti-mucositis activities. Upon administration of the gum Arabic solution in the oral cavity, the polymer forms a protective barrier over the oral mucosa, which may prevent inflammation of the mucosal membranes and may decrease chemotherapy- and/or radiation-induced oral mucositis.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C155888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155888>	C200766|C176018	Autologous Anti-CD19 CAR T-cells IM19|Autologous Anti-CD19 CAR-T Cells IM19|Autologous CD19-specific CAR-T Cells IM19|IM19	A preparation of autologous T-lymphocytes that have been genetically modified and transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed co-stimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR T-cells IM19 target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.			Cell|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155889>	C91105	MD Anderson Symptom Inventory - Gastrointestinal|MD Anderson Symptom Inventory - GI|MD Anderson Symptom Inventory Gastrointestinal Cancer Module|MDASI-GI	A site-specific MDASI module that assesses 5 symptoms specific to gastrointestinal cancer: constipation, diarrhea or watery stools, difficulty swallowing, change in taste, and feeling bloated.			Intellectual Product	
C15588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15588>	C61063	interleukin-6/sargramostim|GM-CSF/IL-6			Obsolete_Concept	Therapeutic or Preventive Procedure	
C155890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155890>	C173936|C107401	Diarrhea or Watery Stools via Stoma at its Worst Question|Diarrhea or Watery Stools via Stoma at its Worst|Your diarrhea, or watery stools via stoma (abdominal opening) at its worst	A question about an individual's diarrhea, or watery stools, via stoma at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Gastrointestinal
C155891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155891>	C173063|C107401	Change in Taste at its Worst Question|Change in Taste at its Worst|Your change in taste at its worst	A question about an individual's change in taste at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Gastrointestinal
C155892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155892>	C173219|C107401	Feeling Bloated at its Worst Question|Feeling Bloated at its Worst|Your feeling bloated at its worst	A question about an individual's bloated feeling at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Gastrointestinal
C155893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155893>	C188083|C107401	Inability to Eat at its Worst Question|Inability to Eat at its Worst|Your inability to eat at its worst	A question about an individual's inability to eat at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Gastrointestinal
C155894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155894>	C107401	Sore Mouth or Throat at its Worst Question|Sore Mouth or Throat at its Worst|Your sore mouth or throat at its worst	A question about an individual's sore mouth or throat at its worst.			Intellectual Product	MD Anderson Symptom Inventory - Gastrointestinal
C155895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155895>	C200085	Mps1 Inhibitor BOS172722|BOS 172722|BOS-172722|BOS172722|Monopolar Spindle 1 Inhibitor BOS172722|TTK Inhibitor BOS172722	An orally bioavailable, selective inhibitor of the serine/threonine-protein kinase monopolar spindle 1 (Mps1; TTK), with potential antineoplastic activity. Upon administration, the Mps1 inhibitor BOS172722 binds to and inhibits the activity of Mps1, a core component of the spindle assembly checkpoint (SAC). Inhibition of Mps1 activity compromises spindle assembly checkpoint, increases chromosome missegregation errors and decreases cancer cell viability. Mps1, a dual-specificity protein kinase expressed in proliferating normal tissues and aberrantly overexpressed in certain tumor types, is activated during mitosis and is essential in proper SAC function and chromosomal alignment.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155897>	C200766|C176018	Autologous Anti-CD19CAR-HER2t/CD22CAR-EGFRt-expressing T-cells	A preparation of autologous human T-lymphocytes engineered to express dual chimeric antigen receptors (CARs) consisting of both anti-CD19 and anti-CD22 binding domains, fused to an as of yet undisclosed co-stimulatory domain, and linked to truncated forms of the human epidermal growth factor receptor 2 (HER2t) and the human epidermal growth factor receptor (EGFRt), respectively with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-CD19CAR-HER2t/CD22CAR-EGFRt-expressing T-cells bind to CD19 and CD22 on the surface of, and induce selective toxicity against tumor cells expressing CD19 and CD22. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt and HER2t facilitate both in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through an antibody-dependent cellular cytotoxicity (ADCC) response. CD19 and CD22, both transmembrane phosphoglycoproteins expressed on the surface of cells in the B lineage, are often overexpressed on malignant B-cells.	Autologous Anti-CD19CAR-HER2t/CD22CAR-EGFRt-expressing T-cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155898>	C1511	Gallium Ga 68-NOTA-anti-HER2 Nanobody VHH1|68Ga-HER2-Nanobody VHH1|68Ga-NOTA-2Rs15d|68Ga-NOTA-anti-HER2 VHH1|Gallium Ga 68-NOTA-anti-HER2-VHH1|VHH1	A radioconjugate composed of a nanobody directed against human epidermal growth factor receptor 2 (HER2, EGFR2, ERBB2) that is linked, through the macrocyclic chelating agent 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA) to the radionuclide gallium (Ga) 68, with potential use in diagnostic imaging using positron emission tomography/computed tomography (PET/CT). Upon administration of gallium Ga 68-NOTA-anti-HER2 Nanobody VHH1, the anti-HER2 antibody moiety targets and binds to HER2-expressing cells. This facilitates both detection of HER2-expressing tumor cells and assessment of responses to HER2-targeted chemotherapeutic agents during PET/CT. HER2, a tyrosine kinase is overexpressed on the cell surfaces of various tumor cell types.			Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	NCI Drug Dictionary Terminology
C155899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155899>	C141215|C129822	Anti-CD20 Monoclonal Antibody B001|B 001|B001	A recombinant humanized monoclonal antibody directed against human CD20 with potential antineoplastic activity. Upon intravenous administration, anti-CD20 monoclonal antibody B001 specifically binds to CD20 on the surfaces of B-cells. Although the exact mechanisms through which B001 exert its effects have not been elucidated, B001 may induce a B-cell directed cell-mediated immune response against CD20-expressing B-cells and/or prevent CD20-medaited signaling. This induces tumor cell apoptosis and inhibits proliferation. CD20 is a non-glycosylated cell surface phosphoprotein which is exclusively expressed on B-cells during most stages of B-cell development and which is often overexpressed in B-cell malignancies.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15589>	C61063	Melphalan/Tumor Necrosis Factor|L-PAM/TNF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1558>	C1500	Extended Spectrum Penicillin Antibiotic	A group of penicillins with extended gram-negative bacterial coverage, including Ticarcillin, Piperacillin, Carbenicillin, Timentin and Mezlocillin.			Chemical Viewed Functionally	
C155900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155900>	C514	Fosmanogepix|(12-Amino-6-oxa-1(3),7(2)-dipyridina-2(5,3)-(1,2)oxazola- 4(1,4)-benzenaheptaphan-11-ium-11-yl)methyl hydrogen phosphate|APX-001|APX001|E1211|FOSMANOGEPIX|Prodrug APX001|Pyridinium, 2-amino-1-((phosphonooxy)methyl)-3-(3-((4-((2-pyridinyloxy)methyl)phenyl)methyl)-5-isoxazolyl)-, inner salt	An orally available small molecule inhibitor of the Gwt1 fungal enzyme with potential antifungal activity. Upon administration, fosmanogepix, a N-phosphonooxymethyl prodrug, is rapidly and completely metabolized by systemic alkaline phosphatases to its active moiety, APX001A (E1210). The active prodrug targets Gwt1, a highly conserved inositol acylase which catalyzes an essential step in the glycosylphosphatidylinositol (GPI)-anchor biosynthesis pathway. Inhibition of Gwt1 prevents localization of cell wall mannoproteins, which compromises cell wall integrity, biofilm formation, germ tube formation, and fungal growth.	Fosmanogepix		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C155901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155901>	C2926|C155902	Unresectable Lung Non-Small Cell Carcinoma|Unresectable Non-Small Cell Lung Carcinoma	Lung non-small cell carcinoma that is not amenable to surgical resection.	Unresectable Lung Non-Small Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155902>	C4878|C179420|C148124	Unresectable Lung Carcinoma	Lung carcinoma that is not amenable to surgical resection.	Unresectable Lung Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155903>	C96963|C162845|C148124	Unresectable Digestive System Carcinoma	A digestive system carcinoma that is not amenable to surgical resection.			Neoplastic Process	
C155904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155904>	C9484	del(3p21-p23)|del(3)(p21;p22)|del(3p21-22)	A cytogenetic abnormality that refers to deletion of chromosome bands 21-22 on the short arm of chromosome 3.			Cell or Molecular Dysfunction	
C155905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155905>	C9484	del(3p25-p26)|del(3)(p25;p26)|del(3p25-26)	A cytogenetic abnormality that refers to deletion of chromosome bands 25-26 on the short arm of chromosome 3.			Cell or Molecular Dysfunction	
C155906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155906>	C9484	del(3p13-p14)|del(3)(p13;p14)|del(3p13-14)	A cytogenetic abnormality that refers to deletion of chromosome bands 13-14 on the short arm of chromosome 3.			Cell or Molecular Dysfunction	
C155907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155907>	C129820	Monoclonal Microbial EDP1503|BIFIDOBACTERIUM ANIMALIS LACTIS EDP1503|EDP 1503|EDP-1503|EDP1503	An orally available preparation derived from a single clone of Bifidobacterium spp. with potential immunomodulatory and antineoplastic activities. Upon oral administration, monoclonal microbial EDP1503 colonizes the gut and may, through a not yet fully elucidated mechanism, promote the activation of dendritic cells (DCs), and enhance the induction and infiltration of cytotoxic T-lymphocytes (CTLs) in the tumor microenvironment (TME). Bifidobacterium is a genus of anaerobic, Gram-positive bacteria, with some species being a commensal part of the human gastrointestinal tract and vaginal flora.	Monoclonal Microbial EDP1503		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155908>	C4124|C3512|C128798	Metastatic Lung Adenocarcinoma	Lung adenocarcinoma that has spread from its original site of growth to another anatomic site.	Metastatic Lung Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155909>	C201275|C200766	Autologous Anti-mesothelin CAR-CD3zeta-4-1-BB-expressing T-cells|Autologous Anti-mesothelin CAR-CD3zeta-4-1-BB-expressing T-lymphocytes|Hu-CART-meso cells|Mesothelin-specific CAR T-cells	A preparation of autologous T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-mesothelin M5 single chain variable fragment (scFv) fused to the costimulatory domains of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), with potential immunomodulating and antineoplastic activities. After isolation, transduction, expansion in culture and reintroduction into the patient, the autologous anti-mesothelin CAR-CD3zeta-4-1BB-expressing T-cells specifically target and induce selective toxicity in mesothelin-expressing tumor cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types.	Autologous Anti-mesothelin CAR-CD3zeta-4-1-BB-expressing T-cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15590>	C61007	Monoclonal Antibody 3F8/Sargramostim|GM-CSF/MOAB 3F8			Obsolete_Concept	Therapeutic or Preventive Procedure	
C155910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155910>	C80307	Smoldering Waldenstrom Macroglobulinemia|Asymptomatic Waldenstrom Macroglobulinemia|Smoldering (Asymptomatic) Waldenstrom Macroglobulinemia	Waldenstrom macroglobulinemia with serum IgM monoclonal protein equal or more than 3 g/dL and/or at least 10% bone marrow lymphoplasmacytic infiltration but no evidence of constitutional symptoms, symptomatic anemia, or hyperviscosity. (Blood 2008, 112:2709)	Smoldering Waldenstrom Macroglobulinemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155911>	C35984	Bone Marrow Lymphoplasmacytic Infiltrate	A morphologic finding indicating the presence of a lymphoplasmacytic infiltrate in a bone marrow specimen.			Finding	
C155913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155913>	C120268	CYP3A5 Inducer|Cytochrome P450 3A5 Inducer	Any substance capable of increasing the activity of cytochrome P450 3A5.			Chemical Viewed Functionally	
C155914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155914>	C209878	CYP3A5 Inhibitor|Cytochrome P450 3A5 Inhibitor	Any substance capable of decreasing the activity of cytochrome P450 3A5.			Chemical Viewed Functionally	
C155915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155915>	C180669	CYP3A4 Substrate|CYP3A4 Sensitive Substrate|Cytochrome P450 3A4 Substrate	Any substance that is metabolized by cytochrome P450 3A4.	CYP3A4 Substrate		Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C155916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155916>	C180669	CYP3A5 Substrate|Cytochrome P450 3A5 Substrate	Any substance that is metabolized by cytochrome P450 3A5.			Substance	
C155917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155917>	C97927|C136423	MAPK1 Gene Mutation|ERK Gene Mutation|ERK-2 Gene Mutation|ERK2 Gene Mutation|ERT1 Gene Mutation|MAPK2 Gene Mutation|Mitogen-Activated Protein Kinase 1 Gene Mutation|P42MAPK Gene Mutation|PRKM1 Gene Mutation|PRKM2 Gene Mutation|p38 Gene Mutation|p40 Gene Mutation|p41 Gene Mutation|p41mapk Gene Mutation|p42-MAPK Gene Mutation	A change in the nucleotide sequence of the MAPK1 gene.	MAPK1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C155919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155919>	C36263|C3576	Metastatic Malignant Neoplasm in the Thoracic Cavity|Metastatic Malignant Neoplasm in the Thorax	A malignant neoplasm that has spread to the thoracic cavity from another anatomic site.	Metastatic Malignant Neoplasm in the Thoracic Cavity		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C15591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15591>	C15669	Prevention of Ovarian Cancer|Ovarian Cancer Prevention	Any method of preventing ovarian cancer including limit of exposure to carcinogens and infectious agents, diet, education, or lifestyle.			Therapeutic or Preventive Procedure	
C155920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155920>	C64940	Diagnostic Fiberoptic Endoscopic Examination|Fiberoptic Endoscopic Examination|Fiberoptic Endoscopy	A diagnostic procedure in which a fiberoptic endoscope is used.			Diagnostic Procedure	
C155921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155921>	C120268	CYP2C8 Inducer|Cytochrome P450 2C8 Inducer	Any substance capable of increasing the activity of cytochrome P450 2C8.	CYP2C8 Inducer		Chemical Viewed Functionally	CTRP Intervention Terminology|CTRP Terminology
C155922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155922>	C120268	CYP2C19 Inducer|Cytochrome P450 2C19 Inducer	Any substance capable of increasing the activity of cytochrome P450 2C19.	CYP2C19 Inducer		Chemical Viewed Functionally	CTRP Intervention Terminology|CTRP Terminology
C155923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155923>	C209878	CYP2C19 Inhibitor|Cytochrome P450 2C19 Inhibitor	Any substance capable of decreasing the activity of cytochrome P450 2C19.	CYP2C19 Inhibitor		Chemical Viewed Functionally	CTRP Intervention Terminology|CTRP Terminology
C155924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155924>	C16119	Suppressive Antiviral Therapy	Ongoing antiviral therapy to reduce the frequency of recurrence or prevent transmission.			Therapeutic or Preventive Procedure	
C155925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155925>	C49236	Upfront Treatment|Up-front Setting|Up-front Treatment|Up-front Treatment Setting|Upfront Therapy	The initial treatment for a disease.			Therapeutic or Preventive Procedure	
C155926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155926>	C61074|C219652	ATR Inhibitor|ATR Kinase Inhibitor	Any agent that inhibits the serine/threonine protein kinase ATR (ataxia telangiectasia; Rad3-related protein).	ATR Inhibitor		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C155927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155927>	C61074|C219652	Chk1 Inhibitor|CHEK1 Inhibitor|Checkpoint Kinase 1 Inhibitor	Any agent that inhibits the cell cycle checkpoint kinase 1 (Chk1).	Chk1 Inhibitor		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C155928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155928>	C217121	Sleep Disturbance Scale for Children|SDSC	A 27-item parent-administered instrument, developed by Bruni et al. in 1996, that utilizes a 5-point Likert rating scale to assess sleep disorders in children.			Intellectual Product	
C155929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155929>	C217121	Cornell Scale for Depression in Dementia	A 19-item clinician-administered instrument, developed by Alexopoulos et al. in 1986, that utilizes a three-point rating scale to assess signs and symptoms of major depression in patients with dementia, based on interviews with both the patient and a caregiver.			Intellectual Product	
C155930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155930>	C18890	Myeloid Mutation Panel|Myeloid Molecular Profile|Myeloid Molecular Profiling|Myeloid Panel	An assay based on next-generation sequencing techniques designed to detect one or more genetic abnormalities in a set of genes that may have diagnostic, prognostic or therapeutic significance in acute myeloid leukemia, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN) or MDS/MPN overlap disorders.			Laboratory Procedure	
C155931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155931>	C129822|C128057	Betifisolimab|Anti-PD-L1 Monoclonal Antibody MSB2311|Anti-PDL1 Monoclonal Antibody MSB2311|BETIFISOLIMAB|Humanized Anti-PD-L1 Monoclonal Antibody MSB2311|MSB 2311|MSB-2311|MSB2311	A second-generation, humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Betifisolimab contains a unique, not as of yet elucidated, pH-dependent antigen binding property allowing the antibody to only bind to PD-L1 within the acidic tumor microenvironment (TME), while it is not able to bind to PD-L1 in normal, healthy tissue. Upon administration, once able to bind to PD-L1 in the TME, betifisolimab blocks the binding of PD-L1 to and activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on activated T-cells suppresses the immune system and results in immune evasion. PD-1 negatively regulates T-cell activation.	Betifisolimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155932>	C217121	Children's Global Assessment Scale|CGAS	A clinician-assessed rating of psychological and social functioning in children ages six to seventeen that was developed by Shaffer et al. in 1983. The numerical scale, which is an adaptation of the adult Global Assessment Scale (GAS) developed by Endicott et al in 1976, is scored from 0 to 100 based on behaviors and life situations that are applicable to children.			Intellectual Product	
C155933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155933>	C168985|C155934|C153075	Locally Advanced Pancreatic Neuroendocrine Carcinoma	A pancreatic neuroendocrine carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Pancreatic Neuroendocrine Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155934>	C191983|C178271|C155936|C153358	Locally Advanced Digestive System Neuroendocrine Carcinoma|Locally Advanced Gastroenteropancreatic Neuroendocrine Carcinoma|Locally Advanced Gastrointestinal System Neuroendocrine Carcinoma	A neuroendocrine carcinoma that arises from any part of the digestive system and has spread to nearby tissues or lymph nodes.	Locally Advanced Digestive System Neuroendocrine Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155935>	C95405|C191980|C165455|C155903	Unresectable Digestive System Neuroendocrine Carcinoma|Unresectable Gastroenteropancreatic Neuroendocrine Carcinoma|Unresectable Gastrointestinal System Neuroendocrine Carcinoma	A neuroendocrine carcinoma that arises from any part of the digestive system and is not amenable to surgical resection.	Unresectable Digestive System Neuroendocrine Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155936>	C95405|C191981|C156492|C133839	Metastatic Digestive System Neuroendocrine Carcinoma|Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma|Metastatic Gastrointestinal System Neuroendocrine Carcinoma	A neuroendocrine carcinoma that arises from any part of the digestive system and has metastasized to another anatomic site.	Metastatic Digestive System Neuroendocrine Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155937>	C95405|C191979|C158088|C151906	Refractory Digestive System Neuroendocrine Carcinoma|Refractory Gastrointestinal System Neuroendocrine Carcinoma	A neuroendocrine carcinoma that arises from any part of the digestive system and does not respond to treatment.	Refractory Digestive System Neuroendocrine Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155938>	C95405|C7622|C191978|C188228	Recurrent Digestive System Neuroendocrine Carcinoma|Recurrent Gastrointestinal System Neuroendocrine Carcinoma	The reemergence of a neuroendocrine carcinoma in any part of the digestive system after a period of remission.			Neoplastic Process	
C155939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155939>	C217120	Modified Ryan Scheme for Tumor Regression|Ryan TRG	A four-point tumor regression grading system that is used to measure therapeutic response of primary tumors and to predict patient outcomes.			Classification	
C15593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15593>	C1663	gp100 Antigen/Interleukin-2|gp100/IL-2				Pharmacologic Substance	
C155940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155940>	C155712	Anti-HER2/PBD-MA Antibody-drug Conjugate DHES0815A|ADC DHES0815A|Anti-HER2/PBD-MA ADC DHES0815A|Anti-HER2/PBD-Monoamide ADC DHES0815A|DHES-0815A|DHES0815A	An antibody-drug conjugate (ADC) consisting of a monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2) linked to a DNA minor groove crosslinking agent pyrrolo[2,1- c][1,4]benzodiazepine monoamide (PBD-MA), with potential antineoplastic activity. Upon intravenous administration of ADC DHES0815A, the monoclonal antibody moiety targets and binds to HER2 expressed on tumor cells. Following receptor internalization and lysosome-mediated cleavage, the cytotoxic PBD-MA moiety is released. In turn, the imine groups of the PBD-MA moiety bind to and crosslink specific sites of DNA, resulting in DNA strand breaks, cell cycle arrest, and cell death in HER2 expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.	Anti-HER2/PBD-MA Antibody-drug Conjugate DHES0815A		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155941>	C28076	Tumor Regression Score 0|0|Complete Response Score 0	A score on the Modified Ryan Scheme for Tumor Regression that indicates a complete response, defined as having no viable cancer cells.			Classification	GDC Terminology|GDC Value Terminology|Modified Ryan Scheme for Tumor Regression
C155942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155942>	C28076	Tumor Regression Score 1|1|Near Complete Response Score 1	A score on the Modified Ryan Scheme for Tumor Regression that indicates a near complete response, defined as the presence of single cells or rare small groups of cancer cells.			Classification	GDC Terminology|GDC Value Terminology|Modified Ryan Scheme for Tumor Regression
C155943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155943>	C28076	Tumor Regression Score 2|2|Partial Response Score 2	A score on the Modified Ryan Scheme for Tumor Regression that indicates a partial response, defined as the presence of residual cancer with evident tumor regression but more than single cells or rare small groups of cancer cells.			Classification	GDC Terminology|GDC Value Terminology|Modified Ryan Scheme for Tumor Regression
C155944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155944>	C28076	Tumor Regression Score 3|3|Poor or No Response Score 3	A score on the Modified Ryan Scheme for Tumor Regression that indicates poor or no response, defined as extensive residual cancer with no evident tumor regression.			Classification	GDC Terminology|GDC Value Terminology|Modified Ryan Scheme for Tumor Regression
C155945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155945>	C129820	NLRP3 Agonist BMS-986299|BMS 986299|BMS-986299|BMS-986299|BMS986299|NLR Family Pyrin Domain Containing 3 Agonist BMS-986299	A nucleotide-binding domain and leucine-rich repeat (NLR) family pyrin domain containing 3 (NLRP3; NACHT, LRR and PYD Containing Protein 3; NALP3) agonist with potential immunomodulatory and antineoplastic activities. Upon administration, NLRP3 agonist BMS-986299 binds to and activates NLRP3, potentially promoting NLRP3 inflammasome-mediated secretion of interleukin-8 (IL-8), which may induce tumoricidal activity of natural killer (NK) cells against tumor cells. NLRP3, a sensor component of the NLRP3 inflammasome plays a significant role in immunity and inflammation, and may protect against tumorigenesis in some cancers.	NLRP3 Agonist BMS-986299		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155946>	C165276	INC Terminology|International Neonatal Consortium Terminology	Terminology developed by NCIt EVS and the International Neonatal Consortium (INC), a C-Path consortium formed to forge a predictable regulatory path for evaluating the safety and effectiveness of therapies for neonates.  Operating in the pre-competitive space, INC addresses the need for measurement and assessment of clinical outcomes in neonates through teams that share data and expertise to advance regulatory science.			Intellectual Product	Pediatric Terminologies
C155947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155947>	C7007|C4874	Cerebral Hemangioblastoma	A hemangioblastoma that arises from the cerebrum.	Cerebral Hemangioblastoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155948>	C7007	Spinal Hemangioblastoma	A hemangioblastoma that arises from the spinal cord.	Spinal Hemangioblastoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155949>	C5147	Medullary Hemangioblastoma	A hemangioblastoma that arises from the medulla oblongata.	Medullary Hemangioblastoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C15594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15594>	C61063	Interleukin-2/Monoclonal Antibody HuG1-M195|IL-2/MOAB HuM195			Obsolete_Concept	Therapeutic or Preventive Procedure	
C155950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155950>	C9479|C9297	Hereditary Malignant Urinary System Neoplasm	A malignant urinary system neoplasm that has developed in relatives of patients with a history of malignant urinary system neoplasm.	Hereditary Malignant Urinary System Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155951>	C4146	Chromophobe Renal Cell Carcinoma Associated with Birt-Hogg-Dube Syndrome	Chromophobe renal cell carcinoma that develops in a patient with Birt-Hogg-Dube syndrome.	Chromophobe Renal Cell Carcinoma Associated with Birt-Hogg-Dube Syndrome		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155952>	C2974|C126493	Uterine Ligament Papillary Cystadenoma	A cystadenoma that arises from the broad or other uterine ligaments. It is characterized by the presence of small papillary projections in the inner surface of the cysts. It may be sporadic or associated with von Hippel-Lindau disease.			Neoplastic Process	
C155953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155953>	C2974|C162483	Epididymal Papillary Cystadenoma	A cystadenoma that arises from the epididymis. It is characterized by the presence of small papillary projections in the inner surface of the cysts. It may be sporadic or associated with von Hippel-Lindau disease.	Epididymal Papillary Cystadenoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155954>	C28193	Intestinal Polyposis Syndrome	A syndrome associated with the development of multiple polyps throughout the intestine. It includes familial adenomatous polyposis , hamartomatous polyposis syndromes, and other rare polyposis syndromes.	Intestinal Polyposis Syndrome		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C155956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155956>	C200052|C192742|C192741|C124800	CDK2/4/6/FLT3 Inhibitor FN-1501|4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide|CDK/FLT3 Inhibitor FN-1501|FN 1501|FN-1501|FN-1501|FN1501	A small molecule multi-kinase inhibitor of cyclin-dependent kinase (CDK) subtypes 2 (CDK2), 4 (CDK4), and 6 (CDK6) and FMS-related tyrosine kinase 3 (FLT3, FLK2, STK1), with potential antineoplastic activity. Upon intravenous administration, CDK2/4/6/FLT3 inhibitor FN-1501 binds to and inhibits CDK2, CDK4, and CDK6, as well as FLT3. This may induce apoptosis and inhibit tumor cell proliferation in cancer cells that overexpress these kinases. CDKs are serine/threonine kinases that assist in cell cycle regulation and cellular proliferation. FLT3, a class III tyrosine kinase receptor, is overexpressed or mutated in many cancer types.	CDK2/4/6/FLT3 Inhibitor FN-1501		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155957>	C3502	Thyroid Gland Spindle Cell Follicular Adenoma	A rare thyroid gland follicular adenoma composed predominantly of spindle cells.			Neoplastic Process	
C155958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155958>	C3502	Thyroid Gland Black Follicular Adenoma	A thyroid gland follicular adenoma seen in patients treated with minocycline. The tumors have black discoloration visible on macroscopic examination and cytoplasmic accumulation of black pigment. (WHO 2017)			Neoplastic Process	
C155959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155959>	C125008	Tissue Black Discoloration	Color change of a tissue to black.			Finding	
C15595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15595>	C15747	Transitional Care Planning|transitional care	Support given to patients when they move from one phase of disease or treatment to another, such as from hospital care to home care. It involves helping patients and families with medical, practical, and emotional needs as they adjust to different levels and goals of care.	Transitional Care Planning		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C155960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155960>	C35867	Cytoplasmic Accumulation of Black Pigment	A morphologic finding indicating the presence of black pigment within the cytoplasm of cells in a tissue sample.			Finding	
C155961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155961>	C19498	Decision Aid	Printed or electronic materials designed to provide evidence-based information about the harms and benefits of reasonable healthcare options to help individuals deliberate about their preferences and be meaningfully involved in treatment decisions. Patients who are informed and involved in their healthcare decisions have lower anxiety, experience less decision regret, and achieve higher quality of life.	Decision Aid		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C155962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155962>	C35867	Submucosal Invasion Depth|tumor depth|tumor_depth	A morphological finding indicating the depth of tumor invasion into the submucosal tissue.			Finding	GDC Property Terminology|GDC Terminology
C155963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155963>	C155962	Submucosal 1 Invasion|Submucosal Invasion Depth Class 1	Submucosal tumor invasion into the upper third of the submucosal tissue.			Finding	
C155964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155964>	C155962	Submucosal 2 Invasion|Submucosal Invasion Depth Class 2	Submucosal tumor invasion into the middle third of the submucosal tissue.			Finding	
C155965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155965>	C155962	Submucosal 3 Invasion|Submucosal Invasion Depth Class 3	Submucosal tumor invasion into the lower third of the submucosal tissue.			Finding	
C155966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155966>	C91105	Survey of Autonomic Symptoms|SAS	A questionnaire developed by Zilliox et al. in 2011 that consists of 11 items for women and 12 items for men, and utilizes a five-point rating scale to assess the severity of autonomic symptoms in patients with neuropathy.			Intellectual Product	
C155967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155967>	C199488|C129822	Alsevalimab|ALSEVALIMAB|Anti-B7-H4 Monoclonal Antibody FPA150|FPA 150|FPA-150|FPA150	A fully human, glycoengineered monoclonal antibody targeting B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1) with potential antineoplastic and immune checkpoint inhibitory activities. Upon intravenous administration, alsevalimab binds to B7-H4 on the surface of tumor cells, thereby preventing B7-H4 binding to T-cells and abrogating the B7-H4-mediated negative regulation of T-cell activation. This increases a cytotoxic T-lymphocyte (CTL)-mediated immune response against B7-H4-expressing tumor cells. In addition, the afucosylated Fc region of the anti-B7-H4 monoclonal antibody FPA150 enhances its binding affinity for human FcgammaRIIIa receptors (CD16) on natural killer (NK) cells, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) against B7-H4-expressing tumor cells. B7-H4, a member of the B7 family of immune modulators, is upregulated in a variety of tumor cell types and negatively regulates T-cell immune responses.	Alsevalimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155968>	C2124	Carbon C 14 Mivavotinib Citrate|14C-labeled Mivavotinib Citrate|[14 C]-TAK-659|[14C]TAK 659|[14C]TAK-659	A radioconjugate composed of the citrate form of mivavotinib, an orally bioavailable selective inhibitor of the non-receptor tyrosine kinase (RTK) spleen tyrosine kinase (Syk), labeled with the radioisotope carbon C 14, with potential use for evaluating the pharmacokinetic profile of mivavotinin. Upon administration of carbon C 14 mivavotinib citrate, mivavotinib targets, binds to and inhibits Syk. Labeling of mivavotinib with the radioactive tracer carbon C 14 permits the evaluation of this agent's pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME). Syk, a B-cell receptor (BCR)-associated non-receptor tyrosine kinase that mediates B-cell activation, chemotaxis, adhesion and proliferation, is expressed in hematopoietic tissues and is often overexpressed in hematopoietic malignancies.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C155969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155969>	C28681|C129826	Total Tumor mRNA-pulsed Tumor-specific Ex vivo-expanded Autologous Lymphocyte Transfer Cells|Autologous TTRNA mRNA-loaded Lymphocyte Transfer Cells|TTRNA-xALT|TTRNA-xALT Cells	A preparation of ex vivo expanded, autologous lymphocyte transfer cells (xALTs) that are loaded with total tumor RNA (TTRNA) derived from autologous tumor cells, with potential immunostimulatory and antineoplastic activities. Upon re-infusion of the TTRNA-loaded ALTs into the patient, these ALTs may elicit a highly specific cytotoxic T-lymphocyte (CTL) response against the tumor-associated antigens (TAAs) encoded by the TTRNA.	Total Tumor mRNA-pulsed Tumor-specific Ex vivo-expanded Autologous Lymphocyte Transfer Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15596>	C61063	Interleukin-2/Vinblastine|IL-2/VBL			Obsolete_Concept	Therapeutic or Preventive Procedure	
C155970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155970>	C201282|C200367	Anti-CD33/CD3 Bispecific Antibody GEM 333|Anti-CD33 Bispecific Antibody GEM 333|Anti-CD33/Anti-CD3 Bispecific Antibody GEM 333|Anti-CD33/CD3 Antibody GEM 333|GEM 333|GEM-333|GEM333	A bispecific antibody possessing two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for the tumor-associated antigen (TAA) CD33, with potential immunostimulating and antineoplastic activities. Upon administration of anti-CD33/CD3 bispecific antibody GEM 333, this bispecific antibody binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD33 antigen found on CD33-expressing tumor cells, thereby crosslinking tumor cells and CTLs. This activates and redirects CTLs to CD33-expressing tumor cells, which results in the CTL-mediated cell death of CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem and progenitor cells (HSPCs) and is overexpressed on a variety of cancer cell types, including acute myeloid leukemia (AML). It plays a key role in tumor initiation, proliferation and progression.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155971>	C69145|C129825	MEK inhibitor CS3006|CS 3006|CS-3006|CS3006|MAPK Kinase Inhibitor CS3006	An orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPKK; MEK), with potential antineoplastic activity. Upon oral administration, MEK inhibitor CS3006 specifically targets, binds to and inhibits the catalytic activity of MEK, thereby inhibiting the activation of MEK-dependent effector proteins including extracellular signal-regulated kinase (ERK) and inhibits the proliferation of tumor cells in which the RAS/RAF/MEK/ERK signaling pathway is overactivated. The threonine/tyrosine protein kinase MEK plays a key role in the  RAS/RAF/MEK/ERK signaling pathway, which is frequently upregulated in a variety of tumor cell types. The RAS/RAF/MEK/ERK pathway regulates key cellular activities including cell growth, proliferation, survival, differentiation and apoptosis.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155972>	C2124	Fluorine F 18-AIF-NOTA-neurotensin|18F-AlF-NOTA-NT|18F-AlF-NOTA-neurotensin|18F-aluminum Fluoride-1,4,7-triazacyclononane-1,4,7-triacetic Acid-neurotensin|Fluorine F 18-Al-NOTA-neurotensin|[18F]AlF-NOTA-neurotensin|[18F]Aluminum Fluoride-1,4,7-triazacyclononane-1,4,7-triacetic Acid-neurotensin	A radioconjugate containing neurotensin (NT) linked to the radionuclide fluorine F 18 (18F), by the macrocyclic chelating agent, 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA), through a method that first couples 18F to aluminum (Al), with potential use in diagnostic imaging using positron emission tomography/computed tomography (PET/CT). Upon administration of fluorine F 18-Al-NOTA-neurotensin, the ligand moiety targets and binds to the neurotensin receptor (NTR). Upon PET/CT, NTR-expressing tumor cells can then be visualized and NTR tumor cell expression can be assessed, as well as the diagnosis and stage of cancer. The neuropeptide NT is overexpressed in certain types of cancers and plays a key role in tumor cell proliferation.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C155973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155973>	C4813|C2947	Recurrent Chordoma	The reemergence of chordoma after a period of remission.	Recurrent Chordoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155974>	C129986	Babaodan Capsule|BBD|BD|Babao Dan	An orally available mixed powder of traditional Chinese medicine containing eight constituents including natural calculus bovis, snake gall, antelope horn, pearl, musk, radix notoginseng, and other as of yet not disclosed ingredients, with potential antifibrotic, immunomodulatory, and antineoplastic activities. Upon oral administration, babaodan may ameliorate substance-induced liver injury and fibrosis, and inhibit lipopolysaccharide (LPS)-induced hepatic stellate cell (HSC) activation and proliferation through toll-like receptor 4 (TLR4)/nuclear factor-kappa B and TLR4/extracellular-signal-regulated kinase (ERK) pathways. Babaodan may, through an as of yet not elucidated mechanism, enhance the efficacy of chemotherapeutic drugs and may inhibit the occurrence and development of certain tumor types.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155976>	C159583	Urabrelimab|Anti-CD47 Monoclonal Antibody SRF231|SRF 231|SRF-231|SRF231|URABRELIMAB	A human monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, urabrelimab selectively binds to CD47 on tumor cells and blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages. This prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.	Urabrelimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155977>	C200225|C1511	Thorium Th 227 Anetumab Corixetan|227Th Anetumab Corixetan|ANETUMAB CORIXETAN THORIUM TH-227|BAY 2287411|BAY2287411|Thorium Th 227 Monoclonal Antibody BAY2287411|Thorium-227 Labeled Anetumab|Thorium-227 Labeled Antibody-chelator Conjugate BAY2287411	A radioimmunoconjugate consisting of anetumab, a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface glycoprotein mesothelin, conjugated to the chelating agent corixetan, and labeled with the alpha-emitting radioisotope thorium Th 227, with potential antineoplastic activity. Upon administration of thorium Th 227 anetumab corixetan, the anetumab moiety binds to the tumor-associated antigen (TAA) mesothelin, delivering a cytotoxic dose of alpha radiation to cells expressing mesothelin.	Thorium Th 227 Anetumab Corixetan		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C155978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155978>	C187284	Thyroid Gland Follicular Tumor of Uncertain Malignant Potential|FT-UMP|Thyroid Gland Follicular Neoplasm of Uncertain Malignant Potential	An encapsulated or well-circumscribed thyroid gland tumor composed of well-differentiated follicular cells with no nuclear features of papillary thyroid carcinoma and with questionable capsular or vascular invasion. This is a tumor indeterminate between follicular adenoma and follicular carcinoma. (WHO)			Neoplastic Process	Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C155979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155979>	C36117	Questionable Invasive Lesion	A neoplastic lesion in which the adjacent tissues, surrounding capsule, or vessels may or may not be invaded by neoplastic cells.			Finding	
C15597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15597>	C61063	Incomplete Freund's Adjuvant/Interleukin-12/MART-1 Antigen|IFA/IL-12/MART-1			Obsolete_Concept	Therapeutic or Preventive Procedure	
C155980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155980>	C138961	PSA Level Greater than or Equal to 0.8|PSA Level 0.8 or Greater	A blood concentration of prostate specific antigen greater than or equal to 0.8 ng/mL.	PSA Level Greater than or Equal to 0.8		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C155981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155981>	C263	Defibrotide|DEFIBROTIDE FREE ACID	A mixture of single-stranded oligodeoxyribonucleotides derived from the intestinal mucosa of pigs, with anti-thrombotic, thrombolytic, and fibrinolytic activities. Upon administration, and although the exact mechanism of action has yet to be fully elucidated, defibrotide induces the release of prostaglandin I2 (PGI2), E2 (PGE2), and prostacyclin and reduces the expression of adhesion molecules on endothelial cells. This relaxes the smooth muscle of blood vessels and prevents platelets from adhering to each other and to the endothelium. This protects the endothelium lining bloods vessels. Defibrotide increases tissue plasminogen activator (t-PA) and decreases plasminogen activator inhibitor-1 activity. This increases the activity of plasmin, prevents blood clot formation and dissolves blood clots.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C155982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155982>	C263	Defibrotide (Bovine)|DEFIBROTIDE (BOVINE)	A mixture of single-stranded oligodeoxyribonucleotides derived from bovine pulmonary tissue, with anti-thrombotic, thrombolytic, and fibrinolytic activities. Upon administration, and although the exact mechanism of action has yet to be fully elucidated, defibrotide induces the release of prostaglandin I2 (PGI2), E2 (PGE2), and prostacyclin and reduces the expression of adhesion molecules on endothelial cells. This relaxes the smooth muscle of blood vessels and prevents platelets from adhering to each other and to the endothelium. This protects the endothelium lining bloods vessels. Defibrotide increases tissue plasminogen activator (t-PA) and decreases plasminogen activator inhibitor-1 activity. This increases the activity of plasmin, prevents blood clot formation and dissolves blood clots.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C155983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155983>	C8567|C71698|C132506	Recurrent Visual Pathway Glioma	The reemergence of visual pathway glioma after a period of remission.	Recurrent Visual Pathway Glioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155984>	C8567|C71702|C147107	Refractory Visual Pathway Glioma	Visual pathway glioma that is resistant to treatment.	Refractory Visual Pathway Glioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155985>	C3273	Recurrent Neurofibromatosis Type 1	The reemergence of neurofibromatosis type 1 after a period of remission.	Recurrent Neurofibromatosis Type 1		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C155986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155986>	C3273	Refractory Neurofibromatosis Type 1	Neurofibromatosis type 1 that is resistant to treatment.	Refractory Neurofibromatosis Type 1		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C155987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155987>	C3798|C148301	Refractory Malignant Peripheral Nerve Sheath Tumor	Malignant peripheral nerve sheath tumor that is resistant to treatment.	Refractory Malignant Peripheral Nerve Sheath Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C155988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155988>	C21072	Quadratus Lumborum Block|QL Block	A technique for regional anesthesia that uses ultrasound-guided injection of an anesthetic agent into the posterior abdominal wall.	Quadratus Lumborum Block		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C155989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155989>	C158758	Synchronous Resection|Synchronous Excision|Synchronous Tumor Resection	A surgical procedure for the removal of multiple tumors within a single operative procedure.			Health Care Activity	
C15598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15598>	C61063	Bispecific Antibody 520C9XH22/Filgrastim|BsAb 520C9xH22/G-CSF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C155990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155990>	C158758	Staged Resection|Staged Excision|Staged Tumor Resection	A surgical procedure for the removal a tumor or multiple tumors during multiple operative procedures.			Health Care Activity	
C155991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155991>	C94299|C177692	ROS1 Positive|MCF3 Positive|Proto-Oncogene Tyrosine-Protein Kinase ROS Positive|Proto-Oncogene c-Ros Positive|Proto-Oncogene c-Ros-1 Positive|ROS Positive|ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Positive|Receptor Tyrosine Kinase c-Ros Oncogene 1 Positive|c-Ros Positive|c-Ros-1 Positive	An indication that expression of ROS1 has been detected in a sample.	ROS1 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C155992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155992>	C171054|C160359	ETV6 Gene Rearrangement|ETS Variant 6 Gene Rearrangement|ETS Variant Gene 6 Rearrangement|ETV6 Rearrangement|ETV6 rearranged|TEL Gene Rearrangement|TEL Oncogene Rearrangement	A molecular abnormality indicating rearrangement of the ETV6 gene.	ETV6 Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C155993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155993>	C147055	Blasts 2 Percent or More of Peripheral Blood White Cells|Blasts Greater than or Equal to 2 Percent of Peripheral Blood White Cells	A semi-quantitative microscopic finding indicating that 2 percent or more of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.	Blasts 2 Percent or More of Peripheral Blood White Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C155994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155994>	C164199	Folate Receptor Alpha Negative|FBP Negative|FOLR Negative|FOLR1 Negative|FR-Alpha Negative|Folate Receptor 1 Negative|Folate-Binding Protein, Adult Negative	An indication that folate receptor alpha has not been detected in a sample.	Folate Receptor Alpha Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C155995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155995>	C35880	Myeloblasts Present|Myeloblasts Positive|Myeloid Blast Cells Positive|Myeloid Blast Cells Present|Myeloid Blast Positive|Myeloid Blasts Positive|Myeloid Blasts Present	A microscopic finding indicating the presence of immature mononuclear cells of myeloid origin in a sample.	Myeloblasts Present		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C155996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155996>	C82341	Ataxia with Isolated Vitamin E Deficiency|AVED	An autosomal recessive condition caused by mutation(s) in the TTPA gene, encoding alpha-tocopherol transfer protein. It is characterized by spinocerebellar ataxia and extremely low concentrations of vitamin E.			Disease or Syndrome	Cellosaurus Disease Terminology
C155997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155997>	C16809	MR Sialography|MRI Sialography|Magnetic Resonance Sialography	The use of magnetic resonance imaging to evaluate the salivary glands and ducts.	MR Sialography		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C155998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155998>	C122814	Developmental and Epileptic Encephalopathy 32|DEE32|EIEE32|Early Infantile Epileptic Encephalopathy 32	An autosomal dominant form of early infantile epileptic encephalopathy, caused by mutation(s) in the KCNA2 gene, encoding potassium voltage-gated channel subfamily A member 2.			Disease or Syndrome	Cellosaurus Disease Terminology
C155999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C155999>	C84638	Primary Ciliary Dyskinesia 15|CILD15	An autosomal recessive primary ciliary motility defect caused by mutation(s) in the CCDC40 gene, encoding coiled-coil domain-containing protein 40.			Disease or Syndrome	Cellosaurus Disease Terminology
C15599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15599>	C63475|C15471	Hormone Replacement Therapy|HRT|HRT|Hormone Replacement Rx|hormone replacement therapy|hormone replacement therapy type|hormone_replacement_therapy_type|menopausal hormone therapy	Treatment with estrogens or estrogen/progesterone after menopause or ovariectomy to prevent pathological effects of decreased estrogen production.			Therapeutic or Preventive Procedure	GDC Property Terminology|GDC Terminology
C1559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1559>	C2078	Levoleucovorin|CL-307,782|Elvorine, Isovorin, Levofolene, Levorin|Isovorin|L-5-Formyltetrahydrofolate|L-Leucovorin|LEVOLEUCOVORIN|Levofolinate|Levofolinic acid	The active l-isomer of the racemic mixture of the 5-formyl derivative of tetrahydrofolic acid. Metabolically active, l-leucovorin, also known levoleucovorin, does not require bioactivation by dihydrofolate reductase, an enzyme inhibited by folic acid antagonists. This agent may enhance the effects of fluoropyrimidines by stabilizing their binding to the enzyme thymidylate synthase. (NCI04)	Levoleucovorin		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C156000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156000>	C146669	Myeloblasts More than 5 Percent of Bone Marrow Nucleated Cells|Myeloblasts Greater than 5 Percent of Bone Marrow Nucleated Cells|Myeloblasts Over 5 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that more than 5 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells of myeloid origin.	Myeloblasts More than 5 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C156001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156001>	C17728	IL6R Gene Product	A protein encoded by the IL6R gene.			Amino Acid, Peptide, or Protein	
C156002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156002>	C156001	Soluble Interleukin-6 Receptor Subunit Alpha|Soluble CD126|Soluble CD126 Antigen|Soluble IL-6 Receptor|Soluble IL-6 Receptor Alpha|Soluble IL-6R|Soluble IL-6R Subunit Alpha|Soluble IL-6R-Alpha|Soluble IL-6RA|Soluble IL6R|Soluble IL6RA|Soluble Interleukin 6 Receptor|Soluble Interleukin 6 Receptor Subunit Alpha|Soluble Interleukin-6 Receptor|Soluble gp80|sIL-6R|sIL-6RA	Soluble interleukin-6 receptor subunit alpha is encoded by the human IL6R gene. This protein, which is produced by metalloproteinase-mediated cleavage of the membrane-bound form, is involved in the modulation of interleukin-6-mediated signaling by CD4-positive T-lymphocytes.	Soluble Interleukin-6 Receptor Subunit Alpha		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156003>	C157377	Testosterone Less than or Equal to 100 ng/dL|Testosterone Less than or Equal to 100 Nanograms per Deciliter|Testosterone Less than or Equal to 100 Nanograms/Deciliter	A semiquantitative finding indicating that the concentration of testosterone in a sample is less than or equal to 100 ng/dL.	Testosterone Less than or Equal to 100 ng/dL		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C156004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156004>	C12558	M1 Macrophage	A macrophage that expresses CD80 and CD86 on the cell surface, produces high levels of interleukin (IL)-8 and IL-12 and converts arginine to nitric oxide. These cells promote inflammation.	M1 Macrophage		Cell	CTRP Biomarker Terminology|CTRP Terminology
C156005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156005>	C67208	M1 Macrophage to M2 Macrophage Ratio Measurement|M1 to M2 Macrophage Ratio|M1 to M2 Macrophage Ratio Measurement|M1 to M2 Ratio Measurement|M1/M2 Macrophage Ratio|M1/M2 Macrophage Ratio Measurement|M1/M2 Ratio|M1/M2 Ratio|M1/M2 Ratio Measurement	The determination of the ratio of M1 macrophages to M2 macrophages present in a sample.	M1/M2 Ratio		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Terminology
C156006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156006>	C206076	Absolute Neutrophil Count Greater than or Equal to 500/mm3|ANC Greater than or Equal to 0.5x10^9/L|ANC Greater than or Equal to 500 per Cubic Millimeter|ANC Greater than or Equal to 500 per Microliter|ANC Greater than or Equal to 500/mm3|ANC Greater than or Equal to 500/uL|Absolute Neutrophil Count Greater than or Equal to 500 per Cubic Millimeter|Absolute Neutrophil Count Greater than or Equal to 500 per Microliter|Absolute Neutrophil Count Greater than or Equal to 500/ul|Absolute Neutrophil Count Greater than or equal to 0.5 x 10^3/uL|Neutrophil Count Greater than or Equal to 500|Neutrophil Count Greater than or Equal to 500 per cubic millimeter	A quantitative microscopic finding indicating that neutrophils are found at greater than or equal to 500 per cubic millimeter field in a sample.	Absolute Neutrophil Count Greater than or Equal to 500/mm3		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C156007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156007>	C138961	PSA Level Less than or Equal to Four|PSA Level 4 or Less|PSA Level Four or Less|PSA Level Less than or Equal to 4	A blood concentration of prostate specific antigen less than or equal to 4 ng/mL.	PSA Level Less than or Equal to Four		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156008>	C93102|C154230	Deleterious HDAC2 Gene Mutation|Deleterious HD2 Gene Mutation|Deleterious Histone Deacetylase 2 Gene Mutation|Deleterious RPD3 Gene Mutation|Deleterious YAF1 Gene Mutation	A change in the nucleotide sequence of the HDAC2 gene that is associated with increased risk of disease.	Deleterious HDAC2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156009>	C141248|C132006	Deleterious RAD54L Gene Mutation|Deleterious HR54 Gene Mutation|Deleterious HRAD54 Gene Mutation|Deleterious RAD54 Homolog Gene Mutation|Deleterious RAD54-like (S. cerevisiae) Gene Mutation|Deleterious RAD54A Gene Mutation|Deleterious hHR54 Gene Mutation	A change in the nucleotide sequence of the RAD54L gene that is associated with increased risk of disease.	Deleterious RAD54L Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15600>	C70820	Phase I Trial|1|Clinical Trials, Phase I|Early-Stage Clinical Trials|PHASE I TRIAL|Phase 1|Phase 1|Phase 1 Study|Phase I Clinical Trials|Phase I Protocol|Phase I Study|Trial Phase 1|phase 1|phase I trial	A clinical research protocol designed to test a new biomedical intervention in a small group of people for the first time. A Phase I trial can be to establish the toxicity of a new treatment with escalating intensity of the treatment administered and/or to determine the side effects of a new treatment for a particular indication in subjects.			Research Activity	CDISC Glossary Terminology|CDISC SDTM Terminology|CDISC SDTM Trial Phase Terminology|Clinical Data Interchange Standards Consortium Terminology|HL Authorized Value Terminology|HL Subject Characteristics Table|ICH M11 Terminology|ICH M11 Trial Phase Value Set Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C156010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156010>	C93102|C154229	Deleterious GEN1 Gene Mutation|Deleterious GEN1 Holliday Junction 5' Flap Endonuclease Gene Mutation|Deleterious Gen Gene Mutation|Deleterious Gen Homolog 1, Endonuclease Gene Mutation	A change in the nucleotide sequence of the GEN1 gene that is associated with increased risk of disease.	Deleterious GEN1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156011>	C93102|C131795	Deleterious RAD51 Gene Mutation|Deleterious BRCC5 Gene Mutation|Deleterious FANCR Gene Mutation|Deleterious HRAD51 Gene Mutation|Deleterious HsRad51 Gene Mutation|Deleterious RAD51 Homolog (S. cerevisiae) Gene Mutation|Deleterious RAD51 Recombinase Gene Mutation|Deleterious RAD51, S. cerevisiae, Homolog of A Gene Mutation|Deleterious RAD51A Gene Mutation|Deleterious RECA Gene Mutation	A change in the nucleotide sequence of the RAD51 gene that is associated with increased risk of disease.	Deleterious RAD51 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C156012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156012>	C93102|C154227	Deleterious ERCC3 Gene Mutation|Deleterious BTF2 Gene Mutation|Deleterious ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit Gene Mutation|Deleterious Excision Repair Cross-Complementation Group 3 Gene Mutation|Deleterious Excision Repair Cross-Complementing Rodent Repair Deficiency, Complementation Group 3 Gene Mutation|Deleterious Excision-Repair, Complementing Defective, in Chinese Hamster, 3 Gene Mutation|Deleterious GTF2H Gene Mutation|Deleterious RAD25 Gene Mutation|Deleterious TTD2 Gene Mutation|Deleterious XPB Gene Mutation|Deleterious Xeroderma Pigmentosum Group B Complementing Gene Mutation	A change in the nucleotide sequence of the ERCC3 gene that is associated with increased risk of disease.	Deleterious ERCC3 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156013>	C93102|C154228	Deleterious ABRAXAS1 Gene Mutation|Deleterious ABRA1 Gene Mutation|Deleterious ABRAXAS Gene Mutation|Deleterious Abraxas 1, BRCA1 A Complex Subunit Gene Mutation|Deleterious CCDC98 Gene Mutation|Deleterious FAM175A Gene Mutation|Deleterious Family with Sequence Similarity 175 Member A Gene Mutation	A change in the nucleotide sequence of the ABRAXAS1 gene that is associated with increased risk of disease.	Deleterious ABRAXAS1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156014>	C177686	UGT1A1 Polymorphism Positive|GNT1 Polymorphism Positive|UDP Glucuronosyltransferase Family 1 Member A1 Polymorphism Positive|UDPGT 1-1 Polymorphism Positive|UDPGT Polymorphism Positive|UGT1 Polymorphism Positive|UGT1A Polymorphism Positive	An indication that polymorphism of the UGT1A1 gene has been detected in a sample.	UGT1A1 Polymorphism Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156015>	C1663	Adenoviral Cancer Vaccine PF-06936308|PF 06936308|PF-06936308|PF06936308	A cancer vaccine composed of a replication-defective E1-deleted adenovirus vector based on chimpanzee adenovirus serotype 68 (AdC68) expressing three not yet disclosed tumor-associated antigens (TAAs), with potential immunostimulating and antineoplastic activities. Upon vaccination with the adenoviral cancer vaccine PF-06936308, the adenovirus infects cells and expresses the TAAs. In turn, the TAAs activate the immune system to produce a cytotoxic T-lymphocyte (CTL) response against cells expressing the TAAs.	Adenoviral Cancer Vaccine PF-06936308		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156016>	C97927|C174175|C159204	FANCG Gene Mutation|FA Complementation Group G Gene Mutation|FACG Gene Mutation|FAG Gene Mutation|Fanconi Anemia Complementation Group G Gene Mutation|Fanconi Anemia, Complementation Group G Gene Mutation|X-Ray Repair Complementing Defective Repair In Chinese Hamster Cells 9 Gene Mutation|X-Ray Repair, Complementing Defective, In Chinese Hamster, 9 Gene Mutation|XRCC9 Gene Mutation	A change in the nucleotide sequence of the FANCG gene.	FANCG Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156017>	C2189|C208255	Batiraxcept|AVB S6 500|AVB-500|AVB-S6-500|AVBS6500|AXL Fc Fusion Protein AVB-S6-500|Anti-AXL Fusion Protein AVB-S6-500|BATIRAXCEPT|RUGA-S6	A soluble fusion protein comprised of the extracellular domain of the receptor tyrosine kinase (RTK) AXL (UFO) fused to a human immunoglobulin G1 (IgG1) Fc domain, with potential antineoplastic activity. Upon administration, batiraxcept selectively binds to growth arrest-specific protein 6 (GAS6), the endogenous ligand for AXL. This may inhibit GAS6/AXL-mediated signaling, which plays a key role in tumor cell proliferation, survival, invasion and metastasis, as well as immune evasion and resistance to other anticancer agents. AXL, a member of the Tyro3, AXL and Mer (TAM) family of RTKs, is overexpressed by many tumor cell types and its expression is associated with drug resistance and poor prognosis.	Batiraxcept		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156018>	C16048	Archive|Archival	A place or collection containing records, documents, or other materials, especially those of historical interest.			Intellectual Product	GDC Terminology|GDC Value Terminology
C156019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156019>	C25404	Archived|Archival	Collected and stored for long-term retrieval.			Activity	
C15601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15601>	C70820	Phase II Trial|2|Clinical Trials, Phase II|PHASE II TRIAL|Phase 2|Phase 2|Phase 2 Study|Phase II Clinical Trial|Phase II Protocol|Phase II Study|Trial Phase 2|phase 2|phase II trial	A clinical research protocol designed to study a biomedical or behavioral intervention in a larger group of people (several hundred), to evaluate the drug's effectiveness for a particular indication in patients with the disease or condition under study, and to determine the common short-term side effects and risks associated with the intervention.			Research Activity	CDISC Glossary Terminology|CDISC SDTM Terminology|CDISC SDTM Trial Phase Terminology|Clinical Data Interchange Standards Consortium Terminology|HL Authorized Value Terminology|HL Subject Characteristics Table|ICH M11 Terminology|ICH M11 Trial Phase Value Set Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C156020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156020>	C25404	Donation|Donated	The act of giving money or materials or other items of worth.			Activity	
C156021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156021>	C1511	Zirconium Zr 89 DFO-Daratumumab|(89)Zr-Daratumumab|89Zr-DFO-Daratumumab|DARATUMUMAB-DFO ZR-89|Zr 89-DFO-Daratumumab	A radioimmunoconjugate containing daratumumab, a human immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against the cell surface glycoprotein CD38, and linked, via the chelator desferrioxamine (DFO), to the radioisotope zirconium Zr 89 (Zr89), with potential diagnostic properties upon positron emission tomography (PET) imaging. Upon administration, the monoclonal antibody moiety of zirconium Zr 89-DFO-daratumumab specifically targets and binds to cell surface antigen CD38. Upon binding, the radioisotope moiety may be detected using PET, thereby allowing the imaging and quantification of CD38-expressing tumor cells. CD38, a cell surface glycoprotein, is expressed on various hematopoietic cells and is overexpressed on multiple myeloma (MM) cells.	Zirconium Zr 89 DFO-Daratumumab		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C156022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156022>	C97927|C159204	FANCB Gene Mutation|FA Complementation Group B Gene Mutation|FA2 Gene Mutation|FAAP90 Gene Mutation|FAAP95 Gene Mutation|FAB Gene Mutation|FACB Gene Mutation|Fanconi Anemia Complementation Group B Gene Mutation|Fanconi Anemia, Complementation Group B Gene Mutation	A change in the nucleotide sequence of the FANCB gene.	FANCB Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156023>	C97927|C159204	FANCI Gene Mutation|FA Complementation Group I Gene Mutation|FACI Gene Mutation|Fanconi Anemia Complementation Group I Gene Mutation|Fanconi Anemia, Complementation Group I Gene Mutation|KIAA1794 Gene Mutation	A change in the nucleotide sequence of the FANCI gene.	FANCI Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156024>	C97927|C159204	FANCL Gene Mutation|FA Complementation Group L Gene Mutation|FAAP43 Gene Mutation|FACL Gene Mutation|Fanconi Anemia Complementation Group L Gene Mutation|Fanconi Anemia, Complementation Group L Gene Mutation|PHD Finger Protein 9 Gene Mutation|PHF9 Gene Mutation|POG Gene Mutation	A change in the nucleotide sequence of the FANCL gene.	FANCL Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156025>	C103223	High Tumor Mutation Burden|High TMB|High Tumor Mutational Burden|TMB Positive|TMB-H|Tumor Mutational Burden Positive	An indication that a tumor sample has a high number of genetic mutations per megabase (mb) of sequenced DNA.	High Tumor Mutation Burden		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C156027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156027>	C128839	Human Papillomavirus-6 Positive|HPV-6 Positive|HPV6 Positive|Human Papilloma Virus 6 Positive|Human Papilloma Virus-6 Positive|Human Papillomavirus 6 Positive	Indicates that human papillomavirus-6 has been detected in a sample.	Human Papillomavirus-6 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C156028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156028>	C133155	Receptor Tyrosine Kinase Gene Rearrangement|RTK Family Gene Rearrangement|RTK Family Rearrangement|RTK Gene Rearrangement|RTK Rearrangement|Receptor Tyrosine Kinase Family Gene Rearrangement|Receptor Tyrosine Kinase Rearrangement|Tyrosine Kinase Receptor Family Rearrangement|Tyrosine Kinase Receptor Gene Rearrangement|Tyrosine Kinase Receptor Rearrangement	A molecular abnormality indicating rearrangement of a receptor tyrosine kinase family gene.	Receptor Tyrosine Kinase Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156029>	C45581	Receptor Tyrosine Kinase Gene Amplification|RTK Amplification|RTK Family Amplification|RTK Family Gene Amplification|RTK Gene Amplification|Receptor Tyrosine Kinase Amplification|Receptor Tyrosine Kinase Family Gene Amplification|Tyrosine Kinase Receptor Amplification|Tyrosine Kinase Receptor Family Amplification|Tyrosine Kinase Receptor Gene Amplification	A molecular abnormality indicating the presence of multiple copies of a receptor tyrosine kinase family gene.	Receptor Tyrosine Kinase Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15602>	C70820	Phase III Trial|3|Clinical Trials, Phase III|PHASE III TRIAL|Phase 3|Phase 3|Phase 3 Study|Phase III Clinical Trial|Phase III Protocol|Phase III Study|Phase III Trials|Trial Phase 3|phase 3|phase III trial	A clinical research protocol designed to investigate the efficacy of the biomedical or behavioral intervention in large groups of human subjects (from several hundred to several thousand), to confirm efficacy, to monitor adverse reactions to the new medication or treatment regimen with respect to long-term use and by comparing the intervention to other standard or experimental interventions as well as to a placebo.			Research Activity	CDISC Glossary Terminology|CDISC SDTM Terminology|CDISC SDTM Trial Phase Terminology|Clinical Data Interchange Standards Consortium Terminology|HL Authorized Value Terminology|HL Subject Characteristics Table|ICH M11 Terminology|ICH M11 Trial Phase Value Set Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C156031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156031>	C53543	Xeroderma Pigmentosum-Cockayne Syndrome Complex|XP-CS|XP/CS|Xeroderma Pigmentosum/Cockayne Syndrome	A condition characterized by the cutaneous features of xeroderma pigmentosum and the systemic and neurological features of Cockayne syndrome.	Xeroderma Pigmentosum-Cockayne Syndrome Complex		Disease or Syndrome	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology
C156032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156032>	C97174	Genodermatosis	A group of inherited skin disorders that present with multisystem involvement. It includes ichthyosis, epidermolysis bullosa, ectodermal dysplasia, cutis laxa, progeroid conditions, xeroderma pigmentosum, Rothmund Thomson syndrome, and dyskeratosis congenita.	Genodermatosis		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C156034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156034>	C4035|C36035	Encapsulated Variant Thyroid Gland Papillary Carcinoma	A typical papillary thyroid gland carcinoma that is totally surrounded by a fibrous capsule, which may be intact or only focally infiltrated by tumor growth. It accounts for about 10% of all cases of papillary thyroid gland carcinoma and has an excellent prognosis. Regional nodal metastases may be present, but bloodborne metastases are rare. The survival rate is nearly 100%. (WHO 2017)			Neoplastic Process	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Morphology PT Terminology|Mapped ICDO3.1 Morphology Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C156035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156035>	C5123	Frontal Lobe Anaplastic Astrocytoma	An anaplastic astrocytoma occurring in the frontal lobe.			Neoplastic Process	
C156036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156036>	C5123	Temporal Lobe Anaplastic Astrocytoma	An anaplastic astrocytoma occurring in the temporal lobe.			Neoplastic Process	
C156037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156037>	C201975	Third Ventricle Pilocytic Astrocytoma	A pilocytic astrocytoma occurring in the third ventricle.			Neoplastic Process	
C156038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156038>	C40315	Hypothalamic-Chiasmatic Pilomyxoid Astrocytoma	A pilomyxoid astrocytoma occurring in the hypothalamic-chiasmatic region.			Neoplastic Process	
C156039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156039>	C3222	Fourth Ventricle Medulloblastoma	A medulloblastoma occurring in the fourth ventricle.			Neoplastic Process	
C15603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15603>	C70820	Phase IV Trial|4|Clinical Trials, Phase IV|PHASE IV TRIAL|Phase 4|Phase 4 Study|Phase IV Clinical Trials|Phase IV Study|Trial Phase 4|phase 4|phase IV trial	A randomized, controlled trial that is designed to evaluate the long-term safety and efficacy of a drug for a given indication. Often they are designed to study side effects that may have become apparent after the phase III study was completed.			Research Activity	CDISC Glossary Terminology|CDISC SDTM Terminology|CDISC SDTM Trial Phase Terminology|Clinical Data Interchange Standards Consortium Terminology|ICH M11 Terminology|ICH M11 Trial Phase Value Set Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C156040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156040>	C6284	Third Ventricle Germinoma	A germinoma that arises from the third ventricle.			Neoplastic Process	
C156041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156041>	C60780|C4323|C3397|C201977	Supratentorial Pleomorphic Xanthoastrocytoma	A pleomorphic xanthoastrocytoma that arises from the supratentorial region of the brain.			Neoplastic Process	
C156042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156042>	C4323	Temporal Lobe Pleomorphic Xanthoastrocytoma	A pleomorphic xanthoastrocytoma that arises from the temporal lobe of the brain.			Neoplastic Process	
C156043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156043>	C1511	Zirconium Zr 89 Panitumumab|89Zr-labeled Panitumumab|89Zr-panitumumab|ZIRCONIUM PANITUMUMAB ZR-89|Zr 89-Panitumumab	A radioimmunoconjugate composed of panitumumab, a human immunoglobulin G2 (IgG2) monoclonal antibody directed against the epidermal growth factor receptor (EGFR; HER1; ErbB1), labeled with the radioisotope zirconium Zr 89, with potential use as an imaging agent upon positron emission tomography (PET). Upon administration of zirconium Zr 89 panitumumab, the antibody moiety targets and binds to the extracellular domain of EGFR on tumor cells. Upon PET imaging, EGFR-expressing tumor cells can be visualized and assessed. This allows quantification of EGFR-expressing tumor cells and may allow selection of patients that would respond to panitumumab therapy. EGFR, a receptor tyrosine kinase overexpressed on the cell surfaces of many tumor cell types, plays a key role in tumor cell proliferation.	Zirconium Zr 89 Panitumumab		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology
C156044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156044>	C164175	Vulvar Biopsy Patient|Vulva Biopsy Patient	A patient who had or will have a vulva biopsy.	Vulvar Biopsy Patient		Patient or Disabled Group	CTRP Intervention Terminology|CTRP Terminology
C156045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156045>	C4035	Spindle Cell Variant Thyroid Gland Papillary Carcinoma	Papillary carcinoma of the thyroid gland with focal areas of spindle cell metaplasia.			Neoplastic Process	
C156046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156046>	C40430|C178119	Inactivating BRAF Gene Mutation|BRAF Class 3 Gene Mutation|BRAF Class 3 Mutation|BRAF Class III Alteration|BRAF Class III Gene Mutation|BRAF Gene Inactivation|BRAF Inactivation|Class 3 BRAF Gene Mutation|Class 3 BRAF Mutation|Class III BRAF Gene Mutation|Inactivating B-RAF Gene Mutation|Inactivating B-RAF1 Gene Mutation|Inactivating BRAF Mutation|Inactivating BRAF1 Gene Mutation|Inactivating v-raf Murine Sarcoma Viral Oncogene Homolog B1 Gene Mutation	A change in the nucleotide sequence of the BRAF gene that inhibits expression or results in the translation of either low-activity or inactive forms of the serine/threonine-protein kinase B-raf protein.	Inactivating BRAF Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156047>	C165233	ATRX Negative|ATP-Dependent Helicase ATRX Loss|ATP-Dependent Helicase ATRX Negative|ATRX Loss|Loss of ATRX Expression|Loss of Transcriptional Regulator ATRX Expression|RAD54 Negative|RAD54L Negative|Transcriptional Regulator ATRX Negative	An indication that ATRX expression has not been detected in a sample.	ATRX Negative		Finding	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156048>	C178119|C153504	Inactivating SETD2 Gene Mutation|Inactivating HBP231 Gene Mutation|Inactivating HIF-1 Gene Mutation|Inactivating HIP-1 Gene Mutation|Inactivating HYPB Gene Mutation|Inactivating KMT3A Gene Mutation|Inactivating LLS Gene Mutation|Inactivating SET Domain Containing 2 Gene Mutation|Inactivating SET2 Gene Mutation|Inactivating p231HBP Gene Mutation|SETD2 Deficiency|SETD2 Deficient|SETD2 Inactivating Gene Mutation|SETD2 Loss|SETD2 Loss of Function Mutation	A change in the nucleotide sequence of the SETD2 gene that inhibits expression or results in the translation of either low-activity or inactive forms of the histone-lysine methyltransferase SETD2 protein.	Inactivating SETD2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156049>	C165233	TP53 Negative|Antigen NY-CO-13 Negative|Cellular Tumor Antigen p53 Negative|TP53 Loss|TRP53 Negative|Transformation-Related Protein 53 Negative|Tumor Protein p53 Negative|Tumor Suppressor p53 Negative|p53 Loss|p53 Negative	An indication that TP53 expression or activity has not been detected in a sample.	TP53 Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15604>	C15669	Chemoprevention|Cancer Chemoprevention|Chemoprevention of Cancer|chemoprevention	The use of natural or synthetic substances (e.g., drugs, vitamins, hormones, plant products) or food supplements to reduce the risk of developing a disease, to reduce the chance that disease will recur, or to delay the recurrence.	Chemoprevention		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C156050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156050>	C4035	Hobnail Variant Thyroid Gland Papillary Carcinoma	A rare variant of papillary thyroid gland carcinoma in which more than 30% of cells have hobnail features. (WHO)			Neoplastic Process	
C156051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156051>	C165233	MTAP Negative|5'-Methylthioadenosine Phosphorylase Negative|MTA Phosphorylase Negative|MTAP Deficiency|MTAP Deficient|MTAP Loss|MTAP Null|MTAPase Negative|Methylthioadenosine Phosphorylase Loss|Methylthioadenosine Phosphorylase Negative|Methylthioadenosine Phosphorylase Null|S-Methyl-5'-Thioadenosine Phosphorylase Loss|S-Methyl-5'-Thioadenosine Phosphorylase Negative	An indication that MTAP expression or activity has not been detected in a sample.	MTAP Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156053>	C63468	Cabazitaxel/Prednisone Regimen|Cabazitaxel and Prednisone|Cabazitaxel-Prednisone|Cabazitaxel-Prednisone Regimen|Cabazitaxel/Prednisone	A regimen consisting of cabazitaxel and prednisone that can be used for the treatment of prostate cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156054>	C14226	Human Papillomavirus-63|HPV-63|HPV63|HPV63|Human Papilloma Virus 63|Human Papilloma Virus-63|Human Papillomavirus 63	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-63 may be associated with a risk for cervical cancer.			Virus	GDC Terminology|GDC Value Terminology
C156055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156055>	C14226	Human Papillomavirus-70|HPV 70|HPV-70|HPV70|HPV70|HUMAN PAPILLOMAVIRUS TYPE 70|Human Papilloma Virus 70|Human Papilloma Virus-70|Human Papillomavirus 70	A virus comprised of a protein coat (capsid) surrounding a circular, double-stranded DNA organized into coding and non-coding regions, which can induce epithelial lesions. Infection with human papillomavirus-70 may be associated with a high risk for cervical cancer.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C156056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156056>	C153598	ATAC-Seq|ATAC-seq (assay for Transposase-Accessible Chromatin (ATAC) strategy is used to study genome-wide chromatin accessibility)|Assay for Transposase Accessible Chromatin with High-Throughput Sequencing|Assay for Transposase-Accessible Chromatin Sequencing|Assay for Transposase-Accessible Chromatin Using Sequencing|atacseq	A molecular genetic technique that isolates and sequences chromosomal regions that are rich in open chromatin. First, nuclei are harvested from a cellular sample. Then a hyperactive Tn5 transposase is added to the nuclei where it excises non-nucleosomal DNA strands and ligates co-administered high-throughput sequencing adapters (tagmentation).  The tagged DNA fragments are isolated, amplified by PCR and sequenced. The number of reads for specific region of DNA correlate with increased chromatin accessibility and this method can identify regions of transcription factor and nucleosome binding.			Molecular Biology Research Technique	CTDC Value Terminology|GDC Terminology|GDC Value Terminology
C156057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156057>	C192768	MicroRNA Sequencing|MicroRNA-Seq|miRNA Sequencing|miRNA-Seq|miRNA-Seq|miRNA-Seq (microRNA sequencing)|microRNA Sequencing	A next-generation or massively parallel high-throughput DNA sequencing-based procedure that can identify and quantify the microRNA sequences present in a biological sample.			Molecular Biology Research Technique	CTDC Value Terminology|GCT Authorized Value Terminology|GCT Lab Table|GDC Terminology|GDC Value Terminology
C156058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156058>	C281|C20401	Gontivimab|ALX 0171|ALX-0171|ALX0171|Anti-RSV F Nanobody ALX-0171|Anti-RSV Protein F Nanobody ALX-0171|GONTIVIMAB|RSV-specific Nanobody ALX-0171	A trivalent nanobody composed of three monovalent Nb017 moieties linked with glycine-serine (GS) linkers, directed against the fusion protein (F protein) of human respiratory syncytial virus (RSV), with potential activity against RSV infections. Upon administration via nebulization and inhalation, gontivimab targets and binds to RSV F protein, neutralizing the virus, and preventing viral entry into host cells. RSV F protein is a small envelope glycoprotein required for cytopathic syncytia formation that results from cell-to-cell fusion.	Gontivimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C156059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156059>	C177687	FLT3 Tyrosine Kinase Domain Mutation Negative|FLT3-TKD Mutation Negative|FLT3-TKD Negative|FLT3/TKD Mutation Negative|FLT3/TKD Negative	An indication that FLT3 gene mutations in the region encoding the tyrosine kinase domain have not been detected in a sample.	FLT3 Tyrosine Kinase Domain Mutation Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15605>	C15824	Nutrition Research, Trace Elements|Micronutrients|Trace Element Nutrition|Trace Nutrients	The study of the role of trace elements in cancer causation or prevention and in general health.			Research Activity	
C156061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156061>	C176988	Mupadolimab|Anti-CD73 Monoclonal Antibody CPI-006|CPI 006|CPI-006|CPI006|CPX-006|MUPADOLIMAB	A type II humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, mupadolimab targets and binds to CD73 on tumor cells, leading to internalization of CD73. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine, thereby preventing adenosine-mediated suppression of lymphocyte activity and increasing the activity of cytotoxic T-lymphocytes (CTLs). This also activates macrophages, and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes. By abrogating the inhibitory effect on the immune system and enhancing the CTL-mediated immune response against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, is upregulated on a number of cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment.	Mupadolimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C156062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156062>	C4912|C213705	Metastatic Bladder Carcinoma	A carcinoma that arises from the bladder and has metastasized to another anatomic site.	Metastatic Bladder Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156063>	C3867|C213702	Metastatic Fallopian Tube Carcinoma	A carcinoma that arises from the fallopian tube and has metastasized to another anatomic site.	Metastatic Fallopian Tube Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156064>	C4908|C213702	Metastatic Ovarian Carcinoma	A carcinoma that arises from the ovary and has metastasized to another anatomic site.	Metastatic Ovarian Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156065>	C3917|C213702	Metastatic Vaginal Carcinoma	A carcinoma that arises from the vagina and has metastasized to another anatomic site.	Metastatic Vaginal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156066>	C4866|C213702	Metastatic Vulvar Carcinoma	A carcinoma that arises from the vulva and has metastasized to another anatomic site.	Metastatic Vulvar Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156067>	C28310|C181141	Autologous CMV-pp65-flLAMP mRNA Loaded Dendritic Cell Vaccine|Autologous CMV pp65-LAMP mRNA-loaded DC Vaccine|Autologous CMV-pp65-flLamp DCs|Autologous flLAMP-pp65 mRNA-pulsed DC Vaccine|Autologous flLAMP-pp65-DC Vaccine|Autologous flLAMP-pp65-DCs|Autologous pp65-flLAMP DC Vaccine|Autologous pp65-flLAMP DCs	A cancer cell vaccine consisting of autologous dendritic cells (DCs) loaded with mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) as a fusion protein with the full-length lysosome-associated membrane protein (flLAMP), with potential immunostimulatory and antineoplastic activities. Upon vaccination, the autologous CMV-pp65-flLAMP mRNA loaded DC vaccine exposes the immune system to the CMV pp65 peptide, which may elicit a cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells. The incorporation of flLAMP may route CMV pp-65 antigens into the lysosomal compartment, resulting in enhanced MHC class II antigen presentation, thereby promoting CD4-positive T-cell responses. The CMV pp65 protein is the primary component of the enveloped subviral particle of CMV and is expressed in certain tumor types.	Autologous CMV-pp65-flLAMP mRNA Loaded Dendritic Cell Vaccine		Cell|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156068>	C7558|C213702|C213048	Metastatic Endometrial Carcinoma	A carcinoma that arises from the endometrium and has metastasized to another anatomic site.	Metastatic Endometrial Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156069>	C207229|C170458|C155852	Metastatic Pancreatic Carcinoma	A carcinoma that arises from the pancreas and has metastasized to another anatomic site.			Neoplastic Process	
C15606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15606>	C64386	Acupressure Therapy|Acupressure|Ischemic Compression|acupressure	The application of non-invasive finger pressure along energy points throughout the body in order to relieve pain and induce a feeling of well-being.	Acupressure Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C156070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156070>	C9325|C4124|C215187	Metastatic Adrenal Cortical Carcinoma|Metastatic Adrenal Cortex Carcinoma	A carcinoma that arises from the adrenal cortex and has metastasized to another anatomic site.			Neoplastic Process	
C156071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156071>	C7707|C153069	Metastatic Adult Soft Tissue Sarcoma	A sarcoma that arises from the soft tissues during adulthood and has spread from the original site of growth to another anatomic site.			Neoplastic Process	
C156072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156072>	C8925|C3510|C170811	Metastatic Cutaneous Melanoma	A melanoma that arises from the skin and has metastasized to another anatomic site.			Neoplastic Process	
C156073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156073>	C3513|C133839	Metastatic Esophageal Carcinoma	A carcinoma that arises from the esophagus and has metastasized to another anatomic site.	Metastatic Esophageal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156074>	C4124|C4025|C156073	Metastatic Esophageal Adenocarcinoma	An adenocarcinoma that arises from the esophagus and has metastasized to another anatomic site.			Neoplastic Process	
C156075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156075>	C4104|C4024|C156073	Metastatic Esophageal Squamous Cell Carcinoma	A squamous cell carcinoma that arises from the esophagus and has metastasized to another anatomic site.			Neoplastic Process	
C156076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156076>	C7405	Autoimmune Atrophic Chronic Gastritis|Autoimmune atrophic chronic gastritis	Chronic atrophic gastritis that is caused by autoimmune destruction of parietal cells in the stomach resulting in hypochlorhydria and decreased production of intrinsic factor.			Disease or Syndrome	GDC Terminology|GDC Value Terminology
C156077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156077>	C7992|C150209	Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma	A keratinizing squamous cell carcinoma that arises from the nasopharynx and has metastasized to another anatomic site.			Neoplastic Process	
C156078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156078>	C8023|C177153	Metastatic Nasopharyngeal Undifferentiated Carcinoma	An undifferentiated carcinoma that arises from the nasopharynx and has metastasized to another anatomic site.			Neoplastic Process	
C156079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156079>	C3871|C156080	Metastatic Nasopharyngeal Carcinoma	A carcinoma that arises from the nasopharynx and has metastasized to another anatomic site.	Metastatic Nasopharyngeal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C15607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15607>	C15220	Clinical Diagnosis	A diagnosis made from a study of the signs and symptoms of a disease.			Diagnostic Procedure	
C156080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156080>	C9466|C126465	Metastatic Pharyngeal Carcinoma	A carcinoma that arises from the pharynx and has metastasized to another anatomic site.			Neoplastic Process	
C156081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156081>	C9465|C156080	Metastatic Hypopharyngeal Carcinoma	A carcinoma that arises from the hypopharynx and has metastasized to another anatomic site.			Neoplastic Process	
C156082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156082>	C9105|C156080	Metastatic Oropharyngeal Carcinoma	A carcinoma that arises from the oropharynx and has metastasized to another anatomic site.			Neoplastic Process	
C156083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156083>	C4086	High Grade Dysplasia|Dysplasia; high grade|High Grade	A subjective characterization of the phenomenon of dysplasia, based on microscopic examination of the architectural and/or cytological changes in a tissue sample, that is determined to be high.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C156084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156084>	C4086	Low Grade Dysplasia|Dysplasia; low grade|Low Grade	A subjective characterization of the phenomenon of dysplasia, based on microscopic examination of the architectural and/or cytological changes in a tissue sample, that is determined to be low.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C156085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156085>	C4855|C126465	Metastatic Laryngeal Carcinoma	A carcinoma that arises from the larynx and has metastasized to another anatomic site.			Neoplastic Process	
C156086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156086>	C9315|C126465	Metastatic Lip and Oral Cavity Carcinoma	A carcinoma that arises from the lip and/or oral cavity and has metastasized to another anatomic site.			Neoplastic Process	
C156087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156087>	C8990|C156086	Metastatic Oral Cavity Carcinoma	A carcinoma that arises from the oral cavity and has metastasized to another anatomic site.			Neoplastic Process	
C156088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156088>	C3490|C156086	Metastatic Lip Carcinoma	A carcinoma that arises from the lip and has metastasized to another anatomic site.			Neoplastic Process	
C156089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156089>	C8179|C157638|C156087	Metastatic Oral Cavity Adenoid Cystic Carcinoma	An adenoid cystic carcinoma that arises from the oral cavity and has metastasized to another anatomic site.			Neoplastic Process	
C15608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15608>	C16205	Staging|STAGING|staging	The process of defining at what point in the natural history of a malignant disease a patient is when a diagnosis is made.			Diagnostic Procedure	CDISC SDTM Medical History Event Date Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156090>	C8177|C156087	Metastatic Oral Cavity Mucoepidermoid Carcinoma	A mucoepidermoid carcinoma that arises from the oral cavity and has metastasized to another anatomic site.			Neoplastic Process	
C156091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156091>	C4042|C156088|C148153	Metastatic Lip Squamous Cell Carcinoma	A squamous cell carcinoma that arises from the lip and has metastasized to another anatomic site.			Neoplastic Process	
C156092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156092>	C4104|C3493|C153202	Metastatic Lung Squamous Cell Carcinoma	A squamous cell carcinoma that arises from the lung and has metastasized to another anatomic site.			Neoplastic Process	
C156093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156093>	C9133|C156094	Metastatic Lung Adenosquamous Carcinoma	An adenosquamous carcinoma that arises from the lung and has metastasized to another anatomic site.	Metastatic Lung Adenosquamous Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156094>	C2926|C165537|C153202	Metastatic Lung Non-Small Cell Carcinoma	A non-small cell carcinoma that arises from the lung and has metastasized to another anatomic site.	Metastatic Lung Non-Small Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156095>	C4917|C192797|C158911	Metastatic Lung Small Cell Carcinoma	A small cell carcinoma that arises from the lung and has metastasized to another anatomic site.	Metastatic Lung Small Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156096>	C2955|C162780|C133839	Metastatic Colorectal Carcinoma	A carcinoma that arises from the colon or rectum and has metastasized to another anatomic site.	Metastatic Colorectal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156097>	C4910|C156096	Metastatic Colon Carcinoma	A carcinoma that arises from the colon and has metastasized to another anatomic site.	Metastatic Colon Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156098>	C9382|C156096	Metastatic Rectal Carcinoma	A carcinoma that arises from the rectum and has metastasized to another anatomic site.			Neoplastic Process	
C156099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156099>	C8054|C173979	Metastatic Thyroid Gland Follicular Carcinoma	A follicular carcinoma that arises from the thyroid gland and has metastasized to another anatomic site.			Neoplastic Process	
C15609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15609>	C49165	Anastomosis|ANASTOMOSIS|Anastomotic|anastomosis	A natural or surgically-induced connection between tubular structures in the body.	Anastomosis		Therapeutic or Preventive Procedure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C1560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1560>	C2169|C1557	Brequinar|6-Fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-4-quinolinecarboxylic Acid|BREQUINAR|Bipenquinate	A synthetic quinolinecarboxylic acid analogue with antineoplastic properties.  Brequinar inhibits the enzyme dihydroorotate dehydrogenase, thereby blocking de novo pyrimidine biosynthesis.  This agent may also enhance the in vivo antitumor effect of antineoplastic agents such as 5-FU. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C156100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156100>	C4035|C173979	Metastatic Thyroid Gland Papillary Carcinoma|Metastatic Papillary Thyroid Carcinoma	A papillary carcinoma that arises from the thyroid gland and has metastasized to another anatomic site.			Neoplastic Process	
C156101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156101>	C36263|C3270	Metastatic Neuroblastoma	A neuroblastoma that has metastasized from its original site of growth to another anatomic site.			Neoplastic Process	
C156103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156103>	C7203|C212211	Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm	The reemergence of a blastic plasmacytoid dendritic cell neoplasm after a period of remission.	Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156104>	C7203|C212212	Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm	A blastic plasmacytoid dendritic cell neoplasm that is resistant to treatment.	Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156105>	C21154	Symptom Screening in Pediatrics|SSPedi|SSPedi - Symptom Screening in Pediatrics	A self-report screening tool, originally developed by Tomlinson et al. in 2013, that is used for symptom assessment in children with cancer and pediatric hematopoietic stem cell transplantation recipients.			Intellectual Product	
C156106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156106>	C173160	Feel Disappointed or Sad Question|Feel Disappointed or Sad|Feeling disappointed or sad	A question about whether an individual feels or felt disappointed or sad.			Intellectual Product	Symptom Screening in Pediatrics
C156107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156107>	C173160	Feel Scared or Worried Question|Feel Scared or Worried|Feeling scared or worried	A question about whether an individual feels or felt scared or worried.			Intellectual Product	Symptom Screening in Pediatrics
C156108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156108>	C173160	Feel Cranky or Angry Question|Feel Cranky or Angry|Feeling cranky or angry	A question about whether an individual feels or felt cranky or angry.			Intellectual Product	Symptom Screening in Pediatrics
C156109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156109>	C173597	Problems With Thinking or Remembering Things Question|Problems With Thinking or Remembering Things|Problems with thinking or remembering things	A question about whether an individual has or had problems with thinking or remembering things.			Intellectual Product	Symptom Screening in Pediatrics
C15610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15610>	C61063	Aspirin/Interferon Alfa|ASA/IFN-A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C156110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156110>	C176022	Changes in How Body or Face Looks Question|Changes in How Body or Face Looks|Changes in how your body or face look	A question about whether there are changes in how an individual's body or face looks.			Intellectual Product	Symptom Screening in Pediatrics
C156111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156111>	C173346	Hurt or Pain Other Than Headache Question|Hurt or Pain Other Than Headache|Hurt or pain (other than headache)	A question about whether an individual has or had pain other than headache.			Intellectual Product	Symptom Screening in Pediatrics
C156112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156112>	C173734	Tingly or Numb Hands or Feet Question|Tingly or Numb Hands or Feet|Tingly or numb hands or feet	A question about whether an individual has or had tingly or numb hands or feet.			Intellectual Product	Symptom Screening in Pediatrics
C156113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156113>	C173219	Throwing Up or Feeling Like May Throw Up Question|Throwing Up or Feeling Like May Throw Up|Throwing up or feeling like you may throw up	A question about whether an individual vomited or feels or felt like vomiting.			Intellectual Product	Symptom Screening in Pediatrics
C156114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156114>	C173160	Feeling More or Less Hungry Than Usual Question|Feeling More or Less Hungry Than Usual|Feeling more or less hungry than you usually do	A question about whether an individual feels or felt more or less hungry than usual.			Intellectual Product	Symptom Screening in Pediatrics
C156115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156115>	C172982	Other Things That Have Bothered Lately Question|Other Things That Have Bothered Lately|Please tell us about other things that have bothered you lately by writing them out here	A question about other things that have bothered an individual lately.			Intellectual Product	Symptom Screening in Pediatrics
C156116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156116>	C175303	Moderately Bothered|Medium	A response indicating that an individual is or was moderately bothered.			Intellectual Product	Symptom Screening in Pediatrics
C156117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156117>	C113124	Cell-Free DNA Blood Collection Tube|Cell-Free DNA BCT|Streck BCT|Streck Blood Collection Tube|Streck Cell-Free DNA BCT|Streck Cell-Free DNA Tube|Streck tube|cfDNA Blood Collection Tube	A blood collection tube with a formaldehyde-free preservative which stabilizes nucleated blood cells, preventing the release of genomic DNA, and allowing isolation of high-quality cell-free DNA.			Manufactured Object	
C156118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156118>	C16960	Ovarian Ablation Patient	A patient who had or will have an ovarian ablation.	Ovarian Ablation Patient		Patient or Disabled Group	CTRP Intervention Terminology|CTRP Terminology
C156119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156119>	C48579	Hundred Million International Units|10*8.[IU]|10*8.[IU]|10*8.[iU]|10*8.[iU]|10^8 IU|10^8 IU|10^8.[IU]|10^8.[IU]|10^8.[iU]|10^8.[iU]|10^8[iU]|One Hundred Million IU|One Hundred Million International Units	A unit of biological activity equal to one hundred million international units.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15611>	C61063	Interferon Alfa/Monoclonal Antibody CC49|IFN-A/MOAB CC49			Obsolete_Concept	Therapeutic or Preventive Procedure	
C156120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156120>	C4326|C162993	Frontal Lobe Anaplastic Oligodendroglioma	An anaplastic oligodendroglioma occurring in the frontal lobe.			Neoplastic Process	
C156121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156121>	C93175|C111031	TP53 Mutation Carrier|P53 Gene Mutation Carrier|Tumor Protein p53 Gene Mutation Carrier|p53 Mutation Carrier	An individual who carries an inheritable mutation in the TP53 gene, without manifestation of any associated condition.	TP53 Mutation Carrier		Group Attribute	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156122>	C8054	Thyroid Gland Follicular Carcinoma, Encapsulated Angioinvasive|FTC, Encapsulated Angioinvasive|Follicular thyroid carcinoma (FTC), encapsulated angioinvasive	An encapsulated follicular carcinoma of the thyroid gland which shows angioinvasion.			Neoplastic Process	GDC Terminology|GDC Value Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C156123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156123>	C9480|C8054	Thyroid Gland Follicular Carcinoma, Widely Invasive|FTC, Widely Invasive	A follicular carcinoma of the thyroid gland with extension into surrounding thyroid or extrathyroid tissues.			Neoplastic Process	
C156124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156124>	C217122	Health Utilities Index|HUI|Health Utilities Index (HUI)	A family of generic health profiles and preference-based systems for measuring health status, reporting health-related quality of life, and producing utility scores.			Intellectual Product	
C156125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156125>	C176426|C173790|C173045	Ability to See Well Enough to Read Ordinary Newsprint Question|Ability to See Well Enough to Read Ordinary Newsprint|Subject's ability to see well enough to read ordinary newsprint	A question about an individual's ability to see well enough to read ordinary newsprint.			Intellectual Product	Health Utilities Index
C156126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156126>	C173790|C173045	Ability to See Well Enough to Recognize Friend on Other Side of Street Question|Ability to See Well Enough to Recognize Friend on Other Side of Street|Subject's ability to see well enough to recognize a friend on the other side of the street	A question about an individual's ability to see well enough to recognize a friend on the other side of the street.			Intellectual Product	Health Utilities Index
C156127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156127>	C173059|C173045	Ability to Hear What Was Said in Group Conversation with at Least Three Other People Question|Ability to Hear What Was Said in Group Conversation with at Least Three Other People|Subject's ability to hear what was said in a group conversation with at least three other people	A question about an individual's ability to hear what was said in a group conversation with at least 3 other people.			Intellectual Product	Health Utilities Index
C156128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156128>	C173059|C173045	Ability to Hear What Was Said in Conversation with One Other Person in Quiet Room Question|Ability to Hear What Was Said in Conversation with One Other Person in Quiet Room|Subject's ability to hear what was said in a conversation with one other person in a quiet room	A question about an individual's ability to hear what was said with one other person in a quiet room.			Intellectual Product	Health Utilities Index
C156129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156129>	C173045	Ability to be Understood When Speaking Own Language with People Who do not Know the Subject Question|Ability to be Understood When Speaking Own Language with People Who do not Know the Subject|Subject's ability to be understood when speaking his/her own language with people who do not know the subject	A question about an individual's ability to be understood when speaking their own language with people who do not know them.			Intellectual Product	Health Utilities Index
C15612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15612>	C61007	interleukin-2/Monoclonal Antibody OKT3|IL-2/MOAB OKT3			Obsolete_Concept	Therapeutic or Preventive Procedure	
C156130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156130>	C173045	Ability to be Understood When Speaking with People Who Know the Subject Well Question|Ability to be Understood When Speaking with People Who Know the Subject Well|Subject's ability to be understood when speaking with people who know the subject well	A question about an individual's ability to be understood when speaking with people who know them well.			Intellectual Product	Health Utilities Index
C156131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156131>	C173160	Subject's Feelings Question|Feelings|Individual's Feelings|Subject's Feelings|Subject's feelings	A question about an individual's feelings.			Intellectual Product	Health Utilities Index
C156132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156132>	C173518|C173346	Pain and Discomfort Question|Pain and Discomfort|The pain and discomfort the subject has experienced	A question about an individual's pain and discomfort.			Intellectual Product	Health Utilities Index
C156133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156133>	C173135	Ability to Walk Question|Ability to Walk|Able to Walk|Subject's ability to walk|Walking Ability|Walking Ability Question	A question about an individual's ability to walk.			Intellectual Product	Health Utilities Index
C156134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156134>	C173045	Ability to Use Hands and Fingers Question|Ability to Use Hands and Fingers|Able to Use Hands and Fingers|Subject's ability to use his/her hands and fingers	A question about an individual's ability to use their hands and fingers.			Intellectual Product	Health Utilities Index
C156135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156135>	C105890	Ability to Remember Things Question|Ability to Remember Things|Able to Remember Things|Subject's ability to remember things	A question about an individual's ability to remember things.			Intellectual Product	Health Utilities Index
C156136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156136>	C28681|C138180|C129826	Autologous PRAME-targeting TCR-modified T Cells MDG1011|Autologous Anti-PRAME-TCR-expressing T Cells MDG1011|Autologous PRAME TCR Modified T Cells MDG1011|Autologous TCR Modified T Cells MDG1011|MDG 1011|MDG-1011|MDG1011|PRAME-TCR Gene Modified Autologous T Cells MDG1011	Human autologous T-lymphocytes transduced with a retroviral vector encoding a human leukocyte antigen (HLA)-A*02:01-restricted T-cell receptor (TCR) specific for the human tumor-associated antigen (TAA) preferentially expressed antigen in melanoma (PRAME) coupled to the CD3 signaling complex, with potential antineoplastic activity. Upon reintroduction into the patient, the autologous PRAME-targeting TCR-modified T cells MDG1011 target and bind to tumor cells expressing PRAME. This may induce cell death in and halt the growth of PRAME-expressing tumor cells. The TAA PRAME is overexpressed by a variety of cancer cell types.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology
C156137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156137>	C173597|C173045	Ability to Think and Solve Day-to-day Problems Question|Ability to Think and Solve Day-to-day Problems|Able to Think and Solve Day-to-day Problems|Subject's ability to think and solve day to day problems	A question about an individual's ability to think and solve day-to-day problems.			Intellectual Product	Health Utilities Index
C156138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156138>	C173045	Ability to Perform Basic Activities Question|Ability to Perform Basic Activities|Able to Perform Basic Activities|Subject's ability to perform basic activities	A question about an individual's ability to perform basic activities.			Intellectual Product	Health Utilities Index
C156139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156139>	C2496|C129822	Anti-VEGF Monoclonal Antibody hPV19|Anti-VEGF MAb hPV19|MoAb hPV19|hPV 19|hPV-19|hPV19	A humanized monoclonal antibody directed against human vascular endothelial growth factor (VEGF), with potential anti-angiogenic and antineoplastic activities. Upon administration, anti-VEGF monoclonal antibody hPV19 targets and binds to VEGFR at a unique binding site and inhibits VEGF binding to its receptors, VEGFR1 and VEGFR2, thereby preventing VEGF/VEGFR-mediated signaling. This prevents the growth and maintenance of tumor blood vessels. This decreases nutrient supply to tumor cells, resulting in tumor cell death. Increased VEGF/VEGFR signaling is associated with increased invasiveness and decreased survival.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15613>	C61063	interleukin-2/Monoclonal Antibody OKT3/Tumor Necrosis Factor|IL-2/MOAB OKT3/TNF			Obsolete_Concept	Therapeutic or Preventive Procedure	
C156140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156140>	C173518|C173346	Pain or Discomfort Question|Pain or Discomfort|Pain or Discomfort Experienced|Pain or discomfort the subject has experienced	A question about an individual's pain or discomfort.			Intellectual Product	Health Utilities Index
C156141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156141>	C211912|C201141	Mecbotamab Vedotin|ADC BA3011|BA 3011|BA-3011|BA3011|CAB Anti-AXL ADC BA3011|CAB-AXL-ADC BA3011|Conditionally Active Biologic Anti-AXL Antibody-drug Conjugate BA3011|MECBOTAMAB VEDOTIN	An antibody-drug conjugate (ADC) composed of a conditionally active biologic (CAB) antibody against AXL receptor tyrosine kinase (AXL; UFO) conjugated to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of mecbotamab vedotin, the anti-AXL antibody becomes activated through an as of yet not fully elucidated process only under the unique microphysical conditions that are present in the tumor microenvironment (TME) as a result of the glycolytic metabolism of cancer cells, and not in the microenvironment of normal, healthy tissues. Upon selective binding to AXL-expressing tumor cells and internalization, the cytotoxic agent kills the tumor cells through an as of yet undisclosed mechanism of action (MoA). AXL, a member of the TAM (TYRO3, AXL and MER) family of receptor tyrosine kinases normally expressed on many normal, healthy cells and overexpressed by many tumor cell types, plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance and poor prognosis. The CAB antibody allows for efficient and reversible binding to AXL-expressing tumor cells under conditions that are present only in the TME, thereby maximizing efficacy while minimizing toxicity by avoiding activation and thus binding of the antibody to normal, healthy AXL-expressing cells under normal conditions.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156142>	C28510	CREB3L2/PPARG Fusion Gene|CREB3L2-PPARG Fusion Gene|CREB3L2-PPARgamma Fusion Gene|CREB3L2/PPARgamma Fusion Gene|CREB3L2::PPARG Fusion Gene	A fusion gene that results from a chromosomal translocation t(3;7)(p25;q34) which fuses exon 1 and 2 of the CREB3L2 gene with exons 1-6 of the PPARG gene. This rearrangement is associated with thyroid follicular carcinoma.			Gene or Genome	
C156143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156143>	C17561	CREB3L2/PPARG Fusion Protein|CREB3L2-PPARG Fusion Protein|CREB3L2-PPARgamma Fusion Protein|CREB3L2/PPARgamma Fusion Protein|CREB3L2::PPARG Fusion Protein|Cyclic AMP-Responsive Element-Binding Protein 3-Like Protein 2/Peroxisome Proliferator-Activated Receptor Gamma Fusion Protein	A fusion protein encoded by the CREB3L2/PPARG fusion gene. This protein is comprised of the first 106 amino acids of the N-terminal DNA binding domain of cyclic AMP-responsive element-binding protein 3-like protein 2, including most of the transactivation domain, and the entire peroxisome proliferator-activated receptor gamma protein, including the ligand binding, DNA binding and activation domains.			Amino Acid, Peptide, or Protein	
C156144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156144>	C226581	Able to See Well Enough without Correction|Able to see well enough without glasses or contact lenses	A response indicating that an individual is or was able to see well enough without glasses or contact lenses.			Intellectual Product	Health Utilities Index
C156145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156145>	C226581	Able to See Well Enough with Correction|Able to see well enough with glasses or contact lenses	A response indicating that an individual is able to see well enough with glasses or contact lenses.			Intellectual Product	Health Utilities Index
C156146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156146>	C226581	Unable to See Well Enough even with Correction|Unable to see well enough even with glasses or contact lenses	A response indicating that an individual is or was unable to see well enough even with glasses or contact lenses.			Intellectual Product	Health Utilities Index
C156147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156147>	C226581|C226578	Unable to See at All|Unable to See|Unable to see at all	A response indicating that an individual is or was unable to see at all.			Intellectual Product	Health Utilities Index
C156148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156148>	C226579	Able to Hear without Hearing Aids|Able to Hear|Able to hear what was said without a hearing aid	A response indicating that an individual is or was able to hear what was said without hearing aids.			Intellectual Product	Health Utilities Index
C156149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156149>	C226579	Able to Hear with Hearing Aids|Able to hear what was said with a hearing aid	A response indicating that an individual is or was able to hear what was said with hearing aids.			Intellectual Product	Health Utilities Index
C15614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15614>	C61063	interleukin-2/Monoclonal Antibody OKT3/pentoxifylline|IL-2/MOAB OKT3/PTX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C156150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156150>	C226579	Unable to Hear even with Hearing Aids|Unable to hear what was said even with a hearing aid	A response indicating that an individual is or was unable to hear what was said even with hearing aids.			Intellectual Product	Health Utilities Index
C156151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156151>	C226579	Unable to Hear, but did not Wear Hearing Aids|Unable to hear what was said, but did not wear a hearing aid	A response indicating that an individual is or was unable to hear what was said, but was not wearing their hearing aids.			Intellectual Product	Health Utilities Index
C156152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156152>	C226579	Unable to Hear at All|Unable to Hear|Unable to hear at all	A response indicating that an individual is or was unable to hear at all.			Intellectual Product	Health Utilities Index
C156153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156153>	C1663	Autologous B-cell/Monocyte-presenting HER2/neu Antigen Vaccine BVAC-B|BVAC B|BVAC-B|BVACB|HER2/neu-specific Autologous B-cell/Monocyte Vaccine BVAC-B	An autologous vaccine composed of the antigen presenting cells (APCs) B-lymphocytes and monocytes presenting the tumor-associated antigen (TAA) human epidermal growth factor receptor type 2 (HER2/neu; HER-2; EGFR2; ErbB2). Upon administration of the autologous B-cell- and monocyte-presenting HER2/neu antigen vaccine BVAC-B, the APCs may stimulate the immune system to mount a HER2/neu-specific cytotoxic T-lymphocyte (CTL) immune response as well as a natural killer (NK) cell, and antibody-mediated immune response against HER-2/neu-positive tumor cells, which may result in tumor cell death and decreased tumor growth. HER-2, a tyrosine kinase receptor for epidermal growth factor (EGF), is overexpressed by a variety of tumors.			Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156155>	C798	Cisplatin Transmucosal Patch|Cisplatin Drug-loaded Patch|Cisplatin Transmucosal System|PRV 111|PRV-111|PRV111	A transmucosal patch containing cisplatin, an inorganic platinum agent, with potential antineoplastic activity. Upon mucosal application to the tumor site in the oral cavity, and upon subsequent release from the patch, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and growth inhibition of tumor cells.	Cisplatin Transmucosal Patch		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C156156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156156>	C200766	Autologous HER2-specific/EGFRt-expressing CD4/CD8-positive CAR T-cells|Autologous HER2 CAR/EGFRt-expressing CD4+ and CD8+ T-cells	A preparation of CD4+ and CD8+ autologous T-lymphocytes transduced with a lentiviral vector expressing a human epidermal growth factor receptor type 2 (HER2; EGFR2; ErbB2)-specific chimeric antigen receptor (CAR) coupled to a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, the autologous HER2-specific/EGFRt-expressing CD4/CD8-positive CAR T-cells are directed to and induce selective toxicity in HER2-expressing tumor cells. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of these cells through an anti-EGFR antibody-induced antibody-dependent cellular cytotoxicity (ADCC) response. HER2, a receptor tyrosine kinase (RTK) overexpressed by a variety of tumor cell types, belongs to the EGFR superfamily and plays a key role in tumor cell proliferation.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156157>	C226560	Able to be Understood Completely|Able to be understood completely	A response indicating that an individual is or was able to be understood completely.			Intellectual Product	Health Utilities Index
C156158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156158>	C226560	Able to be Understood Partially|Able to be understood partially	A response indicating that an individual is or was able to be understood partially.			Intellectual Product	Health Utilities Index
C156159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156159>	C226560	Unable to be Understood|Unable to be understood	A response indicating that an individual is or was unable to be understood.			Intellectual Product	Health Utilities Index
C15615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15615>	C61063	gp100 Antigen/Incomplete Freund's Adjuvant|gp100 Antigen with Incomplete Freund's Adjuvant|gp100/IFA			Obsolete_Concept	Therapeutic or Preventive Procedure	
C156160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156160>	C226578	Unable to Speak at All|Unable to Speak|Unable to speak at all	A response indicating that an individual is or was unable to speak at all.			Intellectual Product	
C156161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156161>	C226674	Happy and Interested in Life|Happy and interested in life	A response indicating that an individual is or was happy and interested in life.			Intellectual Product	Health Utilities Index
C156162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156162>	C226674	Somewhat Happy|Somewhat happy	A response indicating that an individual is or was somewhat happy.			Intellectual Product	Health Utilities Index
C156163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156163>	C226674	Somewhat Unhappy|Somewhat unhappy	A response indicating that an individual is or was somewhat unhappy.			Intellectual Product	Health Utilities Index
C156164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156164>	C226674	Very Unhappy|Very unhappy	A response indicating that an individual is or was very unhappy.			Intellectual Product	Health Utilities Index
C156165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156165>	C226674	So Unhappy that Life was not Worthwhile|So unhappy that life was not worthwhile	A response indicating that an individual is or was so unhappy that life was not worthwhile.			Intellectual Product	Health Utilities Index
C156166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156166>	C9296|C216181	Localized Gastroesophageal Junction Adenocarcinoma	An adenocarcinoma that arises from the gastroesophageal junction and has not spread to other anatomic sites.			Neoplastic Process	
C156167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156167>	C4911|C216181	Localized Gastric Carcinoma	A carcinoma that arises from the stomach and has not spread to other anatomic sites.			Neoplastic Process	
C156168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156168>	C28681|C129826	Autologous Natural Killer Cell-like CTLs|Autologous CTLs Sensitized Ex-vivo with Autologous TAA-loaded alphaDC1|Autologous NK-like CTLs|Autologous Natural Killer-like Cytotoxic Lymphocytes|Autologous aDC1-induced CTLs|Autologous nCTLs|In Vitro DC-sensitized CTLs|In-vitro DC-sensitized Autologous CTLs|Therapeutic iNKT Cells|Therapeutic nCTLs|Tumor Neo-antigen-specific nCTLs	A preparation of cytotoxic T-lymphocytes (CTLs) that express natural killer (NK)-like features (nCTLs), with potential immunomodulating and antineoplastic activities. The nCTLs are derived from autologous lymphocytes that have been in vitro exposed to autologous alpha-type-1 polarized dendritic cells that are pulsed with specific autologous tumor-associated antigens (TAAs); the nCTLs are subsequently expanded in the presence of the cytokine human interleukin-2 (IL-2). The generated nCTLs are potent CTLs that produce high amounts of granzyme B and perforin, and interferon-gamma (IFNg) with high killer activity and tumor-homing potential. Upon infusion of the autologous nCTLs, these cells specifically recognize the TAAs on the tumor cells, then bind to and directly lyse tumor cells.	Autologous Natural Killer Cell-like CTLs		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156169>	C222322|C200766|C176018	Autologous Anti-CD19CAR-CD3zeta-4-1BB-IL-15-PD1-expressing Tri-functional T-lymphocytes	A preparation of autologous T-lymphocytes engineered to express a tri-functional chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19), and an extracellular domain consisting of interleukin 15 (IL-15) and programmed cell death 1 (PD1; PDCD1; CD279; programmed death-1), linked to the intracellular signaling domains of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), with potential antineoplastic activity. Upon intravenous administration, autologous anti-CD19CAR-CD3zeta-4-1BB-IL-15-PD1-expressing tri-functional T-lymphocytes target, bind to, and induce selective toxicity in CD19-expressing tumor cells. IL-15 is a pro-survival cytokine that promotes T-cell persistence and potentiates the immune response against tumor cells. The PD1 moiety binds to programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) on tumor cells, reversing T-cell inactivation caused by endogenous PD1/PD-L1 signaling and enhancing the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. CD19 is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. Incorporation of the costimulatory signaling domains increases human T-cell function, expansion, and survival.	Autologous Anti-CD19CAR-CD3zeta-4-1BB-IL-15-PD1-expressing Tri-functional T-lymphocytes		Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156170>	C201510|C200766	Autologous Anti-CD38 A2 CAR2-expressing T-cells|Autologous Anti-CD38 A2 CAR2 T-cells|Autologous CAR2 Anti-CD38 A2 CAR T-cells|Autologous CAR2 Anti-CD38 A2 T-lymphocytes|Autologous CD38-A2 CAR2-expressing T-lymphocytes	A preparation of genetically modified autologous T-cells expressing a chimeric antigen receptor recognizing the tumor-associated antigen (TAA) cluster of differentiation 38 (CD38), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, autologous anti-CD38 A2 CAR2-expressing T-cells are directed to and induce selective toxicity in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.	Autologous Anti-CD38 A2 CAR2-expressing T-cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156171>	C2701	IgM-enriched Immunoglobulins|IgM-enriched Immunoglobulin|Immunoglobulin GMA|Immunoglobulin M-enriched Immunoglobulins|Pentaglobin|ivIgGMA	An immunoglobulin preparation consisting of immunoglobulin G (IgG) and immunoglobulin A (IgA), supplemented with immunoglobulin M (IgM), with potential antibacterial and immunomodulatory properties. Upon intravenous administration, IgM-enriched immunoglobulins may increase the elimination of infectious pathogens in comparison to immunoglobulin regimens lacking IgM. IgM is the major immunoglobulin secreted during the primary immune response and plays a significant role in compliment activation and in the neutralization of bacterial endo- and exotoxins.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C156172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156172>	C93170|C129822	Vulinacimab|Anti-VEGFR2 Monoclonal Antibody HLX06|HLX 06|HLX-06|HLX06|VULINACIMAB	A fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with potential anti-angiogenesis and antineoplastic activities. Upon administration, vulinacimab specifically binds to and inhibits VEGFR-2, which may inhibit tumor angiogenesis and tumor cell proliferation. VEGFR-2, a tyrosine-protein kinase that plays an essential role in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells, is overexpressed in certain tumor types.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156173>	C213665|C129825	Orelabrutinib|BTK Inhibitor ICP-022|ICP 022|ICP-022|ICP022|ORELABRUTINIB	A small molecule inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase) with potential antineoplastic activity. Upon administration, orelabrutinib binds to and inhibits the activity of BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.	Orelabrutinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156174>	C797	Curcumin/Chondroitin Sulfate/Hyaluronic Acid/Quercetin Soft Gels	An orally available preparation containing curcumin, quercetin, hyaluronic acid, and chondroitin sulfate with potential radioprotective activity. Upon administration, the glycosaminoglycans may improve barrier function and reduce inflammation and irritation in the genitourinary tract caused by radiotherapy.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C156175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156175>	C93221|C1931	Alkylglycerol/Rosemary Capsules|Alkylglycerol and Rosemary Capsules|Rosemary/Alkylglycerol Dietary Supplement	An orally available capsule containing alkylglycerols and Rosmarinus officinalis extracts standardized to diterpenes, including carnosic acid and carnosol, with potential antineoplastic and anti-inflammatory activities. Upon administration, carnosic acid and carnosol may induce apoptosis by decreasing apoptosis regulator B-cell lymphoma 2 (Bcl-2) expression, decrease tumor cell growth through inhibition of mammalian target of rapamycin (mTOR) phosphorylation, and inhibit metastatic activity by preventing the adhesion of tumor cells to type I collagen and fibronectin. Additionally, these diterpenes may decrease inflammation by downregulating cyclooxygenase (COX) type 2 (COX-2) protein synthesis. Alkylglycerols (alkyl-Gro) are bioactive ether lipids that may, through a not yet fully elucidated mechanism, inhibit tumor cell growth and metastases.			Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156176>	C20401|C129822	Falbikitug|AZD 0171|AZD-0171|AZD0171|Anti-LIF Monoclonal Antibody MSC-1|FALBIKITUG|MSC 1|MSC-1|MSC1	A humanized immunoglobulin G1 (IgG1) monoclonal antibody against leukemia inhibitory factor (LIF), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, falbikitug binds to LIF and inhibits LIF signaling by blocking the recruitment of glycoprotein 130 (gp130) to the LIF-LIF receptor (LIFR)-gp130 signaling complex. This inhibits signal transducer and activator of transcription 3 (STAT3) signaling and inhibits tumor cell growth. In addition, the inhibition of LIF signaling abrogates the immunosuppressive tumor microenvironment (TME) by decreasing immunosuppressive M2 macrophages and allows for the activation of natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs) against tumor cells. LIF, a member of the interleukin-6 (IL-6) family of cytokines, is involved in many physiological and pathological processes and plays an important role in both creating the TME and promoting the activity of cancer-initiating cells (CICs). LIF is overexpressed in many tumor cell types and its expression correlates with poor prognosis.	Falbikitug		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156177>	C134305	Anti-LAG-3 Monoclonal Antibody Sym022|SYM-022|Sym 022|Sym-022|Sym022	A recombinant, human Fc-inert monoclonal antibody targeting lymphocyte-activation gene 3 protein (LAG-3; LAG3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, monoclonal antibody Sym022 binds to human LAG-3 and blocks the interaction between LAG-3 and major histocompatibility complex class II (MHCII) molecules on the surface of antigen-presenting cells (APCs) and tumor cells. This prevents the negative regulation of T-cell activity that occurs via LAG-3-MHCII binding and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Additionally, Sym022 decreases LAG-3 surface levels through internalization and shredding. LAG-3 plays a key role in the activation of T-cells and natural killer (NK) cells.	Anti-LAG-3 Monoclonal Antibody Sym022		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156178>	C175455	Free of Pain and Discomfort|Free of pain and discomfort	A response indicating that an individual is or was free of pain or discomfort.			Intellectual Product	Health Utilities Index
C156179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156179>	C175455	Mild to Moderate Pain or Discomfort that Did Not Prevent Activities|Mild to moderate pain or discomfort that prevented no activities	A response indicating that an individual has or had mild to moderate pain or discomfort, but it did not prevent activities.			Intellectual Product	Health Utilities Index
C15617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15617>	C61063	Monoclonal Antibody 17-1A/sargramostim|GM-CSF/MOAB 17-1A			Obsolete_Concept	Therapeutic or Preventive Procedure	
C156180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156180>	C175455	Moderate Pain or Discomfort that Prevented Some Activities|Moderate pain or discomfort that prevented some activities	A response indicating that an individual has or had moderate pain or discomfort that prevented some activities.			Intellectual Product	Health Utilities Index
C156181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156181>	C175455	Moderate to Severe Pain or Discomfort that Prevented Some Activities|Moderate to severe pain or discomfort that prevented some activities	A response indicating that an individual has or had moderate to severe pain or discomfort that prevented some activities.			Intellectual Product	Health Utilities Index
C156182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156182>	C175455	Severe Pain or Discomfort that Prevented Most Activities|Severe pain or discomfort that prevented most activities	A response indicating that an individual has or had severe pain or discomfort that prevented most activities.			Intellectual Product	Health Utilities Index
C156183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156183>	C226701|C226575	Able to Walk Around Neighborhood Without Difficulty; No Walking Equipment Needed|Able to walk around the neighborhood without difficulty, and without walking equipment	A response indicating that an individual is or was able to walk around the neighborhood without difficulty and without walking equipment.			Intellectual Product	Health Utilities Index
C156184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156184>	C226701|C226575|C178389	Able to Walk Around Neighborhood with Difficulty; No Walking Equipment or Help Required|Able to walk around the neighborhood with difficulty; but did not require walking equipment or the help of another person	A response indicating that an individual is or was able to walk around the neighborhood with difficulty, but did not require walking equipment or the help of another person.			Intellectual Product	Health Utilities Index
C156185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156185>	C226701|C226575|C178389	Able to Walk Around Neighborhood with Walking Equipment; No Help Required|Able to walk around the neighborhood with walking equipment, but without the help of another person	A response indicating that an individual is or was able to walk around the neighborhood with walking equipment, but without the help of another person.			Intellectual Product	Health Utilities Index
C156186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156186>	C226576|C226575	Able to Walk Only Short Distances with Walking Equipment; Required a Wheelchair to Get Around the Neighborhood|Able to walk only short distances with walking equipment, and required a wheelchair to get around the neighborhood	A response indicating that an individual is or was able to walk only short distances with walking equipment and required a wheelchair to get around the neighborhood.			Intellectual Product	Health Utilities Index
C156187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156187>	C226710|C226576|C226575	Unable to Walk Alone, Even with Walking Equipment; Able to Walk Short Distances with Help; Require Wheelchair to Get Around the Neighborhood|Unable to walk alone, even with walking equipment. Able to walk short distances with the help of another person, and required a wheelchair to get around the neighborhood	A response indicating that an individual is or was unable to walk alone, even with walking equipment, but was able to walk short distances with the help of another person and required a wheelchair to get around the neighborhood.			Intellectual Product	Health Utilities Index
C156188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156188>	C226710|C226575	Unable to Walk at All|Unable to Walk|Unable to walk at all	A response indicating that an individual is or was unable to walk at all.			Intellectual Product	Health Utilities Index
C156189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156189>	C50166	Pressure Specified Sensory Device|PSSD|Pronged Sensation Device	A computer-based quantitative sensory testing device that detects cutaneous pressure perception and two-point discrimination. It is designed to quantify and record both specific peripheral nerve threshold levels and peripheral nerve innervation density.	Pressure Specified Sensory Device		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C15618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15618>	C15891	Cancer and Suicide|suicide and cancer				Idea or Concept	
C156190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156190>	C175275	Limitations in Use of Hands or Fingers|Limitations in the use of hands or fingers, but did not require special tools or the help of another person	A response indicating that an individual has limitations in the use of their hands or fingers, but does not require special tools or the help of another person.			Intellectual Product	Health Utilities Index
C156191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156191>	C175275	Full Use of Hands and Fingers|Full use of two hands and ten fingers	A response indicating that an individual has full use of both hands and all 10 fingers.			Intellectual Product	Health Utilities Index
C156192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156192>	C175275	Limitations in Use of Hands or Fingers; Requires Special Tools for Independence|Limitations in the use of hands or fingers, independent with use of special tools (did not require the help of another person)	A response indicating that an individual has limitations in the use of their hands or fingers, but remains independent through the use of special tools.			Intellectual Product	Health Utilities Index
C156193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156193>	C175275	Limitations in Use of Hands or Fingers; Requires Help for Some Tasks|Limitations in the use of hands or fingers, required the help of another person for some tasks (not independent even with use of special tools)	A response indicating that an individual has limitations in the use of their hands or fingers that requires the help of another person for some tasks, even with use of special tools.			Intellectual Product	Health Utilities Index
C156194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156194>	C175275	Limitations in Use of Hands or Fingers; Requires Help for Most Tasks|Limitations in the use of hands or fingers, required the help of another person for most tasks (not independent even with use of special tools)	A response indicating that an individual has limitations in the use of their hands or fingers that requires the help of another person for most tasks, even with use of special tools.			Intellectual Product	Health Utilities Index
C156195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156195>	C175275	Limitations in Use of Hands or Fingers; Requires Help for All Tasks|Limitations in the use of hands or fingers, required the help of another person for all tasks (not independent even with use of special tools)	A response indicating that an individual has limitations in the use of their hands or fingers that requires the help of another person for all tasks, even with use of special tools.			Intellectual Product	Health Utilities Index
C156196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156196>	C226562	Able to Remember Most Things|Able to remember most things	A response indicating that an individual is or was able to remember most things.			Intellectual Product	Health Utilities Index
C156197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156197>	C226670	Somewhat Forgetful|Somewhat forgetful	A response indicating that an individual is or was somewhat forgetful.			Intellectual Product	Health Utilities Index
C156198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156198>	C226670	Very Forgetful|Very forgetful	A response indicating that an individual is or was very forgetful.			Intellectual Product	Health Utilities Index
C156199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156199>	C226562	Unable to Remember Anything|Unable to Remember|Unable to remember anything at all	A response indicating that an individual is or was unable to remember anything.			Intellectual Product	Health Utilities Index
C15619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15619>	C61063	Edetate Calcium Disodium/Interferon Alfa/Monoclonal Antibody CC49|EDTA/IFN-A/MOAB CC49			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1561>	C20401|C129822	Monoclonal Antibody Lym-1|IgG2a murine monoclonal antibody Lym-1|Lym-1|MoAb Lym-1|Monoclonal Antibody Lym-1, IgG2a Murine	A murine IgG2a monoclonal antibody directed against the HLA-Dr10 protein, a cell surface marker present on over eighty percent of lymphoma cells.  When conjugated with a radioactive isotope, Lym-1 monoclonal antibody selectively transports the cytotoxic radioisotope to HLA-Dr10-expressing tumor cells, thereby sparing healthy B-cells and normal tissues.  This agent also mediates antibody-dependent cytotoxicity thereby promoting Raji B-lymphoid cell lysis by human neutrophils. (NCI04)			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156200>	C226582	Able to Think Clearly and Solve Day-to-day Problems|Able to think clearly and solve day to day problems	A response indicating that an individual is or was able to think clearly and solve day to day problems.			Intellectual Product	Health Utilities Index
C156201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156201>	C226582|C176243	Had a Little Difficulty When Trying to Think and Solve Day-to-day Problems|Had a little difficulty when trying to think and solve day to day problems	A response indicating that an individual has or had a little difficulty when trying to think and solve day to day problems.			Intellectual Product	Health Utilities Index
C156202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156202>	C226582|C176243	Had Some Difficulty When Trying to Think and Solve Day-to-day Problems|Had some difficulty when trying to think and solve day to day problems	A response indicating that an individual has or had some difficulty when trying to think and solve day to day problems.			Intellectual Product	Health Utilities Index
C156203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156203>	C226582|C176243	Had Great Difficulty When Trying to Think and Solve Day-to-day Problems|Had great difficulty when trying to think and solve day to day problems	A response indicating that an individual has or had great difficulty when trying to think and solve day to day problems.			Intellectual Product	Health Utilities Index
C156204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156204>	C226582	Unable to Think or Solve Day-to-day Problems|Unable to think or solve day to day problems	A response indicating that an individual is or was unable to think or solve day-to-day problems.			Intellectual Product	Health Utilities Index
C156205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156205>	C226566	Eat, Bathe, Dress, and Use Toilet Normally|Eat, bathe, dress and use the toilet normally	A response indicating that an individual is or was able to eat, bathe, dress, and use the toilet normally.			Intellectual Product	Health Utilities Index
C156206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156206>	C226566	Eat, Bathe, Dress, and Use Toilet with Difficulty|Eat, bathe, dress or use the toilet independently with difficulty	A response indicating that an individual is or was able to eat, bathe, dress, and use the toilet independently, but with difficulty.			Intellectual Product	Health Utilities Index
C156207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156207>	C226701	Required Mechanical Equipment to Eat, Bathe, Dress, or Use Toilet Independently|Required mechanical equipment to eat, bathe, dress or use the toilet independently	A response indicating that an individual is or was able to eat, bathe, dress, and use the toilet independently, but required mechanical equipment.			Intellectual Product	Health Utilities Index
C156208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156208>	C226566	Required Help to Eat, Bathe, Dress, or Use Toilet|Required the help of another person to eat, bathe, dress or use the toilet	A response indicating that an individual required help from another person to eat, bathe, dress, or use the toilet.			Intellectual Product	Health Utilities Index
C156209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156209>	C226674|C175346	Generally Happy and Free from Worry|Generally happy and free from worry	A response indicating that an individual is or was generally happy and free from worry.			Intellectual Product	Health Utilities Index
C15620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15620>	C15511	Antibiotic Therapy|Treatment of Bacterial Infectious Disease	Treatment of bacterial infections with antibiotics.	Antibiotic Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C156210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156210>	C175321	Occasionally Fretful, Angry, Irritable, Anxious, or Depressed|Occasionally fretful, angry, irritable, anxious or depressed	A response indicating that an individual is or was occasionally fretful, angry, irritable, anxious, or depressed.			Intellectual Product	Health Utilities Index
C156211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156211>	C63587|C63522|C63360	Carboplatin/Paclitaxel/Nivolumab Regimen|Carboplatin and Paclitaxel (CP) and Nivolumab|Carboplatin-Paclitaxel-Nivolumab|Carboplatin-Paclitaxel-Nivolumab Regimen|Carboplatin/Nivolumab/Paclitaxel|Carboplatin/Paclitaxel Plus Nivolumab|Carboplatin/Paclitaxel/Nivolumab|Carboplatin/Paclitaxel/Opdivo	A regimen consisting of carboplatin, paclitaxel and nivolumab that may be used for the treatment of head and neck squamous cell carcinoma, ovarian cancer, and non-small cell lung cancer (NSCLC).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156212>	C175321	Often Fretful, Angry, Irritable, Anxious, or Depressed|Often fretful, angry, irritable, anxious or depressed	A response indicating that an individual is or was often fretful, angry, irritable, anxious, or depressed.			Intellectual Product	Health Utilities Index
C156213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156213>	C175321	Almost Always Fretful, Angry, Irritable, Anxious, or Depressed|Almost always fretful, angry, irritable, anxious or depressed	A response indicating that an individual is or was almost always fretful, angry, irritable, anxious, or depressed.			Intellectual Product	Health Utilities Index
C156214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156214>	C175321	Extremely Fretful, Angry, Irritable, Anxious, or Depressed; Needing Professional Help|Extremely fretful, angry, irritable, anxious or depressed; to the point of needing professional help	A response indicating that an individual is or was extremely fretful, angry, irritable, anxious, or depressed, to the point of needing professional help.			Intellectual Product	Health Utilities Index
C156215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156215>	C175455	Occasional Pain or Discomfort; Relief from Non-prescription Drugs or Activity; No Disruption of Normal Activities|Occasional pain or discomfort.  Discomfort relieved by non-prescription drugs or self-control activity without disruption of normal activities	A response indicating that an individual has or had occasional pain or discomfort that was relieved by non-prescription drugs or self-control activities, without disruption of normal activities.			Intellectual Product	Health Utilities Index
C156216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156216>	C175455	Frequent Pain or Discomfort; Relief from Oral Medicines; Occasional Disruption of Normal Activities|Frequent pain or discomfort.  Discomfort relieved by oral medicines with occasional disruption of normal activities	A response indicating that an individual has or had frequent pain or discomfort that was relieved by oral medicines, with occasional disruption of normal activities.			Intellectual Product	Health Utilities Index
C156217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156217>	C175455	Frequent Pain or Discomfort; Relief Requires Prescription Narcotics; Frequent Disruption of Normal Activities|Frequent pain or discomfort; frequent disruption of normal activities. Discomfort required prescription narcotics for relief	A response indicating that an individual has or had frequent pain or discomfort that required prescription narcotics for relief, with frequent disruption of normal activities.			Intellectual Product	Health Utilities Index
C156218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156218>	C175455	Severe Pain or Discomfort; Pain not Relieved by Drugs; Constant Disruption of Normal Activities|Severe pain or discomfort.  Pain not relieved by drugs and constantly disrupted normal activities	A response indicating that an individual has or had severe pain or discomfort that was not relieved by drugs and constantly disrupted normal activities.			Intellectual Product	Health Utilities Index
C156219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156219>	C223627	PROMIS Pediatric and Parent Proxy Physical Health Domain|PROMIS Ped Fatigue|Ped Fatigue	The set of PROMIS measures that assess the physical health of pediatric subjects through self-report or parent proxy report.			Functional Concept	
C15621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15621>	C69308	H2 Receptor Antagonist Therapy	A type of treatment that uses histamine H2-receptor antagonists.	H2 Receptor Antagonist Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C156220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156220>	C173935|C173398	Being Tired Made it Hard to Keep up with Schoolwork Question|Being Tired Made it Hard to Keep up with Schoolwork|Being tired made it hard for me to keep up with my schoolwork	A question about whether an individual feels or felt that being tired made it hard for them to keep up with their schoolwork.			Intellectual Product	PROMIS Pediatric and Parent Proxy Physical Health Domain
C156221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156221>	C173935|C173458|C173398	Being Tired Made it Hard to Play or Go Out with Friends as Much as Would Like Question|Being Tired Made it Hard to Play or Go Out with Friends as Much as Would Like|Being tired made it hard for me to play or go out with my friends as much as I'd like	A question about whether an individual feels or felt that being tired made it hard for them to play or go out with friends as much as they would like.			Intellectual Product	PROMIS Pediatric and Parent Proxy Physical Health Domain
C156222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156222>	C173935|C173398	Hard to Pay Attention Because of Tiredness Question|Hard to Pay Attention Because of Tiredness|I was so tired it was hard for me to pay attention	A question about whether an individual has or had trouble paying attention because they are tired.			Intellectual Product	PROMIS Pediatric and Parent Proxy Physical Health Domain
C156223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156223>	C173935|C173458	Too Tired for Sports or Exercise Question|I was too tired to do sports or exercise|Too Tired for Sports or Exercise	A question about whether an individual is or was too tired to do sports or exercise.			Intellectual Product	PROMIS Pediatric and Parent Proxy Physical Health Domain
C156224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156224>	C173935	Too Tired to Do Things Outside Question|I was too tired to do things outside|Too Tired to Do Things Outside	A question about whether an individual is or was too tired to do things outside.			Intellectual Product	PROMIS Pediatric and Parent Proxy Physical Health Domain
C156225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156225>	C173935	Too Tired to Enjoy the Things I Like to Do Question|I was too tired to enjoy the things I like to do|Too Tired to Enjoy the Things I Like to Do	A question about whether an individual is or was too tired to enjoy the things they like to do.			Intellectual Product	PROMIS Pediatric and Parent Proxy Physical Health Domain
C156226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156226>	C158948	EPOR Fusion Positive|EPO-R Fusion Positive|Erythropoietin Receptor Fusion Positive	An indication that expression of a fusion containing sequences from EPOR has been detected in a sample.	EPOR Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156227>	C171054|C16606	SH2B3 Gene Deletion|LNK Gene Deletion|SH2B Adaptor Protein 3 Gene Deletion|SH2B3 Deletion	A molecular abnormality referring to the loss of at least one copy of the SH2B3 gene.	SH2B3 Gene Deletion		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C156228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156228>	C97927	IL7R Gene Mutation|CD127 Gene Mutation|CDW127 Gene Mutation|IL-7R-Alpha Gene Mutation|IL7RA Gene Mutation|Interleukin 7 Receptor Gene Mutation|Interleukin-7 Receptor Subunit Alpha Gene Mutation	A change in the nucleotide sequence of the IL7R gene.	IL7R Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156229>	C148275	Prolonged-Release Suspension for Injection in Pre-filled Pen Dosage Form|Prolonged-release suspension for injection in pre-filled pen	Medicinal product consisting of a prolonged-release suspension for injection presented in a pre-filled pen.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C15622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15622>	C49165|C16185	Radioimmunoguided Surgery|Radioguided Surgery|radioimmunoguided surgery	Radioguided surgery is an innovative means by which a radionuclide is used to preoperatively image and intraoperatively visualize a structure of interest to the surgeon for excisional biopsy. This technology has allowed a cost-effective, highly specific means by which to locate a structure (usually a lymph node) and access it for pathologic analysis. The result of radioguided surgery is increased specificity in tissue obtained for biopsy, minimal access incisions, and the reduction of inpatient hospital utilization. (from Medscape)			Health Care Activity	
C156230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156230>	C49236	Proactive Therapy|Proactive	Therapy that is received or administered before a condition or symptom begins.	Proactive Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C156231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156231>	C49236	Reactive Therapy|Reactive	Therapy that is received or administered after a condition or symptom begins.	Reactive Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C156232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156232>	C9251|C9244	Recurrent Aggressive Non-Hodgkin Lymphoma	An aggressive non-Hodgkin lymphoma that has recurred after a period of remission.			Neoplastic Process	
C156233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156233>	C9244|C8701	Refractory Aggressive Non-Hodgkin Lymphoma	An aggressive non-Hodgkin lymphoma that is resistant to treatment.			Neoplastic Process	
C156234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156234>	C35957	Complete Tumor Cell Necrosis|Complete Necrosis (No Viable Tumor)	A morphologic finding indicating the presence of tumor cell necrosis involving the entire neoplastic cellular infiltrate in a tissue sample. Viable tumor cells are absent.			Finding	GDC Terminology|GDC Value Terminology
C156235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156235>	C35957	Incomplete Tumor Cell Necrosis|Incomplete Necrosis (Viable Tumor Present)	A morphologic finding indicating the presence of focal or diffuse tumor cell necrosis involving part of the neoplastic cellular infiltrate in a tissue sample. Viable tumor cells are still present.			Finding	GDC Terminology|GDC Value Terminology
C156236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156236>	C168971	No Evidence of Tumor Cell Necrosis Present|Not identified	A morphologic finding indicating the absence of focal or diffuse tumor cell necrosis in a tissue sample.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C156237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156237>	C49236	Swallowing Therapy|Swallowing Intervention	Any treatment designed to lessen the effects of dysphagia. Treatment may include restoration of normal swallow function (rehabilitative), modifications to diet consistency and patient behavior (compensatory), or a combination of these approaches.	Swallowing Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C156238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156238>	C50560	Feeding Tube Dependency|Feeding Tube Dependence	The inability of a patient to received their nutrition other than through a feeding tube.	Feeding Tube Dependency		Finding	CTRP Disease Terminology|CTRP Terminology
C156239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156239>	C25676	Hallucination Severity|Hallucination Severity Scale	An indication of the type of a hallucination and its impact on a subject.			Qualitative Concept	
C15623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15623>	C15687|C15313	Intraoperative Radiation Therapy|IORT|IORT|IORT|Intraoperative Radiotherapy|Radiotherapy - intraoperative control (procedure)|intraoperative radiation therapy|radiotherapy, intraoperative	The use of any form of radiation therapy during a surgical procedure.	Intraoperative Radiation Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|mCode Brachytherapy High Dose Rate Electronic Technique Value Set|mCode Brachytherapy High Dose Rate Technique Value Set|mCode Brachytherapy Technique Value Set|mCode Electron Beam Technique Value Set|mCode Photon Beam Technique Value Set|mCode Radiotherapy Technique Value Set|mCode Teleradiotherapy Technique Value Set|mCode Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C156240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156240>	C63719|C63586|C63361|C159454	FUOX Regimen|FUOX|FUOX|Fluorouracil-Oxaliplatin|Fluorouracil-Oxaliplatin Regimen|Fluorouracil/Oxaliplatin|Fluorouracil/Oxaliplatin Regimen	A regimen consisting of 5-fluorouracil and oxaliplatin that may be used for the treatment of colorectal, esophageal and esophagogastric junction, gastric and hepatobiliary cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156241>	C156239	Very Mild Hallucination|Very mild	While resting or going to sleep, sees visions, smells odors or hears voices, sounds, or whispers in the absence of external stimulation, but no impairment in functioning.			Qualitative Concept	
C156242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156242>	C156239	Mild Hallucination|Mild	While in a clear state of consciousness, hears a voice calling the individual's name, experiences non-verbal auditory hallucinations (e.g., sounds or whispers), formless visual hallucinations or has sensory experiences in the presence of a modality relevant stimulus (e.g., visual illusions) infrequently (e.g., 1-2 times per week) and with no functional impairment.			Qualitative Concept	
C156243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156243>	C156239	Moderate Hallucination|Moderate	Occasional verbal, visual, gustatory, olfactory or tactile hallucinations with no functional impairment; or non-verbal auditory hallucinations/visual illusions more than infrequently or with impairment.			Qualitative Concept	
C156244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156244>	C156239	Severe Hallucination|Severe	Experiences verbal or visual hallucinations several times a day, or many areas of functioning are disrupted by these hallucinations.			Qualitative Concept	
C156245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156245>	C156239	Extremely Severe Hallucination|Extremely severe	Persistent verbal or visual hallucinations throughout the day, or most area of functioning are disrupted by these hallucinations.			Qualitative Concept	
C156246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156246>	C63442	R-CHOP-Methotrexate Regimen|CHOP-R Plus Methotrexate|Cyclophosphamide/Doxorubicin/Methotrexate/Prednisone/Rituximab/Vincristine Regimen|Methotrexate Plus R-CHOP|R-CHOP Plus MTX|R-CHOP Plus Methotrexate Regimen|R-M-CHOP|R-M-CHOP|R-M-CHOP (rituximab-abbs)|R-M-CHOP (rituximab-arrx)|R-M-CHOP (rituximab-blit)|R-M-CHOP (rituximab-pvvr)|R-M-CHOP (rituximab-rite)|R-M-CHOP (rituximab-rixa)|R-M-CHOP (rituximab-rixi)|Rituximab-Cyclophosphamide-Hydroxydaunorubicin-Oncovin-Prednisone-Methotrexate Regimen	A regimen consisting of rituximab, cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine (Oncovin), prednisone (R-CHOP), and methotrexate used to treat certain types of lymphomas.	R-CHOP Plus Methotrexate Regimen		Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156247>	C63519	Megestrol/Tamoxifen Regimen|Megace/Tamoxifen Regimen|Megestrol Acetate/Tamoxifen Regimen|Megestrol Alternating with Tamoxifen|Megestrol and Tamoxifen|Tamoxifen-Megace|Tamoxifen-Megestrol Acetate|Tamoxifen/Megace Regimen|Tamoxifen/Megestrol Regimen	A regimen consisting of alternating megestrol acetate and tamoxifen with potential use in the treatment of endometrial carcinoma.			Therapeutic or Preventive Procedure	GDC Regimen Terminology|GDC Terminology|HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156248>	C63358	Anastrozole/Tamoxifen Regimen|Anastrozole and Tamoxifen|Arimidex-Tamoxifen Regimen|Tamoxifen-Anastrozole|Tamoxifen-Anastrozole Regimen|Tamoxifen/Anastrozole Regimen|Tamoxifen/Arimidex Regimen	A regimen consisting of tamoxifen and anastrozole that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156249>	C159200	Lisaftoclax|APG 2575|APG-2575|APG2575|Bcl-2 Inhibitor APG 2575|LISAFTOCLAX	An orally bioavailable and selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon oral administration, lisaftoclax targets, binds to and inhibits the activity of Bcl-2. This restores apoptotic processes in tumor cells. Bcl-2 is overexpressed in many cancers and plays an important role in the negative regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival.	Lisaftoclax		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15624>	C61063	9-cis-Retinoic Acid/Interferon Alfa|9-CRA/IFN-A	A combination drug therapy.		Obsolete_Concept	Therapeutic or Preventive Procedure	
C156250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156250>	C63359	Carboplatin/Topotecan Regimen|Carboplatin and Topotecan	A regimen consisting of carboplatin and topotecan with potential use in the treatment of some cancers, including small cell lung, ovarian and cervical cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156251>	C201173|C200766	Autologous Anti-CD22 CAR-4-1BB-TCRz-transduced T-lymphocytes CART22-65s|Autologous Anti-CD22 CAR T-Cells CART22-65s|Autologous Anti-CD22 scFv CAR 4-1BB-TCRz-expressing T-lymphocytes CART22-65s|Autologous CART22-65s Cells|Autologous CART22-65s T-cells|Autologous CART22-65s-expressing T-cells|CART22-65s	Autologous human T-lymphocytes transduced with a recombinant lentiviral vector encoding a chimeric antigen receptor (CAR) consisting of an anti-CD22 human single chain variable fragment (scFv) and linked to the co-stimulatory domain 4-1BB (CD137) coupled to the zeta chain of the TCR/CD3 complex (CD3-zeta), with potential immunostimulating and antineoplastic activities. Upon reintroduction into the patient, the autologous anti-CD22 CAR-4-1BB-TCRz -transduced T-lymphocytes CART22-65s express anti-CD22-CAR on their cell surfaces and bind to the CD22 antigen on tumor cell surfaces, resulting in lysis of CD22-expressing tumor cells. CD22, a B-lineage-restricted, transmembrane phosphoglycoprotein, is expressed on malignant B-cells.	Autologous Anti-CD22 CAR-4-1BB-TCRz-transduced T-lymphocytes CART22-65s		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156252>	C156239	Moderately Severe Hallucination|Moderately severe	Experiences daily hallucinations, or some areas of functioning are disrupted by hallucinations.			Qualitative Concept	
C156253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156253>	C53649	Recurrent Cytomegalovirus Infection	A cytomegalovirus infection that has recurred after a period of remission.	Recurrent Cytomegalovirus Infection		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C156254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156254>	C115149	Recurrent Adenovirus Infection	An adenovirus infection that has recurred after a period of remission.	Recurrent Adenovirus Infection		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C156255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156255>	C38759	Recurrent EBV Infection|Recurrent Epstein-Barr Virus Infection|Recurrent Epstein-Barr Virus Infection	An Epstein-Barr virus infection that has recurred after a period of remission.	Recurrent Epstein-Barr Virus Infection		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C156256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156256>	C28676	Partially HLA-matched AdV/CMV/EBV-specific Allogeneic T-Lymphocytes|Allogeneic HLA-matched VSTs|Allogeneic HLA-matched Virus-specific T-cell Lines|Allogeneic Partially HLA-matched AdV/CMV/EBV-specific T-cells|Partially HLA-matched AdV/CMV/EBV-specific Allogeneic T-cells|Partially HLA-matched Adenovirus/Cytomegalovirus/Epstein-Barr Virus-specific Allogeneic Cytotoxic T-Lymphocytes	Partially or closely human leukocyte antigen (HLA)-matched allogeneic cytotoxic T-lymphocytes (CTLs), derived from cell lines, specifically reactive to the three human viruses adenovirus (AdV), cytomegalovirus (CMV) and Epstein-Barr virus (EBV), with potential antiviral activity. Upon infusion of the partially HLA-matched AdV/CMV/EBV-specific allogeneic T-lymphocytes in immunocompromised patients or upon allogeneic hematopoietic stem cell transplantation (HSCT) in an immunodeficient recipient, these CTLs may kill AdV, CMV, and/or EBV-infected cells, and may prevent or reduce the severity of viral infections by these pathogens.	Partially HLA-matched AdV/CMV/EBV-specific Allogeneic T-Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C156257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156257>	C63358	Anastrozole/Lapatinib Regimen|Anastrozole and Lapatinib|Anastrozole-Lapatinib|Anastrozole-Lapatinib Regimen|Anastrozole/Lapatinib|Lapatinib/Anastrozole Regimen|Tykerb/Anastrozole	A regimen consisting of anastrozole and lapatinib that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156258>	C63358	Abemaciclib/Fulvestrant Regimen|Abemaciclib and Fulvestrant|Abemaciclib-Fulvestrant|Abemaciclib-Fulvestrant Regimen|Abemaciclib/Fulvestrant|Fulvestrant/Abemaciclib Regimen|Verzenio/Faslodex	A regimen consisting of abemaciclib and fulvestrant that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156259>	C63358	Anastrozole/Lapatinib/Trastuzumab Regimen|Anastrozole, Lapatinib, Trastuzumab|Anastrozole, Lapatinib, Trastuzumab-anns|Anastrozole, Lapatinib, Trastuzumab-dkst|Anastrozole, Lapatinib, Trastuzumab-dttb|Anastrozole, Lapatinib, Trastuzumab-herw|Anastrozole, Lapatinib, Trastuzumab-pkrb|Anastrozole, Lapatinib, Trastuzumab-qyyp|Anastrozole, Lapatinib, Trastuzumab-strf|Anastrozole, Lapatinib, Trastuzumab-zerc|Anastrozole-Lapatinib-Trastuzumab|Anastrozole-Lapatinib-Trastuzumab Regimen|Anastrozole/Lapatinib/Trastuzumab|Anastrozole/Tykerb/Herceptin|Tykerb/Anastrozole/Herceptin	A regimen consisting of anastrozole, lapatinib, and trastuzumab that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C15625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15625>	C61007	QS21/Tyrosinase Peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C156260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156260>	C63360	Temozolomide/Veliparib Regimen|ABT-888 and Temozolomide|Temozolomide Plus Veliparib|Temozolomide and Veliparib|Temozolomide-Veliparib|Temozolomide/ABT-888|Temozolomide/Veliparib|Veliparib/Temozolomide|Veliparib/Temozolomide Regimen	A regimen consisting of temozolomide and veliparib that can potentially be used for the treatment of various cancers, such as non-small cell lung cancer (NSCLC) and acute myeloid leukemia (AML).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156261>	C156290	Cyclophosphamide/Dacarbazine/Vincristine Regimen|CVD|Cyclophosphamide, Dacarbazine, Vincristine|Cyclophosphamide-Vincristine-Dacarbazine|Cyclophosphamide/Vincristine/Dacarbazine|Cyclophosphamide/Vincristine/Dacarbazine Regimen|Cytoxan/Vincristine/Dacarbazine	A regimen consisting of cyclophosphamide, vincristine and dacarbazine that can be used for the treatment of malignant paraganglioma and pheochromocytoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156262>	C63522|C159901|C159900	Carboplatin/Liposomal Doxorubicin Regimen|Carboplatin and Pegylated liposomal doxorubicin|Carboplatin-Doxil|Carboplatin-Doxil Regimen|Doxil-Carboplatin|Doxil/Carboplatin|Doxil/Carboplatin Regimen|Liposomal Doxorubicin/Carboplatin Regimen	A regimen consisting of carboplatin and liposomal doxorubicin that can be used for the treatment of ovarian, fallopian tube and primary peritoneal cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156263>	C63358	AC-TAM Regimen|AC-TAM|Adriamycin/Cyclophosphamide/Tamoxifen|Doxorubicin-Cyclophosphamide-Tamoxifen|Doxorubicin/Cyclophosphamide/Tamoxifen|Doxorubicin/Cyclophosphamide/Tamoxifen Regimen	A regimen consisting of doxorubicin, cyclophosphamide and tamoxifen that can potentially be used for the treatment of breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156264>	C63442|C140180	Leucovorin/High-dose Methotrexate Regimen|HD Methotrexate-Leucovorin|HD Methotrexate/Leucovorin|HD-MTX-LCV|High-Dose Methotrexate/Leucovorin|High-dose Methotrexate/Leucovorin Regimen	A regimen consisting of high-dose methotrexate and leucovorin that can potentially be used for the treatment of various central nervous system (CNS) cancers and various types of lymphoma, such as diffuse large B-cell lymphoma (DLBCL).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156265>	C63467	Fluorouracil/Mitomycin Regimen|Fluorouracil and Mitomycin|Fluorouracil-Mitomycin|Fluorouracil/Mitomycin|Mitomycin-5-FU|Mitomycin-Fluorouracil|Mitomycin/5-FU	A regimen consisting of fluorouracil and mitomycin that may be used for the treatment of a variety of cancers, such as anal, vulvar, bladder and penile cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156266>	C63467|C63358	Gemcitabine/Cisplatin/Everolimus Regimen|Everolimus/Gemcitabine/Cisplatin|GPE|Gemcitabine and Cisplatin with Everolimus|Gemcitabine-Cisplatin-Everolimus|Gemcitabine/Cisplatin/Everolimus|Gemcitabine/Platinol/Everolimus	A regimen consisting of gemcitabine, cisplatin and everolimus that may be used for the treatment of a variety of cancers, such as urothelial, bladder and breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156267>	C4815	Thyroid Gland Mucinous Carcinoma	A rare primary carcinoma of the thyroid gland characterized by the presence of clusters of malignant epithelial cells associated with abundant extracellular mucin deposition.			Neoplastic Process	
C156268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156268>	C3414|C3411	Intrathyroidal Thymoma|Ectopic Thyroid Gland Thymoma	A rare thymoma arising within or is attached to the thyroid gland.			Neoplastic Process	
C156269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156269>	C8933|C168985|C168978	Locally Advanced Pancreatic Adenocarcinoma	A pancreatic adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Pancreatic Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C15626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15626>	C63475	Neuroendocrine Therapy	Drug therapy that uses a neuroendocrine hormone.			Therapeutic or Preventive Procedure	
C156270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156270>	C129820	Subasumstat|SUBASUMSTAT|TAK 981|TAK-981|TAK981	A small molecule inhibitor of sumoylation, with potential immune-activating and antineoplastic activities. Upon intravenous administration, subasumstat targets and covalently binds to the small ubiquitin-like modifier (SUMO; small ubiquitin-related modifier) protein, forming an adduct with SUMO protein (subasumstat-SUMO adduct). This prevents the transfer of SUMO from the SUMO-activating enzyme (SAE) to SUMO-conjugating enzyme UBC9. This prevents SUMO conjugation to lysine residues on target proteins and abrogates many sumoylated protein-mediated cellular processes that play key roles in tumor cells, including proliferation, DNA repair, metastasis and survival. In addition, by preventing sumoylation, subasumstat is able to increase the production of type 1 interferon (IFN), thereby increasing type 1 IFN-mediated signaling, activating innate effector cells and enhancing the antitumor innate immune responses. This may further increase tumor cell killing. Sumoylation, a post-translational modification that attaches the SUMO protein to target proteins, plays a key role in regulating their activity, function, subcellular localization and stability.  Sumoylation also plays a key role in inhibiting innate immune responses, specifically by inhibiting the pattern recognition receptor (PRR) pathway and preventing type 1 IFN expression. Abnormal sumoylation of target proteins is associated with many cancers.	Subasumstat		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156271>	C200766|C176018	Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T-lymphocytes huCART19|Anti-CD19 CAR-T Cells huCART19|Anti-CD19 Humanized scFv TCRz-41BB-CAR Lentiviral Vector-transduced Autologous T-lymphocytes|Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells huCART19|CTL119|CTL119 Cells|huCART19 Cells|huCART19 T-lymphocytes	Autologous T-lymphocytes that have been transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) consisting of a humanized single chain variable fragment (scFv) of anti-CD19 coupled to the cytoplasmic portion of the zeta chain of the human T-cell receptor (CD3zeta) and the co-stimulatory molecule 4-1BB (CD137), with potential immunostimulating and antineoplastic activities. Upon re-introduction into the patient, the autologous anti-CD19 CAR TCR-zeta/4-1BB-transduced T-lymphocytes huCART19 target and bind to CD19-expressing neoplastic B-cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells, resulting in tumor cell lysis. CD19 (cluster of differentiation 19) is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. Incorporation of the co-stimulatory signaling domains increases human T-cell function, expansion, and survival.	Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T-lymphocytes huCART19		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156272>	C200766|C176023	Autologous Anti-BCMA-CAR-TCRz/4-1BB-expressing T-lymphocytes CART-BCMA|Autologous BCMA 4-1BBz CAR T-Cells CART-BCMA|Autologous BCMA-specific CAR-TCRz/4-1BB-expressing T-Lymphocytes CART-BCMA|CART-BCMA|CART-BCMA Cells	A preparation of autologous T-lymphocytes that have been ex vivo transduced with a genetically-engineered lentiviral vector (LV) expressing a chimeric antigen receptor (CAR) containing an extracellular human single chain variable fragment (scFv) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) fused to an intracellular tandem signaling domain comprised of the co-stimulatory domain of 4-1BB (CD137) and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3z), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-lymphocytes specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.	Autologous Anti-BCMA-CAR-TCRz/4-1BB-expressing T-lymphocytes CART-BCMA		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156273>	C3750|C156274	Tongue Alveolar Soft Part Sarcoma'	An alveolar soft part sarcoma involving the tongue. It usually occurs in children.			Neoplastic Process	
C156274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156274>	C9345|C173481	Tongue Sarcoma	A sarcoma that arises from the tongue.			Neoplastic Process	
C156276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156276>	C6095|C3750	Orbital Alveolar Soft Part Sarcoma	An alveolar soft part sarcoma that arises from the orbit. Although it is a rare sarcoma, it affects the orbit relatively frequently.			Neoplastic Process	
C156277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156277>	C4669|C3750	Bladder Alveolar Soft Part Sarcoma	An alveolar soft part sarcoma involving the bladder.			Neoplastic Process	
C156278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156278>	C7158|C6587	Cellular Neurothekeoma|Neurothekeoma|Neurothekeoma	A benign cutaneous neoplasm of uncertain differentiation that usually affects children and young adults and presents as a usually solitary well-circumscribed dermal nodule, predominantly in the face. It is a multilobulated neoplasm composed of nests of epithelioid cells with pale eosinophilic cytoplasm and vesicular nucleus. The nests of neoplastic cells are usually separated by collagenous or myxoid stroma.			Neoplastic Process	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Morphology PT Terminology|Mapped ICDO3.1 Morphology Terminology|Mapped ICDO3.1 Terminology
C156279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156279>	C5495|C3194	Colon Liposarcoma	A liposarcoma that arises from the colon.			Neoplastic Process	
C15627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15627>	C61063	Interferon Alfa/Monoclonal Antibody CC49/Paclitaxel|IFN-A/MOAB CC49/TAX			Obsolete_Concept	Therapeutic or Preventive Procedure	
C156280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156280>	C5983|C3525	Parotid Gland Sarcoma	A sarcoma that arises from the parotid gland.			Neoplastic Process	
C156281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156281>	C202611|C156280	Parotid Gland Liposarcoma	A liposarcoma that arises from the parotid gland.			Neoplastic Process	
C156282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156282>	C5615|C156283	Scrotal Liposarcoma	A liposarcoma involving the scrotum.			Neoplastic Process	
C156283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156283>	C9306|C3560|C169100	Scrotal Sarcoma	A sarcoma involving the scrotum.			Neoplastic Process	
C156284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156284>	C8946|C164143	Advanced Prostate Carcinoma	A prostatic carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.			Neoplastic Process	
C156285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156285>	C8946|C167069	Locally Advanced Prostate Carcinoma	A prostatic carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Prostate Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156286>	C8945|C159556|C156284	Advanced Prostate Adenocarcinoma	A prostatic adenocarcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Prostate Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156287>	C8945|C168978|C156285	Locally Advanced Prostate Adenocarcinoma	A prostatic adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.			Neoplastic Process	
C156288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156288>	C171611|C156285|C155698	Locally Advanced Unresectable Prostate Carcinoma	A prostatic carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.			Neoplastic Process	
C156289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156289>	C223267|C156288|C156287	Locally Advanced Unresectable Prostate Adenocarcinoma	A prostatic adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.			Neoplastic Process	
C15628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15628>	C61063	Interferon Alfa/Monoclonal Antibody CC49/Pentetic Acid|DTPA/IFN-A/MOAB CC49			Obsolete_Concept	Therapeutic or Preventive Procedure	
C156290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156290>	C62634	Regimen Used to Treat Malignant Neuroendocrine and Adrenal Neoplasm|Chemotherapy Regimen Used to Treat Malignant Neuroendocrine and Adrenal Carcinoma	Any regimen that can be used for the treatment of malignant neuroendocrine and adrenal neoplasms.			Therapeutic or Preventive Procedure	
C156291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156291>	C222044	CARTOX Grade 0|CARTOX No Neurological Impairment|CARTOX Score 10	A score of 10 on the CARTOX-10 assessment, indicating no neurotoxicity.			Intellectual Product	
C156292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156292>	C122458	High Risk Acute Myeloid Leukemia|High-Risk Acute Myeloid Leukemia	Acute myeloid leukemia characterized by poor response to induction chemotherapy and poor long-term survival following treatment with consolidation chemotherapy.	High Risk Acute Myeloid Leukemia		Finding	CTRP Disease Terminology|CTRP Terminology
C156293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156293>	C226332|C167435	High Risk Chronic Myelomonocytic Leukemia|High-Risk Chronic Myelomonocytic Leukemia	Chronic myelomonocytic leukemia with cytogenetic abnormalities including trisomy 8, complex karyotypes, monosomy 7, and del17q. Mutations in RUNX1, NRAS, SETBP1, and ASXL1 are independently associated with inferior overall survival time. (Oncology Letters 15:7132-7138, 2018)	High Risk Chronic Myelomonocytic Leukemia		Finding	CTRP Disease Terminology|CTRP Terminology
C156294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156294>	C213709|C153387	Advanced Cervical Carcinoma	A cervical carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Cervical Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156295>	C213703|C153387	Locally Advanced Cervical Carcinoma	A cervical carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Cervical Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156296>	C63358	Everolimus/Fulvestrant Regimen|Everolimus-Fulvestrant|Everolimus-Fulvestrant Regimen|Everolimus/Fulvestrant|Fulvestrant/Everolimus|Fulvestrant/Everolimus Regimen	A regimen consisting of everolimus and fulvestrant that may be used in the treatment of  breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156297>	C206200|C168978|C153389	Locally Advanced Cervical Adenocarcinoma	A cervical adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.			Neoplastic Process	
C156299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156299>	C174029|C156300|C156297	Locally Advanced Unresectable Cervical Adenocarcinoma	A cervical adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.			Neoplastic Process	
C15629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15629>	C61063	Keyhole Limpet Hemocyanin/MUC-1 Antigen|KLH/MUC-1|KLH/MUC-1 Antigen|KLH/Mucin Peptide|Keyhole Limpet Hemocyanin/Mucin Peptide			Obsolete_Concept	Therapeutic or Preventive Procedure	
C1562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1562>	C2199|C2124|C129819	Rhenium Re 186 Etidronate|186Re-Etidronate|RHENIUM RE-186 ETIDRONATE|Re 186 Hydroxyethylidene Diphosphonate|Re-186 HEDP|Re-186 Hydroxyethylidene Diphosphonate|Rhenium Re-186 Hydroxyethylidene Diphosphonate|Rhenium-186 HEDP	An synthetic compound containing the organic phosphonate hydroxyethylidene diphosphonate (HEDP) labeled with the radioisotope rhenium Re 186. Re-186 etidronate binds to hydroxyapatite in bone, delivering a cytotoxic dose of beta radiation to primary and metastatic bone tumors. Re-186 is a beta emitter with a short half-life, a radioisotope profile that provides localized antitumor radiocytotoxicity while sparing extramedullary bone marrow tissues.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156300>	C213700|C174024|C156295	Locally Advanced Unresectable Cervical Carcinoma	A cervical carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.			Neoplastic Process	
C156302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156302>	C63358	Everolimus/Tamoxifen Regimen|Everolimus and Tamoxifen|Everolimus-Tamoxifen|Everolimus-Tamoxifen Regimen|Everolimus/Tamoxifen|Tamoxifen and Everolimus|Tamoxifen/Everolimus|Tamoxifen/Everolimus Regimen	A regimen consisting of everolimus and tamoxifen that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156303>	C63358	Exemestane/Lapatinib/Trastuzumab Regimen|Exemestane, Lapatinib, Trastuzumab|Exemestane, Lapatinib, Trastuzumab-anns|Exemestane, Lapatinib, Trastuzumab-dkst|Exemestane, Lapatinib, Trastuzumab-dttb|Exemestane, Lapatinib, Trastuzumab-herw|Exemestane, Lapatinib, Trastuzumab-pkrb|Exemestane, Lapatinib, Trastuzumab-qyyp|Exemestane, Lapatinib, Trastuzumab-strf|Exemestane, Lapatinib, Trastuzumab-zerc|Exemestane-Lapatinib-Trastuzumab|Exemestane-Lapatinib-Trastuzumab Regimen|Exemestane-Trastuzumab-Lapatinib|Exemestane/Lapatinib/Herceptin|Exemestane/Lapatinib/Trastuzumab|Exemestane/Trastuzumab/Lapatinib|Exemestane/Trastuzumab/Lapatinib Regimen	A regimen consisting of exemestane, lapatinib, and trastuzumab that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156304>	C206199|C159556|C153389	Advanced Cervical Adenocarcinoma	A cervical adenocarcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Cervical Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156305>	C63358	Exemestane/Lapatinib Regimen|Exemestane and Lapatinib|Exemestane-Lapatinib|Exemestane-Lapatinib Regimen|Exemestane/Lapatinib|Lapatinib/Exemestane|Lapatinib/Exemestane Regimen	A regimen consisting of exemestane and lapatinib that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156306>	C63358	Fulvestrant/Trastuzumab Regimen|Fulvestrant-Trastuzumab|Fulvestrant-Trastuzumab Regimen|Fulvestrant/Herceptin|Fulvestrant/Trastuzumab|Trastuzumab/Fulvestrant|Trastuzumab/Fulvestrant Regimen	A regimen consisting of fulvestrant and trastuzumab that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156307>	C63358	Lapatinib/Letrozole/Trastuzumab Regimen|Lapatinib, Letrozole, Trastuzumab|Lapatinib, Letrozole, Trastuzumab-anns|Lapatinib, Letrozole, Trastuzumab-dkst|Lapatinib, Letrozole, Trastuzumab-dttb|Lapatinib, Letrozole, Trastuzumab-herw|Lapatinib, Letrozole, Trastuzumab-pkrb|Lapatinib, Letrozole, Trastuzumab-qyyp|Lapatinib, Letrozole, Trastuzumab-strf|Lapatinib, Letrozole, Trastuzumab-zerc|Lapatinib-Letrozole-Trastuzumab|Lapatinib-Letrozole-Trastuzumab Regimen|Lapatinib/Letrozole/Herceptin|Lapatinib/Letrozole/Trastuzumab|Letrozole/Lapatinib/Trastuzumab|Letrozole/Lapatinib/Trastuzumab Regimen	A regimen consisting of lapatinib, letrozole, and trastuzumab that can be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156308>	C63358	Letrozole/Trastuzumab Regimen|Letrozole and Trastuzumab|Letrozole and Trastuzumab-anns|Letrozole and Trastuzumab-dkst|Letrozole and Trastuzumab-dttb|Letrozole and Trastuzumab-herw|Letrozole and Trastuzumab-pkrb|Letrozole and Trastuzumab-qyyp|Letrozole and Trastuzumab-strf|Letrozole and Trastuzumab-zerc|Letrozole-Trastuzumab|Letrozole-Trastuzumab Regimen|Letrozole/Herceptin|Letrozole/Trastuzumab|Trastuzumab/Letrozole|Trastuzumab/Letrozole Regimen	A regimen consisting of letrozole and trastuzumab that can be used in the treatment of  breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156309>	C84392|C53543	Intellectual Developmental Disorder, Autosomal Dominant 39|MRD39|Mental Retardation, Autosomal Dominant 39	An autosomal dominant condition caused by mutation(s) in the MYT1L gene, encoding myelin transcription factor 1-like protein. It is characterized by intellectual disability and mild dysmorphic facial features.			Disease or Syndrome	Cellosaurus Disease Terminology
C15630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15630>	C180543	Vegan Diet	A type of vegetarian diet that excludes all animal products, including dairy, eggs, meat, poultry, fish, and animal fats.			Daily or Recreational Activity	
C156310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156310>	C85075	Spinal Muscular Atrophy Type 2|SMA2	An autosomal recessive condition caused by mutation(s) in the SMN1 gene, encoding survival motor neuron protein. It is characterized by onset between 3 and 15 months of age, and is intermediate in terms of severity between spinal muscular atrophy (SMA) type I and SMA type III.			Disease or Syndrome	Cellosaurus Disease Terminology
C156311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156311>	C53543	Diastrophic Dysplasia|DTD	An autosomal recessive condition caused by mutation(s) in the SLC26A2 gene, encoding sulfate transporter. It is characterized by  cartilaginous and bony abnormalities, in particular very short arms and legs and the "hitchhiker" thumb, resulting from deformity of the first metacarpal.			Disease or Syndrome	Cellosaurus Disease Terminology
C156312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156312>	C87194	Brazilian State	Any of the 27 federal units of Brazil, which include the 26 federal states of Brazil, plus the Federal District which contains the capital city, Brasilia.			Geographic Area	
C156313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156313>	C156312	Acre	A state in the westernmost part of the North Region of Brazil. Its capital is Rio Branco.			Geographic Area	
C156314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156314>	C156312	Alagoas	A state in the eastern part of the Northeast Region of Brazil. Its capital is Maceio.			Geographic Area	
C156315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156315>	C156312	Amapa	A state in the North Region of Brazil. Its capital is Macapa.			Geographic Area	
C156316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156316>	C156312	Amazonas	A state in the North Region of Brazil. Its capital is Manaus.			Geographic Area	
C156317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156317>	C156312	Bahia	A state in the Northeast Region of Brazil. Its capital is Salvador.			Geographic Area	
C156318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156318>	C156312	Ceara	A state in the Northeast Region of Brazil. Its capital is Fortaleza.			Geographic Area	
C156319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156319>	C156312	Distrito Federal	A state in the Central-West Region of Brazil. It contains the Brazilian capital city, Brasilia.			Geographic Area	
C15631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15631>	C49165	Aspiration|ASPIRATION|aspiration	Procedure using suction, usually with a thin needle and syringe, to remove bodily fluid or tissue.			Therapeutic or Preventive Procedure	CDISC SDTM Specimen Collection Method Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156320>	C156312	Espirito Santo	A state in the Southeast Region of Brazil. Its capital is Vitoria.			Geographic Area	
C156321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156321>	C156312	Goias	A state in the Central-West Region of Brazil. Its capital is Goiania			Geographic Area	
C156322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156322>	C156312	Maranhao	A state in the Northeast Region of Brazil. Its capital is Sao Luis.			Geographic Area	
C156323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156323>	C156312	Mato Grosso	A state in the Central-West Region of Brazil. Its capital is Cuiaba.			Geographic Area	
C156324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156324>	C156312	Mato Grosso do Sul	A state in the Central-West Region of Brazil. Its capital is Campo Grande.			Geographic Area	
C156325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156325>	C156312	Minas Gerais	A state in the Southeast Region of Brazil. Its capital is Belo Horizonte.			Geographic Area	
C156326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156326>	C156312	Parana	A state in the South Region of Brazil. Its capital is Curitiba.			Geographic Area	
C156327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156327>	C156312	Paraiba	A state in the Northeast Region of Brazil. Its capital is Joao Pessoa.			Geographic Area	
C156328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156328>	C156312	Para	A state in the North Region of Brazil. Its capital is Belem.			Geographic Area	
C156329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156329>	C156312	Pernambuco	A state in the Northeast Region of Brazil. Its capital is Recife.			Geographic Area	
C15632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15632>	C49236	Chemotherapy|CHEMO|CHEMOTHERAPY|Chemo|Chemotherapy (NOS)|Chemotherapy, Cancer, General|chemotherapy	The use of synthetic or naturally-occurring chemicals for the treatment of diseases.	Chemotherapy		Therapeutic or Preventive Procedure	ALL Authorized Value Terminology|ALL Non-protocol Therapy Table|AML Authorized Value Terminology|AML Survival Characteristics Table|CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Codelists Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Medical History Form|CPTAC Terminology|CPTAC Treatments Codelist|CRF5 Response Evaluation Clinical Evaluation Table|CTRP Intervention Terminology|CTRP Terminology|EWS Authorized Value Terminology|EWS Non-Protocol Therapy Table|GCT Authorized Value Terminology|GCT Growing Teratoma Syndrome Table|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HL Adverse Events Table|HL Authorized Value Terminology|HL Biopsy/Surgical Procedures Table|HL Concomitant Medication Table|HL Course Timing Table|HL Function Test Table|HL Histology Table|HL Imaging Table|HL Immunohistochemistry Table|HL Lab Table|HL Lesion Characteristics Table|HL Non-protocol Therapy Table|HL Off Protocol Therapy/Study Table|HL Protocol Treatment Modifications Table|HL Radiation Therapy Table|HL Secondary Malignant Neoplasm Table|HL Staging Table|HL Stem Cell Transplant Table|HL Subject Response Table|HL Survival Characteristics Table|HL Total Dose Table|HL Transfusion Medicine Procedures Table|HL Vitals Table|Operational Ontology for Radiation Oncology Prostate Cancer Terminology|OS Authorized Value Terminology|OS Course Timing Table|OS Subject Characteristics Table
C156330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156330>	C156312	Piaui	A state in the Northeast Region of Brazil. Its capital is Teresina.			Geographic Area	
C156331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156331>	C156312	Rio de Janeiro	A state in the Southeast Region of Brazil. Its capital is Rio de Janeiro.			Geographic Area	
C156332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156332>	C156312	Rio Grande do Norte	A state in the Northeast Region of Brazil. Its capital is Natal.			Geographic Area	
C156333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156333>	C156312	Rio Grande do Sul	A state in the South Region of Brazil. Its capital is Porto Alegre.			Geographic Area	
C156334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156334>	C156312	Rondonia	A state in the North Region of Brazil. Its capital is Porto Velho.			Geographic Area	
C156335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156335>	C156312	Roraima	A state in the North Region of Brazil. Its capital is Boa Vista.			Geographic Area	
C156336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156336>	C156312	Santa Catarina	A state in the South Region of Brazil. Its capital is Florianopolis.			Geographic Area	
C156337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156337>	C156312	Sergipe	A state in the Northeast Region of Brazil. Its capital is Aracaju.			Geographic Area	
C156338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156338>	C156312	Sao Paulo	A state in the Southeast Region of Brazil. Its capital is Sao Paulo.			Geographic Area	
C156339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156339>	C156312	Tocantins	A state in the North Region of Brazil. Its capital is Palmas.			Geographic Area	
C15633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15633>	C16212	Cancer Pain Management|management of cancer pain	Therapy directed toward reduction and control of cancer pain.	Cancer Pain Management		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C156340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156340>	C41430|C3628	Thyroid Gland Schwannoma	A rare schwannoma that arises from the thyroid gland.			Neoplastic Process	
C156341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156341>	C6041|C202878	Thyroid Gland Malignant Peripheral Nerve Sheath Tumor	A rare malignant peripheral nerve sheath tumor that arises from the thyroid gland.			Neoplastic Process	
C156342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156342>	C7389|C3628	Benign Thyroid Gland Vascular Neoplasm	A rare benign vascular neoplasm that arises from the thyroid gland. This category includes hemangiomas, cavernous hemangiomas, and lymphangiomas.			Neoplastic Process	
C156343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156343>	C3085|C156342	Thyroid Gland Hemangioma	A rare hemangioma that arises from the thyroid gland.			Neoplastic Process	
C156344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156344>	C3086|C156343	Thyroid Gland Cavernous Hemangioma	A rare cavernous hemangioma that arises from the thyroid gland.			Neoplastic Process	
C156345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156345>	C202654|C156342	Thyroid Gland Lymphangioma	An extremely rare lymphangioma that arises from the thyroid gland.			Neoplastic Process	
C156346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156346>	C3628|C202711	Thyroid Gland Leiomyoma	A leiomyoma that arises from the thyroid gland.			Neoplastic Process	
C156347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156347>	C6041|C202853	Thyroid Gland Leiomyosarcoma	A leiomyosarcoma that arises from the thyroid gland.	Thyroid Gland Leiomyosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156348>	C4731	Chemotherapy-Induced Peripheral Neuropathy|CIPN|Chemotherapeutic Drug - Induced Peripheral Neuropathy	Any disorder affecting the peripheral nerves resulting from exposure to chemotherapeutic agents.	Chemotherapy-Induced Peripheral Neuropathy		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C156349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156349>	C7634|C3414	Thyroid Gland Solitary Fibrous Tumor	A rare solitary fibrous tumor that arises from the thyroid gland.			Neoplastic Process	
C15634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15634>	C61063	70-kD Heat-Shock Protein/MUC-1 Antigen|70-kD Heat-Shock Protein/Mucin/Peptide|HSP70/MUC-1|HSP70/MUC-1 Antigen|HSP70/Mucin/Peptide	A fusion protein of the MUC-1 colorectal cancer surface marker with HSP70 as a carrier.  In trials as a cancer vaccine.		Obsolete_Concept	Therapeutic or Preventive Procedure	
C156350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156350>	C3420|C186964	RARA Gene Translocation|NR1B1 Gene Translocation|RARA Translocation|RARalpha Gene Translocation|Retinoic Acid Receptor Alpha Gene Translocation	A cytogenetic abnormality that refers to any translocation involving the RARA gene.	RARA Gene Translocation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156351>	C20401	Chimeric Monoclonal Antibody 81C6|ch81c6	A chimeric, murine-human monoclonal antibody directed against the tumor-associated antigen (TAA) tenascin (hexabrachion) that may, when conjugated with a radioisotope, be useful in radiotherapy or radioimaging. Tenascin, an extracellular matrix glycoprotein is upregulated in certain pathological conditions such as infection, inflammation and tumor growth, and is highly expressed in the tumor microenvironment in some malignancies.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology
C156353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156353>	C63719|C63587|C63467|C63361|C166388|C159457|C159454|C159448|C159439	Cisplatin/Fluorouracil Regimen|CF|CF Regimen|Cisplatin and Fluorouracil (CF)|Cisplatin-Fluorouracil|Cisplatin-Fluorouracil Regimen|Cisplatin/Fluorouracil|FUP|FUP Regimen|Fluorouracil/Cisplatin|Fluorouracil/Cisplatin Regimen|PF|PF Regimen|Wayne State Protocol	A regimen consisting of cisplatin and fluorouracil that can be used in the treatment of head and neck, gastric, anal, esophageal and esophagogastric junction, hepatobiliary, occult primary, penile, vulvar, bladder and squamous cell skin cancer,and cancer of the nasopharynx.			Therapeutic or Preventive Procedure	GDC Regimen Terminology|GDC Terminology|HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156355>	C63360|C63358	Docetaxel/Vandetanib Regimen|Docetaxel and Vandetanib|Docetaxel-Vandetanib|Docetaxel/Caprelsa|Docetaxel/Vandetanib|Vandetanib/Docetaxel|Vandetanib/Docetaxel Regimen	A regimen consisting of docetaxel and vandetanib that may be useful in the treatment of a variety of cancers, such as breast and non-small cell lung cancers.			Therapeutic or Preventive Procedure	GDC Regimen Terminology|GDC Terminology|HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156356>	C217122	Emotion Regulation Index|ERI	A component of the Behavior Rating Inventory of Executive Function (BRIEF). The Emotion Regulation Index (ERI) represents the child's ability to regulate emotional responses and to shift set or adjust to changes in environment, people, plans, or demands. It is composed of the Shift and Emotional Control scales.			Intellectual Product	Behavior Rating Inventory of Executive Function
C156359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156359>	C217122	Cognitive Regulation Index|CRI	A component of the Behavior Rating Inventory of Executive Function (BRIEF). The Cognitive Regulation Index (CRI) reflects the child's ability to control and manage cognitive processes and to problem solve effectively. It is composed of the Initiate, Working Memory, Plan/Organize, Task-Monitor, and Organization of Materials scales and relates directly to the ability to actively problem solve in a variety of contexts and to complete tasks such as schoolwork.			Intellectual Product	Behavior Rating Inventory of Executive Function
C15635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15635>	C61063	gp100 Antigen/Incomplete Freund's Adjuvant/interleukin-2|gp100/IFA/IL-2			Obsolete_Concept	Therapeutic or Preventive Procedure	
C156360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156360>	C53543|C3501	Neuropathy, Hereditary Sensory and Autonomic, Type V|HSAN5|Hereditary Sensory and Autonomic Neuropathy Type V	An autosomal recessive condition caused by mutation(S) in the NGF gene, encoding beta-nerve growth factor. It is characterized by loss of pain sensation, particularly in the extremities.			Disease or Syndrome	Cellosaurus Disease Terminology
C156361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156361>	C197907	Torsion Dystonia 6|DYT6	An autosomal dominant condition caused by mutation(s) in the THAP1 gene, encoding THAP domain-containing protein 1. It is characterized by dystonic craniofacial movements, dysarthria, and dysphagia. Limb involvement is common.			Disease or Syndrome	Cellosaurus Disease Terminology
C156362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156362>	C134528	Feline Melanoma	A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes that occurs in a cat.			Neoplastic Process	Cellosaurus Disease Terminology
C156363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156363>	C213431|C213366	Tavokinogene Telseplasmid|IT-Tavo-EP|Plasmid IL-12 pUMVC3-hIL-12-NGVL3|TAVOKINOGENE TELSEPLASMID|Tavo	A DNA plasmid that encodes genes for both the p35 and p40 subunits of the heterodimeric human interleukin 12 (hIL-12) protein that are separated by an internal ribosome entry site (IRES) and under the control of a single cytomegalovirus (CMV) promoter, with potential immunomodulatory and antineoplastic activities. Upon administration via intratumoral injection and electroporation, the plasmid is introduced into human cells resulting in expression and highly-localized secretion of a functional IL-12 p70 protein into the tumor microenvironment (TME). IL-12 is a pro-inflammatory cytokine that plays a significant role in priming and maintaining T-helper (Th) cells, activating natural killer (NK) cells, and regulating the reactivation and survival of memory T-cells (Tm). Increased levels of IL-12 in the TME may augment host immune response against tumor cells by inhibiting regulatory T-cells (Tregs), T-helper 2 (Th2) responses, and myeloid-derived suppressor cells (MDSCs).	Tavokinogene Telseplasmid		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156364>	C63358	Eribulin/Trastuzumab Regimen|Eribulin and Trastuzumab|Eribulin and Trastuzumab-anns|Eribulin and Trastuzumab-dkst|Eribulin and Trastuzumab-dttb|Eribulin and Trastuzumab-herw|Eribulin and Trastuzumab-pkrb|Eribulin and Trastuzumab-qyyp|Eribulin and Trastuzumab-zerc|Eribulin-Trastuzumab|Eribulin-Trastuzumab Regimen|Eribulin/Trastuzumab|Halaven/Herceptin|Trastuzumab-Eribulin|Trastuzumab/Eribulin|Trastuzumab/Eribulin Regimen	A regimen consisting of eribulin and trastuzumab that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156365>	C63358	Cyclophosphamide/Trastuzumab Regimen|Cyclophosphamide-Trastuzumab|Cyclophosphamide-Trastuzumab Regimen|Cyclophosphamide/Herceptin|Cyclophosphamide/Trastuzumab|Trastuzumab-Cyclophosphamide|Trastuzumab/Cyclophosphamide|Trastuzumab/Cyclophosphamide Regimen	A regimen consisting of cyclophosphamide and trastuzumab that may be used in the treatment of HER-2 (EGFR2; ErbB2)-positive breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156366>	C63358	Cisplatin/Trastuzumab Regimen|Cisplatin-Trastuzumab|Cisplatin/Herceptin|Cisplatin/Trastuzumab|Trastuzumab-Cisplatin|Trastuzumab/Cisplatin|Trastuzumab/Cisplatin Regimen	A regimen consisting of cisplatin and trastuzumab that may be used in the treatment of recurrent and metastatic HER-2 (EGFR2; ErbB2)-positive breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156367>	C63358	Anastrozole/Palbociclib Regimen|Anastrozole and Palbociclib|Anastrozole-Palbociclib|Anastrozole-Palbociclib Regimen|Anastrozole/Palbociclib|Arimidex/Ibrance|Palbociclib-Anastrozole|Palbociclib/Anastrozole|Palbociclib/Anastrozole Regimen	A regimen consisting of anastrozole and palbociclib that is used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156368>	C63358	Exemestane/Palbociclib Regimen|Aromasin/Ibrance|Exemestane and Palbociclib|Exemestane-Palbociclib|Exemestane-Palbociclib Regimen|Exemestane/Palbociclib|Palbociclib-Exemestane|Palbociclib/Exemestane|Palbociclib/Exemestane Regimen	A regimen consisting of exemestane and palbociclib that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156369>	C63358	Fulvestrant/Palbociclib Regimen|Faslodex/Ibrance|Fulvestrant and Palbociclib|Fulvestrant-Palbociclib|Fulvestrant-Palbociclib Regimen|Fulvestrant/Palbociclib|Palbociclib-Fulvestrant|Palbociclib/Fulvestrant|Palbociclib/Fulvestrant Regimen	A regimen consisting of fulvestrant and palbociclib that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C15636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15636>	C61063	gp100 Antigen/Incomplete Freund's Adjuvant/Interleukin-12|gp100/IFA/IL-12			Obsolete_Concept	Therapeutic or Preventive Procedure	
C156370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156370>	C63358	Anastrozole/Ribociclib Regimen|Anastrozole and Ribociclib|Anastrozole-Ribociclib|Anastrozole-Ribociclib Regimen|Anastrozole/Ribociclib|Arimidex/Kisqali|Ribociclib-Anastrozole|Ribociclib/Anastrozole|Ribociclib/Anastrozole Regimen	A regimen consisting of anastrozole and ribociclib that may be used as a treatment for hormone receptor (HR)-positive advanced or metastatic breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156371>	C63358	Exemestane/Ribociclib Regimen|Aromasin/Kisqali|Exemestane-Ribociclib|Exemestane-Ribociclib Regimen|Exemestane/Ribociclib|Ribociclib-Exemestane|Ribociclib/Exemestane|Ribociclib/Exemestane Regimen	A regimen consisting of exemestane and ribociclib that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156372>	C63358	Trastuzumab/Nab-paclitaxel Regimen|Albumin-bound Paclitaxel/Trastuzumab|Nab-paclitaxel-Trastuzumab|Nab-paclitaxel/Trastuzumab|Trastuzumab-Albumin-bound Paclitaxel|Trastuzumab-Albumin-bound Paclitaxel Regimen|Trastuzumab-Nab-paclitaxel|Trastuzumab/Albumin-bound Paclitaxel|Trastuzumab/Albumin-bound Paclitaxel Regimen|Trastuzumab/Nab-paclitaxel|nab-Paclitaxel and Trastuzumab|nab-Paclitaxel and Trastuzumab-anns|nab-Paclitaxel and Trastuzumab-dkst|nab-Paclitaxel and Trastuzumab-dttb|nab-Paclitaxel and Trastuzumab-herw|nab-Paclitaxel and Trastuzumab-pkrb|nab-Paclitaxel and Trastuzumab-qyyp|nab-Paclitaxel and Trastuzumab-strf|nab-Paclitaxel and Trastuzumab-zerc	A regimen consisting of trastuzumab and nab-paclitaxel, an albumin-bound formulation of paclitaxel, that may be used for the treatment of HER-2 (EGFR2; ErbB2)-positive breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156373>	C63358	Carboplatin/Trastuzumab Regimen|Carboplatin-Trastuzumab|Carboplatin-Trastuzumab Regimen|Carboplatin/Trastuzumab|Trastuzumab-Carboplatin|Trastuzumab/Carboplatin|Trastuzumab/Carboplatin Regimen	A regimen consisting of carboplatin and trastuzumab that may be used for the treatment of HER-2 (EGFR2; ErbB2)-positive breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156374>	C63358	Tamoxifen/Trastuzumab Regimen|Tamoxifen and Trastuzumab|Tamoxifen and Trastuzumab-anns|Tamoxifen and Trastuzumab-dkst|Tamoxifen and Trastuzumab-dttb|Tamoxifen and Trastuzumab-herw|Tamoxifen and Trastuzumab-pkrb|Tamoxifen and Trastuzumab-qyyp|Tamoxifen and Trastuzumab-strf|Tamoxifen and Trastuzumab-zerc|Tamoxifen-Trastuzumab|Tamoxifen-Trastuzumab Regimen|Tamoxifen/Trastuzumab|Trastuzumab-Tamoxifen|Trastuzumab/Tamoxifen|Trastuzumab/Tamoxifen Regimen	A regimen consisting of tamoxifen and trastuzumab that may be used for the treatment of hormone receptor (HR)-positive/HER-2 (EGFR2; ErbB2)-positive breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156375>	C63358	Ribociclib/Tamoxifen Regimen|Ribociclib-Tamoxifen|Ribociclib/Tamoxifen|Tamoxifen-Ribociclib|Tamoxifen-Ribociclib Regimen|Tamoxifen/Kisqali|Tamoxifen/Ribociclib|Tamoxifen/Ribociclib Regimen	A regimen consisting of tamoxifen and ribociclib that may be used in the treatment of hormone receptor (HR)-positive advanced or metastatic breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156376>	C63358	Fulvestrant/Ribociclib Regimen|Faslodex/Kisqali|Fulvestrant and Ribociclib|Fulvestrant-Ribociclib|Fulvestrant-Ribociclib Regimen|Fulvestrant/Ribociclib|Ribociclib-Fulvestrant|Ribociclib/Fulvestrant|Ribociclib/Fulvestrant Regimen	A regimen consisting of fulvestrant and ribociclib that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156377>	C63358	Abemaciclib/Letrozole Regimen|Abemaciclib and Letrozole|Abemaciclib-Letrozole|Abemaciclib-Letrozole Regimen|Abemaciclib/Letrozole|Letrozole-Abemaciclib|Letrozole/Abemaciclib|Letrozole/Abemaciclib Regimen|Verzenio/Femara	A regimen consisting of abemaciclib and letrozole that can be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156378>	C63358	Abemaciclib/Exemestane Regimen|Abemaciclib-Exemestane|Abemaciclib-Exemestane Regimen|Abemaciclib/Exemestane|Aromasin/Verzenio|Exemestane-Abemaciclib|Exemestane/Abemaciclib|Exemestane/Abemaciclib Regimen	A regimen consisting of abemaciclib and exemestane that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156379>	C63358	Abemaciclib/Anastrozole Regimen|Abemaciclib and Anastrozole|Abemaciclib-Anastrozole|Abemaciclib/Anastrozole|Anastrozole-Abemaciclib|Anastrozole-Abemaciclib Regimen|Anastrozole/Abemaciclib|Anastrozole/Abemaciclib Regimen|Arimidex/Verzenio	A regimen consisting of abemaciclib and anastrozole that may be used as a treatment for hormone receptor (HR)-positive breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C15637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15637>	C61063	gp100 Antigen/interleukin-2/MART-1 Antigen|gp100/IL-2/MART-1			Obsolete_Concept	Therapeutic or Preventive Procedure	
C156380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156380>	C63358	Trastuzumab/Pertuzumab/Vinorelbine Regimen|Pertuzumab/Trastuzumab/Vinorelbine|Trastuzumab-Pertuzumab-Vinorelbine|Trastuzumab-Pertuzumab-Vinorelbine Regimen|Trastuzumab/Pertuzumab/Vinorelbine|VHP|VHP|VHP (trastuzumab-anns)|VHP (trastuzumab-dkst)|VHP (trastuzumab-dttb)|VHP (trastuzumab-herw)|VHP (trastuzumab-pkrb)|VHP (trastuzumab-qyyp)|VHP (trastuzumab-zerc)	A regimen consisting of trastuzumab, pertuzumab, and vinorelbine that may be used as a treatment for recurrent and metastatic HER-2 (EGFR2; ErbB2)-positive advanced or metastatic breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156381>	C63358	Ixabepilone/Trastuzumab Regimen|Ixabepilone-Trastuzumab Regimen|Ixabepilone/Trastuzumab|Ixempra/Herceptin|Tamoxifen and Trastuzumab|Trastuzumab-Ixabepilone|Trastuzumab/Ixabepilone|Trastuzumab/Ixabepilone Regimen	A regimen consisting of ixabepilone and trastuzumab that may be used for the treatment of HER-2 (EGFR2; ErbB2)-positive metastatic breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C156382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156382>	C28681|C138180|C129826	Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR|Autologous CD8+ and CD4+ T-cells transduced with TCR A2-MCC1|FH-MCVA2TCR|FH-MCVA2TCR Autologous CD8+ and CD4+ T-cells Transduced with TCR A2-MCC1	A preparation of autologous CD4+ and CD62L-expressing CD8+ T-cells transduced with a third generation lentiviral vector (LV) to express the high affinity T-cell receptor (TCR) A2 -MCC1, specific for the human leukocyte antigen (HLA)-A02-restricted Merkel cell polyomavirus (MCPyV; MCV) viral oncoprotein, with potential immunomodulating and antineoplastic activities. Upon reintroduction into the patient, the autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD8+ and CD4+ T-cells FH-MCVA2TCR selectively bind to the KLLEIAPNC epitope (KLL epitope) within the MCPyV viral oncoprotein. This results in cytotoxic T-lymphocyte (CTL)-mediated elimination of tumor cells expressing the MCPyV viral oncoprotein. Additionally, tumor-specific HLA-A02-restricted CD4+ cells promote class I-restricted CD8+ proliferation, survival and effector functions by producing interleukin (IL)-2 and facilitating the activation of dendritic cells (DCs). MCPyV viral oncoprotein is highly expressed in Merkel cell carcinoma (MCC) caused by MCPyV.	Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156383>	C36646|C185349	del11q22.3/ATM Locus|del11q22.3 (ATM)|del11q22.3/ATM|del11q22.3/Ataxia Telangiectasia Mutated Gene Locus	A cytogenetic abnormality that refers to the deletion of the chromosomal band 11q22.3, which also results in the deletion of the ATM gene.			Cell or Molecular Dysfunction	
C156384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156384>	C25180	Combination Product Report Indicator	An indication as to whether the Individual Case Safety Report (ICSR) contains at least one suspected medical product that is a combination product.			Functional Concept	FDA Individual Case Safety Report Terminology
C156385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156385>	C25375	Malfunction Only (No AE) Report	A report of a device malfunction that does not include an adverse event.			Intellectual Product	FDA Individual Case Safety Report Terminology|Type of Report ICSR Terminology
C156386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156386>	C146661|C138065	Lymphoblasts More Than 50 Percent of Bone Marrow Nucleated Cells|Lymphoblasts Greater than 50 Percent of Bone Marrow Nucleated Cells|Lymphoblasts Over 50 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that more than 50 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells of lymphoid origin.	Lymphoblasts More Than 50 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C156387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156387>	C33061	Alpha/Beta T-Lymphocyte|Alpha Beta T Cell|Alpha Beta T Lymphocyte|Alpha Beta T-Cell|Alpha Beta T-Lymphocyte|Alpha/Beta T Cell|Alpha/Beta T Lymphocyte|Alpha/Beta T-Cell	A mature T-cell that expresses a T-cell receptor complex comprised of the highly variable alpha and beta chains complexed with the invariant CD3 antigen complex and plays a primary role in adaptive immunity.	Alpha/Beta T-Lymphocyte		Cell	CTRP Biomarker Terminology|CTRP Terminology
C156388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156388>	C18520	Histone H3 Lysine 79|H3K79|Histone H3 Lys79|Histone H3 Lys80|Histone H3 Lysine 80|Lysine 79 of Histone H3	The lysine residue found at amino acid position 79 in the histone H3 protein. Methylation of this residue by DOT1L protein disrupts telomeric silencing and may be a marker for cellular transformation and disease progression in patients with leukemia.	Histone H3 Lysine 79		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156389>	C41024	Neoplastic Plasma Cells 5 Percent or Less of Bone Marrow Nucleated Cells|Neoplastic Plasma Cells Less than or Equal to 5 Percent of Bone Marrow Nucleated Cells|Neoplastic Plasma Cells Under or Equal to 5 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that 5 percent or less of the nucleated cells in a bone marrow sample are neoplastic plasma cells.	Neoplastic Plasma Cells 5 Percent or Less of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C15638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15638>	C15709	Genetic Testing for Cancer Risk|Cancer Risk Assessment with Genetic Testing and Counseling	Analyzing DNA to look for a genetic alteration that may indicate an increased risk for developing a cancer.			Diagnostic Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C156390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156390>	C36249|C141299	Lymphoblasts 5 Percent or More of Peripheral Blood White Cells|Lymphoblasts Greater than or Equal to 5 Percent of Peripheral Blood White Cells	A semi-quantitative microscopic finding indicating that 5 percent or more of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells of lymphoid origin.	Lymphoblasts 5 Percent or More of Peripheral Blood White Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C156391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156391>	C123611	PSA Level Equal to Nadir Plus 2 ng/mL|PSA Level Equal to Nadir Plus 2|PSA Level Equal to Nadir Plus Two ng/mL|PSA Nadir Plus 2|PSA Nadir Plus 2 ng/mL|PSA Nadir Plus Two ng/mL	A finding indicating that the blood concentration of prostate specific antigen in a subject's sample has increased by 2 ng/mL over the lowest value recorded for a sample from that subject.	PSA Level Equal to Nadir Plus 2 ng/mL		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156392>	C25790	HHLA2 Gene|HERV-H LTR-Associating 2 Gene|HHLA2|HHLA2	This gene plays a role in the modulation of T-cell activation.	HHLA2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C156393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156393>	C156392	HHLA2 wt Allele|B7 Homolog 7 Gene|B7-H5|B7-H7|B7H7|B7y|HERV-H LTR-Associating 2 wt Allele|HHLA-2|Human Endogenous Retrovirus-H Long Terminal Repeat-Associating 2 Gene	Human HHLA2 wild-type allele is located in the vicinity of 3q13.13 and is approximately 92 kb in length. This allele, which encodes HERV-H LTR-associating protein 2, is involved in costimulatory signaling through the T-cell receptor complex.	HHLA2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156394>	C16725	HERV-H LTR-Associating Protein 2|B7 Homolog 7|B7-H7|HHLA-2|HHLA2|Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2	HERV-H LTR-associating protein 2 (414 aa, ~47 kDa) is encoded by the human HHLA2 gene. This protein plays a role in the regulation of T-cell receptor-mediated T-cell activation.	HERV-H LTR-Associating Protein 2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156395>	C177177|C177176	Resiquimod Sulfate|BDB 001|BDB-001|BDB001|C151008135D|EIK 1001|EIK-1001|EIK1001|R848 Sulfate|RESIQUIMOD SULFATE|TLR Agonist BDB001|TLR7/8 Agonist EIK1001|Toll-like Receptor 7/8 Agonist EIK1001|Toll-like Receptor Agonist BDB001	The sulfate salt form of resiquimod, a toll-like receptor type 7 and 8 (TLR7/8) agonist, with potential immunostimulating and antineoplastic activities. Upon administration, resiquimod targets, binds to and activates TLR7 and 8, thereby activating TLR7/8-mediated pathways. This stimulates the maturation and activation of antigen-presenting cells (APCs), including dendritic cells (DCs). Activation of DCs results in the production of pro-inflammatory cytokines, and the activation of cytotoxic T-lymphocyte (CTL)- and B-lymphocyte-mediated immune responses. This may lead to tumor cell lysis. TLR7 and 8, members of the TLR family, play fundamental roles in the activation of the innate immune system, myeloid cell responses and tumor antigen presentation.	Resiquimod Sulfate		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C156396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156396>	C357	Ceftolozane-Tazobactam|CXA 201|CXA-201|CXA201|Ceftolozane/Tazobactam|Zerbaxa	A combination preparation containing ceftolozane, a semi-synthetic, broad-spectrum, fifth-generation cephalosporin and tazobactam, a beta-lactamase inhibitor, with activity against Gram-negative and Gram-positive bacteria. Upon intravenous administration, ceftolozane binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. This interferes with the final transpeptidation step required to form peptidoglycan chain cross-links, which are a key component of and provide strength and rigidity to the bacterial cell wall. This inhibits bacterial cell wall synthesis and reduces cell wall stability, which weakens the bacterial cell wall and causes bacterial cell lysis. Tazobactam irreversibly inhibits certain penicillinases and cephalosporinases and covalently binds to some chromosomal and plasmid-mediated bacterial beta-lactamases, thereby protecting ceftolozane from degradation and improving ceftolozane's activity.			Antibiotic|Pharmacologic Substance	NCI Drug Dictionary Terminology
C156397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156397>	C1505	Ginseng/Lingzhi Mushroom/Cordyceps sinensis/Rose Oral Liquid|Ginseng/Lingzhi Mushroom/Cordyceps sinensis/Rose Supplement|Shen-Ling-Cao|Shenlingcao Oral Liquid	An orally available supplement containing ginseng, lingzhi mushroom, Cordyceps sinensis, and rose with potential immunostimulating activities. Upon oral administration, ginseng/lingzhi mushroom/Cordyceps sinensis/rose oral liquid may, through a not yet elucidated mechanism, enhance immune responses and relieve fatigue.			Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156398>	C20401|C129822	Monoclonal Antibody NEO-201|NEO 201|NEO-201|NEO-201|NEO201|Neoantigen-targeting Antibody NEO-201|h16C3|h16C3 Antibody	A humanized immunoglobulin G1 (IgG1) monoclonal antibody derived from an immunogenic preparation of tumor-associated antigens (TAAs) from pooled allogeneic colon cancer tissue extracts, with potential antineoplastic and immunomodulatory activities. Upon intravenous administration, monoclonal antibody NEO-201 targets and binds to malignant tissues with tumor-specific mutations in the membrane-anchored proteins, carcinoembryonic antigen-related cell adhesion molecules 5 and 6 (CEACAM5 and CEACAM6). This prevents the interaction between tumor cell CEACAM 5 and natural killer (NK) cell CEACAM1, and reverses CEACAM1-dependent inhibition of NK cytotoxicity. This may result in the activation of NKs and results in NK-mediated tumor cell killing. Additionally, monoclonal antibody NEO-201 may activate innate immune responses against tumor cells such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). CEACAM 5, and 6 are members of the CEA family of proteins. These membrane proteins are over expressed in a variety of cancer cell types and play a key role in cell migration, invasion, and adhesion.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156399>	C213866|C201282	Emirodatamab|AMG 427|AMG-427|AMG427|Anti-FLT3 x Anti-CD3 BiTE AMG 427|Anti-FLT3/CD3 BiTE Antibody AMG 427|BiTE Antibody AMG 427|Bispecific T-cell Engager Antibody AMG 427|EMIRODATAMAB|FLT3/CD3-directed Bispecific T-cell Engager Antibody AMG 427	A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) FLT3 tyrosine kinase receptor (Fms-like tyrosine kinase 3; FLT3; FLT-3; CD135; fetal liver kinase-2; FLK2), fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, emirodatamab binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and FLT3 found on FLT3-expressing tumor cells. This activates and redirects CTLs to FLT3-expressing tumor cells, which results in the CTL-mediated cell death of FLT3-expressing tumor cells. FLT3, a cytokine receptor belonging to the class III tyrosine kinase receptors, is overexpressed or mutated in most B-lineage and acute myeloid leukemias (AMLs).	Emirodatamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15639>	C15791	Level of Evidence|levels of evidence	A formal ranking system of the strength of evidence linked to a reported result.			Classification	
C1563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1563>	C333	Dexverapamil|DEXVERAPAMIL|R Verapamil|R-Verapamil	The R-enantiomer of the calcium channel blocker verapamil. Dexverapamil competitively inhibits the multidrug resistance efflux pump P-glycoprotein (MDR-1), thereby potentially increasing the effectiveness of a wide range of antineoplastic drugs which are inactivated by MDR-1 mechanisms.  This agent exhibits decreased calcium antagonistic activity and toxicity compared to racemic verapamil. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C156400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156400>	C201534|C129822	Anetumab|ANETUMAB	A monoclonal antibody directed against the tumor-associated antigen (TAA) mesothelin.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C156401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156401>	C155321|C129822	Daratumumab and Recombinant Human Hyaluronidase|DARA Co-formulated with rHuPH20|DARA/rHuPH20|Daratumumab + rHuPH20|Daratumumab and Hyaluronidase|Daratumumab and Hyaluronidase-fihj|Daratumumab and Hyaluronidase-fihj|Daratumumab and Vorhyaluronidase Alfa|Daratumumab and hyaluronidase|Daratumumab and vorhyaluronidase|Daratumumab with rHuPH20|Daratumumab-rHuPH20|Daratumumab/Hyaluronidase-fihj|Daratumumab/rHuPH20 Co-formulation|Darzalex Faspro|Darzalex/rHuPH20|Darzquro|HuMax-CD38-rHuPH20|Recombinant Human Hyaluronidase Mixed with Daratumumab	A co-formulation composed of daratumumab, a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against the cell surface glycoprotein cluster of differentiation 38 (CD-38; CD38), and a recombinant form of human hyaluronidase (rHuPH20), with potential antineoplastic activity. Upon subcutaneous administration of daratumumab and hyaluronidase-fihj, daratumumab targets and binds to CD38 on certain CD38-expressing tumors, such as multiple myeloma (MM) and plasma cell leukemia. This binding induces direct apoptosis through Fc-mediated cross-linking and triggers immune-mediated tumor cell lysis through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP) immune responses. CD38, a transmembrane glycoprotein, is expressed in both hematopoietic and non-hematopoietic lineage cells. Hyaluronidase-fihj hydrolyzes and degrades the glycosaminoglycan hyaluronic acid (HA), thereby decreasing interstitial viscosity and enhancing penetration of daratumumab through the interstitial space. This facilitates the delivery of daratumumab to CD38-expressing tumor cells.	Daratumumab and Hyaluronidase-fihj		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156402>	C20401|C129822	Anti-NRP1 Antibody ASP1948|ASP 1948|ASP-1948|ASP-1948|ASP1948|Anti-neuropilin-1 Antibody ASP1948|PTZ 329|PTZ-329|PTZ329	A human immunoglobulin G4 (IgG4) monoclonal antibody directed against neuropilin-1 (NRP1; CD304; BDCA-4), with potential immunomodulatory and antineoplastic activities. Upon administration, anti-NRP1 antibody ASP1948 specifically targets and binds to NRP1. This prevents the binding of NRP1 to its ligand and may block the immune inhibitory actions of regulatory T-cells (Tregs) mediated by the interaction of NRP1 with its ligand. This may enhance the immune response against tumor cells. NRP1 is a transmembrane co-receptor protein expressed in Tregs; it plays an important role in maintaining the stability and function of Tregs.	Anti-NRP1 Antibody ASP1948		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156403>	C53268	Radiation Therapy Recipient	An individual receiving radiation therapy.	Radiation Therapy Recipient		Human	CTRP Intervention Terminology|CTRP Terminology
C156404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156404>	C15184	STEPS to Enhance Physical Activity|STEPS|STEPS Intervention|STEPS to Enhance Physical Activity (STEPS)	A free-living physical activity intervention that uses pedometers, or other physical activity tracking, to reduce sitting time and other sedentary behaviors to improve fatigue, functional ability, muscle strength, physical activity, and quality of life, and promote positive health outcomes.	STEPS to Enhance Physical Activity		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C156405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156405>	C98275	Airway Tumor Mass	A tumor mass that is located in the airways.	Airway Tumor Mass		Finding	CTRP Disease Terminology|CTRP Terminology
C156406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156406>	C3414|C173485	Thyroid Gland Histiocytic and Dendritic Cell Neoplasm	A rare histiocytic and dendritic cell neoplasm that affects the thyroid gland.			Neoplastic Process	
C156407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156407>	C173486|C156406	Thyroid Gland Langerhans Cell Histiocytosis	Langerhans cell histiocytosis involving the thyroid gland focally or diffusely. It is exceedingly rare and usually occurs in patients with multifocal disease.			Neoplastic Process	
C156408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156408>	C7510|C173580|C156406	Thyroid Gland Follicular Dendritic Cell Sarcoma	A rare follicular dendritic cell sarcoma involving the thyroid gland. It may be associated with chronic lymphocytic thyroiditis.			Neoplastic Process	
C156409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156409>	C202971|C156406	Thyroid Gland Rosai-Dorfman-Destombes Disease|Thyroid Gland Rosai-Dorfman Disease|Thyroid Gland Sinus Histiocytosis with Massive Lymphadenopathy	Rosai-Dorfman-Destombes disease affecting the thyroid gland. It is rare and is usually accompanied by involvement of cervical lymph nodes.			Neoplastic Process	
C15640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15640>	C15431	Umbilical Cord Blood Transplantation|Cord Blood|Cord Blood Transplantation|Cord Blood Transplantation|UCB transplantation|UMBILICAL CORD BLOOD TRANSPLANT|umbilical cord blood transplantation	A therapeutic procedure that involves the transplantation of hematopoietic stem cells collected from the umbilical cord.	Umbilical Cord Blood Transplantation		Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|HL Authorized Value Terminology|HL Stem Cell Transplant Table|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C156410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156410>	C6044|C202926	Thyroid Gland Follicular Lymphoma	A rare follicular lymphoma primarily involving the thyroid gland.			Neoplastic Process	
C156411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156411>	C67107	Grade 1 Teratoma	A teratoma that contains mature tissue elements and a limited amount of immature tissue elements.			Neoplastic Process	
C156414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156414>	C1590	Odafosfamide, (R)-|(R)-OBI-3424|AKR1C3-activated Prodrug AST-3424|AKR1C3-activated Prodrug OBI-3424|AKR1C3-activated Prodrug TH-3424|AST-3424, (R)-|Aldo-keto Reductase 1c3-activated Prodrug OBI-3424|OBI 3424|OBI-3424|OBI3424|ODAFOSFAMIDE, (R)-|Odafosfamide|TH 3424|TH-3424|TH3424	The R-isoform of odafosfamide, a small-molecule nitro-benzene, aldo-keto reductase 1C3 (AKR1C3)-activated prodrug of N,N'-bisethylenephosphoramidate, a DNA bis-alkylating agent, with potential antineoplastic activity. Upon intravenous administration, odafosfamide is converted to its active form by AKR1C3, which is upregulated in certain tumor cell types while not expressed in normal healthy cells. The active metabolite selectively binds to and alkylates DNA in AKR1C3-overexpressing tumor cells, resulting in DNA base pair mismatching, interstrand crosslinking and inhibition of DNA repair and synthesis, cell-cycle arrest, and apoptosis. As the expression of AKR1C3 is restricted to tumors, Odafosfamide is selectively converted to its active metabolite in tumor cells only while its conversion in normal, healthy tissue is absent; this allows for an increased cytotoxic effect of the alkylating agent in tumor cells while decreasing its toxicity.	Odafosfamide		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156416>	C129823	Anti-CD46 Antibody-drug Conjugate FOR46|ADC FOR46|Anti-CD46 ADC FOR46|Antibody-drug Conjugate FOR46|CD46-ADC FOR46|FG 3246|FG-3246|FG3246|FOR 46|FOR-46|FOR46	An antibody-drug conjugate (ADC) composed of a human monoclonal antibody directed against the cluster of differentiation 46 (CD46; membrane cofactor protein; MCP) and conjugated to an as of yet undisclosed cytotoxic payload, with potential antineoplastic activity. Upon administration, anti-CD46 ADC FOR46 specifically targets and binds to a specific conformational epitope on the immune modulatory receptor CD46 expressed on certain tumor cells. Upon binding and internalization, the cytotoxic payload kills the CD46-expressing tumor cells. The conformational epitope of CD46 is highly expressed in multiple tumor cell types while minimally expressed or absent in normal, healthy tissues.  FOR46 does not interfere with other CD46-mediated pathways that naturally occur in normal, healthy tissues.	Anti-CD46 Antibody-drug Conjugate FOR46		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156417>	C181040	Days Between Diagnosis and Treatment|Days to Treatment	The number of days from the date of initial pathologic diagnosis to when treatment began.			Quantitative Concept	
C156418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156418>	C181061	Days Between Birth and Diagnosis|Days from Birth|Days to birth	The time interval from a person's date of birth to the date of initial pathologic diagnosis, represented as a calculated number of days.			Quantitative Concept	
C156419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156419>	C181060	Days between Diagnosis and Death|Days to death|Time from diagnosis to decease (if known)	The time interval from a person's date of death to the date of initial pathologic diagnosis, represented as a calculated number of days.			Quantitative Concept	Canine Glioma Project Property Terminology|ICDC Terminology
C15641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15641>	C15406	Screening for Neuroblastoma|early detection of neuroblastoma|neuroblastoma early detection|neuroblastoma screening	The use of any device, marker, or other means for the purpose of detecting the presence of neuroblastoma, usually before there are symptoms.			Diagnostic Procedure	
C156420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156420>	C213228	Age at Diagnosis|AGE_AT_TUMOR_ASSESSMENT|Age at diagnosis|Age at diagnosis	The age of an individual at the time of initial pathologic diagnosis.			Organism Attribute	CRF1 Registration Table|NAACCR Terminology|OS Tumor Assessment Table|OS Variable Terminology
C156421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156421>	C171435	Site of Resection or Biopsy|Site of resection or biopsy|site of resection or biopsy|site_of_resection_or_biopsy	The anatomic site from which a biopsy sample, or other tissue, was removed.			Body Location or Region	GDC Property Terminology|GDC Terminology
C156422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156422>	C13717	Tissue or Organ of Origin|Tissue or Organ Origin|Tissue or organ of origin|tissue or organ of origin|tissue_or_organ_of_origin	The anatomic site of a tumor or pathological process.			Body Location or Region	GDC Property Terminology|GDC Terminology
C156423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156423>	C99800	Smoking Onset Year|Tobacco smoking onset year|tobacco smoking onset year|tobacco_smoking_onset_year	The year in which an individual began smoking.			Temporal Concept	GDC Property Terminology|GDC Terminology
C156424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156424>	C53543	Hereditary Folate Malabsorption	An autosomal recessive condition caused by mutation(s) in the SCL46A1 gene, encoding proton-coupled folate transporter. It is characterized by low concentrations of folate resulting in megaloblastic anemia, immune deficiency, and neurologic deficits.			Disease or Syndrome	Cellosaurus Disease Terminology
C156425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156425>	C159612	Smoking Cessation Year|Smoking Quit Year|Tobacco smoking quit year|tobacco smoking quit year|tobacco_smoking_quit_year	The year in which an individual quit smoking.			Temporal Concept	GDC Property Terminology|GDC Terminology
C156426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156426>	C159612	Year of Death|Death Year|Year of death|year of death|year_of_death	The year in which an individual died.			Temporal Concept	GDC Property Terminology|GDC Terminology
C156427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156427>	C28554	Cancer-Related Death|Cancer Death|Cancer Related|Cancer Related Death	A death attributed to the progression of a cancer-related pathologic condition.			Finding	GDC Terminology|GDC Value Terminology
C156428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156428>	C28554	Non-Cancer Related Death|Non-Cancer Death|Non-Cancer Related|Not Cancer Related|Not Cancer Related	A death attributed to any cause other than the progression of a cancer-related pathologic condition.			Finding	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C156429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156429>	C126378	Social Drinker	An individual who generally only drinks at social events.			Qualitative Concept	GDC Terminology|GDC Value Terminology
C15642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15642>	C64381	Epidural Block|Epidural Analgesia|epidural block	An anesthetic procedure that involves administering pharmaceutical agents into the epidural space of the spinal canal. Frequently administered agents include local anesthetics and analgesics.	Epidural Block		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|Newborn Screening Terminology|NICHD Terminology
C156430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156430>	C53543	Immunodeficiency-Centromeric Instability-Facial Anomalies Syndrome 1	An autosomal recessive condition caused by mutation(s) in the DNMT3B gene, encoding DNA (cytosine-5)-methyltransferase 3B. It is characterized by immunoglobulin deficiency, centromeric instability of chromosomes 1,9, and 19 (rarely chromosome 2), and facial dysmorphism.			Disease or Syndrome	Cellosaurus Disease Terminology
C156431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156431>	C13039	Anterior Endometrium|Anterior endometrium	The part of the endometrium that is located in the anterior uterine wall.			Body Part, Organ, or Organ Component	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C156432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156432>	C13039	Posterior Endometrium|Posterior endometrium	The part of the endometrium that is located in the posterior uterine wall.			Body Part, Organ, or Organ Component	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C156433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156433>	C4924	Trichothiodystrophy 1, Photosensitive	An autosomal recessive subtype of trichothiodystrophy caused by mutation(s) in the ERCC2 gene, encoding general transcription and DNA repair factor IIH helicase subunit XPD.			Disease or Syndrome	Cellosaurus Disease Terminology
C156434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156434>	C70713	Analyte Type|analyte type|analyte_type	The type of biospecimen subjected to analysis.			Qualitative Concept	GDC Property Terminology|GDC Terminology
C156435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156435>	C84514|C198567	Formalin-Fixed Paraffin-Embedded DNA|FFPE DNA|FFPE DNA|FFPE DNA	A DNA sample derived from a formalin-fixed paraffin-embedded tissue sample.			Nucleic Acid, Nucleoside, or Nucleotide	GDC Terminology|GDC Value Terminology
C156436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156436>	C84514|C198568	Formalin-Fixed Paraffin-Embedded RNA|FFPE RNA|FFPE RNA|FFPE RNA	An RNA sample derived from a formalin-fixed paraffin-embedded tissue sample.			Nucleic Acid, Nucleoside, or Nucleotide	GDC Terminology|GDC Value Terminology
C156437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156437>	C198567|C165587	REPLI-g Pooled DNA|Repli-G Pooled (Qiagen) DNA|Repli-G Pooled (Qiagen) DNA|Repli-G Pooled (Qiagen) DNA	A genomic DNA sample produced from a pool of samples from several subjects that is amplified using REPLI-g technology.			Nucleic Acid, Nucleoside, or Nucleotide	GDC Terminology|GDC Value Terminology
C156438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156438>	C20401|C129822	Sibrotuzumab|HuMoAb F19|Humanized F19 Monoclonal Antibody|SIBROTUZUMAB	A humanized monoclonal antibody (MoAb) against human fibroblast activation protein (FAP). FAP is a 95 kDa cell surface glycoprotein and an inducible tumor stromal antigen of epithelial cancers and of a subset of soft tissue sarcomas. FAP shows a very limited distribution pattern in normal tissues, thereby sibrotuzumab has possible diagnostic and therapeutic applications in epithelial cancers.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C156439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156439>	C198567	REPLI-g X DNA|Repli-G X (Qiagen) DNA|Repli-G X (Qiagen) DNA|Repli-G X (Qiagen) DNA	A genomic DNA sample that has been produced by two rounds of REPLI-g amplification.			Nucleic Acid, Nucleoside, or Nucleotide	GDC Terminology|GDC Value Terminology
C15643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15643>	C48935|C15454	Neck Dissection|neck dissection	Surgery to remove lymph nodes and other tissues in the neck.	Neck Dissection		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C156440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156440>	C18009	Metastatic Tumor Sample|Additional Metastatic|Metastatic|Metastatic Sample	A biospecimen derived from a metastatic tumor.			Tissue	GDC Deprecated Terminology|GDC Terminology|ICDC Terminology|ICDC Value Terminology
C156441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156441>	C18009	Sample Derived from New Primary|New Primary Tumor Sample|Sample Derived from New Primary Tumor	A biospecimen derived from a new primary tumor.			Tissue	GDC Deprecated Terminology|GDC Terminology
C156442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156442>	C64355	Control Analyte|Input Control	A biospecimen that is used as a comparator for an experimental sample.			Conceptual Entity	GDC Terminology|GDC Value Terminology
C156443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156443>	C70699	Cell Line-Derived Xenograft|CDX|Cell Line Derived Xenograft Tissue	A biospecimen derived from the culturing of a derived cell line in a non-human organism.			Body Substance	GDC Deprecated Terminology|GDC Terminology
C156444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156444>	C70699	Post Neoadjuvant Therapy Sample|Post Neo-adjuvant Therapy Sample	A biospecimen derived from a subject after treatment with a neoadjuvant therapeutic.			Body Substance	GDC Deprecated Terminology|GDC Terminology
C156445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156445>	C16403	Derived Cell Line	A biospecimen generated by in vitro culturing of a single cell isolated from a tissue of interest.			Cell	GDC Terminology|GDC Value Terminology
C156446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156446>	C84691	Epidermolysis Bullosa Dystrophica, Autosomal Recessive|Autosomal Recessive Generalized Dystrophic Epidermolysis Bullosa|RDEB|Recessive Dystrophic Epidermolysis Bullosa	An autosomal recessive allelic variant of epidermolysis bullosa dystrophica caused by mutation(s) in the COL7A1 gene, encoding collagen alpha-1(VII) chain.			Disease or Syndrome	Cellosaurus Disease Terminology
C156447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156447>	C180729	T2 (Observed)-Weighted Imaging|T2*-Weighted Imaging|T2*MRI|T2*WI	MRI imaging based on the observed T2 relaxation time of tissues.			Diagnostic Procedure	
C156448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156448>	C74679	Milligram Iron per Gram Liver (Dry Weight)|mg Fe/g (dry weight)|mg Fe/g liver (dry weight)|mg iron per g liver (dry weight)|mg iron per gram liver (dry weight)	A measurement of iron in the liver expressed as a ratio of milligrams of iron to grams of dry weight of the liver sample.			Laboratory Procedure	
C156449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156449>	C217122	Loes Score	A rating of the severity of abnormalities in the brain found on MRI. It ranges from 0 to 34, based on a point system derived from the location and extent of disease and the presence of atrophy in the brain, either localized to specific points or globally throughout the brain.			Intellectual Product	
C15644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15644>	C64989|C215116	Bone Marrow Aspiration|bone marrow aspiration	Aspiration of immature hematopoietic elements and blood from the bone marrow.  It is done for the evaluation of hematopoietic disorders and for the evaluation of infectious diseases and cytogenetic studies.	Bone Marrow Aspiration		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C156450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156450>	C48298	International System for Human Cytogenetic Nomenclature|ISCN	An international standard for human chromosome nomenclature, which includes band names, symbols and abbreviated terms used in the description of human chromosome and chromosome abnormalities.			Intellectual Product	
C156451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156451>	C18095|C17712	Tolerance Induction in Solid Organ Transplantation|Tolerance induction associated with solid organ transplant|Transplantation Tolerance Induction	An immunological environment, mediated by T-regulatory cells, favoring regulation, supporting graft survival, without interfering with crucial immune surveillance mechanisms and, concurrently, abolishing immunosuppressant-related toxicity.			Organ or Tissue Function	
C156452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156452>	C333	Dexverapamil Hydrochloride|DEXVERAPAMIL HYDROCHLORIDE|R Verapamil Hydrochloride|R-Verapamil Hydrochloride|Verapamil (R)-form Hydrochloride|Verapamil Hydrochloride, (+)-	The R-enantiomer of the calcium channel blocker verapamil. Dexverapamil competitively inhibits the multidrug resistance efflux pump P-glycoprotein (MDR-1), thereby potentially increasing the effectiveness of a wide range of antineoplastic drugs which are inactivated by MDR-1 mechanisms.  This agent exhibits decreased calcium antagonistic activity and toxicity compared to racemic verapamil. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C156453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156453>	C40023|C170767	Recurrent Primary Peritoneal Serous Adenocarcinoma	The reemergence of primary peritoneal serous adenocarcinoma after a period of remission.	Recurrent Primary Peritoneal Serous Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156454>	C156453|C126354	Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma	The reemergence of primary peritoneal low grade serous adenocarcinoma after a period of remission.	Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156455>	C153615|C105556	Recurrent Ovarian Low Grade Serous Adenocarcinoma|Recurrent Low Grade Ovarian Serous Adenocarcinoma|Recurrent Low Grade Ovarian Serous Adenocarcinoma|Recurrent Ovarian Low-Grade Serous Adenocarcinoma	The reemergence of ovarian low-grade serous adenocarcinoma after a period of remission.	Recurrent Low Grade Ovarian Serous Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156456>	C126457	Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma	The reemergence of low grade fallopian tube serous adenocarcinoma after a period of remission.	Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156457>	C3915|C191977	Extrapulmonary Small Cell Neuroendocrine Carcinoma|ESCC|Extrapulmonary SCC|Extrapulmonary Small Cell Carcinoma|Extrapulmonary Small Cell Carcinoma|Small cell car. (extrapulmonary)|Small cell carcinoma (extrapulmonary)	A small cell neuroendocrine carcinoma that arises from an anatomic site other than the lung.	Extrapulmonary Small Cell Carcinoma|Extrapulmonary Small Cell Neuroendocrine Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|NCI CTEP SDC Neuroendocrine Cancer Sub-Category Terminology|NCI CTEP Simplified Disease Classification Terminology
C156458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156458>	C20401|C129822	Anti-CD32B Monoclonal Antibody BI-1206|Anti-hFcgRIIB Monoclonal Antibody BI-1206|Anti-hFcgammaRIIB mAb BI-1206|BI 1206|BI-1206|BI-1206|BI1206	A fully human monoclonal antibody targeting the Fc gamma receptor IIB (FcgRIIB; CD32B) with potential immunomodulatory and antineoplastic activities. Upon intravenous administration, anti-CD32B monoclonal antibody BI-1206 selectively binds to CD32B, a receptor expressed on the surface of B-cells. This prevents CD32B-mediated internalization of anti-CD20 monoclonal antibodies, such as rituximab, which abrogates tumor cell resistance caused by CD32B-mediated monoclonal antibody internalization and degradation of CD32B-expressing B-cells. By blocking CD32B, BI-1206 may recover and enhance the activity of rituximab and other anti CD20 monoclonal antibodies. In addition, BI-1206 itself activates the immune system to exert an immune-mediated tumor cell death of B-cells. CD32B, an inhibitory member of the FcgammaR family, is implicated in immune cell desensitization and tumor cell resistance.	Anti-CD32B Monoclonal Antibody BI-1206		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15645>	C49236	Other Therapy	A type of therapy not listed.			Therapeutic or Preventive Procedure	
C156460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156460>	C36115	Malignant Primitive Cellular Infiltrate	A morphologic finding indicating the presence of a malignant primitive cellular infiltrate in a tissue sample.			Finding	
C156461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156461>	C177298	Pharmacological Ascorbate|Ascorbate Injection|Ascorbic Acid Injection|HD Ascorbate|HD P-AscH-|HD Vitamin C|High Dose Ascorbic Acid|High-Dose Parenteral Ascorbate|High-Dose Vitamin C|High-dose Ascorbate|High-dose Ascorbic Acid|IV Ascorbate|Intravenous Ascorbate|Intravenous High Dose Ascorbate	A high dose (HD) of ascorbic acid, a pro-oxidant agent, with potential antineoplastic and radio-chemo-sensitizing activities. Upon intravenous (IV) administration, pharmacological ascorbate is able to generate reactive oxygen species (ROS) by donating an electron to oxygen (O2) and forming hydrogen peroxide (H2O2), thereby causing oxidative stress and overwhelming the cell's anti-oxidant defense mechanisms. This induces DNA double-stranded breaks (DSBs) and cell death. Tumor cells are highly susceptible to ascorbate-mediated oxidative stress and cytotoxicity while normal, healthy cells are mostly unaffected. This induces the cell death of susceptible tumor cells and decreases tumor cell growth. Higher plasma ascorbate concentrations are achieved upon higher intravenous doses of ascorbate; oral administration of ascorbate is limited and uptake does not increase after a certain amount is administered. Only IV ascorbate produces plasma concentrations high enough to induce ascorbate-mediated cytotoxicity to susceptible tumor cells. In addition, HD parenteral ascorbate enhances radio- and chemo-sensitivity of susceptible cancer cells.	Pharmacological Ascorbate		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156462>	C3017|C201977	Brain Ependymoma|Intracranial Ependymoma	An ependymoma that arises from the brain.	Brain Ependymoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156463>	C40998|C177694|C156752	Loss of Immunohistochemical Expression of Succinate Dehydrogenase (SDH) B|Loss of Immunohistochemical Expression of SDHB	An immunohistochemical test result indicating the loss of expression of succinate dehydrogenase (SDH) B in the neoplastic cells of a tumor sample.			Laboratory or Test Result	
C156464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156464>	C9385|C189241	Succinate Dehydrogenase-Deficient Renal Cell Carcinoma|SDH Deficient Renal Cell Carcinoma|SDH-Deficient Renal Cell Carcinoma|SDH-RCC|Succinate Dehydrogenase Renal Cell Carcinoma	A very rare renal cell carcinoma that usually affects young adults. It is characterized by mutations in one of the four subunits of the SDH complex (SDHA, SDHB, SDHC, or SDHD gene). Most frequently, the mutations occur in the SDHB subunit. It has a relatively good prognosis.	Succinate Dehydrogenase-Deficient Renal Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C156465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156465>	C49236	Low Intensity Vibration Therapy|LIV|Low Intensity Vibration	The use of a low magnitude (<1 g), high frequency (30 Hz) signal to mitigate deleterious effects of estrogen deprivation on both bone health and muscle function. A low intensity vibration can be delivered synchronously to the lower extremities by a platform, transmitting the signal throughout the skeleton, recapitulating some of the mechanical stimulation experienced during exercise.	Low Intensity Vibration Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C156466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156466>	C78225	Endobronchial Obstruction	Partial or complete blockage of the bronchial lumen by a pathological process that occurs within the bronchus.	Endobronchial Obstruction		Finding	CTRP Disease Terminology|CTRP Terminology
C156467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156467>	C67365	Enzyme Unit per Meter Squared|Enzyme U/m2|Enzyme U/m2|Enzyme Unit per Square Meter|{Enzyme}.U/m2|{Enzyme}.U/m2	A unit of concentration (catalytic activity) equal to one enzyme unit of substance per one square meter of surface area.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156468>	C67375	Milligram Equivalent|mg.eq|mg.eq|mgEq|mgEq	A unit of relative amount of substance concentration equal to one thousandth of a gram of an equivalent weight.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156469>	C64430	STAT3 Measurement|STAT3|STAT3|STAT3|Signal Transducer and Activator of Transcription 3	The determination of the amount of STAT3 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15646>	C15824	Nutrition Research, Calories	The study of the role of caloric intake in cancer causation or prevention and in general health.			Research Activity	
C156470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156470>	C64430	Pyruvate Kinase Measurement|PK|PK Measurement|PYK|Phosphoenol Transphosphorylase Measurement|Phosphoenolpyruvate Kinase Measurement|Pyruvate Kinase|Pyruvate Kinase	The determination of the amount of pyruvate kinase present in a sample.	Pyruvate Kinase Measurement		Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156471>	C64774	Area Under the Curve Ratio|AUC Ratio|RAAUC|Ratio AUC|Ratio AUC	The determination of the ratio of one AUC value compared to another AUC value. The measurement may be expressed as a ratio or percentage.			Qualitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156472>	C20181	Name and Version	An identifier that includes the words or language units by which a thing is known and the form or variant of the original.			Classification	
C156473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156473>	C142605	Auxiliary Medicinal Product|AxIMP|NIMP|NIMP|auxiliary medicinal product	A medicinal product that is used in a clinical trial for purposes other than as an investigational agent			Chemical Viewed Functionally	CDISC DDF Product Designation Value Set Terminology|CDISC DDF Terminology|CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|ICH M11 Investigational Medicinal Product Indicator Value Set Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C156474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156474>	C9087|C225411|C139001	Refractory Kaposi Sarcoma	A Kaposi sarcoma that is resistant to treatment.	Refractory Kaposi Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156475>	C9087|C153069	Metastatic Kaposi Sarcoma	Kaposi sarcoma that has spread from its original site of growth to another anatomic site.			Neoplastic Process	
C156476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156476>	C162194|C156475	Advanced Kaposi Sarcoma	Kaposi sarcoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Kaposi Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156477>	C42934	Intrauterine Gel Dosage Form|Intrauterine gel	Semi-solid preparation consisting of a gel intended for intrauterine use.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C156479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156479>	C200766|C176018	Autologous iC9-deltaNGFR-CD19CAR-CD3zeta-4-1BB-expressing T-lymphocytes|Autologous iC9-deltaNGFR-CD19CAR-CD3zeta-4-1BB-expressing T-cells|iCasp9-deltaNGFR-CD19CAR-CD3zeta-4-1BB-expressing Autologous T-cells|iCasp9-deltaNGFR-CD19CAR-CD3zeta-4-1BB-expressing Autologous T-lymphocytes	A preparation of autologous T-lymphocytes that have been transduced with a retroviral vector to express a chimeric antigen receptor (CAR) consisting of an anti-CD19 single chain variable fragment (scFv) fused to a human immunoglobulin G1 (IgG1) hinge and a CD8alpha transmembrane domain, linked to the co-stimulatory molecule 4-1BB (CD137) and the cytoplasmic portion of the zeta chain of the human T-cell receptor (CD3zeta), containing the apoptosis-inducible suicide gene human caspase 9 (iCASP9 or iC9), linked to a drug binding domain, and a truncated low-affinity nerve growth factor receptor (deltaNGFR), with potential immunostimulating and antineoplastic activities. The iC9 construct consists of the sequence of the human FK506-binding protein (FKBP12) with an F36V mutation, connected through a Ser-Gly-Gly-Gly-Ser linker to the gene-encoding human caspase 9, which is deleted of its endogenous caspase activation and recruitment domain. Upon transfusion, the iCasp9-deltaNGFR-CD19CAR-CD3zeta-4-1BB-expressing autologous T-lymphocytes target and bind to CD19-expressing neoplastic B-cells. Prior to administration, deltaNGFR is used to select the CAR19-transduced T-cells for further enrichment by flow cytometry using an anti-NGFR antibody.	Autologous iC9-deltaNGFR-CD19CAR-CD3zeta-4-1BB-expressingT-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15647>	C15404	Anterior Mediastinotomy|Chamberlain procedure|anterior mediastinotomy	Surgical opening of the anterior mediastinum.			Therapeutic or Preventive Procedure	
C156480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156480>	C213143|C155712	Trastuzumab Botidotin|A 166|A-166|A166|ADC A166|Anti-HER2 ADC A166|Anti-HER2 Antibody-drug Conjugate A166|TRASTUZUMAB BOTIDOTIN	An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), conjugated, via a cleavable linker, to the microtubule inhibitor and auristatin derivative duostatin-5 (Duo-5), with potential antineoplastic activity. Upon administration of trastuzumab botidotin, the trastuzumab moiety targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, duo-5 binds to tubulin and inhibits its polymerization, which results in cell cycle arrest and induces tumor cell apoptosis. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.	Trastuzumab Botidotin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156481>	C28681|C129826	Young Autologous Tumor-infiltrating Lymphocytes|Therapeutic Young Autologous TILs|Young Autologous TIL|Young Autologous TILs|Young Autologous Tumor Infiltrating Lymphocytes	A preparation of autologous young tumor infiltrating lymphocytes (TILs), that are isolated from the patient's tumor tissue and minimally cultured ex vivo, with potential antineoplastic and immunomodulating activities. Upon re-administration of the young TILs, the TILs re-infiltrate the tumor, recognize the tumor cells and initiate tumor cell lysis. This inhibits tumor cell growth.	Young Autologous Tumor-infiltrating Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156482>	C3263|C156660	Genitourinary System Neoplasm	A benign or malignant neoplasm that affects the genitourinary system.	Genitourinary System Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156483>	C3677|C156482	Benign Genitourinary System Neoplasm	A neoplasm that arises from the genitourinary system and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.			Neoplastic Process	
C156484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156484>	C9305|C156482	Malignant Genitourinary System Neoplasm|Genitourinary Cancer|Genitourinary System Cancer|Malignant Genitourinary Neoplasm	A primary or metastatic malignant neoplasm that affects the genitourinary system.	Malignant Genitourinary System Neoplasm		Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C156485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156485>	C3809|C215797	Metastatic Neuroendocrine Neoplasm	A neuroendocrine neoplasm that has spread from its original site of growth to another anatomic site.	Metastatic Neuroendocrine Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156486>	C9270|C156485	Advanced Neuroendocrine Neoplasm	A neuroendocrine neoplasm that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Neuroendocrine Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156488>	C27720|C204037|C165447	Metastatic Pancreatic Neuroendocrine Tumor|Metastatic Pancreatic Islet Cell Tumor	A neuroendocrine tumor that arises from the islet cells of the pancreas and has spread to another anatomic site.	Metastatic Pancreatic Neuroendocrine Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156489>	C204036|C165448|C156488	Advanced Pancreatic Neuroendocrine Tumor|Advanced Pancreatic Islet Cell Tumor	A pancreatic neuroendocrine tumor that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Pancreatic Neuroendocrine Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C15648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15648>	C21087	Continuous Infusion Procedure|Continuous Infusion|continuous infusion	The administration of a fluid into a blood vessel, usually over a prolonged period of time.			Therapeutic or Preventive Procedure	
C156490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156490>	C20401|C143250|C129822	Bapotulimab|Anti-ILDR2 Inhibitor BAY1905254|Anti-ILDR2 Monoclonal Antibody BAY 1905254|Anti-immunoglobulin-like Domain Containing Receptor 2 MoAb BAY1905254|BAPOTULIMAB|BAY 1905254|BAY-1905254|BAY1905254|ILDR2 Function-blocking Antibody BAY1905254|Immune Checkpoint Inhibitor BAY1905254	A mouse/human cross-reactive immunoglobulin G2 (IgG2) monoclonal antibody against the immune checkpoint immunoglobulin-like domain containing receptor 2 (ILDR2; Chromosome 1 Open Reading Frame 32; C1orf32), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, bapotulimab targets, binds to and inhibits ILDR2, thereby blocking the immunosuppressive activity of ILDR2. This prevents ILDR2-mediated inhibition of T-cell activities and induces a cytotoxic T-lymphocyte (CTL) response against tumor cells. ILDR2, a type I transmembrane protein belonging to the B7 family of immunomodulatory receptors, negatively regulates T-cell responses.	Bapotulimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156492>	C27721|C162255|C156485	Metastatic Digestive System Neuroendocrine Neoplasm|Metastatic Gastroenteropancreatic Neuroendocrine Neoplasm	A neuroendocrine neoplasm that arises from any part of the digestive system and has metastasized to another anatomic site.	Metastatic Digestive System Neuroendocrine Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156493>	C5169|C170728|C156485	Metastatic Breast Neuroendocrine Neoplasm	A neuroendocrine neoplasm that arises from the breast and has metastasized to another anatomic site.			Neoplastic Process	
C156494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156494>	C53264	Magnetic Field Strength|MAGFSTR|magneticFieldStrength	A measurement of the force of magnetism that acts in the region around a magnetic material or a moving electrical charge.			Qualitative Concept	BRIDG Attribute Terminology|BRIDG Terminology|CDISC SDTM Device Properties Test Code Terminology|CDISC SDTM Device Properties Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156495>	C25337	Number of Unsuppressed Water Averages|USH2OAVN	The integer that describes that number of averages that are captured of the unsuppressed water spectrum signal during imaging.			Quantitative Concept	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156496>	C25345	Spectral Width|SPECTWD	The width of the wavelength interval at half maximum amplitude.			Quantitative Concept	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156497>	C95003	X-Axis Voxel Dimension|VOXDIMX	The linear measurement of a voxel along the X-axis.			Quantitative Concept	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156498>	C95003	Y-Axis Voxel Dimension|VOXDIMY	The linear measurement of a voxel along the Y-axis.			Quantitative Concept	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156499>	C95003	Z-Axis Voxel Dimension|VOXDIMZ	The linear measurement of a voxel along the Z-axis.			Quantitative Concept	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15649>	C16011	Diet Research	A scientific study that focuses on the effects of what a person eats and drinks. In particular, this may include or exclude certain items to meet specific requirements of the individual, or include a prescribed course of eating and drinking in which the amount and kind of food, as well as the times at which it is to be taken, are regulated for therapeutic purposes or selected with reference to a particular state of health.			Research Activity	
C1564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1564>	C2161	Pyrazoloacridine|PYRAZOLOACRIDINE|pyrazoloacridine	A 9-methoxy acridine compound containing a reducible 5-nitro substituent.  Pyrazoloacridine appears to intercalate into DNA and inhibit RNA synthesis, DNA synthesis, and the activities of topoisomerases I and II, thereby causing cytotoxicity. (NCI04)	Pyrazoloacridine		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156500>	C45788	Voxel Orientation|VOXORIEN|Voxel Angle	The orientation of the voxel relative to the coordinate system of the scanner. May be measured in degrees or radians depending on the scanner make and model.			Spatial Concept	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156501>	C82572	STEAM Pulse Sequence Mixing Time|SPSMTIME|Stimulated Echo Acquisition Mode Pulse Sequence Mixing Time	The time elapsed between the second and third pulses of the stimulated echo acquisition mode (STEAM) pulse sequence.			Temporal Concept	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156502>	C64493	Thrice|THRICE|Three Times	Three times.			Quantitative Concept	CDISC SDTM Frequency Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156503>	C181043	Bowel Obstruction Indicator|BWOBIND	An indication as to whether bowel obstruction has occurred.			Conceptual Entity	CDISC SDTM Gastrointestinal Test Code Terminology|CDISC SDTM Gastrointestinal Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156504>	C181043	Bowel Perforation Indicator|BWPFIND	An indication as to whether bowel perforation has occurred.			Conceptual Entity	CDISC SDTM Gastrointestinal Test Code Terminology|CDISC SDTM Gastrointestinal Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156505>	C181043	Lymphovascular Invasion Indicator|LVINVIND	An indication as to whether lymphovascular invasion by tumor cells has occurred.			Conceptual Entity	CDISC SDTM Gastrointestinal Test Code Terminology|CDISC SDTM Gastrointestinal Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156506>	C32889	Tibiotarsal Joint|TIBIOTARSAL JOINT	The joint connecting the lower part of the tibia with the upper part of the tarsus bones, specifically articulating with the talus bone.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156507>	C33966	Subarachnoid Space|SUBARACHNOID SPACE|Subarachnoid|Subarachnoid|Subarachnoid Area|Subarachnoid Area	The space between the arachnoid membrane and the pia mater; it contains connective tissue, cerebrospinal fluid, and large blood vessels that supply the brain and spinal cord.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156509>	C64430	Nuclear Matrix Protein 22 Measurement|NMP22|NUMA1|Nuclear Matrix Protein 22|Nuclear Matrix Protein 22|Nuclear Mitotic Apparatus Protein 1	The determination of the amount of nuclear matrix protein 22 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15650>	C93323|C15846	Electron Beam Therapy|ELECTRON Therapy|Electron Beam Radiation Therapy|Electron Beam Radiation Therapy|External beam radiation therapy using electrons (procedure)	Radiation therapy using electron beam.	Electron Beam Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|mCode Radiotherapy Modality Value Set|mCode Teleradiotherapy Modality Value Set|mCode Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C156510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156510>	C75342	Cocaethylene Measurement|COCAETH|Cocaethylene|Cocaethylene|Cocaine Ethyl|Ethyl Cocaine Measurement|Ethylbenzoylecgonine Measurement	The determination of the amount of cocaethylene present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156511>	C84818	24,25-Dihydroxyvitamin D3 Measurement|24,25-Dihydroxycholecalciferol|24,25-Dihydroxyvitamin D|24,25-Dihydroxyvitamin D3|24,25-Dihydroxyvitamin D3|24,25-Dihydroxyvitamin D3|VTD32425	The determination of the amount of 24,25-dihydroxyvitamin D present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156512>	C64467	Aspartate Aminotransferase to Platelet Ratio Index|APRI|APRI|APRI Score|AST to Platelet Ratio Index|AST to Platelet Ratio Index|AST to Platelet Ratio Index	A calculation that indicates the likely presence of liver cirrhosis and fibrosis, measured as the relative measurement of aspartate aminotransferase (AST) to AST upper limit of normal, divided by the platelet count, and multiplied by 100.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156513>	C96623	HDL Phospholipid Measurement|HDL Phospholipid|HDL Phospholipid|HDL-PL|HDLPL	The determination of the amount of high-density lipoprotein phospholipid present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156514>	C105586	4-Beta-Hydroxycholesterol Measurement|4-Beta-Hydroxy Cholesterol Measurement|4-Beta-Hydroxycholesterol|4-Beta-Hydroxycholesterol|4-Beta-OHC Measurement|CHOLOH4B|Cholest-5-ene-3beta,4beta-diol Measurement	The determination of the amount of 4-beta-hydroxycholesterol present in a sample.	4-Beta-Hydroxycholesterol Measurement		Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C156515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156515>	C74722	Hemoglobin Cast Measurement|HGBCS|Hemoglobin Casts|Hemoglobin Casts	The determination of the amount of hemoglobin casts present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156516>	C74954	Fatty Liver Index|FATLVIDX|FLI	A calculation that indicates the likely presence of fatty liver disease, taking into account waist circumference, body mass index, triglyceride concentrations, and gamma-glutamyltransferase activity. (Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006 Nov 2;6:33.)			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156517>	C147376	Free Immunoglobulin Light Chain Measurement|IMMGLCFR|Immunoglobulin Light Chains, Free|Immunoglobulin Light Chains, Free	The determination of the amount of free immunoglobulin light chains present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156518>	C85534	Interleukin 1 Excretion Rate|IL1EXR	The determination of the amount of interleukin 1 being excreted in a biological specimen over a defined period of time.			Quantitative Concept	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156519>	C85534	Interleukin 18 Excretion Rate|IL18EXR	The determination of the amount of interleukin 18 being excreted in a biological specimen over a defined period of time.			Quantitative Concept	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15651>	C15195	High-Dose Rate Brachytherapy|Brachytherapy, High Dose|HDR|HIGH-DOSE RATE BRACHYTHERAPY|High dose brachytherapy (procedure)	Internal radiation treatment that targets a cancerous tissue with accurate, high doses of radiation through the use of inserted temporary implants.	High-Dose Rate Brachytherapy		Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|mCode Brachytherapy Modality Value Set|mCode Radiotherapy Modality Value Set|mCode Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C156520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156520>	C85534	Chemokine (C-C Motif) Ligand 2 Excretion Rate|C-C Motif Chemokine 2 Excretion Rate|CCL2 Excretion Rate|CCL2EXR|Chemokine (C-C Motif) Ligand 2 Excr Rate|Chemokine (C-C Motif) Ligand 2 Excr Rate|MCP1 Excretion Rate	The determination of the amount of chemokine (C-C Motif) ligand 2 being excreted in a biological specimen over a defined period of time.			Quantitative Concept	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156521>	C156469	Phosphorylated STAT3 Measurement|Phospho-STAT3 Measurement|Phosphorylated STAT3|Phosphorylated STAT3|Phosphorylated Signal Transducer and Activator of Transcription 3 Measurement|Phosphorylated-Signal Transducer and Activator of Transcription 3 Measurement|STAT3P|pSTAT3|pSTAT3 Measurement	The determination of the amount of phosphorylated STAT3 present in a sample.	Phosphorylated STAT3 Measurement		Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156522>	C156469	Phosphorylated STAT3 to STAT3 Ratio Measurement|Phosphorylated STAT3/STAT3|Phosphorylated STAT3/STAT3|STAT3PS3|pSTAT3/STAT3	The determination of the ratio of phosphorylated STAT3 compared to STAT3 present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156523>	C64430	Pro-gastrin Releasing Peptide Measurement|PROGRP|Pro-GRP Measurement|Pro-gastrin Releasing Peptide|Pro-gastrin Releasing Peptide|proGRP	The determination of the amount of pro-gastrin releasing peptide present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156524>	C48938	Pyocytes Measurement|PYOCYTES|Pyocytes|Pyocytes	The determination of the amount of pyocytes present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156525>	C85534	TNF Superfamily Member 12 Excretion Rate|TNF12EXR|TNFSF12 Excretion Rate|TWEAK Excretion Rate|Tumor Necrosis Factor Ligand Superfamily Member 12 Excretion Rate	The determination of the amount of TNF superfamily member 12 being excreted in a biological specimen over a defined period of time.			Quantitative Concept	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156526>	C165990	Soluble TNF Superfamily Member 12 Measurement|Soluble TNF Superfamily Member 12|Soluble TNF Superfamily Member 12|Soluble TNFSF12|Soluble TNFSF12 Measurement|Soluble TWEAK Measurement|Soluble Tumor Necrosis Factor Ligand Superfamily Member 12 Measurement|TNF12S	The determination of the amount of soluble TNF superfamily member 12 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156527>	C165771	Vascular Endothelial Growth Factor Receptor 2 Measurement|KDR Measurement|VEGFR2|VEGFR2 Measurement|Vasc Endothelial Growth Factor Rec 2|Vasc Endothelial Growth Factor Rec 2|Vascular Endothelial Growth Factor Receptor 2	The determination of the amount of vascular endothelial growth factor receptor 2 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156528>	C74904	25-Hydroxyvitamin D2 Measurement|25-Hydroxycalciferol|25-Hydroxycalciferol|25-Hydroxyergocalciferol|25-Hydroxyergocalciferol|25-Hydroxyvitamin D2|25-Hydroxyvitamin D2|Ercalcidiol|Ercalcidiol|V25HD2	The determination of the amount of 25-hydroxyvitamin D2 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156529>	C74905	25-Hydroxyvitamin D3 Measurement|25-Hydroxycholcalciferol|25-Hydroxycholecalciferol|25-Hydroxyvitamin D|25-Hydroxyvitamin D|25-Hydroxyvitamin D3|25-Hydroxyvitamin D3|Calcidiol|Calcidiol|Calcifediol|Calcifediol|Inactive Vitamin D|Inactive Vitamin D|V25HD3	The determination of the amount of 25-hydroxyvitamin D3 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15652>	C15189	Image Guided Biopsy|Image-Guided Biopsy|Image-Guided Biopsy|Imaging Guided Biopsy|Imaging for Biopsy	The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis, using imaging technology.	Image-Guided Biopsy		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C156530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156530>	C156470	Pyruvate Kinase Muscle Isozyme Measurement|PKM|PKM Measurement|Pyruvate Kinase Muscle Isozyme|Pyruvate Kinase Muscle Isozyme	The determination of the amount of pyruvate kinase muscle isozyme present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156531>	C156470	Pyruvate Kinase Isozyme M2 Measurement|PKM2|PKM2 Measurement|Pyruvate Kinase Isozyme M2|Pyruvate Kinase Isozyme M2	The determination of the amount of pyruvate kinase isozyme M2 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156532>	C156470	Pyruvate Kinase Isozyme M1 Measurement|PKM1|PKM1 Measurement|Pyruvate Kinase Isozyme M1|Pyruvate Kinase Isozyme M1	The determination of the amount of pyruvate kinase isozyme M1 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156533>	C74948	Drug Crystal Measurement|CYDRUG|Drug Crystals|Drug Crystals	The determination of the amount of drug crystals present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156534>	C81183	Acylglycine Measurement|ACYGLYCN|Acylglycine|Acylglycine	The determination of the amount of acylglycine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156535>	C81183	Acylcarnitine Measurement|ACYCRNTN|Acylcarnitine|Acylcarnitine	The determination of the amount of acylcarnitine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156536>	C74949	Decanoylcarnitine Measurement|C10|DCCARNIT|Decanoylcarnitine|Decanoylcarnitine	The determination of the amount of decanoylcarnitine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156537>	C81183	Delta Aminolevulinate Measurement|5-Aminolevulinic Acid|5ALA|DALA|Delta Aminolevulinate|Delta Aminolevulinate|Delta Aminolevulinic Acid|dALA	The determination of the amount of delta aminolevulinate present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156538>	C74760	Delta Aminolevulinate to Creatinine Ratio Measurement|DALACRT|Delta Aminolevulinate/Creatinine|Delta Aminolevulinate/Creatinine	The determination of the ratio of delta aminolevulinate compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156539>	C74760	Porphobilinogen Measurement|PBG|Porphobilinogen|Porphobilinogen	The determination of the amount of porphobilinogen present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15653>	C217464	Drug Formulation Process|Drug Formulation|Formulation	The act or process of developing or preparing a mixture of ingredients to create a desired end drug product, such as a specific flavor, aroma, or polymer; or the desired final drug product itself; also, a listing of the ingredients and composition of the dosage form.			Activity	
C156540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156540>	C74760	Porphobilinogen to Creatinine Ratio Measurement|PBGCREAT|Porphobilinogen/Creatinine|Porphobilinogen/Creatinine	The determination of the ratio of porphobilinogen compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156541>	C25188	Separated|SEPARATED	A person who is separated from their spouse, whether or not there is a legal arrangement.			Organism Attribute	CDISC SDTM Marital Status Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C156542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156542>	C49188	Human Parvovirus B19 Measurement|B19V|Human Parvovirus B19|Human Parvovirus B19	The determination of the amount of the organism assigned to the human parvovirus B19 species in a biological sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156543>	C187863	Mycoplasma pneumoniae Measurement|MPN|Mycoplasma pneumoniae|Mycoplasma pneumoniae	The determination of the amount of the organism assigned to the Mycoplasma pneumoniae species in a biological sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156544>	C48938	CD68 Expressing Cell Count	The determination of the amount of the CD68 expressing cells in a sample.			Laboratory Procedure	
C156545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156545>	C18190	Blood Vessel Density|BLDVESD	An evaluation of the degree of blood vessel density present in a sample.			Diagnostic Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156546>	C64430	Beta-defensin 1 Measurement|BD1|Beta-defensin 1|Beta-defensin 1|DEFB1 Measurement	The determination of the amount of beta-defensin 1 in a biological specimen.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156547>	C114791	Intact Epithelial Reticular Basement Membrane Length to Total Epithelial Reticular Basement Membrane Length Ratio Measurement|ERLIERLT|Epi RBM Lngth, Intact/Epi RBM Lngth, Tot|Epi RBM Lngth, Intact/Epi RBM Lngth, Tot|Epithelial RBM Length, Intact/Epithelial RBM Length, Total	The determination of the ratio of intact epithelial reticular basement membrane length compared to total epithelial reticular basement membrane length present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156548>	C48938	Positive Cell Count|POSITIVE CELL COUNT	A measurement of the number of cells that stain positively in a sample.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Detail Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156549>	C91893	Injection Needle Reuse|INJECTION NEEDLE REUSE	The use of injection needles that have been previously used.			Functional Concept	CDISC SDTM Mode of Disease Transmission Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15654>	C15751	Fractionated Radiotherapy|Fractionated|Fractions|fractionation	Radiation therapy in which the total dose delivered is divided into several smaller, equal doses delivered over a period of several days.			Therapeutic or Preventive Procedure	CRF4 Treatment Radiation Table
C156550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156550>	C25180	Susceptibility Score Mutations Indicator|SUSMUIND	An indication as to whether one or more scored mutations of interest that may confer susceptibility in the microorganism is present.			Conceptual Entity	CDISC SDTM Microbiology Susceptibility Test Code Terminology|CDISC SDTM Microbiology Susceptibility Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156551>	C45501	No Longer Clinically Benefiting|NLCB|NLCB|NO LONGER CLINICALLY BENEFITING	An indication that a treatment or therapy was changed or discontinued because it is no longer clinically beneficial to the subject or patient, based on the primary therapeutic objective for which it is being administered and assessed. (Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Scher HI, Morris MJ, Stadler WM, et al.; Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016 Apr 20;34(12):1402-18.)			Clinical Attribute	CDISC SDTM Reason for Non-Completion Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156552>	C99553	Total Sleep Time|TST|TST	The total amount of sleep time from sleep onset to sleep offset, determined by summing the N1 sleep, N2 sleep, N3 sleep, and REM sleep durations.			Research Activity	CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156553>	C99553	Sleep Efficiency|SE|SE	A relative measurement (percentage) of the time spent asleep (N1 sleep + N2 sleep + N3 sleep + REM sleep) to the total time spent in bed.			Research Activity	CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156554>	C99553	Wake After Sleep Onset|Awake After Sleep Onset|WASO|WASO|Wake Time After Sleep Onset	A measurement of the sum of durations of wakefulness episodes throughout the night, not including the wakefulness before sleep onset.			Research Activity	CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156555>	C99553	N1 Sleep to Total Sleep Time Ratio Measurement|N1 Sleep/Total Sleep Time|N1 Sleep/Total Sleep Time|N1SLPTST	The determination of the ratio of N1 sleep time compared to total sleep time. The measurement may be expressed as a ratio or percentage.			Research Activity	CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156556>	C99553	N2 Sleep to Total Sleep Time Ratio Measurement|N2 Sleep/Total Sleep Time|N2 Sleep/Total Sleep Time|N2SLPTST	The determination of the ratio of N2 sleep time compared to total sleep time. The measurement may be expressed as a ratio or percentage.			Research Activity	CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156557>	C99553	N3 Sleep to Total Sleep Time Ratio Measurement|N3 Sleep/Total Sleep Time|N3 Sleep/Total Sleep Time|N3SLPTST	The determination of the ratio of N3 sleep time compared to total sleep time. The measurement may be expressed as a ratio or percentage.			Research Activity	CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156558>	C99553	REM to Total Sleep Time Ratio Measurement|REM/Total Sleep Time|REM/Total Sleep Time|REMTST	The determination of the ratio of REM sleep time compared to total sleep time. The measurement may be expressed as a ratio or percentage.			Research Activity	CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156559>	C70831	Peak Response Amplitude|PEAKRA	The maximum height change between the wave and the equilibrium point of a stimulus-response waveform.			Spatial Concept	CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15655>	C49163	Thoracic Surgical Procedure|Chest Surgery|Thoracic Surgery|Thoracic Surgical Procedures	Any surgery performed inside the thoracic cavity.	Thoracic Surgical Procedure		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C156560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156560>	C82572	Peak Response Amplitude Latency|PEAKRAL	The time duration between the stimulus and the maximum response.			Temporal Concept	CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156561>	C81183	N-Acetyl Aspartate Measurement|N-Acetyl Aspartate|N-Acetyl Aspartate|NAA	The determination of the amount of N-acetyl aspartate in a biological specimen.			Laboratory Procedure	CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156562>	C49237	Myo-Inositol Measurement|INOSM|Myo-Inositol|Myo-Inositol|mI	The determination of the amount of myo-inositol in a biological specimen.			Laboratory Procedure	CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156563>	C81183	Glutamate and Glutamine Measurement|GLX|Glutamate Plus Glutamine|Glutamate and Glutamine|Glutamate and Glutamine	The determination of the amount of glutamate and glutamine in a biological specimen.	Glutamate and Glutamine Measurement		Laboratory Procedure	CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C156564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156564>	C50995	Anatomic Response|ANATRESP	An assessment of the anatomic response (based on changes in size of anatomic structures) of the disease to the therapy.			Finding	CDISC SDTM Terminology|CDISC SDTM Tumor Response Assessment Test Code Terminology|CDISC SDTM Tumor Response Assessment Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C156565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156565>	C85761	Metabolite Ratio for AUC Infinity Observed	The ratio of AUC infinity observed for the metabolite to the AUC infinity observed for the parent analyte.			Quantitative Concept	
C156566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156566>	C85785	Metabolite Ratio for AUC Infinity Predicted	The ratio of AUC infinity predicted for the metabolite to the AUC infinity predicted for the parent analyte.			Quantitative Concept	
C156567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156567>	C85565	Metabolite Ratio AUC Last Nonzero Concentration	The ratio of AUC to last nonzero concentration for the metabolite to the AUC to last nonzero concentration for the parent analyte.			Quantitative Concept	
C156568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156568>	C85567	Metabolite Ratio for AUC Dosing Interval	The ratio of AUC over dosing interval (TAU) for the metabolite to the AUC over dosing interval (TAU) for the parent analyte.			Quantitative Concept	
C156569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156569>	C70918	Metabolite Ratio for Maximum Concentration	The ratio of metabolite maximum concentration to the parent analyte maximum concentration.			Quantitative Concept	
C15656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15656>	C49163	Neurosurgical Procedure|Neurological Surgery|Neurosurgery|Neurosurgical Procedures|Surgery, Neurological	Any surgical procedure performed on nervous system tissue.			Therapeutic or Preventive Procedure	
C156570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156570>	C85570	Volume of Distribution Steady State Observed by Fraction of Dose Absorbed|VSSOF|Vol Dist Steady State Obs by F|Vol Dist Steady State Obs by F	The volume of distribution at steady state based on the observed CLST for a substance administered by extravascular dosing, divided by the fraction of dose absorbed.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156571>	C85794	Volume of Distribution Steady State Predicted by Fraction of Dose Absorbed|VSSPF|Vol Dist Steady State Pred by F|Vol Dist Steady State Pred by F	The volume of distribution at steady state based on the predicted CLST for a substance administered by extravascular dosing, divided by the fraction of dose absorbed.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156572>	C85570	Volume of Distribution Steady State Observed by Unbound Drug|VSSOUB|Vol Dist Steady State Obs by UB|Vol Dist Steady State Obs by UB	The volume of distribution at steady state based on the observed CLST for a substance administered by extravascular dosing, divided by the fraction of unbound drug.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156573>	C85794	Volume of Distribution Steady State Predicted by Unbound Drug|VSSPUB|Vol Dist Steady State Pred by UB|Vol Dist Steady State Pred by UB	The volume of distribution at steady state based on the predicted CLST for a substance administered by extravascular dosing, divided by the fraction of unbound drug.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156574>	C85570	Volume of Distribution Steady State Observed by Bound Drug|VSSOBD|Vol Dist Steady State Obs by B|Vol Dist Steady State Obs by B	The volume of distribution at steady state based on the observed CLST for a substance administered by extravascular dosing, divided by the fraction of bound drug.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156575>	C85794	Volume of Distribution Steady State Predicted by Bound Drug|VSSPBD|Vol Dist Steady State Pred by B|Vol Dist Steady State Pred by B	The volume of distribution at steady state based on the predicted CLST for a substance administered by extravascular dosing, divided by the fraction of bound drug.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156576>	C85534	Fractional Excretion from T1 to T2|FREXINT|Fract Excr from T1 to T2|Fract Excr from T1 to T2	The fraction of the administered dose that is recovered from the specimen type, over the interval between T1 and T2.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156577>	C156471	Area Under the Curve Ratio Infinity Predicted|RAAUCIFP|Ratio AUC Infinity Pred|Ratio AUC Infinity Pred	The ratio of two AUC infinity predicted values.			Qualitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156578>	C156471	Area Under the Curve Ratio Infinity Observed|RAAUCIFO|Ratio AUC Infinity Obs|Ratio AUC Infinity Obs	The ratio of two AUC infinity observed values.			Qualitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156579>	C43242	Cmax to Cmax Ratio Measurement|RACMAX|Ratio CMAX|Ratio CMAX	The determination of the ratio of one Cmax value compared to another Cmax value. The measurement may be expressed as a ratio or percentage.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15657>	C49236	Blood Treatment|Hematologic Procedure|Therapeutic Procedures Hematopoietic System	General term for hemodialysis, plasmapheresis, blood transfusions, and related procedures involving autologous removal, alteration, and replacement of patients' blood or blood components.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Procedures Codelist|CPTAC Terminology
C156580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156580>	C43242	Cmax to Cmin Ratio Measurement|RAMAXMIN|Ratio of CMAX to CMIN|Ratio of CMAX to CMIN	The determination of the ratio of one Cmax value compared to a Cmin value. The measurement may be expressed as a ratio or percentage.			Conceptual Entity	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156581>	C85775	Observed Volume of Distribution of Absorbed Fraction for Unbound Drug|VZFOUB|Vz Obs by F for UB|Vz Obs by F for UB	The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using the observed value of the last non-zero concentration and corrected for unbound drug.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156582>	C15262	Local Immunotherapy Procedure|LOCAL IMMUNOTHERAPY|Local Immunotherapy	Any immunotherapy that targets, or is restricted to, a specific anatomical location.			Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156583>	C67109	Southern African Coloured|SOUTHERN AFRICAN COLOURED	A person of mixed race, whose ancestry is from one or more of the naturalized racial groups of Southern Africa (typically Western European, South Asian, or Southeastern Asian) and one or more of the indigenous Southern African peoples.			Population Group	CDISC CDASH Terminology|CDISC SDTM Collected Race Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156584>	C38081	Alveolar Volume|ALVVOL|VA	The quantity of fresh gas that enters the alveoli during inspiration.			Diagnostic Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156585>	C117720	Menses Flow Rate Description|MENFRD	A subjective description of the menstrual flow rate during a menstrual cycle.			Finding	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156586>	C117720	Menses Duration|MENFDUR|Menses Flow Duration|Menses Flow Duration	The number of days during which menses is expelled from the uterus.			Finding	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156587>	C117720	Menstrual Cycle Regularity|MENREG	A description of how an individual's menstrual cycle conforms to a consistent temporal pattern.			Finding	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156588>	C25180	Induced Abortion Indicator|INABOIND	An indication as to whether the female subject has had an induced abortion procedure.			Conceptual Entity	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156589>	C25180	Live Birth Indicator|BRTLVIND	An indication as to whether the subject has delivered live-born offspring.			Conceptual Entity	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15658>	C16199|C15820	Cancer and Nutrition Research	Systematic investigation into the role that nutrition plays in cancer.			Biomedical Occupation or Discipline	
C156590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156590>	C38114	Intramandibular Route of Administration|INTRAMANDIBULAR	Administration within the mandible.			Functional Concept	CDISC SDTM Route of Administration Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156591>	C32725	Bone Marrow Mononuclear Cell|BMMC|BONE MARROW MONONUCLEAR CELL	Any cell with a single nucleus found in the bone marrow, for example lymphocytes, monocytes, mesenchymal stem cells and hematopoietic progenitor cells.			Cell	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156592>	C49658	Open Label for Treatment And Double Blind to Dose|OPEN LABEL TO TREATMENT AND DOUBLE BLIND TO IMP DOSE	A study in which the therapeutic treatment is open label but the dosing information of the investigational medicinal product (IMP) is double-blinded.			Research Activity	CDISC SDTM Terminology|CDISC SDTM Trial Blinding Schema Terminology|Clinical Data Interchange Standards Consortium Terminology
C156593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156593>	C73432	Enlargement from Nadir|ENLARGEMENT FROM NADIR	An increase in size, volume, or quantity in comparison to nadir.			Activity	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C156594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156594>	C142367	Further Enlargement from Nadir|FURTHER ENLARGEMENT FROM NADIR	An increase in size, volume, or quantity in comparison to a previous state that was enlarged from nadir.			Activity	CDISC SDTM Terminology|CDISC SDTM Tumor or Lesion Properties Test Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C156595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156595>	C124444	Induction Clinical Trial Setting|INDUCTION	A clinical trial or treatment setting in which the therapy of interest is considered induction therapy.			Classification	CDISC SDTM Terminology|CDISC SDTM Treatment Setting Terminology|Clinical Data Interchange Standards Consortium Terminology
C156596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156596>	C124444	Mobilization Clinical Trial Setting|MOBILIZATION	A clinical trial or treatment setting in which the therapy of interest is considered mobilization therapy.			Classification	CDISC SDTM Terminology|CDISC SDTM Treatment Setting Terminology|Clinical Data Interchange Standards Consortium Terminology
C156597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156597>	C124444	Conditioning Clinical Trial Setting|CONDITIONING	A clinical trial or treatment setting in which the therapy of interest is considered conditioning therapy.			Classification	CDISC SDTM Terminology|CDISC SDTM Treatment Setting Terminology|Clinical Data Interchange Standards Consortium Terminology
C156598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156598>	C124444	Maintenance Clinical Trial Setting|MAINTENANCE	A clinical trial or treatment setting in which the therapy of interest is considered maintenance therapy.			Classification	CDISC SDTM Terminology|CDISC SDTM Treatment Setting Terminology|Clinical Data Interchange Standards Consortium Terminology
C156599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156599>	C124444	Consolidation Clinical Trial Setting|CONSOLIDATION	A clinical trial or treatment setting in which the therapy of interest is considered consolidation therapy.			Classification	CDISC SDTM Terminology|CDISC SDTM Treatment Setting Terminology|Clinical Data Interchange Standards Consortium Terminology
C15659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15659>	C15820	Aging and Nutrition Research	The study of how nutritional needs change with aging.			Research Activity	
C1565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1565>	C1907	Aloe Vera Gel	A preparation of leaf pulp from the parenchymal tissue of the plant Aloe vera (Liliaceae). Aloe vera gel contains carbohydrate polymers, such as glucomannans or pectic acid, and various vitamins and essential amino acids, as well as other organic and inorganic compounds. This agent has been used internally or externally for sunburn, skin problems, insect bites, ulcers, arthritis, constipation, and as an immune system enhancer.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C156600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156600>	C124444	Salvage Clinical Trial Setting|SALVAGE	A clinical trial or treatment setting in which the therapy of interest is considered salvage therapy.			Classification	CDISC SDTM Terminology|CDISC SDTM Treatment Setting Terminology|Clinical Data Interchange Standards Consortium Terminology
C156601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156601>	C70705	Additional Outcome Measure|OUTMSADD	Additional key measures that will be used to evaluate the intervention(s) or, for observational studies, that are a focus of the study, but which are not considered primary or secondary outcome measures.			Intellectual Product	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C156602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156602>	C156472	CDISC Therapeutic Area User Guide Name and Version|CDISC Therapeutic Area User Guide|CDISC Therapeutic Area User Guide|CTAUG	The name and version of the CDISC therapeutic area user guide that is being used in the study submission.			Classification	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C156603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156603>	C156472	FDA Technical Specification Name and Version|FDA Technical Specification|FDA Technical Specification|FDATCHSP	The name and version of the FDA technical specification that is being used in the study submission.			Classification	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C156604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156604>	C25714	Study Data Tabulation Model Implementation Guide Version|SDTIGVER|SDTM IG Version|SDTM IG Version|SDTM IG Version|SDTM Implementation Guide Version|SDTMIG Version	The version of the CDISC Study Data Tabulation Model implementation guide that is being used in the study submission.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C156605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156605>	C25714	Study Data Tabulation Model Version|SDTM Version|SDTM Version|SDTM Version|SDTMVER	The version of the CDISC Study Data Tabulation Model that is being used in the study submission.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C156606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156606>	C172255	Chest Circumference|CHESTCIR	A circumferential measurement of the chest.			Spatial Concept	CDISC SDTM Terminology|CDISC SDTM Vital Sign Test Code Terminology|CDISC SDTM Vital Sign Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C156607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156607>	C134576	Experimental Organism Endocardial Schwannoma|SCHWANNOMA, ENDOCARDIAL, MALIGNANT	A malignant schwannoma of the heart arising from subendocardial schwann cells that appear as an expansile spindle cell mass, which may infiltrate the myocardium and protrude into the ventricular lumen. (INHAND)			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C156608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156608>	C134576	Experimental Organism Intramural Schwannoma|SCHWANNOMA, INTRAMURAL, MALIGNANT	A malignant schwannoma of the heart of the heart arising from intramural swan cells that appears as a poorly circumscribed spindle cell mass within the ventricular myocardium with a more discrete boundary, that is generally more infiltrative than expansile. (INHAND)			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C156609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156609>	C134576	Experimental Organism Ductal Cell Adenocarcinoma|ADENOCARCINOMA, DUCTAL CELL, MALIGNANT	An experimental organism carcinoma that arises from a ductal structure.			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C15660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15660>	C26028	Vaccine Development	Research focused on the development of a vaccine.			Health Care Activity	
C156610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156610>	C134576	Experimental Organism Ductal Cell Adenoma|ADENOMA, DUCTAL CELL, BENIGN	An experimental organism adenoma that arises from a ductal structure.			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C156611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156611>	C134576	Experimental Organism Brunner's Gland Carcinoma|CARCINOMA, BRUNNER'S GLAND, MALIGNANT	A malignant epithelial neoplasm arising from the cells of the Brunner's gland with desmoplasia being the most dominant feature along with a diminished or lost glandular structure. (INHAND)			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C156612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156612>	C134576	Experimental Organism Benign Thecoma	A benign sex cord/stromal neoplasm characterized by densely packed fusiform theca cells arranged in interlacing bundles and whorls giving a nodular appearance. (INHAND)			Neoplastic Process	
C156613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156613>	C134576	Experimental Organism Malignant Thecoma|THECOMA, MALIGNANT	A malignant sex cord/stromal neoplasm characterized by densely packed fusiform theca cells arranged in interlacing bundles and whorls giving a nodular appearance. (INHAND)			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Clinical Data Interchange Standards Consortium Terminology
C156614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156614>	C154898	Irreversible Inhibitor|IRREVERSIBLE INHIBITOR	A class of substances that irreversibly and permanently binds to and decreases the activity of, and/or deactivates a target.			Chemical Viewed Functionally	CDISC SEND Planned Pharmacologic Target Mode of Action Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156615>	C94373	Physiologic Antagonist|PHYSIOLOGIC ANTAGONIST	A substance that binds to and activates a receptor and produces a biological effect which inhibits or negates the biological response produced by an agonist at a different receptor.			Chemical Viewed Functionally	CDISC SEND Planned Pharmacologic Target Mode of Action Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156616>	C25714	SEND Developmental and Reproductive Toxicology Implementation Guide Version 1.1|SEND DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY IMPLEMENTATION GUIDE VERSION 1.1|SEND IG DART Version 1.1	The 1.1 version of the standard for exchange of nonclinical data (SEND) developmental and reproductive toxicology (DART) implementation guide.			Conceptual Entity	CDISC SEND Terminology|CDISC SEND Version Terminology|Clinical Data Interchange Standards Consortium Terminology
C156617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156617>	C142605	Authorized Investigational Medicinal Product|authorised investigational medicinal product	A medicinal product with marketing authorization that is being tested or used as a reference in a clinical trial.			Chemical Viewed Functionally	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C156618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156618>	C156473	Authorized Auxiliary Medicinal Product|authorised auxiliary medicinal product	A medicinal product with marketing authorization that is used in a clinical trial for purposes other than as the investigational agent.			Chemical Viewed Functionally	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C15661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15661>	C48800	ATCC|American Type Culture Collection	A global nonprofit bioscience organization (located at 10801 University Boulevard, Manassas, VA 20110-2209 703-365-2700) that provides biological products, technical services, and educational programs to private industry, government, and academic organizations around the world.  Biological products for academic and industrial labs, as well as educational and technical services.  For the collection, preservation and distribution of cultures of living microorganisms, viruses, DNA probes, plants, and human and animal			Professional or Occupational Group	
C156620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156620>	C142452	Clinical Trial Results Registry|clinical trial results registry	A clinical trial registry that serves as a publicly available database of clinical trial results.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C156621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156621>	C17564	Attributable, Legible, Contemporaneous, Original, Accurate|ALCOA|ALCOA	Fundamental elements of data integrity as described by the US Food and Drug Administration; this acronym stands for attributable, legible, contemporaneous, original, and accurate.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C156622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156622>	C17564	Attributable, Legible, Contemporaneous, Original, Accurate Plus|ALCOA Plus|ALCOA+|ALCOA+	A modified guide to the fundamental elements of data integrity originally described by the US Food and Drug Administration; this acronym stands for attributable, legible, contemporaneous, original, and accurate, as well as the additional elements of complete, consistent, enduring, and available.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C156623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156623>	C17941	Individual Exposure|exposure (individual)	An exposure measured in direct proximity to an individual.			Phenomenon or Process	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C156624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156624>	C25332	Extent of Exposure|extent of exposure	An assessment of the amount, duration, and number of individuals affected by an exposure.			Quantitative Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C156625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156625>	C25392	Device Manufacture|manufacturer (device)	A person or entity that designs, manufactures, fabricates, assembles, or processes a finished device.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C156626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156626>	C25392	Drug Manufacturer|manufacturer (drug)	A person or entity that is engaged in the manufacturing, preparing, propagating, compounding, processing, packaging, repackaging, or labeling of a prescription drug.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C156627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156627>	C43369	Medication Error|medication error	An error associated with the prescribing, dispensing, or giving/taking a medication by a healthcare professional, patient, or consumer that causes or leads to inappropriate medication use or patient harm.			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C156628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156628>	C43369	Device Use Error|use error (device)	An error associated with the use of a medical device, due to problems with the design of the device or the manner in which the device is used, that causes or leads to inappropriate device use or patient harm.			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C15662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15662>	C15533	Neuroprotection	The use of drugs to protect nerve cells from damage by cancer therapy agents.			Therapeutic or Preventive Procedure	
C156630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156630>	C70703	Clinical Trial Temporary Halt|temporary halt (of a clinical trial)	An interruption in clinical trial activity by the sponsor that is not in the clinical protocol, with an intention to resume the study.			Functional Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C156631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156631>	C70703	Clinical Trial Suspension|suspension (of a clinical trial)	An interruption in some or all clinical trial activities.			Functional Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C156632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156632>	C78690	Clinical Outcome Assessment Content Validation|content validation (COA)|content validation (re COA)	A performance outcome measure that assesses the degree of correspondence between clinical outcome assessment measures and how patients feel or function in everyday life.			Quantitative Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C156633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156633>	C78691	Clinical Outcome Assessment Construct Validation|construct validation (COA)|construct validation (re COA)	A performance outcome measure that assesses, using quantitative methods, the degree to which the relationships among items, domains, and concepts of a clinical outcome assessment conform to a priori hypotheses concerning logical relationships that should exist with other measures of characteristics of patients and patient groups.			Quantitative Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C156634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156634>	C78692	Clinical Outcome Assessment Criterion Validation|criterion validation (COA)|criterion validation (re COA)	A performance outcome measure that assesses the degree to which the scores of a clinical outcome assessment instrument are related to a known gold standard measure of the same concept.			Quantitative Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C156635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156635>	C142602	Mutual Recognition Procedure|MRP|mutual recognition procedure (MRP)	A European authorization process in which a marketing authorization holder for a product that is already authorized in at least one Member State, known as the Reference Member State, seeks to obtain marketing authorization for the same product in at least one other Member State, known as the Concerned Member State(s).			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C156636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156636>	C50996	Serious Breach|serious breach	A deviation from clinical trial protocol that is likely to affect, to a significant degree, the safety, physical, or mental integrity of the subjects of the trial, or the scientific value of the trial.			Research Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C156637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156637>	C51977	Privacy Breach|privacy breach	Unauthorized access to, or disclosure of, an individual's personal information.			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C156638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156638>	C25425	Accelerated Approval|accelerated approval|fast track designation	A regulatory process that allows for shortened time to approval of drugs that treat serious conditions and/or fill an unmet medical need based on surrogate or intermediate clinical endpoints.			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C156639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156639>	C71473	Subject Monitoring|subject monitoring	The act of observing, recording, and reporting the status, safety, and performance of clinical trial participants as specified in the study protocol.			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C15663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15663>	C168699	Nicotine Gum|Nicorette|Nicotine Polacrilex|Nicotine Polacrilex|nicotine gum	A chewing gum containing nicotine used as a substitute for the active ingredient in tobacco. Nicotine chewing gum reduces the withdrawal symptoms associated with smoking cessation.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C156640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156640>	C87194	Concerned Member State|CMS|concerned member state (CMS)	A European Economic Area country that is seeking to obtain marketing authorization, through Mutual Recognition or Decentralized procedures, for a medicinal product that has already been authorized in at least one other European Economic Area country.			Geographic Area	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C156641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156641>	C87194	Reference Member State|RMS|reference member state (RMS)	A European Economic Area country with marketing authorization for a medicinal product that evaluates the marketing authorization application dossier and prepares the assessment report on behalf of another European Economic Area country that is seeking to obtain marketing authorization for the same product through Mutual Recognition or Decentralized procedures.			Geographic Area	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C156642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156642>	C41192	Marketing Authorization|marketing approval|marketing authorization	A license issued by a regulatory authority that allows a medicinal product to be put on the market.			Governmental or Regulatory Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C156643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156643>	C25161	Medicinal Product Classification|medicinal product classification	The categorization of medicinal products based on chemical, pharmacological, or therapeutic properties or regulatory status.			Classification	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C156644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156644>	C1708	Biosimilar|biosimilar	A biological product that is highly similar in structure and function to, and has no clinically meaningful differences from, an FDA-approved reference product.			Classification	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C156645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156645>	C45412	ADROIT Electronically Generated Information Service|AEGIS|AEGIS (ADROIT Electronically Generated Information Service)	An online subscription service that provides access to anonymized adverse drug reaction data on the ADROIT database.			Manufactured Object	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C156646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156646>	C199143	American Health Information Community|AHIC|AHIC (American Health Information Community)	A US federal government advisory committee that was established by the Secretary of Health and Human Services in 2005 to make recommendations for accelerating the development and adoption of health information technology.			Professional or Occupational Group	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C156647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156647>	C165839	Consolidated Health Informatics|CHI|CHI (consolidated health informatics)	A US federal government initiative, established in 2001, to create and adopt health information interoperability standards for implementation across government agencies in order to enable the exchange of electronic health information.			Professional or Occupational Group	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C156648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156648>	C25164	Development International Birth Date|DIBD|DIBD (development international birth date)	The date of a sponsor's first authorization to conduct a clinical trial in any country worldwide.			Temporal Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C156649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156649>	C114457	Electronic Document Room|EDR|EDR (electronic document room)	The online repository for electronic FDA CDER submissions; it is an extension of the Central Document Room.			Manufactured Object	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C15664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15664>	C84377	Technology Development	The establishment and growth of technology.			Activity	
C156650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156650>	C16205	Health Information Exchange|HIE|HIE (Health Information Exchange)	The process of sharing patient-level health information through electronic networks among disparate health information systems, primarily to permit immediate access at the point of care.	Health Information Exchange		Health Care Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C156651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156651>	C25256	No Observable Effect Level|NOEL|NOEL (no observable effect level)	The greatest amount, or highest dose or exposure level, of a substance that produces no noticeable toxicity.			Quantitative Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C156652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156652>	C199143	Regional Health Information Organization|RHIO|RHIO (Regional Health Information Organization)	A group of stakeholders in a given geographic region that govern and share healthcare-related information among them, often electronically, according to accepted healthcare information technology standards.			Professional or Occupational Group	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C156653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156653>	C142416	Standard for the Exchange of Nonclinical Data|SEND|SEND (standard for the exchange of nonclinical data)	An implementation of the CDISC SDTM standard for the collection and storage of nonclinical study data.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C15665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15665>	C15675	Neoadjuvant Therapy|Induction Therapy|Neo-Adjuvant|Neoadjuvant|Neoadjuvant|Neoadjuvant|Pre-Adjuvant|Pre-Adjuvant Therapy|Pre-Adjuvant Therapy|Preoperative Therapy|induction therapy|neoadjuvant therapy|neoadjuvant therapy	Therapy administered prior to the primary treatment for the purpose of making the primary treatment more effective.	Neoadjuvant Therapy		Therapeutic or Preventive Procedure	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CRF4 Treatment Chemotherapy Table|CRF4 Treatment Complementary Table|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|OS Authorized Value Terminology|OS Course Timing Table
C156660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156660>	C27551	Genitourinary System Disorder|Genitourinary Disorder|Urogenital Disease	A non-neoplastic or neoplastic disorder that affects the genitourinary system.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology|HL Authorized Value Terminology|HL Late Effects Table
C156661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156661>	C17369	Water Signal Suppression Method|H2OSUPPR	The technique used to suppress the signal that is generated from body water during imaging.			Diagnostic Procedure	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156662>	C25180	Small for Gestational Age Indicator|SMGAIND	An indication as to whether the fetus or infant is small for the gestational age.			Conceptual Entity	CDISC SDTM Subject Characteristic Test Code Terminology|CDISC SDTM Subject Characteristic Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156663>	C198998	Minor Person|Minor|minor|minor				Human	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C156664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156664>	C53531|C156660	Non-Neoplastic Genitourinary System Disorder	A non-neoplastic disorder that affects the genitourinary system.			Disease or Syndrome	
C156665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156665>	C67502	Micro Needle Array-Doxorubicin|D-MNA|Dissolvable Microneedles-containing Doxorubicin|Doxorubicin-coated Patches|Doxorubicin-loaded Patches|MNA-D|MNA-D Patches|MNA-Doxorubicin|Micro-needle Array Doxorubicin|Microneedle Applicator-Doxorubicin|Microneedle Array Doxorubicin	A formulation composed of dissolvable small, adhesive-like patches composed of a biocompatible material which is coated with the anthracycline antibiotic doxorubicin, with potential antineoplastic and immunomodulating activities. Upon cutaneous administration of the microneedle-array-doxorubicin, the microneedles degrade once inserted into the skin and doxorubicin is released from the dissolvable microneedle array delivery device directly into the tumor microenvironment (TME). Doxorubicin is taken up by tumor cells and intercalates into DNA and interferes with topoisomerase II activity. This inhibits DNA replication and RNA synthesis, leading to tumor cell growth inhibition and apoptosis. This agent also interacts with cell membrane lipids causing lipid peroxidation. In addition, doxorubicin induces innate, adaptive, and tumor-specific effector and memory immune responses, thereby further killing the tumor cells. Delivery of doxorubicin using the microneedle array delivery system allows direct and specific administration of doxorubicin to the TME which may improve drug concentration into tumor cells and may reduce systemic toxicity, compared to the administration of systemic doxorubicin alone.	Micro Needle Array-Doxorubicin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156666>	C17423	Microneedle Drug Delivery System|Dissolvable Microneedle Array|Dissolvable Microneedle Array|MNA|Micro Needle Array|Micro-Needle Applicator|Microneedle Applicator|Microneedle Array|Microneedle Patch	A drug delivery device consisting of an adhesive-like patch covered with solid or hollow projections (microneedles), usually ranging in length from 50 to 900 micrometers, designed to deliver therapeutic agents through the skin.	Dissolvable Microneedle Array		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C156667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156667>	C20103	ILDR2 Gene|ILDR2|ILDR2|Immunoglobulin Like Domain Containing Receptor 2 Gene	This gene may play a role in Notch signaling, insulin homeostasis, inflammation and the unfolded protein response pathway.	ILDR2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C156668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156668>	C156667	ILDR2 wt Allele|C1orf32|Chromosome 1 Open Reading Frame 32 Gene|Immunoglobulin Like Domain Containing Receptor 2 wt Allele|LISCH-Like Gene|dJ782G3.1	Human ILDR2 wild-type allele is located in the vicinity of 1q24.1 and is approximately 93 kb in length. This allele, which encodes immunoglobulin-like domain-containing receptor 2 protein, may be involved in immunomodulation, Notch signaling, the response to glucose and cellular homeostasis. Overexpression of the gene may be associated with increased susceptibility for type 2 diabetes.	ILDR2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156669>	C18106	Immunoglobulin-Like Domain-Containing Receptor 2|ILDR2|Immunoglobulin Like Domain Containing Receptor 2|Immunoglobulin-Like Domain Containing Receptor 2	Immunoglobulin-like domain-containing receptor 2 (639 aa, ~71 kDa) is encoded by the human ILDR2 gene. This protein may play a role in insulin secretion, immunomodulation, signaling and cellular stress responses.	Immunoglobulin-Like Domain-Containing Receptor 2		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15666>	C20985|C15687	Radiofrequency Ablation|Ablation, Radiofrequency|RFA|Radiofrequency Interstitial Ablation|radiofrequency ablation	A therapeutic procedure to kill tissue using radiowaves to generate heat. The procedure is performed by the insertion of an electrode into a target tissue. Electrical energy delivered to the electrode heats and destroys the tissue.	Radiofrequency Ablation		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C156670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156670>	C136648	Blasts More than 15 Percent of Bone Marrow Nucleated Cells|Blasts Greater than 15 Percent of Bone Marrow Nucleated Cells|Blasts Over 15 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that more than 15 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts More than 15 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C156671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156671>	C113159	Steroid-Refractory Pneumonitis	Pneumonitis that does not respond to corticosteroid therapy.	Steroid-Refractory Pneumonitis		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C156672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156672>	C118970	CDISC Clinical Classification COVI Test Name Terminology|CC-COVI TEST|COVI01TN|Covi Anxiety Scale Clinical Classification Test Name	Test names of clinical classification questions associated with the Covi Anxiety Scale (COVI) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156673>	C118970	CDISC Clinical Classification COVI Test Code Terminology|CC-COVI TESTCD|COVI01TC|Covi Anxiety Scale Clinical Classification Test Code	Test codes of clinical classification questions associated with the Covi Anxiety Scale (COVI) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156674>	C211913	COVI Clinical Classification Question	A question associated with the COVI clinical classification.			Intellectual Product	
C156675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156675>	C118969	Covi Anxiety Scale Clinical Classification|COVI|COVI|COVI01	A standardized three-item clinician-administered questionnaire published in 1982 by Lipman et al. that utilizes a five-point response scale to assess the severity of anxiety in adults based on patient verbal report, behavior, and somatic symptoms.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156676>	C156674	COVI - Verbal Report|COVI01-Verbal Report|COVI01-Verbal Report|COVI0101	Covi Anxiety Scale (COVI) Verbal report.			Intellectual Product	CDISC Clinical Classification COVI Test Code Terminology|CDISC Clinical Classification COVI Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156677>	C156674	COVI - Behavior|COVI01-Behavior|COVI01-Behavior|COVI0102	Covi Anxiety Scale (COVI) Behavior.			Intellectual Product	CDISC Clinical Classification COVI Test Code Terminology|CDISC Clinical Classification COVI Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156678>	C156674	COVI - Somatic Symptoms of Anxiety|COVI01-Somatic Symptoms of Anxiety|COVI01-Somatic Symptoms of Anxiety|COVI0103	Covi Anxiety Scale (COVI) Somatic symptoms of anxiety.			Intellectual Product	CDISC Clinical Classification COVI Test Code Terminology|CDISC Clinical Classification COVI Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C156679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156679>	C156674	COVI - Total Score|COVI01-Total Score|COVI01-Total Score|COVI0104	Covi Anxiety Scale (COVI) Total score.			Intellectual Product	CDISC Clinical Classification COVI Test Code Terminology|CDISC Clinical Classification COVI Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15667>	C51900	Sentinel Lymph Node Biopsy|SENTINEL LYMPH NODE BIOPSY|SLNB|SNB|Sentinel Node Biopsy|Sentinel node biopsy alone|sentinel lymph node biopsy	Surgical removal and examination of the sentinel node, the lymph node which is first in receiving the lymphatic drainage of a specified anatomic location and is most likely to be affected by the lymphatic spread of cancer.	Sentinel Lymph Node Biopsy		Diagnostic Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C156680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156680>	C2021|C1557	Fosifloxuridine Nafalbenamide|5-FU Analog Prodrug NUC-3373|FOSIFLOXURIDINE NAFALBENAMIDE|L-Alanine, N-(-2'-Deoxy-2',2'-difluoro-p-1-naphthalenyl-5'-cytidylyl)-, Phenylmethyl Ester|NUC 3373|NUC-3373|NUC3373|Nucleotide Analog NUC-3373|Phosphoramidate-FUDR-MP Prodrug NUC-3373	A phosphoramidate-based prodrug of the monophosphate (MP) form of 5-fluoro-2'-deoxyuridine (FUdR; FUDR), the active metabolite of fluorouracil (5-FU), an antimetabolite fluoropyrimidine analog of the pyrimidine nucleoside, with potential antineoplastic activity. Upon administration of the nucleotide analog prodrug fosifloxuridine nafalbenamide, fosifloxuridine nafalbenamide is readily taken up by tumor cells. In the tumor cell, the phosphoramidate moiety is removed and fosifloxuridine nafalbenamide is converted to its active form FUDR-MP. In turn, FUDR-MP binds to and inhibits thymidylate synthase (TS), resulting in the depletion of thymidine triphosphate (TTP) and thus DNA synthesis. With the phosphoramidate moiety attached to FUDR-MP, fosifloxuridine nafalbenamide, compared to 5-FU, is more lipophilic and accumulates in cancer cells by passive diffusion and does not require a nucleoside transporter, thereby generating higher intracellular concentrations. In addition, compared to 5-FU, once inside the cell FUDR-MP does not need to be phosphorylated and is already in its active form. Unlike 5-FU, fosifloxuridine nafalbenamide does not get deactivated or converted into toxic metabolites by dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (TP), which leads to both a longer half-life and less toxicity.	Fosifloxuridine Nafalbenamide		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156681>	C226341	PSMA/CD3 Tri-specific T-cell Activating Construct HPN424|Anti-PSMA/CD3 TriTAC HPN424|HPN 424|HPN-424|HPN-424|HPN424|PSMA/CD3 TriTAC HPN424|PSMA/CD3-specific TriTAC HPN424|TriTAC HPN424	A recombinant antibody derivative composed of tri-specific T-cell activating construct (TriTAC) directed against the human tumor-associated antigen (TAA) prostate-specific membrane antigen (PSMA; FOLH1) and the CD3 antigen found on T-lymphocytes and an albumin-binding domain, with potential immunostimulating and antineoplastic activities.  Upon administration, PSMA/CD3 tri-specific T-cell antibody construct HPN424 targets and binds PSMA on tumor cells and CD3 on cytotoxic T-lymphocytes (CTLs), thereby bringing PSMA-expressing tumor cells and CTLs together, which results in the CTL-mediated cell death of PSMA-expressing tumor cells. The albumin-binding domain targets and binds to serum albumin, thereby extending the serum half-life of HPN424. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate tumor cells.	PSMA/CD3 Tri-specific T-cell Activating Construct HPN424		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156682>	C95884|C155936|C153320	Metastatic Gastric Neuroendocrine Carcinoma	A gastric neuroendocrine carcinoma that has spread from its original site of growth to another anatomic site.			Neoplastic Process	
C156683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156683>	C203253|C165299|C156682	Advanced Gastric Neuroendocrine Carcinoma	A gastric neuroendocrine carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.			Neoplastic Process	
C156684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156684>	C95885|C191990|C156683	Advanced Gastric Large Cell Neuroendocrine Carcinoma	A gastric large cell neuroendocrine carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.			Neoplastic Process	
C156685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156685>	C6764|C191993|C156683	Advanced Gastric Small Cell Neuroendocrine Carcinoma|Advanced Gastric Small Cell Carcinoma	A gastric small cell neuroendocrine carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.			Neoplastic Process	
C156686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156686>	C96064|C8637|C155936	Metastatic Small Intestinal Neuroendocrine Carcinoma	A small intestinal neuroendocrine carcinoma that has spread from its original site of growth to another anatomic site.			Neoplastic Process	
C156687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156687>	C207863|C203253|C156686	Advanced Small Intestinal Neuroendocrine Carcinoma	A small intestinal neuroendocrine carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.			Neoplastic Process	
C156688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156688>	C27449|C191993|C156687	Advanced Small Intestinal Small Cell Neuroendocrine Carcinoma|Advanced Small Intestinal Small Cell Carcinoma	A small intestinal small cell neuroendocrine carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.			Neoplastic Process	
C156689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156689>	C96065|C191990|C156687	Advanced Small Intestinal Large Cell Neuroendocrine Carcinoma	A small intestinal large cell neuroendocrine carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.			Neoplastic Process	
C15668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15668>	C15669	Prevention of Liver Cancer|Liver Cancer Prevention	Any method of preventing liver cancer including limit of exposure to carcinogens and infectious agents, diet, education, or lifestyle.			Therapeutic or Preventive Procedure	
C156690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156690>	C138057	Blasts 25 Percent or Less of Bone Marrow Nucleated Cells|Blasts Less than or Equal to 25 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that 25 percent or less of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts 25 Percent or Less of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C156691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156691>	C199456	Iptacopan|Factor B Inhibitor LNP023|IPTACOPAN|LNP 023|LNP-023|LNP023	An orally available, small-molecule inhibitor of complement factor B (FB) with potential immunomodulatory activity. Upon administration, iptacopan binds to FB and prevents the formation of the alternative pathway (AP) C3-convertase (C3bBb). This limits the cleavage of C3 to the active fragment C3b and may prevent C3b-mediated extravascular hemolysis in certain complement-driven disorders such as paroxysmal nocturnal hemoglobinuria (PNH).			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C156692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156692>	C129822|C128057	Benmelstobart|APL502|Anti-PD-L1 Monoclonal Antibody CBT-502|Anti-PD-L1 Monoclonal Antibody TQB2450|BENMELSTOBART|CBT 502|CBT-502|CBT502|TQB 2450|TQB-2450|TQB2450	A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, benmelstobart specifically targets and binds to PD-L1, preventing the binding and subsequent activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1, a transmembrane protein expressed on activated T-cells, is overexpressed in some cancer types and plays a significant role in immune evasion by tumor cells.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156693>	C142078	ECT-001 Expanded Cord Blood|ECT-001 Expanded UCB|ECT-001 Expanded Umbilical Cord Blood|UM171 Expanded Cord Blood	A preparation of umbilical cord blood (UCB) co-cultured and expanded in an optimized culture system with a small molecule agonist of hematopoietic stem cell (HSC) renewal, with potential use in hematopoietic cell transplantation (HCT). Upon administration, the ECT-001 expanded cord blood cells increase and restore the number of hematopoietic stem and progenitor cells (HSPCs) that can differentiate into a variety of cell types and promote blood cell recovery. Compared to untreated UBCs, ECT-001 expanded UCB cells may exhibit enhanced stem cell proliferation and engraftment.	ECT-001 Expanded Cord Blood		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C156694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156694>	C1505	Antitumor B Key Active Component-alpha|Antitumor B KAC-a|C156694|Chinese Herbal Mixture Antitumor B KAC-a	An orally available concentrated preparation of antitumor B (ATB, Zeng Sheng Ping), a Chinese herbal formula comprised of Sophora tonkinensis, Polygonum bistorta, Prunella vulgaris, Sonchus brachyotus, Dictamnus dasycarpus, and Dioscorea bulbifera, with potential antineoplastic activity. Upon administration, antitumor B key active component-alpha (ATB-KAC-alpha) may, through a not yet fully elucidated mechanism, inhibit tumorigenesis and prevent the development of certain cancers.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156695>	C129825	SHP-1 Agonist SC-43|1-[4-Chloro-3(trifluoromethyl)phenyl-3-[3-(4-cyanophenoxy)] Urea|SC 43|SC-43|SC-43|SC-43 Oral Solution|SC43	An orally available, small molecule agonist of Src homology region 2 domain-containing phosphatase-1 (SHP-1; tyrosine-protein phosphatase non-receptor type 6; PTPN6) with potential antineoplastic activity. Upon administration, SHP-1 agonist SC-43 enhances SHP-1 activity by impairing the association between the N-terminal Src homology 2 (N-SH2) domain and the protein tyrosine phosphatase (PTP) domain of SHP-1, triggering a conformational change of SHP-1 and relieving its autoinhibition. Activation of SHP-1 represses signal transducer and activator of transcription 3 (STAT3) signaling by inhibiting constitutive and interleukin-6 (IL-6)-induced STAT3 phosphorylation. The STAT3 pathway is overly active in many cancer types and is implicated in cancer stem cell-mediated growth, recurrence, stemness, and resistance to conventional chemotherapies.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156696>	C9496|C8852	Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma	The reemergence of T-cell/histiocyte-rich large B-cell lymphoma after a period of remission.	Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156697>	C67422	Halichondrin Analogue E7130|E 7130|E-7130|E-7130|E7130	A halichondrin analogue derived from a marine sponge with potential antineoplastic activity. Upon intravenous infusion, halichondrin analogue E7130 may bind to the vinca domain of tubulin and inhibit the polymerization of tubulin and the assembly of microtubules, thereby inhibiting mitotic spindle assembly and inducing cell cycle arrest at the G2/M phase.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156698>	C2199|C2124|C129819	Rhenium Re-188 Etidronate|188Re-HEDP|88Re-Etidronate|RHENIUM RE-188 ETIDRONATE|Re 188 Etidronic Acid|Re 188 Hydroxyethylidene Diphosphonate|Re-188 Etidronate|Re-188 HEDP|Re-188 Hydroxyethylidene Diphosphonate|Re-188Etidronate|Rhenium Re-188 Hydroxyethylidene Diphosphonate (SY)|Rhenium-188 Etidronate|Rhenium-188 HEDP	A synthetic compound containing the bisphosphonate etidronate (hydroxyethylidene diphosphonate, HEDP) labeled with rhenium Re188, a beta-emitting radioisotope with potential antineoplastic activity. Upon administration, Re-188 etidronate binds to hydroxyapatite in bone, delivering a cytotoxic dose of beta radiation to primary and metastatic bone tumors. The beta-radiation may provide localized anti-tumor radiotoxicity while sparing extramedullary bone marrow tissues.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156699>	C179717	Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma Transformed from Underlying Marginal Zone Lymphoma	Histologic transformation of a marginal zone lymphoma to an aggressive diffuse large B-cell lymphoma.			Neoplastic Process	
C15669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15669>	C15843	Cancer Prevention	All methods of preventing cancer including limit of exposure to carcinogens and infectious agents, diet, education, etc	Cancer Prevention		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C1566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1566>	C514	Liposomal Amphotericin B|Abelcet|AmBisome|Amphotericin B Liposomal|Amphotericin B-Lipid Complex|DKF-5122|L-AMB|Lipid Complex, Amphotericin B	A liposome-encapsulated formulation of the polyene antifungal antibiotic amphotericin B produced by the bacterium Streptomyces nodosus with antifungal activity. Amphotericin B binds to ergosterol, an essential component of the fungal cell membrane, and alters cell membrane integrity, resulting in leakage of intracellular components and cell rupture. This agent may also induce oxidative damage in fungal cells and has been reported to stimulate host immune cells. Compared to amphotericin B alone, liposomal delivery of amphotericin B allows for a greater drug concentration in target tissues while decreasing systemic side effects.	Liposomal Amphotericin B		Antibiotic|Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C156700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156700>	C143099|C129825	Gumarontinib|GUMARONTINIB|Glumetinib|SCC 244|SCC-244|SCC244	An orally bioavailable, small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration, gumarontinib targets and binds to the c-Met protein, thereby disrupting c-Met-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156701>	C202063	Zamaporvint|Porcupine Inhibitor RXC004|RXC 004|RXC-004|RXC004|ZAMAPORVINT	An orally available inhibitor of porcupine (PORCN), with potential antineoplastic activity. Upon oral administration, zamaporvint binds to and inhibits PORCN in the endoplasmic reticulum (ER), which blocks post-translational acylation of Wnt ligands and inhibits their secretion. This prevents the activation of Wnt ligands, interferes with Wnt-mediated signaling, and inhibits cell growth in Wnt-driven tumors. Porcupine, a membrane-bound O-acyltransferase (MBOAT), is required for the palmitoylation of Wnt ligands, and plays a key role in Wnt ligand secretion and activity. Wnt signaling is dysregulated in a variety of cancers.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156702>	C129839	Para-toluenesulfonamide|P-TOLUENESULFONAMIDE|PTS|PTS 100|PTS-100|PTS100	A low-molecular-weight organic compound with potential antineoplastic activity. Upon intra-tumoral injection, para-toluenesulfonamide increases lysosomal membrane permeabilization (LMP) and the release of cathepsin B. Cytosolic cathepsin B released from lysosomes cleaves and activates proapoptotic B-cell lymphoma 2 (Bcl-2) family member BH3 interacting-domain death agonist (Bid) and poly [ADP-ribose] polymerase 1 (PARP-1), which may induce tumor cell death.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C156703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156703>	C19332	Fine Motor Skills|Dexterity|Fine motor skills|Manual Dexterity	The ability to control the movement of the small muscles of the fingers and hands.			Organism Attribute	
C156705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156705>	C201282|C155711	Runimotamab|Anti-HER2 x Anti-CD3 Bispecific Monoclonal Antibody BTRC 4017A|Anti-HER2 x Anti-CD3 Bispecific Monoclonal Antibody RG 6194|Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody 4017A|Anti-HER2/Anti-CD3 Bispecific Monoclonal Antibody BTRC 4017A|BTRC 4017A|BTRC-4017A|BTRC4017A|RG 6194|RG-6194|RG6194|RUNIMOTAMAB	An anti-human epidermal growth factor receptor 2 (HER2)/anti-CD3 T-cell-dependent bispecific (TDB) monoclonal antibody with potential immunostimulatory and antineoplastic activities. Upon administration, runimotamab possesses two antigen recognition sites, one for HER2, a tyrosine kinase receptor overexpressed by many cancer cell types, and one for the CD3 complex, a group of T-cell surface glycoproteins that interact with the T-cell receptor (TCR). Upon administration of runimotamab, this bispecific monoclonal antibody simultaneously binds to both CD3-expressing T-cells and HER2-expressing cancer cells, thereby crosslinking HER2-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in potent CTL-mediated lysis of HER2-expressing tumor cells. HER2 plays a key role in tumor cell proliferation and tumor vascularization.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156706>	C200766|C176023	Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes|Anti-BCMA-CAR-mRNA-transfected Autologous CD8+ T-cells|Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-cells|Autologous Anti-BCMA-CAR-mRNA-transfected CD8-positive T-cells|Descartes-08	A preparation of autologous CD8-positive T-lymphocytes that have been genetically modified via transient mRNA transfection to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and containing, as of yet undisclosed co-stimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-BCMA-CAR-mRNA transfected CD8+ T-lymphocytes specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.	Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156707>	C129823	Anti-GCC Antibody-Drug Conjugate TAK-164|Anti-GCC ADC TAK-164|TAK 164|TAK-164|TAK-164|TAK164	An antibody-drug conjugate (ADC) comprised of a full-length, fully-human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) directed against the extracellular domain of guanylyl cyclase C (GCC; GUCY2C), conjugated using the peptide-linked indolino-benzodiazepine DNA alkylator DGN549 (IGN-P1), with potential antineoplastic activity. Upon intravenous administration of TAK-164, the antibody moiety selectively binds to GCC-expressing cells. Upon antibody/antigen binding and internalization, the cytotoxic DGN549 payload is released and binds to guanine residues on opposing strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of GCC-expressing cells. GCC, a transmembrane receptor normally found on intestinal cells and dopamine neurons in the brain, is overexpressed on the surface of certain tumor cells.	Anti-GCC Antibody-Drug Conjugate TAK-164		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156708>	C63474	eHealth for Sedentary Behavior|eHealth Interventions for Sedentary Behavior	The use of websites, applications, or other electronic means to induce individuals to partake in spontaneous movement and reduce their sedentary behavior.	eHealth for Sedentary Behavior		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C156709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156709>	C162996	Brigimadlin|BI 907828|BI-907828|BI907828|BRIGIMADLIN|MDM2 Inhibitor BI 907828	An orally available inhibitor of murine double minute 2 (MDM2), with potential antineoplastic activity. Upon oral administration, brigimadlin binds to MDM2 protein and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. By preventing MDM2-p53 interaction, the transcriptional activity of p53 is restored. This leads to p53-mediated induction of tumor cell apoptosis. Compared to currently available MDM2 inhibitors, the pharmacokinetic properties of BI 907828 allow for more optimal dosing and dose schedules that may reduce myelosuppression, an on-target, dose-limiting toxicity for this class of inhibitors.	Brigimadlin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15670>	C20985|C15415	Thermal Ablation Therapy|thermal ablation	A procedure using heat to remove tissue or a part of the body, or destroy its function.	Thermal Ablation Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C156710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156710>	C1910	Goserelin Acetate Extended-release Microspheres LY01005|Goserelin Acetate Extended-release Microspheres|LY 01005|LY-01005|LY01005	A long-acting, extended-release microsphere formulation of the acetate form of goserelin, a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH), with potential antineoplastic activity. Upon administration, goserelin binds to and activates pituitary gonadotropin-releasing hormone (GnRH) receptors. Prolonged administration of goserelin inhibits the secretion of pituitary gonadotropin, thereby decreasing levels of testosterone (in males) and estradiol (in females).  Administration of this agent in an extended-release formulation may result in the regression of sex hormone-sensitive tumors and a reduction in sex organ size and function.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156711>	C9305|C7337	Malignant Peritoneal and Retroperitoneal Neoplasm	A primary or metastatic malignant neoplasm that affects the peritoneum and/or retroperitoneum.			Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology
C156712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156712>	C33904	Peritoneum and Retroperitoneum|Retroperitoneum and peritoneum	A term that refers to the peritoneum and the space behind it (retroperitoneum).			Anatomical Structure	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C156713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156713>	C7337|C3677	Benign Peritoneal and Retroperitoneal Neoplasm	A neoplasm that arises from the peritoneum and/or retroperitoneum and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.			Neoplastic Process	
C156714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156714>	C9305	Malignant Abdominal Neoplasm|Malignant neoplasm of abdomen	A primary or metastatic malignant neoplasm that affects the organs and structures of the abdomen.			Neoplastic Process	Cellosaurus Disease Terminology|CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|mCode Cancer Disorder Value Set|mCode Elixhauser Malignant Solid Tumors without Metastases Value Set|mCode Primary Cancer Disorder Value Set|mCode Primary Malignant Neoplasm Disorder Value Set|mCode Terminology
C156715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156715>	C9305	Malignant Pelvic Neoplasm|Malignant neoplasm pelvis|Pelvis Cancer|Pelvis Cancer	A primary or metastatic malignant neoplasm that affects the organs and structures of the pelvis.	Pelvis Cancer		Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology|mCode Cancer Disorder Value Set|mCode Elixhauser Malignant Solid Tumors without Metastases Value Set|mCode Primary Cancer Disorder Value Set|mCode Primary Malignant Neoplasm Disorder Value Set|mCode Terminology
C156716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156716>	C27753|C148427	Recurrent Acute Myeloid Leukemia Not Otherwise Specified	The reemergence of acute myeloid leukemia not otherwise specified after a period of remission.			Neoplastic Process	
C156717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156717>	C7463|C156716	Recurrent Acute Myelomonocytic Leukemia|Acute myelomonocytic leukemia, in relapse|Relapsed Acute Myelomonocytic Leukemia	The reemergence of acute myelomonocytic leukemia after a period of remission.			Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|mCode Cancer Disorder Value Set|mCode Elixhauser Leukemia Value Set|mCode Primary Cancer Disorder Value Set|mCode Primary Malignant Neoplasm Disorder Value Set|mCode Terminology
C156718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156718>	C7175|C148427	Recurrent Acute Myeloid Leukemia with Recurrent Genetic Abnormalities	The reemergence of acute myeloid leukemia with a recurrent genetic abnormality after a period of remission.			Neoplastic Process	
C156719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156719>	C82403|C193407	Recurrent Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A|Recurrent Acute Myeloid Leukemia with t(9;11)(p21.3; q23.3); MLLT3 (AF9)-KMT2A|Recurrent Acute Myeloid Leukemia with t(9;11)(p21.3; q23.3); MLLT3-MLL|Recurrent Acute Myeloid Leukemia with t(9;11)(p21.3; q23.3); MLLT3::MLL|Recurrent Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A Fusion|Recurrent Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3::KMT2A|Recurrent Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3::KMT2A Fusion|Relapsed Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A	The reemergence of acute myeloid leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A after a period of remission.			Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology
C15671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15671>	C15406	Screening for Endometrial Cancer|early detection of endometrial cancer|endometrial cancer early detection|endometrial cancer screening	Checking an individual for the presence or absence of endometrial cancer.			Diagnostic Procedure	
C156720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156720>	C9289|C125715	Recurrent Acute Myeloid Leukemia with Multilineage Dysplasia|Acute myeloid leukemia with multilineage dysplasia, in relapse|Recurrent Acute Myeloid Leukemia (AML) with Multilineage Dysplasia|Relapsed Acute Myeloid Leukemia with Multilineage Dysplasia	The reemergence of acute myeloid leukemia with multilineage dysplasia after a period of remission.	Recurrent Acute Myeloid Leukemia with Multilineage Dysplasia		Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology|mCode Cancer Disorder Value Set|mCode Elixhauser Leukemia Value Set|mCode Primary Cancer Disorder Value Set|mCode Primary Malignant Neoplasm Disorder Value Set|mCode Terminology
C156721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156721>	C16230	Total Lymphoid Irradiation|TLI	The use of extensive lymphatic irradiation to achieve immunosuppression. The irradiated areas includ the cervical, supraclavicular, and axillary lymph nodes, and the mediastinal region, as well as the the porta hepatis, celiac nodes, splenic pedicle and spleen, and para-aortic, iliac, inguinal, and femoral nodes.	Total Lymphoid Irradiation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C156722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156722>	C7318|C156716	Recurrent Acute Monoblastic and Monocytic Leukemia|Acute monoblastic/monocytic leukemia, in relapse|Relapsed Acute Monoblastic and Monocytic Leukemia	The reemergence of acute monoblastic and monocytic leukemia after a period of remission.	Recurrent Acute Monoblastic and Monocytic Leukemia		Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology|mCode Cancer Disorder Value Set|mCode Elixhauser Leukemia Value Set|mCode Primary Cancer Disorder Value Set|mCode Primary Malignant Neoplasm Disorder Value Set|mCode Terminology
C156723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156723>	C8923|C156716	Recurrent Acute Erythroid Leukemia|Acute erythroid leukemia, in relapse|Relapsed Acute Erythroid Leukemia	The reemergence of acute erythroid leukemia after a period of remission.			Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|mCode Cancer Disorder Value Set|mCode Elixhauser Leukemia Value Set|mCode Primary Cancer Disorder Value Set|mCode Primary Malignant Neoplasm Disorder Value Set|mCode Terminology
C156724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156724>	C3588	Acute Myeloid Leukemia with Multilineage Dysplasia in Remission|Acute myeloid leukemia with multilineage dysplasia, in remission	A finding of acute myeloid leukemia with multilineage dysplasia that is not growing and responds to treatment.			Finding	mCode Cancer Disorder Value Set|mCode Elixhauser Leukemia Value Set|mCode Primary Cancer Disorder Value Set|mCode Primary Malignant Neoplasm Disorder Value Set|mCode Terminology
C156725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156725>	C3588	Acute Monoblastic and Monocytic Leukemia in Remission|Acute monoblastic/monocytic leukemia, in remission	A finding of acute monoblastic and monocytic leukemia that is not growing and responds to treatment.			Finding	mCode Cancer Disorder Value Set|mCode Elixhauser Leukemia Value Set|mCode Primary Cancer Disorder Value Set|mCode Primary Malignant Neoplasm Disorder Value Set|mCode Terminology
C156726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156726>	C129822|C128037	Nofazinlimab|Anti-PD-1 Monoclonal Antibody CS1003|CS 1003|CS-1003|CS1003|NOFAZINLIMAB	A humanized, immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, nofazinlimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156728>	C129825	Sodium-Potassium Adenosine Triphosphatase Inhibitor RX108|Na+/K+-ATPase Inhibitor RX108|RX 108|RX-108|RX108|Sodium-Potassium Pump Inhibitor RX10	A small-molecule, inhibitor of sodium-potassium adenosine triphosphatase (Na+/K+-ATPase) with potential antineoplastic activity. Upon administration, RX108 inhibits the activity of the Na+/K+-ATPase, which prevents the activation of various signal transduction pathways that play a key role in tumor proliferation. This may lead to cell-cycle arrest, apoptosis, and autophagic cell death. Na+/K+-ATPase is overexpressed in certain tumor types and may serve as a scaffold for the assembly of multiple-protein signaling complexes that regulate cell proliferation and motility. In normal, healthy cells, the Na+/K+-ATPase controls transportation of Na+ and K+ across the cell membrane and is essential for electrochemical gradient maintenance, osmotic balance, and cellular pH.	Sodium-Potassium Adenosine Triphosphatase Inhibitor RX108		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156729>	C61074|C129825	Itacnosertib|ACVR1 Inhibitor TP-0184|ALK-2 Inhibitor TP-0184|ALK2 Inhibitor TP-0184|ITACNOSERTIB|TP 0184|TP-0184|TP0184	An orally bioavailable inhibitor of activin A receptor type 1 (activin receptor-like kinase 2; ALK2; ALK-2; ACRV1), with potential antineoplastic activity. Upon oral administration,itacnosertib targets, binds to and inhibits the activity of ALK-2. This prevents ALK-2-mediated signaling and inhibits cell growth in ALK-2-overexpressing tumor cells. In addition, in cancer and inflammatory conditions, ALK-2 is upregulated in response to increased signaling of pro-inflammatory cytokines, especially interleukin-6 (IL-6), and enhances the secretion of hepcidin, a peptide liver hormone and a key modulator of iron homeostasis. Blocking ALK-2-mediated pathways in inflammation and cancer leads to a decrease of hepcidin expression and restores plasma iron levels, thereby preventing low serum iron levels and anemia of chronic disease (ACD). ALK-2, a serine/threonine receptor kinase, is constitutively activated due to activating mutations or upregulated upstream signaling pathways in inflammatory conditions and certain types of cancer.	Itacnosertib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15672>	C15740	Hot Flashes Attenuation	Therapy designed to reduce the frequency or intensity hot flashes.			Therapeutic or Preventive Procedure	
C156730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156730>	C63817	Navarixin|2-Hydroxy-N,N-dimethyl-3-((2-((1R)-1-(5-methylfuran-2-yl)propyl)amine)-3,4- dioxocyclobut-1-enyl)amino)benzamide Monohydrate|MK-7123|NAVARIXIN|PS291822|SCH 527123	An orally available small molecule antagonist of the C-X-C motif chemokine receptor 1 (CXCR1; interleukin-8 receptor alpha; IL8RA) and 2 (CXCR2; interleukin-8 receptor beta; IL8RB), with potential immunomodulating and antineoplastic activities. Upon administration, navarixin binds to and inhibits the activation of CXCR 1 and 2. This inhibits CXCR1/2-mediated signaling, reduces both recruitment and migration of immunosuppressive myeloid-derived suppressor cells (MDSCs) and neutrophils in the tumor microenvironment (TME), inhibits inflammatory processes and abrogates the immunosuppressive nature of the TME. This allows effector cells, such as natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs), to kill and eliminate cancer cells. This inhibits tumor cell migration, metastasis, angiogenesis and tumor cell proliferation. CXCR 1 and 2, G protein-coupled receptor proteins located on myeloid cells and certain tumor cells, play key roles in the immunosuppressive nature of the TME, tumor metastasis, therapy-resistance, myeloid cell suppression, and inflammation.	CCR2 Antagonist PF-04136309|Navarixin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156731>	C3170|C156716	Recurrent Acute Megakaryoblastic Leukemia|Acute megakaryoblastic leukemia, in relapse|Relapsed Acute Megakaryoblastic Leukemia	The reemergence of acute megakaryoblastic leukemia after a period of remission.			Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|mCode Cancer Disorder Value Set|mCode Elixhauser Leukemia Value Set|mCode Primary Cancer Disorder Value Set|mCode Primary Malignant Neoplasm Disorder Value Set|mCode Terminology
C156732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156732>	C1291	EGFR Antisense DNA BB-401|Anti-EGFR ddRNAi BB-401|BB 401|BB-401|BB401|ddRNAi BB-401	A recombinant, plasmid DNA expression vector encoding a 39 nucleotide (nt) short hairpin RNA (shRNA) specific for the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon intratumoral administration, the EGFR antisense DNA BB-401 is taken up by tumor cells and shRNA is transcribed. The shRNA is converted into small interfering RNA (siRNA) via the RNA interference (RNAi) pathway. The siRNA targets and binds to EGFR RNA expressed by tumor cells. This blocks EGFR mRNA translation and prevents EGFR protein expression.			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156733>	C129824|C129821	MARCKS Protein Inhibitor BIO-11006|Aerosolized BIO-11006|BIO 11006|BIO-11006|BIO-11006|BIO-11006 Peptide|BIO11006|Myristoylated Alanine Rich C Kinase Substrate Inhibitor BIO-11006	An aerosolized 10-amino acid peptide that inhibits the myristoylated alanine rich protein kinase C substrate (MARCKS) protein, with potential immunomodulating and antineoplastic activities. Upon inhalation, the MARCKS protein inhibitor BIO-11006 targets, binds to and inhibits the phosphorylation of MARCKS (P-MARCKS). This prevents MARCKS-mediated signaling, thereby preventing the release of phosphatidylinositol 4,5-bisphosphate (PIP2) from the cell membrane upon MARCKS binding. This prevents the PIP2-mediated activation of focal adhesion kinase (FAK) and the FAK-mediated activation of the PI3K/AKT pathway and the activation of integrins, talin, vinculin and paxillin. This leads to an inhibition of tumor cell proliferation, migration, metastasis and survival. In addition, inhibition of MARCKS prevents mucin granule release and reduces the overproduction of mucus in the lungs. This may abrogate airway obstruction, impaired lung function, airway inflammation and bacterial infections associated with overproduction of mucus in the lungs. The MARCKS protein, a filamentous actin crosslinking protein and substrate for protein kinase C (PKC) is localized on the plasma membrane. Upon phosphorylation by PKC or binding to the calcium-calmodulin complex, the association of MARCKS with actin and with the plasma membrane is blocked, leading to its presence in the cytoplasm. The MARCKS protein plays a key role in the exocytosis of a number of vesicles and granules, cell movement, mitogenesis and membrane trafficking.			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156734>	C129822|C128036	Nurulimab|Anti-CTLA-4 Monoclonal Antibody BCD-145|BCD 145|BCD-145|BCD145|NURULIMAB	A monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, nurulimab targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156735>	C2116	Taragarestrant|(2E)-3-(3,5-Dichloro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1hpyrido(3,4-b)indol-1-yl)phenyl)prop-2-enoic acid|2-Propenoic acid, 3-(3,5-dichloro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-2,3,4,9-tetrahydro-3-methyl-1H-pyrido(3,4-b)indol-1-yl)phenyl)-, (2E)-|D 0502|D-0502|D0502|SERD D-0502|Selective Estrogen Receptor Downregulator D-0502|TARAGARESTRANT	An orally available, nonsteroidal selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, taragarestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156736>	C1505	Fermented Prebiotic Dietary Supplement AferBio|AferBio|AferBio Nutritional Supplement|Fermented Food Powder AferBio	A powder-based nutritional supplement composed of Brazilian fermented non-digestible food composed of soy, wheat, and organic wheat germ, and containing a mixture of non-soluble and fermentable fibers rich in oligosaccharides, with potential immunomodulating and prebiotic activities. Upon oral administration of the fermented prebiotic dietary supplement, the high concentrations of beta-glucans are able to stimulate the proliferation of beneficial bacteria in the gastrointestinal (GI) tract. This modulates the GI flora ecosystem, improves the functions of the intestinal barrier and protects against harmful viruses and bacteria. In addition, this prebiotic modulates the immune system and may inhibit inflammation.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C156737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156737>	C129825	RIPK1 Inhibitor GSK3145095|GSK 3145095|GSK-3145095|GSK-3145095|GSK3145095|Receptor-interacting Serine/Threonine-protein Kinase 1 Inhibitor GSK3145095	An orally available, small-molecule inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1; receptor-interacting protein 1; RIP1) with potential antineoplastic and immunomodulatory activities.  Upon administration, GSK3145095 disrupts RIPK1-mediated signaling, which may reduce C-X-C motif chemokine ligand 1 (CXCL1)-driven recruitment and migration of immunosuppressive myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TME). This allows effector cells, such as natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs), to kill and eliminate cancer cells. RIPK1, a serine-threonine kinase that normally plays a key role in inflammation and cell death in response to tissue damage and pathogen recognition, is overexpressed in certain cancer types and may be associated with oncogenesis and promotion of the immunosuppressive nature of the TME.	RIPK1 Inhibitor GSK3145095		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156738>	C129822|C128037	Serplulimab|HLX 10|HLX-10|HLX10|SERPLULIMAB	A humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, serplulimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.	Serplulimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156739>	C1511	Zirconium Zr 89-DFO-cRGDY PEG-Cy5-C' Dots|89Zr-DFO-cRGDY-PEG-Cy5-C' Dot Nanoparticles|89Zr-DFO-cRGDY-PEG-Cy5-C' Dot Particles|89Zr-DFO-cRGDY-PEG-Cy5-C' Dots|Zr 89-DFO-cRGDY PEG-Cy5-C' Dots	A radioconjugate composed of a tumor-selective fluorescent imaging agent containing silica-based nanoparticles labeled with a near-infrared (NIR) fluorophore, cyanine 5 (Cy5), and surrounded by polyethylene glycol (PEG) chains attached to cyclic arginine-glycine-aspartic acid-tyrosine) (cyclo-(Arg-Gly-Asp-Tyr; cRGDY) peptides (C' dots; Cornell prime dots; cRGDY-PEG-C' dots), and linked, via the chelator desferrioxamine (DFO), to the radioisotope zirconium Zr 89 (Zr89), with potential diagnostic properties upon positron emission tomography (PET) imaging. Upon intradermal administration of the zirconium Zr 89 cRGDY PEG-Cy5-C' dots, the cRGDY moiety selectively binds to alphaVbeta3 integrin expressed on tumor cells. Upon binding, the radioisotope moiety may be detected using PET, thereby allowing the imaging and quantification of integrin-expressing tumor cells as well as the visualization of the distribution, uptake and removal within tumor tissues. The fluorescence imaging agent is used to visualize alphaVbeta3-expressing tumor cells and assess the degree of both tumor metastasis and sentinel lymph node (SLN) trafficking. Integrins are transmembrane glycoproteins upregulated on proliferating tumor vessel endothelial cells and various cancer cells; their overexpression has been associated with neovascularization, differentiation, proliferation of tumor cells, metastasis and an overall poor prognosis.			Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	NCI Drug Dictionary Terminology
C15673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15673>	C15411	Keratinocyte Growth Factor Therapy	Drug therapy that uses a keratinocyte growth factor.	Keratinocyte Growth Factor Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C156740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156740>	C137990	Murizatoclax|AMG 397|AMG-397|AMG397|MCL-1 inhibitor AMG 397|MURIZATOCLAX|Myeloid Cell Leukemia 1 Inhibitor AMG 397	An inhibitor of induced myeloid leukemia cell differentiation protein (myeloid cell leukemia-1; Mcl-1; Bcl2-L-3), with potential pro-apoptotic and antineoplastic activities. Upon administration, murizatoclax targets and binds to Mcl-1, thereby preventing the binding of Mcl-1 to and inactivation of certain pro-apoptotic proteins. This promotes apoptosis of cells overexpressing Mcl-1. Mcl-1, an anti-apoptotic protein belonging to the B-cell lymphoma 2 (Bcl-2) family of proteins, is upregulated in cancer cells and promotes tumor cell survival.	Murizatoclax		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156741>	C129822|C128057	Manelimab|BCD 135|BCD-135|BCD135|MANELIMAB	A monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, manelimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156742>	C2124	Carbon C 11-osimertinib|11C-osimertinib|[11C] Osimertinib|[11C]AZD9291	A radioconjugate composed of osimertinib, a third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, labeled with the positron-emitting isotope carbon C 11, with potential use in imaging via positron emission tomography (PET).  Upon intravenous administration of carbon C 11 osimertinib, the osimertinib targets and binds to mutant forms of EGFR on tumor cells. Upon PET imaging, this radioligand may allow for the assessment of EGFR mutant-expressing tumor cells. This also allows assessment of osimetinib's pharmacokinetic profile and affinity of EGFR mutant-positive cancer cells and may identify patients who may respond well to osimertinib.			Indicator, Reagent, or Diagnostic Aid|Organic Chemical|Pharmacologic Substance	NCI Drug Dictionary Terminology
C156743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156743>	C156804	Mevrometostat|1(2H)-Isoquinolinone, 5,8-Dichloro-2-((1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl)-3,4-dihydro-7-((R)-methoxy-3-oxetanylmethyl)-|EZH2 Inhibitor PF-06821497|MEVROMETOSTAT|PF 06821497|PF-06821497|PF06821497	An orally available selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2), with potential antineoplastic activity. Upon oral administration, mevrometostat selectively targets, binds to and inhibits the activity of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 on lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased proliferation of EZH2-expressing cancer cells. EZH2, an HMT class enzyme and the catalytic subunit of the polycomb repressive complex 2 (PRC2), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation; its expression is correlated with tumor initiation, progression, stem cell self-renewal, migration and angiogenesis.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156744>	C220789	Opevesostat|CYP11A1 inhibitor ODM-208|MK 5684|MK-5684|MK5684|ODM 208|ODM-208|ODM208|OPEVESOSTAT	An orally bioavailable, non-steroidal, selective inhibitor of the enzyme cytochrome 450 side-chain cleavage (scc) (CYP11A1), with potential antineoplastic activity. Upon oral administration, opevesostat targets, binds to and inhibits the activity of CYP11A1. This prevents the synthesis of all steroid hormones and their precursors. This may inhibit proliferation of hormone-positive tumor cells. CYP11A1, a mitochondrial enzyme, catalyzes the conversion of cholesterol to pregnenolone (Preg), which is the first rate-liming step in steroid hormone biosynthesis.	Opevesostat		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156745>	C162766|C142867	Locally Advanced Microsatellite Stable Colorectal Carcinoma	A microsatellite stable colorectal carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Microsatellite Stable Colorectal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156746>	C175547|C153171|C133839	Advanced Digestive System Carcinoma	Digestive system carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Digestive System Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156747>	C18194	AssureMDx	A proprietary non-invasive, urine-based test that uses methylation and mutation biomarkers to assess the risk of bladder cancer for patients diagnosed with hematuria.	AssureMDx		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C156748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156748>	C18485	Millimeter-Wave Holographic Imaging|Holographic Millimeter-wave Imaging|Holographic mm-Wave Imaging|MMW|MMW Holographic Imaging|MMW Imaging|Millimeter-wave Imaging	An imaging technology that uses non-ionizing, millimeter-length electromagnetic waves (30GHz to 300GHz) to scan the surface of an object or body. Millimeter-wave imaging (MMW) can image through non-polar and non-metallic materials such as clothing, plastic, and cardboard with relatively little energy loss. Compared to microwaves and radio-frequency waves, MMW can achieve better spatial resolution due to its shorter wavelength. MMW is harmless to humans.	Millimeter-Wave Holographic Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C156749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156749>	C17103	Melanoma Risk Factor	Any factor, such as age, ethnicity, genetic factor, family history, or environmental factor, that increases a person's chance of developing melanoma.			Clinical Attribute	
C15674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15674>	C15669	Prevention of Endometrial Cancer|Endometrial Cancer Prevention	Any method of preventing endometrial cancer including limit of exposure to carcinogens and infectious agents, diet, education, or lifestyle.			Therapeutic or Preventive Procedure	
C156750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156750>	C97927	PPP2R2A Gene Mutation|B55-Alpha Gene Mutation|B55A Gene Mutation|B55ALPHA Gene Mutation|PR52A Gene Mutation|PR55-Alpha Gene Mutation|PR55A Gene Mutation|PR55alpha Gene Mutation|Protein Phosphatase 2 Regulatory Subunit Balpha Gene Mutation	A change in the nucleotide sequence of the PPP2R2A gene.	PPP2R2A Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156751>	C97927	TNFAIP3 Gene Mutation|A20 Gene Mutation|OTUD7C Gene Mutation|TNF Alpha Induced Protein 3 Gene Mutation|TNFA1P2 Gene Mutation	A change in the nucleotide sequence of the TNFAIP3 gene.	TNFAIP3 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156752>	C165233	SDHB Negative|IP Negative|Negative|SDH1 Negative|SDH2 Negative|SDHB Deficiency|SDHB Deficient|SDHB Loss|SDHIP Negative|Succinate Dehydrogenase Complex Iron Sulfur Subunit B Negative|Succinate Dehydrogenase [Ubiquinone] Iron-Sulfur Subunit, Mitochondrial Negative	An indication that SDHB expression or activity has not been detected in a sample.	SDHB Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156753>	C150711	Neoplastic Plasma Cells 10-59 Percent of Bone Marrow Nucleated Cells|Neoplastic Plasma Cells Between 10 and 59 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that between 10 and 59 percent of the nucleated cells in a bone marrow sample are neoplastic plasma cells.	Neoplastic Plasma Cells 10-59 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C156754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156754>	C18962|C15958	Proximity Ligation Assay|PLA	A technique that leverages immunoassay and DNA amplification technology to detect protein-protein interactions with high specificity and sensitivity. A sample is prepared and then exposed to primary antibodies raised in different species recognizing the target epitopes on the proteins of interest. Then, secondary antibodies that are tagged with short oligonucleotides and that target each primary antibody are added. Next, a mixture comprised of a ligase, PCR components and a connector oligonucleotide, which hybridizes to both oligonucleotide tags and can prime rolling DNA circle synthesis, are added and the sample is subjected to real-time PCR to amplify the DNA circles. Rolling circle synthesis and amplification is only possible if the protein epitopes are in close proximity (i.e. in a protein complex). Finally, a labeled complementary nucleotide probe is added to detect and/or visualize the amplified DNA.			Laboratory Procedure	
C156755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156755>	C36292	Raf/KSR/Mek1 Trimer|RAF/KSR/MAP2K1 Trimer|Raf/KSR/MAPKK1 Trimer|Raf/KSR/MKK1 Trimer|Raf/KSR/Mek1 Trimers|Raf/KSR/PRKMK1 Trimer	An indication that trimeric protein complexes containing a RAF family protein, a kinase suppressor of Ras (KSR) family protein and MAP2K1 have been detected after subjecting a sample to a proximity ligation assay.	Raf/KSR/Mek1 Trimer		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156756>	C36292	bRaf/cRaf Dimer|BRAF/RAF1 Dimer|bRaf/cRaf Dimers	An indication that dimeric protein complexes containing BRAF and RAF1 have been detected after subjecting a sample to a proximity ligation assay.	bRaf/cRaf Dimer		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156757>	C4621|C3630|C2855	Parathyroid Gland Adenoma|ADENOMA, PARATHYROID GLAND, BENIGN	A benign ovoid parathyroid gland neoplasm surrounded by a pseudocapsule. It is composed of chief cells, clear cells, oncocytic cells, or a mixture of cell types. It lacks the morphological characteristics of parathyroid gland carcinoma and there is no evidence of capsular invasion, vascular invasion, and perineural invasion.			Neoplastic Process	CDISC SEND Terminology|CDISC SEND Tumor Findings Results Terminology|Cellosaurus Disease Terminology|Clinical Data Interchange Standards Consortium Terminology
C156758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156758>	C158948	RELA Fusion Positive|NF-Kappa B p65 Fusion Positive|NF-Kappa-B Transcription Factor p65 Fusion Positive|NFKB3 Fusion Positive|NFkB p65 Fusion Positive|Nuclear Factor Kappa-B Subunit 3 Fusion Positive|Nuclear Factor of Kappa Light Chain Gene Enhancer in B Cells 3 Fusion Positive|Nuclear Factor of Kappa Light Polypeptide Gene Enhancer in B-Cells 3 Fusion Positive|Transcription Factor p65 Fusion Positive|p65 Fusion Positive|v-REL Avian Reticuloendotheliosis Viral Oncogene Homolog A Fusion Positive	An indication that expression of a fusion containing sequences from RELA has been detected in a sample.	RELA Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156759>	C158131	PRMT1 Inhibitor GSK3368715|GSK 3368715|GSK-3368715|GSK3368715|Protein Arginine Methyltransferase 1 Inhibitor GSK3368715	An orally available inhibitor of protein arginine N-methyltransferase 1 (PRMT1; Histone-arginine N-methyltransferase PRMT1; Interferon receptor 1-bound protein 4) with potential antineoplastic activity. Upon administration, GSK3368715 inhibits monomethylation and asymmetric dimethylation of arginine-bearing substrates, including histones, estrogen receptors, RNA-binding proteins, and numerous non-histone substrates catalyzed by PRMT1. This may inhibit tumor cell proliferation, migration, and invasion that is potentially driven by PRMT1 overexpression or dysregulation. PRMT1-mediated methylation plays a key role in the modulation of protein function, gene expression and cellular signaling. Dysregulation and overexpression of PRMT1 has been associated with a number of solid and hematopoietic cancers.	PRMT1 Inhibitor GSK3368715		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15675>	C16212	Adjuvant Therapy|AJ-Adjuvant Therapy|adjunct therapy|adjunctive therapy|adjuvant therapy|adjuvant therapy	Any therapy that is administered to augment or stimulate other treatment modalities or to minimize or prevent disease recurrence subsequent to the main treatment plan.	Adjuvant Therapy		Therapeutic or Preventive Procedure	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C156760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156760>	C97927	PPM1D Gene Mutation|IDDGIP Gene Mutation|PP2C-DELTA Gene Mutation|PPMID|Protein Phosphatase 1D Gene Mutation|Protein Phosphatase 1D Magnesium-Dependent, Delta Isoform Gene Mutation|Protein Phosphatase 2C, Delta Isoform Gene Mutation|Protein Phosphatase, Mg2+/Mn2+ Dependent 1D Gene Mutation|WIP1 Gene Mutation|Wild-Type p53-Induced Phosphatase 1 Gene Mutation	A change in the nucleotide sequence of the PPM1D gene.	PPM1D Gene Mutation		Cell or Molecular Dysfunction	CRF8 Pathology Review Targeted Genomics Table|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C156761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156761>	C178120|C156760	Activating PPM1D Gene Mutation|Activating IDDGIP Gene Mutation|Activating PP2C-DELTA Gene Mutation|Activating Protein Phosphatase 1D Gene Mutation|Activating Protein Phosphatase 1D Magnesium-Dependent, Delta Isoform Gene Mutation|Activating Protein Phosphatase 2C, Delta Isoform Gene Mutation|Activating Protein Phosphatase, Mg2+/Mn2+ Dependent 1D Gene Mutation|Activating WIP1 Gene Mutation|Activating Wild-Type p53-Induced Phosphatase 1 Gene Mutation|PPM1D Activating Mutation	A change in the nucleotide sequence of the PPM1D gene that results in constitutive activation of protein phosphatase 1D and its downstream signaling pathways.	Activating PPM1D Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156762>	C45581	PPM1D Gene Amplification|IDDGIP Gene Amplification|PP2C-DELTA Gene Amplification|Protein Phosphatase 1D Gene Amplification|Protein Phosphatase 1D Magnesium-Dependent, Delta Isoform Gene Amplification|Protein Phosphatase 2C, Delta Isoform Gene Amplification|Protein Phosphatase, Mg2+/Mn2+ Dependent 1D Gene Amplification|WIP1 Gene Amplification|Wild-Type p53-Induced Phosphatase 1 Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the PPM1D gene.	PPM1D Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C156763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156763>	C45581	MDM4 Gene Amplification|HDMX Gene Amplification|MDM4, p53 Regulator Gene Amplification|MDMX Gene Amplification|Mouse Double Minute 4 Homolog Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the MDM4 gene.	MDM4 Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156764>	C16152	HER2/Neu Low Expression|ERBB2 Low Expressing|ERBB2 Low Expression|HER-2 Low Expression|HER2 Low Expressing|HER2 Low Expression|HER2/Neu Low Expressing	An indication that HER2/Neu (ERBB2) expression was detected at low levels in a sample.	HER2/Neu Low Expression		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156765>	C17369	Static Imaging|Static Acquisition|Static Scan	Imaging data acquired over a single time frame. The result is a single frame that represents the average amount of radioactivity during the scan period. Only semi-quantitative information can be derived from static acquisitions (e.g., relative tracer uptake).			Diagnostic Procedure	
C156766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156766>	C78272	Meclinertant|2-((1-(7-Chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)pyrazol-3-yl)carbonylamino)tricyclo(3.3.1.1.(3.7))decan-2-carboxylic Acid|MECLINERTANT|SR 48692|SR-48692|SR48692|Tricyclo(3.3.1.13,7)decane-2-carboxylic Acid, 2-(((1-(7-Chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl)carbonyl)amino)-				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C156767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156767>	C3784|C2916	Basal Cell Carcinoma|Malignant Basal Cell Neoplasm	A carcinoma involving the basal cells.	Basal Cell Carcinoma		Neoplastic Process	CPTAC Codelists Terminology|CPTAC Neoplasms Codelist|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Morphology PT Terminology|Mapped ICDO3.1 Morphology Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C156768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156768>	C62227	Malignant Basal Cell				Cell	
C156769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156769>	C3482|C156767	Metastatic Basal Cell Carcinoma	A carcinoma that arises from the basal cells and has metastasized to another anatomic site.	Metastatic Basal Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C15676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15676>	C94632	Androgen Suppression|Androgen Ablation|Androgen Deprivation|Testosterone Suppression|androgen ablation|androgen deprivation|androgen suppression	Blockage of the production of male hormones.			Therapeutic or Preventive Procedure	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C156770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156770>	C156769|C148130	Locally Advanced Basal Cell Carcinoma	A basal cell carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Basal Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156771>	C7902	Biochemically Recurrent Prostate Carcinoma|BCR Prostate Carcinoma|Micro-Metastatic Prostate Carcinoma|PSA-Only (Biochemically) Recurrent Prostate Carcinoma|PSA-Only Recurrent Prostate Carcinoma	Increasing prostate-specific antigen (PSA) following prostatectomy or radiation therapy in a patient with a history of localized prostate carcinoma. Signs of metastasis are absent using the currently available scanning technology.	Biochemically Recurrent Prostate Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156772>	C2124	Copper Cu 64-CB-TE1A1P-PEG4-LLP2A|(64)Cu-CB-TE1A1P-PEG4-LLP2A|(64)Cu-labeled CB-TE1A1P-PEG4 LLP2A|(64)Cu-labeled CB-TE1A1P-PEG4-LLP2A|64Cu-CB-TE1A1P-PEG4-LLP2A|64Cu-LLP2A|64Cu-PEG4-LLP2A|Copper Cu 64-LLP2A|Cu[64]-CB-TE1A1P-PEG4-LLP2A	A radioconjugate containing LLP2A, a high-affinity peptidomimetic ligand for the tumor-associated antigen (TAA) very-late-antigen-4 (VLA-4; VLA 4; alpha4beta1 integrin; CD49d/CD29), conjugated, via the chelator 1,4,8,11-tetraazacyclotetradecane-1-(methane phosphonic acid)-8-(methane carboxylic acid) (CB-TE1A1P), to the radioisotope copper Cu 64, and conjugated to polyethylene glycol (PEG) chains that can potentially be used as a diagnostic imaging agent of VLA-4-expressing tumor cells using positron-emitting tomography (PET). Upon administration, copper Cu 64-CB-TE1A1P-PEG4-LLP2A targets, binds to and is taken up by VLA-4-expressing tumor cells. Upon PET, the VLA-4-expressing tumor cells can be visualized, and the tumor can be assessed. VLA-4, a transmembrane adhesion receptor overexpressed and activated on various tumor cell types and surrounding stroma, plays an important role in tumor growth, angiogenesis, metastasis, drug resistance and immune responses. Pegylation optimizes the pharmacokinetic profile of 64Cu-LLP2A.	Copper Cu 62-ATSM|Copper Cu 64-CB-TE1A1P-PEG4-LLP2A		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C156774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156774>	C129825|C129650	Golidocitinib|AZD 4205|AZD-4205|AZD4205|GOLIDOCITINIB|JAK1 Inhibitor AZD4205	An orally available inhibitor of Janus-associated kinase 1 (JAK1), with potential antineoplastic activity. Upon oral administration, golidocitinib inhibits JAK-dependent signaling and may lead to an inhibition of cellular proliferation in JAK1-overexpressing tumor cells. The JAK-STAT (signal transducer and activator of transcription) signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types. Additionally, JAK1 may be a primary driver of STAT3 phosphorylation and signaling, which plays a role in neoplastic transformation, resistance to apoptosis, tumor angiogenesis, metastasis, immune evasion, and treatment resistance.	Golidocitinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156775>	C62736	Neurocognitive Assessment	Tests to assess aspects of cognition, including attention, memory, language, reaction time, and perception.	Neurocognitive Assessment		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C156776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156776>	C62736	Cognitive Electrophysiology Assessment	Assessments of cognition that focus on intracranial recordings of brain activity.	Cognitive Electrophysiology Assessment		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C156777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156777>	C574|C2169	Farudodstat|ASLAN 003|ASLAN-003|ASLAN003|DHODH Inhibitor ASLAN003|Dihydroorotate Dehydrogenase Inhibitor ASLAN003|FARUDODSTAT	An orally available inhibitor of dihydroorotate dehydrogenase (DHODH), with potential antineoplastic activity. Upon administration, farudodstat specifically targets, binds to and prevents the activation of DHODH, thereby preventing the fourth enzymatic step in de novo pyrimidine synthesis. This prevents uridine monophosphate (UMP) formation, DNA synthesis, cell division and cellular proliferation, causes reactive oxygen species (ROS) formation, enables differentiation and induces apoptosis in susceptible tumor cells. DHODH, a mitochondrial enzyme, catalyzes the conversion of dihydroorotate (DHO) to orotate in the endogenous synthesis of UMP.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C156778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156778>	C38060	Vision Assessment	Tests to assess the ability to focus on and discern objects, colors, depth, etc.	Vision Assessment		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C156779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156779>	C29867	Entity With Role in Clinical Study|participant	Any person or entity that has a role or participates in a clinical research study, including both study personnel and study subjects.			Human	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C15677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15677>	C48935	Axillary Lymph Node Dissection|ALND|Axillary Dissection|Axillary Lymphadenectomy|Axillary Node Dissection|Excision Axillary Lymph Nodes|axillary dissection|axillary lymph node dissection	Surgical removal of the lymph nodes located in the cavity beneath the junction of the arm and the thorax, or axilla (armpit).  This procedure is commonly performed as a component of cancer staging.	Axillary Lymph Node Dissection		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C156781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156781>	C8609|C2899|C166418	Biliary Tract Carcinoma	A carcinoma arising from the intrahepatic bile ducts, hepatic ducts, common bile duct, cystic duct, or gallbladder.	Biliary Tract Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156782>	C7622|C156781	Recurrent Biliary Tract Carcinoma	The reemergence of a carcinoma arising from any part of the biliary tract after a period of remission.	Recurrent Biliary Tract Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156783>	C16830	Laryngeal Mask Airway|LMA|Laryngeal Mask	A supraglottic airway device that is composed of an airway tube that connects to an inflatable elliptical mask on the distal end which is inserted through the patient's mouth, down the trachea, and inflated to form an airtight seal on top the glottis.	Laryngeal Mask Airway		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C156784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156784>	C27993	Mature|MATURE|Maturity	Having reached a completed state of growth and development.			Qualitative Concept	CDISC SEND Microscopy Sexual Maturity Status Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C156785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156785>	C13442	Skeletally Mature|Skeletal Maturity	An indication that an individual's growth plates are fused and that bone growth has ceased.			Spatial Concept	
C156786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156786>	C13442	Skeletally Immature|Skeletal Immaturity	An indication that an individual's growth plates are open and that bone growth is likely to continue.			Spatial Concept	
C156787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156787>	C35869	Bone Age|Skeletal Age|Skeletal Maturity	An indication of skeletal growth potential based on skeletal maturity indicators, such as radiologic imaging of growth plates.			Finding	
C156788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156788>	C157330|C156769|C153315	Metastatic Unresectable Basal Cell Carcinoma	A basal cell carcinoma that has spread from its original site of growth to another anatomic site and is not amenable to surgical resection.			Neoplastic Process	
C156789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156789>	C156788|C156770|C155698	Locally Advanced Unresectable Basal Cell Carcinoma	A basal cell carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.	Locally Advanced Unresectable Basal Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C15678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15678>	C21087	Bolus Infusion Procedure|Bolus|Bolus Infusion|bolus dose	A procedure in which a single dose of a pharmalogical substance is administered, generally via injection, over a short period of time.			Therapeutic or Preventive Procedure	
C156790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156790>	C3063	Maternally Derived Graft Versus Host Disease|Maternally Derived GVHD	Graft versus host disease (GVHD) that occurs in an infant as the result of engraftment of maternal lymphocytes, resulting from in utero maternal-fetal cellular trafficking.			Disease or Syndrome	
C156791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156791>	C201512|C129822	Anti-PVRIG Monoclonal Antibody COM701|Anti-poliovirus Receptor-related Immunoglobulin COM701|COM 701|COM-701|COM-701|COM701|PVRIG Inhibitor COM701	A humanized, hybridoma monoclonal antibody against the poliovirus receptor-related immunoglobulin (PVRIG; PVR Related Immunoglobulin Domain Containing Protein; CD112R), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PVRIG monoclonal antibody COM701 targets and binds to PVRIG expressed on cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells within the tumor microenvironment (TME). This blocks the interaction of PVRIG with its ligand nectin cell adhesion molecule 2 (poliovirus receptor-related 2; PVRL2; CD112), which is overexpressed on a variety of tumor cell types. Inhibiting the activation of PVRIG, abrogates the PVRIG-induced inhibition of T-lymphocyte and NK cell activation. This activates CTLs and NK cells, enhances anti-tumor responses and immune-mediated tumor cell killing, and inhibits tumor cell proliferation. PVRIG, a member of the B7/CD28 family and immune checkpoint receptor that, upon activation, negatively regulates the activation of various immune cells. It plays a key role in immunosuppression.	Anti-PVRIG Monoclonal Antibody COM701		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156792>	C1404	Elraglusib|9 ING 41|9-ING-41|ELRAGLUSIB|GSK-3 Inhibitor 9-ING-41|Glycogen Synthase Kinase-3 Inhibitor 9-ING-41	A maleimide-based, small molecule inhibitor of glycogen synthase kinase-3 (GSK-3; serine/threonine-protein kinase GSK3) with potential antineoplastic activity. Upon intravenous administration, elraglusib binds to and competitively inhibits GSK-3, which may lead to downregulation of nuclear factor kappa B (NF-kappaB) and decreased expression of NF-kappaB target genes including cyclin D1, B-cell lymphoma 2 (Bcl-2), anti-apoptotic protein XIAP, and B-cell lymphoma extra-large (Bcl-XL). This may inhibit NF-kappaB-mediated survival and chemoresistance in certain tumor types. GSK-3, a constitutively active serine/threonine kinase that plays a role in numerous pathways involved in protein synthesis, cellular proliferation, differentiation, and metabolism, is aberrantly overexpressed in certain tumor types and may promote tumor cell survival and resistance to chemotherapy and radiotherapy.	Elraglusib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156793>	C36263|C27718	Metastatic Human Papillomavirus-Related Malignant Neoplasm	A malignant neoplasm that is associated with human papillomavirus infection and has spread from its original site of growth to another anatomic site.	Metastatic Human Papillomavirus-Related Malignant Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156794>	C1967|C129825	ITK Inhibitor|Interleukin-2-inducible Kinase Inhibitor	Any agent that inhibits interleukin-2-inducible kinase (ITK).	AXL Inhibitor TP-0903|ITK Inhibitor		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C156795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156795>	C15477	Prior Radiation Therapy of Affected Breast|Prior Ipsilateral Breast Radiation Therapy	An indication that an individual has previously received radiation treatment of their currently affected breast.	Prior Radiation Therapy of Affected Breast		Clinical Attribute	CTRP Intervention Terminology|CTRP Terminology
C156796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156796>	C16171|C156797	Prior Systemic Chemotherapy for Current Cancer	An indication that an individual has previously received systemic chemotherapy for their current malignancy.	Prior Systemic Chemotherapy for Current Cancer		Clinical Attribute	CTRP Intervention Terminology|CTRP Terminology
C156797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156797>	C156800	Prior Systemic Therapy for Current Cancer	An indication that an individual has previously received systemic therapy for their current malignancy.	Prior Systemic Therapy for Current Cancer		Clinical Attribute	CTRP Intervention Terminology|CTRP Terminology
C156798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156798>	C25869|C20103	PVRIG Gene|PVR Related Immunoglobulin Domain Containing Gene|PVRIG|PVRIG	This gene plays a role in the inhibition of T-cell activation and proliferation.			Gene or Genome	
C156799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156799>	C156798	PVRIG wt Allele|C7orf15|CD112R|Chromosome 7 Open Reading Frame 15 Gene|MGC2463|PVR Related Immunoglobulin Domain Containing wt Allele|Poliovirus Receptor Related Immunoglobulin Domain Containing Gene	Human PVRIG wild-type allele is located in the vicinity of 7q22.1 and is approximately 5 kb in length. This allele, which encodes transmembrane protein PVRIG, may be involved in immune checkpoint signaling.			Gene or Genome	
C15679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15679>	C49236	Consolidation Therapy|Consolidation|Consolidation|Consolidation|Consolidation|Consolidation|Post Remission Therapy|Postremission Therapy|consolidation therapy|intensification therapy|postremission therapy	Treatment that is given after initial therapy to kill any remaining cancer cells.			Therapeutic or Preventive Procedure	ALL Authorized Value Terminology|ALL Course Timing Table|ALL Histology Table|ALL Off Protocol Therapy/Study Table|ALL Vitals Table|AML Adverse Events Table|AML Authorized Value Terminology|AML Cellular Immunotherapy Table|AML Concomitant Medication Table|AML Course Timing Table|AML Function Test Table|AML Lab Table|AML Minimal Residual Disease Table|AML Molecular Analysis Table|AML Myeloid Sarcoma Involvement Table|AML Off Protocol Therapy/Study Table|AML Radiation Therapy Table|AML Secondary Malignant Neoplasm Table|AML Stem Cell Transplant Table|AML Subject Response Table|AML Survival Characteristics Table|AML Total Dose Table|AML Transfusion Medicine Procedures Table|AML Vitals Table|CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Terminology|EWS Adverse Events Table|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Course Timing Table|EWS Histology Table|EWS Immunohistochemistry Table|EWS Lab Table|EWS Molecular Analysis Table|EWS Non-Protocol Therapy Table|EWS Off Protocol Therapy/Study Table|EWS Radiation Therapy Table|EWS Secondary Malignant Neoplasm Table|EWS Stem Cell Transplant Table|EWS Subject Response Table|EWS Survival Characteristics Table|EWS Tumor Assessment Table|EWS Vitals Table|GDC Terminology|GDC Value Terminology|OS Adverse Event Table|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Function Test Table|OS Histology Table|OS Lab Table|OS Molecular Analysis Table|OS Off Protocol Therapy/Study Table|OS Radiation Therapy Table|OS Secondary Malignant Neoplasm Table|OS Subject Response Table|OS Survival Characteristics Table|OS Total Dose Table|OS Tumor Assessment Table|OS Vitals Table
C1567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1567>	C799|C2199	Strontium Sr-89|STRONTIUM SR-89|Strontium-89|strontium-89	A radioisotope of strontium, a heavy metal found naturally as a non-radioactive element.  With a half-life of 50 days, strontium-89 is a beta emitter that is metabolized much like calcium.  This agent is preferentially absorbed by osteoblastic bone metastases. (NCI04)			Element, Ion, or Isotope|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology
C156800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156800>	C16124	Prior Treatment of Current Cancer	An indication that an individual has previously received therapy for their current malignancy.	Prior Treatment of Current Cancer		Clinical Attribute	CTRP Intervention Terminology|CTRP Terminology
C156801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156801>	C3108	Treatment-sensitive HIV Infection	An infection with human immunodeficiency virus that responds to therapy.	Treatment-sensitive HIV Infection		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C156802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156802>	C15569	Radiation to Greater than 25 Percent of Bone Marrow|Radiation to More than 25 Percent of Bone Marrow	Bone marrow irradiation targeting greater than 25 percent of the total bone marrow.	Radiation to Greater than 25 Percent of Bone Marrow		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C156803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156803>	C18106	Transmembrane Protein PVRIG|CD 112R|CD112 Receptor|CD112R|Nectin-2 Receptor|Poliovirus Receptor Related Immunoglobulin Domain Containing Protein|Poliovirus Receptor-Related Immunoglobulin Domain-Containing Protein	Transmembrane protein PVRIG (326 aa, ~34 kDa) is encoded by the human PVRIG gene. This protein plays a role in the inhibition of T-cell-mediated immunity.			Amino Acid, Peptide, or Protein|Receptor	
C156804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156804>	C223203	EZH2 Inhibitor|Enhancer of Zeste Homolog 2 Inhibitor	Any agent that inhibits the histone lysine methyltransferase EZH2.	EZH2 Inhibitor		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology|NCIt Antineoplastic Agent Terminology
C156805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156805>	C48191	Tumor Event Information				Clinical Attribute	
C156806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156806>	C40558	New Primary Tumor|New Primary	A finding indicating the development of a tumor in a patient with a history of a previously diagnosed tumor with a different histopathologic profile in another anatomic site as compared to the most recent one.			Finding	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|GDC Terminology|GDC Value Terminology
C156807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156807>	C164324	CPTAC Case Identifier|CPTAC Case ID	The identifier assigned to a case within the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC).			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Medical History Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Normal Endometrial Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Surgery-Anesthesia Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form
C156808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156808>	C164616	Tissue Source Site Identifier|TSS ID|TSS ID	An identifier assigned to a tissue source site.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Medical History Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Normal Endometrial Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Surgery-Anesthesia Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form
C156809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156809>	C25457	Medical Condition	Any kind of illness or circumstance which requires medical monitoring.			Conceptual Entity	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C15680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15680>	C15190	Core Biopsy|BIOPSY, CORE|CNB|Core Needle|Core Needle Biopsy|Core Needle Biopsy|Core Needle Biopsy|Core Needle Biopsy|Needle Biopsy|core biopsy|core needle biopsy	The removal of a tissue sample using a needle with a relatively large diameter, for microscopic examination.	Core Biopsy		Diagnostic Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Specimen Collection Method Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Intervention Terminology|CTRP Terminology|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Biopsy/Surgical Procedures Table|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table
C156810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156810>	C156805	New Tumor Event Information|New Tumor Event	Data pertinent to a newly discovered tumor.			Temporal Concept	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C156811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156811>	C173812|C158612	Is there a History of Treatment Question|History of Treatment|History of Treatment|Is there a History of Treatment	A question about whether there is a known history of treatments.			Clinical Attribute	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C156812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156812>	C25683	Medical History Source	The source providing the medical history.			Qualitative Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C156813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156813>	C15220	Initial Diagnosis|INITIAL DIAGNOSIS	The first diagnosis of the individual's condition.			Diagnostic Procedure	ALL Authorized Value Terminology|ALL Disease Characteristics Table|ALL Disease Phase Timing Table|ALL Histology Table|ALL Off Protocol Therapy/Study Table|ALL Vitals Table|AML Adverse Events Table|AML Authorized Value Terminology|AML Cellular Immunotherapy Table|AML Concomitant Medication Table|AML Disease Characteristics Table|AML Disease Phase Timing Table|AML Function Test Table|AML Lab Table|AML Minimal Residual Disease Table|AML Molecular Analysis Table|AML Myeloid Sarcoma Involvement Table|AML Off Protocol Therapy/Study Table|AML Radiation Therapy Table|AML Secondary Malignant Neoplasm Table|AML Stem Cell Transplant Table|AML Subject Response Table|AML Survival Characteristics Table|AML Total Dose Table|AML Transfusion Medicine Procedures Table|AML Vitals Table|CDISC SDTM Medical History Event Date Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|EWS Adverse Events Table|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Disease Characteristics Table|EWS Disease Phase Timing Table|EWS Histology Table|EWS Immunohistochemistry Table|EWS Lab Table|EWS Molecular Analysis Table|EWS Non-Protocol Therapy Table|EWS Off Protocol Therapy/Study Table|EWS Radiation Therapy Table|EWS Secondary Malignant Neoplasm Table|EWS Stem Cell Transplant Table|EWS Subject Response Table|EWS Survival Characteristics Table|EWS Tumor Assessment Table|EWS Vitals Table|GCT Adverse Events Table|GCT Authorized Value Terminology|GCT Biopsy/Surgical Procedures Table|GCT Concomitant Medication Table|GCT Cytology Table|GCT Disease Characteristics Table|GCT Disease Phase Timing Table|GCT Growing Teratoma Syndrome Table|GCT Histology Table|GCT Immunohistochemistry Table|GCT Lab Table|GCT Molecular Analysis Table|GCT Radiation Therapy Table|GCT Secondary Malignant Neoplasm Table|GCT Staging Table|GCT Stem Cell Transplant Table|GCT Subject Response Table|GCT Survival Characteristics Table|GCT Total Dose Table|GCT Tumor Assessment Table|GCT Vitals Table|GDC Terminology|GDC Value Terminology|HL Adverse Events Table|HL Authorized Value Terminology|HL Biopsy/Surgical Procedures Table|HL Concomitant Medication Table|HL Disease Characteristics Table|HL Disease Phase Timing Table|HL Function Test Table|HL Histology Table|HL Imaging Table|HL Immunohistochemistry Table|HL Lab Table|HL Lesion Characteristics Table|HL Off Protocol Therapy/Study Table|HL Protocol Treatment Modifications Table|HL Radiation Therapy Table|HL Secondary Malignant Neoplasm Table|HL Staging Table|HL Stem Cell Transplant Table|HL Subject Response Table|HL Survival Characteristics Table|HL Total Dose Table|HL Transfusion Medicine Procedures Table|HL Vitals Table|OS Adverse Event Table|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Disease Phase Timing Table|OS Function Test Table|OS Histology Table|OS Lab Table|OS Molecular Analysis Table|OS Off Protocol Therapy/Study Table|OS Radiation Therapy Table|OS Secondary Malignant Neoplasm Table|OS Subject Response Table|OS Survival Characteristics Table|OS Total Dose Table|OS Tumor Assessment Table|OS Vitals Table
C156814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156814>	C226301	Date of Last Therapy|Date of Last Radiation Therapy, Chemotherapy, Molecular Targeted Therapy, Immunotherapy Treatment|date of last dose any therapy|date_of_last_dose_any_therapy	The date of the last radiation treatment, chemotherapy, molecular targeted therapy, or immunotherapy treatment.			Temporal Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology|ICDC Property Terminology|ICDC Terminology
C156815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156815>	C156814	Date of Last Chemotherapy Treatment	The date of the last administration of chemotherapy.			Temporal Concept	
C156816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156816>	C25164	Month-Day-Year|MM/DD/YYYY|MM/DD/YYYY	A format of a date in time, with the month followed by the date followed by the year.			Temporal Concept	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Medical History Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form
C156817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156817>	C91102	Medical Record Documentation about this History of Cancer Treatment Question|Is there Medical Record Documentation of this History of Cancer and Treatment|Medical Record Documentation about this History of Cancer Treatment	The documentation in the medical record regarding previous treatment for cancer.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C156818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156818>	C21090	Current Medication|Current Medications	The current medications an individual is taking.			Therapeutic or Preventive Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C156819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156819>	C25164	Date of Last Administration|date last medication administration|date_last_medication_administration	The date of the last administration of the substance of interest.			Temporal Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology|ICDC Property Terminology|ICDC Terminology
C15681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15681>	C15986|C15632	Cytotoxic Chemotherapy|Cytotoxic|Cytotoxic Therapy|cytotoxic chemotherapy	A drug therapy that is used to destroy cancer cells.	Cytotoxic Chemotherapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C156820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156820>	C178341	Alcohol Consumption Equal to or Less than 2 Drinks per Day for Men and 1 Drink or Less per Day for Women|Alcohol consumption equal to or less than 2 drinks per day for men and 1 drink or less per day for women	Alcohol consumption equal to or less than two drinks per day for men and one drink or less per day for women.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C156821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156821>	C178341	Alcohol Consumption More than 2 Drinks per Day for Men and More than 1 Drink per Day for Women|Alcohol consumption more than 2 drinks per day for men and more than 1 drink per day for women	Alcohol consumption more than two drinks per day for men and more than one drink per day for women.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C156822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156822>	C178341	Current non-drinker with Past Alcohol Consumption|Consumed alcohol in the past, but currently a non-drinker	An indication that an individual has consumed alcohol in the past, but is currently a non-drinker.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C156823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156823>	C178341	Alcohol Use History Not Available|Alcohol consumption history not available	An indication that the alcohol use history of an individual is unavailable.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C156824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156824>	C178341	Number of Years When Consumed More than 2 Drinks per Day for Men and More than 1 Drink per Day for Women|Number of years Participant has consumed more than 2 drinks per day for men and more than 1 drink per day for women	The number of years an individual has consumed more than 2 drinks per day for men and more than 1 drink per day for women.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C156825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156825>	C18772	Smoking History	The history of when and what an individual smoke(s) or smoked.			Clinical Attribute	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C156826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156826>	C175313	Lifelong non-smoker Less than 100 cigarettes smoked in lifetime	An individual who has smoked less than 100 cigarettes in their lifetime.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C156827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156827>	C175313	Current Smoker Includes Daily and Non-daily Smokers|Current smoker Includes daily and non-daily smokers	An indication that an individual is a current smoker that may or may not smoke daily.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C156828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156828>	C67148	Current Reformed Smoker, More than 15 Years|Current Reformed Smoker for > 15 yrs|Current reformed smoker, more than 15 years	An individual who stopped smoking more than 15 years prior.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C156829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156829>	C67148	Current Reformed Smoker Within Past 15 Years|Current Reformed Smoker for < or = 15 yrs|Current reformed smoker within past 15 years	An individual who stopped smoking within the past 15 years.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C15682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15682>	C15697	Dose-Rate|DOSFRQ|dose-rate	The amount of any substance administered over a specific period of time.			Quantitative Concept	CDISC Root Variable Terminology
C156830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156830>	C67148	Current Reformed Smoker, Years Unknown|Current Reformed Smoker, Duration Not Specified|Current reformed smoker, years unknown	An individual who stopped smoking an unknown number of years prior.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C156831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156831>	C175313	Smoking History Not Available|Smoking history not available	An indication that the smoking history of an individual is unavailable.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C156832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156832>	C175313	Age Which Participant Stopped Smoking|The age at which the participant stopped smoking	The chronological age at which an individual stopped smoking.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C156833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156833>	C173060	When Participant Smoked, How Many Cigarettes Smoked Question|On the days that the Participant smoked, how many cigarettes did s/he usually smoke?|When Participant Smoked, How Many Cigarettes Smoked	How many cigarettes did an individual smoke when they smoked.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C156834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156834>	C175313	Number of Pack Years Smoked|Number of pack years smoked	A measurement of the amount of smoking exposure an individual has had over time, which is calculated by multiplying the number of cigarettes smoked per day by the number of years smoked, and dividing the product by the number of cigarettes in a pack.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C156835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156835>	C178395	Participant Exposed to Secondhand Smoke|Yes	The individual was exposed to secondhand smoke.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C156836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156836>	C178395	No/Minimal Secondhand Smoke Exposure|No or minimal exposure to secondhand smoke	There has been no or minimal exposure to second hand smoke.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C156837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156837>	C178395	Secondhand Smoke Exposure in Household during Childhood|Exposure to secondhand smoke in household during Participant's childhood	Secondhand smoke exposure was present in the household during childhood.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C156838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156838>	C178395	Secondhand Smoke Exposure in Current Household|Exposure to secondhand smoke in Participant's current household	Secondhand smoke exposure is present in the current household.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C156839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156839>	C178395	Secondhand Smoke Exposure History Not Available|Exposure to secondhand smoke history not available	The history of secondhand smoke exposure is not available.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C15683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15683>	C15750	Epidural Chemotherapy	Chemotherapy delivered into the epidural space.			Therapeutic or Preventive Procedure	
C156840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156840>	C179451|C156422	Organ of Origin|Primary Organ	The organ identified as the original site of the tumor.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Normal Endometrial Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form
C156841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156841>	C25616	Follow-Up Period|follow-up (clinical study)	The period of time determined to be follow-up.			Temporal Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C156842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156842>	C25616	12 Months	A period of time of twelve months.			Temporal Concept	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C156843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156843>	C25616	24 Months	A period of time of twenty-four months.			Temporal Concept	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C156844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156844>	C25616	36 Months	A period of time of thirty-six months.			Temporal Concept	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C156845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156845>	C25616	48 Months	A period of time of forty-eight months.			Temporal Concept	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C156846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156846>	C48191	Follow-Up Information|Follow Up|Follow-Up|Follow-Up Data|follow up data|follow_up_data	Information regarding the follow-up period.			Conceptual Entity	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|ICDC Property Terminology|ICDC Terminology
C156847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156847>	C156846	Outcome after Follow-Up Form Completion|Outcome at completion of this Follow-up Form	The individual's outcome after the follow-up.			Conceptual Entity	CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Terminology
C156848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156848>	C96643	Tumor Free|TF-Tumor Free|Tumor free	There is no evidence of a tumor in the individual.			Qualitative Concept	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|GDC Terminology|GDC Value Terminology
C156849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156849>	C96643	With Tumor|WT-With Tumor|With tumor	There is evidence of a tumor in an individual.			Qualitative Concept	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|GDC Terminology|GDC Value Terminology
C15684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15684>	C15295	Chemotherapeutic Hyperthermic Perfusion|hyperthermic perfusion	A procedure in which a warmed solution containing anticancer drugs is used to bathe, or is passed through the blood vessels of, the tissue or organ containing the tumor.			Therapeutic or Preventive Procedure	
C156850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156850>	C160157	New Tumor Event After Initial Treatment Present|Yes	There is evidence of a new tumor after the initial treatment.			Clinical Attribute	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C156851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156851>	C158612	New Tumor Event Question|New Tumor Event|New Tumor Event|New Tumor Event Header	A section header about new tumor activity.			Clinical Attribute	CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology
C156852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156852>	C158612	Type of New Tumor Event (Check all that apply) Question|New Tumor Event Type|Type of New Tumor Event|Type of New Tumor Event (Check all that apply)|Type of New Tumor Event (Check all that apply)	The kind of new tumor activity.			Clinical Attribute	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C156853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156853>	C158612	What is the Site of the New Tumor Event Question|New Tumor Event Site|Site|Site of New Tumor Event|What is the Site of the New Tumor Event	A question about the anatomic site of the new tumor activity.			Clinical Attribute	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C156854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156854>	C158612	Specify Site of New Tumor Event Question|Specify Site of New Tumor Event|Specify Site of New Tumor Event	A directive to specify the anatomic site of a new tumor event.			Clinical Attribute	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C156855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156855>	C156805	Date of New Tumor Event|Event Date|New Tumor Event Date	The date of the new tumor event.			Clinical Attribute	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C156856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156856>	C181040	Number of Days from Date of Initial Cancer Diagnosis to Date of New Tumor Event after Initial Treatment|Number of Days from Date of Initial Pathologic Diagnosis to Date of New Tumor Event after Initial Treatment	The number of days from the date of the initial cancer diagnosis to the date of the new tumor event after initial treatment.			Clinical Attribute	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C156857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156857>	C181040	Number of Days from Date of Initial Pathologic Diagnosis to Date of Additional Surgery for New Tumor Event	The number of days from the date of the initial pathologic diagnosis to the date of additional surgery for new tumor event.			Clinical Attribute	CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Terminology
C156858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156858>	C158612	Was Additional Surgery for New Tumor Event Performed Question|Additional Surgery for New Tumor Event|New Tumor Additional Surgery Performed|Was Additional Surgery for New Tumor Event Performed	A question about any additional surgery performed for the new tumor.			Clinical Attribute	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C156859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156859>	C91102	Date of Additional Surgery for New Tumor Event Question|Additional Surgery Date|Date of Additional Surgery for New Tumor Event|Date of Additional Surgery for New Tumor Event|New Tumor Additional Surgery Date	The date of additional surgery for the new tumor event.			Clinical Attribute	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C15685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15685>	C27993	Incubated|INCUBATING|incubated				Qualitative Concept	CDISC Define-XML Terminology|CDISC SDTM Biospecimen Events Dictionary Derived Term Terminology|Clinical Data Interchange Standards Consortium Terminology
C156860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156860>	C181040	Number of Days from Date of Initial Cancer Diagnosis to Date of Additional Surgery for New Tumor Event|Number of Days from Date of Initial Pathologic Diagnosis to Date of Additional Surgery for New Tumor Event	The number of days from the date of the initial cancer diagnosis to the date of additional surgery for the new tumor event.			Clinical Attribute	CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Terminology
C156861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156861>	C813	Human Papillomavirus mRNA|HPV Messenger RNA|HPV Messenger Ribonucleic Acid|HPV mRNA|Human Papilloma Virus mRNA|Human Papillomavirus Messenger RNA	Any RNA molecule that is the product of transcription of a human papillomavirus gene and contains coding information that can be translated into the amino acid sequence of a protein.	Human Papillomavirus mRNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C156862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156862>	C15358	Fractionated Stereotactic Radiation Therapy|Fractionated Stereotactic Radiotherapy	Stereotactic radiation therapy that uses multiple doses of radiation spread over several treatment session.	Fractionated Stereotactic Radiation Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C156863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156863>	C122483	Aluminum Milling|Aluminum Miller|Aluminum milling	An occupation involving the processing or shaping of aluminum using a rotating cutter.			Occupation or Discipline	CPTAC Codelists Terminology|CPTAC Environmental/Occupational Exposure Codelist|CPTAC Terminology
C156864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156864>	C122483	Steel Milling and Casting|Foundry or Steel Milling|Steel Miller|Steel Milling	An occupation involving the processing or shaping of steel either by pouring liquid metal into molds or by shaping it on a rotating cutter.			Occupation or Discipline	CPTAC Baseline Medical Forms Terminology|CPTAC Codelists Terminology|CPTAC Environmental/Occupational Exposure Codelist|CPTAC Medical History Form|CPTAC Terminology
C156865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156865>	C97630	Coal Mining|Coal Miner|Coal mining	An occupation involving the extraction of coal or coal ores from the ground.			Occupation or Discipline	CPTAC Baseline Medical Forms Terminology|CPTAC Codelists Terminology|CPTAC Environmental/Occupational Exposure Codelist|CPTAC Medical History Form|CPTAC Terminology
C156866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156866>	C97630	Hard Rock Mining|Hard Rick Miner|Underground Hard Rock Mining	A process and occupation involving the excavation of hard minerals or their ores from the ground.			Occupation or Discipline	CPTAC Codelists Terminology|CPTAC Environmental/Occupational Exposure Codelist|CPTAC Terminology
C156867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156867>	C25392	Flour, Feed, or Grain Milling|Feed or Grain Miller|Feed or Grain Milling|Flour, Feed or Grain Milling	An occupation involving the grinding of raw agricultural materials into products for farming or industrial applications.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Codelists Terminology|CPTAC Environmental/Occupational Exposure Codelist|CPTAC Medical History Form|CPTAC Terminology
C156868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156868>	C122483	Mineral Cutting|Lapidary|Mineral Cutter	An occupation or process involving the shaping of hard minerals or metals using hammers, saws, or abrasives.			Occupation or Discipline	CPTAC Codelists Terminology|CPTAC Environmental/Occupational Exposure Codelist|CPTAC Terminology
C156869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156869>	C148248	Sand Blasting|Sand Blaster|Sand blasting	An occupation involving forcibly propelling a stream of abrasive material against a surface under high pressure to smooth a rough surface, roughen a smooth surface, shape a surface, or remove surface contaminants.			Occupation or Discipline	CPTAC Codelists Terminology|CPTAC Environmental/Occupational Exposure Codelist|CPTAC Terminology
C15686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15686>	C15296	Isolated Chemotherapeutic Hepatic Perfusion|isolated hepatic perfusion	A procedure in which a catheter is placed into the artery that provides blood to the liver; another catheter is placed into the vein that takes blood away from the liver. This temporarily separates the liver's blood supply from blood circulating throughout the rest of the body and allows high doses of anticancer drugs to be directed to the liver only.			Therapeutic or Preventive Procedure	
C156871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156871>	C16929|C16552	Solder Fume Exposure|Solder Fumes	Environmental, occupational, or consumer-based exposure to vaporized materials during the soldering process.			Finding	CPTAC Codelists Terminology|CPTAC Environmental/Occupational Exposure Codelist|CPTAC Terminology
C156872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156872>	C200417	Cotton or Jute Dust Exposure|Cotton or Jute Dust|Cotton or Jute Fibers|Cotton or Jute processing	Environmental, occupational, or consumer-based exposure to airborne cotton or jute fibers created during the manufacture, processing, or handling of these materials.			Finding	CPTAC Codelists Terminology|CPTAC Environmental/Occupational Exposure Codelist|CPTAC Terminology
C156873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156873>	C45678	Creosote	A class of carbonaceous chemicals formed by the distillation of various tars and pyrolysis of wood or fossil fuel. They are used industrially as antiseptics and preservatives. Large quantities of creosote can be toxic and exposure can cause a wide variety of issues from skin irritation to death depending on the route and level (concentration and duration) of exposure. Creosote buildup in domestic heating systems can cause chimney fires.			Organic Chemical	CPTAC Codelists Terminology|CPTAC Environmental/Occupational Exposure Codelist|CPTAC Terminology
C156874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156874>	C45678	Natural Gas	A naturally occurring gas consisting of a hydrocarbon mixture that is primarily methane, but may include varying amounts of other higher alkanes and a small percentage of carbon dioxide, nitrogen, hydrogen sulfide, or helium. Natural gas is a fossil fuel used as a source of energy for heating, cooking, electricity generation, and transportation. It is also used in the manufacture of plastics and other commercially important organic chemicals.			Chemical Viewed Functionally	CPTAC Codelists Terminology|CPTAC Environmental/Occupational Exposure Codelist|CPTAC Terminology
C156875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156875>	C41161	Other Investigational Agent|Other Clinical Trial Agent|Other Study Agent	An investigational agent that is not the lead agent being investigated in a clinical trial.	Other Investigational Agent		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C156876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156876>	C199143	Cancer Model Development Center|CMDC	National Cancer Institute-funded contributors to the Human Cancer Genome Initiative that are tasked with producing next-generation cancer models from clinical samples.			Professional or Occupational Group	
C156877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156877>	C42608	Smartphone Application|App|Smartphone App	An application designed specifically for use on a smartphone.			Intellectual Product	
C156878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156878>	C156877	Quit2Heal|Quit2Heal App|Quit2Heal Smartphone App|Quit2Heal Smartphone Application	A smartphone-based application for smoking cessation specifically tailored to cancer patients. Quit2Heal is designed for the specific needs of the cancer patient, which include high prevalence of comorbid mental disorders, distress from cancer diagnosis, and lack of awareness of smoking's effects on treatments and outcomes.	Quit2Heal		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C156879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156879>	C156877	QuitGuide|QuitGuide App|QuitGuide Smartphone App|QuitGuide Smartphone Application	A smartphone-based application designed to help an individual to understand their smoking patterns and build the skills needed to become and stay smokefree. The app can be used to track cravings by time of day and location, and get motivational messages for each tracked craving.	QuitGuide		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C15687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15687>	C49236	Local Therapy|Localized Therapy|local therapy	Any therapeutic procedure that targets, or is restricted to, a specific anatomical location.	Local Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C156880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156880>	C74526	HSP90 Inhibitor|Heat Shock Protein 90 Inhibitor|Hsp 90 Inhibitor	Any agent that inhibits heat shock protein (Hsp) 90.	HSP90 Inhibitor		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology|NCIt Antineoplastic Agent Terminology
C156882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156882>	C213143|C155713	Anti-CD22 ADC TRPH-222|Anti-CD22 Antibody-drug Conjugate TRPH-222|Anti-CD22-4AP ADC TRPH-222|CAT-02-106|TRPH 222|TRPH-222|TRPH-222|TRPH222	An antibody-drug conjugate (ADC) composed of an anti-CD22 humanized monoclonal antibody site-specifically conjugated to, via formylglycine (FG) residues and a protease insensitive 4AP linker, a cytotoxic microtubule-targeting maytansinoid payload, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of TRPH-222 binds to B-cell-specific CD22 receptors and is rapidly internalized, thereby delivering the payload intracellularly. Upon proteolytic cleavage, the maytansinoid payload binds to tubulin, disrupting microtubule assembly/disassembly dynamics, inhibiting both cell division and tumor cell proliferation. CD22, a cell surface sialoglycoprotein, is expressed on mature B-cells and on most malignant B-cells. The site specific and stable conjugation to the payload allows for a higher drug-to-antibody ratio (DAR) and an enhanced therapeutic index.	Anti-CD22 ADC TRPH-222		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156883>	C28681|C138180|C129826	Autologous CD4+/CD8+ EGFR806 Specific 4-1BB-CD3zeta-EGFRt-expressing CAR T Cells|Autologous CD4+/CD8+ T Cells Expressing EGFR806-specific CAR/EGFRt|Autologous EGFR806 Specific CAR T Cells|Autologous EGFR806-specific CAR T Cells	A preparation of CD4+ and CD8+ autologous T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) composed of a short chain variable fragment (scFv) binding domain derived from depatuxizumab, a human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MAb806; ABT-806), coupled to the zeta chain of the TCR/CD3 complex (CD3-zeta) and the signaling domain of 4-1BB (CD137),  and linked to a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Depatuxizumab specifically targets abnormal conformational states of EGFR, including the EGFR deletion mutation variant III (EGFRvIII), and activating mutations, with very low affinity for wild-type EGFR. Upon intravenous administration, the autologous CD4+/CD8+ EGFR806 specific 4-1BB-CD3zeta-EGFRt-expressing CAR T-cells are directed to and induce selective toxicity in EGFRvIII-expressing tumor cells. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of these cells through an anti-EGFR antibody-dependent cellular cytotoxicity (ADCC) response. EGFRvIII, an in-frame deletion of exons 2-7 in the EGFR gene, is overexpressed by a variety of cancer cell types but absent in normal, healthy cells. It plays a key role in tumor cell proliferation, tumor angiogenesis and resistance to both radio- and chemotherapy.	Autologous CD4+/CD8+ EGFR806 Specific 4-1BB-CD3zeta-EGFRt-expressing CAR T Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156884>	C140251	HRAS NP_005334.1:p.G12X|GTPase HRas G12X|GTPase HRas Gly12Xxx|H-Ras G12X|H-Ras Gly12Xxx|H-Ras-1 G12X|H-Ras-1 Gly12Xxx|HRAS G12X|HRAS Gly12Xxx|HRAS NP_005334.1:p.Gly12Xxx|HRAS p.G12X|HRAS p.Gly12Xxx|Ha-Ras G12X|Ha-Ras Gly12Xxx|Ha-Ras1 G12X|Ha-Ras1 Gly12Xxx|Harvey Rat Sarcoma Viral Oncoprotein G12X|Harvey Rat Sarcoma Viral Oncoprotein Gly12Xxx|NP_005334.1:p.G12X|NP_005334.1:p.Gly12Xxx|c-H-ras G12X|c-H-ras Gly12Xxx	A change in the amino acid residue at position 12 in the GTPase HRas protein where glycine has been replaced by another amino acid.	HRAS NP_005334.1:p.G12X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156885>	C4571	Malignant Bronchial Neoplasm|Malignant Neoplasm of Bronchus|Malignant neoplasm of unspecified main bronchus	A malignant neoplasm that affects the bronchial tree.	Malignant Bronchial Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|mCode Cancer Disorder Value Set|mCode Elixhauser Malignant Solid Tumors without Metastases Value Set|mCode Primary Cancer Disorder Value Set|mCode Primary Malignant Neoplasm Disorder Value Set|mCode Terminology
C156886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156886>	C45934	HRAS NM_005343.3:c.35G>A|C-H-RAS c.35G>A|C-HA-RAS1 c.35G>A|H-ras c.35G>A|HRAS c.35G>A|HRAS1 c.35G>A|HRas Proto-Oncogene, GTPase c.35G>A|Ha-ras c.35G>A|Harvey Rat Sarcoma Viral Oncogene Homolog c.35G>A|NM_005343.3:c.35G>A|RASH1 c.35G>A|v-Ha-ras Harvey Rat Sarcoma Viral Oncogene Homolog c.35G>A	A nucleotide substitution at position 35 of the coding sequence of the HRAS gene where guanine has been mutated to adenine.	HRAS NM_005343.3:c.35G>A		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156887>	C45934	HRAS NM_005343.3:c.35_36delinsAT|C-H-RAS c.35_36GC>AT|C-H-RAS c.35_36delGCinsAT|C-HA-RAS1 c.35_36GC>AT|C-HA-RAS1 c.35_36delGCinsAT|H-ras c.35_36GC>AT|H-ras c.35_36delGCinsAT|HRAS NM_005343.3:c.35_36GC>AT|HRAS NM_005343.3:c.35_36delGCinsAT|HRAS NM_005343.3:c.35_36delGCinsAT|HRAS c.35_36GC>AT|HRAS c.35_36delGCinsAT|HRAS1 c.35_36GC>AT|HRAS1 c.35_36delGCinsAT|HRas Proto-Oncogene, GTPase c.35_36GC>AT|HRas Proto-Oncogene, GTPase c.35_36delGCinsAT|Ha-ras c.35_36GC>AT|Ha-ras c.35_36delGCinsAT|Harvey Rat Sarcoma Viral Oncogene Homolog c.35_36GC>AT|Harvey Rat Sarcoma Viral Oncogene Homolog c.35_36delGCinsAT|NM_005343.3:c.35_36GC>AT|NM_005343.3:c.35_36delGCinsAT|NM_005343.3:c.35_36delinsAT|RASH1 c.35_36GC>AT|RASH1 c.35_36delGCinsAT|v-Ha-ras Harvey Rat Sarcoma Viral Oncogene Homolog c.35_36GC>AT|v-Ha-ras Harvey Rat Sarcoma Viral Oncogene Homolog c.35_36delGCinsAT	A complex substitution where the nucleotide sequence at positions 35 and 36 of the coding sequence of the HRAS gene has changed from guanine-cytosine to adenine-thymine.	HRAS NM_005343.3:c.35_36delGCinsAT		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156888>	C156884	HRAS NP_005334.1:p.G12D|G12D Mutated HRAS|GTPase HRas G12D|GTPase HRas Gly12Asp|H-Ras G12D|H-Ras Gly12Asp|H-Ras-1 G12D|H-Ras-1 Gly12Asp|HRAS G12D|HRAS G12D Mutation|HRAS Gly12Asp|HRAS NP_005334.1:p.Gly12Asp|HRAS p.G12D|HRAS p.Gly12Asp|Ha-Ras G12D|Ha-Ras Gly12Asp|Ha-Ras1 G12D|Ha-Ras1 Gly12Asp|Harvey Rat Sarcoma Viral Oncoprotein G12D|Harvey Rat Sarcoma Viral Oncoprotein Gly12Asp|NP_005334.1:p.G12D|NP_005334.1:p.Gly12Asp|c-H-ras G12D|c-H-ras Gly12Asp	A change in the amino acid residue at position 12 in the GTPase HRas protein where glycine has been replaced by aspartic acid.	HRAS NP_005334.1:p.G12D		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156889>	C28681|C138180|C129826	Anti-K-RAS G12D mTCR-transduced Autologous Peripheral Blood Lymphocytes|Anti-K-RAS G12D mTCR-transduced Autologous PBLs|Anti-KRAS G12D mTCR-transduced Autologous Peripheral Blood Lymphocytes	Autologous peripheral blood lymphocytes (PBLs) transduced with a retroviral vector encoding for an HLA class I histocompatibility antigen A*11:01 (HLA-A1101)-restricted murine T-cell receptor (mTCR) that recognizes the glycine (Gly, G) to aspartic acid (Asp, D) point mutation at position 12 (G12D) variant of K-RAS (KRAS), with potential immunomodulating and antineoplastic activities. HLA-A1101-positive PBLs are harvested from a K-RAS G12D-expressing cancer patient and transfected with a retroviral vector that encodes anti-K-RAS G12D mTCR. The transduced PBLs are then expanded in culture. When reintroduced to the patient, these anti-K-RAS G12D mTCR-expressing PBLs target and bind to K-RAS G12D-overexpressing tumor cells, which results in both cytokine secretion, including interferon-gamma (IFN-g), and tumor cell lysis. K-RAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutation of K-RAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.	Anti-K-RAS G12V mTCR-transduced Autologous Peripheral Blood Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15688>	C21090|C15632	Maintenance Therapy|Maintenance|Maintenance|Maintenance|Maintenance|Maintenance|maintenance therapy	Continuation of treatment for an extended period of time to prevent relapse.	Maintenance Therapy		Therapeutic or Preventive Procedure	ALL Authorized Value Terminology|ALL Course Timing Table|ALL Histology Table|ALL Off Protocol Therapy/Study Table|ALL Vitals Table|AML Adverse Events Table|AML Authorized Value Terminology|AML Cellular Immunotherapy Table|AML Concomitant Medication Table|AML Course Timing Table|AML Function Test Table|AML Lab Table|AML Minimal Residual Disease Table|AML Molecular Analysis Table|AML Myeloid Sarcoma Involvement Table|AML Off Protocol Therapy/Study Table|AML Radiation Therapy Table|AML Secondary Malignant Neoplasm Table|AML Stem Cell Transplant Table|AML Subject Response Table|AML Survival Characteristics Table|AML Total Dose Table|AML Transfusion Medicine Procedures Table|AML Vitals Table|CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Terminology|CTRP Intervention Terminology|CTRP Terminology|EWS Adverse Events Table|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Course Timing Table|EWS Histology Table|EWS Immunohistochemistry Table|EWS Lab Table|EWS Molecular Analysis Table|EWS Non-Protocol Therapy Table|EWS Off Protocol Therapy/Study Table|EWS Radiation Therapy Table|EWS Secondary Malignant Neoplasm Table|EWS Stem Cell Transplant Table|EWS Subject Response Table|EWS Survival Characteristics Table|EWS Tumor Assessment Table|EWS Vitals Table|GDC Terminology|GDC Value Terminology|OS Adverse Event Table|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Course Timing Table|OS Function Test Table|OS Histology Table|OS Lab Table|OS Molecular Analysis Table|OS Off Protocol Therapy/Study Table|OS Radiation Therapy Table|OS Secondary Malignant Neoplasm Table|OS Subject Response Table|OS Survival Characteristics Table|OS Total Dose Table|OS Tumor Assessment Table|OS Vitals Table
C156890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156890>	C51944	HER2/Neu Expression by Validated Immunohistochemistry|HER2 Testing by Validated IHC Assay|HER2/Neu Expression by Validated IHC|HER2/Neu Testing by Validated IHC|HER2/Neu Testing by Validated Immunohistochemistry	An immunohistochemistry assay for HER2/Neu expression in a tissue sample that uses a validated antibody in a validated testing lab.. A validated testing lab must have only 5% or less of samples classified as either positive or negative disagree with a 'validated' assay.			Occupational Activity	
C156891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156891>	C17563	HER2/Neu Status by Validated Single-probe in Situ Hybridization|HER2 Testing by Validated Single-probe ISH Assay|HER2/Neu Status by Validated Single-probe ISH	An in situ hybridization assay for HER2/Neu that uses a validated assay for HER2 in a validated testing lab.			Molecular Biology Research Technique	
C156892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156892>	C184370	HER2/Neu Status by Validated Dual-probe in Situ Hybridization|HER2 Testing by Validated Dual-probe ISH Assay|HER2/Neu Status by Validated Dual-probe ISH	An in situ hybridization assay for HER2/Neu that combines a validated assay for HER2 with a probe for chromosome 17, with the assay performed in a validated testing lab.			Molecular Biology Research Technique	
C156893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156893>	C143250	PD-1 Ligand Inhibitor|PD-1 Ligand-targeting Agent|PD-1 Ligands Inhibitor	Any agent that binds to any of the ligands for the receptor programmed cell death protein 1 (PD-1; PD1); programmed death ligand 1 (PD-L1; CD274) and 2 (PD-L2; CD273).	PD-1 Ligand Inhibitor		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C156894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156894>	C155725	Glasdegib Maleate|1-((2R,4R)-2-(1H-Benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea Maleate|Daurismo|GLASDEGIB MALEATE|PF 04449913 Maleate	The maleate salt form of glasdegib, an orally bioavailable small-molecule, smoothened (SMO) receptor inhibitor, with potential antineoplastic activity. Upon oral administration, glasdegib targets, binds to and inhibits the activity of SMO. This inhibits the activity of the Hedgehog (Hh) signaling pathway and inhibits the growth of tumor cells in which this pathway is aberrantly activated. SMO, a transmembrane protein, is involved in Hh signal transduction. The Hh signaling pathway plays an important role in cellular growth, differentiation, repair, and cancer stem cell (CSC) survival. Constitutive activation of Hh pathway signaling has been observed in various types of malignancies and is associated with uncontrolled cellular proliferation in a variety of cancers.	Glasdegib Maleate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156895>	C155765	Larotrectinib Sulfate|(3S)-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide;sulfuric acid|1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-Difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-, Sulfate (1:1)|ARRY 470 Sulfate|LAROTRECTINIB SULFATE|LOXO 101 Sulfate|LOXO-101 Sulfate|Vitrakvi	The sulfate salt form of larotrectinib, an orally available, tropomyosin receptor kinase (Trk) inhibitor, with potential antineoplastic activity. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Trk, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.	Larotrectinib Sulfate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156896>	C156877	APPSPIRE|APPSPIRE App|APPSPIRE Application|APPSPIRE Smartphone App|APPSPIRE Smartphone Application	A smartphone application for smoking cessation specifically targeted to 18-24 year olds.	APPSPIRE		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C156897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156897>	C62103	Activity Monitor|Activity Tracker|Activity Tracker Device|Physical Activity Measuring Device	A consumer, wearable device that is designed to collect and display information about an individual's activities. Information collected may include steps, stairs climbed, distance traveled, calories used, heart rate, sleep quality, or other metrics.	Activity Monitor		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C156898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156898>	C45279	Exercise Log|Activity Log|Workout Log	A paper or electronic record of an individual's fitness, exercise, or other physical activities. This usually includes a description of the type of activity and a entry for time at the activity. Other information might include specific details of the activity and subjective feelings about the activity and the individual's perceived effort and fitness.	Exercise Log		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C156899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156899>	C185523	Hemoglobin S/O-Arab Heterozygote|BS/BO-Arab|HBB Heterozygous Hemoglobin S with O-Arab|Hb S/O Arab|Hb S/O(Arab)|Hb S/O-Arab|HbS/O Arab|HbS/O-Arab|HbSO Arab|HbSO-Arab|Hemoglobin Beta Heterozygous Hemoglobin S Plus O-Arab Genotype|Hemoglobin S/Hemoglobin O-Arab Double Heterozygote|Hemoglobin S/O(Arab)|Hemoglobin S/O-Arab|Hemoglobin S/O-Arab Double Heterozygote	A laboratory finding indicating that the subject expresses abnormal hemoglobin containing 2 variant forms of the hemoglobin subunit beta protein (HBB). One HBB protein variant has the amino acid substitution glutamic acid to valine at residue 6, which is associated with the formation of hemoglobin S (HbS), while the other variant has a glutamic acid to lysine substitution at residue 121, which is associated with the formation of hemoglobin O-Arab (HbO(Arab)). Subjects expressing this compound heterozygous HBB genotype may have severe sickling hemoglobinopathy with clinical manifestations similar to those of homozygous sickle cell anemia.	Hemoglobin S/O-Arab Heterozygote		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15689>	C49236	Drug Resistance Inhibition Treatment|Multidrug Resistance Inhibition|multi-drug resistance inhibition|multidrug resistance inhibition	Treatment used to make cancer cells less resistant to anticancer drugs.			Therapeutic or Preventive Procedure	
C1568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1568>	C2089	Safingol|(2S,3S)-2-Amino-1,3-Octadecanediol|Kynacyte|L-(-)-threo-Sphingnine|L-Threo-Dihydrosphingosine|L-Threo-Dihydrosphingosine|L-threo-2-Amino-1,3-octadecanediol|L-threo-dihydrosphingosine|SAFINGOL|SPC-100270|Sphinganine|safingol	A saturated derivative of sphingosine. As an inhibitor of protein kinase C (PKC), safingol competitively binds to the regulatory phorbol-binding domain of PKC, a kinase involved in tumorigenesis. This agent has been shown to act synergistically with other chemotherapeutic agents and may potentiate chemotherapy drug-induced apoptosis in vitro and in vivo.	Safingol		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156900>	C97927	HBB Gene Mutation|Beta-Globin Gene Mutation|Hemoglobin Beta Gene Mutation	A change in the nucleotide sequence of the HBB gene.	HBB Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156901>	C156900	HBB NM_000518.4:c.364G>A|Beta-Globin c.364G>A|HBB c.364G>A|Hemoglobin Beta c.364G>A|NM_000518.4:c.364G>A	A nucleotide substitution at position 364 of the coding sequence of the HBB gene where guanine has been mutated to adenine.	HBB NM_000518.4:c.364G>A		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156902>	C156900	HBB NM_000518.4:c.20A>T|Beta-Globin c.20A>T|HBB c.20A>T|Hemoglobin Beta c.20A>T|NM_000518.4:c.20A>T	A nucleotide substitution at position 20 of the coding sequence of the HBB gene where adenine has been mutated to thymine.	HBB NM_000518.4:c.20A>T		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156903>	C97928	HBB Protein Variant|Beta-Globin Protein Variant|Hemoglobin Beta Chain Protein Variant|Hemoglobin Subunit Beta Protein Variant	A variation in the amino acid sequence for the hemoglobin subunit beta protein.	HBB Protein Variant		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156904>	C156903	HBB NP_000509.1:p.E122K|Beta-Globin E122K|Beta-Globin Glu122Lys|HBB E121K|HBB E122K|HBB Glu121Lys|HBB Glu122Lys|HBB Hemoglobin O (Arab)|HBB Hemoglobin O-Arab|HBB NP_000509.1:p.Glu122Lys|HBB p.E122K|HBB p.Glu122Lys|Hemoglobin Beta Chain E122K|Hemoglobin Beta Chain Glu122Lys|Hemoglobin O (Arab) Variant|Hemoglobin O-Arab Variant|Hemoglobin Subunit Beta E121K|Hemoglobin Subunit Beta E122K|Hemoglobin Subunit Beta Glu121Lys|Hemoglobin Subunit Beta Glu122Lys|NP_000509.1:p.E122K|NP_000509.1:p.Glu122Lys	A change in the amino acid residue at position 122 in the hemoglobin subunit beta protein where glutamic acid has been replaced by lysine.	HBB NP_000509.1:p.E122K		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156905>	C156903	HBB NP_000509.1:p.E7V|Beta-Globin E7V|Beta-Globin Glu7Val|HBB E6V|HBB E7V|HBB Glu6Val|HBB Glu7Val|HBB Hemoglobin S|HBB NP_000509.1:p.Glu7Val|HBB p.E7V|HBB p.Glu7Val|Hemoglobin Beta Chain E7V|Hemoglobin Beta Chain Glu7Val|Hemoglobin Beta S Variant|Hemoglobin S Variant|Hemoglobin Subunit Beta E6V|Hemoglobin Subunit Beta E7V|Hemoglobin Subunit Beta Glu6Val|Hemoglobin Subunit Beta Glu7Val|NP_000509.1:p.E7V|NP_000509.1:p.Glu7Val	A change in the amino acid residue at position 7 in the hemoglobin subunit beta protein where glutamic acid has been replaced by valine.	HBB NP_000509.1:p.E7V		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C156906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156906>	C8294|C5099|C210620	Resectable Pancreatic Adenocarcinoma	Pancreatic adenocarcinoma that is amenable to surgical resection.			Neoplastic Process	
C156907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156907>	C7977|C156906	Resectable Pancreatic Acinar Cell Carcinoma	Pancreatic acinar cell carcinoma that is amenable to surgical resection.			Neoplastic Process	
C156908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156908>	C35417|C27326|C165293	Resectable Intrahepatic Cholangiocarcinoma	Intrahepatic cholangiocarcinoma that is amenable to surgical resection.			Neoplastic Process	
C156909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156909>	C96963|C150604	Resectable Digestive System Carcinoma	A digestive system carcinoma that is amenable to surgical resection.			Neoplastic Process	
C15690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15690>	C49236	Myelosuppressive Therapy|myelosuppressive therapy	Any treatment that decreases the rate of blood cell production in the bone marrow.			Therapeutic or Preventive Procedure	
C156910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156910>	C27813|C212896|C210620	Resectable Bile Duct Adenocarcinoma	Bile duct adenocarcinoma that is amenable to surgical resection.			Neoplastic Process	
C156911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156911>	C8640|C7975|C156910	Resectable Extrahepatic Bile Duct Adenocarcinoma	Extrahepatic bile duct adenocarcinoma that is amenable to surgical resection.			Neoplastic Process	
C156912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156912>	C96643	Tumor Status at Date of Last Contact or Death|Tumor Status (at date of last contact or death)	The tumor status at date of last contact or death.			Qualitative Concept	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C156913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156913>	C93511	Date of Performance Status Assessment|Performance Status Assessment Date	The date of the Performance Status Assessment.			Temporal Concept	CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Terminology
C156914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156914>	C181015	Post-operative Therapy|Post-Operative Therapy	Treatments after surgery with the intention of achieving the best possible surgical outcome.			Therapeutic or Preventive Procedure	CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Terminology
C156915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156915>	C181060	Number of Days from Date of Initial Cancer Diagnosis to Date of Death|Number of Days from Date of Initial Pathologic Diagnosis to Date of Death	The number of days from the date of initial cancer diagnosis to the date of death.			Intellectual Product	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology
C156916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156916>	C141005	Date of Last Contact|Date of Last Contact (if living)|Last Contact Date|date of last contact|date_of_last_contact	The date of the last contact.			Temporal Concept	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CRF1 Registration Table|ICDC Property Terminology|ICDC Terminology
C156917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156917>	C25330	Month Follow-Up	A form header for month follow-up.			Temporal Concept	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Terminology
C156918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156918>	C181040	Number of Days from Date of Initial Cancer Diagnosis to Date of Last Contact|Number of Days from Date of Initial Pathologic Diagnosis to Date of Last Contact	The number of days from the date of initial cancer diagnosis to the date of last contact.			Intellectual Product	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C156919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156919>	C19837	Canonical BAF Complex|BAF|BAF Complex|BRG1- or hBRM-Associated Factor|BRG1-Associated Factor|BRM/BRG1 Associated Factor|BRM/BRG1-Associated Factor|Brg/Brahma-Associated Factor|Canonical BAF|SWI/SNF-A|cBAF	A SWI/SNF family chromatin-remodeling complex comprised of at least ACTB, ARID1A/BAF250A or ARID1B/BAF250B, SMARCA2/BRM and/or SMARCA4/BRG1/BAF190A, ACTL6A/BAF53 or ACTL6B/BAF53B, DPF1/BAF45B, DPF2/BAF45D or DPF3/BAF45C, SMARCE1/BAF57, SMARCC1/BAF155, SMARCC2/BAF170, SMARCB1/SNF5/INI1, BCL7A, BCL7B or BCL7C, and SMARCD1/BAF60A, SMARCD2/BAF60B or SMARCD3/BAF60C.			Amino Acid, Peptide, or Protein	
C15691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15691>	C20985	Ovarian Ablation|ovarian ablation|ovarian suppression	Surgery, radiation therapy, or a drug treatment to stop the functioning of the ovaries.			Therapeutic or Preventive Procedure	
C156920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156920>	C19837	Neuron-Specific BAF Complex|Neuron-Specific BAF|Neuronal BAF|nBAF|nBAF Complex	A SWI/SNF family chromatin-remodeling complex expressed in postmitotic neurons and comprised of at least ACTB, ARID1A/BAF250A, ARID1B/BAF250B or ARID2/BAF200, BCL11A or BCL11B, SMARCA2/BRM/BAF190B or SMARCA4/BRG1/BAF190A, ACTL6B/BAF53B, SMARCB1/BAF47, SMARCC1/BAF155, SMARCE1/BAF57, SMARCC2/BAF170, SS18L1/CREST, PBRM1/BAF180, DPF1/BAF45B or DPF3/BAF45C, BCL7A, BCL7B or BCL7C, and SMARCD1/BAF60A, SMARCD2/BAF60B or SMARCD3/BAF60C.			Amino Acid, Peptide, or Protein	
C156921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156921>	C19837	Neural Progenitor-Specific BAF Complex|Neural Progenitors-Specific BAF|npBAF|npBAF Complex	A SWI/SNF family chromatin-remodeling complex expressed in neural progenitor cells and comprised of at least ACTB, ARID1A/BAF250A or ARID1B/BAF250B, SMARCD1/BAF60A, BCL11A or BCL11B, SMARCA2/BRM/BAF190B or SMARCA4/BRG1/BAF190A, ACTL6A/BAF53A, SMARCB1/BAF47, SMARCC1/BAF155, SMARCE1/BAF57, SMARCC2/BAF170, SS18, PBRM1/BAF180, PHF10/BAF45A or DPF2/BAF45D, and BCL7A, BCL7B or BCL7C.			Amino Acid, Peptide, or Protein	
C156922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156922>	C19837	PBAF Complex|PBAF|Polybromo- and BAF Containing Complex|Polybromo-Associated BAF|Polybromo-Associated BAF Complex|Polybromo-Associated BRM/BRG1-Associated Factor|Polybromo-BAF|SWI/SNF-B	A SWI/SNF family chromatin-remodeling complex comprised of at least ACTB, BRD7, PHF10/BAF45A, SMARCA4/BRG1 and/or SMARCB1/BAF47/SNF5, ACTL6A/BAF53A or ACTL6B/BAF53B, SMARCE1/BAF57, SMARCC1/BAF155, SMARCC2/BAF170, PBRM1/BAF180, ARID2/BAF200, and SMARCD1/BAF60A, SMARCD2/BAF60B or SMARCD3/BAF60C.			Amino Acid, Peptide, or Protein	
C156923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156923>	C19837	Non-Canonical BAF Complex|BRD9/GLTSCR1-Specific BAF|GBAF|GBAF Complex|Glioma Tumor Suppressor Candidate Region-Associated BAF|Non-Canonical BAF|Noncanonical BAF|Noncanonical BRM/BRG1-Associated Factor|ncBAF	A SWI/SNF family chromatin-remodeling complex comprised of least ACTB, BICRA (GLTSCR1) or BICRAL (GLTSCR1L), BRD9, SS18 or SS18L1/CREST, SMARCA2/BRM or SMARCA4/BRG1/BAF190A, ACTL6A/BAF53A or ACTL6B/BAF53B, SMARCC1/BAF155, and SMARCD1/BAF60A, SMARCD2/BAF60B or SMARCD3/BAF60C.			Amino Acid, Peptide, or Protein	
C156925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156925>	C1663	Lutadenovec Autogene|Adenoviral TSNA Priming Vaccine GRT-C901|Adenoviral Tumor-specific Neoantigen Priming Vaccine GRT-C901|GRT C901|GRT-C901|GRTC901|LUTADENOVEC AUTOGENE|Priming Cancer Vaccine GRT-C901	A personalized cancer vaccine comprised of a chimpanzee adenovirus vector (ChAdV) encoding twenty tumor-specific neoantigens (TSNAs) that have been identified through genetic sequencing of a patient's tumor cells, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration of lutadenovec autogene, the adenovirus infects cells and expresses the TSNAs. This stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the TSNAs, leading to tumor cell lysis. Adenoviral-TSNA vaccine GRT-C901 is followed by monthly boosting with a self-amplifying mRNA (SAM) boosting vaccine that encodes the same 20 target TSNAs. The combined immunotherapy product, consisting of priming and boosting vaccines, is referred to as GRANITE-001.	Lutadenovec Autogene		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156926>	C181141	Sapecmeran Autogene|Boosting Cancer Vaccine GRT-R902|GRT R902|GRT-R902|GRTR902|SAPECMERAN AUTOGENE|mRNA-based TSNA Boosting Vaccine GRT-R902|mRNA-based Tumor-specific Neoantigen Boosting Vaccine GRT-R902	An mRNA-based, personalized cancer vaccine consisting of a self-amplifying mRNA (SAM), formulated in a lipid nanoparticle (LNP), targeting twenty tumor-specific neoantigens (TSNAs) that have been identified through genetic sequencing of a patient's tumor cells, with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration of sapecmeran autogene, the mRNA is taken up and translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of APCs. This leads to an induction of both cytotoxic T-lymphocyte and memory T-cell dependent immune responses that specifically target and destroy the patient's cancer cells that express these neoantigens. mRNA-based TSNA boosting vaccine is administered after a single dose of the adenoviral tumor-specific neoantigen priming vaccine GRT-C901.  The combined immunotherapy product, consisting of priming and boosting vaccines, is referred to as GRANITE-001.	Sapecmeran Autogene		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156927>	C25941	PPIA Gene|PPIA|PPIA|Peptidylprolyl Isomerase A Gene	This gene plays a role in protein folding, cyclosporin binding and HIV virion assembly.			Gene or Genome	
C156928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156928>	C156927	PPIA wt Allele|CYPA|CYPH|HEL-S-69p|Peptidylprolyl Isomerase A (Cyclophilin A) Gene|Peptidylprolyl Isomerase A wt Allele|T Cell Cyclophilin Gene	Human PPIA wild-type allele is located in the vicinity of 7p13 and is approximately 28 kb in length. This allele, which encodes peptidyl-prolyl cis-trans isomerase A protein, is involved in viral replication, protein folding and immunosuppression.			Gene or Genome	
C156929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156929>	C16759	Peptidyl-Prolyl Cis-Trans Isomerase A|Cyclophilin A|Cyclosporin A-Binding Protein|EC 5.2.1.8|Epididymis Secretory Sperm Binding Protein Li 69p|PPIA|PPIase A|Peptidyl-Prolyl Isomerase A|Peptidylprolyl Isomerase A|Rotamase A	Peptidyl-prolyl cis-trans isomerase A (165 aa, ~18 kDa) is encoded by the human PPIA gene. This protein plays a role in cyclosporin-mediated immunosuppression, HIV virion assembly and protein folding.			Amino Acid, Peptide, or Protein|Enzyme	NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C15692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15692>	C106541	Perimenopausal|Menopause Transitional Phase|PERIMENOPAUSAL|perimenopausal	Describes the time in a woman's life as she approaches menopause. This is usually three to five years before menopause and is often marked by irregular menstrual periods and many of the symptoms of menopause, including hot flashes, mood swings, night sweats, vaginal dryness, trouble concentrating, and infertility.			Clinical Attribute	CDISC SDTM Menopause Status Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C156930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156930>	C26110	METTL13 Gene|EEF1AKNMT|METTL13|METTL13|Methyltransferase 13, eEF1A N-Terminus and K55 Gene	This gene is involved in both the methylation of translation elongation factor 1a and anti-apoptotic activity.			Gene or Genome	
C156931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156931>	C156930	METTL13 wt Allele|5630401D24Rik|CGI-01|DFNB26|DFNB26M|DFNM1|Deafness (Autosomal Recessive, Nonsyndromic) Modifier 1 Gene|Deafness (Recessive, Non-Syndromic) Modifier 1 Gene|Deafness (Recessive, Nonsyndromic) Modifier 1 Gene|Deafness, Autosomal Recessive 26 Gene|FEAT|Faint Expression in Normal Tissues, Aberrant Overexpression in Tumors Gene|KIAA0859|METTL13|Methyltransferase 13, eEF1A Lysine and N-Terminal Methyltransferase Gene|Methyltransferase 13, eEF1A N-Terminus and K55 wt Allele|Methyltransferase Like 13 Gene|Methyltransferase-Like 13 Gene|eEF1A Lysine and N-Terminal Methyltransferase Gene|feat	Human METTL13 wild-type allele is located in the vicinity of 1q24.3 and is approximately 32 kb in length. This allele, which encodes eEF1A lysine and N-terminal methyltransferase protein, plays a role in the modulation of both apoptosis and protein translation. Mutation of the gene is associated with type 26 autosomal recessive deafness.			Gene or Genome	
C156932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156932>	C16849	eEF1A Lysine and N-Terminal Methyltransferase|Antiapoptotic Protein FEAT|EC 2.1.1.-|EEF1AKNMT|METTL13|Methyltransferase-Like Protein 13|eEF1A Lysine Methyltransferase|eEF1A N-Terminal Methyltransferase|eEF1A-KNMT	eEF1A lysine and N-terminal methyltransferase (699 aa, ~79 kDa) is encoded by the human METTL13 gene. This protein is involved in the inhibition of apoptosis and the methylation of translation elongation factor 1a.			Amino Acid, Peptide, or Protein|Enzyme	
C156933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156933>	C201513|C200766	Human Anti-CD30 CAR-expressing Autologous T-lymphocytes|Human Anti-CD30 CAR-expressing Autologous T-cells|Human Anti-CD30scFv CAR-expressing Autologous T-lymphocytes	A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) derived from a human anti-CD30 monoclonal antibody, with potential immunostimulating and antineoplastic activities. Upon administration, the human anti-CD30 CAR-expressing autologous T-lymphocytes specifically recognize and bind to CD30-expressing tumor cells, resulting in tumor cell lysis. CD30, a cell surface receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is transiently expressed on activated lymphocytes and is constitutively expressed in hematologic malignancies. Compared to CAR-T cells that use murine scFv-based CARs, CAR-T cells containing CARs with human scFv regions reduces the immunogenicity of the CAR-T cells and may improve their longevity.	Human Anti-CD30 CAR-expressing Autologous T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C156934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156934>	C97927	KCNJ5 Gene Mutation|CIR Gene Mutation|GIRK4 Gene Mutation|KATP1 Gene Mutation|KIR3.4 Gene Mutation|LQT13 Gene Mutation|Potassium Channel, Inwardly Rectifying Subfamily J Member 5 Gene Mutation|Potassium Channel, Inwardly Rectifying Subfamily J, Member 5 Gene Mutation|Potassium Voltage-Gated Channel Subfamily J Member 5 Gene Mutation	A change in the nucleotide sequence of the KCNJ5 gene.			Cell or Molecular Dysfunction	
C156935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156935>	C97927	ATP1A1 Gene Mutation|ATPase Na+/K+ Transporting Subunit Alpha 1 Gene Mutation|ATPase, Na+/K+ Transporting, Alpha 1 Polypeptide Gene Mutation|ATPase, Na+/K+ Transporting, Alpha-1 Polypeptide Gene Mutation|CMT2DD Gene Mutation	A change in the nucleotide sequence of the ATP1A1 gene.			Cell or Molecular Dysfunction	
C156936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156936>	C97927	ATP2B3 Gene Mutation|ATPase Plasma Membrane Ca2+ Transporting 3 Gene Mutation|ATPase, Ca(2+)-Transporting, Plasma Membrane, 3 Gene Mutation|ATPase, Ca++ Transporting, Plasma Membrane 3 Gene Mutation|CFAP39 Gene Mutation|CLA2 Gene Mutation|OPCA Gene Mutation|PMCA3 Gene Mutation|SCAX1 Gene Mutation	A change in the nucleotide sequence of the ATP2B3 gene.			Cell or Molecular Dysfunction	
C156937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156937>	C97927	CACNA1D Gene Mutation|CACH3 Gene Mutation|CACN4 Gene Mutation|CACNL1A2 Gene Mutation|CCHL1A2 Gene Mutation|Calcium Channel, Voltage-Dependent, L Type, Alpha 1D Subunit Gene Mutation|Calcium Channel, Voltage-Dependent, L Type, Alpha-1D Subunit Gene Mutation|Calcium Voltage-Gated Channel Subunit Alpha1 D Gene Mutation|Cav1.3 Gene Mutation|PASNA Gene Mutation|SANDD Gene Mutation	A change in the nucleotide sequence of the CACNA1D gene.			Cell or Molecular Dysfunction	
C156938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156938>	C97927	PRKACA Gene Mutation|PKACA Gene Mutation|PPNAD4 Gene Mutation|Protein Kinase A, C-Alpha Subunit Gene Mutation|Protein Kinase cAMP-Activated Catalytic Subunit Alpha Gene Mutation|Protein Kinase, cAMP-Dependent, Alpha Catalytic Subunit Gene Mutation|Protein Kinase, cAMP-Dependent, Catalytic, Alpha Gene Mutation	A change in the nucleotide sequence of the PRKACA gene.			Cell or Molecular Dysfunction	
C156939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156939>	C25320	Interfant-06 Protocol|Interfant-06	A clinical study protocol initiated in 2006 designed to improve the treatment for infant acute lymphoblastic leukemia.			Research Activity	
C15693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15693>	C70820	Phase I/II Trial|1-2|PHASE I/II TRIAL|Phase 1/Phase 2|Phase I/II trial|Trial Phase 1-2|Trial Phase 1/2	A clinical research protocol designed to study the safety, dosage levels and response to new treatment. Phase I/II trials combine a Phase I and a Phase II trial of the same treatment into a single protocol.			Research Activity	CDISC SDTM Terminology|CDISC SDTM Trial Phase Terminology|Clinical Data Interchange Standards Consortium Terminology|ICH M11 Terminology|ICH M11 Trial Phase Value Set Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C156940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156940>	C28404	USP18 Gene|USP18|USP18|Ubiquitin Specific Peptidase 18 Gene	This gene plays a role in the cleavage of ubiquitin-like protein ISG15 conjugates and the regulation of interferon-mediated signaling.			Gene or Genome	
C156941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156941>	C156940	USP18 wt Allele|ISG43|Interferon-Stimulated Gene, 43-kD Gene|PTORCH2|UBP43|Ubiquitin Specific Peptidase 18 wt Allele|Ubiquitin-Specific Protease, 43-kD Gene	Human USP18 wild-type allele is located in the vicinity of 22q11.2 and is approximately 27 kb in length. This allele, which encodes Ubl carboxyl-terminal hydrolase 18 protein, is involved in the cleavage of proteins conjugated with ubiquitin-like protein ISG15. Mutation of the gene is associated with pseudo-TORCH syndrome 2.			Gene or Genome	
C156942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156942>	C16481	Ubl Carboxyl-Terminal Hydrolase 18|43 kDa ISG15-Specific Protease|EC 3.4.19.-|ISG15-Specific-Processing Protease|USP18|Ubiquitin Specific Peptidase 18|Ubiquitin Specific Protease 18|Ubiquitin Thioesterase 18|Ubiquitin-Specific Peptidase 18|Ubiquitin-Specific Protease 18|Ubl Thiolesterase 18|hUBP43	Ubl carboxyl-terminal hydrolase 18 (372 aa, ~43 kDa) is encoded by the human USP18 gene. This protein plays a role in the modulation of type I interferon-dependent signaling through the cleavage of ubiquitin-like protein ISG15 conjugated-proteins.			Amino Acid, Peptide, or Protein|Enzyme	
C156943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156943>	C3794|C2858	Adrenal Cortical Sex Cord-Stromal Tumor|Adrenal Cortex Sex Cord-Stromal Tumor	An extremely rare sex cord-stromal tumor that arises from the adrenal cortex. The reported cases were solitary and unilateral.			Neoplastic Process	
C156944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156944>	C4895|C41430	Adrenal Gland Schwannoma	A rare schwannoma that arises from the adrenal medulla.			Neoplastic Process	
C156945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156945>	C9338|C7353	Adrenal Gland Lymphoma	A rare lymphoma that arises from the adrenal gland.			Neoplastic Process	
C156946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156946>	C25616	Less than 1 hour	An indication that something has lasted, occurred during, or totalled less than one hour.			Temporal Concept	CHAMPS Activities Questionnaire for Older Adults
C156947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156947>	C25616	Between 1 and 2.5 Hours|1-2 1/2 hours	An indication that something has lasted, occurred during, or totalled between 1 and 2.5 hours.			Temporal Concept	CHAMPS Activities Questionnaire for Older Adults
C156948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156948>	C25616	Between 3 and 4.5 Hours|3-4 1/2 hours	An indication that something has lasted, occurred during, or totalled between 3 and 4.5 hours.			Temporal Concept	CHAMPS Activities Questionnaire for Older Adults
C156949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156949>	C25616	Between 5 and 6.5 Hours|5-6 1/2 hours	An indication that something has lasted, occurred during, or totalled between 5 and 6.5 hours.			Temporal Concept	CHAMPS Activities Questionnaire for Older Adults
C15694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15694>	C70820	Phase II/III Trial|2-3|PHASE II/III TRIAL|Phase 2/Phase 3|Trial Phase 2-3|Trial Phase 2/3|phase II/III trial	A type of clinical study that combines elements characteristic of traditional Phase II and Phase III trials.			Research Activity	CDISC SDTM Terminology|CDISC SDTM Trial Phase Terminology|Clinical Data Interchange Standards Consortium Terminology|ICH M11 Terminology|ICH M11 Trial Phase Value Set Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C156950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156950>	C25616	Between 7 and 8.5 Hours|7-8 1/2 hours	An indication that something has lasted, occurred during, or totalled between 7 and 8.5 hours.			Temporal Concept	CHAMPS Activities Questionnaire for Older Adults
C156951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156951>	C25616	More than 9 Hours|9 or more hours	An indication that something has lasted, occurred during, or totalled more than 9 hours.			Temporal Concept	CHAMPS Activities Questionnaire for Older Adults
C156952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156952>	C54443	CPTAC Terminology|Clinical Proteomic Tumor Analysis Consortium Terminology	Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC).			Intellectual Product	
C156953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156953>	C156952	CPTAC Baseline Medical Forms Terminology	Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on obtaining data for baseline medical forms.			Intellectual Product	
C156954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156954>	C156953	CPTAC Medical History Form	Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on Medical History Form data.			Intellectual Product	
C156955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156955>	C159328	CPTAC Follow-Up Form	Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on Follow-Up Form data.			Intellectual Product	
C156956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156956>	C9338|C4832	Adrenal Gland Sarcoma	A rare sarcoma that arises from the adrenal gland.	Adrenal Gland Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C156957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156957>	C91105	CHAMPS Activities Questionnaire for Older Adults|CHAMPS|Community Healthy Activities Model Program for Seniors Questionnaire	A self-report physical activity questionnaire for older men and women, developed to evaluate the outcomes of the Community Healthy Activities Model Program for Seniors (CHAMPS), an intervention to increase physical activity.			Intellectual Product	
C156958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156958>	C176021	Visit with Friends or Family Question|Did you visit with friends or family (other than those you live with)|Visit with Friends or Family	A question about whether an individual visited with friends or family.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156959>	C91102	Go to Senior Center Question|Did you go to the senior center|Go to Senior Center	A question about whether an individual went to the senior center.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C15695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15695>	C15280	Quadrantectomy|Resection of Quadrant of Breast|quadrantectomy	The surgical removal of one quarter of the tissue in a breast tissue, including ipsilateral chest wall muscles within a given margin of the tumor.			Therapeutic or Preventive Procedure	
C156960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156960>	C91102	Do Volunteer Work Question|Did you do volunteer work|Do Volunteer Work	A question about whether an individual did or does volunteer work.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156961>	C173058	Attend Church or Take Part in Church Activities Question|Attend Church or Take Part in Church Activities|Did you attend church or take part in church activities	A question about whether an individual attended church or participated in church activities.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156962>	C173058	Attend Other Club or Group Meetings Question|Attend Other Club or Group Meetings|Did you attend other club or group meetings	A question about whether an individual attended other club or group meetings.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156963>	C91102	Use a Computer Question|Did you use a computer|Use a Computer	A question about whether an individual used a computer.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156964>	C173458	Do You Dance Question|Dance|Did you dance (such as square, folk, line, ballroom) (do not count aerobic dance here)|Do You Dance	A question about whether an individual dances.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156965>	C173458	Do Artwork or Crafts Question|Did you do woodworking, needlework, drawing, or other arts or crafts|Do Arts or Crafts|Do Artwork or Crafts	A question about whether an individual does artwork or crafts.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156966>	C158520	CPTAC Neoplasms Codelist	Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on neoplasms.			Intellectual Product	
C156967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156967>	C25939	GFUS Gene|GDP-L-Fucose Synthase Gene|GFUS|GFUS|TSTA3	This gene is involved in mannose metabolism.			Gene or Genome	
C156968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156968>	C156967	GFUS wt Allele|FX|GDP-Keto-6-Deoxymannose 3,5-Epimerase, 4-Reductase Gene|GDP-L-Fucose Synthase wt Allele|P35B|SDR4E1|Short Chain Dehydrogenase/Reductase Family 4E, Member 1 Gene|Tissue Specific Transplantation Antigen 3 Gene|Tissue Specific Transplantation Antigen P35B Gene	Human GFUS wild-type allele is located in the vicinity of 8q24.3 and is approximately 5 kb in length. This allele, which encodes GDP-L-fucose synthase protein, plays a role in GDP-L-fucose synthesis.			Gene or Genome	
C156969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156969>	C16946	GDP-L-Fucose Synthase|3-5 Epimerase/4-Reductase|EC 1.1.1.271|GDP-4-Keto-6-Deoxy-D-Mannose Epimerase-Reductase|GDP-4-Keto-6-Deoxy-D-Mannose-3,5-Epimerase-4-Reductase|GDP-Keto-6-Deoxymannose-3,5-Epimerase, 4-Reductase|GFUS|Protein FX|Red Cell NADP(H)-Binding Protein|Short-Chain Dehydrogenase/Reductase Family 4E Member 1|TSTA3|Testis Tissue Sperm-Binding Protein Li 45a|Tissue Specific Transplantation Antigen 3|Tissue Specific Transplantation Antigen P35B|Tissue-Specific Transplantation Antigen 3	GDP-L-fucose synthase (321 aa, ~36 kDa) is encoded by the human GFUS gene. This protein is involved in the NADP-dependent conversion of GDP-4-dehydro-6-deoxy-D-mannose to GDP-L-fucose.			Amino Acid, Peptide, or Protein|Enzyme	
C15696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15696>	C64982|C49165|C15313	Radiosurgery|Ablation, Radiosurgical|Radiation Surgery|radiation surgery|radiosurgery	A surgical procedure to treat cancer cells that use high energy beams.	Radiosurgery		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C156970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156970>	C26006	CLN3 Gene|CLN3|CLN3|CLN3, Battenin Gene	This gene plays a role in endosome and lysosome transport.			Gene or Genome	
C156971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156971>	C156970	CLN3 wt Allele|BTN1|BTS|Batten, Spielmeyer-Vogt Disease Gene|CLN3, Battenin wt Allele|Ceroid-Lipofuscinosis, Neuronal 3 Gene|JNCL|Juvenile Neuronal Ceroid Lipofuscinosis Gene	Human CLN3 wild-type allele is located in the vicinity of 16p12.1 and is approximately 29 kb in length. This allele, which encodes battenin protein, is involved in microtubule-dependent transport of organelles. Deletions within the gene are associated with neuronal ceroid lipofuscinosis type 3 (Batten disease).			Gene or Genome	
C156972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156972>	C16386	Battenin|Batten Disease Protein|CLN3|Protein CLN3	Battenin (438 aa, ~48 kDa) is encoded by the human CLN3 gene. This protein plays a role in anterograde transport of late endosomes and lysosomes.			Amino Acid, Peptide, or Protein	
C156973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156973>	C173458	Play Golf and Carry Own Equipment Question|Did you play golf, carrying or pulling your equipment (count walking time only)|Play Golf and Carry Own Equipment	A question about whether an individual plays golf and carries or pulls their equipment.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156974>	C173458	Play Golf, Riding Cart Question|Did you play golf, riding a cart (count walking time only)|Play Golf, Riding Cart	A question about whether an individual plays golf, while riding a golf cart.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156975>	C173058	Attend Concert, Movie, Lecture or Sport Event Question|Attend Concert, Movie, Lecture or Sport Event|Did you attend a concert, movie, lecture, or sport event	A question about whether an individual attended a concert, movie, lecture, or sports event.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156976>	C173458	Play Cards, Bingo, or Board Games with Other People Question|Did you play cards, bingo, or board games with other people|Play Basketball, Soccer, or Racquetball	A question about whether an individual played cards, bingo, or board games with other people.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156977>	C173458	Shoot Pool or Billiards Question|Did you shoot pool or billiards|Shoot Pool or Billiards	A question about whether an individual played pool or billiards.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156978>	C126221	Play Singles Tennis Question|Did you play singles tennis (do not count doubles)|Play Singles Tennis	A question about whether an individual played single tennis.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156979>	C126221	Play Doubles Tennis Question|Did you play doubles tennis (do not count singles)|Play Doubles Tennis	A question about whether an individual played doubles tennis.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C15697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15697>	C49236	Treatment Regimen|Regimen|Regimen/Treatment Period/Vaccination Regimen|Treatment Protocol|Treatment Schedule|regimen|regimen or line of therapy|regimen_or_line_of_therapy	A treatment plan that specifies the dosage, the schedule, and the duration of treatment.			Functional Concept	GDC Property Terminology|GDC Terminology|ICH M11 Protocol Section 6 Data Element Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C156980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156980>	C91102	Go Skating Question|Did you skate (ice, roller, in-line)|Go Skating|Skate	A question about whether an individual skated.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156981>	C173458	Play a Musical Instrument Question|Did you play a musical instrument|Play a Musical Instrument	A question about whether an individual played a musical instrument.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156982>	C176426|C173458	Do Reading Question|Did you read|Do Reading|Read	A question about whether an individual did any reading.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156983>	C110952	Do Heavy Work Around the House Question|Did you do heavy work around the house (such as washing windows, cleaning gutters)|Do Heavy Work Around the House|Do Heavy household Chores	A question about whether an individual did any heavy work around the house.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156984>	C110952	Do Light Work Around the House Question|Did you do light work around the house (such as sweeping or vacuuming)|Do Light Work Around the House|Do Light household Chores	A question about whether an individual did any light work around the house.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156985>	C173458	Do Heavy Gardening Question|Did you do heavy gardening (such as spading, raking)|Do Heavy Gardening	A question about whether an individual did any heavy gardening.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156986>	C173458	Do Light Gardening Question|Did you do light gardening (such as watering plants)|Do Light Gardening	A question about whether an individual did any light gardening.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156987>	C173458	Work on Car, Truck, Lawn Mower, or Other Machinery Question|Did you work on your car, truck, lawn mower, or other machinery|Work on Car, Truck, Lawn Mower, or Other Machinery	A question about whether an individual worked on a car, truck, lawn mower, or other machinery.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156988>	C173458	Go Jogging or Running Question|Did you jog or run|Go Jogging or Running|Jog|Jogging|Jogging or Running|Run|Running	A question about whether an individual jogged or ran.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156989>	C173135	Walk or Hike Uphill Question|Did you walk uphill or hike uphill (count only uphill part)|Hike Uphill|Walk Uphill|Walk or Hike Uphill	A question about whether an individual walked or hiked uphill.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C15698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15698>	C49236	Systemic Therapy|Systemic Treatment|Systemic Treatment|systemic therapy	Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.	Systemic Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C156990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156990>	C173135	Walk Fast or Briskly for Exercise Question|Did you walk fast or briskly for exercise (do not count walking leisurely or uphill)|Walk Fast or Briskly|Walk Fast or Briskly for Exercise	A question about whether an individual walked fast or briskly for exercise.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156991>	C173135	Walk to Do Errands Question|Did you walk to do errands (such as to/from a store or to take children to school (count walk time only)|Walk to Do Errands	A question about whether an individual walked to do errands.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156992>	C173135	Walk Leisurely for Exercise or Pleasure Question|Did you walk leisurely for exercise or pleasure|Walk Leisurely|Walk Leisurely for Exercise or Pleasure	A question about whether an individual walked leisurely for exercise or pleasure.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156993>	C173049	Ride a Bicycle or Stationary Bike Question|Did you ride a bicycle or stationary cycle|Ride Bicycle|Ride a Bicycle or Stationary Bike	A question about whether an individual rode a bicycle or a stationary bike.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156994>	C173458	Use Other Aerobic Equipment Question|Did you do other aerobic machines such as rowing, or step machines (do not count treadmill or stationary cycle)|Use Other Aerobic Equipment	A question about whether an individual used aerobic equipment such as rowing or step machines.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156995>	C173458	Do Water Exercises Other than Swimming Question|Did you do water exercises (do not count other swimming)|Do Water Exercises Other than Swimming	A question about whether an individual did water exercises other than swimming.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156996>	C173594	Swim Moderately or Fast Question|Did you swim moderately or fast|Swim Moderately or Fast	A question about whether an individual did any moderate or fast swimming.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156997>	C173594	Swim Gently Question|Did you swim gently|Swim Gently	A question about whether an individual did any gentle swimming.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156998>	C173458	Do Stretching or Flexibility Exercises Question|Did you do stretching or flexibility exercises (do not count yoga or Tai-chi)|Do Stretching or Flexibility Exercises	A question about whether an individual did stretching or flexibility exercises.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C156999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C156999>	C173458	Do Yoga or Tai-chi Question|Did you do yoga or Tai-chi|Do Yoga or Tai-chi	A question about whether an individual did yoga or tai-chi.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C15699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15699>	C165275	T-Cell Depletion Therapy|T-Cell Depletion|T-Cell Depletion|T-Lymphocyte Depletion Therapy|T-cell depletion	Treatment to destroy T cells, which play an important role in the immune response. Elimination of T cells from a bone marrow graft or peripheral blood stem cell graft from a donor may reduce the chance of an immune reaction against the recipient's tissues.	T-Cell Depletion Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|NICHD Terminology|Pediatric Hematology-Oncology Terminology
C1569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1569>	C75525|C574	Daclizumab|Anti-Tac|Anti-Tac Humanized Monoclonal Antibody|Anti-Tac Monoclonal Antibody|DACLIZUMAB|Dacliximab|Dacliximab|Humanized Anti-Tac Monoclonal Antibody|Monoclonal Antibody Anti-Tac|Zenapax|daclizumab	A recombinant monoclonal antibody interleukin-2 receptor antagonist.  Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway.	Daclizumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157000>	C173458	Do Aerobics or Aerobic Dancing Question|Did you do aerobics or aerobic dancing|Do Aerobics or Aerobic Dancing	A question about whether an individual did aerobics or aerobic dancing.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C157001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157001>	C173458	Do Moderate to Heavy Strength Training Question|Did you do moderate to heavy strength training (such as hand-held weights of more than 5 lbs., weight machines, or push-ups)|Do Moderate to Heavy Strength Training	A question about whether an individual did moderate to heavy strength training.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C157002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157002>	C173458	Do Light Strength Training Question|Did you do light strength training (such as hand-held weights of 5 lbs. or less or elastic bands)|Do Light Strength Training	A question about whether an individual did light strength training.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C157003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157003>	C173458	Do General Conditioning Exercises Question|Did you do general conditioning exercises, such as light calisthenics or chair exercises (do not count strength training)|Do General Conditioning Exercises	A question about whether an individual did general conditioning exercises, like  light calisthenics or chair exercises.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C157004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157004>	C173458	Play Basketball, Soccer, or Racquetball Question|Did you play basketball, soccer, or racquetball (do not count time on sidelines)|Play Basketball, Soccer, or Racquetball	A question about whether an individual played basketball, soccer, or racquetball.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C157005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157005>	C173458	Do Other Physical Activity Question|Do Other Physical Activity|Do other types of physical activity not previously mentioned (please specify)	A question about whether an individual did a physical activity not listed.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C157006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157006>	C17708	Other Physical Activity|Other physical activity, specify	A physical activity not elsewhere listed or specified.			Daily or Recreational Activity	CHAMPS Activities Questionnaire for Older Adults
C157007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157007>	C176021	Activity Hours per Week Question|Activity Hours per Week|Total hours a week did you usually do it	A question about the total number of hours that an individual spent at a particular activity.			Intellectual Product	CHAMPS Activities Questionnaire for Older Adults
C157008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157008>	C16929	Coke Oven Emission Exposure|Coke Oven Emission|Coke ovens	Occupational exposure to gases and particulates produced when coal is processed in a coke oven.			Human-caused Phenomenon or Process	CPTAC Codelists Terminology|CPTAC Environmental/Occupational Exposure Codelist|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C157009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157009>	C156866	Heavy Metal Mining|Copper, Lead, Zinc, Tin, Ore|Heavy Metal Ore Mining	A process and occupation involving the extraction of heavy metals or their ores from the ground.			Occupation or Discipline	CPTAC Codelists Terminology|CPTAC Environmental/Occupational Exposure Codelist|CPTAC Terminology
C15700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15700>	C15757	Total Estrogen Blockade|total estrogen blockade	Therapy used to eliminate estrogen in the body. This may be done with surgery, radiation therapy, chemotherapy, or a combination of these procedures.			Therapeutic or Preventive Procedure	
C157010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157010>	C45678	Paint|Paints	A pigmented liquid or mastic substance that is applied to an object and dries to form a solid thin film, which may color, protect or impart texture to the object's surface. Paints or dry painted surfaces may be toxic if they contain lead or volatile organic compounds (or VOCs).			Chemical Viewed Functionally	CPTAC Codelists Terminology|CPTAC Environmental/Occupational Exposure Codelist|CPTAC Terminology
C157011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157011>	C217121	Edmonton Frail Scale|EFS	An assessment tool designed to be used by clinicians to assess the frailty of older patients. It assesses 10 domains including cognitive impairment and balance and mobility.			Intellectual Product	
C157012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157012>	C222259	Cognition Clock Test	A test of the ability of an individual to accurately place the numbers and hands of a clock in their usual and specified positions.			Intellectual Product	Edmonton Frail Scale
C157013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157013>	C91102	Times Admitted to a Hospital Question|Times Admitted to a Hospital|Times Admitted to a Hospital	A question about the number of times an individual has or had been admitted to a hospital.			Intellectual Product	Edmonton Frail Scale
C157014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157014>	C176021	Activities that Require Help Question|Activities that Require Help|With how many of the following activities do you require help	A question about the activities that an individual did or does require help to do.			Intellectual Product	Edmonton Frail Scale
C157015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157015>	C178350	When Help is Needed Can Count on Someone Willing and Able to Meet Needs Question|When Help is Needed Can Count on Someone Willing and Able to Meet Needs|When you need help, can you count on someone who is willing and able to meet your needs	A question about whether someone who is willing and able is or was available when an individual needed help.			Intellectual Product	Edmonton Frail Scale
C157016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157016>	C173984	Use Five or More Different Prescription Medications Regularly Question|Do you use five or more different prescription medications on a regular basis|Use Five or More Different Prescription Medications Regularly	A question about whether an individual did or does use five or more different prescription medications regularly.			Intellectual Product	Edmonton Frail Scale
C157017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157017>	C176020	Sometimes Forget to Take Prescription Medications Question|At Times Forget to Take Prescription Medication|At times, do you forget to take your prescription medications|Forget to Take Prescription Medications Some of the Time|Sometimes Forget to Take Prescription Medications	A question about whether an individual sometimes forgets to take their prescription medications.			Intellectual Product	Edmonton Frail Scale
C157018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157018>	C173981	Have Recently Lost Weight and Clothing Has Become Looser Question|Have Recently Lost Weight and Clothing Has Become Looser|Have you recently lost weight such that your clothing has become looser	A question about whether an individual has or had recent weight loss so that their clothing has become looser.			Intellectual Product	Edmonton Frail Scale
C157019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157019>	C173160	Often Feel Sad or Depressed Question|Do you often feel sad or depressed|Often Feel Sad or Depressed	A question about whether an individual often feels or felt sad or depressed.			Intellectual Product	Edmonton Frail Scale
C15701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15701>	C15256	Total Hysterectomy|Full Hysterectomy|Simple Hysterectomy|Simple Hysterectomy|complete hysterectomy|total hysterectomy	A surgical procedure to remove the uterine body and cervix. -- 2004	Total Hysterectomy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C157020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157020>	C178809|C173803	Have Urinary Incontinence Question|Do you have a problem with losing control of urine when you don't want to|Have Urinary Incontinence	A question about whether an individual has or had urinary incontinence.			Intellectual Product	Edmonton Frail Scale
C157021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157021>	C20993	Timed Get Up and Go Test	A test that measures the amount of time it takes a person to rise from a chair, walk to a designated point, and return to sitting.			Intellectual Product	Edmonton Frail Scale
C157022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157022>	C25338	Final Score Equals Sum of Column Totals|Final score is the sum of column totals	A final test score, as summed from individual column totals.			Quantitative Concept	Edmonton Frail Scale
C157023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157023>	C227073	No Spacing Errors|No errors	A response indicating that an individual made no spacing errors.			Intellectual Product	Edmonton Frail Scale
C157025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157025>	C797|C2099	L-lysine/L-arginine-containing Amino Acid|Amino Acid Renal Protectant Solution|Amino Acid Solution-containing L-lysine and L-arginine|Intravenous L-lysine/L-arginine-containing Amino Acid Solution|L-lysine/L-arginine AA Solution|Lysine-Arginine Amino Acid Solution|Lysine/Arginine Amino Acid Solution|Radioprotective Amino Acid Solution	An intravenous (IV) amino acid (AA) solution containing the cationic amino acids L-lysine and L-arginine, with radioprotective activity. Upon IV administration of the AA solution, L-lysine and L-arginine are specifically taken up by the kidneys. This protects the kidneys from toxicity by certain co-administered radio-labeled peptides as they compete with radio-labeled peptides for renal uptake. This reduces uptake of the radio-labeled peptides by the kidneys and decreases their renal retention. It also increases the target-to-kidney ratio of the radio-labeled peptides, thereby reducing radiation exposure to the kidneys and preventing nephrotoxicity.	L-lysine/L-arginine-containing Amino Acid		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157026>	C227073	Other Errors|Other errors	A response indicating that an individual made errors not listed or elsewhere specified.			Intellectual Product	Edmonton Frail Scale
C157027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157027>	C226696	No Hospital Admission|0 Hospital Admission	A response indicating that an individual had no hospital admissions.			Intellectual Product	Edmonton Frail Scale
C157028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157028>	C226696	One or Two Hospital Admissions|1-2 Hospital Admissions	A response indicating that an individual had 1 or 2 hospital admissions.			Intellectual Product	Edmonton Frail Scale
C157029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157029>	C226696	Two or More Hospital Admissions|Greater than or Equal to 2 Hospital Admissions	A response indicating that an individual had 2 or more hospital admissions.			Intellectual Product	Edmonton Frail Scale
C15702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15702>	C16185	Video-Assisted Surgery|video-assisted resection|video-assisted surgery	Surgery that is aided by the use of a video camera that projects and enlarges the image on a television screen.	Video-Assisted Surgery		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C157030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157030>	C226677	Excellent, Very Good, or Good Health|Excellent, Very Good, Good Health	A response indicating that an individual was in excellent, very good, or good health.			Intellectual Product	Edmonton Frail Scale
C157031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157031>	C226677	Fair Health	A response indicating that an individual was in fair health.			Intellectual Product	Edmonton Frail Scale
C157032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157032>	C226677	Poor Health	A response indicating that an individual was in poor health.			Intellectual Product	Edmonton Frail Scale
C157033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157033>	C178389	Zero or One Activity Required Help|0-1 Activities required help|None or One Activity Required Help	A response indicating that an individual has or had 0 or 1 activities that required help.			Intellectual Product	Edmonton Frail Scale
C157034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157034>	C178389	Two to Four Activities Required Help|2 to 4 Activities Required Help|2-4 Activities required help	A response indicating that an individual has or had 2-4 activities that required help.			Intellectual Product	Edmonton Frail Scale
C157035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157035>	C178389	Five to Eight Activities Required Help|5 to 8 Activities Required Help|5-8 Activities required help	A response indicating that an individual has or had 5-8 activities that required help.			Intellectual Product	Edmonton Frail Scale
C157036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157036>	C176254	Zero to Ten Seconds Walking|0-10 s walking	A response indicating that an individual can perform a walking exercise in 0-10 seconds.			Intellectual Product	Edmonton Frail Scale
C157037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157037>	C176254	Eleven to Twenty Seconds Walking|11-20 s walking	A response indicating that an individual can perform a walking exercise in 11-20 seconds.			Intellectual Product	Edmonton Frail Scale
C157038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157038>	C226575	Greater Than Twenty Seconds Walking, or Patient Unwilling, or Requires Assistance Walking|Greater than 20 s, or patient unwilling, or requires assistance walking	A response indicating that an individual can perform a walking exercise in greater than 20 seconds, or patient was unwilling, or required assistance to perform a walking exercise.			Intellectual Product	Edmonton Frail Scale
C157039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157039>	C210748	Mitapivat|AG 348|AG-348|AG348|MITAPIVAT|PK-R Activator AG-348|PKR-IN-1|Red Cell Pyruvate Kinase Activator AG-348	An orally available, small-molecule, allosteric activator of the red cell isoform of pyruvate kinase (PK-R), with potential to improve hemolytic anemia in patients with pyruvate kinase deficiency (PKD). Upon oral administration, mitapivat binds to and activates PK-R, thereby enhancing glycolytic pathway activity, improving adenosine triphosphate (ATP) levels and reducing 2,3-diphosphoglycerate (2,3-DPG) levels. Mutations in PK-R cause deficiency in PK-R which prevents adequate red blood cell (RBC) glycolysis, leading to a buildup of the upstream glycolytic intermediate 2,3-DPG and deficiency in the PK-R product ATP.	Mitapivat		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C15703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15703>	C217137|C15389	Colposcopic Biopsy	Removal of tissue from the vagina or cervix by the use of a colposcope.	Colposcopic Biopsy		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C157040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157040>	C25939	GSR Gene|GSR|GSR|Glutathione-Disulfide Reductase Gene	This gene plays a role in glutathione metabolism.	GSR Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C157041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157041>	C157040	GSR wt Allele|GLUR|GR|GRD1|Glutathione Reductase Gene|Glutathione S-Reductase Gene|Glutathione-Disulfide Reductase wt Allele|HEL-75|HEL-S-122m	Human GSR wild-type allele is located in the vicinity of 8p12 and is approximately 50 kb in length. This allele, which encodes glutathione reductase, mitochondrial protein, is involved in cellular glutathione homeostasis. Mutation of the gene is associated with hemolytic anemia due to hereditary glutathione reductase deficiency.	GSR wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157042>	C16946	Glutathione Reductase, Mitochondrial|EC 1.8.1.7|Epididymis Luminal Protein 75|Epididymis Secretory Sperm Binding Protein Li 122m|GR|GRase|GSR|Glutathione Reductase|Glutathione S-Reductase|Glutathione-Disulfide Reductase	Glutathione reductase, mitochondrial (522 aa, ~56 kDa) is encoded by the human GSR gene. This protein plays a role in the synthesis of the sulfhydryl form of glutathione.	Glutathione Reductase, Mitochondrial		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157043>	C25939	SRXN1 Gene|SRXN1|SRXN1|Sulfiredoxin 1 Gene	This gene plays a role in the cellular response to oxidative stress.	SRXN1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C157044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157044>	C157043	SRXN1 wt Allele|C20orf139|Chromosome 20 Open Reading Frame 139 Gene|Npn3|SRX|SRX1|Sulfiredoxin 1 Homolog (S. cerevisiae) Gene|Sulfiredoxin 1 wt Allele|YKL086W|dJ850E9.2	Human SRXN1 wild-type allele is located in the vicinity of 20p13 and is approximately 7 kb in length. This allele, which encodes sulfiredoxin-1 protein, is involved in resistance to oxidative stress.	SRXN1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157045>	C16946	Sulfiredoxin-1|EC 1.8.98.2|SRXN1|Sulfiredoxin 1	Sulfiredoxin-1 (137 aa, ~14 kDa) is encoded by the human SRXN1 gene. This protein plays a role in the reduction of cysteine-sulfinic acid residues in peroxiredoxins.	Sulfiredoxin-1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157046>	C25870	GPAT3 Gene|GPAT3|GPAT3|Glycerol-3-Phosphate Acyltransferase 3 Gene	This gene is involved in triacylglycerol synthesis.	GPAT3 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C157047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157047>	C157046	GPAT3 wt Allele|1-Acylglycerol-3-Phosphate O-Acyltransferase 9 (Lysophosphatidic Acid Acyltransferase, Theta) Gene|AGPAT 10|AGPAT10|AGPAT8|AGPAT9|GPAT, Endoplasmic Reticulum-Associated Gene|Glycerol-3-Phosphate Acyltransferase 3 wt Allele|HMFN0839|LPAAT-Theta|Lung Cancer Metastasis-Associated Gene 1|Lysophosphatidic Acid Acyltransferase, Theta Gene|MAG1|UNQ2753/PRO6492	Human GPAT3 wild-type allele is located in the vicinity of 4q21.23 and is approximately 70 kb in length. This allele, which encodes glycerol-3-phosphate acyltransferase 3 protein, plays a role in glycerolipid biosynthesis.	GPAT3 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157048>	C16259	Glycerol-3-Phosphate Acyltransferase 3|1-AGP Acyltransferase 9|1-AGPAT 9|1-Acyl-Sn-Glycerol-3-Phosphate O-Acyltransferase 10|1-Acyl-Sn-Glycerol-3-Phosphate O-Acyltransferase 9|1-Acylglycerol-3-Phosphate O-Acyltransferase 9|AGPAT 10|Acyl-CoA:Glycerol-3-Phosphate Acyltransferase 3|EC 2.3.1.51|Endoplasmic Reticulum Associated GPAT|GPAT-3|GPAT3|LPAAT-Theta|Lung Cancer Metastasis-Associated Protein 1|Lysophosphatidic Acid Acyltransferase Theta|MAG-1|MAG1 Protein|hGPAT3	Glycerol-3-phosphate acyltransferase 3 (434 aa, ~49 kDa) is encoded by the human GPAT3 gene. This protein is involved in the acylation of lysophosphatidic acid to form phosphatidic acid.	Glycerol-3-Phosphate Acyltransferase 3		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157049>	C17423	Pen Device|Pen	Administration device intended to house a cartridge that contains a sterile, single-dose or multidose, parenteral preparation. It is usually supplied without a fixed needle, and may or may not be fitted with a needle safety device. The cartridge is usually replaceable when it is empty. The pre-defined dose, which may or may not be adjustable, is administered via an actuation, such as the pressing of a button. Dose dispenser is excluded.			Medical Device	EDQM Health Care Terminology|EDQM-HC Administration Device Terminology
C15704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15704>	C15511	Antifungal Therapy|Treatment of Fungal Infectious Disease	Drug treatment to destroy or inhibit the growth or multiplication of fungi.			Therapeutic or Preventive Procedure	
C157051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157051>	C63524	Ipilimumab/Talimogene Laherparepvec Regimen|Intralesional T-VEC/Ipilimumab|Intralesional Talimogene Laherparepvec/Ipilimumab|Ipilimumab Plus Talimogene Laherparepvec|Ipilimumab-Talimogene Laherparepvec Regimen|Ipilimumab/Talimogene Laherparepvec|Talimogene Laherparepvec/Ipilimumab|Yervoy/Imlygic	A regimen consisting of intralesional talimogene laherparepvec followed by intravenous ipilimumab that may be used in the treatment of melanoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C157052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157052>	C78808	LUM Imaging System	A proprietary imaging system designed to detect residual tumor tissue in breast cancer patients by identifying microscopic residual cancer in the tumor bed. The LUM Imaging System consists of the cancer imaging agent LUM015 and a hand-held fluorescence-based imager that detects the emission of activated LUM015 in and around a tumor. The LUM Imaging System is designed to detect microscopic residual cancer cells in real-time.	LUM Imaging System		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C157053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157053>	C19747	LUM Imaging Device	A proprietary hand-held fluorescence-based imager that detects the emission of activated LUM015 in and around a tumor. The LUM Imaging System is designed to detect microscopic residual cancer cells in a tumor bed in real-time.	LUM Imaging Device		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C157054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157054>	C156914|C116681	Incisional Vacuum-Assisted Closure Therapy|Incisional VAC|Incisional Vacuum-Assisted Closure|Incisional Vacuum-Assisted Dressing|iVAC	A type of postoperative wound therapy that uses a dressing composed of a non-adhesive dressing, sponge, and vacuum tubing, all covered with an adhesive, non-permeable material. Suction is applied through the tube. This system results in a decreased need for dressing changes during the immediate postoperative period and a cleaner wound environment.	Incisional Vacuum-Assisted Closure Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C157056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157056>	C5214	Hormone Receptor-Positive Breast Carcinoma|Hormone Receptor Positive Breast Adenocarcinoma|Hormone Receptor Positive Breast Carcinoma|Hormone Receptor Positive Breast Carcinoma	A breast adenocarcinoma that is positive for hormone receptors.	Hormone Receptor Positive Breast Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157057>	C165703|C157056	Refractory Hormone Receptor-Positive Breast Carcinoma|Refractory Hormone Receptor Positive Breast Adenocarcinoma|Refractory Hormone Receptor Positive Breast Carcinoma|Refractory Hormone Receptor-Positive Breast Adenocarcinoma	Hormone receptor-positive breast adenocarcinoma that does not respond to treatment.	Refractory Hormone Receptor-Positive Breast Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157058>	C28227|C141146|C128057	Anti-PD-L1/TIM-3 Bispecific Antibody LY3415244|LY 3415244|LY-3415244|LY-3415244|LY3415244	A bispecific antibody directed against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2) and the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, LY3415244 simultaneously targets and binds to TIM-3 expressed on certain T-cells, including tumor-infiltrating lymphocytes (TILs), and PD-L1 expressed on tumor cells. This blocks the interaction of TIM-3 with some of its physiologic ligands and prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is often co-expressed with PD-1 on tumor-antigen-specific T-cells. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.	Anti-PD-L1/TIM-3 Bispecific Antibody LY3415244		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157059>	C17666|C134473	Germline APC Gene Mutation|APC Gene Germline Mutation|Adenomatous Polyposis Coli Germline Mutation|Germline APC, WNT Signaling Pathway Regulator Gene Mutation|Germline Adenomatous Polyposis Coli Mutation|Germline BTPS2 Gene Mutation|Germline FAP Gene Mutation|Germline FPC Gene Mutation|Germline PPP1R46 Gene Mutation	A change in the nucleotide sequence of the APC gene that originates in the gametes.	Germline APC Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15705>	C158758	Transurethral Resection|TUR|TUR|transurethral resection	Surgery performed with a special instrument inserted through the urethra.			Therapeutic or Preventive Procedure	
C157060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157060>	C85902	Suspicion of Metastasis|Suspicion of Metastases	An impression that a tumor has possibly spread from its original site of growth to another anatomic site.			Classification	
C157061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157061>	C20401|C129822	Anti-S15 Monoclonal Antibody NC318|Anti-S15 mAb NC318|Anti-Siglec-15 Monoclonal Antibody NC318|NC 318|NC-318|NC318	A humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting sialic acid binding Ig-like lectin 15 (Siglec-15; SIGLEC15; S15), a member of the sialic acid-binding immunoglobulin type lectins, with potential antineoplastic and immunomodulatory activities. Upon administration, anti-S15 monoclonal antibody NC318 targets and binds to S15 on the surface of tumor-associated macrophages (TAMs) and certain tumor cells. Binding to S15 may disrupt TAM-mediated activities such as promotion of tumor initiation and metastasis of tumor cells, inhibition of T-cell responses, and stimulation of tumor angiogenesis and disease progression. S15, a highly conserved type 1 cell surface protein, normally involved in osteoclast differentiation and bone remodeling, may play a role in the survival and differentiation of TAMs.	Anti-S15 Monoclonal Antibody NC318		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157062>	C171189|C129822	Ozekibart|Anti-DR5 Agonistic Monoclonal Antibody INBRX-109|INBRX 109|INBRX-109|INBRX109|OZEKIBART	A recombinant, humanized, agonistic, tetravalent monoclonal antibody directed against human death receptor type 5 (DR5), also called tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 (TRAILR2), with potential pro-apoptotic and antineoplastic activities. Upon administration, ozekibart specifically binds to exactly four DR5 receptors per molecule, which mimics the interaction of DR5 with its natural ligand TRAIL. This activates DR5 and the death receptor signaling pathway, which results in the activation of caspase cascades, the induction of tumor cell apoptosis and a reduction in proliferation of DR5-expressing tumor cells. Utilizing a tetravalent monoclonal antibody may overcome the challenge of generating effective DR5 clustering while avoiding toxicities associated with anti-drug antibody (ADA) hyper-clustering. DR5, a member of the TNF receptor superfamily (TNFRSF), is expressed on the surfaces of a variety of tumor cells and plays a key role in the induction of tumor cell apoptosis.	Ozekibart		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157065>	C9184|C114779	Primary Vitreoretinal Non-Hodgkin Lymphoma|PVRL|Primary Vitreoretinal Lymphoma	An uncommon and potentially fatal intraocular non-Hodgkin lymphoma that involves the uvea, retina, vitreous body, and optic nerve. It is a subset of primary central nervous system non-Hodgkin lymphoma. The majority of cases are diffuse large B-cell lymphomas.			Neoplastic Process	
C157066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157066>	C13019	Vitreoretinal Area	The intraocular area that refers to the uvea, retina, vitreous body, and optic nerve.			Body Part, Organ, or Organ Component	
C157067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157067>	C71720|C157065	Primary Vitreoretinal Diffuse Large B-Cell Lymphoma|PVR-LBCL|PVRL DLBCL|PVRL Diffuse Large B-Cell Lymphoma|Primary Large B-Cell Lymphoma of the Vitreoretina	An uncommon and potentially fatal diffuse large B-cell lymphoma that involves the uvea, retina, vitreous body, and optic nerve. It is a subset of primary central nervous system diffuse large B-cell lymphoma.			Neoplastic Process	
C157068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157068>	C212068|C157065	Recurrent Primary Vitreoretinal Non-Hodgkin Lymphoma|Recurrent PVRL|Recurrent Primary Vitreoretinal Lymphoma|Recurrent Primary Vitreoretinal Lymphoma	The reemergence of primary vitreoretinal non-Hodgkin lymphoma after a period of remission.	Recurrent Primary Vitreoretinal Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157069>	C212069|C157065	Refractory Primary Vitreoretinal Non-Hodgkin Lymphoma|Refractory PVRL|Refractory Primary Vitreoretinal Lymphoma	A primary vitreoretinal non-Hodgkin lymphoma that does not respond to treatment.			Neoplastic Process	
C157070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157070>	C157073|C157068|C157067	Recurrent Primary Vitreoretinal Diffuse Large B-Cell Lymphoma|Recurrent PVRL DLBCL	The reemergence of primary vitreoretinal diffuse large B-cell lymphoma after a period of remission.	Recurrent Primary Vitreoretinal Diffuse Large B-Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157071>	C157074|C157069|C157067	Refractory Primary Vitreoretinal Diffuse Large B-Cell Lymphoma|Refractory PVRL DLBCL	A primary vitreoretinal diffuse large B-cell lymphoma that does not respond to treatment.			Neoplastic Process	
C157073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157073>	C71720|C212068|C212058	Recurrent Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System	The reemergence of primary diffuse large B-cell lymphoma of the central nervous system after a period of remission.			Neoplastic Process	
C157074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157074>	C71720|C212069|C212059	Refractory Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System	A primary diffuse large B-cell lymphoma of the central nervous system that does not respond to treatment.			Neoplastic Process	
C157075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157075>	C158520	CPTAC Environmental/Occupational Exposure Codelist|CPTAC Chemical or Occupational Exposure Codelist	Terminology used to support the collection of patient environmental and occupational hazardous exposure data by CPTAC.			Intellectual Product	
C157076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157076>	C35869	Circumferential Margin Status by MRI|Circumferential Margin by MRI	The determination by MRI of the presence or absence of neoplastic tissue outside of a circumferential resection margin.			Finding	
C157077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157077>	C157076	Clear Circumferential Margin by MRI|Negative Circumferential Margin by MRI	The determination by MRI of the absence of neoplastic tissue outside of a circumferential resection margin.			Finding	
C157078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157078>	C157076	Involved Circumferential Margin by MRI|Positive Circumferential Margin by MRI	The determination by MRI of the presence of neoplastic tissue outside of a circumferential resection margin.			Finding	
C157079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157079>	C2078	Arfolitixorin|(6R)-5,10-Methylenetetrahydrofolate|6R-5,10-methyleneTHF|6R-5-10-Methylenetetrahydrofolate|6R-MTHF|6R-methylene THF|ARFOLITIXORIN|Methylenetetrahydrofolic Acid, L-(+)-|Modufolin|Rescufolin|[6R] 5,10-methylenetetrahydrofolate|[6R]-5,10-methylene-tetrahydrofolate	The R-isomer of folitixorin, a reduced folate-based biomodulator and active metabolite of folate drugs leucovorin (LV) and levoleucovorin (l-LV) that can be used to increase the efficacy of certain antimetabolites, such as the cytotoxic agent 5-fluorouracil (5-FU), and reduce as well as protect against certain antimetabolite-associated adverse effects, such as those seen with high-dose (HD) methotrexate. Upon administration of arfolitixorin, 5,10-methylenetetrahydrofolate (MTHF) is a reduced folate substrate for the enzyme thymidylate synthase (TS) and stabilizes, upon co-administration of 5-FU, the covalent binding of the 5-FU metabolite 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP), instead of deoxyuridine monophosphate (dUMP), to its target enzyme TS, which results in an inhibition of TS. This inhibits the synthesis of deoxythymidine monophosphate (dTMP) and leads to the depletion of thymidine triphosphate (TTP), which is a necessary constituent of DNA. This inhibits DNA synthesis, which leads to an inhibition of cellular proliferation and induces tumor cell death. As MTHF is able to stabilize and strengthen the ternary complex, co-administration of arfolitixorin enhances the inhibition of DNA synthesis and increases the cytotoxic effect of 5-FU. As MTHF is the active form of folate and the active metabolite of LV and l-LV, arfolitixorin does not need to be converted to an active metabolite to become activated. In DNA synthesis, a ternary complex is formed between the reduced folate substrate MTHF, the TS enzyme and dUMP in order to convert dUMP to the DNA building block dTMP, which is necessary for DNA synthesis.	Arfolitixorin		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15707>	C49236	Electroporation|EPT|EPT|Electroporation Therapy|Electroporation Therapy|electroporation therapy	A procedure in which in which an electrical field is applied to cells for the purpose of increasing the permeability of the cell membrane, allowing chemicals, drugs, or DNA to be introduced into the cell.	Electroporation Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C157080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157080>	C28533	MFSD8 Gene|MFSD8|MFSD8|Major Facilitator Superfamily Domain Containing 8 Gene	This gene is involved in lysosome functions.			Gene or Genome	
C157081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157081>	C157080	MFSD8 wt Allele|CCMD|CLN7|Ceroid-Lipofuscinosis, Neuronal 7, Late Infantile Gene|Ceroid-Lipofuscinosis, Neuronal 7, Late Infantile, Variant Gene|MGC33302|Major Facilitator Superfamily Domain Containing 8 wt Allele	Human MFSD8 wild-type allele is located in the vicinity of 4q28.2 and is approximately 48 kb in length. This allele, which encodes major facilitator superfamily domain-containing protein 8, plays a role in lysosome activity. Missense mutations in the gene are associated with both macular dystrophy with central cone involvement and late infantile-onset neuronal ceroid lipofuscinosis (vLINCL; neuronal ceroid lipofuscinosis type 7; CLN7 Batten disease).			Gene or Genome	
C157082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157082>	C16386	Major Facilitator Superfamily Domain-Containing Protein 8|Ceroid-Lipofuscinosis Neuronal Protein 7|MFSD8|Major Facilitator Superfamily Domain Containing Protein 8	Major facilitator superfamily domain-containing protein 8 (518 aa, ~58 kDa) is encoded by the human MFSD8 gene. This protein is involved in the modulation of lysosomal functions.			Amino Acid, Peptide, or Protein	
C157083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157083>	C212942	BRD9 Gene|BRD9|BRD9|Bromodomain Containing 9 Gene	This gene plays a role in binding to acylated histones, chromatin remodeling and the regulation of transcription.	BRD9 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C157084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157084>	C157083	BRD9 wt Allele|Bromodomain Containing 9 wt Allele|FLJ13441|LAVS3040|PRO9856|UNQ3040/PRO9856	Human BRD9 wild-type allele is located in the vicinity of 5p15.33 and is approximately 42 kb in length. This allele, which encodes bromodomain-containing protein 9, is involved in chromatin remodeling, transcriptional regulation and acylated histone binding.	BRD9 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157085>	C26199	Bromodomain-Containing Protein 9|BRD9|Rhabdomyosarcoma Antigen MU-RMS-40.8|Sarcoma Antigen NY-SAR-29	Bromodomain-containing protein 9 (597 aa, ~67 kDa) is encoded by the human BRD9 gene. This protein plays a role in transcriptional regulation, acylated histone binding and chromatin remodeling.	Bromodomain-Containing Protein 9		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157086>	C54362	BICRAL Gene|BICRAL|BICRAL|BRD4 Interacting Chromatin Remodeling Complex Associated Protein Like Gene	This gene is involved in chromatin remodeling and transcriptional regulation.			Gene or Genome	
C157087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157087>	C157086	BICRAL wt Allele|BRD4 Interacting Chromatin Remodeling Complex Associated Protein Like wt Allele|GLTSCR1 Like Gene|GLTSCR1-Like Gene|GLTSCR1L|Glioma Tumor Suppressor Candidate Region Gene 1-Like Gene|KIAA0240	Human BICRAL wild-type allele is located in the vicinity of 6p21.1 and is approximately 122 kb in length. This allele, which encodes BRD4-interacting chromatin-remodeling complex-associated protein-like protein, plays a role in SWI/SNF-dependent chromatin remodeling.			Gene or Genome	
C157088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157088>	C26199	BRD4-Interacting Chromatin-Remodeling Complex-Associated Protein-Like|BICRAL|BRD4 Interacting Chromatin Remodeling Complex Associated Protein Like|BRD4 Interacting Chromatin Remodelling Complex Associated Protein Like|GLTSCR1-Like|GLTSCR1L|Glioma Tumor Suppressor Candidate Region Gene 1 Protein-Like	BRD4-interacting chromatin-remodeling complex-associated protein-like (1079 aa, ~115 kDa) is encoded by the human BICRAL gene. This protein is involved in SWI/SNF-mediated chromatin remodeling.			Amino Acid, Peptide, or Protein	
C157089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157089>	C54362|C20348	BCL7B Gene|BCL7B|BCL7B|BCL7B, BAF Complex Component Gene	This gene plays a role in SWI/SNF complex-mediated chromatin remodeling and in the regulation of apoptosis.			Gene or Genome	
C15708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15708>	C15669	Prevention of Oral Cancer|Oral Cancer Prevention	Any method of preventing oral cancer including limiting of exposure to carcinogens and infectious agents, diet, education, or lifestyle.			Therapeutic or Preventive Procedure	
C157090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157090>	C200766|C176018	Autologous CD4+/CD8+ 4-1BB-CD3zeta-EGFR806-CAR-EGFRt/4-1BB-CD3zeta-CD19-CAR-HER2tG-expressing CARs T Cells|Autologous CD4+/CD8+ 4-1BB-CD3zeta-EGFR806-CAR-EGFRt/4-1BB-CD3zeta- CD19-CAR-HER2tG-expressing CARs T Cells|Autologous CD4+/CD8+ T Cells Expressing EGFR806-specific CAR/EGFRt and CD19-specific CAR/HER2tG|Autologous EGFR806-specific CAR T Cells|Autologous EGFR806xCD19 Bispecific CAR T Cells	A preparation of CD4+ and CD8+ autologous T-lymphocytes transduced with a lentiviral vector that co-expresses two different second generation chimeric antigen receptors (CARs), one composed of a short chain variable fragment (scFv) binding domain derived from depatuxizumab, a human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MAb806; ABT-806), coupled to the zeta chain of the TCR/CD3 complex (CD3-zeta) and the signaling domain of 4-1BB (CD137), and linked to a truncated form of the human epidermal growth factor receptor (EGFRt), and one composed of a short chain variable fragment (scFv) binding domain derived from an anti-CD19 monoclonal antibody, coupled to CD3-zeta) and 4-1BB,  and linked to a truncated form of the human epidermal growth factor receptor 2 (HER2tG), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, the autologous CD4+/CD8+ 4-1BB-CD3zeta-EGFR806-CAR-EGFRt/4-1BB-CD3zeta- CD19-CAR-HER2tG-expressing CARs T-cells are directed to, bind to, and induce selective toxicity in EGFR deletion mutation variant III (EGFRvIII)-expressing tumor cells. The binding of these T-cells to CD19 expressed on B-cells enhances their expansion and prolongs their persistence in vivo, thereby increasing the efficacy of these CAR T-cells. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt and HER2tG facilitate in vivo detection of the administered, transduced T-cells and can promote elimination of these cells through an antibody-dependent cellular cytotoxicity (ADCC) response. HER2tG allows for enhanced binding by trastuzumab. EGFRvIII, an in-frame deletion of exons 2-7 in the EGFR gene, is overexpressed by a variety of cancer cell types but absent in normal, healthy cells. It plays a key role in tumor cell proliferation, tumor angiogenesis and resistance to both radio- and chemotherapy. Depatuxizumab specifically targets abnormal conformational states of EGFR, including EGFRvIII, and activating mutations, with lower affinity for wild-type EGFR. CD19, a transmembrane phosphoglycoprotein is expressed on the surface of cells in the B-lineage.	Autologous CD4+/CD8+ 4-1BB-CD3zeta-EGFR806-CAR-EGFRt/4-1BB-CD3zeta- CD19-CAR-HER2tG-expressing CARs T Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157091>	C157089	BCL7B wt Allele|B-Cell CLL/Lymphoma 7B Gene|BCL Tumor Suppressor 7B Gene|BCL7B, BAF Complex Component wt Allele	Human BCL7B wild-type allele is located in the vicinity of 7q11.23 and is approximately 22 kb in length. This allele, which encodes B-cell CLL/lymphoma 7 protein family member B protein, is involved in both the promotion of apoptosis and chromatin remodeling. The chromosome region this gene resides in is associated with Williams-Beuren syndrome.			Gene or Genome	
C157092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157092>	C81182	Perometer	A device designed for the measurement of limb volume. It consists of two sets of light-emitting diodes and photosensors arranged as parallel-acting light curtains. The transmitters are set in a frame, perpendicular to each other, so that as the frame passes over the limb the limb is illuminated and its diameter is measured in two planes.	Perometer		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C157093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157093>	C49235	Form Directive	A direction to fill out a form in a particular manner.			Activity	
C157094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157094>	C157093	CDR Entry Completed by (signature)	A directive to add the signature of the individual completing the Comprehensive Data Resource (CDR).			Activity	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Medical History Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Normal Endometrial Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Surgery-Anesthesia Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form
C157095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157095>	C157093	Confirm AJCC/TNM Cancer Staging Edition	A directive to confirm the relevant edition of the AJCC/TNM Cancer Staging Edition.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uveal Melanoma Baseline Form
C157096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157096>	C157093	Specify Therapeutic Agent|Therapeutic Agent|Therapeutic Agent|Therapeutic Agent(s)	A directive to record the therapeutic agent or agents.			Activity	CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Terminology
C157097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157097>	C157093	Form Completed by (Signature)|Form Completed by (signature)	A directive to provide the signature of the individual completing the form.			Activity	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Medical History Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Normal Endometrial Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Surgery-Anesthesia Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form
C157098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157098>	C157093	If cM1, specify site(s)	A directive to indicate the anatomic sites if metastasis is categorized as cM1.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uveal Melanoma Baseline Form
C157099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157099>	C157093	Specify Site if Documented Distant Metastasis|If distant metastasis documented, specify site|If distant metastasis documented, specify site(s), if known	A directive to specify the anatomic location of any documented distant metastasis.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C15709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15709>	C19770|C15419	Genetic Testing|Genetic Analysis|Genetic Examination|Genetic Test|genetic analysis|genetic testing|genetic testing	The process of isolating and testing the DNA of an embryo or a person to detect the presence of genetic alterations or defects that may predispose to the future development of a disease or disorder.	Genetic Testing		Laboratory Procedure	CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|Neonatal Research Network Terminology|Newborn Screening Terminology|NICHD Terminology
C1570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1570>	C155653	Dinutuximab|Ch 14.18UTC|Ch14.18|Ch14.18|DINUTUXIMAB|Dinutuximab Beta|MOAB Ch14.18|Qarziba|Unituxin|monoclonal antibody Ch14.18	A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Dinutuximab binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells.  GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung.	Dinutuximab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|OS Authorized Value Terminology|OS Total Dose Table
C157100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157100>	C157106	Specify Other Type of Exposure|If other type of exposure, please specify|Other,specify	A directive to specify the type of exposure when the listed responses are not sufficient.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C157101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157101>	C157093	If Other, Specify|If other, please comment|If other, please indicate|If other, please specify|If other, specify	A directive to specify when the listed responses are not sufficient.			Activity	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form|CRF1 Registration Table|CRF3 Diagnosis Biopsy Table|CRF3 Diagnosis Re-Biopsy Table|CRF4 Treatment Additional Surgeries Table|CRF4 Treatment Steroids during Radiation Table|CRF4 Treatment Steroids during Re-Irradiation Table|CRF4 Treatment Surgery Table|CRF4 Treatment Table|CRF7 Pathology Review Table
C157102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157102>	C157093	Specify Site if pM1|If pM1, specify site(s)	A directive to indicate the anatomic sites if metastasis is categorized as pM1.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uveal Melanoma Baseline Form
C157103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157103>	C157093	Select Exposure Types|If yes, please select exposure types (select all that apply)|exposure type|exposure_type	A directive to select all the relevant exposure types.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology|GDC Property Terminology|GDC Terminology
C157104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157104>	C157093	Specify if Yes|If yes, please specify|If yes, specify	A directive to provide a more specific response if the answer to the question is yes.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology|CRF2 History and Physical Exam Family Medical History Table|CRF2 History and Physical Exam Patient Medical History Table
C157105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157105>	C157093	Specify Type of Testing and Results if Yes|If yes, specify (type and result)|If yes, specify (type and results)	A directive to specify the type and results if the response is yes.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C157106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157106>	C157093	Specify Other|Other, Specify|Other, specify|Other, specify	A directive to indicate a response not listed.			Activity	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 3: COVID-19 Diagnosis Terminology|Appendix 6: Symptoms and Signs Terminology|Appendix 8: Pharmacological Therapy Terminology|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|Physical Examination Terminology|Therapies for COVID-19 Terminology
C157107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157107>	C157093	Print, Sign, Date Form|Print this form, then sign and date the section below	A directive to print the form, sign and date the section indicated.			Activity	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Medical History Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Normal Endometrial Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Surgery-Anesthesia Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form
C157108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157108>	C157093	Select All That Apply|Or, Select all that apply	A directive to choose all that apply to the situation.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Surgery-Anesthesia Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C157109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157109>	C157093	Select One	A directive to choose one of the options provided.			Activity	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Normal Endometrial Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uveal Melanoma Baseline Form
C15710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15710>	C15187	Nicotine Replacement|NRT|Nicotine Replacement Therapy|nicotine replacement therapy	Therapy to help control nicotine withdrawal symptoms during tobacco cessation	Nicotine Replacement		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C157110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157110>	C157093	Specify HPV Genotype|HPV Genotype|hpv strain|hpv_strain	A directive to specify the genotype determined by HPV Genotyping.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Property Terminology|GDC Terminology
C157111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157111>	C157093	Transcribe Data into CDR and Record the Following|Transcribe the data from this form into CDR, and record the following	A directive to transcribe the form data into the Comprehensive Data Resource, and record the following information.			Activity	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Medical History Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Normal Endometrial Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Surgery-Anesthesia Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form
C157112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157112>	C18520	Acetaminophen-Cysteine Protein Adduct|APAP-CYS|Acetaminophen Protein Adduct|Acetaminophen-Cysteine|PPA|Paracetamol Protein Adduct|Paracetamol-Cysteine	A modified protein, usually glutathione, where oxidized acetaminophen is bound to the sulfhydryl group of cysteine residues. The presence of acetaminophen-cysteine or its proteolyzed product 3-para cysteinyl acetaminophen in a sample is a specific biomarker for acetaminophen exposure and increased concentrations of these adducts may be associated with acetaminophen toxicity.	Acetaminophen-Cysteine Protein Adduct		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Terminology
C157113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157113>	C165233	TET2 Negative|Methylcytosine Dioxygenase TET2 Loss|Methylcytosine Dioxygenase TET2 Negative|TET2 Deficiency|TET2 Deficient|TET2 Loss|Tet Methylcytosine Dioxygenase 2 Loss|Tet Methylcytosine Dioxygenase 2 Negative|Tet Oncogene Family Member 2 Loss|Tet Oncogene Family Member 2 Negative	An indication that TET2 expression or activity has not been detected in a sample.	TET2 Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157114>	C64548	High Sensitivity C-Reactive Protein Measurement|High Sensitivity C-Reactive Protein|High Sensitivity CRP Measurement|High-Sensitivity C-Reactive Protein Measurement|High-Sensitivity CRP|hs-CRP|hsCRP	The determination of the amount of C-reactive protein (CRP) present in a sample through the use of immunonephelometry, immunoturbidimetry, high-sensitivity enzyme-linked immunosorbent assay (ELISA) and/or resonant acoustic profiling (RAP). This test is optimized to measure lower concentrations of CRP than a conventional CRP test.	High Sensitivity C-Reactive Protein Measurement		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157115>	C35682|C175007	Anti-Poliovirus Antibody Positive|Anti-Poliovirus Positive|Poliovirus Antibody Positive	An indication that antibodies that recognize poliovirus have been detected in a sample.	Anti-Poliovirus Antibody Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C157116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157116>	C138961	PSA Level Less than or Equal to Fifty|PSA Level 50 or Less|PSA Level Fifty or Less|PSA Level Less than or Equal to 50	A blood concentration of prostate specific antigen less than or equal to 50 ng/mL.	PSA Level Less than or Equal to Fifty		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157117>	C24432	tGLI1 Allele|TGLI1|Truncated GLI Family Zinc Finger 1 Allele|Truncated GLI1 Gene|Truncated Glioma-Associated Oncogene Homolog 1 Gene|tGLI	Human tGLI1 allele is located in the vicinity of 12q13.3 and is approximately 12 kb in length. This allele, which encodes truncated glioma-associated oncogene homolog 1 protein, is involved in the modulation of transcription by RNA polymerase II. Expression of this allele is associated with glioblastoma multiforme (GBM).	tGLI1 Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157118>	C17207	GLI1 Gene Product	A protein encoded by the GLI1 gene.	GLI1 Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157119>	C157118	Truncated Glioma-Associated Oncogene Homolog 1 Protein|TGLI1|Truncated GLI-Kruppel Family Member GLI1|Truncated GLI1|Truncated GLI1 Protein|Truncated Glioma Associated Oncogene Homolog 1 Protein|Truncated Glioma-Associated Oncogene Family Zinc Finger 1|Truncated Zinc Finger Protein GLI1|tGLI1	Truncated glioma-associated oncogene homolog 1 protein (1065 aa, ~114 kDa) is encoded by the human GLI1 gene. This protein is involved in transcriptional regulation, tumorigenesis, cell motility and cellular invasiveness.	Truncated Glioma-Associated Oncogene Homolog 1 Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15711>	C15429	Prevention Research	Studies identifying, testing, and implementing interventions among groups of individuals that are designed to prevent the initiation of a substance, such as tobacco or alcohol.			Research Activity	
C157120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157120>	C156805	Site of Tumor|TUMOR_SITE|TUMOR_SITE|TUMOR_SITE|Tumor Site|Tumor site	The anatomic site of the tumor.			Clinical Attribute	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uveal Melanoma Baseline Form|CRF7 Pathology Review Table|EWS Tumor Assessment Table|EWS Variable Terminology|GCT Tumor Assessment Table|GCT Variable Terminology|OS Tumor Assessment Table|OS Variable Terminology
C157121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157121>	C164339	Initial Cancer Diagnosis Date|Date of Initial Cancer Diagnosis|Date of Initial Pathologic Diagnosis|Initial Cancer Diagnosis|Initial Pathologic Diagnosis	The date of the initial cancer diagnosis.			Temporal Concept	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uveal Melanoma Baseline Form|NAACCR Terminology
C157122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157122>	C85865|C84392|C53543	Intellectual Developmental Disorder, X-Linked, Syndromic, Borjeson-Forssman-Lehmann Type|BFLS|Borjeson-Forssman-Lehmann Syndrome|MRXSBFL|Mental Retardation, Epilepsy, and Endocrine Disorders|Mental Retardation, X-Linked, Syndromic, Borjeson-Forssman-Lehmann Type	An X-linked recessive condition caused by mutation(s) in the PHF6 gene, encoding PHD finger protein 6. It is characterized by severe intellectual disability, epilepsy, hypogonadism, hypometabolism, and obesity.			Disease or Syndrome	Cellosaurus Disease Terminology
C157123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157123>	C53543	Infantile-Onset Multisystem Autoimmune Disease 1|ADMIO1	An autosomal dominant condition caused by mutation(s) in the STAT3 gene, encoding signal transducer and activator of transcription 3. It is characterized by variable features along a spectrum of autoimmune disorders affecting multiple organs. Common manifestations may include insulin-dependent diabetes mellitus and autoimmune enteropathy, or celiac disease, and autoimmune hematologic disorders. Other features include short stature and nonspecific dermatitis.			Disease or Syndrome	Cellosaurus Disease Terminology
C157124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157124>	C53543	Phelan-McDermid Syndrome|Chromosome 22q13.3 Deletion Syndrome|PHMDS	An autosomal dominant condition caused by mutation(s) and or deletion of the SHANK3 gene, encoding SH3 and multiple ankyrin repeat domains protein 3. It is characterized by variable features, which may include intellectual disability, autism spectrum disorder, developmental delay and mild dysmorphic features.			Disease or Syndrome	Cellosaurus Disease Terminology
C157125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157125>	C3308|C182030|C157130	Recurrent Paraganglioma	The reemergence of paraganglioma after a period of remission.	Recurrent Paraganglioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157126>	C3308	Unresectable Paraganglioma	Paraganglioma that is not amenable to surgical resection.	Unresectable Paraganglioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157127>	C134305	Tuparstobart|Anti-LAG-3 Monoclonal Antibody INCAGN02385|Anti-LAG3 Monoclonal Antibody INCAGN02385|INCAGN 02385|INCAGN 2385|INCAGN02385|INCAGN2385|TUPARSTOBART	A Fc-engineered immunoglobulin G1-kappa (IgG1k) monoclonal antibody targeting the co-inhibitory receptor lymphocyte-activation gene 3 protein (LAG-3; LAG3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, tuparstobart targets and binds to human LAG-3 on tumor-infiltrating  lymphocytes (TILs) and blocks the interaction between LAG-3 and major histocompatibility complex class II (MHC II) molecules on the surface of antigen-presenting cells (APCs) and tumor cells. This prevents the negative regulation of T-cell activity that occurs via LAG-3-MHC II binding and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells, which leads to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF), negatively regulates both proliferation and activation of T-cells. Its expression on  TILs is associated with tumor-mediated immune suppression.	Tuparstobart		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157128>	C3326|C157126	Unresectable Adrenal Gland Pheochromocytoma	Adrenal gland pheochromocytoma that is not amenable to surgical resection.	Unresectable Adrenal Gland Pheochromocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157129>	C4220|C133713	Locally Advanced Adrenal Gland Pheochromocytoma	Adrenal gland pheochromocytoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Adrenal Gland Pheochromocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C15712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15712>	C15843	Secondary Prevention|Prevention, Secondary|SECONDARY PREVENTION	Procedures or treatment processes designed to prevent complications (e.g., modifying a drug or surgical procedure to prevent complications).			Therapeutic or Preventive Procedure	CDISC SDTM Cardiac Procedure Indication Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C157130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157130>	C4798|C3809	Recurrent Neuroendocrine Neoplasm	The reemergence of a neuroendocrine neoplasm after a period of remission.			Neoplastic Process	
C157131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157131>	C7628|C3809	Refractory Neuroendocrine Neoplasm	A neuroendocrine neoplasm that does not respond to treatment.			Neoplastic Process	
C157132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157132>	C18520	Phosphorylated-STAT3 Y705|Phospho-STAT3 Y705|Phosphorylated STAT3 Y705|Phosphorylated-Signal Transducer and Activator of Transcription 3 Y705|STAT3 (Phospho-Tyr705)|STAT3 (pY705)|STAT3 Phosphorylated on Tyr705|STAT3 pY705|pY-STAT3	A post-translationally modified form of signal transducer and activator of transcription 3 (STAT3) where the tyrosine (Y; Tyr) at residue 705 is phosphorylated. Janus kinase (JAK)-mediated phosphorylation of Y705 activates STAT3 and promotes the formation of STAT3-containing dimers, which translocate into the nucleus and induce STAT3-dependent gene expression.	Phosphorylated-STAT3 Y705		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157133>	C345	Deoxyaminopteroic Acid|2,4-Apa|2,4-Diamino-N(10)-methylpteroic Acid|4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzoic Acid|4-Amino-4-deoxy-N-10-methylpteroic Acid|4-Amino-4-deoxy-N-10-methylpteroic Acid Hydrochloride (2:1)|4-Deoxy-4-amino-N(10)-methylpteroic Acid|DAMPA|N-10-methyl-4-deoxy-4-aminopteroate	A metabolite resulting from the carboxypeptidase-mediated cleavage of methotrexate. Deoxyaminopteroic acid can be used a marker for methotrexate exposure.	Deoxyaminopteroic Acid		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C157134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157134>	C782	Prostaglandin E|PGE	A family comprised of three naturally occurring prostaglandins that are involved in the regulation of many biological functions including vasodilation, inflammation and smooth muscle cell contractility.	Prostaglandin E		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C157135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157135>	C25483	Greatest Dimension Tumor|Greatest Measured Dimension|Tumor Size - greatest dimension|Tumor Size - greatest dimension (largest tumor if multiple)|greatest tumor dimension|greatest_tumor_dimension|tumor largest dimension diameter|tumor_largest_dimension_diameter	A measurement of the widest portion of a tumor.			Spatial Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uveal Melanoma Baseline Form|GDC Property Terminology|GDC Terminology
C157136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157136>	C25871	PKLR Gene|PKLR|PKLR|Pyruvate Kinase L/R Gene	This gene plays a role in the production of ATP in glycolysis.	PKLR Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C157137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157137>	C157136	PKLR wt Allele|PK1|PKL|PKR|PKRL|Pyruvate Kinase L/R wt Allele|Pyruvate Kinase, Liver Type Gene|Pyruvate Kinase, Liver and RBC Gene|Pyruvate Kinase, Red Cell Type Gene|RPK	Human PKLR wild-type allele is located in the vicinity of 1q22 and is approximately 19 kb in length. This allele, which encodes pyruvate kinase PKLR protein, is involved in glycolysis.	PKLR wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157138>	C16984	PKLR Gene Product	A protein encoded by the PKLR gene.			Amino Acid, Peptide, or Protein|Enzyme	
C157139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157139>	C157138	Pyruvate Kinase PKLR|EC 2.7.1.40|PKLR|PKR|Pyruvate Kinase 1|Pyruvate Kinase Isozyme R|Pyruvate Kinase Isozyme R/L|Pyruvate Kinase Isozymes L/R|Pyruvate Kinase Isozymes R|Pyruvate Kinase Isozymes R/L|Pyruvate Kinase L/R|Pyruvate Kinase PKLR Isoform R-Type|Pyruvate Kinase PKR|Pyruvate Kinase R|R-Type PK|R-Type Pyruvate Kinase|R-Type/L-Type Pyruvate Kinase|Red Cell Pyruvate Kinase|Red Cell/Liver Pyruvate Kinase	Pyruvate kinase PKLR (574 aa, ~62 kDa) is encoded by the human PKLR gene. This protein plays a role in the transphosphorylation of phohsphoenolpyruvate into pyruvate and ATP in erythrocytes.	Pyruvate Kinase PKLR		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15713>	C15885	Religion and Spirituality	Used as subcategory of Mind-Body Medicine in CAM.  This area deals with the non-behavioral aspects of spirituality and religion that examine their relationship to biological function or clinical conditions.  It included activities such as prayer, soul retrieval, spiritual healing, Included are: Prayer, Confession, Nonlocality, Nontemporality, Consciousness studies, Spirituality constructs (Love, hope, faith, joy, etc.), Soul retrieval (see Indigenous practices), Spiritual healing, "Special" healers (see "Biofield").			Idea or Concept	
C157140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157140>	C157138	Pyruvate Kinase PKLR Isoform L-Type|EC 2.7.1.40|L-Type PK|L-Type Pyruvate Kinase|Liver Pyruvate Kinase|PKL|PKLR|Pyruvate Kinase Isozyme L|Pyruvate Kinase Isozymes L|Pyruvate Kinase L|Pyruvate Kinase PKL	Pyruvate kinase PKLR isoform L-type (543 aa, ~58 kDa) is encoded by the human PKLR gene. This protein is involved in transphosphorylation of phohsphoenolpyruvate into pyruvate and ATP in the liver.	Pyruvate Kinase PKLR Isoform L-Type		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157141>	C97927	PKLR Gene Mutation|PK1 Gene Mutation|PKL Gene Mutation|PKR Gene Mutation|PKRL Gene Mutation|Pyruvate Kinase L/R Gene Mutation|Pyruvate Kinase, Liver and RBC Gene Mutation|RPK Gene Mutation	A change in the nucleotide sequence of the PKLR gene.	PKLR Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157142>	C18133|C157141	Non-synonymous PKLR Gene Mutation|Non-synonymous PK1 Gene Mutation|Non-synonymous PKL Gene Mutation|Non-synonymous PKR Gene Mutation|Non-synonymous PKRL Gene Mutation|Non-synonymous Pyruvate Kinase L/R Gene Mutation|Non-synonymous Pyruvate Kinase, Liver and RBC Gene Mutation|Non-synonymous RPK Gene Mutation|PKLR Missense Gene Mutation|PKLR Missense Mutation	A point mutation in the PKLR gene that encodes an amino acid substitution in the pyruvate kinase PKLR protein.	Non-synonymous PKLR Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157143>	C17146	CONNECT Video Doctor|Video Doctor	A multimedia interactive intervention that uses an actor-portrayed Video Doctor and a library of digital video clips, extensive branching logic, and participant input, to provide participants with information tailored to their individual responses. The system establishes proactive outreach using brief telephone calls and text messaging to follow up with smokers, provide motivation enhancement, and refer and engage patients in evidence based smoking cessation interventions. A typical session takes 10-15 minutes.	CONNECT Video Doctor		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C157144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157144>	C159979	Was Additional Testing Performed Question|Other testing performed|Was Additional Testing Performed	A question asking if any additional tests were performed during the study.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C157145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157145>	C124447	Number of Lymph Nodes Positive for Tumor by IHC Staining Only	The quantity of lymph nodes that were positive for a neoplastic lesion with immunohistochemical (IHC) staining procedures.			Quantitative Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uveal Melanoma Baseline Form
C157146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157146>	C124447	Number of Lymph Nodes Positive for Tumor by H&E	The quantity of lymph nodes that were positive for a neoplastic lesion with hematoxylin and eosin (H&E) procedures.			Quantitative Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uveal Melanoma Baseline Form
C157147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157147>	C84625	Cerebral Amyloid Angiopathy, APP-Related|HCHWAD|Hereditary Cerebral Hemorrhage with Amyloidosis-Dutch Type	An autosomal dominant form of cerebral amyloid angiopathy caused by mutation(s) in the APP gene, encoding amyloid-beta A4 protein. The deposition of amyloid in cerebral blood vessels wall may lead to degenerative vascular changes that may result in cerebral hemorrhage. Mutation(s) in the APP gene may also cause autosomal dominant Alzheimer disease 1.			Disease or Syndrome	Cellosaurus Disease Terminology
C157148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157148>	C84646	Congenital Dyserythropoietic Anemia Type IV|CDAN4	An autosomal dominant sub-type of congenital dyserythropoietic anemia caused by mutation(s) in the KLF1 gene, encoding Krueppel-like factor 1.			Disease or Syndrome	Cellosaurus Disease Terminology
C157149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157149>	C102533	Pathological Myopia	A sub-type of myopia characterized by high myopia with any posterior myopia-specific pathology resulting from axial elongation.			Finding	Cellosaurus Disease Terminology
C15714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15714>	C15429	Basic Research|BASIC SCIENCE|Basic Science|Basic Science Research	Fundamental research designed to obtain or increase general scientific knowledge.			Research Activity	CDISC SDTM Terminology|CDISC SDTM Trial Indication Type Terminology|Clinical Data Interchange Standards Consortium Terminology|SeroNet Authorized Values|SeroNet Study Descriptors
C157150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157150>	C140267	Spastic Paraplegia 76	An autosomal recessive subtype of hereditary spastic paraplegia caused by mutation(s) in the CAPN1 gene, encoding calpain-1 catalytic subunit.			Disease or Syndrome	Cellosaurus Disease Terminology
C157151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157151>	C18772	Chemical/Occupational Exposure History|Chemical or Occupational Exposure History|History of Chemical/Occupational Exposures	A record of the individual's history of exposure to chemicals and/or occupational hazard.			Clinical Attribute	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C157152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157152>	C158612	Was there a History of Radiation Exposure Question|History of Radiation Exposure|Was there a History of Radiation Exposure	A question about an individual's history of exposure to radiation.			Clinical Attribute	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C157153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157153>	C18772	Risk Factor History|History of Risk Factors	A record of an individual's attribute, characteristic or exposure that increases the likelihood of developing a disease or injury. (WHO)			Clinical Attribute	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C157154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157154>	C156811	Therapeutic Ionizing Radiation to Head History Question|History of Therapeutic Ionizing Radiation to Head|Therapeutic Ionizing Radiation to Head History	A record of an individual's history of exposure to ionizing radiation to the head.			Clinical Attribute	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology
C157155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157155>	C16669	HIV Status	The result of testing to determine if an individual is infected with the human immunodeficiency virus.			Qualitative Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C157156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157156>	C157093	IHC Staining not Done|IHC staining not done	An indication that immunohistochemical staining was not performed.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uveal Melanoma Baseline Form
C157157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157157>	C48655	Indeterminate or Unknown|Indeterminate or Unknown: Could not be determined or unsure.|Unknown: Could not be determined or unsure	An indication that something is indeterminate or unknown.			Qualitative Concept	
C157158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157158>	C53543|C3492|C34563	Tyrosine Hydroxylase Deficiency|Dystonia, Dopa-Responsive, Autosomal Recessive|Parkinsonism, Infantile, Autosomal Recessive|Segawa Syndrome, Autosomal Recessive	An autosomal recessive condition caused by mutation(s) in the TH gene, encoding tyrosine 3-monooxygenase. It is characterized by onset in infancy of dopa-responsive dystonia.			Disease or Syndrome	Cellosaurus Disease Terminology
C157159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157159>	C95149	Ishak Score 1-2|1,2 - Portal Fibrosis|1-2 (Portal Fibrosis)	Portal fibrosis is present.			Classification	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C15715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15715>	C15429	Applied Research|Applied Science	Research directed toward solving a specific problem.			Research Activity	
C157160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157160>	C18280	1p/19q Codeletion Status|1p/19q Co-deletion Status|1p/19q Deletion|1p/19q Status|del(1p/19q) Status	A procedure used to detect concurrent deletion of chromosome arms 1p and 19q.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C157161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157161>	C95149	Ishak Score 3-4|3,4 - Fibrous Septa|3-4 (Fibrous Septa)	Fibrosis extends beyond the portal areas and bridging fibrosis is present.			Classification	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C157162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157162>	C158612	Was Adjuvant I-131 Therapy Administered Question|Adjuvant I-131 Therapy|Was Adjuvant I-131 Therapy Administered	A question whether radioiodine therapy was administered with the intent of suppressing secondary tumor formation.			Therapeutic or Preventive Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C157163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157163>	C36292	AFP Level Finding	A finding that indicates the amount of alpha-fetoprotein tumor marker in a sample.			Laboratory or Test Result	
C157164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157164>	C36292	Albumin Level Finding	A finding that indicates the amount of albumin in a sample.			Laboratory or Test Result	
C157165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157165>	C158502	Androgen Receptor Status by Immunochemistry|AR Status by IHC|AR Status by Immunochemistry|AR Status by Immunohistochemistry	An indication that expression or absence of AR in a sample was determined using immunohistochemical staining techniques.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C157166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157166>	C158852	ATRX Mutation Status by Sequencing|ATRX Sequencing|Alpha Thalassemia/Mental Retardation Syndrome X-Linked Mutation Analysis by Sequencing|RAD54 Homolog Mutation Analysis by Sequencing|RAD54 Mutation Analysis by Sequencing|RAD54L Mutation Analysis by Sequencing|XH2 Mutation Analysis by Sequencing|XNP Mutation Analysis by Sequencing|ZNF-HX Mutation Analysis by Sequencing	An indication that the presence or absence of ATRX gene mutations was determined using sequencing techniques.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology
C157167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157167>	C18302	BAP1 Mutation Analysis|BAP1 Mutation Status|BRCA1 Associated Protein 1 Mutation Analysis|BRCA1-Associated Protein 1 Mutation Analysis|UCHL2 Mutation Analysis	A procedure used to detect and identify mutations in the BAP1 gene.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C15716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15716>	C63536	Population Study|Population Based Study|ecologic study|ecological study|population study	Multidisciplinary study done at the population level or among the population groups, generally to find the cause, incidence or spread of the disease or to see the response to the treatment, nutrition or environment.			Research Activity	
C157170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157170>	C42075	Barrett Esophagus With Metaplastic Goblet Cell Columnar Epithelium|Barrett's Esophagus With Goblet Cells	A finding in an esophageal biopsy specimen indicating the diagnosis of Barrett esophagus associated with the presence of metaplastic columnar epithelium containing goblet cells.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology
C157171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157171>	C42075	Barrett Esophagus With Metaplastic Non-Goblet Cell Columnar Epithelium|Barrett's Esophagus Without Goblet Cells	A finding in an esophageal biopsy specimen indicating the diagnosis of Barrett esophagus associated with the presence of metaplastic non-goblet cell columnar epithelium.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology
C157172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157172>	C18302	BRAF Mutation Analysis|B-RAF Mutation Analysis|B-RAF1 Mutation Analysis|BRAF Mutation Status|BRAF1 Mutation Analysis|v-raf Murine Sarcoma Viral OncoHomolog B1 Mutation Analysis	A procedure used to detect and identify mutations in the BRAF gene.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C157173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157173>	C20181	Reimbursement	A payback for out-of-pocket expenses.			Classification	
C157174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157174>	C27993	Busy	Actively or fully engaged or occupied.			Qualitative Concept	
C157175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157175>	C19975	Clinical Proteomic Tumor Analysis Consortium|CPTAC	A national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics.			Professional or Occupational Group	
C157176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157176>	C18302	CDH1 Mutation Analysis|CD324 Mutation Analysis|CDH1 Mutation Status|CDHE Mutation Analysis|Cadherin 1 Mutation Analysis|E-Cadherin Mutation Analysis|ECAD Mutation Analysis|LCAM Mutation Analysis|UVO Mutation Analysis	A procedure used to detect and identify mutations in the CDH1 gene.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C157177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157177>	C18302	CTNNB1 Mutation Analysis|Beta Catenin Mutation Analysis|Beta-Catenin Mutation Analysis|CTNNB Mutation Analysis|CTNNB1 Mutation Status|Catenin Beta 1 Mutation Analysis	A procedure used to detect and identify mutations in the CTNNB1 gene.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C157178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157178>	C18302	ERBB2 Mutation Analysis|ERBB2 / HER2 Mutation Status|ERBB2 Mutation|ERBB2/HER2 Mutation Status|Erb-B2 Receptor Tyrosine Kinase 2 Mutation Analysis|HER2 Mutation Analysis|HER2/neu Mutation Analysis|NEU Mutation Analysis|v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 Mutation Analysis	A procedure used to detect and identify mutations in the ERBB2 gene.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C157179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157179>	C18302	FGFR1 Mutation Analysis|BFGFR Mutation Analysis|CD331 Mutation Analysis|CEK Mutation Analysis|FGFBR Mutation Analysis|FGFR-1 Mutation Analysis|FGFR1 Mutation Status|FLG Mutation Analysis|FLT-2 Mutation Analysis|FLT2 Mutation Analysis|FMS-Like Tyrosine Kinase 2 Mutation Analysis|Fibroblast Growth Factor Receptor 1 Mutation Analysis|KAL2 Mutation Analysis|N-SAM Mutation Analysis|OGD Mutation Analysis	A procedure used to detect and identify mutations in the FGFR1 gene.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C15717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15717>	C16056	Cytogenetic Map	The visual appearance of a chromosome when stained and examined under a microscope. Particularly important are visually distinct regions, called light and dark bands, which give each of the chromosomes a unique appearance. This feature allows a person's chromosomes to be studied in a clinical test known as a karyotype, which allows scientists to look for chromosomal alterations. (NHGRI Glossary of Genetic Terms)			Intellectual Product	
C157180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157180>	C18302	FGFR2 Mutation Analysis|BEK Mutation Analysis|CD332 Mutation Analysis|ECT1 Mutation Analysis|FGFR-2 Mutation Analysis|FGFR2 Mutation Status|Fibroblast Growth Factor Receptor 2 Mutation Analysis|K-SAM Mutation Analysis|KGFR Mutation Analysis	A procedure used to detect and identify mutations in the FGFR2 gene.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C157181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157181>	C18302	FGFR3 Mutation Analysis|CD333 Mutation Analysis|FGFR-3 Mutation Analysis|FGFR3 Mutation Status|Fibroblast Growth Factor Receptor 3 Mutation Analysis|JTK4 Mutation Analysis	A procedure used to detect and identify mutations in the FGFR3 gene.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C157182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157182>	C18302	GNA11 Mutation Analysis|G Protein Subunit Alpha 11 Mutation Analysis|GA11 Mutation Analysis|GNA-11 Mutation Analysis|GNA11 Mutation Status	A procedure used to detect and identify mutations in the GNA11 gene.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C157183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157183>	C18302	GNAQ Mutation Analysis|CMC1 Mutation Analysis|G Protein Subunit Alpha q Mutation Analysis|G-ALPHA-q Mutation Analysis|GAQ Mutation Analysis|GNAQ Mutation Status|SWS Mutation Analysis	A procedure used to detect and identify mutations in the GNAQ gene.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C157184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157184>	C18302	HRAS Mutation Analysis|C-H-RAS Mutation Analysis|C-HA-RAS1 Mutation Analysis|H-ras Mutation Analysis|HRAS Mutation Status|HRAS1 Mutation Analysis|Ha-ras Mutation Analysis|Harvey Rat Sarcoma Viral Oncogene Homolog Mutation Analysis|RASH1 Mutation Analysis|v-Ha-ras Harvey Rat Sarcoma Viral Oncogene Homolog Mutation Analysis	A procedure used to detect and identify mutations in the HRAS gene.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C157185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157185>	C18302	IDH1/IDH2 Mutation Analysis|IDH1 / IDH2 Mutation Status|IDH1 / IDH2 Mutation Status|IDH1/2 Mutation Analysis|IDH1/2 Mutation Status|IDH1/IDH2 Mutation Status	A procedure used to detect and identify mutations in the IDH1 and IDH2 genes.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C157186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157186>	C157185	IDH1/2 Mutation Status by Sequencing|IDH1 / IDH2 Mutation Status by Sequencing|IDH1/2 Mutation Analysis by Sequencing|IDH1/2 Sequencing|IDH1/IDH2 Sequencing	An indication that the presence or absence of IDH1/IDH2 gene mutations was determined using sequencing techniques.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology
C157187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157187>	C18302	NRAS Mutation Analysis|N-RAS Mutation Analysis|NRAS Mutation|NRAS Mutation Status|Neuroblastoma RAS Viral Oncogene Homolog Mutation Analysis	A procedure used to detect and identify mutations in the NRAS gene.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C157188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157188>	C51961	BRAF Rearrangement Analysis|B-RAF Gene Rearrangement Analysis|B-RAF1 Gene Rearrangement Analysis|BRAF Rearrangement|BRAF Rearrangement Status|BRAF1 Gene Rearrangement Analysis|v-raf Murine Sarcoma Viral Oncogene Homolog B1 Gene Rearrangement Analysis	A procedure used to detect and identify rearrangements involving the BRAF gene.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C157189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157189>	C51961	ERG Rearrangement Analysis|ERG Rearrangement Status|ETS Transcription Factor ERG Rearrangement Analysis	A procedure used to detect and identify rearrangements involving the ERG gene.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology
C15718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15718>	C64386	Homeopathy Therapy|Homeopathic|Homeopathic Remedy|Homeopathy|homeopathic medicine|homeopathy	A method of treating disease with small amounts of remedies that, in large amounts in healthy people, produce symptoms similar to those being treated. Homeopathy seeks to stimulate the body's defense mechanisms and processes so as to prevent or treat illness.	Homeopathy Therapy		Biomedical Occupation or Discipline	CTRP Intervention Terminology|CTRP Terminology
C157190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157190>	C51961	ETV Rearrangement Analysis|ETV Family Rearrangement Analysis|ETV Rearrangement Status|Ets Variant Family Rearrangement Analysis	A procedure used to detect and identify rearrangements involving ETV family genes.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology
C157191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157191>	C51961	FGFR1 Rearrangement Analysis|BFGFR Rearrangement Analysis|CD331 Rearrangement Analysis|CEK Rearrangement Analysis|FGFBR Rearrangement Analysis|FGFR-1 Rearrangement Analysis|FGFR1 Rearrangement Status|FLG Rearrangement Analysis|FLT-2 Rearrangement Analysis|FLT2 Rearrangement Analysis|FMS-Like Tyrosine Kinase 2 Rearrangement Analysis|Fibroblast Growth Factor Receptor 1 Rearrangement Analysis|KAL2 Rearrangement Analysis|N-SAM Rearrangement Analysis|OGD Rearrangement Analysis	A procedure used to detect and identify rearrangements involving the FGFR1 gene.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C157192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157192>	C51961	FGFR2 Rearrangement Analysis|BEK Rearrangement Analysis|CD332 Rearrangement Analysis|ECT1 Rearrangement Analysis|FGFR-2 Rearrangement Analysis|FGFR2 Rearrangement Status|Fibroblast Growth Factor Receptor 2 Rearrangement Analysis|K-SAM Rearrangement Analysis|KGFR Rearrangement Analysis	A procedure used to detect and identify rearrangements involving the FGFR2 gene.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C157193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157193>	C51961	FGFR3 Rearrangement Analysis|CD333 Rearrangement Analysis|FGFR-3 Rearrangement Analysis|FGFR3 Rearrangement Status|Fibroblast Growth Factor Receptor 3 Rearrangement Analysis|JTK4 Rearrangement Analysis	A procedure used to detect and identify rearrangements involving the FGFR3 gene.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C157194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157194>	C51961	PAX8 Rearrangement Analysis|PAX8 Rearrangement Status|Paired Box 8 Rearrangement Analysis|Paired Box Gene 8 Rearrangement Analysis|Paired Domain Gene 8 Rearrangement Analysis	A procedure used to detect and identify rearrangements involving the PAX8 gene.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C157195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157195>	C51961	RET Rearrangement Analysis|RET Rearrangement|RET Rearrangement Status|RET/PTC Rearrangement Analysis|Ret Proto-Oncogene Rearrangement Analysis	A procedure used to detect and identify rearrangements involving the RET gene.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C157196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157196>	C40998|C16150	ESR1 Status by Immunohistochemistry|ER Status by IHC|ER Status by Immunohistochemistry|ER alpha (ESR1) Status by Immunohistochemistry|ER alpha Status by Immunohistochemistry|ERA Status by Immunohistochemistry|ESR Status by Immunohistochemistry|ESRA Status by Immunohistochemistry|Estrogen Receptor 1 Status by Immunohistochemistry|Estrogen Receptor Status by Immunohistochemistry|NR3A1 Status by Immunohistochemistry	An indication that expression or absence of ESR1 in a sample was determined using immunohistochemical staining techniques.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C157197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157197>	C159152	ESR2 Status by Immunohistochemistry|ER beta (ESR2) Status by Immunohistochemistry|ER-Beta Status by Immunohistochemistry|ESR-BETA Status by Immunohistochemistry|ESR2 Status by IHC|ESRB Status by Immunohistochemistry|ESTRB Status by Immunohistochemistry|Estrogen Receptor 2 Status by Immunohistochemistry|Estrogen Receptor Beta Status by Immunohistochemistry|NR3A2 Status by Immunohistochemistry	An indication that expression or absence of ESR2 in a sample was determined using immunohistochemical staining techniques.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C157198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157198>	C41544	Depolymerization	The process that catabolizes the covalent bonds between monomeric structures in a polymer.			Physiologic Function	CBDD Process Terminology|CBDD Terminology
C157199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157199>	C172299	Hydrogenation	The addition of two hydrogen atoms to another molecular entity through the reaction of molecular hydrogen (H2) with that entity.			Phenomenon or Process	CBDD Process Terminology|CBDD Terminology
C15719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15719>	C16084	Surveillance|Epidemiology / Surveillance|surveillance	The systematic collection, analysis, and interpretation of health data on an ongoing basis.			Health Care Activity	GDC Terminology|GDC Value Terminology
C1571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1571>	C213865|C200258|C200052|C192742|C192741	Alvocidib Hydrochloride|(-)-2-(2-Chlorophenyl)-5,7-dihydroxy-8-[(3R,4S)-3-hydroxy-1-methyl-4-piperidinyl]-4H-1-benzopyran-4-one Hydrochloride|4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5, 7-dihydroxy-8-(3-hydroxy-1-methyl-4-piperidinyl)-, hydrochloride, (-)-cis-|ALVOCIDIB HYDROCHLORIDE|Flavopiridol Hydrochloride|HL-275|HMR 1275|HMR 1275|HMR-1275|HMR1275|L 868275|L-86-8275|L-868275|L868275|MDL 107,826A|MDL-107826A	The hydrochloride salt form of alvocidib, a synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (CDKs) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis. This agent is also a competitive inhibitor of adenosine triphosphate activity.	Alvocidib Hydrochloride		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157200>	C172299	Cold Adaptation|Cold adaptation	The process by which the form or structure of an organism or a bioactive molecule is modified to survive or have activity in a low temperature environment.			Phenomenon or Process	CBDD Process Terminology|CBDD Terminology
C157201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157201>	C172299	Combustion	The combination of a substance with oxygen that involves the production of heat and light.			Phenomenon or Process	CBDD Process Terminology|CBDD Terminology
C157202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157202>	C172299	Conjugation|Chemical Conjugation	The formation of one or more covalent or non-covalent links between two or more chemical compounds.			Phenomenon or Process	CBDD Process Terminology|CBDD Terminology
C157203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157203>	C19899	Reduction	A chemical reaction that results in a gain of electrons by one of the chemical species involved in the reaction.			Molecular Function	CBDD Process Terminology|CBDD Terminology
C157204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157204>	C41544|C19899	Fermentation	The exothermic catabolic processing of a substance by bacteria, yeasts, or other microorganisms.			Molecular Function	CBDD Process Terminology|CBDD Terminology
C157205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157205>	C16944	Hydroxylation	The process that introduces a hydroxyl group (-OH) into an organic acceptor molecule.			Molecular Function	CBDD Process Terminology|CBDD Terminology
C157206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157206>	C17597	Adsorption	The adhesion of a gas, liquid or dissolved solid chemical of interest onto a solid surface.			Phenomenon or Process	CBDD Process Terminology|CBDD Terminology
C157207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157207>	C172299	Quaternization	The formation of a quaternary compound.			Natural Phenomenon or Process	CBDD Process Terminology|CBDD Terminology
C157208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157208>	C19899	Succinylation	The process of adding a succinyl radical to an acceptor molecule.			Molecular Function	CBDD Process Terminology|CBDD Terminology
C157209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157209>	C172299	Transesterification	A chemical reaction during which an ester is converted to an alcohol and an alcohol is converted to an ester through the exchange of their respective organic groups.			Phenomenon or Process	CBDD Process Terminology|CBDD Terminology
C15720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15720>	C16974	Pharmacodynamics|pharmacodynamics	The study of the biochemical and physiological effects of drugs and the mechanisms of their actions, including the correlation of actions and effects of drugs with their chemical structure, also, such effects on the actions of a particular drug or drugs.			Biomedical Occupation or Discipline	CDISC Glossary Terminology
C157210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157210>	C19899	Amidation	The process of reacting with or forming an amide.			Molecular Function	CBDD Process Terminology|CBDD Terminology
C157211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157211>	C16396	Cell Expansion|Cell Culture Expansion|Cell expansion	A cell culture procedure that is designed to promote cell growth.			Laboratory Procedure	CBDD Process Terminology|CBDD Terminology
C157212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157212>	C20368	Pegylation|PEGylation|PEGylation	The process of attaching polyethylene glycol (PEG) polymer chains to other macromolecules.			Laboratory Procedure	CBDD Process Terminology|CBDD Terminology
C157213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157213>	C172299	Salt Formation|Salt formation	The production of a compound comprised of a cation bound to or associated with an anion that forms as a result of neutralization of an acid and a base or of a metal or metal cation and an acid or non-metal anion.			Phenomenon or Process	CBDD Process Terminology|CBDD Terminology
C157214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157214>	C19899	Acylation	The addition of an acyl group to an acceptor molecule.			Molecular Function	CBDD Process Terminology|CBDD Terminology
C157215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157215>	C172299	Epoxidation	The conversion of a carbon-carbon double bond and oxygen, peroxide or peroxyacid into an a cyclic ether with a three-atom ring (epoxide or oxirane).			Phenomenon or Process	CBDD Process Terminology|CBDD Terminology
C157216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157216>	C19899	Esterification	The process of converting an alcohol and an acid into an ester and water.			Molecular Function	CBDD Process Terminology|CBDD Terminology
C157217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157217>	C113066	Viral Hemagglutinin Purification|Viral hemagglutinin purification	The process used to isolate hemagglutinin from a viral sample.			Laboratory Procedure	CBDD Process Terminology|CBDD Terminology
C157218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157218>	C113066	Viral Neuraminidase Purification|Viral neuraminidase purification	The process used to isolate neuraminidase from a viral sample.			Laboratory Procedure	CBDD Process Terminology|CBDD Terminology
C157219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157219>	C113066	Viral Envelope Glycoprotein Purification|Viral envelope glycoproteins purification	The process used to isolate envelope glycoproteins from a viral sample.			Laboratory Procedure	CBDD Process Terminology|CBDD Terminology
C15721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15721>	C15429	Epidemiology Research|Epidemiologic Research|Epidemiologic Study|Epidemiologic Trial|Epidemiological Research|Epidemiological Study	The study of human populations to identify causes of disease and factors determining and influencing the frequency and distribution of disease, injury, and other health related events.	Epidemiology Research		Research Activity	CTRP Intervention Terminology|CTRP Terminology|SeroNet Authorized Values|SeroNet Study Descriptors
C157220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157220>	C70700	Antigen Cultivation|Antigen Harvesting|Antigen Purification|Antigen cultivation|Antigen generation	The method used to collect and isolate the antigenic proteins or DNA from a pathogen or pathologic sample.			Laboratory Procedure	CBDD Process Terminology|CBDD Terminology
C157221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157221>	C172299	Monomer Deletion Process|Monomer deletion	The process of removing one or more monomeric units from a polymer.			Phenomenon or Process	CBDD Process Terminology|CBDD Terminology
C157222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157222>	C14134	Polymer Branch Connection Points	The chemical structures that make up the head and branch points found between repeating units in a branched polymer.			Chemical Viewed Structurally	
C157223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157223>	C14134	Nucleotide Bond|Nucleic Acid Bond	The phosphodiester bonds that are formed between nucleotides in a nucleic acid.			Chemical Viewed Structurally	
C157224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157224>	C45576	Nucleotide Substitution Site|Nucleic Acid Variation Site|Nucleotide Variation Site|Nucleotide substitution point|Nucleotide substitution site	The nucleotide position that is substituted in a nucleic acid variant.			Cell or Molecular Dysfunction	CBDD Structure Terminology|CBDD Terminology
C157225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157225>	C54443	CBDD Terminology|CBDD|CBDD Vocabulary|Chemical Biology and Drug Development Terminology|Chemical Biology and Drug Development Vocabulary	The Chemical Biology and Drug Development (CBDD) Terminology is a set of terms used in design, development, and description of drug substances, mainly but not exclusively pertaining to the chemistry (including chemical reactions) of small molecules and polymers. The terminology is intended to support the chemoinformatics community's effort to develop conceptual models for describing modern drug design such as performed by the NCI Computer-Aided Drug Design (CADD) Group (part of the NCI Chemical Biology Laboratory) and collaborators at NIH, academia, and other government agencies.			Intellectual Product	
C157226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157226>	C173045	Problems Paying Medical Bills Question|Did you have problems paying or were unable to pay any medical bills|Problems Paying Medical Bills	A question about whether an individual has or had problems paying any medical bills.			Intellectual Product	
C157227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157227>	C173509|C173151|C173045	Unable to Pay Medical Bills Question|Do you or anyone in your family currently have medical bills that you are unable to pay at all|Unable to Pay Medical Bills	A question about whether an individual, or anyone in individual's family, currently has medical bills they are unable to pay at all.			Intellectual Product	
C157228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157228>	C173509|C173151	Paying Medical Bills Over Time Question|Do you or anyone in your family currently have medical bills that are being paid off over time|Paying Medical Bills Over Time	A question about whether an individual, or anyone in individual's family, currently has medical bills that are being paid off over time.			Intellectual Product	
C157229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157229>	C91102	Referral Made Based on This Score Question|Referral Made Based on This Score|Was a referral made based on this score	A question about whether a referral was made based on this score.			Intellectual Product	Edmonton Frail Scale
C15722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15722>	C16205|C15719	Patient Observation|Active Surveillance|Observation|Watchful Waiting|active surveillance|deferred therapy|expectant management|observation|watchful waiting	Closely watching a patient's condition but not giving treatment unless there are changes in test results. Active surveillance avoids problems that may be caused by treatments such as radiation or surgery. It is used to find early signs that the condition is getting worse. During active surveillance, patients will be given certain exams and tests done on a regular schedule.	Patient Observation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C157230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157230>	C91102	Referral Made Based on Final Score Question|Referral Made Based on Final Score|Was a referral made based on the final score	A question about whether a referral was made based on the final score.			Intellectual Product	Edmonton Frail Scale
C157231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157231>	C80509	Nimesulide-Hyaluronic Acid Conjugate CA102N|CA 102N|CA-102N|CA102N|HA-Nim Conjugate CA102N|HA-Nimesulide|Hyaluronic Acid Nimesulide-NH2 Bioconjugate|Nim-HA Conjugate	A covalently bound conjugate composed of the biological polymer sodium hyaluronate (NaHA) and the hydrophobic, cyclooxygenase 2 (COX-2) inhibitor and cytotoxic agent nimesulide (Nim), with potential antineoplastic activity. Upon intravenous administration of Nim-HA conjugate CA102N, the HA moiety targets and binds to CD44. Following endocytosis of CA102N and enzymatic degradation within the lysosomal compartment, Nim is released inside CD44-expressing tumor cells, causing Nim-mediated induction of cell cycle arrest tumor cell apoptosis and decreases tumor cell growth. In addition, Nim inhibits various tumor cell signaling pathways thereby further inhibiting tumor cell proliferation. CD44, a transmembrane glycoprotein and HA receptor expressed in healthy tissue, plays a key role in cellular growth, survival, differentiation and motility. Overexpressed in a variety of cancer cell types, CD44 plays a key role in tumor cell proliferation, migration and survival. Conjugation of HA to Nim allows for increased solubility of Nim and for targeted delivery of Nim to CD44-expressing tumor cells, thereby increasing efficacy and safety of Nim.	Nimesulide-Hyaluronic Acid Conjugate CA102N		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157232>	C157093	FIGO/TNM Stage	A staging system that involved either the FIGO (International Federation of Gynecology and Obstetrics) and/or the TNM system.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C157233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157233>	C173457|C158612	What is the First Presenting Symptom Related to Disease Question|First Presenting Symptom Related to Disease|What is the First Presenting Symptom Related to Disease|first symptom prior to diagnosis|first_symptom_prior_to_diagnosis	A question about the first symptom that is related to a disease of interest.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology|GDC Property Terminology|GDC Terminology
C157234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157234>	C16929|C16552	Welding Exposure|Welding dust and fumes|Welding dust and fumes	Environmental, occupational, or consumer-based exposure to vaporized materials or dusts created during the welding process.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Codelists Terminology|CPTAC Environmental/Occupational Exposure Codelist|CPTAC Medical History Form|CPTAC Terminology
C157235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157235>	C7950	Breast Histiocytoid Carcinoma|HBC|Histiocytoid Breast Carcinoma|Histiocytoid Breast Carcinoma|Histiocytoid Lobular Breast Carcinoma|Infiltrating Histiocytoid Breast Carcinoma|Infiltrating Histiocytoid Lobular Breast Carcinoma|Invasive Histiocytoid Breast Carcinoma|Invasive Histiocytoid Lobular Breast Carcinoma	A rare variant of invasive lobular breast carcinoma characterized by the presence of histiocyte-like malignant cells with pale cytoplasm forming sheets or linear patterns. Apocrine differentiation may be present. It usually has an aggressive clinical course.			Neoplastic Process	
C157236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157236>	C3280	Thoracic Nodule|Chest Wall Nodule	A nodular lesion that develops in the chest wall.			Finding	
C157237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157237>	C18302	TERT Promoter Mutation Analysis|TERT Promoter Mutation Status|TRT Promoter Mutation Analysis|Telomerase Reverse Transcriptase Promoter Mutation Analysis	A procedure used to detect and identify mutations in the promoter sequences for the TERT gene.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C157238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157238>	C158957	TP53 Mutation Status by Sequencing|TP53 Sequencing|Tumor Protein p53 Mutation Analysis by Sequencing|p53 Mutation Analysis by Sequencing	An indication that the presence or absence of TP53 gene mutations was determined using sequencing techniques.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology
C15723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15723>	C49165	Bypass|bypass	A surgical procedure in which the doctor creates a new pathway for the flow of body fluids.			Therapeutic or Preventive Procedure	
C157240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157240>	C163998|C129820	Tivumecirnon|CCR4 Inhibitor FLX475|FLX 475|FLX-475|FLX475|TIVUMECIRNON	An orally available, small molecule antagonist of C-C chemokine receptor type 4 (CCR4) with potential immunomodulatory and antineoplastic activities. Upon oral administration, tivumecirnon inhibits the binding of CCR4 to its signaling molecules, thereby blocking the recruitment of regulatory T-cells (Tregs) to the tumor microenvironment (TME). This may abrogate the immunosuppressive effects of Tregs and promote an effective anti-tumor immune response. CCR4, a chemokine receptor normally expressed on circulating and tissue-resident T-cells, is highly expressed on circulating Tregs and is associated with poor prognosis in certain cancers.	Tivumecirnon		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157242>	C141146	Surzebiclimab|Anti-TIM-3 Monoclonal Antibody BGB-A425|BGB A425|BGB-A425|BGBA425|SURZEBICLIMAB	A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, surzebiclimab binds to TIM-3 expressed on certain T-cells, including tumor-infiltrating lymphocytes (TILs), thereby preventing the engagement of TIM-3 by its ligands, phosphatidylserine (PtdSer) and galectin-9. This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor cell proliferation. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.	Surzebiclimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157243>	C7646|C42057	Adrenal Gland Ganglioneuroblastoma, Intermixed	An intermixed ganglioneuroblastoma arising from the adrenal gland.			Neoplastic Process	
C157244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157244>	C7646|C42058	Adrenal Gland Ganglioneuroblastoma, Nodular	A nodular ganglioneuroblastoma arising from the adrenal gland.			Neoplastic Process	
C157245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157245>	C5427|C4895	Adrenal Gland Ganglioneuroma|Adrenal Gland Ganglioneuroma (Schwannian Stroma-Dominant)	A ganglioneuroma arising from the adrenal gland.			Neoplastic Process	
C157246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157246>	C3308	Composite Paraganglioma|Composite Pheochromocytoma and Paraganglioma|Composite Pheochromocytoma/Paraganglioma	A neoplasm that combines morphologic characteristics of paraganglioma and neuroectodermal tumors such as neuroblastoma, ganglioneuroma, ganglioneuroblastoma, or peripheral nerve sheath tumor.			Neoplastic Process	
C157247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157247>	C1663	Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L/IL-23/IL-36gamma mRNA-2752|Lipid Nanoparticle Encapsulated OX40L/IL-23/IL-36gamma mRNAs mRNA-2752|Lipid Nanoparticle Encapsulated mRNAs Encoding Human OX40L/IL-23/IL-36gamma mRNA-2752|mRNA 2752|mRNA-2752|mRNA2752	A lipid nanoparticle encapsulating mRNAs encoding for the human co-stimulatory protein tumor necrosis factor ligand superfamily member 4 (TNFSF4; OX40 Ligand; OX40L), the pro-inflammatory cytokines interleukin-23 (IL-23) and interleukin-36gamma (IL-36gamma), with potential immunomodulatory and anti-tumor activities. Upon intratumoral (IT) injection of the lipid nanoparticle encapsulated mRNAs encoding human OX40L/IL-23/IL-36gamma mRNA-2752, the lipid nanoparticle binds to the plasma membrane of cells and releases the mRNAs into the cell. The OX40L mRNA is then translated by the cellular protein translation machinery to produce OX40L protein, which is then expressed on the plasma membrane of the cells that internalized the OX40L mRNA. OX40L binds to and activates signaling pathways downstream of its cognate receptor tumor necrosis factor receptor superfamily member 4 (TNFRSF4; OX40), which is expressed on activated T-cells. OX40L/OX40 binding promotes increased cytokine production, which can induce proliferation of memory and effector T-lymphocytes against the nearby tumor cells. The co-administration of IL-23 and IL-36gamma further stimulates anti-tumor immune responses. Altogether, this may enhance T-cell mediated anti-tumor immune responses thereby killing of the tumor cells. OX40L, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) ligand superfamily, provides a co-stimulatory signal for the proliferation and survival of activated T-cells. IL-36gamma activates innate immune cells and promotes T-helper 1 (Th1) responses, whereas IL-23 has been implicated in Th1/Th17 immunity as well as in the modulation of antigen-presenting cells (APCs).	Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L/IL-23/IL-36gamma mRNA-2752		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157248>	C5329|C3326	Hereditary Adrenal Gland Pheochromocytoma|Familial Adrenal Gland Pheochromocytoma	A hereditary adrenal gland pheochromocytoma caused by mutations in SDHB, SDHC, and SDHD genes.			Neoplastic Process	
C157249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157249>	C209559	ERBB2 Amplification Status|ERBB2 / HER2 Amplification Status|ERBB2 Amplification Analysis|ERBB2/HER2 Amplification Status|Erb-B2 Receptor Tyrosine Kinase 2 Amplification Analysis|HER2 Amplification Analysis|HER2/neu Amplification Analysis|NEU Amplification Analysis|v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 Amplification Analysis	A procedure used to detect amplifications involving all or part of the ERBB2 gene.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C15724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15724>	C15288	Inguinal Orchiectomy|inguinal orchiectomy	Surgical removal of a testis through an inguinal approach.			Therapeutic or Preventive Procedure	
C157250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157250>	C28042	Ki-67 Labeling Index|Anti-KI67 Labeling Index|Anti-Ki-67 Labeling Index|Anti-MKI67 Labeling Index|Ki-67 MIB1 Labeling Index|MIB-1 Antibody Labeling Index|MIB-1 Labeling Index|MIB1 Antibody Labeling Index|MIB1 Labeling Index	The percentage of cells in a sample that are dividing that is determined by immunohistochemical staining techniques using MIB-1 antibody (anti-Ki-67 protein antibody).			Quantitative Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology
C157251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157251>	C209559	MET Amplification Status|HGFR Amplification Analysis|Hepatocyte Growth Factor Receptor Amplification Analysis|MET Amplification Analysis|MET Proto-Oncogene, Receptor Tyrosine Kinase Amplification Analysis|c-Met Amplification Analysis	A procedure used to detect amplifications involving all or part of the MET gene.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C157252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157252>	C81983	Serum CEA Measurement|Serum CEA|Serum Carcinoembryonic Antigen|Serum Carcinoembryonic Antigen Measurement	The determination of the amount of carcinoembryonic antigen present in a serum sample.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C157253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157253>	C81982	Serum CA 19-9 Measurement|Serum CA 19-9|Serum CA 19-9|Serum CA 19-9 Assay|Serum CA-19-9 Measurement|Serum CA19-9 Measurement|Serum Cancer Antigen 19-9|Serum Carbohydrate Antigen 19-9 Measurement	The determination of the amount of cancer antigen 19-9 present in a serum sample.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C157254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157254>	C14349	HPV-Low Risk|Low Risk HPV|Low Risk Human Papilloma Virus|Low Risk Human Papillomavirus|Low-Risk HPV|Low-Risk HPV Strain|Low-Risk HPV Subtype|Low-Risk Human Papilloma Virus|Low-Risk Human Papillomavirus|Low-Risk Subtype (6, 11, etc.)	Any of a number of strains of human papillomavirus (HPV) that cause genital warts in humans and are rarely associated with carcinogenesis.			Virus	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C157255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157255>	C171145	HPV Typing Method|Human Papilloma Virus Typing Method|Human Papillomavirus Typing Method|Method of HPV Typing	The method used to perform human papillomavirus (HPV) genotyping.			Diagnostic Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C157256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157256>	C49940	Endoscope Distal Attachment Cap|Disposable Distal Attachment Cap|Distal Attachment|Distal Attachment Cap|Olympus Disposable Distal Attachment Cap	A transparent cap for the end of an endoscope designed to maintain a constant distance between the endoscope and the mucosa to increase the detection of visible lesions.	Endoscope Distal Attachment Cap		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C157257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157257>	C201511|C201282|C129822	Mipletamig|APVO 436|APVO-436|APVO436|Anti-CD123 x Anti-CD3 Bispecific Antibody APVO436|Anti-CD123/CD3 Bispecific Antibody APVO436|Bispecific Anti-CD123 x Anti-CD3 Antibody APVO436|CD123 x CD3 Targeting Bispecific Antibody APVO436|MIPLETAMIG	An immunoglobulin Fc-modified bispecific monoclonal antibody against the tumor-associated antigen (TAA) CD123 and the human T-cell surface antigen CD3 bispecific monoclonal antibody, with potential immunostimulatory and antineoplastic activities. Upon administration, mipletamig simultaneously binds to both CD3-expressing T-cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This results in the activation and proliferation of T-cells and causes CTL-mediated cell lysis of CD123-expressing tumor cells. CD123, the interleukin-3 receptor alpha chain, is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells. The Fc domain on the antibody prolongs the half-life of the bispecific antibody. Compared to some other CD123 x CD3 targeting bispecific antibodies, mipletamig causes less cytokine release upon T-cell stimulation.	Mipletamig		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157258>	C26199	B-Cell CLL/Lymphoma 7 Protein Family Member B|Allergen Hom S 3|B-Cell CLL/Lymphoma 7B|BCL Tumor Suppressor 7B|BCL7B	B-cell CLL/lymphoma 7 protein family member B (202 aa, ~22 kDa) is encoded by the human BCL7B gene. This protein plays a role in chromatin remodeling and apoptotic signaling.			Amino Acid, Peptide, or Protein	
C157259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157259>	C54362	BCL7C Gene|BCL7C|BCL7C|BCL7C, BAF Complex Component Gene	This gene may be involved in apoptosis and nucleosome structure.			Gene or Genome	
C15725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15725>	C49165	Laparoscopic Surgery|laparoscopic surgery|laparoscopic-assisted resection|laparoscopy-assisted surgery	Surgery done using a laparoscope.	Laparoscopic Surgery		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C157260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157260>	C157259	BCL7C wt Allele|B-Cell CLL/Lymphoma 7C Gene|BCL Tumor Suppressor 7C Gene|BCL7C, BAF Complex Component wt Allele	Human BCL7C wild-type allele is located in the vicinity of 16p11.2 and is approximately 61 kb in length. This allele, which encodes B-cell CLL/lymphoma 7 protein family member C protein, may play a role in apoptosis and nucleosome remodeling.			Gene or Genome	
C157261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157261>	C26199	B-Cell CLL/Lymphoma 7 Protein Family Member C|B-Cell CLL/Lymphoma 7C|BCL Tumor Suppressor 7C|BCL7C	B-cell CLL/lymphoma 7 protein family member C (217 aa, ~23 kDa) is encoded by the human BCL7C gene. This protein may be involved in nucleosome remodeling and apoptosis.			Amino Acid, Peptide, or Protein	
C157262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157262>	C1663	pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0|Autologous Cancer Cell-transfected with Plasmid DNA Encoding for Emm55 Streptococcal Antigen IFx-Hu2.0|IFx-Hu2.0|ImmuneFx|Plasmid DNA Autologous Cancer Vaccine IFx-Hu2.0|Plasmid DNA Vaccine Encoding S. pyogenes Emm55 Protein|pDNA Autologous Cancer Cell Vaccine IFx-Hu2.0	A whole cell cancer vaccine composed of irradiated autologous whole tumor cells that are transfected, ex vivo, with a plasmid DNA encoding the highly immunogenic Streptococcus pyogenes (S. pyogenes) bacterial antigen Emm55, with potential immunostimulating and antineoplastic activities. Upon intralesional administration of IFx-Hu2.0, the tumor cells expressing the Emm55 bacterial antigen on their cell surface are taken up and processed by antigen-presenting cells (APCs), thereby presenting both the Emm55 and the patient-specific tumor-associated antigens (TAAs) to the immune system. This activates the immune system to elicit a tumor antigen-specific cytotoxic T-lymphocyte (CTL)-mediated immune response against the tumor cells expressing the TAAs.	pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157263>	C212942	BRD7 Gene|BRD7|BRD7|Bromodomain Containing 7 Gene	This gene plays a role in SWI/SNF complex-dependent chromatin remodeling, Wnt signaling and p53-mediated cell cycle arrest.			Gene or Genome	
C157264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157264>	C157263	BRD7 wt Allele|BP75|Bromodomain Containing 7 wt Allele|Bromodomain Protein, 75-kD Gene|Bromodomain-Containing 7 Gene|CELTIX1|NAG4	Human BRD7 wild-type allele is located in the vicinity of 16q12.1 and is approximately 55 kb in length. This allele, which encodes bromodomain-containing protein 7, is involved in Wnt signaling, p53-mediated G1 to S phase arrest and chromatin remodeling.			Gene or Genome	
C157265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157265>	C26199	Bromodomain-Containing Protein 7|75 kDa Bromodomain Protein|BRD7|Protein CELTIX-1	Bromodomain-containing protein 7 (651 aa, ~74 kDa) is encoded by the human BRD7 gene. This protein plays a role in p53-dependent G1/S phase arrest, SWI/SNF-mediated chromatin remodeling and Wnt signaling.			Amino Acid, Peptide, or Protein	
C157266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157266>	C99544	Left Ventricular Noncompaction 7|LVNC7	An autosomal dominant sub-type of left ventricular noncompaction syndrome caused by heterozygous mutation(s) of the MIB1 gene, encoding E3 ubiquitin-protein ligase MIB1.			Disease or Syndrome	Cellosaurus Disease Terminology
C157267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157267>	C53543	POLG-Related Spectrum Disorders	A group of disorders with overlapping phenotypes caused by mutation(s) of the POLG gene, encoding DNA polymerase subunit gamma-1. Phenotypic variations include Alpers-Huttenlocher syndrome (AHS), childhood myocerebrohepatopathy spectrum (MCHS), myoclonic epilepsy myopathy sensory ataxia (MEMSA), ataxia neuropathy spectrum (ANS), autosomal recessive progressive external ophthalmoplegia (arPEO), and autosomal dominant progressive external ophthalmoplegia (adPEO).			Disease or Syndrome	Cellosaurus Disease Terminology
C157268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157268>	C53543	Relapsing Polychondritis	A rare autoimmune disorder characterized by recurrent episodes of inflammation of cartilage and other connective tissues.			Disease or Syndrome	Cellosaurus Disease Terminology
C157269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157269>	C54729	Aspira Indwelling Catheter|Aspira|Aspira Catheter	A proprietary indwelling catheter used to drain accumulated fluid from the pleural or peritoneal cavity to relieve symptoms associated with malignant pleural effusion or malignant ascites. The Aspira system connects to a low-vacuum siphon pump that drains into a bag.	Aspira Indwelling Catheter		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C15726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15726>	C49165|C15655	Thoracoscopic Surgery	A minimally invasive thoracic surgical procedure that makes use of a thoracoscope.	Thoracoscopic Surgery		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C157270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157270>	C54362	PHF10 Gene|PHD Finger Protein 10 Gene|PHF10|PHF10	This gene is involved in the proliferation of neural progenitor cells and chromatin remodeling.			Gene or Genome	
C157271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157271>	C157270	PHF10 wt Allele|BAF45A|BRG1-Associated Factor, 45-kD, A Gene|FLJ10975|PHD Finger Protein 10 wt Allele|XAP135	Human PHF10 wild-type allele is located in the vicinity of 6q27 and is approximately 22 kb in length. This allele, which encodes PHD finger protein 10, plays a role in chromatin remodeling and neural progenitor cell maintenance.			Gene or Genome	
C157272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157272>	C26199	PHD Finger Protein 10|BAF45a|BRG1-Associated Factor 45a|PHD Zinc Finger Protein XAP135|PHF10|XAP135	PHD finger protein 10 (498 aa, ~56 kDa) is encoded by the human PHF10 gene. This protein is involved in SWI/SNF-mediated chromatin remodeling and promotion of neural progenitor cell proliferation.			Amino Acid, Peptide, or Protein	
C157273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157273>	C54362	ACTL6A Gene|ACTL6A|ACTL6A|Actin Like 6A Gene	This gene plays a role in transcriptional activation and repression of selected genes through chromatin remodeling.			Gene or Genome	
C157274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157274>	C157273	ACTL6A wt Allele|ACTL6|ARPN-BETA|Actin Like 6A wt Allele|Actin-Related Protein, Beta Gene|Arp4|BAF53|BAF53A|BRG1-Associated Factor, 53-kD Gene|INO80K	Human ACTL6A wild-type allele is located in the vicinity of 3q26.33 and is approximately 26 kb in length. This allele, which encodes actin-like protein 6A, is involved in chromatin remodeling.			Gene or Genome	
C157275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157275>	C26199	Actin-Like Protein 6A|53 kDa BRG1-Associated Factor A|ACTL6A|Actin-Related Protein 4|Actin-Related Protein Baf53a|ArpNbeta|BAF Complex 53 kDa Subunit|BAF53A|BRG1-Associated Factor 53A|INO80 Complex Subunit K	Actin-like protein 6A (429 aa, ~47 kDa) is encoded by the human ACTL6A gene. This protein plays a role in the regulation of both chromatin remodeling and histone acetyltransferase activity.			Amino Acid, Peptide, or Protein	
C157276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157276>	C54362	ACTL6B Gene|ACTL6B|ACTL6B|Actin Like 6B Gene	This gene is involved in chromatin remodeling-dependent transcriptional regulation.			Gene or Genome	
C157277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157277>	C157276	ACTL6B wt Allele|ACTL6|ARPN-ALPHA|Actin Like 6B wt Allele|Actin-Like 6 Gene|Actin-Related Protein, Alpha Gene|ArpNalpha|BAF53B|arpNalpha|hArpN Alpha	Human ACTL6B wild-type allele is located in the vicinity of 7q22.1 and is approximately 13 kb in length. This allele, which encodes actin-like protein 6B, plays a role in nucleosome remodeling.			Gene or Genome	
C157278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157278>	C26199	Actin-Like Protein 6B|53 kDa BRG1-Associated Factor B|ACTL6B|Actin-Related Protein Baf53b|ArpNalpha|BAF53B|BRG1-Associated Factor 53B	Actin-like protein 6B (426 aa, ~47 kDa) is encoded by the human ACTL6B gene. This protein is involved in chromatin remodeling and transcriptional regulation.			Amino Acid, Peptide, or Protein	
C157279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157279>	C201516	Mirzotamab Clezutoclax|ABBV 155|ABBV-155|ABBV155|ADC ABBV-155|Antibody-drug Conjugate ABBV-155|MIRZOTAMAB CLEZUTOCLAX	An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) conjugated, via a solubilizing linker, to a B-cell lymphoma extra long (Bcl-XL) inhibitor, with potential antineoplastic activity. Upon administration of mirzotamab clezutoclax, the anti-B7-H3 monoclonal antibody moiety targets and binds to B7-H3 expressed on tumor cells. Upon binding, internalization and linker cleavage, the Bcl-XL inhibitor targets, binds to and inhibits the activity of the pro-survival protein Bcl-XL. This restores apoptotic processes and inhibits the proliferation of B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It plays a key role in tumor growth and immune responses.	Mirzotamab Clezutoclax		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15727>	C16223	cDNA Library|Library	A collection of DNA molecules that have been cloned in vectors.  In the case of a cDNA library the DNA inserts are copies of RNAs that have been reverse-transcribed into DNA prior to cloning.			Manufactured Object	
C157280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157280>	C2124	4-[18F]Fluoroglutamic Acid|(2S)-2-Amino-4-[F-18]-fluoro Pentanedioic Acid|BAY 85-8050|BAY 858050|BAY-85-8050|Fluorine F 18-BAY 85-8050|[18F] 4-L-fluoroglutamine (2S,4R)|[F-18]BAY 85-8050	A radioconjugate composed of the radionuclide fluorine F 18 conjugated to L-glutamic acid, with potential imaging activity upon positron emission tomography (PET). Upon intravenous administration, the glutamic acid moiety of  4-[18F]fluoroglutamic acid specifically binds to tumor cells and is preferentially taken up by tumor cells due to the higher metabolic activity and enhanced glutaminolytic pathway in these cells compared to normal, healthy cells. Upon internalization and PET, tumor cells can be imaged and assessed. Tumor cells use the amino acid glutamine for nutritional purposes necessary for energy production and growth; as tumor cells proliferate more rapidly than normal healthy cells, glutamine uptake is higher in certain cancer cells.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C157281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157281>	C201495|C200766	Autologous CLL1-CD33 Compound CAR T Cells|Autologous Anti-CLL1/Anti-CD33 CARs-expressing T-lymphocytes|Autologous CLL1-CD33 cCAR|Autologous CLL1-CD33 cCAR T Cells|Autologous CLL1-CD33 cCAR T-lymphocytes	Autologous T-lymphocytes transduced with a lentiviral vector expressing a compound chimeric antigen receptor (cCAR) containing two CARs, one specific for the CD33 antigen and one specific for the C-type-lectin-like molecule-1 (CLL1; C-type lectin domain family 12 member A; CLEC12A), with potential immunomodulating and antineoplastic activities. Upon administration, the CD33/CLL1-specific CARs lentiviral vector-transduced autologous T-lymphocytes, expressing both the anti-CD33 CAR and the anti-CLL1 CAR on their surfaces, specifically and simultaneously target and bind to CD33- and CLL1-expressing tumor cells, with their anti-CD33 CAR and their anti-CLL1 CAR, respectively. This induces selective toxicity in tumor cells that express the CD33 antigen and the CLL1 antigen. CD33 is expressed on normal non-pluripotent hematopoietic stem cells and is overexpressed on myeloid leukemia cells. CLL1, a member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily, is overexpressed in leukemic stem cells (LSCs) and plays an important role in disease progression and relapse for myeloid malignancies.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157283>	C25804	ADAR Gene|ADAR|ADAR|Adenosine Deaminase, RNA Specific Gene	This gene plays a role in the metabolism of double-stranded RNA.			Gene or Genome	
C157284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157284>	C157283	ADAR wt Allele|ADAR1|AGS6|Adenosine Deaminase Acting on RNA 1 Gene|Adenosine Deaminase, RNA Specific wt Allele|Adenosine Deaminase, RNA-Specific Gene|Adenosine Deaminase, RNA-Specific, 1 Gene|DRADA|DSH|DSRAD|G1P1|IFI-4|IFI4|K88DSRBP|P136	Human ADAR wild-type allele is located in the vicinity of 1q21.3 and is approximately 46 kb in length. This allele, which encodes double-stranded RNA-specific adenosine deaminase protein, is involved in ribonucleotide deamination. Mutations in the gene are associated with dyschromatosis symmetrica hereditaria and Aicardi-Goutieres syndrome type 6.			Gene or Genome	
C157285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157285>	C16701	Double-Stranded RNA-Specific Adenosine Deaminase|136 kDa Double-Stranded RNA-Binding Protein|ADAR|DRADA|EC 3.5.4.37|IFI-4|Interferon-Induced Protein 4|Interferon-Inducible Protein 4|K88DSRBP|RNA-Specific Adenosine Deaminase|dsRNA Adenosine Deaminase|p136	Double-stranded RNA-specific adenosine deaminase (1226 aa, ~136 kDa) is encoded by the human ADAR gene. This protein plays a role in the deamination of adenosine to inosine in double-stranded RNA (A-to-I RNA editing).			Amino Acid, Peptide, or Protein|Enzyme	
C157286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157286>	C16135	Temporally-Feathered Intensity-Modulated Radiation Therapy|TFRT|Temporally Feathered Intensity-Modulated Radiation Therapy|Temporally Feathered Radiation Therapy	A modification of intensity-modulated radiation therapy that optimizes the temporal dimension through which radiation therapy is delivered to further reduce radiation-induced toxicity by increasing the time for normal tissue recovery.	Temporally-Feathered Intensity-Modulated Radiation Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C157287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157287>	C157653	Blasts 0.1 Percent or More of Bone Marrow Nucleated Cells|Blasts Greater than or Equal to 0.1 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that at least 0.1 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts 0.1 Percent or More of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C157288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157288>	C16615	ONECUT2 Gene|ONECUT2|ONECUT2|One Cut Homeobox 2 Gene	This gene is involved in the transcriptional activation of genes affecting melanocyte and hepatocyte differentiation.			Gene or Genome	
C157289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157289>	C157288	ONECUT2 wt Allele|HNF6B|OC-2|OC2|One Cut Domain Family Member 2 Gene|One Cut Domain, Family Member 2 Gene|One Cut Homeobox 2 wt Allele	Human ONECUT2 wild-type allele is located in the vicinity of 18q21.31 and is approximately 56 kb in length. This allele, which encodes one cut domain family member 2 protein, plays a role in DNA binding, transcriptional regulation and organogenesis.			Gene or Genome	
C15728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15728>	C15910	Reiki Therapy|Reiki	An alternative medical practice.  The practitioners of reiki believe that health and disease are a matter of the life force being disrupted.  Reiki healers claim to channel reiki into "diseased" individuals for "rebalancing." (from Skeptic's Dictionary)	Reiki Therapy		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C157290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157290>	C17207	One Cut Domain Family Member 2|HNF-6-Beta|Hepatocyte Nuclear Factor 6-Beta|OC-2|ONECUT-2 Homeodomain Transcription Factor|ONECUT2|One Cut Homeobox 2|Onecut 2|Transcription Factor ONECUT-2	One cut domain family member 2 (504 aa, ~54 kDa) is encoded by the human ONECUT2 gene. This protein is involved in transcriptional regulation and liver development.			Amino Acid, Peptide, or Protein	
C157291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157291>	C20993	Hearing Handicap Inventory for the Elderly|HHIE|Hearing Handicap Inventory for the Elderly (HHIE)	A self-assessment tool designed to assess the effects of hearing impairment on the emotional and social adjustment of elderly people. The inventory is comprised of two subscales: a 13-item subscale that explores the emotional consequences of hearing impairment, and a 12-item subscale that explores both social and situational effects.			Intellectual Product	
C157292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157292>	C173059	Use Phone Less Often than Would Like Due to Hearing Problem Question|Does a hearing problem cause you to use the phone less often than you would like|Use Phone Less Often than Would Like Due to Hearing Problem	A question about whether hearing problems cause an individual to use the phone less often than they would like.			Intellectual Product	Hearing Handicap Inventory for the Elderly
C157294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157294>	C175989|C173059	Avoid Groups of People Due to Hearing Problem Question|Avoid Groups of People Due to Hearing Problem|Does a hearing problem cause you to avoid groups of people	A question about whether hearing problems cause an individual to avoid groups of people.			Intellectual Product	Hearing Handicap Inventory for the Elderly
C157295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157295>	C173059	Irritable Due to Hearing Problem Question|Does a hearing problem make you irritable|Irritable Due to Hearing Problem	A question about whether a hearing problem makes an individual irritable.			Intellectual Product	Hearing Handicap Inventory for the Elderly
C157297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157297>	C173398|C173059|C173058	Difficulty Attending Party Due to Hearing Problem Question|Difficulty Attending Party Due to Hearing Problem|Does a hearing problem cause you difficulty when attending a party	A question about whether a hearing problem causes an individual difficulty when attending a party.			Intellectual Product	Hearing Handicap Inventory for the Elderly
C157298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157298>	C173160|C173059	Feel Stupid or Dumb Due to Hearing Problem Question|Does a hearing problem cause you to feel "stupid" or "dumb"|Feel Stupid or Dumb Due to Hearing Problem	A question about whether a hearing problem causes an individual to feel stupid or dumb.			Intellectual Product	Hearing Handicap Inventory for the Elderly
C15729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15729>	C49236	Sequential Treatment|sequential treatment	The use of two or more consecutive treatment modalities.			Therapeutic or Preventive Procedure	
C1572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1572>	C96404	Recombinant Viral Vaccine	A vaccine produced from genetically engineered viral vector by introduction of foreign genetic materials to activate immune response in a host.			Chemical Viewed Functionally	NICHD Terminology|Pediatric Immunization Terminology
C157300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157300>	C21295	CD96 Gene|CD96|CD96|CD96 Molecule Gene	This gene may play a role in T-cell and natural killer (NK) cell adhesion.	CD96 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C157301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157301>	C157300	CD96 wt Allele|CD96 Molecule wt Allele|T Cell Activation, Increased Late Expression Gene|T-Cell Activation Antigen, Increased Late Expression Gene|TACTILE	Human CD96 wild-type allele is located within 3q13.13-q13.2 and is approximately 373 kb in length. This allele, which encodes T-cell surface protein tactile, may be involved in immune cell matrix adhesion.	CD96 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157303>	C17728	T-Cell Surface Protein Tactile|CD96|CD96 Antigen|Cell Surface Antigen CD96|T Cell-Activated Increased Late Expression Protein	T-cell surface protein tactile (585 aa, ~66 kDa) is encoded by the human CD96 gene. This protein may play a role in immunoregulation.	T-Cell Surface Protein Tactile		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157304>	C54362	DPF1 Gene|DPF1|DPF1|Double PHD Fingers 1 Gene	This gene is involved in the regulation of cell survival.			Gene or Genome	
C157305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157305>	C157304	DPF1 wt Allele|BAF45B|BAF45b|BRG1-Associated Factor, 45-kD Gene|D4, Zinc and Double PHD Fingers Family 1 Gene|D4, Zinc and Double PHD Fingers Family, Member 1 Gene|Double PHD Fingers 1 wt Allele|NEUD4|Neuro-D4 Gene|Neuro-D4 Homolog Gene|Neuro-D4, Rat, Homolog of Gene	Human DPF1 wild-type allele is located in the vicinity of 19q13.2 and is approximately 19 kb in length. This allele, which encodes zinc finger protein neuro-d4, plays a role in neuronal cell survival and dendrite growth.			Gene or Genome	
C157306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157306>	C26199	Zinc Finger Protein Neuro-D4|BAF45B|BRG1-Associated Factor 45B|D4, Zinc and Double PHD Fingers Family 1|DPF1|Double PHD Fingers 1	Zinc finger protein neuro-d4 (380 aa, ~43 kDa) is encoded by the human DPF1 gene. This protein is involved in neuronal dendrite growth and cell survival.			Amino Acid, Peptide, or Protein	
C157307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157307>	C54362	DPF2 Gene|DPF2|DPF2|Double PHD Fingers 2 Gene	This gene plays a role in DNA binding and histone modification and binding.			Gene or Genome	
C157308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157308>	C157307	DPF2 wt Allele|BAF45D|BAF45d|CSS7|D4, Zinc and Double PHD Fingers Family 2 Gene|D4, Zinc and Double PHD Fingers Family, Member 2 Gene|Double PHD Fingers 2 wt Allele|REQ|Requiem, Apoptosis Response Zinc Finger Gene|UBID4|ubi-d4	Human DPF2 wild-type allele is located in the vicinity of 11q13.1 and is approximately 19 kb in length. This allele, which encodes zinc finger protein ubi-d4, is involved in histone binding and modification. Mutation of the gene is associated with Coffin-Siris syndrome 7.			Gene or Genome	
C157309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157309>	C26199	Zinc Finger Protein Ubi-D4|Apoptosis Response Zinc Finger Protein|BAF45D|BRG1-Associated Factor 45D|D4, Zinc and Double PHD Fingers Family 2|DPF2|Double PHD Fingers 2|Protein Requiem|UBI-D4/Requiem Homolog	Zinc finger protein ubi-d4 (391 aa, ~44 kDa) is encoded by the human DPF2 gene. This protein plays a role in transcriptional regulation and DNA binding.			Amino Acid, Peptide, or Protein	
C15730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15730>	C15581|C15295	Chemotherapeutic Peritoneal Perfusion|peritoneal perfusion	A method of delivering fluids and drugs directly to tumors in the peritoneal cavity.			Therapeutic or Preventive Procedure	
C157310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157310>	C54362	DPF3 Gene|DPF3|DPF3|Double PHD Fingers 3 Gene	This gene is involved in neuron-specific chromatin remodeling.			Gene or Genome	
C157311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157311>	C157310	DPF3 wt Allele|BAF45C|BAF45c|CER-D4, Mouse, Homolog of Gene|CERD4|Cerd4|D4, Zinc and Double PHD Fingers, Family 3 Gene|D4, Zinc and Double PHD Fingers, Family, Member 3 Gene|Double PHD Fingers 3 wt Allele|cer-d4	Human DPF3 wild-type allele is located in the vicinity of 14q24.2 and is approximately 285 kb in length. This allele, which encodes zinc finger protein DPF3, plays a role in chromatin remodeling in differentiated neurons.			Gene or Genome	
C157312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157312>	C26199	Zinc Finger Protein DPF3|BAF45C|BRG1-Associated Factor 45C|D4, Zinc and Double PHD Fingers Family 3|DPF3|Double PHD Fingers 3|Zinc Finger Protein Cer-d4	Zinc finger protein DPF3 (378 aa, ~43 kDa) is encoded by the human DPF3 gene. This protein is involved in neuron-specific chromatin remodeling.			Amino Acid, Peptide, or Protein	
C157313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157313>	C173059	Nervous Due to Hearing Problem Question|Does a hearing problem cause you to be nervous|Nervous Due to Hearing Problem	A question about whether having a hearing problem causes an individual to be nervous.			Intellectual Product	Hearing Handicap Inventory for the Elderly
C157314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157314>	C173059	Visit People Less Often than Like Due to Hearing Problem Question|Does a hearing problem cause you to visit friends, relatives, or neighbors less often than you would like|Visit People Less Often than Like Due to Hearing Problem	A question about whether having a hearing problem causes an individual to visit friends, relatives, or neighbors less often than they would like.			Intellectual Product	Hearing Handicap Inventory for the Elderly
C157315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157315>	C173059	Go Shopping Less Often than Like Due to Hearing Problem Question|Does a hearing problem cause you to go shopping less often than you would like|Go Shopping Less Often than Like Due to Hearing Problem	A question about whether having a hearing problem causes an individual to go shopping less often than they would like.			Intellectual Product	Hearing Handicap Inventory for the Elderly
C157316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157316>	C173398|C173059	Upset by Problem or Difficulty with Hearing Question|Does any problem or difficulty with your hearing upset you at all|Upset by Problem or Difficulty with Hearing	A question about whether any problem or difficulty with an individual's hearing upsets them at all.			Intellectual Product	Hearing Handicap Inventory for the Elderly
C157317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157317>	C173059	Want to be Alone Due to Hearing Problem Question|Does a hearing problem cause you to want to be by yourself|Want to be Alone Due to Hearing Problem	A question about whether a hearing problem causes an individual to want to be by themself.			Intellectual Product	Hearing Handicap Inventory for the Elderly
C157318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157318>	C173151	Talk to Family Members Less Often than Like Due to Hearing Problem Question|Does a hearing problem cause you to talk to family members less often than you would like|Talk to Family Members Less Often than Like Due to Hearing Problem	A question about whether having a hearing problem causes an individual to talk to family members less often than they would like.			Intellectual Product	Hearing Handicap Inventory for the Elderly
C157319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157319>	C173059|C104309	Feel Depressed Due to Hearing Problem Question|Does a hearing problem cause you to feel depressed|Feel Depressed Due to Hearing Problem	A question about whether having a hearing problem causes an individual to feel depressed.			Intellectual Product	Hearing Handicap Inventory for the Elderly
C15731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15731>	C15388	Intrahepatic Infusion Procedure|HAI|Hepatic Arterial Infusion|Hepatic Artery Infusion|IHI|Intrahepatic Infusion|hepatic arterial infusion|intrahepatic infusion	Administration of a fluid form of the drug via a blood vessel into the liver over the sustained period of time.	Intrahepatic Infusion Procedure		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C157320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157320>	C4819|C224628|C157324	Unresectable Skin Squamous Cell Carcinoma	Skin squamous cell carcinoma that is not amenable to surgical resection.	Unresectable Skin Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157321>	C173059	Listen to TV or Radio Less Often than Like Due to Hearing Problem Question|Does a hearing problem cause you to listen to TV or radio less often than you would like|Listen to TV or Radio Less Often than Like Due to Hearing Problem	A question about whether having a hearing problem causes an individual to listen to TV or radio less often than they would like.			Intellectual Product	Hearing Handicap Inventory for the Elderly
C157322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157322>	C173160|C173059	Feel Uncomfortable when Talking with Friends Due to Hearing Problem Question|Does a hearing problem cause you to feel uncomfortable when talking to friends|Feel Uncomfortable when Talking with Friends Due to Hearing Problem	A question about whether having a hearing problem causes an individual to feel uncomfortable when talking to friends.			Intellectual Product	Hearing Handicap Inventory for the Elderly
C157324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157324>	C4914|C148124	Unresectable Skin Carcinoma	Skin carcinoma that is not amenable to surgical resection.			Neoplastic Process	
C157325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157325>	C173059|C111717	Feel Left Out When with a Group of Friends Due to Hearing Problem Question|Does a hearing problem cause you to feel left out when you are with a group of people|Feel Left Out When with a Group of Friends Due to Hearing Problem	A question about whether having a hearing problem causes an individual to feel left out when they are with a group of people.			Intellectual Product	Hearing Handicap Inventory for the Elderly
C157326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157326>	C173398|C173059	Difficulty Hearing or Understanding Co-workers, Clients, or Customers Due to Hearing Problem Question|Difficulty Hearing or Understanding Co-workers, Clients, or Customers Due to Hearing Problem|Do you have difficulty hearing / understanding co-workers, clients or customers	A question about whether an individual has or had difficulty hearing or understanding co-workers, clients or customers.			Intellectual Product	Hearing Handicap Inventory for the Elderly
C157327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157327>	C173398|C173059	Difficulty in Movies or Theater Due to Hearing Problem Question|Difficulty in Movies or Theater Due to Hearing Problem|Does a hearing problem cause you difficulty in the movies or in the theater	A question about whether a hearing problem causes an individual difficulty in the movies or in the theater.			Intellectual Product	Hearing Handicap Inventory for the Elderly
C157329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157329>	C94726	Ondansetron Hydrochloride Anhydrous|4H-Carbazol-4-one, 1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-, Monohydrochloride, (+-)-|ONDANSETRON HYDROCHLORIDE ANHYDROUS				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C15732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15732>	C15730|C15684	Continuous Chemotherapeutic Hyperthermic Peritoneal Perfusion|CHPP|CHPP|continuous hyperthermic peritoneal perfusion	A procedure that bathes the abdominal cavity in fluid that contains anticancer drugs. This fluid is warmer than body temperature. This procedure appears to kill cancer cells without harming normal cells.			Therapeutic or Preventive Procedure	
C157330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157330>	C156767|C148124	Unresectable Basal Cell Carcinoma	Basal cell carcinoma that is not amenable to surgical resection.			Neoplastic Process	
C157331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157331>	C2921|C157330|C157324	Unresectable Skin Basal Cell Carcinoma	Basal cell carcinoma of the skin that is not amenable to surgical resection.			Neoplastic Process	
C157332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157332>	C130200	Kidney Transplant Recipient|Kidney Transplantation Recipient	An individual who is receiving or has received a transplant of a kidney.	Kidney Transplant Recipient		Human	CTRP Intervention Terminology|CTRP Terminology
C157333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157333>	C213366|C129821	Inodiftagene Vixteplasmid|BC 819|BC-819|BC819|Diphtheria-toxin-A-H19|INODIFTAGENE VIXTEPLASMID|dT-A-H19	A recombinant DNA plasmid carrying the gene for diphtheria toxin-A (dT-A) chain under the regulation of the H19 promoter, with potential antineoplastic activity. Upon intravesical administration, dT-A chain expression is triggered by the presence of H19 transcription factors that are upregulated in tumor cells. The dT-A chain binds to nicotinamide adenine dinucleotide (NAD) and inactivates the ADP-ribosylation of elongation factor 2 (EF2), resulting in the inhibition of protein synthesis and cell death leading to tumor cell destruction. Inodiftagene Vixteplasmid does not carry the gene for the diphtheria toxin-B (dT-B) chain, thereby preventing the transfer of the toxic dT-A chain between cells. H19, a paternally imprinted, oncofetal gene, is highly expressed in embryonic and certain malignant tissues, but minimally expressed in normal, adult tissues.	Inodiftagene Vixteplasmid		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157334>	C151940|C127155	Metastatic Extracranial Malignant Solid Neoplasm|Metastatic Extracranial Malignant Solid Tumor	A malignant solid neoplasm that arises from any anatomic site other than the brain and has spread from its original site of growth to another anatomic site.	Metastatic Extracranial Malignant Solid Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157335>	C157334|C129707	Advanced Extracranial Malignant Solid Neoplasm|Advanced Extracranial Malignant Solid Tumor	A malignant solid neoplasm that arises from any anatomic site other than the brain and has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Extracranial Malignant Solid Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157336>	C115149	Refractory Adenovirus Infection	An adenovirus infection that does not respond to treatment.	Refractory Adenovirus Infection		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C157337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157337>	C17204	Multi-detector Computed Tomography|MDCT|Multidetector CT|Multidetector Computed Tomography	A type of computed tomography that uses a two-dimensional detector array, allowing for the acquisition of multiple slices simultaneously. This results in an increase in imaging acquisition speed, more coverage of the patient, and high spatial resolution. MDCT acquires volume data instead of individual slice data.	Multi-detector Computed Tomography		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C157338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157338>	C202408|C157337	Multi-detector Computed Tomography Angiography|MDCT Angiography|MDCTA|Multidetector Computed Tomography Angiography	Angiography that uses multi-detector computed tomography.	Multi-detector Computed Tomography Angiography		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C15733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15733>	C208218	Diagnostic Trial|Clinical Trials, Diagnosis|diagnostic trial	Clinical evaluation of the utility of diagnostic procedures.			Research Activity	
C157340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157340>	C28676	Allogeneic CMV Antigen-specific CD4+/CD8+ T-lymphocytes|Allogeneic CMV-specific Antigen-selected T-cells|Allogeneic Cytomegalovirus-specific CD4+ and CD8+ T-cells|Allogeneic Cytomegalovirus-specific CD4+ and CD8+ T-lymphocytes	A population of allogeneic T-lymphocytes specifically reactive to cytomegalovirus (CMV) with potential antiviral activity. Allogeneic CMV antigen-specific T-cells are prepared via ex vivo stimulation of donor-derived peripheral blood mononuclear cells (PBMCs) with major cytomegalovirus structural protein, pp65 (ppUL83). T-cells that secrete interferon (IFN)-gamma in response to pp65 antigen exposure are selected and expanded for administration. Administration of the CMV antigen-specific CD4+ and CD8+T-lymphocytes into hematopoietic stem cell transplant (HSCT) or immunocompromised patients infected with CMV may potentially reconstitute virus-specific responses, thereby controlling CMV infections.	Allogeneic CMV Antigen-specific CD4+/CD8+ T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157341>	C28676	Allogeneic HAdV Antigen-specific T-lymphocytes|Allogeneic HAdV Antigen-selected T-cells|Allogeneic HAdV Antigen-selected T-lymphocytes|Allogeneic HAdV Antigen-specific T-cells|Allogeneic Human Adenovirus-specific T-lymphocytes	A population of allogeneic T-lymphocytes specifically reactive to human adenovirus (HAdV) with potential antiviral activity. Allogeneic HAdV antigen-specific T-cells are prepared via ex vivo stimulation of donor-derived peripheral blood mononuclear cells (PBMCs) with HAdV hexon protein. T-cells that secrete interferon (IFN)-gamma in response to HAdV antigen exposure are selected and expanded for administration. Infusion of the HAdV antigen-specific T-lymphocytes into hematopoietic stem cell transplant (HSCT) patients infected with HAdV may potentially reconstitute virus-specific responses, thereby controlling HAdV infections.	Allogeneic HAdV Antigen-specific T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157343>	C150588	Monoclonal Gammopathy of Renal Significance|MGRS	A condition caused by a B-cell or plasma cell clone resulting in the deposition of the secreted monoclonal immunoglobulin, without evidence for overt lymphoma or myeloma. This category includes a wide spectrum of renal pathology and include such lesions as immunoglobulin-associated amyloidosis, the monoclonal immunoglobulin deposition diseases (MIDDs; light chain deposition disease, heavy chain deposition disease, and light and heavy chain deposition disease), proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID), C3 glomerulopathy with monoclonal gammopathy, light chain proximal tubulopathy (Fanconi syndrome), and several others.			Neoplastic Process	
C157344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157344>	C28681	Autologous CT-RCC-1 HERV-E-TCR-transduced-HLA-A11-restricted CD8+/CD34t+ T-cells|Anti-CT-RCC-1 HERV-E-TCR-transduced-HLA-A11-restricted Autologous CD8+/CD34t+ T-cells (SY)|Autologous CT-RCC-1 HERV-E-TCR-transduced-HLA-A11-restricted CD8+/CD34t+ T-lymphocytes	A preparation of autologous T-lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) sequence specific for CT-RCC-1, a tumor-associated antigen (TAA) and HLA-A11-restricted peptide encoded by human endogenous retrovirus (HERV) type E as well as a truncated CD34 chain (CD34t), with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo and re-introduction into the patient, the autologous CT-RCC-1 HERV-E-TCR-transduced-HLA-A11-restricted CD8+/CD34t+ T-cells bind to and induce selective toxicity in tumor cells expressing both the HLA-A11 allele and the CT-RCC-1 HERV-E antigen. The CD34t protein allows the transduced cells to be identified with an anti-CD34 antibody, and facilitates monitoring of the genetically modified T-cells following adoptive transfer. CT-RCC-1 HERV-E is a TAA found in a high percentage of clear cell renal cell carcinoma (ccRCC) cells.	Autologous CT-RCC-1 HERV-E-TCR-transduced-HLA-A11-restricted CD8+/CD34t+ T-cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157345>	C63586|C63502|C203473|C191676|C159893	Modified FOLFIRINOX Regimen|Dose-adjusted FOLFIRINOX Regimen|Dose-attenuated FOLFIRINOX Regimen|Modified FOLFIRINOX|Modified Fluorouracil/Irinotecan/Leucovorin/Oxaliplatin|Modified Fluorouracil/Irinotecan/Leucovorin/Oxaliplatin Regimen|mFOLFIRINOX|mFOLFIRINOX|mFOLFIRINOX Regimen	A modified, dose-adjusted regimen consisting of fluorouracil, irinotecan, leucovorin and oxaliplatin (FOLFIRINOX) that can be used for the treatment of colorectal cancers, and occult primary, ampullary, pancreatic, small bowel and appendiceal adenocarcinomas.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C157347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157347>	C34808	Borderline Resectable Mass	A tumor mass finding that refers to a continuum between resectable and locally advanced unresectable disease.			Finding	
C15734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15734>	C15669	Prevention of Gastric Cancer	Any method of preventing gastric cancer including limiting of exposure to carcinogens and infectious agents, diet, education, or lifestyle.			Therapeutic or Preventive Procedure	
C157350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157350>	C9120	Borderline Resectable Pancreatic Ductal Adenocarcinoma|BR-PDAC|BRPC|Borderline Resectable Pancreatic Adenocarcinoma|Borderline Resectable Pancreatic Cancer|Borderline Resectable Pancreatic Carcinoma	A pancreatic ductal adenocarcinoma term that refers to a continuum between resectable and locally advanced unresectable disease.	Borderline Resectable Pancreatic Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157351>	C18302	PALB2 Mutation Analysis|FANCN Mutation Analysis|Fanconi Anemia, Complementation Group N Mutation Analysis|PNCA3 Mutation Analysis|Partner and Localizer of BRCA2 Mutation Analysis	A procedure used to detect and identify mutations in the PALB2 gene.			Laboratory Procedure	
C157352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157352>	C62608	Text Message|SMS Text|SMS Text Message|TEXT MESSAGE|Text	A short electronic communication, usually sent and received by a mobile phone.	Text Message		Intellectual Product	CDISC SDTM Mode of Subject Contact Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C157353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157353>	C63845	Monomer Deletion|Deleted Monomer|Monomer Deleted	The physicochemical identity of the repeating monomer unit removed from a polymer.			Chemical Viewed Structurally	
C157354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157354>	C157222	Nucleotide Bond Constituents|Nucleic Acid Bond Constituents	The phosphorus (P) and oxygen (O) atoms found in adjacent nucleotides that form a nucleotide bond.			Chemical Viewed Structurally	
C157355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157355>	C161048|C157366	Colorectal Adenocarcinoma Metastatic in the Liver	An adenocarcinoma that originates from the colorectal area and has spread to the liver.	Colorectal Adenocarcinoma Metastatic in the Liver		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157356>	C16745	Health Insurance|Health Benefit Plan|Health Insurance Coverage|Insurance	A type of insurance designed to cover some of or all the cost of treating an insured person's illnesses or injuries. In some cases, it pays for preventive care, such as annual physicals and diagnostic tests.			Intellectual Product	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C157357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157357>	C157356	National Health Insurance|NHI|SHI|Statutory Health Insurance	A system of health insurance benefits designed to cover a national population against the costs of health care. It may be administered by the public sector, the private sector, or a combination of both.			Intellectual Product	
C157358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157358>	C157356	Medigap|Medigap Insurance	Various private health insurance plans designed to supplement the coverage of Medicare to help pay out-of-pocket costs.			Intellectual Product	
C157359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157359>	C157356	Children's Health Insurance Program|CHIP|Childrens Health Insurance Program	A state-run insurance program that provides low-cost health coverage to children in families that earn too much money to qualify for Medicaid but not enough to buy private insurance.			Intellectual Product	
C15735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15735>	C15669	Prevention of Bladder Cancer	Any method of preventing bladderl cancer including limiingt of exposure to carcinogens and infectious agents, diet, education, or lifestyle.			Therapeutic or Preventive Procedure	
C157360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157360>	C157356	State-sponsored Health Plan|State-sponsored Health Insurance	Health insurance programs that are run and funded at the state level.			Intellectual Product	
C157361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157361>	C157356	Tricare|CHAMPUS|Civilian Health and Medical Program of the Uniformed Services|Private Insurance TRICARE	A federal health care program for uniformed service members, retirees, and their families around the world. The government administers Tricare by contracting with private entities			Intellectual Product	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C157362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157362>	C157356	Civilian Health and Medical Program of the Department of Veterans Affairs|CHAMPVA	A comprehensive health care program, administered by the Department of Veterans Affairs, designed to provide health care services for military veterans.			Intellectual Product	
C157363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157363>	C198659	Veterans Health Administration|Public Health Insurance VA care|VHA	The largest integrated health care system in the United States, providing health care services to over 9 million veterans enrolled in the VA health care program. The VHA manages 1,250 health care facilities, including 172 VA Medical Centers and 1,069 outpatient sites and clinics.			Organization	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C157364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157364>	C156094|C156092|C133254	Metastatic Lung Non-Small Cell Squamous Carcinoma|Metastatic Non-Small Cell Squamous Lung Carcinoma|Metastatic Squamous Non-Small Cell Lung Carcinoma	A squamous non-small cell carcinoma that arises from the lung and has metastasized to another anatomic site.	'Metastatic Lung Non-Small Cell Squamous Carcinoma'		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157365>	C197986|C160783|C157364	Locally Advanced Lung Non-Small Cell Squamous Carcinoma|Locally Advanced Squamous Non-Small Cell Lung Carcinoma	A non-small cell squamous carcinoma of the lung that has spread from its original site of growth to nearby tissues or lymph nodes.			Neoplastic Process	
C157366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157366>	C96767|C156096	Colorectal Carcinoma Metastatic in the Liver	A carcinoma that originates from the colorectal area and has spread to the liver.	Colorectal Carcinoma Metastatic in the Liver		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157367>	C138322	Neoplastic Plasma Cells 30 Percent or More of Bone Marrow Nucleated Cells|Neoplastic Plasma Cells Greater than or Equal to 30 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that at least 30 percent of the nucleated cells in a bone marrow sample are neoplastic plasma cells.	Neoplastic Plasma Cells 30 Percent or More of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C157368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157368>	C91105	Hearing Handicap Inventory Screening Questionnaire for Adults|HHIA-S|Hearing Handicap Inventory for Adults, Screening Version	A 10-item questionnaire, derived from the Hearing Handicap Inventory for the Elderly, developed to assess how adult individuals under 65 perceive the social and emotional effects of hearing loss.			Intellectual Product	
C157369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157369>	C28676	CD45RA-depleted Donor T-lymphocytes|CD45RA-depleted Allogeneic T-cells|CD45RA-depleted Allogeneic T-lymphocytes|CD45RA-depleted Donor T-cells|Donor CD45RA-depleted (memory) T-cells	A preparation of donor lymphocytes that have been depleted of CD45RA-positive cells, that can potentially be used for immune reconstitution purposes. CD45RA depletion results in a cellular product that contains a high amount of memory T-cells (Tm). Upon infusion of the allogeneic CD45RA-depleted T-lymphocytes after a hematopoietic cell transplantation (HCT), these cells provide Tm recovery and are able to prevent viral infections. The depletion of the CD45RA-positive cells reduces the risk of graft-versus-host disease (GvHD) upon infusion. CD45RA is expressed on naive T-cells, whereas Tm cells are CD45RA-negative. Naive T-cells have the potential to induce GvHD.	CD45RA-depleted Donor T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C15736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15736>	C15388	Intracarotid Infusion Procedure|Intracarotid Infusion|intracarotid infusion	The introduction of fluids and drugs directly into the carotid artery, the main artery in the neck that carries blood from the heart to the brain.			Therapeutic or Preventive Procedure	
C157370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157370>	C203000	TCR alpha/beta/CD19-depleted Allogeneic Hematopoietic Progenitor Cells|Allogeneic TCRab/CD19-depleted Hematopoietic Stem Cells|Allogeneic alpha, beta TCR/CD19-depleted HPCs|TCR alpha/beta+/CD19+ Depleted HPCs|TCR alpha/beta+/CD19+ Depleted Hematopoietic Progenitor Cells|TCR alpha/beta/CD19-depleted HPCs|TCRab+/CD19+-depleted Haploidentical Donor HPCs|TCRab-/CD19-depleted Allogeneic Hematopoietic Progenitor Cells|TCRab-/CD19-depleted Hematopoietic Progenitor Cells	A preparation of hematopoietic progenitor cells (HPCs) from a haploidentical donor that have been depleted of T-cell receptor (TCR) alpha and beta (TCRa/b+) as well as CD19-positive (CD19+) cells, that can potentially be used for immune reconstitution purposes. The TCR alpha/beta/CD19-depleted HPCs contain high amounts of natural killer (NK) cells, gamma/delta T-cells, CD34+ stem cells, monocytes, and dendritic cells (DCs), while devoid of alpha/beta T-cells and CD19-positive B-cells. The TCR alpha/beta/CD19-depleted HPCs are used for allogeneic hematopoietic cell transplantation (HCT) and may allow for rapid and sustained engraftment, rapid immune reconstitution, and may prevent or reduce graft-versus-host disease (GvHD).	TCR alpha/beta/CD19-depleted Allogeneic Hematopoietic Progenitor Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C157371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157371>	C19037|C18302	Somatic Mutation Analysis|Somatic Mutation Testing	A procedure used to detect and identify mutations in the genome of a somatic cell sample.			Laboratory Procedure	
C157372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157372>	C2189	Poliglusam|Chitosan|Deacetylchitin|POLIGLUSAM	A naturally occurring polysaccharide composed of beta-1,4-linked glucosamine residues with potential antineoplastic activity. Upon administration, poliglusam may, through a not yet fully elucidated mechanism, reduce advanced glycation end product (AGE) levels. This may reduce the interaction between AGEs and the receptor for advanced glycation end products (RAGE, AGER), which is overexpressed in some tumor types and is associated with poor patient outcomes. AGE-RAGE interaction may induce the phosphorylation and subsequent degradation of retinoblastoma protein (Rb), a key cell cycle inhibitor and tumor suppressor, through the phosphoinositide 3-kinase (PI3K)/protein kinase B (PKB, Akt) signaling pathway. Hyperphosphorylation of Rb leads to the dissociation of the Rb-E2F complex, which triggers the activation of genes required for G1/S transition and tumorigenesis. Reducing AGE levels may limit AGE-RAGE interaction and normalize the G1 to S-phase transition, potentially reducing the development and progression of certain cancers. AGEs are non-enzymatic protein modifications produced during the normal aging process that have been shown to play a role in the development and progression of some cancers.	Poliglusam		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157373>	C73456	Geriatric Physician|Geriatric Medicine Doctor|Geriatric Medicine Specialist|Geriatric Specialist|Geriatrician	A medical doctor who specializes in the diagnosis, treatment, and prevention of disease and disability in older adults.			Professional or Occupational Group	
C157374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157374>	C91102	Did Patient Follow Through with Referral Question|(If yes), did the patient follow through with the referral|Did Patient Follow Through with Referral	A question about whether an individual followed through with a referral.			Intellectual Product	
C157375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157375>	C48832	Primary Care Nurse Navigator	A nurse with special training to guide individuals to primary care services, or to services in the primary care system.			Professional or Occupational Group	
C157376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157376>	C29712|C20401	Mepolizumab|Bosatria|MEPOLIZUMAB|Nucala|SB 240563|SB-240563|SB240563	A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against interleukin-5 (IL-5) with anti-asthmatic and potential immunosuppressive activity. Upon subcutaneous administration, mepolizumab selectively binds to IL-5, preventing it from associating with interleukin-5 receptor subunit alpha (IL5RA) on the surface of eosinophils and their progenitors. IL-5 plays a role in the regulation of eosinophil development from hematopoietic progenitors as well as eosinophil maturation, differentiation, mobilization, activation, and survival. IL-5 also play a role in the pathogenesis of some phenotypes of hypereosinophilic syndrome (HES).	Mepolizumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C157377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157377>	C217568	Testosterone Level Finding	A finding that indicates the amount of testosterone in a sample.			Laboratory or Test Result	
C157378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157378>	C157377	Testosterone Less than 50 ng/dL|Testosterone Less than 50 Nanograms per Deciliter|Testosterone Less than 50 Nanograms/Deciliter	A semiquantitative finding indicating that the concentration of testosterone in a sample is less than 50 ng/dL.	Testosterone Less than 50 ng/dL		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C157379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157379>	C97927|C166407	CCND2 Gene Mutation|CCND2 Mutation|Cyclin D2 Gene Mutation	A change in the nucleotide sequence of the CCND2 gene.	CCND2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C15737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15737>	C15388	Intraventricular Infusion Procedure|Intraventricular Infusion|intraventricular infusion	The delivery of a drug into a fluid-filled cavity within the heart or brain.			Therapeutic or Preventive Procedure	
C157380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157380>	C97927|C157553	CDK6 Gene Mutation|CDK6 Mutation|Cyclin Dependent Kinase 6 Gene Mutation|Cyclin-Dependent Kinase 6 Gene Mutation	A change in the nucleotide sequence of the CDK6 gene.	CDK6 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157381>	C97927|C166407	CCND3 Gene Mutation|CCND3 Mutation|Cyclin D3 Gene Mutation	A change in the nucleotide sequence of the CCND3 gene.	CCND3 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157382>	C97927|C166407	CCNE1 Gene Mutation|CCNE Gene Mutation|CCNE1 Mutation|Cyclin E1 Gene Mutation	A change in the nucleotide sequence of the CCNE1 gene.	CCNE1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157383>	C42636	Live Animal Dosage Form|Live animal	A type of pharmaceutical dose form consisting of a whole, live animal used as a medicinal product, which may have a mechanical function and/or deliver physiologically active substances.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Basic Dose Form Terminology
C157384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157384>	C35655	Normal Liver Function Test|Liver Function Test Normal	A laboratory test result indicating the results of a liver function test are within normal parameters for the age and population.			Laboratory or Test Result	
C157385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157385>	C159583	Letaplimab|Anti-CD47 Monoclonal Antibody IBI188|IBI 188|IBI-188|IBI188|LETAPLIMAB	A human immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47 with potential immunostimulating and antineoplastic activities. Upon intravenous administration, letaplimab selectively binds to CD47 expressed on tumor cells and blocks the interaction of CD47 with signal regulatory protein alpha (SIRPa), a protein expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.	Letaplimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157387>	C35877|C177683|C150123|C131486	BCR-JAK2 Fusion in Hematologic Malignancies	An extremely rare finding in hematologic malignancies indicating an association with BCR-JAK2 fusion gene that results from t(9;22)(p24;q11.2). Most cases exhibit chronic myelogenous leukemia-type phenotype.	BCR-JAK2 Fusion in Hematologic Malignancies		Finding	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157388>	C129820	Immunomodulatory Imide Drug|IMiD	A class of immunomodulatory drugs containing an imide group.	Immunomodulatory Imide Drug		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology|NCIt Antineoplastic Agent Terminology
C157389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157389>	C25337	Number Used Since Last Visit|Number of Drugs Used Since Last Visit	An indication of the number of drugs used during the time since the last visit.			Quantitative Concept	
C15738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15738>	C211883	Dyspnea Management|management of dyspnea	Treatment to manage or alleviate difficult or painful breathing or shortness of breath.	Dyspnea Management		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C157390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157390>	C25337	Number Used at Visit|Number of Drugs Used at Visit	An indication of the number of drugs used during the visit.			Quantitative Concept	
C157391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157391>	C168327	Drug Used at Visit|Use of Drug at Visit|Used Drug at Visit	An indication that a specified drug was used during a visit.			Finding	
C157392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157392>	C168327	Drug Used Since Last Visit|Use of drug Since Last Visit|Used Drug Since Last Visit	An indication that a specified drug was used during the time since the last visit.			Finding	
C157393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157393>	C203001|C119988	Autologous CD34-positive BCL11A-disrupted Hematopoietic Progenitor Cells BIVV003|Autologous CD34+ Hematopoietic Stem Cells BIVV003|Autologous CD34-positive BCL11A-disrupted HPCs BIVV003|BIVV003|HSPCs BIVV003	A population of autologous cluster of differentiation 34 (CD34)-positive hematopoietic progenitor cells (HPCs) that are transfected ex vivo with zinc finger nuclease (ZFN) messenger ribonucleic acid (mRNA) targeting the B-cell lymphoma/leukemia 11A (BCL11A) locus, with potential usage for transplantation in patients with sickle cell disease (SCD). CD34-positive HPCs are isolated from human blood upon apheresis and are genetically modified in vitro using ZFN technology to specifically cleave and disrupt the erythroid enhancer of the BCL11A gene. This suppresses the production of sickle hemoglobin. Upon infusion into the patient following conditioning chemotherapy, the autologous CD34-positive BCL11A-disrupted HPCs BIVV003 can populate the bone marrow and differentiate into a variety of blood cell types including lymphoid cells, myeloid cells and erythroblasts. As BCL11A is a suppressor of fetal hemoglobin (HbF) expression, disruption of the BCL11A enhancer decreases the expression of BCL11A and stimulates the expression of HbF in erythrocytes that differentiate from BIVV003. HbF may compensate for reduced or absent expression of adult hemoglobin in patients with SCD.	Autologous CD34-positive BCL11A-disrupted Hematopoietic Progenitor Cells BIVV003		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C157394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157394>	C65070|C63360	Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel Regimen|ABCP|ABCP|ABCP (bevacizumab-adcd)|ABCP (bevacizumab-awwb)|ABCP (bevacizumab-aybi)|ABCP (bevacizumab-bvzr)|ABCP (bevacizumab-equi)|ABCP (bevacizumab-maly)|ABCP (bevacizumab-onbe)|ABCP (bevacizumab-tnjn)|ABCP Regimen|Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel|Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel Regimen|Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel|Carboplatin and Paclitaxel (CP), Atezolizumab, Bevacizumab|Carboplatin and Paclitaxel (CP), Atezolizumab, Bevacizumab-adcd|Carboplatin and Paclitaxel (CP), Atezolizumab, Bevacizumab-awwb|Carboplatin and Paclitaxel (CP), Atezolizumab, Bevacizumab-aybi|Carboplatin and Paclitaxel (CP), Atezolizumab, Bevacizumab-bvzr|Carboplatin and Paclitaxel (CP), Atezolizumab, Bevacizumab-equi|Carboplatin and Paclitaxel (CP), Atezolizumab, Bevacizumab-maly|Carboplatin and Paclitaxel (CP), Atezolizumab, Bevacizumab-onbe|Tecentriq/Avastin/Carboplatin/Taxol	A regimen consisting of atezolizumab, bevacizumab, carboplatin, and paclitaxel that can be used in the treatment of cervical cancer and non-small cell lung cancer (NSCLC).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C157395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157395>	C63787|C63360|C159454	Atezolizumab/Bevacizumab Regimen|Atezolizumab and Bevacizumab|Atezolizumab and Bevacizumab-adcd|Atezolizumab and Bevacizumab-awwb|Atezolizumab and Bevacizumab-aybi|Atezolizumab and Bevacizumab-bvzr|Atezolizumab and Bevacizumab-equi|Atezolizumab and Bevacizumab-maly|Atezolizumab and Bevacizumab-onbe|Atezolizumab and Bevacizumab-tnjn|Atezolizumab-Bevacizumab|Atezolizumab-Bevacizumab Regimen|Atezolizumab/Bevacizumab|Tecentriq/Avastin	A regimen consisting of atezolizumab and bevacizumab that can be used in the treatment of non-small cell lung cancer (NSCLC), peritoneal mesothelioma and hepatocellular carcinoma (HCC).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C157396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157396>	C65070|C63587|C63519|C63360|C63358|C210232|C159457	Carboplatin/Paclitaxel/Pembrolizumab Regimen|Carboplatin and Paclitaxel (CP) and Pembrolizumab|Carboplatin-Paclitaxel-Pembrolizumab|Carboplatin-Paclitaxel-Pembrolizumab Regimen|Carboplatin/Paclitaxel/Pembrolizumab|Carboplatin/Taxol/Keytruda	A regimen consisting of carboplatin, paclitaxel, and pembrolizumab that can be used in the treatment of breast cancer, cervical cancer, vaginal cancer, vulvar cancer, endometrial carcinoma, head and neck cancers, and metastatic squamous non-small cell lung cancer (NSCLC). Pembrolizumab plus paclitaxel weekly/carboplatin regimen may be used for the treatment of head and neck cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C157397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157397>	C63787|C63360	Cisplatin/Pembrolizumab/Pemetrexed Regimen|Cisplatin, Pemetrexed, Pembrolizumab|Cisplatin-Keytruda-Alimta|Cisplatin-Pembrolizumab-Pemetrexed|Cisplatin-Pembrolizumab-Pemetrexed Regimen|Cisplatin/Pembrolizumab/Pemetrexed	A regimen consisting of cisplatin, pembrolizumab and pemetrexed that can be used in the treatment of metastatic non-squamous non-small cell lung cancer (NSCLC), and peritoneal and pleural mesothelioma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C157398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157398>	C63360	Pembrolizumab/Pemetrexed Regimen|Keytruda-Alimta|Pembrolizumab-Pemetrexed|Pembrolizumab-Pemetrexed Regimen|Pembrolizumab/Pemetrexed|Pemetrexed/Pembrolizumab Regimen	A regimen consisting of pemetrexed and pembrolizumab that can be used in the treatment of non-small cell lung cancer (NSCLC).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C157399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157399>	C28103	Borderline Operable|Borderline Resectable	A disease treatment qualifier indicating that a tumor can neither be described as resectable or unresectable, often applied when a tumor is located near vital structures (such as blood vessels).			Classification	
C15739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15739>	C15262	Immunotoxin Therapy	Drug therapy that uses an immunotoxin.	Immunotoxin Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C1573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1573>	C2554	Incomplete Freund's Adjuvant|Freund's Incomplete Adjuvant|IFA|INCOMPLETE FREUND'S ADJUVANT|ISA-51|Montanide ISA 51|Montanide ISA-51|Montanide ISA-51|incomplete Freund's adjuvant	A water-in-oil emulsion that stimulates the T-cell immune response to antigens and may be used in various types of cancer vaccines. (NCI04)	Incomplete Freund's Adjuvant		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157400>	C1660	HIV Entry Inhibitor|Cell Entry Inhibitor|Entry Inhibitor|Virus Entry Inhibitor	An agent that prevents the human immunodeficiency virus (HIV) from entering a cell.			Chemical Viewed Functionally	
C157401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157401>	C1660	HIV Integrase Inhibitor|INI|Integrase Inhibitor	An agent that blocks the activity of the human immunodeficiency virus (HIV) integrase enzyme.			Chemical Viewed Functionally	
C157402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157402>	C157377	Testosterone Greater than or Equal to 200 ng/dL|Testosterone Greater than or Equal to 200 Nanograms per Deciliter|Testosterone Greater than or Equal to 200 Nanograms/Deciliter	A semiquantitative finding indicating that the concentration of testosterone in a sample is greater than or equal to 200 ng/dL.	Testosterone Greater than or Equal to 200 ng/dL		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C157403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157403>	C1660|C1589	Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate|Atripla|EFV/FTC/TDF|Efavirenz/Emtricitabine/Tenofovir	A fixed combination of efavirenz, a non-nucleoside reverse transcriptase (RT) inhibitor (NNRTI); emtricitabine, a nucleoside RT inhibitor (NRTI) analog of cytidine; and tenofovir disoproxil fumarate, an NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, efavirenz, emtricitabine, and tenofovir disoproxil fumarate inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.	Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology
C157404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157404>	C1660	Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate|EVG/COBI/FTC/TDF|Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir|Stribild	A fixed combination of elvitegravir, a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI); cobicistat, a cytochrome P450 3A (CYP3A) inhibitor; emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine; and tenofovir disoproxil fumarate, an NRTI analog of adenosine monophosphate, that is used to treat HIV infection. Upon oral administration, elvitegravir inhibits the activity of integrase, an HIV-1 coded enzyme that is necessary for viral replication. Inhibition of integrase prevents the integration of HIV-1 DNA into host genomic DNA. Cobicistat inhibits CYP3A, thereby limiting the oxidative metabolism of elvitegravir and increases its systemic exposure. Emtricitabine and tenofovir disoproxil fumarate inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.			Pharmacologic Substance	
C157405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157405>	C1660|C1589	Abacavir Sulfate/Lamivudine|ABC/3TC|Abacavir/Lamivudine|Epzicom|Kivexa|Kivexa	A fixed combination of abacavir sulfate, a nucleoside reverse transcriptase inhibitor (NRTI) analog of guanosine and lamivudine, an NRTI analog of cytidine, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, abacavir and lamivudine are phosphorylated into active metabolites that compete for incorporation into viral DNA. These metabolites inhibit the HIV reverse transcriptase (RT) enzyme competitively and act as a chain terminator of DNA synthesis. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.			Pharmacologic Substance	
C157406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157406>	C280	Delamanid|DELAMANID|Deltyba|Imidazo(2,1-b)oxazole, 2,3-Dihydro-2-methyl-6-nitro-2-((4-(4-(4-(trifluoromethoxy)phenoxy)-1-piperidinyl)phenoxy)methyl)-, (2R)-|OPC 67683|OPC-67683|OPC67683	A nitro-dihydro-imidazooxazole derivative, with antimycobacterial activity. Upon oral administration, delamanid, a prodrug, is activated via the mycobacterial F420 coenzyme system to form a reactive intermediate metabolite that inhibits the synthesis of the mycobacterial cell wall components methoxy-mycolic and keto-mycolic acid. This leads to the depletion of these cell wall components and destruction of mycobacteria.	Delamanid		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C157408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157408>	C1660|C1589	Emtricitabine/Rilpivirine Hydrochloride/Tenofovir Disoproxil Fumarate|Complera|Emtricitabine/Rilpivirine/Tenofovir|Eviplera|Eviplera|FTC/RPV/TDF	A fixed combination of emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine; rilpivirine, a non-nucleoside RT inhibitor (NNRTI); and tenofovir disoproxil fumarate, an NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, rilpivirine binds to HIV RT, thereby blocking RNA and DNA-dependent DNA polymerase activities including viral replication. Emtricitabine and tenofovir disoproxil fumarate inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.			Pharmacologic Substance	
C157409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157409>	C28681|C138180|C129826	Autologous Anti-NY-ESO-1 mTCR Retroviral Vector Transduced PBLs|Anti-NY-ESO-1 mTCR Retroviral Vector Transduced Autologous Peripheral Blood Lymphocytes|Autologous Anti-NY-ESO-1 Murine TCR Retroviral Vector Transduced Peripheral Blood Lymphocytes|NY-ESO-1-Specific mTCR Retroviral Vector Transduced Autologous PBLs	Human autologous peripheral blood lymphocytes (PBLs) transduced with a retroviral vector encoding both alpha and beta chains of a murine T-cell receptor (mTCR) specific for the cancer-testis antigen NY-ESO-1, with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, the autologous anti-NY-ESO-1 mTCR retroviral vector transduced PBLs bind to NY-ESO-1 expressed on tumor cells. This may result in cytotoxic T-lymphocyte (CTL)-mediated killing of NY-ESO-1-positive cancer cells. NY-ESO-1, a tumor-associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types.	Autologous Anti-NY-ESO-1 mTCR Retroviral Vector Transduced PBLs		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15740>	C15747	Menopausal Symptoms Attenuation	Therapy to reduce the effects of menopausal symptoms.  May also be necessary in order to counteract the effect of various chemotherapy treatments.			Therapeutic or Preventive Procedure	
C157410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157410>	C158612	What is the Hormonal Contraceptive Use Status Question|Use of Hormonal Contraceptives|What is the Hormonal Contraceptive Use Status|hormonal contraceptive use|hormonal_contraceptive_use	The current status of an individual with regards to contraceptive use.			Qualitative Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Property Terminology|GDC Terminology
C157411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157411>	C160157	Current Oral Contraceptive User|Current Therapy|Current User	An indication that an individual currently uses oral contraceptives.			Qualitative Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C157412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157412>	C157410	Former Oral Contraceptive User Question|Former Oral Contraceptive User|Former Therapy|Former User	An individual who previously used oral contraceptives.			Qualitative Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C157413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157413>	C157410	Never Used Oral Contraceptives Question|Never|Never Used|Never Used Oral Contraceptives	An individual who has never used oral contraceptives.			Qualitative Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C157414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157414>	C157255	Roche HPV Lab Test|Roche	A human papilloma virus test developed by Roche laboratories.			Diagnostic Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C157415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157415>	C157255	Qiagen HPV Lab Test|Qiagen	A human papilloma virus test developed by Qiagen laboratories.			Diagnostic Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C157416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157416>	C160157	Performance Status Scale Timing Not Evaluated|Not Evaluated: Not provided or available	An indication that the information was not evaluated, not provided or available.			Qualitative Concept	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C157417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157417>	C173060|C158612	Age When Started using Smokeless Tobacco after Regular Use Question|Age When Started using Smokeless Tobacco after Regular Use|If the patient used smokeless tobacco (including chewing tobacco and snuff) regularly for at least six weeks, how old were they when they started using	A question about the age of an individual when they started using smokeless tobacco after at least six weeks regular use.			Qualitative Concept	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology
C157418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157418>	C225418	Proximal Bile Duct|Hilar/Perihilar|Hilar/Perihilar Bile Duct	These include the bile ducts which are located at the hilum of the liver as well as the segment where the left and right hepatic ducts join just outside the liver to form the common bile duct.			Spatial Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C157419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157419>	C225418	Extrahepatic/Distal Bile Duct	Located or occurring outside the liver, including the distal portion of bile duct.			Spatial Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Terminology
C15741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15741>	C15406	Screening for Hepatocellular Cancer|hepatocellular cancer, screening for|liver cancer, screening for|screening for liver cancer	Checking an individual for the presence or absence of hepatocellular cancer.			Diagnostic Procedure	
C157420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157420>	C36292	CA19-9 Level Finding|CA 19-9 Level Finding|CA19-9 Antigen Level Finding|Cancer Antigen 19-9 Level Finding|Carbohydrate Antigen 19-9 Level Finding	A finding that indicates the amount of carbohydrate antigen 19-9 (CA19-9) in a sample.	CA19-9 Level Finding		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C157421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157421>	C36292	International Normalized Ratio of Prothrombin Time Level Finding|Prothrombin Time INR	A finding that indicates the international normalized ratio of prothrombin time level in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C157422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157422>	C70922	Total Bilirubin Level Finding	A finding that indicates the amount of total bilirubin in a sample.			Laboratory or Test Result	
C157423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157423>	C70922	Creatinine Level Finding	A finding that indicates the amount of creatinine in a sample.			Laboratory or Test Result	
C157424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157424>	C5042	Visual Change|Vision Changes|Visual Changes|Visual Changes	An alteration in the visual system of an individual.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C157425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157425>	C62405	Tumor Focality|tumor focality|tumor_focality	The characterization of the location of the tumor.			Qualitative Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|GDC Property Terminology|GDC Terminology
C157426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157426>	C70922	Total Thyroxine Level Finding	A finding that indicates the amount of total thyroxine in a sample.			Laboratory or Test Result	
C157427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157427>	C36292	Serum CEA Level Finding	A finding that indicates the amount of carcinoembryonic antigen (CEA) in a serum sample.			Laboratory or Test Result	
C157428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157428>	C157420	Serum CA 19-9 Level Finding	A finding that indicates the amount of carbohydrate associated antigen (CA19.9) in a serum sample.			Laboratory or Test Result	
C157429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157429>	C5040	Sensory Change|Sensory Changes|Sensory Changes	An alteration in the perceptual senses an individual.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C157430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157430>	C74528	Self-Reported and Medical Record	Information that was obtained from the individual and the medical record.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C157431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157431>	C37927	Red and Violet|Red & Violet|Red & Violet	The combination of red and violet colors.			Qualitative Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form|GDC Terminology|GDC Value Terminology
C157432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157432>	C41132	None Identified	Nothing was identified.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C157433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157433>	C110937	Motor / Movement Change|Motor or Movement Changes|Motor/Movement Changes	An alteration in the motor/movement of an individual.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C157434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157434>	C99801	Month/Year of Diagnosis	The month and the year of the diagnosis.			Temporal Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C157435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157435>	C36280	Mental Status Change|Mental Status Changes	An alteration in the mental status of an individual.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology
C157436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157436>	C102602	Helicobacter pylori Status	The finding of whether an individual is infected with the H.pylori bacteria.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C157437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157437>	C19332	Eye Color|eye color|eye_color	The color of the iris of the eye.			Organism Attribute	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form|GDC Property Terminology|GDC Terminology
C157438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157438>	C158612	First Degree Family History of Cancer Question|Cancer in the immediate family|Family History of Cancer (First degree relatives parents, siblings, or children)|First Degree Family History of Cancer	A question about whether the parents, siblings or children of an individual have a history of cancer.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology|CRF2 History and Physical Exam Family Medical History Table
C157439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157439>	C171237	First Degree Family History of Esophageal or Gastric Esophageal Cancer|Family History of Esophageal or Gastric Esophageal Cancer in First Degree Relative	Parents, siblings or children of an individual have a history of esophageal or gastric esophageal cancer.	First Degree Family History of Esophageal or Gastric Esophageal Cancer		Group Attribute	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C15743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15743>	C63475	Medical Castration|medical castration	The use of drugs to suppress the function of the ovaries or testicles.			Therapeutic or Preventive Procedure	
C157440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157440>	C158612	Is there a First Degree Family History of Primary Brain Tumor Question|Family History of Primary Brain Tumor (First degree relatives parents, siblings, or children)|Is there a First Degree Family History of Primary Brain Tumor	A question about whether the parents, siblings or children of an individual have a history of a primary brain tumor.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology
C157441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157441>	C173151|C158612	Family History of Stomach Cancer Question|Family History of Stomach Cancer	A question about a family history of stomach cancer.			Group Attribute	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C157442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157442>	C158612	Is there a First Degree Family History of Thyroid Cancer Question|Family History of Thyroid Cancer (for First Degree Relatives Only)|Is there a First Degree Family History of Thyroid Cancer	A question whether parents, siblings or children of an individual have a history of thyroid cancer.			Group Attribute	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C157443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157443>	C36291	Extent of Resection|EXTRSCT|EXTRSCT|PROCEDURE_EXTENT|PROCEDURE_EXTENT|PROCEDURE_EXTENT|PROCEDURE_EXTENT	The degree to which the lesion has been cut out, or resected.			Finding	CDISC SDTM Crohn's Disease Findings About Test Code Terminology|CDISC SDTM Crohn's Disease Findings About Test Name Terminology|CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology|EWS Biopsy/Surgical Procedures Table|EWS Variable Terminology|GCT Biopsy/Surgical Procedures Table|GCT Variable Terminology|HL Biopsy/Surgical Procedures Table|HL Variable Terminology|OS Biopsy/Surgical Procedures Table|OS Variable Terminology
C157444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157444>	C205055	Epstein-Barr Viral Status	A viral load assay of the Epstein-Barr virus which may be an indicator of disease status.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C157445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157445>	C156814	Date of Last Targeted Molecular Therapy	The date of the last targeted molecular therapy.			Temporal Concept	
C157446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157446>	C156814	Date of Last Immunotherapy Treatment	The date of the last immunotherapy treatment.			Temporal Concept	
C157447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157447>	C15220	Clinical Diagnosis of Reflux Disease	An indication that an individual has been clinically diagnosed with gastric reflux disease.			Diagnostic Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Terminology
C157448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157448>	C93011	Hybrid Argon Plasma Coagulation|Hybrid APC|Hybrid Argon Plasma Ablation	A modification of argon plasma coagulation ablation (APC) that combines APC with submucosal saline injection. The saline is injected beneath the epithelium to create a cushion that protects the underlying tissue from the ablative procedure.	Hybrid Argon Plasma Coagulation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C157449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157449>	C6432	Multiple Endocrine Neoplasia Type 4|MEN 4|Multiple Endocrine Neoplasia Type 1-Like Syndrome	An autosomal dominant tumor syndrome caused by germline CDKN1B mutations that result in a phenotype similar to that of multiple endocrine neoplasia type 1, characterized by endocrine neoplasms, particularly in the parathyroid glands, pituitary, and pancreas. (WHO 2017)			Neoplastic Process	CCPS Disease Terminology|Childhood Cancer Predisposition Study Terminology
C15744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15744>	C27993	In Vivo|in vivo	Located or occurring in the body.			Functional Concept	
C157450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157450>	C3801	Peripheral Hemangioblastoma	A hemangioblastoma that arises from peripheral nerves or extraneural tissues.			Neoplastic Process	
C157451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157451>	C97927|C48301	SDHAF2 Gene Mutation|C11orf79 Gene Mutation|PGL2 Gene Mutation|Paraganglioma or Familial Glomus Tumors 2 Gene Mutation|SDH5 Gene Mutation|Succinate Dehydrogenase Complex Assembly Factor 2 Gene Mutation	A change in the nucleotide sequence of the SDHAF2 gene.	SDHAF2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157452>	C213314	Metastatic Squamous Cell Carcinoma in the Cervical Lymph Nodes|Metastatic Squamous Cell Carcinoma in Cervical Lymph Node|Metastatic Squamous Cell Carcinoma in Cervical Lymph Node	A squamous cell carcinoma that has spread from its original site of growth to the cervical lymph nodes.	Metastatic Squamous Cell Carcinoma in Cervical Lymph Node		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157453>	C142078	Valproic Acid-Expanded Umbilical Cord Blood-derived CD34-positive Cells|VPA-expanded Cord Blood Stem Cells|VPA-expanded UCB Stem Cells	A preparation of umbilical cord blood (UCB)-derived CD34-positive cells treated with valproic acid (VPA) with potential use in hematopoietic stem cell transplant (HSCT). Upon positive immunomagnetic selection of CD34-positive cells from UCB units, CD34-positive cells are expanded in culture with stem cell factor (SCF), FMS-like tyrosine kinase 3 ligand (Flt3L), thrombopoietin (TPO), and interleukin-3 (IL-3), treated with VPA, and infused into the patient. VPA, a histone deacetylase inhibitor (HDACi), may induce epigenetic changes in UCB hematopoietic stem cells (HSCs), resulting in expansion of CD34-positive cells enriched in short term (ST), intermediate term (IT), and long term (LT) marrow repopulating cells (RCs), which are capable of sustained hematopoietic engraftment following transplantation. Further, VPA-expanded UCB stem cells may shorten the time to neutrophil and platelet recovery and maintain long-term hematopoietic and immune reconstitution compared to untreated UCB grafts.	Valproic Acid-Expanded Umbilical Cord Blood-derived CD34-positive Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C157454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157454>	C19975	Boston University-Boston Medical Center Cancer Center|BU-BMC|BU-BMC Cancer Center	A cancer center with the mission of providing a bridge between the clinical oncology and biomedical research communities at the Boston University Medical and Charles River campuses and the Boston Medical Center.			Professional or Occupational Group	
C157455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157455>	C97927	GCGR Gene Mutation|GGR Gene Mutation|GL-R Gene Mutation|Glucagon Receptor Gene Mutation	A change in the nucleotide sequence of the GCGR gene.			Cell or Molecular Dysfunction	
C157456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157456>	C48168	Brown University Oncology Research Group|BrUOG	A cancer research group created in 1994 to coordinate clinical cancer research for Brown University affiliated hospitals, including Rhode Island Hospital, the Miriam Hospital, Roger Williams Medical Center, Memorial Hospital of Rhode Island, and Women & Infants Hospital of Rhode Island, and the Alpert Medical School faculty, with the mission of improving cancer care through the implementation of innovative, multidisciplinary cancer clinical trials.			Health Care Related Organization	
C157457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157457>	C38186	NASA Jet Propulsion Laboratory|JPL	A federally funded research facility managed by the California Institute of Technology (Caltech) for the National Aeronautics and Space Administration (NASA) with the primary function of constructing and operating planetary robotic spacecraft.			Organization	
C157458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157458>	C3113	Islet Glucagon Cell Hyperplasia	Hyperplasia of the alpha cells of the pancreas.			Disease or Syndrome	
C157459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157459>	C19980	Tisch Cancer Institute at Mount Sinai|TCI	An NCI-Designated Cancer Center that was established in 2008 as part of the Icahn School of Medicine at Mount Sinai with the mission of advancing the field of cancer research, treatment, and prevention; it employs scientists and physicians with expertise in basic, clinical, and population science research to develop innovative and translational research programs.			Professional or Occupational Group	
C15745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15745>	C94421	Hyperfractioned Radiation Therapy|Hyperfractionated|Hyperfractionated Radiation|Hyperfractionated Radiation Therapy|Hyperfractionation|accelerated-fraction radiation therapy|hyperfractionated radiation therapy|hyperfractionation|superfractionated radiation therapy	Radiation treatments in which the total dose of radiation is divided into smaller doses and administered more than once a day.	Hyperfractionation		Therapeutic or Preventive Procedure	CRF4 Treatment Radiation Table|CRF4 Treatment Re-Irradiation Table|CTRP Intervention Terminology|CTRP Terminology
C157460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157460>	C19980	Mays Cancer Center|Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center	A cancer center established by UT Health San Antonio in the 1970s that achieved NCI-Designated Cancer Center status in 1991 and is affiliated with MD Anderson Cancer Center.			Professional or Occupational Group	
C157461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157461>	C35561|C3266	Glucagon Cell Hyperplasia and Neoplasia|GCGR|GCHN|Mahvash Disease|Mahvash Syndrome	An extremely rare autosomal recessive inherited disorder caused by mutations in the GCGR gene. It is characterized by the presence of islet glucagon cell hyperplasia and glucagon cell tumors.			Disease or Syndrome	
C157462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157462>	C97927	ARID1A Gene Mutation|ARID1A mutation|AT Rich Interactive Domain 1A Gene Mutation|B120 Gene Mutation|BAF250 Gene Mutation|BAF250a Gene Mutation|BRG1-Associated Factor 250a Gene Mutation|SMARCF1 Gene Mutation	A change in the nucleotide sequence of the ARID1A gene.	ARID1A Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157463>	C97927|C174175|C159204|C133695	XRCC2 Gene Mutation|DNA Repair Protein XRCC2 Gene Mutation|FANCU Gene Mutation|X-Ray Repair Complementing Defective Repair in Chinese Hamster Cells 2 Gene Mutation|X-Ray Repair Cross Complementing 2 Gene Mutation	A change in the nucleotide sequence of the XRCC2 gene.	XRCC2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157464>	C227071	Questionnaire Not Completed Due to Patient Illness|Patient Illness	A response indicating that a questionnaire was not completed due to patient illness.			Intellectual Product	
C157465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157465>	C227071	Questionnaire Not Completed Due to Institutional Error|Administrative Error	A response indicating that a questionnaire was not completed due to institutional error.			Intellectual Product	
C157466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157466>	C14134	Monomer Connection Points|Branched structural repeat unit connection points	The atoms that make up the head and branch points within a single repeating monomeric unit in a branched polymer.			Chemical Viewed Structurally	CBDD Structure Terminology|CBDD Terminology
C157467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157467>	C157466	Nucleotide Connection Points|Nucleotide connection points	The phosphorus (P) atom found in the phosphate group and the oxygen (O) atom bound to the 3' carbon of the sugar within a single nucleotide, which can each form linkages with adjacent nucleotides during nucleic acid synthesis.			Chemical Viewed Structurally	CBDD Structure Terminology|CBDD Terminology
C157468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157468>	C118873	How Often Took Retroviral Agents Past 6 Months Question|How Often Took Retroviral Agents Last 6 Months|How Often Took Retroviral Agents Past 6 Months	A question regarding how often an individual took antiviral agents during the past 6 months.			Intellectual Product	
C157469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157469>	C175253	100 Percent of the Time	An indication that an individual did something, or something occurred, 100 percent of the time.			Intellectual Product	
C15746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15746>	C15986|C15632	Remission Induction Therapy|remission induction therapy	Initial treatment with anticancer drugs to decrease the signs or symptoms of cancer or make them disappear.			Therapeutic or Preventive Procedure	
C157470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157470>	C175253	95 to 99 Percent of the Time	An indication that an individual did something, or something occurred, between 95 and 99 percent of the time.			Intellectual Product	
C157471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157471>	C175253	75 to 94 Percent of the Time	An indication that an individual did something, or something occurred, between 75 and 94 percent of the time.			Intellectual Product	
C157472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157472>	C175253	Less than 75 Percent of the Time	An indication that an individual did something, or something occurred, less than 75 percent of the time.			Intellectual Product	
C157473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157473>	C1660|C1589	Abacavir Sulfate/Lamivudine/Zidovudine|ABC/3TC/ZDV|Abacavir/Lamivudine/Zidovudine|Trizivir	A fixed combination of abacavir sulfate, a nucleoside reverse transcriptase inhibitor (NRTI) analog of guanosine; lamivudine, an NRTI analog of cytidine; and zidovudine, an NRTI analog of thymidine, that may be used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, abacavir, lamivudine, and zidovudine are phosphorylated into active metabolites that inhibit the HIV reverse transcriptase (RT) enzyme competitively and act as a chain terminator of DNA synthesis. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.			Pharmacologic Substance	
C157474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157474>	C7233|C188180|C172133	Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder|Relapsed Monomorphic Post-Transplant Lymphoproliferative Disorder	The reemergence of monomorphic post-transplant lymphoproliferative disorder after a period of remission.	Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157475>	C7233|C188179|C172280	Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder	A monomorphic post-transplant lymphoproliferative disorder that does not respond to treatment.	Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157476>	C7183|C188180	Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder|Relapsed Polymorphic Post-Transplant Lymphoproliferative Disorder	The reemergence of polymorphic post-transplant lymphoproliferative disorder after a period of remission.	Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157477>	C7183|C188179	Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder	A polymorphic post-transplant lymphoproliferative disorder that does not respond to treatment.	Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157478>	C20923	GCGR Gene|GCGR|GCGR|Glucagon Receptor Gene	This gene is involved in glucose homeostasis.			Gene or Genome	
C157479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157479>	C157478	GCGR wt Allele|GGR|GL-R|Glucagon Receptor wt Allele	Human GCGR wild-type allele is located in the vicinity of 17q25.3 and is approximately 10 kb in length. This allele, which encodes glucagon receptor protein, is involved in hormone-dependent signaling. Mutation of the gene is associated with type 2 diabetes mellitus and glucagon cell hyperplasia and neoplasia.			Gene or Genome	
C15747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15747>	C49236	Supportive Care|SUPPORTIVE CARE|Supportive Therapy|Symptom Management|Therapy, Supportive|supportive care	Supportive care is that which helps the patient and their family to cope with cancer and treatment of it from pre-diagnosis, through the process of diagnosis and treatment, to cure, continuing illness or death and into bereavement. It helps the patient to maximize the benefits of treatment and to live as well as possible with the effects of the disease. Supportive therapy may provide a patient with friendship, encouragement, practical advice such as access to community resources or how to develop a more active social life, vocational counseling, suggestions for minimizing friction with family members, and, above all, hope that the life of the patient may be improved. In all situations, supportive therapy involves the teaching of such life skills as managing medication, learning to socialize, handling finances, and getting a job.	Supportive Care		Therapeutic or Preventive Procedure	CDISC SDTM Terminology|CDISC SDTM Treatment Intent Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C157480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157480>	C18239	Glucagon Receptor|GCGR|GL-R	Glucagon receptor (477 aa, ~54 kDa) is encoded by the human GCGR gene. This protein plays a role in the glucagon-dependent regulation of blood glucose levels.			Amino Acid, Peptide, or Protein|Receptor	
C157482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157482>	C20993	OPTI-Surg Toolkit|OPTI-Surg|OPTI-Surg Pre-Surgical Frailty Assessment with Resource Recommendations	A set of pre-surgical questionnaires, including a frailty assessment, designed to provide resource-customized recommendations to address identified vulnerabilities in individual patients.			Intellectual Product	
C157483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157483>	C25199	Coach	Someone who teaches a special skill (e.g., how to implement a treatment or intervention).	Coach		Social Behavior	CTRP Intervention Terminology|CTRP Terminology
C157484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157484>	C28676|C201933	Allogeneic Tri-functional Anti-CD19 CAR-NK Cells|Allogeneic CD19-TriCAR SILK Cells|Allogeneic CD19-TriCAR-T/SILK|Allogeneic CD19-TriCAR-T/SILK Cells	A preparation of allogeneic natural killer (NK) cells transduced with a retroviral vector expressing the immunostimulatory cytokine interleukin-15 (IL-15) and encoding a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19) that is coupled to the co-stimulatory domains cluster of differentiation 28 (CD28, T-cell-specific surface glycoprotein CD28), cluster of differentiation 137 (CD137; 4-1BB), and the zeta chain of the T-cell receptor (TCR)/CD3 complex (TCRzeta; CD247; CD3zeta); and a blocker for the inhibitory T-cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immunomodulating and antineoplastic activities. Upon transfusion, the allogeneic tri-functional anti-CD19 CAR-NK cells recognize, bind to and induce selective cytotoxicity in CD19-expressing tumor cells. IL-15 enhances the cytotoxic effect of the NK cells and the activated anti-tumor T-cells. The PD-1 inhibitory domain targets and binds to programmed cell death-1 ligand 1 (PD-L1) expressed on tumor cells, thereby preventing the binding of the PD-1 on T-lymphocytes to its ligand, PD-L1 on tumor cells. This prevents PD-1/PD-L1-mediated inhibition of T-lymphocytes and leads to the activation and expansion of T-cells resulting in a cytotoxic T-lymphocyte (CTL) response against tumor cells, thereby enhancing the elimination of tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. The co-stimulatory signaling domains enhance both proliferation of T-cells and anti-tumor activity.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157485>	C129822|C128037	Pimivalimab|Anti-PD-1 Monoclonal Antibody JTX-4014|JTX 4014|JTX-4014|JTX4014|PIMIVALIMAB	A human immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pimivalimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.	Pimivalimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157486>	C2124	Fluorine F 18-Active Site Inhibited Factor VIIa|18F-ASIS	A radioconjugate containing a tissue factor (TF) tracer, a derivative of activated factor VII (FVIIa), labeled with fluorine F 18, with potential use for TF-expressing tumor imaging using positron emission tomography (PET). Upon administration of fluorine F 18 active site inhibited factor VIIa (18F-ASIS), the active site inhibited factor VIIa (FVIIai) moiety selectively targets and binds, with a much higher binding affinity than FVIIa, to TF. Upon PET imaging, tumor cells expressing TF can be visualized and assessed. TF, a transmembrane glycoprotein, is overexpressed on certain tumor cell types and is correlated with tumor aggression and poor prognosis.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C157487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157487>	C28676|C129826	Therapeutic Ex Vivo-expanded Allogeneic gamma delta T-cells TCB-202|Ex-vivo Expanded Allogeneic gd T-lymphocytes|OmnImmune|TCB 202|TCB-202|TCB-202|TCB202|Therapeutic Ex Vivo-expanded Allogeneic gamma, delta T-Cells	An off-the-shelf preparation of a subset of therapeutic, ex vivo-expanded, allogeneic T-lymphocytes that express only gamma chain and delta chain T-cell receptors (TCRs), with potential immunomodulating and antineoplastic activities. Upon administration of the therapeutic ex vivo-expanded allogeneic gamma delta T-cells TCB-202, these cells secrete interferon-gamma (IFN-g) and exert direct killing of tumor cells. In addition, these cells activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against tumor cells. Gamma delta T-lymphocytes play a key role in the activation of the immune system and do not require major histocompatibility complex (MHC)-mediated antigen presentation to exert their cytotoxic effect.	Therapeutic Ex Vivo-expanded Allogeneic gamma delta T-cells TCB-202		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157488>	C28681	EBV LMP-2A-specific Autologous CD8+ T-cells|EBV Latent Membrane Protein-2a Specific Eutil Autologous Blood-derived T-Lymphocytes|EBV-induced Natural T-cells|EBV-induced T-lymphocytes|EBV/LMP-2A-specific CD8 T-Cells|EBViNT|EBViNT Cell|Epstein-Barr Virus Induced Natural T-cells|Eutil Autologous T-lymphocytes	A preparation of autologous cytotoxic T-lymphocytes (CTLs) that are specifically reactive to Epstein-Barr virus (EBV) latent membrane protein-2A (LMP-2A) and expressing the co-stimulatory domain 4-1BB (CD137), with potential antineoplastic activity. Upon administration of the EBV/LMP-2A-specific autologous CD8+ T-cells to patients with EBV-positive tumors, these cells bind to and cause cell death in EBV-infected cells. This inhibits proliferation of EBV LMP-2A-expressing tumor cells. EBV LMP-2A is expressed in various malignancies and plays a key role in tumor cell proliferation and survival. 4-1BB, an inducible costimulatory member of the tumor-necrosis factor receptor (TNFR) family, is expressed on activated T-cells. It activates additional CD8+ T-cells, prevents activation-induced cell death of CD8+ T-cells, and selectively induces T-helper 1 (Th1)-type cytokines such as interferon (IFN)-gamma and tumor-necrosis factor-alpha (TNF-alpha).			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology
C157489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157489>	C201170	Adenosine A2A Receptor Antagonist/Phosphodiesterase 10A PBF-999|A2A/PDE-10A Inhibitor PBF-999|PBF 999|PBF-999|PBF-999|PBF999	An orally bioavailable inhibitor of both the adenosine A2A receptor (A2AR; ADORA2A) and phosphodiesterase 10A (PDE-10A), with potential immunomodulating and antineoplastic activities. Upon administration, A2A/PDE-10A inhibitor PBF-999 selectively binds to and inhibits A2AR expressed on T-lymphocytes. This blocks tumor-released adenosine from interacting with A2AR and prevents the adenosine/A2AR-mediated inhibition of T-lymphocytes. This results in the proliferation and activation of T-lymphocytes and stimulates a T-cell-mediated immune response against tumor cells. A2AR, a G protein-coupled receptor, is highly expressed on the cell surfaces of T-cells and, upon activation by adenosine, inhibits T-cell proliferation and activation. Adenosine is often overproduced by cancer cells and plays a key role in immunosuppression. In addition, PBF-999 binds to and inhibits the activity of PDE-10A, thereby preventing the degradation of cyclic guanosine monophosphate (cGMP) and activates cGMP/cGMP-dependent protein kinase G (PKG) signaling. This induces beta-catenin degradation and thereby prevents the translocation of beta-catenin into the nucleus, and the beta-catenin-mediated induction of transcription of survival proteins, such as cyclin D1 and survivin. It also suppresses RAS/RAF/mitogen-activated protein kinase (MAPK) signaling. This induces apoptosis and inhibits the growth of tumor cells in which PDE-10A is overexpressed. PDE-10A is a cGMP-degrading PDE isozyme that is highly expressed in the brain and overexpressed in certain types of tumor cells. Elevation of intracellular cGMP is known to inhibit tumor proliferation and induce apoptosis. cGMP levels are low in cancer cells resulting from the overexpression PDE-10A.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15748>	C16230	Total Nodal Irradiation|total nodal irradiation	Radiation therapy to the mantle field, the spleen, the lymph nodes in the upper abdomen, and the lymph nodes in the pelvic area.	Total Nodal Irradiation		Clinical Attribute	CTRP Intervention Terminology|CTRP Terminology
C157490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157490>	C93144	Lactobacillus rhamnosus/L. acidophilus/L. plantarum/ Enterococcus faecium Aqueous Probiotic Supplement|Lactobacillus acidophilus/Lactobacillus plantarum/Lactobacillus rhamnosus/Enterococcus faecium Aqueous Probiotic Supplement|PROBIO-FIX INUM|Symprove|Symprove Liquid Probiotic	A water-based multi-strain probiotic composed of an extract of germinated barley containing the four live, activated lactic acid bacteria strains Lactobacillus rhamnosus, L. acidophilus, L. plantarum, and Enterococcus faecium, with potential immunomodulatory and anti-inflammatory activities. Upon oral administration of Lactobacillus rhamnosus/L. acidophilus/L. plantarum/ Enterococcus faecium aqueous probiotic supplement, these four live bacteria modulate the composition of the normal gastrointestinal (GI) microflora, by increasing the beneficial bacteria and decreasing the harmful bacteria, and helps maintain adequate colonization of the GI tract, thereby improving digestion and preventing GI disturbances. These bacteria and the butyric acid produced by them create an environment unfavorable to pathogens by adhering to human epithelial cells, protecting epithelium by maintaining the tight junction integrity and forming a protective mucosal barrier. This prevents attachment of pathogens and reduces the risk of infection, and potentially reduces the severity of mucositis. By restoring gut microbiota, these bacteria may restore or enhance intestinal immune responses.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C157492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157492>	C2079	Xinmailong|XML	A Chinese medicine composed of bioactive composite extracted from Periplaneta americana consisting of adenosine, inosine, protocatechuic acid, and pyroglutamate dipeptides, with potential cardioprotective activity. Upon administration, xinmailong may inhibit the phosphorylation of mitogen-activated protein kinase 3/extracellular signal-regulated kinase 1 (MAPK3/ERK1), mitogen-activated protein kinase 1 (MAPK1)/ERK2, AKT, and glycogen synthase kinase-3 beta (GSK3-beta), thereby decreasing the expression of transcription factor GATA-4. GATA-4 is a key regulator of cardiac hypertrophy, mediating gene expressions in response to heart failure (HF) stimuli by activating a variety of HF-associated genes, such as atrial natriuretic factor (ANF), B-type natriuretic peptide (BNP), and beta-myosin heavy chain (beta-MHC). Decreased expression of GATA-4 may limit the transcription of these genes and offer protection against certain types of HF.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C157493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157493>	C201853	Adagrasib|ADAGRASIB|KRAS G12C Inhibitor MRTX849|Krazati|MRTX 849|MRTX-849|MRTX849	An orally available, small molecule inhibitor that targets the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration adagrasib covalently binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C, thereby inhibiting mutant KRAS-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.	Adagrasib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157494>	C96040|C28227|C128036	Anti-CTLA-4/OX40 Bispecific Antibody ATOR-1015|ADC 1015|ADC-1015|ADC1015|ATOR 1015|ATOR-1015|ATOR1015|CTLA-4 x OX40 Bispecific Antibody ATOR-1015	A bispecific antibody consisting of a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitory protein fused to an OX40 agonistic human immunoglobulin G1 (IgG1) antibody, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CTLA-4/OX40 bispecific antibody ATOR-1015 simultaneously binds to CTLA-4 and OX40, which may inhibit CTLA-4-mediated downregulation of T-cell activation and induce proliferation of memory and effector T-lymphocytes via OX40 activation. Both CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), and OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), are overexpressed by regulatory T-cells (Tregs) in the tumor microenvironment. ATOR-1015 may reduce the number of Tregs and promote the activation of effector T-cells, thereby enhancing the immune-mediated anti-tumor response.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157496>	C1557	Fostroxacitabine Bralpamide|FOSTROXACITABINE BRALPAMIDE|MIV 818|MIV-818|MIV818|Troxacitabine Nucleotide Prodrug MIV-818|Troxacitabine Prodrug MIV-818	A liver-targeting nucleotide phosphoramidate prodrug of troxacitabine monophosphate (TRX-MP), a dioxolane derivative and L-configuration deoxycytidine analogue, with potential antineoplastic activity. Upon oral administration, fostroxacitabine bralpamide is rapidly and specifically hydrolyzed in hepatocytes by liver carboxylesterase 1 (carboxylesterase 1, CE-1), generating high levels of the chain-terminating nucleotide, troxacitabine triphosphate (TRX-TP) in the liver. TRX-TP is then incorporated into tumor cell DNA, leading to termination of DNA synthesis and inhibition of tumor cell proliferation.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157497>	C210981	Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents|Castration-Resistant Prostate Carcinoma Refractory to Second-Generation ARAT Agents	Castration-resistant prostate carcinoma that is refractory to second-generation androgen receptor axis-targeted agents, namely abiraterone and enzalutamide.	Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157498>	C130235	Resistance to Second-Generation Androgen Receptor Axis-Targeted Agents	A finding indicating that a castration-resistant prostate carcinoma is refractory to second-generation androgen receptor axis-targeted agents.			Finding	
C157499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157499>	C129820	Nanoscale Coordination Polymer Nanoparticles CPI-100|CPI 100|CPI-100|CPI100|NCP Nanoparticles CPI-100	A preparation of self-assembled core-shell nanoscale coordination polymer (NCP) nanoparticles containing an as of yet undisclosed payload with potential immunostimulating and antineoplastic activities. Upon intravenous administration, NCP nanoparticle formulation CPI-100 delivers its payload to tumor cells, which may lead to enhanced immune-mediated killing and regression of tumor cells.	Nanoscale Coordination Polymer Nanoparticles CPI-100		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15749>	C49165|C132068	Tumor Debulking|Debulking|Debulking|Debulking Procedure|Debulking Surgery|debulking|tumor debulking	The surgical removal of as much of a malignant tumor as is reasonably possible. This procedure increases the effectiveness of the subsequent administration of chemotherapy and/or radiation therapy.	Tumor Debulking		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C1574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1574>	C804	Alitretinoin|3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-trans-4-trans-6-cis-8-trans-nonatetraenoic Acid|9-Cis-Retinoic Acid|9-cRA|9-cis Retinoic Acid|9-cis retinoic acid|9-cis-RA|9-cis-Retinoic Acid|ALITRETINOIN|ALRT 1057|ALRT-1057|ALRT1057|LGD 1057|LGD-1057|LGD1057|Panretin|Panretyn|Panrexin|Retinoicacid-9-cis	An orally- and topically-active naturally-occurring retinoic acid with antineoplastic, chemopreventive, teratogenic, and embryotoxic activities. Alitretinoin binds to and activates nuclear retinoic acid receptors (RAR) and retinoid X receptors (RXR); these activated receptors act as transcription factors, regulating gene expression that results in the inhibition of cell proliferation, induction of cell differentiation, and apoptosis of both normal cells and tumor cells.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157500>	C28676|C129826	CD56-enriched CD3-positive Donor Lymphocytes|CD56+/CD3+ Donor Cells|CD56-enriched Donor Cells|CD56-enriched Donor Lymphocytes	A population of CD3-positive lymphocytes expressing the CD56 surface antigen, with potential immunomodulating activity. Upon infusion of the CD56-enriched CD3-positive donor lymphocytes, these cells may facilitate the reconstitution of CD4-positive T-cells, regulatory T-cells (Tregs) and natural killer (NK) cells, which may reduce the incidence of post-transplant graft-versus-host disease (GvHD) following haploidentical stem cell transplant (SCT). CD56 is a transmembrane glycoprotein also known as neural cell adhesion molecule 1 (NCAM-1).			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology
C157501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157501>	C192661|C129822	Anzurstobart|ANZURSTOBART|Anti-SIRPa Monoclonal Antibody CC-95251|BMS-986351|CC 95251|CC-95251|CC95251	An immunoglobulin G1 (IgG1) monoclonal antibody targeting signal-regulatory protein alpha (SIRPa; CD172a) with potential immunostimulating and antineoplastic activities. Upon intravenous administration, anzurstobart targets and binds to SIRPa, a cell surface protein expressed on macrophages, thereby blocking the interaction between SIRPa and cluster of differentiation 47 (CD47) expressed on tumor cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages. This results in macrophage activation and the specific phagocytosis of tumor cells. In addition, blocking CD47/SIRPa-mediated signaling activates both an anti-tumor T-lymphocyte immune response and T cell-mediated killing of CD47-expressing tumor cells. SIRPa, also known as tyrosine-protein phosphatase non-receptor type substrate 1, mediates negative regulation of phagocytosis, mast cell activation and dendritic cell activation. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.	Anzurstobart		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157502>	C205055|C175007	HBV Surface Antibody Level Result	The quantity of hepatitis b virus surface antibody in a sample.			Laboratory or Test Result	
C157503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157503>	C134528	Feline Histiocytic Sarcoma	Histiocytic sarcoma occurring in a cat.			Neoplastic Process	Cellosaurus Disease Terminology
C157504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157504>	C98985	Myopathy due to Myoadenylate Deaminase Deficiency|MMDD	An autosomal recessive condition caused by mutation(s) in the AMPD1 gene, encoding AMP deaminase 1. The condition is characterized by exercise-induced muscle pain and/or fatigue, which may be associated with rhabdomyolysis and/or increased concentrations of creatinine kinase.			Disease or Syndrome	Cellosaurus Disease Terminology
C157506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157506>	C205055|C103223	HCV Genotype Finding|HCV Genotype	The determination of the genotype of hepatitis c virus in a blood sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C157507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157507>	C205055	HBV DNA Level Finding	The viral load of hepatitis b virus DNA units in a blood sample.			Laboratory or Test Result	
C157508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157508>	C205055|C103223	HBV Genotype Finding	The determination of the genotype of hepatitis b virus in a blood sample.			Laboratory or Test Result	
C157509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157509>	C16929|C16552	Vinyl Chloride or Derivatives Exposure|Vinyl and/or derivatives	Environmental, occupational, or consumer-based exposure to vinyl chloride or its derivatives during the manufacture or breakdown of polyvinyl chloride (PVC) and other vinyl containing products.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C15750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15750>	C16174|C15912	Intrathecal Chemotherapy|intrathecal chemotherapy	Chemotherapy delivered via the spinal canal.	Intrathecal Chemotherapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C157510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157510>	C77140	Non-Neoplastic Finding|Non-Neoplastic Findings	Clinical, laboratory or molecular evidence, or absence of evidence of a non-neoplastic disease.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C157511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157511>	C36286|C173902	High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma|High Risk NMIBC|High Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma|High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma|High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma	A finding indicating the presence of a high risk bladder urothelial carcinoma that does not invade muscle.	High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma		Finding	CTRP Disease Terminology|CTRP Terminology
C157512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157512>	C157511	Recurrent High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma|Recurrent High Risk NMIBC|Recurrent High Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma|Recurrent High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma|Recurrent High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma	A finding indicating the reemergence of high risk non-muscle invasive bladder urothelial carcinoma after a period of remission.	Recurrent High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma		Finding	CTRP Disease Terminology|CTRP Terminology
C157513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157513>	C15645	No Therapy|No Treatment	An indication that no therapy was done or administered.			Therapeutic or Preventive Procedure	CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Terminology
C157514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157514>	C15986	Single Agent Therapy|Drug Monotherapy|Monotherapy|Single Agent Treatment|Single Drug Therapy	Pharmacotherapy consisting of a single agent.	Single Agent Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C157515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157515>	C15986	Multiple Agent Therapy|Multiple Agent Treatment	Pharmacotherapy that uses more than one agent simultaneously.			Therapeutic or Preventive Procedure	
C157516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157516>	C15697	Unknown Regimen	An indication that the treatment regimen used is not known.			Functional Concept	
C157517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157517>	C49236	Therapy Used at Visit|Type of Therapy Used at Visit|therapy type|therapy_type	An indication of the type of therapy used during a visit.			Finding	ICDC Property Terminology|ICDC Terminology
C157518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157518>	C49236	Therapy Used Since Last Visit|Type of Therapy Used Since Last Visit|treatment since last contact|treatment_since_last_contact	An indication of the type of therapy used since the last visit.			Finding	ICDC Property Terminology|ICDC Terminology
C157519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157519>	C91102	Drug Included in Regimen Question|Drug Included in Regimen|Is Drug Included in Regimen	A question about whether a specified drug or agent was included in a treatment regimen.			Intellectual Product	
C15751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15751>	C15313	External Beam Radiation Therapy|Definitive Radiation Therapy|EBRT|EXTERNAL BEAM RADIATION THERAPY|External Beam RT|External Beam Radiation|External Beam Radiotherapy|External Beam Radiotherapy (conventional)|External Radiation Therapy|External beam radiotherapy|Radiation, External Beam|Teleradiotherapy|Teletherapy|Teletherapy Radiation|external radiation|external-beam radiation	Radiation therapy in which high-energy beams are delivered to the tumor from outside of the body.	External Beam Radiation Therapy		Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|HemOnc Agent Terminology
C157520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157520>	C94631	Potent Antiretroviral Therapy	Antiretroviral therapy using two or more nucleoside reverse transcriptase inhibitors with either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor.			Therapeutic or Preventive Procedure	
C157521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157521>	C35681|C103223	MSI-H Negative|High-Frequency Microsatellite Instability Negative|Microsatellite Instability High Negative|Microsatellite Instability-High Negative	An indication either that low-frequency microsatellite instability (MSI-L) is present or that genomic instability has not been detected in a sample.	MSI-H Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C157522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157522>	C52726	Overlapping/Multiple Zones of Prostate|Overlapping/Multiple Zones|Overlapping/multiple zones	A term that indicates involvement of multiple zones of prostate.			Anatomical Structure	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C157523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157523>	C17220	Tumor Marker Level|Tumor Level	The amount of a tumor marker in a given sample.			Indicator, Reagent, or Diagnostic Aid	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology
C157524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157524>	C156953	CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC BLCA Baseline Form	Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on Bladder Urothelial Carcinoma Baseline Form data.			Intellectual Product	
C157525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157525>	C19498	Survivorship Care Plan	A document that contains a history of an individual's cancer treatment history as well as guidelines for monitoring and maintaining their health, including the need for future check-ups and cancer tests. The information may also include potential long-term late effects of the treatment received.	Survivorship Care Plan		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C157526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157526>	C156953	CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC CESC Baseline Form	Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form data.			Intellectual Product	
C157527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157527>	C156953	CPTAC Esophageal Carcinoma Baseline Form|CPTAC ESCA Baseline Form	Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on Esopohageal Carcinoma Baseline Form data.			Intellectual Product	
C157528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157528>	C156953	CPTAC Cholangiocarcinoma Baseline Form|CPTAC CHOL Baseline Form	Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on  Cholangiocarcioma Baseline Form data.			Intellectual Product	
C157529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157529>	C156953	CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC LIHC Baseline Form	Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on Liver Hepatocellular Carcinoma Baseline Form data.			Intellectual Product	
C15752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15752>	C15986|C15632|C15230	Chemoembolization|Chemotherapy Embolization|chemoembolization	A procedure that introduces chemotherapy to blood vessels adjacent to a tumor, for the purpose of both treating the tumor and interrupt blood flow to the tumor, which serves both to trap the chemotherapeutic agent at the tumor and to decrease the amount of nutrients flowing to the tumor.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|GDC Terminology|GDC Value Terminology
C157530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157530>	C156953	CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC PRAD Baseline Form Terminology	Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on Prostate Adenocarcinoma Baseline Form data.			Intellectual Product	
C157531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157531>	C156953	CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC LGG Baseline Form	Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on Brain Lower Grade Glioma Baseline Form data.			Intellectual Product	
C157532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157532>	C156953	CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC STAD Baseline Form Terminology	Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on Stomach Adenocarcinoma Baseline Form data.			Intellectual Product	
C157533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157533>	C156953	CPTAC Thyroid Carcinoma Baseline Form|CPTAC THCA Baseline Form	Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on Thyroid Carcinoma Baseline Form data.			Intellectual Product	
C157534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157534>	C156953	CPTAC Uveal Melanoma Baseline Form|CPTAC UVM Baseline Form	Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus onUveal Melanoma Baseline Form data.			Intellectual Product	
C157535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157535>	C1660|C1589	Emtricitabine/Tenofovir Disoproxil Fumarate|FTC/TDF|Truvada	A fixed combination of emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine, and tenofovir disoproxil fumarate, an NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, emtricitabine and tenofovir inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.			Pharmacologic Substance	NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C157536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157536>	C97366	Darunavir/Cobicistat|DRV/COBI|Prezcobix|Rezolsta|Rezolsta	A fixed combination of darunavir, an inhibitor of the human immunodeficiency virus (HIV) protease; and cobicistat, a cytochrome P450 3A (CYP3A) inhibitor that may be used to treat HIV infection. Upon oral administration, darunavir binds to and inhibits the dimerization and catalytic activity of the HIV aspartyl protease. This inhibits the cleavage of HIV-encoded Gag and Gag-Pol polyproteins in virus-infected cells, which prevents the formation of mature infectious virions. Cobicistat inhibits CYP3A, thereby limiting the metabolism of darunavir and increases its systemic exposure.			Pharmacologic Substance	NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C157537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157537>	C1660	Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate|EVG/COBI/FTC/TAF|Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide|Genvoya|Genvoya	A fixed combination of elvitegravir, a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI); cobicistat, a cytochrome P450 3A (CYP3A) inhibitor; emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine; and tenofovir alafenamide fumarate, the fumarate salt form of the lipophilic phosphonamidate prodrug of tenofovir, a NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, elvitegravir inhibits the activity of integrase, an HIV-1 coded enzyme that is necessary for viral replication. Inhibition of integrase prevents the integration of HIV-1 DNA into host genomic DNA. Cobicistat inhibits CYP3A, thereby limiting the oxidative metabolism of elvitegravir and increases its systemic exposure. Emtricitabine and tenofovir inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.			Pharmacologic Substance	
C157538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157538>	C1660|C1589	Emtricitabine/Tenofovir Alafenamide Fumarate|Descovy|Emtricitabine/Tenofovir Alafenamide|FTC/TAF	A fixed combination of emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine and tenofovir alafenamide fumarate, the fumarate salt form of the lipophilic phosphonamidate prodrug of tenofovir, a NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, emtricitabine and tenofovir inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.			Pharmacologic Substance	NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C157539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157539>	C1660|C1589	Emtricitabine/Rilpivirine/Tenofovir Alafenamide Fumarate|Emtricitabine/Rilpivirine/Tenofovir Alafenamide|FTC/RPV/TAF|Odefsey	A fixed combination of emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine; rilpivirine, a diarylpyrimidine derivative and non-nucleoside RT inhibitor (NNRTI); and tenofovir alafenamide fumarate, the fumarate salt form of the lipophilic phosphonamidate prodrug of tenofovir, a NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, emtricitabine and tenofovir inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions. Rilpivirine, a non-competitive NNRTI binds to RT and inhibits RNA and DNA-dependent polymerase activities, including viral replication.			Pharmacologic Substance	
C15753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15753>	C16126	Cancer Registry|CancerRegistry|Registry	Cancer registries gather a wide variety of specific information on cancer patients that can be analyzed to identify health disparity trends in cancer incidence, mortality and patient survival.			Intellectual Product	BRIDG Class Terminology|BRIDG Terminology|OS Authorized Value Terminology|OS Subject Characteristics Table
C157540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157540>	C16165	HAART with Hydroxyurea and Didanosine|HAART HU/ddI|HAART using Hydroxyurea and Didanosine|HAART with HU/ddl|HAART with Hydroxyurea Plus Didanosine|Highly Active Antiretroviral Therapy with HU/ddl|Highly Active Antiretroviral Therapy with Hydroxyurea and Didanosine	Treatment for human immunodeficiency virus (HIV) infection that uses a combination of the antiretroviral drugs hydroxyurea and didanosine. The drugs inhibit the ability of the virus to multiply in the body, and they slow down the development of AIDS.			Therapeutic or Preventive Procedure	
C157541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157541>	C97366	Atazanavir/Cobicistat|ATV/COBI|Evotaz	A fixed combination of atazanavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, and cobicistat, a cytochrome P450 3A (CYP3A) inhibitor that may be used to treat HIV-1 infection. Upon oral administration, atazanavir selectively binds to the active site of HIV-1 protease and inhibits the proteolytic cleavage of viral Gag and Gag-Pol polyproteins in HIV-infected cells. This inhibition leads to the production of immature, non-infectious viral proteins that are unable to form mature virions. Cobicistat inhibits CYP3A, thereby limiting the metabolism of atazanavir and increasing its systemic exposure.			Pharmacologic Substance	
C157542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157542>	C281	Ribavirin/Recombinant Interferon alpha-2b|RTCA/IFN alpha-2b|RTCA/IFN-a2b|Rebetol/Intron A|Rebetron	A fixed combination of ribavirin, a synthetic nucleoside analog of ribofuranose, and a recombinant form of interferon alfa-2b (IFN-a2b), with activity against hepatitis C virus (HCV). Upon oral administration of the ribavirin capsules, ribavirin is incorporated into viral RNA, thereby inhibiting viral RNA synthesis, inducing viral genome mutations, and inhibiting normal viral replication. Upon injection, IFN-a2b binds to specific IFN cell-surface receptors. This activates IFN-mediated signal transduction pathways and induces the transcription and translation of genes with interferon-stimulated response elements (ISREs); the protein products mediate antiviral, antiproliferative and immunomodulating effects. Although it's largely unknown how these two agents work together, in combination, this is used to treat hepatitis C infection by fighting and slowing the spread of the virus, thereby decreasing blood levels of HCV.			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	
C157543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157543>	C1589|C157401	Abacavir/Dolutegravir/Lamivudine|ABC/DTG/3TC|Triumeq	A fixed combination of abacavir sulfate, a nucleoside reverse transcriptase inhibitor (NRTI) analog of guanosine; dolutegravir, an integrase strand-transfer inhibitor (INSTI); and lamivudine, an NRTI analog of cytidine, that may be used to treat human immunodeficiency virus (HIV) infection. Upon oral administration, abacavir and lamivudine are phosphorylated into active metabolites that inhibit the HIV reverse transcriptase (RT) enzyme competitively and act as a chain terminator of DNA synthesis. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions. Dolutegravir binds to the active site of integrase, an HIV enzyme that catalyzes the transfer of viral genetic material into human chromosomes. This prevents integrase from binding to retroviral deoxyribonucleic acid (DNA), and blocks the strand transfer step, which is essential for the HIV replication cycle. This further prevents HIV-1 replication.			Pharmacologic Substance	
C157544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157544>	C20921	ARHGAP45 Gene|ARHGAP45|ARHGAP45|Rho GTPase Activating Protein 45 Gene	This gene is involved in the activation of Rho-type GTPases.	ARHGAP45 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C157545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157545>	C157544	ARHGAP45 wt Allele|HA-1|HLA-HA1|HMHA1|Histocompatibility (Minor) HA-1 Gene|KIAA0223|Rho GTPase Activating Protein 45 wt Allele	Human ARHGAP45 wild-type allele is located in the vicinity of 19p13.3 and is approximately 22 kb in length. This allele, which encodes Rho GTPase-activating protein 45, plays a role in the positive regulation of Rho family GTPase activity.	ARHGAP45 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157546>	C17298	Rho GTPase-Activating Protein 45|ARHGAP45|Minor Histocompatibility Antigen HA-1 Precursor|Minor Histocompatibility Protein HA-1 Precursor|Rho GTPase Activating Protein 45	Rho GTPase-activating protein 45 (1136 aa, ~125 kDa) is encoded by the human ARHGAP45 gene. This protein is involved in the activation of Rho family GTPases.	Rho GTPase-Activating Protein 45		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157547>	C97927	ARHGAP45 Gene Mutation|HA-1 Gene Mutation|HLA-HA1 Gene Mutation|HMHA1 Gene Mutation|Histocompatibility (Minor) HA-1 Gene Mutation|Rho GTPase Activating Protein 45 Gene Mutation	A change in the nucleotide sequence of the ARHGAP45 gene.	ARHGAP45 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157548>	C157547	ARHGAP45 NM_012292.4:c.416G>A|ARHGAP45 c.416G>A|HA-1 c.416G>A|HLA-HA1 Gene c.416G>A|HMHA1 Gene c.416G>A|NM_012292.4:c.416G>A|Rho GTPase Activating Protein 45 Gene c.416G>A	A nucleotide substitution at position 416 of the coding sequence of the ARHGAP45 gene where guanine has been mutated to adenine.	ARHGAP45 NM_012292.4:c.416G>A		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157549>	C97928	ARHGAP45 Protein Variant|Minor Histocompatibility Antigen HA-1 Precursor Protein Variant|Minor Histocompatibility Protein HA-1 Precursor Protein Variant|Rho GTPase Activating Protein 45 Protein Variant|Rho GTPase-Activating Protein 45 Protein Variant	A variation in the amino acid sequence for Rho GTPase-activating protein 45.	ARHGAP45 Protein Variant		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15754>	C15426	Geographic Information System|GIS	A system of hardware, software, and geographic data designed to capture, store, update, manipulate, analyze and display data that are linked to location.			Intellectual Product	
C157550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157550>	C157549	ARHGAP45 NP_036424.2:p.R139H|ARHGAP45 Arg139His|ARHGAP45 NP_036424.2:p.Arg139His|ARHGAP45 R139H|ARHGAP45 p.Arg139His|ARHGAP45 p.R139H|HA-1(H) Precursor|Minor Histocompatibility Antigen HA-1 Precursor Arg139His|Minor Histocompatibility Antigen HA-1 Precursor R139H|Minor Histocompatibility Protein HA-1 Precursor Arg139His|Minor Histocompatibility Protein HA-1 Precursor R139H|NP_036424.2:p.Arg139His|NP_036424.2:p.R139H|Rho GTPase Activating Protein 45 Arg139His|Rho GTPase Activating Protein 45 R139H|Rho GTPase-Activating Protein 45 Arg139His|Rho GTPase-Activating Protein 45 R139H|mHag HA-1 Precursor	A change in the amino acid residue at position 139 in Rho GTPase-activating protein 45 where arginine has been replaced by histidine.	ARHGAP45 NP_036424.2:p.R139H		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157551>	C268	Minor Histocompatibility Antigen HA-1|HA-1|HA-1(H)|mHag HA-1	A peptide antigen comprised of 9 amino acids (VLHDDLLEA) that is derived by antigen processing from a variant of Rho GTPase-activating protein 45 where the arginine at amino acid residue 139 is substituted with histidine. This peptide can be presented by MHC class I HLA-A*0201 expressing cells. The complex of this peptide with HLA-A elicits donor-cytotoxic T-lymphocyte (CTL) reactivity following treatment by HLA-identical allogenic bone marrow transplant.	Minor Histocompatibility Antigen HA-1		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157552>	C3120	Pulmonary Arterial Hypertension|PAH	Increased pressure within the pulmonary arterial circulation.			Finding	
C157553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157553>	C36327	CDK Gene Mutation|CDK Family Gene Mutation|CDKx Gene Mutation|Cyclin Dependent Kinase Family Gene Mutation|Cyclin Dependent Kinase Gene Mutation|Cyclin-Dependent Kinase Family Gene Mutation|Cyclin-Dependent Kinase Gene Mutation	A change in the nucleotide sequence in a CDK family gene.	CDK Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157554>	C137953	PI3K Gene Mutation|1-Phosphatidylinositol 3-Kinase Gene Mutation|PI3 Kinase Gene Mutation|PI3-Kinase Gene Mutation|PI3K Family Gene Mutation|PI3K Mutation|PIK3 Gene Mutation|Phosphatidylinositide 3-Kinase Gene Mutation|Phosphatidylinositol 3 Kinase Gene Mutation|Phosphatidylinositol 3-Kinase Gene Mutation|Phosphatidylinositol-3-Kinase Gene Mutation|Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Gene Mutation	A change in the nucleotide sequence in a PI3K family gene.	PI3K Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157555>	C80699	MIR1290 Gene|MIR1290|MIR1290|MicroRNA 1290 Gene	This gene may play a role in tumorigenesis and invasion.	MIR1290 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C157556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157556>	C157555	MIR1290 wt Allele|MIRN1290|MicroRNA 1290 wt Allele|hsa-mir-1290|mir-1290	Human MIR1290 wild-type allele is located in the vicinity of 1p36.13 and is 78 bases in length. This allele, which encodes MIR1290 pre-miRNA, may be involved in tumor cell invasion.	MIR1290 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157557>	C25968	MIR1290 Pre-miRNA|Pre-hsa-mir-1290|Pre-miR1290|Pre-mir-1290	MIR1290 pre-miRNA (78 bases) is encoded by the human MIR1290 gene. This oligoribonucleotide may play a role in transcriptional silencing and tumorigenesis.	MIR1290 Pre-miRNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157558>	C80699	MIR1246 Gene|MIR1246|MIR1246|MicroRNA 1246 Gene	This gene may play a role in tumorigenesis and metastasis.	MIR1246 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C157559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157559>	C157558	MIR1246 wt Allele|MIRN1246|MicroRNA 1246 wt Allele|hsa-mir-1246|mir-1246	Human MIR1246 wild-type allele is located in the vicinity of 2q31.1 and is 73 bases in length. This allele, which encodes MIR1246 pre-miRNA, may be involved in the regulation of gene expression in various cancers.	MIR1246 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15755>	C15280	Lumpectomy|LUMPECTOMY|Lumpectomy of Breast|Partial Mastectomy|lumpectomy|partial mastectomy	The surgical removal of a discrete mass.	Lumpectomy		Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C157560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157560>	C25968	MIR1246 Pre-miRNA|Pre-hsa-mir-1246|Pre-miR1246|Pre-mir-1246	MIR1246 pre-miRNA (73 bases) is encoded by the human MIR1246 gene. This oligoribonucleotide may play a role in tumor cell invasion.	MIR1246 Pre-miRNA		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157561>	C28533	MAGT1 Gene|MAGT1|MAGT1|Magnesium Transporter 1 Gene	This gene is involved in protein glycosylation and magnesium ion transport.	MAGT1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C157562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157562>	C157561	MAGT1 wt Allele|DKFZp564K142|IAP|MRX95|Magnesium Transporter 1 wt Allele|OST3B|Oligosaccharyltransferase 3 Homolog B (S. cerevisiae) Gene|Oligosaccharyltransferase 3 Homolog B Gene|PRO0756|UNQ628/PRO1244|XMEN|bA217H1.1	Human MAGT1 wild-type allele is located in the vicinity of Xq21.1 and is approximately 69 kb in length. This allele, which encodes magnesium transporter protein 1, plays a role in magnesium ion transport and protein modification. Mutation of the gene is associated with X-linked intellectual disabilities and X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia.	MAGT1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157563>	C16386	Magnesium Transporter Protein 1|Dolichyl-Diphosphooligosaccharide--Protein Glycosyltransferase Subunit MAGT1|Dolichyl-Diphosphooligosaccharide-Protein Glycosyltransferase Subunit MAGT1|IAP|Implantation-Associated Protein|MagT1|Oligosaccharyl Transferase Subunit MAGT1	Magnesium transporter protein 1 (335 aa, ~38 kDa) is encoded by the human MAGT1 gene. This protein is involved in magnesium ion transport an N-glycosylation of proteins.	Magnesium Transporter Protein 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157564>	C177692|C103223	HA-1(H) Genotype Positive|HA-1(H) Genotype (rs1801284 A/G, A/A) Positive|HA-1(H) Positive|HA-1(H/H) or HA-1(H/R) Positive|rs1801284 A/G or A/A Positive|rs1801284 A/G or A/A Present|rs1801284 A/G, A/A Positive|rs1801284 A/G, A/A Present	A genetic finding indicating that a subject expresses the HA-1(H) genotype and has a homozygous or heterozygous nucleotide substitution at position 416 of the ARHGAP45 gene where the guanine has been mutated to adenine, which encodes a variant of Rho GTPase-activating protein 45 where the arginine at position 139 has been replaced by histidine. The HA-1(H) form of ARHGAP45 protein can be processed into a nonapeptide that can be presented by HLA-A*0201 and other HLA-A isoforms, while the peptide produced by processing the protein resulting from transcription of the ARHGAP45 gene with guanine at position 416, which will have arginine at amino acid residue 139 (HA-1(R)) cannot bind HLA-A.	HA-1(H) Genotype Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157565>	C35682|C103223	TP53 Gene Alteration Positive|P53 Gene Alteration Positive|Tumor Protein p53 Gene Alteration Positive|p53 Gene Alteration Positive	A finding indicating that mutation, overexpression or rearrangement of the TP53 gene has been detected in a sample.	TP53 Gene Alteration Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157566>	C35682|C103223	RB1 Gene Alteration Positive|RB Gene Alteration Positive|Retinoblastoma 1 Gene Alteration Positive|Retinoblastoma Gene Alteration Positive	A finding indicating that mutation, overexpression or rearrangement of the RB1 gene has been detected in a sample.	RB1 Gene Alteration Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157567>	C25966	MicroRNA 1290|MIR1290|MIRN1290|hsa-miR-1290|miR-1290	A 19 ribonucleotide sequence that is a final product of the processing of MIR1290 pre-miRNA. This oligonucleotide may be involved in the regulation of gene expression in various cancers.	MicroRNA 1290		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157568>	C25966	MicroRNA 1246|MIR1246|MIRN1246|hsa-miR-1246|miR-1246	A 19 ribonucleotide sequence that is a final product of the processing of MIR1246 pre-miRNA. This oligonucleotide may be involved in transcriptional silencing and tumorigenesis.	MicroRNA 1246		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157569>	C38372|C129829	Biallelic CEBPA Gene Mutation|C/EBP-Alpha Biallelic Gene Mutation|C/EBPalpha Biallelic Gene Mutation|CCAAT Enhancer Binding Protein Alpha Biallelic Gene Mutation|CCAAT/Enhancer Binding Protein Alpha Biallelic Gene Mutation|CCAAT/Enhancer Binding Protein, Alpha Biallelic Gene Mutation|CEBP Biallelic Gene Mutation|CEBPA Biallelic Gene Mutation|CEBPA Biallelic Mutation|biCEBPA	The presence of mutations in both alleles of the CEBPA gene.	Biallelic CEBPA Gene Mutation		Cell or Molecular Dysfunction	AML Authorized Value Terminology|AML Minimal Residual Disease Table|AML Molecular Analysis Table|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15756>	C64261	Single Agent Systemic Chemotherapy|Chemotherapy Single Agent Systemic|Chemotherapy single agent systemic	Systemic chemotherapy with a single agent regimen. All routes of administration are acceptable as long as the agent is intended for systemic therapy.			Clinical Attribute	
C157570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157570>	C35125	Adenovirus DNA Viremia|AdV DNA Viremia	A laboratory test result indicating the presence of adenovirus DNA in the blood.	Adenovirus DNA Viremia		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C157571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157571>	C36346	PCM1-JAK2 Fusion Protein Expression|PCM-1/JAK-2 Fusion Protein Expression|PCM1-JAK2 Fusion Protein Positive|PCM1-JAK2 Fusion Protein Positive|PCM1/JAK2 Fusion Protein Expression|Pericentriolar Material 1 Protein/Tyrosine-Protein Kinase JAK2 Fusion Protein Expression	Expression of a fusion protein involving the human genes PCM1 and JAK2. It results from a translocation and is associated with myeloid and lymphoid cancers.	PCM1-JAK2 Fusion Protein Expression		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157572>	C180942|C133155	JAK2 Gene Rearrangement|JAK-2 Gene Rearrangement|JAK2 Rearrangement|JTK10 Gene Rearrangement|Janus Kinase 2 Gene Rearrangement	A molecular abnormality indicating rearrangement of the JAK2 gene.	JAK2 Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C157573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157573>	C8335|C4595	Low Grade Anal Intraepithelial Neoplasia|AIN1|Anal Intraepithelial Neoplasia 1|LG-AIN	Anal canal or perianal skin intraepithelial neoplasia with mild dysplasia.			Neoplastic Process	
C157574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157574>	C7351|C172706	Anal Intraepithelial Neoplasia 2|AIN2|Anal Squamous Intraepithelial Neoplasia 2	Anal canal or perianal skin intraepithelial neoplasia with moderate dysplasia.	Anal Intraepithelial Neoplasia 2		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157575>	C172706	Anal Intraepithelial Neoplasia 3|AIN III|AIN3|Anal Squamous Intraepithelial Neoplasia 3|Anal intraepithelial neoplasia, grade III	Anal canal or perianal skin intraepithelial neoplasia with severe dysplasia.	Anal Intraepithelial Neoplasia 3		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C157576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157576>	C53543	Ankyloblepharon-Ectodermal Defects-Cleft Lip/Palate	An autosomal dominant condition caused by mutation(s) in the TP63 gene, encoding tumor protein 63. It is characterized by congenital ectodermal dysplasia, ankyloblepharon filiforme adnatum, and cleft lip/palate.			Disease or Syndrome	Cellosaurus Disease Terminology
C157577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157577>	C34563	Dystonia 12|DYT12|Rapid-Onset Dystonia-Parkinsonism	An autosomal dominant condition caused by mutation(s) in the ATP1A3 gene, encoding sodium/potassium-transporting ATPase subunit alpha-3. It is characterized by abrupt onset of dystonia and parkinsonism in young adulthood, often triggered by physical or psychological stress.			Disease or Syndrome	Cellosaurus Disease Terminology
C157578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157578>	C28227|C141145|C129822|C128037	Izuralimab|Anti-PD1/Anti-ICOS Bispecific Monoclonal Antibody XmAb23104|Anti-PD1/ICOS Bispecific Monoclonal Antibody XmAb23104|IZURALIMAB|PD1 x ICOS Bispecific Monoclonal Antibody XmAb23104|XmAb 23104|XmAb-23104|XmAb23104	A humanized, Fc-engineered bispecific monoclonal antibody directed against both the human negative immunoregulatory checkpoint receptor, programmed cell death protein 1 (PD-1; PCD-1; CD279), and inducible T-cell co-stimulator (ICOS; CD278), with potential immunomodulating and antineoplastic activities. Upon administration, izuralimab targets and binds to both PD-1 and ICOS expressed on certain T-cells, including tumor-infiltrating lymphocytes (TILs). This prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2), and stimulates ICOS-mediated signaling, which promotes the activation of T-cells and enhances T-cell-mediated immune responses against tumor cells. Combined PD-1 blockade and ICOS stimulation may enhance T-cell activation and proliferation more than targeting each receptor individually. The engineered Fc domain increases the stability and half-life of the antibody.	Izuralimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157579>	C97927	MAGT1 Gene Mutation|IAP Gene Mutation|MagT1 Mutation|Magnesium Transporter 1 Gene Mutation|OST3B Gene Mutation|XMEN Gene Mutation	A change in the nucleotide sequence of the MAGT1 gene.	MAGT1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15757>	C94632|C15691	Antiestrogen Therapy	Drug treatment to block the action of the female hormone estrogen.	Antiestrogen Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C157580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157580>	C178120|C121369	Activating PTEN Gene Mutation|Activating MMAC1 Gene Mutation|Activating Mutated in Multiple Advanced Cancers 1 Gene Mutation|Activating PTEN1 Gene Mutation|Activating Phosphatase and Tensin Homolog Gene Mutation|Activating TEP1 Gene Mutation|PTEN Activating Gene Mutation|PTEN Activating Mutation	A change in the nucleotide sequence of the PTEN gene that results in constitutive activation of both phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN and its downstream signaling pathways.	Activating PTEN Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157581>	C13338	GGAA Microsatellite Repeat|GGAA Microsatellite|GGAA-Microsatellite	A microsatellite containing 18-26 repeats of the tetranucleotide sequence, GGAA. EWSR1/FLI1 and EWSR1/ETS family fusion proteins bind to GGAA microsatellite sequences in certain gene promoters, which aberrantly upregulates transcription of those genes and is associated with Ewing Sarcoma.	GGAA Microsatellite Repeat		Nucleotide Sequence	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157582>	C177692	SHH Positive|HHG1 Positive|Sonic Hedgehog Homolog Positive|Sonic Hedgehog Positive	An indication that SHH expression has been detected in a sample.	SHH Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157583>	C20130	Myokine	A family of soluble proteins that are synthesized and secreted by muscle cells in response to muscle contraction and may drive autocrine, paracrine and endocrine signaling pathways in cells expressing myokine receptors.	Myokine		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Terminology
C157584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157584>	C81326	Elevated DKK1|Elevated DKK-1|Elevated Dickkopf Homolog 1|Elevated Dickkopf-1	A finding indicating elevated concentrations of DKK1 in a sample.	Elevated DKK1		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157585>	C35682|C103223	EGFR Gene Alteration Positive|ERBB Gene Alteration Positive|ERBB1 Gene Alteration Positive|Epidermal Growth Factor Receptor Gene Alteration Positive|HER1 Gene Alteration Positive|c-erbB-1 Gene Alteration Positive	A finding indicating that mutation, overexpression or rearrangement of the EGFR gene has been detected in a sample.	EGFR Gene Alteration Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157586>	C97927	IRAK1 Gene Mutation|IRAK Gene Mutation|Interleukin 1 Receptor Associated Kinase 1 Gene Mutation|Interleukin-1 Receptor-Associated Kinase 1 Gene Mutation|pelle Gene Mutation	A change in the nucleotide sequence of the IRAK1 gene.	IRAK1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157587>	C158948	MYD88 Fusion Positive|Myeloid Differentiation Primary Response 88 Fusion Positive	Indicates that expression of a fusion containing sequences from MYD88 has been detected in a sample.	MYD88 Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157588>	C158948	IRAK1 Fusion Positive|IRAK Fusion Positive|IRAK-1 Fusion Positive|Interleukin 1 Receptor Associated Kinase 1 Fusion Positive|Interleukin-1 Receptor-Associated Kinase 1 Fusion Positive|pelle Fusion Positive	Indicates that expression of a fusion containing sequences from IRAK1 has been detected in a sample.	IRAK1 Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157589>	C158948	JAK3 Fusion Positive|JAK-3 Fusion Positive|JAKL Fusion Positive|Janus Kinase 3 Fusion Positive|L-JAK Fusion Positive|LJAK Fusion Positive|Tyrosine-Protein Kinase JAK3 Fusion Positive	Indicates that expression of a fusion containing sequences from JAK3 has been detected in a sample.	JAK3 Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15758>	C15517	Central Line Management|management of central line	Any activity related to the care and supervision of a central venous catheter.	Central Line Management		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C157590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157590>	C158948	TYK2 Fusion Positive|JTK1 Fusion Positive|Non-Receptor Tyrosine-Protein Kinase TYK2 Fusion Positive|Tyrosine Kinase 2 Fusion Positive	An indication that expression of a fusion containing sequences from TYK2 has been detected in a sample.	TYK2 Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157591>	C97927	TYK2 Gene Mutation|JTK1 Gene Mutation|TYK2 Mutation|Tyrosine Kinase 2 Gene Mutation	A change in the nucleotide sequence of the TYK2 gene.	TYK2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C157592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157592>	C84255|C178120	Activating JAK2 Gene Mutation|Activating JAK-2 Gene Mutation|Activating JAK2 Mutation|Activating JTK10 Gene Mutation|Activating Janus Kinase 2 Gene Mutation|JAK2 Activating Gene Mutation|JAK2 Activating Mutation	A change in the nucleotide sequence of the JAK2 gene that results in constitutive activation of both tyrosine-protein kinase JAK2 and its downstream signaling pathways.	Activating JAK2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157593>	C178120|C136647	Activating JAK3 Gene Mutation|Activating JAK-3 Gene Mutation|Activating JAK3 Mutation|Activating JAKL Gene Mutation|Activating Janus Kinase 3 Gene Mutation|Activating L-JAK Gene Mutation|Activating LJAK Gene Mutation|JAK3 Activating Gene Mutation|JAK3 Activating Mutation	A change in the nucleotide sequence of the JAK3 gene that results in constitutive activation of both tyrosine-protein kinase JAK3 and its downstream signaling pathways.	Activating JAK3 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157594>	C178120|C128175	Activating MYD88 Gene Mutation|Activating MYD88 Mutation|Activating Myeloid Differentiation Primary Response 88 Gene Mutation|MYD88 Activating Gene Mutation|MYD88 Activating Mutation	A change in the nucleotide sequence of the MYD88 gene that results in constitutive activation of both myeloid differentiation primary response protein MyD88 and its downstream signaling pathways.	Activating MYD88 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157595>	C178120|C157586	Activating IRAK1 Gene Mutation|Activating IRAK Gene Mutation|Activating IRAK1 Mutation|Activating Interleukin 1 Receptor Associated Kinase 1 Gene Mutation|Activating Interleukin-1 Receptor-Associated Kinase 1 Gene Mutation|Activating pelle Gene Mutation|IRAK1 Activating Gene Mutation|IRAK1 Activating Mutation	A change in the nucleotide sequence of the IRAK1 gene that results in constitutive activation of both interleukin-1 receptor-associated kinase 1 protein and its downstream signaling pathways.	Activating IRAK1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157596>	C178120|C157591	Activating TYK2 Gene Mutation|Activating JTK1 Gene Mutation|Activating TYK2 Mutation|Activating Tyrosine Kinase 2 Gene Mutation|TKY2 Activating Gene Mutation|TYK2 Activating Mutation	A change in the nucleotide sequence of the TYK2 gene that results in constitutive activation of both non-receptor tyrosine-protein kinase TYK2 protein and its downstream signaling pathways.	Activating TYK2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157597>	C35682|C177693	HIF1A Overexpression Positive|HIF-1A Overexpression Positive|HIF-1alpha Overexpression Positive|HIF-1alpha Upregulation|HIF1-Alpha Overexpression Positive|HIF1-Alpha Upregulation|HIF1A Upregulation|Hypoxia-Inducible Factor 1-Alpha Overexpression Positive|Hypoxia-Inducible Factor1alpha Overexpression Positive	An indication that overexpression of HIF1A has been detected in a sample.			Laboratory or Test Result	
C15759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15759>	C91841|C15290	Urostomy|Non-Continent Diversion|Non-Continent Urinary Diversion|urostomy	The creation of a stoma that connects to the urinary tract so that urine drains continuously into an ostomy bag.			Therapeutic or Preventive Procedure	
C1575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1575>	C2141	Disaccharide Tripeptide Glycerol Dipalmitoyl|DISACCHARIDE TRIPEPTIDE GLYCEROL DIPALMITOYL|DTP-GDP|ImmTher|Liposomal N-Acetylglucosaminyl-N-Acetyhnuramly-L-Ala-D-isoGlu-L-Ala-gylceroldipalmitoyl|N-Acetylglucosaminyl-N-acetyhnuramyl-L-Ala-isoGlu-L-Ala-glycerol Dipalmitate	A lipophilic disaccharide tripeptide derivative of muramyl dipeptide (MDP) with immunomodulatory activity. Disaccharide tripeptide glycerol dipalmitoyl (DTP-GDP)stimulates macrophage activity and increases serum levels of tumor necrosis factor alpha (TNF alpha), neopterin, interleukin (IL)-1 alpha, IL-1 beta, IL-6, IL-8, and IL-12, which may activate host immune system antitumor functions. DTP-GDP may be packaged in liposomes for improved delivery. The immunomodulatory effects of this agent may be superior to those of MDP.	Disaccharide Tripeptide Glycerol Dipalmitoyl		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C157600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157600>	C4325|C182019	Recurrent Giant Cell Glioblastoma	The reemergence of giant cell glioblastoma after a period of remission.	Recurrent Giant Cell Glioblastoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157601>	C3017|C148037|C131617	Recurrent Ependymoma	The reemergence of ependymoma after a period of remission.	Recurrent Ependymoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157602>	C7377|C5670|C156485	Metastatic Lung Neuroendocrine Neoplasm	A neuroendocrine neoplasm that arises from the lung and has spread to another anatomic site.	Metastatic Lung Neuroendocrine Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157603>	C19238	Mold Device|Mold|Mold	A form used to cast an object of a desired shape.	Mold		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C157604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157604>	C18060	Short Somatic Mutation|Short Somatic Variant|Short Somatic Variation|Somatic Short-Variants	Single nucleotide polymorphisms (SNPs) or short nucleotide insertions (ins), deletions (del) or indels that originate in cells that are not destined to become gametes and are not passed on to progeny.			Cell or Molecular Dysfunction	
C157605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157605>	C158375	Mastectomy Patient	A person who is undergoing mastectomy.	Mastectomy Patient		Patient or Disabled Group	CTRP Intervention Terminology|CTRP Terminology
C157606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157606>	C2891	Refractory Barrett Esophagus|Refractory Barrett Dysplasia	Dysplasia in Barrett esophagus that is resistant to treatment.	Refractory Barrett Esophagus		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C157607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157607>	C157816	Non-Neoplastic Chronic Lower Respiratory System Disorder|Chronic Lower Respiratory System Disorder	A non-neoplastic longstanding disorder of the lower respiratory system.			Disease or Syndrome	CPTAC Causes of Death Codelist|CPTAC Codelists Terminology|CPTAC Terminology
C157608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157608>	C105735	Homicide by Assault	Death of an individual by physical violence from another.			Finding	CPTAC Causes of Death Codelist|CPTAC Codelists Terminology|CPTAC Terminology
C157609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157609>	C2959	Complication due to Medical/Surgical Care	An untoward event that can be attributed to care received during a medical/surgical event.			Finding	CPTAC Causes of Death Codelist|CPTAC Codelists Terminology|CPTAC Terminology
C15760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15760>	C15188	Drug Development	Design, identification, synthesis, extraction, purification, modification, or characterization of potential anticancer agents; studies of their metabolism, distribution, excretion, physiological effects, molecular interactions, structural analysis, toxicity, mechanism of action, antitumor effects in vivo (nonhuman species) or in vitro (human or nonhuman), and phase I and phase II clinical trials.			Research Activity	
C157610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157610>	C81239	Death by Overdose	A death that is attributed to an excessive amount of a substance.			Finding	CPTAC Causes of Death Codelist|CPTAC Codelists Terminology|CPTAC Terminology
C157611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157611>	C81239	Death by Alcohol Ingestion	A death that is attributed to excessive alcohol ingestion.			Finding	CPTAC Causes of Death Codelist|CPTAC Codelists Terminology|CPTAC Terminology
C157612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157612>	C3671	Firearm Injury	An injury sustained by a gun.			Finding	CPTAC Causes of Death Codelist|CPTAC Codelists Terminology|CPTAC Terminology
C157613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157613>	C41454	Variably-Sized Cysts Filled With Clear, Serous, or Gelatinous Fluid	A morphologic finding indicating the presence of variably-sized cysts filled with clear, serous, or gelatinous fluid in a tissue sample.			Finding	
C157614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157614>	C36260	BAP1-Mutated Clear Cell Renal Cell Carcinoma|BAP1-Mutant Clear Cell Renal Cell Carcinoma	A clear cell renal cell carcinoma that is associated with a mutation in BAP1 gene. These tumors are typically high grade and associated with poor outcome.			Neoplastic Process	
C157615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157615>	C25499	Other and Unspecified Events of Undetermined Intent and their Sequelae	Events of undetermined intent and their sequelae other than those otherwise specified.			Finding	CPTAC Causes of Death Codelist|CPTAC Codelists Terminology|CPTAC Terminology
C157616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157616>	C26726	Other and Unspecified Infectious and Parasitic Diseases and their Sequelae	Unspecified infectious and parasitic diseases and their sequelae other than those otherwise specified.			Finding	CPTAC Causes of Death Codelist|CPTAC Codelists Terminology|CPTAC Terminology
C157617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157617>	C43637	Symptoms, Signs and Abnormal Clinical and Laboratory Findings, NEC	A header term for symptoms, signs and abnormal clinical and laboratory findings that is not elsewhere classified.			Finding	CPTAC Causes of Death Codelist|CPTAC Codelists Terminology|CPTAC Terminology
C157618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157618>	C63360	Cisplatin/Nab-Paclitaxel/Pembrolizumab Regimen|Abraxane/Platinol/Keytruda|Albumin-bound Paclitaxel-Cisplatin-Pembrolizumab|Albumin-bound Paclitaxel-Cisplatin-Pembrolizumab Regimen|Cisplatin-Nab-Paclitaxel-Pembrolizumab|Cisplatin-Nab-Paclitaxel-Pembrolizumab Regimen|Cisplatin/Albumin-bound Paclitaxel/Pembrolizumab|Cisplatin/Nab-Paclitaxel/Pembrolizumab|Nab-Paclitaxel-Cisplatin-Pembrolizumab Regimen	A regimen consisting of cisplatin, nab-paclitaxel, and pembrolizumab that can be used in the treatment of metastatic squamous non-small cell lung cancer (NSCLC).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C157619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157619>	C63360	Carboplatin/Nab-Paclitaxel/Pembrolizumab Regimen|Abraxane/Carboplatin/Keytruda|Albumin-bound Paclitaxel-Carboplatin-Pembrolizumab|Albumin-bound Paclitaxel-Carboplatin-Pembrolizumab Regimen|Carboplatin, nab-Paclitaxel, Pembrolizumab|Nab-Paclitaxel-Carboplatin-Pembrolizumab Regimen	A regimen consisting of carboplatin, nab-paclitaxel, and pembrolizumab that can be used in the treatment of metastatic squamous non-small cell lung cancer (NSCLC).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C15761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15761>	C15176	Acustimulation Therapy|Acustimulation|acustimulation	Use of a low intensity electrical current to provide mild stimulation of the body's acupuncture points in order to control symptoms such as nausea and vomiting.			Therapeutic or Preventive Procedure	
C157620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157620>	C187306|C173151	Illness is Financial Hardship for My Family and Me Question|Illness is Financial Hardship for My Family and Me|My illness has been a financial hardship to my family and me	A question about whether an individual's illness is or was a financial hardship for them and their family.			Intellectual Product	
C157621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157621>	C3867|C169021	Platinum-Resistant Fallopian Tube Carcinoma|Platinum-Resistant Fallopian Tube Cancer|Platinum-Resistant Fallopian Tube Cancer	Fallopian tube carcinoma that progresses between one and six months of completing platinum therapy.	Platinum-Resistant Fallopian Tube Cancer		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157622>	C40022	Platinum-Resistant Primary Peritoneal Carcinoma|Platinum-Resistant Primary Peritoneal Cancer|Platinum-Resistant Primary Peritoneal Cancer	Primary peritoneal carcinoma that progresses between one and six months of completing platinum therapy.	Platinum-Resistant Primary Peritoneal Cancer		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157623>	C4436|C222831|C142869	Metastatic Cholangiocarcinoma	A cholangiocarcinoma that has metastasized to other anatomic sites.	Metastatic Cholangiocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157624>	C3163	Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma	Histologic transformation of an indolent chronic lymphocytic leukemia to an aggressive diffuse large B-cell lymphoma.	Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157625>	C179717	Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma	Histologic transformation of a small lymphocytic lymphoma to an aggressive diffuse large B-cell lymphoma.	Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157626>	C36386|C18016	Chromosome Arm 1p Loss of Heterozygosity|1p LOH|1p Loss of Heterozygosity	A molecular abnormality that results in monoallelic loss of function mutations located within the short arm of chromosome 1 (1p).	Chromosome Arm 1p Loss of Heterozygosity		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157627>	C18016|C159452	Chromosome Arm 5q Loss of Heterozygosity|5q LOH|5q Loss of Heterozygosity	A molecular abnormality that results in monoallelic loss of function mutations located within the long arm of chromosome 5 (5q).			Cell or Molecular Dysfunction	
C157628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157628>	C18016	Chromosome 6 Loss of Heterozygosity|Chromosome 6 LOH	A molecular abnormality that results in monoallelic loss of function mutations located within chromosome 6.			Cell or Molecular Dysfunction	
C157629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157629>	C18016	Chromosome 8 Loss of Heterozygosity|Chromosome 8 LOH	A molecular abnormality that results in monoallelic loss of function mutations located within chromosome 8.			Cell or Molecular Dysfunction	
C15762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15762>	C65014|C15209	Laparoscopic Colectomy|Laparoscopic-Assisted Colectomy|Laparoscopy-Assisted Colectomy|laparoscopic-assisted colectomy	Surgical removal of part or all of the colon, using a laparoscope.			Therapeutic or Preventive Procedure	
C157630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157630>	C2124|C129819	Lutetium Lu 177 Zalsenertant Tetraxetan|177Lu-3BP-227|177Lu-DOTA-3BP-227|177Lu-DOTA-IPN01087|177Lu-IPN01087|Lutetium Lu 177 DOTA-3BP-227|Lutetium Lu 177 DOTA-IPN01087|ZALSENERTANT TETRAXETAN LUTETIUM LU-177	A radioconjugate consisting of the neurotensin receptor type 1 (NTR1) antagonist, IPN01087 (3BP-227), that is linked, via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and imaging activity during positron emission tomography/computed tomography (PET/CT). Upon administration, lutetium Lu 177 zalsenertant tetraxetan binds to NTR1 expressed on certain tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to NTR1-expressing cells. NTR1, a G-protein coupled receptor, is highly expressed in ductal pancreatic adenocarcinoma but not in normal pancreatic tissue.	Lutetium Lu 177 Zalsenertant Tetraxetan		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157631>	C7623|C4030	Recurrent Urothelial Carcinoma|Recurrent Urothelial Cancer|Recurrent Urothelial Cancer|Relapsed Urothelial Cancer|Relapsed Urothelial Carcinoma	The reemergence of urothelial carcinoma after a period of remission.	Recurrent Urothelial Cancer		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157632>	C28227|C129822|C128057|C128036	Erfonrilimab|Anti-PD-L1 x CTLA-4 Bispecific Antibody KN046|Anti-PD-L1/Anti-CTLA-4 Bispecific Antibody KN046|Anti-PD-L1/CTLA-4 Bispecific Antibody KN046|ERFONRILIMAB|KN 046|KN-046|KN046	A bispecific monoclonal antibody directed against both the immunosuppressive ligand, programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, erfonrilimab targets and binds to both PD-L1 expressed on tumor cells and CTLA-4 expressed on T-cells. This prevents the binding of PD-L1 to its receptor, programmed cell death protein 1 (PD-1, CD279), and inhibits the PD-1 and CTLA-4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a sustained cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-L1, which is overexpressed in many human cancer cell types, and CTLA-4, an inhibitory T-cell receptor, play a role in the downregulation of the immune system and tumor evasion from host immunity.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157633>	C1663	Neoantigen-encoding Personalized Virus-2|PSV-2|PSV2	A personalized cancer vaccine comprised of a not yet disclosed oncolytic virus encoding tumor-specific neoantigens that have been identified through genetic sequencing of a patient's tumor cells, with potential immunostimulatory and antineoplastic activities. Upon administration, the neoantigen-encoding personalized virus-2 (PSV-2) infects cells and expresses the tumor-specific neoantigens (TSNAs). This stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the TSNAs, leading to tumor cell lysis.			Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157634>	C28676|C129826	Expanded/Activated Gamma Delta T-cells|EAGD T-cells|EAGD T-lymphocytes|Expanded and Activated Gamma Delta T-cells|Expanded and Activated Gamma/Delta T-cells	A preparation of gamma delta T-lymphocytes derived from donor T-cells that have been expanded and activated ex-vivo and further depleted of alpha and beta T-cell receptors (TCRs), with potential immunomodulating and antineoplastic activities. Upon administration, these expanded/activated gamma delta (EAGD) T-cells secrete interferon-gamma (IFN-g) and exert direct killing of tumor cells. In addition, these cells activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against tumor cells. Gamma delta T-lymphocytes play a key role in the activation of the immune system and do not require major histocompatibility complex (MHC)-mediated antigen presentation to exert their cytotoxic effect.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157635>	C2124	Gallium Ga 68 NODAGA-CBP8|68Ga-CBP8|CBP-8 GALLIUM GA-68|Gallium-68 NODAGA-CBP8|[68Ga]CBP-8|[68Ga]CBP8	A radiotracer composed of CBP8, a collagen-targeting peptide, linked via a tris(tert-butyl) ester-protected 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA) chelator, to the radioisotope gallium Ga 68, with potential imaging activity upon positron emission tomography/computed tomography (PET/CT). Upon administration, gallium Ga 68 NODAGA-CBP8 selectively binds with high affinity to collagen type 1. Upon PET/CT imaging, gallium Ga 68 NODAGA-CBP8 can be used to detect lung fibrosis, which is characterized by excess deposition of collagens, primarily type 1 collagen, and other extracellular matrix proteins in the parenchyma.	Gallium Ga 68 NODAGA-CBP8		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C157636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157636>	C213707|C175493|C126109	Locally Advanced Urothelial Carcinoma|Locally Advanced Urothelial Cancer	A urothelial carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Urothelial Cancer		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157638>	C3482|C2970	Metastatic Adenoid Cystic Carcinoma|Metastatic Adenoid Cystic Cancer	An adenoid cystic carcinoma that has spread from the original site of growth to other anatomic sites.	Metastatic Adenoid Cystic Cancer		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157639>	C7619|C2970	Recurrent Adenoid Cystic Carcinoma|Recurrent Adenoid Cystic Cancer	The reemergence of adenoid cystic carcinoma after a period of remission.	Recurrent Adenoid Cystic Cancer		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C15763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15763>	C15664	Advanced Manufacturing Technology	Activities, including research and development efforts, leading to new or improved manufacturing processes, equipment, or techniques, as well as related activities to manage and deploy manufacturing technologies.			Research Activity	
C157640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157640>	C18016	Chromosome 10 Loss of Heterozygosity|Chromosome 10 LOH	A molecular abnormality that results in monoallelic loss of function mutations located within chromosome 10.			Cell or Molecular Dysfunction	
C157641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157641>	C18016	Chromosome 11 Loss of Heterozygosity|Chromosome 11 LOH	A molecular abnormality that results in monoallelic loss of function mutations located within chromosome 11.			Cell or Molecular Dysfunction	
C157642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157642>	C18016	Chromosome 15 Loss of Heterozygosity|Chromosome 15 LOH	A molecular abnormality that results in monoallelic loss of function mutations located within chromosome 15.			Cell or Molecular Dysfunction	
C157643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157643>	C18016	Chromosome 18 Loss of Heterozygosity|Chromosome 18 LOH	A molecular abnormality that results in monoallelic loss of function mutations located within chromosome 18.			Cell or Molecular Dysfunction	
C157645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157645>	C18016	Chromosome 22 Loss of Heterozygosity|Chromosome 22 LOH	A molecular abnormality that results in monoallelic loss of function mutations located within chromosome 22.			Cell or Molecular Dysfunction	
C157646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157646>	C36292	Mismatch Repair Proficient|MMR Proficient|MMRp|MSI-H/dMMR Negative|Mismatch Repair Deficiency Negative|Mismatch Repair Deficiency Negative|Mismatch Repair Proficiency|Mismatch Repair-Proficient|No dMMR or MSI-H|Non-MSI-H/dMMR	A finding indicating that a sample has normal concentrations of unmutated mismatch repair proteins and is either microsatellite stable or has low microsatellite instability.	Mismatch Repair Deficiency Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157647>	C81182|C16830	Orchidometer|Orchidometer Bead|Orchidometer Beads|Orchiometer	A medical instrument used to measure the volume of the testicles. It consists of a string of twelve numbered wooden or plastic beads of increasing size from about 1 to 25 milliliters. The beads are compared with the testicles of the patient, and the volume is read off the bead which matches most closely in size.			Manufactured Object	
C157648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157648>	C51580	Hemipelvectomy Type I|Type I Hemipelvectomy	A hemipelvectomy with the resection confined to ilium.			Therapeutic or Preventive Procedure	
C157649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157649>	C51580	Hemipelvectomy Type II|Type II Hemipelvectomy	A hemipelvectomy with the resection confined to the periacetabulum.			Therapeutic or Preventive Procedure	
C15764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15764>	C51359	AIDS, Clinical Trials on Patients with AIDS-Related Malignancies	Clinical trials related to the development of vaccines and therapeutics directed against AIDS-related malignancies. These trials include the following malignancies: Kaposi's sarcoma, non-Hodgkins lymphoma, other lymphomas, and lymphosarcomas.			Research Activity	
C157650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157650>	C51580	Hemipelvectomy Type III|Type III Hemipelvectomy	A hemipelvectomy with the resection confined to the pubis.			Therapeutic or Preventive Procedure	
C157651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157651>	C19700	Type II Hemipelvectomy Patient|Hemipelvectomy Type II Patient|Hemipelvectomy Type II Recipient|Type II Hemipelvectomy Recipient	A patient who is undergoing a type II hemipelvectomy.	Type II Hemipelvectomy Patient		Patient or Disabled Group	CTRP Intervention Terminology|CTRP Terminology
C157652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157652>	C9118|C183184	Pelvic Sarcoma|Sarcoma of Pelvis|Sarcoma of the Pelvis	Sarcoma involving the organs and structures of the pelvis.	Pelvic Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157653>	C35883	Blasts 0.01 Percent or More of Bone Marrow Nucleated Cells|Blasts Greater than or Equal to 0.01 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that at least 0.01 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts 0.01 Percent or More of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C157655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157655>	C200766|C176018	Autologous Anti-CD19CAR-CD28tm/4-1BB/CD3zeta-HER2tG-expressing CD4+/CD8+ T-lymphocytes SCRI-huCAR19v1	A preparation of autologous CD4- and CD8-positive T-lymphocytes that have been transduced with a third-generation self-inactivating (SIN) lentiviral vector (LV) expressing a human-derived immunoglobulin G4 (IgG4) hinge-optimized chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) specific for CD19 that is fused to a human CD28 transmembrane domain (CD28tm), the intracellular cytoplasmic domain of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (CD3zeta), and linked to a truncated form of the human epidermal growth factor receptor 2 (HER2tG), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous CD4+/CD8+ T-lymphocytes SCRI-huCAR19v1 specifically target and bind to CD19-expressing neoplastic B-cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells and causes tumor cell lysis. CD19 is a B-cell-specific cell surface antigen that is overexpressed in B-cell lineage tumors. Incorporation of the costimulatory signaling domains of CD28 and 4-1BB increases human T-cell function, expansion, and survival. Devoid of both ligand binding domains and tyrosine kinase activity, the co-expressed HER2tG both facilitates in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a trastuzumab-induced antibody dependent cellular cytotoxicity (ADCC) response.	Autologous Anti-CD19CAR-CD28tm/4-1BB/CD3zeta-HER2tG-expressing CD4+/CD8+ T-lymphocytes SCRI-huCAR19v1		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157656>	C35869	Nodule Consistency	A description about the radiologic consistency of a nodule.			Finding	
C157657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157657>	C3208|C27359	Unresectable Lymphoma	Lymphoma that is not amenable to surgical resection.	Unresectable Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157658>	C157656	Solid Nodule|Solid	Fully opaque attenuation through which no normally arborizing structures are visible.			Finding	
C157659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157659>	C157656	Pure Ground Glass Nodule|Pure GGN|Pure Ground Glass	Focal increased opacity through which normal parenchymal structures (airways and vessels) can be seen. If, on lung windows, there is a solid component of greater than or equal to 2 mm that is not vascular or airway, the nodule is not pure ground glass.  Visibility of normal underlying interstitium is acceptable.			Finding	
C15765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15765>	C51359	AIDS, Clinical Trials on Minorities	AIDS clinical trials related to individuals of non-Caucasian descent.			Research Activity	
C157660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157660>	C157656	Part-Solid Nodule|PSN|Part-solid	Nodule with both ground-glass and solid components. The solid component corresponds to NO underlying normal anatomy, obscures the underlying lung structures and should measure at least 2 mm. The solid component should be measured in longest dimension.			Finding	
C157661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157661>	C157656	Semiconsolidation Nodule|Semiconsolidation	Nodule with dense (high) attenuation through which some normal underlying structures are visible. Semiconsolidation may appear as subsolid lung attenuation with thickened underlying reticulation or bronchovascular anatomy. In some instances, it may be challenging to distinguish the nodule from pGGNs or PSNs. The nodule is PSN if there is any solid component greater than 2 mm that is not underlying lung.			Finding	
C157662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157662>	C35869	Nodule Margin Conspicuity|Nodule margin conspicuity	A description about the radiologic visiblity of a nodule's margins.			Finding	
C157663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157663>	C157662	Well Marginated Nodule|Well|Well marginated	The nodule margin can be outlined with your pencil. Spiculated margins are not necessarily poorly marginated; ground glass nodules may be well marginated.			Finding	
C157664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157664>	C157662	Poorly Marginated Nodule|Poorly|Poorly marginated	The nodule margin blends into adjacent lung without clear demarcation between nodule edge and normal lung (i.e., the entire circumference of the nodule can't be drawn with confidence). This is to be distinguished from faint (but definable) margination, as with subsolid nodules.			Finding	
C157665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157665>	C35869	Nodule Margin Type|Margin|Margin Type	A description about the radiologic type of a nodule's margins.			Finding	
C157666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157666>	C157665	Smooth Nodule|Smooth	Featureless margin that cleanly demarcates the nodule from surrounding lung with no undulations or irregularities.			Finding	
C157667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157667>	C157665	Lobulated Nodule|Lobulated	Smooth or roughly undulating margin in which two or more regions of the nodule extend out from the adjacent surface but having a broader base and smoother convexity than serrations. Lobulations may be subtle. If the nodule has lobulations that are serrated or spiculated, it should be classified as serrated/spiculated.			Finding	
C157668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157668>	C157665	Notched Nodule|Notched|Notched (Concavity)	Single clear indentation of the nodule surface, resulting in a smooth or sharp concavity along the nodule margin (usually distinguished from lobulated by the fact there is one predominant indentation and the concavity is greater than or equal to 3 mm.			Finding	
C157669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157669>	C157665	Spiculated or Serrated Nodule|Spiculated or Serrated|Spiculated/Serrated	A nodule having either spiculated or serrated margin characteristics.			Finding	
C15766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15766>	C51359	AIDS, Clinical Trials on Patients with Opportunistic Infections	Clinical trials related to the development of vaccines and therapeutics directed against opportunistic infections associated with HIV infection. These trials include the following opportunistic infections: pneumocystosis, toxoplasmosis, cryptosporidiosis, candidacies, cryptococcosis, mycobacteriosis, cytomegalovirus, papillomavirus, herpes simplex, JC virus, coccidioides, hairy leukoplakia, and HIV-related periodontal disease.			Research Activity	
C157670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157670>	C157669	Spiculated Nodule|Micro-spiculations|Spiculated|Spiculation	The presence of two or more linear opacities extending from the nodule margin that taper as their distance from the nodule increases. Use tapering to distinguish from external septal stretching.			Finding	
C157671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157671>	C157669	Serrated Nodule|Micro-serrations|Serrated|Serration	A jagged, ragged, saw-tooth appearance in which individual extensions extend less than 3 mm from adjacent margins. Do NOT include subtle tenting if only observed at the site of external septal stretching.			Finding	
C157672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157672>	C157665	Indeterminate Nodule Type|Indeterminate|Indeterminate Nodule	The margin satisfies none of the other categories or cannot be determined with confidence.			Finding	
C157673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157673>	C35869	Nodule Shape	A description about the radiologic shape of a nodule.			Finding	
C157674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157674>	C157673	Round Nodule|Round	Nodule shape conforming to a roughly spherical shape, independent of spiculations.			Finding	
C157675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157675>	C157673	Ovoid Nodule|Ovoid	Nodule shape conforming to a roughly ovoid shape, in which the perpendicular diameters are dissimilar (there being a long diameter and a short diameter that differ by at least 30 percent).			Finding	
C157676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157676>	C157673	Polygonal Nodule|Polygonal	A nodule shape that is a two dimensional with 3 or more straight sides that do not cross and is a closed shape. Examples of polygons would include triangles, squares, rectangles, hexagons, and octagons. Polygonal nodules are commonly delimited by interlobular septal margins and are a feature of intrapulmonary lymph nodes or possibly bronchiolar/arteriolar disease.			Finding	
C157677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157677>	C157673	Complex Nodule Shape|Complex|Complex Nodule	A complex shape has no normally geometric shape and combines multiple more simple shapes. If no classically defined shape applies, the lesion is likely complex.			Finding	
C157678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157678>	C9496|C8853	Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma	A T-cell/histiocyte-rich large B-cell lymphoma that is resistant to treatment.	Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157679>	C8852|C6915|C131500	Recurrent Primary Effusion Lymphoma|Recurrent HHV8-Positive Primary Effusion Lymphoma	The reemergence of primary effusion lymphoma after a period of remission.	Recurrent Primary Effusion Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C15767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15767>	C51359	AIDS, Clinical Trials on Children	AIDS clinical trials related to children 0-18 years of age. These trials include pregnant females, neonates, and infants.			Research Activity	
C157680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157680>	C8853|C6915	Refractory Primary Effusion Lymphoma|Refractory HHV8-Positive Primary Effusion Lymphoma	A primary effusion lymphoma that is resistant to treatment.	Refractory Primary Effusion Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157681>	C6620|C150524|C134157|C131500	Recurrent Primary Bone Lymphoma|Recurrent Primary Lymphoma of Bone|Recurrent Primary Lymphoma of Bone	The reemergence of primary lymphoma of bone after a period of remission.	Recurrent Primary Lymphoma of Bone		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157682>	C6620|C150525|C134154	Refractory Primary Bone Lymphoma|Refractory Primary Lymphoma of Bone|Refractory Primary Lymphoma of Bone	A primary lymphoma of bone that is resistant to treatment.	Refractory Primary Lymphoma of Bone		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157683>	C8852|C7224	Recurrent Plasmablastic Lymphoma	The reemergence of plasmablastic lymphoma after a period of remission.	Recurrent Plasmablastic Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157684>	C8853|C7224	Refractory Plasmablastic Lymphoma	A plasmablastic lymphoma that is resistant to treatment.	Refractory Plasmablastic Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157685>	C157709|C147861	Recurrent HIV-Related Lymphoproliferative Disorder	The reemergence of HIV-associated lymphoproliferative disorder after a period of remission.	Recurrent HIV-Associated Lymphoproliferative Disorder		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157686>	C9308	Refractory Lymphoproliferative Disorder	Lymphoproliferative disorder that is resistant to treatment.			Disease or Syndrome	
C157687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157687>	C157709|C157686	Refractory HIV-Related Lymphoproliferative Disorder	HIV-associated lymphoproliferative disorder that is resistant to treatment.	Refractory HIV-Associated Lymphoproliferative Disorder		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C157688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157688>	C48693	Female Genital Grading Table|FGGT|Female Genital Grading Table for Use in Microbicide Studies	A table within the standard terminology developed by the NIH Division of AIDS (DAIDS) to report expedited adverse events (EAEs) reported by Clinical Research Sites (CRSs) participating in DAIDS-supported studies. This table contains specific adverse event grading terminology for Female Genital Microbicide Studies.			Intellectual Product	
C157689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157689>	C8688|C128697	Recurrent NK-Cell Lymphoma, Unclassifiable	The reemergence of NK-cell lymphoma, unclassifiable after a period of remission.	Recurrent NK-Cell Lymphoma, Unclassifiable		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C15768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15768>	C51359	AIDS, Clinical Trials on Women	AIDS clinical trials related to females 12 years of age or older. These trials include pregnant women, women at risk of AIDS, female prostitutes, and women who have perinatally transmitted AIDS to a fetus or newborn.			Research Activity	
C157690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157690>	C8689|C128697	Refractory NK-Cell Lymphoma, Unclassifiable	An NK-cell lymphoma, unclassifiable that is resistant to treatment.	Refractory NK-Cell Lymphoma, Unclassifiable		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157691>	C4752|C173411|C150044	Refractory T-Cell Prolymphocytic Leukemia	A T-cell prolymphocytic leukemia that is resistant to treatment.	Refractory T-Cell Prolymphocytic Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157692>	C8647|C193424|C173409|C150043	Recurrent Aggressive NK-Cell Leukemia|Recurrent Aggressive NK-Cell Leukemia/Lymphoma	The reemergence of aggressive NK-cell leukemia after a period of remission.	Recurrent Aggressive NK-Cell Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157693>	C8647|C173411|C150044	Refractory Aggressive NK-Cell Leukemia|Refractory Aggressive NK-Cell Leukemia/Lymphoma	An aggressive NK-cell leukemia that is resistant to treatment.	Refractory Aggressive NK-Cell Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157694>	C96058|C8689|C178556	Refractory Monomorphic Epitheliotropic Intestinal T-cell Lymphoma	A monomorphic epitheliotropic intestinal T-cell lymphoma that is resistant to treatment.	Refractory Monomorphic Epitheliotropic Intestinal T-cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157695>	C7805|C6918|C183513	Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma	The reemergence of subcutaneous panniculitis-like T-cell lymphoma after a period of remission.	Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157696>	C8938|C6918|C183515	Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma	A subcutaneous panniculitis-like T-cell lymphoma that is resistant to treatment.	Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157697>	C4753|C204126|C150044	Refractory B-Cell Prolymphocytic Leukemia	A B-cell prolymphocytic leukemia that is resistant to treatment.	Refractory B-Cell Prolymphocytic Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157698>	C91105	Pediatric Quality of Life Brain Tumor Module Version 1.0|PedsQL 1.0 Brain Tumor|PedsQL-Brain Tumor Module v1	A quality of life questionnaire designed to measure health-related quality of life in a pediatric brain tumor patient. It is derived from the Pediatric Quality of Life Inventory Generic Core Scales.			Intellectual Product	
C157699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157699>	C222046	Cognitive Problems Subscale|Cognitive Problems	A subscale of the Pediatric Quality of Life Brain Tumor Module designed to assess cognitive problems.			Intellectual Product	
C15769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15769>	C15185	Basic Behavioral and Social Science Research	Basic social sciences and behavioral research designed to strengthen the understanding of (a) the determinants and processes that influence HIV-related risk behaviors and (b) the consequences of HIV disease.			Research Activity	
C1576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1576>	C2107	Ledoxantrone Trihydrochloride|2H-(1)Benzothiopyrano(4,3,2-cd)indazol-8-ol, 5-((2-aminoethyl)amino)-2-(2-(diethylamino)ethyl)-, Trihydrochloride|CI 958|CI-958|CI-958|LEDOXANTRONE TRIHYDROCHLORIDE|Sedoxantrone Trihydrochloride|sedoxantrone trihydrochloride	The trihydrochloride salt of the anthrapyrazole antineoplastic antibiotic sedoxantrone with potential antineoplastic activity. Ledoxantrone intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157700>	C222046	Pain and Hurt Subscale|Pain and Hurt	A subscale of the Pediatric Quality of Life Brain Tumor Module designed to assess issues associated with pain and hurting.			Intellectual Product	
C157701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157701>	C222046	Movement and Balance Subscale|Movement and Balance	A subscale of the Pediatric Quality of Life Brain Tumor Module designed to assess issues associated with movement and balance.			Intellectual Product	
C157702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157702>	C222046	Procedural Anxiety Subscale|Procedural Anxiety	A subscale of the Pediatric Quality of Life Brain Tumor Module designed to assess issues associated with procedural anxiety.			Intellectual Product	
C157703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157703>	C222046	Nausea Subscale|Nausea	A subscale of the Pediatric Quality of Life Brain Tumor Module designed to assess issues associated with nausea.			Intellectual Product	
C157704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157704>	C222046	Worry Subscale|Worry	A subscale of the Pediatric Quality of Life Brain Tumor Module designed to assess issues associated with worry.			Intellectual Product	
C157705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157705>	C35886	Reticular Growth Pattern	A morphologic finding where the cells proliferate and give a net-like appearance to the lesion showing multiple spaces of varying sizes in between the cells.			Finding	
C157706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157706>	C35886	Microcystic Growth Pattern	A morphologic finding where cells show numerous small cyst-like spaces that vary in size creating a sieve-like appearance.			Finding	
C157707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157707>	C3671	Assault	A physical attack.			Finding	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157709>	C150672	HIV-Related Lymphoproliferative Disorder|HIV-Associated Lymphoproliferative Disorder	A lymphoproliferative disorder that develops in an individual with HIV infection.			Disease or Syndrome	
C15770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15770>	C15185	Behavior Research, Direct	Research concerning people's behavior in the context of cancer, i.e., how people's behavior affects their chance of developing cancer.			Research Activity	
C157710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157710>	C717|C204441	Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1|Recombinant VSV-IFNbetaTYRP1|Recombinant VSV-expressing IFN-b and TYRP1|VSV-IFN-b/TYRP1|VSV-IFNbetaTYRP1	A recombinant, replicating oncolytic vesicular stomatitis virus (VSV) carrying the human interferon-beta (IFN-b) gene and the tyrosinase related protein 1 (TYRP1) gene, with potential immunomodulating and antineoplastic activities. Upon intratumoral and intravenous administration, recombinant VSV-expressing IFN-b/TYRP1 preferentially replicates in tumor cells. Due to defective IFN-b-mediated innate antiviral host defense mechanisms in tumor cells, VSV is able to replicate in these cells without interference. This induces VSV-mediated cytolytic activity towards the tumor cells. By expressing human IFN-b, an IFN-b-mediated antiviral immune response in surrounding normal cells is activated which protects normal cells against virus replication and the associated VSV-mediated cell lysis.  Also, the IFN-b produced by VSV may activate an immune response in surrounding normal cells, involving the activation of cytotoxic T-lymphocytes (CTL), dendritic cells (DCs) and natural killer (NK) cells. This induces an anti-tumor immune response against the tumor cells. In addition, the expression of TYRP1 further activates the immune system to induce a CTL-mediated immune response against the TYRP1-expressing tumor cells, thereby further killing TYRP1-expressing tumor cells.  VSV, a single-stranded RNA virus belonging to the genus Vesiculovirus of the family Rhabdoviridae, is relatively nonpathogenic to healthy humans but is able to rapidly replicate in and induce apoptosis of tumor cells. TYRP1, a tumor-associated antigen (TAA), is primarily expressed in melanocytes and melanomas.	Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1		Pharmacologic Substance|Virus	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711>	C54443	GDC Terminology|Genomics Data Commons Terminology	Terminology that supports the Genomic Data Commons (GDC).			Intellectual Product	
C157712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712>	C157711	GDC Therapeutic Agent Terminology|AGENT|therapeutic_agents				Intellectual Product	
C157713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157713>	C16830	Orthopedic Devices	Orthopedic devices.			Medical Device	
C157714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157714>	C42076	Malignant Epithelial Cells with Cytoplasmic Vacuoles or Flocculent Cytoplasmic Inclusions Containing Wispy Eosinophilic Material Present	A morphologic finding indicating the presence of malignant epithelial cells with cytoplasmic vacuoles or flocculent cytoplasmic inclusions containing wispy eosinophilic material giving a bubbly appearance.			Finding	
C157715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157715>	C15620	Total Gut Decontamination|TGD	A process that uses combinations of antibiotics to remove or reduce the gut microbiome.	Total Gut Decontamination		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C157717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157717>	C16338	Dermal Injectable Filler|Collagen/Fat Injectable Fillers|Soft Tissue Injectable Filler	A preparation consisting of absorbable or non-absorbable materials, or harvested autologous fat, that may be injected into certain areas of tissue to minimize skin depressions, scars, and signs of aging. Absorbable materials, which include collagen, hyaluronic acid (HA), calcium hydroxylapatite (CaHA), and poly-L-lactic acid (PLLA), tend to have more temporary effects, whereas the effects of non-absorbable materials, such as polymethylmethacrylate (PMMA) microspheres, tend to be more permanent.			Biomedical or Dental Material	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157718>	C9385	Acquired Cystic Disease-Associated Renal Cell Carcinoma|ACD-RCC|Acquired cystic disease-associated renal cell carcinoma (RCC)|Cyst-associated renal cell carcinoma	The most common renal cell carcinoma that develops in patients with end-stage renal disease and acquired cystic disease.			Neoplastic Process	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Morphology PT Terminology|Mapped ICDO3.1 Morphology Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C157719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157719>	C199143	College of American Pathologists|CAP	A member-based physician that serves patients, pathologists, and the public by fostering and advocating best practices in pathology and laboratory medicine.			Professional or Occupational Group	
C15771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15771>	C15185	Behavior Research, Indirect	Research concerning any factor or condition, exposure to which is theoretically susceptible to behavioral modification, but in which no actual behavioral work is being done (e.g., experimental studies on tobacco use, consumption of various dietary components, and exposure to many other environmental carcinogens).			Research Activity	
C157720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157720>	C17617	Vaginal Dilator	A device designed to enlarge the vaginal canal in depth or diameter.	Vaginal Dilator		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C157721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157721>	C35867	Intra or Intercytoplasmic Lumina Present	A morphologic finding where the malignant cell has intra or intercytoplasmic lumina thereby imparting a cribriform or sieve-like architecture.			Finding	
C157723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157723>	C64982|C15454	Otoplasty	A surgical procedure that changes the shape or position of the ears.			Therapeutic or Preventive Procedure	
C157724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157724>	C15651	High-Dose-Rate Vaginal Brachytherapy|HDR-IVB|High-Dose-Rate Intra-Vaginal Brachytherapy	High dose rate radiation delivered by a radiation source contained in an intra-vaginal cylinder to target neoplasms in or surrounding the vaginal canal.	High-Dose-Rate Vaginal Brachytherapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C157725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157725>	C49163	Vascular Surgical Procedure	A surgical procedure performed on an artery, vein, or lymphatic vessel.			Therapeutic or Preventive Procedure	
C157726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157726>	C100110	CDISC Questionnaire PHQ-2 Test Name Terminology|PHQ04TN|Patient Health Questionnaire - 2 Item Questionnaire Test Name|QS-PHQ-2 TEST	Test names of questionnaire questions associated with the Patient Health Questionnaire - 2 Item (PHQ-2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C157727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157727>	C100110	CDISC Questionnaire PHQ-2 Test Code Terminology|PHQ04TC|Patient Health Questionnaire - 2 Item Questionnaire Test Code|QS-PHQ-2 TESTCD	Test codes of questionnaire questions associated with the Patient Health Questionnaire - 2 Item (PHQ-2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C157728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157728>	C211913	PHQ-2 Questionnaire Question	A question associated with the PHQ-2 questionnaire.			Intellectual Product	
C157729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157729>	C157728	PHQ-2 - Little Interest or Pleasure in Doing Things|PHQ04-Little Interest/Pleasure in Things|PHQ04-Little Interest/Pleasure in Things|PHQ0401	Patient Health Questionnaire - 2 Item (PHQ-2) Over the past 2 weeks, how often have you been bothered by any of the following problems? Little interest or pleasure in doing things.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ-2 Test Code Terminology|CDISC Questionnaire PHQ-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15772>	C52647	Biological Response Modifiers Program|BRMP	A program set up to establish cooperative agreements for Clinical Trials of Cancer Therapy with Biological Response Modifiers (CATBRMs) and to develop novel approaches for such therapy.  Funding is provided to foster innovative clinical trials of BRMs by peer-reviewed groups of highly experienced clinical and preclinical investigators who have the unique technical capabilities to study new agents in early clinical trials and to address hypothesis-driven issues of mechanisms of action.			Governmental or Regulatory Activity	
C157730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157730>	C157728	PHQ-2 - Feeling Down, Depressed or Hopeless|PHQ04-Feeling Down Depressed or Hopeless|PHQ04-Feeling Down Depressed or Hopeless|PHQ0402	Patient Health Questionnaire - 2 Item (PHQ-2) Over the past 2 weeks, how often have you been bothered by any of the following problems? Feeling down, depressed or hopeless.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PHQ-2 Test Code Terminology|CDISC Questionnaire PHQ-2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C157731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157731>	C103492	ESS - Total Score|ESS01-Total Score|ESS01-Total Score|ESS0109	Epworth Sleepiness Scale (ESS) Total score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ESS Test Code Terminology|CDISC Questionnaire ESS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C157733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157733>	C3156|C128637	Laryngeal Papillomatosis|Recurrent Respiratory Papillomatosis of the Larynx	Recurrent respiratory papillomatosis that affects the larynx.	Laryngeal Papillomatosis		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157734>	C16742	NeuroBlate System|NBS|NeuroBlate	A proprietary, minimally invasive robotic laser thermotherapy tool, designed specifically for use in the brain, that uses MRI-guided surgical ablation technology. It is designed to provide precise and maximal tumor reduction without the invasiveness of an open neurosurgical procedure.	NeuroBlate System		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C157735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157735>	C49236	Compression Therapy	The use of compression dressings or garments to prevent or treat any of various conditions.	Compression Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C157736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157736>	C157735	Compression Therapy for Neuropathy Prevention|Compression Therapy	The use of compression garments to prevent the development of peripheral neuropathy.	Compression Therapy for Neuropathy Prevention		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C157737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157737>	C4525|C3400	Kidney Synovial Sarcoma|Primary Kidney Synovial Sarcoma|Primary Renal Synovial Sarcoma|Renal Synovial Sarcoma	A rare synovial sarcoma that arises from the kidney.			Neoplastic Process	
C157738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157738>	C18210	Axillary Reverse Mapping|ARM|ARM Procedure|ARM Technique	A technique used to identify the lymph nodes that drain the upper arm. Like axillary or sentinel lymph node mapping a blue dye is injected into the upper volar subcutaneous tissue of the upper arm to map the lymphatic drainage of the area. The goal of ARM, however, is to preserve these nodes and the existing lymphatic drainage field.	Axillary Reverse Mapping		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C157739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157739>	C54710	Smooth Muscle Metaplasia	A morphologic finding indicating the transformation of non-smooth muscle cells to smooth muscle cells.			Finding	
C15773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15773>	C15977	Leukocyte Banking|Blood Banking, Leukocyte	The typing, separation, and storage of leukocytes for subsequent transfusion to recipients.			Laboratory Procedure	
C157740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157740>	C161601	Cancer Surgery	Surgical procedures targeted at minimizing or eliminating a neoplastic process.			Health Care Activity	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157741>	C39766	Cosmetic Surgery	Procedures and techniques focused on improving an individual's appearance.			Therapeutic or Preventive Procedure	
C157742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157742>	C99546|C49803	Valvular Surgery	Surgery to repair any of the valves of the heart.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157743>	C3809|C3150	Kidney Neuroendocrine Neoplasm	An epithelial neoplasm with neuroendocrine differentiation that arises from the kidney.  It includes neuroendocrine tumor, small cell neuroendocrine carcinoma, large cell neuroendocrine carcinoma, and paraganglioma.			Neoplastic Process	
C157745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157745>	C6566|C190608	Childhood Cystic Nephroma|Pediatric Cystic Nephroma	A cystic nephroma that occurs in very young children.			Neoplastic Process	
C157746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157746>	C200766	Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes|Autologous Anti-PSCA(dCH2)BBz-CAR T-cells|Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-cells|PSCA(dCH2)BBzeta-CAR T-cells	A preparation of autologous T-lymphocytes that have been immunomagnetically depleted of CD14+ myeloid cells and CD25+ regulatory T-cells (Tregs), activated with anti-CD3 and anti-CD28 beads, and transduced with a self-inactivating (SIN) lentiviral vector (LV) encoding a chimeric antigen receptor (CAR) containing a prostate stem cell antigen (PSCA)-specific, humanized and affinity matured A11 single chain variable fragment (scFv), a human immunoglobulin G4 (IgG4) Fc spacer lacking the CH2 domain, a human CD4 transmembrane domain, a costimulatory human 4-1BB (CD137) cytoplasmic signaling domain linked to the zeta chain of the human T-cell receptor (TCR)/CD3 complex (CD3zeta), and a truncated human CD19 sequence (CD19t), with potential immunostimulating and antineoplastic activities. Upon intravenous infusion, the autologous anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes recognize and induce selective toxicity in PSCA-expressing tumor cells. PSCA, a glycosyl-phosphatidylinositol (GPI)-linked cell surface antigen, is uniquely and highly expressed in certain cancers including bladder, pancreatic, and prostate cancers. Co-expression of CD19t provides an inert, non-immunogenic surface marker that allows for measurement of genetically modified cells and tracking of T-cells following adoptive transfer. The costimulatory signaling domains improve T-cell function, selectivity, expansion and survival.	Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157747>	C36696|C18016|C129830	TSC2 Monoallelic Inactivation|Monoallelic TSC2 Gene Inactivation|Monoallelic Tuberin Gene Inactivation|Monoallelic Tuberous Sclerosis 2 Gene Inactivation|TSC2 LOH|TSC2 Loss of Heterozygosity|TSC2 Monoallelic Gene Inactivation	Any gain, loss, or exchange of DNA that results in monoallelic loss of function mutations in the TSC2 gene.			Cell or Molecular Dysfunction	
C157748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157748>	C4778|C4092	Metanephric Tumor	A neoplasm arising from the distal convoluted tubule and collecting duct areas of the kidney.			Neoplastic Process	
C157749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157749>	C157748	Metanephric Stromal Tumor	A rare benign renal neoplasm composed of moderately cellular spindle cells. It occurs mostly in infancy and childhood.			Neoplastic Process	
C15774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15774>	C79427|C16212	Breast Cancer Therapeutic Procedure|Breast Cancer Treatment|Breast Cancer, Treatment	Medical or surgical interventions to eradicate breast tumors and/or their metastases.			Therapeutic or Preventive Procedure	
C157750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157750>	C4104|C4031|C156062	Metastatic Bladder Squamous Cell Carcinoma	A bladder squamous cell carcinoma that has spread to another anatomical site.	Metastatic Bladder Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157751>	C39823|C191697|C150513	Metastatic Bladder Plasmacytoid Urothelial Carcinoma|Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant|Metastatic Invasive Bladder Urothelial Carcinoma, Plasmacytoid Variant|Metastatic Plasmacytoid Urothelial Carcinoma of the Bladder	A bladder plasmacytoid urothelial carcinoma that has spread to another anatomic site.			Neoplastic Process	
C157753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157753>	C97927	HOXB13 Gene Mutation|HOXB13|HPC9 Gene Mutation|Homeo Box B13 Gene Mutation|Homeobox B13 Gene Mutation|Hox-B13 Gene Mutation|PSGD Gene Mutation	A change in the nucleotide sequence of the HOXB13 gene.	HOXB13 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C157754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157754>	C39828|C191694|C150513	Metastatic Bladder Lipid-Rich Urothelial Carcinoma|Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Cell Variant|Metastatic Invasive Bladder Urothelial Carcinoma, Lipid-Rich Variant|Metastatic Lipid Rich Bladder Urothelial Carcinoma|Metastatic Lipid-Cell Urothelial Carcinoma of the Bladder	A bladder lipid-rich urothelial carcinoma that has spread to another anatomic site.			Neoplastic Process	
C157755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157755>	C7572|C27806	Metastatic Kidney Medullary Carcinoma	A kidney medullary carcinoma that has spread to another anatomical site.	Metastatic Kidney Medullary Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157756>	C17666|C157753	Germline HOXB13 Gene Mutation|Germline HPC9 Gene Mutation|Germline Homeo Box B13 Gene Mutation|Germline Homeobox B13 Gene Mutation|Germline Hox-B13 Gene Mutation|Germline PSGD Gene Mutation|HOXB13 Germline Mutation	A change in the nucleotide sequence of the HOXB13 gene that originates in the gametes.	Germline HOXB13 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C157757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157757>	C27893|C150595	Metastatic Sarcomatoid Renal Cell Carcinoma|Metastatic Renal Cell Sarcomatoid Carcinoma	A sarcomatoid renal cell carcinoma that has spread to another anatomical site.	Metastatic Sarcomatoid Renal Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157758>	C3809|C2901	Bladder Neuroendocrine Neoplasm	An epithelial neoplasm with neuroendocrine differentiation that arises from the bladder. This category includes neuroendocrine tumors, neuroendocrine carcinomas, and paragangliomas.			Neoplastic Process	
C157759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157759>	C212820|C191977|C157758	Bladder Neuroendocrine Carcinoma	An aggressive high-grade carcinoma with neuroendocrine differentiation that arises from the bladder. This category includes small cell and large cell neuroendocrine carcinoma.			Neoplastic Process	
C15775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15775>	C16199	Breast Cancer Detection Research|Breast Cancer Detection	Research project involving detection of breast tumors (screening, diagnosis clinical trials), development or refinement of diagnostic techniques or devices, education or promotion of breast cancer detection.			Diagnostic Procedure	
C157760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157760>	C191984|C157759	Bladder Large Cell Neuroendocrine Carcinoma	An aggressive high-grade carcinoma with neuroendocrine differentiation that arises from the bladder. It is characterized by the presence of malignant large cells.			Neoplastic Process	
C157762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157762>	C191988|C157760|C156062	Metastatic Bladder Large Cell Neuroendocrine Carcinoma	A bladder large cell neuroendocrine carcinoma that has spread to another anatomical site.	Metastatic Bladder Large Cell Neuroendocrine Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157763>	C9461|C191852|C156062	Metastatic Bladder Small Cell Neuroendocrine Carcinoma|Metastatic Bladder Small Cell Carcinoma	A bladder small cell neuroendocrine carcinoma that has spread to another anatomic site.	Metastatic Bladder Small Cell Neuroendocrine Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157764>	C6766|C191852|C158913	Metastatic Prostate Small Cell Neuroendocrine Carcinoma|Metastatic Prostate Small Cell Carcinoma|Metastatic Small Cell Neuroendocrine Prostate Cancer|Metastatic Small Cell Neuroendocrine Prostate Cancer|Metastatic Small Cell Prostate Cancer	Prostate small cell neuroendocrine carcinoma that has spread to another anatomic site.	Metastatic Small Cell Neuroendocrine Prostate Cancer		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157765>	C61547	Motivational Interviewing|MI|Motivational Interviewing Intervention	A directive, client-centered counseling style that helps people resolve ambivalent feelings and insecurities  in order to find internal motivation and elicit behavior changes.	Motivational Interviewing		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C157766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157766>	C39824|C191736|C150513	Metastatic Bladder Sarcomatoid Urothelial Carcinoma|Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant|Metastatic Invasive Bladder Urothelial Carcinoma, Sarcomatoid Variant|Metastatic Sarcomatoid Bladder Urothelial Carcinoma|Metastatic Sarcomatoid Urothelial Carcinoma of the Bladder	A bladder sarcomatoid urothelial carcinoma that has spread to another anatomical site.			Neoplastic Process	
C157767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157767>	C27202|C191695|C150513	Metastatic Bladder Micropapillary Urothelial Carcinoma|Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant|Metastatic Invasive Bladder Urothelial Carcinoma, Micropapillary Variant|Metastatic Micropapillary Bladder Urothelial Carcinoma|Metastatic Micropapillary Urothelial Carcinoma of the Bladder	A bladder micropapillary urothelial carcinoma that has spread to another anatomic site.			Neoplastic Process	
C157768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157768>	C39827|C191692|C150513	Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma|Metastatic Clear Cell Bladder Urothelial Carcinoma|Metastatic Clear Cell Urothelial Carcinoma of the Bladder|Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant|Metastatic Invasive Bladder Urothelial Carcinoma, Clear Cell (Glycogen-Rich) Variant|Metastatic Invasive Bladder Urothelial Carcinoma, Clear Cell Variant	A bladder clear cell (glycogen-rich) urothelial carcinoma that has spread to another anatomic site.			Neoplastic Process	
C157769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157769>	C39829|C191693|C150513	Metastatic Bladder Giant Cell Urothelial Carcinoma|Metastatic Giant Cell Bladder Urothelial Carcinoma|Metastatic Giant Cell Urothelial Carcinoma of the Bladder|Metastatic Infiltrating Bladder Urothelial Carcinoma with Giant Cells|Metastatic Invasive Bladder Urothelial Carcinoma with Giant Cells	A bladder giant cell urothelial carcinoma that has spread to another anatomic site.			Neoplastic Process	
C15776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15776>	C18020|C16210	Cancer Detection	The act of discovery of a malignant neoplasm, and after treatment, the discovery of minimal residual disease.			Diagnostic Procedure	
C157770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157770>	C39819|C191696|C150513	Metastatic Bladder Nested Urothelial Carcinoma|Metastatic Infiltrating Bladder Urothelial Carcinoma, Nested Variant|Metastatic Invasive Bladder Urothelial Carcinoma, Nested Variant|Metastatic Nested Bladder Urothelial Carcinoma|Metastatic Nested Urothelial Carcinoma of the Bladder	A bladder nested urothelial carcinoma that has spread to another anatomic site.			Neoplastic Process	
C157771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157771>	C177175	Cavrotolimod|AST 008|AST-008|AST008|CAVROTOLIMOD|SNA AST-008|TLR9 Agonist AST-008|Toll-like Receptor 9 Activator AST-008	A spherical nucleic acid (SN)-based agonist of toll-like receptor 9 (TLR9), with potential immunostimulating activity. Upon administration, cavrotolimod targets and is able to enter various immune cells, including monocytes/macrophages, plasmacytoid dendritic cells (pDCs), natural killer (NK) cells and B cells, through endocytosis. Within the endosome, it binds to and activates TLR9. TLR9 activation induces immune signaling pathways and activates various immune cells, including B-cells, pDCs, NKs, and induces both the production of T-helper 1 cells (Th1) and a Th1-mediated immune response as well as a cytotoxic T-lymphocyte (CTL)-based immune response against tumor cells. This results in an inhibition of tumor cell proliferation. TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate and adaptive immune responses. The SNA is a dense, radial arrangement of nucleic acids (DNA) on the surface of liposomal nanoparticles, providing a 3D-construct, that has a high cellular uptake and an increased presentation of the DNA for TLR9 agonism. It also protects against breakdown by nucleases and increases the half-life of the construct compared to linear oligonucleotides that are not in SNA format.	Cavrotolimod		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology
C157772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157772>	C217106|C211912	Zilovertamab Vedotin|Anti-ROR1 ADC VLS-101|Antibody-drug Conjugate VLS-101|MK-2140|VLS 101|VLS-101|VLS101|ZILOVERTAMAB VEDOTIN	An antibody-drug conjugate (ADC) composed of zilovertamab, a humanized, immunoglobulin G (IgG1) monoclonal antibody against the tumor-associated antigen (TAA) receptor tyrosine kinase-like orphan receptor 1 (ROR1) conjugated, via a proteolytically cleavable linker, to the auristatin derivative and microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of zilovertamab vedotin targets and binds to ROR1 expressed on tumor cells. Upon binding, internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces apoptosis in ROR1-expressing tumor cells. ROR1, also known as neurotrophic tyrosine kinase, receptor-related 1 (NTRKR1), is expressed during embryogenesis and by certain leukemias. It plays key roles in tumor cell proliferation and survival.	Zilovertamab Vedotin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157773>	C40030|C157735	Cryocompression Therapy	Therapy that combines compression garments or dressings with cooling of the treated area.	Cryocompression Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C157774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157774>	C36263|C156484	Metastatic Malignant Genitourinary System Neoplasm|Metastatic Genitourinary System Malignant Neoplasm|Metastatic Genitourinary Tumor	A malignant genitourinary system neoplasm that has spread from its original site of growth to other anatomic sites.	Metastatic Genitourinary Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C157775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157775>	C157514	Botulinum Toxin Therapy|Botox|Botox Therapy	Treatment by injections of botulinum toxin. This can diminish signs of aging in the face, reduce excessive sweating and muscle spasms, and treat overactive bladder and lazy eye.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157776>	C717	Maraba Oncolytic Virus Expressing Mutant HPV E6/E7|MG1-E6/E7|MG1-E6E7|MG1-expressing Mutant HPV E6/E7|Oncolytic MG1 Virus-encoding E6E7|Oncolytic Virus MG1-E6E7	A cancer vaccine comprised of a recombinant, attenuated form of the oncolytic rhabdovirus Maraba (MG1) encoding inactive, mutant forms of the human papillomavirus (HPV) transforming proteins E6 and E7, with potential immunostimulating and antineoplastic activities. Upon administration of MG1-E6E7, MG1 preferentially infects tumor cells and induces the expression of the E6 and E7 proteins. The MG1 virus exerts its oncolytic activity, thereby directly lysing tumor cells. Following the lysis of infected cells, the virus is released and can infect adjacent cells, which both induces further tumor cell oncolysis and may activate the immune system to kill the infected tumor cells. The expressed E6 and E7 proteins stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV E6 and E7, thereby further inducing tumor cell lysis. Oncoproteins E6 and E7 play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.	Maraba Oncolytic Virus Expressing Mutant HPV E6/E7		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157777>	C49146|C1663	Adenovirus Expressing Mutant HPV E6/E7|Ad-E6/E7|Ad-E6E7|Adenoviral-HPV E6E7 Vaccine|Adenoviral-expressing Mutant HPV E6/E7|Adenovirus Vaccine Expressing Mutant HPV E6 and E7	A cancer vaccine comprised of a genetically engineered, replication-deficient adenovirus encoding inactive, mutant forms of the human papillomavirus (HPV) transforming proteins E6 and E7, with potential immunostimulating and antineoplastic activities. Upon administration of adenovirus expressing mutant HPV E6/E7, the adenovirus infects and expresses the E6 and E7 proteins. The expressed E6 and E7 proteins stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV E6 and E7, thereby inducing tumor cell lysis. Oncoproteins E6 and E7 play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.	Adenovirus Expressing Mutant HPV E6/E7		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157778>	C80430|C49803	Abdominal Aneurysm Open Repair	A surgical procedure in which the abdomen is surgically incised (as opposed to laparoscopic intervention) and an aneurysm in the abdominal aorta is repaired in open view.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157779>	C20985	Ablation for Barrett's Esophagus	Treatment of an area of Barrett's-affected tissue in the esophagus with heat energy that is delivered through an endoscope.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C15777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15777>	C15669|C15306	Cancer Prevention, Primary	NIH Emphasis Area -- The term "prevention" refers to prophylactic and preventative efforts to achieve a significant reduction in cancer incidence, cancer mortality, and cancer morbidity. "Primary prevention" involves efforts to directly prevent and/or inhibit malignant transformation; to identify, characterize, and manipulate factors that might be effective in achieving that inhibition; and attempts to promote preventative measures, such as appropriate training of scientists and clinicians. Prevention and intervention efforts are biologic activities aimed at the cell - at the genetic and cellular changes that result in the transformation process and that define cancer development			Therapeutic or Preventive Procedure	
C157780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157780>	C121969	Acne Scar Treatment	Any treatment to minimize acne scars.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157781>	C35331|C3097	Acute Hepatitis B Infection|Acute Hepatitis B	A new infection by the hepatitis B virus, which can be transmitted by direct contact of infected blood with mucous membranes or open areas of the skin. Signs and symptoms may include loss of appetite, joint and muscle pain, low-grade fever and stomach pain. Two to six percent of adults progress to a chronic infection, while 90% of infants become chronically ill. A vaccine is available for those at risk.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157782>	C35331|C3098	Acute Hepatitis C Infection|Acute Hepatitis C	A new infection by the hepatitis C virus, which can be detected in blood. Signs and symptoms may include right upper quadrant abdominal pain, jaundice, dark urine, white stools and nausea. Approximately 15%-25% individuals clear the virus from their bodies without treatment. 75%-85% individuals develop chronic hepatitis C. There are possible treatments depending on individual characteristics.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157783>	C35331	Acute Hepatitis E Infection|Acute Hepatitis E	A new infection by the hepatitis E virus, which is usually spread by the fecal-oral route. Signs and symptoms may include fever, fatigue, loss of appetite, nausea, vomiting, abdominal pain, jaundice, dark urine, clay-colored stools and joint pain. There is no specific anti-viral treatment, the infection resolves on its own.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157784>	C201126	Ambulatory Anorectal Surgery	Outpatient surgery on the anus/rectal area.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157785>	C34953	Amebiasis|Amoebiasis|Amoebiasis	A parasitic infection of the colon by Entamoeba histolytica. Signs and symptoms include cramping, diarrhea, bloody stools and fever. It can be treated with antibiotics.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology|NICHD Terminology|Pediatric Infectious Disease Terminology
C157786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157786>	C16522	Amphetamine Use Disorder	The use of amphetamines that results in the development of a dependency that adversely affects an individual's life.			Individual Behavior	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157787>	C38033	Ankle Arthroscopy	Visualization of the ankle joint with an arthroscope.			Diagnostic Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157788>	C157742	Aortic Valve Surgery	Surgery on the aortic valve in the heart.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157789>	C16186	Arthroscopic Surgery	Any surgical procedure that involves an arthroscope.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C15778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15778>	C15712|C15669	Secondary Cancer Prevention|Cancer Prevention, Secondary	A treatment or method for preventing a neoplasm from forming or spreading following treatment of a primary neoplasm.			Therapeutic or Preventive Procedure	
C157790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157790>	C157707	Assault By Firearm	A physical attack with a gun.			Finding	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157791>	C157707	Assault By Sharp Object	A physical attack with a pointed object.			Finding	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157793>	C49803	Atherectomy	The removal of plaque from a blood vessel.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157794>	C27555	Bacterial Skin Disorder	A cutaneous disorder attributed to a bacterial infection.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157795>	C99546	Balloon Valvuloplasty	The use of a balloon catheter to improve the patency of a stenotic heart valve by inserting the catheter into the valve and inflating the balloon to compress the sides and widen the opening.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157796>	C15541	Behavioral Measures For Treating Sleep Disordered Breathing	Any steps taken to modify one's behavior to improve sleep.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157797>	C157740|C15334	Bladder Cancer Surgery|Surgery for Bladder Cancer	Any surgical procedures to treat bladder cancer.			Health Care Activity	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157798>	C157775	Botulinum Toxin for Digestive Disorders	The use of a botulinum toxin injection to treat disorders of the digestive system, such as achalasia, in which the esophageal sphincter is too contracted.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157799>	C21072	Brachial Plexus Block	A regional anesthesia technique that involves injecting local anesthetic agents near the nerves of the brachial plexus to temporarily block sensation and movement of the upper extremity.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C15779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15779>	C213421	Carcinogen Screening|Carcinogenesis, Screening	In vitro or in vivo testing to give a quantitative measure of tumor-inducing potency of the substance.			Research Activity	
C1577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1577>	C511|C2021	Nolatrexed Dihydrochloride|3,4-Dihydro-2-amino-6-methyl-4-oxy-5-(4-pyridylthio)-quinazoline Dihydrochloride|AG-337|AG337|NOLATREXED DIHYDROCHLORIDE|Nolatrexed Hydrochloride|Thymitaq|Thymitaq|nolatrexed	The dihydrochloride salt of nolatrexed, a water-soluble lipophilic quinazoline folate analog with antineoplastic activity. Nolatrexed occupies the folate binding site of thymidylate synthase, resulting in inhibition of thymidylate synthase activity and thymine nucleotide synthesis with subsequent inhibition of DNA replication, DNA damage, S-phase cell cycle arrest, and caspase-dependent apoptosis. This agent also exhibits radiosensitizing activity.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157800>	C193375	Brain Tumor Radiation|Brain Tumor Irradiation|Brain Tumor Radiation Therapy|Brain Tumor Radiotherapy|Radiation for Brain Tumors	The use of radiation, either via external beams or small radioactive pellets, to treat a tumor in the brain.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157801>	C157740|C154268	Brain Tumor Surgery|Surgery for Brain Tumor	A surgical procedure on the brain to remove a tumor.			Health Care Activity	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157802>	C49163	Breast Surgery	A surgical procedure on the breast.			Health Care Activity	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157803>	C39766	Brow Lift	A plastic surgery procedure in which the eyebrows are raised on the forehead to give a more youthful appearance.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157804>	C2890	Campylobacter Enteritis	A gastrointestinal infection attributed to the bacteria campylobacter. It is usually contracted by consuming raw or undercooked poultry or consuming a food that has been in contact with raw poultry. It is characterized by abdominal pain, fever, and  diarrhea and usually resolves in two to five days.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157805>	C61547	Cardiac Behavioral Counseling	Counseling to change behaviors that have a negative effect on an individual's cardiac system.			Health Care Activity	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157806>	C49803	Cardiac Surgery|Cardiac surgery|Heart Surgery|OR Heart Procedures	A surgical procedure on the heart.			Therapeutic or Preventive Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|CPTAC Codelists Terminology|CPTAC Procedures Codelist|CPTAC Terminology|CPTAC Treatments Codelist
C157807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157807>	C52002	Carotid Endarterectomy	A surgical procedure to remove plaque from the carotid arteries.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157808>	C157713	Casts and Splints	Orthopedic appliances designed to immobilized bones.			Medical Device	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157809>	C15331	Cataract Surgery|CATARACT SURGERY	A surgical procedure to remove cataracts from the eyes.			Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C15780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15780>	C15669	Carcinogenesis Inhibition|Carcinogenesis, Inhibition	Suppression or prevention of the carcinogenic process/development of cancer.			Therapeutic or Preventive Procedure	
C157810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157810>	C157740|C15332	Cervical Cancer Surgery|Surgery for Cervical Cancer	A surgical procedure to remove cancer from the cervix.			Health Care Activity	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157811>	C15632	Chemotherapy for Brain Tumor	The administration of drugs to ameliorate the effects of or shrink a brain tumor.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157812>	C2890	Cholera	An acute diarrheal illness caused by consuming water or food contaminated by the bacterium Vibrio cholerae. Adequate rehydration is key to surviving this illness.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157813>	C80078	Chronic Kidney Disease due to Diabetes Mellitus	Longstanding kidney disease as a complication of diabetes.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157814>	C80078	Chronic Kidney Disease due to Hypertension	Longstanding kidney disease as a complication of hypertension.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157815>	C15315	Chronic Pain Rehabilitation	Treatment to assist an individual with longstanding and constant pain.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157816>	C35755	Non-Neoplastic Chronic Respiratory System Disorder|Chronic Respiratory Disease	A non-neoplastic longstanding disorder of the respiratory system.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157817>	C2951	Cirrhosis of the Liver Secondary to Hepatitis B	Cirrhosis of the liver that develops as a sequelae of a hepatitis b infection.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157818>	C2951	Cirrhosis of the Liver Secondary to Hepatitis C	Cirrhosis of the liver that develops as a sequelae of a hepatitis c infection.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157819>	C16522	Cocaine Use Disorder	The use of cocaine that results in the development of a dependency that adversely affects an individual's life.			Individual Behavior	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C15781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15781>	C49236	Carcinogenesis Reversion|Carcinogenesis, Reversion	Treatment designed to return a malignant cell to a non-malignant state.			Therapeutic or Preventive Procedure	
C157820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157820>	C41075|C18130	Cochlear Implant|Cochlear Implants|Cochlear Implants	A two part electronic device with one part that is implanted under the skin with wires that connect to the cochlea, and an external portion that receives the sound. It is for individuals with severe hearing impairment.			Medical Device	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157821>	C64345	Cognitive Behavior Therapy for Insomnia|CBT-I|CBTI|Cognitive Behavioral Therapy for Insomnia	A structured program that helps the patient identify and replace thoughts and behaviors that cause or worsen sleep problems with habits that promote sound sleep. Techniques include stimulus control therapy, sleep restriction, sleep hygiene, sleep environment improvement, relaxation training, remaining passively awake, and biofeedback.	Cognitive Behavior Therapy for Insomnia		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology
C157822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157822>	C15330	Collis Gastroplasty	A surgical procedure that lengthens the esophagus with part of the stomach to provide relief from GERD or Barrett's esophagus.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157824>	C15210	Colorectal Cancer Surgery	Any of a number of surgical procedures that can be done on the colon, rectum and/or anus.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157825>	C27992	Communicable Disorder	A disease that can be transmitted from one individual to another.			Qualitative Concept	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157826>	C16186	Core Decompression	A surgical procedure in which areas of dead bone are drilled to increase blood flow, slow or stop tissue destruction and decrease pressure.			Therapeutic or Preventive Procedure	ALL Adverse Events Table|ALL Authorized Value Terminology|CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157827>	C39766	Cosmetic Plastic Surgery	Surgery to improve the aesthetics of an individual's body.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157828>	C15656	Cranial Base Surgery	Surgery to remove tumors that use high powered microscopes with fiberoptic illumination to identify target areas.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157829>	C100068	Cryoablation for Arrhythmia|cryoablation	The use of cold to freeze heart tissue that is a source of an irregular rhythm. It is administered via a balloon catheter that use advanced radiographic techniques.			Therapeutic or Preventive Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C15782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15782>	C15604	Clinical Chemoprevention|Chemoprevention, Clinical	Chemoprevention use in a clinical setting.			Therapeutic or Preventive Procedure	
C157830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157830>	C157741	Double Eyelid Surgery	Surgery to create an eyelid fold where one does not exist.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157831>	C17705	Driving Simulation Training	Learning how to drive with a machine that simulates the motor vehicle of choice.			Educational Activity	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157832>	C157723	Ear Pinning	Reshaping or suturing of the ear(s) to lie flatter against the head.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157833>	C38033	Elbow Arthroscopy	A procedure to examine the elbow joint via an arthroscope.			Diagnostic Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157834>	C20985	Endometrial Ablation	Destruction of endometrial tissue by cold, heated fluids, microwave energy or high-energy radiofrequency.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157835>	C157740|C15332	Endometrial Cancer Surgery|Surgery for Endometrial Cancer	A surgical procedure to remove or destroy cancer in the endometrium.			Health Care Activity	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157836>	C65013	Endoscopic Sinus Surgery	A surgical procedure on the nasal sinuses with an endoscope.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157837>	C65013	Endoscopic Submucosal Dissection	A surgical procedure on the gastric tract to remove deep tumors via endoscope.	Endoscopic Submucosal Dissection		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology
C157838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157838>	C16546	Endourologic Procedure|Endourology	The use of an endoscopic scope to visualize and treat issues in the urethra, bladder and ureter.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157839>	C64982|C157725	Endovascular Aneurysm Repair	The repair of an aneurysm by deploying a graft into the area of the aneurysm via a special endovascular catheter.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C15783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15783>	C25474	Clinical Data|Clinical|clinical data	Data obtained through patient examination or treatment.			Idea or Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C157840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157840>	C71316	Endovascular Stenting|Endovascular Stent Graft	The repair of an aneurysm by deploying a stent graft into the area of the aneurysm via a special endovascular catheter.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157841>	C34594	Enteropathogenic E coli Infection	A pathotype of Escherichia coli, which is a gram-negative bacteria that is transmitted through the fecal-oral route. It has an incubation period of 9-12 hours and a duration of 12 days. Symptoms may include persistent severe acute diarrhea.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157842>	C34594	Enterotoxigenic E coli Infection	A pathotype of Escherichia coli, which is a gram-negative bacteria that is transmitted through the fecal-oral route. It has an incubation period of 10-72 hours and a duration of 1-5 days. Symptoms may include acute, occasionally severe diarrhea without fever.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157843>	C100068	Epicardial Ablation	Ablation of an area of the heart that the source of a dysrhythmia via the insertion of a catheter placed in the pericardial space.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157844>	C15986	Epidural Steroid Injection	An injection of a steroid into the epidural space, the sleeve that surrounds the spinal sac and cushions the spinal nerves and cords to reduce low back or neck pain associated with inflammation.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157845>	C157740	Esophageal Cancer Surgery|Surgery for Esophageal Cancer	A surgical procedure to remove any cancerous tissue in the esophagus.			Health Care Activity	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157846>	C16820	Esophageal Manometry	A test to determine the strength and muscle coordination of the esophagus. This is measured by pressure sensors in a small catheter that is inserted into the esophagus.			Laboratory Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157847>	C15357	Esophagus Resection	A surgical procedure to remove part of the esophagus.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157848>	C15331	Eye Evisceration and Enucleation	Eye evisceration is the removal of the contents of the eye, leaving the eye muscles and the sclera. Enucleation is the removal of the entire eye.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157849>	C25351	Eye Socket Reconstruction	The remaking or remodeling of the bones that provide a framework for the eye. The actual methods are dependent on the cause.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C15784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15784>	C16927	Clinical Nutrition	An area of medicine that seeks to identify and treat medical disorders in humans that result from improper or inadequate diet, or from diseases that make the body unable to handle the nutrients delivered to it in the normal diet. The usual treatment is dietary, but can be the delivery of nutrients by other means. (from University of Pittsburgh Medical Center glossary)			Biomedical Occupation or Discipline	
C157850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157850>	C49236	Eyelash Growth Stimulation	The application of medication to increase the fullness of eyelashes.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157851>	C157741	Eyelid Lift	A type of surgery that repairs droopy eyelids and may involve removing excessive tissue, fat and muscle from the area.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157852>	C157741	Eyelid Reconstruction	A surgical procedure to remodel the eyelid for cosmetic reasons or to treat an eyelid defect.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157853>	C157741	Facelift	A surgical procedure to remove excess skin from the face to create a more youthful appearance.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157854>	C157741	Facial Implants	The insertion of implantable material into the face to restore a more youthful appearance or correct a facial deformity.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157855>	C157741	Facial Plastic Surgery	Surgery to the face with the intent of making the face more aesthetically pleasing.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157856>	C157725	Femoral Popliteal Bypass|Fem-Pop Bypass	A surgical procedure to treat a diseased femoral artery in which a section of another blood vessel is sewn to the femoral artery to bypass the diseased area.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157857>	C100068	FIRM Ablation|Focal Impulse and Rotor Modulation Ablation	Ablation of an irritable area of the heart that is the source of atrial fibrillation with the technology Focal Impulse and Rotor Modulation (FIRM), which is a mapping technology to precisely identify the area of trouble.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157858>	C64982	Fistula Repair	A surgical procedure to repair a pathologic communication between two areas that should not be communicating.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157859>	C157741	Forehead Lift	A plastic surgery procedure in which excess skin is removed from the forehead to create a more youthful appearance.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C15785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15785>	C16205	Clinical Health Services|Clinical Services|Services	Programs for preventive, assessment, maintenance, diagnosis, treatment, and rehabilitative services, provided in a health care facility.			Health Care Activity	
C157860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157860>	C21072	Gasserian Ganglion Block	An injection of local anesthetics to the bundle of nerves supplying sensation to the face and scalp. This may provide relief from facial pain associated with facial pain syndromes or cancer pain.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157861>	C15723	Gastric Bypass for Esophagus Disorders	Surgery on the stomach to aid in the treatment of an esophageal disorder.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157862>	C64982	Gastric Electrical Stimulation	Abdominal implantation in the abdomen of a device that sends mild electrical impulses to the nerves and muscles of the lower stomach as a treatment for nausea and vomiting.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157863>	C64982	Gastric Pacemaker	A device that is implanted under the skin and has electrodes that attach to the stomach. This device is programmed to stimulate the stomach to empty, which is a problem in individuals with gastroparesis.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157864>	C78162	Gastrostomy Tube Procedure|Gastrostomy (Feeding) Tube	A procedure to insert a tube for feeding into the stomach.			Health Care Activity	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157865>	C157740	Glioma, Glioblastoma & Astrocytoma Surgery|Surgery for Glioma, Glioblastoma, & Astrocytoma	Surgery to treat a glioma, glioblastoma or astrocytoma.			Health Care Activity	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157866>	C15222	Gluten Free Diet	A diet that excludes gluten.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157867>	C118297	Haemophilus influenzae type b Meningitis|H influenzae type b Meningitis|H influenzae type b Meningitis|Hib Meningitis	Meningitis that is attributed to the bacterium Haemophilus influenzae type b.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157868>	C26704	H influenze type B Pneumonia	Pneumonia that is attributed to the bacteria H influenze type B.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157869>	C157741	Hair Removal	Removal of body hair.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C15786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15786>	C49236	Clinical Treatment	Actual observation and treatment of disease in patients (including experimental treatment) as distinct from theoretical or experimental work.			Therapeutic or Preventive Procedure	
C157870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157870>	C157741	Hair Replacement	Replacement of hair, usually on the head.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157871>	C157740|C15454	Head and Neck Cancer Surgery	Surgery on the head or neck to treat cancer.			Health Care Activity	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157872>	C16830	Hearing Devices|Hearing Device	Devices that are used to enhance hearing.			Medical Device	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157873>	C15330	Heller Myotomy	Surgical incision made in the esophageal sphincter to allow easier passage of food and liquids into the stomach.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157874>	C49236	Hepatitis C Treatment	Treatment to cure a hepatitis C infection. Antiviral therapy is prescribed based on the hepatitis C genotype, co-existing medical conditions and prior treatments.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157875>	C38033	Hip Arthroscopy	The use of an arthroscope to visualize the joint of the hip.			Diagnostic Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157876>	C131579	Hip Replacement	A surgical procedure to replace part or all of a hip joint with an orthopedic prosthesis.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Procedures Codelist|CPTAC Terminology|CPTAC Treatments Codelist
C157877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157877>	C49803	Hybrid Coronary Revascularization	The use of a combination of treatments, usually coronary angioplasty and coronary artery bypass to reestablish patency in blocked arteries.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157878>	C20985	Hybrid Surgical-Catheter Ablation	A combination of catheter ablation with thorascopic surgery to treat atrial fibrillation that is resistant to other treatments.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157879>	C35552	Hypertensive Heart Disease|Hypertensive Heart Diseaase	Heart conditions that are caused by high blood pressure, including coronary artery disease and heart failure.			Qualitative Concept	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C15787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15787>	C15320	Clinical Trials Design	The detailed planning of studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.			Research Activity	
C157880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157880>	C21072	Hypogastric Plexus Block	Injections of medication into the hypogastric plexus, which is a bundle of nerves near the bottom of the spinal cord. This will treat pain in the pelvic area.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157881>	C21090	IBD Medical Management	Non-surgical treatment of Irritable Bowel Disease.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157882>	C15438	Immunotherapy for Melanoma	Therapy designed to use an individual's own immune system to recognize and destroy melanoma cancer cells.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157883>	C201922	Implanted Epidural Portal|Epidural Port Implantation	Placement of a device that allows access to the epidural space of the spine for the delivery of pain medications.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157884>	C19160	Integrative Medicine	A personalized therapeutic approach that takes a patient's lifestyle into account.			Biomedical Occupation or Discipline	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157885>	C63334	Interventional Neuroradiology Procedure|Interventional Neuroradiology	Angioplasty and stenting of the vessels of the neck and brain under fluoroscopy.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157886>	C84751	Intestinal Nematode Infection	An infection in the gastrointestinal tract by a nematode.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157887>	C15342	Intestinal Rehabilitation and Transplant	Treatments to eliminate the need for intravenous nutritional support and restore diet and lifestyle for individuals with intestinal failure. Intestinal transplantation may treat irreversible intestinal failure.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157888>	C35117	Intestinal Vascular Disorder|Vascular Disorders of Intestine|Vascular disorder of intestine, unspecified	A non-neoplastic or neoplastic vascular disorder that affects the intestines.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology|mCode Elixhauser Peripheral Vascular Disease Value Set|mCode Terminology
C157889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157889>	C64865	Intragastric Balloon Procedure|Intragastric Balloon	A procedure in which a saline filled balloon is placed in the stomach to assist with weight loss.			Diagnostic Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157890>	C61508	Intraoperative Cholangiogram	A diagnostic procedure during surgery in which dye is injected into the cystic duct to visualize the anatomy of the gallbladder and bile ducts.			Diagnostic Procedure	CPTAC Codelists Terminology|CPTAC Procedures Codelist|CPTAC Terminology
C157891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157891>	C16546	Intraoperative Endoscopy	The use of an endoscope during a surgical procedure to either diagnose or treat a disorder.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157892>	C38045	Intrathecal Catheter Placement	Placement of a catheter into the intrathecal space of the spine.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157893>	C49165	Intrathecal Programmable Pump Placement	Placement of a pump device that delivers medication into the intrathecal space of the spine.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157894>	C38275	Intravenous Lidocaine Infusion	Continuous intravenous administration of a solution with lidocaine.			Functional Concept	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157895>	C157938	Iodine Deficiency	A deficiency of iodine in the diet.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157896>	C38033	Knee Arthroscopy	Visualization of the knee joint with an arthroscope.			Diagnostic Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157897>	C51691|C131579	Arthroplasty of the Knee|Arthroplasty Knee|Knee Replacement	Surgical reconstruction or replacement of all or part of a damaged knee joint with an artificial joint or artificial components.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Procedures Codelist|CPTAC Terminology|CPTAC Treatments Codelist
C157898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157898>	C15257	Kock Pouch Ileostomy Procedure|Kock Pouch Ileostomy	The creation of an internal ileal pouch that is connected to an abdominal stoma with a valve to prevent leakage.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157899>	C84399	Lap Band Surgery	A laparoscopic procedure in which a band is placed around the stomach to decrease the size of the stomach, which contributes to a fuller feeling and assists with losing weight.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C15789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15789>	C15787	Clinical Trials, Monitoring	For clinical decision-making, the purposeful and ongoing acquisition, interpretation, and synthesis of patient data obtained from clinical trials.			Governmental or Regulatory Activity	
C1578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1578>	C28227|C155711	Bispecific Antibody MDX-H210|520C9x22 Bispecific Antibody|520C9xH22 Bispecific Antibody|Antibody, Bispecific 520C9xH22|Bispecific Antibody 520C9 x H22|Bispecific Antibody MDXH210|BsAb 520C9x22|BsAb 520C9xH22|MDX-210|MDX-H210	A humanized bivalent antibody directed against both cytotoxic effector cells expressing Fc gamma receptor type I (Fc gammaRI, or CD64) and HER2/neu-overexpressing tumor cells with potential antineoplastic activity. Bispecific antibody MDX-H210 was constructed by chemically linking Fab' fragments of the anti-HER2/neu-specific monoclonal antibody 520C9 and the Fab' fragments of the anti-Fc gammaRI-specific monoclonal antibody H22. This agent selectively binds to both HER2/neu-expressing tumor cells and Fc gammaRI-expressing cytotoxic effector cells, which may trigger antibody-dependent cell-mediated cytotoxicity (ADCC) and cell lysis of HER2/neu-expressing tumor cells. While HER2/neu is overexpressed in a variety of epithelial malignancies, expression of Fc gammaRI is primarily found in cytotoxic immune cells, including monocytes, macrophages, and cytokine-activated polymorphonuclear (PMN) cells.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C157900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157900>	C91834	Laparoscopic Nissen Fundoplication	A surgical procedure in which a portion of the upper stomach is wrapped around the lower esophageal sphincter to reinforce it and prevent reflux.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157901>	C157741	Laser Resurfacing	The use of a laser that vaporizes layers of skin to resurface it and remove imperfections and make it smoother.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157902>	C157741	Laser Tattoo Removal	The use of a laser to break apart the ink in a tattoo, which is then reabsorbed and the tattoo dissolves.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157903>	C15466	Laser Vein Treatment	The use of a laser beam to destroy a vein, which is done either externally or internally when a laser catheter is passed into the vein.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157904>	C15466	Laser Vision Correction	The use of a laser to change the shape of the cornea to improve vision.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157905>	C49803	Left Atrial Appendage Closure	Blocking the flow of blood from the appendage in the left atrium to reduce the risk of clots entering the bloodstream.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157906>	C49803	Left Ventricular Remodeling	A change in the function, shape or size of the left ventricle, which can be either physiological or pathological. A decline in performance is the result.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157907>	C84399	LINX Procedure|LINX	A laparoscopic procedure that implants a ring of magnetic core titanium beads at the lower esophageal sphincter to stop acid and food regurgitation into the esophagus.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157908>	C157741	Liposuction	The removal of excess fat deposits from the body.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157909>	C15843	Liver Disease Prevention	Steps towards preventing damage to the liver which can include vaccinations against hepatitis A and B, healthy diet, regular exercise, moderate alcohol intake, proper use of medications and avoiding contact with other's blood and body fluids.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C15790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15790>	C49657|C208218	Cancer Prevention Trial|Clinical Trials, Prevention	Clinical trials that study ways of reducing the risk of getting cancer.			Research Activity	
C157910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157910>	C15222	Low FODMAP Diet	A diet that restricts the consumption of fermentable oligo-, di-, mono-saccharides and polyols, which are short chain carbohydrates that are poorly absorbed in the small intestine.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157911>	C15330	Lower Gastrointestinal Therapeutic Surgical Procedure|Lower GI Therapeutic Surgical Procedures|OR Lower GI Therapeutic Procedures	Any surgical treatments on the bowel, which includes the duodenum, jejunum and the ileum.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Procedures Codelist|CPTAC Terminology
C157912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157912>	C157740|C15655	Lung Cancer Surgery|Surgery for Lung Cancer	Surgery to minimize or eliminate a neoplastic process in the lungs.			Health Care Activity	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157913>	C15655	Lung Volume Reduction Surgery	Surgery to remove diseased lung tissue, which is often emphysematous. This reduces the size of the lung, and allows expansion of more healthy lung tissue.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157914>	C49236	Lymphatic System Therapeutic Procedure|Therapeutic Procedures Lymphatic System	Treatment targeted at the lymphatic system, often to reduce excess lymph fluid that can be caused by injury, cancer treatments, infection or a birth defect.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Procedures Codelist|CPTAC Terminology
C157915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157915>	C64385	MammoSite Brachytherapy|Breast Balloon Brachytherapy|Breast Brachytherapy|MammoSite	A method for brachytherapy that uses an implanted catheter to deliver a radioactive seed into the breast site. During a lumpectomy procedure a catheter with a balloon tip is temporarily implanted into the site where the tumor was removed. After surgery a radioactive seed is fed through the catheter to the tumor site.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157916>	C26791	Maternal Hemorrhage	Uncontrolled bleeding from a pregnant or a woman who has recently given birth.			Finding	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157917>	C3364	Maternal Sepsis	A pathologic response to infection in a mother or pregnant woman.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157918>	C15454	Maximandibular Advancement Surgery|Maxillomandibular Advancement	Surgery to reposition the bones of the upper and lower jaw to relieve airway obstruction.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157919>	C157740	Mediastinal Mass Surgery|Surgery for Mediastinal Masses	Surgery on a mass located on the mediastinum.			Health Care Activity	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C15791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15791>	C15336	Clinical Testing	Small-scale testing (usually on SBIRs) of new technology in a small group of patients or normal volunteers. Does not meet the rigorous criteria of a clinical trial.			Health Care Activity	
C157920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157920>	C157740	Melanoma Surgery|Surgery for Melanoma	Surgery to remove or treat a melanoma.			Health Care Activity	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157921>	C157740	Meningioma Surgery|Surgery for Meningioma	Surgery to remove or treat a meningioma.			Health Care Activity	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157922>	C49803|C172727	Minimally Invasive Heart Surgery	Surgical procedures on the heart that are performed through small incisions in the chest, sometimes with a robot assistant.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157923>	C172727|C131579	Minimally Invasive Joint Replacement Surgery	Surgery to replace a joint that is performed that use smaller incisions and less cutting than a traditional surgery for replacement.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157924>	C28208	Mohs Surgery for Melanoma	Surgical removal of a melanoma in which the skin is removed one layer at a time followed by microscopic evaluation for cancer cells. Successive layers are removed whenever cancer cells are found in the previous layer.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157925>	C28208	Mohs Surgery for Non-Melanoma	Surgical removal of non-melanoma cancer in which the skin is removed one layer at a time followed by microscopic evaluation for cancer cells. Successive layers are removed whenever cancer cells are found in the previous layer.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157926>	C15979	MR Guided Focused Ultrasound	The use of magnetic resonance to guide and control the delivery of energy to destroy a target and not damage surrounding tissue.			Health Care Activity	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157927>	C157740	Multiple Myeloma Surgery|Surgery for Multiple Myeloma	Surgical procedures to treat the complications of multiple myeloma. It can be performed to strengthen and stabilize bones.			Health Care Activity	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157928>	C15315	Multiple Sclerosis Rehabilitation	Treatment programs that use strategies to maintain function, participation and quality of life for individuals with multiple sclerosis.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157929>	C15315	Musculoskeletal Rehabilitation	Treatment programs that use strategies to maintain function, participation and quality of life for individuals with musculoskeletal disorders.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C15792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15792>	C19335	Transplantation and Immune System|Clinical, Transplantation, Immune System	The interaction of a recipient's (patient's) immune system with an organ or tissue graft, or with the reactivity of donor-derived passenger leukocytes in the graft with the host's (patient's) body. (NCI/OSP)			Conceptual Entity	
C157930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157930>	C157740	Non-Melanoma Surgery|Surgery for Non-Melanoma	Surgical procedures for non-melanoma cancers which involve removing the cancer, repairing the site, possibly removing the lymph nodes and reducing of pain.			Health Care Activity	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157931>	C15454	Nasal Surgery	Surgery on the nose or nasal passages.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157932>	C50818	Natural Heart Valve Repair	Heart valve repair that use techniques that preserve as much of the natural heart valve structure as possible.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157933>	C25351	Neobladder Reconstruction	The construction of a new bladder with intestinal tissue.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157934>	C15315	Neurological Rehabilitation	Treatment programs that use strategies to maintain function, participation and quality of life for individuals with neurological disorders.	Neurological Rehabilitation		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology
C157935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157935>	C53547	Non-Communicable Disorder	A disorder that is not transmissible from one person to another.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157936>	C3138	Non-infective Inflammatory Bowel Disease	A disease of the intestines that is inflammatory but not infectious.			Qualitative Concept	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157937>	C3390	Non-ischemic Stroke	Any stroke that is not related to an obstructed blood vessel.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157938>	C26836	Nutritional Deficiency	A deficiency of a necessary nutrient.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157939>	C118419	Obstructed Labor	A physical barrier to the natural delivery of a baby.			Finding	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C15793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15793>	C49235	Conduct Clinical Trials	Conduct clinical trials and develop new trial methodologies. Trials should be designed in order to rapidly develop new therapeutic strategies, optimize clinical efficacy and proper use of available modalities, define factors that affect the success of therapeutic strategies (including the role of resistance), and advance our understanding of disease pathogenesis and progression.			Activity	
C157940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157940>	C21072	Occipital Nerve Block	The injection of medications near the greater and lesser occipital nerves to decrease pain due to migraines, spondylosis or nerve damage.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157941>	C39766	Oculoplastic Surgery	Surgery to the orbit, eyelids, tear ducts and face.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157942>	C16522	Opioid Use Disorder	The use of opioids that results in the development of a dependency that adversely affects an individual's life.			Individual Behavior	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157943>	C49236	Oral Appliance Therapy|Oral Appliances	The use of custom fitted oral devices to treat snoring, obstructive sleep apnea or nocturnal grinding of teeth.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157944>	C157740|C15332	Ovarian Cancer Surgery|Surgery for Ovarian Cancer	A surgical procedure to remove cancer from the ovaries.			Health Care Activity	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157945>	C99998	Pacemaker or ICD Lead Extraction	The removal of a pacemaker or implantable cardioverter defibrillator lead.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157946>	C17174	Palate Surgery	A surgical procedure to treat disorders of the palate.			Biomedical Occupation or Discipline	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157947>	C52011	Parathyroid Surgery	A surgical procedure to treat disorders of the parathyroid gland.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157948>	C99939	Patent Foramen Ovale Closure|PFO Closure	Repair of a hole in the foramen ovale.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157949>	C3671	Pedestrian Injury By Road Vehicle	An injury to a pedestrian sustained by a vehicle that travels on the road.			Finding	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C15794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15794>	C20165	Cancer Therapy Evaluation Program|CTEP	The program within the Division of Cancer Treatment and Diagnosis (DCTD) of the NCI which plans, assesses, and coordinates all aspects of clinical trials including extramural clinical research programs, internal resources, treatment methods and effectiveness, and compilation and exchange of data as it pertains to the development and evaluation of anticancer agents.			Health Care Related Organization	
C157950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157950>	C15315	Penile Rehabilitation	Treatment programs that use strategies to maintain function, participation and quality of life for individuals with penile disorders.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157951>	C52003	Percutaneous Thrombectomy	The insertion of a catheter that use x-ray guidance to remove a blood clot.	Percutaneous Thrombectomy		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology
C157952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157952>	C217465	Percutaneous Transluminal Angioplasty of the Femoral Artery	The insertion of a catheter that use x-ray guidance to repair an abnormality in the femoral artery.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157953>	C21072	Peripheral Nerve Block	The injection of medications near peripheral nerves to decrease pain and inflammation.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157954>	C15232	Peritoneal Adhesion Excision|Excision Peritoneal Adhesions	A surgical procedure to remove peritoneal adhesions.			Health Care Activity	CPTAC Codelists Terminology|CPTAC Procedures Codelist|CPTAC Terminology
C157955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157955>	C15330	Peroral Endoscopic Myotomy|POEM	Surgical incisions made in the esophagus via an endoscopic procedure.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157956>	C15302	Physical Therapy for Orthopedics and Sports Medicine|Physical Therapy for Orthopaedics and Sports Medicine	Physical therapy for injuries seen in the orthopedics and sports medicine departments.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157957>	C157740	Pituitary Tumor Surgery|Surgery for Pituitary Tumors	A surgical procedure to remove cancer from the pituitary gland.			Health Care Activity	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157958>	C118298	Pneumococcal Meningitis	Meningitis that is attributed to the bacteria Streptococcus pneumonia.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157959>	C26704	Pneumococcal Pneumonia	Pneumonia that is attributed to the bacteria Streptococcus pneumonia.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C15795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15795>	C15776	Detection of Measurable Residual Disease|Detection of Minimal Residual Disease	The discovery of a tumor or cancer after primary, potentially curative therapy.			Diagnostic Procedure	
C157960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157960>	C49236	Positive Airway Pressure Therapies|PAP Therapies|PAP Therapy|POSITIVE AIRWAY PRESSURE VENTILATION|Positive Airway Pressure Therapy|Positive Airway Pressure Ventilation|Positive pressure ventilation	A set of therapies that use a stream of compressed air to support the airway during sleep.			Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157961>	C34941	Preterm Birth Complication	A complication related to a premature birth that occurs to a baby born prior to 37 weeks gestation.			Finding	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157962>	C157740	Prostate Cancer Surgery|Surgery for Prostate Cancer	A surgical procedure to remove cancer from the prostate.			Health Care Activity	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157963>	C142985	Pulmonary Autograft|Ross Procedure	A surgical procedure in which the diseased portion of the aortic valve is replaced with the pulmonary valve and the pulmonary valve is replaced by a cadaver valve.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157964>	C52001	Pulmonary Embolectomy	The removal of a blockage in an artery of the lungs.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157965>	C94461	Pulmonary Metastasectomy	Removal of metastatic tumors from the lungs.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157966>	C15315	Pulmonary Rehabilitation	Treatment programs that use strategies to maintain function, participation and quality of life for individuals with pulmonary disorders.	Pulmonary Rehabilitation		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology
C157967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157967>	C15301	Pulsed Light Rejuvenation	A broad spectrum light that heats and destroys unwanted cells on the skin.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157968>	C15470	Radioactive Iodine Therapy	The use of radioactive iodine to treat disease.	Radioactive Iodine Therapy		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C157969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157969>	C39766	Reconstructive Plastic Surgery	A surgical procedure to reconstruct a damaged or deformed part of the body to improve function or aesthetics.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C15796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15796>	C27993	Developmental Diagnostic	Refers to diagnostic methods for evaluating developmental problems.			Conceptual Entity	
C157970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157970>	C209812|C15333	Reproductive Surgery	A surgical procedure in the field of reproductive medicine.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157971>	C3354|C3333	Respiratory Syncytial Virus Pneumonia	Pneumonia that is attributed to the respiratory syncytial virus.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157972>	C3671	Road Injury	An injury that occurs on a road or motor way.			Finding	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157973>	C3439	Rotaviral Enteritis	Enteritis attributed to the rotavirus.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157974>	C2890	Salmonellosis	An intestinal bacterial disease caused by Salmonella bacteria.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157975>	C157740	Sarcoma Surgery|Surgery for Sarcoma	A surgical procedure to remove sarcoma or repair adjacent areas.			Health Care Activity	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157976>	C49236	Scoliosis and Kyphosis Deformity Correction	The correction of a scoliosis or kyphosis deformity of the spine.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157977>	C34463	Sexually Transmitted Chlamydial Disease	A chlamydial infection that was sexually transmitted.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157978>	C2890	Shigellosis	An intestinal disease cause by Shigella bacteria.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157979>	C38033	Shoulder Arthroscopy	A visualization of the shoulder joint via an arthroscope.			Diagnostic Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157980>	C131579	Shoulder Replacement Surgery	A surgical procedure to replace the shoulder joint.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157981>	C121366	Shoulder Steroid Injections	A subacromial injection of a steroid to reduce pain or inflammation.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157982>	C121367	Shoulder/Knee Corticosteroid Therapy|Shoulder/Knee Corticosteroid	An injection of a steroid into the shoulder and/or knee to reduce pain or inflammation.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157983>	C51559	Skin Lesion Surgery	A surgical procedure to remove a skin lesion and a margin around the area.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157984>	C15656	Skull Base Surgery	A surgical procedure to treat a disorder or remove a cancer at the base of the skull.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157985>	C15342	Small Bowel Transplantation	Replacing diseased bowel with healthy bowel tissue.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157986>	C52008	Spinal Fusion|Spinal fusion	Fusing two or more vertebrae into one.			Therapeutic or Preventive Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|CPTAC Codelists Terminology|CPTAC Procedures Codelist|CPTAC Terminology
C157987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157987>	C52008	Stabilize Extremity Dislocation|Treatment Dislocation of Lower Extremities	Immobilization of a dislocated extremity.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Procedures Codelist|CPTAC Terminology
C157988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157988>	C52008	Stabilize Femur Fracture|Treatment Femur Fracture	Immobilization of a broken femur.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Procedures Codelist|CPTAC Terminology
C157989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157989>	C52008	Stabilize Hip Fracture|Treatment Hip Fracture	Immobilization of a broken hip.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Procedures Codelist|CPTAC Terminology
C15798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15798>	C15715	Diagnostics Research	Studies that are designed to identify a disease, condition, or injury or to develop and test interventions that are designed to identify a disease, condition, or injury.			Research Activity	
C157990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157990>	C52008	Stabilize Lower Extremity Fracture|Treatment Fracture of Lower Extremity	Immobilization of a dislocated lower extremity.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Procedures Codelist|CPTAC Terminology
C157991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157991>	C118286	Stereotactic Ablative Radiotherapy|SABER|SABR/SBRT	A highly focused radiation therapy which delivers an intense dose of radiation to a tumor.	Stereotactic Ablative Radiotherapy		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology
C157992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157992>	C25351	Stretta Procedure|Esophagus Reconstruction (Stretta Procedure)	An endoscopic procedure that delivers electromagnetic waves through the end of a catheter to the lower esophageal sphincter and the gastric cardia.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157993>	C64982	Strictureplasty	Repair of a narrowing in a tubular portion of an organ.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157994>	C15315	Stroke Rehabilitation	Treatment programs that use strategies to maintain function, participation and quality of life for individuals who have had a stroke.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157995>	C3371	Subcutaneous Disorder	A disorder of the subcutaneous tissue.			Disease or Syndrome	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C157996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157996>	C157725	Subfascial Endoscopic Perforator Surgery	A minimally invasive procedure to treat chronic venous ulcers by ligating abnormal perforator veins under the muscle fascia in the legs.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157997>	C64982	Surgery to Improve Sleep|Sleep Surgery	A surgical procedure to improve breathing during sleep, which improves overall health.			Health Care Activity	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157998>	C93352	Targeted Therapy for Melanoma	Therapy directed at the precise type of melanoma an individual has based on the results of genetic profiling.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C157999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157999>	C15331	Tear Duct Surgery	A surgical procedure on the tear ducts of the eye.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C15799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15799>	C49652	Cancer Diagnostic Study|Diagnostics, Cancer	Studies to develop and test interventions that are designed to identify a neoplastic disease.			Research Activity	
C1579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1579>	C2088	Eflornithine Hydrochloride|2-(Difluoromethyl)-dl-ornithine Hydrochloride, Monohydrate|2-Difluoromethyl-dl-ornithine, Monohydrochloride, Monohydrate|EFLORNITHINE HYDROCHLORIDE|Eflornithine hydrochloride|Eflornithine.HCl|Iwilfin|MDL 71782|MDL-71782|MDL71782|Ornidyl|RMI 71782|RMI-71782|RMI71782|Vaniqa|alpha-Difluoromethylornithine hydrochloride	The hydrochloride form of eflornithine, a difluoromethylated ornithine compound with antineoplastic activity.  Eflornithine irreversibly inhibits ornithine decarboxylase, an enzyme required for polyamine biosynthesis, thereby inhibiting the formation and proliferation of tumor cells. Polyamines are involved in nucleosome oligomerization and DNA conformation, creating a chromatin environment that stimulates neoplastic transformation of cells. (NCI04)	Eflornithine Hydrochloride		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158000>	C38045|C15642	Temporary Epidural Catheter Placement	The temporary placement of a catheter into the epidural space to deliver medications.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C158001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158001>	C15687	Therapeutic Breast Surgery|OR Therapeutic Procedures on Breast	A surgical procedure to remove treat disorders of the breast.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Procedures Codelist|CPTAC Terminology
C158002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158002>	C49236	Therapeutic Mouth Procedure|Therapeutic Procedures on Mouth	A procedure that is done to treat a condition in the mouth.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Procedures Codelist|CPTAC Terminology
C158003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158003>	C49236	Therapeutic Muscle Procedure|Therapeutic Procedures on Muscle	A procedure that is done to treat a condition in the muscle.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Procedures Codelist|CPTAC Terminology
C158004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158004>	C49236	Therapeutic Nervous System Procedures	A procedure that is done to treat a nervous system disorder.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Procedures Codelist|CPTAC Terminology
C158005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158005>	C49236	Therapeutic Nose Procedure|Therapeutic Procedures on Nose	A procedure that is done to treat a condition in the nose.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Procedures Codelist|CPTAC Terminology
C158006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158006>	C49236	Therapeutic Pharynx Procedure|Therapeutic Procedures on Pharynx	A procedure that is done to treat a condition in the pharynx.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Procedures Codelist|CPTAC Terminology
C158007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158007>	C52008	Therapeutic Procedures on Bone	A procedure that is done to treat a condition in the bones.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Procedures Codelist|CPTAC Terminology
C158008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158008>	C121969	Therapeutic Skin Surgery|OR Therapeutic Procedures on Skin	A surgical procedure to remove treat disorders of the skin.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Procedures Codelist|CPTAC Terminology
C158009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158009>	C49236	Therapeutic Tendon Procedure|Therapeutic Procedures on Tendon	A procedure that is done to treat a condition in the tendons.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Procedures Codelist|CPTAC Terminology
C15800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15800>	C15760	Drug Development, Clinical|Drug Testing/Development, Clinical	Drug development activites focused on clinical trials and testing.			Research Activity	
C158010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158010>	C49236	Therapeutic Upper Gastrointestinal Procedures|Upper GI Therapeutic Procedure	A procedure that is done to treat a condition in upper gastrointestinal tract.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Procedures Codelist|CPTAC Terminology
C158011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158011>	C80430|C49803	Thoracic Aortic Aneurysm Open Repair	A surgical procedure to treat a thoracic aortic aneurysm via the traditional open incision method.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C158012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158012>	C157740	Thyroid Cancer Surgery|Surgery for Thyroid Cancer	A surgical procedure to remove cancer from the thyroid.			Health Care Activity	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C158013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158013>	C15454	Tongue Surgery	A surgical procedure to treat disorders or abnormalities of the tongue.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C158014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158014>	C15914	Topical Medications for Melanoma	Medications that are applied to the skin for melanoma.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C158015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158015>	C15914	Topical Medications for Non-Melanoma	Medications that are applied to the skin for non-melanoma lesions.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C158016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158016>	C131579	Total Disc Replacement	A surgical procedure to replace a vertebral disc.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C158017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158017>	C157980	Total Shoulder Replacement	Surgical replacement of the shoulder joint with a metal ball attached to a stem and a plastic socket.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C158018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158018>	C50815	Transcatheter Aortic Valve Replacement	A minimally invasive procedure in which a replacement aortic valve is guided into proper placement in the aortic valve via a catheter.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C158019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158019>	C50818	Transcatheter Mitral Valve Repair	A minimally invasive procedure in which a replacement mitral valve is guided into proper placement in the mitral valve via a catheter.	Transcatheter Mitral Valve Repair		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology
C15801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15801>	C15760	Drug Development, Preclinical|Drug Testing/Development, Preclinical	Drug development activites focused on preclinical trials and testing.			Research Activity	
C158020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158020>	C119202	Transmyocardial Revascularization	The use of a laser to create channels directly into the heart muscle to encourage vascularization and treat severe coronary artery disease in those individuals who are not considered good candidates for standard bypass surgery.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C158021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158021>	C91834	Transoral Incisionless Fundoplication	The use of an endoscope passed orally into the esophagus to repair or recreate a more functional barrier to esophageal reflux			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C158022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158022>	C3671	Transport Injury	An injury to an individual during transport between or to/from departments or facilities.			Finding	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C158023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158023>	C119202	Transthoracic Myocardial Laser Revascularization	The use of a laser to create channels directly into the heart muscle to encourage vascularization and treat severe coronary artery disease in those individuals considered good candidates for standard bypass surgery.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C158024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158024>	C157741	Tummy Tuck	A surgical procedure to remove excess skin and fat from the abdomen.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C158025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158025>	C20985	Tumor Ablation Therapy|Tumor Ablation Therapies	A minimally invasive surgical procedure to treat a solid cancer that uses a probe in conjunction with radiology guidance to burn a tumor.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C158026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158026>	C15752	Uterine Fibroid Embolization	A minimally invasive surgical procedure in which a catheter is inserted into the femoral artery and guided during fluoroscopy to the blood supply of uterine fibroids. An embolic substance is injected into the arteries to block the blood supply of the fibroids.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C158027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158027>	C157742	Valvotomy	A surgical procedure in which an incision is made in a valve to relieve stenosis.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C158028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158028>	C124351	Vascular Study|Vascular Studies	A test that checks the blood flow in arteries and veins.			Health Care Activity	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C158029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158029>	C15333	Vasectomy Reversal Procedure|Vasectomy Reversal	A surgical procedure to reattach a previously cut vas deferens.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C15802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15802>	C15760	Drug Discovery	Strategies and technologies for finding new active natural, synthetic or semi-synthetic ingredients, including endogenous body substances, to be used as therapeutic interventions.			Research Activity	
C158030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158030>	C49803	Vena Cava Filter Surgery|Vena Cava Filter	A surgical procedure to insert, repair or remove an inferior vena cava filter.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C158031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158031>	C3671	Venomous Animal Contact	Contact with a venomous animal.			Finding	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C158032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158032>	C3888|C38151	Kidney Epithelioid Angiomyolipoma|Epithelioid Angiomyolipoma/Epithelioid PEComa of the Kidney|Kidney EAML|Kidney Epithelioid Type Angiomyolipoma|Perivascular Epithelioid Cell Tumor of the Kidney|Renal Epithelioid Angiomyolipoma	An angiomyolipoma that arises from the kidney and is composed exclusively or predominantly of epithelioid cells. It is often associated with cytologic atypia and may recur or metastasize.			Neoplastic Process	
C158033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158033>	C65070|C63587|C63360|C210232	Cisplatin/Paclitaxel/Pembrolizumab Regimen|Cisplatin, Paclitaxel, Pembrolizumab|Cisplatin-Paclitaxel-Pembrolizumab|Cisplatin-Paclitaxel-Pembrolizumab Regimen|Cisplatin/Paclitaxel/Pembrolizumab	A regimen consisting of cisplatin, paclitaxel, and pembrolizumab that can be used in the treatment of cervical, head and neck, vaginal and metastatic squamous non-small cell lung cancer (NSCLC).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C158034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158034>	C158520	CPTAC Causes of Death Codelist	Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on causes of death.			Intellectual Product	
C158035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158035>	C158520	CPTAC Medical Conditions Codelist	Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on medical conditions.			Intellectual Product	
C158036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158036>	C158520	CPTAC Procedures Codelist	Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on medical procedures.			Intellectual Product	
C158037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158037>	C158520	CPTAC Treatments Codelist	Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on medical treatments.			Intellectual Product	
C158038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158038>	C126298	4/8 HLA Match|HLA Match 4/8|Match 4/8	Degree of HLA match is 4/8 alleles with fewer than 2 mismatches per locus at HLA-A, -B, -C and -DRB1.			Classification	
C158039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158039>	C126298	5/8 HLA Match|HLA Match 5/8|Match 5/8	Degree of HLA match is 5/8 alleles with fewer than 2 mismatches per locus at HLA-A, -B, -C and -DRB1.			Classification	
C15803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15803>	C213308	Drug Discovery Groups	Self-identified projects in the Biochemistry and Pharmacology Cancer Activity.			Occupational Activity	
C158040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158040>	C126298	6/8 HLA Match|HLA Match 6/8|Match 6/8	Degree of HLA match is 6/8 alleles with fewer than 2 mismatches per locus at HLA-A, -B, -C and -DRB1.			Classification	
C158041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158041>	C126298	7/8 HLA Match|HLA Match 7/8|Match 7/8	Degree of HLA Match is 7/8 alleles with a single HLA locus mismatch at HLA-A, -B, -C or DRB1.			Classification	
C158042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158042>	C129972	8/8 HLA Match|HLA Match 8/8|Match 8/8	Complete HLA matching for HLA-A, -B, -C, and -DRB1 loci.			Classification	
C158044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158044>	C216199	Lutetium Lu 177 DOTA-N3-CTT1403|177Lu-DOTA-N3-CTT1403|177Lu-DOTA-azide-CTT1403|Lutetium Lu 177 DOTA-azide-CTT1403	A radioconjucate consisting of CTT1403, a phosphoramidate-based irreversible inhibitor of human prostate-specific membrane antigen with an albumin binding moiety, connected via click chemistry to lutetium Lu 177-dodecanetetraacetic acid-azide (177Lu-DOTA-N3), with potential antineoplastic activity. Upon administration, lutetium Lu 177-DOTA-N3-CTT1403 targets and binds to PSMA expressed on tumor cells via its CTT1403 moiety, and upon internalization, delivers cytotoxic beta radiation directly to PSMA-expressing tumor cells. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on most prostate tumor cells. The albumin binding motif extends circulation half-life thereby improving tumor cell uptake of the radioconjugate.	Lutetium Lu 177 DOTA-N3-CTT1403		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158045>	C177686|C150123	NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor|MPNST with NF1 Mutation|MPNST with Neurofibromin 1 Mutation|Malignant Peripheral Nerve Sheath Tumor with NF1 Mutation|Malignant Peripheral Nerve Sheath Tumor with Neurofibromin 1 Mutation|NF1 mutant MPNST	A finding indicating the presence of a NF1 mutation in a sample from a patient with malignant peripheral nerve sheath tumor.	NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor		Laboratory or Test Result	CTRP Disease Terminology|CTRP Terminology
C158046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158046>	C3150	Kidney Mixed Epithelial and Stromal Tumor Family|MEST Family	A family of tumors ranging from predominantly cystic tumors (adult cystic nephromas) to tumors that are variably solid (mixed epithelial and stromal tumors) and contain biphasic epithelial and stromal components with spindle stroma, glands, and cysts. Most of these tumors are benign. (WHO 2016).			Neoplastic Process	
C158047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158047>	C118425	Insect Glycan|INSECT TYPE GLYCAN	An oligosaccharide protein modification that is synthesized by insect cells.			Organic Chemical	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C158048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158048>	C118425	Reptilian Glycan|REPTILIAN TYPE GLYCAN	An oligosaccharide protein modification that is synthesized by reptilian cells.			Organic Chemical	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C158049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158049>	C118431	Mammalian Afucosylated Glycan|MAMMALIAN AFUCOSYLATED GLYCAN	A fucose-free oligosaccharide protein modification that is synthesized by mammalian cells.			Organic Chemical	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C15804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15804>	C16048	EPS Library|EPS Library (DCPC Plus DCEG)	Library located at Executive Plaza South.			Physical Object	
C158050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158050>	C118425	Molluscan Glycan|MOLLUSCAN TYPE GLYCAN	An oligosaccharide protein modification that is synthesized by molluscan cells.			Organic Chemical	FDA Structured Product Labeling Terminology|SPL Substance Indexing Terminology
C158051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158051>	C157142	PKLR NM_000298.5:c.1436G>A|NM_000298.5:c.1436G>A|PK1 c.1436G>A|PKL c.1436G>A|PKLR c.1436G>A|PKR c.1436G>A|PKRL c.1436G>A|Pyruvate Kinase L/R Gene c.1436G>A|Pyruvate Kinase, Liver and RBC Gene c.1436G>A|RPK c.1436G>A	A nucleotide substitution at position 1436 of the coding sequence of the PKLR gene where guanine has been mutated to adenine.	PKLR NM_000298.5:c.1436G>A		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158052>	C97928	PKLR Protein Variant|Pyruvate Kinase 1 Protein Variant|Pyruvate Kinase Isozyme R/L Protein Variant|Pyruvate Kinase Isozymes L/R Protein Variant|Pyruvate Kinase Isozymes R/L Protein Variant|Pyruvate Kinase L/R Protein Variant|Pyruvate Kinase PKLR Protein Variant|R-Type/L-Type Pyruvate Kinase Protein Variant|Red Cell/Liver Pyruvate Kinase Protein Variant	A variation in the amino acid sequence for pyruvate kinase PKLR protein.	PKLR Protein Variant		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158053>	C158052	PKLR NP_000289.1:p.R479H|NP_000289.1:p.Arg479His|NP_000289.1:p.R479H|PKLR Arg479His|PKLR NP_000289.1:p.Arg479His|PKLR R479H|PKLR R479H Mutation|PKLR p.Arg479His|PKLR p.R479H|Pyruvate Kinase 1 Arg479His|Pyruvate Kinase 1 R479H|Pyruvate Kinase Isozyme R/L Arg479His|Pyruvate Kinase Isozyme R/L R479H|Pyruvate Kinase Isozymes L/R Arg479His|Pyruvate Kinase Isozymes L/R R479H|Pyruvate Kinase Isozymes R/L Arg479His|Pyruvate Kinase Isozymes R/L R479H|Pyruvate Kinase L/R Arg479His|Pyruvate Kinase L/R R479H|Pyruvate Kinase PKLR Arg479His|Pyruvate Kinase PKLR R479H|R-Type/L-Type Pyruvate Kinase Arg479His|R-Type/L-Type Pyruvate Kinase R479H|Red Cell/Liver Pyruvate Kinase Arg479His|Red Cell/Liver Pyruvate Kinase R479H	A change in the amino acid residue at position 479 in the pyruvate kinase PKLR protein where arginine has been replaced by histidine.	PKLR NP_000289.1:p.R479H		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158054>	C97927|C150437	NTRK2 Gene Mutation|NTRK2 Mutation|Neurotrophic Tyrosine Kinase Receptor 2 Gene Mutation|Neurotrophic Tyrosine Kinase Receptor Type 2 Gene Mutation|TRKB Gene Mutation|TRKB Tyrosine Kinase Gene Mutation|Tropomyosin-Related Kinase B Gene Mutation	A change in the nucleotide sequence of the NTRK2 gene.	NTRK2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158055>	C97927|C150437	NTRK3 Gene Mutation|NTRK3 Mutation|Neurotrophic Tyrosine Kinase Receptor 3 Gene Mutation|Neurotrophic Tyrosine Kinase Receptor Type 3 Gene Mutation|Neurotrophic Tyrosine Kinase, Receptor, Type 3 Gene Mutation|TRKC Gene Mutation	A change in the nucleotide sequence of the NTRK3 gene.	NTRK3 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158056>	C142111	Neoplastic Plasma Cells 20 Percent or More of Peripheral Blood White Cells|Neoplastic Plasma Cells Greater than or Equal to 20 Percent of Peripheral Blood White Cells	A semi-quantitative microscopic finding indicating that at least 20 percent of the nucleated cells in a peripheral leukocyte sample are neoplastic plasma cells.	Neoplastic Plasma Cells 20 Percent or More of Peripheral Blood White Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C158057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158057>	C97927|C136644	NOTCH3 Gene Mutation|CADASIL Gene Mutation|CASIL Gene Mutation|IMF2 Gene Mutation|Notch (Drosophila) Homolog 3 Gene Mutation|Notch 3 Gene Mutation|Notch Homolog 3 Gene Mutation	A change in the nucleotide sequence of the NOTCH3 gene.	NOTCH3 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158058>	C178120|C158057	Activating NOTCH3 Mutation|Activating CADASIL Gene Mutation|Activating CASIL Gene Mutation|Activating IMF2 Gene Mutation|Activating NOTCH3 Gene Mutation|Activating Notch (Drosophila) Homolog 3 Gene Mutation|Activating Notch 3 Gene Mutation|Activating Notch Homolog 3 Gene Mutation|NOTCH3 Activating Gene Mutation|NOTCH3 Activating Mutation	A change in the nucleotide sequence of the NOTCH3 gene that results in constitutive activation of both neurogenic locus notch homolog protein 3 and its downstream signaling pathways.	Activating NOTCH3 Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158059>	C178120|C148389	Activating NOTCH2 Mutation|Activating AGS2 Gene Mutation|Activating HJCYS Gene Mutation|Activating NOTCH2 Gene Mutation|Activating Notch (Drosophila) Homolog 2 Gene Mutation|Activating Notch 2 Gene Mutation|Activating Notch Homolog 2 Gene Mutation|Activating hN2 Gene Mutation|NOTCH2 Activating Gene Mutation|NOTCH2 Activating Mutation	A change in the nucleotide sequence of the NOTCH2 gene that results in constitutive activation of both neurogenic locus notch homolog protein 2 and its downstream signaling pathways.	Activating NOTCH2 Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15805>	C15820	Experimental Nutrition Research	A scientific study that uses controlled experiments to examine the effect of dietary patterns, foods, nutrients or other dietary components on the health of an organism.			Research Activity	
C158060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158060>	C155711	Trastuzumab/Hyaluronidase-oysk|Herceptin Hylecta|Trastuzumab and Hyaluronidase|Trastuzumab and Hyaluronidase-oysk|Trastuzumab and Recombinant Human Hyaluronidase PH20|Trastuzumab and hyaluronidase|Trastuzumab and rHuPH20|Trastuzumab-Hyaluronidase-oysk	A ready-to-use combination of trastuzumab, a recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2; receptor tyrosine-protein kinase erbB-2), and hyaluronidase-oysk, a recombinant human hyaluronidase PH20 (rHuPH20), that may be used for the treatment of HER2-overexpressing breast cancers. Upon subcutaneous administration, hyaluronidase-oysk temporarily breaks down the hyaluronan barrier, which decreases viscosity of, and allows trastuzumab to spread rapidly through the interstitial space. This improves access to lymphatic and capillary vessels and facilitates the absorption of trastuzumab into the bloodstream. Trastuzumab binds to the extracellular ligand-binding domain of HER2 and mediates the activation of an antibody-dependent cell-mediated cytotoxicity (ADCC) against HER2-expressing tumor cells. HER2 is overexpressed in many adenocarcinomas, particularly breast adenocarcinomas.	Trastuzumab/Hyaluronidase-oysk		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C158061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158061>	C97927|C136644	NOTCH4 Gene Mutation|INT3 Gene Mutation|Notch 4 Gene Mutation|Notch Homolog 4 Gene Mutation	A change in the nucleotide sequence of the NOTCH4 gene.	NOTCH4 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158062>	C178120|C158061	Activating NOTCH4 Mutation|Activating INT3 Gene Mutation|Activating NOTCH4 Gene Mutation|Activating Notch 4 Gene Mutation|Activating Notch Homolog 4 Gene Mutation|NOTCH4 Activating Gene Mutation|NOTCH4 Activating Mutation	A change in the nucleotide sequence of the NOTCH4 gene that results in constitutive activation of both neurogenic locus notch homolog protein 4 and its downstream signaling pathways.	Activating NOTCH4 Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158063>	C45403|C178120	Activating NOTCH1 Mutation|Activating NOTCH1 Gene Mutation|Activating Notch 1 Gene Mutation|Activating Notch Homolog 1 Gene Mutation|Activating TAN1 Gene Mutation|Activating hN1 Gene Mutation|NOTCH1 Activating Gene Mutation|NOTCH1 Activating Mutation	A change in the nucleotide sequence of the NOTCH1 gene that results in constitutive activation of both neurogenic locus notch homolog protein 1 and its downstream signaling pathways.	Activating NOTCH1 Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158064>	C97927	CTNNA1 Gene Mutation|CAP102 Gene Mutation|Catenin Alpha 1 Gene Mutation|Catenin Alpha-1 Gene Mutation|Catenin, Alpha-1 Gene Mutation|MDPT2 Gene Mutation	A change in the nucleotide sequence of the CTNNA1 gene.	CTNNA1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158065>	C35508	Lymphoma Cells More than 25 Percent of Bone Marrow Nucleated Cells|Lymphoma Cells Greater than 25 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that more than 25 percent of the nucleated cells in a bone marrow sample are lymphoma-derived cells.	Lymphoma Cells More than 25 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C158067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158067>	C213143|C200086	Luveltamab Tazevibulin|Anti-FolRa ADC STRO-002|Anti-FolRalpha ADC STRO-002|Anti-Folate Receptor-alpha Antibody Drug Conjugate STRO-002|LUVELTAMAB TAZEVIBULIN|STRO 002|STRO-002|STRO002	An antibody drug conjugate (ADC) composed of SP8166 (H01), an anti-folate receptor alpha (FolRa; FOLR1) human immunoglobulin G1 (IgG1) antibody, conjugated to a proprietary cleavable drug linker, SC239, containing a tubulin-targeting 3-aminophenyl hemiasterlin warhead, SC209, with potential antineoplastic activity. Upon intravenous administration, the SP8166 antibody moiety targets and binds to FolRa expressed on certain tumor cells. Upon binding, internalization, and enzymatic cleavage, the cytotoxic SC209 moiety induces tumor cell death in FolRa-expressing cells. FolRa is a glycosylphosphatidylinositol linked cell-surface glycoprotein that is widely expressed in certain cancers including serous and epithelial ovarian cancer, endometrial adenocarcinoma, non-small cell lung cancer and triple negative breast cancer. In contrast, FolRa expression is limited in normal tissues.	Luveltamab Tazevibulin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158068>	C189831|C177687	Activating ALK Gene Mutation Negative|ALK Activating Gene Mutation Negative|ALK Activating Mutation Negative|Activating ALK Mutation Negative|Activating ALK Receptor Tyrosine Kinase Gene Mutation Negative|Activating Anaplastic Lymphoma Kinase Receptor Gene Mutation Negative|Activating Anaplastic Lymphoma Receptor Tyrosine Kinase Gene Mutation Negative|Activating CD246 Gene Mutation Negative	A genetic finding indicating that mutations in the ALK gene which encode constitutively active forms of the ALK tyrosine kinase receptor protein are not present in a sample.	Activating ALK Gene Mutation Negative		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158069>	C180950|C177687	Activating ROS1 Gene Mutation Negative|Activating MCF3 Gene Mutation Negative|Activating ROS Gene Mutation Negative|Activating ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene Mutation Negative|Activating ROS1 Mutation Negative|Activating c-ros-1 Gene Mutation Negative|ROS Activating Gene Mutation Negative|ROS1 Activating Gene Mutation Negative|ROS1 Activating Mutation Negative	A genetic finding indicating that mutations in the ROS1 gene which encode constitutively active forms of the proto-oncogene tyrosine-protein kinase ROS protein are not present in a sample.	Activating ROS1 Gene Mutation Negative		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15806>	C15203	Health and Behavior in Children Study	A type of study that focuses on the health and well-being of individuals between 2 and 18 years of age, specifically examining observable actions and their relation to physical and mental health.			Research Activity	
C158070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158070>	C49236	Neuromuscular Blockade|NMB	The use of muscle relaxants to induce muscle paralysis.	Neuromuscular Blockade		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C158071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158071>	C210857	Central American Indian Language|Central American Indigenous Language	Any of the languages indigenous to the Mesoamerican cultural area, which covers southern Mexico, all of Guatemala and Belize, and parts of Honduras, El Salvador, and Nicaragua.			Language	
C158072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158072>	C153240	FGFR3 Gene Rearrangement|CD333 Gene Rearrangement|FGFR-3 Gene Rearrangement|Fibroblast Growth Factor Receptor 3 Gene Rearrangement|JTK4 Gene Rearrangement|Positive	A molecular abnormality indicating rearrangement of the FGFR3 gene.	FGFR3 Gene Rearrangement		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158073>	C210857	North American Indigenous Language|North American Indian Language|North American Indian Language	Any of the languages indigenous to Alaska, Nunavut, Greenland, the United States, and the northern areas of Mexico.			Language	
C158074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158074>	C717|C213309	Vusolimogene Oderparepvec|Genetically Modified HSV-1 Oncolytic Immunotherapeutic RP1|HSV-1 Engineered RP1|HSV-1 Oncolytic Viral Strain RP1|HSV-1 RP1|Oncolytic Virus RP1|RP-1|RP1|VUSOLIMOGENE ODERPAREPVEC	A genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic, immunostimulating and antineoplastic activities. Upon administration, vusolimogene oderparepvec specifically targets, infects and replicates in tumor cells only while not infecting normal, healthy cells. This induces tumor cell lysis. The released virus particles, infect and replicate in neighboring tumor cells, thereby further killing tumor cells. The released tumor-associated antigens (TAAs) from the tumor cells activate the immune system to exert an anti-tumor immune response against the tumor cells, thereby further killing the tumor cells. The virus itself also elicits a tumor-specific systemic immune and cytotoxic T-lymphocyte (CTL) response, thereby killing nearby non-infected tumor cells. In RP1, ICP34.5 and 47 proteins of the HSV1 strain have been deleted; RP1 expresses a fusogenic protein for optimal tumor cell infection and killing.	Vusolimogene Oderparepvec		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158075>	C158612	Is Any Metastatic Diagnosis Present Question|Any Metastatic Diagnosis	A question about whether a diagnosis of metastatic disease has or has not been made.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uveal Melanoma Baseline Form
C158076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158076>	C157093	Skip to Next Section If No|If no, skip to next section	A directive to move to the next section if the response to the question was no.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uveal Melanoma Baseline Form
C158077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158077>	C63502|C203473|C159454	Fluorouracil/Liposomal Irinotecan/Leucovorin Regimen|FULV and nanoliposomal Irinotecan|Fluorouracil/Folinic Acid/Nanoliposomal Irinotecan|Folinic Acid/5-FU/Liposomal Irinotecan|Folinic Acid/Fluorouracil/Liposomal Irinotecan|Folinic Acid/Fluorouracil/Onivyde|Leucovorin-Fluorouracil-Liposomal Irinotecan|Leucovorin-Fluorouracil-Liposomal Irinotecan Regimen|Leucovorin/Fluorouracil/Liposomal Irinotecan Regimen|Leucovorin/Fluorouracil/Onivyde	A regimen consisting of folinic acid (leucovorin), 5-fluorouracil, and liposomal irinotecan that may be used in the treatment of ampullary and pancreatic adenocarcinoma, and biliary tract cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C158078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158078>	C275|C26017	Nicotinamide Riboside|NICOTINAMIDE RIBOSIDE|NR|Niagen	An orally available form of vitamin B3 and precursor of nicotinamide adenine dinucleotide (NAD+) with potential use in the treatment of chemotherapy induced peripheral neuropathy (CIPN). Upon oral administration, nicotinamide riboside (NR) is converted to nicotinamide mononucleotide by the NR kinases, nicotinamide riboside kinase 1 (NRK 1) and nicotinamide riboside kinase 2 (NRK 2), to which a second adenine is transferred by nicotinamide mononucleotide adenylyl transferase to generate NAD+. NAD+, an essential redox coenzyme, may offer protective effects against axonal injury from both mechanical and neurotoxic injury, and maintenance of NAD+ may be protective in mitochondrial disease. NR may help elevate and maintain NAD+ levels, which may ameliorate potential mechanisms implicated in the development of CIPN including mitochondrial dysfunction and peripheral nerve degeneration.	Nicotinamide Riboside		Organic Chemical|Pharmacologic Substance|Vitamin	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C158079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158079>	C63467|C63360	GTP Regimen|Cisplatin-Gemcitabine-Paclitaxel|Cisplatin-Gemcitabine-Paclitaxel Regimen|Cisplatin/Gemcitabine/Paclitaxel|Cisplatin/Gemcitabine/Paclitaxel Regimen|GTP|GTP|Gemcitabine/Paclitaxel/Cisplatin|Gemzar-Taxol-Platinol|Gemzar/Taxol/Platinol	A regimen consisting of cisplatin, gemcitabine, and paclitaxel that may be used in the treatment of certain urothelial and non-small cell lung cancers.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C15807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15807>	C15986|C15632	High Dose Chemotherapy|high-dose chemotherapy|high-dose chemotherapy	A cancer treatment having a treatment dose that is higher than the standard dosage levels recommended on the product labeling for that chemotherapeutic agent. This dose is concurrently toxic and destroys the normal bone marrow stem cells.	High Dose Chemotherapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C158080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158080>	C49333	Deep Gray Matter|Deep Gray (e.g. Basal Ganglia, Thalamus)|Deep Gray (e.g. Basal ganglia or Thalamus)	The gray matter that includes the basal ganglia and/or thalamus.			Tissue	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C158081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158081>	C4753|C204124|C193424|C150043	Recurrent B-Cell Prolymphocytic Leukemia|Prolymphocytic leukemia of B-cell type, in relapse	The reemergence of a B-cell prolymphocytic leukemia after a period of remission.	Recurrent B-Cell Prolymphocytic Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|mCode Cancer Disorder Value Set|mCode Elixhauser Leukemia Value Set|mCode Primary Cancer Disorder Value Set|mCode Primary Malignant Neoplasm Disorder Value Set|mCode Terminology
C158082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158082>	C129839	Super Enhancer Inhibitor GZ17-6.02|GZ17 6.02|GZ17-6.02|GZ176.02|Synthetic Arum palaestinum derivative GZ17-6.02	A synthetic formulation of the Arum palaestinum plant that has been fortified with the already naturally occurring constituents of isovanillin, linolenic acid, and beta-sitosterol, with potential antineoplastic activity. Upon oral administration, GZ17-6.02 may induce apoptosis through caspase-3 activation and poly(ADP-ribose) polymerase (PARP) cleavage, inhibit tumor cell progression by attenuating macrophage infiltration, and inhibit the phosphorylation of several mediators of tumor cell proliferation including Src kinase, extracellular signal-regulated kinases 1 (ERK1) and 2 (ERK2), epidermal growth factor receptor (EGFR), serine/threonine protein kinase AKT (protein kinase B), signal transducer and activator of transcription 2 (STAT-2), and serine/threonine-protein kinase Chk2 (Chk-2). GZ17-6.02 may also inhibit certain super enhancers (SEs) that play an important role in the regulation of the sonic hedgehog (SHH) pathway and cancer stem cell activity. Super enhancers (SEs) are unique areas of the genome that are densely bound by numerous transcription factors and play a pivotal role in the cell, including tissue specification, identity and maintenance. SEs are known to regulate the expression of associated genes and often drive high-level transcription.	Super Enhancer Inhibitor GZ17-6.02		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158083>	C1742|C133878|C129822	Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide|Cetuximab-loaded Polymeric Nanoparticles Decorated With Octreotide|Polymeric Nanoparticles Loaded With Cetuximab and Decorated With Octreotide	A preparation of ethylcellulose polymeric nanoparticles loaded with cetuximab, a recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR), and decorated with the somatostatin analog, octreotide, with potential antineoplastic activity. Upon oral administration, the octreotide moiety directs the nanoparticles, which remain inert until a pH of 6.8 is reached, to somatostatin receptors (SSTRs), which are present on the cell membranes of many neuroendocrine tumor (NET) cells. At this pH, cetuximab is selectively released from the ethylcellulose polymer. Cetuximab may then bind to the extracellular domain of EGFR-expressing tumor cells, thereby preventing the activation and subsequent dimerization of the receptor. This may inhibit signal transduction and inhibit tumor cell proliferation in EGFR-dependent tumor cells. EGFR, a member of the EGFR receptor tyrosine kinase family, may be overexpressed on the cell surfaces of various tumor types.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158084>	C28676	Umbilical Cord Blood-derived CD4+/CD25+ T-regulatory Cells CK0801|CK 0801|CK-0801|CK-0802|CK0801|UCB-derived CD4+CD25+ Tregs CK0801	A preparation composed of allogeneic umbilical cord blood (UCB)-derived, ex vivo expanded and enhanced CD4+/CD25+ T-regulatory cells (Tregs) with potential immunomodulatory activity. Upon administration, the UCB-derived CD4+/CD25+ Tregs CK0801 may promote immunologic homeostasis and prevent autoimmunity by suppressing self-reactive T-cells. This may induce tolerance to allogeneic organ transplants, prevent graft-versus-host disease (GvHD), and suppress autoimmune pathology.			Cell|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158085>	C28227|C164001|C133878|C129822	Bafisontamab|Anti-EGFR/Anti-c-Met Bispecific Antibody EMB-01|Anti-EGFR/c-Met Bispecific Antibody EMB-01|Anti-cMET/EGFR Bispecific Antibody EMB-01|BAFISONTAMAB|Bispecific Antibody EMB-01|EMB 01|EMB-01|EMB01|FIT-013a	A human, Fabs-in-tandem immunoglobulin (FIT-Ig)-based, tetravalent, bispecific antibody targeting both the epidermal growth factor receptor EGFR and the hepatocyte growth factor receptor (HGFR;; cMet; c-Met), with potential antineoplastic activity. Upon administration, bafisontamab simultaneously targets and binds to wild-type or certain mutant forms of both EGFR and c-Met expressed on cancer cells, thereby preventing receptor phosphorylation. This prevents the activation of both EGFR- and c-Met-mediated signaling pathways and results in the inhibition of tumor cell proliferation. EGFR and c-Met, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation. In bafisontamab, the two antigen-binding fragments (Fabs) are fused directly in a crisscross orientation resulting in four active and independent antigen binding sites.	Bafisontamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158086>	C281	Pimodivir|JNJ 63623872|JNJ-63623872|JNJ63623872|PIMODIVIR|VX 787|VX-787|VX787	An orally bioavailable non-nucleoside inhibitor of the polymerase basic protein 2 (PB2) subunit of the influenza A virus polymerase complex with potential antiviral activity. Upon administration, pimodivir occupies the 7-methyl GTP (m7GTP) binding site of PB2, thereby blocking the cap-snatching activity of the influenza polymerase complex and inhibiting the synthesis of viral mRNA. PB2 is one of three subunits that make up the influenza A viral polymerase complex, which is responsible for replication and transcription of the viral RNA (vRNA) genome in the nuclei of infected cells.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C158087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158087>	C201510|C176023	Anti-CD38/BCMA CAR T-lymphocytes|Anti-CD38/Anti-BCMA CAR T-cells|Anti-CD38/Anti-BCMA CAR T-lymphocytes|Anti-CD38/BCMA CAR T-cells	A preparation of T-lymphocytes that have been genetically modified to express a dual-targeted chimeric antigen receptor (CAR) recognizing the tumor-associated antigens (TAAs), cluster of differentiation 38 (CD38) and B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, the anti-CD38/BCMA CAR T-cells are directed to and induce selective toxicity in both CD38- and BCMA-expressing cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis. BCMA is found on the surfaces of plasma cells and is and overexpressed on malignant plasma cells.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158088>	C27721|C157131	Refractory Digestive System Neuroendocrine Neoplasm|Refractory Gastroenteropancreatic Neuroendocrine Neoplasm	A digestive system neuroendocrine neoplasm that is resistant to treatment.	Refractory Digestive System Neuroendocrine Neoplasm|Refractory Gastroenteropancreatic Neuroendocrine Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158089>	C175547|C156492|C156486	Advanced Digestive System Neuroendocrine Neoplasm|Advanced Gastroenteropancreatic Neuroendocrine Neoplasm	A digestive system neuroendocrine neoplasm that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Gastroenteropancreatic Neuroendocrine Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C15808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15808>	C15843	Intercept Vertical Transmission-Perinatal Transmission of HIV	Develop, evaluate, and implement strategies for interrupting vertical transmission of HIV from mother to child and extend our understanding of perinatal transmission and the pathogenesis of early infection (treatment of children will be addressed in other objectives). (Note: The OAR Coordinating Committee on Therapeutics feels scientific objectives 3E through 3G are of equal weight in terms of scientific priorities.)			Research Activity	
C158090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158090>	C178271|C165455|C153278	Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm|Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Neoplasm	A digestive system neuroendocrine neoplasm that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.	Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158091>	C28681|C222322|C129826	Autologous Deep IL-15 Primed T-cells TRQ15-01|IL-15 Loaded Autologous T-lymphocytes TRQ15-01|TRQ15-01	A preparation of genetically modified, multi-antigen-directed autologous T-lymphocytes, that have particles, consisting of multiple chemically crosslinked human cytokine interleukin-15 (IL-15)/IL-15 receptor alpha (IL-15Ra)/Fc heterodimers, attached to their surface, with potential immunostimulating and antineoplastic activities. TRQ15-01 is made from monocyte-derived dendritic cells (moDCs) that are pulsed with peptides from multiple tumor-associated antigens (TAAs) to expand cytotoxic T-lymphocytes (CTLs) that are subsequently loaded with IL-15 particles. Upon administration of the autologous deep IL-15 primed T-cells, the IL-15/IL-15Ra fusion proteins are slowly released in vivo from the T-cells in a controlled manner and induce autocrine cytokine stimulation of the administered T-cells, thereby increasing T-cell division of the administered T-cells. The expanded T-cells target, bind to and kill tumor cells. This increases tumor cell growth inhibition by T-cells. IL-15 is a pro-survival, inflammatory cytokine and causes sustained T-cell expansion and enhanced anti-tumor activity. Compared to systemically delivered IL-15, IL-15 attached to the T-cells greatly increases target CD8 T-cell concentrations in the tumor, without significant systemic effects.	Autologous Deep IL-15 Primed T-cells TRQ15-01		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158092>	C1505	Spirulina-based Dietary Supplement|Blue-green Algae Supplement|Spirulina-based Supplement	A nutritional supplement composed of the blue-green microalgae spirulina. Spirulina is high in protein and contains significant amounts of calcium, niacin, potassium, magnesium, B vitamins, vitamin E, iodine, iron, beta-carotene, phycocyanin and chlorophyll. The spirulina dietary supplement may affect the cardiovascular, digestive and immune systems and may improve diabetes and high cholesterol. In addition, spirulina contains antioxidants and may protect against cellular DNA damage by reactive oxygen species (ROS). As spirulina has a high concentration of iodine and contains the amino acid tyrosine, it may improve thyroid function, and ameliorate the size of benign thyroid nodules.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C158093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158093>	C159438	Zeteletinib|BOS 172738|BOS-172738|BOS172738|CAXM-1190B|DS 5010B|DS-5010B|DS5010B|RET Inhibitor DS-5010B|ZETELETINIB	An orally bioavailable selective inhibitor of wild-type, fusion products and mutated forms, including gatekeeper mutations, of the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET), with potential antineoplastic activity. Upon oral administration, zeteletinib selectively binds to and inhibits the activity of RET. This results in an inhibition of cell growth of tumors cells that exhibit increased RET activity. RET overexpression, activating mutations, and fusions result in the upregulation and/or overactivation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role in the development and progression of these cancers.	Zeteletinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158094>	C1505	Cinnamomum cassia Capsules|Cinnamomum aromaticum Bark Capsules	A nutritional supplement composed of the blue-green microalgae spirulina. Spirulina is high in protein and contains significant amounts of calcium, niacin, potassium, magnesium, B vitamins, vitamin E, iodine, iron, beta-carotene, phycocyanin and chlorophyll. The spirulina dietary supplement may affect the cardiovascular, digestive and immune systems and may improve diabetes and high cholesterol. In addition, spirulina contains antioxidants and may protect against cellular DNA damage by reactive oxygen species (ROS). As spirulina has a high concentration of iodine and contains the amino acid tyrosine, it may improve thyroid function, and ameliorate the size of benign thyroid nodules.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C158096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158096>	C146993	Deutenzalutamide|D3-ENT|DEUTENZALUTAMIDE|Deuterated Enzalutamide|Enzalutamide Deuterated|HC 1119|HC-1119|HC1119|N-trideuteromethyl Enzalutamide	A deuterated form of enzalutamide, an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Upon administration, deutenzalutamide competitively binds to and inhibits the activity of ARs expressed on prostate cancer cells, which impairs nuclear translocation and DNA binding, resulting in apoptosis of prostate cancer cells. This results in a reduction in prostate cancer cell growth. AR overexpression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance. Deuterium incorporation, by replacing the hydrogen atoms of the N-CH3 moiety with deuterium atoms, decreases enzalutamide's metabolism and allows for an increased pharmacokinetic profile, thereby enhancing its anti-tumor efficacy compared to non-deuterated enzalutamide. As the deuterated form can't cross the blood-brain barrier (BBB), the deutenzalutamide form also reduces the unwanted brain-related side effects of enzalutamide and improves its safety profile.	Deutenzalutamide		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158097>	C496	Recombinant Bovine Basic Fibroblast Growth Factor|rb-bFGF	A recombinant form of bovine basic fibroblast growth factor (rb-bFGF), with cell growth stimulating activity. bFGF is a multifunctional cell growth factor that stimulates the growth of cells derived from mesodermal and neuroectodermal cells. Upon administration, rb-bFGF induces cellular proliferation and differentiation, promotes tissue repair and reconstruction. rb-bFGF may improve chemotherapy- or radiotherapy-induced oral mucositis.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C158098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158098>	C65141	Black Currant Juice|BLACK CURRANT JUICE|Ribes nigrum L. Juice	The juice from the berries of the black currant (Ribes nigrum L.) shrub belonging to the family Grossulariaceae, with potential antioxidant and protective activities. Black currant juice contains a variety of nutrients, including vitamin C, iron, potassium, manganese, anthocyanins, including delphinidin-3-O-glucoside, delphinidin-3-O-rutinoside, cyanidin-3-O-glucoside, and cyanidin-3-O-rutinoside. The antioxidants in black currant juice scavenge free radicals, thereby protecting cells from damage.			Food	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C158099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158099>	C28681|C137999|C129826	Anti-FL(FITC-E2) CAR T Cells|Anti-FL(FITC-E2) CAR T-lymphocytes|Anti-FL(FITCE2) CAR Expressing T Cells|AntiFL(FITCE2) CAR Expressing T Cells|Fluorescein-specific (FITC-E2)-CAR T Cells	A preparation of genetically modified T-cells transduced with a replication incompetent, self-inactivating (SIN) lentiviral vector expressing a second generation chimeric antigen receptor (CAR) consisting of an anti-fluorescein (anti-FL) fluorescein isothiocyanate (FITC)-E2 single chain variable fragment (scFv), that is coupled, via an immunoglobulin G4 (IgG4) hinge-CH2(L295D)-CH3 spacer, to the costimulatory signaling molecules CD28, CD137 (4-1BB), and CD3 zeta, and linked to a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Prior to the administration of anti-FL(FITC-E2) CAR T-cells, the CAR-T adaptor molecule (CAM) EC17 is administered. EC17 is a bispecific molecule that is composed of folic acid conjugated to FITC (folate-FITC). EC17 targets and binds with its folate moiety with high affinity to folate receptor (FR)-expressing tumor cells. Upon administration of the anti-FL(FITC-E2) CAR T-cells, these cells are attracted by and bind to the FITC antigen moiety of EC17. Upon binding to EC17, the T-cells induce specific tumor cell lysis, cytokine secretion, and proliferation, and activate a robust immune response against the EC17-bound, FR-expressing tumor cells. FR is overexpressed in various tumor cell types and is associated with increased leukemic cell proliferation and aggressiveness. The co-stimulatory molecules are required for full T-cell activation and enhance both proliferation of T-cells and antitumor activity. EGFRt both facilitates detection of the administered T-cells in vivo and can promote elimination of those cells following a cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) response. The reactivity of the anti-FL(FITC-E2) CAR T-cells is dependent on dosing of EC17, and therefore allows CAR T-cell activity to be controlled by dosing of EC17.	Anti-FL(FITC-E2) CAR T Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15809>	C15896	Laboratory Animal Production and Facilities|Research Animal Facility	The production of laboratory animals for research.			Organization	
C1580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1580>	C70547	Anti-DNA Antibody	An antinuclear autoantibody directed against nuclear DNA.	Anti-DNA Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C158100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158100>	C163968	Protein Arginine Methyltransferase 5 Inhibitor PF-06939999|PF 06939999|PF-06939999|PF-06939999|PF06939999|PRMT5 Inhibitor PF-06939999	An orally available inhibitor of protein arginine N-methyltransferase 5 (histone-arginine N-methyltransferase PRMT5; PRMT5) with potential antiproliferative and antineoplastic activities. Although the mechanism of action has not yet been fully elucidated, orally administered PRMT5 inhibitor PF-06939999 inhibits the methyltransferase activity of PRMT5, thereby decreasing the levels of monomethylated and dimethylated arginine residues in histones H2A, H3, and H4, and modulating the expression of genes involved in several cellular processes including cell proliferation. This may increase the expression of antiproliferative genes and/or decrease the expression of genes that promote cell proliferation, and may decrease the growth of rapidly proliferating cells, including cancer cells. PRTM5, an arginine methyltransferase that can catalyze the formation of both omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA) on histones and a variety of other protein substrates, is overexpressed in several neoplasms.	Protein Arginine Methyltransferase 5 Inhibitor PF-06939999		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158101>	C4436|C159563|C153355	Refractory Cholangiocarcinoma	A cholangiocarcinoma that is resistant to treatment.	Refractory Cholangiocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158102>	C25364	Cadastro de Pessoas Fisicas|CPF	A unique federal tax identification number that is assigned by the Brazilian Federal Internal Revenue Department (Receita Federal do Brasil) to citizens and non-citizens entering into financial transactions that result in taxable income.			Intellectual Product	
C158103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158103>	C574|C2169	Dihydroorotate Dehydrogenase Inhibitor AG-636|AG 636|AG-636|AG636|DHODH Inhibitor AG-636	An orally available inhibitor of dihydroorotate dehydrogenase (DHODH), with potential antineoplastic activity. Upon administration, AG-636 specifically targets, binds to and prevents the activation of DHODH, thereby preventing the fourth enzymatic step in de novo pyrimidine synthesis. This prevents uridine monophosphate (UMP) formation, DNA synthesis, cell division and cellular proliferation, causes reactive oxygen species (ROS) formation, enables differentiation and induces apoptosis in susceptible tumor cells. DHODH, a mitochondrial enzyme, catalyzes the conversion of dihydroorotate (DHO) to orotate in the endogenous synthesis of UMP.	Dihydroorotate Dehydrogenase Inhibitor AG-636		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology
C158104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158104>	C177793|C132505	Refractory WHO Grade 2 Glioma|Refractory WHO Grade II Glioma|Refractory WHO Grade II Glioma	WHO grade 2 glioma that is resistant to treatment.	Refractory WHO Grade II Glioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158105>	C103223	RASSF1 Gene Promoter Hypermethylation|123F2 Gene Promoter Hypermethylation|NORE2A Gene Promoter Hypermethylation|RASSF1 Promoter Hypermethylation|RASSF1A Gene Promoter Hypermethylation|RDA32 Gene Promoter Hypermethylation|REH3P21 Gene Promoter Hypermethylation|Ras Association Domain Family Member 1 Gene Promoter Hypermethylation	A genetic finding indicating an excess of DNA methylation in the promoter region of the RASSF1 gene.			Laboratory or Test Result	
C158106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158106>	C103223	CDH1 Gene Promoter Hypermethylation|Arc-1 Gene Promoter Hypermethylation|CD324 Gene Promoter Hypermethylation|CDH1 Promoter Hypermethylation|CDHE Gene Promoter Hypermethylation|Cadherin 1 Gene Promoter Hypermethylation|Cadherin, Epithelial Gene Promoter Hypermethylation|Calcium-Dependent Adhesion Protein, Epithelial Gene Promoter Hypermethylation|E-Cadherin Gene Promoter Hypermethylation|ECAD Gene Promoter Hypermethylation|LCAM Gene Promoter Hypermethylation|UVO Gene Promoter Hypermethylation	A genetic finding indicating an excess of DNA methylation in the promoter region of the CDH1 gene.			Laboratory or Test Result	
C158107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158107>	C103223	EDNRB Gene Promoter Hypermethylation|EDNRB Promoter Hypermethylation|ET-B Gene Promoter Hypermethylation|ET-BR Gene Promoter Hypermethylation|ETB Gene Promoter Hypermethylation|ETB1 Gene Promoter Hypermethylation|ETBR Gene Promoter Hypermethylation|ETRB Gene Promoter Hypermethylation|Endothelin Receptor Type B Gene Promoter Hypermethylation	A genetic finding indicating an excess of DNA methylation in the promoter region of the EDNRB gene.			Laboratory or Test Result	
C158108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158108>	C36661|C35682	VEGF Overexpression Positive|VEGF Family Overexpression Positive|Vascular Endothelial Growth Factor Family Overexpression Positive|Vascular Endothelial Growth Factor Overexpression Positive	An indication that overexpression of a member of the VEGF family has been detected in a sample.			Laboratory or Test Result	
C158109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158109>	C35682|C177693	THBS1 Overexpression Positive|TSP Overexpression Positive|TSP-1 Overexpression Positive|TSP1 Overexpression Positive|Thrombospondin 1 Overexpression Positive|Thrombospondin-1 Overexpression Positive	An indication that overexpression of THBS1 has been detected in a sample.			Laboratory or Test Result	
C15810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15810>	C15783	Laboratory/Correlate Data				Idea or Concept	
C158110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158110>	C45581	E2F3 Gene Amplification|E2F Transcription Factor 3 Gene Amplification|E2F-3 Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the E2F3 gene.			Cell or Molecular Dysfunction	
C158111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158111>	C25164	Date of Reference Time Point|RFTDAT	The date for a fixed reference time point.			Temporal Concept	
C158112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158112>	C25207	Time of Reference Time Point	The time for a fixed reference time point.			Temporal Concept	
C158113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158113>	C66830	CDISC SDTM QRS Method Terminology|QRS Method|QRSMTHOD|SDTM-QRSMTHOD	Terminology associated with the QRS method codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158114>	C81222	CDISC ADaM Geriatric Depression Scale Short Form Questionnaire Parameter Code Terminology|ADaM-GDS02PC|GDS02PC|Geriatric Depression Scale Short Form Questionnaire Parameter Code	Terminology associated with the Geriatric Depression Scale Short Form questionnaire parameter code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Analysis Data Model (ADaM).			Intellectual Product	CDISC ADaM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158115>	C81222	CDISC ADaM Geriatric Depression Scale Short Form Questionnaire Parameter Name Terminology|ADaM-GDS02PN|GDS02PN|Geriatric Depression Scale Short Form Questionnaire Parameter Name	Terminology associated with the Geriatric Depression Scale Short Form questionnaire parameter name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Analysis Data Model (ADaM).			Intellectual Product	CDISC ADaM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158116>	C77526	CDISC SEND Challenge Agent Parameter Code Terminology|ACPARMCD|Challenge Agent Parameter Code|SEND-ACPARMCD	Terminology associated with the challenge agent parameter code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158117>	C77526	CDISC SEND Challenge Agent Parameter Long Name Terminology|ACPARM|Challenge Agent Parameter Long Name|SEND-ACPARM	Terminology associated with the challenge agent parameter long name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158118>	C77526	CDISC SEND Age Estimation Method Response Terminology|AGESMETH|Age Estimation Method Response|SEND-AGESMETH	Terminology associated with the age estimation method response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158119>	C77526	CDISC SEND Biological Challenge Agent Category Response Terminology|BACAT|Biological Challenge Agent Category Response|SEND-BACAT	Terminology associated with the biological challenge agent category response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15811>	C15313	Low Dose Radiation Therapy|Low Dose Radiation	Radiotherapy using radioactive particles that deposit a low amount of energy by radiation per unit length of travel.			Therapeutic or Preventive Procedure	
C158120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158120>	C77526	CDISC SEND Challenge Agent Category Response Terminology|CAGTCAT|Challenge Agent Category Response|SEND-CAGTCAT	Terminology associated with the challenge agent category Response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158121>	C77526	CDISC SEND Rad/Nuc Agent Ionizing Radiation Type Response Terminology|RNAIOTYP|Rad/Nuc Agent Ionizing Radiation Type Response|SEND-RNAIOTYP	Terminology associated with the rad/nuc agent ionizing radiation type Response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158122>	C77526	CDISC SEND Rad/Nuc Agent Source Response Terminology|RNASRC|Rad/Nuc Agent Source Response|SEND-RNASRC	Terminology associated with the rad/nuc agent source response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158123>	C77526	CDISC SEND Restraint Mode Response Terminology|RSTMODRS|Restraint Mode Response|SEND-RSTMODRS	Terminology associated with the restraint mode response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158124>	C77526	CDISC SEND Sexual Maturity Status Response Terminology|SEND-SEXMAT|SEXMAT|Sexual Maturity Status Response	Terminology associated with the sexual maturity status response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158125>	C77526	CDISC SEND Study Report Status Response Terminology|SEND-STRPSTAT|STRPSTAT|Study Report Status Response	Terminology associated with the study report status response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158126>	C210735|C210010	Seroreactivity	The presence of a serum antibody that recognizes, binds and reacts to an antigen.			Laboratory Procedure	
C158128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158128>	C1708	Challenge Agent|challenge agent	A type of substance that is given to healthy subjects in order to induce a physiological response that the investigational medicinal product is intended to counter or treat.			Chemical Viewed Functionally	CDISC DDF Study Intervention Role Value Set Terminology|CDISC DDF Terminology|CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|ICH M11 Intervention Use Value Set Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C158129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158129>	C16847	Restraint	The means or mechanism by which physical movement is reduced or completely impeded.			Laboratory Procedure	
C15812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15812>	C15878	Maternal and Child Health Study	Studies focusing on the involvement of maternal factors (and efforts to modify these factors) that may affect the health of the child or fetus: smoking or exposure to drugs or toxic chemicals during pregnancy, maternal/fetal immunologic interactions.			Research Activity	
C158131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158131>	C223331	PRMT1 Inhibitor|Histone-arginine N-methyltransferase PRMT1 Inhibitor|Interferon Receptor 1-bound Protein 4 Inhibitor|Protein Arginine N-methyltransferase 1 Inhibitor	Any agent that inhibits protein arginine N-methyltransferase 1 (PRMT1; histone-arginine N-methyltransferase PRMT1; interferon receptor 1-bound protein 4).	PRMT1 Inhibitor		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158132>	C176988	Anti-CD73 Monoclonal Antibody NZV930|NZV 930|NZV-930|NZV-930|NZV930|SRF 373|SRF-373|SRF373	A fully human monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, anti-CD73 monoclonal antibody NZV930 targets and binds to CD73 on tumor cells, leading to internalization of CD73. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine, thereby preventing adenosine-mediated suppression of lymphocyte activity and increasing the activity of cytotoxic T-lymphocytes (CTLs). This also activates macrophages and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes. By abrogating the inhibitory effect on the immune system and enhancing the CTL-mediated immune response against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, is upregulated in many cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment.	Anti-CD73 Monoclonal Antibody NZV930		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158133>	C26791	Pelvic Hemorrhage|Pelvic Bleeding|Pelvic Bleeding	Bleeding within the pelvic cavity.	Pelvic Bleeding		Finding	CTRP Disease Terminology|CTRP Terminology
C158134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158134>	C103223	Nonrandom X Chromosome Inactivation|Non-Random X Chromosome Inactivation|Non-Random X Inactivation|Non-Random X-Inactivation|Nonrandom X Inactivation|Nonrandom X-Chromosome Inactivation|Nonrandom X-Inactivation|Skewed X Chromosome Inactivation|Skewed X Inactivation|Skewed X-Inactivation|X Chromosome Skewing	An indication that greater than 75% of cells in a sample demonstrate preferential inactivation of the same X chromosome.			Laboratory or Test Result	
C158135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158135>	C28193	Infantile Liver Failure Syndrome 2	An autosomal recessive condition caused by mutation(s) in the NBAS gene, encoding neuroblastoma-amplified sequence. It is characterized by recurrent episodes of acute liver failure that begin in infancy.			Disease or Syndrome	Cellosaurus Disease Terminology
C158136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158136>	C98083	Empagliflozin|1-Chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene|BI 10773|BI-10773|BI10773|EMPAGLIFLOZIN|Jardiance	An orally available competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2; SLC5A2) with antihyperglycemic activity. Upon oral administration, empagliflozin selectively and potently inhibits SGLT2 in the kidneys, thereby suppressing the reabsorption of glucose in the proximal tubule. Inhibition of SGLT2 increases urinary glucose excretion by the kidneys, resulting in a reduction of plasma glucose levels in an insulin-independent manner. Inhibition of SGLT2 in the kidneys also suppresses the renal reabsorption of 1,5-anhydroglucitol (1,5AG). This lowers serum 1,5AG and neutrophil 1,5-anhydroglucitol-6-phosphate (1,5AG6P) levels, which may improve neutropenia and neutrophil dysfunction in patients with glycogen storage disease type Ib (GSD Ib). SGLT2, a transport protein exclusively expressed in the proximal renal tubules, mediates approximately 90% of renal glucose reabsorption from tubular fluid.	Empagliflozin		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C158137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158137>	C21176	INO80 Complex|INO80 Chromatin Remodeling Complex	An ATP-dependent chromatin remodeling complex comprised of 15 unique subunits that plays a role in transcriptional regulation, DNA replication and both DNA double-strand break repair and nucleotide-excision repair.			Amino Acid, Peptide, or Protein	
C158138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158138>	C3014	Thoracic Endometriosis	A condition characterized by the presence of functioning endometrial tissue in the lung, pleura, chest wall, and/or diaphragm.			Disease or Syndrome	Cellosaurus Disease Terminology
C158139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158139>	C97927	PAX5 Gene Mutation|ALL3 Gene Mutation|BSAP Gene Mutation|Paired Box 5 Gene Mutation|Paired Box Gene 5 Gene Mutation	A change in the nucleotide sequence of the PAX5 gene.			Cell or Molecular Dysfunction	Pediatric Oncology Target Molecular Abnormalities Terminology
C15813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15813>	C63474	Media Intervention	An act or ministration that produces an effect to alter the course of a pathologic process through the use of a variety of media, i.e., CD-ROM, Web application, video, telephone.	Media Intervention		Activity	CTRP Intervention Terminology|CTRP Terminology
C158140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158140>	C97928	PAX5 Protein Variant|B-Cell Lineage Specific Activator Protein Variant|B-Cell Specific Transcription Factor Protein Variant|BSAP Protein Variant|Paired Box Protein Pax-5 Protein Variant	A variation in the amino acid sequence for paired box protein Pax-5.			Cell or Molecular Dysfunction	Pediatric Oncology Target Molecular Abnormalities Terminology
C158141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158141>	C158139	PAX5 NM_016734.2:c.239C>G|ALL3 c.239C>G|BSAP c.239C>G|NM_016734.2:c.239C>G|PAX5 c.239C>G|Paired Box 5 c.239C>G|Paired Box Gene 5 c.239C>G	A nucleotide substitution at position 239 of the coding sequence of the PAX5 gene where cytosine has been mutated to guanine.			Cell or Molecular Dysfunction	
C158142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158142>	C158140	PAX5 NP_057953.1:p.P80R|B-Cell Lineage Specific Activator Protein P80R|B-Cell Lineage Specific Activator Protein Pro80Arg|B-Cell-Specific Transcription Factor P80R|B-Cell-Specific Transcription Factor Pro80Arg|BSAP P80R|BSAP Pro80Arg|NP_057953.1:p.P80R|NP_057953.1:p.Pro80Arg|PAX5 NP_057953.1:p.Pro80Arg|PAX5 P80R|PAX5 Pro80Arg|PAX5 p.P80R|PAX5 p.P80R|PAX5 p.Pro80Arg|Paired Box Protein Pax-5 P80R|Paired Box Protein Pax-5 Pro80Arg	A change in the amino acid residue at position 80 in paired box protein Pax-5 where proline has been replaced by arginine.			Cell or Molecular Dysfunction	
C158143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158143>	C158139	PAX5 NM_016734.2:c.547G>A|ALL3 c.547G>A|BSAP c.547G>A|NM_016734.2:c.547G>A|PAX5 c.547G>A|Paired Box 5 c.547G>A|Paired Box Gene 5 c.547G>A	A nucleotide substitution at position 547 of the coding sequence of the PAX5 gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C158144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158144>	C158140	PAX5 NP_057953.1:p.G183S|B-Cell Lineage Specific Activator Protein G183S|B-Cell Lineage Specific Activator Protein Gly183Ser|B-Cell-Specific Transcription Factor G183S|B-Cell-Specific Transcription Factor Gly183Ser|BSAP G183S|BSAP Gly183Ser|NP_057953.1:p.G183S|NP_057953.1:p.Gly183Ser|PAX5 G183S|PAX5 Gly183Ser|PAX5 NP_057953.1:p.Gly183Ser|PAX5 p.G183S|PAX5 p.Gly183Ser|Paired Box Protein Pax-5 G183S|Paired Box Protein Pax-5 Gly183Ser	A change in the amino acid residue at position 183 in paired box protein Pax-5 where glycine has been replaced by serine.			Cell or Molecular Dysfunction	
C158145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158145>	C97928	IKZF1 Protein Variant|DNA-Binding Protein Ikaros Protein Variant|IKAROS Family Zinc Finger 1 Protein 1 Protein Variant|Lymphoid Transcription Factor LyF-1 Protein Variant	A variation in the amino acid sequence for DNA-binding protein Ikaros.			Cell or Molecular Dysfunction	
C158146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158146>	C158145	IKZF1 NP_006051.1:p.N159Y|DNA-Binding Protein Ikaros Asn159Tyr|DNA-Binding Protein Ikaros N159Y|IKAROS Family Zinc Finger 1 Protein 1 Asn159Tyr|IKAROS Family Zinc Finger 1 Protein 1 N159Y|IKZF1 Asn159Tyr|IKZF1 N159Y|IKZF1 NP_006051.1:p.Asn159Tyr|IKZF1 p.Asn159Tyr|IKZF1 p.N159Y|Lymphoid Transcription Factor LyF-1 Asn159Tyr|Lymphoid Transcription Factor LyF-1 N159Y|NP_006051.1:p.Asn159Tyr|NP_006051.1:p.N159Y	A change in the amino acid residue at position 159 in DNA-binding protein Ikaros where asparagine has been replaced by tyrosine.			Cell or Molecular Dysfunction	
C158147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158147>	C64430	Interleukin 2 Receptor Measurement|IL2R|IL2R Measurement|Interleukin 2 Receptor|Interleukin 2 Receptor|Interleukin-2 Receptor Measurement	The determination of the amount of interleukin 2 receptor present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158148>	C25688|C171083	Sexual Maturity Status|SEXMATS	An indication of whether an organism is capable of sexual reproduction. The capacity of an organism to reproduce via sexual reproduction.			Qualitative Concept	CDISC SEND Subject Characteristic Test Code Terminology|CDISC SEND Subject Characteristic Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158149>	C8841|C8702|C216069	Recurrent Transformed B-Cell Non-Hodgkin Lymphoma|Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma|Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma	The reemergence of transformed B-cell non-Hodgkin lymphoma after a period of remission.	Recurrent Transformed B-cell Non-Hodgkin Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C15814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15814>	C15208	Multicenter Hemophilia Cohort Study|MHCS|MHCS-I	A multi-center study of HIV disease progression and heterosexual transmission begun in 1982.			Health Care Activity	
C158150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158150>	C8842|C216069|C140091	Refractory Transformed B-Cell Non-Hodgkin Lymphoma|Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma|Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma	A transformed B-cell non-Hodgkin lymphoma that is resistant to treatment.	Refractory Transformed B-cell Non-Hodgkin Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158151>	C8645|C157624	Recurrent Transformed Chronic Lymphocytic Leukemia|Recurrent Richter Syndrome	The reemergence of chronic lymphocytic leukemia transformed to aggressive diffuse large B-cell lymphoma (Richter's transformation) after a period of remission.	Recurrent Transformed Chronic Lymphocytic Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158152>	C7886|C157624	Refractory Transformed Chronic Lymphocytic Leukemia|Refractory Richter Syndrome	Chronic lymphocytic leukemia which has undergone histologic transformation to an aggressive diffuse large B-cell lymphoma (Richter's transformation) and has become resistant to treatment.	Refractory Transformed Chronic Lymphocytic Leukemia		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158154>	C17146	Transplant Registry Unified Management Program|TRUMP	A Japanese centralized, computer-based software suite developed to manage hematopoietic stem cell transplant outcome data offline in transplant centers. The system emphasizes convenience to institutes, safety of patient information, quality of data management, and outcomes of transplantations.			Manufactured Object	
C158155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158155>	C106679	Geriatric Depression Scale Short Form - Total Score for Analysis|GDS02-Total Score - Analysis|GDS02-Total Score - Analysis|GDS02TS	Geriatric Depression Scale Short Form total score.			Intellectual Product	CDISC ADaM Geriatric Depression Scale Short Form Questionnaire Parameter Code Terminology|CDISC ADaM Geriatric Depression Scale Short Form Questionnaire Parameter Name Terminology|CDISC ADaM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158156>	C25256	Treatment Amount|TRTAMT|TRTAMT	The concentration or quantity of the medication.			Quantitative Concept	CDISC SDTM Device Properties Test Code Terminology|CDISC SDTM Device Properties Test Name Terminology|CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Mercaptopurine/Methotrexate/Tretinoin
C158157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158157>	C71100	7 Lead Placement Standard for Non-Human Subjects|7 LEAD STANDARD, NON-HUMAN	An electrocardiogram lead placement for non-human species using a five-electrode lead set to monitor and/or record 7 ECG leads, analogous to the standard and augmented human limb leads and one chest lead. (CDISC)			Spatial Concept	CDISC SDTM ECG Test Method Terminology|CDISC SDTM Terminology|CDISC SEND ECG Method Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158158>	C209364	Han Chinese|HA|HA|HAN	A Chinese person from the Han ethnic group (including Chuanqing).			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158159>	C209364	Zhuang Chinese|ZH|ZH|ZHUANG	A Chinese person from the Zhuang ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15815>	C15719	Monitoring for Recurrence	Disease surveillance for recurrence of disease.			Health Care Activity	
C158160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158160>	C209364	Hui Chinese|HU|HU|HUI	A Chinese person from the Hui (including Utsuls of Hainan, descended from Cham refugees) ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158161>	C209364	Man Chinese|MA|MA|MAN	A Chinese person from the Man ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158162>	C209364	Uygur Chinese|UG|UG|UYGUR|Uighur Chinese	A Chinese person from the Uygur ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158163>	C209364	Miao Chinese|MH|MH|MIAO	A Chinese person from the Miao (Including Hmong) ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158164>	C209364	Yi Chinese|YI|YI|YI	A Chinese person from the Yi ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158165>	C209364	Tujia Chinese|TJ|TJ|TUJIA	A Chinese person from the Tujia ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158166>	C209364	Zang Chinese|ZA|ZA|ZANG	A Chinese person from the Zang (including Amdowa, Khampa and some Pumi speakers) ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158167>	C209364	Mongol Chinese|MG|MG|MONGOL	A Chinese person from the Mongol ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158168>	C209364	Dong Chinese|DO|DO|DONG	A Chinese person from the Dong ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158169>	C209364	Buyei Chinese|BUYEI|BY|BY	A Chinese person from the Buyei ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15816>	C16147	Natural History of Progression of HIV-related Diseases	Elucidate the progression of HIV infection, from its earliest stages through long-term sequelae.			Conceptual Entity	
C158170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158170>	C209364	Yao Chinese|YA|YA|YAO	A Chinese person from the Yao ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158171>	C209364	Bai Chinese|BA|BA|BAI	A Chinese person from the Bai ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158172>	C209364	Chosen Chinese|CHOSEN|CS|CS	A Chinese person from the Chosen ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158173>	C209364	Hani Chinese|HANI|HN|HN	A Chinese person from the Hani (including Sangkong) ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158174>	C209364	Li Chinese|LI|LI|LI	A Chinese person from the Li ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158175>	C209364	Kazak Chinese|KAZAK|KZ|KZ	A Chinese person from the Kazak ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158176>	C209364	Dai Chinese|DA|DA|DAI	A Chinese person from the Dai (including several different Tai-speaking groups historically referred to as Bai-yi) ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158177>	C209364	She Chinese|SH|SH|SHE	A Chinese person from the She ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158178>	C209364	Lisu Chinese|LISU|LS|LS	A Chinese person from the Lisu ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158179>	C209364	Dongxiang Chinese|DONGXIANG|DX|DX	A Chinese person from the Dongxiang ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15817>	C19997	Neuroscience and Neuropsychiatric Research	Research related to neuroscience and neuropsychiatry.			Research Activity	
C158180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158180>	C209364	Gelao Chinese|GELAO|GL|GL	A Chinese person from the Gelao ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158181>	C209364	Lahu Chinese|LAHU|LH|LH	A Chinese person from the Lahu ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158182>	C209364	Va Chinese|VA|VA|VA	A Chinese person from the Va ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158183>	C209364	Sui Chinese|SU|SU|SUI	A Chinese person from the Sui ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158184>	C209364	Naxi Chinese|NAXI|NX|NX	A Chinese person from the Naxi (including Mosuo) ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158185>	C209364	Qiang Chinese|QI|QI|QIANG	A Chinese person from the Qiang ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158186>	C209364	Tu Chinese|TU|TU|TU	A Chinese person from the Tu ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158187>	C209364	Mulao Chinese|ML|ML|MULAO	A Chinese person from the Mulao (including the Qago) ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158188>	C209364	Xibe Chinese|XB|XB|XIBE	A Chinese person from the Xibe ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158189>	C209364	Kirgiz Chinese|KG|KG|KIRGIZ	A Chinese person from the Kirgiz ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15818>	C18205	National Surgical Adjuvant Breast and Bowel Project|NSABP	A clinical trials cooperative group supported by the NCI. The group headquarters in Pittsburgh, Pennsylvania and has research sites at nearly 200 major medical centers, university hospitals, large oncology practice groups, and health maintenance organizations in the United States, Canada, Puerto Rico, and Australia. In addition to funding from the NCI, which the NSABP has received since it began, the NSABP also receives support from other sources for ancillary studies, training, and educational programs.			Health Care Related Organization	
C158190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158190>	C209364	Jingpo Chinese|JINGPO|JP|JP	A Chinese person from the Jingpo ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158191>	C209364	Daur Chinese|DAUR|DU|DU	A Chinese person from the Daur ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158192>	C209364	Salar Chinese|SALAR|SL|SL	A Chinese person from the Salar ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158193>	C209364	Blang Chinese|BL|BL|BLANG	A Chinese person from the Blang ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158194>	C209364	Maonan Chinese|MAONAN|MN|MN	A Chinese person from the Maonan (including the Then) ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158195>	C209364	Tajik Chinese|TA|TA|TAJIK	A Chinese person from the Tajik ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158196>	C209364	Pumi Chinese|PM|PM|PUMI	A Chinese person from the Pumi ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158197>	C209364	Achang Chinese|AC|AC|ACHANG	A Chinese person from the Achang ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158198>	C209364	Nu Chinese|NU|NU|NU	A Chinese person from the Nu ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158199>	C209364	Ewenki Chinese|EW|EW|EWENKI	A Chinese person from the Ewenki ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15819>	C15321	Nucleic Acid Resources				Conceptual Entity	
C1581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1581>	C257	Benzydamine Hydrochloride|BENZYDAMINE HYDROCHLORIDE|Difflam|Tantum	An indazole non-steroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic, and anti-edema properties.  Unlike other NSAIDs, benzydamine hydrochloride does not inhibit cyclooxygenases (COX) but stabilizes membranes, resulting in local anesthesia; inhibits the production of pro-inflammatory cytokines; inhibits the generation of reactive oxygen species by neutrophils; inhibits leukocyte aggregation and adhesion; and exhibits antimicrobial properties. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C158200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158200>	C209364	Gin Chinese|GI|GI|GIN	A Chinese person from the Gin ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158201>	C209364	Jino Chinese|JINO|JN|JN	A Chinese person from the Jino ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158202>	C209364	Deang Chinese|DE|DE|DEANG	A Chinese person from the Deang ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158203>	C209364	Bonan Chinese|BN|BN|BONAN	A Chinese person from the Bonan ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158204>	C209364	Russ Chinese|RS|RS|RUSS	A Chinese person from the Russ ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158205>	C209364	Yugur Chinese|YG|YG|YUGUR	A Chinese person from the Yugur ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158206>	C209364	Uzbek Chinese|UZ|UZ|UZBEK	A Chinese person from the Uzbek ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158207>	C209364	Monba Chinese|MB|MB|MONBA	A Chinese person from the Monba ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158208>	C209364	Oroqen Chinese|OR|OR|OROQEN	A Chinese person from the Oroqen ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158209>	C209364	Derung Chinese|DERUNG|DR|DR	A Chinese person from the Derung ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15820>	C15429	Nutritional Research|Nutrition|Nutrition Research|Nutritional Study	Research that focuses on food, the nutrients and other substances contained therein, their action, interaction, and balance in relation to health and disease.	Nutritional Study		Research Activity	CTRP Intervention Terminology|CTRP Terminology
C158210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158210>	C209364	Hezhen Chinese|HEZHEN|HZ|HZ	A Chinese person from the Hezhen ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158211>	C209364	Gaoshan Chinese|GAOSHAN|GS|GS	A Chinese person from the Gaoshan ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158212>	C209364	Lhoba Chinese|LB|LB|LHOBA	A Chinese person from the Lhoba ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158213>	C209364	Tatar Chinese|TATAR|TT|TT	A Chinese person from the Tatar ethnic group.			Population Group	CDISC SDTM Collected Ethnicity Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158214>	C42916	Extended Release Capsule, Hard Dosage Form|CAPSULE, HARD, EXTENDED RELEASE	A capsule, covered with a rigid outer shell, that is designed to release active and/or inert ingredient(s) at a controlled, prolonged rate to reduce dosing frequency.			Biomedical or Dental Material	CDISC SDTM Dosage Form Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158215>	C42916	Extended Release Capsule, Softgel Dosage Form|CAPSULE, SOFTGEL, EXTENDED RELEASE	A capsule, covered with a soft gelatin shell and containing a liquid, suspension, or semisolid, that is designed to release active and/or inert ingredient(s) at a controlled, prolonged rate to reduce dosing frequency.			Biomedical or Dental Material	CDISC SDTM Dosage Form Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158216>	C210012|C158126	HIV-2 Seroreactivity Measurement|HIV-2 Seroreactivity|HIV-2 Seroreactivity|HIV2SR	The determination of the HIV-2 seroreactivity present in a sample.			Laboratory Procedure	CDISC SDTM Immunogenicity Specimen Assessments Test Code Terminology|CDISC SDTM Immunogenicity Specimen Assessments Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158217>	C210012|C158126	HIV-1 Seroreactivity Measurement|HIV-1 Seroreactivity|HIV-1 Seroreactivity|HIV1SR	The determination of the HIV-1 seroreactivity present in a sample.			Laboratory Procedure	CDISC SDTM Immunogenicity Specimen Assessments Test Code Terminology|CDISC SDTM Immunogenicity Specimen Assessments Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158218>	C92291	Monoclonal Protein Spike Region Identification|MPROTR|Monoclonal Protein Band Region|Monoclonal Protein Region|Monoclonal Protein Region|Monoclonal Protein Spike Region	The determination of a monoclonal protein spike region present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158219>	C75340	Fluoxetine Measurement|FLUOXTN|Fluoxetine|Fluoxetine	The determination of the amount of fluoxetine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15821>	C208218|C15715	Nutrition Research, Applied Clinical Trials	Nutrition research that uses rigorous, scientifically controlled studies to investigate the effects of dietary interventions, supplements, or regimens on human health outcomes. Examples include the DASH Diet Trials researching the effects on blood pressure or the FODMAP Diet Trials researching the effects on digestive health.			Research Activity	
C158220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158220>	C209976|C158147	Soluble Interleukin 2 Receptor Measurement|IL2SR|Soluble IL2R Measurement|Soluble Interleukin 2 Receptor|Soluble Interleukin 2 Receptor|sIL2R Measurement	The determination of the amount of soluble interleukin 2 receptor present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158221>	C74760	Glycine to Creatinine Ratio Measurement|GLYCREAT|Glycine/Creatinine|Glycine/Creatinine	The determination of the ratio of glycine compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158222>	C64430	Apolipoprotein A to Apolipoprotein B Ratio Measurement|ALAALB|Apolipoprotein A/Apolipoprotein B|Apolipoprotein A/Apolipoprotein B	The determination of the ratio of apolipoprotein A compared to apolipoprotein B present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158223>	C74760	Taurine to Creatinine Ratio Measurement|TAURCRT|Taurine/Creatinine|Taurine/Creatinine	The determination of the ratio of taurine compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158224>	C74760	Threonine to Creatinine Ratio Measurement|THRCREAT|Threonine/Creatinine|Threonine/Creatinine	The determination of the ratio of threonine compared to creatinine present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158225>	C64467	Aspartate Aminotransferase to Creatine Kinase Ratio Measurement|AST to CK Ratio Measurement|AST/Creatine Kinase|AST/Creatine Kinase|ASTCK|Aspartate Aminotransferase/CPK|Aspartate Aminotransferase/Creatine Kinase	The determination of the ratio of aspartate aminotransferase compared to creatine kinase present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158226>	C74954	Direct Bilirubin to Bilirubin Ratio Measurement|BILDIRBI|Direct Bilirubin/Bilirubin|Direct Bilirubin/Bilirubin	The determination of the ratio of direct bilirubin compared to total bilirubin present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158228>	C64431	Glycated Albumin to Albumin Ratio Measurement|ALBGALB|Glycated Albumin/Albumin|Glycated Albumin/Albumin	The determination of the ratio of glycated albumin compared to total albumin present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158229>	C67208	Plasmacytoid Lymphocytes to Leukocytes Ratio Measurement|LYMPLLE|Plasmacytoid Lymphocytes/Leukocytes|Plasmacytoid Lymphocytes/Leukocytes	The determination of the ratio of plasmacytoid lymphocytes compared to total leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15822>	C48678|C15820	Nutrition Research, Applied Non-Clinical Trials	Applied research on food and its components, performed on in vitro or in vivo test systems, in relation to health and disease.			Research Activity	
C158231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158231>	C67208	Sezary Cells to Leukocytes Ratio Measurement|SEZCELE|Sezary Cells/Leukocytes|Sezary Cells/Leukocytes	The determination of the ratio of Sezary cells compared to total leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158232>	C122095	Symmetric Dimethylarginine Measurement|N,N'-dimethylarginine|SDMA|Symmetric Dimethylarginine|Symmetric Dimethylarginine	The determination of the amount of symmetric dimethylarginine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158233>	C122095	Asymmetric Dimethylarginine Measurement|ADMA|Asymmetric Dimethylarginine|Asymmetric Dimethylarginine|N,N-dimethylarginine	The determination of the amount of asymmetric dimethylarginine present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158234>	C116184	Hemoglobin H Inclusion Bodies Measurement|HBH Inclusion Bodies|HBHIB|HGH Inclusion Bodies|Hemoglobin H Inclusion Bodies|Hemoglobin H Inclusion Bodies	The determination of the amount of hemoglobin H inclusion bodies present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158235>	C80160	Complement C5b-9 Measurement|C5B9|Complement C5b-9|Complement C5b-9|MAC Measurement|Membrane Attack Complex Measurement	The determination of the amount of complement C5b-9 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158236>	C51949	Large Lymphocyte Count|LYMLG|Large Lymphocytes|Large Lymphocytes	The determination of the number of large lymphocytes present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158237>	C74901	Pyridoxal Phosphate Measurement|Active Vitamin B6|PLP|Pyridoxal Phosphate|Pyridoxal Phosphate	The determination of the amount of pyridoxal phosphate present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158238>	C161395|C132301	HIV-1 RNA Measurement|HIV-1 RNA|HIV-1 RNA|HIV1RNA	The determination of the amount of HIV-1 RNA present in a sample.	HIV-1 RNA Measurement		Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Intervention Terminology|CTRP Terminology
C158239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158239>	C116640	Immunodiffusion|IMMUNODIFFUSION	A quantitative technique used to detect and estimate the concentration of an antigen by measuring the precipitation which is formed as a result of the interaction of the antigen and an antibody at optimal concentration.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15823>	C48678|C15820	Nutrition Research, Basic Non-Clinical Trials	Basic research on food and its components, performed on in vitro or in vivo test systems, in relation to health and disease.			Research Activity	
C158240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158240>	C23044	Romanowsky Stain|ROMANOWSKY STAIN	A microscopy staining method that utilizes both cationic and anionic dyes (typically methylene blue and eosin Y, respectively) for the morphological assessment of cells in a biological specimen.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158241>	C23044	Lissamine Green Stain|LISSAMINE GREEN STAIN	A vital staining method that utilizes a green, synthetically-produced phenyl methane dye that preferentially stains degenerate and dead epithelial cells and stroma.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158242>	C23044	Fluorescein Stain|FLUORESCEIN STAIN	A vital staining method that utilizes an orange phthalic indicator dye, which emits green fluorescence in the presence of alkaline solutions.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158243>	C190559	Slit Lamp Photography|SLIT LAMP PHOTOGRAPHY|Slit Lamp Biomicrography	A method of capturing images of the structures of the eye using a horizontally mounted microscope with an attached slit lamp.			Occupational Activity	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158244>	C17156	Thermal Ionization Mass Spectrometry|THERMAL IONIZATION MASS SPECTROMETRY|TIMS	A mass spectrometry method in which chemically-purified samples are heated to create positively ionized atoms that are then accelerated by an electric field and mass separated by an electromagnet.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158245>	C23044	Myeloperoxidase Stain|MPO Stain|MYELOPEROXIDASE STAIN	Immunohistochemical or enzyme cytochemical staining method to detect myeloperoxidase, a lysosomal protein that has peroxidase enzyme activity and is present in granulocytic and monocytic cells, but absent in lymphocytes.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158246>	C38060	Sloan Letter Eye Chart 100 Percent|SLOAN LETTER EYE CHART 100%	A diagrammatic method of vision testing that utilizes black letters on a white background to assess high contrast visual acuity that uses the Sloan optotypes and a 100% contrast level.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158247>	C120695	Fluorescent Antibody Virus Neutralization Assay|FAVN|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY	An immunofluorescence assay method that measures the level of virus-specific neutralizing antibodies in a serum or a plasma sample by the detection of fluorescence in susceptible cells incubated with serial dilutions of the serum/plasma and fluorophore-conjugated virus.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158248>	C60819|C19967	Cell-of-Origin Assay|CELL OF ORIGIN ASSAY|COO Assay|COO Assay	An assay that utilizes gene expression profiling of RNA extracted from formalin-fixed, paraffin-embedded tissue biopsies, in order to determine the cell of origin of the tumor.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158249>	C153598	Immune Repertoire Deep Sequencing|IMMUNE REPERTOIRE DEEP SEQUENCING	DNA sequencing of the full complement of genes associated with T and B cell antigen-specific receptors in an individual, performed with a high number of replications.			Molecular Biology Research Technique	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15824>	C15820	Nutrition Research, Dietary Components	Studies concerning the role of dietary components in general health, including cancer causation or prevention.			Research Activity	
C158250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158250>	C51962|C179019	Multiplex Real-time Polymerase Chain Reaction Assay|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Multiplex Real-Time PCR|Real-Time Multiplex PCR	An assay technique that utilizes the polymerase chain reaction (PCR) method to amplify multiple DNA sequences in a single cycle, with the accumulation of amplification product being measured as the reaction progresses.			Molecular Biology Research Technique	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158251>	C18640	In vitro Gene Expression Assay|IN VITRO GENE EXPRESSION ASSAY	A method that detects gene transcription associated with an in vitro cellular stimulus, through detection of the resulting transcribed mRNA or translated protein.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158252>	C192768|C130177	Targeted Transcriptome Sequencing|TARGETED TRANSCRIPTOME SEQUENCING|Targeted RNA-Seq|Targeted RNA-Seq	A type of whole transcriptome shotgun sequencing technique in which select portions of the transcriptome are selected for sequencing.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158253>	C153598|C130177	Targeted Genome Sequencing|TARGETED GENOME SEQUENCING	A DNA sequencing technique in which selected regions of an individual's genome are sequenced.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158254>	C25338	Chalkley Score|CHALKLEY SCORE|Chalkley Count	A microscopic measurement of the volumetric or area ratios of components of tissues or organs. (Chalkley HW. Method for the quantitative morphological analysis of tissues. J Natl Cancer Inst; 4: 47-52)			Finding	CDISC SDTM Microscopic Findings Test Detail Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158255>	C25180	Flagged Mutations Present Indicator|FLMUTIND	An indication as to whether the pre-specified mutations of interest are present in the subject.			Conceptual Entity	CDISC SDTM Microbiology Susceptibility Test Code Terminology|CDISC SDTM Microbiology Susceptibility Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158256>	C25208|C171083	Fat Mass|FATMASS	The weight of the body fat associated with either a particular body part or the whole body.			Conceptual Entity	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158257>	C19332	Lean Mass|LEANMASS	The weight of a body part or whole body, minus the weight of the fat associated with that body part or whole body.			Conceptual Entity	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158258>	C156561	N-acetylaspartate and N-acetyl-aspartylglutamate Measurement|N-acetylaspartate + N-acetyl-aspartylglutamate|NAA + NAAG Measurement|NAA+NAAG|NAA+NAAG|NAANAAG	The determination of the amount of N-acetylaspartate and N-acetyl-aspartylglutamate present in a sample.			Laboratory Procedure	CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158259>	C74803|C201454	Free Choline and Glycerophosphorylcholine and Phosphorylcholine Measurement|Choline, Free + Glycerophosphorylcholine + Phosphorylcholine|Choline, Free+GPC+PCh|Choline, Free+GPC+PCh|FCGPCPC	The determination of the amount of free choline, glycerophosphorylcholine, and phosphorylcholine present in a sample.			Laboratory Procedure	CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15825>	C15224	Nutrition Research, Fats, Saturated|Lipid Nutrition, Saturated	The study of the role of saturated fats in cancer causation or prevention and in general health.			Research Activity	
C158260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158260>	C74803|C201455	Creatine and Phosphocreatine Measurement|CTNPCTN|Creatine+Phosphocreatine|Creatine+Phosphocreatine	The determination of the amount of creatine and phosphocreatine present in a sample.			Laboratory Procedure	CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158261>	C74803	Glycerophosphorylcholine and Phosphorylcholine Measurement|GPC+PCh|GPC+PCh|GPCPC|Glycerophosphorylcholine + Phosphorylcholine	The determination of the amount of glycerophosphorylcholine and phosphorylcholine present in a sample.			Laboratory Procedure	CDISC SDTM Nervous System Physiology Test Code Terminology|CDISC SDTM Nervous System Physiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158262>	C125932	RANO Ellingson 2017 Oncology Response Criteria|RANO ELLINGSON 2017	Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials (Benjamin M. Ellingson, Patrick Y. Wen, Timothy F. Cloughesy. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials. Neurotherapeutics (2017) 14:307-320).			Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158263>	C125932	IRANO Okada 2015 Oncology Response Criteria|IRANO 2015	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. (Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope WB, Prins R, Sampson JH, Wen PY, Reardon DA. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015 Nov;16(15):e534-e542.)			Intellectual Product	CDISC SDTM Category of Oncology Response Assessment Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158265>	C85774	Volume of Distribution Observed for Unbound Drug|VZOUB|Vz Obs for UB|Vz Obs for UB	The volume of distribution associated with the terminal slope following administration, calculated using the observed value of the last non-zero concentration and corrected for unbound drug.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158266>	C85798	Volume of Distribution Predicted for Unbound Drug|VZPUB|Vz Pred for UB|Vz Pred for UB	The volume of distribution associated with the terminal slope following administration, calculated using the predicted value at the time of the last non-zero concentration and corrected for unbound drug.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158267>	C85798	Volume of Distribution of Fraction Dose Predicted Corrected for Unbound Drug|VZFPUB|Vz Pred by F for UB|Vz Pred by F for UB	The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using the predicted value at the time of the last non-zero concentration and corrected for unbound drug.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158268>	C121547	Visual Analog Scale (100 mm)|100mm VAS|100mm Visual Analog Scale|VAS (100 mm)|VISUAL ANALOG SCALE (100 MM)	A type of visual analog scale composed of a 100mm vertical or horizontal line.			Intellectual Product	CDISC SDTM QRS Method Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158269>	C121547	Visual Analog Scale (50 mm)|50mm VAS|50mm Visual Analog Scale|VAS (50 mm)|VISUAL ANALOG SCALE (50 MM)	A type of visual analog scale composed of a 50mm vertical or horizontal line.			Intellectual Product	CDISC SDTM QRS Method Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15826>	C15820	Nutritional Anthropometry	The study of nutritional effects upon the size, weight, and proportions of the human body.			Research Activity	
C158270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158270>	C121548	Numerical Rating Scale 11-Point|11-Point Numeric Rating Scale|11-Point Numerical Rating Scale|NRS 11-Point|NUMERICAL RATING SCALE 11-POINT|Numeric Rating Scale 11-Point	A type of numerical rating scale composed of 11 points, ranging from 0-10.			Intellectual Product	CDISC SDTM QRS Method Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158271>	C121549	Verbal Rating Scale 4-Point|4-Point Verbal Rating Scale|VERBAL RATING SCALE 4-POINT|VRS 4-Point	A type of verbal rating scale composed of 4 items.			Intellectual Product	CDISC SDTM QRS Method Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158272>	C121549	Verbal Rating Scale 5-Point|5-Point Verbal Rating Scale|VERBAL RATING SCALE 5-POINT|VRS 5-Point	A type of verbal rating scale composed of 5 items.			Intellectual Product	CDISC SDTM QRS Method Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158273>	C121549	Verbal Rating Scale 6-Point|6-Point Verbal Rating Scale|VERBAL RATING SCALE 6-POINT|VRS 6-Point	A type of verbal rating scale composed of 6 items.			Intellectual Product	CDISC SDTM QRS Method Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158274>	C41219	Maori|MAORI	The native people of New Zealand.			Population Group	CDISC CDASH Terminology|CDISC SDTM Collected Race Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158275>	C25337	Number of Births|BRTHN	A measurement of the total number of birth events experienced by a female.			Quantitative Concept	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158276>	C68616	Estimated Next Menstrual Period Start Date|ENMPSDTC|Est Next Menstrual Period Start Date|Est Next Menstrual Period Start Date	The approximate date of the first day of the next menstrual cycle.			Temporal Concept	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158277>	C68806	Gender Identity|GENIDENT	A person's internally held sense of their gender, which may or may not correspond to the individual's genotypic or phenotypic sex. IMPORTANT NOTICE: The NCI Thesaurus contains biomedical terminologies that NCI does not own or control. This concept contains gender-related content that does not comply with Executive Order 14168.			Qualitative Concept	CDISC SDTM Subject Characteristic Test Code Terminology|CDISC SDTM Subject Characteristic Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C158278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158278>	C70714	Lactescent Specimen|LACTESCENT	A specimen that has become or appears milky.			Qualitative Concept	CDISC SDTM Specimen Condition Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158279>	C70714	Non-Hemolyzed Specimen|NON-HEMOLYZED	A specimen that has not undergone the destruction of red blood cells followed by the release of the hemoglobin.			Qualitative Concept	CDISC SDTM Specimen Condition Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C15827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15827>	C15820	Nutritional Biochemistry	The study of the biochemistry of foods and vitamins as they affect the body			Research Activity	
C158280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158280>	C70714	Thawed Specimen|THAWED	A specimen that has changed from a frozen to a liquid or semi-liquid state.			Qualitative Concept	CDISC SDTM Specimen Condition Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158281>	C78730	Mixed Venous Blood|MIXED VENOUS BLOOD	The de-oxygenated blood flowing into the right side of the heart, composed of a mixture of venous blood from the entirety of the systemic circulation.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158282>	C113677	Urine Sediment|URINE SEDIMENT	Material that has settled out of solution in urine.			Body Substance	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C158283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158283>	C49660	Adhesion Performance Study|ADHESION PERFORMANCE	A type of study designed to evaluate the strength of the bond between an adhesive and the application surface.			Research Activity	CDISC SDTM Terminology|CDISC SDTM Trial Type Terminology|Clinical Data Interchange Standards Consortium Terminology
C158284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158284>	C49660	Alcohol Effect Study|ALCOHOL EFFECT	A type of study designed to evaluate the effects of alcohol on drug safety and efficacy.			Research Activity	CDISC SDTM Terminology|CDISC SDTM Trial Type Terminology|Clinical Data Interchange Standards Consortium Terminology
C158285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158285>	C49660	Device-Drug Interaction Study|DEVICE-DRUG INTERACTION	A type of study designed to evaluate the interaction between a device and a drug, where the use of one may affect the disposition, function, efficacy, or safety of the other.			Research Activity	CDISC SDTM Terminology|CDISC SDTM Trial Type Terminology|Clinical Data Interchange Standards Consortium Terminology
C158286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158286>	C49660	Drug-Drug Interaction Study|DRUG-DRUG INTERACTION	A type of study designed to evaluate the interaction between drugs, where the use of one may affect the disposition, efficacy, or safety of the other.			Research Activity	CDISC SDTM Terminology|CDISC SDTM Trial Type Terminology|Clinical Data Interchange Standards Consortium Terminology
C158287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158287>	C49660	Thorough QT Study|THOROUGH QT|TQT Study	A type of study designed to evaluate the potential for an experimental drug to delay cardiac ventricular repolarization.			Research Activity	CDISC SDTM Terminology|CDISC SDTM Trial Type Terminology|Clinical Data Interchange Standards Consortium Terminology
C158288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158288>	C49660	Biosimilarity Study|BIOSIMILARITY	A type of study designed to evaluate whether a biologic test article is highly similar in function and effect to an existing biologic that has already been clinically tested and approved for use.			Research Activity	CDISC SDTM Terminology|CDISC SDTM Trial Type Terminology|Clinical Data Interchange Standards Consortium Terminology
C158289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158289>	C49660	Dose Finding Study|DOSE FINDING	An early phase clinical study with the objective of determining the optimal therapeutic dose of a drug.			Research Activity	CDISC SDTM Terminology|CDISC SDTM Trial Type Terminology|Clinical Data Interchange Standards Consortium Terminology
C15828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15828>	C15321	Other Resources	Resources (facilities, collections, software, information sources, etc.) available to researchers that are not listed in other concepts of Research Resources tree of NCI Metathesaurus.			Physical Object	
C158290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158290>	C49660	Dose Proportionality Study|DOSE PROPORTIONALITY	A type of study designed to evaluate the relationship between dose and resulting exposure.			Research Activity	CDISC SDTM Terminology|CDISC SDTM Trial Type Terminology|Clinical Data Interchange Standards Consortium Terminology
C158291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158291>	C96649	Milligram per Liter Fibrinogen Equivalent Units|FEU mg/L|FEU mg/L|mg FEU/L|mg FEU/L|mg-L-FEU|mg-L-FEU|mg/L FEU|mg/L FEU|mg/L[FEU]|mg/L[FEU]|ug/mL FEU	A unit of equivalent concentration equal to the number of milligrams of fibrinogen per unit volume equal to one liter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158292>	C96649	Microgram per Liter Fibrinogen Equivalent Units|FEU ug/L|FEU ug/L|ng/mL FEU|ng/mL FEU|ug FEU/L|ug FEU/L|ug-L-FEU|ug-L-FEU|ug/L FEU|ug/L FEU|ug/L[FEU]|ug/L[FEU]	A unit of equivalent concentration equal to the number of micrograms of fibrinogen per unit volume equal to one liter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158293>	C68742	Ten Thousand Colony Forming Units|10*4.[CFU]|10*4.[CFU]|10^4 CFU|10^4 CFU|10^4.[CFU]|10^4.[CFU]|Ten Thousand CFU|Ten Thousand CFU	A unit of measurement of viable bacterial numbers equal to 10 to the fourth power colony forming units.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158294>	C68742	Ten Million Colony Forming Units|10*7.[CFU]|10*7.[CFU]|10^7 CFU|10^7 CFU|10^7.[CFU]|10^7.[CFU]|Ten Million CFU|Ten Million CFU	A unit of measurement of viable bacterial numbers equal to 10 to the seventh power colony forming units.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158295>	C70567	Gray per Hour|Gray/Hour|Gy/h|Gy/h|Gy/h	A unit of absorbed radiation dose rate defined as the number of Grays per hour.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158296>	C70567	Gray per Minute|Gray/Minute|Gy/min|Gy/min|Gy/min	A unit of absorbed radiation dose rate defined as the number of Grays per minute.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158297>	C81255	Fetal Head Circumference|FTHDCIRC	A circumferential measurement of the fetal head at the widest point.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Vital Sign Test Code Terminology|CDISC SDTM Vital Sign Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C158298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158298>	C25372	Challenge Agent Category|CAGTCAT	A general classification of the challenge agent used in the study model.			Classification	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158299>	C25180	Multiple Challenge Agent Different Category Indicator|MCCATIND|Multiple Challenge Agent Category Ind|Multiple Challenge Agent Category Ind|Multiple Challenge Agent Category Indicator	An indication as to whether the subject was challenged with more than one challenge agent from a different challenge agent category.			Conceptual Entity	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15829>	C15429	Outcomes and Health Services Research	Research to evaluate the delivery systems, processes, and impacts of evidence-based clinical interventions in communities.			Research Activity	
C1582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1582>	C1594	Carubicin Hydrochloride|CARUBICIN HYDROCHLORIDE|Carubicin hydrochloride	The hydrochloride salt of the anthracycline antineoplastic antibiotic carubicin.  Carubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.			Antibiotic|Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C158300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158300>	C25180	Multiple Challenge Agent Same Category Indicator|MCSCTIND|Multiple Challenge Agent Same Cat Ind|Multiple Challenge Agent Same Cat Ind	An indication as to whether the subject was challenged with more than one challenge agent from the same challenge agent category.			Conceptual Entity	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158301>	C42614	Challenge Agent Supplier Name|CAGTSUPN	The name of the person, company, organization, or institution that supplied the challenge agent employed in the study model.			Conceptual Entity	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158302>	C25407	Challenge Agent Supplier Address|CAGTSUPA	The address of the person, company, organization, or institution that supplied the challenge agent employed in the study model.			Spatial Concept	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158303>	C42614	Biological Agent Biovar Name|BABIOVRN	The biovar name of the biological challenge agent.			Conceptual Entity	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158304>	C42614	Biological Agent Serovar Name|BASEROVN	The serovar name of the biological challenge agent.			Conceptual Entity	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158305>	C42614	Biological Agent Strain Name|BASTRNN	The strain name of the biological challenge agent.			Conceptual Entity	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158306>	C25180	Biological Agent Engineered Indicator|BAENGIND	An indication as to whether the biological challenge agent is engineered rather than naturally occurring.			Conceptual Entity	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158307>	C25180	Biological Agent Certificate of Analysis Indicator|BACOAIND|Biological Agent CoA Indicator|Biological Agent CoA Indicator	An indication as to whether a certificate of analysis exists for the challenge agent.			Conceptual Entity	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158308>	C25284	Biological Agent Type|BACAT|Biological Agent Category|Biological Agent Category	The type of biological agent employed in the model.			Functional Concept	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158309>	C43459	Biological Challenge Agent Scientific Name|BAGENSPC|Biological Agent Genus and Species|Biological Agent Genus and Species|Biological Agent Genus and Species	The genus and species of the biological challenge agent used in the study.			Conceptual Entity	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15830>	C15292	Palliative Care, Other Than Pain and Hospice	Supportive care that is not hospice or pain relief			Health Care Activity	
C158310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158310>	C43530	Master Bank or Seed Stock Immediate Supplier|BAMBSSDS|Bio Ag Master Bank/Seed Stock Dir Supp|Bio Master Bank or Seed Stock Dir Supp|Bio Master Bank or Seed Stock Direct Supplier	The name of the direct supplier of the master bank or seed stock of organisms from which the biological challenge agent came.			Professional or Occupational Group	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158311>	C25162	Material Identification Code|BAMTIDCD|Biological Agent Material Ident Code|Biological Agent Material Ident Code	A distinctive alpha-numeric identification code assigned by the manufacturer or distributor to a specific quantity of manufactured material or product. This may include batch number, lot number, spore lot number, batch/lot number, etc.			Intellectual Product	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158312>	C25180	Biological Agent Nucleotide Sequence Indicator|BANSIND|Biological Agent Nucleotide Sequence Ind|Biological Agent Nucleotide Sequence Ind	An indication as to whether the genetic sequence of the challenge agent has been identified.			Conceptual Entity	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158313>	C25341	Biological Agent Nucleotide Sequence Location|BANSLOC|Biological Agent Nucleotide Sequence Loc|Biological Agent Nucleotide Sequence Loc	The reference, citation, or database location of the nucleotide sequence of the challenge agent.			Spatial Concept	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158314>	C25180	Working Bank or Primary Stock Characterized Indicator|BWBPSIND|Bio Ag Work Bank/Primary Stock Char Ind|Bio Ag Work Bank/Primary Stock Char Ind|Biological Working Bank or Primary Stock Characterized Indicator	An indication as to whether the working bank or primary stock was characterized by molecular or biological techniques.			Conceptual Entity	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158315>	C96972	Chemical Challenge Agent Name|CHAGNAM|Chemical Agent Name|Chemical Agent Name	The name of the chemical challenge agent.			Intellectual Product	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158316>	C54682	Chemical Agent CAS Number|CHAGCAS	The unique numerical identifier assigned by the Chemical Abstract Service (CAS), a division of the American Chemical Society, to the chemical challenge agent used in the study.			Classification	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158317>	C25180	Challenge Agent Metabolite Caused Injury Indicator|CHAMCIND|Chemical Ag Metabolite Causes Injury Ind|Chemical Ag Metabolite Causes Injury Ind|Chemical Agent Metabolite Causes Injury Indicator	An indication as to whether a metabolite of the chemical challenge agent is known to cause or contribute to the injury or condition of interest.			Conceptual Entity	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158318>	C25284	Radiological/Nuclear Challenge Agent Source Type|RNASRC|Rad/Nuc Agent Source|Rad/Nuc Agent Source	The mode by which the radiological or nuclear challenge agent is delivered to the subject.			Qualitative Concept	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158319>	C25284	Radiological/Nuclear Agent Ionizing Radiation Type|RNAIOTYP|Rad/Nuc Agent Ionizing Radiation Type|Rad/Nuc Agent Ionizing Radiation Type|Specify the modality of radiation	The form of ionizing radiation that is emitted by the radiological/nuclear agent source.			Functional Concept	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF4 Treatment Radiation Table
C15831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15831>	C16003|C15715	Pathobiology of Wasting and Growth Retardation	Elucidate the pathogenic mechanisms of HIV-related opportunistic infections. Enhance a bidirectional flow between basic and clinical observations and intervention programs on HIV-related complications and foster interdisciplinary collaborations.			Biomedical Occupation or Discipline	
C158320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158320>	C53264	Radiological/Nuclear Agent Irradiation Source Beam Strength|RNAISBS|Rad/Nuc Agent Irrad Source Beam Strength|Rad/Nuc Agent Irrad Source Beam Strength|Rad/Nuc Agent Irradiation Source Beam Strength	The energy of the irradiation beam produced by the source.			Qualitative Concept	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158321>	C25180	Challenge Agent Type Mixed Field Indicator|RNAMFIND|Rad/Nuc Agent Mixed Field Indicator|Rad/Nuc Agent Mixed Field Indicator	An indication as to whether there is more than one type of ionizing radiation associated with the rad/nuc challenge.			Conceptual Entity	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158322>	C42614	Radioisotope Species Name|RNARADSN|Rad/Nuc Agent Radioisotope Species Name|Rad/Nuc Agent Radioisotope Species Name	The literal identifier of the radioisotope, usually specified as the name of the chemical element followed by the mass number.			Conceptual Entity	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158323>	C163004	Dental Examination|DENTAL EXAM|Dental Exam|Oral Examination	A systematic evaluation of the mouth, face, and neck, which may include tooth counting, cleaning and visual assessments for abnormalities such as caries, gum disease, oral cancer, and structural malformations.			Diagnostic Procedure	CDISC SEND Age Estimation Method Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158324>	C48191	Animal Record Information|ANIMAL RECORDS	Information obtained from medical records, acquisition records, or other official documentation associated with the animal.			Conceptual Entity	CDISC SEND Age Estimation Method Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158325>	C158128	Biological Challenge Agent|BIOLOGICAL	A challenge agent comprising an organism or infectious agent.			Chemical Viewed Functionally	CDISC SEND Challenge Agent Category Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158326>	C158128	Chemical Challenge Agent|CHEMICAL	A challenge agent comprising a non-radioactive chemical or elemental substance.			Chemical Viewed Functionally	CDISC SEND Challenge Agent Category Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158327>	C158128	Radiological/Nuclear Challenge Agent|RADIOLOGICAL/NUCLEAR|Rad/Nuc|Rad/Nuc Challenge Agent	A challenge agent that emits ionizing radiation.			Chemical Viewed Functionally	CDISC SEND Challenge Agent Category Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158328>	C110937	Supernumerary Rib|SUPERNUMERARY RIB|Supernumerary Rib, Full	The presence of more than the usual or expected number of thoracic ribs.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158329>	C158328	Cervical Rib|CERVICAL RIB	Presence of rib formation in the cervical region.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15832>	C41385	Patient Oriented Research	Studies of living individuals or groups of subjects (such as families, communities, or populations defined geographically or demographically), or material of human origin (such as tissues, specimens, and cognitive phenomena, etc.), for understanding of their physiologic and pathophysiologic characteristics, mechanisms of human diseases and development of approaches to diseases treatment and prevention. Includes the laboratory-based development of new forms of technology, studies of health-related professions, institutions, and systems, excludes disease-oriented studies of material, obtained from patients who were unknown to investigators.			Research Activity	
C158330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158330>	C158328	Lumbar Rib|Bone structure of thirteenth rib (body structure)|LUMBAR RIB	Presence of rib formation in the lumbar region.			Finding	CDISC SEND Fetal Pathology Findings Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C158331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158331>	C137801	Experimental Organism Syncytium|SYNCYTIA|Syncytia	A single giant cell that is created from the fusion of mononuclear cells, or a network of cells that serve a particular purpose.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158332>	C45233	Increased Alveolar Macrophages|ALVEOLAR MACROPHAGES, INCREASED	Increased number of macrophages in the terminal air spaces.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158333>	C35867	Increased Granules|GRANULES, INCREASED	Increased number and/or size of granules in the cytoplasm of cells.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158334>	C35867	Decreased Peri-Insular Halos|PERI-INSULAR HALOS, DECREASED	Decreased number and/or size of peri-insular halos.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158335>	C35867	Increased Peri-Insular Halos|PERI-INSULAR HALOS, INCREASED	Increased number and/or size of peri-insular halos.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158336>	C36279	Paneth Cell Reduction|PANETH CELL REDUCTION	Decrease in Paneth cell granules and loss of Paneth cells within the small intestine.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158337>	C35867	Secretory Depletion|SECRETORY DEPLETION	Decreased secretory content (e.g., mucus or granules) in secretory cells.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158338>	C163730	Increased Atretic Follicles|ATRETIC FOLLICLES, INCREASED	Increased number of atretic follicles.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158339>	C176708	Decreased or Absent Follicles	Decreased number or total absence of follicles.			Finding	
C15833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15833>	C15785	Pediatric Clinical Services	Programs for preventive, assessment, maintenance , diagnosis, treatment, and rehabilitative services which are specialized for infants, children, and adolescents.			Health Care Activity	
C158340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158340>	C48205	Booster Synchrotron|BOOSTER SYNCHROTRON	A type of particle accelerator that can generate ionizing radiation by colliding subatomic particles traveling at high speeds along a curved or circular chamber.			Manufactured Object	CDISC SEND Rad/Nuc Agent Source Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158341>	C16742	X-Ray Irradiator|X-RAY IRRADIATOR	A device that exposes samples to X-ray radiation.			Manufactured Object	CDISC SEND Rad/Nuc Agent Source Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158342>	C16742	Nuclear Reactor|NUCLEAR REACTOR	A device that enables a controlled, self-sustaining nuclear reaction and release of energy.			Manufactured Object	CDISC SEND Rad/Nuc Agent Source Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158343>	C158129	Chemical Restraint|CHEMICAL	A chemical substance that is administered in order to restrict movement.			Laboratory Procedure	CDISC SEND Restraint Mode Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158344>	C158129	Physical Restraint|PHYSICAL	A material item that is placed on the body in order to restrict movement.			Laboratory Procedure	CDISC SEND Restraint Mode Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158345>	C158129	Chemical and Physical Restraint|CHEMICAL AND PHYSICAL	A restraint type that includes both chemical and physical restraining methods.			Laboratory Procedure	CDISC SEND Restraint Mode Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158346>	C158148	Sexual Maturity Status at Neutering|SEXMATSN	A description of when the neutering event took place, relative to the subject's sexual maturation status.			Qualitative Concept	CDISC SEND Subject Characteristic Test Code Terminology|CDISC SEND Subject Characteristic Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158347>	C25180	Major Histocompatibility Complex Tested Indicator|MHC Tested Indicator|MHC Tested Indicator|MHCIND	An indication as to whether the study subject has had its major histocompatibility complex characterized.			Conceptual Entity	CDISC SEND Subject Characteristic Test Code Terminology|CDISC SEND Subject Characteristic Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158348>	C25180	Previous Research Experience Indicator|PRVRSIND|PRVRSIND	An indication as to whether the study subject has been in a previous study.			Conceptual Entity	CDISC SEND Subject Characteristic Test Code Terminology|CDISC SEND Subject Characteristic Test Name Terminology|CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C158349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158349>	C25180	Neutered Indicator|NEUTIND|neutered indicator|neutered_indicator	An indication as to whether the animal(s) has been neutered.			Conceptual Entity	CDISC SEND Subject Characteristic Test Code Terminology|CDISC SEND Subject Characteristic Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|ICDC Property Terminology|ICDC Terminology
C15834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15834>	C15321	Pharmaceutical Resources	A collection of pharmaceutical substances available for research use			Conceptual Entity	
C158350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158350>	C25180	Telemeterized Indicator|TELMIND|TELMIND|Telemetered Indicator|Telemetered Indicator|Telemetered Indicator	An indication as to whether the subject was telemeterized during the treatment or assessment.			Conceptual Entity	CDISC SEND Subject Characteristic Test Code Terminology|CDISC SEND Subject Characteristic Test Name Terminology|CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C158351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158351>	C156784	Sexually Mature|SEXUALLY MATURE	The life stage at which the organism is capable of reproduction.			Qualitative Concept	CDISC SEND Sexual Maturity Status Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158352>	C25531	Sexually Immature|SEXUALLY IMMATURE	The life stage before which the organism is capable of reproduction.			Qualitative Concept	CDISC SEND Sexual Maturity Status Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158353>	C38081	Expiratory Flow 50%|EF50	The rate of gas flow during exhalation, beginning at the point at which tidal volume is decreased by 50%.			Diagnostic Procedure	CDISC SEND Respiratory Test Code Terminology|CDISC SEND Respiratory Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158354>	C38081	Apnea Time|AT	A measurement of the apnea duration determined by total sleep time minus the sum of inspiration time and expiration time.			Diagnostic Procedure	CDISC SEND Respiratory Test Code Terminology|CDISC SEND Respiratory Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158355>	C82572	Elapsed Time Between Breaths|ELTMBB	The amount of time between one breath to the next breath calculated by inspiration time plus expiration time.			Temporal Concept	CDISC SEND Respiratory Test Code Terminology|CDISC SEND Respiratory Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158356>	C49666	Efficacy Study With Pre-Exposure Prophylaxis|EFFICACY, PRE-EXPOSURE PROPHYLAXIS	A study that assesses the efficacy of prophylactic treatment (including radioprotectors) given before exposure to an agent(s).			Research Activity	CDISC SEND Study Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158357>	C49666	Efficacy Study With Post-Exposure Prophylaxis|EFFICACY, POST-EXPOSURE PROPHYLAXIS	A study that assesses the efficacy of prophylactic treatment given after exposure to the agent(s) but before the manifestation of the disease or condition.			Research Activity	CDISC SEND Study Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158358>	C49666	Efficacy Study With Post-Exposure Radiomitigation|EFFICACY, POST-EXPOSURE RADIOMITIGATION	A study that assesses the efficacy of a radiomitigator given after exposure to the challenge agent(s) but before the manifestation of the disease or condition.			Research Activity	CDISC SEND Study Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158359>	C68599	Draft Study Report|DRAFT	A preliminary version of the final study report.			Intellectual Product	CDISC SEND Study Report Status Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C15835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15835>	C15864|C15693	Phase I and II Vaccine Trials	Select candidate vaccines or concepts suitable for Phase I and Phase II trials and conduct these trials.			Research Activity	
C158360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158360>	C68599	Interim Study Report|INTERIM	A study report that contains interim evaluations, assessments, or analyses.			Intellectual Product	CDISC SEND Study Report Status Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158361>	C68599	Final Study Report|FINAL	A report that is conclusive in its process or progression and which has been signed by the study director.			Intellectual Product	CDISC SEND Study Report Status Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158362>	C68599	Amended Final Study Report|AMENDED FINAL	A study report that has been signed by the study director and has been changed by correction, addition, substitution or omission.			Intellectual Product	CDISC SEND Study Report Status Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158363>	C25180	Antimicrobial or Acidified/Chlorinated Water During Husbandry Indicator|AACHIND|Antimicrobial Acidified/Chlor H20 Ind|Antimicrobial Acidified/Chlor H20 Ind|Antimicrobial or Acidified/Chlorinated Water At Test Facility Indicator	An indication as to whether the animal received antimicrobials or acidified/chlorinated water during husbandry.			Conceptual Entity	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C158364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158364>	C70865	Study Report Status|STRPSTAT	The status of the study report with respect to the completeness and validity/version of the datasets.			Qualitative Concept	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C158365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158365>	C80324	Excluded Pathogen|PATHEX|Pathogen Exclusion|Pathogen Exclusion	The type of pathogen that an animal is verified to be free of.			Conceptual Entity	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C158366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158366>	C71460	Pathogen Exclusion Verification Method|PATHEXVM	The technique by which the vendor or sponsor ensures that the animals are free from specified pathogens.			Conceptual Entity	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C158367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158367>	C25180	Qualified Animal Model Use Indicator|AMQPIND|FDA Qualified Animal Model Indicator|FDA Qualified Animal Model Indicator	An indication as to whether the study was performed using a qualified animal model.			Conceptual Entity	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C158368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158368>	C25180	Specific Pathogen Free Indicator|SPF Indicator|SPFIND	An indication as to whether the subjects have been shown to be free of a specific pathogen.			Conceptual Entity	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C158369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158369>	C25180	Genetically Modified Subject Indicator|GMSIND	An indication as to whether the study or set contains test subjects that have been genetically modified in some way (e.g., transgenic knock-in, knock-down, etc.).			Conceptual Entity	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C15836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15836>	C71485	Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial|PLCO	The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, or PLCO Trial, is a large-scale study to determine if certain tests will reduce the number of deaths from these cancers.  Sponsored by the National Cancer Institute (NCI), the study will involve 148,000 men and women ages 55 through 74 at medical facilities in 9 geographic areas across the United States.  (Cancer Facts Screening: Questions and Answers About the PLCO Cancer Screening Trial)			Research Activity	
C158370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158370>	C25180	Pharmacokinetic Analysis Indicator|PKANIND	An indication as to whether the study includes a pharmacokinetic assessment.			Conceptual Entity	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C158371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158371>	C25180	Challenge Agent Multiple Route Indicator|CAMRTIND	An indication as to whether the challenge agent is administered by more than one route for any animal(s).			Conceptual Entity	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C158372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158372>	C43242	Toxicological Dose Descriptor|TDOSD|Toxic/Physiologic Dose Descr|Toxic/Physiologic Dose Descr|Toxicologic/Physiologic Dose Description	A statistically derived estimate of a dose with a certain toxicological or physiologic effect in a population, based on data from a dose-response study.			Conceptual Entity	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C158373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158373>	C62438	Factor for Toxicological Dose Descriptor|FTDOSD|Factor for Toxic/Physiologic Dose Descr|Factor for Toxic/Physiologic Dose Descr|Factor for Toxicologic/Physiologic Dose Description	The quantity given for the multiplier of the toxicological dose descriptor			Conceptual Entity	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C158374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158374>	C39854|C2901	Non-Invasive Bladder Urothelial Neoplasm|Bladder Non-Invasive Urothelial Neoplasm	A non-invasive neoplasm that arises from the urothelial lining of the bladder.			Neoplastic Process	
C158375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158375>	C16960	Surgery Patient	A patient who is undergoing a surgical procedure.			Patient or Disabled Group	
C158376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158376>	C158375	Gynecologic Surgery Patient	A patient who is undergoing a gynecologic surgical procedure.	Gynecologic Surgery Patient		Patient or Disabled Group	CTRP Intervention Terminology|CTRP Terminology
C158377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158377>	C158376	Hysterectomy Patient	A patient who is undergoing a hysterectomy.	Hysterectomy Patient		Patient or Disabled Group	CTRP Intervention Terminology|CTRP Terminology
C158378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158378>	C27838|C165289	Refractory Endometrial Serous Adenocarcinoma	An endometrial serous adenocarcinoma that is resistant to treatment.	Refractory Endometrial Serous Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158379>	C40153|C165289	Refractory Endometrial Mixed Cell Adenocarcinoma	An endometrial mixed cell adenocarcinoma that is resistant to treatment.	Refractory Endometrial Mixed Cell Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C15837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15837>	C63474	Population Intervention	A health and wellness program targeted to a specific population rather than to an individual.	Population Intervention		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C158380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158380>	C8028|C165289	Refractory Endometrial Clear Cell Adenocarcinoma	An endometrial clear cell adenocarcinoma that is resistant to treatment.	Refractory Endometrial Clear Cell Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158381>	C9180|C207061|C150092	Refractory Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor	A uterine corpus malignant mixed mesodermal (Mullerian) tumor that is resistant to treatment.	Refractory Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158382>	C7383|C65181|C39831|C213363	Non-Invasive Bladder Papillary Urothelial Carcinoma|Bladder Papillary Urothelial Carcinoma In Situ	Papillary urothelial neoplastic proliferation in the bladder with some level of cytological and architectural disorder visible at low to intermediate magnification, with no invasion beyond the basement membrane (Ta). (WHO 2016)			Neoplastic Process	
C158383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158383>	C172450|C170931|C170930	Advanced Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor	A uterine corpus malignant mixed mesodermal (Mullerian) tumor that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158384>	C21295	SIGLEC15 Gene|SIGLEC15|SIGLEC15|Sialic Acid Binding Ig Like Lectin 15 Gene	This gene plays a role in glycan binding and immunity.	SIGLEC15 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C158385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158385>	C158384	SIGLEC15 wt Allele|CD33 Antigen-Like 3 Gene|CD33 Molecule-Like 3 Gene|CD33L3|HsT1361|S15|SIGLEC-15|Sialic Acid Binding Ig Like Lectin 15 wt Allele	Human SIGLEC15 wild-type allele is located in the vicinity of 18q21.1 and is approximately 19 kb in length. This allele, which encodes sialic acid-binding Ig-like lectin 15 protein, is involved in both innate immunity and sialylated glycan binding.	SIGLEC15 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158386>	C17728	Sialic Acid-Binding Ig-Like Lectin 15|CD33 Antigen-Like 3|CD33 Molecule-Like 3|S15|SIGLEC15|Sialic Acid Binding Ig Like Lectin 15|Sialic Acid Binding Ig-Like Lectin 15|Sialic Acid-Binding Immunoglobulin-Like Lectin 15|Siglec-15	Sialic acid-binding Ig-like lectin 15 (328 aa, ~36 kDa) is encoded by the human SIGLEC15 gene. This protein plays a role in both sialylated glycan binding and innate immunity.	Sialic Acid-Binding Ig-Like Lectin 15		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158387>	C63442	mSMILE Regimen|Dexamethasone-Methotrexate-Ifosfamide-Pegaspargase-Etoposide|Dexamethasone/Methotrexate/Ifosfamide/Pegaspargase/Etoposide|Modified SMILE|Modified SMILE Regimen|Modified-SMILE|mSMILE	A modified version of the SMILE regimen consisting of dexamethasone, methotrexate, ifosfamide, pegaspargase and etoposide that can be used in the treatment of natural killer (NK)/T-cell lymphoma. Compared to SMILE, in mSMILE the pegylated L-asparaginase is substituted for L-asparaginase and the regimen cycle length is shortened.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C158388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158388>	C25870	GSTT2 Gene|GSTT2|GSTT2|Glutathione S-Transferase Theta 2 (Gene/Pseudogene) Gene	This gene is involved in glutathione conjugation.			Gene or Genome	
C158389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158389>	C158388	GSTT2 wt Allele|Glutathione S-Transferase Theta 2 (Gene/Pseudogene) wt Allele|Glutathione S-Transferase, Theta-2 Gene	Human GSTT2 wild-type allele is located in the vicinity of  22q11.23 and is approximately 4 kb in length. This allele, which encodes glutathione S-transferase theta-2 protein, plays a role in glutathione metabolism.			Gene or Genome	
C15838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15838>	C15843	Prevent Transmission of HIV/Safety Blood Supply	Develop and assess multiple and concurrent ethical intervention strategies to reduce or prevent HIV transmission in both domestic and international settings.			Therapeutic or Preventive Procedure	
C158390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158390>	C20075	Glutathione S-Transferase Theta-2|EC 2.5.1.18|GST Class-Theta-2|GSTT2|Glutathione S-Transferase Theta 2|Glutathione-S-Transferase T2	Glutathione S-transferase theta-2 (244 aa, ~28 kDa) is encoded by the human GSTT2 gene. This protein is involved in the conjugation of glutathione to hydrophobic electrophiles.			Amino Acid, Peptide, or Protein|Enzyme	
C158391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158391>	C20194	TINAGL1 Gene|TINAGL1|TINAGL1|Tubulointerstitial Nephritis Antigen Like 1 Gene	This gene may play a role in the regulation of receptor-mediated signaling.			Gene or Genome	
C158392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158392>	C158391	TINAGL1 wt Allele|ARG1|Androgen-Regulated Gene 1|GIS5|LCN7|LIECG3|Lipocalin 7 Gene|OLRG2|Oxidized LDL-Responsive Gene 2|P3ECSL|PP6614|PSEC0088|TINAG-Like 1 Gene|TINAGRP|Tubulointerstitial Nephritis Antigen Like 1 wt Allele|UNQ204/PRO230	Human TINAGL1 wild-type allele is located in the vicinity of 1p35.2 and is approximately 11 kb in length. This allele, which encodes tubulointerstitial nephritis antigen-like protein, may be involved in the modulation of ligand-dependent signaling.			Gene or Genome	
C158393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158393>	C18466	Tubulointerstitial Nephritis Antigen-Like|Glucocorticoid-Inducible Protein 5|Lipocalin 7|OLRG-2|Oxidized LDL-Responsive Gene 2 Protein|TIN Ag-Related Protein|TIN-Ag-RP|TINAG-Like Protein 1|TINAG-Related Protein|TINAGL1|Tubulointerstitial Nephritis Antigen-Related Protein	Tubulointerstitial nephritis antigen-like (467 aa, ~52 kDa) is encoded by the human TINAGL1 gene. This protein may play a role in the modulation of receptor signaling.			Amino Acid, Peptide, or Protein	
C158394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158394>	C35867	Marked Thickening of the Bladder Urothelium Present	A morphologic finding indicating the presence of marked thickening of the urothelium in the bladder.			Finding	
C158395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158395>	C25870	NMT1 Gene|N-Myristoyltransferase 1 Gene|NMT1|NMT1	This gene is involved in the myristoylation of proteins.			Gene or Genome	
C158396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158396>	C158395	NMT1 wt Allele|Alternative, Short Form NMT-S Gene|Long Form, NMT-L Gene|N-Myristoyltransferase 1 wt Allele|NMT	Human NMT1 wild-type allele is located in the vicinity of 17q21.31 and is approximately 57 kb in length. This allele, which encodes glycylpeptide N-tetradecanoyltransferase 1 protein, plays a role in protein myristoylation.			Gene or Genome	
C158397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158397>	C16259	Glycylpeptide N-Tetradecanoyltransferase 1|EC 2.3.1.97|Myristoyl-CoA:Protein N-Myristoyltransferase|Myristoyl-CoA:Protein N-Myristoyltransferase 1|N-Myristoyltransferase 1|NMT 1|NMT-L|NMT1|Peptide N-Myristoyltransferase 1|Type I N-Myristoyltransferase	Glycylpeptide N-tetradecanoyltransferase 1 (496 aa, ~57 kDa) is encoded by the human NMT1 gene. This protein is involved in the irreversible transfer of myristoyl groups from tetradecanoyl-CoA to N-terminal glycines of protein substrates.			Amino Acid, Peptide, or Protein|Enzyme	
C158398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158398>	C15195	Vaginal Cuff Brachytherapy|VCB	Radiation delivered by a radiation source contained in an intra-vaginal cylinder to target neoplasms of the vaginal cuff.			Therapeutic or Preventive Procedure	
C158399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158399>	C158398|C157724	High-Dose-Rate Vaginal Cuff Brachytherapy|HDR-VCB	High dose rate radiation delivered by a radiation source contained in an intra-vaginal cylinder to target neoplasms of the vaginal cuff.	High-Dose-Rate Vaginal Cuff Brachytherapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C15839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15839>	C15857	Prevention and Treatment Evaluation	An assessment of the effectiveness of therapeutic intervention or preventive treatment.			Research Activity	
C1583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1583>	C1594	Daunorubicin Hydrochloride|5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)-, hydrochloride|5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, hydrochloride, (8S-cis)-(9CI)|CERUBIDINE|Cerubidin|Cerubidine|Cerubidine|Cloridrato de Daunorubicina|DAUNORUBICIN HYDROCHLORIDE|Daunoblastin|Daunoblastina|Daunoblastine|Daunomycin Hydrochloride|Daunomycin hydrochloride|Daunomycin, hydrochloride|Daunorubicin hydrochloride|Daunorubicin.HCl|Daunorubicini Hydrochloridum|FI-6339|L-lyxo-Hexopyranoside, 3beta-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-metldioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-,alpha-,hydrochloride|Ondena|RP-13057|Rubidomycin Hydrochloride|Rubilem|daunomycin hydrochloride|daunorubicin hydrochloride	The hydrochloride salt of an anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis.	Daunorubicin Hydrochloride		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158400>	C85254|C158398	Low-Dose-Rate Vaginal Cuff Brachytherapy|LDR-VCB	Low dose rate radiation delivered by a radiation source contained in an intra-vaginal cylinder to target neoplasms of the vaginal cuff.	Low-Dose-Rate Vaginal Cuff Brachytherapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C158401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158401>	C3308|C157131	Refractory Paraganglioma	A paraganglioma that does not respond to treatment.	Refractory Paraganglioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158402>	C3326|C158401	Refractory Adrenal Gland Pheochromocytoma	A pheochromocytoma that does not respond to treatment.	Refractory Adrenal Gland Pheochromocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158403>	C26147	B4GALT5 Gene|B4GALT5|B4GALT5|Beta-1,4-Galactosyltransferase 5 Gene	This gene plays a role in lactosylceramide biosynthesis.			Gene or Genome	
C158404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158404>	C158403	B4GALT5 wt Allele|B4Gal-T5|BETA4-GALT-IV|Beta-1,4-GalT IV|Beta-1,4-GalT-V|Beta-1,4-Galactosyltransferase 5 wt Allele|Beta-1,4-Galactosyltransferase 5, Polypeptide 5 Gene|Beta-1,4GalT-V|Beta4Gal-T5|Beta4GalT-V|UDP-Gal:BetaGlcNAc Beta 1,4- Galactosyltransferase, Polypeptide 5 Gene|UDP-Gal:BetaGlcNAc Beta-1,4- Galactosyltransferase, Polypeptide 5 Gene|gt-V	Human B4GALT5 wild-type allele is located in the vicinity of 20q13.13 and is approximately 81 kb in length. This allele, which encodes beta-1,4-galactosyltransferase 5 protein, is involved in the synthesis of lactosylceramide.			Gene or Genome	
C158405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158405>	C17434	Beta-1,4-Galactosyltransferase 5|B4GALT5|Beta-1,4-GalT II|Beta-1,4-GalT-V|Beta-1,4-GalTase 5|Beta-1,4GalT-V|Beta-1.4-Galactosyltransferase V|Beta4Gal-T5|EC 2.4.1.-|EC 2.4.1.274|Glucosylceramide Beta-1,4-Galactosyltransferase|LacCer Synthase|Lactosylceramide Synthase|Lactosylceramide Synthase Beta-1,4-GalT-V|UDP-Gal:Beta-GlcNAc Beta-1,4-Galactosyltransferase 5|UDP-Galactose:Beta-N-Acetylglucosamine Beta-1,4-Galactosyltransferase 5|b4Gal-T5	Beta-1,4-galactosyltransferase 5 (388 aa, ~45 kDa) is encoded by the human B4GALT5 gene. This protein plays a role in the transfer of galactose from UDP-galactose to glucosylceramide to yield lactosylceramide.			Amino Acid, Peptide, or Protein|Enzyme	
C158406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158406>	C25939	CH25H Gene|CH25H|CH25H|Cholesterol 25-Hydroxylase Gene	This gene plays a role in the metabolism of cholesterol and 25-hydroxycholesterol.			Gene or Genome	
C158407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158407>	C158406	CH25H wt Allele|C25H|Cholesterol 25-Hydroxylase wt Allele	Human CH25H wild-type allele is located in the vicinity of 10q23.31 and is approximately 2 kb in length. This allele, which encodes cholesterol 25-hydroxylase protein, is involved in sterol synthesis.			Gene or Genome	
C158408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158408>	C16946	Cholesterol 25-Hydroxylase|CH25H|Cholesterol 25-Monooxygenase|EC 1.14.99.38|h25OH	Cholesterol 25-hydroxylase (272 aa, ~32 kDa) is encoded by the human CH25H gene. This protein plays a role in the reversible conversion of cholesterol to 25-hydroxycholesterol.			Amino Acid, Peptide, or Protein|Enzyme	NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C158409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158409>	C20194	FNDC5 Gene|FNDC5|FNDC5|Fibronectin Type III Domain Containing 5 Gene	This gene may be involved in exercise-dependent metabolic processes.	FNDC5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C15840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15840>	C15843	Prevention and Treatment of Opportunistic Infection	Improve understanding of the biology of opportunistic pathogens, identify potential molecular targets for effective therapies, and discover and delineate the structure and function of potential agents for prevention and treatment of HIV-associated OIs and other infections that are modified by HIV infection.			Therapeutic or Preventive Procedure	
C158410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158410>	C158409	FNDC5 wt Allele|FRCP2|Fibronectin Type III Domain Containing 5 wt Allele|Irisin Gene	Human FNDC5 wild-type allele is located in the vicinity of 1p35.1 and is approximately 10 kb in length. This allele, which encodes fibronectin type III domain-containing protein 5, may play a role in the cellular response to exercise.	FNDC5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158411>	C18466	FNDC5 Gene Product	A protein encoded by the FNDC5 gene.	FNDC5 Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158412>	C158411	Fibronectin Type III Domain-Containing Protein 5|FNDC5|Fibronectin Type III Domain Containing Protein 5|Fibronectin Type III Repeat-Containing Protein 2	Fibronectin type III domain-containing protein 5 (212 aa, ~24 kDa) is encoded by the human FNDC5 gene. This protein plays a role in the cellular response to physical reactivity.	Fibronectin Type III Domain-Containing Protein 5		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158413>	C158411	Irisin|FNDC5	Irisin (112 aa, ~13 kDa) is encoded by the human FNDC5 gene. This protein may be involved in muscle cell responses to exercise.	Irisin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158414>	C21281	Translocase Gene	Genes encoding a class of enzymes that catalyze the movement of ions or molecules across or within membranes.			Gene or Genome	
C158415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158415>	C25668|C19697	Tissue Section|Tissue Slice	A thin slice of tissue, usually for examination by microscopy.			Tissue	
C158416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158416>	C198567	Blood DNA	DNA extracted from nucleated cell from the peripheral blood.			Body Substance|Nucleic Acid, Nucleoside, or Nucleotide	
C158417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158417>	C19697	Frozen Tissue	A tissue sample that has been frozen prior to analysis.			Tissue	
C158418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158418>	C70699	Stained Specimen	A biospecimen that has been prepared using dyes, reagents, or other materials to produce coloration of structures.			Body Substance	
C158419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158419>	C16554	Translocase|EC 7	A class of enzymes that catalyze the movement of ions or molecules across or within membranes.			Amino Acid, Peptide, or Protein|Enzyme	
C15841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15841>	C15843|C15184	Prevention of High-Risk Behavior	1C2; Basic Sciences Research (includes vaccine and chemotherapy development); Behavioral Research; Prevention of high-risk behaviors (behavioral and pharmacologic interventions)			Therapeutic or Preventive Procedure	
C158420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158420>	C155725	Patidegib Topical Gel|IPI-926 Topical Gel|Patidegib Gel	A topical gel containing patidegib, a cyclopamine-derived inhibitor of the Hedgehog (Hh) pathway, with potential antineoplastic activity. Upon topical application of the patidegib gel, patidegib binds to and inhibits the activity of the G-protein coupled receptor smoothened (SMO), thereby inhibiting Hh pathway signaling. This decreases proliferation and survival in tumor cells in which the Hh pathway is overactivated. Upregulated Hh signaling is associated with uncontrolled tumor cell proliferation. Topical application of patidegib allows for local anti-tumor activity while avoiding systemic exposure and unwanted systemic effects.	Patidegib Topical Gel		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158421>	C3769|C159565	Recurrent Endometrioid Adenocarcinoma	The reemergence of endometrioid adenocarcinoma after a period of remission.	Recurrent Endometrioid Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158422>	C663	SR Mitomycin Intravesical Solution|Intravesical Mitomycin Gel UGN-102|MMC + UG-1 Gel|Mitomycin Intravesical Solution|Mitomycin Urothelial Gel UGN-102|RTGel with Mitomycin C UGN-102|Sustained-release Mitomycin C Hydrogel Formulation UGN-102|UGN 102|UGN-102|UGN102|Vesigel|Zusduri	A sustained-release (SR) reverse thermal (RT) hydrogel formulation containing the antineoplastic antibiotic mitomycin C (MMC), with potential antineoplastic activity. Upon intravesical instillation of SR mitomycin intravesical solution , the liquid converts into gel form and conforms to the bladder wall, allowing MMC to be deposited locally in the bladder to prevent the excretion of this chemotherapeutic agent via urinary flow. In turn, MMC alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis resulting in inhibition of tumor cell proliferation. Due to its reverse thermal-gelation properties, this gel is able to stay in a liquid state at cold temperatures, at 4 degrees Celsius, and transition to a water-soluble gel at body temperature. This allows for increased accumulation of MMC locally in the upper urinary tract which leads to increased efficacy compared to standard intravesical delivery of MMC for bladder cancer. Compared to UGN-101, in SR mitomycin intravesical solution (UGN-102) the strength of MMC is lower.	SR Mitomycin Intravesical Solution		Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158423>	C84280	Chemical Impurity|Chemical Impurities	Any unwanted organic, inorganic, and residual solvents in drug substances and final products.			Chemical Viewed Functionally	
C158424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158424>	C20189	Physical Property|Physical Properties	Any of the characteristics that define the nature of matter or forces that act upon it.			Qualitative Concept	
C158425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158425>	C20189	Biological Property	Characteristics of biological systems.			Qualitative Concept	
C158426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158426>	C8300|C139002	Recurrent Desmoplastic Small Round Cell Tumor	The reemergence of desmoplastic small round cell tumor after a period of remission.	Recurrent Desmoplastic Small Round Cell Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158427>	C8300|C139001	Refractory Desmoplastic Small Round Cell Tumor	Desmoplastic small round cell tumor that is resistant to treatment.	Refractory Desmoplastic Small Round Cell Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158428>	C3043|C148302	Recurrent Fibrosarcoma	The reemergence of fibrosarcoma after a period of remission.	Recurrent Fibrosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158429>	C3043|C148301	Refractory Fibrosarcoma	Fibrosarcoma that is resistant to treatment.	Refractory Fibrosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C15842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15842>	C16209	Prevention, Early Detection of Premalignant Lesions	A procedure that includes screening, diet and behavioral adjustments to prevent and/or detect the transformation of normal cells into cancerous lesions.			Diagnostic Procedure	
C158430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158430>	C27005|C148302	Recurrent Spindle Cell Sarcoma	The reemergence of spindle cell sarcoma after a period of remission.	Recurrent Spindle Cell Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158431>	C27005|C148301	Refractory Spindle Cell Sarcoma	Spindle cell sarcoma that is resistant to treatment.	Refractory Spindle Cell Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158432>	C503	PicoGreen Dye|PicoGreen|PicoGreen Fluorescent Nucleic Acid Dye	A proprietary dye for staining and quantitation of double-stranded DNA. It can selectively detect as little as 25 pg/ml of dsDNA in the presence of ssDNA, RNA, and free nucleotides. The assay is linear over three orders of magnitude and has little sequence dependence.			Indicator, Reagent, or Diagnostic Aid	
C158433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158433>	C503	RiboGreen Dye|RiboGreen|RiboGreen Fluorescent Nucleic Acid Dye	A proprietary dye for staining and quantitation of RNA in solution. It has linear fluorescence detection in the range of 1-200 ng of RNA.			Indicator, Reagent, or Diagnostic Aid	
C158434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158434>	C503	OliGreen Dye|OliGreen|OliGreen Fluorescent Nucleic Acid Dye	A proprietary green-fluorescent nucleic acid stain for quantitating oligonucleotides and single-stranded DNA (ssDNA) in solution.			Indicator, Reagent, or Diagnostic Aid	
C158435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158435>	C113078	Chemical Identification	The identification of a chemical based on certain criteria and tests.			Qualitative Concept	
C158436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158436>	C201282|C129822	Nivatrotamab|Anti-GD2 hu3F8/Anti-CD3 huOKT3 Bispecific Antibody|Humanized 3F8 Bispecific Antibody|Humanized Anti-GD2 x Anti-CD3 Bispecific Antibody|NIVATROTAMAB|hu3F8 x huOKT3 Bispecific Antibody|hu3F8-BsAb	A bispecific antibody comprised of a humanized anti-CD3 OKT3 (huOKT3) single chain variable fragment (scFv), linked to the carboxyl end of a humanized anti-GD2 3F8 (hu3F8) immunoglobulin G1 (IgG1) light chain, with potential antineoplastic activity. Upon intravenous administration, nivatrotamab binds to CD3 on T-cells and disialoganglioside GD2 expressed on certain tumor cells, thereby cross-linking T-cells with GD2-expressing tumor cells. This promotes a selective cytotoxic T-lymphocyte (CTL) response against GD2-expressing cells. The Fc region of the anti-GD2 hu3F8/anti-CD3 huOKT3 bispecific antibody has two amino acid substitutions, N297A and K322A, which may prevent cytokine release syndrome and other unwanted side effects including complement-mediated pain. GD2, a disialoganglioside and tumor-associated antigen (TAA), is overexpressed in a variety of tumor cell types. CD3 is part of the functional T-cell receptor (TCR) complex, which is necessary for antigen recognition by T-cells and is required for signal transduction.	Nivatrotamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158437>	C7359|C159565|C150094	Recurrent Endometrial Adenocarcinoma	The reemergence of endometrial adenocarcinoma after a period of remission.			Neoplastic Process	
C158438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158438>	C28676|C201545	iPSC-derived Natural Killer Cells FT500|FT 500|FT-500|FT500|Induced Pluripotent Stem Cell-derived Natural Killer Cells FT500|iPSC-NK Cells FT500|iPSC-derived NK Cells FT500	A preparation of off-the-shelf, natural killer (NK) cells derived from a clonal master induced pluripotent stem cell (iPSC) line, with potential antineoplastic and immunostimulatory activities. Upon administration, iPSC-derived natural killer cells FT500 bind to stress-induced ligands on tumor cells, leading to tumor cell lysis and release of tumor neoantigens. Additionally, iPSC-NK cells secrete inflammatory cytokines and chemokines including interferon-gamma (IFN-gamma), tumor necrosis factor-alpha (TNF-alpha), C-C motif chemokines 3, 4, and 22 (CCL3, CCL4, and CCL22), and C-X-C motif chemokine 10 (CXCL10), thereby enhancing T-cell activity and recruitment to the tumor site.	iPSC-derived Natural Killer Cells FT500		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158439>	C200766	Autologous Anti-MUC1*-CAR-4-1BB-CD3zeta-expressing T-lymphocytes|Anti-MUC1*-CAR-4-1BB-CD3zeta-expressing Autologous T-lymphocytes|Autologous HuMNC2-CAR44|Autologous huMNC2-CAR44 CAR T Cells|Autologous huMNC2-CAR44 T-lymphocytes	A preparation of autologous T-lymphocytes transduced with a lentiviral vector encoding a human CD8 alpha leader sequence, a humanized MNC2-single chain variable fragment (scFv) targeting the extracellular domain of the cleaved form of mucin-1 (MUC-1), known as MUC1*, portions of human CD8 hinge and transmembrane domains, and human 4-1BB and human CD3-zeta costimulatory domains, with potential antineoplastic and immunostimulating activities. Upon re-introduction into the patient, the autologous anti-MUC1*-CAR-4-1BB-CD3zeta-expressing T-lymphocytes specifically recognize and induce selective toxicity in MUC1*-expressing tumor cells. MUC1* is a post-translationally modified form of MUC1, a single pass type I transmembrane protein that is normally expressed in the glandular or luminal epithelial cells of the esophagus, stomach, duodenum, pancreas, uterus, prostate, and lungs, and may be aberrantly expressed in certain tumor types. MUC1* is a growth factor that is activated by ligand-induced dimerization of its extracellular domain, which may stimulate mitogen-activated protein kinase (MAP kinase, MAPK) signaling and promote tumor cell growth. MUC1* is frequently expressed in certain cancer types, with increased expression noted in higher grade lesions and tumor cells resistant to certain chemotherapies.	Autologous Anti-MUC1*-CAR-4-1BB-CD3zeta-expressing T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15843>	C25218	Preventive Intervention|PREVENTATIVE|PRYLX|Prevention|Prevention|Prevention Measures|Prophylactic|Prophylaxis|Prophylaxis|prevention|prevention|prophylaxis|prophylaxis	Therapeutic, nutritional, environmental, social and/or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease.	Preventive Intervention		Therapeutic or Preventive Procedure	CDISC Glossary Terminology|CDISC SDTM Terminology|CDISC SDTM Treatment Intent Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C158440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158440>	C25939	KDM7A Gene|KDM7A|KDM7A|Lysine Demethylase 7A Gene	This gene is involved in histone demethylation and brain development.			Gene or Genome	
C158441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158441>	C158440	KDM7A wt Allele|JHDM1D|Jumonji C Domain Containing Histone Demethylase 1 Homolog D (S. cerevisiae) Gene|KDM7|KIAA1718|Lysine (K)-Specific Demethylase 7A Gene|Lysine Demethylase 7A wt Allele	Human KDM7A wild-type allele is located in the vicinity of 7q34 and is approximately 92 kb in length. This allele, which encodes lysine-specific demethylase 7A protein, plays a role in brain development and histone modification.			Gene or Genome	
C158442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158442>	C16946	Lysine-Specific Demethylase 7A|EC 1.14.11.-|Histone Lysine Demethylase JHDM1D|JmjC Domain-Containing Histone Demethylation Protein 1D|Jumonji C Domain Containing Histone Demethylase 1 Homolog D|KDM7A|Lysine Demethylase 7A|Lysine-Specific Demethylase 7	Lysine-specific demethylase 7A (941 aa, ~107 kDa) is encoded by the human KDM7A gene. This protein is involved in histone demethylation and brain development.			Amino Acid, Peptide, or Protein|Enzyme	
C158443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158443>	C20194	KDM7A-DT Gene|KDM7A Divergent Transcript Gene|KDM7A-DT|KDM7A-DT	The function of this gene is unknown.			Gene or Genome	
C158444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158444>	C158443	KDM7A-DT wt Allele|AI283268|FLJ22719|JHDM1D Antisense RNA 1 (Head To Head) Gene|JHDM1D Antisense RNA 1 Gene|JHDM1D-AS1|KDM7A Divergent Transcript wt Allele	Human KDM7A-DT wild-type allele is located in the vicinity of 7q34 and is approximately 5 kb in length. This allele, which encodes KDM7A divergent transcript long noncoding RNA, has no known function.			Gene or Genome	
C158445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158445>	C88924	KDM7A Divergent Transcript|JHDM1D Antisense RNA 1|KDM7A-DT	KDM7A divergent transcript (~2 kb) is encoded by the human KDM7A-DT gene. The function of this long noncoding RNA is unknown.			Nucleic Acid, Nucleoside, or Nucleotide	
C158446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158446>	C26057	DHX58 Gene|DExH-Box Helicase 58 Gene|DHX58|DHX58	This gene is involved in modulation of antiviral response signaling.			Gene or Genome	
C158447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158447>	C158446	DHX58 wt Allele|D11LGP2|D11lgp2e|DEXH (Asp-Glu-X-His) Box Polypeptide 58 Gene|DExH-Box Helicase 58 wt Allele|LGP2|LGP2, Mouse, Homolog of Gene|Ortholog of Mouse D11lgp2 Gene|RLR-3	Human DHX58 wild-type allele is located in the vicinity of 17q21.2 and is approximately 11 kb in length. This allele, which encodes probable ATP-dependent RNA helicase DHX58 protein, plays a role in the regulation of antiviral signaling.			Gene or Genome	
C158448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158448>	C17417	ATP-Dependent RNA Helicase DHX58|DEXH Box Polypeptide 58|DHX58|EC 3.6.4.13|Probable ATP-Dependent Helicase LGP2|Probable ATP-Dependent RNA Helicase DHX58|Protein D11Lgp2 Homolog|RIG-I-Like Receptor 3|RIG-I-Like Receptor LGP2|RLR|RLR-3|RNA Helicase LGP2	Probable ATP-dependent RNA helicase DHX58 (678 aa, ~77 kDa) is encoded by the human DHX58 gene. This protein is involved in RNA binding and antiviral responses.			Amino Acid, Peptide, or Protein|Enzyme	NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C158449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158449>	C20917	LIN9 Gene|LIN9|LIN9|Lin-9 DREAM MuvB Core Complex Component Gene	This gene plays a role in the cell cycle G1/S transition.			Gene or Genome	
C15844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15844>	C15920	Protein/Amino Acid Nutrition Research, Animal	The study of the role of dietary animal proteins and amino acids in cancer causation or prevention and in general health.			Research Activity	
C158450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158450>	C158449	LIN9 wt Allele	Human LIN9 wild-type allele is located in the vicinity of 1q42.12 and is approximately 79 kb in length. This allele, which encodes protein lin-9 homolog, is involved in tumor suppression and cell cycle regulation.			Gene or Genome	
C158451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158451>	C17761	Protein Lin-9 Homolog|Beta Subunit-Associated Regulator of Apoptosis|HuLin-9|LIN9|Rb Related Pathway Actor|TUDOR Gene Similar Protein|Type I Interferon Receptor Beta Chain-Associated Protein|hLin-9|pRB-Associated Protein	Protein lin-9 homolog (542 aa, ~62 kDa) is encoded by the human LIN9 gene. This protein plays a role in the G1/S transition of the cell cycle.			Amino Acid, Peptide, or Protein	
C158452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158452>	C20194	MIR210HG Gene|MIR210 Host Gene|MIR210HG|MIR210HG	The function of this gene is unknown.			Gene or Genome	
C158453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158453>	C158452	MIR210HG wt Allele|AW014921|FLJ41489|MIR210 Host Gene (Non-Protein Coding) Gene|MIR210 Host Gene wt Allele	Human MIR210HG wild-type allele is located in the vicinity of 11p15.5 and is approximately 5 kb in length. This allele, which encodes MIR210 host gene long noncoding RNA, has no known function.			Gene or Genome	
C158454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158454>	C88924	MIR210 Host Gene Long Noncoding RNA|MIR210 Host Gene Long Non-Coding RNA|MIR210 Host Gene, Long Non-Coding RNA|MIR210HG	MIR210 host gene long noncoding RNA (~2 kb) is encoded by the human MIR210HG gene. The function of this long noncoding RNA is unknown.			Nucleic Acid, Nucleoside, or Nucleotide	
C158455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158455>	C20194	MS4A7 Gene|MS4A7|MS4A7|Membrane Spanning 4-Domains A7 Gene	This gene may play a role in receptor-mediated signaling.			Gene or Genome	
C158456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158456>	C158455	MS4A7 wt Allele|4SPAN2|CD20L4|MS4A8|Membrane Spanning 4-Domains A7 wt Allele|Membrane-Spanning 4-Domains, Subfamily A, Member 7 Gene	Human MS4A7 wild-type allele is located in the vicinity of 11q12 and is approximately 17 kb in length. This allele, which encodes membrane-spanning 4-domains subfamily A member 7 protein, may be involved in the formation and function of a multimeric receptor complex.			Gene or Genome	
C158457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158457>	C18466	Membrane-Spanning 4-Domains Subfamily A Member 7|CD20 Antigen-Like 4|CD20/FCER1B Family Member 4|CD20/Fc-Epsilon-RI-Beta Family Member 4|Four-Span Transmembrane Protein 2|MS4A7	Membrane-spanning 4-domains subfamily A member 7 (240 aa, ~26 kDa) is encoded by the human MS4A7 gene. This protein may play a role in signal transduction as part of a multimeric receptor complex.			Amino Acid, Peptide, or Protein	
C158458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158458>	C20194	MSANTD3 Gene|MSANTD3|MSANTD3|Myb/SANT DNA Binding Domain Containing 3 Gene	This gene may be involved in protein complex formation or DNA binding.			Gene or Genome	
C158459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158459>	C158458	MSANTD3 wt Allele|C9orf30|Chromosome 9 Open Reading Frame 30 Gene|L8|MGC17337|Myb/SANT DNA Binding Domain Containing 3 wt Allele|Myb/SANT-Like DNA-Binding Domain Containing 3 Gene	Human MSANTD3 wild-type allele is located in the vicinity of 9q31.1 and is approximately 25 kb in length. This allele, which encodes Myb/SANT-like DNA-binding domain-containing protein 3, may play a role in protein complex formation and DNA binding.			Gene or Genome	
C15845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15845>	C15920	Protein/Amino Acid Nutrition Research, Non-Animal	The study of the role of dietary non-animal proteins and amino acids in cancer causation or prevention and in general health.			Research Activity	
C158460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158460>	C18466	Myb/SANT-Like DNA-Binding Domain-Containing Protein 3|MSANTD3|Myb/SANT-Like DNA-Binding Domain Containing 3|UPF0439 Protein C9orf30	Myb/SANT-like DNA-binding domain-containing protein 3 (275 aa, ~32 kDa) is encoded by the human MSANTD3 gene. This protein may be involved in DNA binding and protein complex formation.			Amino Acid, Peptide, or Protein	
C158461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158461>	C17610	Citrate Blood Cell Fraction|Citrate Cellular Fraction	The blood cells that are harvested from a cell collection tube containing sodium citrate.			Body Substance	
C158462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158462>	C17610	EDTA Blood Cell Fraction|EDTA Cellular Fraction	The blood cells that are harvested from a cell collection tube containing EDTA.			Body Substance	
C158463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158463>	C9272|C126465	Metastatic Salivary Gland Carcinoma	A salivary gland carcinoma that has metastasized to another anatomic site.	Metastatic Salivary Gland Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158464>	C158463|C153213	Locally Advanced Salivary Gland Carcinoma	A salivary gland carcinoma that has spread to nearby tissues or lymph nodes.	Locally Advanced Salivary Gland Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158465>	C49666	Challenge Agent Treatment Efficacy Study|EFFICACY, TREATMENT	A study that assesses the efficacy of treatment given after a protocol-defined manifestation of the challenge agent(s)-induced disease or condition.			Research Activity	CDISC SEND Study Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C158466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158466>	C1920|C1663	Attenuated Live Listeria monocytogenes Encoding KRAS G12D|ADXS 503|ADXS-503|ADXS503|Lm-Hot KRAS G12D	An off-the-shelf, plasmid DNA-based cancer vaccine composed of a live-attenuated strain of the Gram-positive bacterium Listeria monocytogenes (Lm) carrying a plasmid vector encoding multiple, not yet disclosed, tumor associated antigens (TAAs) and sequence peptides associated with commonly occurring hotspot mutations, including the aspartic acid substitution for glycine at position 12 (G12D) in KRAS, with potential immunostimulatory and antineoplastic activities. Upon administration, ADXS-503 is taken up by antigen presenting cells (APCs) and the TAAs are processed and presented to immune cells by both major histocompatibility complex (MHC) I and II molecules. This leads to an increase in antigen-specific CD8-positive T-cells and gamma/delta T-cells within the tumor microenvironment (TME) and an inhibition of immunosuppressive tumor-infiltrating T-regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSCs). This may lead to tumor cell death in cells expressing TAAs that are shared across multiple tumor types. The KRAS G12D mutation is thought to drive tumorigenesis and progression in some cancers.	Attenuated Live Listeria monocytogenes Encoding KRAS G12D		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158467>	C40998|C150706	MUC1*-Positive Cells Present|Anti-MUC1* Antibody MNC2 Reactivity Present|Anti-MUC1* Antibody Positive|Anti-MUC1* Antibody Positive Cells Present|Anti-MUC1* Antibody-Positive|Anti-MUC1* Positive|Anti-MUC1* Positive Cells Present|Antibody MNC2 Reactivity Present|MUC1* Positive|MUC1* Positive Cells Present|MUC1* Positive Cells Present	An indication that the cells in sample have cell surface expression of antibody-detectable amounts of a specific membrane-bound fragment of the mucin-1 protein (MUC1), which results from extramembrane cleavage, has growth factor receptor-like activity and is comprised of the cytoplasmic tail, the transmembrane domain and at least forty-five amino acids of the extracellular domain.	MUC1* Positive Cells Present		Finding	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158468>	C25870	OXCT1 Gene|3-Oxoacid CoA-Transferase 1 Gene|OXCT1|OXCT1	This gene plays a role in ketone body catabolism.			Gene or Genome	
C158469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158469>	C158468	OXCT1 wt Allele|3-Oxoacid CoA-Transferase 1 wt Allele|OXCT|SCOT	Human OXCT1 wild-type allele is located in the vicinity of 5p13.1 and is approximately 141 kb in length. This allele, which encodes succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial protein, is involved in ketone body metabolism. Loss of function mutations in the gene are associated with succinyl-CoA:3-oxoacid-CoA transferase deficiency (SCOTD).			Gene or Genome	
C15846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15846>	C15687|C15313	Ionizing Radiotherapy|Radiation|Radiation Ionizing Radiotherapy|Radiation Ionizing Radiotherapy	The use of ionizing radiation to kill cancer cells			Therapeutic or Preventive Procedure	
C158470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158470>	C17210	Succinyl-CoA:3-Ketoacid Coenzyme A Transferase 1, Mitochondrial|3-Oxoacid CoA Transferase|3-Oxoacid CoA Transferase 1|3-Oxoacid CoA-Transferase 1|EC 2.8.3.5|OXCT1|SCOT-s|Somatic-Type Succinyl-CoA:3-Oxoacid CoA-Transferase|Succinyl CoA:3-Oxoacid CoA Transferase|Succinyl CoA:3-Oxoacid-CoA Transferase|Succinyl-CoA:3-Ketoacid-CoA Transferase	Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial (520 aa, ~56 kDa) is encoded by the human OXCT1 gene. This protein plays a role in the catabolism of ketone bodies.			Amino Acid, Peptide, or Protein|Enzyme	
C158471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158471>	C129972	10/10 HLA Match|HLA Match 10/10|Match 10/10	Complete HLA matching for HLA-A, -B, -C, -DRB1, and -DQB1 loci.			Classification	
C158472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158472>	C129972	12/12 HLA Match|HLA Match 12/12|Match 12/12	Complete HLA matching for HLA-A,-B,-C,-DRB1,-DQB1, and -DP loci.			Classification	
C158473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158473>	C126298	9/10 HLA Match|HLA Match 9/10|Match 9/10	Degree of HLA match is 9/10 for HLA-A, -B, -C, -DRB1, and -DQB1 loci.			Classification	
C158474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158474>	C126298	8/10 HLA Match|HLA Match 8/10|Match 8/10	Degree of HLA match is 8/10 for HLA-A, -B, -C, -DRB1, and -DQB1 loci.			Classification	
C158475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158475>	C126298	7/10 HLA Match|HLA Match 7/10|Match 7/10	Degree of HLA match is 7/10 for HLA-A, -B, -C, -DRB1, and -DQB1 loci.			Classification	
C158476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158476>	C126298	6/10 HLA Match|HLA Match 6/10|Match 6/10	Degree of HLA match is 6/10 for HLA-A, -B, -C, -DRB1, and -DQB1 loci.			Classification	
C158477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158477>	C126298	5/10 HLA Match|HLA Match 5/10|Match 5/10	Degree of HLA match is 5/10 for HLA-A, -B, -C, -DRB1, and -DQB1 loci.			Classification	
C158478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158478>	C129972	6/6 HLA Match|HLA Match 6/6|Match 6/6	Complete HLA matching for HLA-A, -B and -DRB1 loci.			Classification	
C158479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158479>	C138935	Body Mass Index 25 or Greater|Body Mass Index Greater than or Equal to 25	Indicates a body mass index measurement of 25 or higher.	Body Mass Index 25 or Greater		Finding	CTRP Disease Terminology|CTRP Terminology
C15847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15847>	C15313	Non-Ionizing Radiotherapy|Radiation Non-Ionizing, Radiotherapy	The use of non-ionizing radiation to kill cancer cells.	Non-Ionizing Radiotherapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C158480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158480>	C28310	Autologous Dendritic Cell/Myeloma Fusion Vaccine|Autologous DC/Multiple Myeloma Fusions|DC/MM Fusion Vaccine|DC/MM Fusions|DC/Multiple Myeloma Fusions|DC/Plasma Cell Myeloma Fusion	A therapeutic cancer vaccine consisting of autologous dendritic cells (DCs) fused with patient-derived plasma cell (multiple) myeloma cells with potential immunostimulatory and antineoplastic activities. Upon administration, autologous DC/multiple myeloma fusions stimulate both helper and cytotoxic T-lymphocyte (CTL) responses through the presentation of internalized and newly synthesized tumor associated antigens (TAAs). This may promote cellular and humoral antitumor immune responses in patients with plasma cell myeloma.	Autologous Dendritic Cell/Myeloma Fusion Vaccine		Cell|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158481>	C20744	PALM2 Gene|PALM2|PALM2|Paralemmin 2 Gene	This gene may be involved in modeling of the actin cytoskeleton.			Gene or Genome	
C158482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158482>	C158481	PALM2 wt Allele|Paralemmin 2 wt Allele	Human PALM2 wild-type allele is located in the vicinity of 9q31.3 and is approximately 311 kb in length. This allele, which encodes paralemmin-2 protein, may play a role in cell shape.			Gene or Genome	
C158483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158483>	C18073	Paralemmin-2|PALM2|Paralemmin 2	Paralemmin-2 (379 aa, ~42 kDa) is encoded by the human PALM2 gene. This protein may be involved in cell shape and cytoskeletal structure.			Amino Acid, Peptide, or Protein	
C158484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158484>	C25997	AKAP2 Gene|A-Kinase Anchoring Protein 2 Gene|AKAP2|AKAP2	This gene is involved in the regulation of protein kinase A activity.			Gene or Genome	
C158485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158485>	C158484	AKAP2 wt Allele|A Kinase (PRKA) Anchor Protein 2 Gene|A-Kinase Anchoring Protein 2 wt Allele|AKAP-2|AKAPKL|DKFZp564L0716|KIAA0920|MISP2|PRKA2	Human AKAP2 wild-type allele is located in the vicinity of 9q31.3 and is approximately 124 kb in length. This allele, which encodes A-kinase anchor protein 2, plays a role in the activity of protein kinase A.			Gene or Genome	
C158486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158486>	C26231	A-Kinase Anchor Protein 2|A Kinase Anchor Protein 2|A-Kinase Anchoring Protein 2|AKAP-2|AKAP-KL|AKAP2|PRKA2|Protein Kinase A Anchoring Protein 2|Protein Kinase A-Anchoring Protein 2|Protein Kinase A2	A-kinase anchor protein 2 (859 aa, ~95 kDa) is encoded by the human AKAP2 gene. This protein is involved in the modulation of protein kinase A activity.			Amino Acid, Peptide, or Protein	
C158487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158487>	C28510	PALM2/AKAP2 Fusion Gene|PALM2 and AKAP2 Fusion Gene|PALM2-AKAP2|PALM2-AKAP2 Readthrough Gene|PALM2-AKAP2 Readthrough Transcript Gene|PALM2/AKAP2|PALM2/AKAP2 Readthrough Gene|PALM2/AKAP2 Readthrough Transcript Gene|PALM2::AKAP2 Fusion Gene|PALM2AKAP2|PALM2AKAP2	A fusion gene (~7 kb) that results from a read-through of 2 genes in the vicinity of 9q31.3 which fuses the PALM2 gene to the AKAP2 gene. Variation in the fusion gene is associated with the variability in human height.			Gene or Genome	
C158488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158488>	C17561	PALM2/AKAP2 Fusion Protein|PALM2 and AKAP2 Fusion Protein|PALM2-AKAP2 Fusion Protein|PALM2-AKAP2 Protein|PALM2-AKAP2 Readthrough Protein|PALM2/AKAP2 Protein|PALM2/AKAP2 Readthrough Protein|PALM2::AKAP2 Fusion Protein|Paralemmin-2-A-Kinase Anchor Protein 2 Fusion Protein|Paralemmin-2/A-Kinase Anchor Protein 2 Fusion Protein	PALM2/AKAP2 fusion protein (1103 aa, ~122 kDa) is encoded by the human PALM2/AKAP2 fusion gene. This protein plays a role in the determination of human height.			Amino Acid, Peptide, or Protein	
C158489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158489>	C25939	QSOX2 Gene|QSOX2|QSOX2|Quiescin Sulfhydryl Oxidase 2 Gene	This gene plays a role in extracellular protein modification.			Gene or Genome	
C15848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15848>	C162700	Radiology, Treatment Planning	The creation of a strategy for radiation therapy.	Radiology, Treatment Planning		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C158490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158490>	C97927	BCL2 Gene Mutation|B-Cell CLL-Lymphoma 2 Gene Mutation|B-Cell CLL/Lymphoma 2 Gene Mutation|BCL2, Apoptosis Regulator Gene Mutation|Bcl-2 Gene Mutation	A change in the nucleotide sequence of the BCL2 gene.	BCL2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158491>	C158489	QSOX2 wt Allele|DKFZp762A2013|QSCN6L1|Quiescin Q6-Like 1 Gene|Quiescin Sulfhydryl Oxidase 2 wt Allele|SOXN|Sulfhydryl Oxidase. Neuroblastoma-Derived Gene	Human QSOX2 wild-type allele is located in the vicinity of 9q34.3 and is approximately 40 kb in length. This allele, which encodes sulfhydryl oxidase 2 protein, is involved in disulfide bond formation in secreted proteins.			Gene or Genome	
C158492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158492>	C16946	Sulfhydryl Oxidase 2|EC 1.8.3.2|Neuroblastoma-Derived Sulfhydryl Oxidase|QSOX2|Quiescin Q6 Sulfhydryl Oxidase 2|Quiescin Q6-Like Protein 1|Quiescin Sulfhydryl Oxidase 2|Thiol Oxidase 2	Sulfhydryl oxidase 2 (698 aa, ~78 kDa) is encoded by the human QSOX2 gene. This protein plays a role in the oxidation of sulfhydryl groups to disulfides in extracellular peptides and proteins.			Amino Acid, Peptide, or Protein|Enzyme	
C158493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158493>	C150581	Platinum-Resistant Lung Small Cell Carcinoma	Lung small cell carcinoma that is resistant to platinum therapy.	Platinum-Resistant Lung Small Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158494>	C50995	Platinum-Sensitive Disease|Platinum-Sensitive	A finding indicating that a cancer responds to platinum therapy initially, but it comes back after a certain period. For ovarian cancer, it refers to cancer relapse at least six months after the end of platinum therapy.			Finding	
C158495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158495>	C4917	Platinum-Sensitive Lung Small Cell Carcinoma|Platinum-Sensitive Small Cell Lung Carcinoma	Lung small cell carcinoma that is sensitive to platinum therapy.	Platinum-Sensitive Lung Small Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158496>	C25784	RAB6B Gene|RAB6B|RAB6B|RAB6B, Member RAS Oncogene Family Gene	This gene is involved in the regulation of retrograde trafficking.			Gene or Genome	
C158497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158497>	C158496	RAB6B wt Allele|RAB6B, Member RAS Oncogene Family wt Allele	Human RAB6B wild-type allele is located in the vicinity of 3q22.1 and is approximately 72 kb in length. This allele, which encodes Ras-related protein Rab-6B, plays a role in GTPase activity that modulates intracellular transport pathways.			Gene or Genome	
C158498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158498>	C62683|C116446	Tomographic Optical Breast Imaging|TOBI	Diffuse optical breast imaging that utilizes near-infrared (NIR) light propagation through breast tissues to assess the optical properties of tissue for the identification of abnormalities.	Tomographic Optical Breast Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C158499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158499>	C18549	Ras-Related Protein Rab-6B|RAB6B|Ras-Associated Protein Rab6B	Ras-related protein Rab-6B (208 aa, ~23 kDa) is encoded by the human RAB6B gene. This protein is involved in the regulation of retrograde transport.			Amino Acid, Peptide, or Protein|Enzyme	
C15849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15849>	C15687|C15313	High-LET Radiotherapy|Radiotherapy, High Linear Energy Transfer|Radiotherapy-High LET|high-dose radiation	Radiotherapy using radioactive particles that deposit a high amount of energy by radiation per unit length of travel.			Therapeutic or Preventive Procedure	
C1584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1584>	C266	Loperamide Hydrochloride|Imodium|Imodium A-D|LOPERAMIDE HYDROCHLORIDE|loperamide hydrochloride	The hydrochloride salt form of loperamide, a synthetic, piperidine derivative and opioid agonist with antidiarrheal activity. Loperamide acts on the mu-receptors in the intestinal mucosa. This leads to a decrease in gastrointestinal motility by decreasing the circular and longitudinal smooth muscle activity of the intestinal wall. This slows intestinal transit and allows for more water and electrolyte absorption from the intestines. Loperamide is not significantly absorbed from the gut and does not cross the blood-brain barrier. Therefore it has no central nervous system effects.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C158500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158500>	C8282|C117719	Globozoospermia	A rare but severe cause of male infertility. It is characterized by the presence of 100% round headed spermatozoa and lack of acrosomes.			Finding	Cellosaurus Disease Terminology
C158502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158502>	C188928	Androgen Receptor Status|AR Status	Refers to the presence or absence of androgen receptor molecules on the surface of the cells in a specimen.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology
C158504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158504>	C181114	Linvoseltamab|Anti-BCMA x Anti-CD3 Bispecific Antibody REGN5458|Anti-BCMA/CD3 Bispecific Antibody REGN5458|BCMA x CD3 Bispecific Antibody REGN5458|LINVOSELTAMAB|Linvoseltamab-gcpt|Lynozyfic|Lynozyfic|REGN 5458|REGN-5458|REGN5458	A human, immunoglobulin G4 (IgG4) bispecific antibody directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, linvoseltamab targets and binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, leading to CTL-mediated killing of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.	Linvoseltamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158505>	C191738|C124946	Lorigerlimab|AEX-1344|AEX1344|Anti-PD-1/Anti-CTLA4 DART Protein MGD019|Bispecific DART Protein MGD019|D-1 x CTLA4 DART Protein MGD019|Dual-affinity Retargeting Protein MGD019|LORIGERLIMAB|MGD 019|MGD-019|MGD019|PD-1 x CTLA4 Bispecific DART Molecule MGD019|PD-1 x CTLA4 DART Protein MGD019	A hinge stabilized immunoglobulin G4 (IgG4) tetravalent bispecific antibody-like protein directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, lorigerlimab specifically binds to both PD-1 and CTLA4 expressed on tumor-infiltrating lymphocytes (TILs) and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. Dual blockade of PD1 and CTLA4 pathways provides enhanced activity against PD1+CTLA4+ double positive cells and may increase T-cell activation and proliferation compared to the blockade of either immune checkpoint alone.	Lorigerlimab		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158506>	C1660	Obefazimod|8-Chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine|ABX 464|ABX-464|ABX464|CBC 80/20 Binder ABX-464|Cap Binding Complex 80/20 Binder ABX-464|OBEFAZIMOD|Rev Inhibitor ABX-464|SPL-464	An orally available, small molecule binder of the cap binding complex (CBC) 80/20, with potential antiviral and anti-inflammatory activities. Upon oral administration, obefazimod binds to the CBC, a complex at the 5'-end of the pre-mRNA transcript that promotes the initial interaction with transcription and processing machinery. This leads to a conformational change in the CBC and enhanced splicing of viral RNA variants and upregulation of the anti-inflammatory microRNA, miR-124, via splicing of a long noncoding RNA at the miR-124-1 locus. In human immunodeficiency virus type 1 (HIV-1)-infected cells, obefazimod interacts with the CBC of HIV-1 mRNA and inhibits viral replication by preventing Rev-mediated export of unspliced HIV-1 transcripts to the cytoplasm. Rev facilitates the nuclear export of unspliced or incompletely spliced viral pre-mRNAs, an essential step in HIV-1 replication. In inflammatory conditions, miR-124 reduces the production of various inflammatory mediators, including interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-alpha), and C-C motif chemokine 2 (CCL2; MCP-1.). miR-124 plays a critical role in innate and adaptive immune responses and is a critical mediator of cholinergic anti-inflammatory action.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C158507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158507>	C96040	Cudarolimab|Anti-OX40 Monoclonal Antibody IBI101|CUDAROLIMAB|IBI 101|IBI-101|IBI101	An agonistic fully human anti-OX40 (tumor necrosis factor receptor superfamily member 4; TNFRSF4; CD134; OX40L receptor) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, cudarolimab selectively binds to and activates OX40. Receptor activation induces proliferation of memory and effector T-lymphocytes and results in a T-cell-mediated immune response against tumor cells, which leads to tumor cell lysis. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and provides a co-stimulatory signal that promotes both the proliferation and survival of activated T-cells.	Cudarolimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158508>	C2152|C129825	Linperlisib|LINPERLISIB|PI3K-delta Inhibitor YY-20394|YY 20394|YY-20394|YY20394	An orally available selective inhibitor of the delta form of phosphatidylinositol 3-kinase (PI3-kinase subunit delta; PI3K-delta; PI3Kdelta), with potential antineoplastic activity. Upon oral administration linperlisib selectively binds to and inhibits PI3K-delta and prevents the activation of the PI3K/AKT signaling pathway. This decreases proliferation of and induces cell death in PI3K-delta over-expressing tumor cells. PI3K-delta also plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of certain hematologic cancer cells. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells, thereby minimizing serious side effects.	Linperlisib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158509>	C1511	Technetium Tc-99m Anti-HER2 Affibody ABH2|99mTc-ABH2|HER2-targeting 99mTc-labeled Affibody	A radioconjugate composed of an optimized affibody labeled with technetium Tc 99m, with potential use as a tracer for human epidermal growth factor receptor type 2 (HER2; ErbB2)-expressing tumors using single photon emission computed tomography (SPECT). Upon administration, the Tc 99m-labeled affibody ABH2 targets and binds to HER2-expressing tumor cells. This facilitates both detection of HER2-expressing tumor cells and assessment of responses to HER2-targeting chemotherapeutic agents using SPECT. HER2, a receptor tyrosine kinase, is mutated in many tumor cell types and plays a key role in tumor cell proliferation and tumor vascularization.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	NCI Drug Dictionary Terminology
C15850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15850>	C15687|C15313	Low-LET Radiotherapy|Radiotherapy, Low LET|Radiotherapy, Low Linear Energy Transfer	Radiotherapy using radioactive particles that deposit a low amount of energy by radiation per unit length of travel.			Therapeutic or Preventive Procedure	
C158510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158510>	C159200	BCL2 Inhibitor VOB560|Bcl-2 Inhibitor S65487|S 65487|S-65487|S65487|VOB 560|VOB-560|VOB-560|VOB560	An inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon intravenous administration, Bcl-2 inhibitor VOB560 binds to and inhibits the activity of Bcl-2, thereby restoring apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in many cancer types and plays an important role in the negative regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival.	BCL2 Inhibitor VOB560		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158511>	C78274|C2196	Polidocanol|Aethoxysklerol|Asclera|Dodecylnonaoxyethylene Glycol Monoether|Laureth 9|Laureth-9|Lauromacrogol 400|Nonaethylene Glycol Monododecyl Ether|POLIDOCANOL	An alkyl polyglycol ether of lauryl alcohol with sclerosing and potential antineoplastic activities. Upon intralesional administration, polidocanol induces endothelial cell injury by disrupting calcium signaling and nitric oxide pathways. Following endothelial damage, platelets aggregate at the site of injury and attach to the venous wall, resulting in a dense network of platelets, cellular debris, and fibrin that occludes the vessel. Inducing endothelial cell damage within melanoma metastases may incite an antitumor response in untreated bystander lesions and inhibit the growth of in transit metastases and other cutaneous lesions.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158512>	C797	Radium bromatum|RADIUM BROMIDE	An orally available homeopathic preparation with potential radioprotective activities. Upon administration, radium bromatum may reduce the occurrence of, and ameliorate the symptoms associated with radiation-induced dermatitis.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158513>	C201552	Anti-c-Met Antibody-drug Conjugate TR1801|Anti-c-Met ADC TR1801|MT 8633|MT-8633|TR 1801|TR-1801|TR1801	An antibody-drug conjugate (ADC) consisting of a non-agonizing anti-c-Met humanized monoclonal antibody that is linked in a site-specific manner to a pyrrolobenzodiazepine dimer (PBD) toxin, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety targets and binds to the c-Met protein, which is overexpressed in certain tumor types. Upon antibody/antigen binding and internalization, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of tumor cell DNA. This induces interstrand cross-links in the minor groove of DNA and inhibits DNA replication, which inhibits the proliferation of c-Met-expressing cells. c-Met, also known as hepatocyte growth factor receptor (HGFR), is a receptor tyrosine kinase that is overexpressed or mutated in many tumor cell types and plays a key role in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.	Anti-c-Met Antibody-drug Conjugate TR1801		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158514>	C15212	Microtransplantation	A treatment that uses chemotherapy followed by adoptive infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells to boost autologous immune activity.	Microtransplantation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C158515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158515>	C1505	Eicosapentaenoic Acid Monoacylglyceride|MAG-EPA|Monoglyceride Eicosapentaenoic Acid	An eicosapentaenoic acid derivative with potential antineoplastic activities. Upon oral administration, eicosapentaenoic acid monoacylglyceride (MAG-EPA) may inhibit epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR) and serine/threonine protein kinase AKT (protein kinase B)-mediated signaling pathways and reduce vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 1-alpha (HIF1-alpha) expression levels in tumor cells. This may promote apoptosis and inhibit tumor cell growth in cells expressing EGFR, AKT, and VEGFR. MAG-EPA may also inhibit androgen-stimulated tumor cell growth and repress androgenic induction of prostate-specific antigen (PSA) expression. PSA, a tumor associated antigen (TAA), is expressed by prostate epithelial cells and is overexpressed in prostate cancer. The AKT signaling pathway is often dysregulated in cancer and is associated with tumor cell proliferation, survival and migration. EGFR and VGFR are receptor tyrosine kinases that are mutated or upregulated in many tumor cell types and play a key role in tumor cell proliferation and tumor vascularization.			Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158516>	C20347	RASSF7 Gene|RASSF7|RASSF7|Ras Association Domain Family Member 7 Gene	This gene plays a role in the negative regulation of stress-induced apoptosis.			Gene or Genome	
C158517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158517>	C25974	Sabizabulin|SABIZABULIN|VERU 111|VERU-111|VERU111	An orally bioavailable, small molecule tubulin inhibitor, with potential antineoplastic, antiviral and anti-inflammatory activities. Upon oral administration, sabizabulin binds to the colchicine-binding site of alpha- and beta-tubulin subunits of microtubules and crosslinks the microtubules, thereby inhibiting microtubule polymerization in tumor blood vessel endothelial cells and tumor cells. This blocks the formation of the mitotic spindle and leads to cell cycle arrest at the G2/M phase. As a result, this agent disrupts the tumor vasculature, tumor blood flow, deprives tumor cells of nutrients, and induces apoptosis. In addition, as microtubules plays an important role in intracellular transport, the inhibition of its polymerization may disrupt the transport of the androgen receptor (AR) into the cell nucleus, as well as virus trafficking around the cell. This may decrease viral replication and assembly. Inhibition of tubulin polymerization may also inhibit the release of pro-inflammatory cytokines and disrupt inflammatory cell activities. Sabizabulin is not a substrate of P-glycoprotein (Pgp), an efflux pump that when overexpressed, may confer resistance to taxane agents.	Sabizabulin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C158518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158518>	C158516	RASSF7 wt Allele|C11orf13|Chromosome 11 Open Reading Frame 13 Gene|HRAS1|HRAS1-Related Cluster 1 Gene|HRAS1-Related Cluster-1 Gene|HRC1|Ras Association (RalGDS/AF-6) Domain Family (N-Terminal) Member 7 Gene|Ras Association (RalGDS/AF-6) Domain Family 7 Gene|Ras Association Domain Family Member 7 wt Allele|Ras Association Domain Family, Member 7 Gene	Human RASSF7 wild-type allele is located in the vicinity of 11p15.5 and is approximately 4 kb in length. This allele, which encodes Ras association domain-containing protein 7, is involved in the inhibition of apoptosis.			Gene or Genome	
C158519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158519>	C19928	Ras Association Domain-Containing Protein 7|HRAS1-Related Cluster Protein 1|RASSF7	Ras association domain-containing protein 7 (373 aa, ~40 kDa) is encoded by the human RASSF7 gene. This protein plays a role in the inhibiting the activation of c-Jun N-terminal kinases (JNK) by dual specificity mitogen-activated protein kinase kinase 7 (MAP2K7), which prevents JNK-dependent apoptosis.			Amino Acid, Peptide, or Protein	
C15851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15851>	C15262	Redirected Cytolysis|Redirected Cytotoxicity	The killing of target cells by changing the natural specificity of cytotoxic T cells by the use of an antibody or other molecule capable of binding to both the T cell and to the target cell.  Often involves hybrid (bispecific) antibodies having distinct specificities for the T cell and for the target cell. (NCI/OSP)			Therapeutic or Preventive Procedure	
C158520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158520>	C156952	CPTAC Codelists Terminology	Terminology used to support the various lists of data useful for tracking trends by CPTAC.			Intellectual Product	
C158521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158521>	C199143	Broad Institute|Broad Institute of MIT and Harvard|Eli and Edythe Broad Institute	A joint research venture of MIT and Harvard, established in 2004 to improve human health by using genomics to advance an understanding of the biology and treatment of human disease, and to help lay the groundwork for a new generation of therapies.			Professional or Occupational Group	
C158522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158522>	C28310|C181141	Autologous CMV-pp65-shLAMP-1 mRNA Loaded Dendritic Cell Vaccine|Autologous pp65-shLAMP-1 DC Vaccine|Autologous shLAMP-1-pp65 mRNA-pulsed DC Vaccine|Autologous shLAMP-1-pp65-DC Vaccine|Autologous shLAMP-1-pp65-DCs|pp65-shLAMP-1 mRNA DCs	A cancer cell vaccine consisting of autologous dendritic cells pulsed with mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) as a fusion construct with a short peptide chimeric antigen from lysosome-associated membrane protein 1 (shLAMP-1), with potential antineoplastic and immunostimulatory activities. Upon vaccination, the autologous CMV-pp65-shLAMP-1 vaccine exposes the immune system to the CMV pp65 peptide, which may elicit a cytotoxic T-lymphocyte (CTL) response against CMV pp65-expressing tumor cells. The incorporation of shLAMP-1 may route CMV pp-65 antigens into the lysosomal compartment, resulting in enhanced MHC class II antigen presentation, thereby promoting CD4-positive T-cell responses. The CMV pp65 protein is the primary component of the enveloped sub-viral particle of CMV and is expressed in certain tumor types.	Autologous CMV-pp65-shLAMP-1 mRNA Loaded Dendritic Cell Vaccine		Cell|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158523>	C81328	Weight at Time of Procedure	The weight of an individual at the time of a procedure.			Organism Attribute	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C158524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158524>	C5036|C3824	Skin Lesion	A localized pathological or traumatic structural change, damage, deformity, or discontinuity of skin.			Finding	
C158525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158525>	C20917	RFC4 Gene|RFC4|RFC4|Replication Factor C Subunit 4 Gene	This gene is involved in DNA elongation during replication.	RFC4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C158526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158526>	C158525	RFC4 wt Allele|A1|Activator 1, 37-kD Subunit Gene|RFC2, Yeast, Homolog of Gene|RFC37|Replication Factor C (Activator 1) 4 (37kD) Gene|Replication Factor C (Activator 1) 4, 37kDa Gene|Replication Factor C Subunit 4 wt Allele|Replication Factor C, 37-kD Subunit Gene|Replication Factor C, Subunit 4 Gene	Human RFC4 wild-type allele is located in the vicinity of 3q27.3 and is approximately 17 kb in length. This allele, which encodes replication factor C subunit 4 protein, plays a role in DNA replication.	RFC4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158527>	C17761	Replication Factor C Subunit 4|A1 37 kDa Subunit|Activator 1 37 kDa Subunit|Activator 1 Subunit 4|RF-C 37 kDa Subunit|RFC 37 kDa Subunit|RFC37|RFC4|Replication Factor C 37 kDa Subunit	Replication factor C subunit 4 (363 aa, ~40 kDa) is encoded by the human RFC4 gene. This protein is involved in the elongation of a primed DNA template.	Replication Factor C Subunit 4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158528>	C20103	RTN4RL1 Gene|RTN4RL1|RTN4RL1|Reticulon 4 Receptor Like 1 Gene	This gene plays a role in axon migration during brain development and axon regeneration.			Gene or Genome	
C158529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158529>	C158528	RTN4RL1 wt Allele|DKFZp547J144|NGRH2|NGRL2|NgR3|Reticulon 4 Receptor Like 1 wt Allele	Human RTN4RL1 wild-type allele is located in the vicinity of 17p13.3 and is approximately 91 kb in length. This allele, which encodes reticulon-4 receptor-like 1 protein, is involved in the development of neurons.			Gene or Genome	
C158530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158530>	C18106	Reticulon-4 Receptor-Like 1|NgR3|Nogo Receptor-Like 2|Nogo-66 Receptor Homolog 2|Nogo-66 Receptor-Related Protein 3|RTN4RL1|Reticulon 4 Receptor Like 1|Reticulon 4 Receptor-Like 1	Reticulon-4 receptor-like 1 (441 aa, ~49 kDa) is encoded by the human RTN4RL1 gene. This protein plays a role in axon migration and regeneration.			Amino Acid, Peptide, or Protein|Receptor	
C158531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158531>	C85865|C84783	Immunodeficiency with Hyper-IgM, X-Linked, Type 1|HIGM1|Hyper-IgM Syndrome 1|X-Linked Hyper-IgM Syndrome	An X-linked subtype of hyper-IgM caused by mutation(s) in the CD40LG gene, encoding CD40 ligand. It is characterized by normal or elevated IgM concentrations, with markedly decreased concentrations of other immunoglobulins. The clinical course is variable; it manifests as susceptibility to bacterial and opportunistic infections, neutropenia, and increased risk of lymphoma.			Disease or Syndrome	
C158532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158532>	C191689	PD-L1 Inhibitor INCB086550|INCB 086550|INCB 86550|INCB-086550|INCB-086550|INCB-86550|INCB086550|INCB86550|PD-1 Ligand 1 Inhibitor INCB086550	An orally available, small molecule inhibitor of the immunosuppressive ligand, programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, PD-L1 inhibitor INCB086550 specifically targets PD-L1 expressed on tumor cells preventing the binding and subsequent activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1, a transmembrane protein expressed on activated T-cells, is overexpressed in some cancer types and plays a significant role in immune evasion by tumor cells.	PD-L1 Inhibitor INCB086550		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158533>	C222322|C200766	Autologous Anti-MUC16 CAR-mbIL15-Safety Switch T-cells PRGN-3005|Autologous Anti-MUC16 CAR-T Cells PRGN-3005|Autologous CAR-T Cells PRGN 3005|Autologous PRGN-3005 UltraCAR-T Cells|PRGN 3005|PRGN-3005|PRGN-3005 UltraCAR-T Cells|PRGN3005	A preparation of autologous T-lymphocytes that have been genetically modified to co-express three transgenes using the Sleeping Beauty (SB) transposon system and include a chimeric antigen receptor (CAR) targeting the unshed portion of the tumor-associated antigen (TAA) human mucin 16 (MUC16, cancer antigen 125; CA125; FLJ14303), a membrane-bound IL-15 (mbIL15) and a safety/kill switch, with potential immunostimulating and antineoplastic activities. Upon introduction of the autologous anti-MUC16 CAR-mbIL15-safety switch T-cells PRGN-3005 into the patient, the T-cells target and bind to MUC16-expressing tumor cells, thereby inducing selective toxicity in MUC16-expressing tumor cells. MUC16, a member of the mucin family of glycoproteins, is overexpressed on a variety of cancer cell types. IL-15 is a pro-survival cytokine that is required for the maintenance of long-lived CD8+ memory T-cells and use of mbIL15 preserves T stem-cell memory (TSCM) through sustained IL-15 signaling, improves T-cell persistence and potentiates the immune response against tumor cells. The safety switch can promote selective elimination of the CAR-T cells. The SB system permits integration of the CAR, the IL-15 fusion variant and safety switch transgenes into T-cells without the need for viral vectors and accelerates the manufacturing process.	Autologous Anti-MUC16 CAR-mbIL15-Safety Switch T-cells PRGN-3005		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158534>	C20194	RUNDC1 Gene|RUN Domain Containing 1 Gene|RUNDC1|RUNDC1	This gene may be involved in the regulation of cellular tumor antigen p53 activity.			Gene or Genome	
C158535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158535>	C158534	RUNDC1 wt Allele|DKFZp761H0421|LP5161|RUN Domain Containing 1 wt Allele|RUND1	Human RUNDC1 wild-type allele is located in the vicinity of 17q21.31 and is approximately 13 kb in length. This allele, which encodes RUN domain-containing protein 1, may play a role in the negative regulation of cellular tumor antigen p53 activity. Aberrant expression of the gene may be associated with increased susceptibility for glioma.			Gene or Genome	
C158536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158536>	C18466	RUN Domain-Containing Protein 1|RUNDC1	RUN domain-containing protein 1 (613 aa, ~68 kDa) is encoded by the human RUNDC1 gene. This protein is involved in the inhibition of cellular tumor antigen p53 activity.			Amino Acid, Peptide, or Protein	
C158537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158537>	C20194	SERF1A Gene|SERF1A|SERF1A|Small EDRK-Rich Factor 1A Gene	This gene may play a role in the development of the spine.			Gene or Genome	
C158538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158538>	C20194	SERF1B Gene|SERF1B|SERF1B|Small EDRK-Rich Factor 1B Gene	This gene may play a role in nervous system development.			Gene or Genome	
C158539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158539>	C158537	SERF1A wt Allele|4F5|FAM2A|H4F5|SERF1|SMAM1|Small EDRK-Rich Factor 1A (Telomeric) Gene|Small EDRK-Rich Factor 1A wt Allele|Spinal Muscular Atrophy-Related Gene H4F5 Gene	Human SERF1A wild-type allele is located in the vicinity of 5q13.2 and is approximately 18 kb in length. This allele, which encodes small EDRK-rich factor 1 protein, may be involved in musculoskeletal development.			Gene or Genome	
C15853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15853>	C15977	Serum Repository Operation|Culturing, in vitro Repository Operations, Serum|Repository Operation, Serum	Procedures designed to run a serum repository facility.			Laboratory Procedure	
C158540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158540>	C158538	SERF1B wt Allele|FAM2B|H4F5C|SERF1|SMAM1|Small EDRK-Rich Factor 1B (Centromeric) Gene|Small EDRK-Rich Factor 1B wt Allele|h4F5	Human SERF1B wild-type allele is located in the vicinity of 5q13.2 and is approximately 18 kb in length. This allele, which encodes small EDRK-rich factor 1 protein, may be involved in the development of the spinal cord and spinal column.			Gene or Genome	
C158541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158541>	C18466	Small EDRK-Rich Factor 1|Protein 4F5|SERF1|SERF1A|SERF1B|SMA Modifier 1|h4F5	Small EDRK-rich factor 1 (110 aa, ~12 kDa) is encoded by the human SERF1A and SERF1B genes. This protein may play a role in the development of the spinal cord, vertebrae and surrounding musculature.			Amino Acid, Peptide, or Protein	
C158543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158543>	C20194	SMIM5 Gene|SMIM5|SMIM5|Small Integral Membrane Protein 5 Gene	This gene encodes a membrane protein of unknown function.			Gene or Genome	
C158544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158544>	C158543	SMIM5 wt Allele|AW024884|C17orf109|Chromosome 17 Open Reading Frame 109 Gene|LOC643008|PP12104	Human SMIM5 wild-type allele is located in the vicinity of 17q25.1 and is approximately 8 kb in length. This allele, which encodes small integral membrane protein 5, has no known function.			Gene or Genome	
C158545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158545>	C18466	Small Integral Membrane Protein 5|SMIM5	Small integral membrane protein 5 (77 aa, ~8 kDa) is encoded by the human SMIM5 gene. This protein has no known function.			Amino Acid, Peptide, or Protein	
C158546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158546>	C25873	STK32B Gene|STK32B|STK32B|Serine/Threonine Kinase 32B Gene	This gene is involved in protein phosphorylation and limb development.			Gene or Genome	
C158547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158547>	C162188	Clonal Hematopoiesis of Indeterminate Potential|CHIP	A term that refers to the presence of somatic mutations in bone marrow or peripheral blood cells in individuals who may be cytopenic but do not have morphologic evidence of hematologic neoplasia. Its prevalence rises with age and is found in approximately 10% of individuals aged 70 to 80. It is associated with an increased risk of hematologic neoplasia. Mutations in the DNMT3A, TET2, or ASXL1 genes are usually identified. Approximately 10%-40% of individuals with age-related clonal hematopoiesis will progress to meet the diagnostic criteria for clonal hematopoiesis of indeterminate potential.	Clonal Hematopoiesis of Indeterminate Potential		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C158548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158548>	C158546	STK32B wt Allele|HSA250839|STK32|STKG6|Serine/Threonine Kinase 32B wt Allele|UNQ3003/PRO9744|YANK2	Human STK32B wild-type allele is located in the vicinity of 4p16.2 and is approximately 450 kb in length. This allele, which encodes serine/threonine-protein kinase 32B protein, plays a role in limb development. Deletion of the gene is associated with the autosomal recessive skeletal dysplasia, Ellis-van Creveld syndrome.			Gene or Genome	
C158549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158549>	C17325	Serine/Threonine-Protein Kinase 32B|EC 2.7.11.1|STK32B|Yet Another Kinase 2|Yet Another Novel Kinase 2	Serine/threonine-protein kinase 32B (414 aa, ~48 kDa) is encoded by the human STK32B gene. This protein is involved in serine/threonine phosphorylation and limb development.			Amino Acid, Peptide, or Protein|Enzyme	
C15854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15854>	C15213	Social Health Service|Social Support Services	Community resources that help people in need with their health.			Health Care Activity	
C158550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158550>	C25869|C20194	TMEM65 Gene|TMEM65|TMEM65|Transmembrane Protein 65 Gene	This gene plays a role in gap junction and mitochondrial functions and cardiac development.			Gene or Genome	
C158551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158551>	C13024	Neck of the Pancreas|Neck|PANCREAS, NECK|Pancreas Neck|Pancreatic Neck|Pancreatic neck	The portion of the pancreas that is the junction of the head and body of the pancreas; the portion of the pancreas that lies anterior to the aorta.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C158552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158552>	C158550	TMEM65 wt Allele|AA555029_RC|LOC286052|Transmembrane Protein 65 wt Allele	Human TMEM65 wild-type allele is located in the vicinity of 8q24.13 and is approximately 65 kb in length. This allele, which encodes transmembrane protein 65, is involved in mitochondrial functionality, cardiac development and gap junction formation.			Gene or Genome	
C158553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158553>	C18466	Transmembrane Protein 65|TMEM65	Transmembrane protein 65 (240 aa, ~26 kDa) is encoded by the human TMEM65 gene. This protein plays a role in heart development and localization of gap junction proteins and mitochondria.			Amino Acid, Peptide, or Protein	
C158554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158554>	C25869|C20194	TMEM74B Gene|TMEM74B|TMEM74B|Transmembrane Protein 74B Gene	This gene may be involved in autophagy.			Gene or Genome	
C158555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158555>	C158554	TMEM74B wt Allele|C20orf46|Chromosome 20 Open Reading Frame 46 Gene|FLJ11190|Transmembrane Protein 74B wt Allele	Human TMEM74B wild-type allele is located in the vicinity of 20p13 and is approximately 8 kb in length. This allele, which encodes transmembrane protein 74B, may play a role in autophagy.			Gene or Genome	
C158556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158556>	C18466	Transmembrane Protein 74B|TMEM74B|Transmembrane Protein C20orf46	Transmembrane protein 74B (256 aa, ~28 kDa) is encoded by the human TMEM74B gene. This protein may be involved in autophagy.			Amino Acid, Peptide, or Protein	
C158557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158557>	C129822|C128036	Botensilimab|AGEN 1181|AGEN-1181|AGEN1181|Anti-CTLA-4 Monoclonal Antibody AGEN1181|BOTENSILIMAB	An Fc-engineered recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA-4 monoclonal antibody  botensilimab binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system. The engineered Fc domain increases the stability and half-life of the antibody.	Botensilimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158558>	C200765|C176018	Azercabtagene Zapreleucel|AZERCABTAGENE ZAPRELEUCEL|Allogeneic Anti-CD19-CAR T-cells PBCAR0191|Allogeneic Anti-CD19-CAR T-lymphocytes PBCAR0191|Anti-CD19-CAR Allogeneic T-cells PBCAR0191|PBCAR0191	A preparation of allogeneic, off-the-shelf, T-lymphocytes that have been genetically modified using a proprietary synthetic nuclease-based system to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 (cluster of differentiation 19) with potential immunostimulating and antineoplastic activities. Upon administration, azercabtagene zapreleucel specifically recognize and kill CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen, which is expressed in all B-cell lineage malignancies and normal B-cells.	Azercabtagene Zapreleucel		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158559>	C21295	MUC6 Gene|MUC6|MUC6|Mucin 6, Oligomeric Mucus/Gel-Forming Gene	This gene is involved in the lubrication of the gastrointestinal tract.			Gene or Genome	
C15855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15855>	C15426	State Cancer Legislative Database	The SCLD maintains information about state legislation and regulation addressing cancer-related topics, including tobacco, breast cancer, genetics, cervical cancer, prostate cancer, testicular cancer, colon cancer, ovarian cancer, access to state-of-the-art cancer treatment, cancer registries, and selected issues related to diet and nutrition, employment discrimination, environmental exposure, and occupational exposure.  The purpose of the SCLD is threefold; it provides necessary information: 1) for evaluating the effect of state legislation on public health and on the application of cancer control science, 2) for facilitating the application of cancer control science, and 3) for monitoring legislative trends that may reflect changing public attitudes and practices. (State Cancer Legislative Database Program)			Intellectual Product	
C158560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158560>	C158559	MUC6 wt Allele|MUC-6|Mucin 6, Gastric Gene|Mucin 6, Oligomeric Mucus/Gel-Forming wt Allele	Human MUC6 wild-type allele is located in the vicinity of 11p15.5 and is approximately 24 kb in length. This allele, which encodes mucin-6 protein, plays a role in the formation of a protective layer of mucus in the gastrointestinal tract.			Gene or Genome	
C158561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158561>	C16883	Mucin-6|Gastric Mucin-6|MUC-6|MUC6|Mucin 6	Mucin-6 (2439 aa, ~257 kDa) is encoded by the human MUC6 gene. This protein is involved in protection of the epithelial surfaces of the gastrointestinal system.			Amino Acid, Peptide, or Protein	
C158562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158562>	C21295	MUC5B Gene|MUC5B|MUC5B|Mucin 5B, Oligomeric Mucus/Gel-Forming Gene	This gene is involved in salivary and cervical mucus lubricating activity.			Gene or Genome	
C158563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158563>	C158562	MUC5B wt Allele|MG1|MUC-5B|MUC5|MUC9|Mucin 5, Subtype B, Tracheobronchial Gene|Mucin 5B, Oligomeric Mucus/Gel-Forming wt Allele	Human MUC5B wild-type allele is located in the vicinity of 11p15.5 and is approximately 39 kb in length. This allele, which encodes mucin-5B protein, is involved in the lubrication of the mouth, airways and cervix. Mutation of the gene is associated with susceptibility to idiopathic pulmonary fibrosis.			Gene or Genome	
C158564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158564>	C16883	Mucin-5B|Cervical Mucin|Cervical Mucin MUC5B|High Molecular Weight Salivary Mucin MG1|MUC-5B|MUC5B|Mucin 5B|Mucin-5 Subtype B, Tracheobronchial|Sublingual Gland Mucin	Mucin-5B (5762 aa, ~596 kDa) is encoded by the human MUC5B gene. This protein plays a role in the lubricant activity and viscoelasticity of saliva and cervical mucus.			Amino Acid, Peptide, or Protein	
C158565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158565>	C20194	TSPYL5 Gene|TSPY Like 5 Gene|TSPYL5|TSPYL5	This gene plays a role in regulating the ubiquitination of cellular tumor antigen p53 (TP53).			Gene or Genome	
C158566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158566>	C158565	TSPYL5 wt Allele|KIAA1750|TSPY Like 5 wt Allele|TSPY-Like 5 Gene	Human TSPYL5 wild-type allele is located in the vicinity of 8q22.1 and is approximately 5 kb in length. This allele, which encodes testis-specific Y-encoded-like protein 5, is involved in inhibiting the deubiquitination of cellular tumor antigen p53 (TP53).			Gene or Genome	
C158567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158567>	C95242	Testis-Specific Y-Encoded-Like Protein 5|TSPY-Like Protein 5|TSPYL5	Testis-specific Y-encoded-like protein 5 (417 aa, ~45 kDa) is encoded by the human TSPYL5 gene. This protein plays a role in the inhibition of cellular tumor antigen p53 (TP53) deubiquitination by ubiquitin carboxyl-terminal hydrolase 7 (USP7).			Amino Acid, Peptide, or Protein	
C158568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158568>	C28404	UCHL5 Gene|UCHL5|UCHL5|Ubiquitin C-Terminal Hydrolase L5 Gene	This gene plays a role in deubiquitination, regulation of proteasome-mediated protein degradation and chromatin remodeling.	UCHL5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C158569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158569>	C158568	UCHL5 wt Allele|CGI-70|INO80R|UCH-L5|UCH37|Ubiquitin C-Terminal Hydrolase L5 wt Allele	Human UCHL5 wild-type allele is located in the vicinity of 1q31.2 and is approximately 48 kb in length. This allele, which encodes ubiquitin carboxyl-terminal hydrolase isozyme L5 protein, is involved in proteasome-mediated protein degradation, chromatin remodeling and hydrolysis of polyubiquitin chains.	UCHL5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158570>	C16481	Ubiquitin Carboxyl-Terminal Hydrolase Isozyme L5|EC 3.4.19.12|INO80 Complex Subunit R|UCHL5|Ubiquitin C-Terminal Hydrolase L5|Ubiquitin C-Terminal Hydrolase UCH37|Ubiquitin Carboxyl-Terminal Esterase L5|Ubiquitin Carboxyl-Terminal Hydrolase L5|Ubiquitin Thioesterase L5	Ubiquitin carboxyl-terminal hydrolase isozyme L5 (329 aa, ~38 kDa) is encoded by the human UCHL5 gene. This protein plays a role in chromatin modification and the removal of lysine-48-linked polyubiquitin chains from substrate proteins.	Ubiquitin Carboxyl-Terminal Hydrolase Isozyme L5		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158571>	C82572	Months Since Completion of Primary Therapy|Months From Completion of Primary Therapy|Months From Completion of Primary Therapy to Present	An indication of the number of months that have passed between the completion of primary therapy and the present.			Quantitative Concept	
C158572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158572>	C20420	ZNF385B Gene|ZNF385B|ZNF385B|Zinc Finger Protein 385B Gene	This gene may play a role in the cellular tumor antigen p53 (TP53)-dependent apoptosis pathway.			Gene or Genome	
C158573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158573>	C158572	ZNF385B wt Allele|FLJ25270|ZNF533|Zinc Finger Protein 385B wt Allele	Human ZNF385B wild-type allele is located within 2q31.2-q31.3 and is approximately 420 kb in length. This allele, which encodes zinc finger protein 385B, may be involved in the regulation of apoptosis.			Gene or Genome	
C158574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158574>	C17207	Zinc Finger Protein 385B|ZNF385B|Zinc Finger Protein 533	Zinc finger protein 385B (471 aa, ~50 kDa) is encoded by the human ZNF385B gene. This protein may play a role in the regulation of cellular tumor antigen p53 (TP53) signaling pathways.			Amino Acid, Peptide, or Protein	
C158575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158575>	C28533	CADPS2 Gene|CADPS2|CADPS2|Calcium Dependent Secretion Activator 2 Gene	This gene is involved in the regulation of neurotransmitter and neuropeptide exocytosis.			Gene or Genome	
C158576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158576>	C158575	CADPS2 wt Allele|CAPS2|Calcium Dependent Secretion Activator 2 wt Allele|KIAA1591	Human CADPS2 wild-type allele is located in the vicinity of 7q31.32 and is approximately 568 kb in length. This allele, which encodes calcium-dependent secretion activator 2 protein, plays a role in the exocytosis of neuropeptides and neurotransmitters. Mutation of the gene may be associated with autism.			Gene or Genome	
C158577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158577>	C16386	Calcium-Dependent Secretion Activator 2|CADPS2|CAPS-2|Ca++-Dependent Activator Protein for Secretion 2|Ca++-Dependent Secretion Activator 2|Ca2+ Dependent Secretion Activator 2|Ca2+-Dependent Activator Protein for Secretion 2|Calcium Dependent Secretion Activator 2|Calcium-Dependent Activator Protein for Secretion 2	Calcium-dependent secretion activator 2 (1296 aa, ~148 kDa) is encoded by the human CADPS2 gene. This protein is involved in the secretion of neurotrophins.			Amino Acid, Peptide, or Protein	
C158578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158578>	C20744	ECPAS Gene|ECPAS|ECPAS|Ecm29 Proteasome Adaptor and Scaffold Gene	This gene plays a role in proteasome assembly and localization.			Gene or Genome	
C158579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158579>	C158578	ECPAS wt Allele|ECM29|ECM29 Homolog (S. cerevisiae) Gene|ECM29, Yeast Homolog of Gene|Ecm29 Proteasome Adaptor and Scaffold wt Allele|FLJ22036|Homolog of Yeast Ecm29 Gene|KIAA0368	Human ECPAS wild-type allele is located in the vicinity of 9q31.3 and is approximately 124 kb in length. This allele, which encodes proteasome adapter and scaffold protein ECM29, is involved in the assembly and cellular localization of the proteasome.			Gene or Genome	
C15857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15857>	C124351	Therapy Evaluation	Determining the efficacy of a particular therapy or treatment.	Therapy Evaluation		Activity	CTRP Intervention Terminology|CTRP Terminology
C158580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158580>	C18073	Proteasome Adapter and Scaffold Protein ECM29|ECPAS|Ecm29 Proteasome Adapter and Scaffold|Ecm29 Proteasome Adaptor and Scaffold|Proteasome-Associated Protein ECM29 Homolog	Proteasome adapter and scaffold protein ECM29 (1845 aa, ~204 kDa) is encoded by the human ECPAS gene. This protein plays a role in proteasome localization and assembly.			Amino Acid, Peptide, or Protein	
C158581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158581>	C173902|C167447	Lymphoma in Remission	A finding of lymphoma that is not growing and responds to treatment.	Lymphoma in Remission		Finding	CTRP Disease Terminology|CTRP Terminology
C158582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158582>	C158581	Non-Hodgkin Lymphoma in Remission|Non-Hodgkin's Lymphoma in Remission	A finding of non-Hodgkin lymphoma that is not growing and responds to treatment.	Non-Hodgkin Lymphoma in Remission		Finding	CTRP Disease Terminology|CTRP Terminology
C158583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158583>	C158581	Hodgkin Lymphoma in Remission	A finding of Hodgkin lymphoma that is not growing and responds to treatment.	Hodgkin Lymphoma in Remission		Finding	CTRP Disease Terminology|CTRP Terminology
C158584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158584>	C166244	Jaundice Status|Jaundice Status (Present or Absent)|Jaundice positive or negative|Jaundice present or absent	A clinical assessment or impression by direct observation indicating whether or not a patient has a condition of jaundice (is jaundiced).			Qualitative Concept	
C158585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158585>	C6166|C150521	Unresectable Urethral Urothelial Carcinoma	Urethral urothelial carcinoma that is not amenable to surgical resection.	Unresectable Urethral Urothelial Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158586>	C39851|C167075|C150521	Unresectable Bladder Urothelial Carcinoma	Bladder urothelial carcinoma that is not amenable to surgical resection.	Unresectable Bladder Urothelial Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158587>	C4830|C164160	Unresectable Ureter Urothelial Carcinoma	Ureter urothelial carcinoma that is not amenable to surgical resection.	Unresectable Ureter Urothelial Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158588>	C7355|C174565|C164160	Unresectable Renal Pelvis Urothelial Carcinoma	A renal pelvis urothelial carcinoma that is not amenable to surgical resection.	Unresectable Renal Pelvis Urothelial Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158589>	C19332	Height at Time of Procedure	The height of an individual at the time of a procedure.			Organism Attribute	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C15858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15858>	C15321	Tissue Resources				Functional Concept	
C158590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158590>	C217121	Physician's Global Assessment Scale of Epidermal Chronic Graft versus Host Disease|PGA-cGVHD|Physician Global Assessment of Epidermal Chronic Graft versus Host Disease|Physician's Global Assessment Scale of Cutaneous Epidermal Chronic Graft versus Host Disease|Physician's Global Assessment Scale of Epidermal Cutaneous Chronic Graft versus Host Disease|Physician's Global Assessment of Epidermal cGVHD	A clinical outcome instrument to measure the severity of epidermal chronic graft versus host disease. Extent of cutaneous involvement is scored using a 5 point scale.			Intellectual Product	
C158591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158591>	C221058	Epidermal cGVHD Score 0|Clear|Score 0	A score of 0 describing clear skin where residual hyperpigmentation may be present.			Intellectual Product	
C158592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158592>	C221058	Epidermal cGVHD Score 1|Almost Clear|Score 1	A score of 1 describing almost clear skin with light erythema, papules and/or scale involving 0-20% of the target area.			Intellectual Product	
C158593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158593>	C221058	Epidermal cGVHD Score 2|Mild|Score 2	A score of 2 describing mild disease with erythema, fine scale and/or papules involving >20% of the target area.			Intellectual Product	
C158594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158594>	C221058	Epidermal cGVHD Score 3|Moderate|Score 3	A score of 3 describing moderate disease with confluent erythema and scale and/or papules covering >50% of target area.			Intellectual Product	
C158595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158595>	C221058	Epidermal cGVHD Score 4|Score 4|Severe	A score of 4 describing severe disease with confluent erythema and scale and/or papules covering >80% of target area.			Intellectual Product	
C158596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158596>	C45235	Lyophilisate for Emulsion for Injection Dosage Form|Lyophilisate for emulsion for injection	Solid sterile preparation for veterinary use consisting of a freeze-dried powder intended to be mixed with the specified liquid to obtain an emulsion for injection.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C158597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158597>	C148268	Lyophilisate and Solvent for Emulsion for Injection Dosage Form|Lyophilisate and solvent for emulsion for injection	Sterile lyophilisate (freeze-dried powder) and sterile solvent intended for the preparation of an emulsion for injection, for veterinary use, by mixing the powder and the solvent.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C158598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158598>	C148268	Effervescent Powder and Powder for Oral Suspension Dosage Form|Effervescent powder and powder for oral suspension	Effervescent powder and powder intended for the preparation of an oral suspension by dissolving and/or dispersing the effervescent powder and the powder in the specified liquid(s). The effervescent powder contains active ingredient(s); the powder may or may not contain active ingredient(s).			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C158599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158599>	C200766	Autologous Cytoplasmic Activated PD-1 CAR T-cells|Autologous CAR19 T-cells Carrying Cytoplasmic Activated PD-1	A preparation of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19), carrying cytoplasmic activated programmed cell death 1 (PD1; PDCD1; CD279; programmed death-1), with potential antineoplastic activity. Upon intravenous administration, autologous cytoplasmic activated PD-1 CAR T-cells target, bind to, and induce selective toxicity in CD19-expressing tumor cells. The cytoplasmic activated PD1, a negative immunoregulatory human cell surface receptor, normally binds to programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) on tumor cells, causing T-cell inactivation. By preventing PD1/PD-L1 signaling, T-cell exhaustion is abrogated, and T-cell activation is enhanced leading to an increased cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. CD19 is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15859>	C15605	Trace Element Nutrition Research, Fluorides	The study of the role of the trace element fluoride, obtained through diet, in cancer causation or prevention and in general health.			Research Activity	
C1585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1585>	C45678	Lubricant|lubricant	Any substance that helps to minimize friction and facilitates motion between interacting surfaces.	Lubricant		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C158600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158600>	C93221|C275|C1892	Green Tea/Licorice Extract-based Antioxidant Solution|Ocoxin and Viusid|Ocoxin-Viusid|Ocoxin/Viusid|Oral Antioxidant Solution	A nutritional supplement containing a variety of antioxidants, vitamins, minerals and amino acids, including glycyrrhizic acid, epigallocatechin gallate (EGCG), zinc, vitamins B5, B6 and B12, vitamin C (ascorbic acid), folic acid, malic acid, glucosamine, arginine, and glycine, with potential immunomodulating, anti-inflammatory, protective, and antineoplastic activities. Upon oral administration, the antioxidants in the solution modulate certain enzymes involved in inflammation and oxidative stress and downregulate certain pro-inflammatory mediators. They also scavenge free radicals. This protects against inflammation- and reactive oxygen species (ROS)-induced cellular damage. In addition, this formulation may also inhibit various signal transduction pathways involved in inflammation and cancer, may suppress the growth of susceptible tumor cells, induce tumor cell cycle arrest, induce apoptosis and reduce angiogenesis and metastasis.			Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158601>	C28681	Autologous Cytotoxic T-lymphocytes Exposed to Dendritic Cells loaded with 6B11 Anti-idiotype Minibody|6B11 Anti-idiotype Minibody-pulsed DCs Induced Autologous CTLs|Autologous CTLs Exposed to 6B11-OCIK|Autologous CTLs Exposed to 6B11mini-ovarian-cytokine-induced-killer Cells|Autologous CTLs Induced with 6B11 Anti-idiotype Minibody-pulsed DCs|Autologous Cytotoxic T-cells Induced by Autologous Dendritic Cells Loaded with 6B11 Anti-idiotype Minibody	A preparation of autologous cytotoxic T-lymphocytes (CTLs) that are exposed, ex vivo, to autologous dendritic cells (DCs) loaded with the anti-idiotype minibody 6B11, which mimics the epithelial ovarian tumor-associated antigen (TAA), OC166-9, with potential immunostimulatory and antineoplastic activities. Upon administration, the CTLs exposed to DCs loaded with 6B11 anti-idiotype minibody target and kill autologous ovarian cells expressing the TAA.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158602>	C213431|C201175	Anti-EGFR CAR-transduced IL-12-expressing T-lymphocytes|EGFR-IL12-CAR T-cells	A preparation of human T-lymphocytes transduced with a retroviral vector encoding an anti-epidermal growth factor receptor (EGFR) chimeric antigen receptor (CAR) gene coupled to the signaling domains from CD28, 4-1BB (CD137) and CD3 zeta, and modified to express the cytokine interleukin-12 (IL-12), with potential immunostimulatory and antineoplastic activities. Upon administration, the anti-EGFR CAR-transduced IL-12-expressing T-lymphocytes target and bind to the EGFR antigen on tumor cell surfaces; subsequently, EGFR-expressing tumor cells may be lysed. IL-12 expression activates the immune system by promoting the secretion of interferon-gamma (IFNg), activating natural killer cells (NKs), and inducing cytotoxic T-cell responses, which may result in both decreased cell proliferation and increased cell death for the EGFR-overexpressing tumor cells. EGFR, overexpressed by a variety of cancer cell types, plays a key role in tumor cell proliferation, tumor angiogenesis and radio- and chemoresistance.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158603>	C202468|C129825	Izorlisib|5-(7-Methylsulfonyl-2-morpholin-4-yl-5,6-dihydropyrrolo[2,3-d]pyrimidin-4-yl)pyrimidin-2-amine|Alpha-selective PI3K Inhibitor MEN1611|CH 5132799|CH-5132799|CH5132799|IZORLISIB|MEN 1611|MEN-1611|MEN1611|PA 799|PA-799|PA799|PI3K-alpha Inhibitor MEN1611|PI3Kalpha Inhibitor MEN1611	An orally bioavailable inhibitor of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) catalytic subunit alpha (PIK3CA), with potential antineoplastic activity. Upon administration, izorlisib selectively binds to and inhibits PIK3CA and its mutated forms in the PI3K/Akt (protein kinase B)/mammalian target of rapamycin (mTOR) pathway. This results in both apoptosis and growth inhibition in PIK3CA-expressing tumor cells. By specifically targeting PIK3CA, izorlisib may be more efficacious and less toxic than pan-PI3K inhibitors. In addition, izorlisib also targets mutated forms of PI3K gamma (PI3Kg). It may also stimulate the immune system to restore CD8+ T-cell activation and cytotoxicity. Dysregulation of the PI3K/Akt/mTOR pathway is often found in solid tumors and results in the promotion of tumor cell growth, survival, and resistance to chemo- and radio-therapy. PIK3CA, one of the most frequently mutated oncogenes, encodes the p110-alpha catalytic subunit of the class I PI3K. In most solid tumors, the activation of the PI3K pathway is induced by mutations of PIK3CA.	Izorlisib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158604>	C200766|C176018	Autologous Anti-CD19 CAR-expressing T-lymphocytes CLIC-1901|Autologous CLIC-1901 CAR-T Cells|CLIC 1901|CLIC-1901|CLIC1901	A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) that targets the human tumor associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR-expressing T-lymphocytes CLIC-1901 bind to and induce selective toxicity against CD19-expressing tumor cells. The CD19 antigen is a B-cell-specific cell surface antigen expressed in all B-cell lineage malignancies.			Cell|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158605>	C210691	Whey Protein Isolate-based Nutritional Supplement|Boost Breeze	A nutritional supplement composed of a lactose- and gluten-free whey-based protein isolate and containing various vitamins and minerals, with potential immunomodulating activity. In addition to whey protein isolate, this supplement contains phosphoric acid, L-cysteine, ascorbic acid, vitamin E, zinc, ferrous sulfate, niacinamide, vitamin A, calcium pantothenate, copper, manganese, vitamin D3, pyridoxine, thiamine, riboflavin, folic acid, biotin, iodine, phytonadione, and vitamin B12. Upon administration, whey protein isolate is broken down in the body into cysteine and glutamylcysteine. The available cysteine allows cells to synthesize glutathione (GSH), a tripeptide containing amino acids glycine, glutamate and cysteine, thereby maintaining and increasing intracellular GSH concentrations. GSH plays a major role as an antioxidant, thereby protecting cells from oxidative damage due to harmful substances such as free radicals and reactive oxygen compounds. In addition, the supplement provides necessary vitamins and minerals to the body, which may stimulate the immune system, help with wound healing and  regulate metabolic dysregulation.			Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158606>	C201275	CRISPR-Cas9-mediated PD-1 and TCR Gene-deleted Anti-mesothelin CAR T-cells|Anti-mesothelin CAR-transduced CRISPR-Cas9-edited T-cells|CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells|CRISPR-Cas9-mediated Anti-mesothelin CAR T-cells|CRISPR-Cas9-mediated Gene-edited Anti-mesothelin CAR-T Cells	A preparation of human T-lymphocytes transduced with a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) mesothelin and gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to eliminate endogenous TCR and programmed death 1 (PD-1; PDCD1; CD279; programmed cell death-1) expression, with potential immunostimulating and antineoplastic activities. The CRISPR guide RNA (gRNA) specifically targets and binds to complementary sites on TCRalpha, TCRbeta and PD-1. In turn, Cas9 cleaves these specific DNA sites, thereby disrupting transcription. Upon isolation, transduction, electroporation with TCRalpha, TCRbeta and PD-1 gRNAs, which are complexed to Cas9 RNA to disrupt expression of endogenous TCRalpha, TCRbeta and PD-1, expansion ex vivo, and introduction into the patient, the CRISPR-Cas9-mediated PD-1 and TCR gene-deleted anti-mesothelin CAR T-cells recognize and bind to mesothelin-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of mesothelin-positive tumor cells. PD-1, an immune checkpoint receptor expressed on T-cells, plays a key role in tumor immune evasion by binding to its ligand programmed death ligand 1 (PD-L1; cluster of differentiation 274; CD274; programmed cell death-1 ligand 1) expressed on tumor cells. By removing PD-1 from T-cells, PD-1-mediated signaling is halted which may decrease T-cell exhaustion and may enhance T-cell activity against the mesothelin-expressing tumor cells. Removal of endogenous TCR reduces TCR competition for expression, increases the persistence and function of the expressed transgenic TCR, enhances resistance to T-cell exhaustion and increases T-cell activity. Mesothelin is upregulated on a variety of tumor cell types.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158607>	C1663	Survivin-expressing CVD908ssb-TXSVN Vaccine|CVD908ssb-TXSVN|Salmonella-based Survivin Vaccine CVD908ssb-TXSVN|TXSVN	An orally bioavailable Salmonella-based survivin vaccine composed of a weakened form of a live strain of  Salmonella bacteria (CVD908ssb strain) that has been genetically modified to produce the tumor-associated antigen (TAA) survivin, with potential immunopotentiating and antineoplastic activities. Upon administration of the CVD908ssb-TXSVN vaccine, the expressed survivin stimulates the immune response to elicit a cytotoxic T-lymphocyte (CTL)-mediated immune response against survivin-expressing cancer cells, resulting in a decrease in tumor cell proliferation and an induction of tumor cell death. Survivin, a member of the inhibitor of apoptosis (IAP) family expressed during embryonic development, is upregulated in a variety of human cancers while absent in most normal adult cells; its expression in tumors is associated with a more aggressive phenotype, decreased survival, and increased resistance to chemotherapy.	Survivin-expressing CVD908ssb-TXSVN Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology
C158609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158609>	C158948	KMT2A Fusion Positive|ALL-1 Fusion Positive|ALL1 Fusion Positive|CXXC7 Fusion Positive|HRX Fusion Positive|HTRX Fusion Positive|Histone-Lysine N-Methyltransferase 2A Fusion Positive|Histone-Lysine N-Methyltransferase MLL Fusion Positive|KMT2A Fusion|Lysine (K)-Specific Methyltransferase 2A Fusion Positive|MLL Fusion|MLL Fusion Positive|Myeloid/Lymphoid or Mixed-Lineage Leukemia Fusion Positive	Indicates that the expression of a KMT2A fusion has been detected in a sample.	KMT2A Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15860>	C15605	Trace Element Nutrition Research, Mercury	The study of the role of the trace element mercury, obtained through diet, in cancer causation or prevention and in general health.			Research Activity	
C158610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158610>	C3769|C158620	Endometrioid Adenocarcinoma, Variant with Squamous Differentiation	An endometrioid adenocarcinoma exhibiting squamous differentiation.			Neoplastic Process	
C158611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158611>	C48191	Donor Information	Information about the donor.			Conceptual Entity	CPTAC Baseline Medical Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C158612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158612>	C91102	CPTAC Question				Intellectual Product	
C158614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158614>	C158612	Was Menopausal Hormone Therapy Ever Used Question|Has the patient ever taken menopausal hormone therapy|Was Menopausal Hormone Therapy Ever Used	A question about whether menopausal hormone therapy was ever used.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C158615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158615>	C158612	Was another Form of Birth Control Ever Used Question|Has the patient ever used another form of birth control|Was another Form of Birth Control Ever Used	A question about whether another form of birth control was ever used.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology
C158616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158616>	C6930|C4783	Borderline Ovarian Mixed Epithelial Tumor/Atypical Proliferative Ovarian Mixed Epithelial Tumor	A low grade, non-invasive mixed epithelial proliferative neoplasm that arises from the ovary. In most cases is composed of serous and endocervical-type mucinous cells.			Neoplastic Process	
C158617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158617>	C213692|C129825	Pirtobrutinib|5-Amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-((2S)-1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide|BTK Inhibitor LOXO-305|Jaypirca|LOXO 305|LOXO-305|LOXO305|LY3527727|PIRTOBRUTINIB	An orally available, selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Upon oral administration, pirtobrutinib selectively and reversibly binds to BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, thereby inhibiting the growth of malignant B-cells that overexpress BTK. Reversible binding of LOXO-305 may preserve antitumor activity in the presence of certain acquired resistance mutations, including C481 mutated BTK, and limit toxicity associated with inhibition of other non-BTK kinases. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.	Pirtobrutinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158618>	C158612	Have Oral Contraceptives Ever Been Taken Question|Has the patient ever taken oral contraceptives|Have Oral Contraceptives Ever Been Taken	A question about whether oral contraceptives were ever taken.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C158619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158619>	C158612	Was Tamoxifen Ever Taken Question|Has the patient ever taken Tamoxifen|Was Tamoxifen Ever Taken	A question about whether Tamoxifen was ever taken.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C15861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15861>	C15605	Trace Element Nutrition Research, Other	The study of the role of other trace elements, obtained through diet, in cancer causation or prevention and in general health.			Research Activity	
C158620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158620>	C7113	Endometrioid Tumor, Variant with Squamous Differentiation	An endometrioid tumor exhibiting squamous differentiation.			Neoplastic Process	
C158621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158621>	C106551	Number of Full Term Pregnancies|Number of full term pregnancies	The number of full term pregnancies.			Quantitative Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C158622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158622>	C8986|C8985|C67090|C3646|C27788	Borderline Serous Cystadenofibroma	A neoplasm of low malignant potential arising from a site in the female reproductive system. Almost all cases have been reported in the ovary. It is characterized by the presence of cystic spaces which are lined by atypical serous epithelial cells. The surrounding ovarian stroma is fibrotic. There is no evidence of stromal invasion.			Neoplastic Process	
C158623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158623>	C226692	Greater Than or Equal to Four|Greater Than or Equal to 4	A response indicating that the reported result, quantity or score is greater than or equal to four.			Intellectual Product	GDC Terminology|GDC Value Terminology
C158624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158624>	C157093	Click or Tap Here to Enter Text|Click or tap here to enter text	A directive to click or tap to enter text.			Activity	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Normal Endometrial Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C158625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158625>	C156420	Age at Initial Pathologic Diagnosis	A question about the age of the individual at the time of the initial pathologic diagnosis.			Organism Attribute	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C158626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158626>	C25164	Date and Method of Initial Pathologic Diagnosis	A section header about the date and method of the initial pathologic diagnosis.			Temporal Concept	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C158627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158627>	C25164	Date of Tumor Progression After Initial Treatment	The data of tumor progression after initial treatment.			Temporal Concept	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Terminology
C158628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158628>	C25164	Date of Tumor Reoccurrence After Initial Treatment	The date of  the tumor reoccurrence after the initial treatment.			Temporal Concept	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Terminology
C158629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158629>	C1511	Iodine I 124 Monoclonal Antibody M5A|124I-M5A|124I-hT84.66-M5A|Iodine I 124 Anti-CEA Monoclonal Antibody M5A|Iodine I 124 Anti-CEA Monoclonal Antibody hT84.66-M5A|Iodine I 124 Monoclonal Antibody hT84.66-M5A	A radioimmunoconjugate comprised of M5A, a humanized monoclonal antibody directed against carcinoembryonic antigen-related cell adhesion molecule 5 (CEA or CEACAM5), labeled with iodine I 124 (I-124) with potential radiolocalization applications. Upon administration, the antibody moiety of iodine I 124 monoclonal antibody M5A specifically binds to cells expressing CEA. Upon binding, the radioisotope moiety can be detected using positron-emission tomography (PET), thereby allowing the imaging and quantification of CEA-expressing tumor cells. CEA, a tumor associated antigen and a member of the CEA family of proteins, plays a key role in cell migration, cell invasion, and cell adhesion and is overexpressed by a variety of cancer types.	Iodine I 124 Monoclonal Antibody M5A		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15862>	C15429	Translational Research|Translational Research Enterprise|Translational Science|translational research|translational research	Studies designed to translate basic science findings into clinically useful tools and applications and to ensure that new treatments and research knowledge reach the patients or populations for whom they are intended and are implemented correctly.			Research Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|SeroNet Authorized Values|SeroNet Study Descriptors
C158630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158630>	C158612	Did the Individual have Multiple Known Primary Tumors at Initial Melanoma Diagnosis Question|Did the Individual have Multiple Known Primary Tumors at Initial Melanoma Diagnosis|Did the patient have multiple known primaries at the time of initial melanoma diagnosis	A question about whether the individual has multiple known primary tumors at the initial melanoma diagnosis.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C158631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158631>	C173812|C158612	What is the First Course Treatment Completion Measure of Success of Outcome Question|Measure of success of outcome at the completion of initial first course treatment|What is the First Course Treatment Completion Measure of Success of Outcome	A question regarding the success outcome after initial first course treatment.			Intellectual Product	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C158632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158632>	C158612	Initial Pathologic Diagnosis Method Question|Method of Initial Pathologic Diagnosis	A question about the method to obtain the initial pathologic diagnosis.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C158633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158633>	C173812|C158612	Did a New Event Occur After Initial Treatment Question|Did a New Event Occur After Initial Treatment|New Event After Initial Treatment	A question whether a new event occurs after the initial treatment.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Terminology
C158634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158634>	C181040	Number of Days from Date of Initial Pathologic Diagnosis to Date of Additional Surgery for New Tumor Event Loco-Regional|Number of Days from Date of Initial Cancer Diagnosis to Date of Additional Surgery for Loco-Regional Tumor	The number of days from the date of the initial pathologic diagnosis to the date of additional surgery for new loco-regional tumor event.			Intellectual Product	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Terminology
C158635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158635>	C181040	Number of Days from Date of Initial Pathologic Diagnosis to Date of Additional Surgery for New Tumor Event Metastasis|Number of Days from Date of Initial Cancer Diagnosis to Date of Additional Surgery for Metastatic Tumor	The number of days from the date of the initial pathologic diagnosis to the date of additional surgery for new metastatic tumor event.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Terminology
C158636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158636>	C3377|C2901	Bladder Soft Tissue Neoplasm	A mesenchymal neoplasm that arises from the bladder.			Neoplastic Process	
C158637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158637>	C181063|C156856	Number of Days from Date of Initial Pathologic Diagnosis to Date of Tumor Progression after Initial Treatment	The number of days from date of the initial cancer diagnosis to the date of tumor progression after the initial treatment.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Terminology
C158638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158638>	C181062|C156856	Number of Days from Date of Initial Pathologic Diagnosis to Date of Tumor Reoccurrence After Initial Treatment	The number of days from date of the initial cancer diagnosis to the date of tumor reoccurrence after the initial treatment.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Terminology
C158639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158639>	C174277	Number of Discontiguous Lesions (New Tumor Event)|discontiguous lesion count|discontiguous_lesion_count	The number of the discontiguous lesions in a new tumor event.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|GDC Property Terminology|GDC Terminology
C15863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15863>	C48800	Cancer Biobank|Cancer Biorepository|Tumor Bank	A repository of biospecimens - including tissue samples, fluids such as blood, serum and urine, and molecular derivatives such as DNA, RNA and proteins pertaining to cancer research. The repository has stringent guidelines regarding the standardized collection, handling, storage and documentation of biological specimens. These guidelines enable an extensive system for specimen storage that allows for the accurate establishment of disease incidences over long periods of time.			Physical Object	
C158640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158640>	C25337	Number of Known Primaries at the Time of Initial Melanoma Diagnosis|Number of known primaries at the time of initial melanoma diagnosis	A request to indicate the number of known primaries at the time of the melanoma diagnosis.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C158641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158641>	C124446	Number of Other Lymph Nodes Examined	A request to specify the number of other lymph nodes that were examined that are not listed on the form.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C158642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158642>	C157146	Number of Other Lymph Nodes Positive for Tumor by H&E	A request to specify the number of other lymph nodes that were positive for tumor by H&E that are not listed on the form.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C158643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158643>	C157145	Number of Other Lymph Nodes Positive for Tumor by IHC staining only	A request to specify the number of other lymph nodes that were positive for tumor by IHC staining that are not listed on the form.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C158644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158644>	C124446	Number of Para-aortic Lymph Nodes Examined	A request to specify the number of para-aortic lymph nodes examined.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C158645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158645>	C157146	Number of Para-aortic Lymph Nodes Positive for Tumor by H&E	A request to specify the number of para-aortic lymph nodes found positive for tumor by H&E..			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C158646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158646>	C157145	Number of Para-aortic Lymph Nodes Positive for Tumor by IHC Staining Only|Number of Para-aortic Lymph Nodes Positive for Tumor by IHC staining only	A request to specify the number of para-aortic lymph nodes found positive for tumor by IHC staining.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C158647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158647>	C124446	Number of Pelvic Lymph Nodes Examined	A request to specify the number of pelvic lymph nodes that were examined.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C158648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158648>	C157146	Number of Pelvic Lymph Nodes Positive for Tumor by H&E	A request to specify the number of pelvic lymph nodes found positive for tumor by H&E.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C158649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158649>	C157145	Number of Pelvic Lymph Nodes Positive for Tumor by IHC staining only	A request to specify the number of pelvic lymph nodes found positive for tumor by IHC staining.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C15864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15864>	C208218	Vaccine Clinical Trial	A research investigation involving human subjects that is designed to answer specific questions about the safety and efficacy of a vaccine.			Research Activity	
C158650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158650>	C191984|C158912	Prostate Large Cell Neuroendocrine Carcinoma|Prostate large cell neuroendocrine carcinoma	An exceptionally rare neuroendocrine carcinoma that arises from the prostate gland. It is characterized by the presence of malignant large cells.			Neoplastic Process	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C158651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158651>	C97927	STX11 Gene Mutation|FHL4 Gene Mutation|HLH4 Gene Mutation|HPLH4 Gene Mutation|Syntaxin 11 Gene Mutation	A change in the nucleotide sequence of the STX11 gene.	STX11 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158652>	C157093	Organ Based|Organ based	A header indicating the choices are organ based.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C158653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158653>	C97927	ITGB2 Gene Mutation|CD18 Gene Mutation|Integrin Subunit Beta 2 Gene Mutation|LAD Gene Mutation|LCAMB Gene Mutation|LFA-1 Gene Mutation|MAC-1 Gene Mutation|MF17 Gene Mutation|MFI7 Gene Mutation	A change in the nucleotide sequence of the ITGB2 gene.	ITGB2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158654>	C97927	PRF1 Gene Mutation|HPLH2 Gene Mutation|P1 Gene Mutation|PFP Gene Mutation|Perforin 1 Gene Mutation	A change in the nucleotide sequence of the PRF1 gene.	PRF1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158655>	C97927	LYST Gene Mutation|CHS Gene Mutation|CHS1 Gene Mutation|Chediak-Higashi Syndrome 1 Gene Mutation|Lysosomal Trafficking Regulator Gene Mutation	A change in the nucleotide sequence of the LYST gene.	LYST Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158656>	C5596|C39903	Usual Prostate Adenocarcinoma with Neuroendocrine Differentiation|Usual Prostate Adenocarcinoma with Neuroendocrine Cells	Acinar adenocarcinoma of the prostate gland characterized by the presence of scattered neuroendocrine cells by immunohistochemistry.			Neoplastic Process	
C158657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158657>	C42077	Scattered Neuroendocrine Cells by Immunohistochemistry Present	A morphologic finding indicating the presence of scattered neuroendocrine cells by immunohistochemistry in a cellular infiltrate.			Finding	
C158658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158658>	C97927	XIAP Gene Mutation|API3 Gene Mutation|BIRC4 Gene Mutation|Baculoviral IAP Repeat-Containing 4 Gene Mutation|IAP-3 Gene Mutation|ILP1 Gene Mutation|MIHA Gene Mutation|X-Linked Inhibitor of Apoptosis Gene Mutation|XLP2 Gene Mutation|hIAP-3 Gene Mutation|hIAP3 Gene Mutation	A change in the nucleotide sequence of the XIAP gene.	XIAP Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158659>	C97927	UNC13D Gene Mutation|FHL3 Gene Mutation|HLH3 Gene Mutation|HPLH3 Gene Mutation|Munc13-4 Gene Mutation|Unc-13 Homolog D Gene Mutation	A change in the nucleotide sequence of the UNC13D gene.	UNC13D Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15865>	C15660	Vaccine Design and Animal Testing	Apply findings from basic, epidemiologic, and clinical research to the design and evaluation of vaccine strategies in laboratory studies and animal models, and foster collaboration with industry in the research and development of candidate vaccines.			Health Care Activity	
C158660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158660>	C97927	STXBP2 Gene Mutation|FHL5 Gene Mutation|MUNC18-2 Gene Mutation|Syntaxin Binding Protein 2 Gene Mutation|UNC18-2 Gene Mutation|UNC18B Gene Mutation	A change in the nucleotide sequence of the STXBP2 gene.	STXBP2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158661>	C158612	Preoperative Karnofsky Performance Status Question|Performance Status Score Karnofsky Score (Preoperative)|Preoperative Karnofsky Performance Status	The Karnofsky Performance Status Score assessed preoperatively.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Normal Endometrial Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form
C158662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158662>	C158612	Preoperative ECOG - Performance Status Question|Performance Status Score: Eastern Cooperative Oncology Group (ECOG) (Preoperative)|Preoperative ECOG - Performance Status	The ECOG Performance Status Score assessed preoperatively.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form
C158663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158663>	C81326	Elevated EBV DNA|EBV DNA Elevated|Elevated Epstein-Barr Virus DNA|Elevated HHV-4 DNA|Elevated HHV4 DNA|Elevated Human Herpesvirus 4 DNA|Elevated Human Herpesvirus-4 DNA	A finding indicating elevated concentrations of Epstein-Barr virus DNA in a sample.	Elevated EBV DNA		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C158664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158664>	C39903	Prostate Adenocarcinoma with Paneth Cell-Like Neuroendocrine Differentiation	A prostate adenocarcinoma characterized by the presence of cells with eosinophilic cytoplasmic granules that are positive for neuroendocrine markers by immunohistochemistry.			Neoplastic Process	
C158665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158665>	C97927	CD40LG Gene Mutation|CD154 Gene Mutation|CD40 Ligand Gene Mutation|CD40L Gene Mutation|HIGM1 Gene Mutation|IGM Gene Mutation|IMD3 Gene Mutation|T-BAM Gene Mutation|TNFSF5 Gene Mutation|TRAP Gene Mutation|gp39 Gene Mutation|hCD40L Gene Mutation	A change in the nucleotide sequence of the CD40LG gene.	CD40LG Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158666>	C97927	RAB27A Gene Mutation|GS2 Gene Mutation|RAB27 Gene Mutation|RAB27A, Member RAS Oncogene Family Gene Mutation|RAM Gene Mutation|RAS-Related Gene From Megakaryocyte Gene Mutation	A change in the nucleotide sequence of the RAB27A gene.	RAB27A Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158667>	C97927	SIX1 Gene Mutation|BOS3 Gene Mutation|DFNA23 Gene Mutation|SIX Homeobox 1 Gene Mutation|Sine Oculis Homeobox Homolog 1 Gene Mutation|TIP39 Gene Mutation	A change in the nucleotide sequence of the SIX1 gene.	SIX1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158668>	C97927	SIX2 Gene Mutation|SIX Homeobox 2 Gene Mutation|Sine Oculis Homeobox Homolog 2 Gene Mutation	A change in the nucleotide sequence of the SIX2 gene.	SIX2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158669>	C97927	DROSHA Gene Mutation|Drosha Ribonuclease III Gene Mutation|ETOHI2 Gene Mutation|RANSE3L Gene Mutation|RN3 Gene Mutation|RNASE3L Gene Mutation|RNASEN Gene Mutation|RNase III Gene Mutation	A change in the nucleotide sequence of the DROSHA gene.	DROSHA Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15866>	C15660	Vaccine Development, AIDS|AIDS Vaccine Development	Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent AIDS. Some vaccines containing antigens are recombinantly produced.			Health Care Activity	
C158670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158670>	C97927	DGCR8 Gene Mutation|C22orf12 Gene Mutation|DGCR8 Microprocessor Complex Subunit Gene Mutation|DGCRK6 Gene Mutation|DiGeorge Syndrome Critical Region Gene 8 Gene Mutation|Gy1 Gene Mutation|Pasha Gene Mutation	A change in the nucleotide sequence of the DGCR8 gene.	DGCR8 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158671>	C97927	MLLT1 Gene Mutation|ENL Gene Mutation|LTG19 Gene Mutation|MLLT1, Super Elongation Complex Subunit Gene Mutation|Mixed Lineage Leukemia, Translocated To, 1 Eleven-Nineteen Leukemia Gene Mutation|Myeloid/Lymphoid Or Mixed-Lineage Leukemia; Translocated To, 1 Gene Mutation|YEATS1 Gene Mutation	A change in the nucleotide sequence of the MLLT1 gene.	MLLT1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158672>	C25873	DCLK1 Gene|DCLK1|DCLK1|Doublecortin Like Kinase 1 Gene	This gene is involved in microtubule polymerization, retrograde transport and neuronal development and migration.	DCLK1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C158673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158673>	C158672	DCLK1 wt Allele|CL1|CLICK1|DCAMKL1|DCDC3A|DCLK|Doublecortin Like Kinase 1 wt Allele|KIAA0369	Human DCLK1 wild-type allele is located in the vicinity of 13q13.3 and is approximately 363 kb in length. This allele, which encodes serine/threonine-protein kinase DCLK1 protein, plays a role in neuronal development and migration, microtubule polymerization and retrograde vesicle transport.	DCLK1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158674>	C17325	Serine/Threonine-Protein Kinase DCLK1|CAMK-Like CREB Regulatory Kinase 1|DCLK1|Doublecortin Domain-Containing Protein 3A|Doublecortin Like Kinase 1|Doublecortin and CaM Kinase-Like 1|Doublecortin- and Calmodulin Kinase-Like 1|Doublecortin- and Calmodulin Kinase-Like 1 Protein|Doublecortin-Like Kinase 1|Doublecortin-Like and CAM Kinase-Like 1|EC 2.7.11.1	Serine/threonine-protein kinase DCLK1 (740 aa, ~82 kDa) is encoded by the human DCLK1 gene. This protein is involved in neurogenesis, neuronal migration, microtubule polymerization and retrograde transport.	Serine/Threonine-Protein Kinase DCLK1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158675>	C81326|C35553	High Level of Hyaluronic Acid|HA High|HA-High|High Hyaluronan|High Hyaluronic Acid|Hyaluronan High|Hyaluronan-High|Hyaluronic Acid High|Hyaluronic Acid-High|Hyaluronic Acid-High	A finding indicating high concentrations of hyaluronic acid in a sample.	Hyaluronic Acid-High		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C158676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158676>	C178119|C131796	CDK12 Loss of Function Mutation|CDC2 Related Protein Kinase 7 Gene Loss of Function Mutation|CDK12 Inactivating Gene Mutation|CDK12 Inactivating Mutation|CDK12 Loss of Function Gene Mutation|CRK7 Loss of Function Mutation|CRKR Loss of Function Mutation|CRKRS Loss of Function Mutation|Cdc2-Related Kinase, Arginine/Serine-Rich Gene Loss of Function Mutation|Cyclin Dependent Kinase 12 Gene Loss of Function Mutation|Cyclin-Dependent Kinase 12 Gene Loss of Function Mutation|Inactivating CDK12 Gene Mutation|Inactivating CDK12 Mutation	A change in the nucleotide sequence of the CDK12 gene that either inhibits expression or results in the translation of an inactive cyclin-dependent kinase 12 protein.	CDK12 Loss of Function Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158677>	C84255	JAK2 Exon 12 Mutation|JAK-2 Exon 12 Mutation|JAK2 Exon 12 Gene Mutation|JTK10 Exon 12 Mutation|Janus Kinase 2 Exon 12 Mutation	A molecular genetic abnormality indicating the presence of a mutation in exon 12 of the JAK2 gene.	JAK2 Exon 12 Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158678>	C18133|C131484	Non-synonymous FBXW7 Gene Mutation|FBXW7 Missense Gene Mutation|FBXW7 Missense Mutation|Non-synonymous AGO Gene Mutation|Non-synonymous Archipelago Homolog Gene Mutation|Non-synonymous Archipelago Homolog, Drosophila Gene Mutation|Non-synonymous CDC4 Gene Mutation|Non-synonymous F-Box and WD Repeat Domain Containing 7 Gene Mutation|Non-synonymous F-box and WD-40 Domain Protein 7 (Archipelago Homolog, Drosophila) Gene Mutation|Non-synonymous FBW6 Gene Mutation|Non-synonymous FBW7 Gene Mutation|Non-synonymous FBX30 Gene Mutation|Non-synonymous FBXW6 Gene Mutation|Non-synonymous SEL-10 Gene Mutation|Non-synonymous SEL10 Gene Mutation	A point mutation in the FBXW7 gene that encodes an amino acid substitution in the F-box/WD repeat-containing protein 7 protein.	Non-synonymous FBXW7 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158679>	C159979	Were Immunophenotype and Cytochemistry Analyses Performed on Bone Marrow Aspirate Question|Were Immunophenotype & Cytochemistry Performed on Bone Marrow Aspirate|Were Immunophenotype and Cytochemistry Analyses Performed on Bone Marrow Aspirate	A question asking if immunophenotyping and cytochemistry were performed on bone marrow aspirate during the study			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C158680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158680>	C158612	Check all that Apply Question|Check all that Apply|Check all that apply|If yes, check all that apply	A directive to check all that apply on the form.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology
C158682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158682>	C222322|C201491|C200766	Autologous Anti-GD2CAR-CD28-CD3zeta-IL-15-expressing Natural Killer T-cells|Autologous Anti-GD2CAR-CD28-CD3zeta-IL-15-expressing|Autologous Anti-GD2CAR-CD28-CD3zeta-IL-15-expressing NKTs|G28z.15 NKTs	A preparation of autologous natural killer T-lymphocytes (NKTs) that have been transduced with a retroviral vector to express both an extracellular domain consisting of interleukin 15 (IL-15) and a chimeric antigen receptor (CAR) specific for the human tumor associated antigen (TAA) GD2, linked to the CD28 and CD3zeta (TCRzeta; CD247) costimulatory signaling domains, with potential antineoplastic activity. Upon intravenous administration, autologous anti-GD2CAR-CD28-CD3zeta-IL-15-expressing NKTs target, bind to, and induce selective toxicity in GD2-expressing tumor cells. IL-15 is a pro-survival cytokine that promotes T-cell persistence and potentiates the immune response against tumor cells. Incorporation of the costimulatory signaling domains increases T-cell function, expansion, and survival. The CD28 costimulatory molecule signaling domain enhances activation and signaling after recognition of GD2. Additionally, inclusion of the CD28 signaling domain may increase proliferation of T-cells and antitumor activity compared to the inclusion of the CD3zeta chain alone. GD2, a disialoganglioside and tumor-associated antigen (TAA), is overexpressed in a variety of tumor cell types.	Autologous Anti-GD2CAR-CD28-CD3zeta-IL-15-expressing Natural Killer T-cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158683>	C16295	Anti-CD34 Antibody|Anti CD34|Anti-Hematopoietic Progenitor Cell Antigen CD34|CD34 Antibody|HPCA1 Antibody|gp105-120 Antibody	Any antibody that recognizes hematopoietic progenitor cell antigen CD34.			Amino Acid, Peptide, or Protein|Immunologic Factor	
C158684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158684>	C199268	Anti-CD45RA Antibody|Anti CD45RA|Anti-Receptor-Type Tyrosine-Protein Phosphatase C Isoform CD45RA|CD45RA Antibody	Any antibody that recognizes receptor-type tyrosine-protein phosphatase C isoform CD45RA.			Amino Acid, Peptide, or Protein|Immunologic Factor	
C158685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158685>	C131912	11q23 Abnormality|11q23 Aberration|11q23 Alteration|11q23 Anomaly	Any cytogenetic abnormality involving chromosome band 11q23.	11q23 Abnormality		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158686>	C20401	Anti-CD34 Monoclonal Antibody|CD34 Monoclonal Antibody|HPCA1 Monoclonal Antibody|Monoclonal Anti CD34|Monoclonal Anti-Hematopoietic Progenitor Cell Antigen CD34 Antibody|gp105-120 Monoclonal Antibody	Any monoclonal antibody that recognizes hematopoietic progenitor cell antigen CD34.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	
C158687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158687>	C20401	Anti-CD45RA Monoclonal Antibody|CD45RA Monoclonal Antibody|Monoclonal Anti CD45RA|Monoclonal Anti-Receptor-Type Tyrosine-Protein Phosphatase C Isoform CD45RA Antibody	Any monoclonal antibody that recognizes receptor-type tyrosine-protein phosphatase C isoform CD45RA.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	
C158688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158688>	C9442	Dense Eosinophilic Basement Membrane Deposit	Accumulation of dense eosinophilic deposits in the basement membrane.			Finding	
C158689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158689>	C68616	Subject Reference Start Date	The date a subject reference began.			Temporal Concept	
C15868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15868>	C15660	Vaccine Related Development, AIDS|AIDS Vaccine Related Development	Vaccine development research focused on AIDS.			Research Activity	
C158690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158690>	C68617	Subject Reference End Date	The date a subject reference period has concluded.			Temporal Concept	
C158691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158691>	C82573	Subject Reference End Time	The time a subject reference period has concluded.			Temporal Concept	
C158692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158692>	C78441	Subject Reference Start Time	The time a subject reference began.			Temporal Concept	
C158693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158693>	C136648	Blasts 10-20 Percent of Bone Marrow Nucleated Cells|Blasts Between 10 and 20 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that between 10 and 20 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts 10-20 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C158694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158694>	C1663	Neoantigen-based Renal Cell Carcinoma-Poly-ICLC Vaccine|NeoVax RCC Vaccine|NeoVax Renal Cell Carcinoma Vaccine	A peptide-based renal cell carcinoma (RCC) vaccine consisting of neoantigens and peptides derived from immunogenic epitopes identified through DNA and RNA sequencing of a patient's tumor cells, combined with the immunostimulant poly-ICLC with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-based RCC vaccine stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, leading to tumor cell lysis. The adjuvant poly-ICLC, composed of double-stranded RNA molecules of polyinosinic-polycytidylic acid stabilized with poly L-lysine in carboxymethylcellulose, is a ligand for toll-like receptor-3 (TLR3) and induces the release of cytokines which may help to boost the immune response against the selected neoantigens.	Neoantigen-based Renal Cell Carcinoma-Poly-ICLC Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158695>	C54650	One Hundred Percent|1|100%	All, one hundred percent.			Qualitative Concept	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C158696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158696>	C25337	Number of Primary Tumors in this Location|# of Primaries in this location	A directive to specify the number of primary tumors in the specified location.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Terminology
C158697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158697>	C25337	Number of Units|#units	The number of units.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C158698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158698>	C96619	Per 50 High Powered Fields|/50 HPF|Per 50HPF	A unit of measurement of the number of entities per unit of area equal to fifty high powered fields.			Quantitative Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C158699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158699>	C96619	Per 10 High Powered Fields|/10 HPF, or for GISTs|/10 HPFs|/10.[HPF]|/10.[HPF]|Per 10HPF	A unit of measurement of the number of entities per unit of area equal to ten high powered fields.			Intellectual Product	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C15869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15869>	C15660	Vaccine Related Development, Cancer|Cancer Vaccine Related Development	Vaccine development research focused on cancer.			Research Activity	
C1586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1586>	C126712	Levofloxacin|(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic Acid Hydrate (2:1)|7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic Acid, 9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, Hydrate (2:1), (S)-|LEVOFLOXACIN|Levaquin|Levofloxacin Hydrate|Quixin|levofloxacin	A broad-spectrum, third-generation fluoroquinolone antibiotic and optically active L-isomer of ofloxacin with antibacterial activity. Levofloxacin diffuses through the bacterial cell wall and acts by inhibiting DNA gyrase (bacterial topoisomerase II), an enzyme required for DNA replication, RNA transcription, and repair of bacterial DNA. Inhibition of DNA gyrase activity leads to blockage of bacterial cell growth.	Levofloxacin		Antibiotic|Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C158700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158700>	C35959	Mitotic Rate Greater than or Equal to One per Square Millimeter|>=1/mm2|Mitoses Greater than or Equal to One per Square Millimeter	A result of a mitotic rate equal to or greater than one per square millimeter.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C158701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158701>	C158612	Was Adjuvant Post-operative Radiation Therapy Administered Question|Adjuvant Post-Operative Radiation Therapy|Was Adjuvant Post-operative Radiation Therapy Administered	A question whether adjuvant post-operative radiation therapy was administered.			Therapeutic or Preventive Procedure	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C158702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158702>	C158612	Was Adjuvant Post-Operative Chemotherapy Administered Question|Adjuvant Post-Operative Chemotherapy|Was Adjuvant Post-Operative Chemotherapy Administered	A question whether adjuvant post-operative chemotherapy was administered.			Therapeutic or Preventive Procedure	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C158703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158703>	C158612	Was Adjuvant Post-Operative Hormone Therapy Administered Question|Was Adjuvant Post-Operative Hormone Therapy Administered	A request to indicate if there was adjuvant post-operative hormone therapy administered.			Therapeutic or Preventive Procedure	
C158704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158704>	C158612	Was Adjuvant Post-Operative Immunological Therapy Administered Question|Adjuvant Post-Operative Immunological Therapy|Adjuvant Post-Operative Immunotherapy|Was Adjuvant Post-Operative Immunological Therapy Administered	A question whether adjuvant post-operative immunological therapy was administered.			Therapeutic or Preventive Procedure	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C158705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158705>	C158612	Was Adjuvant Post-Operative Pharmaceutical Therapy Administered Question|Adjuvant Post-Operative Pharmaceutical Therapy|Adjuvant Post-Operative Pharmacotherapy|Was Adjuvant Post-Operative Pharmaceutical Therapy Administered	A question whether adjuvant post-operative pharmaceutical therapy was administered.			Therapeutic or Preventive Procedure	CPTAC Follow-Up Forms Terminology|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Terminology
C158706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158706>	C158612	Was Adjuvant Post-Operative Targeted Molecular Therapy Administered Question|Adjuvant Post-Operative Target Molecular Therapy|Was Adjuvant Post-Operative Targeted Molecular Therapy Administered	A question whether adjuvant post-operative targeted molecular therapy was administered.			Therapeutic or Preventive Procedure	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C158707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158707>	C15675	Post-Adjuvant Therapy|Post Adjuvant|Post Adjuvant Therapy|Post Adjuvant Therapy	Therapy administered after to the initial therapy.			Therapeutic or Preventive Procedure	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|GDC Terminology|GDC Value Terminology
C158709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158709>	C96643	Unknown Tumor Status|Unknown tumor status	The tumor status is unknown.			Qualitative Concept	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|GDC Terminology|GDC Value Terminology
C15870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15870>	C15660	Vaccine Related Development, Non-Cancer; Non-AIDS|Non-Cancer; Non-AIDS Vaccine Related Development	Vaccine development research focused on diseases and conditions other that cancer or AIDS.			Health Care Activity	
C158710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158710>	C80699	MIR371A Gene|MIR371A|MIR371A|MicroRNA 371a Gene	This gene may play a role in tumor malignancy.			Gene or Genome	
C158711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158711>	C158710	MIR371A wt Allele|MIR371|MIRN371|Micro RNA 371A Gene|MicroRNA 371 Gene|MicroRNA 371a wt Allele|hsa-mir-371|hsa-mir-371a|miRNA371 Gene|miRNA371A Gene	The human MIR371A wild-type allele is located in the vicinity of 19q13.42 and is approximately 67 bases in length. This allele, which encodes MIR371A pre-miRNA, may be involved in the regulation of target gene expression. Alteration in the expression of this gene is associated with malignant germ cell tumors.			Gene or Genome	
C158712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158712>	C25968	MIR371A Pre-miRNA|MIR371A Pre-MicroRNA|Pre-MicroRNA 371A|Pre-miRNA 371A	MIR371A pre-miRNA (67 bases) is an oligoribonucleotide that is encoded by the human MIR371A gene. This ribonucleotide may play a role in both the regulation of gene transcription and tumor malignancy.			Nucleic Acid, Nucleoside, or Nucleotide	
C158713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158713>	C80699	MIR371B Gene|MIR371B|MIR371B|MicroRNA 371b Gene	This gene may be involved in translational inhibition or mRNA degradation.			Gene or Genome	
C158714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158714>	C158713	MIR371B wt Allele|MicroRNA 371b wt Allele|hsa-mir-371b	Human MIR371B wild-type allele is located in the vicinity of 19q13.42 and is approximately 66 kb in length. This allele, which encodes MIR371B pre-miRNA, may play a role in the regulation of gene expression. Alteration in the expression of this gene is associated with malignant germ cell tumors.			Gene or Genome	
C158715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158715>	C25968	MIR371B Pre-miRNA|MIR371B Pre-MicroRNA|Pre-MicroRNA 371B|Pre-miRNA 371B	MIR371B pre-miRNA (66 bases) is encoded by the human MIR371B gene. This ribonucleotide may be involved in both the regulation of gene transcription and tumor malignancy.			Nucleic Acid, Nucleoside, or Nucleotide	
C158716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158716>	C177693|C103223	MiRNA 371-373 Overexpression|MicroRNA 371-373 Overexpression	An indication that microRNAs found in the miRNA 371-373 cluster are overexpressed in a sample.			Laboratory or Test Result	
C158717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158717>	C20923	LHCGR Gene|LHCGR|LHCGR|Luteinizing Hormone/Choriogonadotropin Receptor Gene	This gene plays a role in luteinizing hormone and choriogonadotropin-mediated signaling.			Gene or Genome	
C158718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158718>	C158717	LHCGR wt Allele|HHG|LCGR|LGR2|LH/CG-R|LH/CGR|LHR|LHRHR|LSH-R|Luteinizing Hormone/Choriogonadotropin Receptor wt Allele|ULG5	Human LHCGR wild-type allele is located in the vicinity of 2p16.3 and is approximately 69 kb in length. This allele, which encodes lutropin-choriogonadotropic hormone receptor protein, is involved in binding luteinizing hormone and choriogonadotropin and G protein-coupled receptor signaling. Mutation of the gene is associated with luteinizing hormone resistance in females, precocious puberty in males, somatic Leydig cell adenoma with precocious puberty and Leydig cell hypoplasia with either pseudohermaphroditism or hypergonadotropic hypogonadism.			Gene or Genome	
C158719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158719>	C18239	Lutropin-Choriogonadotropic Hormone Receptor|LH/CG-R|LHCGR|LHR|LSH-R|Luteinizing Hormone Receptor|Luteinizing Hormone/Choriogonadotropin Receptor|Lutropin/Choriogonadotropin Receptor	Lutropin-choriogonadotropic hormone receptor (699 aa, ~79 kDa) is encoded by the human LHCGR gene. This protein plays a role in G protein-coupled receptor signaling mediated by luteinizing hormone and choriogonadotropin binding.			Amino Acid, Peptide, or Protein|Receptor	
C15871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15871>	C15660	Vaccine Related Non-Development, AIDS	Vaccine research, other than vaccine development, focused on AIDS.			Health Care Activity	
C158720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158720>	C97927	LHCGR Gene Mutation|HHG Gene Mutation|LCGR Gene Mutation|LGR2 Gene Mutation|LH/CG-R Gene Mutation|LH/CGR Gene Mutation|LHR Gene Mutation|LHRHR Gene Mutation|LSH-R Gene Mutation|Luteinizing Hormone/Choriogonadotropin Receptor Gene Mutation|ULG5 Gene Mutation	A change in the nucleotide sequence of the LHCGR gene.			Cell or Molecular Dysfunction	
C158721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158721>	C18133|C158720	LHCGR Missense Mutation|HHG Missense Mutation|LCGR Missense Mutation|LGR2 Missense Mutation|LH/CG-R Missense Mutation|LH/CGR Missense Mutation|LHCGR Missense Gene Mutation|LHR Missense Mutation|LHRHR Missense Mutation|LSH-R Missense Mutation|Luteinizing Hormone/Choriogonadotropin Receptor Missense Mutation|Non-synonymous LHCGR Gene Mutation|ULG5 Missense Mutation	A point mutation in the LHCGR gene that encodes an amino acid substitution in the lutropin-choriogonadotropic hormone receptor protein.			Cell or Molecular Dysfunction	
C158722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158722>	C97927	FOXL2 Gene Mutation|BPES Gene Mutation|BPES1 Gene Mutation|Forkhead Box L2 Gene Mutation|PFRK Gene Mutation|PINTO Gene Mutation|POF3 Gene Mutation	A change in the nucleotide sequence of the FOXL2 gene.			Cell or Molecular Dysfunction	
C158723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158723>	C29709	Brimonidine Tartrate Nanoemulsion OCU-300|OCU 300|OCU-300|OCU300	An ophthalmic nanoemulsion consisting of the tartrate salt form of brimonidine, an imidazole derivative and selective alpha-2 adrenergic receptor agonist, with potential anti-inflammatory and vasoconstrictive activities. Upon ophthalmic instillation, brimonidine tartrate nanoemulsion OCU-300 reduces intraocular pressure by promoting the outflow and decreasing the production of aqueous humor and may reduce ocular erythema through direct vasoconstriction. Additionally, brimonidine may disrupt leukocyte extravasation into the ocular tissue, inhibit nociception and reduce inflammation associated with ocular graft-versus-host disease (oGvHD). The nanoemulsion formulation may enhance distribution of brimonidine to target tissues, thereby allowing more of the active drug to reach underlying ocular tissue.	Brimonidine Tartrate Nanoemulsion OCU-300		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology
C158724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158724>	C158612	What is the Other Performance Status Scale: Timing Question|Other Performance Status Scale: Timing|What is the Other Performance Status Scale: Timing	A question about what is the other performance status scale about timing.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Terminology
C158725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158725>	C158612	Performance Status Scale: Timing Question|Performance Status Scale: Timing|Performance Status Scale: Timing	A question about the performance status scale.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C158726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158726>	C157093	Specify Site if cM1b|If cM1b, specify site(s)	A directive to indicate the anatomic sites if metastasis is categorized as cM1b.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C158727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158727>	C157093	Specify Site if pM1b|If pM1b, specify site(s)	A directive to indicate the anatomic sites if metastasis is categorized as pM1b.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C158728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158728>	C158612	Is there a Cancer History Question|Cancer History|History of Cancer|History of prior cancer diagnosis|Is there a Cancer History|Is there a history of cancer	A question about whether a history of cancer exists.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology|CRF2 History and Physical Exam Patient Medical History Table
C158729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158729>	C190742|C177693	GRPR Overexpression Positive|BB2 Overexpression Positive|BB2R Overexpression Positive|Bombesin Receptor 2 Overexpression Positive|GRPR Overexpression|Gastrin Releasing Peptide Receptor Overexpression Positive|Gastrin-Releasing Peptide Receptor Overexpression Positive	An indication that overexpression of GRPR has been detected in a sample.	GRPR Overexpression Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15872>	C15660	Vaccine Related Non-Development, Non-AIDS	Vaccine research, other than vaccine development, focused on diseases or conditions other than AIDS.			Health Care Activity	
C158730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158730>	C3063	Ocular Graft Versus Host Disease	Graft versus host disease occurring in the eye.	Ocular Graft Versus Host Disease		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C158731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158731>	C4981|C158730	Chronic Ocular Graft Versus Host Disease	Chronic graft versus host disease occurring in the eye.	Chronic Ocular Graft Versus Host Disease		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C158732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158732>	C222322|C200766	Autologous iC9-GD2CAR-CD28-CD3zeta-IL-15-expressing T-lymphocytes|Autologous iC9-GD2CAR-CD28-CD3zeta-IL-15-expressing T-cells|iC9.GD2.CAR.IL-15 T-cells	A preparation of autologous T-lymphocytes that have been transduced with the retroviral vector SFG, a Moloney murine leukemia (Mo-MuLV) virus-based vector, expressing both an extracellular domain consisting of interleukin 15 (IL-15) and a GD2-specific chimeric antigen receptor (CAR) derived from the monoclonal antibody 14G2a, linked to the CD28 and CD3zeta (TCRzeta; CD247) costimulatory signaling domains and containing the suicide gene, inducible caspase 9 (iCasp9 or iC9), with potential immunomodulating and antineoplastic activities. Upon administration, the autologous iC9-GD2CAR-CD28-CD3zeta-IL-15-expressing T-lymphocytes recognize, bind to and induce selective cytotoxicity in GD2-expressing tumor cells. IL-15 is a pro-survival cytokine that promotes T-cell persistence and potentiates the immune response against tumor cells. Incorporation of the costimulatory signaling domains increases T-cell function, expansion, and survival. The iCasp9 safety switch consists of a full-length caspase 9, including its caspase recruitment domain, linked to a human FK506 drug-binding domain with an F36V mutation (FKBP12-F36V). If the administered CAR T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903, which binds to the FKBP12-F36V drug-binding domain, activates caspase 9 and results in apoptosis of the administered CAR T-cells, can be administered. GD2, a disialoganglioside and tumor-associated antigen (TAA), is overexpressed on the surface of neuroblastoma cells and other neuroectoderm-derived neoplasms and is minimally expressed on normal, healthy cells.	Autologous iC9-GD2CAR-CD28-CD3zeta-IL-15-expressing T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158733>	C1511	Zirconium Zr 89-DFO-REGN3504|89Zr-DFO-REGN3504	A radioimmunoconjugate consisting of an antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), linked, via the chelator desferrioxamine (DFO), to the radioisotope zirconium Zr 89 (Zr89), with potential diagnostic properties upon positron emission tomography (PET) imaging. Upon administration, the antibody moiety of zirconium Zr 89-DFO-REGN3504 specifically targets and binds to PD-L1. Upon binding, the radioisotope moiety may be detected using PET, thereby allowing the imaging and quantification of PD-L1-expressing tumor cells. PD-L1, a transmembrane protein expressed on activated T-cells, is overexpressed in some cancer types and plays a significant role in immune evasion by tumor cells.	Zirconium Zr 89-DFO-REGN3504		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C158734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158734>	C2124|C129819	Lutetium Lu 177-NeoB|177Lu-NeoB|Lutetium 177-NeoB|Lutetium Lu 177 DOTA-NeoBOMB1|[177Lu]-NeoB	A radioconjugate consisting of the gastrin-releasing peptide receptor (GRPR) antagonist, NeoB, linked via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon administration, lutetium Lu 177 NeoB targets and binds to GRPRs present on certain tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to GRPR-expressing cells. GRPR, also known as bombesin receptor subtype 2, is a G protein-coupled receptor that is overexpressed in some cancer types.	Lutetium Lu 177-NeoB		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158737>	C35682|C175007	Hepatitis B Antigen Positive|HBV Antigen Positive|Hepatitis B Viral Antigen Positive|Hepatitis B Virus Antigen Positive	An indication that hepatitis B antigens have been detected in a sample.	Hepatitis B Antigen Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C158738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158738>	C173145|C158612	Did the Physician Diagnose Diabetes Question|Did the Physician Diagnose Diabetes|Has the patient ever been diagnosed with diabetes by a physician	A question whether a physician has diagnosed diabetes.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C158739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158739>	C158612	Is there a History of Colorectal Cancer Question|Has the patient had colorectal cancer|Is there a History of Colorectal Cancer	A question whether a physician has diagnosed diabetes.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C15873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15873>	C15864|C15602	Phase III Large Scale Vaccine Trial|Vaccine Trial-Phase III Large Scale	Select suitable vaccine candidates and support efficacy trials when appropriate criteria are met.			Research Activity	
C158740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158740>	C158612	What is the Follow-Up Form Completion Outcome Measure of Success Question|Measure of Success of Outcome at completion of this Follow-up Form|What is the Follow-Up Form Completion Outcome Measure of Success	A question regarding the success outcome after completion of this form.			Intellectual Product	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C158741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158741>	C158612	Specify Other Performance Status Scale: Timing Question|Specify Other Performance Status Scale: Timing|Specify Other Performance Status Scale: Timing	A directive to specify a performance status scale other than one listed on the form.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C158742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158742>	C156804	Zeprumetostat|EZH2 Inhibitor SHR2554|Enhancer of Zeste Homolog 2 Inhibitor SHR2554|SHR 2554|SHR-2554|SHR2554|ZEPRUMETOSTAT	An orally available selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2), with potential antineoplastic activity. Upon oral administration, zeprumetostat selectively targets, binds to and inhibits the activity of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 on lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased proliferation of EZH2-expressing cancer cells. EZH2, an HMT class enzyme and the catalytic subunit of the polycomb repressive complex 2 (PRC2), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation; its expression is correlated with tumor initiation, progression, stem cell self-renewal, migration and angiogenesis.	Zeprumetostat		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158743>	C213381	Oncolytic Adenovirus CAdVEC|CAd-VEC|CAdVEC	A genetically modified oncolytic viral strain of human adenovirus (Ad) with potential immunostimulating and antineoplastic activities. Upon intratumoral administration, the oncolytic adenovirus CAdVEC selectively infects and replicates in tumor cells, leading to tumor cell lysis. Additionally, CAdVEC has been genetically modified to express currently undisclosed immunomodulatory molecules that may enhance the anti-tumor effects of endogenous T-lymphocytes as well as adoptively transferred chimeric antigen receptor (CAR) T-cells.	Oncolytic Adenovirus CAdVEC		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158744>	C200766	Autologous HER2-CAR-modified Adenovirus-specific Cytotoxic T-lymphocytes|HER2-AdVST|HER2-CAR-modified Ad-specific CTLs|HER2-CAR-modified Adenovirus-specific CTLs|HER2-CAR-modified Autologous AdVSTs|HER2.CAR.AdVST	A population of autologous cytotoxic T-lymphocytes (CTLs) specifically reactive to human adenovirus (Ad) that have been transduced with a retroviral vector expressing a second-generation human epidermal growth factor receptor type 2 (HER2; EGFR2; ErbB2)-specific chimeric antigen receptor (CAR) comprised of an exodomain based on a anti-CD22 single chain variable fragment (scFv) from the anti-HER2 monoclonal antibody FRP5 that is linked to the costimulatory domains of CD28 and the zeta chain of the TCR/CD3 complex (CD3zeta), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, the autologous HER2-CAR-modified Ad-specific CTLs are directed to and induce selective toxicity in HER2-expressing tumor cells. Additionally, these cells may help reconstitute Ad-specific CTL responses in immunocompromised individuals and others at risk of developing Ad-infection. HER2, a receptor tyrosine kinase (RTK) overexpressed by a variety of tumor cell types, belongs to the EGFR superfamily and plays a key role in tumor cell proliferation.	Autologous HER2-CAR-modified Adenovirus-specific Cytotoxic T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158745>	C1663	Oral Myoma Vaccine V3-myoma|V3 Myoma|V3 Myoma Vaccine|V3-myoma|V3-myoma Vaccine	An orally available therapeutic myoma vaccine containing pooled antigens derived from hydrolyzed, inactivated blood and tumor tissue samples from patients with uterine myoma, with potential antineoplastic and immunomodulatory activities. Upon oral administration, V3-myoma may stimulate the immune system to mount a cytotoxic T-lymphocyte-mediated response against cells expressing myoma-associated antigens. This may reduce the myoma growth and improve myoma-related symptoms.			Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158746>	C199386	Barecetamab|Anti-ErbB3 Antibody ISU104|Anti-HER3 Antibody ISU104|BARECETAMAB|ISU 104|ISU-104|ISU104	A fully human antibody directed against the receptor tyrosine-protein kinase erbB-3 (ErbB3; HER3) with potential antineoplastic activity. Upon intravenous administration, barecetamab targets and binds to domain 3 and weakly interacts with domain 1 of ErbB3. This prevents heregulin (HRG) binding and blocks dimerization of ErbB3, thereby inactivating ErbB3 downstream signaling. ISU104 may also elicit the internalization of ErbB3 from the plasma membrane and downregulate ErbB3 expression. This inhibits cellular proliferation and survival of ErbB3-expressing tumor cells. ErbB3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in a variety of tumors and its overexpression generally correlates with poor prognosis and tumor resistance.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158747>	C177174	TLR Agonist BSG-001|BSG 001|BSG-001|BSG001|Syngenon	A toll-like receptor (TLR) agonist with potential immunomodulating and antineoplastic activities. Upon inhalation, TLR agonist BSG-001 activates one or more not yet disclosed TLRs, which may result in macrophage and plasmacytoid dendritic cell (pDC) stimulation, secretion of interferon alpha (IFNa), production of proinflammatory cytokines, upregulation of co-stimulatory molecules, enhanced T- and B-cell stimulatory responses, T-cell proliferation and a T-helper 1 (Th1) immune response. TLRs are transmembrane receptors that recognize structurally conserved microbial molecules such as bacterial cell-surface lipopolysaccharides (LPS), lipoproteins, lipopeptides, lipoarabinomannan and flagellin, among others. Immune responses stimulated by TLR activation may result in immune-mediated tumor cell killing.			Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158748>	C177692	SOX11 Positive|SOX-11 Positive|SRY Box 11 Positive|SRY-Box 11 Positive|SRY-Related HMG-Box 11 Positive|Sex-Determining Region Y-Box 11 Positive	An indication that SOX11 expression has been detected in a sample.	SOX11 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158749>	C1663	Personalized Neoepitope Yeast Vaccine YE-NEO-001|YE-NEO-001	A cancer vaccine composed of a heat-killed yeast that has been genetically modified to express patient-specific neoantigen epitopes. Upon vaccination, neoepitope yeast vaccine YE-NEO-001 may elicit a targeted CD4+ and CD8+ T-lymphocyte-mediated immune response against tumor cells expressing these specific epitopes.			Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15874>	C16237	Validation of Clinical Utility of Markers	Research to determine if an identified disease marker has clinical utility.			Health Care Activity	
C158750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158750>	C1966	Pegsitacianine|Indocyanine Green-labeled Polymeric Micelles ONM-100|ONM 100|ONM-100|ONM100|PEGSITACIANINE	A micellar polymer tracer labeled with the near-infrared (NIR) fluorescent imaging dye indocyanine green (ICG), with potential fluorescent imaging activity. Upon administration, pegsitacianine accumulates in tumor tissue. The micelles dissociate and subsequently fluoresce upon exposure to the acidic conditions of the tumor microenvironment (TME), allowing the visualization of tumors using infrared-based cameras.	Pegsitacianine		Indicator, Reagent, or Diagnostic Aid	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158751>	C4001|C203331	Unresectable Breast Inflammatory Carcinoma|Unresectable Inflammatory Breast Carcinoma|Unresectable Inflammatory Breast Carcinoma	Inflammatory breast carcinoma that is not amenable to surgical resection.	Unresectable Inflammatory Breast Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158752>	C4872|C148124	Unresectable Breast Carcinoma	Breast carcinoma that is not amenable to surgical resection.	Unresectable Breast Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158753>	C16212	Post-secondary Therapy|Post Secondary Therapy|Post-Secondary Therapy	Therapy administered after the second treatment.			Therapeutic or Preventive Procedure	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|GDC Terminology|GDC Value Terminology
C158754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158754>	C158612	Progression of Disease at Recurrence Question|At Recurrence/Progression of Disease|Progression of Disease at Recurrence|Recurrence/Progression	At the time of the progression or recurrence of a disease.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|GDC Terminology|GDC Value Terminology
C158755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158755>	C158612	No Evidence of Disease at Follow-Up Question|At Follow up/No evidence of Disease|No Evidence of Disease at Follow-Up|No evidence of disease (NED)	No evidence of disease at the follow-up assessment.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C158756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158756>	C158612	What is the Procedure Type for New Tumor Event Question|Procedure Type for New Tumor Event|What is the Procedure Type for New Tumor Event	A question about the procedure type for the new tumor event.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C158757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158757>	C158612	Other Procedure Type for New Tumor Event Question|Other Procedure Type for New Tumor Event|Other Procedure Type for New Tumor Event	A directive to specify the procedure which is other than is listed on the form.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C158758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158758>	C49165	Resection|SURGICAL RESECTION|Surgical Resection|Surgical Resection|Surgical Resection|Surgical Resection|resection	The surgical removal of all or part of an organ or tissue structure that may include a lesion.	Resection		Health Care Activity	CDISC SDTM Specimen Collection Method Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CRF7 Pathology Review Table|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C158759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158759>	C158612	Other Method, Specify Below Question|Other Method, Specify Below|Other Method, specify below	A directive to specify the method below which is other than is listed on the form.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C15875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15875>	C16237	Validation of Technology	The process of determining that a type of technology achieves its goal.			Occupational Activity	
C158760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158760>	C158612	What is the Status of the Residual Tumor After Surgery for New Tumor Event Question|Residual Tumor After Surgery for New Tumor Event|What is the Status of the Residual Tumor After Surgery for New Tumor Event	A question about the residual tumor status after surgery.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C158761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158761>	C158612	Was Additional Treatment Administered for New Tumor Event Question|Was Additional Treatment Administered for New Tumor Event	A request to indicate if there was additional treatment administered for new tumor event.			Intellectual Product	
C158764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158764>	C159979	Were Immunophenotype and Cytochemistry Analyses Performed on Peripheral Blood Samples Question|Were Immunophenotype & Cytochemistry Performed on Peripheral Blood|Were Immunophenotype and Cytochemistry Analyses Performed on Peripheral Blood Samples	A question asking if immunophenotyping and cytochemistry were performed on peripheral blood samples during the study.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C158765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158765>	C158612	Bone Marrow Aspirate Immunophenotype & Cytochemistry Question|Bone Marrow Aspirate Immunophenotype & Cytochemistry|Immunophenotype & Cytochemistry for Bone Marrow Aspirate	A section header for lab results related to bone marrow aspirate immunophenotype and cytochemistry.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C158766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158766>	C158612	Peripheral Blood Immunophenotype & Cytochemistry Question|Immunophenotype & Cytochemistry for Peripheral Blood|Peripheral Blood Immunophenotype & Cytochemistry	A section header for lab results related to peripheral blood immunophenotype and cytochemistry.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C158767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158767>	C158612	Is the New Disease Multifocal Question|Is the New Disease Multifocal|Is the New Disease Multifocal	A question about whether the new disease is multifocal.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology
C158768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158768>	C120284	Radiologic Tumor Size of New Tumor	A question about the size of the tumor via a radiologic procedure.			Quantitative Concept	CPTAC Follow-Up Forms Terminology|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology
C158769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158769>	C200479|C158768	Radiographic Length|Radiologic Length	The longest perpendicular diameter of a tumor from the results of an imaging modality.			Quantitative Concept	CPTAC Follow-Up Forms Terminology|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology
C15876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15876>	C16199	Virus Cancer Research	Experimental or epidemiological studies of viruses as carcinogens or co-carcinogens.			Research Activity	
C158770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158770>	C200480|C158768	Radiographic Width|Radiologic Width	The longest diameter of a tumor from the results of an imaging modality.			Quantitative Concept	CPTAC Follow-Up Forms Terminology|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology
C158771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158771>	C25333|C158768	Radiographic Depth|Radiologic Depth	The longest front to back measurement of a tumor from the results of an imaging modality.			Quantitative Concept	CPTAC Follow-Up Forms Terminology|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology
C158772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158772>	C120284	Pathologic Tumor Size of New Tumor	A question about the size of a tumor from the pathology examination of a specimen.			Quantitative Concept	CPTAC Follow-Up Forms Terminology|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology
C158773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158773>	C200479|C158772	Pathologic Length	The longest perpendicular diameter of a tumor from the pathology examination of a specimen.			Quantitative Concept	CPTAC Follow-Up Forms Terminology|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology
C158774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158774>	C200480|C158772	Pathologic Width	The longest diameter of a tumor from the pathology examination of a specimen.			Quantitative Concept	CPTAC Follow-Up Forms Terminology|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology
C158775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158775>	C25333|C158772	Pathologic Depth	The longest front to back measurement of a tumor from the pathology examination of a specimen.			Quantitative Concept	CPTAC Follow-Up Forms Terminology|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology
C158776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158776>	C28384	Radiologic Burden of New Tumor	The estimate of the number of cells, or size of the tumor from the results of an imaging modality.			Quantitative Concept	CPTAC Follow-Up Forms Terminology|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology
C158777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158777>	C28384	Pathologic Burden of New Tumor	The estimate of the number of cells, or size of the tumor from the results of a pathology examination.			Quantitative Concept	CPTAC Follow-Up Forms Terminology|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology
C158778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158778>	C158612	Well-Differentiated or De-Differentiated New Tumor Question|Is the New Tumor Well-Differentiated or De-Differentiated|Well-Differentiated or De-Differentiated New Tumor	A question about whether a new tumor is well-differentiated or de-differentiated.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology
C158779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158779>	C158612	Diagnostic Evidence of Recurrence/Relapse Question|Diagnostic Evidence of Recurrence/Relapse|Diagnostic Evidence of Recurrence/Relapse	Evidence from testing or observation that there has been a recurrence or relapse.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Terminology
C15877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15877>	C15213	Worksite Health Service	Clinical service at the physical site of employment.			Health Care Activity	
C158780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158780>	C158612	Biopsy with Histologic Confirmation Question|Biopsy with Histologic Confirmation|Biopsy with Histologic Confirmation|Biopsy with Histologic Confirmation	A biopsy with microscopic confirmation.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C158781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158781>	C42078	Dedifferentiated Lesion|De-Differentiated	A lesion composed of cells that have undergone transformation to less mature forms.			Finding	CPTAC Follow-Up Forms Terminology|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology
C158782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158782>	C158612	Convincing Image Source Question|Convincing Image (i.e. CT/PET/MRI)|Convincing Image Source|Convincing Image Source	Radiologic evidence that supports a diagnosis.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C158783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158783>	C134526	Canine Gastrointestinal Stromal Tumor	A gastrointestinal stromal tumor occurring in a dog.			Neoplastic Process	Cellosaurus Disease Terminology
C158784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158784>	C134526	Canine Granular Cell Tumor	A granular cell tumor occurring in a dog.			Neoplastic Process	Cellosaurus Disease Terminology
C158785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158785>	C134526	Canine Langerhans Cell Histiocytosis	Langerhans cell histiocytosis occurring in a dog.			Neoplastic Process	Cellosaurus Disease Terminology
C158786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158786>	C134526	Canine Nephroblastoma	A nephroblastoma occurring in a dog.			Neoplastic Process	Cellosaurus Disease Terminology
C158787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158787>	C53543|C27644	Deafness, Autosomal Recessive 4, with Enlarged Vestibular Aqueduct|Autosomal Recessive Deafness-4 with Enlarged Vestibular Aqueduct|DFNB4	An autosomal recessive condition caused by mutation(s) in one of several genes, most often SLC26A4 encoding pendrin. It is characterized by  hearing loss and enlargement of the vestibular aqueduct. Mutation(s) in the SLC26A4 gene also cause Pendred syndrome.			Disease or Syndrome	Cellosaurus Disease Terminology
C158788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158788>	C53543	Macrothrombocytopenia and Granulocyte Inclusions with or without Nephritis or Sensorineural Hearing Loss	An autosomal dominant disorder caused by mutation(s) of the MYH9 gene, encoding myosin-9. Clinical features include thrombocytopenia, giant platelets, and characteristic inclusions in peripheral blood leukocytes, and may be associated with other organ dysfunction. It comprises the Epstein syndrome, Fechtner syndrome, May-Hegglin anomaly, and Sebastian syndrome-- all of which were previously believed to be distinct entities.			Disease or Syndrome	Cellosaurus Disease Terminology
C158789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158789>	C158612	Related to Head and Neck Cancer Question|Related to Head & Neck Cancer|Related to Head and Neck Cancer	A request to indicate if there is a relationship to head and neck cancer.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology
C15878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15878>	C15716	Population Research	Research on fertility, contraceptives, transplacental carcinogenesis or other in utero or pre-conception disease induction.			Research Activity	
C158790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158790>	C158612	Related to Another Cancer Question|Related to Another Cancer|Related to Another Cancer	A request to indicate if relates an event to another cancer.			Intellectual Product	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology
C158792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158792>	C158612	Related to Acute Myeloid Leukemia Question|Related to AML|Related to Acute Myeloid Leukemia	A request to indicate if relates an event to acute myeloid leukemia.			Intellectual Product	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Terminology
C158793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158793>	C158612	Type of New Melanoma Related Tumor Event Question|Type of New Melanoma Related Tumor Event|Type of New Melanoma Related Tumor Event	A directive to specify the type of new melanoma related tumor event.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Terminology
C158794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158794>	C158612	Specify Cause of Death Question|Specify Cause of Death|Specify Cause of Death	A directive to specify the cause of death.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology
C158795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158795>	C173060|C158612	Did the Individual use Smokeless Tobacco Use at Diagnosis Question|Did the Individual use Smokeless Tobacco Use at Diagnosis|Did the patient use smokeless tobacco (including chewing tobacco and snuff) at the time of diagnosis	A question whether an individual was using smokeless tobacco at time of diagnosis.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology
C158796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158796>	C173060|C158612	Regular Smokeless Tobacco Use for Six Weeks or More Question|Did the patient ever use smokeless tobacco (including chewing tobacco and snuff) regularly for a period of six weeks or more|Regular Smokeless Tobacco Use for Six Weeks or More	A question about whether the individual ever used smokeless tobacco regularly for a period of six weeks or more.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology
C158797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158797>	C173060|C158612	Average Daily Use Smokeless Tobacco after Use for Six Weeks Question|Average Daily Use Smokeless Tobacco after Use for Six Weeks|If the patient used smokeless tobacco (including chewing tobacco and snuff) regularly for at least six weeks, on average how many times per day did they use	A question about how many times per day an individual who has used smokeless tobacco regularly for at least six weeks.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology
C158798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158798>	C160157	Not Applicable - Never Quit|Not Applicable - Never quit				Intellectual Product	
C158799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158799>	C173060|C158612	Age When Quit using Smokeless Tobacco after Regular Use Question|Age When Quit using Smokeless Tobacco after Regular Use|If the patient used smokeless tobacco (including chewing tobacco and snuff) regularly for at least six weeks, how old were they when they quit using|smokeless tobacco quit age|smokeless_tobacco_quit_age	A question about the age of an individual when they started using smokeless tobacco, once they have been using regularly for six weeks.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology|GDC Deprecated Terminology|GDC Terminology
C15879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15879>	C15969	Infrastructure Activities	NIH Emphasis Area: Infrastructure activities are new or expanded programs in the following: Research Training; Shared Instrumentation and Services; Technology Development; Information Technology and Clinical Research. Again, only new or expanded program initiatives should be reported-e.g., an increase in training related only to the increase in stipends should not be reported as an Infrastructure Initiative.			Conceptual Entity	
C1587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1587>	C1594	Idarubicin Hydrochloride|IDARUBICIN HYDROCHLORIDE|IMI-30|Idamycin|Idamycin PFS|Idarubicin HCl|Idarubicin hydrochloride|SC-33428|Zavedos	The hydrochloride salt of the anthracycline antineoplastic antibiotic idarubicin.  Idarubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.  Due to its high lipophilicity, idarubicin penetrates cell membranes more efficiently than other anthracycline antibiotic compounds	Idarubicin Hydrochloride		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158800>	C158612	Definitive Therapy Date of Completion|Date of Completion of Definitive (Curative) Therapy	The date of completion of the curative therapy.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology
C158801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158801>	C158612	What is the Definitive Therapy Method Question|Definitive Therapy Method|Method of Definitive (Curative) Therapy|Method of Definitive Therapy|What is the Definitive Therapy Method	A question about what is the definitive therapy method.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology
C158802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158802>	C15632	Concurrent Chemotherapy	Chemotherapy that is administered at the same time as another chemotherapy.			Therapeutic or Preventive Procedure	
C158803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158803>	C15632	Non-Concurrent Chemotherapy|Chemotherapy (not given concurrently)	Chemotherapy that is administered at different times.			Therapeutic or Preventive Procedure	
C158804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158804>	C158612	Was Evidence of Disease Present after Completion of Therapy Question|After the completion of definitive (curative) therapy, was there evidence of disease|Evidence of Disease Present after Completion of Therapy|Was Evidence of Disease Present after Completion of Therapy	A question about whether evidence of disease was present after the completion of therapy.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology
C158805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158805>	C173812|C158612	Was Tumor Progression Present After Initial Treatment Question|Tumor Progression After Initial Treatment|Was Tumor Progression Present After Initial Treatment	A question about whether the tumor progression was present after the initial treatment.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Terminology
C158806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158806>	C173812|C158612	Was Tumor Reoccurrence Present After Initial Treatment Question|Tumor Reoccurrence After Initial Treatment|Was Tumor Reoccurrence Present After Initial Treatment	A question whether tumor reoccurrence was present after the initial treatment.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Terminology
C158807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158807>	C159241	Greater than or Equal to 50% Myometrial Invasion|>= 50% myometrial invasion	A response that there is greater than or equal to 50% myometrial invasion.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C158808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158808>	C158612	Were Local Anesthesia Agents Administered Question|Local Anesthesia agents administered|Were Local Anesthesia Agents Administered|Were Local Anesthesia Agents Administered	A question about whether local anesthesia agents were administered.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C158809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158809>	C158612	Additional Pathologic Findings Question|Additional Pathologic Findings|Additional Pathologic Findings|additional pathology findings|additional_pathology_findings	A section header that includes additional pathologic findings.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Pancreatic Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|GDC Property Terminology|GDC Terminology
C15880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15880>	C15969	Biology of the Brain Disorders	NIH Emphasis Area -- New emphasis on the biology of brain disorders reflects the extraordinary rate at which the neurosciences, with strong support from the fields of molecular genetics, imaging, and cell biology, is growing.  Efforts in neural development; neurodegeneration, especially in Alzheimer's disease, Parkinson's disease, mental illness and traumatic injury to the brain and spinal cord are few examples of the promise of this field.			Conceptual Entity	
C158810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158810>	C158612	At Time of Diagnosis Question|At Time of Diagnosis|at time of diagnosis	A specification that indicates the time to assess is the time of diagnosis.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C158811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158811>	C158612	Were Routine Cytogenetics Completed Question|Were Routine Cytogenetics Completed|Were Routine Cytogenetics Done	A question about whether routine cytogenetic tests were completed.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C158812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158812>	C158612	Total Number of Metaphases Question|Total Number of Metaphases|Total Number of Metaphases	A section requesting the input of the total number of metaphases.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C158813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158813>	C17188	Videotelephony|Video Call|Video Conference|Videoconference	The use of audio and visual signals to link users at different locations for communication in real-time.	Video Conference		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C158814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158814>	C35553	Iron Deficiency	Subnormal concentrations of iron resulting from low iron intake, inefficient iron absorption in the gastrointestinal tract, or increased iron loss.			Finding	
C158815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158815>	C200225|C1511	Actinium Ac 225-FPI-1434|225Ac-FPI-1434|Actinium Ac 225-FPI-1397-FPI-1175|Actinium Ac 225-labeled FPI-1434|FPI 1434|FPI-1434|FPI1434|FPX 01|FPX-01|FPX01|[225Ac]-FPI-1434|[Ac-225]-FPI-1434	A radioconjugate consisting of veligrotug, a humanized monoclonal antibody directed against insulin-like growth factor-1 receptor (IGF-1R) linked, via a bifunctional chelate, to the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic activity. Upon administration of actinium Ac 225-FPI-1434, the veligrotug moiety targets and binds to IGF-1R expressed on tumor cells. Upon binding, the radioisotope moiety delivers a cytotoxic dose of alpha radiation to IGF-1R-expressing tumor cells. Activation of IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by various cancer cell types, stimulates cell proliferation, promotes angiogenesis, enables oncogenic transformation, and suppresses apoptosis.	Actinium Ac 225-FPI-1434		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158816>	C1511	Indium In 111-FPI-1547|Indium In 111-FPI-1397-FPI-1175|Indium In 111-labeled FPI-1547|[111In]-FPI-1547	A radioimmunoconjugate composed of FPI-1175 (AVE1642), a humanized monoclonal antibody against insulin-like growth factor-1 receptor (IGF-1R) linked, via the bifunctional chelate FPI-1397, to the radioisotope indium-111 (111In or In-111), with potential imaging activity upon single photon emission computed tomography (SPECT). Upon administration of indium In 111-FPI-1547, the FPI-1547 moiety targets and binds to IGF-1R expressed on tumor cells. Upon uptake and imaging, IGF-1R-expressing tumor cells can be visualized. This allows assessment of IGF-1R expression on tumor cells as well as tumor uptake of the agent. The linker promotes increased clearance of the radioisotope.	Indium In 111-FPI-1547		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C158817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158817>	C158814	Iron Deficiency without Anemia|Non-Anemic Iron Deficiency	Subnormal concentrations of iron resulting from low iron intake, inefficient iron absorption in the gastrointestinal tract, or increased iron loss; occurring in the absence of anemia.	Iron Deficiency without Anemia		Finding	CTRP Disease Terminology|CTRP Terminology
C158818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158818>	C1185	Abaloparatide|ABALOPARATIDE|BA058|BIM-44058|C2.29-methyl(22-L-glutamic Acid(F>E),23-L-leucine(F>L),25-L-glutamic Acid(H>E),26-L-lysine(H>K),28-L-leucine(I>L),30-L-lysine(E>K),31-L-leucine(I>L))Human Parathyroid Hormone-related Protein-(1-34)-proteinamide|L-Alaninamide, L-alanyl-L-valyl-L-seryl-L-alpha-glutamyl-L-histidyl-L-glutaminyl-L-leucyl-L-leucyl-L-histidyl-L-alpha-aspartyl-L-lysylglycyl-L-lysyl-L-seryl-L-isoleucyl-L-glutaminyl-L-alpha-aspartyl-L-leucyl-L-arginyl-L-arginyl-L-arginyl-L-alpha-glutamyl-L-leucyl-L-leucyl-L-alpha-glutamyl-L-lysyl-L-leucyl-L-leucyl-2-methylalanyl-L-lysyl-L-leucyl-L-histidyl-L-threonyl-|Tymlos	A 34 amino acid synthetic analog of human parathyroid hormone-related protein (PTHrP) (PTHrP(1-34) analog), with bone-growing and bone density conserving activities. Upon subcutaneous administration, abaloparatide acts similar to PTHrP and targets, binds to and activates parathyroid hormone 1 (PTH1) receptor (PTH1R), a G protein-coupled receptor (GPCR) expressed in osteoblasts and bone stromal cells. PTH1R activates the cyclic AMP (cAMP) signaling pathway and the bone anabolic signaling pathway, leading to bone growth, increased bone mineral density (BMD) and volume. This correlates with increased bone mass and strength and prevents or treats osteoporosis and decreases fractures.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C15881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15881>	C15969	New Approaches to Pathogenesis	NIH Emphasis Area -- Innovative approaches to pathogenesis, resulting from more precise understanding of genes, proteins, and cells, are transforming traditional descriptions of disease processes.  For example, research in this arena will uncover new mechanisms of carcinogenesis and cardiovascular disease and will lead to better understanding of osteoarthritis, birth defects and growth disorders.  These new insights into pathogenesis are, in turn, stimulating new preventive strategies against disease such as the development of new vaccines against a variety of pathogens.			Conceptual Entity	
C158820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158820>	C226471	Alcohol-free Hypoallergenic Barrier Film Solution|3M Cavilon Advanced Skin Protectant	An alcohol-free, hypoallergenic, polymeric-cyanoacrylate-based solution that provides a barrier film, with potential skin protective and healing activities. Upon topical application of the barrier film solution to intact or damaged skin, the alcohol-free barrier film solution forms a breathable, transparent film over the skin and maintains and enhances skin integrity, provides long-lasting protection against skin injury, infection, and irritation, and maintains moisture to the skin.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C158821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158821>	C514	Opelconazole|4-[4-(4-{[(3R,5R)-5-(2,4-Difluorophenyl)-5-(1H-1,2,4-triazol-1-ylmethyl)oxolan-3-yl]methoxy}-3-methylphenyl)piperazin-1-yl]-N-(4-fluorophenyl)benzamide|Antifungal PC945|Inhaled Antifungal PC945|OPELCONAZOLE|PC 945|PC-945|PC945|Triazole Antifungal PC945	A synthetic triazole antifungal agent, with activity against a variety of pathogenic fungi that can potentially be used against invasive pulmonary aspergillosis. Upon inhalation by nebulizer, opelconazole is delivered in high concentrations to the lungs and resides in the lung tissues for a long period of time with minimal systemic exposure. Opelconazole selectively binds to and inhibits the CYP450-dependent 14-alpha-sterol demethylase in fungi, thereby preventing the production of ergosterol, which is an essential constituent of the fungal cell membrane. This results in fungal cell lysis and inhibits fungal infection in the lungs.	Opelconazole		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C158822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158822>	C136634	FLT3 NM_004119.2:c.2073T>A|CD135 c.2073T>A|FLK2 c.2073T>A|FLT3 c.2073T>A|FMS-Related Tyrosine Kinase 3 c.2073T>A|NM_004119.2:c.2073T>A	A nucleotide substitution at position 2073 of the coding sequence of the FLT3 gene where thymine has been mutated to adenine.			Cell or Molecular Dysfunction	
C158823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158823>	C128920	FLT3 NP_004110.2:p.F691L|CD135 Antigen F691L|CD135 Antigen Phe691Leu|FLT3 F691L|FLT3 F691L Mutation|FLT3 NP_004110.2:p.Phe691Leu|FLT3 Phe691Leu|FLT3 p.F691L|FLT3 p.Phe691Leu|Fetal Liver Kinase-2 F691L|Fetal Liver Kinase-2 Phe691Leu|Flt-3 Receptor F691L|Flt-3 Receptor Phe691Leu|Fms-Related Tyrosine Kinase 3 F691L|Fms-Related Tyrosine Kinase 3 Phe691Leu|NP_004110.2:p.F691L|NP_004110.2:p.Phe691Leu|Receptor-Type Tyrosine-Protein Kinase FLT3 F691L|Receptor-Type Tyrosine-Protein Kinase FLT3 Phe691Leu|Stem Cell Tyrosine Kinase 1 F691L|Stem Cell Tyrosine Kinase 1 Phe691Leu	A change in the amino acid residue at position 691 in the receptor-type tyrosine-protein kinase FLT3 protein where phenylalanine has been replaced by leucine.	FLT3 NP_004110.2:p.F691L		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158824>	C28404	USP46 Gene|USP46|USP46|Ubiquitin Specific Peptidase 46 Gene	This gene plays a role in both deubiquitination and gamma-aminobutyric acid (GABA) synthesis regulation.			Gene or Genome	
C158825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158825>	C158824	USP46 wt Allele|FLJ12552|Ubiquitin Specific Peptidase 46 wt Allele	Human USP46 wild-type allele is located in the vicinity of 4q12 and is approximately 68 kb in length. This allele, which encodes ubiquitin carboxyl-terminal hydrolase 46 protein, is involved in protein modification and neurotransmitter-dependent behavior.			Gene or Genome	
C158826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158826>	C16481	Ubiquitin Carboxyl-Terminal Hydrolase 46|Deubiquitinating Enzyme 46|EC 3.4.19.12|USP46|Ubiquitin Specific Peptidase 46|Ubiquitin Specific Protease 46|Ubiquitin Thioesterase 46|Ubiquitin Thiolesterase 46|Ubiquitin-Specific Peptidase 46|Ubiquitin-Specific Protease 46|Ubiquitin-Specific-Processing Protease 46	Ubiquitin carboxyl-terminal hydrolase 46 (366 aa, ~42 kDa) is encoded by the human USP46 gene. This protein plays a role in the regulation of glutamate-dependent responses and protein deubiquitination.			Amino Acid, Peptide, or Protein|Enzyme	
C158827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158827>	C158612	No Pathologic Evidence of Distant Metastasis Question|No Pathologic Evidence of Distant Metastasis|No pathologic evidence of distant metastasis	A result that there is no pathologic evidence of distant metastasis.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C158828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158828>	C158612	Premenopausal Greater than 6 months since LMP and no Prior Bilateral Oophorectomy and Not on Estrogen Replacement Question|Premenopausal Greater than 6 months since LMP and no Prior Bilateral Oophorectomy and Not on Estrogen Replacement|Premenopausal: <6 months since LMP AND no prior bilateral oophorectomy AND not on estrogen replacement	A request to indicate if an individual is considered premenopausal, as it has been  longer than 6 months since LMP and there was no prior bilateral oophorectomy and she is not on estrogen replacement.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C158829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158829>	C158612	Perimenopausal 6 to 12 Months Since LMP Question|Perimenopausal 6 to 12 Months Since LMP|Perimenopausal 6 to 12 Months Since Last Menstrual Period|Perimenopausal: 6-12 months since last menstrual period	A time period of 6-12 months since the last menstrual period.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C15882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15882>	C15969	New Prevention Strategies Against Disease	NIH Emphasis Area: Research in new procedures and approaches to prevent disease.			Conceptual Entity	
C158830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158830>	C158612	Postmenopausal with no Prior Oophorectomy Status Question|Postmenopausal with no Prior Oophorectomy Status|Postmenopausal: >12 months since LMP with no prior oophorectomy OR prior bilateral oophorectomy|Was the patient Postmenopausal at diagnosis, where it was >12 months since LMP with no prior oophorectomy OR prior bilateral oophorectomy	A question about whether a patient was postmenopausal at diagnosis for longer than 12 months since the last menstrual period with no prior oophorectomy or prior bilateral oophorectomy.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C158831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158831>	C158612	Were Subsequent Known Primary Melanoma(s) Found During the Follow-Up Question|Did the patient have subsequent known primary melanoma(s) during the follow-up period|Were Subsequent Known Primary Melanoma(s) Found During the Follow-Up	A question about whether subsequent known primary melanoma(s) were found during the follow-up period.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Terminology
C158832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158832>	C160157	Melanoma Related Only Event Occurred after Initial Treatment|Yes- Melanoma Related Only	A response that a melanoma related only event occurred after the initial treatment.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Terminology
C158833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158833>	C160157	Non-Melanoma Related Only Event Occurred after Initial Treatment|Yes- Non- Melanoma Related Only	A response that a non-melanoma related only event occurred after the initial treatment.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Terminology
C158834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158834>	C158612	Primary Site of New Non-Melanoma Tumor Event Question|Primary Site of New Non-Melanoma Tumor Event|Primary Site of New Non-Melanoma Tumor Event	A directive to identify the primary site to the new non-melanoma tumor event.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Terminology
C158835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158835>	C158612	Histological Type of New Non-Melanoma Tumor Event Question|Histological Type of New Non-Melanoma Tumor Event|Histological Type of New Non-Melanoma Tumor Event|New Non-Melanoma Tumor Histological Type	A directive to identify the histological type of new non-melanoma tumor event.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Terminology
C158836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158836>	C158612	Site of New Primary Melanoma Question|Site of New Primary Melanoma|Site of New Primary Melanoma	A directive to specify the site of the new primary melanoma.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Terminology
C158837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158837>	C158612	Site of New Distant Metastasis Tumor Event Question|Site of New Distant Metastasis Tumor Event|Site of New Distant Metastasis Tumor Event	A directive to specify the site of the new distant metastatic tumor event.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Terminology
C158838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158838>	C20420	TEAD4 Gene|TEA Domain Transcription Factor 4 Gene|TEAD4|TEAD4	This gene plays a role in hippo pathway-mediated regulation of gene transcription.			Gene or Genome	
C158839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158839>	C158838	TEAD4 wt Allele|EFTR-2|RTEF1|Related Transcription Enhancer Factor 1B Gene|TCF13L1|TEA Domain Transcription Factor 4 wt Allele|TEF-3|TEF3|TEFR-1|Transcriptional Enhancer Factor 1-Related Gene|hRTEF-1B	Human TEAD4 wild-type allele is located in the vicinity of 12p13.33 and is approximately 81 kb in length. This allele, which encodes transcriptional enhancer factor TEF-3 protein, is involved in both the regulation of organ size and tumor suppression.			Gene or Genome	
C15883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15883>	C15969	New Avenues for the Development of Therapeutics	NIH Emphasis Area -- The result of efforts in chemistry, structural biology, genetics, and cellular and molecular biology are providing new means to design therapies for a variety of diseases.  Efforts to discover and develop drugs to combat cancer and drug and alcohol addiction and methods of bioengineering to repair tissues are ripe for discovery.			Conceptual Entity	
C158840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158840>	C17207	Transcriptional Enhancer Factor TEF-3|TEA Domain Family Member 4|TEA Domain Transcription Factor 4|TEAD-4|TEAD4|Transcription Factor 13-Like 1|Transcription Factor RTEF-1|Transcriptional Enhancer Factor 3	Transcriptional enhancer factor TEF-3 (434 aa, ~48 kDa) is encoded by the human TEAD4 gene. This protein plays a role in transcriptional regulation in the hippo signaling pathway.			Amino Acid, Peptide, or Protein	
C158841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158841>	C29697	PEG4000/Simethicone/Sodium Sulphate/Sodium Bicarbonate/Electrolytes Oral Solution|Macrogol 4000-based Oral Osmotic Laxative|PEG4000/Simethicone/Sodium Sulphate/Sodium Bicarbonate/Electrolytes|Powder-for-oral-solution containing PEG4000/Simethicone/Sodium Sulphate/Sodium Bicarbonate/Electrolyte|SELG-ESSE	A powder for oral solution containing polyethylene glycol (PEG) 4000 (Macrogol 4000), simethicone, sodium sulphate, sodium bicarbonate, and electrolytes, with laxative and bowel cleansing activities. Upon oral administration, macrogol 4000-based oral osmotic laxative promotes the retention of water in the bowel, thereby increasing the water content of stool, which results in increased gastrointestinal (GI) motility, accelerated stool transit time and evacuation of colonic contents.			Organic Chemical|Pharmacologic Substance	NCI Drug Dictionary Terminology
C158842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158842>	C20420	AKNA Gene|AKNA|AKNA|AT-Hook Transcription Factor Gene	This gene is involved in the regulation of transcription of the CD40 and CD40LG genes.			Gene or Genome	
C158843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158843>	C158842	AKNA wt Allele|AT-Hook Transcription Factor wt Allele|KIAA1968	Human AKNA wild-type allele is located in the vicinity of 9q32 and is approximately 64 kb in length. This allele, which encodes AT-hook-containing transcription factor protein, plays a role in the transcriptional activation of the CD40 and CD40LG genes.			Gene or Genome	
C158844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158844>	C17207	AT-Hook-Containing Transcription Factor|AKNA|AT-Hook Transcription Factor AKNA	AT-hook-containing transcription factor (1439 aa, ~155 kDa) is encoded by the human AKNA gene. This protein is involved in the positive regulation of expression of tumor necrosis factor receptor superfamily member 5 (CD40; TNFRSF5) and CD40 ligand.			Amino Acid, Peptide, or Protein	
C158845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158845>	C158851	Specify Identified Mutation|Mutation identified, specify	A request to enter the specific mutation that was identified in the study.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C158846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158846>	C158954	Specify Mutation Analysis Method|Mutational Analysis Testing Method	A request to enter the specific molecular analysis method used to detect and identify mutations in that section of the form.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C158847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158847>	C160766	Presence of Another Mutation Question|Other Mutation|Other Mutation|Presence of Another Mutation	A question to determine if another mutation was found in the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C158848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158848>	C158954	1p/19q Deletion Analysis Testing Method	A request to enter the specific molecular analysis method used to determine the 1q/19q deletion status.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C158849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158849>	C2950	3q Abnormality|3q|3q Aberration|Chromosome 3q Abnormality	An irregularity in the structure of the long arm of chromosome 3.			Cell or Molecular Dysfunction	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C15884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15884>	C15969	Computers and Advanced Instrumentation	NIH Emphasis Area -- Recent advances in basic biology, genetics, diagnosis, and health care have all been closely linked to the development of new research instruments and computer hardware and software.  Improvements in the detection of early cancers and technologies to better visualize the living body in health and disease states will provide a wealth of knowledge that can lead to new and improved diagnostics, treatments and prevention strategies.			Conceptual Entity	
C158850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158850>	C158954	ALK Rearrangement Testing Method|ALK Rearrangement Analysis Testing Method	A request to enter the specific molecular analysis method used to detect and identify rearrangements involving the ALK gene.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C158851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158851>	C157093	Specify Molecular Abnormalities in Study|Molecular Study Abnormalities	A request to enter the specific molecular abnormalities assayed in a study.			Activity	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C158852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158852>	C18302	ATRX Mutation Analysis|ATRX Gene Mutation Analysis|ATRX Mutation Status|ATRX, Chromatin Remodeler Mutation Analysis|Alpha Thalassemia/Mental Retardation Syndrome X-Linked Mutation Analysis|RAD54 Homolog Mutation Analysis|RAD54 Mutation Analysis|RAD54L Mutation Analysis|XH2 Mutation Analysis|XNP Mutation Analysis|ZNF-HX Mutation Analysis	A procedure used to detect and identify mutations in the ALK gene.			Laboratory Procedure	
C158853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158853>	C158846	ATRX Mutation Analysis Testing Method|ATRX Mutational Analysis Testing Method	A request to enter the specific molecular analysis method used to detect and identify mutations in the ATRX gene.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C158854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158854>	C40430	BRAF Exon 15 Mutation|B-RAF Exon 15 Mutation|B-RAF1 Exon 15 Mutation|BRAF Exon 15 Gene Mutation|BRAF1 Exon 15 Mutation|Exon 15|v-raf Murine Sarcoma Viral Oncogene Homolog B1 Exon 15 Mutation	A molecular genetic abnormality indicating the presence of a mutation in exon 15 of the BRAF gene.			Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C158855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158855>	C51950	Neutrophil Recovery Time|Time to Neutrophil Recovery	The duration of time it takes for an individual who has had chemotherapy-induced neutropenia to achieve an acceptable numbers of neutrophils.			Laboratory Procedure	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Terminology
C158856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158856>	C158846	BRAF Mutation Analysis Testing Method|BRAF Mutational Analysis Testing Method	A request to enter the specific molecular analysis method used to detect and identify mutations in the BRAF gene.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C158857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158857>	C158954	BRAF Rearrangement Testing Method|BRAF Rearrangement Analysis Testing Method|BRAF Rearrangement Analysis Testing Method	A request to enter the specific molecular analysis method used to detect and identify rearrangements involving the BRAF gene.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C158858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158858>	C49286	Time to Platelet Recovery	The duration of time it takes for an individual who has had chemotherapy-induced low platelets to achieve an acceptable number of platelets in the blood.			Laboratory Procedure	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Terminology
C158859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158859>	C156805	Pathologic/Prognostic Information	A header on a form about the pathologic/prognostic information.			Clinical Attribute	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C15885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15885>	C15178	Mind-Body System|Mind-Body Method	This sub-category of CAM contains numerous specific modalities used in mind-body approaches to health.  Examples are meditation, hypnosis, biofeedback, support groups, etc.  These are often considered conventional practice and become CAM related when applied to conditions for which they are not usually used, such as hypnosis for genetic problems, support groups for cancer survival, meditation to slow aging.  Included are: Psychotherapy, Meditation, Imagery, Hypnosis, Biofeedback, Support groups, Art therapy, Music therapy, Dance therapy, Journalizing, Humor, Body Psychotherapy, Yoga, Qi Gong, and Tai Chi.			Idea or Concept	
C158860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158860>	C133155	CBFB Gene Rearrangement|CBF-Beta Gene Rearrangement|CBFB|CBFB Rearrangement|Core-Binding Factor Subunit Beta Gene Rearrangement|PEBP2B Gene Rearrangement	A molecular abnormality indicating rearrangement of the CBFB gene.			Cell or Molecular Dysfunction	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C158861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158861>	C25337	Days to Absolute Neutrophil Count Greater than 1000 per Microliter|days to ANC >1000 per mcl	The number of days to achieve a neutrophil count of greater than 1000 per microliter.			Quantitative Concept	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Terminology
C158862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158862>	C25337	Days to Platelet Count Greater than 100,000 per Microliter|days to platelet count >100,000 per mcl	The number of days to achieve a platelet count of greater than 100,000 per microliter.			Quantitative Concept	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Terminology
C158863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158863>	C186452|C158948	Chromosome Deletion Detected|Chromosomal Deletion Detected|Cytogenetic Deletion Detected|Deletion Identified	An indication that a chromosomal deletion was detected in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C158864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158864>	C35681|C103223	Cytogenetic Abnormalities Not Detected|Cytogenetic Abnormalities Absent|Cytogenetically Normal|No Cytogenetic Abnormalities Detected|No abnormality detected|None Detected|None detected|Normal	An indication that cytogenetic abnormalities were not detected in a sample.			Laboratory or Test Result	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology|EWS Authorized Value Terminology|EWS Molecular Analysis Table
C158865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158865>	C96270|C36511	del(10q23)/PTEN Gene Locus Deletion|10q23/PTEN Locus Deletion|Deletion identified|del10q23/Phosphatase and Tensin Homolog Gene Locus	A cytogenetic abnormality that refers to the deletion of the chromosomal band 10q23, which also results in the deletion of the PTEN gene.			Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C158866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158866>	C181330	del(10q23)/PTEN Gene Locus Deletion Analysis|10q23 (PTEN Locus) Deletion|del(10q23)/PTEN Gene Locus Deletion Status|del10q23/Phosphatase and Tensin Homolog Gene Locus Deletion Analysis	A procedure used to detect and identify deletion of the PTEN gene located in the vicinity of 10q23.			Activity	
C158867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158867>	C158612	What is the Cell Source Question|Source of Cells used for Analysis|What is the Cell Source	A question about the source of the cells for analysis.			Qualitative Concept	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C158868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158868>	C19988	Adaptation|Adapt|Adapted|Adaption	The alteration or adjustment in structure or habits, often occurring through natural selection, by which a species becomes better able to function in its environment.			Organism Function	
C158869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158869>	C158954	del(10q23)/PTEN Gene Locus Deletion Analysis Method|Chromosome 10q23 (PTEN Locus) Deletion Analysis Testing Method|del(10q23)/PTEN Gene Locus Deletion Analysis Testing Method	A request to enter the specific molecular analysis method used to detect and identify deletion of the PTEN gene located in the vicinity of 10q23.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C158870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158870>	C158954	EGFR Amplification Analysis Testing Method	A request to enter the specific molecular analysis method used to detect and identify amplification of the EGFR gene.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C158871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158871>	C209559	EGFR Amplification Status|EGFR Amplification Analysis|EGFR Gene Amplification Analysis|EGFR amplification status|Epidermal Growth Factor Receptor Amplification Analysis|HER1 Amplification Analysis|c-erbB1 Amplification Analysis	A procedure used to detect and identify amplification of the EGFR gene.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C158872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158872>	C18302	EGFR Mutation Analysis|EGFR Gene Mutation Analysis|EGFR Mutation Status|Epidermal Growth Factor Receptor Mutation Analysis|HER1 Mutation Analysis|c-erbB1 Mutation Analysis	A procedure used to detect and identify mutations in the EGFR gene.			Laboratory Procedure	
C158873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158873>	C158846	EGFR Mutation Analysis Testing Method|EGFR Mutational Analysis Testing Method	A request to enter the specific molecular analysis method used to detect and identify mutations in the EGFR gene.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C158874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158874>	C93589	Primary Site of Disease|primary disease site|primary site|primary_disease_site|primary_site	The anatomic location where a disease of interest originated.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|GDC Property Terminology|GDC Terminology|ICDC Property Terminology|ICDC Terminology
C158875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158875>	C160157	Specify Site of Metastasis|Metastatic site, specify	A request to specify the site of the metastasis.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C158876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158876>	C16212	Induction Therapy|Induction|Induction|Induction|Induction|Induction|Induction	The first choice of treatment for a particular type of cancer.			Therapeutic or Preventive Procedure	ALL Authorized Value Terminology|ALL Course Timing Table|ALL Histology Table|ALL Off Protocol Therapy/Study Table|ALL Vitals Table|AML Adverse Events Table|AML Authorized Value Terminology|AML Cellular Immunotherapy Table|AML Concomitant Medication Table|AML Course Timing Table|AML Function Test Table|AML Lab Table|AML Minimal Residual Disease Table|AML Molecular Analysis Table|AML Myeloid Sarcoma Involvement Table|AML Off Protocol Therapy/Study Table|AML Radiation Therapy Table|AML Secondary Malignant Neoplasm Table|AML Stem Cell Transplant Table|AML Subject Response Table|AML Survival Characteristics Table|AML Total Dose Table|AML Transfusion Medicine Procedures Table|AML Vitals Table|CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Terminology|EWS Adverse Events Table|EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Course Timing Table|EWS Histology Table|EWS Immunohistochemistry Table|EWS Lab Table|EWS Molecular Analysis Table|EWS Non-Protocol Therapy Table|EWS Off Protocol Therapy/Study Table|EWS Radiation Therapy Table|EWS Secondary Malignant Neoplasm Table|EWS Stem Cell Transplant Table|EWS Subject Response Table|EWS Survival Characteristics Table|EWS Tumor Assessment Table|EWS Vitals Table|GDC Terminology|GDC Value Terminology|OS Adverse Event Table|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Function Test Table|OS Histology Table|OS Lab Table|OS Molecular Analysis Table|OS Off Protocol Therapy/Study Table|OS Radiation Therapy Table|OS Secondary Malignant Neoplasm Table|OS Subject Response Table|OS Survival Characteristics Table|OS Total Dose Table|OS Tumor Assessment Table|OS Vitals Table
C158877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158877>	C16212	Reinduction Therapy|Re-Induction	Treatment administered after a relapse of cancer.			Therapeutic or Preventive Procedure	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Terminology
C158878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158878>	C25499	Event During Procedure|Other notable events during the procedure	A question about whether there was a notable event during the procedure.			Event	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C158879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158879>	C48570	Percent Blasts in Peripheral Blood at Diagnosis	A finding of the percentage of blasts in the peripheral blood at the time of diagnosis.			Quantitative Concept	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C15887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15887>	C15885	Social and Contextual Areas|Social and Contextual Areas of Mind Body Medicine	Subcategory of Mind-Body Medicine in CAM classification.  This area deals with social, cultural, symbolic and contextual interventions not covered in other areas.  For example, the study cross-cultural explanatory models, placebo or "meaning response" research, and caring-based approaches to health care fall into this category.  Included are: Placebo, Explanatory models, Caring-based approaches, Community- based approaches, Intuitive diagnosis.			Idea or Concept	
C158880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158880>	C158612	Classified by World Health Organization Only Question|Classified by WHO only|Classified by World Health Organization Only	A request to indicate if the bone marrow was classified by the World Health Organization (WHO) only.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C158881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158881>	C158612	Complete Blood Count from Clinical Peripheral Blood (Within 24 Hours of Banking) Question|Complete Blood Count from Clinical Peripheral Blood (Within 24 Hours of Banking)|Complete Blood Count from Clinical Peripheral Blood (Within 24 Hours of Banking)	A section header for lab results related to a complete blood count from clinical peripheral blood obtained within 24 hours of banking.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C158882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158882>	C157093	Epstein-Barr Virus Analysis Method|Epstein-Barr virus (Epstein-Barr virus encoded RNA [EBER], other)	A request to enter the specific molecular analysis method used to detect Epstein-Barr Virus.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C158883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158883>	C150633	ERBB2 NM_004448.2:c.2326_2327insTCT|CD340 c.2326_2327insTCT|ERBB2 c.2326_2327insTCT|Erb-B2 Receptor Tyrosine Kinase 2 c.2326_2327insTCT|HER-2 c.2326_2327insTCT|HER2 c.2326_2327insTCT|HER2/Neu c.2326_2327insTCT|NM_001005862.2:c.2236_2237insTCT|NM_004448.2:c.2326_2327insTCT|Neu c.2326_2327insTCT|c-erbB2 c.2326_2327insTCT|v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 c.2326_2327insTCT	An insertion of 3 nucleotides, thymine-cytosine-thymine, between position 2326 and 2327 of the coding sequence of the ERBB2 gene.			Cell or Molecular Dysfunction	
C158884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158884>	C98358	ERBB2 NP_004439.2:p.G776delinsVC|ERBB2 776_776G>VC|ERBB2 776_776G>VC Insertion|ERBB2 776_776G>VC insertion mutation|ERBB2 776_776GdelinsVC|ERBB2 776_776Gly>ValCys|ERBB2 776_776GlydelinsValCys|ERBB2 G776>VC|ERBB2 Gly776>ValCys|ERBB2 NP_004439.2:p.Gly776delinsValCys|ERBB2 p.776_776G>VC|ERBB2 p.776_776GdelinsVC|ERBB2 p.776_776Gly>ValCys|ERBB2 p.776_776GlydelinsValCys|NP_001005862.1:p.G746delinsVC|NP_001005862.1:p.Gly746delinsValCys|NP_004439.2:p.G776delinsVC|NP_004439.2:p.Gly776delinsValCys|Proto-Oncogene Neu G776delinsVC|Proto-Oncogene Neu Gly776delinsValCys|Receptor Tyrosine-Protein Kinase erbB-2 G776delinsVC|Receptor Tyrosine-Protein Kinase erbB-2 Gly776delinsValCys|Tyrosine Kinase-Type Cell Surface Receptor HER2 G776delinsVC|Tyrosine Kinase-Type Cell Surface Receptor HER2 Gly776delinsValCys	A deletion of the glycine and insertion of the amino acid sequence valine-cysteine at position 776 of the receptor tyrosine-protein kinase erbB-2 protein.			Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C158885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158885>	C158846	ERBB2 Mutation Analysis Testing Method|ERBB2 Mutational Analysis Testing Method	A request to enter the specific molecular analysis method used to detect and identify mutations in the ERBB2 gene.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C158886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158886>	C97927	ERG Gene Mutation|ERG|ERG Mutation|ETS Transcription Factor ERG Gene Mutation|Erg-3 Gene Mutation|Erythroblastosis Virus E26 Oncogene Like Gene Mutation|p55 Gene Mutation	A change in the sequence of the ERG gene.			Cell or Molecular Dysfunction	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C158887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158887>	C158846	IDH1/2 Mutation Analysis Testing Method|IDH1/2 Mutational Analysis Testing Method	A request to enter the specific molecular analysis method used to detect and identify mutations in the genes IDH1 and IDH2.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C158888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158888>	C158845|C157106	Specify Other BRAF Mutation|If other BRAF mutation, specify|Other BRAF mutation, specify	A request to enter the specific BRAF mutation that was identified in the study but is not present in the form.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C158889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158889>	C158888	Specify Other BRAF Codon 600 Mutation|If other BRAF V600 mutation, specify|Specify Other BRAF V600 Mutation	A request to enter the specific mutation involving BRAF codon 600 that was identified in the study but is not present in the form.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C15888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15888>	C15178	Alternative Medical System	NIH: Major category of Complementary and Alternative Medicine classification.  This category involves complete systems of theory and practice that are alternatives to the Western biomedical approach.  Includes: Acupuncture and oriental medicine; Traditional Indigenous Systems; Unconventional Western systems; and Naturopathy.			Biomedical Occupation or Discipline	
C158890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158890>	C158845|C157106	Specify Other KRAS Codon Mutation|If other codon, specify|Other codon	A request to enter the specific KRAS codon where a mutation was identified in the study but it is not present in the form.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C158891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158891>	C158845|C157106	Specify Other ERBB2 Non-Exon 20 Mutation|If other ERBB2 mutation (non-exon 20), specify	A request to enter the specific EGFR non-exon 20 mutation that was identified in the study but is not present in the form.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C158892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158892>	C158845|C157106	Specify Other NRAS Mutation|If Other NRAS mutation, specify	A request to enter the specific NRAS mutation that was identified in the study but is not present in the form.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C158893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158893>	C158851	Specify Polysomy/Monosomy|If polysomy/monosomy, specify|Specify Polysomy or Monosomy	A request to specify if monosomy or polysomy was present.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C158894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158894>	C157157	Indeterminate Microsatellite Instability|Indeterminate|MSI Indeterminate|MSI-I	An indication that microsatellite instability was not assessed or that it is not known if it was assessed.			Qualitative Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C158895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158895>	C136635|C104668	KIT NM_000222.2:c.1727T>C|CD117 c.1727T>C|KIT L576P (c.1727T>C) mutation|KIT Proto-Oncogene Tyrosine Protein Kinase c.1727T>C|KIT c.1727T>C|NM_000222.2:c.1727T>C|c-KIT c.1727T>C|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.1727T>C	A nucleotide substitution at position 1727 of the coding sequence of the KIT gene where thymine has been mutated to cytosine.	KIT NM_000222.2:c.1727T>C		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158896>	C136635|C104668	KIT NM_000222.2:c.1676T>C|CD117 c.1676T>C|KIT Proto-Oncogene Tyrosine Protein Kinase c.1676T>C|KIT V559A (c.1676T>C) mutation|KIT c.1676T>C|NM_000222.2:c.1676T>C|c-KIT c.1676T>C|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.1676T>C	A nucleotide substitution at position 1676 of the coding sequence of the KIT gene where thymine has been mutated to cytosine.	KIT NM_000222.2:c.1676T>C		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158897>	C136635|C104668	KIT NM_000222.2:c.1669T>A|CD117 c.1669T>A|KIT Proto-Oncogene Tyrosine Protein Kinase c.1669T>A|KIT W557R (c.1669T>A) mutation|KIT c.1669T>A|NM_000222.2:c.1669T>A|c-KIT c.1669T>A|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.1669T>A	A nucleotide substitution at position 1669 of the coding sequence of the KIT gene where thymine has been mutated to adenine.	KIT NM_000222.2:c.1669T>A		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158898>	C136635|C104668	KIT NM_000222.2:c.1669T>C|CD117 c.1669T>C|KIT Proto-Oncogene Tyrosine Protein Kinase c.1669T>C|KIT c.1669T>C|NM_000222.2:c.1669T>C|c-KIT c.1669T>C|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog c.1669T>C	A nucleotide substitution at position 1669 of the coding sequence of the KIT gene where thymine has been mutated to cytosine.	KIT NM_000222.2:c.1669T>C		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158899>	C126819	KIT NP_000213.1:p.L576P|CD117 Antigen L576P|CD117 Antigen Leu576Pro|KIT L576P|KIT Leu576Pro|KIT NP_000213.1:p.Leu576Pro|KIT p.L576P|KIT p.Leu576Pro|Mast/Stem Cell Growth Factor Receptor Kit L576P|Mast/Stem Cell Growth Factor Receptor Kit Leu576Pro|NP_000213.1:p.L576P|NP_000213.1:p.Leu576Pro|Proto-Oncogene Tyrosine-Protein Kinase Kit L576P|Proto-Oncogene Tyrosine-Protein Kinase Kit Leu576Pro|Proto-Oncogene c-Kit L576P|Proto-Oncogene c-Kit Leu576Pro|Stem Cell Factor Receptor L576P|Stem Cell Factor Receptor Leu576Pro|Tyrosine-Protein Kinase Kit L576P|Tyrosine-Protein Kinase Kit Leu576Pro|c-KIT L576P|c-KIT Leu576Pro|c-KIT p.L576P|c-KIT p.Leu576Pro	A change in the amino acid residue at position 576 in the mast/stem cell growth factor receptor Kit protein where leucine has been replaced by proline.	KIT NP_000213.1:p.L576P		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15889>	C180905	Traditional Indigenous System	Subcategory of Alternative Medical Systems in CAM. This sub-category refers to major indigenous systems of medicine other than acupuncture and traditional oriental medicine. It includes systems such as Ayurvedic medicine, Native American Medicine, Unani-Tibbi, Kampo, Traditional African systems and community based traditional medical systems. This sub-category may become subdivided further as these systems become better studied and more familiar in the U.S. Included are: Native American Medicine, Ayurvedic Medicine, Unani-Tibbi, SADHU, Kampo Medicine, Traditional African Medicine, Traditional Aboriginal Medicine, Curandersimo, Central and South American practices, Psychic surgery.			Occupation or Discipline	
C1588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1588>	C217648	Ganciclovir Sodium|9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine, Monosodium Salt|BIOLF-62|BW-759|BW-759U|Cymevene|Cytovene|Cytovene-IV|DHPG Sodium|DHPG sodium|Denosine|GANCICLOVIR SODIUM|GCV Sodium|GCV sodium|Ganciclovir sodium|RS-21592 Sodium	The sodium salt form of ganciclovir, a synthetic, antiviral, purine nucleoside analog with antiviral activity, especially against cytomegalovirus (CMV). Ganciclovir sodium is a prodrug that is phosphorylated and subsequently converted into its triphosphate form, the active metabolite ganciclovir-5-triphosphate (ganciclovir-TP), in the infected cells by cellular kinases. Ganciclovir-TP competes as a substrate with nucleotide triphosphates for viral DNA polymerase. Once it gets incorporated into DNA strand, it prevents further polymerization of DNA, thereby interfering with viral DNA replication.			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C158900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158900>	C126819	KIT NP_000213.1:p.V559A|CD117 Antigen V559A|CD117 Antigen Val559Ala|KIT NP_000213.1:p.Val559Ala|KIT V559A|KIT Val559Ala|KIT p.V559A|KIT p.Val559Ala|Mast/Stem Cell Growth Factor Receptor Kit V559A|Mast/Stem Cell Growth Factor Receptor Kit Val559Ala|NP_000213.1:p.V559A|NP_000213.1:p.Val559Ala|Proto-Oncogene Tyrosine-Protein Kinase Kit V559A|Proto-Oncogene Tyrosine-Protein Kinase Kit Val559Ala|Proto-Oncogene c-Kit V559A|Proto-Oncogene c-Kit Val559Ala|Stem Cell Factor Receptor V559A|Stem Cell Factor Receptor Val559Ala|Tyrosine-Protein Kinase Kit V559A|Tyrosine-Protein Kinase Kit Val559Ala|c-KIT V559A|c-KIT Val559Ala|c-KIT p.V559A|c-KIT p.Val559Ala	A change in the amino acid residue at position 559 in the mast/stem cell growth factor receptor Kit protein where valine has been replaced by alanine.	KIT NP_000213.1:p.V559A		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158901>	C126819	KIT NP_000213.1:p.W557R|CD117 Antigen Trp557Arg|CD117 Antigen W557R|KIT NP_000213.1:p.Trp557Arg|KIT Trp557Arg|KIT W557R|KIT p.Trp557Arg|KIT p.W557R|Mast/Stem Cell Growth Factor Receptor Kit Trp557Arg|Mast/Stem Cell Growth Factor Receptor Kit W557R|NP_000213.1:p.Trp557Arg|NP_000213.1:p.W557R|Proto-Oncogene Tyrosine-Protein Kinase Kit Trp557Arg|Proto-Oncogene Tyrosine-Protein Kinase Kit W557R|Proto-Oncogene c-Kit Trp557Arg|Proto-Oncogene c-Kit W557R|Stem Cell Factor Receptor Trp557Arg|Stem Cell Factor Receptor W557R|Tyrosine-Protein Kinase Kit Trp557Arg|Tyrosine-Protein Kinase Kit W557R|c-KIT Trp557Arg|c-KIT W557R|c-KIT p.Trp557Arg|c-KIT p.W557R	A change in the amino acid residue at position 557 in the mast/stem cell growth factor receptor Kit protein where tryptophan has been replaced by arginine.	KIT NP_000213.1:p.W557R		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158902>	C18302	KIT Mutation Analysis|CD117 Mutation Analysis|KIT Mutation Status|KIT Proto-Oncogene Tyrosine Protein Kinase Mutation Analysis|c-KIT Mutation Analysis|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Mutation Analysis	A procedure used to detect and identify mutations in the KIT gene.			Laboratory Procedure	
C158903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158903>	C158846	KIT Mutation Analysis Testing Method|KIT Mutational Analysis Testing Method	A request to enter the specific molecular analysis method used to detect and identify mutations in the KIT gene.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C158905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158905>	C158846	KRAS Mutation Analysis Testing Method|KRAS Mutational Analysis Testing Method	A request to enter the specific molecular analysis method used to detect and identify mutations in the KRAS gene.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C158906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158906>	C574|C1967|C129825	Itacitinib Adipate|INCB-039110 Adipate|INCB039110 Adipate|ITACITINIB ADIPATE	The adipate salt form of itacitinib, an orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1) with potential antineoplastic and immunomodulating activities. Upon oral administration, itacitinib selectively inhibits JAK-1, thereby inhibiting the phosphorylation of signal transducer and activator of transcription (STAT) proteins and the production of proinflammatory factors induced by other cytokines, including interleukin-23 (IL-23) and interleukin-6 (IL-6). The JAK-STAT pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.	Itacitinib Adipate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C158907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158907>	C158612	List Exons Assessed Question|Exons assessed|List Exons Assessed	A request to enter the exons assessed for mutations in this section of the form.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C158908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158908>	C6875|C155869	Metastatic Large Cell Neuroendocrine Carcinoma	A large cell neuroendocrine carcinoma that has metastasized from its original site of growth to another anatomic site.	Metastatic Large Cell Neuroendocrine Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158909>	C167332|C155869|C148130	Locally Advanced Neuroendocrine Carcinoma	A neuroendocrine carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.			Neoplastic Process	
C15890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15890>	C15888	Unconventional Western System	NIH: Subcategory of alternative medical systems in CAM.  This sub-category deals with alternative medical systems developed in the West that are not dealt with elsewhere.  This includes systems such as homeopathy, Anthroposophically- extended Medicine, Environmental Medicine, Functional Medicine, Radionics, Cayce-based therapies, etc.  Included are: Homeopathy, Environmental Medicine, Functional Medicine, Anthroposophically-extended medicine, Radionics, Radiesthesia, Psionic medicine, Cayce-based systems.			Occupation or Discipline	
C158910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158910>	C158909|C158908	Locally Advanced Large Cell Neuroendocrine Carcinoma	A large cell neuroendocrine carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Large Cell Neuroendocrine Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158911>	C3915|C155869	Metastatic Small Cell Neuroendocrine Carcinoma|Metastatic Small Cell Carcinoma	A small cell neuroendocrine carcinoma that has metastasized from its original site of growth to another anatomic site.	Metastatic Small Cell Neuroendocrine Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158912>	C5545|C48596|C191977	Prostate Neuroendocrine Carcinoma	An aggressive high-grade carcinoma with neuroendocrine differentiation that arises from the prostate gland. It is classified as either small or large cell neuroendocrine carcinoma based on the size of the malignant cells, the prominence of the nucleoli, and the amount of cytoplasm.			Neoplastic Process	
C158913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158913>	C8946|C191981|C158912	Metastatic Prostate Neuroendocrine Carcinoma	A neuroendocrine carcinoma that arises from the prostate gland and has spread to other anatomic sites.	Metastatic Prostate Neuroendocrine Carcinoma		Neoplastic Process	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology
C158914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158914>	C191983|C158913|C156285	Locally Advanced Prostate Neuroendocrine Carcinoma	A prostate neuroendocrine carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Prostate Neuroendocrine Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158915>	C158911|C158909	Locally Advanced Small Cell Neuroendocrine Carcinoma|Locally Advanced Small Cell Carcinoma	A small cell neuroendocrine carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Small Cell Neuroendocrine Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158916>	C40998|C177694	Loss of Nuclear Expression|Loss of nuclear expression	An indication that expression of a nuclear factor is not detected in the nuclei of cells in a sample.			Laboratory or Test Result	
C158917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158917>	C18302	MET Mutation Analysis|HGFR Mutation Analysis|Hepatocyte Growth Factor Receptor Mutation Analysis|MET Gene Mutation Analysis|MET Mutation Status|MET Proto-Oncogene, Receptor Tyrosine Kinase Mutation Analysis|Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Mutation Analysis|c-met Mutation Analysis	A procedure used to detect and identify mutations in the MET gene.			Laboratory Procedure	
C158918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158918>	C158846	MET Mutation Analysis Testing Method|MET Mutational Analysis Testing Method	A request to enter the specific molecular analysis method used to detect and identify mutations in the MET gene.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C158919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158919>	C158954	MGMT Promoter Methylation Testing Method	A request to enter the specific molecular analysis method used to detect the methylation of promoter sequences of the MGMT gene.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C15891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15891>	C20181	Social Aspects of Cancer|Psychosocial Influences|Psychosocial Issues	Influence of social factors, such as community, policy, and legislation on cancer control and outcomes			Idea or Concept	
C158920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158920>	C103223	MLH1 Gene Promoter Hypermethylation|COCA2 Promoter Hypermethylation|HNPCC2 Promoter Hypermethylation|MLH1 Promoter Hypermethylation|MutL Homolog 1 Promoter Hypermethylation|MutL, E. coli, Homolog of, 1 Promoter Hypermethylation|Present	A genetic finding indicating that an excess of DNA methylation in the promoter region of the MLH1 gene has been detected in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C158921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158921>	C97927	MN1 Gene Mutation|MGCR Gene Mutation|MGCR1 Gene Mutation|MGCR1-PEN Gene Mutation|MN1|MN1 Proto-Oncogene, Transcriptional Regulator Gene Mutation|Meningioma Chromosome Region 1 Gene Mutation|Meningioma Chromosome Region Gene Mutation	A change in the sequence of the MN1 gene.	MN1 Gene Mutation		Cell or Molecular Dysfunction	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158922>	C18302	NF1 Mutation Analysis|NF1 Gene Mutation Analysis|NF1 Mutation Status|NFNS Mutation Analysis|Neurofibromin 1 Mutation Analysis	A procedure used to detect and identify mutations in the NF1 gene.			Laboratory Procedure	
C158923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158923>	C158846	NF1 Mutation Analysis Testing Method|NF1 Mutational Analysis Testing Method	A request to enter the specific molecular analysis method used to detect and identify mutations in the NF1 gene.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C158924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158924>	C158846	NRAS Mutation Analysis Testing Method|NRAS Mutational Analysis Testing Method	A request to enter the specific molecular analysis method used to detect and identify mutations in the NRAS gene.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C158925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158925>	C135718	NRAS NM_002524.4:c.34G>C|N-ras c.34G>C|NM_002524.4:c.34G>C|NRAS G12R (c.34G>C) mutation|NRAS c.34G>C|NRAS1 c.34G>C|Neuroblastoma RAS Viral (v-ras) Oncogene Homolog c.34G>C	A nucleotide substitution at position 34 of the coding sequence of the NRAS gene where guanine has been mutated to cytosine.	NRAS NM_002524.4:c.34G>C		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158926>	C135718	NRAS NM_002524.4:c.37G>A|N-ras c.37G>A|NM_002524.4:c.37G>A|NRAS G13S (c.37G>A) mutation|NRAS c.37G>A|NRAS1 c.37G>A|Neuroblastoma RAS Viral (v-ras) Oncogene Homolog c.37G>A	A nucleotide substitution at position 37 of the coding sequence of the NRAS gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C158927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158927>	C107483	NRAS NP_002515.1:p.G12R|GTPase NRas G12R|GTPase NRas Gly12Arg|NP_002515.1:p.G12R|NP_002515.1:p.Gly12Arg|NRAS G12R|NRAS G12R Mutation|NRAS Gly12Arg|NRAS NP_002515.1:p.Gly12Arg|NRAS p.G12R|NRAS p.Gly12Arg|Transforming Protein N-Ras G12R|Transforming Protein N-Ras Gly12Arg	A change in the amino acid residue at position 12 in the GTPase NRas protein where glycine has been replaced by arginine.	NRAS NP_002515.1:p.G12R		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158928>	C107484	NRAS NP_002515.1:p.G13S|GTPase NRas G13S|GTPase NRas Gly13Ser|NP_002515.1:p.G13S|NP_002515.1:p.Gly13Ser|NRAS G13S|NRAS Gly13Ser|NRAS NP_002515.1:p.Gly13Ser|NRAS p.G13S|NRAS p.Gly13Ser|Transforming Protein N-Ras G13S|Transforming Protein N-Ras Gly13Ser	A change in the amino acid residue at position 13 in the GTPase NRas protein where glycine has been replaced by serine.			Cell or Molecular Dysfunction	
C158929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158929>	C40998	Nuclear Expression Intact|Intact nuclear expression	An indication that expression of a nuclear factor is detected in the nuclei of cells in a sample.			Finding	
C15892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15892>	C15787	Evaluation of Risk Factors	A study designed to identify risk factors that contribute to a disease or disorder and determine the strength of their contributuon.			Health Care Activity	
C158930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158930>	C138961	PSA Level Twenty to One Hundred Fifty or Greater|PSA Level 20 to 150 or Greater|PSA Level Between 20 and 150 or Greater|PSA Level Between Twenty and One Hundred Fifty or Greater|PSA Level Greater than or Equal to Twenty to One Hundred Fifty	A blood concentration of prostate specific antigen between 20 ng/mL and 150 ng/mL or greater.	PSA Level Twenty to One Hundred Fifty or Greater		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158931>	C138961	PSA Level Greater than One Hundred Fifty|PSA Level Greater than 150|PSA Level Greater than One Hundred and Fifty	A blood concentration of prostate specific antigen greater than 150 ng/mL.	PSA Level Greater than One Hundred Fifty		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C158932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158932>	C158847	Is Another BRAF Mutation Present Question|Is Another BRAF Mutation Present|Other BRAF mutation|Other BRAF mutation present	A question to determine if a BRAF mutation that is not listed on the form was found in the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Terminology
C158933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158933>	C158890	Specify Other KRAS Codon 12 Mutation|Other codon 12 mutation, specify:	A request to enter the specific KRAS codon 12 mutation that was identified in the study but is not present in the form.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C158934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158934>	C158890	Specify Other KRAS Codon 13 Mutation|Other codon 13 mutation, specify:	A request to enter the specific KRAS codon 13 mutation that was identified in the study but is not present in the form.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C158935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158935>	C158890	Specify Other KRAS Codon 61 Mutation|Other codon 61 mutation, specify:	A request to enter the specific KRAS codon 61 mutation that was identified in the study but is not present in the form.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C158936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158936>	C158847	Is Another Non-Exon 20 ERBB2 Mutation Present Question|Is Another Non-Exon 20 ERBB2 Mutation Present|Other ERBB2 mutation (non-exon 20)	A question to determine if an ERBB2 mutation that is not located in exon 20 and not listed on the form was found in the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C158937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158937>	C158847	Is Another KIT Mutation Present Question|Is Another KIT Mutation Present|Other KIT mutation	A question to determine if a KIT mutation that is not listed on the form was found in the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C158938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158938>	C158845|C157106	Specify Other MET Mutation|Specify other MET mutation:	A request to enter the specific MET mutation that was identified in the study but is not present in the form.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C158939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158939>	C158938	Specify Other MET Exon 14 Mutation|Other MET exon 14 mutation, specify	A request to enter the specific MET exon 14 mutation that was identified in the study but is not present in the form.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C15893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15893>	C48800	Cell Bank	Repository of cell samples			Physical Object	
C158940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158940>	C158938	Specify Other MET Intron 13 Mutation|Other MET intron 13 mutation, specify	A request to enter the specific MET intron 13 mutation that was identified in the study but is not present in the form.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C158941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158941>	C158938	Specify Other MET Intron 14 Mutation|Other MET intron 14 mutation, specify	A request to enter the specific MET intron 14 mutation that was identified in the study but is not present in the form.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C158942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158942>	C158847	Is Another NRAS Mutation Present Question|Is Another NRAS Mutation Present|Other NRAS mutation	A question to determine if a NRAS mutation that is not listed on the form was found in the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C158943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158943>	C129258	p16 Positive by Immunohistochemistry|CDKN2A-p16 Positive by Immunohistochemistry|CDKN2A-p16(INK4a) Positive by Immunohistochemistry|Cyclin-Dependent Kinase 4 Inhibitor A Positive by Immunohistochemistry|Cyclin-Dependent Kinase Inhibitor 2A Positive by Immunohistochemistry|p16 Positive (>70% nuclear and cytoplasmic staining)|p16(INK4a) Positive by Immunohistochemistry|p16-INK4 Positive by Immunohistochemistry|p16INK4 Positive by Immunohistochemistry|p16INK4a Positive by Immunohistochemistry	An indication that CDKN2A-p16 expression has been detected in a sample using immunohistochemical techniques.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C158944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158944>	C18302	PDGFRA Mutation Analysis|CD140A Mutation Analysis|PDGFR-2 Mutation Analysis|PDGFR2 Mutation Analysis|PDGFRA Gene Mutation Analysis|PDGFRA Mutation Status|PDGFRalpha Mutation Analysis|Platelet-Derived Growth Factor Receptor Alpha Mutation Analysis|RHEPDGFRA Mutation Analysis	A procedure used to detect and identify mutations in the PDGFRA gene.			Laboratory Procedure	
C158945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158945>	C158846	PDGFRA Mutation Analysis Testing Method|PDGFRA Mutational Analysis Testing Method	A request to enter the specific molecular analysis method used to detect and identify mutations in the PDGFRA gene.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C158946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158946>	C18302	PTEN Mutation Analysis|MMAC1 Mutation Analysis|Mutated in Multiple Advanced Cancers 1 Mutation Analysis|PTEN Gene Mutation Analysis|PTEN Mutation Status|PTEN1 Mutation Analysis|Phosphatase and Tensin Homolog Mutation Analysis|TEP1 Mutation Analysis	A procedure used to detect and identify mutations in the PTEN gene.			Laboratory Procedure	
C158947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158947>	C158846	PTEN Mutation Analysis Testing Method|PTEN Mutational Analysis Testing Method	A request to enter the specific molecular analysis method used to detect and identify mutations in the PTEN gene.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C158948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158948>	C35682	Rearrangement Detected|Chromosomal Rearrangement Detected|Chromosome Rearrangement Detected|Cytogenetic Rearrangement Detected|Cytogenetic Rearrangement Positive|Cytogenetic Rearrangement Present|Rearrangement Positive|Rearrangement Present|Rearrangement identified	An indication that a cytogenetic rearrangement was detected in a sample.			Laboratory or Test Result	
C158949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158949>	C35681	Rearrangement Negative|Chromosomal Rearrangement Negative|Chromosome Rearrangement Negative|Cytogenetic Rearrangement Negative|No rearrangement detected|Rearrangement Absent	An indication that cytogenetic rearrangements were not detected in a sample.			Laboratory or Test Result	
C15894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15894>	C189155	Epidemiologic Technique Development|Epidemiologic Method Development	Develop and evaluate new laboratory assays, behavioral methods, and statistical techniques for epidemiologic studies. (FMB)			Research Activity	
C158950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158950>	C158954	RET Rearrangement Testing Method|RET Rearrangement Analysis Testing Method	A request to enter the specific molecular analysis method used to detect and identify rearrangements involving the RET gene.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C158951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158951>	C3360|C171054	Ring Chromosome 12|Ring form of chromosome 12 (Liposarcoma)|r12	An aberration of chromosome 12 where the arms have fused to form a ring.			Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C158952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158952>	C51961	ROS1 Rearrangement Analysis|MCF3 Rearrangement Analysis|ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Rearrangement Analysis|ROS Rearrangement Analysis|ROS1 Gene Rearrangement Analysis|ROS1 Rearrangement|ROS1 Rearrangement Status|c-ros-1 Rearrangement Analysis	A procedure used to detect and identify rearrangements involving the ROS1 gene.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C158953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158953>	C158954	ROS1 Rearrangement Testing Method|ROS1 Rearrangement Analysis Testing Method	A request to enter the specific molecular analysis method used to detect and identify rearrangements involving the ROS1 gene.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C158954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158954>	C157093	Specify Molecular Abnormality Analysis Method|MOLECULAR_ANALYSIS_METHOD|MOLECULAR_ANALYSIS_METHOD|MOLECULAR_ANALYSIS_METHOD|MOLECULAR_ANALYSIS_METHOD|MOLECULAR_ANALYSIS_METHOD|Type of Molecular Analysis	A request to enter the specific molecular analysis method used to detect abnormalities in the study.			Activity	ALL Molecular Analysis Table|ALL Variable Terminology|AML Molecular Analysis Table|AML Variable Terminology|CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|EWS Molecular Analysis Table|EWS Variable Terminology|GCT Molecular Analysis Table|GCT Variable Terminology|OS Molecular Analysis Table|OS Variable Terminology
C158955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158955>	C18302	SDH Complex Mutation Analysis|Mitochondrial Complex II Mutation Analysis|Mitochondrial Respiratory Chain Complex II Mutation Analysis|SDH Complex Gene Mutation Analysis|SDH Complex Mutation Status|SDH Family Mutation Analysis|SDH Mutation Analysis|SDH Mutation Status|Succinate Dehydrogenase Mutation Analysis|Succinate-CoQ Reductase Mutation Analysis|Succinate-Coenzyme Q Reductase Mutation Analysis	A procedure used to detect and identify mutations in any gene that encodes one of the proteins in the succinate dehydrogenase (SDH) complex.			Laboratory Procedure	
C158956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158956>	C158846	SDH Complex Mutation Analysis Testing Method|SDHA/B/C/D Mutational Analysis Testing Method	A request to enter the specific molecular analysis method used to detect and identify mutations in any gene that encodes one of the proteins in the succinate dehydrogenase (SDH) complex..			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C158957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158957>	C18302	TP53 Mutation Analysis|P53 Mutation Analysis|TP53 Gene Mutation Analysis|TP53 Mutation Status|Tumor Protein p53 Mutation Analysis|p53 Gene Analysis|p53 Mutation Analysis|p53 Mutation Status	A procedure used to detect and identify mutations in the TP53 gene.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C158958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158958>	C158846	TP53 Mutation Analysis Testing Method|TP53 Mutational Analysis Testing Method	A request to enter the specific molecular analysis method used to detect and identify mutations in the TP53 gene.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C158959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158959>	C157377	Testosterone Greater than 200 ng/dL|Testosterone Greater than 200 Nanograms per Deciliter|Testosterone Greater than 200 Nanograms/Deciliter	A semiquantitative finding indicating that the concentration of testosterone in a sample is greater than 200 ng/dL.	Testosterone Greater than 200 ng/dL		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C158960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158960>	C9120|C8933	Metastatic Pancreatic Ductal Adenocarcinoma	An adenocarcinoma that arises from the exocrine pancreatic ducts and has metastasized to other anatomic sites.	Metastatic Pancreatic Ductal Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158961>	C9120	Early Stage Pancreatic Ductal Adenocarcinoma	Pancreatic ductal adenocarcinoma that has not spread beyond the pancreas.	Early Stage Pancreatic Ductal Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C158962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158962>	C3819	AH Amyloidosis	A rare type of amyloidosis characterized by the monoclonal deposition of immunoglobulin heavy chain fragments in organs and tissues. It is associated with plasma cell or B-cell lymphoproliferative disorders.			Neoplastic Process	
C158963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158963>	C3819	AL Amyloidosis|Ig Light Chain Amyloidosis|Immunoglobulin-Related Amyloidosis	The most common type of amyloidosis. It is characterized by the monoclonal deposition of immunoglobulin light chain fragments in organs and tissues. It is associated with plasma cell or B-cell lymphoproliferative disorders.			Neoplastic Process	Cellosaurus Disease Terminology
C158964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158964>	C3819	AHL Amyloidosis	An extremely rare type of amyloidosis characterized by the monoclonal deposition of immunoglobulin heavy chain and light chain fragments in organs and tissues.			Neoplastic Process	
C158965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158965>	C7151	Light and Heavy Chain Deposition Disease|LHCDD	A subtype of monoclonal immunoglobulin deposition disease in which heavy and light chains deposition results in non-amyloid tissue deposits which may cause organ dysfunction.			Neoplastic Process	
C158966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158966>	C114477	Light Chain Proximal Tubulopathy without Crystals|Proximal Tubulopathy without Crystals	A morphologic variant of light chain proximal tubulopathy with no evidence of crystal formation. It is characterized by acute tubular injury with no evidence lysosomal immunoglobulin crystals.			Disease or Syndrome	
C158967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158967>	C53543	Crystal-Storing Histiocytosis	A condition characterized by histiocytes containing intra-lysosomal accumulation of immunoglobulin light chains. Crystal-storing histiocytosis is often associated with plasma cell dyscrasias and lymphoproliferative disorders.			Disease or Syndrome	
C158968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158968>	C26784	Immunotactoid Glomerulopathy|GOMMID|Glomerulonephritis with Organized Monoclonal Microtubular Immunoglobulin Deposits	Glomerulonephritis characterized by the presence of Congo-red negative microfibrils in the mesangium and capillary walls of the glomeruli. Morphologic findings include formation of microtubules, evident on electron microscopy, that are larger than those seen in fibrillary glomerulonephritis (30-50 versus 16-24 nm in diameter). There may be some overlap in the size of fibrils found in both conditions.			Disease or Syndrome	
C158969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158969>	C123179	Type I Cryoglobulinemic Glomerulonephritis	Glomerulonephritis caused by cryoglobulins which are composed of monoclonal immunoglobulins IgG, IgA, or IgM. It occurs in patients with lymphoproliferative disorders.			Finding	
C15896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15896>	C38186	Core Facility	Shared facilities which provide services of a particular area of expertise.			Organization	
C158970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158970>	C35281	Proliferative Glomerulonephritis with Monoclonal IgG Deposits|PGNMID	A sub-type of monoclonal gammopathy of renal significance, characterized by restriction to a single immunoglobulin G heavy chain subclass and a single light chain isotype. Light microscopy often shows an endocapillary proliferative or membranoproliferative glomerulopathy. Electron microscopy reveals electron-dense subendothelial and mesangial deposits.			Disease or Syndrome	
C158971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158971>	C123043	C3 Glomerulopathy with Monoclonal Gammopathy	A subset of C3 glomerulopathy in which there is an associated finding of monoclonal gammopathy.			Disease or Syndrome	
C158973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158973>	C164005|C129823	Anti-CD30 Antibody-drug Conjugate|Anti-CD30 ADC|Anti-TNFRSF8 ADC	Any antibody-drug conjugate (ADC) that is directed against the human tumor necrosis factor (TNF) receptor superfamily member 8  (TNFRSF8) CD30.			Chemical Viewed Functionally	
C158974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158974>	C20401	Anti-SLAMF7 Monoclonal Antibody|Anti-CS1 Monoclonal Antibody	Any monoclonal antibody directed against the human antigen  CS1 (CD2 subunit 1; CRACC; SLAMF7; CD319).			Chemical Viewed Functionally	
C158975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158975>	C19015	Neoplasm Polygenic Risk Score|Neoplasm Genetic Risk Score|Neoplasm Polygenic Score|PRS|Polygenic Risk Score	A numeric value that estimates the risk of development of a specified neoplastic disease that is based on weighted regression analysis of disease-specific gene variants at multiple genetic loci.	Polygenic Risk Score		Quantitative Concept	CTRP Biomarker Terminology|CTRP Terminology
C158976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158976>	C158975	High Neoplasm Polygenic Risk Score|High PRS|High Polygenic Risk Score	A polygenic risk score value that indicates that an individual patient is likely to develop a specified neoplastic disease in their lifetime.	High Polygenic Risk Score		Quantitative Concept	CTRP Biomarker Terminology|CTRP Terminology
C158977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158977>	C158975	Low Neoplasm Polygenic Risk Score|Low PRS|Low Polygenic Risk Score	A polygenic risk score value that indicates that an individual patient is unlikely to develop a specified neoplastic disease in their lifetime.	Low Polygenic Risk Score		Quantitative Concept	CTRP Biomarker Terminology|CTRP Terminology
C158978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158978>	C173924|C173092	Did Caregiving Responsibilities Make it Difficult to Work the Required Number of Job Hours Question|Did Caregiving Responsibilities Make it Difficult to Work the Required Number of Job Hours|How much of the time did your caregiving responsibilities make it difficult for you to work the required number of hours at your job	A question about if an individual's caregiving responsibilities made it difficult to work the required number of hours at their job.			Intellectual Product	
C158979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158979>	C173924|C173092	Did Caregiving Responsibilities Make it Difficult to Get Going Easily at Beginning of Workday Question|Did Caregiving Responsibilities Make it Difficult to Get Going Easily at Beginning of Workday|How much of the time did your caregiving responsibilities make it difficult for you to get going easily at the beginning of your workday	A question about if an individual's caregiving responsibilities made it difficult to get going easily at the beginning the workday			Intellectual Product	
C15897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15897>	C16199	Cancer Causation Research|Causation Research	Cancer causation research studies the events involved in the initiation and promotion of cancer. It encompasses chemical and physical carcinogenesis, biological carcinogenesis, epidemiology, chemoprevention, and nutrition research. Studies focus on external agents such as chemicals, radiation, fibers and other particles, viruses, parasitic infections, and host factors such as hormone levels, nutritional and immunologic status, and the genetic endowment of the individual, all of which contribute to the initiation and promotion of cancer.			Research Activity	
C158980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158980>	C173924|C173092	Did Caregiving Responsibilities Make it Difficult to Start Job on Arrival at Work Question|Did Caregiving Responsibilities Make it Difficult to Start Job on Arrival at Work|How much of the time did your caregiving responsibilities make it difficult for you to start on your job as soon as you arrived at work	A question about if an individual's caregiving responsibilities made it difficult to start on job as soon as arrival at work.			Intellectual Product	
C158981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158981>	C173924|C173092	Did Caregiving Responsibilities Make it Difficult to do Work Without Stopping For Breaks or Rests Question|Did Caregiving Responsibilities Make it Difficult to do Work Without Stopping For Breaks or Rests|How much of the time did your caregiving responsibilities make it difficult for you to do your work without stopping to take breaks or rests	A question about if an individual's caregiving responsibilities made it difficult to do work without stopping to take breaks for rests.			Intellectual Product	
C158982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158982>	C173924|C173092	Did Caregiving Responsibilities Make it Difficult to Stick to Job Routine or Schedule Question|Did Caregiving Responsibilities Make it Difficult to Stick to Job Routine or Schedule|How much of the time did your caregiving responsibilities make it difficult for you to stick to a routine or schedule in your job	A question about if an individual's caregiving responsibilities made it difficult to stick to a routine or schedule in their job.			Intellectual Product	
C158983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C158983>	C2124	Copper Cu 64-DOTA-ECL1i|64Cu-DOTA-ECL1i|64Cu-d(LGTFLKC)	A radiotracer composed of ECL1i (extracellular loop 1 inverso; d(LGTFLKC)), an allosteric peptidic modulator of CC chemokine receptor type 2 (CCR2), conjugated with 1,4,7,10-tetra-azacyclododecane-1,4,7,10-tetra-acetic acid (DOTA) and labeled with the radionuclide copper Cu 64, with potential imaging activity upon positron emission tomography (PET). Upon administration, the ECL1i moiety targets and allosterically binds to CCR2 expressing tumor cells. Upon PET imaging, the copper Cu 64 moiety can be visualized, thereby allowing the quantification of CCR2-expressing cells. CCR2, a G-protein coupled receptor expressed on the surface of monocytes and macrophages, stimulates the migration and infiltration of these cell types, and plays a significant role in angiogenesis, inflammation, tumor cell migration, and proliferation. Quantification of CCR2 may help predict chemotherapy resistance and identify early metastatic disease in certain cancers.	Copper Cu 64-DOTA-ECL1i		Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C15898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15898>	C15178	Lifestyle and Disease Prevention|Lifestyle and Disease Prevention (with ODP)	Major category of Complementary and Alternative Medicine. This category deals with theories and practices designed to prevent the development of illness, identify and treat risk factors, or support of healing and recovery processes.  It is concerned with integrated approaches for the prevention and management of chronic disease-in-general (DIG) or the common determinants of chronic disease.			Occupation or Discipline	
C15899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15899>	C15898	Clinical Preventive Practices	Subcategory of Lifestyle and Disease Prevention in CAM. This sub-category deals with unconventional approaches whose purpose is to screen for and prevent health-related imbalances, dysfunction's and disease.  Examples include, unconventional screening and diagnostic practices, such as electro-dermal diagnostics, medical intuition, chiriography, functional cellular enzyme measures, and preventive practices such as panchakarma.			Occupation or Discipline	
C1589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1589>	C471|C281	Reverse Transcriptase Inhibitor|Viral Reverse Transcriptase Inhibitor	Any substance that inhibits the activity of viral reverse transcriptase, an RNA-dependent DNA polymerase that transcribes viral RNA into DNA during virus replication.			Chemical Viewed Functionally	
C15900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15900>	C49236	Lifestyle Therapy	Therapy dealing with lifestyle management and includes: behavioral and dietary modifications, exercise, stress management, and addiction control. This therapy must be used as major adjunct to "standard care" or be applied as alternative treatment to conventional medicine practices.	Lifestyle Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C15902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15902>	C48800	Molecular Bank				Research Device	
C15903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15903>	C16124	No Prior Cancer Therapy	No prior cancer treatment.			Clinical Attribute	
C15904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15904>	C15477	Prior Extensive Radiation	Having received extensive radiation before the present time.			Clinical Attribute	
C15905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15905>	C15477	Prior Limited Radiation	Cancer therapy using ionizing radiation to a limited (< 50%) portion of the body.			Clinical Attribute	
C15906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15906>	C51976	CAM Pharmacological or Biological Treatment|Pharmacological or Biological Treatment	The use of pharmacotherapy or biotherapy in non-traditional ways.			Therapeutic or Preventive Procedure	
C15907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15907>	C51976	Manipulative and Body-Based Intervention Procedure|Manipulative and Body-Based Intervention|Manipulative and Body-Based Methods|Manipulative and Body-Based Systems	Procedures which rely upon movement and manipulation of the body.They focus primarily on the structures and systems of the body, including the bones and joints, the soft tissues, and the circulatory and lymphatic systems			Therapeutic or Preventive Procedure	
C15908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15908>	C15907	Massage and Body Work|Massage Therapy|Massage and Body Therapeutic Techniques|Therapeutic Massage	Complementary or alternative medical treatment that uses masage or other types of physical manipulation.			Therapeutic or Preventive Procedure	
C15909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15909>	C15907	Unconventional Physical Therapy	The use of physical therapy in non-traditional ways.			Therapeutic or Preventive Procedure	
C1590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1590>	C2842	Antineoplastic Alkylating Agent|Chemotherapy Alkylating Agents|Chemotherapy Alkylators	An antineoplastic agent that replaces hydrogen atom(s) in nucleophilic moieties with alky radical(s), hindering proper function. Alkylating agents exhibit cytotoxic effects through the alkylation of DNA, resulting in strand cross-linking, ultimately inhibiting DNA replication and cancer cell growth.			Chemical Viewed Functionally	
C15910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15910>	C16206	Biofield Therapy|Biofield Medicine|Biofields	A form of therapy that involves systems using "subtle energy" fields in and around the body for medical/therapeutic purposes. Examples include Therapeutic Touch, Reiki, Huna, laying-on-of-hands, external Qi-Gong, Healing Science, Healing touch, Natural healing, Specific Human Energy Nexus (SHEN), and Bio-Relaxation.			Therapeutic or Preventive Procedure	
C15912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15912>	C15986|C15687|C15632	Regional Chemotherapy|regional chemotherapy	A form of chemotherapy in which the drug(s) are placed into a specific location, including a body cavity or individual organ, for the purpose of killing cancer cells while minimizing systemic toxicity.	Regional Chemotherapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C15913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15913>	C51988|C15916	Prophylactic Cranial Irradiation|PCI|prophylactic cranial irradiation	Radiation therapy to the head to reduce the risk that cancer will spread to the brain.	Prophylactic Cranial Irradiation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C159141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159141>	C173924|C173398|C173092|C173045	Have Difficulty with Sitting, Standing, or Staying in One Position Longer than 15 Minutes While Working Due to Caregiving Responsibilities Question|Have Difficulty with Sitting, Standing, or Staying in One Position Longer than 15 Minutes While Working Due to Caregiving Responsibilities|How much of the time were you able to sit, stand, or stay in one position for longer than 15 minutes while working, without difficulty caused by your caregiving responsibilities	A question about if an individual was able to sit, stand, or stay in one position for longer than 15 minutes while working, without difficulty caused by caregiving responsibilities.			Intellectual Product	
C159142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159142>	C173924|C173398|C173092|C173045	Have Difficulty Repeating Same Motions Repeatedly While Working Due to Caregiving Responsibilities Question|Have Difficulty Repeating Same Motions Repeatedly While Working Due to Caregiving Responsibilities|How much of the time were you able to repeat the same motions over and over again while working, without difficulty caused by your caregiving responsibilities	A question about if an individual was able to repeat the same motions over and over again while working, without difficulty caused by caregiving responsibilities.			Intellectual Product	
C159143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159143>	C173924|C173092	Did Caregiving Responsibilities Make it Difficult to Keep Mind on Work Question|Did Caregiving Responsibilities Make it Difficult to Keep Mind on Work|How much of the time did your caregiving responsibilities make it difficult for you to keep your mind on your work	A question about if an individual's caregiving responsibilities made it difficult to keep their mind on work.			Intellectual Product	
C159144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159144>	C173924|C173092	Did Caregiving Responsibilities Make it Difficult to Do Work Carefully Question|Did Caregiving Responsibilities Make it Difficult to Do Work Carefully|How much of the time did your caregiving responsibilities make it difficult for you to do your work carefully	A question about if an individual's caregiving responsibilities made it difficult to work carefully.			Intellectual Product	
C159145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159145>	C173924|C173597|C173092	Did Caregiving Responsibilities Make it Difficult to Think Clearly When Working Question|Did Caregiving Responsibilities Make it Difficult to Think Clearly When Working|How much of the time did your caregiving responsibilities make it difficult for you to think clearly when working	A question about if an individual's caregiving responsibilities made it difficult to think clearly when working.			Intellectual Product	
C159146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159146>	C173924|C173092	Did Caregiving Responsibilities Make it Difficult to Concentrate on Work Question|Did Caregiving Responsibilities Make it Difficult to Concentrate on Work|How much of the time did your caregiving responsibilities make it difficult for you to concentrate on your work	A question about if an individual's caregiving responsibilities made it difficult to concentrate on work.			Intellectual Product	
C159147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159147>	C173924|C173597|C173092	Did Caregiving Responsibilities Make it Difficult to Work Without Losing Train of Thought Question|Did Caregiving Responsibilities Make it Difficult to Work Without Losing Train of Thought|How much of the time did your caregiving responsibilities make it difficult for you to work without losing your train of thought	A question about if an individual's caregiving responsibilities made it difficult to work without losing train of thought.			Intellectual Product	
C159148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159148>	C176426|C173924|C173092	Did Caregiving Responsibilities Make it Difficult to Easily Read or Use Eyes When Working Question|Did Caregiving Responsibilities Make it Difficult to Easily Read or Use Eyes When Working|How much of the time did your caregiving responsibilities make it difficult for you to easily read or use your eyes when working	A question about if an individual's caregiving responsibilities made it difficult to easily read or use their eyes when working.			Intellectual Product	
C159149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159149>	C173924|C173092	Did Caregiving Responsibilities Make it Difficult to Speak With People In-Person, in Meetings, or Phone When Working Question|Did Caregiving Responsibilities Make it Difficult to Speak With People In-Person, in Meetings, or Phone When Working|How much of the time did your caregiving responsibilities make it difficult for you to speak with people in-person, in meetings or on the phone when working	A question about if an individual's caregiving responsibilities made it difficult to speak with people in-person, in meetings or on the phone when working.			Intellectual Product	
C15914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15914>	C15912	Topical Chemotherapy|topical chemotherapy	Treatment with anticancer drugs in a lotion or cream applied to the skin.			Therapeutic or Preventive Procedure	
C159150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159150>	C173924|C173092	Did Caregiving Responsibilities Make it Difficult to Control Temper Around People When Working Question|Did Caregiving Responsibilities Make it Difficult to Control Temper Around People When Working|How much of the time did your caregiving responsibilities make it difficult for you to control your temper around people when working	A question about if an individual's caregiving responsibilities made it difficult to control their temper around people when working.			Intellectual Product	
C159151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159151>	C173924|C173092	Did Caregiving Responsibilities Make it Difficult to Help Other People to Get Work Done Question|Did Caregiving Responsibilities Make it Difficult to Help Other People to Get Work Done|How much of the time did your caregiving responsibilities make it difficult for you to help other people to get work done	A question about if an individual's caregiving responsibilities made it difficult to help other people to get work done.			Intellectual Product	
C159152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159152>	C94299	ESR2 Status|ER Beta Status|ER-Beta Status|ERB Status|ESR-Beta Status|ESRB Status|ESTRB Status|Estrogen Receptor 2 Status|Estrogen Receptor Beta Status|NR3A2 Status|Nuclear Receptor Subfamily 3 Group A Member 2 Status	Refers to the presence or absence of ESR2 in a sample.			Laboratory or Test Result	
C159153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159153>	C165233|C159152	ESR2 Negative|ER Beta Negative|ER-Beta Negative|ERB Negative|ESR-Beta Negative|ESRB Negative|ESTRB Negative|Estrogen Receptor 2 Negative|Estrogen Receptor Beta Negative|NR3A2 Negative|Negative|Nuclear Receptor Subfamily 3 Group A Member 2 Negative	An indication that expression of ESR2 has not been detected in a sample.	ESR2 Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159154>	C42075	Proliferation of Squamous Nests with Little Stromal Reaction	A microscopic finding indicating the proliferation of squamous cell nests with minimal stromal reaction in a tumor sample. This is finding often seen in HPV-related non-keratinizing tumors.			Finding	
C159155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159155>	C35886	Labyrinthine Growth Pattern	A morphologic finding where cells are arranged in the form of a maze.			Finding	
C159156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159156>	C1967|C163760|C129825	HER2 Inhibitor|ERBB2 Inhibitor|HER-2 Inhibitor|Human Epidermal Growth Factor Receptor 2 Inhibitor	Any agent that inhibits the human epidermal growth factor receptor 2 (HER2; HER-2; ERBB2).	HER2 Inhibitor		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C159157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159157>	C113304	WHO AML Classification of Tumors|AML World Health Organization (WHO) Classification|WHO_AML	A classification of acute myeloid leukemia tumors by the World Health Organization (WHO).			Classification	AML Disease Characteristics Table|AML Variable Terminology|CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C159158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159158>	C2124	Carbon C 11 Martinostat|MARTINOSTAT C-11|Martinostat C-11|[11C]Martinostat	A radioconjugate composed of martinostat, a histone deacetylase (HDAC) inhibitor, labeled with the positron-emitting isotope carbon C 11, with potential use in imaging via positron emission tomography (PET)/magnetic resonance imaging (MRI). Upon intravenous administration of carbon C 11 martinostat, the martinostat moiety targets and binds to HDAC on tumor cells. Upon PET/MRI imaging, this radioligand may allow for the assessment of HDAC-expressing tumor cells. HDACs, upregulated in many tumor cell types, are a family of metalloenzymes responsible for the deacetylation of chromatin histone proteins.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C159159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159159>	C177692|C159152	ESR2 Positive|ER Beta Positive|ER-Beta Positive|ERB Positive|ESR-Beta Positive|ESRB Positive|ESTRB Positive|Estrogen Receptor 2 Positive|Estrogen Receptor Beta Positive|NR3A2 Positive|Nuclear Receptor Subfamily 3 Group A Member 2 Positive|Positive	An indication that expression of ESR2 has been detected in a sample.	ESR2 Positive		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15915>	C15330	Tracheoesophageal Puncture|tracheoesophageal puncture	A surgical procedure that creates a fistula between the trachea and esophagus in a patient who has previously undergone a total laryngectomy for the purpose of inserting a voice prosthesis to allow for esophageal speech.			Therapeutic or Preventive Procedure	
C159160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159160>	C176537|C173924|C173092	Did Caregiving Responsibilities Make it Difficult to Listen Well to New Information Given at Work Question|Did Caregiving Responsibilities Make it Difficult to Listen Well to New Information Given at Work|How much of the time did your caregiving responsibilities make it difficult for you to listen well to new information given to you at work	A question about if an individual's caregiving responsibilities made it difficult to listen well to new information given at work.			Intellectual Product	
C159161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159161>	C173924|C173092	Did Caregiving Responsibilities Make it Difficult to Control Feelings of Sadness or Grief When Working Question|Did Caregiving Responsibilities Make it Difficult to Control Feelings of Sadness or Grief When Working|How much of the time did your caregiving responsibilities make it difficult for you to control feelings of sadness or grief when working	A question about if an individual's caregiving responsibilities made it difficult to control feelings of sadness or grief when working.			Intellectual Product	
C159162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159162>	C173924|C173092	Did Caregiving Responsibilities Make it Difficult to Handle Workload Question|Did Caregiving Responsibilities Make it Difficult to Handle Workload|How much of the time did your caregiving responsibilities make it difficult for you to handle the workload	A question about if an individual's caregiving responsibilities made it difficult for them to handle the workload.			Intellectual Product	
C159163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159163>	C173924|C173092	Did Caregiving Responsibilities Make it Difficult to Work Fast Enough Question|Did Caregiving Responsibilities Make it Difficult to Work Fast Enough|How much of the time did your caregiving responsibilities make it difficult for you to work fast enough	A question about if an individual's caregiving responsibilities made it difficult for them to work fast enough.			Intellectual Product	
C159164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159164>	C173924|C173092	Did Caregiving Responsibilities Make it Difficult to Finish Work on Time Question|Did Caregiving Responsibilities Make it Difficult to Finish Work on Time|How much of the time did your caregiving responsibilities make it difficult for you to finish work on time	A question about if an individual's caregiving responsibilities made it difficult for them to finish work on time.			Intellectual Product	
C159165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159165>	C173924|C173092	Did Caregiving Responsibilities Make it Difficult to Do Work Without Making Mistakes Question|Did Caregiving Responsibilities Make it Difficult to Do Work Without Making Mistakes|How much of the time did your caregiving responsibilities make it difficult for you to do your work without making mistake	A question about if an individual's caregiving responsibilities made it difficult for them to do work without making mistake.			Intellectual Product	
C159166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159166>	C173092	Did Caregiving Responsibilities Make it Difficult to Feel You've Done What You're Capable of Doing Question|Did Caregiving Responsibilities Make it Difficult to Feel You've Done What You're Capable of Doing|How much of the time did your caregiving responsibilities make it difficult for you to feel you've done what you are capable of doing	A question about if an individual's caregiving responsibilities made it difficult for them to feel they have done what they are capable of doing.			Intellectual Product	
C159167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159167>	C176021|C173398|C173092	Have Difficulty Doing Usual Household Chore or Activity Because of Caregiving Responsibilities Question|Have Difficulty Doing Usual Household Chore or Activity Because of Caregiving Responsibilities|How much of the time did you have difficulty doing your usual household chores or activities because of your caregiving responsibilities	A question about if an individual had difficulty doing usual household chores or activities because of their caregiving responsibilities.			Intellectual Product	
C159168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159168>	C176988	Uliledlimab|Anti-CD73 Monoclonal Antibody TJ4309|TJ 004309|TJ 4309|TJ-004309|TJ-4309|TJ004309|TJ4309|TJD5|ULILEDLIMAB	A humanized monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. Upon administration, uliledlimab targets and binds to CD73 on tumor cells, thereby inhibiting CD73 activity. This prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine, preventing adenosine-mediated suppression of lymphocyte activity and increasing the activity of cytotoxic T-lymphocytes (CTLs). This also activates macrophages and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes (Tregs). By abrogating the inhibitory effect on the immune system and enhancing the CTL-mediated immune response against cancer cells, tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, is upregulated on a number of cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the tumor microenvironment (TME).	Uliledlimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C159169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159169>	C172728	Someone There for Suggestions About How to Deal with Personal Problem Question|How often is there someone to turn to for suggestions about how to deal with a personal problem|Someone There for Suggestions About How to Deal with Personal Problem	A question about if there is someone to turn to for suggestions about how to deal with a personal problem.			Intellectual Product	
C15916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15916>	C49236	Central Nervous System Prophylaxis|CNS Prophylaxis|CNS prophylaxis|CNS sanctuary therapy|central nervous system prophylaxis|central nervous system sanctuary therapy	Chemotherapy or radiation therapy given to the central nervous system as a preventive treatment. It kills cancer cells that may be in the brain and spinal cord, even though no cancer has been detected there.	Central Nervous System Prophylaxis		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C159170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159170>	C173160|C172728	Someone There to Love and Make You Feel Wanted Question|How often is there someone to love and make you feel wanted|Someone There to Love and Make You Feel Wanted|to love and make you feel wanted	A question about if there is someone for an individual to love and make them feel wanted.			Intellectual Product	Medical Outcomes Study Physical Functioning Scale|Work Limitations Questionnaire
C159172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159172>	C172728	Someone There to Get Together for Relaxation Question|How often is there someone to get together with for relaxation|Someone There to Get Together for Relaxation	A question about if there is someone for an individual to get together with for relaxation.			Intellectual Product	
C159173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159173>	C172728	Someone There to Help With Daily Chores if Sick Question|How often is there someone to help with daily chores if you were sick|Someone There to Help With Daily Chores if Sick	A question about if there is someone for an individual to help with daily chores if they were sick.			Intellectual Product	
C159174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159174>	C172728	Someone There to Perform Caregiving Responsibilities When You Cannot Question|How often is there someone to perform your caregiving responsibilities when you can't|Someone There to Perform Caregiving Responsibilities When You Cannot	A question about if there is someone for an individual to perform their caregiving responsibilities when they cannot.	Work Limitations Questionnaire, Adapted		Intellectual Product	
C159175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159175>	C172728	Someone There for Questions or Concerns About Caregiving Question|How often is there someone you can go to when you have questions or concerns about caregiving|Someone There for Questions or Concerns About Caregiving	A question about if there is someone for an individual to go to when they have questions or concerns about caregiving.	Work Limitations, Adapted		Intellectual Product	
C159176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159176>	C173048	Being Able to Provide Assistance as Caregiver is Emotionally Rewarding for Me Question|Being Able to Provide Assistance as Caregiver is Emotionally Rewarding for Me|Being able to provide assistance as a caregiver is emotionally rewarding for me	A question about whether an individual being able to provide assistance as a caregiver is emotionally rewarding.			Intellectual Product	
C159177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159177>	C173048	Being Able to Provide Assistance as Caregiver is Spiritually Rewarding for Me Question|Being Able to Provide Assistance as Caregiver is Spiritually Rewarding for Me|Being able to provide assistance as a caregiver is spiritually rewarding for me	A question about whether an individual being able to provide assistance as a caregiver is spiritually rewarding.			Intellectual Product	
C159178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159178>	C173160|C173048	Being Able to Provide Assistance as Caregiver Helps Me Feel in Control of Situation Question|Being Able to Provide Assistance as Caregiver Helps Me Feel in Control of Situation|Being able to provide assistance as a caregiver helps me feel in control of the situation	A question about whether an individual being able to provide assistance as a caregiver helps them feel in control of the situation.			Intellectual Product	
C159179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159179>	C173048	Being Able to Provide Assistance as Caregiver is Important to Me Question|Being Able to Provide Assistance as Caregiver is Important to Me|Being able to provide assistance as a caregiver is important to me	A question about whether an individual being able to provide assistance as a caregiver is important to them.			Intellectual Product	
C15917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15917>	C15230	Arterial Embolization|TAE|Transarterial Embolization|arterial embolization	Therapeutic blockage of an artery by a clot of foreign material.	Arterial Embolization		Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology
C159180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159180>	C173048	Being Able to Provide Assistance as Caregiver is My Duty as Responsible Adult Question|Being Able to Provide Assistance as Caregiver is My Duty as Responsible Adult|Being able to provide assistance as a caregiver is my duty as a responsible adult	A question about whether an individual being able to provide assistance as a caregiver is their duty as a responsible adult.			Intellectual Product	
C159181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159181>	C173509	Currently Paying Someone to Assist with Caregiving Question|Are you currently paying someone to assist you with caregiving|Currently Paying Someone to Assist with Caregiving	A question about whether an individual is currently paying someone to assist them with caregiving.			Intellectual Product	
C159182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159182>	C173924|C173092	Plan to Take Leave of Absence From Work Over Next Year Because of Caregiving Question|Do you plan to take a leave of absence from work over the next year because of your caregiving|Plan to Take Leave of Absence From Work Over Next Year Because of Caregiving	A question about whether an individual plans to take a leave of absence from work over the next year because of their caregiving.			Intellectual Product	
C159183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159183>	C176243	Difficult All of the Time|Difficult all of the time	A response indicating that something is or was difficult all of the time.			Intellectual Product	
C159184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159184>	C176243	Difficult Most of the Time|Difficult most of the time	A response indicating that something is or was difficult most of the time.			Intellectual Product	
C159185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159185>	C176243	Difficult Some of the Time|Difficult some of the time	A response indicating that something is or was difficult some of the time.			Intellectual Product	
C159186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159186>	C176243	Difficult a Slight Bit of the Time|Difficult a slight bit of the time	A response indicating that something is or was difficult a slight bit of the time.			Intellectual Product	
C159187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159187>	C177166	Does Not Apply to My Job	A response indicating that something does not apply to an individual's job.			Intellectual Product	
C159188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159188>	C176243	Difficult None of the Time|Difficult none of the time	A response indicating that something is or was difficult none of the time.			Intellectual Product	
C159189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159189>	C226565	Able All of the Time|Able all of the time	A response indicating that an individual is or was able all of the time.			Intellectual Product	
C15918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15918>	C15262	Chemical Immunotherapy|Immunotherapy, Chemical	The use of chemicals to enhance the immune system in treatment of cancer			Therapeutic or Preventive Procedure	
C159190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159190>	C226565	Able Most of the Time|Able most of the time	A response indicating that an individual is or was able most of the time.	Work Limitations Questionnaire, Adapted		Intellectual Product	
C159191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159191>	C226565	Able Some of the Time|Able some of the time	A response indicating that an individual is or was able some of the time.	Work Limitations Questionnaire, Adapted		Intellectual Product	
C159192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159192>	C226565	Able a Slight bit of the Time|Able a slight bit of time	A response indicating that an individual is or was able a slight bit of the time.			Intellectual Product	
C159193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159193>	C226565	Able None of the Time|Able none of the time	A response indicating that an individual is or was able none of the time.			Intellectual Product	
C159194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159194>	C226708|C226678	Pay For Full-time Help|Yes, I pay someone for full time help	A response indicating that an individual pays someone for full-time help.			Intellectual Product	
C159195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159195>	C226708|C226678	Pay For Part-time Help|Yes, I pay someone for part time help	A response indicating that an individual pays someone for part-time help.			Intellectual Product	
C159196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159196>	C226678	Don't Want Help|No, I don't want help	A response indicating that an individual does not want help.			Intellectual Product	
C159197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159197>	C226678	Can't Get Help|No, I want the help but can't get it	A response indicating that an individual wants help but can't get it.			Intellectual Product	
C159198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159198>	C1967|C163999|C129825	c-KIT Inhibitor|KIT Inhibitor|Mast/Stem Cell Growth Factor Receptor Kit Inhibitor|SCFR Inhibitor|cKIT Inhibitor	Any agent that inhibits the receptor tyrosine kinase mast/stem cell factor receptor c-Kit (SCFR; cKIT; CD117).			Chemical Viewed Functionally	
C159199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159199>	C1967|C164037	PDGFR Inhibitor|Platelet-derived Growth Factor Receptor Inhibitor	Any agent that inhibits the platelet-derived growth factor receptor (PDGFR).			Chemical Viewed Functionally	
C15919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15919>	C15824	Nutrition Research, Plant Components	The study of the role of plant-derived nutrients in cancer causation or prevention and in general health.			Research Activity	
C1591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1591>	C1593	Recombinant Beta Chemokine|C-C Chemokines|CC Chemokines|CC beta Chemokine	Formulated therapeutic analogs of one of a number of endogenous chemotactic polypeptide cytokines.  Beta chemokine is synthesized and released by macrophages, endothelial cells, keratinocytes, fibroblasts, and smooth muscle cells in response to infection or tissue damage, recruiting circulating macrophages to sites of production.  This agent may regulate tumor growth by modulating tumor-associated angiogenesis and metastasis and may either promote or inhibit tumor growth. (NCI04)			Chemical Viewed Functionally	
C159200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159200>	C192025	BCL-2 Inhibitor|B-cell Lymphoma 2 Inhibitor|BCL2 Inhibitor	Any agent that inhibits the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2; Bcl2).			Chemical Viewed Functionally	
C159201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159201>	C157093	Biospecimen Submitted to BCR	A section header about biospecimens submitted to BCR.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C159202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159202>	C158612	CO2 Level at Organ Excision Time Question|CO2 Level at Organ Excision Time|CO2 Level at Organ Excision Time|Carbon Dioxide level (CO2) recorded at time closest to organ excision	A question about the CO2 level that was recorded at the time closest to organ excision.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159203>	C204466	Ascites Fluid Sample|Ascitic Fluid|Peritoneal Ascitic Fluid	A biospecimen of ascitic fluid.			Body Substance	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|GCT Authorized Value Terminology|GCT Tumor Assessment Table|GDC Terminology|GDC Value Terminology
C159204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159204>	C131783	Fanconi Anemia Complementation Group Gene Mutation|BRCA2 and FANC gene mutations|FA Complementation Group Gene Mutation|FANC Family Gene Mutation|FANC Gene Mutation|Fanconi Anemia Complementation Family Gene Mutation|Fanconi Anemia Group Gene Mutation	A change in the nucleotide sequence for a gene that is a member of the Fanconi anemia complementation group.	Fanconi Anemia Complementation Group Gene Mutation		Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Pancreatic Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159205>	C4525|C171026	Kidney Angiosarcoma|Renal Angiosarcoma	A rare angiosarcoma arising from the kidney.			Neoplastic Process	
C159206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159206>	C4525|C214845	Kidney Rhabdomyosarcoma|Renal Rhabdomyosarcoma	An extremely rare rhabdomyosarcoma arising from the kidney. Most cases are of embryonal type.			Neoplastic Process	
C159207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159207>	C19676	FA Complementation Group Gene|FANC Gene|Fanconi Anemia Complementation Group Gene	A gene that encodes a member of a structurally diverse group of proteins that regulate both DNA repair and the cell cycle. Mutation of genes in this family are associated with disorders caused by deficiencies in DNA repair resulting in genomic instability.	FA Complementation Group Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159208>	C7135|C4525	Kidney Ewing Sarcoma|Renal Ewing Sarcoma	A rare Ewing sarcoma arising from the kidney.			Neoplastic Process	
C159209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159209>	C6510|C4778	Kidney Leiomyoma|Renal Leiomyoma	A benign smooth muscle neoplasm arising from the kidney.			Neoplastic Process	
C15920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15920>	C15824	Nutrition Research, Protein/Amino Acids|Protein/Amino Acid Nutrition	The study of the role of proteins and amino acids in cancer causation or prevention and in general health.			Research Activity	
C159210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159210>	C45233	Lung Parenchyma Tumor Location|Tumor Location in Parenchymal Tumor	A section header to choose the location of the parenchyma in the lung.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C159211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159211>	C4778|C3085	Kidney Hemangioma|Renal Hemangioma	A rare hemangioma arising from the kidney.			Neoplastic Process	
C159212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159212>	C159210	Peripheral Lung Parenchyma Tumor|Peripheral Lung	A response that the parenchyma tumor is in the peripheral lung.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C159213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159213>	C159210	Central Lung Parenchyma Tumor|Central Lung	A response that the parenchyma tumor is in the central lung.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C159214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159214>	C8965|C4778	Kidney Lymphangioma|Renal Lymphangioma	A rare lymphangioma arising from the kidney.			Neoplastic Process	
C159215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159215>	C186452	Cytogenetic Abnormality Positive by FISH|Was FISH Abnormality Detected	A section header requesting results for FISH detected cytogenetic abnormalities.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C159216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159216>	C157093	Specify if Present|If present, specify	A request to specify if present.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C159217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159217>	C157093	Specify Percentage|If present, specify percentage	A directive to specify a percentage.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C159218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159218>	C32870	Renomedullary Interstitial Cell|RMIC|Renal Medullary Interstitial Cell	A cell located in the inner renal medulla. It expresses receptors for vasoactive peptides.			Cell	
C15921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15921>	C15660	Vaccine Related Non-Development, Total	All vaccine research other than research on vaccine development.			Health Care Activity	
C159220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159220>	C42076	Small, Stellate, or Spindled Cells Present	A morphologic finding indicating the presence of small, stellate, or spindled cells in a cellular infiltrate.			Finding	
C159221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159221>	C4778|C41430	Kidney Schwannoma|Renal Schwannoma	A rare schwannoma arising from the kidney.			Neoplastic Process	
C159222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159222>	C7634|C3150	Kidney Solitary Fibrous Tumor|Renal Solitary Fibrous Tumor	A rare solitary fibrous tumor arising from the kidney.			Neoplastic Process	
C159223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159223>	C188218|C157743	Kidney Neuroendocrine Tumor|Kidney Well Differentiated Neuroendocrine Neoplasm|Kidney Well-Differentiated Neuroendocrine Neoplasm	A well-differentiated neuroendocrine neoplasm arising from the kidney. It is characterized by the presence of uniform cells with stippled chromatin and inconspicuous nucleoli. Mitotic activity is low and tumor necrosis is absent.			Neoplastic Process	
C159224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159224>	C9384|C191977|C157743	Kidney Neuroendocrine Carcinoma	An aggressive high-grade carcinoma with neuroendocrine differentiation that arises from the kidney. It is classified as either small or large cell neuroendocrine carcinoma based on the size of the malignant cells, the prominence of the nucleoli, and the amount of cytoplasm.			Neoplastic Process	
C159225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159225>	C191984|C159224	Kidney Large Cell Neuroendocrine Carcinoma	An aggressive high-grade carcinoma with neuroendocrine differentiation that arises from the kidney. It is characterized by the presence of malignant large cells.			Neoplastic Process	
C159226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159226>	C7046|C157743	Kidney Paraganglioma|Renal Paraganglioma	An extremely rare paraganglioma that arises from the renal hilum. Paragangliomas that arise from the perihilar sympathetic ganglia are not included in this category.			Neoplastic Process	
C159227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159227>	C3918|C3150	Kidney Germ Cell Tumor|Renal Germ Cell Tumor	A rare benign or malignant germ cell tumor that arises from the kidney.			Neoplastic Process	
C159228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159228>	C36292	Homologous Recombination Repair Proficient|HR Proficient|HR-Deficiency Negative|HR-Proficient|HRD Negative|HRD-Proficient|HRR Proficient|Homologous Recombination Repair Deficiency Negative|Homologous Recombination Repair Proficiency	A finding indicating that a sample exhibits normal or near normal levels of homologous recombination DNA repair activity.	Homologous Recombination Repair Proficient		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159229>	C160157	Cytogenetic Risk Group-CALGB Criteria for AML|Cytogenetic Risk Group (CALGB Criteria)|calgb risk group|calgb_risk_group	A classification strategy for Acute Myeloid Leukemia (AML)developed by the cancer research cooperative group Cancer And Leukemia Group B that assigns a rating based on the cytogenetic and molecular features of a particular disease.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|GDC Property Terminology|GDC Terminology
C15922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15922>	C15429	Smoking and Health Research|Smoking and Health	Research focusing on all activities associated with tobacco smoking; concerns factors that influence individuals to start or stop smoking, how these factors differ by age, sex, ethnic group, educational or socioeconomic level, etc.			Research Activity	
C159230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159230>	C48620	Margin Involved by Invasive Carcinoma|Margin(s) involved by invasive carcinoma	A result that the margin is involved by invasive carcinoma.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C159231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159231>	C4897	Acute Bilineal Leukemia in Remission	A finding of acute bilineal leukemia that is not growing and responds to treatment.	Acute Bilineal Leukemia in Remission		Finding	CTRP Disease Terminology|CTRP Terminology
C159232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159232>	C48620	Margin Involved by Invasive Melanoma|Margin(s) involved by invasive melanoma	A result that the margin is involved by invasive melanoma.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C159233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159233>	C48620	Margin Involved by Sarcoma|Margin(s) involved by sarcoma	The margin of the sample has sarcoma.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C159234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159234>	C48621	Margin Uninvolved by Invasive Carcinoma|Margins uninvolved by invasive carcinoma	A result that the margin is not uninvolved by invasive carcinoma.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C159235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159235>	C48621	Margin Uninvolved by Sarcoma|Margins uninvolved by sarcoma	The margin of the sample has no sarcoma.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C159236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159236>	C36286	Kidney Tumor, Upper Pole|Upper Pole Kidney Tumor|Upper pole	A tumor located in the upper pole of the kidney.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C159237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159237>	C36286	Kidney Tumor, Lower Pole|Lower Pole Kidney Tumor|Lower pole	A tumor located in the lower pole of the kidney.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C159238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159238>	C36286	Kidney Tumor, Middle Section|Middle	A tumor located in the middle section of the kidney.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C159239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159239>	C158582	Diffuse Large B-Cell Lymphoma in Complete Remission	A finding of diffuse large B-cell lymphoma  with no evidence of disease after therapy.	Diffuse Large B-Cell Lymphoma in Complete Remission		Finding	CTRP Disease Terminology|CTRP Terminology
C15923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15923>	C213308	Cancer Genome Anatomy Project|CGAP	The Cancer Genome Anatomy Project (CGAP) is an interdisciplinary program to establish the information and technological tools needed to decipher the molecular anatomy of a cancer cell.  The Cancer Genome Anatomy Project (CGAP) will unite the newest technologies, along with those both cost-effective and capable of high-throughput, to identify all the genes responsible for the establishment and growth of cancer.  CGAP has two overall goals: 1. Enhance discovery of the acquired and inherited molecular changes in cancer. 2. Evaluate the clinical potential of these discoveries. This requires the creation and dissemination of technologies that can read and interpret the molecular features of cancer.			Research Activity	
C159240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159240>	C158582	Diffuse Large B-Cell Lymphoma in Partial Remission	A finding of diffuse large B-cell lymphoma  with some evidence of disease after therapy.	Diffuse Large B-Cell Lymphoma in Partial Remission		Finding	CTRP Disease Terminology|CTRP Terminology
C159241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159241>	C117720	Myometrial Invasion|Present	A finding indicating that there is invasion of the myometrium by cancer.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C159242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159242>	C159241	Less than 50% Myometrial Invasion|<50% myometrial invasion	A response that there is less than 50% myometrial invasion.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C159243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159243>	C28108	Staging Incomplete	A lack of clinical and/or pathology information to assign a stage conclusively.			Classification	
C159244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159244>	C7729	Human Papillomavirus-Independent Penile Squamous Cell Carcinoma|HPV-Independent Penile Squamous Cell Carcinoma|HPV-Negative Penile Squamous Cell Carcinoma|Human Papillomavirus-Negative Penile Squamous Cell Carcinoma|Penile HPV-Independent Squamous Cell Carcinoma|Penile Human Papillomavirus-Independent Squamous Cell Carcinoma	A squamous cell carcinoma that arises from the penis and is not caused by human papillomavirus infection. Morphologic variants include pseudohyperplastic, pseudoglandular, verrucous, papillary, and sarcomatoid carcinoma.			Neoplastic Process	
C159245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159245>	C159244	Penile Pseudohyperplastic Carcinoma|Pseudohyperplastic Carcinoma of the Penis	A multifocal, extremely differentiated squamous cell carcinoma of the penis. It typically occurs in older patients and is associated with lichen sclerosus.			Neoplastic Process	
C159246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159246>	C4106|C159244	Penile Acantholytic Squamous Cell Carcinoma|Penile Pseudoglandular Carcinoma|Pseudoglandular Carcinoma of the Penis	A penile squamous cell carcinoma characterized by cellular discohesion of the tumor cells that results in the formation of pseudolumina resembling glandular structures.			Neoplastic Process	
C159247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159247>	C6982	Penile Carcinoma Cuniculatum|Carcinoma Cuniculatum of the Penis	A variant of verrucous carcinoma of the penis characterized by a labyrinthine growth pattern.			Neoplastic Process	
C159248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159248>	C9061|C3727	Penile Adenosquamous Carcinoma|Adenosquamous Carcinoma of the Penis	An extremely rare carcinoma that arises from the penis and is characterized by the presence of glandular and squamous components.			Neoplastic Process	
C159249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159249>	C6980	Penile Papillary-Basaloid Carcinoma|Papillary-Basaloid Carcinoma of the Penis	A variant of penile basaloid squamous cell carcinoma. It is characterized by a papillary exophytic or endophytic growth pattern.			Neoplastic Process	
C159250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159250>	C39959|C27682	Penile Warty-Basaloid Carcinoma|Warty-Basaloid Carcinoma of the Penis	A squamous cell carcinoma that arises from the penis. It is characterized by warty (condylomatous) and basaloid features.			Neoplastic Process	
C159251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159251>	C65180|C27682	Penile Clear Cell Squamous Cell Carcinoma|Clear Cell Squamous Cell Carcinoma of the Penis	A variant of penile squamous cell carcinoma characterized by the presence of malignant cells with clear cytoplasm.			Neoplastic Process	
C159252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159252>	C4107|C27682	Penile Lymphoepithelioma-Like Carcinoma|Lymphoepithelioma-Like Carcinoma of the Penis	A variant of penile squamous cell carcinoma characterized by the presence of islands of malignant cells with uniform vesicular nuclei and prominent nucleoli, and a dense lymphocytic infiltrate.			Neoplastic Process	
C159253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159253>	C157093	Specify If Other Studies|Other studies, specify:	A directive to specify if other studies were performed that are not listed on the form.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C159254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159254>	C38630	Palms of Hands and Soles of Feet|Palms and soles	The palmar aspect of the hands and the bottom of the feet.			Body Part, Organ, or Organ Component	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C159255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159255>	C160579|C157106	Specify Other KIT Mutation|If other KIT mutation, specify	A request to enter the specific KIT mutation that was identified in the study but is not present in the form.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C159257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159257>	C173812|C158612	Was Interferon Gamma Treatment Administered Prior to Specimen Resection Question|Prior to the resection of the specimen submitted, did the donor receive interferon gamma treatment|Was Interferon Gamma Treatment Administered Prior to Specimen Resection	A question about whether interferon gamma treatment was administered prior to the specimen resection.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C159258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159258>	C173812|C158612	Was Interferon Gamma Treatment Administered 90 Days Prior to Specimen Resection Question|If administered, was interferon gamma treatment administered at least 90 days prior to the resection of the study specimen|Was Interferon Gamma Treatment Administered 90 Days Prior to Specimen Resection	A question about whether interferon gamma treatment was administered 90 days prior to the specimen resection.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C159259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159259>	C20194	SNCB Gene|SNCB|SNCB|Synuclein Beta Gene	This gene may play a role in the inhibition of both cell death and alpha-synuclein aggregation.			Gene or Genome	
C15925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15925>	C15824	Nutrition Research, Alcohol	The study of the role of alcoholic beverages in cancer causation or prevention and in general health.			Research Activity	
C159260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159260>	C159259	SNCB wt Allele|Synuclein Beta wt Allele|Synuclein, Beta Gene	Human SNCB wild-type allele is located in the vicinity of 5q35.2 and is approximately 10 kb in length. This allele, which encodes beta-synuclein protein, may be involved in cell survival. Mutation in the gene is associated with Lewy body dementia.			Gene or Genome	
C159261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159261>	C35886	Growth Phase	The morphologic architectural pattern in which the tumor cells spread.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C159262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159262>	C18466	Beta-Synuclein|SNCB|Synuclein Beta|Β-Synuclein	Beta-synuclein (134 aa, ~14 kDa) is encoded by the human SNCB gene. This protein may play a role in the inhibition of alpha-synuclein aggregation and in cell survival.			Amino Acid, Peptide, or Protein	
C159263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159263>	C159261	Indeterminate Growth Phase|Indeterminate	A response that the growth phase is undetermined.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C159264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159264>	C158612	Method of Left Lymph Node Dissection Question|Method of Left Lymph Node Dissection|Method of Lymph Node Neck Dissection, Left	A request to identify the method employed to dissect the left lymph node.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C159265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159265>	C25941	PTGDS Gene|PTGDS|PTGDS|Prostaglandin D2 Synthase Gene	This gene is involved in synthesis of prostaglandin D2.			Gene or Genome	
C159266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159266>	C158612	Method of Right Lymph Node Dissection Question|Method of Lymph Node Neck Dissection, Right|Method of Right Lymph Node Dissection	A request to identify the method employed to dissect the right lymph node.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C159267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159267>	C159265	PTGDS wt Allele|L-PGDS|LPGDS|PDS|PGD2|PGDS|PGDS2|Prostaglandin D Synthase, Lipocalin-Type Gene|Prostaglandin D2 Synthase (21kD, Brain) Gene|Prostaglandin D2 Synthase 21kDa (Brain) Gene|Prostaglandin D2 Synthase wt Allele|Prostaglandin D2 Synthase, Brain Gene	Human PTGDS wild-type allele is located in the vicinity of 9q34.3 and is approximately 7 kb in length. This allele, which encodes prostaglandin-H2 D-isomerase protein, plays a role in prostaglandin metabolism.			Gene or Genome	
C159268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159268>	C16759	Prostaglandin-H2 D-Isomerase|Beta-Trace Protein|Cerebrin-28|EC 5.3.99.2|Glutathione-Independent PGD Synthase|Glutathione-Independent PGD Synthetase|Lipocalin-Type Prostaglandin D Synthase|Lipocalin-Type Prostaglandin-D Synthase|PGD2 Synthase|PGDS|PGDS2|PTGDS|Prostaglandin D2 Synthase|Prostaglandin-D2 Synthase|Testis Tissue Sperm-Binding Protein Li 63n	Prostaglandin-H2 D-isomerase (190 aa, ~21 kDa) is encoded by the human PTGDS gene. This protein is involved in the conversion of prostaglandin H2 (PGH2) to prostaglandin D2 (PGD2).			Amino Acid, Peptide, or Protein|Enzyme	
C159269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159269>	C159511	Special Education|Special Ed|Special-needs Education	The practice of educating students with identified disabilities through specialized instruction that addresses their individual differences and needs.			Educational Activity	
C15926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15926>	C15824	Nutrition Research, Minerals	The study of the role of minerals in cancer causation or prevention and in general health.			Research Activity	
C159270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159270>	C158612	Other Notable Events During Surgery Question|Other Notable Events During Surgery|Other Notable Events During Surgery|Other notable events during surgery	A question about other notable events that happened during surgery.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159271>	C69074	Classroom|Schoolroom	A room or space, especially in a school, where classes are held.			Geographic Area	
C159272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159272>	C158612	Description of Epochs of O2 Desaturation Less than 92% Greater than 5 Minutes Prior to Organ Excision Question|Describe Epochs of Oxygen (O2) desaturation of <92% for >5 minutes prior to organ excision|Description Of Epochs O2 Desaturation Prior To Organ Excision|Description of Epochs of O2 Desaturation Less than 92% Greater than 5 Minutes Prior to Organ Excision|Description of Epochs of O2 Desaturation Less than 92% Greater than 5 Minutes Prior to Organ Excision	A textual representation of the information regarding an O2 desaturation epoch of less than 92 percent, lasting greater than 5 minutes, prior to organ excision.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159273>	C116518	Speech Language Therapy	The treatment of communication disorders (speech disorders and language disorders), cognitive-communication disorders, voice disorders, and swallowing disorders.			Health Care Activity	
C159274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159274>	C171086	Currently Receiving|Person Currently Receiving	An indication that an individual is receiving something at the present time.			Qualitative Concept	
C159275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159275>	C25338	Raw Score	A single score that is derived from a test or an observation and that has not been transformed or altered.			Quantitative Concept	
C159276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159276>	C42078	Satellite Lesion	Nodules of melanoma located more than 0.05 mm from the primary lesion.			Finding	
C159277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159277>	C159276	Macroscopic Satellite Nodule is Present|Present	Satellite nodule in melanoma observed macroscopically.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C159278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159278>	C159276	Microsatellitosis	One or more discontinuous nests of melanoma cells measuring at least 0.3 mm in diameter and separated from the primary lesion by more than 0.05 mm of normal tissue.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C159279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159279>	C8510	Melanoma Involvement of Regional Cutaneous or Subcutaneous Tissue|Regional cutaneous or subcutaneous tissue (includes satellite & in-transit metastasis)	A finding indicating the spread of cutaneous melanoma to regional cutaneous or subcutaneous tissue, including satellite and in-transit metastasis.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C15927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15927>	C16016	Nutrition Research, Vitamin B	The study of the role of Vitamin B, its precursons, and its analogs in cancer causation or prevention and in general health.			Research Activity	
C159280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159280>	C25207	Time of First Temperature|Time of first temperature	A question about the time that the first body temperature was recorded.			Temporal Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159281>	C25207	Time of Second Temperature|Time of second temperature	A question about the time that the second body temperature was recorded.			Temporal Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159282>	C174446	First OR Temperature|First Operating Room Temperature|First Participant temperature recorded in OR	The first body temperature recorded in the operating room for the participant.			Quantitative Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159283>	C174446	Second OR Temperature|Second Operating Room Temperature|Second Participant temperature recorded in OR	The second body temperature recorded in the operating room for the participant.			Quantitative Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159284>	C158612	Intraoperative Blood Product Administration Question|Intraoperative Blood Product Administration|Intraoperative blood product administration (Optional)	A header for a form section about intraoperative blood product administration.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159285>	C25207	Time Specimen Left OR|Time Specimen left OR	A question about the time that a specimen left the operating room.			Temporal Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159286>	C157093	Surgical Procedure Details|Surgical procedure details	A header for a form section about other surgical procedure details.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159287>	C158612	Other Medication Question|Other Medication|Other Medication	A directive to specify the other medication administered.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159288>	C158612	Were Other Medications Administered During Surgery Question|Were Other Medications Administered During Surgery|Were Other Medications Administered During Surgery|Were other medications administered during surgery	A question about whether other medications were administered during surgery.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159289>	C158612	Antibiotics Administered During Surgery Question|Antibiotics Administered During Surgery|Antibiotics Administered During Surgery|Were Antibiotics Administered During Surgery|Were Antibiotics administered during surgery	A question about whether antibiotics were administered during surgery.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C15928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15928>	C16016	Nutrition Research, Vitamin C	The study of the role of Vitamin C, its precursons, and its analogs in cancer causation or prevention and in general health.			Research Activity	
C159290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159290>	C158612	Were Steroids Administered During Surgery Question|Were Steroids Administered During Surgery|Were Steroids Administered During Surgery|Were Steroids administered during surgery	A question about whether steroids were administered during surgery.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159291>	C158612	Was Insulin Administered During Surgery Question|Was Insulin Administered During Surgery|Was Insulin Administered During Surgery|Was Insulin administered during surgery	A question about whether insulin was administered during surgery.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159292>	C158612	Other Medications Administered During Surgery Prior to Tumor Tissue Removal Question|Other Medications Administered During Surgery Prior to Tumor Tissue Removal|Other medications administered during surgery prior to removal of the tumor tissue	A header on the form for medications administered during surgery prior to removal of the tumor tissue.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159293>	C157093	Surgery Information Indicate If any of the Following Medications were Administered During Surgery|Surgery information Indicate whether any of the following medications were administered during surgery	A directive to indicate whether any of the following medications listed on the form were administered during surgery.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159294>	C157093	Specify Additional Anesthesia|Specify additional anesthesia	A directive to specify additional anesthesia agents administered.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159295>	C158612	Was Inhalation Anesthesia Administered Question|Inhalation Anesthesia agents administered|Was Inhalation Anesthesia Administered|Was Inhalation Anesthesia Administered	A question about whether inhalation anesthesia was administered.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159296>	C158612	Specify Other Muscle Relaxants Administered Question|Other Muscle Relaxants (specify)|Specify Other Muscle Relaxants Administered|Specify Other Muscle Relaxants Administered	A request to specify muscle relaxants that were administered but not included on a list.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159297>	C159296	Were IV Muscle Relaxants Administered Question|IV Muscle Relaxants Administered|Were IV Muscle Relaxants Administered	A question about whether intravenous muscle relaxants were administered.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159298>	C158612	Specify Other Narcotics or Opiates Administered Question|Other Narcotics/Opiates (specify)|Specify Other Narcotics or Opiates Administered|Specify Other Narcotics or Opiates Administered	A request to specify narcotics or opiates that were administered but not included on a list.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159299>	C158612	Was IV Anesthesia Administered Question|IV Anesthesia Agents Administered|Was IV Anesthesia Administered|Was IV Anesthesia Administered	A question about whether intravenous anesthesia was administered.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C15929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15929>	C16016	Nutrition Research, Vitamin E	The study of the role of Vitamin E (alpha-tocopherol), its precursons, and its analogs in cancer causation or prevention and in general health.			Research Activity	
C1592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1592>	C1593	Recombinant Alpha Chemokine|Alpha Chemokines|C-X-C Chemokines|CXC Chemokines|CXC alpha Chemokine	One of a number of chemotactic cytokines. Alpha chemokines are small polypeptides released by macrophages, endothelial cells, keratinocytes, fibroblasts, and smooth muscle cells in the presence of infection or physical tissue damage.  In a therapeutic setting, these agents may act as chemoattractants to recruit neutrophils and T cells from the blood to sites of infection or damage and may either promote or inhibit tumor growth by modulating tumor-associated angiogenesis and metastasis. Also known as CXC chemokines. (NCI04)			Chemical Viewed Functionally	
C159300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159300>	C15723	Lymphovenous Bypass|Lymphovenous Anastomosis	A surgical procedure in which anastomoses are created from lymphatic vessels to veins..	Lymphovenous Bypass		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C159301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159301>	C158612	Was Regional Anesthesia Administered Question|Regional (Spinal/Epidural) Anesthesia agents administered|Was Regional Anesthesia Administered|Was Regional Anesthesia Administered	A question about whether regional anesthesia was administered.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159302>	C158612	Were Other Preoperative IV Medications Administered Question|Other Pre-operative IV Medications administered|Were Other Preoperative IV Medications Administered|Were Other Preoperative IV Medications Administered	A question about whether other preoperative intravenous medications were administered.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159303>	C158612	Were Preoperative IV Antacids Administered Question|Pre-operative IV Anti-acids administered|Were Preoperative IV Antacids Administered|Were Preoperative IV Antacids Administered	A question about whether preoperative intravenous antacids were administered.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159304>	C158612	Were Preoperative IV Antiemetics Administered Question|Pre-operative IV Antiemetics administered|Were Preoperative IV Antiemetics Administered|Were Preoperative IV Antiemetics Administered	A question about whether preoperative intravenous antiemetics were administered.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159305>	C158612	Were Preoperative IV Opiates Administered Question|Pre-operative IV Opiates Administered|Were Preoperative IV Opiates Administered|Were Preoperative IV Opiates Administered	A question about whether preoperative intravenous opiates were administered.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159306>	C158612	Specify Other Preoperative IV Sedation Administered Question|Other IV Sedation (specify)|Specify Other Preoperative IV Sedation Administered	A directive to specify any intravenous sedation administered that is not on the form.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159307>	C158612	Was Preoperative IV Sedation Administered Question|Pre-operative IV Sedation administered|Was Preoperative IV Sedation Administered|Was Preoperative IV Sedation Administered	A question about whether preoperative intravenous sedation was administered.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159308>	C158612	Date of Surgical Procedure Question|Date of Surgery/Procedure|Date of Surgical Procedure|Date of Surgical Procedure|Date of surgery|date of surgery|date_of_surgery	A question about the date on which a surgical procedure was performed.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology|CRF4 Treatment Additional Surgeries Table|CRF4 Treatment Surgery Table|ICDC Property Terminology|ICDC Terminology
C159309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159309>	C158612	Highest Grade Pancreatic Intraepithelial Neoplasia Question|Highest Grade Pancreatic Intraepithelial Neoplasia|Highest grade	A directive to choose the highest grade of pancreatin intraepithelial neoplasia.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Pancreatic Baseline Form|CPTAC Terminology
C159310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159310>	C54625	Clinical History	A clinical history section header on a form.			Conceptual Entity	CPTAC Baseline Medical Forms Terminology|CPTAC Pancreatic Baseline Form|CPTAC Terminology
C159311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159311>	C5242	Borderline Ovarian Mucinous Tumor/Atypical Proliferative Ovarian Mucinous Tumor with Microinvasion	A low grade ovarian epithelial neoplasm characterized by the presence of neoplastic mucinous epithelial cells, atypia, and microinvasion of the ovarian stroma.			Neoplastic Process	
C159312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159312>	C122586	Borderline Ovarian Mucinous Tumor/Atypical Proliferative Ovarian Mucinous Tumor with Intraepithelial Carcinoma	A low grade ovarian epithelial neoplasm characterized by the presence of neoplastic mucinous epithelial cells, atypia, and the presence of intraepithelial carcinoma.			Neoplastic Process	
C159313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159313>	C179259	Borderline Ovarian Seromucinous Tumor/Atypical Proliferative Ovarian Seromucinous Tumor with Microinvasion	A low grade ovarian epithelial neoplasm characterized by the presence of atypical neoplastic serous and mucinous cells. Microinvasion of the ovarian stroma is present.			Neoplastic Process	
C159314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159314>	C158612	Which Pulmonary Function Tests Were Performed Question|Pulmonary Function Tests Performed|Which Pulmonary Function Tests Were Performed	A question about which pulmonary tests were performed.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C159315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159315>	C38083	FEV1% REF Pre-Bronchodilator|FEV1% REF pre-bronchodilator (Pre- Bronchodilator Lung Forced Expiratory Volume I Test Lab Percentage Value)|fev1 ref pre bronch percent|fev1_ref_pre_bronch_percent	The test for pre-bronchodilator lung forced expiratory volume 1 test lab percentage value.			Diagnostic Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Property Terminology|GDC Terminology
C159316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159316>	C38081	FEV1% REF Post-Bronchodilator|FEV1% REF post- bronchodilator (Post - Bronchodilator Lung Forced Expiratory Volume I Test Lab Percentage Value)|fev1 ref post bronch percent|fev1_ref_post_bronch_percent	The test for post-bronchodilator lung forced expiratory volume 1 test lab percentage value.			Diagnostic Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Property Terminology|GDC Terminology
C159317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159317>	C38081	FEV1/FVC Pre-Bronchodilator|FEV1/FVC pre- bronchodilator (Pre- Bronchodilator FEV1/FVC Percentage Value)|fev1 fvc pre bronch percent|fev1_fvc_pre_bronch_percent	The test for pre-bronchodilator forced expiratory volume over the forced vital capacity percentage value.			Diagnostic Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Property Terminology|GDC Terminology
C159318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159318>	C38081	FEV1/FVC Post-Bronchodilator|FEV1/FVC post- bronchodilator (Post- Bronchodilator FEV1/FVC Percentage Value)|fev1 fvc post bronch percent|fev1_fvc_post_bronch_percent	The test for post-bronchodilator forced expiratory volume over the forced vital capacity percentage value.			Diagnostic Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Property Terminology|GDC Terminology
C159319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159319>	C38081	DLCO % REF|DLCO % REF (Lung Carbon Monoxide Diffusing Capability Test) Assessment Predictive Percentage Value|dlco ref predictive percent|dlco_ref_predictive_percent	The lung carbon monoxide diffusing capability test assessment predictive percentage value.			Diagnostic Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Property Terminology|GDC Terminology
C15931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15931>	C49235	Clinical Management	To oversee clinical services in an institution.			Activity	
C159320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159320>	C158612	Pathologic Findings in Non-Neoplastic Kidney Question|Pathologic Findings in Non-Neoplastic Kidney|Pathologic Findings in Nonneoplastic Kidney	A section header requesting results for the pathologic findings in the non-neoplastic kidney.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C159321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159321>	C158612	Prognostic Features Used for Tumor Prognosis Question|Prognostic Features Used for Tumor Prognosis|Prognostic/Predictive/Lifestyle Features Used for Tumor Prognosis or Responsiveness to Treatment	A form section header about prognostic features used for tumor prognosis.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C159322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159322>	C158612	Renal Vein or Vena Cava Thrombosis or Other Coagulopathies Question|Renal Vein or Vena Cava Thrombosis or Other Coagulopathies|Renal vein or vena caval thrombosis or other coagulopathies (specify)	A section header for renal vein or vena cava thromboses or other coagulopathies.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C159323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159323>	C99107	Vena Cava Thrombosis|Vena caval thrombosis	The formation of a thrombus in the vena cava.			Disease or Syndrome	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C159324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159324>	C160157	Left Lymph Node Dissection not Done|Not done, Left	A response that the left lymph node dissection was not done.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C159325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159325>	C160157	Right Lymph Node Dissection not Done|Not done, Right	A response that the left lymph node dissection was not done.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C159326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159326>	C158612	HPV Status by PCR Question|HPV Status by PCR|HPV Status by PCR	A procedure to determine the HPV status by PCR.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C159327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159327>	C158612	HPV Status by in situ Hybridization Question|HPV Status by ISH|HPV Status by ISH Testing|HPV Status by in situ Hybridization|HPV Status by in situ Hybridization	A procedure to determine HPV status by in situ hybridization.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C159328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159328>	C156952	CPTAC Follow-Up Forms Terminology	Terminology used in support of the data collection efforts of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) with the focus on obtaining data for follow-up medical forms.			Intellectual Product	
C159329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159329>	C156953	CPTAC Normal Endometrial Baseline Form				Intellectual Product	
C159330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159330>	C159328	CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form				Intellectual Product	
C159331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159331>	C159328	CPTAC Sarcoma Follow-Up Form				Intellectual Product	
C159332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159332>	C159328	CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form				Intellectual Product	
C159333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159333>	C159328	CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form				Intellectual Product	
C159334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159334>	C159328	CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form				Intellectual Product	
C159335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159335>	C159328	CPTAC Glioblastoma Multiforme Follow-Up Form				Intellectual Product	
C159336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159336>	C159328	CPTAC Melanoma Follow-Up Form				Intellectual Product	
C159337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159337>	C159328	CPTAC Renal Cell Carcinoma Follow-Up Form				Intellectual Product	
C159338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159338>	C159328	CPTAC Acute Myeloid Leukemia Follow-Up Form				Intellectual Product	
C159339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159339>	C156953	CPTAC Acute Myeloid Leukemia Baseline Form				Intellectual Product	
C159340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159340>	C38068	Peritoneal Lavage|Peritoneal Washing	A minimally invasive procedure that permits sampling of peritoneal fluid for cytopathologic analysis.	Peritoneal Lavage		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C159341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159341>	C91102	How Much Time Did it Take Question|How Much Time Did it Take|How much time did it take	A question about how much time it took to do something.			Intellectual Product	
C159342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159342>	C50434	Ascites Drainage	The systematic withdrawal of ascitic fluid  from the abdominal cavity.			Health Care Activity	GDC Terminology|GDC Value Terminology
C159343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159343>	C173398	How Much Effort Did it Take Question|How Difficult was it|How Much Effort Did it Take|How much effort/difficulty did it take	A question about how difficult it was to do something.			Intellectual Product	
C159344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159344>	C12770	Pelvic Peritoneum	A membranous lining of the pelvic organs.			Tissue	GDC Terminology|GDC Value Terminology
C159345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159345>	C91102	Prepare and Give Medicines, Fluids, Nutrition Intravenously Question|Prepare and Give Medicines, Fluids, Nutrition Intravenously|Preparing and giving medicines, fluids and tpn (nutrition) intravenously (iv) (preparation includes: tubing, pumps, drawing up medications)	A question about preparing and giving medicines, fluids, or nutrition intravenously.			Intellectual Product	
C159346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159346>	C91102	Prepare and Give Medicine as Shot in Muscle or Under Skin Question|Prepare and Give Medicine as Shot in Muscle or Under Skin|Preparing and giving medicine as a shot in the muscle (im) or under the skin (sq) (this includes: drawing up medications, applying emla cream)	A question about preparing and giving medicine as a shot in the muscle or under the skin.			Intellectual Product	
C159347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159347>	C91102	Prepare and Give Medications by Mouth Question|Prepare and Give Medications by Mouth|Preparing and giving medications by mouth (examples include: breaking up pills, disguising taste, etc.)	A question about preparing and giving medications by mouth.			Intellectual Product	
C159348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159348>	C225418	Left Tubo-Ovarian	A term that implies the left fallopian tube and left ovary.			Spatial Concept	
C159349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159349>	C91102	Prepare and Give Catheter Flushes Question|Prepare and Give Catheter Flushes|Preparing and giving catheter flushes	A question about preparing and performing catheter flushes.			Intellectual Product	
C159350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159350>	C225418	Right Tubo-Ovarian	A term that implies the right fallopian tube and right ovary.			Spatial Concept	
C159351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159351>	C173890	Change Dressing on Your Child's Catheter and Change Catheter Cap Question|Change Dressing on Your Child's Catheter and Change Catheter Cap|Changing the dressing on your child's catheter (i.e., broviac, hickman, port, etc.) and changing catheter cap(s)	A question about an individual changing their child's catheter dressing and catheter cap.			Intellectual Product	
C159352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159352>	C173933|C173890	Manage Child's Side Effects of Cancer or its Treatment Question|Manage Child's Side Effects of Cancer or its Treatment|Managing side effects of cancer or its treatment (examples include: vomiting, mouth sores, diarrhea, frequent voiding/diaper changing)	A question about an individual managing side effects of cancer or its treatment for their child with cancer.			Intellectual Product	
C159353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159353>	C173890|C173346	Keep Your Child Comfortable and Without Pain Question|Keep Your Child Comfortable and Without Pain|Keeping your child comfortable and without pain	A question about an individual keeping their child comfortable and without pain.			Intellectual Product	
C159354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159354>	C173890	Manage Other Childhood Illnesses for Your Child with Cancer Question|Manage Other Childhood Illnesses for Your Child with Cancer|Managing other childhood illnesses for your child with cancer (examples include: cold, flu, ear infections, other)	A question about an individual managing other childhood illnesses for their child with cancer.			Intellectual Product	
C159355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159355>	C12770	Abdominal Peritoneum	A membranous lining of the abdominal cavity and abdominal organs.			Tissue	GDC Terminology|GDC Value Terminology
C159356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159356>	C21114	EDA Gene|EDA|EDA|Ectodysplasin A Gene	This gene plays a role in ectodermal structure morphogenesis.			Gene or Genome	
C159357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159357>	C159356	EDA wt Allele|ECTD1|ED1|ED1-A1|ED1-A2|EDA|EDA-A1|EDA-A2|EDA1|EDA2|Ectodermal Dysplasia 1, Anhidrotic Gene|Ectodysplasin A wt Allele|Ectodysplasin Gene|HED|HED1|ODT1|Oligodontia 1 Gene|STHAGX1|TNLG7C|XHED|XLHED	Human EDA wild-type allele is located in the vicinity of Xq13.1 and is approximately 423 kb in length. This allele, which encodes ectodysplasin-A protein, is involved in the morphogenesis of ectodermally derived tissues. Mutation of the gene is associated with X-linked hypohidrotic ectodermal dysplasia type 1 and X-linked, selective tooth agenesis type 1.			Gene or Genome	
C159358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159358>	C20500	EDA Gene Product	A protein encoded by the EDA gene.			Amino Acid, Peptide, or Protein	
C159359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159359>	C159358	Ectodysplasin-A1|ED1-A1|EDA Protein|EDA-A1|EDA1|Ectodermal Dysplasia Protein 4|Ectodysplasin A|Ectodysplasin A Isoform 1|Ectodysplasin A1|Ectodysplasin A1 Isoform|Ectodysplasin-A|Ectodysplasin-A Isoform 1|Tumor Necrosis Factor Ligand 7C|X-Linked Anhidroitic Ectodermal Dysplasia Protein	Ectodysplasin-A1 (391 aa, ~41 kDa) is encoded by the human EDA gene. This protein plays a role in the positive regulation of signaling mediated by tumor necrosis factor receptor superfamily member EDAR.			Amino Acid, Peptide, or Protein	
C15935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15935>	C16063	Surveillance Modeling	A modeling technique used to analyze how interventions like screening and treatment impact long-term population outcomes.			Research Activity	
C159360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159360>	C159358	Ectodysplasin-A2|ED1-A2|EDA-A2|EDA2|Ectodysplasin A Isoform 3|Ectodysplasin A2|Ectodysplasin A2 Isoform|Ectodysplasin-A Isoform 3	Ectodysplasin-A2 (389 aa, ~41 kDa) is encoded by the human EDA gene. This protein is involved in the positive regulation of signaling mediated by tumor necrosis factor receptor superfamily member 27.			Amino Acid, Peptide, or Protein	
C159361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159361>	C21165	EDAR Gene|EDAR|EDAR|Ectodysplasin A Receptor Gene	This gene is involved in ectodysplasin-A1-mediated signaling.			Gene or Genome	
C159362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159362>	C159361	EDAR wt Allele|DL|Downless, Mouse, Homolog of Gene|ECTD10A|ECTD10B|ED1R|ED3|ED5|EDA-A1R|EDA1R|EDA3|Ectodysplasin 1, Anhidrotic Receptor Gene|Ectodysplasin A Receptor wt Allele|HRM1	Human EDAR wild-type allele is located in the vicinity of 2q13 and is approximately 95 kb in length. This allele, which encodes tumor necrosis factor receptor superfamily member EDAR protein, plays a role in the development of ectodermally derived tissues. Mutation of the gene is associated with hypohidrotic ectodermal dysplasia types 10A and 10B.			Gene or Genome	
C159363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159363>	C19285	Tumor Necrosis Factor Receptor Superfamily Member EDAR|Anhidrotic Ectodysplasin Receptor 1|Downless Homolog|EDA-A1 Receptor|EDAR|Ectodermal Dysplasia Receptor|Ectodysplasin A Receptor|Ectodysplasin A1 Isoform Receptor|Ectodysplasin-A Receptor	Tumor necrosis factor receptor superfamily member EDAR (448 aa, ~49 kDa) is encoded by the human EDAR gene. This protein is involved in signaling that modulates the development of ectodermal structures.			Amino Acid, Peptide, or Protein|Receptor	
C159364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159364>	C21165	EDA2R Gene|EDA2R|EDA2R|Ectodysplasin A2 Receptor Gene|TNFRSF27	This gene plays a role in ectodysplasin-A2-mediated signaling.			Gene or Genome	
C159365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159365>	C159364	EDA2R wt Allele|EDA-A2R|EDAA2R|Ectodysplasin A2 Receptor wt Allele|Ectodysplasin Receptor, X-Linked Gene|TNFRSF27|UNQ2448/PRO5727/PRO34080|XEDAR	Human EDA2R wild-type allele is located in the vicinity of Xq12 and is approximately 45 kb in length. This allele, which encodes tumor necrosis factor receptor superfamily member 27 protein, is involved in signaling that modulates the development of ectodermal structures.			Gene or Genome	
C159366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159366>	C19285	Tumor Necrosis Factor Receptor Superfamily Member 27|EDA-A2 Receptor|EDA2R|Ectodysplasin A2 Isoform Receptor|Ectodysplasin A2 Receptor|Ectodysplasin-A2 Receptor|TNFRSF27|Tumor Necrosis Factor Receptor Superfamily Member XEDAR|X-Linked Ectodysplasin-A2 Receptor	Tumor necrosis factor receptor superfamily member 27 (297 aa, ~33 kDa) is encoded by the human EDA2R gene. This protein plays a role in the development and maintenance of ectodermally derived tissues.			Amino Acid, Peptide, or Protein|Receptor	
C159367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159367>	C217122	Chemotherapy Response Score|CRS	A three-tier chemotherapy response score (CRS) system used to assess the histopathologic response and prognosis of patients with tubo-ovarian high-grade serous carcinoma (HGSC) receiving neoadjuvant chemotherapy.			Intellectual Product	
C159368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159368>	C159367	Chemotherapy Response Score 1|CRS1|CRS1	No or minimal tumor response.			Intellectual Product	
C159369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159369>	C159367	Chemotherapy Response Score 2|CRS2|CRS2	Appreciable tumor response amid viable tumor that is readily identifiable.			Intellectual Product	
C15936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15936>	C16237	Validity of Self Report|Validation of Self Report	The process of determining that a self-report tool gives meaningful and valid results.			Qualitative Concept	
C159370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159370>	C159367	Chemotherapy Response Score 3|CRS3	Complete or near complete response with no residual tumor OR minimal irregularly scatter tumor foci seen as individual cells, cell groups, or nodules up to 2 mm maximum size.			Intellectual Product	
C159371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159371>	C21165	TNFRSF10D Gene|TNF Receptor Superfamily Member 10d Gene|TNFRSF10D|TNFRSF10D	This gene plays a role in the inhibition of apoptotic signaling.			Gene or Genome	
C159372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159372>	C159371	TNFRSF10D wt Allele|CD264|DCR2|TNF Receptor Superfamily Member 10d wt Allele|TRAIL-R4|TRAILR4|TRUNDD|Tumor Necrosis Factor Receptor Superfamily, Member 10d Gene|Tumor Necrosis Factor Receptor Superfamily, Member 10d, Decoy without an Intracellular Domain Gene|UNQ251/PRO288	Human TNFRSF10D wild-type allele is located in the vicinity of 8p21.3 and is approximately 28 kb in length. This allele, which encodes tumor necrosis factor receptor superfamily member 10D protein, is involved in the regulation of tumor necrosis factor ligand superfamily member 10-mediated signaling.			Gene or Genome	
C159373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159373>	C19285	Tumor Necrosis Factor Receptor Superfamily Member 10D|CD264|CD264 Antigen|DcR2|Decoy Receptor 2|TNF Receptor Superfamily Member 10d|TNF Receptor-Related Receptor for TRAIL|TNF-Related Apoptosis-Inducing Ligand Receptor 4|TNFRSF10D|TRAIL Receptor 4|TRAIL Receptor with a Truncated Death Domain|TRAIL-R4	Tumor necrosis factor receptor superfamily member 10D (386 aa, ~42 kDa) is encoded by the human TNFRSF10D gene. This protein plays a role in cell survival.			Amino Acid, Peptide, or Protein|Receptor	
C159374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159374>	C173890	Manage Unexpected Events Related to Your Child's Illness Question|Manage Unexpected Events Related to Your Child's Illness|Managing unexpected events related to your child's illness (examples include: admission for fever, unscheduled appointment for blood transfusion, changes in treatment schedule because of low blood counts)	A question about an individual managing unexpected events related to their child's illness.			Intellectual Product	
C159375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159375>	C173890	Additional Household Tasks Related to Your Child's Illness Question|'Additional Household Tasks Related to Your Child's Illness'|Additional household tasks related to your child's illness (examples include: cleaning and maintenance of equipment, etc.)	A question about an individual's additional household tasks related to their child's illness.			Intellectual Product	
C159376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159376>	C173890	Coordinate, Arrange, and Manage Child's Medical Services Question|Coordinate, Arrange, and Manage Child's Medical Services|Coordinating, arranging, and managing medical services (examples include: scheduling appointments, locating equipment and negotiating services)	A question about an individual coordinating, arranging, and managing their child's medical services.			Intellectual Product	
C159377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159377>	C198102|C176545	Travel to and From Hospital for Medical Care Question|Travel to and From Hospital for Medical Care|Travel to and from the hospital for medical care	A question about travel to and from the hospital for medical care.			Intellectual Product	
C159378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159378>	C91102	How Much Time Spent at Hospital for Appointments Question|How Much Time Spent at Hospital for Appointments|How much time was spent at the hospital for appointments (examples include: oncology, neurology, radiation oncology, surgery clinic, scans, and other tests)	A question about how much time was spent at the hospital for appointments.			Intellectual Product	
C159379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159379>	C173398	How Much Effort or Difficulty for Time Spent at Hospital for Appointments Question|How Much Effort or Difficulty for Time Spent at Hospital for Appointments|How much effort/difficulty did it take for time spent at the hospital for appointments (examples include: oncology, neurology, radiation oncology, surgery clinic, scans, and other tests)	A question about how much effort or difficulty for time spent at the hospital for appointments.			Intellectual Product	
C15937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15937>	C15213	Community Practice	Healthcare services rendered within a given population or segment of a society.			Health Care Activity	
C159380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159380>	C173890	Provide Emotional Support for Your Child with Cancer Question|Provide Emotional Support for Your Child with Cancer|Providing emotional support for your child with cancer	A question about an individual providing emotional support for their child with cancer.			Intellectual Product	
C159381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159381>	C173890|C173151	Provide Emotional Support for Other Children in the Family Question|Provide Emotional Support for Other Children in the Family|Providing emotional support for other children in the family	A question about an individual providing emotional support for the extended family.			Intellectual Product	
C159382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159382>	C173151	Provide Emotional Support for Extended Family Question|Provide Emotional Support for Extended Family|Providing emotional support for the extended family (examples include: grandparents, aunts, uncles, friends, etc.)	A question about an individual providing emotional support for other children in the family.			Intellectual Product	
C159383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159383>	C91102	Provide Support for Spouse or Partner Question|Provide Support for Spouse or Partner|Providing emotional support for your spouse/partner	A question about an individual providing emotional support for their spouse or partner.			Intellectual Product	
C159384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159384>	C91102	Meet Your Own Emotional Support Needs Question|Meet Your Own Emotional Support Needs|Meeting your own emotional support needs	A question about an individual meeting their own emotional support needs.			Intellectual Product	
C159385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159385>	C173890	Comfort Your Child Through Pain of Cancer and its Treatment Question|Comfort Your Child Through Pain of Cancer and its Treatment|Comforting your child through the pain of the cancer and its treatment (examples include: procedures, mouth sores, bone pain, etc.)	A question about an individual comforting their child through the pain of the cancer and its treatment.			Intellectual Product	
C159386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159386>	C173890	Take Care of Discipline and/or Behavior Problems of Child with Cancer Question|Take Care of Discipline and/or Behavior Problems of Child with Cancer|Taking care of discipline and/or behavior problems of the child with cancer (crying, irritability, moodiness)	A question about taking care of discipline and/or behavior problems of the child with cancer.			Intellectual Product	
C159387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159387>	C173890	Take Care of Finances, Bills, and Forms Related to Child's Illness Question|Take Care of Finances, Bills, and Forms Related to Child's Illness|Taking care of finances, bills, and forms related to the child's illness	A question about an individual taking care of finances, bills, and forms related to their child's illness.			Intellectual Product	
C159388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159388>	C173890|C173812	Plan Activities for Your Child with Cancer Around Treatment and Illness Question|Plan Activities for Your Child with Cancer Around Treatment and Illness|Planning activities for your child with cancer around the treatment and illness (examples include: school, playtime, rest, things for the child to do, other)	A question about an individual planning activities for their child with cancer around the treatment and illness.			Intellectual Product	
C159389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159389>	C173812|C173151	Plan Activities for Your Family Around Treatment and Illness Question|Plan Activities for Your Family Around Treatment and Illness|Planning activities for your family around the treatment and illness (examples include: recreation, vacation, school functions, other)	A question about an individual planning activities for their family around the treatment and illness of their child with cancer.			Intellectual Product	
C15938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15938>	C15753	Cooperative Family Registry|Family-Based Registry	A comprehensive, collaborative infrastructure, linked to an informatics structure, to help speed the genetic and epidemiologic study of heritable cancers. Twelve participating institutions are located in the United States, Canada, and Australia.			Intellectual Product	
C159390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159390>	C173890	Get Child Care or Babysitting Help for Your Ill Child Question|Get Child Care or Babysitting Help for Your Ill Child|Getting child care/babysitting help for your ill child	A question about an individual getting child care or babysitting help for their ill child.			Intellectual Product	
C159391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159391>	C173890	Get Child Care or Babysitting for Siblings of Ill Child Question|Get Child Care or Babysitting for Siblings of Ill Child|Obtaining child care/babysitting for brothers and sisters of the ill child	A question about an individual getting child care or babysitting for brothers and sisters of the ill child.			Intellectual Product	
C159392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159392>	C176537	Communicate Information About Cancer to Schools, Day Care, Babysitters, Extended Family, and Friends Question|Communicate Information About Cancer to Schools, Day Care, Babysitters, Extended Family, and Friends|Communicating information about cancer to schools, day care, babysitters, extended family and friends	A question about an individual communicating information about cancer to schools, day care, babysitters, extended family, and friends.			Intellectual Product	
C159393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159393>	C173890	Watch for and Report Your Child's Physical Symptoms and Medical Condition to Medical Team Question|Watch for and Report Your Child's Physical Symptoms and Medical Condition to Medical Team|Watching for and reporting your child's physical symptoms and medical condition to the medical team	A question about an individual watching for and reporting their child's physical symptoms and medical condition to the medical team.			Intellectual Product	
C159394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159394>	C176537|C173890	Get Information on Your Child's Illness and Treatment Question|Get Information on Your Child's Illness and Treatment|Getting information on your child's illness and the treatment (examples include: library, medical team, community agencies)	A question about an individual getting information on their child's illness and treatment.			Intellectual Product	
C159395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159395>	C173890	Anything Else You Wish to Tell About Taking Care of Your Child with Cancer Question|Anything Else You Wish to Tell About Taking Care of Your Child with Cancer|Is there anything else that you wish to tell us about taking care of your child with cancer	A question asking an individual to tell about anything else not asked about taking care of their child with cancer.			Intellectual Product	
C159396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159396>	C226662	A Great Deal of Effort|A great deal	A response indicating that something took a great deal of effort.			Intellectual Product	
C159397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159397>	C226662	Quite a lot of Effort|Quite a lot	A response indicating that something took quite a lot of effort.			Intellectual Product	
C159398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159398>	C226662	A Moderate Amount of Effort|Moderate	A response indicating that something took a moderate amount of effort.			Intellectual Product	
C159399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159399>	C226662	A Small Amount of Effort|A small amount	A response indicating that something took only a small amount of effort.			Intellectual Product	
C15939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15939>	C15923	Cancer Chromosome Aberration Project|CCAP|Cancer Chromosome Aberration Project (CCAP)	NCI Initiative to integrate the cytogenetic and physical maps of the human genome, generate a repository of BAC clones arrayed across the genetic and physical map, and to develop a publicly available database displaying this clone repository and providing a platform for correlation with other databases of chromosomal aberrations, as well as clinical and histopathological information.			Research Activity	
C1593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1593>	C1283	Recombinant Chemokine|Chemokines	Formulated therapeutic analogs of one of a number of endogenous small polypeptide cytokines with potential antineoplastic activity. Synthesized by macrophages, endothelial cells, keratinocytes, fibroblasts, and smooth muscle cells, chemokines are released in the presence of infection or physical tissue damage, and act as chemoattractants to recruit macrophages, neutrophils, and T cells from the blood to sites of infection or damage.  These agents may regulate tumor growth by modulating tumor-associated angiogenesis and metastasis and can either promote or retard tumor growth. (NCI04)			Chemical Viewed Functionally	
C159400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159400>	C226662	No Effort|None	A response indicating that something took no effort.			Intellectual Product	
C159401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159401>	C21165	RELT Gene|RELT|RELT|RELT TNF Receptor Gene|TNFRSF19L	This gene may be involved in the regulation of apoptosis.			Gene or Genome	
C159402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159402>	C159401	RELT wt Allele|FLJ14993|RELT TNF Receptor wt Allele|TNF Receptor Superfamily Member 19-Like Gene|TNFRSF19L|TRLT|Tumor Necrosis Factor Receptor Superfamily, Member 19-Like Gene	Human RELT wild-type allele is located in the vicinity of 11q13.2 and is approximately 21 kb in length. This allele, which encodes tumor necrosis factor receptor superfamily member 19L protein, may play a role in apoptotic signaling pathways.			Gene or Genome	
C159403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159403>	C19285	Tumor Necrosis Factor Receptor Superfamily Member 19L|RELT|RELT Tumor Necrosis Factor Receptor|Receptor Expressed In Lymphoid Tissues|TNF Receptor Superfamily Member 19-Like|TNF Receptor Superfamily Member 19L|TNFRSF19L	Tumor necrosis factor receptor superfamily member 19L (430 aa, ~46 kDa) is encoded by the human RELT gene. This protein may be involved in the promotion of apoptotic signaling.			Amino Acid, Peptide, or Protein|Receptor	
C159404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159404>	C21165	TNFRSF19 Gene|TNF Receptor Superfamily Member 19 Gene|TNFRSF19|TNFRSF19	This gene is involved in the activation of the c-Jun N-terminal kinase (JNK) pathway and the mediation of caspase-independent cell death.			Gene or Genome	
C159405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159405>	C159404	TNFRSF19 wt Allele|TAJ|TAJ-Alpha|TNF Receptor Superfamily Member 19 wt Allele|TRADE|TROY|Tumor Necrosis Factor Receptor Superfamily, Member 19|UNQ1888/PRO4333	Human TNFRSF19 wild-type allele is located in the vicinity of 13q12.12 and is approximately 106 kb in length. This allele, which encodes tumor necrosis factor receptor superfamily member 19 protein, plays a role in the mediation of caspase-independent apoptosis and the regulation of the JNK pathway.			Gene or Genome	
C159406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159406>	C19285	Tumor Necrosis Factor Receptor Superfamily Member 19|TNF Receptor Superfamily Member 19|TNFRSF19|TRADE|Toxicity and JNK Inducer	Tumor necrosis factor receptor superfamily member 19 (423 aa, ~46 kDa) is encoded by the human TNFRSF19 gene. This protein is involved in the activation of both the JNK pathway and caspase-independent cell death.			Amino Acid, Peptide, or Protein|Receptor	
C159407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159407>	C163032	Botulinum Toxin E EB-001|BOTULINUM TOXIN TYPE E|BoNT/E EB-001|Botulinum Type E EB-001|EB 001|EB-001|EB001	An injectable formulation containing the bacterial Clostridium botulinum type E neurotoxin, with neuromuscular transmission inhibitory and analgesic activities. Upon injection of botulinum toxin E EB-001 into the muscles of the affected area, the heavy chain portion of botulinum toxin type E binds to the cell membrane of the presynaptic nerve terminal and is internalized via endocytosis. Upon entry into the cytoplasm, the light chain portion of the toxin binds to and cleaves synaptosomal-associated protein 25 (SNAP-25), thereby preventing the fusion of acetylcholine (ACh)-containing synaptic vesicles with the cell membrane and, thus the release of the neurotransmitter ACh into the neuromuscular junction. This prevents the binding of ACh to the motor end-plate nicotinic acid receptors and ACh-mediated muscle contraction. This causes flaccid paralysis and may decrease musculoskeletal pain and may improve wound healing and reduce scar formation due to the absence of muscle contractions. In addition, EB-001 may inhibit the release of neuropeptides, such as substance P and glutamate, which may contribute to its analgesic activity. Compared to other botulinum toxin types, type E has the fastest onset and the shortest duration of action.	Botulinum Toxin E EB-001		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C159408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159408>	C63358	Atezolizumab/Nab-paclitaxel Regimen|Atezolizumab-Nab-paclitaxel|Atezolizumab/Albumin-bound Paclitaxel|Atezolizumab/Nab-paclitaxel|Atezolizumab/Nanoparticle Albumin-bound Paclitaxel|Tecentriq/Abraxane|nab-Paclitaxel and Atezolizumab	A regimen consisting of atezolizumab and nab-paclitaxel that may be used in the treatment of programmed cell death 1 ligand 1 (PD-L1)-positive triple-negative breast cancer (TNBC).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C159409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159409>	C48621	Margin Uninvolved by Invasive Melanoma|Margins uninvolved by invasive melanoma	A result that the margin is uninvolved by invasive melanoma.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C15940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15940>	C19498	Genetic Annotation Index	A listing of genetic variations in genes important to cancer			Intellectual Product	
C159410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159410>	C129824	EBNA-1 inhibitor VK-2019|Epstein-Barr Nuclear Antigen 1 Inhibitor VK-2019|VK 2019|VK-2019|VK-2019|VK2019	An orally available, small molecule inhibitor of Epstein-Barr nuclear antigen 1 (EBNA-1) with potential antineoplastic activity. Upon administration, EBNA-1 inhibitor VK-2019 binds to EBNA-1 and inhibits EBNA-1 DNA binding activity. This disrupts the replication, maintenance and segregation of the Epstein-Barr virus (EBV) genome, which may lead to tumor cell death in EBV-associated malignancies. EBNA1, a sequence-specific DNA binding protein, plays an important role in EBV episomal genome maintenance and gene transactivation.	EBNA-1 inhibitor VK-2019		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C159411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159411>	C129822|C128058	Anti-GITR Agonistic Monoclonal Antibody ASP1951|ASP 1951|ASP-1951|ASP-1951|ASP1951|Anti-GITR Agonistic Monoclonal Antibody PTZ-522|PTZ 522|PTZ-522|PTZ522	A human, high-affinity, tetravalent monospecific agonistic monoclonal antibody targeting glucocorticoid-induced tumor necrosis factor receptor (GITR; tumor necrosis factor superfamily member 18; TNFRSF18; CD357), with potential immune checkpoint modulating activity. Upon administration, anti-GITR agonistic monoclonal antibody ASP1951 binds to and activates GITR, which is expressed on the cell surface of multiple types of T-lymphocytes. This induces both the activation and proliferation of tumor antigen-specific T-effector cells (Teffs), and suppresses the function of activated T-regulatory cells (Tregs), which may promote the elimination of tumor cells. GITR, a member of the TNF receptor superfamily and T-cell receptor co-stimulator, is expressed on the surface of multiple immune cell types, including Tregs, Teffs, B-cells, and natural killer (NK) cells. Inappropriately activated Tregs suppress both Teffs and T-cell receptor (TCR) signaling.	Anti-GITR Agonistic Monoclonal Antibody ASP1951		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C159412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159412>	C156953	CPTAC Surgery-Anesthesia Form				Intellectual Product	
C159413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159413>	C156953	CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form				Intellectual Product	
C159414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159414>	C156953	CPTAC Sarcoma Baseline Form				Intellectual Product	
C159415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159415>	C156953	CPTAC Melanoma Baseline Form				Intellectual Product	
C159416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159416>	C156953	CPTAC Pancreatic Baseline Form				Intellectual Product	
C159417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159417>	C156953	CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form				Intellectual Product	
C159418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159418>	C156953	CPTAC Clear Cell Renal Cell Carcinoma Baseline Form				Intellectual Product	
C159419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159419>	C156953	CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form				Intellectual Product	
C15941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15941>	C16199	Interdisciplinary Studies in the Genetic Epidemiology of Cancer	Collaborative and interdisciplinary genetic epidemiology investigations designed to identify and evaluate the interactions of genetic and epidemiologic risk factors leading to cancer susceptibility in individuals, families and populations, and factors influencing the rate of increase with age in cancer susceptibility. Emphasis on multi-site, cooperative research by multi- disciplinary teams of investigators wishing to collaborate within the common theme of the genetic epidemiology of cancer.  Particular emphasis is placed on encouraging interdisciplinary, population-based research focusing on the etiologic mechanisms underlying the interaction of genetic and epidemiologic risk factors for cancer susceptibility. The effect on cancer susceptibility of age-related changes over the lifespan, and the genetic factors leading to older age at onset of cancer are also of interest.			Research Activity	
C159420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159420>	C156953	CPTAC Glioblastoma Multiforme Baseline Form				Intellectual Product	
C159421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159421>	C92172	EGFR NM_005228.3:c.323G>A|EGFR c.323G>A|ERBB c.323G>A|ERBB1 c.323G>A|Epidermal Growth Factor Receptor Gene c.323G>A|HER1 c.323G>A|NM_005228.3:c.323G>A	A nucleotide substitution at position 323 of the coding sequence of the EGFR gene where guanine has been mutated to adenine.	EGFR NM_005228.3:c.323G>A		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159422>	C98356	EGFR NP_005219.2:p.R108K|Activating R108K Mutation|EGFR Arg108Lys|EGFR NP_005219.2:p.Arg108Lys|EGFR R108K|EGFR R108K Mutation|EGFR p.Arg108Lys|EGFR p.R108K|Epidermal Growth Factor Receptor Arg108Lys|Epidermal Growth Factor Receptor R108K|NP_005219.2:p.Arg108Lys|NP_005219.2:p.R108K|Proto-Oncogene c-ErbB-1 Arg108Lys|Proto-Oncogene c-ErbB-1 R108K|Receptor Tyrosine-Protein Kinase erbB-1 Arg108Lys|Receptor Tyrosine-Protein Kinase erbB-1 R108K	A change in the amino acid residue at position 108 in the epidermal growth factor receptor protein where arginine has been replaced by lysine.	EGFR NP_005219.2:p.R108K		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159423>	C98357	EGFR NM_005228.3:c.787A>C|EGFR c.787A>C|ERBB c.787A>C|ERBB1 c.787A>C|Epidermal Growth Factor Receptor Gene c.787A>C|HER1 c.787A>C|NM_005228.3:c.787A>C	A nucleotide substitution at position 787 of the coding sequence of the EGFR gene where adenine has been mutated to cytosine.	EGFR NM_005228.3:c.787A>C		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159424>	C98356	EGFR NP_005219.2:p.T263P|EGFR NP_005219.2:p.Thr263Pro|EGFR T263P|EGFR T263P Mutation|EGFR Thr263Pro|EGFR p.T263P|EGFR p.Thr263Pro|Epidermal Growth Factor Receptor T263P|Epidermal Growth Factor Receptor Thr263Pro|NP_005219.2:p.T263P|NP_005219.2:p.Thr263Pro|Proto-Oncogene c-ErbB-1 T263P|Proto-Oncogene c-ErbB-1 Thr263Pro|Receptor Tyrosine-Protein Kinase erbB-1 T263P|Receptor Tyrosine-Protein Kinase erbB-1 Thr263Pro	A change in the amino acid residue at position 263 in the epidermal growth factor receptor protein where threonine has been replaced by proline.	EGFR NP_005219.2:p.T263P		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159425>	C16830	Photodynamic Bone Stabilization System|PBSS	A system for the repair of bone fractures comprised of a PET or Dacron balloon mounted on an insertion catheter. The balloon catheter is delivered through a small pathway into the intramedullary canal transiting the fracture site and is then infused with a biocompatible monomer, causing it to expand, fill, and conform to the patient's intramedullary canal. The monomer infused balloon is activated to cure by visible light. The cured implant provides both longitudinal strength and rotational stability to allow for fracture repair and stabilization.	Photodynamic Bone Stabilization System		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C159426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159426>	C98357	EGFR NM_005228.3:c.866C>T|EGFR c.866C>T|ERBB c.866C>T|ERBB1 c.866C>T|Epidermal Growth Factor Receptor Gene c.866C>T|HER1 c.866C>T|NM_005228.3:c.866C>T	A nucleotide substitution at position 866 of the coding sequence of the EGFR gene where cytosine has been mutated to thymine.	EGFR NM_005228.3:c.866C>T		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159427>	C98356	EGFR NP_005219.2:p.A289V|Activating A289V Mutation|EGFR A289V|EGFR A289V Mutation|EGFR Ala289Val|EGFR NP_005219.2:p.Ala289Val|EGFR p.A289V|EGFR p.Ala289Val|Epidermal Growth Factor Receptor A289V|Epidermal Growth Factor Receptor Ala289Val|NP_005219.2:p.A289V|NP_005219.2:p.Ala289Val|Proto-Oncogene c-ErbB-1 A289V|Proto-Oncogene c-ErbB-1 Ala289Val|Receptor Tyrosine-Protein Kinase erbB-1 A289V|Receptor Tyrosine-Protein Kinase erbB-1 Ala289Val	A change in the amino acid residue at position 289 in the epidermal growth factor receptor protein where alanine has been replaced by valine.	EGFR NP_005219.2:p.A289V		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159428>	C98357	EGFR NM_005228.3:c.866C>A|EGFR c.866C>A|ERBB c.866C>A|ERBB1 c.866C>A|Epidermal Growth Factor Receptor Gene c.866C>A|HER1 c.866C>A|NM_005228.3:c.866C>A	A nucleotide substitution at position 866 of the coding sequence of the EGFR gene where cytosine has been mutated to adenine.	EGFR NM_005228.3:c.866C>A		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159429>	C98356	EGFR NP_005219.2:p.A289D|EGFR A289D|EGFR A289D Mutation|EGFR Ala289Asp|EGFR NP_005219.2:p.Ala289Asp|EGFR p.A289D|EGFR p.Ala289Asp|Epidermal Growth Factor Receptor A289D|Epidermal Growth Factor Receptor Ala289Asp|NP_005219.2:p.A289D|NP_005219.2:p.Ala289Asp|Proto-Oncogene c-ErbB-1 A289D|Proto-Oncogene c-ErbB-1 Ala289Asp|Receptor Tyrosine-Protein Kinase erbB-1 A289D|Receptor Tyrosine-Protein Kinase erbB-1 Ala289Asp	A change in the amino acid residue at position 289 in the epidermal growth factor receptor protein where alanine has been replaced by aspartic acid.	EGFR NP_005219.2:p.A289D		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15942>	C16199|C15769	Basic Behavioral Studies in Cancer-Related Behaviors	Basic behavioral studies designed to strengthen the understanding of the determinants and processes that influence cancer-related risk behaviors.			Research Activity	
C159430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159430>	C92172	EGFR NM_005228.3:c.865G>A|EGFR c.865G>A|ERBB c.865G>A|ERBB1 c.865G>A|Epidermal Growth Factor Receptor Gene c.865G>A|HER1 c.865G>A|NM_005228.3:c.865G>A	A nucleotide substitution at position 865 of the coding sequence of the EGFR gene where guanine has been mutated to adenine.	EGFR NM_005228.3:c.865G>A		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159431>	C98356	EGFR NP_005219.2:p.A289T|Activating A289T Mutation|EGFR A289T|EGFR A289T Mutation|EGFR Ala289Thr|EGFR NP_005219.2:p.Ala289Thr|EGFR p.A289T|EGFR p.Ala289Thr|Epidermal Growth Factor Receptor A289T|Epidermal Growth Factor Receptor Ala289Thr|NP_005219.2:p.A289T|NP_005219.2:p.Ala289Thr|Proto-Oncogene c-ErbB-1 A289T|Proto-Oncogene c-ErbB-1 Ala289Thr|Receptor Tyrosine-Protein Kinase erbB-1 A289T|Receptor Tyrosine-Protein Kinase erbB-1 Ala289Thr	A change in the amino acid residue at position 289 in the epidermal growth factor receptor protein where alanine has been replaced by threonine.	EGFR NP_005219.2:p.A289T		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159432>	C92172	EGFR NM_005228.3:c.1793G>T|EGFR c.1793G>T|ERBB c.1793G>T|ERBB1 c.1793G>T|Epidermal Growth Factor Receptor Gene c.1793G>T|HER1 c.1793G>T|NM_005228.3:c.1793G>T	A nucleotide substitution at position 1793 of the coding sequence of the EGFR gene where guanine has been mutated to thymine.	EGFR NM_005228.3:c.1793G>T		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159433>	C98356	EGFR NP_005219.2:p.G598V|Activating G598V Mutation|EGFR G598V|EGFR G598V Mutation|EGFR Gly598Val|EGFR NP_005219.2:p.Gly598Val|EGFR p.G598V|EGFR p.Gly598Val|Epidermal Growth Factor Receptor G598V|Epidermal Growth Factor Receptor Gly598Val|NP_005219.2:p.G598V|NP_005219.2:p.Gly598Val|Proto-Oncogene c-ErbB-1 G598V|Proto-Oncogene c-ErbB-1 Gly598Val|Receptor Tyrosine-Protein Kinase erbB-1 G598V|Receptor Tyrosine-Protein Kinase erbB-1 Gly598Val	A change in the amino acid residue at position 598 in the epidermal growth factor receptor protein where glycine has been replaced by valine.	EGFR NP_005219.2:p.G598V		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159434>	C128663	EGFR Exon 20 Deletion Mutation|EGFR Exon 20 Gene Deletion Mutation|ERBB Exon 20 Deletion Mutation|ERBB1 Exon 20 Deletion Mutation|Epidermal Growth Factor Receptor Gene Exon 20 Deletion Mutation|HER1 Exon 20 Deletion Mutation	A molecular genetic abnormality indicating the presence of an in-frame deletion mutation occurring within exon 20 of the EGFR gene.	EGFR Exon 20 Deletion Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159435>	C62634	Regimen Used to Treat Malignant Thymus Neoplasm|Chemo(immuno)therapy Regimen Used to Treat Thymoma and Thymic Carcinoma	Any regimen that can be used for the treatment of malignant thymus neoplasms.			Therapeutic or Preventive Procedure	
C159436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159436>	C63467	Dose-dense MVAC-Growth Factor Regimen|Accelerated MVAC with GF|Accelerated MVAC with Growth Factor|DDMVAC Regimen with Growth Factor|DDMVAC plus Growth Factor|DDMVAC with GF|DDMVAC with Growth Factor|DDMVAC-GF|DDMVAC/GF|Dose-dense MVAC with Growth Factor|Dose-dense Methotrexate/Vinblastine/Doxorubicin/Cisplatin with Growth Factor|MVAC, dose-dense	A regimen consisting of methotrexate, vinblastine, doxorubicin, cisplatin (DDMVAC) and the addition of a selected growth factor to support the (neo)adjuvant treatment of bladder cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C159437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159437>	C51646	Nephroureterectomy with Cuff of Bladder	Surgical resection of the kidney, renal pelvis, ureter, and bladder cuff.			Therapeutic or Preventive Procedure	
C159438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159438>	C1967|C129825	RET Inhibitor|Rearranged During Transfection Inhibitor|Rearranged During Transfection Kinase Inhibitor|c-RET Inhibitor	Any agent that inhibits the receptor tyrosine kinase rearranged during transfection (RET).			Chemical Viewed Functionally	
C159439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159439>	C203470	Regimen Used to Treat Malignant Anal Neoplasm	Any regimen that can be used for the treatment of malignant anal neoplasms.			Therapeutic or Preventive Procedure	
C15943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15943>	C49057	Directory of Cancer Genetics Providers				Intellectual Product	
C159440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159440>	C62634	Regimen Used to Treat Bone Cancer	Any regimen that can be used for the treatment of bone cancer.			Therapeutic or Preventive Procedure	
C159441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159441>	C186720|C173974|C159872	Regimen Used to Treat Chronic Myeloid Leukemia|Chemo(immuno)therapy Regimen Used to Treat CML|Chemo(immuno)therapy Regimen Used to Treat Chronic Myelogenous Leukemia	Any regimen that can be used for the treatment of chronic myeloid leukemia (CML).			Therapeutic or Preventive Procedure	
C159442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159442>	C15189	Biopsy Mapping	A method in which multiple biopsies are taken from specified locations to determine the boundaries and extent of a lesion or disease.			Diagnostic Procedure	
C159443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159443>	C62634	Regimen Used to Treat Merkel Cell Carcinoma	Any regimen that can be used for the treatment of Merkel cell carcinoma.			Therapeutic or Preventive Procedure	
C159444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159444>	C64983	Ilioinguinal Lymphadenectomy	Surgical removal of the inguinal, iliac, and obturator lymph nodes.			Diagnostic Procedure	
C159445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159445>	C159872	Regimen Used to Treat Myelodysplastic Syndromes|Chemo(immuno)therapy Regimen Used to Treat MDS	Any regimen that can be used for the treatment of myelodysplastic syndromes (MDS).			Therapeutic or Preventive Procedure	
C159446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159446>	C159447	Distal Urethrectomy	Surgical removal of part or all of the urethra.			Therapeutic or Preventive Procedure	
C159447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159447>	C15333	Urethrectomy	Surgical removal of part or all of the urethra.			Therapeutic or Preventive Procedure	
C159448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159448>	C62634	Regimen Used to Treat Penile Cancer	Any regimen that can be used for the treatment of penile cancer.			Therapeutic or Preventive Procedure	
C159449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159449>	C63510|C213158	Regimen Used to Treat Kaposi Sarcoma|Chemo(immuno)therapy Regimen Used to Treat KS	Any regimen that can be used for the treatment of Kaposi sarcoma.			Therapeutic or Preventive Procedure	
C15944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15944>	C15923	Mouse Cancer Genome Anatomy Project|Mouse CGAP	Similar to the human CGAP. The overall goals of the m-CGAP are: a comparative assessment of mouse cancer stages with those of cognate human cancers, both to validate the mouse models and to promote crossfeeding in the identification of genes that characterize those cancers; the discovery of new genes and gene pathways involved in the stages of carcinogenesis.			Research Activity	
C159450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159450>	C51621	Partial Penectomy	Surgical removal of part of the penis.			Therapeutic or Preventive Procedure	
C159451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159451>	C51621	Total Penectomy	Surgical removal of the entire penis.			Therapeutic or Preventive Procedure	
C159452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159452>	C2950	Chromosome 5 Abnormality|-5, del(5q) or t(5q)|Aberrant Chromosome 5|Chromosome 5 Aberration	A cytogenetic abnormality that refers to any structural irregularity in chromosome 5.			Cell or Molecular Dysfunction	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C159453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159453>	C16546|C158758	Endoscopic Resection	Surgical resection using endoscopy.			Therapeutic or Preventive Procedure	
C159454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159454>	C203470	Regimen Used to Treat Hepatobiliary Cancer	Any regimen that can be used for the treatment of hepatobiliary cancer.			Therapeutic or Preventive Procedure	
C159455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159455>	C2950	Chromosome 7 Abnormality|-7, del(7q) or t(7q)|Aberrant Chromosome 7|Chromosome 7 Aberration	A cytogenetic abnormality that refers to any structural irregularity in chromosome 7.	Chromosome 7 Abnormality		Cell or Molecular Dysfunction	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159456>	C78296	Light Chain Fanconi Syndrome	Fanconi syndrome that is caused by light chain deposition resulting in a proximal tubulopathy.			Disease or Syndrome	
C159457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159457>	C62634	Regimen Used to Treat Vulvar Cancer	Any regimen that can be used for the treatment of vulvar cancer.			Therapeutic or Preventive Procedure	
C159458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159458>	C63587	Regimen Used to Treat Thyroid Cancer|Regimen Used to Treat Thyroid Carcinoma	Any regimen that can be used for the treatment of thyroid cancer.			Therapeutic or Preventive Procedure	
C159459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159459>	C186720	Regimen Used to Treat Mastocytosis	Any regimen that can be used for the treatment of mastocytosis.			Therapeutic or Preventive Procedure	
C15945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15945>	C52647	Small Animal Imaging Resource Programs|SAIRP|Small Animal Imaging Resource Programs (SAIRPs)	A program to improve access to researchers testing new approaches to diagnosis, treatment and prevention in animal models of cancer.  Focus will be on functional, quantitative imaging.  (Bypass Budget)			Research Activity	
C159460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159460>	C186719	Regimen Used to Treat Plasma Cell Neoplasm	Any regimen that can be used for the treatment of plasma cell neoplasms.			Therapeutic or Preventive Procedure	
C159461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159461>	C159460	Regimen Used to Treat Primary Amyloidosis	Any regimen that can be used for the treatment of primary amyloidosis.			Therapeutic or Preventive Procedure	
C159462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159462>	C62634	Regimen Used to Treat Malignant Soft Tissue Neoplasm	Any regimen that can be used for the treatment of malignant soft tissue neoplasms.			Therapeutic or Preventive Procedure	
C159463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159463>	C176244	Partly Agree|Partially Agree	A response indicating that an individual is in partial agreement with something.			Intellectual Product	
C159464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159464>	C226653	Partly Disagree|Partially Disagree	A response indicating that an individual is in partial disagreement with something.			Intellectual Product	
C159465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159465>	C42076	Carcinoma Exhibiting Undifferentiated or Dedifferentiated Features|Undifferentiated or dedifferentiated carcinoma	A microscopic finding that refers to a carcinoma which is composed either exclusively of an undifferentiated cellular infiltrate, or a mixture of well differentiated and undifferentiated cellular infiltrates.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C159466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159466>	C226650	Occasional Urinary Incontinence|Occasional Urinary Accident|occasional accident	A response indicating that an individual has an occasional accident related to urinary incontinence.			Intellectual Product	
C159467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159467>	C226778	Occasional Fecal Incontinence|Occasional Fecal Accident|occasional accident	A response indicating that an individual has an occasional accident related to fecal incontinence.			Intellectual Product	
C159468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159468>	C226573	Immobile or Less Than 50 Yards|immobile or less than 50 yards	A response indicating that an individual is immobile or can move less than 50 yards.			Intellectual Product	
C159469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159469>	C226576	Wheelchair Independent, Greater Than 50 Yards|wheelchair independent, including corners, greater than 50 yards	A response indicating that an individual is independent with use of a wheelchair, including corners, and can move more than 50 yards.			Intellectual Product	
C15946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15946>	C20021	Development and Application of Imaging in Therapeutic Studies	This initiative will encourage applications that apply imaging technologies in the assessment of investigational cancer therapeutic agents. The proposed research projects will focus on the development and application of non-invasive tools for the functional or quantitative assessment of biochemical, genetic, or pharmacologic activity of specific therapeutic agents, or the defined biochemical pathway(s) in which they act. (from an RFA description)			Research Activity	
C159470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159470>	C226575|C178389	Walks with Help of One Person, Greater Than 50 Yards|walks with help of one person (verbal or physical) greater than 50 yards	A response indicating that an individual can walk with verbal or physical help of one person and can move more than 50 yards.			Intellectual Product	
C159471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159471>	C226701	Mobility Independent But May Use Any Aid, Greater Than 50 Yards|independent (but may use any aid; for example, stick) greater than 50 yards	A response indicating that an individual is independently mobile but may use any aid and can move more than 50 yards.			Intellectual Product	
C159472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159472>	C159476	Normal Immune Presence|Normal	Less than 10 percent of the tissue surface area is occupied by immune cell infiltration.			Finding	
C159473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159473>	C159476	Mild Immune Presence|Mild immune presence	Approximately 10-20 percent of the tissue surface area is occupied by immune cell infiltration.			Finding	
C159474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159474>	C159476	Moderate Immune Presence|Moderate immune presence	Greater than 20-50 percent of the tissue surface area is occupied by immune cell infiltration.			Finding	
C159475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159475>	C159476	Severe Immune Presence|Severe immune presence	Greater than 50 percent of the tissue surface area is occupied by immune cell infiltration.			Finding	
C159476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159476>	C35867	Immune Presence	Describes the percent of a tissue's surface area occupied by immune cell infiltration.			Finding	
C159477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159477>	C48570	Percent of Positive Nuclei|Percent Biomarker Positive Nuclei|Percent Positive Nuclei|Percentage of Positive Nuclei|Percentage of positive nuclei	A quantitative measurement of the percent of nuclei that are positive for a biomarker of interest compared to the total number of nuclei in a sample.			Quantitative Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C159478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159478>	C48570	Percent of Granulocytes|Percent Granulocytes|percent granulocyte infiltration|percent_granulocyte_infiltration	A quantitative measurement of the percent of granulocytes compared to the number of total cells present in a sample.			Quantitative Concept	GDC Property Terminology|GDC Terminology
C159479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159479>	C48570	Percent Inflammatory Marker Positive|Percent Inflammation|percent inflam infiltration|percent_inflam_infiltration	A quantitative measurement of the percent of a sample that is positive for inflammatory markers, including the presence of capillary dilatation, edema and increased leukocytes.			Quantitative Concept	GDC Property Terminology|GDC Terminology
C15947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15947>	C19975	Cooperative Trial in Diagnostic Imaging	A single national Network of investigators that will perform multi-institutional clinical trials in diagnostic imaging related to cancer. The Network will have the capability to conduct a broad spectrum of clinical trials in imaging. This Network will generate new trials in areas of high scientific opportunity.  The Network will consist of a Headquarters office that coordinates operations, a Biostatistics and Data Management Center (BDMC), and a number of participating institutions in which the studies are performed.  Participating institutions will be selected by the Network's scientific leadership for their ability to contribute to the particular trials in the Network's research repertoire.			Research Activity	
C159480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159480>	C48570	Percent of Monocytes|Percent Monocytes|percent monocyte infiltration|percent_monocyte_infiltration	A quantitative measurement of the percent of monocytes compared to the number of total cells present in a sample.			Quantitative Concept	GDC Property Terminology|GDC Terminology
C159481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159481>	C48570	Percent of Necrosis|% Necrosis|NECROSIS_PCT|NECROSIS_PCT|Percent Necrosis|necrosis percent|necrosis_percent|percent necrosis|percent_necrosis	A quantitative measurement of the percent of cells undergoing necrosis compared to the number of total cells present in a sample.			Quantitative Concept	EWS Subject Response Table|EWS Variable Terminology|GDC Property Terminology|GDC Terminology|OS Subject Response Table|OS Variable Terminology
C159482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159482>	C48570	Percent of Neutrophils|Percent Neutrophils|percent neutrophil infiltration|percent_neutrophil_infiltration	A quantitative measurement of the percent of neutrophils compared to the number of total cells present in a sample.			Quantitative Concept	GDC Property Terminology|GDC Terminology
C159483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159483>	C48570	Percent of Stromal Cells|Percent Stromal Cells|percent stromal cells|percent_stromal_cells	A quantitative measurement of the percent of stromal cells compared to the number of total cells present in a sample.			Quantitative Concept	GDC Property Terminology|GDC Terminology
C159484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159484>	C48570	Percent of Tumor Cells|Percent Tumor Cells|percent tumor cells|percent_tumor_cells	A quantitative measurement of the percent of tumor cells compared to the number of total cells present in a sample.			Quantitative Concept	GDC Property Terminology|GDC Terminology
C159485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159485>	C165615|C159477	Percent of Tumor Marker Positive Nuclei|Percent Tumor Nuclei	A quantitative measurement of the percent of nuclei that are positive for a nuclear tumor marker compared to the total number of nuclei in a sample.			Quantitative Concept	
C159486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159486>	C179251	Borderline Ovarian Endometrioid Tumor/Atypical Proliferative Ovarian Endometrioid Tumor with Microinvasion	A low grade ovarian epithelial neoplasm characterized by the presence of glandular or cystic spaces which contain atypical glandular epithelial cells resembling endometrial cells. Microinvasion of the ovarian stroma is present.			Neoplastic Process	
C159487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159487>	C15680	Core Biopsy of Bone|Bone Marrow Core Biopsy	The removal of  bone marrow tissue using a needle with a relatively large diameter, for microscopic examination.			Diagnostic Procedure	
C159488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159488>	C18202|C164009	Bone Marrow Core Biopsy Sample|BONE MARROW, CORE	A specimen of bone marrow tissue obtained by using a relatively large diameter needle designed to acquire a core specimen.			Tissue	CDISC SDTM Specimen Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C159489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159489>	C79688|C28197	Michelia alba Leaf Oil|MA Leaf Oil|MICHELIA ALBA LEAF OIL	A steam distilled essential oil composed of the oil from the leaves of the Michelia alba (MA) plant belonging to the Magnolia family, with potential anti-anxiety activity. Upon administration of drops of the MA leaf oil on the inside of an oxygen face mask, the aroma from the leaf oil, containing high amounts of the terpene alcohol component linalool, may improve anxiety and may help sedate, relax and soothe the patient.	Michelia alba Leaf Oil		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C15948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15948>	C20021	Development and Testing of Digital Mammography Displays and Workstations	This initiative is intended to advance the state-of-the-art in digital mammography displays and workstation design to facilitate clinical acceptance and implementation of digital mammography for improved breast cancer diagnosis. This PA will solicit research and development in three critical areas in digital mammography: 1) Softcopy Display Hardware; 2) Workstation Software and Design; and 3) Image Perception.			Research Activity	
C159490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159490>	C217121	Negativity Scale|Negativity Scale Score	Uses the "N" items that received a score of 3. It indicates the degree to which the respondent answers selected questions in an unusually negative manner.			Quantitative Concept	Behavior Rating Inventory of Executive Function
C159491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159491>	C217121	Inconsistency Scale|Inconsistency Scale Score	Uses the 10 item pairs. For each pair the absolute value of the difference for the items is summed to get the Inconsistency Scale score.			Quantitative Concept	Behavior Rating Inventory of Executive Function
C159492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159492>	C217121	Infrequency Scale|Infrequency Scale Score	Measures the extent to which the respondent endorsed items in an atypical fashion. This consists of three items where marking Sometimes or Often to any of the items is highly unusual, even for adolescents with severe cognitive impairment.			Quantitative Concept	Behavior Rating Inventory of Executive Function
C159493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159493>	C25493	Highly Elevated	An indication that something is highly raised or increased above normal levels or limits.			Qualitative Concept	Behavior Rating Inventory of Executive Function
C159494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159494>	C27993	Inconsistent	Not in agreement.			Qualitative Concept	Behavior Rating Inventory of Executive Function
C159495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159495>	C201516	Vobramitamab Duocarmazine|Anti-B7H3 ADC|Anti-B7H3 Antibody-drug Conjugate MGC018|MG-C018|MGC 018|MGC018|VOBRAMITAMAB DUOCARMAZINE	An antibody-drug conjugate (ADC) comprised of vobamitamab, an anti-B7-homolog 3 (B7-H3, CD276) humanized immunoglobulin G1 (IgG1)/kappa monoclonal antibody, conjugated to the cleavable linker-duocarmycin payload duocarmazine (valine-citrulline-seco duocarmycin hydroxybenzamide azaindole; vc-seco-DUBA), with potential antineoplastic activity. Upon administration of vobramitamab duocarmazine, vobramitamab specifically targets and binds to the cell surface antigen B7-H3, leading to internalization of the ADC by B7-H3-expressing tumor cells. The vc linker is cleaved inside the tumor cell by proteases, thereby releasing the duocarmycin payload. Duocarmycin binds to the minor groove of DNA, alkylates adenine at the N3 position, and induces cell death. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells but is minimally expressed by normal human tissues. B7-H3 is a negative regulator of T-cell activation and its overexpression plays a key role in immuno-evasion, tumor cell invasion and metastasis, and its expression is correlated with poor prognosis.	Vobramitamab Duocarmazine		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C159496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159496>	C1946|C129825	HDAC8 Inhibitor NBM-BMX|BMX|HDAC8i NBM-BMX|NBM BMX|NBM-BMX|NBM-T-BMX-OS 01|NBM-T-L-BMX-OS01|NBMBMX	An orally bioavailable inhibitor of histone deacetylase (HDAC) type 8 (HDAC8; HDAC-8), with potential antineoplastic activity. Upon administration, NBM-BMX targets and inhibits the activity of HDAC8. This results in an accumulation of highly acetylated chromatin histones, chromatin remodeling, and selective transcription of tumor suppressor genes, ultimately promoting cell-cycle arrest and induction of tumor cell apoptosis. HDAC8, a class 1 histone deacetylase, plays a key role in transcriptional regulation and cell cycle progression. Aberrant expression of HDAC8 or deregulated interactions with transcription factors may contribute to tumorigenesis. Isotype-selective HDAC inhibitors may be associated with fewer adverse effects compared to pan-HDAC inhibitors.	HDAC8 Inhibitor NBM-BMX		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C159497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159497>	C129821	Alpha-lactalbumin-derived Synthetic Peptide-lipid Complex Alpha1H|Alpha 1H|Alpha-1H|Alpha-lactalbumin-derived Synthetic Proteolipid Complex Alpha1H|Alpha1H	A synthetic proteolipid complex comprised of the alpha-1 domain of alpha-lactalbumin (lactose synthase B protein) and oleic acid, with potential antineoplastic activity. Upon intravesical instillation, alpha1H selectively accumulates in the nuclei of tumor cells and binds to histones H3, H4, and H2B. By binding to histones, alpha1H disrupts chromatin assembly and interferes with intact chromatin, thereby preventing tumor cell transcription and replication. Additionally, alpha1H inhibits the phosphorylation of multiple kinases involved in cancer-associated pathways including the Ras/Raf/ERK, PI3K/AKT, p38 MAPK and JNK signaling pathways. This may inhibit tumor cell proliferation and induce apoptosis in tumor cells that are driven by the dysregulation of certain kinases and oncogenic GTPases.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C159499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159499>	C2201|C2152	PI3K/mTOR Kinase Inhibitor WXFL10030390|PI3K/mTOR Kinase Inhibitor WX390|WX 390|WX-390|WX390|WXFL 10030390|WXFL-10030390|WXFL10030390	An orally bioavailable, small molecule inhibitor of certain phosphoinositide 3-kinase (PI3K) isoforms and mammalian target of rapamycin kinase (mTOR) in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Upon oral administration, PI3K/mTOR inhibitor WXFL10030390 (WX390) inhibits mTOR kinase and certain PI3K isoforms. Consequently, this disrupts phosphorylation of substrates downstream of PI3K and mTOR and may result in apoptosis and growth inhibition in susceptible tumor cells. The PI3K/mTOR pathway is upregulated in a variety of tumor cells and plays a key role in promoting cancer cell proliferation, and survival, motility and resistance to chemotherapy and radiotherapy. mTOR, a serine/threonine kinase downstream of PI3K, may also be activated in a PI3K-independent fashion; therefore, this agent may be more potent than an agent that inhibits either PI3K or mTOR alone.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15949>	C15426	Human Tumor Gene Index|CGAP/TGI|Tumor Gene Index	Catalog of genes expressed in cells at various stages of tumor development.  hGTI is part of CGAP. (Bypass Budget)			Intellectual Product	
C1594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1594>	C259|C2115|C1968	Anthracycline Antineoplastic Antibiotic|Anthracyclines|Chemotherapy, Cancer, Anthracyclines|anthracycline	An antineoplastic antibiotic that is structurally similar to the benzoquinone ansamycin antibiotic geldanamycin. A geldanamycin analogue binds to HSP90, a chaperone protein that aids in the assembly, maturation, and folding of proteins. Subsequently, the function of HSP90 is inhibited, leading to the degradation and depletion of client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction.	Anthracycline Antineoplastic Antibiotic		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C159500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159500>	C177298	Misetionamide|GP 2250|GP-2250|GP2250|MISETIONAMIDE|Taurultam Analogue GP-2250	An oxathiazine-based structural analogue of taurultam (TRLT), which is the main derivative of the anti-infective agent taurolidine (TRD), with potential antineoplastic activity. Upon administration,misetionamide selectively induces reactive oxygen species (ROS)-mediated apoptosis in and inhibits proliferation of susceptible tumor cells.	Misetionamide		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C159501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159501>	C54443	BRIDG Terminology|Biomedical Research Integrated Domain Group Model Terminology				Intellectual Product	
C159502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159502>	C159501	BRIDG Attribute Terminology				Intellectual Product	
C159503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159503>	C159501	BRIDG Class Terminology				Intellectual Product	
C159504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159504>	C159501	BRIDG Class and Attribute Terminology				Intellectual Product	
C159505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159505>	C159501	BRIDG Data Type Terminology				Intellectual Product	
C159506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159506>	C159501	BRIDG Sub-Domain Terminology				Intellectual Product	
C159507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159507>	C3538|C34448	Primary Peritoneal Carcinosarcoma|Primary Peritoneal Malignant Mixed Mesodermal (Mullerian) Tumor	An extremely rare and highly aggressive malignant neoplasm arising from the peritoneum.  Morphologically, it is a high grade tumor, composed of carcinomatous and sarcomatous elements.	Primary Peritoneal Carcinosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C159508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159508>	C20103	STAB1 Gene|STAB1|STAB1|Stabilin 1 Gene	This gene is involved in acetylated low density lipoprotein binding and signal transduction.	STAB1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C159509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159509>	C159508	STAB1 wt Allele|CLEVER-1|FEEL-1|FEEL1|FELE-1|FEX1|KIAA0246|SCARH2|STAB-1|Stabilin 1 wt Allele	Human STAB1 wild-type allele is located in the vicinity of 3p21.1 and is approximately 29 kb in length. This allele, which encodes stabilin-1 protein, plays a role in cell-cell signaling and binding to both bacteria and acetylated low density lipoprotein particles.	STAB1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15950>	C15896	Advanced Technology Center	The concept of the Center was to have a facility whereby individuals (geneticists, cell biologists, and laboratory-based clinicians) could assemble in an arena to review technologies that are mature enough to span both science and clinics. One section of the ATC is the genome's National Institutes Sequencing Center (NISC) where the NCI sequencing and genotyping group will be located, and another part is the array facility.			Organization	
C159510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159510>	C18106	Stabilin-1|CLEVER-1|Common Lymphatic Endothelial and Vascular Endothelial Receptor-1|FEEL-1|Fasciclin EGF-Like, Laminin-Type EGF-Like, and Link Domain-Containing Scavenger Receptor 1|Fasciclin EGF-Like, Laminin-Type EGF-Like, and Link Domain-Containing Scavenger Receptor-1|Fasciclin, EGF-Like, Laminin-Type EGF-Like and Link Domain-Containing Scavenger Receptor 1|MS-1 Antigen|STAB-1|STAB1|Stabilin 1	Stabilin-1 (2570 aa, ~275 kDa) is encoded by the human STAB1 gene. This protein is involved in signal transduction mediated by acetylated low density lipoprotein binding.	Stabilin-1		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159511>	C16529	Education Type	An indication of the type of schooling an individual receives or received.			Educational Activity	
C159512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159512>	C159511	Traditional Education|Conventional Education|Conventional Schooling|Traditional|Traditional Classroom|Traditional Schooling	Education that takes place in a public school, divided into grades, and governed by a school district.	Traditional Education		Educational Activity	CTRP Intervention Terminology|CTRP Terminology
C159513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159513>	C159511	Home School|Home Education|Home Schooled|Home Schooling	Education that takes place outside of a traditional school, in a home or other facility, with the teaching being conducted by a parent, tutor, or online instructor.			Educational Activity	
C159514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159514>	C159511	Homebound Instruction|Homebound|Homebound|Homebound Education	Instruction to children unable to attend school because of physical disabilities, special health problems, or temporary injuries or illness. This instruction is usually provided by the local school district, usually with a teacher visiting the child in their home, but would include alternative methods, such as online teaching.			Educational Activity	
C159515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159515>	C3824	Lung Lesion	A localized pathological or traumatic structural change, damage, deformity, or discontinuity of the lung.	Lung Lesion		Finding	CTRP Disease Terminology|CTRP Terminology
C159516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159516>	C3824	Liver Lesion	A localized pathological or traumatic structural change, damage, deformity, or discontinuity of the liver.	Liver Lesion		Finding	CTRP Disease Terminology|CTRP Terminology
C159517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159517>	C177692	SLAMF7 Positive|19A Positive|CD319 Positive|CRACC Positive|CS1 Positive|SLAM Family Member 7 Positive	An indication that SLAMF7 expression has been detected in a sample.	SLAMF7 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159518>	C78808	HD Chest|HD Chest System|High Definition Chest Software	A proprietary combination of PET/CT hardware and software designed to provide relatively motion-free images with higher count statistics for improved image quality and small lesion conspicuity. Using a highly automated, amplitude-based gating technology, HD Chest adapts to every patients breathing and automatically selects the optimal data range with the least amount of motion and the highest count statistics, producing images the chest and upper abdomen in high-definition without respiratory motion.	HD Chest		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C159519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159519>	C158612	Additional Anesthesia Agents Used Question|Additional Anesthesia Agents Used|Additional Anesthesia Agents Used|Additional Anesthesia agents used|Were Additional Anesthesia Agents Used	A question about whether additional anesthesia was administered.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C15951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15951>	C15321	Human Specimen Resources				Research Activity	
C159520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159520>	C42729	Patient Case Review	Analysis of a patient case report to create a knowledge repository.			Activity	
C159521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159521>	C17562	Dual-probe in Situ Hybridization|DISH|Dual in Situ Hybridization	An in situ hybridization assay for HER2/Neu that uses probes for both HER2 and chromosome 17.			Molecular Biology Research Technique	
C159522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159522>	C158612	Undetermined Explanation Question|Cannot be determined, explain|Request for Explanation|Undetermined Explanation	A request to provide an explanation.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C159523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159523>	C158612	Were IV Narcotic/Opiate Agents Administered Question|IV Narcotic or Opiate Agents Administered|IV Narcotic/Opiate agents administered|Were IV Narcotic/Opiate Agents Administered|Were IV Narcotic/Opiate Agents Administered	A question about whether intravenous narcotics or opiates were administered.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159524>	C116518	Early Intervention|Early Intervention Services	A range of targeted services and supports that are available to babies and young children with developmental delays or specific health conditions.			Health Care Activity	
C159525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159525>	C171086	Donor Status	Vital information about a donor at the time of donation.			Qualitative Concept	
C159526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159526>	C159525	Tissue Donor Eligibility	Determination that potential adult or cord blood donor does or does not possess risk factors for relevant communicable diseases (as defined by the FDA) and identified through screening, testing, physical evidence, and review of readily available relevant medical records.			Qualitative Concept	
C159527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159527>	C159525	Tissue Donor Suitability	Determination that a potential donor is healthy and medically fit to proceed with the donation process.			Qualitative Concept	
C159528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159528>	C159526	Hematopoietic Cell Donor Eligibility	Determination that potential hematopoietic cell donor does or does not possess risk factors for relevant communicable diseases (as defined by the FDA) and identified through screening, testing, physical evidence, and review of readily available relevant medical records.			Qualitative Concept	
C159529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159529>	C159527	Hematopoietic Cell Donor Suitability	Determination that a potential hematopoietic cell donor is healthy and medically fit to proceed with the donation process.			Qualitative Concept	
C15952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15952>	C52647	Cancer Control Research Program	A type of research program having an objective of reducing risk, incidence, and mortality from cancer and to enhancing the quality of life for cancer survivors. Realized through an orderly sequence of measures from genetic, epidemiologic, behavioral, social, applied, and surveillance cancer research to the development and implementation of effective interventions, and monitor and analysis of cancer trends in all segments of the population.			Research Activity	
C159530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159530>	C28227|C134305|C128036	Pavunalimab|Anti-CTLA-4/Anti-LAG-3 Bispecific Monoclonal Antibody XmAb22841|Anti-CTLA-4/LAG-3 Bispecific Antibody XmAb22841|BAVUNALIMAB|Bavunalimab|CTLA-4 x LAG-3 Bispecific Antibody XmAb22841|XmAb 22841|XmAb-22841|XmAb22841	An Fc-engineered bispecific antibody directed against the human negative immunoregulatory checkpoint receptors cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4) and lymphocyte activation gene 3 protein (LAG3; LAG-3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, bavunalimab targets and binds to both CTLA-4 and LAG-3 expressed on T-cells in the tumor microenvironment (TME). Both CTLA-4 and LAG-3 are inhibitory receptors and members of the immunoglobulin superfamily (IgSF); they are overexpressed by regulatory T-cells (Tregs) in the TME where they downregulate T-cell activation and proliferation. Dual checkpoint blockade of CTLA-4 and LAG-3 with XmAb22841 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone. The engineered Fc domain increases the stability and half-life of the antibody.	Bavunalimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C159531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159531>	C155322	BRAF Inhibitor LUT014|LUT 014|LUT-014|LUT-014|LUT014	A topically bioavailable small molecule inhibitor of serine/threonine-protein kinase B-raf (BRAF) protein with potential chemoprotective activity. Upon topical administration, BRAF inhibitor LUT014 targets and binds BRAF and, through the paradoxical effect of BRAF inhibition, induces mitogen-activated protein kinase (MAPK) signaling, which leads to the proliferation and migration of healthy human keratinocytes. This decreases dermal toxicities associated with epidermal growth factor (EGFR) inhibitor therapy. BRAF, a member of the raf family of serine/threonine protein kinases, plays a role in the regulation of MAPK/extracellular signal-regulated kinase (ERK) signaling pathways.	BRAF Inhibitor LUT014		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C159532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159532>	C215112	Psychomotor Assessment|Psychomotor Evaluation|Psychomotor Examination	Testing designed to evaluate an individual's precision, coordination, control, dexterity, and reaction time in mechanical motor responses.	Psychomotor Assessment		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C159535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159535>	C155725	SMO Protein Inhibitor ZSP1602|Smoothened Inhibitor ZSP1602|ZSP 1602|ZSP-1602|ZSP1602	An orally bioavailable small molecule SMO (Smoothened) inhibitor with potential antineoplastic activity. SMO inhibitor BMS-833923 inhibits the sonic hedgehog (SHH) pathway protein SMO, which may result in a suppression of the SHH signaling pathway.  SMO is a G-protein coupled receptor that lies just downstream of the SHH ligand cell surface receptor Patched-1 in the SHH pathway; in the absence of ligand Patched-1 inhibits SMO and ligand binding to Patched-1 results in increased levels of SMO. The SHH signaling pathway plays an important role in cellular growth, differentiation and repair; constitutive activation of this pathway is associated with uncontrolled cellular proliferation and has been observed in a variety of cancers.			Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C159536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159536>	C20401|C129822	Bexmarilimab|Anti-stabilin-1 Monoclonal Antibody FP-1305|BEXMARILIMAB|Clevegen|FP 1305|FP-1305|FP1305	A monoclonal antibody directed against common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1; stabilin-1; FEEL-1), with potential immunomodulatory and antineoplastic activities. Upon administration, bexmarilimab targets and binds to CLEVER-1 that is expressed on tumor endothelial cells. This prevents the recruitment, infiltration and attachment of tumor-associated macrophages (TAMs) at the tumor site. By preventing the binding of TAMs to tumor cells, the infiltration of activated T-regulatory cells (Tregs) to the tumor and the TAM-mediated immune suppression is abrogated, leading to the polarization of TAM from the immunosuppressive M2 macrophages to the anti-inflammatory and immunostimulatory M1 macrophages. This leads to the activation of the immune system, resulting in a cytotoxic T-lymphocyte (CTL)-mediated immune response and inhibition of tumor cell growth and metastasis. CLEVER-1 is an endothelial cell surface molecule involved in immune suppression, cancer growth and metastasis.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C159537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159537>	C2124|C200225	Radium Ra 224-labeled Calcium Carbonate Microparticles|224Ra-labeled Calcium Carbonate Micro-particles|Alpha-emitting 224Ra Calcium Carbonate Microspheres|Ra-224 Alpha-emitting Calcium Carbonate Microparticles|Radspherin	A radiopharmaceutical composed of biodegradable calcium carbonate microspheres labeled with the alpha-emitting radioisotope radium Ra 224, with antineoplastic activity. Upon intraperitoneal (IP) administration of the radium Ra 224-labeled calcium carbonate microparticles, Ra 224 kills tumor cells through local emission of high energy alpha particles, causing DNA double-strand breaks. The short range effects of alpha emission allows for localized DNA damage with limited toxicity to nearby healthy tissue.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C159538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159538>	C129822|C128057	Anti-PD-L1 Monoclonal Antibody GR1405|GR 1405|GR-1405|GR1405	A monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-L1 monoclonal antibody GR1405 specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C159539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159539>	C159616	Was EGFR Amplification Assessed Question|EGFR Amplification Assessed|Was EGFR Amplification Assessed	A question asking if EGFR amplification was analyzed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C15953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15953>	C15938	Cooperative Family Registries for Breast and Colorectal Cancer Studies|CFRBCS	Cooperative family registries specific for breast and colorectal cancer studies.			Intellectual Product	
C159540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159540>	C1663	Oral Cancer Vaccine V3-OVA|Cancer Vaccine V3-OVA|Tableted Vaccine V3-OVA|V3 OVA|V3-OVA|V3OVA	An orally available cancer vaccine composed of autologous ovarian cancer antigens obtained from hydrolyzed, inactivated blood and tumor tissue of patients with ovarian cancer, with potential immunostimulatory and antineoplastic activities. Upon oral administration of the oral cancer vaccine V3-OVA, the ovarian cancer antigens stimulate the immune system and activate a cytotoxic T-lymphocyte (CTL) immune response against ovarian cancer cells.			Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C159541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159541>	C20401	Emicizumab|ACE 910|ACE-910|ACE910|EMICIZUMAB|Emicizumab-kxwh|Hemlibra|Immunoglobulin G4-kappa, Bispecific, Anti-(Homo sapiens F9a (Activated Coagulation Factor F9, Activated Coagulation Factor IX) and Anti-(Homo sapiens F10 (Coagulation Factor 10, Coagulation Factor X)), Humanized Monoclonal Antibody	A humanized, immunoglobulin G4 (IgG4), bispecific monoclonal antibody against both the activated coagulation factor IX (FIXa) and factor X (FX) that can be used for the treatment of hemophilia A (HA). Upon administration, emicizumab targets and binds to both the FIXa and to FX, thereby bridging FIXa and FX, activating FX, and allowing for the activation and continuation of the coagulation cascade. FX is normally activated by coagulation factor VIII (FVIII); FVIII is missing in HA patients.	Emicizumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology
C159542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159542>	C4032|C191769	Bladder Endometrioid Adenocarcinoma|Bladder Endometrioid Carcinoma	A rare bladder adenocarcinoma with the histologic characteristics of endometrioid adenocarcinoma of the endometrium.			Neoplastic Process	
C159543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159543>	C154752	Bethesda Assay	An assay designed to standardize measurement of serum inhibitors of blood clotting in a factor VIII neutralization assay.			Laboratory Procedure	
C159544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159544>	C154752	Nijmegen-Bethesda Assay|Bethesda Assay with Nijmegen Modification	A modification of the Bethesda Assay where the pH and the protein concentration of the test mixture is further standardized, such that the factor VIII coagulant activity (FVIII:C) in the test mixture is less prone to artifactual deterioration and the test has improved specificity.			Laboratory Procedure	
C159545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159545>	C160157	Bladder, NOS	An unspecified area of the bladder.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C159546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159546>	C18213	RECIST Stable Disease|Stable Disease	Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter since start of treatment.			Finding	CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Terminology
C159547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159547>	C18058	RECIST Partial Response|Partial Response	At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter.			Finding	CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Terminology
C159548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159548>	C159556|C156746|C150577	Advanced Gastroesophageal Junction Adenocarcinoma	Gastroesophageal junction adenocarcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Gastroesophageal Junction Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C159549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159549>	C129822|C128037	Zimberelimab|AB 122|AB-122|AB122|Anti-PD-1 Monoclonal Antibody GLS-010|GLS 010|GLS-010|GLS010|Sepalizumab|WBP 3055|WBP-3055|WBP3055|ZIMBERELIMAB	A human immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, zimberelimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; B7-H1; CD274) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.	Zimberelimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15954>	C15923	Genetic Annotation Initiative|CGAP Genetic Annotation Initiative|CGAP-GAI|GAI|Genetic Annotation Initiative (GAI)	NCI initiate to explore, develop and then apply technology for identification and characterization of genes important in cancer.  Based on gene discovery program in CGAP, the GAI is currently exploring the application of multiple technological approaches to searching the 3'UTR of genes for sequence variation.  Once identified and confirmed, these variants will be put into public databases maintained by NCIBI's dbSNP and CGAP web resources.  See also Cancer Genome Anatomy Project.			Research Activity	
C159550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159550>	C103399	One-Stage Clotting Factor Assay|One-Stage Clotting Assay	A clotting factor assay where FVIII-deficient plasma is added to test plasma and the APTT reagent, mixed and incubated for 3-5 min. The mixture is then recalcified, and the coagulation time is recorded and compared to a standard curve.			Laboratory Procedure	
C159551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159551>	C103399	Two-Stage Clotting Factor Assay|Two-Stage Clotting Assay	A two-staged test with purified coagulation factors in the first stage, and a FXa-specific chromogenic substrate in the second stage. In the first stage, diluted sample plasma, which has been treated with Al(OH)3 to remove prothrombin, is mixed with a combined reagent (human serum, factor V, phospholipids and calcium). In the second stage, a subsample from the first stage is mixed with normal plasma, providing prothrombin and fibrinogen, and the clotting time is measured to deduce the amount of FVIII present.			Laboratory Procedure	
C159552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159552>	C103399	Chromogenic Substrate Clotting Factor Assay|Chromogenic Substrate Assay|Chromogenic Substrate Assay	A reagent containing purified coagulation factors (FIXa, FX and thrombin) in optimal concentrations is added to test plasma in the first stage, which does not rely on the extrinsic or intrinsic initiation pathways as the thrombin activates FVIII. The amount of FXa generated in the first stage is measured by its action on a specific chromogenic substrate, which releases a chromophore upon cleavage. The color intensity produced is directly proportional to the amount of FXa, which in turn is directly proportional to the FVIII activity in the sample.			Laboratory Procedure	
C159553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159553>	C20993	Hemophilia Joint Health Score|HJHS	A physiotherapist-administered assessment that measures the impact of recurrent bleeding on the elbows, knees, and ankles across 11 symptoms: swelling, duration of swelling, muscle atrophy, axial alignment, crepitus on motion, flexion loss, instability, joint pain, strength, and gait. Each of the 11 symptoms is rated on a Likert-style scale ranging from 1 to 4, with higher numbers indicating greater severity of symptoms. Scores from the individual items are added together to give a joint score, gait score, and a total score, with higher scores indicating greater joint damage.			Intellectual Product	
C159554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159554>	C217121	Validated Hemophilia Regimen Treatment Adherence Scale - On-Demand|VERITAS-PRN|Validated Hemophilia Regimen Treatment Adherence Scale - On-Demand (VERITAS-PRN)	A standardized tool for evaluating adherence to episodic hemophilia treatment regimens. The tool consists of 24 questions presented as a 5-point Likert scale ranging from Always to Never. Total scores can range from 24 (most adherent) to 120 (least adherent), with subscores ranging from 1-4 in six categories: treat, time, dose, plan, remember, and communicate.			Intellectual Product	
C159555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159555>	C217121	Validated Hemophilia Regimen Treatment Adherence Scale - Prophylaxis|VERITAS-Pro|Validated Hemophilia Regimen Treatment Adherence Scale - Prophylaxis (VERITAS-Pro)	A standardized tool for evaluating adherence to hemophilia prophylaxis, consisting of 24 questions utilizing 5-point Likert scales, with total scores ranging from 24 (most adherent) to 120 (least adherent). In addition to producing a total adherence score, questions are divided into six subscales (time, dose, plan, remember, skip, and communicate) to delineate the areas of nonadherence.			Intellectual Product	
C159556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159556>	C4124|C153171	Advanced Adenocarcinoma	An adenocarcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C159557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159557>	C63442	DHAX Regimen|DHA-Ox|DHA-Oxaliplatin|DHA-Oxaliplatin Regimen|DHAX|Dexamethasone/Cytarabine/Oxaliplatin|Dexamethasone/Cytarabine/Oxaliplatin Regimen	A regimen consisting of dexamethasone, cytarabine and oxaliplatin that can be used to treat diffuse large B-cell lymphoma (DLBCL), T-cell lymphoma and mycosis fungoides/Sezary syndrome.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C159558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159558>	C63442	CHP-Brentuximab Vedotin Regimen|BV-CHP|BV-CHP|BV-CHP Regimen|Brentuximab Vedotin with CHP|Brentuximab Vedotin with CHP Regimen|Brentuximab Vedotin/Cyclophosphamide/Doxorubicin/Prednisone|Brentuximab Vedotin/Cyclophosphamide/Doxorubicin/Prednisone Regimen|CHP-BV|CHP-Brentuximab Vedotin	A regimen consisting of brentuximab vedotin, cyclophosphamide, doxorubicin and prednisone that can be used to treat T-cell lymphomas, Hodgkin lymphoma, primary cutaneous CD30+ T-cell lymphoproliferative disorders and post-transplant lymphoproliferative disorders.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C15955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15955>	C15429	Heart Research	A scientific study of the heart and its function. The studies may involve research into the health and disease process of the heart as well as new ways to screen, prevent, diagnose and treat disease.			Research Activity	
C159560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159560>	C63442	GELOX Regimen|GELOX|Gemcitabine/Asparaginase/Oxaliplatin|Gemcitabine/Asparaginase/Oxaliplatin Regimen|Gemcitabine/L-asparaginase/Oxaliplatin|Gemcitabine/L-asparaginase/Oxaliplatin Regimen|Gemcitabine/Oxaliplatin/Asparaginase|Gemcitabine/Oxaliplatin/Asparaginase Regimen	A regimen consisting of gemcitabine, oxaliplatin and asparaginase that can be used to treat extranodal natural killer (NK)/T-cell lymphoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C159561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159561>	C20993	Hemophilia Activities List|HAL|Haemophilia Activities List|Haemophilia Activities List (HAL)	A disease-specific, self- or proxy-administered questionnaire that includes 53 multiple-choice items across seven domains: sitting/kneeling/standing, functions of the legs, functions of the arms, use of transportation, self-care, household tasks, and leisure activities and sports. Each item is rated on a 6-point Likert scale that ranges from 1 (impossible) to 6 (never), describing difficulty due to hemophilia in the past month. Scores from individual items can be summed to give a total score or component scores for upper extremity, basic lower extremity, and complex lower extremity activities. Higher scores indicate greater functional status.			Intellectual Product	
C159562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159562>	C162768|C153170	Advanced Clear Cell Renal Cell Carcinoma	A clear cell renal cell carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Clear Cell Renal Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C159563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159563>	C8511|C2852	Refractory Adenocarcinoma	An adenocarcinoma that does not respond to treatment.	Refractory Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C159564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159564>	C201171|C201170	Etrumadenant|A2AR/A2BR Antagonist AB928|AB 928|AB-928|AB928|Adenosine A2A/A2B Receptor Antagonist AB928|Dual A2AR/A2BR Antagonist AB928|ETRUMADENANT	An orally bioavailable antagonist of both the immunomodulatory checkpoint molecules adenosine A2A receptor (A2AR; ADORA2A) and A2B receptor (A2BR; ADORA2B), with potential immunomodulating and antineoplastic activities. Upon administration, etrumadenant competes with tumor-released adenosine for binding to A2AR and A2BR expressed on numerous intra-tumoral immune cells, such as dendritic cells (DCs), natural killer (NK) cells, macrophages and T-lymphocytes. The binding of AB928 to A2AR and A2BR inhibits A2AR/A2BR activity and prevents adenosine-A2AR/A2BR-mediated signaling. A2AR/A2BR inhibition activates and enhances the proliferation of various immune cells, abrogates the adenosine-mediated immunosuppression in the tumor microenvironment (TME) and activates the immune system to exert anti-tumor immune responses against cancer cells, which leads to tumor cell killing. A2AR and A2BR, G protein-coupled signaling receptors, are expressed on the cell surfaces of numerous immune cells. Adenosine is often overproduced by tumor cells and plays a key role in immunosuppression and tumor cell proliferation.	Etrumadenant		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C159565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159565>	C7619|C2852	Recurrent Adenocarcinoma	An adenocarcinoma that has recurred after a period of remission.	Recurrent Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C159566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159566>	C158612	Indeterminate Macroscopic Satellite Nodule Question|Indeterminate|Indeterminate Macroscopic Satellite Nodule	Unable to determine if a macroscopic satellite nodule exists.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C159567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159567>	C158612	Other Site of New Distant Metastasis Tumor Event Question|Other Site of New Distant Metastasis Tumor Event|Other Site of New Distant Metastasis Tumor Event	A directive to specify the other site of the new distant metastatic tumor event.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Terminology
C159568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159568>	C160157	Stomach, NOS	An area of the stomach, not otherwise specified.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C159569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159569>	C158612	Specify Pelvic Area Question|Pelvic, specify|Specify Pelvic Area	A request to specify the area of the pelvis.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C15956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15956>	C15986|C15632	Nucleotide Analog Chemotherapy	Use of nucleotide analogs in cancer treatment.			Therapeutic or Preventive Procedure	
C159570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159570>	C158612	Specify New Primary Tumor Question|New Primary Tumor, specify|Specify New Primary Tumor	A directive to specify the new primary tumor.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology
C159571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159571>	C158612	History of any Treatments Question|History of any Treatments|History of any Treatments	The history of known treatments for an individual.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C159572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159572>	C158612	Other Site of New Tumor Event Question|Other Site of New Tumor Event|Other Site of New Tumor Event|Other, specify	The site of the new tumor event was identified in the study but is not present in the form.			Intellectual Product	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C159573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159573>	C158612	Specify Site of Other New Tumor Event Question|Other New Tumor Event Site|Other Site|Specify Site of Other New Tumor Event|Specify other Site of New Tumor Event	A directive to specify the site of the other new tumor event.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Terminology
C159574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159574>	C20993	Paediatric Haemophilia Activities List|Paediatric Haemophilia Activities List (PedHAL)|PedHAL	An adapted version of the Haemophilia Activities List designed to assess the impact of hemophilia on a child's activities of daily living. The questionnaire consists of  53 multiple-choice items across seven domains: sitting/kneeling/standing, functions of the legs, functions of the arms, use of transportation, self-care, household tasks, and leisure activities and sports. A parent/proxy is designed for children ages 4-8) and a self-administered version for children ages 8-18.			Intellectual Product	
C159575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159575>	C158612	Other Site of New Primary Melanoma Question|Other Site of New Primary Melanoma|Other Site of New Primary Melanoma	A directive to specify the other site of the new primary melanoma.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Terminology
C159576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159576>	C173060|C158612	Was the Individual Exposed to Second-Hand Smoke Question|Secondhand Smoke Exposure|Was the Individual Exposed to Second-Hand Smoke|Was the Individual Exposed to Second-Hand Smoke|Was the Participant exposed to secondhand smoke	A question about whether an individual has been exposed to secondhand tobacco smoke.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C159577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159577>	C157151	Chemical/Occupational Exposure Present|Yes	An indication that a history of chemical/occupational exposures exists.			Clinical Attribute	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C159578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159578>	C157151	Chemical/Occupational Exposure Absent|No	An indication that a history of chemical/occupational exposures does not exist.			Clinical Attribute	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C159579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159579>	C157151	Chemical/Occupational Exposure Type Unknown|Unknown	The chemical/occupation exposure type is unknown.			Clinical Attribute	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C15957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15957>	C16085	Breast Cancer, Basic Research|Breast Cancer-Basic	Research on the molecular, genetic, biochemical, cellular, structural, immunological, pharmacological mechanisms and factors as they relate to the causation, progression, diagnosis, and treatment of breast cancer.			Research Activity	
C159580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159580>	C19498	Diary	A written record of an inividual's experiences and observations.	Diary		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C159581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159581>	C159580	Sleep Diary|Sleep Journal|Sleep Log	A record of an individual's experiences and observations about their sleeping. This usually includes: time going to bed and time awakening; times awake during the night; and subjective opinion of sleep quality, but can also include information about sleep preparations: time and amount of caffeine or alcohol consumed; food and drink consumed; medications taken; exercise during the day and pre-sleep activities; and emotional or stress status.	Sleep Diary		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C159582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159582>	C188218|C157758	Bladder Neuroendocrine Tumor|Bladder Well Differentiated Neuroendocrine Neoplasm|Bladder Well-Differentiated Neuroendocrine Neoplasm	A well-differentiated neuroendocrine neoplasm arising from the bladder. It is characterized by the presence of uniform cells with stippled chromatin and inconspicuous nucleoli. Mitotic activity is low and tumor necrosis is absent.			Neoplastic Process	
C159583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159583>	C20401|C192655|C129822	Anti-CD47 Monoclonal Antibody	Any monoclonal antibody that targets the CD47 antigen.			Chemical Viewed Functionally	NCIt Antineoplastic Agent Terminology
C159584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159584>	C158612	Specify Other Inhalation Anesthesia Agents Question|Other Inhalation Anesthesia Agents (specify)|Specify Other Inhalation Anesthesia Agents|Specify Other Inhalation Anesthesia Agents	A request to specify inhalation anesthesia that was administered but not included on a list.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159585>	C158612	Specify Other Preoperative IV Anesthesia Administered Question|Other IV Anesthesia Agents (specify)|Specify Other Preoperative IV Anesthesia Administered|Specify Other Preoperative IV Anesthesia Administered	A request to specify intravenous anesthesia that was administered but not included on a list.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159586>	C160157	Preoperative IV Sedation was Not Administered|No	A response indicating that preoperative intravenous sedation was not administered.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159587>	C160157	Preoperative IV Sedation was Administered|Yes	A response indicating that preoperative intravenous sedation was administered.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159588>	C36291|C173902	Peritoneal Surface Disease Finding|Peritoneal Surface Disease	A finding indicating the presence of widespread neoplastic disease in the peritoneum. Most often, the origin of the neoplasm is outside the peritoneum, but in rare cases the tumor may be primary.	Peritoneal Surface Disease		Finding	CTRP Disease Terminology|CTRP Terminology
C159589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159589>	C160157	Preoperative IV Opiates were Administered|Yes	A response indicating that preoperative intravenous opiates were administered.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C15958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15958>	C60819	In Vitro Assay|in vitro Assay	An assay conducted in an artificial environment, such as in a test tube, under a defined and controlled set of solvent and solute conditions.			Research Activity	
C159590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159590>	C160157	Other Preoperative IV Medications were Administered|Yes	A response indicating that other preoperative intravenous medications were administered.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159591>	C110937	Myopenia	A condition characterized by a clinically relevant degree of muscle wasting that is associated either with impaired functional capacity and/or with increased risk of morbidity or mortality.	Myopenia		Finding	CTRP Disease Terminology|CTRP Terminology
C159592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159592>	C160157	Preoperative IV Antiemetics were Administered|Yes	A response indicating that preoperative intravenous opiates were administered.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159593>	C160157	Preoperative IV Antacids were Administered|Yes	A response indicating that preoperative intravenous antacids were administered.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159594>	C3824	Breast Lesion	A localized pathological or traumatic structural change, damage, deformity, or discontinuity of the breast.	Breast Lesion		Finding	CTRP Disease Terminology|CTRP Terminology
C159595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159595>	C160157	Preoperative IV Antacids were not Administered|No	A response indicating that preoperative intravenous antacids were not administered.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159596>	C160157	Preoperative IV Antiemetics were not Administered|No	A response indicating that preoperative intravenous opiates were not administered.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159597>	C160157	Other Preoperative IV Medications were not Administered|No	A response indicating that other preoperative intravenous medications were not administered.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159598>	C160157	Preoperative IV Opiates were not Administered|No	A response indicating that preoperative intravenous opiates were not administered.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159599>	C717|C308|C222795	Enadenotucirev-expressing Anti-CD40 Agonistic Monoclonal Antibody NG-350A|NG 350A|NG-350A|NG350A|Oncolytic Adenoviral Vector Expressing Anti-CD40 Antibody NG-350A|Oncolytic Adenoviral Vector-expressing Anti-CD40 Agonistic Antibody NG-350A	An oncolytic adenoviral vector, enadenotucirev (EnAd), that expresses a full-length agonistic anti-CD40 monoclonal antibody, with potential immunomodulating and antineoplastic activities. Upon intratumoral administration of NG-350A, enadenotucirev specifically infects and replicates in tumor cells and not in normal, noncancerous tissue, and selectively expresses the agonistic anti-CD40 antibody. The locally expressed anti-CD40 antibody targets and binds to CD40 on a variety of immune cells, including B-cells, T-cells and dendritic cells (DCs) in the tumor microenvironment (TME). This induces CD40-dependent signaling pathways, which activates these immune cells and induces a cytotoxic T-lymphocyte (CTL)-mediated antitumor immune response and leads to tumor cell death. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells and plays a key role in the activation of the immune system.	Enadenotucirev-expressing Anti-CD40 Agonistic Monoclonal Antibody NG-350A		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15959>	C15958	Cellular Assay	In vitro experiments conducted with intact, living cells.			Research Activity	
C1595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1595>	C784|C258	Tetracycline Antibiotic|Tetracycline Antibiotics|Tetracyclines	Any of a group of broad spectrum naphthacene antibiotics isolated from various species of Streptomyces or produced semisynthetically. In bacteria, tetracycline antibiotics block binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis. (NCI05)			Chemical Viewed Functionally	NCI Drug Dictionary Terminology
C159600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159600>	C159583	Anti-CD47 Monoclonal Antibody AO-176|AO 176|AO-176|AO176	A humanized immunoglobulin G2 (IgG2) monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody AO-176 preferentially binds to CD47 on tumor cells because it exhibits enhanced binding at the acidic pH found in the tumor microenvironment (TME). This blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of tumor cells. Additionally, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T-cell-mediated killing of CD47-expressing tumor cells. In addition, AO-176 induces immunogenic cell death (ICD) and releases damage-associated molecular patterns (DAMPs) from tumor cells, thereby further stimulating immune responses. AO-176 is also able to induce direct cytotoxic cell death by a cell autonomous mechanism. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.	Anti-CD47 Monoclonal Antibody AO-176		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C159601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159601>	C1663	Personalized ALL-specific Multi-HLA-binding Peptide Vaccine|Individualized Multi-HLA-binding Peptide Vaccine|Personalized Multi-HLA-binding Peptide Vaccine	An individualized peptide-based cancer vaccine comprised of three to five human leukocyte antigen (HLA) binding tumor-specific peptides obtained from the autologous mutated proteins from the tumor cells of patients with acute lymphoblastic leukemia (ALL), with potential immunomodulating and antineoplastic activity. Upon intradermal administration of the personalized multi-HLA-binding peptide vaccine, the peptides may induce a tumor-specific cytotoxic T-lymphocyte (CTL) response against the peptides that are expressed by the tumor cells.			Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C159602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159602>	C116699	Caregiver Oncology Needs Evaluation Tool|CONNECT	A technology-based intervention which may increase lung cancer caregivers' knowledge about the benefits of supportive care resources, identify their unmet needs, and connect them with supportive care resources. CONNECT is designed to empower and educate caregivers about the benefits of supportive care resources and to systematically identify unmet needs and connect lung cancer caregivers with tailored supportive care resources. It consists of a multi-component e-tool with the following: (1) a brief educational video that seeks to empower and educate caregivers about the importance of self-care and benefits of supportive care resource use; (2) an assessment of multidimensional supportive care needs (e.g., psychological, behavioral, social, financial, educational, spiritual); (3) a tailored resource list that includes local and national resources corresponding to caregivers needs; and (4) an optional automated referral to a caregiver navigator to facilitate connection to resources.	Caregiver Oncology Needs Evaluation Tool		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C159603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159603>	C160157	Local Anesthesia Agents were not Administered|No	A response indicating that local anesthesia agents were not administered.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159604>	C160157	Local Anesthesia Agents were Administered|Yes	A response indicating that local anesthesia agents were administered.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159605>	C160157	Regional Anesthesia was Administered|Yes	A response indicating that regional anesthesia agents were administered.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159606>	C160157	Regional Anesthesia was not Administered|No	A response indicating that regional anesthesia agents were not administered.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159607>	C160157	IV Anesthesia was Administered|Yes	A response indicating that intravenous anesthesia medications were administered.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C159608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159608>	C160157	IV Anesthesia was not Administered|No	A response indicating that intravenous anesthesia medications were not administered.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C15960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15960>	C15419	Blood Screening	Examination of the blood from a group of usually asymptomatic individuals to detect those with a high probability of having a given disease, typically by means of inexpensive diagnostic tests.			Diagnostic Procedure	
C159610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159610>	C28264	Magnetic Seed Localization|Magseed and Sentimag	A localization technique in which a magnetic seed marker implanted at the site of a lesion or disease is detected using a magnetic probe.	Magnetic Seed Localization		Conceptual Entity	CTRP Intervention Terminology|CTRP Terminology
C159611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159611>	C66897|C16135	Intensity-Modulated Proton Therapy|IMPT	A type of proton beam radiation therapy in which complex spatial control of the proton beam is achieved through modulation of the dose, deflection, and penetration.	Intensity-Modulated Proton Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C159612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159612>	C25164	Year Date|YYYY|YYYY	The year in four digit format.			Temporal Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C159613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159613>	C160157	Other Histologic Type|Other	A selected option that indicated an other histologic type.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C159614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159614>	C158075	Metastatic Diagnosis Present Question|Any Metastatic Diagnosis Present|Metastatic Diagnosis Present|Yes	An indication that metastatic disease has been diagnosed.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uveal Melanoma Baseline Form
C159615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159615>	C158075	Metastatic Diagnosis Absent Question|Any Metastatic Diagnosis Absent|Metastatic Diagnosis Absent|No	An indication that metastatic disease has not been diagnosed.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uveal Melanoma Baseline Form
C159616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159616>	C159979	Was Molecular Analysis Performed Question|Was Molecular Analysis Performed	A question asking if any molecular analyses were performed during the study.			Intellectual Product	
C159617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159617>	C125932	Response Evaluation Criteria In Lymphoma 2017|RECIL|RECIL 2017	The 2017 update to an international-consensus set of response criteria for lymphoma first established in 1999. These guidelines were refined in 2007 to incorporate assessment of tumor metabolism by [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) and further refined in 2017 to incorporate a scoring system to enhance the reproducibility of the interpretation and reporting of FDG-PET results, and to update the recommended procedures for staging evaluation.			Intellectual Product	
C159618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159618>	C159617	RECIL CR|CR|Complete Response|RECIL Complete Response	Complete disappearance of all target lesions and all nodes with long axis less than10mm; greater than or equal to 30 percent decrease in the sum of longest diameters of target lesions (partial response) with normalization of FDG-PE.			Intellectual Product	
C159619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159619>	C159617	RECIL PR|PR|PR|Partial Response|RECIL Partial Response	Greater than or equal to 30 percent decrease in the sum of longest diameters of target lesions but not a complete response.			Intellectual Product	
C15961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15961>	C49652	Rehabilitation Study|Rehabilitation Clinical Study|Rehabilitation Research	A study designed to investigate new or improved ways to restore function to an individual following disease, illness, or injury.			Research Activity	
C159620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159620>	C159617	RECIL MR|MR|Minor Response|RECIL Minor Response	Greater than or equal to 10 percent decrease in the sum of longest diameters of target lesions but not a partial response.			Intellectual Product	
C159621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159621>	C159617	RECIL SD|RECIL Stable Disease|SD|Stable Disease	Less Than 10 percent decrease or less than or equal to 20 percent increase in the sum of longest diameters of target lesions.			Intellectual Product	
C159622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159622>	C159617	RECIL PD|PD|PD|Progressive Disease|RECIL Progressive Disease	Greater than 20 percent increase in the sum of longest diameters of target lesions; For small lymph nodes measuring less than15 mm post therapy, a minimum absolute increase of 5 mm and the long diameter should exceed 15 mm; Appearance of a new lesion.			Intellectual Product	
C159623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159623>	C157120	Exocervix Tumor|Exocervix	An indication that the tumor is in the exocervix.			Clinical Attribute	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C159624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159624>	C157120	Endocervix Tumor|Endocervix	An indication that the tumor is in the endocervix.			Clinical Attribute	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C159625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159625>	C18068	Gray per Fraction|Gray/Fraction|Gy per Fraction|Gy/Fraction	A unit of absorbed radiation dose equal to the number of grays per fraction.			Quantitative Concept	
C159626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159626>	C18068	Centigray per Fraction|Centigray/Fraction|cGy per Fraction|cGy/Fraction	A unit of absorbed radiation dose equal to the number of centigrays per fraction.			Quantitative Concept	
C159627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159627>	C158612	Other Edition Question|Other|Other Edition	An indication that the edition is other than those listed.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uveal Melanoma Baseline Form
C159628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159628>	C158612	If Other Edition, Specify Question|If Other Edition, Specify|If Other, Specify	A directive to specify the edition if it is other than those listed.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uveal Melanoma Baseline Form
C159629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159629>	C158612	Specify Number of Lymph Nodes Examined Question|Specify|Specify Number of Lymph Nodes Examined	A directive to specify the number of lymph nodes that were examined.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uveal Melanoma Baseline Form
C15962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15962>	C16085	Tumor-Infiltrating Lymphocytes Research|TIL Research	Research on tumor-infiltrating lymphocytes and their use as a cancer treatment.			Research Activity	
C159630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159630>	C158612	Indeterminate or Unknown Menopause Status Question|Indeterminate or Unknown Menopause Status|Indeterminate or Unknown: Could not be determined or unsure.	The menopause status is unknown.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C159631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159631>	C159616|C157144	Were Additional Molecular Studies Performed Question|Were Additional Molecular Studies Performed|Were other molecular studies performed	A question asking if additional molecular testing was performed during the study.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C159632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159632>	C159616	Was 10q23/PTEN Locus Deletion Analysis Performed Question|10q23 (PTEN Locus) Deletion Analysis Performed|Was 10q23/PTEN Locus Deletion Analysis Performed	A question asking if 10q23/PTEN deletion analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C159633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159633>	C159616	Was 1p/19q Deletion Analysis Performed Question|1p/19q Deletion Analysis Performed|Was 1p/19q Deletion Analysis Performed	A question asking if 1p/19 deletion analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C159634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159634>	C159616	Was ATRX Mutation Analysis Performed Question|ATRX Mutational Analysis Performed|Was ATRX Mutation Analysis Performed	A question asking if ATRX mutations were analyzed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C159635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159635>	C159616	Was BRAF Mutation Analysis Performed Question|BRAF Mutational Analysis Performed|Was BRAF Mutation Analysis Performed	A question asking if BRAF mutations were analyzed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C159636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159636>	C159616	Was ERBB2 Mutation Analysis Performed Question|ERBB2 Mutational Analysis Performed|Was ERBB2 Mutation Analysis Performed	A question asking if ERBB2 mutations were analyzed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C159637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159637>	C159616	Was IDH Family Mutation Analysis Performed Question|IDH1/2 Mutational Analysis Performed|Was IDH Family Mutation Analysis Performed	A question asking if mutations in IDH family members were analyzed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C159638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159638>	C159979	Was Immunohistochemical Testing Performed Question|Immunohistochemistry performed|Was Immunohistochemical Testing Performed	A question asking if any immunohistochemical tests were performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C159639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159639>	C159638|C157144	Was Additional Immunohistochemical Testing Performed Question|Other Immunohistochemistry performed|Was Additional Immunohistochemical Testing Performed	A question asking if additional immunochemical tests were performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C15963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15963>	C16199	Cancer Control Research	A systematic, scientific study on reducing risk, incidence, and mortality from cancer and to enhancing the quality of life for cancer survivors. Realized through an orderly sequence of measures from genetic, epidemiologic, behavioral, social, applied, and surveillance cancer research to the development and implementation of effective interventions, and monitor and analysis of cancer trends in all segments of the population.			Research Activity	
C159640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159640>	C159631	Was Additional Mutation Analysis Performed Question|Other Mutational Analysis Performed|Was Additional Mutation Analysis Performed	A question asking if any additional mutation analysis was performed suring the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C159641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159641>	C159616	Was KIT Mutation Analysis Performed Question|KIT Mutational Analysis Performed|Was KIT Mutation Analysis Performed	A question asking if KIT mutations were analyzed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C159642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159642>	C159616	Was KRAS Mutation Analysis Performed Question|KRAS Mutational Analysis Performed|Was KRAS Mutation Analysis Performed	A question asking if KRAS mutations were analyzed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C159643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159643>	C159979	Was Lymph Node Dissection Performed Question|Lymph Node Neck Dissection performed|Was Lymph Node Dissection Performed|lymph nodes removed|lymph_nodes_removed	A question asking if lymph node dissection was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology|GDC Property Terminology|GDC Terminology
C159644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159644>	C159616	Was MET Mutation Analysis Performed Question|MET Mutational Analysis Performed|Was MET Mutation Analysis Performed	A question asking if MET mutations were analyzed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C159645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159645>	C159616	Was MGMT Promoter Methylation Testing Performed Question|MGMT Promoter Methylation Testing Performed|Was MGMT Promoter Methylation Testing Performed	A question asking if MGMT promoter methylation was analyzed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C159646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159646>	C159616	Was NF1 Mutation Analysis Performed Question|NF1 Mutational Analysis Performed|Was NF1 Mutation Analysis Performed	A question asking if NF1 mutations were analyzed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C159647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159647>	C159616	Was NRAS Mutation Analysis Performed Question|NRAS Mutational Analysis Performed|Was NRAS Mutation Analysis Performed	A question asking if NRAS mutations were analyzed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C159648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159648>	C159616	Was PTEN Mutation Analysis Performed Question|PTEN Mutational Analysis Performed|Was PTEN Mutation Analysis Performed	A question asking if PTEN mutations were analyzed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C159649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159649>	C159616	Was SDH Complex Mutation Analysis Performed Question|SDHA/B/C/D Mutational Analysis Performed|Was SDH Complex Mutation Analysis Performed	A question asking if mutations in subunits of the SDH complex were analyzed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C15964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15964>	C15429	Neurosciences Research	Investigations in the disciplines concerned with the nervous system.			Biomedical Occupation or Discipline	
C159650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159650>	C159616	Was TP53 Mutation Analysis Performed Question|TP53 Mutational Analysis Performed|Was TP53 Mutation Analysis Performed	A question asking if TP53 mutations were analyzed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C159651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159651>	C159616	Was Fluorescence In Situ Hybridization Performed Question|Was FISH Performed|Was Fluorescence In Situ Hybridization Performed	A question asking if fluorescence in situ hybridization assays were performed during the study.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C159652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159652>	C181114	Pacanalotamab|AMG 420|AMG-420|AMG420|Anti-BCMA x Anti-CD3 BiTE AMG 420|Anti-BCMA/CD3 BiTE Antibody AMG 420|BCMA/CD3-directed Bispecific T-cell Engager Antibody AMG 420|BI 836909|BI-836909|BI836909|BiTE Antibody AMG 420|Bispecific T-cell Engager Antibody AMG 420|PACANALOTAMAB	A short half-life bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17), fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of pacanalotamab, this bispecific antibody binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA found on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated cell death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.	Pacanalotamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C159653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159653>	C74996	Joubert Syndrome 7|JBTS7	An autosomal recessive sub-type of Joubert syndrome caused by mutation(s) in the RPGRIP1L gene, encoding a protein thought to function in programmed cell death. It is characterized by cerebellar and oculomotor apraxia, hypotonia and psychomotor delay, neonatal respiratory abnormalities, renal abnormalities, and retinal dystrophy.			Disease or Syndrome	Cellosaurus Disease Terminology
C159654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159654>	C81315	Mild Non-BH4-Deficient Hyperphenylalaninemia|HPANBH4	An autosomal recessive condition caused by mutation(s) in the DNAJC12 gene, encoding dnaJ homolog subfamily C member 12. It is characterized by increased serum phenylalanine concentrations resulting in variable neurologic defects, including movement defects and intellectual disability. BH4 metabolism is normal.			Disease or Syndrome	Cellosaurus Disease Terminology
C159655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159655>	C28193	CALFAN Syndrome|Cholestasis, Acute Liver Failure, and Neurodegeneration	A condition caused by biallelic mutation(s) in the SCYL1 gene, encoding N-terminal kinase-like protein. It is characterized by peripheral neuropathy, cerebellar atrophy, ataxia, and recurrent episodes of liver failure.			Disease or Syndrome	Cellosaurus Disease Terminology
C159656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159656>	C177692	PSCA Positive|PRO232 Positive|Prostate Stem Cell Antigen Positive	An indication that PSCA expression has been detected in a sample.	PSCA Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159657>	C62634	Regimen Used to Treat or Prevent Graft Rejection	Any regimen that can be used to treat or prevent graft rejection.			Therapeutic or Preventive Procedure	
C159658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159658>	C27992	Obese|Obesity	Weighing well above a person's ideal weight, generally characterized as a Body Mass Index (BMI) of 30 and above.	Obese		Qualitative Concept	CTRP Disease Terminology|CTRP Terminology
C159659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159659>	C53268	Transplant Recipient|Transplantation Recipient	An individual receiving a transplant.			Human	
C159660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159660>	C159659	Stem Cell Transplant Recipient|Stem Cell Transplantation Recipient	An individual receiving a stem cell transplant.			Human	
C159661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159661>	C159660	Autologous Stem Cell Transplant Recipient|Autologous Stem Cell Transplantation Recipient	A person receiving an autologous stem cell transplant.	Autologous Stem Cell Transplant Recipient		Human	CTRP Intervention Terminology|CTRP Terminology
C159662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159662>	C159660	Allogeneic Stem Cell Transplant Recipient|Allogeneic Stem Cell Transplantation Recipient	A person receiving an allogeneic stem cell transplant.	Allogeneic Stem Cell Transplant Recipient		Human	CTRP Intervention Terminology|CTRP Terminology
C159663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159663>	C9334|C178453	Bladder Melanoma	A rare melanoma that arises from the bladder mucosa.			Neoplastic Process	
C159664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159664>	C158612	No Risk Factors Question|No Risk Factors	A request to indicate if there are no risk factors.			Intellectual Product	
C159665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159665>	C7507|C178453	Urethral Melanoma	A rare melanoma that arises from the urethral mucosa.			Neoplastic Process	
C159667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159667>	C4669|C214845	Bladder Rhabdomyosarcoma	A malignant mesenchymal neoplasm with skeletal muscle differentiation arising from the bladder.			Neoplastic Process	
C159668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159668>	C8971|C159667	Bladder Embryonal Rhabdomyosarcoma	An embryonal rhabdomyosarcoma arising from the bladder. It is the most common type of rhabdomyosarcoma of the bladder affecting young children.			Neoplastic Process	
C159669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159669>	C3749|C159667	Bladder Alveolar Rhabdomyosarcoma	An alveolar rhabdomyosarcoma arising from the bladder. It is the most common type of rhabdomyosarcoma of the bladder affecting older children and adolescents.			Neoplastic Process	
C15966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15966>	C16016	Nutrition Research, Vitamins, Other	The study of the role of vitamins other than those previously specified, their precursons, and their analogs in cancer causation or prevention and in general health.			Research Activity	
C159670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159670>	C4669|C3158	Bladder Leiomyosarcoma	A leiomyosarcoma that arises from the bladder. It is the most common type of bladder sarcoma in adults.			Neoplastic Process	
C159671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159671>	C4669|C171026	Bladder Angiosarcoma	A very rare angiosarcoma that arises from the bladder.			Neoplastic Process	
C159672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159672>	C157153	Risk Factor History Negative|None|None	The determination that an individual's risk factor history is negative.			Clinical Attribute	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C159673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159673>	C38150|C158636	Bladder PEComa|Bladder Perivascular Epithelioid Cell Tumor	A benign or malignant perivascular epithelioid cell tumor arising from the bladder.			Neoplastic Process	
C159674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159674>	C3618|C159673|C121791	Bladder Benign PEComa|Bladder Benign Perivascular Epithelioid Cell Tumor	A benign perivascular epithelioid cell tumor arising from the bladder.			Neoplastic Process	
C159675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159675>	C7376|C150535	Refractory Pleural Malignant Mesothelioma	Pleural malignant mesothelioma that is resistant to treatment.	Refractory Pleural Malignant Mesothelioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C159676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159676>	C213709|C172450|C156068	Advanced Endometrial Carcinoma	An endometrial carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Endometrial Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C159677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159677>	C9334|C159673|C121792	Bladder Malignant PEComa|Bladder Malignant Perivascular Epithelioid Cell Tumor	A malignant perivascular epithelioid cell tumor arising from the bladder.			Neoplastic Process	
C159678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159678>	C16588	Diaphragm Fluoroscopy|Sniff Test	A fluoroscopic medical test done to evaluate the function of the diaphragm. The subject is asked to sniff quickly and the movement of the diaphragm is monitored with a fluoroscope. It is a quick and easy real-time assessment of diaphragmatic motor function.	Diaphragm Fluoroscopy		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C159679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159679>	C7634|C158636	Bladder Solitary Fibrous Tumor	A solitary fibrous tumor that arises from the bladder. Most of these tumors are benign.			Neoplastic Process	
C15967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15967>	C15299	ADME Study|ADME|Absorption, Distribution, Metabolism and Excretion|Absorption, Distribution, Metabolism, and Excretion Study	A group of pharmacokinetic parameters commonly investigated during preclinical drug development.			Research Activity	CDISC SEND Study Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C159680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159680>	C3618|C3085	Bladder Hemangioma	A hemangioma that arises from the bladder. Most tumors occur in adults.			Neoplastic Process	
C159681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159681>	C3474|C2901	Bladder Granular Cell Tumor	A rare granular cell tumor arising from the bladder. Most tumors are benign.			Neoplastic Process	
C159682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159682>	C3618|C3272	Bladder Neurofibroma	A plexiform or diffuse neurofibroma arising from the bladder.			Neoplastic Process	
C159683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159683>	C158612	Specify Residual Tumor Question|Specify Residual Tumor	A request to specify any residual tumor.			Intellectual Product	
C159684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159684>	C158612	Select Histologic Type Question|Select Histologic Type|Select One	A direction to select one of the listed histologic sites.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C159685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159685>	C158612	ECOG Performance Status not Evaluated, not Provided or Available Question|ECOG Performance Status not Evaluated, not Provided or Available|Not Evaluated: Not provided or available	The ECOG performance status was not evaluated or available.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form
C159686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159686>	C158612	Unknown ECOG Performance Status Question|Unknown ECOG Performance Status|Unknown: Could not be determined or unsure	The ECOG performance status was not unknown.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form
C159687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159687>	C20993	Modified Severity Weighted Assessment Tool|Modified Severity Weighted Assessment Tool - mSWAT|mSWAT	A clinical measurement tool for measuring skin tumor burden in mycosis fungoides (MF) and Sezary syndrome (SS). It involves determining the percentage of body surface area (BSA) covered by patch, plaque, or tumor of MF/SS, then multiplying each lesion BSA by a factor that gives gradations of weight to patch versus plaque versus tumor and summing these scores. The change in mSWAT from the beginning of treatment can be used to assess overall response.			Intellectual Product	
C159688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159688>	C27993	Prevalent	Widespread, especially in a particular area or at a particular time.			Qualitative Concept	
C159689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159689>	C173772	HIV Seroconversion|Converter|HIV Seroconverter|Seroconversion	An indication that HIV antibodies have developed and become detectable in the serum.			Finding	
C15968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15968>	C49057	Linscott's Directory	Linscott's Directory of Immunological and Biological Reagents.  No other source in the world tells you where to buy more than 54,000 different products used in Biomedical Research.			Intellectual Product	
C159690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159690>	C82547	Identified at Death	An indication that some condition was identified upon an individual's death.			Finding	
C159691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159691>	C39723	Serostatus	An indication of the presence or absence of antibodies in the serum for a particular factor.			Finding	
C159692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159692>	C35682|C159691	Seropositive	A laboratory result which shows the presence of antibodies in the serum for the factor being tested.			Laboratory or Test Result	
C159693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159693>	C95341	Last Time Seen	An indication of the most recent time that a particular event or status was noted.			Health Care Activity	
C159694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159694>	C95341	Last Visit Seen|Last Visit Seen With	An indication of the most recent visit during which a particular event or status was noted.			Health Care Activity	
C159695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159695>	C95341	First Time Seen	An indication of the first time that a particular event or status was noted.			Health Care Activity	
C159696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159696>	C95341	First Visit Seen	An indication of the first visit during which a particular event or status was noted.			Health Care Activity	
C159697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159697>	C95341	Last Reported Free	An indication of the last noted time an individual was without something.			Health Care Activity	
C159698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159698>	C95341	Last Reported Free Visit	An indication of the last visit during which an individual was noted to be without something.			Health Care Activity	
C159699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159699>	C95341	First Reported Year	The year that something was first noted.			Health Care Activity	
C15969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15969>	C19498	NIH Areas of Research Emphasis|NIH Emphasis Area	Research emphasis areas are medical and scientific research topics that warrant expanded support based on scientific need and opportunity, public health importance, and/or legislative mandate.  These emphasis areas are developed jointly with the scientific, medical, and public health communities.			Conceptual Entity	
C1596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1596>	C1742	ZD0101|CM 101|CM-101|ZD 0101	An antiangiogenic polysaccharide toxin derived from group B streptococcus.			Organic Chemical|Pharmacologic Substance	
C159700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159700>	C95341	Last Reported Free Year	An indication of the year during which an individual was last noted to be without something.			Health Care Activity	
C159701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159701>	C95341	First Reported Visit	An indication of the visit during which something was first noted.			Health Care Activity	
C159702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159702>	C95341	Last Year Seen|Last Year Seen With	An indication of the most recent year that a particular event or status was noted.			Health Care Activity	
C159703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159703>	C95341	First Year Seen|First Year Seen With	An indication of the first year that a particular event or status was noted.			Health Care Activity	
C159704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159704>	C95341	First Confirmed Year	An indication of the first year that a particular event or status was confirmed.			Health Care Activity	
C159705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159705>	C95341	First Confirmed Visit	An indication of the first visit during which a particular event or status was confirmed.			Health Care Activity	
C159706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159706>	C95341	First Visit Year with All Necessary Components to Determine	An indication of the first year that all components needed to determine something were present.			Health Care Activity	
C159707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159707>	C95341	First Visit with All Necessary Components to Determine	An indication of the first visit during which all components needed to determine something were present.			Health Care Activity	
C159708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159708>	C95341	First Visit Year	An indication of the year of an individual's first visit.			Health Care Activity	
C159709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159709>	C95341	Use Before Visit	An indication that an individual used something prior to their baseline visit.			Health Care Activity	
C15970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15970>	C15969	Genetics and Medicine	An NIH Emphasis area			Conceptual Entity	
C159710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159710>	C95341	Ever Used	An indication that an individual used something at least one time.			Health Care Activity	
C159711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159711>	C62439	Two Hundred|200	A natural number greater than 199 and less than 201 and the quantity that it denotes.			Quantitative Concept	
C159712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159712>	C95341	Year of Last Study Visit Attended	An indication of the last study visit attended by a study sujbect.			Health Care Activity	
C159713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159713>	C95341	Last Year of Contact	An indication of the last year during which a subject was seen or spoken with.			Health Care Activity	
C159714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159714>	C159612	Mortality Cut-off Year, National Death Index|Mortality cut-off year based on NDI submission	The last year of data used in the National Death Index.			Temporal Concept	
C159715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159715>	C4870	RECIST Complete Response|Complete Response	Disappearance of all target lesions.			Finding	CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Terminology
C159716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159716>	C35571	RECIST Progressive Disease|Progressive Disease	At lease a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.			Finding	CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Terminology
C159717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159717>	C9308	EBV-Related Lymphoproliferative Disorder|EBV Lymphoproliferation|EBV Lymphoproliferation|Epstein-Barr Virus-Associated Lymphoproliferative Disorder|Epstein-Barr Virus-Related Lymphoproliferative Disorder	A lymphoproliferative disorder associated with Epstein-Barr virus. This category includes, but is not limited to, Burkitt lymphoma, classic Hodgkin lymphoma, and lymphomas arising in immunocompromised individuals.			Disease or Syndrome	GDC Terminology|GDC Value Terminology
C159718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159718>	C158612	Undetermined Histologic Type Question|Indeterminate|Undetermined Histologic Type	Unable to determine the histologic type.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C159719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159719>	C129839	Cantrixil|TRX E 002 1|TRX-E-002-1|TRX-E-002-1|TRXE0021|cis-4-(para-hydroxyphenyl)-7,4'-dihydroxy-3',5'-dimethoxy-8-methylisoflavan	A cyclodextrin-encapsulated, third generation super-benzopyran (SBP) compound with potential antineoplastic activity. Upon intraperitoneal (IP) administration, cantrixil enhances the activation and expression of c-Jun, downregulates phosphorylated extracellular signal-regulated kinase (p-ERK) and induces activation of caspase-3, -7 and -9, thereby inducing tumor cell apoptosis. c-Jun, an activator protein-1 (AP-1) transcription factor component, is involved in a wide range of cellular processes including cell cycle progression, differentiation, cell transformation and apoptosis.	Cantrixil		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C15971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15971>	C16205	Cancer Control|Cancer Control Science	Integrated program having an objective of reducing risk, incidence, and mortality from cancer and to enhancing the quality of life for cancer survivors. Realized through an orderly sequence of measures from genetic, epidemiologic, behavioral, social, applied, and surveillance cancer research to the development and implementation of effective interventions, and monitor and analysis of cancer trends in all segments of the population.			Health Care Activity	GDC Terminology|GDC Value Terminology
C159720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159720>	C157106	Specify Other Exons|Other exons, specify	A request to specify the other exons which are not included in the form.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C159721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159721>	C158075	Specify Site If Distant Metastasis Submitted Question|If distant metastasis submitted, specify site|Specify Site If Distant Metastasis Submitted	A request to specify the site if distant metastasis was submitted.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C159722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159722>	C158612	Specify New Tumor Metastasis Site Question|If distant metastasis documented, specify site|Specify New Tumor Metastasis Site	A directive to specify the new tumor metastasis site.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology
C159723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159723>	C159243	Incomplete Staging (cM)|Staging Incomplete	A lack of clinical and/or pathology information to assign a cM stage conclusively.			Classification	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C159724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159724>	C159243	Incomplete Staging (pM)|Incomplete Staging	A lack of clinical and/or pathology information to assign a pM stage conclusively.			Classification	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C159725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159725>	C173890	How Many Places Lived with Child Question|How Many Places Lived with Child|How many places have you and your child lived in the past year	A question about the number of places an individual has lived with their child.			Intellectual Product	
C159726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159726>	C187306|C173045	Struggle with Rent or Mortgage Due to Financial Difficulties Question|In the 6 months before your child's diagnosis, was there a time when you were not able to pay the rent or mortgage on time because of financial difficulties	A question about whether an individual struggled with rent or mortgage due to financial difficulties.			Intellectual Product	
C159727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159727>	C187306	Live with Others Due to Financial Difficulties Question|In the 6 months before your child's diagnosis, did you and your child had to temporarily live with other people because of financial difficulties|Live with Others Due to Financial Difficulties	A question about whether an individual lived with others due to financial difficulties.			Intellectual Product	
C159728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159728>	C173924|C173045	Lack of Reliable Transportation Keeps from Appointments, Meetings, Work, or Daily Living Question|In the 6 months before your child's diagnosis, did lack of reliable transportation keep you or anyone in your family from medical appointments, meetings, work or getting things needed for daily living|Lack of Reliable Transportation Keeps from Appointments, Meetings, Work, or Daily Living	A question about whether an individual was unable to get to medical appointments, meetings, work, or getting things needed for daily living due to lack of reliable transportation.			Intellectual Product	
C159729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159729>	C187306	Utility Company Threatened to Shut Off Services for not Paying Bills Question|Has the gas/electric/oil company sent you a letter threatening to shut off or not deliver the gas/electricity/oil to the house for not paying bills|Utility Company Threatened to Shut Off Services for not Paying Bills	A question about whether an individual has utility companies threatening to cut off service due to not paying bills.			Intellectual Product	
C15972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15972>	C15262	Biological Immunotherapy|Cancer Biologics and Immunotherapy for Brain Tumors|Immunotherapy-Biological	The use of biological agents to enhance the host immune system.			Therapeutic or Preventive Procedure	CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist
C159730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159730>	C187306	Utility Company Shut Off Services for not Paying Bills Question|Has the gas/electric/oil company shut off electricity/gas or refused to deliver oil for not paying bills|Utility Company Shut Off Services for not Paying Bills	A question about whether an individual had utility companies cut off service due to not paying bills.			Intellectual Product	
C159731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159731>	C187306	Days Home Not Heated or Cooled Because Bills Not Paid Question|Days Home Not Heated or Cooled Because Bills Not Paid|Were there any days that your home was not heated/cooled because you couldn't pay the bills	A question about whether an individual did not heat or cool their home because they did not pay the bills.			Intellectual Product	
C159732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159732>	C187306	Used Cooking Stove to Heat Home Because Bills Not Paid Question|Have you had to use a cooking stove to heat your home because you couldn't pay the bills|Used Cooking Stove to Heat Home Because Bills Not Paid	A question about whether an individual used a cooking stove to heat their home because they did not pay the bills.			Intellectual Product	
C159733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159733>	C187306	Telephone Service Disconnected Due to Bill Not Paid Question|Did you have service disconnected on your telephone (including cell phones) because you couldn't pay the bill|Telephone Service Disconnected Due to Bill Not Paid	A question about whether an individual's phone service was cut off due to not paying bills.			Intellectual Product	
C159734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159734>	C173934	Worried Food Would Run Out Before Get Money to Buy More Question|We worried whether our food would run out before we got money to buy more|Worried Food Would Run Out Before Get Money to Buy More	A question about whether an individual is or was worried their food would run out before getting money to buy more.			Intellectual Product	
C159735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159735>	C187306	Food Bought Didn't Last and Didn't Have Money to Get More Question|Food Bought Didn't Last and Didn't Have Money to Get More|The food that we bought just didn't last, and we didn't have money to get more	A question about whether an individual's food didn't last and didn't have money to get more.			Intellectual Product	
C159736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159736>	C187306	If Lose Current Income Sources and Live Off Savings, How Long Could Continue to Live at Current Address and Standard of Living Question|If Lose Current Income Sources and Live Off Savings, How Long Could Continue to Live at Current Address and Standard of Living|If you lost all of your current sources of income and had to live off of your savings, how long could you continue to live at your current address and standard of living	A question about how long an individual could live at their current address and standard of living if they lost their income source and lived off of savings.			Intellectual Product	
C159737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159737>	C173151	Family Received Food from Food Pantry or Soup Kitchen Question|Did your family receive food from a food pantry (sometimes called a food bank or soup kitchen)|Family Received Food from Food Pantry or Soup Kitchen	A question about whether a family received food from a food pantry or soup kitchen.			Intellectual Product	
C159738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159738>	C173151	Family Received Energy Assistance Question|Did your family receive any energy assistance (discounted gas/electric bills such as LIHEAP or utility discounts)|Family Received Energy Assistance	A question about whether a family received any energy assistance or discounts.			Intellectual Product	
C159739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159739>	C173151	Family Received Disability Benefits Question|Did your family receive Disability benefits (i.e. SSI, Supplemental Security Income)|Family Received Disability Benefits	A question about whether a family received disability benefits.			Intellectual Product	
C15973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15973>	C15739|C15438	Immunotoxin Cancer Immunotherapy|Immunotherapy, Cancer, Immunotoxin|Immunotoxin Immunotherapy For Cancer	Semisynthetic conjugates of various toxic molecules, including radioactive isotopes and bacterial or plant toxins, with specific immune substances such as immunoglobulins, monoclonal antibodies, and antigens. The antitumor or antiviral immune substance carries the toxin to the tumor or infected cell where the toxin exerts its poisonous effect.			Therapeutic or Preventive Procedure	
C159740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159740>	C173151	Family Received Low-Income or Subsidized Housing Question|Did your family receive any low-income or subsidized housing|Family Received Low-Income or Subsidized Housing	A question about whether a family received low-income housing or subsidized housing.			Intellectual Product	
C159741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159741>	C173151	Family Received Free or Subsidized School Lunch Question|Did your family receive free/subsidized school lunch|Family Received Free or Subsidized School Lunch	A question about whether a family received free or subsidized school lunches.			Intellectual Product	
C159742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159742>	C173151	Family Received Income Support Question|Did your family receive income support (e.g. welfare or social assistance)|Family Received Income Support	A question about whether a family received income support, such as welfare or social assistance.			Intellectual Product	
C159743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159743>	C173151	Family Received Employment Insurance Question|Did your family receive employment insurance|Family Received Employment Insurance	A question about whether a family received employment insurance.			Intellectual Product	
C159744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159744>	C173151	Family Received Canada Child Benefit Question|Did your family receive Canada Child Tax Credit|Family Received Canada Child Benefit	A question about whether a family received Canada child benefit (CCB).			Intellectual Product	
C159745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159745>	C173151	Family Received Disability Tax Credit Question|Did your family receive Disability Tax Credit|Family Received Disability Tax Credit	A question about whether a family received disability tax credits.			Intellectual Product	
C159746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159746>	C17953	College Completion|College|College Degree|College Degree|College Graduate|College graduate	Indicates that a person has attended college and receive a degree.			Organism Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|GDC Terminology|GDC Value Terminology
C159747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159747>	C86029	Mobile Home|Mobile home	A dwelling on a trailer that that can be parked in one place, connected to utilities, and used as permanent housing.			Geographic Area	
C159748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159748>	C86029|C69074	Rented Room|Rented room	A room within a larger dwelling used as an individual living space in exchange for money.			Geographic Area	
C159749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159749>	C86029	Shelter or Transitional Living Situation|Shelter or transitional living situation	Indicates that a person lives or lived in an emergency shelter or in transitional housing.			Geographic Area	
C15974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15974>	C15972|C15438	Biological Cancer Immunotherapy|Biological Immunotherapy for Cancer|Immunotherapy, Cancer, Biological	The use of biological agents to enhance the host immune system in the treatment of cancer.			Therapeutic or Preventive Procedure	
C159750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159750>	C86029	No Steady Place to Sleep at Night|No steady place to sleep at night	Indicates that a person did not have a single fixed location to sleep each night.			Geographic Area	
C159751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159751>	C141286	Own Car|Own car	Transportation using a vehicle that is owned by the individual.			Activity	
C159752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159752>	C141286	Rides from Others|Rides from others (friends or family)	Getting rides from other people for transportation.			Activity	
C159753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159753>	C141286	Volunteer Driving Program|Volunteer driving program	A transportation service where volunteers provide rides.			Activity	
C159754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159754>	C141286	Handicap Transportation Service|Handibus (or other ride system)	A transportation service directed to, or reserved for, handicapped individuals.			Activity	
C159755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159755>	C226559	Can Do Very Well|Very Well	An indication that someone can do something quite well.			Intellectual Product	
C159756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159756>	C175338	Not True at All|Not at All True|Not at all true|Not true at all	A subjective response indicating that something is not at all true.			Intellectual Product	
C159757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159757>	C175338	Rarely True|Rarely true	A subjective response indicating that something is rarely true.			Intellectual Product	
C159758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159758>	C175338	Sometimes True|Sometimes true	A subjective response indicating that something is sometime true.			Intellectual Product	
C159759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159759>	C175338	Often True|Often true	A subjective response indicating that something is often true.			Intellectual Product	
C15975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15975>	C15918|C15438	Chemical Cancer Immunotherapy|Immunotherapy, Cancer, Chemical|chemical immunotherapy for cancer	Chemical Cancer Immunotherapy is the use of chemical substances to alter the interaction between the host's immune defenses and cancer cells to boost, direct, or restore the body's ability to fight cancer.			Therapeutic or Preventive Procedure	
C159760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159760>	C175338	True Nearly All of the Time|True nearly all the time|Very true	A subjective response indicating that something is true nearly all of the time.			Intellectual Product	
C159761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159761>	C176242	Several Days|Several days	A subjective response indicating that something is true or present several days.			Intellectual Product	
C159762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159762>	C175338	True or Present Nearly Every Day|Nearly Every Day|Nearly everyday	A subjective response indicating that something is true or present nearly every day.			Intellectual Product	
C159763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159763>	C175338	True or Present More than Half the Days|More than Half of the Days|More than half the days	A subjective response indicating that something is true or present more than half of the days.			Intellectual Product	
C159764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159764>	C129822|C128036	Anti-CTLA-4 Monoclonal Antibody REGN4659|REGN 4659|REGN-4659|REGN-4659|REGN4659	A fully human immunoglobulin G1 (IgG1) antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, anti-CTLA-4 monoclonal antibody REGN4659 targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.	Anti-CTLA-4 Monoclonal Antibody REGN4659		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C159765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159765>	C158612	Specify Number of Lymph Nodes Positive for Tumor by IHC Staining Only Question|Specify|Specify Number of Lymph Nodes Positive for Tumor by IHC Staining Only	A directive to specify the number of lymph nodes found positive for tumor by immunohistochemical (IHC) staining procedures.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uveal Melanoma Baseline Form
C159766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159766>	C158612	Specify Number of Lymph Nodes Positive for Tumor by H&E Question|Specify|Specify Number of Lymph Nodes Positive for Tumor by H&E	A directive to specify the number of lymph nodes positive for tumor by H&E.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uveal Melanoma Baseline Form
C159767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159767>	C158621	Zero Full Term Pregnancies|0	A response indicating there were no full term pregnancies.			Quantitative Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C159768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159768>	C158621	One Full Term Pregnancy|1	A response indicating there was one full term pregnancy.			Quantitative Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C159769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159769>	C158621	Two Full Term Pregnancies|2	A response indicating there were two full term pregnancies.			Quantitative Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C15976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15976>	C15944	Mouse Tumor Gene Index	A component of CGAP.			Intellectual Product	
C159770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159770>	C158621	Three Full Term Pregnancies|3	A response indicating there were three full term pregnancies.			Quantitative Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C159771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159771>	C158621	Greater than or equal to Four Pregnancies|>=4|Greater Than or Equal to 4 Pregnancies	A response indicating there were greater than or equal to four full term pregnancies.			Quantitative Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C159772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159772>	C160157	Menopause Status not Evaluated|Not Evaluated: Not provided or available	The menopause status has not been evaluated.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C159773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159773>	C157410	Unknown Oral Contraceptive Use Question|Unknown|Unknown Oral Contraceptive Use|Unknown: Could not be determined or unsure	An individual whose use of oral contraceptives is unknown.			Qualitative Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C159774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159774>	C157377	Testosterone Greater than or Equal to 150 ng/dL|Testosterone Greater than or Equal to 150 Nanograms per Deciliter|Testosterone Greater than or Equal to 150 Nanograms/Deciliter	A semiquantitative finding indicating that the concentration of testosterone in a sample is greater than or equal to 150 ng/dL.	Testosterone Greater than or Equal to 150 ng/dL		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C159775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159775>	C4911|C175304|C155903	Unresectable Gastric Carcinoma	A gastric carcinoma that is not amenable to surgical resection.	Unresectable Gastric Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C159776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159776>	C41278	Continuous Glucose Monitoring System|CGM|Continuous Glucose Monitoring	A system that uses a sensor under the skin to monitor glucose levels at regular intervals, providing real-time, or near real-time, glucose information.	Continuous Glucose Monitoring System		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C159777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159777>	C138961	PSA Level Twenty to One Hundred Fifty|PSA Level 20 to 150|PSA Level Between 20 and 150|PSA Level Between Twenty and One Hundred Fifty	A blood concentration of prostate specific antigen between 20 ng/mL and 150 ng/mL.	PSA Level Twenty to One Hundred Fifty		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159778>	C177696	Fanconi Anemia Complementation Group Gene Mutation Negative|FA Complementation Group Gene Mutation Negative|FA Complementation Group Gene Wild-Type|FA/BRCA Pathway Gene Wild-Type|FANC Family Gene Mutation Negative|FANC Gene Mutation Negative|FANC Wild-Type|FANC Wildtype|FANC wt|Fanconi Anemia Complementation Family Gene Mutation Negative|Fanconi Anemia Complementation Group Wild-Type|Fanconi Anemia Group Gene Mutation Negative	A genetic finding indicating that Fanconi anemia complementation group gene mutations have not been detected in a sample.	Fanconi Anemia Complementation Group Gene Mutation Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159779>	C159778	PALB2 Gene Mutation Negative|FANCN Gene Mutation Negative|Fanconi Anemia, Complementation Group N Gene Mutation Negative|PALB2 Gene Wild-Type|PALB2 Wild-Type|PALB2 Wildtype|PALB2 wt|PNCA3 Gene Mutation Negative|Partner and Localizer of BRCA2 Gene Mutation Negative	A genetic finding indicating that PALB2 gene mutations have not been detected in a sample.	PALB2 Gene Mutation Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15977>	C74957	Repository Operation	Procedures designed to run a repository facility.			Laboratory Procedure	
C159780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159780>	C159778	BRIP1 Gene Mutation Negative|BACH1 Gene Mutation Negative|BRCA1 Interacting Protein C-Terminal Helicase 1 Gene Mutation Negative|BRIP1 Gene Wild-Type|BRIP1 Wild-Type|BRIP1 Wildtype|BRIP1 wt|FANCJ Gene Mutation Negative	A genetic finding indicating that BRIP1 gene mutations have not been detected in a sample.	BRIP1 Gene Mutation Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159781>	C159778	FANCL Gene Mutation Negative|FAAP43 Gene Mutation Negative|FACL Gene Mutation Negative|FANCL Gene Wild-Type|FANCL Wild-Type|FANCL Wildtype|FANCL wt|Fanconi Anemia Complementation Group L Gene Mutation Negative|Fanconi Anemia, Complementation Group L Gene Mutation Negative|PHD Finger Protein 9 Gene Mutation Negative|PHF9 Gene Mutation Negative|POG Gene Mutation Negative	A genetic finding indicating that FANCL gene mutations have not been detected in a sample.	FANCL Gene Mutation Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159782>	C159778	RAD51 Gene Mutation Negative|BRCC5 Gene Mutation Negative|FANCR Gene Mutation Negative|HRAD51 Gene Mutation Negative|HsRad51 Gene Mutation Negative|RAD51 Gene Wild-Type|RAD51 Homolog (S. cerevisiae) Gene Mutation Negative|RAD51 Recombinase Gene Mutation Negative|RAD51 Wild-Type|RAD51 Wildtype|RAD51 wt|RAD51, S. cerevisiae, Homolog of A Gene Mutation Negative|RAD51A Gene Mutation Negative|RECA Gene Mutation Negative	A genetic finding indicating that RAD51 gene mutations have not been detected in a sample.	RAD51 Gene Mutation Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159783>	C177696	ATM Gene Mutation Negative|A-T Mutated Gene Mutation Negative|AT Mutated Gene Mutation Negative|ATM Gene Wild-Type|ATM Serine/Threonine Kinase Gene Mutation Negative|ATM Wild-Type|ATM Wildtype|ATM wt|Ataxia Telangiectasia Mutated Gene Mutation Negative	A genetic finding indicating that ATM gene mutations have not been detected in a sample.	ATM Gene Mutation Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159784>	C20727	CST1 Gene|CST1|CST1|Cystatin SN Gene	This gene plays a role in cysteine proteinase inhibition in saliva and other tissues.	CST1 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C159785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159785>	C159784	CST1 wt Allele|Cystatin 1 Gene|Cystatin SN wt Allele	Human CST1 wild-type allele is located in the vicinity of 20p11.21 and is approximately 4 kb in length. This allele, which encodes cystatin-SN protein, is involved in the inhibition of papain, cathepsin C and ficin.	CST1 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159786>	C18072	Cystatin-SN|CST1|Cystain-SA-I|Cystatin 1|Cystatin SA-I|Cystatin SN|Cystatin-1|Salivary Cystatin-SA-1	Cystatin-SN (141 aa, ~16 kDa) is encoded by the human CST1 gene. This protein plays a role in the inhibition of certain cysteine proteinases in the saliva, tears, urine and seminal fluid.	Cystatin-SN		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159787>	C125202	Checkpoint Inhibitor Relapsed Tumor	A finding indicating the treatment of a relapsed malignant tumor with checkpoint inhibitors to boost the immune response.	Checkpoint Inhibitor Relapsed Tumor		Finding	CTRP Disease Terminology|CTRP Terminology
C159788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159788>	C20727	CST2 Gene|CST2|CST2|Cystatin SA Gene	This gene plays a role in cysteine proteinase inhibition in submandibular and sublingual saliva.	CST2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C159789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159789>	C159788	CST2 wt Allele|Cystatin 2 Gene|Cystatin SA wt Allele	Human CST2 wild-type allele is located in the vicinity of 20p11.21 and is approximately 3 kb in length. This allele, which encodes cystatin-SA protein, plays a role in the regulation of salivary cysteine proteinase activity.	CST2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C15978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15978>	C15977	Tissue Repository Operation|Culturing, in vitro Vertebrate Repository Operations, Tissue|Repository Operation, Tissue	Procedures designed to run a tissue repository facility.			Laboratory Procedure	
C159790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159790>	C18072	Cystatin-SA|CST2|Cystatin 2|Cystatin S5|Cystatin SA|Cystatin-2|Cystatin-S5	Cystatin-SA (141 aa, ~16 kDa) is encoded by the human CST2 gene. This protein is involved in salivary cysteine proteinase inhibition.	Cystatin-SA		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159791>	C20727	CST4 Gene|CST4|CST4|Cystatin S Gene	This gene plays a role in the inhibition of cysteine proteinases in the saliva, tears, urine and seminal fluid.	CST4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C159792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159792>	C159791	CST4 wt Allele|Cystatin 4 Gene|Cystatin S wt Allele	Human CST4 wild-type allele is located in the vicinity of 20p11.21 and is approximately 3 kb in length. This allele, which encodes cystatin-S protein, is involved in cysteine proteinase inhibition.	CST4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159793>	C18072	Cystatin-S|CST4|Cystain-SA-III|Cystatin 4|Cystatin S|Cystatin-4|Salivary Acidic Protein 1	Cystatin-S (141 aa, ~16 kDa) is encoded by the human CST4 gene. This protein plays a role in the inhibition of papain, ficin and several other cysteine proteinases.	Cystatin-S		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159794>	C20727	CST5 Gene|CST5|CST5|Cystatin D Gene	This gene is involved in the inhibition of cathepsins in the oral cavity.	CST5 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C159795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159795>	C159794	CST5 wt Allele|Cystatin 5 Gene|Cystatin D wt Allele	Human CST5 wild-type allele is located in the vicinity of 20p11.21 and is approximately 3 kb in length. This allele, which encodes cystatin-D protein, plays a role in cathepsin inhibition.	CST5 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159796>	C18072	Cystatin-D|CST5|Cystatin 5|Cystatin D|Cystatin-5	Cystatin-D (142 aa, ~16 kDa) is encoded by the human CST5 gene. This protein is involved in the inhibition of cathepsin-mediated proteolysis.	Cystatin-D		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159798>	C201556|C129826	Tasadenoturev-infected Allogeneic Bone Marrow-derived Mesenchymal Stem Cells|Ad5-DNX-2401-infected Allogeneic Bone Marrow MSCs|Ad5-DNX-2401-infected Allogeneic Bone Marrow Mesenchymal Stem Cells|Allogeneic BM-hMSC-D24|Allogeneic BM-hMSC-Delta-24-RGD|Allogeneic Bone Marrow Mesenchymal Stem Cells Loaded with Oncolytic Adenovirus DNX-2401|Allogeneic Bone Marrow Mesenchymal Stem Cells loaded with DNX-2401|Allogeneic Bone Marrow Mesenchymal Stem Cells loaded with Tasadenoturev|BM-hMSC-D24|BM-hMSC-Delta-24-RGD|Oncolytic Adenovirus Ad5-DNX-2401-infected Allogeneic Bone Marrow Mesenchymal Stem Cells	A preparation of bone marrow-derived allogeneic mesenchymal stem cells (MSCs) infected with tasadenoturev (Ad5-DNX-2401), an adenovirus serotype 5 strain that is selectively replication competent in cells defective in the Rb/p16 tumor suppressor pathway, with potential antineoplastic activity. Upon infusion of the tasadenoturev-infected bone marrow-derived MSCs, these cells target and deliver the adenovirus to tumor cells. The oncolytic virus then selectively transfects and replicates in the tumor cells, eventually leading to tumor cell lysis and the release of virus particles and various tumor associated antigens (TAAs). This may induce a systemic immune response against tumor cells expressing these TAAs and further infection and killing of nearby tumor cells by the released viral particles. Ad5-DNX-2401 contains an integrin binding RGD-4C motif, allowing Coxsackievirus and adenovirus receptor-independent infection of tumor cells, which are often deficient for Coxsackievirus and adenovirus receptors (CARs). As integral components of the late G1 restriction point, the Rb gene product and p16 are negative regulators of the cell cycle and are often defective in certain cancer types.	Tasadenoturev-infected Allogeneic Bone Marrow-derived Mesenchymal Stem Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C159799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159799>	C125932	International Myeloma Working Group Minimal Residual Disease Criteria|IMWG Minimal Residual Disease Criteria	Uniform consensus criteria created by the International Myeloma Working Group to describe response to treatment for minimal residual disease.			Intellectual Product	
C15979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15979>	C28003	Focused Ultrasound Therapy|Focused Ultrasound|Focused Ultrasound Surgery|High Power Focused Ultrasound|Therapy (Focused US)|Therapy, Focused Ultrasound	Minimally invasive procedure for ablating tumors.  The primary mechanism of tissue damage is thermal.			Therapeutic or Preventive Procedure	
C159800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159800>	C159799	IMWG Sustained MRD-negative|Sustained MRD-negative|Sustained Minimal Residual Disease Negative	Minimal residual disease negativity in the marrow, by next-generation flow cytometry or next-generation sequencing, or both, and by imaging, confirmed a minimum of 1 year apart.			Intellectual Product	
C159801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159801>	C159799	IMWG Flow MRD-negative|Flow MRD-negative|Flow Minimal Residual Disease-negative	Absence of phenotypically aberrant clonal plasma cells by next-generation flow cytometry on bone marrow aspirates using the EuroFlow standard operation procedure for minimal residual disease detection in multiple myeloma (or validated equivalent method) with a minimum sensitivity of 1 in 10^5 nucleated cells or higher.			Intellectual Product	
C159802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159802>	C159799	IMWG Sequencing MRD-negative|Sequencing MRD-negative|Sequencing Minimal Residual Disease-negative	Absence of clonal plasma cells by next-generation sequencing on bone marrow aspirate in which presence of a clone is defined as less than two identical sequencing reads obtained after DNA sequencing of bone marrow aspirates using the LymphoSIGHT platform (or validated equivalent method) with a minimum sensitivity of 1 in 10^5 nucleated cells or higher.			Intellectual Product	
C159803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159803>	C159799	IMWG Imaging plus MRD-negative|Imaging plus MRD-negative|Imaging plus Minimal Residual Disease-negative	Minimal residual disease negativity as defined by next-generation flow cytometry or next-generation sequencing plus disappearance of every area of increased tracer uptake found at baseline or a preceding PET/CT or decrease to less mediastinal blood pool standard uptake value or decrease to less than that of surrounding normal tissue.			Intellectual Product	
C159804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159804>	C125932	International Myeloma Working Group Standard Response Criteria|IMWG Standard Response Criteria	Uniform consensus criteria created by the International Myeloma Working Group to describe response to treatment.			Intellectual Product	
C159805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159805>	C159804	IMWG Stringent Complete Response|Stringent Complete Response	Complete response, plus normal free light chain ratio and absence of clonal cells in bone marrow biopsy by immune-histochemistry (kappa/lambda ratio less than or equal to 4:1 or greater than or equal to 1:2 for kappa and lambda patients, respectively, after counting at least 100 plasma cells).			Intellectual Product	
C159806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159806>	C159804	IMWG Complete Response|Complete Response	Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and less than 5 percent plasma cells in bone marrow aspirates.			Intellectual Product	
C159807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159807>	C159804	IMWG Very Good Partial Response|Very Good Partial Response	Serum and urine M-protein detectable by immunofixation but not on electrophoresis or at least 90 percent reduction in serum M-protein plus urine M-protein level less than 100 mg per 24 hours.			Intellectual Product	
C159808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159808>	C159804	IMWG Partial Response|Partial Response	At least 50 percent reduction of serum M-protein plus reduction in 24 hour urinary M-protein by at least 90 percent or to less than 200 mg per 24 hour. If the serum and urine M-protein are unmeasurable, at least a 50 percent decrease in the difference between involved and uninvolved free light chain levels is required in place of the M-protein criteria. If serum and urine M-protein are unmeasurable, and serum-free light assay is also unmeasurable, at least a 50 percent reduction in plasma cells is required in place of M-protein, provided baseline bone marrow plasma-cell percentage was at least 30 percent. In addition to these criteria, if present at baseline, at least 50 percent reduction in the size (sum of products of diameters) of soft tissue plasmacytomas is also required.			Intellectual Product	
C159809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159809>	C159804	IMWG Minimal Response|Minimal Response	At least 25 percent but less than 50 percent reduction of serum M-protein and reduction in 24-hour urine M-protein by 50-89 percent. In addition to the above listed criteria, if present at baseline, at least a 50 percent reduction in the size (sum of products of diameters) of soft tissue plasmacytomas is also required.			Intellectual Product	
C15980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15980>	C15312	Radiometry (Microwave)	The measurement of radiation by photography, as in x-ray film and film badge, by Geiger-Mueller tube, and by scintillation counting.			Research Activity	
C159810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159810>	C159804	IMWG Stable Disease|Stable Disease	Not recommended for use as an indicator of response. Stability of disease is best described by providing the time-to-progression estimates. Not meeting criteria for complete response, very good partial response, partial response, minimal response, or progressive disease.			Intellectual Product	
C159811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159811>	C159804	IMWG Progressive Disease|Progressive Disease	Any one or more of the following criteria: increase of 25 percent from lowest confirmed response value in one or more of the following criteria: serum M-protein (absolute increase must be at least 0.5 g/dL); serum M-protein increase at least 1 g/dL, if the lowest M component was at least 5 g/dL; urine M-protein (absolute increase must be at least 200 mg/24 h); in patients without measurable serum and urine M-protein levels, the difference between involved and uninvolved free light chain levels (absolute increase must be greater than 10 mg/dL); in patients without measurable serum and urine M-protein levels and without measurable involved free light chain levels, bone marrow plasma-cell percentage irrespective of baseline status (absolute increase must be at least 10 percent); appearance of a new lesion(s), at least 50 percent increase from nadir in sum of products of diameters of greater than 1 lesion, or at least 50 percent increase in the longest diameter of a previous lesion greater than 1 cm in short axis; at least 50 percent increase in circulating plasma cells (minimum of 200 cells per uL) if this is the only measure of disease.			Intellectual Product	
C159812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159812>	C158612	Outcome Measure of Success at Completion of Initial Treatment Course Not Applicable Question|Not Applicable|Outcome Measure of Success at Completion of Initial Treatment Course Not Applicable	A request to indicate if the measure of success of outcome after the completion of the first treatment is not applicable.			Intellectual Product	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Terminology
C159813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159813>	C158612	Outcome Measure of Success at Completion of Initial Treatment Unknown Question|Not Applicable|Outcome Measure of Success at Completion of Initial Treatment Unknown	A request to indicate if the measure of success of outcome after the completion of the first treatment is unknown.			Intellectual Product	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Terminology
C159815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159815>	C160157	Performance Status Scale Timing Unknown|Unknown|Unknown: Could not be determined or unsure	The timing of the performance scale is unknown.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C159816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159816>	C160157	Performance Status Scale Timing Not Applicable|Not Applicable	A response that the performance status scale timing is not applicable.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C159817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159817>	C208255|C207756|C129820	TGFbeta Receptor Ectodomain-IgG Fc Fusion Protein BMS-986416|AVID 200|AVID-200|AVID-200|AVID200|BMS 986416|BMS-986416|BMS986416|TGF-beta 1/3 Inhibitor AVID200|TGFb Inhibitor AVID200|TGFbeta Ligand Trap AVID200|TGFbeta-neutralizing Agent AVID200	A fusion protein composed of the ectodomain of the transforming growth factor (TGF) beta (TGF-beta; TGFb) receptor fused to the human immunoglobulin G (IgG) Fc domain, with potential antineoplastic, immunomodulating and anti-fibrotic activities. Upon administration of the TGFb receptor ectodomain-IgG Fc fusion protein BMS-986416, the fusion protein specifically and selectively targets, binds to and neutralizes the TGF ligands TGF-beta isoform 1 (TGFb1) and 3 (TGFb3). This prevents TGF ligands from binding to TGF receptors and prevents TGFb-mediated signaling. This abrogates TGFb1/3-mediated immunosuppression, enhances anti-tumor immunity in the tumor microenvironment (TME) and promotes a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGFb-dependent proliferation of cancer cells. By preventing TGFb1/3-mediated signaling, BMS-986416 also prevents bone marrow fibrosis and promotes the proliferation of normal hematopoietic progenitors. TGFb, overproduced in myelodysplastic syndrome (MDS) and in many other types of cancer, plays a key role in immunosuppression in the TME, enhances tumor cell proliferation, and promotes cancer progression. The TGFb1 and TGFb3 isoforms are negative regulators of hematopoiesis that play key roles in the pathogenesis and progression of fibrotic diseases. By selectively targeting only specific isoforms of TGFb with minimal activity against TGFb2, BMS-986416 minimizes the potential for cardiotoxicity and promotion of metastasis. The TGFb2 isoform promotes hematopoiesis and plays a key role in normal cardiac function while the inhibition of the TGFb2 isoform promotes metastasis.	TGFbeta Receptor Ectodomain-IgG Fc Fusion Protein BMS-986416		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C159818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159818>	C160157	HPV-Other Type|Other	An indication that the strain of human papillomavirus (HPV) was identified in the study but is not present in the form.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C15981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15981>	C15986|C15632	Supportive Cancer Chemotherapy|Chemotherapy, Cancer, Supportive	Treatment designed to improve the health of a chemotherapy patient but that does not directly affect the tumor.			Therapeutic or Preventive Procedure	
C159820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159820>	C158612	Other HPV Typing Method Question|Other|Other HPV Typing Method	An indication that the method used to perform human papillomavirus (HPV) genotyping was identified in the study but is not present in the form.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C159821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159821>	C25651	Healthcare Device Direct Feed Reporting	An indication that vital sign data came directly from a device in a healthcare facility.			Activity	
C159822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159822>	C548	[Leu15] Gastrin-17|GAST 17|GAST-17|GAST17	A C-terminal amidated synthetic gastrin analog with a single amino acid change at position 15, where leucine replaces methionine, with potential hypoglycemic and immunomodulatory activities. Following pancreatic islet cell transplantation, subcutaneous administration of [Leu15] Gastrin-17 (GAST-17) may induce pancreatic beta cell regeneration and expansion and enhance the insulin secretory capacity of islet cell grafts. Additionally, GAST-17 may reduce inflammation within the islet cell environment, which could potentially improve islet graft survival and function. Gastrin, a gastrointestinal peptide, may induce beta cell neogenesis via induction of the duodenal and pancreatic homeobox transcription factor, PDX-1. Gastrin may also promote beta cell proliferation and neogenesis indirectly through increasing the production of clustrin, a beta cell expansion factor.	[Leu15] Gastrin-17		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C159823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159823>	C70732	Not Lost to Follow-Up|No	The individual was not lost to follow-up.			Qualitative Concept	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C159824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159824>	C158612	Is Individual Lost to Follow-Up Question|Is Individual Lost to Follow-Up|Is this Patient Lost to Follow-Up|Patient Lost to Follow-Up|lost to followup|lost_to_followup	A question about whether the individual was lost to follow-up.			Intellectual Product	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|GDC Property Terminology|GDC Terminology
C159825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159825>	C91106	Describes Very Well|Very Well	An indication that something describes the individual's situation very well.			Intellectual Product	
C159826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159826>	C77812	Aboriginal North American|Aboriginal|Indigenous North America|Indigenous People of North America	Denotes any of the indigenous people who lived in North America at the time Europeans reached the continent, including Native American, First Nations, Inuit, and Metis people.			Population Group	
C159827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159827>	C173151|C173045	Usually Stay on Top of Things Question|Usually Stay on Top of Things|We are usually able to stay on top of things	A question about whether an individual and their family is able to stay on top of things.			Intellectual Product	
C159828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159828>	C173151	Home is a Zoo Question|Home is a Zoo|It's a real zoo in our home	A question about whether an individual's home is or was like a zoo.			Intellectual Product	
C159829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159829>	C173597	Can't Hear Yourself Think at Home Question|Can't Hear Yourself Think at Home|You can't hear yourself think in our home	A question about whether you can hear yourself think in an individual's home.			Intellectual Product	
C15982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15982>	C15760	Drug Development, Experimental|Drug Testing/Development, Experimental	Drug development activites focused on the phases preceding preclinical trials and testing.			Research Activity	
C159830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159830>	C91102	Usually a Television is On Question|There is usually a television turned on somewhere in our home|Usually a Television is On	A question about whether there is usually a television turned on in an individual's home.			Intellectual Product	
C159831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159831>	C173151	Home Atmosphere is Calm Question|Home Atmosphere is Calm|The atmosphere in our home is calm	A question about whether an individual's home atmosphere is calm.			Intellectual Product	
C159832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159832>	C173151	Have a Regular Morning Routine in Our Home Question|Have a Regular Morning Routine in Our Home|We have a regular morning routine in our home	A question about whether an individual and their family has a regular morning routine at home.			Intellectual Product	
C159833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159833>	C173045	Able to Adapt When Changes Occur Question|Able to Adapt When Changes Occur|I am able to adapt when changes occur	A question about whether an individual is able to adapt when changes occur.			Intellectual Product	
C159834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159834>	C91102	Can Deal with Whatever Comes my Way Question|Can Deal with Whatever Comes my Way|I can deal with whatever comes my way	A question about whether an individual is able to deal with whatever comes their way.			Intellectual Product	
C159835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159835>	C91102	Try to See Humorous Side of Things When Faced with Problems Question|I try to see the humorous side of things when I am faced with problems|Try to See Humorous Side of Things When Faced with Problems	A question about whether an individual tries to see the humorous side of things when faced with problems.			Intellectual Product	
C159836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159836>	C91102	Having to Cope with Stress can Make me Stronger Question|Having to Cope with Stress can Make me Stronger|Having to cope with stress can make me stronger	A question about whether an individual feels that coping with stress can make them stronger.			Intellectual Product	
C159837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159837>	C91102	Tend to Bounce Back After Illness, Injury, or Other Hardships Question|I tend to bounce back after illness, injury, or other hardships|Tend to Bounce Back After Illness, Injury, or Other Hardships	A question about whether an individual tends to bounce back after illness, injury, or other hardships.			Intellectual Product	
C159838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159838>	C173045	Can Achieve my Goals, Even if There are Obstacles Question|Can Achieve my Goals, Even if There are Obstacles|I believe I can achieve my goals, even if there are obstacles	A question about whether an individual believes they can achieve their goals, even if there are obstacles.			Intellectual Product	
C159839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159839>	C173597	Stay Focused and Think Clearly Under Pressure Question|Stay Focused and Think Clearly Under Pressure|Under pressure, I stay focused and think clearly	A question about whether an individual is able to stay focused and think clearly under pressure.			Intellectual Product	
C15983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15983>	C15212	Combined Pharmacological and Behavioral Treatment|Combined Pharmacological/Behavioral Treatment|Combined Pharmacological/Behavioral Treatments	Pharmacological and behavioral interventions, such as the combined use of nicotine replacement and biofeedback, for the treatment of physiological addictions, such as nicotine. (NCI/TRIP)			Therapeutic or Preventive Procedure	
C159840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159840>	C91102	Not Easily Discouraged by Failure Question|I am not easily discouraged by failure|Not Easily Discouraged by Failure	A question about whether an individual is not easily discouraged by failure.			Intellectual Product	
C159841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159841>	C173597	Think of Myself as a Strong Person When Dealing with Life's Challenges and Difficulties Question|I think of myself as a strong person when dealing with life's challenges and difficulties|Think of Myself as a Strong Person When Dealing with Life's Challenges and Difficulties	A question about whether an individual thinks of themselves as a strong person when dealing with life's challenges and difficulties.			Intellectual Product	
C159842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159842>	C173160|C173045	Able to Handle Unpleasant or Painful Feelings Question|Able to Handle Unpleasant or Painful Feelings|I am able to handle unpleasant or painful feelings like sadness, fear, and anger	A question about whether an individual is able to handle unpleasant or painful feelings, like sadness, fear, and anger.			Intellectual Product	
C159843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159843>	C91102	Treated with Less Courtesy or Respect than Other People Question|Treated with Less Courtesy or Respect than Other People|You are treated with less courtesy or respect than other people	A question about whether an individual feels or felt that they are treated with less courtesy and respect than other people.			Intellectual Product	
C159844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159844>	C91102	Receive Poorer Service Than Other People at Restaurant or Stores Question|Receive Poorer Service Than Other People at Restaurant or Stores|You receive poorer service than other people at restaurants or stores	A question about whether an individual feels or felt that they receive poorer service than other people at restaurants or stores.			Intellectual Product	
C159845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159845>	C173597	People Act as if They Think You are Not Smart Question|People Act as if They Think You are Not Smart|People act as if they think you are not smart	A question about whether an individual feels or felt that people act as if they think the individual is not smart.			Intellectual Product	
C159846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159846>	C91102	People Act as if They are Afraid of You Question|People Act as if They are Afraid of You|People act as if they are afraid of you	A question about whether an individual feels or felt that people act as if they are afraid of the individual.			Intellectual Product	
C159847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159847>	C173160	Threatened or Harassed Question|Threatened or Harassed|You are threatened or harassed	A question about whether an individual feels or felt that they have been threatened or harassed.			Intellectual Product	
C159848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159848>	C175990|C173597	Reason for the Experience Question|Reason for the Experience|what do you think is the main reason for these experiences	A question about what an individual feels is the reason for their experiences.			Intellectual Product	
C159849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159849>	C157093	If Answered|If you answered	A directive to do something if a question was answered in a particular way.			Activity	
C15984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15984>	C15997|C15711	Combined Prevention/Cessation Research	Studies identifying, testing, and implementing interventions among groups of individuals that are designed to both prevent and stop current use of specific substances, such as tobacco or alcohol. (NCI/TRIP)			Research Activity	
C159850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159850>	C25515	Less Than Once a Year|Less than once a year	Happening less than one time during a year.			Quantitative Concept	
C159851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159851>	C25515	A Few Times a Year|A few times a year	Happening a few times during a year.			Quantitative Concept	
C159852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159852>	C25515	A Few Times a Month|A few times a month	Happening a few times during a month.			Quantitative Concept	
C159853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159853>	C25515	At Least Once a Week|At least once a week	Happening at least once during a week.			Quantitative Concept	
C159854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159854>	C35877	Aberrant Clonal Plasma Cell Population|Aberrant Clonal Plasma Cells|Abnormal Clonal Plasma Cell Population	A population of plasma cells which display atypical morphological features, an abnormal immunophenotypic profile, and molecular genetic characteristics of clonality (monoclonality).			Laboratory or Test Result	
C159855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159855>	C178371	Other Aspect of Physical Appearance|Some other aspect of your physical appearance	A response about some other aspect of an individual's physical appearance.			Intellectual Product	
C159856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159856>	C226694	Very Well|Very well	A subjective response of strong agreement or ability.			Intellectual Product	
C159857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159857>	C16960	Esophagogastroduodenoscopy Patient	A patient who is undergoing an esophagogastroduodenoscopy.	Esophagogastroduodenoscopy Patient		Patient or Disabled Group	CTRP Intervention Terminology|CTRP Terminology
C159858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159858>	C50344	Cleveland Multiport Catheter|CMC	A catheter designed for convection-enhanced delivery to the brain, incorporating four microcatheters.	Cleveland Multiport Catheter		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C159859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159859>	C201922	Stereotactic Implantation	A procedure in which a computer and a 3-dimensional scanning device are used place an implant.	Stereotactic Implantation		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C15985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15985>	C70819	Nicotine Dependence/Addiction on Treatment	Research Studies that assess the behavioral and/or pharmacological treatment of individuals for nicotine dependence/addiction.  The specific focus of treatment interventions is the individual in clinical and physician-based settings. (NCI/TRIP)			Research Activity	
C159860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159860>	C217122	BASC-3 F Index|F Index|F-Index	A classically derived infrequency scale, designed to assess the possibility that a rater has depicted a child's behavior in an inordinately negative fashion.			Intellectual Product	Behavior Assessment System for Children, Third Edition
C159861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159861>	C217122	BASC-3 Response Pattern Index|Response Pattern Index	Detects two types of repeat patterns: repeated and cylindrical response patterning.			Intellectual Product	Behavior Assessment System for Children, Third Edition
C159862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159862>	C217122	BASC-3 Consistency Index|Consistency Index	Flags cases in which child has given different responses to items that usually are answered similarly; a measure of random responding.			Intellectual Product	Behavior Assessment System for Children, Third Edition
C159863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159863>	C28013	Karnofsky Performance Status Not Evaluated|Not Evaluated: Not provided or available	The Karnofsky Performance Status Score was not evaluated.			Clinical Attribute	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Normal Endometrial Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C159864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159864>	C28013	Karnofsky Performance Status Unknown|Unknown: Could not be determined or unsure	The Karnofsky Performance Status Score is unknown.			Clinical Attribute	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Baseline Form|CPTAC Melanoma Follow-Up Form|CPTAC Normal Endometrial Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Baseline Form|CPTAC Sarcoma Follow-Up Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form|CPTAC Uveal Melanoma Baseline Form|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C159865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159865>	C17103	Unknown Risk Factor|Unknown: Could not be determined or unsure	The risk factor status is unknown.			Clinical Attribute	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C159866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159866>	C17103	Other Risk Factor|Other	The risk factor status is was identified in the study but is not present in the form .			Clinical Attribute	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C159867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159867>	C121007	Child-Pugh Class Unknown|Unknown: Could not be determined or unsure	Unable to determine the Child-Pugh class.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C159868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159868>	C95149	Ishak Score Unknown|Unknown: Could not be determined or unsure	Unknown Ishak score.			Classification	CPTAC Baseline Medical Forms Terminology|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C159869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159869>	C158612	Other Non-Neoplastic Finding Question|Other|Other Non-Neoplastic Finding	A selection that the choice was identified in the study but is not present in the form.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C15986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15986>	C49236	Pharmacotherapy|Drug Therapy|Drug Therapy|Drug Therapy|Pharmaceutical Therapy|Pharmaceutical Therapy, NOS|Pharmacological Treatment|Pharmacological Treatments|Treatment With Medication|drug therapy|drug therapy	Treatment of disease through the use of drugs.	Pharmacotherapy		Therapeutic or Preventive Procedure	CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology|CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|NICHD Terminology
C159870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159870>	C158612	Specify Other Non-Neoplastic Finding Question|If Other, Specify|Specify Other Non-Neoplastic Finding	A directive to specify the other non-neoplastic finding.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C159871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159871>	C177693|C142105	FGFR2B Overexpression|FGFR-2 IIIb Overexpression|FGFR2 IIIb Overexpression|FGFR2(IIIb) Overexpression|FGFR2-IIIb Overexpression|FGFR2IIIb Overexpression|Fibroblast Growth Factor Receptor 2 Isoform IIIb Overexpression	An indication that overexpression of FGFR2B has been detected in a sample.	FGFR2B Overexpression		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159872>	C62634	Regimen Used to Treat Malignant Bone Marrow Neoplasm	Any regimen that can be used for the treatment of malignant bone marrow neoplasms.			Therapeutic or Preventive Procedure	
C159873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159873>	C15697	Enumerated Treatment Regimens	Treatment regimens that are enumerated to provide disctinction from each other.			Functional Concept	
C159874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159874>	C159873	Treatment Regimen #1	The first treatment regimen.			Functional Concept	CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Terminology
C159875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159875>	C159873	Treatment Regimen #2	The second treatment regimen.			Functional Concept	CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Terminology
C159876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159876>	C159873	Treatment Regimen #3	The third treatment regimen.			Functional Concept	CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Terminology
C159877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159877>	C159873	Treatment Regimen #4	The fourth treatment regimen.			Functional Concept	CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Terminology
C159878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159878>	C159873	Treatment Regimen #5	The fifth treatment regimen.			Functional Concept	CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Terminology
C159879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159879>	C217137|C15190	Transvaginal Biopsy	Biopsy of structures in the pelvis obtained by a needle inserted through the vaginal wall.			Diagnostic Procedure	
C15987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15987>	C16053	Tobacco Use and Related Risk Factors, Surveillance	Research studies that assess trends in tobacco-related risk factors, behaviors and health services to determine changes over time and the influence of these trends on cancer incidence, morbidity, mortality and survival.  (NCI/TRIP)			Health Care Activity	
C159880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159880>	C15290	Ureteroureterostomy	An end-to-end anastomosis of segments of the same ureter, with excision of the intervening ureter.			Therapeutic or Preventive Procedure	
C159881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159881>	C15290	Ureteroileostomy	Surgical diversion of a ureter into an isolated segment of the ileum which drains through an abdominal stoma.			Therapeutic or Preventive Procedure	
C159882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159882>	C16482	Cystourethroscopy	Endoscopic examination of the bladder and urethra.			Health Care Activity	
C159883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159883>	C17204	CT Urography|Urography Computed Tomography	The use of computed tomography to image the kidney and urinary system.			Diagnostic Procedure	
C159884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159884>	C16809	MR Urography|Magnetic Resonance Urography	The use of magnetic resonance to image the kidney and urinary system.			Diagnostic Procedure	
C159885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159885>	C17230	Renal Ultrasound|Renal Ultrasound Imaging	The use of ultrasound to image the kidney.			Health Care Activity	
C159886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159886>	C16502	Retrograde Ureteropyelography	Imaging of the ureter and kidney by fluoroscopy or radiography following injection of contrast medium into the ureter.			Diagnostic Procedure	
C159887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159887>	C38068	Retrograde Selective Washing of Upper Tract|Retrograde Selective Washing of Ureter and Renal Pelvis	Lavage of the ureter and renal pelvis with collection of the fluid to sample cells for pathology.			Diagnostic Procedure	
C159888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159888>	C47792	Extended-release Galantamine Hydrobromide|ER Galantamine Hydrobromide|Galantamine Hydrobromide ER|Galantamine Hydrobromide Extended Release|Lycoremine Hydrobromide ER|Razadyne ER	An extended-release (ER) formulation of the hydrobromide salt form of galantamine, a tertiary alkaloid obtained synthetically or naturally from the bulbs and flowers of Narcissus and several other genera of the Amaryllidaceae family, with anticholinesterase and neurocognitive-enhancing activities. Upon administration, galantamine competitively and reversibly inhibits acetylcholinesterase, thereby increasing the concentration and enhancing the action of acetylcholine (Ach). In addition, galantamine is a ligand for nicotinic acetylcholine receptors, which may increase the presynaptic release of Ach and activate postsynaptic receptors. This agent may improve neurocognitive function in mild and moderate Alzheimer's disease and may, through its Ach stimulating effect on nicotinic receptors, help quit smoking and reduce abstinence-induced cognitive symptoms that promote smoking relapse.	Extended-release Galantamine Hydrobromide		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C159889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159889>	C38068	Selective Washing	A procedure to collect the fluid from selected body sites in order to sample cells for cytology.	Selective Washing		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C15988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15988>	C15922|C15714	Tobacco Use Basic Biological Research	Laboratory-based research studies that assess the effects of tobacco and tobacco products on cell biology and cellular mechanisms of action, including the role of tobacco and tobacco byproducts in the initiation and promotion of cancer and the biological.  (NCI/TRIP)			Research Activity	
C159890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159890>	C138935	Body Mass Index Greater than or Equal to 30|BMI Greater than or Equal to 30	Indicates a body mass index of 30 or higher.	Body Mass Index Greater than or Equal to 30		Finding	CTRP Disease Terminology|CTRP Terminology
C159891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159891>	C116681	Negative Pressure Wound Therapy|NPWT|Vacuum-Assisted Wound Closure	A wound dressing system that continuously or intermittently applies subatmospheric pressure to the surface of a wound to draw out fluid and promote healing.	Negative Pressure Wound Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C159892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159892>	C200043	CEA-targeting Agent RG6123|RG 6123|RG-6123|RG6123|RO 7172508|RO-7172508|RO7172508	An agent targeting the tumor-associated antigen (TAA) carcinoembryonic antigen (CEA), with potential antineoplastic activity. Upon administration, CEA-targeting agent RG6123 targets and binds to human CEA that is specifically expressed on certain tumor cells. This may, through an as of yet not elucidated mechanism of action, kill CEA-expressing tumor cells. CEA is overexpressed in many cancer cell types.	CEA-targeting Agent RG6123		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C159893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159893>	C203470	Regimen Used to Treat Malignant Intestinal Neoplasm	Any regimen that can be used for the treatment of malignant intestinal neoplasms.			Therapeutic or Preventive Procedure	
C159894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159894>	C158612	RECIST Comments Question|Comments|RECIST Comments	Any comments pertaining to the RECIST evaluation.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Terminology
C159895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159895>	C158612	Unknown Outcome Question|Unknown Outcome|Unknown: Could not be determined or unsure	The outcome is unknown.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C159896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159896>	C158612	Not Applicable Outcome Question|Not Applicable|Not Applicable Outcome	The outcome is not applicable.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C159897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159897>	C177681	ERBB2 Gene Amplification Negative|ERBB2 Non-Amplified|Erb-B2 Receptor Tyrosine Kinase 2 Gene Amplification Negative|HER-2 Gene Amplification Negative|HER2 Gene Amplification Negative|HER2 Non-Amplified|HER2/neu Gene Amplification Negative|NEU Gene Amplification Negative|Negative|v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 Gene Amplification Negative	An indication that amplification of the ERBB2 gene was not detected in a sample.	ERBB2 Gene Amplification Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159898>	C173151	Family Received Food Stamps Question|Family Received Food Stamps|Family received food stamps|Food Stamps|SNAP|Supplemental Nutrition Assistance Program	A question about whether a family received assistance to buy food, such as from the Supplemental Nutrition Assistance Program (SNAP).			Intellectual Product	
C159899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159899>	C158612	Was a New Tumor Event Present After Initial Treatment Question|Event After Initial Treatment|New Tumor Event After Initial Treatment|Was a New Tumor Event Present After Initial Treatment	A question about whether a new tumor was present after the initial treatment.			Intellectual Product	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C15989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15989>	C15604	Tobacco Use, Chemoprevention	Studies that assess the administration of specific and/or dietary modifications to reverse or suppress the carcinogenic effects of tobacco and prevent the development of invasive cancer.  (NCI/TRIP)			Therapeutic or Preventive Procedure	
C1598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1598>	C574	Gusperimus Trihydrochloride|(+-)-15-Deoxyspergualin|(+/-)-15-Deoxyspergualin Hydrochloride|(+/-)-Deoxyspergualin Hydrochloride|1-Amino-19-guanidino-11-hydroxy-4,9,12-triazanonadecane-10,13-dione|15-Deoxyspergualin|15-Deoxyspergualin Hydrochloride|7-[(Aminoiminomethyl)amino]-N-[2-[[4-[(3-aminopropyl)amino]butyl]amnio]-1-hydroxy-2-oxoethyl]heptanamide|BMS-181173|BMY-42215-1|DSG|Deoxyspergualin|GUSPERIMUS TRIHYDROCHLORIDE|N-[[[4-[(3-Aminopropyl)amino]-butyl]carbamoyl]hydroxymethyl]-7-guanidinoheptanamide|NKT-01|Spanidin	A derivative of the antitumor antibiotic spergualin with immunosuppressant activity.  Gusperimus inhibits the interleukin-2-stimulated maturation of T cells to the S and G2/M phases and the polarization of the T cells into IFN-gamma-secreting Th1 effector T cells, resulting in the inhibition of growth of activated naive CD4 T cells; this agent may suppress growth of certain T-cell leukemia cell lines. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C159900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159900>	C62634	Regimen Used to Treat Malignant Fallopian Tube Neoplasm	Any regimen that can be used for the treatment of malignant fallopian tube neoplasms.			Therapeutic or Preventive Procedure	
C159901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159901>	C62634	Regimen Used to Treat Malignant Peritoneal Neoplasm	Any regimen that can be used for the treatment of malignant peritoneal neoplasms.			Therapeutic or Preventive Procedure	
C159902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159902>	C4908|C224161	Platinum-Sensitive Ovarian Carcinoma|Platinum Sensitive Ovarian Cancer|Platinum-Sensitive Ovarian Cancer	An ovarian carcinoma that has a documented response to platinum-based chemotherapy.	Platinum Sensitive Ovarian Cancer		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C159903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159903>	C176863|C153171|C148128	Advanced Thymus Carcinoma|Advanced Thymic Carcinoma|Advanced Thymic Carcinoma	A thymus carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Thymic Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C159904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159904>	C9270|C7904	Advanced Malignant Thymoma	A malignant thymoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Malignant Thymoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C159905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159905>	C177692|C128808	CEACAM6 Positive|CD66c Antigen Positive|CD66c Positive|CEAL Positive|Carcinoembryonic Antigen Related Cell Adhesion Molecule 6 Positive|Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6 Positive|NCA Positive|Non-Specific Cross Reacting Antigen Positive|Non-Specific Crossreacting Antigen Positive|Nonspecific Crossreacting Antigen Positive|Normal Cross-Reacting Antigen Positive|Normal Crossreacting Antigen Positive	An indication that CEACAM6 expression has been detected in a sample.	CEACAM6 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C159906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159906>	C18473|C15229	Drug Response Predictor|DRP	A proprietary screening platform that utilizes messenger RNA gene expression signatures from patient biopsies to identify patients with a high likelihood of responding to specific cancer-fighting therapies.			Laboratory Procedure	
C159907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159907>	C159906	2X-121 DRP|2X-121 Drug Response Prediction	A screening assay that uses messenger RNA gene expression signatures from patient biopsies to identify patients with a high likelihood of responding to PARP/Tankyrase Inhibitor 2X-121 (2X-121).	2X-121 DRP		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C159908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159908>	C20993	Lymphedema Symptom Intensity and Distress Survey - Arm|LSIDS-A|Lymphedema Symptom Intensity and Distress Survey-Arm (LSIDS-A)	A self-report tool designed to evaluate arm lymphedema and associated symptoms in breast cancer survivors.			Intellectual Product	
C159909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159909>	C62634	Regimen Used to Treat Malignant Germ Cell Tumor	Any regimen that can be used to treat malignant germ cell tumors.			Therapeutic or Preventive Procedure	
C15990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15990>	C15922	Tobacco Use, Community and State Intervention Research	Research studies that test group and population-based interventions and the dissemination of group and population-based interventions to prevent and reduce tobacco use. (NCI/TRIP)			Research Activity	
C159910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159910>	C62634	Regimen Used to Treat Malignant Reproductive Endocrine Neoplasm	Any regimen that can be used to treat malignant reproductive endocrine neoplasms.			Therapeutic or Preventive Procedure	
C159911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159911>	C173981	Have Heaviness in Your Arm Question|Have Heaviness in Your Arm|Heaviness in your arm	A question about whether an individual experiences or experienced heaviness in their arm.			Intellectual Product	Lymphedema Symptom Intensity and Distress Survey - Arm
C159912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159912>	C173981	Have Tightness in Your Arm Question|Have Tightness in Your Arm|Tightness in your arm	A question about whether an individual experiences or experienced tightness in their arm.			Intellectual Product	Lymphedema Symptom Intensity and Distress Survey - Arm
C159913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159913>	C91126	Have Pain in Your Arm Question|Have Pain in Your Arm|Pain in your arm	A question about whether an individual experiences or experienced pain in their arm.			Intellectual Product	Lymphedema Symptom Intensity and Distress Survey - Arm
C159914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159914>	C159913	Have Stabbing Pain in Your Arm Question|Have Stabbing Pain in Your Arm|Stabbing pain in your arm	A question about whether an individual experiences or experienced stabbing pain in their arm.			Intellectual Product	Lymphedema Symptom Intensity and Distress Survey - Arm
C159915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159915>	C159913	Have Cramping Pain in Your Arm Question|Cramping pain in your arm|Have Cramping Pain in Your Arm	A question about whether an individual experiences or experienced cramping pain in their arm.			Intellectual Product	Lymphedema Symptom Intensity and Distress Survey - Arm
C159916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159916>	C105777	Have Numbness in Your Arm Question|Have Numbness in Your Arm|Numbness in your arm	A question about whether an individual experiences or experienced numbness in their arm.			Intellectual Product	Lymphedema Symptom Intensity and Distress Survey - Arm
C159917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159917>	C173981	Have Achiness in Your Arm Question|Achiness in your arm|Have Achiness in Your Arm	A question about whether an individual experiences or experienced achiness in their arm.			Intellectual Product	Lymphedema Symptom Intensity and Distress Survey - Arm
C159918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159918>	C105770	Have Swelling in Your Arm Question|Have Swelling in Your Arm|Swelling in your arm	A question about whether an individual experiences or experienced swelling in their arm.			Intellectual Product	Lymphedema Symptom Intensity and Distress Survey - Arm
C159919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159919>	C173981	Have Hardness in Your Arm Question|Hardness in your arm|Have Hardness in Your Arm	A question about whether an individual experiences or experienced hardness in their arm.			Intellectual Product	Lymphedema Symptom Intensity and Distress Survey - Arm
C15991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15991>	C15997	Tobacco Use, Cessation Research	Studies to test and implement interventions among groups of individuals that are designed to stop current use of tobacco.  (NCI/TRIP)			Research Activity	
C159920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159920>	C173734	Have Tingling in Your Arm Question|Have Tingling in Your Arm|Tingling in your arm	A question about whether an individual experiences or experienced tingling in their arm.			Intellectual Product	Lymphedema Symptom Intensity and Distress Survey - Arm
C159921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159921>	C173981	Have Pins and Needles in Your Arm Question|Have Pins and Needles in Your Arm|Pins and needles in your arm	A question about whether an individual experiences or experienced pins and needles in their arm.			Intellectual Product	Lymphedema Symptom Intensity and Distress Survey - Arm
C159922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159922>	C173398	Have Difficulty Moving Arm Side to Side Question|Difficulty moving arm side to side|Have Difficulty Moving Arm Side to Side	A question about whether an individual experiences or experienced difficulty moving their arm from side to side.			Intellectual Product	Lymphedema Symptom Intensity and Distress Survey - Arm
C159923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159923>	C173398	Have Difficulty Raising Arm Above Head Question|Difficulty in raising arm above head|Have Difficulty Raising Arm Above Head	A question about whether an individual experiences or experienced difficulty raising their arm above their head.			Intellectual Product	Lymphedema Symptom Intensity and Distress Survey - Arm
C159924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159924>	C173086	Have Lack of Confidence in Self Question|Have Lack of Confidence in Self|Lack of confidence in self	A question about whether an individual experiences or experienced a lack of confidence in their self.			Intellectual Product	Lymphedema Symptom Intensity and Distress Survey - Arm
C159925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159925>	C173086	Have Lack of Confidence in Insurance Provider Question|Have Lack of Confidence in Insurance Provider|Lack of confidence in your insurance provider	A question about whether an individual experiences or experienced a lack of confidence in their insurance provider.			Intellectual Product	Lymphedema Symptom Intensity and Distress Survey - Arm
C159926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159926>	C176022|C173084	Have Concerns About How You Look Question|Concerns about how you look|Have Concerns About How You Look	A question about whether an individual experiences or experienced concerns about how they look.			Intellectual Product	Lymphedema Symptom Intensity and Distress Survey - Arm
C159927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159927>	C173160	Feel Misunderstood by Spouse or Significant Other Question|Feel Misunderstood by Spouse or Significant Other|Feeling misunderstood by spouse/significant other	A question about whether an individual feels or felt misunderstood by their spouse or significant other.			Intellectual Product	Lymphedema Symptom Intensity and Distress Survey - Arm
C159928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159928>	C173160	Feel Frustration with Insurance Company Question|Feel Frustration with Insurance Company|Frustration with your insurance company	A question about whether an individual feels or felt frustration with their insurance company.			Intellectual Product	Lymphedema Symptom Intensity and Distress Survey - Arm
C159929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159929>	C173086	Have Loss of Confidence in Body Question|Have Loss of Confidence in Body|Loss of confidence in your body	A question about whether an individual feels or felt a loss of confidence in their body.			Intellectual Product	Lymphedema Symptom Intensity and Distress Survey - Arm
C15992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15992>	C15984	Tobacco Use, Combined Prevention/Cessation Research	Studies to test and implement interventions among groups of individuals that are designed to both prevent the initiation of tobacco use and stop current tobacco use.  (NCI/TRIP)			Research Activity	
C159930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159930>	C173704	Partner Has Lack of Interest in Sex Question|Partner Has Lack of Interest in Sex|Partner having lack of interest in sex	A question about whether an individual's partner has or had a lack of interest in sex.			Intellectual Product	Lymphedema Symptom Intensity and Distress Survey - Arm
C159931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159931>	C173981	Have Inability to Complete Hobbies or Leisure Activities Question|Have Inability to Complete Hobbies or Leisure Activities|Inability to complete hobbies or leisure activities you used to do	A question about whether an individual has or had an inability to complete hobbies or leisure activities they used to do.			Intellectual Product	Lymphedema Symptom Intensity and Distress Survey - Arm
C159932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159932>	C91102	Consistently Decreased Social Activities Question|Consistently Decreased Social Activities|Consistently decreased social activities	A question about whether an individual experiences or experienced consistently decreased interest or participation in social activities.			Intellectual Product	Lymphedema Symptom Intensity and Distress Survey - Arm
C159933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159933>	C173981|C173704	Have Decrease in Sexual Activity Question|Decrease in sexual activity|Have Decrease in Sexual Activity	A question about whether an individual has or had a decrease in sexual activity.			Intellectual Product	Lymphedema Symptom Intensity and Distress Survey - Arm
C159934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159934>	C85429	Symptoms Intensity and Distress Likert Scale	A scale for the subjective scoring of a symptom's intensity and distress that ranges from 1: Slight to 5: Severe.			Intellectual Product	Lymphedema Symptom Intensity and Distress Survey - Arm
C159935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159935>	C221037	Intensity and Distress 1|1|1 - Slight|1 Slight|Slight	A subjective score of 1 on a symptom's intensity and distress scale that ranges from 1: Slight to 5: Severe.			Intellectual Product	
C159936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159936>	C221037	Intensity and Distress 2|2	A subjective score of 2 on a symptom's intensity and distress scale that ranges from 1: Slight to 5: Severe.			Intellectual Product	
C159937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159937>	C221037	Intensity and Distress 3|3	A subjective score of 3 on a symptom's intensity and distress scale that ranges from 1: Slight to 5: Severe.			Intellectual Product	
C159938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159938>	C221037	Intensity and Distress 4|4	A subjective score of 4 on a symptom's intensity and distress scale that ranges from 1: Slight to 5: Severe.			Intellectual Product	
C159939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159939>	C221037	Intensity and Distress 5|5|5 Severe|5-Severe|Severe	A subjective score of 5 on a symptom's intensity and distress scale that ranges from 1: Slight to 5: Severe.			Intellectual Product	
C15993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15993>	C15999	Tobacco Use Policy Research	Research studies that assess the effect of policies, including worksite, community, state and Federal policies, on tobacco initiation and use. (NCI/TRIP)			Research Activity	
C159940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159940>	C201557	Alpha/beta T-cell/CD19+ B-cell-depleted Unrelated or Partially Matched Donor-derived Allogeneic Peripheral Blood Stem Cells|Alpha/beta T-cell and CD19+ B-cell-depleted Allogeneic PBSCs Derived from an Unrelated or Partially Matched Donor|Alpha/beta T-cell/CD19+ B-cell-depleted Unrelated or Partially Matched Donor-derived Allogeneic PBSCs	A preparation of allogeneic peripheral blood stem cells (PBSCs) from an unrelated or partially matched related donor that have been selectively depleted of alpha/beta T-cells and CD19-positive (CD19+) B-cells with potential immune reconstituting activity. The alpha/beta T-cell/CD19+ B-cell-depleted stem cells contain high amounts of natural killer (NK) cells, gamma/delta T-cells, CD34+ stem cells, and dendritic cells (DCs), while devoid of alpha/beta T-cells and CD19-positive B-cells. Depletion of alpha/beta T-cells, which are implicated in the adaptive immune response that mediates graft-versus-host disease (GvHD), may promote rapid and sustained engraftment, immune reconstitution, and may prevent or reduce the development of GvHD. The depletion of CD19+ B-cells may reduce the risk of Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disorders. The retained CD3+ gamma/delta T-cells and NK cells may synergistically exert an anti-leukemic and antiviral effector function, which may further promote engraftment and immune reconstitution.	Alpha/beta T-cell/CD19+ B-cell-depleted Unrelated or Partially Matched Donor-derived Allogeneic Peripheral Blood Stem Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C159942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159942>	C15190	Coaxial Biopsy|Coaxial Biopsy System|Coaxial System|Coaxial Technique	A biopsy system that uses a special needle to permit obtaining multiple samples through a single puncture.			Diagnostic Procedure	
C159943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159943>	C128462	Molibresib Besylate|2-((4S)-6-(4-Chlorophenyl)-8-methoxy-1-methyl-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepin-4-yl)-N-ethylacetamide monobenzenesulfonate salt|GSK525762C|MOLIBRESIB BESYLATE	The besylate salt of molibresib, a small molecule inhibitor of the BET (Bromodomain and Extra-Terminal) family of bromodomain-containing proteins with potential antineoplastic activity. Upon administration, molibresib binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histone peptides. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomain at the N-terminus, BET proteins, comprising of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.	Molibresib Besylate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C159944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159944>	C217122	Global Response Score|GR Score|GRS|Global Response Score in Mycosis Fungoides and Sezary Syndrome	A scoring system for assessing overall response to treatment in skin, lymph nodes, blood, and viscera.			Intellectual Product	
C159945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159945>	C50995	Global Response	An indication of response to disease treatment that takes into account multiple body systems.			Finding	
C159946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159946>	C159945	Global Complete Response|Complete Response	Complete disappearance of all clinical evidence of disease with skin, nodes, blood and viscera categories having complete response or noninvolvement.			Finding	Global Response Score
C159947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159947>	C159945	Global Partial Response|PR|Partial Response	Regression of measurable disease with complete response in skin and nodes, blood and viscera categories not having complete response or noninvolvement and where no category has progressive disease. Partial response is also assigned when there is partial response in skin and no nodes, blood and viscera category has a progressive disease and if any category involved at baseline at least one has a complete or partial response.			Finding	Global Response Score
C159948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159948>	C159945	Global Stable Disease|SD|Stable Disease	Failure to attain complete response, partial response, or progressive disease representative of all disease.  Partial response in skin and no nodes, blood and viscera category has a progressive disease and if any category involved at baseline, no complete or partial response in any.			Finding	Global Response Score
C159949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159949>	C159945	Global Progressive Disease|PD|Progressive Disease	Progressive disease in any skin, nodes, blood, or viscera category.			Finding	Global Response Score
C15994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15994>	C15185	Basic Biobehavioral Research	The assessment of basic principles of behavior, including both basic laboratory research and research directed at individuals.			Research Activity	
C159950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159950>	C159945	Global Relapse|Relapse	Recurrence of disease in prior complete response or relapse in any skin, nodes, blood, or viscera category.			Finding	Global Response Score
C159951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159951>	C159945	Global Response in Skin|Global Skin Response|Response in Skin|Skin Response	Criteria for the response to treatment in skin lesions, as a component of global response.			Finding	Global Response Score
C159952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159952>	C159951|C159946	Global Complete Response in Skin|CR|Complete Response|Complete Response in Skin|Skin Complete Response	100 percent clearance of skin lesions.			Finding	Global Response Score
C159953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159953>	C159951|C159947	Global Partial Response in Skin|PR|Partial Response|Partial Response in Skin|Skin Partial Response	50-99 percent clearance of skin disease from baseline without new tumors (T3) in patients with T1, T2, or T4 only skin disease.			Finding	Global Response Score
C159954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159954>	C159951|C159948	Global Stable Disease in Skin|SD|Skin Stable Disease|Stable Disease|Stable Disease in Skin	Less than 25 percent increase to less than 50 percent clearance in skin disease from baseline without new tumors (T3) in patients with T1, T2, or T4, only skin disease.			Finding	Global Response Score
C159955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159955>	C159951|C159949	Global Progressive Disease in Skin|PD|Progressive Disease|Progressive Disease in Skin|Skin Progressive Disease	25 percent or greater increase in skin disease from baseline; or new tumors (T3) in patients with T1, T2, or T4 only skin disease; or loss of response: in those with complete or partial response, increase of skin score of greater than the sum of nadir plus 50 percent baseline score.			Finding	Global Response Score
C159956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159956>	C159951|C159950	Global Relapse in Skin|Relapse|Relapse in Skin|Skin Relapse	Any disease recurrence in those with complete response.			Finding	Global Response Score
C159957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159957>	C159945	Global Response in Lymph Nodes|Global Lymph Node Response|Lymph Node Response|Response in Lymph Nodes	Criteria for the response to treatment in lymph nodes, as a component of global response.			Finding	Global Response Score
C159958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159958>	C159957|C159946	Global Complete Response in Lymph Nodes|CR|Complete Response|Complete Response in Lymph Nodes|Lymph Node Complete Response	All lymph nodes are now 1.5 cm or less in greatest transverse (long axis) diameter by method used to assess lymph nodes at baseline or biopsy negative for lymphoma; in addition, lymph nodes that were N3 classification and 1.5 cm or less in their long axis and more than 1 cm in their short axis at baseline, must now be 1 cm or less in their short axis or biopsy negative for lymphoma.			Finding	Global Response Score
C159959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159959>	C159957|C159947	Global Partial Response in Lymph Nodes|Lymph Node Partial Response|PR|Partial Response|Partial Response in Lymph Nodes	Cumulative reduction of 50 percent or more of the sum of products of diameter of each abnormal lymph node at baseline and no new lymph node greater than 1.5 cm in the diameter of the long axis or greater than 1.0 cm in the diameter of the short axis if the long axis is 1-1.5 cm diameter.			Finding	Global Response Score
C15995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15995>	C15185	Behavioral and Biological Associations Research|Behavioral/ Biological Associations	The basic relationships between biological and behavioral factors and/or their potential relationship to prevention and/or cessation interventions.			Research Activity	
C159960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159960>	C159957|C159948	Global Stable Disease in Lymph Nodes|Lymph Node Stable Disease|SD|Stable Disease|Stable Disease in Lymph Nodes	Fails to attain the criteria for complete response, partial response, or progressive disease.			Finding	Global Response Score
C159961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159961>	C159957|C159949	Global Progressive Disease in Lymph Nodes|Lymph Node Progressive Disease|PD|Progressive Disease|Progressive Disease in Lymph Nodes	50 percent or greater increase in the sum of products of diameter from baseline of lymph nodes; or any new node greater than 1.5 cm in the long axis or greater than 1cm in the short axis if 1-1.5 cm in the long axis that is proven to be N3 histologically; or loss of response with greater than 50 percent increase from nadir in sum of products of diameter of lymph nodes in those with partial response (whichever occurs first).			Finding	Global Response Score
C159962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159962>	C159957|C159950	Global Relapse in Lymph Nodes|Lymph Node Relapse|Relapse|Relapse in Lymph Nodes	Any new lymph node greater than 1.5 cm in the long axis in those with complete response proven to be N3 histologically.			Finding	Global Response Score
C159963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159963>	C159945	Global Response in Viscera|Global Viscera Response|Response in Viscera|Viscera Response	Criteria for the response to treatment in viscera, as a component of global response.			Finding	Global Response Score
C159964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159964>	C159963|C159946	Global Complete Response in Viscera|CR|Complete Response|Complete Response in Viscera|Viscera Complete Response	Liver or spleen or any organ considered involved at baseline should not be enlarged on physical exam and should be considered normal by imaging; no nodules should be present on imaging of liver or spleen; any post treatment mass must be determined by biopsy to be negative for lymphoma.			Finding	Global Response Score
C159965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159965>	C159963|C159947	Global Partial Response in Viscera|PR|Partial Response|Partial Response in Viscera|Viscera Partial Response	50 percent or greater regression in any splenic or liver nodules, or in measurable disease (sum of products of diameter) in any organs abnormal at baseline; no increase in size of liver or spleen and no new sites of involvement.			Finding	Global Response Score
C159966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159966>	C159963|C159948	Global Stable Disease in Viscera|SD|Stable Disease|Stable Disease in Viscera|Viscera Stable Disease	Fails to attain the criteria for complete response, partial response, or progressive disease.			Finding	Global Response Score
C159967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159967>	C159963|C159949	Global Progressive Disease in Viscera|PD|Progressive Disease|Progressive Disease in Viscera|Viscera Progressive Disease	Greater than 50 percent increase in size by sum of products of diameter (SPD) of any organs involved at baseline; or new organ involvement or loss of response: greater than 50 percent increase from nadir in the size (SPD) of any previous organ involvement in those with partial response (whichever occurs first).			Finding	Global Response Score
C159968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159968>	C159963|C159950	Global Relapse in Viscera|Relapse|Relapse in Viscera|Viscera Relapse	New organ involvement in those with complete response.			Finding	Global Response Score
C159969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159969>	C159945	Global Response in Blood|Blood Response|Global Blood Response|Response in Blood	Criteria for the response to treatment in blood, as a component of global response.			Finding	Global Response Score
C15996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15996>	C15185	Behavioral Mechanisms Research|Mechanisms of Behavior and Behavior Change	Studies that develop and test specific interventions aimed at changing negative health behaviors.			Research Activity	
C159970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159970>	C159969|C159946	Global Complete Response in Blood|Blood Complete Response|CR|Complete Response|Complete Response in Blood	A score of B0 by repeat bone marrow biopsy with no residual disease.			Finding	Global Response Score
C159971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159971>	C159969|C159947	Global Partial Response in Blood|Blood Partial Response|PR|Partial Response|Partial Response in Blood	Greater than 50 percent decrease in quantitative measurements of blood tumor burden in baseline from those with high tumor burden at baseline (B2).			Finding	Global Response Score
C159973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159973>	C217549|C217517	Elbasvir/Grazoprevir|Elbasvir-Grazoprevir|Grazoprevir-Elbasvir|Grazoprevir/Elbasvir|MK-8742/ MK-5172|Zepatier	A fixed dose combination of elbasvir, an inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A), and grazoprevir, a second-generation inhibitor of the HCV NS3/4A serine protease, with activity against certain HCV genotypes. Upon oral administration of elbasvir/grazoprevir, elbasvir inhibits the activity of the NS5A protein, leading to disruption of the viral RNA replication complex, blockage of HCV RNA production, and inhibition of viral replication. Grazoprevir inhibits the NS3/4A serine protease enzyme, thereby disrupting the cleavage of the virally encoded polyprotein into mature proteins and preventing the formation of the viral replication complex. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family; HCV infection is associated with the development of certain cancers.	Elbasvir/Grazoprevir		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology
C159974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159974>	C159969|C159948	Global Stable Disease in Blood|Blood Stable Disease|SD|Stable Disease|Stable Disease in Blood	Fails to attain the criteria for complete response, partial response, or progressive disease.			Finding	Global Response Score
C159975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159975>	C159969|C159949	Global Progressive Disease in Blood|Blood Progressive Disease|PD|Progressive Disease|Progressive Disease in Blood	A change from B0 to B2; or greater than 50 percent increase from baseline and at least 5,000 neoplastic cells per microliter; or loss of response: in those with partial response who were originally B2 at baseline, greater than 50 percent increase from nadir and at least 5,000 neoplastic cells per microliter.			Finding	Global Response Score
C159976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159976>	C159969|C159950	Global Relapse in Blood|Blood Relapse|Relapse|Relapse in Blood	Increase of neoplastic blood lymphocytes to B1 or greater in those with complete response.			Finding	Global Response Score
C159977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159977>	C28681|C138180|C129826	Autologous HPV16 E7-specific HLA-A*02:01-restricted TCR Gene Engineered Lymphocytes KITE-439|HPV16 E7 T-cell Receptor Engineered T-cells KITE-439|HPV16 E7-specific HLA-A*02:01-restricted TCR Gene Engineered Autologous T-lymphocytes KITE-439|KITE 439|KITE-439|KITE439	A preparation of autologous T-lymphocytes that have been genetically modified to express a T-cell receptor (TCR) specific for the human leukocyte antigen (HLA)-A*02:01-restricted human papillomavirus type 16 isoform E7 protein (HPV16 E7) with potential antineoplastic activity. Upon isolation, transduction, expansion ex vivo and re-introduction into the patient, the autologous HPV16 E7-specific HLA-A*02:01-restricted T-lymphocytes KITE-439 target and bind HPV16 E7-expressing tumor cells. This may lead to cytotoxic T-lymphocyte (CTL)-mediated elimination of tumor cells expressing the HPV16 E7 antigen. HPV16 E7, a cell surface glycoprotein and tumor-associated antigen (TAA), is overexpressed in various HPV-mediated cancers.	Autologous HPV16 E7-specific HLA-A*02:01-restricted TCR Gene Engineered Lymphocytes KITE-439		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C159978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159978>	C28227|C155745|C129822|C128057	Enristomig|Anti-PD-L1/4-1BB Bispecific Antibody INBRX-105|Anti-PD-L1/CD137 Bispecific Antibody INBRX-105|ENRISTOMIG|ES 101|ES-101|ES101|INBRX 105|INBRX-105|INBRX105|PDL1 x 4-1BB Bispecific Antibody INBRX-105|PDL1 x CD137 Bispecific Antibody INBRX-105	A recombinant, humanized, bispecific antibody targeting both the human programmed death-ligand 1 (PD-L1) and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, enristomig simultaneously targets and binds to 4-1BB, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes, and PD-L1 expressed on tumor cells. Through 4-1BB binding, enristomig acts as a conditional 4-1BB agonist, resulting in T-cell co-stimulation and enhanced anti-tumor activity. At the same time, Ienristomig prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.	Enristomig		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C159979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159979>	C158612	Was Testing Performed Question|Was Testing Performed	A question to determine if specific tests were performed during the study.			Intellectual Product	
C15997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15997>	C213420|C15922	Cessation Research	Studies to develop and test interventions that aid in the discontinuation of tobacco use among individuals.			Research Activity	
C159980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159980>	C63510|C63358	Abemaciclib Regimen|Abemaciclib monotherapy|Verzenio Regimen	A regimen consisting of abemaciclib that may be used in the treatment of advanced or metastatic breast cancer, and dedifferentiated liposarcoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C159981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159981>	C63443|C63442	Acalabrutinib Regimen|Acalabrutinib monotherapy|Calquence Regimen	A regimen consisting of acalabrutinib that may be used in the treatment of mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), gastric and nongastric MALT lymphoma, nodal marginal zone lymphoma (NMZL), splenic marginal zone lymphoma (SMZL), and Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C159982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159982>	C63360|C63358|C191713	Ado-trastuzumab Emtansine Regimen|Kadcyla Regimen	A regimen consisting of ado-trastuzumab emtansine that may be used in the treatment of HER2-positive metastatic breast cancer, salivary gland tumors and non-small cell lung cancer (NSCLC).			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C159983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159983>	C63587|C63360	Afatinib Regimen|Afatinib monotherapy|Gilotrif Regimen	A regimen consisting of afatinib that may be used in the treatment of non-small cell lung cancer (NSCLC) and head and neck cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C159984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159984>	C65070|C63524|C63522|C63519|C63467|C63360|C63358|C210232|C159901|C159900|C159893|C159449	Nab-paclitaxel Regimen|Abraxane Regimen|Albumin-bound Paclitaxel Regimen|Protein-bound Paclitaxel Regimen|nab-Paclitaxel monotherapy	A regimen consisting of albumin-bound paclitaxel that may be used in the treatment of non-small cell lung, ovarian, fallopian tube, primary peritoneal, endometrial, breast, bladder, vaginal, and cervical cancers; cutaneous and uveal melanoma, small bowel adenocarcinoma and Kaposi sarcoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C159985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159985>	C63510|C63442|C63360|C205537	Alectinib Regimen|Alecensa Regimen|Alectinib monotherapy	A regimen consisting of alectinib that may be used in the treatment of non-small cell lung cancer (NSCLC), inflammatory myofibroblastic tumor (IMT), diffuse large B-cell lymhoma, T-cell lymphoma, uterine sarcoma, and histiocytic neoplasms, including Erdheim-Chester disease.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C159986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159986>	C63443|C63442|C173974	Alemtuzumab Regimen|Alemtuzumab monotherapy|Campath Regimen	A regimen consisting of alemtuzumab that may be used in the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), T-cell large granular lymphocytic leukemia, T-cell lymphomas, T-cell prolymphocytic leukemia, mycosis fungoides and Sezary syndrome.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C159987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159987>	C63522	Altretamine Regimen|Altretamine monotherapy|Hexalen Regimen	A regimen consisting of altretamine that may be used in the treatment of ovarian, fallopian tube, and primary peritoneal cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C159988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159988>	C63522|C63519|C63510|C63358|C159910|C159901|C159900	Anastrozole Regimen|Anastrozole monotherapy|Arimidex Regimen	A regimen consisting of anastrozole that may be used in the treatment of breast, ovarian, fallopian tube, and primary peritoneal cancer, endometrial carcinoma, malignant sex cord-stromal tumors, and uterine sarcoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C159989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159989>	C159445	Antithymocyte Globulin Equine Regimen|ATG Equine Regimen|ATG, Equine Regimen|Anti-thymocyte Globulin, Equine Regimen|Atgam Regimen|Equine Anti-thymocyte Globulin Regimen	A regimen consisting of antithymocyte globulin equine that may be used in the treatment of myelodysplastic syndromes.			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C15998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15998>	C49236	Minimal Contact Treatment	Minimal interventions directed at individuals that do not involve a health care provider, such as self-help and telephone counseling.			Therapeutic or Preventive Procedure	
C159990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159990>	C63468	Apalutamide Regimen|Apalutamide monotherapy|Erleada Regimen	A regimen consisting of apalutamide that may be used in the treatment of prostate cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C159991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159991>	C63589|C63442	Arsenic Trioxide Regimen|Arsenic Regimen|Arsenic trioxide monotherapy|Trisenox Regimen	A regimen consisting of arsenic trioxide that may be used in the treatment of acute promyelocytic leukemia (APL) and T-cell lymphomas.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C159992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159992>	C63586|C63524|C63510|C63467|C63360|C63359|C159893|C159454	Atezolizumab Regimen|Atezolizumab monotherapy|Tecentriq Regimen	A regimen consisting of atezolizumab that may be used in the treatment of bladder cancer, non-small cell lung cancer (NSCLC), alveolar soft part sarcoma (ASPS), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), small bowel adenocarcinoma, colon cancer, and melanoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C159993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159993>	C67509|C63586|C63519|C63467|C63442|C159893|C159443	Avelumab Regimen|Avelumab monotherapy|Bavencio Regimen	A regimen consisting of avelumab that may be used in the treatment of bladder cancer, metastatic Merkel cell carcinoma, endometrial carcinoma, T-cell lymphomas, gestational trophoblastic neoplasia, colon cancer, and small bowel adenocarcinoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C159994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159994>	C67290|C191713|C159458	Axitinib Regimen|Axitinib monotherapy|Inlyta Regimen	A regimen consisting of axitinib that may be used in the treatment of follicular, papillary and Hurthle cell thyroid carcinomas, salivary gland tumors, and kidney cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C159995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159995>	C63589|C219691|C159445	Azacitidine Regimen|Azacitidine monotherapy|Vidaza Regimen	A regimen consisting of azacitidine that may be used in the treatment of myeloproliferative neoplasms and myelodysplastic syndromes, acute myeloid leukemia (AML).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C159996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159996>	C63467	BCG Regimen|Bacillus Calmette-Guerin (BCG) monotherapy|Bacillus Calmette-Guerin Regimen	A regimen consisting of Bacillus Calmette-Guerin (BCG) that may be used in the treatment of bladder cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C159997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159997>	C63496|C63442|C63359|C63356|C159459	Bendamustine Regimen|Bendamustine monotherapy	A regimen consisting of bendamustine that may be used in the treatment of diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL), T-cell lymphoma, mantle cell lymphoma (MCL), plasma cell (multiple) myeloma, T-cell prolymphocytic leukemia, small cell lung cancer (SCLC), Waldenstrom's macroglobulinemia (WM) and lymphoplasmacytic lymphoma (LPL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C159998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159998>	C67290|C65070|C63522|C63519|C63510|C63360|C210232|C159910|C159901|C159900|C159462|C140180	Bevacizumab Regimen|Avastin Regimen|Bevacizumab monotherapy|Bevacizumab-tnjn monotherapy	A regimen consisting of bevacizumab that may be used in the treatment of soft tissue sarcoma, including angiosarcoma, and AIDS-related Kaposi sarcomas; anaplastic gliomas and glioblastomas; adult intracranial and spinal ependymomas (excluding subependymomas and myxopapillary ependymomas); and otherr central nervous system (CNS) cancers, kidney, cervical, endometrial, vaginal, ovarian/fallopian tube/primary peritoneal and non-small cell lung cancers (NSCLCs), and malignant sex cord-stromal tumors.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C159999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C159999>	C63468|C191713	Bicalutamide Regimen|Bicalutamide monotherapy|Casodex Regimen	A regimen consisting of bicalutamide that may be used in the treatment of prostate cancer and salivary gland tumor.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C15999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C15999>	C15429	Policy Research	Research studies assessing the effect of policies, including worksite, community, state and Federal policies as related to a variety of health issues.			Research Activity	
C1599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1599>	C146993	Bicalutamide|(+/-)-N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide|4'-Cyano-alpha,alpha,alpha-trifuloro-3-[(p-fluorophenyl)sulfonyl]-2-methyl-m-lactotoluidide|4-Cyano-3-trifluoromethyl-N-(3-p-fluorophenylsulfonyl-2-hydroxy-2-methylpropionyl)aniline|BICALUTAMIDE|Casodex|Cassotide|Cosudex|ICI 176,334|ICI 176334|N-[4-Cyano-3-(trifluoromethyl)phenyl]3-3[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-propanamide|Utamide|bicalutamide	A synthetic, nonsteroidal antiandrogen.  Bicalutamide competitively binds to cytosolic androgen receptors in target tissues, thereby inhibiting the receptor binding of androgens. This agent does not bind to most mutated forms of androgen receptors. (NCI04)	Bicalutamide		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C160000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160000>	C63588	Blinatumomab Regimen|Blinatumomab monotherapy|Blincyto Regimen	A regimen consisting of blinatumomab that may be used in the treatment of acute lymphoblastic leukemia (ALL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160001>	C63588|C63496|C63442|C159461|C159459|C159449	Bortezomib Regimen|Bortezomib monotherapy|Velcade Regimen	A regimen consisting of bortezomib that may be used in the treatment of mantle cell lymphoma (MCL), plasma cell (multiple) myeloma, primary systemic light (AL) chain amyloidosis, Waldenstrom macroglobulinemia (WM) and lymphoplasmacytic lymphoma (LPL), acute lymphoblastic leukemia (ALL), Kaposi sarcoma, mycosis fungoides/Sezary syndrome, and T-cell lymphoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160002>	C63588|C186720|C186719|C159441	Bosutinib Regimen|Bosulif Regimen|Bosutinib monotherapy	A regimen consisting of bosutinib that may be used in the treatment of chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) and myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160003>	C63442|C63356	Brentuximab Vedotin Regimen|Adcetris Regimen|Brentuximab vedotin monotherapy	A regimen consisting of brentuximab vedotin that may be used in the treatment of diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL), T-cell lymphoma, primary cutaneous CD30+ T-cell lymphoproliferative disorders, and mycosis fungoides/Sezary syndrome.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160004>	C67338|C67290|C63519|C63510|C63361|C63360|C159893|C159462|C159458|C159454|C159440|C156290	Cabozantinib Regimen|Cabometyx Regimen|Cabozantinib S-malate Regimen|Cabozantinib monotherapy|Cometriq Regimen	A regimen consisting of cabozantinib that may be used in the treatment of follicular, medullary, papillary and Hurthle cell thyroid carcinomas,  bone, hepatobiliary, endometrial and kidney cancers, gastrointestinal stromal tumors (GIST), non-small cell lung cancer (NSCLC), alveolar soft part sarcoma, soft tissue sarcoma, extraskeletal myxoid chondrosarcoma, adrenal gland tumors, well-differentiated grade 3 neuroendocrine tumors (NETs) and NETs of the pancreas, gastrointestinal tract, lung, and thymus.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160005>	C67509|C63719|C63587|C63586|C63522|C63502|C63467|C63361|C63358|C203473|C191676|C166388|C159910|C159901|C159900|C159893|C159454|C159448|C159439|C156290	Capecitabine Regimen|Capecitabine monotherapy|Xeloda Regimen	A regimen consisting of capecitabine that may be used in the treatment of anal carcinoma, breast (and its metastases to the central nervous system), bladder, colon, esophageal and esophagogastric junction, gastric, hepatobiliary, penile, ovarian, squamous cell skin, fallopian tube, primary peritoneal, rectal and head and neck cancer, including cancer of the nasopharynx, appendiceal, small bowel, ampullary and pancreatic adenocarcinoma, occult primary and gestational trophoblastic tumors, extrapulmonary poorly differentiated neuroendocrine carcinoma, large or small cell carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm, and neuroendocrine tumors (NETs) of the gastrointestinal (GI) tract, lung, and thymus.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160006>	C65070|C63787|C63587|C63522|C63519|C63487|C63358|C210232|C159901|C159900|C159457|C159443|C140180	Carboplatin Regimen|Carboplatin monotherapy	A regimen consisting of carboplatin that may be used in the treatment of certain central nervous system (CNS), breast, cervical, head and neck, including cancer of the nasopharynx, testicular, vaginal, ovarian, fallopian tube, primary peritoneal, endometrial, and vulvar cancers, peritoneal mesothelioma, and Merkel cell carcinoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160007>	C140180	Carmustine Regimen|BiCNU Regimen|Carmustine monotherapy	A regimen consisting of carmustine that can be used in the treatment of anaplastic gliomas and glioblastomas; adult low-grade infiltrative supratentorial astrocytoma/oligodendroglioma (excluding pilocytic astrocytoma); and adult intracranial and spinal ependymomas (excluding subependymomas and myxopapillary ependymomas).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160008>	C63510|C63442|C63360|C205537|C159462	Ceritinib Regimen|Ceritinib monotherapy|Zykadia Regimen	A regimen consisting of ceritinib that may be used in the treatment of inflammatory myofibroblastic tumor (IMT) with ALK translocation, uterine sarcoma, non-small cell lung cancer (NSCLC), T-cell lymphomas and certain histiocytic neoplasms, such as Erdheim-Chester disease.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160009>	C63587|C63586|C191676|C166388|C159448	Cetuximab Regimen|Cetuximab monotherapy|Erbitux Regimen	A regimen consisting of cetuximab that may be used in the treatment of colorectal, penile, squamous cell skin, appendiceal, and head and neck cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160010>	C63443|C63442	Chlorambucil Regimen|Chlorambucil monotherapy|Leukeran Regimen	A regimen consisting of chlorambucil that may be used in the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), follicular lymphoma (grade 1-2), extranodal marginal zone lymphoma of the stomach and nongastric sites, splenic marginal zone lymphoma, nodal marginal zone lymphoma, and mycosis fungoides/Sezary syndrome.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160011>	C65070|C63587|C63522|C63519|C63467|C63358|C210232|C166388|C159901|C159900|C159457|C159448|C140180	Cisplatin Regimen|Cisplatin monotherapy|Platinol Regimen	A regimen consisting of cisplatin that may be used in the treatment of head and neck, including cancer of the nasopharynx, bladder, endometrial, penile, vaginal, vulvar, ovarian, fallopian tube, primary peritoneal, breast, cervical, squamous cell skin, and certain central nervous system (CNS) cancers. High-dose cisplatin regimen may be used for the treatment of head and neck cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160012>	C63442|C205537|C173974|C159459	Cladribine Regimen|Cladribine monotherapy|Leustatin Regimen	A regimen consisting of cladribine that may be used in the treatment of systemic mastocytosis, hairy cell leukemia, Waldenstrom's macroglobulinemia (WM), lymphoplasmacytic lymphoma (LPL), T-cell lymphoma, systemic mastocytosis, T-cell large granular lymphocytic leukemia and certain histiocytic neoplasms, such as Langerhans cell histiocytosis, Erdheim-Chester disease and Rosai-Dorfman disease.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160013>	C63524|C63510|C63442|C63360|C159462	Crizotinib Regimen|Crizotinib monotherapy|Xalkori Regimen	A regimen consisting of crizotinib that may be used in the treatment of inflammatory myofibroblastic tumor (IMT) with ALK translocation, non-small cell lung cancer (NSCLC), cutaneous melanoma, T-cell lymphoma and uterine sarcoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160014>	C63522|C63496|C63442|C63358|C159901|C159900|C140180	Cyclophosphamide Regimen|Cyclophosphamide monotherapy|Cytoxan Regimen	A regimen consisting of cyclophosphamide that can be used in the treatment of anaplastic gliomas and glioblastomas, multiple myeloma, some forms of non-Hodgkin's lymphoma (NHL), and ovarian, fallopian tube, primary peritoneal and breast cancers. High-dose cyclophosphamide regimen may be used for the treatment of central nervous system (CNS) cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160015>	C63589|C63588|C63442|C205537|C140180	Cytarabine Intrathecal Regimen|IT Cytarabine monotherapy|Intrathecal Ara-C Regimen|Intrathecal Cytarabine Regimen	A regimen consisting of intrathecal cytarabine that may be used in the treatment of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), blastic plasmacytoid dendritic cell neoplasm (BPDCN), central nervous system (CNS) cancer, and diffuse large B-cell lymphoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160016>	C63589	Cytarabine Subcutaneous Regimen|Subcutaneous Ara-C Regimen|Subcutaneous Cytarabine Regimen	A regimen consisting of subcutaneous cytarabine that may be used in the treatment of acute myeloid leukemia (AML).			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160017>	C63524|C63360|C205537|C159458	Dabrafenib Regimen|Dabrafenib Mesylate Regimen|Dabrafenib monotherapy|Tafinlar Regimen	A regimen consisting of dabrafenib that may be used in the treatment of non-small cell lung cancer (NSCLC), oncocytic, follicular, papillary, and Hurthle cell thyroid carcinomas; cutaneous melanoma, and certain histiocytic neoplasms, such as Erdheim-Chester disease and Langerhans cell histiocytosis.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160018>	C63524|C63510|C159462|C156290	Dacarbazine Regimen|DTIC Regimen|Dacarbazine monotherapy	A regimen consisting of dacarbazine that may be used in the treatment of cutaneous and uveal melanoma; neuroendocrine tumors (NETs) of the gastrointestinal tract, pancreas, lung and thymus; and soft tissue and uterine sarcomas.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160019>	C63588|C63496|C159461	Daratumumab Regimen|Daratumumab monotherapy|Darzalex Regimen	A regimen consisting of daratumumab that may be used in the treatment of plasma cell (multiple) myeloma, acute lymphoblastic leukemia (ALL) and systemic light chain amyloidosis.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160020>	C63588|C63524|C186720|C186719|C159893|C159441|C159440	Dasatinib Regimen|Dasatinib monotherapy|Sprycel Regimen	A regimen consisting of dasatinib that may be used in the treatment of cutaneous melanoma, bone cancer, chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GISTs), acute lymphoblastic leukemia (ALL), and myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160021>	C63589|C219691|C159445	Decitabine Regimen|Dacogen Regimen|Decitabine monotherapy	A regimen consisting of decitabine that may be used in the treatment of acute myeloid leukemia (AML), myeloproliferative neoplasms, and myelodysplastic syndromes.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160022>	C63468	Degarelix Regimen|Degarelix monotherapy|Firmagon Regimen	A regimen consisting of degarelix that may be used in the treatment of advanced prostate cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160023>	C159440	Denosumab Regimen|Denosumab monotherapy|Xgeva Regimen	A regimen consisting of denosumab that may be used in the treatment of giant cell tumor (GCT) of the bone; and bone metastases from solid tumors and bone complications from plasma cell (multiple) myeloma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160024>	C65070|C63719|C63587|C63522|C63519|C63510|C63468|C63467|C63360|C63359|C63358|C210232|C159910|C159909|C159901|C159900|C159893|C159458	Docetaxel Regimen|Docetaxel monotherapy|Taxotere Regimen	A regimen consisting of docetaxel that can be used in the treatment of breast, bladder, gastric, cervical, head and neck, non-small cell lung, small cell lung, vaginal, ovarian, fallopian tube, primary peritoneal, prostate, endometrial, esophageal and esophagogastric junction cancers; malignant sex cord-stromal (SCST) and malignant germ cell tumors (GCTs); angiosarcoma and small bowel adenocarcinoma, and anaplastic carcinoma. Docetaxel every 21 days regimen may be used for the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160025>	C63522|C63519|C63510|C63358|C159901|C159900|C159462|C159458|C159440	Doxorubicin Regimen|Doxorubicin HCl Regimen|Doxorubicin Hydrochloride Regimen|Doxorubicin monotherapy	A regimen consisting of doxorubicin that may be used in the treatment of soft tissue and uterine sarcomas, rhabdomyosarcomas, anaplastic thyroid, endometrial, breast, bone, ovarian, fallopian tube, and primary peritoneal cancers, and desmoid tumors (aggressive fibromatoses).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160026>	C63586|C63360|C159893|C159454	Durvalumab Regimen|Durvalumab monotherapy|Imfinzi Regimen	A regimen consisting of durvalumab that may be used in the treatment of non-small cell lung cancer (NSCLC) small bowel adenocarcinoma, colon cancer, and hepatobiliary cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160027>	C63443|C63442	Duvelisib Regimen|Copiktra Regimen|Duvelisib monotherapy	A regimen consisting of duvelisib that may be used in the treatment of T-cell lymphoma, chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), and mycosis fungoides and Sezary syndrome.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160028>	C63468	Enzalutamide Regimen|Enzalutamide monotherapy|Xtandi Regimen	A regimen consisting of enzalutamide that may be used in the treatment of prostate cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160029>	C63519|C63510|C63358|C159462	Epirubicin Regimen|Ellence Regimen|Epirubicin monotherapy	A regimen consisting of epirubicin that may be used in the treatment of breast cancer; and soft tissue and uterine sarcomas.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160030>	C63519|C63358|C159462	Eribulin Regimen|Eribulin HCl Regimen|Eribulin Hydrochloride Regimen|Eribulin monotherapy|Halaven Regimen	A regimen consisting of eribulin that may be used in the treatment of breast cancer; and soft tissue and uterine sarcomas.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160031>	C67290|C63510|C63360|C159462|C159457|C159440	Erlotinib Regimen|Erlotinib HCl Regimen|Erlotinib Hydrochloride Regimen|Erlotinib monotherapy|Tarceva Regimen	A regimen consisting of erlotinib that may be used in the treatment of soft tissue sarcoma, kidney, vulvar and bone cancers, and non-small cell lung cancer (NSCLC), including brain metastases from NSCLC.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160032>	C63358	Estradiol Regimen|Estradiol monotherapy	A regimen consisting of estradiol that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160033>	C191727|C159449|C159435	Etoposide Regimen|Etoposide monotherapy|VP-16 Regimen	A regimen consisting of etoposide that may be used in the treatment of Kaposi sarcoma, thymomas and thymic carcinomas, and Castleman disease.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160034>	C67290|C63510|C63442|C63356|C159462|C159458|C159435|C156290	Everolimus Regimen|Afinitor Regimen|Everolimus monotherapy	A regimen consisting of everolimus that may be used in the treatment of well-differentiated grade 3 neuroendocrine tumors (NETs), NETs of the gastrointestinal (GI) tract, pancreas, lung, and thymus; follicular, papillary and Hurthle cell thyroid carcinomas; thymomas and thymic carcinomas; Hodgkin lymphoma (HL); kidney cancer; perivascular epithelioid cell tumor (PEComa) and uterine sarcoma, recurrent angiomyolipoma, and lymphangioleiomyomatosis (LAM); Waldenstrom's macroglobulinemia (WM) and lymphoplasmacytic lymphoma (LPL); subependymal giant cell astrocytoma (SEGA); and oncocytic carcinoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160035>	C63522|C63519|C63510|C63358|C159910|C159901|C159900	Exemestane Regimen|Aromasin Regimen|Exemestane monotherapy	A regimen consisting of exemestane that may be used in the treatment of endometrial carcinoma, breast, ovarian, fallopian tube, and primary peritoneal cancers, malignant sex cord-stromal tumors, and uterine sarcoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160036>	C63442|C173974	Fludarabine Regimen|Fludara Regimen|Fludarabine Phosphate Regimen|Fludarabine monotherapy	A regimen consisting of fludarabine that may be used in the treatment of Waldenstrom's macroglobulinemia (WM) and lymphoplasmacytic lymphoma (LPL), and T-cell large granular lymphocytic leukemia.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160037>	C67290|C63719|C63587|C63586|C159893|C159457|C159439	Fluorouracil Continuous Infusion Regimen|Continuous Infusion 5-FU Regimen|Continuous Infusion Fluorouracil Regimen	A regimen consisting of continuous infusion fluorouracil that may be used in the treatment of esophageal and esophagogastric junction, head and neck, including cancer of the nasopharynx, occult primary, colon, rectal, and gastric cancers, and pancreatic and small bowel adenocarcinoma, and anal carcinoma.			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160038>	C63587|C63467|C159454	Fluorouracil Regimen|5-FU Regimen|Fluorouracil monotherapy	A regimen consisting of fluorouracil that may be used in the treatment of head and neck, bladder, and hepatobiliary cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160039>	C63358	Fluoxymesterone Regimen|Fluoxymesterone monotherapy|Halotestin Regimen	A regimen consisting of fluoxymesterone that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C16003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16003>	C15429	Infectious Diseases Research|Infectious Disease Research|Infectious Diseases / Laboratory	The study of infectious diseases in the laboratory			Research Activity	
C160040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160040>	C63468	Flutamide Regimen|Eulexin Regimen|Flutamide monotherapy	A regimen consisting of flutamide that may be used in the treatment of prostate cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160041>	C63522|C63519|C63510|C63358|C159901|C159900	Fulvestrant Regimen|Faslodex Regimen|Fulvestrant monotherapy	A regimen consisting of fulvestrant that may be used in the treatment of breast, endometrial, ovarian, fallopian tube and primary peritoneal cancers, and uterine sarcoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160042>	C63360	Gefitinib Regimen|Gefitinib monotherapy|Iressa Regimen	A regimen consisting of gefitinib that may be used in the treatment of non-small cell lung cancer (NSCLC).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160043>	C67509|C65070|C63787|C63587|C63522|C63519|C63510|C63502|C63467|C63442|C63360|C63359|C63358|C63356|C210232|C203473|C159901|C159900|C159462|C159457|C159454|C159435	Gemcitabine Regimen|Gemcitabine HCl Regimen|Gemcitabine Hydrochloride Regimen|Gemcitabine monotherapy|Gemzar Regimen|Infugem Regimen	A regimen consisting of gemcitabine that may be used in the treatment of bone, soft tissue, uterine and Kaposi sarcomas; bladder, breast, cervical, endometrial, hepatobiliary, small cell lung, and non-small cell lung, ovarian, fallopian tube, primary peritoneal, vaginal, and vulvar cancers; malignant pleural and peritoneal mesothelioma; ampullary and pancreatic adenocarcinoma; thymomas and thymic carcinomas; cancer of the nasopharynx; mycosis fungoides/Sezary syndrome; T-cell lymphoma; Hodgkin lymphoma; and gestational trophoblastic neoplasia (GTN). Low-dose gemcitabine regimen may be used for the treatment of bladder cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160044>	C63522|C63510|C63468|C63358|C191713|C159901|C159900	Goserelin Regimen|Goserelin Acetate Regimen|Goserelin monotherapy|Zoladex Regimen	A regimen consisting of goserelin that may be used in the treatment of breast, prostate, ovarian, fallopian tube, and primary peritoneal cancers, malignant sex cord-stromal tumors, uterine sarcoma, and salivary gland tumors.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160045>	C67290|C63524	High-dose Aldesleukin Regimen|Aldesleukin High-dose Regimen|High-dose Interleukin-2|High-dose Interleukin-2 Regimen|High-dose Proleukin Regimen|High-dose Recombinant Human IL-2 Regimen|High-dose Recombinant Human Interleukin-2 Regimen|Recombinant Human IL-2 High-dose Regimen	A regimen consisting of high-dose aldesleukin (recombinant human interleukin-2) that may be used in the treatment of kidney cancer and cutaneous melanoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160046>	C63589|C63442	High-Dose Cytarabine Regimen|Cytarabine High-dose Regimen|HiDAC|HiDAC|High-dose Ara-C Regimen|High-dose Cytarabine monotherapy (HiDAC)	A regimen consisting of high-dose cytarabine that may be used in the treatment of acute myeloid leukemia (AML) primary central nervous system (CNS) lymphoma, and Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma.	High-Dose Cytarabine Regimen		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|HemOnc Regimen Terminology|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database|Single-agent Therapeutic Regimens
C160047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160047>	C63524	High-dose Ipilimumab Regimen|High-dose Yervoy Regimen|Ipilimumab Regimen High-dose	A regimen consisting of high-dose ipilimumab that may be used in the treatment of cutaneous melanoma.			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160048>	C63442|C63358|C159440|C140180	High-Dose Methotrexate Regimen|High-Dose MTX Regimen|High-Dose Methotrexate Sodium Regimen|Methotrexate High-Dose Regimen|Methotrexate Sodium High-Dose Regimen	A regimen consisting of high-dose methotrexate that may be used in the treatment of chronic lymphocytic leukemia (CLL); small lymphocytic, primary central nervous system (CNS), and diffuse large B-cell lymphomas; bone cancer, breast cancer leptomeningeal metastases, and Bing-Neel syndrome manifestation of Waldenstrom macroglobulinemia.	High-Dose Methotrexate Regimen		Therapeutic or Preventive Procedure	CTRP Agent Terminology|CTRP Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160049>	C63468	Histrelin Regimen|Histrelin Acetate Regimen|Histrelin monotherapy|Vantas Regimen	A regimen consisting of histrelin that may be used in the treatment of prostate cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160050>	C63589|C219691|C205537	Hydroxyurea Regimen|Droxia Regimen|HU Regimen|Hydrea Regimen|Hydroxyurea monotherapy	A regimen consisting of hydroxyurea that may be used in the treatment of myeloproliferative neoplasms, acute myeloid leukemia (AML), and Langerhans cell histiocytosis (LCH).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160051>	C63443|C63442|C140180	Ibrutinib Regimen|Ibrutinib monotherapy|Imbruvica Regimen	A regimen consisting of ibrutinib that may be used in the treatment of mantle cell lymphoma, Waldenstrom's macroglobulinemia (WM), lymphoplasmacytic lymphoma (LPL), diffuse large B-cell lymphoma (DLBCL), gastric MALT lymphoma, nongastric MALT lymphoma, nodal marginal zone lymphoma, extranodal marginal zone lymphoma of nongastric sites and the stomach, splenic marginal zone lymphoma, hairy cell leukemia, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and central nervous system (CNS) cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160052>	C63443	Idelalisib Regimen|Idelalisib monotherapy|Zydelig Regimen	A regimen consisting of idelalisib that may be used in the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160053>	C67338|C65070|C63522|C63519|C63510|C63467|C159901|C159900|C159462|C159440|C159435	Ifosfamide Regimen|Ifex Regimen|Ifosfamide monotherapy|Ifosfamide/Mesna	A regimen consisting of ifosfamide that may be used in the treatment of bladder, bone, cervical, endometrial, ovarian, fallopian tube and primary peritoneal cancers, soft tissue and uterine sarcomas, extraskeletal osteosarcoma, and malignant thymomas and thymic carcinomas.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160054>	C63588|C63524|C186720|C159893|C159462|C159459|C159449|C159441|C159440	Imatinib Regimen|Gleevec Regimen|Imatinib Mesylate Regimen|Imatinib monotherapy	A regimen consisting of imatinib that may be used in the treatment of bone cancer, acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), pigmented villonodular synovitis (PVNS), dermatofibrosarcoma protuberans (DFSP), Kaposi sarcoma, cutaneous melanoma, systemic mastocytosis, tenosynovial giant cell, gastrointestinal (GI) stromal, and desmoid tumors (aggressive fibromatoses), other myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes, and myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) overlap neoplasms.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160055>	C159449|C159440|C159435|C156290	Interferon alfa-2b Regimen|IFN alfa-2b Regimen|Interferon alfa-2b monotherapy|Intron A Regimen	A regimen consisting of interferon (IFN) alfa-2b that may be used in the treatment of bone cancer; Kaposi sarcoma; desmoid tumors (aggressive fibromatoses); neuroendocrine tumors (NET) of the gastrointestinal (GI) tract, lung, and thymus; myeloproliferative neoplasms; and systemic mastocytosis.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160056>	C140180	Intra-CSF Interferon Alfa-2b Regimen|Intra-CSF IFN alfa-2b Regimen|Intra-CSF Intron A Regimen|Intra-cerebrospinal Fluid Interferon alfa-2b Regimen	A regimen consisting of intra-cerebrospinal fluid (CSF) interferon (IFN) alfa-2b that may be used in the treatment of leptomeningeal metastases.			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160057>	C140180	Methotrexate Intra-Cerebrospinal Fluid Regimen|Intra-CSF MTX Regimen|Intra-CSF Methotrexate Regimen|Intra-cerebrospinal Fluid Methotrexate Regimen|Methotrexate Intra-CSF Regimen|Methotrexate Intra-cerebrospinal Fluid Regimen	A regimen consisting of intra-cerebrospinal fluid (CSF) methotrexate that may be used in the treatment of leptomeningeal metastases.			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160058>	C140180	Intra-CSF Thiotepa Regimen|Intra-cerebrospinal Fluid Thiotepa Regimen|Intrathecal Thiotepa Regimen|Thiotepa Intra-CSF Regimen|Thiotepa Intrathecal Regimen	A regimen consisting of intra-cerebrospinal fluid (CSF) thiotepa that may be used in the treatment of leptomeningeal metastases.			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160059>	C140180	Intra-CSF Topotecan Regimen|Intra-CSF Topotecan HCl Regimen|Intra-CSF Topotecan Hydrochloride Regimen|Intra-cerebrospinal Fluid Topotecan Regimen|Intrathecal Topotecan Regimen|Topotecan Intra-CSF Regimen|Topotecan Intrathecal Regimen	A regimen consisting of intra-cerebrospinal fluid (CSF) topotecan that may be used in the treatment of leptomeningeal metastases.			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C16005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16005>	C19335	New Agents	Research into new physical or chemical means to treat disease.			Classification	
C160060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160060>	C63524	Aldesleukin Intralesional Regimen|Interleukin-2 Intralesional Regimen|Intralesional Aldesleukin Regimen|Intralesional IL-2 Regimen|Intralesional Interleukin-2 Regimen|Intralesional Proleukin Regimen	A regimen consisting of intralesional aldesleukin (recombinant human interleukin-2) that may be used in the treatment of cutaneous melanoma.			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160061>	C63524	Intralesional BCG Regimen|BCG Intralesional Regimen|Bacillus Calmette-Guerin Intralesional Regimen|Intralesional Bacillus Calmette-Guerin Regimen	A regimen consisting of intralesional Bacillus Calmette-Guerin (BCG) that may be used in the treatment of cutaneous melanoma.			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160062>	C63524	Intralesional Interferon Alfa-2b Regimen|Interferon Alfa-2b Intralesional Regimen|Intralesional IFN Alfa-2b Regimen|Intralesional Intron A Regimen	A regimen consisting of intralesional interferon alfa-2b that may be used in the treatment of cutaneous melanoma.			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160063>	C63524|C159443	Talimogene Laherparepvec Intralesional Regimen|Intralesional Imlygic Regimen|Intralesional T-VEC|Intralesional T-VEC Regimen|Intralesional Talimogene Laherparepvec Regimen	A regimen consisting of intralesional talimogene laherparepvec that may be used in the treatment of cutaneous melanoma and Merkel cell carcinoma.			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160064>	C63442	Intralesional Triamcinolone Regimen	A regimen consisting of intralesional triamcinolone that may be used in the treatment of primary cutaneous B-cell lymphomas.			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160065>	C159462|C159449	Intralesional Vinblastine Regimen|Intralesional Vinblastine Sulfate Regimen	A regimen consisting of intralesional vinblastine that may be used in the treatment of Kaposi sarcoma and desmoid tumors.			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160066>	C63589|C63588|C63443|C63442	Methotrexate Intrathecal Regimen|Intrathecal MTX Regimen|Intrathecal Methotrexate Regimen|Intrathecal Methotrexate Sodium Regimen|Methotrexate Sodium Intrathecal Regimen	A regimen consisting of intrathecal methotrexate that may be used in the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute lymphoblastic, chronic lymphocytic and acute myeloid leukemias;  Bing-Neel syndrome manifestation of Waldenstrom macroglobulinemia, and diffuse large B-cell and small lymphocytic lymphomas, with central nervous system (CNS) involvement.			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160067>	C63524	Ipilimumab Regimen|Ipilimumab monotherapy|Yervoy Regimen	A regimen consisting of ipilimumab that may be used in the treatment of cutaneous and uveal melanoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160068>	C63586|C191676|C159893	Irinotecan Every 14 Days Regimen|Camptosar Every 14 Days Regimen|Every 14 Days Irinotecan Regimen|Irinotecan HCl Every 14 Days Regimen|Irinotecan Hydrochloride Every 14 Days Regimen	A regimen consisting of irinotecan every 14 days that can be used in the treatment of colorectal cancer, and appendiceal and small bowel adenocarcinoma.			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160069>	C63586|C191676|C159893	Irinotecan Every 21 Days Regimen|Every 21 Days Irinotecan Regimen	A regimen consisting of irinotecan every 21 days that can be used in the treatment of colorectal cancer, and appendiceal and small bowel adenocarcinoma.			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C16006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16006>	C15660	Vaccine Design	Determining the antigens (whole virus, parts or crossreacting) to be incorporated in a vaccine			Health Care Activity	
C160070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160070>	C67297|C65070|C63719|C63586|C63522|C63361|C63359|C210232|C191676|C159901|C159900|C159893|C159440	Irinotecan Regimen|Camptosar Regimen|Irinotecan HCl Regimen|Irinotecan Hydrochloride Regimen|Irinotecan monotherapy	A regimen consisting of irinotecan that may be used in the treatment of appendiceal and small bowel adenocarcinomas, bone, cervical, vaginal, gastric, esophageal, esophagogastric junction, colorectal, ovarian, fallopian tube, primary peritoneal, small cell lung cancers (SCLCs); and rhabdomyosarcoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160071>	C63358	Ixabepilone Regimen|Ixabepilone monotherapy|Ixempra Regimen	A regimen consisting of ixabepilone that may be used in the treatment of advanced breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160072>	C63496|C159461	Ixazomib Regimen|Ixazomib monotherapy|Ninlaro Regimen	A regimen consisting of ixazomib that may be used in the treatment of systemic light chain (AL) amyloidosis and multiple myeloma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160073>	C63358|C159440	Lapatinib Regimen|Lapatinib monotherapy|Tykerb Regimen	A regimen consisting of lapatinib that can be used in the treatment of bone and breast cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160074>	C65070|C63719|C63586|C63524|C63522|C63519|C63510|C63502|C63361|C63360|C63358|C210232|C203473|C191713|C191676|C159900|C159893|C159462|C159458|C159457|C159454|C156290|C140180	Larotrectinib Regimen|Larotrectinib monotherapy|Vitrakvi Regimen	A regimen consisting of larotrectinib that can be used in the treatment of breast, central nervous system (CNS), cervical, colorectal, endometrial, esophageal and esophagogastric junction, gastric, hepatobiliary, ovarian, fallopian tube, primary peritoneal, vaginal, and vulvar cancers, non-small cell lung cancer (NSCLC), gastrointestinal stromal tumors (GIST), salivary gland tumors, Hurthle cell, papillary and follicular carcinomas, cutaneous melanoma, ampullary, ampullary, appendiceal, pancreatic and small bowel adenocarcinomas, soft tissue and uterine sarcoma, anaplastic, occult primary and oncocytic carcinoma, and extrapulmonary poorly differentiated neuroendocrine carcinoma/large or small cell carcinoma/mixed neuroendocrine/non-neuroendocrine neoplasm.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160075>	C63496|C63443|C63442	Lenalidomide Maintenance Regimen|Revlimid Maintenance Regimen	A regimen consisting of lenalidomide maintenance that may be used in the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), and plasma cell (multiple) myeloma..			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160076>	C63496|C63443|C63442|C63356|C191727|C159449|C159445	Lenalidomide Regimen|Lenalidomide monotherapy|Revlimid Regimen	A regimen consisting of lenalidomide that can be used in the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), diffuse large B-cell, classic follicular, (grade 1-2), Hodgkin, mantle cell, T-cell and central nervous system (CNS) lymphomas, plasma cell (multiple) myeloma, myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) overlap neoplasms, Kaposi sarcoma, and Castleman disease.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160077>	C63519|C191713|C159458|C159454|C159435	Lenvatinib Regimen|Lenvatinib Mesylate Regimen|Lenvatinib monotherapy|Lenvima Regimen	A regimen consisting of lenvatinib that may be used in the treatment of hepatocellular carcinoma (HCC), salivary gland tumors, endometrial, thymic, follicular, medullary, papillary, Hurthle cell thyroid and oncocytic carcinomas.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160078>	C63522|C63519|C63510|C63358|C159901|C159900	Letrozole Regimen|Femara Regimen|Letrozole monotherapy	A regimen consisting of letrozole that may be used in the treatment of breast cancer, endometrial, ovarian, fallopian tube and primary peritoneal cancers, malignant sex cord-stromal tumors, and uterine sarcoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160079>	C63522|C63510|C63468|C63358|C191713|C159901|C159900	Leuprolide Acetate Regimen|Leuprolide monotherapy|Lupron Regimen	A regimen consisting of leuprolide acetate that may be used in the treatment of breast, prostate, ovarian, fallopian tube and primary peritoneal cancers, granulosa cell tumors, salivary gland tumors, uterine sarcoma, and malignant sex cord-stromal tumors.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C16007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16007>	C16048	Cancer Information Service|CIS|CIS	A nationwide cancer information and education network sponsored by the NCI.  Provides information on prevention, treatment, and ongoing clinical trials to cancer patients and their families, people at risk for cancer, and health professionals.			Intellectual Product	
C160080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160080>	C63522|C63519|C63510|C63442|C63358|C191727|C159901|C159900|C159462|C159449	Liposomal Doxorubicin Regimen|Doxil Regimen|Doxorubicin Hydrochloride Liposomal Regimen|Liposomal Doxorubicin HCl Regimen|Liposomal Doxorubicin Hydrochloride Regimen|Pegylated liposomal doxorubicin monotherapy	A regimen consisting of liposomal doxorubicin that may be used in the treatment of desmoid tumors (aggressive fibromatoses); soft tissue, uterine, and Kaposi sarcomas; mycosis fungoides and Sezary syndrome; Castleman disease; and ovarian, fallopian tube, primary peritoneal, breast, and endometrial cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160081>	C140180	Lomustine Regimen|CCNU Regimen|Gleostine Regimen|Lomustine monotherapy	A regimen consisting of lomustine that may be used in the treatment of anaplastic gliomas and glioblastomas; adult low-grade infiltrative supratentorial astrocytomas (excluding pilocytic astrocytomas) and oligodendrogliomas; and adult intracranial and spinal ependymomas (excluding subependymomas and myxopapillary ependymomas).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160082>	C63442|C63360|C205537	Lorlatinib Regimen|Lorbrena Regimen|Lorlatinib monotherapy	A regimen consisting of lorlatinib that may be used in the treatment of ALK-positive or ROS1-positive advanced non-small cell lung cancer (NSCLC), uterine sarcoma, diffuse large B-cell lymphoma (DLBCL), T-cell lymphomas, inflammatory myofibroblastic tumor (IMT), and certain histiocytic neoplasms, such as Erdheim-Chester disease.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160083>	C63519|C63510|C63358	Megestrol Regimen|Megace Regimen|Megestrol Acetate Regimen|Megestrol monotherapy	A regimen consisting of megestrol that may be used in the treatment of breast cancer, endometrial carcinoma and uterine sarcoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160084>	C63522|C159901|C159900	Melphalan Regimen|Alkeran Regimen|Melphalan monotherapy	A regimen consisting of melphalan that may be used in the treatment of ovarian, fallopian tube and primary peritoneal cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160085>	C67509|C63587|C63467|C63442	Methotrexate Regimen|MTX Regimen|Methotrexate Sodium Regimen|Methotrexate monotherapy	A regimen consisting of methotrexate that may be used in the treatment of bladder, and head and neck cancers, gestational trophoblastic neoplasia (GTN), and mycosis fungoides/Sezary syndrome.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160086>	C63589|C186720|C186719|C159459	Midostaurin Regimen|Midostaurin monotherapy|Rydapt Regimen	A regimen consisting of midostaurin that may be used in the treatment of acute myeloid leukemia (AML), myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes and systemic mastocytosis.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160087>	C65070|C63787|C63467	Mitomycin Regimen|MMC Regimen	A regimen consisting of mitomycin that may be used in the treatment of bladder cancers, peritoneal mesothelioma,  and for radiosensitization in cervical cancers.			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160088>	C156290	Mitotane Regimen|Lysodren Regimen|Mitotane monotherapy	A regimen consisting of mitotane that may be used in the treatment of adrenocortical carcinomas.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160089>	C63588	Nelarabine Regimen|Arranon Regimen|Nelarabine monotherapy	A regimen consisting of nelarabine that may be used in the treatment of acute lymphoblastic leukemia (ALL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C16008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16008>	C52647	Cooperative Group Program	NCI-sponsored program that promotes and supports clinical trials in cancer treatment, (largely combined modality approaches); cancer prevention, and early detection within setting of a Cooperative Group.			Governmental or Regulatory Activity	
C160090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160090>	C63358	Neratinib Regimen|Neratinib Maleate Regimen|Neratinib monotherapy|Nerlynx Regimen	A regimen consisting of neratinib that may be used in the treatment of HER2-positive breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160091>	C63588|C63524|C186720|C186719|C159462|C159441	Nilotinib Regimen|Nilotinib Hydrochloride Regimen|Nilotinib monotherapy|Tasigna Regimen	A regimen consisting of nilotinib that may be used in the treatment of cutaneous melanoma, gastrointestinal stromal tumors (GISTs), acute lymphoblastic leukemia (ALL), myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes, chronic myeloid leukemia (CML), and pigmented villonodular synovitis (PVNS)/tenosynovial giant cell tumor (TGCT).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160092>	C63468	Nilutamide Regimen|Nilandron Regimen	A regimen consisting of nilutamide that may be used in the treatment of advanced prostate cancer.			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160093>	C67290|C65070|C63787|C63719|C63587|C63524|C63519|C63510|C63467|C63443|C63442|C63360|C63359|C210232|C203473|C191676|C166388|C159893|C159462|C159458|C159457|C159454|C159449|C159443|C159440|C159439	Nivolumab Regimen|Nivolumab monotherapy|Opdivo Regimen	A regimen consisting of nivolumab that may be used in the treatment of Hodgkin lymphoma (HL), T-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), ampullary, appendiceal and small bowel adenocarcinoma; chronic lymphocytic leukemia (CLL); small lymphocytic lymphoma (SLL); anal, bladder, bone, hepatobiliary, colorectal, kidney, cervical, endometrial, vaginal, vulvar, head and neck, including cancer of the nasopharynx, esophageal and esophagogastric junction, squamous cell skin, small cell lung and non-small cell lung cancers; peritoneal and pleural mesothelioma, cutaneous and uveal melanoma, Merkel cell carcinoma, anaplastic thyroid carcinoma, gestational trophoblastic neoplasia (GTN), and Kaposi and soft tissue sarcoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160094>	C63443|C63442|C173974	Obinutuzumab Regimen|Gazyva Regimen|Obinutuzumab monotherapy	A regimen consisting of obinutuzumab that may be used in the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), follicular lymphoma, and  Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160095>	C159443|C156290|C140180	Octreotide Long-acting Release Regimen|Octreotide Acetate LAR Regimen|Octreotide Acetate Long-acting Release Regimen|Octreotide LAR Regimen|Octreotide LAR monotherapy|Sandostatin LAR Depot Regimen	A regimen consisting of long-acting release octreotide that may be used in the treatment of well-differentiated grade 3 neuroendocrine tumors (NETs), NETs of the pancreas, gastrointestinal (GI) tract, lung, and the thymus, pheochromocytoma/paraganglioma, meningiomas, and Merkel cell carcinoma.	Octreotide Long-acting Release Regimen		Therapeutic or Preventive Procedure	CTRP Agent Terminology|CTRP Terminology|HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160096>	C63443|C63442	Ofatumumab Regimen|Arzerra Regimen|Ofatumumab monotherapy	A regimen consisting of ofatumumab that may be used in the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and Waldenstrom's macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160097>	C63522|C63510|C63502|C63468|C63358|C159901|C159900|C159462	Olaparib Regimen|Lynparza Regimen|Olaparib monotherapy	A regimen consisting of olaparib that may be used in the treatment of BRCA mutation-positive, HER2-negative breast cancer, BRCA mutation-positive ovarian, fallopian tube and primary peritoneal cancers, BRCA mutation-positive pancreatic adenocarcinoma, and castration-resistant, metastatic prostate cancer, and uterine sarcoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160098>	C159441	Omacetaxine Regimen|Omacetaxine Mepesuccinate Regimen|Omacetaxine monotherapy|Synribo Regimen	A regimen consisting of omacetaxine that may be used in the treatment of chronic myeloid leukemia (CML).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160099>	C63522|C63487|C63442|C63359|C191727|C159909|C159901|C159900|C159435|C140180	Etoposide Oral Regimen|Oral Etoposide Regimen|Oral VP-16 Regimen	A regimen consisting of oral etoposide that may be used in the treatment of adult medulloblastomas; supratentorial primitive neuroectodermal tumors (PNETs); anaplastic gliomas/glioblastomas; adult intracranial and spinal ependymomas (excluding subependymomas and myxopapillary ependymomas); thymomas and thymic carcinomas; ovarian, fallopian tube, primary peritoneal, small cell lung and testicular cancers; Castleman disease; mycosis fungoides/Sezary syndrome, and malignant germ cell tumors.			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C16009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16009>	C20161	Developmental Therapeutics Program|DTP|Developmental Therapeutics|Developmental Therapy	As the drug discovery and development arm of the National Cancer Institute, the Developmental Therapeutics Program (DTP) plans, conducts, and facilitates development of therapeutic agents for cancer and AIDS.  They are a resource for research materials, including Web-accessible data and tools, vialed and plated compounds, tumor cells, animals, and Investigational New Drug (IND)-directed studies.  (DTP web site)			Research Activity	
C1600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1600>	C217648	Cidofovir|1(3-hydroxy-2-phosphonomethoxypropyl) Cytosine|CDV|CIDOFOVIR|Cidofovir Dihydrate|DRG-0145|GS-0504|HPMPC|Vistide|cidofovir	A synthetic, acyclic, monophosphate nucleotide analog of deoxycytidine with antiviral activity, and mostly used against cytomegalovirus (CMV). After incorporation into the host cell, cidofovir is phosphorylated by pyruvate kinases to its active metabolite cidofovir diphosphate. Cidofovir diphosphate, bearing structural similarity to nucleotides, competes with deoxycytosine-5-triphosphate (dCTP) for viral DNA polymerase and gets incorporated into the growing viral DNA strands. As a result, it prevents further DNA polymerization and disrupts DNA replication of viruses.	Cidofovir		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology
C160100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160100>	C63360	Osimertinib Regimen|Osimertinib Mesylate Regimen|Osimertinib monotherapy|Tagrisso Regimen	A regimen consisting of osimertinib that may be used in the treatment of non-small cell lung cancer (NSCLC).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160101>	C63719|C63522|C63361|C159901|C159900	Oxaliplatin Regimen|Eloxatin Regimen|Oxaliplatin monotherapy	A regimen consisting of oxaliplatin that may be used in the treatment of esophageal and esophagogastric junction, gastric, ovarian, fallopian tube and primary peritoneal cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160102>	C65070|C63719|C63587|C63524|C63522|C63519|C63467|C63361|C63360|C63359|C63358|C210232|C159910|C159909|C159901|C159900|C159893|C159458|C159457|C159449|C159448|C159435	Paclitaxel Regimen|Paclitaxel monotherapy|Taxol Regimen	A regimen consisting of paclitaxel that may be used in the treatment of anaplastic thyroid carcinomas, thymomas and thymic carcinomas; soft tissue and Kaposi sarcomas; bladder, cervical, esophageal and esophagogastric junction, gastric, head and neck, endometrial, penile, ovarian, fallopian tube, primary peritoneal, vaginal, and vulvar cancers; small cell and non-small cell lung cancers; small bowel adenocarcinoma; cutaneous and uveal melanoma; salivary gland tumor, and malignant sex cord-stromal and malignant germ cell tumors. Paclitaxel every 21 days regimen may be used for the treatment of breast, ovarian, fallopian tube, and primary peritoneal cancers. Paclitaxel every 14 days regimen may be used for the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160103>	C65070|C63522|C63358|C213158|C210232|C159901|C159900	Paclitaxel Weekly Regimen|Taxol Weekly Regimen|Weekly Paclitaxel Regimen|Weekly Taxol Regimen	A regimen consisting of weekly paclitaxel that may be used in the treatment of breast, cervical, ovarian, fallopian tube, primary peritoneal, and vaginal cancers, and epithelioid hemangioendothelioma.			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160104>	C63586|C191676	Panitumumab Regimen|Panitumumab monotherapy|Vectibix Regimen	A regimen consisting of panitumumab that may be used in the treatment of wild-type RAS metastatic colorectal cancer, and appendiceal cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160105>	C67290|C63522|C63519|C63510|C213158|C159901|C159900|C159893|C159462|C159458|C159443|C159440	Pazopanib Regimen|Pazopanib HCl Regimen|Pazopanib Hydrochloride Regimen|Pazopanib monotherapy|Votrient Regimen	A regimen consisting of pazopanib that may be used in the treatment of alveolar soft part sarcoma, extraskeletal myxoid chondrosarcoma, bone cancer, desmoid tumors, ovarian, fallopian tube and primary peritoneal cancers, solitary fibrous tumor, soft tissue and uterine sarcomas, Merkel cell, follicular, medullary, papillary and Hurthle cell thyroid carcinomas, gastrointestinal stromal tumors (GISTs), kidney cancer, and epithelioid hemangioendothelioma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160106>	C63442|C219691|C173974|C159459	Peginterferon Alfa-2a Regimen|Pegasys Regimen|Peginterferon alfa-2a monotherapy	A regimen consisting of peginterferon alfa-2a that may be used in the treatment of myeloproliferative neoplasms, primary cutaneous anaplastic large cell lymphoma (ALCL) with multifocal lesions, systemic mastocytosis, hairy cell leukemia, and mycosis fungoides/Sezary syndrome.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160107>	C219691|C159459	Peginterferon Alfa-2b Regimen|Peginterferon alfa-2b monotherapy|Pegintron Regimen|Sylatron Regimen	A regimen consisting of peginterferon alfa-2b that may be used in the treatment of myeloproliferative neoplasms and systemic mastocytosis.	Peginterferon Alfa-2b Regimen		Therapeutic or Preventive Procedure	CTRP Agent Terminology|CTRP Terminology|HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160108>	C67338|C67290|C65070|C63719|C63587|C63586|C63524|C63522|C63519|C63510|C63502|C63487|C63468|C63467|C63443|C63442|C63361|C63360|C63359|C63358|C63356|C210232|C203473|C191676|C166388|C159909|C159901|C159900|C159893|C159462|C159458|C159457|C159454|C159449|C159448|C159443|C159440|C159439|C159435|C156290	Pembrolizumab Regimen|Keytruda Regimen|Pembrolizumab monotherapy	A regimen consisting of pembrolizumab that may be used in the treatment of anal, anaplastic, Merkel cell, and thymic carcinomas; ampullary, appendiceal, pancreatic, and small bowel adenocarcinomas; alveolar soft part sarcoma; angiosarcoma, soft tissue sarcoma, uterine sarcoma, and Kaposi sarcoma; bladder, breast, esophageal and esophagogastric junction, kidney, occult primary, gastric, bone, colorectal, cervical, non-small cell lung, small cell lung, penile, testicular, prostate, hepatobiliary, endometrial, vaginal, vulvar, ovarian, fallopian tube and primary peritoneal cancers; head and neck cancer including cancer of the nasopharynx; gestational trophoblastic neoplasia; chronic lymphocytic leukemia (CLL); small lymphocytic lymphoma (SLL); diffuse large B-cell lymphoma (DLBCL); Hodgkin lymphoma; T-cell lymphomas; mycosis fungoides/Sezary syndrome; follicular, medullary, papillary and Hurthle cell thyroid carcinomas; malignant germ cell tumors; adrenal gland and well-differentiated grade 3 neuroendocrine tumors (NETs); extrapulmonary poorly differentiated neuroendocrine carcinoma, large or small cell carcinoma, and mixed neuroendocrine-non-neuroendocrine neoplasm; squamous cell skin cancer; and cutaneous and uveal melanoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160109>	C65070|C63787|C63522|C63467|C63360|C63358|C210232|C159901|C159900|C159435|C140180	Pemetrexed Regimen|Alimta Regimen|Pemetrexed Disodium Regimen|Pemetrexed monotherapy	A regimen consisting of pemetrexed that may be used in the treatment of primary central nervous system (CNS) lymphoma; malignant peritoneal and pleural mesothelioma; bladder, cervical, non-small cell lung, vaginal, ovarian, fallopian tube, and primary peritoneal cancers; and thymomas and thymic carcinomas.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C16010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16010>	C52647	Scientist Exchange Program	Office of International Activities sponsors two international scientist exchange programs: Short-Term Scientist Exchange Program and Oncology Research Faculty Development Program			Occupational Activity	
C160110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160110>	C63496|C63442|C159449	Pomalidomide Regimen|Pomalidomide monotherapy|Pomalyst Regimen	A regimen consisting of pomalidomide that may be used in the treatment of Kaposi sarcoma, primary central nervous system (CNS) lymphoma and plasma cell (multiple) myeloma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160111>	C63588|C186720|C186719|C159462|C159441	Ponatinib Regimen|Iclusig Regimen|Ponatinib HCl Regimen|Ponatinib Hydrochloride Regimen|Ponatinib monotherapy	A regimen consisting of ponatinib that may be used in the treatment of chronic myeloid leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), gastrointestinal stromal tumors (GIST), and myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160112>	C63719|C159893|C159454	Ramucirumab Regimen|Cyramza Regimen|Ramucirumab monotherapy	A regimen consisting of ramucirumab that may be used in the treatment of esophageal and esophagogastric junction, gastric, gastroesophageal junction and hepatobiliary cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160113>	C67338|C63586|C63510|C191676|C159462|C159454|C159440|C140180	Regorafenib Regimen|Regorafenib monotherapy|Stivarga Regimen	A regimen consisting of regorafenib that may be used in the treatment of appendiceal adenocarcinoma, colorectal and hepatobiliary cancers, bone cancer, central nervous system (CNS) cancers, angiosarcoma, soft tissue sarcoma, uterine sarcoma, and gastrointestinal stromal tumors (GISTs).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160114>	C63443|C63442|C63356	Rituximab and Hyaluronidase Human Regimen|Rituxan Hycela Regimen|Rituximab and Human Hyaluronidase Regimen|Rituximab and hyaluronidase monotherapy|Rituximab/Hyaluronidase Human Regimen	A regimen consisting of a fixed-dose combination of rituximab and human hyaluronidase that may be used in the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic, follicular, diffuse large B-cell and primary cutaneous B-cell lymphomas, hairy cell leukemia, Waldenstrom macroglobulinemia or lymphoplasmacytic lymphoma, and nodular lymphocyte-predominant Hodgkin lymphoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160115>	C63588|C63443|C63442|C191727	Rituximab Regimen|Rituxan Regimen|Rituximab monotherapy	A regimen consisting of rituximab that may be used in the treatment of acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and hairy cell leukemia, mantle cell, small lymphocytic, diffuse large B-cell, primary cutaneous B-cell, classic follicular, central nervous system (CNS), nodal marginal zone, splenic marginal zone, and mucosa-associated lymphoid tissue (MALT) lymphomas, extranodal marginal zone lymphoma of nongastric sites (noncutaneous) and the stomach, Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma, nodular lymphocyte-predominant Hodgkin lymphoma, and post-transplant lymphoproliferative disorders.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160116>	C219691|C186720|C186719|C173974|C159445	Ruxolitinib Regimen|Jakafi Regimen|Ruxolitinib Phosphate Regimen|Ruxolitinib monotherapy	A regimen consisting of ruxolitinib that may be used in the treatment of myeloproliferative neoplasms, myelodysplastic/myeloproliferative neoplasm (MDS/MPN), myeloid or lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes, T-cell lymphoma, T-cell prolymphocytic leukemia and T-cell large granular lymphocytic leukemia.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160117>	C67290|C63510|C213158|C191727|C159462|C159449	Sirolimus Regimen|Rapamune Regimen	A regimen consisting of sirolimus that may be used in the treatment of epithelioid hemangioendothelioma, Kaposi sarcoma, uterine sarcoma, kidney cancer, perivascular epithelioid cell tumors (PEComas), angiomyolipomas and lymphangioleiomyomatosis (LAM), and Castleman disease.			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160118>	C67338|C67290|C63589|C63510|C191713|C186720|C186719|C159462|C159458|C159454|C159440	Sorafenib Regimen|Nexavar Regimen|Sorafenib Tosylate Regimen|Sorafenib monotherapy	A regimen consisting of sorafenib that may be used in the treatment of soft tissue sarcoma, gastrointestinal stromal and desmoid tumors (aggressive fibromatoses), follicular, medullary, papillary and Hurthle cell thyroid carcinomas, bone, hepatobiliary and kidney cancers, acute myeloid leukemia (AML), angiosarcoma, salivary gland and solitary fibrous tumors, and myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160119>	C63510|C186720|C186719|C159893|C159462|C159458|C159440|C159435|C156290|C140180	Sunitinib Regimen|Sunitinib Malate Regimen|Sunitinib monotherapy|Sutent Regimen	A regimen consisting of sunitinib that may be used in the treatment of soft tissue sarcomas, including extraskeletal myxoid chondrosarcoma, alveolar soft part sarcomas and angiosarcoma; follicular, medullary, papillary, Hurthle cell thyroid carcinomas; thymic carcinomas and thymomas; gastrointestinal stromal tumors (GISTs); kidney and bone cancers; solitary fibrous tumor/hemangiopericytoma; and pancreatic neuroendocrine tumors (NETs), well-differentiated grade 3 NETs, pheochromocytoma/paraganglioma, myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions, and meningioma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C16011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16011>	C15820	Diet and Nutrition Research	Epidemiology studies looking at the role of dietary patterns, foods, and nutrients or other dietary components in cancer incidence and prevention.			Research Activity	
C160120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160120>	C63358	Talazoparib Regimen|Talazoparib Tosylate Regimen|Talazoparib monotherapy|Talzenna Regimen	A regimen consisting of talazoparib that may be used in the treatment of BRCA mutation-positive, HER2-negative advanced breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160121>	C63522|C63519|C63358|C159901|C159900	Tamoxifen Regimen|Nolvadex Regimen|Tamoxifen Citrate Regimen|Tamoxifen monotherapy	A regimen consisting of tamoxifen that may be used in the treatment of breast, endometrial, ovarian, fallopian tube, and primary peritoneal cancer, and malignant sex cord-stromal tumors.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160122>	C63524|C63510|C63442|C63359|C159462|C156290|C140180	Temozolomide Regimen|Temodar Regimen|Temozolomide monotherapy	A regimen consisting of temozolomide that may be used in the treatment of soft tissue and uterine sarcoma, cutaneous and uveal melanoma, small cell lung cancer (SCLC), central nervous system (CNS) cancers, mycosis fungoides and Sezary syndrome, pheochromocytoma and paraganglioma, and extrapulmonary poorly differentiated neuroendocrine carcinoma, large or small cell carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm, and neuroendocrine tumors (NETs), including well-differentiated grade 3 NETs and NETs of the gastrointestinal (GI) tract, lung, thymus and pancreas.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160123>	C67290|C63519|C63510|C159462	Temsirolimus Regimen|Temsirolimus monotherapy|Torisel Regimen	A regimen consisting of temsirolimus that may be used in the treatment of uterine sarcoma, kidney cancer, endometrial carcinoma, perivascular epithelioid cell tumors (PEComas), angiomyolipomas, and lymphangioleiomyomatosis (LAM).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160124>	C191727|C159449	Thalidomide Regimen|Thalidomide monotherapy|Thalomid Regimen	A regimen consisting of thalidomide that may be used in the treatment of Kaposi sarcoma and Castleman disease.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160125>	C159449	Topical Alitretinoin Regimen|Alitretinoin monotherapy|Topical Panretin Regimen	A regimen consisting of topical alitretinoin that may be used in the treatment of Kaposi sarcoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160126>	C63442	Topical Bexarotene Regimen|Bexarotene Topical Regimen|Topical Targretin Regimen	A regimen consisting of topical bexarotene that may be used in the treatment of primary cutaneous B-cell lymphomas, mycosis fungoides, and Sezary syndrome.			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160127>	C159448	Topical Fluorouracil Regimen|Fluorouracil Topical Regimen|Topical 5-FU Regimen	A regimen consisting of topical fluorouracil that may be used in the treatment of penile cancer.			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160128>	C63524|C63442|C159449|C159448	Topical Imiquimod Regimen|Imiquimod Topical Regimen|Topical Aldara Regimen|Topical Zyclara Regimen	A regimen consisting of topical imiquimod that may be used in the treatment of primary cutaneous lymphomas, Kaposi sarcoma, cutaneous melanoma, penile cancers, mycosis fungoides and Sezary syndrome.	Topical Imiquimod Regimen		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160129>	C63522|C159901|C159900	Topotecan Daily Regimen|Daily Hycamtin Regimen|Daily Topotecan HCl Regimen|Daily Topotecan Hydrochloride Regimen|Daily Topotecan Regimen	A regimen consisting of daily topotecan that may be used in the treatment of ovarian, fallopian tube, and primary peritoneal cancers.			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C16012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16012>	C15824	Nutrition Research, Artificial Sweeteners	The study of artificial sweeteners as potential carcinogens and in relation to general health.			Research Activity	
C160130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160130>	C65070|C210232	Topotecan Every 28 Days Regimen|Every 28 Days Hycamtin Regimen|Every 28 Days Topotecan Regimen	A regimen consisting of topotecan every 28 days that may be used in the treatment of cervical and vaginal cancer.			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160131>	C67297|C63522|C63519|C63442|C63359|C159901|C159900|C159443	Topotecan Regimen|Hycamtin Regimen|Topotecan HCl Regimen|Topotecan Hydrochloride Regimen|Topotecan monotherapy	A regimen consisting of topotecan that may be used in the treatment of Merkel cell carcinoma; primary central nervous system (CNS) lymphoma, rhabdomyosarcoma, small cell lung cancer (SCLC), and endometrial, ovarian, fallopian tube, and primary peritoneal cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160132>	C65070|C63522|C210232|C159901|C159900	Topotecan Weekly Regimen|Weekly Hycamtin Regimen|Weekly Topotecan HCl Regimen|Weekly Topotecan Hydrochloride Regimen|Weekly Topotecan Regimen	A regimen consisting of weekly topotecan that may be used in the treatment of cervical, vaginal, ovarian, fallopian tube, and primary peritoneal cancers.			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160133>	C63358	Toremifene Regimen|Fareston Regimen|Toremifene Citrate Regimen|Toremifene monotherapy	A regimen consisting of toremifene that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160134>	C63519|C63510|C159462	Trabectedin Regimen|Trabectedin monotherapy|Yondelis Regimen	A regimen consisting of trabectedin that may be used in the treatment of soft tissue and uterine sarcoma, including uterine leiomyosarcoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160135>	C63358|C191713	Trastuzumab Regimen|Herceptin Regimen|Trastuzumab monotherapy|Trastuzumab-anns monotherapy|Trastuzumab-dkst monotherapy|Trastuzumab-dttb monotherapy|Trastuzumab-herw monotherapy|Trastuzumab-pkrb monotherapy|Trastuzumab-qyyp monotherapy|Trastuzumab-strf monotherapy|Trastuzumab-zerc monotherapy	A regimen consisting of trastuzumab that may be used in the treatment of breast cancer and salivary gland tumors.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160136>	C63719|C63586|C63361|C191676	Tipiracil/Trifluridine Regimen|Lonsurf Regimen|Trifluridine and Tipiracil Regimen|Trifluridine and tipiracil monotherapy	A regimen consisting of tipiracil and trifluridine that may be used in the treatment of appendiceal adenocarcinoma, esophageal and esophagogastric junction and gastric cancers, and metastatic colorectal cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160137>	C63587|C63510|C63468|C63358	Triptorelin Regimen|Trelstar Regimen|Triptorelin Pamoate Regimen|Triptorelin monotherapy	A regimen consisting of triptorelin that may be used in the treatment of prostate and breast cancer, salivary gland tumor, and uterine sarcoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160138>	C63467	Valrubicin Regimen|Intravesical Valrubicin Regimen|Intravesicular Valrubicin monotherapy|Valstar Regimen	A regimen consisting of valrubicin that may be used in the treatment of refractory carcinoma in situ (CIS) of the bladder.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160139>	C159458	Vandetanib Regimen|Caprelsa Regimen|Vandetanib monotherapy	A regimen consisting of vandetanib that may be used in the treatment of advanced follicular, medullary, papillary and Hurthle cell thyroid carcinomas.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C16013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16013>	C15824	Nutrition Research, Antioxidants	The study of the role of antioxidants in cancer causation or prevention and in general health.			Research Activity	
C160140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160140>	C63524|C63360|C205537|C173974|C159458	Vemurafenib Regimen|Vemurafenib monotherapy|Zelboraf Regimen	A regimen consisting of vemurafenib that may be used in the treatment of follicular, papillary and Hurthle cell thyroid carcinomas, cutaneous melanoma, hairy cell leukemia, non-small cell lung cancer (NSCLC), and certain histiocytic neoplasms, such as Langerhans cell histiocytosis and Erdheim-Chester disease.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160141>	C63443|C63442|C173974	Venetoclax Regimen|Venclexta Regimen|Venetoclax monotherapy	A regimen consisting of venetoclax that may be used in the treatment of hairy cell leukemia, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), mantle cell lymphoma and Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160142>	C63588	Vincristine Liposomal Regimen|Liposomal Vincristine Regimen|Liposomal Vincristine Sulfate Regimen|Marqibo Regimen|Vincristine liposomal monotherapy	A regimen consisting of vincristine sulfate liposome that may be used in the treatment of acute lymphoblastic leukemia (ALL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160143>	C67297|C65070|C63787|C63522|C63510|C63358|C210232|C159901|C159900|C159462|C159449	Vinorelbine Regimen|Navelbine Regimen|Vinorelbine Tartrate Regimen|Vinorelbine monotherapy	A regimen consisting of vinorelbine that may be used in the treatment of soft tissue and Kaposi sarcoma; angiosarcoma; rhabdomyosarcoma, peritoneal and pleural mesothelioma, breast, cervical, vaginal, ovarian, fallopian tube, primary peritoneal, and small cell lung cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160144>	C28193	Low Anterior Resection Syndrome	A collection of symptoms following removal of part or all of the rectum that may include frequency or urgency of stools, numerous bowel movements over a few hours, fecal incontinence, constipation alternating with numerous bowel movements, and/or increased intestinal gas.	Low Anterior Resection Syndrome		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C160145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160145>	C41075|C18130	Sacral Nerve Stimulator|Sacral Neuromodulator	A surgically implanted medical device that sends electrical impulses to the sacral nerve. It is used to treat bladder or bowel dysfunction.	Sacral Nerve Stimulator		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C160146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160146>	C49839	Sacral Nerve Stimulator Battery|Sacral Neuromodulator Battery	A rechargeable battery that powers a surgically implanted sacral nerve stimulator.	Sacral Nerve Stimulator Battery		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C160147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160147>	C203022	Safimaltib|1-(1-Oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazole-4-carboxamide|JNJ 67856633|JNJ-67856633|JNJ67856633|MALT1 Inhibitor JNJ-67856633|Mucosa-associated Lymphoid Tissue Lymphoma Translocation Protein 1 Inhibitor JNJ-67856633|SAFIMALTIB	An orally bioavailable inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), with potential antineoplastic activity. Upon administration, safimaltib targets, binds to, and prevents the activity of MALT1. This inhibits MALT1-dependent signaling, reduces interleukin-10 (IL-10) and upregulates interferon (IFN). This results in the inhibition of Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling and nuclear factor-kappa B (NF-kB) signaling, induces apoptosis, and inhibits tumor cell growth of MALT1-expressing tumor cells. MALT1 belongs to the caspase family of proteases and is the active component of the CARD11-BCL10-MALT1 (CBM) signaling complex. It plays an essential role in B- and T-lymphocyte activation and is over-activated in certain tumor cells.	Safimaltib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160148>	C17423	Brass Mesh Bolus|BMB|Brass mesh	A brass mesh material used to increase the radiation dose at or near the skin surface. This material is used in place of tissue-equivalent bolus material to achieve improved conformity to the chest wall.			Manufactured Object	
C160149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160149>	C27691|C134154	Refractory EBV-Related Lymphoma|Refractory EBV-Associated Lymphoma	An EBV-related lymphoma that is resistant to treatment.	Refractory EBV-Related Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16014>	C15824	Nutrition Research, Caffeine	The study of the role of caffeine in cancer causation or prevention and in general health.			Research Activity	
C160150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160150>	C159717|C150673	EBV-Related Lymphoproliferative Disease with Primary Immunodeficiency|EBV- Associated Lymphoproliferative Disease with Primary Immunodeficiency|Epstein-Barr Virus-Related Lymphoproliferative Disease with Primary Immunodeficiency	An EBV-related lymphoid proliferation that arises in the setting of immune deficiency due to a primary immunodeficiency or immunoregulatory disorder.			Disease or Syndrome	
C160151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160151>	C160150|C147861	Recurrent EBV-Related Lymphoproliferative Disease with Primary Immunodeficiency|Recurrent Epstein-Barr Virus-Related Lymphoproliferative Disease with Primary Immunodeficiency|Recurrent Epstein-Barr Virus-Related Lymphoproliferative Disease with Primary Immunodeficiency	The reemergence of EBV-associated lymphoproliferative disease with primary immunodeficiency after a period of remission.	Recurrent Epstein-Barr Virus-Associated Lymphoproliferative Disease with Primary Immunodeficiency		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C160152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160152>	C160150|C157686	Refractory EBV-Related Lymphoproliferative Disease with Primary Immunodeficiency|Refractory Epstein-Barr Virus-Related Lymphoproliferative Disease with Primary Immunodeficiency|Refractory Epstein-Barr Virus-Related Lymphoproliferative Disease with Primary Immunodeficiency	EBV-associated lymphoproliferative disease with primary immunodeficiency that is resistant to treatment.	Refractory Epstein-Barr Virus-Associated Lymphoproliferative Disease with Primary Immunodeficiency		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C160153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160153>	C158612	Specify Other Risk Factor Question|If Other, specify|Specify Other Risk Factor	A directive to specify the other risk factor.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C160154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160154>	C158612	Unknown New Tumor Event Question|Unknown New Tumor Event|Unknown: Could not be determined or unsure	The new tumor event is unknown.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Terminology
C160155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160155>	C191755	Bladder Diverticulum	A pouch or sac-like protrusion in the bladder wall.			Finding	
C160156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160156>	C160157	Unknown Site of New Tumor Event|Unknown|Unknown: Could not be determined or unsure	The site of the new tumor event is unknown.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160157>	C91106	CPTAC Responses				Intellectual Product	
C160158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160158>	C4912|C191753	Bladder Diverticulum Carcinoma|Bladder Diverticular Carcinoma|Carcinoma Arising in Bladder Diverticulum	A carcinoma arising in a bladder diverticulum. Approximately one-third to half of the cases represent non-invasive, low-grade or high-grade urothelial carcinomas. Approximately half of the invasive carcinomas are urothelial. The rest include adenocarcinomas, squamous cell carcinomas, and small cell carcinomas.			Neoplastic Process	
C160159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160159>	C158612	Other Tumor Site Question|Other|Other Tumor Site	The site of the tumor was identified in the study but is not present in the form.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C16015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16015>	C16016	Nutrition Research, Vitamin A	The study of the role of Vitamin A, its precursons, and its analogs in cancer causation or prevention and in general health.			Research Activity	
C160160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160160>	C158612	Specify Other Tumor Site Question|If Other, Specify|Specify Other Tumor Site	A directive to specify the other tumor site.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C160161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160161>	C158612	Unknown Supratentorial Localization Question|Unknown Supratentorial Localization|Unknown: Could not be determined or unsure	The supratentorial location is unknown.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology
C160162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160162>	C160157	Therapeutic Ionizing Radiation to Head History Present|Yes	There is a history of the individual receiving therapeutic ionizing radiation to the head.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology
C160163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160163>	C160157	Therapeutic Ionizing Radiation to Head History Absent|No	There is no history of the individual receiving therapeutic ionizing radiation to the head.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology
C160164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160164>	C160157	Therapeutic Ionizing Radiation to Head History Unknown|Unknown: Could not be determined or unsure	The history of the individual receiving therapeutic ionizing radiation to the head is unknown			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology
C160165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160165>	C160157	First Degree Family History Cancer Positive|Yes	The parents, siblings or children of an individual have a history of cancer.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology
C160166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160166>	C160157	First Degree Family History Cancer Negative|No	The parents, siblings or children of an individual have no history of cancer.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology
C160167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160167>	C160157	First Degree Family History Cancer Unknown|Unknown: Could not be determined or unsure	The history of cancer of the parents, siblings or children of an individual is unknown.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology
C160168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160168>	C160157	First Degree Family History of Primary Brain Tumor Positive|Yes	The parents, siblings or children of an individual have a history of primary brain tumors.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology
C160169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160169>	C160157	First Degree Family History of Primary Brain Tumor Negative|No	The parents, siblings or children of an individual have no history of primary brain tumors.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology
C16016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16016>	C15824	Nutrition Research, Vitamins	The study of the role of vitamins in cancer causation or prevention and in general health.			Research Activity	
C160170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160170>	C160157	First Degree Family History of Primary Brain Tumor Unknown|Unknown: Could not be determined or unsure	The history of primary brain tumors of the parents, siblings or children of an individual is unknown.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology
C160171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160171>	C160766	Was a BRAF Mutation Identified Question|BRAF Mutation Identified|Was a BRAF Mutation Identified	A question asking if a BRAF mutation was identified during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160172>	C160766	Was an IDH Family Mutation Identified Question|IDH1/2 Mutation Identified|Was an IDH Family Mutation Identified	A question asking if IDH family gene mutations were identified during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160173>	C160157	First Presenting Symptom Related to Disease Unknown|Unknown: Could not be determined or unsure	The first presenting symptom related to the disease is unknown.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Terminology
C160174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160174>	C160766	Was an ATRX Mutation Identified Question|ATRX Mutation Identified|Was an ATRX Mutation Identified	A question asking if an ATRX mutation was identified during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160175>	C160766	Was an EGFR Amplification Identified Question|EGFR Amplification Identified|Was an EGFR Amplification Identified	A question asking if an EGFR amplification was identified during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160176>	C160766	Was a PTEN Mutation Identified Question|PTEN Mutation Identified|Was a PTEN Mutation Identified	A question asking if a PTEN mutation was identified during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160177>	C160766	Was a TP53 Mutation Identified Question|TP53 Mutation Identified|Was a TP53 Mutation Identified	A question asking if a TP53 mutation was identified during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160178>	C160157	Non-Neoplastic Finding Absent|None|None Identified	There is no non-neoplastic finding.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C160179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160179>	C160157	History of Medical Treatment Present|Yes	An indication that a history of medical treatment is present.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C16017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16017>	C15605	Trace Element Nutrition Research, Selenium|Nutrition, Selenium	The study of the role of selenium in cancer causation or prevention and in general health.			Research Activity	
C160180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160180>	C160157	History of Medical Treatment Absent|No	An indication that a history of medical treatment is absent.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C160181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160181>	C160157	History of Medical Treatment Unknown|Unknown	The history of medical treatments is unknown.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C160182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160182>	C160157	Cancer History Present|Yes	An indication that a cancer history is present.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C160183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160183>	C82847	US English|English, US|United States English	A form of the English language spoken in the United States.			Language	
C160184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160184>	C82847	Canadian English|English, Canada	A form of the English language spoken in Canada.			Language	
C160185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160185>	C160157	Cancer History Absent|No	An indication that a cancer history is absent.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C160186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160186>	C82847	UK English|England English|English, UK|United Kingdom English	A form of the English language spoken in the United Kingdom.			Language	
C160187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160187>	C160157	Cancer History Unknown|Unknown	An indication that a cancer history is unknown.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C160188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160188>	C123785	Canadian French|French, Canada	A form of the French language spoken in Canada.			Language	
C160189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160189>	C120587	US Spanish|Spanish, US|United States Spanish	A form of the Spanish language spoken in the United States.			Language	
C160190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160190>	C120587	Mexican Spanish|Spanish, Mexico	A form of the Spanish language spoken in Mexico.			Language	
C160191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160191>	C160157	History of Other Medical Treatment|Other	There is a history of other medical treatment.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C160192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160192>	C717	Tezemlimogene Daxadenorepvec|DNX 2440|DNX-2440|DNX2440|OX40L-expressing Oncolytic Adenovirus DNX-2440|Oncolytic Adenovirus Armed With OX40L DNX-2440|TEZEMLIMOGENE DAXADENOREPVEC	A selectively replication competent oncolytic adenovirus that is engineered to express OX40 ligand (OX40L) with potential oncolytic and immunostimulatory activities. Upon administration, tezemlimogene daxadenorepvec, which contains an integrin binding RGD-4C motif, infects tumor cells in a Coxsackievirus-adenovirus receptor-independent manner and selectively replicates in tumor cells that are defective in retinoblastoma gene (Rb) or cyclin-dependent kinase inhibitor-2A (p16). Tumor cell selectivity is achieved through a 24-base pair deletion in the E1A gene, which renders the oncolytic adenovirus unable to replicate in normal cells that maintain a functional Rb pathway, but fully replication competent in Rb/p16 defective tumor cells.  Active replication of the OX40L-expressing oncolytic adenovirus within tumor cells may induce oncolysis and release of OX40L. OX40L may then bind to and activate signaling pathways downstream of its cognate receptor, tumor necrosis factor receptor superfamily member 4 (TNFRSF4; OX40), which is expressed on activated T-cells. OX40L/OX40 binding promotes increased cytokine production, which can induce proliferation of memory and effector T-lymphocytes and promote the killing of nearby tumor cells. OX40L, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) ligand family, provides a co-stimulatory signal for the proliferation and survival of activated T-cells. The Rb gene product and p16 are negative regulators of the cell cycle and are defective in certain tumor types.	Tezemlimogene Daxadenorepvec		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160193>	C160157	Documentation Present|Yes	Documentation is present.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C160194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160194>	C160157	Documentation Absent|No	Documentation is absent.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C160195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160195>	C211621	Inobrodib|CCS 1477|CCS-1477|CCS1477|INOBRODIB|p300 HAT/CREB Binding Protein Inhibitor CCS1477|p300/CBP Bromodomain Inhibitor CCS1477	An orally bioavailable, small molecule inhibitor of the highly conserved bromodomains of the histone acetyltransferase (HAT) paralogs, p300 (E1A-associated protein p300; p300 HAT) and CREB binding protein (CBP), with potential antineoplastic activity. Upon oral administration, inobrodib selectively and reversibly binds to the bromodomains of p300 and CBP. This disrupts the acetylation of histones and other proteins and prevents the co-activation of key transcription factors that contribute to tumor progression including the androgen receptor (AR), androgen receptor splice variants (AR-SV), hypoxia-inducible factor 1-alpha (HIF-1-alpha) and Myc proto-oncogene protein (c-Myc). The HAT paralogs p300 and CBP are key transcriptional co-activators that are essential for a multitude of cellular processes and are implicated in the progression and therapeutic resistance of certain cancers.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160196>	C160157	Documentation Unknown|Unknown	Documentation is unknown.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C160197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160197>	C1663	CALR Exon 9 Mutant Peptide Vaccine/Montanide ISA-51|CALR Exon 9 Mutant Peptide Vaccine With Montanide ISA-51|CALRLong36 Peptide Vaccine/Montanide ISA-51	A peptide vaccine consisting of a calreticulin (CALR) mutant peptide, CALRLong36, and montanide ISA 51 with potential antineoplastic activity. Upon vaccination, the CALR exon 9 mutant peptide vaccine may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL)-mediated response against tumor cells harboring mutations in exon 9 of the calreticulin gene. CALR, an endoplasmic reticulum chaperone protein that normally facilitates protein folding, immune response, and hematopoiesis, is often mutated in patients with chronic myeloproliferative neoplasms. In its mutant form, CALR is secreted into the plasma, where it binds to and activates the thrombopoietin receptor MPL and initiates downstream JAK/STAT signaling. Montanide ISA-51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil (w/o) emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens.			Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160198>	C160157	Unknown Tumor Zone|Unknown zone|Unknown: Could not be determined or unsure	An indication that the tumor zone is unknown.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C160199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160199>	C160157	Tumor Laterality Right|Right|Right	A finding indicating the tumor location is on the right side of the specimen.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form|HL Authorized Value Terminology|HL Lesion Characteristics Table
C1601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1601>	C2018	Vorozole|(+)-6-((4-Chlorophenyl)-1H-1,2,4-triazol-1-ylmethyl)-1-methyl-1H-benzotriazole|(+)-Vorozole|R 83 842|R83842|Rivizor|VOROZOLE|vorozole				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C160200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160200>	C160157	Tumor Laterality Left|Left|Left	A finding indicating the tumor location is on the left side of the specimen.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form|HL Authorized Value Terminology|HL Lesion Characteristics Table
C160201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160201>	C160157	Tumor Laterality Bilateral|Bilateral	A finding indicating the tumor location is on the both sides of the specimen.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology
C160202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160202>	C159583	Anti-CD47 Monoclonal Antibody SHR-1603|SHR 1603|SHR-1603|SHR1603	A monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, anti-CD47 monoclonal antibody SHR-1603 preferentially binds to CD47 on tumor cells. This blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of tumor cells. Additionally, blocking CD47 signaling activates both an anti-tumor T-lymphocyte immune response and T-cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160203>	C210987	Nuvisertib|2-((1R,4R)-4-((3-(3-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)cyclohexyl)propan-2-ol|NUVISERTIB|PIM Inhibitor TP-3654|PIM Kinase Inhibitor TP-3654|SGI 9481|SGI-9481|SGI9481|TP 3654|TP-3654|TP3654	An orally available, second-generation and selective ATP-competitive inhibitor of proviral integration site for Moloney murine leukemia virus (PIM) kinases, with potential antineoplastic activity. Upon oral administration, nuvisertib selectively binds to and prevents the activation of the PIM kinases. This prevents the activation of PIM-mediated signaling pathways and inhibits proliferation in cells that overexpress PIM. PIMs, constitutively active proto-oncogenic serine/threonine kinases, are upregulated in various types of cancers and play key roles in tumor cell proliferation and survival.	Nuvisertib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160204>	C199673	Anti-ILT4 Monoclonal Antibody MK-4830|Anti-LIR2 Monoclonal Antibody MK-4830|Anti-leukocyte Immunoglobulin-like Receptor 2 Monoclonal Antibody MK-4830|MK 4830|MK-4830|MK4830	A human monoclonal antibody directed against the inhibitory immune checkpoint receptor immunoglobulin-like transcript 4 (ILT4; leukocyte immunoglobulin-like receptor subfamily B member 2; LILRB2; lymphocyte immunoglobulin-like receptor 2; LIR2; monocyte/macrophage immunoglobulin-like receptor 10; MIR-10; CD85d), with potential immunomodulating and antineoplastic activities. Upon administration, anti-ILT4 monoclonal antibody MK-4830 targets and binds to ILT4. This prevents the binding of ILT4 ligands to their receptor and prevents ILT4-mediated signaling. This abrogates the immunosuppressive activities of ILT4 in the tumor microenvironment (TME), activates the expression of pro-inflammatory cytokines, including GM-CSF and tumor necrosis factor alpha (TNFalpha), and enhances a cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response. ILT4, plays a key role in tumor immune evasion. ILT4, a transmembrane protein and inhibitory member of the immunoglobulin-like transcript (ILT) family of proteins, is expressed primarily by myeloid cells, including monocytes, macrophages, dendritic cells (DCs) and granulocytes, and certain tumor cells.	Anti-ILT4 Monoclonal Antibody MK-4830		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160205>	C160157	Family History of Stomach Cancer Present|Yes	There is a family history of stomach cancer.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C160206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160206>	C160157	Family History of Stomach Cancer Absent|No	There is no family history of stomach cancer.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C160207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160207>	C185612	SHP2 Inhibitor JAB-3068|JAB 3068|JAB-3068|JAB-3068|JAB3068	An orally bioavailable inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; Src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic activity. Upon oral administration, SHP2 inhibitor JAB-3068 targets, binds to and inhibits the activity of SHP2. This prevents SHP2-mediated signaling, inhibits MAPK signaling and prevents growth of SHP2-expressing tumor cells. SHP2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the Ras-Raf-MEK-ERK signaling pathway. The Ras-MAPK pathway is often hyperactivated in cancer cells due to specific mutations and rearrangements and are dependent on SHP2 for their oncogenic signaling. SHP2 also regulates programmed cell death 1 (PD-1)-mediated signal transduction and is involved in immune checkpoint modulation.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160208>	C160157	Bilateral Thyroid Glands|Bilateral	Both the left and the right thyroid glands.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C160209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160209>	C160157	Thyroid, NOS	An area of the thyroid gland not otherwise specified.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C16020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16020>	C15553	Breast Cancer Prevention, Education, and Diagnosis Program Initiative	A program designed to improve prevention, diagnosis, and education for breast cancer.			Health Care Activity	
C160210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160210>	C160157	First Degree Family History Thyroid Cancer Negative|No	There is no first degree family history of thyroid cancer.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C160211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160211>	C160157	First Degree Family History Thyroid Cancer Positive|Yes	There is a first degree family history of thyroid cancer.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C160212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160212>	C160157	First Degree Family History Thyroid Cancer Unknown|Unknown: Could not be determined or unsure	There is an unknown first degree family history of thyroid cancer.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C160213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160213>	C160157	Radiation History Unknown|Unknown: Could not be determined or unsure	There is an unknown history of radiation exposure.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C160214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160214>	C160157	Radiation History Positive|Yes	There is a history of radiation exposure.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C160215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160215>	C160157	Radiation History Negative|No	There is no history of radiation exposure.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C160216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160216>	C160157	Adjuvant I-131 Therapy Positive|Yes	Adjuvant I-131 therapy was administered.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C160217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160217>	C160157	Adjuvant I-131 Therapy Negative|No	Adjuvant I-131 therapy was not administered.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C160218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160218>	C160157	Adjuvant I-131 Therapy Unknown|Unknown: Could not be determined or unsure	Adjuvant I-131 therapy administration is unknown.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C160219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160219>	C176545|C173151|C173045	Needed Medical Care or Prescription Medicine but Unable to Afford it Question|Needed Medical Care or Prescription Medicine but Unable to Afford it|Was there a time when you or another household member needed medical care or a prescription medicine but were unable to get it because your family could not afford it.	A question about whether a household member was unable to get  needed medical care or a prescription medicine because the family couldn't afford it.			Intellectual Product	
C16021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16021>	C16847	Nutrition Monitoring Technique	Any method for determining as accurately as possible total food amount and composition ingested by subjects in dietary studies or amount of specific dietary components.			Therapeutic or Preventive Procedure	
C160220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160220>	C176545|C173151|C173045	Who Needed Medical Care but Family Unable to Afford it Question|Who Needed Medical Care but Family Unable to Afford it|Who needed medical care but were unable to get it because your family could not afford it	A question about which household member was unable to get needed medical care because the family couldn't afford it.			Intellectual Product	
C160221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160221>	C173151|C173045	Who Needed Prescription Medicine but Family Unable to Afford it Question|Who Needed Prescription Medicine but Family Unable to Afford it|Who needed a prescription medicine but were unable to get it because your family could not afford it	A question about which household member was unable to get needed prescription medicine because the family couldn't afford it.			Intellectual Product	
C160222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160222>	C15239	Medical Care	Services obtained from a medical professional for the maintenance of health, prevention of illness, and treatment of illness or injury.			Health Care Activity	
C160223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160223>	C226708	More Than Enough Money Left Over|More than enough money left over	A response indicating that there was more than enough money left over.			Intellectual Product	
C160224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160224>	C226708	Some Money Left Over|Some money left over	A response indicating that there was some money left over.			Intellectual Product	
C160225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160225>	C226708	Just Enough to Make Ends Meet|Just enough to make ends meet	A response indicating that there was just enough money left over to make ends meet.			Intellectual Product	
C160226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160226>	C226708	Almost Enough to Make Ends Meet|Almost enough to make ends meet	A response indicating that there was almost enough money left over to make ends meet.			Intellectual Product	
C160227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160227>	C226708	Not Enough to Make Ends Meet|Not enough to make ends meet	A response indicating that there was not enough money left over to make ends meet.			Intellectual Product	
C160228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160228>	C160157	First Course Treatment Completion Measure of Success of Outcome Not Applicable|Not Applicable	A response that the first course treatment completion measure of success of outcome is not applicable.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology
C160229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160229>	C8852|C138211	Recurrent High Grade B-Cell Lymphoma|Recurrent High-Grade B-Cell Lymphoma|Recurrent High-Grade B-Cell Lymphoma	The reemergence of high-grade B-cell lymphoma after a period of remission.	Recurrent High-Grade B-Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16022>	C15972	Antibody-Directed Enzyme Prodrug Therapy|ADEPT	A systemic therapy which ensures that a specific prodrug is not converted into the active moiety anywhere but at the sites where the enzyme-linked, tumor-specific antibodies have localized.			Therapeutic or Preventive Procedure	
C160230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160230>	C36080|C165240	Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type	The reemergence of diffuse large B-cell lymphoma germinal center B-cell type after a period of remission.	Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160231>	C36081|C178553|C165240	Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type|Recurrent Diffuse Large B-Cell Lymphoma Non-GC/ABC|Recurrent Diffuse Large B-Cell Lymphoma Non-Germinal Center/Activated B-Cell Type|Recurrent Non-GC/ABC DLBCL	The reemergence of diffuse large B-cell lymphoma activated B-cell type after a period of remission.	Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160232>	C165799|C158149|C139681	Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma	The reemergence of diffuse large B-cell lymphoma that resulted from the transformation of follicular lymphoma, after a period of remission.	Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160233>	C8853|C138211	Refractory High Grade B-Cell Lymphoma|Refractory High-Grade B-Cell Lymphoma|Refractory High-Grade B-Cell Lymphoma	A high-grade B-cell lymphoma that is resistant to treatment.	Refractory High-Grade B-Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160234>	C160157	Few Tumor Infiltrating Lymphocytes|Few	A finding of few tumor infiltrating lymphocytes in a biospecimen.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C160235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160235>	C160157	Many Tumor Infiltrating Lymphocytes|Many	A finding of many tumor infiltrating lymphocytes in a biospecimen.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C160236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160236>	C160157	Moderate Tumor Infiltrating Lymphocytes|Moderate	A finding of a moderate number of tumor infiltrating lymphocytes in a biospecimen.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C160237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160237>	C160157	Unknown Tumor Infiltrating Lymphocytes|Unknown: Could not be determined or unsure	A finding of an unknown number of tumor infiltrating lymphocytes in a biospecimen.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C160238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160238>	C36080|C165241	Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type	A diffuse large B-cell lymphoma germinal center B-cell type that is resistant to treatment.	Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160239>	C36081|C178555|C165241	Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type|Refractory Diffuse Large B-Cell Lymphoma Non-GC/ABC|Refractory Diffuse Large B-Cell Lymphoma Non-Germinal Center/Activated B-Cell Type|Refractory Non-GC/ABC DLBCL	A diffuse large B-cell lymphoma activated B-cell type that is resistant to treatment.	Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16023>	C15809	Transgenic Mouse Facility	A shared facility for creation and propagation of transgenic mice.			Organization	
C160240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160240>	C7228|C158150|C139681	Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma	A transformed follicular lymphoma to diffuse large B-cell lymphoma that is resistant to treatment.	Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160241>	C19568|C16956	Virus Reactivation|Viral Reactivation	A mechanism whereby a latent virus that has infected a host cell switches to a lytic stage, undergoing productive viral replication and allowing the virus to spread.			Phenomenon or Process	
C160242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160242>	C160241	Adenovirus Reactivation|AdV Reactivation|Adenoviral Reactivation	The switching of latent adenovirus to a lytic infection.	Adenovirus Reactivation		Phenomenon or Process	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C160243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160243>	C160157	Unknown Eye Color|Unknown: Could not be determined or unsure	The eye color is unknown.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C160244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160244>	C160157	Other Eye Color|Other	The color of the eye was identified in the study but is not present in the form.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form|GDC Terminology|GDC Value Terminology
C160245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160245>	C160241	BK Virus Reactivation	The switching of latent BK virus to a lytic infection.	BK Virus Reactivation		Phenomenon or Process	CTRP Disease Terminology|CTRP Terminology
C160246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160246>	C160241	Cytomegalovirus Virus Reactivation	The switching of latent cytomegalovirus to a lytic infection.			Phenomenon or Process	
C160247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160247>	C160157	Patient was Postmenopausal with no Prior Oophorectomy|Yes	A response that the  patient was postmenopausal at diagnosis for longer than 12 months since the last menstrual period with no prior oophorectomy or prior bilateral oophorectomy.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology
C160248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160248>	C160157	Patient was not Postmenopausal with no Prior Oophorectomy|No	A response that the patient was not postmenopausal at diagnosis for longer than 12 months since the last menstrual period with no prior oophorectomy or prior bilateral oophorectomy.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology
C160249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160249>	C160157	Currently Using Menopausal Hormone Therapy|Current Therapy|Current User	A response indicating current use of menopausal hormonal therapy.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C16024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16024>	C15809	Animal Barrier Facility	A shared facility which maintains a breeding stock of animals in a disease-free state.			Organization	
C160250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160250>	C160157	Formerly Used Menopausal Hormone Therapy|Former Therapy|Former User	A response indicating former use of menopausal hormonal therapy.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160251>	C160157	Never Used Menopausal Hormone Therapy|Never|Never Used	A response indicating menopausal hormonal therapy was never used.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160252>	C160157	Unknown Use of Menopausal Hormone Therapy|Unknown	A response indicating unknown use of menopausal hormonal therapy.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160253>	C160157	Another Form of Birth Control was Used|Yes	A response indicating that another form of birth control was used.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology
C160254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160254>	C160157	Another Form of Birth Control was not Used|No	A response indicating that another form of birth control was not used.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology
C160255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160255>	C160157	Unknown if Another form of Birth Control was Used|Unknown	A response indicating that use of another form of birth control is unknown.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology
C160256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160256>	C158612	Specify Another Form of Birth Control that was Used Question|Other|Specify Another Form of Birth Control that was Used	A directive to specify another form of birth control that was used.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology
C160257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160257>	C128462	Amredobresib|1,2,4-Triazolo(4,3-a)pyrazin-8-amine, N,3-dimethyl-6-(6-(4-methyl-1-piperazinyl)-1-(phenylmethyl)-1hbenzimidazol-2-yl)|6-(1-Benzyl-6-(4-methylpiperazin-1-yl)-1H-1,3-benzodiazol-2-yl)-N,3-dimethyl-(1,2,4)triazolo(4,3-a)pyrazin-8-amine|AMREDOBRESIB|BET inhibitor BI 894999|BI 894999|BI-894999|BI894999	An orally bioavailable inhibitor of the bromodomain and extra-terminal (BET) family of proteins with potential antineoplastic activity. Upon oral administration, amredobresib binds to bromodomain-containing proteins 2, 3, and 4 (BRD2, BRD3, and BRD4) as well as bromodomain testis-specific protein (BRDT), thereby preventing the interaction between BET proteins and acetylated histones. This disrupts chromatin remodeling and suppresses the expression of certain oncogenes, including Myc and other transcriptional regulators. Preventing the expression of certain growth-promoting genes may lead to an inhibition of tumor cell growth. Characterized by a tandem repeat of bromodomains at the N-terminus, BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during cellular development and growth.	Amredobresib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C160258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160258>	C210989	TGF-beta Receptor 1 Inhibitor PF-06952229|PF 06952229|PF-06952229|PF-06952229|PF06952229|TGFbR1 Inhibitor PF-06952229	An orally bioavailable inhibitor of transforming growth factor-beta receptor 1 (TGFbR1), with potential antineoplastic activity. Upon administration, TGF-betaR1 inhibitor PF-06952229 specifically targets and binds to TGFbR1, which prevents TGFbR1-mediated signal transduction. This abrogates TGFbR1-mediated immunosuppression, enhances anti-tumor immunity in the tumor microenvironment (TME) and promotes a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGFbR1-dependent proliferation of cancer cells. The TGFb signaling pathway is often deregulated in tumors and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, and angiogenesis. It plays a key role in immunosuppression in the TME.	TGF-beta Receptor 1 Inhibitor PF-06952229		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160259>	C160157	Current User Tamoxifen|Current Therapy|Current User	A response indicating Tamoxifen is currently being used.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C16025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16025>	C16027	DNA Sequencing Facility|Sequencing Core	A shared facility which provides services for DNA sequencing			Organization	
C160260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160260>	C160157	Former User Tamoxifen|Former Therapy|Former User	A response indicating Tamoxifen was used in the past.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160261>	C160157	Never Used Tamoxifen|Never Used	A response indicating Tamoxifen has never been taken.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160262>	C160157	Unknown Tamoxifen Use|Unknown	A response indicating unknown Tamoxifen use.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160263>	C160157	Unknown Number of Full Term Pregnancies|Unknown	A response indicating there an unknown number of full term pregnancies.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Follow-Up Forms Terminology|CPTAC Normal Endometrial Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160264>	C160157	Adjuvant Post-operative Radiation Therapy Was Administered|Yes	A response indicating that adjuvant post-operative radiation therapy was administered.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160265>	C160157	Adjuvant Post-operative Radiation Therapy Was Not Administered|No	A response indicating that adjuvant post-operative radiation therapy was not administered.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160266>	C160157	Adjuvant Post-operative Radiation Therapy Administration Unknown|Unknown	A response indication the administration of adjuvant post-operative radiation therapy is unknown.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160267>	C160157	Adjuvant Post-operative Pharmaceutical Therapy Was Administered|Yes	A response indicating that adjuvant post-operative pharmaceutical therapy was administered.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Terminology
C160268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160268>	C160157	Adjuvant Post-operative Pharmaceutical Therapy Was Not Administered|No	A response indicating that adjuvant post-operative pharmaceutical therapy was not administered.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Terminology
C160269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160269>	C160157	Adjuvant Post-operative Pharmaceutical Therapy Administration Unknown|Unknown	A response indication the administration of adjuvant pharmaceutical post-operative therapy is unknown.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Terminology
C16026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16026>	C15986|C15632	Blood-Brain Barrier Disruption Chemotherapy|BBBD|BBBD Chemotherapy|Blood Brain Barrier Disruption Chemotherapy|blood-brain barrier disruption	Treatment modality used to increase the delivery of chemotherapeutic agents and monoclonal antibodies to the central nervous system tissue through temporal disruption of the blood brain barrier.	Blood-Brain Barrier Disruption Chemotherapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C160270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160270>	C160157	Adjuvant Post-operative Immunological Therapy Was Administered|Yes	A response indicating that adjuvant post-operative immunological therapy was administered.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160271>	C160157	Adjuvant Post-operative Immunological Therapy Was Not Administered|No	A response indicating that adjuvant post-operative immunological therapy was not administered.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160272>	C160157	Adjuvant Post-operative Immunological Therapy Administration Unknown|Unknown	A response indication the administration of adjuvant post-operative immunological therapy is unknown.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160273>	C158612	Does the Individual have Hypertension Question|Hypertension	A question about whether an individual has or had hypertenstion.			Intellectual Product	
C160274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160274>	C160157	Hypertension Present|Yes	A response indicating that hypertension is present.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160275>	C160157	Hypertension Absent|No	A response indicating that hypertension is absent.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160276>	C160157	Hypertension Unknown|Unknown	A response indicating that hypertension status is unknown.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160277>	C160157	Physician Diagnosed Diabetes Present|Yes	A response indicating that physician diagnosed diabetes is present.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160278>	C160157	Physician Diagnosed Diabetes Unknown|Unknown	A response indicating that physician diagnosed diabetes status is unknown.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160279>	C160157	Physician Diagnosed Diabetes Absent|No	A response indicating that physician diagnosed diabetes is absent.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C16027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16027>	C15896	Nucleic Acid Core Facility	A shared facility which usually provides services for DNA and RNA isolation and DNA cloning and sequencing.			Organization	
C160280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160280>	C160157	History of Colorectal Cancer Positive|Yes	A response indicating that a history of colorectal cancer is present.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160281>	C160157	History of Colorectal Cancer Negative|No	A response indicating that a history of colorectal cancer is absent.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160282>	C160157	History of Colorectal Cancer Unknown|Unknown: Could not be determined or unsure	A response indicating that a history of colorectal cancer status is unknown.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160284>	C160157	Follow-Up Form Outcome Measure of Success Not Applicable|Not Applicable	The outcome after completion of this form is not applicable.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160285>	C160157	Performance Status Scale Timing Other|Other|Other	An indication that the response was other than the presented options.			Qualitative Concept	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160286>	C160157	New Tumor Event After Initial Treatment Absent|No	There is evidence of a new tumor after the initial treatment.			Clinical Attribute	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160287>	C160157	New Tumor Event After Initial Treatment Unknown|Unknown|Unknown: Could not be determined or unsure	It is unknown if a new tumor exists after the initial treatment.			Clinical Attribute	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160288>	C160157	Testing Was Not Performed|Not Performed	An indication that specific tests were not performed during the study.			Intellectual Product	SeroNet Authorized Values|SeroNet Prior Test Result
C160289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160289>	C160157	Testing Was Performed	An indication that specific tests were performed during the study.			Intellectual Product	
C16028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16028>	C16027	Oligonucleotide Synthesis Facility	A shared facility which provides services for oligonucleotide synthesis.			Organization	
C160290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160290>	C160157	Not Known if Testing Was Performed	An indication that it is not known what tests were performed during the study.			Intellectual Product	
C160291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160291>	C160288	Additional Testing Was Not Performed|No	An indication that additional tests were not performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C160292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160292>	C160289	Additional Testing Was Performed|Yes	An indication that additional tests were performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C160293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160293>	C129821|C129820	Enterococcus gallinarum Strain MRx0518|E. gallinarum MRx0518|Gut Microbiota-derived Strain MRx0518|MRx 0518|MRx-0518|MRx0518	A live strain of the flagellin-producing Gram-positive bacterium Enterococcus (E.) gallinarum that is isolated from a healthy human gut, with potential immunomodulating and antineoplastic activities. Upon oral administration, MRx0518 modulates the intestinal microbiota and targets both intestinal epithelial cells (IECs), and various immune cells, such as macrophages and dendritic cells (DCs)  and is able to induce the production of both pro- and anti-inflammatory mediators, such as interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-a), IL-1beta, IL-6, IL-23, in these cells and activates the innate immune system. The flagellin produced by MRx0518 interacts with and activates toll-like receptor 5 (TLR5), thereby activating the adaptive immune system and modulating the tumor microenvironment (TME). This activates the immune system to mount a cytotoxic T-lymphocyte (CTL) immune response against tumor cells.	Enterococcus gallinarum Strain MRx0518		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160294>	C28676	Cord Blood-derived CMV/AdV/EBV/BKV-specific Cytotoxic T-lymphocytes|Allogeneic Cord Blood-derived CMV/AdV/EBV/BKV-specific CTLs|Cord Blood-derived CMV/AdV/EBV/BKV-specific T-cells|UCB-derived CMV/AdV/EBV/BKV-specific T-cells	A population of allogeneic expanded cord blood (CB)-derived cytotoxic T-lymphocytes (CTLs) that are specifically reactive to cytomegalovirus (CMV), Epstein-Barr virus (EBV), adenovirus (AdV), and human polyomavirus type I (BKV), with potential antiviral activity. Infusion of the CB-derived CMV/AdV /EBV/BKV-specific CTLs into CB hematopoietic stem cell transplant (HSCT) recipients may provide virus-specific cellular immunity, thereby preventing the infection or reactivation of certain viral-associated diseases.	Cord Blood-derived CMV/AdV/EBV/BKV-specific Cytotoxic T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C160295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160295>	C4917|C192018|C192014	Unresectable Lung Small Cell Carcinoma	Lung small cell carcinoma that is not amenable to surgical resection.	Unresectable Lung Small Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160296>	C215394|C192798|C156095	Advanced Lung Small Cell Carcinoma	Small cell lung carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Lung Small Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160297>	C45716|C3482	Metastatic NUT Carcinoma|Metastatic NMC	NUT carcinoma that has spread from its original site of growth to another anatomic site.	Metastatic NUT Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160298>	C160297|C153171	Advanced NUT Carcinoma	NUT carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced NUT Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160299>	C160157	Additional Surgery for New Tumor Event Present|Yes	Additional surgery for the new tumor event was performed.			Intellectual Product	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C16029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16029>	C15415	Modest-Temperature Hyperthermia|MTH|Mild-Temperature Hyperthermia	Heating of tumors to the 40.5-42.5C range. Increases the oxygenation of tumors thereby enhancing the effect of radiation therapy.			Therapeutic or Preventive Procedure	
C1602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1602>	C97366	Saquinavir Mesylate|Invirase|SAQUINAVIR MESYLATE|saquinavir mesylate	The mesylate salt form of saquinavir, a peptidomimetic inhibitor of human immunodeficiency virus (HIV) protease.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C160300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160300>	C160157	Additional Surgery for New Tumor Event Absent|No	Additional surgery for the new tumor event was not performed.			Intellectual Product	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160301>	C45716|C148124	Unresectable NUT Carcinoma	NUT carcinoma that is not amenable to surgical resection.	Unresectable NUT Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160302>	C160157	Additional Surgery for New Tumor Event Unknown|Unknown	Additional surgery for the new tumor event is unknown.			Intellectual Product	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160303>	C160290	Not Known if Additional Testing Was Performed|Unknown	An indication that it is not known whether additional tests were performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C160304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160304>	C160288	10q23/PTEN Locus Deletion Analysis Was Not Performed|No	An indication that 10q23/PTEN deletion analysis was not performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160305>	C160289	10q23/PTEN Locus Deletion Analysis Was Performed|Yes	An indication that 10q23/PTEN deletion analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160306>	C158949|C103223	10q23/PTEN Locus Deletion Negative|Negative|None detected|del(10q23)/PTEN Gene Locus Deletion Negative|del10q23/Phosphatase and Tensin Homolog Gene Locus Negative	A genetic finding indicating that deletion of 10q23/PTEN has not been detected in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160307>	C160157	Unknown Procedure Type for New Tumor Event|Unknown	The surgical procedure for the new tumor event is unknown			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160308>	C160288	1p/19q Deletion Analysis Was Not Performed|No	An indication that 1p/19q deletion analysis was not performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160309>	C160289	1p/19q Deletion Analysis Was Performed|Yes	An indication that 1p/19q deletion analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C16030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16030>	C15187	Carbogen Breathing	Increases the oxygenation of tumors thereby enhancing the effect of radiation therapy.			Therapeutic or Preventive Procedure	
C160310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160310>	C160382|C160291	Additional Immunohistochemistry Was Not Performed|No	An indication that additional immunohistochemical tests were not performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C160311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160311>	C160383|C160292	Additional Immunohistochemistry Was Performed|Yes	An indication that additional immunohistochemical tests were performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C160312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160312>	C160291	Additional Molecular Studies Were Not Performed|No	An indication that additional molecular tests were not performed during the study.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C160313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160313>	C160292	Additional Molecular Studies Were Performed|Yes	An indication that additional molecular tests were performed during the study.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C160314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160314>	C160288	Mutation Analysis Was Not Performed|No	An indication that mutation analysis was not performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C160315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160315>	C160289	Mutation Analysis Was Performed|Mutation Analysis Performed|Mutational Analysis Performed|Yes	An indication that mutation analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C160316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160316>	C51961	ALK Rearrangement Analysis|ALK Gene Rearrangement Analysis|ALK Gene Rearrangement Status|ALK Rearrangement|Anaplastic Lymphoma Kinase Gene Rearrangement Analysis|Anaplastic Lymphoma Receptor Tyrosine Kinase Gene Rearrangement Analysis|CD246 Gene Rearrangement Analysis	A procedure used to detect and identify rearrangements involving the ALK gene.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C160317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160317>	C160288	ALK Rearrangement Analysis Was Not Performed|No	An indication that ALK rearrangement analysis was not performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C160318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160318>	C160289	ALK Rearrangement Analysis Was Performed|Yes	An indication that ALK rearrangement analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C160319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160319>	C165233	ANO1 Negative|Anoctamin-1 Negative|DOG1 Negative|Negative|ORAOV2 Negative|TAOS2 Negative|TMEM16A Negative	An indication that expression of ANO1 has not been detected in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C16031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16031>	C15675	Perioperative Adjuvant Therapy	Treatment given at the time of an operation to augment the effects of the operation.			Therapeutic or Preventive Procedure	
C160320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160320>	C177692	ANO1 Positive|Anoctamin-1 Positive|DOG1 Positive|ORAOV2 Positive|Positive|TAOS2 Positive|TMEM16A Positive	An indication that expression of ANO1 has been detected in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160321>	C177696	ATRX Gene Mutation Negative|ATRX Mutation Negative|ATRX Wild-Type|ATRX Wildtype|ATRX wt|ATRX, Chromatin Remodeler Gene Mutation Negative|Alpha Thalassemia/Mental Retardation Syndrome X-Linked Gene Mutation Negative|Negative|No|RAD54 Gene Mutation Negative|RAD54 Homolog Gene Mutation|RAD54L Gene Mutation Negative|XH2 Gene Mutation Negative|XNP Gene Mutation Negative|ZNF-HX Gene Mutation Negative	A genetic finding indicating that ATRX gene mutations have not been detected in a sample.	ATRX Gene Mutation Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160322>	C160314	ATRX Mutation Analysis Was Not Performed|No	An indication that ATRX mutation analysis was not performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160323>	C160315	ATRX Mutation Analysis Was Performed|Yes	An indication that ATRX mutation analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160324>	C177696	BAP1 Gene Mutation Negative|BAP1 Mutation Negative|BAP1 Wild-Type|BAP1 Wildtype|BAP1 wt|BRCA1 Associated Protein 1 Gene Mutation Negative|BRCA1-Associated Protein 1 Gene Mutation Negative|Negative|UCHL2 Gene Mutation Negative	A genetic finding indicating that BAP1 gene mutations have not been detected in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C160325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160325>	C160288	Bone Marrow Aspirate Immunophenotyping and Cytochemistry Were Not Performed|No	An indication that immunophenotyping and cytochemistry were not performed on bone marrow aspirates during the study.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C160326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160326>	C160289	Bone Marrow Aspirate Immunophenotyping and Cytochemistry Were Performed|Yes	An indication that immunophenotyping and cytochemistry were performed on bone marrow aspirates during the study.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C160327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160327>	C160157	Bone Marrow Transplantation Performed				Intellectual Product	
C160328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160328>	C180944|C158949	BRAF Gene Rearrangement Negative|B-RAF Gene Rearrangement Negative|B-RAF1 Gene Rearrangement Negative|BRAF Rearrangement Negative|Negative|No rearrangement detected|v-raf Murine Sarcoma Viral Oncogene Homolog B1 Gene Rearrangement Negative	A genetic finding indicating that rearrangement of the BRAF gene has not been detected in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C160329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160329>	C160157	Bone Marrow Transplantation Not Performed				Intellectual Product	
C16032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16032>	C16033	Long-term Follow-up|LTFU|long term follow-up (clinical study)|long-term follow-up (research)	Follow-up activities that continue beyond the active intervention period.	Long-term Follow-up		Health Care Activity	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C160331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160331>	C160157	Bone Marrow Transplantation Status Unknown				Intellectual Product	
C160332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160332>	C160314	BRAF Mutation Analysis Was Not Performed|No	An indication that BRAF mutation analysis was not performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160333>	C160315	BRAF Mutation Analysis Was Performed|Yes	An indication that BRAF mutation analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160334>	C160288	BRAF Rearrangement Analysis Was Not Performed|No	An indication that BRAF rearrangement analysis was not performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160335>	C160289	BRAF Rearrangement Analysis Was Performed|Yes	An indication that BRAF rearrangement analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160336>	C160157	Chemotherapy Received|Yes				Intellectual Product	
C160337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160337>	C160157	Chemotherapy Not Received|No				Intellectual Product	
C160338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160338>	C160157	Chemotherapy Status Unknown|Unknown				Intellectual Product	
C160339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160339>	C160157	Immunotherapy Received				Intellectual Product	
C16033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16033>	C16205	Follow-Up|Active Follow-up|CLSFUP|Clinical Signs Follow-up|Clinical Signs Follow-up|Follow Up|Follow-up|Follow-up|Follow-up|Followed|Followup|follow up|follow-up|follow_up	The process by which information about the health status of an individual is obtained after a study has officially closed; an activity that continues something that has already begun or that repeats something that has already been done.	Follow-up		Health Care Activity	CDISC SEND Macroscopic Findings Test Code Terminology|CDISC SEND Macroscopic Findings Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|ICDC Node Terminology|ICDC Terminology
C160340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160340>	C160157	Immunotherapy Not Received				Intellectual Product	
C160341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160341>	C160157	Immunotherapy Status Unknown|Unknown				Intellectual Product	
C160342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160342>	C160157	Pharmacotherapy Received				Intellectual Product	
C160343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160343>	C160157	Pharmacotherapy Not Received				Intellectual Product	
C160344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160344>	C160157	Pharmacotherapy Status Unknown				Intellectual Product	
C160345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160345>	C160157	Radiation Therapy Was Received				Intellectual Product	
C160346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160346>	C160157	Radiation Therapy Not Received|No				Intellectual Product	
C160347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160347>	C160157	Radiation Therapy Status Unknown				Intellectual Product	
C160348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160348>	C201511|C201282|C129822	Anti-CD123/CD3 BiTE Antibody SAR440234|Bispecific T-cell Engager Antibody SAR440234|CD123xCD3 Bispecific T-cell Engager SAR440234|SAR 440234|SAR-440234|SAR440234	A bispecific T-cell engager (BiTE) antibody comprised of a humanized Fc-silenced immunoglobulin G1 (IgG1) backbone and two single-chain variable fragments (scFvs): one directed against the CD3 antigen expressed on T-lymphocytes and another directed against the alpha-chain of the interleukin-3 receptor (IL-3RA; CD123), with potential immunostimulating and antineoplastic activities. Upon intravenous infusion, anti-CD123/CD3 BiTE antibody SAR440234 binds to both CD3 expressed on T-cells and CD123 expressed on tumor cells. This activates and redirects cytotoxic T-lymphocytes (CTLs) to CD123-expressing tumor cells, leading to enhanced CTL-mediated elimination of CD123-expressing tumor cells. CD123 is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells.	Anti-CD123/CD3 BiTE Antibody SAR440234		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160349>	C155712	Anti-HER2 Immune Stimulator-antibody Conjugate NJH395|Anti-HER2 ISAC NJH395|NJH 395|NJH-395|NJH-395|NJH395	An immune stimulator-antibody conjugate (ISAC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated to a not yet disclosed immune stimulator, with potential antineoplastic and immunostimulating activities. Upon administration of the anti-HER2 immune stimulator-antibody conjugate NJH395, the antibody moiety targets and binds to HER2 expressed on tumor cells. Upon antibody/antigen binding, the immune-stimulating moiety may, through an as of yet undisclosed mechanism, enhance the immune-mediated killing of HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed in many cancer types and plays a key role in tumor cell proliferation and tumor vascularization.	Anti-HER2 Immune Stimulator-antibody Conjugate NJH395		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C16034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16034>	C37947	Progenitor Cell Engraftment	Establishment of a self replicating population of stem cells with subsequent repopulation of differentiated cell types.	Progenitor Cell Engraftment		Conceptual Entity	CTRP Biomarker Terminology|CTRP Terminology
C160350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160350>	C177696	CDH1 Gene Mutation Negative|Arc-1 Gene Mutation Negative|CD324 Gene Mutation Negative|CDH1 Mutation Negative|CDH1 Wild-Type|CDH1 Wildtype|CDH1 wt|CDHE Gene Mutation Negative|Cadherin 1 Gene Mutation Negative|Cadherin, Epithelial Gene Mutation Negative|Calcium-Dependent Adhesion Protein, Epithelial Gene Mutation Negative|E-Cadherin Gene Mutation Negative|ECAD Gene Mutation Negative|LCAM Gene Mutation Negative|Negative|UVO Gene Mutation Negative	A genetic finding indicating that CDH1 gene mutations have not been detected in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C160351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160351>	C177696	CTNNB1 Gene Mutation Negative|Beta Catenin Gene Mutation Negative|Beta-Catenin Gene Mutation Negative|CTNNB Gene Mutation Negative|CTNNB1 Mutation Negative|CTNNB1 Wild-Type|CTNNB1 Wildtype|CTNNB1 wt|Cadherin-Associated Protein, Beta Gene Mutation Negative|Catenin Beta 1 Gene Mutation Negative|Catenin Beta-1 Gene Mutation Negative|Negative	A genetic finding indicating that CTNNB1 gene mutations have not been detected in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C160352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160352>	C160288	EGFR Amplification Analysis Was Not Performed|No	An indication that EGFR amplification analysis was not performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160353>	C160289	EGFR Amplification Analysis Was Performed|Yes	An indication that EGFR amplification analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160354>	C160314	EGFR Mutation Analysis Was Not Performed|No	An indication that EGFR mutation analysis was not performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C160355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160355>	C160315	EGFR Mutation Analysis Was Performed|Yes	An indication that EGFR mutation analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C160356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160356>	C160314	ERBB2 Mutation Analysis Was Not Performed|No	An indication that ERBB2 mutation analysis was not performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C160357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160357>	C160315	ERBB2 Mutation Analysis Was Performed|Yes	An indication that ERBB2 mutation analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C160358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160358>	C158949|C103223	ERG Gene Rearrangement Negative|ERG Rearrangement Negative|ETS Transcription Factor ERG Gene Rearrangement Negative|Erg-3 Gene Rearrangement Negative|Negative|p55 Gene Rearrangement Negative|v-Ets Erythroblastosis Virus E26 Oncogene Like Gene Rearrangement Negative	A genetic finding indicating that rearrangement of the ERG gene has not been detected in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology
C160359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160359>	C186727	ETV Gene Rearrangement|ETV Family Gene Rearrangement|ETV Family Rearrangement|ETV Rearrangement|Ets Variant Family Rearrangement|Ets Variant Gene Family Rearrangement|Positive	A molecular abnormality indicating rearrangement of an ETV family gene.			Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology
C16035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16035>	C15313	3-Dimensional Conformal Radiation Therapy|3-dimensional conformal radiation therapy|3-dimensional radiation therapy|3D CONFORMAL RADIATION THERAPY|3D CRT|3D Conformal|3D Conformal|3D Conformal|3D radiotherapy|3D-CRT|Conformal Therapy|Radiation Conformal Therapy|Radiation, 3D Conformal|Three dimensional external beam radiation therapy (procedure)	A process by which a dose of radiation is automatically shaped to closely conform to the entire volume of the tumor, so that surrounding normal tissue is spared and treatment toxicity is decreased.	3-Dimensional Conformal Radiation Therapy		Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|EWS Authorized Value Terminology|EWS Radiation Therapy Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Radiation Therapy Table|mCode Electron Beam Technique Value Set|mCode Neutron Beam Technique Value Set|mCode Photon Beam Technique Value Set|mCode Radiotherapy Technique Value Set|mCode Teleradiotherapy Technique Value Set|mCode Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology|OS Authorized Value Terminology|OS Radiation Therapy Table
C160360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160360>	C158949|C103223	ETV Gene Rearrangement Negative|ETV Family Gene Rearrangement Negative|ETV Family Rearrangement Negative|ETV Rearrangement Negative|Ets Variant Family Rearrangement Negative|Ets Variant Gene Family Rearrangement Negative|Negative	A genetic finding indicating that rearrangement of ETV family genes have not been detected in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Terminology
C160361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160361>	C177696|C150613	FGFR1 Gene Mutation Negative|BFGFR Gene Mutation Negative|CD331 Gene Mutation Negative|CEK Gene Mutation Negative|FGFBR Gene Mutation Negative|FGFR-1 Gene Mutation Negative|FGFR1 Mutation Negative|FGFR1 Wild-Type|FGFR1 Wildtype|FGFR1 wt|FLG Gene Mutation Negative|FLT-2 Gene Mutation Negative|FLT2 Gene Mutation Negative|FMS-Like Tyrosine Kinase 2 Gene Mutation Negative|Fibroblast Growth Factor Receptor 1 Gene Mutation Negative|KAL2 Gene Mutation Negative|N-SAM Gene Mutation Negative|Negative|OGD Gene Mutation Negative	A genetic finding indicating that FGFR1 gene mutations have not been detected in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C160362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160362>	C158949|C150613|C103223	FGFR1 Gene Rearrangement Negative|BFGFR Gene Rearrangement Negative|CD331 Gene Rearrangement Negative|CEK Gene Rearrangement Negative|FGFBR Gene Rearrangement Negative|FGFR-1 Gene Rearrangement Negative|FGFR1 Rearrangement Negative|FLG Gene Rearrangement Negative|FLT-2 Gene Rearrangement Negative|FLT2 Gene Rearrangement Negative|FMS-Like Tyrosine Kinase 2 Gene Rearrangement Negative|Fibroblast Growth Factor Receptor 1 Gene Rearrangement Negative|KAL2 Gene Rearrangement Negative|N-SAM Gene Rearrangement Negative|Negative|OGD Gene Rearrangement Negative	A genetic finding indicating that rearrangement of the FGFR1 gene has not been detected in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C160363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160363>	C177696|C150613	FGFR2 Gene Mutation Negative|BEK Gene Mutation Negative|CD332 Gene Mutation Negative|ECT1 Gene Mutation Negative|FGFR-2 Gene Mutation Negative|FGFR2 Mutation Negative|FGFR2 Wild-Type|FGFR2 Wildtype|FGFR2 wt|Fibroblast Growth Factor Receptor 2 Gene Mutation Negative|K-SAM Gene Mutation Negative|KGFR Gene Mutation Negative|Keratinocyte Growth Factor Receptor Gene Mutation Negative|Negative	A genetic finding indicating that FGFR2 gene mutations have not been detected in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C160364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160364>	C158949|C150613|C103223	FGFR2 Gene Rearrangement Negative|BEK Gene Rearrangement Negative|CD332 Gene Rearrangement Negative|ECT1 Gene Rearrangement Negative|FGFR-2 Gene Rearrangement Negative|FGFR2 Rearrangement Negative|Fibroblast Growth Factor Receptor 2 Gene Rearrangement Negative|K-SAM Gene Rearrangement Negative|KGFR Gene Rearrangement Negative|Keratinocyte Growth Factor Receptor Gene Rearrangement Negative|Negative	A genetic finding indicating that rearrangement of the FGFR2 gene has not been detected in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C160365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160365>	C177696|C150613	FGFR3 Gene Mutation Negative|CD333 Gene Mutation Negative|FGFR-3 Gene Mutation Negative|FGFR3 Mutation Negative|FGFR3 Wild-Type|FGFR3 Wildtype|FGFR3 wt|Fibroblast Growth Factor Receptor 3 Gene Mutation Negative|JTK4 Gene Mutation Negative|Negative	A genetic finding indicating that FGFR3 gene mutations have not been detected in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C160366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160366>	C158949|C150613|C103223	FGFR3 Gene Rearrangement Negative|CD333 Gene Rearrangement Negative|FGFR-3 Gene Rearrangement Negative|FGFR3 Rearrangement Negative|Fibroblast Growth Factor Receptor 3 Gene Rearrangement Negative|JTK4 Gene Rearrangement Negative|Negative	A genetic finding indicating that rearrangement of the FGFR3 gene has not been detected in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Terminology
C160367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160367>	C177696	GNA11 Gene Mutation Negative|G Protein Subunit Alpha 11 Gene Mutation Negative|GA11 Gene Mutation Negative|GNA-11 Gene Mutation Negative|GNA11 Mutation Negative|GNA11 Wild-Type|GNA11 Wildtype|GNA11 wt|Guanine Nucleotide Binding Protein (G Protein), Alpha 11 Gene Mutation Negative|Guanine Nucleotide-Binding Protein, Alpha-11 Gene Mutation Negative|Negative	A genetic finding indicating that GNA11 gene mutations have not been detected in a sample.			Laboratory or Test Result	
C160368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160368>	C177696	GNAQ Gene Mutation Negative|CMC1 Gene Mutation Negative|G Protein Subunit Alpha q Gene Mutation Negative|G-ALPHA-q Gene Mutation Negative|GAQ Gene Mutation Negative|GNAQ Mutation Negative|GNAQ Wild-Type|GNAQ Wildtype|GNAQ wt|Guanine Nucleotide Binding Protein (G Protein), Q Polypeptide Gene Mutation Negative|Negative|SWS Gene Mutation Negative	A genetic finding indicating that GNAQ gene mutations have not been detected in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C160369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160369>	C35682	Helicobacter pylori Positive|H. pylori Positive|Positive	An indication that Helicobacter pylori has been detected in a sample.	Helicobacter pylori Positive		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Terminology
C16036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16036>	C15896	Histopathology Facility	A core facility for preparation and analysis of histopathology samples.			Organization	
C160370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160370>	C35681|C175007	Hepatitis B Virus Core Antibody Negative|Anti-HBc Antibody Negative|Anti-HBc Negative|Anti-HBcAb Negative|Anti-Hepatitis B Core Antibody Negative|Anti-Hepatitis B Virus Core Antibody Negative|HBcAb Negative|Hepatitis B Core Antibody Negative|Negative	An indication that antibodies that recognize a hepatitis B virus core protein have not been detected in a sample.	Hepatitis B Virus Core Antibody Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C160371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160371>	C165233	Hepatitis B Virus Surface Antigen Negative|HBs Antigen Negative|HBs Negative|HBsAg Negative|Hepatitis B Surface Antigen Negative|Hepatitis B Surface Protein Antigen Negative|Negative	An indication that the hepatitis B virus surface protein antigen has not been detected in a sample.	Hepatitis B Virus Surface Antigen Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C160372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160372>	C158737	Hepatitis B Virus Surface Antigen Positive|HBs Antigen Positive|HBs Positive|HBsAg Positive|Hepatitis B Surface Antigen Positive|Hepatitis B Surface Protein Antigen Positive|Positive	An indication that the hepatitis B virus surface protein antigen has been detected in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C160373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160373>	C132847	HRAS Gene Mutation Negative|C-HA-RAS1 Gene Mutation Negative|H-ras Gene Mutation Negative|HRAS Mutation Negative|HRAS Wild-Type|HRAS Wildtype|HRAS wt|HRas Proto-Oncogene, GTPase Gene Mutation Negative|Ha-ras Gene Mutation Negative|Harvey Rat Sarcoma Viral Oncogene Homolog Gene Mutation Negative|Negative|RASH1 Gene Mutation Negative|v-Ha-ras Harvey Rat Sarcoma Viral Oncogene Homolog Gene Mutation Negative	A genetic finding indicating that HRAS gene mutations have not been detected in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C160374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160374>	C160157	Adjuvant Post-operative Chemotherapy Was Administered|Yes	A response indicating that adjuvant post-operative chemotherapy was administered.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160375>	C160157	Adjuvant Post-operative Chemotherapy Was Not Administered|No	A response indicating that adjuvant post-operative chemotherapy was not administered.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160376>	C160157	Adjuvant Post-operative Chemotherapy Administration Unknown|Unknown	A response indication the administration of adjuvant post-operative chemotherapy is unknown.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160377>	C160157	Adjuvant Post-operative Hormone Therapy Was Administered				Intellectual Product	
C160378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160378>	C160157	Adjuvant Post-operative Hormone Therapy Was Not Administered				Intellectual Product	
C160379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160379>	C160157	Adjuvant Post-operative Hormone Therapy Administration Unknown				Intellectual Product	
C16037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16037>	C15896	Organic Synthesis Facility	A core facility for the preparation and synthesis of organic molecules.			Organization	
C160380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160380>	C160314	IDH Family Mutation Analysis Was Not Performed|No	An indication that IDH family mutation analysis was not performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160381>	C160315	IDH Family Mutation Analysis Was Performed|Yes	An indication that IDH family mutation analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160382>	C160288	Immunohistochemistry Was Not Performed|No	An indication that immunohistochemical testing was not performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160383>	C160289	Immunohistochemistry Was Performed|Yes	An indication that immunohistochemical testing was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160384>	C160290	Not Known if Mutation Analysis Was Performed|Unknown	An indication that it is not known whether mutation analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C160385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160385>	C160387|C160303	Not Known if Additional Immunohistochemistry Was Performed|Unknown	An indication that it is not known whether additional immunohistochemical tests were performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C160386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160386>	C160303	Not Known if Additional Molecular Studies Were Performed|Unknown	An indication that it is not known whether additional molecular analysis was performed during the study.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C160387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160387>	C160290	Not Known if Immunohistochemistry Was Performed|Unknown	An indication that it is not known whether immunohistochemical tests were performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160388>	C160157	Adjuvant Post-operative Targeted Molecular Therapy Was Administered|Yes	A response indicating that adjuvant post-operative targeted molecular therapy was administered.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160389>	C160157	Adjuvant Post-operative Targeted Molecular Therapy Was Not Administered|No	A response indicating that adjuvant post-operative targeted molecular therapy was not administered.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C16038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16038>	C15714	Investigation of Mechanisms of Drug Resistance	Basic research to understand the mechanisms that cells use to avoid being killed by cytotoxic drugs.			Research Activity	
C160390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160390>	C160157	Adjuvant Post-operative Targeted Molecular Therapy Administration Unknown|Unknown	A response indication the administration of adjuvant post-operative targeted molecular therapy is unknown.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160391>	C160314	KIT Mutation Analysis Was Not Performed|No	An indication that KIT mutation analysis was not performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160392>	C160315	KIT Mutation Analysis Was Performed|Yes	An indication that KIT mutation analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160393>	C160157	First Course Treatment Completion Measure of Success of Outcome Unknown|Unknown	A response that the first course treatment completion measure of success of outcome is unknown.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology
C160395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160395>	C94299|C165233	KIT Negative|CD117 Negative|CD117 Negative|KIT Proto-Oncogene Tyrosine Protein Kinase Negative|Mast/Stem Cell Growth Factor Receptor Kit Negative|Negative|c-KIT Negative|v-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Negative	An indication that expression of KIT has not been detected in a sample.			Laboratory or Test Result	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160396>	C160314	KRAS Mutation Analysis Was Not Performed|No	An indication that KRAS mutation analysis was not performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C160397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160397>	C160315	KRAS Mutation Analysis Was Performed|Yes	An indication that KRAS mutation analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C160398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160398>	C160288	Lymph Node Dissection Was Not Performed|No	An indication that lymph node dissection was not performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C160399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160399>	C160289	Lymph Node Dissection Was Performed|Yes	An indication that lymph node dissection was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C16039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16039>	C15431|C142985	Autologous Hematopoietic Stem Cell Transplantation|AHSCT|Autologous|Autologous|Autologous|Autologous|Autologous Hematopoietic Cell Transplantation|Autologous Stem Cell Transplant|Autologous Stem Cell Transplantation|Stem Cell Transplantation, Autologous|autologous stem cell transplantation	Stem cell transfer or transplantation in which the patient is their own donor.	Autologous Hematopoietic Stem Cell Transplantation		Therapeutic or Preventive Procedure	ALL Authorized Value Terminology|ALL Stem Cell Transplant Table|AML Authorized Value Terminology|AML Stem Cell Transplant Table|CTRP Intervention Terminology|CTRP Terminology|EWS Authorized Value Terminology|EWS Stem Cell Transplant Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Non-protocol Therapy Table|HL Stem Cell Transplant Table
C1603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1603>	C697	Tallimustine|FCE 24517|PNU-152241|TALLIMUSTINE	A benzoyl mustard derivative of the antiviral agent distamycin A with potential antineoplastic activity. Tallimustine selectively binds to A-T rich regions in the minor groove of DNA and alkylates at the N3 position of adenine in a highly sequence-specific manner. This prevents DNA replication, inhibits cellular proliferation and triggers apoptosis. Moreover, unlike other clinical nitrogen mustards, tallimustine does not carry out guanine-N7 alkylation in the major groove of DNA, which may lead to a high selectivity of action.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160400>	C190667|C177681	MET Gene Amplification Negative|HGFR Gene Amplification Negative|Hepatocyte Growth Factor Receptor Gene Amplification Negative|MET Amplification Negative|MET Proto-Oncogene, Receptor Tyrosine Kinase Gene Amplification Negative|Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Gene Amplification Negative|Negative|c-MET Gene Amplification Negative|c-Met Amplification Negative	An indication that amplification of the MET gene was not detected in a sample.	MET Gene Amplification Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160401>	C190667|C177696	MET Gene Mutation Negative|HGFR Gene Mutation Negative|Hepatocyte Growth Factor Receptor Gene Mutation Negative|MET Mutation Negative|MET Proto-Oncogene, Receptor Tyrosine Kinase Gene Mutation Negative|MET Wild-Type|MET Wildtype|MET wt|Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) Gene Mutation Negative|No mutation detected|c-MET Gene Mutation Negative|c-Met Mutation Negative	A genetic finding indicating that MET gene mutations have not been detected in a sample.	MET Gene Mutation Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160402>	C160157	Follow-Up Form Completion Outcome Measure of Success Unknown|Unknown	A response that the follow-up form completion  measure of success of outcome is unknown.			Intellectual Product	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160403>	C160157	Follow-Up Form Completion Outcome Measure of Success Not Applicable|Not Applicable	A response that the follow-up form completion  measure of success of outcome is not applicable.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology
C160404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160404>	C160314	MET Mutation Analysis Was Not Performed|No	An indication that MET mutation analysis was not performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C160405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160405>	C160315	MET Mutation Analysis Was Performed|Yes	An indication that MET mutation analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C160406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160406>	C160288	MGMT Promoter Methylation Testing Was Not Performed|No	An indication that MGMT promoter methylation analysis was not performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160407>	C160289	MGMT Promoter Methylation Testing Was Performed|Yes	An indication that MGMT promoter methylation analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160408>	C35681|C103223	MLH1 Gene Promoter Hypermethylation Negative|Absent|COCA2 Promoter Hypermethylation Negative|HNPCC2 Promoter Hypermethylation Negative|MLH1 Negative|MLH1 Promoter Hypermethylation Negative|MutL Homolog 1 Promoter Hypermethylation Negative|MutL, E. coli, Homolog of, 1 Promoter Hypermethylation Negative	A genetic finding indicating the absence of DNA hypermethylation in the promoter region of the MGMT gene.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C160409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160409>	C129890	MLH1 Gene Promoter Hypermethylation Status|COCA2 Promoter Hypermethylation Status|HNPCC2 Promoter Hypermethylation Status|MLH1 Gene Promoter Hypermethylation Analysis|MLH1 Promoter Hypermethylation|MLH1 Promoter Hypermethylation Analysis|MLH1 Promoter Hypermethylation Status|MutL Homolog 1 Promoter Hypermethylation Status|MutL, E. coli, Homolog of, 1 Promoter Hypermethylation Status	A procedure used to detect and identify hypermethylation of promoter sequences for the MLH1 gene.			Laboratory Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C16040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16040>	C45427	Immunooncology	The study of cell surface markers on tumor cells which can be recognized by antibodies, and the development of diagnostic reagents or therapeutic strategies which rely upon immune recognition.			Biomedical Occupation or Discipline	
C160410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160410>	C35681	Hepatitis B Virus Negative|HBV Negative|Hep B Negative	An indication that hepatitis virus B has not been detected in a sample.	Hepatitis B Virus Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C160411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160411>	C35682|C175007	Hepatitis C Virus Antibody Positive|Anti-HCV Antibody Positive|Anti-Hepatitis C Antibody Positive|Anti-Hepatitis C Virus Antibody Positive|HCV Antibody Positive|Hepatitis C Antibody Positive|Positive	An indication that antibodies that recognize the hepatitis C virus have been detected in a sample.	Hepatitis C Virus Antibody Positive		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C160412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160412>	C97927	CYSLTR2 Gene Mutation|CYSLT2 Gene Mutation|CYSLT2R Gene Mutation|Cysteinyl Leukotriene Receptor 2 Gene Mutation|GPCR21 Gene Mutation	A change in the nucleotide sequence of the CYSLTR2 gene.	CYSLTR2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160413>	C158916	MLH1 Loss of Nuclear Expression|COCA2 Loss of Nuclear Expression|DNA Mismatch Repair Protein Mlh1 Loss of Nuclear Expression|FCC2 Loss of Nuclear Expression|HNPCC Loss of Nuclear Expression|HNPCC2 Loss of Nuclear Expression|Loss of Nuclear MLH1|Loss of nuclear expression|Mismatch DNA Repair Protein MLH1 Loss of Nuclear Expression|Mismatch Repair Protein MLH1 Loss of Nuclear Expression|MutL Protein Homolog 1 Loss of Nuclear Expression	An indication that expression of MLH1 was not detected in the nuclei of cells in a sample.	MLH1 Loss of Nuclear Expression		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160414>	C158929	MLH1 Nuclear Expression Intact|COCA2 Nuclear Expression Intact|DNA Mismatch Repair Protein Mlh1 Nuclear Expression Intact|FCC2 Nuclear Expression Intact|HNPCC Nuclear Expression Intact|HNPCC2 Nuclear Expression Intact|Intact nuclear expression|Mismatch DNA Repair Protein MLH1 Nuclear Expression Intact|Mismatch Repair Protein MLH1 Nuclear Expression Intact|MutL Protein Homolog 1 Nuclear Expression Intact	An indication that expression of MLH1 was detected in the nuclei of cells in a sample.	MLH1 Nuclear Expression Intact		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160415>	C158916	MSH2 Loss of Nuclear Expression|DNA Mismatch Repair Protein Msh2 Loss of Nuclear Expression|Loss of Nuclear MSH2|Loss of nuclear expression|MutS Homolog 2 Loss of Nuclear Expression|MutS Protein Homolog 2 Loss of Nuclear Expression	An indication that expression of MSH2 was not detected in the nuclei of cells in a sample.	MSH2 Loss of Nuclear Expression		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160416>	C158929	MSH2 Nuclear Expression Intact|DNA Mismatch Repair Protein Msh2 Nuclear Expression Intact|Intact nuclear expression|MutS Homolog 2 Nuclear Expression Intact|MutS Protein Homolog 2 Nuclear Expression Intact	An indication that expression of MSH2 was detected in the nuclei of cells in a sample.	MSH2 Nuclear Expression Intact		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160417>	C158929	MSH6 Nuclear Expression Intact|DNA Mismatch Repair Protein Msh6 Nuclear Expression Intact|G/T Mismatch Binding Protein Nuclear Expression Intact|G/T Mismatch-Binding Protein Nuclear Expression Intact|GTBP Nuclear Expression Intact|GTMBP Nuclear Expression Intact|Intact nuclear expression|MutS Homolog 6 Nuclear Expression Intact|MutS-Alpha 160 kDa Subunit Nuclear Expression Intact|Sperm-Associated Protein Nuclear Expression Intact	An indication that expression of MSH6 was detected in the nuclei of cells in a sample.	MSH6 Nuclear Expression Intact		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160418>	C158916	MSH6 Loss of Nuclear Expression|DNA Mismatch Repair Protein Msh6 Loss of Nuclear Expression|G/T Mismatch Binding Protein Loss of Nuclear Expression|G/T Mismatch-Binding Protein Loss of Nuclear Expression|GTBP Loss of Nuclear Expression|GTMBP Loss of Nuclear Expression|Loss of Nuclear MSH6|Loss of nuclear expression|MutS Homolog 6 Loss of Nuclear Expression|MutS-Alpha 160 kDa Subunit Loss of Nuclear Expression|Sperm-Associated Protein Loss of Nuclear Expression	An indication that expression of MSH6 was not detected in the nuclei of cells in a sample.	MSH6 Loss of Nuclear Expression		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160419>	C158929	PMS2 Nuclear Expression Intact|DNA Mismatch Repair Protein PMS2 Nuclear Expression Intact|Intact nuclear expression|Mismatch Repair Endonuclease PMS2 Nuclear Expression Intact|PMS1 Protein Homolog 2 Nuclear Expression Intact	An indication that expression of PMS2 was detected in the nuclei of cells in a sample.	PMS2 Nuclear Expression Intact		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C16041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16041>	C70824	Ancillary Study|Ancillary Studies|Companion Protocol|ancillary test	A study that is secondary to another study.			Research Activity	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CPTAC Uveal Melanoma Baseline Form
C160420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160420>	C158916	PMS2 Loss of Nuclear Expression|DNA Mismatch Repair Protein PMS2 Loss of Nuclear Expression|Loss of Nuclear PMS2|Loss of nuclear expression|Mismatch Repair Endonuclease PMS2 Loss of Nuclear Expression|PMS1 Protein Homolog 2 Loss of Nuclear Expression	An indication that expression of PMS2 was not detected in the nuclei of cells in a sample.	PMS2 Loss of Nuclear Expression		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160421>	C158929	TP53 Nuclear Expression Intact|Antigen NY-CO-13 Nuclear Expression Intact|Cellular Tumor Antigen p53 Nuclear Expression Intact|Intact nuclear expression|TRP53 Nuclear Expression Intact|Transformation-Related Protein 53 Nuclear Expression Intact|Tumor Protein p53 Nuclear Expression Intact|Tumor Suppressor p53 Nuclear Expression Intact|p53 Nuclear Expression Intact	An indication that expression of TP53 was detected in the nuclei of cells in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C160422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160422>	C158916	TP53 Loss of Nuclear Expression|Antigen NY-CO-13 Loss of Nuclear Expression|Cellular Tumor Antigen p53 Loss of Nuclear Expression|Loss of Nuclear TP53|Loss of Nuclear p53|Loss of nuclear expression|TRP53 Loss of Nuclear Expression|Transformation-Related Protein 53 Loss of Nuclear Expression|Tumor Protein p53 Loss of Nuclear Expression|Tumor Suppressor p53 Loss of Nuclear Expression|p53 Loss of Nuclear Expression	An indication that expression of TP53 was not detected in the nuclei of cells in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C160423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160423>	C34022	Peritoneal Surface|Peritoneal Surfaces	The outer layer of the serous membrane that lines the abdominal cavity.			Body Substance	CPTAC Follow-Up Forms Terminology|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Terminology
C160424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160424>	C160157	Non-Regional Lymph Node New Tumor Event|Non-Regional Lymph Nodes/ Distant Lymph Nodes	Lymph nodes located outside the region of interest.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Terminology
C160425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160425>	C177696	NF1 Gene Mutation Negative|NF1 Mutation Negative|NF1 Wild-Type|NF1 Wildtype|NF1 wt|NFNS Gene Mutation Negative|Neurofibromin 1 Gene Mutation Negative|Neurofibromin Gene Mutation Negative|No mutation detected	A genetic finding indicating that NF1 gene mutations have not been detected in a sample.	NF1 Gene Mutation Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160426>	C160315	NF1 Mutation Analysis Was Performed|Yes	An indication that NF1 mutation analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160427>	C160314	NF1 Mutation Analysis Was Not Performed|No	An indication that NF1 mutation analysis was not performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160428>	C160290	Not Known if 10q23/PTEN Locus Deletion Analysis Was Performed|Unknown	An indication that it is not known whether 10q23/PTEN deletion analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160429>	C160290	Not Known if 1p/19q Deletion Analysis Was Performed|Unknown	An indication that it is not known whether 1p/19q deletion analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C16042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16042>	C49165	Limb Salvage Procedure|Limb Salvage|Limb Salvage Procedures|Limb Sparing Procedure|Limb-Salvage|Limb-Salvage|SURGERY_TYPE_LIMB_SALVAGE	A procedure to avoid amputation of an arm or leg.			Therapeutic or Preventive Procedure	EWS Authorized Value Terminology|EWS Biopsy/Surgical Procedures Table|EWS Variable Terminology|OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table
C160430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160430>	C160290	Not Known if ALK Rearrangement Analysis Was Performed|Unknown	An indication that it is not known whether ALK rearrangement analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C160431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160431>	C160384	Not Known if ATRX Mutation Analysis Was Performed|Unknown	An indication that it is not known whether ATRX mutation analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160432>	C160290	Not Known if Bone Marrow Aspirate Immunophenotyping and Cytochemistry Were Performed|Unknown	An indication that it is not known if immunophenotyping and cytochemistry were performed on bone marrow aspirates during the study.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C160433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160433>	C160384	Not Known if BRAF Mutation Analysis Was Performed|Unknown	An indication that it is not known whether BRAF mutation analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160434>	C160290	Not Known if BRAF Rearrangement Analysis Was Performed|Unknown	An indication that it is not known whether BRAF rearrangement analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160435>	C173449|C139795	Activating Non-V600 BRAF Mutation|Activating Non-Codon 600 BRAF Gene Mutation|Activating Non-Codon 600 BRAF Mutation|BRAF Class II Alteration|BRAF Class II Mutation|Class 2 BRAF Mutation|Class II BRAF Alteration|Class II BRAF Mutation|Non-Codon 600 Activating BRAF Gene Mutation|Non-Codon 600 Activating BRAF Mutation|Non-Codon 600 Activating BRAF1 Mutation|Non-Codon 600 B-RAF Activating Mutation|Non-Codon 600 B-RAF1 Activating Mutation|Non-Codon 600 BRAF Activating Mutation|Non-V600 Activating BRAF Mutation	A change in the nucleotide sequence of the BRAF gene that occurs outside of codon 600 and results in activation of both serine/threonine-protein kinase B-raf and its downstream signaling pathways.	Activating Non-V600 BRAF Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160436>	C158612	Was Additional Surgery for New Loco-Regional Tumor Event Performed Question|Additional Surgery for New Tumor Event: Loco-regional|Was Additional Surgery for New Loco-Regional Tumor Event Performed	A question about any additional surgery performed for the new loco-regional tumor.			Clinical Attribute	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Terminology
C160437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160437>	C96067|C135090	Jejunal Neuroendocrine Tumor G2|Jejunal NET G2|Malignant carcinoid tumor of the jejunum	A well-differentiated, intermediate-grade neuroendocrine neoplasm that arises from the jejunum. The mitotic count is 2-20 per 2 mm2 and/or the Ki-67 index is 3 to 20%.	Jejunal Neuroendocrine Tumor G2		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|mCode Cancer Disorder Value Set|mCode Elixhauser Malignant Solid Tumors without Metastases Value Set|mCode Primary Cancer Disorder Value Set|mCode Primary Malignant Neoplasm Disorder Value Set|mCode Terminology
C160438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160438>	C158612	Was Additional Surgery for New Metastatic Tumor Event Performed Question|Additional Surgery for New Tumor Event: Metastasis|Was Additional Surgery for New Metastatic Tumor Event Performed	A question about any additional surgery performed for the new metastatic tumor.			Clinical Attribute	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Terminology
C160439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160439>	C158612	Date of Additional Surgery for New Tumor Event: Loco-Regional Question|Date of Additional Surgery for New Tumor Event: Loco-Regional|Date of Additional Surgery for New Tumor Event: Loco-Regional	Date of additional surgery for the new loco-regional tumor event.			Clinical Attribute	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Terminology
C16043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16043>	C15896	Electron Microscopy Facility	A shared facility which provides services for electron microscopy.			Organization	
C160440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160440>	C96067|C135092	Ileal Neuroendocrine Tumor G2|Ileal NET G2|Malignant carcinoid tumor of the ileum	A well-differentiated, intermediate-grade neuroendocrine neoplasm that arises from the ileum. The mitotic count is 2-20 per 2 mm2 and/or the Ki-67 index is 3 to 20%.	Ileal Neuroendocrine Tumor G2		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|mCode Cancer Disorder Value Set|mCode Elixhauser Malignant Solid Tumors without Metastases Value Set|mCode Primary Cancer Disorder Value Set|mCode Primary Malignant Neoplasm Disorder Value Set|mCode Terminology
C160441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160441>	C158612	Date of Additional Surgery for New Tumor Event: Metastatic Question|Date of Additional Surgery for New Tumor Event: Metastatic|Date of Additional Surgery for New Tumor Event: Metastatic	Date of additional surgery for the new metastatic tumor event.			Clinical Attribute	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Terminology
C160442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160442>	C96067|C135080	Duodenal Neuroendocrine Tumor G2|Duodenal NET G2|Malignant carcinoid tumor of the duodenum	A well-differentiated, intermediate-grade neuroendocrine neoplasm that arises from the duodenum. The mitotic count is 2-20 per 2 mm2 and/or the Ki-67 index is 3 to 20%.	Duodenal Neuroendocrine Tumor G2		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|mCode Cancer Disorder Value Set|mCode Elixhauser Malignant Solid Tumors without Metastases Value Set|mCode Primary Cancer Disorder Value Set|mCode Primary Malignant Neoplasm Disorder Value Set|mCode Terminology
C160443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160443>	C96163|C135212	Colon Neuroendocrine Tumor G2|Colon NET G2	A well-differentiated, intermediate-grade neuroendocrine neoplasm that arises from the colon. The mitotic count is 2-20 per 2 mm2 and/or the Ki-67 index is 3 to 20%.	Colon Neuroendocrine Tumor G2		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160444>	C160157	Additional Surgery for New Loco-Regional Tumor Event Was Performed|Yes	Additional surgery was performed for a new loco-regional tumor event.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Terminology
C160445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160445>	C160157	Additional Surgery for New Loco-Regional Tumor Event Was Not Performed|No	Additional surgery was not performed for a new loco-regional tumor event.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Terminology
C160446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160446>	C160157	Additional Surgery for New Loco-Regional Tumor Event Unknown|Unknown	It is unknown if additional surgery was performed for a new loco-regional tumor event.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Terminology
C160447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160447>	C160157	Additional Surgery for New Metastatic Tumor Event Unknown|Unknown	It is unknown if additional surgery was performed for a new metastatic tumor event.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Terminology
C160449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160449>	C160157	Additional Surgery for New Metastatic Tumor Event Was Not Performed|No	Additional surgery was not performed for a new metastatic tumor event.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Terminology
C16044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16044>	C15896	Biostatistics Core	A shared facility providing biostatistical services.			Organization	
C160450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160450>	C160157	Additional Surgery for New Metastatic Tumor Event Was Performed|Yes	Additional surgery was performed for a new metastatic tumor event.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Terminology
C160451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160451>	C96163|C135213	Rectal Neuroendocrine Tumor G2|Malignant carcinoid tumor of the rectum|Rectal NET G2	A well-differentiated, intermediate-grade neuroendocrine neoplasm that arises from the rectum. The mitotic count is 2-20 per 2 mm2 and/or the Ki-67 index is 3 to 20%.	Rectal Neuroendocrine Tumor G2		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|mCode Cancer Disorder Value Set|mCode Elixhauser Malignant Solid Tumors without Metastases Value Set|mCode Primary Cancer Disorder Value Set|mCode Primary Malignant Neoplasm Disorder Value Set|mCode Terminology
C160452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160452>	C160290	Not Known if EGFR Amplification Analysis Was Performed|Unknown	An indication that it is not known whether EGFR amplification analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160453>	C160384	Not Known if EGFR Mutation Analysis Was Performed|Unknown	An indication that it is not known whether EGFR mutation analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C160454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160454>	C160384	Not Known if ERBB2 Mutation Analysis Was Performed|Unknown	An indication that it is not known whether ERBB2 mutation analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C160455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160455>	C160384	Not Known if IDH Family Mutation Analysis Was Performed|Unknown	An indication that it is not known whether IDH family mutation analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160456>	C160384	Not Known if KIT Mutation Analysis Was Performed|Unknown	An indication that it is not known whether KIT mutation analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160457>	C160384	Not Known if KRAS Mutation Analysis Was Performed|Unknown	An indication that it is not known whether KRAS rearrangement analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C160458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160458>	C160290	Not Known if Lymph Node Dissection Was Performed|Unknown	An indication that it is not known whether lymph node dissection was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C160459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160459>	C160384	Not Known if MET Mutation Analysis Was Performed|Unknown	An indication that it is not known whether MET mutation analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C16045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16045>	C19706	Food Patterns|Dietary Patterns|Food Consumption Patterns	The types of food combinations that are commonly eaten by a population.			Research Activity	
C160460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160460>	C160290	Not Known if MGMT Promoter Methylation Testing Was Performed|Unknown	An indication that it is not known whether MGMT promoter methylation analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160461>	C160384	Not Known if NF1 Mutation Analysis Was Performed|Unknown	An indication that it is not known whether NF1 mutation analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160462>	C160384	Not Known if NRAS Mutation Analysis Was Performed|Unknown	An indication that it is not known whether NRAS rearrangement analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C160463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160463>	C160384	Not Known if PDGFRA Mutation Analysis Was Performed|Unknown	An indication that it is not known whether PDGFRA mutation analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160464>	C160290	Not Known if Peripheral Blood Immunophenotyping and Cytochemistry Were Performed|Unknown	An indication that it is not known if immunophenotyping and cytochemistry were performed on peripheral blood samples during the study.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C160465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160465>	C160384	Not Known if PTEN Mutation Analysis Was Performed|Unknown	An indication that it is not known whether PTEN mutation analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160466>	C160290	Not Known if RET Rearrangement Analysis Was Performed|Unknown	An indication that it is not known whether RET rearrangement analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C160467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160467>	C160157	Use of Smokeless Tobacco at Time of Diagnosis Positive|Yes	A response was that the individual was using smokeless tobacco at the time of diagnosis.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology
C160468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160468>	C160290	Not Known if ROS1 Rearrangement Analysis Was Performed|Unknown	An indication that it is not known whether ROS1 rearrangement analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C160469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160469>	C160157	Use of Smokeless Tobacco at Time of Diagnosis Negative|No	A response was that the individual was not using smokeless tobacco at the time of diagnosis.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology
C16046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16046>	C20161	Diagnostic Imaging Program|Biomedical Imaging Program|Cancer Imaging Program|DIP	The National Cancer Institute (NCI) established the Diagnostic Imaging Program (DIP) in October 1996. The name of the program has changed twice during this time, from the Diagnostic Imaging Program to the Biomedical Imaging Program in 2001 and to the Cancer Imaging Program in 2003, to more clearly reflect the role of the program, both to NCI and to the public. The staff members and administered grants are divided among four branches: the Clinical Trials Branch, the Molecular Imaging Branch, the Image-Guided Intervention Branch, and the Imaging Technology Development Branch.			Research Activity	
C160470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160470>	C160157	Use of Smokeless Tobacco at Time of Diagnosis Unknown|Unknown	A response was that it was unknown if the individual was using smokeless tobacco at the time of diagnosis.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology
C160471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160471>	C160157	Regular Smokeless Tobacco Use for Six Weeks or More Positive|Yes	A response that the individual used smokeless tobacco regularly for six weeks or longer.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology
C160472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160472>	C160157	Regular Smokeless Tobacco Use for Six Weeks or More Negative|No	A response that the individual did not use smokeless tobacco regularly for six weeks or longer.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology
C160473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160473>	C160157	Regular Smokeless Tobacco Use for Six Weeks or More Unknown|Unknown	A response that it is unknown if the individual used smokeless tobacco regularly for six weeks or longer.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology
C160474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160474>	C160157	Average Daily Use Smokeless Tobacco after Use for Six Weeks Unknown|Unknown	A response that it the daily use of smokeless tobacco after at least six weeks of use is unknown.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology
C160475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160475>	C173060|C158612	Never Quit using Smokeless Tobacco after Regular Use Question|Never Quit using Smokeless Tobacco after Regular Use|Not Applicable - Never quit	A question about the age of an individual when they quit using smokeless tobacco, once they have been using regularly for six weeks.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology
C160476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160476>	C160384	Not Known if SDH Complex Mutation Analysis Was Performed|Unknown	An indication that it is not known whether SDH complex mutation analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160477>	C160384	Not Known if TP53 Mutation Analysis Was Performed|Unknown	An indication that it is not known whether TP53 mutation analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160478>	C160314	NRAS Mutation Analysis Was Not Performed|No	An indication that NRAS mutation analysis was not performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C160479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160479>	C160315	NRAS Mutation Analysis Was Performed|Yes	An indication that NRAS mutation analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C16047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16047>	C15213	Community Oncology and Rehabilitation	Introduction, application, and evaluation of effective and practical cancer prevention, control, and rehabilitation intervention programs in community settings.			Health Care Activity	
C160480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160480>	C133155	PAX8 Gene Rearrangement|PAX8 Rearrangement|Paired Box 8 Gene Rearrangement|Paired Box Gene 8 Gene Rearrangement|Paired Domain Gene 8 Gene Rearrangement|Positive	A molecular abnormality indicating rearrangement of the PAX8 gene.			Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C160481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160481>	C158949|C103223	PAX8 Gene Rearrangement Negative|Negative|PAX8 Rearrangement Negative|Paired Box 8 Gene Rearrangement Negative|Paired Box Gene 8 Gene Rearrangement Negative|Paired Domain Gene 8 Gene Rearrangement Negative	A genetic finding indicating that rearrangement of the PAX8 gene has not been detected in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form
C160482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160482>	C160314	PDGFRA Mutation Analysis Was Not Performed|No	An indication that PDGFRA mutation analysis was not performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160483>	C160315	PDGFRA Mutation Analysis Was Performed|Yes	An indication that PDGFRA mutation analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160484>	C217517	Glecaprevir/Pibrentasvir|ABT-493/ABT-530|GLE/PIB|Glecaprevir and Pibrentasvir|Glecaprevir-Pibrentasvir|Mavyret	A fixed dose combination of glecaprevir, an inhibitor of the hepatitis C virus (HCV) NS3/4A serine protease, and pibrentasvir, an inhibitor of the HCV non-structural protein 5A (NS5A), with activity against HCV genotypes 1-6. Upon oral administration of glecaprevir/pibrentasvir, glecaprevir inhibits the HCV NS3/4A serine protease enzyme, thereby disrupting the cleavage of the virally encoded polyprotein into mature proteins and preventing the formation of the viral replication complex. Pibrentasvir inhibits the activity of the NS5A protein, leading to disruption of the viral RNA replication complex, blockage of HCV RNA production, and inhibition of viral replication. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family; HCV infection is associated with the development of certain cancers.	Glecaprevir/Pibrentasvir		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology
C160485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160485>	C159477	Percentage of Ki-67 Positive Nuclei|MIB-1 (%)|Percent of Ki-67 Positive Nuclei|Percentage of positive nuclei	A quantitative measurement of the percent of nuclei that are positive for expression of antigen Ki-67 compared to the total number of nuclei in a sample.			Quantitative Concept	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology|CRF7 Pathology Review Immunohistochemistry Test Table
C160486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160486>	C160288	Peripheral Blood Immunophenotyping and Cytochemistry Were Not Performed|No	An indication that immunophenotyping and cytochemistry were not performed on peripheral blood samples during the study.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C160487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160487>	C160289	Peripheral Blood Immunophenotyping and Cytochemistry Were Performed|Yes	An indication that immunophenotyping and cytochemistry were performed on peripheral blood samples during the study.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C160488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160488>	C177696	PTEN Gene Mutation Negative|MMAC1 Gene Mutation Negative|Mutated in Multiple Advanced Cancers 1 Gene Mutation Negative|No|No mutation detected|PTEN Mutation Negative|PTEN Wild-Type|PTEN Wildtype|PTEN wt|Phosphatase and Tensin Homolog Gene Mutation Negative|TEP1 Gene Mutation Negative	A genetic finding indicating that PTEN gene mutations have not been detected in a sample.	PTEN Gene Mutation Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C16048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16048>	C20865	Information Resource	Sources of information such as libraries, databases, and websites.			Intellectual Product	
C160490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160490>	C160314	PTEN Mutation Analysis Was Not Performed|No	An indication that PTEN mutation analysis was not performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160491>	C160315	PTEN Mutation Analysis Was Performed|Yes	An indication that PTEN mutation analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160492>	C200647	Intravesical Bacillus Calmette-Guerin Therapy Failure|BCG Failure|BCG Refractory	Failure to achieve a disease-free state following BCG treatment.			Finding	
C160493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160493>	C190668|C158949	RET Gene Rearrangement Negative|Negative|No rearrangement detected|RET Rearrangement Negative|RET/PTC Rearrangement Negative|Ret Proto-Oncogene Rearrangement Negative	A genetic finding indicating that rearrangement of the RET gene has not been detected in a sample.	RET Gene Rearrangement Negative		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160494>	C160288	RET Rearrangement Analysis Was Not Performed|No	An indication that RET rearrangement analysis was not performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C160495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160495>	C160289	RET Rearrangement Analysis Was Performed|Yes	An indication that RET rearrangement analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C160496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160496>	C160288	ROS1 Rearrangement Analysis Was Not Performed|No	An indication that ROS1 rearrangement analysis was not performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C160497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160497>	C160289	ROS1 Rearrangement Analysis Was Performed|Yes	An indication that ROS1 rearrangement analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C160498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160498>	C160314	SDH Complex Mutation Analysis Was Not Performed|No	An indication that SDH complex mutation analysis was not performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160499>	C160315	SDH Complex Mutation Analysis Was Performed|Yes	An indication that SDH complex mutation analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C16049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16049>	C15429	Radiotherapy Research|Radiation	[Therapeutic implications] Research in radiotherapy using ionizing and non-ionizing radiation and those areas in radiobiology and radiation physics that relate to radiation therapy, including laboratory investigations at the molecular, cellular, tissue, and whole animal levels. (DEA-CAACT)			Research Activity	
C1604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1604>	C927	DC-Cholesterol Liposome|DC-Chol Liposomes|Dimethylaminoethane-carbamoyl-cholesterol Liposomes	A cationic cholesterol derivative mixed with dimethylaminoethane-carbamoyl and sonicated to form small unilamellar vesicles that can complex with DNA, DNA/protein complexes and other drug complexes and mediates the delivery into the cytosol from the endosome compartment. (NCI)			Biomedical or Dental Material|Organic Chemical	NCI Drug Dictionary Terminology
C160500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160500>	C177177	TLR8 Agonist DN1508052|DN A1|DN-1508052|DN-A1|DN1508052|DN1508052-01|DNA1|TLR8 Agonist DN-A1|TLR8 Agonist DN1508052-01	A small molecule Toll-like receptor 8 (TLR8; CD288) agonist with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, TLR8 agonist DN1508052 binds to TLR8, which is expressed in myeloid dendritic cells (mDCs), monocytes, and natural killer (NK) cells. This may lead to the activation of nuclear factor NF-kappa-B, the release of proinflammatory cytokines and a Th1-weighted anti-tumor immune response. Additionally, activation of TLR8 signaling in tumor cells may block the induction and reverse the suppression of senescent naive and tumor-specific T-cells, resulting in enhanced anti-tumor immunity. TLR8, like other TLRs, recognizes pathogen-associated molecular patterns (PAMPs) and plays a key role in innate and adaptive immunity.	TLR8 Agonist DN1508052		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology
C160502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160502>	C63522|C63519|C159909|C159901|C159900	Ifosfamide/Paclitaxel Regimen|Ifex/Mesnex/Taxol|Ifosfamide and Paclitaxel|Ifosfamide-Mesna-Paclitaxel|Ifosfamide/Mesna/Paclitaxel	A regimen consisting of ifosfamide, mesna and paclitaxel that can be used in the treatment of uterine, ovarian, fallopian tube, or primary peritoneal cancer, malignant germ cell tumors, malignant sex cord-stromal tumors, and certain carcinosarcomas, such as malignant mixed Müllerian tumors.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160503>	C63468|C191713	Abiraterone/Prednisone Regimen|Abiraterone-Prednisone|Abiraterone/Prednisone|Prednisone-Abiraterone|Prednisone-Abiraterone Regimen|Prednisone/Abiraterone	A regimen consisting of abiraterone and prednisone that can be used for the treatment of prostate cancer and salivary gland tumors.	Abiraterone/Prednisone Regimen		Therapeutic or Preventive Procedure	CTRP Agent Terminology|CTRP Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160504>	C63468	Apalutamide/Degarelix Regimen|Apalutamide-Degarelix|Apalutamide/Degarelix|Degarelix-Apalutamide|Degarelix-Apalutamide Regimen|Degarelix/Apalutamide	A regimen consisting of apalutamide and degarelix that can be used for the treatment of prostate cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160505>	C159657	Antithymocyte Globulin Rabbit/Tacrolimus Regimen|Antithymocyte Globulin (ATG) Rabbit/Tacrolimus|Antithymocyte Globulin Rabbit/Tacrolimus|Rabbit ATG/Tacrolimus|Rabbit Antithymocyte Globulin/Tacrolimus	A regimen consisting of rabbit antithymocyte globulin and tacrolimus that can be used for the prevention and treatment of acute rejection following organ transplantation.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160506>	C63519	Everolimus/Letrozole Regimen|Everolimus and Letrozole|Everolimus/Letrozole|Letrozole and Everolimus|Letrozole/Everolimus	A regimen consisting of everolimus and letrozole that can be used for the treatment of endometrial cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160507>	C63443	High-dose Methylprednisolone/Obinutuzumab Regimen|HD Methylprednisolone/Obinutuzumab Regimen|HDMP/Obinutuzumab Regimen|High-dose Methylprednisolone/Obinutuzumab|Obinutuzumab/High-Dose Methylprednisolone|Obinutuzumab/High-dose Methylprednisolone Regimen	A regimen consisting of high-dose methylprednisolone and obinutuzumab that can be used for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160508>	C63522|C159901|C159900	Cisplatin/Paclitaxel/Intraperitoneal Paclitaxel Regimen|Cisplatin/IP Paclitaxel/IV Paclitaxel|Cisplatin/Paclitaxel/IP Paclitaxel Regimen|Cisplatin/Paclitaxel/Paclitaxel IP|Cisplatin/Paclitaxel/Paclitaxel IP Regimen	A regimen consisting of intravenous (IV) paclitaxel, cisplatin, and intraperitoneal (IP) paclitaxel that can be used for the treatment of ovarian, fallopian tube, and primary peritoneal cancers.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160509>	C63468	Bicalutamide/Degarelix Regimen|Bicalutamide-Degarelix|Bicalutamide/Degarelix|Degarelix-Bicalutamide|Degarelix-Bicalutamide Regimen|Degarelix/Bicalutamide Regimen	A regimen consisting of bicalutamide and degarelix that can be used for the treatment of prostate cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C16050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16050>	C52647	Cancer Surveillance Program|Cancer Surveillance|Surveillance Program|Surveillance Program	The ongoing, timely, and systematic collection and analysis of information on new cancer cases, extent of disease, screening tests, treatment, survival, and cancer deaths.	Surveillance Program		Research Activity	CTRP Intervention Terminology|CTRP Terminology
C160510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160510>	C63468	Degarelix/Docetaxel Regimen|Degarelix-Docetaxel|Degarelix-Docetaxel Regimen|Docetaxel-Degarelix|Docetaxel/Degarelix	A regimen consisting of degarelix and docetaxel that can be used for the treatment of prostate cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160511>	C159657	Horse Antithymocyte Globulin/Tacrolimus Regimen|ATGAM/Tacrolimus|Antithymocyte Globulin Equine/Tacrolimus|Equine Antithymocyte Globulin/Tacrolimus|Horse Antithymocyte Globulin/Tacrolimus	A regimen consisting of horse antithymocyte globulin and tacrolimus that can be used for the prevention and treatment of acute rejection following organ transplantation.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160512>	C63468	Apalutamide/Triptorelin Regimen|Apalutamide-Triptorelin|Apalutamide/Triptorelin|Triptorelin-Apalutamide|Triptorelin/Apalutamide|Triptorelin/Apalutamide Regimen	A regimen consisting of apalutamide and triptorelin that can be used for the treatment of prostate cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160513>	C63468	Enzalutamide/Triptorelin Regimen|Enzalutamide-Triptorelin|Enzalutamide/Triptorelin|Triptorelin-Enzalutamide|Triptorelin/Enzalutamide|Triptorelin/Enzalutamide Regimen	A regimen consisting of enzalutamide and triptorelin that can be used for the treatment of prostate cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160514>	C63468	Docetaxel/Triptorelin Regimen|Docetaxel-Triptorelin|Docetaxel/Triptorelin|Triptorelin-Docetaxel|Triptorelin/Docetaxel|Triptorelin/Docetaxel Regimen	A regimen consisting of docetaxel and triptorelin that can be used for the treatment of prostate cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160515>	C63468	Palbociclib/Tamoxifen Regimen|Palbociclib and Tamoxifen|Palbociclib-Tamoxifen|Palbociclib/Tamoxifen|Tamoxifen-Palbociclib|Tamoxifen/Palbociclib|Tamoxifen/Palbociclib Regimen	A regimen consisting of palbociclib and tamoxifen that can be used for the treatment of prostate cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160516>	C63468	Degarelix/Enzalutamide Regimen|Degarelix-Enzalutamide|Degarelix-Enzalutamide Regimen|Degarelix/Enzalutamide|Enzalutamide-Degarelix|Enzalutamide/Degarelix	A regimen consisting of degarelix and enzalutamide that can be used for the treatment of prostate cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160517>	C63468	Docetaxel/Goserelin Regimen|Docetaxel-Goserelin|Docetaxel/Goserelin|Goserelin-Docetaxel|Goserelin-Docetaxel Regimen|Goserelin/Docetaxel Regimen	A regimen consisting of docetaxel and goserelin that can be used for the treatment of prostate cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160518>	C63468	Apalutamide/Goserelin Regimen|Apalutamide-Goserelin|Apalutamide/Goserelin|Goserelin-Apalutamide|Goserelin-Apalutamide Regimen|Goserelin/Apalutamide Regimen	A regimen consisting of apalutamide and goserelin that can be used for the treatment of prostate cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160519>	C63468	Enzalutamide/Goserelin Regimen|Enzalutamide-Goserelin|Enzalutamide/Goserelin|Goserelin-Enzalutamide|Goserelin-Enzalutamide Regimen|Goserelin/Enzalutamide Regimen	A regimen consisting of enzalutamide and goserelin that can be used for the treatment of prostate cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C16051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16051>	C15533	Toxicity Attenuation	Therapy designed to reduce toxicity to cells, tissues, or organs.			Therapeutic or Preventive Procedure	
C160520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160520>	C63468	Apalutamide/Leuprolide Regimen|Apalutamide-Leuprolide|Apalutamide/Leuprolide|Leuprolide-Apalutamide|Leuprolide-Apalutamide Regimen|Leuprolide/Apalutamide Regimen	A regimen consisting of apalutamide and leuprolide that can be used for the treatment of prostate cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160521>	C63468	Enzalutamide/Leuprolide Regimen|Enzalutamide and Leuprolide|Enzalutamide-Leuprolide|Enzalutamide/Leuprolide|Leuprolide-Enzalutamide|Leuprolide-Enzalutamide Regimen|Leuprolide/Enzalutamide Regimen	A regimen consisting of enzalutamide and leuprolide that can be used for the treatment of prostate cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160522>	C63443|C63442	Chlorambucil/Obinutuzumab Regimen|Chlorambucil and Obinutuzumab (GClb)|Chlorambucil/Obinutuzumab|Obinutuzumab/Chlorambucil|Obinutuzumab/Chlorambucil Regimen	A regimen consisting of chlorambucil and obinutuzumab that can be used for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160523>	C63468	Abemaciclib/Tamoxifen Regimen|Abemaciclib-Tamoxifen|Abemaciclib/Tamoxifen|Tamoxifen-Abemaciclib|Tamoxifen/Abemaciclib|Tamoxifen/Abemaciclib Regimen	A regimen consisting of abemaciclib and tamoxifen that can be used for the treatment of prostate cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160524>	C63442|C63356	Bendamustine/Brentuximab Vedotin Regimen|Adcetris/Bendamustine|Bendamustine and Brentuximab vedotin|Bendamustine-Brentuximab Vedotin|Bendamustine/Adcetris|Bendamustine/Brentuximab Vedotin|Bendeka/Adcetris|Brentuximab Vedotin-Bendamustine|Brentuximab Vedotin/Bendamustine|Brentuximab Vedotin/Bendamustine Regimen	A regimen consisting of bendamustine and brentuximab vedotin that can be used for the treatment of Hodgkin lymphoma (HL), T-cell lymphomas, and mycosis fungoides/Sezary syndrome.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160525>	C63522|C159901|C159900	Bevacizumab/Liposomal Doxorubicin Regimen|Avastin/Doxil|Bevacizumab-Liposomal Doxorubicin|Bevacizumab/Liposomal Doxorubicin|Bevacizumab/Pegylated Liposomal Doxorubicin|Doxil/Avastin|Liposomal Doxorubicin/Bevacizumab Regimen|Non-pegylated liposomal doxorubicin and Bevacizumab-tnjn|Pegylated Liposomal Doxorubicin/Bevacizumab|Pegylated liposomal doxorubicin and Bevacizumab|Pegylated liposomal doxorubicin and Bevacizumab-adcd|Pegylated liposomal doxorubicin and Bevacizumab-awwb|Pegylated liposomal doxorubicin and Bevacizumab-aybi|Pegylated liposomal doxorubicin and Bevacizumab-bvzr|Pegylated liposomal doxorubicin and Bevacizumab-equi|Pegylated liposomal doxorubicin and Bevacizumab-maly|Pegylated liposomal doxorubicin and Bevacizumab-onbe|Pegylated liposomal doxorubicin and Bevacizumab-tnjn	A regimen consisting of bevacizumab and liposomal doxorubicin that can be used for the treatment of ovarian, fallopian tube, and primary peritoneal cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160526>	C140180	Bevacizumab/Lomustine Regimen|Bevacizumab-Lomustine|Bevacizumab/Lomustine|Lomustine and Bevacizumab|Lomustine and Bevacizumab-adcd|Lomustine and Bevacizumab-awwb|Lomustine and Bevacizumab-aybi|Lomustine and Bevacizumab-bvzr|Lomustine and Bevacizumab-equi|Lomustine and Bevacizumab-maly|Lomustine and Bevacizumab-onbe|Lomustine and Bevacizumab-tnjn|Lomustine-Bevacizumab|Lomustine/Bevacizumab|Lomustine/Bevacizumab Regimen	A regimen consisting of bevacizumab and lomustine that can be used for the treatment of certain central nervous system (CNS) cancers including oligodendroglioma, astrocytoma, glioblastoma (GBM) and gliosarcoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160527>	C63470	Bevacizumab/Carboplatin Regimen|Bevacizumab-Carboplatin|Bevacizumab-Carboplatin Regimen|Bevacizumab/Carboplatin|Carboplatin and Bevacizumab|Carboplatin and Bevacizumab-adcd|Carboplatin and Bevacizumab-awwb|Carboplatin and Bevacizumab-aybi|Carboplatin and Bevacizumab-bvzr|Carboplatin and Bevacizumab-equi|Carboplatin and Bevacizumab-maly|Carboplatin and Bevacizumab-onbe|Carboplatin and Bevacizumab-tnjn|Carboplatin-Bevacizumab|Carboplatin/Bevacizumab|Carboplatin/Bevacizumab Regimen	A regimen consisting of bevacizumab and carboplatin that can be used for the treatment of recurrent malignant glioma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160528>	C63470	Bevacizumab/Temozolomide Regimen|Avastin/Temodar|Bevacizumab-Temozolomide|Bevacizumab/Temozolomide|Temozolomide and Bevacizumab|Temozolomide and Bevacizumab-adcd|Temozolomide and Bevacizumab-awwb|Temozolomide and Bevacizumab-aybi|Temozolomide and Bevacizumab-bvzr|Temozolomide and Bevacizumab-equi|Temozolomide and Bevacizumab-maly|Temozolomide and Bevacizumab-onbe|Temozolomide and Bevacizumab-tnjn	A regimen consisting of bevacizumab and temozolomide that may be used in the treatment of central nervous system (CNS) cancers, including astrocytoma, oligodendroglioma and glioblastoma, and solitary fibrous tumors (SFTs).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160529>	C63443|C63442	Ibrutinib/Rituximab Regimen|Ibrutinib and Rituximab|Ibrutinib and Rituximab-abbs|Ibrutinib and Rituximab-arrx|Ibrutinib and Rituximab-blit|Ibrutinib and Rituximab-pvvr|Ibrutinib and Rituximab-rite|Ibrutinib and Rituximab-rixa|Ibrutinib and Rituximab-rixi|Ibrutinib-Rituximab|Ibrutinib/Rituximab|Imbruvica/Rituxan	A regimen consisting of ibrutinib and rituximab that may be used in the treatment of Waldenström macroglobulinemia and certain non-Hodgkin lymphomas (NHL), such as mantle cell lymphoma, and chronic lymphocytic leukemia/small lymphocytic lymphoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C16052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16052>	C15315	Breast Cancer Rehabilitation	Any intervention to help breast cancer patients overcome the physical or psychological effects of their disease or its treatment.			Therapeutic or Preventive Procedure	
C160530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160530>	C63443	Idelalisib/Rituximab Regimen|Idelalisib and Rituximab|Idelalisib and Rituximab-abbs|Idelalisib and Rituximab-arrx|Idelalisib and Rituximab-blit|Idelalisib and Rituximab-pvvr|Idelalisib and Rituximab-rite|Idelalisib and Rituximab-rixa|Idelalisib and Rituximab-rixi|Idelalisib-Rituximab|Idelalisib/Rituximab|Zydelig/Rituxan	A regimen consisting of idelalisib and rituximab that may be used in the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160531>	C63587	Cisplatin/Temozolomide Regimen|Cisplatin and Temozolomide|Cisplatin-Temozolomide|Cisplatin/Temozolomide|Platinol/Temodar	A regimen consisting of cisplatin and temozolomide that may be used in the treatment of mucosal melanoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160532>	C63510|C63358	Anastrozole/Leuprolide Regimen|Anastrozole-Leuprolide|Anastrozole/Leuprolide|Arimidex/Lupron	A regimen consisting of anastrozole and leuprolide that may be used in the treatment of certain hormone receptor (HR)-positive breast cancers and uterine sarcoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160533>	C63510|C63358	Exemestane/Leuprolide Regimen|Aromasin/Lupron|Exemestane-Leuprolide|Exemestane/Leuprolide	A regimen consisting of exemestane and leuprolide that may be used in the treatment of breast cancers and uterine sarcoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160534>	C63510|C63358	Letrozole/Leuprolide Regimen|Femara/Lupron|Letrozole-Leuprolide|Letrozole/Leuprolide	A regimen consisting of letrozole and leuprolide that may be used in the treatment of certain hormone receptor (HR)-positive breast cancers and uterine sarcoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160535>	C63719|C63361	Paclitaxel/Ramucirumab Regimen|Paclitaxel and Ramucirumab|Paclitaxel-Ramucirumab|Paclitaxel/Ramucirumab|Taxol/Cyramza	A regimen consisting of paclitaxel and ramucirumab that may be used in the treatment of certain esophageal, esophagogastric junction and gastric cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160536>	C63522|C159901|C159900	Bevacizumab/Topotecan Regimen|Avastin/Hycamtin|Bevacizumab-Topotecan|Bevacizumab/Topotecan|Topotecan and Bevacizumab|Topotecan and Bevacizumab-adcd|Topotecan and Bevacizumab-awwb|Topotecan and Bevacizumab-aybi|Topotecan and Bevacizumab-bvzr|Topotecan and Bevacizumab-equi|Topotecan and Bevacizumab-maly|Topotecan and Bevacizumab-onbe|Topotecan and Bevacizumab-tnjn	A regimen consisting of topotecan and bevacizumab that may be used in the treatment of certain ovarian, peritoneal, and fallopian tube cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160537>	C63443|C173974	Rituximab/Venetoclax Regimen|Rituxan/Venclexta|Rituximab-Venetoclax|Rituximab/Venetoclax|Venetoclax and Rituximab|Venetoclax and Rituximab-abbs|Venetoclax and Rituximab-arrx|Venetoclax and Rituximab-blit|Venetoclax and Rituximab-pvvr|Venetoclax and Rituximab-rite|Venetoclax and Rituximab-rixa|Venetoclax and Rituximab-rixi	A regimen consisting of rituximab and venetoclax that may be used in the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and hairy cell leukemia.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160538>	C63442	High-dose Cytarabine/Rituximab Regimen|Cytarabine-Rituximab|Cytosar-U/Rituxan|HD AraC/Rituximab|HD Cytarabine/Rituximab|High-dose Cytarabine/Rituximab|R-HiDAC|R-HiDAC|R-HiDAC (rituximab-abbs)|R-HiDAC (rituximab-arrx)|R-HiDAC (rituximab-blit)|R-HiDAC (rituximab-pvvr)|R-HiDAC (rituximab-rite)|R-HiDAC (rituximab-rixa)|R-HiDAC (rituximab-rixi)	A regimen consisting of high-dose cytarabine and rituximab that may be used in the treatment of Burkitt lymphoma and mantle cell lymphoma (MCL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160539>	C63468	AAP-D Regimen|AAP-D|Abiraterone-Prednisone-Degarelix|Abiraterone/Degarelix/Prednisone|Abiraterone/Prednisone/Degarelix|Abiraterone/Prednisone/Degarelix Regimen|Zytiga/Firmagon/Deltasone	A regimen consisting of abiraterone, degarelix, and prednisone that may be used in the treatment of prostate carcinoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C16053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16053>	C16199|C15721	Cancer Surveillance Research	Studies related to the ongoing, timely, and systematic collection and analysis of information on new cancer cases, extent of disease, screening tests, treatment, survival, and cancer deaths.			Research Activity	
C160540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160540>	C63468	Abiraterone/Prednisone/Triptorelin Regimen|Abiraterone-Prednisone-Triptorelin|Abiraterone/Prednisone/Triptorelin|Zytiga/Deltasone/Trelstar	A regimen consisting of triptorelin, abiraterone, and prednisone that may be used in the treatment of certain types of prostate carcinoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160541>	C63496	Bortezomib/Dexamethasone/Venetoclax Regimen|Bortezomib-Dexamethasone-Venetoclax|Bortezomib/Dexamethasone/Venetoclax|Velcade/Decadron/Venclexta	A regimen consisting of bortezomib, dexamethasone, and venetoclax that may be used in the treatment of relapsed/refractory plasma cell (multiple) myeloma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160542>	C63719|C63358	Capecitabine/Oxaliplatin/Trastuzumab Regimen|CAPOX-Trastuzumab|CapeOx and Trastuzumab|CapeOx and Trastuzumab-anns|CapeOx and Trastuzumab-dkst|CapeOx and Trastuzumab-dttb|CapeOx and Trastuzumab-herw|CapeOx and Trastuzumab-pkrb|CapeOx and Trastuzumab-qyyp|CapeOx and Trastuzumab-strf|CapeOx and Trastuzumab-zerc|CapeOx/Trastuzumab|Capecitabine-Oxaliplatin-Trastuzumab|Capecitabine/Oxaliplatin/Trastuzumab|Xeloda/Eloxatin/Herceptin	A regimen consisting of capecitabine, oxaliplatin, and trastuzumab that may be used in the treatment of esophageal and esophagogastric junction and gastric cancers. Low-dose capecitabine/oxaliplatin/trastuzumab regimen may be used for the treatment of gastric, esophageal and esophagogastric junction cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160543>	C63468	Abiraterone/Goserelin/Prednisone Regimen|Abiraterone-Goserelin-Prednisone|Abiraterone/Goserelin/Prednisone|Zytiga/Zoladex/Deltasone	A regimen consisting of abiraterone, goserelin, and prednisone that may be used in the treatment of certain types of prostate carcinoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160544>	C63468	Abiraterone/Leuprolide/Prednisone Regimen|Abiraterone-Leuprolide-Prednisone|Abiraterone/Leuprolide/Prednisone|Zytiga/Lupron/Deltasone	A regimen consisting of abiraterone, leuprolide, and prednisone that may be used in the treatment of certain types of prostate carcinoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160545>	C63442|C191727	BDR Regimen|BDR|BDR|BDR (rituximab-abbs)|BDR (rituximab-arrx)|BDR (rituximab-blit)|BDR (rituximab-pvvr)|BDR (rituximab-rite)|BDR (rituximab-rixa)|BDR (rituximab-rixi)|BORID|Bortezomib-Dexamethasone-Rituximab|Bortezomib/Dexamethasone + Rituximab|Bortezomib/Dexamethasone Plus Rituximab|Bortezomib/Dexamethasone/Rituximab|Bortezomib/Dexamethasone/Rituximab Regimen|Velcade/Decadron/Rituxan	A regimen consisting of bortezomib, dexamethasone, and rituximab that may be used in the treatment of Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma, Castleman disease, and mantle cell lymphoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160546>	C63496	VTD Regimen|Bortezomib-Thalidomide-Dexamethasone|Bortezomib/Dexamethasone/Thalidomide|Bortezomib/Thalidomide/Dexamethasone|Bortezomib/Thalidomide/Dexamethasone Regimen|VDT|VTD|VTD|Velcade/Immunoprin/Decadron|Velcade/Thalidomide/Dexamethasone	A regimen consisting of bortezomib, thalidomide, and dexamethasone that may be used in the treatment of plasma cell (multiple) myeloma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C160547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160547>	C63358	Abemaciclib/Fulvestrant/Leuprolide Regimen|Abemaciclib-Fulvestrant-Leuprolide|Abemaciclib/Fulvestrant/Leuprolide|Verzenio/Faslodex/Lupron	A regimen consisting of abemaciclib, fulvestrant, and leuprolide that may be used in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer in premenopausal women.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160548>	C63358	BR-Ibrutinib Regimen|Bendamustine and Rituximab (BR) and Ibrutinib|Bendamustine and Rituximab-abbs (BR) and Ibrutinib|Bendamustine and Rituximab-arrx (BR) and Ibrutinib|Bendamustine and Rituximab-blit (BR) and Ibrutinib|Bendamustine and Rituximab-pvvr (BR) and Ibrutinib|Bendamustine and Rituximab-rite (BR) and Ibrutinib|Bendamustine and Rituximab-rixa (BR) and Ibrutinib|Bendamustine and Rituximab-rixi (BR) and Ibrutinib|Bendamustine/Ibrutinib/Rituximab|Ibrutinib-Bendamustine-Rituximab|Ibrutinib/Bendamustine + Rituximab|Ibrutinib/Bendamustine Plus Rituximab|Ibrutinib/Bendamustine/Rituximab|Ibrutinib/Bendamustine/Rituximab Regimen|Imbruvica/Treanda/Rituxan	A regimen consisting of ibrutinib, bendamustine and rituximab that may be used in the treatment of certain types of relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160549>	C63443	Bendamustine/Idelalisib/Rituximab Regimen|BR and Idelalisib|Bendamustine and Rituximab (BR) and Idelalisib|Bendamustine and Rituximab-abbs (BR) and Idelalisib|Bendamustine and Rituximab-arrx (BR) and Idelalisib|Bendamustine and Rituximab-blit (BR) and Idelalisib|Bendamustine and Rituximab-pvvr (BR) and Idelalisib|Bendamustine and Rituximab-rite (BR) and Idelalisib|Bendamustine and Rituximab-rixa (BR) and Idelalisib|Bendamustine and Rituximab-rixi (BR) and Idelalisib|Bendamustine/Idelalisib/Rituximab|IBR|IBR Regimen|Idelalisib/Bendamustine/Rituximab|Idelalisib/Bendamustine/Rituximab Regimen	A regimen consisting of bendamustine, idelalisib and rituximab that can be used in the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C16054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16054>	C16009	Drug Synthesis and Chemistry Branch|Drug Synthesis|Drug Synthesis and Chemistry	A branch of the Developmental Therapeutics Program of the National Cancer Institute. It is responsible for activities that support the discovery and development of novel anti-cancer agents, including management of the storage, inventory, documentation, and distribution of samples for research purposes; and synthesis of cold and radiolabelled compounds for in vivo studies and anti-angiogenesis standards.			Research Activity	
C160550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160550>	C63358	Letrozole/Leuprolide/Palbociclib Regimen|Femara/Lupron/Ibrance|Letrozole-Leuprolide-Palbociclib|Letrozole/Leuprolide/Palbociclib	A regimen consisting of letrozole, leuprolide and palbociclib that can be used in the treatment of estrogen receptor (ER)-positive and HER-2/neu-negative metastatic or advanced breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160551>	C63719|C63361	Capecitabine/Cisplatin/Trastuzumab Regimen|Capecitabine and Cisplatin (CX) and Trastuzumab|Capecitabine and Cisplatin (CX) and Trastuzumab-anns|Capecitabine and Cisplatin (CX) and Trastuzumab-dkst|Capecitabine and Cisplatin (CX) and Trastuzumab-dttb|Capecitabine and Cisplatin (CX) and Trastuzumab-herw|Capecitabine and Cisplatin (CX) and Trastuzumab-pkrb|Capecitabine and Cisplatin (CX) and Trastuzumab-qyyp|Capecitabine and Cisplatin (CX) and Trastuzumab-strf|Capecitabine and Cisplatin (CX) and Trastuzumab-zerc|Capecitabine-Cisplatin-Trastuzumab|Capecitabine/Cisplatin/Trastuzumab|Xeloda/Platinol/Herceptin	A regimen consisting of capecitabine, cisplatin and trastuzumab that can be used in the treatment of esophageal and esophagogastric junction, and gastric cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160552>	C63522|C159901|C159900	Bevacizumab/Carboplatin/Gemcitabine Regimen|Avastin/Paraplatin/Gemzar|Bevacizumab/Carboplatin/Gemcitabine|Carboplatin and Gemcitabine (GCb) and Bevacizumab|Carboplatin and Gemcitabine (GCb) and Bevacizumab-adcd|Carboplatin and Gemcitabine (GCb) and Bevacizumab-awwb|Carboplatin and Gemcitabine (GCb) and Bevacizumab-aybi|Carboplatin and Gemcitabine (GCb) and Bevacizumab-bvzr|Carboplatin and Gemcitabine (GCb) and Bevacizumab-equi|Carboplatin and Gemcitabine (GCb) and Bevacizumab-maly|Carboplatin and Gemcitabine (GCb) and Bevacizumab-onbe|Carboplatin and Gemcitabine (GCb) and Bevacizumab-tnjn|Carboplatin, Gemcitabine, Bevacizumab|Carboplatin, Gemcitabine, Bevacizumab-adcd|Carboplatin, Gemcitabine, Bevacizumab-awwb|Carboplatin, Gemcitabine, Bevacizumab-aybi|Carboplatin, Gemcitabine, Bevacizumab-bvzr|Carboplatin, Gemcitabine, Bevacizumab-equi|Carboplatin, Gemcitabine, Bevacizumab-maly|Carboplatin, Gemcitabine, Bevacizumab-onbe|GC + Bev|GC Plus Bev|Gemcitabine/Carboplatin/Bevacizumab|Gemcitabine/Carboplatin/Bevacizumab Regimen	A regimen consisting of gemcitabine, carboplatin, and bevacizumab that may be used in the treatment of ovarian, fallopian tube, or primary peritoneal cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160553>	C65070|C63719|C63587|C63361	TCF Regimen|Carboplatin-Docetaxel-Fluorouracil|Carboplatin/Docetaxel/Fluorouracil|Carboplatin/Docetaxel/Fluorouracil Regimen|Docetaxel/Carboplatin/Fluorouracil|TCF|Taxotere/Carboplatin/Fluorouracil	A regimen consisting of carboplatin, docetaxel and 5-fluorouracil that can be used in the treatment of gastric, cervical, head and neck, and esophageal and esophagogastric junction cancers.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160554>	C63496	CCD Regimen|CCD|CCd|CCyd|Carfilzomib-Cyclophosphamide-Dexamethasone|Carfilzomib/Cyclophosphamide/Dexamethasone|Carfilzomib/Cyclophosphamide/Dexamethasone Regimen|KCD|KCD|KCD Regimen|KCyd|Kyprolis/Cyclophosphamide/Dexamethasone	A regimen consisting of carfilzomib, cyclophosphamide and dexamethasone that can be used in the treatment of plasma cell (multiple) myeloma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160555>	C63442	CaRD Regimen|CaRD|CaRD|CaRD (rituximab-abbs)|CaRD (rituximab-arrx)|CaRD (rituximab-blit)|CaRD (rituximab-pvvr)|CaRD (rituximab-rite)|CaRD (rituximab-rixa)|CaRD (rituximab-rixi)|Carfilzomib/Dexamethasone/Rituximab|Carfilzomib/Dexamethasone/Rituximab Regimen|Kyprolis/Decadron/Rituxan	A regimen consisting of carfilzomib, dexamethasone and rituximab that may be used in the treatment of Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160556>	C63442	Cyclophosphamide/Dexamethasone/Rituximab Regimen|Cyclophosphamide-Dexamethasone-Rituximab|Cyclophosphamide/Dexamethasone/Rituximab|Cytoxan/Decadron/Rituxan|DRC|DRC|DRC (SC rituximab) (rituximab-abbs)|DRC (SC rituximab) (rituximab-arrx)|DRC (SC rituximab) (rituximab-blit)|DRC (SC rituximab) (rituximab-pvvr)|DRC (SC rituximab) (rituximab-rite)|DRC (SC rituximab) (rituximab-rixa)|DRC (SC rituximab) (rituximab-rixi)|DRC (rituximab-abbs)|DRC (rituximab-arrx)|DRC (rituximab-blit)|DRC (rituximab-pvvr)|DRC (rituximab-rite)|DRC (rituximab-rixa)|DRC (rituximab-rixi)|DRC Regimen|Dexamethasone/Rituximab/Cyclophosphamide|Dexamethasone/Rituximab/Cyclophosphamide Regimen|Oral Cyclophosphamide/Dexamethasone Plus Rituximab|Oral Cyclophosphamide/Dexamethasone/Rituximab	A regimen consisting of cyclophosphamide, dexamethasone and rituximab that may be used in the treatment of Waldenstrom macroglobulinemia.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160557>	C63496	Dara-Pd Regimen|DPd|DPd Regimen|Dara-Pd|Dara-Pd|Daratumumab-Dexamethasone-Pomalidomide|Daratumumab/Dexamethasone/Pomalidomide|Daratumumab/Dexamethasone/Pomalidomide Regimen|Darzalex/Decadron/Pomalyst	A regimen consisting of daratumumab, dexamethasone and pomalidomide that can be used in the treatment of relapsed/refractory plasma cell (multiple) myeloma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160558>	C63442	R-DHA Regimen|Dexamethasone/High-dose Cytarabine/Rituximab|R-DHA|Rituxan/Decadron/High-dose Cytosar-U|Rituximab-Dexamethasone-High-dose Cytarabine|Rituximab/Dexamethasone/High-dose Ara-C Regimen|Rituximab/Dexamethasone/High-dose Cytarabine	A regimen consisting rituximab, dexamethasone and high dose cytarabine that can be used for the treatment of relapsed/refractory mantle cell lymphoma (MCL).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160559>	C159657|C159445	Rabbit Anti-thymocyte Globulin/Prednisone/Tacrolimus Regimen|Leporine ATG/Prednisone/Tacrolimus|Leporine ATG/Prednisone/Tacrolimus Regimen|Rabbit ATG/Prednisone/Tacrolimus|Rabbit ATG/Prednisone/Tacrolimus Regimen|rATG/Prednisone/Tacrolimus	A regimen consisting of rabbit anti-thymocyte globulin, prednisone and tacrolimus that can be used in the treatment of myelodysplastic syndrome (MDS) and the prevention and treatment of graft rejection.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C16055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16055>	C16056	CEPH/Genethon Map	An integrated physical and genetic linkage map of the human genome produced by the Centre d'Etude du Polymorphisme Humain (CEPH) and the Genethon research laboratories.			Intellectual Product	
C160560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160560>	C63496	Dexamethasone/Elotuzumab/Pomalidomide Regimen|Decadron/Empliciti/Pomalyst|Dexamethasone-Elotuzumab-Pomalidomide|Dexamethasone/Elotuzumab/Pomalidomide|Elo-PD|Elo-Pd|Pomalidomide/Dexamethasone/Elotuzumab	A regimen consisting of dexamethasone, elotuzumab and pomalidomide that can be used for the treatment of plasma cell (multiple) myeloma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160561>	C65070|C63359	Atezolizumab/Carboplatin/Etoposide Regimen|Atezolizumab-Carboplatin-Etoposide|Atezolizumab/Carboplatin/Etoposide|Carboplatin and Etoposide (CE) and Atezolizumab|Tecentriq/Paraplatin/VePesid	A regimen consisting of atezolizumab, carboplatin and etoposide that can be used in the treatment of small cell lung cancer (SCLC) and cervical cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160562>	C159657|C159445	Equine Anti-thymocyte Globulin/Prednisone/Tacrolimus Regimen|Equine ATG/Prednisone/Tacrolimus|Equine ATG/Prednisone/Tacrolimus Regimen|Horse ATG/Prednisone/Tacrolimus|Horse ATG/Prednisone/Tacrolimus Regimen|eATG/Prednisone/Tacrolimus	A regimen consisting of equine anti-thymocyte globulin, prednisone and tacrolimus that can be used in the treatment of myelodysplastic syndrome (MDS) and the prevention and treatment of graft rejection.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160563>	C63356	AAVD Regimen|A+AVD|A+AVD Regimen|A-AVD|A-AVD|AAVD|AVD Plus Brentuximab Vedotin|AVD-A|AVD/Brentuximab Vedotin Regimen|Adcetris/Adriamycin/Vinblastine/Dacarbazine|Adcetris/Adriamycin/Vinblastine/Dacarbazine Regimen|B-AVD|BV-AVD Regimen|Brentuximab Vedotin Followed by AVD|Brentuximab Vedotin Plus AVD Regimen|Brentuximab Vedotin Plus Dacarbazine-Doxorubicin-Vinblastine|Brentuximab Vedotin-Dacarbazine-Doxorubicin-Vinblastine|Brentuximab Vedotin/AVD Regimen|Brentuximab Vedotin/Dacarbazine/Doxorubicin/Vinblastine|Brentuximab Vedotin/Dacarbazine/Doxorubicin/Vinblastine Regimen|Brentuximab Vedotin/Doxorubicin/Vinblastine/Dacarbazine|Doxorubicin/Vinblastine/Dacarbazine Plus Brentuximab Vedotin	A regimen consisting of brentuximab vedotin, doxorubicin, vinblastine and dacarbazine that can be used in the treatment of Hodgkin lymphoma (HL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160564>	C63442|C186719	CEOP Regimen|CEOP|CEOP|Cyclophosphamide-Etoposide-Vincristine-Prednisone|Cyclophosphamide/Etoposide/Oncovin/Prednisone|Cyclophosphamide/Etoposide/Oncovin/Prednisone Regimen|Cyclophosphamide/Etoposide/Prednisone/Vincristine|Cyclophosphamide/Etoposide/Prednisone/Vincristine Regimen	A regimen consisting of cyclophosphamide, etoposide, vincristine and prednisone that can be used in the treatment of non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), and post-transplant lymphoproliferative disorders.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160565>	C63719|C63361	FLOT Regimen|Docetaxel/Fluorouracil/Leucovorin/Oxaliplatin|Docetaxel/Fluorouracil/Leucovorin/Oxaliplatin Regimen|FLOT|FLOT|FLOT|Fluorouracil-Leucovorin-Oxaliplatin/Docetaxel|Fluorouracil/Leucovorin/Oxaliplatin/Docetaxel|Fluorouracil/Leucovorin/Oxaliplatin/Taxotere|Fluorouracil/Leucovorin/Oxaliplatin/Taxotere Regimen	A regimen consisting of 5-fluorouracil, leucovorin, oxaliplatin and docetaxel that can be used in the treatment of gastric, esophageal and esophagogastric junction cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C160566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160566>	C63496	DCEP/Bortezomib Regimen|Bortezomib/Dexamethasone/Cyclophosphamide/Etoposide/Cisplatin|Bortezomib/Dexamethasone/Cyclophosphamide/Etoposide/Cisplatin Regimen|Bortezomib/Dexamethasone/Cyclophosphamide/Etoposide/Platinol Regimen|DCEP Plus Bortezomib|DCEP Plus Velcade|DCEP/Bortezomib|DCEP/Velcade|Velcade/Decadron/Cytoxan/VePesid/Platinol	A regimen consisting of bortezomib, dexamethasone, cyclophosphamide, etoposide, and cisplatin that can be used in the treatment of plasma cell (multiple) myeloma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160567>	C63442	R-CODOX-M Regimen|CODOX-M-R|Cyclophosphamide/Doxorubicin/Methotrexate/Rituximab/Vincristine|Cyclophosphamide/Doxorubicin/Methotrexate/Rituximab/Vincristine Regimen|R-CODOX-M|R-CODOX-M|R-CODOX-M (rituximab-abbs)|R-CODOX-M (rituximab-arrx)|R-CODOX-M (rituximab-blit)|R-CODOX-M (rituximab-pvvr)|R-CODOX-M (rituximab-rite)|R-CODOX-M (rituximab-rixa)|R-CODOX-M (rituximab-rixi)|Rituxan/Cytoxan/Oncovin/Adriamycin/Methotrexate|Rituximab-Cyclophosphamide-Vincristine-Doxorubicin-Methotrexate|Rituximab/Cyclophosphamide/Oncovin/Doxorubicin/Methotrexate|Rituximab/Cyclophosphamide/Oncovin/Doxorubicin/Methotrexate Regimen	A regimen consisting of cyclophosphamide, vincristine, doxorubicin and high-dose methotrexate (CODOX-M) and rituximab that can be used in the treatment of non-Hodgkin lymphoma (NHL), including Burkitt lymphoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160568>	C63442	R-GCVP Regimen|R-GCVP|R-GCVP|R-GCVP (rituximab-abbs)|R-GCVP (rituximab-arrx)|R-GCVP (rituximab-blit)|R-GCVP (rituximab-pvvr)|R-GCVP (rituximab-rite)|R-GCVP (rituximab-rixa)|R-GCVP (rituximab-rixi)|Rituxan-Gemzar-Cytoxan-Oncovin-Prednisolone|Rituximab-Gemcitabine-Cyclophosphamide-Vincristine-Prednisolone|Rituximab-Gemcitabine-Cyclophosphamide-Vincristine-Prednisolone Regimen	A regimen consisting of rituximab, gemcitabine, cyclophosphamide, vincristine, and prednisolone that can be used in the treatment of non-Hodgkin lymphoma (NHL) including the de novo treatment of diffuse large B-cell lymphoma (DLBCL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160569>	C63442	Dose-adjusted R-EPOCH Plus High-dose Methotrexate Regimen|DA-EPOCH-R/HD-M|DA-EPOCH-R/High-dose Methotrexate|DA-EPOCH-R/High-dose Methotrexate Regimen|DA-R-EPOCH Plus High-dose Methotrexate|DA-R-EPOCH Plus High-dose Methotrexate Regimen|DA-R-EPOCH/HD-M|Dose-adjusted Rituximab/Etoposide/Prednisone/Vincristine/Cyclophosphamide/Doxorubicin with High-dose Methotrexate	A regimen consisting of rituximab, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (R-EPOCH) in a dose-adjusted (DA) version with high dose methotrexate that can be used for the treatment of non-Hodgkin lymphoma (NHL).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C16056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16056>	C16048	Physical Map of the Human Genome|Physical Maps	A map of the locations of identifiable landmarks on DNA (for example, restriction enzyme cutting site, genes), regardless of inheritance. Distance is measured in base pairs. For the human genome, the lowest-resolution physical map is the banding patterns on the 24 different chromosomes, the highest-resolution map would be the complete nucleotide sequence of the chromosomes.			Intellectual Product	
C160570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160570>	C63442	R-CODOX-M Alternating with R-IVAC Regimen|R-CODOX-M Alternating With R-IVAC|R-CODOX-M/R-IVAC|R-CODOX-M/R-IVAC|R-CODOX-M/R-IVAC (rituximab-abbs)|R-CODOX-M/R-IVAC (rituximab-arrx)|R-CODOX-M/R-IVAC (rituximab-blit)|R-CODOX-M/R-IVAC (rituximab-pvvr)|R-CODOX-M/R-IVAC (rituximab-rite)|R-CODOX-M/R-IVAC (rituximab-rixa)|R-CODOX-M/R-IVAC (rituximab-rixi)|R-CODOX-M/R-IVAC Regimen|R-IVAC + R-CODOX-M|R-IVAC Alternating with R-CODOX-M|Rituximab/Cyclophosphamide/Oncovin/Doxorubicin/Methotrexate and Rituximab/Ifosfamide/VePesid/AraC Regimen|Rituximab/Cyclophosphamide/Vincristine/Doxorubicin/Methotrexate and Rituximab/Ifosfamide/Etoposide/Cytarabine	A regimen consisting of rituximab, cyclophosphamide, vincristine, doxorubicin and high-dose methotrexate (R-CODOX-M) alternating with rituximab, ifosfamide, etoposide and high-dose cytarabine (R-IVAC) that may be used in the treatment of non-Hodgkin lymphoma (NHL), including Burkitt lymphoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160571>	C177696	SDH Complex Gene Mutation Negative|Mitochondrial Complex II Gene Mutation Negative|Mitochondrial Respiratory Chain Complex II Gene Mutation Negative|No mutation detected|SDH Family Gene Mutation Negative|SDH Gene Mutation Negative|SDHA/B/C/D Mutation Negative|Succinate Dehydrogenase Gene Mutation Negative|Succinate-CoQ Reductase Gene Mutation Negative|Succinate-Coenzyme Q Reductase Gene Mutation Negative	A genetic finding indicating that SDH complex mutations have not been detected in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160572>	C165233	SDHA Negative|Flavoprotein Subunit of Complex II Negative|Fp Negative|Negative|SDH2 Negative|SDHF Negative|Succinate Dehydrogenase Complex Flavoprotein Subunit A Negative|Succinate Dehydrogenase [Ubiquinone] Flavoprotein Subunit, Mitochondrial Negative	An indication that expression of SDHA has not been detected in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160573>	C177692	SDHA Positive|Flavoprotein Subunit of Complex II Positive|Fp Positive|Positive|SDH2 Positive|SDHF Positive|Succinate Dehydrogenase Complex Flavoprotein Subunit A Positive|Succinate Dehydrogenase [Ubiquinone] Flavoprotein Subunit, Mitochondrial Positive	An indication that expression of SDHA has been detected in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160574>	C177692	SDHB Positive|IP Positive|Positive|SDH1 Positive|SDH2 Positive|SDHIP Positive|Succinate Dehydrogenase Complex Iron Sulfur Subunit B Positive|Succinate Dehydrogenase [Ubiquinone] Iron-Sulfur Subunit, Mitochondrial Positive	An indication that SDHB expression has been detected in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160575>	C27992	Potential for Malignancy|Malignancy Potential|Malignant Potential	Relating to the potential of a neoplasm to undergo malignant transformation.			Qualitative Concept	
C160576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160576>	C127812	Adjacent Tissue Transfer or Rearrangement|ATT/R|Adjacent Tissue Rearrangement|Adjacent Tissue Transfer|Adjacent Tissue Transfer/Rearrangement|Local Tissue Rearrangement	A reconstructive procedure that relocates a flap of healthy skin from a donor site to an adjacent laceration, scar, or other discontinuity. A portion of the flap is left intact to supply blood to the grafted area. Adjacent tissue transfer/rearrangement (ATT/R) may be for repair of traumatic skin wounds, lesion excision, or rearrangement/reconstruction of tissues.			Therapeutic or Preventive Procedure	
C160577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160577>	C158907	Specify BRAF Exons Assessed Question|Exons assessed|Specify BRAF Exons Assessed	A request to enter the BRAF exons assessed for mutations in this section of the form.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160578>	C158845	Specify IDH Family Mutation|Mutation identified, specify	A request to enter the specific IDH family mutations that were identified in the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160579>	C158845	Specify KIT Mutation|Mutation identified, specify	A request to enter the specific KIT mutations that were identified in the study.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C16057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16057>	C16056	Clone-Based Physical Map	A physical map based on an overlapping series of clones for the whole genome.			Intellectual Product	
C160580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160580>	C158845	Specify PDGFRA Mutation|Mutation identified, specify	A request to enter the specific PDGFRA mutations that were identified in the study.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160581>	C158845	Specify NF1 Mutation|Mutation identified, specify	A request to enter the specific NF1 mutations that were identified in the study.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160582>	C158845	Specify SDH Complex Mutation|Mutation identified, specify	A request to enter the specific SDH complex mutations that were identified in the study.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160583>	C158907	Specify KIT Exons Assessed Question|Exons assessed|KIT Exons Assessed|Specify KIT Exons Assessed	A request to enter the KIT exons assessed for mutations in this section of the form.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160584>	C158907	Specify PDGFRA Exons Assessed Question|Exons assessed|Specify PDGFRA Exons Assessed	A request to enter the PDGFRA exons assessed for mutations in this section of the form.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160585>	C190205|C131104	TERT Promoter Mutation|EST2 Promoter Mutation|Positive|TCS1 Promoter Mutation|TERT Gene Promoter Mutation|TP2 Promoter Mutation|TRT Promoter Mutation|Telomerase Reverse Transcriptase Gene Promoter Mutation	A molecular abnormality indicating mutation in the promoter region of the TERT gene.			Cell or Molecular Dysfunction	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C160586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160586>	C177687	TERT Promoter Mutation Negative|EST2 Promoter Mutation Negative|Negative|TCS1 Promoter Mutation Negative|TERT Gene Promoter Mutation Negative|TP2 Promoter Mutation Negative|TRT Promoter Mutation Negative|Telomerase Reverse Transcriptase Gene Promoter Mutation Negative	A genetic finding indicating that mutations in the promoter of the TERT gene have not been detected in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C160587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160587>	C46083	Executive Function Disorder|EFD|Executive Dysfunction|Executive Functioning Deficit|Impairment of Executive Functions	Cognitive, emotional, and behavioral difficulties that often occur in conjunction with frontal lobe disorders, including traumatic injury and dementia. It is also a feature of attention deficit disorder and other non-trauma-induced conditions.	Executive Function Disorder		Mental or Behavioral Dysfunction	CTRP Disease Terminology|CTRP Terminology
C160588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160588>	C160314	TP53 Mutation Analysis Was Not Performed|No	An indication that TP53 mutation analysis was not performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160589>	C160315	TP53 Mutation Analysis Was Performed|Yes	An indication that TP53 mutation analysis was performed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C16058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16058>	C15426	Recombinant Interval Database				Intellectual Product	
C160590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160590>	C159616	Was ALK Rearrangement Analysis Performed Question|ALK Rearrangement assessed|Was ALK Rearrangement Analysis Performed	A question asking if ALK rearrangements were analyzed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C160591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160591>	C159616	Was BRAF Rearrangement Analysis Performed Question|BRAF Rearrangement assessed|Was BRAF Rearrangement Analysis Performed	A question asking if BRAF rearrangements were analyzed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Terminology
C160592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160592>	C159616	Was PDGFRA Mutation Analysis Performed Question|PDGFRA Mutation Status assessed|Was PDGFRA Mutation Analysis Performed	A question asking if PDGFRA mutations were analyzed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160593>	C159616	Was RET Rearrangement Analysis Performed Question|RET Rearrangement assessed|Was RET Rearrangement Analysis Performed	A question asking if RET rearrangements were analyzed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C160594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160594>	C159616	Was ROS1 Rearrangement Analysis Performed Question|ROS1 Rearrangement assessed|Was ROS1 Rearrangement Analysis Performed	A question asking if ROS1 rearrangements were analyzed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C160595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160595>	C159616	Was EGFR Mutation Analysis Performed Question|EGFR Mutation Status assessed|Was EGFR Mutation Analysis Performed	A question asking if EGFR mutations were analyzed during the study.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C160596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160596>	C160289	Fluorescence In Situ Hybridization Was Performed|Yes	An indication that fluorescence in situ hybridization was performed during the study.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C160597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160597>	C160288	Fluorescence In Situ Hybridization Was Not Performed|No	An indication that fluorescence in situ hybridization was not performed during the study.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C160598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160598>	C160290	Not Known if Fluorescence In Situ Hybridization Was Performed|Unknown	An indication that it is not known whether fluorescence in situ hybridization was performed during the study.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C160599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160599>	C156746|C156073	Advanced Esophageal Carcinoma	An esophageal carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Esophageal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16059>	C16056	Sequence-Ready Map	A physical map of a genome that provides the necessary templates for large-scale sequencing. A sequence-ready map must meet the following criteria. (1) It must be composed of clones that are efficient sequencing templates. (2) It must be assembled using a method that examines the entire cloned insert such as restriction digest fingerprinting. (3) The contig must have sufficient depth to allow the validation of the selected clones in the face of restriction pattern inconsistencies. In addition, increased contig depth will allow the selection of a more efficient minimal tiling path. A uniform depth of 6- to 10-fold coverage is recommended. (4) For large-scale projects, as large a contig as possible should be constructed in advance of selecting the minimal tiling path to avoid future closure problems.			Intellectual Product	
C1605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1605>	C1971	Tecogalan Sodium|DS-4152|SP-PG|Sulfated Polysaccharide Tecogalan DS-4152	A sulfated polysaccharide isolated from various Arthrobacter bacterial species.  Possessing potential antiangiogenic and antineoplastic properties, tecogalan binds to basic fibroblast growth factor (bFGF), thereby preventing bFGF from binding to its receptors.  Disruption of this receptor binding results in the inhibition of bFGF-stimulated endothelial cell growth, proliferation, and migration. (NCI04)			Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160600>	C158612	Unknown Age When Started using Smokeless Tobacco after Regular Use Question|Unknown|Unknown Age When Started using Smokeless Tobacco after Regular Use	A request to indicate if the age an individual started using smokeless tobacco after six weeks regular use is unknown.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology
C160601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160601>	C160157	Evidence of Disease Present after Completion of Therapy|Yes	A response that evidence of disease was present after completion of therapy.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology
C160602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160602>	C160157	Evidence of Disease Absent after Completion of Therapy|No	A response that evidence of disease was not present after completion of therapy.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology
C160603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160603>	C2116	Camizestrant|AZ-14066724|AZD 9833|AZD-9833|AZD9833|CAMIZESTRANT|N-(1-(3-Fluoropropyl)-3-azetidinyl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo(4,3-f)isoquinolin-6-yl)-3-pyridinamine|SERD AZD9833|Selective Estrogen Receptor Degrader AZD9833	An orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon administration, camizestrant binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This prevents ER-mediated signaling and inhibits the growth and survival of ER-expressing cancer cells.	Camizestrant		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160604>	C160157	Evidence of Disease Unknown after Completion of Therapy|Unknown	A response that evidence of disease is unknown after completion of therapy.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology
C160605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160605>	C28227|C128057|C128037	Reozalimab|Anti-PD-1/Anti-PD-L1 Bispecific Antibody LY3434172|Anti-PD-1/PD-L1 Bispecific Antibody LY3434172|Bispecific Antibody LY3434172|LY 3434172|LY-3434172|LY3434172|REOZALIMAB	A bispecific antibody targeting both the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and its ligand, human programmed death-ligand 1 (PD-L1; CD274), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, reozalimab simultaneously targets and binds to PD-1, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes in the tumor microenvironment (TME), and PD-L1 expressed on tumor cells. This prevents PD-L1 from binding to and activating its receptor PD-1 and inhibits the PD-L1/PD-1-mediated downregulation of T-cell activation and proliferation. This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion.	Reozalimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160606>	C1946|C129825	Bocodepsin Besylate|BOCODEPSIN BESYLATE|Class 1/4 Histone Deacetylase Inhibitor OKI-179|Class-1/4 HDACi OKI-179|HDAC Inhibitor OKI-179|HDAC1/4i OKI-179|HDACi 1/4 OKI-179|HDACi OKI-179|OKI 179|OKI-179|OKI179	The besylate form of bocodepsin, an orally bioavailable inhibitor of the histone deacetylase (HDAC) subtypes 1 and 4, with potential antineoplastic activity. Upon administration,bocodepsin targets, binds to and inhibits the activity of HDAC1/4. This results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. This consequently results in a selective transcription of tumor suppressor genes, tumor suppressor protein-mediated inhibition of tumor cell division and an induction of apoptosis in tumor cells that overexpress HDAC1/4. HDAC, which is upregulated in many tumor cell types, deacetylates chromatin histone proteins and plays a key role in transcriptional regulation and cell cycle progression.	Bocodepsin Besylate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160607>	C160608	Bulbar Urethra|Bulbar Portion of the Urethra	The portion of the penile urethra that spans the bulb of the penis.			Body Part, Organ, or Organ Component	
C160608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160608>	C13035	Urethra Part	A named segment of the urethra.			Body Part, Organ, or Organ Component	
C160609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160609>	C160157	Surgical Procedure was Curative Therapy|Surgery	A response that a surgical procedure was the curative therapy.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology
C16060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16060>	C16056	Single Nucleotide Polymorphism Map|SNP Map	A diagram of a gene or genome showing the location of known single nucleotide polymorphisms.			Intellectual Product	
C160610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160610>	C160157	Non-Concurrent Chemotherapy was Curative Therapy|Chemotherapy (not given concurrently)	A response that non-concurrent chemotherapy was the curative therapy.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology
C160611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160611>	C160157	Concurrent Chemotherapy was Curative Therapy|Concurrent Chemotherapy	A response that concurrent chemotherapy was the curative therapy.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology
C160612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160612>	C160157	Radiation Therapy was Curative Therapy|Definitive|Radiation	A response that radiation therapy was the curative therapy.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C160613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160613>	C13035	Ureter Part	A named segment of the ureter.			Body Part, Organ, or Organ Component	
C160614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160614>	C160613	Upper Ureter	The segment of the ureter that extends from the renal pelvis to the upper border of the sacrum.			Body Part, Organ, or Organ Component	
C160615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160615>	C160613	Middle Ureter	The segment of the ureter that extends between the upper to lower borders of the sacrum.			Body Part, Organ, or Organ Component	
C160616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160616>	C160613	Distal Ureter	The segment of the ureter that extends from the lower border of the sacrum to the bladder.			Body Part, Organ, or Organ Component	
C160617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160617>	C160613	Abdominal Ureter	The segment of the ureter that extends from the renal pelvis to the iliac vessels.			Body Part, Organ, or Organ Component	
C160618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160618>	C160613	Pelvic Ureter	The segment of the ureter that extends from the iliac vessels to the bladder.			Body Part, Organ, or Organ Component	
C160619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160619>	C8403|C150526	Recurrent Malignant Ovarian Granulosa Cell Tumor	The reemergence of malignant ovarian granulosa cell tumor after a period of remission.	Recurrent Malignant Ovarian Granulosa Cell Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16061>	C16056	Whitehead Map of the Human Genome	Comprehensive maps integrating genetic, physical, STS, EST and radiation hybrid data.			Intellectual Product	
C160620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160620>	C160157	Tumor Reoccurrence Present After Initial Treatment|Yes	A response that the tumor reoccurrence was present after the initial treatment.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Terminology
C160621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160621>	C28676|C201557	Allogeneic CD34+-enriched and CD45RA-depleted PBSCs|Allogeneic Tn-depleted CD34-preserved PBSCs|Allogeneic TnD- CD34+ PBSCs|Donor-derived Tn Cell Depleted CD34-enriched PBSCs|Naive T-cell Depleted CD34+ Allogeneic Peripheral Blood Stem Cells	A preparation of donor-derived peripheral blood stem cells (PBSCs) that have been enriched with CD34-positive stem cells and have been depleted of CD45RA-positive cells, that can potentially be used for immune reconstitution purposes. CD45RA depletion results in a cellular product that contains a high amount of memory T-cells (Tm). Upon infusion of the allogeneic CD34+-enriched and CD45RA-depleted PBSCs after a hematopoietic cell transplantation (HCT), these cells provide Tm recovery and are able to prevent viral infections. The depletion of the CD45RA-positive cells reduces the risk of graft-versus-host disease (GvHD) upon infusion. CD45RA is expressed on naive T-cells (Tn), whereas Tm cells are CD45RA-negative. Tn cells have the potential to induce more severe GvHD than Tm cells.	Allogeneic CD34+-enriched and CD45RA-depleted PBSCs		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C160622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160622>	C160157	Tumor Reoccurrence Absent After Initial Treatment|No	A response that tumor reoccurrence was not present after the initial treatment.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Terminology
C160623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160623>	C160157	Tumor Reoccurrence Unknown After Initial Treatment|Unknown	A response that tumor reoccurrence status was unknown after the initial treatment.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Terminology
C160624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160624>	C93317	TRAM Flap Procedure|TRAM Flap|Transverse Rectus Abdominis Myocutaneous Flap	A grafting procedure where a piece of tissue, including skin, fat, and all or part of the underlying transverse rectus abdominis muscle are used for breast reconstruction.			Therapeutic or Preventive Procedure	
C160625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160625>	C93317	Latissimus Dorsi Flap Reconstruction|Latissimus Dorsi Flap	A grafting procedure where an oval flap of skin, fat, muscle, and blood vessels from your upper back (latissimus dorsi muscle) is used for breast reconstruction.			Therapeutic or Preventive Procedure	
C160626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160626>	C28676|C201557	Allogeneic CD34-positive Enriched Peripheral Blood Stem Cells|Allogeneic CD34+ PBSCs|Allogeneic CD34+-enriched Peripheral Blood Stem Cells|Donor-derived CD34-positive PBSCs	A preparation of allogeneic CD34+ selected peripheral blood stem cells (PBSCs) that can potentially be used for immune reconstitution purposes. Upon administration of the allogeneic CD34-positive enriched PBSCs after a hematopoietic cell transplantation (HCT), these cells may provide memory T-cell (Tm) recovery and potentially prevent viral infections. They potentially reduce the occurrence of graft-versus-host disease (GvHD) without increasing the risk of graft failure or poor graft function.	Allogeneic CD34-positive Enriched Peripheral Blood Stem Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C160627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160627>	C15354	Tissue Expander-Implant Breast Reconstruction|Implant Surgery after Expanders|Tissue Expander Followed by Implant	A method of breast reconstruction. During the mastectomy procedure a tissue expander is implanted beneath the chest wall muscle. Over a period or weeks or months the volume of the implant is increased, causing the overlying muscle and skin to stretch. Later, the expander is removed and replaced by a permanent breast implant.	Tissue Expander-Implant Breast Reconstruction		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C160628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160628>	C20189	Permanent|Permanence	Continuing or enduring over time, without fundamental or marked change.			Conceptual Entity	
C160629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160629>	C173812|C158612	Was Radiation Administered as an Additional Treatment for a New Tumor Event Question|Additional Treatment for New Tumor Event Radiation Therapy|Was Radiation Administered as an Additional Treatment for a New Tumor Event	A question whether radiation was administered as an additional treatment for a new tumor event.			Intellectual Product	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C16062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16062>	C15426	Electronic Tracking Database		Electronic Tracking Database		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C160630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160630>	C173812|C158612	Was Chemotherapy Administered as an Additional Treatment for a New Tumor Event Question|Additional Treatment for New Tumor Event Chemotherapy|Was Chemotherapy Administered as an Additional Treatment for a New Tumor Event	A question whether chemotherapy was administered as an additional treatment for a new tumor event.			Intellectual Product	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160631>	C173812|C158612	Was Immunotherapy Administered as an Additional Treatment for a New Tumor Event Question|Additional Treatment for New Tumor Event Immunotherapy|Was Immunotherapy Administered as an Additional Treatment for a New Tumor Event	A question whether immunotherapy was administered as an additional treatment for a new tumor event.			Intellectual Product	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160632>	C173812|C158612	Was Hormone Therapy Administered as an Additional Treatment for a New Tumor Event Question|Additional Treatment for New Tumor Event Hormone Therapy|Additional Treatment for New Tumor Event Hormone Therapy Question|Was Hormone Therapy Administered as an Additional Treatment for a New Tumor Event	A question about whether hormone therapy was administered as an additional treatment for a new tumor event.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Terminology
C160633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160633>	C173812|C158612	Was Targeted Molecular Therapy Administered as an Additional Treatment for a New Tumor Event Question|Additional Treatment for New Tumor Event Targeted Molecular Therapy|Was Targeted Molecular Therapy Administered as an Additional Treatment for a New Tumor Event	A question whether targeted molecular therapy was administered as an additional treatment for a new tumor event.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160634>	C160157	Radiation Was Administered as an Additional Treatment for a New Tumor Event|Yes	A response that radiation was administered as an additional treatment for a new tumor event.			Intellectual Product	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160635>	C160157	Radiation Was Not Administered as an Additional Treatment for a New Tumor Event|No	A response that radiation was not administered as an additional treatment for a new tumor event.			Intellectual Product	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160636>	C160157	Unknown if Radiation Was Administered as an Additional Treatment for a New Tumor Event|Unknown	A response that indicates it is unknown if radiation was administered as an additional treatment for a new tumor event.			Intellectual Product	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160637>	C160157	Chemotherapy Was Administered as an Additional Treatment for a New Tumor Event|Yes	A response that chemotherapy was administered as an additional treatment for a new tumor event.			Intellectual Product	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160638>	C160157	Chemotherapy Was Not Administered as an Additional Treatment for a New Tumor Event|No	A response that chemotherapy was not administered as an additional treatment for a new tumor event.			Intellectual Product	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160639>	C160157	Unknown if Chemotherapy Was Administered as an Additional Treatment for a New Tumor Event|Unknown	A response that indicates it is unknown if chemotherapy was administered as an additional treatment for a new tumor event.			Intellectual Product	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C16063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16063>	C16847	Modeling	The use of statistical analysis, computer analysis, or model organisms to predict outcomes of research. (doegenomes.org)			Research Activity	
C160640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160640>	C160157	Immunotherapy Was Administered as an Additional Treatment for a New Tumor Event|Yes	A response that immunotherapy was administered as an additional treatment for a new tumor event.			Intellectual Product	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160641>	C160157	Immunotherapy Was Not Administered as an Additional Treatment for a New Tumor Event|No	A response that immunotherapy was not administered as an additional treatment for a new tumor event.			Intellectual Product	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160642>	C160157	Unknown if Immunotherapy Was Administered as an Additional Treatment for a New Tumor Event|Unknown	A response that indicates it is unknown if immunotherapy was administered as an additional treatment for a new tumor event.			Intellectual Product	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160643>	C160157	Hormone Therapy Was Administered as an Additional Treatment for a New Tumor Event|Yes	A response that hormone therapy was administered as an additional treatment for a new tumor event.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Terminology
C160644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160644>	C160157	Hormone Therapy Was Not Administered as an Additional Treatment for a New Tumor Event|No	A response that hormone therapy was not administered as an additional treatment for a new tumor event.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Terminology
C160645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160645>	C160157	Unknown if Hormone Therapy Was Administered as an Additional Treatment for a New Tumor Event|Unknown	A response that it was unknown if hormone therapy was administered as an additional treatment for a new tumor event.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Terminology
C160646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160646>	C160157	Targeted Molecular Therapy Was Administered as an Additional Treatment for a New Tumor Event|Yes	A response that targeted molecular therapy was administered as an additional treatment for a new tumor event.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160647>	C160157	Targeted Molecular Therapy Was Not Administered as an Additional Treatment for a New Tumor Event|No	A response that targeted molecular therapy was not administered as an additional treatment for a new tumor event.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160648>	C160157	Unknown if Targeted Molecular Therapy Was Administered as an Additional Treatment for a New Tumor Event|Unknown	A response that indicates it is unknown if targeted molecular therapy was administered as an additional treatment for a new tumor event.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Head and Neck Squamous Cell Carcinoma Follow-Up Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Follow-Up Form|CPTAC Melanoma Follow-Up Form|CPTAC Pancreatic Ductal Adenocarcinoma Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C160649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160649>	C219644	IDH1 NM_005896.3:c.394_395delinsGT|IDH c.394_395CG>GT|IDH c.394_395delCGinsGT|IDH1 NM_005896.3:c.394_395CG>GT|IDH1 NM_005896.3:c.394_395delCGinsGT|IDH1 NM_005896.3:c.394_395delCGinsGT|IDH1 c.394_395CG>GT|IDH1 c.394_395delCGinsGT|Isocitrate Dehydrogenase 1 (NADP(+)), Cytosolic c.394_395CG>GT|Isocitrate Dehydrogenase 1 (NADP+), Soluble c.394_395delCGinsGT|NM_005896.3:c.394_395CG>GT|NM_005896.3:c.394_395delCGinsGT|NM_005896.3:c.394_395delinsGT	A complex substitution where the nucleotide sequence at positions 394 and 395 of the coding sequence of the IDH1 gene has changed from cytosine-guanine to guanine-thymine.	IDH1 NM_005896.3:c.394_395delCGinsGT		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C16064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16064>	C53344	Cancer Burden|National Cancer Burden	A measure of the incidence of cancer within the population and an estimate of the financial, emotional, or social impact it creates. The burden of disease is not borne equally by all population groups in the United State.			Quantitative Concept	
C160650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160650>	C117280	IDH1 NP_005887.2:p.R132V|Cytosolic NADP-Isocitrate Dehydrogenase Protein Arg132Val|Cytosolic NADP-Isocitrate Dehydrogenase Protein R132V|IDH1 Arg132Val|IDH1 NP_005887.2:p.Arg132Val|IDH1 R132V|IDH1 R132V Mutation|IDH1 p.Arg132Val|IDH1 p.R132V|Isocitrate Dehydrogenase [NADP] Cytoplasmic Arg132Val|Isocitrate Dehydrogenase [NADP] Cytoplasmic R132V|NP_005887.2:p.Arg132Val|NP_005887.2:p.R132V	A change in the amino acid residue at position 132 in the isocitrate dehydrogenase [NADP] cytoplasmic protein where arginine has been replaced by valine.	IDH1 NP_005887.2:p.R132V		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160651>	C219645	IDH2 NM_002168.3:c.418C>T|IDH c.418C>T|IDH2 c.418C>T|Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial c.418C>T|Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial c.418C>T|NM_002168.3:c.418C>T	A nucleotide substitution at position 418 of the coding sequence of the IDH2 gene where cytosine has been mutated to thymine.	IDH2 NM_002168.3:c.418C>T		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160652>	C117281	IDH2 NP_002159.2:p.R140W|IDH2 Arg140Trp|IDH2 NP_002159.2:p.Arg140Trp|IDH2 R140W|IDH2 R140W Mutation|IDH2 p.Arg140Trp|IDH2 p.R140W|Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial Arg140Trp|Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial R140W|Isocitrate Dehydrogenase [NADP], Mitochondrial Arg140Trp|Isocitrate Dehydrogenase [NADP], Mitochondrial R140W|NP_002159.2:p.Arg140Trp|NP_002159.2:p.R140W	A change in the amino acid residue at position 140 in the isocitrate dehydrogenase [NADP], mitochondrial protein where arginine has been replaced by tryptophan.	IDH2 NP_002159.2:p.R140W		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160653>	C19987	Oligoprogression|Oligoprogressive	Disease progression at a limited number of anatomic sites, in the context of stable disease at other anatomic sites.	Oligoprogression		Classification	CTRP Disease Terminology|CTRP Terminology
C160654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160654>	C219645	IDH2 NM_002168.3:c.419G>T|IDH c.419G>T|IDH2 c.419G>T|Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial c.419G>T|Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial c.419G>T|NM_002168.3:c.419G>T	A nucleotide substitution at position 419 of the coding sequence of the IDH2 gene where guanine has been mutated to thymine.	IDH2 NM_002168.3:c.419G>T		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160655>	C117281	IDH2 NP_002159.2:p.R140L|IDH2 Arg140Leu|IDH2 NP_002159.2:p.Arg140Leu|IDH2 R140L|IDH2 R140L Mutation|IDH2 p.Arg140Leu|IDH2 p.R140L|Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial Arg140Leu|Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial R140L|Isocitrate Dehydrogenase [NADP], Mitochondrial Arg140Leu|Isocitrate Dehydrogenase [NADP], Mitochondrial R140L|NP_002159.2:p.Arg140Leu|NP_002159.2:p.R140L	A change in the amino acid residue at position 140 in the isocitrate dehydrogenase [NADP], mitochondrial protein where arginine has been replaced by leucine.	IDH2 NP_002159.2:p.R140L		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160656>	C19697	Archival Tissue	Tissue stored in a biospecimen repository for future study use.			Tissue	
C160658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160658>	C16279	Plutonium-239 Alpha Particle Radiation	Alpha rays produced by the decay of plutonium-239.			Natural Phenomenon or Process	Cellosaurus Resistance and Transformant Physical Factor Terminology
C160659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160659>	C219645|C172344	IDH2 NM_002168.3:c.419G>A|IDH c.419G>A|IDH2 c.419G>A|Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial c.419G>A|Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial c.419G>A|NM_002168.3:c.419G>A	A nucleotide substitution at position 419 of the coding sequence of the IDH2 gene where guanine has been mutated to adenine.	IDH2 NM_002168.3:c.419G>A		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C16065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16065>	C20161	Cancer Surveillance Research Program|CSRP|Surveillance Research Program	The Surveillance Research Program (SRP) directs a program of cancer surveillance involving the collection and analysis of pertinent data in order to answer key questions about cancer incidence, morbidity, mortality, and cancer-related health status in diverse regions and in general and specific populations of the U.S. defined by sociodemographic measures.			Research Activity	
C160660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160660>	C16279	Americium-241 Alpha Particle Radiation	Alpha rays produced by the decay of americium-241.			Natural Phenomenon or Process	
C160661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160661>	C117281	IDH2 NP_002159.2:p.R140Q|IDH2 Arg140Gln|IDH2 NP_002159.2:p.Arg140Gln|IDH2 R140Q|IDH2 R140Q Mutation|IDH2 p.Arg140Gln|IDH2 p.R140Q|Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial Arg140Gln|Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial R140Q|Isocitrate Dehydrogenase [NADP], Mitochondrial Arg140Gln|Isocitrate Dehydrogenase [NADP], Mitochondrial R140Q|NP_002159.2:p.Arg140Gln|NP_002159.2:p.R140Q	A change in the amino acid residue at position 140 in the isocitrate dehydrogenase [NADP], mitochondrial protein where arginine has been replaced by glutamine.	IDH2 NP_002159.2:p.R140Q		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160662>	C84392|C53543	Intellectual Developmental Disorder, Autosomal Dominant 28|ADNP Syndrome|Autosomal Dominant Mental Retardation 28|HVDAS|Helsmoortel-Van Der AA Syndrome|MRD28|Mental Retardation, Autosomal Dominant 28	An autosomal dominant condition caused by mutation(s) in the ADNP gene, encoding activity-dependent neuroprotector homeobox protein. It is characterized by impaired intellectual development, motor delay, autism spectrum disorder, facial dysmorphisms, hypotonia, congenital heart disease, visual difficulties, and gastrointestinal issues.			Disease or Syndrome	Cellosaurus Disease Terminology
C160663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160663>	C219645|C172344	IDH2 NM_002168.3:c.516G>C|IDH c.516G>C|IDH2 c.516G>C|Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial c.516G>C|Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial c.516G>C|NM_002168.3:c.516G>C	A nucleotide substitution at position 516 of the coding sequence of the IDH2 gene where guanine has been mutated to cytosine.	IDH2 NM_002168.3:c.516G>C		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160664>	C219645|C172344	IDH2 NM_002168.3:c.516G>T|IDH c.516G>T|IDH2 c.516G>T|Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial c.516G>T|Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial c.516G>T|NM_002168.3:c.516G>T	A nucleotide substitution at position 516 of the coding sequence of the IDH2 gene where guanine has been mutated to thymine.	IDH2 NM_002168.3:c.516G>T		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160665>	C117282	IDH2 NP_002159.2:p.R172S|IDH2 Arg172Ser|IDH2 NP_002159.2:p.Arg172Ser|IDH2 R172S|IDH2 R172S Mutation|IDH2 p.Arg172Ser|IDH2 p.R172S|Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial Arg172Ser|Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial R172S|Isocitrate Dehydrogenase [NADP], Mitochondrial Arg172Ser|Isocitrate Dehydrogenase [NADP], Mitochondrial R172S|NP_002159.2:p.Arg172Ser|NP_002159.2:p.R172S	A change in the amino acid residue at position 172 in the isocitrate dehydrogenase [NADP], mitochondrial protein where arginine has been replaced by serine.	IDH2 NP_002159.2:p.R172S		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160666>	C4819	Hematologic Malignancy-Associated Skin Squamous Cell Carcinoma|HMCSCC|Hematologic Malignancy-Associated Cutaneous Squamous Cell Carcinoma	A squamous cell carcinoma that arises from the skin in a patient with a history of hematologic malignancy, usually non-Hodgkin lymphoma or chronic lymphocytic leukemia.	Hematologic Malignancy-Associated Skin Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160667>	C160157	Melanoma and Non-Melanoma Related Event Occurred after Initial Treatment|Yes- Melanoma & Non-Melanoma Related	A response that a melanoma and non-melanoma related only event occurred after the initial treatment.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Terminology
C160668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160668>	C158612	Was Additional Pharmaceutical Treatment for New Tumor Event Administered Question|Was Additional Pharmaceutical Treatment for New Tumor Event Administered	A request to indicate if there was additional pharmaceutical treatment for new tumor event administered.			Intellectual Product	
C160669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160669>	C158612	Classified by FAB Only Question|Classified by FAB Only|Classified by FAB Only	A request to indicate if the bone marrow was classified by the French-American-British (FAB) method only.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C16066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16066>	C43433	Mortality Map	A visual representation of the national cancer burden.  These maps display cancer mortality data by county and state economic regions across the country.  They are color coded to distinguish between regions with high, intermediate, and low rates of cancer mortality.			Intellectual Product	
C160670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160670>	C158612	Select One Tumor Site Question|Select One|Select One Tumor Site	A direction to select one of the listed tumor sites.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Terminology
C160671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160671>	C160157	Current Hormonal Contraceptive User|Current User|Current User	The individual is a current user of hormonal contraceptives.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C160672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160672>	C160157	Former Hormonal Contraceptive User|Former User|Former User	The individual is a former user of hormonal contraceptives.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C160673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160673>	C160157	Never Used Hormonal Contraceptives|Never Used|Never Used	The individual has never used of hormonal contraceptives.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C160674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160674>	C160157	Unknown Use of Hormonal Contraceptives|Unknown: Could not be determined or unsure	The individual's use of hormonal contraceptives is unknown.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C160675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160675>	C160157	Human Immunodeficiency Virus Unknown|Unknown: Could not be determined or unsure	Indicates that human immunodeficiency virus status of a sample is unknown.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C160676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160676>	C160157	Specify Other Histologic Type|If Other, Specify	A directive to specify the other histologic type.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Brain Lower Grade Glioma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C160677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160677>	C181040	Number of Days from Date of Collection to Date of Last Contact	The number of days from the date of collection of the specimen to the date of last contact.			Clinical Attribute	CPTAC Follow-Up Forms Terminology|CPTAC Follow-Up Form|CPTAC Terminology
C160678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160678>	C157151	Chemical/Occupational Exposure History Unknown|Unknown	An indication that a history of chemical/occupational exposures is unknown.			Clinical Attribute	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C160679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160679>	C19747	Hyperspectral Camera System|HCS|Hyperspectral Imaging System|Quest Hyperspectral Imaging System	A proprietary imaging system that combines three sensors for spectral imaging. For 2D reference, and to facilitate annotating the data, a high resolution (full HD) color image, recorded with an RGB-sensor, is included with each hyperspectral dataset.	Hyperspectral Camera System		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C16067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16067>	C16199	Black/White Cancer Survival Study|BWCSS|Black/White Cancer Study	A study designed to investigate the significance of social, behavioral, lifestyle, biological, treatment, and health care factors in relation to the observed differences in cancer survival between African-Americans and white Americans. Data was collected on more than 3,400 patients, focusing on cancers of the breast, colon, uterus, and bladder.			Research Activity	
C160680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160680>	C160157	Family History of Stomach Cancer Unknown|Unknown: Could not be determined or unsure	There is an unknown family history of stomach cancer.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C160681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160681>	C160157	New Disease is Multifocal|Yes	A response that the new disease is multifocal.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology
C160682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160682>	C160157	New Disease is not Multifocal|No	A response that the new disease is not multifocal.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology
C160683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160683>	C160157	Unknown if New Disease is Multifocal|Unknown	It is unknown if the new disease is multifocal.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Sarcoma Follow-Up Form|CPTAC Terminology
C160684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160684>	C360|C1742	Tetrathiomolybdate|CCRIS 9412|Molybdate(2-), Tetrathioxo-, (T-4)- (9CI)|TIOMOLIBDATE ION|TM|Tetrathioxomolybdate(2-)	An orally bioavailable metal copper (Cu) chelator, with potential antiangiogenic, anti-metastatic and antitumor activities. Upon oral administration, tetrathiomolybdate (TM) targets and binds to copper and food protein in the gastrointestinal (GI) tract, thereby forming stable complexes and preventing copper uptake and reabsorption. Additionally, absorbed free TM targets and binds to copper and serum albumin in the bloodstream. This depletes systemic copper reserves and deprives the tumor microenvironment (TME) from copper. Chelation of copper by TM downregulates the expression of angiogenic factors of which copper is a cofactor, such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and prevents the production of nuclear factor-kappa B (NF-kB). Copper deprivation also inhibits the activity and levels of copper-dependent angiogenic enzymes, such as vascular endothelial growth factor receptor (VEGFR). This modulates the activity of VEGFR-positive endothelial progenitor cells (EPCs) that are necessary for metastasis. EPC deficiency results in the inhibition of angiogenesis and prevents metastasis. TM also inhibits the activities of other copper-containing metalloenzymes, including superoxide dismutase 1 (SOD1) in endothelial cells, cytochrome C oxidase, vascular adhesion protein-1 (VAP-1), antioxidant 1 copper chaperone (ATOX-1) and matrix metalloproteinase 9 (MMP-9). Inhibition of these enzymes interferes with the activation of several signal transduction pathways required for cellular proliferation and angiogenesis. TM also inhibits the activity and levels of lysyl oxidase-like 2 (LOXL2; lysyl oxidase homolog 2), a copper dependent amine oxidase that is critical for modeling the pre-metastatic niche and promotes metastasis, tumor cell migration and invasiveness. In addition, copper depletion also attenuates the activation of host cells within the tumor microenvironment including cancer-associated fibroblasts (CAFs), modulates tumor associated macrophages (TAMs) and promotes cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses.	Tetrathiomolybdate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C160685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160685>	C60663	Tumor Invasion of the Mucosa|Mucosal Invasion	A finding indicating that a neoplastic cellular infiltrate has broken the basement membrane and invaded the lamina propria.			Finding	
C160686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160686>	C45412	YES Portal|YES|Young, Empowered, and Strong|Young, Empowered, and Strong (YES)	A web-based research intervention tool designed to collect and assess participants' toxicities and symptoms, as well as informational needs in between visits with their clinician.	YES Portal		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C160687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160687>	C62439	Seventy Five|75|Seventy-Five	A natural number greater than seventy-four and less than seventy-six and the quantity that it denotes.			Quantitative Concept	
C160688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160688>	C160157	Additional Pharmacotherapy for New Tumor Event Absent				Intellectual Product	
C160689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160689>	C160157	Additional Pharmacotherapy for New Tumor Event Received				Intellectual Product	
C16068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16068>	C213308	Cancer Surveillance Project	Surveillance projects which focus on issues of cancer			Research Activity	
C160690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160690>	C160157	Additional Pharmacotherapy for New Tumor Event Unknown				Intellectual Product	
C160691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160691>	C471	Lenumlostat|GB 2064|GB-2064|GB2064|LENUMLOSTAT|LOXL2 Inhibitor GB2064|Lysyl Oxidase-like Protein 2 Inhibitor PAT-1251|PAT 1251|PAT-1251|PAT1251	An orally available, small-molecule, irreversible inhibitor of lysyl oxidase homolog 2 (lysyl oxidase-like protein 2; LOXL2) with potential antifibrotic activity. Upon oral administration, the aminomethyl pyridine moiety of lenumlostat interacts with the active site of LOXL2 to form a pseudo-irreversible inhibitory complex, thereby inhibiting the catalytic activity of LOXL2. LOXL2, a secreted glycoprotein, catalyzes the post-translational oxidative deamination of lysine residues on target proteins, including collagen and elastin, leading to the formation of deaminated lysine (allysine). Condensation with other allysines or lysines drives the formation of inter- and intramolecular cross-linkages that impact remodeling of the extracellular matrix (ECM), potentially leading to fibrosis. Inhibition of LOXL2, which is often upregulated in fibrotic tissue, may reduce fibrosis in certain chronic fibrotic diseases.	Lenumlostat		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160692>	C209927	Tumor Invasion of the Prostatic Ducts and Acini	A morphologic finding indicating the presence of a malignant cellular infiltrate invading the ductal and acinar structures of the prostate gland.			Finding	
C160693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160693>	C209922	Indeterminate Extranodal Tumor Extension|Indeterminate	An indication that the extranodal tumor extension is undetermined.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C160694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160694>	C209922	Indeterminate Lymphovascular Invasion|Indeterminate	An indication that the lymphatic invasion in a specimen is indeterminate.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160695>	C209922	Indeterminate Perineural Invasion|Indeterminate	An indication that the perineural invasion in a specimen is indeterminate.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Terminology
C160696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160696>	C209922	Indeterminate Tumor Regression|Indeterminate	An indication that the tumor regression is indeterminate.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C160697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160697>	C160157	Indeterminate Ulceration|Indeterminate	A result that determining if ulceration exists is not possible.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C160698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160698>	C160157	Multiple Known Primary Tumors Present at Initial Melanoma Diagnosis|Yes	A response that multiple known primary tumors were present at the initial melanoma diagnosis.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C160699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160699>	C160157	Multiple Known Primary Tumors Absent at Initial Melanoma Diagnosis|No	A response that multiple known primary tumors were absent at the initial melanoma diagnosis.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C16069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16069>	C15790	Breast Cancer Prevention Trial|BCPT	Part of the National Surgical Adjuvant Breast and Bowel Project, the Breast Cancer Prevention Trial (BCPT) was a clinical trial designed to see whether taking the drug tamoxifen would prevent breast cancer in women who are at an increased risk of developing the disease. The BCPT also looked at whether taking tamoxifen would decrease the number of heart attacks and reduce the number of bone fractures in these women. The study began recruiting participants in April 1992 and closed enrollment in September 1997.			Research Activity	
C1606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1606>	C2140	Labradimil|Cereport|DRG-0182|L-Prolinamide, L-Arginyl-L-prolyl-trans-4- hydroxy-L-prolyl-3-(2- thienyl)-L-alanylglycl -L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1- -carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-, (S-(R*,R*))|LABRADIMIL|Lobradimil|RMP-7|lobradimil	A synthetic analog of bradykinin.  Lobradimil is a potent, specific bradykinin B-2 receptor agonist that stimulates B-2 receptors expressed on the surface of brain capillary endothelial cells, thereby reversibly increasing the permeability of the blood-brain barrier (BBB).  Compared to bradykinin, this agent possesses enhanced receptor selectivity, greater plasma stability, and a longer half-life. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C160700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160700>	C160157	Multiple Known Primary Tumors Unknown at Initial Melanoma Diagnosis|Unknown	A response that multiple known primary tumors were unknown at the initial melanoma diagnosis.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C160701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160701>	C160157	Unknown Clark Level|Unknown	A finding of an unknown Clark level.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C160702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160702>	C160157	Tumor Necrosis Not Identified|Not Identified	A response that tumor necrosis has not been identified.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C160703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160703>	C160157	Tumor Necrosis Present|Present				Intellectual Product	
C160704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160704>	C200766|C176023	Autologous Anti-BCMA CAR T-cells IM21|Autologous BCMA-specific CAR T-cells IM21|IM21 CAR T-cells	A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector (LV) expressing a chimeric antigen receptor (CAR) targeting the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and containing, as of yet undisclosed costimulatory signaling domains, with potential antineoplastic activity. Upon administration, the autologous anti-BCMA CAR T-cells IM21 recognize and induce selective toxicity against BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and is overexpressed on malignant plasma cells.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160705>	C160157	Margin Status Cannot be Assessed|Cannot be assessed	A result that the margin status cannot be assessed.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C160706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160706>	C1946|C129825	HDAC Class I/IIb Inhibitor HG146|Class I/IIb HDACi HG146|HDAC I/IIb Selective Inhibitor HG146|HG 146|HG-146|HG0146|HG146|HG280146|HG280146-P1	An orally available inhibitor of histone deacetylase (HDAC) classes I and IIb with potential antineoplastic activities. Upon oral administration, HDAC I/IIb inhibitor HG146 selectively inhibits the catalytic activity of class I and IIb HDACs, which results in an accumulation of highly acetylated chromatin histones, the induction of chromatin remodeling and an altered pattern of gene expression. This leads to the inhibition of tumor oncogene transcription, and the selective transcription of tumor suppressor genes, which inhibits tumor cell division and induces tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins. Class I HDACs are located in the nucleus and include HDACs 1, 2, 3, and 8; class IIb HDACs include HDAC 6 and 10 and are located in both the nucleus and the cytoplasm.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160707>	C160157	Ulceration is Present|Present	A result that ulceration is present			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C160708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160708>	C160157	Ulceration is Absent|Absent	A result that ulceration is absent			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C160709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160709>	C160157	No Pathologic Findings Identified|None Identified	A response that no pathologic findings were identified.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C16070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16070>	C15790	Prostate Cancer Prevention Trial|PCPT	A phase III, randomized, placebo-controlled cancer prevention trial of >18,000 men coordinated by the Southwest Oncology Group.  The trial will determine the effect of a daily dose of finasteride taken for seven years on the biopsy-proven prevalence of prostate cancer.  It is scheduled to be completed in 2004.			Research Activity	
C160710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160710>	C160157	Other Pathologic Findings|Other	A response that indicates pathologic findings were present other than those on the form.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C160711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160711>	C200766	Autologous Anti-CS1 Hinge-optimized CAR-4-1BB-EGFRt-expressing Memory-enriched T-cells|Anti-CS1 Hinge-optimized CAR-4-1BB-EGFRt-expressing Memory-enriched Autologous T-cells|Anti-CS1 Hinge-optimized CAR-4-1BB-EGFRt-expressing Memory-enriched Autologous T-lymphocytes|Autologous Anti-CS1 Hinge-optimized CAR-4-1BB-EGFRt-expressing Memory-enriched T-lymphocytes|CS1-CAR T-cells|CS1-CAR T-lymphocytes	A preparation of autologous central memory-enriched T-cells (Tcm) that have been transduced with a self-inactivating (SIN) lentiviral vector expressing a hinge-optimized chimeric antigen receptor (CAR) comprised of a CS1 (CD2 subset 1; SLAM family member 7; SLAMF7; CD319; CRACC)-specific single chain variable fragment (scFV), fused to the costimulatory signaling domain of 4-1BB (CD137), and a truncated human epidermal growth factor receptor (huEGFRt), with potential antineoplastic activity. Upon intravenous infusion, anti-CS1-CAR-4-1BB-CD3z-EGFRt-expressing Tcm-enriched T-lymphocytes target and induce selective toxicity in CS-1-expressing tumor cells. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed huEGFRt facilitates both in vivo detection of the administered, transduced T-cells and can promote elimination of those cells through a cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) response. CS1, a cell surface glycoprotein of the signaling lymphocyte activation molecule (SLAM) receptor family, is highly expressed on certain malignant plasma cells.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160712>	C129986	Bushen Culuan Decoction|Bushen Culuan TCM Decoction|Bushen Culuan Traditional Chinese Medicine Decoction	A traditional Chinese medicine (TCM) decoction containing a mixture of ten Chinese herbs including Tusizi, Yinyanghuo, Xianmao, Xuduan, Gouqizi, Nvzhenzi, Zelan, Shengpuhuang, Xiangfu and Chuanshanlong, with potential to induce ovulation. Upon oral administration, Bushen Culuan decoction may, through a not yet fully elucidated mechanism, depress follicle-stimulating hormone (FSH) levels, elevate anti-Mullerian hormone (AMH) levels, and increase the number of antral follicle counts (AFCs), thereby promoting ovulation.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160713>	C160157	GIST Grade Cannot be Assessed|GX Grade cannot be assessed	A GIST grade that cannot be assessed.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160714>	C28227|C141146|C128037	Lomvastomig|Anti-PD-1 x TIM-3 Bispecific Antibody RO7121661|Anti-PD-1/Anti-TIM-3 Bispecific Antibody RO7121661|Anti-PD-1/TIM-3 Bispecific Antibody RO7121661|LOMVASTOMIG|RO 7121661|RO-7121661|RO7121661	A bispecific antibody directed against both the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, lomvastomig simultaneously targets and binds to both TIM-3 and PD-1 expressed on certain T-cells. This blocks the interaction of TIM-3 with some of its physiologic ligands and prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is often co-expressed with PD-1 on tumor-antigen-specific T-cells. Dual checkpoint blockade of PD-1 and TIM-3 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160715>	C155745	Anti-CD137 Agonistic Monoclonal Antibody ADG106|4-1BB-directed Agonistic Monoclonal Antibody ADG106|ADG 106|ADG-106|ADG-106|ADG106|Anti-4-1BB Agonistic Monoclonal Antibody ADG106|CD137-directed Agonistic Monoclonal Antibody ADG106	A human agonistic monoclonal antibody targeting CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating activity. Upon administration, anti-CD137 agonistic monoclonal antibody ADG106 binds to and activates CD137 expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytokine production and promotes T-cell mediated anti-tumor immune responses. CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.	Anti-CD137 Agonistic Monoclonal Antibody ADG106		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160716>	C143250	PD-1 Directed Probody CX-188|Anti-PD-1 Probody CX-188|CX 188|CX-188|CX188	A probody composed of a monoclonal antibody directed against the negative immunoregulatory human cell surface receptor, programmed cell death protein 1 (PD-1; PDCD1; CD279), linked to a proprietary masking peptide that covers the active antigen binding site of the antibody through a protease-cleavable linker, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of PD-1-directed probody CX-188, the masking peptide is cleaved by tumor-associated proteases within the tumor microenvironment (TME). Protease-mediated removal of the linker enables binding of the unmasked monoclonal antibody moiety to PD-1, thereby disrupting PD-1 signaling. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity. Tumor-associated proteases are present in high concentrations and aberrantly activated in the TME.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160717>	C129822|C128037	Pucotenlimab|Anti-PD-1 Monoclonal Antibody HX008|HX 008|HX-008|HX008|PUCOTENLIMAB	A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pucotenlimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160718>	C158612	Is Tumor Necrosis Present Question|Is Tumor Necrosis Present|Tumor Necrosis	A question about whether tumor necrosis is present.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160719>	C41227	Surgical Margin Cannot be Assessed|Cannot be assessed	The determination of the presence of actual or potential neoplastic tissue which has been left outside the boundary of a resected specimen within the patient cannot be assessed.			Clinical Attribute	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C16071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16071>	C15185	Pharmacobehavioral Research	Evaluates new pharmacologic agents and methods of behavior modification.			Research Activity	
C160720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160720>	C158612	Is Lymphatic Invasion Present Question|Is Lymphatic Invasion Present|Lymph-vascular Invasion|lymphatic invasion present|lymphatic_invasion_present	A question about whether lymphatic invasion is present.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology|GDC Property Terminology|GDC Terminology
C160721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160721>	C160157	Lymphatic Invasion Absent|Not identified	A response that lymphatic invasion is absent in a specimen.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160722>	C16064	Residual Cancer Burden|RCB	An indication of the amount of invasive cancer in breast or lymph node tissue after completion of neoadjuvant chemotherapy.			Quantitative Concept	
C160723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160723>	C217122	Residual Cancer Burden Index|RCB Index	A score estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. Variables used in the calculation include: primary tumor bed area, overall cancer cellularity, percentage of cancer that is in situ disease, number of positive lymph nodes, and diameter of largest metastasis. These scores are divided into 4 classes that stratify patients based on their chance of disease recurrence.			Intellectual Product	
C160724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160724>	C118969	Residual Cancer Burden Class|RCB Class	Residual cancer burden classes that use pre-defined cut-points representing progressively greater extents of residual cancer and indicating a greater risk of recurrence.			Intellectual Product	
C160725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160725>	C160724	Residual Cancer Burden Class 0|RCB-0|pCR	No traces of residual disease; lowest chance of disease recurrence.			Intellectual Product	
C160726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160726>	C160724	Residual Cancer Burden Class 1|RCB-I	Minimal residual disease; low chance of disease recurrence.			Intellectual Product	
C160727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160727>	C160724	Residual Cancer Burden Class 2|RCB-II	Moderate residual disease; moderate chance of disease recurrence.			Intellectual Product	
C160728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160728>	C160724	Residual Cancer Burden Class 3|RCB-III	Extensive residual disease; highest chance of disease recurrence.			Intellectual Product	
C160729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160729>	C28676	Allogeneic CD25/Treg-depleted Donor Lymphocytes|Allogeneic Treg-depleted Donor Lymphocytes|CD25/Treg-depleted Donor Lymphocytes|CD25hi-depleted Donor Lymphocytes	A preparation of allogeneic peripheral blood mononuclear cells (PBMCs) derived from an 8/8 HLA-matched donor that have been selectively depleted of CD4+CD25hiFoxp3+ regulatory T-cells (Tregs; CD25hi Tregs) with potential to enhance graft-versus-tumor (GVT) immune responses in patients with myeloid relapse following a hematopoietic stem cell transplant (HSCT) from a matched donor. Following collection and ex-vivo depletion of CD25hi Tregs from PBMCs derived from the original donor, the CD25/Treg-depleted donor lymphocytes are infused into the patient. Upon administration, the CD25/Treg-depleted donor lymphocyte infusion (DLI) may enhance the proliferation of CD4+ and CD8+ effector T-cells (Teffs) and potentially induce curative GVT immune responses in patients with myeloid relapse following HSCT.	Allogeneic CD25/Treg-depleted Donor Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C160730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160730>	C160157	FNCLCC Sarcoma Grade GX Grade cannot be assessed|GX Grade cannot be assessed	A sarcoma with a GX  grade that cannot be assessed.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160731>	C18000	GIST Histologic Grade|Histologic Grade (GISTs)	An assessment of the GIST histologic grade.			Classification	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160732>	C160731	GIST Grade 1|G1 Low grade	A grade that may refer to GISTs with benign histologic characteristics.			Classification	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160733>	C160731	GIST Grade 2|G2 High grade	A grade that may refer to GISTs with malignant histologic characteristics.			Classification	CPTAC Baseline Medical Forms Terminology|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C160734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160734>	C158612	Is Paraneoplastic Syndrome Present Question|Is Paraneoplastic Syndrome Present|Paraneoplastic syndrome present	A question whether paraneoplastic syndrome is present.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C160735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160735>	C160157	Paraneoplastic Syndrome is Not Present|No	A response that paraneoplastic syndrome is not present.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C160736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160736>	C160157	Paraneoplastic Syndrome Status is Unknown|Unknown	A response that paraneoplastic syndrome status is unknown.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C160737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160737>	C3288|C203285|C148037	Recurrent Oligodendroglioma	The reemergence of oligodendroglioma after a period of remission.	Recurrent Oligodendroglioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160738>	C160157	Tumor Progression Present After Initial Treatment|Yes	A response that tumor progression was present after initial treatment.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Terminology
C160739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160739>	C160157	Tumor Progression Absent After Initial Treatment|No	A response that tumor progression was not present after initial treatment.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Terminology
C16073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16073>	C19975	Marker Network for Bladder Cancer	The goal of the network is to evaluate biochemical, immunologic, genetic, and other quantifiable markers for diagnosis and prognosis of urinary bladder cancer.			Research Activity	
C160740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160740>	C160157	Tumor Progression Unknown After Initial Treatment|Unknown	A response that it is unknown if there was tumor progression after initial treatment.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Terminology
C160741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160741>	C160157	Subsequent Known Primary Melanoma(s) Found During the Follow-Up|Yes	A response that a subsequent known primary melanoma was found during the follow-up period.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Terminology
C160742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160742>	C160157	Subsequent Known Primary Melanoma(s) Not Found During the Follow-Up|No	A response that a subsequent known primary melanoma was not found during the follow-up period.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Terminology
C160743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160743>	C160157	Unknown if Subsequent Known Primary Melanoma(s) Found During the Follow-Up|Unknown	A response that it is unknown if a subsequent known primary melanoma was found during the follow-up period.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Melanoma Follow-Up Form|CPTAC Terminology
C160744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160744>	C21176	DREAM Complex|Dimerization Partner, RB-Like, E2F and Multi-Vulval Class B Complex|LINC Complex	A protein complex that is involved in the repression of cycle-dependent gene expression during the G0 phase.			Amino Acid, Peptide, or Protein	
C160745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160745>	C160157	Additional Surgery for New Metastatic Tumor Event Not Evaluated|Not Evaluated	The need for additional surgery for a new metastatic tumor event was not evaluated.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Terminology
C160746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160746>	C158612	Was Bone Marrow Transplantation Performed Question|Was Bone Marrow Transplantation Performed	A request to indicate if there was bone marrow transplantation performed.			Intellectual Product	
C160747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160747>	C158612	Was Radiation Therapy Administered Question|Was Radiation Therapy Administered|Was the patient treated with radiotherapy	A question whether radiation therapy was administered.			Intellectual Product	CRF4 Treatment Radiation Table
C160748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160748>	C158612	Was Pharmacotherapy Administered Question|Was Pharmacotherapy Administered	A request to indicate if there was pharmacotherapy administered.			Intellectual Product	
C160749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160749>	C158612	Was Immunotherapy Administered Question|Was Immunotherapy Administered	A request to indicate if there was immunotherapy administered.			Intellectual Product	
C16074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16074>	C16097	Minority-Based Community Clinical Oncology Program	A system designed to ensure adequate representation of minority groups in clinical trials.			Research Activity	
C160750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160750>	C63468	Docetaxel/Leuprolide Regimen|Docetaxel and Leuprolide|Docetaxel-Leuprolide|Docetaxel/Leuprolide|Leuprolide-Docetaxel|Leuprolide-Docetaxel Regimen|Leuprolide/Docetaxel Regimen	A regimen consisting of docetaxel and leuprolide that can be used for the treatment of prostate cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160751>	C15184	Intimacy Enhancement Intervention|IE|Intimacy Enhancement	Phone-based cognitive behavioral couple's therapy and sex therapy designed to help couples cope with sexual concerns and enhance their intimate relationship following breast cancer diagnosis and treatment. The intervention consists of education and skills training to enhance physical and emotional intimacy.	Intimacy Enhancement		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C160752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160752>	C15184	Living Healthy Together|LHT	Intervention that focuses on delivering education and support to breast cancer survivors and their partners across a range of topics including social support, sleep and fatigue, stress and stress management, nutrition, and physical activity.	Living Healthy Together		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C160753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160753>	C19498	Handout	Printed information provided free of charge, especially that distributed to people attending a speech, lecture, or meeting.	Handout		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C160754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160754>	C160157	Routine Cytogenetics Were Completed|Yes	A response that routine cytogenetic testing was completed.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C160755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160755>	C160157	Routine Cytogenetics Were not Completed|No	A response that routine cytogenetic testing was not completed.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C160756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160756>	C160157	Unknown if Routine Cytogenetics were Completed|Unknown	A response that the status of complete routine cytogenetic testing is unknown.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C160757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160757>	C159229	Favorable CALGB Criteria|Favorable|Favorable	A rating for AML by CALGB which indicates the outlook on the patient recovery is favored towards recovery.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C160758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160758>	C159229	Intermediate CALGB Criteria|Intermediate/Normal	A rating for AML by CALGB which indicates the outlook on the patient recovery can be considered between favorable and poor.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C160759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160759>	C159229	Poor CALGB Criteria|Poor|Poor	A rating for AML by CALGB which indicates the outlook on the patient recovery can be considered poor.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C16075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16075>	C15832|C15365	Patient-Focused Outcomes|Patient-Centered Outcomes	Traditional methods for evaluating treatment outcome focus on disease state.  Patient-Focused Outcomes places a greater emphasis on quality of life issues.			Research Activity	
C160760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160760>	C159229	Remission CALGB Criteria|N/A-Remission	A rating for AML by CALGB which indicates the patient has met the CALGB criteria for remission.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C160761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160761>	C160157	Other Cytogenetic Analysis Abnormality Type|Other	A result that is other than those presented in the form.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C160762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160762>	C160157	Specify if Other Cytogenetic Analysis Abnormality Type|If Other, specify	A directive to specify if other cytogenetic analysis abnormalities were present.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C160763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160763>	C160157	Other Molecular Analysis|Other|specialized molecular test|specialized_molecular_test	A response of a type of molecular analysis other than what is included on the form.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|GDC Property Terminology|GDC Terminology
C160764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160764>	C160157	Unknown Molecular Analysis|Unknown	A response of an unknown molecular analysis.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C160765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160765>	C160157	Specify Other Molecular Analysis|If Other, specify	A request to specify the other molecular analysis type.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C160766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160766>	C158612	Were Molecular Abnormalities Detected Question|Were Molecular Abnormalities Detected|Were Molecular Abnormalities Detected	A question about whether molecular abnormalities were detected.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C160767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160767>	C160157	Molecular Abnormalities Detected|Yes	A response that molecular abnormalities were detected.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C160768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160768>	C160157	Molecular Abnormalities Not Detected|No	A response that molecular abnormalities were not detected.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C160769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160769>	C160157	Molecular Abnormalities Unknown|Unknown	A response that it is unknown if molecular abnormalities were detected.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C16076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16076>	C213308	Childhood Cancer Survivor Study|CCSS	An NCI-funded multi-institution project designed to better understand late effects of cancer upon cancer survivors			Research Activity	
C160770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160770>	C15342	Vascularized Lymph Node Transfer|VLNT	A surgical treatment for lymphedema. This involves the microsurgical transfer of lymph node-containing tissue to a lymphedematous limb, which works based on the movement of lymphatic fluid from the affected limb into the transferred lymph node and drainage via the newly anastomosed venous route.	Vascularized Lymph Node Transfer		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C160771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160771>	C17157	Coherent Anti-Stokes Raman Spectroscopy|CARS|Coherent anti-Stokes Raman Scattering Spectroscopy	A nonlinear Raman spectroscopy technique. It uses two very strong collinear lasers to irradiate a sample, instead of the traditional single laser and is orders of magnitude stronger than spontaneous Raman emission.	Coherent Anti-Stokes Raman Spectroscopy		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C160772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160772>	C28227|C155745|C129822|C128057	Anti-PD-L1/CD137 Bispecific Antibody MCLA-145|Anti-PD-L1/4-1BB Bispecific Antibody MCLA-145|Anti-PD-L1/Anti-CD137 Bispecific Antibody MCLA-145|MCLA 145|MCLA-145|MCLA145	A full-length, Fc-silenced immunoglobulin G1 (IgG1) bispecific antibody targeting both the human programmed death-ligand 1 (PD-L1) and CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, anti-PD-L1/CD137 bispecific antibody MCLA-145 simultaneously targets and binds to CD137, which is expressed on a variety of leukocyte subsets including activated T-lymphocytes, and PD-L1 expressed on tumor cells, thereby crosslinking PD-L1-expressing tumor cells and T-lymphocytes. Through CD137 binding, MCLA-145 acts as a conditional CD137 agonist, resulting in T-cell co-stimulation and enhanced anti-tumor activity. At the same time, MCLA-145 prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells, suppresses the immune system and results in immune evasion. CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. Crosslinking of PD-L1-expressing tumor cells and activated T-lymphocytes may enhance T-lymphocyte-mediated lysis of PD-L1-expressing tumor cells.	Anti-PD-L1/CD137 Bispecific Antibody MCLA-145		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160773>	C42619	Progress Notes|Clinical Notes|Clinician Notes	The part of a medical record where healthcare professionals record details to document a patient's clinical status or achievements. They are meant to facilitate communication and coordination among the team, and as a way to document the goals, objectives and the services being provided.			Intellectual Product	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C160774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160774>	C95646	Discrete Set Data Type IV|DSET<IV>	A collection of identifiers from an external system that contains distinct and discrete values in no particular order.			Qualitative Concept	
C160775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160775>	C95646	Discrete Set Telecommunication URL Data Type|DSET<TEL_URL>	A collection of locatable resources that are identified by a URI, such as a web page, a telephone number (voice, fax or some other resource mediated by telecommunication equipment), an e-mail address, or any other locatable resource that can be specified by a URL that returns binary content.			Qualitative Concept	
C160776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160776>	C42078	Malignant Lesion	A lesion characterized by the presence of a malignant cellular population.	Malignant Lesion		Finding	CTRP Disease Terminology|CTRP Terminology
C160777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160777>	C200766|C176018	Autologous Anti-CD19/Anti-CD20-CAR-CD28-4-1BB-CD3zeta-EGFRt+-expressing Tn/mem Cells|Autologous Anti-CD19/20 Bispecific CAR-CD28-BBz-EGFRt+-expressing Tn/mem Cells|Autologous Anti-CD19/20 CAR-CD28-4-1BB-CD3zeta-EGFRt+-expressing Naive and Memory T-lymphocytes	A preparation of genetically modified autologous naive/memory T-cells (Tn/mem),  that have been transduced with a self-inactivating (SIN) lentiviral vector to express a bispecific chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) of anti-CD19, derived from the anti-CD19 monoclonal antibody FMC63, in tandem with an anti-CD20 scFv, derived from the anti-CD20 monoclonal antibody Leu16, and fused to the hinge domain of human immunoglobulin (Ig) G4, the transmembrane domain of human CD28, and the cytoplasmic signaling domains of 4-1BB (CD137) and the T-cell antigen receptor complex zeta chain (CD3-zeta) (BBz), and linked via the T2A sequence to a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon transfusion, autologous anti-CD19/anti-CD20-CAR-CD28-4-1BB-CD3zeta-EGFR+-expressing Tn/mem cells recognize and induce selective toxicity in CD19/CD20-expressing tumor cells, resulting in tumor cell lysis. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, EGFRt both facilitates in vivo detection of the administered T-cells and can promote elimination of those cells upon a cetuximab-induced antibody dependent cellular cytotoxicity (ADCC) response.	Autologous Anti-CD19/Anti-CD20-CAR-CD28-4-1BB-CD3zeta-EGFRt+-expressing Tn/mem Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160778>	C62634	Regimen Used to Treat Non-neoplastic Hematologic Disorders	Any regimen that can be used for the treatment of hematologic disorders, such as anemia and neutropenia, and excludes regimens for the treatment of hematologic malignancies.			Therapeutic or Preventive Procedure	
C160779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160779>	C50764	Atypical Lymph Node	A lymph node that deviates from usual in terms of size, shape, and internal architecture.	Atypical Lymph Node		Finding	CTRP Disease Terminology|CTRP Terminology
C16077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16077>	C15426	Clinical Trials Database	Mandated by the FDA Modernization Act of 1997.  An NIH-wide database of information about federally and privately funded clinical trials regarding serious or life-threatening diseases or conditions.			Research Device	
C160780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160780>	C28681|C129826	Gavocabtagene Autoleucel|Autologous Anti-mesothelin T-cell Receptor Fusion Construct T-cells TC-210|Autologous Anti-mesothelin TRuC T-cells TC-210|GAVOCABTAGENE AUTOLEUCEL|Gavo-cel|TC 210|TC-210|TC-210 T Cells|TC210	A preparation of autologous T-lymphocytes that have been genetically engineered to express a single-domain antibody that recognizes human mesothelin, fused to the N-terminus of the CD3-epsilon T-cell receptor (TCR) subunit which, upon expression is incorporated into the endogenous TCR complex, with potential antineoplastic activity. Upon administration, gavocabtagene autoleucel specifically target and bind to mesothelin-expressing tumor cells. This leads to T-cell activation and T-cell mediated lysis of mesothelin-expressing tumor cells. Mesothelin, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types. Compared to chimeric antigen receptor (CAR) T-cells, TRuCs may be associated with less pro-inflammatory cytokine secretion and fewer adverse effects without compromising therapeutic efficacy.	Gavocabtagene Autoleucel		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160781>	C7550|C224630	Unresectable Ovarian Serous Adenocarcinoma	An ovarian serous adenocarcinoma that is not amenable to surgical resection.	Unresectable Ovarian Serous Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160782>	C7550|C4124|C156064	Metastatic Ovarian Serous Adenocarcinoma	An ovarian serous adenocarcinoma that has spread from its original site of growth to another anatomic site.	Metastatic Ovarian Serous Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160783>	C156094|C153206	Locally Advanced Lung Non-Small Cell Carcinoma	A non-small cell carcinoma of the lung that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Lung Non-Small Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160784>	C36280	High Risk Meningioma|High-Risk Meningioma	Meningioma that is classified as 1) a newly diagnosed or recurrent WHO grade III meningioma 2) a recurrent WHO grade II meningioma or 3) a newly diagnosed WHO grade II meningioma with subtotal resection.	High Risk Meningioma		Finding	CTRP Disease Terminology|CTRP Terminology
C160785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160785>	C199143	Clinical Laboratory Evaluation Program|CLEP	A program of the New York State Department of Health that administers the activities of the Clinical Laboratory Reference System and provides the oversight of over 1,000 clinical laboratories and blood banks, including out-of-state facilities that accept clinical specimens collected in New York State. CLEP seeks to ensure the accuracy and reliability of results of laboratory tests on specimens obtained within the state through on-site inspections, review of proficiency testing performance, and evaluation of the qualifications of personnel of state permit-holding clinical laboratories and blood banks.			Professional or Occupational Group	
C160786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160786>	C308	Avadomide|2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-|AVADOMIDE|CC 122|CC-122|CC122	A novel, small molecule cereblon-modulating agent with potential antineoplastic, antiangiogenic and immunomodulatory activities. Upon oral administration, avadomide binds to and modulates cereblon to promote recruitment of the hematopoietic transcription factors Aiolos and Ikaros to the Cullin-4 RING E3 ubiquitin ligase complex. This binding results in the ubiquitination and rapid proteasomal degradation of Aiolos and Ikaros and the derepression of interferon (IFN)-stimulated genes, including DDX58 and IRF7, leading to apoptosis of certain tumor cells. Additionally, Aiolos degredation leads to derepression of the IL2 gene, thereby enhancing interleukin-2 production, costimulation of T-lymphocytes and IL-2-induced T-cell proliferation. Avadomide may also promote the activation of natural killer (NK) cells, potentially enhancing tumor cell killing. Aiolos and Ikaros are transcriptional repressors known to play an important role in normal B- and T-cell function.	Avadomide		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160787>	C72960|C129822	Anti-CD52 Monoclonal Antibody ALLO-647|ALLO 647|ALLO-647|ALLO647	A monoclonal antibody directed against the cell surface glycoprotein CD52 (CAMPATH-1 antigen; Cambridge pathology 1 antigen), with potential immunodepleting activity. Upon administration, anti-CD52 monoclonal antibody ALLO-647 selectively targets and binds to CD52, thereby triggering a host immune response that results in the lysis of CD52-positive lymphocytes. This leads to immunodepletion and may prevent graft-versus-host disease (GvHD). CD52 is a glycoprotein expressed on the surface of many immune cells, including essentially all B- and T-lymphocytes.	Anti-CD52 Monoclonal Antibody ALLO-647		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160788>	C202101	Bavdegalutamide|AR PROTAC ARV-110|AR-targeted PROTAC Protein Degrader ARV-110|ARV 110|ARV-110|ARV110|Androgen Receptor Degrader ARV-110|Androgen Receptor PROTAC Degrader ARV-110|BAVDEGALUTAMIDE|PROTAC Degrader ARV-110	An orally available selective androgen receptor (AR)-targeted protein degrader, using the proteolysis targeting chimera (PROTAC) technology, with potential antineoplastic activity. Bavdegalutamide is composed of an AR ligand attached to an E3 ligase recognition moiety. Upon oral administration, bavdegalutamide targets and binds to the AR ligand binding domain. E3 ligase is recruited to the AR by the E3 ligase recognition moiety and the AR target protein is tagged by ubiquitin. This causes ubiquitination and degradation of AR by the proteasome. This prevents the expression of AR target genes and halts AR-mediated signaling. This results in an inhibition of proliferation in AR-overexpressing tumor cells. In addition, the degradation of the AR protein releases the ARV-110 is released and can bind to additional AR target proteins. AR plays a key role in the proliferation of castration-resistant prostate cancer cells (CRPC).	Bavdegalutamide		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160789>	C158612	Histologic Grade for Other Carcinomas Question|Histologic Grade for Other Carcinomas|Histologic Grade: For other carcinomas	A request to specify the histologic grade for other carcinomas.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C16078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16078>	C161601	Pediatric Surgical Procedures|Pediatric Surgery	Surgery performed on children.			Therapeutic or Preventive Procedure	
C160790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160790>	C160157	Other Histologic Grade|Other	A response that the histologic grade is other than is specified on the form.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C160791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160791>	C160157	Specify Other Histologic Grade|If Other, specify	A request to specify the other histologic grade.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C160792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160792>	C160157	Myometrial Invasion Not Identified|Not Identified	A response that myometrial invasion has not been identified.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C160793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160793>	C158612	Is Myometrial Invasion Present Question|Is Myometrial Invasion Present|Myometrial Invasion	A question about whether myometrial invasion is present.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C160794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160794>	C63468	Abiraterone Regimen|Abiraterone monotherapy|Zytiga Regimen	A regimen consisting of abiraterone acetate that may be used in the treatment of metastatic prostate cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160795>	C63442	Belinostat Regimen|Beleodaq Regimen|Belinostat monotherapy	A regimen consisting of belinostat that may be used in the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160796>	C63524|C63522|C159901|C159900	Binimetinib Regimen|Binimetinib monotherapy|Mektovi Regimen	A regimen consisting of binimetinib that may be used in the treatment of unresectable or metastatic melanoma, ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160797>	C63468	Cabazitaxel Regimen|Jevtana Regimen	A regimen consisting of cabizitaxel that may be used in the treatment of metastatic, castration-resistant prostate cancer (mCRPC).			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160798>	C63496|C159461	Carfilzomib Regimen|Carfilzomib monotherapy|Kyprolis Regimen	A regimen consisting of carfilzomib that may be used in the treatment of relapsed or refractory plasma cell myeloma  and systemic light chain amyloidosis.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160799>	C63442	Copanlisib Regimen|Aliqopa Regimen|Copanlisib monotherapy	A regimen consisting of copanlisib that may be used in the treatment of relapsed follicular lymphoma, gastric and nongastric MALT lymphomas, and nodal and splenic marginal zone lymphomas.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C16079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16079>	C49165	Conventional Surgery	Surgery using a scalpel.  As opposed to laser surgery, cryosurgery, etc	Conventional Surgery		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C1607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1607>	C2018	Anastrozole|2,2'-[5-(1H-1,2,4-Triazol-1-ylmethyl)-1,3-phenylene]di(2-methylpropionitrile)|ANASTROZOLE|Alpha,alpha,alpha', alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetonitrile|Anastrazole|Arimidex|ICI D1033|ICI-D1033|ZD-1033|anastrozole	A nonsteroidal inhibitor of estrogen synthesis that resembles paclitaxel in chemical structure.  As a third-generation aromatase inhibitor, anastrozole selectively binds to and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex found in many tissues including those of the premenopausal ovary, liver, and breast; aromatase catalyzes the aromatization of androstenedione and testosterone into estrone and estradiol, the final step in estrogen biosynthesis.  In estrogen-dependent breast cancers, ananstrozole may inhibit tumor growth. (NCI04)	Anastrozole		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160800>	C160778	Darbepoetin Regimen|Aranesp Regimen	A regimen consisting of darbepoetin alfa that may be used in the management of anemia secondary to chemotherapy or chronic kidney disease (CKD).			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160801>	C160778	Epoetin Alfa Regimen|Epogen Regimen|Procrit Regimen	A regimen consisting of epoetin alfa that may be used in the management of anemia secondary to chemotherapy, HIV infection, or chronic kidney disease (CKD); and in the prevention of anemia in certain patients undergoing elective non-cardiac surgical procedures.			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160802>	C160778	Filgrastim Regimen|Neupogen Regimen	A regimen consisting of filgrastim that may be used in the prevention of febrile neutropenia; in the harvest of peripheral blood stem cells (PBSCs); and in the symptomatic management of neutropenic disorders.			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160804>	C67290|C63524	Aldesleukin Regimen|IL-2 monotherapy|Proleukin Regimen|Recombinant Human IL-2 Regimen|Recombinant Human Interleukin-2 Regimen	A regimen consisting of aldesleukin that may be used in the treatment of metastatic melanoma and metastatic renal cell carcinoma (RCC).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160805>	C63588	High-dose Methylprednisolone Regimen|HDMP|HDMP|High-dose Solumedrol Regimen	A regimen consisting of high-dose methylprednisolone sodium succinate that may be used in the palliative management of acute lymphoblastic leukemia (ALL); and in the management of severe allergic conditions, hypercalcemia of malignancy, idiopathic thrombocytopenic purpura (ITP), Crohn's disease, and other inflammatory disorders.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160806>	C63589	Low-dose Cytarabine Regimen|LD-AraC Regimen|LDAC Regimen|LoDAC|Low Dose Ara-C Regimen|Low-dose AraC Regimen|Low-dose Cytarabine monotherapy (LoDAC)	A regimen consisting of low-dose cytarabine that may be used in the treatment of acute myeloid leukemia (AML).	Low-dose Cytarabine Regimen		Therapeutic or Preventive Procedure	CTRP Agent Terminology|CTRP Terminology|HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160807>	C63522|C159901|C159900	Niraparib Regimen|Niraparib monotherapy|Zejula Regimen	A regimen consisting of niraparib tosylate monohydrate that may be used as maintenance therapy in the treatment of certain recurrent ovarian, fallopian tube, or primary peritoneal cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160808>	C63510|C159462	Palbociclib Regimen|Ibrance Regimen	A regimen consisting of palbociclib that may be used in the treatment of well-differentiated/dedifferentiated liposarcoma and uterine sarcoma.			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160809>	C160778	Pegfilgrastim Regimen|Neulasta Regimen	A regimen consisting of pegfilgrastim that may be used in the prevention of febrile neutropenia; in the harvest of peripheral blood stem cells (PBSCs); and in the symptomatic management of neutropenic disorders.			Therapeutic or Preventive Procedure	Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C16080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16080>	C15747	Surgical Management	Postoperative care of surgery patients.			Therapeutic or Preventive Procedure	
C160810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160810>	C63442	Pralatrexate Regimen|Folotyn Regimen|Pralatrexate monotherapy	A regimen consisting of pralatrexate that may be used in the treatment of T-cell lymphomas, mycosis fungoides/Sezary syndrome, and primary cutaneous CD30+ T-cell lymphoproliferative disorders. Low-dose pralatrexate regimen and standard-dose pralatrexate regimen may be used for the treatment of mycosis fungoides/Sezary syndrome.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160811>	C63442	Romidepsin Regimen|Istodax Regimen|Romidepsin monotherapy	A regimen consisting of romidepsin that may be used in the treatment of T-cell lymphomas, and mycosis fungoides and Sezary syndrome.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160812>	C63522|C63510|C63502|C63468|C159901|C159900|C159462	Rucaparib Regimen|Rubraca Regimen|Rucaparib monotherapy	A regimen consisting of rucaparib that may be used in the treatment of uterine sarcoma, pancreatic adenocarcinoma, castration-resistant, metastatic prostate cancer, and recurrent ovarian, fallopian tube, or primary peritoneal cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160813>	C63468	Sipuleucel-T Regimen|Provenge Regimen|Sipuleucel-T monotherapy	An autologous cellular immunotherapy regimen that may be used in the treatment of metastatic, hormone refractory prostate cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160814>	C63524	Talimogene Laherparepvec Regimen|Imlygic Regimen|T-VEC Regimen|Talimogene laherparepvec monotherapy	A regimen consisting of talimogene laherparepvec that may be used in the treatment of recurrent, unresectable, cutaneous, subcutaneous, and nodal melanoma lesions.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C160815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160815>	C25164	Anchor Date|Anchor date|Base date	The base date from which all other dates within a cohort or data set are derived.			Temporal Concept	
C160816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160816>	C15751	Carbon Ion Radiotherapy|CARBON Therapy|CIRT|Carbon Ion Radiation Therapy|Carbon Ion Radiation Therapy|External beam radiation therapy using carbon ions (procedure)	Ion beam radiation therapy that uses charged carbon particle. Compared to proton beam therapy, the larger mass of carbon results in decreased beam scattering, yielding a sharper dose distribution border with minimal penumbra and two to three times the relative biological effect.	Carbon Ion Radiation Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|mCode Radiotherapy Modality Value Set|mCode Teleradiotherapy Modality Value Set|mCode Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C160817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160817>	C5596	Prostate Acinar Microcystic Adenocarcinoma|Prostate Microcystic Adenocarcinoma	Acinar prostate adenocarcinoma characterized by the presence of microcystic foci.			Neoplastic Process	
C160818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160818>	C5596|C3779	Prostate Acinar Pleomorphic Giant Cell Adenocarcinoma|Prostate Pleomorphic Giant Cell Adenocarcinoma	An extremely rare prostate acinar adenocarcinoma characterized by the presence of giant, bizarre anaplastic cells with pleomorphic nuclei and lack of a spindle cell component.			Neoplastic Process	
C160819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160819>	C4349|C161048|C156097	Metastatic Colon Adenocarcinoma	An adenocarcinoma that arises from the colon and has metastasized to another anatomic site.	Metastatic Colon Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16081>	C92722	Laboratory Test Method Sensitivity|LBTMTHSN|Laboratory Sensitivity|Test Method Sensitivity	An attribute of a laboratory technique regarding how likely that test is able to detect an analyte that is actually present within the specimen.			Qualitative Concept	
C160820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160820>	C9383|C161048|C156098	Metastatic Rectal Adenocarcinoma	An adenocarcinoma that arises from the rectum and has metastasized to another anatomic site.	Metastatic Rectal Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160821>	C160157	Peritoneal Fluid is Negative for Malignancy|Negative for malignancy/normal/benign	A result that the peritoneal fluid is negative for malignancy.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C160822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160822>	C160157	Atypical Peritoneal Fluid|Atypical and/or suspicious	A result that the peritoneal fluid is atypical.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C160823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160823>	C160157	Peritoneal Fluid Positive for Malignancy|Positive for malignancy	A result that the peritoneal fluid is positive for malignancy.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C160824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160824>	C15670	NanoTherm Therapy|MagForce NanoTherm Therapy System|NanoTherm|NanoTherm Therapy System	A procedure for the focal treatment of solid tumors. Magnetic nanoparticles of iron oxide are introduced either directly into the tumor or into the resection cavity wall. These particles are subjected to an alternating magnetic field that causes the particles to generate heat and kill the cancer cells by thermal ablation.	NanoTherm Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C160825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160825>	C160157	Peritoneal Fluid Not Examined|Not examined	A response that the peritoneal fluid was not examined.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C160826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160826>	C158612	Is Tumor Cell Necrosis Present Question|Is Tumor Cell Necrosis Present|Tumor Cell Necrosis	A question whether tumor cell necrosis is present.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C160827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160827>	C158612	Is Macroscopic Satellite Nodule Present Question|Is Macroscopic Satellite Nodule Present|Macroscopic Satellite Nodule(s)|satellite nodule present|satellite_nodule_present	A question about whether the macroscopic satellite nodule is present.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology|GDC Property Terminology|GDC Terminology
C160828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160828>	C158612	Macroscopic Satellite Nodule Not Identified Question|Macroscopic Satellite Nodule Not Identified|Not Identified	The macroscopic satellite nodule is not identified.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C160829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160829>	C158612	Is Microsatellitosis Present Question|Is Microsatellitosis Present|Microsatellitosis	A question about whether microsatellitosis is present.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C16082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16082>	C15188	Marker Discovery	Strategies and technologies for molecular phenotyping and biological marker discovery to improve understanding of disease and aid the pharmaceutical industry's ability to develop new therapeutic products efficiently and cost effectively.			Activity	
C160830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160830>	C35867	Microsatellitosis Absent|Not identified	An indication that microsatellitosis is absent.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C160831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160831>	C35867	Perineural Invasion Absent|Not identified	An indication that perineural invasion is absent.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Terminology
C160832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160832>	C158612	Are Tumor Infiltrating Lymphocytes Present Question|Are Tumor Infiltrating Lymphocytes Present|Tumor Infiltrating Lymphocytes	A question whether tumor infiltrating lymphocytes are present.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology|CPTAC Uveal Melanoma Baseline Form
C160833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160833>	C35867	Tumor Infiltrating Lymphocyte Absent|Not identified|TIL Absent|TIL Negative	A response that there are no tumor infiltrating lymphocytes.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C160834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160834>	C158612	Is Tumor Regression Present Question|Is Tumor Regression Present|Tumor Regression	A question about whether tumor regression is present.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C160835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160835>	C90169	Tumor Regression Absent|Not identified	An indication that tumor regression is not observed.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C160836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160836>	C18243	Tumor Regression|Decreasing|Present|Tumor Decreasing|regression	A decrease in the size of a tumor or in the extent of cancer in the body.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C160837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160837>	C181043	Is Extranodal Tumor Involvement Present Question|Extranodal Tumor Extension|Is Extra-nodal Extension Present|Is Extranodal Extension Present|Is Extranodal Tumor Involvement Present|extranodal extension|extranodal_extension	A question about whether extranodal tumor involvement is present.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology|GDC Property Terminology|GDC Terminology
C160838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160838>	C209927	Absent Extranodal Tumor Extension|No Extranodal Extension|Not identified	A finding that the extranodal tumor extension is absent.			Finding	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C160839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160839>	C160157	Interferon Gamma Treatment was Administered Prior to Specimen Resection|Yes	A response that interferon gamma treatment was administered prior to the specimen resection.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C16083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16083>	C25320	Prevention Protocol	The protocol associated with a clinical trial that is focused on cancer prevention.			Research Activity	
C160840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160840>	C160157	Interferon Gamma Treatment was not Administered Prior to Specimen Resection|No	A response that interferon gamma treatment was not administered prior to the specimen resection.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C160841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160841>	C160157	Unknown if Interferon Gamma Treatment was Administered Prior to Specimen Resection|Unknown	A response that it is unknown if interferon gamma treatment was administered prior to the specimen resection.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C160842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160842>	C160157	Interferon Gamma Treatment was Administered 90 Days Prior to Specimen Resection|Yes	A response that interferon gamma treatment was administered 90 days prior to the specimen resection.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C160843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160843>	C160157	Interferon Gamma Treatment was not Administered 90 Days Prior to Specimen Resection|No	A response that interferon gamma treatment was not administered 90 days prior to the specimen resection.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C160844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160844>	C160157	Interferon Gamma Treatment Administration 90 Days Prior to Specimen Resection Unknown|Unknown	A response that it is unknown if interferon gamma treatment was administered 90 days prior to the specimen resection.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C160845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160845>	C158612	Are Sarcomatoid Features Present Question|Are Sarcomatoid Features Present|Sarcomatoid Features	A question about whether sarcomatoid features are present in a specimen.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C160846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160846>	C160157	Sarcomatoid Features Absent|Not identified	A response that sarcomatoid features are absent in a specimen.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C160847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160847>	C222322|C201495|C200766	Autologous Anti-CD33 CAR-mbIL15-Safety Switch T-cells PRGN-3006|Autologous Anti-CD33 CAR-T Cells PRGN-3006|Autologous CAR-T Cells PRGN 3006|PRGN 3006|PRGN-3006|PRGN3006	A preparation of autologous T-lymphocytes that have been genetically modified to co-express three transgenes using the Sleeping Beauty (SB) transposon system and include a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD33, a membrane-bound IL-15 (mbIL15) and a safety/kill switch, with potential immunostimulating and antineoplastic activities. Upon introduction of the autologous anti-CD33 CAR-mbIL15-safety switch T-cells PRGN-3006 into the patient, the T-cells target and bind to CD33-expressing tumor cells, thereby inducing selective toxicity in CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem cells and overexpressed on a variety of cancer cell types, including acute myeloid leukemia (AML). It plays a key role in tumor initiation, proliferation and progression. IL-15 is a pro-survival cytokine that is required for the maintenance of long-lived CD8+ memory T-cells and use of mbIL15 preserves T stem-cell memory (TSCM) through sustained IL-15 signaling, improves T-cell persistence and potentiates the immune response against tumor cells. The safety switch can promote selective elimination of the CAR-T cells. The SB system permits integration of the CAR, the IL-15 fusion variant and safety switch transgenes into T-cells without the need for viral vectors and accelerates the manufacturing process.	Autologous Anti-CD33 CAR-mbIL15-Safety Switch T-cells PRGN-3006		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160849>	C35869	Predominantly Fatty Breast|Predominantly fatty	The breasts are almost entirely fatty, as defined by the visually estimated content of fibroglandular-density tissue within the breast, based on updated editions of the American College of Radiology's Breast Imaging Reporting and Data System (BI-RADS).			Finding	
C16084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16084>	C208216	Observational Study|OBSERVATIONAL|Observational Trial|observational study|observational study|observational study	Studies among cancer patients and healthy populations that involve no intervention or alteration in the status of the participants.			Research Activity	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|CDISC SDTM Study Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C160850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160850>	C35869	Breast Scattered Fibroglandular Densities|Scattered Fibroglandular Densities in Breast|Scattered Fibroglandular Densities of Breast|Scattered fibroglandular densities	There are scattered areas of fibroglandular density, as defined by the visually estimated content of fibroglandular-density tissue within the breast, based on updated editions of the American College of Radiology's Breast Imaging Reporting and Data System (BI-RADS).			Finding	
C160851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160851>	C81326	Elevated Type I Collagen Cross-Linked N-Telopeptide|Elevated Collagen Cross-Linked N-Telopeptide|Elevated Cross-Linked Type I Collagen N-Telopeptide|Elevated N-Telopeptide|Elevated N-Telopeptide of Type I Collagen|Elevated N-Terminal Telopeptide|Elevated N-Terminal Type I Collagen Cross-Linked|Elevated NTx|Elevated NTxI|Elevated Type I Collagen N-Telopeptide|Elevated Type I Collagen X-Linked N-Telopeptides	A laboratory test result indicating the presence of an increased level of the bone resorption marker type I collagen cross-linked N-telopeptide (NTx or NTxI) in a biological sample.	Elevated Type I Collagen Cross-Linked N-Telopeptide		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C160852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160852>	C8559|C156486	Advanced Paraganglioma	A paraganglioma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Paraganglioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160853>	C4220|C160852	Advanced Adrenal Gland Pheochromocytoma	An adrenal gland pheochromocytoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Adrenal Gland Pheochromocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160855>	C20993	Clinical Evaluation of Language Fundamentals, Fifth Edition|CELF-5|Clinical Evaluation of Language Fundamentals-Fifth Edition (CELF-5)	An interviewer-administered test designed to assess a student's language and communication skills in a variety of contexts, determine the presence of a language disorder, describe the nature of the language disorder and plan for intervention or treatment. It asks a student to imitate sentences presented by the examiner. As the test progresses, the sentences become longer and more complex. Respondents are scored for the number of errors made in each sentence.			Intellectual Product	
C160856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160856>	C20993	Rice Grammaticality Judgment Task	An examiner-administered, 20-item grammar judgment task. The respondent listens to a series of prerecorded sentences (items) and indicates whether the sentence is grammatically correct.			Intellectual Product	
C160857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160857>	C91105	Aging Voice Index|AVI|Aging Voice Index (AVI)	A questionnaire specifically designed for aging adults with voice disorders. It consists of a 23-item, self-administered questionnaire that asks individuals about the effects of their voice on their lives.			Intellectual Product	
C160858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160858>	C20993	Test of Word Reading Efficiency, Second Edition|TOWRE-2|Test of Word Reading Efficiency-Second Edition (TOWRE-2)	A measure designed to provide professionals in schools and clinics with a reliable and valid measure of fluency and accuracy of print-based word-reading skills. It is a nationally normed measure of word reading accuracy and speed, comprised of two subtests: the Sight Word Efficiency (SWE) subtest, a measure of an individual's ability to pronounce printed words, and the Phonemic Decoding Efficiency (PDE) subtest, a measure of an individual's ability to pronounce phonemically regular nonwords.			Intellectual Product	
C160859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160859>	C20993	Oral Mechanism/Cranial Nerve Examination for Young Children|Cranial Nerve/Oral Mech Exam	A clinical protocol developed for the purpose of assessing the oral and speech motor abilities of children. The protocol can be administered in 7-10 minutes, and a child's performance can be compared to developmental norms.			Intellectual Product	
C16085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16085>	C16199|C15714	Basic Cancer Research	Fundamental research designed to obtain or increase general knowledge about cancer, performed without the goal of solving or addressing a specific cancer-related issue or condition.			Research Activity	
C160860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160860>	C20993	Consensus Auditory-Perceptual Evaluation of Voice|CAPE-V|Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V)	A tool for clinical auditory-perceptual assessment of voice. Its primary purpose is to describe the severity of auditory-perceptual attributes of a voice problem, in a way that can be communicated among clinicians. Its secondary purpose is to contribute to hypotheses regarding the anatomic and physiological bases of voice problems and to evaluate the need for additional testing.			Intellectual Product	
C160861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160861>	C156877	hearScreen USA	A clinically validated, US national hearing screening application (app) designed for accurate detection of hearing impairment. The screening analyzes the person's ability to perceive speech-in-noise. Based on the person's response, the app automatically generates a hearing score that indicates whether there may be a possible hearing loss.			Intellectual Product	
C160862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160862>	C20993	Phonological Awareness Test|Phonological Awareness	A test to assess the ability of the respondent to repeat multi-syllable nonsense words. It is is used to assess an individual's ability to code and temporarily store information phonologically. This ability is related to verbal memory and language acquisition.			Intellectual Product	
C160863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160863>	C20993	Syllable Repetition Task|SRT|Syllable Repetition Task (SRT)	An 18-item imitation task that assesses a speaker's ability to repeat nonwords. This nonword repetition task was designed specifically for speakers whose incomplete inventories invalidate use of conventional nonword repetition tasks and/or who have speech production patterns that are difficult to transcribe and score.			Intellectual Product	
C160864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160864>	C91105|C222260	Tinnitus Screener	An interviewer-administered questionnaire that assesses, during the past year, whether tinnitus is present at all, and, if so, whether it is acute or chronic, constant or temporary, intermittent or occasional.			Intellectual Product	
C160865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160865>	C15749	Primary Debulking Surgery|PDS	Debulking surgery undertaken as the first treatment modality.	Primary Debulking Surgery		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C160866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160866>	C15749	Interval Debulking Surgery|IDS	Debulking surgery that is performed after neoadjuvant chemotherapy or induction chemotherapy and is followed by additional adjuvant chemotherapy of the same type.	Interval Debulking Surgery		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C160867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160867>	C213431|C1962|C129820	Lipid Nanoparticle Encapsulated mRNAs Encoding Human IL-12A/IL-12B MEDI-1191|LNP Encapsulated Human IL-12A/IL-12B mRNAs MEDI-1191|MEDI-1191|MEDI1191	A formulation consisting of lipid nanoparticle encapsulated messenger RNA (mRNA) encoding human interleukin-12 subunit beta (IL-12B; IL-12 subunit p40) and interleukin-12 subunit alpha (IL-12A; IL-12 subunit p35) with potential immunomodulatory and antineoplastic activities. Although the exact mechanism of action has not been completely characterized, upon intratumoral injection, the lipid nanoparticle moiety presumably binds to the plasma membrane of nearby cells and releases the IL-12A and IL-12B mRNA into the cell. The mRNA is then translated by the cellular protein translation machinery to produce a single-chain fusion protein of IL-12B and IL-12A subunits, which is secreted into the local tumor microenvironment (TME). Secretion of IL-12 activates the immune system by promoting the secretion of interferon-gamma, activating natural killer cells (NKs), and inducing cytotoxic T-cell responses, which may result in both decreased tumor cell proliferation and enhanced immune-mediated destruction of tumor cells.	Lipid Nanoparticle Encapsulated mRNAs Encoding Human IL-12A/IL-12B MEDI-1191		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C160868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160868>	C138961	PSA Level Greater than 0.5|PSA Level Greater than 0.5 ng/mL	A blood concentration of prostate specific antigen greater than 0.5 ng/mL.	PSA Level Greater than 0.5		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160869>	C171165	Biopsy Clip|Biopsy Marker	A surgically placed marker that is used to identify the site of a biopsy.			Medical Device	
C160870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160870>	C15322	Respiratory Muscle Training|RMT	A series of breathing and other exercises that are performed to improve the function of the respiratory muscles through resistance and endurance training.	Respiratory Muscle Training		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C160871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160871>	C16830	Respiratory Muscle Training Device|Power Lung Device	A handheld breathing device that is used to strengthen the respiratory muscles through resistance training.	Respiratory Muscle Training Device		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C160872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160872>	C40022	Platinum-Sensitive Primary Peritoneal Carcinoma|Platinum-Sensitive Peritoneal Cancer|Platinum-Sensitive Peritoneal Carcinoma|Platinum-Sensitive Primary Peritoneal Cancer	Primary peritoneal carcinoma that has a documented response to platinum-based chemotherapy.	Platinum-Sensitive Primary Peritoneal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160873>	C3867|C224161	Platinum-Sensitive Fallopian Tube Carcinoma|Platinum-Sensitive Fallopian Tube Cancer|Platinum-Sensitive Fallopian Tube Cancer	Fallopian tube carcinoma that has a documented response to platinum-based chemotherapy.	Platinum-Sensitive Fallopian Tube Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160874>	C4981|C27555	Chronic Cutaneous Graft Versus Host Disease|Chronic Cutaneous GvHD	Chronic graft versus host disease (GvHD) occurring in the skin.	Chronic Cutaneous Graft Versus Host Disease		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C160875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160875>	C49236	Biopsy Guidance	Any of various methods to assist in directing a biopsy needle into the area of interest.			Therapeutic or Preventive Procedure	
C160876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160876>	C20993	Head and Neck Survivorship Tool: Assessment and Recommendations|HN-STAR	A modified electronic platform that uses an algorithmic approach that integrates treatment summaries, self-assessments, discussion guides, and survivorship care plans to provide personalized care in cancer survivorship clinics.	Head and Neck Survivorship Tool: Assessment and Recommendations		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C160877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160877>	C178120|C136423	Activating ERK Family Gene Mutation|Activating ERK Mutation|Activating Extracellular Signal-Regulated Kinase Family Gene Mutation|Activating MAPK Family Gene Mutation|Activating MAPK Mutation|Activating Mitogen-Activated Protein Kinase Family Gene Mutation	A mutation in a ERK family gene that encodes a constitutively active MAP family serine/threonine-protein kinase and results in aberrant activation of its downstream pathways.	Activating ERK Family Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160878>	C93102|C160412	Deleterious CYSLTR2 Gene Mutation|CYSLTR2 Driver Mutation|Deleterious CYSLT2 Gene Mutation|Deleterious CYSLT2R Gene Mutation|Deleterious Cysteinyl Leukotriene Receptor 2 Gene Mutation|Deleterious GPCR21 Gene Mutation	A change in the nucleotide sequence of the CYSLTR2 gene that is associated with increased risk of disease.	Deleterious CYSLTR2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160879>	C93102|C89713	Deleterious GNAQ Gene Mutation|Deleterious CMC1 Gene Mutation|Deleterious G Protein Subunit Alpha q Gene Mutation|Deleterious G-ALPHA-q Gene Mutation|Deleterious GAQ Gene Mutation|Deleterious Guanine Nucleotide Binding Protein (G Protein), Q Polypeptide Gene Mutation|GNAQ Driver Mutation	A change in the nucleotide sequence of the GNAQ gene that is associated with increased risk of disease.	Deleterious GNAQ Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C16087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16087>	C15336	Animal Testing	The use of animals for testing the safety and efficacy of drugs or treatments.			Research Activity	
C160880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160880>	C213268	NRAS Gene Amplification|N-RAS Gene Amplification|NRAS Amplification|NRAS Proto-Oncogene, GTPase Gene Amplification|NRAS1 Gene Amplification|Neuroblastoma RAS Viral Oncogene Homolog Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the NRAS gene.	NRAS Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160881>	C138961	PSA Level Greater than or Equal to Fifty|PSA Level 50 or Greater|PSA Level Fifty or Greater|PSA Level Greater than or Equal to 50	A blood concentration of prostate specific antigen greater than or equal to 50 ng/mL.	PSA Level Greater than or Equal to Fifty		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160882>	C177692	VTCN1 Positive|B7 Homolog 4 Positive|B7-H4 Positive|B7H4 Positive|B7S1 Positive|B7X Positive|B7h.5 Positive|V-Set Domain Containing T Cell Activation Inhibitor 1 Positive|V-Set Domain-Containing T-Cell Activation Inhibitor 1 Positive|VCTN1 Positive	An indication that VTCN1 expression has been detected in a sample.	VTCN1 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160883>	C25952	PLCB4 Gene|PLCB4|PLCB4|Phospholipase C Beta 4 Gene	This gene is involved in the biosynthesis of second messenger molecules.	PLCB4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C160885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160885>	C160883	PLCB4 wt Allele|ARCND2|DJ1119D9.2|PI-PLC|Phopholipase C, Beta-4 Gene|Phospholipase C Beta 4 wt Allele|Phospholipase C, Beta 4 Gene	Human PLCB4 wild-type allele is located within 20p12.3-p12.2 and is approximately 412 kb in length. This allele, which encodes 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-4 protein, plays a role in diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) synthesis. Mutation of the gene is associated with auriculocondylar syndrome 2.	PLCB4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160886>	C16980	1-Phosphatidylinositol 4,5-Bisphosphate Phosphodiesterase Beta-4|1-Phosphatidylinositol 4,5-Bisphosphate Phosphodiesterase Beta 4|1-Phosphatidylinositol-4,5-Bisphosphate Phosphodiesterase Beta 4|EC 3.1.4.11|PLC-Beta-4|PLCB4|Phosphoinositide Phospholipase C-Beta-4|Phospholipase C Beta 4|Phospholipase C-Beta-4	1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-4 (1175 aa, ~134 kDa) is encoded by the human PLCB4 gene. This protein is involved in the synthesis of diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3).	1-Phosphatidylinositol 4,5-Bisphosphate Phosphodiesterase Beta-4		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160887>	C97927	PLCB4 Gene Mutation|ARCND2 Gene Mutation|PI-PLC Gene Mutation|Phospholipase C Beta 4 Gene Mutation	A change in the nucleotide sequence of the PLCB4 gene.	PLCB4 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160888>	C93102|C160887	Deleterious PLCB4 Gene Mutation|Deleterious ARCND2 Gene Mutation|Deleterious PI-PLC Gene Mutation|Deleterious Phospholipase C Beta 4 Gene Mutation|PLCB4 Driver Mutation	A change in the nucleotide sequence of the PLCB4 gene that is associated with increased risk of disease.	Deleterious PLCB4 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160889>	C1946|C129825	Abexinostat Tosylate|ABEXINOSTAT TOSYLATE|PCI-24781 Tosylate	The tosylate salt form of abexinostat, an orally bioavailable hydroxamate-based pan-inhibitor of histone deacetylase (HDAC), with potential antineoplastic and radiosensitizing activities. Upon administration, abexinostat inhibits HDAC, resulting in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling; the selective transcription of tumor suppressor genes; and the tumor suppressor protein-mediated inhibition of tumor cell division and induction of tumor cell apoptosis. In addition, abexinostat decreases the expression of the DNA-repair protein RAD51, thereby reducing the RAD51 protein, preventing repair of DNA double-strand breaks and increasing sensitivity of tumor cells to DNA damaging agents. HDAC, upregulated in many tumor types, is an enzyme that is responsible for the deacetylation of chromatin histone proteins.	Abexinostat Tosylate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C16088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16088>	C20021	Extraordinary Opportunities for Investment|Extraordinary Opportunities in Cancer Research	Research areas of exceptional promise in the cancer field.  To qualify as extraordinary opportunities these research initiatives must: Respond to important recent developments in knowledge and technology; Offer approaches to cancer research beyond the size, scope, and funding of our current research activities; Be implemented with specific, defined investments; Be described in terms of achievable milestones, with clear consequences for not investing; and Promise advances for making progress against all cancers. (from 2001 Bypass Budget)			Research Activity	
C160891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160891>	C201556	Adipose-derived Expanded Mesenchymal Stem Cells SCM-010|ADSCs SCM-010|Adipose Derived Stem Cells SCM-010|SCM 010|SCM-010|SCM010	A preparation of human adipose-derived mesenchymal stem cells (MSCs), that can potentially be used for engraftment purposes in certain autoimmune disorders. Upon intrathecal administration, adipose-derived expanded mesenchymal stem cells SCM-010 migrate to the bone marrow. These MSCs are pluripotent and capable of differentiating along specific lineages and may activate the immune system and repair damage to the nervous system.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology
C160892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160892>	C199140	Class of Case	A designation assigned to a group of cases within a study or trial.			Group	NAACCR Terminology
C160893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160893>	C25164	Date of Last Contact or Death	The date of the last contact with an individual or the date of their death.			Temporal Concept	NAACCR Terminology
C160894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160894>	C25162	Diagnostic Confirmation Code	The code for the method of cancer diagnostic confirmation.			Intellectual Product	NAACCR Terminology
C160895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160895>	C25162	Computed Spanish/Hispanic Ethnicity Code	Code identifying individuals for which ethnicity was determined by matching Last Name and Maiden Name to a computer list of Spanish/Hispanic names or by a software algorithm.			Intellectual Product	NAACCR Terminology
C160896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160896>	C25162	Histology Type Code ICD-O-3	Codes for the histologic type of the tumor being reported using ICD-O-3.			Intellectual Product	NAACCR Terminology
C160897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160897>	C93592	Marital Status Code at Diagnosis	Code for the patient's marital status at the time of diagnosis.			Intellectual Product	NAACCR Terminology
C160898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160898>	C70688	Primary Healthcare Payer at Diagnosis	Primary payer/insurance carrier at the time of initial diagnosis and/or treatment.			Organization	NAACCR Terminology
C160899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160899>	C93641	SEER Race Code	Race code in accordance with the SEER Program Coding and Staging Manual.			Intellectual Product	NAACCR Terminology
C16089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16089>	C16088	Extraordinary Opportunity: Cancer Genetics	Research of exceptional promise in the area of cancer genetics, covering the heredity and the biological process of transmission of characteristics from progenitor to offspring, especially concerning a heritable predisposition to cancer susceptibility. Research initiatives must respond to important recent developments in knowledge and technology; offer approaches to cancer research beyond the size, scope, and funding of our current research activities; be implemented with specific, defined investments; be described in terms of achievable milestones, with clear consequences for not investing; and promise advances for making progress against all cancers. (from 2001 Bypass Budget)			Research Activity	
C1608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1608>	C1941	Recombinant Lymphotoxin Beta|LT-beta|LTB Protein|Lymphotoxin Beta|TNFC|Tumor Necrosis Factor C	Lymphotoxin is a cytokine that orchestrates lymphoid neogenesis and is present on the surface of activated T-, B-, and LAK cells as a heterotrimer of alpha and beta subunits. It is also secreted as an alpha homotrimer. LT beta glycoprotein is a 33 kD type II membrane protein that anchors LT alpha to the cell surface.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C160900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160900>	C68926	Rural-Urban Continuum Code 2003|Beale Codes	Codes published by the Office of Management and Budget (OMB) in 2003 that separate counties into four metropolitan and six non-metropolitan categories based on the size their populations and form a classification scheme that distinguishes metropolitan counties by size and non-metropolitan counties by degree of urbanization and proximity to metro areas.			Classification	NAACCR Terminology
C160901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160901>	C68926	Rural-Urban Continuum Codes 2013	Codes published by the Office of Management and Budget (OMB) in 2013 that separate counties into four metropolitan and six non-metropolitan categories based on the size their populations and form a classification scheme that distinguishes metropolitan counties by size and non-metropolitan counties by degree of urbanization and proximity to metro areas.			Classification	NAACCR Terminology
C160902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160902>	C16899	SEER Summary Stage 2000	A methodology published by the Surveillance, Epidemiology and End Results Program (SEER) in 2000 to categorize how far a cancer has spread from its point of origin.			Qualitative Concept	NAACCR Terminology
C160903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160903>	C25162	ICD-O Tumor Topography Code|ICD-O Topography Code	A code for the primary site of a tumor being reported using either ICD-O-2 or ICD-O-3.			Intellectual Product	NAACCR Terminology
C160904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160904>	C212992|C148038|C129327	Recurrent Anaplastic Pleomorphic Xanthoastrocytoma	The reemergence of anaplastic pleomorphic xanthoastrocytoma after a period of remission.	Recurrent Anaplastic Pleomorphic Xanthoastrocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160905>	C216102|C153865|C129327	Refractory Anaplastic Pleomorphic Xanthoastrocytoma	Anaplastic pleomorphic xanthoastrocytoma that is resistant to treatment.	Refractory Anaplastic Pleomorphic Xanthoastrocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160906>	C124446	Number of Regional Lymph Nodes Examined	The number of regional lymph nodes that were removed and examined by the pathologist.			Quantitative Concept	NAACCR Terminology
C160907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160907>	C124447	Number of Regional Lymph Nodes Positive	The number of regional nodes examined by the pathologist and found to contain metastases.			Quantitative Concept	NAACCR Terminology
C160908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160908>	C25162	Sex Code	A code which indicates the sex of an individual.			Intellectual Product	NAACCR Terminology
C16090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16090>	C16088	Extraordinary Opportunity: Molecular Classification of Tumors|Director's Challenge|Director's Challenge: Towards a Molecular Classification of Tumors|Extraordinary Opportunities: the Director's Challenge: Toward a Molecular Classification of Tumors|Extraordinary Opportunity: Defining the Signatures of Cancer Cells: Detection and Diagnosis|Molecular Fingerprinting Initiative|Molecular Profiling Initiative	Challenge to research community to revolutionize the classification of human tumors, away from classification based on morphology, toward a more clinically predictive and useful classification system based on molecular characterization of tumors.  (Bypass Budget)			Intellectual Product	
C160910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160910>	C25162	ICD-O-3 Behavior Code	The code for the behavior of the tumor being reported using ICD-O-3.			Intellectual Product	NAACCR Terminology
C160911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160911>	C54443	NAACCR Terminology	Terminology developed to assist the North American Association of Central Cancer Registries with their data standards.			Intellectual Product	
C160912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160912>	C4049|C148038|C131617	Recurrent Anaplastic Ependymoma	The reemergence of anaplastic ependymoma after a period of remission.	Recurrent Anaplastic Ependymoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160913>	C4049|C153865	Refractory Anaplastic Ependymoma	Anaplastic ependymoma that is resistant to treatment.	Refractory Anaplastic Ependymoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160914>	C4717|C203302|C153823	Recurrent Anaplastic Ganglioglioma	The reemergence of anaplastic ganglioglioma after a period of remission.	Recurrent Anaplastic Ganglioglioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160915>	C4717|C224959|C153842	Refractory Anaplastic Ganglioglioma	Anaplastic ganglioglioma that is resistant to treatment.	Refractory Anaplastic Ganglioglioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160916>	C8816|C153071	Locally Advanced Liposarcoma	A liposarcoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Liposarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160917>	C8813|C153071	Locally Advanced Leiomyosarcoma	A leiomyosarcoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Leiomyosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160918>	C113842	Non-mass-like Enhancement|Magnetic Resonance Imaging Non-mass Like Enhancement|NMLE|Non-mass Enhancement|Non-masslike Enhancement|Nonmass Enhancement|Nonmass-like Enhancement	An area of enhancement on MRI that does not belong to a 3D mass or have distinct features of a mass. These lesions are characterized by their distribution, internal enhancement pattern, and symmetry (or lack thereof). (BI-RADS)			Finding	
C160919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160919>	C4926|C153066	Locally Advanced Undifferentiated Pleomorphic Sarcoma	An undifferentiated pleomorphic sarcoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Undifferentiated Pleomorphic Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16091>	C16088	Extraordinary Opportunity: Imaging Technologies	Goal: to develop a comprehensive imaging research program to fit the development of imaging technology with medical needs to create a system to evaluate new imaging technologies rapidly and effectively. (NCI Web)			Research Activity	
C160920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160920>	C153238|C148130	Locally Advanced Breast Carcinoma	A breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Breast Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C160921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160921>	C103175	CDISC Protocol Study Population Attribute Terminology|PROT-Att Study Population|Study Population Attribute Terminology|Study Population Attribute Terminology	Terminology associated with the protocol entity study population attribute codelist of the Clinical Data Interchange Standards Consortium (CDISC).			Intellectual Product	
C160922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160922>	C66830	CDISC SDTM Laboratory Analytical Method Calculation Formula Terminology|LBANMET|Laboratory Analytical Method Calculation Formula|SDTM-LBANMET	Terminology associated with the laboratory analytical method calculation formula codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C160923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160923>	C66830	CDISC SDTM Model Version ResponseTerminology|SDTM Version Response|SDTM-SDTMVRS|SDTMVRS	Terminology associated with the SDTM model version response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C160924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160924>	C66830|C165634	CDISC SDTM Implementation Guide Version Response Terminology|SDTM-SDTMIGRS|SDTMIG Version Response|SDTMIGRS	Terminology associated with the SDTM implementation guide version response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Define-XML Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C160925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160925>	C66830	CDISC Therapeutic Area User Guide Response Terminology|CDISC Therapeutic Area User Guide Response|CTAUGRS|SDTM-CTAUGRS	Terminology associated with the CDISC therapeutic area user guide response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C160926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160926>	C66830	CDISC SDTM FDA Technical Specification Response Terminology|FDA Technical Specification Response|FDATSRS|SDTM-FDATSRS	Terminology associated with the FDA technical specification response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C160927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160927>	C77526	CDISC SEND Body Irradiation Model Response Terminology|BIRRMRS|Body Irradiation Model Response|SEND-BIRRMRS	Terminology associated with the body irradiation model response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C160928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160928>	C77526	CDISC SEND Rad/Nuc Targeted Injury Model Response Terminology|RNTIMRS|Rad/Nuc Targeted Injury Model Response|SEND-RNTIMRS	Terminology associated with the rad/nuc targeted injury model response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C160929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160929>	C77526	CDISC SEND Expected Onset of Rad/Nuc Targeted Injury Response Terminology|EORNTI|Expected Onset of Rad/Nuc Targeted Injury Response|SEND-EORNTI	Terminology associated with the expected onset of rad/nuc targeted injury Response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16092>	C16088	Extraordinary Opportunity: Preclinical Models of Cancer	Goal: refine current models, create models that more closely parallel human cancers, devise efficient procedures that will make models available to all researchers who need them. (NCI Web)			Research Activity	
C160930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160930>	C77526	CDISC SEND Chemical Challenge Agent Name Response Terminology|CHAGNAMR|Chemical Challenge Agent Name Response|SEND-CHAGNAMR	Terminology associated with the chemical challenge agent name response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C160931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160931>	C77526	CDISC SEND Genus and Species Response Terminology|GENUSSPC|Genus and Species Response|SEND-GENUSSPC	Terminology associated with the genus and species response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C160932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160932>	C1932	Nerve Agent				Chemical Viewed Functionally	
C160933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160933>	C14252	Papio hamadryas	The baboon species, Papio hamadryas.			Mammal	
C160934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160934>	C161030	Saimiri|SQUIRREL|Squirrel Monkey|Squirrel Monkey				Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C160935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160935>	C80160	Complement C5 Measurement|C5|C5 Measurement|Complement C5|Complement C5	The determination of the amount of complement C5 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C160936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160936>	C49188	Beta-lactamase Positive Bacteria Measurement|BLPBAC|Beta-lactamase Positive Bacteria|Beta-lactamase Positive Bacteria	The determination of the amount of beta-lactamase positive bacteria in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C160937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160937>	C49188	Beta-lactamase Negative Bacteria Measurement|BLNBAC|Beta-lactamase Negative Bacteria|Beta-lactamase Negative Bacteria	The determination of the amount of beta-lactamase negative bacteria in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C160938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160938>	C48191	Latex Safety Information|Latex Safety				Intellectual Product	FDA CDRH GUDID Terminology
C160939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160939>	C160943	Implantable Device Status|Device Implantable Status	The status of the implantable device.			Qualitative Concept	FDA CDRH GUDID Terminology
C16093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16093>	C63475	Exogenous Hormone Therapy|Exogenous Hormone Use	Drug therapy that uses an exogenous hormone.			Therapeutic or Preventive Procedure	
C160941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160941>	C17357	Non-Binary Gender|Enby|Gender Variant|Gender Variant|NB|Non-binary|Non-binary Gender|Nonbinary|Nonbinary Gender	Having a gender that is neither male nor female. IMPORTANT NOTICE: The NCI Thesaurus contains biomedical terminologies that NCI does not own or control. This concept contains gender-related content that does not comply with Executive Order 14168.			Organism Attribute	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C160942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160942>	C122711	Reduced Device Function|Reduced Function	A decrease in the functionality of a device.			Event	FDA CDRH GUDID Terminology
C160943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160943>	C171084	Device Status	The current status of the device.			Qualitative Concept	FDA CDRH GUDID Terminology
C160944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160944>	C70865	Reported in Error	A report was made erroneously.			Qualitative Concept	FDA CDRH GUDID Terminology
C160945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160945>	C160943	Device Status Unknown|Unknown	The status of the device is unknown.			Qualitative Concept	FDA CDRH GUDID Terminology
C160946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160946>	C71460	UDI Entry Method|UDI Entry Type|Unique Device Identifier Entry Method	The method in which data was obtained about a device.			Conceptual Entity	FDA CDRH GUDID Terminology
C160947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160947>	C142379	Data Card|Card	A card which contains data for automatic processing of an item.			Intellectual Product	FDA CDRH GUDID Terminology
C160948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160948>	C142379	Unknown Data Entry Method|Unknown	The method of data entry is unknown.			Intellectual Product	FDA CDRH GUDID Terminology
C160949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160949>	C160946	AIDC UDI|Automatic Identification and Data Capture Unique Device Identifier	A method of encoding a UDI (and possibly other information) on a low cost and portable device that can be detected by a computer system.			Research Activity	FDA CDRH GUDID Terminology
C16094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16094>	C100084	Cardiac Function Study	The study and analysis of the normal or abnormal functioning of the heart using methods such as echocardiography, exercise stress cardiography, 24-hour Holter EKG and magnetic resonance imaging.			Diagnostic Procedure	
C160950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160950>	C54443	Pharmacotherapy Regimens	A set of concepts that are used as regimens to treat a disease.			Intellectual Product	
C160951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160951>	C160950	Single-agent Therapeutic Regimens	A course of drug therapy with one agent.			Intellectual Product	
C160952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160952>	C160950	Multi-agent Therapeutic Regimens	A course of drugs that contain multiple substances.			Intellectual Product	
C160953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160953>	C161901	Malayo-Polynesian Language	An Austronesian language spoken by the Austronesian people of the island nations of Southeast Asia and the Pacific Ocean, with a smaller number in continental Asia.			Language	
C160954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160954>	C210927	Northwest Caucasian Language|Abkhazo-Adyghean|Circassic|West Caucasian	A group of languages spoken in the northwestern Caucasus region, chiefly in three Russian republics (Adygea, Kabardino-Balkaria, Karachay-Cherkessia), the territory of Abkhazia, and Turkey, with smaller communities scattered throughout the Middle East.			Language	
C160955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160955>	C51277	Afroasiatic Language|Afrasian Language|Afro-Asiatic Language|Chamito-Semitic|Hamito-Semitic|Semito-Hamitic	A large language family of about 300 languages, including languages spoken predominantly in West Asia, North Africa, the Horn of Africa and parts of the Sahel.			Language	
C160956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160956>	C161904	West Germanic Language	A group of Germanic languages that developed in the region of the North Sea, Rhine-Weser, and Elbe.			Language	
C160957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160957>	C64493	Every Evening|EVERY EVENING	Planned or occurring every evening.			Qualitative Concept	CDISC SDTM Frequency Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C160958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160958>	C161852	Central Tano Language	Languages of the Niger-Congo family spoken in Ghana and Ivory Coast by the Akan people.			Language	
C160959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160959>	C63587|C159448	Carboplatin/Fluorouracil/Pembrolizumab Regimen|Carboplatin, Fluorouracil, Pembrolizumab|Carboplatin-Fluorouracil-Pembrolizumab|Carboplatin-Fluorouracil-Pembrolizumab Regimen|Carboplatin/5-FU/Pembrolizumab|Carboplatin/Fluorouracil/Keytruda|Carboplatin/Fluorouracil/Pembrolizumab	A regimen consisting of carboplatin, fluorouracil (5-FU) and pembrolizumab that may be used in the treatment of penile, and head and neck cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C16095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16095>	C70819|C208218|C16199	Cancer Control Trial|Clinical Trials: Cancer Control	A clinical trial with the intent of cancer prevention, risk reduction, earlier diagnosis, treatment improvements, increased survival, and quality of life improvements for cancer patients.			Research Activity	
C160962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160962>	C51277	Indo-European Language	A family of languages that developed and spread within the Indian subcontinent in the east to its westernmost reach in Europe.			Language	
C160963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160963>	C41397	Blasts 15 Percent or Less of Bone Marrow Nucleated Cells|Blasts Less than or Equal to 15 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that at most 15 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts 15 Percent or Less of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C160965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160965>	C63719|C63587|C63361|C159448	Cisplatin/Fluorouracil/Pembrolizumab Regimen|Cisplatin and Fluorouracil (CF) and Pembrolizumab|Cisplatin-Fluorouracil-Pembrolizumab|Cisplatin-Fluorouracil-Pembrolizumab Regimen|Cisplatin/Fluorouracil/Pembrolizumab	A regimen consisting of cisplatin, fluorouracil (5-FU) and pembrolizumab that may be used in the treatment of esophageal and esophagogastric junction, head and neck, penile, and gastric cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C160966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160966>	C160955	Semitic Language	A branch of the Afroasiatic language family originating in the Middle East that is spoken across much of Western Asia, North Africa and the Horn of Africa.			Language	
C160967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160967>	C190823|C177687	Sensitizing EGFR Mutation Negative|EGFR Sensitizing Gene Mutation Negative|EGFR Sensitizing Mutation Negative|Sensitizing EGFR Gene Mutation Negative|Sensitizing ERBB1 Mutation Negative|Sensitizing Epidermal Growth Factor Receptor Mutation Negative|Sensitizing HER1 Mutation Negative|Sensitizing c-erbB1 Mutation Negative	A finding indicating that mutations in the EGFR gene that impart increased sensitivity to EGFR inhibitory agents were not detected in a sample.	Sensitizing EGFR Mutation Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C160968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160968>	C17705	Cogmed Training Program|Cogmed Program|Cogmed Training|Cogmed Training Method	Online training sessions consisting of a selection of various game-like tasks that target the different aspects of working memory. The program includes versions for preschoolers, children 8-18, and adults.	Cogmed Training Program		Educational Activity	CTRP Intervention Terminology|CTRP Terminology
C160969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160969>	C222259	Cogstate Assessment Battery	Five measures to assess for visual learning, executive function, visual attention, processing speed, and working memory.	Cogstate Assessment Battery		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C16096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16096>	C208218	Cancer Treatment Trial|Clinical Trials: Cancer Treatment	A clinical study designed to evaluate biomedical or behavioral cancer interventions, generating safety data and efficacy information.			Research Activity	
C160970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160970>	C20993	Non-Cogstate Baseline and Follow-up Measures|Non-Cogstate Baseline and Follow-up Assessment Battery	A set of test and questionnaires consisting of one interview to capture demographic information, and one measure each for executive function and subjective assessment.	Non-Cogstate Baseline and Follow-up Measures		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C160973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160973>	C34076	Maxillary Alveolar Process|Alveolar process, maxillary	The portion of the maxilla that contains the sockets of the teeth.			Body Part, Organ, or Organ Component	
C160974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160974>	C5948|C3680	Cribriform Adenocarcinoma of Minor Salivary Gland|CAMSG	A minor salivary gland adenocarcinoma characterized by a cribriform pattern. It often metastasizes to the neck lymph nodes.			Neoplastic Process	
C160975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160975>	C34076	Mandibular Alveolar Process|Alveolar process, mandibular	The portion of the mandible that contains the sockets of the teeth.			Body Part, Organ, or Organ Component	
C160976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160976>	C54293|C215426	Sinonasal Adenocarcinoma|Nasal Cavity and Paranasal Sinus Adenocarcinoma	Adenocarcinomas that arises from the sinonasal tract. This category includes salivary-type and non-salivary type adenocarcinomas. The latter includes intestinal-type and non-intestinal-type adenocarcinomas.			Neoplastic Process	
C160977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160977>	C161008	Sinonasal Adenocarcinoma, Non-Intestinal-Type |Nasal Cavity and Paranasal Sinus Adenocarcinoma, Non-Intestinal-Type|Sinonasal Adenocarcinoma, Non-Intestinal-Type	An adenocarcinoma that arises from the sinonasal tract. It is characterized by the absence of features that resemble intestinal adenocarcinoma.			Neoplastic Process	
C160978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160978>	C43341|C215426|C213333	Head and Neck Sebaceous Carcinoma	A sebaceous carcinoma that arises from the head and neck region.			Neoplastic Process	
C160979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160979>	C34022	Laryngeal Surface of the Epiglottis|Epiglottis, laryngeal aspect	The surface of the epiglottis that is oriented toward the larynx.			Anatomical Structure	
C16097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16097>	C52647	Community Clinical Oncology Program|CCOP|Community Oncology|Oncology Programs	The Community Clinical Oncology Program (CCOP) was established by the National Cancer Institute (NCI) in 1983. Through this program, community physicians work with scientists conducting NCI-supported clinical trials.			Health Care Activity	
C160980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160980>	C35850|C191977|C188222	Head and Neck Neuroendocrine Carcinoma|Primary Head and Neck Neuroendocrine Carcinoma	A rare neuroendocrine carcinoma that arises from the head and neck. It is classified as small cell or large cell neuroendocrine carcinoma.			Neoplastic Process	
C160981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160981>	C160980|C156457	Head and Neck Small Cell Neuroendocrine Carcinoma|Head and Neck Small Cell Carcinoma|Head and Neck Small Cell Carcinoma	A neuroendocrine carcinoma that arises from the head and neck and is composed of malignant small cells. The mitotic count is more than 10 per 2 mm2 and/or the Ki-67 index is more than 20% (often more than 70%).			Neoplastic Process	
C160982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160982>	C191984|C160980	Head and Neck Large Cell Neuroendocrine Carcinoma	A neuroendocrine carcinoma that arises from the head and neck and is composed of malignant large cells. The mitotic count is more than 10 per 2 mm2 and/or the Ki-67 index is more than 20% (often more than 55%).			Neoplastic Process	
C160983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160983>	C34022	Lateral Surface of the Tongue|Lateral border of tongue	The side of the tongue.			Anatomical Structure	
C160984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160984>	C116316	Sinonasal Adenocarcinoma, Intestinal-Type with Papillary Pattern	An intestinal-type adenocarcinoma that arises from the sinonasal tract. It is characterized by the presence of a papillary growth pattern.			Neoplastic Process	
C160985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160985>	C35886	Tubuloglandular Pattern	A morphologic finding indicating the presence of a tubuloglandular growth pattern in a cellular infiltrate.			Finding	
C160986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160986>	C116316	Sinonasal Adenocarcinoma, Intestinal-Type with Colonic Pattern	An intestinal-type adenocarcinoma that arises from the sinonasal tract. It is characterized by the presence of a tubuloglandular growth pattern.			Neoplastic Process	
C160987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160987>	C116316	Sinonasal Adenocarcinoma, Intestinal-Type with Solid Pattern	An intestinal-type adenocarcinoma that arises from the sinonasal tract. It is characterized by the presence of a solid growth pattern.			Neoplastic Process	
C160988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160988>	C38617	Lateral Wall of the Nose|Nasal lateral wall	The outside wall of the nasal passages.			Body Part, Organ, or Organ Component	
C160989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160989>	C38617	Nasal Vestibule|Nasal vestibule	The most anterior part of the nasal cavity, lined by squamous epithelium.			Body Part, Organ, or Organ Component	
C160990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160990>	C14322	Sus|Mammals, Pigs|Pig|Porcine Species|porcine	The taxonomic genus Sus.			Mammal	
C160991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160991>	C160990	Sus scrofa|PIG|SUS SCROFA|Swine	The taxonomic species of pig, Sus scrofa.			Mammal	CDISC SEND Genus and Species Response Terminology|CDISC SEND Laboratory Animal Species Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C160992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160992>	C38617|C13393	Parotid Gland Superficial Lobe|Parotid gland, superficial lobe	The portion of the parotid gland that is superficial to the facial vein and facial nerve.			Body Part, Organ, or Organ Component	
C160993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160993>	C165195	Mandibular Vestibule of the Mouth|Vestibule of mouth, mandibular	The area of the mouth between the cheeks and the teeth of the mandible.			Body Part, Organ, or Organ Component	
C160994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160994>	C165195	Maxillary Vestibule of the Mouth|Vestibule of mouth, maxillary	The area of the mouth between the cheeks and the teeth of the maxilla.			Body Part, Organ, or Organ Component	
C160995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160995>	C26712|C116316	Sinonasal Adenocarcinoma, Intestinal-Type with Mucinous Pattern	An intestinal-type adenocarcinoma that arises from the sinonasal tract. It is characterized by the presence of malignant glandular cells with intracytoplasmic mucin.			Neoplastic Process	
C160996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160996>	C36282	Transglottic Extension of Laryngeal Tumor|Transglottic Extension|transglottic extension|transglottic_extension	Extension of a laryngeal tumor beyond the glottic opening into the ventricles and vocal cords.			Finding	GDC Property Terminology|GDC Terminology
C160997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160997>	C15454	Palatectomy	Surgical removal of part or all of the palate.			Therapeutic or Preventive Procedure	GDC Terminology|GDC Value Terminology
C160998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160998>	C14246	Rat|Mammals, Rats|RAT				Mammal	CDISC SEND Laboratory Animal Species Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C160999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C160999>	C15454	Endolaryngeal Excision|Endolaryngeal excision	Surgical excision performed through the mouth and glottic opening.			Therapeutic or Preventive Procedure	GDC Terminology|GDC Value Terminology
C16099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16099>	C38186	Cooperative Breast Cancer Tissue Resource|CBCTR	Provides researchers with access to approximately 8,000 cases of formalin-fixed, paraffin-embedded primary breast cancer specimens, with associated clinical data.  The collection is particularly well-suited for validation studies of diagnostic and prognostic markers.			Physical Object	
C1609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1609>	C97366	Ritonavir|Norvir|Norvir|Norvir|RIT|RITONAVIR|ritonavir	A peptidomimetic agent that inhibits both HIV-1 and HIV-2 proteases. Ritonavir is highly inhibited by serum proteins but boosts the effect of other HIV proteases by blocking their degradation by cytochrome P450.	Ritonavir		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C161000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161000>	C116316	Sinonasal Adenocarcinoma, Intestinal-Type with Mixed Pattern	An intestinal-type adenocarcinoma that arises from the sinonasal tract. It is characterized by the presence of a mixture of growth patterns.			Neoplastic Process	
C161001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161001>	C77097	Mustela putorius furo|Domestic Ferret|MUSTELA PUTORIUS FURO|Mustela furo	The common domestic ferret, Mustela putorious furo.			Mammal	CDISC SEND Genus and Species Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161002>	C51490	Deep Parotidectomy|Parotidectomy, deep	Surgical removal of part or all of the deep lobe of the parotid gland.			Therapeutic or Preventive Procedure	GDC Terminology|GDC Value Terminology
C161003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161003>	C156877	Automated Video-Assisted Smoking Treatment|AVAST	A fully automated and interactive smartphone-based treatment program that comprises interactive text messaging, images and audio/video clips to enable smoking cessation treatment content to be presented in an interactive, structured format anytime and anywhere.	Automated Video-Assisted Smoking Treatment		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C161004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161004>	C36282	Glottic Laryngeal Tumor with Subglottic Extension|Glottis, with subglottic extension	A finding of glottic involvement from a laryngeal tumor with extension of the tumor into the subglottis.			Finding	
C161005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161005>	C53543|C3020	Familial Focal Epilepsy with Variable Foci 1|FFEVF1	An autosomal dominant familial form of epilepsy caused by mutation(s) in the DEPDC5 gene, encoding GATOR complex protein DEPDC5. It is characterized by focal seizures usually arising from the frontal or temporal lobe. The onset of seizures may occur from infancy to adulthood.			Disease or Syndrome	Cellosaurus Disease Terminology
C161006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161006>	C134526	Canine Thyroid Gland Medullary Carcinoma	Thyroid gland medullary carcinoma occurring in a dog.			Neoplastic Process	Cellosaurus Disease Terminology
C161007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161007>	C160976	Sinonasal Adenocarcinoma, Salivary-Type|Nasal Cavity and Paranasal Sinus Adenocarcinoma, Salivary-Type	Adenocarcinomas that arise from the seromucinous glands and surface epithelium of the nasal cavity and paranasal sinuses. These adenocarcinomas morphologically resemble the adenocarcinomas that arise from the major and minor salivary glands.			Neoplastic Process	
C161008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161008>	C160976	Sinonasal Adenocarcinoma, Non-Salivary-Type|Nasal Cavity and Paranasal Sinus Adenocarcinoma, Non-Salivary-Type|Surface Epithelial (Non-Salivary-Type) Sinonasal Adenocarcinoma	Adenocarcinomas that arise from the nasal cavity and paranasal sinuses and do not resemble salivary gland adenocarcinomas. This category includes intestinal-type and non-intestinal type adenocarcinomas.			Neoplastic Process	
C161009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161009>	C48881	Clinical Primary Tumor TNM Finding|Clinical T Category	A clinical finding about one or more characteristics of a specific cancer, following the rules of the TNM classification system as they pertain to evaluating primary tumor.			Finding	
C16100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16100>	C16084	Correlative Study|Correlative	A type of study that tests for a relationship between a condition and a potential causal factor of the condition.			Research Activity	
C161011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161011>	C35886	Morphologic Features Resembling Salivary Gland Adenocarcinoma	A morphologic finding indicating that an adenocarcinoma which arises from a site other than the salivary glands, resembles a salivary gland adenocarcinoma.			Finding	
C161013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161013>	C161030	Marmoset	Twenty-two species of new world monkeys in the genera Callithrix, Cebuella, Callibella, and Mico.			Mammal	
C161014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161014>	C14192	Bos taurus|BOS TAURUS|Bos bovis|Bos bovis|Bos primigenius taurus|Bos primigenius taurus	The domesticated cow species, Bos taurus.			Mammal	CDISC SEND Genus and Species Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161015>	C14210	Capra hircus|CAPRA HIRCUS|Capra aegagrus hircus	The domesticated goat species, Capra hircus.			Mammal	CDISC SEND Genus and Species Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161016>	C4086	Non-Keratinizing Dysplasia|Nonkeratinizing|Nonkeratinizing Dysplasia|Nonkeratinizing dysplasia	Intraepithelial proliferation of dysplastic epithelial cells not associated with keratin formation.			Finding	GDC Terminology|GDC Value Terminology
C161017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161017>	C4086	Keratinizing Dysplasia|Keratinizing|Keratinizing dysplasia	Epithelial dysplasia in which the dysplastic changes, although limited to the lower basal zone, are so severe, that there is a high probability of progression to invasive carcinoma.			Finding	GDC Terminology|GDC Value Terminology
C161018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161018>	C35867	High Grade Transformation	Dedifferentiation of a malignant neoplasm.			Finding	
C161019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161019>	C223845|C127155	Oligometastatic Malignant Solid Neoplasm	A malignant solid neoplasm that has metastasized to a limited number of sites.	Oligometastatic Malignant Solid Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16101>	C52647	HIV Drug Resistance Program|HDRP|HIV DRP	This HIV initiative will create a center for retrovirology research, with emphasis on basic and translational research related to viral evolution and resistance biology. Scientific issues to be addressed in solving the problem of HIV drug resistance will require the coordinated efforts of experts in structural biology and biochemistry, molecular and clinical or in vivo virology, epidemiology, and chemistry. The new program also will include animal model studies of population dynamics and population genetics of HIV, mathematical modeling of virus populations and evolution, and, ultimately, translation of the findings into drug development.			Research Activity	
C161020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161020>	C40557	Oligometastatic Disease	A finding of a malignant solid neoplasm that has metastasized to a limited number of sites-existing in a state intermediate between localized disease and widespread metastatic disease.			Finding	
C161021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161021>	C717	Oncolytic Virus ASP9801|ASP 9801|ASP-9801|ASP9801	An engineered oncolytic virus with potential antineoplastic and immunomodulating activities. Upon intratumoral injection of ASP-9801, the oncolytic virus selectively targets and replicates in cancer cells without being able to infect and replicate in normal, healthy cells. This induces selective oncolytic virus-mediated cytotoxicity in cancer cells, which leads to cancer cell lysis. Following the lysis of infected cells, the replicated virus is released and can infect adjacent tumor cells, which both induces further tumor cell oncolysis and may activate the immune system to exert an anti-tumor immune response against the tumor cells.	Oncolytic Virus ASP9801		Pharmacologic Substance|Virus	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C161022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161022>	C4863|C213452	Prostate Intraductal Carcinoma|IDC-P|Intraductal Carcinoma of the Prostate|Intraductal Prostate Adenocarcinoma|Intraductal Prostate Carcinoma|Prostate Intraductal carcinoma	An intra-acinar and/or intraductal neoplastic epithelial proliferation in the prostate gland that has some features of high-grade prostatic intraepithelial neoplasia but exhibits much greater architectural and/or cytological atypia, typically associated with high-grade, high-stage prostate carcinoma. (WHO 2016)			Neoplastic Process	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C161023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161023>	C160934	Saimiri boliviensis boliviensis|Bolivian Squirrel Monkey|SAIMIRI BOLIVIENSIS BOLIVIENSIS	The Bolivian squirrel monkey sub-species, Saimiri boliviensis boliviensis.			Mammal	CDISC SEND Genus and Species Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161024>	C14285	Xenopus tropicalis|Tropical Clawed Frog|Western Clawed Frog|XENOPUS TROPICALIS|Xenopus laevis tropicalis	The Western clawed frog, Xenopus tropicalis.			Amphibian	CDISC SEND Genus and Species Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161025>	C14252	Papio anubis|Doguera Baboon|Kenya Baboon|PAPIO ANUBIS|Papio cynocephalus anubis|Papio doguera|Papio hamadryas anubis	The baboon species, Papio anubis.			Mammal	CDISC SEND Genus and Species Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161026>	C14252	Papio cynocephalus|PAPIO CYNOCEPHALUS|Papio hamadryas cynocephalus|Yellow Baboon	The baboon species, Papio cynocephalus.			Mammal	CDISC SEND Genus and Species Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161027>	C160933	Papio hamadryas hamadryas|PAPIO HAMADRYAS HAMADRYAS	The baboon sub-species, Papio hamadryas hamadryas.			Mammal	CDISC SEND Genus and Species Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161028>	C14252	Papio papio|Guinea Baboon|PAPIO PAPIO|Papio cynocephalus papio|Papio hamadryas papio	The baboon species, Papio papio.			Mammal	CDISC SEND Genus and Species Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161029>	C14243	Old World Monkey|Cercopithecidae				Mammal	
C16102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16102>	C15429	Investigator-Initiated Research	Research conceived and conducted by scientists in laboratories and clinics across the country and at NCI.			Research Activity	
C161030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161030>	C14243	New World Monkey				Mammal	
C161031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161031>	C161029	Chlorocebus	The old world monkeys in the genus chlorocebus.			Mammal	
C161032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161032>	C161031	Chlorocebus aethiops|CHLOROCEBUS AETHIOPS|Cercopithecus aethiops|Ceropithecus aethiops	The diurnal primate species, Chlorocebus aethiops.			Mammal	CDISC SEND Genus and Species Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161033>	C14231	Macaca nemestrina|MACACA NEMESTRINA|Southern Pig-Tailed Macaque	A medium sized macaque with a buff brown color and a short tail that is held semi-erect, found in Southern Thailand, Malaysia and Indonesia.			Mammal	CDISC SEND Genus and Species Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161034>	C7731|C3400	Prostate Synovial Sarcoma	A rare synovial sarcoma that arises from the prostate gland.			Neoplastic Process	
C161035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161035>	C8810|C7731	Prostate Osteosarcoma	A rare osteosarcoma that arises from the prostate gland.			Neoplastic Process	
C161036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161036>	C161029	Erythrocebus				Mammal	
C161037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161037>	C161036	Erythrocebus patas|Cercopithecus patas|ERYTHROCEBUS PATAS|Hussar Monkey|Patas Monkey|Wadi Monkey	The diurnal primate species, Erythrocebus patas.			Mammal	CDISC SEND Genus and Species Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161038>	C7731|C4247	Prostate Undifferentiated Pleomorphic Sarcoma	A rare undifferentiated pleomorphic sarcoma that arises from the prostate gland.			Neoplastic Process	
C161039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161039>	C14264	Rabbit Breed				Mammal	
C16103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16103>	C15429	Intramural Research	Research that takes place on the NCI campus.			Research Activity	
C161040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161040>	C14264	Oryctolagus				Mammal	
C161041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161041>	C161040	Oryctolagus cuniculus|Domestic Rabbit|Lepus cuniculus|ORYCTOLAGUS CUNICULUS	The rabbit species, Oryctolagus cuniculus.			Mammal	CDISC SEND Genus and Species Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161042>	C6481|C161045	Prostate Inflammatory Myofibroblastic Tumor	A rare inflammatory myofibroblastic tumor that arises from the prostate gland.			Neoplastic Process	
C161043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161043>	C14273	Sheep Breed				Mammal	
C161044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161044>	C14273	Ovis aries|Domestic Sheep|OVIS ARIES|Ovis ammon aries|Ovis orientalis aries|Ovis ovis	The domesticated sheep species, Ovis aries.			Mammal	CDISC SEND Genus and Species Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161045>	C3377|C3343	Prostate Soft Tissue Neoplasm|Prostate Mesenchymal Neoplasm	A mesenchymal neoplasm that arises from the prostate gland.			Neoplastic Process	
C161046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161046>	C27158	Supraventricular Bigeminy by ECG Finding|SUPRAVENTRICULAR BIGEMINY	An electrocardiographic finding of a supraventricular QRS complex followed by a premature supraventricular complex for 3 or more consecutive cycles; a regularly irregular rhythm of normal and abnormal QRS complexes in a 1-1 ratio. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161047>	C27158	Supraventricular Trigeminy by ECG Finding|SUPRAVENTRICULAR TRIGEMINY	An electrocardiographic finding of two supraventricular QRS complexes followed by a premature supraventricular complex for 3 or more consecutive cycles; a regularly irregular rhythm of normal and abnormal QRS complexes in a 2-1 ratio. (CDISC)			Finding	CDISC SDTM ECG Finding Terminology|CDISC SDTM Holter ECG Results Terminology|CDISC SDTM Terminology|CDISC SEND ECG Standard Character Result Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161048>	C5105|C4124|C156096	Metastatic Colorectal Adenocarcinoma	Colorectal adenocarcinoma that has spread from the original site of growth to other anatomic sites.	Metastatic Colorectal Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16104>	C70824|C208217	Multi-Institutional Clinical Trial|Central|Multicenter Clinical Trial|multicenter study|multicenter study|multicenter trial|multicenter trial	Clinical trial conducted according to a single protocol but at more than one site and, therefore, carried out by more than one investigator.			Research Activity	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology|GCT Authorized Value Terminology|GCT Histology Table
C16105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16105>	C16199|C15721	Nurses' Health Study	The Nurses' Health Study was begun in 1976 with the establishment of a cohort of 120,700 women aged 30-55 and was principally designed to assess risk factors for breast cancer. Cohort members initially resided in 11 geographically dispersed states representing the Northeast (Massachusetts, Connecticut, New York, New Jersey, Pennsylvania, Maryland), Northcentral (Ohio, Michigan), the West (California) and the South (Texas, Florida); although the majority of participants still reside in the original 11 states, members of the cohort currently live in all 50 states. These women report on exposures and disease outcomes every two years and follow-up in the cohort has been maintained at a level of better than 90% through 1990.			Research Activity	
C16106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16106>	C15224	Nutrition Research, Fats, Monosaturated	The study of the role of monunsaturated fats in cancer causation or prevention and in general health.			Research Activity	
C16107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16107>	C15776	Non-Invasive Cancer Detection|Non-Invasive Detection	Methods of detection which do not require penetration of the body or body openings.			Diagnostic Procedure	
C16108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16108>	C16126	Population-Based Registry				Intellectual Product	
C1610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1610>	C2843	Lurtotecan|7-(4-methylpiperazinomethylene)-10,11-ethylenedioxy-20(S)-camptothecin|GG 211|GI147211|LURTOTECAN|lurtotecan	A semisynthetic analogue of camptothecin with antineoplastic activity. Lurtotecan selectively stabilizes the topoisomerase I-DNA covalent complex and forms an enzyme-drug-DNA ternary complex. As a consequence of the formation of this complex, both the initial cleavage reaction and religation steps are inhibited and subsequent collision of the replication fork with the cleaved strand of DNA results in inhibition of DNA replication, double strand DNA breakage and triggering of apoptosis. Independent from DNA replication inhibition, lurtotecan also inhibits RNA synthesis, multi-ubiquitination and degradation of topoisomerase I and chromatin reorganization.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C16110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16110>	C16069	Study of Tamoxifen and Raloxifene|STAR	Part of the National Surgical Adjuvant Breast and Bowel Project.  A study to compare the efficacy of Tamoxifen to Raloxifene in prevention of primary breast cancer among women at high risk for the disease.			Research Activity	
C16111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16111>	C15224	Nutrition Resarch, Fats, Polyunsaturated	The study of the role of polyunsatured fats in cancer causation or prevention and in general health.			Research Activity	
C16112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16112>	C15787	Clinical Trial Eligibility Criteria|Eligibility Criteria for Clinical Trials|Study Eligibility Criteria|Study Eligibility Criteria|Study Eligibility Criterion|Trial Eligibility Criteria|Trial Eligibility Criteria|Trial Eligibility Criterion|eligibility criteria|eligibility criteria|eligibility criteria	Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.			Research Activity	CDISC DDF Entities Terminology|CDISC DDF Terminology|CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C16113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16113>	C16222	Psychological Impact of Cancer		Psychological Impact of Cancer		Idea or Concept	CTRP Disease Terminology|CTRP Terminology
C16114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16114>	C15843	Smoking Prevention	Interventions designed to keep people from starting to smoke.			Therapeutic or Preventive Procedure	
C16115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16115>	C15238	Suicide Gene Therapy	Targeted cancer therapy that forces cancer cells to self-destruct. Suicide gene therapy involves delivering a transgene into cancer cells through various targeted delivery methods followed by systemic exposure to a pro-drug. Within target cells the pro-drug is converted to an active form by the transgene, resulting in cell death.			Therapeutic or Preventive Procedure	
C16116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16116>	C200004	C51 Cytotoxicity Assay	A method of measuring the ability of cytotoxic lymphocytes to kill target cells.			Occupational Activity	
C16117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16117>	C16230	Craniospinal Axis Irradiation in Children	Having had craniospinal axis irradiation as a child.			Clinical Attribute	
C16118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16118>	C94631	Anti-HIV Therapy|AIDS anti-HIV therapy|therapy, AIDS anti-HIV|therapy, anti-HIV	Treatment of human immunodeficiency virus (HIV) infections with medications that target the virus directly, limiting the ability of infected cells to produce new HIV particles.			Therapeutic or Preventive Procedure	
C16119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16119>	C15511	Antiviral Therapy|Infectious Diseases / Treatment, Viral|Treatment of Infectious Diseases, Viral|treatment of viral infectious disease	Treatment of viral infections with agents that prevent viral replication in infected cells without impairing the host cell function.	Antiviral Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C1611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1611>	C1594	7-Cyanoquinocarcinol|(+)-DX 52-1|DX 52-1|DX-52-1|DX-52-1|DX-52-1	A semisynthetic analogue of the Streptomyces melanovinaceus-derived tetracyclic antitumor antibiotic quinocarmycin with potential antineoplastic activity. Quinocarmycin belongs to the naphthyridinomycin/saframycin class of antitumor antibiotics. These antibiotics appear to act through DNA alkylation.			Antibiotic|Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C16120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16120>	C49163	Abdominal Surgical Procedure|Abdominal Surgery	Surgery performed on any part of the abdominal region of the body.	Abdominal Surgical Procedure		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C16121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16121>	C15812	Neoplastic Disease and Pregnancy Study	Studies focusing on the effect of neoplastic disease on pregnancy, especially maternal factors (and efforts to modify these factors) that may affect the health of the child or fetus.			Research Activity	
C16122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16122>	C15429	Biomaterials Research	Research concerned with the application of biomaterials and the development of novel biomaterials.			Research Activity	
C16123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16123>	C71104	Clinical Trial, Other|Clinical Trials, Other|Other Clinical Trial	A clinical trial that is not therapeutic, preventive or diagnostic.			Research Activity	
C16124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16124>	C49236	Prior Therapy|Former Therapy|Prior Treatment|previously treated|previously_treated|prior therapy|prior treatment|prior_therapy|prior_treatment	Prior action or administration of therapeutic agents that produced an effect that is intended to alter or stop a pathologic process.			Clinical Attribute	GDC Property Terminology|GDC Terminology|ICDC Node Terminology|ICDC Property Terminology|ICDC Terminology
C16125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16125>	C15807|C15469	High Dose Interferon Alpha 2a	A treatment approved by FDA for treatment following surgery for melanoma patients who are at high risk of disease recurrence. (Bypass Budget)			Therapeutic or Preventive Procedure	
C16126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16126>	C15426	Population Database	Example: SEER and other cancer registries			Intellectual Product	
C16127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16127>	C15878|C15721	Long Island Breast Cancer Study|LIBCSP|Long Island Breast Cancer Study Project	The multistudy effort to investigate whether exposure to certain environmental factors (water quality, air pollution, electromagnetic fields, pesticides and other toxic chemicals, hazardous and municipal waste, etc.) contribute to the increased risk of breast cancer. Project started in 1993 under Public Law 103-43 and is funded and coordinated by the National Cancer Institute and the National Institute of Environmental Health Sciences. The study is conducted in Suffolk, Nassau, and Schoharie counties in New York and in Tolland County, Conn. It includes more than 10 studies: epidemiologic studies, family breast and ovarian cancer registry, laboratory research, and the creation of a new research tool, a Geographic Information System.			Research Activity	
C16128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16128>	C19896	Molecular Target	Every point of difference between premalignant or malignant cells and their normal counterparts is a potential target of opportunity for drug discovery - a molecular target of prevention or treatment.			Conceptual Entity	
C16129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16129>	C16130	Small Molecule Chemical Library	Collection of small compounds (predominantly druglike organic substances synthesized using methods of combinatorial chemistry) used for screening for antineoplastic properties.			Manufactured Object	
C1612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1612>	C697	Glufosfamide|Beta-D-Glucosyl-Ifosfamide Mustard|D-19575|GLUFOSFAMIDE|glc-IPM|glufosfamide	A compound consisting of the mustard agent ifosforamide conjugated to glucose, with potential alkylating activity. Glufosfamide is cleaved by glucosidases in tumor cells and forms ifosforamide. In turn, ifosforamide alkylates and forms DNA crosslinks, thereby inhibiting DNA replication and subsequent cell growth. The glucose moiety may enhance this agent's uptake by tumor cells.	Glufosfamide		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C16130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16130>	C48800	Diversity Library	Collections of different molecules, often produced through combinatorial synthetic methods, used as a starting pool to screen against a desired pharmacological target.			Manufactured Object	
C161312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161312>	C25365	Evidence of Malignant Disease Description|MALEVDES|Malignancy Evidence Description|Malignancy Evidence Description	A description of the basis for the determination that a malignancy is present.			Intellectual Product	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161313>	C156602	CDISC Diabetes Therapeutic Area User Guide Version 1.0 - Supplement for ADaM|Diabetes Therapeutic Area User Guide v1.0 - Supplement for ADaM	The 1.0 version of the CDISC Diabetes therapeutic area user guide ADaM supplement.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161314>	C65003|C51896|C146855	Robot-Assisted Salvage Pelvic Lymph Node Dissection	A surgical technique that uses a specially designed robotic system to aid removal of pelvic lymph nodes after failure of initial surgery or other treatment modalities.	Robot-assisted Salvage Pelvic Lymph Node Dissection		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C161315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161315>	C146855	Robot-assisted Salvage Pelvic Mass Resection	A surgical technique that uses a specially designed robotic system to aid removal of a pelvic mass after failure of initial surgery or other treatment modalities.	Robot-assisted Salvage Pelvic Mass Resection		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C161316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161316>	C16576	Female of Childbearing Potential	A female study subject or patient who has the potential to become pregnant.			Organism Attribute	
C161317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161317>	C70705	Population Rationale|Population Inclusion Rationale	An explanation as to the fundamental reasons for why a specific population of subjects is being considered for inclusion in a clinical study.			Intellectual Product	
C161318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161318>	C70705	Justification of Special Population	The explanation or reason as to why a special population of subjects is considered for inclusion in a clinical study.			Intellectual Product	
C161319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161319>	C93360	Condition or Disease under Study|diagnosis is primary disease|diagnosis_is_primary_disease	Primary disease(s) or condition(s) being studied in the trial, or the focus of the study. (clinicaltrials.gov)			Qualitative Concept	GDC Property Terminology|GDC Terminology
C16131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16131>	C213308	CDC Behavioral Risk Factor Surveillance Survey	A CDC-sponsored system of health-related telephone surveys that collect state data about U.S. residents regarding their health-related risk behaviors, chronic health conditions, and use of preventive services.			Health Care Activity	
C161320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161320>	C25457	Comorbid Condition|concurrent disease|concurrent_disease|synchronous malignancy|synchronous_malignancy	Medical or health condition that is concomitant or concurrent with the primary condition or disease under study.			Conceptual Entity	GDC Property Terminology|GDC Terminology|ICDC Property Terminology|ICDC Terminology
C161321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161321>	C70833	Reference Group	The study population that is defined for the purpose of comparison to the population under investigation.			Population Group	
C161322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161322>	C70833	Treatment Group|Clinical trial arm	A study population that receives an intervention(s) within a trial. This could include the investigational product(s) or a comparator (e.g., placebo or an approved intervention).			Population Group	
C161323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161323>	C70833	Experimental Group	A study population that receives the intervention that is the focus of the study.			Population Group	
C161324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161324>	C17005	Demographic Group	A population group that is characterized by a common descriptive factor such as age, sex, race, education, etc.			Population Group	
C161325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161325>	C225418	Frontal|FRONTAL	Of, or related to, or in the direction of the front of the body.			Spatial Concept	CDISC SDTM Directionality Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161326>	C225418	Occipital|OCCIPITAL	Of, or related to, or in the direction of the occiput, or back of the head.			Spatial Concept	CDISC SDTM Directionality Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161327>	C13442	Facial|FACIAL	Of, or related to, or in the direction of the face.			Spatial Concept	CDISC SDTM Directionality Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161328>	C25472	Threshold Cycle|Cp Number|Crossing point Number|Ct|Ct|Ct Number|Cycle Threshold|Cycle Threshold|Cycle Threshold #|Cycle Threshold Number|Elbow Value|QUANTIFICATION CYCLE NUMBER|THRSHCYC|TOP Number|Take-off Point Number|Threshold Cycle Number	The number of signal amplification cycles at which the signal reaches an intensity above the background signal.			Temporal Concept	CDISC SDTM Device Properties Test Code Terminology|CDISC SDTM Device Properties Test Name Terminology|CDISC SDTM Microbiology Findings Test Details Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161329>	C49556	Non-host Organism Identifiers Domain|Non-host Organism Identifiers|OI	A special-purpose domain utilized for the submission of information encompassing and representing data, vocabulary or records related to the levels of taxonomic nomenclature of microbes or parasites that have been either experimentally determined in the course of a study or are previously known.			Idea or Concept	CDISC SDTM Submission Domain Abbreviation Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16132>	C16088	Extraordinary Opportunity: Genes and the Environment	Goal: identify and characterize every major human gene that predisposes people to cancer; begin to apply these discoveries through clinical practice to help patients at risk; address the psychosocial, ethical, and legal issues associated with inherited cancer susceptibility (NCI Web)			Research Activity	
C161332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161332>	C64493	Every Twelve Weeks|EVERY 12 WEEKS|Q12S	Planned or occurring every twelve weeks.			Quantitative Concept	CDISC SDTM Frequency Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161333>	C64493	Every Three Years|EVERY 3 YEARS	Planned or occurring every three years.			Quantitative Concept	CDISC SDTM Frequency Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161334>	C64493	Every Five Years|EVERY 5 YEARS	Planned or occurring every five years.			Quantitative Concept	CDISC SDTM Frequency Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161335>	C64493	Every Six Days|Q6D	Planned or occurring every six days.			Quantitative Concept	CDISC SDTM Frequency Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161336>	C64493	Every Sixteen Weeks|EVERY 16 WEEKS|Q16S	Planned or occurring every sixteen weeks.			Quantitative Concept	CDISC SDTM Frequency Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161337>	C67208	T-Lymphocyte Proliferation Index|TLYMPIDX	A relative measurement (ratio or percentage) of T-lymphocyte proliferation due to stimulation by an antigen of interest to a non-stimulated T-lymphocyte proliferation control.			Laboratory Procedure	CDISC SDTM Immunogenicity Specimen Assessments Test Code Terminology|CDISC SDTM Immunogenicity Specimen Assessments Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161338>	C19044	CKD-EPI Creatinine Formula|CKD-EPI CREATININE FORMULA|CKD-EPI Creatinine 2009 Formula	A formula to estimate glomerular filtration rate that takes into account sex, age, race, and serum creatinine (SCr). eGFR(mL/min/1.73 m2)=141 x min(SCr/k, 1)^a x max(SCr/k, 1)^-1.209 x 0.993^Age x 1.018 [if female] x 1.159 [if black] where: SCr is in mg/dL; k=0.7 for Female and 0.9 for Male; a=-0.329 for female and -0.411 for male. (Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.)			Quantitative Concept	CDISC SDTM Laboratory Analytical Method Calculation Formula Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161339>	C19044	CKD-EPI Cystatin C Formula|CKD-EPI CYSTATIN C FORMULA|CKD-EPI Cystatin C 2012 Formula	A formula to estimate glomerular filtration rate that takes into account sex, age, race, and serum cystatin C (Scys). eGFR(mL/min/1.73 m2)=133 x min(Scys/0.8, 1)^-0.499 x max (Scys/0.8, 1)^-1.328 x 0.996^Age x 0.932 [if female]. (Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20-29.)			Quantitative Concept	CDISC SDTM Laboratory Analytical Method Calculation Formula Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16133>	C16088	Extraordinary Opportunity: Cancer Communications	Research of exceptional promise in the area of cancer communications, including disseminating cancer information to all audiences who will benefit, including patients, caregivers, health professionals, researchers, and the news media, both in the United States and abroad. Research initiatives must respond to important recent developments in knowledge and technology; offer approaches to cancer communications research beyond the size, scope, and funding of our current research activities; be implemented with specific, defined investments; be described in terms of achievable milestones, with clear consequences for not investing; and promise advances for making progress against all cancers. (from NCI OPCL and 2001 Bypass Budget)			Research Activity	
C161340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161340>	C19044	CKD-EPI Creatinine-Cystatin C Formula|CKD-EPI CREATININE-CYSTATIN C FORMULA|CKD-EPI Creatinine-Cystatin C 2012 Formula	A formula to estimate glomerular filtration rate that takes into account sex, age, race, serum creatinine (SCr) and serum cystatin C (Scys). eGFR(mL/min/1.73 m2)=135 x min(SCr/k, 1)a x max(SCr/k, 1)-0.601 x min(Scys/0.8, 1)-0.375 x max(Scys/0.8, 1)-0.711 x 0.995^Age x 0.969 [if female] x 1.08 [if black]. (Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20-29.)			Quantitative Concept	CDISC SDTM Laboratory Analytical Method Calculation Formula Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161341>	C19044	CKD-EPI Formula|CKD-EPI FORMULA|CKD-EPI GFR Formula Unspecified|Chronic Kidney Disease Epidemiology Collaboration Formula Unspecified	An unspecified formula to estimate glomerular filtration rate that takes into account factors such as sex, age, race, and biomarker measurements.			Quantitative Concept	CDISC SDTM Laboratory Analytical Method Calculation Formula Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161342>	C166363	Cockcroft-Gault Formula|COCKCROFT-GAULT FORMULA	A formula to estimate creatinine clearance that takes into account sex, age, weight, and serum creatinine (SCr). CCr=(140 - Age) x Wgt (Kg) / 72xCrt (mg/dL) x 1 (if M) or 0.85 (if F), for conventional units. CCr=(140 - Age) x Wgt (Kg) / 72xCrt (MCMOL/L) x 88.4 x 1 (if M) or 0.85 (if F) [If Wgt is in lbs; Wgt (Kg) = Wgt (lbs) x 0.45], for SI units. (Cockcroft, D.W. and M.H. Gault. Prediction of creatinine clearance from serum creatinine. Nephron. 1976. 16(1):31-41.)			Quantitative Concept	CDISC SDTM Laboratory Analytical Method Calculation Formula Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161343>	C19044	MDRD 4 Variable Formula|MDRD 4 VARIABLE FORMULA	A formula to estimate glomerular filtration rate that takes into account age, sex, race, and serum creatinine (Scr). eGFR (mL/min/1.73 m2) = 186 x (Scr)^-1.154 x (Age)^-0.203 x (0.742 if female) x (1.210 if African American). (Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-70.)			Quantitative Concept	CDISC SDTM Laboratory Analytical Method Calculation Formula Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161344>	C19044	MDRD 5 Variable Formula|MDRD 5 VARIABLE FORMULA	A formula to estimate glomerular filtration rate that takes into account age, sex, race, serum creatinine and serum urea nitrogen. eGFR (mL/min/1.73 m = 270 x creatinine (mg/dl)^-1.007 x age^-0.180 x 1.178 (if black) x 0.762 (if female) x serum urea nitrogen^-0.169. (Levey AS, Greene T, Kusek JW, Beck GJ, MDRD study group. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000; 11: A0828.)			Quantitative Concept	CDISC SDTM Laboratory Analytical Method Calculation Formula Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161345>	C19044	MDRD 6 Variable Formula|MDRD 6 VARIABLE FORMULA	A formula to estimate glomerular filtration rate that takes into account age, sex, race, serum creatinine, serum urea nitrogen, and albumin. eGFR (mL/min/1.73 m2) = 170 x (SCr/88.4)^-0.999 x age^-0.176 x (SU x 2.78)^-0.170 x albumin^0.318 x (0.762, if female) x (1.18, if African American). (Levey AS, Greene T, Kusek JW, Beck GJ, MDRD study group. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000; 11: A0828.)			Quantitative Concept	CDISC SDTM Laboratory Analytical Method Calculation Formula Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161346>	C19044	MDRD Enzymatic Formula|IDMS MDRD|MDRD ENZYMATIC FORMULA	A formula to estimate glomerular filtration rate that takes into account age, sex, race, and serum creatinine. eGFR (mL/min/1.73 m2)=175 x (serum Cr [conv mg/dL])^-1.154 x (Age)^ -0.203 x (0.742 if female) x (1.212 if black), for conventional units. eGFR=175 x (serum Cr [SI UMOL/L]/88.4)^-1.154 x (Age)^ -0.203 x (0.742 if female) x (1.212 if black), for SI units. (Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-12.)			Quantitative Concept	CDISC SDTM Laboratory Analytical Method Calculation Formula Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161347>	C19044	MDRD Enzymatic Japanese Formula|MDRD ENZYMATIC JAPANESE FORMULA|MDRD Enzymatic Japanese 2007 Formula|MDRD Enzymatic Japanese Imai 2007 Formula	A formula to estimate glomerular filtration rate in Japanese subjects that takes into account age, sex, and serum creatinine. eGFR (ml/min/1.73m2) = 194 x PD93 power^-1.094 x Age power^- 0.287 x Sex; where PD93 = Serum Cr (mg/dL), Sex = 1.00 for male and 0.739 for female. (Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S. Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan. Am J Kidney Dis. 2007 Dec;50(6):927-37.)			Quantitative Concept	CDISC SDTM Laboratory Analytical Method Calculation Formula Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161348>	C19044	Schwartz Method For Children Formula|SCHWARTZ METHOD FOR CHILDREN FORMULA|Schwartz Method for Children 1985 Formula	A formula to estimate glomerular filtration rate in children that takes into account age, height, and serum creatinine. eGFR (mL/min/1.73 m2) = k x Height (cm)/Serum creatinine (mg/dL) where k=0.33 for pre-term babies, 0.45 for full-term babies and 0.55 for girls ages 1-13 or 0.70 for boys ages 1-13. (Schwartz GJ, Gauthier B. A simple estimate of glomerular filtration rate in adolescent boys. J Pediatr. 1985 Mar;106(3):522-6.)			Quantitative Concept	CDISC SDTM Laboratory Analytical Method Calculation Formula Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161349>	C74679	Fractional Iron Absorption|FRFEABS|IAD	A relative measurement (ratio or percentage) of the iron absorbed into tissue or cells to the total available iron.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16134>	C213420|C15922	Biobehavioral Determinants of Tobacco Use and Addiction	Studies of the links between biology and behavior aimed at identifying preexisting vulnerabilities to tobacco use and addiction.  By determining how these vulnerabilities interact with sociocultural and psychological influences on tobacco use, and by improving the ability to assess risks quantitatively, more effective prevention and cessation interventions can be developed and tailored to those most likely to benefit from them.			Occupational Activity	
C161350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161350>	C74678	Fructosamine Corrected for Total Protein Measurement|FRUMCRTP|Fructosamine Corrected for Total Protein|Fructosamine Corrected for Total Protein	The determination of the amount of fructosamine, corrected for total protein, present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161351>	C147376	Kappa Light Chain to Lambda Light Chain Ratio Measurement|KLCLLC|Kappa Lambda Ratio|Kappa Light Chain/Lambda Light Chain|Kappa Light Chain/Lambda Light Chain	The determination of the ratio of kappa light chain compared to lambda light chain present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161352>	C49237	Nitrate Measurement|NITRATE|Nitrate|Nitrate|Nitric Acid|Nitric Acid Measurement	The determination of the amount of nitrate present in a sample.	Nitrate Measurement		Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C161353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161353>	C67208	Large Platelets to Total Platelets Ratio Measurement|Large Platelets/Total Platelets|Large Platelets/Total Platelets|PLCR|PLTLPLT|Platelet Large Cell Ratio	The determination of the ratio of large platelets compared to total platelets present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161354>	C49237	Anisochromia Measurement|ANISOCHR|Anisochromia|Anisochromia	A measurement of the color variation of erythrocytes in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161355>	C64430	Cytochrome P450 2C9 Measurement|CYP2C9|CYP2C9 Measurement|Cytochrome P450 2C9|Cytochrome P450 2C9	The determination of the amount of cytochrome P450 2C9 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161356>	C161355	Cytochrome P450 2C9 Activity Measurement|CYP2C9 Activity Measurement	The determination of the amount of the biological activity of cytochrome P450 2C9 in a sample.			Laboratory Procedure	
C161357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161357>	C160935	Free Complement C5 Measurement|C5FR|Complement C5, Free|Complement C5, Free|Free C5 Measurement	The determination of the amount of free complement C5 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161358>	C49237	Inorganic Pyrophosphate Measurement|Inorganic Pyrophosphate|Inorganic Pyrophosphate|PPI|PPi Measurement	The determination of the amount of inorganic pyrophosphate present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161359>	C49237	Pus Measurement|PUS|Pus|Pus	The determination of the amount of pus present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16135>	C16035	Intensity-Modulated Radiation Therapy|IMRT|IMRT|IMRT|INTENSITY-MODULATED RADIATION THERAPY|Intensity Modulated RT|Intensity modulated radiation therapy (procedure)|Intensity-Modulated Radiotherapy|Radiation, Intensity-Modulated Radiotherapy|intensity-modulated radiation therapy	An advanced form of 3-Dimensional Conformal Radiation Therapy (3D CRT) that involves the use of varying intensities of small radiation beams to produce dosage distributions that are more precise than those possible with 3D CRT.	Intensity-Modulated Radiation Therapy		Therapeutic or Preventive Procedure	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|EWS Authorized Value Terminology|EWS Radiation Therapy Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Radiation Therapy Table|mCode Photon Beam Technique Value Set|mCode Radiotherapy Technique Value Set|mCode Teleradiotherapy Technique Value Set|mCode Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology|OS Authorized Value Terminology|OS Radiation Therapy Table
C161360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161360>	C81867	Chemokine (C-X-C Motif) Ligand 11 Measurement|CXCL11|CXCL11 Measurement|Chemokine (C-X-C Motif) Ligand 11|Chemokine (C-X-C Motif) Ligand 11|I-TAC|IFN-inducible T Cell Alpha Chemoattractant|ITAC	The determination of the amount of chemokine (C-X-C Motif) ligand 11 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161361>	C81867	Chemokine (C-X3-C Motif) Ligand 1 Measurement|CX3CL1|CX3CL1 Measurement|Chemokine (C-X3-C Motif) Ligand 1|Chemokine (C-X3-C motif) Ligand 1|Fractalkine|Fractalkine Measurement|Neurotactin	The determination of the amount of chemokine (C-X3-C Motif) ligand 1 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161362>	C81867	Chemokine (C-C Motif) Ligand 20 Measurement|CCL20|CCL20|CCL20 Measurement|Chemokine (C-C Motif) Ligand 20|Chemokine (C-C Motif) Ligand 20|LARC|Liver Activation Regulated Chemokine|MIP3A|Macrophage Inflammatory Protein-3 Alpha	The determination of the amount of chemokine (C-C Motif) ligand 20 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161363>	C64848	Hemoglobin Fraction Pattern|HGBFPATN	A description of the hemoglobin fraction pattern in a biological specimen.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161364>	C67208	Unspecified Cells to Leukocytes Ratio Measurement|UNSPCELE|Unspecified Cells/Leukocytes|Unspecified Cells/Leukocytes	The determination of the ratio of unspecified cells compared to leukocytes present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161365>	C74663	Progressive Spermatozoa to Total Spermatozoa Ratio Measurement|SPMPSPM|Spermatozoa, Progressive/Spermatozoa|Spermatozoa, Progressive/Spermatozoa	The determination of the ratio of progressive spermatozoa compared to total spermatozoa present in a sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161366>	C74663	Progressive Spermatozoa Measurement|SPERMP|Spermatozoa, Progressive|Spermatozoa, Progressive	The determination of the amount of progressive spermatozoa present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161367>	C45997	pH Adjusted for Body Temperature Measurement|PHADJT|pH Adjusted for Body Temp|pH Adjusted for Body Temp	The determination of the pH, adjusted for body temperature, present in a sample.			Phenomenon or Process	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161368>	C147438	Thyroid Stimulating Immunoglobulin Actual to Control Ratio Measurement|TSI Actual/Control|TSI Actual/Control|TSIAC|Thyroid Stimulating Immunoglobulin Actual/Control|Thyroid Stimulating Immunoglobulin Actual/Normal	The determination of the ratio of the thyroid stimulating immunoglobulin in a subject's specimen compared to a control sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Immunogenicity Specimen Assessments Test Code Terminology|CDISC SDTM Immunogenicity Specimen Assessments Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161369>	C102277	APTT-LA Actual to Control Ratio Measurement|APTT-LA Actual/Control|APTT-LA Actual/Control|APTTLAAC|Lupus Anticoagulant Sensitive APTT Actual/Control	The determination of the ratio of the Lupus anticoagulant sensitive APTT in a subject's specimen compared to a control sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16136>	C16147	Natural History and Cofactors Study	A study that monitors the development and progression of a disease or condition, with particular emphasis on those cofactors that may affect the natural history and progression of the disease or condition, with no emphasis on diagnosis or treatment.			Conceptual Entity	
C161370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161370>	C80365	Thrombin Time Actual to Control Ratio Measurement|TTAC|Thrombin Time Actual/Control|Thrombin Time Actual/Control	The determination of the ratio of the thrombin time in a subject's specimen compared to a control sample. The measurement may be expressed as a ratio or percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161371>	C92745|C62662	Thrombin Antithrombin Complex Measurement|TAT|TATC|Thrombin Antithrombin Complex|Thrombin Antithrombin Complex|Thrombin Antithrombin Complex Antigen	The determination of the amount of thrombin antithrombin complex present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161372>	C102277	APTT-LA Screen to Confirm Percent Difference|APLASCPD|APTT-LA Screen to Confirm Pct Difference|PTT-LA Screen to Confirm Pct Difference	A measurement to confirm the presence of Lupus anticoagulants, calculated as [(Screen aPTT - Confirm aPTT)/Screen aPTT]x100.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161373>	C62662	dRVVT Screen to Confirm Percent Difference|DRVTSCPD|dRVVT Screen to Confirm Pct Difference|dRVVT Screen to Confirm Pct Difference	A measurement to confirm the presence of Lupus anticoagulants, calculated as [(Screen dRVVT - Confirm dRVVT)/Screen dRVVT]x100.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161374>	C147128	Choriogonadotropin Adjusted for Maternal Weight Measurement|CGADJMW|Choriogonadotropin Adj for Maternal Wt|Choriogonadotropin Adj for Maternal Wt|Choriogonadotropin Adjusted for Maternal Weight	The determination of the amount of choriogonadotropin, adjusted for maternal weight, present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161375>	C116184	Erythrocyte Inclusion Bodies Measurement|Erythrocyte Inclusion Bodies|Erythrocyte Inclusion Bodies|INCLBRBC	The determination of the amount of erythrocyte inclusion bodies present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161376>	C74697	Tramadol Measurement|TRAMADOL|Tramadol|Tramadol	The determination of the amount of tramadol present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161377>	C13039	Vaginal Wall|VAGINAL WALL|Vaginal wall (body structure)	The tissue layers that enclose the vaginal canal.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C161378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161378>	C52754	Skin of the Forearm|SKIN OF THE FOREARM	The integument that covers the forearm.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161379>	C12295	Skin of the Chest|SKIN OF THE CHEST	The integument that covers the chest.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16137>	C15878	Special Populations Research	Multidisciplinary research aimed at addressing and modifying the excessive cancer incidence and/or mortality rates, the lower cancer survival rates, or the inadequate cancer prevention and control services for special populations.  The term "special populations" refers to those population segments that may experience, or are known to experience, high cancer rates and/or are underserved in terms of cancer prevention and control programs.  Special populations include Alaskan natives, American Indians, Hispanics, Asian- Americans, Blacks, blue-collar groups, the elderly, lower-income groups, native Hawaiians, and American Samoans. (DEA-CAACT)			Research Activity	
C161380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161380>	C12470	Skin of the Inguinal Region|SKIN OF THE INGUINAL REGION	The integument that covers the inguinal region.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C161381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161381>	C38629	Heel of the Foot|HEEL OF THE FOOT|Heel (calcaneus)	The rounded back part of the foot below the ankle and behind the arch.			Body Part, Organ, or Organ Component	ALL Adverse Events Table|ALL Authorized Value Terminology|CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161382>	C38628	Heel of the Hand|HEEL OF THE HAND|Heel of the Palm	The raised part of the palm of the hand that is adjacent to the wrist.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161383>	C13045	Finger Flexor Tendons|FINGER FLEXOR TENDONS	The tendons located on the palm side of the fingers that connect the flexor muscles of the forearm and hand to bones in the fingers, enabling flexion towards the palm.			Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161384>	C13045	Finger Extensor Tendons|FINGER EXTENSOR TENDONS	The tendons located on the dorsal side of the fingers that connect muscles of the forearm and hand to bones in the fingers, enabling straightening of the fingers.			Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161385>	C13045	Wrist Joint Flexor Tendons|WRIST JOINT FLEXOR TENDONS	The tendons located along the inside of the forearm that cross at the wrist and connect muscles of the forearm to wrist and hand bones, enabling bending of the wrist towards the palm.			Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161386>	C13045	Wrist Joint Extensor Tendons|WRIST JOINT EXTENSOR TENDONS	The tendons located along the back part of the forearm that cross to the thumb side of the wrist and connect muscles of the forearm to the base of hand bones, enabling bending of the wrist back and towards the thumb.			Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161387>	C13045	Shoulder Joint Tendons|SHOULDER JOINT TENDONS	The tendons that connect the muscles and bones that comprise the glenohumeral and acromioclavicular joints and enable abduction of the arm and stabilization of the shoulder.			Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161388>	C13045	Knee Joint Tendons|KNEE JOINT TENDONS	The tendons that connect the quadriceps muscles to the kneecap, the hamstring muscles to the shin bone and fibula, and the patella to the top part of the fibula, enabling flexion, extension, and slight rotation of the knee.			Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161389>	C13045	Ankle Joint Anterior Flexor Tendons|ANKLE JOINT ANTERIOR FLEXOR TENDONS	The tendons in the anterior compartment of the leg that connect muscles that originate on the surfaces of the femur, tibia, and fibula to bones in the toes and enable plantar flexion of the foot at the ankle.			Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16138>	C16088	Extraordinary Opportunity: Molecular Targets of Prevention and Treatment	Goal: we now have very focused targets against which to direct prevention and therapy efforts. The Molecular Targets Initiative will seek to discover and develop novel prevention, therapeutic, diagnostic, and imaging agents based on our understanding of these targets.  (NCI Web)			Research Activity	
C161390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161390>	C13045	Ankle Joint Anterior Extensor Tendons|ANKLE JOINT ANTERIOR EXTENSOR TENDONS	The tendons in the anterior compartment of the leg that cross the tibiotalar joint anteriorly and connect muscles that originate on the surfaces of the tibia and fibula to bones in the toes and enable dorsiflexion of the foot at the ankle and extension of the toes.			Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161391>	C142318	Skin of the Infrascapular Region|SKIN OF THE INFRASCAPULAR REGION	The integument that covers the region of the back, lateral to the vertebral region and below the scapula.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161392>	C184659|C135409	Chlamydia trachomatis DNA Measurement|CTRDNA|Chlamydia trachomatis DNA|Chlamydia trachomatis DNA	The determination of the amount of Chlamydia trachomatis DNA present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161393>	C161395|C132301	HIV-1/2 RNA Measurement|HIV-1/2 RNA|HIV-1/2 RNA|HIV12RNA	The determination of the amount of HIV-1/2 RNA present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161394>	C184672|C135409	Cytomegalovirus DNA Measurement|CMVDNA|Cytomegalovirus DNA|Cytomegalovirus DNA	The determination of the amount of Cytomegalovirus DNA present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161395>	C49188	Human Immunodeficiency Virus Measurement|HIV|HIV Measurement|Human Immunodeficiency Virus|Human Immunodeficiency Virus	The determination of the amount of Human Immunodeficiency Virus present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161396>	C187848	Enterococcus faecalis Measurement|EFA|Enterococcus faecalis|Streptococcus faecalis	The determination of the amount of Enterococcus faecalis present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161398>	C160936	Neisseria gonorrhoeae, Beta-lactamase Positive Measurement|N. gonorrhoeae, Beta-lactamase Positive|N. gonorrhoeae, Beta-lactamase Positive|NGOBLP	The determination of the amount of beta-lactamase positive Neisseria gonorrhoeae present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161399>	C160937	Neisseria gonorrhoeae, Beta-lactamase Negative Measurement|N. gonorrhoeae, Beta-lactamase Negative|N. gonorrhoeae, Beta-lactamase Negative|NGOBLN	The determination of the amount of beta-lactamase negative Neisseria gonorrhoeae present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16139>	C16088	Extraordinary Opportunity: Research on Tobacco and Tobacco Related Cancers	Goal : to expand our understanding of tobacco addiction and the biological mechanisms underlying tobacco-induced cancers, develop ways to keep people of all ages from using tobacco, create interventions to prevent tobacco-related cancers in smokers and former smokers, and develop treatments for tobacco addiction and the cancers it causes. (from NCI Initiatives Web page)			Research Activity	
C1613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1613>	C2500	Antineoplaston AS2-1|AS2-1|Astugenal|L-Glutamine, N2-(phenylacetyl)-, Monosodium Salt, Mixture with Sodium Benzeneacetate	A 4:1 mixture of phenylacetate and phenylacetylgluatmine, degradation products of the antineoplaston agent A10.  Antineoplaston AS2-1 inhibits the incorporation of L-glutamine into tumor-cell proteins, leading to cell cycle arrest in the G1 phase and inhibition of mitosis.  This agent may also inhibit RAS oncogene expression and activate tumor suppressor gene p53, resulting in cell differentiation and apoptosis. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C161400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161400>	C64430|C49188	Bacterial Beta-lactamase Measurement|BACBLACT|Bacterial Beta-lactamase|Bacterial Beta-lactamase	The determination of the amount of bacterial Beta-lactamase present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161401>	C154812	Gram Negative Cocci Measurement|GMNCOC|Gram Negative Cocci|Gram Negative Cocci	The determination of the amount of gram negative cocci present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161402>	C221610	Gardnerella vaginalis Measurement|Corynebacterium vaginalis|GVA|Gardnerella vaginalis|Gardnerella vaginalis	The determination of the amount of Gardnerella vaginalis present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161403>	C49188	Trichomonas vaginalis Measurement|TVA|Trichomonas vaginalis|Trichomonas vaginalis	The determination of the amount of Trichomonas vaginalis present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161404>	C179757	Candida albicans Measurement|CAL|Candida albicans|Candida albicans|Candida stellatoidea	The determination of the amount of Candida albicans present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161405>	C17204	Quantitative Computed Tomography|QCT|QUANTITATIVE COMPUTED TOMOGRAPHY	A type of computed tomography in which a calibration standard correlates radiodensity values to quantitative tissue density values.	Quantitative Computed Tomography		Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C161406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161406>	C17455	Single-Molecule Array|SINGLE-MOLECULE ARRAY|SiMoA|Single Molecule Array Immunoassay	A type of enzyme-linked immunoassay in which single molecules can be detected through the use of femtomolar-sized reaction chambers and an excess of fluorescently labeled antibody-bound beads.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161407>	C116518	Dynamometry|DYNAMOMETRY	A technique that measures the torque, or force, of muscle action.	Dynamometry		Health Care Activity	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C161408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161408>	C38081	Multiple Inert Gas Elimination Technique|MIGET|MIGET	A technique that measures the pulmonary exchange of a set of six different inert gases dissolved together in saline (or dextrose) and infused intravenously. The measurements are then used to compute the distribution of ventilation/perfusion ratios that best describes the exchange of the six gases simultaneously. (Wagner PD. The multiple inert gas elimination technique (MIGET). Intensive Care Med. 2008 Jun;34(6):994-1001.)			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161409>	C49132	Kleihauer-Betke Staining Procedure|KLEIHAUER-BETKE	A biospecimen collection and staining procedure in which maternal blood smear is prepared and stained using Shepard's staining method, followed by microscopic examination to identify fetal-maternal hemorrhage (fetal hemoglobin transference to the mother's bloodstream).			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16140>	C208219	Intervention Trial	A pre-clinical or clinical study in human beings in which individuals are assigned by an investigator based on a protocol to receive specific interventions. The individuals are then followed and biomedical and/or health outcomes are assessed.			Research Activity	
C161410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161410>	C49627	Subject Removed at Sponsor Request|SPONSOR REQUEST	An indication that the study subject was removed from the study at the sponsor's request.			Idea or Concept	CDISC SDTM Reason for Non-Completion Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161411>	C49627	Non-Compliance With Study Schedule|NON-COMPLIANCE WITH STUDY SCHEDULE	An indication that a study subject has not followed the schedule of activities.			Idea or Concept	CDISC SDTM Reason for Non-Completion Terminology|CDISC SDTM Terminology|CDISC SDTM Tobacco Study Completion/Reason for Non-Completion Terminology|Clinical Data Interchange Standards Consortium Terminology
C161412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161412>	C135483	No Steroid Use Beyond Physiologic Replacement Dose|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE	An indication that the subject's steroid dose is the same as their physiologic replacement dose.			Qualitative Concept	CDISC SDTM Terminology|CDISC SDTM Tumor Response Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C161413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161413>	C85761	Natural Log Transformed Observed Area Under the Curve Infinity|AUC Infinity Obs LN Transformed|AUC Infinity Obs LN Transformed|AUCIFOLN	The natural log transformed area under the curve (AUC) extrapolated to infinity, calculated using the observed value of the last non-zero concentration.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161414>	C85565	Natural Log Transformed Area Under the Curve From Dosing to Last Concentration|AUC to Last Nonzero Conc LN Transformed|AUC to Last Nonzero Conc LN Transformed|AUCLSTLN	The natural log transformed area under the curve (AUC) from the time of dosing to the last measurable concentration.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161415>	C70918	Natural Log Transformed Cmax|CMAXLN|Max Conc LN Transformed|Max Conc LN Transformed	The natural log transformed maximum concentration occurring at Tmax.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161416>	C43242	PK Swing|SWING|Swing|Swing	The difference between Cmax and Cmin standardized to Cmin within a dosing interval.			Conceptual Entity	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161417>	C70732	Subject Entered Into Trial|ENTERED INTO TRIAL	An indication that the subject has met eligibility criteria and is enrolled in the study. The subject may or may not subsequently be randomized.			Conceptual Entity	CDISC SDTM Protocol Milestone Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161418>	C19683	Informed Assent|INFORMED ASSENT OBTAINED|assent	Assent given by a minor or adult who is unable to give consent on their own behalf, to participate in a clinical trial. Assent must be accompanied by consent from a parent or legal guardian for full participation in the study.			Individual Behavior	CDISC MRCT Center Clinical Research Glossary|CDISC SDTM Protocol Milestone Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161419>	C41260	East Asian|EAST ASIAN	A person having origins in any of the original peoples of East Asian, including China, Japan, Korea, or Mongolia.			Population Group	CDISC CDASH Terminology|CDISC SDTM Collected Race Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16141>	C15715	Pain Research	Research as to the cause of pain and the treatment thereof			Research Activity	
C161420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161420>	C71384|C21481	First Degree Biological Relative|RELATIVE, BIOLOGICAL, FIRST DEGREE	Any individual related biologically to another individual and considered immediate family as in the case of a parent, sibling or child.			Human	CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161421>	C71384|C19811	Second Degree Biological Relative|RELATIVE, BIOLOGICAL, SECOND DEGREE	Any individual related biologically to another individual and considered one degree removed from the immediate family as in the case of grandparents, aunts and uncles.			Human	CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161422>	C119241	Effusion Indicator|EFFIND	An indication as to whether effusion is present.			Conceptual Entity	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161423>	C181043	Malignant Disease Indicator|MALIND|Malignancy Indicator|Malignancy Indicator	An indication as to whether a malignancy is present.			Conceptual Entity	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161424>	C74720	Effusion Volume Measurement|EFFVOL|Effusion Volume|Effusion Volume	The amount of three dimensional space occupied by the effusion fluid.			Laboratory Procedure	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161425>	C156605	CDISC SDTM Model Version 1.1|1.1|SDTM Version 1.1	The 1.1 version of the CDISC Study Data Tabulation Model (SDTM).			Conceptual Entity	CDISC SDTM Model Version ResponseTerminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161426>	C156605	CDISC SDTM Model Version 1.2|1.2|SDTM Version 1.2	The 1.2 version of the CDISC Study Data Tabulation Model (SDTM).			Conceptual Entity	CDISC SDTM Model Version ResponseTerminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161427>	C156605	CDISC SDTM Model Version 1.3|1.3|SDTM Version 1.3	The 1.3 version of the CDISC Study Data Tabulation Model (SDTM).			Conceptual Entity	CDISC SDTM Model Version ResponseTerminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161428>	C156605	CDISC SDTM Model Version 1.4|1.4|SDTM Version 1.4	The 1.4 version of the CDISC Study Data Tabulation Model (SDTM).			Conceptual Entity	CDISC SDTM Model Version ResponseTerminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161429>	C156605	CDISC SDTM Model Version 1.5|1.5|SDTM Version 1.5	The 1.5 version of the CDISC Study Data Tabulation Model (SDTM).			Conceptual Entity	CDISC SDTM Model Version ResponseTerminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16142>	C15888	Acupuncture and Oriental Medicine|Oriental Medicine|Oriental medicine|TCM|traditional Chinese medicine	A subcategory of Alternative Medical Systems in Complementary and Alternative Medicine. These systems of practice include areas acupuncture, acupressure, herbal applications, massage, diet, and exercises. These practices, especially in the form of Traditional Chinese Medicine have a prominent position in the U.S.			Biomedical Occupation or Discipline	
C161430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161430>	C156605	CDISC SDTM Model Version 1.6|1.6|SDTM Version 1.6	The 1.6 version of the CDISC Study Data Tabulation Model (SDTM).			Conceptual Entity	CDISC SDTM Model Version ResponseTerminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161431>	C156605	CDISC SDTM Model Version 1.7|1.7|SDTM Version 1.7	The 1.7 version of the CDISC Study Data Tabulation Model (SDTM).			Conceptual Entity	CDISC SDTM Model Version ResponseTerminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161432>	C156604	CDISC SDTM Implementation Guide Version 3.1.1|3.1.1|SDTMIG Version 3.1.1	The 3.1.1 version of the CDISC Study Data Tabulation Model (SDTM) implementation guide.			Conceptual Entity	CDISC Define-XML Terminology|CDISC SDTM Implementation Guide Version Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161433>	C156604	CDISC SDTM Implementation Guide Version 3.1.2|3.1.2|SDTMIG Version 3.1.2	The 3.1.2 version of the CDISC Study Data Tabulation Model (SDTM) implementation guide.			Conceptual Entity	CDISC Define-XML Terminology|CDISC SDTM Implementation Guide Version Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161434>	C156604	CDISC SDTM Implementation Guide Version 3.1.2 Amendment 1|SDTMIG Version 3.1.2 Amendment 1|Version 3.1.2 Amendment 1	Amendment 1 of the 3.1.2 version of the CDISC Study Data Tabulation Model (SDTM) implementation guide.			Conceptual Entity	CDISC Define-XML Terminology|CDISC SDTM Implementation Guide Version Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161435>	C156604	CDISC SDTM Implementation Guide Version 3.1.3|3.1.3|SDTMIG Version 3.1.3	The 3.1.3 version of the CDISC Study Data Tabulation Model (SDTM) implementation guide.			Conceptual Entity	CDISC Define-XML Terminology|CDISC SDTM Implementation Guide Version Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161436>	C156604	CDISC SDTM Implementation Guide Version 3.2|3.2|SDTMIG Version 3.2	The 3.2 version of the CDISC Study Data Tabulation Model (SDTM) implementation guide.			Conceptual Entity	CDISC Define-XML Terminology|CDISC SDTM Implementation Guide Version Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161437>	C156604	CDISC SDTM Implementation Guide Version 3.3|3.3|SDTMIG Version 3.3	The 3.3 version of the CDISC Study Data Tabulation Model (SDTM) implementation guide.			Conceptual Entity	CDISC Define-XML Terminology|CDISC SDTM Implementation Guide Version Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161438>	C156602	CDISC Chronic Hepatitis C Therapeutic Area User Guide Version 1.0|Chronic Hepatitis C Therapeutic Area User Guide v1.0	The 1.0 version of the CDISC Chronic Hepatitis C therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161439>	C156602	CDISC Diabetic Kidney Disease Therapeutic Area User Guide Version 1.0|Diabetic Kidney Disease Therapeutic Area User Guide v1.0	The 1.0 version of the CDISC Diabetic Kidney Disease therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C16143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16143>	C45322	Repository|Bank	A facility where items can be deposited for storage or safekeeping.	Repository		Physical Object	CTRP Intervention Terminology|CTRP Terminology
C161440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161440>	C156602	CDISC Duchenne Muscular Dystrophy Therapeutic Area User Guide Version 1.0|Duchenne Muscular Dystrophy Therapeutic Area User Guide v1.0	The 1.0 version of the CDISC Duchenne Muscular Dystrophy therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161441>	C156602	CDISC Dyslipidemia Therapeutic Area User Guide Version 1.0|Dyslipidemia Therapeutic Area User Guide v1.0	The 1.0 version of the CDISC Dyslipidemia therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161442>	C156602	CDISC Ebola Therapeutic Area User Guide Version 1.0|Ebola Therapeutic Area User Guide v1.0	The 1.0 version of the CDISC Ebola therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161443>	C156602	CDISC Influenza Therapeutic Area User Guide Version 1.1|Influenza Therapeutic Area User Guide v1.1	The 1.1 version of the CDISC Influenza therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161444>	C156602	CDISC Influenza Therapeutic Area User Guide Version 1.0|Influenza Therapeutic Area User Guide v1.0	The 1.0 version of the CDISC Influenza therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161445>	C156602	CDISC Kidney Transplant Therapeutic Area User Guide Version 1.0|Kidney Transplant Therapeutic Area User Guide v1.0	The 1.0 version of the CDISC Kidney Transplant therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161446>	C156602	CDISC Major Depressive Disorder Therapeutic Area User Guide Version 1.0|Major Depressive Disorder Therapeutic Area User Guide v1.0	The 1.0 version of the CDISC Major Depressive Disorder therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161447>	C156602	CDISC Malaria Therapeutic Area User Guide Version 1.0|Malaria Therapeutic Area User Guide v1.0	The 1.0 version of the CDISC Malaria therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161448>	C156602	CDISC Prostate Cancer Therapeutic Area User Guide Version 1.0|Prostate Cancer Therapeutic Area User Guide v1.0	The 1.0 version of the CDISC Prostate Cancer therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161449>	C156602	CDISC QT Studies Therapeutic Area User Guide Version 1.0|QT Studies Therapeutic Area User Guide v1.0	The 1.0 version of the CDISC QT Studies therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C16144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16144>	C15986	Combination Drug Therapy|Drug Therapy, Combination	Drug therapy with two or more drugs given separately or together for a combined effect.			Therapeutic or Preventive Procedure	
C161450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161450>	C156602	CDISC Rheumatoid Arthritis Therapeutic Area User Guide Version 1.0|Rheumatoid Arthritis Therapeutic Area User Guide v1.0	The 1.0 version of the CDISC Rheumatoid Arthritis therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161451>	C156602	CDISC Schizophrenia Therapeutic Area User Guide Version 1.1|Schizophrenia Therapeutic Area User Guide v1.1	The 1.1 version of the CDISC Schizophrenia therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161452>	C156602	CDISC Schizophrenia Therapeutic Area User Guide Version 1.0|Schizophrenia Therapeutic Area User Guide v1.0	The 1.0 version of the CDISC Schizophrenia therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161453>	C156602	CDISC Traumatic Brain Injury Therapeutic Area User Guide Version 1.0|Traumatic Brain Injury Therapeutic Area User Guide v1.0	The 1.0 version of the CDISC Traumatic Brain Injury therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161454>	C156602	CDISC Tuberculosis Therapeutic Area User Guide Version 2.0|Tuberculosis Therapeutic Area User Guide v2.0	Version2.0 of the CDISC Tuberculosis therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161455>	C156602	CDISC Vaccines Therapeutic Area User Guide Version 1.1|Vaccines Therapeutic Area User Guide v1.1	The 1.1 version of the CDISC Vaccines therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161456>	C156602	CDISC Virology Therapeutic Area User Guide Version 2.1|Virology Therapeutic Area User Guide v2.1	The 2.1 version of the CDISC Virology therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161457>	C156602	CDISC Virology Therapeutic Area User Guide Version 2.0|Virology Therapeutic Area User Guide v2.0	The 2.0 version of the CDISC Virology therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161458>	C156602	CDISC Alzheimer's Therapeutic Area User Guide Version 1.0|Alzheimer's Therapeutic Area User Guide v1.0	The 1.0 version of the CDISC Alzheimer's therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161459>	C156602	CDISC Alzheimer's Therapeutic Area User Guide Version 2.0|Alzheimer's Therapeutic Area User Guide v2.0	The 2.0 version of the CDISC Alzheimer's therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C16145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16145>	C77273|C15545	Donor Lymphocyte Infusion|DLI|Donor Leukocyte Infusion|donor lymphocyte infusion	The infusion of donor lymphocytes following hematopoietic stem cell transplantation for the purpose of augmenting the host immune response or preventing the rejection of the graft.	Donor Lymphocyte Infusion		Therapeutic or Preventive Procedure	AML Authorized Value Terminology|AML Cellular Immunotherapy Table|CTRP Intervention Terminology|CTRP Terminology
C161460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161460>	C156602	CDISC Asthma Therapeutic Area User Guide Version 1.0|Asthma Therapeutic Area User Guide v1.0	The 1.0 version of the CDISC Asthma therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161461>	C156602	CDISC Breast Cancer Therapeutic Area User Guide Version 1.0|Breast Cancer Therapeutic Area User Guide v1.0	The 1.0 version of the CDISC Breast Cancer therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161462>	C156602	CDISC Cardiovascular Studies Therapeutic Area User Guide Version 1.0|Cardiovascular Studies Therapeutic Area User Guide v1.0	The 1.0 version of the CDISC Cardiovascular Studies therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161463>	C156602	CDISC Colorectal Cancer Therapeutic Area User Guide Version 1.0|Colorectal Cancer Therapeutic Area User Guide v1.0	The 1.0 version of the CDISC Colorectal Cancer therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161464>	C156602	CDISC COPD Therapeutic Area User Guide Version 1.0|COPD Therapeutic Area User Guide v1.0	The 1.0 version of the CDISC COPD therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161465>	C156602	CDISC HIV Therapeutic Area User Guide Version 1.0|HIV Therapeutic Area User Guide v1.0	The 1.0 version of the CDISC HIV therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161466>	C156602	CDISC Huntington's Disease Therapeutic Area User Guide Version 1.0|Huntington's Disease Therapeutic Area User Guide v1.0	The 1.0 version of the CDISC Huntington's Disease therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161467>	C156602	CDISC Multiple Sclerosis Therapeutic Area User Guide Version 1.0|Multiple Sclerosis Therapeutic Area User Guide v1.0	The 1.0 version of the CDISC Multiple Sclerosis therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161468>	C156602	CDISC Pain Therapeutic Area User Guide Version 1.0|Pain Therapeutic Area User Guide v1.0	The 1.0 version of the CDISC Pain therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161469>	C156602	CDISC Pain Therapeutic Area User Guide Version 1.1|Pain Therapeutic Area User Guide v1.1	The 1.1 version of the CDISC Pain therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C16146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16146>	C16199	Public Health Applications Research|Public Health Applications	Involvement of the public health community (i.e., state and local health departments) in the development of initiatives and programs for cancer risk reduction, and cancer prevention and control.  Primary interest is in 1) research on interventions in cancer control in public health settings and 2) the dissemination and application of research findings among public health agencies and professionals.			Research Activity	
C161470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161470>	C156602	CDISC Parkinson's Disease Therapeutic Area User Guide Version 1.0|Parkinson's Disease Therapeutic Area User Guide v1.0	The 1.0 version of the Parkinson's Disease CDISC therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161471>	C156602	CDISC Polycystic Kidney Disease (PKD) Therapeutic Area User Guide Version 1.0|Polycystic Kidney Disease (PKD) Therapeutic Area User Guide v1.0	The 1.0 version of the Polycystic Kidney Disease CDISC therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161472>	C156602	CDISC Post Traumatic Stress Disorder Therapeutic Area User Guide Version 1.0|Post Traumatic Stress Disorder Therapeutic Area User Guide v1.0	The 1.0 version of the Post Traumatic Stress Disorder CDISC therapeutic area user guide.			Classification	CDISC SDTM Terminology|CDISC Therapeutic Area User Guide Response Terminology|Clinical Data Interchange Standards Consortium Terminology
C161473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161473>	C156603	US FDA HIV Technical Specifications Guidance v1.0|HIV Technical Specifications Guidance v1.0	The 1.0 version of the FDA HIV Technical Specifications Guidance.			Classification	CDISC SDTM FDA Technical Specification Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161474>	C156603	US FDA Vaccines Technical Specification Guidance v1.0|Vaccines Technical Specification Guidance v1.0	The 1.0 version of the FDA Vaccines Technical Specifications Guidance.			Classification	CDISC SDTM FDA Technical Specification Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161475>	C156603	US FDA Clinical Endpoint BE Studies v1.0|Clinical Endpoint BE Studies v1.0	The 1.0 version of the FDA Clinical Endpoint BE Studies Technical Specifications Guidance.			Classification	CDISC SDTM FDA Technical Specification Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161476>	C156603	US FDA Study Data Technical Conformance Guide v4.2.1|Study Data Technical Conformance Guide v4.2.1	The 4.2.1 version of the FDA Study Data Technical Conformance Guide.			Classification	CDISC SDTM FDA Technical Specification Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161477>	C49660	Position Effect Trial|POSITION EFFECT	A type of trial designed to evaluate the effect of body position during and/or after administration of the investigational product.			Research Activity	CDISC SDTM Terminology|CDISC SDTM Trial Type Terminology|Clinical Data Interchange Standards Consortium Terminology
C161478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161478>	C49660	Swallowing Function Trial|SWALLOWING FUNCTION	A type of trial designed to evaluate the effect of the investigational product on the physiologic act of swallowing.			Research Activity	CDISC SDTM Terminology|CDISC SDTM Trial Type Terminology|Clinical Data Interchange Standards Consortium Terminology
C161479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161479>	C49660	Usability Testing Study|USABILITY TESTING	A type of study designed to evaluate the user experience with a product.			Research Activity	CDISC SDTM Terminology|CDISC SDTM Trial Type Terminology|Clinical Data Interchange Standards Consortium Terminology
C16147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16147>	C16084	Natural History Study|NATURAL HISTORY|Natural History|natural history study	A study that monitors the development and progression of a disease or condition with no emphasis on diagnosis or treatment.			Occupational Activity	CDISC SEND Study Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161480>	C49660	Water Effect Trial|WATER EFFECT	A type of trial designed to evaluate the effects of water on investigational product safety and/or efficacy.			Research Activity	CDISC SDTM Terminology|CDISC SDTM Trial Type Terminology|Clinical Data Interchange Standards Consortium Terminology
C161481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161481>	C25341	Anatomical Location of Interest|Anatomic LOI|LOCATION OF INTEREST	The identification of an anatomical location that may contain a tumor, lesion or site of disease, and is part of the assessment of the response to the therapeutic intervention.			Spatial Concept	CDISC SDTM Terminology|CDISC SDTM Tumor and Lesion Identification Test Result Terminology|Clinical Data Interchange Standards Consortium Terminology
C161482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161482>	C93593|C181043	Measurable Tumor Indicator|MEASIND	An indication as to whether a measurable tumor is present.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Tumor Identification Test Code Terminology|CDISC SDTM Tumor Identification Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C161483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161483>	C25180	Non-Target Indicator|NTIND	An indication as to whether a non-target tumor, lesion, or site of disease is present.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Tumor Identification Test Code Terminology|CDISC SDTM Tumor Identification Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C161484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161484>	C181043	Fibrotic Lesion Indicator|FIBLIND	An indication as to whether a fibrotic lesion is present.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Tumor Identification Test Code Terminology|CDISC SDTM Tumor Identification Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C161485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161485>	C181043	Cardiovascular Lesion Indicator|CVLIND	An indication as to whether a cardiovascular lesion is present.			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Tumor Identification Test Code Terminology|CDISC SDTM Tumor Identification Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C161486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161486>	C66973	Milligram Per Kilogram Per Week|Milligram per Kilogram per Week|mg/kg/week|mg/kg/week|mg/kg/wk|mg/kg/wk|ng/ukg/week|ug/g/week	A dose calculation unit expressed in milligram(s) per kilogram per period of time equal to seven days.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161487>	C48470	Drink Dosing Unit|DRINK|{DRINK}|{DRINK}	A dosing measurement based on the drink unit.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161488>	C68667	Degree Per Millimeter|deg/mm|deg/mm|deg/mm	A unit of rotation expressed as the number of degrees per unit of length equal to one millimeter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161489>	C42574	Square Millisecond|ms2|ms2|ms2	A unit of time which is equal to one thousandth of a second squared.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161490>	C42574	Per Millisecond|/ms|/ms|/ms|1/ms|1/ms|Reciprocal of Millisecond|Reciprocal of Millisecond|ms^-1|ms^-1	A unit of time, which is equal to the reciprocal of one thousandth of a second.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161491>	C68717	Electrochemiluminescence Unit|ECL unit|ECL unit|{ECL unit}|{ECL unit}	A unit for measuring concentration or/and reactivity of a test substance as defined in the literature reference standard for the particular quantitative electrochemiluminescent method.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161492>	C67375|C48463	Genomic Equivalents per Milliliter|GE/mL|GE/mL|genEq/mL|genEq/mL|{genEq}/mL|{genEq}/mL|{genEq}/ml|{genEq}/ml	A unit of concentration defined as the number of genomic equivalents per milliliter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161493>	C48463	Genomic Equivalents|GE|GE|genEq|genEq|{genEq}|{genEq}	A unit defined as the number of whole organism genomes in a sample.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161494>	C48463	D-Dimer Unit|DDU|DDU|{DDU}|{DDU}	A unit of measure for the concentration of fibrin degradation products in a sample, calculated based upon the mass of D-dimers contained within that sample.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161495>	C67375|C48463	Micrograms DDU Per Liter|ug DDU/L|ug.{DDU}/L|ug.{DDU}/L|ug.{DDU}/l|ug.{DDU}/l|ug/L DDU|ug/L DDU	A unit of equivalent concentration equal to the number of micrograms of D-dimer per unit volume equal to one liter.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161496>	C111129	Phosphatidylserine IgM Antibody Unit|Immunoglobin M Phosphatidylserine Units|Immunoglobin M Phosphatidylserine Units|MPS U|MPS U|{MPS U}|{MPS U}	A unit for semiquantitative measurement of IgM autoantibodies to proteins associated with phosphatidylserine evaluated against an established reference standard.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161497>	C111129	Phosphatidylserine IgG Antibody Unit|GPS U|GPS U|Immunoglobin G Phosphatidylserine Units|Immunoglobin G Phosphatidylserine Units|{GPS U}|{GPS U}	A unit for semiquantitative measurement of IgG autoantibodies to proteins associated with phosphatidylserine evaluated against an established reference standard.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161498>	C111129	Phosphatidylserine IgA Antibody Unit|APS U|APS U|IgA Antiphosphatidylserine Unit|Immunoglobin A Phosphatidylserine Units|Immunoglobin A Phosphatidylserine Units|{APS U}|{APS U}|{APS'U}	A unit for semiquantitative measurement of IgA autoantibodies to proteins associated with phosphatidylserine evaluated against an established reference standard.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161499>	C80519	Body Irradiation Model|BIRRMDL	A description of the area or extent of the body that is exposed to radiation. This may include information about the body part that is irradiated as well as procedures that may be done in conjunction with the radiation.			Qualitative Concept	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16149>	C188928	Progesterone Receptor Status|PgR Status|Progesterone Receptor	Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards)	Progesterone Receptor Status		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C1614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1614>	C1594	KRN5500|6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl]amino-L-glycero-beta-L-mannohepto-pyranosyl]amino-9H-purine|KRN-5500	A semisynthetic derivative of the nucleoside-like antineoplastic antibiotic spicamycin, originally isolated from the bacterium Streptomyces alanosinicus.  KRN 5500 inhibits protein synthesis by interfering with endoplasmic reticulum and Golgi apparatus functions.  This agent also induces cell differentiation and caspase-dependent apoptosis. (NCI04)	KRN5500		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C161500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161500>	C48570	Percent Bone Marrow Shielded|PCTBMNIR|Percent Bone Marrow Not Irradiated|Percent Bone Marrow Not Irradiated	The proportion of the body's bone marrow (expressed as a percentage) protected from radiation exposure.			Quantitative Concept	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161501>	C71164	Rad/Nuc Targeted Injury Model|RNTINJRM	A description of the type of radiation injury or syndrome that is being induced in the animal model.			Qualitative Concept	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161502>	C94495	Expected Onset of Rad/Nuc Targeted Injury|EORNINJR|Exp Onset of Rad/Nuc Targeted Injury|Exp Onset of Rad/Nuc Targeted Injury	A description as to the expected onset of the targeted effect produced by the challenge agent.			Temporal Concept	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161503>	C25180	Chemical Agent Certificate of Analysis Indicator|CHCOAIND|Chemical Agent CoA Indicator|Chemical Agent CoA Indicator	An indication as to whether a certificate of analysis exists for the chemical challenge agent.			Conceptual Entity	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161504>	C25162	Chemical Agent Material Identification Code|CHMTIDCD|Chemical Agent Material Ident Code|Chemical Agent Material Ident Code	The unique identifier code assigned by the manufacturer or distributor to a specific quantity of chemical challenge agent. This may include batch number, lot number, batch/lot number, etc.			Intellectual Product	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161505>	C49236	Total Body Irradiation Plus Bone Marrow Transplant|TOTAL BODY IRRADIATION PLUS BONE MARROW TRANSPLANT	A procedure in which total body irradiation is given along with a bone marrow transplant.			Therapeutic or Preventive Procedure	CDISC SEND Body Irradiation Model Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161506>	C16230	Top-Up Model Irradiation|TOP-UP MODEL IRRADIATON|Top-Off Model Irradiation|Top-Off Model Irradiation	An irradiation procedure in which total body irradiation is given along with an additional dose at a focal site.			Therapeutic or Preventive Procedure	CDISC SEND Body Irradiation Model Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161507>	C201542	Focal Cutaneous Irradiation|CUTANEOUS IRRADIATION	A procedure involving irradiation to a specific, limited area of the skin.			Therapeutic or Preventive Procedure	CDISC SEND Body Irradiation Model Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161508>	C204078|C16230	Right and Left Lung Irradiation|Bilateral Lungs Irradiation|TLI|Total Lung Irradiation|WHOLE LUNG IRRADIATION|WLI|WTLI|Whole Thorax Lung Irradiation	An irradiation procedure done on the entire lung.			Therapeutic or Preventive Procedure	CDISC SEND Body Irradiation Model Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161509>	C204078|C16230	Single Lung Irradiation|SINGLE LUNG IRRADIATION|Single Lung Radiation Therapy	An irradiation procedure done on a single lung.			Therapeutic or Preventive Procedure	CDISC SEND Body Irradiation Model Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16150>	C188928	Estrogen Receptor Status|ER Alpha Status|ER Status|ER-Alpha Status|ERA Status|ESR Status|ESR1 Status|ESRA Status|ESTRR Status|Estrogen Receptor|Estrogen Receptor 1 Status|Estrogen Receptor Alpha Status|NR3A1 Status|Nuclear Receptor Subfamily 3 Group A Member 1 Status	The estrogen receptor level measured in a primary tumor or in metastases.  There are essentially two distinct forms of breast cancer, one that tends to have an early onset and is characterized by an ER- status, and one that tends to have a late onset and is characterized by an ER+ status.  However, these two variants tend to overlap with respect to age, so it is possible for a young woman to have a "late-onset" form of breast cancer and for an older woman to have an "early-onset" variant of the disease.	Estrogen Receptor Status		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C161510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161510>	C204078|C16230	Lung with Heart Shielded Irradiation|LUNG WITH HEART-SHIELDED IRRADIATION	An irradiation procedure done on the entire lung while the heart is covered and protected from radiation exposure.			Therapeutic or Preventive Procedure	CDISC SEND Body Irradiation Model Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161511>	C16230	Total Body Irradiation with Bone Marrow Not Irradiated|TOTAL BODY IRRADIATION WITH BONE MARROW NOT IRRADIATED	An irradiation procedure done on the entire body and the bones containing bone marrow are covered and protected from radiation exposure.			Therapeutic or Preventive Procedure	CDISC SEND Body Irradiation Model Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161512>	C27962	Hematopoietic Radiation Injury|Bone Marrow Radiation Injury|HEMATOPOIETIC RADIATION INJURY	Radiation injury of the hematopoietic system.			Finding	CDISC SEND Rad/Nuc Targeted Injury Model Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161513>	C27962|C185646	Gastrointestinal Radiation Injury|GASTROINTESTINAL RADIATION INJURY	Radiation injury of the gastrointestinal system.			Finding	CDISC SEND Rad/Nuc Targeted Injury Model Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161514>	C27962	Lung Radiation Injury|LUNG RADIATION INJURY|Pulmonary Radiation Syndrome	Radiation injury of the pulmonary system.			Finding	CDISC SEND Rad/Nuc Targeted Injury Model Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161515>	C27962	Cutaneous Radiation Injury|CUTANEOUS RADIATION INJURY	Radiation injury of the skin.			Finding	CDISC SEND Rad/Nuc Targeted Injury Model Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161516>	C27962|C115459	Renal Radiation Injury|RENAL RADIATION INJURY	Radiation injury of the kidney.			Finding	CDISC SEND Rad/Nuc Targeted Injury Model Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161517>	C27962	Cardiovascular Radiation Injury|CARDIOVASCULAR RADIATION INJURY	Radiation injury of the cardiovascular system.			Finding	CDISC SEND Rad/Nuc Targeted Injury Model Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161518>	C4974|C27962	Central Nervous System Radiation Injury|CENTRAL NERVOUS SYSTEM RADIATION INJURY	Radiation injury of the central nervous system.			Finding	CDISC SEND Rad/Nuc Targeted Injury Model Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161519>	C27962|C185645	Liver Radiation Injury|Hepatic Radiation Injury|LIVER RADIATION INJURY	Radiation injury of the liver.			Finding	CDISC SEND Rad/Nuc Targeted Injury Model Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161520>	C25279	Acute Onset|ACUTE ONSET	The start of an event or episode that is characterized as occurring suddenly or at a relatively short period of time after a reference time.			Temporal Concept	CDISC SEND Expected Onset of Rad/Nuc Targeted Injury Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161521>	C25279	Delayed Onset|DELAYED ONSET	The start of an event or episode that is characterized as occurring later or at a relatively long period of time after a reference time.			Temporal Concept	CDISC SEND Expected Onset of Rad/Nuc Targeted Injury Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161522>	C25279	Acute and Delayed Onset|ACUTE AND DELAYED ONSET	The start of an event or episode that is characterized as having both acute and delayed onsets.			Temporal Concept	CDISC SEND Expected Onset of Rad/Nuc Targeted Injury Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161523>	C697	Nitrogen Mustard HN-1|HN1|HN1|NITROGEN MUSTARD HN-1	A nitrogen mustard vesicant that is a slow-evaporating colorless to yellow oily liquid with a faint musty or fishy odor. It is absorbed into the body by inhalation, ingestion, eye contact, and skin contact, and is a powerful alkylating agent that binds to and crosslinks DNA, preventing cell duplication.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161524>	C697	Nitrogen Mustard HN-3|HN3|HN3|NITROGEN MUSTARD HN-3	A nitrogen mustard vesicant that is a slow evaporating colorless to yellow oily liquid that may smell like butter almond but is odorless when pure, and is absorbed into the body by inhalation, ingestion, eye contact, and skin contact. It is a powerful alkylating agent that binds to and crosslinks DNA, preventing cell duplication.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161525>	C160932	G-Series Nerve Agent GA|G-SERIES NERVE AGENT GA|GA|GA|Tabun|Tabun	An alkylphosphonic acid ester nerve agent that is a colorless or amber liquid with a bitter almond-like fruity odor and is absorbed into the body by inhalation, ingestion, skin contact, or eye contact. GA causes excessive cholinergic stimulation by inhibiting acetylcholinesterase at neuromuscular junctions and in the central nervous system.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161526>	C160932	G-Series Nerve Agent GB|G-SERIES NERVE AGENT GB|GB|GB|Sarin|Sarin	A rapid-acting non-persistent organophosphorus ester nerve agent that is a clear, colorless and odorless liquid and is absorbed into the body by inhalation, ingestion, skin contact, or eye contact. GB causes excessive cholinergic stimulation by producing potent and irreversible inhibition of cholinesterase.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161527>	C160932	G-Series Nerve Agent GC|Chlorosarin|Chlorosarin|G-SERIES NERVE AGENT GC|GC|GC	A highly toxic chemical precursor of the nerve agent sarin, a rapid-acting non-persistent organophosphorus ester that is a clear, colorless and odorless liquid and is absorbed into the body by inhalation, ingestion, skin contact, or eye contact, and causes excessive cholinergic stimulation by producing potent and irreversible inhibition of cholinesterase. The effects of GC are similar but less severe than sarin.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161528>	C160932	G-Series Nerve Agent GD|G-SERIES NERVE AGENT GD|GD|GD|Soman|Soman	A man-made highly toxic organic phosphate nerve agent that is a clear, colorless liquid that gives off a colorless vapor and smells like camphor or rotting fruit, and is absorbed into the body by inhalation, ingestion, skin contact, or eye contact. GD inhibits acetylcholinesterase, increasing the neurotransmitter acetylcholine at central and peripheral neuronal synapses.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161529>	C160932	G-Series Nerve Agent GE|Ethylsarin|Ethylsarin|G-SERIES NERVE AGENT GE|GE|GE	A structural analog of the nerve agent sarin, a rapid-acting non-persistent organophosphorus ester that is a clear, colorless and odorless liquid and is absorbed into the body by inhalation, ingestion, skin contact, or eye contact, and causes excessive cholinergic stimulation by producing potent and irreversible inhibition of cholinesterase.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16152>	C94299	HER2/Neu Status|ERBB2 Status|Her2/Neu Value	The presence or absence of Her2/Neu on a tissue sample.	HER2/Neu Status		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C161530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161530>	C160932	G-Series Nerve Agent GF|Cyclosarin|Cyclosarin|G-SERIES NERVE AGENT GF|GF|GF	A man-made highly toxic organic phosphate that is more persistent and less lethal than its nerve agent predecessor, Sarin. It is a colorless liquid with a sweet, musty odor that is rapidly absorbed through skin and inhibits acetylcholinesterase, increasing the neurotransmitter acetylcholine at central and peripheral neuronal synapses.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161531>	C160932	V-Series Nerve Agent VX|V-SERIES NERVE AGENT VX|VX|VX	An organic thiophosphate nerve agent that is a persistent, odorless, amber-colored oily liquid at room temperature that is absorbed into the body through inhalation or skin contact, and is an acetylcholinesterase inhibitor and neurotoxin.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161532>	C160932	V-Series Nerve Agent RVX|RVX|RVX|Russian VX|Russian VX|V-SERIES NERVE AGENT RVX|rVX|rVX	An organophosphate nerve agent developed by the former Soviet Union that is similar to the nerve agent VX and is a colorless transparent liquid that is absorbed into the body through inhalation or skin contact. This organophosphate is an acetylcholinesterase inhibitor and neurotoxin.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161533>	C160932	V-Series Nerve Agent CVX|CH VX|CH VX|CVX|CVX|Chinese VX|Chinese VX|V-SERIES NERVE AGENT CVX	An organophosphate nerve agent developed by China that is the structural isomer of the nerve agent VX, an acetylcholinesterase inhibitor and neurotoxin.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161534>	C160932	V-Series Nerve Agent VE|V-SERIES NERVE AGENT VE|VE|VE	An organophosphate nerve agent, closely related to the nerve agent VX, that is a persistent, oily liquid at room temperature, is absorbed into the body through inhalation or skin contact and is an acetylcholinesterase inhibitor and neurotoxin.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161535>	C160932	V-Series Nerve Agent VG|V-SERIES NERVE AGENT VG|VG|VG	An organophosphate nerve agent, closely related to the nerve agent VX, that is a persistent, oily liquid at room temperature, is absorbed into the body through inhalation or skin contact, and is an acetylcholinesterase inhibitor and neurotoxin.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161536>	C160932	V-Series Nerve Agent VM|V-SERIES NERVE AGENT VM|VM|VM	An organophosphate nerve agent, closely related to the nerve agent VX, that is a persistent, oily liquid at room temperature, is absorbed into the body through inhalation or skin contact, and is an acetylcholinesterase inhibitor and neurotoxin.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161537>	C160932	V-Series Nerve Agent VP|V-SERIES NERVE AGENT VP|VP|VP	An organophosphate nerve agent, closely related to the nerve agent VX, that is a persistent, oily liquid at room temperature, is absorbed into the body through inhalation or skin contact and is an acetylcholinesterase inhibitor and neurotoxin.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161538>	C160932	V-Series Nerve Agent VS|V-SERIES NERVE AGENT VS|VS|VS	An organophosphate nerve agent, closely related to the nerve agent VX, that is a persistent, oily liquid at room temperature, is absorbed into the body through inhalation or skin contact, and is an acetylcholinesterase inhibitor and neurotoxin.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161539>	C137801	Vascular Infiltration by Hepatocytes|HEPATOCYTES, SUBINTIMAL	Presence of normal hepatocytes in hepatic veins and within the contour of the vessel. (INHAND)			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16153>	C15787	Stratification Factors|STRATFCT|Stratification Factor|Stratification Factor	Selected pre-treatment factors by which patients are segregated to assure equal balance of these factors before randomization to the intervention arms of a clinical protocol.			Health Care Activity	CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C161540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161540>	C35867	Astrocyte Swelling|ASTROCYTE SWELLING	A morphologic finding indicating the presence of astrocytes with intracytoplasmic swelling.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161541>	C35867	Astrocyte Swelling And Vacuolation|ASTROCYTE SWELLING/VACUOLATION	A morphologic finding indicating the presence of astrocytes with intracytoplasmic swelling and vacuolation.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161542>	C36280	Neuroaxonal Dystrophy|Axonal Dystrophy|DYSTROPHY, AXONAL|NAD	A finding that refers to the axonal swelling (spheroids) located throughout the central and peripheral nervous system.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161543>	C137801	Experimental Organism Keratinizing Cyst|KERATINIZING CYST	A thin, uniform cyst wall composed of well differentiated, flattened squamous epithelium undergoing orderly maturation and filled with large amounts of keratin.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161544>	C137801	Basophilic Tubule|BASOPHILIC TUBULE|Basophilia, Tubule	A basophilic tinctorial change in renal tubular epithelium that is often associated with enlarged cells.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161545>	C35867	Endothelial Attenuation|ATTENUATION, ENDOTHELIUM	Endothelial cell enlargement and other adaptations for injury or aging-induced cell loss and decreased endothelial cell function.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161546>	C9442	Subretinal Extracellular Matrix Deposit|DEPOSITS, EXTRACELLULAR MATRIX, SUBRETINA|Drusen	Subretinal accumulation of extracellular matrix components.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161547>	C137802	Ocular Dermoid|DERMOID, OCULAR	Choristomatous tissue arising from an ectodermal anlage.			Disease or Syndrome	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161548>	C120874	Dilatation and Diverticulum|DILATATION/DIVERTICULUM|Dilation/Diverticulum	A finding indicating the presence of dilatation and diverticulum in a tubular anatomic structure.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161549>	C99209	Sensory Hair Cell Loss|HAIR CELL, DECREASED NUMBER	A finding indicating the loss of sensory hair cells.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16154>	C15787	Treatment Step|Step|current step|current_step	A specific stage of progression through a sequential treatment protocol.			Health Care Activity	CTDC Property Terminology
C161550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161550>	C20480	Keratinization|KERATINIZATION	The presence of keratin in an epithelial tissue.			Cell Function	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161551>	C99208	Narrowed Filtration Angle of Trabecular Meshwork|NARROWED FILTRATION ANGLE	A smaller than normal angle between the sclerocorneal junction and the iris at the periphery of the anterior chamber of the eye, which is the main exit site for aqueous fluid.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161552>	C99209	Otolith Loss Or Disorganization|OTOLITH LOSS OR DISORGANIZATION	Displacement of the otoliths within the inner ear and resulting vestibular dysfunction, usually due to aging, labyrinthine disease or infection, or head trauma.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161553>	C98887	Persistent Hyaloid Vessels|PERSISTENT HYALOID VESSELS	A congenital abnormality of the eye caused by failure of regression of the fetal eye vasculature.			Congenital Abnormality	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161554>	C98887	Persistent Hyperplastic Primary Vitreous|PERSISTENT HYPERPLASTIC PRIMARY VITREOUS|PHPV	A congenital abnormality of the eye caused by failure of regression of the primary vitreous and hyaloid vasculature anteriorly and/or posteriorly.			Congenital Abnormality	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161555>	C98887	Persistent Pupillary Membrane|PERSISTENT PUPILLARY MEMBRANE|PPM	A congenital abnormality of the eye caused by incomplete regression of the tunica vasculosa lentis, which is the vascular structure that nourishes the crystalline lens in utero.			Congenital Abnormality	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161556>	C82986	Loss of Cell Polarity|POLARITY, LOSS	A morphologic finding indicating the loss of polarity and disorganization of cells affected by cancer.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161557>	C81326|C35553	Increased Porphyrin|PORPHYRIN, INCREASED	Increase in the amount of porphyrin.			Laboratory or Test Result	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161558>	C99208	Trabecular Meshwork Proliferation|PROLIFERATION, TRABECULAR MESHWORK	Activation of abnormal cell growth within the trabecular meshwork of the eye, usually due to injury.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161559>	C34930	Increased Pigmentation|PIGMENT, INCREASED	Increase in the amount of pigment.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16155>	C16171	Prior Adjuvant HDC/ASCT|Prior Adjuvant High-Dose Chemotherapy with Stem Cell Support	Having had prior high-dose chemotherapy with autologous stem cell transplantation (HDC/ASCT).			Clinical Attribute	
C161560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161560>	C34930	Decreased Pigmentation|PIGMENT, DECREASED	Decrease in the amount of pigment.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161561>	C137802	Rodent Progressive Cardiomyopathy|RODENT PROGRESSIVE CARDIOMYOPATHY	A spontaneous, age-related cardiac disease of rats and mice, characterized by myocardial changes presenting a continuum that begins as focal to multifocal individual cardiomyocyte necrosis attended by a few inflammatory cells progressing at different rates in different animals to include multifocal mononuclear cell inflammation and even fibrosis for larger lesions. (INHAND)			Disease or Syndrome	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161562>	C60925	Increased Dentin|DENTIN, INCREASED	Increase in the amount of dentin.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161563>	C120874	Degeneration And Vacuolation|DEGENERATION/VACUOLATION	A finding that generally has features of degeneration and vacuolation.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161564>	C137801	Experimental Organism Increased Number of Glial Cells|GLIAL CELLS, INCREASED NUMBER	Increase in the number of glial cells.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161565>	C137801	Retinal Rosette|RETINAL ROSETTE|Retinal Rosettes	Focal to multifocal rosette-like and tubular structures expanding and distorting the inner and outer nuclear layers. (INHAND)			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161566>	C99208	Photoreceptor Nuclei Displacement|DISPLACEMENT, PHOTORECEPTOR NUCLEI	Photoreceptor cell located external to the retinal outer limiting membrane. (INHAND)			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161567>	C36280	Myelin Sheath Regeneration|MYELIN, INCREASED|Remyelination	Formation of new myelin sheaths on demyelinated axons.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161568>	C35867	Extracellular Vacuolation|VACUOLATION, EXTRACELLULAR	A morphologic finding indicating the presence of extracellular clear spaces in a tissue sample.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161569>	C99208	Pre-Retinal Arteriolar Loop|ARTERIOLAR LOOP, PRE-RETINAL	Arteriole emerging from the central retinal artery, coursing through the posterior vitreous and reconnecting to the inner retina. (INHAND)			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161570>	C13039	Uterine Horn|UTERINE HORN	The portion of the reproductive tract that connects the fallopian tubes to the uterus. The prominence of the uterine horns are variable across species and may be the location at which embryo implantation occurs in some species.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C161571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161571>	C54684	Investigational Product SMILES String|Chemical Structure as SMILES String|TRTSMILE|Treatment's Chemical Structure as SMILES|Treatment's Chemical Structure as SMILES	The chemical structure of an investigational product represented as a simplified molecular-input line-entry system (SMILES) string.			Intellectual Product	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C161572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161572>	C83039	Planned Challenge Agent Exposure|PCAEX	The amount of challenge agent planned to be administered to the subject at one time or the total quantity administered.			Quantitative Concept	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C161573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161573>	C83035	Planned Challenge Agent Exposure Units|PCAEXU	The unit of measure for the challenge agent dosage form.			Quantitative Concept	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C161574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161574>	C83043	Planned Challenge Agent Exposure Frequency|PCAEXFRQ|Planned Challenge Agent Exposure Freq|Planned Challenge Agent Exposure Freq	The planned number of challenge agent doses administered per a specific interval.			Quantitative Concept	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C161575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161575>	C69281	Planned Challenge Agent Exposure Rate|PCAEXRTE	The planned amount of challenge agent exposure per unit of time.			Intellectual Product	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C161576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161576>	C83121	Planned Challenge Agent Exposure Route|PCAROUTE	The planned route of exposure for the challenge agent.			Functional Concept	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C161577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161577>	C69281	Planned Treatment Administration Rate|PTRTRTE	The planned amount of treatment per unit of time during a single administration.			Intellectual Product	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C161578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161578>	C54190	Treatment Trigger|TRIGINT|Trigger for Intervention|Trigger for Intervention	The indicator that triggers the administration of study treatment in an efficacy study.			Qualitative Concept	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C161579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161579>	C7634|C161045	Prostate Solitary Fibrous Tumor	A rare solitary fibrous tumor that arises from the prostate gland.			Neoplastic Process	
C16157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16157>	C16168	Prior Adjuvant Immunotherapy	Having had prior adjuvant immunotherapy.			Clinical Attribute	
C161580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161580>	C7378|C6894|C161579	Malignant Prostate Solitary Fibrous Tumor|Prostate Malignant Solitary Fibrous Tumor	A rare malignant solitary fibrous tumor that arises from the prostate gland.			Neoplastic Process	
C161581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161581>	C3613|C3085	Prostate Hemangioma	A rare hemangioma that arises from the prostate gland.			Neoplastic Process	
C161582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161582>	C3474|C161045	Prostate Granular Cell Tumor	A rare granular cell tumor that arises from the prostate gland.			Neoplastic Process	
C161583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161583>	C36263|C156715	Metastatic Malignant Neoplasm in the Pelvic Cavity	The spread of a malignant neoplasm from a primary site to the pelvic cavity.			Neoplastic Process	
C161584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161584>	C8946|C161583	Prostate Carcinoma Metastatic in the Pelvic Cavity	A carcinoma that arises from the prostate gland and has spread to the pelvic cavity.	Prostate Carcinoma Metastatic in the Pelvic Cavity		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C161585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161585>	C3745|C153069	Metastatic Clear Cell Sarcoma of Soft Tissue	A clear cell sarcoma of soft tissue that has spread from the original site of growth to other anatomic sites.	Metastatic Clear Cell Sarcoma of Soft Tissue		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C161586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161586>	C162194|C161585	Advanced Clear Cell Sarcoma of Soft Tissue	A clear cell sarcoma of soft tissue that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Clear Cell Sarcoma of Soft Tissue		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C161587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161587>	C8946|C213275	Metastatic Prostate Carcinoma in the Lymph Nodes|Prostate Carcinoma Metastatic in Lymph Node|Prostate Carcinoma Metastatic in Lymph Node|Prostate Carcinoma Metastatic in the Lymph Nodes	A carcinoma that arises from the prostate gland and has spread to the lymph nodes.	Prostate Carcinoma Metastatic in Lymph Node		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C161588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161588>	C5044	Extravascular Volume Overload	Fluid volume expansion that occurs outside of the vascular system, which may be characterized by peripheral edema, pleural effusion, ascites, and pericardial effusion.			Finding	
C161589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161589>	C16431	1-Dimensional Chromatography	The use of a single chromatography-based technique to separate the various substances in a mixture.			Laboratory Procedure	
C16158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16158>	C16124	Prior Adjuvant Other Therapy	Having had adjuvant other therapy.			Clinical Attribute	
C161590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161590>	C63586|C191676	FOLFOXIRI-Panitumumab Regimen|FOLFOXIRI Plus Panitumumab|FOLFOXIRI and Panitumumab|FOLFOXIRI-Panitumumab|FOLFOXIRI-Vectibix|FOLFOXIRI/Panitumumab|FOLFOXIRI/Panitumumab Regimen	A regimen consisting of fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFOXIRI), plus panitumumab that may be used in the treatment of certain types of colon and rectal cancers, and appendiceal cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C161591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161591>	C63586|C191676	FOLFOXIRI-Cetuximab Regimen|FOLFOXIRI Plus Cetuximab|FOLFOXIRI-Cetuximab|FOLFOXIRI-Erbitux|FOLFOXIRI/Cetuximab|FOLFOXIRI/Cetuximab Regimen	A regimen consisting of fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFOXIRI), plus cetuximab that may be used in the treatment of certain types of colon and rectal cancers, and appendiceal cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C161592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161592>	C81326|C187275	Elevated LDH|Elevated|Elevated Lactate Dehydrogenase|LDH Elevated|LDH Increased|Lactate Dehydrogenase Elevated|Lactate Dehydrogenase Increased|Lactate Dehydrogenase Increased	An indication that the concentration of lactate dehydrogenase found in a sample is higher than previous noted or above the normal range.	Elevated LDH		Laboratory or Test Result	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C161593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161593>	C63586	Dabrafenib-Trametinib-Cetuximab Regimen|Dabrafenib-Trametinib-Cetuximab|Dabrafenib/Trametinib/Cetuximab|Dabrafenib/Trametinib/Cetuximab Regimen|Tafinlar-Mekinist-Erbitux	A regimen consisting of dabrafenib, trametinib and cetuximab that can be used in the treatment of certain BRAF-mutated colon and rectal cancers.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C161594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161594>	C63586	Dabrafenib-Trametinib-Panitumumab Regimen|Dabrafenib, Trametinib, Panitumumab|Dabrafenib-Trametinib-Panitumumab|Dabrafenib/Trametinib/Panitumumab|Dabrafenib/Trametinib/Panitumumab Regimen|Tafinlar-Mekinist-Vectibix	A regimen consisting of dabrafenib, trametinib and panitumumab that can be used in the treatment of certain BRAF-mutated colon and rectal cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C161595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161595>	C63586	Encorafenib-Binimetinib-Cetuximab Regimen|Binimetinib, Encorafenib, Cetuximab|Braftovi-Mektovi-Erbitux|Encorafenib-Binimetinib-Cetuximab|Encorafenib/Binimetinib/Cetuximab|Encorafenib/Binimetinib/Cetuximab Regimen	A regimen consisting of encorafenib, binimetinib and cetuximab that can be used in the treatment of certain BRAF-mutated colon and rectal cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C161596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161596>	C63586	Encorafenib-Binimetinib-Panitumumab Regimen|Braftovi-Mektovi-Vectibix|Encorafenib-Binimetinib-Panitumumab|Encorafenib/Binimetinib/Panitumumab|Encorafenib/Binimetinib/Panitumumab Regimen	A regimen consisting of encorafenib, binimetinib and panitumumab that can be used in the treatment of certain BRAF-mutated colon and rectal cancers.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C161597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161597>	C129822|C128037	Zeluvalimab|AMG 404|AMG-404|AMG404|Anti-PD-1 Monoclonal Antibody AMG 404|ZELUVALIMAB	A human monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, zeluvalimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, programmed cell death-1 ligand 1 (PD-L1; B7-H1; CD274) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.	Zeluvalimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C161598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161598>	C93259|C213472|C200418|C143099	Zanzalintinib|1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-(4-((7-methoxy-6-((methylamino)carbonyl)-4-quinolinyl)oxy)phenyl)-|Multi-kinase Inhibitor XL092|N-(4-Fluorophenyl)-N'-(4-((7-methoxy-6- (methylcarbamoyl)quinolin-4- yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide|XL 092|XL-092|XL092|ZANZALINTINIB	An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) hepatocyte growth factor receptor (c-Met; HGFR), vascular endothelial growth factor receptor type 2 (VEGFR2), AXL and MER, with potential anti-angiogenesis and antineoplastic activities. Upon oral administration, zanzalintinib targets and binds to c-Met, VEGFR2, AXL and MER, and prevents their RTK activity. This blocks c-Met/VEGFR2/AXL/MER-mediated signal transduction pathways, and inhibits the proliferation and migration of c-Met-, VEGFR2-, AXL- and MER-overexpressing tumor cells. c-Met, overexpressed in many tumor cell types, plays a critical role in tumor formation, proliferation, invasion and metastasis, and contributes to tumor resistance. VEGFR2, overexpressed in certain tumor types, plays an essential role in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells. AXL and MER, both members of the TAM (Tyro3, Axl and Mer) family of RTKs, are overexpressed by many tumor cell types. They play key roles in tumor cell proliferation, survival, invasion, angiogenesis and metastasis, and their expression is associated with enhanced immunosuppression, drug resistance and poor prognosis.	Zanzalintinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C161599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161599>	C129823	Anti-SEZ6 Antibody-drug Conjugate ABBV-011|ABBV 011|ABBV-011|ABBV011|Anti-SEZ6 ADC ABBV-011|SC 011|SC-011|SC011	An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against seizure protein 6 homolog (SEZ6) linked to the cytotoxic antitumor antibiotic calicheamicin, with potential antineoplastic activity. Upon administration of anti-SEZ6 ADC ABBV-011, the monoclonal antibody moiety targets and binds to SEZ6 expressed on tumor cells. Upon binding and internalization, calicheamicin is released. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in apoptosis of SEZ6-expressing tumor cells. SEZ6, overexpressed in certain cancers while minimally expressed in normal tissues, plays a role in cell-cell recognition and in neuronal membrane signaling.	Anti-SEZ6 Antibody-drug Conjugate ABBV-011		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C16159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16159>	C16171	Number of Prior Chemotherapies|Multiple Agents Therapy	Number of prior chemotherapy regimens: If a patient has received a chemotherapy regimen, provide the number of different single or multi agent chemotherapy regimens the patient has received.  A regimen is described as a distinctive collection of agent(s) and/or modalities to be utilized together during a cycle or course of therapy.  A chemotherapy regimen may have been discontinued for any reason (e.g. completion of therapy, toxicity, disease progression).  If the planned treatment is ABVD/MOPP code as one chemotherapy regimen.			Clinical Attribute	
C1615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1615>	C582	Elinafide|ELINAFIDE|LU 79553|LU 79553|LU-79553|N,N'-(Trimethylenebis(iminoethylene))dinaphthalimide	A symmetrical dimeric bis-naphthalimide compound and a topoisomerase II inhibitor with antineoplastic activity. Elinafide contains two neutral chromophores joined by a cationic linker and is capable of bis-intercalation at the TpG and CpA steps of the DNA hexanucleotide. Intercalation inhibits topoisomerase II activity and causing DNA stand breakage, thereby leads to inhibition of DNA, RNA, and protein synthesis.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C161600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161600>	C1323	Bio-enhanced Curcumin Extract Formulation|BCM-95 (R) CG|BCM-95 CG Curcumin|BCM-95 CG Curcumin Extract|BCM-95CG|BCM95 CG|BCM95CG|Bio-enhanced BCM-95 CG Curcumin|Biocurcumax|Curcumin BCM-95CG	A bio-enhanced extract-based preparation containing curcumin, a poorly water-soluble phytopolylphenol pigment isolated from the plant Curcuma longa, commonly known as turmeric, with a variety of pharmacologic properties, including antineoplastic, chemopreventive, antioxidant, anti-angiogenic, neuroprotective and anti-inflammatory activities.  Upon oral administration, curcumin blocks the formation of reactive-oxygen species, neutralizes free radicals, and prevents oxidative stress and DNA damage. Curcumin also possesses anti-inflammatory properties as a result of inhibition of cyclooxygenases (COX) and other enzymes involved in inflammation. It disrupts various cell signal transduction pathways involved in carcinogenesis and prevents the expression of many transcription factors. In addition, curcumin modulates phase II enzymes. Altogether, this prevents and/or inhibits tumor cell formation and proliferation. Compared to the very poorly absorbed curcumin alone, this extract formulation, by micronizing curcumin and adding turmeric essential oils, has a much greater bioavailability, an improved pharmacokinetic profile and increased efficacy.	Bio-enhanced Curcumin Extract Formulation		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C161601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161601>	C15329	Surgical Procedure by Type|PROCEDURE_TYPE|PROCEDURE_TYPE|PROCEDURE_TYPE|PROCEDURE_TYPE	A categorization of surgical procedures by type or purpose.			Classification	EWS Biopsy/Surgical Procedures Table|EWS Variable Terminology|GCT Biopsy/Surgical Procedures Table|GCT Variable Terminology|HL Biopsy/Surgical Procedures Table|HL Variable Terminology|OS Biopsy/Surgical Procedures Table|OS Variable Terminology
C161602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161602>	C8851|C5534	Prostate Diffuse Large B-Cell Lymphoma|Primary Prostate Diffuse Large B-Cell Lymphoma	A rare diffuse large B-cell lymphoma that arises from the prostate gland.			Neoplastic Process	
C161603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161603>	C5534|C3209	Prostate Follicular Lymphoma	A rare follicular lymphoma that arises from the prostate gland.			Neoplastic Process	
C161604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161604>	C5534|C4337	Prostate Mantle Cell Lymphoma	A rare mantle cell lymphoma that arises from the prostate gland.			Neoplastic Process	
C161605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161605>	C7540|C5534	Prostate Small Lymphocytic Lymphoma	A rare small lymphocytic lymphoma that arises from the prostate gland.			Neoplastic Process	
C161606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161606>	C3613|C2972	Prostate Cystadenoma	A rare cystadenoma affecting the prostate gland. It is characterized by the presence of multilocular prostatic cysts.			Neoplastic Process	
C161607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161607>	C7378|C3267	Prostate Wilms Tumor|Prostate Nephroblastoma	A rare Wilms tumor affecting the prostate gland.			Neoplastic Process	
C161608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161608>	C7378|C6586|C189269	Extrarenal Rhabdoid Tumor of the Prostate|Extrarenal Malignant Rhabdoid Tumor of the Prostate	A rare extrarenal rhabdoid tumor affecting the prostate gland.			Neoplastic Process	
C161609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161609>	C210981	Double-Negative Prostate Carcinoma|Double Negative Prostate Cancer	A metastatic, castration-resistant prostate carcinoma that is composed of fibroblast growth factor-driven malignant cells.	Double-Negative Prostate Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16160>	C15716	Genetic Population Study	Multidisciplinary study done among the population groups that share similar genetic markers, generally to find the cause, incidence or spread of a the disease or to see the response to the treatment, nutrition or environment.			Research Activity	
C161610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161610>	C12745	Fixed Lymph Node	A lymph node that has reduced mobility or is attached to adjacent structures.			Body Part, Organ, or Organ Component	
C161611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161611>	C8711|C7378	Prostate Melanoma	An exceptionally rare melanoma arising from the prostate gland.			Neoplastic Process	
C161612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161612>	C5545|C3309	Prostate Paraganglioma	A paraganglioma that affects the prostate gland.			Neoplastic Process	
C161613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161613>	C81326	Increased Fibroblast Growth Factor Pathway Activation|Elevated Fibroblast Growth Factor Pathway Activation	A finding indicating increases in fibroblast growth factor (FGF) activity, activation of FGF-dependent pathways and proliferation of cells in a cellular sample.			Laboratory or Test Result	
C161614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161614>	C35552	NHLBI Coronary Artery Dissection Type	A categorization of coronary artery dissections based on angiographic assessment that was developed by the National Heart, Lung and Blood Institute (NHLBI). Classification ranges from types A and B, which are generally clinically benign, through types C through F, which have clinically significant morbidity and mortality if untreated.			Qualitative Concept	
C161615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161615>	C35552	TIMI Coronary Thrombus Grade	A categorization of coronary artery thrombi based on angiographic assessment that was developed by the Thrombolysis In Myocardial Infarction (TIMI) study group. Values range from grade 0 (no thrombus) to grade 5 (total occlusion).			Qualitative Concept	
C161616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161616>	C100110	CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Name Terminology|EOR02TN|European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire - Palliative Care Version 1.0 Questionnaire Test Name|QS-EORTC QLQ-C15-PAL Version 1 TEST	Test names of questionnaire questions associated with the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Palliative Care Version 1.0 (EORTC QLQ-C15-PAL Version 1) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161617>	C100110	CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Code Terminology|EOR02TC|European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire - Palliative Care Version 1.0 Questionnaire Test Code|QS-EORTC QLQ-C15-PAL Version 1 TESTCD	Test codes of questionnaire questions associated with the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Palliative Care Version 1.0 (EORTC QLQ-C15-PAL Version 1) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161618>	C100110	CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|EOR01TN|European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 Questionnaire Test Name|QS-EORTC QLQ-C30 Version 3 TEST	Test names of questionnaire questions associated with the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161619>	C100110	CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|EOR01TC|European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 Questionnaire Test Code|QS-EORTC QLQ-C30 Version 3 TESTCD	Test codes of questionnaire questions associated with the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16161>	C15697|C15372	4A's Treatment Protocol|4A's Treatment Strategy|4As Treatment Protocol|4As Treatment Strategy	A smoking cessation strategy recommended by the National Cancer Institute.  The first 'A' is to ask patients about their smoking status at every visit and record this information. The second 'A' is to advise smokers to quit. The third 'A' is to assist patients' cessation attempts where possible by helping them to set a quit date, providing self-help materials, prescribing pharmacological treatment, and recommending counseling. The final 'A' is to arrange follow-up contact. (from Medscape)			Therapeutic or Preventive Procedure	
C161620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161620>	C100110	CDISC Questionnaire T1-DDS Test Name Terminology|DDS01TN|Diabetes Distress Scale for Adults with Type 1 Diabetes Questionnaire Test Name|QS-T1-DDS TEST	Test names of questionnaire questions associated with the Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161621>	C100110	CDISC Questionnaire T1-DDS Test Code Terminology|DDS01TC|Diabetes Distress Scale for Adults with Type 1 Diabetes Questionnaire Test Code|QS-T1-DDS TESTCD	Test codes of questionnaire questions associated with the Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161622>	C118970	CDISC Clinical Classification AVPU Test Name Terminology|AVPU01TN|Alert Verbal Painful Unresponsive Scale Clinical Classification Test Name|CC-AVPU TEST	Test names of clinical classification questions associated with the Alert Verbal Painful Unresponsive Scale (AVPU) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161623>	C118970	CDISC Clinical Classification AVPU Test Code Terminology|AVPU01TC|Alert Verbal Painful Unresponsive Scale Clinical Classification Test Code|CC-AVPU TESTCD	Test codes of clinical classification questions associated with the Alert Verbal Painful Unresponsive Scale (AVPU) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161624>	C118970	CDISC Clinical Classification BPRS 1988 Version Test Name Terminology|BPRS01TN|Brief Psychiatric Rating Scale 1988 Version Clinical Classification Test Name|CC-BPRS 1988 Version TEST	Test names of clinical classification questions associated with the Brief Psychiatric Rating Scale 1988 Version (BPRS 1988 Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161625>	C118970	CDISC Clinical Classification BPRS 1988 Version Test Code Terminology|BPRS01TC|Brief Psychiatric Rating Scale 1988 Version Clinical Classification Test Code|CC-BPRS 1988 Version TESTCD	Test codes of clinical classification questions associated with the Brief Psychiatric Rating Scale 1988 Version (BPRS 1988 Version) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161626>	C118970	CDISC Clinical Classification E-TRIP Test Name Terminology|CC-E-TRIP TEST|ETRP01TN|Emory Treatment Resistance Interview for PTSD Clinical Classification Test Name	Test names of clinical classification questions associated with the Emory Treatment Resistance Interview for PTSD (E-TRIP) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161627>	C118970	CDISC Clinical Classification E-TRIP Test Code Terminology|CC-E-TRIP TESTCD|ETRP01TC|Emory Treatment Resistance Interview for PTSD Clinical Classification Test Code	Test codes of clinical classification questions associated with the Emory Treatment Resistance Interview for PTSD (E-TRIP) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161628>	C211913	EORTC QLQ-C15-PAL Version 1 Questionnaire Question	A question associated with the EORTC QLQ-C15-PAL Version 1 questionnaire.			Intellectual Product	
C161629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161629>	C211913	EORTC QLQ-C30 Version 3 Questionnaire Question	A question associated with the EORTC QLQ-C30 Version 3 questionnaire.			Intellectual Product	
C16162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16162>	C168699	Nicotine Nasal Spray|Nicotrol NS|nicotine nasal spray	A nasal spray composed of an aqueous solution containing the alkaloid nicotine with nicotine replacement activity. Upon administration of the spray into the nostrils, nicotine is taken up from the nasal mucosa into the bloodstream. Although nicotine binds to nicotinic cholinergic receptors at the autonomic ganglia, adrenal medulla and at neuromuscular junctions as well, the binding of nicotine to the receptors in the central nervous system (CNS) appears to be responsible for the addictive nature of nicotine. Binding to CNS nicotinic acetylcholine receptors causes the release of the neurotransmitter dopamine which appears to be responsible for the addiction of nicotine. Administration of nicotine may prevent nicotine craving and may help with the withdrawal symptoms associated with smoking cessation.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C161630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161630>	C211913	T1-DDS Questionnaire Question	A question associated with the T1-DDS questionnaire.			Intellectual Product	
C161631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161631>	C211913	AVPU Clinical Classification Question	A question associated with the AVPU clinical classification.			Intellectual Product	
C161632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161632>	C211913	BPRS 1988 Version Clinical Classification Question	A question associated with the BPRS 1988 Version clinical classification.			Intellectual Product	
C161633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161633>	C211913	E-TRIP Clinical Classification Question	A question associated with the E-TRIP clinical classification.			Intellectual Product	
C161634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161634>	C2929|C192130	Seminal Vesicle Squamous Cell Carcinoma	An extremely rare squamous cell carcinoma that arises from the seminal vesicle. Glandular formation and mucin secretion are absent.			Neoplastic Process	
C161635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161635>	C200766	Autologous Anti-SLAMF7 CAR-expressing T-cells|Anti-CS1 CAR-expressing T-cells|Anti-SLAMF7 CAR-expressing T-lymphocytes|Autologous Anti-SLAMF7 CAR T-cells	A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) recognizing human SLAM family member 7 (SLAMF7; CD319 CRACC; CS-1) with potential antineoplastic activity. Upon intravenous administration, the autologous anti-SLAMF7 CAR-expressing T-cells target and induce selective toxicity in SLAMF7-expressing tumor cells. SLAMF7 is a member of the signaling lymphocytic activation molecule (SLAM) family of transmembrane receptors that modulate the function of immune cells through immunoreceptor tyrosine-based switch motifs (ITSMs) and intracellular adaptor proteins. SLAMF7 is highly expressed on certain malignant plasma cells and is minimally expressed on healthy immune cells.	Autologous Anti-SLAMF7 CAR-expressing T-cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C161636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161636>	C6930|C39908	Seminal Vesicle Mixed Epithelial and Stromal Tumor	A rare biphasic neoplasm that arises from the seminal vesicle. It is characterized by the presence of stromal and benign epithelial components. Rarely, the stromal component may display atypia and mitotic activity and the tumor may behave in a malignant clinical course.			Neoplastic Process	
C161637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161637>	C39908|C3377	Seminal Vesicle Soft Tissue Neoplasm	A mesenchymal neoplasm that arises from the seminal vesicle.			Neoplastic Process	
C161638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161638>	C6510|C161643|C161637	Seminal Vesicle Leiomyoma	A leiomyoma that arises from the seminal vesicle.			Neoplastic Process	
C161639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161639>	C3269|C161643|C161637	Seminal Vesicle Schwannoma	A schwannoma that affects the seminal vesicle.			Neoplastic Process	
C16163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16163>	C70819|C49657	Polyp Prevention Trial	Investigated low fat, high fiber diets in preventing recurrence of colorectal polyps			Research Activity	
C161640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161640>	C161643|C161637|C121181	Seminal Vesicle Mammary-Type Myofibroblastoma	An extramammary myofibroblastoma that affects the seminal vesicle.			Neoplastic Process	
C161641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161641>	C9306|C3158|C161644|C161637	Seminal Vesicle Leiomyosarcoma	A rare leiomyosarcoma that affects the seminal vesicle.			Neoplastic Process	
C161642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161642>	C171026|C161644|C161637	Seminal Vesicle Angiosarcoma	An extremely rare angiosarcoma that affects the seminal vesicle.			Neoplastic Process	
C161643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161643>	C4777|C39908	Benign Seminal Vesicle Neoplasm	A neoplasm that arises from the seminal vesicle and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.			Neoplastic Process	
C161644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161644>	C8561|C39908	Malignant Seminal Vesicle Neoplasm	A primary or metastatic malignant neoplasm that affects the seminal vesicle.			Neoplastic Process	
C161645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161645>	C217122	International Prognostic Index Score|IPI Score	The score in a prognostic index based on: age (> 60 years); increased serum LDH; ECOG Performance status > 1; clinical stage III or IV.			Intellectual Product	
C161646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161646>	C161645	IPI Score 0-1|IPI 0-1|Score 0-1	A score of 0 or 1 on the International Prognostic Index indicating that an individual has a low risk of progression of non-Hodgkin lymphoma and a 5 year survival of 73%.			Intellectual Product	
C161647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161647>	C161645	IPI Score 2|IPI 2|Score 2	A score of 2 on the International Prognostic Index indicating that an individual has a low-intermediate risk of progression of non-Hodgkin lymphoma and a 5 year survival of 69%.			Intellectual Product	
C161648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161648>	C161645	IPI Score 3|IPI 3|Score 3	A score of 3 on the International Prognostic Index indicating that an individual has a high-intermediate risk of progression of non-Hodgkin lymphoma and a 5 year survival of 46%.			Intellectual Product	
C161649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161649>	C192664|C161644	Metastatic Malignant Neoplasm in the Seminal Vesicle	The spread of a malignant neoplasm to the seminal vesicle from an adjacent or distant anatomic site.			Neoplastic Process	
C16164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16164>	C15222	Low Fat, High Fiber Diet	A diet of foods that are high in carbohydrates and fiber and low in fat.			Qualitative Concept	
C161650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161650>	C161645	IPI Score 4-5|IPI 4-5|Score 4-5	A score of 4 or 5 on the International Prognostic Index indicating that an individual has a high risk of progression of non-Hodgkin lymphoma and a 5 year survival of 32%.			Intellectual Product	
C161651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161651>	C28681|C138180|C129826	Gene-edited Autologous Neoantigen-targeted NeoTCR-P1 T-cells|NeoTCR-P1|NeoTCR-P1 T-cells	A preparation of autologous CD4- and CD8-positive T-lymphocytes that have been engineered with site-specific nucleases to suppress the expression of most endogenous forms of the T-cell receptor (TCR) and promote expression of a single, native TCR targeting a neoepitope that is presented on the surface of a patient's tumor cells, with potential immunostimulating and antineoplastic activities. Upon reintroduction into the patient, the gene-edited autologous neoantigen-targeted NeoTCR-P1 T-cells recognize and bind to tumor cells expressing the targeted neoantigen, resulting in a cytotoxic T-lymphocyte (CTL)-mediated immune response against the patient's tumor cells.	Gene-edited Autologous Neoantigen-targeted NeoTCR-P1 T-cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C161652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161652>	C1983	Allogeneic GM-CSF-secreting Myeloma Vaccine |Allogeneic GM-CSF-secreting Multiple Myeloma Vaccine|Allogeneic GM-CSF-secreting Myeloma Vaccine|Allogeneic GM-CSF-secreting Myeloma Vaccine|Allogeneic GVAX Myeloma Vaccine|Allogeneic Myeloma Vaccine with GM-CSF-secreting K562 Cells|GVAX Allogeneic Myeloma Vaccine	An allogeneic plasma cell myeloma vaccine consisting two multiple myeloma cell lines, H929 and U266, admixed with GM-CSF-secreting K562 cells, with potential antineoplastic and immunopotentiating activities. Upon administration, the secreted GM-CSF modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells, with some specificity towards stimulation of leukocyte production, and may reverse treatment-induced neutropenia. This agent also promotes antigen presentation, upregulates antibody-dependent cellular cytotoxicity (ADCC), increases interleukin-2-mediated lymphokine-activated killer cell (LAK) function and may augment host antitumoral immunity. For safety, the myeloma cells are irradiated prior to vaccination.	Allogeneic GM-CSF-secreting Myeloma Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C161653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161653>	C91105	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Palliative Care Version 1.0|EOR02|EORTC QLQ-C15-PAL V1.0|EORTC QLQ-C15-PAL Version 1	A standardized 15-item questionnaire, developed in 2006 by the European Organization for Research and Treatment of Cancer as an abbreviated version of the cancer-specific quality of life questionnaire European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30), that utilizes a four-point response scale to assess the symptoms and problems for which patients are frequently treated in palliative care, and a seven-point response scale to assess overall quality of life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161654>	C104355	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0|EOR01|EORTC QLQ-C30 V3.0|EORTC QLQ-C30 Version 3	A standardized 30-item self-administered quality of life questionnaire, developed by the European Organization for the Research and Treatment of Cancer Quality of Life Group in 1995 as an update to the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 36 (EORTC QLQ-C36), which was originally developed in 1987 and then modified to become EORTC QLQ-C30 in 1993. EORTC QLQ-C30 V3.0 utilizes a four-point response scale to assess functional, symptom, and global health status/quality of life scales, as well as five additional single symptoms and perceived financial impact, and a seven-point response scale to assess overall health and quality of life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161655>	C91105	Diabetes Distress Scale for Adults with Type 1 Diabetes Questionnaire|DDS01|T1-DDS|T1-DDS	A standardized 28-item self-report questionnaire first published by Fisher et al. in 2015 that utilizes a six-point response scale to assess seven major sources of diabetes distress for adults with Type 1 Diabetes: powerlessness, management distress, hypoglycemia distress, negative social perceptions, eating distress, physician distress, and friends/family distress.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161656>	C118969	Alert Verbal Painful Unresponsive Scale Clinical Classification|AVPU|AVPU|AVPU01	A standardized assessment algorithm published by the American College of Surgeons Committee on Trauma in the Advanced Trauma Life Support protocol in 1989 that uses the criterion of "alert", "responsive to verbal stimulation", "responsive to painful stimulation", or "unresponsive" to determine a patient's level of consciousness.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161657>	C118969	Brief Psychiatric Rating Scale 1988 Version Clinical Classification|BPRS 1988 VERSION|BPRS 1988 Version|BPRS01	A standardized 18-item clinician-rated instrument, initially published as a 16-item questionnaire in 1962 by Drs. John Overall and Donald Gorham and revised in 1974 and 1988, that utilizes a seven-point response scale to assess the symptoms of somatic concern, anxiety, emotional withdrawal, conceptual disorganization, guilt feelings, tension, mannerisms and posturing, grandiosity, depressive mood, hostility, suspiciousness, hallucinatory behavior, motor retardation, uncooperativeness, unusual thought content, blunted affect, excitement, and disorientation in individuals with psychotic disorders.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161658>	C118969	Emory Treatment Resistance Interview for PTSD Clinical Classification|E-TRIP|E-TRIP|ETRP01	A standardized clinician-administered semi-structured interview tool created by Dunlop et al. in 2014 that assesses the adequacy and benefit derived from a patient's past treatment for posttraumatic stress disorder (PTSD) in order to quantify the degree of treatment resistance PTSD.			Intellectual Product	CDISC Clinical Classification Category Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161659>	C161628	EORTC QLQ-C15-PAL Version 1 - Trouble Taking Short Walk Outside|EOR02-Trouble Taking Short Walk Outside|EOR02-Trouble Taking Short Walk Outside|EOR0201	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Palliative Care Version 1.0 (EORTC QLQ-C15-PAL Version 1) Do you have any trouble taking a short walk outside of the house?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16165>	C94631	Highly Active Antiretroviral Therapy|HAART|HAART|On_HAART_Therapy|haart treatment indicator|haart_treatment_indicator|highly active antiretroviral therapy	Drug therapy which targets retrovirus function by multiple mechanisms.			Therapeutic or Preventive Procedure	GDC Property Terminology|GDC Terminology|SeroNet Prior Test Result|SeroNet Variables
C161660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161660>	C161628	EORTC QLQ-C15-PAL Version 1 - Stay in Bed or Chair During the Day|EOR02-Stay in Bed/Chair During the Day|EOR02-Stay in Bed/Chair During the Day|EOR0202	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Palliative Care Version 1.0 (EORTC QLQ-C15-PAL Version 1) Do you need to stay in bed or a chair during the day?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161661>	C161628	EORTC QLQ-C15-PAL Version 1 - Need Help Eating, Dressing, Washing|EOR02-Need Help Eating/Dressing/Washing|EOR02-Need Help Eating/Dressing/Washing|EOR0203	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Palliative Care Version 1.0 (EORTC QLQ-C15-PAL Version 1) Do you need help with eating, dressing, washing yourself or using the toilet?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161662>	C161628	EORTC QLQ-C15-PAL Version 1 - Were You Short of Breath|EOR02-Were You Short of Breath|EOR02-Were You Short of Breath|EOR0204	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Palliative Care Version 1.0 (EORTC QLQ-C15-PAL Version 1) During the past week: Were you short of breath?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161663>	C161628	EORTC QLQ-C15-PAL Version 1 - Have You Had Pain|EOR02-Have You Had Pain|EOR02-Have You Had Pain|EOR0205	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Palliative Care Version 1.0 (EORTC QLQ-C15-PAL Version 1) During the past week: Have you had pain?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161664>	C161628	EORTC QLQ-C15-PAL Version 1 - Have You Had Trouble Sleeping|EOR02-Have You Had Trouble Sleeping|EOR02-Have You Had Trouble Sleeping|EOR0206	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Palliative Care Version 1.0 (EORTC QLQ-C15-PAL Version 1) During the past week: Have you had trouble sleeping?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161665>	C161628	EORTC QLQ-C15-PAL Version 1 - Have You Felt Weak|EOR02-Have You Felt Weak|EOR02-Have You Felt Weak|EOR0207	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Palliative Care Version 1.0 (EORTC QLQ-C15-PAL Version 1) During the past week: Have you felt weak?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161666>	C161628	EORTC QLQ-C15-PAL Version 1 - Have You Lacked Appetite|EOR02-Have You Lacked Appetite|EOR02-Have You Lacked Appetite|EOR0208	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Palliative Care Version 1.0 (EORTC QLQ-C15-PAL Version 1) During the past week: Have you lacked appetite?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161667>	C161628	EORTC QLQ-C15-PAL Version 1 - Have You Felt Nauseated|EOR02-Have You Felt Nauseated|EOR02-Have You Felt Nauseated|EOR0209	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Palliative Care Version 1.0 (EORTC QLQ-C15-PAL Version 1) During the past week: Have you felt nauseated?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161668>	C161628	EORTC QLQ-C15-PAL Version 1 - Have You Been Constipated|EOR02-Have You Been Constipated|EOR02-Have You Been Constipated|EOR0210	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Palliative Care Version 1.0 (EORTC QLQ-C15-PAL Version 1) During the past week: Have you been constipated?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161669>	C161628	EORTC QLQ-C15-PAL Version 1 - Were You Tired|EOR02-Were You Tired|EOR02-Were You Tired|EOR0211	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Palliative Care Version 1.0 (EORTC QLQ-C15-PAL Version 1) During the past week: Were you tired?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16166>	C16075	Prostate Cancer Outcomes Study|PCOS	A study initiated in 1994 by researchers at the National Cancer Institute (NCI) to look at the impact that treatments for primary prostate cancer have on the quality of life of patients.  PCOS is the first systematic evaluation of health-related quality-of-life issues for prostate cancer patients conducted on a multiregional scale.			Research Activity	
C161670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161670>	C161628	EORTC QLQ-C15-PAL Version 1 - Pain Interfere Daily Activities|EOR02-Pain Interfere Daily Activities|EOR02-Pain Interfere Daily Activities|EOR0212	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Palliative Care Version 1.0 (EORTC QLQ-C15-PAL Version 1) During the past week: Did pain interfere with your daily activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161671>	C161628	EORTC QLQ-C15-PAL Version 1 - Did You Feel Tense|EOR02-Did You Feel Tense|EOR02-Did You Feel Tense|EOR0213	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Palliative Care Version 1.0 (EORTC QLQ-C15-PAL Version 1) During the past week: Did you feel tense?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161672>	C161628	EORTC QLQ-C15-PAL Version 1 - Did You Feel Depressed|EOR02-Did You Feel Depressed|EOR02-Did You Feel Depressed|EOR0214	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Palliative Care Version 1.0 (EORTC QLQ-C15-PAL Version 1) During the past week: Did you feel depressed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161673>	C161628	EORTC QLQ-C15-PAL Version 1 - Rate Your Overall Quality of Life|EOR02-Rate Your Overall Quality of Life|EOR02-Rate Your Overall Quality of Life|EOR0215	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Palliative Care Version 1.0 (EORTC QLQ-C15-PAL Version 1) How would you rate your overall quality of life during the past week?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161674>	C161629	EORTC QLQ-C30 Version 3 - Trouble Doing Strenuous Activities|EOR01-Trouble Doing Strenuous Activities|EOR01-Trouble Doing Strenuous Activities|EOR0101	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) Do you have any trouble doing strenuous activities, like carrying a heavy shopping bag or a suitcase?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161675>	C161629	EORTC QLQ-C30 Version 3 - Trouble Taking Long Walk|EOR01-Trouble Taking Long Walk|EOR01-Trouble Taking Long Walk|EOR0102	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) Do you have any trouble taking a long walk?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161676>	C161629	EORTC QLQ-C30 Version 3 - Trouble Taking Short Walk Outside|EOR01-Trouble Taking Short Walk Outside|EOR01-Trouble Taking Short Walk Outside|EOR0103	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) Do you have any trouble taking a short walk outside of the house?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161677>	C161629	EORTC QLQ-C30 Version 3 - Stay in Bed or Chair During the Day|EOR01-Stay in Bed/Chair During the Day|EOR01-Stay in Bed/Chair During the Day|EOR0104	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) Do you need to stay in bed or a chair during the day?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161678>	C161629	EORTC QLQ-C30 Version 3 - Need Help Eating, Dressing, Washing|EOR01-Need Help Eating/Dressing/Washing|EOR01-Need Help Eating/Dressing/Washing|EOR0105	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) Do you need help with eating, dressing, washing yourself or using the toilet?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161679>	C161629	EORTC QLQ-C30 Version 3 - Limited in Work or Daily Activities|EOR01-Limited in Work/Daily Activities|EOR01-Limited in Work/Daily Activities|EOR0106	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) During the past week: Were you limited in doing either your work or other daily activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16167>	C2517	gp100 Human Melanoma Peptide Vaccine with Incomplete Freund's Adjuvant|gp100 human melanoma peptide vaccine/incomplete Freund's adjuvant|gp100 human melanoma-associated antigen with incomplete Freund's adjuvant|gp100 human melanoma-associated antigen/incomplete Freund's adjuvant	A vaccine consisting of synthetic glycoprotein 100 (gp100) melanoma antigen and incomplete Freund's adjuvant (IFA), an emulsifying agent and immune system stimulant, with antineoplastic activity.  Vaccination with gp100 human melanoma peptide vaccine with IFA may stimulate the host immune system to direct cytotoxic T lymphocytes (CTL) against gp100 positive melanoma cells, resulting in decreased tumor growth. (NCI04)			Immunologic Factor|Pharmacologic Substance	NCIt Antineoplastic Agent Terminology
C161680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161680>	C161629	EORTC QLQ-C30 Version 3 - Limited Hobbies or Leisure Activities|EOR01-Limited Hobbies/Leisure Activities|EOR01-Limited Hobbies/Leisure Activities|EOR0107	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) During the past week: Were you limited in pursuing your hobbies or other leisure time activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161681>	C161629	EORTC QLQ-C30 Version 3 - Were You Short of Breath|EOR01-Were You Short of Breath|EOR01-Were You Short of Breath|EOR0108	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) During the past week: Were you short of breath?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161682>	C161629	EORTC QLQ-C30 Version 3 - Have You Had Pain|EOR01-Have You Had Pain|EOR01-Have You Had Pain|EOR0109	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) During the past week: Have you had pain?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161683>	C161629	EORTC QLQ-C30 Version 3 - Did You Need to Rest|EOR01-Did You Need to Rest|EOR01-Did You Need to Rest|EOR0110	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) During the past week: Did you need to rest?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161684>	C161629	EORTC QLQ-C30 Version 3 - Have You Had Trouble Sleeping|EOR01-Have You Had Trouble Sleeping|EOR01-Have You Had Trouble Sleeping|EOR0111	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) During the past week: Have you had trouble sleeping?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161685>	C161629	EORTC QLQ-C30 Version 3 - Have You Felt Weak|EOR01-Have You Felt Weak|EOR01-Have You Felt Weak|EOR0112	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) During the past week: Have you felt weak?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161686>	C161629	EORTC QLQ-C30 Version 3 - Have You Lacked Appetite|EOR01-Have You Lacked Appetite|EOR01-Have You Lacked Appetite|EOR0113	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) During the past week: Have you lacked appetite?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161687>	C161629	EORTC QLQ-C30 Version 3 - Have You Felt Nauseated|EOR01-Have You Felt Nauseated|EOR01-Have You Felt Nauseated|EOR0114	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) During the past week: Have you felt nauseated?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161688>	C161629	EORTC QLQ-C30 Version 3 - Have You Vomited|EOR01-Have You Vomited|EOR01-Have You Vomited|EOR0115	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) During the past week: Have you vomited?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161689>	C161629	EORTC QLQ-C30 Version 3 - Have You Been Constipated|EOR01-Have You Been Constipated|EOR01-Have You Been Constipated|EOR0116	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) During the past week: Have you been constipated?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16168>	C16124	Prior Immunotherapy	Originally, therapeutic administration of serum or gamma globulin containing preformed antibodies produced by another individual; currently, immunotherapy includes nonspecific systemic stimulation, adjuvants, active specific immunotherapy, and adoptive immunotherapy.  New forms of immunotherapy include the use of monoclonal antibodies.  This approach has been widely adopted by cancer specialists, often in cases which fail to respond to other treatment.  Immunotherapy aims to boost immune system function, as with the administration of interferons and interleukin-2, or to attack cancerous cells directly, as with the injection of monoclonal antibodies.  Various immunotherapeutic techniques have also been employed among AIDS patients.  In addition, a number of alternative medical practices are claimed to enhance immune function, and various over-the-counter substances (e.g., goldenseal, lysine have gained popularity for this supposed property.			Clinical Attribute	
C161690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161690>	C161629	EORTC QLQ-C30 Version 3 - Have You Had Diarrhea|EOR01-Have You Had Diarrhea|EOR01-Have You Had Diarrhea|EOR0117	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) During the past week: Have you had diarrhea?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161691>	C161629	EORTC QLQ-C30 Version 3 - Were You Tired|EOR01-Were You Tired|EOR01-Were You Tired|EOR0118	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) During the past week: Were you tired?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161692>	C161629	EORTC QLQ-C30 Version 3 - Pain Interfere Daily Activities|EOR01-Pain Interfere Daily Activities|EOR01-Pain Interfere Daily Activities|EOR0119	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) During the past week: Did pain interfere with your daily activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161693>	C161629	EORTC QLQ-C30 Version 3 - Difficulty Concentrating on Things|EOR01-Difficulty Concentrating on Things|EOR01-Difficulty Concentrating on Things|EOR0120	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) During the past week: Have you had difficulty in concentrating on things, like reading a newspaper or watching television?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161694>	C161629	EORTC QLQ-C30 Version 3 - Did You Feel Tense|EOR01-Did You Feel Tense|EOR01-Did You Feel Tense|EOR0121	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) During the past week: Did you feel tense?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161695>	C161629	EORTC QLQ-C30 Version 3 - Did You Worry|EOR01-Did You Worry|EOR01-Did You Worry|EOR0122	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) During the past week: Did you worry?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161696>	C161629	EORTC QLQ-C30 Version 3 - Did You Feel Irritable|EOR01-Did You Feel Irritable|EOR01-Did You Feel Irritable|EOR0123	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) During the past week: Did you feel irritable?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161697>	C161629	EORTC QLQ-C30 Version 3 - Did You Feel Depressed|EOR01-Did You Feel Depressed|EOR01-Did You Feel Depressed|EOR0124	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) During the past week: Did you feel depressed?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161698>	C161629	EORTC QLQ-C30 Version 3 - Had Difficulty Remembering Things|EOR01-Had Difficulty Remembering Things|EOR01-Had Difficulty Remembering Things|EOR0125	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) During the past week: Have you had difficulty remembering things?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161699>	C161629	EORTC QLQ-C30 Version 3 - Condition Interfered Family Life|EOR01-Condition Interfered Family Life|EOR01-Condition Interfered Family Life|EOR0126	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) During the past week: Has your physical condition or medical treatment interfered with your family life?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16169>	C16124	Prior Surgery|prior surgery|prior_surgery	An indication that a subject has had a surgical procedure in the past.			Clinical Attribute	ICDC Node Terminology|ICDC Terminology
C1616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1616>	C1967	Lavendustin B|LAVENDUSTIN B	A weak tyrosine kinase inhibitor which has been used as a negative control analogue for Lavendustin A. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C161700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161700>	C161629	EORTC QLQ-C30 Version 3 - Condition Interfered Social Activities|EOR01-Condition Interfered Social Activ|EOR01-Condition Interfered Social Activ|EOR0127	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) During the past week: Has your physical condition or medical treatment interfered with your social activities?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161701>	C161629	EORTC QLQ-C30 Version 3 - Condition Caused Financial Difficulties|EOR01-Condition Caused Financial Diff|EOR01-Condition Caused Financial Diff|EOR0128	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) During the past week: Has your physical condition or medical treatment caused you financial difficulties?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161702>	C161629	EORTC QLQ-C30 Version 3 - Rate Your Overall Health|EOR01-Rate Your Overall Health|EOR01-Rate Your Overall Health|EOR0129	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) How would you rate your overall health during the past week?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161703>	C161629	EORTC QLQ-C30 Version 3 - Rate Your Overall Quality of Life|EOR01-Rate Your Overall Quality of Life|EOR01-Rate Your Overall Quality of Life|EOR0130	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Version 3.0 (EORTC QLQ-C30 Version 3) How would you rate your overall quality of life during the past week?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology|CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161704>	C161630	T1-DDS - Not Skilled at Managing Diabetes|DDS01-Not Skilled at Managing Diabetes|DDS01-Not Skilled at Managing Diabetes|DDS0101	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Over the past month, please indicate the degree to which each of the following may have been a problem for you: Feeling that I am not as skilled at managing diabetes as I should be.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161705>	C161630	T1-DDS - I Don't Eat Carefully as I Should|DDS01-I Don't Eat Carefully as I Should|DDS01-I Don't Eat Carefully as I Should|DDS0102	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Over the past month, please indicate the degree to which each of the following may have been a problem for you: Feeling that I don't eat as carefully as I probably should.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161706>	C161630	T1-DDS - Don't Notice Signs of Hypoglycemia|DDS01-Don't Notice Signs of Hypoglycemia|DDS01-Don't Notice Signs of Hypoglycemia|DDS0103	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Over the past month, please indicate the degree to which each of the following may have been a problem for you: Feeling that I don't notice the warning signs of hypoglycemia as well as I used to.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161707>	C161630	T1-DDS - People Treat Me Differently|DDS01-People Treat Me Differently|DDS01-People Treat Me Differently|DDS0104	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Over the past month, please indicate the degree to which each of the following may have been a problem for you: Feeling that people treat me differently when they find out I have diabetes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161708>	C161630	T1-DDS - Discouraged See High Blood Glucose|DDS01-Discouraged See High Blood Glucose|DDS01-Discouraged See High Blood Glucose|DDS0105	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Over the past month, please indicate the degree to which each of the following may have been a problem for you: Feeling discouraged when I see high blood glucose numbers that I can't explain.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161709>	C161630	T1-DDS - Family Make Bigger Deal Diabetes|DDS01-Family Make Bigger Deal Diabetes|DDS01-Family Make Bigger Deal Diabetes|DDS0106	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Over the past month, please indicate the degree to which each of the following may have been a problem for you: Feeling that my family and friends make a bigger deal out of diabetes than they should.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16170>	C16124	Prior Gene Therapy	Having had prior gene therapy.			Clinical Attribute	
C161710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161710>	C161630	T1-DDS - Can't Tell Doctor What on My Mind|DDS01-Can't Tell Doctor What on My Mind|DDS01-Can't Tell Doctor What on My Mind|DDS0107	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Over the past month, please indicate the degree to which each of the following may have been a problem for you: Feeling that I can't tell my diabetes doctor what is really on my mind.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161711>	C161630	T1-DDS - Not Taking Insulin as I Should|DDS01-Not Taking Insulin as I Should|DDS01-Not Taking Insulin as I Should|DDS0108	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Over the past month, please indicate the degree to which each of the following may have been a problem for you: Feeling that I am not taking as much insulin as I should.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161712>	C161630	T1-DDS - Too Much Diabetes Equipment With Me|DDS01-Too Much Diabetes Equipment w/Me|DDS01-Too Much Diabetes Equipment w/Me|DDS0109	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Over the past month, please indicate the degree to which each of the following may have been a problem for you: Feeling that there is too much diabetes equipment and stuff I must always have with me.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161713>	C161630	T1-DDS - Have to Hide My Diabetes|DDS01-Have to Hide My Diabetes|DDS01-Have to Hide My Diabetes|DDS0110	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Over the past month, please indicate the degree to which each of the following may have been a problem for you: Feeling like I have to hide my diabetes from other people.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161714>	C161630	T1-DDS - Family Worry About Hypoglycemia|DDS01-Family Worry About Hypoglycemia|DDS01-Family Worry About Hypoglycemia|DDS0111	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Over the past month, please indicate the degree to which each of the following may have been a problem for you: Feeling that my friends and family worry more about hypoglycemia than I want them to.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161715>	C161630	T1-DDS - Don't Check Glucose as I Should|DDS01-Don't Check Glucose as I Should|DDS01-Don't Check Glucose as I Should|DDS0112	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Over the past month, please indicate the degree to which each of the following may have been a problem for you: Feeling that I don't check my blood glucose level as often as I probably should.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161716>	C161630	T1-DDS - Worried Develop Complications|DDS01-Worried Develop Complications|DDS01-Worried Develop Complications|DDS0113	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Over the past month, please indicate the degree to which each of the following may have been a problem for you: Feeling worried that I will develop serious long-term complications, no matter how hard I try.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161717>	C161630	T1-DDS - Don't Get Help From Doctor|DDS01-Don't Get Help From Doctor|DDS01-Don't Get Help From Doctor|DDS0114	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Over the past month, please indicate the degree to which each of the following may have been a problem for you: Feeling that I don't get help I really need from my diabetes doctor about managing diabetes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161718>	C161630	T1-DDS - Hypoglycemic Event When Asleep|DDS01-Hypoglycemic Event When Asleep|DDS01-Hypoglycemic Event When Asleep|DDS0115	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Over the past month, please indicate the degree to which each of the following may have been a problem for you: Feeling frightened that I could have a serious hypoglycemic event when I'm asleep.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161719>	C161630	T1-DDS - Food and Eating Control My Life|DDS01-Food and Eating Control My Life|DDS01-Food and Eating Control My Life|DDS0116	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Over the past month, please indicate the degree to which each of the following may have been a problem for you: Feeling that thoughts about food and eating control my life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16171>	C16124	Prior Chemotherapy|Prior Chemotherapy Regimens	Previous chemotherapy administered as treatment for this cancer.			Clinical Attribute	
C161720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161720>	C161630	T1-DDS - Family Treat Me More Fragile|DDS01-Family Treat Me More Fragile|DDS01-Family Treat Me More Fragile|DDS0117	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Over the past month, please indicate the degree to which each of the following may have been a problem for you: Feeling that my friends or family treat me as if I were more fragile or sicker than I really am.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161721>	C161630	T1-DDS - Doctor Doesn't Understand|DDS01-Doctor Doesn't Understand|DDS01-Doctor Doesn't Understand|DDS0118	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Over the past month, please indicate the degree to which each of the following may have been a problem for you: Feeling that my diabetes doctor doesn't really understand what it's like to have diabetes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161722>	C161630	T1-DDS - Less Attractive to Employers|DDS01-Less Attractive to Employers|DDS01-Less Attractive to Employers|DDS0119	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Over the past month, please indicate the degree to which each of the following may have been a problem for you: Feeling concerned that diabetes may make me less attractive to employers.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161723>	C161630	T1-DDS - Family Act Like Diabetes Police|DDS01-Family Act Like Diabetes Police|DDS01-Family Act Like Diabetes Police|DDS0120	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Over the past month, please indicate the degree to which each of the following may have been a problem for you: Feeling that my friends or family act like 'diabetes police' (bother me too much).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161724>	C161630	T1-DDS - Be Perfect With Diabetes Management|DDS01-Be Perfect w/Diabetes Management|DDS01-Be Perfect w/Diabetes Management|DDS0121	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Over the past month, please indicate the degree to which each of the following may have been a problem for you: Feeling that I've got to be perfect with my diabetes management.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161725>	C161630	T1-DDS - Hypoglycemic Event While Driving|DDS01-Hypoglycemic Event While Driving|DDS01-Hypoglycemic Event While Driving|DDS0122	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Over the past month, please indicate the degree to which each of the following may have been a problem for you: Feeling frightened that I could have a serious hypoglycemic event while driving.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161726>	C161630	T1-DDS - Eating Is Out of Control|DDS01-Eating Is Out of Control|DDS01-Eating Is Out of Control|DDS0123	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Over the past month, please indicate the degree to which each of the following may have been a problem for you: Feeling that my eating is out of control.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161727>	C161630	T1-DDS - People Think Less of Me|DDS01-People Think Less of Me|DDS01-People Think Less of Me|DDS0124	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Over the past month, please indicate the degree to which each of the following may have been a problem for you: Feeling that people will think less of me if they knew I had diabetes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161728>	C161630	T1-DDS - Never Be Good Enough|DDS01-Never Be Good Enough|DDS01-Never Be Good Enough|DDS0125	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Over the past month, please indicate the degree to which each of the following may have been a problem for you: Feeling that no matter how hard I try with my diabetes, it will never be good enough.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161729>	C161630	T1-DDS - Doctor Doesn't Know Enough|DDS01-Doctor Doesn't Know Enough|DDS01-Doctor Doesn't Know Enough|DDS0126	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Over the past month, please indicate the degree to which each of the following may have been a problem for you: Feeling that my diabetes doctor doesn't know enough about diabetes and diabetes care.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16172>	C16124	Other Prior Therapy	Having had other prior therapy.			Clinical Attribute	
C161730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161730>	C161630	T1-DDS - Be Safe From Hypoglycemic Event|DDS01-Be Safe From Hypoglycemic Event|DDS01-Be Safe From Hypoglycemic Event|DDS0127	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Over the past month, please indicate the degree to which each of the following may have been a problem for you: Feeling that I can't ever be safe from the possibility of a serious hypoglycemic event.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161731>	C161630	T1-DDS - Don't Give Diabetes Attention|DDS01-Don't Give Diabetes Attention|DDS01-Don't Give Diabetes Attention|DDS0128	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Over the past month, please indicate the degree to which each of the following may have been a problem for you: Feeling that I don't give my diabetes as much attention as I probably should.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161732>	C161630	T1-DDS - Total Scale|DDS01-Total Scale|DDS01-Total Scale|DDS0129	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Total scale.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161733>	C161630	T1-DDS - Subscale 1: Powerlessness|DDS01-Subscale 1: Powerlessness|DDS01-Subscale 1: Powerlessness|DDS0130	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Subscale 1 - Powerlessness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161734>	C161630	T1-DDS - Subscale 2: Management Distress|DDS01-Subscale 2: Management Distress|DDS01-Subscale 2: Management Distress|DDS0131	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Subscale 2 - Management distress.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161735>	C161630	T1-DDS - Subscale 3: Hypoglycemia Distress|DDS01-Subscale 3: Hypoglycemia Distress|DDS01-Subscale 3: Hypoglycemia Distress|DDS0132	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Subscale 3 - Hypoglycemia distress.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161736>	C161630	T1-DDS - Subscale 4: Negative Social Perceptions|DDS01-Subscale 4: Neg Social Perceptions|DDS01-Subscale 4: Neg Social Perceptions|DDS0133	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Subscale 4 - Negative social perceptions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161737>	C161630	T1-DDS - Subscale 5: Eating Distress|DDS01-Subscale 5: Eating Distress|DDS01-Subscale 5: Eating Distress|DDS0134	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Subscale 5 - Eating distress.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161738>	C161630	T1-DDS - Subscale 6: Physician Distress|DDS01-Subscale 6: Physician Distress|DDS01-Subscale 6: Physician Distress|DDS0135	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Subscale 6 - Physician distress.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161739>	C161630	T1-DDS - Subscale 7: Friend/Family Distress|DDS01-Subscale 7: Friend/Family Distress|DDS01-Subscale 7: Friend/Family Distress|DDS0136	Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) Subscale 7 - Friend/family distress.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire T1-DDS Test Code Terminology|CDISC Questionnaire T1-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16173>	C52647	National Breast and Cervical Cancer Early Detection Program|NBCCEDP|Women's Health Check Program	A program of the CDC.  Established by an act of Congress in 1990 it provides for screening exams to underserved women.			Health Care Related Organization	
C161740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161740>	C161631	AVPU - Responsiveness|AVPU01-Responsiveness|AVPU01-Responsiveness|AVPU0101	Alert Verbal Painful Unresponsive Scale (AVPU) Responsivenesss.			Intellectual Product	CDISC Clinical Classification AVPU Test Code Terminology|CDISC Clinical Classification AVPU Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161741>	C161632	BPRS 1988 Version - Somatic Concern|BPRS01-Somatic Concern|BPRS01-Somatic Concern|BPRS0101	Brief Psychiatric Rating Scale 1988 Version (BPRS 1988 Version) Somatic concern.			Intellectual Product	CDISC Clinical Classification BPRS 1988 Version Test Code Terminology|CDISC Clinical Classification BPRS 1988 Version Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161742>	C161632	BPRS 1988 Version - Anxiety|BPRS01-Anxiety|BPRS01-Anxiety|BPRS0102	Brief Psychiatric Rating Scale 1988 Version (BPRS 1988 Version) Anxiety.			Intellectual Product	CDISC Clinical Classification BPRS 1988 Version Test Code Terminology|CDISC Clinical Classification BPRS 1988 Version Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161743>	C161632	BPRS 1988 Version - Emotional Withdrawal|BPRS01-Emotional Withdrawal|BPRS01-Emotional Withdrawal|BPRS0103	Brief Psychiatric Rating Scale 1988 Version (BPRS 1988 Version) Emotional withdrawal.			Intellectual Product	CDISC Clinical Classification BPRS 1988 Version Test Code Terminology|CDISC Clinical Classification BPRS 1988 Version Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161744>	C161632	BPRS 1988 Version - Conceptual Disorganization|BPRS01-Conceptual Disorganization|BPRS01-Conceptual Disorganization|BPRS0104	Brief Psychiatric Rating Scale 1988 Version (BPRS 1988 Version) Conceptual disorganization.			Intellectual Product	CDISC Clinical Classification BPRS 1988 Version Test Code Terminology|CDISC Clinical Classification BPRS 1988 Version Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161745>	C161632	BPRS 1988 Version - Guilt Feelings|BPRS01-Guilt Feelings|BPRS01-Guilt Feelings|BPRS0105	Brief Psychiatric Rating Scale 1988 Version (BPRS 1988 Version) Guilt feelings.			Intellectual Product	CDISC Clinical Classification BPRS 1988 Version Test Code Terminology|CDISC Clinical Classification BPRS 1988 Version Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161746>	C161632	BPRS 1988 Version - Tension|BPRS01-Tension|BPRS01-Tension|BPRS0106	Brief Psychiatric Rating Scale 1988 Version (BPRS 1988 Version) Tension.			Intellectual Product	CDISC Clinical Classification BPRS 1988 Version Test Code Terminology|CDISC Clinical Classification BPRS 1988 Version Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161747>	C161632	BPRS 1988 Version - Mannerisms and Posturing|BPRS01-Mannerisms and Posturing|BPRS01-Mannerisms and Posturing|BPRS0107	Brief Psychiatric Rating Scale 1988 Version (BPRS 1988 Version) Mannerisms and posturing.			Intellectual Product	CDISC Clinical Classification BPRS 1988 Version Test Code Terminology|CDISC Clinical Classification BPRS 1988 Version Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161748>	C161632	BPRS 1988 Version - Grandiosity|BPRS01-Grandiosity|BPRS01-Grandiosity|BPRS0108	Brief Psychiatric Rating Scale 1988 Version (BPRS 1988 Version) Grandiosity.			Intellectual Product	CDISC Clinical Classification BPRS 1988 Version Test Code Terminology|CDISC Clinical Classification BPRS 1988 Version Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161749>	C161632	BPRS 1988 Version - Depressive Mood|BPRS01-Depressive Mood|BPRS01-Depressive Mood|BPRS0109	Brief Psychiatric Rating Scale 1988 Version (BPRS 1988 Version) Depressive mood.			Intellectual Product	CDISC Clinical Classification BPRS 1988 Version Test Code Terminology|CDISC Clinical Classification BPRS 1988 Version Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16174>	C15687	Compartmental Treatment	A therapy that treat a single body compartment.			Therapeutic or Preventive Procedure	
C161750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161750>	C161632	BPRS 1988 Version - Hostility|BPRS01-Hostility|BPRS01-Hostility|BPRS0110	Brief Psychiatric Rating Scale 1988 Version (BPRS 1988 Version) Hostility.			Intellectual Product	CDISC Clinical Classification BPRS 1988 Version Test Code Terminology|CDISC Clinical Classification BPRS 1988 Version Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161751>	C161632	BPRS 1988 Version - Suspiciousness|BPRS01-Suspiciousness|BPRS01-Suspiciousness|BPRS0111	Brief Psychiatric Rating Scale 1988 Version (BPRS 1988 Version) Suspiciousness.			Intellectual Product	CDISC Clinical Classification BPRS 1988 Version Test Code Terminology|CDISC Clinical Classification BPRS 1988 Version Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161752>	C161632	BPRS 1988 Version - Hallucinatory Behavior|BPRS01-Hallucinatory Behavior|BPRS01-Hallucinatory Behavior|BPRS0112	Brief Psychiatric Rating Scale 1988 Version (BPRS 1988 Version) Hallucinatory behavior.			Intellectual Product	CDISC Clinical Classification BPRS 1988 Version Test Code Terminology|CDISC Clinical Classification BPRS 1988 Version Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161753>	C161632	BPRS 1988 Version - Motor Retardation|BPRS01-Motor Retardation|BPRS01-Motor Retardation|BPRS0113	Brief Psychiatric Rating Scale 1988 Version (BPRS 1988 Version) Motor retardation.			Intellectual Product	CDISC Clinical Classification BPRS 1988 Version Test Code Terminology|CDISC Clinical Classification BPRS 1988 Version Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161754>	C161632	BPRS 1988 Version - Uncooperativeness|BPRS01-Uncooperativeness|BPRS01-Uncooperativeness|BPRS0114	Brief Psychiatric Rating Scale 1988 Version (BPRS 1988 Version) Uncooperativeness.			Intellectual Product	CDISC Clinical Classification BPRS 1988 Version Test Code Terminology|CDISC Clinical Classification BPRS 1988 Version Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161755>	C161632	BPRS 1988 Version - Unusual Thought Content|BPRS01-Unusual Thought Content|BPRS01-Unusual Thought Content|BPRS0115	Brief Psychiatric Rating Scale 1988 Version (BPRS 1988 Version) Unusual thought content.			Intellectual Product	CDISC Clinical Classification BPRS 1988 Version Test Code Terminology|CDISC Clinical Classification BPRS 1988 Version Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161756>	C161632	BPRS 1988 Version - Blunted Affect|BPRS01-Blunted Affect|BPRS01-Blunted Affect|BPRS0116	Brief Psychiatric Rating Scale 1988 Version (BPRS 1988 Version) Blunted affect.			Intellectual Product	CDISC Clinical Classification BPRS 1988 Version Test Code Terminology|CDISC Clinical Classification BPRS 1988 Version Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161757>	C161632	BPRS 1988 Version - Excitement|BPRS01-Excitement|BPRS01-Excitement|BPRS0117	Brief Psychiatric Rating Scale 1988 Version (BPRS 1988 Version) Excitement.			Intellectual Product	CDISC Clinical Classification BPRS 1988 Version Test Code Terminology|CDISC Clinical Classification BPRS 1988 Version Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161758>	C161632	BPRS 1988 Version - Disorientation|BPRS01-Disorientation|BPRS01-Disorientation|BPRS0118	Brief Psychiatric Rating Scale 1988 Version (BPRS 1988 Version) Disorientation.			Intellectual Product	CDISC Clinical Classification BPRS 1988 Version Test Code Terminology|CDISC Clinical Classification BPRS 1988 Version Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161759>	C161632	BPRS 1988 Version - Total Score|BPRS01-Total Score|BPRS01-Total Score|BPRS0119	Brief Psychiatric Rating Scale 1988 Version (BPRS 1988 Version) Total score.			Intellectual Product	CDISC Clinical Classification BPRS 1988 Version Test Code Terminology|CDISC Clinical Classification BPRS 1988 Version Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16175>	C16124	Prior Hormone Therapy|prior hormonal therapy	An indication that an individual has been previously treated with hormonal therapy.			Clinical Attribute	
C161760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161760>	C161633	E-TRIP - Medication Total Points|ETRP01-Medication Total Points|ETRP01-Medication Total Points|ETRP0101	Emory Treatment Resistance Interview for PTSD (E-TRIP) Medication total points.			Intellectual Product	CDISC Clinical Classification E-TRIP Test Code Terminology|CDISC Clinical Classification E-TRIP Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161761>	C161633	E-TRIP - Psychotherapy Total Points|ETRP01-Psychotherapy Total Points|ETRP01-Psychotherapy Total Points|ETRP0102	Emory Treatment Resistance Interview for PTSD (E-TRIP) Psychotherapy total points.			Intellectual Product	CDISC Clinical Classification E-TRIP Test Code Terminology|CDISC Clinical Classification E-TRIP Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161762>	C161633	E-TRIP - Total Points|ETRP01-Total Points|ETRP01-Total Points|ETRP0103	Emory Treatment Resistance Interview for PTSD (E-TRIP) Total points.			Intellectual Product	CDISC Clinical Classification E-TRIP Test Code Terminology|CDISC Clinical Classification E-TRIP Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161763>	C106675	TDI - Transition Focal Score|TDI01-Transition Focal Score|TDI01-Transition Focal Score|TDI0104	Transition Dyspnea Index (TDI) Transition focal score.			Intellectual Product	CDISC Clinical Classification TDI Test Code Terminology|CDISC Clinical Classification TDI Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161764>	C106674	BDI - Baseline Focal Score|BDI01-Baseline Focal Score|BDI01-Baseline Focal Score|BDI0104	Baseline Dyspnea Index (BDI) Baseline focal score.			Intellectual Product	CDISC Clinical Classification BDI Test Code Terminology|CDISC Clinical Classification BDI Test Name Terminology|CDISC Clinical Classification Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C161765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161765>	C4815	Progressive Thyroid Gland Carcinoma|Progressive Thyroid Carcinoma|Progressive Thyroid Carcinoma	A thyroid gland carcinoma that is worsening in terms of extent or severity.	Progressive Thyroid Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C161767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161767>	C157383	Medicinal Leech Dosage Form|Medicinal leech	Whole, live, medicinal leech, usually of the Hirudo genus (e.g. Hirudo medicinalis, Hirudo verbana), usually intended to be applied to the skin in order to restore or improve local blood flow or to provide other local effects. After attaching itself to the host, the leech creates an incision in the skin and secretes saliva containing a variety of active substances (e.g. anaesthetics, anticoagulants, anti-inflammatories, vasodilators) that allow it to feed on the blood of the host.			Functional Concept	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C161768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161768>	C16431	2-Dimensional Chromatography	The use of two chromatography-based techniques in sequence to separate the various substances in a mixture.			Laboratory Procedure	
C161769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161769>	C16431	3-Dimensional Chromatography	The use of three chromatography-based techniques in sequence to separate the various substances in a mixture.			Laboratory Procedure	
C16176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16176>	C15719	Tobacco Surveillance	Surveillance to improve the capacity to identify and understand emerging disparities in tobacco use, particularly among at risk youth. (from The NCI Strategic Plan to Reduce Health Disparities)			Research Activity	
C161770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161770>	C16434|C16432	Reversed-Phase Liquid Chromatography|RP-HPLC|RPLC	A form of high performance liquid chromatography where the stationary phase is hydrophobic.Hydrophilic molecules in the sample will absorb to the stationary phase and can be shifted to the mobile phase through the use of an increasingly polar solvent gradient.			Laboratory Procedure	
C161771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161771>	C161770	Basic Reversed-Phase Liquid Chromatography|High pH Reversed-Phase Chromatography|Hp-RP|bRPLC	A form of reversed-phase liquid chromatography where the mobile phase has a pH greater than 7.			Laboratory Procedure	
C161772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161772>	C161771	pH 7.5 Basic Reversed-Phase Liquid Chromatography|bRPLC (pH 7.5)	A form of basic reversed-phase liquid chromatography where the mobile phase has a pH of 7.5.			Laboratory Procedure	
C161773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161773>	C161771	pH 10 Basic Reversed-Phase Liquid Chromatography|bRPLC (pH 10)	A form of basic reversed-phase liquid chromatography where the mobile phase has a pH of 10.			Laboratory Procedure	
C161774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161774>	C16432	Strong-Cation-Exchange Chromatography|SCX	A form of column chromatography where the stationary phase contains functional groups that are negatively charged.			Laboratory Procedure	
C161775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161775>	C161770	2-Dimensional Reversed-Phase Liquid Chromatography|2D-RPLC	The use of two reversed-phase liquid chromatography columns in sequence to separate substances in a mixture.			Laboratory Procedure	
C161776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161776>	C47874	Octadecyl Carbon Chain-Bonded Silica|C18|C18 Column|Octadecyl Carbon Chain-Bonded Silica Column	Silica beads that are bound to octadecyl carbon chains and are used to fill columns as the stationary phase for a number of chromatography-based techniques.			Research Device	
C161777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161777>	C47874	New Objective Column	A proprietary separation column manufactured by New Objective.			Research Device	
C161778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161778>	C1752|C1663	Galinpepimut-S|3D189|GALINPEPIMUT-S|SLS 001|SLS-001|SLS001|WT-1 Analog Peptide Vaccine SLS-001	A peptide cancer vaccine comprised of four peptide chains derived from the Wilms' tumor gene 1 (WT1) protein, with potential immunomodulating and antineoplastic activities. Upon administration, galinpepimut-S, which is comprised of one WT1-derived peptide (WT-A1) that may stimulate CD8-positive T-cell responses; two WT1 peptides (WT1-427 long, WT1-331 long) that may stimulate CD4-positive T-cell responses; and one modified peptide (WT1-122A1 long) that may stimulate both CD4-positive and CD8-positive T-cells, may elicit a targeted innate immune response against WT1-expressing tumor cells. WT1 protein, a zinc finger DNA-binding protein and transcription factor, is overexpressed in leukemic cells and in many non-hematological solid tumors.	Galinpepimut-S		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C161779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161779>	C47874	PicoFrit Self-Pack Column|PicoFrit SELF-PK	A proprietary separation column that is designed to optimize sample separation for use in nanospray applications. The stationary phase can be either factory or user loaded into the column.			Research Device	
C16177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16177>	C20172	NCI Strategic Plan to Reduce Health Disparities	The overall goal is to understand the causes of health disparities in cancer and to develop effective interventions to eliminate these disparities. (from The NCI Strategic Plan to Reduce Health Disparities)			Intellectual Product	
C161780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161780>	C48061	Higher-Energy Collisional Dissociation|HCD|Higher-Energy C-Trap Dissociation	A method to induce ion fragmentation that is a variant of the collision-induced dissociation technique and uses higher voltage to retain and allow collisions between the fragmented ions in a trap before the ions move through the detector.			Laboratory Procedure	
C161781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161781>	C19236	Electron-Transfer Dissociation|ETD	A method to induce ion fragmentation of large cationic molecules through the transfer of negatively charged electrons.			Laboratory Procedure	
C161782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161782>	C19236	Electron-Capture Dissociation|ECD	A method to induce ion fragmentation through the introduction of low-energy electrons to ions trapped in a gaseous phase.			Laboratory Procedure	
C161783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161783>	C308|C172200	Ritlecitinib|JAK3 Inhibitor PF-06651600|PF 06651600|PF-06651600|PF06651600|RITLECITINIB	An orally available small-molecule inhibitor of tyrosine-protein kinase JAK3 (Janus kinase 3; JAK3) with potential immunomodulatory and anti-inflammatory activities. Upon administration, ritlecitinib selectively and irreversibly binds to JAK3 and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of certain pro-inflammatory cytokines and prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases. By selectively targeting JAK3, PF-06651600 may spare interleukin (IL)-6 signaling, as well as other JAK1-dependent immunoregulatory cytokines such as IL-10, IL-27, and IL-35, which may offer a safety benefit compared to non-selective JAK inhibitors. JAK kinases are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation.	Ritlecitinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C161784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161784>	C71460	Proteomics Data Acquisition Method	A method applied to a proteomics study in order to collect the experimental data.			Conceptual Entity	
C161785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161785>	C161784	Data-Dependent Acquisition|DDA	A method for collecting tandem mass spectrometry data where the m/z values are prerecorded for a fixed number of precursor ions followed by a second stage of mass spectrometry and m/z analysis.			Conceptual Entity	
C161786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161786>	C161784	Data-Independent Acquisition|DIA	A method for collecting tandem mass spectrometry data where the m/z values for all the ions are fragmented and analyzed during the second stage of spectrometry.			Conceptual Entity	
C161787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161787>	C161784	Selected Reaction Monitoring|SRM	A method for collecting tandem mass spectrometry data where an ion of a particular mass is selected in the first stage and a fragmented ion product is selected in the second mass spectrometer stage for detection. Selected reaction monitoring (SRM)-based experiments are generally performed in a triple quadrupole (QqQ) mass spectrometer.			Conceptual Entity	
C161788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161788>	C161784	Parallel Reaction Monitoring|PRM	A method for collecting tandem mass spectrometry data where an ion of a particular mass is selected in the first stage and a fragmented ion product is selected in the second mass spectrometer stage for detection. Parallel reaction monitoring (PRM)-based experiments are generally performed in a high-resolution hybrid quadrupole-Orbitrap (Q-OT) or time-of-flight mass spectrometer.			Conceptual Entity	
C161789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161789>	C16432	Immobilized Metal Affinity Chromatography|IMAC	A method to purify proteins or peptides from a mixture that leverages their affinity to positively charged ions immobilized on NTA-agarose beads.			Laboratory Procedure	
C16178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16178>	C199143	Centers for Population Health	Centers for Population Health will be created to: 1) expand understanding of the social (e.g., income disparities, racial discrimination) and other causes of cancer-related health disparities, 2) develop new hypotheses for cancer control at social, institutional, and policy levels, and 3) develop, apply, evaluate, and disseminate interventions to improve population health. (from The NCI Strategic Plan to Reduce Health Disparities)			Health Care Related Organization	
C161790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161790>	C217122	Peripheral T-cell Lymphoma Prognostic Index Score|PIT Score|Prognostic Index Score for Peripheral T-cell Lymphoma|Prognostic Index for Peripheral T-cell Lymphoma (PIT) Score	A list of four factors to assess how an individual with peripheral T-cell lymphoma might respond to treatment and predict the risk of disease recurrence. The factors are: patient's age, LDH levels: serum levels often correlate with the amount of tumor in the body, performance status, and bone marrow involvement.			Intellectual Product	
C161791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161791>	C161790	Peripheral T-cell Lymphoma Prognostic Index Score 0|PIT Score 0	A risk group associated with a total score of 0 on the Prognostic Index for Peripheral T-cell Lymphoma indicating that an individual has a low risk.			Intellectual Product	
C161792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161792>	C161790	Peripheral T-cell Lymphoma Prognostic Index Score 1|PIT Score 1	A risk group associated with a total score of 1 on the Prognostic Index for Peripheral T-cell Lymphoma indicating that an individual has a low-intermediate risk.			Intellectual Product	
C161793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161793>	C161789	Immobilized Metal Affinity Chromatography with Phosphopeptide Enrichment|Phosphopeptide Enrichment	A method to purify phosphoproteins or phosphopeptides from a mixture that leverages their affinity to ferric ion-charged NTA-agarose beads. The mixture is loaded on the column at low pH and the phosphorylated proteins or peptides are eluted using alkaline buffers containing edetate at a pH range of 10-11 or phosphate-containing buffers.			Laboratory Procedure	
C161794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161794>	C161790	Peripheral T-cell Lymphoma Prognostic Index Score 2|PIT Score 2	A risk group associated with a total score of 2 on the Prognostic Index for Peripheral T-cell Lymphoma indicating that an individual has a intermediate-high risk.			Intellectual Product	
C161795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161795>	C161790	Peripheral T-cell Lymphoma Prognostic Index Score 3-4|PIT Score 3-4	A risk group associated with a total score of 3 or 4 on the Prognostic Index for Peripheral T-cell Lymphoma indicating that an individual has a high risk.			Intellectual Product	
C161796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161796>	C18276	Phosphoproteome	The quantity and identity of all the phosphorylated proteins in a biological entity or sample.			Conceptual Entity	
C161797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161797>	C18276	Glycoproteome	The quantity and identity of all the glycosylated proteins in a biological entity or sample.			Conceptual Entity	
C161798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161798>	C308|C224658|C129650	Brepocitinib|BREPOCITINIB|PF 06700841|PF-06700841|PF-841|PF06700841|TYK2/JAK1 Inhibitor PF-06700841	An orally available, selective inhibitor of non-receptor tyrosine-protein kinase TYK2 (tyrosine kinase 2) and tyrosine-protein kinase JAK1 (Janus kinase 1; JAK1) with potential immunomodulatory and anti-inflammatory activities. Upon oral administration, brepocitinib selectively binds to and inhibits the activation of TYK2 and JAK1, thereby disrupting TYK2 and JAK-1-dependent cytokine signaling. This may reduce inflammatory responses and prevent inflammation-induced damage caused by certain immunological diseases. TYK2 and JAK-1 are members of the Janus kinase family of non-receptor tyrosine kinases and are involved in signaling pathways affecting hematopoiesis, immunity and inflammation.	Brepocitinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C161799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161799>	C181005	MS3|MS/MS/MS	Three mass spectrometers coupled in series. The targeted compound is selectively ionized, and its characteristic ions are separated from others in the mixture in the first mass spectrometer. The selected primary ions are then decomposed by collision in the second stage of mass spectrometry. The second stage products are fragmented again and the resulting products are run through the final mass analyzer.			Laboratory Procedure	
C16179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16179>	C49666|C16070	Selenium and Vitamin E Efficacy Trial|SELECT|Selenium and Vitamin E Cancer Prevention Trial	The Selenium and Vitamin E Efficacy Trial (SELECT) will provide more definitive evidence of the efficacy of these drugs in preventing prostate cancer. (from The NCI Strategic Plan to Reduce Health Disparities)			Research Activity	
C1617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1617>	C129823	BR96-Doxorubicin Immunoconjugate|BMS-182248-01|BR96-DOX|BR96-DOX immunoconjugate|BR96-Doxorubicin|BR96-Doxorubicin Conjugate|SGN-15|cBR96-Doxorubicin Immunoconjugate	An antibody-drug conjugate composed of the chimeric monoclonal antibody BR96 chemically linked to the cytotoxic drug doxorubicin.  The antibody moiety of BMS-182248-1 binds to Lewis Y, a cell surface antigen expressed on many solid tumor types.  Thus, the doxorubicin conjugate is targeted specifically to Lewis Y-expressing tumor cells, where it intercalates with DNA, thereby inhibiting DNA replication and repair, RNA synthesis and protein synthesis. (NCI)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C161800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161800>	C17156	Label-Free Mass Spectrometry|Label Free|Label Free MS|Label-Free|Label-Free MS	Mass spectrometry performed with samples that have not been subjected to isotopic labeling.			Laboratory Procedure	
C161801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161801>	C19236	Isobaric Peptide Termini Labeling|IPTL	A method for generating isobarically labeled peptides through the attachment of complementary isotope tags to each peptide termini.			Laboratory Procedure	
C161802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161802>	C19236	Isotope-Coded Protein Label|ICPL	A method for mass spectrometry analysis that attaches stable isotope tags to the free amino groups of intact proteins or peptides in the sample.			Laboratory Procedure	
C161803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161803>	C208255|C143250	ARC Fusion Protein SL-279252|Agonist Redirected Checkpoint Fusion Protein SL-279252|PD1-Fc-OX40L ARC Fusion Protein|SL 279252|SL-279252|SL279252	An agonist redirected checkpoint (ARC) fusion protein consisting of the extracellular domains of human programmed cell death 1 (PD-1; PDCD1; CD279) and tumor necrosis factor ligand superfamily member 4 (TNFSF4; OX40 ligand; OX40L; CD252), linked by a central Fc domain (PD1-Fc-OX40L), with potential immunostimulatory and antineoplastic activities. Upon intravenous administration, ARC fusion protein SL-279252 simultaneously binds to both tumor necrosis factor receptor superfamily member 4 (TNFRSF4; OX40) and PD-1 expressed on T-lymphocytes. Stimulation of OX40 may promote cytokine production and induce proliferation of memory and effector T-lymphocytes against tumor cells, while PD-1 binding disrupts PD-1 signaling and may restore immune function through the activation of T-cells. This may enhance the immune-mediated elimination of tumor cells more effectively than PD-1 blockade or OX40-agonism alone. OX40L, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) ligand family, provides a co-stimulatory signal for the proliferation and survival of activated T-cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.	ARC Fusion Protein SL-279252		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C161804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161804>	C19236	Stable Isotope Labeling with Amino Acids in Cell Culture|AACT|Amino Acid-Coded Mass Tags|SILAC|Stable Isotope Labeling by Amino Acids in Cell Culture|Stable Isotope Labeling by/with Amino Acids in Cell Culture	A method for generating labeled proteins or peptides for mass spectrometry analysis that leverages the cellular protein translation machinery. Briefly, cells are grown through several rounds of cell division in a culture medium that lacks a standard essential amino acid and insteady contains a non-radioactive isotope-labeled version of that amino acid. After a set number of cell doublings, each occurrence of the essential amino acid will be replaced with the labeled analog.			Laboratory Procedure	
C161805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161805>	C20993	International Prognostic Index Risk Group|IPI Risk Group	A risk group based on: age (> 60 years); increased serum LDH; ECOG Performance status > 1; clinical stage III or IV.			Intellectual Product	
C161806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161806>	C161805	International Prognostic Index Low Risk Group|IPI Low Risk|IPI Low Risk Group|Low Risk|Low Risk	A risk group associated with a total score of 0 or 1 on the International Prognostic Index indicating that an individual has a 5 year survival prognosis of 73%.			Intellectual Product	GDC Terminology|GDC Value Terminology
C161807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161807>	C161805	International Prognostic Index Low-Intermediate Risk Group|IPI Low-Intermediate Risk|IPI Low-Intermediate Risk Group|Low-Intermediate Risk|Low-Intermediate Risk	A risk group associated with a total score of 2 on the International Prognostic Index indicating that an individual has a 5 year survival prognosis of 69%.			Intellectual Product	GDC Terminology|GDC Value Terminology
C161808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161808>	C161805	International Prognostic Index High-Intermediate Risk Group|High-Intermediate Risk|High-Intermediate Risk|IPI High-Intermediate Risk|IPI High-Intermediate Risk Group	A risk group associated with a total score of 3 on the International Prognostic Index indicating that an individual has a 5 year survival prognosis of 46%.			Intellectual Product	GDC Terminology|GDC Value Terminology
C161809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161809>	C161805	International Prognostic Index High Risk Group|High Risk|High Risk|IPI High Risk|IPI Low High Group	A risk group associated with a total score of 4 or 5 on the International Prognostic Index indicating that an individual has a 5 year survival prognosis of 32%.			Intellectual Product	GDC Terminology|GDC Value Terminology
C16180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16180>	C15232|C15210	Total Mesorectal Excision|TME	Surgery for rectal cancer involving precise removal of an intact mesorectal envelope with tumor-free margins.  Associated with local recurrence rates below 5% in clinical trials.  (from Medscape)	Total Mesorectal Excision		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C161810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161810>	C71460	Proteomic Quantification Method|Proteomic Quantitation Method|Proteomics Quantification Method	A method applied to a proteomics study in order to quantify the experimentally-collected data.			Conceptual Entity	
C161811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161811>	C161810	Absolute Proteomic Quantification|AQUA|Absolute Proteomic Quantitation|Absolute Quantitation	A proteomic quantitation method where a known quantity of synthetic, isotopically- or chemically-labeled peptides are added into a sample that is subjected to liquid chromatography mass spectrometry (LC/MS)-based quantification analysis. The labeled peptide co-elutes with the unlabeled analog peptide in the sample and the amount of total target peptide is determined by comparing the total peptide in the elute with the initial concentration of labeled peptide relative to a predetermined standard curve.			Conceptual Entity	
C161812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161812>	C161810	Isobaric Label Quantification|Isobaric Label Quantitation	A proteomic quantitation method where isobaric mass tags are added into a sample that is subjected to quantification analysis using liquid chromatography/tandem mass spectrometry (LC-MS/MS). The tagged peptides co-elute with the unlabeled analog peptide in the sample and the amount of total target peptide is determined by comparing the intensities of the reporter ions in the MS/MS spectra.			Conceptual Entity	
C161813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161813>	C161810	LC/MS Label-Free Quantification|LC/MS Label-Free Quantitation|LFQP|Label-Free Quantitative Proteomics	A proteomic quantitation method where a sample is subjected to liquid chromatography mass spectrometry (LC/MS) quantification applications in the absence of tracer molecules.			Conceptual Entity	
C161814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161814>	C161810	14-N/15-N Metabolic Labeling Quantification|14-N/15-N Metabolic Labeling Quantitation	A proteomic quantitation method where the samples are prepared for mass spectrometry-based quantification by culturing the organism or cells with the heavy nitrogen isotope, 15-N before the sample is collected. Then the proteins are processed and subjected to mass spectrometry-based analysis.			Conceptual Entity	
C161815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161815>	C161810	MS1 Quantification by Isotope Labeling|Full Scan Precursor Spectra|MS1 Label-Based Quantification|MS1 Label-Based Quantitation	A proteomic quantitation method where isotopically-labeled peptides are quantified during a single round of mass spectrometry.			Conceptual Entity	
C161816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161816>	C161810	MS2 Quantification by Isotope Labeling|Data-Dependent Fragmentation Spectra|MS2 Label-Based Quantification|MS2 Label-Based Quantitation|MS2 Tag-Based Quantification|MS2 Tag-Based Quantitation	A proteomic quantitation method where isotopically-labeled peptides are quantified during a second round of mass spectrometry (tandem mass spectrometry).			Conceptual Entity	
C161817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161817>	C161810	SILAC Quantification|SILAC Quantitation	A proteomic quantitation method where a sample is produced using stable isotope labeling with amino acids in cell culture (SILAC) before being subjected to protein digestion and mass spectrometry-based quantification analysis.			Conceptual Entity	
C161818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161818>	C161810	Spectral Counting	A proteomic quantitation method where a sample is subjected to tandem mass spectrometry (MS/MS)--based quantification analysis. The spectra for a pre-identified protein are counted and then normalized. Multiple samplings of the protein peak are needed to accurately measure peptide abundance.			Conceptual Entity	
C161819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161819>	C161810	Selected Reaction Monitoring Quantification|SRM Quantification|SRM Quantitation|Selected Reaction Monitoring Quantitation	A method for quantifying tandem mass spectrometry data following a selected reaction monitoring (SRM)-based experiment.			Conceptual Entity	
C16181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16181>	C199143	Cancer Biomarkers Research Group	The mission of the CBRG is to engage basic and clinical scientists as well as epidemiologists and statisticians in a search for and validation of promising early cancer biomarkers. To do so, the CBRG supports and facilitates a broad spectrum of national and international research activities in molecular biology and genetics, particularly for the discovery of biomarkers for risk prediction and early detection of cancer. The CBRG also supports the development of databases and informatics systems to optimize tracking and assessment of biomarker utility and expression patterns.			Organization	
C161820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161820>	C154898	Non-VEGFR Tyrosine Kinase Inhibitor|Non-VEGFR TK Inhibitor	Any tyrosine kinase inhibitor that does not target and inhibit vascular endothelial growth factor receptor (VEGFR).			Chemical Viewed Functionally	
C161821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161821>	C25337	Negative Exponent	How many times to divide by a number.			Quantitative Concept	
C161822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161822>	C113003	Next Generation Flow|NGF|NGF-MRD	A highly-sensitive variant of flow cytometry used to monitor minimal residual disease (MRD). It makes use of an optimized combination of fluorochromes and antibody reagents for increased specificity at very low MRD levels.			Laboratory Procedure	
C161823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161823>	C49236	Amyloid Fibril-Directed Therapy	Any therapeutic modality that directly blocks the formation of amyloid fibril formation or, especially, those that directly target the accumulated proteins for clearance.			Therapeutic or Preventive Procedure	
C161825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161825>	C161813	Label-free Protein Quantification by LC/MS|Label-Free Protein Level Quantification|Label-Free Protein Level Quantitation	A method for quantitating proteins in label-free samples subjected to liquid chromatography-mass spectrometry (LC/MS).			Conceptual Entity	
C161826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161826>	C161813	Label-Free Peptide Level Quantification by LC/MS|Label-Free Peptide Level Quantification|Label-Free Peptide Level Quantitation	A method for quantitating peptides in label-free samples subjected to liquid chromatography-mass spectrometry (LC/MS).			Conceptual Entity	
C161827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161827>	C161813	Label-Free Protein Group Level Quantification by LC/MS|Label-Free Protein Group Level Quantification|Label-Free Protein Group Level Quantitation	A method for quantitating protein groups in label-free samples subjected to liquid chromatography-mass spectrometry (LC/MS).			Conceptual Entity	
C161828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161828>	C161813	Label-Free Raw Feature Quantification by LC/MS|Label-Free Raw Feature Quantification|Label-Free Raw Feature Quantitation	A method for quantitating raw signal data peaks in label-free samples subjected to liquid chromatography-mass spectrometry (LC/MS).			Conceptual Entity	
C161829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161829>	C161813	Label-Free Gene Level Quantification by LC/MS|Label-Free Gene Level Quantification|Label-Free Gene Level Quantitation	A method for estimating protein amounts based on gene expression quantitation analysis in label-free samples subjected to liquid chromatography-mass spectrometry (LC/MS).			Conceptual Entity	
C16182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16182>	C15938	Cooperative Family Registry for Epidemiologic Studies of Colon Cancer	Cooperative family registries specific for colon cancer studies.			Intellectual Product	
C161830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161830>	C167189|C153238	Metastatic BRCA Hereditary Breast Carcinoma|BRCA-Mutated Metastatic Breast Carcinoma|BRCA-Mutated Metastatic Breast Carcinoma|Metastatic BRCA Familial Breast Cancer|Metastatic BRCA Familial Breast Carcinoma|Metastatic BRCA Hereditary Breast Cancer|Metastatic BRCA-Associated Breast Carcinoma|Metastatic BRCA-Mutated Breast Carcinoma	BRCA hereditary breast carcinoma that has spread to another anatomic site.	BRCA-Mutated Metastatic Breast Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C161832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161832>	C201177|C200766	Autologous Anti-CD7 CAR/28zeta CRISPR-edited T-lymphocytes|Autologous CRISPR-edited CD7-targeting CAR-CD28zeta T Cells|CD7.CAR/28zeta CAR CRISPR-edited T Cells	A preparation of autologous T-lymphocytes (ATL) that have been gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-caspase 9 (Casp9) to remove the CD7 antigen and genetically engineered to express a chimeric antigen receptor (CAR) composed of a single-chain variable fragment (scFv) directed against the CD7 antigen and linked to the co-stimulatory domains of CD28 and the zeta chain of the TCR/CD3 complex (CD3-zeta) (CD28zeta), with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-CD7 CAR/28zeta CRISPR-edited T-lymphocytes specifically recognize and bind to CD7-expressing tumor cells, resulting in specific T-cell-mediated tumor cell lysis. CD7 is a transmembrane glycoprotein expressed by T-cells and natural killer (NK) cells and their precursors. It is expressed in the majority of lymphoblastic T-cell leukemias and lymphomas and in a subset of peripheral T-cell lymphomas. Removal of the endogenous CD7 antigen from the T-cell surface increases expansion and viability of the CAR-T cells and increases T-cell cytotoxic activity.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C161833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161833>	C1752|C1663	Arginase-1 Peptide Vaccine|ARG-1 Peptide Vaccine	A vaccine comprised of arginase-1 peptides, with potential antineoplastic activity. Upon vaccination, the arginase-1 peptide vaccine may activate the immune system to induce an immune response against arginase-1-expressing cells. Arginase-1 is expressed by some cancer cells and by immune inhibitory cells, such as myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs); its expression is associated with poor prognosis.			Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C161834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161834>	C308	CRTH2 Antagonist ACT-774312|ACT 774312|ACT-774312|ACT-774312|ACT774312|Prostaglandin D2 Receptor 2 Antagonist ACT-774312	An orally bioavailable, selective antagonist of the chemoattractant receptor-homologous molecule expressed on T-helper (Th) 2 cells (CRTH2; prostaglandin D2 receptor 2; G-protein coupled receptor 44), with potential anti-allergic and anti-inflammatory activities. Upon administration, CRTH2 antagonist ACT-774312 selectively binds to and prevents the activation of CRTH2 by prostaglandin D2 (PGD2). This may inhibit the recruitment of eosinophils, basophils, innate lymphoid cells type 2 (ILC2), and Th2 cells, thereby reducing the number of inflammatory cells within the affected tissue. Additionally, this may reduce the release of cytokines at the site of allergen entry and block type 2 cytokine-mediated effects such as tissue remodeling. CRTH2, a G-protein-coupled receptor, is mainly expressed on eosinophils, basophils, macrophages, monocytes, mast cells, Th2 cells, ILC2 and dendritic cells (DCs).			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C161835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161835>	C209427	IMADetect	A proprietary diagnostic device designed to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in Immatics clinical trials.	IMADetect		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C161836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161836>	C157377	Testosterone Less than or Equal to 50 ng/dL|Testosterone Less than or Equal to 50 Nanograms per Deciliter|Testosterone Less than or Equal to 50 Nanograms/Deciliter	A semiquantitative finding indicating that the concentration of testosterone in a sample is less than or equal to 50 ng/dL.	Testosterone Less than or Equal to 50 ng/dL		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C161837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161837>	C15220	Biochemical Diagnosis|Biochemical|Biochemical Markers Diagnosis|Biochemical Response	An indication that a patient had cancer diagnosed using biochemical markers specific to the disease.			Diagnostic Procedure	
C161838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161838>	C3728	Hepatocellular Malignant Neoplasm, Not Otherwise Specified|HCN-NOS|HEMNOS|Hepatocellular Malignant Neoplasm, NOS	A rare childhood malignant liver neoplasm with overlapping features of hepatoblastoma and hepatocellular carcinoma.	Hepatocellular Malignant Neoplasm, Not Otherwise Specified	Provisional_Concept	Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C161839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161839>	C40998|C146686	Ki-67 Positive Cells Less than 10 Percent|Antigen Ki-67 Positive Cells Less than 10 Percent|KI67 Positive Cells Less than 10 Percent|Ki-67 Antigen Positive Cells Less than 10 Percent|Ki-67 Less than 10 percent positive|Less than 10 percent positive|MKI67 Positive Cells Less than 10 Percent	A semi-quantitative microscopic finding indicating that less than 10 percent of the cells in a sample are detected following staining using an anti-Ki-67 antibody.	Ki-67 Positive Cells Less than 10 Percent		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C161840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161840>	C40998|C146686	Ki-67 Positive Cells 10-20 Percent|10-20 percent positive|Antigen Ki-67 Positive Cells 10-20 Percent|KI67 Positive Cells 10-20 Percent|Ki-67 10-20 percent positive|Ki-67 Antigen Positive Cells 10-20 Percent|MKI67 Positive Cells 10-20 Percent	A semi-quantitative microscopic finding indicating that between 10 and 20 percent of the cells in a sample are detected following staining using an anti-Ki-67 antibody.			Laboratory or Test Result	
C161841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161841>	C40998|C146686	Ki-67 Positive Cells Greater than 20 Percent|Antigen Ki-67 Positive Cells Greater than 20 Percent|Greater than 20 percent positive|KI67 Positive Cells Greater than 20 Percent|Ki-67 Antigen Positive Cells Greater than 20 Percent|Ki-67 Greater than 20 percent positive|MKI67 Positive Cells Greater than 20 Percent	A semi-quantitative microscopic finding indicating that more than 20 percent of the cells in a sample are detected following staining using an anti-Ki-67 antibody.	Ki-67 Positive Cells Greater than 20 Percent		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C161842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161842>	C161845	Eastern Romance Language	A group of romance languages centered in Romania.			Language	
C161843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161843>	C161844	Eastern Indo-Aryan Language	A group of Indo-Aryan languages that derive from Magadhan Apabhraṃśa Prakrit.			Language	
C161844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161844>	C160962	Indo-Aryan Language|Indic Language	A branch of Indo-Europen languages spoken on the Indian subcontinent.			Language	
C161845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161845>	C160962	Romance Language|Neo-Latin Language|Romanic Language	The modern languages that evolved from Vulgar Latin between the third and eighth centuries and that form a subgroup of the Italic languages within the Indo-European language family.			Language	
C161846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161846>	C210927	Northeast Caucasian Language|Nakh-Daghestanian Language|North Caspian Language	A family of languages spoken in the Russian republics of Dagestan, Chechnya and Ingushetia and in northern Azerbaijan as well as in diaspora populations.			Language	
C161847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161847>	C51277	Turkic Language	A language family spoken by the Turkic peoples of Eurasia.			Language	
C161848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161848>	C131759	Allogeneic Bone Marrow Transplantation Recipient	An individual receiving an allogeneic bone marrow transplant.	Allogeneic Bone Marrow Transplantation Recipient		Human	CTRP Intervention Terminology|CTRP Terminology
C161849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161849>	C131759	Autologous Bone Marrow Transplantation Recipient	An individual receiving an autologous bone marrow transplant.	Autologous Bone Marrow Transplantation Recipient		Human	CTRP Intervention Terminology|CTRP Terminology
C16184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16184>	C15312	Gel Dosimetry	Gel dosimetry involves filling a model of a body part, such as the head, neck or breast, with a gel mixture. The gel-filled model (phantom) then undergoes MRI, CT, ultrasound, or radiation therapy, to gauge how effective the same procedure might be for the patient. Radiation alters the chemical structure of the gel, and the changes appear when scientists view a cross-section of the phantom on the computer screen.  (from Medscape)			Laboratory Procedure	
C161850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161850>	C16462	Virtual Avatar Interaction Program	Interactive technology that uses motion capture to animate a digital version of an individual. The system allows patients to freely act out representations of themselves, significant others, or family members in a personal and engaging way, allowing users to observe their stories in real time, potentially encouraging deeper reflection and memory retrieval.	Virtual Avatar Interaction Program		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C161851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161851>	C161854	Manding Language|Manden Language	Dialects of the Mande language family spoken in West Africa.			Language	
C161852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161852>	C51277	Niger-Congo Language|NIC|Niger-Congo|Niger-Kordofanian|Niger-Kordofanian Languages	A large family of languages spoken in Africa, predominantly in sub-Saharan Africa.			Language	
C161853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161853>	C161852	Bantu Language|Narrow Bantu Language	A large family of languages spoken by the Bantu peoples throughout Sub-Saharan Africa.			Language	
C161854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161854>	C161852	Mande Language	A branch of the Niger-Congo language spoken by the Mande people.			Language	
C161855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161855>	C160962	Balto-Slavic Language	A branch of the Indo-European family of languages. It traditionally comprises the Baltic and Slavic languages.			Language	
C161856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161856>	C161855	Slavic Language	The Indo-European languages spoken by the Slavic peoples.			Language	
C161857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161857>	C161856	East Slavic Language	A regional subgroup of the Slavic languages, currently spoken throughout Eastern Europe, Northern Asia, and the Caucasus.			Language	
C161858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161858>	C161856	South Slavic Language|South Slavic|Southern Slavic|ZLS	A branch of the Slavic languages spoken mainly in the Balkans.			Language	
C161859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161859>	C161856	West Slavic Language	A subdivision of the Slavic language group spoken across a continuous region encompassing the Czech Republic, Slovakia, and Poland.			Language	
C16185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16185>	C49236	Image-Guided Therapy|Image Guided Therapy|Imaging Guided Therapy	The use of imaging techniques to provide the basis for therapy, e.g., enabling surgeons to visualize internal structures through an automated overlay of 3D reconstructions of internal anatomy on top of live video views of a patient. Also used for guidance of biopsy needles.	Image-Guided Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C161860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161860>	C160962	Celtic Language	A branch of the Indo-European language family spoken in the northwestern fringe of Europe and a few diaspora communities.			Language	
C161861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161861>	C51277	Mongolic Language	A group of languages spoken in East-Central Asia, mostly in Mongolia and surrounding areas.			Language	
C161862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161862>	C51277	Sino-Tibetan Language	A large family of languages spoken in China and from the Tibetan plateau in the north to the Malay peninsula in the south, and from northern Pakistan in the west to northeastern Vietnam in the east.			Language	
C161863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161863>	C94364	Hydrazide Beads	Superparamagnetic silica particles coated with hydrazide used in affinity chromatography for the isolation of glycosylated proteins and peptides from a biological sample.			Indicator, Reagent, or Diagnostic Aid	
C161864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161864>	C96040	Revdofilimab|ABBV 368|ABBV-368|ABBV368|Agonistic Anti-OX40 Monoclonal Antibody ABBV-368|Anti-OX40 Agonist Monoclonal Antibody ABBV-368|Anti-OX40 Agonistic Monoclonal Antibody ABBV-368|PR1628103|REVDOFILIMAB	An agonistic humanized IgG1 monoclonal antibody that recognizes the co-stimulatory receptor OX40 (CD134; tumor necrosis factor receptor superfamily member 4; TNFRSF4), with potential immunostimulatory activity. Upon administration, revdofilimab selectively binds to and activates OX40. This may induce the proliferation of memory and effector T-lymphocytes and inhibit the function of T-regulatory cells (Tregs) in the tumor microenvironment (TME). OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and plays an essential role in T-cell activation and differentiation.	Revdofilimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C161865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161865>	C94364	Ferric Ion-Charged NTA-Agarose|Fe3+ NTA-Agarose	A cross-linked agarose matrix linker-bound to nitrilotriacetic acid (NTA) and charged with ferric ions. This reagent is used in immobilized metal affinity chromatography for the purification of proteins or peptides from a biological sample.			Indicator, Reagent, or Diagnostic Aid	
C161866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161866>	C2480	Tandem Mass Tag|TMT	A group of amine-reactive reagents used as tags for isobaric mass labeling that are comprised of a mass reporter region (M), a cleavable linker region (F), a mass normalization region (N) and a protein reactive group (R). Tandem mass tags (TMT) are added to peptides following sample collection, protein purification and protein digestion. These tags are identical in chemical composition but isotope substitutions in the M and N regions allow these regions to have different molecular masses. The number of isotope substitutions is equal to the number of distinct samples that can be tagged and assayed.			Indicator, Reagent, or Diagnostic Aid	
C161867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161867>	C2480	Isobaric Tags for Relative and Absolute Quantitation|iTRAQ	A group of amine-reactive reagents used as tags for isobaric mass labeling. These tags are identical in chemical composition but isotope substitutions allow individual tags to be identified.			Indicator, Reagent, or Diagnostic Aid	
C161868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161868>	C161867	Isobaric Tags for Relative and Absolute Quantitation 4-plex|iTRAQ 4-plex|iTRAQ-4|iTRAQ4	An isobaric tag for relative and absolute quantitation reagent preparation containing four distinct isotope substitutions.			Indicator, Reagent, or Diagnostic Aid	
C161869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161869>	C161866	Tandem Mass Tag 10-plex|TMT-10|TMT10|TMT10plex	A tandem mass tag reagent preparation containing ten distinct isotope substitutions.			Indicator, Reagent, or Diagnostic Aid	
C16186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16186>	C64982|C49163	Orthopedic Surgical Procedure|Orthopedic Surgical Procedures	A surgical procedure to treat and correct deformities, diseases, and injuries to the skeletal system, its articulations, and associated structures.	Orthopedic Surgical Procedure		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C161870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161870>	C161866	Tandem Mass Tag 11-plex|TMT-11|TMT11|TMT11plex	A tandem mass tag reagent preparation containing eleven distinct isotope substitutions.			Indicator, Reagent, or Diagnostic Aid	
C161871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161871>	C161866	Glyco-Tandem Mass Tag|Glyco-TMT	A tandem mass tag reagent preparation bearing a reactive group that enables labeling and quantitative profiling of glycopeptides, carbohydrates, steroids, or oxidized proteins.			Indicator, Reagent, or Diagnostic Aid	
C161872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161872>	C161871	Aminoxy-Tandem Mass Tag|Aminooxy TMT|Aminooxy-TMT|Aminoxy-TMT|AminoxyTMT	A tandem mass tag reagent preparation that is coupled to a carbonyl-reactive aminoxy group that enables labeling and quantitative profiling of glycopeptides, carbohydrates, steroids, or oxidized proteins.			Indicator, Reagent, or Diagnostic Aid	
C161873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161873>	C2480	Deuterium Isobaric Amine Reactive Tag|DiART	A reagent used for isobaric mass labeling that is amine reactive and tagged with the heavy hydrogen isotope deuterium. Deuterium isobaric amine reactive tags have been used in phosphoproteomic studies.			Indicator, Reagent, or Diagnostic Aid	
C161874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161874>	C2480	N,N-dimethyl Leucine Isobaric Labeling Reagent|DiLeu	A set of isobaric mass tags that contain dimethyl leucine.			Indicator, Reagent, or Diagnostic Aid	
C161875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161875>	C161871	Hydrazide-Tandem Mass Tag|Hydrazide TMT|Hydrazide-TMT	A tandem mass tag reagent preparation that is coupled to a carbonyl-reactive hydrazide group that enables labeling and quantitative profiling of glycopeptides, carbohydrates, steroids, or oxidized proteins.			Indicator, Reagent, or Diagnostic Aid	
C161876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161876>	C161866	Iodoacetyl-Activated Tandem Mass Tag|IodoTMT	A tandem mass tag reagent preparation that is iodoacetyl-activated, which enables labeling and quantitative profiling of sulfhydryl groups and nitrosylated proteins.			Indicator, Reagent, or Diagnostic Aid	
C161877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161877>	C161867	Hydrazide-Isobaric Tags for Relative and Absolute Quantitation|iTRAQ Hydrazide|iTRAQ-Hydrazide|iTRAQH	An isobaric tags for relative and absolute quantitation reagent preparation that is coupled to a carbonyl-reactive hydrazide group that enables labeling and quantitative profiling of glycopeptides, carbohydrates, steroids, or oxidized proteins.			Indicator, Reagent, or Diagnostic Aid	
C161878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161878>	C802	Protein Cleavage Reagent	A reagent used to produce peptide fragments for peptide mapping.			Indicator, Reagent, or Diagnostic Aid	
C161879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161879>	C161878	Arg-C, Asp-N Protein Cleavage Reagent|Arg-C, Asp-N	A protein cleavage reagent comprised of a mixture of the bacterial endopeptidases Arg-C and Asp-N that cleaves proteins into peptides at the C-terminal side of a lysine or arginine residue and the N-terminal side of an aspartate residue.			Indicator, Reagent, or Diagnostic Aid	
C16187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16187>	C193375|C16230	Whole-Brain Radiotherapy|WBRT|whole-brain radiation therapy|whole-brain radiotherapy	Radiation treatment modality used as major component in treatment of primary and metastatic brain tumors. This is a standard treatment for multiple brain metastases.	Whole-Brain Radiotherapy		Clinical Attribute	CTRP Intervention Terminology|CTRP Terminology
C161880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161880>	C161878	Endopeptidase Arg-C Protein Cleavage Reagent|Arg-C|Clostripain Protein Cleavage Reagent	A protein cleavage reagent comprised of bacterial endopeptidase Arg-C that cleaves proteins into peptides at the C-terminal side of a lysine or arginine residue.			Indicator, Reagent, or Diagnostic Aid	
C161881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161881>	C161878	Endopeptidase Asp-N Protein Cleavage Reagent|Asp-N	A protein cleavage reagent comprised of the bacterial endopeptidase Asp-N that cleaves proteins into peptides at the N-terminal side of an aspartate residue.			Indicator, Reagent, or Diagnostic Aid	
C161882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161882>	C161878	Endopeptidase Asp-N in Ammonium Bicarbonate Protein Cleavage Reagent|Asp-N_ambic|Endopeptidase Asp-N_ambic Protein Cleavage Reagent	A protein cleavage reagent comprised of a form of the bacterial endopeptidase Asp-N in a solution containing ammonium bicarbonate that cleaves proteins into peptides at the N-terminal side of an aspartate or glutamate residue.			Indicator, Reagent, or Diagnostic Aid	
C161883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161883>	C161878	Chymotrypsin Protein Cleavage Reagent	A protein cleavage reagent comprised of the serine proteinase chymotrypsin that cleaves proteins into peptides at the C-terminal side of a phenylalanine, tyrosine, tryptophan or leucine residue unless that residue is followed by a proline.			Indicator, Reagent, or Diagnostic Aid	
C161884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161884>	C161878	Glutamyl Endopeptidase Protein Cleavage Reagent|Endopeptidase Glu-C Protein Cleavage Reagent|Glu-C|Protease V8 Protein Cleavage Reagent	A protein cleavage reagent comprised of the bacterial serine proteinase glutamyl endopeptidase that cleaves proteins into peptides at the C-terminal side of glutamic acid or aspartic acid residues.			Indicator, Reagent, or Diagnostic Aid	
C161885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161885>	C161878	Leukocyte Elastase Protein Cleavage Reagent	A protein cleavage reagent comprised of the serine proteinase leukocyte elastase that cleaves proteins into peptides at the C-terminus of alanine, valine, serine, glycine, leucine and isoleucine.			Indicator, Reagent, or Diagnostic Aid	
C161886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161886>	C161878	Endoproteinase Lys-C Protein Cleavage Reagent|Lys-C	A protein cleavage reagent comprised of the bacterial endoproteinase Lys-C that cleaves proteins into peptides at the C-terminal side of lysine residues unless that residue is followed by proline.			Indicator, Reagent, or Diagnostic Aid	
C161887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161887>	C161878	Endoproteinase Lys-C/P Protein Cleavage Reagent|Lys-C/P	A protein cleavage reagent comprised of a form of the bacterial endoproteinase Lys-C/P that cleaves proteins into peptides at the C-terminal side of lysine residues.			Indicator, Reagent, or Diagnostic Aid	
C161888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161888>	C70845	No Protein Cleavage Reagent Used	A technique for processing protein samples for physicochemical analysis where no protein cleavage reagents were used.			Research Activity	
C161889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161889>	C70845	No Cleavage Enzyme Used	A technique for processing protein samples for physicochemical analysis where no protease-based reagents were used.			Research Activity	
C16188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16188>	C204439	Transurethral Electrovaporization of the Prostate|TUVP	Application of electrical energy to electrosurgically vaporize or remove the obstructive enlarged prostatic tissue.  In electrosurgical vaporization, the electrode rapidly heats the tissue cells so that they turn into steam, leaving a space where the prostate tissue was previously present. (from Columbia University Department of Urology)			Therapeutic or Preventive Procedure	
C161890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161890>	C161878	Pepsin A Protein Cleavage Reagent	A protein cleavage reagent comprised of the aspartic proteinase pepsin A, which cleaves proteins into peptides at the C-terminal side of a phenylalanine or leucine residue.			Indicator, Reagent, or Diagnostic Aid	
C161891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161891>	C161878	Proline Endopeptidase Protein Cleavage Reagent|Neurolysin Protein Cleavage Reagent|Prolyl Endopeptidase Protein Cleavage Reagent	A protein cleavage reagent comprised of the proline endopeptidase neurolysin that cleaves proteins into peptides at the C-terminal side of a proline residue.			Indicator, Reagent, or Diagnostic Aid	
C161892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161892>	C161878	Trypsin/Chymotrypsin Protein Cleavage Reagent|TrypChymo	A protein cleavage reagent comprised of a mixture of trypsin and chymotrypsin that cleaves proteins into peptides at the C-terminal side of a phenylalanine, tyrosine, tryptophan, leucine, lysine or arginine residue unless that residue is followed by a proline.			Indicator, Reagent, or Diagnostic Aid	
C161893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161893>	C161878	Trypsin Protein Cleavage Reagent|Tryptic Protein Cleavage Reagent	A protein cleavage reagent comprised of the a form of the serine proteinase trypsin that cleaves proteins into peptides at the C-terminal side of a lysine or arginine residue unless that residue is followed by a proline.			Indicator, Reagent, or Diagnostic Aid	
C161894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161894>	C161878	Trypsin/P Protein Cleavage Reagent|Trypsin/P	A protein cleavage reagent comprised of the serine proteinase trypsin/P that cleaves proteins into peptides at the C-terminal side of a lysine or arginine residue.			Indicator, Reagent, or Diagnostic Aid	
C161895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161895>	C161884	V8-Asp/Glu Protein Cleavage Reagent|Glutamyl Endopeptidase Asp/Glu Digestion Reagent|Glutamyl Endopeptidase V8-Asp/Glu Digestion Reagent|V8-Asp/Glu|V8-DE|V8-DE Digestion Reagent	A protein cleavage reagent comprised of the bacterial serine proteinase V8-Asp/Glu that cleaves proteins into peptides at the C-terminal side of an asparagine, aspartate, glutamate or glutamine residue unless that residue is followed by a proline.			Indicator, Reagent, or Diagnostic Aid	
C161896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161896>	C161884	V8-Glu Protein Cleavage Reagent|Glutamyl Endopeptidase V8-Glu Digestion Reagent|V8-E|V8-E Digestion Reagent|V8-Glu	A protein cleavage reagent comprised of the bacterial serine proteinase V8-Glu that cleaves proteins into peptides at the glutamate or glutamine residue unless that residue is followed by a proline.			Indicator, Reagent, or Diagnostic Aid	
C161897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161897>	C70845	Unspecified Cleavage Reagents Used	An indication that any reagents used in the preparation of cleaved peptides for physicochemical analysis were not specified.			Research Activity	
C161898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161898>	C802	Iodoacetamide|2-Iodoacetamide|Acetamide, 2-iodo-|IAA|Monoiodoacetamide|N-(3-Methoxy-4-butoxybenzyl)thiobarbituric acid	A sulfhydryl alkylating reagent that forms covalent bonds with the thiol group of cysteines so the protein or peptide no longer forms disulfide bonds.	Iodoacetamide		Indicator, Reagent, or Diagnostic Aid|Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C161899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161899>	C802	Chloroacetamide|2-Chloracetamide|2-Chloroacetamide|2-Chloroethanamide|Acetamide, 2-chloro-|CAA|Chloracetamide	A chlorinated sulfhydryl alkylating reagent that forms covalent bonds with the thiol group of cysteines so the protein or peptide no longer forms disulfide bonds.			Indicator, Reagent, or Diagnostic Aid|Organic Chemical	
C16189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16189>	C15426	Atlas of Cancer Mortality in the United States|Atlas of Cancer Mortality|Cancer Maps	The NCI's Atlas of Cancer Mortality in the United States, 1950-94, shows the geographic patterns of cancer death rates in over 3,000 counties across the country over more than four decades. It contains the 254 color-coded maps (for about 40 cancers), that will make it easy for researchers and state health departments to identify places where high or low rates occur, and to uncover patterns of cancer that would escape notice if larger areas, such as states, were mapped. The atlas will not tell researchers why death rates are higher in certain localities than in others, but it will provide important clues for further in-depth studies into the causes and control of cancer.			Intellectual Product	
C1618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1618>	C912	BAGE Tumor Antigen|B Melanoma Antigen|BAGE	The BAGE gene family encodes CT antigens, recognized by cytotoxic T-lymphocytes.  BAGE is expressed in normal adult testis and in some melanomas, infiltrating bladder carcinomas, mammary carcinomas, head and neck squamous cell carcinomas, and non-small cell lung carcinomas.  The function of BAGE protein is unknown.			Amino Acid, Peptide, or Protein|Immunologic Factor	
C161900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161900>	C802	Tris(2-carboxyethyl)phosphine|3,3',3''-Phosphinidynetrispropanoic acid|Propanoic acid, 3,3',3''-phosphinidynetris-|TCEP	An agent used in peptide mapping to reduce cysteine-containing disulfides to thiols.			Indicator, Reagent, or Diagnostic Aid|Organic Chemical	
C161901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161901>	C51277	Austronesian Language	A language family that is widely dispersed throughout Maritime Southeast Asia, Madagascar and the islands of the Pacific Ocean, with a few members in continental Asia.			Language	
C161902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161902>	C51277	Austroasiatic Language|Mon-Khmer	A large language family of Mainland Southeast Asia, also scattered throughout parts of India, Bangladesh, Nepal and southern China.			Language	
C161903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161903>	C161901	Polynesian Language	A language family spoken in geographical Polynesia and on a patchwork of outliers from south central Micronesia to small islands off the northeast of the larger islands of the southeast Solomon Islands and sprinkled through Vanuatu.			Language	
C161904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161904>	C160962	Germanic Language	A branch of the Indo-European language family spoken natively mainly in Europe, North America, Oceania, and Southern Africa.			Language	
C161905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161905>	C51277	Nilotic Language	A group of Eastern Sudanic languages spoken across a wide area between South Sudan and Tanzania by the Nilotic peoples.			Language	
C161906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161906>	C95397|C222802	Esophageal Intramucosal Adenocarcinoma	An adenocarcinoma that arises from the esophagus and is confined entirely to the mucosa.	Esophageal Intramucosal Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C161907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161907>	C51277	Uralic Language	A language family spoken predominantly in Northern Eurasia and in the European Union.			Language	
C161908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161908>	C210937	Sami Language	A group of Uralic languages spoken by the Sami people in Northern Europe.			Language	
C161909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161909>	C51277	Dravidian Language	A language family spoken mainly in Southern India and parts of Central and Eastern India, as well as in Sri Lanka with small pockets in southwestern Pakistan, southern Afghanistan, Nepal, Bangladesh and Bhutan.			Language	
C16190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16190>	C19975	Cancer Care Outcomes Research and Surveillance Consortium|CanCORS	A funding project supporting research towards measuring the quality of cancer care in the United States.  It is to be a five-year project (starting which will support prospective cohort studies on 10,000 patients with newly diagnosed lung or colorectal cancers. The project is designed to increase the knowledge of the relationship between cancer care practices in the general population and patient outcomes including survival and quality of life.			Health Care Related Organization	
C161910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161910>	C51277	Kra-Dai Language	A language family of tonal languages found in southern China, Northeast India and Southeast Asia.			Language	
C161911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161911>	C177686	Non-BRCA Gene Mutation|Non-BRCA Gene Mutation Positive|Non-BRCA Gene Mutation Present|Non-BRCA Gene Variant	A genetic finding indicating the presence of gene mutations in a sample that may be associated with cancer predisposition and are in located in genes other than BRCA1 and BRCA2.	Non-BRCA Gene Mutation		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C161912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161912>	C51277	Arawakan Language|Maipuran|Maipure|Maipurean|Maipureano	A language family that developed among ancient indigenous peoples in South America.			Language	
C161913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161913>	C158073	Na-Dene Language|Athabaskan-Eyak-Tlingit|Na-Dene|Nadene|Tlina-Dene	family of Native American languages that includes at least the Athabaskan languages, Eyak, and Tlingit languages.			Language	
C161914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161914>	C63587	BCMF Regimen|BCMF|BCMF|Bleomycin-Cyclophosphamide-Methotrexate-Fluorouracil|Bleomycin/Cyclophosphamide/Fluorouracil/Methotrexate|Bleomycin/Cyclophosphamide/Methotrexate/Fluorouracil|Bleomycin/Cyclophosphamide/Methotrexate/Fluorouracil Regimen	A regimen consisting of bleomycin, cyclophosphamide, fluorouracil and methotrexate that may be used in the treatment of certain head and neck cancers.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161915>	C140180	Cisplatin/Cytarabine/Dacarbazine/Hydroxyurea/Lomustine/Methylprednisolone/Procarbazine/Vincristine Regimen|8 in 1|Cisplatin-Cytarabine-Dacarbazine-Hydroxyurea-Lomustine-Methylprednisolone-Procarbazine-Vincristine|Cisplatin-Cytarabine-Dacarbazine-Hydroxyurea-Lomustine-Methylprednisolone-Procarbazine-Vincristine Regimen|Cisplatin/Cytarabine/Dacarbazine/Hydroxyurea/Lomustine/Methylprednisolone/Procarbazine/Vincristine	A regimen consisting of cisplatin, cytarabine, dacarbazine, hydroxyurea, lomustine, methylprednisolone, procarbazine, and vincristine used for the treatment of low grade glioma and medulloblastoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161916>	C63522	Carmustine/Cyclophosphamide/Doxorubicin Regimen|ABC|Carmustine-Cyclophosphamide-Doxorubicin|Carmustine/Cyclophosphamide/Doxorubicin	A regimen consisting of carmustine, cyclophosphamide and doxorubicin that may be used for the treatment of ovarian cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161917>	C63356	Bleomycin/Dacarbazine/Doxorubicin/Lomustine Regimen|ABCD|Bleomycin-Dacarbazine-Doxorubicin-Lomustine|Bleomycin/Dacarbazine/Doxorubicin/Lomustine	A regimen consisting of bleomycin, dacarbazine, doxorubicin and lomustine that may be used for the treatment of Hodgkin lymphoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161919>	C63356	Bleomycin/Dacarbazine/Doxorubicin Regimen|ABD|Bleomycin-Dacarbazine-Doxorubicin|Bleomycin/Dacarbazine/Doxorubicin	A regimen consisting of bleomycin, dacarbazine and doxorubicin that may be used for the treatment of Hodgkin lymphoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C16191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16191>	C52647	Tissue Array Research Program|TARP	The new Tissue Array Research Program (TARP) is a collaborative effort between the National Human Genome Research Institute and NCI to continued advances in detection, diagnosis, and development of targeted cancer therapies.  Among its aims are: 1) Advance tissue microarray technology research and development, 2) Produce tissue microarrays for use by the research community, 3) Serve as an arraying facility for groups with unique tissue materials, such as clinical trial groups or consortiums of rare diseases, 4) Disseminate tissue microarray technology by providing training, workshops, establishing protocols and standards.			Research Activity	
C161920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161920>	C159435	ADOC Regimen|ADOC|ADOC|ADOC|Adriamycin/cis-Diamminedichloroplatinum/Oncovin/Cyclophosphamide|Cisplatin/Cyclophosphamide/Doxorubicin/Vincristine|Cisplatin/Cyclophosphamide/Doxorubicin/Vincristine Regimen|Doxorubicin-cis-Diamminedichloroplatinum-Vincristine-Cyclophosphamide|Doxorubicin/cis-Diamminedichloroplatinum/Vincristine/Cyclophosphamide	A regimen consisting of cisplatin, doxorubicin, vincristine, and cyclophosphamide that may be used for the treatment of thymomas and thymic carcinomas.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161921>	C63358	Doxorubicin/Melphalan Regimen|Adria-L-PAM|Doxorubicin-Melphalan|Doxorubicin/Melphalan|Melphalan-Doxorubicin|Melphalan/Doxorubicin	A regimen consisting of doxorubicin and melphalan that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161922>	C140180	Cytarabine/Filgrastim/Methotrexate Regimen|Cytarabine-Filgrastim-Methotrexate|Cytarabine/Filgrastim/Methotrexate|ara-C/MTX	A regimen consisting of cytarabine and methotrexate that may be used in the treatment of certain central nervous system (CNS) lymphomas.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161923>	C63356	ASHAP Regimen|ASHAP|ASHAP|Adriamycin/Solu-Medrol/High-dose AraC/Platinol|Cisplatin/Cytarabine/Doxorubicin/Methylprednisolone|Doxorubicin-Methylprednisolone-Cytarabine-Cisplatin|Doxorubicin/Methylprednisolone/Cytarabine/Cisplatin|Doxorubicin/Methylprednisolone/Cytarabine/Cisplatin Regimen	A regimen consisting of doxorubicin, methylprednisolone, cytarabine, and cisplatin that may be used in the treatment of Hodgkin lymphoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161924>	C63442	ASHAP Alternating with M-BACOS Regimen|ASHAP/M-BACOS|ASHAP/M-BACOS|ASHAP/M-BACOS Regimen|Adriamycin/Solu-Medrol/High-dose Ara-C/Platinol/Methotrexate/Bleomycin/Cyclophosphamide/Oncovin|Bleomycin/Cisplatin/Cyclophosphamide/Cytarabine/Doxorubicin/Methotrexate/Methylprednisolone/Vincristine|Doxorubicin-Methylprednisolone-Cytarabine-Cisplatin-Methotrexate-Bleomycin-Cyclophosphamide-Vincristine|Doxorubicin/Methylprednisolone/Cytarabine/Cisplatin/Methotrexate/Bleomycin/Cyclophosphamide/Vincristine	A regimen consisting of doxorubicin, methylprednisolone, cytarabine, and cisplatin (ASHAP) alternating with methotrexate, leucovorin, doxorubicin, vincristine, bleomycin, cyclophosphamide, and methylprednisolone for the treatment of non-Hodgkin lymphoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161925>	C63589	ATGO Regimen|ATGO|Ara-C/Topotecan/Gemtuzumab Ozogamicin|Cytarabine Plus Gemtuzumab Ozogamicin Plus Topotecan|Cytarabine-Topotecan-Gemtuzumab Ozogamicin|Cytarabine-Topotecan-Gemtuzumab Ozogamicin Regimen|Cytarabine/Gemtuzumab Ozogamicin/Topotecan	A regimen consisting of cytarabine (Ara-C), topotecan, and gemtuzumab ozogamicin that may be used as induction therapy in myelodysplastic syndrome (MDS) and for the treatment of secondary or relapsed acute myeloid leukemia (AML).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161926>	C63589	Gemtuzumab Ozogamicin/Tretinoin Regimen|ATRA (263)|ATRA/Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin Plus Tretinoin|Gemtuzumab Ozogamicin-Tretinoin|Gemtuzumab Ozogamicin/ATRA|Gemtuzumab Ozogamicin/Tretinoin|Tretinoin/Gemtuzumab Ozogamicin	A regimen consisting of tretinoin (all-trans retinoic acid or ATRA) and gemtuzumab ozogamicin that may be used in the treatment of acute promyelocytic leukemia (APL).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161928>	C159435	BAPP Regimen|BAPP|BAPP|Bleomycin-Adriamycin-Platinol-Prednisone|Bleomycin-Doxorubicin-Cisplatin-Prednisone|Bleomycin/Adriamycin/Platinol/Prednisone|Bleomycin/Cisplatin/Doxorubicin/Prednisone|Bleomycin/Doxorubicin/Cisplatin/Prednisone|Bleomycin/Doxorubicin/Cisplatin/Prednisone Regimen	A regimen consisting of bleomycin, doxorubicin, cisplatin, and prednisone for the treatment of invasive thymoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161929>	C63496	BCAP Regimen|BCAP|BCAP|BCNU/Cyclophosphamide/Adriamycin/Prednisone|Carmustine-Cyclophosphamide-Doxorubicin-Prednisone|Carmustine/Cyclophosphamide/Doxorubicin/Prednisone|Carmustine/Cyclophosphamide/Doxorubicin/Prednisone Regimen	A regimen consisting of carmustine, cyclophosphamide, doxorubicin, and prednisone that may be used in the treatment of plasma cell myeloma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C16192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16192>	C49132	Sputum Cytology|Sputum Cytology Screening|sputum cytology	An examination of cells obtained from a sample of sputum.			Laboratory Procedure	
C161930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161930>	C63356	BCAVe Regimen|BCAVe|BCAVe|Bleomycin-Lomustine-Doxorubicin-Vinblastine|Bleomycin/CCNU/Adriamycin/Velban|Bleomycin/Doxorubicin/Lomustine/Vinblastine|Bleomycin/Lomustine/Doxorubicin/Vinblastine|Bleomycin/Lomustine/Doxorubicin/Vinblastine Regimen	A regimen consisting of bleomycin, lomustine, doxorubicin, and vinblastine that may be used in the treatment of Hodgkin lymphoma (HL).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161931>	C63442|C63356	BCOP Regimen|BCNU/Cyclophosphamide/Oncovin/Prednisone|BCNU/Cyclophosphamide/Oncovin/Prednisone Regimen|BCOP|BCOP|BCVP|Carmustine-Cyclophosphamide-Vincristine-Prednisone|Carmustine/Cyclophosphamide/Vincristine/Prednisone|Carmustine/Cyclophosphamide/Vincristine/Prednisone Regimen	A regimen consisting of carmustine, cyclophosphamide, vincristine, and prednisone that may be used in the treatment of malignant lymphoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161932>	C63442	B-DOPA Regimen|B-DOPA|B-DOPA|Bleomycin-Dacarbazine-Vincristine-Prednisone-Doxorubicin|Bleomycin/Dacarbazine/Doxorubicin/Prednisone/Vincristine|Bleomycin/Dacarbazine/Oncovin/Prednisone/Adriamycin|Bleomycin/Dacarbazine/Vincristine/Prednisone/Doxorubicin|Bleomycin/Dacarbazine/Vincristine/Prednisone/Doxorubicin Regimen	A regimen consisting of bleomycin, dacarbazine, vincristine, prednisone, and doxorubicin, for treating patients with non-Hodgkin lymphoma (NHL) relapse after primary or radiation therapy.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161933>	C65070	BIC Regimen|BIC|BIC|Bleomycin-Ifosfamide-Carboplatin|Bleomycin/Carboplatin/Ifosfamide|Bleomycin/Ifosfamide/Carboplatin|Bleomycin/Ifosfamide/Carboplatin Regimen	A regimen consisting of bleomycin, ifosfamide, and carboplatin that may be used in the treatment of cervical cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161934>	C63496	BiRd Regimen|BIRD|BiRd|BiRd|Biaxin/Revlimid/Dexamethasone|Clarithromycin-Lenalidomide-Dexamethasone|Clarithromycin/Lenalidomide/Dexamethasone|Clarithromycin/Lenalidomide/Dexamethasone Regimen	A regimen consisting of clarithromycin, lenalidomide and dexamethasone that may be used in the treatment of plasma cell myeloma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161935>	C63587	Bleomycin/Cyclophosphamide/Fluorouracil/Methotrexate/Vincristine Regimen|BLEO-COMF|Bleomycin-Cyclophosphamide-Fluorouracil-Methotrexate-Vincristine|Bleomycin/Cyclophosphamide/Fluorouracil/Methotrexate/Vincristine	A regimen consisting of bleomycin, cyclophosphamide, fluorouracil, methotrexate and vincristine for the treatment of some head and neck cancers.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161936>	C63496	BLT-D Regimen|BLT-D|BLTD|Biaxin/Low-dose Thalidomide/Dexamethasone|Clarithromycin-Low-dose Thalidomide-Dexamethasone. Clarithromycin/Dexamethasone/Low-dose Thalidomide|Clarithromycin/Low-dose Thalidomide/Dexamethasone	A regimen consisting of clarithromycin, dexamethasone, and low-dose thalidomide for the treatment of plasma cell myeloma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161937>	C63496|C63442|C63356	Busulfan/Cyclophosphamide/Etoposide Regimen|BuCyE|Busulfan-Cyclophosphamide-Etoposide|Busulfan-Cyclophosphamide-Etoposide Regimen|Busulfan/Cyclophosphamide/Etoposide	A regimen consisting of busulfan, cyclophosphamide and etoposide that may be used as a conditioning regimen prior to stem cell transplant in patients with plasma cell myeloma and some lymphomas.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161939>	C63358	CAMELEON Regimen|CAMELEON|CAMLO|Cytarabine-Methotrexate-Leucovorin-Vincristine|Cytarabine/Leucovorin/Methotrexate/Vincristine|Cytarabine/Methotrexate/Leucovorin/Vincristine|Cytarabine/Methotrexate/Leucovorin/Vincristine Regimen|Cytosine Arabinoside/Methotrexate/Leucovorin/Oncovin	A regimen consisting of cytarabine, methotrexate with leucovorin rescue, and vincristine for the treatment of metastatic breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C16193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16193>	C15238	Genoplasty	An alternative to traditional gene therapy, genoplasty is a repair technology that uses short DNA fragments to induce a cell to repair its genome.			Molecular Biology Research Technique	
C161940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161940>	C63468	Cisplatin/Cyclophosphamide/Estramustine/Fluorouracil Regimen|CCFE|Cisplatin-Cyclophosphamide-Estramustine-Fluorouracil|Cisplatin/Cyclophosphamide/Estramustine/Fluorouracil	A regimen consisting of cisplatin, cyclophosphamide, fluorouracil, and estramustine that may be used in the treatment of prostate cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161941>	C63359	CCV Alternating with AV Regimen|CCV-AV|CCV-AV|CCV-AV Regimen|CCV/AV|Cyclophosphamide-CCNU-Vincristine Alternating With Adriamycin-Vincristine|Cyclophosphamide/CCNU/Vincristine Alternating With Adriamycin/Vincristine|Cyclophosphamide/Lomustine/Vincristine Alternating With Doxorubicin/Vincristine	A regimen consisting of cyclophosphamide, doxorubicin, lomustine, and vincristine that may be used in the treatment of small cell lung cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161942>	C63522|C63358	CAC Regimen|CAC|CDC|Carboplatin-Doxorubicin-Cyclophosphamide|Carboplatin/Adriamycin/Cyclophosphamide|Carboplatin/Doxorubicin/Cyclophosphamide|Carboplatin/Doxorubicin/Cyclophosphamide Regimen	A regimen consisting of carboplatin, cyclophosphamide and doxorubicin that may be used in the treatment of breast and ovarian cancers.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161943>	C63442	CEPP Regimen|CEPP|CEPP|Cyclophosphamide-Etoposide-Procarbazine-Prednisone|Cyclophosphamide/Etoposide/Procarbazine/Prednisone|Cyclophosphamide/Etoposide/Procarbazine/Prednisone Regimen	A regimen consisting of cyclophosphamide, etoposide, prednisone, and procarbazine for the treatment of non-Hodgkin lymphoma (NHL).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161944>	C63443	CFAR Regimen|Alemtuzumab/Cyclophosphamide/Fludarabine/Rituximab|CFAR|CFAR|CFAR|CFAR (rituximab-abbs)|CFAR (rituximab-arrx)|CFAR (rituximab-blit)|CFAR (rituximab-pvvr)|CFAR (rituximab-rite)|CFAR (rituximab-rixa)|CFAR (rituximab-rixi)|Cyclophosphamide-Fludarabine-Alemtuzumab-Rituximab|Cyclophosphamide/Fludarabine/Alemtuzumab/Rituximab|Cyclophosphamide/Fludarabine/Alemtuzumab/Rituximab Regimen	A regimen consisting of cyclophosphamide, fludarabine, alemtuzumab, and rituximab that may be used in the treatment of chronic lymphocytic leukemia (CLL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161945>	C63358	CFPT Regimen|CFPT|CFPT|Cyclophosphamide-Fluorouracil-Prednisone-Tamoxifen|Cyclophosphamide/Fluorouracil/Prednisone/Tamoxifen|Cyclophosphamide/Fluorouracil/Prednisone/Tamoxifen Regimen	A regimen consisting of cyclophosphamide, fluorouracil, prednisone, and tamoxifen that may be used in the treatment of advanced breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161946>	C159909	GIP Regimen|CGI|Cisplatin/Gemcitabine/Ifosfamide|GIP|GIP|Gemcitabine-Ifosfamide-Cisplatin|Gemcitabine/Ifosfamide/Cisplatin|Gemcitabine/Ifosfamide/Cisplatin Regimen|Gemcitabine/Ifosfamide/Platinol	A regimen consisting of gemcitabine, ifosfamide, and cisplatin that may be useful in the treatment of certain germ cell tumors.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161947>	C63522|C63519|C159901|C159900	CIM Regimen|CIM|CIM|Cisplatin and Ifosfamide|Cisplatin-Ifosfamide-Mesna|Cisplatin/Ifosfamide/Mesna|Cisplatin/Ifosfamide/Mesna Regimen	A regimen consisting of cisplatin, ifosfamide, and mesna that may be used in the treatment of endometrial and ovarian cancer, and malignant mixed Müllerian tumors.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161948>	C159909	CisCAII Alternating with VBIV Regimen|CISCAii/BViv|CisCAII-VBIV Regimen|CisCAII/VBIV|Cisplatin/Cyclophosphamide/Adriamycin Alternating with Vinblastine/Bleomycin Cisplatin-Cyclophosphamide-Doxorubicin Alternating with Vinblastine-Bleomycin|Cisplatin/Cyclophosphamide/Doxorubicin Alternating with Vinblastine/Bleomycin	A regimen consisting of cyclophosphamide, doxorubicin, cisplatin, vinblastine, and bleomycin that may be used in the treatment of extragonadal germ cell tumors.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161949>	C63589	CLAG Regimen|CLAG|CLAG|CLAG|CLAG (filgrastim-aafi)|CLAG (filgrastim-ayow)|CLAG (filgrastim-sndz)|Cladarabine/Ara-C/G-CSF|Cladarabine/Ara-C/Granulocyte-Colony Stimulating Factor|Cladribine-Cytarabine-Filgrastim|Cladribine/Cytarabine/Filgrastim|Cladribine/Cytarabine/Filgrastim Regimen	A regimen consisting of cladribine, cytarabine and filgrastim that may be used in the treatment of childhood and adult acute myeloid leukemia (AML).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C16194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16194>	C63475	Preoperative Endocrine Therapy	Short term endocrine therapy, prior to surgery, to "down-stage" primary breast cancer in order to increase the rate of breast-conserving surgery.  (from JMCC 7:557-562, 2000 via Medscape)			Therapeutic or Preventive Procedure	
C161950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161950>	C63589	CLAG-M Regimen|CLAG-M|CLAG-M|CLAG-M|CLAG-M (filgrastim-aafi)|CLAG-M (filgrastim-ayow)|CLAG-M (filgrastim-sndz)|Cladarabine/Ara-C/Granulocyte-Colony Stimulating Factor/Mitoxantrone|Cladribine-Cytarabine-Filgrastim-Mitoxantrone|Cladribine/Ara-C/G-CSF/Mitoxantrone|Cladribine/Cytarabine/Filgrastim/Mitoxantrone|Cladribine/Cytarabine/Filgrastim/Mitoxantrone Regimen	A regimen consisting of cladribine, cytarabine, filgrastim, and mitoxantrone that may be used in the treatment of acute myeloid leukemia (AML).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161951>	C63359	CMC Alternating with VAP Regimen|CMC-VAP|CMC-VAP|CMC-VAP Regimen|Cyclophosphamide-Methotrexate-CCNU Alternating With Vincristine-Adriamycin-Procarbazine|Cyclophosphamide/Methotrexate/CCNU Alternating With Vincristine/Adriamycin/Procarbazine|Cyclophosphamide/Methotrexate/Lomustine Alternating with Vincristine/Doxorubicin/Procarbazine	A regimen consisting of high-dose cyclophosphamide, methotrexate, and lomustine (CMC) alternating with vincristine, doxorubicin, and procarbazine (VAP) that may be used in the treatment of small cell lung cancer (SCLC).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161952>	C63360	CMFH Regimen|CMFH|CMFH|Cyclophosphamide-Methotrexate-Fluorouracil-Hydroxyurea|Cyclophosphamide/Fluorouracil/Hydroxyurea/Methotrexate|Cyclophosphamide/Methotrexate/Fluorouracil/Hydroxyurea|Cyclophosphamide/Methotrexate/Fluorouracil/Hydroxyurea Regimen	A regimen consisting of cyclophosphamide, fluorouracil, hydroxyurea, and methotrexate that may be used in the treatment of non-small cell lung cancer (NSCLC).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161953>	C63442	COMLA Regimen|COMLA|COMLA|Cyclophosphamide-Vincristine-Methotrexate-Leucovorin-Cytarabine|Cyclophosphamide/Cytarabine/Leucovorin/Methotrexate/Vincristine|Cyclophosphamide/Oncovin/Methotrexate/Leucovorin/Ara-C|Cyclophosphamide/Vincristine/Methotrexate/Leucovorin/Cytarabine|Cyclophosphamide/Vincristine/Methotrexate/Leucovorin/Cytarabine Regimen	A regimen consisting of cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine that may be used in the treatment of non-Hodgkin lymphomas (NHL).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161954>	C63587	ETPF Regimen|C-TPF|Cetuximab Plus Docetaxel/Cisplatin/Fluorouracil|Cetuximab-Docetaxel-Cisplatin-Fluorouracil|Cetuximab/Cisplatin/Docetaxel/Fluorouracil|Cetuximab/Docetaxel/Cisplatin/Fluorouracil|Cetuximab/Docetaxel/Cisplatin/Fluorouracil Regimen|ETPF|Erbitux Plus Taxotere/Platinol/Fluorouracil|Erbitux-TPF Regimen|Erbitux/Taxotere/Platinol/Fluorouracil	A regimen consisting of cetuximab, docetaxel, cisplatin, and 5-fluorouracil for the treatment of squamous cell carcinoma of the oropharynx.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161955>	C63356	Bleomycin/Dexamethasone/Lomustine/Vinblastine Regimen|Bleomycin-Dexamethasone-Lomustine-Vinblastine|Bleomycin/Dexamethasone/Lomustine/Vinblastine|CVBD	A regimen consisting of bleomycin, dexamethasone, lomustine, and vinblastine that may be used in the treatment of Hodgkin lymphoma (HL).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161956>	C63496	CVDD Regimen|Bortezomib/Cyclophosphamide/Dexamethasone/Liposomal Doxorubicin|CVDD|CVDD|Cyclophosphamide-Bortezomib-Liposomal Doxorubicin-Dexamethasone|Cyclophosphamide/Bortezomib/Liposomal Doxorubicin/Dexamethasone|Cyclophosphamide/Bortezomib/Liposomal Doxorubicin/Dexamethasone Regimen|Cyclophosphamide/Velcade/Doxil/Dexamethasone	A regimen consisting of cyclophosphamide, bortezomib, dexamethasone and pegylated liposomal doxorubicin that may be used in the treatment of plasma cell myeloma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161957>	C63496	CYCLONE Regimen|CYCLONE|CYCLONE|CYKLONE|Carfilzomib/Cyclophosphamide/Dexamethasone/Thalidomide|Carfilzomib/Cyclophosphamide/Thalidomide/Dexamethasone|Cyclophosphamide-Carfilzomib-Thalidomide-Dexamethasone|Cyclophosphamide/Carfilzomib/Thalidomide/Dexamethasone|Cyclophosphamide/Carfilzomib/Thalidomide/Dexamethasone Regimen	A regimen consisting of cyclophosphamide, carfilzomib, thalidomide and dexamethasone that may be used in the treatment of plasma cell  myeloma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161958>	C63510	Methotrexate/Leucovorin/Vincristine Regimen|CytaBOM|Methotrexate-Folinic Acid-Vincristine|Methotrexate-Folinic Acid-Vincristine Regimen|Methotrexate-Leucovorin-Vincristine|Methotrexate-Leucovorin-Vincristine Regimen|Methotrexate/Folinic Acid/Vincristine|Methotrexate/Folinic Acid/Vincristine Regimen|Methotrexate/Leucovorin/Vincristine	A regimen consisting of high-dose methotrexate with leucovorin rescue plus vincristine that may be used in the treatment of advanced sarcoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161959>	C63360	DAP Regimen|Cisplatin/Dianhydrodulcitol/Doxorubicin|DAP|DAP|Dianhydrodulcitol-Doxorubicin-Cisplatin|Dianhydrodulcitol-Doxorubicin-Cisplatin Regimen|Dianhydrodulcitol/Adriamycin/Platinol|Dianhydrodulcitol/Doxorubicin/Cisplatin	A regimen consisting of dianhydrogalactitol (dianhydrodulcitol), doxorubicin, and cisplatin that may be used in the treatment of non-small cell lung cancer (NSCLC).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C16195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16195>	C38186	AIDS and Cancer Specimen Bank|ACSB	The ACSB provides qualified researchers with tissue, cell, blood and fluid specimens, as well as clinical data from patients with HIV-related malignancies.  The ACSB contains formalin-fixed paraffin embedded tissues, fresh frozen tissues, malignant cell suspensions, fine needle aspirates, and cell lines from patients with HIV-related malignancies. The bank also contains serum, plasma, urine, bone marrow, cervical and anal specimens, saliva, semen and multi-site autopsy tissues from patients with HIV-related malignancies including those who have participated in clinical trials. The bank has an associated database that contains prognostic, staging, outcome and treatment data on patients from whom tissues were obtained. (CancerNet)			Physical Object	
C161960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161960>	C63358	Mitolactol/Doxorubicin/Vincristine Regimen|DAV|Dibromodulcitol-Doxorubicin-Vincristine|Dibromodulcitol/Adriamycin/Vincristine|Dibromodulcitol/Doxorubicin/Vincristine|Mitolactol/Doxorubicin/Vincristine	A regimen consisting of mitolactol (dibromodulcitol), doxorubicin, and vincristine that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161961>	C63589	DCCMP Regimen|Cyclocytidine/Daunorubicin/Mercaptopurine/Prednisone|DCCMP|DCCMP|Daunorubicin-Cyclocytidine-Mercaptopurine-Prednisone|Daunorubicin/Cyclocytidine/Mercaptopurine/Prednisone|Daunorubicin/Cyclocytidine/Mercaptopurine/Prednisone Regimen	A regimen consisting of daunorubicin, cyclocytidine, 6-mercaptopurine, and prednisone that may be used in the treatment of acute myeloid leukemia (AML).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161962>	C63524	Dacarbazine/Dactinomycin Regimen|DTIC-ACTD|DTIC-Act-D|DTIC-Actinomycin-D|Dacarbazine and Dactinomycin|Dacarbazine-Dactinomycin|Dacarbazine/Dactinomycin|Dactinomycin/Dacarbazine	A regimen consisting of dactinomycin and dacarbazine that may be used in the treatment of advanced melanoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161963>	C63587	DVM Regimen|Cisplatin-Vindesine-Mitoguazone|Cisplatin/Mitoguazone/Vindesine|Cisplatin/Vindesine/Mitoguazone|Cisplatin/Vindesine/Mitoguazone Regimen|DDP/Vindesine/Mitoguazone|DVM|DVM	A regimen consisting of cisplatin, vindesine, and mitoguazone that may be used in the treatment of certain head and neck cancers.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161964>	C63502	5-Azacitidine/Gemcitabine Regimen|5-Azacitidine-Gemcitabine|5-Azacitidine/Gemcitabine|Azacitidine-Gemcitabine|Azacitidine-Gemcitabine Regimen|Azacitidine/Gemcitabine|Azacitidine/Gemcitabine Regimen|ECOG	A regimen consisting of 5-azacitidine and gemcitabine that may be used in the treatment of pancreatic cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161965>	C63719|C63361	EOF Regimen|EOF|EOF|EOF|Epirubicin-Oxaliplatin-Fluorouracil|Epirubicin/Fluorouracil/Oxaliplatin|Epirubicin/Oxaliplatin/Fluorouracil|Epirubicin/Oxaliplatin/Fluorouracil Regimen	A regimen consisting of epirubicin, oxaliplatin, and fluorouracil that may be used in the treatment of some esophageal and gastric cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161966>	C63358	ACFTOR-BCG Regimen|ACFTOR-BCG|Adriamycin/Cyclophosphamide/Ftorafur/BCG|Adriamycin/Cyclophosphamide/Tegafur/BCG|Doxorubicin-Cyclophosphamide-Tegafur-BCG|Doxorubicin/Cyclophosphamide/Tegafur/BCG|Doxorubicin/Cyclophosphamide/Tegafur/Bacillus Calmette-Guerin|Doxorubicin/Cyclophosphamide/Tegafur/Bacillus Calmette-Guerin Regimen|FAC-BCG|FAC-BCG|FAC-BCG Regimen	A regimen consisting of tegafur, doxorubicin, cyclophosphamide, and Bacillus Calmette-Guerin (BCG) that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161967>	C63358	Cyclophosphamide/Doxorubicin/Fluorouracil/Levamisole Regimen|Cyclophosphamide-Doxorubicin-Fluorouracil-Levamisole|Cyclophosphamide-Doxorubicin-Fluorouracil-Levamisole Regimen|Cyclophosphamide/Doxorubicin/Fluorouracil/Levamisole|FAC-LEV|FAC-LEV|FAC-LEV Regimen|Fluorouracil/Adriamycin/Cyclophosphamide/Levamisole	A regimen consisting of cyclophosphamide, doxorubicin, fluorouracil, and levamisole that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161968>	C63361	Doxorubicin/Fluorouracil/Levoleucovorin/Mitomycin Regimen|FAM-CF|FAM-CF|FAM-CF Regimen|Fluorouracil/Adriamycin/Mitomycin/Citrovorum Factor|Fluorouracil/Doxorubicin/Mitomycin/Citrovorum Factor|Fluorouracil/Doxorubicin/Mitomycin/Levoleucovorin	A regimen consisting of 5-fluorouracil, doxorubicin, mitomycin C, and leucovorin that may be used to treat advanced gastric carcinoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161969>	C63361	FAMMe Regimen|Doxorubicin/Fluorouracil/Mitomycin/Semustine|FAMMe|FAMMe|Fluorouracil-Doxorubicin-Mitomycin-Semustine|Fluorouracil/Adriamycin/Mitomycin/MeCCNU|Fluorouracil/Doxorubicin/Mitomycin/Semustine|Fluorouracil/Doxorubicin/Mitomycin/Semustine Regimen	A regimen consisting of doxorubicin, fluorouracil, mitomycin, and semustine that may be used in the treatment of certain gastric cancers.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C16196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16196>	C38186	Clinical Trials Cooperative Groups Human Tissue Resources|CTCG Human Tissue Resources	A collection of banked tumor specimens from large numbers of uniformly treated cancer patients with a variety of malignancies.			Physical Object	
C161970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161970>	C67292|C63502	GEMOX-B Regimen|Bevacizumab/Gemcitabine/Oxaliplatin|GEMOX Plus Bevacizumab|GEMOX-B|GEMOX-B|GEMOX-B|GEMOX-B (bevacizumab-adcd)|GEMOX-B (bevacizumab-awwb)|GEMOX-B (bevacizumab-aybi)|GEMOX-B (bevacizumab-bvzr)|GEMOX-B (bevacizumab-equi)|GEMOX-B (bevacizumab-maly)|GEMOX-B (bevacizumab-onbe)|GEMOX-B (bevacizumab-tnjn)|GEMOX-Bevacizumab|Gemcitabine-Oxaliplatin-Bevacizumab|Gemcitabine/Oxaliplatin/Bevacizumab|Gemcitabine/Oxaliplatin/Bevacizumab Regimen	A regimen consisting of gemcitabine, oxaliplatin, and bevacizumab that may be used in the treatment of certain liver and pancreatic cancers.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161971>	C63589	Hi-C-Daze Regimen|Azacitidine/High-dose Cytarabine/Daunorubicin/Etoposide|HI-CDAZE|Hi-C-Daze|High-dose Ara-C/Daunorubicin/Azacitidine/Etoposide|High-dose Cytarabine-Daunorubicin-Azacitidine-Etoposide|High-dose Cytarabine/Daunorubicin/Azacitidine/Etoposide	A regimen consisting of high-dose cytarabine, daunorubicin, azacitidine, and etoposide that may be used in the treatment of childhood acute myeloid leukemia (AML).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161972>	C63359	ICE-V Regimen|Carboplatin/Etoposide/Ifosfamide/Vincristine|ICE-V|ICE-V|ICE-V|Ifosfamide-Carboplatin-Etoposide-Vincristine|Ifosfamide/Carboplatin/Etoposide/Vincristine|Ifosfamide/Carboplatin/Etoposide/Vincristine Regimen	A regimen consisting of ifosfamide, carboplatin, etoposide, and vincristine that may be used in the treatment of small-cell lung cancer (SCLC).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161973>	C63358	Fluorouracil/Ifosfamide/Mesna/Methotrexate Regimen|Fluorouracil/Ifosfamide/Mesna/Methotrexate|Fluorouracil/Ifosfamide/Methotrexate|IMF|IMF|IMF Regimen|Ifosfamide-Methotrexate-Fluorouracil|Ifosfamide/Methotrexate/Fluorouracil	A regimen consisting of ifosfamide, mesna, methotrexate and 5-fluorouracil that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161974>	C63361|C63359	Bevacizumab/Cisplatin/Irinotecan Regimen|Bevacizumab/Cisplatin/Irinotecan|IBP|IPB|Irinotecan-Bevacizumab-Cisplatin|Irinotecan/Bevacizumab/Cisplatin|Irinotecan/Bevacizumab/Platinol	A regimen consisting of bevacizumab, cisplatin, and irinotecan that may be used in the treatment of certain gastric cancers and small-cell lung cancers (SCLC).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161975>	C63358	LOMAC Regimen|Cyclophosphamide/Doxorubicin/Leucovorin/Methotrexate/Vincristine|LOMAC|LOMAC|Leucovorin-Vincristine-Methotrexate-Doxorubicin-Cyclophosphamide|Leucovorin/Oncovin/Methotrexate/Adriamycin/Cyclophosphamide Regimen|Leucovorin/Vincristine/Methotrexate/Doxorubicin/Cyclophosphamide	A regimen consisting of cyclophosphamide, doxorubicin, vincristine, and methotrexate with leucovorin that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161976>	C63442	LSA2L2 Regimen|Carmustine-Cyclophosphamide-Cytarabine-Daunorubicin-Hydroxyurea-L-asparaginase-Methotrexate-Prednisone-Thioguanine-Vincristine|Carmustine/Cyclophosphamide/Cytarabine/Daunorubicin/Hydroxyurea/L-asparaginase/Methotrexate/Prednisone/Thioguanine/Vincristine|LSA2-L2|LSA2-L2|LSA2L2	A regimen consisting of an induction phase with cyclophosphamide, daunorubicin, vincristine, prednisone, and intrathecal methotrexate; a consolidation phase with cytarabine, thioguanine, L-asparaginase, carmustine and intrathecal methotrexate; and a maintenance phase with thioguanine, cyclophosphamide, hydroxyurea, daunorubicin, intravenous and oral methotrexate and vincristine that may be used in the treatment of non-Hodgkin lymphoma (NHL).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161977>	C63356	MABOP Regimen|MABOP|MABOP|Mechlorethamine-Doxorubicin-Bleomycin-Vincristine-Prednisone|Mechlorethamine/Adriamycin/Bleomycin/Oncovin/Prednisone|Mechlorethamine/Doxorubicin/Bleomycin/Vincristine/Prednisone|Mechlorethamine/Doxorubicin/Bleomycin/Vincristine/Prednisone Regimen	A regimen consisting of mechlorethamine, doxorubicin, bleomycin, vincristine and prednisone that may be used in the treatment of Hodgkin lymphoma (HL).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161978>	C63588	MACHO Regimen|Cyclophosphamide/Doxorubicin/Asparaginase/Methotrexate/Vincristine|MACHO|MACHO|Methotrexate- Asparaginase-Cyclophosphamide-Doxorubicin-Vincristine|Methotrexate/Asparaginase/Cyclophosphamide/Doxorubicin/Vincristine|Methotrexate/Asparaginase/Cyclophosphamide/Hydroxydaunomycin/Oncovin|Methotrexate/Asparaginase/Cyclophosphamide/Vincristine Regimen	A regimen consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone, followed by methotrexate and L-asparaginase, that may be used for the treatment of acute lymphoblastic leukemia (ALL).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161979>	C63361	Cisplatin/Fluorouracil/Mitomycin Regimen|Cisplatin/Fluorouracil/Mitomycin|MCF|MCF|MCF|Mitomycin-Cisplatin-Fluorouracil|Mitomycin/Cisplatin/Fluorouracil	A regimen consisting of cisplatin, fluorouracil, and mitomycin that may be used in the treatment of gastric cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161980>	C63442	Cyclophosphamide/Melphalan/Prednisone Regimen|Cyclophosphamide-Melphalan-Prednisone|Cyclophosphamide/Melphalan/Prednisone|MCP|MCP|MCP Regimen|Melphalan-Cyclophosphamide-Prednisone|Melphalan/Cyclophosphamide/Prednisone	A regimen consisting of cyclophosphamide, melphalan and prednisone that may be used in the treatment of Waldenstrom's macroglobulinemia.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161981>	C63519	Fluorouracil/Medroxyprogesterone/Melphalan Regimen|Fluorouracil/Medroxyprogesterone/Melphalan|MFP|Melphalan-Fluorouracil-Medroxyprogesterone|Melphalan/Fluorouracil/Medroxyprogesterone|Melphalan/Fluorouracil/Provera	A regimen consisting of fluorouracil, melphalan, and medroxyprogesterone acetate that may be used in the treatment of advanced or recurrent endometrial cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161982>	C63442|C63356	MINE-ESHAP Regimen|Cisplatin/Cytarabine/Etoposide/Etoposide/Ifosfamide/Mesna/Methylprednisolone/Mitoxantrone|MINE-ESHAP|MINE-ESHAP|Mesna-Ifosfamide-Mitoxantrone-Etoposide-Etoposide-Methylprednisolone-Cytarabine-Cisplatin|Mesna/Ifosfamide/Mitoxantrone/Etoposide/Etoposide/Methylprednisolone/Cytarabine/Cisplatin|Mesna/Ifosfamide/Novantrone/Etoposide/Etoposide/Solumedrol/Ara-C/Platinol|Mesna/Ifosfamide/Novantrone/Etoposide/Etoposide/Solumedrol/High-dose Ara-C/Platinol	A regimen consisting of mesna, ifosfamide, mitoxantrone and etoposide (MINE) alternated with etoposide, methylprednisolone, high-dose cytarabine, and cisplatin (ESHAP) that may be used in the treatment of Hodgkin and non-Hodgkin lymphomas.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161983>	C63589	Mito-FLAG Regimen|Cytarabine/Filgrastim/Fludarabine/Mitoxantrone|FLAG-Mito|Mito-FLAG|Mitoxantrone-Fludarabine-Cytarabine-Filgrastim|Mitoxantrone/Fludarabine/Ara-C/G-CSF|Mitoxantrone/Fludarabine/Cytarabine/Filgrastim|Mitoxantrone/Fludarabine/Cytarabine/Filgrastim Regimen	A regimen consisting of mitoxantrone, fludarabine, cytarabine, and filgrastim (G-CSF) that may be used in the treatment of relapsed or refractory acute myeloid leukemia (AML).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens
C161984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161984>	C63358	MMV Regimen|MMV|MMV|Methotrexate-Mitomycin-Vincristine|Methotrexate/Mitomycin/Vincristine|Methotrexate/Mitomycin/Vincristine Regimen	A regimen consisting of methotrexate, mitomycin, and vincristine that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161985>	C63588	MOAP Regimen|MOAP|MOAP|Methotrexate-Vincristine-Pegaspargase-Prednisone|Methotrexate/Oncovin/Pegaspargase/Prednisone|Methotrexate/Pegaspargase/Prednisone/Vincristine|Methotrexate/Vincristine/Pegaspargase/Prednisone	A regimen consisting of methotrexate, vincristine, pegaspargase, and prednisone that may be used in the treatment of acute lymphoblastic leukemia (ALL).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161986>	C63356	MOMP Regimen|MOMP|MOMP|Mechlorethamine-Oncovin-Methotrexate-Prednisone|Mechlorethamine-Vincristine-Methotrexate-Prednisone|Mechlorethamine/Oncovin/Methotrexate/Prednisone|Mechlorethamine/Vincristine/Methotrexate/Prednisone|Mechlorethamine/Vincristine/Methotrexate/Prednisone Regimen	A regimen consisting of mechlorethamine, vincristine, methotrexate, and prednisone that may be used in the treatment of Hodgkin lymphoma (HL).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161987>	C63356	MOP-BAP Regimen|Bleomycin/Doxorubicin/Mechlorethamine/Prednisone/Procarbazine/Vincristine|MOP-BAP|MOP-BAP|Mechlorethamine-Vincristine-Procarbazine-Bleomycin-Doxorubicin-Prednisone|Mechlorethamine/Oncovin/Procarbazine-Bleomycin/Adriamycin/Prednisone|Mechlorethamine/Vincristine/Procarbazine-Bleomycin/Doxorubicin/Prednisone	A regimen consisting of mechlorethamine, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine that may be used in the treatment of Hodgkin lymphoma (HL).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161988>	C63587	Cisplatin/Fluorouracil/Leucovorin/Methotrexate Regimen|Cisplatin-Fluorouracil-Leucovorin-Methotrexate|Cisplatin/Fluorouracil/Leucovorin/Methotrexate|MPFL|MPFL|MPFL Regimen|Methotrexate-Platinol-Fluorouracil-Leucovorin|Methotrexate/Platinol/Fluorouracil/Leucovorin	A regimen consisting of cisplatin, fluorouracil, leucovorin, and methotrexate that may be used in the treatment of squamous cell carcinoma of the head and neck.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161989>	C63358	MVF Regimen|Fluorouracil/Mitoxantrone/Vincristine|MVF|MVF|Mitoxantrone-Vincristine-Fluorouracil|Mitoxantrone/Vincristine/Fluorouracil|Mitoxantrone/Vincristine/Fluorouracil Regimen	A regimen consisting of mitoxantrone, vincristine, and 5-fluorouracil that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C16198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16198>	C213308	Protein Structure Initiative|PSI	A NIGMS initiative to define the basic protein shapes and to catalog all proteins in terms of these shapes.  This project will require the determination of a large number (perhaps 10,000) of protein structures in a high throughput mode.  (from RFA: GM-99-009)			Research Activity	
C161990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161990>	C63358	NFL Regimen|Fluorouracil-Leucovorin-Mitoxantrone|Fluorouracil/Leucovorin/Mitoxantrone|Fluorouracil/Leucovorin/Mitoxantrone Regimen|Mitoxantrone-Fluorouracil-Leucovorin|Mitoxantrone/Fluorouracil/Leucovorin|NFL|NFL|Novantrone/Fluorouracil/Leucovorin	A regimen consisting of fluorouracil, leucovorin, and mitoxantrone that may be used in the treatment of metastatic breast cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161991>	C63356	NOVP Regimen|Mitoxantrone-Vincristine/Vinblastine/Prednisone|Mitoxantrone/Prednisone/Vinblastine/Vincristine|Mitoxantrone/Vincristine/Vinblastine/Prednisone|Mitoxantrone/Vincristine/Vinblastine/Prednisone Regimen|NOVP|NOVP|NOVP|Novantrone/Oncovin/Vinblastine/Prednisone	A regimen consisting of mitoxantrone, vincristine, vinblastine, and prednisone that may be used in the treatment of Hodgkin lymphoma (HL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161992>	C63361	Cisplatin/Docetaxel/Fluorouracil/Panitumumab Regimen|Cisplatin/Docetaxel/Fluorouracil/Panitumumab|Pan-TPF|Pan-TPF|Panitumumab-Docetaxel-Cisplatin-Fluorouracil|Panitumumab-Docetaxel/Cisplatin/Fluorouracil|Panitumumab-Taxotere/Platinol/Fluorouracil	A regimen consisting of cisplatin, docetaxel, fluorouracil, and panitumumab that may be used in the treatment of certain gastric cancers.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161993>	C63522|C63358	PMF Regimen|Fluorouracil/Melphalan/Methotrexate|L-PAM/Methotrexate/Fluorouracil|Melphalan-Methotrexate-Fluorouracil|Melphalan/Methotrexate/Fluorouracil|Melphalan/Methotrexate/Fluorouracil Regimen|PMF|PMF|Phenylalanine Mustard/Methotrexate/Fluorouracil	A regimen consisting of fluorouracil, melphalan, and methotrexate that may be used in the treatment of advanced breast and ovarian cancers.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161994>	C62634	Etanidazole/Cisplatin Regimen|Cisplatin-Etanidazole|Cisplatin/Etanidazole|Etanidazole-Cisplatin|Etanidazole/Cisplatin|PRH-E|PRH-E|PRH-E Regimen|Platinol/Etanidazole	A regimen consisting of etanidazole and cisplatin that may be used in the treatment of certain superficial tumors in combination with local hyperthermia and radiation therapy.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161995>	C63510	Bleomycin/Cisplatin/Cyclophosphamide/Dactinomycin/Doxorubicin/Methotrexate Regimen|Bleomycin-Cisplatin-Cyclophosphamide-Dactinomycin-Doxorubicin-Methotrexate|Bleomycin/Cisplatin/Cyclophosphamide/Dactinomycin/Doxorubicin/Methotrexate|MSKCC T12|SK	A regimen consisting of high-dose methotrexate, doxorubicin, bleomycin, cyclophosphamide, dactinomycin and cisplatin that may be used in the treatment of certain osteosarcomas.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161996>	C63358	Exemestane/Tamoxifen Regimen|Exemestane-Tamoxifen|Exemestane/Tamoxifen|Tam Exemestane|Tamoxifen-Exemestane|Tamoxifen-Exemestane|Tamoxifen/Exemestane	A regimen consisting of exemestane and tamoxifen that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161997>	C63470	TPCH Regimen|Hydroxyurea/Lomustine/Procarbazine/Thioguanine|Hydroxyurea/Lomustine/Procarbazine/Thioguanine Regimen|TPCH|TPCH|Thioguanine-Procarbazine-Lomustine-Hydroxyurea|Thioguanine/Procarbazine/CCNU/Hydroxyurea|Thioguanine/Procarbazine/Lomustine/Hydroxyurea	A regimen consisting of hydroxyurea, lomustine, procarbazine, and thioguanine that may be used in the treatment of recurrent, malignant gliomas.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161998>	C63442	Paclitaxel/Rituximab/Topotecan Regimen|Paclitaxel-Rituximab-Topotecan|Paclitaxel-Topotecan-Rituximab|Paclitaxel/Rituximab/Topotecan|Paclitaxel/Topotecan/Rituximab|TT-R|TT-R|TTR|TTR (rituximab-abbs)|TTR (rituximab-arrx)|TTR (rituximab-blit)|TTR (rituximab-pvvr)|TTR (rituximab-rite)|TTR (rituximab-rixa)|TTR (rituximab-rixi)|Taxol/Topotecan/Rituximab	A regimen consisting of paclitaxel, rituximab, and topotecan that may be used in the treatment of relapsed, refractory non-Hodgkin lymphoma (NHL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C161999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C161999>	C63356	VABCD Regimen|Bleomycin/Dacarbazine/Doxorubicin/Lomustine/Vinblastine|VABCD|VABCD|Vinblastine-Doxorubicin-Bleomycin-Lomustine-Dacarbazine|Vinblastine/Adriamycin/Bleomycin/CCNU/Dacarbazine|Vinblastine/Doxorubicin/Bleomycin/Lomustine/Dacarbazine|Vinblastine/Doxorubicin/Bleomycin/Lomustine/Dacarbazine Regimen	A regimen consisting of vinblastine, doxorubicin, bleomycin, lomustine (CCNU), and dacarbazine that may be used in the treatment of refractory Hodgkin lymphoma (HL).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C16199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16199>	C15429	Cancer Research|Cancer Research Programs|Cancer Research Project	Systematic investigation into the causes of cancer and development of strategies for prevention, diagnosis, treatment, and cure.			Research Activity	
C1619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1619>	C78532	LMB-7 Immunotoxin|B3(Fv)-PE38|B3(Fv)-PE38 Immunotoxin|HB21(Fv)PE40|Immunotoxin LMB-7|Immunotoxin LMB-7|LMB-7 (Single-Chain Immunotoxin)|LMB-7 immunotoxin	A single chain chimeric protein consisting of a monoclonal antibody fragment attached to a portion of the Pseudomonas exotoxin A. LMB-7 immunotoxin attaches to B3, a Lewis Y-related carbohydrate epitope on some solid tumor cells.  The antibody attaches to the cell and the exotoxin inhibits protein synthesis by inactivating elongation factor 2. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162000>	C63496	VAD/v Regimen|VAD/V|VAD/v|Vincristine-Doxorubicin-Dexamethasone-Verapamil|Vincristine/Adriamycin/Dexamethasone/Verapamil|Vincristine/Doxorubicin/Dexamethasone/Verapamil|Vincristine/Doxorubicin/Dexamethasone/Verapamil Regimen	A regimen consisting of vincristine, doxorubicin, and dexamethasone with oral verapamil that may be used in the treatment of plasma cell myeloma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C162001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162001>	C63496	VMPT Regimen|Bortezomib-Melphalan-Prednisone-Thalidomide|Bortezomib/Melphalan/Prednisone/Thalidomide|Bortezomib/Melphalan/Prednisone/Thalidomide Regimen|VMPT|VMPT|VMPT|Velcade-Melphalan-Prednisone-Thalidomide|Velcade/Melphalan/Prednisone/Thalidomide	A regimen consisting of bortezomib, melphalan, prednisone, and thalidomide that may be used in the treatment of plasma cell myeloma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C162002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162002>	C63442	VNCOP-B Regimen|Bleomycin/Cyclophosphamide/Etoposide/Mitoxantrone/Prednisone/Vincristine|Etoposide-Mitoxantrone-Cyclophosphamide-Vincristine-Prednisone-Bleomycin|Etoposide/Mitoxantrone/Cyclophosphamide/Vincristine/Prednisone/Bleomycin|Etoposide/Mitoxantrone/Cyclophosphamide/Vincristine/Prednisone/Bleomycin Regimen|VNCOP-B|VNCOP-B|VNCOP-B|VePesid/Novantrone/Cyclophosphamide/Oncovin/Prednisone/Bleomycin	A regimen consisting of cyclophosphamide, mitoxantrone, vincristine, etoposide, bleomycin, and prednisone that may be used in the treatment of non-Hodgkin lymphoma (NHL).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C162003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162003>	C63359	CAV Alternating with EP Regimen|CAV-EP Regimen|CAV/EP|Cyclophosphamide-Adriamycin-Vincristine Alternating with Etoposide-Cisplatin|Cyclophosphamide/Adriamycin/Vincristine Alternating with Etoposide/Cisplatin|VOCAP	A regimen consisting of alternating cyclophosphamide, doxorubicin, vincristine with etoposide and cisplatin that may be used in the treatment of small cell lung cancer (SCLC).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C162004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162004>	C63522	DDP-MECY Regimen|Cisplatin-Methotrexate-Leucovorin-Cyclophosphamide|Cisplatin/Cyclophosphamide/Leucovorin/Methotrexate|Cisplatin/Methotrexate/Leucovorin/Cyclophosphamide|Cisplatin/Methotrexate/Leucovorin/Cyclophosphamide Regimen|DDP-MECY|DDP-MECY|DDP/Methotrexate/Leucovorin/Cyclophosphamide	A regimen consisting of cisplatin followed by high-dose methotrexate with leucovorin rescue, and cyclophosphamide that may be used in the treatment of ovarian cancer.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C162005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162005>	C63442	AVAD Regimen|AVAD|AVAD|Adriamycin/Vincristine/Ara-C/Dexamethasone|Cytarabine/Dexamethasone/Doxorubicin/Vincristine|Doxorubicin-Vincristine-Cytarabine-Dexamethasone|Doxorubicin/Vincristine/Cytarabine/Dexamethasone|Doxorubicin/Vincristine/Cytarabine/Dexamethasone Regimen	A regimen consisting of doxorubicin, vincristine, dexamethasone, and cytarabine that may be used in the treatment of non-Hodgkin Lymphoma (NHL).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C162006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162006>	C63442	BVAM Regimen|BCNU/Vincristine/Ara-C/Methotrexate|BVAM|BVAM|Carmustine-Vincristine-Cytarabine-Methotrexate|Carmustine/Cytarabine/Methotrexate/Vincristine|Carmustine/Vincristine/Cytarabine/Methotrexate|Carmustine/Vincristine/Cytarabine/Methotrexate Regimen	A regimen consisting of carmustine, vincristine, methotrexate, and cytarabine for the treatment of non-Hodgkin lymphoma (NHL).			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|SEER Rx Interactive Antineoplastic Drugs Database-Regimen|SEER Rx Interactive Antineoplastic Drugs Database
C162007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162007>	C82529	Functional Tests Group Identifier|FTGRPID	A character or string that represents a functional test group.			Intellectual Product	
C162008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162008>	C82529	Meal Data Group Identifier|MLGRPID	A character or string that represents a meal data group.			Intellectual Product	
C162009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162009>	C82529	Musculoskeletal Findings, Connective and Soft Tissue Findings Group Identifier|MKGRPID	A character or string that represents a musculoskeletal system findings group.			Intellectual Product	
C16200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16200>	C15429	Stem Cell Research	General research on stem cells and their use in medicine.			Biomedical Occupation or Discipline	
C162010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162010>	C156794|C129820	Soquelitinib|CPI 818|CPI-818|CPI818|ITK Inhibitor CPI-818|Interleukin-2 Inducible T-cell Kinase Inhibitor CPI-818|SOQUELITINIB	An orally available, small-molecule, irreversible inhibitor of interleukin-2 inducible T-cell kinase (ITK) with potential immunomodulatory and antineoplastic activities. Upon oral administration, soquelitinib selectively and covalently binds to the cysteine residue at position 442 (CYS-442) of ITK, thereby disrupting ITK-mediated signal transduction, while sparing tyrosine-protein kinase TXK (resting lymphocyte kinase, RLK) activity. This may abrogate T-cell receptor (TCR) signaling through ITK and inhibit TCR-induced proliferation of malignant T-cells. Additionally, inhibiting ITK activation may prevent the upregulation of GATA-3, a transcription factor that drives T-helper 2 (Th2) cell differentiation and is overexpressed in certain T-cell lymphomas. Thus, selective inhibition of ITK may inhibit Th2 responses without affecting T-helper 1 (Th1)-dependent immunity. ITK, a member of the Tec family of non-receptor protein tyrosine kinases plays a significant role in the T-cell development, differentiation and production of pro-inflammatory cytokines.	Soquelitinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162011>	C82529	Nervous System Findings Group Identifier|NVGRPID	A character or string that represents a nervous system findings group.			Intellectual Product	
C162012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162012>	C82529	Ophthalmic Examinations Group Identifier|OEGRPID	A character or string that represents an ophthalmic examinations group.			Intellectual Product	
C162013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162013>	C82529	Procedure Agents Group Identifier|AGGRPID	A character or string that represents a procedure agents group.			Intellectual Product	
C162014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162014>	C82529	Urinary System Findings Group Identifier|URGRPID	A character or string that represents a urinary system findings group.			Intellectual Product	
C162015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162015>	C8294|C159563|C142808	Refractory Pancreatic Adenocarcinoma	Pancreatic adenocarcinoma that is resistant to treatment.	Refractory Pancreatic Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162016>	C8294|C5018|C129654	Unresectable Pancreatic Adenocarcinoma	A pancreatic adenocarcinoma that is not amenable to surgical resection.	Unresectable Pancreatic Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162017>	C117050	Cardiovascular System Findings Link Identifier|CVLNKID	A sequence of characters used as a linkage between related cardiovascular system findings identifier records.			Intellectual Product	
C162018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162018>	C117050	Microbiology Specimen Link Identifier|MBLNKID	A sequence of characters used as a linkage between related microbiology specimen identifier records.			Intellectual Product	
C162019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162019>	C117050	Microbiology Susceptibility Link Identifier|MSLNKID	A sequence of characters used as a linkage between related microbiology susceptibility test identifier records.			Intellectual Product	
C16201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16201>	C16200	Hematopoietic Stem Cell Research	General research on hematopoietic stem cells and research on their use in medicine.			Biomedical Occupation or Discipline	
C162020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162020>	C117050	Musculoskeletal Findings, Connective and Soft Tissue Findings Link Identifier|MKLNKID	A sequence of characters used as a linkage between related musculoskeletal system findings identifier records.			Intellectual Product	
C162021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162021>	C117050	Nervous System Findings Link Identifier|NVLNKID	A sequence of characters used as a linkage between related nervous system identifier records.			Intellectual Product	
C162022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162022>	C117050	Ophthalmic Examinations Link Identifier|OELNKID	A sequence of characters used as a linkage between related ophthalmic examinations identifier records.			Intellectual Product	
C162023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162023>	C117050	Procedure Agents Link Identifier|AGLNKID	A sequence of characters used as a linkage between related procedure agents identifier records.			Intellectual Product	
C162024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162024>	C117050	Reproductive System Findings Link Identifier|RPLNKID	A sequence of characters used as a linkage between related reproductive system findings identifier records.			Intellectual Product	
C162025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162025>	C117050	Respiratory System Link Identifier|RELNKID	A sequence of characters used as a linkage between related respiratory system findings identifier records.			Intellectual Product	
C162026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162026>	C117050	Urinary System Findings Link Identifier|URLNKID	A sequence of characters used as a linkage between related urinary system findings identifier records.			Intellectual Product	
C162027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162027>	C42994	Suspension for Spray Dosage Form|Suspension for Spray	Liquid preparation consisting of a suspension intended for use in the preparation of a spray.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C162028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162028>	C117049	Microbiology Specimen Link Group Identifier|MBLNKGRP	A sequence of characters used to link multiple microbiology specimen records to a single finding.			Intellectual Product	
C162029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162029>	C117049	Musculoskeletal Findings, Connective and Soft Tissue Findings Link Group Identifier|MKLNKGRP	A sequence of characters used to link multiple musculoskeletal system findings records to a single finding.			Intellectual Product	
C16202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16202>	C16200	Non-Hematopoietic Stem Cell Research	General research on non-hematopoietic stem cells and their use in medicine.			Biomedical Occupation or Discipline	
C162030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162030>	C117049	Procedure Agents Link Group Identifier|AGLNKGRP	A sequence of characters used to link multiple procedure agents records to a single finding.			Intellectual Product	
C162031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162031>	C117049	Reproductive System Findings Link Group Identifier|RPLNKGRP	A sequence of characters used to link multiple reproductive system findings records to a single finding.			Intellectual Product	
C162032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162032>	C117049	Tumor Identification Link Group Identifier|TULNKGRP	A sequence of characters used to link multiple tumor identification records to a single finding.			Intellectual Product	
C162033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162033>	C117049	Urinary System Findings Link Group Identifier|URLNKGRP	A sequence of characters used to link multiple urinary system findings records to a single finding.			Intellectual Product	
C162034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162034>	C117049	Cardiovascular System Findings Link Group|CVLNKGRP	A sequence of characters used to link multiple cardiovascular system findings to a single finding.			Intellectual Product	
C162035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162035>	C117049	Nervous System Findings Link Group|NVLNKGRP	A sequence of characters used to link multiple nervous system findings to a single finding.			Intellectual Product	
C162036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162036>	C117049	Ophthalmic Examinations Link Group|OELNKGRP	A sequence of characters used to link multiple ophthalmic examinations to a single finding.			Intellectual Product	
C162037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162037>	C117049	Respiratory System Link Group|RELNKGRP	A sequence of characters used to link multiple respiratory system findings to a single finding.			Intellectual Product	
C162038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162038>	C113124	CellSave Blood Collection Tube|CellSave BCT|CellSave Preservative Tube|CellSave Tube	A proprietary blood collection tube designed for venous blood collection, containing EDTA anticoagulant and a cell preservative. The EDTA absorbs calcium ions, which prevents the blood from clotting. The preservative preserves the morphology and cell surface antigen expression of the epithelial cells and leukocytes. This blood collection tube has been used for the preservation of circulating tumor cells and lymphocyte subsets.			Manufactured Object	
C162039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162039>	C155745	Anti-CD137 Agonistic Monoclonal Antibody CTX-471|Anti-4-1BB Agonistic Monoclonal Antibody CTX-471|CTX 471|CTX-471|CTX471	A fully human immunoglobulin G4 (IgG4) agonistic monoclonal antibody targeting CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD137 agonistic monoclonal antibody CTX-471 binds to and activates CD137 expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytokine production and promotes T-cell mediated anti-tumor immune responses. CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.	Anti-CD137 Agonistic Monoclonal Antibody CTX-471		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C16203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16203>	C43431	Clinical or Research Activity	Any specific activity undertaken during the course of a clinical study or research protocol.	Clinical or Research Activity		Activity	CTRP Intervention Terminology|CTRP Terminology
C162040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162040>	C40459|C178119	Inactivating ATM Gene Mutation|ATM Gene Inactivation|ATM Loss of Function Gene Mutation|ATM Loss of Function Mutation|Inactivating A-T Mutated Gene Mutation|Inactivating AT Mutated Gene Mutation|Inactivating ATM Serine/Threonine Kinase Gene Mutation|Inactivating Ataxia Telangiectasia Mutated Gene Mutation	A change in the nucleotide sequence of the ATM gene that either inhibits expression of the serine-protein kinase ATM protein or results in the translation of an inactive serine-protein kinase ATM protein.	Inactivating ATM Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C162041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162041>	C93102|C131484	Deleterious FBXW7 Gene Mutation|Deleterious AGO Gene Mutation|Deleterious Archipelago Homolog Gene Mutation|Deleterious Archipelago Homolog, Drosophila Gene Mutation|Deleterious CDC4 Gene Mutation|Deleterious F-Box and WD Repeat Domain Containing 7 Gene Mutation|Deleterious F-box and WD-40 Domain Protein 7 (Archipelago Homolog, Drosophila) Gene Mutation|Deleterious FBW6 Gene Mutation|Deleterious FBW7 Gene Mutation|Deleterious FBX30 Gene Mutation|Deleterious FBXW6 Gene Mutation|Deleterious FBXW7 Mutation|Deleterious SEL-10 Gene Mutation|Deleterious SEL10 Gene Mutation|FBXW7 Deleterious Gene Mutation|FBXW7 Deleterious Mutation	A change in the nucleotide sequence of the FBXW7 gene that is associated with increased risk of disease.	Deleterious FBXW7 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C162042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162042>	C35682	Hepatitis C Virus RNA Positive|HCV RNA Positive|Hep C RNA Positive|Hepatitis C RNA Positive|Hepatitis C Viral RNA Positive|Positive	An indication that hepatitis C RNA has been detected in a sample.	Hepatitis C Virus RNA Positive		Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Terminology
C162043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162043>	C35682	Hepatitis B DNA Positive|Positive	An indication that hepatitis B DNA has been detected in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Terminology
C162044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162044>	C157427|C138073	Serum CEA Level Elevated|Elevated	The amount of carcinoembryonic antigen present in a serum sample is elevated.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C162045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162045>	C157427	Serum CEA Level Normal|Normal	The amount of carcinoembryonic antigen present in a serum sample is normal.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C162046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162046>	C157427	Serum CEA Level Low|Low	The amount of carcinoembryonic antigen present in a serum sample is low.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C162047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162047>	C84331|C138070	Serum CA 19-9 Elevated|Elevated	The amount of cancer antigen 19-9 present in a serum sample is elevated.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C162048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162048>	C157428	Serum CA 19-9 Normal|Normal	The amount of cancer antigen 19-9 present in a serum sample is normal.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C162049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162049>	C84331	Serum CA 19-9 Low|Low	The amount of cancer antigen 19-9 present in a serum sample is low.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology
C16204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16204>	C61063	MAGE-3/PADRE 965.10|MAGE-3.1/PADRE 965.10			Obsolete_Concept	Therapeutic or Preventive Procedure	
C162050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162050>	C157144	Was Another CD Antigen Tested Question|Other CD|Was Another CD Antigen Tested	A question asking if testing for a CD antigen that is no present on the form was performed during the study.			Intellectual Product	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162051>	C165233	XK Negative|KX Negative|Kell Blood Group Precursor Negative|Kell Complex 37 kDa Component Negative|Kx Antigen Negative|Kx Blood Group Antigen Negative|Membrane Transport Protein XK Negative|NA Negative|NA Negative|X-Linked Kx Blood Group Negative|X1k Negative|XKR1 Negative	An indication that XK expression has not been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162052>	C165233	MPX Negative|Negative MPX Test|Negative cobas MPX|Negative cobas TaqScreen MPX|Negative cobas TaqScreen MPX Test	An indication that none of the viral RNAs probed by the polymerase chain reaction-based cobas MPX test have been detected in a plasma or serum sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162053>	C165233	ENO2 Negative|Enolase 2 Negative|Gamma-Enolase Negative|NSE Negative|NSE Negative|Neural Enolase Negative|Neuron-Specific Enolase Negative	An indication that ENO2 expression has not been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162054>	C165233	DNTT Negative|Deoxynucleotidyl Terminal Transferase Negative|TDT Negative|TDT Negative|Terminal Transferase Negative	An indication that DNTT expression has not been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162055>	C165233	Cytoplasmic CD3 Negative|Cy CD3 Negative|Cytoplasmic CD3 Complex Negative|Cytoplasmic T-Cell Surface Glycoprotein CD3 Negative|Cytoplasmic T3 Complex Negative	An indication that cytoplasmic expression of the CD3 complex has not been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162056>	C165233	CD4 Negative|CD4 Antigen Negative|CD4 Molecule Negative|OKT4 Antigen Negative|T-Cell Antigen T4/Leu3 Negative|T-Cell Surface Glycoprotein CD4 Negative|T4/Leu-3 Negative	An indication that CD4 expression has not been detected in a sample.	CD4 Negative		Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162057>	C165233	CD5 Negative|CD5 Antigen Negative|CD5 Molecule Negative|LEU1 Negative|Lymphocyte Antigen CD5 Negative|Lymphocyte Antigen T1/Leu-1 Negative	An indication that CD5 expression has not been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162058>	C165233	CD7 Negative|Antigen CD7 Negative|CD7 Antigen Negative|CD7 Molecule Negative|GP40 Negative|LEU9 Negative|Leu-9 Negative|T-Cell Antigen CD7 Negative|T-Cell Leukemia Antigen Negative|TP40 Negative|TP41 Negative	An indication that CD7 expression has not been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162059>	C165233	CD8 Negative|CD8 Antigen Negative|CD8 Co-Receptor Negative|T-Cell Surface Glycoprotein CD8 Negative	An indication that expression of the CD8 complex has not been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C16205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16205>	C16203	Healthcare Activity|Health Care|Health Care Activity|Healthcare	The actions of prevention, treatment, and management of illness and the preservation of mental and physical well-being through the services offered by the medical and allied health professions.	Healthcare Activity		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C162060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162060>	C165233	CD11c Negative|AlphaX Integrin Chain Negative|Axb2 Negative|CD11 Antigen-Like Family Member C Negative|CD11c Antigen Negative|Cr4 Negative|ITGAX Negative|Integrin Alpha X Negative|Integrin Alpha-X Negative|Leu M5 Negative|Leukocyte Adhesion Glycoprotein P150,95, Alpha Chain Negative|Leukocyte Surface Antigen P150, 95 Negative|Myeloid Membrane Antigen, Alpha Subunit Negative|p150, 95 Integrin Alpha Chain Negative	An indication that CD11c expression has not been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162061>	C165233	ITGAD Negative|ADB2 Negative|CD11 Antigen-Like Family Member D Negative|CD11d Antigen Negative|CD11d Negative|CD11d Negative|Integrin Alpha-D Negative|Leukointegrin Alpha D Negative	An indication that ITGAD expression has not been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162062>	C165233	ANPEP Negative|AP-M Negative|AP-N Negative|APN Negative|Alanyl Aminopeptidase Negative|Aminopeptidase M Negative|Aminopeptidase N Negative|CD13 Negative|CD13 Negative|LAP1 Negative|Microsomal Aminopeptidase Negative|PEPN Negative|gp150 Negative|p150 Negative	An indication that ANPEP expression has not been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162063>	C165233	CD14 Negative|CD14 Antigen Negative|CD14 Molecule Negative|Lipopolysaccharide Receptor Negative|Monocyte Differentiation Antigen CD14 Negative|Myeloid Cell-Specific Leucine-Rich Glycoprotein Negative	An indication that CD14 expression has not been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162064>	C165233	CD15 Negative|3-Fucosyl-N-Acetyl-Lactosamine Negative|CD15 Antigen Negative|LeX Negative|Lewis X Negative|LewisX Antigen Negative|SSEA-1 Negative|Stage-Specific Embryonic Antigen 1 Negative	An indication that CD15 antigen expression has not been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162065>	C165233	CD22 Negative|B-Cell Antigen CD22 Negative|B-Cell Receptor CD22 Negative|B-Lymphocyte Cell Adhesion Molecule Negative|BL-CAM Negative|CD22 Antigen Negative|CD22 Molecule Negative|SIGLEC-2 Negative|SIGLEC2 Negative|Sialic Acid-Binding Ig-Like Lectin 2 Negative|Sialic Acid-Binding Immunoglobulin-Like Lectin 2 Negative|T-Cell Surface Antigen Leu-14 Negative	An indication that CD22 expression has not been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162066>	C165233	CD33 Negative|CD33 Antigen Negative|CD33 Molecule Negative|Myeloid Cell Surface Antigen CD33 Negative|SIGLEC-3 Negative|SIGLEC3 Negative|gp67 Negative|p67 Negative	An indication that CD33 expression has not been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162067>	C165233	CD36 Negative|CD36 Antigen Negative|CD36 Molecule Negative|CSVTCG-Specific Receptor Negative|CSVTCG-Specific TSP-1 Receptor Negative|Cysteine-Serine-Valine-Threonine-Cysteine-Glycine Specific TSP-1 Receptor Negative|FAT Negative|Fatty Acid Translocase Negative|GP IIIb Negative|GP IV Negative|GP3B Negative|GP4 Negative|GPIIIB Negative|GPIV Negative|Glycoprotein IIIb Negative|Leukocyte Differentiation Antigen CD36 Negative|PAS IV Negative|PAS-4 Negative|PASIV Negative|Platelet Collagen Receptor Negative|Platelet Glycoprotein 4 Negative|Platelet Glycoprotein IV Negative|SCARB3 Negative|Scavenger Receptor Class B Member 3 Negative|Thrombospondin Receptor Negative	An indication that CD36 expression has not been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162068>	C165233	CD38 Negative|ADP-Ribosyl Cyclase 1 Negative|ADPRC1 Negative|CD38 Antigen Negative|CD38 Molecule Negative|T10 Negative	An indication that CD38 expression has not been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162069>	C165233	SPN Negative|Antigen CD43 Negative|CD43 Antigen Negative|CD43 Negative|CD43 Negative|GALGP Negative|LSN Negative|Leukocyte Large Sialoglycoprotein Negative|Leukocyte Sialoglycoprotein Negative|Leukosialin Negative|Sialophorin Negative|gpL115 Negative	An indication that SPN expression has not been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C16206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16206>	C51976	Energy Therapy|energy healing|energy therapy	A form of complementary and alternative medicine based on the belief that a vital energy flows through the human body. The goal of energy therapy is to balance the energy flow in the patient. It is used to reduce stress and anxiety and promote well-being. Energy therapy is being studied in patients receiving cancer therapy, to find out if it can improve quality of life, boost the immune system, or reduce side effects.			Therapeutic or Preventive Procedure	
C162070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162070>	C165233	PTPRC Negative|B220 Negative|CD45 Antigen Negative|CD45 Negative|CD45 Negative|CD45R Negative|GP180 Negative|L-CA Negative|LCA Negative|LY5 Negative|Leukocyte Common Antigen Negative|Receptor-Type Tyrosine-Protein Phosphatase C Negative|T200 Negative	An indication that PTPRC expression has not been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162071>	C165233	FCGR1A Negative|CD64 Antigen Negative|CD64 Negative|CD64 Negative|FCG1 Negative|FCGR1 Negative|FCRI Negative|Fc Gamma Receptor I A1 Negative|Fc-Gamma RI Negative|Fc-Gamma RIA Negative|High Affinity Immunoglobulin Gamma Fc Receptor I Negative|IGFR1 Negative|IgG Fc Receptor I Negative	An indication that FCGR1A expression has not been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162072>	C165233	CD65 Negative|Ceramide Dodecasaccharide Negative|VIM2 Negative	An indication that CD65 antigen expression has not been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162073>	C165233	CD79A Negative|CD79a Antigen Negative|CD79a Negative|IGA Negative|Ig-Alpha Negative|MB-1 Negative|MB1 Negative|Membrane-Bound Immunoglobulin-Associated Protein Negative|Surface IgM-Associated Protein Negative	An indication that CD79A expression has not been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162074>	C165233	FMC7 Negative|FMC7 Antigen Negative	An indication that expression of the B-lymphocyte antigen FMC7 has not been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162075>	C165233	HLA-DR Negative|HLA-DR Antigen Negative|Human Leukocyte Antigen-DR Isotype Negative	An indication that expression of an HLA-DR antigen has not been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162076>	C165233	MKI67 Negative|Antigen Ki-67 Negative|KI67 Negative|Ki 67 Negative|Ki 67 Negative|Ki-67 Antigen Negative|Ki-67 Negative	An indication that MKI67 expression has been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162077>	C35681	PAS Negative|Periodic Acid-Schiff Negative|Periodic Acid-Schiff Staining Negative	An indication that a sample does not have detectable periodic acid-Schiff staining.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162078>	C165233	PAX5 Negative|ALL3 Negative|B-Cell Lineage Specific Activator Negative|B-Cell Specific Transcription Factor Negative|BSAP Negative|Paired Box 5 Negative|Paired Box Protein Pax-5 Negative	An indication that PAX5 expression has not been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162079>	C165233	SBB Negative|Sudan Black B Negative|Sudan Black B Staining Negative	An indication that a sample does not have detectable Sudan black B staining.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C16207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16207>	C16206	Electromagnetic-Based Therapy|Bioelectro-Magnetics|Bioelectromagnetic Therapies|Bioelectromagnetic-Based Therapy|Bioelectromagnetics	The unconventional use of electromagnetic fields for medical or therapeutic purposes.			Therapeutic or Preventive Procedure	
C162080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162080>	C165233	MPO Negative|Myeloperoxidase Negative	An indication that expression of MPO has not been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162081>	C165233	IGK Negative|Ig Kappa Chain Negative|Ig Light Chain Kappa Negative|Immunoglobulin Kappa Chain Negative|Immunoglobulin Kappa Light Chain Negative|Immunoglobulin Kappa Light-Chain Negative|Immunoglobulin Kappa Negative|Kappa Light Chain Negative|kappa Negative	An indication that IGK expression has not been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162082>	C177692	XK Positive|KX Positive|Kell Blood Group Precursor Positive|Kell Complex 37 kDa Component Positive|Kx Antigen Positive|Kx Blood Group Antigen Positive|Membrane Transport Protein XK Positive|NA Positive|NA Positive|X-Linked Kx Blood Group Positive|X1k Positive|XKR1 Positive	An indication that XK expression has been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162083>	C35682	MPX Positive|Positive MPX Test|Positive cobas MPX|Positive cobas TaqScreen MPX|Positive cobas TaqScreen MPX Test	An indication that at least one of the viral RNAs probed by the polymerase chain reaction-based cobas MPX test have been detected in a plasma or serum sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162084>	C177692	ENO2 Positive|Enolase 2 Positive|Gamma-Enolase Positive|NSE Positive|NSE Positive|Neural Enolase Positive|Neuron-Specific Enolase Positive	An indication that ENO2 expression has been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162085>	C177692	DNTT Positive|Deoxynucleotidyl Terminal Transferase Positive|TDT Positive|TDT Positive|TDT Positive|Terminal Transferase Positive	An indication that DNTT expression has been detected in a sample.	TDT Positive		Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162086>	C131386	Cytoplasmic CD3 Positive|Cy CD3 Positive|Cytoplasmic CD3 Antigen Positive|Cytoplasmic CD3 Complex Positive|Cytoplasmic T3 Complex Positive	An indication that cytoplasmic expression of the CD3 complex has been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162087>	C177692	MME Positive|CALLA Positive|CD10 Positive|CD10 Positive|Common ALL Antigen Positive|Common Acute Lymphoblastic Leukemia Antigen Positive|Membrane Metalloendopeptidase Positive|NEP Positive|Neprilysin Positive|SFE Positive|Skin Fibroblast Elastase Positive	An indication that MME expression has been detected in a sample.	MME Positive		Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162088>	C177692	ITGAD Positive|ADB2 Positive|CD11 Antigen-Like Family Member D Positive|CD11d Antigen Positive|CD11d Positive|CD11d Positive|Integrin Alpha-D Positive|Leukointegrin Alpha D Positive	An indication that ITGAD expression has been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162089>	C177692	ANPEP Positive|AP-M Positive|AP-N Positive|APN Positive|Alanyl Aminopeptidase Positive|Aminopeptidase M Positive|Aminopeptidase N Positive|CD13 Positive|CD13 Positive|LAP1 Positive|Microsomal Aminopeptidase Positive|PEPN Positive|gp150 Positive|p150 Positive	An indication that ANPEP expression has been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C16208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16208>	C16232	EST Library|Expressed Sequence Tag Library	A random cDNA library comprised of 200-800 bp random pooled mRNA clones isolated from a specific organism, specific tissue and/or a given stage of development. Clones are randomly selected for single-pass sequencing reads, the raw sequence reads are processed to remove low-quality sequence information and contaminating vector sequence and the resulting higher-quality sequences can be aggregated and aligned with others to assemble complete genetic or genomic sequences.			Manufactured Object	
C162090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162090>	C177692	CD14 Positive|CD14 Antigen Positive|CD14 Molecule Positive|Lipopolysaccharide Receptor Positive|Monocyte Differentiation Antigen CD14 Positive|Myeloid Cell-Specific Leucine-Rich Glycoprotein Positive	An indication that CD14 expression has been detected in a sample.	CD14 Positive		Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162091>	C177692	CD15 Positive|3-Fucosyl-N-Acetyl-Lactosamine Positive|CD15 Antigen Positive|LeX Positive|Lewis X Positive|LewisX Antigen Positive|SSEA-1 Positive|Stage-Specific Embryonic Antigen 1 Positive	An indication that CD15 expression has been detected in a sample.			Laboratory or Test Result	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162092>	C94299|C177692	CD36 Positive|CD36 Antigen Positive|CD36 Molecule Positive|CSVTCG-Specific Receptor Positive|CSVTCG-Specific TSP-1 Receptor Positive|Cysteine-Serine-Valine-Threonine-Cysteine-Glycine Specific TSP-1 Receptor Positive|FAT Positive|Fatty Acid Translocase Positive|GP IIIb Positive|GP IV Positive|GP3B Positive|GP4 Positive|GPIIIB Positive|GPIV Positive|Glycoprotein IIIb Positive|Leukocyte Differentiation Antigen CD36 Positive|PAS IV Positive|PAS-4 Positive|PASIV Positive|Platelet Collagen Receptor Positive|Platelet Glycoprotein 4 Positive|Platelet Glycoprotein IV Positive|SCARB3 Positive|Scavenger Receptor Class B Member 3 Positive|Thrombospondin Receptor Positive	An indication that CD36 expression has been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162093>	C94299|C177692	FCGR1A Positive|CD64 Antigen Positive|CD64 Positive|CD64 Positive|FCG1 Positive|FCGR1 Positive|FCRI Positive|Fc Gamma Receptor I A1 Positive|Fc-Gamma RI Positive|Fc-Gamma RIA Positive|High Affinity Immunoglobulin Gamma Fc Receptor I Positive|IGFR1 Positive|IgG Fc Receptor I Positive	An indication that FCGR1A expression has been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162094>	C177692	CD65 Positive|Ceramide Dodecasaccharide Positive|VIM2 Positive	An indication that CD65 antigen expression has been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162095>	C177692	CD79A Positive|CD79a Antigen Positive|CD79a Positive|IGA Positive|Ig-Alpha Positive|MB-1 Positive|MB1 Positive|Membrane-Bound Immunoglobulin-Associated Protein Positive|Surface IgM-Associated Protein Positive	An indication that CD79A expression has been detected in a sample.	CD79A Positive		Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162096>	C177692	FMC7 Positive|FMC7 Antigen Positive	An indication that expression of the B-lymphocyte antigen FMC7 has been detected in a sample.	FMC7 Positive		Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162097>	C177692	HLA-DR Positive|HLA-DR Antigen Positive|Human Leukocyte Antigen-DR Isotype Positive	An indication that expression of an HLA-DR antigen has been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162098>	C35682	PAS Positive|Periodic Acid-Schiff Positive|Periodic Acid-Schiff Staining Positive	An indication that a sample has detectable periodic acid-Schiff staining.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162099>	C177692	PAX5 Positive|ALL3 Positive|B-Cell Lineage Specific Activator Positive|B-Cell Specific Transcription Factor Positive|BSAP Positive|Paired Box 5 Positive|Paired Box Protein Pax-5 Positive	An indication that PAX5 expression has been detected in a sample.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C16209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16209>	C15776	Early Detection	Use of a device, marker, or other means for the purpose of detecting the presence of a tumor early in its development.			Diagnostic Procedure	
C1620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1620>	C582|C1904	Becatecarin|1,11-Dichloro-6-[2-(diethylamino)ethyl]-12,13-dihydro-12-(4-O-methyl-beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione|5H-Indolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7(6H)-dione, 1,11-dichloro-6-(2-(diethylamino)ethyl)-12,13-dihydro-12-(4-O-methyl-beta-D-glucopyranosyl)-|BECATECARIN|BMS-181176|BMY-27557-14|DEAE-Rebeccamycin|NSC 655649|Rebeccamycin Analogue|Rebeccamycin Analogue, Tartrate Salt|Rebeccamycin analog|XL119|rebeccamycin analog	A synthetic diethylaminoethyl analogue of the indolocarbazole glycoside antineoplastic antibiotic rebeccamycin.  Becatecarin intercalates into DNA and stabilizes the DNA-topoisomerase I complex, thereby interfering with the topoisomerase I-catalyzed DNA breakage-reunion reaction and initiating DNA cleavage and apoptosis.  (NCI04)	Becatecarin		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162100>	C35682	SBB Positive|Sudan Black B Positive|Sudan Black B Staining Positive	An indication that a sample has detectable Sudan black B staining.			Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162101>	C177692	IGK Positive|Ig Kappa Chain Positive|Ig Light Chain Kappa Positive|Immunoglobulin Kappa Chain Positive|Immunoglobulin Kappa Light Chain Positive|Immunoglobulin Kappa Light-Chain Positive|Immunoglobulin Kappa Positive|Kappa Light Chain Positive|Kappa Positive|kappa Positive	An indication that IGK expression has been detected in a sample.	IGK Positive		Finding	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162102>	C26683	Low LDH Level|Low	A lower than average level of lactate dehydrogenase in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C162103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162103>	C81326	High Calcium Level|Elevated	A higher than average level of calcium in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C162104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162104>	C26683	Low Calcium Level|Low	A lower than average level of calcium in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C162105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162105>	C200435|C187275	High Hemoglobin Level|Elevated	A higher than average level of hemoglobin in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C162106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162106>	C200435|C187275	Low Hemoglobin Level|Low	A lower than average level of hemoglobin in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C162107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162107>	C81326	High Platelet Count|Elevated	A higher than average level of platelets in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C162108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162108>	C35877	Low Platelet Count|Low	A lower than average level of platelets in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C162109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162109>	C81326	High Leukocyte Count|Elevated	A higher than average level of leukocytes in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C16210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16210>	C25217	Detection Assessment|Detected|Detected Finding|Detection	The act of perceiving, discerning, discovering, or identifying.			Activity	
C162110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162110>	C35877	Low Leukocyte Count|Low|Low White Blood Cell Count	A lower than average level of leukocytes in a sample.			Laboratory or Test Result	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C162111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162111>	C81326	Elevated Sedimentation Rate|Elevated	A higher than average sedimentation rate in a sample.			Laboratory or Test Result	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Terminology
C162112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162112>	C142248	Solid Dispersion Immediate Release Tablet Dosage Form|TABLET, IMMEDIATE RELEASE, SOLID DISPERSION	A solid dosage form containing one or more active pharmaceutical ingredient which can be dispersed in a carrier at solid state, and immediately released upon administration.			Biomedical or Dental Material	CDISC SDTM Dosage Form Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C162113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162113>	C202500|C173162|C172227	Locally Advanced Unresectable Esophageal Adenocarcinoma	An esophageal adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.	Locally Advanced Unresectable Esophageal Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162114>	C202500|C162759|C150578	Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma	A gastroesophageal junction adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.	Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162116>	C4349|C180406|C171585	Unresectable Colon Adenocarcinoma	A colon adenocarcinoma that is not amenable to surgical resection.			Neoplastic Process	
C162117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162117>	C9383|C211964|C171585	Unresectable Rectal Adenocarcinoma	A rectal adenocarcinoma that is not amenable to surgical resection.			Neoplastic Process	
C162118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162118>	C25364	Procedure Agent Sponsor Identifier|AGSPID	One or more sponsor defined characters used to identify, name, or characterize the procedure agents.			Intellectual Product	
C162119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162119>	C42614	Procedure Agent Reported Name|AGTRT	The name of a medical product, practice, or application reported in a clinical trial.			Conceptual Entity	
C16211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16211>	C213420|C15922	Tobacco Use Prevention Research	Studies to develop and test interventions that are designed to prevent the initiation of tobacco use among individuals. (NCI/TRIP)			Research Activity	
C162120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162120>	C42614	Procedure Agent Modified Reported Name|AGMODIFY	An indication or description of a change in a procedure agent name.			Conceptual Entity	
C162121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162121>	C90372	Procedure Agent Class|AGCLAS	The variable assigned to a procedure agent class.			Group	
C162122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162122>	C82501	Procedure Agent Class Code|AGCLASCD	A character or string that represents a procedure agent class.			Intellectual Product	
C162123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162123>	C25488	Procedure Agent Dose per Administration|AGDOSE	The dose of study procedure agent taken per administration.			Conceptual Entity	
C162124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162124>	C70961	Procedure Agent Dose Description|AGDOSTXT	A textual description of the procedure agent dose level(s) or range(s) per subject, according to the study protocol.			Intellectual Product	
C162125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162125>	C13108	Gerota Fascia|Anterior Perirenal Fascia|Gerota's Fascia|Gerota's fascia|Renal Fascia|renal fascia	A fibrous connective tissue covering the kidney and adrenal gland, which separates the perinephric fat from paranephric fat.			Body Part, Organ, or Organ Component	GDC Terminology|GDC Value Terminology
C162127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162127>	C82531	Cardiovascular System Findings Reference Identifier|CVREFID	A character or string used to name, or characterize a cardiovascular system findings reference.			Intellectual Product	
C162128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162128>	C99098	Description of Unplanned Actual Arm|ACTARMUD	Description of the unplanned actual arm (of the clinical trial) in which the subject participated during the trial.			Intellectual Product	
C162129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162129>	C82572	Disease Response Elapsed Time|RSELTM	The interval between two disease response reference time points.			Temporal Concept	
C16212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16212>	C79426|C49236	Cancer Therapeutic Procedure|Cancer Therapy|Cancer Treatment|Malignant Neoplasm Therapy|Malignant Neoplasm Treatment|anticancer therapy	Any intervention for management of a malignant neoplasm.	Cancer Therapeutic Procedure		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C162130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162130>	C82576	Disease Response Time Point Reference|RSTPTREF	The point in time that acts as a fixed reference point to a disease response assessment.			Temporal Concept	
C162131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162131>	C82531	Functional Tests Reference Identifier|FTREFID	A character or string that represents a functional test assessment event reference.			Intellectual Product	
C162132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162132>	C25364	Functional Tests Sponsor-Defined Identifier|FTSPID	One or more sponsor-defined characters used to identify, name, or characterize the functional tests.			Intellectual Product	
C162133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162133>	C185631	Functional Test Result or Finding in Original Units|FTORRES	The outcome of the functional test assessment as originally received or collected.			Quantitative Concept	
C162134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162134>	C47922	Functional Tests External File Path|FTXFN	The literal identifier of a functional test external file name.			Intellectual Product	
C162135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162135>	C117200	Functional Tests Vendor Name|FTNAM	The literal identifier of the vendor or laboratory that performs a functional test assessment.			Intellectual Product	
C162136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162136>	C82572	Functional Tests Elapsed Time|FTELTM	The interval between two functional test reference time points.			Temporal Concept	
C162137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162137>	C82576	Functional Tests Time Point Reference|FTTPTREF	The point in time that acts as a fixed reference point to a functional test assessment.			Temporal Concept	
C162138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162138>	C25364	Meal Data Sponsor-Defined Identifier|MLSPID	One or more sponsor defined characters used to identify, name, or characterize the meal data.			Intellectual Product	
C162139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162139>	C8591	Regressed Testicular Germ Cell Tumor|Burnt-Out Germ Cell Tumor|Regressed Germ Cell Tumor	A testicular germ cell tumor that has undergone either partial or complete regression, resulting in the creation of a fibrotic nodule in the testis.			Neoplastic Process	
C16213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16213>	C15220	Cancer Diagnosis	General term for detecting and classifying cancer in patients.			Diagnostic Procedure	
C162140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162140>	C42614	Meal Data Name|MLTRT	Verbatim food product name that is either pre-printed or collected on a CRF.			Conceptual Entity	
C162141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162141>	C2886	Invasive Pulmonary Aspergillosis|IPA	A form of aspergillosis characterized by the presence of septate, acute, branching hyphae invading lung tissue.	Invasive Pulmonary Aspergillosis		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C162142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162142>	C177692	HLA-C*08 Positive Cells Present|HLA-C*08|HLA-C*08 Positive|HLA-C08|HLA-C08 Positive|HLA-C08 Positive Cells Present	An indication that cells expressing HLA-C*08 have been detected in a sample.	HLA-C*08 Positive Cells Present		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162143>	C162195	Microbiology Specimen Focus of Study-Specific Interest|MBFOCID	Identification of a focus of study-specific interest on or within a microbiology specimen as called out in the protocol for which a measurement, test, or examination was performed.			Qualitative Concept	
C162144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162144>	C117062	Microbiology Specimen Measurement, Test or Examination Detail|MBTSTDTL	Further description of a microbiology test or microbiology test code.			Idea or Concept	
C162145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162145>	C25364	Microbiology Susceptibility Non-host Organism Identifier|NHOID	Sponsor-defined identifier for a non-host organism.			Intellectual Product	
C162146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162146>	C117062	Microbiology Susceptibility Measurement, Test or Examination Detail|MSTSTDTL	Further description of a microbiology susceptibility test or microbiology susceptibility test code.			Idea or Concept	
C162147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162147>	C42614	Microbiology Susceptibility Agent Name|MSAGENT	The name of the agent for which resistance is tested. The agent specified may be based on genetic markers or direct phenotypic drug sensitivity testing.			Conceptual Entity	
C162148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162148>	C42614	Microbiology Susceptibility Modified Reported Name|MSMODIFY	An indication or description of a change in a microbiology susceptibility agent.			Conceptual Entity	
C162149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162149>	C47922	Microbiology Susceptibility External File Path|MSXFN	The literal identifier of a microbiology susceptibility external file name.			Intellectual Product	
C16214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16214>	C213421	Mutagenicity Test	A method that evaluates a substance's potential to induce mutations, or changes in the DNA sequence or structure, in organisms, which can then lead to heritable changes and potentially, carcinogenesis.			Research Activity	
C162150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162150>	C117039	Microbiology Susceptibility Analysis Method|MSANMETH	Analysis method applied to obtain a summarized microbiology susceptibility result.			Conceptual Entity	
C162151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162151>	C25330	Microbiology Susceptibility Collected Duration|MSCDUR	Collected duration of a microbiology susceptibility event or finding.			Temporal Concept	
C162152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162152>	C167238|C166257|C160819	Advanced Colon Adenocarcinoma	Colon adenocarcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Colon Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162153>	C8933|C165452|C159556	Advanced Pancreatic Adenocarcinoma	Pancreatic adenocarcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Pancreatic Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162154>	C5105|C159563|C147982	Refractory Colorectal Adenocarcinoma	Colorectal adenocarcinoma that is resistant to treatment.			Neoplastic Process	
C162155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162155>	C4349|C162154|C153351	Refractory Colon Adenocarcinoma	Colon adenocarcinoma that is resistant to treatment.	Refractory Colon Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162156>	C9382|C147982	Refractory Rectal Carcinoma	Rectal carcinoma that is resistant to treatment.			Neoplastic Process	
C162157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162157>	C9383|C162156|C162154	Refractory Rectal Adenocarcinoma	Rectal adenocarcinoma that is resistant to treatment.	Refractory Rectal Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162158>	C156094|C153203	Advanced Lung Non-Small Cell Carcinoma	Lung non-small cell carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.			Neoplastic Process	
C162159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162159>	C116436	Stereotactic Accelerated Partial Breast Irradiation|SAPBI|SPBI|Stereotactic Partial Breast Irradiation	Partial breast irradiation using real-time tracking, respiratory motion management, and submillimeter accuracy. It results in a reduced target and treatment uncertainty allowing for treatment intensification and maximal target coverage while protecting normal breast tissue from unnecessary high-dose irradiation.	Stereotactic Accelerated Partial Breast Irradiation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C16215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16215>	C15196	Soft Agar Assay	Soft agar colony formation assay is performed to assay for anchorage independent growth.			Research Activity	
C162160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162160>	C60758	Community Health Advisor	A healthcare worker in a local health, mental health, or social services department who formulates, organizes, directs, designs, or develops programs that generate improved community health outcomes. Work includes administrative direction and coordination of work with multiple community partners and non-profit agencies.	Community Health Advisor		Professional or Occupational Group	CTRP Intervention Terminology|CTRP Terminology
C162161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162161>	C15687	Liver-directed Therapy	Any therapy designed to treat the liver while sparing nearby tissues and organs. Treatment modalities include hepatic arterial infusion, embolization therapies, selective internal radiation therapy, and stereotactic body radiation therapy.	Liver-directed Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C162162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162162>	C74954	Cholate Clearance Test|Dual Cholate Test	A test of liver function that measures the clearance of orally-administered cholate to provide an assessment of portal blood flow and IV-administered cholate to provide an assessment of systemic blood flow.	Cholate Clearance Test		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C162163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162163>	C2124	Cholic-2,2,4,4-D4 Acid|2,2,4,4-2H Cholate	A deuterated form of cholic acid with potential diagnostic applications. Upon intravenous administration, cholic-2,2,4,4-D4 acid levels may be used to measure first pass hepatic extraction of cholate, which is influenced primarily by portal blood flow and portal-systemic shunt.	Cholic-2,2,4,4-D4 Acid		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C162164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162164>	C2124	Cholic Acid-24-13C|24-13C Cholate|Carbon C 13 Cholic Acid	A preparation of carbon C 13-labeled cholic acid with potential diagnostic applications. Upon intravenous administration, cholic acid-24-13C levels may be used to measure first pass hepatic extraction of cholate, which is influenced primarily by portal blood flow and portal-systemic shunt.	Cholic Acid-24-13C		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C162165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162165>	C80454	First Study Treatment Date|Date of First Study Treatment|Demographics Date of First Study Treatment|RFXSTDAT	The date of the subject's first study treatment.			Temporal Concept	
C162166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162166>	C200765	MOv19 CAR-CD3zeta-4-1BB-expressing Allogeneic T-lymphocytes|Allogeneic MOv19 CAR-CD3zeta-4-1BB-expressing T-lymphocytes|Anti-Folate Receptor Alpha-CAR-CD3zeta-4-1BB-expressing Allogeneic T-lymphocytes|MOv19-CAR-CD3zeta-4-1BB-expressing Allogeneic T-cells	A preparation of allogeneic CD4-positive and CD8-positive T-lymphocytes that have been transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) comprised of an anti-folate receptor alpha (FR-alpha; ovarian tumor-associated antigen MOv18) single chain variable fragment (scFv) (MOv19) and the zeta chain of the T-cell receptor (TCR)/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. Upon administration, MOv19-CAR-CD3zeta-4-1BB-expressing allogeneic T-lymphocytes target, bind to and induce selective toxicity in folate receptor alpha-expressing tumor cells. The costimulatory signaling domain enhances both proliferation of T-cells and antitumor activity. Folate receptor alpha is a glycosylphosphatidylinositol-linked cell-surface glycoprotein that is widely expressed in certain cancers including serous and epithelial ovarian cancer, endometrial adenocarcinoma, non-small cell lung cancer and triple negative breast cancer. In contrast, folate receptor alpha expression is limited in normal tissues.	MOv19 CAR-CD3zeta-4-1BB-expressing Allogeneic T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162167>	C226301	Last Study Treatment Date|Date of Last Study Treatment|Demographics Date of Last Study Treatment|RFXENDAT	The date of the subject's final study treatment.			Temporal Concept	
C162168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162168>	C25207	Time of Therapeutic Procedure	The time that a specific therapeutic procedure was performed.			Temporal Concept	
C162169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162169>	C162168	First Study Treatment Time|Demographics Time of First Study Treatment|RFXSTTIM|Time of First Study Treatment	The time of the subject's first study treatment.			Temporal Concept	
C16216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16216>	C15196	Matrigel Invasion Assay	This in vitro invasion assay utilizes matrigel, a reconstituted basement membrane, to assess the ability of cells to degrade and cross tissue barriers. This "in-vitro angiogenesis assay" can be used to screen potential anti-angiogenic compounds as well as to study angiogenic pathways underlying neoplasia.			Research Activity	
C162170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162170>	C162168	Last Study Treatment Time|Demographics Time of Last Study Treatment|RFXENTIM|Time of Last Study Treatment	The time of the subject's final study treatment.			Temporal Concept	
C162171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162171>	C25207	Informed Consent Time|Demographics Time of Informed Consent|RFICTIM|Time of Informed Consent	The time of informed consent collection.			Temporal Concept	
C162172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162172>	C68617	Participation End Date|Date of End of Participation|Demographics Date of End of Participation|RFPENDAT	The date of the end of a subject's participation in the study.			Temporal Concept	
C162173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162173>	C82573	Participation End Time|Demographics Time of End of Participation|RFPENTIM|Time of End of Participation	The time of the end of a subject's participation in the study.			Temporal Concept	
C162174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162174>	C93511	Disease Response Assessment Date|Disease Response Date of Assessment|RSDAT	The date on which a disease response assessment is completed.			Temporal Concept	
C162175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162175>	C25207	Disease Response Assessment Time|Disease Response Time of Assessment|RSTIM	The time at which a disease response assessment is completed.			Temporal Concept	
C162176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162176>	C93511	Study Subject Assessment Date|SSDAT|Study Subject Date of Assessment	The date of the subject status assessment.			Temporal Concept	
C162177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162177>	C25207	Study Subject Assessment Time|SSTIM|Study Subject Time of Assessment	The time of the subject status assessment.			Temporal Concept	
C162178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162178>	C25164	Tumor Identification Date|Date of Tumor Identification|TUDAT	The date of tumor identification data collection.			Temporal Concept	
C162179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162179>	C25207	Tumor Identification Time|TUTIM|Time of Tumor Identification	The time of tumor identification data collection.			Temporal Concept	
C16217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16217>	C15196	Tumor Formation in Athymic Mice	Research on tumor formation in mice lacking t-cell immunity.			Laboratory Procedure	
C162180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162180>	C93511	Tumor Results Measurement Date|Date of Tumor/Lesion Measurement|TRDAT|Tumor Results Date of Measurement|Tumor/Lesion Measurement Date	The date of the tumor scan, image, or physical exam.			Temporal Concept	
C162181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162181>	C25207	Tumor Results Measurement Time|TRTIM|Time of Tumor/Lesion Measurement|Tumor Results Time of Measurement|Tumor/Lesion Measurement Time	The time of the tumor scan, image, or physical exam.			Temporal Concept	
C162182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162182>	C160920|C158752|C155698	Locally Advanced Unresectable Breast Carcinoma	A breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.	Locally Advanced Unresectable Breast Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162183>	C19636|C18060	Somatic BRCA2 Gene Mutation|Somatic BRCA2 Mutation|Somatic BROVCA2 Gene Mutation|Somatic Breast Cancer Type 2 Susceptibility Gene Mutation|Somatic FANCD1 Gene Mutation|Somatic XRCC11 Gene Mutation	A change in the nucleotide sequence of the BRCA2 gene that originates in non-germline cells.	Somatic BRCA2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162184>	C19635|C18060	Somatic BRCA1 Gene Mutation|Somatic BRCA1 Mutation|Somatic BROVCA1 Gene Mutation|Somatic Breast Cancer Type 1 Susceptibility Gene Mutation	A change in the nucleotide sequence of the BRCA1 gene that originates in non-germline cells.	Somatic BRCA1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162185>	C514	Ibrexafungerp|IBREXAFUNGERP|IBX|MK 3118|MK-3118|MK3118|SCY 078|SCY-078|SCY078	An intravenous and orally bioavailable semisynthetic derivative of enfumafungin with potential antifungal activity. Upon administration, ibrexafungerp inhibits beta-1,3-D-glucan synthase, an enzyme essential for fungal cell wall synthesis. This results in weakening of the fungal cell wall, thereby leading to osmotic lysis and eventually fungal cell death.	Ibrexafungerp		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C162186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162186>	C181141	mRNA-derived KRAS-targeted Vaccine V941|V 941|V941|mRNA 5671|mRNA-5671|mRNA-5671 Vaccine	A lipid nanoparticle (LNP)-formulated mRNA-based cancer vaccine that targets four of the most commonly occurring KRAS mutations (G12D, G12V, G13D, and G12C), with potential immunostimulatory and antineoplastic activities. Upon vaccination, the mRNA-derived KRAS-targeted vaccine V941 (mRNA-5671) is taken up and translated by antigen presenting cells (APCs). Following translation, the epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy tumor cells harboring these specific KRAS mutations. KRAS, a tumor-associated antigen (TAA), is mutated in a variety of tumor cell types. It plays a key role in tumor cell proliferation and survival and is associated with tumor initiation, metastasis and poor prognosis.	mRNA-derived KRAS-targeted Vaccine V941		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162187>	C1505	Microbial Ecosystem Therapeutics-4|MET 4|MET-4|MET4	An orally available formulation consisting of a well-defined mixture of over thirty intestinal bacteria isolated from a healthy donor stool sample with potential immunomodulatory effects. Upon administration, the bacteria in microbial ecosystem therapeutics-4 (MET4) may help maintain adequate colonization of the gastrointestinal (GI) tract and modulate the composition of the normal microflora. Upon colonization of the GI tract, the probiotic bacteria form a protective barrier that helps maintain the integrity of the epithelial barrier. This will interfere with the attachment of pathogenic bacteria and other harmful substances, prevent inflammation and improve GI function. Additionally, increased gut microbiota diversity and the presence of certain bacterial genera present in MET4 may improve outcomes following immunotherapy, potentially via certain mucosal and systemic immune responses induced by the microbiome across the gut barrier.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C162188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162188>	C27274	Clonal Hematopoiesis	Cellular proliferation of hematopoietic cells where a substantial proportion of the cells is derived from a single hematopoietic stem cell lineage.	Clonal Hematopoiesis		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C16218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16218>	C15399|C113420	Nerve-Sparing Prostatectomy|Nerve-Sparing Surgery|nerve-sparing radical prostatectomy|nerve-sparing surgery	A type of surgical prostatectomy which attempts to spare the nerves that control erection.	Nerve-Sparing Prostatectomy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C162191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162191>	C41179	Monoclonal Hematopoietic Stem and Progenitor Cells Present|Monoclonal HSPCs Present	A finding indicating the presence of a monoclonal population of hematopoietic stem and progenitor cells in a tissue sample.			Laboratory or Test Result	
C162192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162192>	C281	Furosemide/Digoxin Topical Gel CLS003|CLS 003|CLS-003|CLS003|Digoxin-Furosemide Topical Gel CLS003|ICVT Product CLS003	A topical ionic contra-viral therapy (ICVT) gel-based formulation that combines furosemide, a sulfamoylanthranilic acid derivative and loop diuretic, and digoxin, a cardiac glycoside, with potential antiviral activity. Upon topical administration, furosemide interacts with the cell membrane ion co-transporter, Na+-K+-2Cl-co-transporter-1(NKCC1; SLC12A2) and digoxin reversibly inhibits the sodium/potassium-transporting ATPase, leading to a decrease in potassium influx. This may prevent the replication of certain DNA viruses including human papillomavirus (HPV), that rely on potassium for replication.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C162193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162193>	C26170	Pollen Extract PCC-100	A pollen extract with potential use in the management of certain vasomotor symptoms of menopause. Upon administration, pollen extract PCC-100 may, through a non-estrogenic but not fully elucidated mechanism of action, reduce the incidence and severity of vasomotor symptoms and may be a safe alternative for some individuals.			Organic Chemical|Pharmacologic Substance	NCI Drug Dictionary Terminology
C162194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162194>	C153185|C153069	Advanced Soft Tissue Sarcoma	A sarcoma of soft tissue that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Soft Tissue Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162195>	C25737	Focus of Study-Specific Interest|FOCID	Identification of a focus of study-specific interest on or within a subject or specimen as called out in the protocol for which a measurement, test, or examination was performed.			Qualitative Concept	
C162198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162198>	C82530	Musculoskeletal Findings, Connective and Soft Tissue Findings Sponsor-Defined Identifier|MKSPID	One or more sponsor defined characters used to identify, name, or characterize the musculoskeletal finding.			Intellectual Product	
C162199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162199>	C82530	Nervous System Sponsor-Defined Identifier|NVSPID	One or more sponsor defined characters used to identify, name, or characterize the nervous system finding.			Intellectual Product	
C16219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16219>	C66891|C201922	Seed Implantation	A type of cancer treatment using radioactive seeds or pellets, that are implanted into the affected organ, and which act as an encapsulated radiation source within the cancerous tissue while limiting the exposure to sorrounding tissues.			Therapeutic or Preventive Procedure	
C1621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1621>	C2124	Ho 166 DOTMP|166 Holmium-DOTMP|Ho-166-(1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrayltetrakis(methylene))tetrakisphosphonic Acid|Holmium Ho 166 DOTMP|holmium Ho 166 DOTMP				Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	NCI Drug Dictionary Terminology
C162200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162200>	C82530	Urinary System Findings Sponsor-Defined Identifier|URSPID	One or more sponsor defined characters used to identify, name, or characterize the urinary system finding.			Intellectual Product	
C162201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162201>	C82572	Musculoskeletal Findings, Connective and Soft Tissue Findings Elapsed Time|MKELTM	The interval between two musculoskeletal findings reference time points.			Temporal Concept	
C162202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162202>	C82572	Nervous System Elapsed Time|NVELTM	The interval between two nervous system findings reference time points.			Temporal Concept	
C162203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162203>	C82572	Ophthalmic Examinations Elapsed Time|OEELTM	The interval between two ophthalmic examination reference time points.			Temporal Concept	
C162204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162204>	C82572	Reproductive System Findings Elapsed Time|RPELTM	The interval between two reproductive system findings reference time points.			Temporal Concept	
C162205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162205>	C82572	Urinary System Findings Elapsed Time|URELTM	The interval between two urinary system findings reference time points.			Temporal Concept	
C162206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162206>	C82531	Musculoskeletal Findings, Connective and Soft Tissue Findings Reference Identifier|MKREFID	A character or string that represents a musculoskeletal finding event reference.			Intellectual Product	
C162207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162207>	C82531	Nervous System Reference Identifier|NVREFID	A character or string that represents a nervous system assessment event reference.			Intellectual Product	
C162208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162208>	C82531	Respiratory System Findings Reference Identifier|REREFID	A character or string that represents a respiratory system findings procedure event reference.			Intellectual Product	
C162209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162209>	C82531	Urinary System Findings Reference Identifier|URREFID	A character or string that represents a urinary system findings event reference.			Intellectual Product	
C16220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16220>	C16208	ORESTES Library	Expressed Sequence Tags positioned in open reading frames.			Manufactured Object	
C162210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162210>	C82576	Musculoskeletal Findings, Connective and Soft Tissue Findings Time Point Reference|MKTPTREF	The point in time that acts as a fixed reference point to a musculoskeletal finding.			Temporal Concept	
C162211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162211>	C82576	Nervous System Time Point Reference|NVTPTREF	The point in time that acts as a fixed reference point to a nervous system finding.			Temporal Concept	
C162212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162212>	C82576	Ophthalmic Examinations Time Point Reference|OETPTREF	The point in time that acts as a fixed reference point to an ophthalmic examination.			Temporal Concept	
C162213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162213>	C82576	Reproductive System Findings Time Point Reference|RPTPTREF	The point in time that acts as a fixed reference point to a reproductive system finding.			Temporal Concept	
C162214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162214>	C82586	Respiratory System Findings Reference Result in Original Units|REORREF	The reference result for continuous respiratory measurements in original units.			Quantitative Concept	
C162216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162216>	C34028	Renal Calyx and Pelvis|Pelvicalyceal System|Pyelocalyceal|Pyelocalyceal Region	The portion of the kidney comprising the renal calices and pelvis.			Body Part, Organ, or Organ Component	
C162217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162217>	C34028	Renal Parenchyma|Renal Cortex and Medulla	The functional part of the kidney, comprising the renal cortex and medulla.			Body Part, Organ, or Organ Component	Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology
C162218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162218>	C33904	Perinephric Fat	A layer of fatty tissue surrounding the kidney, bounded by the renal capsule and the renal fascia.			Anatomical Structure	GDC Terminology|GDC Value Terminology
C162219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162219>	C34028	Renal Sinus	A cavity in the kidney containing the pelvicalyceal system, blood vessels, nerves and fat. It communicates with the perinephric space.			Body Part, Organ, or Organ Component	GDC Terminology|GDC Value Terminology
C16221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16221>	C15471	Protein Replacement Therapy|Enzyme Replacement Therapy	Administration of a protein to compensate for the loss, as from disease or surgery, of a gland or tissue that would normally produce the protein.			Therapeutic or Preventive Procedure	
C162220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162220>	C67290|C63510	Axitinib/Pembrolizumab Regimen|Axitinib and Pembrolizumab|Axitinib-Pembrolizumab|Axitinib/Pembrolizumab|Inlyta/Keytruda|Keytruda/Inlyta|Pembrolizumab-Axitinib|Pembrolizumab/Axitinib|Pembrolizumab/Axitinib Regimen	A regimen consisting of axitinib and pembrolizumab that can be used for the treatment of renal cell carcinoma (RCC) and alveolar soft part sarcoma (ASPS).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology
C162221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162221>	C15220	Metastatic Diagnosis|Diagnosis of Metastasis|Metastasis Diagnosis|metastasis at diagnosis|metastasis_at_diagnosis	Any diagnosis indicating the presence of metastatic disease.			Diagnostic Procedure	CPTAC Baseline Medical Forms Terminology|CPTAC Bladder Urothelial Carcinoma Baseline Form|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Cholangiocarcinoma Baseline Form|CPTAC Esophageal Carcinoma Baseline Form|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Prostate Adenocarcinoma Baseline Form|CPTAC Stomach Adenocarcinoma Baseline Form|CPTAC Terminology|CPTAC Thyroid Carcinoma Baseline Form|CPTAC Uveal Melanoma Baseline Form|GDC Property Terminology|GDC Terminology
C162222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162222>	C96248	FIGO Stage IB3	A FIGO stage term that applies to gynecologic cancers. For cervical cancer, it refers to invasive cancer measuring 4 cm or more in greatest dimension.			Classification	
C162223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162223>	C96253	FIGO Stage IIA1|Stage IIA1	A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer limited to the upper two-thirds of the vagina without parametrial involvement, less than 4 cm in greatest dimension.			Classification	GDC Terminology|GDC Value Terminology
C162224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162224>	C96253	FIGO Stage IIA2|Stage IIA2	A FIGO stage term that applies to gynecologic cancers.  For cervical cancer, it refers to cancer limited to the upper two-thirds of the vagina without parametrial involvement, equal or more than 4 cm in greatest dimension.			Classification	GDC Terminology|GDC Value Terminology
C162225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162225>	C9039	Cervical Cancer by FIGO Stage 2018|Cervical Carcinoma by FIGO Stage 2018	A term that refers to the staging of cervical cancer according to the International Federation of Gynecology and Obstetrics (FIGO) staging, 2018.			Neoplastic Process	
C162226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162226>	C162225	Stage I Cervical Cancer FIGO 2018|Stage I Cervical Carcinoma FIGO 2018	The carcinoma is strictly confined to the cervix (extension to the uterine corpus should be disregarded). (FIGO 2018)			Neoplastic Process	
C162227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162227>	C162226	Stage IA Cervical Cancer FIGO 2018|Stage IA Cervical Carcinoma FIGO 2018	Invasive cervical carcinoma that can be diagnosed only by microscopy, with maximum depth of invasion less than 5 mm. (FIGO 2018)			Neoplastic Process	
C162228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162228>	C162227	Stage IA1 Cervical Cancer FIGO 2018|Stage IA1 Cervical Carcinoma FIGO 2018	Cervical carcinoma with measured stromal invasion less than 3 mm in depth. (FIGO 2018)			Neoplastic Process	
C162229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162229>	C162227	Stage IA2 Cervical Cancer FIGO 2018|Stage IA2 Cervical Carcinoma FIGO 2018	Cervical carcinoma with measured stromal invasion equal or more than 3 mm and less than 5 mm in depth. (FIGO 2018)			Neoplastic Process	
C16222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16222>	C122929	Psychological Impact	The impact of sickness on the mental wellbeing of both the patient and the patient's family.			Mental Process	
C162230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162230>	C162226	Stage IB Cervical Cancer FIGO 2018|Stage IB Cervical Carcinoma FIGO 2018	Invasive cervical carcinoma with measured deepest invasion equal or more than 5 mm (greater than Stage IA), lesion limited to the cervix uteri. (FIGO 2018)			Neoplastic Process	
C162231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162231>	C162230	Stage IB1 Cervical Cancer FIGO 2018|Stage IB1 Cervical Carcinoma FIGO 2018	Invasive cervical carcinoma with equal or more than 5 mm depth of stromal invasion, and less than 2 cm in greatest dimension. (FIGO 2018)			Neoplastic Process	
C162232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162232>	C162230	Stage IB2 Cervical Cancer FIGO 2018|Stage IB2 Cervical Carcinoma FIGO 2018	Invasive cervical carcinoma equal or more than 2 cm and less than 4 cm in greatest dimension. (FIGO 2018)			Neoplastic Process	
C162233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162233>	C162230	Stage IB3 Cervical Cancer FIGO 2018|Stage IB3 Cervical Carcinoma FIGO 2018	Invasive cervical carcinoma equal or more than 4 cm in greatest dimension. (FIGO 2018)			Neoplastic Process	
C162234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162234>	C162225	Stage II Cervical Cancer FIGO 2018|Stage II Cervical Carcinoma FIGO 2018	The cervical carcinoma invades beyond the uterus, but has not extended onto the lower third of the vagina or to the pelvic wall. (FIGO 2018)			Neoplastic Process	
C162235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162235>	C162234	Stage IIA Cervical Cancer FIGO 2018|Stage IIA Cervical Carcinoma FIGO 2018	Cervical carcinoma limited to the upper two-thirds of the vagina without parametrial involvement. (FIGO 2018)			Neoplastic Process	
C162236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162236>	C162235	Stage IIA1 Cervical Cancer FIGO 2018|Stage IIA1 Cervical Carcinoma FIGO 2018	Cervical carcinoma limited to the upper two-thirds of the vagina without parametrial involvement, less than 4 cm in greatest dimension. (FIGO 2018)			Neoplastic Process	
C162237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162237>	C162235	Stage IIA2 Cervical Cancer FIGO 2018|Stage IIA2 Cervical Carcinoma FIGO 2018	Cervical carcinoma limited to the upper two-thirds of the vagina without parametrial involvement, equal or more than 4 cm in greatest dimension. (FIGO 2018)			Neoplastic Process	
C162238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162238>	C162234	Stage IIB Cervical Cancer FIGO 2018|Stage IIB Cervical Carcinoma FIGO 2018	Cervical carcinoma with parametrial involvement but not up to the pelvic wall. (FIGO 2018)			Neoplastic Process	
C162239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162239>	C162225	Stage III Cervical Cancer FIGO 2018|Stage III Cervical Carcinoma FIGO 2018	Cervical carcinoma that involves the lower third of the vagina and/or extends to the pelvic wall and/or causes hydronephrosis or nonfunctioning kidney and/or involves pelvic and/or para-aortic lymph nodes. (FIGO 2018)			Neoplastic Process	
C16223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16223>	C198567	DNA Library|Library	A collection of DNA molecules that have been cloned in vectors.			Manufactured Object	
C162240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162240>	C162239	Stage IIIA Cervical Cancer FIGO 2018|Stage IIIA Cervical Carcinoma FIGO 2018	Cervical carcinoma that involves the lower third of the vagina, with no extension to the pelvic wall. (FIGO 2018)			Neoplastic Process	
C162241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162241>	C162239	Stage IIIB Cervical Cancer FIGO 2018|Stage IIIB Cervical Carcinoma FIGO 2018	Cervical carcinoma with extension to the pelvic wall and/or hydronephrosis or nonfunctioning kidney (unless known to be due to another cause). (FIGO 2018)			Neoplastic Process	
C162242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162242>	C162239	Stage IIIC Cervical Cancer FIGO 2018|Stage IIIC Cervical Carcinoma FIGO 2018	Cervical carcinoma with involvement of pelvic and/or para-aortic lymph nodes, irrespective of tumor size and extent (with r and p notations). (FIGO 2018)			Neoplastic Process	
C162243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162243>	C162242	Stage IIIC1 Cervical Cancer FIGO 2018|Stage IIIC1 Cervical Carcinoma FIGO 2018	Cervical carcinoma with pelvic lymph node metastasis only. (FIGO 2018)			Neoplastic Process	
C162244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162244>	C162242	Stage IIIC2 Cervical Cancer FIGO 2018|Stage IIIC2 Cervical Carcinoma FIGO 2018	Cervical carcinoma with para-aortic lymph node metastasis. (FIGO 2018)			Neoplastic Process	
C162245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162245>	C162225	Stage IV Cervical Cancer FIGO 2018|Stage IV Cervical Carcinoma FIGO 2018	The cervical carcinoma has extended beyond the true pelvis or has involved (biopsy proven) the mucosa of the bladder or rectum. (A bullous edema, as such, does not permit a case to be allotted to Stage IV). (FIGO 2018)			Neoplastic Process	
C162246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162246>	C162245	Stage IVA Cervical Cancer FIGO 2018|Stage IVA Cervical Carcinoma FIGO 2018	The cervical carcinoma has spread to adjacent pelvic organs. (FIGO 2018)			Neoplastic Process	
C162247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162247>	C162245	Stage IVB Cervical Cancer FIGO 2018|Stage IVB Cervical Carcinoma FIGO 2018	The cervical carcinoma has spread to distant organs. (FIGO 2018)			Neoplastic Process	
C162248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162248>	C142078	Engineered Human Umbilical Vein Endothelial Cells AB-205|AB 205|AB-205|AB-205 Cell Product|AB205|Engineered HUVEC AB-205	A population of ex vivo expanded, genetically engineered CD31 (platelet endothelial cell adhesion molecule; PECAM-1)-positive human umbilical vein endothelial cells (HUVECs) derived from human umbilical vein tissue, that can be used to enhance the hematopoietic stem and progenitor cells (HSPCs) transplantation potential and improve blood cell recovery. Following autologous stem cell transplantation (ASCT) and upon the administration of the engineered HUVEC AB-205, the endothelial cells secrete angiocrine growth factors and interact with the HSPCs, thereby forming endothelial cell network structures and improving engraftment potential. AB-205 also interacts with injured or damaged vascular niche cells, thereby promoting blood cell recovery and improving tissue regeneration. This enhances recovery from toxicities related to chemo/radiation regimens.	Engineered Human Umbilical Vein Endothelial Cells AB-205		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology
C162249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162249>	C116239	Thousand Cells per Kilogram|1000 cells per kilogram|10E3 Cells/kg|10^3 Cells/Kilogram|10^3 Cells/kg|10^3{Cells}/kg	A derived unit expressed as a number of cells in thousands per unit of mass equal to one kilogram.			Quantitative Concept	
C16224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16224>	C16232	SAGE Library	Serial analysis of gene expression (SAGE) is novel method of assessing the variation in the type or amount of genes expressed in different tissues, at different times in development or in normal versus malignant cells.			Manufactured Object	
C162250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162250>	C1987	Autologous mDC3 Vaccine|Autologous Mature DC3 Vaccine|Autologous Peptide-pulsed mDC3 Vaccine	An antineoplastic vaccine composed of autologous mature dendritic cells (mDCs) pulsed with mutated peptides, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous mDC3 vaccine may elicit a cytotoxic T-cell (CTL) response against cancer cells.	Autologous mDC3 Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162251>	C86584	Semantic Clustering	The tendency to group items according to their semantic category.			Mental Process	California Verbal Learning Test - Second Edition|California Verbal Learning Test, Children's Version
C162252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162252>	C70744	Learning Slope	A measure of an individual's learning rate.			Conceptual Entity	California Verbal Learning Test - Second Edition|California Verbal Learning Test, Children's Version
C162253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162253>	C51070	Recognition Hits	Correctly recognized items.			Entity	California Verbal Learning Test - Second Edition|California Verbal Learning Test, Children's Version
C162254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162254>	C4913|C157774	Metastatic Malignant Female Reproductive System Neoplasm	A malignant neoplasm that arises in the female reproductive system and has spread from its original site of growth to other anatomic sites.	Metastatic Malignant Female Reproductive System Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162255>	C4890|C36263	Metastatic Malignant Digestive System Neoplasm	A malignant neoplasm that arises in the digestive system and has spread from its original site of growth to other anatomic sites.	Metastatic Malignant Digestive System Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162256>	C2955	Hypermutated Colorectal Carcinoma|Hypermutated Colorectal Cancer	A colorectal carcinoma characterized by a high mutational rate caused by DNA mismatch repair deficiency or POLE/POLD1 driver mutations.	Hypermutated Colorectal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162257>	C2955|C156909	Resectable Colorectal Carcinoma	Colorectal carcinoma that is amenable to surgical resection.	Resectable Colorectal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162258>	C167282	Hypermutated Sample	A molecular finding indicating that the mutation rate is higher than 10 mutations per megabase (Mb) in a tissue sample.			Laboratory or Test Result	
C162259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162259>	C117719	Extraprostatic Extension	A finding indicating the presence of a prostatic carcinoma that has invaded the prostatic capsule and has spread to nearby tissues or distant anatomic sites.			Finding	
C16225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16225>	C16016	Nutrition Research, Vitamin D	The study of the role of Vitamin D, its precursons, and its analogs in cancer causation or prevention and in general health.			Research Activity	
C162260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162260>	C28681|C138180|C129826	Autologous Anti-HLA-A*02/AFP TCRm-expressing T-cells ET140202|ET 140202|ET-140202|ET140202|ET140202 Autologous T-cells	A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector to express a T-cell receptor mimetic (TCRm) antibody synthesized by a proprietary phage display platform, targeting the immunogenetic human tumor-associated antigen (TAA) alpha-fetoprotein (AFP) complexed with human leukocyte antigen (HLA)-A*02 (HLA-A*02/AFP), with potential antineoplastic and immunomodulatory activities. Upon administration, the autologous anti-HLA-A*02/AFP TCRm-expressing T-cells ET140202 specifically recognize and selectively bind to AFP peptides presented by HLA-A*02. This results in cytotoxic T-lymphocyte (CTL)-mediated elimination of AFP-expressing tumor cells. AFP, an intracellularly expressed fetal glycoprotein rarely expressed in adult tissues, is overexpressed in certain tumors of endodermal origin and plays a key role in tumor cell proliferation and survival. AFP is processed into peptides and presented by class I major histocompatibility complexes (MHCs) on the surface of tumor cells.	Autologous Anti-HLA-A*02/AFP TCRm-expressing T-cells ET140202		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162261>	C1708	Platinum Doublet|Platinum Doublets|Platinum-based Chemotherapy Doublet|Platinum-based Chemotherapy Doublets|Platinum-based Double Chemotherapy Combination|Platinum-based Doublet|Platinum-based Doublets	A drug combination of a platinum agent, such as cisplatin (CDDP), carboplatin (CBDCA) or nedaplatin (CDGP), and a third-generation agent, such as docetaxel (DTX), paclitaxel (PTX), vinorelbine (VNR), gemcitabine (GEM), irinotecan (CPT-11), pemetrexed (PEM), or tegafur/gimeracil/oteracil (S-1).	Platinum Doublet		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C162262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162262>	C177692	HLA-B*07 Positive Cells Present|HLA-B*07 Positive|HLA-B07 Positive	An indication that cells expressing HLA-B*07 have been detected in a sample.	HLA-B*07 Positive Cells Present		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162263>	C82572	Meal Data Elapsed Time|MLELTM	The interval between two meal data reference time points.			Temporal Concept	
C162264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162264>	C82576	Meal Data Time Point Reference|MLTPTREF	The point in time that acts as a fixed reference point to meal data.			Temporal Concept	
C162265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162265>	C42614	Disease Milestone Instance Name|MIDS	The name of a specific event or activity that can be anticipated in the course of a disease, but whose timing is not controlled by the study schedule.			Conceptual Entity	
C162266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162266>	C25648	Temporal Relation to Milestone Instance|RELMIDS	A textual description of the temporal relationship between the observation and the disease milestone.			Conceptual Entity	
C162267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162267>	C25164	Disease Milestone Instance Date|MIDSDAT	The date of a specific disease milestone.			Temporal Concept	
C162268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162268>	C25207	Disease Milestone Instance Time|MIDSTTIM	The time of a specific disease milestone.			Temporal Concept	
C162269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162269>	C1987	Autologous mDC3/8-KRAS Vaccine|Autologous Peptide-pulsed mDC3/8 KRAS Vaccine	An antineoplastic vaccine composed of autologous mature dendritic cells (mDCs) pulsed with mutant KRAS peptides specific to a patient's tumor mutation and human leukocyte antigen (HLA) type, with potential immunostimulating and antineoplastic activities. Upon administration, this vaccine, which is administered as an mDC3 primer, followed by an mDC8 booster, may elicit a cytotoxic T-cell (CTL) response against cancer cells expressing certain KRAS mutations. K-RAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutation of K-RAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.	Autologous mDC3/8-KRAS Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C16226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16226>	C15185	Health and Behavior Research	Research into the combination of knowledge, practices, and attitudes that motivate the actions we take regarding health.			Research Activity	
C162270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162270>	C215683|C202500|C190413|C171585	Locally Advanced Unresectable Colorectal Adenocarcinoma	A colorectal adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.	Locally Advanced Unresectable Colorectal Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162271>	C190415|C162270|C162116	Locally Advanced Unresectable Colon Adenocarcinoma	A colon adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.	Locally Advanced Unresectable Colon Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162272>	C174122|C162270|C162117	Locally Advanced Unresectable Rectal Adenocarcinoma	A rectal adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.	Locally Advanced Unresectable Rectal Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162273>	C43585|C161048	Metastatic Colorectal Mucinous Adenocarcinoma	Colorectal mucinous adenocarcinoma that has spread from the original site of growth to other anatomic sites.	Metastatic Colorectal Mucinous Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162274>	C43558|C182104	Metastatic Appendix Mucinous Adenocarcinoma|Metastatic Appendiceal Mucinous Adenocarcinoma	A mucinous adenocarcinoma of the appendix that has spread from the original site of growth to other anatomic sites.	Metastatic Appendix Mucinous Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162275>	C9330|C133839	Metastatic Appendix Carcinoma|Metastatic Appendiceal Carcinoma	An appendix carcinoma that has spread from the original site of growth to other anatomic sites.			Neoplastic Process	
C162276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162276>	C39788	MET NM_000245.3:c.3749T>C|HGFR c.3749T>C|MET Proto-Oncogene, Receptor Tyrosine Kinase c.3749T>C|Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) c.3749T>C|NM_000245.3:c.3749T>C|NM_001127500.2:c.3803T>C|c-Met c.3749T>C	A nucleotide substitution at position 3749 of the coding sequence of the MET gene where thymine has been mutated to cytosine.			Cell or Molecular Dysfunction	
C162277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162277>	C136286	MET NP_000236.2:p.M1250T|C-MET M1250T|C-MET Met1250Thr|HGF Receptor M1250T|HGF Receptor Met1250Thr|HGFR M1250T|HGFR Met1250Thr|Hepatocyte Growth Factor Receptor M1250T|Hepatocyte Growth Factor Receptor Met1250Thr|MET M1250T|MET Met1250Thr|MET NP_000236.2:p.Met1250Thr|MET p.M1250T|MET p.Met1250Thr|NP_000236.2:p.M1250T|NP_000236.2:p.Met1250Thr|NP_001120972.1:p.M1268T|NP_001120972.1:p.Met1268Thr|Proto-Oncogene c-Met M1250T|Proto-Oncogene c-Met Met1250Thr|Scatter Factor Receptor M1250T|Scatter Factor Receptor Met1250Thr|Tyrosine-Protein Kinase Met M1250T|Tyrosine-Protein Kinase Met Met1250Thr	A change in the amino acid residue at position 1250 in the hepatocyte growth factor receptor protein where methionine has been replaced by threonine.			Cell or Molecular Dysfunction	
C162278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162278>	C136286	MET NP_000236.2:p.S1236R|C-MET S1236R|C-MET Ser1236Arg|HGF Receptor S1236R|HGF Receptor Ser1236Arg|HGFR S1236R|HGFR Ser1236Arg|Hepatocyte Growth Factor Receptor S1236R|Hepatocyte Growth Factor Receptor Ser1236Arg|MET NP_000236.2:p.Ser1236Arg|MET S1236R|MET Ser1236Arg|MET p.S1236R|MET p.Ser1236Arg|NP_000236.2:p.S1236R|NP_000236.2:p.Ser1236Arg|NP_001120972.1:p.S1254R|NP_001120972.1:p.Ser1254Arg|Proto-Oncogene c-Met S1236R|Proto-Oncogene c-Met Ser1236Arg|Scatter Factor Receptor S1236R|Scatter Factor Receptor Ser1236Arg|Tyrosine-Protein Kinase Met S1236R|Tyrosine-Protein Kinase Met Ser1236Arg	A change in the amino acid residue at position 1236 in the hepatocyte growth factor receptor protein where serine has been replaced by arginine.			Cell or Molecular Dysfunction	
C162279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162279>	C39788	MET NM_000245.3:c.3688T>C|HGFR c.3688T>C|MET Proto-Oncogene, Receptor Tyrosine Kinase c.3688T>C|Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) c.3688T>C|NM_000245.3:c.3688T>C|NM_001127500.2:c.3742T>C|c-Met c.3688T>C	A nucleotide substitution at position 3688 of the coding sequence of the MET gene where thymine has been mutated to cytosine.			Cell or Molecular Dysfunction	
C16227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16227>	C16228	MOP Photochemotherapy	UV light therapy that exposes cells to methoxypsoralen and long-wavelength ultraviolet A light.			Therapeutic or Preventive Procedure	
C162280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162280>	C201938	MET NP_000236.2:p.Y1230H|C-MET Tyr1230His|C-MET Y1230H|HGF Receptor Tyr1230His|HGF Receptor Y1230H|HGFR Tyr1230His|HGFR Y1230H|Hepatocyte Growth Factor Receptor Tyr1230His|Hepatocyte Growth Factor Receptor Y1230H|MET NP_000236.2:p.Tyr1230His|MET Tyr1230His|MET Y1230H|MET p.Tyr1230His|MET p.Y1230H|NP_000236.2:p.Tyr1230His|NP_000236.2:p.Y1230H|NP_001120972.1:p.Tyr1248His|NP_001120972.1:p.Y1248H|Proto-Oncogene c-Met Tyr1230His|Proto-Oncogene c-Met Y1230H|Scatter Factor Receptor Tyr1230His|Scatter Factor Receptor Y1230H|Tyrosine-Protein Kinase Met Tyr1230His|Tyrosine-Protein Kinase Met Y1230H	A change in the amino acid residue at position 1230 in the hepatocyte growth factor receptor protein where tyrosine has been replaced by histdine.			Cell or Molecular Dysfunction	
C162281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162281>	C39788	MET NM_000245.3:c.3689A>G|HGFR c.3689A>G|MET Proto-Oncogene, Receptor Tyrosine Kinase c.3689A>G|Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) c.3689A>G|NM_000245.3:c.3689A>G|NM_001127500.2:c.3743A>G|c-Met c.3689A>G	A nucleotide substitution at position 3689 of the coding sequence of the MET gene where adenine has been mutated to guanine.			Cell or Molecular Dysfunction	
C162282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162282>	C201938	MET NP_000236.2:p.Y1230C|C-MET Tyr1230Cys|C-MET Y1230C|HGF Receptor Tyr1230Cys|HGF Receptor Y1230C|HGFR Tyr1230Cys|HGFR Y1230C|Hepatocyte Growth Factor Receptor Tyr1230Cys|Hepatocyte Growth Factor Receptor Y1230C|MET NP_000236.2:p.Tyr1230Cys|MET Tyr1230Cys|MET Y1230C|MET p.Tyr1230Cys|MET p.Y1230C|NP_000236.2:p.Tyr1230Cys|NP_000236.2:p.Y1230C|NP_001120972.1:p.Tyr1248Cys|NP_001120972.1:p.Y1248C|Proto-Oncogene c-Met Tyr1230Cys|Proto-Oncogene c-Met Y1230C|Scatter Factor Receptor Tyr1230Cys|Scatter Factor Receptor Y1230C|Tyrosine-Protein Kinase Met Tyr1230Cys|Tyrosine-Protein Kinase Met Y1230C	A change in the amino acid residue at position 1230 in the hepatocyte growth factor receptor protein where tyrosine has been replaced by cysteine.			Cell or Molecular Dysfunction	
C162283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162283>	C39788	MET NM_000245.3:c.3682G>A|HGFR c.3682G>A|MET Proto-Oncogene, Receptor Tyrosine Kinase c.3682G>A|Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) c.3682G>A|NM_000245.3:c.3682G>A|NM_001127500.2:c.3736G>A|c-Met c.3682G>A	A nucleotide substitution at position 3682 of the coding sequence of the MET gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C162284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162284>	C201937	MET NP_000236.2:p.D1228N|C-MET Asp1228Asn|C-MET D1228N|HGF Receptor Asp1228Asn|HGF Receptor D1228N|HGFR Asp1228Asn|HGFR D1228N|Hepatocyte Growth Factor Receptor Asp1228Asn|Hepatocyte Growth Factor Receptor D1228N|MET Asp1228Asn|MET D1228N|MET NP_000236.2:p.Asp1228Asn|MET p.Asp1228Asn|MET p.D1228N|NP_000236.2:p.Asp1228Asn|NP_000236.2:p.D1228N|NP_001120972.1:p.Asp1246Asn|NP_001120972.1:p.D1246N|Proto-Oncogene c-Met Asp1228Asn|Proto-Oncogene c-Met D1228N|Scatter Factor Receptor Asp1228Asn|Scatter Factor Receptor D1228N|Tyrosine-Protein Kinase Met Asp1228Asn|Tyrosine-Protein Kinase Met D1228N	A change in the amino acid residue at position 1228 in the hepatocyte growth factor receptor protein where aspartic acid has been replaced by asparagine.			Cell or Molecular Dysfunction	
C162285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162285>	C39788	MET NM_000245.3:c.3613T>G|HGFR c.3613T>G|MET Proto-Oncogene, Receptor Tyrosine Kinase c.3613T>G|Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) c.3613T>G|NM_000245.3:c.3613T>G|NM_001127500.2:c.3667T>G|c-Met c.3613T>G	A nucleotide substitution at position 3613 of the coding sequence of the MET gene where thymine has been mutated to guanine.			Cell or Molecular Dysfunction	
C162286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162286>	C136286	MET NP_000236.2:p.L1205V|C-MET L1205V|C-MET Leu1205Val|HGF Receptor L1205V|HGF Receptor Leu1205Val|HGFR L1205V|HGFR Leu1205Val|Hepatocyte Growth Factor Receptor L1205V|Hepatocyte Growth Factor Receptor Leu1205Val|MET L1205V|MET Leu1205Val|MET NP_000236.2:p.Leu1205Val|MET p.L1205V|MET p.Leu1205Val|NP_000236.2:p.L1205V|NP_000236.2:p.Leu1205Val|NP_001120972.1:p.L1223V|NP_001120972.1:p.Leu1223Val|Proto-Oncogene c-Met L1205V|Proto-Oncogene c-Met Leu1205Val|Scatter Factor Receptor L1205V|Scatter Factor Receptor Leu1205Val|Tyrosine-Protein Kinase Met L1205V|Tyrosine-Protein Kinase Met Leu1205Val	A change in the amino acid residue at position 1205 in the hepatocyte growth factor receptor protein where leucine has been replaced by valine.			Cell or Molecular Dysfunction	
C162287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162287>	C39788	MET NM_000245.3:c.3598T>A|HGFR c.3598T>A|MET Proto-Oncogene, Receptor Tyrosine Kinase c.3598T>A|Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) c.3598T>A|NM_000245.3:c.3598T>A|NM_001127500.2:c.3652T>A|c-Met c.3598T>A	A nucleotide substitution at position 3598 of the coding sequence of the MET gene where thymine has been mutated to adenine.			Cell or Molecular Dysfunction	
C162288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162288>	C136286	MET NP_000236.2:p.F1200I|C-MET F1200I|C-MET Phe1200Ile|HGF Receptor F1200I|HGF Receptor Phe1200Ile|HGFR F1200I|HGFR Phe1200Ile|Hepatocyte Growth Factor Receptor F1200I|Hepatocyte Growth Factor Receptor Phe1200Ile|MET F1200I|MET NP_000236.2:p.Phe1200Ile|MET Phe1200Ile|MET p.F1200I|MET p.Phe1200Ile|NP_000236.2:p.F1200I|NP_000236.2:p.Phe1200Ile|NP_001120972.1:p.F1218I|NP_001120972.1:p.Phe1218Ile|Proto-Oncogene c-Met F1200I|Proto-Oncogene c-Met Phe1200Ile|Scatter Factor Receptor F1200I|Scatter Factor Receptor Phe1200Ile|Tyrosine-Protein Kinase Met F1200I|Tyrosine-Protein Kinase Met Phe1200Ile	A change in the amino acid residue at position 1200 in the hepatocyte growth factor receptor protein where phenylalanine has been replaced by isoleucine.			Cell or Molecular Dysfunction	
C162289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162289>	C39788	MET NM_000245.3:c.3280C>T|HGFR c.3280C>T|MET Proto-Oncogene, Receptor Tyrosine Kinase c.3280C>T|Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) c.3280C>T|NM_000245.3:c.3280C>T|NM_001127500.2:c.3334C>T|c-Met c.3280C>T	A nucleotide substitution at position 3280 of the coding sequence of the MET gene where cytosine has been mutated to thymine.			Cell or Molecular Dysfunction	
C16228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16228>	C15344	UVA Light Therapy|UVA Phototherapy	Light therapy using ultraviolet radiation between 100 and 400nm.			Therapeutic or Preventive Procedure	
C162290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162290>	C136286	MET NP_000236.2:p.H1094Y|C-MET H1094Y|C-MET His1094Tyr|HGF Receptor H1094Y|HGF Receptor His1094Tyr|HGFR H1094Y|HGFR His1094Tyr|Hepatocyte Growth Factor Receptor H1094Y|Hepatocyte Growth Factor Receptor His1094Tyr|MET H1094Y|MET His1094Tyr|MET NP_000236.2:p.His1094Tyr|MET p.H1094Y|MET p.His1094Tyr|NP_000236.2:p.H1094Y|NP_000236.2:p.His1094Tyr|NP_001120972.1:p.H1112Y|NP_001120972.1:p.His1112Tyr|Proto-Oncogene c-Met H1094Y|Proto-Oncogene c-Met His1094Tyr|Scatter Factor Receptor H1094Y|Scatter Factor Receptor His1094Tyr|Tyrosine-Protein Kinase Met H1094Y|Tyrosine-Protein Kinase Met His1094Tyr	A change in the amino acid residue at position 1094 in the hepatocyte growth factor receptor protein where histidine has been replaced by tyrosine.			Cell or Molecular Dysfunction	
C162291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162291>	C39788	MET NM_000245.3:c.3274G>A|HGFR c.3274G>A|MET Proto-Oncogene, Receptor Tyrosine Kinase c.3274G>A|Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) c.3274G>A|NM_000245.3:c.3274G>A|NM_001127500.2:c.3328G>A|c-Met c.3274G>A	A nucleotide substitution at position 3274 of the coding sequence of the MET gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C162292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162292>	C136286	MET NP_000236.2:p.V1092I|C-MET V1092I|C-MET Val1092Ile|HGF Receptor V1092I|HGF Receptor Val1092Ile|HGFR V1092I|HGFR Val1092Ile|Hepatocyte Growth Factor Receptor V1092I|Hepatocyte Growth Factor Receptor Val1092Ile|MET NP_000236.2:p.Val1092Ile|MET V1092I|MET Val1092Ile|MET p.V1092I|MET p.Val1092Ile|NP_000236.2:p.V1092I|NP_000236.2:p.Val1092Ile|NP_001120972.1:p.V1110I|NP_001120972.1:p.Val1110Ile|Proto-Oncogene c-Met V1092I|Proto-Oncogene c-Met Val1092Ile|Scatter Factor Receptor V1092I|Scatter Factor Receptor Val1092Ile|Tyrosine-Protein Kinase Met V1092I|Tyrosine-Protein Kinase Met Val1092Ile	A change in the amino acid residue at position 1092 in the hepatocyte growth factor receptor protein where valine has been replaced by isoleucine.			Cell or Molecular Dysfunction	
C162293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162293>	C39788	MET NM_000245.3:c.3208G>A|HGFR c.3208G>A|MET Proto-Oncogene, Receptor Tyrosine Kinase c.3208G>A|Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) c.3208G>A|NM_000245.3:c.3208G>A|NM_001127500.2:c.3262G>A|c-Met c.3208G>A	A nucleotide substitution at position 3208 of the coding sequence of the MET gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C162294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162294>	C136286	MET NP_000236.2:p.V1070M|C-MET V1070M|C-MET Val1070Met|HGF Receptor V1070M|HGF Receptor Val1070Met|HGFR V1070M|HGFR Val1070Met|Hepatocyte Growth Factor Receptor V1070M|Hepatocyte Growth Factor Receptor Val1070Met|MET NP_000236.2:p.Val1070Met|MET V1070M|MET Val1070Met|MET p.V1070M|MET p.Val1070Met|NP_000236.2:p.V1070M|NP_000236.2:p.Val1070Met|NP_001120972.1:p.V1088M|NP_001120972.1:p.Val1088Met|Proto-Oncogene c-Met V1070M|Proto-Oncogene c-Met Val1070Met|Scatter Factor Receptor V1070M|Scatter Factor Receptor Val1070Met|Tyrosine-Protein Kinase Met V1070M|Tyrosine-Protein Kinase Met Val1070Met	A change in the amino acid residue at position 1070 in the hepatocyte growth factor receptor protein where valine has been replaced by methionine.			Cell or Molecular Dysfunction	
C162295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162295>	C39788	MET NM_000245.3:c.3209T>G|HGFR c.3209T>G|MET Proto-Oncogene, Receptor Tyrosine Kinase c.3209T>G|Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) c.3209T>G|NM_000245.3:c.3209T>G|NM_001127500.2:c.3263T>G|c-Met c.3209T>G	A nucleotide substitution at position 3209 of the coding sequence of the MET gene where thymine has been mutated to guanine.			Cell or Molecular Dysfunction	
C162296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162296>	C201282|C200367	Anti-CD33/CD3 Bispecific Antibody JNJ-67571244|JNJ 67571244|JNJ-67571244|JNJ67571244	A bispecific antibody possessing two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for the tumor-associated antigen (TAA) CD33, with potential immunostimulating and antineoplastic activities. Upon intravenous administration, anti-CD33/CD3 bispecific antibody JNJ-67571244 binds to both the CD3 antigen on cytotoxic T-lymphocytes (CTLs) and the CD33 antigen expressed on certain tumor cells, thereby crosslinking tumor cells and CTLs. This activates and redirects CTLs to CD33-expressing tumor cells, which results in CTL-mediated killing of CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem and progenitor cells (HSPCs) and is overexpressed on a variety of cancer cell types, including acute myeloid leukemia (AML). It plays a key role in tumor initiation, proliferation and progression.	Anti-CD33/CD3 Bispecific Antibody JNJ-67571244		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162297>	C136286	MET NP_000236.2:p.V1070G|C-MET V1070G|C-MET Val1070Gly|HGF Receptor V1070G|HGF Receptor Val1070Gly|HGFR V1070G|HGFR Val1070Gly|Hepatocyte Growth Factor Receptor V1070G|Hepatocyte Growth Factor Receptor Val1070Gly|MET NP_000236.2:p.Val1070Gly|MET V1070G|MET Val1070Gly|MET p.V1070G|MET p.Val1070Gly|NP_000236.2:p.V1070G|NP_000236.2:p.Val1070Gly|NP_001120972.1:p.V1088G|NP_001120972.1:p.Val1088Gly|Proto-Oncogene c-Met V1070G|Proto-Oncogene c-Met Val1070Gly|Scatter Factor Receptor V1070G|Scatter Factor Receptor Val1070Gly|Tyrosine-Protein Kinase Met V1070G|Tyrosine-Protein Kinase Met Val1070Gly	A change in the amino acid residue at position 1070 in the hepatocyte growth factor receptor protein where valine has been replaced by glycine.			Cell or Molecular Dysfunction	
C162298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162298>	C39788	MET NM_000245.3:c.3209T>A|HGFR c.3209T>A|MET Proto-Oncogene, Receptor Tyrosine Kinase c.3209T>A|Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) c.3209T>A|NM_000245.3:c.3209T>A|NM_001127500.2:c.3263T>A|c-Met c.3209T>A	A nucleotide substitution at position 3209 of the coding sequence of the MET gene where thymine has been mutated to adenine.			Cell or Molecular Dysfunction	
C162299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162299>	C136286	MET NP_000236.2:p.V1070E|C-MET V1070E|C-MET Val1070Glu|HGF Receptor V1070E|HGF Receptor Val1070Glu|HGFR V1070E|HGFR Val1070Glu|Hepatocyte Growth Factor Receptor V1070E|Hepatocyte Growth Factor Receptor Val1070Glu|MET NP_000236.2:p.Val1070Glu|MET V1070E|MET Val1070Glu|MET p.V1070E|MET p.Val1070Glu|NP_000236.2:p.V1070E|NP_000236.2:p.Val1070Glu|NP_001120972.1:p.V1088E|NP_001120972.1:p.Val1088Glu|Proto-Oncogene c-Met V1070E|Proto-Oncogene c-Met Val1070Glu|Scatter Factor Receptor V1070E|Scatter Factor Receptor Val1070Glu|Tyrosine-Protein Kinase Met V1070E|Tyrosine-Protein Kinase Met Val1070Glu	A change in the amino acid residue at position 1070 in the hepatocyte growth factor receptor protein where valine has been replaced by glutamic acid.			Cell or Molecular Dysfunction	
C16229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16229>	C16084	Case Series|Case Series Study|case series	A collection of case reports involving patients with similar exposures or conditions that have undergone similar treatments.			Research Activity	SeroNet Authorized Values|SeroNet Study Descriptors
C1622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1622>	C67437|C1922	Epothilone A|EPOTHILONE A	An extract from the myxobacteria Sorangium cellulosum that promotes tubulin polymerization and microtubule stabilization, thereby inhibiting mitosis. Epothilone A appears to be less potent than Epothilone B. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C162300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162300>	C39788	MET NM_000245.3:c.1510G>C|HGFR c.1510G>C|MET Proto-Oncogene, Receptor Tyrosine Kinase c.1510G>C|Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) c.1510G>C|NM_000245.3:c.1510G>C|NM_001127500.2:c.1510G>C|c-Met c.1510G>C	A nucleotide substitution at position 1510 of the coding sequence of the MET gene where guanine has been mutated to cytosine.			Cell or Molecular Dysfunction	
C162301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162301>	C136286	MET NP_000236.2:p.V504L|C-MET V504L|C-MET Val504Leu|HGF Receptor V504L|HGF Receptor Val504Leu|HGFR V504L|HGFR Val504Leu|Hepatocyte Growth Factor Receptor V504L|Hepatocyte Growth Factor Receptor Val504Leu|MET NP_000236.2:p.Val504Leu|MET V504L|MET Val504Leu|MET p.V504L|MET p.Val504Leu|NP_000236.2:p.V504L|NP_000236.2:p.Val504Leu|NP_001120972.1:p.V504L|NP_001120972.1:p.Val504Leu|Proto-Oncogene c-Met V504L|Proto-Oncogene c-Met Val504Leu|Scatter Factor Receptor V504L|Scatter Factor Receptor Val504Leu|Tyrosine-Protein Kinase Met V504L|Tyrosine-Protein Kinase Met Val504Leu	A change in the amino acid residue at position 504 in the hepatocyte growth factor receptor protein where valine has been replaced by leucine.			Cell or Molecular Dysfunction	
C162302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162302>	C39788	MET NM_000245.3:c.1915A>C|HGFR c.1915A>C|MET Proto-Oncogene, Receptor Tyrosine Kinase c.1915A>C|Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) c.1915A>C|NM_000245.3:c.1915A>C|NM_001127500.2:c.1915A>C|c-Met c.1915A>C	A nucleotide substitution at position 1915 of the coding sequence of the MET gene where adenine has been mutated to cytosine.			Cell or Molecular Dysfunction	
C162303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162303>	C136286	MET NP_000236.2:p.I639L|C-MET I639L|C-MET Ile639Leu|HGF Receptor I639L|HGF Receptor Ile639Leu|HGFR I639L|HGFR Ile639Leu|Hepatocyte Growth Factor Receptor I639L|Hepatocyte Growth Factor Receptor Ile639Leu|MET I639L|MET Ile639Leu|MET NP_000236.2:p.Ile639Leu|MET p.I639L|MET p.Ile639Leu|NP_000236.2:p.I639L|NP_000236.2:p.Ile639Leu|NP_001120972.1:p.I639L|NP_001120972.1:p.Ile639Leu|Proto-Oncogene c-Met I639L|Proto-Oncogene c-Met Ile639Leu|Scatter Factor Receptor I639L|Scatter Factor Receptor Ile639Leu|Tyrosine-Protein Kinase Met I639L|Tyrosine-Protein Kinase Met Ile639Leu	A change in the amino acid residue at position 639 in the hepatocyte growth factor receptor protein where isoleucine has been replaced by leucine.			Cell or Molecular Dysfunction	
C162304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162304>	C4911|C27690	EBV-Related Gastric Carcinoma|EBV-Associated Gastric Carcinoma|EBVaGC|Epstein-Barr Virus-Associated Gastric Carcinoma|Epstein-Barr Virus-Related Gastric Carcinoma	A gastric carcinoma that is caused by Epstein-Barr virus infection.	EBV-Related Gastric Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162305>	C27707|C27689	EBV-Related Sarcoma|EBV-Associated Sarcoma|Epstein-Barr Virus-Associated Sarcoma|Epstein-Barr Virus-Related Sarcoma	Sarcoma that is caused by Epstein-Barr virus infection.			Neoplastic Process	
C162306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162306>	C3158|C162305	EBV-Related Leiomyosarcoma|EBV LMS|EBV-Associated Leiomyosarcoma|Epstein-Barr Virus-Associated Leiomyosarcoma|Epstein-Barr Virus-Related Leiomyosarcoma	Leiomyosarcoma that is caused by Epstein-Barr virus infection.	EBV-Related Leiomyosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162307>	C165233	MLH1 Negative|COCA2 Negative|DNA Mismatch Repair Protein Mlh1 Negative|HNPCC2 Negative|MutL Homolog 1 Negative	An indication that expression of MLH1 has not been detected in a sample.	MLH1 Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162308>	C165233	MSH2 Negative|COCA1 Negative|DNA Mismatch Repair Protein Msh2 Negative|HNPCC1 Negative|MutS Homolog 2 Negative	An indication that expression of MSH2 has not been detected in a sample.	MSH2 Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162309>	C165233	MSH6 Negative|DNA Mismatch Repair Protein Msh6 Negative|G/T Mismatch-Binding Protein Negative|GTBP Negative|GTMBP Negative|HNPCC5 Negative|MutS Homolog 6 Negative|Sperm-Associated Protein Negative	An indication that expression of MSH6 has not been detected in a sample.	MSH6 Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C16230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16230>	C15313	Extensive Radiation	Cancer therapy using ionizing radiation to a significant (>50%) portion of the body, e.g. craniospinal, total body irradiation, or pelvic radiation.			Therapeutic or Preventive Procedure	
C162310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162310>	C165233	PMS2 Negative|Mismatch Repair Endonuclease PMS2 Negative|PMS1 Homolog 2 Negative|PMS1 Homolog 2, Mismatch Repair System Component Negative|PMS2CL Negative|PMSL2 Negative|Postmeiotic Segregation Increased 2 Negative	An indication that expression of PMS2 has not been detected in a sample.	PMS2 Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162311>	C709	Inosinic Acid|2'-Inosine-5'-Monophosphate|5'-IMP|5'-Inosinate|5'-Inosine Monophosphate|5'-Inosinic Acid|Hypoxanthosine 5'-Monophosphate|IMP|Inosine 5'-Monophosphate|Inosine 5'-Phosphate|Inosine Monophosphate	A purine ribonucleotide with hypoxanthine as the base and one phosphate group attached to the sugar moiety. Inosinic acid and its salt forms are used as flavor enhancers in industrial food production. In vivo, inosinic acid is involved in purine metabolism and acts as an intermediate in the synthesis of adenine and guanine, which are precursors for the second messenger signaling molecules adenosine monophosphate (AMP) and guanosine monophosphate (GMP), respectively.	Inosinic Acid		Nucleic Acid, Nucleoside, or Nucleotide	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C162312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162312>	C42966	Urethral Ointment Dosage Form|Urethral ointment	Semi-solid preparation consisting of an ointment intended for urethral use by means of a suitable applicator.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Administrable Dose Form Terminology|EDQM-HC Pharmaceutical Dosage Form Terminology
C162313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162313>	C148275	Solution for Infusion in Cartridge Dosage Form|Solution for infusion in cartridge	Medicinal product consisting of a solution for infusion presented in a cartridge, intended to be used in a specially designed device such as an infusion pump.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C162314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162314>	C148268	Powder and Solution for Suspension for Injection Dosage Form|Powder and solution for suspension for injection	Sterile powder (including freeze-dried powder) and sterile solution, both of which contain active substance(s), intended for the preparation of a suspension for injection by dispersing the powder in the solution.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Pharmaceutical Dose Form Terminology
C162315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162315>	C148275	Nasal Powder in Single-Dose Container Dosage Form|Nasal powder in single-dose container	Medicinal product consisting of a nasal powder presented in a single-dose container, usually with an integral device to facilitate nasal administration.			Biomedical or Dental Material	EDQM Health Care Terminology|EDQM-HC Combined Term Terminology
C162316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162316>	C29934	Proton Multiple Quantum Coherence Magnetic Resonance Spectroscopic Imaging|1H MQC MRSI	A form of magnetic resonance spectroscopic imaging that increases the selectivity of a spectroscopic measurement by increasing the number of quantum states in a quantum mechanical superposition state, allowing for studies of complex systems.	Proton Multiple Quantum Coherence Magnetic Resonance Spectroscopic Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C162317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162317>	C47922	Ophthalmic Examinations External File Path|OEXFN	The literal identifier of an ophthalmic examination external file name.			Intellectual Product	
C162318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162318>	C82576	Urinary System Findings Time Point Reference|URTPTREF	The point in time that acts as a fixed reference point to a urinary system finding.			Temporal Concept	
C162319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162319>	C82438	Adverse Event Previous Occurrence|AEPRIOR	An indication or description that a particular adverse event happened in the past.			Conceptual Entity	
C16231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16231>	C15569	Myeloablative Chemotherapy|myeloablative chemotherapy	The administration of high-dose chemotherapy, with or without total body irradiation, to eradicate the underlying disease and/or ablate the immune system of the patient.			Therapeutic or Preventive Procedure	
C162320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162320>	C82438	Clinical Event Previous Occurrence|CEPRIOR	An indication or description that a particular disease response or clinical classification happened in the past.			Conceptual Entity	
C162321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162321>	C82438	Disease Response or Clinical Classification Previous Occurrence|RSPRIOR	An indication or description that a particular disease response or clinical classification was obtained in the past.			Conceptual Entity	
C162322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162322>	C82438	Functional Tests Previous Occurrence|FTPRIOR	An indication or description that a particular functional test happened in the past.			Conceptual Entity	
C162323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162323>	C82438	Healthcare Encounter Previous Occurrence|HOPRIOR	An indication or description that a particular healthcare encounter event happened in the past.			Conceptual Entity	
C162324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162324>	C82438	Microbiology Susceptibility Previous Occurrence|MSPRIOR	An indication or description that a particular microbiology susceptibility event happened in the past.			Conceptual Entity	
C162325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162325>	C82438	Agent Previous Occurrence|AGPRIOR	An indication or description that a particular agent administration event happened in the past.			Conceptual Entity	
C162326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162326>	C82438	Substance Use Previous Occurrence|SUPRIOR	An indication or description that a particular substance use event happened in the past.			Conceptual Entity	
C162327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162327>	C82438	Disease Response or Clinical Classification Ongoing|RSONGO	An indication or description that assessment of disease response or clinical classification of the disease is continuing.			Conceptual Entity	
C162328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162328>	C82438	Ongoing Microbiology Susceptibility|MSONGO|Microbiology Susceptibility Ongoing	An indication or description that a microbiology susceptibility assessment is continuing.			Conceptual Entity	
C162329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162329>	C82438	Ongoing Procedure Agents|AGONGO|Procedure Agents Ongoing	An indication or description that a procedure agent administration is continuing.			Conceptual Entity	
C16232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16232>	C15727	Expression Library				Manufactured Object	
C162330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162330>	C82438	Ongoing Substance Use|SUONGO|Substance Use Ongoing	An indication or description that substance usage is continuing.			Conceptual Entity	
C162331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162331>	C41202	Functional Tests Completion Status|FTSTAT	A term used to describe the state or condition of the completeness of the functional test data.			Functional Concept	
C162332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162332>	C41202	Meal Data Completion Status|MLSTAT	A term used to describe the state or condition of the completeness of the meal data.			Functional Concept	
C162333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162333>	C41202	Musculoskeletal Findings, Connective and Soft Tissue Findings Completion Status|MKSTAT	A term used to describe the state or condition of the completeness of the musculoskeletal system findings data.			Functional Concept	
C162334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162334>	C41202	Nervous System Findings Completion Status|NVSTAT	A term used to describe the state or condition of the completeness of the nervous system findings data.			Functional Concept	
C162335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162335>	C41202	Ophthalmic Examinations Completion Status|OESTAT	A term used to describe the state or condition of the completeness of the ophthalmic examination data.			Functional Concept	
C162336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162336>	C41202	Procedure Agents Completion Status|AGSTAT	A term used to describe the state or condition of the completeness of the procedure agent administration data.			Functional Concept	
C162337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162337>	C41202	Substance Use Completion Status|SUSTAT	A term used to describe the state or condition of the completeness of the substance use data.			Functional Concept	
C162338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162338>	C41202	Urinary System Findings Completion Status|URSTAT	A term used to describe the state or condition of the completeness of the urinary system findings data.			Functional Concept	
C162339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162339>	C212990	Src Kinase Inhibitor M475271|4-Quinazolinamine, N-(2-chloro-5-methoxyphenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-|AZM 475271|AZM-475271|AZM475271|M 475271|M-475271|M-475271|M475271|N-(2-Chloro-5-methoxyphenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine	An inhibitor of Src tyrosine kinase, with potential antineoplastic activity. Upon administration, Src kinase inhibitor M-475271 targets and binds to Src kinase. This inhibits Src-mediated signaling and the proliferation of tumor cells overexpressing Src. Src tyrosine kinase, a non-receptor tyrosine kinase upregulated in many tumor cell types, plays an important role in tumor cell proliferation, motility, invasiveness and survival.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C16233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16233>	C15824	Nutrition Research, Macronutrients|Macronutrients	The study of the role of macronutrients in cancer causation or prevention and in general health.			Research Activity	
C162340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162340>	C200712	Berbamine Dihydrochloride|16H-1,24:6,9-Dietheno-11,15-metheno-2H-pyrido(2',3':17,18)(1,11)dioxacycloeicosino(2,3,4-ij)isoquinolin-12-ol, 3,4,4a,5,16a,17,18,19-Octahydro-21,22,26-trimethoxy-4,17-dimethyl-, Hydrochloride (1:2), (4aS,16aR)-|BERBAMINE DIHYDROCHLORIDE|Berbaman-12-ol, 6,6',7-trimethoxy-2,2'-dimethyl-, Dihydrochloride				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C162341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162341>	C200712	Berbamine|6,6',7-Trimethoxy-2,2'-dimethylberbaman-12-ol|BERBAMINE|BRN 0078902|Berbaman-12-ol, 6,6',7-Trimethoxy-2,2'-dimethyl- (9CI)|CCRIS 6538|d-Berbamine				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C162342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162342>	C155727	FGFR4 Inhibitor BLU 9931|2-Propenamide, N-(2-((6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl)amino)-3-methylphenyl)-|BLU 9931|BLU-9931|BLU-9931|BLU9931|N-(2-((6-(2,6-Dichloro-3,5-dimethoxyphenyl)-2-quinazolinyl)amino)-3-methylphenyl)-2-propenamide	An orally bioavailable, selective inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon oral administration, FGFR4 antagonist BLU 9931 specifically and irreversibly binds to the cysteine residue at position 552 (Cys 552) that is within the active site of FGFR4. This blocks FGFR4 autophosphorylation and activation of receptor tyrosine kinase activity that would normally occur after binding to its ligand, fibroblast growth factor 19 (FGF19), which both inhibits FGFR4-mediated signaling and leads to an inhibition of tumor cell proliferation in FGF19- and FGFR4-overexpressing cells. FGFR4, a receptor tyrosine kinase, is involved in angiogenesis and in the proliferation, differentiation, and survival of tumor cells. FGFR4 expression is associated with poor prognosis. FGF19 is overexpressed by certain tumor cell types.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C162343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162343>	C25974	Vascular Disrupting Agent BNC105|2-Methyl-7-hydroxy-3-(3,4,5-trimethoxybenzoyl)-6-methoxybenzofuran|BNC 105|BNC-105|BNC-105|BNC105	A vascular disrupting agent (VDA), with potential anti-vascular and antineoplastic activities. Upon administration, vascular disrupting agent BNC105 binds to tubulin and inhibits its polymerization, which results in a blockage of mitotic spindle formation, cell cycle arrest, and disruption of the tumor vasculature. This deprives tumor cells of nutrients and results in tumor cell apoptosis. In addition to its VDA activity, this agent has a direct cytotoxic effect on tumor cells by inhibiting tubulin polymerization.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C162344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162344>	C67421	Combretastatin A-1|1,2-Benzenediol, 3-Methoxy-6-(2-(3,4,5-trimethoxyphenyl)ethenyl)-, (Z)-|CA1|COMBRETASTATIN A-1|Combretastatin A1	A stilbenoid originally isolated from the plant Combretum caffrum, with vascular-disrupting and antineoplastic activities. Upon administration, combretastatin A1 (CA1) promotes rapid microtubule depolymerization; endothelial cell mitotic arrest and apoptosis; destruction of the tumor vasculature; disruption of tumor blood flow; and tumor cell necrosis. In addition, orthoquinone intermediates, metabolized from combretastatin A1 by oxidative enzymes found to be elevated in some tumor types, may bind to tumor cell thiol-specific antioxidant proteins and DNA, and stimulate oxidative stress by enhancing superoxide/hydrogen peroxide production.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C162345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162345>	C2196	TRPM8 Agonist D-3263|D 3263|D-3263|D-3263|D3263	A small-molecule agonist for transient receptor potential melastatin member 8 (TRPM8 or Trp-p8), with potential antineoplastic activity. Upon administration, TRPM8 agonist D-3263 targets, binds to and activates TRPM8, which may result in an increase in intracellular calcium and sodium influx; the disruption of calcium and sodium homeostasis; and the induction of cell death in TRPM8-expressing tumor cells. This agent may decrease dihydrotestosterone (DHT) levels, which may contribute to its inhibitory effects on prostate cancer and benign prostatic hyperplasia (BPH). TRPM8 is a transmembrane calcium channel protein that is normally expressed in prostate cells and appears to be overexpressed in BPH and in prostate cancer.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C162346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162346>	C2201|C2152|C129825	Dactolisib Tosylate|2-Methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo(4,5-c)quinolin-1-yl)phenyl)propanenitrile 4-Methylbenzenesulfonate|Benzeneacetonitrile, 4-(2,3-Dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-, 4-Methylbenzenesulfonate (1:1)|DACTOLISIB TOSYLATE|NVP-BEZ235-ANA|NVP-BEZ235-NX	The tosylate salt form of dactolisib, an orally bioavailable imidazoquinoline targeting the phosphatidylinositol 3 kinase (PI3K) and the mammalian target of rapamycin (mTOR), with potential antineoplastic activity. Upon administration, dactolisib inhibits PI3K kinase and mTOR kinase in the PI3K/AKT/mTOR kinase signaling pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K/mTOR-overexpressing tumor cells. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy. mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C162347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162347>	C20401|C129822	Detumomab|DETUMOMAB|Immunoglobulin G1, Anti-(Human B Lymphoma Cell) (Mouse Monoclonal SPECIFID Heavy Chain), Disulfide with Mouse Monoclonal SPECIFID Light Chain, Dimer	A recombinant mouse immunoglobulin G1 (IgG1) monoclonal antibody directed against an undisclosed B-cell lymphoma tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, detumomab targets and binds to a TAA expressed on B-cell lymphoma cells. This prevents TAA-mediated signaling and kills the tumor cells.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C162348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162348>	C2843	Exatecan Mesylate Anhydrous|10H,13H-Benzo(de)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-10,13-dione, 1-Amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-, (1S,9S)-, Methanesulfonate (1:1)|EXATECAN MESYLATE ANHYDROUS	The anhydrous, mesylate salt form of exatecan, a semisynthetic, water-soluble derivative of camptothecin, with antineoplastic activity. Upon administration, exatecan mesylate inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA and inhibiting re-ligation of DNA breaks, thereby inhibiting DNA replication and triggering apoptotic cell death.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C162349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162349>	C82532	Ophthalmic Examinations Normal or Reference Range Indicator|OENRIND	A indication that ophthalmic examination data is outside the normal or reference range.			Intellectual Product	
C16234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16234>	C92722	Clinical Test Method Sensitivity	How well a clinical test performs when applied to patients with the disease or condition in question.			Qualitative Concept	
C162350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162350>	C82532	Microbiology Susceptibility Normal or Reference Range Indicator|MSNRIND	A indication that microbiology susceptibility data is outside the normal or reference range.			Intellectual Product	
C162351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162351>	C70713	Microbiology Susceptibility Specimen Type|MSSPEC	The type of material sample used for microbiology susceptibility testing.			Qualitative Concept	
C162352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162352>	C70713	Urinary System Findings Specimen Type|URSPEC	The type of material sample used for urinary system testing.			Qualitative Concept	
C162353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162353>	C25180	Procedure Agent Yes No Indicator|AGYN	An indication of whether procedure agent usage has occurred.			Conceptual Entity	
C162354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162354>	C67375	Microbiology Susceptibility Agent Concentration Unit|MSCONCU	The unit of measure related to the microbiology susceptibility agent concentration.			Quantitative Concept	
C162355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162355>	C63496	Dexamethasone/Selinexor Regimen|Dexamethasone-Selinexor|Dexamethasone/Selinexor|Dexamethasone/Xpovio|Selinexor and Dexamethasone (Sd)|Selinexor-Dexamethasone|Selinexor/Dexamethasone|Selinexor/Dexamethasone Regimen|Xpovio/Dexamethasone	A regimen consisting of dexamethasone and selinexor that may be used for the treatment of relapsed or refractory multiple myeloma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C162356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162356>	C21295	IQCK Gene|IQ Motif Containing K Gene|IQCK|IQCK	This gene is involved in binding to EF-hand domain-containing proteins.			Gene or Genome	
C162357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162357>	C162356	IQCK wt Allele|FLJ36575|IQ Motif Containing K wt Allele|MGC35048	Human IQCK wild-type allele is located in the vicinity of 16p12.3 and is approximately 142 kb in length. This allele, which encodes IQ domain-containing protein K, plays a role in protein-protein interactions.			Gene or Genome	
C162358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162358>	C17728	IQ Domain-Containing Protein K|IQCK	IQ domain-containing protein K (287 aa, ~33 kDa) is encoded by the human IQCK gene. This protein is involved in binding to EF-hand proteins.			Amino Acid, Peptide, or Protein	
C162359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162359>	C25941	ECHDC3 Gene|ECHDC3|ECHDC3|Enoyl-CoA Hydratase Domain Containing 3 Gene	This gene may play a role in fatty acid metabolism.			Gene or Genome	
C16235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16235>	C16214	Ames Assay	An in vivo assay test used to determine if an agent, such as a chemical, is capable of causing mutations in living organisms, and if so, the strength of its mutagenic activity. The procedure uses animal tissue to create active metabolites of the substance which are then tested on bacteria.			Laboratory Procedure	
C162360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162360>	C162359	ECHDC3 wt Allele|Enoyl-CoA Hydratase Domain Containing 3 wt Allele|FLJ20909|PP1494|PP8332	Human ECHDC3 wild-type allele is located in the vicinity of 10p14 and is approximately 22 kb in length. This allele, which encodes enoyl-CoA hydratase domain-containing protein 3, mitochondrial, may be involved in fatty acid biosynthesis.			Gene or Genome	
C162361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162361>	C16759	Enoyl-CoA Hydratase Domain-Containing Protein 3, Mitochondrial|ECHDC3|Enoyl Coenzyme A Hydratase Domain Containing 3|Testis Tissue Sperm-Binding Protein Li 76m	Enoyl-CoA hydratase domain-containing protein 3, mitochondrial (303 aa, ~33 kDa) is encoded by the human ECHDC3 gene. This protein may play a role in the metabolism of fatty acids.			Amino Acid, Peptide, or Protein|Enzyme	
C162362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162362>	C28533	SLC24A4 Gene|SLC24A4|SLC24A4|Solute Carrier Family 24 Member 4 Gene	This gene is involved in ion transport, hair and eye pigmentation and olfaction.			Gene or Genome	
C162363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162363>	C162362	SLC24A4 wt Allele|AI2A5|NCKX4|SHEP6|SLC24A2|Solute Carrier Family 24 (Sodium/Potassium/Calcium Exchanger), Member 4 Gene|Solute Carrier Family 24 Member 4 wt Allele	Human SLC24A4 wild-type allele is located in the vicinity of 14q32.12 and is approximately 179 kb in length. This allele, which encodes sodium/potassium/calcium exchanger 4 protein, plays a role in ion antiporter activity. Mutation of the gene is associated with hypomaturation type IIA5 amelogenesis imperfecta.			Gene or Genome	
C162364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162364>	C16386	Sodium/Potassium/Calcium Exchanger 4|Na(+)/K(+)/Ca(2+)-Exchange Protein 4|SLC24A4|Solute Carrier Family 24 Member 4	Sodium/potassium/calcium exchanger 4 (622 aa, ~69 kDa) is encoded by the human SLC24A4 gene. This protein is involved in sodium ion-dependent calcium and potassium transport.			Amino Acid, Peptide, or Protein	
C162365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162365>	C28533|C158414	ABCA7 Gene|ABCA7|ABCA7|ATP Binding Cassette Subfamily A Member 7 Gene	This gene plays a role in both lipid homeostasis and macrophage-mediated phagocytosis.			Gene or Genome	
C162366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162366>	C162365	ABCA7 wt Allele|ABCA-SSN|ABCX|AD9|ATP Binding Cassette Subfamily A Member 7 wt Allele|ATP-Binding Cassette, Sub-Family A (ABC1), Member 7 Gene|ATP-Binding Cassette, Subfamily A, Member 7 Gene	Human ABCA7 wild-type allele is located in the vicinity of 19p13.3 and is approximately 25 kb in length. This allele, which encodes phospholipid-transporting ATPase ABCA7 protein, is involved in phagocytosis of apoptotic cells by macrophages and lipid transport. Deletion and nonsense mutations in the gene are associated with susceptibility to Alzheimer disease type 9.			Gene or Genome	
C162367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162367>	C17750|C158419	Phospholipid-Transporting ATPase ABCA7|ABCA-SSN|ABCA7|ATP Binding Cassette Subfamily A Member 7|ATP-Binding Cassette Sub-Family A Member 7|Autoantigen SS-N|EC 7.6.2.1|Macrophage ABC Transporter|Sjogren Syndrome Antigen SS-N|Sjögren Syndrome Antigen SS-N	Phospholipid-transporting ATPase ABCA7 (2146 aa, ~234 kDa) is encoded by the human ABCA7 gene. This protein plays a role in both macrophage-mediated phagocytosis and lipid transport.			Amino Acid, Peptide, or Protein|Enzyme	
C162368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162368>	C217122	Fagotti Score	A laparoscopy-based score to predict the chances of optimal cytoreductive surgery in advanced ovarian cancer patients. It consists of seven criteria (omental cake, peritoneal carcinosis, diaphragmatic carcinosis, mesenteric retraction, bowel infiltration, stomach infiltration, and liver metastases), each assigned a predictive index value of 0-2. The total Fagotti score ranges from 0-14.			Intellectual Product	
C162369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162369>	C25997	CASS4 Gene|CASS4|CASS4|Cas Scaffold Protein Family Member 4 Gene	This gene is involved in the modulation of tyrosine kinase-dependent signaling.			Gene or Genome	
C16236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16236>	C15187	Antisense Therapy|Antisense|Antisense Oligonucleotide Therapy|antisense oligonucleotide therapy|antisense therapy	Treatment using nucleic acid oligomers to bind to specific mRNA to deter protein production and alter disease process.	Antisense Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C162370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162370>	C162369	CASS4 wt Allele|C20orf32|CAS4|Cas Scaffold Protein Family Member 4 wt Allele|Chromosome 20 Open Reading Frame 32 Gene|HEFL|HEPL	Human CASS4 wild-type allele is located in the vicinity of 20q13.31 and is approximately 49 kb in length. This allele, which encodes Cas scaffolding protein family member 4 protein, plays a role in cell signaling, cellular adhesion and cell spreading.			Gene or Genome	
C162371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162371>	C26231	Cas Scaffolding Protein Family Member 4|CASS4|HEF-Like Protein|HEF1-, EFS-, and p130Cas-Like Protein|HEF1-EFS-p130Cas-Like Protein|HEPL	Cas scaffolding protein family member 4 (786 aa, ~87 kDa) is encoded by the human CASS4 gene. This protein is involved in the positive regulation of tyrosine kinase-mediated signaling.			Amino Acid, Peptide, or Protein	
C162372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162372>	C20420	GRHL2 Gene|GRHL2|GRHL2|Grainyhead Like Transcription Factor 2 Gene	This gene plays a role in embyronic brain development and in epithelial development and maintenance.			Gene or Genome	
C162373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162373>	C162372	GRHL2 wt Allele|AA404325|AA834945|AI224578|BF675485|BOM|DFNA28|Deafness, Autosomal Dominant 28 Gene|ECTDS|FLJ13782|FLJ38245|Grainyhead Like Transcription Factor 2 wt Allele|Grainyhead, Drosophila, Homolog of, 2 Gene|Grainyhead-Like 2 (Drosophila) Gene|Grainyhead-Like 2 Gene|PPCD4|TFCP2L3	Human GRHL2 wild-type allele is located in the vicinity of 8q22.3 and is approximately 186 kb in length. This allele, which encodes grainyhead-like protein 2 homolog protein, is involved in development and maintenance of epithelial tissues and neurulation. Mutation of the gene is associated with non-syndromic sensorineural deafness autosomal dominant type 28.			Gene or Genome	
C162374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162374>	C17207	Grainyhead-Like Protein 2 Homolog|Brother of Mammalian Grainyhead|Brother-of-MGR|GRHL2|Grainyhead-Like 2|Transcription Factor CP2-Like 3	Grainyhead-like protein 2 homolog (625 aa, ~71 kDa) is encoded by the human GRHL2 gene. This protein plays a role in neurulation and the morphogenesis and maintenance of epithelially derived tissues.			Amino Acid, Peptide, or Protein	
C162375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162375>	C177899	Plogosertib|CYC 140|CYC-140|CYC140|PLK-1 Inhibitor CYC140|PLK1 Inhibitor CYC140|PLOGOSERTIB|Polo-like Kinase 1 Inhibitor CYC140	A competitive inhibitor for adenosine triphosphate (ATP) binding to polo-like kinase 1 (PLK1; PLK-1; STPK13), with potential antineoplastic activity. Upon administration, plogosertib selectively targets, binds to and inhibits PLK1, which disrupts mitosis and induces selective G2/M cell-cycle arrest followed by apoptosis in PLK1-overexpressing tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase that is crucial for the regulation of mitosis, and plays a key role in tumor cell proliferation, transformation and invasion. PLK1 expression is upregulated in a variety of tumor cell types and high expression is associated with increased aggressiveness and poor prognosis.	Plogosertib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162376>	C20103	CLEC12A Gene|C-Type Lectin Domain Family 12 Member A Gene|CLEC12A|CLEC12A	This gene is involved in carbohydrate binding, signal transduction and the negative regulation of macrophage/granulocyte functions.	CLEC12A Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C162377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162377>	C162376	CLEC12A wt Allele|C-Type Lectin Domain Family 12 Member A wt Allele|C-Type Lectin Domain Family 12, Member A Gene|CD371|CLL-1|CLL1|DCAL-2|MICL	Human CLEC12A wild-type allele is located in the vicinity of 12p13.31 and is approximately 48 kb in length. This allele, which encodes C-type lectin domain family 12 member A protein, plays a role in carbohydrate binding, cell signaling and the inhibition of myeloid cell functions.	CLEC12A wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162378>	C18106	C-Type Lectin Domain Family 12 Member A|C-Type Lectin Protein CLL-1|C-Type Lectin-Like Molecule 1|C-Type Lectin-Like Molecule-1|CD371|CD371 Antigen|CLEC12A|CLL-1|CLL1|DCAL-2|Dendritic Cell-Associated Lectin 2|MICL|Myeloid Inhibitory C-Type Lectin-Like Receptor	C-type lectin domain family 12 member A (265 aa, ~31 kDa) is encoded by the human CLEC12A gene. This protein is involved in carbohydrate binding and signal transduction.	C-Type Lectin Domain Family 12 Member A		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162379>	C25939	TET3 Gene|TET3|TET3|Tet Methylcytosine Dioxygenase 3 Gene	This gene plays a role in epigenetic oxygenation of modified deoxycytosines in DNA strands.			Gene or Genome	
C16237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16237>	C15791	Validation|validation|validity	The act of validating; finding or testing the truth of something.			Research Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C162380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162380>	C162379	TET3 wt Allele|KIAA0401|MGC22014|Tet Methylcytosine Dioxygenase 3 wt Allele|Tet Oncogene Family Member 3 Gene|hCG_40738	Human TET3 wild-type allele is located in the vicinity of 2p13.1 and is approximately 125 kb in length. This allele, which encodes methylcytosine dioxygenase TET3 protein, is involved in DNA demethylation.			Gene or Genome	
C162381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162381>	C28459	Methylcytosine Dioxygenase TET3|EC 1.14.11.80|EC 1.14.11.n2|TET3|Tet Oncogene Family Member 3	Methylcytosine dioxygenase TET3 (1660 aa, ~179 kDa) is encoded by the human TET3 gene. This protein plays a role in oxidative demethylation of DNA.			Amino Acid, Peptide, or Protein|Enzyme	
C162382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162382>	C80699	MIR30C1 Gene|MIR30C1|MIR30C1|MicroRNA 30c-1 Gene	This gene may be involved in the modulation of gene expression during wound healing and angiogenesis.			Gene or Genome	
C162383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162383>	C80699	MIR30C2 Gene|MIR30C2|MIR30C2|MicroRNA 30c-2 Gene	This gene may play a role in wound healing and angiogenesis.			Gene or Genome	
C162384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162384>	C162382	MIR30C1 wt Allele|MIRN30C1|Micro RNA 30c-1 Gene|MicroRNA 30c-1 wt Allele|hsa-mir-30c-1|miRNA30C1|mir-30c-1	Human MIR30C1 wild-type allele is located in the vicinity of 1p34.2 and is approximately 89 bases in length. This allele, which encodes MIR30C1 pre-miRNA, plays a role in the modulation of gene expression.			Gene or Genome	
C162385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162385>	C162383	MIR30C2 wt Allele|MIRN30C2|Micro RNA 30c-2 Gene|MicroRNA 30c-2 wt Allele|hsa-mir-30c-2|miR-30c|miRNA30C2|mir-30c-2	Human MIR30C2 wild-type allele is located in the vicinity of 6q13 and is approximately 72 bases in length. This allele, which encodes MIR30C2 pre-miRNA, may be involved in wound healing and angiogenesis.			Gene or Genome	
C162386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162386>	C25968	MIR30C1 Pre-miRNA|Pre-MIR30C1|Pre-MicroRNA 30C1|Pre-miRNA 30C1|Pre-miRNA MIR30C1|Pre-miRNA30C1	MIR30C1 pre-miRNA (89 bases) is encoded by the human MIR30C1 gene. This ribonucleotide may be involved in the regulation of target gene transcription.			Nucleic Acid, Nucleoside, or Nucleotide	
C162387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162387>	C25968	MIR30C2 Pre-miRNA|Pre-MIR30C2|Pre-MicroRNA 30C2|Pre-miRNA 30C2|Pre-miRNA MIR30C2|Pre-miRNA30C2	MIR30C2 pre-miRNA (72 bases) is encoded by the human MIR30C2 gene. This ribonucleotide may be involved in the modulation of gene expression during wound healing and angiogenesis.			Nucleic Acid, Nucleoside, or Nucleotide	
C162388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162388>	C25966	MicroRNA 30c|MIR30C|MIRN30c|hsa-miR-30c|hsa-miR-30c-5p|hsa-mir-30c-1-5p|hsa-mir-30c-2-5p|miR-30c|miR30c|miRNA 30c|miRNA-30c|miRNA30c	A 23 ribonucleotide sequence that is a final product of the processing of either MIR30C1 pre-miRNA or MIR30C2 pre-miRNA. This oligonucleotide may be involved in the regulation of gene expression, and its expression is associated with decreased angiogenesis.			Nucleic Acid, Nucleoside, or Nucleotide	
C162389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162389>	C20420	KLF2 Gene|KLF2|KLF2|Kruppel-Like Factor 2 Gene	This gene is involved in the promotion of target gene expression.			Gene or Genome	
C16238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16238>	C25712	Predictive Value	An expression of the likelihood that a given test result correlates with the presence or absence of disease.			Qualitative Concept	
C162390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162390>	C162389	KLF2 wt Allele|Kruppel Like Factor 2 wt Allele|Kruppel-Like Factor 2 (Lung) Gene|LKLF|Lung Kruppel-Like Factor Gene	Human KLF2 wild-type allele is located in the vicinity of 19p13.11 and is approximately 3 kb in length. This allele, which encodes krueppel-like factor 2 protein, plays a role in endothelial cell proliferation and T-cell quiescence. A fusion involving this gene and the DDX5 gene may be associated with childhood B acute lymphoblastic leukemia (B-ALL).			Gene or Genome	
C162391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162391>	C17207	Krueppel-Like Factor 2|KLF2|Kruppel Like Factor 2|Kruppel-Like Factor LKLF|Lung Krueppel-Like Factor|Lung Kruppel-Like Factor|Lung Kruppel-Like Zinc Finger Transcription Factor	Krueppel-like factor 2 (355 aa, ~37 kDa) is encoded by the human KLF2 gene. This protein is involved in the positive regulation of gene expression.			Amino Acid, Peptide, or Protein	
C162392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162392>	C20420	KLF3 Gene|KLF3|KLF3|Kruppel-Like Factor 3 Gene	This gene plays a role in the regulation of erythroid-specific gene expression.			Gene or Genome	
C162393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162393>	C162392	KLF3 wt Allele|BKLF|Basic Kruppel Like Factor Gene|Basic Kruppel-Like Factor Gene|Kruppel Like Factor 3 wt Allele|Kruppel-Like Factor 3 (Basic) Gene|Transcript Ch138	Human KLF3 wild-type allele is located in the vicinity of 4p14 and is approximately 37 kb in length. This allele, which encodes krueppel-like factor 3 protein, is involved in the modulation of gene expression in erythrocytes.			Gene or Genome	
C162394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162394>	C17207	Krueppel-Like Factor 3|Basic Krueppel-Like Factor|Basic Kruppel Like Factor|Basic Kruppel-Like Factor|CACCC-Box-Binding Protein BKLF|KLF3|Kruppel Like Factor 3|TEF-2	Krueppel-like factor 3 (345 aa, ~39 kDa) is encoded by the human KLF3 gene. This protein plays a role in gene expression in erythrocytes.			Amino Acid, Peptide, or Protein	
C162395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162395>	C175689	TP53 NM_000546.5:c.542G>A|LFS1 c.542G>A|Li-Fraumeni Syndrome c.542G>A|NM_000546.5:c.542G>A|P53 c.542G>A|TP53 c.542G>A|Tumor Protein p53 c.542G>A	A nucleotide substitution at position 542 of the coding sequence of the TP53 gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C162396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162396>	C146884	TP53 NP_000537.3:p.R181H|Antigen NY-CO-13 Arg181His|Antigen NY-CO-13 R181H|Cellular Tumor Antigen p53 Arg181His|Cellular Tumor Antigen p53 R181H|NP_000537.3:p.Arg181His|NP_000537.3:p.R181H|TP53 Arg181His|TP53 NP_000537.3:p.Arg181His|TP53 R181H|TP53 p.Arg181His|TP53 p.R181H|Transformation-Related Protein 53 Arg181His|Transformation-Related Protein 53 R181H|Tumor Protein p53 Arg181His|Tumor Protein p53 R181H|Tumor Suppressor p53 Arg181His|Tumor Suppressor p53 R181H	A change in the amino acid residue at position 181 in the cellular tumor antigen p53 protein where arginine has been replaced by histidine.			Cell or Molecular Dysfunction	
C162398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162398>	C84733	Glycogen Storage Disease Type Ia|GSD1A|Glucose-6 Phosphatase Deficiency|Hepatorenal Glycogenosis|Von Gierke Disease	An autosomal recessive condition caused by mutation(s) in the G6PC gene, encoding glucose-6-phosphatase. It is characterized by accumulation of glycogen in the kidneys and liver resulting in  hypoglycemia, hyperlipidemia, and hyperuricemia. Adults may have a high incidence of hepatic adenomas.			Disease or Syndrome	Cellosaurus Disease Terminology
C162399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162399>	C35194	Cone-Rod Dystrophy 2|CORD2|CRD2	An inherited condition caused by mutations in the CRX gene, encoding cone-rod homeobox protein. It is characterized by loss of visual acuity in early childhood or late adolescence, impaired color vision, loss of peripheral vision, and nyctalopia. The severity of symptoms may vary.			Disease or Syndrome	Cellosaurus Disease Terminology
C16239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16239>	C18507	Oncogene ErbB2|HER -2|HER-2/NEU|Oncogene, C-Erb -2|Oncogene, C-ErbB-2|Oncogene, ERBB2|Oncogene, NEU	Human Oncogene ErbB2 is a mutated variant of ERBB2 Gene, which encodes ERRB2 Receptor Protein Tyrosine Kinase, a 185-kDa type I membrane glycoprotein similar to EGFR that controls cell growth. Ligand binding increases ERBB2 tyrosine phosphorylation. A heterodimer with ERBB3 and ERBB4, p185ERBB2 is an essential component of the heregulin/neuregulin receptor. ERBB2 forms an IL6-dependent complex with IL6R gp130, resulting in ERBB2 tyrosine phosphorylation and MAPK activation. Oncogene ERBB2 disrupts normal cell function.			Gene or Genome	
C1623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1623>	C67437|C1922	Patupilone|(-)-Epothilone B|(1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione|(1S,3S,7S,10R,11S,12S,16R)-7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione|EPO-906A|EPO906|Epothilone B|PATUPILONE|epothilone B	A compound isolated from the myxobacterium Sorangium cellulosum.  Similar to paclitaxel, patupilone induces microtubule polymerization and stabilizes microtubules against depolymerization conditions.  In addition to promoting tubulin polymerization and stabilization of microtubules, this agent is cytotoxic for cells overexpressing P-glycoprotein, a characteristic that distinguishes it from the taxanes.  Patupilone may cause complete cell-cycle arrest.	Patupilone		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162400>	C21295	KHDRBS3 Gene|KH RNA Binding Domain Containing, Signal Transduction Associated 3 Gene|KHDRBS3|KHDRBS3	This gene is involved in exon exclusion.			Gene or Genome	
C162401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162401>	C162400	KHDRBS3 wt Allele|Etle|KH Domain Containing, RNA Binding, Signal Transduction Associated 3 Gene|KH RNA Binding Domain Containing, Signal Transduction Associated 3 wt Allele|SALP|SLM-2|SLM2|Sam68-Like Phosphotyrosine Protein, T-STAR Gene|T-STAR|TSTAR|etoile	Human KHDRBS3 wild-type allele is located in the vicinity of 8q24.23 and is approximately 199 kb in length. This allele, which encodes KH domain-containing, RNA-binding, signal transduction-associated protein 3, plays a role in the regulation of alternative splicing. A fusion involving this gene and the ANGPT1 gene may be associated with acute myeloid leukemia.			Gene or Genome	
C162402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162402>	C21298	KH Domain-Containing, RNA-Binding, Signal Transduction-Associated Protein 3|KHDRBS3|RNA-Binding Protein T-Star|SLM-2|Sam68-Like Mammalian Protein 2|Sam68-Like Phosphotyrosine Protein	KH domain-containing, RNA-binding, signal transduction-associated protein 3 (346 aa, ~39 kDa) is encoded by the human KHDRBS3 gene. This protein is involved in the alternative splicing of RNA.			Amino Acid, Peptide, or Protein	
C162403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162403>	C38534	CREM Gene|CREM|CREM|cAMP Responsive Element Modulator Gene	This gene plays a role in the regulation of cAMP response element (CRE)-dependent gene transcription.			Gene or Genome	
C162404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162404>	C162403	CREM wt Allele|CREM-2|ICER|cAMP Responsive Element Modulator wt Allele|hCREM-2	Human CREM wild-type allele is located in the vicinity of 10p11.21 and is approximately 86 kb in length. This allele, which encodes cAMP-responsive element modulator protein, is involved in the modulation of gene transcription. A fusion involving this gene and either the EWSR1 gene or the FUS gene may be associated with epithelial tumors.			Gene or Genome	
C162405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162405>	C17286	cAMP-Responsive Element Modulator|CREM|ICER|Inducible cAMP Early Repressor|Inducible cAMP Early Repressor ICER|cAMP Response Element Modulator	cAMP-responsive element modulator (345 aa, ~37 kDa) is encoded by the human CREM gene. This protein plays a role in the regulation of gene expression.			Amino Acid, Peptide, or Protein	
C162406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162406>	C20194	TMEFF2 Gene|TMEFF2|TMEFF2|Transmembrane Protein with EGF Like and Two Follistatin Like Domains 2 Gene	This gene may play a role in promoting cell survival.			Gene or Genome	
C162407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162407>	C162406	TMEFF2 wt Allele|CT120.2|Cancer/Testis Antigen Family 120, Member 2 Gene|HPP1|Hyperplastic Polyposis Gene 1|TENB2|TPEF|TR|TR-2|Transmembrane Protein with EGF Like and Two Follistatin Like Domains 2 wt Allele|UNQ178/PRO204	Human TMEFF2 wild-type allele is located in the vicinity of 2q32.3 and is approximately 247 kb in length. This allele, which encodes tomoregulin-2 protein, may be involved in neuronal cell survival.			Gene or Genome	
C162408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162408>	C18466	Tomoregulin-2|Hyperplastic Polyposis Protein 1|TMEFF2|TR-2|Tomoregulin|Transmembrane Protein TENB2|Transmembrane Protein with EGF-Like and 2 Follistatin-Like Domains 2|Transmembrane Protein with EGF-Like and Two Follistatin-Like Domains|Transmembrane Protein with EGF-Like and Two Follistatin-Like Domains 2	Tomoregulin-2 (374 aa, ~41 kDa) is encoded by the human TMEFF2 gene. This protein may play a role in the positive regulation of cell growth and cell survival.			Amino Acid, Peptide, or Protein	
C162409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162409>	C25943	ASNS Gene|ASNS|ASNS|Asparagine Synthetase (Glutamine-Hydrolyzing) Gene	This gene is involved in amino acid synthesis.	ASNS Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|Pediatric Oncology Biomarkers/Targets Associated with Other Relevant Evidence
C16240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16240>	C18344	Oncogene CSF1R|Oncogene FMS	Human colony stimulating factor 1 receptor (CSF1R) gene, located at 5q33.2-q33.3, encodes macrophage colony stimulating factor I receptor protein. Mutations in this gene have been detected in both chronic myelomonocytic leukemia and type M4 acute myeloblastic leukemia. One out of fifty hematologically normal individuals exhibit a CSFR1 variant allele (Y969C) that may cause a predisposition to myeloid malignancy.			Gene or Genome	
C162410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162410>	C162409	ASNS wt Allele|ASNSD|Asparagine Synthetase (Glutamine-Hydrolyzing) wt Allele|Human Complement for Hamster Temperature-Sensitive Mutant ts11 Gene|TS11	Human ASNS wild-type allele is located in the vicinity of 7q21.3 and is approximately 20 kb in length. This allele, which encodes asparagine synthetase [glutamine-hydrolyzing] protein, plays a role in amino acid conversion. A fusion involving this gene and the KMT2E gene may be associated with early T-cell precursor acute lymphoblastic leukemia (ETP-ALL).	ASNS wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162411>	C16796	Asparagine Synthetase [Glutamine-Hydrolyzing]|ASNS|Asparagine Synthetase|Asparagine Synthetase (Glutamine-Hydrolyzing)|Cell Cycle Control Protein TS11|EC 6.3.5.4|Glutamine-Dependent Asparagine Synthetase|TS11 Cell Cycle Control Protein	Asparagine synthetase [glutamine-hydrolyzing] (561 aa, ~64 kDa) is encoded by the human ASNS gene. This protein is involved in the reversible conversion of aspartate and glutamine to asparagine and glutamate.	Asparagine Synthetase [Glutamine-Hydrolyzing]		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Biomarkers/Targets Associated with Other Relevant Evidence
C162412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162412>	C20420	E2F5 Gene|E2F Transcription Factor 5 Gene|E2F5|E2F5	This gene is involved in centriole biogenesis, multiciliate cell differentiation and cell proliferation.			Gene or Genome	
C162413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162413>	C162412	E2F5 wt Allele|E2F Transcription Factor 5 wt Allele|E2F Transcription Factor 5, p130-Binding Gene|E2F-5	Human E2F5 wild-type allele is located in the vicinity of 8q21.2 and is approximately 40 kb in length. This allele, which encodes transcription factor E2F5 protein, plays a role in cell proliferation, centriole biogenesis and multiciliate cell differentiation.			Gene or Genome	
C162414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162414>	C17207	Transcription Factor E2F5|E2F Transcription Factor 5|E2F-5|E2F5	Transcription factor E2F5 (346 aa, ~38 kDa) is encoded by the human E2F5 gene. This protein is involved in multiciliate cell differentiation, cell proliferation and centriole biogenesis.			Amino Acid, Peptide, or Protein	
C162415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162415>	C20917	LIN37 Gene|LIN37|LIN37|Lin-37 DREAM MuvB Core Complex Component Gene	This gene plays a role in DREAM complex-dependent cell cycle regulation.			Gene or Genome	
C162416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162416>	C162415	LIN37 wt Allele|F25965|Lin-37 DREAM MuvB Core Complex Component wt Allele|Lin-37 Homolog (C. elegans) Gene|ZK418.4|lin-37	Human LIN37 wild-type allele is located in the vicinity of 19q13.12 and is approximately 6 kb in length. This allele, which encodes protein lin-37 homolog, is involved in cell cycle regulation.			Gene or Genome	
C162417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162417>	C17761	Protein Lin-37 Homolog|Antolefinin|LIN37|Lin-37 Homolog|Protein F25965	Protein lin-37 homolog (246 aa, ~28 kDa) is encoded by the human LIN37 gene. This protein plays a role in the regulation of cell cycle-dependent gene expression.			Amino Acid, Peptide, or Protein	
C162418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162418>	C20917	LIN52 Gene|LIN52|LIN52|Lin-52 DREAM MuvB Core Complex Component Gene	This gene is involved in the regulation of cell cycle gene expression.			Gene or Genome	
C162419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162419>	C162418	LIN52 wt Allele|C14orf46|Chromosome 14 Open Reading Frame 46 Gene|Lin-52 DREAM MuvB Core Complex Component wt Allele|Lin-52 Homolog (C. elegans) Gene|c14_5549	Human LIN52 wild-type allele is located in the vicinity of 14q24.3 and is approximately 116 kb in length. This allele, which encodes protein lin-52 homolog, plays a role in the regulation of cell cycle gene expression.			Gene or Genome	
C162420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162420>	C17761	Protein Lin-52 Homolog|LIN52|Lin-52 Homolog	Protein lin-52 homolog (116 aa, ~13 kDa) is encoded by the human LIN52 gene. This protein is involved in the regulation of G0 phase arrest.			Amino Acid, Peptide, or Protein	
C162421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162421>	C20917|C20420	LIN54 Gene|LIN54|LIN54|Lin-54 DREAM MuvB Core Complex Component Gene	This gene plays a role in both DNA binding and the regulation of cell cycle arrest.			Gene or Genome	
C162422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162422>	C17761|C17207	Protein Lin-54 Homolog|CXC Domain-Containing Protein 1|LIN54|Lin-54 Homolog	Protein lin-54 homolog (749 aa, ~79 kDa) is encoded by the human LIN54 gene. This protein plays a role in DREAM complex-dependent cell cycle regulation.			Amino Acid, Peptide, or Protein	
C162423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162423>	C162421	LIN54 wt Allele|CXC Domain Containing 1 Gene|CXCDC1|DKFZp686L1814|JC8.6|KIAA2037|LIN54, C. elegans, Homolog of Gene|Lin-54 DREAM MuvB Core Complex Component wt Allele|Lin-54 Homolog (C. elegans) Gene|MIP120|TCX1	Human LIN54 wild-type allele is located in the vicinity of 4q21.22 and is approximately 103 kb in length. This allele, which encodes protein lin-54 homolog, is involved in the modulation of cell cycle progression.			Gene or Genome	
C162424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162424>	C3248	Recurrent Myelofibrosis	The reemergence of myelofibrosis after a period of remission.	Recurrent Myelofibrosis		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C162425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162425>	C3248	Refractory Myelofibrosis	Myelofibrosis that is resistant to treatment.	Refractory Myelofibrosis		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C162426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162426>	C25784	RAB44 Gene|RAB44|RAB44|RAB44, Member RAS Oncogene Family Gene	This gene is involved in GTP-mediated signaling and neutrophil degranulation.			Gene or Genome	
C162427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162427>	C162426	RAB44 wt Allele|RAB44, Member RAS Oncogene Family wt Allele|RAS-Like, Family 13 Gene|RASD Family, Member 3 Gene|RASD3|RASL13|dJ431A14.3	Human RAB44 wild-type allele is located in the vicinity of 6p21.2 and is approximately 35 kb in length. This allele, which encodes Ras-related protein Rab-44, plays a role in neutrophil degranulation. A fusion involving this gene and the TP53 gene may be associated with osteosarcoma.			Gene or Genome	
C162428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162428>	C18549	Ras-Related Protein Rab-44|RAB44	Ras-related protein Rab-44 (1021 aa, ~111 kDa) is encoded by the human RAB44 gene. This protein is involved in signaling and neutrophil degranulation.			Amino Acid, Peptide, or Protein|Enzyme	
C162429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162429>	C20194	KLHL33 Gene|KLHL33|KLHL33|Kelch Like Family Member 33 Gene	This gene may play a role in protein-protein interactions.			Gene or Genome	
C16242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16242>	C16561	Exonuclease	An Exonuclease is a hydrolase (nuclease) that specifically catalyzes the hydrolysis of terminal phosphodiester bonds of deoxyribonucleotide or ribonucleotide chains, releasing mononucleotides.			Amino Acid, Peptide, or Protein|Enzyme	
C162430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162430>	C162429	KLHL33 wt Allele|Kelch Like Family Member 33 wt Allele|Kelch-Like 33 (Drosophila) Gene	Human KLHL33 wild-type allele is located in the vicinity of 14q11.2 and is approximately 10 kb in length. This allele, which encodes kelch-like protein 33, may involved in protein-protein interactions. A fusion involving this gene and the TEP1 gene may be associated with sinus carcinoma.			Gene or Genome	
C162431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162431>	C18466	Kelch-Like Protein 33|KLHL33|Kelch Like Family Member 33	Kelch-like protein 33 (533 aa, ~58 kDa) is encoded by the human KLHL33 gene. This protein may play a role in protein-protein interactions.			Amino Acid, Peptide, or Protein	
C162432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162432>	C20194	NCSTN Gene|NCSTN|NCSTN|Nicastrin Gene	This gene is involved in the regulation of gamma-secretase activity.			Gene or Genome	
C162433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162433>	C162432	NCSTN wt Allele|APH2|ATAG1874|Anterior Pharynx Defective 2, C elegans, Homolog of Gene|Anterior Pharynx-Defective 2 Gene|KIAA0253|Nicastrin wt Allele|UNQ1874/PRO4317	Human NCSTN wild-type allele is located in the vicinity of 1q23.2 and is approximately 16 kb in length. This allele, which encodes nicastrin protein, plays a role in intramembrane cleavage of Notch and APP family proteins. Mutation of the gene is associated with familial acne inversa type 1. Mutagenesis of the gene can caused increased levels of amyloid-beta secretion and deletions in the gene may inhibit amyloid-beta production.			Gene or Genome	
C162434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162434>	C18466	Nicastrin|NCSTN	Nicastrin (709 aa, ~78 kDa) is encoded by the human NCSTN gene. This protein is involved in the regulation of intramembrane cleavage catalyzed by the gamma-secretase complex.			Amino Acid, Peptide, or Protein	
C162435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162435>	C26006	STX7 Gene|STX7|STX7|Syntaxin 7 Gene	This gene plays a role in endocytic vesicle trafficking.			Gene or Genome	
C162436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162436>	C162435	STX7 wt Allele|Syntaxin 7 wt Allele	Human STX7 wild-type allele is located in the vicinity of 6q23.2 and is approximately 67 kb in length. This allele, which encodes syntaxin-7 protein, is involved in the trafficking of endocytic vesicles. A fusion involving this gene and the ICAM2 gene may be associated with acute monoblastic and monocytic leukemia.			Gene or Genome	
C162437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162437>	C16386	Syntaxin-7|STX7|Syntaxin 7	Syntaxin-7 (261 aa, ~30 kDa) is encoded by the human STX7 gene. This protein plays a role in endocytosis.			Amino Acid, Peptide, or Protein	
C162438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162438>	C20194	FEM1C Gene|FEM1C|FEM1C|Fem-1 Homolog C Gene	This gene is involved in the regulation of E3 ubiquitin-protein ligase complex activity.			Gene or Genome	
C162439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162439>	C162438	FEM1C wt Allele|EUROIMAGE686608|EUROIMAGE783647|FEM1A|Fem-1 Homolog C (C. elegans) Gene|Fem-1, C. elegans, Homolog of, C Gene|KIAA1785	Human FEM1C wild-type allele is located in the vicinity of 5q22.3 and is approximately 24 kb in length. This allele, which encodes protein fem-1 homolog C, plays a role in ubiquitin protein-ligase activity. A fusion involving this gene and the SEMA6A gene may be associated with B-cell acute lymphoblastic leukemia (B-ALL).			Gene or Genome	
C16243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16243>	C16242	5'-3' Exonuclease	Five Prime-Three Prime Exonucleases specifically catalyze the hydrolysis of terminal phosphodiester bonds of nucleic acids. Human XRN1 and XRN2 are similar to mouse Dhm1 and yeast dhp1, involved in homologous recombination, meiosis, telomere maintenance, RNA synthesis and RNA trafficking. XRN1 localizes to cytoplasmic complexes of mRNA-degrading enzymes and prefers RNA over DNA substrates. XRN2 promotes transcription termination by 5-prime to 3-prime exonuclease activity and autocatalytic cotranscriptional cleavage that may induce dissociation of RNA polymerase II from the DNA template, but function has not yet been fully determined.			Amino Acid, Peptide, or Protein|Enzyme	
C162440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162440>	C95242	Protein Fem-1 Homolog C|FEM1-Gamma|FEM1c	Protein fem-1 homolog C (617 aa, ~69 kDa) is encoded by the human FEM1C gene. This protein is involved in E3 ubiquitin-protein ligase complex activity regulation.			Amino Acid, Peptide, or Protein	
C162441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162441>	C8625|C5105|C159565	Recurrent Colorectal Adenocarcinoma	The reemergence of colorectal adenocarcinoma after a period of remission.			Neoplastic Process	
C162442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162442>	C4349|C3998|C162441	Recurrent Colon Adenocarcinoma	The reemergence of colon adenocarcinoma after a period of remission.	Recurrent Colon Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162443>	C9383|C9238|C162441	Recurrent Rectal Adenocarcinoma	The reemergence of rectal adenocarcinoma after a period of remission.	Recurrent Rectal Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162444>	C25971	TXK Gene|TXK|TXK|TXK Tyrosine Kinase Gene	This gene plays a role in the regulation of adaptive immune responses.			Gene or Genome	
C162445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162445>	C162444	TXK wt Allele|BTKL|PSCTK5|PTK4|PTK4 Protein Tyrosine Kinase 4 Gene|RLK|TKL|TXK Tyrosine Kinase wt Allele	Human TXK wild-type allele is located in the vicinity of 4p12 and is approximately 68 kb in length. This allele, which encodes tyrosine-protein kinase TXK protein, is involved in tyrosine phosphorylation.			Gene or Genome	
C162447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162447>	C17020	Tyrosine-Protein Kinase TXK|EC 2.7.10.2|Protein Tyrosine Kinase 4|Protein-Tyrosine Kinase 4|Protein-Tyrosine Kinase TXK|RLK|Resting Lymphocyte Kinase	Tyrosine-protein kinase TXK (527 aa, ~61 kDa) is encoded by the human TXK gene. This protein plays a role in both tyrosine phosphorylation and adaptive immunity.			Amino Acid, Peptide, or Protein|Enzyme	
C162448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162448>	C97927	COL7A1 Gene Mutation|Collagen Type VII Alpha 1 Chain Gene Mutation|Collagen, Type VII, Alpha 1 Gene Mutation|EBD1 Gene Mutation|EBDCT Gene Mutation|EBR1 Gene Mutation|NDNC8 Gene Mutation	A change in the nucleotide sequence of the COL7A1 gene.	COL7A1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162449>	C15470	Peptide Receptor Radionuclide Therapy|PRRT|Peptide Receptor Radionuclide Therapy (PRRT)|Peptide Receptor Radiotherapy	Treatment with a radioactive substance that is linked to a peptide receptor so that it will attach to a specific cell type when injected into the body. It is currently being used to treat neuroendocrine tumors, using octreotide as the targeting peptide.	Peptide Receptor Radionuclide Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C162450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162450>	C3099|C159563|C153352	Refractory Hepatocellular Carcinoma	Hepatocellular carcinoma that is resistant to treatment.	Refractory Hepatocellular Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162451>	C160229|C131913	Recurrent High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements|Recurrent High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements|Recurrent High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements	The reemergence of high-grade B-cell lymphoma with MYC, BCL2, and BCL6 rearrangements after a period of remission.	Recurrent High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162452>	C1291	Antisense Oligonucleotide QR-313|QR 313|QR-313|QR313	A twenty-one nucleotide-containing antisense oligonucleotide (AON) with potential use in the treatment of recessive dystrophic epidermolysis bullosa (RDEB) due to mutations in exon 73 of the COL7A1 gene. Upon topical administration, QR-313 hybridizes to a specific sequence in COL7A1 pre-mRNA, resulting in exclusion of exon 73 from mRNA and translation of a functional type VII collagen protein. This may restore functionality of integument anchoring fibrils, prevent blistering, and improve wound healing in patients with DEB. Type VII collagen is a major component of anchoring fibrils, attachment structures that mediate dermal-epidermal adherence in human skin. DEB is an inherited mechano-bullous disorder caused by mutations in the COL7A1 gene, which lead to perturbations in anchoring fibrils.	Antisense Oligonucleotide QR-313		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology
C162453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162453>	C160233|C131913	Refractory High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements|Refractory High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements|Refractory High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements	A high-grade B-cell lymphoma with MYC, BCL2, and BCL6 rearrangements that is resistant to treatment.	Refractory High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162454>	C163968	Protein Arginine Methyltransferase 5 Inhibitor PRT543|PRMT5 inhibitor PRT543|PRT 543|PRT-543|PRT543	An orally available small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), with potential antiproliferative and antineoplastic activities. Although the exact mechanism of action has not been completely determined, upon oral administration, PRMT5 inhibitor PRT543 selectively binds to the substrate recognition site of PRMT5 and inhibits its methyltransferase activity. This decreases the levels of both monomethylated and dimethylated arginine residues in histones H2A, H3 and H4 and modulates the expression of genes involved in several cellular processes, including cellular proliferation. As a result, PRT543 may increase the expression of antiproliferative genes and/or decrease the expression of genes that promote cell proliferation, which may lead to decreased growth of rapidly proliferating cells, including cancer cells. PRTM5, an arginine methyltransferase that catalyzes the formation of both omega-N monomethylarginine (MMA) and symmetric dimethylarginine (sDMA) on histones and a variety of other protein substrates, is overexpressed in several neoplasms.	Protein Arginine Methyltransferase 5 Inhibitor PRT543		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162455>	C20401	Dupilumab|DUPILUMAB|Dupixent|REGN 668|REGN-668|REGN668|SAR 231893|SAR-231893|SAR231893	A recombinant human monoclonal immunoglobulin G4 (IgG4) antibody directed against the alpha chain of the interleukin-4 receptor (IL-4R alpha) with potential immunomodulatory activities. Upon injection, dupilumab selectively binds to the IL-4R alpha chain. This disrupts IL-4/IL-13 signaling and prevents the activation of downstream pathways that mediate type 2 inflammation and may potentially inhibit tumor cell proliferation, survival, and metastasis. IL-4 and IL-13 receptors are present on the surface of numerous cells involved in the pathophysiology of type-2 helper T-cell (Th2) allergic responses, including B-lymphocytes, eosinophils, dendritic cells (DCs), monocytes, macrophages, basophils, keratinocytes, bronchial epithelial cells, endothelial cells, fibroblasts, and airway smooth muscle cells. Additionally, both IL-4 and IL-13 receptors are overexpressed in a variety of cancers and IL-4 and IL-13 and may serve as biomarkers for cancer aggressiveness. IL-4 and IL-13 are thought to be key regulatory cytokines in the tumor microenvironment (TME) and may play a role in the activation of tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) that mediate tumor cell survival.	Dupilumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C162456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162456>	C226330	Intermediate Risk Acute Myeloid Leukemia	Acute myeloid leukemia with a risk of relapse or refractoriness between favorable and high risk acute myeloid leukemia, and cytogenetic and molecular genetic abnormalities that categorize it as intermediate risk acute myeloid leukemia.			Finding	
C162457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162457>	C156292	Refractory High Risk Acute Myeloid Leukemia	The reemergence of high risk acute myeloid leukemia after a period of remission.	Refractory High Risk Acute Myeloid Leukemia		Finding	CTRP Disease Terminology|CTRP Terminology
C162458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162458>	C162456	Refractory Intermediate Risk Acute Myeloid Leukemia	The reemergence of intermediate risk acute myeloid leukemia after a period of remission.	Refractory Intermediate Risk Acute Myeloid Leukemia		Finding	CTRP Disease Terminology|CTRP Terminology
C162459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162459>	C208255|C1512	HPV16 E7-specific HLA-A*02:01-restricted IgG1-Fc Fusion Protein CUE-101|Anti-HPV16 E7 Fusion Protein CUE-101|CUE 101|CUE-101|CUE101	A fusion protein composed of a human leukocyte antigen (HLA) complex, HLA-A*0201, with a peptide epitope derived from the human papillomavirus type 16 (HPV16) E7 protein (amino acid residues 11-20), a reduced affinity human interleukin-2 (IL-2) variant, and an effector attenuated human immunoglobulin G1 (IgG1) Fc domain, with potential antineoplastic and immunostimulatory activities. Upon administration, CUE-101 targets and selectively binds to E7-specific CD8-positive T-cells present in patients with HPV16-driven malignancies. This may induce the secretion of inflammatory cytokines such as interferon gamma (IFN gamma) and promote the activation and expansion of tumor-specific CD8-positive cells, which may lead to T-cell-mediated elimination of tumor cells expressing the HPV16 E7 antigen. The HPV16 E7 oncoprotein is a cell surface glycoprotein and tumor-associated antigen (TAA) that is overexpressed in various HPV-associated cancers.	HPV16 E7-specific HLA-A*02:01-restricted IgG1-Fc Fusion Protein CUE-101		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162460>	C6450|C3809	Thymus Neuroendocrine Neoplasm|Thymic Neuroendocrine Neoplasm	An epithelial neoplasm with neuroendocrine differentiation that arises from the thymus. This category includes neuroendocrine tumors (carcinoid tumors) and neuroendocrine carcinomas.			Neoplastic Process	
C162461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162461>	C4962|C162460|C156485	Metastatic Thymus Neuroendocrine Neoplasm|Metastatic Thymic Neuroendocrine Neoplasm|Metastatic Thymic Neuroendocrine Neoplasm	A thymus neuroendocrine neoplasm that has spread from its original site of growth to another anatomic site.	Metastatic Thymic Neuroendocrine Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162462>	C20401	Anti-MAGE-A4 T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-C103C|IMC C103C|IMC-C103C|IMCC103C|ImmTAC IMC-C103C|ImmTAC Molecule IMC-C103C|Immune Mobilizing Monoclonal TCR Against Cancer IMC-C103C|T-cell Redirecting Bi-specific Biologic IMC-C103C	A T-cell re-directing bi-specific biologic composed of a modified form of human T-cell receptor (TCR) specific for the tumor-associated antigen (TAA) human melanoma-associated antigen A4 (MAGE-A4) and fused to an anti-CD3 single-chain variable fragment (scFv), with potential antineoplastic activity. Upon intravenous administration of IMC-C103C, the TCR moiety of this agent targets and binds to MAGE-A4 on tumor cells and the anti-CD3 scFv moiety binds to CD3- expressing T-lymphocytes. This selectively cross-links tumor cells and T-lymphocytes and results in a CTL-mediated death of MAGE-A4-expressing tumor cells. MAGE-A4 is overexpressed by a variety of cancer cell types.	Anti-MAGE-A4 T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-C103C		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162463>	C38060	10-2 Visual Field Testing|10-2 Visual Field|10-2 Visual Field Test|Central 10-2 Visual Field Testing	A test for visual field defects that tests the central 10 degrees, creating 68 points with 2 degrees between points. It is most often used on patients with conditions that affect central vision (e.g., macular degeneration, diabetic retinopathy) or when only a small amount of central vision remains (e.g., end-stage glaucoma).			Diagnostic Procedure	
C162464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162464>	C20828	Spectral Domain-Optical Coherence Tomography|SD-OCT|SD-OCT|SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY|Spectral Domain Optical Coherence Tomography	A modification of optical coherence tomography with an increased ability to provide depth-resolved tissue structure information. It is used to perform high-resolution cross-sectional imaging and analysis of structural changes in the eye during disease progression.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C162465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162465>	C38060	Fundus Autofluorescence Imaging|FAF|Fundus Autofluorescence	A retinal imaging test that maps the presence of lipofuscin in the retina pigment epithelium.			Diagnostic Procedure	
C162466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162466>	C6358	Intratubular Large Cell Hyalinizing Sertoli Cell Neoplasia	A clinically benign intratubular neoplastic proliferation of large Sertoli cells in the testis. It is associated with prominent basement membrane deposits. It occurs almost exclusively in patients with Peutz-Jeghers syndrome.			Neoplastic Process	Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C162467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162467>	C8851|C6810	Testicular Diffuse Large B-Cell Lymphoma|Primary Diffuse Large B-Cell Lymphoma of the Testis|Primary Large B-Cell Lymphoma of the Testis|Primary Testicular Diffuse Large B-Cell Lymphoma	A diffuse large B-cell lymphoma that arises from the testis. It predominantly affects older men. Patients usually present with a unilateral hard painless mass. Bilateral masses have been described in a minority of patients.	Testicular Diffuse Large B-Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162468>	C6810|C4684	Testicular Nasal Type Extranodal NK/T-Cell Lymphoma	A nasal type extranodal NK/T-cell lymphoma affecting the testis. Patients usually present with unilateral testicular enlargement. Bilateral involvement is rare. The prognosis is poor.			Neoplastic Process	
C162469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162469>	C7251|C3520	Testicular Myeloid Sarcoma	A rare myeloid sarcoma that arises from the testis. At presentation the involvement is usually unilateral.			Neoplastic Process	
C162470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162470>	C7251|C4002	Testicular Plasmacytoma	A rare plasmacytoma that arises in the testis. At presentation the involvement is usually unilateral.			Neoplastic Process	
C162471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162471>	C157106	Specify Other HPV Typing Method|If Other, specify	A directive to specify the method of HPV typing.			Activity	CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology
C162472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162472>	C122814	Developmental and Epileptic Encephalopathy 4|DEE4|EIEE4|Early Infantile Epileptic Encephalopathy 4	An autosomal dominant form of early infantile epileptic encephalopathy, caused by mutation(s) in the STXBP1 gene, encoding syntaxin-binding protein 1.			Disease or Syndrome	Cellosaurus Disease Terminology
C162473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162473>	C134526	Canine Transmissible Venereal Tumor|CTVT	A sexually transmitted tumor arising from histiocytes and occurring in dogs.			Neoplastic Process	Cellosaurus Disease Terminology
C162474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162474>	C90598	Epidermolysis Bullosa, Junctional, with Pyloric Atresia|Carmi Syndrome|PA-JEB	An autosomal recessive condition caused by mutation(s), in the ITGA6 or ITGB4 genes, encoding integrin alpha-6  and integrin beta-4 respectively. It is characterized by junctional epidermolysis and pyloric stenosis/atresia.			Disease or Syndrome	Cellosaurus Disease Terminology
C162475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162475>	C156746|C156096	Advanced Colorectal Carcinoma	Colorectal carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Colorectal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162476>	C3762|C192144|C192140	Paratesticular Adenomatoid Tumor|Benign Paratesticular Mesothelioma	An adenomatoid tumor arising from the paratesticular structures. It is the most common tumor of the paratesticular region. The tail of the epididymis is the most common site of involvement.			Neoplastic Process	
C162477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162477>	C4456|C192144|C192139	Paratesticular Malignant Mesothelioma|Testicular Malignant Mesothelioma|Tunica Vaginalis Malignant Mesothelioma	A rare malignant mesothelioma that arises from the tunica vaginalis.	Paratesticular Malignant Mesothelioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162478>	C97927	EMSY Gene Mutation|C11orf30 Gene Mutation|EMSY Transcriptional Repressor, BRCA2 Interacting Gene Mutation|EMSY, BRCA2 Interacting Transcriptional Repressor Gene Mutation|EMSY, BRCA2-Interacting Transcriptional Repressor Gene Mutation|GL002 Gene Mutation	A change in the nucleotide sequence of the EMSY gene.	EMSY Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162480>	C217486	MetAP2 Inhibitor APL-1202|APL 1202|APL-1202|APL1202|Methionine Aminopeptidase Type II Inhibitor APL-1202	An orally available inhibitor of methionine aminopeptidase II type (MetAP2) with potential antiangiogenic and antineoplastic activities. Upon administration, APL-1202 binds to and reversibly inhibits MetAP2, thereby preventing MetAP2-mediated signal transduction pathways. This may suppress endothelial cell growth and inhibit tumor angiogenesis, resulting in tumor cell death. MetAP2, a member of the dimetallohydrolase family, is upregulated in certain tumor cell types and plays a key role in angiogenesis, proliferation and survival.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162481>	C200766	Autologous c-Met/PD-L1-specific CAR T-cells|Autologous Anti-c-Met/PD-L1 CAR T-cells|Autologous c-Met/PD-L1-specific CAR T-lymphocytes	A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) specific for human hepatocyte growth factor receptor (HGFR or c-Met) and the immunosuppressive ligand, programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential antineoplastic activities. Upon infusion, the autologous c-Met/PD-L1-specific CAR T-cells bind to and induce selective toxicity in c-Met- and PD-L1-expressing tumor cells. cMET, a receptor tyrosine kinase that is overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis. PD-L1 is also overexpressed by many human cancer cell types and plays a key role in the downregulation of the immune system and tumor evasion from host immunity.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162482>	C200766	Autologous CD138-specific CAR T-cells|Autologous CD138-specific CAR T-lymphocytes|Autologous Syndecan-1-sepcific CAR T-cells|Autologous Syndecan-1-specific CAR T-lymphocytes	A preparation of autologous T-lymphocytes that have been engineered to express a chimeric antigen receptor (CAR) specific for syndecan-1 (CD138), with potential immunomodulating and antineoplastic activities. Upon administration, the autologous CD138 CAR-expressing T-cells target and induce selective toxicity in syndecan-1-expressing tumor cells. Syndecan-1, a type 1 transmembrane proteoglycan and tumor-associated antigen (TAA), is overexpressed in a variety of cancer cells and plays a key role in the regulation of cell growth, differentiation, and adhesion.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162483>	C3614|C2972|C192122	Epididymal Cystadenoma	A benign cystadenoma that arises from the epididymis.			Neoplastic Process	
C162485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162485>	C3054	Paratesticular Neoplasm|Neoplasm of Paratesticular Structures|Neoplasm of the Testicular Adnexa|Paratesticular Tumor|Testicular Adnexa Neoplasm|Testicular Adnexa Tumor|Tumor of Paratesticular Structures	A benign, borderline, or malignant neoplasm that affects the paratesticular structures.			Neoplastic Process	
C162486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162486>	C2929|C192129	Paratesticular Squamous Cell Carcinoma	An extremely rare squamous cell carcinoma that arises from the paratesticular structures.			Neoplastic Process	
C162488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162488>	C3717|C3614	Epididymal Melanotic Neuroectodermal Tumor|Paratesticular Melanotic Neuroectodermal Tumor	A rare neoplasm that arises from the epididymis and is characterized by the presence of a mixture of melanin-containing epithelial cells and smaller neuroblast-like cells. It usually occurs in infants and has a benign clinical course.			Neoplastic Process	
C162489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162489>	C3267|C192139	Paratesticular Wilms Tumor|Paratesticular Nephroblastoma	A rare Wilms tumor that arises from the paratesticular structures.			Neoplastic Process	
C162490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162490>	C3309|C192122	Paratesticular Paraganglioma	An extremely rare paraganglioma that arises from the paratesticular structures.			Neoplastic Process	
C162491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162491>	C12680	Paratesticular Region|Paratesticular|Testicular Adnexa	A small anatomical compartment that contains the testicular collecting system, and mesothelial and mesenchymal components that represent extensions of the abdominal cavity and retroperitoneum.			Body Location or Region	OS Authorized Value Terminology|OS Biopsy/Surgical Procedures Table|OS Radiation Therapy Table|OS Tumor Assessment Table
C162492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162492>	C3377|C162485	Paratesticular Soft Tissue Neoplasm|Paratesticular Mesenchymal Neoplasm	A mesenchymal neoplasm that arises from the paratesticular region.			Neoplastic Process	
C162493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162493>	C9306|C3194|C192139|C162492	Paratesticular Liposarcoma	A liposarcoma that arises from the paratesticular region.			Neoplastic Process	
C162494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162494>	C6510|C192140|C162492	Paratesticular Leiomyoma	A leiomyoma that arises from the paratesticular region.			Neoplastic Process	
C162495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162495>	C9306|C3158|C192139|C162492	Paratesticular Leiomyosarcoma	A leiomyosarcoma that arises from the paratesticular region.			Neoplastic Process	
C162496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162496>	C49166|C192140|C162492	Paratesticular Rhabdomyoma	A rhabdomyoma that arises from the paratesticular region.			Neoplastic Process	
C162497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162497>	C9306|C214845|C192139|C162492	Paratesticular Rhabdomyosarcoma	A rhabdomyosarcoma that arises from the paratesticular region.			Neoplastic Process	
C162498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162498>	C27257|C192140|C162492	Paratesticular Cellular Angiofibroma	A cellular angiofibroma that arises from the paratesticular region.			Neoplastic Process	
C1624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1624>	C97366	Nelfinavir Mesylate|AG1343|NELFINAVIR MESYLATE|Viracept|nelfinavir mesylate	The mesylate salt form of nelfinavir, a synthetic antiviral agent that selectively binds to and inhibits human immunodeficiency virus (HIV) protease. Nelfinavir has activity against HIV 1 and 2.	Nelfinavir Mesylate		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C162500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162500>	C192140|C162492|C121181	Paratesticular Mammary-Type Myofibroblastoma	An extramammary myofibroblastoma that arises from the paratesticular region.			Neoplastic Process	
C162501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162501>	C6936|C192140|C162492	Paratesticular Deep (Aggressive) Angiomyxoma|Paratesticular Deep "Aggressive" Angiomyxoma	A locally infiltrating, non-metastasizing angiomyxoma that arises from the paratesticular region.			Neoplastic Process	
C162502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162502>	C41430|C192140|C162492	Paratesticular Schwannoma	A schwannoma that arises from the paratesticular region.			Neoplastic Process	
C162503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162503>	C4242|C3085|C192140|C162492	Paratesticular Hemangioma	A capillary or cavernous hemangioma that arises from the paratesticular region.			Neoplastic Process	
C162504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162504>	C129822|C128057	Socazolimab|Anti-PD-L1 Monoclonal Antibody ZKAB001|Anti-PDL1 Monoclonal Antibody ZKAB001|SOCAZOLIMAB|STI A1014|STI-A1014|STIA1014|ZKAB 001|ZKAB-001|ZKAB001	A human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, socazolimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162505>	C129822|C128036	Anti-CTLA-4 Monoclonal Antibody ADU-1604|ADU 1604|ADU-1604|ADU1604	A humanized immunoglobulin G1 (IgG1) antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, anti-CTLA-4 monoclonal antibody ADU-1604 targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162506>	C200766|C176023	Autologous BCMA-targeted CAR T Cells LCAR-B4822M|Autologous LCAR-B4822M CAR T Cells|BCMA-specific CAR-expressing T-lymphocytes LCAR-B4822M|LCAR B4822M|LCAR-B4822M|LCAR-B4822M CAR-T-lymphocytes|LCAR-B4822M-02 Cells|LCARB4822M	A preparation of autologous peripheral blood T-lymphocytes (PBTLs) that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, autologous BCMA-targeted CAR T-cells LCAR-B4822M specifically recognize and kill BCMA-expressing tumor cells. BCMA, a tumor specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in plasma cell survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.			Cell|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162507>	C192742|C192741	Abemaciclib Mesylate|ABEMACICLIB MESYLATE|LY-2835219 Methanesulfonate|LY-2835219 methanesulfonate	The mesylate salt of abemaciclib, an orally available cyclin-dependent kinase (CDK) inhibitor that targets the cyclin D1-CDK4 and cyclin D3-CDK6 cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C162508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162508>	C1557	Pegylated Deoxycytidine Analogue DFP-14927|DFP 14927|DFP-14927|DFP14927|Nucleoside Analog DFP-10917|PEGylated DFP-10917|Polymeric Nucleoside Analogue DFP-14927	A pegylated formulation containing DFP-10917, an analogue of the nucleoside deoxycytidine, with potential antineoplastic activity. Upon administration, the pegylated deoxycytidine analogue DFP-14927 is incorporated into the DNA of rapidly proliferating cells, such as tumor cells, and directly inhibits the activity of DNA polymerase, which results in the inhibition of DNA replication and cell cycle arrest, DNA fragmentation, and tumor cell apoptosis.	Pegylated Deoxycytidine Analogue DFP-14927		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162509>	C183052|C129818	Glucocorticoid Receptor Antagonist ORIC-101|19,21-Dinorchol-4-en-20(22)-yn-3-one, 17-Hydroxy-23,23-dimethyl-11-(4-(methyl(1-methylethyl)amino)phenyl)-, (11.Beta.,17.Alpha.)-|GR Antagonist ORIC-101|ORIC 101|ORIC-101|ORIC-101|ORIC101	A mifepristone-based steroidal glucocorticoid receptor (GR) antagonist with potential antineoplastic activity. Upon oral administration, ORIC-101 selectively binds to GRs, thereby inhibiting the activation of GR-mediated proliferative and anti-apoptotic gene expression pathways. The GR, a member of the nuclear receptor superfamily of ligand-dependent transcription factors, is overexpressed in certain tumor types and may be associated with tumor cell proliferation and treatment resistance. Inhibition of GR activity may potentially slow tumor cell growth and disease progression in certain cancers. Due to its reduced androgen receptor (AR) agonistic activity and improved cytochrome P450 2C8 (CYP2C8) and 2C9 (CYP2C9) inhibition profile, ORIC-101 may be useful in the treatment of AR-positive tumors with reduced potential for drug-drug interactions.	Glucocorticoid Receptor Antagonist ORIC-101		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162510>	C165233	MYCN Negative|N-Myc Negative|N-Myc Proto-Oncogene Negative|NMYC Negative|Neuroblastoma MYC Negative|v-myc Avian Myelocytomatosis Viral Oncogene Neuroblastoma Derived Homolog Negative	An indication that MYCN expression has not been detected in a sample.	MYCN Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162511>	C165233	MYC Negative|Myc Proto-Oncogene Negative|Proto-Oncogene c-Myc Negative|c-MYC Negative|v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog Negative	An indication that MYC expression has not been detected in a sample.	MYC Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162512>	C157287	Blasts 1 Percent or More of Bone Marrow Nucleated Cells|Blasts Greater than or Equal to 1 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that at least 1 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts 1 Percent or More of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C162513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162513>	C97927	MLL Gene Mutation|KMT2A Gene Mutation|KMT2A Gene Mutation|KMT2A Mutation|Lysine (K)-Specific Methyltransferase 2A Gene Mutation|Lysine Methyltransferase 2A Gene Mutation|MLL Mutation|Mixed Lineage Leukemia Gene Mutation|Myeloid/Lymphoid Leukemia Gene Mutation|Myeloid/Lymphoid or Mixed Lineage Leukemia Gene Mutation|Myeloid/Lymphoid or Mixed-Lineage Leukemia (Trithorax Homolog, Drosophila) Gene Mutation	A change in the nucleotide sequence of the MLL (KMT2A) gene.	KMT2A Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162514>	C93102|C89714	Deleterious GNA11 Gene Mutation|Deleterious G Protein Subunit Alpha 11 Gene Mutation|Deleterious GA11 Gene Mutation|Deleterious GNA-11 Gene Mutation|Deleterious Guanine Nucleotide Binding Protein (G Protein), Alpha 11 Gene Mutation|Deleterious Guanine Nucleotide-Binding Protein, Alpha-11 Gene Mutation|GNA11 Deleterious Gene Mutation|GNA11 Deleterious Mutation|GNA11 Driver Mutation	A change in the nucleotide sequence of the GNA11 gene that is associated with increased risk of disease.	Deleterious GNA11 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162515>	C36345	Loss of MSH2 Expression|Loss of DNA Mismatch Repair Protein Msh2 Expression|Loss of MSH2 Protein Expression|Loss of MutS Homolog 2 Expression|Loss of MutS Protein Homolog 2 Expression|MSH2 Loss of Expression	A molecular abnormality indicating the absence of MSH2 protein.	Loss of MSH2 Expression		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162516>	C140413	Somatic Hypermutation|Somatic Hypermutation Phenotype|Somatic Hypermutator Phenotype	The presence of a hypermutation phenotype in non-germline cells.	Somatic Hypermutation		Organism Attribute	CTRP Biomarker Terminology|CTRP Terminology
C162517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162517>	C177692|C157163	Alpha-Fetoprotein Positive|AFP Positive|Alpha Fetoprotein Positive	An indication that alpha-fetoprotein has been detected in a sample.	Alpha-Fetoprotein Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162518>	C209443	Nicotine Metabolite Ratio Measurement|3-Hydroxycotinine to Cotinine Ratio Measurement|NMR|Nicotine Metabolite Ratio|Nicotine Metabolite Ratio	A measurement of the ratio of the nicotine metabolites 3-hydroxycotinine (3HC) to cotinine in a sample.	Nicotine Metabolite Ratio		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Terminology
C162519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162519>	C25939	PLOD2 Gene|PLOD2|PLOD2|Procollagen-Lysine,2-Oxoglutarate 5-Dioxygenase 2 Gene	This gene is involved in the synthesis of hydroxylysine, which promotes collagen glycosylation and increases the stability of cross-linked collagen fibrils.	PLOD2 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C162520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162520>	C162519	PLOD2 wt Allele|BRKS2|LH2|Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase (Lysine Hydroxylase) 2 Gene|Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase 2 Gene|Procollagen-Lysine,2-Oxoglutarate 5-Dioxygenase 2 wt Allele|TLH	Human PLOD2 wild-type allele is located in the vicinity of 3q24 and is approximately 94 kb in length. This allele, which encodes procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 protein, plays a role in post-translational protein modification and collagen fibril stabilization. Mutation of the gene is associated with Bruck syndrome type 2.	PLOD2 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162521>	C141145|C129822	Alomfilimab|ALOMFILIMAB|Anti-ICOS Monoclonal Antibody KY1044|KY 1044|KY-1044|KY1044	A human immunoglobulin G1 (IgG1) kappa monoclonal antibody that recognizes inducible T-cell co-stimulator (ICOS; CD278), with potential immunomodulating and antineoplastic activities. Upon administration, alomfilimab selectively binds to dimeric ICOS expressed on certain T-cells. This prevents the interaction between ICOS-positive T-cells and plasmacytoid dendritic cells (pDCs), which express the ICOS ligand (ICOSL). Blocking ICOS activation prevents the pDC-induced proliferation and accumulation of regulatory ICOS-positive T-cells (ICOS+ Tregs) and inhibits interleukin-10 (IL-10) secretion by CD4+ infiltrating T-cells. This may abrogate Treg-mediated immune suppression and may enhance cytotoxic T-lymphocyte (CTL)-mediated immune responses against tumor cells. Additionally, KY1044 may eliminate ICOS-positive T-cells via antibody-dependent cellular cytotoxicity (ADCC). ICOS, a T-cell specific, CD28-superfamily costimulatory molecule and immune checkpoint protein, plays a key role in the proliferation and activation of T-cells. It is normally expressed on both activated CD4+ T-cells, which is a subset of memory T-cells (Tm), and follicular helper T-cells (Tfh). ICOS is highly expressed on Tregs infiltrating various tumors and its expression is associated with a poor prognosis; ICOS-positive Tregs play a key role in immune suppression and tumor immune evasion.	Alomfilimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162522>	C28459	Procollagen-Lysine,2-Oxoglutarate 5-Dioxygenase 2|EC 1.14.11.4|LH2|Lysine Hydroxylase 2|Lysyl Hydroxlase 2|Lysyl Hydroxylase 2|PLOD2|Procollagen Lysyl Hydroxylase 2|Procollagen-Lysine 5-Dioxygenase|Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase 2|Telopeptide Lysyl Hydroxylase	Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 (85 aa, ~737 kDa) is encoded by the human PLOD2 gene. This protein is involved in the formation of hydroxylysine residues in -Xaa-Lys-Gly- sequences in collagens.	Procollagen-Lysine,2-Oxoglutarate 5-Dioxygenase 2		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162523>	C162448	COL7A1 Exon 73 Mutation|COL7A1 Exon 73 Gene Mutation|Collagen Type VII Alpha 1 Chain Exon 73 Mutation|Collagen, Type VII, Alpha 1 Exon 73 Mutation|EBD1 Exon 73 Mutation|EBDCT Exon 73 Mutation|EBR1 Exon 73 Mutation|NDNC8 Exon 73 Mutation	A molecular genetic abnormality indicating the presence of a mutation in exon 73 of the COL7A1 gene.	COL7A1 Exon 73 Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162524>	C1742|C129821	Recombinant Human Plasminogen Kringle 5 Domain ABT 828|ABT 828|ABT-828|ABT828|rhK5	A recombinant human plasminogen kringle 5 domain with potential antiangiogenic and antineoplastic activities. Upon administration, recombinant human plasminogen kringle 5 domain ABT 828 may promote caspase activity and apoptosis in proliferating endothelial cells, thereby inhibiting migration. Kringle 5 (K5), an internal proteolytic fragment of plasminogen specifically inhibits endothelial cell growth via its interaction with endothelial cell surface ATP synthase, which sequentially triggers the activation of caspases -8, -9, and -3.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C162525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162525>	C25974	Tubulin Polymerization Inhibitor AEZS 112|AEZS 112|AEZS-112|AEZS112|ZEN 012|ZEN-012|ZEN012	An orally bioavailable small molecule tubulin polymerization inhibitor with potential antineoplastic activity. Upon oral administration, tubulin polymerization inhibitor AEZS 112 binds to tubulin and prevents its polymerization in tumor blood vessel endothelial cells and tumor cells. This blocks the formation of the mitotic spindle and leads to cell cycle arrest at the G2/M phase. As a result, this agent disrupts the tumor vasculature and tumor blood flow, deprives tumor cells of nutrients and induces tumor cell apoptosis. In addition, this agent has a direct cytotoxic effect on tumor cells by inhibiting tubulin polymerization.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C162526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162526>	C158612	30 Day Prior Medications Question|30 Day Prior Medications|Medications, vitamins, supplements administered within the 30 days prior to the CPTAC III specimen collection	A header in a CPTAC document regarding medication use 30 days prior.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C162527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162527>	C25974	Tubulin Inhibitor ALB-109564|ALB 109564|ALB-109564|ALB-109564|ALB109564	A semi-synthetic derivative of the vinka alkaloid vinblastine with potential antineoplastic activity. Tubulin inhibitor ALB-109564 binds to tubulin monomers and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the G2/M phase of the cell cycle. Check for active clinical trials using this agent.	Tubulin Inhibitor ALB-109564		Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C162528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162528>	C214992|C181108	Anti-BCMA Antibody-drug Conjugate AMG 224|AMG 224|AMG-224|AMG-224|AMG224	An antibody-drug conjugate (ADC) comprised of an anti-human B-cell maturation antigen (BCMA) immunoglobulin G1 (IgG1) antibody conjugated via the noncleavable linker 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (MCC), to the cytotoxic maytansine-derivative, DM1, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of AMG 224 selectively binds to BCMA expressed on the surface of tumor cells. Upon internalization, the DM1 moiety binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting both cell division and proliferation of tumor cells that express BCMA. BCMA, a receptor for a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor (TNF) receptor superfamily (TNFRSF)and plays a key role in plasma cell survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.	Anti-BCMA Antibody-drug Conjugate AMG 224		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C162529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162529>	C82547	Colon Polyp Observed During Examination|Observed Colon Polyp	Direct observation of a colon polyp upon examination, during surgical procedure, or colonoscopy.			Finding	
C162530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162530>	C17003	cobas MPX Test|MPX Test|cobas TaqScreen MPX Test	A proprietary qualitative polymerase chain reaction-based test used to directly detect RNAs from human immunodeficiency virus (HIV) type 1 groups M and O, HIV-2, hepatitis C virus (HCV) and hepatitis B Virus (HBV) in patient-derived blood samples.			Laboratory Procedure	
C162531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162531>	C9480|C7676	Invasive Adenocarcinoma in Adenomatous Polyp|Invasive Adenocarcinoma in Gastrointestinal Adenomatous Polyp	An invasive adenocarcinoma that arises from an adenomatous polyp.			Neoplastic Process	
C162532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162532>	C93259|C62556|C213472|C209713|C172200|C159199	Tinengotinib|Multi-kinase Inhibitor TT-00420|Multi-target Kinase Inhibitor TT-00420|Multiple Kinase Inhibitor TT-00420|TINENGOTINIB|TT 00420|TT-00420|TT00420	An orally available small molecule inhibitor of Aurora kinases (AKs) A and B, Janus kinases (JAKs), fibroblast growth factor receptors (FGFRs) and vascular endothelial growth factor receptors (VEGFRs), with potential antineoplastic and immunomodulatory activities. Upon oral administration, tinengotinib selectively binds to and inhibits AKs A and B, which inhibit cell division in tumor cells that overexpress AKs. Tinengotinib also targets JAKs that are involved in cytokine signaling and inflammation, and FGFRs and VEGFRs, which  are overexpressed in the microenvironment (TME) and contribute to neovascularization, tumor growth and metastasis.  These kinases are overexpressed by a wide variety of cancer cell types and drive tumor cell proliferation.	Tinengotinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162533>	C212990	Src Kinase Inhibitor AP 23846|AP 23846|AP-23846|AP23846	A novel small molecule Src family kinase inhibitor with potential antiangiogenic activity. Upon administration, Src kinase inhibitor AP23846 selectively binds to and stabilizes an inactive ATP-binding site conformation leading to reduced Src kinase activity. This may reduce the production of pro-angiogenic factors, vascular endothelial growth factor (VEGF) and interleukin (IL)-8. Src tyrosine kinases are upregulated in many tumor cells and play important roles in tumor cell proliferation, survival, migration, invasion and angiogenesis.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C162534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162534>	C158375	Abdominal Surgery Patient	A person who is undergoing an abdominal surgical procedure.	Abdominal Surgery Patient		Patient or Disabled Group	CTRP Intervention Terminology|CTRP Terminology
C162535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162535>	C129839	Dasminapant|APG 1387|APG-1387|APG1387|DASMINAPANT|IAP Antagonist APG-1387|IAP Inhibitor APG-1387|Pyrrolo(1,2-a)(1,5)diazocine-8-carboxamide, 3,3'-(1,3-phenylenebis(sulfonyl))bis(N-(diphenylmethyl)decahydro-5-(((2S)-2-(methylamino)-1-oxopropyl)amino)-6-oxo-, (5S,5'S,8S,8'S,10aR,10'ar)-|SM-1387|SMAC-mimetic APG-1387	A small molecule, second mitochondria-derived activator of caspases (SMAC)-mimetic targeting inhibitor of apoptosis proteins (IAPs) with potential apoptosis-inducing and antineoplastic activities. Upon administration, dasminapant selectively binds to and inhibits the activity of IAPs including X chromosome-linked IAP (XIAP) and cellular IAPs 1 (c-IAP1) and 2 (c-IAP2). This may restore and promote the induction of apoptosis through apoptotic signaling pathways and enhance proteasomal degradation of IAPs. Additionally, dasminapant may work synergistically with cytotoxic drugs to overcome tumor cell resistance to apoptosis. IAPs are overexpressed by many cancer cell types, suppressing apoptosis by binding and inhibiting active caspases-3, -7 and -9 via their BIR (baculoviral lAP repeat) domains.	Dasminapant		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162537>	C222318|C210686	Lorukafusp alfa|APN 301|APN-301|APN301|EMD 273063|EMD-273063|Hu 14.18/IL - 2 Fusion Protein|Hu14.18-IL2|Hu14.18-IL2|Hu14.18-IL2 Fusion Protein EMD 273063|LORUKAFUSP ALFA|hu14.18-interleukin-2 fusion protein	A recombinant fusion protein comprised of hu14.18, a humanized immunoglobulin G1 (IgG1) chimeric monoclonal antibody directed against the surface disialoganglioside GD2, fused to two human pro-inflammatory cytokine interleukin (IL)-2 molecules, with potential antineoplastic and immunomodulatory activities. Upon intravenous administration, the antibody moiety of lorukafusp alfa specifically targets and binds to GD2 expressed on certain tumor cells. This may stimulate the activation of immune effector cells including natural killer (NK) and T-cells, leading to tumor cell death via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and GD2-specifc T-cell responses. By delivering IL-2 directly to the tumor microenvironment (TME), IL-2 is able to further stimulate NK and T-cell antitumor cellular immune responses locally. The glycosphingolipid GD2 is a tumor-associated antigen (TAA) overexpressed on the surface of many tumor cells.	Lorukafusp alfa		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162538>	C9296|C210424|C159563	Refractory Gastroesophageal Junction Adenocarcinoma	Gastroesophageal junction adenocarcinoma that does not respond to treatment.	Refractory Gastroesophageal Junction Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162539>	C4596|C164249	Differentiated Penile Intraepithelial Neoplasia, Human Papillomavirus-Independent|Differentiated (Simplex) PeIN|Differentiated (Simplex) Penile Intraepithelial Neoplasia|Differentiated PeIN|Differentiated Penile Intraepithelial Neoplasia|Differentiated Penile Intraepithelial Neoplasia, HPV-Independent	Intraepithelial neoplasia of the penis that is not caused by human papillomavirus infection. It usually presents as a solitary white or pink macule or plaque that may be slightly elevated. A background of long-standing lichen sclerosus is often present. It is characterized by a thickened epithelium, subtle abnormal cellular maturation, and atypical basal layer cells. Parakeratosis is common. (WHO 2016)			Neoplastic Process	
C16253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16253>	C21295	CFC1 Gene|CFC1|CFC1|Cripto, FRL-1, Cryptic Family 1 Gene	This gene is involved in intercellular signaling during vertebrate embryogenesis.			Gene or Genome	
C162540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162540>	C699	Aranose|3-(alpha-L-Arabinopyranosyl)-1-methyl-1-nitrosourea|ARANOSE|Aranoza|CRC 0510375|CRC-0510375	A nitrosourea derivative with potential antineoplastic activity. Upon administration, aranose alkylates and crosslinks DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest and apoptosis.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C162541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162541>	C4596	Human Papillomavirus-Related Penile Intraepithelial Neoplasia|HPV-Related PeIN|Human Papillomavirus-Associated Penile Intraepithelial Neoplasia|Human Papillomavirus-Related PeIN|Penile Intraepithelial Neoplasia, HPV-Associated|Penile Intraepithelial Neoplasia, HPV-Related|Penile Intraepithelial Neoplasia, Human Papillomavirus- Related|Penile Intraepithelial Neoplasia, Human Papillomavirus-Associated	Intraepithelial neoplasia of the penis caused by human papillomavirus infection.			Neoplastic Process	
C162542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162542>	C162541	Basaloid (Undifferentiated) Penile Intraepithelial Neoplasia|Basaloid (Undifferentiated) PeIN|Basaloid PeIN|Basaloid Penile Intraepithelial Neoplasia	Intraepithelial neoplasia of the penis characterized by full-thickness replacement of the squamous epithelium by immature, small, monotonous, basophilic cells. The cells have round to oval nuclei, inconspicuous nucleoli, and scant cytoplasm. Apoptosis and mitotic figures are prominent. (WHO 2016)			Neoplastic Process	
C162543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162543>	C162541	Warty (Bowenoid) Penile Intraepithelial Neoplasia|Warty (Bowenoid) PeIN|Warty PeIN|Warty Penile Intraepithelial Neoplasia	Intraepithelial neoplasia of the penis characterized by a slightly spiking papillomatous surface with atypical parakeratosis. There is prominent cellular pleomorphism, koilocytosis, and mitoses. Unlike in basaloid penile intraepithelial neoplasia, there is squamous maturation. (WHO 2016)			Neoplastic Process	
C162544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162544>	C575	Zinostatin Stimalamer|SMANCS|YM 881|YM-881|YM881	A highly lipophilic conjugate protein comprised of the lipophilic antitumor protein, neocarzinostatin (NCS), conjugated with a water-soluble copolymer of styrene-maleic acid (SMA) with potential antineoplastic activity. Upon intra-hepatic arterial administration, zinostatin stimalamer is deposited within tumor tissues, where the NCS moiety induces sequence-specific single and double-stranded breaks via free-radical based mechanisms, resulting in tumor cell death.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C162545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162545>	C2826	Uroacitides|CDA-II|Cell Differentiation Agent II	A mixture of peptides, organic acids, pigments, and phenylacetylglutamine isolated from healthy human urine with potential antineoplastic activity. Upon administration, uroacitides, also known as cell differentiation agent II (CDA-II) may inhibit telomerase activity in tumor cells. This may lead to an accumulation of tumor cells in G1 phase and inhibition of tumor cell proliferation.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C162546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162546>	C162541	Warty-Basaloid Penile Intraepithelial Neoplasia|Warty-Basaloid PeIN	Intraepithelial neoplasia of the penis characterized by the presence of a variable mixture of warty and basaloid cells. (WHO 2016)			Neoplastic Process	
C162547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162547>	C7547|C3224	Penile Melanoma|Melanoma of the Penis	A melanoma that arises from the penis. It may be cutaneous or mucosal. The most common site of involvement is glans penis.			Neoplastic Process	
C162548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162548>	C7547|C7185	Penile Lymphoma|Lymphoma of the Penis|Primary Penile Lymphoma	A lymphoma that arises from penile skin, subcutis, corpora cavernosa, and spongiosum. Diffuse large B-cell lymphoma is the most common primary penile lymphoma. (WHO 2016)			Neoplastic Process	
C162549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162549>	C7547|C192664	Metastatic Malignant Neoplasm in the Penis	The spread of a malignant neoplasm to the penis from an adjacent or distant anatomic site.			Neoplastic Process	
C16254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16254>	C16946	Estradiol 17-Beta-Dehydrogenase 2|17-Beta Hydroxysteroid Dehydrogenase|17-Beta-HSD|17-Beta-HSD 2|17-Beta-Hydroxysteroid Dehydrogenase Type 2|20 Alpha-Hydroxysteroid Dehydrogenase|20-Alpha-HSD|E2DH|EC 1.1.1.62|EC 1.1.1.63|Estradiol 17 Beta-Dehydrogenase|HSD17B2|Hydroxysteroid 17-Beta Dehydrogenase 2|Microsomal 17-Beta-Hydroxysteroid Dehydrogenase|Testosterone 17-Beta-Dehydrogenase	Estradiol 17-beta-dehydrogenase 2 (387 aa, ~43 kDa) is encoded by the human HSD17B2 gene. This protein is involved in the synthesis of both androgens and estrogens.			Amino Acid, Peptide, or Protein|Enzyme	
C162551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162551>	C157093	Post-Operative Therapy Rounds Section|Post-Operative Therapy Rounds	A form header for post-operative therapy round information.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Renal Cell Carcinoma Follow-Up Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Follow-Up Form
C162552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162552>	C2167|C129825	Xiliertinib|HMPL 309|HMPL-309|HMPL309|Theliatinib|XILIERTINIB	An orally available, ATP-competitive inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration, xiliertinib binds to and inhibits the activity of EGFR. This prevents EGFR-mediated signaling, and may lead to both induction of cell death and inhibition of tumor growth in EGFR-overexpressing cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C162553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162553>	C213309|C204256|C129821	Sitimagene Ceradenovec|EG 009|EG-009|EG009	A replication-deficient adenovirus type 5 (Ad5) with E1 and partial E3 deletions containing cDNA for the herpes simplex virus thymidine kinase (HSV-Tk), which, when administered in combination with ganciclovir (GCV), possesses potential antineoplastic activity. Following administration, transgene-expressing cells produce thymidine kinase, which phosphorylates GCV to ganciclovir triphosphate, a cytotoxic nucleotide analog that is incorporated into DNA resulting in chain termination and induction of apoptosis in rapidly dividing cells. This process spares normal neurons as they do not proliferate and are therefore not susceptible to the toxic effects of GCV metabolites.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C162554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162554>	C2167|C1742|C129825	Pyrotinib Dimaleate|PYROTINIB MALEATE|Pyrotinib Maleate|SHR-1258 Maleate	The dimaleate ester of pyrotinib, an orally bioavailable, dual kinase inhibitor of the epidermal growth factor receptor (EGFR, ErbB1 or HER-1) and the human epidermal growth factor receptor 2 (ErbB2 or HER-2), with potential antineoplastic activity. Upon oral administration, pyrotinib binds to and inhibits both EGFR and HER2, which may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumor cells. EGFR and HER2 are receptor tyrosine kinases that are upregulated in various tumor cell types and play major roles in tumor cell proliferation and tumor vascularization.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162555>	C2152|C129825	Puquitinib|PUQUITINIB|XC-302 Free Base	An orally available selective inhibitor of the delta form of phosphatidylinositol 3-kinase (PI3-kinase subunit delta; PI3K-delta; PI3Kdelta), with potential antineoplastic activity. Upon oral administration, puquitinib selectively binds to the ATP-binding pocket of PI3K-delta and prevents the activation of the PI3K/AKT signaling pathway. This decreases proliferation of and induces cell death in PI3K-delta over-expressing tumor cells. PI3K-delta also plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of certain hematologic cancer cells. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells, thereby minimizing serious side effects.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C162556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162556>	C2152|C129825	Puquitinib Mesylate|PUQUITINIB MESYLATE|XC-302 Anhydrous	The mesylate salt of puquitinib, an orally available selective inhibitor of the delta form of phosphatidylinositol 3-kinase (PI3-kinase subunit delta; PI3K-delta; PI3Kdelta), with potential antineoplastic activity. Upon oral administration, puquitinib selectively binds to the ATP-binding pocket of PI3K-delta and prevents the activation of the PI3K/AKT signaling pathway. This decreases proliferation of and induces cell death in PI3K-delta over-expressing tumor cells. PI3K-delta also plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of certain hematologic cancer cells. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells, thereby minimizing serious side effects.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C162557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162557>	C40030|C15215	Endobronchial Cryotherapy	Cryoablation applied as treatment for benign and malignant central airway obstruction or the treatment of low-grade airway malignancy.	Endobronchial Cryotherapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C162558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162558>	C17230	B-Mode Ultrasound Imaging|B-Mode Ultrasound|Brightness-mode Ultrasound	A two-dimensional ultrasound imaging that displays the acoustic impedance of cross-section of tissue as bright dots representing the ultrasound echoes. The brightness of each dot is determined by the amplitude of the returned echo signal. This is the most common mode of ultrasound imaging.	B-Mode Ultrasound Imaging		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C162559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162559>	C17230	Acoustic Angiography	An ultrasound method for imaging blood vessels that uses dual-frequency ultrasound transducer technology to produce images with high resolution and a high contrast-to-tissue ratio and without significant contribution from background tissues.	Acoustic Angiography		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C16255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16255>	C19899	Acetylation|acetylation	Acetylation involves the covalent linkage of an acetyl group into an organic molecule.			Molecular Function	CBDD Process Terminology|CBDD Terminology
C162562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162562>	C40022|C3692	Primary Peritoneal Undifferentiated Carcinoma	An extremely rare carcinoma arising from the peritoneum. It is characterized by the presence of a diffuse malignant infiltrate that is composed of epithelial cells without evidence of glandular or squamous differentiation.	Primary Peritoneal Undifferentiated Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162563>	C2124|C129819	Lutetium Lu-177 Rituximab|177Lu-Rituximab|Lutetium-177 Labeled Rituximab	A radioconjugate composed of rituximab, a recombinant chimeric murine/human immunoglobulin G1 (IgG1) antibody directed against the CD20 antigen, conjugated to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon administration, the rituximab moiety targets and binds to CD20 expressed on tumor cells and delivers a cytotoxic dose of beta radiation to CD20-expressing cells. CD20 is expressed on the surface of pre-B and mature B-lymphocytes and is overexpressed in a variety of B-cell malignancies.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C162564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162564>	C40022|C2930	Primary Peritoneal Transitional Cell Carcinoma	An extremely rare transitional cell carcinoma that arises from the peritoneum.	Primary Peritoneal Transitional Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162565>	C1511|C129819	Lutetium Lu 177 Lilotomab-satetraxetan|177Lu Lilotomab Satetraxetan|177Lu-Lilotomab-satetraxetan|Betalutin|LUTETIUM (LU177) LILOTOMAB SATETRAXETAN|Lutetium Lu-177 Lilotomab Satetraxetan|Lutetium Lu-177 Lilotomab-satetraxetan	A radioconjugate consisting of lilotomab, a murine immunoglobulin G1 (IgG1) antibody directed against the CD37 antigen, conjugated via the chelating agent 2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-tetraacetic acid (p-SCN-Bn-DOTA) with potential antineoplastic activities. Upon administration of lutetium Lu 177 lilotomab-satetraxetan, the lilotomab moiety binds to CD37 expressed on certain tumor cells. Upon binding, lutetium Lu 177 lilotomab-satetraxetan delivers a cytotoxic dose of beta radiation to CD37-expressing cells. CD37 is a transmembrane glycoprotein expressed at high-levels on B-cells and to a lesser extent on T-cells and myeloid cells, and is frequently overexpressed in certain B-cell lymphomas.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C162566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162566>	C3766|C170733	Primary Peritoneal Clear Cell Adenocarcinoma|Primary Peritoneal Clear Cell Carcinoma|Primary Peritoneal Clear Cell Carcinoma	An extremely rare adenocarcinoma that arises from the peritoneum and is characterized by the presence of malignant epithelial clear cells.	Primary Peritoneal Clear Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162567>	C156880	Luminespib Mesylate|LUMINESPIB MESYLATE|Luminespib Mesilate|Luminespib Mesylate Hydrate|NVP-AUY922-AGB	The mesylate salt of luminespib, a derivative of 4,5-diarylisoxazole and a third-generation heat shock protein 90 (Hsp90) inhibitor with potential antineoplastic activity. Upon administration, luminespib binds with high affinity to and inhibits Hsp90, resulting in the proteasomal degradation of oncogenic client proteins; the inhibition of cell proliferation; and the elevation of heat shock protein 72 (Hsp72) in a wide range of human tumor cell lines. Hsp90, a 90 kDa molecular chaperone, plays a key role in the conformational maturation, stability and function of other substrate or "client" proteins within the cell, many of which are involved in signal transduction, cell cycle regulation and apoptosis, including kinases, transcription factors and hormone receptors.  Hsp72 exhibits anti-apoptotic functions; its up-regulation may be used as a surrogate marker for Hsp90 inhibition.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C162568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162568>	C1742|C155727	Infigratinib Mesylate|BGJ 398 Mesylate|BGJ-398 Mesylate|INFIGRATINIB MESYLATE	The mesylate salt of infigratinib, an orally bioavailable pan-inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. Upon administration, infigratinib selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. FGFRs are a family of receptor tyrosine kinases which may be upregulated in various tumor cell types and may be involved in tumor cell differentiation and proliferation, tumor angiogenesis, and tumor cell survival.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C162569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162569>	C7625|C35850|C216139	Localized Head and Neck Carcinoma|Non-Metastatic Head and Neck Carcinoma|Non-Metastatic Head and Neck Carcinoma	A head and neck carcinoma that is confined to the site in which it initially manifested without evidence of spread to other anatomic sites.	Non-Metastatic Head and Neck Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16256>	C27993	Acoustic|acoustic				Qualitative Concept	
C162570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162570>	C7625|C4878|C216138	Localized Lung Carcinoma|Non-Metastatic Lung Carcinoma|Non-Metastatic Lung Carcinoma	A lung carcinoma that is confined to the site in which it initially manifested without evidence of spread to other anatomic sites.	Non-Metastatic Lung Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162572>	C9231|C191981	Metastatic Merkel Cell Carcinoma|Secondary Merkel cell carcinoma	A Merkel cell carcinoma that has spread from the original site of growth to another anatomic site.	Metastatic Merkel Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|mCode Cancer Disorder Value Set|mCode Elixhauser Metastatic Cancer Value Set|mCode Secondary Cancer Disorder Value Set|mCode Terminology
C162573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162573>	C213692|C129825|C124800	Luxeptinib|32,72,74,76-Tetrafluoro-14-methyl-21,23-dihydro-11h-4,6-diaza-2(4,7)-isoindola- 1(2)-imidazola-3(1,4),7(1)-dibenzenaheptaphane-2,35-dione|CG 806|CG'806|CG-026806|CG-806|CG806|FLT3/BTK Inhibitor CG 806|LUXEPTINIB|Pan-FLT3/BTK Multi-Kinase Inhibitor CG 806|Pan-FLT3/Pan-BTK Inhibitor CG-806|Pan-FLT3/Pan-BTK Multi-kinase Inhibitor CG-806	An orally bioavailable reversible, pan-inhibitor of both FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2) and Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), with potential antineoplastic activity. Upon oral administration, luxeptinib targets, non-covalently binds to and inhibits the activity of both FLT3, including both wild-type (WT) FLT3 and FLT3-ITD (internal tandem duplications), tyrosine kinase domain (FLT3-TKD), and gatekeeper (FLT3-F691L) mutant forms, and BTK, including both the WT and its C481S mutant (BTK-C481S) form. This inhibits both uncontrolled FLT3-mediated and B-cell antigen receptor (BCR)-mediated signaling, respectively. This results in the inhibition of proliferation in tumor cells overexpressing FLT3 and BTK. In addition, CG-806 also inhibits, to a lesser degree, other oncogenic kinases, such as MET, RET, discoidin domain-containing receptor 2 (DDR2), Aurora kinase A, and interleukin-2-inducible T-cell kinase (ITK). FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias (AMLs), and plays a key role in tumor cell proliferation. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases essential to BCR signaling, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B-lymphocytes.	Luxeptinib		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162574>	C3377|C3317	Penile Soft Tissue Neoplasm|Penile Mesenchymal Neoplasm	A rare mesenchymal neoplasm that arises from the penis.			Neoplastic Process	
C162575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162575>	C17646	99mTc Bone Scintography|99mTc Bone Scintigraphy|99mTc Bone Scintiscan|99mTc Bone Scintiscanning	An imaging modality that reflects alterations in the metabolic activity of bone through the use of radiopharmaceutical agents, commonly technetium-99m-labeled methylene diphosphonate (MDP).			Diagnostic Procedure	GDC Terminology|GDC Value Terminology
C162576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162576>	C62669	ProMark Proteomic Prognostic Test|ProMark|ProMark Proteomic Prognostic Test for Prostate Cancer|Promark	A proprietary tissue-based test that uses multiplex immunofluorescent staining with monoclonal antibodies to provide a personalized prediction for prostate cancer aggressiveness. It detects an 8-protein signature (DERL1, CUL2, SMAD4, PDSS2, HSPA9, FUS, pS6 (phosphorylated S6), YBOX1).			Laboratory Procedure	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C162577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162577>	C28227|C155711	Anbenitamab|ANBENITAMAB|Anti-HER-2 Bispecific Antibody KN026|Anti-HER2 Heterodimeric Antibody KN026|HER2 Bispecific Antibody KN026|KN 026|KN-026|KN026	An engineered Fc-based heterodimeric bispecific monoclonal antibody, derived from trastuzumab and pertuzumab, directed against two distinct epitopes of the extracellular dimerization domain of the tumor-associated antigen (TAA) human tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), with potential immunomodulating and antineoplastic activities. Upon administration, anbenitamab simultaneously targets and binds to two separate, non-overlapping epitopes of HER-2, thereby inhibiting HER-2 heterodimerization and prevents the activation of HER-2 signaling pathways. By binding to HER-2, KN026 induces an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER-2. This results in tumor cell apoptosis and inhibits tumor cell proliferation of HER-2-overexpressing tumor cells. HER-2, overexpressed on a variety of tumor cell types, plays an important role in proliferation, differentiation and survival.	Anbenitamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162578>	C7730|C35218|C121671	Penile Angiosarcoma	A rare angiosarcoma that affects the penis.			Neoplastic Process	
C162579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162579>	C4905|C35218|C3489|C162574	Penile Hemangioma	A hemangioma that occurs in the skin of the penis.			Neoplastic Process	
C16257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16257>	C17728|C16492	Actin-Binding Protein|ABP|Actin Binding Protein|Actin Binding Proteins	A diverse group of proteins that bind to actin. These proteins direct a complex network of protein filaments that provide stability to the cellular infrastructure by supporting the dynamic motility of microfilaments, thereby enabling intracellular translocation and organelle transport.			Amino Acid, Peptide, or Protein|Biologically Active Substance	
C162580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162580>	C7393|C162579	Penile Epithelioid Hemangioma	An epithelioid hemangioma that occurs in the skin of the penis.			Neoplastic Process	
C162581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162581>	C7547|C4867|C3800|C35218|C162574	Penile Epithelioid Hemangioendothelioma	An epithelioid hemangioendothelioma that occurs in the penis.			Neoplastic Process	
C162582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162582>	C3060|C162574	Penile Glomus Tumor	A glomus tumor that occurs in the penis.			Neoplastic Process	
C162583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162583>	C6510|C3489|C162574	Penile Leiomyoma	A leiomyoma that occurs in the penis.			Neoplastic Process	
C162584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162584>	C7730|C3798	Penile Malignant Peripheral Nerve Sheath Tumor	A rare malignant peripheral nerve sheath tumor that occurs in the penis.			Neoplastic Process	
C162585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162585>	C7730|C3158	Penile Leiomyosarcoma	A leiomyosarcoma that occurs in the penis.			Neoplastic Process	
C162586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162586>	C41430|C3489	Penile Schwannoma	A schwannoma that occurs in the penis.			Neoplastic Process	
C162587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162587>	C3489|C3272	Penile Neurofibroma	A neurofibroma that occurs in the penis.			Neoplastic Process	
C162588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162588>	C7730|C214845	Penile Rhabdomyosarcoma	A rhabdomyosarcoma that occurs in the penis. It usually affects young children. Embryonal rhabdomyosarcoma is the most common type.			Neoplastic Process	
C162589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162589>	C7730|C4247	Penile Undifferentiated Pleomorphic Sarcoma	A rare undifferentiated pleomorphic sarcoma that occurs in the penis.			Neoplastic Process	
C16258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16258>	C16852	Actin	A globular subunit of microfilaments, highly conserved Actin is one of the most abundant proteins in eukaryotic cells. Monomeric actin, a slow ATPase composed of a 375 amino acid polypeptide chain, interacts with one molecule of ATP or ADP and contains high affinity and low affinity binding sites for divalent cations. Actin can quickly assemble into long microfilament polymers. In conjunction with myosin, actin is responsible for the contraction and relaxation of muscle.			Amino Acid, Peptide, or Protein|Biologically Active Substance	
C162590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162590>	C4242|C3489|C162574	Penile Myointimoma|Myointimoma	A rare benign mesenchymal neoplasm that occurs in the glans and corpora of the penis. It is characterized by the proliferation of spindle-shaped myofibroblasts in the intravascular spaces.			Neoplastic Process	Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C162591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162591>	C35963	Intravascular Myofibroblastic Proliferation	A morphologic finding indicating the proliferation of spindle-shaped myofibroblasts within vascular spaces in a tissue sample.			Finding	
C162592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162592>	C35218|C3489|C27509|C162574	Penile Lymphangioma	A lymphangioma that occurs in the skin of the penis.			Neoplastic Process	
C162594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162594>	C4013|C36263	Metastatic Malignant Neoplasm in the Head and Neck|Metastatic Malignant Neoplasm to the Head and Neck	The spread of a malignant neoplasm to the head and neck.  This may be from a primary head and neck malignant neoplasm, or from a malignant neoplasm at a distant site.			Neoplastic Process	
C162595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162595>	C3812|C162594	Head and Neck Carcinoma of Unknown Primary|Head and Neck CUP	A carcinoma that has metastasized to the head and neck region from an unknown primary anatomic site. Metastatic squamous cell carcinoma in the neck lymph nodes accounts for the vast majority of these lesions.	Head and Neck Carcinoma of Unknown Primary		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162596>	C91102	Was In Situ Hybridization Performed Question|Was ISH Performed|Was In Situ Hybridization Performed|Was In Situ Hybridization Performed	A question asking if in situ hybridization assays were performed during the study.			Intellectual Product	
C162597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162597>	C63480	Protein Expression Analysis by Immunohistochemistry|Expression by IHC|Expression by Immunohistochemistry|Protein Expression Analysis by IHC|Protein Expression by Immunohistochemistry	The use of immunohistochemical methods to detect the expression of proteins in a sample.			Laboratory Procedure	
C162598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162598>	C160157	Additional Surgery for new Loco-Regional Tumor Event Not Evaluated|Not-Evaluated: Not provided or available	The need for additional surgery for a new loco-regional tumor event was not evaluated.			Intellectual Product	CPTAC Follow-Up Forms Terminology|CPTAC Glioblastoma Multiforme Follow-Up Form|CPTAC Terminology
C162599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162599>	C91102	Was RT-PCR Performed Question|Was RT-PCR Performed|Was RT-PCR Performed|Was Reverse Transcriptase-Polymerase Chain Reaction Analysis Performed	A question asking if reverse transcriptase-polymerase chain reaction assays were performed during the study.			Intellectual Product	
C16259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16259>	C17210	Acyltransferase|Acetyltransferase|EC 2.3	Class of enzymes that catalyze the transfer of acyl groups, most commonly a carboxylic acyl group forming either esters or amides.			Amino Acid, Peptide, or Protein|Enzyme	
C1625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1625>	C69145|C2149	MEK Inhibitor PD-98059|2'-Amino-3'-methoxyflavone|2-(2-Amino-3-methoxyphenyl)-4H-1-benzopyran-4-one|2-(2-Amino-3-methoxyphenyl)-4H-1-benzopyran-4-one|4H-1-Benzopyran-4-one, 2-(2-amino-3-methoxyphenyl)-|PD 098059|PD 98059|PD-98059	A cell-permeable, selective mitogen-activated protein (MAP) kinase inhibitor which exhibits activity through the inhibition of the phosphorylation and activation of MAP kinase. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C162600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162600>	C2955|C155903	Unresectable Colorectal Carcinoma	A colorectal carcinoma that is not amenable to surgical resection.	Unresectable Colorectal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162601>	C157093	Bone Marrow Differential Count within 24 Hours of Banking|Differential Count, Bone Marrow (Within 24 Hours of Banking)	A section header for lab results related to a bone marrow differential count obtained within 24 hours of banking.			Activity	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology
C162602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162602>	C4131|C27345	Unresectable Fibrolamellar Carcinoma|Unresectable Fibrolamellar Hepatocellular Carcinoma	A fibrolamellar carcinoma that is not amenable to surgical resection.	Unresectable Fibrolamellar Hepatocellular Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162603>	C160157	Additional Surgery for New Tumor Event Not Evaluated|Not-Evaluated: Not provided or available	The need for additional surgery for a new tumor event was not evaluated.			Intellectual Product	CPTAC Acute Myeloid Leukemia Follow-Up Form|CPTAC Follow-Up Forms Terminology|CPTAC Terminology
C162604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162604>	C160157	Paraneoplastic Syndrome is Present|Yes	A response that paraneoplastic syndrome is present.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Glioblastoma Multiforme Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C162605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162605>	C160157	Lymphatic Invasion is Present|Present	A response that lymphatic invasion is present in a specimen.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology
C162606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162606>	C160157	Tumor Cell Necrosis is Present|Present	A response indicating the presence of tumor cell necrosis.	Tumor Cell Necrosis		Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Clear Cell Renal Cell Carcinoma Baseline Form|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Melanoma Baseline Form|CPTAC Pancreatic Baseline Form|CPTAC Sarcoma Baseline Form|CPTAC Terminology|CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form
C162607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162607>	C160157	Tumor Infiltrating Lymphocyte is Present|Present	An indication of the presence of tumor infiltrating lymphocytes.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Melanoma Baseline Form|CPTAC Terminology
C162608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162608>	C116655	Navigated Transcranial Magnetic Stimulation|Navigated TMS|nTMS	Transcranial magnetic stimulation that uses image-based knowledge of individual patient brain anatomy for determining the dose and location targeting of stimulation. Navigation combines data on anatomical structures with known delivery of stimulation, forming the basis for dose determination and targeting.	Navigated Transcranial Magnetic Stimulation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C162609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162609>	C48881	Clinical Regional Lymph Nodes TNM Finding|Clinical N Category	A clinical finding about one or more characteristics of a specific cancer, following the rules of the TNM classification system as they pertain to evaluating regional lymph nodes.			Finding	
C16260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16260>	C17434	Adenine Phosphoribosyltransferase|APRT|EC 2.4.2.7	Adenine phosphoribosyltransferase (180 aa, ~20 kDa) is encoded by the human APRT gene. This protein is involved in the recycling of adenine and AMP.			Amino Acid, Peptide, or Protein|Enzyme	
C162610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162610>	C48881	Clinical Distant Metastasis TNM Finding|Clinical M Category	A clinical finding about one or more characteristics of a specific cancer, following the rules of the TNM classification system as they pertain to evaluating distant metastases.			Finding	
C162611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162611>	C34378	Warm Antibody Autoimmune Hemolytic Anemia|WAHA|Warm Autoimmune Hemolytic Anemia|wAIHA	The most common form of autoimmune hemolytic anemia, in which the autoantibodies react with red blood cells at temperatures greater than or equal to 37 degrees Celsius.	Warm Antibody Autoimmune Hemolytic Anemia		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C162612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162612>	C4726|C148077	Recurrent Adamantinomatous Craniopharyngioma	The reemergence of adamantinomatous craniopharyngioma after a period of remission.	Recurrent Adamantinomatous Craniopharyngioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162613>	C215116	Hand Function Test|Hand Sensory Test	Various tasks that test an individual's grip strength, pinch strength, and ability to use and feel with their hands.	Hand Function Test		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C162614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162614>	C160157	Tumor Laterality Midline|Midline|Midline	A finding indicating the tumor location is on the midline of the specimen.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology|HL Authorized Value Terminology|HL Lesion Characteristics Table
C162615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162615>	C160157	Tumor Laterality Unknown|Unknown	A finding indicating the tumor laterality is unknown.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form|CPTAC Terminology
C162616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162616>	C9356|C164159|C150515	Locally Advanced Ureter Urothelial Carcinoma	A ureter urothelial carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Ureter Urothelial Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162617>	C172277|C164159|C150514	Locally Advanced Renal Pelvis Urothelial Carcinoma	A renal pelvis urothelial carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Renal Pelvis Urothelial Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162618>	C167071|C157636|C150513	Locally Advanced Bladder Urothelial Carcinoma	A bladder urothelial carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Bladder Urothelial Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162619>	C7639|C157636|C150512	Locally Advanced Urethral Urothelial Carcinoma	A urethral urothelial carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Urethral Urothelial Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16261>	C16701	Adenosine Deaminase|ADA|Adenine Deaminase|Adenosine Aminohydrolase|EC 3.5.4.4	Adenosine deaminase (363 aa, ~41 kDa) is encoded by the human ADA gene. This protein plays a role in purine metabolism.	Adenosine Deaminase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162620>	C201173|C200766|C176018	Autologous Anti-CD19/CD22 CAR T-cells AUTO3|AUTO 3|AUTO-3|AUTO3|Anti-CD19/CD22 CAR Autologous T-lymphocytes AUTO3	A preparation of autologous T-lymphocytes that have been transduced with a bicistronic retroviral vector encoding both an anti-CD19 chimeric antigen receptor (CAR) fused to OX40 co-stimulatory domain and an anti-CD22 CAR linked to the intracellular signaling domains of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), optimized with a novel pentameric spacer derived from the collagen oligomeric matrix protein (COMP), with potential antineoplastic activity. Upon administration, the autologous anti-CD19/CD22 CAR T-cells AUTO3 bind to and induce selective toxicity in tumor cells expressing CD19 and CD22. CD19 and CD22, both transmembrane phosphoglycoproteins expressed on the surface of cells in the B lineage, are often overexpressed on malignant B-cells. By simultaneously targeting two B-cell antigens, this preparation may minimize relapse due to single antigen loss in patients with B-cell malignancies.	Autologous Anti-CD19/CD22 CAR T-cells AUTO3		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162621>	C42729	QC Slide Review|Quality Control Slide Review|Slide Review|Slide Review, Quality Control	Tissue Source Sites (TSS) will perform a QC review of tumor biospecimens by review of slides from corresponding FFPE QC blocks. For each tumor segment, an H&E-stained slide is to be prepared and reviewed by the TSS pathologist to confirm accuracy of tissue diagnosis and tumor composition.			Activity	
C162622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162622>	C18009	Tumor Segment	Sufficient total material from each patient, divided to yield a minimum of one aliquot, preferably divided into three to five aliquots, of specified cancer tissue suitable for processing for proteomic and genomic analysis.			Tissue	
C162623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162623>	C19697	Normal Tissue Sample|Normal Tissue|Normal Tissue Segment|Normal Tissue Segment|Normal Tissue Segment|Uninvolved Tissue, NOS	Tissue sample with cellular composition and architectural patterns expected for the particular anatomic site in which it belongs. There is no evidence of abnormal cellular infiltrates or tumor mass formation.			Tissue	GDC Terminology|GDC Value Terminology
C162624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162624>	C28681|C213868|C129826	Patient-derived WT1/PRAME/Survivin-specific Cytotoxic T-lymphocytes|Autologous Tumor Antigen Associated Cytotoxic T-Lymphocytes|Patient-derived Multi-antigen Associated Cytotoxic T-lymphocytes|Patient-derived WT1/PRAME/Survivin-specific T-lymphocytes|TAA-T|TAATs	A preparation of autologous cytotoxic T-lymphocytes (CTLs) specifically reactive to the tumor associated antigens (TAAs) human Wilms tumor protein (WT1), preferentially expressed antigen of melanoma (PRAME, melanoma antigen preferentially expressed in tumors; Opa-interacting protein 4), and survivin (baculoviral IAP repeat-containing protein 5), with potential antineoplastic activities. Upon collection, expansion, and stimulation with antigen presenting cells pulsed with an overlapping peptide library spanning the TAAs, the multi-antigen associated CTLs are re-introduced into the patient and may induce a CTL-mediated response against tumor cells expressing WT1, PRAME, or survivin, potentially leading to tumor cell lysis and inhibition of tumor cell proliferation. WT1, PRAME, and survivin, are expressed on certain tumor cell types and play key role in tumor cell proliferation and survival.	Patient-derived WT1/PRAME/Survivin-specific Cytotoxic T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162625>	C141146|C129820	Verzistobart|Anti-TIM-3 Monoclonal Antibody INCAGN02390|INCAGN 02390|INCAGN-02390|INCAGN02390|VERZISTOBART	A fully human Fc-engineered immunoglobulin G1 kappa (IgG1kappa) antibody directed against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, verzistobart forms a high-affinity interaction with TIM-3 expressed on certain T-cells, thereby preventing the engagement of TIM-3 by its ligands, phosphatidylserine (PtdSer) and galectin-9. This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor cell proliferation. Additionally, INCAGN02390 elicits TIM-3 receptor internalization, potentially preventing interactions with other ligands.TIM-3, a transmembrane protein and immune checkpoint receptor expressed on certain lymphocytes, including tumor infiltrating lymphocytes (TILs), is associated with tumor-mediated immune suppression.	Verzistobart		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162626>	C222322|C200766	Autologous Anti-gp100CAR-CD3zeta-4-1BB-IL-15-PD1-expressing Tri-functional T-lymphocytes|GPA-TriMAR-T-cells|PA-TriMAR Lentiviral Vector-transduced Autologous T-cells	A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector encoding a tri-functional chimeric antigen receptor (TriCAR) comprised of an extracellular domain consisting of an antigen binding domain specific to glycoprotein 100 (gp100) peptides 209-217 complexed with human leukocyte antigen A2 (HLA-A2), interleukin 15 (IL-15) and programmed cell death 1 (PD1; PDCD1; CD279; programmed death-1), which are linked by a transmembrane domain to the intracellular signaling domains of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), with potential antineoplastic activity. Upon administration, the autologous anti-gp100CAR-CD3zeta-4-1BB-IL-15-PD1-expressing tri-functional T-lymphocytes selectively bind to gp100 peptides presented by HLA-A2. Upon binding to the gp100-HLA complex, the T-cells release cytokines and induce selective toxicity in gp100-expressing tumor cells. IL-15 is a pro-survival cytokine that promotes T-cell persistence and potentiates the immune response against tumor cells. The PD1 moiety binds to programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) on tumor cells, reversing T-cell inactivation caused by endogenous PD1/PD-L1 signaling and enhancing the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162627>	C28681|C138180|C129826	Autologous LMP1/LMP2/EBNA1-specific HLA-A02:01/24:02/11:01-restricted TCR-expressing T-lymphocytes YT-E001|Autologous EBV-specific TCR T-cells YT-E001|YT E001|YT-E001|YTE001	A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector encoding a T-cell receptor (TCR) specific for human leukocyte antigen (HLA)-A02:01/24:02/11:01-restricted Epstein-Barr virus (EBV) latent membrane proteins (LMP) 1 and 2, and EBV nuclear antigen 1 (EBNA1), with potential antineoplastic activity. Upon administration, the autologous LMP1/LMP2/EBNA1-specific, HLA-A02:01/24:02/11:01-restricted TCR-expressing T-lymphocytes YT-E001 recognize and bind to HLA-presented EBV peptides, which may promote cell death and inhibit the growth of tumor cells expressing LMP1, LMP2 or EBNA1. LMP1, LMP2, and EBNA1 are expressed in various, EBV-associated malignancies, including nasopharyngeal cancer and EBV-positive Hodgkin lymphoma.	Autologous LMP1/LMP2/EBNA1-specific HLA-A02:01/24:02/11:01-restricted TCR-expressing T-lymphocytes YT-E001		Cell|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162628>	C16230|C16135	Whole Abdominopelvic Intensity-Modulated Radiotherapy|Abdominopelvic Intensity-Modulated Radiotherapy|Whole Abdominopelvic Intensity Modulated Radiotherapy	Intensity-Modulated radiation therapy meant to expose all tissues and organs within the abdominal cavity and pelvic region.	Whole Abdominopelvic Intensity-Modulated Radiotherapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C162629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162629>	C190796	Sacubitril Valsartan Sodium Hydrate|3-(1-Biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-3'-methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylmethyl)amino)butyrate|Entresto|Entresto|L-Valine, N-(1-oxopentyl)-N-((2'-(2H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, compd. with alpha-ethyl(alphaR,gammaS)-gamma-((3-carboxy-1-oxopropyl)amino)-alpha-methyl(1,1'-biphenyl)-4-pentanoate, sodium salt, hydrate (2:2:6:5)|LCZ 696|LCZ-696|LCZ696|SACUBITRIL VALSARTAN SODIUM HYDRATE|Sacubitril Mixture With Valsartan|Sacubitril-Valsartan|Sacubitril/Valsartan Sodium Hydrate|Trisodium (3-(1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-3'-methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylmethyl)amino)butyrate) hemipentahydrate	A combination of sacubitril and valsartan with natriuretic and anti-hypertensive properties. Upon administration, sacubitril is metabolized by esterases to its active metabolite, LBQ657 (sacubitrilat), which inhibits neprilysin, a neutral endopeptidase that cleaves natriuretic peptides such as atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and c-type natriuretic peptide (CNP), as well as certain vasoconstricting peptides including as angiotensin I and II, and endothelin-1. Inhibition of neprilysin leads to increased concentrations of endogenous natriuretic peptides, which function to activate downstream receptors that promote vasodilation, natriuresis and diuresis, while simultaneously increasing the concentration of vasoconstricting peptides such as angiotensin II. Co-administration with valsartan, an angiotensin II receptor blocker, prevents the vasoconstrictive effects of neprilysin inhibition and promotes a decrease in vascular resistance and blood pressure.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology
C16262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16262>	C17077	Purinergic P1 Receptor|Adenosine Receptor	One of the purinergic P1 receptors that prefers adenosine to other endogenous purines.			Amino Acid, Peptide, or Protein|Receptor	
C162630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162630>	C105822	HOXB1 Gene|HOXB1|HOXB1|HOXB1|Homeobox B1 Gene	This gene is involved in the development of anterior embryonic structures and facial nerves.			Gene or Genome	GDC Terminology|GDC Value Terminology
C162631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162631>	C162630	HOXB1 wt Allele|HCFP3|HOX2|HOX2I|Homeo Box B1 Gene|Homeobox 2I Gene|Homeobox B1 wt Allele|Hox-2.9|Hox-2.9, Mouse, Homolog of Gene	Human HOXB1 wild-type allele is located in the vicinity of 17q21.32 and is approximately 2 kb in length. This allele, which encodes homeobox protein Hox-B1, plays a role in the the regulation of anterior-posterior axis polarity. Mutation of the gene is associated with hereditary congenital facial palsy 3.			Gene or Genome	
C162632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162632>	C17207	Homeobox Protein Hox-B1|HOXB1|Homeobox Protein Hox-2I	Homeobox protein Hox-B1 (301 aa, ~32 kDa) is encoded by the human HOXB1 gene. This protein is involved in anterior-posterior patterning and facial nerve development.			Amino Acid, Peptide, or Protein	
C162633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162633>	C1752|C1663	Personalized Neoantigen Peptide Vaccine iNeo-Vac-P01|iNeo-Vac-P01	A peptide-based, personalized cancer vaccine consisting of patient-specific mutated long peptides, which are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. Upon vaccination with the personalized neoantigen peptide vaccine iNeo-Vac-P01, the peptides stimulate the host immune system to mount a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis.	Personalized Neoantigen Peptide Vaccine iNeo-Vac-P01		Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162634>	C213309	Adenoviral Vector Encoding VEGF-C LX-1101|AdAptVEGF-C Adenoviral Vector LX-1101|LX 1101|LX-1101|LX1101|Lymfactin|VEGFC-expressing Gene Therapeutic LX-1101	A genetically engineered, replication-deficient adenovirus carrying the gene encoding for the human vascular endothelial growth factor C (VEGFC; VEGF-C; Flt4 ligand), with potential pro-angiogenic activity. Upon perinodal administration of the AdAptVEGF-C adenoviral vector LX-1101, the adenovirus infects cells and promotes expression of VEGF-C. In turn, VEGF-C induces vascular and lymphatic endothelial cell proliferation locally, and may help re-grow the lymphatic system and improve symptoms associated with lymphedema (LE). VEGF-C, a lymphatic growth factor, plays a key role in (lymph)angiogenesis and the functioning of the lymphatic system.			Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162635>	C717	Oncolytic HSV-1 C134|C 134|C-134|C134|C134-HSV-1|IRS-1 HSV C134|oHSV C134	A neurovirulent, oncolytic second-generation, replication-competent, recombinant and genetically-engineered herpes simplex virus type 1 (HSV-1) where the gene for ICP34.5 has been deleted and the gene encoding the human cytomegalovirus (HCMV), protein kinase R (PKR) evasion protein IRS1, with potential oncolytic and immunostimulating activities. Upon intratumoral administration, oncolytic HSV-1 C134 specifically infects and replicates within the rapidly dividing, glioma cells, thereby directly lysing tumor cells. The released virus particles, in turn, infect and replicate in neighboring tumor cells, thereby further killing tumor cells. Tumor antigens released from the lysed tumor cells also activate the immune system to induce a tumor-specific systemic immune and cytotoxic T-lymphocyte (CTL) response, thereby killing nearby non-infected tumor cells. Deletion of the gene encoding for ICP34.5 imparts tumor selectivity by preventing replication in healthy cells. IRS1 expression allows the virus to replicate within tumors but limits viral spread.	Oncolytic HSV-1 C134		Pharmacologic Substance|Virus	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162636>	C129822|C128037	Rulonilimab|Anti-PD-1 Monoclonal Antibody F520|F 520|F520|RULONILIMAB	A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration,rulonilimab targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; B7-H1; CD274) and 2 (PD-L2); it plays an important role in tumor evasion from host immunity.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162637>	C129826	Chimeric Costimulatory Converting Receptor-modified NK-92 Cells|CCCR-NK92 Cells|CCCR-modified NK92 Cells|Chimeric Co-stimulatory Converting Receptor-modified NK92 Cells	A preparation of genetically-modified natural killer (NK) cells derived from the allogeneic NK-92 cell line that are transduced with an as of yet unspecified chimeric costimulatory converting receptor (CCCR) for cancer retargeting purposes, with potential cytolytic, immunomodulating and antineoplastic activities. Upon infusion of the CCCR-modified NK-92 cells, the redirected NK cells recognize and bind to tumor cells. This leads to the secretion and release of perforins, granzymes, cytokines and chemokines, which results in selective tumor cell lysis. The NK-92 cells are derived from a human cytotoxic cell line composed of allogeneic, activated, interleukin-2-(IL-2) dependent-NK cells from a 50-year old male patient with rapidly progressive non-Hodgkin's lymphoma. As NK-92 cells are devoid of killer inhibitory receptors (KIRs; also called killer cell immunoglobulin-like receptors), which are negative regulators of NK cell activity, cancer cells are unable to suppress the cancer cell killing ability of the NK-92 cells.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162639>	C35682|C175007	Paraneoplastic Antibody Positive|Anti-Paraneoplastic Antigen Antibody Positive|Paraneoplastic Antigen Antibody Positive	An indication that autoantibodies that recognize paraneoplastic antigens have been detected in a sample.	Paraneoplastic Antibody Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C16263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16263>	C20130	ATPase|ATP Hydrolase|Adenosine Triphosphatase|Adenosinetriphosphatase	ATPases are a group of enzymes that catalyze ATP hydrolysis coupled with another function such as transporting Ca(2+) across a membrane. These enzymes may be dependent on Ca(2+), Mg(2+), anions, H+, or DNA. Many structural (e.g. myosin) and transport (e.g. ion pump) proteins include an ATPase domain.			Amino Acid, Peptide, or Protein|Enzyme	
C162640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162640>	C48966	Paraneoplastic Antibody|Anti-Paraneoplastic Antigen Antibody|Paraneoplastic Antigen Antibody	Any autoantibody produced by an individual organism in response to antigens expressed by a neoplasm present in that individual. These antibodies can cause harmful autoimmune responses in tissues or organs that are distant from the site of the neoplasm.	Paraneoplastic Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Terminology
C162641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162641>	C1511	Indium In 111-Autologous CMV-pp65-LAMP mRNA Loaded Dendritic Cells|111In-labeled Autologous CMV-pp65-LAMP mRNA Loaded Dendritic Cells|111In-labeled pp65-LAMP mRNA Loaded Mature Autologous DCs|Indium In 111-CMV pp65-LAMP mRNA-pulsed Autologous DCs|Indium In 111-labeled CMV pp65 Peptide-pulsed Autologous DCs	A radioimmunoconjugate composed of mature autologous dendritic cells (DCs) generated from peripheral blood leukocytes pulsed with mRNA encoding for a fusion protein comprised of the human cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) fused with the lysosome-associated membrane protein (pp65-LAMP) and radiolabeled with the isotope indium In 111, with potential ability to track DC migration upon single-photon emission computed tomography (SPECT)/ computed tomography (CT). Upon intradermal injection of the indium In 111-autologous CMV pp65-LAMP mRNA loaded DCs into the groin area, the DCs migrate in vivo to the inguinal lymph nodes. Upon SPECT/CT imaging, DC in vivo migration to the lymph nodes can be assessed.	Indium In 111-Autologous CMV-pp65-LAMP mRNA Loaded Dendritic Cells		Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C162642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162642>	C155901|C135017	Unresectable Lung Non-Squamous Non-Small Cell Carcinoma	Lung non-squamous non-small cell carcinoma that is not amenable to surgical resection.	Unresectable Lung Non-Squamous Non-Small Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162644>	C16809	MR Fingerprinting|MRF	A novel application of magnetic resonance imaging. Instead of using a repeated, serial acquisition of data for the characterization of individual parameters of interest, MRF uses a pseudorandomized acquisition that causes the signals from different materials or tissues to have a unique signal evolution or "fingerprint" that is simultaneously a function of the multiple material properties under investigation. The processing after acquisition involves a pattern recognition algorithm to match the fingerprints to a predefined dictionary of predicted signal evolutions. These can then be translated into quantitative maps of the MR parameters of interest.	MR Fingerprinting		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C162645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162645>	C587	Pegenzileukin|IL-2 Variant THOR-707|PEGENZILEUKIN|Pegylated Recombinant IL-2 Variant THOR-707|Pegylated Recombinant Interleukin-2 THOR-707|SAR 444245|SAR-444245|SAR444245|THOR 707|THOR-707|THOR707	A pegylated recombinant, engineered variant of cytokine interleukin-2 (IL-2; IL2) where novel amino acid is encoded in the IL-2 gene that is leveraged for use in site-specific pegylation, with potential immunostimulating activity. Upon administration of pegenzileukin, the IL-2 variant moiety binds to dimers containing the IL-2 receptor beta and gamma chains (IL2Rbg; IL2Rbetagamma) on immune cells, such as cytotoxic T-lymphocytes (CTLs) and natural killer (NK) cells, thereby activating these cells and inducing their expansion. It also induces the expression of certain cytotoxic cytokines, such as interferon-gamma (IFNg) and transforming growth factor-beta (TGFb). The specific induction of T-cell-mediated cytotoxic immune responses against tumor cells causes tumor cell destruction. The addition of the novel amino acid and the concurrent pegylation prevents the binding of the IL-2 moiety to the IL-2 receptor alpha chain (IL2Ra), thereby blocking the IL2Ra-mediated activation of CD4-positive regulatory and immunosuppressive T-cells (Tregs). Since it cannot bind to IL2Ra expressed on innate lymphoid cells in the vascular endothelium, pegenzileukin prevents IL-2-mediated recruitment and activation of eosinophils, and inhibits the induction of eosinophil-mediated vascular leak syndrome (VLS). Pegylation also extends the half-life of pegenzileukin. Compared to recombinant IL-2, pegenzileukin allows for increased IL-2Rbg binding and proliferation of CTLs without stimulating the toxicity caused by binding to IL-2Ra.	Pegenzileukin		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162646>	C16809	7 Tesla Magnetic Resonance Imaging|7 T MRI|7 Tesla MRI	MRI that uses a magnet capable of producing a 7 tesla field strength. This increased magnet strength is can produce images with greater signal-to-noise ratio and increased spatial resolution, or faster imaging at standard resolution.	7 Tesla Magnetic Resonance Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C162647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162647>	C15372	Behavioral Activation Intervention to Smoking Cessation and to Post-Cessation Weight Gain|BAS+	A smoking cessation program. The goal of the BAS+ is to maintain a level of overall reward after cessation by structuring and enhancing opportunities for reinforcement to: ensure that not smoking is as reinforcing as smoking; and prevent an over-reliance on food as a substitute reinforcer for smoking so that post-cessation weight gain does not precipitate smoking relapse.	Behavioral Activation Intervention to Smoking Cessation and to Post-Cessation Weight Gain		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C162648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162648>	C153238|C153171	Advanced Breast Carcinoma	Breast carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Breast Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162649>	C575	Engineered Toxin Body Targeting HER2 MT-5111|ETB Targeting HER2 MT-5111|HER2-targeted ETB MT-5111|Immunotoxin MT-5111|MT 5111|MT-5111|MT5111|Recombinant Fusion Protein MT-5111|Targeted Engineered Toxin Body MT-5111	An engineered toxin body (ETB) composed of a single chain variable fragment (scFv) from an antibody targeting the human epidermal growth factor receptor 2 (HER2; HER-2), fused to the enzymatically active de-immunized, ribosome-inactivating cytotoxic payload Shiga-like toxin-A subunit (SLTA), with potential antineoplastic activity. Upon administration, the scFv moiety of MT-5111 specifically targets and binds to a distinct epitope on HER2-expressing cells. Upon internalization, the SLTA moiety is released and acts as an N-glycosidase, which binds to and cleaves an adenine nucleobase in the 28S RNA component of the 60S subunit of ribosomes and prevents ribosome activity. This inhibits protein synthesis and leads to apoptosis in HER2-expressing tumor cells. HER2, a tumor-associated antigen (TAA), is overexpressed in a variety of tumor cell types.	Engineered Toxin Body Targeting HER2 MT-5111		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C16264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16264>	C20130	Adenylate Cyclase|3',5'-Cyclic AMP Synthetase|ATP Diphosphate-Lyase (Cyclizing)|ATP Diphosphate-Lyase (Cyclizing; 3',5'-Cyclic-AMP-Forming)|ATP Pyrophosphate-Lyase|Adenyl Cyclase|Adenylyl Cyclase|Adenylylcyclase|EC 4.6.1.1	Adenylyl cyclases are membrane-associated enzymes of the lyase class that are expressed in most human tissues. These enzymes catalyze the formation of cyclic AMP and pyrophosphate from ATP and are regulated by a family of G protein-coupled receptors, protein kinases, and calcium.			Amino Acid, Peptide, or Protein|Enzyme	
C162650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162650>	C209927	Localized Metastasis|Focal Metastasis	The focal spread of a malignant tumor in a single anatomic site.			Finding	
C162651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162651>	C38674	Widespread Metastasis|Extensive Metastasis|Non-Focal Metastasis	The spread of a malignant tumor in multiple distant anatomic sites.			Finding	
C162652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162652>	C7619|C2929	Recurrent Squamous Cell Carcinoma	A squamous cell carcinoma that has recurred after a period of remission.	Recurrent Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162653>	C4104|C153171	Advanced Squamous Cell Carcinoma	A squamous cell carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162654>	C142346	ISUP Grade Pattern 1|Grade Group 1|Pattern 1	Circumscribed nodule of closely packed but separate, uniform, rounded to oval, medium-sized acini (larger glands than pattern 3).			Classification	
C162655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162655>	C142346	ISUP Grade Pattern 2|Grade Group 2|Pattern 2	Like pattern 1, fairly circumscribed, yet at the edge of the tumor nodule there may be minimal infiltration; Glands are more loosely arranged and not quite as uniform as Gleason pattern 1.			Classification	
C162656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162656>	C142346	ISUP Grade Pattern 3|Grade Group 3|Pattern 3	Discrete glandular units; typically smaller glands than seen in Gleason pattern 1 or 2; infiltrates in and amongst nonneoplastic prostate acini; marked variation in size and shape; smoothly circumscribed small cribriform nodules of tumor.			Classification	
C162657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162657>	C142346	ISUP Grade Pattern 4|Grade Group 4|Pattern 4	Fused microacinar glands; ill-defined glands with poorly formed glandular lumina; large cribriform glands; cribriform glands with an irregular border; hypernephromatoid.			Classification	
C162658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162658>	C142346	ISUP Grade Pattern 5|Grade Group 5|Pattern 5	Essentially no glandular differentiation, composed of solid sheets, cords, or single cells; comedocarcinoma with central necrosis surrounded by papillary, cribriform, or solid masses.			Classification	
C16265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16265>	C164215	Teenager|Teenagers	An individual between the ages of 13 and 19.			Human	
C162660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162660>	C29637	Ethanol-containing Nasal Solution|Ethanol-based Intranasal Solution|Ethanol-based Nasal Sanitizer|Nozin	An intranasal solution containing ethanol with antimicrobial activity. Upon intranasal application, ethanol-containing nasal solution may prevent colonization of the nasal cavity.  The antimicrobial effect of ethanol is due, in part, to its denaturing of microbial proteins.	Ethanol-Containing Nasal Solution		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C162661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162661>	C9145|C150605	Resectable Osteosarcoma	Osteosarcoma that is amenable to surgical resection.	Resectable Osteosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162662>	C25466	Planned Eligibility Criterion|PlannedEligibilityCriterion				Idea or Concept	
C162663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162663>	C25466	Planned Exclusion Criterion|PlannedExclusionCriterion				Idea or Concept	
C162664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162664>	C25466	Planned Inclusion Criterion|PlannedInclusionCriterion				Idea or Concept	
C162665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162665>	C48176	Defined Material Process Step|DefinedMaterialProcessStep				Temporal Concept	
C162666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162666>	C60824	Defined Material Storage|DefinedMaterialStorage	An administrative activity defined at a global library level that represents the action of safekeeping harvested material in a repository or depository. (BRIDG)			Activity	BRIDG Class Terminology|BRIDG Terminology
C162667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162667>	C25714	Principal Statistical Analysis Plan Version|PrincipalStatisticalAnalysisPlanVersion				Conceptual Entity	
C162668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162668>	C93484	Statistical Analysis Plan Document Version|StatisticalAnalysisPlanDocumentVersion				Conceptual Entity	
C162669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162669>	C61575	Performed Substance Extraction|PerformedSubstanceExtraction	The completed action of extracting something from an associated study subject for the purpose of the extracted product to be administered to a subject.			Activity	
C162670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162670>	C156914	Support Education Activity	Postoperative care consisting of 1) a supportive cancer-related education activity including a direct 10-15 minute phone conversation with a Registered Nurse researcher each week for 6-weeks after returning home from the hospital; 2) wear a pedometer each day of the study; 3) record pedometer steps in the daily diary each day.	Support Education Activity		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C162671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162671>	C1802	Ventilated Cigarette	A cigarette that incorporates a special filter perforated with small holes. A cigarette of this design results in lower machine-measured tar and nicotine yields and was promoted as safer and marketed as a "light" cigarette.	Ventilated Cigarette		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C162672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162672>	C1802	Unventilated Cigarette	A cigarette that incorporates a conventional filter.	Unventilated Cigarette		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C162673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162673>	C158612	Specify Other Preoperative IV Antacids Administered Question|Other IV Anti-acids (specify)|Specify Other Preoperative IV Antacids Administered	A request to specify intravenous antacids that were administered preoperatively but not included on a list.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C162674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162674>	C18000	Highest Grade	A morphologic grade that refers to the maximum grade that a malignant tumor can exhibit  (usually grade III or IV-poorly differentiated).			Classification	
C162675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162675>	C158612	Specify Other Preoperative IV Antiemetics Administered Question|Other IV Antiemetics (specify)|Specify Other Preoperative IV Antiemetics Administered	A request to specify intravenous antiemetics that were administered preoperatively but not included on a list.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C162676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162676>	C213472|C212990|C198646|C143099	Elzovantinib|ELZOVANTINIB|MET/Src/CSF1R Tyrosine Kinase Inhibitor TPX-0022|Multi-kinase Inhibitor TPX-0022|Multikinase Inhibitor TPX-0022|TPX 0022|TPX-0022|TPX0022	An orally bioavailable, multi-targeted kinase inhibitor with potential antineoplastic activity. Upon oral administration, elzovantinib binds to and inhibits three tyrosine kinases that are often overexpressed in a variety of cancer cell types, including MET (c-Met; hepatocyte growth factor receptor; HGFR) , Src, and colony stimulating factor 1 receptor (CSF1R; CSF-1R; C-FMS; CD115; macrophage colony-stimulating factor receptor; M-CSFR) thereby disrupting their respective signaling pathways. MET, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and in tumor angiogenesis. Src, a non-receptor tyrosine kinase upregulated in many tumor cell types, plays an important role in tumor cell proliferation, motility, invasiveness and survival. CSF1R is a cell-surface receptor for colony stimulating factor 1 (CSF1); this receptor tyrosine kinase is overexpressed by tumor-associated macrophages (TAMs) in the tumor microenvironment (TME), and plays a major role in both immune suppression and the induction of tumor cell proliferation.	Elzovantinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162677>	C20993	Revised International Prognostic Scoring System|IPSS-R|Revised International Prognostic Scoring System (IPSS-R)|Revised International Prognostic Scoring System for Myelodysplastic Syndromes	A revision of the International Prognostic Scoring System for Myelodysplastic Syndromes. It covers the same disease factors as the IPSS, but the factors are identified in a more detailed way. The revised version includes: blasts in the bone marrow, cytogenetic abnormalities, hemoglobin level, absolute neutrophil count, and platelet count.			Intellectual Product	
C162678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162678>	C158612	Specify Other Spinal/Epidural Anesthesia Agents Administered Question|Other Regional (Spinal/Epidural) Anesthesia Agents|Specify Other Spinal/Epidural Anesthesia Agents Administered	A request to specify epidural/spinal agents that were administered but not included on a list.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Surgery-Anesthesia Form|CPTAC Terminology
C162679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162679>	C226329	IPSS-R Risk Category|IPSS-R Risk Category Cytogenetic Group|Revised International Prognostic Scoring System for Myelodysplastic Syndrome Risk Category	The risk category for myelodysplastic syndrome progression that is derived from IPSS-R risk score.			Finding	
C16267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16267>	C25464	Afghanistan|004|AF|AFG|AFG|AFGHANISTAN|AFGHANISTAN	A country in southern Asia, north and west of Pakistan, east of Iran.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C162680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162680>	C162679	IPSS-R Risk Category Very Low|IPSS-R Very Low Risk|Revised International Prognostic Scoring System for Myelodysplastic Syndrome Very Low Risk Category|Very Low|Very Low Risk	A total IPSS-R score of 1.5 or lower, indicating very low risk.			Finding	
C162681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162681>	C162679	IPSS-R Risk Category Low|IPSS-R Low Risk|Low|Low Risk|Revised International Prognostic Scoring System for Myelodysplastic Syndrome Low Risk Category	A total IPSS-R score of more than 1.5 to 3, indicating low risk.			Finding	
C162682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162682>	C162679	IPSS-R Risk Category Intermediate|IPSS-R Intermediate Risk|Intermediate|Intermediate Risk|Revised International Prognostic Scoring System for Myelodysplastic Syndrome Intermediate Risk Category	A total IPSS-R score of 3.5 to 4.5, indicating intermediate risk.			Finding	
C162683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162683>	C162679	IPSS-R Risk Category High|High|High Risk|IPSS-R High Risk|Revised International Prognostic Scoring System for Myelodysplastic Syndrome High Risk Category	A total IPSS-R score of 5 to 6, indicating high risk.			Finding	
C162684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162684>	C162679	IPSS-R Risk Category Very High|IPSS-R Very High Risk|Revised International Prognostic Scoring System for Myelodysplastic Syndrome Very High Risk Category|Very High|Very High Risk	A total IPSS-R score of 6.5 or higher, indicating very high risk.			Finding	
C162685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162685>	C1802	Low Nicotine Content Cigarette|LNCC	A cigarette with a nicotine content around 1.3 mg nicotine/g tobacco.	Low Nicotine Content Cigarette		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C162686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162686>	C215359	Virus-Related Hemophagocytic Lymphohistiocytosis|Virus-Associated Hemophagocytic Lymphohistiocytosis|Virus-Associated Hemophagocytic Syndrome|Virus-Associated Hemophagocytic Syndrome	Hemophagocytic lymphohistiocytosis associated with a viral infection.	Virus-Associated Hemophagocytic Syndrome		Disease or Syndrome	CPTAC Terminology|CTRP Disease Terminology|CTRP Terminology
C162687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162687>	C38759	Severe Chronic Active EBV Infection|Severe Chronic Active Epstein-Barr Virus Infection	A severe form of chronic Epstein-Barr virus infection characterized by continued intermittent fever, lymphadenopathy, thrombocytopenia, lymphocytopenia, neutropenia, polyclonal gammopathy, and greatly elevated titers for antibodies to EBV-related antigens.	Severe Chronic Active EBV Infection		Disease or Syndrome	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology
C162688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162688>	C9470|C9250	Recurrent Systemic Anaplastic Large Cell Lymphoma	The reemergence of systemic anaplastic large cell lymphoma after a period of remission.	Recurrent Systemic Anaplastic Large Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162689>	C9470|C8658	Refractory Systemic Anaplastic Large Cell Lymphoma	A systemic anaplastic large cell lymphoma that is resistant to treatment.	Refractory Systemic Anaplastic Large Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16268>	C20587	Elderly|Aged 65 and Over|ELDERLY|Elderly (Over 65)|Senior Citizen	An age group comprised of individuals 65 years of age and older.			Age Group	
C162690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162690>	C25364	Slide ID Examined by Pathologist|hpe slide id|hpe_slide_id	The identifier for an slide that has been examined by a pathologist.			Intellectual Product	Canine Glioma Project Property Terminology|ICDC Terminology
C162691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162691>	C25364	Image ID Examined by Pathologist	The identifier for an image that has been examined by a pathologist.			Intellectual Product	
C162692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162692>	C85871|C70631	Aperio Format	A data storage format consisting of a single-file pyramidal tiled TIFF, with non-standard metadata and compression format.			Qualitative Concept	
C162693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162693>	C201164	Eltivutabart|Anti-CD39 Monoclonal Antibody TTX-030|ELTIVUTABART|TTX 030|TTX-030|TTX030	A fully human monoclonal antibody directed against the cell surface receptor CD39 (cluster of differentiation 39; ectonucleoside triphosphate diphosphohydrolase-1; NTPDase1; ENTPD1) with potential immunomodulating and antineoplastic activities. Upon administration, eltivutabart specifically binds to the CD39 antigen, which may inhibit both the conversion of adenosine triphosphate (ATP) to adenosine monophosphate (AMP) and the subsequent generation of immunosuppressive extracellular adenosine in the tumor microenvironment (TME). CD39, a cell surface ectonucleosidase, is upregulated on tumor cells as an immune evasion strategy; blocking its action may promote the stimulation of dendritic and other myeloid-derived cells that are necessary for both innate and adaptive immunity.	Eltivutabart		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162694>	C3472	Severe Combined Immunodeficiency, Athabascan Type|ART-SCID|Artemis-Deficient SCID|Artemis-Deficient Severe Combined Immunodeficiency|RS-SCID|Severe Combined Immunodeficiency, Athabaskan Type	An autosomal recessive condition caused by mutation(s) in the DCLRE1C gene, encoding protein artemis. It is characterized by severe combined immunodeficiency that is T-cell negative, B-cell negative, NK-cell positive. Sensitivity to ionizing radiation and a high incidence of occurrence amongst the Athabascan Indians are also characteristic of this disease.			Disease or Syndrome	Cellosaurus Disease Terminology
C162695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162695>	C61238	Severe Combined Immunodeficiency due to NHEJ1 Deficiency|Cernunnos / XLF deficiency|NHEJ1-SCID	An autosomal recessive condition caused by mutation(s) in the NHEJ1 gene, encoding non-homologous end-joining factor 1. It is characterized by severe combined immunodeficiency that is T-cell negative, B-cell negative, NK-cell positive. Microcephaly, growth retardation, and sensitivity to ionizing radiation are also characteristic of this disease.			Disease or Syndrome	Cellosaurus Disease Terminology
C162696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162696>	C53543	Familial Platelet Disorder with Associated Myeloid Malignancy|FPD/AML|FPDMM|Familial Platelet Disorder and AML Syndrome	An autosomal dominant condition caused by mutation(s) in the RUNX1 gene, encoding runt-related transcription factor 1. It is characterized by thrombocytopenia, abnormal platelet function, and a propensity to develop acute myeloid leukemia.			Disease or Syndrome	CCPS Disease Terminology|Cellosaurus Disease Terminology|Childhood Cancer Predisposition Study Terminology
C162697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162697>	C158916	EPCAM Loss of Nuclear Expression|CD326 Antigen Loss of Nuclear Expression|CD326 Loss of Nuclear Expression|Ep-CAM Loss of Nuclear Expression|Epithelial Cell Adhesion Molecule Loss of Nuclear Expression|GA733-2 Loss of Nuclear Expression|Gastrointestinal Tumor-Associated Antigen 2 Loss of Nuclear Expression|KSA Glycoprotein Loss of Nuclear Expression|Loss of Nuclear EPCAM|TACSTD1 Loss of Nuclear Expression|Tumor-Associated Calcium Signal Transducer 1 Loss of Nuclear Expression	An indication that expression of EPCAM was not detected in the nuclei of cells in a sample.	EPCAM Loss of Nuclear Expression		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162698>	C158916	MSH3 Loss of Nuclear Expression|DNA Mismatch Repair Protein Msh3 Loss of Nuclear Expression|DUP Loss of Nuclear Expression|Divergent Upstream Protein Loss of Nuclear Expression|Loss of Nuclear MSH3|MRP1 Loss of Nuclear Expression|Mismatch Repair Protein 1 Loss of Nuclear Expression|hMSH3 Loss of Nuclear Expression	An indication that expression of MSH3 was not detected in the nuclei of cells in a sample.	MSH3 Loss of Nuclear Expression		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162699>	C201176	Anti-CD70 CAR-expressing T Lymphocytes|Anti-CD70 CAR-expressing T-cells|CD70 CAR T-cells|CD70 CAR T-lymphocytes	A preparation of human T-lymphocytes transduced with a recombinant viral vector encoding a chimeric T-cell receptor (chimeric antigen receptor or CAR) consisting of one or more binding domains that target the tumor-associated antigen (TAA) CD70 (CD27 ligand; tumor necrosis factor superfamily member 7; TNFSF7) fused to one or more co-stimulatory TCR-signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD70 CAR-expressing T-lymphocytes, express anti-CD70-CAR on their cell surfaces and bind to the CD70 antigen on tumor cell surfaces thereby neutralizing the activity of CD70. This may induce antibody-dependent cellular cytotoxicity (ADCC) against CD70-expressing tumor cells. CD70, a cytokine belonging to the tumor necrosis superfamily (TNFSF) and the ligand for the costimulatory receptor CD27, is expressed on the surfaces of various types of cancer cells; its overexpression may play an important role in the evasion of immune surveillance.	Anti-CD70 CAR-expressing T Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C16269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16269>	C21172	Aging	The process of change in the structure and function of an organism that occurs with the passage of time.			Organism Function	
C1626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1626>	C308	Etalocib|2-[2-Propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]phenoxy]benzoic Acid|2-[3-[3-[(5-Ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-2-propylphenoxy]benzoic Acid|2-[3-[3-[(5-Ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-2-propylphenoxy]benzoic Acid|ETALOCIB|LY293111|LY293111	A second-generation selective leukotriene B4 receptor (LTB4R) antagonist with potential antineoplastic activity. Although the exact underlying mechanism through which LY293111 exerts its effects has not been fully elucidated, this agent selectively binds to and blocks LTB4Rs, thereby inhibiting the downstream signalling pathway. LY29311 has been shown to induce apoptosis and inhibits cellular proliferation in LTB4R expressing cells, such as pancreatic cancer cells.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162700>	C16205	Treatment Planning	The process of developing an appropriate therapeutic strategy for a patient.	Treatment Planning		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C162701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162701>	C138079	Clinical Trial Candidate	A patient who meets the eligibility criteria for participation in a clinical trial.			Conceptual Entity	
C162702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162702>	C4813|C4005	Recurrent Childhood Malignant Neoplasm	The reemergence of a childhood malignant neoplasm after a period of remission.	Recurrent Childhood Malignant Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162703>	C4005|C120186	Refractory Childhood Malignant Neoplasm	A childhood malignant neoplasm that does not respond to treatment.	Refractory Childhood Malignant Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162704>	C50995	No Response to Treatment|No Response To Treatment|No response to treatment (situation)	No apparent pathologic and/or clinical changes resulting from treatment.			Finding	mCode Terminology|mCode Treatment Termination Reason Value Set|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C162705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162705>	C16960	New Patient	A patient who has not previously received professional services from a healthcare provider.			Patient or Disabled Group	
C162706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162706>	C3879|C191981|C133193	Metastatic Thyroid Gland Medullary Carcinoma	A thyroid gland medullary carcinoma that has spread from the original site of growth to another anatomic site.	Metastatic Thyroid Gland Medullary Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162707>	C38060	Eye Movement Measurement	Assessment of the parameters of eye movement, including horizontal and vertical rotations of the eye, opening or closing of the eyes in response to stimuli, pupil response to light, and blink reflex.	Eye Movement Measurement		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C162708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162708>	C160157	No 30 Day Prior Medications|No medications/vitamins/supplements administered within the 30 days prior to the CPTAC specimen collection	A response indicating there have been no medications 30 days prior to specimen collection.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology
C162709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162709>	C222259	Montreal Cognitive Assessment Visuospatial/Executive Test|Visuospatial/Executive	These two abilities are assessed through the Trails B Test, which requires an individual to draw a line to correctly sequence alternating digits and numbers (1-A, 2-B, etc.) and through a task which requires them to draw a copy of a cube shape.			Intellectual Product	Montreal Cognitive Assessment Functional Test
C16270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16270>	C17187	Agriculture	The practice of cultivating the land or raising stock, as well as the work, business, or study of farming.			Occupation or Discipline	
C162710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162710>	C222259	Montreal Cognitive Assessment Naming Test|Naming	In this test three pictures of animals are shown and the individual is asked to name each one.			Intellectual Product	Montreal Cognitive Assessment Functional Test
C162711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162711>	C222259	Montreal Cognitive Assessment Attention - Digits Test|Attention - Digits	This test involves repeating digits forward and backward.			Intellectual Product	Montreal Cognitive Assessment Functional Test
C162712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162712>	C222259	Montreal Cognitive Assessment Attention - Letters Test|Attention - Letters	This test involves acknowledging spoken letters.			Intellectual Product	Montreal Cognitive Assessment Functional Test
C162713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162713>	C222259	Montreal Cognitive Assessment Attention - Subtraction Test|Attention - Subtraction	This test requires an individual to count backward from 100 by sevens.			Intellectual Product	Montreal Cognitive Assessment Functional Test
C162714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162714>	C222259	Montreal Cognitive Assessment Language - Repeat Test|Language - Repeat	This task consists of repeating two sentences correctly.			Intellectual Product	Montreal Cognitive Assessment Functional Test
C162715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162715>	C222259	Montreal Cognitive Assessment Language - Fluency Test|Language - Fluency	This task requires an individual to list all of the words from two sentences they can be recalled that begin with the letter "F".			Intellectual Product	Montreal Cognitive Assessment Functional Test
C162716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162716>	C222259	Montreal Cognitive Assessment Abstraction Test|Abstraction	This task requires an individual to explain how two items are alike, such as a train and a bicycle.			Intellectual Product	Montreal Cognitive Assessment Functional Test
C162717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162717>	C222259	Montreal Cognitive Assessment Delayed Recall Test|Delayed Recall	Five words are read, the test-taker is asked to repeat them, they are read again and asked to repeat again. After completing other tasks, the person is asked to repeat each of the five words again and given a cue of the category that the word belongs to if they are not able to recall them without the cue.			Intellectual Product	Montreal Cognitive Assessment Functional Test
C162718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162718>	C222259	Montreal Cognitive Assessment Orientation Test|Orientation	The individual is asked to state the date, month, year, day, place, and city.			Intellectual Product	Montreal Cognitive Assessment Functional Test
C162719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162719>	C8511|C181197|C150543	Refractory Urinary System Carcinoma	Urinary system carcinoma that does not respond to treatment.			Neoplastic Process	
C16271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16271>	C25464	Albania|008|AL|ALB|ALB|ALBANIA|ALBANIA	A country in southeastern Europe, bordering the Adriatic and Ionian Seas, between Greece and Montenegro.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C162720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162720>	C120457	Montreal Cognitive Assessment Total Score|Total Score	The total score received in a Motreal Congitive Assessment test.			Quantitative Concept	Montreal Cognitive Assessment Functional Test
C162721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162721>	C2947|C120186	Refractory Chordoma	A chordoma that does not respond to treatment.			Neoplastic Process	
C162722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162722>	C3714|C139001	Refractory Epithelioid Sarcoma	An epithelioid sarcoma that does not respond to treatment.	Refractory Epithelioid Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162723>	C6906|C153842|C142858	Refractory Atypical Teratoid/Rhabdoid Tumor	An atypical teratoid/rhabdoid tumor that does not respond to treatment.	Refractory Atypical Teratoid/Rhabdoid Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162724>	C8823|C6561	Recurrent Epithelioid Malignant Peripheral Nerve Sheath Tumor	The reemergence of an epithelioid malignant peripheral nerve sheath tumor after a period of remission.	Recurrent Epithelioid Malignant Peripheral Nerve Sheath Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162725>	C6561|C155987	Refractory Epithelioid Malignant Peripheral Nerve Sheath Tumor	An epithelioid malignant peripheral nerve sheath tumor that does not respond to treatment.	Refractory Epithelioid Malignant Peripheral Nerve Sheath Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162726>	C7572|C172622	Recurrent Kidney Medullary Carcinoma	The reemergence of kidney medullary carcinoma after a period of remission.	Recurrent Kidney Medullary Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162727>	C7572|C172623	Refractory Kidney Medullary Carcinoma	A kidney medullary carcinoma that does not respond to treatment.	Refractory Kidney Medullary Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162728>	C48876|C155973	Recurrent Dedifferentiated Chordoma	The reemergence of dedifferentiated chordoma after a period of remission.	Recurrent Dedifferentiated Chordoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162729>	C48876|C162721	Refractory Dedifferentiated Chordoma	A dedifferentiated chordoma that does not respond to treatment.	Refractory Dedifferentiated Chordoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16272>	C20130	Alcohol Dehydrogenase|ADH|Alcohol Dehydrogenase Family|EC 1.1.1.1	Members of this enzyme family metabolize a wide variety of substrates, including ethanol, retinol, other aliphatic alcohols, hydroxysteroids, and lipid peroxidation products.			Amino Acid, Peptide, or Protein|Enzyme	
C162730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162730>	C8715|C162702|C150542|C142849|C115445	Recurrent Rhabdoid Tumor of the Kidney	The reemergence of a rhabdoid tumor of the kidney after a period of remission.	Recurrent Rhabdoid Tumor of the Kidney		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162731>	C8715|C162703|C150543|C142858	Refractory Rhabdoid Tumor of the Kidney	A rhabdoid tumor of the kidney that does not respond to treatment.	Refractory Rhabdoid Tumor of the Kidney		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162732>	C7619|C7596	Recurrent Malignant Myoepithelioma|Recurrent Myoepithelial Carcinoma	The reemergence of a malignant myoepithelioma after a period of remission.	Recurrent Malignant Myoepithelioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162733>	C8511|C7596	Refractory Malignant Myoepithelioma|Refractory Myoepithelial Carcinoma	A malignant myoepithelioma that does not respond to treatment.	Refractory Malignant Myoepithelioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162734>	C226330	Non-M3 Acute Myeloid Leukemia	A finding indicating that an acute myeloid leukemia does not have the characteristics of M3 acute myeloid leukemia, according to the FAB classification criteria.	Non-M3 Acute Myeloid Leukemia		Finding	CTRP Disease Terminology|CTRP Terminology
C162735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162735>	C162456	Normal Karyotype Intermediate Risk Acute Myeloid Leukemia	Acute myeloid leukemia with an intermediate risk of relapse or refractoriness that has a normal karyotype.	Normal Karyotype Intermediate Risk Acute Myeloid Leukemia		Finding	CTRP Disease Terminology|CTRP Terminology
C162737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162737>	C25161	Baker Classification of Capsular Contracture of Breast|Baker Classification	A classification system that refers to breast capsular contraction proposed by J.L. Baker Jr., et al.			Classification	
C162738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162738>	C162737	Grade I Breast Capsule Contracture|Capsular Contracture Grade I|Grade I Capsular Contracture	Breast is soft and appears natural in size and shape.			Classification	
C162739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162739>	C162737	Grade II Breast Capsule Contracture|Capsular Contracture Grade II|Grade II Capsular Contracture	Minimal contracture; there is some firmness, but the breast appears natural.			Classification	
C16273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16273>	C19683	Alcohol Consumption	Consumption of liquids containing ethanol, including the behaviors associated with drinking the alcohol.			Individual Behavior	CPTAC Baseline Medical Forms Terminology|CPTAC Liver Hepatocellular Carcinoma Baseline Form|CPTAC Medical History Form|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C162740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162740>	C162737	Grade III Breast Capsule Contracture|Capsular Contracture Grade III|Grade III Capsular Contracture	Moderate contracture; the breast is firm and appears abnormal.			Classification	
C162741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162741>	C162737	Grade IV Breast Capsule Contracture|Capsular Contracture Grade IV|Grade IV Capsular Contracture	Severe contracture; the breast is hard, painful to touch, and appears abnormal.			Classification	
C162742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162742>	C225455|C129825	NAMPT Inhibitor OT-82|NAMPTi OT-82|Nicotinamide Phosphoribosyltransferase Inhibitor OT-82|OT 82|OT-82|OT82	An orally bioavailable, small molecule inhibitor of the nicotinamide adenine dinucleotide (NAD)-synthesizing enzyme nicotinamide phosphoribosyltransferase (NAMPT; NAMPRTase), with potential antineoplastic activity. Upon oral administration, NAMPT inhibitor OT-82 binds to and inhibits the activity of NAMPT. This depletes cellular NAD and inhibits NAD-dependent enzymes, both of which are needed for rapid cell proliferation; this results in cell death in NAMPT-overexpressing cancer cells. NAMPT, an enzyme that is responsible for maintaining the intracellular NAD pool, plays a key role in the regulation of cellular metabolism and has cytokine-like activities. NAMPT is overexpressed in a variety of cancers and metabolic disorders; tumor cells rely on NAMPT activity for their NAD supply.	NAMPT Inhibitor OT-82		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162743>	C15908	Reflexology	The application of pressure to specific zones on the ears, hands, and feet in order to reduce stress and promote healing in corresponding glands, organs, parts, and systems of the body that are believed to be connected through energy channels.	Reflexology		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C162744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162744>	C93102|C128825	Deleterious STK11 Gene Mutation|Deleterious LKB1 Gene Mutation|Deleterious Liver Kinase B1 Gene Mutation|Deleterious STK11 Mutation|Deleterious Serine/Threonine Kinase 11 Gene Mutation	A change in the nucleotide sequence of the STK11 gene that is associated with increased risk of disease.	Deleterious STK11 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162745>	C93102|C137691	Deleterious DICER1 Gene Mutation|Deleterious DCR-1 Gene Mutation|Deleterious DCR1 Gene Mutation|Deleterious DICER Gene Mutation|Deleterious Dicer 1, Double-Stranded RNA-Specific Endoribonuclease Gene Mutation|Deleterious Dicer 1, Ribonuclease III Gene Mutation|Deleterious Dicer 1, Ribonuclease Type III Gene Mutation|Deleterious HERNA Gene Mutation|Deleterious MNG1 Gene Mutation|Deleterious RMSE2 Gene Mutation	A change in the nucleotide sequence of the DICER1 gene that is associated with increased risk of disease.	Deleterious DICER1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162746>	C93102|C142126	Deleterious SMARCA4 Gene Mutation|Deleterious BAF190 Gene Mutation|Deleterious BAF190A Gene Mutation|Deleterious BRG-1 Gene Mutation|Deleterious BRG1 Gene Mutation|Deleterious BRM/SWI2-Related Gene 1 Mutation|Deleterious SNF2 Gene Mutation|Deleterious SNF2-Beta Gene Mutation|Deleterious SNF2L4 Gene Mutation|Deleterious SNF2LB Gene Mutation|Deleterious SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily A, Member 4 Gene Mutation|Deleterious SWI2 Gene Mutation|Deleterious hSNF2b Gene Mutation	A change in the nucleotide sequence of the SMARCA4 gene that is associated with increased risk of disease.	Deleterious SMARCA4 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C162747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162747>	C93102|C150473	Deleterious CDH1 Gene Mutation|Deleterious Arc-1 Gene Mutation|Deleterious CD324 Gene Mutation|Deleterious CDHE Gene Mutation|Deleterious Cadherin 1 Gene Mutation|Deleterious Cadherin 1, Type 1, E-Cadherin (Epithelial) Gene Mutation|Deleterious Cadherin, Epithelial Gene Mutation|Deleterious Calcium-Dependent Adhesion Protein, Epithelial Gene Mutation|Deleterious E-Cadherin Gene Mutation|Deleterious ECAD Gene Mutation|Deleterious LCAM Gene Mutation|Deleterious UVO Gene Mutation	A change in the nucleotide sequence of the CDH1 gene that is associated with increased risk of disease.	Deleterious CDH1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162748>	C53649	Refractory Cytomegalovirus Infection	A cytomegalovirus infection that is resistant to treatment.	Refractory Cytomegalovirus Infection		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C162749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162749>	C162996	MDM2 Antagonist ASTX295|ASTX 295|ASTX-295|ASTX295|MDM2 Inhibitor ASTX295	An orally available, small molecule inhibitor of the human homolog of murine double minute 2 (MDM2; HDM2), with potential antineoplastic activity. Upon oral administration, MDM2 antagonist ASTX295 targets and binds to MDM2 protein and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. This prevents p53 proteasomal degradation and restores the transcriptional activity of p53. This leads to p53-mediated induction of apoptosis in cancers with a wild-type p53 gene. MDM2, an E3 ubiquitin ligase, regulates the level and activity of p53.	MDM2 Antagonist ASTX295		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C16274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16274>	C25464	Algeria|012|ALGERIA|ALGERIA|DZ|DZA|DZA	A country in northern Africa, bordering the Mediterranean Sea, between Morocco and Tunisia.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C162750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162750>	C185305|C156781	Refractory Biliary Tract Carcinoma	Biliary tract carcinoma that is resistant to treatment.			Neoplastic Process	
C162751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162751>	C217201|C170458|C156781	Metastatic Biliary Tract Carcinoma	A biliary tract carcinoma that has spread from its original site of growth to other anatomic sites.			Neoplastic Process	
C162752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162752>	C225026|C157623|C142870	Advanced Cholangiocarcinoma	A cholangiocarcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Cholangiocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162753>	C3844|C162750	Refractory Gallbladder Carcinoma	Gallbladder carcinoma that is resistant to treatment.	Refractory Gallbladder Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162754>	C3844|C162751	Metastatic Gallbladder Carcinoma	A gallbladder carcinoma that has spread from the original site of growth to other anatomic sites.	Metastatic Gallbladder Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162755>	C171331|C162754	Advanced Gallbladder Carcinoma	A gallbladder carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Gallbladder Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162756>	C46083	Cancer-related Cognitive Dysfunction|Cancer-related Cognitive Difficulties	The effects of cancer and its treatments on cognitive processes.	Cancer-related Cognitive Dysfunction		Mental or Behavioral Dysfunction	CTRP Disease Terminology|CTRP Terminology
C162757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162757>	C29712	Beclomethasone Dipropionate/Formoterol Fumarate Inhalation Solution|Beclomethasone/Formoterol Inhalation Solution|Fostair Inhalation Solution	An inhalation solution composed of a fixed combination of the dipropionate salt form of the synthetic glucocorticoid beclomethasone and the fumarate salt form of the long-acting and selective sympathomimetic beta-receptor agonist formoterol, with anti-inflammatory and bronchial smooth muscle-relaxing activities. Upon pressurized inhalation of the beclomethasone/formoterol solution, beclomethasone binds to intracellular glucocorticoid receptors (GRs), exhibiting inhibitory activities against multiple cell types and mediators associated with allergic inflammation. Formoterol selectively binds to beta-2 adrenergic receptors in bronchial smooth muscle, activating intracellular adenylyl cyclase, an enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3', 5'-adenosine monophosphate (cAMP). Increased intracellular cAMP results in the relaxation of bronchial smooth muscle and inhibition of the cellular release of mediators of immediate hypersensitivity, especially from mast cells. This may improve lung function.			Pharmacologic Substance	
C162758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162758>	C154321|C153213|C148153	Locally Advanced Head and Neck Squamous Cell Carcinoma	A head and neck squamous cell carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Head and Neck Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162759>	C210257|C168978|C150577	Locally Advanced Gastroesophageal Junction Adenocarcinoma	Gastroesophageal junction adenocarcinoma that has spread to nearby tissues or lymph nodes.	Locally Advanced Gastroesophageal Junction Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16275>	C97331	Algorithm|Algorithms|algorithm	A defined procedure for solving a problem. Applied to a problem-solving procedure implemented in software to be executed by a computer.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C162760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162760>	C6975|C150595	Metastatic Papillary Renal Cell Carcinoma	A papillary renal cell carcinoma that has spread from the original site of growth to another anatomic site.			Neoplastic Process	
C162761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162761>	C162760|C153170	Advanced Papillary Renal Cell Carcinoma	A papillary renal cell carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.			Neoplastic Process	
C162762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162762>	C153185|C153073	Advanced Bone Sarcoma	A bone sarcoma that has spread extensively to other anatomic sites or is no longer responding to treatment.			Neoplastic Process	
C162763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162763>	C168701|C148298	Advanced Myxoid Liposarcoma|Advanced Myxoid/Round Cell Liposarcoma	A myxoid liposarcoma that has spread extensively to other anatomic sites or is no longer responding to treatment.			Neoplastic Process	
C162764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162764>	C129826	WT1/PRAME/Survivin-specific Cytotoxic T-lymphocytes|WT1/PRAME/Survivin-specific CTLs	A preparation of  cytotoxic T-lymphocytes (CTLs) specifically reactive to the tumor-associated antigens (TAAs) human Wilms tumor protein (WT1), preferentially expressed antigen of melanoma (PRAME; melanoma antigen preferentially expressed in tumors; Opa-interacting protein 4; OIP-4), and survivin (baculoviral IAP repeat-containing protein 5; BIRC5), with potential immunomodulating and antineoplastic activities. Upon collection of peripheral blood mononuclear cells (PBMCs), these cells are stimulated with antigen presenting cells (APCs) pulsed with WT1, PRAME and survivin peptides; reactive T-cells are selectively expanded. Upon administration of the WT1/PRAME/Survivin-specific CTLs, these T-cells induce a CTL-mediated response against tumor cells expressing WT1, PRAME, or survivin, leading to tumor cell lysis and inhibition of tumor cell proliferation. WT1, PRAME, and survivin, are expressed on certain tumor cell types and play key roles in tumor cell proliferation and survival.	WT1/PRAME/Survivin-specific Cytotoxic T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162765>	C201557	CD3+/CD19+ Cell-depleted Unrelated or Partially Matched Donor-derived Allogeneic Peripheral Blood Stem Cells|CD3+ T-cell-depleted /CD19+ B-cell-depleted Unrelated or Partially Matched Donor-derived Allogeneic Peripheral Blood Stem Cells|CD3+ and CD19+ Cell-depleted Allogeneic PBSCs Derived from an Unrelated or Partially Matched Donor|CD3+/CD19+ Cell-depleted Unrelated or Partially Matched Donor-derived Allogeneic PBSCs	A preparation of allogeneic peripheral blood stem cells (PBSCs) from an unrelated or partially matched related donor that have been selectively depleted of CD3-positive  (CD3+) T-cells and CD19-positive (CD19+) B-cells via leukapheresis with potential immune reconstituting activity. The CD3+/CD19+ cell-depleted PBSCs are used for allogeneic hematopoietic cell transplantation (HCT) and may allow for rapid and sustained engraftment, immune reconstitution, and may prevent or reduce graft-versus-host disease (GvHD) and Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disorders.	CD3+/CD19+ Cell-depleted Unrelated or Partially Matched Donor-derived Allogeneic Peripheral Blood Stem Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C162766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162766>	C156096|C153358	Locally Advanced Colorectal Carcinoma	A colorectal carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.			Neoplastic Process	
C162767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162767>	C168978|C162772|C153319	Locally Advanced Gastric Adenocarcinoma	A gastric adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Gastric Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162768>	C4033|C150595	Metastatic Clear Cell Renal Cell Carcinoma	A clear cell renal cell carcinoma that has spread from its original site of growth to other anatomic sites.			Neoplastic Process	
C162769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162769>	C40998|C163005	ASPH-Positive Neoplastic Cells Present|ASP Beta-Hydroxylase-Positive Neoplastic Cells Present|Aspartate Beta-Hydroxylase-Positive Neoplastic Cells Present|Aspartyl/Asparaginyl-Beta-Hydroxylase-Positive Neoplastic Cells Present|HAAH-Positive Neoplastic Cells Present|Peptide-Aspartate Beta-Dioxygenase-Positive Neoplastic Cells Present	An immunophenotypic finding indicating the expression of ASPH gene in the neoplastic cells of a tumor sample.	ASPH-Positive Neoplastic Cells Present		Finding	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C16276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16276>	C16981	Alkaline Phosphatase|ALKP|ALP|AP|Alk Phos|AlkPhos|Alkaline Phosphomonoesterase|Phosphatase, Alkaline	An enzyme that catalyses the cleavage of inorganic phosphate non-specifically from a wide variety of phosphate esters and having a high (greater than 8) pH optimum.	Alkaline Phosphatase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162770>	C34447	ASPH-Positive Head and Neck Squamous Cell Carcinoma	A head and neck squamous cell carcinoma in which the malignant cells are positive for ASPH gene.	ASPH-Positive Head and Neck Squamous Cell Carcinoma		Finding	CTRP Disease Terminology|CTRP Terminology
C162772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162772>	C153358|C153320	Locally Advanced Gastric Carcinoma	A gastric carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Gastric Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162773>	C61078	Submicron Particle Paclitaxel Sterile Suspension|NanoPac|Sterile Nanoparticle-based Paclitaxel Suspension|Sterile Nanoparticulate Paclitaxel|Submicron Particle Paclitaxel|Submicron Particle Paclitaxel Formulation	A suspension composed of uncoated, stable, submicron particles of the water-insoluble taxane paclitaxel, with potential antineoplastic activity. Upon intra-tumoral administration of the submicron particle paclitaxel sterile suspension, paclitaxel binds to tubulin and inhibits the disassembly of microtubules, which leads to the inhibition of cell division, thereby halting the proliferation of rapidly-dividing tumor cells. The submicron particle paclitaxel is produced through a specific proprietary method of submicron particle production without the need for coating agents or carriers and allows for prolonged retention and sustained release at the tumor site.	Submicron Particle Paclitaxel Sterile Suspension		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162774>	C129822|C128037|C128036	Iparomlimab/Tuvonralimab|Anti-PD-1/Anti-CTLA-4 Monoclonal Antibody Mixture PSB205|Anti-PD-1/CTLA-4 MabPair PSB205|Anti-PD1/Anti-CTLA4 Antibody Mixture PSB205|Anti-PD1/Anti-CTLA4 Antibody Mixture QL1706|Anti-PD1/CTLA4 Antibodies PSB205|Bifunctional MabPair Product PSB205|PSB 205|PSB-205|PSB205|QL 1706|QL-1706|QL1706	A mixture of the two engineered monoclonal antibodies iparomlimab, which is an immunoglobulin G4 (IgG4) monoclonal antibody directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and tuvonralimab, which is an IgG1 monoclonal antibody directed against the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of iparomlimab/tuvonralimab, iparomlimab and tuvonralimab target and bind to PD-1 and CTLA4 expressed on tumor-infiltrating lymphocytes (TILs), respectively. This inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T-cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD-1 and CTLA4 enhances T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone.	Iparomlimab/Tuvonralimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162775>	C198957	Acute Myeloid Leukemia with Trisomy 8|Acute Myeloid Leukemia with tri8	An acute myeloid leukemia with trisomy 8. Trisomy 8 is one of the most frequent occurring cytogenetic abnormalities in acute myeloid leukemia. It is grouped as intermediate risk in cytogenetic classifications of acute myeloid leukemia.	Acute Myeloid Leukemia with Trisomy 8		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162776>	C80342	B Acute Lymphoblastic Leukemia with t(4;11)(q21;23.3); KMT2A-AFF1|Acute Lymphoblastic Leukemia with t(4;11)(q21;23)|B Acute Lymphoblastic Leukemia with t(4;11)(q21;23.3)|B Acute Lymphoblastic Leukemia with t(4;11)(q21;23.3); KMT2A::AFF1|B-Cell Acute Lymphoblastic Leukemia with t(4;11)(q21;23.3)	A B-cell acute lymphoblastic leukemia associated with t(4;11)(q21;23.3). This translocation leads to the generation of the fusion gene KMT2A-AFF1.	B Acute Lymphoblastic Leukemia with t(4;11)(q21;23)		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162777>	C226329	Higher Risk Myelodysplastic Syndrome|Higher-Risk Myelodysplastic Syndrome	Myelodysplastic syndrome with a score of INT-2 (intermediate-2) or higher (the category above INT-2).	Higher Risk Myelodysplastic Syndrome		Finding	CTRP Disease Terminology|CTRP Terminology
C162778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162778>	C29862	Lottery	A selection process for which the outcome is determined by chance.	Lottery		Functional Concept	CTRP Intervention Terminology|CTRP Terminology
C162779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162779>	C35681|C175007	Human Immunodeficiency Virus Antibody Negative|Anti-HIV Antibody Negative|Anti-Human Immunodeficiency Virus Antibody Negative|HIV Antibody Negative	An indication that antibodies that recognize the human immunodeficiency virus have not been detected in a sample.	Human Immunodeficiency Virus Antibody Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C16277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16277>	C19896	Allele|Alleles|Alleles|allele	Mutually exclusive alternative forms of the same gene occupying the same locus on homologous chromosomes, differing in nucleotide sequence and governing the same biochemical and developmental process.	Allele		Functional Concept	CTRP Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C162780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162780>	C4978|C162255	Metastatic Malignant Colorectal Neoplasm	A malignant neoplasm that arises in the colon or rectum that has spread from its original site of growth to other anatomic sites.	Metastatic Malignant Colorectal Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162781>	C217122	Mantle Cell Lymphoma International Prognostic Index|MCL International Prognostic Index|MIPI	A prognostic index for mantle cell lymphoma based on: age, performance status, lactate dehydrogenase (LDH), and leukocyte count. It differentiates patients into low-, intermediate-, and high-risk groups.			Intellectual Product	
C162782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162782>	C7625|C4872	Localized Breast Carcinoma|Non-Metastatic Breast Carcinoma|Non-Metastatic Breast Carcinoma	A breast carcinoma that is confined to the breast site in which it initially manifested without evidence of spread to other anatomic sites.	Non-Metastatic Breast Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162784>	C1490	Docetaxel/Ritonavir|ModraDoc006/r|Oral Docetaxel/Ritonavir	An orally bioavailable combination agent containing docetaxel, a second generation taxane, and ritonavir, a cytochrome P450 (CYP) 3A4 inhibitor, with potential enhanced antineoplastic activity. Docetaxel binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell-cycle arrest at the G2/M phase and cell death.  Docetaxel is metabolized by CYP3A4  enzymes which is inhibited by the presence of ritonavir. This increases the plasma concentration of docetaxel and may increase docetaxel's efficacy.	Docetaxel/Ritonavir		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162785>	C50111	BardPort Titanium Implanted Port with Peritoneal Catheter	An implantable access device designed to provide repeated access to the peritoneal cavity for the delivery of medications and other fluids. Port access is performed by percutaneous needle insertion using a non-coring needle. The system consists of two primary components: an injection port with a self-sealing silicone septum and a radiopaque silicone rubber catheter.	BardPort Titanium Implanted Port with Peritoneal Catheter		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C162786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162786>	C9231|C191980	Unresectable Merkel Cell Carcinoma	Merkel cell carcinoma that is not amenable to surgical resection.	Unresectable Merkel Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162787>	C8181|C132012	Resectable Oropharyngeal Squamous Cell Carcinoma	An oropharyngeal squamous cell carcinoma that is amenable to surgical resection.	Resectable Oropharyngeal Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162788>	C35552	Left Ventricular Hypertrophy with Strain	A finding of left ventricular hypertrophy based on the analysis of diagnostic metrics that may indicate a higher risk for cardiovascular events.			Finding	
C162789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162789>	C154300	H2BC20P Gene|H2B Clustered Histone 20, Pseudogene Gene|H2BC20P|H2BC20P|HIST2H2BC	This gene may play a role in the regulation of chromatin structure.			Gene or Genome	
C16278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16278>	C17728	Alpha-Fetoprotein|AFP|AFP|Alpha Fetal Protein|Alpha Fetoprotein|Alpha-1-Fetoprotein|Alpha-Fetoglobulin|alpha-Fetoprotein|alpha-fetoprotein	Alpha-fetoprotein (609 aa, ~69 kDa) is encoded by the human AFP gene. This protein plays a role in the binding to copper, nickel, bilirubin and fatty acids in the fetal circulation.	Alpha-Fetoprotein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162790>	C162789	H2BC20P wt Allele|AC239868.1|H2B Clustered Histone 20, Pseudogene wt Allele|H2B/t|HIST2H2BC|Histone 2, H2bc Gene|Histone Cluster 2 H2B Family Member C (Pseudogene) Gene|Histone Cluster 2, H2bc (Pseudogene) Gene|Histone Cluster 2, H2bc Gene	Human H2BC20P wild-type allele is located in the vicinity of 1q21.2 and is approximately 6 kb in length. This allele, which encodes putative histone H2B type 2-C protein, may be involved in the structure of histone complexes.			Gene or Genome	
C162791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162791>	C17460	Putative Histone H2B Type 2-C|H2B/t|H2BC20P|H2bc|HIST1H2BC|Histone H2B.t	Putative histone H2B type 2-C (193 aa, ~21 kDa) is encoded by the human H2BC20P gene. This protein may play a role in nucleosomal structure.			Amino Acid, Peptide, or Protein	
C162792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162792>	C154300	H2BC19P Gene|H2B Clustered Histone 19, Pseudogene Gene|H2BC19P|H2BC19P|HIST2H2BD	This gene may be involved in the structure of histone complexes.			Gene or Genome	
C162793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162793>	C162792	H2BC19P wt Allele|H2B Clustered Histone 19, Pseudogene wt Allele|H2B Histone Family, Member O Gene|H2B/o|H2B/s|H2BFO|HIST2H2BD|Histone 2, H2bd Gene|Histone Cluster 2 H2B Family Member D (Pseudogene) Gene|Histone Cluster 2, H2bc Gene|Histone Cluster 2, H2bd (Pseudogene) Gene	Human H2BC19P wild-type allele is located in the vicinity of 1q21.2 and is approximately 4 kb in length. This allele, which encodes putative histone H2B type 2-D protein, may play a role in nucleosomal structure.			Gene or Genome	
C162794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162794>	C17460	Putative Histone H2B Type 2-D|H2B/o|H2B/s|H2BC19P|H2BFO|H2bd|HIST2H2BD	Putative histone H2B type 2-D (164 aa, ~18 kDa) is encoded by the human H2BC19P gene. This protein may be involved in histone-mediated processes.			Amino Acid, Peptide, or Protein	
C162795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162795>	C157377	Testosterone Greater than 50 ng/dL|Testosterone Greater than 50|Testosterone Greater than 50 Nanograms per Deciliter|Testosterone Greater than 50 Nanograms/Deciliter|Testosterone Level Greater than 50	A semiquantitative finding indicating that the concentration of testosterone in a sample is greater than 50 ng/dL.	Testosterone Greater than 50 ng/dL		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C162796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162796>	C154267	H1-0 Gene|H1-0|H1-0|H1.0 Linker Histone Gene|H1F0	This gene plays a role in histone functions in terminally differentiated cells.			Gene or Genome	
C162797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162797>	C162796	H1-0 wt Allele|H1 Histone Family Member 0 Gene|H1 Histone Family, Member 0 Gene|H1(0)|H1.0|H1.0 Linker Histone wt Allele|H10|H1F0|H1FV	Human H1-0 wild-type allele is located in the vicinity of 22q13.1 and is approximately 2 kb in length. This allele, which encodes histone H1.0 protein, is involved in the formation of high order chromatin structures and terminal differentiation.			Gene or Genome	
C162798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162798>	C16683	Histone H1.0|H1-0|H1-0 Histone|H1F0|Histone H1'|Histone H1(0)	Histone H1.0 (194 aa, ~21 kDa) is encoded by the human H1-0 gene. This protein plays a role in terminal differentiation and chromatin structure regulation.			Amino Acid, Peptide, or Protein	
C162799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162799>	C154267	H1-7 Gene|H1-7|H1-7|H1.7 Linker Histone Gene|H1FNT	This gene is involved in DNA condensation during spermatogenesis.			Gene or Genome	
C16279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16279>	C18982	Alpha Radiation|ALPHA PARTICLE|Alpha Particle Radiation|Alpha-Radiation|Helium Ion Radiation|Helium-Ion Radiation|Helium-Ion Radiation	An emission of positively charged particles composed of two protons and two neutrons, i.e., helium nuclei, emitted during disintegration of very heavy isotopes; a beam of alpha particles or an alpha ray has very strong ionizing power, but weak penetrability.			Natural Phenomenon or Process	CDISC SEND Rad/Nuc Agent Ionizing Radiation Type Response Terminology|CDISC SEND Terminology|Cellosaurus Resistance and Transformant Physical Factor Terminology|Clinical Data Interchange Standards Consortium Terminology
C1627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1627>	C912	Lewis Y Antigen|LEWIS Y ANTIGEN|LeY Antigen	A carbohydrate molecule expressed on the surface of solid tumors including lung, intestinal, breast, prostate, pancreatic, esophageal, stomach, colon, rectal or ovarian cancers.	Lewis Y Antigen		Immunologic Factor|Organic Chemical|Pharmacologic Substance	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C162800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162800>	C162799	H1-7 wt Allele|H1 Histone Family Member N, Testis Specific Gene|H1 Histone Family, Member N, Testis-Specific Gene|H1.7|H1.7 Linker Histone wt Allele|H1FNT|H1T2|HANP1|HIST1H1T2	Human H1-7 wild-type allele is located in the vicinity of 12q13.11 and is approximately 1 kb in length. This allele, which encodes testis-specific H1 histone protein, plays a role in chromosome condensation during spermatozoa maturation.			Gene or Genome	
C162801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162801>	C16683	Testis-Specific Histone H1|H1-7|H1FNT|Haploid Germ Cell-Specific Nuclear Protein 1|Histone H1t2|Testis Secretory Sperm-Binding Protein Li 223n	Testis-specific H1 histone (255 aa, ~28 kDa) is encoded by the human H1-7 gene. This protein is involved in the histone-protamine transition of sperm chromatin.			Amino Acid, Peptide, or Protein	
C162803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162803>	C36292	CDKN2A-p16 Status|CDKN2A-p16(INK4a) Status|Cyclin-Dependent Kinase 4 Inhibitor A Status|Cyclin-Dependent Kinase Inhibitor 2A Status|p16 Status|p16(INK4a) Status|p16-INK4 Status|p16INK4 Status|p16INK4a Status	An indication of whether CDKN2A-p16 expression has been detected in a sample.			Laboratory or Test Result	
C162804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162804>	C28681|C138180|C129826	Uzatresgene Autoleucel|ADP-A2M4CD8|Autologous Genetically-modified MAGE-A4 C1032 CD8alpha T Cells|Autologous Genetically-modified MAGE-A4 C1032 CD8alpha T Lymphocytes|Autologous Genetically-modified Melanoma Antigen A4 CD8alpha T Cells|Autologous MAGE-A4 C1032 TCR-modified CD8alpha T Cells|Autologous TCR-transduced MAGE-A4 C1032 CD8alpha T Cells|MAGE-A4 SPEAR CD8alpha T-cells|MAGE-A4-specific TCR gene-transduced C1032 CD8alpha T-lymphocytes|SPEAR T-cell ADP-A2M4CD8|UZATRESGENE AUTOLEUCEL	Autologous human T-lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the human melanoma antigen A4 (MAGE-A4) and the CD8alpha co-receptor, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, isolation, transduction, expansion ex vivo, and reintroduction into the patient, uzatresgene autoleucel bind to tumor cells expressing MAGE-A4. This may result in both inhibition of growth and increased cell death of MAGE-A4-expressing tumor cells. The tumor-associated antigen MAGE-A4, a member of the MAGE-A family of cancer testis antigens, is overexpressed by a variety of cancer cell types. Co-expression of CD8alpha may broaden the immune response against tumors and increase antitumor activity by converting CD4+ helper T-cells into CD8+ cytotoxic T-cells.	Uzatresgene Autoleucel		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162805>	C49146|C1663	Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP|GAd-209-FSP|GAd20-209-FSP|Great Ape Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP	An off-the-shelf neoantigen priming vaccine comprised of a great ape adenovirus (GAd) encoding tumor-specific neoantigens (TSNAs) derived from as of yet undisclosed frameshift peptides (FSPs) with potential immunostimulatory and antineoplastic activities. Upon intramuscular administration of the adenoviral tumor-specific neoantigen priming vaccine GAd-209-FSP, the adenovirus infects cells and expresses the TSNAs. This stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the TSNAs, leading to tumor cell lysis. Adenoviral-TSNA priming vaccine GAd-209-FSP is followed by boosting with a vaccine that encodes the same target TSNAs.	Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162806>	C2313|C1663	MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP|MVA-209-FSP|Modified Vaccinia Ankara Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP|Modified Vaccinia Virus Ankara Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP	An off-the-shelf neoantigen boosting vaccine comprised of a modified Vaccinia virus Ankara (MVA) encoding tumor-specific neoantigens (TSNAs) derived from the same as of yet undisclosed frameshift peptides (FSPs) targeted by the priming vaccine, great ape adenoviral tumor-specific neoantigen priming vaccine GAd-209-FSP, with potential immunostimulatory and antineoplastic activities. Following intramuscular administration of the priming vaccine GAd-209-FSP, the booster MVA tumor-specific neoantigen boosting vaccine MVA-209-FSP may serve to further expand and improve the phenotyping of antigen-specific T-cells targeted to the tumor cells expressing the TSNAs.	MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162807>	C1291	Cimdelirsen|CIMDELIRSEN|GHR Antisense Oligonucleotide IONIS-GHR-LRx|Growth Hormone Receptor Antisense Oligonucleotide IONIS-GHR-LRx|IONIS GHR LRX|IONIS-GHR-LRx|ISIS-766720|LICA Drug IONIS-GHR-LRx|Ligand-conjugated Antisense Drug IONIS-GHR-LRx	An antisense oligonucleotide targeting the growth hormone receptor (GHR; somatotropin receptor) mRNA, with potential somatotropin-inhibiting activity. Upon subcutaneous administration, cimdelirsen hybridizes with GHR mRNA, which blocks translation of the GHR protein. Reduction of GHR levels in turn decreases the circulating level of insulin-like growth factor-1 (IGF-1). IGF-1 is a hormone that plays an important role in childhood growth and has anabolic effects in adults. Excess production of IGF-1 results in various disease states including acromegaly.	Cimdelirsen		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C162808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162808>	C158375	Lobectomy Patient	A patient undergoing the surgical removal of a lobe of an organ.	Lobectomy Patient		Patient or Disabled Group	CTRP Intervention Terminology|CTRP Terminology
C162809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162809>	C154267	H1-8 Gene|H1-8|H1-8|H1.8 Linker Histone Gene|H1FOO	This gene plays a role in chromosome instability in embryonic cells and oocytes.			Gene or Genome	
C16280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16280>	C17106	Alternate Splicing|Alternative Splicing	Alternate Splicing is a process in which multiple protein isoforms or products are generated from a single gene as a result of splicing together different nonconsecutive exons during the processing of initially identical nascent transcripts of a gene into mature mRNA transcripts. An exon may be connected to any one of several alternative exons to form the mRNA and generate related proteins, often in a tissue or developmental stage specific manner.			Genetic Function	
C162810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162810>	C162809	H1-8 wt Allele|H1 Histone Family Member O Oocyte Specific Gene|H1 Histone Family, Member O, Oocyte-Specific Gene|H1.8|H1.8 Linker Histone wt Allele|H1FOO|H1OO|H1oo|OSH1|osH1	Human H1-8 wild-type allele is located in the vicinity of 3q22.1 and is approximately 8 kb in length. This allele, which encodes histone H1oo protein, is involved in chromatin structural regulation during oogenesis and embryogenesis.			Gene or Genome	
C162811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162811>	C16683	Histone H1oo|H1-8|H1FOO|Oocyte-Specific Histone H1|Oocyte-Specific Linker Histone H1|osH1	Histone H1oo (346 aa, ~36 kDa) is encoded by the human H1-8 gene. This protein plays a role in the modulation of chromatin structure during embryogenesis and oogenesis.			Amino Acid, Peptide, or Protein	
C162812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162812>	C53268	Lentiviral Vector Recipient|Lentivirus Vector Recipient	A recipient of a gene vector based on a lentivirus genome.	Lentiviral Vector Recipient		Human	CTRP Intervention Terminology|CTRP Terminology
C162813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162813>	C154267	H1-10 Gene|H1-10|H1-10|H1.10 Linker Histone Gene|H1FX	This gene is involved in the condensation of nucleosomes into higher-order structures.			Gene or Genome	
C162814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162814>	C162813	H1-10 wt Allele|H1 Histone Family Member X Gene|H1 Histone Family, Member X Gene|H1.10|H1.10 Linker Histone wt Allele|H1FX|H1X	Human H1-10 wild-type allele is located in the vicinity of 3q21.3 and is approximately 2 kb in length. This allele, which encodes histone H1x protein, plays a role in chromosome condensation.			Gene or Genome	
C162815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162815>	C16683	Histone H1x|H1-10|H1FX	Histone H1x (213 aa, ~22 kDa) is encoded by the human H1-10 gene. This protein is involved in DNA condensation.			Amino Acid, Peptide, or Protein	
C162816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162816>	C154299	H2AJ Gene|H2A.J Histone Gene|H2AFJ|H2AJ|H2AJ	This gene plays a role in chromosome stability.			Gene or Genome	
C162817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162817>	C162816	H2AJ wt Allele|FLJ10903|H2A Histone Family Member J Gene|H2A Histone Family, Member J Gene|H2A.J Histone wt Allele|H2AFJ|MGC921	Human H2AJ wild-type allele is located in the vicinity of 12p12.3 and is approximately 4 kb in length. This allele, which encodes histone H2A.J protein, is involved in nucleosomal structure.			Gene or Genome	
C162818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162818>	C12680	Lateral Pharyngeal Space|Parapharyngeal Area|Parapharyngeal Space|Pharyngomaxillary Space	A cone-shaped lateral neck space with its base on the base of the skull and its apex at the hyoid bone.			Body Location or Region	
C162819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162819>	C156897	FitBit	A brand of wearable activity monitors, designed to measure data such as the number of steps walked, heart rate, quality of sleep, steps climbed, and other personal metrics involved in fitness.	FitBit		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C16281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16281>	C21541	Ambulatory Care Facility|ACF|AMB|AMBULATORY CARE FACILITY|Ambulatory|Ambulatory Care|Ambulatory Care Facilities|Clinic|OUTPATIENT CLINIC|Outpatient Care Facility	A medical care center that provides healthcare services on an outpatient basis.			Health Care Related Organization	CDISC SDTM Environmental Setting Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Individual Case Safety Report Terminology|Location of Event Occurrence ICSR Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C162820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162820>	C3260	Parapharyngeal Neoplasm	A benign or malignant neoplasm that affects the parapharyngeal space.			Neoplastic Process	
C162821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162821>	C16684	Histone H2A.J|H2AFJ|H2AJ|H2a/j	Histone H2A.J (129 aa, ~14 kDa) is encoded by the human H2AJ gene. This protein plays a role in chromatin formation.			Amino Acid, Peptide, or Protein	
C162822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162822>	C4884|C162820	Benign Parapharyngeal Neoplasm	A neoplasm that arises from the parapharyngeal space and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.	Benign Parapharyngeal Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162823>	C4940|C162820	Malignant Parapharyngeal Neoplasm	A primary or metastatic malignant neoplasm that affects the parapharyngeal space.	Malignant Parapharyngeal Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162824>	C12680	Retropharyngeal Space|Structure of retropharyngeal space (body structure)	A neck space that is bounded anteriorly by the buccopharyngeal fascia, laterally by the carotid sheath, and posteriorly by the prevertebral fascia.			Body Space or Junction	mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C162825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162825>	C3260	Retropharyngeal Neoplasm	A benign or malignant neoplasm that affects the retropharyngeal space.			Neoplastic Process	
C162826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162826>	C4884|C162825	Benign Retropharyngeal Neoplasm	A neoplasm that arises from the retropharyngeal space and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.	Benign Retropharyngeal Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162827>	C154299	H2AZ2 Gene|H2A.Z Variant Histone 2 Gene|H2AFV|H2AZ2|H2AZ2	This gene may be involved in the formation of constitutive heterochromatin.			Gene or Genome	
C162828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162828>	C4940|C162825	Malignant Retropharyngeal Neoplasm	A primary or metastatic malignant neoplasm that affects the retropharyngeal space.	Malignant Retropharyngeal Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16282>	C199143	American Cancer Society|ACS	A nationwide, community-based voluntary health organization, the largest private source of cancer research funds in the U.S. Headquartered in Atlanta, Georgia, the ACS has state divisions and more than 3,400 local offices. ACS provides information on cancer incidence, mortality, causes, manifestations, treatment, and prevention, as well as on cancer research and clinical trials, and promotes beneficial policies, laws, and regulations for patients and families affected by cancer.			Health Care Related Organization	
C162830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162830>	C162827	H2AZ2 wt Allele|H2A Histone Family Member V Gene|H2A Histone Family, Member V Gene|H2A.Z Variant Histone 2 wt Allele|H2A.Z-2|H2AFV|H2AV|MGC10170|MGC10831|MGC1947	Human H2AZ2 wild-type allele is located in the vicinity of 7p13 and is approximately 21 kb in length. This allele, which encodes histone H2A.V protein, plays a role in chromosome condensation.			Gene or Genome	
C162831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162831>	C16684	H2AZ2 Gene Product	A protein encoded by the H2AZ2 gene.			Amino Acid, Peptide, or Protein	
C162832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162832>	C162831	Histone H2A.V|H2A.F/Z|H2A.Z-2|H2A.Z-2.1|H2A.Z.2|H2A.Z.2|H2A.Z.2.1|H2AFV|H2AZ2|Histone H2A.F/Z|Histone H2A.V Isoform 1|Purine-Rich Binding Element Protein B	Histone H2A.V (128 aa, ~14 kDa) is encoded by the human H2AZ2 gene. This protein is involved in nucleosome formation.			Amino Acid, Peptide, or Protein	GDC Terminology|GDC Value Terminology
C162833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162833>	C8181|C136427	Unresectable Oropharyngeal Squamous Cell Carcinoma	Oropharyngeal squamous cell carcinoma that is not amenable to surgical resection.	Unresectable Oropharyngeal Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162834>	C162831	Histone H2A.V Isoform 2|H2A.Z-2.2|H2A.Z.2.2|H2A.Z.2.2|H2AZ2|Z.2.2	Histone H2A.V isoform 2 (114 aa, ~12 kDa) is encoded by the human H2AZ2 gene. This protein plays a role in nucleosome stability.			Amino Acid, Peptide, or Protein	GDC Terminology|GDC Value Terminology
C162835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162835>	C154300	H2BW2 Gene|H2B.W Histone 2 Gene|H2BFM|H2BM|H2BW2|H2BW2	This gene plays a role in nucleosome wrapping.			Gene or Genome	
C162836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162836>	C162835	H2BW2 wt Allele|H2B Histone Family Member M Gene|H2B Histone Family, Member M Gene|H2B.M Histone Gene|H2B.W Histone 2 wt Allele|H2BFM|H2BM	Human H2BW2 wild-type allele is located in the vicinity of Xq22.2 and is approximately 3 kb in length. This allele, which encodes histone H2B type F-M protein, is involved in chromatin remodeling.			Gene or Genome	
C162837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162837>	C17460	Histone H2B Type F-M|H2BFM|H2BM|H2BW2	Histone H2B type F-M (154 aa, ~17 kDa) is encoded by the human H2BW2 gene. This protein plays a role in nucleosome remodeling.			Amino Acid, Peptide, or Protein	
C162838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162838>	C154300	H2BC12L Gene|H2B Clustered Histone 12 Like Gene|H2BC12L|H2BC12L|H2BFS|H2BS1	This gene is involved in nucleosome remodeling and antimicrobial humoral responses.			Gene or Genome	
C162839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162839>	C162838	H2BC12L wt Allele|H2B Clustered Histone 12 Like wt Allele|H2B Histone Family Member S (Pseudogene) Gene|H2B Histone Family Member S Gene|H2B Histone Family, Member S (Pseudogene) Gene|H2B Histone Family, Member S Gene|H2B.S Histone 1 Gene|H2B/s|H2BFS|H2BS1	Human H2BC12L wild-type allele is located in the vicinity of 21q22.3 and is approximately 1 kb in length. This allele, which encodes histone H2B type F-S protein, plays a role in antimicrobial defense responses and chromatin condensation.			Gene or Genome	
C162840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162840>	C17460	Histone H2B Type F-S|H2B-Clustered Histone 12 Like|H2B.S Histone 1|H2B/s|H2BC12L|H2BFS|H2BS1|Histone H2B.s	Histone H2B type F-S (126 aa, ~14 kDa) is encoded by the human H2BC12L gene. This protein is involved in histone-mediated processes and innate immunity.			Amino Acid, Peptide, or Protein	
C162841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162841>	C154300	H2BW1 Gene|H2B.W Histone 1 Gene|H2BFWT|H2BW1|H2BW1	This gene may play a role in spermatogenesis and nucleosome formation.			Gene or Genome	
C162842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162842>	C162841	H2BW1 wt Allele|H2B Histone Family Member W, Testis Specific Gene|H2B Histone Family, Member W, Testis-Specific Gene|H2B.W Histone 1 wt Allele|H2BFWT	Human H2BW1 wild-type allele is located in the vicinity of Xq22.2 and is approximately 3 kb in length. This allele, which encodes histone H2B type W-T protein, may be involved in nucleosome formation and sperm maturation.			Gene or Genome	
C162843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162843>	C17460	Histone H2B Type W-T|H2B Histone Family Member W Testis-Specific|H2BFWT|H2BW1	Histone H2B type W-T (175 aa, ~20 kDa) is encoded by the human H2BW1 gene. This protein may play a role in male germ cell differentiation and nucleosome assembly.			Amino Acid, Peptide, or Protein	
C162844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162844>	C19332	Pregnant at Time of Vaccination	An individual was pregnant at the time a vaccination was administered.			Organism Attribute	FDA Individual Case Safety Report Terminology|Observation ICSR Terminology
C162845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162845>	C4890|C27359	Unresectable Malignant Digestive System Neoplasm	A malignant digestive system neoplasm that is not amenable to surgical resection.	Unresectable Malignant Digestive System Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162846>	C49235	Regulatory Action|Action	A regulatory measure taken against an entity, such as a company, or a product, such as a drug.			Functional Concept	FDA Structured Product Labeling Terminology
C162847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162847>	C49235	FDA Inactivation|Inactivated	FDA initiated and completed the inactivation of a registration or listing record due to inaccuracies, incompleteness or incompliance.			Activity	FDA Structured Product Labeling Terminology
C162849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162849>	C154267	H1-5 Gene|H1-5|H1-5|H1.5 Linker Histone, Cluster Member Gene|HIST1H1B	This gene is involved in nucleosome organization.			Gene or Genome	
C16284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16284>	C99387	Amylase|amylase	Amylase is an enzyme which helps digest glycogen and starch. It is produced mainly in the pancreas and salivary glands.			Amino Acid, Peptide, or Protein|Enzyme	
C162850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162850>	C162849	H1-5 wt Allele|H1 Histone Family, Member 5 Gene|H1 Histone Family, Member 5, Formerly Gene|H1.5|H1.5 Linker Histone, Cluster Member wt Allele|H1B|H1F5|H1s-3|HIST1 Cluster, H1b Gene|HIST1H1B|Histone 1, H1b Gene|Histone Cluster 1 H1 Family Member B Gene|Histone Cluster 1, H1b Gene|Histone Gene Cluster 1, H1 Histone Family, Member B Gene|Histone Gene Cluster 1, H1b Gene	Human H1-5 wild-type allele is located in the vicinity of 6p22.1 and is approximately 1 kb in length. This allele, which encodes histone H1.5 protein, plays a role in histone-mediated processes.			Gene or Genome	
C162851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162851>	C16683	Histone H1.5|H1-5|HIST1H1B|Histone H1a|Histone H1b|Histone H1s-3	Histone H1.5 (226 aa, ~23 kDa) is encoded by the human H1-5 gene. This protein is involved in linker histone activity.			Amino Acid, Peptide, or Protein	
C162852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162852>	C155727	FGFR4 Inhibitor ICP-105|FGFR4 Antagonist ICP-105|ICP 105|ICP-105|ICP105	An orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon oral administration, ICP-105 specifically targets, binds to and blocks the binding of the ligand FGF19 to FGFR4. This prevents the activation of FGFR4, inhibits FGFR4-mediated signaling and leads to an inhibition of tumor cell proliferation in FGFR4-overexpressing cells. FGFR4, a receptor tyrosine kinase overexpressed on a variety of cancer cell types, is involved in tumor cell proliferation, differentiation, angiogenesis, and survival. FGF19 is overexpressed by certain tumor cell types.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162853>	C154267	H1-2 Gene|H1-2|H1-2|H1.2 Linker Histone, Cluster Member Gene|HIST1H1C	This gene plays a role in linker histone-dependent nucleosome spacing.			Gene or Genome	
C162854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162854>	C162853	H1-2 wt Allele|H1 Histone Family, Member 2 Gene|H1 Histone Family, Member 2, Formerly Gene|H1.2|H1.2 Linker Histone, Cluster Member wt Allele|H1C|H1F2|H1s-1|HIST1 Cluster, H1c Gene|HIST1H1C|Histone 1, H1c Gene|Histone Cluster 1 H1 Family Member C Gene|Histone Cluster 1, H1c Gene|Histone Gene Cluster 1, H1 Histone Family, Member C Gene|Histone Gene Cluster 1, H1c Gene	Human H1-2 wild-type allele is located in the vicinity of 6p22.2 and is approximately 1 kb in length. This allele, which encodes histone H1.2 protein, is involved in chromatin wrapping.			Gene or Genome	
C162855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162855>	C93144	Bifidobacterium longum/Lactobacillus acidophilus/Enterococcus faecalis Probiotic Supplement|B. longum/L. acidophilus/E. faecalis Probiotic Supplement|Bifico|Bifidobacterium longum/Lactobacillus acidophilus/Enterococcus faecalis Supplement	An orally bioavailable, probiotic supplement containing the microorganisms Bifidobacterium longum (B. longum), Lactobacillus acidophilus (L. acidophilus) and Enterococcus faecalis (E. faecalis), with potential immunomodulating, anti-diarrheal and mucosal protective activities. Upon oral ingestion, the naturally-occurring bacterial components in B. longum/L. acidophilus/E. faecalis probiotic supplement may improve digestion and help to maintain adequate colonization of the gastrointestinal (GI) tract by modulating the composition of the normal microflora. They produce lactic acid, hydrogen peroxide and other substances during fermentation, thereby creating an acidic environment that is unfavorable for pathogens. During colonization in the GI tract, the bacteria may also form a protective intestinal barrier, which may prevent damage to the mucosal epithelium, maintain the integrity of the epithelial barrier from potential damage by toxins and certain chemicals, and reduce the potential for attachment of pathogens. This further protects against bacterial translocation and infection. In addition, this agent may reduce the secretion of pro-inflammatory cytokines and may potentiate natural and acquired immunity. Altogether, this may increase immunity, prevent GI mucosal damage, malabsorption, inflammation, and reduce diarrhea.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C162856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162856>	C200766|C176018	Autologous Anti-CD19 CAR-CD28 T-cells ET019002|Anti-CD19 Autologous CAR T-cells ET019002|ET019002-T Cells	A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) consisting of a single chain variable fragment (scFv) of anti-CD19, coupled to the costimulatory domain of CD28, with potential immunostimulating and antineoplastic activities. Upon transfusion, the autologous anti-CD19 CAR-CD28 T-cells ET019002 target, bind to, and induce selective toxicity in CD19-expressing B-cells. The CD19 antigen is a B-cell-specific cell surface antigen expressed in all B-cell lineage malignancies.			Cell|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162857>	C16683	Histone H1.2|H1-2|HIST1H1C|Histone H1c|Histone H1d|Histone H1s-1	Histone H1.2 (213 aa, ~21 kDa) is encoded by the human H1-2 gene. This protein plays a role in nucleosome condensation.			Amino Acid, Peptide, or Protein	
C162858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162858>	C141137|C129820	IDO1/TDO2 Inhibitor DN1406131|DN 1406131|DN-1406131|DN131|DN1406131|Indoleamine 2,3-Dioxygenase 1/Tryptophan 2,3-Dioxygenase 2 Inhibitor DN1406131	An inhibitor of both the enzymes indoleamine 2,3-dioxygenase 1 (IDO1; IDO-1) and tryptophan 2,3-dioxygenase 2 (TDO2; TDO-2), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1/TDO2 inhibitor DN1406131 targets, binds to and inhibits both IDO1 and TDO2, which catalyze the first and rate-limiting step in the production of the immunosuppressive transcription factor aryl hydrocarbon receptor (AhR) ligand kynurenine (KYN). This inhibits the IDO1/TDO2-KYN-AhR pathway. Abrogation of AhR activation prevents the activation of immune-tolerant dendritic cells (DCs) and regulatory T-cells (Tregs) in the tumor microenvironment (TME). This may restore the immune response against tumor cells in which IDO1 and/or TDO2 are overexpressed. The IDO1/TDO2-KYN-AhR pathway is overexpressed in a variety of tumor cell types, plays a key role in immunosuppression and its expression is correlated with poor prognosis.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162859>	C275	Eggplant Peel Extract Cream|Brinjal Peel Extract Cream|Solanum melongena L. Extract Cream	A cream containing an extract from the skin of the vegetable Solanum melongena (eggplant; S. melongena; aubergine; brinjal) containing high levels of bioactive components, such as anthocyanins, with potential anti-oxidant, keratolytic, and antineoplastic activities. Upon topical administration of the eggplant peel extract cream, the active ingredients in the eggplant extract may exert antioxidant, anti-proliferative and protective effects on skin cells.			Organic Chemical|Pharmacologic Substance	NCI Drug Dictionary Terminology
C16285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16285>	C18106|C18072	Amyloid-Beta Precursor Protein|AAA|ABPP|APP|APP|APPI|Alzheimer Disease 1 Protein|Alzheimer Disease Amyloid A4 Protein Homolog|Alzheimer Disease Amyloid Protein|Alzheimer's Disease Amyloid Protein|Amyloid|Amyloid Beta (A4) Precursor Protein|Amyloid Beta A4 Protein|Amyloid Beta A4 Protein|Amyloid Beta A4 Protein Precursor|Amyloid Beta-Peptide|Amyloid Precursor Protein|Amyloid of Aging and Alzheimer Disease Protein|Amyloid-Beta (A4) Precursor Protein|Amyloid-Beta A4 Protein|CVAP|Cerebral Vascular Amyloid Peptide|Cerebralvascular Amyloid Peptide|PN II|PN-II|PN2|PreA4|Protease Nexin II|Protease Nexin-II|Protease Nexin-II, Alzheimer Disease	Amyloid-beta precursor protein (770 aa, ~87 kDa) is encoded by the human APP gene. This protein is involved in cell surface receptor-mediated signaling and is processed by secretases into soluble peptides, membrane-anchored fragments, plaque amyloid components, transcriptional regulatory molecules and neurotoxic fragments.	Amyloid Beta A4 Protein		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C162860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162860>	C1511	Zirconium Zr 89-labeled Envafolimab|89Zr-Envafolimab|89Zr-KN035|Zirconium Zr 89-Anti-PD-L1 Monoclonal Antibody KN035|Zirconium Zr 89-Envafolimab|Zirconium Zr 89-KN035	A radioimmunoconjugate composed of envafolimab, a monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and labeled with the radioisotope zirconium Zr 89, with potential use for assessing PD-L1 tumor antigen expression using positron emission tomography (PET). Upon administration of zirconium Zr 89-labeled envafolimab, the envafolimab moiety targets and binds to the PD-L1 expressed on certain tumor cells. Upon uptake and PET imaging, the radioisotope moiety can be visualized and the extent of PD-L1 expression can be assessed. This can be used to predict the therapeutic response to envafolimab and other PD-L1-targeting agents.			Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	NCI Drug Dictionary Terminology
C162861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162861>	C154267	H1-3 Gene|H1-3|H1-3|H1.3 Linker Histone, Cluster Member Gene|HIST1H1D	This gene is involved in nucleosome condensation into higher-order structures.			Gene or Genome	
C162862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162862>	C162861	H1-3 wt Allele|H1 Histone Family, Member 3 Gene|H1 Histone Family, Member 3, Formerly Gene|H1.3|H1.3 Linker Histone, Cluster Member wt Allele|H1D|H1F3|H1s-2|HIST1 Cluster, H1d Gene|HIST1H1D|Histone 1, H1d Gene|Histone Cluster 1 H1 Family Member D Gene|Histone Cluster 1, H1d Gene|Histone Gene Cluster 1, H1 Histone Family, Member D Gene|Histone Gene Cluster 1, H1d Gene	Human H1-3 wild-type allele is located in the vicinity of 6p22.2 and is approximately 1 kb in length. This allele, which encodes histone H1.3 protein, plays a role in chromosome condensation.			Gene or Genome	
C162863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162863>	C16683	Histone H1.3|H1-3|HIST1H1D|Histone H1c|Histone H1d|Histone H1s-2	Histone H1.3 (221 aa, ~22 kDa) is encoded by the human H1-3 gene. This protein is involved in nucleosome spacing.			Amino Acid, Peptide, or Protein	
C162864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162864>	C154267	H1-6 Gene|H1-6|H1-6|H1.6 Linker Histone, Cluster Member Gene|HIST1H1T	This gene plays a role in the formation of relaxed chromatin structures.			Gene or Genome	
C162865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162865>	C162864	H1-6 wt Allele|H1 Histone Family, Member T (Testis-Specific) Gene|H1 Histone Family, Member T, Formerly Gene|H1 Histone, Testis-Specific Gene|H1.6|H1.6 Linker Histone, Cluster Member wt Allele|H1.T|H1FT|H1T|H1t|HIST1 Cluster, H1t Gene|HIST1H1T|Histone 1, H1t Gene|Histone Cluster 1 H1 Family Member T Gene|Histone Cluster 1, H1t Gene|Histone Gene Cluster 1, H1 Histone Family, Member T Gene|Histone Gene Cluster 1, H1 Histone Family, Testis-Specific Member Gene|Histone Gene Cluster 1, H1t Gene|dJ221C16.2	Human H1-6 wild-type allele is located in the vicinity of 6p22.2 and is approximately 1 kb in length. This allele, which encodes histone H1t protein is involved in chromatin architecture.			Gene or Genome	
C162866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162866>	C16683	Histone H1t|H1-6|H1.T|HIST1H1T|Histone H1.t|Testicular H1 Histone	Histone H1t (207 aa, ~22 kDa) is encoded by the human H1-6 gene. This protein plays a role in chromatin condensation.			Amino Acid, Peptide, or Protein	
C162867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162867>	C154267	H1-9 Gene|H1-9|H1-9P|H1-9P|H1.9 Linker Histone (Pseudogene) Gene|HILS1	This gene is involved in histone-mediated processes during spermiogenesis.			Gene or Genome	
C162868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162868>	C162867	H1-9 wt Allele|H1-9P|H1.9|H1.9 Linker Histone (Pseudogene) wt Allele|H1.9 Linker Histone Gene|HILS1|Histone Linker H1 Domain, Spermatid-Specific 1 (Pseudogene) Gene|Histone Linker H1 Domain, Spermatid-Specific 1 Gene	Human H1-9 wild-type allele is located in the vicinity of 17q21.33 and is approximately 10 kb in length. This allele, which encodes spermatid-specific linker histone H1-like protein, plays a role in DNA accessibility during spermiogenesis.			Gene or Genome	
C162869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162869>	C16683	Spermatid-Specific Linker Histone H1-Like Protein|H1-9|H1.9|HILS1|Histone TS H1.9	Spermatid-specific linker histone H1-like protein (231 aa, ~26 kDa) is encoded by the human H1-9 gene. This protein is involved in chromatin condensation during spermatogenesis.			Amino Acid, Peptide, or Protein	
C16286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16286>	C20349	Anaphase|Mitotic Anaphase	The third phase of mitosis during which the two groups of daughter chromosomes separate and move along the fibers of the central spindle, each toward one of the asters, forming the diaster.			Cell Function	
C162870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162870>	C36279	Gastrointestinal Dysfunction	A finding of any disturbance, impairment, or abnormality of function of the gastrointestinal system.	Gastrointestinal Dysfunction		Finding	CTRP Disease Terminology|CTRP Terminology
C162871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162871>	C129822|C128037	Anti-PD-1 Monoclonal Antibody BAT1306|Anti-PD1 Monoclonal Antibody BAT1306|BAT 1306|BAT-1306|BAT1306	A recombinant, humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-PD-1 monoclonal antibody BAT1306 targets, binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162872>	C208255|C207756|C198860|C1742	Anti-VEGF/TGF-beta 1 Fusion Protein HB-002T|HB 002T|HB-002T|HB002.1T|HB002T	A recombinant, human immunoglobulin Fc fusion protein targeting both the transforming growth factor (TGF) beta 1 (TGF-beta 1; TGFb1) and the vascular endothelial growth factor (VEGF), with potential anti-angiogenic and antineoplastic activities. Upon administration of anti-VEGF/TGF-beta 1 fusion protein HB-002T, the fusion protein specifically and selectively targets, binds to and neutralizes both TGF-beta 1 and VEGF. This prevents TGFb1- and VEGF-mediated signaling and abrogates VEGF/VEGFR-induced angiogenesis and TGFb1-mediated induction of VEGF, which further inhibits angiogenesis. It also inhibits TGFb1-mediated immunosuppression, thereby enhancing anti-tumor immunity in the tumor microenvironment (TME) and promoting a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162873>	C201491|C200766	Autologous Active IL-7 Receptor Co-expressing GD2-specific CAR T-cells|Autologous C7R-GD2.CART Cells|Autologous T-lymphocytes Expressing GD2-specific Chimeric Antigen and Constitutively Active IL-7 Receptors|Constitutively Active IL-7 Receptor Co-expressing GD2-specific CAR T-cells	A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the human tumor-associated antigen (TAA) GD2, and the constitutively active interleukin 7 (IL-7) receptor (C7R), with potential antineoplastic activity. Upon intravenous administration, autologous active IL-7 receptor co-expressing GD2-specific CAR T-cells target, bind to, and induce selective toxicity in GD2-expressing tumor cells. C7R triggers IL-7-mediated signaling that promotes T-cell proliferation, survival, and anti-tumor activity. GD2, a disialoganglioside and TAA, is overexpressed in a variety of tumor cell types.	Autologous Active IL-7 Receptor Co-expressing GD2-specific CAR T-cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162874>	C1752|C1663	Neoantigen Vaccine GEN-009|GEN 009|GEN-009|GEN-009 Vaccine|GEN009|Personalized Cancer Vaccine GEN-009	A peptide-based, personalized cancer vaccine consisting of patient-specific mutated synthetic long peptides (SLPs), which are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. Upon subcutaneous vaccination with the personalized neoantigen peptide vaccine GEN-009, and administration along with the immunoadjuvant poly-ICLC, the peptides stimulate the host immune system to mount a specific and potent cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. The Antigen Lead Acquisition System (ATLAS) will be used to identify neoantigens in each patient's tumor that are recognized by their CD4 and/or CD8 T-cells and will be incorporated into GEN-009 in the form of SLPs. Each personalized vaccine contains between four and twenty SLPs.	Neoantigen Vaccine GEN-009		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162875>	C134787|C129822	Domvanalimab|AB 154|AB-154|AB154|Anti-TIGIT Monoclonal Antibody AB154|DOMVANALIMAB	A humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity. Upon administration, domvanalimab targets and binds to TIGIT expressed on various immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs), thereby preventing the interaction of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2) and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK) cells and CD8+ T-cells. This leads to CD226 dimerization and CD226-mediated signaling and activates the immune system to exert a T-cell-mediated immune response against cancer cells. TIGIT, a member of the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in the suppression of T-cell proliferation and activation; it is involved in tumor cell immune evasion, and the inhibition of antiviral immune responses.	Domvanalimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162876>	C8193|C162882	Metastatic Paranasal Sinus Squamous Cell Carcinoma	A paranasal sinus squamous cell carcinoma that has spread from its original site of growth to another anatomic site.	Metastatic Paranasal Sinus Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162877>	C797|C275	Lignin-derived Polyphenolic Composition with Ammonium Molybdate BP-C2|BP C2|BP-C2|BPC2|Benzene-poly-carboxylic Acid Complex with Molybdenum BP-C2|Molybdenum Salts of Benzene-polycarboxylic Acids BP-C2	An orally bioavailable solution containing lignin-derived benzene-polycarboxylic acids mixed with ammonium molybdate, with potential use as an adjuvant and with potential radioprotective and regenerative activities. Upon oral administration, lignin-derived polyphenolic composition with ammonium molybdate BP-C2 is also able to stimulate the innate immune system and upregulates a variety of cytokines including interferon (IFN), tumor necrosis factor-alpha (TNF-alpha), granulocyte macrophage-colony stimulating factor (GM-CSF), and various interleukins (ILs) such as IL-6, IL-22 and IL-25, and induces the production of innate lymphoid cells. BP-C2 stimulates the production of intestinal epithelial cells thereby protecting the gastrointestinal (GI) tract against GI-induced cytotoxic side effects caused by certain anti-tumor agents. Additionally, BP-C2 scavenges free radicals, inhibits lipid oxidation, and protects cells against radiation-induced damage. Molybdenum, an essential micronutrient, acts as a cofactor in multiple detoxification system enzymes. BP-C2 may also stimulate the production of hematopoietic progenitor cells, thereby correcting hematological abnormalities such as anemia, thrombocytopenia and neutropenia, which are also caused by certain anti-cancer agents.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C162878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162878>	C129820	Lenalidomide Analog KPG-121|KPG 121|KPG-121|KPG121	A lenalidomide analog with potential anti-angiogenic and immunomodulatory activities. Upon oral administration, lenalidomide analog KPG-121 may inhibit tumor necrosis factor alpha (TNF-alpha) production, stimulate T-lymphocytes, reduce serum levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF; FGF2), and inhibit angiogenesis. Additionally, KPG-121 may promote G1 cell cycle arrest and induce apoptosis in malignant cells.	Lenalidomide Analog KPG-121		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162879>	C208255|C1742|C1512	Conbercept|CONBERCEPT|FP 3|FP-3|FP3|KH 902|KH 903|KH-902|KH-903|KH902|KH903	A recombinant, soluble, vascular endothelial growth factor receptor (VEGFR) protein composed of the second immunoglobulin (Ig) domain of VEGFR-1, the third and fourth Ig domains of VEGFR-2, and the constant region (Fc) of human immunoglobulin G1 (IgG1) with potential anti-angiogenic activities. Upon intravitreal injection, conbercept, functioning as a soluble decoy receptor, binds with high affinity to all VEGF-A isoforms, VEGF-B, as well as placenta growth factor (PlGF)-1 and PlGF-2. This prevents the binding of these growth factors to their endogenous receptors, potentially inhibiting angiogenesis and tumor cell growth.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C16287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16287>	C16344	Anatomical Sciences|Anatomy|anatomy	The science concerned with the physical structure of animals and plants.			Biomedical Occupation or Discipline	
C162881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162881>	C170782|C162758|C150202	Locally Advanced Oropharyngeal Squamous Cell Carcinoma	An oropharyngeal squamous cell carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Oropharyngeal Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162882>	C68611|C200584|C148153	Metastatic Sinonasal Squamous Cell Carcinoma|Metastatic Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma	A nasal cavity and/or paranasal sinus squamous cell carcinoma that has spread from its original site of growth to another anatomic site.			Neoplastic Process	
C162883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162883>	C78275	Rusfertide|Hepcidin Agonist PTG-300|Hepcidin Mimetic PTG-300|PTG 300|PTG-300|PTG300|RUSFERTIDE	An injectable peptide mimetic of hepcidin (hepcidin antimicrobial peptide; HAMP; putative liver tumor regressor; PLTR; liver-expressed antimicrobial peptide 1; LEAP-1) with potential use in the treatment of iron deficiency anemia and iron overload secondary to hematologic disorders. Upon administration, rusfertide mimics endogenous hepcidin, a  protein primarily produced in hepatocytes, and increases hepcidin levels. As hepcidin plays a key role in the homeostasis of systemic iron, rusfertide may serve to normalize iron levels. Low levels of endogenous hepcidin are associated with iron overload secondary to excessive absorption of iron as seen in beta thalassemia and paradoxically with iron deficiency anemia.	Rusfertide		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C162884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162884>	C154299	H2AC1 Gene|H2A Clustered Histone 1 Gene|H2AC1|H2AC1|HIST1H2AA	This gene is involved in chromatin wrapping.			Gene or Genome	
C162885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162885>	C162884	H2AC1 wt Allele|H2A Clustered Histone 1 wt Allele|H2A Histone Family, Member R Gene|H2A/R|H2AA|H2AFR|HIST1 Cluster, H2AA Gene|HIST1H2AA|Histone 1, H2aa Gene|Histone Cluster 1 H2A Family Member A Gene|Histone Cluster 1, H2aa Gene|Histone Gene Cluster 1, H2A Histone Family, Member A Gene|Histone Gene Cluster 1, H2AA Gene|TH2A|bA317E16.2	Human H2AC1 wild-type allele is located in the vicinity of 6p22.2 and is approximately 1 kb in length. This allele, which encodes histone H2A type 1-A protein, plays a role in DNA compaction.			Gene or Genome	
C162886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162886>	C16684	Histone H2A Type 1-A|H2A/R|H2AC1|HIST1H2AA|Histone H2A/r	Histone H2A type 1-A (131 aa, ~14 kDa) is encoded by the human H2AC1 gene. This protein is involved in chromatin remodeling.			Amino Acid, Peptide, or Protein	
C162887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162887>	C154299	H2AC4 Gene|H2A Clustered Histone 4 Gene|H2AC4|H2AC4|HIST1H2AB	This gene plays a role in DNA compaction.			Gene or Genome	
C162888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162888>	C162887	H2AC4 wt Allele|H2A Clustered Histone 4 wt Allele|H2A Histone Family, Member M Gene|H2A/m|H2AFM|HIST1 Cluster, H2ab Gene|HIST1H2AB|Histone 1, H2AB Gene|Histone Cluster 1 H2A Family Member B Gene|Histone Cluster 1, H2AB Gene|Histone Gene Cluster 1, H2A Histone Family, Member B Gene|Histone Gene Cluster 1, H2ab Gene	Human H2AC4 wild-type allele is located in the vicinity of 6p22.2 and is approximately 1 kb in length. This allele, which encodes histone H2A type 1-B/E protein, is involved in nucleosome wrapping.			Gene or Genome	
C162889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162889>	C154299	H2AC8 Gene|H2A Clustered Histone 8 Gene|H2AC8|H2AC8|HIST1H2AE	This gene is involved in nucleosome structure.			Gene or Genome	
C16288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16288>	C16287	Comparative Anatomy|Anatomy, Comparative|comparative anatomy|comparative anatomy	The study of similarities and differences in homologous and analagous structures between different organisms.			Biomedical Occupation or Discipline	
C162890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162890>	C162889	H2AC8 wt Allele|H2A Clustered Histone 8 wt Allele|H2A Histone Family, Member A Gene|H2A.2|H2A/a|H2AFA|HIST1 Cluster, H2ae Gene|HIST1H2AE|Histone 1, H2AE Gene|Histone Cluster 1 H2A Family Member E Gene|Histone Cluster 1, H2AE Gene|Histone Gene Cluster 1, H2A Histone Family, Member E Gene|Histone Gene Cluster 1, H2ae Gene	Human H2AC8 wild-type allele is located in the vicinity of 6p22.2 and is approximately 1 kb in length. This allele, which encodes histone H2A type 1-B/E protein, plays a role in the formation of chromatin.			Gene or Genome	
C162891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162891>	C16684	Histone H2A Type 1-B/E|H2AC4/8|HIST1H2AB/E|Histone H2A.2|Histone H2A/a|Histone H2A/m	Histone H2A type 1-B/E (130 aa, ~14 kDa) is encoded by the human H2AC4 and H2AC8 genes. This protein is involved in chromosome condensation.			Amino Acid, Peptide, or Protein	
C162892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162892>	C154299	H2AC6 Gene|H2A Clustered Histone 6 Gene|H2AC6|H2AC6|HIST1H2AC	This gene plays a role in the regulation of nucleosomes.			Gene or Genome	
C162893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162893>	C162892	H2AC6 wt Allele|H2A Clustered Histone 6 wt Allele|H2A Histone Family, Member L Gene|H2A/l|H2AFL|HIST1 Cluster, H2AC Gene|HIST1H2AC|Histone 1, H2ac Gene|Histone Cluster 1 H2A Family Member C Gene|Histone Cluster 1, H2ac Gene|Histone Gene Cluster 1, H2A Histone Family, Member C Gene|Histone Gene Cluster 1, H2AC Gene|dJ221C16.4	Human H2AC6 wild-type allele is located in the vicinity of 6p22.2 and is approximately 15 kb in length. This allele, which encodes histone H2A type 1-C protein, is involved in nucleosome formation.			Gene or Genome	
C162894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162894>	C16684	Histone H2A Type 1-C|H2A/L|H2AC6|HIST1H2AC|Histone H2A/l|Histone H2AC	Histone H2A type 1-C (130 aa, ~14 kDa) is encoded by the human H2AC6 gene. This protein plays a role in the modulation of chromatin structure.			Amino Acid, Peptide, or Protein	
C162895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162895>	C154299	H2AC7 Gene|H2A Clustered Histone 7 Gene|H2AC7|H2AC7|HIST1H2AD	This gene is involved in nucleosome assembly.			Gene or Genome	
C162896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162896>	C162895	H2AC7 wt Allele|H2A Clustered Histone 7 wt Allele|H2A Histone Family, Member G Gene|H2A.3|H2A/g|H2AFG|HIST1 Cluster, H2AD Gene|HIST1H2AD|Histone 1, H2ad Gene|Histone Cluster 1 H2A Family Member D Gene|Histone Cluster 1, H2ad Gene|Histone Gene Cluster 1, H2A Histone Family, Member D Gene|Histone Gene Cluster 1, H2AD Gene	Human H2AC7 wild-type allele is located in the vicinity of 6p22.2 and is approximately 1 kb in length. This allele, which encodes histone H2A type 1-D protein, plays a role in chromatin formation.			Gene or Genome	
C162897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162897>	C16684	Histone H2A Type 1-D|H2A/G|H2AC7|HIST1H2AD|Histone H2A.3|Histone H2A/g|Histone H2AD	Histone H2A type 1-D (130 aa, ~14 kDa) is encoded by the human H2AC7 gene. This protein is involved in the modulation of nucleosome structure.			Amino Acid, Peptide, or Protein	
C162898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162898>	C154299	H2AC11 Gene|H2A Clustered Histone 11 Gene|H2AC11|H2AC11|HIST1H2AG	This gene plays a role in transcription regulation, DNA repair, DNA replication and chromosomal stability.			Gene or Genome	
C162899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162899>	C162898	H2AC11 wt Allele|H2A Clustered Histone 11 wt Allele|H2A Histone Family, Member P Gene|H2A.1b|H2A/p|H2AFP|H2AG|HIST1 Cluster, H2ag Gene|HIST1H2AG|Histone 1, H2AG Gene|Histone Cluster 1 H2A Family Member G Gene|Histone Cluster 1, H2AG Gene|Histone Gene Cluster 1, H2A Histone Family, Member G Gene|Histone Gene Cluster 1, H2ag Gene|pH2A/f	Human H2AC11 wild-type allele is located in the vicinity of 6p22.1 and is approximately 2 kb in length. This allele, which encodes histone H2A type 1 protein, is involved in histone complex formation.			Gene or Genome	
C16289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16289>	C25464	Andorra|020|AD|AND|AND|ANDORRA|ANDORRA	A country in southwestern Europe, between France and Spain.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C1628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1628>	C1974	Polyandrol	A quassinoid phytochemical isolated from Castela polyandra and other plant species with potential antineoplastic activity. (NCI04)			Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C162900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162900>	C154299	H2AC13 Gene|H2A Clustered Histone 13 Gene|H2AC13|H2AC13|HIST1H2AI	This gene is involved in histone-mediated transcription regulation, DNA repair, DNA replication and chromosomal stability.			Gene or Genome	
C162901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162901>	C162900	H2AC13 wt Allele|H2A Clustered Histone 13 wt Allele|H2A Histone Family, Member C Gene|H2A/c|H2AFC|HIST1 Cluster, H2ai Gene|HIST1H2AI|Histone 1, H2AI Gene|Histone Cluster 1 H2A Family Member I Gene|Histone Cluster 1, H2AI Gene|Histone Gene Cluster 1, H2A Histone Family, Member I Gene|Histone Gene Cluster 1, H2ai Gene	Human H2AC13 wild-type allele is located in the vicinity of 6p22.1 and is approximately 1 kb in length. This allele, which encodes histone H2A type 1 protein, plays a role in chromosome organization.			Gene or Genome	
C162902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162902>	C154299	H2AC15 Gene|H2A Clustered Histone 15 Gene|H2AC15|H2AC15|HIST1H2AK	This gene plays a role in histone-dependent chromosomal stability.			Gene or Genome	
C162903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162903>	C162902	H2AC15 wt Allele|H2A Clustered Histone 15 wt Allele|H2A Histone Family, Member D Gene|H2A/d|H2AFD|HIST1 Cluster, H2ak Gene|HIST1H2AK|Histone 1, H2AK Gene|Histone Cluster 1 H2A Family Member K Gene|Histone Cluster 1, H2AK Gene|Histone Gene Cluster 1, H2A Histone Family, Member K Gene|Histone Gene Cluster 1, H2ak Gene	Human H2AC15 wild-type allele is located 6p22.1 and is approximately 1 kb in length. This allele, which encodes histone H2A type 1 protein, is involved in histone-mediated nucleosome assembly.			Gene or Genome	
C162904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162904>	C154299	H2AC16 Gene|H2A Clustered Histone 16 Gene|H2AC16|H2AC16|HIST1H2AL	This gene is involved in histone-dependent nucleosome assembly.			Gene or Genome	
C162905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162905>	C162904	H2AC16 wt Allele|H2A Clustered Histone 16 wt Allele|H2A Histone Family, Member I Gene|H2A.i|H2A/i|H2AFI|HIST1 Cluster, H2al Gene|HIST1H2AL|Histone 1, H2AL Gene|Histone Cluster 1 H2A Family Member L Gene|Histone Cluster 1, H2AL Gene|Histone Gene Cluster 1, H2A Histone Family, Member L Gene|Histone Gene Cluster 1, H2al Gene|dJ193B12.9	Human H2AC16 wild-type allele is located in the vicinity of 6p22.1 and is approximately 1 kb in length. This allele, which encodes histone H2A type 1 protein, plays a role in histone-mediated cellular processes.			Gene or Genome	
C162906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162906>	C154299	H2AC17 Gene|H2A Clustered Histone 17 Gene|H2AC17|H2AC17|HIST1H2AM	This gene plays a role in histone-mediated chromatin remodeling.			Gene or Genome	
C162907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162907>	C162906	H2AC17 wt Allele|H2A Clustered Histone 17 wt Allele|H2A Histone Family, Member N Gene|H2A.1|H2A/n|H2AFN|HIST1 Cluster, H2am Gene|HIST1H2AM|Histone 1, H2AM Gene|Histone Cluster 1 H2A Family Member M Gene|Histone Cluster 1, H2AM Gene|Histone Gene Cluster 1, H2A Histone Family, Member M Gene|Histone Gene Cluster 1, H2am Gene|dJ193B12.1	Human H2AC17 wild-type allele is located in the vicinity of 6p22.1 and is approximately 1 kb in length. This allele, which encodes histone H2A type 1 protein, is involved in chromatin remodeling.			Gene or Genome	
C162908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162908>	C16684	Histone H2A Type 1|H2A.1|Histone H2A.1|Histone H2A/Ptl	Histone H2A type 1 (130 aa, ~14 kDa) is encoded by the human H2AC11, H2AC13, H2AC15, H2AC16 and H2AC17 genes. This protein plays a role in histone-dependent transcription regulation, DNA repair, DNA replication and chromosomal stability.			Amino Acid, Peptide, or Protein	
C162909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162909>	C27961	Immune Effector Cell Associated Neurotoxicity Syndrome|ICANS|IEC-associated Neurotoxicity Syndrome|Immune Effector Cell Encephalopathy	Neurotoxicity associated with immune effector cell therapy. It may be characterized by aphasia, altered level of consciousness, motor weakness, seizures, and cerebral edema.			Disease or Syndrome	
C16290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16290>	C19477	Angiogram	An image of blood vessels.	Angiogram		Laboratory or Test Result	CTRP Intervention Terminology|CTRP Terminology
C162910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162910>	C154299	H2AC12 Gene|H2A Clustered Histone 12 Gene|H2AC12|H2AC12|HIST1H2AH	This gene is involved in histone-mediated chromatin compaction.			Gene or Genome	
C162911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162911>	C162910	H2AC12 wt Allele|H2A Clustered Histone 12 wt Allele|H2A/S|H2AFALii|H2AH|HIST1 Cluster, H2ah Gene|HIST1H2AH|Histone 1, H2AH Gene|Histone Cluster 1 H2A Family Member H Gene|Histone Cluster 1, H2AH Gene|Histone Gene Cluster 1, H2A Histone Family, Member H Gene|Histone Gene Cluster 1, H2ah Gene|dJ86C11.1	Human H2AC12 wild-type allele is located in the vicinity of 6p22.1 and is approximately 1 kb in length. This allele, which encodes histone H2A type 1-H protein, plays a role in nucleosome remodeling.			Gene or Genome	
C162912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162912>	C16684	Histone H2A Type 1-H|H2A/S|H2AC12|HIST1H2AH|Histone H2A/s	Histone H2A type 1-H (128 aa, ~14 kDa) is encoded by the human H2AC12 gene. This protein is involved in nucleosome assembly.			Amino Acid, Peptide, or Protein	
C162913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162913>	C154299	H2AC14 Gene|H2A Clustered Histone 14 Gene|H2AC14|H2AC14|HIST1H2AJ	This gene plays a role in histone-mediated nucleosome formation.			Gene or Genome	
C162914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162914>	C162913	H2AC14 wt Allele|H2A Clustered Histone 14 wt Allele|H2A Histone Family, Member E Gene|H2A/E|H2AFE|HIST1 Cluster, H2aj Gene|HIST1H2AJ|Histone 1, H2AJ Gene|Histone Cluster 1 H2A Family Member J Gene|Histone Cluster 1, H2AJ Gene|Histone Gene Cluster 1, H2A Histone Family, Member J Gene|Histone Gene Cluster 1, H2aj Gene|dJ160A22.4	Human H2AC14 wild-type allele is located in the vicinity of 6p22.1 and is approximately 1 kb in length. This allele, which encodes histone H2A type 1-J protein, is involved in DNA wrapping and compaction.			Gene or Genome	
C162915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162915>	C16684	Histone H2A Type 1-J|H2A/E|H2AC14|HIST1H2AJ|Histone H2A/e	Histone H2A type 1-J (128 aa, ~14 kDa) is encoded by the human H2AC14 gene. This protein plays a role in chromatin structure regulation.			Amino Acid, Peptide, or Protein	
C162916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162916>	C20993	Immune Effector Encephalopathy - ICE Assessment|ICE Assessment|ICE Tool|Immune Effector Encephalopathy Assessment	A grading system for Immune Effector Cell Associated Neurotoxicity Syndrome that includes: orientation to year, month, city, hospital; ability to name objects; ability to follow simple commands; ability to write a standard sentence; and ability to count backwards from 100 by 10. Grading ranges from 10: no impairment to 0: patient unarousable and unable to perform ICE assessment.			Intellectual Product	
C162917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162917>	C116521	Virtual Technology Intervention|Virtual Reality Intervention|Virtual Technology|Virtual Technology	An intervention that uses an immersive, computer-generated environment that a person can interact with and navigate through.	Virtual Technology		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C162918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162918>	C154300	H2BC1 Gene|H2B Clustered Histone 1 Gene|H2BC1|H2BC1|HIST1H2BA	This gene is involved in histone-mediated chromatin remodeling in male germ cells.			Gene or Genome	
C162919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162919>	C162918	H2BC1 wt Allele|H2B Clustered Histone 1 wt Allele|H2B Histone Family, Member U Gene|H2B Histone Family, Member U, (Testis-Specific) Gene|H2BFU|HIST1 Cluster, H2BA Gene|HIST1H2BA|Histone 1, H2ba Gene|Histone Cluster 1 H2B Family Member A Gene|Histone Cluster 1, H2ba Gene|Histone Gene Cluster 1, H2B Histone Family, Member A Gene|Histone Gene Cluster 1, H2ba Gene|STBP|TH2B|TSH2B|TSH2B.1|bA317E16.3|hTSH2B	Human H2BC1 wild-type allele is located in the vicinity of 6p22.2 and is approximately 1 kb in length. This allele, which encodes histone H2B type 1-A protein, plays a role in chromatin stability.			Gene or Genome	
C16291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16291>	C190556	Digital Subtraction Angiography|Angiography, Digital Subtraction|DS|Medical Imaging, Digital Subtraction Angiography	A technique which subtracts two images that are obtained before and after contrast media is administered to the patient for the purpose of studying blood vessels.			Diagnostic Procedure	
C162920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162920>	C17460	Histone H2B Type 1-A|H2BC1|HIST1H2BA|Histone H2B, Testis|TSH2B.1|Testis-Specific Histone H2B|hTSH2B	Histone H2B type 1-A (127 aa, ~14 kDa) is encoded by the human H2BC1 gene. This protein is involved in the modulation of nucleosome stability in germ cells.			Amino Acid, Peptide, or Protein	
C162921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162921>	C154300	H2BC3 Gene|H2B Clustered Histone 3 Gene|H2BC3|H2BC3|HIST1H2BB	This gene plays a role in DNA accessibility.			Gene or Genome	
C162922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162922>	C162921	H2BC3 wt Allele|H2B Clustered Histone 3 wt Allele|H2B Histone Family, Member F Gene|H2B.1|H2B/f|H2BFF|HIST1 Cluster, H2BB Gene|HIST1H2BB|Histone 1, H2bb Gene|Histone Cluster 1 H2B Family Member B Gene|Histone Cluster 1, H2bb Gene|Histone Gene Cluster 1, H2B Histone Family, Member B Gene|Histone Gene Cluster 1, H2bb Gene	Human H2BC3 wild-type allele is located in the vicinity of 6p22.2 and is approximately 1 kb in length. This allele, which encodes histone H2B type 1-B protein, is involved in chromatin compaction.			Gene or Genome	
C162923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162923>	C17460	Histone H2B Type 1-B|H2B/f|H2BC3|HIST1H2BB|Histone H2B.1	Histone H2B type 1-B (126 aa, ~14 kDa) is encoded by the human H2BC3 gene. This protein plays a role in the regulation of DNA wrapping.			Amino Acid, Peptide, or Protein	
C162924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162924>	C154300	H2BC4 Gene|H2B Clustered Histone 4 Gene|H2BC4|H2BC4|HIST1H2BC	This gene is involved in histone complex formation.			Gene or Genome	
C162925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162925>	C162924	H2BC4 wt Allele|H2B Clustered Histone 4 wt Allele|H2B Histone Family, Member L Gene|H2B.1|H2B/l|H2BFL|HIST1 Cluster, H2BC Gene|HIST1H2BC|Histone 1, H2bc Gene|Histone Cluster 1 H2B Family Member C Gene|Histone Cluster 1, H2bc Gene|Histone Gene Cluster 1, H2B Histone Family, Member C Gene|Histone Gene Cluster 1, H2bc Gene|dJ221C16.3	Human H2BC4 wild-type allele is located in the vicinity of 6p22.2 and is approximately 9 kb in length. This allele, which encodes histone H2B type 1-C/E/F/G/I protein, plays a role in DNA compaction.			Gene or Genome	
C162926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162926>	C154300	H2BC6 Gene|H2B Clustered Histone 6 Gene|H2BC6|H2BC6|HIST1H2BE	This gene plays a role in histone-mediated cellular processes.			Gene or Genome	
C162927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162927>	C162926	H2BC6 wt Allele|H2B Clustered Histone 6 wt Allele|H2B Histone Family, Member H Gene|H2B.h|H2B/h|H2BFH|HIST1 Cluster, H2BE Gene|HIST1H2BE|Histone 1, H2be Gene|Histone Cluster 1 H2B Family Member E Gene|Histone Cluster 1, H2be Gene|Histone Gene Cluster 1, H2B Histone Family, Member E Gene|Histone Gene Cluster 1, H2be Gene|dJ221C16.8	Human H2BC6 wild-type allele is located in the vicinity of 6p22.2 and is approximately 13 kb in length. This allele, which encodes histone H2B type 1-C/E/F/G/I protein, is involved in transcription regulation, DNA repair, DNA replication and chromosomal stability.			Gene or Genome	
C162928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162928>	C154300	H2BC7 Gene|H2B Clustered Histone 7 Gene|H2BC7|H2BC7|HIST1H2BF	This gene is involved in histone-mediated DNA compaction.			Gene or Genome	
C162929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162929>	C162928	H2BC7 wt Allele|H2B Clustered Histone 7 wt Allele|H2B Histone Family, Member G Gene|H2B/g|H2BFG|HIST1 Cluster, H2BF Gene|HIST1H2BF|Histone 1, H2bf Gene|Histone Cluster 1 H2B Family Member F Gene|Histone Cluster 1, H2bf Gene|Histone Gene Cluster 1, H2B Histone Family, Member F Gene|Histone Gene Cluster 1, H2bf Gene	Human H2BC7 wild-type allele is located in the vicinity of 6p22.2 and is approximately 1 kb in length. This allele, which encodes histone H2B type 1-C/E/F/G/I protein, plays a role in chromosomal structure regulation.			Gene or Genome	
C16292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16292>	C25464	Angola|024|AGO|AGO|ANGOLA|ANGOLA|AO	A country in southern Africa, bordering the South Atlantic Ocean, between Namibia and Democratic Republic of the Congo.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C162930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162930>	C154300	H2BC8 Gene|H2B Clustered Histone 8 Gene|H2BC8|H2BC8|HIST1H2BG	This gene plays a role in histone-dependent transcription regulation, DNA repair, DNA replication and chromosomal stability.			Gene or Genome	
C162931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162931>	C162930	H2BC8 wt Allele|H2B Clustered Histone 8 wt Allele|H2B Histone Family, Member A Gene|H2B.1A|H2B/a|H2BFA|HIST1 Cluster, H2BG Gene|HIST1H2BG|Histone 1, H2bg Gene|Histone Cluster 1 H2B Family Member G Gene|Histone Cluster 1, H2bg Gene|Histone Gene Cluster 1, H2B Histone Family, Member G Gene|Histone Gene Cluster 1, H2bg Gene	Human H2BC8 wild-type allele is located in the vicinity of 6p22.2 and is approximately 2 kb in length. This allele, which encodes histone H2B type 1-C/E/F/G/I protein, is involved in histone complex formation.			Gene or Genome	
C162932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162932>	C154300	H2BC10 Gene|H2B Clustered Histone 10 Gene|H2BC10|H2BC10|HIST1H2BI	This gene is involved in histone-mediated nucleosome formation.			Gene or Genome	
C162933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162933>	C162932	H2BC10 wt Allele|H2B Clustered Histone 10 wt Allele|H2B Histone Family, Member K Gene|H2B/k|H2BFK|HIST1 Cluster, H2BI Gene|HIST1H2BI|Histone 1, H2bi Gene|Histone Cluster 1 H2B Family Member I Gene|Histone Cluster 1, H2bi Gene|Histone Gene Cluster 1, H2B Histone Family, Member I Gene|Histone Gene Cluster 1, H2bi Gene	Human H2BC10 wild-type allele is located in the vicinity of 6p22.2 and is approximately 1 kb in length. This allele, which encodes histone H2B type 1-C/E/F/G/I protein, plays a role in chromosomal compaction.			Gene or Genome	
C162934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162934>	C17460	Histone H2B Type 1-C/E/F/G/I|H2B.1A|H2B/a|H2B/g|H2B/h|H2B/k|H2B/l|H2BC10|Histone H2B.1 A|Histone H2B.a|Histone H2B.g|Histone H2B.h|Histone H2B.k|Histone H2B.l	Histone H2B type 1-C/E/F/G/I (126 aa, ~14 kDa) is encoded by the human H2BC4, H2BC6, H2BC7, H2BC8 and H2BC10 gene. This protein is involved in histone-mediated transcription regulation, DNA repair, DNA replication and chromosomal stability.			Amino Acid, Peptide, or Protein	
C162935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162935>	C210958|C129820	Mesothelin/CD3e Tri-specific T-cell Activating Construct HPN536|HPN 536|HPN-536|HPN536|MSLN-specific TriTAC HPN536|MSLN/CD3e TriTAC HPN536|Mesothelin-targeting T-cell Engager HPN536|Mesothelin/CD3e-specific TriTAC HPN536|TriTAC HPN536	recombinant antibody derivative composed of a tri-specific T-cell activating construct (TriTAC) directed against the human tumor-associated antigen (TAA) mesothelin (MSLN) and the epsilon domain of CD3 antigen (CD3e) found on T-lymphocytes which are both linked to either side of an anti-albumin single domain antibody, with potential immunostimulating and antineoplastic activities. Upon administration of the MSLN/CD3e TriTAC HPN536, the anti-MSLN single antibody domain targets and binds MSLN on tumor cells and the anti-CD3e single-chain variable fragment (scFv) targets and binds to CD3e on cytotoxic T-lymphocytes (CTLs), thereby bringing MSLN-expressing tumor cells and CTLs together, which results in the CTL-mediated cell death of MSLN-expressing tumor cells. The albumin-binding domain targets and binds to serum albumin, thereby extending the serum half-life of HPN536. MSLN is overexpressed on the surface of certain tumor cell types. Overexpression of MSLN is often associated with poor prognosis.	Mesothelin/CD3e Tri-specific T-cell Activating Construct HPN536		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162936>	C28227|C226341	Nezastomig|Anti-PSMA/Anti-CD28 Bispecific Antibody REGN5678|Anti-PSMA/CD28 Bispecific Antibody REGN5678|Anti-PSMAxCD28 Antibody REGN5678|NEZASTOMIG|REGN 5678|REGN-5678|REGN5678	A bispecific antibody directed against both the tumor-associated antigen (TAA) prostate-specific membrane antigen (PSMA) and the co-stimulatory T-cell-specific surface glycoprotein CD28, with potential immunostimulating and antineoplastic activities. Upon administration of nezastomig this bispecific antibody binds to both CD28 on cytotoxic T-lymphocytes (CTLs) and PSMA found on PSMA-expressing tumor cells. This activates and redirects CTLs to PSMA-expressing tumor cells, which may result in the CTL-mediated cell death of PSMA-expressing tumor cells. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.	Nezastomig		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162937>	C154300	H2BC9 Gene|H2B Clustered Histone 9 Gene|H2BC9|H2BC9|HIST1H2BH	This gene plays a role in the regulation of chromosome structure.			Gene or Genome	
C162938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162938>	C162937	H2BC9 wt Allele|H2B Clustered Histone 9 wt Allele|H2B Histone Family, Member J Gene|H2B/j|H2BFJ|HIST1 Cluster, H2BH Gene|HIST1H2BH|Histone 1, H2bh Gene|Histone Cluster 1 H2B Family Member H Gene|Histone Cluster 1, H2bh Gene|Histone Gene Cluster 1, H2B Histone Family, Member H Gene|Histone Gene Cluster 1, H2bh Gene	Human H2BC9 wild-type allele is located in the vicinity of 6p22.2 and is approximately 2 kb in length. This allele, which encodes histone H2B type 1-H protein, is involved in the modulation of chromatin structure.			Gene or Genome	
C162939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162939>	C17460	Histone H2B Type 1-H|H2B/j|H2BC9|HIST1H2BH|Histone H2B.j	Histone H2B type 1-H (126 aa, ~14 kDa) is encoded by the human H2BC9 gene. This protein plays a role in the modulation of histone-dependent cellular processes.			Amino Acid, Peptide, or Protein	
C16293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16293>	C16270	Animal Husbandry	The science of breeding and caring for farm animals.			Occupation or Discipline	
C162940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162940>	C9350|C7985	Peritoneal Epithelioid Mesothelioma	Malignant mesothelioma that arises from the peritoneum. It is characterized by the presence of cells with epithelioid morphology. The epithelioid cells usually have eosinophilic cytoplasm, bland nuclei, and form tubulopapillary, microglandular, or sheet-like patterns.	Peritoneal Epithelioid Mesothelioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162941>	C35877	B-Cell Aplasia	A condition characterized by extremely low B-cell counts. It occurs when anti-CD19 CAR T-cells attack and kill CD19-expressing B-lymphocytes.			Finding	
C162942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162942>	C143012|C133709|C133252	Recurrent Head and Neck Cutaneous Squamous Cell Carcinoma|Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck|Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck	The reemergence of cutaneous squamous cell carcinoma of the head and neck after a period of remission.	Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162943>	C170464|C133252|C132012	Resectable Head and Neck Cutaneous Squamous Cell Carcinoma|Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck|Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck	A cutaneous squamous cell carcinoma of the head and neck that is amenable to surgical resection.	Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162944>	C154300	H2BC11 Gene|H2B Clustered Histone 11 Gene|H2BC11|H2BC11|HIST1H2BJ	This gene is involved in chromatin structural regulation.			Gene or Genome	
C162945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162945>	C162944	H2BC11 wt Allele|H2B Clustered Histone 11 wt Allele|H2B Histone Family, Member R Gene|H2B/r|H2BFR|H2BJ|HIST1 Cluster, H2BJ Gene|HIST1H2BJ|Histone 1, H2bj Gene|Histone Cluster 1 H2B Family Member J Gene|Histone Cluster 1, H2bj Gene|Histone Gene Cluster 1, H2B Histone Family, Member J Gene|Histone Gene Cluster 1, H2bj Gene	Human H2BC11 wild-type allele is located in the vicinity of 6p22.1 and is approximately 7 kb in length. This allele, which encodes histone H2B type 1-J protein, plays a role in chromatin wrapping and compaction.			Gene or Genome	
C162946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162946>	C17460	Histone H2B Type 1-J|H2B/r|H2BC11|HIST1H2BJ|Histone H2B.1|Histone H2B.r	Histone H2B type 1-J (126 aa, ~14 kDa) is encoded by the human H2BC11 gene. This protein is involved in the wrapping and compaction of DNA.			Amino Acid, Peptide, or Protein	
C162947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162947>	C154300	H2BC12 Gene|H2B Clustered Histone 12 Gene|H2BC12|H2BC12|HIST1H2BK	This gene plays a role in histone-mediated processes and humoral antimicrobial responses.			Gene or Genome	
C162948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162948>	C162947	H2BC12 wt Allele|H2B Clustered Histone 12 wt Allele|H2B Histone Family, Member T Gene|H2B/S|H2B/t|H2BFAiii|H2BFT|H2BK|HIRIP1|HIST1 Cluster, H2BK Gene|HIST1H2BK|Histone 1, H2bk Gene|Histone Cluster 1 H2B Family Member K Gene|Histone Cluster 1, H2bk Gene|Histone Gene Cluster 1, H2B Histone Family, Member K Gene|Histone Gene Cluster 1, H2bk Gene	Human H2BC12 wild-type allele is located in the vicinity of 6p22.1 and is approximately 9 kb in length. This allele, which encodes histone H2B type 1-K protein, is involved in antimicrobial activity and chromatin packaging.			Gene or Genome	
C162949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162949>	C17460	Histone H2B Type 1-K|H2B K|H2BC12|HIRA-Interacting Protein 1|HIST1H2BK	Histone H2B type 1-K (126 aa, ~14 kDa) is encoded by the human H2BC12 gene. This protein plays a role in chromatin condensation and antimicrobial defenses.			Amino Acid, Peptide, or Protein	
C16294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16294>	C17141	Anthropology	The branch of science concerned with origin and development of humans in all their physical, social, and cultural relationships.			Occupation or Discipline	
C162950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162950>	C154300	H2BC13 Gene|H2B Clustered Histone 13 Gene|H2BC13|H2BC13|HIST1H2BL	This gene is involved in chromatin packaging.			Gene or Genome	
C162951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162951>	C162950	H2BC13 wt Allele|H2B Clustered Histone 13 wt Allele|H2B Histone Family, Member C Gene|H2B/c|H2BFC|HIST1 Cluster, H2BL Gene|HIST1H2BL|Histone 1, H2bl Gene|Histone Cluster 1 H2B Family Member L Gene|Histone Cluster 1, H2bl Gene|Histone Gene Cluster 1, H2B Histone Family, Member L Gene|Histone Gene Cluster 1, H2bl Gene|dJ97D16.4	Human H2BC13 wild-type allele is located in the vicinity of 6p22.1 and is approximately 1 kb in length. This allele, which encodes histone H2B type 1-L protein, plays a role in chromatin stability.			Gene or Genome	
C162952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162952>	C17460	Histone H2B Type 1-L|H2B/c|H2BC13|HIST1H2BL|Histone H2B.c	Histone H2B type 1-L (126 aa, ~14 kDa) is encoded by the human H2BC13 gene. This protein is involved in nucleosome stabilization.			Amino Acid, Peptide, or Protein	
C162953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162953>	C154300	H2BC14 Gene|H2B Clustered Histone 14 Gene|H2BC14|H2BC14|HIST1H2BM	This gene plays a role in chromatin stabilization.			Gene or Genome	
C162954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162954>	C162953	H2BC14 wt Allele|H2B Clustered Histone 14 wt Allele|H2B Histone Family, Member E Gene|H2B/e|H2BFE|HIST1 Cluster, H2BM Gene|HIST1H2BM|Histone 1, H2bm Gene|Histone Cluster 1 H2B Family Member M Gene|Histone Cluster 1, H2bm Gene|Histone Gene Cluster 1, H2B Histone Family, Member M Gene|Histone Gene Cluster 1, H2bm Gene|dJ160A22.3	Human H2BC14 wild-type allele is located in the vicinity of 6p22.1 and is approximately 1 kb in length. This allele, which encodes histone H2B type 1-M protein, is involved in the regulation of nucleosome assembly.			Gene or Genome	
C162955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162955>	C17460	Histone H2B Type 1-M|H2B/e|H2BC14|HIST1H2BM|Histone H2B.e	Histone H2B type 1-M (126 aa, ~14 kDa) is encoded by the human H2BC14 gene. This protein plays a role in DNA accessibility.			Amino Acid, Peptide, or Protein	
C162956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162956>	C154300	H2BC15 Gene|H2B Clustered Histone 15 Gene|H2BC15|H2BC15|HIST1H2BN	This gene is involved in DNA accessibility and nucleosome remodeling.			Gene or Genome	
C162957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162957>	C162956	H2BC15 wt Allele|H2B Clustered Histone 15 wt Allele|H2B Histone Family, Member D Gene|H2B/d|H2BFD|HIST1 Cluster, H2BN Gene|HIST1H2BN|Histone 1, H2bn Gene|Histone Cluster 1 H2B Family Member N Gene|Histone Cluster 1, H2bn Gene|Histone Gene Cluster 1, H2B Histone Family, Member N Gene|Histone Gene Cluster 1, H2bn Gene	Human H2BC15 wild-type allele is located in the vicinity of 6p22.1 and is approximately 28 kb in length. This allele, which encodes histone H2B type 1-N protein, plays a role in chromatin condensation.			Gene or Genome	
C162958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162958>	C17460	Histone H2B Type 1-N|H2B/d|H2BC15|HIST1H2BN|Histone H2B.d	Histone H2B type 1-N (126 aa, ~14 kDa) is encoded by the human H2BC15 gene. This protein is involved in the modulation of DNA accessibility.			Amino Acid, Peptide, or Protein	
C162959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162959>	C154300	H2BC17 Gene|H2B Clustered Histone 17 Gene|H2BC17|H2BC17|HIST1H2BO	This gene plays a role in chromatin stability.			Gene or Genome	
C16295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16295>	C16725	Antibody|Ab|Antibodies|antibody|antibody|antibody	A type of protein made by B lymphocytes in response to a foreign substance (antigen). Each antibody only binds to a specific antigen, helping to destroy the antigen directly or by assisting white blood cells to destroy the antigen.	Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology|NICHD Terminology|Pediatric Rheumatology Terminology
C162960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162960>	C162959	H2BC17 wt Allele|H2B Clustered Histone 17 wt Allele|H2B Histone Family, Member N Gene|H2B.2|H2B/n|H2BFN|HIST1 Cluster, H2BO Gene|HIST1H2BO|Histone 1, H2bo Gene|Histone Cluster 1 H2B Family Member O Gene|Histone Cluster 1, H2bo Gene|Histone Gene Cluster 1, H2B Histone Family, Member O Gene|Histone Gene Cluster 1, H2bo Gene|dJ193B12.2	Human H2BC17 wild-type allele is located in the vicinity of 6p22.1 and is approximately 1 kb in length. This allele, which encodes histone H2B type 1-O protein, is involved in the regulation of DNA accessibility.			Gene or Genome	
C162961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162961>	C17460	Histone H2B Type 1-O|H2B/n|H2BC17|HIST1H2BO|Histone H2B.2|Histone H2B.n	Histone H2B type 1-O (126 aa, ~14 kDa) is encoded by the human H2BC17 gene. This protein plays a role in the maintenance of chromatin.			Amino Acid, Peptide, or Protein	
C162962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162962>	C154299	H2AC18 Gene|H2A Clustered Histone 18 Gene|H2AC18|H2AC18|HIST2H2AA3	This gene is involved in the maintenance of chromatin.			Gene or Genome	
C162963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162963>	C162962	H2AC18 wt Allele|H2A Clustered Histone 18 wt Allele|H2A Histone Family, Member O Gene|H2A.2|H2A/O|H2AFO|H2a-615|HIST2 Cluster, H2AA3 Gene|HIST2H2AA|HIST2H2AA3|Histone 2, H2AA Gene|Histone 2, H2AA3 Gene|Histone Cluster 2 H2A Family Member A3 Gene|Histone Cluster 2, H2AA3 Gene|Histone Gene Cluster 2, H2A Histone Family, Member A3 Gene|Histone Gene Cluster 2, H2AA3 Gene	Human H2AC18 wild-type allele is located in the vicinity of 1q21.2 and is approximately 1 kb in length. This allele, which encodes histone H2A type 2-A protein, plays a role in DNA wrapping and compaction.			Gene or Genome	
C162964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162964>	C154299	H2AC19 Gene|H2A Clustered Histone 19 Gene|H2AC19|H2AC19|HIST2H2AA4	This gene plays a role in chromatin wrapping and compaction.			Gene or Genome	
C162965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162965>	C162964	H2AC19 wt Allele|H2A Clustered Histone 19 wt Allele|H2A Histone Family, Member R Gene|H2A/R|HIST2 Cluster, H2AA4 Gene|HIST2H2AA4|Histone 2, H2AA4 Gene|Histone Cluster 2 H2A Family Member A4 Gene|Histone Cluster 2, H2AA4 Gene|Histone Gene Cluster 2, H2A Histone Family, Member A4 Gene|Histone Gene Cluster 2, H2AA4 Gene	Human H2AC19 wild-type allele is located in the vicinity of 1q21.2 and is approximately 1 kb in length. This allele, which encodes histone H2A type 2-A protein, is involved in nucleosome maintenance.			Gene or Genome	
C162966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162966>	C39949	Testicular Signet Ring Stromal Tumor|PSRSTT|Primary Signet Ring Stromal Tumor of the Testis|Testicular Signet-Ring Stromal Tumor	An extremely rare tumor that arises from the testis. It is characterized by the proliferation of epithelioid cells with signet ring appearance separated by fibrous tissue into trabeculae and nests. The histologic features are bland and there is no mucin production. Mutations of CTNNB1 gene have been identified in the reported cases. It is considered a special type of sex cord-stromal tumor. All reported cases had a benign clinical course without metastases.			Neoplastic Process	
C162967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162967>	C16684	Histone H2A Type 2-A|H2A-Clustered Histone 18|H2A-Clustered Histone 19|HIST2H2AA|Histone H2A.2|Histone H2A/R|Histone H2A/o	Histone H2A type 2-A (130 aa, ~14 kDa) is encoded by the human H2AC18 and H2AC19 genes. This protein plays a role in the modulation of chromatin compaction.			Amino Acid, Peptide, or Protein	
C162968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162968>	C154299	H2AC21 Gene|H2A Clustered Histone 21 Gene|H2AC21|H2AC21|HIST2H2AB	This gene is involved in DNA wrapping and compaction.			Gene or Genome	
C162969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162969>	C162968	H2AC21 wt Allele|H2A Clustered Histone 21 wt Allele|H2AB|HIST2 Cluster, H2AB Gene|HIST2H2AB|Histone 2, H2AB Gene|Histone Cluster 2 H2A Family Member B Gene|Histone Cluster 2, H2AB Gene|Histone Gene Cluster 2, H2A Histone Family, Member B Gene|Histone Gene Cluster 2, H2AB Gene	Human H2AC21 wild-type allele is located in the vicinity of 1q21.2 and is approximately 1 kb in length. This allele, which encodes histone H2A type 2-B protein, plays a role in histone-dependent DNA accessibility.			Gene or Genome	
C16296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16296>	C16295	Anti-Idiotype Antibody|Anti-Anti-Idiotype|Antibody, Anti-Idiotypic	An antibody directed against the individual antigenic determinants (idiotopes) on the variable region of an immunoglobulin molecule.  In principle an anti-idiotype antibody should inhibit a specific immune response and they are important to the regulation of the immune system.			Amino Acid, Peptide, or Protein|Immunologic Factor	
C162970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162970>	C16684	Histone H2A Type 2-B|H2AC21|HIST2H2AB	Histone H2A type 2-B (130 aa, ~14 kDa) is encoded by the human H2AC21 gene. This protein is involved in chromatin wrapping.			Amino Acid, Peptide, or Protein	
C162971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162971>	C154299	H2AC20 Gene|H2A Clustered Histone 20 Gene|H2AC20|H2AC20|HIST2H2AC	This gene plays a role in chromatin packaging.			Gene or Genome	
C162972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162972>	C162971	H2AC20 wt Allele|H2A Clustered Histone 20 wt Allele|H2A Histone Family, Member Q Gene|H2A-GL101|H2A/Q|H2AFQ|HIST2 Cluster, H2AC Gene|HIST2H2AC|Histone 2, H2AC Gene|Histone Cluster 2 H2A Family Member C Gene|Histone Cluster 2, H2AC Gene|Histone Gene Cluster 2, H2A Histone Family, Member C Gene|Histone Gene Cluster 2, H2AC Gene	Human H2AC20 wild-type allele is located in the vicinity of 1q21.2 and is approximately 1 kb in length. This allele, which encodes histone H2A type 2-C protein, is involved in DNA wrapping.			Gene or Genome	
C162973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162973>	C3680	Non-Invasive Cribriform Carcinoma	A carcinoma characterized by the presence of a cribriform architectural pattern. There is no evidence of surrounding stromal invasion by the malignant cells.			Neoplastic Process	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Morphology PT Terminology|Mapped ICDO3.1 Morphology Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C162974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162974>	C16684	Histone H2A Type 2-C|H2AC20|HIST2H2AC|Histone H2A-GL101|Histone H2A/q	Histone H2A type 2-C (129 aa, ~14 kDa) is encoded by the human H2AC20 gene. This protein plays a role in DNA condensation.			Amino Acid, Peptide, or Protein	
C162975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162975>	C154300	H2BC21 Gene|H2B Clustered Histone 21 Gene|H2BC21|H2BC21|HIST2H2BE	This gene is involved in packaging DNA into chromatin and antimicrobial activity.			Gene or Genome	
C162976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162976>	C162975	H2BC21 wt Allele|GL105|H2B Clustered Histone 21 wt Allele|H2B Histone Family, Member Q Gene|H2B.1|H2B/q|H2BFQ|H2BGL105|H2BQ|HIST2 Cluster, H2BE Gene|HIST2H2BE|Histone 2, H2be Gene|Histone Cluster 2 H2B Family Member E Gene|Histone Cluster 2, H2be Gene|Histone Gene Cluster 2, H2B Histone Family, Member E Gene|Histone Gene Cluster 2, H2be Gene	Human H2BC21 wild-type allele is located in the vicinity of 1q21.2 and is approximately 2 kb in length. This allele, which encodes histone H2B type 2-E protein, plays a role in antimicrobial activity and nucleosome formation.			Gene or Genome	
C162977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162977>	C17460	Histone H2B Type 2-E|H2B/q|H2BC21|HIST2H2BE|Histone H2B-GL105|Histone H2B.q	Histone H2B type 2-E (126 aa, ~14 kDa) is encoded by the human H2BC21 gene. This protein is involved in DNA wrapping and antimicrobial activity.			Amino Acid, Peptide, or Protein	
C162978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162978>	C154300	H2BC18 Gene|H2B Clustered Histone 18 Gene|H2BC18|H2BC18|HIST2H2BF	This gene plays a role in chromosomal structure organization.			Gene or Genome	
C162979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162979>	C162978	H2BC18 wt Allele|H2B Clustered Histone 18 wt Allele|HIST2 Cluster, H2BF Gene|HIST2H2BF|Histone 2, H2bf Gene|Histone Cluster 2 H2B Family Member F Gene|Histone Cluster 2, H2bf Gene|Histone Gene Cluster 2, H2B Histone Family, Member F Gene|Histone Gene Cluster 2, H2bf Gene	Human H2BC18 wild-type allele is located in the vicinity of 1q21.2 and is approximately 58 kb in length. This allele, which encodes histone H2B type 2-F protein, is involved in the organization of chromatin-containing structures.			Gene or Genome	
C16297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16297>	C158424	Avidity	Strength of binding, usually of a small molecule with multiple binding sites by a larger, particularly the binding of a complex antigen by an antibody.			Molecular Function	
C162980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162980>	C17460	Histone H2B Type 2-F|H2BC18|HIST2H2BF	Histone H2B type 2-F (126 aa, ~14 kDa) is encoded by the human H2BC18 gene. This protein plays a role in cellular processes that are modulated by the histone code.			Amino Acid, Peptide, or Protein	
C162981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162981>	C154299	H2AC25 Gene|H2A Clustered Histone 25 Gene|H2AC25|H2AW|HIST3H2A	This gene is involved in cellular functions that are modulated by the histone code.			Gene or Genome	
C162982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162982>	C162981	H2AC25 wt Allele|H2A Clustered Histone 25 wt Allele|H2A.W Histone Gene|H2AW|HIST3 Cluster, H2A Gene|HIST3H2A|Histone 3, H2a Gene|Histone Cluster 3 H2A Gene|Histone Cluster 3, H2a Gene|Histone Gene Cluster 3, H2A Gene|Histone Gene Cluster 3, H2A Histone Gene|MGC3165	Human H2AC25 wild-type allele is located in the vicinity of 1q42.13 and is approximately 23 kb in length. This allele, which encodes histone H2A type 3 protein, plays a role in nucleosome remodeling.			Gene or Genome	
C162984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162984>	C16684	Histone H2A Type 3|H2A-Clustered Histone 25|H2A.W|H2A.W Histone|H2AC25|H2AW|HIST3H2A|Histone H2A.W	Histone H2A type 3 (130 aa, ~14 kDa) is encoded by the human H2AC25 gene. This protein is involved in chromatin remodeling.			Amino Acid, Peptide, or Protein	
C162985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162985>	C154300	H2BC26 Gene|H2B Clustered Histone Gene|H2BC26|H2BC26|H2BU1|HIST3H2BB	This gene plays a role in organization of chromatin-containing structures.			Gene or Genome	
C162986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162986>	C162985	H2BC26 wt Allele|H2B Clustered Histone wt Allele|H2B.U Histone 1 Gene|H2BU1|H2Bb|HIST3 Cluster, H2BB Gene|HIST3H2BB|Histone 3, H2bb Gene|Histone Cluster 3 H2B Family Member B Gene|Histone Cluster 3, H2bb Gene|Histone Gene Cluster 3, H2B Histone Family, Member B Gene|Histone Gene Cluster 3, H2BB Gene	Human H2BC26 wild-type allele is located in the vicinity of 1q42.13 and is approximately 5 kb in length. This allele, which encodes histone H2B type 3-B protein, is involved in DNA wrapping in nucleosomes.			Gene or Genome	
C162987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162987>	C17460	Histone H2B Type 3-B|H2B Type 12|H2B-Clustered Histone 26|H2B.U Histone 1|H2BC26|H2BU1|HIST3H2BB	Histone H2B type 3-B (126 aa, ~14 kDa) is encoded by the human H2BC26 gene. This protein plays a role in chromosome structure condensation.			Amino Acid, Peptide, or Protein	
C162989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162989>	C155946	INC Demographic and Maternal Terminology	Demographic and Maternal Terminology developed by NCIt EVS and INC to indicate demographic and maternal terminology that should always be reported in neonatal clinical trials.			Intellectual Product	INC Terminology
C16298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16298>	C17709	Antibody-Dependent Cellular Cytotoxicity|ADCC|ADCC|Antibody-Mediated Lympholysis|antibody-dependent cell-mediated cytotoxicity|antibody-dependent cellular cytotoxicity	The target killing of a cell depending on antibody recognition.  An antibody is directed to the target by antigen-binding arms and anchors to the killer cell by an Fc receptor. The identity of the target cell varies, but it must possess surface IgG whose Fc portion is intact.  The effector "killer" cell possesses Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent.	Antibody-Dependent Cellular Cytotoxicity		Cell Function	CTRP Biomarker Terminology|CTRP Terminology
C162990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162990>	C25164	Date of Neonatal Intensive Care Unit Admission	Date of admission to a neonatal intensive care unit.			Temporal Concept	INC Demographic and Maternal Terminology|INC Terminology
C162991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162991>	C36280|C35869	Classical Leptomeningeal Disease Finding|Classical Leptomeningeal Disease|cLMD	A finding of diffuse spread of neoplastic cells to the leptomeninges that may be characterized by thin, linear leptomeningeal enhancement in the central nervous system on MRI.			Finding	
C162992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162992>	C36280|C35869	Nodular Leptomeningeal Disease Finding|Nodular Leptomeningeal Disease|nLMD	A finding of diffuse spread of neoplastic cells to the leptomeninges that may be characterized by focal nodular enhancement on the dural, pial, or meningeal surface on MRI.			Finding	
C162993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162993>	C4822|C3568|C170814	Malignant Brain Glioma|Brain High Grade Glioma|Brain High-Grade Glioma|Brain Malignant Glioma|High Grade Brain Glioma|High-Grade Brain Glioma	A grade 3 or 4 glioma that arises from the brain. This category includes anaplastic astrocytoma, anaplastic ependymoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, anaplastic pleomorphic xanthoastrocytoma (all grade 3 gliomas), and glioblastoma (grade 4 glioma).	Malignant Brain Glioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C162994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162994>	C17423	Drug Delivery Microdevice|Microdevice	A drug delivery system integrated within a single micro/nanofluidic chip, designed to provide even distribution to the whole body through blood circulation.	Drug Delivery Microdevice		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C162995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162995>	C129825|C125450|C124800	Fedratinib Hydrochloride|Benzenesulfonamide, N-(1,1-Dimethylethyl)-3-((5-methyl-2-((4-(2-(1-pyrrolidinyl)ethoxy)phenyl)amino)-4-pyrimidinyl)amino)-, Hydrochloride, Hydrate (1:2:1)|FEDRATINIB HYDROCHLORIDE|Fedratinib Dihydrochloride Monohydrate|Inrebic|N-tert-butyl-3-((5-methyl-2-((4-(2-pyrrolidin-1-ylethoxy)phenyl)amino)pyrimidin-4-yl)amino) Benzenesulfonamide Dihydrochloride Monohydrate|SAR302503a	The monohydrate dihydrochloride salt form of fedratinib, an orally bioavailable, small-molecule, ATP-competitive inhibitor of Janus-associated kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration, fedratinib competes with wild-type JAK2 as well as mutated forms for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, inhibition of tumor cell proliferation and induction of tumor cell apoptosis. JAK2 is the most commonly mutated gene in bcr-abl-negative myeloproliferative disorders (MPDs). In addition, fedratinib targets, binds to and inhibits the activity of FLT3. This inhibits uncontrolled FLT3 signaling and results in the inhibition of proliferation in tumor cells overexpressing FLT3. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias and plays a key role in tumor cell proliferation.	Fedratinib Hydrochloride		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C162996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C162996>	C129839	MDM2 Inhibitor|HDM2 Inhibitor|HDM2-p53 Interaction Inhibitor|MDM2-p53 Interaction Inhibitor|MDM2/MDMX Inhibitor|p53-HDM2 Interaction Inhibitor|p53/MDM2 Interaction Inhibitor	Any agent that binds to mouse double minute 2 (human double minute 2 homolog; MDM2; HDM2) and/or prevents the interaction with the tumor suppressor protein p53, with potential antineoplastic activity.	MDM2 Inhibitor		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C16299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16299>	C21045	Negative Regulation of Coagulation|Anticoagulation	Events or activities that prevent or inhibit coagulation.			Molecular Function	
C1629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1629>	C511|C2021	Plevitrexed|(alphaS)-alpha-[[4-[[(1,4-Dihydro-2,7-dimethyl-4-oxo-6-quinazolinyl)methyl]-2-propynylamino]-2-fluorobenzoyl]amino]-1H-tetrazole-5-butanoic Acid|(alphaS)-alpha-[[4-[[(1,4-Dihydro-2,7-dimethyl-4-oxo-6-quinazolinyl)methyl]-2-propynylamino]-2-fluorobenzoyl]amino]-1H-tetrazole-5-butanoic Acid|BGC 9331|PLEVITREXED|Vamidex|Vamydex|ZD9331	An orally bioavailable, small molecule, non-polyglutamatable, antifolate quinazoline derivative thymidine synthetase inhibitor with potential antineoplastic activity. Plevitrexed is transported into the cell via the physiological reduced folate carrier (RFC) system. Intracellularly, this agent selectively binds to the folate binding site of thymidylate synthase and inhibits thymidine synthesis, which may result in DNA synthesis inhibition and apoptosis.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C163003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163003>	C7062	Non-Malignant Neoplasm|Non-malignant Neoplasm	A category that includes benign neoplasms and neoplasms with uncertain malignant potential. The latter are characterized by clinicopathological features that are not benign, including some degree of mild or mild/moderate atypia/dysplasia, but lack overt malignant morphologic characteristics and there is no evidence of metastasis at the time of diagnosis.	Non-Malignant Neoplasm		Neoplastic Process	CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|CTRP Disease Terminology|CTRP Terminology
C163004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163004>	C124351	Oral Examination|Oral Evaluation	A systematic evaluation of the tissues and structures in the mouth.	Oral Examination		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C163005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163005>	C177692	ASPH Positive|ASP Beta-Hydroxylase Positive|Aspartate Beta-Hydroxylase Positive|Aspartyl/Asparaginyl-Beta-Hydroxylase Positive|HAAH Positive|Peptide-Aspartate Beta-Dioxygenase Positive	An indication that ASPH expression has been detected in a sample.	ASPH Positive		Finding	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C163006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163006>	C3230|C203309	Unresectable Meningioma	A meningioma that is not amenable to surgical resection.	Unresectable Meningioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C163007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163007>	C150461	Blasts 60 Percent or More of Peripheral Blood White Cells|Blasts Greater than or Equal to 60 Percent of Peripheral Blood White Cells	A semi-quantitative microscopic finding indicating that 60 percent or more of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.	Blasts 60 Percent or More of Peripheral Blood White Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C163008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163008>	C138065	Blasts 60 Percent or More of Bone Marrow Nucleated Cells|Blasts Greater than or Equal to 60 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that at least 60 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts 60 Percent or More of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C163009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163009>	C150123	ATM Proficient Tumor|A-T Mutated Proficient Tumor|AT Mutated Proficient Tumor|ATM Serine/Threonine Kinase Proficient Tumor|Ataxia Telangiectasia Mutated Proficient Tumor|Serine-Protein Kinase ATM Proficient Tumor	A finding indicating that the expression and activity of ATM in a tumor sample is detected at or near normal levels.	ATM Proficient Tumor		Finding	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C16300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16300>	C16393	T-Cell Surface Glycoprotein CD4|CD4|CD4|CD4 Antigen|CD4 Antigen (P55)|CD4 Protein|OKT4 Antigen|T-Cell Antigen T4/Leu3|T-Cell Surface Antigen T4/Leu-3	T-cell surface glycoprotein CD4 (458 aa, ~51 kDa) is encoded by the human CD4 gene. This protein plays a role in antigen recognition and HIV entry.	T-Cell Surface Glycoprotein CD4		Amino Acid, Peptide, or Protein|Immunologic Factor|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C163010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163010>	C177692	CKB Positive|B-CK Positive|Brain Creatine Kinase Positive|CK-BB Positive|CKBB Positive|Creatine Kinase B-Type Positive|Creatine Kinase-B Chain Positive|Creatine Kinase-B Positive	An indication that CKB expression has been detected in a sample.	CKB Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C163011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163011>	C162142	HLA-C*0802 Positive Cells Present|HLA-C*0802 Positive|HLA-C*08:02 Positive|HLA-C*08:02 Positive Cells Present|HLA-C0802 Positive	An indication that cells expressing HLA-C*0802 have been detected in a sample.	HLA-C*0802 Positive Cells Present		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C163012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163012>	C36345	Loss of PMS2 Expression|Loss of DNA Mismatch Repair Protein PMS2 Expression|Loss of Mismatch Repair Endonuclease PMS2 Expression|Loss of PMS1 Protein Homolog 2 Expression|Loss of PMS2 Protein Expression|PMS2 Loss of Expression	A molecular abnormality indicating the absence of PMS2 protein.	Loss of PMS2 Expression		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C163013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163013>	C36345	Loss of MSH3 Expression|Loss of DNA Mismatch Repair Protein Msh3 Expression|Loss of DUP Expression|Loss of Divergent Upstream Protein Expression|Loss of MRP1 Expression|Loss of MSH3 Protein Expression|Loss of Mismatch Repair Protein 1 Expression|Loss of hMSH3 Expression|MSH3 Loss of Expression	A molecular abnormality indicating the absence of MSH3 protein.	Loss of MSH3 Expression		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C163014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163014>	C36345	Loss of EPCAM Expression|EPCAM Loss of Expression|Loss of CD326 Antigen Expression|Loss of CD326 Expression|Loss of EPCAM Protein Expression|Loss of Ep-CAM Expression|Loss of Epithelial Cell Adhesion Molecule Expression|Loss of GA733-2 Expression|Loss of Gastrointestinal Tumor-Associated Antigen 2 Expression|Loss of KSA Glycoprotein Expression|Loss of TACSTD1 Expression|Loss of Tumor-Associated Calcium Signal Transducer 1 Expression	A molecular abnormality indicating the absence of EPCAM protein.	Loss of EPCAM Expression		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C163015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163015>	C36345	Loss of MSH6 Expression|Loss of DNA Mismatch Repair Protein Msh6 Expression|Loss of G/T Mismatch Binding Protein Expression|Loss of G/T Mismatch-Binding Protein Expression|Loss of GTBP Expression|Loss of GTMBP Expression|Loss of MSH6 Protein Expression|Loss of MutS Homolog 6 Expression|Loss of MutS-Alpha 160 kDa Subunit Expression|Loss of Sperm-Associated Protein Expression|MSH6 Loss of Expression	A molecular abnormality indicating the absence of MSH6 protein.	Loss of MSH6 Expression		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C163016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163016>	C36345	Loss of MLH1 Expression|Loss of COCA2 Expression|Loss of DNA Mismatch Repair Protein Mlh1 Expression|Loss of FCC2 Expression|Loss of HNPCC Expression|Loss of HNPCC2 Expression|Loss of MLH1 Protein Expression|Loss of Mismatch DNA Repair Protein MLH1 Expression|Loss of Mismatch Repair Protein MLH1 Expression|Loss of MutL Protein Homolog 1 Expression|MLH1 Loss of Expression	A molecular abnormality indicating the absence of MLH1 protein.	Loss of MLH1 Expression		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C163017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163017>	C70922	25-Hydroxyvitamin D Less than 32 ng/ml|25(OH)D Less than 32 Nanograms per Milliliter|25(OH)D Less than 32 Nanograms/Milliliter|25(OH)D Less than 32 ng/mL|25-Hydroxyvitamin D Less than 32 Nanograms per Milliliter|25-Hydroxyvitamin D Less than 32 Nanograms/Milliliter|25-OH-VitD Less than 32 Nanograms per Milliliter|25-OH-VitD Less than 32 Nanograms/Milliliter|25-OH-VitD Less than 32 ng/mL|25-OH-Vitamin D Less than 32 Nanograms per Milliliter|25-OH-Vitamin D Less than 32 Nanograms/Milliliter|25-OH-Vitamin D Less than 32 ng/mL|Calcidiol Less than 32 Nanograms per Milliliter|Calcidiol Less than 32 Nanograms/Milliliter|Calcidiol Less than 32 ng/mL|Calcifediol Less than 32 Nanograms per Milliliter|Calcifediol Less than 32 Nanograms/Milliliter|Calcifediol Less than 32 ng/mL|Vitamin D Less than 32 ng/ml	A semiquantitative finding indicating that the concentration of 25-hydroxyvitamin D2 plus 25-hydroxyvitamin D3 is less than 32 ng/mL.	25-Hydroxyvitamin D Less than 32 ng/ml		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C163018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163018>	C96862|C180953	EGFR Exon 20 Tyrosine Kinase Inhibitor Resistant Mutation|EGFR Exon 20 Resistance Mutation|EGFR Exon 20 TKI-Resistant Mutation|ERBB Exon 20 TKI-Resistant Mutation|ERBB1 Exon 20 TKI-Resistant Mutation|Epidermal Growth Factor Receptor Gene Exon 20 TKI-Resistant Mutation|HER1 Exon 20 TKI-Resistant Mutation	A molecular genetic abnormality indicating the presence of secondary mutations in exon 20 of the EGFR gene that result in the translation of an epidermal growth factor receptor protein that is resistant to tyrosine kinase inhibitor therapies.	EGFR Exon 20 Tyrosine Kinase Inhibitor Resistant Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C163019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163019>	C3420	t(4;22)	A chromosomal translocation that involves the chromosomes 4 and 22.	t(4;22)		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C163020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163020>	C20401|C129822	Avdoralimab|AVDORALIMAB|Anti-C5aR-215|IPH 5401|IPH-5401|IPH5401|NN 8210	A human monoclonal antibody targeting the C5a receptor (C5aR), with potential immunomodulating activity.  Upon administration, avdoralimab specifically targets, binds to and blocks C5aR expressed on subsets of myeloid-derived suppressor cells (MDSCs) and neutrophils. This prevents the binding of its ligand C5a to C5aR and prevents the C5aR-mediated activation and accumulation of these cells in the tumor microenvironment (TME), and abrogates the secretion of inflammatory and angiogenic factors by these cells. This results in the activation of T- and natural killer (NK) cells, the induction of anti-tumor immune responses and inhibits tumor cell proliferation. C5a, a factor in the complement cascade, is often overexpressed in tumors, where it attracts and activates MDSCs and neutrophils in the TME.	Avdoralimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C163021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163021>	C226473	Topical Cantharidine Solution|Cantharone|Topical Cantharidin|Topical Cantharidine	A topical, diluted solution composed of the terpenoid cantharidin, which is a natural toxin extracted from blister beetles, that is dissolved in a film-forming vehicle, that can be used for its vesicant and keratolytic activities. Upon application of the topical cantharidine solution to the surface of the wart, the film dries and cantharidin is absorbed by the epidermal cells, thereby releasing serine proteases, and inducing acantholysis, thereby causing the disintegration and detachment of the desmosomes from the tonofilaments. This results in the formation of a small blister under the wart, which eventually falls off with the blistered skin.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C163022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163022>	C200711	Epcoritamab|Anti-CD20/CD3 Bispecific Antibody GEN3013|DuoBody-CD3xCD20|EPCORITAMAB|Epcoritamab-bysp|Epkinly|GEN 3013|GEN-3013|GEN3013|Tepkinly	A bispecific monoclonal antibody, with potential immunomodulating and antineoplastic activities. Epcoritamab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, epcoritamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells.	Epcoritamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C163023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163023>	C1752|C1663	EGF Vaccine EGF-PTI|EGF Pathway Targeted Immunization Agent|EGF Pathway Targeted Immunotherapy Agent|EGF Pathway-targeted Immunotherapeutic|EGF-TPI	A cancer vaccine containing epidermal growth factor (EGF), with immunomodulating and antineoplastic activities. Upon administration of the EGF vaccine EGF-PTI, EGF induces an immune response against EGFR, which results in the formation of anti-EGF-specific neutralizing antibodies. This causes binding of the anti-EGF antibodies to endogenous EGF, reduces levels of circulating EGF and prevents the binding of EGF to its receptor EGFR. This prevents EGF/EGFR pathway activation and may result in an inhibition of proliferation in EGFR-overexpressing tumor cells. EGF/EGFR-mediated signaling is overactivated in certain cancer types and drives tumor cell proliferation and progression.			Immunologic Factor|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C163025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163025>	C20194	ASPH Gene|ASPH|ASPH|Aspartate Beta-Hydroxylase Gene	This gene is involved in calcium ion channel regulation and amino acid hydroxylation.	ASPH Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C163026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163026>	C103175	CDISC Protocol Study Monitoring Attribute Terminology|PROT-Attr Study Monitoring|Study Monitoring Attribute Terminology|Study Monitoring Attribute Terminology	Terminology associated with the protocol entity study monitoring attribute codelist of the Clinical Data Interchange Standards Consortium (CDISC).			Intellectual Product	
C163027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163027>	C66830	CDISC SDTM Type 1 Diabetes Findings About Test Code Terminology|D1FATSCD|SDTM-D1FATSCD|Type 1 Diabetes Findings About Test Code	Terminology associated with the type 1 diabetes findings about test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163028>	C66830	CDISC SDTM Type 1 Diabetes Findings About Test Name Terminology|D1FATS|SDTM-D1FATS|Type 1 Diabetes Findings About Test Name	Terminology associated with the type 1 diabetes findings about test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163029>	C77526	CDISC SEND Irradiation Field Orientation/Sequence Response Terminology|IRORSEQR|Irradiation Field Orientation/Sequence Response|SEND-IRORSEQR	Terminology associated with the irradiation field orientation/sequence response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16302>	C17254	T-Antigen|T-Antigens	Proteins encoded by the genomes of specific DNA tumor viruses that are associated with the neoplastic transformation of infected cells. T-antigens stimulate the production of antibodies and are immunogenic.			Amino Acid, Peptide, or Protein|Immunologic Factor	
C163030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163030>	C77526	CDISC SEND Microbiology Test Code Terminology|SEND Microbiology Test Code|SEND-SMBTSTCD|SMBTSTCD	Terminology associated with the SEND microbiology test code codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163031>	C77526	CDISC SEND Microbiology Test Name Terminology|SEND Microbiology Test Name|SEND-SMBTST|SMBTST	Terminology associated with the SEND microbiology test name codelist of the Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Non-clinical Data (SEND).			Intellectual Product	CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163032>	C296	Botulinum Toxin				Hazardous or Poisonous Substance	
C163033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163033>	C163032	Botulinum Toxin Type B				Hazardous or Poisonous Substance	
C163034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163034>	C163032	Botulinum Toxin Type C				Hazardous or Poisonous Substance	
C163035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163035>	C163032	Botulinum Toxin Type D|BOTULINUM NEUROTOXIN D|BoNT/D|Clostridium botulinum Toxin D	Immunological serotype D of the botulinum neurotoxin, which is a common source of botulism in animals.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163036>	C163032	Botulinum Toxin Type E				Hazardous or Poisonous Substance	
C163037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163037>	C163032	Botulinum Toxin Type F				Hazardous or Poisonous Substance	
C163038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163038>	C688	Conotoxin				Hazardous or Poisonous Substance	
C163039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163039>	C163025	ASPH wt Allele|AAH|Aspartate Beta-Hydroxylase wt Allele|BAH|CASQ2BP1|Cardiac Junctin Gene|FDLAB|HAAH|Humbug Gene|JCTN|Junctate Gene|Junctin Gene	Human ASPH wild-type allele is located in the vicinity of 8q12.3 and is approximately 214 kb in length. This allele, which encodes aspartyl/asparaginyl beta-hydroxylase, junctin-1, junctin-2 and junctate proteins, plays a role in amino acid hydroxylation and calcium ion sensing. Mutation of the gene is associated with facial dysmorphism, lens dislocation, anterior segment abnormalities, and spontaneous filtering blebs (FDLAB or Traboulsi syndrome).	ASPH wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C16303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16303>	C25464	Antigua and Barbuda|028|AG|ANTIGUA AND BARBUDA|ANTIGUA AND BARBUDA|ATG|ATG	A group of islands in the Caribbean Sea, east of Saint Kitts and Nevis.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C163040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163040>	C18466	ASPH Gene Product	A protein encoded by the human ASPH gene.			Amino Acid, Peptide, or Protein	
C163041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163041>	C16946|C163040	Aspartyl/Asparaginyl Beta-Hydroxylase|AAH|ASP Beta-Hydroxylase|ASPH|ASPH Isoform 1|Asparagine Hydroxylase|Aspartate Beta-Hydroxylase|Aspartyl/Asparaginyl-Beta-Hydroxylase|BAH|EC 1.14.11.16|HAAH|Peptide-Aspartate Beta-Dioxygenase	Aspartyl/asparaginyl beta-hydroxylase (758 aa, ~86 kDa) is encoded by the human ASPH gene. This protein is involved in amino acid hydroxylation.	Aspartyl/Asparaginyl Beta-Hydroxylase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C163042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163042>	C163040	Junctin-1|ASPH Isoform 3|Cardiac Junctin|JCTN-1	Junctin-1 (225 aa, ~26 kDa) is encoded by the human ASPH gene. This protein is involved in calcium homeostasis in cardiac muscle.	Junctin-1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C163043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163043>	C163040	Junctin-2|ASPH Isoform 4|JCTN|JCTN-2|Junctin	Junctin-2 (210 aa, ~24 kDa) is encoded by the human ASPH gene. This protein is involved in calcium homeostasis in striated muscle.	Junctin-2		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C163044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163044>	C21214|C163040	Junctate|ASPH Isoform 8|Humbug	Junctate (210 aa, ~24 kDa) is encoded by the human ASPH gene. This protein is involved in calcium binding.	Junctate		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C163045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163045>	C73712	Fluorescence Intensity Unit|FIU|Fluorescence Intensity|MFI|MFI|{MFI}|{MFI}	A unit of measure for the fluorescence intensity when the mathematic calculation is unspecified or unknown.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163046>	C163045	Mean Fluorescence Intensity Unit|MFI|Mean Fluorescence Intensity|MnFI|MnFI|{MnFI}|{MnFI}	A unit of measure for the mean fluorescence intensity.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16304>	C17187	Architecture|Engineering / Architecture	The art or science of building; especially, the art of building houses, churches, bridges, and other structures, for the purposes of civil life			Occupation or Discipline	
C16305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16305>	C25464	Argentina|032|AR|ARG|ARG|ARGENTINA|ARGENTINA	A country in southern South America, bordering the South Atlantic Ocean, between Chile and Uruguay.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF1 Registration Table|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16306>	C25464	Armenia|051|AM|ARM|ARM|ARMENIA|ARMENIA	A country in southwestern Asia, east of Turkey and south of Georgia.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16307>	C16484	Aromatase|Aromatase Cytochrome P450|CYP19A1|CYPXIX|Cytochrome P-450AROM|Cytochrome P450 19A1|Cytochrome P450, Family 19, Subfamily A, Polypeptide 1|EC 1.14.14.14|Estrogen Synthetase|Flavoprotein-Linked Monooxygenase|Microsomal Monooxygenase|p450arom	Aromatase (503 aa, ~58 kDa) is encoded by the human CYP19A1 gene. This protein is involved in the conversion of androgens to estrogens.	Aromatase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C16308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16308>	C20080	Arteriography|arteriography	The X-ray examination of the arterial blood vessels.	Arteriography		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C16309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16309>	C18141	Artificial Intelligence|artificial intelligence (AI)	Artificial intelligence is the branch of computer science that deals with writing computer programs that can solve problems creatively.			Occupational Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C1630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1630>	C593	Recombinant Interleukin-14|HMW-BCGF|High Molecular Weight-B-Cell Growth Factor|IL-14|Interleukin 14	A recombinant peptide, which is chemically identical or similar to the endogenous cytokine interleukin-14 (IL-14). The cytokine inhibits immunoglobulin secretion and selectively expands activated B-cell subpopulations. An IL-14 receptor is found on activated B-cells, but not in resting B-cells. This agent is unrelated to other cytokines but has homology with complement factor Bb. Autocrine or paracrine production of IL-14 may play a significant role in the rapid proliferation of aggressive non-Hodgkin lymphoma (NHL-B). Interrupting this pathway could be a useful goal of therapy for patients resistant to conventional chemotherapy.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C16310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16310>	C17049	Asian American|ASIAN AMERICAN|Asian Americans	Denotes a person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent, and who was either born in the United States or who was naturalized as a citizen of the United States.			Population Group	CDISC CDASH Terminology|CDISC SDTM Collected Race Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16311>	C76349|C25464	Australia|036|AU|AUS|AUS|AUSTRALIA|AUSTRALIA	The continent and country between the Indian Ocean and the South Pacific Ocean, south of Asia.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF1 Registration Table|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16312>	C25464	Austria|040|AT|AUSTRIA|AUSTRIA|AUT|AUT	A country in central Europe, northeast of Italy and southeast of Germany.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16313>	C16956	Autoimmune Reaction|Autoimmune Process|Autoimmune Response	A specific humoral or cell-mediated immune response against autologous (self) antigens.			Phenomenon or Process	HL Authorized Value Terminology|HL Late Effects Table
C16314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16314>	C38101	Autoradiography	A technique used to locate radioactively labeled molecules, or fragments of molecules, by recording on a photographic or sensor plate the radiation emitted by radioactive material within a molecule.	Autoradiography		Research Activity	CTRP Intervention Terminology|CTRP Terminology
C16315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16315>	C20181	Award|Awards	A prize given for achievement in a specific area, including monies given on the basis of merit.			Governmental or Regulatory Activity	
C16316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16316>	C25464	Azerbaijan|031|AZ|AZE|AZE|AZERBAIJAN|AZERBAIJAN	A country in southwestern Asia, bordering the Caspian Sea, between Iran and Russia.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16317>	C16835	B16 Malignant Melanoma|B16 Melanoma		B16 Malignant Melanoma		Experimental Model of Disease|Neoplastic Process	
C16319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16319>	C20158	Bacterial Protein	Proteins that originated from bacteria sources.			Amino Acid, Peptide, or Protein	
C1631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1631>	C578	Recombinant Inhibin A|Inhibin A	A recombinant therapeutic agent which is chemically identical to or similar to an endogenous glycoprotein which inhibits pituitary production of follicle-stimulating hormone (FSH).  Produced and secreted by the testis or ovarian follicle, endogenous inhibin A contributes to the control of gametogenesis, embryonic and fetal development, and hematopoiesis and enhances LH-stimulated androgen secretion by human thecal cells. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C16320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16320>	C16851	Bacteriology	The branch of science that studies bacteria, especially in relation to medicine and agriculture.			Biomedical Occupation or Discipline	
C16321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16321>	C25464	Bahamas|044|BAHAMAS|BAHAMAS, THE|BHS|BHS|BS	A chain of islands in the North Atlantic Ocean, southeast of Florida and north of Cuba.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16322>	C25464	Bahrain|048|BAHRAIN|BAHRAIN|BH|BHR|BHR	An archipelago in the Persian Gulf, on the east coast of Saudi Arabia.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16323>	C25464	Bangladesh|050|BANGLADESH|BANGLADESH|BD|BGD|BGD	A country in southern Asia, bordering the Bay of Bengal, between Burma and India.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16324>	C25464	Barbados|052|BARBADOS|BARBADOS|BB|BRB|BRB	An island between the Caribbean Sea and the North Atlantic Ocean, east of Saint Vincent and the Grenadines.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16325>	C213232|C16934	BCR/ABL1 Fusion Protein|BCR ABL Fusion Protein|BCR-ABL Oncoprotein|BCR-ABL Protein Tyrosine Kinase|BCR-ABL fusion protein|BCR-ABL1 Fusion Protein|BCR/ABL|BCR/ABL Chimeric Protein|BCR/ABL Fusion Protein|BCR/ABL Oncoprotein|BCR::ABL1 Fusion Protein|Breakpoint Cluster Region/Tyrosine-Protein Kinase ABL1 Fusion Protein|Breakpoint Cluster Region::Tyrosine-Protein Kinase ABL1 Fusion Protein	A fusion protein encoded by the BCR/ABL1 fusion gene. This protein is comprised of the N-terminus of the breakpoint cluster region protein fused to almost the entire tyrosine-protein kinase ABL1 protein.	BCR/ABL1 Fusion Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C16326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16326>	C43431	Behavior|Attitude|Behavioral|Conduct	The actions or reactions of an object or organism, usually in relation to the environment or surrounding world of stimuli.			Behavior	ICDC Terminology|ICDC Value Terminology|NICHD Terminology
C16327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16327>	C19491|C16833	Behavioral Medicine|Behavioral	The study, prevention, and treatment of medical and psychosomatic disorders and of undesirable behaviors, such as overeating and substance abuse, by the application of behavior therapy techniques, such as biofeedback, relaxation training, and hypnosis.			Biomedical Occupation or Discipline	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C16328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16328>	C19160	Behavioral Sciences	The scientific disciplines concerned with the analysis and investigation of human and animal behavior through observation and scientific experimentation.			Occupation or Discipline	
C16329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16329>	C25464	Belgium|056|BE|BEL|BEL|BELGIUM|BELGIUM	A country in western Europe, bordering the North Sea, between France and the Netherlands.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C1632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1632>	C2186	Diarylsulfonylurea Compound ILX-295501|ILX 295501|ILX-295501|ILX295501|LY 295501|LY-295501|LY-295501|LY295501|N-(((3,4-Dichlorophenyl)amino)carbonyl)-2,3-dihydro-5-benzofuransulfonamide|N-(5-(2,3-Dihydrobenzofuryl)sulfonyl)-N'-(3,4-dichlorophenyl)urea	ILX-295501 is a novel sulfonylurea compound that has demonstrated in-vivo antitumor activity against a broad spectrum of solid tumors.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C16330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16330>	C20188	Belief System	Faith based on a series of beliefs but not formalized into a religion; also, a fixed coherent set of beliefs prevalent in a community or society.			Idea or Concept	
C16331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16331>	C25464	Belize|084|BELIZE|BELIZE|BLZ|BLZ|BZ	A country in central America, bordering the Caribbean Sea, between Guatemala and Mexico.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16333>	C25464	Benin|204|BEN|BEN|BENIN|BENIN|BENIN REPUBLIC|BJ|Benin Republic|Bénin|Bénin Republic|DHY|DY|Dahomey|Kingdom of Dahomey	A country in western Africa, bordering the North Atlantic Ocean, between Nigeria and Togo.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16334>	C25464	Bermuda|060|BERMUDA|BERMUDA|BM|BMU|BMU|Bermuda Islands|Bermudas	A group of islands in the North Atlantic Ocean, east of South Carolina.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16335>	C17125	Beta Globulin	A type of globulin in plasma that in electrically charged solutions exhibits colloidal mobility between that of the alpha and gamma globulins.			Amino Acid, Peptide, or Protein|Biologically Active Substance	
C16336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16336>	C25464	Bhutan|064|BHUTAN|BHUTAN|BT|BTN|BTN	A country in southern Asia, between China and India, east of Nepal and north of Bangladesh.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16337>	C16344	Biochemistry|Chemistry, Biological	The study of the chemical substances and vital processes occurring in living organisms.			Biomedical Occupation or Discipline	
C163384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163384>	C100110	CDISC Questionnaire ADSD Version 1.0 Test Name Terminology|ADSD01TN|Asthma Daytime Symptom Diary v1.0 Questionnaire Test Name|QS-ADSD Version 1.0 TEST	Test names of questionnaire questions associated with the Asthma Daytime Symptom Diary V1.0 (ADSD Version 1.0) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163385>	C100110	CDISC Questionnaire ADSD Version 1.0 Test Code Terminology|ADSD01TC|Asthma Daytime Symptom Diary v1.0 Questionnaire Test Code|QS-ADSD Version 1.0 TESTCD	Test codes of questionnaire questions associated with the Asthma Daytime Symptom Diary V1.0 (ADSD Version 1.0) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163386>	C100110	CDISC Questionnaire ANSD Version 1.0 Test Name Terminology|ANSD01TN|Asthma Nighttime Symptom Diary v1.0 Questionnaire Test Name|QS-ANSD Version 1.0 TEST	Test names of questionnaire questions associated with the Asthma Nighttime Symptom Diary V1.0 (ANSD Version 1.0) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163387>	C100110	CDISC Questionnaire ANSD Version 1.0 Test Code Terminology|ANSD01TC|Asthma Nighttime Symptom Diary v1.0 Questionnaire Test Code|QS-ANSD Version 1.0 TESTCD	Test codes of questionnaire questions associated with the Asthma Nighttime Symptom Diary V1.0 (ANSD Version 1.0) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163388>	C100110	CDISC Questionnaire GAD-7 Version 2 Test Name Terminology|GAD02TN|Generalized Anxiety Disorder - 7 Version 2 Questionnaire Test Name|QS-GAD-7 Version 2 TEST	Test names of questionnaire questions associated with the Generalized Anxiety Disorder - 7 Version 2 (GAD-7 Version 2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163389>	C100110	CDISC Questionnaire GAD-7 Version 2 Test Code Terminology|GAD02TC|Generalized Anxiety Disorder - 7 Version 2 Questionnaire Test Code|QS-GAD-7 Version 2 TESTCD	Test codes of questionnaire questions associated with the Generalized Anxiety Disorder - 7 Version 2 (GAD-7 Version 2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16338>	C1908	Biomedical Material|Biomaterial	Any substance other than pharmacologic substance that can be applied in biomedical research or in constructing artificial organs, devices, or prostheses that can be introduced into the human body.			Biomedical or Dental Material	
C163390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163390>	C100110	CDISC Questionnaire GMSS Version Type 1 Diabetes Test Name Terminology|GMSS01TN|QS-GMSS Version Type 1 Diabetes TEST|The Glucose Monitoring System Satisfaction Survey Version: Type 1 Diabetes Questionnaire Test Name	Test names of questionnaire questions associated with the Glucose Monitoring Satisfaction Survey Version: Type 1 Diabetes (GMSS Version Type 1 Diabetes) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163391>	C100110	CDISC Questionnaire GMSS Version Type 1 Diabetes Test Code Terminology|GMSS01TC|QS-GMSS Version Type 1 Diabetes TESTCD|The Glucose Monitoring System Satisfaction Survey Version: Type 1 Diabetes Questionnaire Test Code	Test codes of questionnaire questions associated with the Glucose Monitoring Satisfaction Survey Version: Type 1 Diabetes (GMSS Version Type 1 Diabetes) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163392>	C100110	CDISC Questionnaire HCS Test Name Terminology|HCS01TN|Hypoglycemic Confidence Scale Questionnaire Test Name|QS-HCS TEST	Test names of questionnaire questions associated with the Hypoglycemic Confidence Scale (HCS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163393>	C100110	CDISC Questionnaire HCS Test Code Terminology|HCS01TC|Hypoglycemic Confidence Scale Questionnaire Test Code|QS-HCS TESTCD	Test codes of questionnaire questions associated with the Hypoglycemic Confidence Scale (HCS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163394>	C100110	CDISC Questionnaire PARENT-DDS Test Name Terminology|DDS02TN|Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes Questionnaire Test Name|QS-PARENT-DDS TEST	Test names of questionnaire questions associated with the Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163395>	C100110	CDISC Questionnaire PARENT-DDS Test Code Terminology|DDS02TC|Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes Questionnaire Test Code|QS-PARENT-DDS TESTCD	Test codes of questionnaire questions associated with the Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163396>	C100110	CDISC Questionnaire PARTNER-DDS Test Name Terminology|DDS03TN|Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes Questionnaire Test Name|QS-PARTNER-DDS TEST	Test names of questionnaire questions associated with the Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163397>	C100110	CDISC Questionnaire PARTNER-DDS Test Code Terminology|DDS03TC|Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes Questionnaire Test Code|QS-PARTNER-DDS TESTCD	Test codes of questionnaire questions associated with the Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163398>	C211913	ADSD Version 1.0 Questionnaire Question	A question associated with the ADSD Version 1.0 questionnaire.			Intellectual Product	
C163399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163399>	C211913	ANSD Version 1.0 Questionnaire Question	A question associated with the ANSD Version 1.0 questionnaire.			Intellectual Product	
C16339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16339>	C16830	Bioelectric Energy Sources	Implantable devices which convert biological energy (chemical energy of the metabolism of continuously regenerating body fluids or mechanical energy of periodic movements) to electrical energy. The sources include biogalvanic cells, biofuel cells, and ionic concentration cells.			Medical Device	
C1633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1633>	C2517	Polyvalent Melanoma Vaccine|PMCV|Polyvalent Melanoma Cell Vaccine	A cancer vaccine consisting of whole irradiated heterologous melanoma cells which express multiple melanoma-related antigens.  Polyvalent melanoma vaccine may stimulate an antitumoral cytotoxic T-cell immune response in the host, resulting in inhibition of tumor cell proliferation and tumor cell death. (NCI04)	Polyvalent Melanoma Vaccine		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C163400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163400>	C211913	GAD-7 Version 2 Questionnaire Question	A question associated with the GAD-7 Version 2 questionnaire.			Intellectual Product	
C163401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163401>	C211913	GMSS Version Type 1 Diabetes Questionnaire Question	A question associated with the GMSS Version Type 1 Diabetes questionnaire.			Intellectual Product	
C163402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163402>	C211913	HCS Questionnaire Question	A question associated with the HCS questionnaire.			Intellectual Product	
C163403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163403>	C211913	PARENT-DDS Questionnaire Question	A question associated with the PARENT-DDS questionnaire.			Intellectual Product	
C163404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163404>	C211913	PARTNER-DDS Questionnaire Question	A question associated with the PARTNER-DDS questionnaire.			Intellectual Product	
C163405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163405>	C21072	Serratus Plane Block|SAPB|Serratus Anterior Plane Block|Serratus Nerve Block	An ultrasound-guided regional anesthesia technique of the thorax. It uses a single-injection that targets the lateral cutaneous branches of the thoracic intercostal nerves to anesthetize the chest wall.	Serratus Plane Block		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C163406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163406>	C25619	Data and Safety Monitoring Plan|DSMP|Data Safety Monitoring Plan|Safety Data Monitoring Plan	A written plan that prospectively identifies and documents monitoring activities intended to protect the safety of the subjects, the validity of the data and the integrity of the research study. The DSMP may also identify when to terminate a subject's participation (i.e. individual stopping rules) and/or the appropriate termination of a study (i.e. study stopping rules). (Mayo Clinic)			Intellectual Product	
C163407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163407>	C49154	GCP Adherence Statement|Good Clinical Practice Adherence Statement	A written message that asserts, affirms, or declares that the study is conducted in accordance with Good Clinical Practice (GCP).			Idea or Concept	
C163408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163408>	C142488	Safety Data Monitoring	Periodic review of cumulative study safety data to ensure subject/participant safety, proper study conduct, and scientific integrity.			Activity	
C163409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163409>	C142707	Safety Monitoring	Review of safety data to ensure safety of the individuals who are participating in the study, or to identify potential safety concerns for the duration of the study lifecycle.			Activity	
C16340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16340>	C39796	Biomedical Ethics|Bioethics	The branch of ethics that studies moral values in the biomedical sciences.			Biomedical Occupation or Discipline	
C163410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163410>	C49154	Study Monitoring Statement	A written message that asserts, affirms, or declares that the study will be monitored in adherence to a clinical monitoring plan and in accordance with Good Clinical Practice (GCP).			Idea or Concept	
C163411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163411>	C142674	Suicidal Risk Monitoring	A systematic approach to identify and assess the risks of participant suicidal ideation and/or suicide.			Governmental or Regulatory Activity	
C163412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163412>	C71466	Action Taken With Subject|ACNSBJ|ACNSBJ	Action taken with respect to a study subject or participant.			Activity	CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|CDISC SDTM Type 1 Diabetes Findings About Test Code Terminology|CDISC SDTM Type 1 Diabetes Findings About Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C163413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163413>	C25506	Precipitating Factor|PPTFCT|PPTFCT	The factor(s) that cause or trigger the onset of an occurrence.			Functional Concept	CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|CDISC SDTM Type 1 Diabetes Findings About Test Code Terminology|CDISC SDTM Type 1 Diabetes Findings About Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C163414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163414>	C25648	Relationship to Device|RLDEV|RLDEV	The relationship of an event or occurrence to a device.			Conceptual Entity	CDISC SDTM Findings About Test Code Terminology|CDISC SDTM Findings About Test Name Terminology|CDISC SDTM Terminology|CDISC SDTM Type 1 Diabetes Findings About Test Code Terminology|CDISC SDTM Type 1 Diabetes Findings About Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C163415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163415>	C142730	Clinical Data Interchange Standards Consortium Controlled Terminology|CDISC CT|CDISC Controlled Terminology|CDISC/NCI|CT	A standard terminology developed and maintained by Clinical Data Interchange Standards Consortium (CDISC) and the National Cancer Institute Enterprise Vocabulary Services (NCI-EVS) to support CDISC models, domains and specifications for data representation in regulated research.			Intellectual Product	CDISC Define-XML Standard Name Terminology|CDISC Define-XML Standard Type Terminology|CDISC Define-XML Terminology|CDISC Dictionary Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163416>	C142730	Medication Reference Terminology|MED-RT|NDF-RT	A standard terminology developed and maintained by the Veterans Health Administration (VHA) that includes terminology to support the mechanism of action, physiologic effect, and asserted pharmacologic classification relationships of medications. MED-RT incorporates terminology from RxNORM, MeSH, and SNOMED CT.			Intellectual Product	CDISC Dictionary Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163417>	C16048	Substance Registration System-Unique Ingredient Identifier|SRS-UNII|UNII|VA/VHA SRS-UNII	A standard terminology developed and maintained by the Department of Veterans Affairs/Veterans Health Administration designated federal collaborative Structured Product Labeling Interagency Expert Panel (SPLIEP). It contains terminology to support the mechanism of action, physiologic effect, and asserted pharmacologic classification relationships of drug ingredients and food allergens.			Intellectual Product	CDISC Dictionary Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163418>	C163747	Carbohydrate to Insulin Ratio Device Setting|CBINRATS|Carbohydrate to Insulin Ratio Setting|Carbohydrate to Insulin Ratio Setting	A setting on a device that specifies the ratio of the carbohydrates to insulin in the administered product.			Conceptual Entity	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163419>	C64430	Acid Labile Subunit Measurement|ALS|ALS|Acid Labile Subunit|Acid Labile Subunit|IGFALS|IGFALS Measurement|Insulin Like Growth Factor Binding Protein Acid Labile Subunit	The determination of the amount of acid labile subunit present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16341>	C60819	Bioassay|Assay|bioanalytical assays	A laboratory test or analysis of the biological activity of a substance performed by studying its effect on an organism or in a test tube under controlled conditions.			Laboratory Procedure	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C163420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163420>	C81971|C120626	Anti-Neutrophil Cytoplasmic IgG Antibody Measurement|ANCA IgG Measurement|ANCIGAB|Anti-Neutrophil Cytoplasmic IgG Antibody|Anti-Neutrophil Cytoplasmic IgG Antibody|Anti-Neutrophil Cytoplasmic IgG Autoantibody|Antineutrophil Cytoplasmic IgG Antibody Measurement	The determination of the amount of anti-neutrophil cytoplasmic IgG antibody present in a sample.			Laboratory Procedure	CDISC SDTM Immunogenicity Specimen Assessments Test Code Terminology|CDISC SDTM Immunogenicity Specimen Assessments Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163421>	C75385	Angiopoietin 2 Measurement|ANG2|ANGPT2|ANGPT2 Measurement|Ang-2 Measurement|Ang2 Measurement|Angiopoietin 2|Angiopoietin 2	The determination of the amount of angiopoietin 2 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163422>	C64430	Alpha-Smooth Muscle Actin Measurement|A-SMA Measurement|ASMA Measurement|ASMACT|Alpha-Actin 2|Alpha-SMA|Alpha-SMA Measurement|Alpha-Smooth Muscle Actin|Alpha-Smooth Muscle Actin	The determination of the amount of alpha-smooth muscle actin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163423>	C80175	Complement C3a DesArg Measurement|ASP|Acylation-Stimulating Protein|C3ADARG|C3a DesArg Measurement|Complement C3a DesArg|Complement C3a DesArg	The determination of the amount of complement C3a DesArg present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163424>	C61044	Carnitine Excretion Rate|CARNTEXR	The determination of the amount of carnitine being excreted in a biological specimen over a defined period of time.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163425>	C61044	Citrate Excretion Rate|CITRTEXR	The determination of the amount of citrate being excreted in a biological specimen over a defined period of time.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163426>	C64430	Cytidine-Uridine Monophosphate Kinase 2 Measurement|CMPK2|CMPK2 Measurement|Cytidine-Uridine Monophosphate Kinase 2|Cytidine-Uridine Monophosphate Kinase 2|Cytidine/Uridine Monophosphate Kinase 2	The determination of the amount of cytidine-uridine monophosphate kinase 2 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163427>	C61044	Free Cortisol Excretion Rate|CRTFREXR|Cortisol, Free Excretion Rate|Cortisol, Free Excretion Rate	The determination of the amount of free cortisol being excreted in a biological specimen over a defined period of time.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163428>	C64430	DEAD Box Protein 58 Measurement|Antiviral Innate Immune Response Receptor RIG-I Measurement|DDX58|DDX58 Measurement|DEAD Box Protein 58|DEAD Box Protein 58|DExD/H-Box Helicase 58|Probable ATP-Dependent RNA Helicase DDX58|RIGI Measurement	The determination of the amount of DEAD box protein 58 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163429>	C61044	Dopamine Excretion Rate|DOPAMEXR	The determination of the amount of dopamine being excreted in a biological specimen over a defined period of time.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16342>	C20047	Biomarker|Biological Marker|Biological Markers|Biomarkers|Molecular Marker|Signature Molecule|biological marker|biomarker|biomarker|biomarker|marker|molecular marker|signature molecule	A characteristic that can be objectively measured and serves as an indicator for normal biologic processes, pathogenic processes, state of health or disease, the risk for disease development and/or prognosis, or responsiveness to a particular therapeutic intervention.			Functional Concept	BRIDG Class Terminology|BRIDG Terminology|CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C163430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163430>	C62662	Dilute Russell's Viper Venom Time to Confirm Ratio Measurement|DRVVT Screen to Confirm Ratio|DRVVT Screen to Confirm Ratio|DRVVTSCR	The determination of the dilute Russell's viper venom time (dRVVT) without the presence of excess phospholipid to the dRVVT in the presence of excess phospholipid in a biological sample. The measurement may be expressed as either a ratio or a percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163431>	C75345	Estrone Sulfate Measurement|E1S|E1S|Estrone 3-Sulfate|Estrone Sulfate|Estrone Sulfate	The determination of the amount of estrone sulfate present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163432>	C210010	Endomysial Antibody Measurement	The determination of the amount of endomysial antibody present in a sample.			Laboratory Procedure	
C163433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163433>	C61044	Epinephrine Excretion Rate|Adrenaline Excretion Rate|EPINEXR	The determination of the amount of epinephrine being excreted in a biological specimen over a defined period of time.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163434>	C64430	Epithelial Stromal Interaction 1 Measurement|BRESI1|EPSTI1|EPSTI1 Measurement|Epithelial Stromal Interaction Protein 1|Epithelial Stromal Interaction Protein 1	The determination of the amount of epithelial stromal interaction 1 protein present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163435>	C92745|C62662	Factor XI Measurement|F11 Measurement|FACTXI|FXI Measurement|Factor XI|Factor XI	The determination of the amount of factor XI present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163436>	C163435	Factor XI Activity Measurement|F11a Measurement|FACTXIA|FXIa Measurement|Factor XI Activity|Factor XI Activity|Factor XIa Activity	The determination of the amount of factor XI activity present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163437>	C92745|C62662	Factor XII Measurement|F12 Measurement|FACTXII|FXII Measurement|Factor XII|Factor XII	The determination of the amount of factor XII present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163438>	C163437	Factor XII Activity Measurement|F12a Measurement|FACTXIIA|FXIIa Measurement|Factor XII Activity|Factor XII Activity	The determination of the amount of factor XII activity present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163439>	C64430	Galactose Mutarotase Measurement|GALM|GALM Measurement|Galactose Mutarotase|Galactose Mutarotase	The determination of the amount of galactose mutarotase present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16343>	C16344	Psychobiology|Biological Psychiatry	The study of the interrelationships of the biology and psychology in cognitive functioning, including intellectual, memory, and related neurocognitive processes.			Biomedical Occupation or Discipline	
C163440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163440>	C64430	Guanylate Binding Protein 1 Measurement|GBP1|GBP1 Measurement|Guanylate Binding Protein 1|Guanylate Binding Protein 1	The determination of the amount of guanylate binding protein 1 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163441>	C64430	Guanylate Binding Protein 2 Measurement|GBP2|GBP2 Measurement|Guanylate Binding Protein 2|Guanylate Binding Protein 2	The determination of the amount of guanylate binding protein 2 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163442>	C110935	Estimated Glomerular Filtration Rate from Creatinine and Urea Nitrogen Adjusted for Standard BSA|GFR from Creat and UreaN Adj BSA|GFR from Creat and UreaN Adj BSA|GFR from Creatinine and Urea Nitrogen Adjusted for BSA|GFRBSCU	The determination of the glomerular filtration rate by measurement of creatinine and urea nitrogen clearance and whose result is adjusted for body surface area.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163443>	C110935	Estimated Glomerular Filtration Rate from Creatinine, Urea Nitrogen, and Albumin Adjusted for Standard BSA|GFR from Creat,UreaN,Alb Adj BSA|GFR from Creat,UreaN,Alb Adj BSA|GFR from Creatinine, Urea Nitrogen and Albumin Adjusted for BSA|GFRBSCUA	The determination of the glomerular filtration rate by measurement of creatinine, urea nitrogen, and albumin clearance and whose result is adjusted for body surface area.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163444>	C64430	Growth Hormone Binding Protein Measurement|GH Binding Protein|GHBP|GHBP Measurement|GHR Measurement|Growth Hormone Binding Protein|Growth Hormone Binding Protein|Somatotropin Receptor	The determination of the amount of growth hormone binding protein present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163445>	C74738	Alpha Globulin Measurement|Alpha Globulin|Alpha Globulin|GLOBA	The determination of the amount of alpha globulin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163446>	C41376	Plasma Equivalent Glucose Measurement|GLUCPE|Plasma Equivalent Glucose|Plasma Equivalent Glucose|Plasma-Equivalent Glucose Measurement	The determination of the amount of plasma equivalent glucose present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163447>	C41376	Plasma Equivalent Glucose Distribution Measurement|GLUCPED|Plasma Equivalent Glucose Distribution|Plasma Equivalent Glucose Distribution|Plasma-Equivalent Glucose Distribution Measurement	The determination of the amount of plasma equivalent glucose distribution present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163449>	C80185	Glutathione S-Transferase Y1 Subunit Measurement|GSTY1|Glutathione S-Transferase, Y1|Glutathione S-Transferase, Y1	The determination of the amount of glutathione S-transferase Y1 subunit present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16344>	C19160	Biological Sciences	The division of the natural sciences that is concerned with the phenomenon of life and vital processes.			Biomedical Occupation or Discipline	
C163450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163450>	C213030	Hemoglobin A1A Measurement|Glycated Hemoglobin 1A|HBA1A|Hb A1a Measurement|HbA1a Measurement|Hemoglobin A1A|Hemoglobin A1A	The determination of the amount of hemoglobin A1A present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163451>	C213030	Hemoglobin A1B Measurement|Glycated Hemoglobin 1B|HBA1B|Hb A1b Measurement|HbA1b Measurement|Hemoglobin A1B|Hemoglobin A1B	The determination of the amount of hemoglobin A1B present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163452>	C64430	Human Epididymis Protein 4 Measurement|HE4|Human Epididymis Protein 4|Human Epididymis Protein 4|WAP Four-Disulfide Core Domain Protein 2 Measurement|WFDC2 Measurement	The determination of the amount of human epididymis protein 4 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163453>	C64430	Hect Domain and RLD 5 Measurement|E3 ISG15--Protein Ligase HERC5|HECT and RLD Domain Containing E3 Ubiquitin Protein Ligase 5|HERC5|HERC5 Measurement|Hect Domain and RLD 5|Hect Domain and RLD 5	The determination of the amount of Hect domain and RLD 5 protein present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163454>	C61044	5-Hydroxyindoleacetic Acid Excretion Rate|5-HIAA Excretion Rate|5-HydroxyindoleaceticAcid Excretion Rate|5-HydroxyindoleaceticAcid Excretion Rate|IA5OHEXR	The determination of the amount of 5-hydroxyindoleacetic acid being excreted in a biological specimen over a defined period of time.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163455>	C64430	Interferon Alpha-Inducible Protein 27 Measurement|IFI27|IFI27 Measurement|Interferon Alpha-Induced Protein 27|Interferon Alpha-Inducible Protein 27|Interferon Alpha-Inducible Protein 27	The determination of the amount of interferon alpha-inducible protein 27 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163456>	C64430	Interferon-Induced Protein 44 Measurement|IFI44|IFI44 Measurement|Interferon-Induced Protein 44|Interferon-Induced Protein 44	The determination of the amount of interferon-induced protein 44 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163457>	C64430	Interferon-Induced Protein 44-Like Measurement|IFI44L|IFI44L Measurement|Interferon-Induced Protein 44-Like|Interferon-Induced Protein 44-Like	The determination of the amount of interferon-induced protein 44-Like present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163458>	C64430	Interferon Alpha-Inducible Protein 6 Measurement|IFI6|IFI6 Measurement|Interferon Alpha-Inducible Protein 6|Interferon Alpha-Inducible Protein 6	The determination of the amount of interferon alpha-inducible protein 6 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163459>	C64430	Interferon-Induced 56 kDa Protein Measurement|IFIT1|IFIT1 Measurement|Interferon-Induced 56 kDa Protein|Interferon-Induced 56 kDa Protein|Interferon-Induced Protein With Tetratricopeptide Repeats 1	The determination of the amount of interferon-induced 56 kDa protein present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16345>	C16344	Biology|Biologic|Biological	The scientific study of living organisms.			Biomedical Occupation or Discipline	
C163460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163460>	C64430	Interferon-Induced 60 kDa Protein Measurement|IFIT3|IFIT3 Measurement|Interferon-Induced 60 kDa Protein|Interferon-Induced 60 kDa Protein|Interferon-Induced Protein With Tetratricopeptide Repeats 3	The determination of the amount of interferon-induced 60 kDa protein present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163461>	C64430	Ubiquitin-Like Protein ISG15 Measurement|ISG15|ISG15 Measurement|ISG15 Ubiquitin-Like Modifier|Ubiquitin-Like Protein ISG15|Ubiquitin-Like Protein ISG15	The determination of the amount of ubiquitin-like protein ISG15 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163462>	C150822	Kidney Injury Molecule-1 Excretion Rate|HAVCR1 Excretion Rate|Hepatitis A Virus Cellular Receptor 1 Excretion Rate|KIM1EXR	The determination of the amount of kidney injury molecule-1 being excreted in a biological specimen over a defined period of time.			Quantitative Concept	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163463>	C64430	Lymphocyte Antigen 6E Measurement|LY6E|LY6E Measurement|Lymphocyte Antigen 6 Family Member E|Lymphocyte Antigen 6E|Lymphocyte Antigen 6E	The determination of the amount of lymphocyte antigen 6E present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163464>	C81867	Macrophage Inflammatory Protein 1 Measurement|MIP1|Macrophage Inflammatory Protein 1|Macrophage Inflammatory Protein 1	The determination of the amount of macrophage inflammatory protein 1 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163465>	C81971|C147395	Mitochondrial M2 IgG Antibody Measurement|AMA-M2 IgG Measurement|Anti-Mitochondrial M2 IgG Antibody Measurement	The determination of the amount of mitochondrial M2 IgG antibody present in a sample.			Laboratory Procedure	
C163466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163466>	C74804	Macrophage Migration Inhibitory Factor Measurement|MIF|MIF Measurement|MMIF|MMIF Measurement|Macrophage Migration Inhibitory Factor|Macrophage Migration Inhibitory Factor	The determination of the amount of macrophage migration inhibitory factor present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163467>	C150822	Monoclonal Protein Excretion Rate|M Protein Excretion Rate|M Protein Excretion Rate|M-Spike Protein Excretion Rate|MPROTEXR|Monoclonal Protein Spike Excretion Rate|Myeloma Protein Excretion Rate|Paraprotein Excretion Rate|Spike Protein Excretion Rate	The determination of the amount of monoclonal protein spike being excreted in a biological specimen over a defined period of time.			Quantitative Concept	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163468>	C61044	Metanephrine Excretion Rate|METANEXR	The determination of the amount of metanephrine being excreted in a biological specimen over a defined period of time.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163469>	C64430	Interferon-Induced Protein p78 Measurement|Interferon-Induced GTP-Binding Protein Mx1|Interferon-Induced Protein p78|Interferon-Induced Protein p78|MX1|MX1 Measurement	The determination of the amount of interferon-induced protein p78 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16346>	C16349	Biomechanics	The study of the mechanics of a living body, especially of the forces exerted by muscles and gravity on the skeletal structure.			Biomedical Occupation or Discipline	
C163470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163470>	C64547|C103419	N-acetyl-Beta-D-glucosaminidase to Creatinine Ratio Measurement|N-acetyl-B-D-glucosaminidase/Creatinine|N-acetyl-B-D-glucosaminidase/Creatinine|NAGASECR|OGA to Creatinine Ratio Measurement|Protein O-GlcNAcase to Creatinine Ratio Measurement	The determination of the N-acetyl-B-D-glucosaminidase to creatinine in a biological sample. The measurement may be expressed as either a ratio or a percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163471>	C64430	N-Demethylase Measurement|N-Demethylase|N-Demethylase|NDMTASE	The determination of the amount of N-demethylase present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163472>	C61044	Norepinephrine Excretion Rate|NOREPEXR	The determination of the amount of norepinephrine being excreted in a biological specimen over a defined period of time.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163473>	C64430	Neurokinin A Measurement|NKA|NKA Measurement|NKINA|Neurokinin A|Neurokinin A|Substance K|Substance K Measurement	The determination of the amount of neurokinin A present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163474>	C61044	Normetanephrine Excretion Rate|NORMEEXR	The determination of the amount of normetanephrine being excreted in a biological specimen over a defined period of time.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163475>	C64430	Neurotensin Measurement|NT Measurement|NTENS|NTS|Neurotensin|Neurotensin	The determination of the amount of neurotensin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163476>	C64430	2-5-Oligoadenylate Synthase 1 Measurement|2-5-Oligoadenylate Synthase 1|2-5-Oligoadenylate Synthase 1|OAS1|OAS1 Measurement	The determination of the amount of 2-5-oligoadenylate synthase 1 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163477>	C64430	2-5-Oligoadenylate Synthase 2 Measurement|2-5-Oligoadenylate Synthase 2|2-5-Oligoadenylate Synthase 2|OAS2|OAS2 Measurement	The determination of the amount of 2-5-oligoadenylate synthase 2 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163478>	C64430	2-5-Oligoadenylate Synthase 3 Measurement|2-5-Oligoadenylate Synthase 3|2-5-Oligoadenylate Synthase 3|OAS3|OAS3 Measurement	The determination of the amount of 2-5-oligoadenylate synthase 3 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163479>	C64430	O-Demethylase Measurement|O-Demethylase|O-Demethylase|ODMTASE	The determination of the amount of O-demethylase present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16347>	C17167	Biostatistics|Biometrics|Biometry|Biometry and Biostatistics|Biometry and Statistics|biometrics|biometry|biostatistics|biostatistics	The application of statistical methods to biological studies.			Biomedical Occupation or Discipline	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C163480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163480>	C61044	Oxalate Excretion Rate|OXAEXR	The determination of the amount of oxalate being excreted in a biological specimen over a defined period of time.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163481>	C64430	Platelet Derived Growth Factor Isoform AA Measurement|PDGF Isoform AA|PDGFA Homodimer Measurement|PDGFAA|Platelet Derived Growth Factor IsoformAA|Platelet Derived Growth Factor IsoformAA|Platelet Derived Growth Factor-AA Isoform	The determination of the amount of platelet derived growth factor isoform AA present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163482>	C64430	Placental Growth Factor Measurement|PGF|PGF Measurement|PIGF|PLCGF|PLGF|PLGF Measurement|Placental Growth Factor|Placental Growth Factor	The determination of the amount of placental growth factor present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163483>	C64430	Phospholipid Scramblase 1 Measurement|PLSCR1|PLSCR1 Measurement|Phospholipid Scramblase 1|Phospholipid Scramblase 1	The determination of the amount of phospholipid scramblase 1 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163484>	C64430	Cytomegalovirus-Induced Gene 5 Protein Measurement|Cytomegalovirus-Induced Gene 5 Protein|Cytomegalovirus-Induced Gene 5 Protein|RSAD2|RSAD2 Measurement|Radical S-adenosyl Methionine Domain-Containing Protein 2	The determination of the amount of cytomegalovirus-induced gene 5 protein present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163485>	C177993	Steroid Sulfatase Activity Measurement|STS Activity Measurement|Steryl-Sulfatase Activity Measurement	The determination of the amount of steroid sulfatase activity present in a sample.			Laboratory Procedure	
C163486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163486>	C64430	Peptide Transporter TAP1 Measurement|ABCB2 Measurement|Antigen Peptide Transporter 1|Peptide Transporter TAP1|Peptide Transporter TAP1|TAP1|TAP1 Measurement	The determination of the amount of peptide transporter TAP1 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163487>	C64430	Translocase Inner Mitochondrial Membrane 10 Measurement|TIMM10|TIMM10 Measurement|Translocase Inner Mitochondrial Membr 10|Translocase Inner Mitochondrial Membr 10|Translocase of Inner Mitochondrial Membrane 10	The determination of the amount of translocase inner mitochondrial membrane 10 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163488>	C64430	Tissue Polypeptide Antigen Measurement|TPA|TPAG|Tissue Polypeptide Antigen|Tissue Polypeptide Antigen	The determination of the amount of tissue polypeptide antigen present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163489>	C84810	Free Tau Protein Measurement|TPROTFR|Tau Protein, Free|Tau Protein, Free	The determination of the amount of free tau protein present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16348>	C19988	Biological Rhythm|Biological Rhythm and Oscillation	A biologically inherent cyclic variation or recurrence of an event or state, such as the sleep cycle, circadian rhythms, or periodic diseases.			Organism Function	
C163490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163490>	C64430	TPR-Ankyrin Repeat-containing Protein 1 Measurement|TPR and Ankyrin Repeat-Containing Protein 1|TPR-Ankyrin Repeat-Containing Protein 1|TPR-Ankyrin Repeat-Containing Protein 1|TRANK1|TRANK1 Measurement	The determination of the amount of TPR-ankyrin repeat-containing protein 1 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163491>	C64430	Tripartite Motif Containing Protein 21 Measurement|E3 Ubiquitin-Protein Ligase TRIM21|Ro(SS-A)|Sjogren Syndrome Type A Antigen|TRIM21|TRIM21 Measurement|Tripartite Motif Containing Protein 21|Tripartite Motif Containing Protein 21	The determination of the amount of tripartite motif containing protein 21 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163492>	C64430	Tripartite Motif Containing Protein 38 Measurement|RNF15 Measurement|TRIM38|TRIM38 Measurement|Tripartite Motif Containing Protein 38|Tripartite Motif Containing Protein 38	The determination of the amount of tripartite motif containing protein 38 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163493>	C81185|C64547|C154739	Tryptophan to Creatinine Ratio Measurement|TRPCRT|Tryptophan/Creatinine|Tryptophan/Creatinine	The determination of the tryptophan to creatinine in a biological sample. The measurement may be expressed as either a ratio or a percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163494>	C64430	Trypsin Measurement|TRYPSIN|Trypsin|Trypsin	The determination of the amount of trypsin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163495>	C64430	Thrombospondin 1 Measurement|THBS1|THBS1 Measurement|TSP-1 Measurement|TSP1|Thrombospondin 1|Thrombospondin 1	The determination of the amount of thrombospondin 1 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163496>	C81971|C163969	Tissue Transglutaminase IgG Antibody Measurement|TG2 IgG Measurement|TGC IgG Measurement|TGM2 IgG Measurement|tTG IgG Measurement	The determination of the amount of tissue transglutaminase IgG antibody present in a sample.			Laboratory Procedure	
C163497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163497>	C61044	11-Dehydro-Thromboxane B2 Excretion Rate|11-Dehydrothromboxane B2 Excretion Rate|TXB2D11R	The determination of the amount of 11-dehydro-thromboxane B2 being excreted in a biological specimen over a defined period of time.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163498>	C64814|C61044	Urate Excretion Rate|URATEEXR|Uric Acid Excretion Rate	The determination of the amount of urate being excreted in a biological specimen over a defined period of time.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163499>	C61044	Urea Nitrogen Excretion Rate|UREANEXR	The determination of the amount of urea nitrogen being excreted in a biological specimen over a defined period of time.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16349>	C16344	Biophysics|Biophysical|Medical Physics	Physics as applied to biological problems; an interdisciplinary science that applies theories and methods of the physical sciences to questions of biology.			Biomedical Occupation or Discipline	
C1634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1634>	C67422	Cemadotin Hydrochloride|CEMADOTIN HYDROCHLORIDE|LU-103793|LU-103793|LU103793	The hydrochloride salt form of cemadotin, a synthetic dolastatin 15 analogue with potential antineoplastic activity.  Cemadotin suppresses spindle microtubule dynamics by binding to tubulin, thereby blocking mitosis. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C163500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163500>	C48938	Urothelial Cell Count|UROTHCE|Urothelial Cells|Urothelial Cells	The determination of the amount of urothelial cells present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163501>	C92514	Vascular Endothelial Growth Factor C Measurement|FLT4 Ligand Measurement|VEGF-C Measurement|VEGFC|VRP Measurement|Vascular Endothelial Growth Factor C|Vascular Endothelial Growth Factor C	The determination of the amount of vascular endothelial growth factor C present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163502>	C64430	Vasoactive Intestinal Polypeptide Measurement|VIP|VIP|VIP Measurement|Vasoactive Intestinal Polypeptide|Vasoactive Intestinal Polypeptide	The determination of the amount of vasoactive intestinal polypeptide present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163503>	C61044	Vanillyl Mandelic Acid Excretion Rate|VMA Excretion Rate|VMAEXR|Vanillylmandelic Acid Excretion Rate	The determination of the amount of vanillyl mandelic acid being excreted in a biological specimen over a defined period of time.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163504>	C13056	Abductor Digiti Minimi Muscle|ABDUCTOR DIGITI QUINTI MUSCLE|Abductor Digiti Minimi|Abductor Minimi Digiti	A muscle in the foot that flexes and abducts the fifth toe at the metatarsophalangeal joint and supports the lateral arch. It originates in the medial and lateral processes of the posterior calcaneal tuberosity and inserts into the lateral side of the base of the proximal phalanx of the fifth toe and the fifth metatarsal. It is innervated by the lateral planter nerve and is supplied by the lateral planter artery.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163505>	C13056	Abductor Hallucis Muscle|ABDUCTOR HALLUCIS MUSCLE	A muscle in the foot that abducts and flexes the great toe at metatarsophalangeal joint. It originates in the medial process of the posterior calcaneal tuberosity and the flexor retinaculum and inserts into the medial side of the base of the proximal phalanx of the great toe. It is innervated by the medial plantar nerve and is supplied by the medial plantar artery.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163506>	C13056	Adductor Brevis Muscle|ADDUCTOR BREVIS MUSCLE	A muscle in the lower extremity that adducts, flexes, and helps to rotate the thigh. It originates on the external surface of body of pubis and the anterior surface of the inferior pubic ramus and inserts in the pectineal line and the medial lip of the linea aspera. It is innervated by the anterior or posterior division of the obturator nerve and is supplied by the obturator and medial circumflex femoral arteries.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163507>	C25769	Oblique Head of Adductor Hallucis Muscle|ADDUCTOR HALLUCIS MUSCLE, OBLIQUE HEAD	The larger of two heads of the adductor hallucis muscle. It originates from the sheath of the peroneus longus tendon and the plantar surface of the bases of the second to fourth metatarsal bones in the foot.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163508>	C25769	Transverse Head of Adductor Hallucis Muscle|ADDUCTOR HALLUCIS MUSCLE, TRANSVERSE HEAD	The smaller of two heads of the adductor hallucis muscle. It originates from the deep transverse metatarsal ligament and the plantar surface of the metatarsophalangeal joints of the lateral three toes.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163509>	C13056	Adductor Longus Muscle|ADDUCTOR LONGUS MUSCLE	A muscle located in the medial compartment of the thigh that adducts and medially rotates the thigh. It originates on the external surface of the pubis body and inserts into the middle third of the linea aspera. It is innervated by the obturator nerve and branches of the sciatica nerve and supplied by the obturator and medial circumflex femoral arteries.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16350>	C16351	Biosensors	The coupling of a biological material (for example, enzyme, receptor, antibody, whole cell, organelle) with a microelectronic system or device to enable rapid, accurate, low level detection of various substances in body fluids, water, and air.			Biomedical Occupation or Discipline	
C163510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163510>	C13056	Adductor Magnus Muscle|ADDUCTOR MAGNUS MUSCLE	A muscle located in the medial compartment of the thigh that adducts, flexes, extends, and medially rotates the thigh at the hip joint. It originates on the ischiopubic ramus and ischial tuberosity, and inserts into the gluteal tuberosity of the femur, medial lip of the linea aspera, medial supracondylar ridge, and adductor tubercle. It is innervated by the obturator and tibial nerves and supplied by branches of the deep femoral and popliteal arteries, and the inferior gluteal and obturator arteries.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163511>	C13073	Corrugator Supercilii Muscle|CORRUGATOR SUPERCILII MUSCLE	One of two small facial muscles that are located behind the occipitofrontalis and orbicularis oculis muscles, with which they blend, and allow movement of the eyebrows. They originate in the medial superciliary arch and insert into the skin above the middle of the supraorbital margins. They are innervated by the temporal branch of the facial nerve and supplied by branches from the superficial temporal and ophthalmic arteries.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163512>	C13056	Elbow Extensors|ELBOW EXTENSOR MUSCLES	Two muscles located in the upper extremity, the triceps brachii and anconeus, that allow for straightening of the arm at the elbow joint.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163513>	C13056	Elbow Flexors|ELBOW FLEXOR MUSCLES	A group of three muscles located in the upper extremity, the brachialis, biceps brachii, and the brachioradialis, that allow for bending of the arm at the elbow joint.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163514>	C13056	Extensor Digitorum Brevis Muscle|EXTENSOR DIGITORUM BREVIS MUSCLE	A muscle on the dorsal side of the foot that helps to extend the second, third and fourth toes. It originates on the superolateral surface of the anterior calcaneus and inserts into the lateral sides of the tendons of extensor digitorum longus on the second, third and fourth toes. It is innervated by the deep peroneal nerve and supplied by the dorsalis pedis artery.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163515>	C13056	Extensor Hallucis Brevis Muscle|EXTENSOR HALLUCIS BREVIS MUSCLE	A muscle on the dorsal side of the foot that helps to extend the big toe. It originates on the superior surface of the anterior calcaneus and inserts into the dorsal surface of the base of the proximal phalanx of the big toe. It is innervated by the deep fibular nerve and supplied by the dorsalis pedis artery.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163516>	C13056	Finger Extensors|FINGER EXTENSOR MUSCLES	A group of muscles that originate on the bones on the posterior side of the forearm and insert into the bones of the phalanges through long tendons. The finger extensors, including the abductor pollicis longus, extensor pollicis brevis, extensor pollicis longus, extensor indicis, extensor digitorum, and extensor digiti minimi muscles, allow for straightening of the fingers to open the hand.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163517>	C13056	Finger Flexors|FINGER FLEXOR MUSCLES	A group of muscles that originate on the bones on the palmar side of the arm and forearm and insert into the bones of the phalanges of the hand through long tendons; the finger flexors, including the flexor digitorum superficialis, flexor digitorum profundus, and flexor pollicis longus muscles, allow for bending of the fingers.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163518>	C13056	Flexor Digitorum Brevis Muscle|FLEXOR DIGITORUM BREVIS MUSCLE	A muscle in the foot that allows flexion of the four lateral toes and supports the medial and lateral longitudinal arches. It originates on the medial process of the posterior calcaneal tuberosity and inserts as tendons into the borders of the middle phalanx of the four lateral toes. It is innervated by the medial plantar nerve and supplied by the medial and lateral plantar arteries.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163519>	C25769	Lateral Head of Gastrocnemius Muscle|GASTROCNEMIUS MUSCLE, LATERAL HEAD	One of two heads of the gastrocnemius muscle, originating on the lateral femoral condyle.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16351>	C17187	Biotechnology	The field devoted to applying the techniques of biochemistry, cellular biology, biophysics, and molecular biology to addressing issues related to human beings and the environment.			Biomedical Occupation or Discipline	
C163520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163520>	C25769	Medial Head of Gastrocnemius Muscle|GASTROCNEMIUS MUSCLE, MEDIAL HEAD	One of two heads of the gastrocnemius muscle, originating on the medial femoral condyle.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163521>	C74715	HIV-2 gp36 Antibody Measurement	The determination of the amount of HIV-2 gp36 antibody present in a sample.			Laboratory Procedure	
C163522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163522>	C74715	HIV-2 gp140 Antibody Measurement	The determination of the amount of HIV-2 gp140 antibody present in a sample.			Laboratory Procedure	
C163523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163523>	C74713	HIV-1 p31 Antibody Measurement	The determination of the amount of HIV-1 p31 antibody present in a sample.			Laboratory Procedure	
C163524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163524>	C74713	HIV-1 gp160 Antibody Measurement	The determination of the amount of HIV-1 gp160 antibody present in a sample.			Laboratory Procedure	
C163525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163525>	C74713	HIV-1 p24 Antibody Measurement	The determination of the amount of HIV-1 p24 antibody present in a sample.			Laboratory Procedure	
C163526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163526>	C74713	HIV-1 gp41 Antibody Measurement	The determination of the amount of HIV-1 gp41 antibody present in a sample.			Laboratory Procedure	
C163527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163527>	C81970	Fusarium proliferatum IgE Antibody Measurement	The determination of the amount of Fusarium proliferatum IgE antibody present in a sample.			Laboratory Procedure	
C163528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163528>	C181398	Malassezia Species IgE Antibody Measurement	The determination of the amount of Malassezia species IgE antibody present in a sample.			Laboratory Procedure	
C163529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163529>	C81971|C111125	Adenovirus IgG Antibody Measurement	The determination of the amount of Adenovirus IgG antibody present in a sample.			Laboratory Procedure	
C16352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16352>	C17049	Black or African American|BLACK OR AFRICAN AMERICAN|BLACK OR AFRICAN AMERICAN|BLACK_OR_AFRICAN_AMERICAN|black or african american	Individuals with origins in any of the Black racial groups of Africa, including, for example, African American, Jamaican, Haitian, Nigerian, Ethiopian. and Somali.			Population Group	ALL Authorized Value Terminology|ALL Demographics Table|AML Authorized Value Terminology|AML Demographics Table|CDISC CDASH Terminology|CDISC SDTM Collected Race Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF1 Registration Table|CTDC Value Terminology|EWS Authorized Value Terminology|EWS Demographics Table|FDA Structured Product Labeling Terminology|GCT Authorized Value Terminology|GCT Demographics Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Demographics Table|Operational Ontology for Radiation Oncology Prostate Cancer Terminology|OS Authorized Value Terminology|OS Demographics Table|SeroNet Authorized Values|SeroNet Research Participant Metadata|SeroNet Study Descriptors|SPL Race Terminology
C163530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163530>	C81972|C111125	Adenovirus IgM Antibody Measurement	The determination of the amount of Adenovirus IgM antibody present in a sample.			Laboratory Procedure	
C163531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163531>	C210011|C210010	Bordetella pertussis Serotype Fimbrae 2/3 Antibody Measurement	The determination of the amount of Bordetella pertussis serotype Fimbrae 2/3 antibody present in a sample.			Laboratory Procedure	
C163532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163532>	C210011|C210010	Bordetella pertussis Filament Haemagglutinin Antibody Measurement	The determination of the amount of Bordetella pertussis filament haemagglutinin antibody present in a sample.			Laboratory Procedure	
C163533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163533>	C210011|C210010	Bordetella pertussis Pertactin Antibody Measurement	The determination of the amount of Bordetella pertussis pertactin antibody present in a sample.			Laboratory Procedure	
C163534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163534>	C210011|C210010	Bordetella pertussis Toxin Antibody Measurement	The determination of the amount of Bordetella pertussis toxin antibody present in a sample.			Laboratory Procedure	
C163535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163535>	C210011|C210010	Corynebacterium diphtheriae Toxoid Antibody Measurement	The determination of the amount of Corynebacterium diphtheriae toxoid antibody present in a sample.			Laboratory Procedure	
C163536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163536>	C81971|C163748	Chlamydia pneumoniae IgG Antibody Measurement	The determination of the amount of Chlamydia pneumoniae IgG antibody present in a sample.			Laboratory Procedure	
C163537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163537>	C210011|C210010	Clostridium tetani Toxin Antibody Measurement	The determination of the amount of Clostridium tetani toxin antibody present in a sample.			Laboratory Procedure	
C163538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163538>	C92534|C81971	Hepatitis A Virus IgG Antibody Measurement	The determination of the amount of Hepatitis A virus IgG antibody present in a sample.			Laboratory Procedure	
C163539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163539>	C210012|C210010|C161395	HIV-1/2 Antigen/Antibody Measurement|HIV-1/2 Antigen/Antibody|HIV-1/2 Antigen/Antibody|HIV12AGB	The determination of the amount of HIV-1/HIV-2 antigens and/or HIV-1/HIV-2 antibodies present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16353>	C41510	Blood Circulation|Blood Flow|Bloodstream|Circulation|Circulatory|circulation	The movement of blood to and from the heart and to the rest of the body's organs, tissues, and cells through the network of arteries, veins, and capillaries. (NCI)			Organ or Tissue Function	
C163540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163540>	C199960|C135409	JC Virus DNA Measurement|JC Polyomavirus DNA|JC Virus DNA|JC Virus DNA|JCV DNA|JCVDNA|John Cunningham Virus DNA	The determination of the amount of JC virus DNA present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163541>	C81972	Mumps Virus IgM Antibody Measurement	The determination of the amount of Mumps virus IgM antibody present in a sample.			Laboratory Procedure	
C163542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163542>	C81969|C163750	Mycoplasma pneumoniae IgA Antibody Measurement	The determination of the amount of Mycoplasma pneumoniae IgA antibody present in a sample.			Laboratory Procedure	
C163543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163543>	C81972|C163750	Mycoplasma pneumoniae IgM Antibody Measurement	The determination of the amount of Mycoplasma pneumoniae IgM antibody present in a sample.			Laboratory Procedure	
C163544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163544>	C81972|C163751	Rubella IgM Antibody Measurement	The determination of the amount of Rubella IgM antibody present in a sample.			Laboratory Procedure	
C163545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163545>	C116553	BrdU Cellular Proliferation Assay|BRDU CELLULAR PROLIFERATION ASSAY|BrdU Assay|Bromodeoxyuridine Cellular Proliferation Assay|Broxuridine Cellular Proliferation Assay	A type of cellular proliferation assay in which bromodeoxyuridine (BrdU) is used as a substitute for thymidine in the DNA of replicating cells.			Research Activity	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163546>	C158239	Double Immunodiffusion|DID|DID|DOUBLE IMMUNODIFFUSION|Ouchterlony Double Immunodiffusion|Ouchterlony Double Immunodiffusion|Passive Double Immunodiffusion|Passive Double Immunodiffusion	A qualitative technique used to identify specific antibodies bound to an antigen by the appearance of a precipitation band (precipitin band) formed between wells in an agar gel plate as a result of the interaction of the antigen and antibodies at optimal concentration.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163547>	C17007	Immuno-Positron Emission Tomography Scan|IMMUNO-PET SCAN|Immuno-PET Scan	A type of positron emission tomography in which labeled monoclonal antibodies are tracked and quantitated after administration to the subject.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163548>	C215116	Orchidometry Measurement|ORCHIDOMETERY	A method used to measure testicular volume by comparing the size of one's testicles to the beads in a orchidometer, which consists of a string of 12 numbered beads of increasing sizes of 1 to 6, 8, 10, 12, 15, 20, and 25mL.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163549>	C69411	Becquerel per Gram per Kilobecquerel per Kilogram|(Bq/g)/(Bq/g)|(Bq/g)/(kBq/kg)|(Bq/g)/(kBq/kg)|(Bq/g)/(kBq/kg)|(Bq/g)/(kBq/kg)	A unit of specific radioactivity that is equal to becquerel per gram divided by dose in kilobecquerel per kilogram body weight.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16354>	C17728	Coagulation Factor|Blood Coagulation Factor|Clotting Factor	Factors in the blood that are essential for blood coagulation. The absence or mutation of these factors can lead to hemophilia and blood clotting disorders.			Amino Acid, Peptide, or Protein|Biologically Active Substance	
C163550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163550>	C69411	Becquerel per Milliliter per Kilobecquerel per Kilogram|(Bq/mL)/(Bq/g)|(Bq/mL)/(kBq/kg)|(Bq/mL)/(kBq/kg)|(Bq/mL)/(kBq/kg)|(Bq/mL)/(kBq/kg)|(Bq/ml)/(kBq/kg)|(Bq/ml)/(kBq/kg)	A unit of specific radioactivity that is equal to becquerel per milliliter divided by dose in kilobecquerel per kilogram body weight.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163551>	C69411	Hour Times Becquerel per Gram per Kilobecquerel per Kilogram|(h*Bq/g)/(Bq/g)|(h*Bq/g)/(kBq/kg)|(h*Bq/g)/(kBq/kg)|(h*Bq/g)/(kBq/kg)|(h.Bq/g)/(kBq/kg)|(h.Bq/g)/(kBq/kg)	A unit of specific radioactivity that is equal to hours times becquerel per gram divided by dose in kilobecquerel per kilogram body weight.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163552>	C69411	Hour Times Becquerel per Milliliter per Kilobecquerel per Kilogram|(h*Bq/mL)/(Bq/g)|(h*Bq/mL)/(kBq/kg)|(h*Bq/mL)/(kBq/kg)|(h*Bq/mL)/(kBq/kg)|(h.Bq/mL)/(kBq/kg)|(h.Bq/mL)/(kBq/kg)	A unit of specific radioactivity that is equal to hours times becquerel per milliliter divided by dose in kilobecquerel per kilogram body weight.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163553>	C69438	Gigabecquerel/nL|GBq/nL|GBq/nL|GBq/nL|GBq/nl|GBq/nl|MBq/pL|TBq/nL	A metric unit of volumetric radioactivity concentration defined as a concentration of a radionuclide with an activity equal to one gigabecquerel per unit volume equal to one nanoliter.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163554>	C69411	Hour Times Becquerel per Gram|h*Bq/g|h*Bq/g|h.Bq/g|h.Bq/g	A unit of specific radioactivity used to determine the area under the curve that is equal to hours times becquerel per gram.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163555>	C69411	Hour Times Becquerel per milliliter|h*Bq/mL|h*Bq/mL|h.Bq/mL|h.Bq/mL	A unit of specific radioactivity used to determine the area under the curve that is equal to hours times becquerel per milliliter.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163556>	C54126	Relative Size Change|RELSZCHG	An assessment of the size difference in comparison to a baseline or previous value.			Quantitative Concept	CDISC SDTM Respiratory Test Code Terminology|CDISC SDTM Respiratory Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163557>	C25180	Products of Conception Examined Indicator|PRDCEIND|Products of Conception Examined Ind|Products of Conception Examined Ind	An indication as to whether the products of conception have been examined.			Conceptual Entity	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163558>	C25164	Pregnancy End Date|Date Pregnancy Ended|Date Pregnancy Ended|PRGENDTC	The date on which the pregnancy ended.			Temporal Concept	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163559>	C142450	Trial Exploratory Objective|Exploratory Objective|Exploratory Objective|OBJEXP|Study Exploratory Objective|exploratory objective	The exploratory purpose of the trial.			Idea or Concept	CDISC DDF Objective Level Value Set Terminology|CDISC DDF Terminology|CDISC Glossary Terminology|CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology|ICH M11 Protocol Section 3 Data Element Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C16355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16355>	C18473	Northern Blotting|Blotting, Northern|Northern Blot	A common molecular biology procedure for detection of RNA molecules.  RNA extracted from a sample was denatured and separated by slab gel electrophoresis, then blotted on to a nitrocellulose or nylon sheet and hybridized with labeled DNA or RNA that is complementary to the desired RNA, whose presence is subsequently indicated by autoradiography or other visualization techniques.			Laboratory Procedure	
C163560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163560>	C67313	Percent per Second|%/s|%/s|%/s|%/sec	A unit of frequency expressed as the percentage of entities or events per second.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163561>	C66973	Billion per Dose|10*9/{dose}|10*9/{dose}|10^9/dose|10^9/dose|10^9/{dose}|10^9/{dose}	A dose calculation unit equal to 10 to the ninth power of the number of entities per single dose.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163562>	C163046	Arithmetic Mean Fluorescence Intensity Unit|aMFI|aMFI|{aMFI}|{aMFI}	A unit of measure for the arithmetic mean fluorescence intensity.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163563>	C163046	Geometric Mean Fluorescence Intensity Unit|gMFI|gMFI|{gMFI}|{gMFI}	A unit of measure for the geometric mean fluorescence intensity.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163564>	C48568	Milliliter per Cubic Centimeter per Minute|mL/cm3/min|mL/cm3/min|mL/cm3/min|mL/mL/min|ml/cm3/min|ml/cm3/min	A unit of flow rate equal to one milliliter per cm3 per unit of time equal to one minute.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163565>	C66973	Millisecond per Millimeter Mercury|ms/mmHg|ms/mm[Hg]|ms/mm[Hg]|msec/mmHg	A unit of measure equal to one millisecond per one millimeter of mercury (mmHg).			Conceptual Entity	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163566>	C67375|C48463	Vector Genomes per Kilogram|VGC/kg|Vector Genomic Copies/kg|vg/kg|vg/kg|{vg}/kg|{vg}/kg	A unit for the vector amount expressed as the number of vector genomes per kilogram of body weight.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163567>	C48919	BMI-for-Age Percentile|BMIAPCTL	A measurement of an individual's body mass index in relationship to age, in comparison to a reference percentile curve.			Qualitative Concept	CDISC SDTM Terminology|CDISC SDTM Vital Sign Test Code Terminology|CDISC SDTM Vital Sign Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C163568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163568>	C48919	Height-for-Age Percentile|HTAPCTL	A measurement of an individual's height in relationship to age, in comparison to a reference percentile curve.			Qualitative Concept	CDISC SDTM Terminology|CDISC SDTM Vital Sign Test Code Terminology|CDISC SDTM Vital Sign Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C163569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163569>	C48919	Weight-for-Age Percentile|WTAPCTL	A measurement of an individual's weight in relationship to age, in comparison to a reference percentile curve.			Qualitative Concept	CDISC SDTM Terminology|CDISC SDTM Vital Sign Test Code Terminology|CDISC SDTM Vital Sign Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C16356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16356>	C17632	Southern Blotting|Blotting, Southern|Southern|Southern Blot|Southern Blot Hybridization|Southern blot	A technique for the detection of specific DNA fragments that have been separated by polyacrylamide-gel electrophoresis, transferred to a nitrocellulose or other type of paper or nylon membrane, and detected by hybridization and visualization with a labeled probe.			Laboratory Procedure	CPTAC Acute Myeloid Leukemia Baseline Form|CPTAC Baseline Medical Forms Terminology|CPTAC Terminology|GDC Terminology|GDC Value Terminology
C163570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163570>	C48919	Weight-for-Height Percentile|WTHTPCTL	A measurement of an individual's weight in relationship to height, in comparison to a reference percentile curve.			Qualitative Concept	CDISC SDTM Terminology|CDISC SDTM Vital Sign Test Code Terminology|CDISC SDTM Vital Sign Test Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C163571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163571>	C25180	Radiation Combined Injury Indicator|CIRNRIND|Combined Injury (Rad and Non-Rad) Ind|Combined Injury (Rad and Non-Rad) Ind|Combined Injury (Radiation and Non-Radiation) Indicator	An indication as to whether the radiation injury is combined with infectious, physical, thermal, and/or chemical trauma.			Conceptual Entity	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163572>	C54648	Irradiation Field Orientation Sequence|IRORSEQ|Irradiation Field Orientation/Sequence|Irradiation Field Orientation/Sequence	A description of the irradiation field as it pertains to orientation to the body and, when appropriate, the sequencing of exposure(s).			Body Location or Region	CDISC SEND Challenge Agent Parameter Code Terminology|CDISC SEND Challenge Agent Parameter Long Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163573>	C737|C160932	A-230|A230	An organophosphate acetylcholinesterase inhibitor that is used as a chemical weapon. It is one of a class of binary nerve agents, called Novichok nerve agents, that was first developed by the former Soviet Union in the 1970s.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163574>	C737|C160932	A-232|A232|Novichok-5	A carboxamidine compound and organophosphate acetylcholinesterase inhibitor that is used as a chemical weapon. It is one of a class of binary nerve agents, called Novichok nerve agents, that was first developed by the former Soviet Union in the 1970s.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163575>	C737|C160932	A-234|A234|Novichok-7	An organophosphate acetylcholinesterase inhibitor that is used as a chemical weapon. It is one of a class of binary nerve agents, called Novichok nerve agents, that was first developed by the former Soviet Union in the 1970s.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163576>	C894	Abrin|ABRIN	A highly toxic protein, derived from the seeds of the rosary pea plant, that inhibits protein synthesis in exposed cells. It is characterized as a white to yellowish white powder and exposure occurs by inhalation, ingestion, or contact.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163577>	C737	Acephate|ACEPHATE|ACEPHATE	A synthetic organic thiophosphate compound and weak organophosphate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a moderately persistent and highly soluble colorless to white solid, and exposure occurs by inhalation, contact, or ingestion.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163578>	C737	Aldicarb|ALDICARB|ALDICARB	A synthetic oxime carbamate compound and carbamate acetylcholinesterase inhibitor, endocrine disruptor, and neurotoxin that is used as a pesticide. It is characterized as a highly toxic colorless or white crystalline solid with a slightly sulfurous odor, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163579>	C163038	Alpha-Conotoxin Ac1.1A|ALPHA-CONOTOXIN AC1.1A|Alpha-Ac1.1a|Alpha-Ac1.1a	A 17-amino acid alpha3/5-conotoxin isolated from the venom of the cone snail Conus achatinus that is a competitive antagonist of the muscle-type nicotinic acetylcholine receptors, blocking synaptic transmission at the neuromuscular junction. Alpha-conotoxins are identified by a characteristic arrangement of four-cysteine residues (-CC-C-C-) and disulfide bonding of Cys1-Cys3 and Cys2-Cys4. In addition, alpha3/5-conotoxins are further classified as having three residues in the first intercysteine loop and five residues in the second intercysteine loop.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16357>	C18962|C17638	Western Blotting|Blotting, Western|WESTERN BLOT|Western Blot	A laboratory procedure for the detection or identification of proteins or peptides that have been separated by gel electrophoresis and transferred onto nitrocellulose or other type of paper or nylon membrane. The proteins are then detected by reaction with enzymatically labeled or radiolabeled antibody probes.	Western Blotting		Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C163580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163580>	C163038	Alpha-Conotoxin CnIA|ALPHA-CONOTOXIN CNIA|Alpha-CnIA|Alpha-CnIA	A 14-amino acid alpha3/5-conotoxin isolated from the venom of the cone snail Conus consors that is a competitive antagonist of the muscle-type nicotinic acetylcholine receptors, blocking synaptic transmission at the neuromuscular junction. Alpha-conotoxins are identified by a characteristic arrangement of four-cysteine residues (-CC-C-C-) and disulfide bonding of Cys1-Cys3 and Cys2-Cys4. In addition, alpha3/5-conotoxins are further classified as having three residues in the first intercysteine loop and five residues in the second intercysteine loop.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163581>	C163038	Alpha-Conotoxin CnIB|ALPHA-CONOTOXIN CNIB|Alpha-CnIB|Alpha-CnIB	A 12-amino acid alpha3/5-conotoxin isolated from the venom of the cone snail Conus consors that is a competitive antagonist of the muscle-type nicotinic acetylcholine receptors, blocking synaptic transmission at the neuromuscular junction. Alpha-conotoxins are identified by a characteristic arrangement of four-cysteine residues (-CC-C-C-) and disulfide bonding of Cys1-Cys3 and Cys2-Cys4. In addition, alpha3/5-conotoxins are further classified as having three residues in the first intercysteine loop and five residues in the second intercysteine loop.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163582>	C163038	Alpha-Conotoxin GI|ALPHA-CONOTOXIN GI|Alpha-GI|Alpha-GI	A 13-amino acid alpha-conotoxin that is isolated from the venom of the cone snail Conus geographus. It is a competitive antagonist of the muscle-type nicotinic acetylcholine receptors, blocking synaptic transmission at the neuromuscular junction. Alpha-conotoxins are identified by a characteristic arrangement of four-cysteine residues (-CC-C-C-) and disulfide bonding of Cys1-Cys3 and Cys2-Cys4.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163583>	C163038	Alpha-Conotoxin GIA|ALPHA-CONOTOXIN GIA|Alpha-GIA|Alpha-GIA	A 15-amino acid alpha-conotoxin isolated from the venom of the cone snail Conus geographus that is a competitive antagonist of the muscle-type nicotinic acetylcholine receptors, blocking synaptic transmission at the neuromuscular junction. Alpha-conotoxins are identified by a characteristic arrangement of four-cysteine residues (-CC-C-C-) and disulfide bonding of Cys1-Cys3 and Cys2-Cys4. Alpha-conotoxin GIA is identical in sequence to the neurotoxin alpha-conotoxin GI except for the presence of additional residues of glycine and lysine at the carboxyl terminus.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163584>	C163038	Alpha-Conotoxin MI|ALPHA-CONOTOXIN MI|Alpha-MI|Alpha-MI	A small alpha-conotoxin isolated from the venom of the cone snail Conus magus that is a competitive antagonist of the muscle-type nicotinic acetylcholine receptors, blocking synaptic transmission at the neuromuscular junction. Alpha-conotoxins are identified by a characteristic arrangement of four-cysteine residues (-CC-C-C-) and disulfide bonding of Cys1-Cys3 and Cys2-Cys4.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163585>	C737	Aminocarb|AMINOCARB|AMINOCARB	A synthetic toluene compound and carbamate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a white to beige colored crystalline solid, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163586>	C45678	Arsine|ARSINE	A toxic form of arsenic that is used as a chemical weapon agent. It is an arsenic and hydrogen compound characterized as a colorless, odorless gas that is produced when metallic arsenides are decomposed by water or reducing acids.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163587>	C737	Azinphos-Ethyl|AZINPHOS-ETHYL|AZINPHOS-ETHYL	A synthetic organic thiophosphate compound and organophosphate acetylcholinesterase inhibitor and neurotoxicant that is used as a pesticide. It is characterized as a persistent and relatively volatile colorless, needle-shaped crystalline solid, and exposure occurs by inhalation, ingestion, or contact.			Hazardous or Poisonous Substance|Organic Chemical	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163588>	C737	Azinphos-Methyl|AZINPHOS-METHYL|AZINPHOS-METHYL	A synthetic organic thiophosphate compound and organophosphate acetylcholinesterase inhibitor and neurotoxicant that is used as a pesticide. It is characterized as a non-persistent and volatile colorless, white, or brown crystalline solid, and exposure occurs by inhalation, ingestion, or contact.			Hazardous or Poisonous Substance|Organic Chemical	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163589>	C737	Bendiocarb|BENDIOCARB|BENDIOCARB	A synthetic benzodioxole compound and carbamate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a highly toxic, white, odorless crystalline solid, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16358>	C19332	Body Mass Index|BMI|BMI|BMI|BMI|BMI|BMI|Body mass index|Body mass index (BMI) [Ratio]|Quetelet Index|Vital Signs – BMI|bmi|body mass index	An individual's weight in kilograms divided by the square of the height in meters.			Clinical Attribute	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|AML Authorized Value Terminology|AML Vitals Table|Appendix 6: Symptoms and Signs Terminology|CDISC SDTM Terminology|CDISC SDTM Vital Sign Test Code Terminology|CDISC SDTM Vital Sign Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Medical History Form|CPTAC Terminology|EWS Authorized Value Terminology|EWS Vitals Table|GDC Property Terminology|GDC Terminology|Physical Examination Terminology
C163590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163590>	C737	Benfuracarb|BENFURACARB|BENFURACARB	A synthetic 1-benzofuran and ethyl ester compound, and carbamate acetylcholinesterase inhibitor, that is used as a pesticide. It is characterized as a pale yellow viscous oily liquid, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163591>	C82623	Botulinum Toxin Type A1|BOTULINUM NEUROTOXIN A1|BoNT/A1|Clostridium botulinum Toxin A1	Subtype 1 of botulinum neurotoxin serotype A. This genetic variant is currently used as a therapeutic to achieve long-lasting flaccid paralysis with local injection.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163592>	C82623	Botulinum Toxin Type A2|BOTULINUM NEUROTOXIN A2|BoNT/A2|Clostridium botulinum Toxin A2	Subtype 2 of botulinum neurotoxin serotype A.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163593>	C82623	Botulinum Toxin Type A3|BOTULINUM NEUROTOXIN A3|BoNT/A3|Clostridium botulinum Toxin A3	Subtype 3 of botulinum neurotoxin serotype A.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163594>	C82623	Botulinum Toxin Type A4|BOTULINUM NEUROTOXIN A4|BoNT/A4|Clostridium botulinum Toxin A4	Subtype 4 of botulinum neurotoxin serotype A.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163595>	C82623	Botulinum Toxin Type A5|BOTULINUM NEUROTOXIN A5|BoNT/A5|Clostridium botulinum Toxin A5	Subtype 5 of botulinum neurotoxin serotype A.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163596>	C82623	Botulinum Toxin Type A6|BOTULINUM NEUROTOXIN A6|BoNT/A6|Clostridium botulinum Toxin A6	Subtype 6 of botulinum neurotoxin serotype A.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163597>	C82623	Botulinum Toxin Type A7|BOTULINUM NEUROTOXIN A7|BoNT/A7|Clostridium botulinum Toxin A7	Subtype 7 of botulinum neurotoxin serotype A.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163598>	C82623	Botulinum Toxin Type A8|BOTULINUM NEUROTOXIN A8|BoNT/A8|Clostridium botulinum Toxin A8	Subtype 8 of botulinum neurotoxin serotype A.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163599>	C163033	Botulinum Toxin Type B1|BOTULINUM NEUROTOXIN B1|BoNT/B1|Clostridium botulinum Toxin B1	Subtype 1 of botulinum neurotoxin serotype B.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16359>	C25464	Bolivia, Plurinational State of|068|BO|BOL|BOL|BOLIVIA|BOLIVIA|BOLIVIA, PLURINATIONAL STATE OF|Bolivia|Bolivia	A country in central South America, southwest of Brazil.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C1635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1635>	C804	Bexarotene|3-methyl TTNEB|4-[1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]benzoic Acid|BEXAROTENE|LGD 1069|LGD-1069|LGD1069|LGD1069|Targretin|Targretin|bexarotene	A synthetic retinoic acid agent with potential antineoplastic, chemopreventive, teratogenic and embryotoxic properties.  Bexarotene selectively binds to and activates retinoid X receptors (RXRs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, apoptosis of some cancer cell types, and tumor regression. (NCI04)	Bexarotene		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C163600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163600>	C163033	Botulinum Toxin Type B2|BOTULINUM NEUROTOXIN B2|BoNT/B2|Clostridium botulinum Toxin B2	Subtype 2 of botulinum neurotoxin serotype B.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163601>	C163033	Botulinum Toxin Type B3|BOTULINUM NEUROTOXIN B3|BoNT/B3|Clostridium botulinum Toxin B3	Subtype 3 of botulinum neurotoxin serotype B.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163602>	C163033	Botulinum Toxin Type B4|BOTULINUM NEUROTOXIN B4|BoNT/B4|Clostridium botulinum Toxin B4	Subtype 4 of botulinum neurotoxin serotype B.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163603>	C163033	Botulinum Toxin Type B5|BOTULINUM NEUROTOXIN B5|BoNT/B5|Clostridium botulinum Toxin B5	Subtype 5 of botulinum neurotoxin serotype B.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163604>	C163033	Botulinum Toxin Type B6|BOTULINUM NEUROTOXIN B6|BoNT/B6|Clostridium botulinum Toxin B6	Subtype 6 of botulinum neurotoxin serotype B.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163605>	C163033	Botulinum Toxin Type B7|BOTULINUM NEUROTOXIN B7|BoNT/B7|Clostridium botulinum Toxin B7	Subtype 7 of botulinum neurotoxin serotype B.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163606>	C163033	Botulinum Toxin Type B8|BOTULINUM NEUROTOXIN B8|BoNT/B8|Clostridium botulinum Toxin B8	Subtype 8 of botulinum neurotoxin serotype B.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163607>	C163034	Botulinum Toxin Type C1|BOTULINUM NEUROTOXIN C1|BoNT/C1|Clostridium botulinum Toxin C1	Subtype 1 of botulinum neurotoxin serotype C.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163608>	C163034	Botulinum Toxin Type Cd|BOTULINUM NEUROTOXIN CD|BoNT/CD|Clostridium botulinum Toxin CD	A mosaic variant of the botulinum neurotoxin serotypes C and D that causes botulism in animals, and is two-thirds botulinum neurotoxin serotype C and one-third botulinum neurotoxin serotype D.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163609>	C163035	Botulinum Toxin Type Dc|BOTULINUM NEUROTOXIN DC|BoNT/DC|Clostridium botulinum Toxin DC	A mosaic variant of the botulinum neurotoxin serotypes C and D that causes botulism in animals, and is two-thirds botulinum neurotoxin serotype D and one-third botulinum neurotoxin serotype C.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16360>	C19498	Book	A volume made up of pages fastened along one edge and enclosed between protective covers, or its electronic equivalent.			Manufactured Object	eCTD Promotional Material Type Terminology|FDA eCTD Terminology
C163610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163610>	C163036	Botulinum Toxin Type E1|BOTULINUM NEUROTOXIN E1|BoNT/E1|Clostridium botulinum Toxin E1	Subtype 1 of botulinum neurotoxin serotype E.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163611>	C163036	Botulinum Toxin Type E10|BOTULINUM NEUROTOXIN E10|BoNT/E10|Clostridium botulinum Toxin E10	Subtype 10 of botulinum neurotoxin serotype E.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163612>	C163036	Botulinum Toxin Type E11|BOTULINUM NEUROTOXIN E11|BoNT/E11|Clostridium botulinum Toxin E11	Subtype 11 of botulinum neurotoxin serotype E.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163613>	C163036	Botulinum Toxin Type E12|BOTULINUM NEUROTOXIN E12|BoNT/E12|Clostridium botulinum Toxin E12	Subtype 12 of botulinum neurotoxin serotype E.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163614>	C163036	Botulinum Toxin Type E2|BOTULINUM NEUROTOXIN E2|BoNT/E2|Clostridium botulinum Toxin E2	Subtype 2 of botulinum neurotoxin serotype E.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163615>	C163036	Botulinum Toxin Type E3|BOTULINUM NEUROTOXIN E3|BoNT/E3|Clostridium botulinum Toxin E3	Subtype 3 of botulinum neurotoxin serotype E.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163616>	C163036	Botulinum Toxin Type E4|BOTULINUM NEUROTOXIN E4|BoNT/E4|Clostridium botulinum Toxin E4	Subtype 4 of botulinum neurotoxin serotype E.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163617>	C163036	Botulinum Toxin Type E5|BOTULINUM NEUROTOXIN E5|BoNT/E5|Clostridium botulinum Toxin E5	Subtype 5 of botulinum neurotoxin serotype E.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163618>	C163036	Botulinum Toxin Type E6|BOTULINUM NEUROTOXIN E6|BoNT/E6|Clostridium botulinum Toxin E6	Subtype 6 of botulinum neurotoxin serotype E.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163619>	C163036	Botulinum Toxin Type E7|BOTULINUM NEUROTOXIN E7|BoNT/E7|Clostridium botulinum Toxin E7	Subtype 7 of botulinum neurotoxin serotype E.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16361>	C25464	Bosnia and Herzegovina|070|BA|BIH|BIH|BOSNIA AND HERZEGOVINA|BOSNIA AND HERZEGOVINA|BOSNIA-HERZEGOVINA|Bosnia-Herzegovina	A country in southeastern Europe, bordering the Adriatic Sea, between Croatia and Serbia.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C163620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163620>	C163036	Botulinum Toxin Type E8|BOTULINUM NEUROTOXIN E8|BoNT/E8|Clostridium botulinum Toxin E8	Subtype 8 of botulinum neurotoxin serotype E.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163621>	C163036	Botulinum Toxin Type E9|BOTULINUM NEUROTOXIN E9|BoNT/E9|Clostridium botulinum Toxin E9	Subtype 9 of botulinum neurotoxin serotype E.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163622>	C163037	Botulinum Toxin Type F1|BOTULINUM NEUROTOXIN F1|BoNT/F1|Clostridium botulinum Toxin F1	Subtype 1 of botulinum neurotoxin serotype F.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163623>	C163037	Botulinum Toxin Type F2|BOTULINUM NEUROTOXIN F2|BoNT/F2|Clostridium botulinum Toxin F2	Subtype 2 of botulinum neurotoxin serotype F.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163624>	C163037	Botulinum Toxin Type F3|BOTULINUM NEUROTOXIN F3|BoNT/F3|Clostridium botulinum Toxin F3	Subtype 3 of botulinum neurotoxin serotype F.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163625>	C163037	Botulinum Toxin Type F4|BOTULINUM NEUROTOXIN F4|BoNT/F4|Clostridium botulinum Toxin F4	Subtype 4 of botulinum neurotoxin serotype F.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163626>	C163037	Botulinum Toxin Type F5|BOTULINUM NEUROTOXIN F5|BoNT/F5|Clostridium botulinum Toxin F5	Subtype 5 of botulinum neurotoxin serotype F.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163627>	C163037	Botulinum Toxin Type F6|BOTULINUM NEUROTOXIN F6|BoNT/F6|Clostridium botulinum Toxin F6	Subtype 6 of botulinum neurotoxin serotype F.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163628>	C163037	Botulinum Toxin Type F7|BOTULINUM NEUROTOXIN F7|BoNT/F7|Clostridium botulinum Toxin F7	Subtype 7 of botulinum neurotoxin serotype F.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163629>	C163037	Botulinum Toxin Type F8|BOTULINUM NEUROTOXIN F8|BoNT/F8|Clostridium botulinum Toxin F8	Subtype 8 of botulinum neurotoxin serotype F.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16362>	C16345	Botany	Botany; the branch of biology that studies plants.			Occupation or Discipline	
C163630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163630>	C163032	Botulinum Toxin Type H|BOTULINUM NEUROTOXIN FA(H)|BoNT/FA|BoNT/FA(H)|BoNT/H|BoNT/HA|Botulinum Neurotoxin FA|Botulinum Neurotoxin Fa(H)|Botulinum Neurotoxin H|Botulinum Neurotoxin HA|Clostridium botulinum Toxin FA|Clostridium botulinum Toxin FA(H)|Clostridium botulinum Toxin H|Clostridium botulinum Toxin HA	A mosaic variant of the botulinum neurotoxin serotypes A and F, consisting of a light chain that is like botulinum neurotoxin F5 and a unique heavy chain with a receptor binding domain like botulinum neurotoxin A1.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163631>	C163032	Botulinum Toxin Type G|BOTULINUM NEUROTOXIN G|BoNT/G|Clostridium botulinum Toxin G	Immunological serotype G of the botulinum neurotoxin.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163632>	C45678	Bromine|BROMINE	A naturally occurring halogen element with atomic symbol Br, atomic number 35, and atomic mass 79.904. Bromine, which is found in the earth's crust and sea water, is used in many industrial processes, as well as in insecticides, fire extinguishers, pharmaceuticals, and food and drink products. It is characterized as a dark reddish-brown liquid with an irritating pungent odor, and exposure occurs by inhalation of fumes, ingestion, or contact.			Element, Ion, or Isotope	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163633>	C737	Bromophos|BROMOPHOS	A synthetic organic thiophosphate compound and organophosphate acetylcholinesterase inhibitor and neurotoxicant that is used as a pesticide. It is characterized as a white crystalline solid, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163634>	C737	Butocarboxim|BUTOCARBOXIM|BUTOCARBOXIM	A synthetic carbamate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a pale brown viscous liquid, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163635>	C737	Cadusafos|CADUSAFOS|CADUSAFOS	A synthetic organic thiophosphate compound and organophosphate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a volatile and persistent clear liquid, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163636>	C737	Carbofuran|CARBOFURAN|CARBOFURAN	A synthetic carbamate pesticide that is an odorless, white crystalline solid, and exposure occurs by inhalation, ingestion, and contact, and it is an acetylcholinesterase inhibitor, and endocrine disruptor, and a probable reproduction/development intoxicant.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163637>	C737	Carbophenothion|CARBOPHENOTHION	A synthetic organophosphate acetylcholinesterase inhibitor and neurotoxin that is used as a pesticide. It is characterized as a persistent and highly toxic off-white to yellow/brown liquid with a mild rotten egg odor, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163638>	C737	Carbosulfan|CARBOSULFAN|CARBOSULFAN	A synthetic 1-benzofuran compound and carbamate acetylcholinesterase inhibitor and skin sensitizer that is used as a pesticide. It is characterized as a toxic and nonpersistent orange-yellow or brown viscous liquid, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163639>	C737	Chlorethoxyfos|CHLORETHOXYFOS|CHLORETHOXYPHOS	A synthetic organophosphate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a highly toxic colorless or gray to brown liquid, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16363>	C25464	Botswana|072|BOTSWANA|BOTSWANA|BW|BWA|BWA	A country in southern Africa, north of South Africa and east of Namibia.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C163640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163640>	C45678	Chloropicrin|CHLOROPICRIN	A synthetic C-nitro, one-carbon, and organochlorine compound that is a strong lachrymator. Chloropicrin has been used as a chemical warfare agent, fumigant, and pesticide. It is characterized as a slightly oily colorless to yellow liquid with a strong irritating odor, and exposure occurs by inhalation, ingestion, or contact.			Organic Chemical	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163641>	C737	Chlorpyrifos|CHLORPYRIFOS|CHLORPYRIFOS	A synthetic organophosphate acetylcholinesterase inhibitor, reproduction toxicant, and neurotoxicant that is used as a pesticide. It is characterized as a highly toxic colorless, white, or light brown crystalline solid with a mild rotten egg odor, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163642>	C737	Chlorpyrifos-methyl|CHLORPYRIFOS-METHYL|CHLORPYRIPHOS-METHYL	A synthetic organophosphate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a volatile and non-persistent white to pale yellow solid with a slight mercaptan odor, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163643>	C45678	Cyanogen Chloride|CYANOGEN CHLORIDE	A highly toxic form of cyanide that is used as a chemical weapon agent. It is an characterized as a colorless gas or liquid with a strong acrid/pungent odor that causes irritation of the eyes and respiratory tract, as well as other systemic effects, and exposure occurs by inhalation, ingestion, skin contact, or eye contact.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163644>	C737	Cyanophos|CYANOPHOS|CYANOPHOS	A synthetic organophosphate acetylcholinesterase inhibitor and neurotoxin that is used as a pesticide. It is characterized as a volatile yellow-brown or reddish-yellow liquid with a faint odor, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163645>	C737	Demeton-O|DEMETON-O|DEMETON-O	A synthetic organic thiophosphate compound that is used as a pesticide. It is characterized as a colorless oily liquid, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163647>	C737	Dicrotophos|DICROTOPHOS|DICROTOPHOS	A synthetic dialkyl phosphate compound and organophosphate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a volatile yellow brown liquid with a mild ester odor, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163649>	C737	Dimethoate|DIMETHOATE|DIMETHOATE	A synthetic organic thiophosphate compound and organophosphate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a volatile white to gray crystalline solid that has a camphor-like odor, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16364>	C25464	Brazil|076|BR|BRA|BRA|BRAZIL|BRAZIL	A country in eastern South America, bordering the Atlantic Ocean.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF1 Registration Table|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C163650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163650>	C737	Dimetilan|DIMETILAN|DIMETILAN	A synthetic pyrazole compound and carbamate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a colorless or yellow to reddish-brown solid, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163651>	C45678	Diphosgene|DIPHOSGENE	A moderately persistent synthetic organic compound, formed by chlorination of methyl chloroformate, that is a respiratory irritant and lachrymator. Trichloromethyl Chloroformate has been used as a chemical warfare agent and is characterized as a colorless liquid with an odor that is like newly mown hay. Exposure occurs by inhalation, ingestion, or contact.			Organic Chemical	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163652>	C737	Disulfoton|DISULFOTON|DISULFOTON	A synthetic organic thiophosphate compound and organophosphate acetylcholinesterase inhibitor, neurotoxicant, and possible carcinogen that is used as a pesticide. It is characterized as a toxic colorless to yellow oily liquid that has an unidentifiable or sulfur-like odor, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163653>	C296	Clostridium perfringens Epsilon Toxin|EPSILON TOXIN|Epsilon Toxin	A potent protein toxin produced by the bacteria Clostridium perfringens type B and D strains that induces transmembrane pore formation in eukaryotic cells, causing cell dysfunction and life-threatening enteric disease in domestic ruminants.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163654>	C737	Ethiofencarb|Croneton|ETHIOFENCARB|ETHIOFENCARB	A synthetic phenyl methylcarbamate compound and carbamate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a colorless crystalline solid with a mercaptan-like odor, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163655>	C737	Ethion|ETHION|ETHION	A synthetic organophosphate pesticide that is an acetylcholinesterase inhibitor. It is characterized as a clear to yellow or amber liquid with a sulfur-like smell, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163656>	C737	Fenamiphos|FENAMIPHOS|FENAMIPHOS	A synthetic phosphoramidate ester compound and organophosphate acetylcholinesterase inhibitor and neurotoxicant that is used as a pesticide. It is characterized as a highly toxic colorless or brown waxy solid, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163657>	C737	Fenobucarb|BPMC|FENOBUCARB|FENOBUCARB	A synthetic carbamate ester compound and carbamate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as an oily yellow liquid, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163658>	C737	Fenoxycarb|FENOXYCARB|FENOXYCARB	A synthetic carbamate ester compound and juvenile hormone mimic that is used as a pesticide. It is characterized as a colorless to white crystalline solid, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163659>	C737	Fonofos|FONOFOS|FONOFOS	A synthetic organic thiophosphate compound and organophosphate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a colorless or yellow liquid with a mercaptan-like odor and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16365>	C25464	British Indian Ocean Territory|086|BRITISH INDIAN OCEAN TERRITORY|BRITISH INDIAN OCEAN TERRITORY|IO|IOT|IOT	An archipelago in the Indian Ocean, south of Africa, about one-half the way from Africa to Indonesia and south of the Maldives.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Geopolitical Entities, Names, and Codes Terminology
C163660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163660>	C737	Formetanate|FORMETANATE|FORMETANATE	A synthetic carbamate ester and acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a colorless or white crystalline solid with a faint odor, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163661>	C737	Formothion|FORMOTHION|FORMOTHION	A synthetic dicarboximide compound and organophosphate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a viscous yellow oily liquid or crystalline solid, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163662>	C737	Formparanate|FORMPARANATE|FORMPARANATE	A synthetic carbamate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a white solid, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163663>	C737	Glufosinate-Ammonium|GLUFOSINATE AMMONIUM	A synthetic organophosphate glutamine synthetase inhibitor and neurotoxin that is used as a pesticide. It is characterized as a highly soluble and volatile white to light yellow crystalline solid with a slightly pungent odor, and exposure occurs by inhalation, ingestion, or contact.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163664>	C737	Glyphosate|GLYPHOSATE|Roundup	A synthetic organophosphate compound that blocks the activity of enolpyruvylshikimate-3-phosphate (EPSP) synthase and is used as a broad-spectrum pesticide. It is characterized as a volatile, moderately toxic, colorless, odorless crystalline solid or powder, and exposure occurs by inhalation, ingestion, or contact.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163665>	C737	Glyphosine|GLYPHOSINE	A synthetic glycine derivative and phosphonic acid plant growth retardant that increases sucrose storage and decreases fiber production. It is characterized as a colorless solid, and exposure occurs by inhalation, ingestion, or contact.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163666>	C45678	Hydrogen Sulfide|HYDROGEN SULFIDE	A highly flammable conjugate acid of a cyanide that occurs naturally in crude petroleum, natural gas, and hot springs, and can be produced by bacterial breakdown of organic material and waste. It is used as a chemical weapon agent and is characterized as a colorless gas with a strong rotten egg odor that causes irritation of the eyes and respiratory tract, as well as toxic systemic effects.			Chemical Viewed Functionally	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163667>	C737	Isazophos|ISAZOFOS|ISAZOPHOS|Isazofos	A synthetic organic thiophosphate compound and organophosphate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a yellow or amber liquid, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163668>	C737	Isofenphos|ISOFENPHOS|ISOFENPHOS	A synthetic organophosphate acetylcholinesterase inhibitor, derived from an isopropyl salicylate, that is used as a pesticide. It is characterized as a colorless oily liquid with a characteristic odor, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163669>	C737	Isoprocarb|ISOPROCARB|ISOPROCARB	A synthetic carbamate ester compound and acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a colorless crystalline solid, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16366>	C16546	Bronchoscopy|bronchoscopy	Endoscopic examination of the tracheobronchial tree.	Bronchoscopy		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C163670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163670>	C737	M-Cumenyl Methylcarbamate|M-CUMENYL METHYLCARBAMATE|M-ISOPROPYLPHENOL METHYLCARBAMATE	A synthetic carbamate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a white crystalline odorless solid, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163671>	C737	Methamidophos|METHAMIDOPHOS|METHAMIDOPHOS	A synthetic organic thiophosphate compound and organophosphate acetylcholinesterase inhibitor and neurotoxin that is used as a pesticide. It is characterized as a volatile colorless or off-white crystalline solid with a pungent odor, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163672>	C737	Methidathion|METHIDATHION|METHIDATHION	A synthetic organic thiophosphate compound and organophosphate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a colorless crystalline solid, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163673>	C737	Methiocarb|METHIOCARB|METHIOCARB	A synthetic carbamate ester, aryl sulfide compound, acetylcholinesterase inhibitor, and neurotoxin that is used as a pesticide. It is characterized as a highly toxic, colorless or white crystalline solid with a mild odor, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163674>	C737	Methomyl|METHOMYL|METHOMYL	A synthetic carbamate ester, aryl sulfide compound, and acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a highly toxic, white crystalline solid with a slight sulfurous odor, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163675>	C45678	Methyl Bromide|METHYL BROMIDE	A methyl halide, bromomethane, and bromohydrocarbon that is composed of one carbon, one hydrogen, and three bromine atoms. It is both manufactured and naturally produced by marine algae, and it has a role as a pesticide, a fire extinguishing agent, and in the synthesis of other chemicals. It is characterized as a colorless gas with a chloroform-like odor at high concentrations. Exposure occurs by inhalation, ingestion, or contact.			Organic Chemical	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163676>	C45678	Methyl Isocyanate|METHYL ISOCYANATE	A synthetic organic compound composed of isocyanate that is methane modified by a single isocyanato substituent. Methyl isocyanate has a role as an apoptosis inducer and is used in the manufacture of polyurethane foam, pesticides, and plastics. It is characterized as a colorless liquid with a sharp pungent odor that evaporates quickly when exposed to air. Exposure occurs by inhalation, ingestion, or contact.			Organic Chemical	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163677>	C737	Methyl Parathion|METHYL PARATHION|PARATHION-METHYL	A synthetic organic thiophosphate compound and organophosphate acetylcholinesterase inhibitor that is the methyl homolog of parathion and is used as a pesticide. It is characterized as a colorless to white or tan crystalline solid that is odorless or has a pungent garlic-like odor, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163678>	C737	Metolcarb|METOLCARB|METOLCARB	A synthetic carbamate ester compound and acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a colorless crystalline solid, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163679>	C737	Mevinphos|MEVINPHOS|MEVINPHOS	A synthetic organophosphate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a highly toxic colorless to pale yellow or orange liquid with a weak odor, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16367>	C25464	Brunei Darussalam|096|BN|BRN|BRN|BRUNEI|BRUNEI|BRUNEI DARUSSALAM|Brunei|Brunei	A country in southeastern Asia, bordering the South China Sea and surrounded by Malaysia.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C163680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163680>	C737	Mexacarbate|MEXACARBATE|MEXACARBATE	A synthetic benzene compound and carbamate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as an odorless white crystalline solid, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163681>	C737	Monocrotophos|MONOCROTOPHOS|MONOCROTOPHOS	A synthetic organophosphate acetylcholinesterase and monoamine oxidase inhibitor that is used as a pesticide. It is characterized as a highly toxic colorless or reddish-brown crystalline solid with a mild ester odor, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163682>	C737	Omethoate|OMETHOATE|OMETHOATE	A synthetic organophosphate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a colorless to yellow oily liquid with a mercaptan-like odor, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163683>	C45678	Osmium Tetroxide|OSMIUM TETROXIDE|Osmium(VIII) Oxide|Tetraoxoosmium	An osmium oxide composed of four oxygen atoms bound to a central osmium atom. Osmium tetroxide is most commonly used as a fixative, and in oxidation reactions and biological staining. It is characterized as a colorless, or pale-yellow crystalline solid with a pungent odor. Exposure occurs by inhalation, ingestion, or contact.			Inorganic Chemical	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163684>	C737	Oxamyl|OXAMYL|OXAMYL	A synthetic carbamate ester compound, acetylcholinesterase inhibitor, and neurotoxicant that is used as a pesticide. It is characterized as a colorless or white crystalline solid with a slight sulfurous odor, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163685>	C737	Parathion|PARATHION|PARATHION	A synthetic organic thiophosphate compound and organophosphate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a deep brown to yellow liquid with a faint garlic odor, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163686>	C737	Phenthoate|PHENTHOATE|PHENTHOATE	A synthetic organic thiophosphate compound and organophosphate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a colorless crystalline solid with an aromatic odor, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163687>	C737	Phorate|PHORATE|PHORATE	A synthetic organophosphate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a colorless to pale yellow or light brown liquid with a skunk-like odor, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163688>	C45678	Phosgene|PHOSGENE	A synthetic formaldehyde derivative with both hydrogens substituted by chlorine. Phosgene is used in the manufacture of other chemicals, pesticides, and pharmaceuticals. It can also be used to separate ores, and has been used as a chemical warfare agent. It is characterized as a colorless to light yellow gas at room temperature and normal pressure or as a liquid under pressure or with refrigeration, with an odor of freshly cut hay. Exposure occurs by inhalation, ingestion, or contact.			Organic Chemical	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163689>	C45678	Phosgene Oxime|PHOSGENE OXIME	A synthetic nettle agent developed in Germany in 1929 as a potential chemical warfare agent that causes corrosive skin and tissue injuries. It is characterized as a colorless crystalline solid or yellowish-brown liquid that is odorless or has a fruity odor. Exposure occurs by inhalation, ingestion, or contact.			Organic Chemical	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16368>	C25464	Bulgaria|100|BG|BGR|BGR|BULGARIA|BULGARIA|Republic of Bulgaria	A country in southeastern Europe, bordering the Black Sea, between Romania and Turkey.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C163690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163690>	C737	Phosphamidon|PHOSPHAMIDON|PHOSPHAMIDON	A synthetic trialkyl phosphate compound and organophosphate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a colorless or yellow oily liquid with a faint odor, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163691>	C45678	Phosphine|PHOSPHINE	A highly toxic phosphorus hydride that is formed naturally via the anaerobic decay of phosphorus-containing organic matter or is prepared by an alkali metal hydroxide or white phosphorus hydrolysis reaction. Phosphine is used in industrial processes, in flame retardant production, and as a pesticide. It is characterized as a colorless gas that is odorless when pure. Exposure occurs by inhalation, ingestion, or contact.			Inorganic Chemical	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163693>	C737	Pirimicarb|PIRIMICARB|PIRIMICARB	A synthetic aminopyrimidine and tertiary amino compound, derived from a dimethylcarbamic acid, and carbamate acetylcholinesterase inhibitor that is used as pesticide. It is characterized as a colorless or white solid, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163694>	C45678	Potassium Cyanide|POTASSIUM CYANIDE	A synthetic cyanide salt and potassium salt that is a neurotoxin and cytochrome c oxidase and superoxide dismutase inhibitor. It is used in many industrial processes, including as a pesticide, and is characterized as a white crystalline solid that is odorless or has a faint bitter almond odor. Exposure occurs by inhalation, ingestion, or contact.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163695>	C737	Promecarb|PROMECARB|PROMECARB	A synthetic alkylbenzene compound and carbamate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as an almost odorless, colorless crystalline solid, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163696>	C737	Prophenofos|PROPHENOFOS	A synthetic organic thiophosphate compound and organophosphate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as  an oily, amber liquid with a garlic-like odor. Exposure occurs by inhalation, ingestion, and contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163697>	C737	Quinalphos|QUINALPHOS|QUINALPHOS	A synthetic organic thiophosphate compound and organophosphate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a colorless crystalline solid, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163698>	C688|C1923	Saxitoxin|SAXITOXIN	A carbamate alkaloid neurotoxin isolated from marine dinoflagellates and cyanobacteria that inhibits nerve conduction by blocking neuronal voltage-gated sodium channels in excitable cells. Exposure usually occurs through ingestion of contaminated shellfish, resulting in an illness called paralytic shellfish poisoning.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163699>	C45678	Sodium Cyanide|SODIUM CYANIDE	A toxic cyanide salt, sodium salt, and one-carbon compound that is used as an insecticide, a test reagent for the function of chemoreceptors, and in many industrial processes. It is characterized as a white crystalline solid, colorless gas, or aqueous solution that is odorless or has a faint, bitter almond-like odor. Exposure occurs by inhalation, ingestion, or contact.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16369>	C25464	Burkina Faso|854|BF|BFA|BFA|BURKINA FASO|BURKINA FASO	A country in western Africa, between Mali and Ghana.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C1636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1636>	C548	Therapeutic Steroid Hormone|Steroid Hormone|Synthetic Steroids|steroid drug	Synthetically made hormones possessing the steroid ring system; e.g., androgens, estrogens, and adrenocortical hormones.			Chemical Viewed Functionally	
C163700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163700>	C45678	Sodium Monofluoroacetate|SODIUM FLUOROACETATE|SODIUM MONOFLUOROACETATE|Sodium Fluoroacetate	An organic sodium salt and fluoroacetic acid derivative that is used as a rodenticide. It is characterized as a fine, white powdered solid that is odorless, and exposure occurs by inhalation, ingestion, or contact.			Organic Chemical	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163701>	C470	Staphylococcal Enterotoxin D|SED|STAPHYLOCOCCAL ENTEROTOXIN D	An exotoxin and superantigen, primarily produced by Staphylococcus aureus, that is a common cause of food poisoning worldwide. Staphylococcal enterotoxin D activates T cell cytokine production by sequentially binding to antigens on the alpha and beta chains of major histocompatibility complex class II molecules outside the peptide-binding groove and the variable region of the T cell receptor beta chain.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163702>	C470	Staphylococcal Enterotoxin E|SEE|STAPHYLOCOCCAL ENTEROTOXIN E	An exotoxin and superantigen, primarily produced by Staphylococcus aureus, that has been documented in some cases of food poisoning. Staphylococcal enterotoxin E activates T cell cytokine production by sequentially binding to antigens on the beta chain of major histocompatibility complex class II molecules outside the peptide-binding groove and the variable region of the T cell receptor beta chain.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163703>	C45678	Stibine|STIBINE|Stilbane				Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163704>	C737	Sulfotep|SULFOTEP|SULFOTEP	A synthetic organic thiophosphate compound and organophosphate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a highly toxic colorless to pale yellow oily liquid with a garlic-like odor, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163705>	C737	Sulprofos|SULPROFOS|SULPROFOS	A synthetic organic thiophosphate compound and organophosphate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a colorless or tan to brown oily liquid with a mercaptan-like odor. Exposure occurs by inhalation, ingestion, and contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163706>	C894	T-2 Toxin|T-2 TOXIN	A type A trichothecene mycotoxin produced by Fusarium langsethiae, Fusarium poae, and Fusarium sporotrichioides that interferes with the metabolism of membrane phospholipids by inhibiting protein synthesis and disrupting DNA and RNA synthesis. It is frequently responsible for the contamination of various grain crops and elicits a severe inflammatory reaction in animals.			Hazardous or Poisonous Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163707>	C737	Terbufos|TERBUFOS|TERBUFOS	A synthetic organic thiophosphate compound and organophosphate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a colorless to pale yellow liquid with a mercaptan-like odor, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163709>	C737	Tetraethyl Pyrophosphate|TEPP|TEPP|TETRAETHYL PYROPHOSPHATE|TETRAETHYL PYROPHOSPHATE	A synthetic organic diphosphate compound and organophosphate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a colorless to amber liquid with a faint, fruity odor, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16370>	C25464	Myanmar|104|BURMA|Burma|MM|MMR|MMR|MYANMAR|Republic of the Union of Myanmar|Union of Burma|Union of Myanmar	A country in southeastern Asia, bordering the Andaman Sea and the Bay of Bengal, southwest of China, between Bangladesh and Thailand.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C163710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163710>	C45678	Tetramethylenedisulfotetramine|TETRAMETHYLENEDISULFOTETRAMINE|TETS	A neurotoxic synthetic polyhedral organic compound and type A gamma-aminobutyric acid receptor (GABAAR) antagonist that was banned worldwide for use as a pesticide in 1991. It is characterized as a colorless and odorless solid, and exposure occurs by inhalation, ingestion, or contact.			Chemical Viewed Functionally	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163711>	C737	Thiofanox|THIOFANOX|THIOFANOX	A synthetic carbamate compound and acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a colorless solid with a pungent odor, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163712>	C737	Triazophos|TRIAZOPHOS|TRIAZOPHOS	A synthetic organic thiophosphate compound and organophosphate acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a yellow-brown oily liquid, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163713>	C737	2,3,5-Trimethacarb|2,3,5-Trimethylphenyl Methylcarbamate|2,3,5-Trimethylphenyl Methylcarbamate|TRIMETHACARB|TRIMETHACARB	A synthetic carbamate ester compound and acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a volatile, off-white to brown solid, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163714>	C737	3,5-Xylyl Methylcarbamate|3,5-XYLYL METHYLCARBAMATE|3,5-Xylyl-methylcarbamate|XMC|XMC	A synthetic carbamate ester compound, derived from a methylcarbamic acid and a 3,5-xylenol, and a acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a colorless crystalline solid, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163715>	C737	Xylylcarb|XYLYLCARB|XYLYLCARB	A synthetic carbamate ester compound, derived from a methylcarbamic acid and a 3,4-xylenol, and a acetylcholinesterase inhibitor that is used as a pesticide. It is characterized as a white solid, and exposure occurs by inhalation, ingestion, or contact.			Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163716>	C15313	Anteroposterior/Posteroanterior Sequential Radiotherapy|AP-PA Sequential|AP-PA Sequential|AP/PA SEQUENTIAL|APPA Sequential|APPA Sequential|AnteriorPosterior-PosteriorAnterior Sequential|AnteriorPosterior-PosteriorAnterior Sequential|Anteroposterior-Posteroanterior Sequential|Anteroposterior-Posteroanterior Sequential	A type of radiation procedure in which radiation is applied first in an anteroposterior anatomical plane and then in a posteroanterior anatomical plane.			Therapeutic or Preventive Procedure	CDISC SEND Irradiation Field Orientation/Sequence Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163717>	C15313	Posteroanterior/Anteroposterior Simultaneous Radiotherapy|AP-PA Simultaneous|AP-PA Simultaneous|AP/PA SIMULTANEOUS|APPA Simultaneous|APPA Simultaneous|AnteriorPosterior-PosteriorAnterior Simultaneous|AnteriorPosterior-PosteriorAnterior Simultaneous|Anteroposterior-Posteroanterior Simultaneous|Anteroposterior-Posteroanterior Simultaneous	A type of radiation procedure in which radiation is applied simultaneously in the anteroposterior anatomical plane and in the posteroanterior anatomical plane.			Therapeutic or Preventive Procedure	CDISC SEND Irradiation Field Orientation/Sequence Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163718>	C15313	Bilateral Sequential Radiotherapy|BILATERAL SEQUENTIAL	A type of radiation procedure in which radiation is applied to both halves of the body or body part in a sequential manor.			Therapeutic or Preventive Procedure	CDISC SEND Irradiation Field Orientation/Sequence Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163719>	C15313	Bilateral Simultaneous Radiotherapy|BILATERAL SIMULTANEOUS	A type of radiation procedure in which radiation is applied to both halves of the body or body part at the same time.			Therapeutic or Preventive Procedure	CDISC SEND Irradiation Field Orientation/Sequence Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16371>	C25464	Burundi|108|BDI|BDI|BI|BURUNDI|BURUNDI	A country in central Africa, east of the Democratic Republic of the Congo and south of Rwanda.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C163720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163720>	C16956	Aplasia/Hypoplasia|APLASIA/HYPOPLASIA	A finding that generally has features of aplasia and hypoplasia.			Phenomenon or Process	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163721>	C35867	Apoptosis and Single Cell Necrosis|APOPTOSIS/SINGLE CELL NECROSIS	A finding that generally has features of apoptosis and single cell necrosis.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163722>	C43265	Colloid Alteration|COLLOID ALTERATION	Stippled, granular or clumped colloid, and/or variable staining characteristics, and often contains mineralized material and desquamated follicular cells. (INHAND)			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163723>	C43265	Decreased Colloid|COLLOID, DECREASED	Decrease in the amount of colloid.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163724>	C81326|C43265	Increased Colloid|COLLOID, INCREASED	Increase in the amount of colloid.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163725>	C16568	Degranulation|DEGRANULATION	A process by which cells release or lose their intracytoplasmic granules.			Cell Function	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163726>	C82547|C60925	Decreased Enamel|ENAMEL, DECREASED	Decrease in the amount of enamel.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163727>	C176708	Absent Follicles|FOLLICLES, ABSENT	Absence of follicles.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163728>	C176708	Decreased Follicles|FOLLICLES, DECREASED	Decreased number and/or size of follicles.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163729>	C176708	Decreased Follicles and Absent Follicles|FOLLICLES, DECREASED/FOLLICLES, ABSENT|Follicles, Decreased/Absent	A finding that generally has features of decreased follicles and absent follicles.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16372>	C25464	Belarus|112|BELARUS|BELARUS|BLR|BLR|BY|Byelarus	A country in eastern Europe, east of Poland and north of Ukraine.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C163730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163730>	C176708	Increased Follicles|FOLLICLES, INCREASED	Increased number and/or size of follicles.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163731>	C110937	Growth Plate Partially Closed|GROWTH PLATE PARTIALLY CLOSED|Physis Partially Closed	A finding indicating that the epiphyseal plate is partially calcified.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163732>	C35959	Increased Mitotic Activity|Increased Mitotic Figures|MITOTIC FIGURES, INCREASED	An increase in the frequency of mitotic activity.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163733>	C124570	Persistent Thyroglossal Duct|PERSISTENT THYROGLOSSAL DUCT	Incomplete and delayed regression of the thyroglossal duct.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163734>	C22188	Persistent X-Zone|PERSISTENT X-ZONE	Incomplete and delayed regression of the X-zone.			Body Part, Organ, or Organ Component	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163735>	C186225	Proteinaceous Fluid in the Aqueous Humor|PROTEINACEOUS FLUID, AQUEOUS HUMOR	The aqueous humor contains a higher than normal amount of protein.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163736>	C4086	Thyroid Dysplasia|THYROID DYSPLASIA	A transformation of the cells of the thyroid characterized by enlarged follicular cells, apically displaced nuclei, and large intracellular vacuole with homogeneous eosinophilic content located at the base of follicular epithelial cells. (INHAND)			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163737>	C124570	Ultimobranchial Cyst|ULTIMOBRANCHIAL CYST	A congenital remnant of the embryonic ultimobranchial duct is present.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163738>	C49556	Challenge Agent Characterization Domain|AC|Challenge Agent Characterization	A domain utilized for the submission of information encompassing and representing data, vocabulary or records related to challenge agents.			Idea or Concept	CDISC SEND Domain Abbreviation Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163739>	C120936	Corrected Minute Volume|MVCR|Minute Volume Adjusted|Minute Volume, Corrected|Minute Volume, Corrected|Mvadj	A measurement of the minute volume, which has been calculated using the corrected tidal volume.			Diagnostic Procedure	CDISC SEND Respiratory Test Code Terminology|CDISC SEND Respiratory Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16373>	C16393	Cadherin	The cadherins are transmembrane glycoproteins involved in calcium dependent specific cell-cell adhesion through homophilic binding. They are crucial for morphogenesis and synapse formation, but also are involved in tumor invasion. The classical cadherins have five homologous extracellular domains and a cytosolic domain which binds through catenin to the cytoskeleton. The extracellular domains are immunoglobulin-like beta-sandwiches comprising usually 7 strands in the two sheets.			Amino Acid, Peptide, or Protein	
C163740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163740>	C111324	Corrected Tidal Volume|TVCR|Tidal Volume, Adjusted|Tidal Volume, Corrected|Tidal Volume, Corrected|Tvadj	A measurement of the tidal volume, corrected using an adjustment factor that takes into account temperature, pressure, and humidity.			Quantitative Concept	CDISC SEND Respiratory Test Code Terminology|CDISC SEND Respiratory Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163741>	C161039	Chinchilla Bastard Rabbit|CHB|CHB Rabbit Strain	A grey-black lagomorph with pigmented eyes derived from a cross between a chinchilla rabbit and New Zealand White rabbit.			Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163742>	C161039	Himalayan Chinchilla Bastard Rabbit|CHBB:HM|CHBB:HM Rabbit Strain|Himalayan Rabbit	A medium sized lagomorph that is mostly white with colored points on the feet, ears, tail and muzzle. It has a double copy of the ch gene.			Mammal	CDISC SEND Laboratory Animal Strain Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163743>	C23044	Trypan Blue Staining Method|TRYPAN BLUE STAIN	A microscopy staining method that utilizes trypan blue, an acid azo dye that can traverse the cell membrane of dead cells and is used to differentiate between living and dead cells.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C163744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163744>	C180963	EGFR NM_005228.2:c.2499G>T|EGFR c.2499G>T|ERBB c.2499G>T|ERBB1 c.2499G>T|Epidermal Growth Factor Receptor Gene c.2499G>T|HER1 c.2499G>T|NM_005228.2:c.2499G>T	A nucleotide substitution at position 2499 of the coding sequence of the EGFR gene where guanine has been mutated to thymine.	EGFR NM_005228.2:c.2499G>T		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C163746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163746>	C98356	EGFR NP_005219.2:p.L833F|EGFR L833F|EGFR L833F Mutation|EGFR Leu833Phe|EGFR NP_005219.2:p.Leu833Phe|EGFR p.L833F|EGFR p.Leu833Phe|Epidermal Growth Factor Receptor L833F|Epidermal Growth Factor Receptor Leu833Phe|NP_005219.2:p.L833F|NP_005219.2:p.Leu833Phe|Proto-Oncogene c-ErbB-1 L833F|Proto-Oncogene c-ErbB-1 Leu833Phe|Receptor Tyrosine-Protein Kinase erbB-1 L833F|Receptor Tyrosine-Protein Kinase erbB-1 Leu833Phe	A change in the amino acid residue at position 833 in the epidermal growth factor receptor protein where leucine has been replaced by phenylalanine.	EGFR NP_005219.2:p.L833F		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C163747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163747>	C215448	Device Setting	The user preferences that are entered into a control panel or other platform and regulate the activity of a device.			Conceptual Entity	
C163748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163748>	C210011|C210010	Chlamydia pneumoniae Antibody Measurement	The determination of the amount of Chlamydia pneumoniae antibody present in a sample.			Laboratory Procedure	
C163749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163749>	C222543|C180953	EGFR NM_005228.5:c.2305G>T|EGFR c.2305G>T|ERBB c.2305G>T|ERBB1 c.2305G>T|Epidermal Growth Factor Receptor Gene c.2305G>T|HER1 c.2305G>T|NM_005228.5:c.2305G>T	A nucleotide substitution at position 2305 of the coding sequence of the EGFR gene where guanine has been mutated to thymine.	EGFR NM_005228.5:c.2305G>T		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C16374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16374>	C16754	Calcium Channel	An ion channel with selective permeability to calcium.			Amino Acid, Peptide, or Protein	
C163750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163750>	C210011|C210010	Mycoplasma pneumoniae Antibody Measurement	The determination of the amount of Mycoplasma pneumoniae antibody present in a sample.			Laboratory Procedure	
C163751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163751>	C210011|C210010	Rubella Antibody Measurement	The determination of the amount of Rubella antibody present in a sample.			Laboratory Procedure	
C163752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163752>	C98356	EGFR NP_005219.2:p.V769L|EGFR NP_005219.2:p.Val769Leu|EGFR V769L|EGFR V769L Mutation|EGFR Val769Leu|EGFR p.V769L|EGFR p.Val769Leu|Epidermal Growth Factor Receptor V769L|Epidermal Growth Factor Receptor Val769Leu|NP_005219.2:p.V769L|NP_005219.2:p.Val769Leu|Proto-Oncogene c-ErbB-1 V769L|Proto-Oncogene c-ErbB-1 Val769Leu|Receptor Tyrosine-Protein Kinase erbB-1 V769L|Receptor Tyrosine-Protein Kinase erbB-1 Val769Leu	A change in the amino acid residue at position 769 in the epidermal growth factor receptor protein where valine has been replaced by leucine.	EGFR NP_005219.2:p.V769L		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C163753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163753>	C574	Liposomal Alpha Galactosylceramide|Liposomal KRN-7000|Liposomal RGI-7000|Liposomal alpha-GalCer|RGI 2001|RGI-2001|RGI2001	A liposomal formulation of alpha galactosylceramide, a synthetic glycolipid isolated from the Okinawan marine sponge (Agelas mauritianus) with potential immunosuppressing activity. Upon administration, alpha galactosylceramide serves as a ligand for CD1d which is expressed on various antigen-presenting cells (APCs) including dendritic cells (DCs), macrophages, and B-cells. This induces the activation of the immunoregulatory invariant natural killer T-cells (iNKTs), which induces the expansion of tolerogenic regulatory DCs and, in turn, regulatory T-cells (Tregs). Tregs may specifically suppress T-cell responses against host alloantigens, thereby reducing graft rejection while maintaining normal immune cell function. CD1d is a non-polymorphic, major histocompatibility complex (MHC) class I-like antigen-presenting molecule with an antigen-binding groove adapted for the presentation of lipid antigens.	Liposomal Alpha Galactosylceramide		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C163754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163754>	C84392|C53543	Intellectual Developmental Disorder, Autosomal Dominant 40|MRD40|Mental Retardation, Autosomal Dominant 40	An autosomal dominant condition caused by mutation(s) in the CHAMP1 gene, encoding chromosome alignment-maintaining phosphoprotein 1. It is characterized by moderate to severe intellectual disability with poor speech acquisition. Variable dysmorphic features may be present as well.			Disease or Syndrome	Cellosaurus Disease Terminology
C163755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163755>	C85065	Short-Rib Thoracic Dysplasia 3 with or without Polydactyly|SRTD3	An autosomal recessive type of short rib-polydactyly syndrome caused by mutation(s) in the DYNC2H1 gene, encoding cytoplasmic dynein 2 heavy chain 1. Additionally, there is evidence that it may be caused by digenic biallelic mutation in DYNC2H1 and in NEK1 (the latter encoding serine/threonine-protein kinase Nek1). It is characterized by a constricted thoracic cage, short ribs, and a 'trident' appearance of the acetabular roof. Polydactyly may or may not be present.			Disease or Syndrome	Cellosaurus Disease Terminology
C163756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163756>	C82341	Spinocerebellar Ataxia Type 19/22|SCA 19/22	An autosomal dominant form of spinocerebellar ataxia (SCA), caused by mutation(s) in the KCND3 gene, encoding potassium voltage-gated channel subfamily D member 3. SCA19 and SCA22 were initially described independently, but the molecular basis for both conditions is mutation(s) in the KCND3 gene.			Disease or Syndrome	Cellosaurus Disease Terminology
C163757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163757>	C162534	Liver Surgery Patient	A person who is undergoing a surgical procedure that includes the liver.	Liver Surgery Patient		Patient or Disabled Group	CTRP Intervention Terminology|CTRP Terminology
C163758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163758>	C274	Targeted Therapy Agent|Anti-tumor Targeted Therapy Agent|Molecularly Targeted Therapy Agent|Targeted Agent|Targeted Therapeutic Agent|Targeting	Any agent that specifically targets or interferes with the synthesis or function of a molecule that is expressed specifically in or on cells of the tumor and/or the tumor microenvironment (TME), such as immune cells or surrounding blood vessels. The targeted molecule is usually overexpressed or mutated in tumors but minimally or not expressed by normal, healthy tissues; additionally, expression is typically associated with tumor cell proliferation, progression and/or survival. By blocking the function or expression of the tumor-associated target, the targeted therapy agent may exert potential antineoplastic and/or immunomodulatory activities.			Chemical Viewed Functionally	NCIt Antineoplastic Agent Terminology
C163759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163759>	C3824	Central Nervous System Lesion	A localized pathological or traumatic structural change, damage, deformity, or discontinuity in the central nervous system.	Central Nervous System Lesion		Finding	CTRP Disease Terminology|CTRP Terminology
C16375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16375>	C21214	Calmodulin|CALM|CALM1|CALM2|CALM3|CAM|CaM|Calmodulin 1|Calmodulin 2|Calmodulin 3|Calmodulin-1|Calmodulin-2|Calmodulin-3|Phosphorylase Kinase Delta|Phosphorylase Kinase Delta Subunit|Phosphorylase Kinase Subunit Delta	Calmodulin (149 aa, ~17 kDa) is encoded by the human CALM1, CALM2 and CALM3 genes. This protein plays a role in the regulation of a number of enzymes, ion channels and signaling pathways.	Calmodulin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C163760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163760>	C163758	HER2-targeting Agent|ERBB2-Targeting Agent	Any agent that targets the receptor tyrosine kinase human epidermal growth factor receptor 2 (HER2/neu; HER-2; erbB-2).	HER2-targeting Agent		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C163761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163761>	C20189	Feasibility	The state or degree of being easily or conveniently done, used, made, or dealt with.			Conceptual Entity	
C163762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163762>	C1511	Zirconium Zr 89-TAK-164|89Zr-TAK-164	A radioimmunoconjugate composed of TAK-164, an antibody-drug conjugate (ADC) comprised of a full-length, human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) directed against the extracellular domain of guanylyl cyclase C (GCC; GUCY2C) conjugated to the DNA alkylator DGN549 (IGN-P1), and linked to the radioisotope zirconium Zr 89 (Zr89), with potential use in imaging of GCC-expressing tumor cells upon positron emission tomography (PET). Upon administration of zirconium Zr 89-TAK-164, the TAK-164 moiety targets and binds to GCC. After binding, Zr89 facilitates the visualization and detection of GCC-expressing tumor cells using PET. This assesses GCC-expression and may predict or evaluate the tumor's response to TAK-164.	Zirconium Zr 89-TAK-164		Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C163763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163763>	C158375	Craniotomy Patient	A patient who is undergoing a craniotomy.	Craniotomy Patient		Patient or Disabled Group	CTRP Intervention Terminology|CTRP Terminology
C163764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163764>	C163759	Brain Lesion	A localized pathological or traumatic structural change, damage, deformity, or discontinuity of the brain.	Brain Lesion		Finding	CTRP Disease Terminology|CTRP Terminology
C163765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163765>	C171646|C137685	Lymphoblasts Less than 5 Percent of Bone Marrow Nucleated Cells|Lymphoblasts Under 5 Percent of Bone Marrow Nucleated Cells|Lymphoblasts Under 5% of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that less than 5 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells of lymphoid origin.	Lymphoblasts Less than 5 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C163766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163766>	C217121	Illness Intrusiveness Ratings Scale|IIRS|Illness Intrusiveness Ratings Scale (IIRS)	A questionnaire and scale designed to assess the extent that a person's illness, and/or its treatment, interferes with aspects of their life. Responses range from 1: Not Very Much to 7: Very Much.			Intellectual Product	
C163767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163767>	C221059	Illness Intrusiveness Rating 1|1|Not Very Much	A response of 1 on an illness intrusiveness scale that ranges from 1: Not Very Much to 7: Very Much.			Intellectual Product	
C163768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163768>	C221059	Illness Intrusiveness Rating 2|2	A response of 2 on an illness intrusiveness scale that ranges from 1: Not Very Much to 7: Very Much.			Intellectual Product	
C163769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163769>	C221059	Illness Intrusiveness Rating 3|3	A response of 3 on an illness intrusiveness scale that ranges from 1: Not Very Much to 7: Very Much.			Intellectual Product	
C16376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16376>	C17325	Mitogen-Activated Protein Kinase|EC 2.7.2-|ERK|Extracellular Signal-Regulated Kinases|MAPK|Map Kinase	Mitogen-activated protein kinases (MAPKs) are serine-threonine protein kinases activated in response to a variety of extracellular stimuli and encoded by a multigene family. The MAPKs are part of complex protein kinase cascades. One of the several classes of MAPKs includes (among other ERKs) the extracellular signal-regulated kinases ERK1 (p44MAPK) and ERK2 (p42MAPK), activated by the RAF/MEK/ERK signaling pathway. ERK1/2 are widely involved in eukaryotic signal transduction. Upon activation, ERKs translocate to the nucleus and phosphorylate nuclear targets. Phosphorylated ERKs form essential dimers with phosphorylated and unphosphorylated ERK partners. Dimerization is part of the mechanism of MAP kinase family action. Mitogen-activated protein kinases (MAPKs) promote entry in the cell cycle.  (from OMIM 601795, 176948, Swiss-Prot P27361, P28482 and NCI)	Mitogen-Activated Protein Kinase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C163770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163770>	C221059	Illness Intrusiveness Rating 4|4	A response of 4 on an illness intrusiveness scale that ranges from 1: Not Very Much to 7: Very Much.			Intellectual Product	
C163771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163771>	C221059	Illness Intrusiveness Rating 5|5	A response of 5 on an illness intrusiveness scale that ranges from 1: Not Very Much to 7: Very Much.			Intellectual Product	
C163772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163772>	C221059	Illness Intrusiveness Rating 6|6	A response of 6 on an illness intrusiveness scale that ranges from 1: Not Very Much to 7: Very Much.			Intellectual Product	
C163773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163773>	C221059	Illness Intrusiveness Rating 7|7|Very Much	A response of 7 on an illness intrusiveness scale that ranges from 1: Not Very Much to 7: Very Much.			Intellectual Product	
C163774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163774>	C163758	BTK-targeting Agent	Any agent that targets Bruton's agammaglobulinemia tyrosine kinase (BTK).			Chemical Viewed Functionally	
C163775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163775>	C173812|C173584	How Much Does Illness and/or Treatment Interfere with Health Question|How Much Does Illness and/or Treatment Interfere with Health|How much does your illness and/or its treatment interfere with your HEALTH	A question about how much an individual's illness and/or treatment interferes with their health.			Intellectual Product	Illness Intrusiveness Ratings Scale
C163776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163776>	C173812|C173584	How Much Does Illness and/or Treatment Interfere with Diet Question|How Much Does Illness and/or Treatment Interfere with Diet|How much does your illness and/or its treatment interfere with your DIET	A question about how much an individual's illness and/or treatment interferes with their diet.			Intellectual Product	Illness Intrusiveness Ratings Scale
C163777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163777>	C173924|C173812|C173584	How Much Does Illness and/or Treatment Interfere with Work Question|How Much Does Illness and/or Treatment Interfere with Work|How much does your illness and/or its treatment interfere with your WORK	A question about how much an individual's illness and/or treatment interferes with their work.			Intellectual Product	Illness Intrusiveness Ratings Scale
C163778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163778>	C173812|C173584	How Much Does Illness and/or Treatment Interfere with Active Recreation Question|How Much Does Illness and/or Treatment Interfere with Active Recreation|How much does your illness and/or its treatment interfere with your ACTIVE RECREATION	A question about how much an individual's illness and/or treatment interferes with their active recreation.			Intellectual Product	Illness Intrusiveness Ratings Scale
C163779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163779>	C173812|C173584	How Much Does Illness and/or Treatment Interfere with Passive Recreation Question|How Much Does Illness and/or Treatment Interfere with Passive Recreation|How much does your illness and/or its treatment interfere with your PASSIVE RECREATION	A question about how much an individual's illness and/or treatment interferes with their passive recreation.			Intellectual Product	Illness Intrusiveness Ratings Scale
C16377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16377>	C16481	Calpain|Calcium-Activated Neutral Protease|Calcium-Activated Neutral Proteinase|Papain-Like Cysteine Protease	A class of calcium-dependent thiol-proteases that proteolytically cleave a wide variety of cytoskeletal, membrane-associated, and regulatory proteins. There are two main isoforms of the protein, which differ in their calcium requirement for activation. These enzymes have been linked to both acute and chronic neurodegenerative processes, such as: ischemia, trauma, and Alzheimer's disease.			Amino Acid, Peptide, or Protein|Enzyme	
C163780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163780>	C187306|C173812|C173584	How Much Does Illness and/or Treatment Interfere with Financial Situation Question|How Much Does Illness and/or Treatment Interfere with Financial Situation|How much does your illness and/or its treatment interfere with your FINANCIAL SITUATION	A question about how much an individual's illness and/or treatment interferes with their financial situation.			Intellectual Product	Illness Intrusiveness Ratings Scale
C163781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163781>	C173812|C173584	How Much Does Illness and/or Treatment Interfere with Relationship with Spouse Question|How Much Does Illness and/or Treatment Interfere with Relationship with Spouse|How much does your illness and/or its treatment interfere with your RELATIONSHIP WITH YOUR SPOUSE	A question about how much an individual's illness and/or treatment interferes with their relationship with their spouse.			Intellectual Product	Illness Intrusiveness Ratings Scale
C163782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163782>	C173812|C173704|C173584	How Much Does Illness and/or Treatment Interfere with Sex Life Question|How Much Does Illness and/or Treatment Interfere with Sex Life|How much does your illness and/or its treatment interfere with your SEX LIFE	A question about how much an individual's illness and/or treatment interferes with their sex life.			Intellectual Product	Illness Intrusiveness Ratings Scale
C163783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163783>	C173812|C173584|C173151	How Much Does Illness and/or Treatment Interfere with Family Relations Question|How Much Does Illness and/or Treatment Interfere with Family Relations|How much does your illness and/or its treatment interfere with your FAMILY RELATIONS	A question about how much an individual's illness and/or treatment interferes with their family relations.			Intellectual Product	Illness Intrusiveness Ratings Scale
C163784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163784>	C173812|C173584	How Much Does Illness and/or Treatment Interfere with Other Social Relations Question|How Much Does Illness and/or Treatment Interfere with Other Social Relations|How much does your illness and/or its treatment interfere with your OTHER SOCIAL RELATIONS	A question about how much an individual's illness and/or treatment interferes with their social relations.			Intellectual Product	Illness Intrusiveness Ratings Scale
C163785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163785>	C173812|C173584	How Much Does Illness and/or Treatment Interfere with Self-Expression or Self-Improvement Question|How Much Does Illness and/or Treatment Interfere with Self-Expression or Self-Improvement|How much does your illness and/or its treatment interfere with your SELF-EXPRESSION/SELF-IMPROVEMENT	A question about how much an individual's illness and/or treatment interferes with their self-expression or self-improvement.			Intellectual Product	Illness Intrusiveness Ratings Scale
C163786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163786>	C173812|C173584	How Much Does Illness and/or Treatment Interfere with Religious Expression Question|How Much Does Illness and/or Treatment Interfere with Religious Expression|How much does your illness and/or its treatment interfere with your RELIGIOUS EXPRESSION	A question about how much an individual's illness and/or treatment interferes with their religious expression.			Intellectual Product	Illness Intrusiveness Ratings Scale
C163787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163787>	C173812|C173584	How Much Does Illness and/or Treatment Interfere with Community and Civic Involvement Question|How Much Does Illness and/or Treatment Interfere with Community and Civic Involvement|How much does your illness and/or its treatment interfere with your COMMUNITY AND CIVIC INVOLVEMENT	A question about how much an individual's illness and/or treatment interferes with their community and civic involvement.			Intellectual Product	Illness Intrusiveness Ratings Scale
C163788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163788>	C86586	Active Recreation	Outdoor recreational activities, such as organized sports, playground activities, and the use of motorized vehicles, that require extensive facilities or development or that have a considerable environmental impact on the recreational site.			Daily or Recreational Activity	
C163789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163789>	C86586	Passive Recreation	Outdoor recreational activities, such as nature observation, hiking, and canoeing or kayaking, that require a minimum of facilities or development and that have minimal environmental impact on the recreational site.			Daily or Recreational Activity	
C16378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16378>	C25464	Cambodia|116|CAMBODIA|CAMBODIA|KH|KHM|KHM|Kampuchea	A country in southeastern Asia, bordering the Gulf of Thailand, between Thailand, Vietnam, and Laos.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C163790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163790>	C163758	Flt-3-targeting Agent	Any agent that targets Flt-3 (Flt3).			Chemical Viewed Functionally	
C163791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163791>	C20993	Reproductive Concerns After Cancer|RCAC|Reproductive Concerns After Cancer (RCAC)	A scale that measures concerns related to fertility and parenthood for young adult female cancer survivors, including concerns about fertility potential, partner disclosure, child's health, personal health, acceptance, and becoming pregnant.			Intellectual Product	
C163792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163792>	C173978|C173047|C173045	Afraid Won't be Able to Have (More) Children Question|Afraid Won't be Able to Have (More) Children|I am afraid I won't be able to have any (more) children.	A question about whether an individual is afraid they won't be able to have any, or more, children.			Intellectual Product	Reproductive Concerns After Cancer
C163793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163793>	C173934	Worried About Passing on Genetic Risk for Cancer to Children Question|I am worried about passing on a genetic risk for cancer to my children|Worried About Passing on Genetic Risk for Cancer to Children	A question about whether an individual is worried about passing on a genetic risk for cancer to their children.			Intellectual Product	Reproductive Concerns After Cancer
C163794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163794>	C173978|C173934|C173045	Worry About Telling Spouse or Partner May be Unable to Have Children Question|I worry about telling my (potential) spouse/partner that I may be unable to have children|Worry About Telling Spouse or Partner May be Unable to Have Children|Worry About Telling Spouse or Partner May be Unable to Have Children	A question about whether an individual is worried about telling their current or potential spouse or partner that they may be unable to have children.			Intellectual Product	Reproductive Concerns After Cancer
C163795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163795>	C91102	Scared of Not Being Around to Take Care of Children Someday Question|I am scared of not being around to take care of my children someday|Scared of Not Being Around to Take Care of Children Someday	A question about whether an individual is scared of not being around to take care of their children someday.			Intellectual Product	Reproductive Concerns After Cancer
C163796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163796>	C173978|C173045	Can Accept if I am Unable to Have (More) Children Question|Can Accept if I am Unable to Have (More) Children|I can accept it if I'm unable to have (more) children	A question about whether an individual can accept if they are unable to have any, or more, children.			Intellectual Product	Reproductive Concerns After Cancer
C163797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163797>	C173597	Overwhelmed by Thought of Trying to get Pregnant Question|I am overwhelmed by the thought of trying to get pregnant (again)|Overwhelmed by Thought of Trying to get Pregnant	A question about whether an individual is overwhelmed by the thought of trying to get pregnant.			Intellectual Product	Reproductive Concerns After Cancer
C163798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163798>	C173084	Concerned that Spouse or Partner Will be Disappointed if Can't Get Pregnant Question|Concerned that Spouse or Partner Will be Disappointed if Can't Get Pregnant|I am concerned that my (potential) spouse/partner will be disappointed if I can't get pregnant	A question about whether an individual is concerned that their current or potential spouse or partner will be disappointed if they can't get pregnant.			Intellectual Product	Reproductive Concerns After Cancer
C163799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163799>	C173934	Worried About Ability to Get Pregnant Question|I am worried about my ability to get pregnant (again)|Worried About Ability to Get Pregnant	A question about whether an individual is worried about their ability to get pregnant.			Intellectual Product	Reproductive Concerns After Cancer
C16379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16379>	C25464	Cameroon|120|CAMEROON|CAMEROON|CM|CMR|CMR	A country in western Africa, bordering the Gulf of Guinea, between Equatorial Guinea and Nigeria.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C1637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1637>	C471	Xanthine Oxidase Inhibitor	Any substance that inhibits xanthine oxidase, an enzyme that catalyzes the oxidation of hypoxanthine to xanthine and xanthine to uric acid, along with the generation of reactive oxygen species (ROS). Inhibition of xanthine oxidase can reduce the production of uric acid.			Chemical Viewed Functionally	
C163800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163800>	C173934|C173890|C173151	Worried About How Family History Might Affect Children's Health Question|I am worried about how my family history might affect my children's health|Worried About How Family History Might Affect Children's Health	A question about whether an individual is worried about how their family history might affect their children's health.			Intellectual Product	Reproductive Concerns After Cancer
C163801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163801>	C173978|C173160	Will Be Happy with Life Whether or Not I Have (More) Children Someday Question|I will be happy with life whether or not I have (more) children someday|Will Be Happy with Life Whether or Not I Have (More) Children Someday	A question about whether an individual will be happy with life whether or not they have any, or more, children someday.			Intellectual Product	Reproductive Concerns After Cancer
C163802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163802>	C173978	Having (More) Children Will Make me More Nervous About Getting Cancer Again Question|Having (More) Children Will Make me More Nervous About Getting Cancer Again|Having (more) children will make me more nervous about getting cancer again	A question about whether an having any, or more, children will make an individual nervous about getting cancer again.			Intellectual Product	Reproductive Concerns After Cancer
C163803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163803>	C173934	Worry that Getting Pregnant Would Take Too Much Time and Effort Question|I worry that getting pregnant (again) would take too much time and effort|Worry that Getting Pregnant Would Take Too Much Time and Effort	A question about whether an individual worries that getting pregnant (again) would take too much time and effort.			Intellectual Product	Reproductive Concerns After Cancer
C163804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163804>	C173978	Am Cautious About Having (More) Children Because Might Not be Around to Raise Them Question|Am Cautious About Having (More) Children Because Might Not be Around to Raise Them|I am cautious about having (more) children because I might not be around to raise them	A question about whether an individual is cautious about having any, or more, children because they might not be around to raise them.			Intellectual Product	Reproductive Concerns After Cancer
C163805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163805>	C173597	Stressful to Think About Trying to Get Pregnant Question|It is stressful to think about trying to get pregnant (again)|Stressful to Think About Trying to Get Pregnant	A question about whether it is stressful for an individual to think about trying to get pregnant.			Intellectual Product	Reproductive Concerns After Cancer
C163806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163806>	C173978|C173160	Will Feel Content if do Not Have (More) Children Question|I will feel content if I do not have (more) children|Will Feel Content if do Not Have (More) Children	A question about whether an individual will feel content if they do not have any, or more, children.			Intellectual Product	Reproductive Concerns After Cancer
C163807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163807>	C2124	Fluorine F 18-AlF-cys-variant 3 pH Low Insertion Peptides|18F-AlF-Var3 pHLIP|Fluorine F 18-cys-Var3 pHLIP|[18F]AlF-cysVar3 pHLIP	A radioconjugate composed of pH (low) insertion peptides (pHLIP) variant 3 (Var3) conjugated, via a cysteine residue, to fluorine F 18-labeled aluminum fluoride (AlF) complex, with potential use as an imaging agent for the acidic extracellular environment surrounding tumors upon positron emission tomography (PET). Upon administration of fluorine F 18-AlF-cys-Var3 pHLIP, the Var3 pHLIP moiety specifically targets, tightly binds to and gets inserted into the cellular membrane of tumor cells in environments with low extracellular pH. Upon PET, tumor cells and the extent of acidity can be visualized and assessed using PET. Tumor cell environments are more acidic than normal, healthy tissue environments. The pHLIPs specifically fold into an alpha-helical conformation and become inserted across the membrane at low extracellular pH whereas they are unfolded and unbound at higher pHs.	Fluorine F 18-AlF-cys-variant 3 pH Low Insertion Peptides		Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C163808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163808>	C173978|C173597	Thought of Telling Spouse or Partner that I May be Unable to Have Children Makes me Uncomfortable Question|The thought of telling my (potential) spouse/partner that I may be unable to have children makes me uncomfortable|Thought of Telling Spouse or Partner that I May be Unable to Have Children Makes me Uncomfortable	A question about whether the thought of telling their current or potential spouse or partner that they may be unable to have children makes an individual uncomfortable.			Intellectual Product	Reproductive Concerns After Cancer
C163809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163809>	C173978|C173084|C173045	Concerned May Not be Able to Have (More) Children Question|Concerned May Not be Able to Have (More) Children|I am concerned that I may not be able to have (more) children	A question about whether an individual is concerned that they may not be able to have any, or more, children.			Intellectual Product	Reproductive Concerns After Cancer
C16380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16380>	C25464	Canada|124|CA|CAN|CAN|CANADA|CANADA	A country in northern North America, bordering the North Atlantic Ocean on the east, North Pacific Ocean on the west, and the Arctic Ocean on the north, north of the conterminous US.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF1 Registration Table|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C163810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163810>	C173890|C173047	Afraid Children Would Have High Chance of Getting Cancer Question|Afraid Children Would Have High Chance of Getting Cancer|I am afraid my children would have a high chance of getting cancer	A question about whether an individual is afraid that their children would have a high chance of getting cancer.			Intellectual Product	Reproductive Concerns After Cancer
C163811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163811>	C91105	Asthma Daytime Symptom Diary V1.0 Questionnaire|ADSD V1.0|ADSD Version 1.0|ADSD01	A six-item self-administered questionnaire, developed by Gater et al. in 2016, that utilizes a ten-point rating scale to assess a patient's experience with core asthma symptoms during the preceding day, including difficulty breathing, wheezing, shortness of breath, chest tightness, chest pain, and cough.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163812>	C91105	Asthma Nighttime Symptom Diary V1.0 Questionnaire|ANSD V1.0|ANSD Version 1.0|ANSD01	A six-item self-administered questionnaire, developed by Gater et al. in 2016, that utilizes a ten-point rating scale to assess a patient's experience with core asthma symptoms during the preceding night, including difficulty breathing, wheezing, shortness of breath, chest tightness, chest pain, and cough.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163813>	C91105	Generalized Anxiety Disorder - 7 Version 2 Questionnaire|GAD-7 V2|GAD-7 Version 2|GAD02	A revised version of the Generalized Anxiety Disorder - 7 Questionnaire, which is a seven-item, self-administered assessment tool published by Spitzer et al. in 2006 that utilizes a four-point rating scale to screen for and measure the severity of generalized anxiety disorder. The revised questionnaire has alternative wording in two of the rating scale options, and does not include the supplementary question at the end of the questionnaire.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163814>	C91105	The Glucose Monitoring Satisfaction Survey Version: Type 1 Diabetes Questionnaire|GMSS VERSION TYPE 1 DIABETES|GMSS Version Type 1 Diabetes|GMSS01	A 15-item self-administered questionnaire, published by Polonsky et al. in 2015, that utilizes a five-point rating scale to assess patient treatment satisfaction with glucose monitoring devices for type 1 diabetes; the instrument includes four subscales that address openness, emotional burden, behavioral burden, and trust.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163815>	C91105	Hypoglycemic Confidence Scale Questionnaire|HCS|HCS|HCS01	A nine-item self-administered questionnaire, published by Polonsky et al. in 2017, that utilizes a four-point rating scale to assess the degree to which patients with diabetes feel secure regarding their ability to stay safe from hypoglycemia-related problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163816>	C91105	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes Questionnaire|DDS02|PARENT-DDS|PARENT-DDS	A 20-item self-administered questionnaire, published by Hessler et al. in 2016, that utilizes a five-point rating scale to assess diabetes distress in parents of teens with type 1 diabetes; the instrument includes four subscales that address key dimensions of parent-related distress, including personal distress, teen management distress, parent/teen relationship distress and healthcare team distress.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163817>	C91105	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes Questionnaire|DDS03|PARTNER-DDS|PARTNER-DDS	A 21-item self-administered questionnaire, published by Hessler et al. in 2016, that utilizes a five-point rating scale to assess diabetes distress in partners of adults with type 1 diabetes; the instrument includes four subscales that address key dimensions of partner-related distress, including "my partner's diabetes management", "how best to help", "diabetes and me", and hypoglycemia.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163818>	C163398	ADSD Version 1.0 - Rate Breathing at Its Worst|ADSD01-Rate Breathing at Its Worst|ADSD01-Rate Breathing at Its Worst|ADSD0101	Asthma Daytime Symptom Diary V1.0 (ADSD Version 1.0) Please rate your difficulty breathing at its worst since you got up this morning.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADSD Version 1.0 Test Code Terminology|CDISC Questionnaire ADSD Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163819>	C163398	ADSD Version 1.0 - Rate Wheezing at Its Worst|ADSD01-Rate Wheezing at Its Worst|ADSD01-Rate Wheezing at Its Worst|ADSD0102	Asthma Daytime Symptom Diary V1.0 (ADSD Version 1.0) Please rate your wheezing at its worst since you got up this morning.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADSD Version 1.0 Test Code Terminology|CDISC Questionnaire ADSD Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163820>	C163398	ADSD Version 1.0 - Rate Shortness of Breath at Worst|ADSD01-Rate Shortness of Breath at Worst|ADSD01-Rate Shortness of Breath at Worst|ADSD0103	Asthma Daytime Symptom Diary V1.0 (ADSD Version 1.0) Please rate your shortness of breath at its worst since you got up this morning.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADSD Version 1.0 Test Code Terminology|CDISC Questionnaire ADSD Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163821>	C163398	ADSD Version 1.0 - Rate Chest Tightness at Its Worst|ADSD01-Rate Chest Tightness at Its Worst|ADSD01-Rate Chest Tightness at Its Worst|ADSD0104	Asthma Daytime Symptom Diary V1.0 (ADSD Version 1.0) Please rate your chest tightness at its worst since you got up this morning.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADSD Version 1.0 Test Code Terminology|CDISC Questionnaire ADSD Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163822>	C163398	ADSD Version 1.0 - Rate Chest Pain at Its Worst|ADSD01-Rate Chest Pain at Its Worst|ADSD01-Rate Chest Pain at Its Worst|ADSD0105	Asthma Daytime Symptom Diary V1.0 (ADSD Version 1.0) Please rate your chest pain at its worst since you got up this morning.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADSD Version 1.0 Test Code Terminology|CDISC Questionnaire ADSD Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163823>	C163398	ADSD Version 1.0 - Rate Cough at Its Worst|ADSD01-Rate Cough at Its Worst|ADSD01-Rate Cough at Its Worst|ADSD0106	Asthma Daytime Symptom Diary V1.0 (ADSD Version 1.0) Please rate your cough at its worst since you got up this morning.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADSD Version 1.0 Test Code Terminology|CDISC Questionnaire ADSD Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163824>	C163398	ADSD Version 1.0 - Total Score|ADSD01-Total Score|ADSD01-Total Score|ADSD0107	Asthma Daytime Symptom Diary V1.0 (ADSD Version 1.0) Total score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ADSD Version 1.0 Test Code Terminology|CDISC Questionnaire ADSD Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163825>	C163399	ANSD Version 1.0 - Rate Breathing at Its Worst|ANSD01-Rate Breathing at Its Worst|ANSD01-Rate Breathing at Its Worst|ANSD0101	Asthma Nighttime Symptom Diary V1.0 (ANSD Version 1.0) Please rate your difficulty breathing at its worst since you went to bed last night.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ANSD Version 1.0 Test Code Terminology|CDISC Questionnaire ANSD Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163826>	C163399	ANSD Version 1.0 - Rate Wheezing at Its Worst|ANSD01-Rate Wheezing at Its Worst|ANSD01-Rate Wheezing at Its Worst|ANSD0102	Asthma Nighttime Symptom Diary V1.0 (ANSD Version 1.0) Please rate your wheezing at its worst since you went to bed last night.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ANSD Version 1.0 Test Code Terminology|CDISC Questionnaire ANSD Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163827>	C163399	ANSD Version 1.0 - Rate Shortness of Breath at Worst|ANSD01-Rate Shortness of Breath at Worst|ANSD01-Rate Shortness of Breath at Worst|ANSD0103	Asthma Nighttime Symptom Diary V1.0 (ANSD Version 1.0) Please rate your shortness of breath at its worst since you went to bed last night.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ANSD Version 1.0 Test Code Terminology|CDISC Questionnaire ANSD Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163828>	C163399	ANSD Version 1.0 - Rate Chest Tightness at Its Worst|ANSD01-Rate Chest Tightness at Its Worst|ANSD01-Rate Chest Tightness at Its Worst|ANSD0104	Asthma Nighttime Symptom Diary V1.0 (ANSD Version 1.0) Please rate your chest tightness at its worst since you went to bed last night.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ANSD Version 1.0 Test Code Terminology|CDISC Questionnaire ANSD Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163829>	C163399	ANSD Version 1.0 - Rate Chest Pain at Its Worst|ANSD01-Rate Chest Pain at Its Worst|ANSD01-Rate Chest Pain at Its Worst|ANSD0105	Asthma Nighttime Symptom Diary V1.0 (ANSD Version 1.0) Please rate your chest pain at its worst since you went to bed last night.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ANSD Version 1.0 Test Code Terminology|CDISC Questionnaire ANSD Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16382>	C25464	Cabo Verde|132|CABO VERDE|CAPE VERDE|CPV|CPV|CV|Cape Verde|Cape Verde	A group of islands in the North Atlantic Ocean, west of Senegal.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C163830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163830>	C163399	ANSD Version 1.0 - Rate Cough at Its Worst|ANSD01-Rate Cough at Its Worst|ANSD01-Rate Cough at Its Worst|ANSD0106	Asthma Nighttime Symptom Diary V1.0 (ANSD Version 1.0) Please rate your cough at its worst since you went to bed last night.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ANSD Version 1.0 Test Code Terminology|CDISC Questionnaire ANSD Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163831>	C163399	ANSD Version 1.0 - Total Score|ANSD01-Total Score|ANSD01-Total Score|ANSD0107	Asthma Nighttime Symptom Diary V1.0 (ANSD Version 1.0) Total score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire ANSD Version 1.0 Test Code Terminology|CDISC Questionnaire ANSD Version 1.0 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163832>	C163400	GAD-7 Version 2 - Feeling Nervous Anxious or On Edge|GAD02-Feeling Nervous Anxious or On Edge|GAD02-Feeling Nervous Anxious or On Edge|GAD0201	Generalized Anxiety Disorder - 7 Version 2 (GAD-7 Version 2) Feeling nervous, anxious or on edge.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GAD-7 Version 2 Test Code Terminology|CDISC Questionnaire GAD-7 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163833>	C163400	GAD-7 Version 2 - Not Able to Stop or Control Worrying|GAD02-Not Able to Stop/Control Worrying|GAD02-Not Able to Stop/Control Worrying|GAD0202	Generalized Anxiety Disorder - 7 Version 2 (GAD-7 Version 2) Not being able to stop or control worrying.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GAD-7 Version 2 Test Code Terminology|CDISC Questionnaire GAD-7 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163834>	C163400	GAD-7 Version 2 - Worrying Too Much About Things|GAD02-Worrying Too Much About Things|GAD02-Worrying Too Much About Things|GAD0203	Generalized Anxiety Disorder - 7 Version 2 (GAD-7 Version 2) Worrying too much about different things.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GAD-7 Version 2 Test Code Terminology|CDISC Questionnaire GAD-7 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163835>	C163400	GAD-7 Version 2 - Trouble Relaxing|GAD02-Trouble Relaxing|GAD02-Trouble Relaxing|GAD0204	Generalized Anxiety Disorder - 7 Version 2 (GAD-7 Version 2) Trouble relaxing.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GAD-7 Version 2 Test Code Terminology|CDISC Questionnaire GAD-7 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163836>	C163400	GAD-7 Version 2 - Being Restless Hard to Sit Still|GAD02-Being Restless Hard to Sit Still|GAD02-Being Restless Hard to Sit Still|GAD0205	Generalized Anxiety Disorder - 7 Version 2 (GAD-7 Version 2) Being so restless that it is hard to sit still.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GAD-7 Version 2 Test Code Terminology|CDISC Questionnaire GAD-7 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163837>	C163400	GAD-7 Version 2 - Becoming Easily Annoyed or Irritable|GAD02-Becoming Easily Annoyed/Irritable|GAD02-Becoming Easily Annoyed/Irritable|GAD0206	Generalized Anxiety Disorder - 7 Version 2 (GAD-7 Version 2) Becoming easily annoyed or irritable.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GAD-7 Version 2 Test Code Terminology|CDISC Questionnaire GAD-7 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163838>	C163400	GAD-7 Version 2 - Feel Afraid If Something Awful Happen|GAD02-Feel Afraid/Something Awful Happen|GAD02-Feel Afraid/Something Awful Happen|GAD0207	Generalized Anxiety Disorder - 7 Version 2 (GAD-7 Version 2) Feeling afraid as if something awful might happen.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GAD-7 Version 2 Test Code Terminology|CDISC Questionnaire GAD-7 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163839>	C163400	GAD-7 Version 2 - Total Score|GAD02-Total Score|GAD02-Total Score|GAD0208	Generalized Anxiety Disorder - 7 Version 2 (GAD-7 Version 2) Total score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GAD-7 Version 2 Test Code Terminology|CDISC Questionnaire GAD-7 Version 2 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16383>	C17254	Capsid Protein|Capsid	The outer protective shell of a virus. The structure of the shell is icosahedral with either helical or complex symmetry. Capsid proteins surround and protect the viral nucleic acid core.	Capsid Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C163840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163840>	C163401	GMSS Version Type 1 Diabetes - More Satisfied With My Diabetes|GMSS01-More Satisfied With My Diabetes|GMSS01-More Satisfied With My Diabetes|GMSS0101	The Glucose Monitoring Satisfaction Survey Version: Type 1 Diabetes (GMSS Version Type 1 Diabetes) My current monitor: Helps me feel more satisfied with how things are going with my diabetes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Code Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163841>	C163401	GMSS Version Type 1 Diabetes - Think About Diabetes More|GMSS01-Think About Diabetes More|GMSS01-Think About Diabetes More|GMSS0102	The Glucose Monitoring Satisfaction Survey Version: Type 1 Diabetes (GMSS Version Type 1 Diabetes) My current monitor: Makes me think about diabetes more than I want to.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Code Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163842>	C163401	GMSS Version Type 1 Diabetes - Takes Too Much Time to Use|GMSS01-Takes Too Much Time to Use|GMSS01-Takes Too Much Time to Use|GMSS0103	The Glucose Monitoring Satisfaction Survey Version: Type 1 Diabetes (GMSS Version Type 1 Diabetes) My current monitor: Takes too much time to use.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Code Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163843>	C163401	GMSS Version Type 1 Diabetes - Doesn't Seem as Accurate|GMSS01-Doesn't Seem as Accurate|GMSS01-Doesn't Seem as Accurate|GMSS0104	The Glucose Monitoring Satisfaction Survey Version: Type 1 Diabetes (GMSS Version Type 1 Diabetes) My current monitor: Doesn't seem to be as accurate as I would like it to be.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Code Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163844>	C163401	GMSS Version Type 1 Diabetes - Makes Me Worry a Lot|GMSS01-Makes Me Worry a Lot|GMSS01-Makes Me Worry a Lot|GMSS0105	The Glucose Monitoring Satisfaction Survey Version: Type 1 Diabetes (GMSS Version Type 1 Diabetes) My current monitor: Makes me worry a lot.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Code Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163845>	C163401	GMSS Version Type 1 Diabetes - Is Too Much of a Hassle to Use|GMSS01-Is Too Much of a Hassle to Use|GMSS01-Is Too Much of a Hassle to Use|GMSS0106	The Glucose Monitoring Satisfaction Survey Version: Type 1 Diabetes (GMSS Version Type 1 Diabetes) My current monitor: Is too much of a hassle to use.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Code Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163846>	C163401	GMSS Version Type 1 Diabetes - Gives Me Numbers I Don't Trust|GMSS01-Gives Me Numbers I Don't Trust|GMSS01-Gives Me Numbers I Don't Trust|GMSS0107	The Glucose Monitoring Satisfaction Survey Version: Type 1 Diabetes (GMSS Version Type 1 Diabetes) My current monitor: Gives me numbers that I don't entirely trust.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Code Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163847>	C163401	GMSS Version Type 1 Diabetes - Feel Less Restricted by Diabetes|GMSS01-Feel Less Restricted by Diabetes|GMSS01-Feel Less Restricted by Diabetes|GMSS0108	The Glucose Monitoring Satisfaction Survey Version: Type 1 Diabetes (GMSS Version Type 1 Diabetes) My current monitor: Helps me feel less restricted by diabetes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Code Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163848>	C163401	GMSS Version Type 1 Diabetes - More Frustrated With My Diabetes|GMSS01-More Frustrated With My Diabetes|GMSS01-More Frustrated With My Diabetes|GMSS0109	The Glucose Monitoring Satisfaction Survey Version: Type 1 Diabetes (GMSS Version Type 1 Diabetes) My current monitor: Makes me feel more frustrated with my diabetes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Code Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163849>	C163401	GMSS Version Type 1 Diabetes - Be More Spontaneous in My Life|GMSS01-Be More Spontaneous in My Life|GMSS01-Be More Spontaneous in My Life|GMSS0110	The Glucose Monitoring Satisfaction Survey Version: Type 1 Diabetes (GMSS Version Type 1 Diabetes) My current monitor: Helps me be more spontaneous in my life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Code Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16384>	C16393	Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5|CD66e Antigen|CEA|CEA|CEACAM5|Carcinoembryonic Antigen|Meconium Antigen 100	Carcinoembryonic antigen-related cell adhesion molecule 5 (702 aa, ~77 kDa) is encoded by the human CEACAM5 gene. This protein is involved in cell-cell adhesion, apotosis regulation and signaling.	Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C163850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163850>	C163401	GMSS Version Type 1 Diabetes - Too Many Skin Irritations/Bruises|GMSS01-Too Many Skin Irritations/Bruises|GMSS01-Too Many Skin Irritations/Bruises|GMSS0111	The Glucose Monitoring Satisfaction Survey Version: Type 1 Diabetes (GMSS Version Type 1 Diabetes) My current monitor: Causes too many skin irritations or bruises.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Code Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163851>	C163401	GMSS Version Type 1 Diabetes - Gives Me Results Don't Make Sense|GMSS01-Gives Me Results Don't Make Sense|GMSS01-Gives Me Results Don't Make Sense|GMSS0112	The Glucose Monitoring Satisfaction Survey Version: Type 1 Diabetes (GMSS Version Type 1 Diabetes) My current monitor: Often gives me results that don't make sense.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Code Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163852>	C163401	GMSS Version Type 1 Diabetes - Feel More Down and Depressed|GMSS01-Feel More Down and Depressed|GMSS01-Feel More Down and Depressed|GMSS0113	The Glucose Monitoring Satisfaction Survey Version: Type 1 Diabetes (GMSS Version Type 1 Diabetes) My current monitor: Makes me feel more down and depressed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Code Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163853>	C163401	GMSS Version Type 1 Diabetes - More Open to New Experiences|GMSS01-More Open to New Experiences|GMSS01-More Open to New Experiences|GMSS0114	The Glucose Monitoring Satisfaction Survey Version: Type 1 Diabetes (GMSS Version Type 1 Diabetes) My current monitor: Helps me be more open to new experiences in life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Code Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163854>	C163401	GMSS Version Type 1 Diabetes - Is Too Painful to Use|GMSS01-Is Too Painful to Use|GMSS01-Is Too Painful to Use|GMSS0115	The Glucose Monitoring Satisfaction Survey Version: Type 1 Diabetes (GMSS Version Type 1 Diabetes) My current monitor: Is too painful to use.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Code Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163855>	C163401	GMSS Version Type 1 Diabetes - Subscale: Openness|GMSS01-Subscale: Openness|GMSS01-Subscale: Openness|GMSS0116	The Glucose Monitoring Satisfaction Survey Version: Type 1 Diabetes (GMSS Version Type 1 Diabetes) Subscale: Openness.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Code Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163856>	C163401	GMSS Version Type 1 Diabetes - Subscale: Emotional Burden|GMSS01-Subscale: Emotional Burden|GMSS01-Subscale: Emotional Burden|GMSS0117	The Glucose Monitoring Satisfaction Survey Version: Type 1 Diabetes (GMSS Version Type 1 Diabetes) Subscale: Emotional burden.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Code Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163857>	C163401	GMSS Version Type 1 Diabetes - Subscale: Behavioral Burden|GMSS01-Subscale: Behavioral Burden|GMSS01-Subscale: Behavioral Burden|GMSS0118	The Glucose Monitoring Satisfaction Survey Version: Type 1 Diabetes (GMSS Version Type 1 Diabetes) Subscale: Behavioral burden.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Code Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163858>	C163401	GMSS Version Type 1 Diabetes - Subscale: Trust|GMSS01-Subscale: Trust|GMSS01-Subscale: Trust|GMSS0119	The Glucose Monitoring Satisfaction Survey Version: Type 1 Diabetes (GMSS Version Type 1 Diabetes) Subscale: Trust.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Code Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163859>	C163401	GMSS Version Type 1 Diabetes - Total Scale|GMSS01-Total Scale|GMSS01-Total Scale|GMSS0120	The Glucose Monitoring Satisfaction Survey Version: Type 1 Diabetes (GMSS Version Type 1 Diabetes) Total scale.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Code Terminology|CDISC Questionnaire GMSS Version Type 1 Diabetes Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16385>	C16990	Cardiovascular Physiology	Study of the functions and activities of the cardiovascular system as a whole or of any of its parts.			Biomedical Occupation or Discipline	
C163860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163860>	C163402	HCS - When You Are Exercising|HCS01-When You Are Exercising|HCS01-When You Are Exercising|HCS0101	Hypoglycemic Confidence Scale (HCS) How confident are you that you can stay safe from serious problems with hypoglycemia: When you are exercising?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HCS Test Code Terminology|CDISC Questionnaire HCS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163861>	C163402	HCS - When You Are Sleeping|HCS01-When You Are Sleeping|HCS01-When You Are Sleeping|HCS0102	Hypoglycemic Confidence Scale (HCS) How confident are you that you can stay safe from serious problems with hypoglycemia: When you are sleeping?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HCS Test Code Terminology|CDISC Questionnaire HCS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163862>	C163402	HCS - When You Are Driving|HCS01-When You Are Driving|HCS01-When You Are Driving|HCS0103	Hypoglycemic Confidence Scale (HCS) How confident are you that you can stay safe from serious problems with hypoglycemia: When you are driving?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HCS Test Code Terminology|CDISC Questionnaire HCS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163863>	C163402	HCS - When You Are in Social Situations|HCS01-When You Are in Social Situations|HCS01-When You Are in Social Situations|HCS0104	Hypoglycemic Confidence Scale (HCS) How confident are you that you can stay safe from serious problems with hypoglycemia: When you are in social situations?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HCS Test Code Terminology|CDISC Questionnaire HCS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163864>	C163402	HCS - When You Are Alone|HCS01-When You Are Alone|HCS01-When You Are Alone|HCS0105	Hypoglycemic Confidence Scale (HCS) How confident are you that you can stay safe from serious problems with hypoglycemia: When you are alone?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HCS Test Code Terminology|CDISC Questionnaire HCS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163865>	C163402	HCS - Avoid Serious Problems|HCS01-Avoid Serious Problems|HCS01-Avoid Serious Problems|HCS0106	Hypoglycemic Confidence Scale (HCS) In general, how confident are you that you can: Avoid serious problems due to hypoglycemia?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HCS Test Code Terminology|CDISC Questionnaire HCS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163866>	C163402	HCS - Catch Before Sugars Get Too Low|HCS01-Catch Before Sugars Get Too Low|HCS01-Catch Before Sugars Get Too Low|HCS0107	Hypoglycemic Confidence Scale (HCS) In general, how confident are you that you can: Catch and respond to hypoglycemia before your blood sugars get too low?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HCS Test Code Terminology|CDISC Questionnaire HCS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163867>	C163402	HCS - Continue to Do Things Really Want|HCS01-Continue to Do Things Really Want|HCS01-Continue to Do Things Really Want|HCS0108	Hypoglycemic Confidence Scale (HCS) In general, how confident are you that you can: Continue to do the things you really want to do in your life, despite the risks of hypoglycemia?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HCS Test Code Terminology|CDISC Questionnaire HCS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163868>	C163402	HCS - Your Ability to Avoid Problems|HCS01-Your Ability to Avoid Problems|HCS01-Your Ability to Avoid Problems|HCS0109	Hypoglycemic Confidence Scale (HCS) If you have a spouse or partner: What is your best guess about how confident your spouse or partner feels about your ability to avoid serious problems due to hypoglycemia?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HCS Test Code Terminology|CDISC Questionnaire HCS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163869>	C163402	HCS - Mean HCS Score|HCS01-Mean HCS Score|HCS01-Mean HCS Score|HCS0110	Hypoglycemic Confidence Scale (HCS) Mean HCS score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire HCS Test Code Terminology|CDISC Questionnaire HCS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16386>	C17728	Transport Protein|Carrier Protein|Transporter Protein	A protein that is involved in the directed movement of substances into, out of, within or between cells.			Amino Acid, Peptide, or Protein	
C163870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163870>	C163403	PARENT-DDS - Don't Work Well Together|DDS02-Don't Work Well Together|DDS02-Don't Work Well Together|DDS0201	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) During the past month, I have been: Feeling that my teen and I just don't work well together when it comes to diabetes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163871>	C163403	PARENT-DDS - Unappreciated for Ways I Help|DDS02-Unappreciated for Ways I Help|DDS02-Unappreciated for Ways I Help|DDS0202	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) During the past month, I have been: Feeling unappreciated for all the ways I try to help my teen manage diabetes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163872>	C163403	PARENT-DDS - Trust Teen Take Care of Diabetes|DDS02-Trust Teen Take Care of Diabetes|DDS02-Trust Teen Take Care of Diabetes|DDS0203	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) During the past month, I have been: Feeling that I can't trust my teen to take good care of his/her diabetes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163873>	C163403	PARENT-DDS - Low Blood Sugars Away From Home|DDS02-Low Blood Sugars Away From Home|DDS02-Low Blood Sugars Away From Home|DDS0204	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) During the past month, I have been: Worrying about my teen's low blood sugars when he/she is away from home.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163874>	C163403	PARENT-DDS - Teen Ignore or Forget Diabetes|DDS02-Teen Ignore/Forget Diabetes|DDS02-Teen Ignore/Forget Diabetes|DDS0205	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) During the past month, I have been: Worrying that my teen will ignore or forget diabetes if I don't keep reminding him/her.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163875>	C163403	PARENT-DDS - Taking Too Much of My Energy|DDS02-Taking Too Much of My Energy|DDS02-Taking Too Much of My Energy|DDS0206	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) During the past month, I have been: Feeling that diabetes is taking up too much of my mental and physical energy every day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163876>	C163403	PARENT-DDS - Help Teen Is a Battle|DDS02-Help Teen Is a Battle|DDS02-Help Teen Is a Battle|DDS0207	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) During the past month, I have been: Feeling that trying to help my teen with his/her diabetes is always a battle.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163877>	C163403	PARENT-DDS - Low Blood Sugars When Sleeping|DDS02-Low Blood Sugars When Sleeping|DDS02-Low Blood Sugars When Sleeping|DDS0208	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) During the past month, I have been: Worrying about my teen's low blood sugars when he/she is sleeping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163878>	C163403	PARENT-DDS - No One Notices Diabetes Hard on Me|DDS02-No One Notices Diabetes Hard on Me|DDS02-No One Notices Diabetes Hard on Me|DDS0209	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) During the past month, I have been: Feeling that no one notices that diabetes is hard on me, not just on my teen.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163879>	C163403	PARENT-DDS - Doesn't Do Enough Manage Diabetes|DDS02-Doesn't Do Enough Manage Diabetes|DDS02-Doesn't Do Enough Manage Diabetes|DDS0210	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) During the past month, I have been: Feeling that my teen doesn't do enough to manage his/her diabetes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16387>	C16849	Catechol O-Methyltransferase|COMT|EC 2.1.1.6	Catechol O-methyltransferase (271 aa, ~30 kDa) is encoded by the human COMT gene. This protein is involved in the metabolism of neurotransmitters.	Catechol O-Methyltransferase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C163880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163880>	C163403	PARENT-DDS - Teen Doesn't Have Right Doctor|DDS02-Teen Doesn't Have Right Doctor|DDS02-Teen Doesn't Have Right Doctor|DDS0211	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) During the past month, I have been: Worrying that my teen doesn't have the right doctor for him/her.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163881>	C163403	PARENT-DDS - Blame Me If Not Well-controlled|DDS02-Blame Me If Not Well-controlled|DDS02-Blame Me If Not Well-controlled|DDS0212	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) During the past month, I have been: Worrying that others will blame me if my teen's diabetes is not well-controlled.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163882>	C163403	PARENT-DDS - Leave Home and Cannot Protect Him|DDS02-Leave Home and Cannot Protect Him|DDS02-Leave Home and Cannot Protect Him|DDS0213	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) During the past month, I have been: Worrying that my teen will soon leave home and I cannot protect him.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163883>	C163403	PARENT-DDS - Teen Ignores My Suggestions|DDS02-Teen Ignores My Suggestions|DDS02-Teen Ignores My Suggestions|DDS0214	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) During the past month, I have been: Frustrated because my teen ignores my suggestions about diabetes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163884>	C163403	PARENT-DDS - Lack Support From Friends and Family|DDS02-Lack Support From Friends/Family|DDS02-Lack Support From Friends/Family|DDS0215	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) During the past month, I have been: Frustrated by the lack of understanding and support for diabetes I get from friends and family members.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163885>	C163403	PARENT-DDS - Doesn't Get Expert Medical Help|DDS02-Doesn't Get Expert Medical Help|DDS02-Doesn't Get Expert Medical Help|DDS0216	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) During the past month, I have been: Worrying that my teen doesn't get all of the expert medical help he/she needs.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163886>	C163403	PARENT-DDS - Motivate Teen Take Care Diabetes|DDS02-Motivate Teen Take Care Diabetes|DDS02-Motivate Teen Take Care Diabetes|DDS0217	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) During the past month, I have been: Feeling uncertain about how to motivate my teen to take better care of his/her diabetes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163887>	C163403	PARENT-DDS - Teen Not Prepared Once Adult|DDS02-Teen Not Prepared Once Adult|DDS02-Teen Not Prepared Once Adult|DDS0218	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) During the past month, I have been: Concerned that my teen is not prepared to deal with the world of insurance and doctors once he/she is an adult.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163888>	C163403	PARENT-DDS - Only One Takes Responsibility|DDS02-Only One Takes Responsibility|DDS02-Only One Takes Responsibility|DDS0219	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) During the past month, I have been: Frustrated that I am the only one who takes responsibility for helping my teen manage diabetes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163889>	C163403	PARENT-DDS - My Nagging Hurting Relationship|DDS02-My Nagging Hurting Relationship|DDS02-My Nagging Hurting Relationship|DDS0220	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) During the past month, I have been: Worrying that my nagging about diabetes is hurting my relationship with my teen.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16388>	C28411|C16389	Cathepsin D|CTSD|EC 3.4.23.5|Epididymis Secretory Sperm Binding Protein Li 130P	Cathepsin D (412 aa, ~45 kDa) is encoded by the human CTSD gene. This protein is involved in proteolysis.	Cathepsin D		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C163890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163890>	C163403	PARENT-DDS - Total DDS Score: Sum|DDS02-Total DDS Score: Sum|DDS02-Total DDS Score: Sum|DDS0221	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) Total DDS score: Sum of 20 item scores.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163891>	C163403	PARENT-DDS - Total DDS Score: Mean|DDS02-Total DDS Score: Mean|DDS02-Total DDS Score: Mean|DDS0222	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) Total DDS score: Mean item score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163892>	C163403	PARENT-DDS - Total DDS Score: Moderate|DDS02-Total DDS Score: Moderate|DDS02-Total DDS Score: Moderate|DDS0223	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) Total DDS score: Moderate distress or greater? (mean score > 2).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163893>	C163403	PARENT-DDS - Personal Distress: Sum|DDS02-Personal Distress: Sum|DDS02-Personal Distress: Sum|DDS0224	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) Personal distress: Sum of 6 items (2, 6, 9, 12, 15, 19).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163894>	C163403	PARENT-DDS - Personal Distress: Mean|DDS02-Personal Distress: Mean|DDS02-Personal Distress: Mean|DDS0225	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) Personal distress: Mean item score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163895>	C163403	PARENT-DDS - Personal Distress: Moderate|DDS02-Personal Distress: Moderate|DDS02-Personal Distress: Moderate|DDS0226	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) Personal distress: Moderate distress or greater? (mean score > 2).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163896>	C163403	PARENT-DDS - Teen Management Distress: Sum|DDS02-Teen Management Distress: Sum|DDS02-Teen Management Distress: Sum|DDS0227	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) Teen management distress: Sum of 4 items (4, 8, 13, 18).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163897>	C163403	PARENT-DDS - Teen Management Distress: Mean|DDS02-Teen Management Distress: Mean|DDS02-Teen Management Distress: Mean|DDS0228	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) Teen management distress: Mean item score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163898>	C163403	PARENT-DDS - Teen Management Distress: Moderate|DDS02-Teen Management Distress: Moderate|DDS02-Teen Management Distress: Moderate|DDS0229	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) Teen management distress: Moderate distress or greater? (mean score > 2).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163899>	C163403	PARENT-DDS - Parent/Teen Relationship Distress: Sum|DDS02-Parent/Teen Rel Distress: Sum|DDS02-Parent/Teen Rel Distress: Sum|DDS0230	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) Parent/teen relationship distress: Sum of 8 items (1, 3, 5, 7, 10, 14, 17, 20).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16389>	C16965	Cathepsin|CATHEPSIN|Cathepsins	Lysosomal proteinases or endopeptidases that function optimally at an acidic pH to catalyze the hydrolysis of peptidic bonds. Elevated cathepsin enzyme activity in either serum or extracellular matrix is often indicative of pathological conditions such as Alzheimer's disease, several types of cancer, arthritis, and osteoporosis.	Cathepsin		Amino Acid, Peptide, or Protein|Enzyme	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C1638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1638>	C799	Carbon C-14|14 Carbon|C-14|CARBON C-14|Carbon, Isotope of Mass 14|Carbon-14	An unstable isotope of carbon created when a neutron collides with a nitrogen atom, causing capture of the neutron and release of the proton converting nitrogen to a carbon with fourteen nucleons (6 protons and 8 neutrons).  Carbon-14 emits beta particles as it decays and reverts back to nitrogen.			Element, Ion, or Isotope|Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C163900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163900>	C163403	PARENT-DDS - Parent/Teen Relationship Distress: Mean|DDS02-Parent/Teen Rel Distress: Mean|DDS02-Parent/Teen Rel Distress: Mean|DDS0231	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) Parent/teen relationship distress: Mean item score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163901>	C163403	PARENT-DDS - Parent/Teen Relationship Distress: Moderate|DDS02-Parent/Teen Rel Distress: Moderate|DDS02-Parent/Teen Rel Distress: Moderate|DDS0232	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) Parent/teen relationship distress: Moderate distress or greater? (mean score > 2).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163902>	C163403	PARENT-DDS - Healthcare Team Distress: Sum|DDS02-Healthcare Team Distress: Sum|DDS02-Healthcare Team Distress: Sum|DDS0233	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) Healthcare team distress: Sum of 2 items (11, 16).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163903>	C163403	PARENT-DDS - Healthcare Team Distress: Mean|DDS02-Healthcare Team Distress: Mean|DDS02-Healthcare Team Distress: Mean|DDS0234	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) Healthcare team distress: Mean item score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163904>	C163403	PARENT-DDS - Healthcare Team Distress: Moderate|DDS02-Healthcare Team Distress: Moderate|DDS02-Healthcare Team Distress: Moderate|DDS0235	Diabetes Distress Scale for Parents of Teens with Type 1 Diabetes (PARENT-DDS) Healthcare team distress: Moderate distress or greater? (mean score > 2).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARENT-DDS Test Code Terminology|CDISC Questionnaire PARENT-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163905>	C163404	PARTNER-DDS - Worry About Low Blood Sugars|DDS03-Worry About Low Blood Sugars|DDS03-Worry About Low Blood Sugars|DDS0301	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) During the past month, I have been: Worrying about my partner's low blood sugars.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163906>	C163404	PARTNER-DDS - How Involved Managing Diabetes|DDS03-How Involved Managing Diabetes|DDS03-How Involved Managing Diabetes|DDS0302	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) During the past month, I have been: Feeling unclear about exactly how much I should be involved in managing my partner's diabetes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163907>	C163404	PARTNER-DDS - Partner Shuts Me Out|DDS03-Partner Shuts Me Out|DDS03-Partner Shuts Me Out|DDS0303	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) During the past month, I have been: Frustrated that my partner shuts me out of his/her diabetes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163908>	C163404	PARTNER-DDS - Partner Doesn't Try Hard Enough|DDS03-Partner Doesn't Try Hard Enough|DDS03-Partner Doesn't Try Hard Enough|DDS0304	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) During the past month, I have been: Feeling that my partner doesn't try hard enough to manage his/her diabetes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163909>	C163404	PARTNER-DDS - Overwhelmed by Constant Demands|DDS03-Overwhelmed by Constant Demands|DDS03-Overwhelmed by Constant Demands|DDS0305	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) During the past month, I have been: Feeling overwhelmed by the constant demands of my partner's diabetes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16390>	C25638	Etiology|Causation|Cause|etiology	The cause of a disease or abnormal condition.			Conceptual Entity	
C163910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163910>	C163404	PARTNER-DDS - How to Best Help Partner Manage|DDS03-How to Best Help Partner Manage|DDS03-How to Best Help Partner Manage|DDS0306	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) During the past month, I have been: Worrying that don't know how to best help my partner manage diabetes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163911>	C163404	PARTNER-DDS - Silent About My Partner's Diabetes|DDS03-Silent About My Partner's Diabetes|DDS03-Silent About My Partner's Diabetes|DDS0307	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) During the past month, I have been: Feeling that I stay silent about my partner's diabetes more than I really should.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163912>	C163404	PARTNER-DDS - Taking Too Much of My Energy|DDS03-Taking Too Much of My Energy|DDS03-Taking Too Much of My Energy|DDS0308	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) During the past month, I have been: Feeling that diabetes is taking up too much of my mental and physical energy every day.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163913>	C163404	PARTNER-DDS - No One Notices Diabetes Hard On Me|DDS03-No One Notices Diabetes Hard On Me|DDS03-No One Notices Diabetes Hard On Me|DDS0309	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) During the past month, I have been: Feeling that no one notices that diabetes is hard on me, not just on my partner.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163914>	C163404	PARTNER-DDS - More I Try The Worse Things Get|DDS03-More I Try The Worse Things Get|DDS03-More I Try The Worse Things Get|DDS0310	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) During the past month, I have been: Frustrated that the more I try to help my partner manage his/her diabetes, the worse things get between us.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163915>	C163404	PARTNER-DDS - Guilty Not Doing Enough to Help|DDS03-Guilty Not Doing Enough to Help|DDS03-Guilty Not Doing Enough to Help|DDS0311	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) During the past month, I have been: Feeling guilty about not doing enough to help my partner with diabetes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163916>	C163404	PARTNER-DDS - Can't Get Partner Improve Attitude|DDS03-Can't Get Partner Improve Attitude|DDS03-Can't Get Partner Improve Attitude|DDS0312	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) During the past month, I have been: Frustrated that I can't get my partner to improve his/her attitude about diabetes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163917>	C163404	PARTNER-DDS - Failing to Help Partner Manage|DDS03-Failing to Help Partner Manage|DDS03-Failing to Help Partner Manage|DDS0313	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) During the past month, I have been: Worrying that I am failing to help my partner manage diabetes more successfully.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163918>	C163404	PARTNER-DDS - Help My Partner Always a Battle|DDS03-Help My Partner Always a Battle|DDS03-Help My Partner Always a Battle|DDS0314	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) During the past month, I have been: Feeling that trying to help my partner with his/her diabetes is always a battle.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163919>	C163404	PARTNER-DDS - Partner Ignores My Suggestions|DDS03-Partner Ignores My Suggestions|DDS03-Partner Ignores My Suggestions|DDS0315	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) During the past month, I have been: Frustrated because my partner ignores my suggestions about diabetes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16391>	C25464	Cayman Islands|136|CAYMAN ISLANDS|CAYMAN ISLANDS|CYM|CYM|KY	An island group in the Caribbean Sea, south of Cuba and west of Jamaica.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C163920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163920>	C163404	PARTNER-DDS - Diabetes Often Interrupts Plans|DDS03-Diabetes Often Interrupts Plans|DDS03-Diabetes Often Interrupts Plans|DDS0316	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) During the past month, I have been: Frustrated that diabetes often interrupts our plans.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163921>	C163404	PARTNER-DDS - Low Blood Sugars When Sleeping|DDS03-Low Blood Sugars When Sleeping|DDS03-Low Blood Sugars When Sleeping|DDS0317	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) During the past month, I have been: Worrying about my partner's low blood sugars when he/she is sleeping.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163922>	C163404	PARTNER-DDS - Partner Driving Low Blood Sugars|DDS03-Partner Driving Low Blood Sugars|DDS03-Partner Driving Low Blood Sugars|DDS0318	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) During the past month, I have been: Worrying about my partner's driving because of possible low blood sugars.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163923>	C163404	PARTNER-DDS - Leaving Alone Low Blood Sugars|DDS03-Leaving Alone Low Blood Sugars|DDS03-Leaving Alone Low Blood Sugars|DDS0319	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) During the past month, I have been: Worrying about leaving my partner alone because of the possible danger of low blood sugars.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163924>	C163404	PARTNER-DDS - Not Working Well Together|DDS03-Not Working Well Together|DDS03-Not Working Well Together|DDS0320	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) During the past month, I have been: Concerned that my partner and I are not working well together when it comes to diabetes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163925>	C163404	PARTNER-DDS - Never Get a Break From Worrying|DDS03-Never Get a Break From Worrying|DDS03-Never Get a Break From Worrying|DDS0321	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) During the past month, I have been: Feeling that I never get a break from worrying about my partner's diabetes.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163926>	C163404	PARTNER-DDS - Total DDS Score: Sum|DDS03-Total DDS Score: Sum|DDS03-Total DDS Score: Sum|DDS0322	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) Total DDS score: Sum of 21 item scores.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163927>	C163404	PARTNER-DDS - Total DDS Score: Mean|DDS03-Total DDS Score: Mean|DDS03-Total DDS Score: Mean|DDS0323	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) Total DDS score: Mean item score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163928>	C163404	PARTNER-DDS - Total DDS Score: Moderate|DDS03-Total DDS Score: Moderate|DDS03-Total DDS Score: Moderate|DDS0324	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) Total DDS score: Moderate distress or greater? (mean score > 2).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163929>	C163404	PARTNER-DDS - Partner Diabetes Management: Sum|DDS03-Partner Diabetes Management: Sum|DDS03-Partner Diabetes Management: Sum|DDS0325	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) My partner's diabetes management: Sum of 7 items (3, 4, 10, 12, 14, 15, 20).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163930>	C163404	PARTNER-DDS - Partner Diabetes Management: Mean|DDS03-Partner Diabetes Management: Mean|DDS03-Partner Diabetes Management: Mean|DDS0326	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) My partner's diabetes management: Mean item score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163931>	C163404	PARTNER-DDS - Partner Diabetes Manage: Moderate|DDS03-Partner Diabetes Manage: Moderate|DDS03-Partner Diabetes Manage: Moderate|DDS0327	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) My partner's diabetes management: Moderate distress or greater? (mean score > 2).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163932>	C163404	PARTNER-DDS - How Best to Help: Sum|DDS03-How Best to Help: Sum|DDS03-How Best to Help: Sum|DDS0328	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) How best to help: Sum of 5 items (2, 6, 7, 11, 13).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163933>	C163404	PARTNER-DDS - How Best to Help: Mean|DDS03-How Best to Help: Mean|DDS03-How Best to Help: Mean|DDS0329	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) How best to help: Mean item score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163934>	C163404	PARTNER-DDS - How Best to Help: Moderate|DDS03-How Best to Help: Moderate|DDS03-How Best to Help: Moderate|DDS0330	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) How best to help: Moderate distress or greater? (mean score > 2).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163935>	C163404	PARTNER-DDS - Diabetes and Me: Sum|DDS03-Diabetes and Me: Sum|DDS03-Diabetes and Me: Sum|DDS0331	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) Diabetes and me: Sum of 5 items (5, 8, 9, 16, 21).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163936>	C163404	PARTNER-DDS - Diabetes and Me: Mean|DDS03-Diabetes and Me: Mean|DDS03-Diabetes and Me: Mean|DDS0332	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) Diabetes and me: Mean item score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163937>	C163404	PARTNER-DDS - Diabetes and Me: Moderate|DDS03-Diabetes and Me: Moderate|DDS03-Diabetes and Me: Moderate|DDS0333	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) Diabetes and me: Moderate distress or greater? (mean score > 2).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163938>	C163404	PARTNER-DDS - Hypoglycemia: Sum|DDS03-Hypoglycemia: Sum|DDS03-Hypoglycemia: Sum|DDS0334	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) Hypoglycemia: Sum of 4 items (1, 17, 18, 19).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163939>	C163404	PARTNER-DDS - Hypoglycemia: Mean|DDS03-Hypoglycemia: Mean|DDS03-Hypoglycemia: Mean|DDS0335	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) Hypoglycemia: Mean item score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16393>	C17728	Cell Adhesion Molecule|Adhesion Molecule|CAM|CAMs	A diverse family of cell surface and extracellular glycoproteins involved in cell-cell adhesion, cell-extracellular matrix adhesion, recognition, and activation. There are four main classes of cell adhesion molecules: integrins, selectins, cadherins, and immunoglobulin-like adhesion molecules.			Amino Acid, Peptide, or Protein	
C163940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163940>	C163404	PARTNER-DDS - Hypoglycemia: Moderate|DDS03-Hypoglycemia: Moderate|DDS03-Hypoglycemia: Moderate|DDS0336	Diabetes Distress Scale for Partners of Adults with Type 1 Diabetes (PARTNER-DDS) Hypoglycemia: Moderate distress or greater? (mean score > 2).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire PARTNER-DDS Test Code Terminology|CDISC Questionnaire PARTNER-DDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163941>	C150797	FACT-C Version 4 - Physical Subscale Score|FAC008-Physical Subscale Score|FAC008-Physical Subscale Score|FAC00838	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Physical Well-Being: Subscale score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163942>	C150797	FACT-C Version 4 - Social/Family Subscale Score|FAC008-Social/Family Subscale Score|FAC008-Social/Family Subscale Score|FAC00839	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Social/Family Well-Being: Subscale score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163943>	C150797	FACT-C Version 4 - Emotional Subscale Score|FAC008-Emotional Subscale Score|FAC008-Emotional Subscale Score|FAC00840	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Emotional Well-Being: Subscale score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163944>	C150797	FACT-C Version 4 - Functional Subscale Score|FAC008-Functional Subscale Score|FAC008-Functional Subscale Score|FAC00841	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Functional Well-Being: Subscale score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163945>	C150797	FACT-C Version 4 - Additional Concern Subscale Score|FAC008-Additional Concern Subscale Score|FAC008-Additional Concern Subscale Score|FAC00842	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Additional Concerns: Subscale score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163946>	C150797	FACT-C Version 4 - Total Score|FAC008-Total Score|FAC008-Total Score|FAC00845	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Total score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163947>	C147554	FACIT-Fatigue 13-Item Version 4 - Total Score|FAC070-Total Score|FAC070-Total Score|FAC07014	Functional Assessment of Chronic Illness Therapy-Fatigue 13-Item Scale Version 4 (FACIT-Fatigue 13-Item Version 4) Total score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Code Terminology|CDISC Questionnaire FACIT-Fatigue 13-Item Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163948>	C106679	GDS-SF - Total Score|GDS02-Total Score|GDS02-Total Score|GDS0216	Geriatric Depression Scale, Short Form (GDS-SF) Total score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS-SF Test Code Terminology|CDISC Questionnaire GDS-SF Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C163949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163949>	C106678	GDS - Total Score|GDS01-Total Score|GDS01-Total Score|GDS0131	Geriatric Depression Scale (GDS) Total score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire GDS Test Code Terminology|CDISC Questionnaire GDS Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16394>	C20480	Cell Aging|Aging, Cellular|Cell Senescence|Cellular Aging|Cellular Senescence	Progression of the cell from its inception to the end of its lifespan.			Cell Function	
C163950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163950>	C20401|C163998	Anti-CCR4 Monoclonal Antibody	Any monoclonal antibody that targets C-C chemokine receptor 4 (CCR4; CCR-4).			Chemical Viewed Functionally	NCIt Antineoplastic Agent Terminology
C163951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163951>	C20401	Anti-IL-6 Monoclonal Antibody|Anti-interleukin-6 Monoclonal Antibody	Any monoclonal antibody targeting the cytokine interleukin-6 (IL-6).	Anti-IL-6 Monoclonal Antibody		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C163952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163952>	C163758	EGFR-targeting Agent	Any agent that targets the human epidermal growth factor receptor (EGFR).	EGFR-targeting Agent		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C163953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163953>	C163758	VEGFR-targeting Agent	Any agent that targets the human vascular endothelial growth factor receptor (VEGFR).	VEGFR-targeting Agent		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C163954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163954>	C167338|C150513|C148493	Advanced Bladder Urothelial Carcinoma	A bladder urothelial carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Bladder Urothelial Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C163955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163955>	C8716|C172276|C150515	Advanced Ureter Urothelial Carcinoma	A ureter urothelial carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Ureter Urothelial Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C163956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163956>	C4536|C167333	Locally Advanced Pituitary Neuroendocrine Tumor|Locally Advanced PitNET|Locally Advanced Pituitary Gland Carcinoma|Locally Advanced Pituitary Gland Carcinoma	Pituitary neuroendocrine tumor that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Pituitary Gland Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C163958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163958>	C9044|C168978|C153213	Locally Advanced Parathyroid Gland Carcinoma	A parathyroid gland carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Parathyroid Gland Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C163959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163959>	C4536|C165453|C153279	Metastatic Unresectable Pituitary Neuroendocrine Tumor|Unresectable Metastatic PitNET|Unresectable Metastatic Pituitary Neuroendocrine Tumor|Unresectable Pituitary Gland Carcinoma|Unresectable Pituitary Gland Carcinoma	Metastatic pituitary neuroendocrine tumor that is not amenable to surgical resection.	Unresectable Pituitary Gland Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16395>	C21124	Intercellular Communication Process|Cell to Cell Communication and Signaling|Cell-Cell Signaling|Intercellular Communication|Short-Range Multicellular Communication|cell-to-cell signaling	Any process by which signals are passed from one cell to another through a direct multicellular interaction. This process is involved widely in communication, and is seen in immune response, neuronal transmission, inflammation and other processes.			Cell Function	
C163960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163960>	C146734|C125890	Refractory Small Cell Glioblastoma	A small cell glioblastoma that is resistant to treatment.			Neoplastic Process	
C163961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163961>	C182019|C125890	Recurrent Small Cell Glioblastoma	The reemergence of small cell glioblastoma after a period of remission.	Recurrent Small Cell Glioblastoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C163962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163962>	C3796|C146734	Refractory Gliosarcoma	A gliosarcoma that is resistant to treatment.			Neoplastic Process	
C163963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163963>	C213675|C150512|C148493	Advanced Urethral Urothelial Carcinoma	A urethral urothelial carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Urethral Urothelial Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C163964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163964>	C191982|C170517|C162706	Advanced Thyroid Gland Medullary Carcinoma	Thyroid gland medullary carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Thyroid Gland Medullary Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C163965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163965>	C6142|C27806	Metastatic Renal Pelvis Carcinoma	A renal pelvis carcinoma that has spread from the original site of growth to other anatomic sites.			Neoplastic Process	
C163966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163966>	C172617|C163965	Advanced Renal Pelvis Carcinoma	A renal pelvis carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Renal Pelvis Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C163967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163967>	C95406|C215398|C133839	Metastatic Digestive System Mixed Adenoneuroendocrine Carcinoma	A mixed adenoneuroendocrine carcinoma that arises from the digestive system and has metastasized to other anatomic sites.	Metastatic Digestive System Mixed Adenoneuroendocrine Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C163968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163968>	C223331	PRMT5 Inhibitor	Any agent that inhibits PRMT5.			Chemical Viewed Functionally	
C163969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163969>	C210010	Tissue Transglutaminase Antibody Measurement	The determination of the amount of tissue transglutaminase antibody in a sample.			Laboratory Procedure	
C16396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16396>	C17201	Cell Culture|CellCulture|Expansion/Differentiation/Production, Cell Product	General term referring to the maintenance of cell strains or lines in the laboratory.			Laboratory Procedure	BRIDG Class Terminology|BRIDG Terminology|FDA eManufacturing Terminology|GDC Terminology|GDC Value Terminology
C163970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163970>	C68637	Death Certificate	A certified document issued by either a medical practitioner or a governmental agency that details the date, location and cause of a death of an individual.			Manufactured Object	GDC Terminology|GDC Value Terminology
C163971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163971>	C19796	Smoking Status Not Documented|Smoking history not documented	Indicates that a person's smoking status has not been recorded.			Organism Attribute	GDC Terminology|GDC Value Terminology
C163972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163972>	C41278|C156897	BodiMetrics Performance Monitor|BodiMetric Device	A proprietary wrist cuff device designed to monitor ECG, heart rate, systolic blood pressure, blood oxygenation, and body temperature. It also incorporates a pedometer and syncs to a smartphone.	BodiMetrics Performance Monitor		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C163974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163974>	C3879|C191980|C129784	Unresectable Thyroid Gland Medullary Carcinoma	Thyroid gland medullary carcinoma that is not amenable to surgical resection.	Unresectable Thyroid Gland Medullary Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C163975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163975>	C3812|C155869	Neuroendocrine Carcinoma of Unknown Primary	A neuroendocrine carcinoma that has metastasized from an  unknown primary site.	Neuroendocrine Carcinoma of Unknown Primary		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C163976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163976>	C226341|C201282|C129822	Voxalatamab|Anti-PSMA/CD3 Bispecific Antibody JNJ-63898081|JNJ 63898081|JNJ-63898081|JNJ-8081|JNJ63898081|VOXALATAMAB	An immunoglobulin G4 (IgG4) bispecific antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA), fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, voxalatamab simultaneously binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and PSMA found on PSMA-expressing tumor cells. This activates and redirects CTLs to PSMA-expressing tumor cells, which results in the CTL-mediated cell death of PSMA-expressing tumor cells. PSMA, a tumor associated antigen, is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.	Voxalatamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C163977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163977>	C159583	Lemzoparlimab|Anti-CD47 Monoclonal Antibody TJC4|LEMZOPARLIMAB|TJ 011133|TJ-011133|TJ011133|TJC4	A human monoclonal antibody targeting the human cell surface antigen CD47, with potential phagocytosis-inducing and antineoplastic activities. Upon administration, lemzoparlimab preferentially binds to a unique epitope of CD47 on tumor cells. This blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of tumor cells. Additionally, blocking CD47 signaling activates an anti-tumor T-lymphocyte immune response and T-cell-mediated killing of CD47-expressing tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate. TJC4, compared to other anti-CD47 monoclonal antibodies, is designed to minimize inherent binding to normal red blood cells (RBCs), which may results in a more advantageous hematologic safety profile.	Lemzoparlimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C163978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163978>	C213431|C1663	DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Formulation INO-5151|Formulation INO-5150 with INO-9012|INO 5151|INO-5150 with INO-9012|INO-5150/INO-9012 Formulation|INO-5151|INO5151	A DNA-based combined formulation composed of INO-5150, DNA plasmids encoding the tumor-associated antigens (TAAs) prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA), and INO-9012, a plasmid DNA vaccine encoding the immune activator and pro-inflammatory cytokine human interleukin-12 (IL-12), with potential immunoactivating and antineoplastic activities. Upon intramuscular delivery of INO-5151 and electroporation of the PSA/PSMA DNA plasmid INO-5150, PSA and PSMA are translated in cells and elicit a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing PSA and PSMA, resulting in tumor cell lysis. Upon electroporation of the DNA plasmid encoding IL-12 INO-9012, IL-12 is translated in cells and the expressed IL-12 activates the immune system by promoting the activation of natural killer cells (NK cells), inducing secretion of interferon-gamma (IFN-g) and promoting CTL responses against tumor cells. This boosts the immune response and results in increased CTL-mediated tumor cell death as compared with the administration of INO-5150 alone. PSA and PSMA are overexpressed on a variety of cancer cell types.	DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Formulation INO-5151		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C163979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163979>	C25168	Mismatched Related Donor|PMRD|Partially Mismatched Related Donor	A donor who is related to the recipient but is mismatched at at least 1 HLA locus.			Human	
C16397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16397>	C21102	Cell Cycle Process|Cell Cycle|Cell Growth/Cell Cycle|Mitotic Cell Cycle|cell cycle	The complex series of phenomena, occurring between the end of one cell division and the end of the next, by which cellular material is divided between daughter cells.  The cell cycle is an ordered set of events, culminating in cell growth and division into two daughter cells.  The stages of cell cycle includes G1-S-G2-M.  The G1 stage stands for "GAP 1".  The S stage stands for "Synthesis".  This is the stage when DNA replication occurs.  The G2 stage stands for "GAP 2".  The M stage stands for "mitosis", and is when nuclear (chromosomes separate) and cytoplasmic (cytokinesis) division occur.			Phenomenon or Process	
C163980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163980>	C163968	Onametostat|JNJ 64619178|JNJ-64619178|JNJ64619178|ONAMETOSTAT|PRMT5 Inhibitor JNJ-64619178|Protein Arginine Methyltransferase 5 Inhibitor JNJ-64619178	An orally available small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), with potential antiproliferative and antineoplastic activities. Upon oral administration,onametostat selectively targets and irreversibly binds to the S-adenosylmethionine (SAM)- and substrate-binding pockets of the PRMT5/methylosome protein 50 (MEP50) complex, and inhibits its function. By inhibiting its methyltransferase activity, levels of both monomethylated and dimethylated arginine residues in histones H2A, H3 and H4 are decreased. This modulates the expression of genes involved in several cellular processes, including cellular proliferation. This may increase the expression of antiproliferative genes and/or decrease the expression of genes that promote cell proliferation, which may lead to decreased growth of rapidly proliferating cells, including cancer cells. PRMT5, a type II methyltransferase that catalyzes the formation of both omega-N monomethylarginine (MMA) and symmetric dimethylarginine (sDMA) on histones and a variety of other protein substrates involved in signal transduction and cellular transcription, is overexpressed in several neoplasms. Elevated levels are associated with decreased patient survival.	Onametostat		Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C163981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163981>	C133878|C129822	Pimurutamab|Anti-EGFR Monoclonal Antibody HLX-07|Cetuximab Biobetter HLX07|HLX 07|HLX-07|HLX07|PIMURUTAMAB	A glycoengineered humanized version of the monoclonal antibody of cetuximab, with potential antineoplastic activity. Upon intravenous administration, pimurutamab selectively targets and binds to the extracellular domain of the epidermal growth factor receptor (EGFR), thereby preventing the activation and subsequent dimerization of the receptor. This may prevent EGFR-mediated signaling and inhibit EGFR-dependent tumor cell proliferation.  In addition, the glyco-optimization promotes antibody-dependent cell-mediated cytotoxicity (ADCC). EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surfaces of certain tumor types.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C163982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163982>	C123667	Montreal Cognitive Assessment, Version 8.1|MOCA v8.1|Montreal Cognitive Assessment (MoCA) version 8.1|Montreal Cognitive Assessment, v8.1	The version of the Montreal Cognitive Assessment that added the Memory Index Score to the MoCA test. It contains additional scoring precisions and replaced version 7.1.			Intellectual Product	
C163983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163983>	C123667	Montreal Cognitive Assessment, Version 8.2|MOCA v8.2|Montreal Cognitive Assessment (MoCA) version 8.2|Montreal Cognitive Assessment, v8.2	An alternate version of MOCA v8 that can be administered to decrease any potential test re-test interactions.			Intellectual Product	
C163984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163984>	C123667	Montreal Cognitive Assessment, Version 8.3|MOCA v8.3|Montreal Cognitive Assessment (MoCA) version 8.3|Montreal Cognitive Assessment, v8.3	An alternate version of MOCA v8 that can be administered to decrease any potential test re-test interactions.			Intellectual Product	
C163985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163985>	C213865	Avotaciclib|AVOTACICLIB|BEY 1107|BEY-1107|BEY-A|BEY1107|BEY1107G|BEY1107P|CDK1 Inhibitor BEY1107	An orally bioavailable, cyclin dependent kinase 1 (CDK1) inhibitor, with potential antineoplastic activity. Upon administration, avotaciclib targets, binds to and inhibits the activity of CDK1. This may inhibit cancer stem cell (CSC) division, cause cell cycle arrest, and induce apoptosis. This may inhibit tumor cell proliferation. CDK1, an ATP-dependent serine/threonine kinase, plays a key role in regulating cell division, cell cycle progression and proliferation. It is frequently overexpressed in tumor cells.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C163986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163986>	C15241	Hybrid Selected Genomic Library	A genomic library where the sample has been subjected to enrichment via nucleic acid hybridization.			Manufactured Object	GDC Terminology|GDC Value Terminology
C163987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163987>	C15241	Affinity Enriched Genomic Library	A genomic library where the sample has been subjected to enrichment via binding to a target protein or oligonucleotide prior to molecular analysis.			Manufactured Object	GDC Terminology|GDC Value Terminology
C163988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163988>	C15241	Poly-A Enriched Genomic Library|Poly(A) Enriched Genomic Library|Poly(A) Selected Genomic Library|Poly-A Selected Genomic Library|Poly-A Selected Genomic Library|Poly-T Enriched Genomic Library|PolyA Selected Genomic Library	A genomic library where the sample has been subjected to enrichment via binding to immobilized poly-T oligonucleotides, which will preferentially isolate polyadenylated (poly-A) RNAs.			Manufactured Object	GDC Terminology|GDC Value Terminology
C163989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163989>	C15241	Randomly Selected Genomic Library	A genomic library constructed to generate random DNA fragments by subjecting a genomic sample to either amplification using random primers or fragmentation via exposure to restriction enzymes or shear stress. The fragments can then be cloned or sequenced directly.			Manufactured Object	GDC Terminology|GDC Value Terminology
C163990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163990>	C15241	rRNA Depleted Genomic Library	A genomic library where the sample has been subjected to a ribosomal RNA depletion step before it is amplified.			Manufactured Object	GDC Terminology|GDC Value Terminology
C163991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163991>	C15241	miRNA Size Fractionated Genomic Library	A RNA library that has been fractionated by size exclusion methods to enrich for microRNAs.			Manufactured Object	GDC Terminology|GDC Value Terminology
C163992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163992>	C129822|C128057	Tagitanlimab|A 167|A-167|A167|Anti-PD-L1 Monoclonal Antibody A167|KL A167|KL-A167|KLA167|TAGITANLIMAB	A humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tagitanlimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C163993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163993>	C12958	EBV Immortalized Lymphocytes	A biospecimen consisting of lymphocytes that have been isolated from whole blood and are then infected in vitro by Epstein-Barr virus (EBV; HHV4). The infected cells are then cultured to select indefinitely proliferating colonies that can be maintained in tissue culture.			Cell	GDC Terminology|GDC Value Terminology
C163994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163994>	C1742	Foslinanib Disodium|4(1H)-Quinolinone, 2-(3-Fluorophenyl)-6-methoxy-5-(phosphonooxy)-, Sodium Salt (1:2)|CVM-1118 Disodium|FOSLINANIB DISODIUM|TRX-818|TRX818 Disodium	The disodium salt form of foslinanib, an orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry activities. Upon oral administration, foslinanib targets and inhibits the formation of vasculogenic mimicry (VM; vascular mimicry). By destroying the VM channels and network, cancer cells are devoid of perfusion leading to an induction of cancer cell apoptosis and inhibition of cancer cell proliferation. VM is associated with tumor metastasis.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C163995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163995>	C198568	Total RNA|T	A biological sample comprised of all of the RNA collected from an experimental subject.			Nucleic Acid, Nucleoside, or Nucleotide	GDC Terminology|GDC Value Terminology
C163996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163996>	C1946|C129825	Bisthianostat|CF367|CFH367 C|CFH367-C|CFH367C|PY-1	An orally bioavailable pan-inhibitor of human histone deacetylase (HDAC), with potential antineoplastic activity. Upon administration, bisthianostat selectively binds to and inhibits HDACs, which inhibits deacetylation of histone proteins and leads to the accumulation of highly acetylated histones. This may result in an induction of chromatin remodeling, the inhibition of tumor oncogene transcription, and the selective transcription of tumor suppressor genes. This prevents cell division, induces cell cycle arrest and apoptosis. This may inhibit the proliferation of susceptible tumor cells. HDACs, upregulated in many tumor cell types, are a family of enzymes that deacetylate histone proteins.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C163997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163997>	C217133|C15389	Thoracoscopic Biopsy	The use of a thoracoscope to obtain a biopsy from the pleural cavity and/or thoracic cavity.			Diagnostic Procedure	GDC Terminology|GDC Value Terminology
C163998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163998>	C163758	CCR4-targeting Agent	Any agent that inhibits the activity of the C-C chemokine receptor 4 (CCR4).			Chemical Viewed Functionally	
C163999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C163999>	C163758	cKIT-targeting Agent	Any agent that targets  the receptor tyrosine kinase mast/stem cell factor receptor c-Kit (SCFR; cKIT; CD117).			Chemical Viewed Functionally	
C16399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16399>	C20480	Cell Differentiation Process|Cell Differentiation|Cytodifferentiation|Differentiated|Differentiation|cell differentiation	Progressive restriction of the developmental potential and increasing specialization of cellular function which takes place during the formation of specialized cells, tissues, and organs.			Cell Function	
C1639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1639>	C2462|C129819	Iodine I-131|131-Iodine|Bound Iodide I-131|I 131|I-131|IODINE I-131|Iodide I-131|Iodide, I-131|Iodine 131|Iodine-131|Iodine-131|Iodotope|Iodotrope	A radioactive isotope of iodine with an atomic mass of 131, a half life of eight days, and potential antineoplastic activity. Selectively accumulating in the thyroid gland, iodine I 131 emits beta and gamma particles, thereby killing thyroid cells and decreasing thyroid hormone production.	Iodine I-131		Element, Ion, or Isotope|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C164000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164000>	C163758	c-Met-targeting Agent	Any agent that targets the receptor tyrosine kinase c-Met (hepatocyte growth factor receptor; HGFR; cMet).	c-Met-targeting Agent		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C164001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164001>	C20401|C164000	Anti-c-Met Monoclonal Antibody	Any monoclonal antibody against the receptor tyrosine kinase c-Met (hepatocyte growth factor receptor; HGFR; cMET).			Chemical Viewed Functionally	
C164002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164002>	C20401|C164005	Anti-CD30 Monoclonal Antibody	Any monoclonal antibody that is directed against CD30.			Chemical Viewed Functionally	
C164003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164003>	C32926	Colonic Mucosa|COLONIC MUCOSA|colon mucosa|colon mucous membrane|colonic mucosa|colonic mucosa|colonic mucous membrane|large bowel mucosa|mucosa of colon|mucosa of large bowel	The mucus membrane lining the inner surface of the colon.			Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|UBERON Terminology
C164004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164004>	C12471	Mediastinal Soft Tissue|MEDIASTINAL SOFT TISSUE|Mediastinal soft tissue	Any non-hardened or non-calcified tissue found in the mediastinum.			Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C164005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164005>	C163758	CD30-targeting Agent	Any agent that targets CD30.			Chemical Viewed Functionally	
C164006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164006>	C12471	Nasal Soft Tissue|NASAL SOFT TISSUE|Nasal soft tissue	Any non-hardened or non-calcified tissue found in the nose.			Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C164007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164007>	C12471	Periorbital Soft Tissue|PERI-ORBITAL SOFT TISSUE|Peri-orbital soft tissue	Any non-hardened or non-calcified tissue found in the periorbital area.			Tissue	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C164008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164008>	C163758	CD38-targeting Agent	Any agent that targets CD38.			Chemical Viewed Functionally	
C164009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164009>	C70699	Bone Marrow Sample|Bone Marrow|Bone Marrow|Bone Marrow NOS|Bone Marrow Specimen	A biological sample containing components collected from bone marrow of an experimental subject.			Body Substance	ALL Authorized Value Terminology|ALL Lab Table|ALL Minimal Residual Disease Table|ALL Molecular Analysis Table|AML Authorized Value Terminology|AML Lab Table|AML Minimal Residual Disease Table|GDC Terminology|GDC Value Terminology
C164010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164010>	C116388	Bone Marrow-Derived Fibroblasts|Fibroblasts from Bone Marrow	A biological sample containing fibroblasts isolated from the bone marrow of an experimental subject.			Cell	GDC Terminology|GDC Value Terminology
C164011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164011>	C116388	Bone Marrow-Derived Mononuclear Cells|BM-MNC|BMMC|Bone Marrow-Derived Unselected Mononuclear Cell|Mononuclear Cells from Bone Marrow|Non-Selected Mononuclear Cell|Total Mononuclear Cell Population|Unselected Mononuclear Cell|Unselected Mononuclear Cell|tMNC	A biological sample containing mononuclear cells isolated from the bone marrow of an experimental subject.			Cell	GDC Terminology|GDC Value Terminology
C164012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164012>	C157638|C153171	Advanced Adenoid Cystic Carcinoma	Adenoid cystic carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Adenoid Cystic Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C164013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164013>	C2970|C148124	Unresectable Adenoid Cystic Carcinoma	Adenoid cystic carcinoma that is not amenable to surgical resection.	Unresectable Adenoid Cystic Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C164014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164014>	C19697	Solid Tissue Specimen|Solid Tissue|Solid Tissue Sample	A biological sample containing components collected from non-liquid tissue of an experimental subject.			Tissue	GDC Terminology|GDC Value Terminology
C164015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164015>	C164009	Blood Cancer-Derived Bone Marrow Specimen|Blood Cancer-Derived Bone Marrow Sample	A bone marrow specimen collected from a subject that has been diagnosed with a liquid tumor.			Cell	GDC Deprecated Terminology|GDC Terminology
C164016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164016>	C171088	Minority Health	Distinctive health characteristics and attributes of a racial and/or ethnic group who is socially disadvantaged and/or subject to potential discriminatory acts.			Clinical Attribute	
C164017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164017>	C164009	Blood Cancer-Derived Bone Marrow Specimen, Post-Treatment|Blood Cancer-Derived Bone Marrow Sample, Post-Treatment	A bone marrow specimen collected from a subject after receiving treatment for a liquid tumor.			Cell	GDC Deprecated Terminology|GDC Terminology
C164018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164018>	C15429	Minority Health Research	The scientific investigation of distinctive health characteristics and attributes of minority racial and/or ethnic groups who are underrepresented in biomedical research.			Research Activity	
C164019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164019>	C16863	Minority Health Populations	The Revisions to the Standards for the Classification of Federal Data on Race and Ethnicity (The OMB Statistical Policy Directive No. 15) define racial and ethnic categories as follows: American Indian or Alaska Native, Asian, Black or African American, Hispanic/Latino American, Native Hawaiian or Other Pacific Islander.			Population Group	
C16401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16401>	C20368	Cell Fusion|Cell Biology, Cell Fusion	A technique to form a single hybrid cell, by fusion of two or more dissimilar cells, either spontaneously or by induced fusion. The cells fuse and coalesce, but their nuclei may remain separated.  The cell fusion technique can be used as a method of assigning genes to specific chromosomes.			Research Activity	
C164020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164020>	C102711	Health Disparity	A health difference that adversely affects disadvantaged populations.			Clinical Attribute	
C164021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164021>	C83031|C146721	First Patient Visit Date|First Patient Visit	The date for the first patient visit.			Temporal Concept	GDC Terminology|GDC Value Terminology
C164022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164022>	C80454|C146721	First Treatment Date|Date of First Therapy|Date of First Treatment|Date of Initial Treatment|Initial Treatment Date	The date for the initiation of a patient treatment plan.			Temporal Concept	GDC Terminology|GDC Value Terminology
C164023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164023>	C199397|C146721	Initial Genomic Sequencing Date|Date of Initial Genomic Sequencing|Initial Genomic Sequencing	The date for the first round of genomic sequencing of a subject's DNA.			Temporal Concept	GDC Terminology|GDC Value Terminology
C164024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164024>	C25164	Sample Procurement Date	The date that a sample was collected or obtained.			Temporal Concept	GDC Terminology|GDC Value Terminology
C164025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164025>	C68641	Biospecimen Data Supplement|Biospecimen Supplement|Biospecimen Supplement	Additional documentation or textual matter added to a study report that contains biospecimen data or related information.			Temporal Concept	GDC Terminology|GDC Value Terminology
C164026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164026>	C164027|C15365	Health Disparity Outcomes	Higher incidence prevalence, including earlier onset or more aggressive progression; Premature or excessive mortality from specific conditions; Greater global burden as indicated by population health measures; Poorer health behaviors and clinical outcomes (related to above); Worse self-reported outcomes measures that reflect daily functioning or symptoms from specific conditions.			Research Activity	
C164027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164027>	C15245	Health Disparity Research	A multi-disciplinary field of study devoted to gaining greater scientific knowledge about the influence of health determinants, and translating this knowledge into interventions to reduce or eliminate adverse health differences.			Research Activity	
C164028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164028>	C68641	Clincal Data Supplement|Clinical Supplement|Clinical Supplement	Additional documentation or textual matter added to a study report that contains clinical data or related information.			Temporal Concept	GDC Terminology|GDC Value Terminology
C164029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164029>	C16863	Health Disparity Populations	Populations that include racial/ethnic minorities, low socioeconomic status, sexual minorities, the disabled, those living in rural or disadvantaged locations, and/or others subject to discrimination or the disparity type, who have poorer health outcomes often attributed to being socially disadvantaged, which results in being underserved in the full spectrum of health care.			Population Group	
C16402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16402>	C21101	Cell Growth|Cellular Expansion|Cellular Growth	The complex series of phenomena occurring after cell division and before cell death.			Cell Function	
C164030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164030>	C41067	Blood Cancer-Derived Blood Specimen|Blood Cancer-Derived Blood Sample|Blood Cancer-Derived Peripheral Blood Sample|Blood Cancer-Derived Peripheral Blood Specimen	A whole blood specimen collected from a subject that has been diagnosed with a liquid tumor.			Cell	GDC Deprecated Terminology|GDC Terminology
C164031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164031>	C41067	Blood Cancer-Derived Blood Specimen, Post-Treatment|Blood Cancer-Derived Blood Sample, Post-Treatment|Blood Cancer-Derived Peripheral Blood Sample, Post-Treatment|Blood Cancer-Derived Peripheral Blood Specimen, Post-Treatment	A whole blood specimen collected from a subject after receiving treatment for a liquid tumor.			Cell	GDC Deprecated Terminology|GDC Terminology
C164032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164032>	C19697	Tumor-Adjacent Normal Specimen|Peritumoral|Tumor-Adjacent Normal Sample	A specimen comprised of morphologically normal tissue collected from the area immediately surrounding a tumor in an experimental subject.			Tissue	
C164033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164033>	C164032|C156444	Tumor-Adjacent Normal Post Neoadjuvant Therapy Sample	A specimen derived from a tumor-adjacent normal tissue specimen that was collected from the subject after treatment with a neoadjuvant therapeutic.			Body Substance	GDC Deprecated Terminology|GDC Terminology
C164034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164034>	C163758	CD20-targeting Agent	Any agent targeting CD20.			Chemical Viewed Functionally	
C164035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164035>	C163758	FGFR-targeting Agent	Any agent that targets FGFR.	FGFR-targeting Agent		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C164036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164036>	C20401|C164037	Anti-PDGFR Monoclonal Antibody	Any monoclonal antibody that is directed against PDGFR.			Chemical Viewed Functionally	
C164037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164037>	C163758	PDGFR-targeting Agent	Any agent that targets PDGFR.			Chemical Viewed Functionally	
C164038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164038>	C12788	Limb Skeletal System|Skeletal System of the Extremities|Skeletal System of the Limb	The bones, joints, ligaments and cartilage found in the limbs (extremities).			Anatomical Structure	GDC Terminology|GDC Value Terminology
C164039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164039>	C4086	Indefinite Dysplasia|Indefinite|Indefinite for Dysplasia|Indefinite for Dysplasia	An indication that there is an ambiguous morphological pattern in a tissue sample such that the presence or absence of dysplasia cannot be determined.			Finding	GDC Terminology|GDC Value Terminology
C16403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16403>	C192998	Cell Line|CELL LINE|Cell-Line|CellLine|cultured cell line|cultured cells	A permanently established cell culture that will proliferate indefinitely given appropriate fresh medium and space.			Cell	BRIDG Class Terminology|BRIDG Terminology|CDISC SEND Biospecimens Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|ICDC Terminology|ICDC Value Terminology
C164040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164040>	C4086|C35681	Dysplasia Negative|Negative for Dysplasia|Negative/ No Dysplasia|No Dysplasia|No Dysplasia	An indication that signs of dysplasia were not found in a sample.			Finding	GDC Terminology|GDC Value Terminology
C164041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164041>	C35867|C35681	Metastasis Negative|Negative for Metastasis|No Metastasis|No Metastasis	An indication that signs of metastasis were not found in a sample.			Finding	GDC Terminology|GDC Value Terminology
C164042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164042>	C35867|C117720	Ovarian Capsule Intact	A microscopy finding indicating that the ovarian capsule in a biopsy is intact.			Finding	GDC Terminology|GDC Value Terminology
C164044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164044>	C35867|C117720	Ovarian Capsule Ruptured	A microscopy finding indicating that a portion of the ovarian capsule in a biopsy has ruptured.			Finding	GDC Terminology|GDC Value Terminology
C164045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164045>	C35867|C117720	Ovarian Capsule Fragmented	A microscopy finding indicating that a portion of the ovarian capsule in a biopsy was fragmented.			Finding	GDC Terminology|GDC Value Terminology
C164046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164046>	C45659|C35681	Vascular Invasion Negative|No Vascular Invasion|No Vascular Invasion	An indication that signs of vascular invasion have not been found in a sample.			Finding	GDC Terminology|GDC Value Terminology
C164047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164047>	C53276	Skin of the Lower Extremity|Lower Extremity Skin|SKIN OF THE LOWER LIMB|Skin of the Lower Limb|Skin, lower extremity, local|hindlimb skin	The integumentary covering of the lower extremities.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|UBERON Terminology
C164048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164048>	C53276	Skin of the Upper Extremity|SKIN OF THE UPPER LIMB|Skin of the Upper Limb|Skin, upper extremity, local|Upper Extremity Skin|forelimb skin	The integumentary covering of the upper extremities.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|UBERON Terminology
C164049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164049>	C171252	Tab-Separated Value Format|TSV|TSV|Tab-Delimited File Format|Tab-Delimited Format|Tab-Delimited Value Format|Tab-Delimited Values	A file format where each line in the file contains a single piece of data and where each field or value in a line of data is separated from the next by a tab character.			Qualitative Concept	GDC Terminology|GDC Value Terminology
C16404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16404>	C28486	Cell Motility|Motility|Motility, Cellular|cell motility	Cell Motility consists of active translocation of a whole cell, or cell body, from one site to another; distinct from cell motion that involves movement of cell processes (e.g., axons, microvilli, etc.). (NCI)			Cell Function	
C164050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164050>	C85871	Excel Open XML Format|XLSX|XLSX	A proprietary file format developed by Microsoft that allows the user to save a spreadsheet created in Excel in an open XML-format. The file then can be read and opened by other spreadsheet-compatible applications.			Qualitative Concept	GDC Terminology|GDC Value Terminology
C164051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164051>	C53327	Methylation Beta Value|Beta Value|DNA Methylation Beta Value	An estimate for the level of DNA methylation in a set of samples that is calculated as the ratio of average signal intensities for methylated alleles (M) divided by the average signal intensities of M plus unmethylated alleles (U), such that beta (b) equals M/(M+U). Beta values must fall between zero and one.			Research Activity	GDC Terminology|GDC Value Terminology
C164052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164052>	C17565	Aligned Sequence Read|Aligned Read|Aligned Reads	The determination of the order of a set of sequenced nucleic acid fragments via alignment to a reference genome.			Laboratory Procedure	GDC Terminology|GDC Value Terminology
C164053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164053>	C17565	Unaligned Sequence Read|Unaligned Read|Unaligned Reads	A set of sequenced nucleic acid fragments that have not been aligned to each other or to a reference sequence or genome.			Laboratory Procedure	GDC Terminology|GDC Value Terminology
C164055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164055>	C1708	Vinegar Soaks|Vinegar Soak|Vinegar Water Soaks	A topical treatment consisting of white vinegar diluted in water. The vinegar solution may be applied to the skin using an applicator material, or a body part may be immersed in it.			Chemical Viewed Functionally	
C164057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164057>	C19447	Smoke Exposure|Smoke|Smoke exposure, NOS|type of smoke exposure|type_of_smoke_exposure	Environmental, occupational or consumer-based exposure to airborne gases and particulates produced when materials undergo combustion or thermal decomposition.			Finding	GDC Property Terminology|GDC Terminology|GDC Value Terminology
C164058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164058>	C164057	Fire Smoke Exposure|Fire smoke, NOS	Environmental or occupational exposure to airborne gases and particulates produced when materials are rapidly oxidized via combustion.			Finding	GDC Terminology|GDC Value Terminology
C164059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164059>	C164058	Accidental Fire Smoke Exposure|Accidental fire smoke, NOS	Environmental exposure to airborne gases and particulates produced during a fire that was not caused by deliberate human actions.			Finding	GDC Terminology|GDC Value Terminology
C16405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16405>	C17992	Cell Physiology|Cellular Function|Cellular Physiology	Characteristics and physiological processes of cells from cell division to cell death.			Biomedical Occupation or Discipline	
C164060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164060>	C164057	Coal Smoke Exposure|Coal smoke, NOS	Environmental or occupational exposure to airborne gases and particulates produced when coal is rapidly oxidized via combustion.			Finding	GDC Terminology|GDC Value Terminology
C164061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164061>	C164057	Cooking-Related Smoke Exposure|Cooking-related smoke, NOS	Environmental, occupational or consumer-based exposure to vaporized materials produced when food products are being cooked.			Finding	GDC Terminology|GDC Value Terminology
C164062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164062>	C164057	Electronic Cigarette Smoke Exposure|Electronic cigarette smoke, NOS|e-Cigarette Smoke Exposure	Environmental, occupational or consumer-based exposure to airborne gases and particulates produced by direct or nearby use of an electronic cigarette.			Finding	GDC Terminology|GDC Value Terminology
C164063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164063>	C164057	Burning Oil Smoke Exposure|Oil Burning Smoke Exposure|Oil burning smoke, NOS	Environmental or occupational exposure to airborne gases and particulates produced when oils are rapidly oxidized via combustion.			Finding	GDC Terminology|GDC Value Terminology
C164064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164064>	C164057	Indoor Stove or Fireplace Smoke Exposure|Indoor stove or fireplace smoke, NOS	Environmental or occupational exposure to airborne gases and particulates produced when materials are subjected to combustion in an indoor stove or fireplace.			Finding	GDC Terminology|GDC Value Terminology
C164065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164065>	C164058	Burning Wood Smoke Exposure|Wood Burning Smoke Exposure|Wood burning smoke, NOS	Environmental or occupational exposure to airborne gases and particulates produced when wood is subjected to combustion.			Finding	GDC Terminology|GDC Value Terminology
C164066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164066>	C164059	Accidental Building Fire Smoke Exposure|Accidental building fire smoke	Environmental or occupational exposure to airborne gases and particulates produced during a building fire that was not caused by deliberate human actions.			Finding	GDC Terminology|GDC Value Terminology
C164067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164067>	C164059	Accidental Grass Fire Smoke Exposure|Accidental fire smoke, grass	Environmental or occupational exposure to airborne gases and particulates produced during a grass fire that was not caused by deliberate human actions.			Finding	GDC Terminology|GDC Value Terminology
C164068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164068>	C164059	Accidental Forest Fire Smoke Exposure|Accidental forest fire smoke	Environmental or occupational exposure to airborne gases and particulates produced during a forest fire that was not caused by deliberate human actions.			Finding	GDC Terminology|GDC Value Terminology
C164069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164069>	C164059	Accidental Vehicle Fire Smoke Exposure|Accidental vehicle fire smoke	Environmental or occupational exposure to airborne gases and particulates produced during a vehicle fire that was not caused by deliberate human actions.			Finding	GDC Terminology|GDC Value Terminology
C16406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16406>	C20368|C128947	Cell Sorting|Cell Isolation|Cell Separation|Cell Separation Technology	Any of various processes to isolate one or more specific cell populations from a heterogeneous mixture of cells.	Cell Sorting		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C164070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164070>	C8816|C3704	Metastatic Dedifferentiated Liposarcoma	Dedifferentiated liposarcoma that has spread from its original site of growth to another anatomic site.	Metastatic Dedifferentiated Liposarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C164071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164071>	C164070|C160916	Locally Advanced Dedifferentiated Liposarcoma	Dedifferentiated liposarcoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Dedifferentiated Liposarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C164072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164072>	C164057	Aircraft Smoke Exposure|Aircraft smoke	Environmental, occupational or consumer-based exposure to airborne gases and particulates produced when an aircraft is in operation.			Finding	GDC Terminology|GDC Value Terminology
C164074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164074>	C8822|C153071	Locally Advanced Malignant Peripheral Nerve Sheath Tumor	A malignant peripheral nerve sheath tumor that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Malignant Peripheral Nerve Sheath Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C164075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164075>	C164058	Burning Tree Smoke Exposure|Burning tree smoke	Environmental or occupational exposure to airborne gases and particulates produced when trees are undergoing combustion.			Finding	GDC Terminology|GDC Value Terminology
C164076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164076>	C8796|C153066	Locally Advanced Alveolar Soft Part Sarcoma	Alveolar soft part sarcoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Alveolar Soft Part Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C164077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164077>	C164058	Electrical Fire Smoke Exposure|Electrical fire smoke|Electrical fire smoke, NOS	Environmental or occupational exposure to airborne gases and particulates produced during an electrical fire.			Finding	GDC Terminology|GDC Value Terminology
C164078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164078>	C3750|C153068	Unresectable Alveolar Soft Part Sarcoma	An alveolar soft part sarcoma that is not amenable to surgical resection.	Unresectable Alveolar Soft Part Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C164079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164079>	C68751	Smoking at Diagnosis|Smoker at Diagnosis|Smoker at Diagnosis|Smoker at Time of Diagnosis	An indication that a person was a smoker at the time they received a pathologic diagnosis.			Organism Attribute	GDC Terminology|GDC Value Terminology
C16407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16407>	C21099	Cell Survival	A process that encompasses the viability of a cell and its ability to subsist and maintain the integrity of cellular processes. Survival mechanisms ensure that the cell will be able to adapt and carry on cellular activities such as replication, repair, and metabolism.			Cell Function	
C164080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164080>	C7807|C153071	Locally Advanced Ewing Sarcoma	Ewing sarcoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Ewing Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C164081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164081>	C164057	Factory Smokestack Smoke Exposure|Factory Smokestack Emission Exposure|Factory smokestack smoke	Environmental or occupational exposure to airborne gases and particulates emitted by a factory smokestack.			Finding	GDC Terminology|GDC Value Terminology
C164082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164082>	C164058	Field Burning Smoke Exposure|Field burning smoke	Environmental or occupational exposure to airborne gases and particulates produced when trees, brush and grass in a field are burning.			Finding	GDC Terminology|GDC Value Terminology
C164083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164083>	C164057	Furnace or Boiler Smoke Exposure|Furnace or boiler smoke	Environmental, occupational or consumer-based exposure to airborne gases and particulates emitted by a boiler or furnace.			Finding	GDC Terminology|GDC Value Terminology
C164084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164084>	C164057	Propane Smoke Exposue|Burning Propane Smoke Exposue|Gas burning smoke, propane	Environmental, occupational or consumer-based exposure to airborne gases and particulates produced when propane is rapidly oxidized via combustion.			Finding	GDC Terminology|GDC Value Terminology
C164085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164085>	C164061|C164058	Grease Fire Smoke Exposure|Grease fire smoke	Environmental, occupational or consumer-based exposure to airborne gases and particulates produced during a grease fire.			Finding	GDC Terminology|GDC Value Terminology
C164086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164086>	C164061	Grilling Smoke Exposure|Grilling smoke	Environmental, occupational or consumer-based exposure to airborne gases and particulates emitted by an indoor or outdoor grill used for cooking.			Finding	GDC Terminology|GDC Value Terminology
C164087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164087>	C164057	Hashish Smoke Exposure|Hashish smoke	Environmental, occupational or consumer-based exposure to airborne gases and particulates produced by direct or nearby use of a vaporized or combusted product made from cannabis plant resin.			Finding	GDC Terminology|GDC Value Terminology
C164088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164088>	C164064|C164060	Coal-Burining Indoor Stove or Fireplace Smoke Exposure|Indoor Coal-Burining Stove or Fireplace Smoke Exposure|Indoor stove or fireplace smoke, coal burning	Environmental or occupational exposure to airborne gases and particulates produced when coal is subjected to combustion in an indoor stove or fireplace.			Finding	GDC Terminology|GDC Value Terminology
C164089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164089>	C164065|C164064	Wood-Burning Indoor Stove or Fireplace Smoke Exposure|Indoor Wood-Burning Stove or Fireplace Smoke Exposure|Indoor stove or fireplace smoke, wood burning	Environmental or occupational exposure to airborne gases and particulates produced when wood is subjected to combustion in an indoor stove or fireplace.			Finding	GDC Terminology|GDC Value Terminology
C16408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16408>	C199143	Centers for Disease Control and Prevention|CDC	An agency of the US Public Health Service that serves as the national focus for developing and applying disease prevention and control, environmental health and health promotion and health education activities designed to improve the health of the people of the United States. The CDC is responsible for controlling the induction and spread of infectious diseases, and provides consultation and assistance to other nations and international agencies to assist in improving their disease prevention and control, environmental health, and health promotion activities.			Health Care Related Organization	
C164090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164090>	C164057	Machine Smoke Exposure|Machine smoke	Environmental or occupational exposure to airborne gases and particulates through the direct or nearby use of a machine.			Finding	GDC Terminology|GDC Value Terminology
C164091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164091>	C164057	Marijuana Smoke Exposure|Marijuana smoke	Environmental, occupational or consumer-based exposure to airborne gases and particulates produced by direct or nearby use of a vaporized or combusted product made from the leaves and flowers of the cannabis plant.			Finding	GDC Terminology|GDC Value Terminology
C164092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164092>	C164057	No Smoke Exposure	An indication that a subject has no history of smoke exposure from any source.			Finding	GDC Terminology|GDC Value Terminology
C164093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164093>	C164063	Kerosene Smoke Exposure|Burning Kerosene Smoke Exposure|Oil burning smoke, Kerosene	Environmental, occupational or consumer-based exposure to airborne gases and particulates produced when kerosene is rapidly oxidized via combustion.			Finding	GDC Terminology|GDC Value Terminology
C164094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164094>	C164058	Recreational Fire Smoke Exposure|Recreational fire smoke	Environmental, occupational or consumer-based exposure to airborne gases and particulates produced when materials (usually wood) are burned for recreational purposes.			Finding	GDC Terminology|GDC Value Terminology
C164095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164095>	C164061	Smokehouse Smoke Exposure|Smokehouse smoke	Environmental, occupational or consumer-based exposure to airborne gases and particulates produced during indoor smoke curing of food products.			Finding	GDC Terminology|GDC Value Terminology
C164096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164096>	C16960	Embolization Therapy Patient	A person who is receiving embolization therapy.	Embolization Therapy Patient		Patient or Disabled Group	CTRP Intervention Terminology|CTRP Terminology
C164097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164097>	C44456	Cigar Smoke Exposure|Tobacco smoke, cigar	Environmental, occupational or consumer-based exposure to airborne gases and particulates produced by direct or nearby use of a cigar.			Finding	GDC Terminology|GDC Value Terminology
C164098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164098>	C44456	Cigarette Smoke Exposure|Tobacco Smoke, Cigarette|Tobacco smoke, cigarette	Environmental, occupational or consumer-based exposure to airborne gases and particulates produced by direct or nearby use of a cigarette.			Finding	GDC Terminology|GDC Value Terminology
C164099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164099>	C44456	Tobacco Pipe Smoke Exposure|Pipe Smoke Exposure|Tobacco smoke, pipe	Environmental, occupational or consumer-based exposure to airborne gases and particulates produced by direct or nearby use of a tobacco pipe.			Finding	GDC Terminology|GDC Value Terminology
C16409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16409>	C25464	Central African Republic|140|CAF|CAF|CENTRAL AFRICAN REPUBLIC|CENTRAL AFRICAN REPUBLIC|CF	A country in central Africa, north of Democratic Republic of the Congo, between Cameroon and South Sudan.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C1640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1640>	C799	Indium In-111|111 Indium|INDIUM IN-111|In-111|Indium 111	A radioisotope with a physical half-life of 2.83 days, used to label agents for diagnosis, disease progression and treatment. (NCI)			Element, Ion, or Isotope	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C164100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164100>	C164057	Volcanic Smoke Exposure|Volcanic smoke	Environmental exposure to airborne gases and particulates produced by a volcanic event.			Finding	GDC Terminology|GDC Value Terminology
C164101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164101>	C164057	Burning Waste Smoke Exposure|Waste burning smoke	Environmental or occupational exposure to airborne gases and particulates produced when trash or waste is burned.			Finding	GDC Terminology|GDC Value Terminology
C164102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164102>	C164065	Wood-Burning Factory Smoke Exposure|Wood burning smoke, factory	Environmental or occupational exposure to airborne gases and particulates produced when wood is burned in a factory setting.			Finding	GDC Terminology|GDC Value Terminology
C164103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164103>	C16929|C164057	Work-Related Smoke Exposure|Work-related smoke, NOS	Occupational exposure to airborne gases and particulates produced when materials undergo combustion or thermal decomposition.			Finding	GDC Terminology|GDC Value Terminology
C164104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164104>	C164103|C164090	Occupational Artificial Smoke Machine Smoke Exposure|Work-related smoke, artificial smoke machines	Occupational exposure to airborne gases and particulates during the operation of a machine that produces artificial smoke.			Finding	GDC Terminology|GDC Value Terminology
C164105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164105>	C164103	Occupational Fire Fighting Smoke Exposure|Work-related smoke, fire fighting	Occupational exposure to airborne gases and particulates while preventing, controlling or extinguishing fires.			Finding	GDC Terminology|GDC Value Terminology
C164106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164106>	C164103	Occupational Foundry Smoke Exposure|Work-related smoke, foundry	Occupational exposure to airborne gases and particulates during the operation of a foundry.			Finding	GDC Terminology|GDC Value Terminology
C164107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164107>	C164103	Occupational Generator Smoke Exposure|Work-related smoke, generators	Occupational exposure to airborne gases and particulates during the operation of a power generator.			Finding	GDC Terminology|GDC Value Terminology
C164108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164108>	C217121	Sexual Adjustment and Body Image Scale for Gynecologic Cancer|SABIS-G|Sexual Adjustment and Body Image Scale for Gynecologic Cancer (SABIS-G)	A 9-item self-report measure developed to assess disturbances in body image and sexual adjustment after gynecologic cancer.			Intellectual Product	
C164109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164109>	C173792|C173517	How Satisfied with Physical Attractiveness After Gynecologic Cancer Question|After having gynecologic cancer, how satisfied are you with your physical attractiveness|How Satisfied with Physical Attractiveness After Gynecologic Cancer	A question about how satisfied an individual is with their physical attractiveness after having gynecologic cancer.			Intellectual Product	Sexual Adjustment and Body Image Scale for Gynecologic Cancer
C16410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16410>	C18653	Centrifugation|CENTRIFUGATION|CENTRIFUGING|Fractionation, Centrifugation	A process where a rotating machine exposes a specimen to centrifugal force. This process can be used to remove moisture from a specimen, to subject an organism to increased gravitational forces, or to separate the components of heterogeneous mixtures based on density differences.			Laboratory Procedure	CDISC SDTM Biospecimen Events Dictionary Derived Term Terminology|CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C164110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164110>	C173517	How Comfortable with Showing Your Body After Gynecologic Cancer Question|After having gynecologic cancer, how comfortable are you with showing your body to others|How Comfortable with Showing Your Body After Gynecologic Cancer	A question about how comfortable an individual is with showing their body to others after having gynecologic cancer.			Intellectual Product	Sexual Adjustment and Body Image Scale for Gynecologic Cancer
C164111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164111>	C173517	How Comfortable with Changes in Your Body After Gynecologic Cancer Question|How Comfortable with Changes in Your Body After Gynecologic Cancer|How comfortable are you with the changes in your body after having gynecologic cancer	A question about how comfortable an individual is with the changes in their body after having gynecologic cancer.			Intellectual Product	Sexual Adjustment and Body Image Scale for Gynecologic Cancer
C164112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164112>	C173704|C173517	How has Gynecologic Cancer Affected Your Desire for Sexual Contact Question|How has Gynecologic Cancer Affected Your Desire for Sexual Contact|How has having gynecologic cancer affected your desire for sexual contact	A question about how having gynecologic cancer has affected an individual's desire for sexual contact.			Intellectual Product	Sexual Adjustment and Body Image Scale for Gynecologic Cancer
C164113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164113>	C173704|C173517	How has Gynecologic Cancer Affected Your Sexual Relationships Question|How has Gynecologic Cancer Affected Your Sexual Relationships|How has having gynecologic cancer affected your sexual relationship(s)	A question about how having gynecologic cancer has affected an individual's sexual relationship(s).			Intellectual Product	Sexual Adjustment and Body Image Scale for Gynecologic Cancer
C164114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164114>	C173704|C173517	How has Gynecologic Cancer Affected How Often You Initiate Sexual Contact Question|How has Gynecologic Cancer Affected How Often You Initiate Sexual Contact|How has having gynecologic cancer affected how often you initiate sexual contact	A question about how having gynecologic cancer has affected how often an individual initiates sexual contact.			Intellectual Product	Sexual Adjustment and Body Image Scale for Gynecologic Cancer
C164115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164115>	C164103	Occupational Military Smoke Exposure|Work-related smoke, military	Occupational exposure to airborne gases and particulates during a military posting or deployment.			Finding	GDC Terminology|GDC Value Terminology
C164116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164116>	C164103	Occupational Paint Baking Smoke Exposure|Work-related smoke, paint baking	Occupational exposure to airborne gases and particulates during the operation of a paint oven.			Finding	GDC Terminology|GDC Value Terminology
C164117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164117>	C173792|C173704|C173517	How has Gynecologic Cancer Affected Your Sexual Satisfaction when You have Sex Question|How has Gynecologic Cancer Affected Your Sexual Satisfaction when You have Sex|How has having gynecologic cancer affected your sexual satisfaction when you have sex	A question about how having gynecologic cancer has affected an individual's satisfaction when they have sex.			Intellectual Product	Sexual Adjustment and Body Image Scale for Gynecologic Cancer
C164118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164118>	C164103	Occupational Plastics Factory Smoke Exposure|Work-related smoke, plastics factory	Occupational exposure to airborne gases and particulates during the manufacturing of plastics.			Finding	GDC Terminology|GDC Value Terminology
C164119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164119>	C164103	Occupational Plumbing Smoke Exposure|Work-related smoke, plumbing	Occupational exposure to airborne gases and particulates during the installation of plumbing pipes and fixtures.			Finding	GDC Terminology|GDC Value Terminology
C16411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16411>	C16410	Density Gradient Centrifugation|Fractionation, Density Gradient	A method of separating macromolecules by either their differential rate of sedimentation in a centrifugal gradient or their differential buoyancy in a density gradient. (from biology-text.com)			Laboratory Procedure	
C164120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164120>	C164103	Occupational Soldering/Welding Smoke Exposure|Work-related smoke, soldering/welding	Occupational exposure to airborne gases and particulates during the operation of a soldering iron or welding machine.			Finding	GDC Terminology|GDC Value Terminology
C164121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164121>	C175284	Time Between Waking and First Smoke - Within 5 Minutes|Within 5 Minutes	An indication that less than 5 minutes passes between waking and smoking the first cigarette of the day.			Intellectual Product	GDC Terminology|GDC Value Terminology
C164122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164122>	C176250	Not At All Satisfied|not at all satisfied	A subjective response indicating that an individual is not at all satisfied.			Intellectual Product	Sexual Adjustment and Body Image Scale for Gynecologic Cancer
C164123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164123>	C91213|C226647	Not At All Comfortable|not at all comfortable	A subjective response indicating that an individual is not at all comfortable.			Intellectual Product	Sexual Adjustment and Body Image Scale for Gynecologic Cancer
C164124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164124>	C175284	Time Between Waking and First Smoke - Between 6 and 30 Minutes|6-30 Minutes	An indication that between 6 and 30 minutes passes between waking and smoking the first cigarette of the day.			Intellectual Product	GDC Terminology|GDC Value Terminology
C164126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164126>	C175284	Time Between Waking and First Smoke - Between 31 and 60 Minutes|31-60 Minutes	An indication that between 31 and 60 minutes passes between waking and smoking the first cigarette of the day.			Intellectual Product	GDC Terminology|GDC Value Terminology
C164127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164127>	C175284	Time Between Waking and First Smoke - After 60 Minutes|After 60 Minutes	An indication that more than 60 minutes passes between waking and smoking the first cigarette of the day.			Intellectual Product	GDC Terminology|GDC Value Terminology
C164128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164128>	C226647	Somewhat Comfortable|somewhat comfortable	A subjective response indicating that an individual is or was somewhat comfortable.			Intellectual Product	Sexual Adjustment and Body Image Scale for Gynecologic Cancer
C164129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164129>	C226647	Moderately Comfortable|moderately comfortable	A subjective response indicating that an individual is or was moderately comfortable.			Intellectual Product	Sexual Adjustment and Body Image Scale for Gynecologic Cancer
C16412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16412>	C25464	Chad|148|CHAD|CHAD|TCD|TCD|TD	A country in central Africa, south of Libya, between Niger and Sudan.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C164130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164130>	C226647	Very Comfortable|very comfortable	A subjective response indicating that an individual is or was very comfortable.			Intellectual Product	Sexual Adjustment and Body Image Scale for Gynecologic Cancer
C164131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164131>	C226647	Extremely Comfortable|extremely comfortable	A subjective response indicating that an individual is or was extremely comfortable.			Intellectual Product	Sexual Adjustment and Body Image Scale for Gynecologic Cancer
C164132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164132>	C226684	Decreased	A subjective response indicating that something is or has decreased.			Intellectual Product	Sexual Adjustment and Body Image Scale for Gynecologic Cancer
C164133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164133>	C164132	Substantially Decreased	A subjective response indicating that something is or was substantially decreased.			Intellectual Product	Sexual Adjustment and Body Image Scale for Gynecologic Cancer
C164134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164134>	C226661	No Effect|No effect	A subjective response indicating that something has or had no effect.			Intellectual Product	GDC Terminology|GDC Value Terminology|Sexual Adjustment and Body Image Scale for Gynecologic Cancer
C164135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164135>	C226684	Increased	A subjective response indicating that something is or was increased.			Intellectual Product	Sexual Adjustment and Body Image Scale for Gynecologic Cancer
C164136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164136>	C164135	Substantially Increased	A subjective response indicating that something is or was substantially increased.			Intellectual Product	Sexual Adjustment and Body Image Scale for Gynecologic Cancer
C164139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164139>	C125459	Very Much Improved|Very much Improved	A subjective response indicating that something is or was very much improved.			Intellectual Product	Sexual Adjustment and Body Image Scale for Gynecologic Cancer
C16413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16413>	C16548	Chemical Engineering	Chemical Engineering; engineering dealing with the industrial application of chemistry. (WWWebster Dictionary)			Occupation or Discipline	
C164140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164140>	C28676|C201545	iPSC-derived CD16-expressing Natural Killer Cells FT516|FT 516|FT-516|FT-516|FT516|Induced Pluripotent Stem Cell-derived CD16-expressing NK Cells FT516|Induced Pluripotent Stem Cell-derived CD16-expressing Natural Killer Cells FT516	An allogeneic, off-the-shelf, natural killer (NK) cell product derived from a clonal master induced pluripotent stem cell (iPSC) line, and engineered to express a high-affinity, non-cleavable CD16 (hnCD16) Fc receptor, with potential antineoplastic and immunostimulatory activities. Upon administration, iPSC-derived CD16-expressing NK cells FT516 bind to the Fc portion of tumor cell-bound monoclonal antibodies and activate NK cell activation, cytokine secretion and antibody-dependent cellular cytotoxicity (ADCC). CD16, also known as Fc-gamma receptor III, is normally expressed on the surface of NK cells, neutrophils, monocytes and macrophages, and plays a key role in initiating ADCC. It is often downregulated in certain cancers, thereby inhibiting the anti-tumor immune response. FT516 NK cells' hnCD16 Fc receptor prevents downregulation and optimizes binding to tumor-targeting antibodies for enhanced ADCC.	iPSC-derived CD16-expressing Natural Killer Cells FT516		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C164141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164141>	C2916|C156484	Genitourinary System Carcinoma	A carcinoma arising from the genitourinary system. Representative examples include kidney carcinoma, bladder carcinoma, prostate carcinoma, endometrial carcinoma, cervical carcinoma, and ovarian carcinoma.			Neoplastic Process	
C164142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164142>	C42769	Mepitel Film	A proprietary transparent film dressing designed to protect fragile and sensitive skin and minimize risk of skin breakdown. It provides a flexible transparent covering to protect a wound from microbial contamination, fluid strikethrough, or other external contamination.	Mepitel Film		Medical Device	
C164143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164143>	C176859|C153171|C146893	Advanced Genitourinary System Carcinoma	A genitourinary system carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.			Neoplastic Process	
C164144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164144>	C2916	Micropapillary Carcinoma	A carcinoma characterized by the presence of a predominant micropapillary pattern.			Neoplastic Process	
C164145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164145>	C27809	Hodgkin's Sarcoma	An obsolete term referring to a Hodgkin lymphoma that lacks inflammatory elements.			Neoplastic Process	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Morphology PT Terminology|Mapped ICDO3.1 Morphology Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C164146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164146>	C2135	Cedazuridine|(4R)-2'-Deoxy-2',2'-difluoro-3,4,5,6-tetrahydrouridine|CDA Inhibitor E7727|CEDAZURIDINE|E7727|Uridine, 2'-Deoxy-2',2'-difluoro-3,4,5,6-tetrahydro-, (4R)	An orally available synthetic nucleoside analog derived from tetrahydrouridine (THU) and cytidine deaminase inhibitor (CDAi), that can potentially be used to prevent the breakdown of cytidines. Upon oral administration, cedazuridine binds to and inhibits CDA, an enzyme primarily found in the gastrointestinal (GI) tract and liver that catalyzes the deamination of cytidine and cytidine analogs. Given in combination with a cytidine, such as the antineoplastic hypomethylating agent decitabine, it specifically prevents its breakdown and increases its bioavailability and efficacy. In addition, this allows for lower doses of decitabine to be administered, which results in decreased decitabine-associated GI toxicity.	Cedazuridine		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C164147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164147>	C18515	DENND2B Gene Product	A protein encoded by the DENND2B gene.			Amino Acid, Peptide, or Protein	
C164148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164148>	C17494|C164147	Suppression of Tumorigenicity 5 Protein Isoform 2|DENND2B Isoform 2|p82	Suppression of tumorigenicity 5 protein isoform 2 (717 aa, ~82 kDa) is encoded by the human DENND2B gene. This protein is involved in the activation of Ras-related proteins Rab-9A and Rab-9B.			Amino Acid, Peptide, or Protein	
C164149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164149>	C164147	Suppression of Tumorigenicity 5 Protein Isoform 3|DENND2B Isoform 3|p70	Suppression of tumorigenicity 5 protein isoform 3 (609 aa, ~70 kDa) is encoded by the human DENND2B gene. This protein may play a role in the modulation of cell morphology, cell growth and tumor supression.			Amino Acid, Peptide, or Protein	
C16414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16414>	C16987	Chemistry	The science of the composition, structure, properties, and reactions of matter, especially of atomic and molecular systems.			Occupation or Discipline	
C164150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164150>	C20130	CCN Family Protein|CCN|CCN Family|CCN Protein|CCN intercellular Signaling Protein|CYR61, CTGF, NOV Family Protein|CYR61/CTGF/NOV Family Protein|Cellular Communication Network Factor Family	A family of dynamically expressed, non-structural, extracellular matrix (ECM)-associated proteins that are involved in a diverse set of cellular signaling pathways. Members of this family are characterized by having four conserved cysteine-rich domains, which includes an N-terminal insulin-like growth factor-binding domain (IGFBP), a von Willebrand factor type C domain (VWFC), a thrombospondin type 1 repeat (TSP type-1), and a C-terminal cysteine knot domain (CTCK).			Amino Acid, Peptide, or Protein	
C164151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164151>	C54131	Miltenyi Biotec	A global provider of products and services associated with advance biomedical research and cellular therapy that support scientists, clinical researchers, and physicians across basic research, translational research, and clinical applications.			Organization	
C164152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164152>	C138961	PSA Level Greater than or Equal to 0.7|PSA Level 0.7 or Greater	A blood concentration of prostate specific antigen greater than or equal to 0.7 ng/mL.	PSA Level Greater than or Equal to 0.7		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C164153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164153>	C26837	Osteogenesis Imperfecta Type XIX|OI19|Osteogenesis Imperfecta 19	An X-linked recessive sub-type of osteogenesis imperfecta caused by mutation(s) in the MBTPS2 gene, encoding membrane-bound transcription factor site-2 protease. It is characterized by prenatal fractures and osteopenia, with severe short stature in adulthood. Variable dysmorphic features may occur including scoliosis, pectal deformity, and anterior angulation of the tibia.			Disease or Syndrome	Cellosaurus Disease Terminology
C164154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164154>	C53543	Intellectual Developmental Disorder with Cardiac Arrhythmia|IDDCA	An autosomal recessive condition caused by mutation(s) in the GNB5 gene, encoding guanine nucleotide-binding protein subunit beta-5. It is characterized by severe intellectual disability, poor speech acquisition, and cardiac arrhythmia. Biallelic missense mutation in the GNB5 gene can cause language delay and attention deficit-hyperactivity disorder/cognitive impairment with or without cardiac arrhythmia, which is a less-severe disorder with overlapping features.			Disease or Syndrome	Cellosaurus Disease Terminology
C164155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164155>	C35194	Retinal Dystrophy with or without Extraocular Anomalies|RDEOA	An autosomal recessive condition caused by mutation(s) in the RCBTB1 gene, encoding RCC1 and BTB domain-containing protein 1. It is characterized by severe retinal dystrophy. Associated extraocular abnormalities may or may not be present.			Disease or Syndrome	Cellosaurus Disease Terminology
C164156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164156>	C9385|C189241	Fumarate Hydratase-Deficient Renal Cell Carcinoma|FH-Deficient RCC|FH-Deficient Renal Cell Carcinoma|Fumarate Hydratase Deficient Renal Cell Carcinoma	A rare, highly aggressive renal cell carcinoma caused by germline or (in a subset) somatic mutation of fumarate hydratase gene. It arises mostly in the setting of hereditary leiomyomatosis-renal cell carcinoma syndrome.	Fumarate Hydratase-Deficient Renal Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C164157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164157>	C157609	Surgical Complication|Surgical Complications	A disease or disorder that occurs during, soon after or as a result of a surgical procedure.			Finding	GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Protocol Treatment Modifications Table|HL Survival Characteristics Table
C164158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164158>	C164157	Post-Surgical Complication	A disease or disorder that occurs soon after or as a result of a surgical procedure.			Finding	
C164159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164159>	C8064|C157636	Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma	A renal pelvis and ureter urothelial carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16415>	C16414	Analytical Chemistry|Chemistry, Analytical	The branch of chemistry that deals with the quantitative and qualitative identification of substances.			Occupation or Discipline	
C164160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164160>	C7716|C150521	Unresectable Renal Pelvis and Ureter Urothelial Carcinoma	Renal pelvis and ureter urothelial carcinoma that is not amenable to surgical resection.	Unresectable Renal Pelvis and Ureter Urothelial Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C164162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164162>	C215372	Chemotherapy-Induced Alopecia	Alopecia caused by treatment with chemotherapeutic agents.	Chemotherapy-Induced Alopecia		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C164163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164163>	C2348	Therapeutic Growth Hormone|Therapeutic GH	Any agent that is chemically identical to, similar to or can be used as a replacement for endogenous human growth hormone (GH).			Chemical Viewed Functionally	
C164164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164164>	C16546	White Light Endoscopy|WLE|White Light Endoscopic Imaging	Endoscopic examination that uses full-spectrum visible light. An image is captured using a standard color camera, sensitive only to red, green and blue spectral components, replicating the vision of the human eye.	White Light Endoscopy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C164165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164165>	C16546	Hyperspectral Endoscopy|HSI|Hyperspectral Endoscopic Imaging	Endoscopic examination that uses wavelengths of light beyond the standard red/green/blue spectrum. A two-dimensional image is collected, at many different wavelengths enabling both spatial and spectral information to be recorded from a given image.	Hyperspectral Endoscopy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C164166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164166>	C19332	Vaping Status	An indication of an individual's current vaping use.			Organism Attribute	
C164167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164167>	C164166	Current Vaper	A person who uses a vaping device at the present time.	Current Vaper		Organism Attribute	CTRP Disease Terminology|CTRP Terminology
C164168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164168>	C49337	Microwave Tissue Processing|Microwave Processing	A tissue processing technique that uses a microwave oven to uniformly warm the tissue blocks from within the tissue, allowing faster penetration of tissue processing chemicals and resulting in more a rapid process for making paraffin blocks.			Laboratory Procedure	
C164169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164169>	C97928	ABL1 Protein Variant|Abelson Murine Leukemia Viral Oncogene Homolog 1 Protein Variant|Abelson Tyrosine-Protein Kinase 1 Protein Variant|Proto-Oncogene Tyrosine-Protein Kinase ABL Protein Variant|Proto-Oncogene c-Abl Protein Variant|Tyrosine-Protein Kinase ABL1 Protein Variant|p150 Protein Variant	A variation in the amino acid sequence for tyrosine-protein kinase ABL1.			Cell or Molecular Dysfunction	Pediatric Oncology Target Molecular Abnormalities Terminology
C16416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16416>	C16418|C16337	Bioinorganic Chemistry	The scientific field that examines the relationship between biochemistry and inorganic chemistry.			Occupation or Discipline	
C164170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164170>	C164169	ABL1 NP_005148.2:p.A34V|ABL1 NP_005148.2:p.Ala34Val|Abelson Murine Leukemia Viral Oncogene Homolog 1 A34V|Abelson Murine Leukemia Viral Oncogene Homolog 1 Ala34Val|Abelson Tyrosine-Protein Kinase 1 A34V|Abelson Tyrosine-Protein Kinase 1 Ala34Val|NP_005148.2:p.A34V|NP_005148.2:p.Ala34Val|Proto-Oncogene Tyrosine-Protein Kinase ABL A34V|Proto-Oncogene Tyrosine-Protein Kinase ABL Ala34Val|Proto-Oncogene c-Abl A34V|Proto-Oncogene c-Abl Ala34Val|Tyrosine-Protein Kinase ABL1 A34V|Tyrosine-Protein Kinase ABL1 Ala34Val|p150 A34V|p150 Ala34Val	A change in the amino acid residue at position 34 in the tyrosine-protein kinase ABL1 protein where alanine has been replaced by valine.			Cell or Molecular Dysfunction	
C164171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164171>	C133466	ALK NP_004295.2:p.F1245I|ALK F1245I|ALK NP_004295.2:p.Phe1245Ile|ALK Phe1245Ile|ALK Tyrosine Kinase Receptor F1245I|ALK Tyrosine Kinase Receptor Phe1245Ile|ALK p.F1245I|ALK p.Phe1245Ile|Anaplastic Lymphoma Kinase F1245I|Anaplastic Lymphoma Kinase Phe1245Ile|CD246 Antigen F1245I|CD246 Antigen Phe1245Ile|NP_004295.2:p.F1245I|NP_004295.2:p.Phe1245Ile	A change in the amino acid residue at position 1245 in the ALK tyrosine kinase receptor protein where phenylalanine has been replaced by isoleucine.			Cell or Molecular Dysfunction	
C164172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164172>	C137952	ALK NM_004304.4:c.3733T>A|ALK Receptor Tyrosine Kinase c.3733T>A|ALK c.3733T>A|Anaplastic Lymphoma Kinase (Ki-1) c.3733T>A|Anaplastic Lymphoma Receptor Tyrosine Kinase c.3733T>A|CD246 c.3733T>A|NM_004304.4:c.3733T>A	A nucleotide substitution at position 3733 of the coding sequence of the ALK gene where thymine has been mutated to adenine.			Cell or Molecular Dysfunction	
C164173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164173>	C97928	APC Protein Variant|Adenomatosis Polyposis Coli Tumor Suppressor Protein Variant|Adenomatous Polyposis Coli Protein Variant|Deleted In Polyposis 2.5 Protein Variant	A variation in the amino acid sequence for adenomatosis polyposis coli protein.			Cell or Molecular Dysfunction	
C164174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164174>	C164173	APC NP_000029.2:p.D917Y|APC Asp917Tyr|APC D917Y|APC NP_000029.2:p.Asp917Tyr|APC Protein Asp917Tyr|APC Protein D917Y|APC p.Asp917Tyr|APC p.D917Y|Adenomatosis Polyposis Coli Tumor Suppressor Asp917Tyr|Adenomatosis Polyposis Coli Tumor Suppressor D917Y|Adenomatous Polyposis Coli Protein Asp917Tyr|Adenomatous Polyposis Coli Protein D917Y|Deleted In Polyposis 2.5 Asp917Tyr|Deleted In Polyposis 2.5 D917Y|NP_000029.2:p.Asp917Tyr|NP_000029.2:p.D917Y|Protein APC Asp917Tyr|Protein APC D917Y	A change in the amino acid residue at position 917 in the adenomatosis polyposis coli protein where aspartic acid has been replaced by tyrosine.			Cell or Molecular Dysfunction	
C164175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164175>	C16960	Biopsy Patient	A person who is undergoing a biopsy procedure.	Biopsy Patient		Patient or Disabled Group	CTRP Intervention Terminology|CTRP Terminology
C164176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164176>	C158375	Lumpectomy Patient	A person who is undergoing a lumpectomy.	Lumpectomy Patient		Patient or Disabled Group	CTRP Intervention Terminology|CTRP Terminology
C164177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164177>	C97927	B2M Gene Mutation|Beta Chain of MHC Class I Molecules Gene Mutation|Beta-2-Microglobulin Gene Mutation|IMD43 Gene Mutation	A change in the nucleotide sequence of the B2M gene.			Cell or Molecular Dysfunction	
C164178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164178>	C164177	B2M NM_004048.3:c.2T>G|B2M c.2T>G|Beta Chain of MHC Class I Molecules Gene c.2T>G|Beta-2-Microglobulin Gene c.2T>G|IMD43 c.2T>G|NM_004048.3:c.2T>G	A nucleotide substitution at position 2 of the coding sequence of the B2M gene where thymine has been mutated to guanine.			Cell or Molecular Dysfunction	
C164179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164179>	C97928	B2M Protein Variant|Beta-2 Microglobulin Protein Variant|Beta-2-Microglobin Protein Variant|Beta-2-Microglobulin Protein Variant	A variation in the amino acid sequence for the beta-2-microglobulin protein.			Cell or Molecular Dysfunction	
C16417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16417>	C18706|C16415	Clinical Chemistry	The department responsible for performing chemical and enzymatic analyses of body fluids and tissues. (from Handbook of Medical Informatics)			Biomedical Occupation or Discipline	
C164180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164180>	C164179	B2M NP_004039.1:p.M1R|B2M M1R|B2M Met1Arg|B2M NP_004039.1:p.Met1Arg|B2M p.M1R|B2M p.Met1Arg|Beta-2 Microglobulin M1R|Beta-2 Microglobulin Met1Arg|Beta-2-Microglobin M1R|Beta-2-Microglobin Met1Arg|Beta-2-Microglobulin M1R|NP_004039.1:p.M1R|NP_004039.1:p.Met1Arg	A change in the amino acid residue at position 1 in the beta-2-microglobulin protein where methionine has been replaced by arginine.			Cell or Molecular Dysfunction	
C164181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164181>	C198980|C174461	BCOR Final Exon Internal Tandem Duplication|ANOP2 Final Exon Internal Tandem Duplication|BCL6 Co-Repressor Final Exon Internal Tandem Duplication|BCL6 Corepressor Final Exon Internal Tandem Duplication|BCOR Exon 15 ITD|BCOR Exon 16 ITD|BCOR Final Exon ITD|MAA2 Final Exon Internal Tandem Duplication|MCOPS2 Final Exon Internal Tandem Duplication	A genetic abnormality that arises from tandem duplications of the exon encoding the C-terminus of the BCL-6 corepressor (BCOR) protein, which results in constitutive activation of BCOR protein and its downstream signaling pathways.			Cell or Molecular Dysfunction	
C164182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164182>	C98307	BRAF NP_004324.2:p.V504_R506dup|BRAF NP_004324.2:V504_R506dup|BRAF NP_004324.2:p.R506_K507insVLR|BRAF NP_004324.2:p.Val504_Arg506dup|BRAF R506_K507insVLR|BRAF V504_R506 Duplication Mutation|BRAF V504_R506dup|BRAF Val504_Arg506dup|BRAF p.R506_K507insVLR|BRAF p.V504_R506dup|BRAF p.Val504_Arg506dup|NP_004324.2:p.R506_K507insVLR|NP_004324.2:p.V504_R506dup|NP_004324.2:p.Val504_Arg506dup|Serine/Threonine-Protein Kinase B-raf V504_R506dup|Serine/Threonine-Protein Kinase B-raf Val504_Arg506dup	A duplication of the amino acid residues at positions 504, 505 and 506 in the serine/threonine protein kinase B-raf protein that result in a duplication of the sequence valine-leucine-arginine prior to the lysine at residue 507.			Cell or Molecular Dysfunction	
C164183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164183>	C98307	BRAF NP_004324.2:p.A320V|BRAF A320V|BRAF Ala320Val|BRAF NP_004324.2:p.Ala320Val|BRAF p.A320V|BRAF p.Ala320Val|NP_004324.2:p.A320V|NP_004324.2:p.Ala320Val|Serine/Threonine-Protein Kinase B-raf A320V|Serine/Threonine-Protein Kinase B-raf Ala320Val	A change in the amino acid residue at position 320 in the serine/threonine protein kinase B-raf protein where alanine has been replaced by valine.			Cell or Molecular Dysfunction	
C164184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164184>	C98275|C34333	Abdominal Neoplasm, Excluding Pancreas Neoplasm	A  finding of a neoplastic disease in the abdominal cavity, excluding pancreatic neoplastic disease.	Abdominal Neoplasm, Excluding Pancreas Neoplasm		Finding	CTRP Disease Terminology|CTRP Terminology
C164185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164185>	C2919	Aggressive Prostate Adenocarcinoma	Prostate adenocarcinoma that metastasizes quickly to other anatomic sites. It usually has a Gleason score between 8 and 10, a PSA level higher than 20 ng/ml, and is classified as T3b or T4.	Aggressive Prostate Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C164186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164186>	C91233|C2919	Prostate Adenocarcinoma by AJCC v7 Stage	A term that refers to the staging of prostate adenocarcinoma according to the American Joint Committee on Cancer, 7th edition.			Neoplastic Process	
C164187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164187>	C53458	Decerebrate Posture|Decerebrate Posturing	A posture characterized body rigidity and by extension of the neck, arms, and legs. It may indicate brain stem damage and may suggest herniation of the brain.			Finding	
C164188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164188>	C53458	Decorticate Posture|Decorticate Posturing	A posture characterized by body rigidity, flexion of the arms over the chest, clenched fists,  and extension of the legs. It may indicate cerebral damage.			Finding	
C164189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164189>	C25404	Awaken|Awake|Wake|Wake Up	To wake up or become awake.			Conceptual Entity	
C16418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16418>	C16414	Inorganic Chemistry	A field of chemistry concerned with the study of inorganic compounds and ions.			Occupation or Discipline	
C164190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164190>	C48261	Prescreen|Prescreened|Prescreening	To screen in advance of a time or event, often before a more detailed selection process.			Diagnostic Procedure	
C164191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164191>	C54131	Janssen Pharmaceuticals|JRD|Janssen|Janssen Pharmaceutica|Janssen Research and Development|Johnson & Johnson	A pharmaceutical company providing medicines for an array of health concerns in several therapeutic areas. The company conducts research and development into oncology, mental illness, neurological disorders, gastrointestinal disorders, fungal infection, and allergies.			Organization	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 8: Pharmacological Therapy Terminology|Therapies for COVID-19 Terminology
C164192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164192>	C157377	Testosterone Greater than or Equal to 125 ng/dL|Testosterone Greater than or Equal to 125 Nanograms per Deciliter|Testosterone Greater than or Equal to 125 Nanograms/Deciliter	A semiquantitative finding indicating that the concentration of testosterone in a sample is greater than or equal to 125 ng/dL.	Testosterone Greater than or Equal to 125 ng/dL		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C164193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164193>	C177683	NRG1 Gene Fusion Positive|ARIA Gene Fusion Positive|GGF2 Gene Fusion Positive|HGL Gene Fusion Positive|HRG Gene Fusion Positive|HRG1 Gene Fusion Positive|HRGA Gene Fusion Positive|Heregulin Gene Fusion Positive|Heregulin, Alpha Gene Fusion Positive|NDF Gene Fusion Positive|NEU Differentiation Factor Gene Fusion Positive|NRG1 Fusion|NRG1 Fusion Mutation|NRG1 Gene Fusion|Neuregulin 1 Gene Fusion Positive|SMDF Gene Fusion Positive	An indication that the expression of a fusion containing sequences derived from the NRG1 gene has been detected in a sample.	NRG1 Gene Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C164194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164194>	C36345	Loss of SDH Expression|Loss of Mitochondrial Complex II Expression|Loss of Mitochondrial Respiratory Chain Complex II Expression|Loss of Respiratory Complex II Expression|Loss of SDH Complex Expression|Loss of SDH Protein Complex Expression|Loss of SQR Expression|Loss of Succinate Dehydrogenase Expression|Loss of Succinate-Coenzyme Q Reductase Expression|Loss of Succinic Dehydrogenase Expression|SDH Expression Loss	A molecular abnormality indicating the absence of the SDH protein complex.	Loss of SDH Expression		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C164195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164195>	C36345	Loss of FH Expression|FH Expression Loss|FH Loss of Expression|Loss of FH Protein Expression|Loss of Fumarase Expression|Loss of Fumarate Hydratase Expression|Loss of Fumarate Hydratase, Mitochondrial Expression	A molecular abnormality indicating the absence of FH protein.	Loss of FH Expression		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C164196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164196>	C153103|C107579	Activating FGFR2 Gene Mutation|Activating BEK Gene Mutation|Activating CD332 Gene Mutation|Activating ECT1 Gene Mutation|Activating FGFR-2 Gene Mutation|Activating FGFR2 Mutation|Activating Fibroblast Growth Factor Receptor 2 Gene Mutation|Activating K-SAM Gene Mutation|Activating KGFR Gene Mutation|FGFR2 Activating Mutation|FGFR2 Gain of Function Gene Mutation|FGFR2 Gain of Function Mutation|FGFR2 Gene Activation|Fibroblast Growth Factor Receptor 2 Gene Activation|Gain of Function FGFR2 Mutation	A change in the nucleotide sequence of the FGFR2 gene that results in constitutive activation of fibroblast growth factor 2 and its downstream signaling pathways.	Activating FGFR2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C164197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164197>	C153103|C129632	Activating FGFR1 Gene Mutation|Activating BFGFR Gene Mutation|Activating CD331 Gene Mutation|Activating CEK Gene Mutation|Activating FGFBR Gene Mutation|Activating FGFR-1 Gene Mutation|Activating FGFR1 Mutation|Activating FLG Gene Mutation|Activating FLT-2 Gene Mutation|Activating FLT2 Gene Mutation|Activating FMS-Like Tyrosine Kinase 2 Gene Mutation|Activating Fibroblast Growth Factor Receptor 1 Gene Mutation|Activating KAL2 Gene Mutation|Activating N-SAM Gene Mutation|Activating OGD Gene Mutation|FGFR1 Activating Mutation|FGFR1 Gain of Function Gene Mutation|FGFR1 Gain of Function Mutation|FGFR1 Gene Activation|Fibroblast Growth Factor Receptor 1 Gene Activation|Gain of Function FGFR1 Mutation	A change in the nucleotide sequence of the FGFR1 gene that results in constitutive activation of fibroblast growth factor 1 and its downstream signaling pathways.	Activating FGFR1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C164198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164198>	C9118|C4013	Head and Neck Sarcoma	A sarcoma that arises from the head and neck region.			Neoplastic Process	
C164199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164199>	C94299|C165233	Folate Receptor Family Negative|Folate Binding Protein Negative|Folate Receptor Negative|Folate-Binding Protein Negative	An indication that expression of a member of the folate receptor family has not been detected in a sample.	Folate Receptor Family Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C16419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16419>	C16414	Organic Chemistry	A branch of chemistry that deals specifically with the structures, synthesis and reactions of carbon-containing compounds.			Occupation or Discipline	
C1641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1641>	C799	Yttrium Y-90|Y-90|YTTRIUM Y-90|Yttrium 90|yttrium Y 90	Radioactive isotope of yttrium.  A beta/gamma-emitter with a half life of 2.7 days.			Element, Ion, or Isotope	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C164200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164200>	C177686	CYP3A5 Polymorphism Positive|CP35 Polymorphism Positive|CYP3A5 Gene Polymorphism Positive|CYPIIIA5 Polymorphism Positive|Cytochrome P450 Family 3 Subfamily A Member 5 Polymorphism Positive|P450PCN3 Polymorphism Positive|PCN3 Polymorphism Positive	An indication that polymorphism of the CYP3A5 gene has been detected in a sample.	CYP3A5 Polymorphism Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C164201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164201>	C177686	CYP3A4 Polymorphism Positive|CP33 Polymorphism Positive|CP34 Polymorphism Positive|CYP3A3 Polymorphism Positive|CYP3A4 Gene Polymorphism Positive|CYPIIIA3 Polymorphism Positive|CYPIIIA4 Polymorphism Positive|Cytochrome P450 Family 3 Subfamily A Member 4 Polymorphism Positive|HLP Polymorphism Positive|NF-25 Polymorphism Positive|P450C3 Polymorphism Positive|P450PCN1 Polymorphism Positive	An indication that polymorphism of the CYP3A4 gene has been detected in a sample.	CYP3A4 Polymorphism Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C164202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164202>	C160241	Epstein-Barr Virus Reactivation|EBV Reactivation|HHV-4 Reactivation|HHV4 Reactivation|Human Herpesvirus 4 Reactivation|Human Herpesvirus-4 Reactivation	The switching of latent Epstein-Barr virus to a lytic infection.	Epstein-Barr Virus Reactivation		Phenomenon or Process	CTRP Biomarker Terminology|CTRP Terminology
C164203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164203>	C138961	Percent Free Prostate-Specific Antigen Less than 25|Free PSA Less than 25 Percent|Percent Free PSA Less than 25|Percent Free PSA Less than 25 Percent|Percent Free Prostate-Specific Antigen Less than 25 Percent	An indication that less than 25 percent of the prostate-specific antigen in the blood is not bound to other proteins.	Percent Free Prostate-Specific Antigen Less than 25		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C164204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164204>	C81326	Elevated LIF|Elevated D Factor|Elevated Differentiation-Stimulating Factor|Elevated Leukemia Inhibitory Factor|Elevated Leukemia-Inhibitory Factor|Elevated MLPLI|Elevated Melanoma-Derived LPL Inhibitor|LIF High|LIF-High|Leukemia Inhibitory Factor High|Leukemia Inhibitory Factor-High	A finding indicating elevated concentrations of LIF in a sample.	Elevated LIF		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C164205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164205>	C27005|C173118	Biphenotypic Sinonasal Sarcoma|BSNS|Biphenotypic sinonasal sarcoma|Low Grade Sinonasal Sarcoma with Neural and Myogenic Differentiation|Low-Grade Sinonasal Sarcoma with Neural and Myogenic Differentiation|Sinonasal Biphenotypic Sarcoma	A rare, slow-growing, low-grade soft tissue sarcoma arising from the sinonasal tract. It presents with non-specific obstructive nasal symptoms. Morphologically, it is an infiltrative, cellular spindle cell neoplasm. It is associated with rearrangement of the PAX3 gene.			Neoplastic Process	GDC Terminology|GDC Value Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C164206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164206>	C3420|C186814	BRD4 Gene Translocation|BRD4 Translocation|Bromodomain Containing 4 Gene Translocation|Bromodomain-Containing 4 Gene Translocation|CAP Gene Translocation|Chromosome-Associated Protein Gene Translocation|HUNK1 Gene Translocation|HUNKI Gene Translocation|MCAP Gene Translocation	A cytogenetic abnormality that refers to a translocation involving the BRD4 gene.	BRD4 Gene Translocation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C164207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164207>	C133155	PAX3 Gene Rearrangement|HUP2 Gene Rearrangement|PAX3 Rearrangement|Paired Box 3 Gene Rearrangement|Paired Domain Gene 3 Gene Rearrangement	A molecular abnormality indicating rearrangement of the PAX3 gene.			Cell or Molecular Dysfunction	
C164208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164208>	C3420|C180942	BRD3 Gene Translocation|BRD3 Translocation|Bromodomain Containing 3 Gene Translocation|Bromodomain-Containing 3 Gene Translocation|ORFX Gene Translocation|RING3-Like Gene Translocation|RING3L Gene Translocation	A cytogenetic abnormality that refers to a translocation involving the BRD3 gene.	BRD3 Gene Translocation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C164209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164209>	C3420|C212833	MYCN Gene Translocation|MYCN Proto-Oncogene, bHLH Transcription Factor Gene Translocation|MYCN Translocation|N-myc Gene Translocation|NMYC Gene Translocation|Neuroblastoma-Derived V-Myc Avian Myelocytomatosis Viral Related Oncogene Translocation|V-Myc Avian Myelocytomatosis Viral Oncogene Neuroblastoma Derived Homolog Gene Translocation|bHLHe37 Gene Translocation	A cytogenetic abnormality that refers to a translocation involving the MYCN gene.	MYCN Gene Translocation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C16420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16420>	C16974	Medicinal Chemistry|Pharmaceutical Chemistry	A chemistry-based discipline, also involving aspects of biological, medical and pharmaceutical sciences. It is concerned with the invention, discovery, design, identification and preparation of biologically active compounds, the study of their metabolism, the interpretation of their mode of action at the molecular level and the construction of structure-activity relationships.			Biomedical Occupation or Discipline	
C164210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164210>	C129888	PTGS2 c.-765G/C Polymorphism Profile|COX-2 -765G/C Polymorphism Profile|COX2 -765G/C Polymorphism Profile|PTGS2 -765G/C Polymorphism Profile|PTGS2 -765G/C SNP Polymorphism Profile|PTGS2 -765G/C SNP Profile	The determination of the whether the nucleotide at position -765 upstream of the start site of the PTGS2 gene is a guanine or cytosine. The presence of cytosine at this site may indicate a decreased risk for coronary artery disease and an increased risk for gastric cancer in certain populations.	PTGS2 c.-765G/C Polymorphism Profile		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C164211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164211>	C1404|C129825	Multi-mode Kinase Inhibitor EOC317|ACTB-1003|ACTB-1003|EDP317|EOC 317|EOC-317|EOC317|ONC201MMKI EOC317|Urea, N-[4-[4-amino-6-(methoxymethyl)-7-(4-morpholinylmethyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]-2-fluorophenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]-	An orally available, small molecule, multi-mode kinase inhibitor (MMKI), with potential antineoplastic activity. Upon oral administration, MMKI EOC317 targets, binds to and inhibits the activity of a variety of kinases, such as phosphatidylinositol 3 kinase (PI3K), and the receptor tyrosine kinases, fibroblast growth factor receptor (FGFR), angiopoietin-1 receptor (TIE 2), and vascular endothelial growth factor receptor-2 (VEGFR-2). This inhibition may result in an induction of apoptosis of susceptible tumors cells in which these kinases are overexpressed.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C164212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164212>	C158758	Tumor Resection	A surgical procedure in which cancerous tissue is surgically removed.			Health Care Activity	GDC Terminology|GDC Value Terminology
C164213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164213>	C26718	Recurrent Pyogenic Cholangitis|Cholangiohepatitis|RPC	A recurrent form of cholangitis that is characterized by intrabiliary pigment stone formation, biliary tree stricture and obstruction, and recurrent bouts of cholangitis. There is an association with biliary parasitosis, but evidence supporting these infections in the pathogenesis of recurrent pyogenic cholangitis is inconclusive. The most common causes of death are sepsis, liver failure, or complications from cirrhosis. Patients are also at increased risk of cholangiocarcinoma.			Disease or Syndrome	GDC Terminology|GDC Value Terminology
C164214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164214>	C162153|C158960	Advanced Pancreatic Ductal Adenocarcinoma	Pancreatic ductal adenocarcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Pancreatic Ductal Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C164215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164215>	C25190	Person by Age Group	A person characterized by their age group.			Human	
C164216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164216>	C164215	Child Individual|Child	An individual between the ages of 2-12. There can be some variation depending on the culture.			Human	
C164217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164217>	C20401|C129822	Anti-GFRAL Monoclonal Antibody NGM120|GFRAL Antagonistic Monoclonal Antibody NGM120|NGM 120|NGM-120|NGM120	A long-acting monoclonal antibody directed against glial-cell-derived neurotrophic factor (GDNF) family receptor alpha-like (GFRAL), with potential anti-anorexia and anti-cachexia activities. Upon administration, NGM120 targets, binds to and blocks GFRAL. This prevents binding of growth differentiation factor 15 (GDF15; MIC-1) to its receptor GFRAL and prevents GDF15/GFRAL-mediated signaling. This may abrogate loss of appetite and uncontrolled weight loss associated with high serum levels of GDF15. GDF15, a stress response cytokine and divergent member of the TGF-beta superfamily, plays a key role in the regulation of body weight through central mechanisms. High GDF15 plasma levels, as seen in individuals with advanced cancers, are associated with loss of body mass.	Anti-GFRAL Monoclonal Antibody NGM120		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C164218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164218>	C185612	Sitneprotafib|JAB 3312|JAB-3312|JAB3312|SHP2 Inhibitor JAB-3312|SITNEPROTAFIB	An orally bioavailable allosteric inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; Src homology region 2 domain phosphatase; PTPN11), with potential antineoplastic activity. Upon oral administration, sitneprotafib targets, binds to and inhibits the activity of SHP2. This prevents SHP2-mediated signaling, inhibits MAPK signaling and prevents growth of SHP2-expressing tumor cells. SHP2, an oncoprotein overexpressed in a variety of cancer cell types, regulates cell survival, differentiation and proliferation through activation of the Ras-Raf-MEK-ERK signaling pathway. The Ras-MAPK pathway is often hyperactivated in cancer cells due to specific mutations and rearrangements, which are dependent on SHP2 for their oncogenic signaling. SHP2 also regulates programmed cell death 1 (PD-1)-mediated signal transduction and is involved in immune checkpoint modulation.	Sitneprotafib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C164219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164219>	C19332	Breast Measurement	A description of the physical dimensions of a breast, which may include height, width, depth, and volume.	Breast Measurement		Organism Attribute	CTRP Intervention Terminology|CTRP Terminology
C16421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16421>	C16414	Physical Chemistry|Chemistry, Physical	The branch of chemistry dealing with the physical properties of chemical substances. Chemical thermodynamics, chemical kinetics, quantum chemistry, statistical mechanics, and spectroscopy are some areas of chemistry comprising the bulk of physical chemistry.			Occupation or Discipline	
C164220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164220>	C36286	Renal Function|Kindey Function	Pertaining to the physiologic processes of the kidneys.	Renal Function		Finding	CTRP Disease Terminology|CTRP Terminology
C164221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164221>	C3837	Cushing Triad|Cushing's Triad	A group of signs that often occurs in response to increased intracranial pressure: hypertension, bradycardia, and irregular breathing.			Finding	
C164222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164222>	C156829	Current Reformed Smoker Within 1 Year	An individual who stopped smoking within the past 12 months.	Current Reformed Smoker Within 1 Year		Intellectual Product	CTRP Disease Terminology|CTRP Terminology
C164223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164223>	C164167	Current Daily Vaper|Daily Vaper|Every Day Vaper	A person who uses a vaping device at least once every day.	Current Daily Vaper		Organism Attribute	CTRP Disease Terminology|CTRP Terminology
C164224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164224>	C140267	Spastic Paraplegia 47|SPG47	An autosomal recessive sub-type of hereditary spastic paraplegia caused by mutation(s) in the AP4B1 gene, encoding AP-4 complex subunit beta-1. It is characterized by severe mental retardation and spasticity.			Disease or Syndrome	Cellosaurus Disease Terminology
C164225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164225>	C101216	Nemaline Myopathy 4|NEM4	An autosomal dominant myopathy caused by mutation(s) in the TPM2 gene, encoding tropomyosin beta chain. Classification of nemaline myopathies by clinical features is not optimal, as the phenotypes are highly variable.			Disease or Syndrome	Cellosaurus Disease Terminology
C164226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164226>	C84528	Achromatopsia 5|ACHM5	An autosomal recessive condition caused by mutation(s) in the PDE6C gene, encoding cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha. It is characterized by low visual acuity and severe color vision defects. This condition is closely related to cone dystrophy 4, which is also caused by mutation(s) in the PDE6C gene.			Disease or Syndrome	Cellosaurus Disease Terminology
C164227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164227>	C185877	Ziftomenib|KO 539|KO-539|KO539|Komzifti|Menin-KMT2A Inhibitor KO 539|Menin-MLL Inhibitor KO-539|Menin-MLL Interaction Inhibitor KO 539|Menin-Mixed Lineage Leukemia Protein-Protein Interaction Inhibitor KO 539|ZIFTOMENIB	An orally bioavailable inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) fusion protein, with potential antineoplastic activity. Upon oral administration, ziftomenib prevents the interaction between the two proteins menin and MLL, and thus the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of MLL-rearranged leukemic cells. The menin-MLL complex plays a key role in the survival, growth and proliferation of certain kinds of leukemia cells.	Ziftomenib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C164228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164228>	C9479|C4910	Hereditary Colon Carcinoma	Colon carcinoma that has developed in relatives of patients with a history of colon carcinoma.	Hereditary Colon Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C164229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164229>	C27993	Identified By|Identifier|Identifying Person	Indicates the person or authoritative body who made an identification.			Qualitative Concept	
C16422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16422>	C28486	Chemotactic Process|Chemotaxis	The characteristic directional movement or orientation of an organism or cell along a chemical concentration gradient either toward or away from the chemical stimulus.			Phenomenon or Process	
C164230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164230>	C28681	NSCLC-specific Marrow Infiltrating Lymphocytes|MILs-NSCLC|Marrow Infiltrating Lymphocytes-Non-Small Cell Lung Cancer|NSCLC-specific MILs	A preparation of autologous, ex-vivo activated and expanded, bone marrow-derived infiltrating lymphocytes (MILs) from a non-small cell lung cancer (NSCLC) patient, with potential antineoplastic and immunomodulating activities. Upon administration of the NSCLC-specific MILs, the T cells target and destroy the destroy the patient's NSCLC cells.	NSCLC-specific Marrow Infiltrating Lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C164231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164231>	C16960	Imaging Patient	A person undergoing a medical imaging procedure.			Patient or Disabled Group	
C164232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164232>	C164231	Radiation Therapy Patient	A person undergoing radiation therapy.	Radiation Therapy Patient		Patient or Disabled Group	CTRP Intervention Terminology|CTRP Terminology
C164233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164233>	C164231	MRI Patient	A person undergoing magnetic resonance imaging.	MRI Patient		Patient or Disabled Group	CTRP Intervention Terminology|CTRP Terminology
C164234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164234>	C164231	PET/CT Patient	A person undergoing PET/CT imaging.	PET/CT Patient		Patient or Disabled Group	CTRP Intervention Terminology|CTRP Terminology
C164235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164235>	C16742	AVATAR|Audiovisual-Assisted Therapeutic Ambience in Radiation Therapy	An audiovisual system consisting of a digital media player with wireless streaming and pico projector, and a radiolucent display screen positioned within a child's field of view to provide them with entertainment and distraction for the duration of serial radiation therapy treatments without the need for daily anesthesia.	AVATAR		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C164236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164236>	C4033|C165745	Refractory Clear Cell Renal Cell Carcinoma	A clear cell renal cell carcinoma that is resistant to treatment.	Refractory Clear Cell Renal Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C164238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164238>	C61471	Chemical Attenuation|Chemical attenuation	The use of a chemical agent to reduce the force or intensity of something.			Activity	CBDD Process Terminology|CBDD Terminology
C164239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164239>	C61471	Ultraviolet Irradiation Attenuation|UV Irradiation-Based Attenuation|Ultraviolet irradiation attenuation	The use of ultraviolet radiation to reduce the force or intensity of something.			Activity	CBDD Process Terminology|CBDD Terminology
C16423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16423>	C20587	Child|CHILD|Children|Children (0-21)	An age group comprised of individuals who are not yet an adult. The specific cut-off age will vary by purpose.			Age Group	National Health Interview Survey|NICHD Terminology
C164241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164241>	C14134	Cross-Linked Chemical Connection Points|Cross-Linking Connection Points|Cross-linked structural repeat unit connection points	The atoms that make up the head and the tail points within a structural repeat unit that are involved in cross-links in a polymer.			Chemical Viewed Structurally	CBDD Structure Terminology|CBDD Terminology
C164242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164242>	C73478	Nucleotide Polymer|Polynucleotide|Polynucleotide	A biopolymer composed of nucleotide monomers.			Chemical Viewed Structurally	CBDD Structure Terminology|CBDD Terminology
C164243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164243>	C103246	Structural Repeat Unit|Structural Repeating Unit|Structural repeat unit	A chemical fragment that represents a single repeating structure in a polymer.			Conceptual Entity	CBDD Structure Terminology|CBDD Terminology
C164244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164244>	C103246	Repeat Unit|Repeating Unit|mer	One or more chemical structures that represent a repeating element in a polymer. A repeat unit may be made of one or more structural repeat units.			Conceptual Entity	
C164245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164245>	C153069|C121792	Metastatic Malignant PEComa	A malignant PEComa that has spread from its original site of growth to another anatomic site.	Metastatic Malignant PEComa		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C164246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164246>	C164245|C162194	Advanced Malignant PEComa	A malignant PEComa that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Malignant PEComa		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C164247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164247>	C226556|C153476	Locally Advanced Unresectable Malignant PEComa	A malignant PEComa that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.	Locally Advanced Unresectable Malignant PEComa		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C164248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164248>	C4102	Warty Carcinoma	A squamous cell carcinoma characterized by a papillary growth pattern, hyperkeratosis, and koilocytosis.			Neoplastic Process	Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C164249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164249>	C8366	Differentiated Intraepithelial Neoplasia	Intraepithelial neoplasia of the penis or vulva. It usually presents as a solitary white or pink macule or plaque that may be slightly elevated. A background of long-standing lichen sclerosus is often present.			Neoplastic Process	Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C16424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16424>	C19683	Childhood Abuse and Neglect|Child Abuse and Neglect	Cases of harm to a child caused by parents or other caregivers, defined by the Federal government as: any recent act or failure to act on the part of a parent or caretaker which results in death, serious physical or emotional harm, sexual abuse or exploitation; or an act or failure to act which presents an imminent risk of serious harm.			Event	
C164250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164250>	C2929	Human Papillomavirus-Independent Squamous Cell Carcinoma|HPV-Independent Squamous Cell Carcinoma|HPV-Negative Squamous Cell Carcinoma|Human Papillomavirus-Negative Squamous Cell Carcinoma|Squamous cell carcinoma, HPV-negative	A squamous cell carcinoma not associated with human papilloma virus infection.			Neoplastic Process	GDC Terminology|GDC Value Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C164251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164251>	C4117	Sinonasal Exophytic Papilloma|Sinonasal Exophytic Schneiderian Papilloma|Sinonasal Papilloma, Exophytic Type	A papilloma with an exophytic growth arising from the sinonasal track.			Neoplastic Process	Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C164252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164252>	C4120|C39853	Invasive Sarcomatoid Urothelial Carcinoma|Infiltrating Urothelial Carcinoma, Sarcomatoid Variant|Invasive Urothelial Carcinoma, Sarcomatoid Variant	An invasive urothelial carcinoma that exhibits spindle cell sarcomatoid features.			Neoplastic Process	Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C164253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164253>	C36207	Gastrointestinal Tract Adenoma, Intestinal-Type|Adenoma, Intestinal-Type|Digestive System Adenoma, Intestinal-Type|GI Adenoma, Intestinal-Type|GI Tract Adenoma, Intestinal-Type	An adenoma that arises from the glandular epithelium of the gastrointestinal tract and is associated with intestinal-type differentiation.			Neoplastic Process	Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C164254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164254>	C54241	Neuroendocrine and Non-Neuroendocrine Neoplastic Components Present	A microscopic finding indicating the presence of two cellular neoplastic components, neuroendocrine and non-neuroendocrine, in a tissue sample.			Finding	
C164255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164255>	C6930|C3709	Mixed Neuroendocrine Non-Neuroendocrine Neoplasm|MINEN|MiNEN	A rare neoplasm that consists of neuroendocrine and non-neuroendocrine cellular components. At least 30% of either component should be present for the diagnosis to be made.			Neoplastic Process	GDC Terminology|GDC Value Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C164256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164256>	C4603|C4117	Nasal Cavity Papilloma|Nasal Cavity Schneiderian Papilloma	A papilloma that arises from the ciliated respiratory mucosa that lines the nasal cavity.			Neoplastic Process	
C164257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164257>	C16960	Benign Gynecologic Care Patient	A person who is being medically treated for a non-malignant gynecological condition.	Benign Gynecologic Care Patient		Patient or Disabled Group	CTRP Intervention Terminology|CTRP Terminology
C164258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164258>	C17354|C157381	CCND3 NM_001760.4:c.766_776del11|CCND3 c.766_776del11|Cyclin D3 c.766_776del11|NM_001760.4:c.766_776del|NM_001760.4:c.766_776del11	A deletion of eleven nucleotides from the coding sequence of the CCND3 gene from position 766 through 776.			Cell or Molecular Dysfunction	
C164259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164259>	C97928	CCND3 Protein Variant|Cyclin D3 Protein Variant|Cyclin-D3 Protein Variant|G1/S-Specific Cyclin D3 Protein Variant|G1/S-Specific Cyclin-D3 Protein Variant	A variation in the amino acid sequence for the G1/S-specific cyclin-D3 protein.			Cell or Molecular Dysfunction	
C16425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16425>	C17026	Child Psychiatry	A subdiscipline of psychology centered on the special mental health needs of non-adults.			Biomedical Occupation or Discipline	
C164260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164260>	C164259	CCND3 NP_001751.1:p.R256fs*64|CCND3 Arg256fsTer64|CCND3 NP_001751.1:p.Arg256fsTer64|CCND3 R256fs*64|CCND3 p.Arg256fsTer64|CCND3 p.R256fs*64|Cyclin D3 Arg256fsTer64|Cyclin D3 R256fs*64|Cyclin-D3 Arg256fsTer64|Cyclin-D3 R256fs*64|G1/S-Specific Cyclin D3 Arg256fsTer64|G1/S-Specific Cyclin D3 R256fs*64|G1/S-Specific Cyclin-D3 Arg256fsTer64|G1/S-Specific Cyclin-D3 R256fs*64|NP_001751.1:p.Arg256Serfs*64|NP_001751.1:p.Arg256fsTer64|NP_001751.1:p.R256Sfs*64|NP_001751.1:p.R256fs*64	A change in the amino acid composition of the G1/S-specific cyclin-D3 protein where a frameshift mutation results in the insertion of 63 non-canonic amino acids followed by a stop codon immediately after the arginine residue at position 256.			Cell or Molecular Dysfunction	
C164261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164261>	C97927	CD74 Gene Mutation|CD74 Molecule Gene Mutation|DHLAG Gene Mutation|Gamma Chain of Class II Antigens Gene Mutation|HLA-DR-Gamma Gene Mutation|HLADG Gene Mutation|II Gene Mutation|Ia-GAMMA Gene Mutation|Ii Gene Mutation|MHC HLA-DR Gamma Chain Gene Mutation	A change in the nucleotide sequence of the CD74 gene.			Cell or Molecular Dysfunction	
C164262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164262>	C97928	CD74 Protein Variant|CD74 Antigen Protein Variant|HLA Class II Histocompatibility Antigen Gamma Chain Protein Variant|HLA-DR Antigens-Associated Invariant Chain Protein Variant|Ia Antigen-Associated Invariant Chain Protein Variant|Ii Protein Variant	A variation in the amino acid sequence for the HLA class II histocompatibility antigen gamma chain protein.			Cell or Molecular Dysfunction	
C164263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164263>	C164262	CD74 NP_001020329.1:p.P98S|CD74 Antigen P98S|CD74 Antigen Pro98Ser|CD74 NP_001020329.1:p.Pro98Ser|CD74 P98S|CD74 Pro98Ser|CD74 p.P98S|CD74 p.Pro98Ser|HLA Class II Histocompatibility Antigen Gamma Chain P98S|HLA Class II Histocompatibility Antigen Gamma Chain Pro98Ser|HLA-DR Antigens-Associated Invariant Chain P98S|HLA-DR Antigens-Associated Invariant Chain Pro98Ser|Ia Antigen-Associated Invariant Chain P98S|Ia Antigen-Associated Invariant Chain Pro98Ser|Ii P98S|Ii Pro98Ser|NP_001020329.1:p.P98S|NP_001020329.1:p.Pro98Ser	A change in the amino acid residue at position 98 in the HLA class II histocompatibility antigen gamma chain protein where proline has been replaced by serine.			Cell or Molecular Dysfunction	
C164264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164264>	C43375	CDC73 NM_024529.4:c.1A>G|C1orf28 c.1A>G|CDC73 c.1A>G|Cell Division Cycle 73 c.1A>G|Chromosome 1 Open Reading Frame 28 c.1A>G|FIHP c.1A>G|HPTJT c.1A>G|HRPT1 c.1A>G|HRPT2 c.1A>G|HYX c.1A>G|Hyperparathyroidism 1 c.1A>G|Hyperparathyroidism 2 (With Jaw Tumor) c.1A>G|NM_024529.4:c.1A>G	A nucleotide substitution at position 1 of the coding sequence of the CDC73 gene where adenine has been mutated to guanine.			Cell or Molecular Dysfunction	
C164265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164265>	C97928	CDC73 Protein Variant|Cell Division Cycle Protein 73 Homolog Protein Variant|Hyperparathyroidism 2 Protein Variant|Paf1/RNA Polymerase II Complex Component Protein Variant|Parafibromin Protein Variant	A variation in the amino acid sequence for the parafibromin protein.			Cell or Molecular Dysfunction	
C164266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164266>	C164265	CDC73 NP_078805.3:p.M1V|CDC73 M1V|CDC73 Met1Val|CDC73 NP_078805.3:p.Met1Val|CDC73 p.M1V|CDC73 p.Met1Val|Cell Division Cycle Protein 73 Homolog M1V|Cell Division Cycle Protein 73 Homolog Met1Val|Hyperparathyroidism 2 Protein M1V|Hyperparathyroidism 2 Protein Met1Val|NP_078805.3:p.M1V|NP_078805.3:p.Met1Val|Paf1/RNA Polymerase II Complex Component M1V|Paf1/RNA Polymerase II Complex Component Met1Val|Parafibromin M1V|Parafibromin Met1Val	A change in the amino acid residue at position 1 in the parafibromin protein where methionine has been replaced by valine.			Cell or Molecular Dysfunction	
C164267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164267>	C128817	CDKN2A NM_000077.4:c.305C>T|CDK4I c.305C>T|CDKN2 c.305C>T|CDKN2A c.305C>T|Cyclin Dependent Kinase Inhibitor 2A c.305C>T|INK4A c.305C>T|MLM c.305C>T|MTS-1 c.305C>T|MTS1 c.305C>T|NM_000077.4:c.305C>T	A nucleotide substitution at position 305 of the coding sequence of the CDKN2A gene where cytosine has been mutated to thymine.			Cell or Molecular Dysfunction	
C164269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164269>	C146926	CDKN2A NP_000068.1:p.A102V|CDK4I Protein Variant A102V|CDK4I Protein Variant Ala102Val|CDKN2A A102V|CDKN2A Ala102Val|CDKN2A NP_000068.1:p.Ala102Val|CDKN2A p.A102V|CDKN2A p.Ala102Val|Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant A102V|Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant Ala102Val|Cyclin-Dependent Kinase Inhibitor 2A Protein Variant A102V|Cyclin-Dependent Kinase Inhibitor 2A Protein Variant Ala102Val|Cyclin-Dependent Kinase Inhibitor p16 Protein Variant A102V|Cyclin-Dependent Kinase Inhibitor p16 Protein Variant Ala102Val|NP_000068.1:p.A102V|NP_000068.1:p.Ala102Val|p16(INK4a) Protein Variant A102V|p16(INK4a) Protein Variant Ala102Val|p16-INK4 Protein Variant A102V|p16-INK4 Protein Variant Ala102Val|p16INK4A Protein Variant A102V|p16INK4A Protein Variant Ala102Val	A change in the amino acid residue at position 102 in the cyclin-dependent kinase inhibitor 2 protein where alanine has been replaced by valine.			Cell or Molecular Dysfunction	
C16426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16426>	C18740	Developmental Psychology, Child	Developmental psychology research focusing on the childhood years.			Biomedical Occupation or Discipline	
C164270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164270>	C146926	CDKN2A NP_000068.1:p.R80X|CDK4I Protein Variant Arg80Xxx|CDK4I Protein Variant R80X|CDKN2A Arg80Xxx|CDKN2A NP_000068.1:p.Arg80Xxx|CDKN2A R80X|CDKN2A p.Arg80Xxx|CDKN2A p.R80X|Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant Arg80Xxx|Cyclin-Dependent Kinase 4 Inhibitor A Protein Variant R80X|Cyclin-Dependent Kinase Inhibitor 2A Protein Variant Arg80Xxx|Cyclin-Dependent Kinase Inhibitor 2A Protein Variant R80X|Cyclin-Dependent Kinase Inhibitor p16 Protein Variant Arg80Xxx|Cyclin-Dependent Kinase Inhibitor p16 Protein Variant R80X|NP_000068.1:p.Arg80Xxx|NP_000068.1:p.R80X|p16(INK4a) Protein Variant Arg80Xxx|p16(INK4a) Protein Variant R80X|p16-INK4 Protein Variant Arg80Xxx|p16-INK4 Protein Variant R80X|p16INK4A Protein Variant Arg80Xxx|p16INK4A Protein Variant R80X	A change in the amino acid residue at position 80 in the cyclin-dependent kinase inhibitor 2 protein where arginine has been replaced by another amino acid.			Cell or Molecular Dysfunction	
C164271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164271>	C97928	CSF1R Protein Variant|CD115 Antigen Protein Variant|CD115 Protein Variant|CSF-1 Receptor Protein Variant|CSF-1-R Protein Variant|CSF-1R Protein Variant|Colony Stimulating Factor 1 Receptor Protein Variant|M-CSF-R Protein Variant|Macrophage Colony Stimulating Factor I Receptor Protein Variant|Macrophage Colony-Stimulating Factor 1 Receptor Protein Variant|Proto-Oncogene c-Fms Protein Variant|c-FMS Protein Variant	A variation in the amino acid sequence for the macrophage colony-stimulating factor 1 receptor protein.			Cell or Molecular Dysfunction	
C164272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164272>	C133687	CSF1R NM_005211.3:c.1085A>G|CD115 c.1085A>G|CSF-1R Gene Mutation c.1085A>G|CSF1R c.1085A>G|CSFR c.1085A>G|Colony Stimulating Factor 1 Receptor c.1085A>G|FMS c.1085A>G|M-CSF-R c.1085A>G|Macrophage Colony-Stimulating Factor 1 Receptor c.1085A>G|NM_005211.3:c.1085A>G|c-FMS c.1085A>G|v-FMS McDonough Feline Sarcoma Viral Oncogene Homolog c.1085A>G	A nucleotide substitution at position 1085 of the coding sequence of the CSF1R gene where adenine has been mutated to guanine.			Cell or Molecular Dysfunction	
C164273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164273>	C164271	CSF1R NP_005202.2:p.H362R|CD115 Antigen H362R|CD115 Antigen His362Arg|CD115 H362R|CD115 His362Arg|CSF-1 Receptor H362R|CSF-1 Receptor His362Arg|CSF-1-R H362R|CSF-1-R His362Arg|CSF-1R H362R|CSF-1R His362Arg|CSF1R H362R|CSF1R His362Arg|CSF1R NP_005202.2:p.His362Arg|CSF1R p.H362R|CSF1R p.His362Arg|Colony Stimulating Factor 1 Receptor H362R|Colony Stimulating Factor 1 Receptor His362Arg|M-CSF-R H362R|M-CSF-R His362Arg|Macrophage Colony Stimulating Factor I Receptor H362R|Macrophage Colony Stimulating Factor I Receptor His362Arg|Macrophage Colony-Stimulating Factor 1 Receptor H362R|Macrophage Colony-Stimulating Factor 1 Receptor His362Arg|NP_005202.2:p.H362R|NP_005202.2:p.His362Arg|Proto-Oncogene c-Fms H362R|Proto-Oncogene c-Fms His362Arg|c-FMS H362R|c-FMS His362Arg	A change in the amino acid residue at position 362 in the macrophage colony-stimulating factor 1 receptor protein where histidine has been replaced by arginine.			Cell or Molecular Dysfunction	
C164274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164274>	C164271	CSF1R NP_005202.2:p.N648S|CD115 Antigen Asn648Ser|CD115 Antigen N648S|CD115 Asn648Ser|CD115 N648S|CSF-1 Receptor Asn648Ser|CSF-1 Receptor N648S|CSF-1-R Asn648Ser|CSF-1-R N648S|CSF-1R Asn648Ser|CSF-1R N648S|CSF1R Asn648Ser|CSF1R N648S|CSF1R NP_005202.2:p.Asn648Ser|CSF1R p.Asn648Ser|CSF1R p.N648S|Colony Stimulating Factor 1 Receptor Asn648Ser|Colony Stimulating Factor 1 Receptor N648S|M-CSF-R Asn648Ser|M-CSF-R N648S|Macrophage Colony Stimulating Factor I Receptor Asn648Ser|Macrophage Colony Stimulating Factor I Receptor N648S|Macrophage Colony-Stimulating Factor 1 Receptor Asn648Ser|Macrophage Colony-Stimulating Factor 1 Receptor N648S|NP_005202.2:p.Asn648Ser|NP_005202.2:p.N648S|Proto-Oncogene c-Fms Asn648Ser|Proto-Oncogene c-Fms N648S|c-FMS Asn648Ser|c-FMS N648S	A change in the amino acid residue at position 648 in the macrophage colony-stimulating factor 1 receptor protein where asparagine has been replaced by serine.			Cell or Molecular Dysfunction	
C164275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164275>	C97928	CSF3R Protein Variant|CD114 Antigen Protein Variant|CD114 Protein Variant|Colony Stimulating Factor 3 Receptor Protein Variant|G-CSF Receptor Protein Variant|G-CSF-R Protein Variant|GCSF Receptor Protein Variant|GCSFR Protein Variant|Granulocyte Colony-Stimulating Factor Receptor Protein Variant	A variation in the amino acid sequence for the granulocyte colony-stimulating factor receptor protein.			Cell or Molecular Dysfunction	
C164276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164276>	C164275	CSF3R NP_758519.1:p.G751A|CD114 Antigen G751A|CD114 Antigen Gly751Ala|CD114 G751A|CD114 Gly751Ala|CSF3R G751A|CSF3R Gly751Ala|CSF3R NP_758519.1:p.Gly751Ala|CSF3R p.G751A|CSF3R p.Gly751Ala|Colony Stimulating Factor 3 Receptor G751A|Colony Stimulating Factor 3 Receptor Gly751Ala|G-CSF Receptor G751A|G-CSF Receptor Gly751Ala|G-CSF-R G751A|G-CSF-R Gly751Ala|GCSF Receptor G751A|GCSF Receptor Gly751Ala|GCSFR G751A|GCSFR Gly751Ala|Granulocyte Colony-Stimulating Factor Receptor G751A|Granulocyte Colony-Stimulating Factor Receptor Gly751Ala|NP_758519.1:p.G751A|NP_758519.1:p.Gly751Ala	A change in the amino acid residue at position 751 in the granulocyte colony-stimulating factor receptor protein where glycine has been replaced by alanine.			Cell or Molecular Dysfunction	
C164277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164277>	C16664	Nutrition Education	Any combination of educational strategies designed to facilitate voluntary adoption of food choices and other food- and nutrition-related behaviors conducive to health and well-being.	Nutrition Education		Educational Activity	CTRP Intervention Terminology|CTRP Terminology
C164278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164278>	C16742	Cancer Vision Goggles|CVG	See-through goggles that allow a surgeon to interoperably see cancer cells that have taken up a fluorescent dye, allowing the surgeon to distinguish tumor tissue from healthy tissue in real-time.	Cancer Vision Goggles		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C164279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164279>	C97928	CTNNB1 Protein Variant|Beta Catenin Protein Variant|Beta-Catenin Protein Variant|CTNNB Protein Variant|Cadherin-Associated Protein, Beta Protein Variant|Catenin Beta-1 Protein Variant|Catenin, Beta-1 Protein Variant	A variation in the amino acid sequence for the catenin beta-1 protein.			Cell or Molecular Dysfunction	Pediatric Oncology Target Molecular Abnormalities Terminology
C16427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16427>	C25464	Chile|152|CHILE|CHILE|CHL|CHL|CL	A country in southwestern South America, bordering the South Pacific Ocean, between Argentina and Peru.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF1 Registration Table|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C164280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164280>	C36659	CTNNB1 NM_001098209.2:c.121A>G|Beta Catenin c.121A>G|Beta-Catenin c.121A>G|CTNNB c.121A>G|CTNNB1 c.121A>G|Cadherin-Associated Protein, Beta 1 (88kD) c.121A>G|Cadherin-Associated Protein, Beta c.121A>G|Catenin Beta 1 c.121A>G|Catenin Beta-1 c.121A>G|NM_001098209.2:c.121A>G	A nucleotide substitution at position 121 of the coding sequence of the CTNNB1 gene where adenine has been mutated to guanine.	CTNNB1 NM_001098209.2:c.121A>G		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C164281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164281>	C164279	CTNNB1 NP_001091679.1:p.T41A|Beta Catenin T41A|Beta Catenin Thr41Ala|Beta-Catenin T41A|Beta-Catenin Thr41Ala|CTNNB T41A|CTNNB Thr41Ala|CTNNB1 NP_001091679.1:p.Thr41Ala|CTNNB1 T41A|CTNNB1 T41A Mutation|CTNNB1 Thr41Ala|CTNNB1 p.T41A|CTNNB1 p.Thr41Ala|Cadherin-Associated Protein, Beta T41A|Cadherin-Associated Protein, Beta Thr41Ala|Catenin Beta-1 T41A|Catenin Beta-1 Thr41Ala|Catenin, Beta-1 T41A|Catenin, Beta-1 Thr41Ala|NP_001091679.1:p.T41A|NP_001091679.1:p.Thr41Ala	A change in the amino acid residue at position 41 in the catenin beta-1 protein where threonine has been replaced by alanine.	CTNNB1 NP_001091679.1:p.T41A		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C164282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164282>	C38617	Laryngeal Posterior Commissure|GLOTTIS, POSTERIOR COMMISSURE|Posterior Glottic Commissure	The posterior surface of the glottic opening at the level of the vocal cords.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C164283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164283>	C97928	DDR2 Protein Variant|CD167 Antigen-Like Family Member B Protein Variant|CD167b Antigen Protein Variant|CD167b Protein Variant|Discoidin Domain Receptor 2 Protein Variant|Discoidin Domain-Containing Receptor 2 Protein Variant|Discoidin Domain-Containing Receptor Tyrosine Kinase 2 Protein Variant|NTRKR3 Protein Variant|Neurotrophic Tyrosine Kinase, Receptor-Related 3 Protein Variant|Receptor Protein-Tyrosine Kinase TKT Protein Variant|Tyrosine-Protein Kinase TYRO10 Protein Variant	A variation in the amino acid sequence for the discoidin domain-containing receptor 2 protein.			Cell or Molecular Dysfunction	
C164284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164284>	C164283	DDR2 NP_001014796.1:p.R742W|CD167 Antigen-Like Family Member B Arg742Trp|CD167 Antigen-Like Family Member B R742W|CD167b Antigen Arg742Trp|CD167b Antigen R742W|CD167b Arg742Trp|CD167b R742W|DDR2 Arg742Trp|DDR2 NP_001014796.1:p.Arg742Trp|DDR2 R742W|DDR2 p.Arg742Trp|DDR2 p.R742W|Discoidin Domain Receptor 2 Arg742Trp|Discoidin Domain Receptor 2 R742W|Discoidin Domain-Containing Receptor 2 Arg742Trp|Discoidin Domain-Containing Receptor 2 R742W|Discoidin Domain-Containing Receptor Tyrosine Kinase 2 Arg742Trp|Discoidin Domain-Containing Receptor Tyrosine Kinase 2 R742W|NP_001014796.1:p.Arg742Trp|NP_001014796.1:p.R742W|NTRKR3 Arg742Trp|NTRKR3 R742W|Neurotrophic Tyrosine Kinase, Receptor-Related 3 Arg742Trp|Neurotrophic Tyrosine Kinase, Receptor-Related 3 R742W|Receptor Protein-Tyrosine Kinase TKT Arg742Trp|Receptor Protein-Tyrosine Kinase TKT R742W|Tyrosine-Protein Kinase TYRO10 Arg742Trp|Tyrosine-Protein Kinase TYRO10 R742W	A change in the amino acid residue at position 742 in the discoidin domain-containing receptor 2 protein where arginine has been replaced by tryptophan.			Cell or Molecular Dysfunction	
C164285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164285>	C93441	Clinical Trial Auditor|Auditor	A person who audits and monitors a clinical trial. Duties include reviews of protocols and amendments, verification of proper reporting, auditing and monitoring study data, including the consent process, eligibility criteria, and case report forms, generation of audit reports.			Professional or Occupational Group	
C164286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164286>	C93441	Clinical Trial Executive Officer|Executive Officer	A top-level manager who is responsible for the running of a clinical trial, usually overseeing the day-to-day activities.			Professional or Occupational Group	
C164287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164287>	C97928	DICER1 Protein Variant|Endoribonuclease Dicer Protein Variant|Helicase MOI Protein Variant|Helicase with RNase Motif Protein Variant|Helicase-MOI Protein Variant	A variation in the amino acid sequence for the endoribonuclease Dicer protein.			Cell or Molecular Dysfunction	
C164288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164288>	C137691	DICER1 NM_177438.2:c.5438A>G|DCR-1 c.5438A>G|DCR1 c.5438A>G|DICER c.5438A>G|DICER1 c.5438A>G|Dicer 1, Double-Stranded RNA-Specific Endoribonuclease c.5438A>G|Dicer 1, Ribonuclease III c.5438A>G|Dicer 1, Ribonuclease Type III c.5438A>G|HERNA c.5438A>G|NM_177438.2:c.5438A>G	A nucleotide substitution at position 5438 of the coding sequence of the DICER1 gene where adenine has been mutated to guanine.			Cell or Molecular Dysfunction	
C164289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164289>	C164287	DICER1 NP_803187.1:p.E1813D|DICER1 E1813D|DICER1 Glu1813Asp|DICER1 NP_803187.1:p.Glu1813Asp|DICER1 p.E1813D|DICER1 p.Glu1813Asp|Endoribonuclease Dicer E1813D|Endoribonuclease Dicer Glu1813Asp|Helicase MOI E1813D|Helicase MOI Glu1813Asp|Helicase with RNase Motif E1813D|Helicase with RNase Motif Glu1813Asp|Helicase-MOI E1813D|Helicase-MOI Glu1813Asp|NP_803187.1:p.E1813D|NP_803187.1:p.Glu1813Asp	A change in the amino acid residue at position 1813 in the endoribonuclease Dicer protein where glutamic acid has been replaced by aspartic acid.			Cell or Molecular Dysfunction	
C16428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16428>	C25464	China|156|CHINA|CHINA|CHN|CHN|CN	A country in eastern Asia, bordering the East China Sea, Korea Bay, Yellow Sea, and South China Sea, south of Kazakhstan, Mongolia and Russia.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF1 Registration Table|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C164290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164290>	C164287	DICER1 NP_803187.1:p.Y1225X|DICER1 NP_803187.1:p.Tyr1225Xxx|DICER1 Tyr1225Xxx|DICER1 Y1225X|DICER1 p.Tyr1225Xxx|DICER1 p.Y1225X|Endoribonuclease Dicer Tyr1225Xxx|Endoribonuclease Dicer Y1225X|Helicase MOI Tyr1225Xxx|Helicase MOI Y1225X|Helicase with RNase Motif Tyr1225Xxx|Helicase with RNase Motif Y1225X|Helicase-MOI Tyr1225Xxx|Helicase-MOI Y1225X|NP_803187.1:p.Tyr1225Xxx|NP_803187.1:p.Y1225X	A change in the amino acid residue at position 1225 in the endoribonuclease Dicer protein where tyrosine has been replaced by another amino acid.			Cell or Molecular Dysfunction	
C164291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164291>	C97928	DNMT3A Protein Variant|DNA (Cytosine-5)-Methyltransferase 3A Protein Variant|DNA MTase HsaIIIA Protein Variant|DNA Methyltransferase 3A Protein Variant|DNA Methyltransferase HsaIIIA Protein Variant	A variation in the amino acid sequence for the DNA (cytosine-5)-methyltransferase 3A protein.			Cell or Molecular Dysfunction	
C164292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164292>	C150497	DNMT3A NM_022552.4:c.2711C>T|DNA Methyltransferase 3 Alpha c.2711C>T|DNA Methyltransferase 3A c.2711C>T|DNMT3A c.2711C>T|NM_022552.4:c.2711C>T	A nucleotide substitution at position 2711 of the coding sequence of the DNMT3A gene where cytosine has been mutated to thymine.			Cell or Molecular Dysfunction	
C164293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164293>	C199144	U.S. Postal Service|Postal Service|The Post Office|U.S. Mail|US Mail|US Post Office|US Postal Service|USPS|United States Post Office|United States Postal Service	An independent agency of the executive branch of the United States federal government responsible for providing postal service in the United States.			Professional or Occupational Group	
C164294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164294>	C164291	DNMT3A NP_072046.2:p.P904L|DNA (Cytosine-5)-Methyltransferase 3A P904L|DNA (Cytosine-5)-Methyltransferase 3A Pro904Leu|DNA MTase HsaIIIA P904L|DNA MTase HsaIIIA Pro904Leu|DNA Methyltransferase 3A P904L|DNA Methyltransferase 3A Pro904Leu|DNA Methyltransferase HsaIIIA P904L|DNA Methyltransferase HsaIIIA Pro904Leu|DNMT3A NP_072046.2:p.Pro904Leu|DNMT3A P904L|DNMT3A Pro904Leu|DNMT3A p.P904L|DNMT3A p.Pro904Leu|NP_072046.2:p.P904L|NP_072046.2:p.Pro904Leu	A change in the amino acid residue at position 904 in the DNA (cytosine-5)-methyltransferase 3A protein where proline has been replaced by leucine.			Cell or Molecular Dysfunction	
C164295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164295>	C97927	DPYD Gene Mutation|DHP Gene Mutation|DHPDHASE Gene Mutation|DPD Gene Mutation|Dihydropyrimidine Dehydrogenase Gene Mutation	A change in the nucleotide sequence of the DPYD gene.	DPYD Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C164296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164296>	C164295	DPYD NM_000110.3:c.1627A>G|DHP c.1627A>G|DHPDHASE c.1627A>G|DPD c.1627A>G|DPYD c.1627A>G|Dihydropyrimidine Dehydrogenase c.1627A>G|NM_000110.3:c.1627A>G	A nucleotide substitution at position 1627 of the coding sequence of the DPYD gene where adenine has been mutated to guanine.			Cell or Molecular Dysfunction	
C164297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164297>	C97928	DPYD Protein Variant|DHPDHase Protein Variant|DPD Protein Variant|Dihydropyrimidine Dehydrogenase Protein Variant|Dihydropyrimidine Dehydrogenase [NADP(+)] Protein Variant|Dihydrouracil Dehydrogenase Protein Variant	A variation in the amino acid sequence for the dihydropyrimidine dehydrogenase [NADP(+)] protein.	DPYD Protein Variant		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C164298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164298>	C164297	DPYD NP_000101.2:p.I543V|DHPDHase I543V|DHPDHase Ile543Val|DPD I543V|DPD Ile543Val|DPYD I543V|DPYD Ile543Val|DPYD NP_000101.2:p.Ile543Val|DPYD p.I543V|DPYD p.Ile543Val|Dihydropyrimidine Dehydrogenase I543V|Dihydropyrimidine Dehydrogenase Ile543Val|Dihydropyrimidine Dehydrogenase [NADP(+)] I543V|Dihydropyrimidine Dehydrogenase [NADP(+)] Ile543Val|Dihydrothymine Dehydrogenase I543V|Dihydrothymine Dehydrogenase Ile543Val|Dihydrouracil Dehydrogenase I543V|Dihydrouracil Dehydrogenase Ile543Val|NP_000101.2:p.I543V|NP_000101.2:p.Ile543Val	A change in the amino acid residue at position 543 in the dihydropyrimidine dehydrogenase [NADP(+)] protein where isoleucine has been replaced by valine.			Cell or Molecular Dysfunction	
C164299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164299>	C173045	Wheelchair Bed Transfer Question|Move from Wheelchair to Bed and Return|Moving from wheelchair to bed and return|Wheelchair Bed Transfer	A question about an individual's ability to move from wheelchair to bed and back.			Intellectual Product	Barthel Index of Activities of Daily Living
C16429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16429>	C16319	Chloramphenicol O-acetyltransferase|Chloramphenicol Acetyl Transferase|Chloramphenicol Transacetylase|EC 2.3.1.28|cat|cat I|cat II|cat III	Bacterial chloramphenicol-O-acetyltransferase protein (219 aa, 26 kD) is encoded by the bacterial chloramphenicol-O-acetyltransferase (cat) gene. This enzyme detoxifies the antibiotic chloramphenicol via acetylation to yield chloramphenicol 3-acetate. The presence of this enzyme confers chloramphenicol resistance to bacteria, which is used as a marker for selection in molecular techniques that utilize genetic transfection.			Amino Acid, Peptide, or Protein|Enzyme	
C1642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1642>	C799	Technetium TC-99m|TECHNETIUM TC-99M|Tc 99m|Technetium 99m	One of the radioactive isotopes of technetium, a gamma/beta-emitter with a half life of 6 hours.	Technetium TC-99m		Element, Ion, or Isotope	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C164300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164300>	C156133	Walk on Level Surface Question|Walk on Level Surface|Walking on level surface	A question about an individual's ability to walk on a level surface.			Intellectual Product	Barthel Index of Activities of Daily Living
C164301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164301>	C173458	Propel Wheelchair Question|Propel Wheelchair|Propel wheelchair	A question about an individual's ability to propel a wheelchair.			Intellectual Product	Barthel Index of Activities of Daily Living
C164302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164302>	C226571	Independent for Feeding|Feeding Independent|Feeding independent|Feeds Self without Help	A response indicating that an individual can feed themselves independent of help from others.			Intellectual Product	Barthel Index of Activities of Daily Living
C164303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164303>	C226574	Needs Help with Transfer|Moving from wheelchair to bed and return with help|Needs Help Moving Between Wheelchair and Bed|Needs Help with Wheelchair Transfer	A response indicating that an individual needs help with moving from wheelchair to bed and return.			Intellectual Product	Barthel Index of Activities of Daily Living
C164304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164304>	C226577	Needs Help for Toilet Use|Getting on and off toilet (handling clothes, wipe, flush) with help|Uses Toilet with Help	A response indicating that an individual is able to use the toilet with help.			Intellectual Product	Barthel Index of Activities of Daily Living
C164305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164305>	C226575|C178389	Needs Help to Walk on Level Surface|Walking on level surface with help|Walks on Level Surface with Help	A response indicating that an individual is able to walk on a level surface with help.			Intellectual Product	Barthel Index of Activities of Daily Living
C164306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164306>	C226575	Independent Walking on Level Surface|Walking on level surface independent|Walks on Level Surface without Help	A response indicating that an individual is able to walk on a level surface independent of help from others.			Intellectual Product	Barthel Index of Activities of Daily Living
C164307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164307>	C226576	Needs Help to Propel Wheelchair|Propel wheelchair with help|Propels Wheelchair with Help	A response indicating that an individual is able propel their wheelchair with help.			Intellectual Product	Barthel Index of Activities of Daily Living
C164308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164308>	C226576	Independent to Propel Wheelchair|Propel wheelchair independent|Propels Wheelchair without Help	A response indicating that an individual is able to propel their wheelchair independent of help from others.			Intellectual Product	Barthel Index of Activities of Daily Living
C164309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164309>	C226569	Needs Help Controlling Bowels|Controlling bowels with help|Controls Bowels with Help	A response indicating that an individual is able to control their bowels with help.			Intellectual Product	Barthel Index of Activities of Daily Living
C16430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16430>	C16546	Endoscopic Retrograde Cholangiopancreatography|ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY|ERCP|ERCP|ERCP|endoscopic retrograde cholangiopancreatography	A procedure in which the bile ducts, pancreatic duct, and gallbladder are examined using a combination of endoscopy and fluoroscopy.	Endoscopic Retrograde Cholangiopancreatography		Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C164310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164310>	C226568|C178389	Needs Help Controlling Bladder|Controlling bladder with help|Controls Bladder with Help	A response indicating that an individual is able to control their bladder with help.			Intellectual Product	Barthel Index of Activities of Daily Living
C164311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164311>	C226568	Independent for Controlling Bladder|Controlling bladder independent|Controls Bladder without Help	A response indicating that an individual is able to control their bladder independent of help from others.			Intellectual Product	Barthel Index of Activities of Daily Living
C164312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164312>	C3798|C148331	Unresectable Malignant Peripheral Nerve Sheath Tumor	A malignant peripheral nerve sheath tumor that is not amenable to surgical resection.	Unresectable Malignant Peripheral Nerve Sheath Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C164313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164313>	C3798	NF1-Associated Malignant Peripheral Nerve Sheath Tumor	A malignant peripheral nerve sheath tumor that is associated with NF1 gene inactivation and a history of neurofibromatosis type 1.			Neoplastic Process	
C164314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164314>	C3798	Sporadic Malignant Peripheral Nerve Sheath Tumor	A malignant peripheral nerve sheath tumor that is not caused by inherited genetic mutations.	Sporadic Malignant Peripheral Nerve Sheath Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C164315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164315>	C27557	Interstitial Lung Disease	A category of lung diseases characterized by varying degrees of inflammation and fibrosis of the interstitial lung tissue. Causes include occupational lung exposures and drugs. In a minority of cases there is no clear cause and such cases are termed idiopathic interstitial pneumonia.	Interstitial Lung Disease		Disease or Syndrome	
C164316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164316>	C3798	Radiation-Induced Malignant Peripheral Nerve Sheath Tumor	A malignant peripheral nerve sheath tumor that is the result of exposure to ionizing radiation.			Neoplastic Process	
C164317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164317>	C129820	Ilantimod|AhR Antagonist BAY2416964|AhR Inhibitor BAY2416964|Aryl Hydrocarbon Receptor Antagonist BAY2416964|Aryl Hydrocarbon Receptor Inhibitor BAY2416964|BAY 2416964|BAY-2416964|BAY2416964|ILANTIMOD	An orally available formulation containing a small molecule antagonist of the aryl hydrocarbon receptor (AhR; class E basic helix-loop-helix protein 76; bHLHe76) with potential immunomodulating and antineoplastic activities. Upon oral administration, ilantimod specifically binds to AhR, inhibits AhR activation, and prevents AhR-mediated signaling. Abrogation of AhR activation prevents the activation of immune-tolerant dendritic cells (DCs) and regulatory T-cells (Tregs) in the tumor microenvironment (TME). This may restore the immune response against tumor cells. AhR, a member of the basic helix-loop-helix/Per-Arnt-Sim (bHLH/PAS) family of transcription factors, has important roles in regulating immunity and cellular differentiation. AhR can exhibit both pro-oncogenic and tumor suppressor-like functions depending on the tumor type; therefore, its expression may serve as a negative or positive prognostic factor.	Ilantimod		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C164318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164318>	C25365	Adverse Event Grade Description|adverse event grade description|adverse_event_grade_description	A textual description of the grade of an adverse event.			Intellectual Product	ICDC Property Terminology|ICDC Terminology
C164319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164319>	C25488	Adverse Event Dose|ae dose|ae_dose	The dose of a therapeutic agent considered to be causally linked to an adverse event.			Conceptual Entity	ICDC Property Terminology|ICDC Terminology
C16431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16431>	C18653	Chromatography|CHROMATOGRAPHY|Chromatography / Separation Science|chromatography	A technique for the separation of complex mixtures that relies on the differential affinities of substances for a gas or liquid mobile medium and for a stationary adsorbing medium through which they pass.	Chromatography		Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Terminology
C164320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164320>	C45559	Adverse Event Term|adverse event term|adverse_event_term	A term that refers to an adverse event, often taken from a list of standardized terms.			Idea or Concept	ICDC Property Terminology|ICDC Terminology
C164321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164321>	C42614	Adverse Event Agent Name|ae agent name|ae_agent_name	The name of a therapeutic agent considered to be causally linked to an adverse event.			Conceptual Entity	ICDC Property Terminology|ICDC Terminology
C164322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164322>	C42614	Drug Name|Agent Name|agent name|agent_name	The identifier or name of a therapeutic agent.			Intellectual Product	ICDC Property Terminology|ICDC Terminology
C164323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164323>	C13717	Surgical Site|PROCEDURE_SITE|PROCEDURE_SITE|PROCEDURE_SITE|PROCEDURE_SITE|anatomical site of surgery|anatomical_site_of_surgery	The anatomical site on which surgery was performed.			Spatial Concept	EWS Biopsy/Surgical Procedures Table|EWS Variable Terminology|GCT Biopsy/Surgical Procedures Table|GCT Variable Terminology|HL Biopsy/Surgical Procedures Table|HL Variable Terminology|ICDC Property Terminology|ICDC Terminology|OS Biopsy/Surgical Procedures Table|OS Variable Terminology
C164324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164324>	C25364	Case Identifier|Case ID|case id|case id|case_id|case_id	A unique alphanumeric identifier assigned to a specific case.			Intellectual Product	CTDC Property Terminology|ICDC Property Terminology|ICDC Terminology
C164325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164325>	C83119	Body Temperature Measurement|Vital Signs – Body Temperature	The result of the measurement of the body temperature.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C164326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164326>	C25161	Concurrent Disease Type|concurrent disease type|concurrent_disease_type	The classification and naming of comorbid conditions.			Classification	ICDC Property Terminology|ICDC Terminology
C164327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164327>	C93399	Case Report Form Identifier|crf id|crf_id	A unique alphanumeric identifier assigned to a specific case report form.			Intellectual Product	ICDC Property Terminology|ICDC Terminology
C164328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164328>	C25164	Date of First Dose|date of first dose|date_of_first_dose	The date on which the first dose of a specified treatment regiment was administered.			Temporal Concept	ICDC Property Terminology|ICDC Terminology
C164329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164329>	C25164	Date of Last Dose|date of last dose|date_of_last_dose	The date on which the last dose of a specified treatment regiment was administered.			Temporal Concept	ICDC Property Terminology|ICDC Terminology
C16432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16432>	C18242	Affinity Chromatography	A chromatographic separation technique based on the ability of proteins to bind specific ligands reversibly.			Laboratory Procedure	
C164330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164330>	C20641	Modified ECOG Performance Status|modified ecog|modified_ecog	A version of the ECOG performance status scale for use in canines.			Clinical Attribute	ICDC Property Terminology|ICDC Terminology
C164331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164331>	C5043	Respiratory Pattern|respiration pattern|respiration_pattern	A description of the breathing cycle at a point in time, which is informed by the rate, depth, and regularity of respiration.			Sign or Symptom	ICDC Property Terminology|ICDC Terminology
C164333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164333>	C25488	NSAID Total Dose|total number of doses nsaid|total_number_of_doses_nsaid	The total number of doses of NSAIDs given in a given period of time.			Conceptual Entity	ICDC Property Terminology|ICDC Terminology
C164334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164334>	C25488	Steroid Total Dose|total number of doses steroid|total_number_of_doses_steroid	The total number of doses of steroids given in a given period of time.			Conceptual Entity	ICDC Property Terminology|ICDC Terminology
C164335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164335>	C15783	Treatment Data|treatment data|treatment_data	Data pertaining to the medical or surgical treatment of a patient.			Idea or Concept	ICDC Property Terminology|ICDC Terminology
C164336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164336>	C19326	Veterinary Medical Center|veterinary medical center|veterinary_medical_center	A veterinary institution that provides medical or surgical care and treatment for the sick or the injured.			Health Care Related Organization	ICDC Property Terminology|ICDC Terminology
C164337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164337>	C25364	Patient Identifier|Patient ID|patient id|patient_id|source id|source_id	An alphanumeric identifier assigned to a specific patient.			Intellectual Product	CRF1 Registration Table|CRF2 History and Physical Exam Table|CRF3 Diagnosis Table|CRF4 Treatment Table|CRF5 Response Evaluation Table|CRF6 DIPG Imaging Assessment Table|CRF6 DMG Imaging Assessment Table|CRF7 Pathology Review Table|CRF8 Pathology Review Table|CTDC Property Terminology|ICDC Property Terminology|ICDC Terminology
C164338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164338>	C69260	Age of Enrollment|patient age at enrollment|patient_age_at_enrollment	The age of a subject when entering a group, catalog, list, or study.			Organism Attribute	ICDC Property Terminology|ICDC Terminology
C164339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164339>	C25164	Date of Diagnosis|Diagnosis|date of diagnosis|date_of_diagnosis	The date on which a diagnosis of disease was made.			Temporal Concept	GDC Terminology|GDC Value Terminology|ICDC Property Terminology|ICDC Terminology
C16433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16433>	C18242	Gel Filtration Chromatography|Gel Permeation Chromatography|SIZE EXCLUSION CHROMATOGRAPHY|Size Exclusion Chromatography	Gel permeation or sieve chromatography that is performed on porous gels that separate solutes on the basis of size. Smaller solutes are included within the particles of the gel matrix more frequently than larger solutes, thus affecting elution rates.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C164340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164340>	C25164	Date of Evaluation|date of evaluation|date_of_evaluation	The date on which an evaluation was performed.			Temporal Concept	ICDC Property Terminology|ICDC Terminology
C164341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164341>	C36291	Surgical Finding|surgical finding|surgical_finding	A finding or observation that is made during surgery.			Finding	ICDC Property Terminology|ICDC Terminology
C164342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164342>	C25164	Date of Last NSAID Administration|date of last dose nsaid|date_of_last_dose_nsaid	The date on which a patient last received an NSAID.			Temporal Concept	ICDC Property Terminology|ICDC Terminology
C164343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164343>	C25164	Date of Last Steroid Administration|date of last dose steroid|date_of_last_dose_steroid	The date on which a patient last received steroid.			Temporal Concept	ICDC Property Terminology|ICDC Terminology
C164344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164344>	C50996	Did Not Meet Eligibility Criteria|Did not meet eligibility criteria|ELIGIBILITY CRITERIA NOT MET|Eligibility Criteria Not Met By Subject|Subject Did Not Meet Eligibility Criteria	An indication that the subject has not fulfilled the criteria needed to continue to the next study period.			Conceptual Entity	CDISC SDTM Protocol Milestone Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C164345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164345>	C50996	Informed Consent Process Deviation|Informed Consent (IC) process deviation|Informed consent (IC) process	An indication that the informed consent processes or procedures defined the study protocol were not followed.			Conceptual Entity	
C164346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164346>	C50996	Failure to Follow Trial Randomization|Failure to follow trial randomization	An indication that the trial randomization processes or procedures defined in the study protocol were not followed.			Conceptual Entity	
C164347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164347>	C50996	Failure to Discontinue Treatment|Failure to discontinue treatment	An indication that a subject's treatment was not discontinued as per the protocol.			Conceptual Entity	
C164348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164348>	C50996	Study Procedure Deviation|Study procedures	An indication that a protocol deviation involved the trial processes or procedures defined in the study protocol.			Conceptual Entity	
C164349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164349>	C50996	Study Agent Deviation|Study agent/medication	An indication that a protocol deviation involved a study agent.			Conceptual Entity	
C16434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16434>	C18242|C16435	High Performance Liquid Chromatography|HPLC|HPLC	Frequently referred to simply as HPLC, this form of column chromatography is used frequently in biochemistry. The analyte is forced through a column by liquid at high pressure, which decreases the time the separated components remain on the stationary phase. Less time on the column then translates to narrower peaks in the resulting chromatogram and thence to better selectivity and sensitivity.	High Performance Liquid Chromatography		Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Intervention Terminology|CTRP Terminology
C164350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164350>	C50996	Concomitant Medication Used was not Permitted per Protocol|Con med used was not permitted per protocol	An indication that a concomitant agent was administered but this agent was not permitted by the protocol.			Conceptual Entity	
C164351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164351>	C50996	Lab, Imaging, or Other Investigation Deviation|Lab/Imaging/Other Investigation Deviation|Lab/Imaging/Other investigation	An indication that a protocol deviation involved a lab test or procedure, an imaging event, or some other investigation.			Conceptual Entity	
C164352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164352>	C50996	Failure to Report Serious Adverse Event within Defined Timeframe|Failure to report SAE within defined timeframe	An indication that a protocol deviation was due to a failure to report a serious adverse event within the timeframe established in the study protocol.			Conceptual Entity	
C164353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164353>	C50996	Patient Did Not Have a Safety Follow Up as Required|Patient does not have a safety follow up as required	An indication that a subject's safely follow up did not occur as required by the study protocol.			Conceptual Entity	
C164354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164354>	C50996	Baseline Assessments Are Out of Window|Baseline assessments are out of window	An indication that a subject's baseline assessments did not occur within the time window required by the study protocol.			Conceptual Entity	
C164355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164355>	C50996	Disease Outcome or Response  Not Covered|Disease Outcome or Response|Disease Outcome/Response	An indication that a subject's disease outcome or response is not covered by the study protocol.			Conceptual Entity	
C164356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164356>	C50996	Study Device Deviation|Study device	An indication that a protocol deviation involved a study device.			Conceptual Entity	
C164357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164357>	C62289	Biospecimen Sub-Domain	The Biospecimen sub-domain includes concepts related to a biologic specimen, including collection and processing.			Functional Concept	BRIDG Sub-Domain Terminology|BRIDG Terminology
C164358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164358>	C62289	Experiment Sub-Domain	The Experiment sub-domain includes concepts related to the design, planning, resourcing and execution of experiments, which are intended to test hypotheses or lead to discoveries.			Functional Concept	BRIDG Sub-Domain Terminology|BRIDG Terminology
C164359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164359>	C62289	Imaging Sub-Domain	The Imaging sub-domain represents the core concepts related to this domain, including imaging protocols, imaging activities, images and other related concepts.			Functional Concept	BRIDG Sub-Domain Terminology|BRIDG Terminology
C16435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16435>	C16431	Liquid Chromatography|LC	A type of chromatography in which separation of a mixture is achieved by passing a sample in a stream of liquid solvent through some form of material that will provide resistance by virtue of chemical interactions between the components of the sample and the material.	Liquid Chromatography		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C164360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164360>	C62289	Molecular Biology Sub-Domain	The Molecular Biology sub-domain represents the core concepts related to this domain, including gene, protein, molecular sequence, chromosome, genome, and numerous other related concepts. Also includes the representation of these concepts in bioinformatics resources, such as public databases.			Functional Concept	BRIDG Sub-Domain Terminology|BRIDG Terminology
C164361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164361>	C62289	Statistical Analysis Sub-Domain	The Statistical Analysis Sub-Domain includes concepts describing the planning and performance of the statistical analysis of data collected during clinical trial research and their relationships. This sub-domain will eventually include the semantics for the entire Statistical Analysis lifecycle, but for BRIDG 3.2, only the Statistical Analysis Plan semantics are included.			Functional Concept	BRIDG Sub-Domain Terminology|BRIDG Terminology
C164362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164362>	C48792	Protocol Element	An artifact that is one of the individual components of the study protocol.			Qualitative Concept	
C164363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164363>	C60824	Material Storage	Storage of materials for further use or manufacture.			Activity	
C164364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164364>	C48167	Product Transport	The act of conveying or transporting a product from one place to another.			Activity	
C164365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164365>	C42619	Patient Note	A brief written record regarding the patient.			Intellectual Product	
C164366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164366>	C48151	Report Generation	The act of bringing a report into being.			Conceptual Entity	
C164367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164367>	C77951	Specimen Relocation	The act of moving a biospecimen from one location to another.			Activity	
C164368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164368>	C42651	Process Protocol|ProcessProtocol	A standard operating procedure (SOP) that is a collection of activities and the rules that describe when each activity is performed to achieve a specific purpose or objective(s).			Intellectual Product	BRIDG Class Terminology|BRIDG Terminology
C164369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164369>	C42581	Change Summary	A shortened version of the reported alterations made from one version to the next.			Intellectual Product	
C16436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16436>	C1746	Chromogranin|CHG	Chromogranins are acidic secretory glycoproteins with a widespread but specific distribution in neuroendocrine tissues. The chromogranin family is heterogenous, consisting of propeptides such as chromogranin-A, chromogranin-B and secretogranin II, which can either elicit an effect themselves, or serve as precursors to a large number of peptides, which are biologically more active.			Amino Acid, Peptide, or Protein	
C164370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164370>	C71460	Payment Method	Methodology used to compensate an individual or organization for the good or service provided.			Conceptual Entity	
C164371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164371>	C21599	Amino Acid Physical Location|AminoAcidPhysicalLocation	The position of an amino acid within an amino acid sequence.			Conceptual Entity	BRIDG Class Terminology|BRIDG Terminology
C164372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164372>	C21599	Amino Acid Sequence Feature|AminoAcidSequenceFeature	A descriptive annotation on a specified amino acid sequence.			Conceptual Entity	BRIDG Class Terminology|BRIDG Terminology
C164373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164373>	C62103	Authoring Device|AuthoringDevice	An instrument, apparatus, or machine that is responsible for generating documents.			Manufactured Object	BRIDG Class Terminology|BRIDG Terminology
C164374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164374>	C25161	Biologic Entity Classification|BiologicEntityClassification|IDENTIFICATION	The systematic arrangement of biological entities into classes or groups based on mutual similarity and certain differing characteristics.			Classification	BRIDG Class Terminology|BRIDG Terminology|CDISC SDTM Microbiology Findings Test Details Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C164375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164375>	C164362	CT Imaging Acquisition Protocol Element|CTImagingAcquisitionProtocolElement	A set of scanning parameter values necessary to perform a single CT scan in the acquisition protocol. (adapted from NEMA XR 25-2010, https://www.nema.org/Standards/Pages/Computed-Tomography-Dose-Check.aspx)			Qualitative Concept	BRIDG Class Terminology|BRIDG Terminology
C164376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164376>	C164362	CT Imaging Reconstruction Protocol Element|CTImagingReconstructionProtocolElement	A set of image generation parameter values necessary to create a single set of images from a single CT scan.			Qualitative Concept	BRIDG Class Terminology|BRIDG Terminology
C164377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164377>	C21599	Cytoband Range|CytobandRange	A region within a nucleic acid sequence that corresponds to a region of interest bounded by cytobands.			Conceptual Entity	BRIDG Class Terminology|BRIDG Terminology
C164378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164378>	C49149	Defined Eligibility Criterion Answer|DefinedEligibilityCriterionAnswer	The response to a defined eligibility criterion question.			Intellectual Product	BRIDG Class Terminology|BRIDG Terminology
C16437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16437>	C18280	Chromosome Banding	The treatment of chromosomes to reveal characteristic patterns of horizontal bands.  The banding patterns lend each chromosome a distinctive appearance so the 22 pairs of human non-sex chromosomes and the X and Y chromosomes can be identified and distinguished without ambiguity. Banding also permits the recognition of chromosome deletions (lost segments), chromosome duplications (surplus segments) and other types of structural rearrangements of chromosomes.			Laboratory Procedure	
C164380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164380>	C164364	Defined Product Transport|DefinedProductTransport	An activity defined at a global library level that represents the transportation of a product between a point of origin and a point of destination.			Activity	BRIDG Class Terminology|BRIDG Terminology
C164381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164381>	C25463	Defined Progress Count|DefinedProgressCount	An administrative activity defined at a global library level that represents the action of producing a set of quantitative information (counts of objects), and which, when gathered and recorded over a period of time, reflects the progress of a goal.			Quantitative Concept	BRIDG Class Terminology|BRIDG Terminology
C164382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164382>	C25712	Device Parameter Value|DeviceParameterValue	The value of a parameter setting for a device.			Conceptual Entity	BRIDG Class Terminology|BRIDG Terminology
C164383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164383>	C67045	Document Version Representation|DocumentVersionRepresentation	A format-specific representation of a particular edition or snapshot of a document as it exists at a particular point in time.			Activity	BRIDG Class Terminology|BRIDG Terminology
C164384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164384>	C142431	Experimental Activity Item|ExperimentalActivityItem	The role the entity (specifically an Animal, a BiologicEntityGroup, a Material, or a MolecularSequence) plays within the execution of an activity. (BRIDG)			Idea or Concept	BRIDG Class Terminology|BRIDG Terminology
C164385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164385>	C25506	Experimental Factor|ExperimentalFactor	An independent variable manipulated by the experimentalist with the intention to affect biological systems in a way that can be measured by an assay. (BRIDG)			Functional Concept	BRIDG Class Terminology|BRIDG Terminology
C164386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164386>	C25712	Experimental Factor Value|ExperimentalFactorValue	A specific type, time period, compound, dose, temperature, magnitude, quantity, element, aspect or other item in a variable manipulated by the experimentalist. (BRIDG)			Conceptual Entity	BRIDG Class Terminology|BRIDG Terminology
C164387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164387>	C113416	General Statistical Consideration|General Considerations|GeneralStatisticalConsideration	Careful thought or deliberation related to the planned conduct of statistical analyses.			Mental Process	BRIDG Class Terminology|BRIDG Terminology|ICH M11 Protocol Section 10 Data Element Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C164388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164388>	C164396	Genetic Reference Sequence|GeneticReference|reference	A published genetic sequence that is used as a reference sequence against which other sequences are compared.			Spatial Concept	BRIDG Class Terminology|BRIDG Terminology|CTDC Property Terminology
C164389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164389>	C164362	Imaging Acquisition Protocol Element|ImagingAcquisitionProtocolElement	A set of scanning parameter values necessary to perform a single scan in the acquisition protocol. (adapted from NEMA XR 25-2010, https://www.nema.org/Standards/Pages/Computed-Tomography-Dose-Check.aspx)			Qualitative Concept	BRIDG Class Terminology|BRIDG Terminology
C16438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16438>	C19235	Gene Mapping|Gene Localization|Gene Mapping, Total Human and Non-Human|Genetic Mapping|Genetics, Gene Mapping	Determination of the relative positions of genes on a DNA molecule (chromosome or plasmid) and of the distance, in linkage units or physical units, between them.	Gene Mapping		Molecular Biology Research Technique	CTRP Intervention Terminology|CTRP Terminology
C164390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164390>	C164362	Imaging Process Protocol Element|ImagingProcessProtocolElement	A set of parameter values necessary to obtain or reconstruct a set of images for an imaging process protocol.			Qualitative Concept	BRIDG Class Terminology|BRIDG Terminology
C164391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164391>	C164362	Imaging Reconstruction Protocol Element|ImagingReconstructionProtocolElement	A set of image generation parameter values necessary to create a single set of images from a single scan.			Qualitative Concept	BRIDG Class Terminology|BRIDG Terminology
C164392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164392>	C198997	Insured Person|InsuredPerson	A human being that is covered under an insurance policy. This individual may or may not be in the policy holder.			Human	BRIDG Class Terminology|BRIDG Terminology
C164393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164393>	C164362	Magnetic Resonance Imaging Acquisition Protocol Element|MRImagingAcquisitionProtocolElement	A set of scanning parameter values necessary to perform a single MR scan in the acquisition protocol. (adapted from NEMA XR 25-2010, https://www.nema.org/Standards/Pages/Computed-Tomography-Dose-Check.aspx)			Qualitative Concept	BRIDG Class Terminology|BRIDG Terminology
C164394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164394>	C164362	Magnetic Resonance Imaging Reconstruction Protocol Element|MRImagingReconstructionProtocolElement	A set of image generation parameter values necessary to create a single set of images from a single MR scan.			Qualitative Concept	BRIDG Class Terminology|BRIDG Terminology
C164395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164395>	C20047	Molecular Biomarker Group|MolecularBiomarkerGroup	A collection of molecular biomarkers that are associated with the medical conclusion, condition, or process.			Clinical Attribute	BRIDG Class Terminology|BRIDG Terminology
C164396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164396>	C53414|C25673	Molecular Sequence|MolecularSequence	A serial arrangement of molecules.			Spatial Concept	BRIDG Class Terminology|BRIDG Terminology
C164397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164397>	C21599	Nucleic Acid Physical Location|NucleicAcidPhysicalLocation	The position of an nucleic acid within an amino acid sequence.			Conceptual Entity	BRIDG Class Terminology|BRIDG Terminology
C164398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164398>	C21599	Nucleic Acid Sequence Feature|NucleicAcidSequenceFeature	A descriptive annotation on a specified nucleic acid sequence.			Conceptual Entity	BRIDG Class Terminology|BRIDG Terminology
C164399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164399>	C25648	Observation Result Action Taken Relationship|ObservationResultActionTakenRelationship	Specifies the link between an observation result and the actions taken as a result of that outcome.			Conceptual Entity	BRIDG Class Terminology|BRIDG Terminology
C16439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16439>	C18145	Clinical Informatics|Health Informatics|Medical Informatics	The application of informatics methods to manage medical information and improve healthcare.			Biomedical Occupation or Discipline	
C1643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1643>	C2848	Pneumococcal Polyvalent Vaccine|PCV 23|PPSV|PPSV23|PPSV23 Vaccine|Pneumococcal 23-valent Polysaccharide Vaccine|Pneumococcal Polysaccharide Vaccine|Pneumococcal Vaccine Polyvalent|Pneumovax 23|Pnu-Imune 23	An polyvalent vaccine used to prevent infection by the bacterium Streptococcus pneumoniae. Pneumococcal polyvalent vaccine contains highly purified capsular antigens from the 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae to ensure cross-protection. Following vaccination, protective capsular type-specific antibody levels typically develop by the third week; serotype-specific antibody levels generally decline after 5-10 years.	Pneumococcal Polyvalent Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NICHD Terminology|Pediatric Immunization Terminology
C164400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164400>	C48835	Organization Staff Role|OrganizationStaffRole	The function performed by the staff person within the organization.			Conceptual Entity	BRIDG Class Terminology|BRIDG Terminology
C164401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164401>	C25648	Performed Activity Relationship|PerformedActivityRelationship	Specifies the link between an activity to another activity or an external document.			Conceptual Entity	BRIDG Class Terminology|BRIDG Terminology
C164402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164402>	C25648	Performed Diagnosis Procedure Relationship|PerformedDiagnosisProcedureRelationship	Specifies the link between a diagnosis and the procedure performed to address it.			Conceptual Entity	BRIDG Class Terminology|BRIDG Terminology
C164403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164403>	C62143	Performed Encounter|PerformedEncounter	The completed activity within the context of a given study that represents a physical or virtual contact between a patient (or trial subject) and healthcare provider.			Conceptual Entity	BRIDG Class Terminology|BRIDG Terminology
C164404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164404>	C25598	Performed Genetic Observation|PerformedGeneticObservation	The completed activity within the context of a given study that represents a genetic assessment.			Activity	BRIDG Class Terminology|BRIDG Terminology
C164405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164405>	C76125	Performed Genetic Observation Result|PerformedGeneticObservationResult	The completed activity within the context of a given study that represents the result of a genetic assessment.			Finding	BRIDG Class Terminology|BRIDG Terminology
C164406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164406>	C36291	Performed Histopathology Result|PerformedHistopathologyResult	The completed activity within the context of a given study that represents the results of a histopathology assessment.			Finding	BRIDG Class Terminology|BRIDG Terminology
C164407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164407>	C63859	Performed Imaging Study|PerformedImagingStudy	The completed activity within the context of a given study that represents the imaging study.			Diagnostic Procedure	BRIDG Class Terminology|BRIDG Terminology
C164408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164408>	C71473	Performed Material Process Step|PerformedMaterialProcessStep	The completed activity within the context of a given study that represents the processing of some material.			Health Care Activity	BRIDG Class Terminology|BRIDG Terminology
C164409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164409>	C164363	Performed Material Storage|PerformedMaterialStorage	The completed activity within the context of a given study that represents the storage of some material.			Activity	BRIDG Class Terminology|BRIDG Terminology
C16440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16440>	C18706|C16833	Clinical Medicine|Medical Sciences, Clinical	The practice of medicine based on direct observation of patients.			Biomedical Occupation or Discipline	
C164410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164410>	C70900	Performed Medical Record Abstraction|PerformedMedicalRecordAbstraction	The completed activity within the context of a given study that represents the abstraction of a medical record.			Health Care Activity	BRIDG Class Terminology|BRIDG Terminology
C164411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164411>	C164365	Performed Patient Note|PerformedPatientNote	The completed activity within the context of a given study that represents the			Intellectual Product	BRIDG Class Terminology|BRIDG Terminology
C164412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164412>	C71473	Performed Product Supply|PerformedSupply	Successful completion of providing the product for use in a clinical setting.			Health Care Activity	BRIDG Class Terminology|BRIDG Terminology
C164413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164413>	C25463	Performed Progress Count|PerformedProgressCount	The completed activity within the context of a given study that represents the number of things within an activity or program.			Quantitative Concept	BRIDG Class Terminology|BRIDG Terminology
C164414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164414>	C164366	Performed Report Generation|PerformedReportGeneration	The completed activity within the context of a given study that represents the formation or origination of the report.			Conceptual Entity	BRIDG Class Terminology|BRIDG Terminology
C164415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164415>	C164367	Performed Specimen Move|PerformedSpecimenMove	The completed activity within the context of a given study that represents the location or re-location of a specimen or group of specimens.			Activity	BRIDG Class Terminology|BRIDG Terminology
C164416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164416>	C164362	PET Imaging Acquisition Protocol Element|PETImagingAcquisitionProtocolElement	A set of scanning parameter values necessary to perform a single PET scan in the acquisition protocol. (adapted from NEMA XR 25-2010, https://www.nema.org/Standards/Pages/Computed-Tomography-Dose-Check.aspx)			Qualitative Concept	BRIDG Class Terminology|BRIDG Terminology
C164417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164417>	C76125	Planned Experimental Unit Allocation Result|PlannedExperimentalUnitAllocationResult	The outcome of an intended experimental unit allocation.			Finding	BRIDG Class Terminology|BRIDG Terminology
C164418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164418>	C41189	Planned Study Subject|PlannedStudySubject	A kind of physical entity describing a group of intended study subjects, which is the primary unit of operational and/or administrative interest in a study.			Functional Concept	BRIDG Class Terminology|BRIDG Terminology
C164419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164419>	C25648	Product Relationship|ProductRelationship	Specifies the link between two or more products.			Conceptual Entity	BRIDG Class Terminology|BRIDG Terminology
C16441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16441>	C37925	Cell Clone	A population of genetically identical cells derived by mitosis from a single progenitor.			Cell	
C164420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164420>	C60778	Project Conduct|ProjectConduct	An ongoing and/or past performance of a project.			Activity	BRIDG Class Terminology|BRIDG Terminology
C164421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164421>	C25648	Project Relationship|ProjectRelationship	Specifies the link between two or more projects.			Conceptual Entity	BRIDG Class Terminology|BRIDG Terminology
C164422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164422>	C68821	Relevant Regulation for Clinical Trial Regulation|RelevantRegulation	Specifies the jurisdictional law applicable for registering the study to a clinical trial registry.			Intellectual Product	BRIDG Class Terminology|BRIDG Terminology
C164423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164423>	C70772	Research Staff Specialty|StaffInterest	The discrete area of expertise or interest that the research staff member has.			Conceptual Entity	BRIDG Class Terminology|BRIDG Terminology
C164424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164424>	C113416	Sample Size Consideration|SampleSizeConsideration	Careful thought or deliberation related to the calculation of the sample size.			Mental Process	BRIDG Class Terminology|BRIDG Terminology
C164425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164425>	C70699	Specimen Collection Group|SpecimenCollectionGroup	A group of specimens collected from the same participant in the same accession event.			Body Substance	BRIDG Class Terminology|BRIDG Terminology
C164426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164426>	C164368	Specimen Collection Protocol|SpecimenCollectionProtocol	The rule which guides how a specimen collection should be performed.			Intellectual Product	BRIDG Class Terminology|BRIDG Terminology
C164427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164427>	C164369	Statistical Analysis Plan Version Modification Summary|StatisticalAnalysisPlanVersionModificationSummary	A shortened version of the modifications to the statistical analysis plan.			Intellectual Product	BRIDG Class Terminology|BRIDG Terminology
C164428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164428>	C70865	Statistical Analysis Plan Version Status|StatisticalAnalysisPlanVersionStatus	The state of the statistical analysis plan.			Qualitative Concept	BRIDG Class Terminology|BRIDG Terminology
C164429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164429>	C93441	Study Country Personnel|StudyCountryPersonnel	A person engaged in research within a study site country.			Professional or Occupational Group	BRIDG Class Terminology|BRIDG Terminology
C16442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16442>	C19235	Cloning	Any of the techniques that produce identical individuals.			Molecular Biology Research Technique	
C164430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164430>	C93480|C70783	Study Site Recruitment Status|StudySiteRecruitmentStatus	Status of finding and enrolling appropriate study subjects at an individual study site.			Functional Concept	BRIDG Class Terminology|BRIDG Terminology
C164431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164431>	C25648	Study Site Relationship|StudySiteRelationship	Specifies the link between two or more study sites.			Conceptual Entity	BRIDG Class Terminology|BRIDG Terminology
C164432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164432>	C38186	Study Subject Registration Center|RegistrationCenter	A facility that performs the service of recording subject participation in a study.			Organization	BRIDG Class Terminology|BRIDG Terminology
C164433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164433>	C164370	Subject Payment Method|SubjectPaymentMethod	Methodology used to compensate a subject for care provided during the study.			Conceptual Entity	BRIDG Class Terminology|BRIDG Terminology
C164434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164434>	C25648	Substance Extraction Administration Relationship|SubstanceExtractionAdministrationRelationship	Specifies the link between a performed substance extraction and the performed substance administration.			Conceptual Entity	BRIDG Class Terminology|BRIDG Terminology
C164435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164435>	C93484	Supplemental Statistical Analysis Plan Version|SupplementalStatisticalAnalysisPlanVersion	An addendum to the statistical analysis plan that provides specification for additional analyses not included as part of the principal statistical analysis plan version.			Intellectual Product	BRIDG Class Terminology|BRIDG Terminology
C164436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164436>	C16108	Transplant Donor Registry|DonorRegistry	An entity that records and enrolls donors of transplantation materials.			Intellectual Product	BRIDG Class Terminology|BRIDG Terminology
C164437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164437>	C25180	Accepted Indicator|acceptedIndicator	An indication as to whether the outcome of the assessment or observation is considered acceptable for usage, among the several assessments provided.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164438>	C25162	Acquisition Contrast Code|acquisitionContrastCode				Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164439>	C93698	Acquisition Type Code|acquisitionTypeCode	A coded value specifying spatial aspects of the mechanism of data collection.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C16443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16443>	C16442	Gene Cloning|Molecular Biology, Gene Cloning	The insertion of a DNA sequence into a vector that can then be propagated in a host organism, generating a large number of copies of the sequence.			Molecular Biology Research Technique	
C164440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164440>	C25162	Action Mode Code|actionModeCode	A coded value specifying the mode of action through which this substance produces a pharmacological effect.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164441>	C93545	Active Date Range|activeDateRange	The time span within which the entity is active.			Temporal Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164442>	C41009	Additional Qualifier|additionalQualifier	A value specifying a supplemental characterization of the observation or entity.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164443>	C25162	Additional Qualifier Code|additionalQualifierCode	A coded value specifying a supplemental characterization of the observation or entity.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164444>	C25180	Adjustable Indicator|adjustableIndicator	An indication as to whether an entity is adaptable or malleable.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164445>	C154625	Admitting Diagnosis Code|admittingDiagnosisCode	A coded value specifying the identified disease(s) or illness(es) at the time of admission.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164446>	C93698	Agent Administration Care Setting Type Code|agentAdministrationCareSettingTypeCode	A coded value specifying the medical setting within which the agent administration took place.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164447>	C25162	Algorithm Code|algorithmCode	A coded value specifying the algorithm used in the calculation or operation.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164448>	C25180	Aliquot In Same Container Indicator|aliquotInSameContainerIndicator	An indication as to whether the specimen aliquots are located in the same container.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164449>	C25162	Allele Indicator Code|alleleIndicatorCode	A coded value specifying the individual allele.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C16444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16444>	C16835	Cloudman S91 Malignant Melanoma|Cloudman S91 Melanoma	A transplantable melanoma that arose spontaneously in a mouse of DBA strain, and which grows and metastasizes in mice of related strains. (dictionarybarn.com)	Cloudman S91 Malignant Melanoma		Experimental Model of Disease|Neoplastic Process	
C164450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164450>	C93595	Analysis Method Code|analysisMethodCode	A coded value specifying the technique used for secondary processing applied to a complex observation result (e.g. an image or a genetic sequence) to obtain a summarized result.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164451>	C25180	Applicable Indicator|applicableIndicator	An indication as to whether entity is relevant or suitable for a particular condition.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164452>	C25162	Approach Anatomic Site Directionality Code|approachAnatomicSiteDirectionalityCode	A coded value specifying the  approach anatomic site directionality.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164453>	C25162	Arterial Spin Labeling Contrast Code|arterialSpinLabelingContrastCode	A coded value specifying the arterial spin labeling contrast agent.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164454>	C25683	Assembly Source|assemblySource	The originating source from which the composite parts are put together.			Qualitative Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164455>	C25714	Assembly Version|assemblyVersion	The version identifier for the assembly.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164456>	C25256	Barrier Distance Quantity|barrierDeltaQuantity	A numeric value describing the distance from the Point of Reference to the separator material.			Quantitative Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164457>	C25162	Biosafety Level Code|biosafetyLevelCode	A coded value specifying an assessment of the potential risk associated with the handling of the biospecimen.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164458>	C25162	Birth State Code|birthStateCode	A coded value specifying the name of the state within which the birth occurred.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164459>	C42614	Blinded Substance Name|blindedName	The literal identifier for a blinded substance in use in the study.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C16445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16445>	C25464	Cocos (Keeling) Islands|166|CC|CCK|CCK|COCOS (KEELING) ISLANDS|COCOS (KEELING) ISLANDS	A group of islands in the Indian Ocean, south of Indonesia and west of Christmas Island.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Geopolitical Entities, Names, and Codes Terminology
C164460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164460>	C25256	Bottom Thickness Quantity|bottomDeltaQuantity	A numeric value describing the thickness of the lowest surface of an entity.			Quantitative Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164461>	C25704	Build Number Text|buildNumberText	A human-readable text label to represent the build number.			Manufactured Object	BRIDG Attribute Terminology|BRIDG Terminology
C164462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164462>	C93595	Cardiac Synchronization Technique Code|cardiacSynchronizationTechniqueCode	A coded value specifying the cardiac synchronization technique.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164463>	C25180	CE Mark Indicator|ceMarkIndicator	An indication as to whether the product or device bears a Conformite Europeenne (CE) mark.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164464>	C38013	Cessation Pause Quantity Range|cessationPauseQuantityRange	An integer falling within minimum and maximum bounds that specifies the elapsed time between the result and the cessation of a repeating activity.			Quantitative Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164465>	C25162	Characteristic Behavior Code|characteristicBehaviorCode	A coded value specifying the essential traits of the material that result from the chemical and physical composition and properties of the entity.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164466>	C25180	Characteristic Modified Indicator|characteristicModifiedIndicator	An indication as to whether the entity's characteristic is altered.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164467>	C25162	Checkpoint Code|checkpointCode	A coded value specifying the points within the course of an activity that serve as gates between contiguous steps of that activity..			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164468>	C25162	Classification Code|classificationCode	A coded value specifying the categorization of the event or entity.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164469>	C25162	Clinical Stage Descriptor Code|clinicalStageDescriptorCode	A coded value specifying additional information about the clinical stage of the disease entity.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C16446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16446>	C16840	Cognition|cognition	The mental process of knowing, thinking, learning and judging; the psychological result of perception and learning and reasoning.			Mental Process	
C164470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164470>	C25704	Code Modified Text|codeModifiedText	A coded value specifying a revision of the original text of the product.			Manufactured Object	BRIDG Attribute Terminology|BRIDG Terminology
C164471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164471>	C42614	Common Name|Colloquial Name|commonName	The generally-used, literal identifier of the entity.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164472>	C25164	Completion Date|completionDate	The date on which the activity or entity is finished.			Temporal Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164473>	C25162	Complex Image Component Code|complexImageComponentCode	A coded value specifying the channel of the quadrature detected data, or the combination derived from those channels, used to reconstruct the image. (BRIDG)			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164474>	C25162	Computed Ethnicity Code|computedEthnicityCode	A coded value specifying the an ethnicity value, as determined by a computer algorithm.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164475>	C47901	Computed Ethnicity Source Code|computedEthnicitySourceCode	A coded value specifying the database, method, or computer algorithm used to compute the ethnicity.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164476>	C93529	Condition Status Change Reason|conditionStatusChangeReason	The rationale for why the condition state changed.			Idea or Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164477>	C25162	Condition Status Code|conditionStatusCode	A coded value specifying the state of the condition.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164478>	C25180	Confidential Indicator|confidentialIndicator	An indication as to whether the  information is considered classified or private.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164479>	C25180	Consents Waived Indicator|consentsWaivedIndicator	An indication as to whether consent requirements no longer need to be followed.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C16447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16447>	C17351	Collagen|collagen	A family of large fibrous proteins that are the main components of connective tissue and are responsible for maintaining tissue structure.	Collagen		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C164480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164480>	C25162	Convolution Kernel Group Code|convolutionKernelGroupCode	A coded value specifying the family of mathematical operations to use to reconstruct images from the acquired data. (BRIDG)			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164481>	C25180	Corresponding Author indicator|correspondingAuthorIndicator	An indication that the specific author is considered the corresponding author.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164482>	C25162	Count Type Detail Code|countTypeDetailCode	A coded value specifying a further description of the type of item being counted.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164483>	C25164	Created Date|createdDate	The date on which the activity or entity is created.			Temporal Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164484>	C93698	CTDI Phantom Type Code|ctdiPhantomTypeCode	A coded value specifying the kind of phantom used for the computed tomography dose index measurement.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164485>	C25285	Data Collection Location Diameter|dataCollectionDiameter	The diameter of the region within which the data is collected.			Spatial Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164486>	C25162	Date Range Validation Code|dateRangeValidationCode	A coded value specifying the degree of authoritativeness or certitude of the date range.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164487>	C25180	Death Date Estimated Indicator|deathDateEstimatedIndicator	An indication as to whether the date of death has been approximated.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164488>	C25180	Delayed Registry Posting Indicator|delayedRegistryPostingIndicator	An indication as to whether there is to be a delay in the disclosure of the information within a registry.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164489>	C93595	Derivation Method Code|derivationMethodCode	A coded value specifying the procedure or technique used to derive the date.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C16448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16448>	C21176|C16447	Collagen IV|Collagen Type IV|Type IV Collagen	The major structural component of basement membranes, Collagen-IV consists of six subunits encoded by genes COL4A1, COL4A2, COL4A3, COL4A4, COL4A5 and COL4A6.			Amino Acid, Peptide, or Protein	
C164490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164490>	C25162	Derived Ethnicity Origin Code|derivedEthnicityOriginCode	A coded value specifying the result of the programmatic classification of the ethnicity.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164491>	C25180	Derived Indicator|derivedIndicator	An indication as to whether the result or observation is copied or inferred from source data.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164492>	C25337	DICOM Series Count|seriesCount	The number of DICOM series.			Quantitative Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164493>	C25364	DICOM Study Identifier|dicomStudyID	The user- or equipment-generated identifier of an instance of a DICOM study entity. (BRIDG)			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164494>	C84380	Diffusion B Value|diffusionBValue	The factor by which the acquisition is sensitized to the Brownian motion of water molecules. (BRIDG)			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164495>	C25162	Diffusion Directionality Code|diffusionDirectionalityCode	A coded value specifying whether diffusion conditions for the frame are directional, or isotropic with respect to direction.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164496>	C25443	Dimension One Capacity|dimensionOneCapacity	The maximum amount that can be contained, in the first dimension of size. (BRIDG)			Quantitative Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164497>	C45561	Dimension One Label|dimensionOneLabel	A descriptive marker assigned to the first dimension of size.			Manufactured Object	BRIDG Attribute Terminology|BRIDG Terminology
C164498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164498>	C42703	Dimension Point of Origin|dimensionPointOfOrigin	The point within the entity from which definition of container capacity originates.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164499>	C25443	Dimension Three Capacity|dimensionThreeCapacity	The maximum amount that can be contained, in the third dimension of size. (BRIDG)			Quantitative Concept	BRIDG Attribute Terminology|BRIDG Terminology
C16449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16449>	C25464	Colombia|170|CO|COL|COL|COLOMBIA|COLOMBIA	A country in northern South America, bordering the Caribbean Sea and the North Pacific Ocean, between Ecuador and Venezuela.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C1644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1644>	C62761	Attenuated Corynebacterium granulosum|Corynebacterium granulosum	A species of Gram-positive, facultatively anaerobic bacteria in the phylum Actinobacteria that are used therapeutically as an immune-stimulant to fight cancer.			Bacterium|Pharmacologic Substance	
C164500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164500>	C45561	Dimension Three Label|dimensionThreeLabel	A descriptive marker assigned to the third dimension of size.			Manufactured Object	BRIDG Attribute Terminology|BRIDG Terminology
C164501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164501>	C25443	Dimension Two Capacity|dimensionTwoCapacity	The maximum amount that can be contained, in the second dimension of size. (BRIDG)			Quantitative Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164502>	C45561	Dimension Two Label|dimensionTwoLabel	A descriptive marker assigned to the second dimension of size.			Manufactured Object	BRIDG Attribute Terminology|BRIDG Terminology
C164503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164503>	C25162	Directionality Code|directionalityCode	A coded value specifying the directional portion of the anatomic site that is a target of the observation result.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164504>	C25162	Disease Status Missing Reason Code|diseaseStatusMissingReasonCode	A coded value specifying rationale for a missing disease status.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164505>	C93698	Donor Type Code|donorTypeCode	A coded value specifying the kind of organ donor.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164506>	C25180	Echo-Planar Pulse Sequence Indicator|echoPlanarPulseSequenceIndicator	An indication as to whether multiple echos of different phase steps are acquired using rephasing gradients instead of repeated 180-degree pulses. (BRIDG)			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164507>	C13355	End Chromosome Arm|endChromosomeArm	The chromosomal arm that contains the terminus of the range. (BRIDG)			Gene or Genome	BRIDG Attribute Terminology|BRIDG Terminology
C164508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164508>	C13432	End Chromosome Band|endBand	The cytoband that contains the terminus of the range, expressed without the chromosome or arm designation. (BRIDG)			Gene or Genome	BRIDG Attribute Terminology|BRIDG Terminology
C164509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164509>	C44465	End Coordinate|endCoordinate	The terminal coordinate of the range (inclusive), given as an integer offset from the start of the sequence. (BRIDG)			Spatial Concept	BRIDG Attribute Terminology|BRIDG Terminology
C16450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16450>	C78162	Colonoscopy|COLONOSCOPY|colonoscopy	Endoscopic examination of the luminal surface of the colon.	Colonoscopy		Health Care Activity	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C164510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164510>	C25162	Ethnic Surname Or Origin Code|ethnicSurnameOrOriginCode	A coded value specifying patients with a surname or origin associated with a particular ethnicity.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164511>	C25364	Evaluator Alias|evaluatorAlias	A non-unique textual identifier for the evaluator that is an alternative to the evaluator name.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164512>	C25180	Expanded Access Indicator|expandedAccessIndicator	An indication as to whether the product or substance is available to patients as part of an expanded access pathway.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164513>	C25162	Expected Handling Condition Code|expectedHandlingConditionCode	A coded value specifying the likely or anticipated handling conditions of the entity.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164514>	C70863	Expected Resubmission Date|expectedResubmissionDate	The date on which the activity or entity is considered likely to be re-submitted.			Temporal Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164515>	C93545	Expected Use Date Range|expectedUseDateRange	The time span within which the entity is likely to be used.			Temporal Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164516>	C25164	Expiration Date|expirationDate	The date assigned by the manufacturer on which the product should no longer be used.			Temporal Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164517>	C25180	Exploratory Indicator|exploratoryIndicator	An indication as to whether			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164518>	C93698	Exposure Modulation Type Code|exposureModulationTypeCode	A coded value specifying the kind of variation in exposure.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164519>	C25180	First In Human Indicator|firstInHumanIndicator	An indication as to whether the product or substance is being administered to a human for the first time.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C16451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16451>	C16546	Colposcopy|CP|colposcopy	Endoscopic examination of the uterine cervix and vagina.	Colposcopy		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C164520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164520>	C25162	First In Human Risk Factor Code|firstInHumanRiskFactorCode	A coded value specifying the risk factors associated with administration of the agent for the first time to any human.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164521>	C44465	From Position Dimension One|fromPositionDimensionOne	A reference to the first directional coordinate of the entity in the old location.			Spatial Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164522>	C44465	From Position Dimension Three|fromPositionDimensionThree	A reference to the third directional coordinate of the entity in the old location.			Spatial Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164523>	C44465	From Position Dimension Two|fromPositionDimensionTwo	A reference to the second directional coordinate of the entity in the old location.			Spatial Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164524>	C93698	Function Type Code|functionTypeCode	A coded value specifying the role an entity plays in an activity.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164525>	C93524	Funding Category Code|fundingCategoryCode	A coded value specifying the classification of the funding.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164526>	C48433|C163747	Gantry Detector Tilt|gantryDetectorTilt	Nominal angle of tilt of the scanning gantry. (BRIDG)			Qualitative Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164527>	C25162	Gender Identity Code|genderIdentityCode	A coded value specifying the self-reported gender identity. IMPORTANT NOTICE: The NCI Thesaurus contains biomedical terminologies that NCI does not own or control. This concept contains gender-related content that does not comply with Executive Order 14168.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164528>	C45822	Genetic Location|geneticLocation	The location of the genetic or genomic sequence that is described by the test result.			Gene or Genome	BRIDG Attribute Terminology|BRIDG Terminology
C164529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164529>	C45822	Genetic Location Of Interest|geneticLocationOfInterest	The region and position of the genetic or genomic sequence that is the focus of the test.			Gene or Genome	BRIDG Attribute Terminology|BRIDG Terminology
C16452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16452>	C16326	Communication|Communicative	The exchange of information between objects, people, or groups.			Social Behavior	
C164530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164530>	C45822	Genetic Region of Interest|geneticRegionOfInterest	The region or sub-location of the genetic or genomic sequence that is described by the test.			Gene or Genome	BRIDG Attribute Terminology|BRIDG Terminology
C164531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164531>	C93698	Genetic Region Type Code|geneticRegionTypeCode	A coded value specifying the kind of region within the genome that is the focus.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164532>	C15426	Genetic Sequence Database|sequenceDatabase	The name of a repository representing a collection of assemblies of nucleotides. (BRIDG)			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164533>	C45822	Genetic Subregion|geneticSubregion	The sub-region of the genetic or genomic sequence that is described by the test result.			Gene or Genome	BRIDG Attribute Terminology|BRIDG Terminology
C164534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164534>	C13299	Genetic Target|geneticTarget	The nucleotide or amino acid within the genetic location of interest that is to be compared to the subject's test result. (BRIDG)			Nucleotide Sequence	BRIDG Attribute Terminology|BRIDG Terminology
C164535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164535>	C25162	Identifier Code|identifierCode	A coded value specifying the identifying number.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164536>	C25180	Identifier Embedded Indicator|identifierEmbeddedIndicator	An indication as to whether an identifier is placed within an entity.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164537>	C25162	Identifier Location Code|identifierLocationCode	A coded value specifying the physical place of the identifying number.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164538>	C93698	Identifier Reader Type Code|identifierReaderTypeCode	A coded value specifying the type of device required to read the identifying number.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164539>	C93698	Identifier Type Code|identifierTypeCode	A coded value specifying the kind of identifying number.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C16453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16453>	C17005	Community	A set of individuals with some shared element. The substance of shared element varies widely, from geography to a situation to interest to lives and values. The term is widely used to evoke sense of collectivity.			Conceptual Entity	
C164540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164540>	C25463	Image Count|imageCount	The number of DICOM instances in the imaging study.			Quantitative Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164541>	C93698	Image Type Code|imageTypeCode	A coded value specifying the kind of image.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164542>	C25364	Imaging Accession Identifier|imagingAccessionIdentifier	A control number unique to an image and used to identify the object among other images in a collection.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164543>	C25180	Informed Consent Indicator|informedConsentIndicator	An indication as to whether informed consent was obtained.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164544>	C25180	Interruptible Indicator|interruptibleIndicator	An indication as to whether an activity or process can be halted, either temporarily or indefinitely.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164545>	C93698	Intervention Type Code|interventionTypeCode	A coded value specifying the kind of intervention.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164546>	C25180	Inversion Recovery Indicator|inversionRecoveryIndicator	An indication as to whether the pulse sequence is an inversion recovery pulse sequence.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164547>	C25704	IRB Approval Number Text|irbApprovalNumberText	A human-readable text label to represent the number assigned to the institutional review board approval.			Manufactured Object	BRIDG Attribute Terminology|BRIDG Terminology
C164548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164548>	C25162	Join Code|joinCode	A coded value specifying whether and how two entities should be merged together.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164549>	C25164	Last Follow-Up Date|Last Follow-Up|lastFollowUpDate	The date on which the temporally most recent follow-up took place.			Temporal Concept	BRIDG Attribute Terminology|BRIDG Terminology
C16454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16454>	C21541	Community Health Center|Community Health Centers|Community service center|Local Community Health Center	A private, non-profit organization that provides primary health services and related services to residents of a defined geographic area that is medically underserved. They are designed to improve access to care for low income, underserved, vulnerable populations and provide a fully comprehensive range of primary care services. Typically, they involve the community in both the management and governance of the center.			Health Care Related Organization	
C164550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164550>	C25162	Laterality Code|lateralityCode	A coded value specifying the side of the entity.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164551>	C25704	Lesion Identifier Text|lesionIdentifierText	A human-readable text label used for the identification of an individual lesion.			Manufactured Object	BRIDG Attribute Terminology|BRIDG Terminology
C164552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164552>	C93545	License Effective Date Range|licenseEffectiveDateRange	The time span within which the usage license is valid.			Temporal Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164553>	C46002	License Key|licenseKey	The non-unique textual key that certifies that the copy of the computer program is original. (BRIDG)			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164554>	C93698	License Type Code|licenseTypeCode	A coded value specifying the kind of license to be able to do or own a specified thing.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164555>	C25180	Lossy Image Compression Indicator|lossyImageCompressionIndicator	An indication as to whether  any images in the study are irreversibly altered during encoding. (BRIDG)			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164556>	C49154	Medical Statement|medicalStatement	A verbal and/or written message that asserts, affirms, or declares something related to a medical record or medical data.			Idea or Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164557>	C93643	Missing Identifier Reason Code|missingIdentifierReasonCode	A coded value specifying rationale for why an identifier is not present.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164558>	C25180	Multiple Spin Echo Indicator|multipleSpinEchoIndicator	An indication as to whether the pulse sequence is a multiple spin Echo sequence.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164559>	C93698	Mutation Type Code|mutationTypeCode	A coded value specifying the genomic source of the variant.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C16455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16455>	C16664	Community Health Education|Community Education	Draws on social relationships and organizations to reach large populations through media and interpersonal strategies that deliver messages and mechanisms to reduce chronic diseases.	Community Health Education		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C164560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164560>	C25162	NCI Program Code|nciProgramCode	A coded value specifying the organizational unit within the US National Cancer Institute (NCI).			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164561>	C25162	Non-Acquisition Modalities In Study Code|nonAcquisitionModalitiesInStudyCode	A coded value specifying the types of devices or data sources that may have created images, other than those used to acquire the original imaging data.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164562>	C25180	Non-Host Organism Indicator|nonHostIndicator	An indication as to whether the organism is one that is harbored or nourished by another organism.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164563>	C25337	Number of Supply Days|daysSupply	The number of days of coverage for a patient or subject with respect to the medication, based on the number of doses.			Quantitative Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164564>	C25704	Number Text|numberText	A human-readable text label to represent the number.			Manufactured Object	BRIDG Attribute Terminology|BRIDG Terminology
C164565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164565>	C25162	Occurrence Date Range Validation Code|occurrenceDateRangeValidationCode	A coded value specifying the degree of authoritativeness or certitude of the occurrence date.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164566>	C25164	Order Date|orderDate	The date on which the activity or entity was ordered.			Temporal Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164567>	C25364	Order Identifier|orderIdentifier	A sequence of letters, numbers, or other characters that specifically identifies a particular order.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164568>	C25162	Order Urgency Code|orderUrgencyCode	A coded value specifying the pressing importance of the order.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164569>	C25337	Ordered Number of Repeats|orderedNumberOfRepeats	The number of times something recurs.			Quantitative Concept	BRIDG Attribute Terminology|BRIDG Terminology
C16456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16456>	C16926	Community Health Nursing|Community-based Nursing	A discipline in nursing with a focus on the delivery of health care and disease prevention to residents living in a common geographic area.			Biomedical Occupation or Discipline	
C164570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164570>	C42614	Origin Cell Name|originCellName	The name of the cell from which the biological specimen was derived.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164571>	C25162	Participating Location Code|participatingLocationCode	A coded value specifying the locations that are taking part in the activity.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164572>	C25337	Passage Number|passage count|passageNumber|passage_count	The number of sub-culture processes the cells have undergone since the original harvest.			Quantitative Concept	BRIDG Attribute Terminology|BRIDG Terminology|GDC Property Terminology|GDC Terminology
C164573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164573>	C25162	Pathologic Stage Descriptor Code|pathologicStageDescriptorCode	A coded value specifying additional information about the pathologic stage of the disease entity.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164574>	C164588	Pause Quantity Range|pauseQuantityRange	An integer falling within minimum and maximum bounds that specifies the time between when an activity is ready for execution and the actual beginning of the execution.			Quantitative Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164575>	C25180	Pediatric Formulation Indicator|pediatricFormulationIndicator	An indication as to whether the composition of the dosage form is intended for pediatric use.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164576>	C25180	Phase Contrast Indicator|phaseContrastIndicator	An indication as to whether the pulse sequence is a phase contrast sequence.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164577>	C71610	Planned Investigational Exposure Quotient|plannedInvestigationalExposureQuotient	The number of subjects to be exposed to investigational therapy, independent of dose or other factors, divided by the total number of subjects.			Quantitative Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164578>	C38013	Planned Site Number Range|plannedSiteNumberRange	An integer falling within minimum and maximum bounds that specifies the  number of study sites that are expected to participate in the study.			Quantitative Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164579>	C25162	Portion Code|portionCode	A coded value specifying the arrangement or apportionment of the body (or a paired organ)			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C16457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16457>	C16495	Comorbidity|Intercurrent Illness|Intercurrent illness|comorbidities|comorbidity	The coexistence of two or more disease processes.			Idea or Concept	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|GDC Property Terminology|GDC Terminology
C164580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164580>	C25162	Present At Admission Code|presentAtAdmissionCode	A coded value specifying the whether an entity exists at admission.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164581>	C93504	Primary Anatomic Site Code|primaryAnatomicSiteCode	A coded value specifying the anatomic site of the entity.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164582>	C93698	Primary Purpose Type Code|primaryPurposeTypeCode	A coded value specifying the primary intent of the entity or activity.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164583>	C25180	Primary Role Indicator|primaryRoleIndicator	An indication as to whether the role that the entity plays is the primary role.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164584>	C25180	Principal Indicator|principalIndicator	An indication as to whether the entity is the primary entity within the context.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164585>	C70961	Product Dose Description|productDoseDescription	The textual representation of dosing amounts or ranges for the product.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164586>	C42614	Pulse Sequence Name|pulseSequenceName	The literal identifier for the pulse sequence.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164587>	C25162	Purpose Code|purposeCode	A coded value specifying the intent or rationale of the entity or activity.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164588>	C38013	Quantity Range|quantityRange	An integer falling within minimum and maximum bounds.			Quantitative Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164589>	C25162	Radionuclide Code|radionuclideCode	A coded value specifying the radionuclide of interest.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C16458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16458>	C25464	Comoros|174|COM|COM|COMOROS|COMOROS|KM	A group of islands in the Mozambique Channel, about two-thirds of the way between northern Madagascar and northern Mozambique, northwest of Mayotte.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C164590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164590>	C25164	Received Date|receivedDate	The date on which the entity was received.			Temporal Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164591>	C25285	Reconstruction Diameter|reconstructionDiameter	The diameter of the region from which data is used in creating the reconstruction of the image. (BRIDG)			Spatial Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164592>	C25347	Reconstruction Field of View Height|reconstructionFieldOfViewHeight	The vertical dimension of the rectangular region from which data is used in creating the reconstruction of the image. (BRIDG)			Quantitative Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164593>	C25345	Reconstruction Field of View Width|reconstructionFieldOfViewWidth	The horizontal dimension of the rectangular region from which data is used in creating the reconstruction of the image. (BRIDG)			Quantitative Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164594>	C25543	Reconstruction Interval|reconstructionInterval	The cross-plane distance between the centers of adjacent, parallel reconstructed images. (BRIDG)			Quantitative Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164595>	C25162	Relation Code|relationCode	A coded value specifying the relationship between two entities.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164596>	C25162	Repeat Frequency Range Max Code|repeatFrequencyRangeMaxCode	A coded value specifying the maximum value of the repeat frequency range.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164597>	C25162	Repeat Frequency Range Min Code|repeatFrequencyRangeMinCode	A coded value specifying the minimum value of the repeat frequency range.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164598>	C164588	Repeat Quantity Range|repeatQuantityRange	An integer falling within minimum and maximum bounds that specifies how many times something is repeated.			Quantitative Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164599>	C25180	Required Indicator|requiredIndicator	An indication as to whether entity is mandatory.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C16459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16459>	C16725	Complement	The complement system is a complex system of serum proteins that interact in a cascade.  Many of the early components are serine proteases that activate each other sequentially. This complement system consists of three separate activation triggers: (1) Ab binding to a cell surface, (2) formation of immune complexes, and (3) a carbohydrate component of a microbe's cell membrane.  Along with this triggers, there are also two sets of mechanisms.  Both of these mechanisms, classical pathway and alternative or properdin pathway, make MAC (Membrane Attack Complex), which can lyse and destroy the cell.			Amino Acid, Peptide, or Protein|Immunologic Factor	
C1645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1645>	C1737	Dimethyl Ether|DIMETHYL ETHER|DME|Dimethyl Oxide|Methyl Ether|Oxybismethane	A colorless volatile poisonous liquid compound used as a solvent, fuel, aerosol, propellant and refrigerant. (NCI)			Hazardous or Poisonous Substance|Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C164600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164600>	C25162	Resonant Nucleus Code|resonantNucleusCode	A coded value specifying the atomic nucleus.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164601>	C93595	Respiratory Motion Technique Code|respiratoryMotionTechniqueCode	A coded value specifying the respiratory motion technique.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164602>	C25162	Result Code|resultCode	A coded value specifying the			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164603>	C93643	Revision Reason Code|revisionReasonCode	A coded value specifying rationale for why a revision was made.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164604>	C25180	Saturation Recovery Indicator|saturationRecoveryIndicator	An indication as to whether the pulse sequence is a saturation recovery sequence.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164605>	C93600	Scientific Name Code|scientificNameCode	A coded value specifying the medically appropriate literal identifier of an event or entity.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164606>	C25180	Separable Indicator|separableIndicator	An indication as to whether the two entities may be detached from each other.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164607>	C25364	Sequence Identifier|sequenceIdentifier	A sequence of letters, numbers, or other characters that specifically identifies a particular sequence.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164608>	C25162	Seriousness Code|seriousnessCode	A coded value specifying the seriousness of the entity or event.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164609>	C25162	Sex Genotype Code|sexGenotypeCode	A coded value specifying the biological sex of the individual, based upon genetic analysis.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C16460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16460>	C18141	Computer Graphics	The field of visual computing, where one utilizes computers both to generate visual images synthetically and to integrate or alter visual and spatial information sampled from the real world.			Machine Activity	
C164610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164610>	C25162	Sexual Orientation Code|sexualOrientationCode	A coded value specifying the sexual orientation of the individual.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164611>	C19067	Short Title|shortTitle	The short descriptive name for the document.			Qualitative Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164612>	C25345	Single Collimation Width|singleCollimationWidth	The width of a single row of acquired data. (BRIDG)			Quantitative Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164613>	C25150	Source Age|sourceAge	The age of the entity from which another entity is derived.			Organism Attribute	BRIDG Attribute Terminology|BRIDG Terminology
C164614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164614>	C93504	Source Anatomic Site Code|sourceAnatomicSiteCode	A coded value specifying the anatomic site from which the biospecimen is derived.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164615>	C43531	Source Developmental Stage|sourceDevelopmentalStage	The developmental age of the entity from which another entity is derived.			Temporal Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164616>	C25364	Source Identifier|sourceIdentifier	A sequence of letters, numbers, or other characters that specifically identifies a particular source.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164617>	C93698	Source Tissue Type Code|sourceTissueTypeCode	A coded value specifying the type of tissue from which the biospecimen is derived.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164618>	C93698	Source Type Code|sourceTypeCode	A coded value specifying the origination source of the entity.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164619>	C25180	Specimen Available For DNA Extraction Indicator|specimenAvailableForDNAExtractionIndicator	An indication as to whether the biological specimen has potential for DNA extraction.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C16461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16461>	C19233|C16063	Computer Modeling|Mathematical Models and Simulations|Simulation|simulation	A technique which attempts to provide an abstract model of a particular system. It utilizes a mathematical model, which attempts to predict the behavior of the system from a set of parameters and initial conditions.			Research Activity	
C164620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164620>	C25180	Biospecimen Retention Indicator|BRIND|Specimen Retention Indicator|specimenRetentionIndicator	An indication as to whether the biological specimen is retained for a period of time.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology|CDISC DDF Biospecimen Retention Attribute Terminology|CDISC DDF Terminology|CDISC SDTM Terminology|CDISC SDTM Trial Summary Parameter Long Name Terminology|CDISC SDTM Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C164621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164621>	C25162	Spectrally Selected Suppression Code|spectrallySelectedSuppressionCode	A coded value specifying the spectrally selected suppression.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164622>	C93524	Spin-Echo Pulse Sequence Category Code|echoPulseSequenceCategoryCode	The coded value specifying the Spin-ECHO pulse sequence category.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164623>	C44256	Spiral Pitch Factor|spiralPitchFactor	Ratio of the distance that the table moves during a complete revolution of the source around the gantry orbit, to the width of the total collimation over the area of active x-ray detection. (BRIDG)			Quantitative Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164624>	C25180	Standard Time Indicator|standardTimeIndicator	An indication as to whether the activity or event is specified using standard time.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164625>	C13355	Start Chromosome Arm|startChromosomeArm	The chromosomal arm that contains the beginning of the range. (BRIDG)			Gene or Genome	BRIDG Attribute Terminology|BRIDG Terminology
C164626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164626>	C13432	Start Chromosome Band|startBand	The cytoband that contains the beginning of the range, expressed without the chromosome or arm designation. (BRIDG)			Gene or Genome	BRIDG Attribute Terminology|BRIDG Terminology
C164627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164627>	C44465	Start Coordinate|startCoordinate	The beginning coordinate of the range (inclusive), given as an integer offset from the start of the sequence. (BRIDG)			Spatial Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164628>	C25162	Status Code|statusCode	A coded value specifying the state of the entity or event.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164629>	C25162	Steady State Pulse Sequence Code|steadyStatePulseSequenceCode	A coded value specifying the steady state pulse sequence.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C16462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16462>	C19238	Computer System	A set of hardware and software which processes data in a meaningful way.			Manufactured Object	
C164630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164630>	C25364	Storage SOP Classes In Study|storageSOPClassesInStudy	The unique identifier of a DICOM Storage Service-Object Pair Class. (BRIDG)			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164631>	C25393	Strain Comment|strainComment	Additional information (e.g. a written explanation, observation or criticism) about the animal or microbial strain.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164632>	C25364	Strain Stock Identifier|strainStockIdentifier	A sequence of letters, numbers, or other characters that specifically identifies a particular strain stock.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164633>	C25514	Study Agent Randomization Fraction|studyAgentRandomizationFraction	A number representing the quantity of study subjects in the overall study who receive at least one study agent (as opposed to placebo) divided by the quantity of subjects in the study overall - independent of dosage or other protocol variations. (BRIDG)			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164634>	C25347	Body Height|Height|Height|Height|Height|Height|Height|Height|Height|height|subjectHeight	The vertical measurement or distance from the base to the top of a subject or participant.			Quantitative Concept	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|ALL Authorized Value Terminology|ALL Vitals Table|AML Authorized Value Terminology|AML Vitals Table|Appendix 6: Symptoms and Signs Terminology|BRIDG Attribute Terminology|BRIDG Terminology|EWS Authorized Value Terminology|EWS Vitals Table|GCT Authorized Value Terminology|GCT Vitals Table|GDC Property Terminology|GDC Terminology|HL Authorized Value Terminology|HL Vitals Table|Operational Ontology for Radiation Oncology Prostate Cancer Terminology|OS Authorized Value Terminology|OS Vitals Table|Physical Examination Terminology
C164635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164635>	C54625	Subject History|subjectHistory	The aggregate of past events related to the subject's life.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164636>	C25180	Substance Unknown Indicator|substanceUnknownIndicator	An indication as to whether the administered substance is unknown.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164637>	C25162	Synonym Code|synonymCode	A coded value specifying the synonym of the event or entity.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164638>	C41146	Table Speed|tableSpeed	A scalar measure of the rate of movement of the platform.			Quantitative Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164639>	C25162	Target Anatomic Site Portion Code|targetAnatomicSitePortionCode	A coded value specifying the  target anatomic site portion.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C16463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16463>	C18141	Computer Systems Development|Systems Development				Occupational Activity	
C164640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164640>	C25162	Target Biomarker Code|targetBiomarkerCode	A coded value specifying the target biomarker.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164641>	C25162	Taxonomy Identifier Code|taxonomyIdentifierCode	A coded value specifying the taxonomic identifier.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164642>	C25162	Taxonomy Rank Code|taxonomyRankCode	A coded value specifying the taxonomy rank.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164643>	C38013	Temperature Capability Range|temperatureCapabilityRange	An integer falling within minimum and maximum bounds that specifies the temperature capability of the system.			Quantitative Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164644>	C38013	Temperature Range|temperatureRange	An integer falling within minimum and maximum bounds that specifies the temperature of an entity.			Quantitative Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164645>	C25162	Therapeutic Area Code|therapeuticAreaCode	A coded value specifying the therapeutic area.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164646>	C25180	Time of Flight Contrast Indicator|timeOfFlightContrastIndicator	An indication as to whether contrast is created by the inflow of blood in the saturated plane. (BRIDG)			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164647>	C25162	Time Point Code|timePointCode	A coded value specifying the point in time of the entity or the event.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164648>	C25365	Timing Description|Timing|timingDescription	Text description of a timing or reference time point aspect.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology|CDISC DDF Terminology|CDISC DDF Timing Attribute Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF4 Treatment Complementary Table
C164649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164649>	C44465	To Position Dimension One|toPositionDimensionOne	A reference to the first directional coordinate of the entity in the new location.			Spatial Concept	BRIDG Attribute Terminology|BRIDG Terminology
C16464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16464>	C171256	Computer	A machine for performing calculations automatically.			Manufactured Object	
C164650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164650>	C44465	To Position Dimension Three|toPositionDimensionThree	A reference to the third directional coordinate of the entity in the new location.			Spatial Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164651>	C44465	To Position Dimension Two|toPositionDimensionTwo	A reference to the second directional coordinate of the entity in the new location.			Spatial Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164652>	C25345	Total Collimation Width|totalCollimationWidth	The width of the total collimation. (BRIDG)			Quantitative Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164653>	C25365	Transition Description|transitionDescription	Text description of the change in state, stage, or location.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164654>	C25256	Treatment Vehicle Quantity|treatmentVehicleQuantity	The amount of treatment vehicle.			Quantitative Concept	BRIDG Attribute Terminology|BRIDG Terminology
C164655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164655>	C168631	Unplanned Treatment Indicator|unplannedTreatmentIndicator	An indication as to whether the administered substance was not expected or scheduled.			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164656>	C25704	Value Code Modified Text|valueCodeModifiedText	A coded value specifying the modified text corresponding to the original value code.			Manufactured Object	BRIDG Attribute Terminology|BRIDG Terminology
C164657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164657>	C25180	Value Negation Indicator|valueNegationIndicator	An indication as to whether the finding communicated by the value attribute was not found. (BRIDG)			Conceptual Entity	BRIDG Attribute Terminology|BRIDG Terminology
C164658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164658>	C93698	Value Type Code|valueTypeCode	A coded value specifying the kind of result value.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C164659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164659>	C93643	Variance Reason Code|varianceReasonCode	A coded value specifying rationale for why a deviation occurred.			Intellectual Product	BRIDG Attribute Terminology|BRIDG Terminology
C16465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16465>	C21173	Conception|conception	Fertilization of an ovum by a spermatozoon resulting in formation of a viable zygote.			Cell Function	
C164660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164660>	C128056	Dynamic Susceptibility Contrast-Perfusion-Weighted Imaging|DSC|DSC-PWI|Dynamic Susceptibility Contrast Perfusion Weighted Imaging|Dynamic Susceptibility Contrast Perfusion-Weighted MR Imaging|Dynamic Susceptibility Contrast-Enhanced MR Perfusion	A type of diffusion-weighted magnetic resonance imaging that monitors the passage of contrast medium through a capillary bed. It is based on inhomogeneity of the magnetic field during the passage of a short bolus of contrast medium through the capillary bed. It can demonstrate the characteristics of the vascular physiology and hemodynamics of tumors and has been used to differentiate recurrence from radiation injury.	Dynamic Susceptibility Contrast-Perfusion-Weighted Imaging		Diagnostic Procedure	CRF6 DIPG Imaging Assessment Perfusion Table|CTRP Intervention Terminology|CTRP Terminology
C164661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164661>	C16830	EndoRotor|Endoscopic Mucosal Resection System	A non-thermal, automated mechanical endoscopic resection system designed to remove benign mucosal neoplastic tissue throughout the gastrointestinal tract. It uses suction pressure to pull in mucosa and rapidly and precisely cut it while automatically transporting the samples to a collection trap for later histologic evaluation.	EndoRotor		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C164662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164662>	C198997	User	A person who makes use of something.			Human	
C164663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164663>	C164662	Electronic Nicotine Delivery System User|Electronic Nicotine Delivery Device User	A person who uses or used an electronic nicotine delivery device.	Electronic Nicotine Delivery System User		Human	CTRP Intervention Terminology|CTRP Terminology
C164664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164664>	C41278	Puffing Topography Monitor|Electronic Vaping Usage Monitor|Puff Topography Monitor|Puffing Behavior Monitor|Vaping Behavior Monitor	A device that monitors an individual's e-cigarette usage.	Puffing Topography Monitor		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C164665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164665>	C155320	Reference Sequence Read Depth|Reference Coverage|Reference Sequence Coverage	The number of times that a reference sequence is found in a read.			Conceptual Entity	
C164666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164666>	C155320	Alternative Sequence Read Depth|Alternative Coverage|Alternative Sequence Coverage	The number of times that a variant sequence is found in a read.			Conceptual Entity	
C164667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164667>	C25337	Sequence Read Count|Read Count|total reads|total_reads	The number of sequencing reaction results that were pooled to assemble a sequence for a genomic region of interest.			Quantitative Concept	GDC Property Terminology|GDC Terminology
C164668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164668>	C181114	Etentamig|ABBV 383|ABBV-383|ABBV383|Anti-BCMA x aCD3 T-BsAb TNB-383B|Anti-BCMA x aCD3 T-cell Engaging Bispecific Antibody TNB-383B|Anti-BCMA/Anti-CD3 T-cell Engaging Bispecific Antibody ABBV-383|Anti-alpha BCMA/Anti-alpha CD3 T-cell Engaging Bispecific Antibody TNB-383B|BCMA x CD3 T-cell Engaging Bispecific Antibody ABBV-383|ETENTAMIG|TNB 383B|TNB-383B|TNB383B	A T-cell engaging, human, bispecific, immunoglobulin G4 (IgG4) monoclonal antibody (T-BsAb) directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities.  Upon administration, etentamig binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA found on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated cell death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival. Binding to low-activating CD3 preferentially activates effector over regulatory T-cells and stimulates minimum cytokine release.	Etentamig		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C164669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164669>	C155320	Pharmacogenomics Read Depth|Pharmacogenomics Coverage|Pharmacogenomics Sequence Coverage	The number of times that a pharmacogenomics region of interest was fully sequenced.			Conceptual Entity	
C16466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16466>	C20181	Confidentiality|confidentiality|confidentiality	Treatment of information so that it is not divulged in ways that are inconsistent with the understanding of the original disclosure. Particularly, the ethical principle or legal right that a physician or other health professional will hold secret all information relating to a patient, unless the patient gives consent permitting disclosure.			Idea or Concept	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C164670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164670>	C164669|C164666	Pharmacogenomics Alternative Sequence Read Depth|Pharmacogenomics Alternative Coverage|Pharmacogenomics Alternative Sequence Coverage	The number of times that a variant sequence was found in a read of a pharmacogenomics region of interest.			Conceptual Entity	
C164671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164671>	C164669|C164665	Pharmacogenomics Reference Sequence Read Depth|Pharmacogenomics Reference Coverage|Pharmacogenomics Reference Sequence Coverage	The number of times that a known reference sequence was found in a read of a pharmacogenomics region of interest.			Conceptual Entity	
C164672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164672>	C164667	Pharmacogenomics Read Count|Pharmacogenomics Read Counts	The number of sequencing reaction results that were pooled to obtain the pharmacogenomics coverage.			Quantitative Concept	
C164673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164673>	C49142	Pharmacogenomics Copy Number	The number of times that a pharmacogenomics region of interest is present in the genome.			Quantitative Concept	
C164674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164674>	C17248	Single Nucleotide Variant|SNV|SNV, NOS|Single Nucleotide Variants|Single-Nucleotide Variant|snv variant|snv_variant	A variation of a single nucleotide at a specific location of the genome due to base substitution, which is found at any frequency in the population.			Nucleotide Sequence	ALL Authorized Value Terminology|ALL Molecular Analysis Table|AML Authorized Value Terminology|AML Molecular Analysis Table|CTDC Node Terminology|EWS Authorized Value Terminology|EWS Molecular Analysis Table|GCT Authorized Value Terminology|GCT Molecular Analysis Table|pFDA Bioinformatics/Genomics Terminology|precisionFDA Terminology
C164675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164675>	C7757|C28193	Warsaw Breakage Syndrome	An autosomal recessive condition caused by mutation(s) in the DDX11 gene, encoding ATP-dependent DNA helicase DDX11. It is characterized by severe intellectual disability and variable dysmorphic features.			Disease or Syndrome	Cellosaurus Disease Terminology
C164676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164676>	C3138	Inflammatory Bowel Disease 28|IBD28	An autosomal recessive condition caused by mutation(s) in the IL10RA gene, encoding interleukin-10 receptor subunit alpha. It is characterized by early-onset chronic relapsing intestinal inflammation.			Disease or Syndrome	Cellosaurus Disease Terminology
C164677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164677>	C62505	Fanconi Anemia, Complementation Group L|FANCL	Fanconi anemia caused by mutations in the FANCL gene, encoding E3 ubiquitin-protein ligase FANCL.			Disease or Syndrome	Cellosaurus Disease Terminology
C164678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164678>	C62727|C62726	Hypofractionated Image-Guided Radiation Therapy|Hypofractionated Image-Guided Radiotherapy	Hypofractionated radiation therapy that uses an image to guide the radiation beam.	Hypofractionated Image-Guided Radiation Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C164679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164679>	C186783	Human Acellular Dermal Matrix|D-ADM|DermACELL|Human ADM|hADM	An allograft composed of sterile, decellularized regenerative human dermal tissue matrix, with soft tissue reconstructive and transplantation purposes. In this human acellular dermal matrix (hADM), which is composed of the dermal layer and extracellular matrix of thin layers of donated skin that have had the epidermal layer removed, the donor cellular material is removed, which minimizes immunological response in ADM recipients. The hADM retains native growth factors, collagen and elastin. Using hADM to support tissue expanders or implants for soft tissue reconstruction or to aid in wound healing, the matrix allows for rapid cellular proliferation and infiltration, integration of mesenchymal cells into the matrix and re-vascularization. This facilitates surgical reconstruction and protects against wound exposure and wound infection.	Human Acellular Dermal Matrix		Pharmacologic Substance|Tissue	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C16467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16467>	C25464	Congo|178|CG|COG|COG|CONGO|CONGO (BRAZZAVILLE)|Republic of the Congo	A country in western Africa, bordering the South Atlantic Ocean, between Gabon and the Democratic Republic of the Congo.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C164680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164680>	C93608	Adverse Event Occurrence Date Range|AdverseEvent.occurrenceDateRange				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164681>	C153132	Adverse Event Occurrence Study Day Range|AdverseEvent.occurrenceStudyDayRange				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164683>	C104437	Adverse Event Treatment Emergent Indicator|AdverseEvent.treatmentEmergentIndicator|treatment emergent adverse event|treatment_emergent_adverse_event				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology|GDC Property Terminology|GDC Terminology
C164684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164684>	C164509	Amino Acid Physical Location End Coordinate|AminoAcidPhysicalLocation.endCoordinate				Spatial Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164685>	C164627	Amino Acid Physical Location Start Coordinate|AminoAcidPhysicalLocation.startCoordinate				Spatial Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164686>	C93698	Amino Acid Sequence Feature Type Code|AminoAcidSequenceFeature.typeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164687>	C25407	Authoring Device Physical Address|AuthoringDevice.physicalAddress	The physical device of the authoring device.			Spatial Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164688>	C70806	Authoring Device Telecom Address|AuthoringDevice.telecomAddress	The telecom address of the authoring device.			Classification	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164689>	C93523	Biologic Entity Classification Breed Code|BiologicEntityClassification.breedCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16468>	C19464	Consent Form|IC Form|ICF|Informed Consent Document|Informed Consent Form|Informed Consent Form|Informed Consent Form|consent form|consent form|informed consent form	A document explaining all the relevant information to assist an individual in understanding the expectations and risks in making a decision about a procedure. This document is presented to and signed by the individual or guardian.			Intellectual Product	CareLex eTMF Terminology|CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C164690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164690>	C164471	Biologic Entity Classification Common Name|BiologicEntityClassification.commonName				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164691>	C164562	Biologic Entity Classification Non-Host Indicator|BiologicEntityClassification.nonHostIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164692>	C164605	Biologic Entity Classification Scientific Name Code|BiologicEntityClassification.scientificNameCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164693>	C14419	Biologic Entity Classification Strain|BiologicEntityClassification.strain				Organism	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164694>	C164631	Biologic Entity Classification Strain Comment|BiologicEntityClassification.strainComment				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164695>	C164632	Biologic Entity Classification Strain Stock Identifier|BiologicEntityClassification.strainStockIdentifier				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164696>	C164637	Biologic Entity Classification Synonym Code|BiologicEntityClassification.synonymCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164697>	C164641	Biologic Entity Classification Taxonomy Identifier Code|BiologicEntityClassification.taxonomyIdentifierCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164698>	C164642	Biologic Entity Classification Taxonomy Rank Code|BiologicEntityClassification.taxonomyRankCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164699>	C164487	Biologic Entity Death Date Estimated Indicator|BiologicEntity.deathDateEstimatedIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16469>	C25464	Cook Islands|184|CK|COK|COK|COOK ISLANDS|COOK ISLANDS	A group of islands in the South Pacific Ocean, east of Australia, between Tonga and French Polynesia.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C1646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1646>	C1410	Ancestim|ANCESTIM|N-L-Methionyl-1-165-C-Kit Ligand|N-L-Methionyl-1-165-Hematopoietic Cell Growth Factor KL (Human Clone V19.8:Hscf162), Dimer|N-L-Methionyl-1-165-MGF|N-L-Methionyl-1-165-Mast Cell Growth Factor|N-L-Methionyl-1-165-SCF|Recombinant Human Methionyl Stem Cell Factor|Stemgen|Stemgen|ancestim|r-metHuSCF|r-metHuSCF|recombinant human methionyl stem cell factor|recombinant-methionyl human stem cell factor	A hematopoietic growth factor with activity on mature and immature hematopoietic progenitor cells.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology
C164700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164700>	C93546	Biologic Entity Death Indicator|BiologicEntity.deathIndicator				Finding	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164701>	C25364	Biologic Entity Group Identifier|BiologicEntityGroup.identifier				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164702>	C164557	Biologic Entity Missing Identifier Reason Code|BiologicEntity.missingIdentifierReasonCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164703>	C42614	Biologic Entity Name|BiologicEntity.name				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164704>	C164588	Biologic Entity Part Quantity Range|BiologicEntityPart.quantityRange				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164705>	C164609	Biologic Entity Sex Genotype Code|BiologicEntity.sexGenotypeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164706>	C42614	Biomarker Name|Biomarker.name				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164707>	C93698	Biomarker Type Code|Biomarker.typeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164708>	C25364	Cancer Registry Identifier|CancerRegistry.identifier				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164709>	C164457	Cell Culture Biosafety Level Code|CellCulture.biosafetyLevelCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16470>	C25464	Costa Rica|188|COSTA RICA|COSTA RICA|CR|CRI|CRI	A country in Central America, bordering both the Caribbean Sea and the North Pacific Ocean, between Nicaragua and Panama.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C164710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164710>	C164570	Cell Line Origin Cell Name|CellLine.originCellName				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164711>	C164572	Cell Line Passage Number|CellLine.passageNumber				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164712>	C164613	Cell Line Source Age|CellLine.sourceAge				Organism Attribute	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164713>	C164614	Cell Line Source Anatomic Site Code|CellLine.sourceAnatomicSiteCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164714>	C164615	Cell Line Source Developmental Stage|CellLine.sourceDevelopmentalStage				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164715>	C164617	Cell Line Source Tissue Type Code|CellLine.sourceTissueTypeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164716>	C42614	Chromosome Name|Chromosome.name				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164717>	C164645	Clinical Development Plan Therapeutic Area Code|ClinicalDevelopmentPlan.therapeuticAreaCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164718>	C164456	Container Barrier Delta Quantity|Container.barrierDeltaQuantity				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164719>	C164460	Container Bottom Delta Quantity|Container.bottomDeltaQuantity				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164720>	C25443	Container Capacity Quantity|Container.capacityQuantity				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164721>	C61532	Container Configuration|Container.configuration				Spatial Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164722>	C25285	Container Diameter|Container.diameter				Spatial Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164723>	C164496	Container Dimension One Capacity|Container.dimensionOneCapacity				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164724>	C164497	Container Dimension One Label|Container.dimensionOneLabel				Manufactured Object	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164725>	C164498	Container Dimension Point of Origin|Container.dimensionPointOfOrigin				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164726>	C164499	Container Dimension Three Capacity|Container.dimensionThreeCapacity				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164727>	C164500	Container Dimension Three Label|Container.dimensionThreeLabel				Manufactured Object	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164728>	C164501	Container Dimension Two Capacity|Container.dimensionTwoCapacity				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164729>	C164502	Container Dimension Two Label|Container.dimensionTwoLabel				Manufactured Object	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16472>	C61331	Cost/Benefit Analysis|Economics, Cost/Benefit	An analysis of the cost effectiveness of different alternatives in order to see whether the benefits outweigh the costs			Occupational Activity	
C164730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164730>	C95339	Container Handling Code|Container.handlingCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164731>	C164536	Container Identifier Embedded Indicator|Container.identifierEmbeddedIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164732>	C164537	Container Identifier Location Code|Container.identifierLocationCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164733>	C164538	Container Identifier Reader Type Code|Container.identifierReaderTypeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164734>	C164484	CT Imaging Acquisition Protocol Element CTDI Phantom Type Code|CTImagingAcquisitionProtocolElement.ctdiPhantomTypeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164735>	C101138	CT Imaging Acquisition Protocol Element CTDI VOL|CTImagingAcquisitionProtocolElement.ctdiVol				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164736>	C164518	CT Imaging Acquisition Protocol Element Exposure Modulation Type Code|CTImagingAcquisitionProtocolElement.exposureModulationTypeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164737>	C164526	CT Imaging Acquisition Protocol Element Gantry Detector Tilt|CTImagingAcquisitionProtocolElement.gantryDetectorTilt				Qualitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164738>	C48432	CT Imaging Acquisition Protocol Element kVp|CTImagingAcquisitionProtocolElement.kVp				Qualitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164739>	C164612	CT Imaging Acquisition Protocol Element Single Collimation Width|CTImagingAcquisitionProtocolElement.singleCollimationWidth				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16473>	C16984	Creatine Kinase B-Type|B-CK|Brain Creatine Kinase|CKB|Creatine Kinase-B|Creatine Kinase-B Chain|EC 2.7.3.2	Creatine kinase B-type (381 aa, ~43 kDa) is encoded by the human CKB gene. This protein plays a role in both energy homeostasis and creatine metabolism.	Creatine Kinase B-Type		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C164740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164740>	C164623	CT Imaging Acquisition Protocol Element Spiral Pitch Factor|CTImagingAcquisitionProtocolElement.spiralPitchFactor				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164741>	C164638	CT Imaging Acquisition Protocol Element Table Speed|CTImagingAcquisitionProtocolElement.tableSpeed				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164742>	C164652	CT Imaging Acquisition Protocol Element Total Collimation Width|CTImagingAcquisitionProtocolElement.totalCollimationWidth				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164743>	C41832	CT Imaging Reconstruction Protocol Element Convolution Kernel|CTImagingReconstructionProtocolElement.convolutionKernel				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164744>	C164480	CT Imaging Reconstruction Protocol Element Convolution Kernel Group Code|CTImagingReconstructionProtocolElement.convolutionKernelGroupCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164745>	C164508	Cytoband Range End Band|CytobandRange.endBand				Gene or Genome	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164746>	C164507	Cytoband Range End Chromosome Arm|CytobandRange.endChromosomeArm				Gene or Genome	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164747>	C164626	Cytoband Range Start Band|CytobandRange.startBand				Gene or Genome	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164748>	C164625	Cytoband Range Start Chromosome Arm|CytobandRange.startChromosomeArm				Gene or Genome	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164749>	C25365	Data Monitoring Committee Charter Version Description|DataMonitoringCommitteeCharterVersion.description				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16474>	C25464	Croatia|191|CROATIA|CROATIA|HR|HRV|HRV	A country in southeastern Europe, bordering the Adriatic Sea, between Bosnia and Herzegovina and Slovenia.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C164750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164750>	C164598	Defined Activity Repeat Quantity Range|DefinedActivity.repeatQuantityRange				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164751>	C164548	Defined Composition Relationship Join Code|DefinedCompositionRelationship.joinCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164752>	C164574	Defined Composition Relationship Pause Quantity Range|DefinedCompositionRelationship.pauseQuantityRange				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164753>	C164467	Defined Contingent On Relationship Checkpoint Code|DefinedContingentOnRelationship.checkpointCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164754>	C164574	Defined Contingent On Relationship Pause Quantity Range|DefinedContingentOnRelationship.pauseQuantityRange				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164755>	C70763	Defined Contingent On Relationship Priority Number|DefinedContingentOnRelationship.priorityNumber				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164756>	C164548	Defined Criterion Group Composition Relationship Join Code|DefinedCriterionGroupCompositionRelationship.joinCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164757>	C164574	Defined Criterion Group Composition Relationship Pause Quantity Range|DefinedCriterionGroupCompositionRelationship.pauseQuantityRange				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164758>	C164574	Defined Criterion Group Option Relationship Pause Quantity Range|DefinedCriterionGroupOptionRelationship.pauseQuantityRange				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164759>	C164599	Defined Eligibility Criterion Answer Required Indicator|DefinedEligibilityCriterionAnswer.requiredIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16475>	C64262	Cryopreservation|Cryopreserved|Cryopreserved|Storage, Cryopreservation|cryopreservation	Preservation of cells, tissues, organs, or embryos by storage at low temperatures.	Cryopreservation		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology|FDA eManufacturing Terminology|GDC Terminology|GDC Value Terminology|PQ/CMC Unit Operations Subcategory Terminology
C164760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164760>	C93601	Defined Material Storage Name Code Modified Text|DefinedMaterialStorage.nameCodeModifiedText				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164761>	C93507	Defined Observation Approach Anatomic Site Code|DefinedObservation.approachAnatomicSiteCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164762>	C25712	Defined Observation Result Value|DefinedObservationResult.value				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164763>	C164657	Defined Observation Result Value Negation Indicator|DefinedObservationResult.valueNegationIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164764>	C164574	Defined Option Relationship Pause Quantity Range|DefinedOptionRelationship.pauseQuantityRange				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164765>	C164443	Defined Procedure Additional Qualifier Code|DefinedProcedure.additionalQualifierCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164766>	C93601	Defined Procedure Name Code Modified Text|DefinedProcedure.nameCodeModifiedText				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164767>	C153112	Defined Procedure Target Anatomic Site Directionality Code|DefinedProcedure.targetAnatomicSiteDirectionalityCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164768>	C93601	Defined Product Transport Name Code Modified Text|DefinedProductTransport.nameCodeModifiedText				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164769>	C164482	Defined Progress Count Type Detail Code|DefinedProgressCount.countTypeDetailCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16476>	C20368	Crystallography	The study of molecular and crystalline structures and properties.			Laboratory Procedure	
C164770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164770>	C93698	Defined Progress Count Type Code|DefinedProgressCount.typeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164771>	C164464	Defined Repeat Activity Until Rule Cessation Pause Quantity Range|DefinedRepeatActivityUntilRule.cessationPauseQuantityRange				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164772>	C164467	Defined Repeat Activity Until Rule Checkpoint Code|DefinedRepeatActivityUntilRule.checkpointCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164773>	C70763	Defined Repeat Activity Until Rule Priority Number|DefinedRepeatActivityUntilRule.priorityNumber				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164774>	C25330	Defined Subject Activity Group Duration|DefinedSubjectActivityGroup.duration				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164775>	C93566	Defined Substance Administration Fasting Status Indicator|DefinedSubstanceAdministration.fastingStatusIndicator				Finding	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164776>	C82554	Defined Substance Administration Flow Rate|DefinedSubstanceAdministration.flowRate				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164777>	C95342	Defined Substance Administration Period Product Dose Total|DefinedSubstanceAdministration.periodProductDoseTotal				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164778>	C95344	Defined Substance Administration Product Dose|DefinedSubstanceAdministration.productDose				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164779>	C164639	Defined Substance Administration Target Anatomic Site Portion Code|DefinedSubstanceAdministration.targetAnatomicSitePortionCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16477>	C25464	Cuba|192|CU|CUB|CUB|CUBA|CUBA	An island between the Caribbean Sea and the North Atlantic Ocean, 150 km south of Key West, Florida.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C164780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164780>	C164463	Device CE Mark Indicator|Device.ceMarkIndicator	A CE (Conformite Europeenne) mark indicated on the device.			Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164781>	C25365	Device Parameter Description|DeviceParameter.description	A description of the device parameter.			Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164782>	C42614	Device Parameter Name|DeviceParameter.name	The name of the device parameter.			Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164783>	C164628	Device Parameter Status Code|DeviceParameter.statusCode	A status code of the device parameter.			Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164784>	C93698	Device Parameter Type Code|DeviceParameter.typeCode	A type code of the device parameter.			Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164785>	C25712	Device Parameter Value With Attribute Value|DeviceParameterValue.value	The device parameter value with the attribute value.			Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164786>	C164481	Document Author Corresponding Author indicator|DocumentAuthor.correspondingAuthorIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164787>	C25164	Document Author Date|DocumentAuthor.date				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164788>	C25364	Document Author Identifier|DocumentAuthor.identifier				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164789>	C70763	Document Author Priority Number|DocumentAuthor.priorityNumber				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16478>	C20188	Culture|Cultural|Culturally|culture	A pattern of learned beliefs, values, and behavior that are shared within a group. It includes language, styles of communication, practices, customs, and views on roles and relationships.			Idea or Concept	
C164790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164790>	C93538	Document Version Confidentiality Code|DocumentVersion.confidentialityCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164791>	C25364	Document Version Identifier|DocumentVersion.identifier|revision				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology|GDC Property Terminology|GDC Terminology
C164792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164792>	C51279	Document Version Language Code|DocumentVersion.languageCode				Classification	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164793>	C44476	Document Version Representation Content|DocumentVersionRepresentation.content				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164794>	C42743	Document Version Representation Uniform Resource Locator|DocumentVersionRepresentation.uniformResourceLocator				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164795>	C164603	Document Version Revision Reason Code|DocumentVersion.revisionReasonCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164796>	C25364	Donor Registry Identifier|DonorRegistry.identifier				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164797>	C164440	Drug Action Mode Code|Drug.actionModeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164798>	C25393	Evaluated Activity Relationship Comment|EvaluatedActivityRelationship.comment				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164799>	C15320	Experiment Design Type|Experiment.designType	The classification of an experiment based on the overall experimental design.			Research Activity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16479>	C21176	Protein Kinase A|PKA|cAMP-Dependent Protein Kinase	Most cellular effects of cAMP are mediated through PKA by serine or threonine phosphorylation of target proteins. Human Protein Kinase A (cAMP Ser/Thr Protein Kinase Family) is an inactive tetrameric cytoplasmic holoenzyme composed of homo- or heterodimeric regulatory subunits associated with two catalytic subunits. cAMP causes dissociation of inactive holoenzyme into a cAMP-bound dimer of regulatory subunits and two free monomeric catalytic subunits that phosphorylate many cytoplasmic and nuclear substrates. In human, regulatory PRKAR1A, PRKAR1B, PRKAR2A, and PRKAR2B subunits and catalytic PRKACA, PRKACB, and PRKACG subunits have been identified. (NCI)	Protein Kinase A		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Biomarkers/Targets Associated with Other Relevant Evidence
C1647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1647>	C155711	Trastuzumab|ABP 980|ALT02|Biceltis|CANMab|CT-P06|CT-P6|HLX 02|HLX-02|HLX02|Herceptin|Herceptin|Herceptin Biosimilar PF-05280014|Herceptin Trastuzumab Biosimilar PF-05280014|Hercessi|Herclon|Hertraz|Herwenda|Herzuma|Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman p185(Sup c-erbB2) Receptor), Disulfide with Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer|Kanjinti|Ogivri|Ontruzant|PF 05280014|PF-05280014|PF05280014|QL 1701|QL-1701|QL1701|RO0452317|SB3|TRASTUZUMAB|Trastuzumab Biosimilar ABP 980|Trastuzumab Biosimilar ALT02|Trastuzumab Biosimilar CT-P6|Trastuzumab Biosimilar HLX02|Trastuzumab Biosimilar PF-05280014|Trastuzumab Biosimilar QL1701|Trastuzumab Biosimilar SB3|Trastuzumab Biosimilar SIBP-01|Trastuzumab-anns|Trastuzumab-anns|Trastuzumab-dkst|Trastuzumab-dkst|Trastuzumab-dttb|Trastuzumab-dttb|Trastuzumab-herw|Trastuzumab-pkrb|Trastuzumab-pkrb|Trastuzumab-qyyp|Trastuzumab-qyyp|Trastuzumab-strf|Trastuzumab-strf|Trastuzumab-zerc|Trazimera|Zercepac|rhuMAb HER2|trastuzumab|trastuzumab biosimilar EG12014	A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)	Trastuzumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C164800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164800>	C164587	Experiment Purpose Code|Experiment.purposeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164801>	C164524	Experimental Activity Item Function Type Code|ExperimentalActivityItem.functionTypeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164802>	C42614	Experimental Factor Name|ExperimentalFactor.name				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164803>	C25284	Experimental Factor Type|ExperimentalFactor.type				Functional Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164804>	C25712	Experimental Factor Value With Attribute Value|ExperimentalFactorValue.value				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164805>	C164655	Experimental Unit Unplanned Treatment Indicator|ExperimentalUnit.unplannedTreatmentIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164806>	C42614	Gene Name|Gene.name				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164807>	C25704	General Statistical Consideration Text|GeneralStatisticalConsideration.text				Manufactured Object	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164808>	C93698	General Statistical Consideration Type Code|GeneralStatisticalConsideration.typeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164809>	C95346	Genetic Reference Type Code|GeneticReference.referenceTypeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16480>	C25464	Cyprus|196|CY|CYP|CYP|CYPRUS|CYPRUS	An island in the Mediterranean Sea, south of Turkey.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C164810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164810>	C164532	Genetic Reference Sequence Database|GeneticReference.sequenceDatabase				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164811>	C164607	Genetic Reference Sequence Identifier|GeneticReference.sequenceIdentifier				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164812>	C25712	Genetic Reference Value|GeneticReference.value				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164813>	C45766	Genetic Variation Identifier|GeneticVariation.identifier|external variant id|external_variant_id|variant id|variant_id	A unique identifier maintained by an authoritative database that represents a genetic variation.			Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology|CTDC Property Terminology
C164814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164814>	C164454	Genome Assembly Source|Genome.assemblySource				Qualitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164815>	C164455	Reference Genome Assembly Version|Genome Assembly Version|Genome.assemblyVersion|Reference Genome Assembly|reference genome|reference_genome	The source-specific version of the published genome assembly.			Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology|CTDC Property Terminology
C164816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164816>	C164525	Government Funding Category Code|GovernmentFunding.fundingCategoryCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164817>	C164560	Government Funding NCI Program Code|GovernmentFunding.nciProgramCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164818>	C93666	Healthcare Provider Role Code|HealthcareProvider.roleCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164819>	C93560	ID Effective Date Range|ID.effectiveDateRange				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16481>	C16965	Cysteine Proteinase|Cysteine Endopeptidase|Cysteine Peptidase|Cysteine Protease|Thiol Protease	An enzyme that contains an unpaired cysteine in the active site which acts as a nucleophilic thiol to catalyze the proteolytic processing of other proteins or polypeptides.			Amino Acid, Peptide, or Protein|Enzyme	
C164820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164820>	C25364	ID Identifier|ID.identifier				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164821>	C164539	ID Identifier Type Code|ID.identifierTypeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164822>	C93631	ID Primary Indicator|ID.primaryIndicator				Qualitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164823>	C70663|C164616	Source Unique Identifier|ID Source Identifier|ID.sourceIdentifier				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164824>	C164618	ID Source Type Code|ID.sourceTypeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164825>	C164439	Imaging Acquisition Protocol Element Acquisition Type Code|ImagingAcquisitionProtocolElement.acquisitionTypeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164826>	C93521	Imaging Acquisition Protocol Element Body Position Code|ImagingAcquisitionProtocolElement.bodyPositionCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164827>	C164462	Imaging Acquisition Protocol Element Cardiac Synchronization Technique Code|ImagingAcquisitionProtocolElement.cardiacSynchronizationTechniqueCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164828>	C164485	Imaging Acquisition Protocol Element Data Collection Diameter|ImagingAcquisitionProtocolElement.dataCollectionDiameter				Spatial Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164829>	C164541	Imaging Acquisition Protocol Element Image Type Code|ImagingAcquisitionProtocolElement.imageTypeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16482>	C16546	Cystoscopy|CS|CYSTOSCOPY|cystoscopy	Endoscopic examination of the urinary bladder or urethra.	Cystoscopy		Health Care Activity	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C164830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164830>	C164601	Imaging Acquisition Protocol Element Respiratory Motion Technique Code|ImagingAcquisitionProtocolElement.respiratoryMotionTechniqueCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164831>	C164581	Imaging Process Protocol Element Primary Anatomic Site Code|ImagingProcessProtocolElement.primaryAnatomicSiteCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164832>	C42581	Imaging Process Protocol Element Summary|ImagingProcessProtocolElement.summary				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164833>	C164447	Imaging Reconstruction Protocol Element Algorithm Code|ImagingReconstructionProtocolElement.algorithmCode|Reconstruction Algorithm Code				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164834>	C164591	Imaging Reconstruction Protocol Element Reconstruction Diameter|ImagingReconstructionProtocolElement.reconstructionDiameter				Spatial Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164835>	C164592	Imaging Reconstruction Protocol Element Reconstruction Field of View Height|ImagingReconstructionProtocolElement.reconstructionFieldOfViewHeight				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164836>	C164593	Imaging Reconstruction Protocol Element Reconstruction Field of View Width|ImagingReconstructionProtocolElement.reconstructionFieldOfViewWidth				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164837>	C164594	Imaging Reconstruction Protocol Element Reconstruction Interval|ImagingReconstructionProtocolElement.reconstructionInterval				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164838>	C106534	Imaging Reconstruction Protocol Element Slice Thickness|ImagingReconstructionProtocolElement.sliceThickness				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164839>	C93698	Imaging Reconstruction Protocol Element Type Code|ImagingReconstructionProtocolElement.typeCode|Reconstruction Type Code				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16483>	C16681	Cytochemistry|Histology, Cytochemistry	Branch of histochemistry associated with the localization of cellular components by specific staining methods, as for example the localization of acid phosphatases by the Gomori method.			Biomedical Occupation or Discipline	
C164840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164840>	C25364	Insured Person Identifier|InsuredPerson.identifier				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164841>	C70946	Insured Person Postal Address|InsuredPerson.postalAddress				Classification	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164842>	C93666	Insured Person Role Code|InsuredPerson.roleCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164843>	C70806	Insured Person Telecom Address|InsuredPerson.telecomAddress				Classification	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164844>	C98715	Interventional Study Protocol Version Confirmed Response Minimum Duration|InterventionalStudyProtocolVersion.confirmedResponseMinimumDuration				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164845>	C127790	Interventional Study Protocol Version Data Monitoring Committee Indicator|InterventionalStudyProtocolVersion.dataMonitoringCommitteeIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164846>	C164545	Interventional Study Protocol Version Intervention Type Code|InterventionalStudyProtocolVersion.interventionTypeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164847>	C98783	Interventional Study Protocol Version Stable Disease Minimum Duration|InterventionalStudyProtocolVersion.stableDiseaseMinimumDuration				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164848>	C164633	Interventional Study Protocol Version Study Agent Randomization Fraction|InterventionalStudyProtocolVersion.studyAgentRandomizationFraction				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164849>	C93545	Marital Status Date Range|MaritalStatus.dateRange				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16484>	C16865|C16486	Cytochrome P450|CYP|CYP450|Cytochrome P-450|Cytochrome P450 Enzyme|Cytochrome P450 Family|Cytochrome P450 Protein|Cytochrome-P450|P450|cytochrome P450 enzyme system	A family of cytochromes that are involved in electron transport and oxidative metabolism of drugs and other bioactive molecules. When the catalytic heme is reduced the absorbance peak for this protein occurs at 450 nm.	Cytochrome P450		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C164850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164850>	C164465	Material Characteristic Behavior Code|Material.characteristicBehaviorCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164851>	C25162	Material Code|Material.code				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164852>	C45766	Messenger RNA Identifier|MessengerRNA.identifier				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164853>	C164556	Molecular Biomarker Group Medical Statement|MolecularBiomarkerGroup.medicalStatement				Idea or Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164854>	C42614	Molecular Biomarker Group Name|MolecularBiomarkerGroup.name				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164855>	C25712	Molecular Sequence Value|MolecularSequence.value				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164856>	C164438	MR Imaging Acquisition Protocol Element Acquisition Contrast Code|MRImagingAcquisitionProtocolElement.acquisitionContrastCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164857>	C164453	MR Imaging Acquisition Protocol Element Arterial Spin Labeling Contrast Code|MRImagingAcquisitionProtocolElement.arterialSpinLabelingContrastCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164858>	C164494	MR Imaging Acquisition Protocol Element Diffusion B Value|MRImagingAcquisitionProtocolElement.diffusionBValue				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164859>	C164495	MR Imaging Acquisition Protocol Element Diffusion Directionality Code|MRImagingAcquisitionProtocolElement.diffusionDirectionalityCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16485>	C16484	Cytochrome P450 2E1|CYP2E1|CYPIIE1|Cytochrome P450, Family 2, Subfamily E, Polypeptide 1|Cytochrome P450, Subfamily IIE|Cytochrome P450, Subfamily IIE (Ethanol-Inducible)|Cytochrome P450, subfamily IIE (Ethanol-Inducible), Polypeptide 1|EC 1.14.14.1|Ethanol-Inducible P450|Flavoprotein-Linked Monooxygenase|Microsomal Monooxygenase|P450-2E1|P450-J|Xenobiotic Monooxygenase	Cytochrome P450 2E1 (493 aa, ~57 kDa) is encoded by the human CYP2E1 gene. This protein plays a role in the both the metabolism of drugs, ethanol and other xenobiotics and the oxidative activation of nitrosamines.	Cytochrome P450 2E1		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C164860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164860>	C164506	MR Imaging Acquisition Protocol Element Echo-Planar Pulse Sequence Indicator|MRImagingAcquisitionProtocolElement.echoPlanarPulseSequenceIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164861>	C164546	MR Imaging Acquisition Protocol Element Inversion Recovery Indicator|MRImagingAcquisitionProtocolElement.inversionRecoveryIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164862>	C156494	MR Imaging Acquisition Protocol Element Magnetic Field Strength|MRImagingAcquisitionProtocolElement.magneticFieldStrength				Qualitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164863>	C164558	MR Imaging Acquisition Protocol Element Multiple Spin Echo Indicator|MRImagingAcquisitionProtocolElement.multipleSpinEchoIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164864>	C164576	MR Imaging Acquisition Protocol Element Phase Contrast Indicator|MRImagingAcquisitionProtocolElement.phaseContrastIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164865>	C164586	MR Imaging Acquisition Protocol Element Pulse Sequence Name|MRImagingAcquisitionProtocolElement.pulseSequenceName				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164866>	C164600	MR Imaging Acquisition Protocol Element Resonant Nucleus Code|MRImagingAcquisitionProtocolElement.resonantNucleusCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164867>	C164604	MR Imaging Acquisition Protocol Element Saturation Recovery Indicator|MRImagingAcquisitionProtocolElement.saturationRecoveryIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164868>	C164621	MR Imaging Acquisition Protocol Element Spectrally Selected Suppression Code|MRImagingAcquisitionProtocolElement.spectrallySelectedSuppressionCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164869>	C164622	MR Imaging Acquisition Protocol Element Spin-Echo Pulse Sequence Category Code|MRImagingAcquisitionProtocolElement.echoPulseSequenceCategoryCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16486>	C16946	Cytochrome|Cytochromes	A family of membrane-associated, heme-containing proteins that catalyze oxidation and reduction to promote electron transport reactions.			Amino Acid, Peptide, or Protein|Enzyme	
C164870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164870>	C164629	MR Imaging Acquisition Protocol Element Steady State Pulse Sequence Code|MRImagingAcquisitionProtocolElement.steadyStatePulseSequenceCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164871>	C164646	MR Imaging Acquisition Protocol Element Time of Flight Contrast Indicator|MRImagingAcquisitionProtocolElement.timeOfFlightContrastIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164872>	C164473	MR Imaging Reconstruction Protocol Element Complex Image Component Code|MRImagingReconstructionProtocolElement.complexImageComponentCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164873>	C164509	Nucleic Acid Physical Location End Coordinate|NucleicAcidPhysicalLocation.endCoordinate				Spatial Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164874>	C164627	Nucleic Acid Physical Location Start Coordinate|NucleicAcidPhysicalLocation.startCoordinate				Spatial Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164875>	C48673	Nucleic Acid Sequence Feature Orientation|NucleicAcidSequenceFeature.orientation				Functional Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164876>	C93698	Nucleic Acid Sequence Feature Type Code|NucleicAcidSequenceFeature.typeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164877>	C93548	Observation Result Action Taken Relationship Delay Duration|ObservationResultActionTakenRelationship.delayDuration				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164878>	C164619	Observational Study Protocol Version Specimen Available For DNA Extraction Indicator|ObservationalStudyProtocolVersion.specimenAvailableForDNAExtractionIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164879>	C164620	Observational Study Protocol Version Specimen Retention Indicator|ObservationalStudyProtocolVersion.specimenRetentionIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16487>	C16624	Cytogenetics|Cytogenetic|cytogenetics	The branch of biology that studies the cellular aspects of heredity, especially the chromosomes. Includes the study of disease states caused by numerical and structural chromosome abnormalities.			Biomedical Occupation or Discipline	EWS Authorized Value Terminology|EWS Molecular Analysis Table|GCT Authorized Value Terminology|GCT Molecular Analysis Table|OS Authorized Value Terminology|OS Molecular Analysis Table
C164880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164880>	C93560	Organization Effective Date Range|Organization.effectiveDateRange				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164881>	C25364	Organization Relationship Identifier|OrganizationRelationship.identifier				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164882>	C164628	Organization Relationship Status Code|OrganizationRelationship.statusCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164883>	C93675	Organization Relationship Status Date|OrganizationRelationship.statusDate				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164884>	C25364	Organization Staff Identifier|OrganizationStaff.identifier				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164885>	C164478	Organization Staff Role Confidential Indicator|OrganizationStaffRole.confidentialIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164886>	C93560	Organization Staff Role Effective Date Range|OrganizationStaffRole.effectiveDateRange				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164887>	C25364	Organization Staff Role Identifier|OrganizationStaffRole.identifier				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164888>	C70946	Organization Staff Role Postal Address|OrganizationStaffRole.postalAddress				Classification	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164889>	C164583	Organization Staff Role Primary Role Indicator|OrganizationStaffRole.primaryRoleIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16488>	C20694	Keratin, Type I Cytoskeletal 19|40-kDa Keratin Intermediate Filament|CK-19|CK19|Cytokeratin 19|Cytokeratin-19|K19|KRT19|Keratin 19|Keratin-19	Keratin, type I cytoskeletal 19 (400 aa, ~44 kDa) is encoded by the human KRT19 gene. This protein plays a role in myofiber organization.	Keratin, Type I Cytoskeletal 19		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C164890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164890>	C93666	Organization Staff Role Code|OrganizationStaffRole.roleCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164891>	C70806	Organization Staff Role Telecom Address|OrganizationStaffRole.telecomAddress				Classification	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164892>	C19067	Organization Staff Role Title|OrganizationStaffRole.title				Qualitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164893>	C25365	Pathway Description|Pathway.description				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164894>	C25364	Pathway Identifier|Pathway.identifier				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164895>	C42614	Pathway Name|Pathway.name				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164896>	C25284	Pathway Type|Pathway.type				Functional Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164897>	C93545	Performed Activity Date Range|PerformedActivity.dateRange				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164898>	C164486	Performed Activity Date Range Validation Code|PerformedActivity.dateRangeValidationCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164899>	C25330	Performed Activity Duration|PerformedActivity.duration				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16489>	C20349	Cytokinesis	Process in which the cytoplasm of a cell is divided after nuclear division (mitosis) is complete.			Cell Function	
C1648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1648>	C1479	ALVAC-CEA Vaccine|ALVAC-CEA|ALVAC-CEA vaccine	A cancer vaccine consisting of ALVAC, a highly attenuated poxvirus strain derived from the canarypox virus, encoding for the tumor associated antigen (TAA) carcinoembryonic antigen (CEA), with potential antineoplastic activity. Upon administration, ALVAC-CEA vaccine expresses CEA and may stimulate a host immune response against tumor cells expressing CEA. This may result in the inhibition of tumor growth and/or metastasis. CEA is overexpressed in a variety of tumor cell types.			Chemical Viewed Functionally	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C164900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164900>	C93566	Performed Activity Fasting Status Indicator|PerformedActivity.fastingStatusIndicator				Finding	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164901>	C153138	Performed Activity Information Source Type Code|PerformedActivity.informationSourceTypeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164902>	C95341	Performed Activity Medical History Indicator|PerformedActivity.medicalHistoryIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164903>	C93601	Performed Activity Name Code Modified Text|PerformedActivity.nameCodeModifiedText				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164904>	C102861	Performed Activity Negation Indicator|PerformedActivity.negationIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164905>	C82556	Performed Activity Negation Reason|PerformedActivity.negationReason				Idea or Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164906>	C153139	Performed Activity Order Care Setting Type Code|PerformedActivity.orderCareSettingTypeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164907>	C164566	Performed Activity Order Date|PerformedActivity.orderDate				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164908>	C164568	Performed Activity Order Urgency Code|PerformedActivity.orderUrgencyCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164909>	C164569	Performed Activity Ordered Number of Repeats|PerformedActivity.orderedNumberOfRepeats				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16490>	C74942	Cytological Procedure|Cytologic Procedure|Cytologic Technique|Cytological Techniques|Cytology	Technique or procedure for manipulation of cells and analysis of cell properties and subcellular features.			Laboratory Procedure	
C164910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164910>	C164606	Performed Activity Relationship Separable Indicator|PerformedActivityRelationship.separableIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164911>	C70710	Performed Activity Relationship Sequence Number|PerformedActivityRelationship.sequenceNumber				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164912>	C93698	Performed Activity Relationship Type Code|PerformedActivityRelationship.typeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164913>	C164659	Performed Administrative Activity Variance Reason Code|PerformedAdministrativeActivity.varianceReasonCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164914>	C164628	Performed Clinical Result Status Code|PerformedClinicalResult.statusCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164915>	C164640	Performed Clinical Result Target Biomarker Code|PerformedClinicalResult.targetBiomarkerCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164916>	C164437	Performed Diagnosis Accepted Indicator|PerformedDiagnosis.acceptedIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164917>	C93521	Performed Diagnosis Body System Code|PerformedDiagnosis.bodySystemCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164918>	C164469	Performed Diagnosis Clinical Stage Descriptor Code|PerformedDiagnosis.clinicalStageDescriptorCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164919>	C164504	Performed Diagnosis Disease Status Missing Reason Code|PerformedDiagnosis.diseaseStatusMissingReasonCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16491>	C16681	Cytology|Histology, Cytology|cytology	The light microscopic study of normal and abnormal cells in fine needle aspirates (FNAs), body cavity fluids, and smears.			Biomedical Occupation or Discipline	GCT Authorized Value Terminology|GCT Lab Table|GDC Terminology|GDC Value Terminology
C164920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164920>	C164573	Performed Diagnosis Pathologic Stage Descriptor Code|PerformedDiagnosis.pathologicStageDescriptorCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164921>	C164580	Performed Diagnosis Present At Admission Code|PerformedDiagnosis.presentAtAdmissionCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164922>	C153107	Performed Diagnosis Priority At Discharge Code|PerformedDiagnosis.priorityAtDischargeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164923>	C93631	Performed Diagnosis Procedure Relationship Primary Indicator|PerformedDiagnosisProcedureRelationship.primaryIndicator				Qualitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164924>	C164468	Performed Encounter Classification Code|PerformedEncounter.classificationCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164925>	C164529	Performed Genetic Observation Genetic Location Of Interest|PerformedGeneticObservation.geneticLocationOfInterest				Gene or Genome	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164926>	C164530	Performed Genetic Observation Genetic Region of Interest|PerformedGeneticObservation.geneticRegionOfInterest				Gene or Genome	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164927>	C164531	Performed Genetic Observation Genetic Region Type Code|PerformedGeneticObservation.geneticRegionTypeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164928>	C164449	Performed Genetic Observation Result Allele Indicator Code|PerformedGeneticObservationResult.alleleIndicatorCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164929>	C164528	Performed Genetic Observation Result Genetic Location|PerformedGeneticObservationResult.geneticLocation				Gene or Genome	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16492>	C18073	Cytoskeletal Protein	A protein that is a structural part of the cytoskeleton. These proteins are involved in cell shape, organelle and protein localization, cell movement, cell division, endocytosis, exocytosis, and signal transduction.			Amino Acid, Peptide, or Protein	
C164930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164930>	C164530	Performed Genetic Observation Result Genetic Region of Interest|PerformedGeneticObservationResult.geneticRegionOfInterest				Gene or Genome	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164931>	C164531	Performed Genetic Observation Result Genetic Region Type Code|PerformedGeneticObservationResult.geneticRegionTypeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164932>	C164533	Performed Genetic Observation Result Genetic Subregion|PerformedGeneticObservationResult.geneticSubregion				Gene or Genome	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164933>	C164534	Performed Genetic Observation Result Genetic Target|PerformedGeneticObservationResult.geneticTarget				Nucleotide Sequence	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164934>	C164559	Performed Genetic Observation Result Mutation Type Code|PerformedGeneticObservationResult.mutationTypeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164935>	C117058	Performed Genetic Observation Run Identifier|PerformedGeneticObservation.runIdentifier				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164936>	C93526	Performed Histopathology Result Differentiation Grade Code|PerformedHistopathologyResult.differentiationGradeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164937>	C93581	Performed Histopathology Result Involved Surgical Margin Indicator|PerformedHistopathologyResult.involvedSurgicalMarginIndicator				Qualitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164938>	C164445	Performed Imaging Study Admitting Diagnosis Code|PerformedImagingStudy.admittingDiagnosisCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164939>	C25365	Performed Imaging Study Description|PerformedImagingStudy.description				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16493>	C25683	Data Source|DATA_SOURCE|Data Sources|data origin	The person or authoritative body who provided the information.			Quantitative Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|OS Subject Characteristics Table|OS Variable Terminology
C164940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164940>	C164493	Performed Imaging Study DICOM Study ID|PerformedImagingStudy.dicomStudyID				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164941>	C164540	Performed Imaging Study Image Count|PerformedImagingStudy.imageCount	The number of DICOM instances in the performed imaging study.			Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164942>	C164542	Performed Imaging Study Imaging Accession Identifier|PerformedImagingStudy.imagingAccessionIdentifier				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164943>	C164555	Performed Imaging Study Lossy Image Compression Indicator|PerformedImagingStudy.lossyImageCompressionIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164944>	C164561	Performed Imaging Study Non-Acquisition Modalities In Study Code|PerformedImagingStudy.nonAcquisitionModalitiesInStudyCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164945>	C164492	Performed Imaging Study Series Count|PerformedImagingStudy.seriesCount				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164946>	C164630	Performed Imaging Study Storage SOP Classes In Study|PerformedImagingStudy.storageSOPClassesInStudy				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164947>	C69260	Performed Imaging Study Subject Age|PerformedImagingStudy.subjectAge				Organism Attribute	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164948>	C164634	Performed Imaging Study Subject Height|PerformedImagingStudy.subjectHeight				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164949>	C93421	Performed Imaging Study Subject History|PerformedImagingStudy.subjectHistory				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164950>	C81328	Performed Imaging Study Subject Weight|PerformedImagingStudy.subjectWeight				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164951>	C164437	Performed Lesion Description Accepted Indicator|PerformedLesionDescription.acceptedIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164952>	C164551	Performed Lesion Description Lesion Identifier Text|PerformedLesionDescription.lesionIdentifierText				Manufactured Object	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164953>	C164624	Performed Material Process Step Standard Time Indicator|PerformedMaterialProcessStep.standardTimeIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164954>	C93595	Performed Material Storage Method Code|PerformedMaterialStorage.methodCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164955>	C164644	Performed Material Storage Temperature Range|PerformedMaterialStorage.temperatureRange				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164956>	C93532	Performed Medical Condition Result Clinically Significant Indicator|PerformedMedicalConditionResult.clinicallySignificantIndicator				Finding	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164957>	C164476	Performed Medical Condition Result Condition Status Change Reason|PerformedMedicalConditionResult.conditionStatusChangeReason				Idea or Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164958>	C164477	Performed Medical Condition Result Condition Status Code|PerformedMedicalConditionResult.conditionStatusCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164959>	C93561	Performed Medical Condition Result End Relative to Reference Code|PerformedMedicalConditionResult.endRelativeToReferenceCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16495>	C171088	Demographics|Demographic Factor|Demographic Factors|Demography|Population Studies / Demography	The statistical characterization of human populations or segments of human populations (e.g., characterization by age, sex, race, or income).			Organism Attribute	Newborn Screening Terminology|NICHD Terminology
C164960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164960>	C93608	Performed Medical Condition Result Occurrence Date Range|PerformedMedicalConditionResult.occurrenceDateRange				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164961>	C164565	Performed Medical Condition Result Occurrence Date Range Validation Code|PerformedMedicalConditionResult.occurrenceDateRangeValidationCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164962>	C153132	Performed Medical Condition Result Occurrence Study Day Range|PerformedMedicalConditionResult.occurrenceStudyDayRange				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164963>	C93670	Performed Medical Condition Result Severity Code|PerformedMedicalConditionResult.severityCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164964>	C164549	Performed Medical Record Abstraction Last Follow Up Date|PerformedMedicalRecordAbstraction.lastFollowUpDate				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164965>	C153127	Performed Medical Record Abstraction Last Follow Up Source Type Code|PerformedMedicalRecordAbstraction.lastFollowUpSourceTypeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164966>	C154672	Performed Medical Record Abstraction Reporting Source Type Code|PerformedMedicalRecordAbstraction.reportingSourceTypeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164967>	C164442	Performed Observation Additional Qualifier|PerformedObservation.additionalQualifier				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164968>	C164450	Performed Observation Analysis Method Code|PerformedObservation.analysisMethodCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164969>	C93521	Performed Observation Body System Code|PerformedObservation.bodySystemCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16496>	C25464	Denmark|208|DENMARK|DENMARK|DK|DNK|DNK	A country in northern Europe, bordering the Baltic Sea and the North Sea, consisting of a peninsula on the north coast of Germany and several major islands.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C164970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164970>	C164489	Performed Observation Derivation Method Code|PerformedObservation.derivationMethodCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164971>	C164483	Performed Observation Result Created Date|PerformedObservationResult.createdDate				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164972>	C164491	Performed Observation Result Derived Indicator|PerformedObservationResult.derivedIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164973>	C25712	Performed Observation Result Value|PerformedObservationResult.value				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164974>	C164656	Performed Observation Result Value Code Modified Text|PerformedObservationResult.valueCodeModifiedText				Manufactured Object	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164975>	C164647	Performed Observation Time Point Code|PerformedObservation.timePointCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164976>	C19067	Performed Patient Note Title|PerformedPatientNote.title				Qualitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164977>	C104441	Performed Procedure Non-Reason Code|PerformedProcedure.nonReasonCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164978>	C164584	Performed Procedure Principal Indicator|PerformedProcedure.principalIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164979>	C25256	Performed Procedure Quantity|PerformedProcedure.quantity				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16497>	C17153	Dentistry	A clinical specialty responsible for the maintenance of teeth and the oral cavity, and for the medical management of any diseases or disorders associated with these tissues.			Biomedical Occupation or Discipline	
C164980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164980>	C153112	Performed Procedure Target Anatomic Site Directionality Code|PerformedProcedure.targetAnatomicSiteDirectionalityCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164981>	C164639	Performed Procedure Target Anatomic Site Portion Code|PerformedProcedure.targetAnatomicSitePortionCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164982>	C93595	Performed Product Transport Method Code|PerformedProductTransport.methodCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164983>	C164624	Performed Product Transport Standard Time Indicator|PerformedProductTransport.standardTimeIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164984>	C25337	Performed Progress Count With Attribute Count|PerformedProgressCount.count				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164985>	C93608	Performed Protocol Deviation Occurrence Date Range|PerformedProtocolDeviation.occurrenceDateRange				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164986>	C93670	Performed Protocol Deviation Severity Code|PerformedProtocolDeviation.severityCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164987>	C164567	Performed Report Generation Order Identifier|PerformedReportGeneration.orderIdentifier				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164988>	C164513	Performed Specimen Move Expected Handling Condition Code|PerformedSpecimenMove.expectedHandlingConditionCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164989>	C164521	Performed Specimen Move From Position Dimension One|PerformedSpecimenMove.fromPositionDimensionOne				Spatial Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16498>	C16984	Deoxycytidine Kinase|2'-Deoxycytidine Kinase|ARA-C Kinase|DCK|EC 2.7.1.74|dCK	Deoxycytidine kinase (260 aa, ~31 kDa) is encoded by the human DCK gene. This protein is involved in nucleotide metabolism.	Deoxycytidine Kinase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C164990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164990>	C164522	Performed Specimen Move From Position Dimension Three|PerformedSpecimenMove.fromPositionDimensionThree				Spatial Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164991>	C164523	Performed Specimen Move From Position Dimension Two|PerformedSpecimenMove.fromPositionDimensionTwo				Spatial Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164992>	C25206	Performed Specimen Move Temperature|PerformedSpecimenMove.temperature				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164993>	C164649	Performed Specimen Move To Position Dimension One|PerformedSpecimenMove.toPositionDimensionOne				Spatial Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164994>	C164650	Performed Specimen Move To Position Dimension Three|PerformedSpecimenMove.toPositionDimensionThree				Spatial Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164995>	C164651	Performed Specimen Move To Position Dimension Two|PerformedSpecimenMove.toPositionDimensionTwo				Spatial Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164996>	C164563	Performed Study Agent Transfer Days Supply|PerformedStudyAgentTransfer.daysSupply				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164997>	C164543	Performed Study Subject Milestone Informed Consent Indicator|PerformedStudySubjectMilestone.informedConsentIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164998>	C93579	Performed Subject Milestone Informed Consent Date|PerformedSubjectMilestone.informedConsentDate				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C164999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C164999>	C164452	Performed Substance Administration Approach Anatomic Site Directionality Code|PerformedSubstanceAdministration.approachAnatomicSiteDirectionalityCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16499>	C16561	Deoxyribonuclease	Enzymes that catalyze the hydrolytic cleavage of phosphodiester bond linkages in the DNA backbone. Deoxyribonucleases belong to a larger family of nucleases, which cleave DNA bases at various positions in the DNA backbone.			Amino Acid, Peptide, or Protein|Enzyme	
C1649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1649>	C1962|C129820	Allovectin-7|HLA-B7/Beta2M DNA Lipid (DMRIE/DOPE) Complex|HLA-B7/Beta2M DNA Lipid Complex|HLA-B7/Beta2M Plasmid DNA/DMRIE/DOPE Lipid Complex|HLA-B7/Beta2M Plasmid DNA/Lipid Complex|HLA-B7/Beta2Microglobulin DNA-Liposome Complex		Allovectin-7		Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165000>	C104442	Performed Substance Administration Distinct Product Count|PerformedSubstanceAdministration.distinctProductCount	The number of products (resulting from different collections) used for this substance administration. This is a count of distinct donations, typically used for stem cell transplants.			Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165001>	C95342	Performed Substance Administration Period Product Dose Total|PerformedSubstanceAdministration.periodProductDoseTotal				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165002>	C95344	Performed Substance Administration Product Dose|PerformedSubstanceAdministration.productDose				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165003>	C164585	Performed Substance Administration Product Dose Description|PerformedSubstanceAdministration.productDoseDescription				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165004>	C164624	Performed Substance Administration Standard Time Indicator|PerformedSubstanceAdministration.standardTimeIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165005>	C164636	Performed Substance Administration Substance Unknown Indicator|PerformedSubstanceAdministration.substanceUnknownIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165006>	C164654	Performed Substance Administration Treatment Vehicle Quantity|PerformedSubstanceAdministration.treatmentVehicleQuantity				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165007>	C164515	Performed Supply Expected Use Data Range|PerformedSupply.expectedUseDateRange				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165008>	C25256	Performed Supply Quantity|PerformedSupply.quantity				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165009>	C164511	Performer Evaluator Alias|Performer.evaluatorAlias				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16500>	C17153	Dermatology	The branch of medicine focused on the study of the skin, and responsible for the medical management of its associated diseases.			Biomedical Occupation or Discipline	
C165010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165010>	C164458	Person Birth State Code|Person.birthStateCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165011>	C164474	Person Computed Ethnicity Code|Person.computedEthnicityCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165012>	C164475	Person Computed Ethnicity Source Code|Person.computedEthnicitySourceCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165013>	C164490	Person Derived Ethnicity Origin Code|Person.derivedEthnicityOriginCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165014>	C164510	Person Ethnic Surname Or Origin Code|Person.ethnicSurnameOrOriginCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165015>	C164527	Person Gender Identity Code|Person.genderIdentityCode	IMPORTANT NOTICE: The NCI Thesaurus contains biomedical terminologies that NCI does not own or control. This concept contains gender-related content that does not comply with Executive Order 14168.			Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165016>	C164610	Person Sexual Orientation Code|Person.sexualOrientationCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165017>	C164526	PET Imaging Acquisition Protocol Element Gantry Detector Tilt|PETImagingAcquisitionProtocolElement.gantryDetectorTilt				Qualitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165018>	C93500	Place Actual Indicator|Place.actualIndicator				Qualitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165019>	C164535	Place Identifier Code|Place.identifierCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16501>	C16345	Developmental Biology	The study of how a multicellular organism develops from its early immature forms (e.g., zygote, larva, embryo) into an adult.			Occupation or Discipline	
C165020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165020>	C164446	Planned Activity Agent Administration Care Setting Type Code|PlannedActivity.agentAdministrationCareSettingTypeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165021>	C93625	Planned Activity Duration|PlannedActivity.duration				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165022>	C164544	Planned Activity Interruptible Indicator|PlannedActivity.interruptibleIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165023>	C164596	Planned Activity Repeat Frequency Range Max Code|PlannedActivity.repeatFrequencyRangeMaxCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165024>	C164597	Planned Activity Repeat Frequency Range Min Code|PlannedActivity.repeatFrequencyRangeMinCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165025>	C164598	Planned Activity Repeat Quantity Range|PlannedActivity.repeatQuantityRange				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165026>	C164653	Planned Activity Transition Description|PlannedActivity.transitionDescription				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165027>	C164548	Planned Composition Relationship Join Code|PlannedCompositionRelationship.joinCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165028>	C164574	Planned Composition Relationship Pause Quantity Range|PlannedCompositionRelationship.pauseQuantityRange				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165029>	C164467	Planned Contingent On Relationship Checkpoint Code|PlannedContingentOnRelationship.checkpointCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16502>	C18020|C17369	Diagnostic Imaging Testing|Diagnostic Imaging|Diagnostic Imaging|Diagnostic Imaging|Medical Imaging	Any method that uses a visual display of structural or functional patterns of organs or tissues for diagnostic evaluation.	Diagnostic Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C165030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165030>	C164574	Planned Contingent On Relationship Pause Quantity Range|PlannedContingentOnRelationship.pauseQuantityRange				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165031>	C70763	Planned Contingent On Relationship Priority Number|PlannedContingentOnRelationship.priorityNumber				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165032>	C164548	Planned Criterion Group Composition Relationship Join Code|PlannedCriterionGroupCompositionRelationship.joinCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165033>	C164574	Planned Criterion Group Composition Relationship Pause Quantity Range|PlannedCriterionGroupCompositionRelationship.pauseQuantityRange				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165034>	C164574	Planned Criterion Group Option Relationship Pause Quantity Range|PlannedCriterionGroupOptionRelationship.pauseQuantityRange				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165035>	C25365	Planned Experimental Unit Allocation Result Description|PlannedExperimentalUnitAllocationResult.description				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165036>	C164574	Planned Option Relationship Pause Quantity Range|PlannedOptionRelationship.pauseQuantityRange				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165037>	C164464	Planned Repeat Activity Until Rule Cessation Pause Quantity Range|PlannedRepeatActivityUntilRule.cessationPauseQuantityRange				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165038>	C164467	Planned Repeat Activity Until Rule Checkpoint Code|PlannedRepeatActivityUntilRule.checkpointCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165039>	C70763	Planned Repeat Activity Until Rule Priority Number|PlannedRepeatActivityUntilRule.priorityNumber				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16503>	C41481	Digestion|Digestive|digestion	The process or act of converting food into chemical substances that can be absorbed and assimilated.			Organ or Tissue Function	
C165040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165040>	C93625	Planned Study Site Duration|PlannedStudySite.duration				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165041>	C164588	Planned Study Subject Quantity Range|PlannedStudySubject.quantityRange				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165042>	C93689	Planned Subject Activity Group Target Accrual Number Range|PlannedSubjectActivityGroup.targetAccrualNumberRange				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165043>	C93560	Point Of Contact Effective Date Range|PointOfContact.effectiveDateRange				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165044>	C70946	Point Of Contact Postal Address|PointOfContact.postalAddress				Classification	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165045>	C93631	Point Of Contact Primary Indicator|PointOfContact.primaryIndicator				Qualitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165046>	C70806	Point Of Contact Telecom Address|PointOfContact.telecomAddress				Classification	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165047>	C19067	Point Of Contact Title|PointOfContact.title				Qualitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165048>	C93698	Point Of Contact Type Code|PointOfContact.typeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165049>	C19067	Process Protocol Title|ProcessProtocol.title				Qualitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16504>	C71164	Animal Model of Disease|Disease Models, Animal|animal model	Animal disease whose pathologic mechanisms are sufficiently similar to those of a human disease for the animal disease to serve as a model.			Experimental Model of Disease	
C165050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165050>	C164470	Product Code Modified Text|Product.codeModifiedText				Manufactured Object	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165051>	C93497	Product Relationship Active Ingredient Indicator|ProductRelationship.activeIngredientIndicator				Qualitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165052>	C25256	Product Relationship Quantity|ProductRelationship.quantity				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165053>	C93545	Project Conduct Date Range|ProjectConduct.dateRange				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165054>	C25365	Project Description|Project.description				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165055>	C25364	Project Identifier|Project.identifier				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165056>	C42614	Project Name|Project.name|project	The name applied to an investigational project.			Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology|GDC Property Terminology|GDC Terminology
C165057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165057>	C93698	Project Relationship Type Code|ProjectRelationship.typeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165058>	C25284	Project Type|Project.type				Functional Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165059>	C25364	Protein Identifier|Protein.identifier				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16505>	C171083	Susceptibility|Predisposition|Susceptible	The constitutional or inborn state disposing to a disease, group of diseases, or metabolic or structural anomaly.			Qualitative Concept	
C165060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165060>	C42614	Protein Name|Protein.name				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165061>	C54191	Protein Symbol|Protein.symbol				Functional Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165062>	C164589	Radiopharmaceutical Radionuclide Code|Radiopharmaceutical.radionuclideCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165063>	C25712	Reference Result Value|ReferenceResult.value				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165064>	C164658	Reference Result Value Type Code|ReferenceResult.valueTypeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165065>	C164472	Regulatory Assessment Completion Date|RegulatoryAssessment.completionDate				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165066>	C164514	Regulatory Assessment Expected Resubmission Date|RegulatoryAssessment.expectedResubmissionDate				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165067>	C164602	Regulatory Assessment Result Code|RegulatoryAssessment.resultCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165068>	C164628	Regulatory Assessment Status Code|RegulatoryAssessment.statusCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165069>	C164451	Relevant Regulation Applicable Indicator|RelevantRegulation.applicableIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16506>	C25464	Djibouti|262|DJ|DJI|DJI|DJIBOUTI|DJIBOUTI	A country in eastern Africa, bordering the Gulf of Aden and the Red Sea, between Eritrea and Somalia.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C165070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165070>	C25162	Relevant Regulation Code|RelevantRegulation.code				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165071>	C25364	Resource Identifier|Resource.identifier				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165072>	C42614	Resource Name|Resource.name				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165073>	C93698	Resource Type Code|Resource.typeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165074>	C25162	Result Classification Code|ResultClassification.code				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165075>	C93698	Result Classification Type Code|ResultClassification.typeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165076>	C25704	Sample Size Consideration Text|SampleSizeConsideration.text				Manufactured Object	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165077>	C95349	Scheduled Activity Study Day Range|ScheduledActivity.studyDayRange				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165078>	C95337	Scheduled Substance Administration Active Ingredient Dose|ScheduledSubstanceAdministration.activeIngredientDose				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165079>	C93556	Scheduled Substance Administration Dose Frequency Code|ScheduledSubstanceAdministration.doseFrequencyCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16507>	C19154	DNA Damage	Drug-, radiation-induced, or spontaneous injuries to DNA that introduce deviations from its normal double-helical conformation. These changes include structural distortions that interfere with replication and transcription, as well as point mutations that disrupt base pairs and exert damaging effects on future generations through changes in DNA sequence. If the damage is minor, it can often be repaired (DNA repair); extensive damage can induce apoptosis.	DNA Damage		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Terminology
C165080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165080>	C93557	Scheduled Substance Administration Dose Period Code|ScheduledSubstanceAdministration.dosePeriodCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165081>	C95342	Scheduled Substance Administration Period Product Dose Total|ScheduledSubstanceAdministration.periodProductDoseTotal				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165082>	C164585	Scheduled Substance Administration Product Dose Description|ScheduledSubstanceAdministration.productDoseDescription				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165083>	C25364	Service Delivery Location Identifier|ServiceDeliveryLocation.identifier				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165084>	C93666	Service Delivery Location Role Code|ServiceDeliveryLocation.roleCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165085>	C164461	Software Build Number Text|Software.buildNumberText				Manufactured Object	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165086>	C44476	Software Content|Software.content				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165087>	C164552	Software License Effective Date Range|Software.licenseEffectiveDateRange				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165088>	C164553	Software License Key|Software.licenseKey				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165089>	C164554	Software License Type Code|Software.licenseTypeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16508>	C16849	DNA Methyltransferase|DNA MTase|DNA Modification Methylase|DNA methylase|DNA methyltransferase|DNA-Methyltransferase|Dnmt|Site-Specific DNA-methyltransferase	DNA Methyltransferases are a subclass of transferase enzymes that catalyze the transfer of a methyl group from a donor compound to DNA.	DNA Methyltransferase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Biomarkers/Targets Associated with Other Relevant Evidence
C165090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165090>	C93703	Software Version Number Text|Software.versionNumberText				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165091>	C25402	Specimen Collection Group Accession Number Text|SpecimenCollectionGroup.accessionNumberText				Classification	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165092>	C42614	Specimen Collection Group Name|SpecimenCollectionGroup.name				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165093>	C164441	Specimen Collection Protocol Active Date Range|SpecimenCollectionProtocol.activeDateRange				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165094>	C164448	Specimen Collection Protocol Aliquot In Same Container Indicator|SpecimenCollectionProtocol.aliquotInSameContainerIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165095>	C164479	Specimen Collection Protocol Consents Waived Indicator|SpecimenCollectionProtocol.consentsWaivedIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165096>	C164547	Specimen Collection Protocol IRB Approval Number Text|SpecimenCollectionProtocol.irbApprovalNumberText				Manufactured Object	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165097>	C164611	Specimen Collection Protocol Short Title|SpecimenCollectionProtocol.shortTitle				Qualitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165098>	C93689	Specimen Collection Protocol Target Accrual Number Range|SpecimenCollectionProtocol.targetAccrualNumberRange				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165099>	C93536	Specimen Condition Code|Specimen.conditionCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16509>	C19172	DNA Nucleotidylexotransferase|DNTT|Deoxynucleotidyl Terminal Transferase|EC 2.7.7.31|TDT|TdT|Terminal Addition Enzyme|Terminal Deoxynucleotidyltransferase|Terminal Deoxyribonucleotidyl Transferase|Terminal Transferase	DNA nucleotidylexotransferase (509 aa, ~59 kDa) is encoded by the human DNTT gene. This protein plays a role in DNA polymerization and specifically catalyzes the insertion of nucleotides (N regions) at the V(H)-D and D-J(H) junctions of immunoglobulin genes.	DNA Nucleotidylexotransferase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C1650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1650>	C2151	Peldesine|4H-Pyrrolo(3,2-d)pyrimidin-4-one,1,5-dihydro-2-amino-7-(3-pyridinylmethyl)|9-(3-Pyridinylmethyl)-7H-9-deazaguanine|BCX-34|PELDESINE|Peldesina|peldesine	A pyrimidine analogue and purine nucleoside phosphorylase inhibitor with immunosuppressive and antineoplastic properties. Peldesine inhibits purine nucleoside phosphorylase (PNP) that plays a pivotal role in T-cell proliferation and is responsible for the catalysis of the reversible phosphorolytic cleavage of purine ribonucleosides and 2'-deoxyribonucleosides. Inhibition of PNP results in accumulation of dGTP and the subsequent failure of DNA synthesis. This agent maybe used in T-cell related autoimmune diseases including psoriasis, rheumatoid arthritis and Crohn s disease and T-cell cancers			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165100>	C25162	Staff Interest Code|StaffInterest.code				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165101>	C164478	Staff Interest Confidential Indicator|StaffInterest.confidentialIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165102>	C93560	Staff Interest Effective Date Range|StaffInterest.effectiveDateRange				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165103>	C93631	Staff Interest Primary Indicator|StaffInterest.primaryIndicator				Qualitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165104>	C25365	Statistical Analysis Plan Version Description|StatisticalAnalysisPlanVersion.description				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165105>	C25364	Statistical Analysis Plan Version Identifier|StatisticalAnalysisPlanVersion.identifier				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165106>	C25164	Statistical Analysis Plan Version Modification Summary Date|StatisticalAnalysisPlanVersionModificationSummary.date				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165107>	C93643	Statistical Analysis Plan Version Modification Summary Reason Code|StatisticalAnalysisPlanVersionModificationSummary.reasonCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165108>	C25704	Statistical Analysis Plan Version Modification Summary Text|StatisticalAnalysisPlanVersionModificationSummary.text				Manufactured Object	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165109>	C164648	Statistical Analysis Plan Version Modification Summary Timing Description|StatisticalAnalysisPlanVersionModificationSummary.timingDescription				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16510>	C16319	DNA Polymerase Alpha|Alpha DNA polymerase	An enzyme that plays major roles in DNA metabolism. The protein, which exhibits bidirectional nuclease activity is required for both DNA synthesis and repair. DNA polymerase alpha is most active in dividing cells, and is primarily involved with lagging strand synthesis.			Amino Acid, Peptide, or Protein|Enzyme	
C165110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165110>	C25162	Statistical Analysis Plan Version Status Code|StatisticalAnalysisPlanVersionStatus.code				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165111>	C25164	Statistical Analysis Plan Version Status Date|StatisticalAnalysisPlanVersionStatus.date				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165112>	C93698	Statistical Analysis Plan Version Type Code|StatisticalAnalysisPlanVersion.typeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165113>	C164444	Storage Equipment Adjustable Indicator|StorageEquipment.adjustableIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165114>	C164496	Storage Equipment Dimension One Capacity|StorageEquipment.dimensionOneCapacity				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165115>	C164497	Storage Equipment Dimension One Label|StorageEquipment.dimensionOneLabel				Manufactured Object	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165116>	C164498	Storage Equipment Dimension Point of Origin|StorageEquipment.dimensionPointOfOrigin				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165117>	C164499	Storage Equipment Dimension Three Capacity|StorageEquipment.dimensionThreeCapacity				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165118>	C164500	Storage Equipment Dimension Three Label|StorageEquipment.dimensionThreeLabel				Manufactured Object	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165119>	C164501	Storage Equipment Dimension Two Capacity|StorageEquipment.dimensionTwoCapacity				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16511>	C21176	DNA Polymerase Delta|DNA Polymerase Delta Complex|Delta DNA Polymerase	A protein complex that has dual enzymatic activities in DNA synthesis. The enzyme complex both facilitates DNA synthesis by acting as a polymerase and exhibits exonuclease activity that degrades single stranded DNA in the 3' to 5' direction. It is a heterotetramer comprised of the DNA polymerase delta catalytic subunit and 3 DNA polymerase delta accessory subunits.			Amino Acid, Peptide, or Protein|Enzyme	
C165120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165120>	C164502	Storage Equipment Dimension Two Label|StorageEquipment.dimensionTwoLabel				Manufactured Object	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165121>	C164643	Storage Equipment Temperature Capability Range|StorageEquipment.temperatureCapabilityRange				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165122>	C25365	Stratum Group Description|StratumGroup.description				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165123>	C164459	Study Agent Blinded Name|StudyAgent.blindedName				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165124>	C164466	Study Agent Characteristic Modified Indicator|StudyAgent.characteristicModifiedIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165125>	C164512	Study Agent Expanded Access Indicator|StudyAgent.expandedAccessIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165126>	C164519	Study Agent First In Human Indicator|StudyAgent.firstInHumanIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165127>	C164520	Study Agent First In Human Risk Factor Code|StudyAgent.firstInHumanRiskFactorCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165128>	C164575	Study Agent Pediatric Formulation Indicator|StudyAgent.pediatricFormulationIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165129>	C67005	Study Agent Substitution Allowed Indicator|StudyAgent.substitutionAllowedIndicator	Specifies whether this agent as identified by its active substance is permitted to be substituted by a local brand.			Activity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16512>	C19172	DNA-directed DNA Polymerase|DNA-Dependent DNA Polymerase|EC 2.7.7.7	Catalyses DNA-template-directed extension of the 3'- end of a DNA strand by one nucleotide at a time. Cannot initiate a chain de novo. Requires a primer, which may be DNA or RNA. (IUBMB Enzyme Nomenclature)			Amino Acid, Peptide, or Protein|Enzyme	
C165130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165130>	C153145	Study Conduct Enrolled Study Subject Number|StudyConduct.enrolledStudySubjectNumber				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165131>	C20108	Study Country Code|StudyCountry.countryCode				Classification	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165132>	C93560	Study Country Personnel Effective Date Range|StudyCountryPersonnel.effectiveDateRange				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165133>	C70946	Study Country Personnel Postal Address|StudyCountryPersonnel.postalAddress				Classification	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165134>	C93631	Study Country Personnel Primary Indicator|StudyCountryPersonnel.primaryIndicator				Qualitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165135>	C93666	Study Country Personnel Role Code|StudyCountryPersonnel.roleCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165136>	C70806	Study Country Personnel Telecom Address|StudyCountryPersonnel.telecomAddress				Classification	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165137>	C93698	Study Objective Type Code|StudyObjective.typeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165138>	C25365	Study Outcome Measure Description|StudyOutcomeMeasure.description				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165139>	C164517	Study Outcome Measure Exploratory Indicator|StudyOutcomeMeasure.exploratoryIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16513>	C18300	DNA Repair|DNA Damage Repair|Unscheduled DNA Synthesis	Enzymatic restoration of DNA structure after chemical, radiation, or spontaneous damage.	DNA Repair		Genetic Function	CTRP Biomarker Terminology|CTRP Terminology
C165140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165140>	C42614	Study Protocol Document Version Public Title Name|StudyProtocolDocumentVersionPublicTitle.name				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165141>	C93698	Study Protocol Document Version Public Title Type Code|StudyProtocolDocumentVersionPublicTitle.typeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165142>	C146995	Study Protocol Version Adaptive Design Indicator|StudyProtocolVersion.adaptiveDesignIndicator				Research Activity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165143>	C98717	Study Protocol Version Data Cutoff Date|StudyProtocolVersion.dataCutoffDate				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165144>	C164488	Study Protocol Version Delayed Registry Posting Indicator|StudyProtocolVersion.delayedRegistryPostingIndicator				Conceptual Entity	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165145>	C164571	Study Protocol Version Participating Location Code|StudyProtocolVersion.participatingLocationCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165146>	C164577	Study Protocol Version Planned Investigational Exposure Quotient|StudyProtocolVersion.plannedInvestigationalExposureQuotient				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165147>	C164578	Study Protocol Version Planned Site Number Range|StudyProtocolVersion.plannedSiteNumberRange				Quantitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165148>	C164582	Study Protocol Version Primary Purpose Type Code|StudyProtocolVersion.primaryPurposeTypeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165149>	C164645	Study Protocol Version Therapeutic Area Code|StudyProtocolVersion.therapeuticAreaCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16514>	C21080	DNA Replication|DNA replication|Replication	The process by which the two strands of a DNA double helix separate, allowing each strand to act as a template for the synthesis of a complementary strand by specific base pairing. Includes autonomous but not virus replication.			Genetic Function	
C165150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165150>	C25364	Study Registry Identifier|StudyRegistry.identifier				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165151>	C93578	Study Resource Inactive Comment|StudyResource.inactiveComment				Qualitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165152>	C83078	Study Site Investigator Identifier|StudySiteInvestigator.identifier				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165153>	C93560	Study Site Oversight Status Effective Date Range|StudySiteOversightStatus.effectiveDateRange				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165154>	C25162	Study Site Recruitment Status Code|StudySiteRecruitmentStatus.code				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165155>	C25164	Study Site Recruitment Status Date|StudySiteRecruitmentStatus.date				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165156>	C93698	Study Site Relationship Type Code|StudySiteRelationship.typeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165157>	C25162	Subject Payment Method Code|SubjectPaymentMethod.code				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165158>	C93545	Subject Payment Method Date Range|SubjectPaymentMethod.dateRange				Temporal Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165159>	C93631	Subject Payment Method Primary Indicator|SubjectPaymentMethod.primaryIndicator				Qualitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C16515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16515>	C16499	Restriction Endonuclease|Restriction Enzyme|fragmentation enzyme|fragmentation_enzyme	Enzymes that exhibit endonuclease activity at a specific short nucleotide sequence to cleave strands of DNA.			Amino Acid, Peptide, or Protein|Enzyme	GDC Property Terminology|GDC Terminology
C165160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165160>	C164505	Substance Extraction Administration Relationship Donor Type Code|SubstanceExtractionAdministrationRelationship.donorTypeCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165161>	C164595	Substance Extraction Administration Relationship Relation Code|SubstanceExtractionAdministrationRelationship.relationCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165162>	C93643	Supplemental Statistical Analysis Plan Version Reason Code|SupplementalStatisticalAnalysisPlanVersion.reasonCode				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165163>	C25364	System Of Record Identifier|SystemOfRecord.identifier				Intellectual Product	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165165>	C93631	Target Anatomic Site Primary Indicator|TargetAnatomicSite.primaryIndicator				Qualitative Concept	BRIDG Class and Attribute Terminology|BRIDG Terminology
C165166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165166>	C200711	Imvotamab|Anti-CD20/Anti-CD3 Bispecific IgM Antibody IGM2323|Bispecific CD20xCD3 IgM Antibody IGM2323|Bispecific IgM Antibody IGM2323|IGM 2323|IGM-2323|IGM2323|IMVOTAMAB|IgM Pentamer IGM2323	An engineered immunoglobulin M (IgM) bispecific antibody, with potential antineoplastic activity. Imvotamab contains ten high affinity binding domains for the tumor-associated antigen (TAA) CD20, and one binding domain for CD3, a T-cell surface antigen. Upon administration, imvotamab binds to both T-cells and CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B-cells. Additionally, imvotamab induces complement-dependent cytotoxicity (CDC) to a greater extent than anti-CD20/anti-CD3 IgG bispecific antibodies, thereby further enhancing the killing CD20-expressing tumor cells. The extra binding units of imvotamab may bind cancer cells that express relatively low amounts of CD20. Also, compared to IgG format bispecific T-cell engaging antibodies, imvotamab appears to induce less cytokine release, which may reduce the risk of cytokine release syndrome (CRS). CD20 is exclusively expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell malignancies.	Imvotamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165167>	C162534	Pancreaticoduodenectomy Patient|Whipple Procedure Patient	A person who is undergoing a pancreaticoduodenectomy (Whipple procedure).	Pancreaticoduodenectomy Patient		Patient or Disabled Group	CTRP Intervention Terminology|CTRP Terminology
C165168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165168>	C159580	Food Diary	A record of an individual's daily intake of food.	Food Diary		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C165169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165169>	C15222	Standard Diet	A typical, daily diet. In the United States a typical diet consists of about 2,200 calories per day, with 50% of calories from carbohydrates, 15% protein, and 35% fat.	Standard Diet		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C16516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16516>	C20646	DNA Topoisomerase 1|DNA Topoisomerase I|DNA Topoisomerase I|EC 5.99.1.2|SCL-70|Scl-70 Antigen|Scl-70 Antigen|Scleroderma-70|TOP1|Top1|Topo I|Topoisomerase (DNA) I|Topoisomerase 1|Topoisomerase I|Topoisomerase I|Topoisomerase, DNA, I|Type I DNA Topoisomerase	DNA topoisomerase 1 (765 aa, ~91 kDa) is encoded by the human TOP1 gene. This protein plays a role in the regulation of DNA topology.	Topoisomerase I		Amino Acid, Peptide, or Protein|Enzyme	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Biomarkers/Targets Associated with Other Relevant Evidence
C165170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165170>	C210691	High-Protein Nutritional Supplement|High-Protein Dietary Supplement	A nutritional supplement that emphasizes protein content over fats or carbohydrates.	High-Protein Nutritional Supplement		Chemical Viewed Functionally	CTRP Intervention Terminology|CTRP Terminology
C165171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165171>	C7927|C35648|C129654	Unresectable Liver Carcinoma|Unresectable Liver and Intrahepatic Bile Duct Carcinoma|Unresectable Liver and Intrahepatic Bile Duct Carcinoma	A liver carcinoma that is not amenable to surgical resection.	Unresectable Liver and Intrahepatic Bile Duct Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165172>	C8638|C3908	Unresectable Ampulla of Vater Carcinoma	A carcinoma that arises from the ampulla of Vater and is not amenable to surgical resection.	Unresectable Ampulla of Vater Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165173>	C27322|C175516	Unresectable Periampullary Adenocarcinoma	An adenocarcinoma that arises from the periampullary region and is not amenable to surgical resection.	Unresectable Periampullary Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165174>	C35850|C148124	Unresectable Head and Neck Carcinoma	Carcinoma that arises from the head and neck region and is not amenable to surgical resection.	Unresectable Head and Neck Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165175>	C19498	Identifier Datatype|ID				Intellectual Product	BRIDG Class Terminology|BRIDG Terminology
C165176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165176>	C3871|C165174	Unresectable Nasopharyngeal Carcinoma	Nasopharyngeal carcinoma that is not amenable to surgical resection.	Unresectable Nasopharyngeal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165177>	C32669	Anal Sphincter|ANAL SPHINCTER|Structure of sphincter ani muscle (body structure)|anal region sphincter|anal sphincter|sphincter analia	The internal and external muscles surrounding the anus that maintain continence.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography Terminology|mCode Radiotherapy Treatment Location Value Set|mCode Terminology|UBERON Terminology
C165178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165178>	C65013|C164212	Endorectal Tumor Resection|Endo Rectal Tumor Resection|Endorectal Endoscopic Tumor Resection|Endorectal Surgery	The use of an endoscope to guide the surgical removal of tumor and any surrounding tissue located inside the rectum.			Therapeutic or Preventive Procedure	GDC Terminology|GDC Value Terminology
C165179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165179>	C165182|C103268	Hand Assisted Laparoscopic Radical Nephrectomy	A radical nephrectomy procedure performed using hand assisted laparoscopy.			Therapeutic or Preventive Procedure	GDC Terminology|GDC Value Terminology
C16517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16517>	C20423	DNA Helicase|EC 3.6.4.12|Helicase	A class of enzymes that utilizes the energy of ATP hydrolysis to unwind (unzipped) dsDNA. The enzyme participate in various of biological process including DNA replication, transcription and recombination.			Amino Acid, Peptide, or Protein|Enzyme	
C165180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165180>	C64994|C15389	Laparoscopic Biopsy	A biospy procedure performed with the aid of a laparoscope.			Diagnostic Procedure	GDC Terminology|GDC Value Terminology
C165181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165181>	C65014|C51928	Laparoscopic Partial Nephrectomy	A partial nephrectomy procedure performed with the aid of a laparoscope.			Therapeutic or Preventive Procedure	GDC Terminology|GDC Value Terminology
C165182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165182>	C65014|C51778	Laparoscopic Radical Nephrectomy	A radical nephrectomy procedure performed with the aid of a laparoscope.			Therapeutic or Preventive Procedure	GDC Terminology|GDC Value Terminology
C165183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165183>	C165184|C116509	Laparoscopic Radical Prostatectomy with Robotics|RARP|Robot-assisted Radical Prostatectomy	A radical prostatectomy procedure performed with the aid of a robotic laparoscope.			Therapeutic or Preventive Procedure	GDC Terminology|GDC Value Terminology
C165184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165184>	C94452|C15399	Laparoscopic Radical Prostatectomy|Laparoscopic Radical Prostatectomy without Robotics	A radical prostatectomy procedure performed with the aid of a laparoscope.	Laparoscopic Radical Prostatectomy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C165185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165185>	C53268	Chemotherapy Recipient	An individual receiving chemotherapy.	Chemotherapy Recipient		Human	CTRP Intervention Terminology|CTRP Terminology
C165186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165186>	C51928|C126391	Open Partial Nephrectomy	A partial nephrectomy procedure performed using a long incision for visualization and the insertion of instruments.			Therapeutic or Preventive Procedure	GDC Terminology|GDC Value Terminology
C165187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165187>	C51778|C126391	Open Radical Nephrectomy	A radical nephrectomy procedure performed using a long incision for visualization and the insertion of instruments.			Therapeutic or Preventive Procedure	GDC Terminology|GDC Value Terminology
C165188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165188>	C92983|C15399	Open Radical Prostatectomy	A radical prostatectomy procedure performed using a long incision for visualization and the insertion of instruments.			Therapeutic or Preventive Procedure	GDC Terminology|GDC Value Terminology
C165189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165189>	C15313	Conventional Radiotherapy|2-Dimensional Conventional Radiation Therapy|2D Conventional Radiotherapy|2D Radiotherapy|2D-RT|Radiation, 2D Conventional	A course of radiotherapy where minimal imaging support (i.e. X-rays films) is used to determine the positioning of radiotherapy.	Conventional Radiotherapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C16518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16518>	C17728	DNA Binding Protein	Proteins that non-covalently interact with deoxyribonucleic acid as a result of intermolecular physical forces and spatial complementarity. Many genetic regulatory DNA binding proteins bind to double- or single-stranded DNA in a sequence-specific manner and share common structural motifs such as the zinc-finger, helix-turn-helix, and leucine zipper.			Amino Acid, Peptide, or Protein	
C165190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165190>	C9306	Soft Tissue Sarcoma of the Trunk and Extremities	A soft tissue sarcoma that arises from the trunk or the extremities.	Soft Tissue Sarcoma of the Trunk and Extremities		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165191>	C12680	Trunk and Extremities	Body regions referring to the trunk and upper or lower extremity.			Body Location or Region	
C165192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165192>	C15212	Combination Radiotherapy|Radiation, Combination	Simultaneous or consecutive use of radiotherapy and one or more non-radiation based treatment modalities.			Therapeutic or Preventive Procedure	GDC Terminology|GDC Value Terminology
C165193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165193>	C12680	Epitrochlear Region|Epitrochlear|Epitrochlear	The inner surface of the upper arm adjacent to the elbow.			Body Location or Region	GDC Terminology|GDC Value Terminology
C165194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165194>	C49236	Stem Cell Therapy|Stem Cell Treatment|Stem Cell Treatment	A treatment modality that leverages stem cells to prevent or treat disease.			Therapeutic or Preventive Procedure	GDC Terminology|GDC Value Terminology
C165195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165195>	C38617	Vestibule of Mouth|Vestibule of mouth	The area inside the mouth between the cheek or lips, and the teeth.			Body Location or Region	GDC Terminology|GDC Value Terminology|Mapped ICDO3.1 Terminology|Mapped ICDO3.1 Topography PT Terminology|Mapped ICDO3.1 Topography Terminology|Mapped ICDO3.2 Terminology|Mapped ICDO3.2 Topography PT Terminology|Mapped ICDO3.2 Topography Terminology
C165196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165196>	C50995	Biochemical Evidence of Disease|BED-Biochemical Evidence of Disease|Biochemical	An indication that biochemical markers of a disease are present.			Finding	GDC Terminology|GDC Value Terminology
C165197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165197>	C165196	Biochemical Evidence of Disease without Structural Correlate|Biochemical evidence of disease without structural correlate	An indication that biochemical markers of a disease are present but morphological markers are absent.			Finding	GDC Terminology|GDC Value Terminology
C165198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165198>	C50995	Complete Response Unconfirmed|CRU-Complete Response Unconfirmed	An indication that a finding of complete response to treatment has not been confirmed.			Finding	GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Lesion Characteristics Table
C165199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165199>	C192742|C192741	Fovinaciclib|CDK4/6 Inhibitor FCN-437|Cyclin-dependent Kinase 4/6 Inhibitor FCN-437|FCN 437|FCN-437|FCN-437c|FCN437|FOVINACICLIB	An orally bioavailable inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon administration, fovinaciclib selectively inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1/S transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play key roles in the regulation of both cell cycle progression from the G1-phase into the S-phase and cell proliferation.	Fovinaciclib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C16519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16519>	C25464	Dominica|212|DM|DMA|DMA|DOMINICA|DOMINICA	An island between the Caribbean Sea and the North Atlantic Ocean, south of Guadeloupe and north of Martinique.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C1651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1651>	C1420	Motexafin Lutetium|Antrin|Lu tex|Lu-Tex|Lutetium Texaphrin|Lutetium Texaphyrin|Lutetium texaphyrin|Lutex|Lutex|Lutrin|MOTEXAFIN LUTETIUM|Optrin|PCI-0123|lutetium texaphyrin|motexafin lutetium	A pentadentate aromatic metallotexaphyrin with photosensitizing properties. Motexafin lutetium preferentially accumulates in tumor cells due to their increased rates of metabolism and absorbs light, forming an extended high energy conformational state that produces high quantum yields of singlet oxygen, resulting in local cytotoxic effects. (NCI04)	Motexafin Lutetium		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165200>	C82438	Medically Treated Reflux|Medically Treated|Reflux Medically Treated	An indication that a subject has used or is using medication to treat gastrointestinal reflux.			Finding	GDC Terminology|GDC Value Terminology
C165201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165201>	C1505	Digestible Starch|DS|Digestive Starch	A polymeric carbohydrate that is digested by enzymes in the gastrointestinal (GI) tract with dietary supplemental activity. Upon consumption of digestible starch (DS), it is degraded in the small intestine by GI enzymes within hours of ingestion. Digestion of starch releases glucose into the bloodstream which, in turn, triggers an insulinemic response. DS may be further categorized as slowly (SDS) or rapidly digestible (RDS) with the former producing a more sustained release of glucose and a more gradual rise in postprandial blood glucose levels. Consumption of a diet high in RDS may be associated with an increased risk of insulin resistance, obesity and metabolic syndrome.	Digestible Starch		Organic Chemical	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C165202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165202>	C50995	Mixed Response|MX-Mixed Response	An indication that some disease characteristics are improving while others are worsening over time.			Finding	GDC Terminology|GDC Value Terminology
C165203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165203>	C275|C1892|C1145	Flaxseed Lignan|Flax Lignan	A group of bioactive polyphenolic phytoestrogens derived from the seed of the flax plant (Linum usitatissimum) with potential antioxidant and chemopreventive activities. Flaxseed lignan is primarily comprised of secoisolariciresinol diglucoside (SDG), isolariciresinol, matairesinol, pinoresinol and lariciresinol. SDG is converted to the enterolignans enterolactone (EL) and enterodiol (ED) by the intestinal microflora in the proximal colon. EL and ED have both weakly estrogenic and anti-estrogenic activities depending upon the tissue. The anti-estrogenic effects in reproductive tissue may help reduce the risk of hormone-associated cancers, while the estrogenic effects in bone may help maintain bone density.  Flaxseed is the richest dietary source of lignans.	Flaxseed Lignan		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C165204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165204>	C162704	No Palliative Benefit|NPB-No Palliative Benefit	An indication that the treatment for a patient is not relieving symptoms or providing comfort.			Finding	GDC Terminology|GDC Value Terminology
C165205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165205>	C90169	Persistent Distant Metastasis|PDM-Persistent Distant Metastasis|Persistent Distant Metastases	An indication that distant metastases have remained despite treatment.			Finding	GDC Terminology|GDC Value Terminology
C165206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165206>	C50995	Responsive Disease|RD-Responsive Disease|RP-Response|Response observed|response	An indication that a patient's disease is responding to treatment.			Finding	CRF5 Response Evaluation Time Point Table|GDC Terminology|GDC Value Terminology
C165207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165207>	C17747	Hyperprogression	Paradoxical acceleration of tumor progression following the initiation of therapy.			Pathologic Function	
C165208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165208>	C35571|C123627	Radiographic Progressive Disease|RPD-Radiographic Progressive Disease	An indication that the radiographically detectable signs of disease are becoming more prominent over time.			Finding	GDC Terminology|GDC Value Terminology
C165209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165209>	C82438	Treatment Ongoing|Ongoing Treatment	An indication that a subject is still undergoing therapy to prevent, mitigate or cure a disease.			Finding	GDC Terminology|GDC Value Terminology
C16520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16520>	C25464	Dominican Republic|214|DO|DOM|DOM|DOMINICAN REPUBLIC|DOMINICAN REPUBLIC	A country comprising the eastern two-thirds of the island of Hispaniola, between the Caribbean Sea and the North Atlantic Ocean, east of Haiti.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C165210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165210>	C25657	Data Custodian	The person responsible for a specific data set.			Human	
C165211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165211>	C52095	Analysis Metadata	Supporting information that describes the processes used to analyze the experimental data in a study.			Intellectual Product	GDC Terminology|GDC Value Terminology
C165212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165212>	C48179	Cell Culture Image	Any image of cells grown or manipulated in a tissue culture.			Laboratory or Test Result	GDC Terminology|GDC Value Terminology
C165213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165213>	C53327	Copy Number Estimate	An estimation on the number of copies of a nucleic acid sequence of interest found in a sample using an algorithm that is based on the length and average mass of the sequence of interest and/or involves the normalization of a set of results gathered from similar samples or duplicate runs of a single sample.			Research Activity	GDC Terminology|GDC Value Terminology
C165214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165214>	C52095	Run Metadata	Supporting information that describes the nucleic acid sequencing run(s) in a study.			Intellectual Product	GDC Terminology|GDC Value Terminology
C165215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165215>	C48179	Slide Image	Any image of cells or tissue sections on a slide.			Laboratory or Test Result	GDC Terminology|GDC Value Terminology
C165216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165216>	C52095	Experiment Metadata	Supporting information that describes the experimental design in a study.			Intellectual Product	GDC Terminology|GDC Value Terminology
C165217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165217>	C199143	Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Center Group|ECOG-ACRIN|ECOG-ACRIN Cancer Research Group	A multidisciplinary, membership-based scientific organization that designs and conducts biomarker-driven cancer research involving adults who have or are at risk of developing cancer. The Group's stated purpose is to achieve research advances in all aspects of cancer care and thereby reduce the burden of cancer and improve the quality of life and survival in patients with cancer.			Professional or Occupational Group	
C165218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165218>	C50178	Diagnostic Slide	A slide on which a biospecimen has been mounted in order to perform a microscopy-based diagnostic test.			Manufactured Object	GDC Terminology|GDC Value Terminology
C165219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165219>	C45447|C18477	Genotyping Array	The application of microarray technology to the determination of the nucleotide sequence of the genetic material of an individual.			Molecular Biology Research Technique	GDC Terminology|GDC Value Terminology
C16521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16521>	C19077	Transcriptional Repression|Gene Down-Regulation|Gene Repression|Transcription Repression	Decreased expression of some gene product.			Genetic Function	
C165220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165220>	C101294	Low-Pass Whole Genome Sequencing|LP WGS|LP-WGS|Low Pass WGS|Low Pass Whole Genome Sequencing|Low-Pass WGS|Low-Pass Whole-Genome Sequencing	A form of whole genome sequencing where the sequencing read depth falls between 0.1 and 30 times.			Molecular Biology Research Technique	GDC Deprecated Terminology|GDC Terminology
C165221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165221>	C165220	Low-Coverage Whole Genome Sequencing|LC WGS|LC-WGS|Low-Coverage Whole-Genome Sequencing|Ultra Low-Pass WGS|lcWGS|lcWGS	A form of low-pass whole genome sequencing where the sequencing read depth falls between 0.1 and 3 times.			Molecular Biology Research Technique	
C165222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165222>	C63328|C18477	DNA Methylation Array|Methylation Array|Methylation Array	The use of a high-throughput microarray where all of the known CpG islands either in a single specimen or all of the known promoter sequences of a specimen or a population group are coupled to beads or microwells to determine which are methylated.			Molecular Biology Research Technique	GDC Terminology|GDC Value Terminology
C165223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165223>	C50178	Tissue Slide|Slides	A slide on which a tissue section has been mounted.			Manufactured Object	CRF7 Pathology Review Table|GDC Terminology|GDC Value Terminology
C165224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165224>	C23044	Nuclear Staining Method|Nuclear Staining|Nuclear Staining	A microscopy staining method that uses a dye or a contrast agent that specifically binds to chromosomal material and/or nucleoproteins, which permits visualization of a cellular nucleus.			Laboratory Procedure	GDC Terminology|GDC Value Terminology
C165225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165225>	C62199|C19296	Inframe Deletion	A loss of three consecutive nucleotides (one codon) or multiple codons in a gene that encodes for a protein where one or more canonical amino acids are deleted but does not result in a frameshift mutation.			Cell or Molecular Dysfunction	GDC Terminology|GDC Value Terminology
C165226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165226>	C62199|C19295	Inframe Insertion	A gain of three consecutive nucleotides (one codon) or multiple codons in a gene that encodes for a protein where one or more non-wildtype amino acids are inserted but does not result in a frameshift mutation.			Cell or Molecular Dysfunction	GDC Terminology|GDC Value Terminology
C165227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165227>	C97928	Mature miRNA Variant|Mature MicroRNA Variant	A ribonucleotide variation in the sequence of a fully processed microRNA.			Cell or Molecular Dysfunction	GDC Terminology|GDC Value Terminology
C165228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165228>	C2873	Near Diploidy|Near Diploid|Near Diploid	A chromosomal abnormality in which the total chromosome number is slightly more (hyperdiploid) or slightly less (hypodiploid) than the normal diploid number.			Cell or Molecular Dysfunction	GDC Terminology|GDC Value Terminology
C165229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165229>	C82438	Test Value Reported Indicator|Test Value Reported|Test Value Reported	An indication as to whether a test value has been reported or recorded.			Finding	GDC Terminology|GDC Value Terminology
C16522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16522>	C18272	Drug Abuse|Drug Use Disorder|Recreational Drug Use|drug abuse	The use of a drug for a reason other than which it was intended or in a manner or in quantities other than directed.			Individual Behavior	CPTAC Codelists Terminology|CPTAC Medical Conditions Codelist|CPTAC Terminology
C165230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165230>	C6823|C45576	Conversion Mutation|Conversion	A rearrangement where nonreciprocal transfer of genetic information between two sites in the genome lead to the deletion of one sequence and the duplication of the transferred sequence.			Cell or Molecular Dysfunction	GDC Terminology|GDC Value Terminology
C165231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165231>	C103223	Partial DNA Methylation|Partial Methylation|Partial Methylation	An indication that 10-90% of the CpG islands in a gene or gene promoter have detectable methylation.			Cell or Molecular Dysfunction	GDC Terminology|GDC Value Terminology
C165232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165232>	C153329|C142663	Raw Sequencing Data|Raw Nucleic Acid Sequencing Data|Raw Nucleotide Sequencing Data	Nucleic acid sequence data that has not been subjected to any normalization, alignment or other data processing steps.			Idea or Concept	GDC Terminology|GDC Value Terminology
C165233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165233>	C35681	Expression Negative|Absent|LOST|Loss of Expression|Loss of Expression|Negative|Not Expressed	An indication that expression of a gene, RNA species or protein is not detected in a sample.			Cell or Molecular Dysfunction	CTDC Value Terminology|GDC Terminology|GDC Value Terminology
C165234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165234>	C17423	Conductive Chemohyperthermia System|Conductive CHT|Conductive Hyperthermia System	A treatment system that combines hyperthermia with intravesical chemotherapy. A chemotherapy solution is heated externally and then instilled into and circulated through the bladder in a closed system.			Medical Device	
C165235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165235>	C53693	Foundation Stock Service	A breed registry program that is part of the AKC, in which breeders can record the birth and parentage of a rare breed they are trying to establish in the United States.			Mammal	
C165236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165236>	C25162	Treatment Assignment Code|TAC|Treatment Identification Code|ctep treatment assignment code|ctep_treatment_assignment_code	An identification code assigned to each unique treatment regimen to uniformly group patients for separate analysis of adverse events and response data.			Intellectual Product	ICDC Property Terminology|ICDC Terminology
C165237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165237>	C25365	Treatment Assignment Description|TAD	A complete description of each unique treatment regimen to uniformly group patients for separate analysis of adverse events and response data.			Intellectual Product	
C165238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165238>	C209713	Aurora A Kinase Inhibitor LY3295668 Erbumine|AK-01 ERBUMINE|AK-01 Erbumine|Aurora Kinase A Inhibitor LY3295668 Erbumine|LY 3295668 Erbumine|LY-3295668 Erbumine|LY3295668 Erbumine	The tert-butylamine salt form of LY3295668, an orally bioavailable inhibitor of the serine/threonine protein kinase aurora A, with potential antimitotic and antineoplastic activities. Upon administration, aurora A kinase inhibitor LY3295668 targets, binds to and inhibits the activity of aurora A kinase. This may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, inhibition of cell division and the induction of apoptosis in cells overexpressing aurora A kinase. Aurora A kinase, overexpressed in a wide variety of cancers, plays an essential role in the regulation of spindle assembly and mitosis.	Aurora A Kinase Inhibitor LY3295668 Erbumine		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165239>	C138961	PSA Level Greater than Zero|PSA Level Greater than 0	A blood concentration of prostate specific antigen greater than 0 ng/mL.	PSA Level Greater than Zero		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C16523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16523>	C41546	Drug Resistance Process|Drug Resistance|drug resistance	Mechanisms, functions, activities, or processes exhibited by tumors or pathogens to withstand previously toxic drugs.			Molecular Function	
C165240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165240>	C8852|C80280	Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified	The reemergence of diffuse large B-cell lymphoma, not otherwise specified after a period of remission.	Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165241>	C8853|C80280	Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified	A diffuse large B-cell lymphoma, not otherwise specified that is resistant to treatment.	Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165242>	C177684|C165233	BRD4/NUTM1 Fusion Negative|BRD4-C15orf55 Fusion Negative|BRD4-NUT Fusion Negative|BRD4-NUT Rearrangement Negative|BRD4-NUTM1 Fusion Negative|BRD4-NUTM1 Rearrangement Negative|BRD4/C15orf55 Fusion Negative|BRD4/NUT Fusion Negative|BRD4/NUT Rearrangement Negative|BRD4/NUTM1 Rearrangement Negative	An indication that expression of a BRD4/NUTM1 fusion has not been detected in a sample.	BRD4/NUTM1 Fusion Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C165243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165243>	C35682|C103223	Strata Immune Signature Positive	An indication that a tumor sample subjected to the proprietary StrataNGS (next-generation sequencing) protocol has a molecular profile that may respond to treatment with an immunotherapeutic agent.	Strata Immune Signature Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C165244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165244>	C3420|C153269	NUTM1 Gene Translocation|C15orf55 Gene Translocation|FAM22H Gene Translocation|NUT Gene Translocation|NUT Midline Carcinoma, Family Member 1 Gene Translocation|NUT Translocation|NUTM1 Translocation|Nuclear Protein in Testis Gene Translocation	A cytogenetic abnormality that refers to any translocation involving the NUTM1 gene.	NUTM1 Gene Translocation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C165245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165245>	C177692	NUTM1 Positive|NUT Family Member 1 Positive|NUT Midline Carcinoma Family Member 1 Positive|NUT Positive|Nuclear Protein in Testis Positive	An indication that NUTM1 expression has been detected in a sample.	NUTM1 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C165246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165246>	C177694	Reduced WAS Protein Expression|Reduced WASP Expression|Reduced WASp Expression|Reduced Wiskott-Aldrich Syndrome Protein Expression	An indication that reduced expression of Wiskott-Aldrich Syndrome protein (WASP; WASp) has been detected in a sample.	Reduced WAS Protein Expression		Finding	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C165247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165247>	C50371	Sit-Stand Workstation|Sit/Stand Workstation	An adjustable-height table, or table-top accessory, which allows users to easily alternate between working from a seated position to a standing position.	Sit-Stand Workstation		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C165248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165248>	C3420|C129438	t(17;19)	A cytogenetic abnormality that involves a translocation between chromosomes 17 and 19.	t(17;19)		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C165249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165249>	C157377	Testosterone Less than 100 ng/dL|Testosterone Less than 100 Nanograms per Deciliter|Testosterone Less than 100 Nanograms/Deciliter	A semiquantitative finding indicating that the concentration of testosterone in a sample is less than 100 ng/dL.	Testosterone Less than 100 ng/dL		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C165250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165250>	C103223	PCA3 Score Greater than 35|PCA3 Level Greater than 35|Prostate Cancer Antigen 3 Score Greater than 35|Prostate Cancer Associated 3 Score Greater than 35	An indication that the ratio of prostate cancer antigen 3 (PCA3) RNA to prostate specific antigen (PSA) mRNA multiplied by 1000 is greater than 35.	PCA3 Score Greater than 35		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C165251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165251>	C19967	Decipher Bladder Cancer Assay|Decipher Bladder|Decipher Bladder Assay	A genomic subtyping tool designed to identify muscle invasive bladder cancer patients who may benefit from neoadjuvant chemotherapy prior to surgery.	Decipher Bladder Cancer Assay		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C165252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165252>	C4456|C36263	Metastatic Malignant Mesothelioma	Malignant mesothelioma that has spread from its original site of growth to another anatomic site.	Metastatic Malignant Mesothelioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165253>	C7619|C3773|C157130|C150540	Recurrent Neuroendocrine Carcinoma	The reemergence of neuroendocrine carcinoma after a period of remission.	Recurrent Neuroendocrine Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165254>	C124800	Tuspetinib|FLT3 Inhibitor HM43239|FMS-like Tyrosine Kinase 3 Inhibitor HM43239|HM 43239|HM-43239|HM43239|TUSPETINIB	A selective, reversible type I inhibitor of FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2) with potential antineoplastic activity. Upon administration, tuspetinib reversibly binds to and inhibits the activity of FLT3. This inhibits the proliferation of FLT3-expressing cancer cells. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias.	Tuspetinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165255>	C155820	Upper Aerodigestive Invasive Malignancy	A finding indicating the presence of an invasive upper aerodigestive tract malignancy.	Upper Aerodigestive Invasive Malignancy		Finding	CTRP Disease Terminology|CTRP Terminology
C165256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165256>	C1663	Antigen-presenting Cells-expressing HPV16 E6/E7 SQZ-PBMC-HPV|APCs Expressing HPV16 E6/E7 SQZ-PBMC-HPV|SQZ PBMC HPV|SQZ-PBMC-HPV	A preparation of antigen presenting cells (APCs) specific for human papillomavirus (HPV) type 16 E6 and E7 proteins, with potential immunomodulating and antineoplastic activities. Autologous peripheral blood mononuclear cells (PBMCs) were ex vivo manipulated, using a technique involving membrane disruption to get the HPV16 E6 and E7 proteins into the cells; the resulting APCs present the antigens in a major histocompatibility type I (MHC-I) manner.  Upon administration of the APCs-expressing HPV16 E6/E7 SQZ-PBMC-HPV, these cells activate the immune system to mount a cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing HPV16 E6 and E7.  HPV16 E6 and E7 play an important role in the development of certain types of cancer.	Antigen-presenting Cells-expressing HPV16 E6/E7 SQZ-PBMC-HPV		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165258>	C192842	Cellosaurus Disease Terminology	The Cellosaurus Disease Terminology is a set of terms used to annotate cell lines originating from a diseased patient or animal. For inherited diseases, the relevant terms are only applied to cell lines originating from individuals suffering or at risk for a disease and not for individuals that are carriers for such disease. For cancers, the relevant terms are only applied to cell lines established from a cancerous tissue. The Cellosaurus is developed by Dr. Amos Bairoch of the CALIPHO group at the Swiss Institute of Bioinformatics.	Cellosaurus Disease Terminology		Intellectual Product	Cellosaurus Terminology
C16525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16525>	C16094	Echocardiography Test|EC|ECHOCARDIOGRAPHY|Echocardiography|Echocardiography|Echocardiography|Echocardiography|echocardiography	A procedure that uses high-frequency sound waves (ultrasound) to create an image of the heart.	Echocardiography		Diagnostic Procedure	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|Appendix 7: Diagnostic Procedures Terminology|CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|OS Authorized Value Terminology|OS Function Test Table
C165260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165260>	C3769|C170733	Primary Peritoneal Endometrioid Adenocarcinoma	An exceedingly rare endometrioid adenocarcinoma arising from the peritoneum.			Neoplastic Process	
C165261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165261>	C7431|C201136	Solid Pseudopapillary Neoplasm of the Ovary|Primary Ovarian Solid Pseudopapillary Neoplasm|Primary Ovarian Solid Pseudopapillary Tumor|Solid Pseudopapillary Tumor of the Ovary	An exceedingly rare solid pseudopapillary neoplasm that occurs in ectopic pancreatic tissue in the ovary.			Neoplastic Process	Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C165262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165262>	C153615|C105555	Recurrent Ovarian High Grade Serous Adenocarcinoma|Recurrent High Grade Ovarian Serous Adenocarcinoma|Recurrent High Grade Ovarian Serous Adenocarcinoma|Recurrent Ovarian High-Grade Serous Adenocarcinoma	The reemergence of ovarian high-grade serous adenocarcinoma after a period of remission.	Recurrent High Grade Ovarian Serous Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165263>	C67437	Docetaxel Polymeric Micelles|Docetaxel Lipid Emulsion|Docetaxel-PM|Docetaxel-loaded PM|Docetaxel-loaded PMs|Docetaxel-loaded Polymeric Micelles|NANOXEL-M|NanoxelM	A nanoparticle-based formulation consisting of polymeric micelles (PMs), made with poly(N-vinylpyrrolidone)-block-poly(D,L-lactide) (PVP-b-PDLLA) block polymers, encapsulating the taxane docetaxel, a semi-synthetic analogue of paclitaxel, with potential antineoplastic activity. Upon intravenous administration of the docetaxel PMs, the nanoparticles are able to accumulate at the tumor site due to the unique characteristics of the tumor's vasculature, while avoiding normal, healthy tissue. In turn, docetaxel is released locally at the target tumor site where it binds specifically to the beta-tubulin subunit of the microtubule, thereby stabilizing tubulin and inhibiting microtubule disassembly. This results in cell-cycle arrest at the G2/M phase, thereby preventing cell proliferation. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and induces various mediators of the inflammatory response. Compared to docetaxel alone, this formulation may enhance stability and improve delivery, thereby increasing docetaxel's efficacy while avoiding systemic exposure, which minimizes its toxicity.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165265>	C6279|C170766|C158421	Recurrent Fallopian Tube Endometrioid Adenocarcinoma	The reemergence of fallopian tube endometrioid adenocarcinoma after a period of remission.	Recurrent Fallopian Tube Endometrioid Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165266>	C2152|C129825	PI3K-delta Inhibitor SHC014748M|PI3Kd Inhibitor SHC014748M|SHC 014748M|SHC-014748M|SHC014748M	An orally available selective inhibitor of the delta isoform of phosphatidylinositol 3-kinase (PI3-kinase subunit delta; PI3K-delta; PI3Kdelta), with potential antineoplastic activity. Upon oral administration, PI3K delta inhibitor SHC014748M selectively binds to and inhibits PI3K delta and prevents the activation of the PI3K/AKT signaling pathway. This decreases proliferation of and induces cell death in PI3K delta over-expressing tumor cells. PI3K delta also plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of certain hematologic cancer cells. The targeted inhibition of PI3K delta is designed to preserve PI3K signaling in normal, non-neoplastic cells, thereby minimizing serious side effects.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165267>	C170766|C126456	Recurrent Fallopian Tube High Grade Serous Adenocarcinoma|Recurrent Fallopian Tube High-Grade Serous Adenocarcinoma|Recurrent High Grade Fallopian Tube Serous Adenocarcinoma|Recurrent High Grade Fallopian Tube Serous Adenocarcinoma	The reemergence of fallopian tube high-grade serous adenocarcinoma after a period of remission.	Recurrent High Grade Fallopian Tube Serous Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165268>	C156453|C126353	Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma	The reemergence of primary peritoneal high-grade serous adenocarcinoma after a period of remission.	Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165269>	C170767|C165260|C158421	Recurrent Primary Peritoneal Endometrioid Adenocarcinoma|Recurrent Endometrioid Primary Peritoneal Carcinoma|Recurrent Endometrioid Primary Peritoneal Carcinoma	The reemergence of primary peritoneal endometrioid adenocarcinoma after a period of remission.	Recurrent Endometrioid Primary Peritoneal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16526>	C16345	Ecology	The branch of biology concerned with the relations between organisms and their environment.			Occupation or Discipline	
C165270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165270>	C129822|C128057	Opucolimab|Anti-PD-L1 Monoclonal Antibody HLX20|HLX 20|HLX-20|HLX20|OPUCOLIMAB|PD-L1-targeting Monoclonal Antibody HLX20	A recombinant human monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, opucolimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed cell death 1 (PD-1; cluster of differentiation 279; CD279). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein belonging to the immunoglobulin superfamily (IgSF) expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8-positive T-cells.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165271>	C2124	Gallium Ga 68-THP-PSMA|68GA-THP-PSMA|68Ga-THP-PSMA|Gallium Ga 68-Tris(hydroxypyridinone)-Prostate-specific Membrane Antigen|Gallium Ga 68-labeled THP-PSMA|PSMA-THP GALLIUM GA-68|THP-PSMA GA-68	A radioconjugate composed of a human prostate specific membrane antigen (PSMA)-targeting agent conjugated, via the tris(hydroxypyridinone) (THP) chelator, to the radioisotope gallium Ga 68, with potential use as a tracer for PSMA-expressing tumors during positron emission tomography (PET). Upon intravenous administration of the gallium Ga 68-THP-PSMA, the PSMA moiety targets and binds to PSMA-expressing tumor cells. Upon PET imaging, PSMA-expressing tumor cells can be detected. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C165272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165272>	C129986	Xiaoai Jiedu Decoction|Xiaoai Jiedu Recipe	A traditional Chinese medicine (TCM) decoction composed of Oldenlandia, Kuh-seng, Codonopsis pilosula, bighead atractylodes rhizome, smoked plum, the rhizome of Chinese goldthread, rhizome zingiberis preparata and semen Coicis, with potential chemopreventive and antineoplastic activities. Upon administration of Xiaoai Jiedu decoction, the active ingredients in this decoction may inhibit a variety of signal transduction pathways involved in carcinogenesis. This may induce cell cycle arrest and tumor cell apoptosis and inhibit tumor cell formation and proliferation.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165273>	C129986	Concentrated Lingzhi Mushroom Extract|Concentrated Ganoderma lucidum Extract|Concentrated Red Reishi Mushroom Extract|Mikei Red Reishi Essence EX	A nutritional supplement and traditional Chinese medicine (TCM) composed of a highly concentrated extract of the fruiting body of the red reishi mushroom Ganoderma lucidum  (G. lucidum; lingzhi), with potential immunomodulating activities. Upon administration, the concentrated lingzhi mushroom extract may support the body's immune function and may support the immune system to eliminate tumor cells. The lingzhi mushroom extract contains high amounts of G. lucidum polysaccharides and G. lucidum triterpenoids (GLTs).			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165274>	C200766	Anti-TRBC1-CAR-CD3zeta-4-1BB-RQR8-expressing Autologous T-lymphocyte Cells AUTO4|AUTO 4|AUTO-4|AUTO4|Anti-TRBC1 CAR T-cells AUTO4|RQR8/TRBC1 CAR T Cells AUTO4|TRBC1-targeting CAR T Cells AUTO4	Autologous human T-lymphocytes that are genetically engineered to express a chimeric antigen receptor (CAR) containing an anti-T-cell receptor beta constant 1 (TRBC1; T-cell receptor beta-1 chain C region) single chain variable fragment (scFv) and the co-stimulatory domain 4-1BB (CD137) coupled to the zeta chain of the TCR/CD3 complex (CD3-zeta), with potential immunostimulating and antineoplastic activities. Upon administration, anti-TRBC1-CAR-CD3zeta-4-1BB-RQR8-expressing autologous T-lymphocyte cells AUTO4 targets and binds to the TRBC1 expressed on tumor cell surfaces. Subsequently, TRBC1-expressing tumor cells are lysed. In addition, AUTO4 carries the universal RQR8 safety "off" switch, which allows selective removal of the T-cells through both complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) following administration of rituximab if unacceptable side-effects occur.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology
C165275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165275>	C201130	Lymphodepletion Therapy|Lymphodepleting Therapy|Lymphodepletion	The destruction of lymphocytes prior to immunotherapy.			Therapeutic or Preventive Procedure	
C165276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165276>	C54443	Pediatric Terminologies	Terminologies created by NCIt EVS and various sources to support the interests and needs of the pediatric population.			Intellectual Product	
C165277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165277>	C15330	Pyloroplasty	Surgery to correct a narrowing of the pyloric sphincter.	Pyloroplasty		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C165278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165278>	C27992	Insulin-Producing	Describes cells or tissues that produce insulin.			Qualitative Concept	
C165279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165279>	C27992	Glucagon-Producing	Describes cells or tissues that produce glucagon.			Qualitative Concept	
C16527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16527>	C61331	Medical Economics	Economic aspects of the field of medicine, the medical profession, and health care. It includes the economic and financial impact of disease in general on the patient, the physician, society, or government.			Occupation or Discipline	
C165280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165280>	C200225|C1511	Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10|211At-OKT10-B10|Astatine 211-labeled Anti-CD38 Monoclonal Antibody OKT10-B10|Astatine At 211 Anti-CD38 MoAb OKT10-B10|Astatine-211-OKT10-B10|At211-OKT10-B10|[211At]OKT10-B10	A radioimmunoconjugate composed of the anti-CD38 monoclonal antibody (MoAb) OKT10-B10 labeled with the alpha-emitting radionuclide astatine (At) 211 (211At), with potential antineoplastic activity. Upon administration of astatine At 211 anti-CD38 MoAb OKT10-B10, the MoAb moiety targets and binds to CD38-expressing tumor cells, thereby delivering a cytotoxic dose of alpha radiation directly to the CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein and tumor-associated antigen (TAA), is present on various immune cells and in hematologic malignancies; its expression has been correlated with poor prognosis.	Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165281>	C15184	Walking School Bus Program|WSB|Walking School Bus	A program where children walk to and from school with adults in order to promote physical activity.	Walking School Bus Program		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C165282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165282>	C150094|C126769	Recurrent Endometrial Dedifferentiated Carcinoma	The reemergence of endometrial dedifferentiated carcinoma after a period of remission.	Recurrent Endometrial Dedifferentiated Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165283>	C8719|C162652|C150094	Recurrent Endometrial Squamous Cell Carcinoma	The reemergence of endometrial squamous cell carcinoma after a period of remission.	Recurrent Endometrial Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165284>	C40154|C150094	Recurrent Endometrial Transitional Cell Carcinoma	The reemergence of endometrial transitional cell carcinoma after a period of remission.	Recurrent Endometrial Transitional Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165285>	C4981	Recurrent Moderate-Severe Chronic Graft Versus Host Disease	The reemergence of moderate-severe chronic graft versus host disease after a period of remission.	Recurrent Moderate-Severe Chronic Graft Versus Host Disease		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C165286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165286>	C150093|C126769	Refractory Endometrial Dedifferentiated Carcinoma	An endometrial dedifferentiated carcinoma that is resistant to treatment.	Refractory Endometrial Dedifferentiated Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165287>	C8719|C171605|C150093	Refractory Endometrial Squamous Cell Carcinoma	An endometrial squamous cell carcinoma that is resistant to treatment.	Refractory Endometrial Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165288>	C40154|C150093	Refractory Endometrial Transitional Cell Carcinoma	An endometrial transitional cell carcinoma that is resistant to treatment.	Refractory Endometrial Transitional Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165289>	C7359|C159563|C150093	Refractory Endometrial Adenocarcinoma	An endometrial adenocarcinoma that is resistant to treatment.			Neoplastic Process	
C16528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16528>	C25464	Ecuador|218|EC|ECU|ECU|ECUADOR|ECUADOR	A country in western South America, bordering the Pacific Ocean at the Equator, between Colombia and Peru.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C165290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165290>	C40144|C165289	Refractory Endometrial Mucinous Adenocarcinoma	An endometrial mucinous adenocarcinoma that is resistant to treatment.	Refractory Endometrial Mucinous Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165291>	C40144|C158437	Recurrent Endometrial Mucinous Adenocarcinoma	The reemergence of endometrial mucinous adenocarcinoma after a period of remission.	Recurrent Endometrial Mucinous Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165292>	C1752|C1663	Multi-epitope HER2 Peptide Vaccine H2NVAC|H2NVAC|HER2 Peptide Vaccine H2NVAC|HER2 Specific Helper T-cell Epitope Vaccine H2NVAC	A peptide vaccine containing four immunogenic epitopes derived from the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (HER2; HER-2; ErbB2; Neu), with potential immunomodulating and antineoplastic activities. Upon intradermal administration, multi-epitope HER2 peptide vaccine H2NVAC may induce a helper T-cell mediated immune response against HER2-overexpressing tumor cells. This may result in long-term immunopotentiation against HER2-expressing tumor cells by increasing the helper T-cell response. HER2, a tyrosine kinase receptor for epidermal growth factor (EGF), is overexpressed in various cancer cell types.	Multi-epitope HER2 Peptide Vaccine H2NVAC		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165293>	C7927|C7692|C156909	Resectable Liver Carcinoma|Resectable Liver and Intrahepatic Bile Duct Carcinoma|Resectable Liver and Intrahepatic Bile Duct Carcinoma	Liver carcinoma that is amenable to surgical resection.	Resectable Liver and Intrahepatic Bile Duct Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165294>	C42534	Computed Tomography Dose Index|CTDI	A metric that quantifies the radiation dose delivered by a computed tomography examination by estimating the average dose absorbed at several locations in an imaged volume.			Quantitative Concept	
C165295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165295>	C226329	Very High Risk Myelodysplastic Syndrome	Myelodysplastic syndrome with more than 6 points, according to the revised International Prognostic Scoring System (IPSS-R).	Very High Risk Myelodysplastic Syndrome		Finding	CTRP Disease Terminology|CTRP Terminology
C165296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165296>	C165295	Recurrent Very High Risk Myelodysplastic Syndrome|Recurrent Very High-Risk Myelodysplastic Syndrome|Recurrent Very High-Risk Myelodysplastic Syndrome	The reemergence of very high-risk myelodysplastic syndrome after a period of remission.	Recurrent Very High Risk Myelodysplastic Syndrome		Finding	CTRP Disease Terminology|CTRP Terminology
C165297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165297>	C165295	Refractory Very High Risk Myelodysplastic Syndrome|Refractory Very High-Risk Myelodysplastic Syndrome|Refractory Very High-Risk Myelodysplastic Syndrome	Very high-risk myelodysplastic syndrome that is resistant to treatment.	Refractory Very High Risk Myelodysplastic Syndrome		Finding	CTRP Disease Terminology|CTRP Terminology
C165298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165298>	C40156|C150093	Refractory Endometrial Undifferentiated Carcinoma	An endometrial undifferentiated carcinoma that is resistant to treatment.	Refractory Endometrial Undifferentiated Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165299>	C156746|C153320	Advanced Gastric Carcinoma	A gastric carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Gastric Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16529>	C18074	Education	The activities of educating or instructing or teaching; activities that impart knowledge or skill.			Educational Activity	
C1652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1652>	C1970	Marimastat|(2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic Acid|(2S,3R)-3-{(S)-[2,2-Dimethyl-1-(methylcarbamoyl) propyl]carbamoyl}-2-hydroxy-5-methylhexanohydroxamic acid|BB 2516|BB-2516|MARIMASTAT|Marimistat|TA-2516|marimastat	An orally-active synthetic hydroxamate with potential antineoplastic activity.  Marimastat covalently binds to the zinc(II) ion in the active site of matrix metalloproteinases (MMPs), thereby inhibiting the action of MMPs, inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.  This agent may also inhibit tumor necrosis factor-alpha converting enzyme (TACE), an enzyme involved in tumor necrosis factor alpha (TNF-alpha) production that may play a role in some malignancies as well as in the development of arthritis and sepsis. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165300>	C191982|C162572	Advanced Merkel Cell Carcinoma	A Merkel cell carcinoma that has metastasized from its original site of growth to distal anatomic sites or is no longer responding to treatment.	Advanced Merkel Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165301>	C53702	American English Coonhound	A sweet, mellow, sociable, and lean hound with a broad head, a domed skull, soft low-hung ears, and dark-brown eyes. This dog is a hunter with a loud, ringing bark. The average height range is 23-26 inches and the average weight range is 45-65 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165302>	C53700	American Hairless Terrier	A small, smart, inquisitive, and playful dog with a broad, wedge-shaped head, and erect V-shaped ears. The skin is smooth and warm to the touch, and eyebrows and whiskers are sometimes present. The average height range is 12-16 inches and the average weight range is 12-16 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165303>	C165235	American Leopard Hound	A very intelligent hound that is loving and affectionate towards its human family and is very protective of children. There are three color patterns and nine different colors, with 60 percent of coats being a solid color. The average height range is 21-27 inches and the average weight range is 45-70 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165304>	C165235	Appenzeller Sennenhunde	An intelligent, high-spirited, reliable, and fearless watchdog. This dog is tri-color, medium-sized, and almost squarely built and balanced. The average height range is 19-22 inches and the average weight range is 48-70 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165305>	C165235	Australian Kelpie	A descendent of Collie type dogs, this herding dog was bred to withstand harsh heat and dry conditions of Australia. This dog is loyal, alert, and intelligent. The coat is either long-hair or smooth-hair and either black, tan or liver brown. The average height range is 17-20 inches and the average weight range is 13-20 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165306>	C165235	Australian Stumpy Tail Cattle Dog	A medium sized herding dog with a natural bob-tail. Coloring is black and white or grey and white. The average height range is 18-20 inches and the average weight range is 32-45 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165307>	C53699	Azawakh	A tall and elegant sighthound with a short, fine coat that can be red, clear sand to fawn, brindled, parti-colored, blue black, or brown. This dog excels as a companion, guardian, and lure courser. The average height range is 23.5-29 inches and the average weight range is 33-55 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165308>	C53700	Barbet	A cheerful, social, and loyal medium size water dog from France with a long, dense covering of curly hair and a distinctive beard. This athletic dog is used to locate, flush, and retrieve birds. The average height range is 19-24.5 inches and the average weight range is 35-65 pounds.			Mammal	ICDC Breeds Terminology|ICDC MISC Breeds|ICDC Terminology
C165309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165309>	C165235	Basset Fauve de Bretagne	A medium sized smart, cheerful, and determined hunting dog that has a coat that is fawn colored, from golden wheaten to red brick in hue, and is very rough, harsh, and short. The average height range is 12.6-15.5 inches and the average weight range is 27-35 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C16530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16530>	C25464	Egypt|818|EG|EGY|EGY|EGYPT|EGYPT	A country in northern Africa, bordering the Mediterranean Sea, east of Libya and north of Sudan.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF1 Registration Table|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C165310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165310>	C165235	Bavarian Mountain Scent Hound	A loyal, calm and balanced hound with an outstanding "cold-nose" tracking ability. The average height range is 17-20.5 inches and the average weight range is 37-66 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165311>	C53698	Beauceron	An imposing, powerful, smart herder with a short dark black coat with red feet. The head is well chiseled and long, and the eyes are dark brown. The average height range is 24-27.5 inches and the average weight range is 70-110 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165312>	C53700	Belgian Laekenois	An alert, affectionate, and intelligent herding dog from Belgium that is protective of his master and property. The coat is rough, tousled, and can be shades of red, fawn, or grey. The average height range is 22-26 inches and the average weight range is 55-65 pounds.			Mammal	ICDC Breeds Terminology|ICDC MISC Breeds|ICDC Terminology
C165313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165313>	C53698	Bergamasco Sheepdog	A large, muscular herding shepherd dog of ancient pedigree. The unique coat is three different textures that form naturally occurring mats that cover the body and legs and provide protection from the fierce cold and wild predators of their ancestral homeland, the Italian Alps. The average height range is 22-23.5 inches and the average weight range is 57-84 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165314>	C53698	Berger Picard	A lanky, sturdy, athletic herding dog with a stubborn streak. This dog must be exercised or their idleness and neglect will likely lead to destructive behavior. The coat is a wavy fawn or brindle color with a strong tail that tapers to a distinctive J-hook. The average height range is 21.5-25.5 inches and the average weight range is 50-70 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165315>	C53700	Biewer Terrier	An elegant, tri-colored toy terrier with a charming and whimsical attitude. The coat is long and black, white, and reddish brown. The average height range is 7-11 inches and the average weight range is 4-8 pounds.			Mammal	ICDC Breeds Terminology|ICDC MISC Breeds|ICDC Terminology
C165316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165316>	C53702	Bluetick Coonhound	A sleek, beautiful, affectionate, and speedy nocturnal hunter with droopy ears and a mottled or "ticked" coat that is black and blue. The average height range is 21-27 inches and the average weight range is 45-80 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165317>	C53699	Boerboel	An imposing and sleek-coated tan mastiff-type dog with a broad and blocky head, powerful jaws, and thick muscles from the neck to the rump. This is an intimidating guardian devoted to the protection of people and places. The average height range is 22-27 inches and the average weight range is 150-200 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165318>	C165235	Bohemian Shepherd	An intelligent, lively, athletic breed with a versatile skill set. This dog is an excellent family member due to its devotion to family and adoration of children. The coat is long-haired and black and tan. The average height range is 19.3-21.7 inches and the average weight range is 37-60 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165319>	C165235	Bolognese	A small, stocky, squarely built companion dog with a long white fluffy coat who is playful, easy-going, and devoted, and does not like to be left alone for long periods of time. The average height range is 10-12 inches and the average weight range is 5.5-9 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C16531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16531>	C21173	Ejaculation|Ejaculatory|ejaculation	The release of semen through the penis during orgasm. (NCI)			Organism Function	
C165320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165320>	C53701	Boykin Spaniel	A medium-sized spaniel with a rich brown coat and webbed toes that was bred to work in the lakes and swamps of South Carolina. This breed is friendly, eager, and lovable. The average height range is 14-18 inches and the average weight range is 25-40 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165321>	C53701	Bracco Italiano	One of the oldest of pointers, this breed is gentle in the home and tireless in the field. The breed is reliable, intelligent, and docile, with lean limbs, well developed muscles, and a sculpted head. The average height range is 21-27 inches and the average weight range is 55-90 pounds.			Mammal	ICDC Breeds Terminology|ICDC MISC Breeds|ICDC Terminology
C165322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165322>	C165235	Braque du Bourbonnais	A calm, gentle pointer with a short coat who is kind and affectionate in the home and a serious, intelligent hunter in the field. This breed has fawn and liver ticking coloring on their coat. The average height range is 19-22.5 inches and the average weight range is 35-53 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165323>	C165235	Braque Francais Pyrenean	A medium-sized, well-proportioned pointer with a soft, short haired white coat with brown ticking. This breed is gentle, friendly, sociable, and submissive. The average height range is 18.5-23 inches and the average weight range is 40-55 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165324>	C165235	Broholmer	A large, mastiff-type breed with a strong, rectangular body and wide, massive head who can protect the home and herd the cattle. His has a fawn colored short coat. The average height range is 27.5-29.5 inches and the average weight range is 90-150 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165325>	C53700	Cane Corso	An intelligent, loyal, eager to please, and willful large intimidating dog. The coat is dark, short, coarse, thick, and waterproof. The average height range is 23.5-27.5 inches and weight is proportionate to the height, usually at least 100 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165326>	C165235	Carolina Dog	A sighthound that has a wolf-like appearance and is loyal, independent, and shy towards strangers. The average height range is 17.75-19.5 inches and the average weight range is 30-55 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165327>	C165235	Caucasian Shepherd Dog	A large, fearless, kind, and serious guardian breed who is devoted to his family. This dog has a thick coat of long hair that is black, tan, and grey. The average height range is 23-30 inches and the average weight range is 99-170 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165328>	C165235	Central Asian Shepherd Dog	A large protective breed of dog that is self-assured, balanced, quiet, and independent. They are known for their fearlessness towards large predators. They have medium length hair that is tricolor- black, brindle, and white. The average height range is 25.5-27.5 inches and the average weight range is 88-110 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165329>	C53700	Cesky Terrier	The national dog of Czechia, this terrier is a clever and adventurous playmate for kids and a walking companion. This hunter is muscular and short-legged, and has a fine, silky coat that may be one of several shades of grey, including platinum. The average height range is 10-13 inches and the average weight range is 14-24 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C16532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16532>	C25464	El Salvador|222|EL SALVADOR|EL SALVADOR|SLV|SLV|SV	A country in Central America, bordering the North Pacific Ocean, between Guatemala and Honduras.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C165331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165331>	C53702	Cirneco dell'Etna	A sleek and sinewy ancient coursing hound from Sicily, this athletic hunter is given to quick bursts of speed. The coat color ranges from light to dark tan or chestnut. They have a loyal and gentle nature. The average height range is 16.5-19.5 inches and the average weight range is 17-26 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165332>	C53700	Coton de Tulear	A bright, charming, sturdy dog with a profuse, long white coat that is as soft as cotton. The average height range is 9-11 inches and the average weight range is 8-15 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165333>	C165235	Croatian Sheepdog	An agile, helpful and humble shepherd dog that excels as a herder, guard, or a companion. This breed is of medium size with a profuse, soft black coat. The average height range is 16-20 inches and the average weight range is 29-44 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165334>	C165235	Czechoslovakian Vlcak	An alert, primitive dog that resembles a wolf in appearance. This breed is highly intelligent, powerful, active, and devoted to their owner. They were originally bred for working border patrol in Czechoslovakia in the 1950s, and are now trained for search and rescue, tracking, and herding in the EU and US. The average height range is 23.5-25.5 inches and the average weight range is 44-57 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165335>	C165235	Danish-Swedish Farmdog	A small, compact and slightly rectangular companion dog with a short white and black or brown coat. This breed is easily trainable, loves to work and, enjoys a challenge. The average height range is 12.5-14.5 inches and the average weight range is 15-20 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165336>	C165235	Deutscher Wachtelhund	A medium-sized hunting dog that has blood tracking ability comparable to a bloodhound. This breed is owned by hunters and gamekeepers in Germany. It has a medium length, soft, curly coat. The average height range is 18-21 inches and the average weight range is 40-55 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165337>	C53701	Dogo Argentino	A pack-hunting dog bred for the pursuit of big-game, with the strength, intelligence and quick responsiveness of a serious athlete. The coat is short, plain, and smooth and is almost all white except for a possible dark patch on the head. The average height range is 23.5-27 inches and the average weight range is 80-100 pounds.			Mammal	ICDC Breeds Terminology|ICDC MISC Breeds|ICDC Terminology
C165338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165338>	C165235	Drentsche Patrijshond	A pointer-like dog bred to be a farm dog, hunt, keep vermin out, and much more. The coat is a long and silky soft white with brown markings. The average height range is 21-25 inches and the average weight range is 48-73 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165339>	C165235	Drever	A robust and strong small hunter who is kept as a hunting dog and, rarely, as a companion dog. The coat is medium length and can be brindle, fawn, red, or tri-colored with sable or white markings. The average height range is 12-15 inches and the average weight range is 35-40 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C16533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16533>	C17050	Electromagnetic Field|EMF|EMF|Radiation, Electromagnetic Field|electromagnetic field	Field of force associated with a moving electric charge and consisting of electric and magnetic fields that are generated at right angles to each other.			Natural Phenomenon or Process	
C165340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165340>	C53698	Dutch Shepherd	A lively, athletic herder. This breed has an independent nature and can be slightly obstinate. The coat is long, soft and either gold brindle, silver brindle, or yellow. The average height range is 21.5-24.5 inches and the average weight range is 42-75 pounds.			Mammal	ICDC Breeds Terminology|ICDC MISC Breeds|ICDC Terminology
C165341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165341>	C53698	Entlebucher Mountain Dog	A tricolor rugged and determined mover of cattle with a short, soft coat. The average height is 21 inches and the average weight range is 40-65 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165342>	C165235	Estrela Mountain Dog	A large and imposing livestock guardian who loves children and family. Coats can be long or short, and may be brindle, fawn, wolfgrey, or yellow with a black mask. The average height range is 24.5-29 inches and the average weight range is 77-132 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165343>	C165235	Eurasier	A medium-sized dog with a thick, medium-long coat that may be a variety of colors. A loyal family dog who needs to stay in close physical contact with his family. The average height range is 19-24 inches and the average weight range is 40-70 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165344>	C53702	Finnish Lapphund	A medium-sized tough and substantial reindeer herder from north of the Arctic Circle. They have a luscious long-hair coat and a profusely coated tail that curves over the back. They are friendly and submissive companions. The average height range is 16-21 inches and the average weight range is 33-53 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165345>	C165235	French Spaniel	A balanced, frank, gentle, and enthusiastic hunter that is sociable with other dogs and an ideal companion. They have long, silky hair that is either brown or white and brown with patches. The average height range is 21.5-24 inches and the average weight range is 50-60 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165346>	C165235	German Longhaired Pointer	A pointer with a full tail, a long coat with dense guard hairs, and a moderate undercoat. This dog loves to swim. The coat is brown and white with roan or speckled markings. The average height range is 22-28 inches and the average weight range is 55-80 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165347>	C165235	German Spitz	An attentive, lively and devoted dog who is easy to train. The coat is long and the colors are varied. The average height range is 12-15 inches and the average weight range is 24-26 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165348>	C53702	Grand Basset Griffon Vendeen	A French scenthound who is somewhat active and never high-strung. This dog has a sweet-faced, long ears, and a shaggy coat with a mustache, beard, and profuse eyebrows. The coat may be one of many colors. The average height range is 15.5-18 inches and the average weight range is 40-45 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165349>	C165235	Hamiltonstovare	A versatile scent hound, bred to hunt hare and fox in Sweden. The coat is short-haired and is a stunning tricolor of brownish-red, black, and white. The average height range is 19-24 inches and the average weight range is 40-75 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C16534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16534>	C17155	Electron Spin Resonance Spectroscopy|ESR|ESR Spectroscopy|Electron Paramagnetic Resonance|Electron Spin Resonance|Spectroscopy, ESR|Spectroscopy, Electron Spin Resonance	A spectrometric method, based on measurement of electron spins and magnetic moments, for detecting and estimating free radicals in reactions and in biological systems.			Research Activity	
C165350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165350>	C165235	Hanoverian Scenthound	A calm and assured scent hound with strong loyalty to the hunter in charge. The body is lean and muscular, and the head is slightly wrinkled with a serious expression. The coat is short and primarily red, but can vary from a pale fawn color to a dark brindle. The average height range is 19-21 inches and the average weight range is 79-99 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165351>	C165235	Hokkaido	A medium-sized, strongly-built, intelligent dog rarely found outside Japan. They have a long, thick coat with a wide chest and small ears. The breed may be a variety of colors. The average height range is 18-20 inches and the average weight range is 44-66 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165352>	C165235	Hovawart	A large, heavy-boned and kind, even-tempered dog with a very good nose. This breed excels at tracking, guarding, and companionship. The coat is long and black and blond with gold markings. The average height range is 23-28 inches and the average weight range is 65-90 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165353>	C53698	Icelandic Sheepdog	Formerly used to herd and guard sheep, horses and cattle, today these small-to-mid-sized dogs make loyal, loving family pets. They have a dense coat, foxy face, pointed ears, and a bushy, curling tail. They may be any of several predominate colors, with white markings. The average height range is 16.5-18 inches and the average weight range is 25-30 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165354>	C53701	Irish Red and White Setter	A medium-sized bird dog bred primarily for hunting. This breed is a bit shorter and stockier than the Irish Setter. The coat is a soft, long hair pearl white sea with vivid red "islands". The average height range is 22.5-26 inches and the average weight range is 35-60 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165355>	C165235	Jagdterrier	A courageous, intelligent, hardworking hunting terrier who is relatively small, compact, and well-proportioned. The dense coat is either hard and rough or coarse and smooth, and is usually black and tan. The average height range is 13-16 inches and the average weight range is 17-22 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165356>	C165235	Japanese Spitz	A little, white, fluffy companion breed, that loves to please its family. The average height range is 12-15 inches and the average weight range is 10-25 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165357>	C165235	Jindo	An independent hunter and loyal companion from Korea. It has a medium length white and buff coat. The average height range is 18-22 inches and the average weight range is 30-50 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165358>	C165235	Kai Ken	A medium-sized dog that is one of the six native Japanese breeds. This breed is highly intelligent and is used to hunt game. The coat is short haired and black, red or grey brindle. The average height range is 15.5 - 19.5 inches and the average weight range is 20-40 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165359>	C165235	Kishu Ken	A faithful, docile, and very alert dog that makes a great companion dog. This breed like to give chase to small animals. Coats are a medium length red, white, or sesame color. The average height range is 17-22 inches and the average weight range is 30-60 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C16535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16535>	C18982	Beta Radiation|Beta-Radiation|Radiation, Charged Particles-Electrons	Radiation of beta particles during radioactive decay.			Natural Phenomenon or Process	
C165360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165360>	C165235	Kromfohrlander	An intelligent, active, and sensitive medium-sized companion breed. There are two coat types, the wirehaired with beard and the smooth haired with long, soft hair. The average height range is 15-18 inches and the average weight range is 20-35 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165361>	C53701	Lagotto Romagnolo	The "truffle dog" of Italy, this medium-sized dog has a curly coat and lots of facial hair. The average height range is 16-19 inches and the average weight range is 24-35 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165362>	C53700	Lancashire Heeler	An intelligent, alert, and friendly dog with a medium to high energy level and small body. Their coat is long, and black and tan or liver and tan. The average height range is 10-12 inches and the average weight is 70 pounds.			Mammal	ICDC Breeds Terminology|ICDC MISC Breeds|ICDC Terminology
C165363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165363>	C165235	Lapponian Herder	An intelligent, energetic, and friendly medium-sized dog. This breed is a herder and needs a place to put its energy. The coat is medium length and either grey-brown, black and white, or tan markings. The average height range is 18-20 inches and the average weight range is 70 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165364>	C53700	Leonberger	A huge and powerful dog with a lush, medium coat of yellow to brown and red with a black mask, and a gentle nature and serene patience. The average height range is 25.5-31.5 inches and the average weight range is 90-170 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165365>	C53697	Manchester Terrier	A spirited, bright, keenly observant sleek racy dog with a terrier's ratting instinct and a tight coat of rich mahogany tan and jet black. There are two varieties, the standard and the toy, the latter not exceeding 12 pounds. The height is up to 16 inches and the weight is up to 22 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165366>	C53698	Miniature American Shepherd	A good natured, intelligent and devoted herding dog that resembles an Australian shepherd. The coat is black, blue merle, red, or red merle. The average height range is 13-18 inches and the average weight range is 20-40 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165367>	C165235	Mountain Cur	A sleek, intelligent, strong-willed hunter with a good treeing instinct that makes a great companion and watch dog. The coat is short and shiny,  and may be a variety of colors. The average height range is 16-26 inches and the average weight range is 30-60 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165368>	C53698	Mudi	A courageous and versatile all purpose Hungarian farm dog that is  useful for the most stubborn livestock, and is a great search and rescue dog in both Finland and the U.S. The coat is short or half-long and curly with a wide range of colors. The average height range is 15-18.5 inches and the average weight range is 18-29 pounds.			Mammal	ICDC Breeds Terminology|ICDC MISC Breeds|ICDC Terminology
C165369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165369>	C53701	Nederlandse Kooikerhondje	A lively, friendly, and alert sporting dog. They are known as the little white and orange dog with a big heart. They have a silky all-weather coat of white with red patches. They have large black-tipped ears and a richly feathered tail. The average height range is 14-17 inches and the average weight range is 20-30 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C16536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16536>	C19235|C18653	Electrophoresis|ELECTROPHORESIS|Fractionation, Electrophoretic|electrophoresis	The motion of charged particles in a colloid under the influence of an electric field; particles with a positive charge go to the cathode and negative to the anode.			Molecular Biology Research Technique	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165371>	C53702	Norwegian Buhund	A densely coated Nordic spitz-type dog, closely associated with the Vikings, that is adept at herding and guarding. The outer coat is thick and hard, with a soft and dense under coat. Coat colors range from wheaten to black with small patches of white on the neck, chest, face, feet, and tip of tail. The average height range is 16-18.5 inches and the average weight range is 26-40 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165372>	C53702	Norwegian Lundehund	A dog created for the sole purpose of puffin hunting, it is a now a friendly, athletic companion. This is a spitz type dog with triangular ears, curving tail, and a dense double coat. It has a distinct "rotary" gait, which is possible due to the flexible shoulders that allow the forelegs to extend to the side, perpendicular to the body. They have a variety of colors and markings. The average height range is 12-15 inches and the average weight range is 20-30 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165373>	C53700	Parson Russell Terrier	A friendly, clever, and athletic dog that is an independent problem solver, and a fast and fearless fox hunter. The coat is broken or smooth, and may be white with black, brown, tan or cream markings. The average height is 13-14 inches and the average weight range is 13-17 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165374>	C165235	Perro de Presa Canario	A moderately large-sized robust dog with a low, deep bark, and a balanced temperament. This breed is well-suited to guarding and cattle herding, and makes a devoted companion. Coats are short. The average height range is 22-26 inches and the average weight range is 84-110 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165375>	C53701	Peruvian Inca Orchid	An elegant sighthound developed in Peru that is agile, smart, and swift. The breed can be hairless or coated in black, brown, grey, pink, tan, or white. The average height range is 9.75-25.75 inches and the weight range is 8.5-55 pounds.			Mammal	ICDC Breeds Terminology|ICDC MISC Breeds|ICDC Terminology
C165376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165376>	C53702	Plott Hound	The state dog of North Carolina, this relentless hunting dog is a fearless, implacable hound, but a gentleman at home. They have a short, brindle coat and a long tail. The average height range is 20-25 inches and the average weight range is 40-60 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165377>	C165235	Porcelaine	An elegant, energetic and fierce hunter who is easy to train. The coat is short, smooth and shiny, and is usually white with orange spots. The average height is 23 inches and the average weight range is 52-62 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165378>	C53701	Portuguese Podengo	A lively, alert, intelligent, and independent hunting-type dog. They may view small dogs and cats as prey. They can have either a smooth or a wire coat, and colors range from white to red. The average height range is 22-28 inches and the average weight range is 44-66 pounds.			Mammal	ICDC Breeds Terminology|ICDC MISC Breeds|ICDC Terminology
C165379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165379>	C165235	Portuguese Pointer	An affectionate, smart and energetic hunting breed who is very dedicated to their owner.  They have a short, smooth yellow, or red yellow coat. The average height range is 20.5-22 inches and the average weight range is 35-59 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C16537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16537>	C18091	Agarose Gel Electrophoresis|Agarose Gel Fractionation|Fractionation, Agarose Gel	A type of electrophoresis that uses a matrix of highly purified agar to separate large molecules.			Molecular Biology Research Technique	
C165380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165380>	C165235	Portuguese Sheepdog	An exceptionally intelligent and lively dog that is devoted to the shepherd and herd and is an excellent companion, sporting dog, and guard dog. Its hair is long and shaggy and may be a variety of colors. The average height range is 16.5-21.5 inches and the average weight range is 37.5-59 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165381>	C53702	Portuguese Podengo Pequeno	An alert, playful, and quick rabbit hunter of ancient lineage. They make charming housemates and have a short, soft coat in shades of white to black. The average height range is 8-12 inches and the average weight range is 9-13 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165382>	C165235	Pudelpointer	A calm, self-controlled and versatile gun dog with a distinct hunting instinct. Their coat can be wire-haired, smooth/short, or rough, and coat colors range from light brown to black. The average height range is 22-26 inches and the average weight range is 45-70 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165383>	C53698	Pumi	A very cute, energetic, lively, ready to work herder of Hungarian origin. The coat is corkscrew-curled with colors that can be white, grey, black, or brown. The average height range is 15-18.5 inches and the average weight range is 22-29 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165384>	C165235	Pyrenean Mastiff	A gentle, brave, noble, and centuries old rare breed from the Pyrenees Mountains, this giant guardian protected flocks from wolves, bears, and thieves.  The coat is dense, thick, and of moderate length. The basic color is white with a well defined mask. The average height range is 25-31 inches and the average weight range is 120-240 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165385>	C53698	Pyrenean Shepherd	An affectionate, active, enthusiastic herder descended from ancient sheepdogs of the Pyrenees mountains. The coat can be rough-shaped or smooth-faced and may be many colors and patterns. The average height range is 15-18.5 inches and the average weight range is 15-30 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165386>	C165235	Rafeiro do Alentejo	A confident, calm, and powerful farm and estate watch dog. Their coat is medium length, thick, straight, and dense; colors can be black, grey, or fawn, with or without brindling. The average height range is 25-29 inches and the average weight range is 77-132 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165387>	C53700	Rat Terrier	A friendly, inquisitive, lovable, compact exterminator breed. The coat is smooth and short, and may be a variety of pied colors. The average height range is 10-18 inches and the average weight range is 10-25 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165388>	C53702	Redbone Coonhound	An even-tempered, amiable, kindly hound at home and a tiger on the trail. The coat is sleek, stunning, and red. The average height range is 21-27 inches and the average weight range is 45-70 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165389>	C165235	Romanian Mioritic Shepherd Dog	A loyal, confident, and independent guard dog from its homeland in Romania that is fiercely protective. The coat is long and shaggy, white and tray with white, black, grey and piebald markings.  The average height range is 22.5-29 inches and the average weight range is 100-130 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C16538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16538>	C18091	Two Dimensional Gel Electrophoresis|2 Dimensional Gel Electrophoresis|2-D Gel Electrophoresis	A laboratory procedure in which proteins are first separated across a gel, usually polyacrylamide, according to their isoelectric point, and then separated in a perpendicular direction on the basis of their molecular weight.			Molecular Biology Research Technique	
C165390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165390>	C53700	Russian Toy	A small, elegant, lively, dog with long legs, fine bones, and lean muscles. This breed loves to snuggle and thrives on human companionship. They can be smooth-coated and long-coated and may be black and tan, chocolate and tan, blue and tan, red, red sable, or red brown. The average height range is 8-11 inches and weight is up to 6.5 pounds.			Mammal	ICDC Breeds Terminology|ICDC MISC Breeds|ICDC Terminology
C165391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165391>	C165235	Russian Tsvetnaya Bolonka	A playful, charming, and inquisitive dog bred to be a house pet for apartment living. The coat is dense, thick, soft, and supple. There are many colors. The average height is 9-10 inches and the average weight range is 4.5-11 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165392>	C165235	Schapendoes	A friendly, watchful and lively shaggy sheepdog that makes a very good family pet. Their coat is long, lightly waved, and can be multiple colors. The average height range is 16-20 inches and the average weight range is 26-55 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165393>	C165235	Segugio Italiano	A friendly, intelligent, calm, and responsive hunter, this sleek dog is a tenacious hunter and excellent pet. The coat has short and smooth hair all over the body and may be solid faun or black and tan. The average height range is 19-23 inches and the average weight range is 40-60 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165394>	C165235	Shikoku	An energetic, alert, enthusiastic hunter with a thick, harsh outer coat and a soft, dense undercoat. Colors can be red, black, tan, or a mixtures of these colors.  The average height range is 17-22 inches and the average weight range is 35-55 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165395>	C53702	Sloughi	A reserved, graceful, noble, lean, and swift coursing hound with a sleek and short coat. The coat colors include shades of light sand to mahogany red-fawn, with or without brindling. The average height range is 24-29 inches and the average weight range is 35-50 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165396>	C165235	Slovensky Cuvac	A mountain dog with an impressive appearance, firm constitution, and thick white coat. This breed is vigilant, fearless, and alert. They can fend off wolves and bears. The average height range is 23-27.5 inches and the average weight range is 68-97 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165397>	C165235	Slovensky Kopov	A hardy, hardworking hunter who was developed to hunt boar, this persistent hunter will follow a scent for hours.  The coat is short, shiny, and soft, and colors are black with tan markings. The average height range is 16-20 inches and the average weight range is 33-44 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165398>	C165235	Small Munsterlander Pointer	A versatile hunter and natural retriever with a solid pointing instinct. The coat is dense, of medium length, possibly wavy, and may be brown-white or brown roan with brown patches. The average height is 20.5-21 inches and the average weight range is 40-60 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165399>	C165235	Solvakian Wirehaired Pointer|Slovakian Wirehaired Pointer	An understated pointer of moderate strength who is obedient. The coat is short, harsh, and grey. The average height range is 22.5-26.5 inches and the average weight range is 50-65 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C16539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16539>	C18091	Polyacrylamide Gel Electrophoresis|Electrophoresis, Polyacrylamide Gel|Fractionation, Polyacrylamide Gel|PAGE	Analytical and separative procedures in which molecules, particularly proteins or nucleic acids, are separated by their different electrophoretic mobilities in a hydrated gel. The gel suppresses convective mixing of the fluid phase through which the electrophoresis takes place and contributes molecular sieving. For proteins, commonly carried out in the presence of the anionic detergent sodium dodecylsulphate (SDS). SDS denatures proteins so that noncovalently associating sub unit polypeptides migrate independently and by binding to the proteins confers a net negative charge roughly proportional to the chain weight.	Polyacrylamide Gel Electrophoresis		Molecular Biology Research Technique	CTRP Intervention Terminology|CTRP Terminology
C1653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1653>	C1744	Biricodar Dicitrate|BIRICODAR DICITRATE|Incel|Incel VX-710|VX-710	The dicitrate salt of a synthetic pipecolinate derivative with potential chemosensitizing activity. Biricodar binds directly to the plasma membrane drug-efflux pumps P-glycoprotein (P-gp) and multidrug resistance protein 1 (MRP-1) and inhibits their activities, which may result in increased intracellular accumulation and retention of cytotoxic agents.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C165400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165400>	C165235	Spanish Mastiff	A powerful, intelligent and affectionate mastiff ready to protect his owner, home, or cattle. His coat is medium length and may be a range of colors including black, fawn, red, grey, or yellow, and can have brindle or white markings. The average height range is 28-35 inches and the average weight range is 140-200 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165401>	C53698	Spanish Water Dog	An inexhaustible and playful herder and waterfowl retriever whose hallmark is a coat of wooly curls. The average height range is 15.75-19.75 inches and the average weight range is 31-49 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165402>	C165235	Stabyhoun	An intelligent, responsive and loving retriever and pointer that likes to hunt ducks and birds. The coat is medium length and straight with a weather-resistant undercoat. The colors are pied in black or brown with white markings, and sometimes back or brown roans. The average height range is 19-21 inches and the average weight range is 40-60 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165403>	C165235	Swedish Lapphund	A playful, intelligent, and lively medium-sized spitz that is easy to train and full of endurance and toughness. This breed is a guard dog and herder. They have a profuse double coat that is weather resistant, with short hair on the head and front of the legs, and longer hair on the brisket, backside, and tail. The coat may be black with some bronzing and possible white patches. The average height range is 16-20 inches and the average weight range is 34-45 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165404>	C53702	Swedish Vallhund	A long, low, and rugged Viking dog of ancient legend, this cattle herder is known for its zest for life, cheerful demeanor, and unique vocalizations. There is a double coat of medium length and sable coloring. The average height range is 11.5-13.75 inches and the average weight range is 20-35 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165405>	C165235	Taiwan Dog	A descendant of the South Asian hunting dogs, this is a loyal, versatile, and intelligent companion dog that is extremely faithful to his master and protective of the family. The coat is short and hard, lying tight to the body, and may be black, brindle, fawn, white and black, white and fawn, or white and brindle. The average height range is 17-20 inches and the average weight range is 26-40 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165406>	C53700	Teddy Roosevelt Terrier	A small-medium sized friendly, affectionate, and stocky dog that is a bold, tenacious hunter of squirrels and vermin. They are delightful companions in the home.  Their coat is short, dense, and medium hard, and they are tri-color or bi-color, always with white included. The average height range is 8-15 inches and the average weight range is 8-25 pounds.			Mammal	ICDC Breeds Terminology|ICDC MISC Breeds|ICDC Terminology
C165407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165407>	C165235	Thai Ridgeback	A muscular, active, intelligent and loyal family dog. They were bred for hunting and guarding, and maintain many of those instincts, although they are mostly companion dogs. The ridge on the back is formed by the hair growing in the opposite direction from the rest of the coat. The coat is short and smooth. Colors include solid blue, black, red, or fawn. The average height range is 20-24 inches and the average weight range is 35-75 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165408>	C53699	Tibetan Mastiff	A watchful, intimidating guardian dog who is sweetly devoted to family and aloof and territorial with strangers. They have a double coat with fairly long thick, coarse guard hair and a heavy soft undercoat. The colors are black, brown, and blue/grey without markings. The height is a minimum 24 inches and the average weight range is 70-150 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165409>	C165235	Tornjak	A friendly, courageous and intelligent guard dog who is devoted to his master and affectionate towards the people living in the immediate vicinity.  This breed is most likely a descendant of the Tibetan mastiff. The coat is long with short hair over the face and legs. The topcoat is long, thick, coarse, and straight, while the winter undercoat is long, thick, and of a nice wooly texture. Usually, they are parti-colored with white being the dominant color. The average height range is 23-28 inches and the average weight range is 62-110 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C16540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16540>	C16910	Electrophysiology|Neurophysiology / Electrophysiology	That branch of physiology that is concerned with the electric phenomena associated with living bodies and involved in their functional activity.			Biomedical Occupation or Discipline	
C165410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165410>	C165235	Tosa	A Japanese dog originally bred for fighting, this patient giant is a vigilant watchdog. The coat is short and dense and can be fawn, red, apricot, black, or brindle with white markings. The average height range is 21.5-23.5 inches and the average weight range is 100-200 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165411>	C165235	Transylvanian Hound	A good natured, athletic, and determined ancient Hungarian hunter. This breed is a scent hound, but also retrieves well.  The body is covered by a short, straight, dense flat coat that is black with tan markings. The average height range is 22-26 inches and the minimum weight is 55 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165412>	C165235	Treeing Tennessee Brindle Coonhound	An exceptionally sturdy and healthy hunting dog that bays during the hunt. They have a short, brindle coat. The average height range is 16-24 inches and the average weight range is 30-50 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165413>	C53702	Treeing Walker Coonhound	A smart, sensible hunter bred to track and tree wild raccoons in their natural haunts. Their coat is smooth, short, and glossy, and they are tri-colored white, black, and tan. The average height range is 20-27 inches and the average weight range is 50-70 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165414>	C53701	Wirehaired Vizsla	A versatile gundog built for long days in the field. This breed forms a tight bond with its owner and does not like to be left alone. They have a sleek golden-rust coat. The average height range is 21-24 inches and the average weight range is 44-60 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165415>	C165235	Working Kelpie	A lithe, active, intelligent herding dog capable of tireless work, who contributed greatly to the success of the Australian economy of the wool industry.  They have a double coat with a short dense undercoat.  The color can be black, black and tan, red, red and ran, fawn, chocolate or smoke blue. The average height range is 17-20 inches.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165416>	C53700	Xoloitzcuintli	The ancient Aztec dog of the gods is a loving companion and vigilant watch dog. They can be one of three sizes, and can be either hairless or coated. Coats may be black, grey-black, red, liver, or bronze. The average height range is 10-23 inches.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165417>	C165235	Yakutian Laika	A devoted companion dog that is used for herding, pulling sleds, and hunting. They were bred by aboriginal peoples of the north-East of Russia. They are affectionate, intelligent, and active. Their coat is medium length, thick, shiny, straight, and coarse to the touch. There is a very well developed undercoat. Coats may be white and any mix (two or three colors). The average height range is 21-23 inches and the average weight range is 40-55 pounds.			Mammal	ICDC Breeds Terminology|ICDC FSS Breeds|ICDC Terminology
C165418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165418>	C53699	Chinook	A rugged, intelligent, patient dog and devoted family pet with a medium tawny coat and muscular body. They are calm, people-oriented dogs with a special feel for children. The average height range is 22-26 inches and the average weight range is 50-90 pounds.			Mammal	ICDC AKC Breeds|ICDC Breeds Terminology|ICDC Terminology
C165419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165419>	C53952	Norrbottenspets	A fearless, agile, and attentive spitz-type hunting dog from Sweden and Finland. They have a short white coat with tan-black markings. The average height range is 16.5-18 inches and the average weight range is 20-30 pounds.			Mammal	ICDC Breeds Terminology|ICDC MISC Breeds|ICDC Terminology
C16541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16541>	C19166	Embryo Transfer	Refers to a step in the process of in vitro fertilization (IVF) whereby one or several embryos are removed from an embryo culture and placed into the uterus of the female with the intent to establish a pregnancy.			Therapeutic or Preventive Procedure	
C165420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165420>	C203677	Vepdegestrant|2,6-Piperidinedione, 3-(1,3-dihydro-1-oxo-5-(4-((1-(4-((1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthalenyl)phenyl)-4-piperidinyl)methyl)-1-piperazinyl)-2H-isoindol-2-yl)-, (3S)-|ARV 471|ARV-471|ARV471|ER alpha PROTAC Protein Degrader ARV-471|ER alpha Proteolysis-targeting Chimera Protein Degrader ARV-471|Estrogen Receptor alpha PROTAC Protein Degrader ARV-471|PF 07850327|PF-07850327|PF07850327|PROTAC Protein Degrader ARV-471|VEPDEGESTRANT	An orally available hetero-bifunctional molecule and selective estrogen receptor (ER) alpha-targeted protein degrader, using the proteolysis targeting chimera (PROTAC) technology, with potential antineoplastic activity. Vepdegestrant is composed of an ER alpha ligand attached to an E3 ligase recognition moiety. Upon oral administration,vepdegestrant targets and binds to the ER ligand binding domain on ER alpha. E3 ligase is recruited to the ER by the E3 ligase recognition moiety and ER alpha is tagged by ubiquitin. This causes ubiquitination and degradation of ER alpha by the proteasome. This decreases ER alpha protein levels, decreases the expression of ER alpha-target genes and halts ER-mediated signaling. This results in an inhibition of proliferation in ER alpha-overexpressing tumor cells. In addition, the degradation of the ER alpha protein releases the ARV-471 and can bind to additional ER alpha target proteins. ER alpha is overexpressed in a variety of cancers and plays a key role in cancer cell proliferation.	Vepdegestrant		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165421>	C217121	Modified Radiation-induced Skin Reaction Assessment Scale|mRISRAS	An eight-item assessment tool that is used to evaluate the extent of radiation-induced skin reactions. It consists of a researcher component that utilizes a five-point scale to rate the visible extent of the skin reactions, and a patient component that utilizes a four-point scale to rate the level of pain, itchiness, burning, and effect on day-to-day life.			Intellectual Product	
C165422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165422>	C40998|C150706	MUC1 with Truncated O-Glycans-Positive Neoplastic Cells Present|MUC1 with Truncated O-Glycans Positive Neoplastic Cells Present|MUC1 with Truncated O-Glycans Positive Neoplastic Cells Present|STnMUC1 Positive Neoplastic Cells Present|Tn-MUC1 Positive|Tn-MUC1 Positive Neoplastic Cells Present|TnMUC1 Positive|TnMUC1 Positive Neoplastic Cells Present|Truncated O-Glycan MUC1 Positive Neoplastic Cells Present|Tumor Antigen TnMUC1 Positive Neoplastic Cells Present	An indication that a the surfaces of cells in sample have detectable amounts of a glycosylated mucin-1 protein (MUC1) that includes a cancer-specific truncated O-glycan modification.	MUC1 with Truncated O-Glycans Positive Neoplastic Cells Present		Finding	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C165423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165423>	C173812|C156140	Have Tenderness, Discomfort, or Pain of Skin in Treatment Area Question|Do you have any tenderness, discomfort or pain of your skin in the treatment area|Have Tenderness, Discomfort, or Pain of Skin in Treatment Area	A question about whether an individual has or had any tenderness, discomfort, or pain of the skin in the treatment area.			Intellectual Product	Modified Radiation-induced Skin Reaction Assessment Scale
C165424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165424>	C173812|C172828	Does Skin in Treatment Area Itch Question|Does Skin in Treatment Area Itch|Does your skin in the treatment area itch	A question about whether an individual's skin in the treatment area itches.			Intellectual Product	Modified Radiation-induced Skin Reaction Assessment Scale
C165425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165425>	C173812|C173219	Have Burning Sensation of Skin in Treatment Area Question|Do you have a burning sensation of your skin in the treatment area|Have Burning Sensation of Skin in Treatment Area	A question about whether an individual has or had a burning sensation of the skin in the treatment area.			Intellectual Product	Modified Radiation-induced Skin Reaction Assessment Scale
C165426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165426>	C173457|C173150	Extent to Which Skin Reaction and Symptoms Affect Day to Day Activities Question|Extent that Skin Reaction and Symptoms Affect Day to Day Activities|Extent to Which Skin Reaction and Symptoms Affect Day to Day Activities|To what extent has your skin reaction and your symptoms affected your day to day activities	A question about whether an individual has or had a burning sensation of the skin in the treatment area.			Intellectual Product	Modified Radiation-induced Skin Reaction Assessment Scale
C165427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165427>	C111657	Dry Desquamation|Dry desquamation	A skin reaction characterized by scaling and pruritus.			Finding	Modified Radiation-induced Skin Reaction Assessment Scale
C165428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165428>	C111657	Moist Desquamation|Moist desquamation	A skin reaction characterized by sloughing of the epidermis and serous exudate.			Finding	Modified Radiation-induced Skin Reaction Assessment Scale
C165429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165429>	C178373	Less than Twenty Five Percent|Less than 25%	A response that indicates less then twenty-five percent.			Intellectual Product	Modified Radiation-induced Skin Reaction Assessment Scale
C16542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16542>	C16501	Embryology	The branch of biology that studies the formation and early development of living organisms.			Biomedical Occupation or Discipline	
C165430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165430>	C178373	Between Twenty Five and Fifty Percent|25-50%	A response that indicates between twenty-five and fifty percent.			Intellectual Product	Modified Radiation-induced Skin Reaction Assessment Scale
C165431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165431>	C178373	Between Fifty and Seventy Five Percent|50-75%	A response that indicates between fifty and seventy-five percent.			Intellectual Product	Modified Radiation-induced Skin Reaction Assessment Scale
C165432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165432>	C178373	Greater than Seventy Five Percent|Greater than 75%	A response that indicates greater than seventy-five percent.			Intellectual Product	Modified Radiation-induced Skin Reaction Assessment Scale
C165433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165433>	C200766	Autologous Tn-MUC1-specific CAR T-lymphocytes|Anti-TnMUC1-CAR-expressing Autologous T-lymphocytes|Autologous Anti-TnMUC1-CAR-expressing T-lymphocytes|Autologous CART-TnMUC1 Cells|Autologous Tn-MUC1-specific CAR T Cells|Autologous TnMUC1-targeted Genetically-Modified CAR T Cells	A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) Tn glycoform of mucin-1 (Tn-MUC1; TnMUC1), with potential antineoplastic and immunostimulating activities. Upon re-introduction into the patient, the autologous Tn-MUC1-specific CAR T-lymphocytes specifically recognize and induce selective toxicity in TnMUC1-expressing tumor cells. TnMUC1 is overexpressed in certain tumor types.	Autologous Tn-MUC1-specific CAR T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165434>	C203001|C119988	Autologous gamma-globinG16D/sh RNA734 Gene-transduced CD34-positive Cells CSL200|CSL 200|CSL-200|CSL200|Human gamma-globinG16D/Short-hairpin RNA734-transduced CD34-positive Cells CSL200	A preparation of autologous, CD34-positive hematopoietic stem cells (HSCs) transduced ex vivo with a lentiviral vector encoding for an engineered form of human gamma-globin (hemoglobin-gamma) gene, gamma-globin G16D, and a short-hairpin (sh) RNA734, with potential to restore gamma-globin expression and function. Autologous CD34-positive stem cells are isolated from the patient's own bone marrow and the cells are transduced with the lentiviral vector. Upon re-infusion of the CD34-positive cells back into the patient, these cells express gamma-globinG16D, thereby replacing defective beta globin chains with gamma globin chains allowing the body to make fetal hemoglobin (HbF) and thus healthy red blood cells with a greater oxygen-carrying capacity. Gamma-globin comprises the gamma-chain of HbF; reactivation of HbF in disorders where beta-globin is defective in adult hemoglobin (HbA), such as sickle cell disease and beta thalassemia, may ameliorate these conditions. The G16D form of gamma-globin has increased anti-sickling activity compared to the wild type protein. The shRNA734 is used for positive gene selection.	Autologous gamma-globinG16D/sh RNA734 Gene-transduced CD34-positive Cells CSL200		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C165435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165435>	C201493|C200766	Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes MB-102|Anti CD123-CAR/CD28-CD3zeta-EGFRt-expressing Autologous T Lymphocytes MB-102|Autologous CD123CAR-CD28-CD3zeta/EGFRt+ T Cells MB-102|CD123-CD28-CD3zeta.EGFRt+ Autologous T Cells MB-102|CD123CAR-CD28-CD3zeta-EGFRt Lentiviral-transduced Autologous T Lymphocytes MB-102|MB 102|MB-102|MB102	A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating (SIN) lentiviral vector expressing a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD123 (interleukin-3 receptor alpha chain or IL3RA) and linked to the  CD28 co-stimulatory signaling domain fused to CD3 zeta, and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, the autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T lymphocytes MB-102 are directed to and induce selective toxicity in CD123-expressing tumor cells. CD123, a subunit of the heterodimeric interleukin-3-receptor (IL-3R), is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with increased leukemic cell proliferation and aggressiveness. Devoid of both ligand binding domains and tyrosine kinase activity, EGFRt both facilitates detection of the administered T-cells in vivo and can promote elimination of those cells following a cetuximab-induced antibody-dependent cellular cytotoxicity (ADCC) response.	Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes MB-102		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165436>	C471	Emzadirib|CYT 0851|CYT-0851|CYT0851|EMZADIRIB|RAD51 Inhibitor CYT-0851	An orally bioavailable inhibitor of the DNA damage repair protein RAD51, with potential antineoplastic and sensitizing activities. Upon oral administration, emzadirib targets, binds to and inhibits the activity of RAD51. This prevents RAD51-mediated DNA damage repair in susceptible tumor cells and induces tumor cell apoptosis. RAD51, the central protein involved in homologous repair (HR) of DNA double-strand breaks (DSBs), is overexpressed in many tumor cell types.	Emzadirib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165437>	C281	Rilematovir|JNJ 53718678|JNJ-53718678|JNJ-678|JNJ-8678|JNJ53718678|RILEMATOVIR|RSV F Protein Inhibitor JNJ-53718678|RSV Fusion Protein Inhibitor JNJ-53718678|Respiratory Syncytial Virus Fusion Protein Inhibitor JNJ-53718678	An orally available inhibitor of human respiratory syncytial virus (RSV) fusion protein (F protein), with potential antiviral activity. Upon oral administration, rilematovir specifically targets and binds to F protein on the viral surface, which inhibits RSV F protein-mediated fusion with the host cell membrane and prevents viral entry. This blocks RSV replication, reduces viral load, and decreases the severity of the disease. RSV F protein, a viral surface glycoprotein, plays a key role in RSV fusion with and entry into target cells.	Rilematovir		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C165438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165438>	C62103	Specimen Toothpick|Toothpick	A fine, hard object that may be tapered on one or both ends and is used to scrape off a specimen from a histological section of tissue.			Manufactured Object	
C165439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165439>	C70700	Tissue on Cap	The deposition of a tissue sample onto a plastic surface as a result of a tissue dissection procedure.			Laboratory Procedure	
C16543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16543>	C16749	Endocrinology|Endocrinology and Metabolism|Metabolism and Endocrinology	The science and medical specialty concerned with the metabolism, physiology, or hormonal secretions and their physiologic and pathologic relations.			Biomedical Occupation or Discipline	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C165440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165440>	C70700	Tissue in Tube	The deposition of a tissue sample into a micro-tube or the well of a micro-well plate as a result of a tissue dissection procedure.			Laboratory Procedure	
C165441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165441>	C70700	RNA in Tube	The deposition of an RNA sample into a collection tube as a result of an RNA extraction procedure.			Laboratory Procedure	
C165442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165442>	C18881	Indexed Sequencing	A sequencing method that involves the addition of a unique identifier called an index sequence to samples during library preparation. This allows multiple libraries to be pooled and processed together.			Molecular Biology Research Technique	
C165443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165443>	C45374	Index Sequence	A unique nucleotide sequence that is added to a sample during library preparation to serve as a unique identifier for the sample.			Nucleotide Sequence	
C165444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165444>	C165442	Single-indexed Sequencing	An indexed sequencing method that includes one index read.			Molecular Biology Research Technique	
C165445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165445>	C165442	Dual-indexed Sequencing	An indexed sequencing method that includes two index reads.			Molecular Biology Research Technique	
C165446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165446>	C176863|C157602|C156486	Advanced Lung Neuroendocrine Neoplasm	A lung neuroendocrine neoplasm that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Lung Neuroendocrine Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165447>	C27031|C156492|C155852	Metastatic Pancreatic Neuroendocrine Neoplasm	A pancreatic neuroendocrine neoplasm that has spread from its original site of growth to another anatomic site.	Metastatic Pancreatic Neuroendocrine Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165448>	C165447|C158089	Advanced Pancreatic Neuroendocrine Neoplasm	A pancreatic neuroendocrine neoplasm that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Pancreatic Neuroendocrine Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165449>	C4033|C154545	Unresectable Clear Cell Renal Cell Carcinoma	A clear cell renal cell carcinoma that is not amenable to surgical resection.	Unresectable Clear Cell Renal Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16544>	C19950	Endocytotic Process|Endocytic Process|Endocytosis	Cellular uptake of extracellular materials within membrane-limited vacuoles or microvesicles. Endosomes play a central role in endocytosis.			Cell Function	
C165450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165450>	C9120|C162015	Refractory Pancreatic Ductal Adenocarcinoma	Pancreatic ductal adenocarcinoma that is resistant to treatment.	Refractory Pancreatic Ductal Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165451>	C54443	ICDC Terminology|Confederated ICDC Terminology|Integrated Canine Data Commons Terminology	Terminology developed by a collaboration between the Integrated Canine Data Commons (ICDC) and NCIt EVS to support research into the feasibility of pet dogs with spontaneous cancers as models of human disease to evaluate new drugs, immunotherapeutic agents and treatments for further development for human cancer patients.			Intellectual Product	
C165452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165452>	C171330|C156069	Advanced Pancreatic Carcinoma	Pancreatic carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Pancreatic Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165453>	C188218|C168973	Unresectable Neuroendocrine Tumor|Unresectable Well Differentiated Neuroendocrine Neoplasm|Unresectable Well Differentiated Neuroendocrine Neoplasm	A neuroendocrine tumor that is not amenable to surgical resection.	Unresectable Well Differentiated Neuroendocrine Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165454>	C7377|C5670|C179420|C168973	Unresectable Lung Neuroendocrine Neoplasm	A lung neuroendocrine neoplasm that is not amenable to surgical resection.	Unresectable Lung Neuroendocrine Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165455>	C27721|C168973|C162845	Unresectable Digestive System Neuroendocrine Neoplasm	A digestive system neuroendocrine neoplasm that is not amenable to surgical resection.	Unresectable Digestive System Neuroendocrine Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165456>	C9005|C27031|C165455	Unresectable Pancreatic Neuroendocrine Neoplasm	A pancreatic neuroendocrine neoplasm that is not amenable to surgical resection.	Unresectable Pancreatic Neuroendocrine Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165457>	C717	Oncolytic Newcastle Disease Virus MEDI5395|MEDI 5395|MEDI-5395|MEDI5395|Oncolytic NDV MEDI5395|Recombinant NDV Expressing GM-CSF|recNDV(GM-CSF)	An oncolytic viral agent containing the oncolytic, live-attenuated, replication-competent strain of the avian paramyxovirus Newcastle disease virus (NDV) that has been engineered to include a transgene encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential antineoplastic and immunostimulating activities. Upon administration, MEDI5395 specifically infects and replicates in cancer cells. This may result in a direct cytotoxic effect involving the lysis of tumor cells via apoptotic mechanisms and may eventually lead to an inhibition of cancer cell proliferation through the increased production and secretion of pro-inflammatory cytokines and chemokines which are able to recruit mediators of both the innate and adaptive immune responses. Additionally, the inclusion of the GM-CSF transgene in the viral construct leads to expression of GM-CSF, which may potentiate and strengthen the anti-tumor immune response.	Oncolytic Newcastle Disease Virus MEDI5395		Pharmacologic Substance|Virus	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165458>	C213709|C156064	Advanced Ovarian Carcinoma	An ovarian carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Ovarian Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165459>	C20181	Checkbox|Check Box|Tick Box|Tickbox	A space on a paper form or an on-screen graphical display that can be filled or selected to choose an option.			Conceptual Entity	
C165460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165460>	C198995	Courier|COURIER	A person or group that facilitates the exchange of items or information.			Human	CDISC SDTM Accountable Party Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C165461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165461>	C175562	Dusky Pink Erythema|Dusky Pink	A response that indicates that the degree of erythematous color change is dusky pink.			Intellectual Product	Modified Radiation-induced Skin Reaction Assessment Scale
C165462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165462>	C175562	Dull Red Erythema|Dull Red	A response that indicates that the degree of erythematous color change is dull red.			Intellectual Product	Modified Radiation-induced Skin Reaction Assessment Scale
C165463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165463>	C175562	Brilliant Red Erythema|Brilliant Red	A response that indicates that the degree of erythematous color change is brilliant red.			Intellectual Product	Modified Radiation-induced Skin Reaction Assessment Scale
C165464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165464>	C175562	Deep Red-purple Erythema|Deep Red-purple	A response that indicates that the degree of erythematous color change is deep red-purple.			Intellectual Product	Modified Radiation-induced Skin Reaction Assessment Scale
C165465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165465>	C4819|C3781	Skin Verrucous Carcinoma	A verrucous carcinoma that arises from the skin. It usually affects the palms, soles, and distal digits.			Neoplastic Process	
C165466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165466>	C4819	Skin Squamous Cell Carcinoma with Osteoclast-Like Giant Cells	A rare squamous cell carcinoma of the skin characterized by the presence of multinucleated non-neoplastic giant cells that resemble osteoclasts.			Neoplastic Process	
C165467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165467>	C4819|C4107	Skin Lymphoepithelial Carcinoma|Skin Lymphoepithelioma-Like Carcinoma	A rare, poorly differentiated squamous cell carcinoma of the skin. It is characterized by the presence of tumor cells islands surrounded and infiltrated by lymphocytes and plasma cells.			Neoplastic Process	
C165468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165468>	C4819|C34448	Skin Squamous Cell Carcinoma with Sarcomatoid Differentiation|Skin Carcinosarcoma|Skin Metaplastic Carcinoma|Skin Sarcomatoid Squamous Cell Carcinoma	A rare carcinoma of the skin characterized by the presence of squamous cell carcinomatous and sarcomatous components.			Neoplastic Process	
C165469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165469>	C83176|C5679	Colorectal Serrated Polyposis|Colorectal Serrated Polyposis Syndrome|Hyperplastic Polyposis Syndrome	The presence of multiple serrated polyps in the colon and rectum. This condition occurs only in the large intestine and does not affect the upper gastrointestinal tract or the small intestine. Affected individuals are at an increased risk of developing colorectal carcinoma.	Colorectal Serrated Polyposis		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C16546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16546>	C17369	Endoscopic Procedure|ENDOSCOPY|ES|Endoscopic|Endoscopic Examination|Endoscopy|Endoscopy|Endoscopy|Endoscopy|endoscopy	A diagnostic or therapeutic procedure in which an endoscope is inserted in a tubular organ to examine the structural architecture and/or remove abnormal tissues.	Endoscopic Procedure		Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C165470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165470>	C3266	Hereditary Colorectal Cancer Syndrome	A group of hereditary neoplastic syndromes that affect the colon and rectum. Included in this grouping are hereditary nonpolyposis colorectal cancer (HNPCCC) , familial adenomatous polyposis (FAP), and the hamartomatous polyposis syndromes.	Hereditary Colorectal Cancer Syndrome		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C165472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165472>	C171281|C162758|C150206	Locally Advanced Oral Cavity Squamous Cell Carcinoma	Oral cavity squamous cell carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Oral Cavity Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165473>	C165560|C162758|C150213	Locally Advanced Laryngeal Squamous Cell Carcinoma	Laryngeal squamous cell carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Laryngeal Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165474>	C8099|C154321	Locally Advanced Squamous Cell Carcinoma of Unknown Primary	A squamous cell carcinoma of unknown primary that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Squamous Cell Carcinoma of Unknown Primary		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165475>	C27531	Arsenical Keratosis|ASK	A hyperkeratotic skin lesion that occurs in patients who have been exposed to arsenic.			Neoplastic Process	
C165476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165476>	C36290	Arsenic Exposure|Arsenic	A finding indicating that an individual has been exposed to arsenic.			Finding	GDC Terminology|GDC Value Terminology
C165477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165477>	C27531	PUVA Keratosis	A hyperkeratotic skin lesion that occurs in patients with a history of prolonged exposure to psoralen and ultraviolet A (PUVA) therapy.			Neoplastic Process	
C165478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165478>	C61398	Psoralen and Ultraviolet A (PUVA) Therapy Exposure	A finding indicating that a patient has been exposed to psoralen and ultraviolet A (PUVA) therapy for a benign or malignant condition.			Finding	
C165479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165479>	C2152|C129825	Pictilisib|2-(1H-indazol-4-yl)-6-((4-(methanesulfonyl)piperazin-1-yl)methyl)-4-(morpholin-4-yl)thieno(3,2-d)pyrimidine|4-(2-(1H-indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno(3,2-d)pyrimidin-4-yl)morpholine|GDC 0941|GDC-0941|GDC0941|PICTILISIB	A small molecule inhibitor of class I phosphatidylinositol 3 kinase (PI3K), with potential antineoplastic activity. Upon administration, pictilisib selectively binds to PI3K in an ATP-competitive manner, inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K/Akt signaling pathway. This may result in inhibition of tumor cell growth, motility and survival in susceptible tumor cell populations. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis; dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCIt Antineoplastic Agent Terminology
C16547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16547>	C21198	Energy Metabolism Process|Energy Metabolism	Any subcellular or molecular event, process, or condition concerned with storing and generating metabolic energy.			Phenomenon or Process	
C165480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165480>	C28249	Geneticist	A scientist who studies or works in genetics.	Geneticist		Professional or Occupational Group	CTRP Intervention Terminology|CTRP Terminology
C165481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165481>	C155697	Genetic Counselor	A health professional who has a graduate degree or specialized training in the areas of genetics and genetic counseling.	Genetic Counselor		Occupation or Discipline	CTRP Intervention Terminology|CTRP Terminology
C165482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165482>	C75561	Genetic Counseling Student	A student who is enrolled in courses and studying to be a genetic counselor.	Genetic Counseling Student		Occupation or Discipline	CTRP Intervention Terminology|CTRP Terminology
C165483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165483>	C17007	Non-FDG-Positron Emission Tomography|Non-FDG-PET|Non-Fluoro-2-deoxy-D-glucose- Positron Emission Tomography	Positron emission tomography that uses a tracer other than fluoro-2-deoxy-D-glucose (FDG).	Non-FDG-Positron Emission Tomography		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C165484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165484>	C205628|C153217	Cardiac ATTR Amyloidosis|ATTR-CM	The accumulation of ATTR amyloid deposits in the heart.			Disease or Syndrome	
C165485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165485>	C7419	Lichen Planus-Like Keratosis|Lichenoid Keratosis	A benign intraepidermal squamoproliferative neoplasm characterized by irregular acanthosis, hyperkeratosis, parakeratosis, and prominent chronic inflammation.			Neoplastic Process	
C165486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165486>	C75563	Laid Off|Laid off	An indication that an individual is not working due to being laid off.			Qualitative Concept	
C165487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165487>	C19332	Looking for Work|Looking for work|Seeking Employment|Seeking a Job	An indication that an individual is seeking work.			Organism Attribute	
C165488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165488>	C25172	Raising Children Full-time or Keeping House|Raising children full-time or keeping house	An indication that an individual is employed in their home, either raising children full-time or keeping house.			Organism Attribute	
C165489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165489>	C205629|C165484	Hereditary Cardiac ATTR Amyloidosis|Familial Cardiac ATTR Amyloidosis|Familial Cardiac Transthyretin Amyloidosis|Hereditary Transthyretin Amyloid Cardiomyopathy|Hereditary Transthyretin Amyloid Cardiomyopathy|Hereditary Transthyretin Amyloid Cardiomyopathy|hATTR-CM	The accumulation of ATTR amyloid deposits in the heart due to mutations in the TTR gene.	Hereditary Transthyretin Amyloid Cardiomyopathy		Disease or Syndrome	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology
C16548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16548>	C17187	Engineering	The discipline concerned with the application of scientific knowledge to solve practical issues in commerce or industry.			Occupation or Discipline	
C165490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165490>	C128920	FLT3 NP_004110.2:p.I836X|CD135 Antigen I836X|CD135 Antigen Ile836Xxx|FLT3 I836 Mutation|FLT3 NP_004110.2:p.Ile836Xxx|FLT3 p.I836X|FLT3 p.Ile836Xxx|FLT3-TKD/I836 Mutation|Fetal Liver Kinase-2 I836X|Fetal Liver Kinase-2 Ile836Xxx|Flt-3 Receptor I836X|Flt-3 Receptor Ile836Xxx|Fms-Related Tyrosine Kinase 3 I836X|Fms-Related Tyrosine Kinase 3 Ile836Xxx|I836|I836X|NP_004110.2:p.I836X|NP_004110.2:p.Ile836Xxx|Receptor-Type Tyrosine-Protein Kinase FLT3 I836X|Receptor-Type Tyrosine-Protein Kinase FLT3 Ile836Xxx|Stem Cell Tyrosine Kinase 1 I836X|Stem Cell Tyrosine Kinase 1 Ile836Xxx	A change in the amino acid residue at position 836 in the receptor-type tyrosine-protein kinase FLT3 protein where isoleucine has been replaced by another amino acid.	FLT3 NP_004110.2:p.I836X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C165491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165491>	C71732|C203331	Unresectable Triple-Negative Breast Carcinoma	Triple-negative breast carcinoma that is not amenable to surgical resection.	Unresectable Triple-Negative Breast Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165492>	C200765|C176018	Allogeneic CRISPR-Cas9 Engineered Anti-CD19 CAR T Cells CTX110|Allogeneic Anti-CD19 CAR CRISPR-edited T Cells CTX110|Allogeneic Anti-CD19 CAR-T Cells CTX110|Allogeneic CRISPR-Cas9 Gene-edited CD19-directed CAR T-cells CTX110|Allogeneic CRISPR-Cas9-Engineered Anti-CD19 CAR T Cells CTX110|CTX 110|CTX-110|CTX101|CTX110	A preparation of human allogeneic T-lymphocytes transduced with a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19 and gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to eliminate endogenous TCR, with potential immunostimulating and antineoplastic activities. Upon introduction into the patient, the allogeneic CRISPR-Cas9 engineered anti-CD19 CAR T-cells CTX110 recognize and bind to CD19-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of CD19-positive tumor cells. Removal of endogenous TCR reduces the risk of graft-versus-host disease (GvHD). CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.	Allogeneic CRISPR-Cas9 Engineered Anti-CD19 CAR T Cells CTX110		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165493>	C165451	ICDC Breeds Terminology|Breed Group	A categorization of breeds by ICDC.			Intellectual Product	
C165494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165494>	C103175	PRECINCT				Intellectual Product	
C165496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165496>	C157711	GDC Regimen Terminology|REGIMEN				Intellectual Product	
C165497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165497>	C3510|C204790	Cutaneous Spitz Melanoma|Cutaneous Spitzoid Melanoma|MST|Malignant Spitz Tumor|Spitz Melanoma|Spitz Melanoma|Spitzoid Melanoma	A cutaneous melanoma that is associated with genomic alterations observed in Spitz nevus and Spitz melanocytoma. It shares histopathological and clinical features with Spitz melanocytoma.			Neoplastic Process	Cellosaurus Disease Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C165498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165498>	C9498|C7161	Pigmented Epithelioid Melanocytoma|PEM|Skin Epithelioid Blue Nevus|Skin Pigmented Epithelioid Melanocytoma	A rare cutaneous melanocytic neoplasm that presents as a slow growing pigmented nodule or papule. It is characterized by the proliferation of heavily pigmented epithelioid and dendritic cells, predominantly in the dermis. PRKAR1A gene inactivation is present in the majority of cases. It can spread to regional lymph nodes, but distant metastases are rare.			Neoplastic Process	Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C165499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165499>	C60807	Melanin-Pigmented Epithelioid Cells Present	A morphologic finding indicating the presence of melanin-pigmented epithelioid cells in a tumor sample.			Finding	
C16549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16549>	C17027	Engineering Psychology	Branch of applied psychology that emphasizes the study of machine design, the relationship between humans and machines, and the effects of machines on human behavior. Use a more specific term if possible. (PSY94)			Biomedical Occupation or Discipline	
C1654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1654>	C210732	Multivitamin|Geritol|Vitamin Supplements (NOS)	A dietary supplement containing all or most of the vitamins that may not be readily available in the diet. Vitamins may be classified according to their solubility either in lipids (vitamins A, D, E, K, F) or in water (vitamins C, B-complex). Present in minute amounts in various foods, vitamins are essential to maintaining normal metabolism and biochemical functions. (NCI04)	Multivitamin		Pharmacologic Substance|Vitamin	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C165500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165500>	C82341	Spinocerebellar Ataxia, Autosomal Recessive, with Axonal Neuropathy 2|AOA2|Ataxia with Oculomotor Apraxia Type 2|SCAN2	An autosomal recessive condition caused by mutation(s) in the SETX gene, encoding probable helicase senataxin. It is characterized by juvenile onset progressive cerebellar ataxia, axonal sensorimotor peripheral neuropathy, and increased concentrations of serum alpha-fetoprotein. Oculomotor apraxia is common, but is not always present.			Disease or Syndrome	Cellosaurus Disease Terminology
C165501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165501>	C206077	Aicardi-Goutieres Syndrome 1|AGS1|Cree Encephalitis|Encephalopathy, Familial Infantile, with Intracranial Calcification and Chronic Cerebrospinal Fluid Lymphocytosis|Pseudotoxoplasmosis Syndrome	A heritable condition, caused by mutation(s) in the TREX1 gene, encoding three-prime repair exonuclease 1. Clinical features and onset may vary significantly, but is characterized in its most severe form by cerebral atrophy, leukodystrophy, intracranial calcifications, chronic cerebrospinal fluid (CSF) lymphocytosis, and increased concentrations of CSF alpha-interferon.			Disease or Syndrome	Cellosaurus Disease Terminology
C165502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165502>	C104941	Pencil Beam Scanning|PBS|Pencil Beam Proton Scanning	A precise form of proton therapy that uses an electronically guided scanning system and magnets to deliver a proton beam that is millimeters wide. With this system, beam position and depth can be controlled, allowing for highly precise deposition of radiation to be delivered in all three dimensions of the tumor.	Pencil Beam Scanning		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C165503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165503>	C150473	CDH1 Pathogenic or Likely Pathogenic Gene Mutation|CD324 Pathogenic or Likely Pathogenic Variation|CDH1 PLPV|CDH1 Pathogenic or Likely Pathogenic Gene Variant|CDH1 Pathogenic or Likely Pathogenic Gene Variation|CDH1 Pathogenic or Likely Pathogenic Variant|CDHE Pathogenic or Likely Pathogenic Variation|Cadherin 1 PLPV|Cadherin 1 Pathogenic or Likely Pathogenic Variation|Cadherin-1 PLPV|Cadherin-1 Pathogenic or Likely Pathogenic Variation|E-Cadherin PLPV|E-Cadherin Pathogenic or Likely Pathogenic Variation|ECAD Pathogenic or Likely Pathogenic Variation|UVO Pathogenic or Likely Pathogenic Variation	A change in the nucleotide sequence of the CDH1 gene that is associated with a pathogenic or likely pathogenic prognosis.	CDH1 Pathogenic or Likely Pathogenic Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C165504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165504>	C3113	Reserve Cell Hyperplasia	Hyperplasia of the immature cells located between the surface columnar epithelium and the basal layer.	Reserve Cell Hyperplasia		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C165505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165505>	C2843	Liposomal Topotecan FF-10850|FF 10850|FF-10850|FF10850	A liposome encapsulated formulation of the semisynthetic camptothecin analogue topotecan with potential antineoplastic activity. Upon administration, liposomal topotecan FF-10850 preferentially releases topotecan, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminate, into the tumor environment. Topotecan inhibits topoisomerase I activity by stabilizing the topoisomerase I-DNA covalent complexes during S phase of the cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. The novel liposome used in this agent prolongs its serum half-life while promoting efficient drug delivery into the cytosol from the endosome compartment of the tumor cell, which may minimize the adverse effect of bone marrow suppression.	Liposomal Topotecan FF-10850		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165506>	C17817	Reproductive Endocrinologist|RE	A fertility specialist, a sub-specialist of Obstetrics and Gynecology, addressing hormonal functioning as it pertains to reproduction and issues of infertility.	Reproductive Endocrinologist		Biomedical Occupation or Discipline	CTRP Intervention Terminology|CTRP Terminology
C165507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165507>	C200766|C176023	Zevorcabtagene Autoleucel|Anti-BCMA-CAR-41BB-CD3zeta-expressing T-cells CT053|Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing T-cells CT053|BCMA Car-T (CT053)|CAR-BCMA T-cells CT053|CT 053|CT-053|CT053|CT053 CAR-BCMA T|CT053 CAR-BCMA T Cells|ZEVORCABTAGENE AUTOLEUCEL	A preparation of autologous T-lymphocytes that have been transduced with a vector expressing a chimeric antigen receptor (CAR) containing a humanized single chain variable fragment (scFv) specific for the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) that is fused to the co-stimulatory domain of 4-1BB (CD137) and the T-cell receptor signaling domain of CD3zeta (CD3z), with potential immunostimulating and antineoplastic activities. Upon administration, zevorcabtagene autoleucel specifically recognize and induce selective toxicity against BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in the survival of B-lymphocytes and plasma cells. BCMA is found on the surfaces of B-cells and is overexpressed on malignant plasma cells.	Zevorcabtagene Autoleucel		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165508>	C1663	Neoantigen Peptide Vaccine	A peptide-based cancer vaccine consisting of patient-specific antigens, which are immunogenic and unique to the patient's tumor, with potential immunomodulating and antineoplastic activities. Upon vaccination with the neoantigen peptide vaccine, the peptides stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis.	Neoantigen Peptide Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165509>	C138961	PSA Decline Greater than or Equal to 50 Percent|Greater than or Equal to 50 Percent Reduction in Baseline PSA|Greater than or Equal to 50% Reduction in Baseline PSA|PSA Decline 50 Percent or Greater|PSA Decline 50 Percent or More|PSA Decline Fifty Percent or Greater|PSA Decline Fifty Percent or More|PSA Decline Greater than or Equal to Fifty Percent|PSA Decreased Greater than or Equal to 50 Percent|PSA Decreased Greater than or Equal to Fifty Percent	A finding indicating that the blood concentration of prostate specific antigen in a subject's sample has decreased by at least 50 percent from the concentration recorded for a previous sample from that subject.	PSA Decline Greater than or Equal to 50 Percent		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C16550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16550>	C18858	Entomology	Entomology; the branch of zoology that studies insects.			Occupation or Discipline	
C165510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165510>	C138961	PSA Level Less than or Equal to 0.2|PSA Less than or Equal to 0.2|PSA Less than or Equal to 0.2|PSA Level 0.2 or Less|PSA Level Less than or Equal to 0.2 ng/mL	A blood concentration of prostate specific antigen less than or equal to 0.2 ng/mL.	PSA Less than or Equal to 0.2		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C165511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165511>	C138961	PSA Decline Greater than or Equal to 25 Percent|PSA Decline 25 Percent or Greater|PSA Decline 25 Percent or More|PSA Decline Greater than or Equal to Twenty Five Percent|PSA Decline Greater than or Equal to Twenty-Five Percent|PSA Decline Twenty Five Percent or Greater|PSA Decline Twenty Five Percent or More|PSA Decline Twenty-Five Percent or Greater|PSA Decline Twenty-Five Percent or More|PSA Decreased Greater than or Equal to 25 Percent|PSA Decreased Greater than or Equal to Twenty Five Percent|PSA Decreased Greater than or Equal to Twenty-Five Percent	A finding indicating that the blood concentration of prostate specific antigen in a subject's sample has decreased by at least 25 percent from the concentration recorded for a previous sample from that subject.	PSA Decline Greater than or Equal to 25 Percent		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C165512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165512>	C38617	Sinonasal Tract and Oral Cavity	The anatomic space comprising the sinonasal tract and the oral cavity.	Sinonasal Tract and Oral Cavity		Body Part, Organ, or Organ Component	CTRP Disease Terminology|CTRP Terminology
C165513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165513>	C50772	Cisplatin-Induced Tinnitus	Tinnitus that is caused by exposure to cisplatin.	Cisplatin-Induced Tinnitus		Finding	CTRP Disease Terminology|CTRP Terminology
C165514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165514>	C1663	Neoantigen-based Therapeutic Cancer Vaccine GRT-C903|GRT C903|GRT-C903|GRTC903|Priming Cancer Vaccine GRT-C903|Priming Vaccine GRT-C903|Shared Neoantigen Cancer Vaccine Prime GRT-C903|Shared Neoantigen Priming Cancer Vaccine GRT-C903	A cancer priming vaccine consisting of tumor-specific shared neoantigens, which are immunogenic and unique across a subset of patients, with potential immunostimulating and antineoplastic activities. Upon administration of neoantigen-based therapeutic cancer vaccine GRT-C903, followed by the boosting vaccine GRT-R904, the peptides stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against the shared neoantigens expressed on tumor cells, which results in tumor cell lysis.	Neoantigen-based Therapeutic Cancer Vaccine GRT-C903		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165515>	C1663	Neoantigen-based Therapeutic Cancer Vaccine GRT-R904|Boosting Cancer Vaccine GRT-R904|Boosting Vaccine GRT-R904|GRT R904|GRT-R904|GRTR904|Shared Neoantigen Boosting Cancer Vaccine GRT-R904|Shared Neoantigen Cancer Vaccine Boost GRT-R904	A cancer boosting vaccine consisting of tumor-specific shared neoantigens, which are immunogenic and unique across a subset of patients, with potential immunostimulating and antineoplastic activities. Upon administration of the neoantigen-based therapeutic cancer vaccine GRT-R904, which is administered after the initial administration of the priming vaccine GRT-C903, the peptides stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against the shared neoantigens expressed on tumor cells, which results in tumor cell lysis.	Neoantigen-based Therapeutic Cancer Vaccine GRT-R904		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165516>	C165493	ICDC FSS Breeds|FSS	A breed designation assigned by ICDC based on the American Kennel Club Foundation Stock Service Program guidelines.			Intellectual Product	
C165517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165517>	C165493	ICDC AKC Breeds|AKC	A breed designation assigned by ICDC based on American Kennel Club guidelines.			Intellectual Product	
C165518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165518>	C165493	ICDC MISC Breeds|MISC	A breed designation assigned by the American Kennel Club while the breed is awaiting acceptance into the AKC Registry.			Intellectual Product	
C165519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165519>	C208186	Microbiome SER-401|Microbiome-based Therapeutic SER-401|SER 401|SER-401|SER401	A donor-derived microbiome therapeutic composed of a combination of as of yet not disclosed microbes that were specifically selected to incorporate the bacterial signature found in melanoma patients who have a robust response to immunotherapy, with potential immunomodulating activity. Upon administration, SER-401 may restore the unhealthy, altered gut microbiome, enhance the microbial diversity and function in the gastrointestinal (GI) tact and may re-establish a healthy microbiome in the GI tract. This may enhance the patients' immunological activity and improve patients' response to immunotherapy.	Microbiome SER-401		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C16551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16551>	C20181	Environment|Environmental	The totality of surrounding conditions.			Functional Concept	
C165520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165520>	C165493	ICDC Mixed Breed|MIXED	A category of dog that is not a purebred, but a combination of more than one breed.			Intellectual Product	
C165521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165521>	C54241	Mixture of Melanocytic Neoplastic Components Present	A  finding indicating the presence of at least two morphologic components in a melanocytic tumor sample.			Finding	
C165523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165523>	C165525	Combined BAP1-Inactivated Melanocytoma|Combined BAP1-Inactivated Nevus|Skin Combined BAP1-Inactivated Melanocytoma	A BAP1-inactivated melanocytoma that is combined with a smaller area of melanocytic proliferation in the basal layer of the epidermis.			Neoplastic Process	
C165525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165525>	C9498|C7161	BAP1-Inactivated Melanocytoma|BAP1-Deficient Tumor|BAP1-Inactivated Cutaneous Melanocytic Neoplasm|BAP1-Inactivated Cutaneous Melanocytic Tumor|BAP1-Inactivated Cutaneous Melanocytoma|BAP1-Inactivated Melanocytic Neoplasm|BAP1-Inactivated Melanocytic Tumor|BAP1-Inactivated Nevus|BAP1-Inactivated Skin Melanocytic Neoplasm|BAP1-Inactivated Skin Melanocytic Tumor|BAP1-Inactivated Spitzoid Nevus|BAPoma|BIM|BIMT|MBAIT|Melanocytic BAP1-Mutated Atypical Intradermal Tumor|Skin BAP1-Inactivated Melanocytoma|Wiesner Nevus	A cutaneous melanocytoma caused by the inactivation of BAP1 tumor suppressor gene. It is characterized by the presence of a predominantly intradermal proliferation of large epithelioid melanocytes with a large amount of eosinophilic cytoplasm, and vesicular nuclei with prominent nucleoli. Progression to melanoma is infrequent.			Neoplastic Process	
C165526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165526>	C2124	Fluorine F 18 C-SNAT4|18F C SNAT4|18F-C-SNAT4|[18F]-C-SNAT4	A radiotracer composed of C-SNAT4 radiolabeled with the radioisotope  fluorine F 18, with potential tumor imaging activity upon positron emission topography (PET)/computed tomography (CT). Upon administration, the C-SNAT4 moiety of fluorine F 18 C-SNAT4 selectively targets and binds to a tumor-associated antigen (TAA) on the tumor cell. During PET/CT, TAA-expressing tumor cells can be visualized.	Fluorine F 18 C-SNAT4		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C165527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165527>	C84708	Familial Partial Lipodystrophy Type 2|FPLD2	An autosomal dominant sub-type of familial partial lipodystrophy caused by mutation(s) in the LMNA gene encoding prelamin-A/C.			Disease or Syndrome	Cellosaurus Disease Terminology
C165528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165528>	C16502	Keratography	Diagnostic imaging of the cornea.	Keratography		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C165529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165529>	C7570	Combined Nevus|Melanocytic Nevus with Phenotypic Heterogeneity	A melanocytic nevus that arises from the skin or conjunctiva and is characterized by the presence of two or more morphologically distinct melanocytic nevus components in a single lesion. One component is a conventional nevus component, and the other(s) are usually blue nevus, deep penetrating nevus, Spitz nevus, or balloon cell nevus components.			Neoplastic Process	
C16552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16552>	C19447	Environmental Exposure|Environmental Exposures	Exposure to potentially harmful chemical, physical, or biological agents via the environment.			Finding	
C165530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165530>	C35869	Coronary Slow Flow Phenomenon|CSFP	An angiographic finding characterized by delayed progression of contrast medium into distal epicardial vessels in the absence of significant coronary artery disease.			Finding	Cellosaurus Disease Terminology
C165531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165531>	C89338|C28193	Gabriele-de Vries Syndrome|GADEVS	An autosomal dominant condition caused by mutation(s) in the YY1 gene, encoding transcriptional repressor protein YY1. It is a neurodevelopmental disorder characterized by intellectual disability, developmental delay, and variable functional and morphological abnormalities.			Disease or Syndrome	Cellosaurus Disease Terminology
C165532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165532>	C99704|C35741	Spontaneous Coronary Artery Dissection|SCAD	The spontaneous occurrence of a dissection of the coronary artery. The clinical recognition of this phenomenon has increased as coronary angiography is becoming more commonly used in the treatment of acute coronary syndrome. The etiology of the condition has not been fully elucidated, but the mean age of presentation is 30-45 years, more than 70% are women, and 30% of cases occur in the peripartum period.			Disease or Syndrome	Cellosaurus Disease Terminology
C165533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165533>	C85865|C84392|C28193	Renpenning Syndrome|Intellectual Developmental Disorder, X-Linked, Renpenning Type|Mental Retardation, X-Linked, Renpenning Type	An X-linked recessive disorder caused by mutation(s) in the PQBP1 gene, encoding polyglutamine-binding protein 1. It is characterized by moderate to severe intellectual disability, developmental delay and characteristic dysmorphic features, which may include short stature, microcephaly, and a narrow face.			Mental or Behavioral Dysfunction	Cellosaurus Disease Terminology
C165535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165535>	C4022|C213771	Unresectable Acral Lentiginous Melanoma	An acral lentiginous melanoma that is not amenable to surgical resection.	Unresectable Acral Lentiginous Melanoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165536>	C214948|C114828	Unresectable Mucosal Melanoma	Mucosal melanoma that is not amenable to surgical resection.	Unresectable Mucosal Melanoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165537>	C65151|C3482	Metastatic Non-Small Cell Carcinoma	Non-small cell carcinoma that has spread from its original site of growth to another anatomic site.	Metastatic Non-Small Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165538>	C35682	Neoantigen-Positive	An indication that a unique neoantigen expression has been detected in the cancer samples of one or more patients.			Laboratory or Test Result	
C165539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165539>	C165538	Shared Neoantigen-Positive	An indication that a unique neoantigen expression has been detected in cancers diagnosed across a subset of patients.			Laboratory or Test Result	
C16553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16553>	C17455	ELISA|Enzyme-linked Immunosorbent Assay|Enzyme-linked Immunosorbent Assay|enzyme-linked immunosorbent assay	A highly sensitive technique for detecting and measuring antigens or antibodies in a solution; the solution is run over a surface to which immobilized antibodies specific to the substance have been attached, and if the substance is present, it will bind to the antibody layer, and its presence is verified and visualized with an application of antibodies that have been tagged in some way. (BioTech Life Science Dictionary)	ELISA		Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|SeroNet Authorized Values|SeroNet Study Descriptors
C165540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165540>	C165538	Patient-Specific Neoantigen-Positive	An indication that neoantigen expression has been detected in the cancer sample of a specific patient.			Laboratory or Test Result	
C165542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165542>	C132146	Neoantigen-Positive Malignant Solid Neoplasm|Neoantigen-Positive Malignant Solid Tumor	A malignant solid neoplasm characterized by the expression of antigens resulting from cancer-specific mutations (neoantigens).			Neoplastic Process	
C165543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165543>	C81313	Neuropsychological Assessment|Neuropsychological Examination	A performance-based method to assess cognitive functioning. This method is used to examine the cognitive consequences of brain damage, brain disease, and severe mental illness.	Neuropsychological Assessment		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C165544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165544>	C26170	Moisturizing Cream WO2085|WO 2085|WO-2085|WO2085	A vaginal moisturizing cream that may be used to relieve vulvovaginal dryness. Upon intravaginal administration of the moisturizing cream WO2085, the as of yet not specified ingredients in the cream may help moisturize vaginal tissue and relieve the discomfort that is associated with vaginal dryness.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C165545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165545>	C165542	Patient-Specific Neoantigen-Positive Malignant Solid Neoplasm|Patient-Specific Neoantigen-Positive Malignant Solid Tumor	A malignant solid neoplasm that expresses unique tumor-specific neoantigens in a single patient.			Neoplastic Process	
C165546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165546>	C165542	Shared Neoantigen-Positive Malignant Solid Neoplasm|Shared Neoantigen-Positive Malignant Solid Tumor	A malignant solid neoplasm that expresses unique tumor-specific neoantigens across a subset of patients.	Shared Neoantigen-Positive Malignant Solid Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165547>	C213309	Anti-HIV-1 Lentiviral Vector-expressing sh5/C46 Cal-1|Anti-HIV-1 LV-expressing sh5/C46 Cal-1|Anti-HIV-1 LVsh5/C46|Anti-HIV-1 Lentiviral Vector sh5/C46|Cal-1|Cal-1 Vector|LVsh5/C46|LVsh5/C46 Vector	A gene transfer construct composed of a self-inactivating (SIN) lentiviral vector (LV) expressing a short hairpin RNA (shRNA) that targets the human C-C chemokine receptor type 5 (CCR5) mRNA (sh5) and expressing the HIV entry inhibitor C46, with potential anti-human immunodeficiency virus (HIV) type 1 (HIV-1) activity. Upon transduction of the anti-HIV-1 LVsh5/C46 Cal-1 in specified blood cell populations, such as peripheral blood mononuclear cells (PBMCs), hematopoietic stem/progenitor cells (HSPCs) and CD4+ T-lymphocytes, the cells express shCCR5 and C46. shCCR5 targets and binds to CCR5 mRNA, which inhibits the expression of CCR5 and prevents binding of the virus to the cellular CCR5 co-receptor. The cell surface expression of the cell membrane-anchored C46  peptide blocks HIV-1 fusion to the cellular membrane. The removal of CCR5 from and the production of C46 in the bone marrow and white blood cells, make the transduced cells resistant to and protect them from HIV-1 entry, infection and replication. HIV-resistant HSPCs could provide long-term protection against latent HIV infection and against HIV-associated cancers. C46 is a membrane-anchored 46-amino acid sequence found in HIV-1 gp41. CCR5 is a HIV-1 co-receptor that mediates HIV attachment and cell entry.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165548>	C129820	Alpha-Gal AGI-134|AGI 134|AGI-134|AGI-134|AGI134|Anti-alpha Gal Immunotherapeutic AGI-134|aGal AGI-134	A synthetic alpha Gal (aGal) molecule, with potential immunomodulating and antineoplastic activities. Upon intratumoral injection of aGal AGI-134, aGal coats the cancer cell membranes and triggers an anti-aGal antibody-mediated immune response leading to an initial complement-dependent and antibody-dependent cellular cytotoxicity (ADCC). This cytotoxicity causes release from tumor cells and subsequent uptake of released tumor-associated antigens (TAAs) by antigen-presenting cells (APCs). This may activate a systemic immune response against the TAAs and may eradicate cancer cells. aGal is a cell-surface carbohydrate antigen not expressed by humans while being expressed by all other mammals and bacteria. Anti-aGal antibodies are continuously and abundantly produced by humans due to exposure to aGal present on intestinal bacteria in the digestive system.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165549>	C213472|C159198|C155764|C155700	Olverembatinib|BCR-ABL/KIT/AKT/ERK Inhibitor HQP1351|GZD-824|HQP 1351|HQP-1351|HQP1351|Multi-kinase Inhibitor HQP1351|OLVEREMBATINIB	An orally bioavailable inhibitor of a variety of kinases, including the Bcr-Abl tyrosine kinase, the mast/stem cell growth factor receptor Kit (c-Kit), the serine/threonine protein kinase Akt (protein kinase B), and the extracellular signal-regulated kinase (ERK) with antineoplastic activity. Upon administration,olverembatinib targets, binds to and inhibits the kinase activities of Bcr-Abl, AKT, c-Kit and ERK. This inhibits their mediated signaling pathways and inhibits proliferation of tumor cells in which these kinases are overexpressed and/or mutated. Bcr-Abl, c-Kit, AKT and ERK play key roles in the proliferation, differentiation and survival of tumor cells.	Olverembatinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C16554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16554>	C20027	Enzyme|Enzymes|enzyme	Molecules that catalyze a chemical reaction. They are usually proteins, although catalytic RNA and DNA molecules have been identified.			Enzyme	
C165550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165550>	C2116	SERD SHR9549|SHR 9549|SHR-9549|SHR9549|Selective Estrogen Receptor Degrader SHR9549|Selective Estrogen Receptor Downregulator SHR9549	An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, SERD SHR9549 specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165551>	C176018	Anti-CD19 CAR T-cells XLCART001|CD19-specific CAR T-cells XLCART001|XLCART001	A preparation of T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed co-stimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19 CAR T-cells XLCART001 targets and binds to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165552>	C93221	Carnosine/Hibiscus-based Oral Mucoadhesive Tablet|Aqualief|Oral Mucoadhesive Tablet	A plant-based formulation and food supplement composed of carnosine and hibiscus, with potential anti-xerostomia activity. These two ingredients are mixed in specific proportions to allow for the formation of a pH buffering system in the oral cavity which maintains the pH of the oral cavity at the desired value needed for the regular secretion of saliva. Upon administration of the mucoadhesive tablet, the tablet adheres to the internal side of the cheek and both carnosine and hibiscus are gradually released over a period of at least two hours, thereby creating a buffering system that stimulates the salivary glands and increases saliva production. This produces a protective film of moisture that is deposited over the mucous membranes of the mouth and throat and may relieve radiotherapy-induced xerostomia.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C165553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165553>	C129824	LRP5/6 Antagonist BI 905677|Anti-LRP5/6 Nanobody BI 905677|BI 905677|BI-905677|BI905677	A humanized biparatopic nanobody composed of two blocking domains for the Wnt ligand co-receptors lipoprotein receptor-related proteins (LRP) 5 and 6, with potential antineoplastic and immunomodulating activities. Upon administration, BI 905677 targets and binds to LRP5 and LRP6, thereby blocking the binding of Wnt ligands to LRP5/6. This prevents the activation of the Frizzled (FZD)-Wnt-LRP5/6 trimeric complex and prevents the inactivation of the beta-catenin degradation complex, which leads to beta-catenin degradation. This inhibits the Wnt/beta-catenin signaling pathway, prevents the beta-catenin-mediated activation of Wnt target genes, and inhibits the proliferation and survival of Wnt-driven tumor cells. In addition, inhibition of Wnt signaling by BI 905677 prevents Wnt-mediated immune escape, thereby re-activating the immune system, specifically inducing the activation of dendritic cells (DCs) and activation as well as infiltration of cytotoxic T-cells into the tumor tissue. The FZD-Wnt-LRP5/6 trimeric complex induces phosphorylation of LRP5 or LRP6 intracellular domains leading to inactivation of the beta-catenin degradation complex, allowing beta-catenin accumulation; stabilized beta-catenin enters the nucleus and acts as a transcriptional activator of Wnt target genes. Wnt/beta-catenin signaling plays a key role in tumorigenesis and resistance to immunotherapy.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165554>	C2124	Gallium Ga 68-Vipivotide Tetraxetan|68Ga-PSMA-617|68Ga-Vipivotide Tetraxetan|Gallium Ga 68-PSMA-617|Gallium-68 PSMA-617|VIPIVOTIDE TETRAXETAN GALLIUM GA-68	A radioconjugate composed of vipivotide tetraxetan, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the radioisotope gallium Ga 68, with potential use as a tracer for PSMA-expressing tumors during positron emission tomography (PET)/computed tomography (CT). Upon intravenous administration of 68Ga-vipivotide tetraxetan, the vipivotide tetraxetan moiety targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells can be detected during PET/CT imaging. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165555>	C200258	Alvocidib Prodrug TP-1287|Alvocidib Phosphate|Alvocidib Phosphate TP-1287|TP 1287|TP-1287|TP-1287|TP1287	An orally bioavailable, highly soluble phosphate prodrug of alvocidib, a potent inhibitor of cyclin-dependent kinase-9 (CDK9), with potential antineoplastic activity. Upon administration of the phosphate prodrug TP-1287, the prodrug is enzymatically cleaved at the tumor site and the active moiety alvocidib is released. Alvocidib targets and binds to CDK9, thereby reducing the expression of CDK9 target genes such as the anti-apoptotic protein MCL-1, and inducing G1 cell cycle arrest and apoptosis in CDK9-overexpressing cancer cells.	Alvocidib Prodrug TP-1287		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165556>	C129825	Alkotinib|ZG 0418|ZG-0418|ZG0418	An orally available inhibitor of multiple kinases, including the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1), with potential antineoplastic activity. Upon oral administration, alkotinib binds to and inhibits the wild-type, point mutations and fusion proteins of ALK and ROS1. Inhibition of these kinases leads to the disruption of downstream signaling pathways and the inhibition of proliferation in tumor cells which these kinases are overexpressed, rearranged or mutated.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165557>	C1505	Epidiferphane|EDP	An orally bioavailable, proprietary botanical-based formulation and nutritional supplement consisting of three botanical extracts, including broccoli powder and curcumin, that may be used to reduce taxane-induced side effects and toxicities. Upon oral administration, epidiferphane may be able to decrease inflammation and pain by reducing cytokine levels. It may also reduce taxane-mediated toxicities such as anemia, neutropenia, peripheral neuropathy, and protect the endogenous neural stem cell population against destruction thereby preventing memory problems associated with the loss of neural stem cells.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C165558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165558>	C2124|C129819	Samarium Sm 153-DOTMP|153 Sm-DOTMP|153Sm-DOTMP|CycloSam|DOTMP SM-153|Sm-153-1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetra(methylene)phosphonic Acid|Sm-153-1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrayltetrakis(methylene)tetrakisphosphonic Acid|Sm-153-DOTMP	A radioconjugate composed of the phosphonic acid chelator DOTMP (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylenephosphonic acid) conjugated to the beta- and gamma-emitting radioisotope samarium Sm 153, with potential antineoplastic activity. Upon administration of samarium Sm 153-DOTMP, the DOTMP moiety targets and binds to growing bone, thereby selectively delivering samarium Sm 153-mediated cytotoxic radiation to bone tumor and metastases, which may help destroy bone metastases and mitigate pain from bone metastases.	Samarium Sm 153-DOTMP		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165559>	C1511	Gallium Ga 68 FAPi-46|(68GA)Ga-FAPI-46|68Ga-FAPi-46|FAPI-46 GA-68|Gallium-68-FAPI-46|Gallium-68-FAPi-46	A radioconjugate composed of FAPi-46, a quinoline-based fibroblast activation protein (FAP)-targeted tracer belonging to the group of FAP inhibitors (FAPi), conjugated to the radioisotope gallium Ga 68, with potential use as a tracer for FAP-expressing tumors during positron emission tomography (PET). Upon administration of gallium Ga 68 FAPi-46, the FAPi-46 moiety targets and binds to FAP-expressing tumor cells. Upon binding, FAP-expressing tumor cells can be detected during PET imaging. FAP, a cell surface protein, is overexpressed in a wide variety of cancer cell types.	Gallium Ga 68 FAPi-46		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C16555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16555>	C20368	Epidemiological Method|Epidemiological Technique|Epidemiology, Method	Epidemiological methods involve sophisticated statistics and higher mathematics.  These methods allow epidemiologists to address issues like non-experimental studies of mechanistic questions in disease etiology, including studies of the impact of the social position of individuals in different social contexts.			Research Activity	
C165560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165560>	C156085|C153213	Locally Advanced Laryngeal Carcinoma	Laryngeal carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Laryngeal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165561>	C156080|C153213	Locally Advanced Pharyngeal Carcinoma	Pharyngeal carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Pharyngeal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165562>	C156086|C153213	Locally Advanced Lip and Oral Cavity Carcinoma	Lip and oral cavity carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Lip and Oral Cavity Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165563>	C6014|C203515	Locally Advanced Paranasal Sinus Carcinoma	Paranasal sinus carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Paranasal Sinus Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165564>	C97928	ERCC2 Protein Variant|BTF2 p80 Protein Variant|Basic Transcription Factor 2 80 kDa Subunit Protein Variant|CXPD Protein Variant|DNA Excision Repair Protein ERCC-2 Protein Variant|DNA Repair Protein Complementing XP-D Cells Protein Variant|DNA-Repair Protein XPD Protein Variant|General Transcription and DNA Repair Factor IIH Helicase Subunit XPD Protein Variant|TFIIH 80 kDa Subunit Protein Variant|TFIIH Basal Transcription Factor Complex 80 kDa Subunit Protein Variant|TFIIH Basal Transcription Factor Complex Helicase XPD Subunit Protein Variant|TFIIH Subunit XPD Protein Variant|TFIIH p80 Protein Variant|Xeroderma Pigmentosum Group D-Complementing Protein Protein Variant	A variation in the amino acid sequence for the general transcription and DNA repair factor IIH helicase subunit XPD protein.			Cell or Molecular Dysfunction	
C165565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165565>	C165564	ERCC2 NP_000391.1:p.F332V|BTF2 p80 F332V|BTF2 p80 Phe332Val|Basic Transcription Factor 2 80 kDa Subunit F332V|Basic Transcription Factor 2 80 kDa Subunit Phe332Val|CXPD F332V|CXPD Phe332Val|DNA Excision Repair Protein ERCC-2 F332V|DNA Excision Repair Protein ERCC-2 Phe332Val|DNA Repair Protein Complementing XP-D Cells F332V|DNA Repair Protein Complementing XP-D Cells Phe332Val|DNA-Repair Protein XPD F332V|DNA-Repair Protein XPD Phe332Val|ERCC2 F332V|ERCC2 NP_000391.1:p.Phe322Val|ERCC2 Phe322Val|ERCC2 p.F322V|ERCC2 p.Phe322Val|General Transcription and DNA Repair Factor IIH Helicase Subunit XPD F332V|General Transcription and DNA Repair Factor IIH Helicase Subunit XPD Phe332Val|NP_000391.1:p.F332V|NP_000391.1:p.Phe322Val|TFIIH 80 kDa Subunit F332V|TFIIH 80 kDa Subunit Phe332Val|TFIIH Basal Transcription Factor Complex 80 kDa Subunit F332V|TFIIH Basal Transcription Factor Complex 80 kDa Subunit Phe332Val|TFIIH Basal Transcription Factor Complex Helicase XPD Subunit F332V|TFIIH Basal Transcription Factor Complex Helicase XPD Subunit Phe332Val|TFIIH p80 F332V|TFIIH p80 Phe332Val|TFIIH subunit XPD F332V|TFIIH subunit XPD Phe332Val|Xeroderma Pigmentosum Group D-Complementing Protein F332V|Xeroderma Pigmentosum Group D-Complementing Protein Phe332Val	A change in the amino acid residue at position 332 in the general transcription and DNA repair factor IIH helicase subunit XPD protein where phenylalanine has been replaced by valine.			Cell or Molecular Dysfunction	
C165566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165566>	C176586	STING Agonist SB 11285|SB 11285|SB-11285|SB11285	An agonist of stimulator of interferon genes (STING) protein, with potential immunoactivating and antineoplastic activities. Upon intravenous administration, STING agonist SB 11285 targets and binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor microenvironment (TME). This leads to the production of pro-inflammatory cytokines, including interferons (IFNs). Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens (TAAs) by CD8alpha-positive and CD103-positive dendritic cells (DCs) to cytotoxic T-lymphocytes (CTLs). This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis.	STING Agonist SB 11285		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165567>	C199379	Zipalertinib|CLN 081|CLN-081|CLN081|EGFR Mutant-specific Inhibitor CLN-081|Mutation-specific EGFR TKI TAS6417|Pan- EGFR Inhibitor CLN-081|Pan-mutation-selective EGFR Inhibitor CLN-081|Pan-mutation-selective EGFR Tyrosine Kinase Inhibitor CLN-081|TAS 6417|TAS-6417|TAS6417|ZIPALERTINIB	An orally available selective inhibitor of a broad spectrum of epidermal growth factor receptor (EGFR) mutations, including EGFR exon 20 insertion mutations (EGFR Ex20ins; Ex20ins mutations), with potential antineoplastic activity. CLN-081 is also active against other EGFR mutations including exon 19 deletions (exon19del), L858R, and T790M, as well as the less common G719X, L861Q and S768I mutations. Upon administration, zipalertinib specifically and covalently binds to and inhibits a variety of EGFR mutations, with particularly high selectivity against EGFR Ex20ins, which prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. Compared to some other EGFR inhibitors, CLN-081 may have therapeutic benefits in tumors with EGFR Ex20ins, as most EGFR mutant-selective inhibitors are not active against EGFR Ex20ins. This agent shows minimal activity against wild-type EGFR (wt EGFR), and does not cause dose-limiting toxicities that occur during the use of non-selective EGFR inhibitors, which also inhibit wt EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.	Zipalertinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165569>	C97928	PTEN Protein Variant|Mutated in Multiple Advanced Cancers 1 Protein Variant|PTEN Tyrosine Phosphatase Protein Variant|Phosphatase and Tensin Homolog Protein Variant|Phosphatase and Tensin-Like Protein Protein Variant|Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN Protein Variant	A variation in the amino acid sequence for phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN.			Cell or Molecular Dysfunction	
C16556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16556>	C19491|C16833	Epidemiology|Epidemiologic|Epidemiological|epidemiology	The study of the causes, incidence and distribution of disease in the population and its application for prevention or control.			Biomedical Occupation or Discipline	
C165570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165570>	C175695	PTEN NM_000314.7:c.388C>G|MMAC1 c.388C>G|Mutated in Multiple Advanced Cancers 1 c.388C>G|NM_000314.7:c.388C>G|PTEN c.388C>G|PTEN1 c.388C>G|Phosphatase and Tensin Homolog c.388C>G|TEP1 c.388C>G	A nucleotide substitution at position 388 of the coding sequence of the PTEN gene where cytosine has been mutated to guanine.			Cell or Molecular Dysfunction	
C165571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165571>	C165569	PTEN NP_000305.3:p.R130G|Mutated in Multiple Advanced Cancers 1 Arg130Gly|Mutated in Multiple Advanced Cancers 1 R130G|NP_000305.3:p.Arg130Gly|NP_000305.3:p.R130G|PTEN Arg130Gly|PTEN NP_000305.3:p.Arg130Gly|PTEN R130G|PTEN Tyrosine Phosphatase Arg130Gly|PTEN Tyrosine Phosphatase R130G|PTEN p.Arg130Gly|PTEN p.R130G|Phosphatase and Tensin Homolog Arg130Gly|Phosphatase and Tensin Homolog R130G|Phosphatase and Tensin-Like Protein Arg130Gly|Phosphatase and Tensin-Like Protein R130G|Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN Arg130Gly|Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN R130G	A change in the amino acid residue at position 130 in the phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN protein where arginine has been replaced by glycine.			Cell or Molecular Dysfunction	
C165572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165572>	C175695	PTEN NM_000314.7:c.389G>T|MMAC1 c.389G>T|Mutated in Multiple Advanced Cancers 1 c.389G>T|NM_000314.7:c.389G>T|PTEN c.389G>T|PTEN1 c.389G>T|Phosphatase and Tensin Homolog c.389G>T|TEP1 c.389G>T	A nucleotide substitution at position 389 of the coding sequence of the PTEN gene where guanine has been mutated to thymine.			Cell or Molecular Dysfunction	
C165573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165573>	C165569	PTEN NP_000305.3:p.R130L|Mutated in Multiple Advanced Cancers 1 Arg130Leu|Mutated in Multiple Advanced Cancers 1 R130L|NP_000305.3:p.Arg130Leu|NP_000305.3:p.R130L|PTEN Arg130Leu|PTEN NP_000305.3:p.Arg130Leu|PTEN R130L|PTEN Tyrosine Phosphatase Arg130Leu|PTEN Tyrosine Phosphatase R130L|PTEN p.Arg130Leu|PTEN p.R130L|Phosphatase and Tensin Homolog Arg130Leu|Phosphatase and Tensin Homolog R130L|Phosphatase and Tensin-Like Protein Arg130Leu|Phosphatase and Tensin-Like Protein R130L|Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN Arg130Leu|Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN R130L	A change in the amino acid residue at position 130 in the phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN protein where arginine has been replaced by leucine.			Cell or Molecular Dysfunction	
C165574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165574>	C175695	PTEN NM_000314.7:c.389G>C|MMAC1 c.389G>C|Mutated in Multiple Advanced Cancers 1 c.389G>C|NM_000314.7:c.389G>C|PTEN c.389G>C|PTEN1 c.389G>C|Phosphatase and Tensin Homolog c.389G>C|TEP1 c.389G>C	A nucleotide substitution at position 389 of the coding sequence of the PTEN gene where guanine has been mutated to cytosine.			Cell or Molecular Dysfunction	
C165575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165575>	C165569	PTEN NP_000305.3:p.R130P|Mutated in Multiple Advanced Cancers 1 Arg130Pro|Mutated in Multiple Advanced Cancers 1 R130P|NP_000305.3:p.Arg130Pro|NP_000305.3:p.R130P|PTEN Arg130Pro|PTEN NP_000305.3:p.Arg130Pro|PTEN R130P|PTEN Tyrosine Phosphatase Arg130Pro|PTEN Tyrosine Phosphatase R130P|PTEN p.Arg130Pro|PTEN p.R130P|Phosphatase and Tensin Homolog Arg130Pro|Phosphatase and Tensin Homolog R130P|Phosphatase and Tensin-Like Protein Arg130Pro|Phosphatase and Tensin-Like Protein R130P|Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN Arg130Pro|Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN R130P	A change in the amino acid residue at position 130 in the phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN protein where arginine has been replaced by proline.			Cell or Molecular Dysfunction	
C165576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165576>	C175695	PTEN NM_000314.7:c.389G>A|MMAC1 c.389G>A|Mutated in Multiple Advanced Cancers 1 c.389G>A|NM_000314.7:c.389G>A|PTEN c.389G>A|PTEN1 c.389G>A|Phosphatase and Tensin Homolog c.389G>A|TEP1 c.389G>A	A nucleotide substitution at position 389 of the coding sequence of the PTEN gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C165577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165577>	C165569	PTEN NP_000305.3:p.R130Q|Mutated in Multiple Advanced Cancers 1 Arg130Gln|Mutated in Multiple Advanced Cancers 1 R130Q|NP_000305.3:p.Arg130Gln|NP_000305.3:p.R130Q|PTEN Arg130Gln|PTEN NP_000305.3:p.Arg130Gln|PTEN R130Q|PTEN Tyrosine Phosphatase Arg130Gln|PTEN Tyrosine Phosphatase R130Q|PTEN p.Arg130Gln|PTEN p.R130Q|Phosphatase and Tensin Homolog Arg130Gln|Phosphatase and Tensin Homolog R130Q|Phosphatase and Tensin-Like Protein Arg130Gln|Phosphatase and Tensin-Like Protein R130Q|Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN Arg130Gln|Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN R130Q	A change in the amino acid residue at position 130 in the phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN protein where arginine has been replaced by glutamine.			Cell or Molecular Dysfunction	
C165578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165578>	C175689	TP53 NM_000546.5:c.523C>T|LFS1 c.523C>T|Li-Fraumeni Syndrome c.523C>T|NM_000546.5:c.523C>T|P53 c.523C>T|TP53 c.523C>T|Tumor Protein p53 c.523C>T	A nucleotide substitution at position 523 of the coding sequence of the TP53 gene where cytosine has been mutated to thymine.			Cell or Molecular Dysfunction	
C165579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165579>	C146884	TP53 NP_000537.3:p.R175C|Antigen NY-CO-13 Arg175Cys|Antigen NY-CO-13 R175C|Cellular Tumor Antigen p53 Arg175Cys|Cellular Tumor Antigen p53 R175C|NP_000537.3:p.Arg175Cys|NP_000537.3:p.R175C|TP53 Arg175Cys|TP53 NP_000537.3:p.Arg175Cys|TP53 R175C|TP53 p.Arg175Cys|TP53 p.R175C|Transformation-Related Protein 53 Arg175Cys|Transformation-Related Protein 53 R175C|Tumor Protein p53 Arg175Cys|Tumor Protein p53 R175C|Tumor Suppressor p53 Arg175Cys|Tumor Suppressor p53 R175C	A change in the amino acid residue at position 175 in the cellular tumor antigen p53 protein where arginine has been replaced by cysteine.			Cell or Molecular Dysfunction	
C16557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16557>	C25464	Equatorial Guinea|226|EQUATORIAL GUINEA|EQUATORIAL GUINEA|GNQ|GNQ|GQ	A country in western Africa, bordering the Gulf of Guinea, between Cameroon and Gabon; composed of a mainland portion and five inhabited islands.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C165580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165580>	C175689	TP53 NM_000546.5:c.817C>A|LFS1 c.817C>A|Li-Fraumeni Syndrome c.817C>A|NM_000546.5:c.817C>A|P53 c.817C>A|TP53 c.817C>A|Tumor Protein p53 c.817C>A	A nucleotide substitution at position 817 of the coding sequence of the TP53 gene where cytosine has been mutated to adenine.			Cell or Molecular Dysfunction	
C165581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165581>	C146884	TP53 NP_000537.3:p.R273S|Antigen NY-CO-13 Arg273Ser|Antigen NY-CO-13 R273S|Cellular Tumor Antigen p53 Arg273Ser|Cellular Tumor Antigen p53 R273S|NP_000537.3:p.Arg273Ser|NP_000537.3:p.R273S|TP53 Arg273Ser|TP53 NP_000537.3:p.Arg273Ser|TP53 R273S|TP53 p.Arg273Ser|TP53 p.R273S|Transformation-Related Protein 53 Arg273Ser|Transformation-Related Protein 53 R273S|Tumor Protein p53 Arg273Ser|Tumor Protein p53 R273S|Tumor Suppressor p53 Arg273Ser|Tumor Suppressor p53 R273S	A change in the amino acid residue at position 273 in the cellular tumor antigen p53 protein where arginine has been replaced by serine.			Cell or Molecular Dysfunction	
C165582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165582>	C4980	Refractory Acute Graft Versus Host Disease	Acute graft versus host disease that is resistant to treatment.	Refractory Acute Graft Versus Host Disease		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C165583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165583>	C575|C2435	Anti-CD3/CD7-Ricin Toxin A Immunotoxin|Anti-CD3/CD7-RTA Immunotoxin|CD3/CD7-Ricin A IT|T-Guard	An immunotoxin (IT) combination composed of two antibody-drug conjugates (ADCs), one containing a monoclonal antibody against CD3 and one against the CD7 antigen on activated T-cells and natural killer (NK) cells, and both conjugated to ricin toxin A (RTA), the A-chain form of the potent plant toxin ricin, that can potentially be used to destroy activated T- and NK cells. Upon administration of the anti-CD3/CD7-RTA immunotoxin, the anti-CD3 antibody moiety targets and binds to activated T-cells; the anti-CD7 antibody moiety targets and binds to CD7 on activated T-cells and NK cells. Upon internalization and cleavage, the RTA moiety irreversibly inhibits protein synthesis and induces apoptosis in the activated T-cells. This may eliminate activated T-cells and may improve conditions such as graft-versus-host-disease (GvHD). In addition, the binding and blocking of the anti-CD3 antibody to the T-cell receptor/CD3 complex (TCR/CD3) results in activation-induced cell death (AICD) and immunosuppression.	Anti-CD3/CD7-Ricin Toxin A Immunotoxin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165584>	C33027	Extra-Abdominal Lymph Node|EXTRAABDOMINAL LYMPH NODE|Extraadominal Lymph Node	A lymph node outside the abdominal cavity.			Anatomical Structure	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165585>	C25319	Destination|Destination Site	A place to which one is traveling or to which something is sent.			Spatial Concept	
C165586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165586>	C49165	Morcellation|Morcellated	The process of cutting tissue into smaller pieces.			Laboratory Procedure	
C165587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165587>	C19157	Pooled Sample|Composite Sample|Pooled|Pooled Specimen	A sample containing a mixture of multiple individual specimens of interest that were collected in a study.			Physical Object	
C165588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165588>	C201282|C129822	Vepsitamab|AMG 199|AMG199|Anti-MUC17 x Anti-CD3 BiTE AMG 199|Anti-MUC17/CD3 BiTE Antibody AMG 199|Anti-MUC17/CD3 Bispecific Antibody AMG 199|BiTE Antibody AMG 199|Bispecific T-cell Engager Antibody AMG 199|MUC17/CD3-directed Bispecific T-cell Engager Antibody AMG 199|MUC17xCD3 Bispecific T-cell Engager AMG 199|VEPSITAMAB	A half-life extended (HLE), human bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human mucin 17 (MUC17), and one directed against human CD3, a T-cell surface antigen found on T-lymphocytes, with potential antineoplastic activity. Upon administration vepsitamab binds to both CD3 on T-cells and MUC17 expressed on tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against MUC17-expressing tumor cells. MUC17, a member of the mucin family of glycoproteins, is overexpressed in a variety of tumor cells of epithelial origin and plays a key role in tumor cell dissemination.	Vepsitamab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165589>	C21295	MUC17 Gene|MUC17|MUC17|Mucin 17, Cell Surface Associated Gene	This gene is involved in the lubrication and protection of epithelial surfaces.	MUC17 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C16558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16558>	C25464	Eritrea|232|ER|ERI|ERI|ERITREA|ERITREA	A country in eastern Africa, bordering the Red Sea, between Sudan and Ethiopia.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C165590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165590>	C165589	MUC17 wt Allele|MUC-17|MUC-3|MUC3|Mucin 17, Cell Surface Associated wt Allele	Human MUC17 wild-type allele is located in the vicinity of 7q22.1 and is approximately 39 kb in length. This allele, which encodes mucin-17 protein, plays a role in gut epithelium homeostasis.	MUC17 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C165591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165591>	C16883	Mucin-17|MUC-17|MUC-3|MUC17|Mucin 17|Small Intestinal Mucin MUC3|Small Intestinal Mucin-3	Mucin-17 (4493 aa, ~452 kDa) is encoded by the human MUC17 gene. This protein is involved in the homeostasis of mucosal surfaces.	Mucin-17		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C165592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165592>	C177692	MUC17 Positive|MUC-17 Positive|MUC-3 Positive|MUC3 Positive|Mucin 17 Positive|Mucin-17 Positive|Small Intestinal Mucin-3 Positive	An indication that MUC17 expression has been detected in a sample.	MUC17 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C165593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165593>	C209925	Chronic Disease	A disease condition that persists over a significant span of time.	Chronic Disease		Finding	CDRH Health Effects - Health Impact Terminology|CTRP Disease Terminology|CTRP Terminology
C165594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165594>	C111116	Q-space Trajectory Imaging|QTI	A diffusion MR framework for imaging and modeling of microstructure that uses time-varying gradients to probe a trajectory in q-space.	Q-space Trajectory Imaging		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C165595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165595>	C16535	Tritium Beta Radiation|Hydrogen-3 Beta Radiation	Beta radiation produced from the decay of tritium. The energy of the beta particle emitted as tritium decays to helium averages 5.7 keV.			Natural Phenomenon or Process	Cellosaurus Resistance and Transformant Physical Factor Terminology
C165596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165596>	C84673	Dilated Cardiomyopathy-1A|CMD1A	An autosomal dominant subtype of dilated cardiomyopathy caused by mutation(s) in the LMNA gene, encoding lamin-A and lamin C.			Disease or Syndrome	Cellosaurus Disease Terminology
C165597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165597>	C28193	Williams-Beuren Region Duplication Syndrome|Chromosome 7q11.23 Duplication Syndrome|Somerville-Van Der AA Syndrome|WBS Duplication Syndrome	A rare chromosomal anomaly cause by partial duplication of small segment of chromosome 7 (7q11.23). It is characterized by a highly variable phenotype, typically including mild-moderate intellectual developmental delay, and delayed development of speech and motor skills.			Disease or Syndrome	Cellosaurus Disease Terminology
C165599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165599>	C15189	Biopsy of Soft Tissue|Soft Tissue Biopsy|Soft Tissue Biopsy	Removal of material from a soft tissue for detailed examination.	Soft Tissue Biopsy		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C16559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16559>	C21143	Erythropoiesis	A hematopoietic process that refers to the production of erythrocytes.			Cell Function	
C1655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1655>	C471|C29703	HMG-CoA Reductase Inhibitor|HMG-CoA reductase inhibitor|Hydroxymethylglutaryl CoenzymeA Reductase Inhibitors|Statin|Statin|hydroxymethylglutaryl-coenzyme A reductase inhibitor|statin	Any substance that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis. Inhibition of HMG-CoA reductase acts to lower plasma cholesterol and lipoprotein levels.			Chemical Viewed Functionally	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|Appendix 8: Pharmacological Therapy Terminology|GDC Terminology|GDC Value Terminology|Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission) Terminology
C165600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165600>	C198412	Tumor Panel Sequencing|Tumor Gene Panel Sequencing|Tumor-Targeted Gene Sequencing	An application of next-generation targeted sequencing where tumor-specific genes are selected for sequencing. Using next-generation techniques, chosen sequences can be sequenced to high depths that facilitate the identification of variants that are present at low allele frequencies.	Tumor Panel Sequencing		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Intervention Terminology|CTRP Terminology
C165601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165601>	C1420	Fimaporfin|4,4'-(15,20-Diphenyl-7,8(or 12,13 or 17,18)-dihydro-21H,23H-porphine-5,10-diyl)bisbenzenesulfonic Acid, Mixture of Three Isomers A, B and C (25%,50%,25%)|FIMAPORFIN	A synthetic light-activated compound  composed of three benzenesulfonic acid isomers: fimaporfin A (TPCS2a; tetraphenyl chlorin disulfonate), fimaporfin B, and fimaporfin C, with potential photosensitizing activity upon photodynamic therapy (PDT). Upon intradermal administration, fimaporfin is incorporated into the tumor cells' endosome and lysosome membranes. Subsequently, cytotoxic agents are administered and accumulate in the endosomal and lysosomal compartments; upon local activation by light, fimaporfin produces reactive oxygen species (ROS), such as singlet oxygen, damaging endo/lysosomal membranes and accumulated cytotoxic agents are released into the tumor cell cytosol. This photochemical internalization (PCI) method can enhance the efficacy and selectivity of cytotoxic agents.	Fimaporfin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C165602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165602>	C158678	FBXW7 NM_033632.3:c.1394G>A|AGO c.1394G>A|Archipelago Homolog c.1394G>A|Archipelago Homolog, Drosophila c.1394G>A|CDC4 c.1394G>A|F-Box and WD Repeat Domain Containing 7 c.1394G>A|F-box and WD-40 Domain Protein 7 (Archipelago Homolog, Drosophila) c.1394G>A|FBW6 c.1394G>A|FBW7 c.1394G>A|FBX30 c.1394G>A|FBXW6 c.1394G>A|FBXW7 c.1394G>A|NM_033632.3:c.1394G>A|SEL-10 c.1394G>A|SEL10 c.1394G>A	A nucleotide substitution at position 1394 of the coding sequence of the FBXW7 gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C165603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165603>	C97928	FBXW7 Protein Variant|Archipelago Homolog Protein Variant|F-Box Protein FBW7 Protein Variant|F-Box Protein FBX30 Protein Variant|F-Box Protein SEL-10 Protein Variant|F-Box and WD-40 Domain Protein 7 Protein Variant|F-Box/WD Repeat-Containing Protein 7 Protein Variant|SEL-10 Protein Variant|hCdc4 Protein Variant	A variation in the amino acid sequence for F-box/WD repeat-containing protein 7.			Cell or Molecular Dysfunction	Pediatric Oncology Target Molecular Abnormalities Terminology
C165604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165604>	C165603	FBXW7 NP_361014.1:p.R465H|Archipelago Homolog Arg465His|Archipelago Homolog R465H|F-Box Protein FBW7 Arg465His|F-Box Protein FBW7 R465H|F-Box Protein FBX30 Arg465His|F-Box Protein FBX30 R465H|F-Box Protein SEL-10 Arg465His|F-Box Protein SEL-10 R465H|F-Box and WD-40 Domain Protein 7 Arg465His|F-Box and WD-40 Domain Protein 7 R465H|F-Box/WD Repeat-Containing Protein 7 Arg465His|F-Box/WD Repeat-Containing Protein 7 R465H|FBXW7 Arg465His|FBXW7 NP_361014.1:p.Arg465His|FBXW7 R465H|FBXW7 p.Arg465His|FBXW7 p.R465H|NP_361014.1:p.Arg465His|NP_361014.1:p.R465H|SEL-10 Arg465His|SEL-10 R465H|hCdc4 Arg465His|hCdc4 R465H	A change in the amino acid residue at position 465 in the F-box/WD repeat-containing protein 7 where arginine has been replaced by histidine.			Cell or Molecular Dysfunction	
C165605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165605>	C129820	CD11b Agonist GB1275|ADH 503|ADH-503|ADH-503|ADH503|GB 1275|GB-1275|GB1275|Integrin Alpha-M Agonist GB1275|Integrin CD11b Agonist GB1275	An orally bioavailable small molecule agonist of CD11b (integrin alpha-M; ITGAM; integrin alpha M chain), with potential immunomodulating activity. Upon administration, CD11b agonist GB1275 targets and binds to CD11b, thereby activating CD11b. This leads to CD11b-mediated signaling and promotes pro-inflammatory macrophage polarization while suppressing immunosuppressive macrophage polarization. This reduces influx of tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TME), promotes anti-tumor immune responses, induces cytotoxic T-lymphocytes (CTLs) and suppresses tumor growth. CD11b, a member of the integrin family of cell adhesion receptors highly expressed on immune system cells, is a negative regulator of immune suppression and activates anti-tumor innate immunity.	CD11b Agonist GB1275		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165606>	C67290|C191713|C159435	Avelumab/Axitinib Regimen|Avelumab-Axitinib|Avelumab-Axitinib Regimen|Avelumab/Axitinib|Axitinib and Avelumab|Axitinib-Avelumab|Axitinib/Avelumab|Axitinib/Avelumab Regimen|Bavencio/Inlyta|Inlyta/Bavencio	A regimen consisting of avelumab and axitinib that can be used for the treatment of renal cell carcinoma (RCC), thymic carcinoma, and salivary gland tumors.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology
C165607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165607>	C7153|C159563|C150541|C142983	Refractory Differentiated Thyroid Gland Carcinoma|Refractory Follicular/Papillary Thyroid Gland Carcinoma	A differentiated thyroid gland carcinoma that is resistant to treatment.	Refractory Differentiated Thyroid Gland Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165608>	C4035|C165607	Refractory Thyroid Gland Papillary Carcinoma	A thyroid gland papillary carcinoma that is resistant to treatment.	Refractory Thyroid Gland Papillary Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165609>	C8054|C165607	Refractory Thyroid Gland Follicular Carcinoma	A thyroid gland follicular carcinoma that is resistant to treatment.	Refractory Thyroid Gland Follicular Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16560>	C78162	Esophagoscopy|esophagoscopy	Endoscopic examination of the esophagus.			Diagnostic Procedure	
C165610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165610>	C4946|C165609	Refractory Thyroid Gland Oncocytic Carcinoma|Refractory Thyroid Gland Hurthle Cell Carcinoma|Refractory Thyroid Gland Hurthle Cell Carcinoma|Refractory Thyroid Gland Oncocytic (Hurthle Cell) Carcinoma	A thyroid gland oncocytic carcinoma that is resistant to treatment.	Refractory Thyroid Gland Hurthle Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165611>	C7908|C7153|C159565|C150540	Recurrent Differentiated Thyroid Gland Carcinoma|Recurrent Follicular/Papillary Thyroid Gland Carcinoma	The reemergence of differentiated thyroid gland carcinoma after a period of remission.			Neoplastic Process	
C165612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165612>	C223184	Glutaminase-1 Inhibitor IACS-6274|GLS1 Inhibitor IACS-6274|IACS 6274|IACS-6274|IACS6274|IPN 60090|IPN-60090|IPN-60090|IPN60090	An orally bioavailable inhibitor of the metabolic enzyme glutaminase-1 (GLS1), with potential antineoplastic and immunostimulating activities. Upon oral administration, IACS-6274 selectively targets, binds to and inhibits human GLS1, an enzyme that is essential for the conversion of the amino acid glutamine into glutamate. Blocking glutamine metabolism inhibits proliferation in rapidly growing tumor cells and leads to an induction of cell death. Unlike normal healthy cells, glutamine-dependent tumors heavily rely on the intracellular conversion of exogenous glutamine into glutamate and glutamate metabolites to provide energy and generate building blocks for the production of macromolecules, which are needed for cellular growth and survival.	Glutaminase-1 Inhibitor IACS-6274		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165613>	C173787	Main Daily Activities or Responsibilities Question|Main Daily Activities or Responsibilities|Main Daily Activities or Responsibilities Description	A question that requests a description of an individual's main daily activities or responsibilities.			Intellectual Product	
C165614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165614>	C80693|C28193	Bone Marrow Failure Syndrome	A familial or acquired bone marrow failure syndrome.	Bone Marrow Failure Syndrome		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C165615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165615>	C48570	Percent Tumor Cell Nuclei|Percent tumor nuclei|percent tumor nuclei|percent_tumor_nuclei	A quantitative measurement of the percent of tumor cell nuclei in a sample compared to the total number of nuclei in the sample.			Quantitative Concept	GDC Property Terminology|GDC Terminology
C165616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165616>	C48570	Percent Immune Cell Nuclei|Percent immune cell nuclei	A quantitative measurement of the percent of immune cell nuclei in a sample compared to the total number of nuclei in the sample.			Quantitative Concept	
C165617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165617>	C48570	Percent Stromal Cell Nuclei|Percent stromal cell nuclei	A quantitative measurement of the percent of stromal cell nuclei in a sample compared to the total number of nuclei in the sample.			Quantitative Concept	
C165618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165618>	C48570	Percent Necrotic Surface Area|Percent of the surface area of the tissue section that is necrotic	A quantitative measurement of the area of tissue surface undergoing necrosis compared to the total tissue area present the sample.			Quantitative Concept	
C165619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165619>	C38052	Oral Mucosal Deterging and Dental Prophylaxis	Professionally-administered oral care consisting of tooth brushing, periodontal debridement, tooth polishing, and flossing.	Oral Mucosal Deterging and Dental Prophylaxis		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C16561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16561>	C16701	Esterase|EC 3.1|Ester Hydrolase	Encoded by Esterase Genes, Esterases catalyze hydrolysis of ester bonds to produce alcohol and acid reaction products. (NCI)	Esterase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C165620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165620>	C15687	Localized Vibration Therapy|Hand-Held Vibration Therapy	The use of a hand-held vibrating device to apply vibration therapy to a specific location of the body.	Localized Vibration Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C165621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165621>	C1752|C1663	Therapeutic Cancer Vaccine ATP128|ATP 128|ATP-128|ATP128|Z12-MultiE/TLR Agonist Domain ATP128	A self-adjuvanted chimeric recombinant protein vaccine, based on the self-adjuvanting KISIMA immunization platform, composed of three components: the 42 residue fragment Z12, a cell penetrating peptide (CPP) derived from the ZEBRA protein transduction domain, a toll-like receptor (TLR) peptide agonist as an adjuvant and a chimeric cargo, a multiple antigenic domain (MAD; MultiE), that contains an as of yet not disclosed amount of major histocompatibility class (MHC)-restricted peptides derived from as of yet undisclosed tumor-associated antigens (TAAs) that are specific for colorectal cancer (CRC) patients, with potential immunomodulating and antineoplastic activities. Upon administration of ATP128, the Z12 moiety targets, binds to and penetrates antigen-presenting cells (APCs), specifically dendritic cells (DCs) and promotes the loading of the epitopes into the DCs and transports antigenic cargoes into both endosomal and cytosolic compartments. Upon processing and antigen presentation by MHC II and I, the immune system is stimulated and activates specific CD4+ and CD8+ T-cells, respectively, against the multi-epitopes specific for the CRC cells, thereby killing the CRC cells.	Therapeutic Cancer Vaccine ATP128		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165622>	C110937	Bone Void	A defect or discontinuity of bone resulting from a pathologic process, including trauma and degenerative or neoplastic processes.			Finding	
C165623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165623>	C35869	Bone Lucency	A radiologic finding of an area of bone resulting from decreased absorption of the radiation used in the imaging process.			Finding	
C165625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165625>	C138961	PSA Level Greater than or Equal to 0.5|PSA Level 0.5 or Greater|PSA Level Equal to or Greater than 0.5	A blood concentration of prostate specific antigen greater than or equal to 0.5 ng/mL.	PSA Level Greater than or Equal to 0.5		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C165626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165626>	C483	G Protein-coupled Estrogen Receptor Agonist LNS8801|GPER Agonist LNS8801|LNS 8801|LNS-8801|LNS-8801|LNS8801	An orally bioavailable selective agonist of the G protein-coupled estrogen receptor (G protein-coupled estrogen receptor 1; GPER; GPER1; GPR30), with potential immunomodulating and antineoplastic activities. Upon oral administration, LNS8801 targets, binds to and activates GPER. This activates GPER-mediated signaling and suppresses the expression of various tumor-associated genes, such as c-Myc and programmed cell death-ligand 1 (PD-L1). This leads to an inhibition of tumor cell proliferation. GPER activation may also induce immune memory. GPER is a membrane protein and a member of the G-protein coupled receptors (GPCRs) that are widely distributed in various tissues. GPER is a tumor suppressor in a wide range of cell cancer types.	G Protein-coupled Estrogen Receptor Agonist LNS8801		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165627>	C25763	Proximal Stomach	The proximal portion of the stomach.			Body Part, Organ, or Organ Component	
C165628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165628>	C4004	Proximal Gastric Adenocarcinoma	A gastric adenocarcinoma that arises from the proximal part of the stomach.	Proximal Gastric Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165629>	C201922	TraceIT Tissue Spacer Implantation	Placement of TraceIT proprietary absorbable radiopaque hydrogel spacer.	TraceIT Tissue Spacer Implantation		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C16562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16562>	C25464	Estonia|233|EE|EST|EST|ESTONIA|ESTONIA	A country in eastern Europe, bordering the Baltic Sea and Gulf of Finland, between Latvia and Finland.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C165630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165630>	C165628|C153319	Metastatic Proximal Gastric Adenocarcinoma	A proximal gastric adenocarcinoma that has spread from its original site of growth to another anatomic site.	Metastatic Proximal Gastric Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165631>	C9005|C216142	Localized Malignant Pancreatic Neoplasm	A malignant neoplasm that arises from the pancreas and has not spread to other anatomic sites.	Localized Malignant Pancreatic Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165633>	C15696	Celiac Plexus Radiosurgery	The use of high-dose, ablative radiation to target the celiac plexus nerve bundle to provide pain relief in the posterior abdomen.	Celiac Plexus Radiosurgery		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C165634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165634>	C61410	CDISC Define-XML Terminology|DEFINE-XML	The terminology subset that includes terms relevant to the Clinical Data Interchange Standards Consortium (CDISC) Define-XML standard.			Intellectual Product	Clinical Data Interchange Standards Consortium Terminology
C165635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165635>	C165634	CDISC Define-XML ADaM Basic Data Structure Subclass Terminology|ADaM Basic Data Structure Subclass|BDSSC|DEFINE-BDSSC	Terminology associated with the ADaM  basic data structure subclass codelist of the Clinical Data Interchange Standards Consortium (CDISC) Define-XML standard.			Intellectual Product	CDISC Define-XML Terminology|Clinical Data Interchange Standards Consortium Terminology
C165636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165636>	C103175	CDISC Define-XML ADaM Integrated Basic Data Structure Subclass Terminology|DEFINE-BDSISC	Terminology associated with the ADaM integrated basic data structure subclass codelist of the Clinical Data Interchange Standards Consortium (CDISC) Define-XML standard.			Intellectual Product	
C165637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165637>	C47824	Time-to-Event Dataset|TIME-TO-EVENT|TTE	A dataset containing data that is used for Time-to-Event analyses.			Idea or Concept	CDISC Define-XML ADaM Basic Data Structure Subclass Terminology|CDISC Define-XML Terminology|Clinical Data Interchange Standards Consortium Terminology
C165638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165638>	C1752|C1663	Pooled Mutant KRAS-Targeted Long Peptide Vaccine|KRAS G12D/G12R/G12V/G12A/G12C/G13D Peptide-Poly-ICLC Vaccine mKRASvax|KRAS Peptide Vaccine|Mutant KRAS Peptide-Hiltonol Vaccine mKRASvax|Mutated KRAS Peptide-Poly-ICLC Vaccine mKRASvax|Pooled Mutant KRAS Peptide Vaccine|SLP mKRASvax|Synthetic Long Peptide Mutant KRAS Vaccine|mKRASvax	A cancer vaccine containing a mixture of synthetic long peptides (SLPs) targeting six KRAS mutations, including KRAS G12D, G12R, G12V, G12A, G12C and G13D, and the adjuvant poly-ICLC, with potential immunostimulatory and antineoplastic activities. Upon administration, pooled mutant KRAS-targeted long peptide vaccine may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against KRAS G12D/G12R/G12V/G12A/G12C/G13D-expressing tumor cells. KRAS, a member of the RAS family of oncogenes, plays an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.	Pooled Mutant KRAS-Targeted Long Peptide Vaccine		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165639>	C2341	Irradiated Allogeneic Human Lung Cancer Cells Expressing OX40L-Ig Vaccine HS-130|HS 130|HS-130|HS130	An allogeneic irradiated human lung cancer cell vaccine expressing a fusion protein composed of the OX40 ligand (OX40L) linked to an immunoglobulin (Ig) (OX40L-Ig), with potential immunomodulating and antineoplastic activities. Upon intradermal administration of irradiated allogeneic human lung cancer cells expressing OX40L-Ig vaccine HS-130, the irradiated lung cancer cells continuously express OX40L-Ig. OX40L may then target, bind to and activate its cognate receptor, tumor necrosis factor receptor superfamily member 4 (TNFRSF4; OX40; CD134), which is expressed on activated T-cells. OX40L/OX40 binding promotes increased cytokine production, and induces the proliferation and activation of memory and effector T-lymphocytes against the human lung cancer cells. In turn, this promotes a CTL-mediated immune response against the endogenous lung cancer cells. OX40L, a cell surface glycoprotein and member of the tumor necrosis factor (TNF) ligand family, provides a co-stimulatory signal for the proliferation and survival of activated T-cells.			Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C16563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16563>	C25464	Ethiopia|231|ET|ETH|ETH|ETHIOPIA|ETHIOPIA	A country in eastern Africa, between Somalia and Sudan.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C165640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165640>	C103175	CDISC Protocol Study Oversight Entity Attribute Terminology|PROT-Attr Study Oversight Entity|Study Oversight Entity Attribute Terminology|Study Oversight Entity Attribute Terminology	Terminology associated with the protocol entity study oversight entity attribute codelist of the Clinical Data Interchange Standards Consortium (CDISC).			Intellectual Product	
C165641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165641>	C103175	CDISC Protocol Outcome Measure Attribute Terminology|Outcome Measure Attribute Terminology|Outcome Measure Attribute Terminology|PROT-Attr Outcome Measure	Terminology associated with the protocol entity protocol outcome measure attribute codelist of the Clinical Data Interchange Standards Consortium (CDISC).			Intellectual Product	
C165642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165642>	C103175	CDISC Protocol Oversight Entity Value Set Terminology|Oversight Entity Value Set|Oversight Entity Value Set|PROT-OVENTRS	Terminology associated with the oversight entity value set codelist of the Clinical Data Interchange Standards Consortium (CDISC) protocol entities.			Intellectual Product	
C165643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165643>	C66830	CDISC SDTM Severity Response Terminology|SDTM-SEVRS|SEVRS|Severity Response	Terminology associated with the severity response codelist of the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C165644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165644>	C81222	CDISC ADaM Pool for Integration Terminology|ADaM-POOLINT|POOLINT|Pool for Integration	Terminology associated with the Pool for Integration codelist of the Clinical Data Interchange Standards Consortium (CDISC) Analysis Data Model (ADaM).			Intellectual Product	CDISC ADaM Terminology|Clinical Data Interchange Standards Consortium Terminology
C165645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165645>	C28193|C26940	Retroperitoneal Pain Syndrome	A pain syndrome characterized by epigastric and mid-back pain, typically experienced as a dull or aching pain. Frequent causes include pancreatic cancer and retroperitoneal lymphadenopathy.	Retroperitoneal Pain Syndrome		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C165646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165646>	C1752|C1663	Microbiome-derived Peptide Vaccine EO2401|Cancer Vaccine EO2401|EO 2401|EO-2401|EO2401|Microbial-derived Peptide Vaccine EO2401|Microbiome-derived Therapeutic Cancer Vaccine EO2401	A donor-derived, off-the-shelf, microbiome therapeutic cancer peptide vaccine composed of three bacterial onco-mimics, immunogenic microbiome-derived peptides that are highly homologous to tumor-associated antigens (TAAs), that are obtained and selected from the human gut microbiome and are specific for brain tumors, including glioblastoma, with potential immunomodulating and antineoplastic activities. The three microbiome-derived bacterial antigens in EO2401 mimic three TAAs that are highly expressed by brain tumors. Upon administration of microbiome-derived peptide vaccine EO2401, the peptides are taken up by and presented on dendritic cells (DCs) to T-cells. As the presented antigens display molecular mimicry with selected TAAs on brain cancer cells, a memory T-cell and cytotoxic T-lymphocyte (CTL)-mediated immune response may be mounted against the TAAs expressed on the brain cancer cells, thereby eradicating the brain cancer cells.	Microbiome-derived Peptide Vaccine EO2401		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165647>	C1511	Indium In 111-DOTA-h11B6|111In-DOTA-h11B6|Indium-111 Radiolabeled h11B6	A radioimmunoconjugate containing the recombinant immunoglobulin G1 (IgG1) kappa humanized monoclonal antibody h11B6 that targets human kallikrein-2 (HK2) conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and labeled with the radioisotope indium In 111, with potential use as an imaging agent. Upon administration of indium In 111-DOTA-h11B6, the h11B6 moiety targets and binds to HK2. Upon binding and radioimaging, HK2-expressing tumor cells can be visualized and the binding of h11B6 can be assessed. HK2 is overexpressed on a variety of cancer cells.	Indium In 111-DOTA-h11B6		Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C165648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165648>	C29639	Aloe vera/Chamomile/Thyme Topical Cream|Alantel	A topical skin cream containing aloe vera, chamomile, and thyme, with potential anti-inflammatory, soothing and protective activities. Upon application of the aloe vera/chamomile/thyme topical cream to the affected area(s), the ingredients in the cream may exert anti-inflammatory effects thereby reducing skin inflammation. The cream also soothes, protects irritated skin, and provides moisture.			Pharmacologic Substance	NCI Drug Dictionary Terminology
C165649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165649>	C1505	Antisecretory Factor-enriched Egg Yolk Powder Supplement|AF-enriched Egg Yolk Powder Supplement|Salovum	A dietary supplement composed of dried egg yolk powder that is highly enriched in the protein anti-secretory factor (AF), with anti-inflammatory, anti-diarrheal, immunomodulating and chemo-adjuvant activities. Upon intratumoral administration of the AF-enriched egg yolk powder supplement, AF is able to normalize fluid flow by regulating the ion and fluid balance across the cell membranes, and decreases high interstitial fluid pressure (IFP). As elevated IFP presents a barrier to drug uptake and poor perfusion in solid tumors, reducing IFP levels allows for increased uptake and an enhanced effect of chemotherapeutic agents. In addition, AF may be able to modulate the immune system and may have immunomodulatory effects on myeloid cells. It may also modulate the secretion of immunomodulatory agents from tumor cells. In addition, AF may affect the secretion of various pro-inflammatory mediators such as interleukin-6 (IL-6), IL-8, monocyte chemotactic protein-1 (MCP-1; monocyte chemoattractant protein-1; C-C Motif Chemokine Ligand 2; CCL2), macrophage inflammatory protein-1alpha (MIP-1a), and macrophage inflammatory protein-1beta (MIP-1b). AF, a 41 kilodalton (kDa) endogenous and essential protein secreted in plasma and other tissue fluids in mammals, is increased after exposure to bacterial toxins and endogenous triggers of inflammation.			Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C16564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16564>	C161324	Ethnic Group|ETHNICITY|ETHNICITY|ETHNICITY|ETHNICITY|ETHNICITY|ETHNICITY|Ethnic Origin|Ethnic Origins|Ethnicity|Ethnicity|Ethnicity|Patient Reported Ethnicity|ethnicity|ethnicity|ethnicity	A social group characterized by a distinctive social and cultural tradition that is maintained from generation to generation. Members share a common history and origin and a sense of identification with the group. They have similar and distinctive features in their lifestyle habits and shared experiences. They often have a common genetic heritage which may be reflected in their experience of health and disease.			Population Group	ALL Demographics Table|ALL Variable Terminology|AML Demographics Table|AML Variable Terminology|CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|CTDC Property Terminology|EWS Demographics Table|EWS Variable Terminology|GCT Demographics Table|GCT Variable Terminology|GDC Property Terminology|GDC Terminology|HL Demographics Table|HL Variable Terminology|Newborn Screening Terminology|NICHD Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology|OS Demographics Table|OS Variable Terminology|SeroNet Research Participant Metadata|SeroNet Study Descriptors|SeroNet Variables
C165650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165650>	C67439|C2136	Gallium-based Bone Resorption Inhibitor AP-002|AP 002|AP-002|AP002|TRIS(8-HYDROXYQUINOLINATO)GALLIUM	An orally bioavailable gallium (Ga)-based small molecule agent with potential anti-bone resorption and antineoplastic activities. Upon oral administration, AP-002 selectively inhibits osteoclast differentiation and bone resorption, and may promote the growth of osteoblasts thereby improving the skeletal sequelae of bony metastases which include pain, spinal cord compression, fractures and hypercalcemia of malignancy. Additionally, AP-002 may, through an as of yet undescribed mechanism of action, directly target and kill bone tumor cells.	Gallium-based Bone Resorption Inhibitor AP-002		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165651>	C138901	Body Mass Index Less than or Equal to 30|BMI Less than or Equal to 30	A finding indicating a body mass index measurement less than or equal to 30.	Body Mass Index Less than or Equal to 30		Finding	CTRP Disease Terminology|CTRP Terminology
C165652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165652>	C15438	Immuno-oncology Therapy|IO Therapy|Immunooncology Therapy	Immunotherapy that focuses on mobilizing the patient's own immune cells to recognize and eliminate cancer cells.	Immuno-oncology Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C165653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165653>	C20189	Membership	Belonging to a group or organization.			Conceptual Entity	
C165654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165654>	C165653	Gym Membership	Having the rights to access a gym and use the equipment and facilities.	Gym Membership		Conceptual Entity	CTRP Intervention Terminology|CTRP Terminology
C165655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165655>	C176586	STING Agonist IMSA101|IMSA 101|IMSA-101|IMSA101	A small molecule analogue of cyclic GMP-AMP (cGAMP) that acts as an agonist of the stimulator of interferon genes protein (STING; transmembrane protein 173; TMEM173) with potential immunoactivating and antineoplastic activities. Upon intratumoral administration, STING agonist IMSA101 binds to STING and activates STING-mediated pathways. This activates the immune response through the activation of certain immune cells which induces the expression of pro-inflammatory cytokines and chemokines, promotes tumor-associated antigen (TAA) processing and presentation by dendritic cells (DCs) and leads to an antigen-specific T-cell mediated immune response against cancer cells. STING, a transmembrane protein that activates immune cells in the tumor microenvironment, plays a key role in the activation of the innate immune system.	STING Agonist IMSA101		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165657>	C211912	Anti-Globo H/MMAE Antibody-drug Conjugate OBI 999|ADC OBI 999|Anti-Globo H/MMAE ADC OBI 999|OBI 999|OBI-888/MMAE ADC OBI-999|OBI-999|OBI999	An antibody-drug conjugate (ADC) composed of OBI-888 (OBI 888), a humanized monoclonal antibody directed against the tumor-associated antigen (TAA) globohexaosylceramide (globo H), covalently linked to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration of anti-globo H/MMAE ADC OBI 999, the antibody moiety of OBI 999, OBI 888, targets and binds to globo H on tumor cells and is rapidly internalized, thereby delivering MMAE intracellularly. Upon proteolytic cleavage, MMAE targets and binds to tubulin and inhibits its polymerization, resulting in G2/M checkpoint arrest and apoptosis in globo H-expressing tumor cells. Globo H, a hexasaccharide glycosphingolipid, is (over)expressed on the surface of many types of tumor cells. Globo H is minimally or not expressed on healthy, normal cells; its expression on cancer cells is associated with increased proliferation and poor prognosis.	Anti-Globo H/MMAE Antibody-drug Conjugate OBI 999		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165658>	C36281	Skin with High Degree of Cumulative Sun Damage|Skin with High Degree of Cumulative Sun Damage (CSD)	A finding indicating a high degree of cumulative sun damage in the skin as evidenced by severe solar keratosis.			Finding	
C165659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165659>	C204864	High-CSD Melanoma|Cutaneous Melanoma with a High Degree of Cumulative Sun Damage|Cutaneous Melanoma with a High Degree of Cumulative Sun Damage (CSD)	A cutaneous melanoma that develops on sun-exposed sites with a high degree of cumulative sun damage (CSD).			Neoplastic Process	
C16565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16565>	C20182	Evolution	The process by which organism populations change over successive generations that is influenced by gene mutation and natural selection.			Phenomenon or Process	
C165660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165660>	C38620	Nail Matrix	The part of the nail bed that contains nerves and vessels.			Body Part, Organ, or Organ Component	
C165661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165661>	C200765	Allogeneic CS1-specific Universal CAR-expressing T-lymphocytes UCARTCS1A|Allogeneic Gene-edited CAR T-Cells UCARTCS1A|Allogeneic TALEN Gene-edited CAR T-Cells UCARTCS1A|Allogenic Engineered T-cells Expressing Anti- CS1 CAR UCARTCS1A|UCART CS1A|UCART-CS1A|UCARTCS1A|UCARTCS1A Cells	A preparation of allogeneic, off-the-shelf (OTS), universal transcription activator-like effector nuclease (TALEN)-engineered T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) human CS1 (CD2 subset 1; SLAM family member 7; SLAMF7; CD319; CRACC), with potential immunomodulating and antineoplastic activities. Upon transfusion of allogeneic CS1-specific universal CAR-expressing T-lymphocytes UCARTCS1A, these cells target and bind to cancer cells expressing CS1. This induces selective toxicity in and causes lysis of CS1-expressing tumor cells. SLAMF7 is a member of the signaling lymphocytic activation molecule (SLAM) family of transmembrane receptors that modulate the function of immune cells through immunoreceptor tyrosine-based switch motifs (ITSMs) and intracellular adaptor proteins. SLAMF7 is highly expressed on certain malignant plasma cells and is minimally expressed on healthy immune cells.	Allogeneic CS1-specific Universal CAR-expressing T-lymphocytes UCARTCS1A		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165662>	C54659	Nail Matrix Nevus|NMN	An acral nevus that arises from the nail matrix.			Neoplastic Process	
C165663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165663>	C120224	CIC-DUX4 Sarcoma|CIC::DUX4 Sarcoma	An undifferentiated, high grade small round cell sarcoma affecting predominantly young adults. It is characterized by a recurrent translocation involving the CIC gene on chromosome 19 and DUX4 gene on chromosome 4. The translocation results in CIC-DUX4, t(4;19)(q35;q13) fusions.			Neoplastic Process	Cellosaurus Disease Terminology
C165664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165664>	C142985	Autologous Cryopreserved Cell Infusion|Autologous Cryopreserved Graft Infusion	A transplantation procedure that reintroduces a patient's cryopreserved cells via infusion.	Autologous Cryopreserved Cell Infusion		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C165665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165665>	C120224	CIC-DUX4L Sarcoma|CIC::DUX4L Sarcoma	An undifferentiated, high grade small round cell sarcoma affecting predominantly young adults. It is characterized by a recurrent translocation involving the CIC gene on chromosome 19 and DUX4L gene on chromosome 10. The translocation results in CIC-DUX4L, t(10;19)(q26;q13) fusions.			Neoplastic Process	
C165666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165666>	C1545|C129821|C129820	Polymer-conjugated IL-15 Receptor Agonist NKTR-255				Pharmacologic Substance	
C165667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165667>	C133155	EWSR1 Gene Rearrangement|EWS Gene Rearrangement|EWS Rearrangement|EWSR1 Rearranged|EWSR1 Rearrangement|Ewing Sarcoma Breakpoint Region 1 Gene Rearrangement|Ewing's Sarcoma Gene Rearrangement	A molecular abnormality indicating rearrangement of the EWSR1 gene.			Cell or Molecular Dysfunction	EWS Authorized Value Terminology|EWS Molecular Analysis Table
C165668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165668>	C133155	CIC Gene Rearrangement|CIC Rearranged|CIC Rearrangement|Capicua (Drosophila) Homolog Gene Rearrangement|Capicua Homolog (Drosophila) Gene Rearrangement|Capicua Transcriptional Repressor Gene Rearrangement|Capicua, Drosophila, Homolog of Gene Rearrangement	A molecular abnormality indicating rearrangement of the CIC gene.	CIC Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|EWS Authorized Value Terminology|EWS Molecular Analysis Table
C16566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16566>	C16513	Excision Repair	Excision Repair mechanisms remove and replace damaged nucleotides from DNA molecules with new nucleotide subunits, e.g., Base Excision Repair, Nucleotide Excision Repair, or SOS Function.			Genetic Function	
C165670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165670>	C28510	CIC/DUX4L Fusion Gene|CIC-DUX4L Fusion Gene|CIC::DUX4L Fusion Gene|Capicua Homolog (Drosophila)/Double Homeobox 4-Like Fusion Gene|Capicua Transcriptional Repressor/Double Homeobox 4-Like Fusion Gene|t(10;19)/CIC-DUX4L Fusion Gene	A fusion gene that results from a chromosomal translocation t(10;19)(q26;q13) which fuses the CIC gene to a member of the DUX4L genes clustered at 10q26. This fusion is associated with the CIC-rearranged small blue round cell subtype of soft tissue sarcoma.			Gene or Genome	
C165671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165671>	C3746	EWSR1-Negative Small Round Cell Tumor|EWSR1-Negative Small Blue Round Cell Tumor|EWSR1-Negative Small Cell Sarcoma	A high-grade sarcoma characterized by the absence of EWSR1 rearrangement and the presence of small round malignant cells with a small amount of cytoplasm.			Neoplastic Process	
C165672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165672>	C17561	CIC/DUX4L Fusion Protein|CIC-DUX4L Fusion Protein|CIC::DUX4L Fusion Protein|Protein Capicua Homolog/Double Homeobox 4-Like Fusion Protein|Protein Capicua Homolog::Double Homeobox 4-Like Fusion Protein	A fusion protein encoded by the CIC/DUX4L fusion gene. This protein is comprised of the majority of the protein capicua homolog, including the DNA-binding high-mobility group (HMG)-box and 15 of 16 putative MAPK phosphorylation sites, fused to the double homeobox protein 4-like protein.			Amino Acid, Peptide, or Protein	
C165673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165673>	C206077	Aicardi-Goutieres Syndrome 2|AGS2	An inherited, usually autosomal recessive condition cause by mutation(s) in the RNASEH2B gene, encoding ribonuclease H2 subunit B. Clinical features and onset may vary significantly, but is characterized in its most severe form by cerebral atrophy, leukodystrophy, intracranial calcifications, chronic cerebrospinal fluid (CSF) lymphocytosis, and increased concentrations of CSF alpha-interferon.			Disease or Syndrome	Cellosaurus Disease Terminology
C165674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165674>	C3020|C28193	Myoclonic-Atonic Epilepsy|Doose Syndrome|MAE|Myoclonic-Astatic Epilepsy|Myoclonic-Atonic Seizure	A genetically heterogenous condition characterized by early onset of absence and myoclonic seizures following developmental delay. Intellectual disability may develop following the onset of seizures.			Disease or Syndrome	Cellosaurus Disease Terminology
C165675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165675>	C3243	Relapsing-Remitting Multiple Sclerosis	A type of multiple sclerosis characterized by intermittent flare-ups with a return to few or no symptoms.	Relapsing-Remitting Multiple Sclerosis		Disease or Syndrome	Cellosaurus Disease Terminology|CTRP Disease Terminology|CTRP Terminology
C165676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165676>	C265	Immediate-release Bupropion|Bupropion Immediate Release|IR Bupropion	An immediate-release (IR) tablet formulation of the aminoketone bupropion, with antidepressant activity and for potential use in promoting smoking cessation, increasing sexual desire, and reducing cancer-related fatigue. Bupropion is a weak blocker of the neuronal uptake of serotonin, dopamine and norepinephrine, and is a central nicotinic acetylcholine receptor antagonist. Bupropion may also reduce circulating levels of tumor necrosis factor (TNF) and normalize hypothalamic-pituitary-adrenal (HPA) axis functioning, which is dysregulated in certain cases of cancer-related fatigue.	Immediate-release Bupropion		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C165677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165677>	C50178	Charged Slide	A microscope slide that has a positive surface charge to electrostatically attract and bind tissue sections to the slide.			Manufactured Object	
C165678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165678>	C50178	Uncharged Slide	A microscope slide that lacks a positive surface charge.			Manufactured Object	
C165679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165679>	C19236	Multi-Spin Echo|Multi-echo Spin Echo|Multiple Spin Echo|Multiple Spin Echo Magnetic Resonance Imaging	Stimulation of a magnetic resonance signal with additional 180 degree-pulse(s) to generate additional echo(es).			Activity	
C16567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16567>	C17708	Exercise|Exercise Type	Activity that requires physical or mental exertion, especially when performed to develop or maintain fitness.	Exercise		Daily or Recreational Activity	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|CTRP Intervention Terminology|CTRP Terminology
C165680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165680>	C20189	Orientation|Generic Orientation	The position or alignment of something relative to points of the compass, other specific directions, or some other indexing system.			Conceptual Entity	
C165681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165681>	C20368	Selected Suppression	Any technique designed to reduce a specific response, effect, or phenomenon.			Laboratory Procedure	
C165682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165682>	C20189	Integrated	Combining things, people, or ideas of different types in one effective unit, group, or system.			Conceptual Entity	
C165683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165683>	C27993	Defined	Clearly characterized or delimited.			Conceptual Entity	
C165684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165684>	C201536|C129822	Livmoniplimab|ABBV 151|ABBV-151|ABBV151|ARGX 115|ARGX-115|ARGX115|Anti-GARP Monoclonal Antibody ABBV-151|Anti-glycoprotein A Repetitions Predominant Monoclonal Antibody ABBV-151|LIVMONIPLIMAB	A humanized monoclonal antibody directed against the transforming growth factor beta (TGFbeta) activator, glycoprotein A repetitions predominant (GARP; leucine-rich repeat-containing protein 32; LRRC32), with potential immunomodulating and antineoplastic activities. Upon administration, livmoniplimab selectively targets and binds to GARP which interferes with the production and release of active TGFbeta by regulatory T-cells (Tregs).  Selective inhibition of the release of TGFbeta from Tregs leads to a reversal of immunosuppression thereby increasing the immune response to tumor cells. GARP, a leucine-rich repeat-containing protein, is essential for the expression of TGFbeta on the cell surface of activated Tregs; it plays an important role in regulation of the immune cell function.	Livmoniplimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165685>	C206201|C20401|C129822	Lilotomab|Anti-CD37 Monoclonal Antibody HH1|HH1|LILOTOMAB	A murine immunoglobulin G1 (IgG1) monoclonal antibody directed against the CD37 antigen with potential antineoplastic activity. Upon administration, lilotomab both activates the immune system to induce an antibody-dependent cell-mediated cytotoxicity (ADCC) against CD37-overexpressing tumor cells and induces apoptosis in these tumor cells. CD37 is a transmembrane glycoprotein expressed at high-levels on B-cells and to a lesser extent on T-cells and myeloid cells, and is frequently overexpressed in certain B-cell malignancies.	Lilotomab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165686>	C91105	Shared Decision Making Questionnaire|SDM-Q-9|Shared Decision Making Questionnaire (SDM-Q-9)	A 9-item questionnaire that measures the extent to which patients are involved in the process of decision-making.			Intellectual Product	
C165687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165687>	C174127|C173145	Doctor Made Clear that a Decision Needs to be Made Question|Doctor Made Clear that a Decision Needs to be Made|My doctor made clear that a decision needs to be made	A question about whether an individual's doctor made it clear that a decision needs to be made.			Intellectual Product	Shared Decision Making Questionnaire
C165688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165688>	C174127|C173145	Doctor Wanted to Know Exactly How I Want to be Involved in Making Decision Question|Doctor Wanted to Know Exactly How I Want to be Involved in Making Decision|My doctor wanted to know exactly how I want to be involved in making the decision	A question about whether an individual's doctor wanted to know exactly how they wanted to be involved in making the decision.			Intellectual Product	Shared Decision Making Questionnaire
C165689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165689>	C173145	Doctor Told me That There are Different Options for Treating Medical Condition Question|Doctor Told me That There are Different Options for Treating Medical Condition|My doctor told me that there are different options for treating my medical condition	A question about whether an individual's doctor told them that there are different options for treating their medical condition.			Intellectual Product	Shared Decision Making Questionnaire
C16568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16568>	C17119	Exocytosis	Cellular release of secretory products from within membrane-limited vesicles or granules.			Cell Function	
C165690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165690>	C173812|C173145	Doctor Precisely Explained Advantages and Disadvantages of Treatment Options Question|Doctor Precisely Explained Advantages and Disadvantages of Treatment Options|My doctor precisely explained the advantages and disadvantages of the treatment options	A question about whether an individual's doctor explained the advantages and disadvantages of the treatment options.			Intellectual Product	Shared Decision Making Questionnaire
C165691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165691>	C176537|C173145	Doctor Helped Me Understand All Information Question|Doctor Helped Me Understand All Information|My doctor helped me understand all the information	A question about whether an individual's doctor helped them understand all the information.			Intellectual Product	Shared Decision Making Questionnaire
C165692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165692>	C173812|C173507|C173145	Doctor Asked Which Treatment Option I Prefer Question|Doctor Asked Which Treatment Option I Prefer|My doctor asked me which treatment option I prefer	A question about whether an individual's doctor asked them which treatment option they prefer.			Intellectual Product	Shared Decision Making Questionnaire
C165693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165693>	C173812|C173145	Doctor and I Thoroughly Weighed Different Treatment Options Question|Doctor and I Thoroughly Weighed Different Treatment Options|My doctor and I thoroughly weighed the different treatment options	A question about whether an individual and their doctor thoroughly weighed the different treatment options.			Intellectual Product	Shared Decision Making Questionnaire
C165694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165694>	C173812|C173145	Doctor and I Selected Treatment Option Together Question|Doctor and I Selected Treatment Option Together|My doctor and I selected a treatment option together	A question about whether an individual and their doctor selected a treatment option together.			Intellectual Product	Shared Decision Making Questionnaire
C165695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165695>	C173145	Doctor and I Reached Agreement on how to Proceed Question|Doctor and I Reached Agreement on how to Proceed|My doctor and I reached an agreement on how to proceed	A question about whether an individual and their doctor reached agreement on how to proceed.			Intellectual Product	Shared Decision Making Questionnaire
C165697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165697>	C97928	FGFR1 Protein Variant|BFGFR Protein Variant|Basic Fibroblast Growth Factor Receptor 1 Protein Variant|CD331 Antigen Protein Variant|FGFR-1 Protein Variant|FLT-2 Protein Variant|FMS-Like Tyrosine Kinase 2 Protein Variant|Fibroblast Growth Factor Receptor 1 Protein Variant|N-sam Protein Variant|Proto-Oncogene c-Fgr Protein Variant|bFGF-R-1 Protein Variant	A variation in the amino acid sequence for the fibroblast growth factor receptor 1 protein.			Cell or Molecular Dysfunction	
C165698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165698>	C5214|C4124|C153238	Metastatic Breast Adenocarcinoma	An adenocarcinoma that arises from the breast and has metastasized to another anatomic site.	Metastatic Breast Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165699>	C168978|C165698|C160920	Locally Advanced Breast Adenocarcinoma	Breast adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Breast Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16569>	C16499|C16242	DNA Exonuclease|exodeoxyribonuclease	Enzymes that sequentially catalyze the hydrolysis of single nucleotides from the end of a DNA chain. These enzymes play an important role during DNA repair.			Amino Acid, Peptide, or Protein|Enzyme	
C1656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1656>	C799|C1446	Rhenium Re 186|186Re|RHENIUM RE-186|Re-186|Rhenium 186|Rhenium, Isotope of Mass 186|Rhenium-186	A radioisotope with an atomic number of 75 and a half life of 90 hours that emits beta particles and gamma rays and is used in cancer treatment and diagnostic imaging technique. (NCI)			Element, Ion, or Isotope|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C165700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165700>	C165698|C162648|C159556	Advanced Breast Adenocarcinoma	A breast adenocarcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Breast Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165701>	C171280|C162758|C150212	Locally Advanced Hypopharyngeal Squamous Cell Carcinoma	Hypopharyngeal squamous cell carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Hypopharyngeal Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165702>	C39851|C150364|C150316	Refractory Bladder Urothelial Carcinoma	Bladder urothelial carcinoma that does not respond to treatment.	Refractory Bladder Urothelial Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165703>	C5214|C159563|C147965	Refractory Breast Adenocarcinoma	Breast adenocarcinoma that does not respond to treatment.	Refractory Breast Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165704>	C45479|C27555	Post-Radiation Atypical Vascular Lesion|AVL|Atypical Vascular Lesion|Atypical Vascular Proliferation|Benign Lymphangiomatous Papule|Benign Vascular Lesion in Previously Irradiated Skin|Post-Radiation Therapy Lymphangiectasia|Post-Radiation Therapy Lymphangioma	Benign vascular proliferations in the skin following external radiation. The lesions present in adults, predominantly in elderly women following radiotherapy for breast carcinoma. They consist of papules, small vesicles, or erythematous ecchymotic plaques with prominent telangiectasias. Identical skin lesions can occur after radiation for cervical carcinoma, endometrial carcinoma, ovarian carcinoma, Hodgkin lymphoma, and melanoma. There is an increased risk for subsequent development of angiosarcoma.			Disease or Syndrome	Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C165705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165705>	C91105	Revised Olweus Bully/Victim Questionnaire|Bully/Victim Questionnaire-Revised|OBVQ-R|Olweus Bully-Victim Questionnaire-Revised (OBVQ-R)|Olweus Bully/Victim Questionnaire, Revised	A questionnaire consisting of 40 questions for the measurement of aspects of bully/victim problems: physical, verbal, indirect, racial, sexual forms of bullying harassment; initiation of various forms of bullying other students; where the bullying occurs; pro-bullying and pro-victim attitudes; and the extent to which teachers, peers, and parents are informed about and react to the bullying.			Intellectual Product	
C165706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165706>	C20993	Diagnostic Infant and Preschool Assessment|DIPA|Diagnostic Infant Preschool Assessment|Diagnostic Infant Preschool Assessment (DIPA)	A diagnostic instrument for assessing DSM-IV syndromes in children aged 6 years or younger, administered as an interview for their caregivers.			Intellectual Product	
C165707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165707>	C20993	Finnegan Neonatal Abstinence Score Tool|FNAST|Finnegan Neonatal Abstinence Score Tool (FNAST)|Finnegan's Neonatal Abstinence Scoring Tool	A standardized scoring tool designed to assess opioid withdrawal in a newborn. It is used by well-trained healthcare professionals and enables the practitioner to make an assessment, identify the withdrawal symptoms, document the infant's withdrawal, and initiate the appropriate treatment regimen, when needed.			Intellectual Product	
C165708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165708>	C91105	Alabama Parenting Questionnaire|APQ|Alabama Parenting Questionnaire (APQ)	A 42-item questionnaire that measures five dimensions of parenting: 1) positive involvement with children, 2) supervision and monitoring, 3) use of positive discipline techniques, 4) consistency in the use of such discipline, and 5) use of corporal punishment.			Intellectual Product	
C165709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165709>	C20993	PROMIS Peer Relationships	Questionnaires designed to assess self-reported quality of relationships with friends and other acquaintances. The peer relationships short forms   are universal rather than disease-specific and are available for pediatric self-report (ages 8-17) and for parents serving as proxy reporters for their child (youth ages 5-17).			Intellectual Product	
C16570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16570>	C17123|C16354	Coagulation Factor VII|EC 3.4.21.21|F7|Factor VII|Proconvertin|Serum Prothrombin Conversion Accelerator	Coagulation factor VII (466 aa, ~52 kDa) is encoded by the human F7 gene. This protein is involved in both binding to tissue factor and the initiation of blood coagulation.			Amino Acid, Peptide, or Protein|Enzyme	
C165710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165710>	C91105	Child and Youth Resilience Measure|CYRM|Child and Youth Resilience Measure (CYRM)	A questionnaire designed as a screening tool to explore the resources (individual, relational, communal, and cultural) available to individuals, that may bolster their resilience. Versions are available as Child, designed for ages five through nine years old and Youth, designed for ages ten through 23 years old.			Intellectual Product	
C165711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165711>	C20993	Child Behavior Checklist for Ages 6-18|CBCL/6-18|Child Behavior Checklist for Ages 6-18 (CBCL/6-18)	A standardized measure designed to detect behavioral and emotional problems in children and adolescents. It is completed by the parent/caretaker who spends the most time with the child and provides ratings for 20 competence and 120 problem items.			Intellectual Product	
C165712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165712>	C20993	Child Behavior Checklist for Ages 1.5-5|CBCL/1.5-5|Child Behavior Checklist for Ages 1.5-5 (CBCL/1.5-5)	A standardized measure designed to detect behavioral and emotional problems in children 1.5-5 years old. The forms obtain parents', daycare providers', and teachers' ratings of 99 problem items plus descriptions of problems, disabilities, what concerns respondents most about the child, and the best things about the child.			Intellectual Product	
C165713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165713>	C20993	Achenbach System of Empirically Based Assessment-Adult Self-Report and Adult Behavior Checklist|Achenbach System of Empirically Based Assessment (ASEBA)-Adult Self-Report (ASR) and Adult Behavior Checklist (ABCL)	Assessment tools that span the ages 18-59, the Adult Self-Report (ASR) and the Adult Behavior Checklist (ABCL) obtain information from the adult client and from others who know the adult well. Both forms are valuable for assessing adults in a variety of settings, such as mental health, forensic, counseling, medical, and substance abuse. Profiles display scale scores in relation to norms for each sex at ages 18-35 years and 36-59 years. Includes a Critical Items scale, and both forms have parallel scales for Substance Use, Critical Items, Internalizing, Externalizing, and Total Problems.			Intellectual Product	
C165714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165714>	C165713	Achenbach System of Empirically Based Assessment Adult Self Report|ASEBA-ASR|Achenbach System of Empirically Based Assessment (ASEBA) Adult Self Report (ASR)	A self-administered instrument that examines diverse aspects of adaptive functioning and problems.			Intellectual Product	
C165715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165715>	C165713	Achenbach System of Empirically Based Assessment Adult Behavior Checklist|ASEBA-ABCL|Achenbach System of Empirically Based Assessment (ASEBA) Adult Behavior Checklist (ABCL)	A parallel form used to obtain information about the individual being assessed from others who know the individual well, such as a spouse, partner, family member, or friend.			Intellectual Product	
C165716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165716>	C165723|C150570	Invasive Bladder Mixed Carcinoma|Infiltrating Bladder Mixed Carcinoma|Infiltrating Bladder Mixed Carcinoma	An invasive bladder carcinoma characterized by the presence of more than one histologic pattern.	Infiltrating Bladder Mixed Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165717>	C138961	PSA Level 0.5 to Ten|PSA Level 0.5 to 10|PSA Level Between 0.5 and 10|PSA Level Between 0.5 and Ten	A blood concentration of prostate specific antigen between 0.5 and 10 ng/mL.	PSA Level 0.5 to Ten		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C165718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165718>	C20993	Conners Kiddie Continuous Performance Test, 2nd Edition|Conners K-CPT 2|Conners Kiddie Continuous Performance Test 2nd Edition (Conners K-CPT 2)	A 7.5-minute-long computer-based assessment of attention deficits in children aged 4 through 7 years old. It utilizes images of objects that are familiar to young children requiring a response from the child as they appear on the screen.			Intellectual Product	
C165719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165719>	C91105	Home Observation for Measurement of the Environment, Revised Edition|Home Observation for Measurement of the Environment (HOME), Revised Edition- National Longitudinal Study of Youth Children and Young Adults|Home Observation for Measurement of the Environment (HOME)-Revised Edition	A 38-item questionnaire that evaluates the quality of a child's home environment filled out by the child's primary caregiver. The questions vary based on the age of the child.			Intellectual Product	
C16571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16571>	C16354	Coagulation Factor VIII|AHF|Antihaemophilic Factor|Antihemophilic Factor|Antihemophilic Factor|COAGULATION FACTOR VIII|Coagulation Factor VIIIc|F8|FVIII|Factor VIII|Factor VIII|Factor VIII F8B|Procoagulant Component	Coagulation factor VIII (2351 aa, ~267 kDa) is encoded by the human F8 gene. This protein plays a role in the modulation of coagulation factor IX activity and blood coagulation.	Coagulation Factor VIII		Amino Acid, Peptide, or Protein	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C165720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165720>	C97927	BCL6 Gene Mutation|B-Cell CLL/Lymphoma 6 Gene Mutation|BCL5 Gene Mutation|Bcl-6 Gene Mutation|LAZ3 Gene Mutation|ZBTB27 Gene Mutation|ZNF51 Gene Mutation|Zinc Finger Protein 51 Gene Mutation	A change in the nucleotide sequence of the BCL6 gene.	BCL6 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C165721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165721>	C25790|C20103	LY75 Gene|LY75|LY75|Lymphocyte Antigen 75 Gene	This gene is involved in antigen capture.	LY75 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C165722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165722>	C118286	Lattice Stereotactic Body Radiation Therapy|LRT|Lattice Radiotherapy|Lattice-SBRT|SBRT Delivered with Lattice Radiotherapy|SBRT-LRT	A technique for delivering heterogeneous doses of radiation to voluminous tumors not amenable to surgery. Built from a conventional two-dimensional grid, lattice radiation therapy utilizes three-dimensional radiation allowing the delivery of higher doses of radiation to small spheres, also called vertices, inside bulky tumors while limiting exposure to surrounding healthy tissue.	Lattice Stereotactic Body Radiation Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C165723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165723>	C3729|C2916	Mixed Carcinoma	A carcinoma characterized by the presence of more than one malignant epithelial histologic pattern.			Neoplastic Process	
C165724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165724>	C165721	LY75 wt Allele|CD205|CLEC13B|DEC-205|DEC205|GP200-MR6|LY-75|Lymphocyte Antigen 75 wt Allele	Human LY75 wild-type allele is located in the vicinity of 2q24.2 and is approximately 101 kb in length. This allele, which encodes lymphocyte antigen 75 protein, plays a role in antigen capture and processing. Intergenic splicing that fuses this gene and the CD302 gene may be associated with Hodgkin and Reed-Sternberg (HRS) cell-positive Hodgkin lymphoma.	LY75 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C165726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165726>	C18106|C16725	Lymphocyte Antigen 75|C-Type Lectin Domain Family 13 Member B|CD205|CD205 Antigen|DEC-205|LY75|Ly-75|gp200-MR6	Lymphocyte antigen 75 (1722 aa, ~198 kDa) is encoded by the human LY75 gene. This protein is involved in antigen capture by leukoocytes.	Lymphocyte Antigen 75		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C165727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165727>	C177692	LY75 Positive|C-Type Lectin Domain Family 13 Member B Positive|CD205 Antigen Positive|CD205 Positive|DEC-205 Positive|DEC205 Positive|Ly-75 Positive|Lymphocyte Antigen 75 Positive	An indication that expression of LY75 has been detected in a sample.	LY75 Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C165728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165728>	C170400|C138056	Myeloblasts 10 Percent or More of Peripheral Blood White Cells|Myeloblasts Greater than or Equal to 10 Percent of Peripheral Blood White Cells	A semi-quantitative microscopic finding indicating that at least 10 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells of myeloid origin.	Myeloblasts 10 Percent or More of Peripheral Blood White Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C165729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165729>	C9484|C171053	del(17p13.1)|-17p13.1|17p13.1 Deletion|del(17)(p13.1)	A deletion of chromosomal material at 17p13.1. This chromosomal aberration includes deletion of the TP53 gene and is associated with chronic lymphocytic leukemia.	del(17p13.1)		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C16572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16572>	C16354	von Willebrand Factor|Coagulation Factor VIII VWF|Factor VIII Related Antigen|Factor VIII-von Willebrand Factor|vWF|vWFAg|von Willebrand Factor Antigen	von Willebrand factor (2813 aa, ~309 kDa) is encoded by the human VWF gene. This protein is involved in platelet adhesion and blood coagulation.	von Willebrand Factor		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C165730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165730>	C62198|C133701	ZRSR2 Gene Nonsense Mutation|U2AF1-RS2 Nonsense Mutation|U2AF1L2 Nonsense Mutation|U2AF1RS2 Nonsense Mutation|URP Nonsense Mutation|ZC3H22 Nonsense Mutation|ZRSR2 Nonsense Mutation|Zinc Finger CCCH-type, RNA Binding Motif and Serine/Arginine Rich 2 Gene Nonsense Mutation	A change in the sequence of the ZRSR2 gene that encodes a premature stop codon.	ZRSR2 Gene Nonsense Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C165731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165731>	C61544	Mixed Malignant Epithelial Cell Population	A morphologic finding indicating the presence of a mixed population of malignant epithelial cells in a tumor sample.			Finding	
C165733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165733>	C17354|C133701	ZRSR2 Gene Frameshift Mutation|U2AF1-RS2 Frameshift Mutation|U2AF1L2 Frameshift Mutation|U2AF1RS2 Frameshift Mutation|URP Frameshift Mutation|ZC3H22 Frameshift Mutation|ZRSR2 Frame Shift Mutation|ZRSR2 Frameshift Mutation|ZRSR2 Gene Frame Shift Mutation|Zinc Finger CCCH-type, RNA Binding Motif and Serine/Arginine Rich 2 Gene Frameshift Mutation	A deletion or insertion mutation in the ZRSR2 gene that shifts the reading frame for the transcript.	ZRSR2 Gene Frameshift Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C165734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165734>	C138961	PSA Level Less than or Equal to One Hundred|PSA Level 100 or Less|PSA Level Less Than or Equal to 100 ng/mL|PSA Level Less than or Equal to 100|PSA Level One Hundred or Less	A blood concentration of prostate specific antigen less than or equal to 100 ng/mL.	PSA Level Less than or Equal to One Hundred		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C165735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165735>	C4819|C171605|C150546	Refractory Skin Squamous Cell Carcinoma	Skin squamous cell carcinoma that does not respond to treatment.	Refractory Skin Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165736>	C154608|C143013|C143012	Recurrent Metastatic Skin Squamous Cell Carcinoma	The reemergence of metastatic skin squamous cell carcinoma after a period of remission.	Recurrent Metastatic Skin Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165737>	C190194|C143012	Locally Recurrent Skin Squamous Cell Carcinoma	The reemergence of skin squamous cell carcinoma after a period of remission, at or adjacent to the site of the original tumor.	Locally Recurrent Skin Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165738>	C191983|C162572	Locally Advanced Merkel Cell Carcinoma	A Merkel cell carcinoma that has spread to nearby tissues or lymph nodes.	Locally Advanced Merkel Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165739>	C162572|C154608|C115440	Recurrent Metastatic Merkel Cell Carcinoma	The reemergence of metastatic Merkel cell carcinoma after a period of remission.	Recurrent Metastatic Merkel Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16573>	C25464	Faroe Islands|234|FAROE ISLANDS|FAROE ISLANDS|FO|FRO|FRO|Faeroe Islands	An island group between the Norwegian Sea and the North Atlantic Ocean, about one-half of the way from Iceland to Norway.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C165740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165740>	C190194|C115440	Locally Recurrent Merkel Cell Carcinoma	The reemergence of Merkel cell carcinoma after a period of remission, at or adjacent to the site of the original tumor.	Locally Recurrent Merkel Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165741>	C9231|C191979	Refractory Merkel Cell Carcinoma	Merkel cell carcinoma that does not respond to treatment.	Refractory Merkel Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165742>	C8511|C3773|C157131|C150541	Refractory Neuroendocrine Carcinoma	Neuroendocrine carcinoma that does not respond to treatment.			Neoplastic Process	
C165743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165743>	C5214	Hormone Receptor-Negative Breast Carcinoma|ER and PR Negative Breast Carcinoma|Estrogen Receptor and Progesterone Receptor Negative Breast Carcinoma|Hormone Receptor Negative Breast Adenocarcinoma|Hormone Receptor Negative Breast Carcinoma|Hormone Receptor Negative Breast Carcinoma	Breast adenocarcinoma that is negative for hormone receptors.	Hormone Receptor Negative Breast Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165744>	C188928|C165233	Hormone Receptor Negative	A finding indicating that the tumor cells in a tissue sample are negative for hormone receptors.	Hormone Receptor Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C165745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165745>	C9385|C172623|C159563	Refractory Renal Cell Carcinoma	A renal cell carcinoma that is resistant to treatment.	Refractory Renal Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165746>	C129839|C129824	Zotatifin|4-((5aR,6S,7S,8R,8aS)-7-((Dimethylamino)methyl)-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-6,7,8,8a-tetrahydro-5aH-cyclopenta(4,5)furo(3,2-C)pyridin-5a-yl)benzonitrile|ZOTATIFIN|eFT 226|eFT-226	A selective inhibitor of the eukaryotic translation initiation factor 4A (eIF4A), with potential antineoplastic activity. Upon administration of zotatifin, this agent targets and binds to elF4A, and promotes eIF4A binding to mRNA with specific polypurine motifs within their 5'-untranslated region (5'-UTR), leading to the formation of a stable sequence-specific ternary complex with eIF4A and mRNA (elF4A- zotatifin-mRNA). This results in the translational repression of key oncogenes and anti-apoptotic proteins involved in tumor cell proliferation, survival and metastasis, such as KRAS, Myc, myeloid cell leukemia-1 (Mcl-1), B-cell lymphoma 2 (Bcl-2), cyclin-dependent kinase (CDK) 4 and 6, cyclin D, fibroblast growth factor receptor (FGFR) 1 and 2, human epidermal growth factor receptor 2 (HER2; ERBB2), and beta-catenin. The inhibition of the expression of these oncogenes leads to the inhibition of various oncogenic signal transduction pathways. This inhibits proliferation and induces apoptosis in tumor cells. eIF4A, a RNA helicase and the rate-limiting component of the eukaryotic translation initiation complex, catalyzes the ATP-dependent unwinding of RNA duplexes and facilitates 43S ribosome scanning within the 5'-UTR. elF4A is activated by various oncogenic signaling pathways, including RAS/mitogen-activated protein kinase (MAPK) and phosphatidylinositide 3-kinase (PI3K)/AKT pathways, and regulates the translation of oncogenes and tumor survival factors with complex secondary structures within the 5'-UTRs that are required for tumor cell proliferation, survival and metastasis.	Zotatifin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165747>	C2185	Romaciclib Hydrochloride|4H-Imidazo(4,5,1-ij)quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, Hydrochloride|6,7-Dibromo-5-methyl-2-piperazin-1-yl-1,3-diazatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraene;hydrochloride|7,8-Dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4Himidazo(4,5,1-ij)quinoline Hydrochloride|CDK8/19 Inhibitor RVU120|CDK8/19 Inhibitor SEL 120|RVU 120|RVU-120|RVU120|SEL 120|SEL 120-34|SEL 120-34A|SEL-120|SEL-120|SEL120	The hydrochloride salt form of romaciclib, an orally bioavailable inhibitor of cyclin-dependent kinases 8 and 19 (CDK8/19), with potential antineoplastic and chemoprotective activities. Upon oral administration, romaciclib targets, binds to and inhibits the activity of CDK8/19, which prevents activation of CDK8/19-mediated oncogenic signaling pathways, blocks selective transcription of various tumor-promoting genes, and inhibits proliferation of CDK8/19-overexpressing tumor cells. CDK8/19, serine/threonine kinases involved in the regulation of the cell cycle, are overexpressed in certain cancer cell types and play key roles in tumor cell proliferation.	Romaciclib Hydrochloride		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165748>	C176586	STING Agonist GSK3745417|GSK 3745417|GSK-3745417|GSK3745417	An agonist of the stimulator of interferon genes protein (STING; transmembrane protein 173; TMEM173), with potential immunoactivating and antineoplastic activities. Upon intravenous administration, STING agonist GSK3745417 targets and binds to STING and activates the STING pathway in immune cells in the tumor microenvironment (TME). This leads to the production of pro-inflammatory cytokines, including interferons (IFNs), enhances the cross-presentation of tumor-associated antigens (TAAs) by dendritic cells (DCs), and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. STING, a transmembrane protein that activates immune cells in the TME, plays a key role in the activation of the innate immune system.	STING Agonist GSK3745417		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165749>	C160157	Tumor Location Unknown|Unknown	The location of the tumor is unknown.			Intellectual Product	CPTAC Baseline Medical Forms Terminology|CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form|CPTAC Terminology
C16574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16574>	C16946|C16804|C16561|C16259	Fatty Acid Synthase|EC 2.3.1.85|FAS|FASN|Type I Fatty Acid Synthase	Fatty acid synthase (2511 aa, ~273 kDa) is encoded by the human FASN gene. This protein is involved in long-chain fatty acid synthesis.	Fatty Acid Synthase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C165750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165750>	C201557	Autologous CD34-positive Peripheral Blood Stem Cells|Autologous CD34+ PBSCs|Autologous CD34-positive PBSCs	A population of autologous cluster of differentiation 34 (CD34)-positive peripheral blood stem cells (PBSCs) that can be used for autologous hematopoietic stem cell transplantation (AHSCT). Upon mobilization and collection of the autologous CD34+ PBSCs by leukapheresis, the CD34+ PBSCs are re-infused into the patient. Upon transplantation, these cells can differentiate into a variety of cell types including the formation of new hematopoietic and immune cells.	Autologous CD34-positive Peripheral Blood Stem Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C165751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165751>	C129632	FGFR1 NM_023110.2:c.1966A>G|BFGFR c.1966A>G|CD331 c.1966A>G|CEK c.1966A>G|FGFBR c.1966A>G|FGFR-1 c.1966A>G|FGFR1 c.1966A>G|FLG c.1966A>G|FLT-2 c.1966A>G|FLT2 c.1966A>G|FMS-Like Tyrosine Kinase 2 c.1966A>G|Fibroblast Growth Factor Receptor 1 c.1966A>G|KAL2 c.1966A>G|N-SAM c.1966A>G|NM_023110.2:c.1966A>G|OGD c.1966A>G	A nucleotide substitution at position 1966 of the coding sequence of the FGFR1 gene where adenine has been mutated to guanine.			Cell or Molecular Dysfunction	
C165752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165752>	C165697	FGFR1 NP_075598.2:p.K656E|BFGFR K656E|BFGFR Lys656Glu|Basic Fibroblast Growth Factor Receptor 1 K656E|Basic Fibroblast Growth Factor Receptor 1 Lys656Glu|CD331 Antigen K656E|CD331 Antigen Lys656Glu|FGFR-1 K656E|FGFR-1 Lys656Glu|FGFR1 K656E|FGFR1 Lys656Glu|FGFR1 NP_075598.2:p.Lys656Glu|FGFR1 p.K656E|FGFR1 p.Lys656Glu|FLT-2 K656E|FLT-2 Lys656Glu|FMS-Like Tyrosine Kinase 2 K656E|FMS-Like Tyrosine Kinase 2 Lys656Glu|Fibroblast Growth Factor Receptor 1 K656E|Fibroblast Growth Factor Receptor 1 Lys656Glu|N-sam K656E|N-sam Lys656Glu|NP_075598.2:p.K656E|NP_075598.2:p.Lys656Glu|Proto-Oncogene c-Fgr K656E|Proto-Oncogene c-Fgr Lys656Glu|bFGF-R-1 K656E|bFGF-R-1 Lys656Glu	A change in the amino acid residue at position 656 in the fibroblast growth factor receptor 1 protein where lysine has been replaced by glutamic acid.			Cell or Molecular Dysfunction	
C165753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165753>	C84092	FGFR4 NM_002011.5:c.1162G>A|CD334 c.1162G>A|FGFR-4 c.1162G>A|FGFR4 c.1162G>A|Fibroblast Growth Factor Receptor 4 c.1162G>A|JTK2 c.1162G>A|NM_002011.5:c.1162G>A|TKF c.1162G>A	A nucleotide substitution at position 1162 of the coding sequence of the FGFR4 gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C165754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165754>	C173902|C167447	Diffuse Large B-Cell Lymphoma with Associated Monoclonal Small B-Cell Population in Bone Marrow	A finding indicating the presence of a minor population of monoclonal B-cells in the bone marrow of a patient with diffuse large B-cell lymphoma, without evidence of bone marrow infiltration by diffuse large B-cell lymphoma cells.	Diffuse Large B-Cell Lymphoma with Associated Monoclonal Small B-Cell Population in Bone Marrow		Finding	CTRP Disease Terminology|CTRP Terminology
C165755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165755>	C97928	FGFR4 Protein Variant|CD334 Antigen Protein Variant|FGFR-4 Protein Variant|Fibroblast Growth Factor Receptor 4 Protein Variant|Tyrosine Kinase Related To Fibroblast Growth Factor Receptor Protein Variant	A variation in the amino acid sequence for the fibroblast growth factor receptor 4 protein.			Cell or Molecular Dysfunction	
C165756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165756>	C165755	FGFR4 NP_002002.3:p.G388R|CD334 Antigen G388R|CD334 Antigen Gly388Arg|FGFR-4 G388R|FGFR-4 Gly388Arg|FGFR4 G388R|FGFR4 Gly388Arg|FGFR4 NP_002002.3:p.Gly388Arg|FGFR4 p. G388R|FGFR4 p.Gly388Arg|Fibroblast Growth Factor Receptor 4 G388R|Fibroblast Growth Factor Receptor 4 Gly388Arg|NP_002002.3:p.G388R|NP_002002.3:p.Gly388Arg|Tyrosine Kinase Related To Fibroblast Growth Factor Receptor G388R|Tyrosine Kinase Related To Fibroblast Growth Factor Receptor Gly388Arg	A change in the amino acid residue at position 388 in the fibroblast growth factor receptor 4 protein where glycine has been replaced by arginine.			Cell or Molecular Dysfunction	
C165757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165757>	C128920	FLT3 NP_004110.2:p.Y589D|CD135 Antigen Tyr589Asp|CD135 Antigen Y589D|FLT3 NP_004110.2:p.Tyr589Asp|FLT3 Tyr589Asp|FLT3 Y589D|FLT3 Y589D Mutation|FLT3 p.Tyr589Asp|FLT3 p.Y589D|Fetal Liver Kinase-2 Tyr589Asp|Fetal Liver Kinase-2 Y589D|Flt-3 Receptor Tyr589Asp|Flt-3 Receptor Y589D|Fms-Related Tyrosine Kinase 3 Tyr589Asp|Fms-Related Tyrosine Kinase 3 Y589D|NP_004110.2:p.Tyr589Asp|NP_004110.2:p.Y589D|Receptor-Type Tyrosine-Protein Kinase FLT3 Tyr589Asp|Receptor-Type Tyrosine-Protein Kinase FLT3 Y589D|Stem Cell Tyrosine Kinase 1 Tyr589Asp|Stem Cell Tyrosine Kinase 1 Y589D	A change in the amino acid residue at position 589 in the receptor-type tyrosine-protein kinase FLT3 protein where tyrosine has been replaced by aspartic acid.			Cell or Molecular Dysfunction	
C165758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165758>	C97927	HDAC1 Gene Mutation|HD1 Gene Mutation|Histone Deacetylase 1 Gene Mutation|RPD3 Gene Mutation|RPD3L1 Gene Mutation	A change in the nucleotide sequence of the HDAC1 gene.			Cell or Molecular Dysfunction	
C165759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165759>	C97928	HDAC1 Protein Variant|HD1 Protein Variant|Histone Deacetylase 1 Protein Variant	A variation in the amino acid sequence for the histone deacetylase 1 protein.			Cell or Molecular Dysfunction	
C16575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16575>	C16326	Ingestive Behavior	Eating habits and their role in human disease			Individual Behavior	
C165760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165760>	C165759	HDAC1 NP_004955.2:p.Y303H|HD1 Tyr303His|HD1 Y303H|HDAC1 NP_004955.2:p.Tyr303His|HDAC1 Tyr303His|HDAC1 Y303H|HDAC1 p.Tyr303His|HDAC1 p.Y303H|Histone Deacetylase 1 Tyr303His|Histone Deacetylase 1 Y303H|NP_004955.2:p.Tyr303His|NP_004955.2:p.Y303H	A change in the amino acid residue at position 303 in the histone deacetylase 1 protein where tyrosine has been replaced by histidine.			Cell or Molecular Dysfunction	
C165761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165761>	C97928	HDAC2 Protein Variant|HD2 Protein Variant|Histone Deacetylase 2 Protein Variant|Transcriptional Regulator Homolog RPD3 Protein Variant|YY1-Associated Factor 1 Protein Variant	A variation in the amino acid sequence for the histone deacetylase 2 protein.			Cell or Molecular Dysfunction	
C165762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165762>	C165761	HDAC2 NP_001518.3:p.E455fs*7|HD2 E455fs*7|HD2 Glu455fs*7|HDAC2 E455fs*7|HDAC2 Glu455fs*7|HDAC2 NP_001518.3:p.Glu455fs*7|HDAC2 p.E455fs*7|HDAC2 p.Glu455fs*7|Histone Deacetylase 2 E455fs*7|Histone Deacetylase 2 Glu455fs*7|NP_001518.3:p.E455fs*7|NP_001518.3:p.Glu455fs*7|Transcriptional Regulator Homolog RPD3 E455fs*7|Transcriptional Regulator Homolog RPD3 Glu455fs*7|YY1-Associated Factor 1 E455fs*7|YY1-Associated Factor 1 Glu455fs*7	A change in the amino acid residue at position 455 in the histone deacetylase 2 protein where glutamic acid has been replaced by 6 non-canonical amino acids followed by a premature stop.			Cell or Molecular Dysfunction	
C165764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165764>	C97928	HSP90B1 Protein Variant|94 kDa Glucose-Regulated Protein Variant|Endoplasmin Protein Variant|GRP-94 Protein Variant|Gp96 Homolog Protein Variant|Heat Shock Protein 90 kDa Beta Member 1 Protein Variant|Stress-Inducible Tumor Rejection Antigen Gp96 Protein Variant|Tumor Rejection Antigen 1 Protein Variant	A variation in the amino acid sequence for the endoplasmin protein.			Cell or Molecular Dysfunction	
C165765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165765>	C97927	HSP90B1 Gene Mutation|ECGP Gene Mutation|GP96 Gene Mutation|GRP94 Gene Mutation|HEL-S-125m Gene Mutation|HEL35 Gene Mutation|Heat Shock Protein 90 Beta Family Member 1 Gene Mutation|TRA1 Gene Mutation	A change in the nucleotide sequence of the HSP90B1 gene.			Cell or Molecular Dysfunction	
C165766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165766>	C165764	HSP90B1 NP_003290.1:p.I66T|94 kDa Glucose-Regulated I66T|94 kDa Glucose-Regulated Ile66Thr|Endoplasmin I66T|Endoplasmin Ile66Thr|GRP-94 I66T|GRP-94 Ile66Thr|Gp96 Homolog I66T|Gp96 Homolog Ile66Thr|HSP90B1 I66T|HSP90B1 Ile66Thr|HSP90B1 NP_003290.1:p.Ile66Thr|HSP90B1 p.I66T|HSP90B1 p.Ile66Thr|Heat Shock Protein 90 kDa Beta Member 1 I66T|Heat Shock Protein 90 kDa Beta Member 1 Ile66Thr|NP_003290.1:p.I66T|NP_003290.1:p.Ile66Thr|Stress-Inducible Tumor Rejection Antigen Gp96 I66T|Stress-Inducible Tumor Rejection Antigen Gp96 Ile66Thr|Tumor Rejection Antigen 1 I66T|Tumor Rejection Antigen 1 Ile66Thr	A change in the amino acid residue at position 66 in the endoplasmin protein where isoleucine has been replaced by threonine.			Cell or Molecular Dysfunction	
C165767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165767>	C2926|C190952	Resectable Lung Non-Small Cell Carcinoma	Lung non-small cell carcinoma that is amenable to surgical resection.	Resectable Lung Non-Small Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165768>	C17723	Molecular Pathologist	A pathologist that studies and diagnoses disease by identifying molecular and pathway alterations.	Molecular Pathologist		Biomedical Occupation or Discipline	CTRP Intervention Terminology|CTRP Terminology
C165769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165769>	C25193	Bioinformatician|Bioinformatics Scientist|Bioinformatics Specialist	A person practiced in using computers, databases, and math to organize and analyze biological, medical, and health information.	Bioinformatician		Occupation or Discipline	CTRP Intervention Terminology|CTRP Terminology
C16576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16576>	C171083	Female|F|F|F|F|FEMALE|FEMALE|FEMALE|female	An individual who belongs to the sex that normally produces ova.			Organism Attribute	ALL Authorized Value Terminology|ALL Demographics Table|AML Authorized Value Terminology|AML Demographics Table|CDISC SDTM Sex Assigned At Birth Response Terminology|CDISC SDTM Sex of Individual Terminology|CDISC SDTM Sex of Study Group Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF1 Registration Table|CTDC Value Terminology|EWS Authorized Value Terminology|EWS Demographics Table|FDA Individual Case Safety Report Terminology|FDA Structured Product Labeling Terminology|GCT Authorized Value Terminology|GCT Demographics Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Demographics Table|National Health Interview Survey|Newborn Screening Terminology|NICHD Terminology|Observation ICSR Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology|OS Authorized Value Terminology|OS Demographics Table|SeroNet Authorized Values|SeroNet Study Descriptors|SPL Sex Terminology
C165770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165770>	C25320	Master Protocol|master protocol|master protocol	A trial design that tests multiple drugs and/or multiple subpopulations in parallel under a single protocol, without the need to develop new protocols for every trial. (FDA DRAFT Guidance: Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics. September 2018 and Woodcock J, LaVange LM. Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. N Engl J Med. 2017 Jul 6;377(1):62-70.)			Intellectual Product	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology|FDA-NIH Modernizing Research and Evidence Glossary Terminology
C165771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165771>	C64430	Vascular Endothelial Growth Factor Receptor Measurement|VEGF Receptor Measurement|VEGFR Measurement	The determination of the amount of vascular endothelial growth factor receptor present in a sample.			Laboratory Procedure	
C165772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165772>	C64430	Bruton's Tyrosine Kinase Measurement|ATK|Agammaglobulinemia Tyrosine Kinase|B-cell Progenitor Kinase|BTK|BTK Measurement|Bruton Agammaglobulinemia Tyrosine Kinase Measurement|Bruton Tyrosine Kinase|Bruton Tyrosine Kinase Measurement|Bruton's Tyrosine Kinase|Bruton's Tyrosine Kinase|Tyrosine-protein kinase BTK	The determination of the amount of Bruton's tyrosine kinase present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165773>	C64430	Insulin-Like Growth Factor Binding Protein Measurement|IGFBP Measurement	The determination of the amount of insulin-like growth factor binding protein present in a sample.			Laboratory Procedure	
C165774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165774>	C201174|C200766|C176018	Anti-CD19-CAR-CD28/CD20-CAR-4-1BB-expressing Autologous T-lymphocytes Hu1928-Hu20BB|Autologous CAR-19/CAR-20-T Cells Hu1928-Hu20BB|Hu1928-Hu20BB|nti-CD19/CD20 CAR Autologous T-lymphocytes Hu1928-Hu20BB	A preparation of autologous human T-lymphocytes that have been genetically modified to express the CAR construct Hu1928-Hu20BB that consists of two chimeric antigen receptor (CAR) constructs: one encoding a fully-human anti-CD19 CAR with a co-stimulatory domain of CD28, Hu19-CD828, and one encoding a human anti-CD20 CAR with a co-stimulatory domain of 4-1BB (CD137), Hu20BB, with potential immunostimulating and antineoplastic activities. Upon re-infusion, the anti-CD19-CAR-CD28/CD20-CAR-4-1BB-expressing autologous T-lymphocytes Hu1928-Hu20BB recognize and kill CD19- and/or CD20-expressing tumor B-cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19- and/or CD20-expressing tumor cells, thereby causing tumor cell lysis. Both the tumor-associated antigens (TAAs) CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies.	Anti-CD19-CAR-CD28/CD20-CAR-4-1BB-expressing Autologous T-lymphocytes Hu1928-Hu20BB		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165775>	C40030	Cold Cap Therapy|Cold Cap|PSCS|Paxman Scalp Cooling System|Scalp Cooling|Scalp Cryotherapy|Scalp Hypothermia	The use of a cooling head wrap to achieve scalp cooling.	Cold Cap Therapy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C165776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165776>	C185877	Revumenib|Benzamide, N-ethyl-2-((4-(7-((trans-4-((ethylsulfonyl)amino)cyclohexyl)methyl)-2,7-diazaspiro(3.5)non-2-yl)-5-pyrimidinyl)oxy)-5-fluoro-N-(1-methylethyl)-|Menin-MLL Inhibitor SNDX-5613|Menin-MLL Interaction Inhibitor SNDX-5613|Menin-Mixed Lineage Leukemia Protein-Protein Interaction Inhibitor SNDX-5613|REVUMENIB|SNDX 5613|SNDX-5613|SNDX5613	An orally bioavailable protein-protein interaction (PPI) inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) proteins, with potential antineoplastic activity. Upon oral administration, revumenib targets and binds to the nuclear protein menin, thereby preventing the interaction between the two proteins menin and MLL and the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of MLL-rearranged leukemic cells. The menin-MLL complex plays a key role in the survival, growth, transformation and proliferation of certain kinds of leukemia cells.	Revumenib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C165777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165777>	C36282	Second Primary Squamous Cell Carcinoma of the Head and Neck	A finding indicating the occurrence of a primary head and neck squamous cell carcinoma following the diagnosis of an initial primary squamous cell carcinoma in the head and neck.	Second Primary Squamous Cell Carcinoma of the Head and Neck		Finding	CTRP Disease Terminology|CTRP Terminology
C165778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165778>	C2167|C129825	EGFR/EGFRvIII Inhibitor WSD0922-FU|BBB Penetrable EGFR/EGFRvIII Inhibitor WSD0922-FU|EGFR Mutant Inhibitor WSD0922-FU|WSD 0922-FU|WSD-0922-FU|WSD0922-FU	A blood-brain-barrier (BBB) penetrable selective inhibitor of epidermal growth factor receptor (EGFR) and various EGFR mutations, including but not limited to the EGFR variant III (EGFRvIII) mutant form, with potential antineoplastic activity. Upon administration of EGFR/EGFRvIII inhibitor WSD0922-FU, this agent is able to penetrate the BBB and specifically targets, binds to and inhibits EGFR and specific EGFR mutations, which prevents EGFR/EGFR mutant-mediated signaling and leads to cell death in EGFR/EGFR mutant-expressing tumor cells. Compared to other EGFR inhibitors that are not able to penetrate the BBB, WSD0922-FU may have therapeutic benefits in brain tumors, such as glioblastoma (GBM) and metastatic CNS tumors. EGFR, a receptor tyrosine kinase (RTK) that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and survival.	EGFR/EGFRvIII Inhibitor WSD0922-FU		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165779>	C200765|C176023	Allogeneic Anti-BCMA CAR-transduced T-cells ALLO-715|ALLO 715|ALLO-715|ALLO-715 Cells|ALLO715|ALLOCar T ALLO-715|BCMA Allogeneic CAR T Cells ALLO-715|NENDOCABTAGENE ONOGEDLEUCEL|Nendocabtagene Onogedleucel	A preparation of allogeneic, 'off-the-shelf' (OTS), universal transcription activator-like effector nuclease (TALEN)-engineered, gene-edited T-lymphocytes that have been transduced with a vector expressing a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) derived from a monoclonal antibody specific for the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Using TALEN technology, the T-cell receptor (TCR) alpha chain (TRAC) and CD52 genes are deleted from the CAR T-cells. Upon administration, nendocabtagene onogedleucel specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma cells and plays a key role in plasma cell proliferation and survival. Deletion of the CD52 gene makes the modified donor T-cells resistant to an anti-CD52 monoclonal antibody treatment, that is used during lymphodepletion. The knockout of TRAC eliminates TCR expression and is intended to abrogate the potential induction of graft-versus-host disease (GvHD) by the donor T-cells. The donor-derived, gene-edited CAR T cells have reduced production times and have increased availability when compared to autologous CAR-T cells, which use the patient's own cells and are produced on an individual basis. In addition, if nendocabtagene onogedleucel cause unacceptable side effects, the incorporated CD20-based off-switch permits selective depletion of the ALLO-715 cells when the anti-CD20 monoclonal antibody rituximab is administered.	Nendocabtagene Onogedleucel		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C16577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16577>	C20315	Ferritin	An iron protein complex, containing up to 23% iron, formed by the union of ferric iron with apoferritin; it is found in the intestinal mucosa, spleen, bone marrow, reticulocytes, and liver, and regulates iron storage and transport from the intestinal lumen to plasma.	Ferritin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C165780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165780>	C8813|C153185	Advanced Leiomyosarcoma	A leiomyosarcoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Leiomyosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165781>	C4926|C162194	Advanced Undifferentiated Pleomorphic Sarcoma	An undifferentiated pleomorphic sarcoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Undifferentiated Pleomorphic Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165783>	C3246|C216071	Transformed Mycosis Fungoides|T-MF	Histologic transformation of mycosis fungoides to an aggressive non-Hodgkin lymphoma.			Neoplastic Process	
C165784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165784>	C8686|C165789|C165783	Recurrent Transformed Mycosis Fungoides|Recurrent T-MF	The reemergence of transformed mycosis fungoides after a period of remission.	Recurrent Transformed Mycosis Fungoides		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165785>	C8687|C165791|C165783	Refractory Transformed Mycosis Fungoides|Refractory T-MF	A transformed mycosis fungoides that is resistant to treatment.	Refractory Transformed Mycosis Fungoides		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C165786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165786>	C71410	Female Cousin	A female child of one's aunt or uncle.			Human	GDC Terminology|GDC Value Terminology
C165788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165788>	C71393|C25289	Foster Brother	A male child being fostered by your parents or legal guardians.			Human	GDC Terminology|GDC Value Terminology
C165789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165789>	C8702|C8663|C216071	Recurrent Transformed T-cell Non-Hodgkin Lymphoma	The reemergence of transformed T-cell non-Hodgkin lymphoma after a period of remission.			Neoplastic Process	
C16578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16578>	C19332	Fertility|fertility	The ability of an individual to produce offspring.			Organism Attribute	
C165790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165790>	C71393|C25165	Foster Daughter	A female child you are fostering.			Human	GDC Terminology|GDC Value Terminology
C165791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165791>	C8664|C216071|C140091	Refractory Transformed T-cell Non-Hodgkin Lymphoma	A transformed T-cell non-Hodgkin lymphoma that is resistant to treatment.			Neoplastic Process	
C165792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165792>	C71393|C25174	Foster Father	A male foster parent.			Human	GDC Terminology|GDC Value Terminology
C165793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165793>	C71393|C25189	Foster Mother	A female foster parent.			Human	GDC Terminology|GDC Value Terminology
C165794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165794>	C71393|C25680	Foster Sister	A female child being fostered by your parents or legal guardians.			Human	GDC Terminology|GDC Value Terminology
C165795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165795>	C71393|C25205	Foster Son	A male child you are fostering.			Human	GDC Terminology|GDC Value Terminology
C165796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165796>	C73428|C111201	Fraternal Twin Brother|Dizygotic Twin Brother	A male full sibling that developed from a separately fertilized ova during the same pregnancy.			Human	GDC Terminology|GDC Value Terminology
C165797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165797>	C73428|C111202	Fraternal Twin Sister|Dizygotic Twin Sister	A female full sibling that developed from a separately fertilized ova during the same pregnancy.			Human	GDC Terminology|GDC Value Terminology
C165798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165798>	C71389	Great Nephew|Grand Nephew|Grand Nephew|Grandnephew|Great-Nephew	A male child of one's niece or nephew.			Human	GDC Terminology|GDC Value Terminology
C165799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165799>	C8841|C7056	Recurrent Mature B-Cell Non-Hodgkin Lymphoma	The reemergence of mature B-cell non-Hodgkin lymphoma after a period of remission.			Neoplastic Process	
C16579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16579>	C21173	Fertilization	The process beginning with penetration of the secondary oocyte by the spermatozoon and completed by fusion of the male and female pronuclei.			Cell Function	
C1657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1657>	C67413|C1506	Opiate|opiate	Functionally related to the poppy (Papaver somniferum) alkaloid morphine, natural or synthetic Opiates have widespread effects in the central nervous system, and on smooth muscle, due to activation of specific delta, mu, and kappa opiate receptors (each controlling different brain functions). Opiates include natural ingredients of the poppy and their derivatives - opium, morphine, codeine, and heroin. Morphine preparations are used as analgesic, sedative, or anxiolytic agent, but are also abused as street drugs. (NCI04)			Chemical Viewed Functionally	
C16580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16580>	C93282	In Vitro Fertilization|Artificial Fertilization|IVF|in vitro fertilization	Fertilization of an ovum outside of the body.			Therapeutic or Preventive Procedure	HL Authorized Value Terminology|HL Medical History Table
C16581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16581>	C202649	Fibronectin|CIG|Cold-Insoluble Globulin|FN|FN1|FNZ|Fibronectin 1|Fibronectin Isoform 1|Isoform 1 Fibronectin|LETS|LETS Protein|Large External Transformation-Sensitive Protein|Large, External, Transformation-Sensitive Protein	Fibronectin (2386 aa, ~263 kDa) is encoded by the human FN1 gene. This protein is involved in cell adhesion- and migration-dependent processes including embryogenesis, wound healing, blood coagulation, host defense, and metastasis.	Fibronectin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C165822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165822>	C156473	Background Treatment|background treatment	Medicinal products that are administered to each clinical trial subject, regardless of randomization group, a) to treat the indication which is the object of the study, or b) required in the protocol as part of standard care for a condition that is not the indication under investigation, and is relevant for the clinical trial design. (Recommendations from the expert group on clinical trials for the implementation of Regulation (EU) No 536/2014' dd 28 June 2017)			Chemical Viewed Functionally	CDISC DDF Study Intervention Role Value Set Terminology|CDISC DDF Terminology|CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|ICH M11 Intervention Use Value Set Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C165823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165823>	C165770	Basket Protocol	A type of master protocol designed to test a single investigational drug or drug combination in different populations defined by disease stage, histology, number of prior therapies, genetic or other biomarkers, or demographic characteristics. (FDA DRAFT Guidance: Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics. September 2018 and Woodcock J, LaVange LM. Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. N Engl J Med. 2017 Jul 6;377(1):62-70.)			Intellectual Product	
C165824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165824>	C54695	Co-packaged Product|co-packaged product	Two or more separate products packaged together in a single package or as a unit and composed of drug and device products, device and biological products, or biological and drug products. (21 CFR 3.2 (e) FAQ)			Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C165825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165825>	C54695	Cross-labeled Product|cross-labeled product	An investigational drug, device, or biological product packaged separately that, according to its proposed labeling, is intended for use only with another investigational or approved individually specified drug, device, or biological product where both are required to achieve the intended use, indication, or effect. In the case where an approved product is combined with an investigational product, upon approval of the cross-labeled product the label of the previously approved product should be modified to reflect the combination status. (21 CFR 3.2 (e) FAQ)			Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C165826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165826>	C156473	End-point Assessment Medicinal Product|end-point assessment medicinal product	Medicinal products given to the subject as an aid to assess a relevant clinical trial end-point; it is not being tested or used as a reference in the clinical trial. (Recommendations from the expert group on clinical trials for the implementation of Regulation (EU) No 536/2014' dd 28 June 2017)			Chemical Viewed Functionally	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C165827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165827>	C41079	CDISC General Observation Class|general observation class	In the context of the Study Data Tabulation Model (SDTM), a higher level categorization of the subject-level observation domains. Most CDISC domains are assigned to one of three general observation classes: 1) The Interventions general observation class is a domain that captures investigational treatments, therapeutic treatments, and surgical procedures that are intentionally administered to the subject (usually for therapeutic purposes) either as specified by the study protocol (e.g., exposure), coincident with the study assessment period (e.g., concomitant medications), or other substances self-administered by the subject (such as alcohol, tobacco, or caffeine). 2) The Events general observation class captures occurrences or incidents independent of planned study evaluations occurring during the trial (e.g., "adverse events" or "disposition") or prior to the trial (e.g., "medical history"). 3) The Findings general observation class captures the observations resulting from planned evaluations such as observations made during a physical examination, laboratory tests, ECG testing, and sets of individual questions listed on questionnaires. (SDTM and SDTM Implementation Guide, www.CDISC.org)			Conceptual Entity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C165828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165828>	C76125	Non-confirmatory Result|non-confirmatory result	Clinical trial with results that fail to confirm the preliminary evidence accumulated in earlier phases that a drug is safe and effective for use for the intended indication and recipient population.			Finding	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C165829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165829>	C165770	Platform Protocol	A type of master protocol that tests multiple, targeted therapies for a single disease simultaneously. NOTE: Platform protocols often include an adaptive design that may eliminate or add treatments based on interim analysis. (Saville BR, Berry SM. Efficiencies of platform clinical trials: A vision of the future. Clin Trials. 2016 Jun;13(3):358-66 and Woodcock J, LaVange LM. Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. N Engl J Med. 2017 Jul 6;377(1):62-70.)			Intellectual Product	
C16582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16582>	C25464	Fiji|242|FIJI|FIJI|FJ|FJI|FJI|Republic of Fiji	A group of islands in the South Pacific Ocean, southwest of Wallis and Fortuna and east of Vanuatu.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C165830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165830>	C25474	Real-world Data|RWD|Real World Data|Real World Data|Real World Data (RWD)|Real-World Data (RWD)	Data relating to patient health status and/or the delivery of health care routinely collected from sources other than traditional clinical trials. Examples of sources include data derived from electronic health records (EHRs); medical claims and billing data; data from product and disease registries; patient-generated data, including from in-home-use settings; and data gathered from other sources that can inform on health status, such as mobile devices. (21 U.S.C. 355g(b)).5 and Framework for FDA's Real-World Evidence Program December 2018)			Idea or Concept	CDISC DDF Study Arm Data Origin Type Value Set Terminology|CDISC DDF Terminology|CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology|FDA-NIH Modernizing Research and Evidence Glossary Terminology
C165831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165831>	C43583	Real-world Evidence|RWE|Real World Evidence|Real World Evidence (RWE)|Real-World Evidence (RWE)	The clinical evidence derived from analysis of Real-World Data (RWD) regarding the usage and potential benefits or risks of a medical product. (FDA Guidance: Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices. August 31, 2017)			Idea or Concept	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology|FDA-NIH Modernizing Research and Evidence Glossary Terminology
C165832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165832>	C25364	Regenerative Medicine Advanced Therapy Designation|RMAT Designation|regenerative medicine advanced therapy (RMAT) designation	An FDA designation for regenerative medicine therapies to treat, modify, reverse, or cure serious conditions that are eligible for FDA's expedited programs if they meet the criteria for such programs. (http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm)			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C165833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165833>	C49236	Regenerative Medical Therapy|regenerative medicine therapy (RMT)	A treatment to repair or replace damaged cells, tissues, or organs, including cell therapies, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products. (https://www.sciencedirect.com/topics/engineering/regenerative-medicine and http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm)			Therapeutic or Preventive Procedure	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C165834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165834>	C208217	Remote Clinical Trial|remote clinical trial	A trial designed to make use of virtual subject visits via electronic communications in order to reduce or eliminate travel by subjects to an investigative site.			Research Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C165835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165835>	C156473	Rescue Medications|Rescue Medicine|Rescue Medicine|rescue medications	Medicinal products identified in the protocol as those that may be administered to subjects when the efficacy of the Investigational Medicinal Product is not satisfactory, the effect of the IMP is too great and is likely to cause a hazard to the patient, or to manage an emergency situation. (EU-CTR Recommendations from the expert group on clinical trials for the implementation of Regulation (EU) No 536/2014' dd 28 June 2017)			Chemical Viewed Functionally	CDISC DDF Study Intervention Role Value Set Terminology|CDISC DDF Terminology|CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|ICH M11 Intervention Use Value Set Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C165836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165836>	C54696	Single-entity Product|single-entity product	A product composed of two or more regulated components (i.e., drug/device, biologic/device, drug/biologic, or drug/device/biologic) that are physically, chemically, or otherwise combined or mixed and produced as a single entity. (21 CFR 3.2 (e) FAQ)			Manufactured Object	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C165837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165837>	C16830	Software as a Medical Device|SaMD|software as a medical device (SaMD)	Software intended to be used for the performance of one or more medical purposes, without being part of a hardware medical device. ("Software as a Medical Device": Possible Framework for Risk Categorization and Corresponding Considerations Authoring Group: IMDRF Software as a Medical Device (SaMD) Working Group Date: 18 September 2014)			Medical Device	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C165838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165838>	C62289	Special Purpose Domain|special purpose domain	In the context of the Study Data Tabulation Model (SDTM), a higher level categorization of the subject-level non-observational domains, which are not classified under the SDTM general observation classes. Examples include trial design domains, relationship domains, etc. (SDTM and SDTM Implementation Guide, www.CDISC.org)			Functional Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C165839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165839>	C19711	Standards Development Organization|SDO|Standards Development Organization (SDO)	A domestic or international organization that plans, develops, establishes, or coordinates voluntary consensus standards by using procedures that incorporate the attributes of openness, balance of interests, due process, an appeals process, and consensus. (Office of Management and Budget (OMB) Circular A-119)			Professional or Occupational Group	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C16583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16583>	C25404	Filtration|Fractionation, Filtration	The process of passing a liquid or gas through a filter.			Activity	PQ/CMC Unit Operations Category Terminology
C165840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165840>	C25619	Study Data Standardization Plan|SDSP|Study Data Standardization Plan (SDSP)	A document that describes the data standardization strategy for clinical and nonclinical studies within a development program. NOTE: A Study Data Standardization Plan is intended to include historical, current, and planned information about the use of study data standards for studies to conform with the current technical formats, and terminologies described in the FDA Data Standards Catalog which applies to CDER, CBER, and CDRH. (http://www.phusewiki.org/wiki/images/e/ea/SDSP_Template.pdf, https://www.fda.gov/industry/fda-resources-data-standards/study-data-standards-resources, https://www.fda.gov/media/102719/download)			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C165841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165841>	C25404	Data Traceability|Traceability|traceability (data)	The ability to trace data from source data collection through final use in reporting or analysis to ensure data interoperability, integrity, and interpretability. (CDISC Glossary)			Activity	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA-NIH Modernizing Research and Evidence Glossary Terminology
C165842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165842>	C165770	Umbrella Protocol	A type of master protocol designed to evaluate multiple investigational drugs administered as single drugs or as drug combinations in a single disease population. (FDA DRAFT Guidance: Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics. September 2018 and Woodcock J, LaVange LM. Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. N Engl J Med. 2017 Jul 6;377(1):62-70.)			Intellectual Product	
C165843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165843>	C63358	Alpelisib/Fulvestrant Regimen|Alpelisib and Fulvestrant|Alpelisib-Fulvestrant|Alpelisib-Fulvestrant Regimen|Alpelisib/Fulvestrant|Fulvestrant/Alpelisib Regimen|Piqray/Faslodex	A regimen consisting of alpelisib and fulvestrant that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C165844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165844>	C201492	Anti-B7-H3 CAR T-cells|CARB7H3	A preparation of T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) and containing, as of yet undisclosed co-stimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, anti-B7-H3 CAR T-cells target and bind to B7-H3-expressing tumor cells, thereby inducing selective toxicity in B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It is a negative regulator of T-cell activation and its overexpression plays a key role in tumor cell invasion and metastasis.	Anti-B7-H3 CAR T-cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C165845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165845>	C14134	Monomer Deletion Site|Monomer deletion site	The location of a monomer deletion in a polymer.			Chemical Viewed Structurally	CBDD Structure Terminology|CBDD Terminology
C165846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165846>	C71389	Great Niece|Grand Niece|Grand Niece|Grandniece|Great-Niece	A female child of one's niece or nephew.			Human	GDC Terminology|GDC Value Terminology
C165847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165847>	C71389	Great Grandchild|Great-Grandchild	A child of one's grandchild.			Human	GDC Terminology|GDC Value Terminology
C165848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165848>	C73429|C111201	Identical Twin Brother|Monozygotic Twin Brother	A male full sibling that developed from a shared ovum.			Human	GDC Terminology|GDC Value Terminology
C165849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165849>	C73429|C111202	Identical Twin Sister|Monozygotic Twin Sister	A female full sibling that developed from a shared ovum.			Human	GDC Terminology|GDC Value Terminology
C16584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16584>	C25464	Finland|246|FI|FIN|FIN|FINLAND|FINLAND|Republic of Finland	A country in northern Europe, bordering the Baltic Sea, between Sweden and Russia.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C165850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165850>	C71410	Male Cousin	A male child of one's aunt or uncle.			Human	GDC Terminology|GDC Value Terminology
C165851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165851>	C71412|C71383	Maternal First Cousin Once Removed	A child of one's first cousin who is related by lineage through the mother's side of the family.			Human	GDC Terminology|GDC Value Terminology
C165852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165852>	C71412|C71382	Paternal First Cousin Once Removed	A child of one's first cousin who is related by lineage through the father's side of the family.			Human	GDC Terminology|GDC Value Terminology
C165853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165853>	C71389|C71383	Maternal Great Aunt|Maternal Great-Aunt	The aunt of one's mother.			Human	GDC Terminology|GDC Value Terminology
C165854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165854>	C71389|C71383	Maternal Great Uncle|Maternal Great-Uncle	The uncle of one's mother.			Human	GDC Terminology|GDC Value Terminology
C165856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165856>	C71389|C71382	Paternal Great Aunt|Paternal Great-Aunt	The aunt of one's father.			Human	GDC Terminology|GDC Value Terminology
C165857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165857>	C71389|C71382	Paternal Great Uncle|Paternal Great-Uncle	The uncle of one's father.			Human	GDC Terminology|GDC Value Terminology
C165858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165858>	C25474	Overall Pooled Data|OVERALL	A data pool that includes subject data across all studies within which the subject has participated.			Idea or Concept	CDISC ADaM Pool for Integration Terminology|CDISC ADaM Terminology|Clinical Data Interchange Standards Consortium Terminology
C165859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165859>	C68594	Outcome Measure Time Frame	The timespan over which the study outcome measure is assessed.			Temporal Concept	
C16585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16585>	C74944	Flow Cytometry|FLOW CYTOMETRY|flow cytometry	A technique for counting, examining and sorting microscopic particles suspended in a stream of fluid.	Flow Cytometry		Laboratory Procedure	ALL Authorized Value Terminology|ALL Lab Table|ALL Minimal Residual Disease Table|AML Authorized Value Terminology|AML Lab Table|AML Minimal Residual Disease Table|AML Subject Response Table|CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Genetic Toxicology In vivo Method Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|SeroNet Authorized Values|SeroNet Study Descriptors
C165860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165860>	C19067	Outcome Measure Title	The descriptive name of the outcome measure.			Qualitative Concept	
C165861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165861>	C25284	Outcome Measure Type	A characterization or classification of the identified outcome measure(s) for the study.			Functional Concept	
C165862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165862>	C71476	Study Oversight Entity Approval Date	The date on which the oversight entity approves the clinical study application.			Temporal Concept	
C165863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165863>	C70865	Study Oversight Entity Approval Status	The state of the study application with respect to oversight entity approval.			Qualitative Concept	
C165864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165864>	C25284	Study Oversight Entity Type	A characterization or classification of the oversight entity for the study.			Functional Concept	
C165865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165865>	C53287	Independent Safety Monitor|ISM	An independent physician or health-care professional who evaluates individual and cumulative participant data to make recommendations regarding the safe continuation of the study. (NIH)			Biomedical Occupation or Discipline	
C165866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165866>	C78508	Observational Study Monitoring Committee|OSMB|OSMC|Observational Study Monitoring Board	A group of independent experts who are appointed to monitor the safety and scientific integrity of an observational study, including protecting the confidentiality of participant data and to make recommendations regarding the stopping of the study for safety or for futility. (clinicaltrials.gov)			Population Group	
C165867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165867>	C78508	Safety Monitoring Committee|SMC|Safety Assessment Committee|Safety Monitoring Board	Group of individuals with pertinent expertise that reviews, on a regular basis, accumulating safety data from an ongoing clinical study. This independent committee monitors the safety of participants during the study.			Population Group	
C165868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165868>	C225418	Anterotemporal|ANTEROTEMPORAL	Denoting the area of the body in front and toward the cranium, brain, and eye.			Spatial Concept	CDISC SDTM Directionality Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165869>	C225418	Periventricular|PERIVENTRICULAR	Of, or pertaining to, the area surrounding the ventricles of the brain.			Spatial Concept	CDISC SDTM Directionality Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16586>	C81012	Fluorescence	Fluorescence is a luminescence (i.e., optical phenomenon) in cold bodies, in which a molecule absorbs a high-energy photon, and re-emits it as a lower-energy (longer-wavelength) photon. The energy difference between the absorbed and emitted photons ends up as molecular vibrations (heat).			Phenomenon or Process	
C165870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165870>	C225418	Subcortical|SUBCORTICAL	Denoting the area below a cortex.			Spatial Concept	CDISC SDTM Directionality Terminology|CDISC SDTM Terminology|CDISC SEND Microscopic Findings Result Modifier Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165871>	C146996	Supplemental Qualifiers for Morphology	A dataset used to represent non-standard variables and their association to parent records in the Morphology domain.			Idea or Concept	
C165872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165872>	C163747	Maximum Bolus Device Setting|MAXBOLUS|Max Bolus|Maximum Bolus|Maximum Bolus	A setting and safety feature on a device to control the maximum amount of a substance delivered in a single bolus.			Conceptual Entity	CDISC SDTM Device-In-Use Test Code Terminology|CDISC SDTM Device-In-Use Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165873>	C71738	Observation Study Epoch|OBSERVATION	A period in a clinical study during which subjects are observed, without planned interventions.			Research Activity	CDISC SDTM Epoch Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C165874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165874>	C156603	FDA Study Data Technical Conformance Guide v4.3|Study Data Technical Conformance Guide v4.3	Version 4.3 of the FDA Study Data Technical Conformance Guide.			Classification	CDISC SDTM FDA Technical Specification Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C165875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165875>	C78179|C181398	Bermuda Grass Pollen IgE Antibody RAST Score Measurement|Cynodon dactylon Pollen IgE Antibody RAST Score Measurement	A classification of the amount of Cynodon dactylon pollen antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165876>	C78179|C181398	Birch Pollen IgE Antibody RAST Score Measurement|Betula Pollen IgE Antibody RAST Score Measurement	A classification of the amount of Betula pollen antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165877>	C78179|C181398	Cat Dander IgE Antibody RAST Score Measurement|Felis cattus Dander IgE Antibody RAST Score Measurement	A classification of the amount of Felis catus dander antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165878>	C78179|C181398	German Cockroach IgE Antibody RAST Score Measurement|Blattella germanica IgE Antibody RAST Score Measurement	A classification of the amount of Blattella germanica antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165879>	C78179|C181398	Dermatophagoides farinae IgE Antibody RAST Score Measurement|American House Dust Mite IgE Antibody RAST Score	A classification of the amount of Dermatophagoides farinae IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C16587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16587>	C38060	Fluorophotometry	A technique that is used to assess both the integrity of ocular blood vessels and the permeability of the corneal epithelium following its exposure to fluorescein, which is introduced either by instillation into the eye or by intravenous injection.			Diagnostic Procedure	
C165880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165880>	C78179|C181398	Dermatophagoides pteronyssinus IgE Antibody RAST Score Measurement|European House Dust Mite IgE Antibody RAST Score	A classification of the amount of Dermatophagoides pteronyssinus antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165881>	C181398	White Elm Pollen IgE Antibody Measurement|Ulmus americana Pollen IgE Antibody Measurement	The determination of the amount of Ulmus americana pollen antigen IgE antibody present in a sample.			Laboratory Procedure	
C165882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165882>	C78179|C181398	White Elm Pollen IgE Antibody RAST Score Measurement|Ulmus americana Pollen IgE Antibody RAST Score Measurement	A classification of the amount of Ulmus americana pollen antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165883>	C78179|C181398	Orchard Grass Pollen IgE Antibody RAST Score Measurement|Dactylis glomerata Pollen IgE Antibody RAST Score Measurement	A classification of the amount of Dactylis glomerata pollen antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165884>	C181398	Olive Tree Pollen IgE Antibody Measurement|Olea europaea Pollen IgE Antibody Measurement	The determination of the amount of Olea europaea pollen antigen IgE antibody present in a sample.			Laboratory Procedure	
C165885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165885>	C78179|C181398	Olive Tree Pollen IgE Antibody RAST Score Measurement|Olea europaea Pollen IgE Antibody RAST Score Measurement	A classification of the amount of Olea europaea pollen antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165886>	C78179|C181398	White Oak Pollen IgE Antibody RAST Score Measurement|Quercus alba Pollen IgE Antibody RAST Score Measurement	A classification of the amount of Quercus alba pollen antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165887>	C78179|C181398	English Plantain Pollen IgE Antibody RAST Score Measurement|Plantagio lanceolata Pollen IgE Antibody RAST Score Measurement	A classification of the amount of Plantagio lanceolata pollen antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165888>	C181398	Russian Thistle Pollen IgE Antibody Measurement|Salsola tragus Pollen IgE Antibody Measurement	The determination of the amount of Salsola tragus pollen antigen IgE antibody present in a sample.			Laboratory Procedure	
C165889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165889>	C78179|C181398	Russian Thistle Pollen IgE Antibody RAST Score Measurement|Salsola tragus Pollen IgE Antibody RAST Score Measurement	A classification of the amount of Salsola tragus pollen antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C16588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16588>	C38101	Fluoroscopy|FLUOROSCOPY|RF|Radio Fluoroscopy|Radiographic Fluoroscopy|fluoroscopy	Examination of the tissues and deep structures of the body by x-ray, using the fluoroscope, a device that produces an image when x-rays strike a fluorescent screen.	Fluoroscopy		Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C165890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165890>	C78179|C181398	Timothy Grass Pollen IgE Antibody RAST Score Measurement|Phleum pratense Pollen IgE Antibody RAST Score Measurement	A classification of the amount of Phleum pratense pollen antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165891>	C78179|C181398	Western Ragweed Pollen IgE Antibody RAST Score Measurement|Ambrosia psilostachya Pollen IgE Antibody RAST Score Measurement	A classification of the amount of Ambrosia psilostachya pollen antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165892>	C181398	Wild Rye Pollen IgE Antibody Measurement|Elymus tricoides Pollen IgE Antibody Measurement	The determination of the amount of Elymus tricoides pollen antigen IgE antibody present in a sample.			Laboratory Procedure	
C165893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165893>	C78179|C181398	Wild Rye Pollen IgE Antibody RAST Score Measurement|Elymus tricoides Pollen IgE Antibody RAST Score Measurement	A classification of the amount of Elymus tricoides pollen antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165894>	C130133|C122130	Dermatophagoides farinae Antigen IgG4 Antibody Measurement|American House Dust Mite IgG4 Antibody	The determination of the amount of Dermatophagoides farinae antigen IgG4 antibody present in a sample.			Laboratory Procedure	
C165895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165895>	C182150|C122130	Johnson Grass Pollen IgG4 Antibody Measurement|Sorghum halepense Pollen IgG4 Antibody Measurement	The determination of the amount of Sorghum halepense pollen IgG4 antibody present in a sample.			Laboratory Procedure	
C165896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165896>	C130135|C122130	Dermatophagoides pteronyssinus Antigen IgG4 Antibody Measurement|European House Dust Mite IgG4 Antibody	The determination of the amount of Dermatophagoides pteronyssinus antigen IgG4 antibody present in a sample.			Laboratory Procedure	
C165897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165897>	C81971|C78179|C182150	Bermuda Grass Pollen IgG Antibody RAST Score Measurement|Cynodon dactylon Pollen IgG Antibody RAST Score Measurement	A classification of the amount of Cynodon dactylon pollen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165898>	C81971|C78179|C182150	Birch Pollen IgG Antibody RAST Score Measurement|Betula Pollen IgG Antibody RAST Score Measurement	A classification of the amount of Betula pollen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165899>	C81971|C78179|C182150	Silver Birch Pollen IgG Antibody RAST Score Measurement|Betula verricosa Pollen IgG Antibody RAST Score Measurement	A classification of the amount of Betula verrucosa pollen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C16589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16589>	C16851	Food Microbiology	The field of study concerned with the study of food-borne microorganisms.			Biomedical Occupation or Discipline	
C1658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1658>	C45597|C173064	Warfarin Sodium|Coumadin|Coumadin|Marevan|Panwarfin|Panwarfin|Prothromadin|Prothromadin|Tintorane|WARFARIN SODIUM|Waran|Warfilone	The sodium salt form of warfarin, a coumarin and a vitamin K antagonist, with anticoagulant activity. Warfarin sodium inhibits both vitamin K and vitamin K epoxide reductases, thereby interfering with the cyclic interconversion of vitamin K epoxide to its reduced form, vitamin KH2. Vitamin KH2 is a cofactor for the carboxylation of glutamate residues on the N-terminal regions of vitamin K-dependent proteins.  As a result, maturation of vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S is inhibited. Without these coagulation factors, thrombogenesis and blood clot formation are prevented.	Warfarin Sodium		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology
C165900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165900>	C81971|C78179|C182150	Orchard Grass Pollen IgG Antibody RAST Score Measurement|Dactylis glomerata Pollen IgG Antibody RAST Score Measurement	A classification of the amount of Dactylis glomerata pollen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165901>	C81971|C78179|C182150	English Plantain Pollen IgG Antibody RAST Score Measurement|Plantagio lanceolata Pollen IgG Antibody RAST Score Measurement	A classification of the amount of Plantagio lanceolata pollen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165902>	C81971|C78179|C182150	Timothy Grass Pollen IgG Antibody RAST Score Measurement|Phleum pratense Pollen IgG Antibody RAST Score Measurement	A classification of the amount of Phleum pratense pollen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165903>	C81971|C78179|C182150	Western Ragweed Pollen IgG Antibody RAST Score Measurement|Ambrosia psilostachya Pollen IgG Antibody RAST Score Measurement	A classification of the amount of Ambrosia psilostachya pollen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165904>	C81971|C78179|C182150	Tree Mix Pollen IgG Antibody RAST Score Measurement	A classification of the amount of tree mix pollen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165905>	C81971|C78179|C182150	Grass Mix Pollen IgG Antibody RAST Score Measurement	A classification of the amount of tree grass pollen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165906>	C81971|C78179|C182150	Weed Mix Pollen IgG Antibody RAST Score Measurement	A classification of the amount of weed mix pollen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165907>	C81971|C78179|C182150	Mold Mix IgG Antibody RAST Score Measurement	A classification of the amount of mold mix IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165908>	C81971|C78179|C182150	Animal Mix IgG Antibody RAST Score Measurement	A classification of the amount of animal mix IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165909>	C81971|C78179|C182150	Industrial Mix IgG Antibody RAST Score Measurement	A classification of the amount of industrial mix IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C16590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16590>	C25181	Food Industry	The businesses that raise, process, and distribute foodstuffs.			Organization	
C165910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165910>	C81971|C78179|C182150	Bee Mix IgG Antibody RAST Score Measurement	A classification of the amount of bee mix IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165911>	C81971|C78179|C182150	Dairy Mix IgG Antibody RAST Score Measurement	A classification of the amount of dairy mix IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165912>	C81971|C78179|C182150	Shellfish Mix IgG Antibody RAST Score Measurement	A classification of the amount of shellfish mix IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165913>	C81971|C78179|C182150	Nut Mix IgG Antibody RAST Score Measurement	A classification of the amount of nut mix IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165914>	C81971|C78179|C182150	Cat Dander IgG Antibody RAST Score Measurement|Felis cattus Dander IgG Antibody RAST Score Measurement	A classification of the amount of Felis cattus dander IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165915>	C81971|C78179|C182150	Dog Dander IgG Antibody RAST Score Measurement|Canus lupus Dander IgG Antibody RAST Score Measurement	A classification of the amount of Canis lupus IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165916>	C81971|C78179|C182150	Dermatophagoides farinae IgG Antibody RAST Score Measurement|American House Dust Mite IgG Antibody RAST Score	A classification of the amount of Dermatophagoides farinae antigen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165917>	C81971|C78179|C182150	Dermatophagoides pteronyssinus IgG Antibody RAST Score Measurement|European House Dust Mite IgG Antibody	A classification of the amount of Dermatophagoides pteronyssinus antigen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165918>	C81971|C78179|C182150	American Cockroach IgG Antibody RAST Score Measurement|Periplaneta americana IgG Antibody RAST Score Measurement	A classification of the amount of Periplaneta americana antigen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165919>	C81971|C78179|C182150	German Cockroach IgG Antibody RAST Score Measurement|Blattella germanica IgG Antibody RAST Score Measurement	A classification of the amount of Blattella germanica antigen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C16591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16591>	C17153	Forensic Medicine|Forensics	The application of medical knowledge to questions of law; research, reports and testimony in court by experts in medical science to assist in determining a legal question.			Biomedical Occupation or Discipline	
C165920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165920>	C81971|C78179|C182150	White Elm Pollen IgG Antibody RAST Score Measurement|Ulmus americana Pollen IgG Antibody RAST Score Measurement	A classification of the amount of Ulmus americana pollen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165921>	C78179|C181398	Silver Birch Pollen IgE Antibody RAST Score Measurement|Betula verricosa Pollen IgE Antibody RAST Score Measurement	A classification of the amount of Betula pollen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165922>	C78179|C181398	Mixed Antigen IgE Antibody RAST Score Measurement	A classification of the amount of mixed antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165923>	C78179|C181398	Tree Mix Pollen IgE Antibody RAST Score Measurement	A classification of the amount of tree mix pollen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165924>	C78179|C181398	Grass Mix Pollen IgE Antibody RAST Score Measurement	A classification of the amount of grass mix pollen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165925>	C78179|C181398	Weed Mix Pollen IgE Antibody RAST Score Measurement	A classification of the amount of weed mix pollen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165926>	C78179|C181398	Mold Mix IgE Antibody RAST Score Measurement	A classification of the amount of mold mix pollen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165927>	C78179|C181398	Animal Mix IgE Antibody RAST Score Measurement	A classification of the amount of animal mix pollen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165928>	C78179|C181398	Industrial Mix IgE Antibody RAST Score Measurement	A classification of the amount of industrial mix pollen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165929>	C78179|C181398	Bee Mix IgE Antibody RAST Score Measurement	A classification of the amount of bee mix pollen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C16592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16592>	C25464	France|250|FR|FRA|FRA|FRANCE|FRANCE	A country in western Europe, bordering the Bay of Biscay and the English Channel, between Germany and Spain.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C165930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165930>	C78179|C181398	Shellfish Mix IgE Antibody RAST Score Measurement	A classification of the amount of shellfish mix pollen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165931>	C78179|C181398	Nut Mix IgE Antibody RAST Score Measurement	A classification of the amount of nut mix pollen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165932>	C78179|C181398	Dog Dander IgE Antibody RAST Score Measurement|Canus lupus Dander IgE Antibody RAST Score Measurement	A classification of the amount of canis lupus dander IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165933>	C78179|C181398	American Cockroach IgE Antibody RAST Score Measurement|Periplaneta americana IgE Antibody RAST Score Measurement	A classification of the amount of Periplaneta americana antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165934>	C78179|C181398	Arachis hypogaea IgE Antibody RAST Score Measurement	A classification of the amount of Arachis hypogaea antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165935>	C78179|C181398	Triticum aestivum IgE Antibody RAST Score Measurement	A classification of the amount of Triticum aestivum antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165936>	C78179|C181398	Glycine max IgE Antibody RAST Score Measurement	A classification of the amount of Glycine max antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165937>	C78179|C181398	Zea mays IgE Antibody RAST Score Measurement	A classification of the amount of Zea mays IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165938>	C78179|C181398	Cow Milk Protein IgE Antibody RAST Score Measurement	A classification of the amount of cow milk protein IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165939>	C78179|C181398	Egg White IgE Antibody RAST Score Measurement	A classification of the amount of egg white antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C16593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16593>	C25464	French Guiana|254|FRENCH GUIANA|FRENCH GUIANA|GF|GUF|GUF	A country in northern South America, bordering the North Atlantic Ocean, between Brazil and Suriname.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C165940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165940>	C78179|C181398	Boxelder Pollen IgE Antibody RAST Score Measurement|Acer negundo Pollen IgE Antibody Measurement	A classification of the amount of Acer negundo pollen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165941>	C78179|C181398	Common Ragweed Pollen IgE Antibody RAST Score Measurement|Ambrosia artemisiifolia Pollen IgE Antibody Measurement	A classification of the amount of Ambrosia artemisiifolia pollen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C165942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165942>	C74760	Alkaline Phosphatase Excretion Rate|ALPEXR|AlkPhos Excretion Rate	The determination of the amount of alkaline phosphatase being excreted in a biological specimen over a defined amount of time (e.g. one hour).			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165943>	C64430	AXL Receptor Tyrosine Kinase Measurement|ARK|AXL|AXL Measurement|AXL Receptor Tyrosine Kinase|AXL Receptor Tyrosine Kinase|JTK11|Tyro7|UFO|UFO Measurement	The determination of the amount of AXL receptor tyrosine kinase present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165944>	C165772	Free Bruton's Tyrosine Kinase Measurement|BTKFR|Bruton's Tyrosine Kinase, Free|Bruton's Tyrosine Kinase, Free|Free BTK Measurement	The determination of the amount of free Bruton's tyrosine kinase present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165945>	C64430	Collagen III Neo-Peptide C3M Measurement|C3M|C3M Measurement|Collagen III Neo-Peptide C3M|Collagen III Neo-Peptide C3M|Collagen III Neoantigen Peptide C3M Measurement	The determination of the amount of collagen III neo-peptide C3M present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165946>	C74689	Cannabinoid Metabolite Measurement|CANNABM|Cannabinoid Metabolites|Cannabinoid Metabolites|Cannabis Metabolites|Marijuana Metabolites	A measurement of any cannabinoid drug class metabolite(s) present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165947>	C81867	Chemokine (C-C Motif) Ligand 13 Measurement|C-C Motif Chemokine 13 Measurement|C-C Motif Chemokine Ligand 13|CCL13|CCL13 Measurement|CKb10|Chemokine (C-C Motif) Ligand 13|Chemokine (C-C Motif) Ligand 13|MCP-4|MCP-4 Measurement|Monocyte Chemoattractant Protein 4 Measurement|NCC1|SCYA13|SCYL1	The determination of the amount of CCL13, chemokine (C-C motif) ligand 13, present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165948>	C81867	Chemokine (C-C Motif) Ligand 16 Measurement|C-C Motif Chemokine 16 Measurement|CCL16|CCL16 Measurement|CKb12|Chemokine (C-C Motif) Ligand 16|Chemokine (C-C Motif) Ligand 16|Chemokine CC-4|HCC-4|ILINCK|LCC-1|LEC|LMC|Mtn-1|NCC4|SCYA16|SCYL4	The determination of the amount of CCL16, chemokine (C-C motif) ligand 16, present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165949>	C81867	Chemokine (C-C Motif) Ligand 23 Measurement|C-C Motif Chemokine 23 Measurement|CCL23|CCL23 Measurement|CK-BETA-8|CKb8|Chemokine (C-C Motif) Ligand 23|Chemokine (C-C Motif) Ligand 23|Ckb-8-1|Hmrp-2a|MIP-3 Measurement|MIP3|MPIF-1|MPIF-1 Measurement|Macrophage Inflammatory Protein 3 Measurement|Myeloid Progenitor Inhibitory Factor 1 Measurement|SCYA23	The determination of the amount of CCL23, chemokine (C-C motif) ligand 23, present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16594>	C25464	French Polynesia|258|FRENCH POLYNESIA|FRENCH POLYNESIA|PF|PYF|PYF	An archipelago in the South Pacific Ocean, east of the Cook Islands.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C165950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165950>	C81867	Chemokine (C-C Motif) Ligand 25 Measurement|C-C Motif Chemokine 25 Measurement|CCL25|CCL25 Measurement|Chemokine (C-C Motif) Ligand 25|Chemokine (C-C Motif) Ligand 25|Ckb15|SCYA25|TECK	The determination of the amount of CCL25, chemokine (C-C motif) ligand 25, present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165951>	C81867	Chemokine (C-C Motif) Ligand 8 Measurement|C-C Motif Chemokine 8 Measurement|CCL8|CCL8 Measurement|Chemokine (C-C Motif) Ligand 8|Chemokine (C-C Motif) Ligand 8|HC14|MCP-2 Measurement|MCP2|Monocyte Chemoattractant Protein 2 Measurement|SCYA10|SCYA8	The determination of the amount of CCL8, chemokine (C-C motif) ligand 8, present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165952>	C48938	CD27 Expressing Cell Count|TNFRSF7 Expressing Cell Count|TNFRSF7 Expressing Cell Measurement	A count of the CD27 expressing cells per unit present in a sample.			Laboratory Procedure	
C165953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165953>	C64430	Carboxypeptidase B2 Measurement|CPB2|CPB2 Measurement|CPU|CPU Measurement|Carboxypeptidase B2|Carboxypeptidase B2|PCPB|TAFI|TAFI Measurement	The determination of the amount of carboxypeptidase B2 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165954>	C81867	Chemokine (C-X-C Motif) Ligand 12 Measurement|C-X-C Motif Chemokine 12 Measurement|CXCL12|CXCL12 Measurement|Chemokine (C-X-C Motif) Ligand 12|Chemokine (C-X-C Motif) Ligand 12|IRH|PBSF|SCYB12|SDF1|SDF1 Measurement|SDF1A|SDF1B|Stromal Cell-Derived Factor 1 Measurement|Stromal Cell-Derived Factor-1 Alpha|Stromal Cell-Derived Factor-1 Beta|TLSF|TPAR1	The determination of the amount of CXCL12, chemokine (C-X-C motif) ligand 12, present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165955>	C81867	Chemokine (C-X-C Motif) Ligand 7 Measurement|B-TG1|Beta-TG|C-X-C Motif Chemokine 7 Measurement|CTAP-III|CTAP3|CTAPIII|CXCL7|CXCL7 Measurement|Chemokine (C-X-C Motif) Ligand 7|Chemokine (C-X-C Motif) Ligand 7|LA-PF4|LDGF|MDGF|NAP-2|NAP-2 Measurement|NAP2 Measurement|Neutrophil-Activating Peptide 2|PBP|PBP Measurement|PPBP|PPBP Measurement|Platelet Basic Protein Measurement|Pro-Platelet Basic Protein|Pro-Platelet Basic Protein Measurement|SCYB7|TC1|TC2|TGB|TGB1|THBGB|THBGB1	The determination of the amount of pro-platelet basic protein present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165956>	C81867	Chemokine (C-X-C Motif) Ligand 9 Measurement|C-X-C Motif Chemokine 9 Measurement|CMK|CXCL9|CXCL9 Measurement|Chemokine (C-X-C Motif) Ligand 9|Chemokine (C-X-C Motif) Ligand 9|Humig|MIG|Monokine Induced by Gamma Interferon|SCYB9|crg-10	The determination of the amount of CXCL9, chemokine (C-X-C motif) ligand 9, present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165957>	C64430	Dickkopf WNT Signaling Path Inhibitor 1 Measurement|DKK-1|DKK1|DKK1 Measurement|Dickkopf WNT Signaling Path Inhibitor 1|Dickkopf WNT Signaling Pathway Inhibitor 1|Dickkopf-Related Protein 1 Measurement|SK	The determination of the amount of dickkopf WNT signaling pathway inhibitor 1 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165958>	C64550	Pseudo-Eosinophil Count|EOSPSD|Pseudo-Eosinophils|Pseudo-Eosinophils	The determination of the amount of pseudo-eosinophils present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165959>	C67208	Pseudo-Eosinophils to Leukocyte Ratio Measurement|EOSPSDLE|Pseudo-Eosinophils/Leukocytes|Pseudo-Eosinophils/Leukocytes	A relative measurement (ratio or percentage) of the pseudo-eosinophils to the leukocytes in a biological sample. The measurement may be expressed as either a ratio or a percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16595>	C17434	Fucosyltransferase|Alpha-Fucosyltransferases	Belongs to the family of EC 2.4.1 glycosyltransferases. The enzyme catalyzes the transfer of a fucose molecule from a dinucleotide compound to another carbohydrate compound.			Amino Acid, Peptide, or Protein|Enzyme	
C165960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165960>	C64430	Fas Cell Surface Death Receptor Measurement|ALPS1A|APT1|CD95 Measurement|FAS|FAS Measurement|FAS1|FASTM|Fas Cell Surface Death Receptor|Fas Cell Surface Death Receptor|Soluble CD95|TNF Receptor Superfamily Member 6|TNFRSF6|TNFRSF6 Measurement|Tumor Necrosis Factor Receptor Superfamily Member 6 Measurement	The determination of the amount of Fas cell surface death receptor present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165961>	C81969	Galactose-Deficient IgA1 Measurement|GDIGA1|Galactose-Deficient IgA1|Galactose-Deficient IgA1|Gd-IgA1	The determination of the amount of galactose-deficient IgA1 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165962>	C74760	Gamma Glutamyl Transferase Excretion Rate|GGT Excretion Rate|GGTEXR|GammaGlutamyl Transferase Excretion Rate	The determination of the amount of gamma glutamyl transferase being excreted in a biological specimen over a defined amount of time (e.g. one hour).			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165963>	C64430	Granulin Measurement|GRANULIN|GRN Measurement|Granulin|Granulin|Granulins Measurement|PEPI Measurement	The determination of the amount of granulin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165964>	C165963	Progranulin Measurement|GRN|Pro-Granulin Measurement|Pro-Granulins Measurement|Progranulin|Progranulin|Progranulins Measurement	The determination of the amount of progranulin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165965>	C210010	Human Anti-Human Antibody Measurement|HAHA|HAHA Measurement|Human Anti-Human Antibody|Human Anti-Human Antibody	The determination of the amount of total human anti-human antibody present in a sample.			Laboratory Procedure	CDISC SDTM Immunogenicity Specimen Assessments Test Code Terminology|CDISC SDTM Immunogenicity Specimen Assessments Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165966>	C64430	Helicase MOV-10 Protein Measurement|HELMOV10|Helicase MOV-10 Protein|Helicase MOV-10 Protein|MOV10 Measurement|Moloney Leukemia Virus 10 Protein	A measurement of helicase MOV-10 protein present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165967>	C49286	Heparin Measurement|HEPARIN|Heparin|Heparin	The determination of the amount of heparin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165968>	C124344	Intercellular Adhesion Molecule 3 Measurement|CD50 Measurement|ICAM3|ICAM3 Measurement|Intercellular Adhesion Molecule 3|Intercellular Adhesion Molecule 3	The determination of the amount of intercellular adhesion molecule 3 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165969>	C165773	Insulin-Like Growth Factor Binding Protein 7 Measurement|AGM|Angiomodulin Measurement|FSTL2|IBP-7|IGFBP-7|IGFBP-7 Measurement|IGFBP-7v|IGFBP7|IGFBP7 Measurement|IGFBPRP1|Insulin-Like Growth Factor Binding Prot7|Insulin-Like Growth Factor Binding Prot7|Insulin-like Growth Factor Binding Protein 7|MAC25|PSF|RAMSVPS|TAF	The determination of the amount of insulin-like growth factor binding protein 7 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16596>	C25464	Gabon|266|GA|GAB|GAB|GABON|GABON	A country in central Africa, bordering the Atlantic Ocean at the Equator, between Republic of the Congo and Equatorial Guinea.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C165970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165970>	C225442	Interleukin 1 Receptor Type 2 Measurement|CD121b Measurement|CDw121b|IL-1R-2|IL-1RT2|IL1R2|IL1R2 Measurement|IL1R2c|IL1RB|Interleukin 1 Receptor Type 2|Interleukin 1 Receptor Type 2|Interleukin-1 Receptor Type 2 Measurement|Soluble CD121b	The determination of the amount of interleukin 1 receptor type 2 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165971>	C100433	Soluble Kidney Injury Molecule-1 Measurement|KIM1S|Soluble Hepatitis A Virus Cellular Receptor 1|Soluble Hepatitis A Virus Cellular Receptor 1 Measurement|Soluble KIM-1|Soluble Kidney Injury Molecule-1|Soluble Kidney Injury Molecule-1|sHAVCR1 Measurement	The determination of the amount of soluble kidney injury molecule-1 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165972>	C74760	Lactate Dehydrogenase Excretion Rate|LDH Excretion Rate|LDHEXR	The determination of the amount of lactate dehydrogenase being excreted in a biological specimen over a defined amount of time (e.g. one hour).			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165973>	C64430	Leucine Rich Alpha-2-Glycoprotein 1 Measurement|HMFT1766|LRG Measurement|LRG1|LRG1 Measurement|Leucine Rich Alpha-2-Glycoprotein 1|Leucine Rich Alpha-2-Glycoprotein 1|Leucine-Rich Alpha-2-Glycoprotein Measurement	The determination of the amount of leucine rich alpha-2-glycoprotein 1 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165974>	C67208	Metarubricyte to Leukocyte Ratio Measurement|METARBLE|Metarubricytes/Leukocytes|Metarubricytes/Leukocytes	A relative measurement (ratio or percentage) of the metarubricytes to leukocytes in a biological sample. The measurement may be expressed as either a ratio or a percentage.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165975>	C74760|C103419	N-acetyl-beta-D-glucosaminidase Excretion Rate|N-Acetyl Beta-D-Glucosaminidase Measurement|NAGASE Excretion Rate|NAGASE Excretion Rate|NAGASE Excretion Rate|NAGASEXR	The determination of the amount of N-acetyl-beta-D-glucosaminidase being excreted in a biological specimen over a defined amount of time (e.g. one hour).			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165977>	C64430	Neuropilin-1 Measurement|BDCA4|NP1|NRP|NRP Measurement|NRP1|NRP1 Measurement|Neuropilin-1|Neuropilin-1|Soluble CD304|VEGF165R|VEGF165R Measurement|Vascular Endothelial Cell Growth Factor 165 Receptor Measurement	The determination of the amount of neuropilin-1 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165978>	C49286	Platelet-Granulocyte Aggregate Measurement|PGAG|Platelet-Granulocyte Agg|Platelet-Granulocyte Agg|Platelet-Granulocyte Aggregates	The determination of the amount of aggregates composed of platelets and granulocytes present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165979>	C64430	Pro-C6 Measurement|C-Terminal Propeptide of Collagen Alpha-3(IV) Measurement|C-Terminal Propeptide of Type 6a3 Collagen|C-Terminal Propeptide of Type VIa3 Collagen|C-terminal Pro-Peptide of the Alpha 3 Type VI Collagen Chain|Endotrophin|Endotrophin Measurement|PROC6|Pro-C6|Pro-C6	The determination of the amount of pro-C6 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16597>	C17434	Galactosyltransferase	Enzymes that catalyze the transfer of a galactosyl group from a donor to an acceptor compound. The acceptor molecule is frequently a carbohydrate moiety.			Amino Acid, Peptide, or Protein|Enzyme	
C165980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165980>	C64430	Receptor Advanced Glycation Endproducts Measurement|AGER|AGER Measurement|Advanced Glycosylation End Product-Specific Receptor Measurement|Advanced Glycosylation End-Product Specific Receptor|RAGE|RAGE Measurement|Receptor Advanced Glycation Endproducts|Receptor Advanced Glycation Endproducts|Receptor for Advanced Glycosylation End Products Measurement	The determination of the amount of receptor advanced glycation endproducts present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165981>	C64430	Phosphorylated 40S Ribosomal Protein S6 Measurement|Phos-S6 Ribosomal Protein|Phos-S6 Ribosomal Protein|Phospho-40S Ribosomal Protein S6 Measurement|Phospho-RPS6 Measurement|Phosphorylated S6 protein of the 40S ribosomal subunit|S6PHS|pRPS6 Measurement|pS6RP Measurement	The determination of the amount of phosphorylated S6 protein of the 40S ribosomal subunit present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165982>	C61014|C125940	Serum Amyloid A1 Measurement|PIG4|SAA Measurement|SAA1|SAA1|SAA1 Measurement|Serum Amyloid A-1 Protein|Serum Amyloid A1|Serum Amyloid A1	The determination of the amount of serum amyloid A1 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165983>	C64430	SH2 Domain Containing 1A Protein Measurement|DSHP|Duncan Disease SH2-Protein|EBVS|IMD5|LYP|MTCP1|SAP|SAP Measurement|SAP/SH2D1A|SH2 Domain Containing 1A Protein|SH2 Domain Containing 1A Protein|SH2D1A|SH2D1A Measurement|SLAM-Associated Protein Measurement|XLP|XLPD|XLPD1	The determination of the amount of SH2 domain containing 1A protein present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165984>	C64430	Somatostatin Receptor Type 2 Measurement|SRIF-1|SSTR2|SSTR2 Measurement|Somatostatin Receptor Type 2|Somatostatin Receptor Type 2	The determination of the amount of somatostatin receptor type 2 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165985>	C64430	Transforming Growth Factor Alpha Measurement|Protransforming Growth Factor Alpha|TGF Alpha Measurement|TGF-Alpha|TGF-Alpha Measurement|TGFA|TGFA Measurement|TGFalpha Measurement|Transforming Growth Factor Alpha|Transforming Growth Factor Alpha	The determination of the amount of transforming growth factor alpha present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165986>	C122155	Transforming Growth Factor Beta 2 Measurement|G-TSF|LDS4|TGF Beta 2 Measurement|TGF-Beta-2 Measurement|TGF-beta2|TGFB2|TGFB2|TGFbeta2 Measurement|Transforming Growth Factor Beta 2|Transforming Growth Factor Beta 2	The determination of the amount of transforming growth factor beta 2 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165987>	C122155	Transforming Growth Factor Beta 3 Measurement|ARVD|ARVD1|LAP Measurement|LDS5|Latency-Associated Peptide Measurement|RNHF|TGF Beta 3 Measurement|TGF-Beta-3 Measurement|TGF-beta3|TGFB3|TGFB3 Measurement|TGFbeta3 Measurement|Transforming Growth Factor Beta 3|Transforming Growth Factor Beta 3	The determination of the amount of transforming growth factor beta 3 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165988>	C64430	Tissue Inhibitor of Metalloproteinase 3 Measurement|HSMRK222|K222|K222TA2|MIG-5 Measurement|Metalloproteinase Inhibitor 3|Metalloproteinase Inhibitor 3 Measurement|Protein MIG-5|SFD|TIMP-3 Measurement|TIMP3|TIMP3 Measurement|Tissue Inhibitor of Metalloproteinase 3|Tissue Inhibitor of Metalloproteinase 3|Tissue Inhibitor of Metalloproteinase-3 Measurement	The determination of the amount of tissue inhibitor of metalloproteinase 3 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165989>	C74804	TNF Superfamily Member 10 Measurement|APO2 Ligand Measurement|APO2L|APO2L Measurement|Soluble CD253|TL2|TNF Superfamily Member 10|TNF-Related Apoptosis Inducing Ligand Measurement|TNF-Related Apoptosis-Inducing Ligand|TNF10|TNFSF10|TNFSF10 Measurement|TNLG6A|TRAIL|TRAIL Measurement|Tumor Necrosis Factor Ligand Superfamily Member 10 Measurement	The determination of the amount of total tumor necrosis factor superfamily member 10 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16598>	C25464	The Gambia|270|GAMBIA|GAMBIA, THE|GM|GMB|GMB|Gambia|Gambia|Gambia	A country in western Africa, bordering the North Atlantic Ocean and surrounded by Senegal.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C165990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165990>	C74804	TNF Superfamily Member 12 Measurement|APO3 Ligand Measurement|APO3L|APO3L Measurement|DR3LG|TNF Superfamily Member 12|TNF Superfamily Member 12|TNF-Related Weak Inducer of Apoptosis Measurement|TNF12|TNFSF12 Measurement|TNLG4A|TWEAK|TWEAK Measurement|Tumor Necrosis Factor Ligand Superfamily Member 12 Measurement	The determination of the amount of total tumor necrosis factor superfamily member 12 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165991>	C64430	TNF Receptor 1B Measurement|CD120b|CD120b Measurement|Soluble CD120b|TBPII|TNF Receptor 1B|TNF Receptor 1B|TNF-R-II|TNF-R-II Measurement|TNF-R75|TNFBR|TNFBR Measurement|TNFR1B|TNFR1B|TNFR2|TNFR2 Measurement|TNFR80|Tumor Necrosis Factor Receptor 2|Tumor Necrosis Factor Receptor Superfamily Member 1B Measurement|p75|p75TNFR|p75TNFR Measurement	The determination of the amount of tumor necrosis factor receptor superfamily member 1B present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165992>	C165771	Soluble Vascular Endothelial Growth Factor Receptor Type 1 Measurement|Soluble FLT1 Measurement|Soluble VEGFR-1 Measurement|Soluble VEGFR1 Measurement|Soluble Vasc Endoth Growth Factor Rec1|Soluble Vasc Endoth Growth Factor Rec1|Soluble Vascular Endothelial Growth Factor Receptor 1|VEGFR1S|sFLT1 Measurement|sVEGFR-1 Measurement|sVEGFR1 Measurement	The determination of the amount of soluble vascular endothelial growth factor receptor 1 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165993>	C156527	Soluble Vascular Endothelial Growth Factor Receptor Type 2 Measurement|Soluble FLK-1 Measurement|Soluble FLK1 Measurement|Soluble KDR Measurement|Soluble VEGFR-2 Measurement|Soluble VEGFR2 Measurement|Soluble Vasc Endoth Growth Factor Rec2|Soluble Vasc Endoth Growth Factor Rec2|Soluble Vascular Endothelial Growth Factor Receptor 2|VEGFR2S|sFLK-1 Measurement|sFLK1 Measurement|sKDR Measurement|sVEGFR-2 Measurement|sVEGFR2 Measurement	The determination of the amount of soluble vascular endothelial growth factor receptor 2 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165994>	C165771	Soluble Vascular Endothelial Growth Factor Receptor Type 3 Measurement|Soluble FLT4 Measurement|Soluble VEGFR-3 Measurement|Soluble VEGFR3 Measurement|Soluble Vasc Endoth Growth Factor Rec3|Soluble Vasc Endoth Growth Factor Rec3|Soluble Vascular Endothelial Growth Factor Receptor 3|VEGFR3S|sFLT4 Measurement|sVEGFR-3 Measurement|sVEGFR3 Measurement	The determination of the amount of soluble vascular endothelial growth factor receptor 3 present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165995>	C64430	Vitronectin Measurement|V75|VN|VNT|VTN|VTN Measurement|VTRNCTN|Vitronectin|Vitronectin	The determination of the amount of vitronectin present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165996>	C13056	Abductor Digiti Minimi Muscle of the Hand|ABDUCTOR DIGITI MINIMI MUSCLE OF THE HAND	A muscle of the hand, in general extending from the pisiform bone, the pisohamate ligament, and the flexor retinaculum to the ulnopalmar margin of the proximal phalanx. Primary function is abduction of the little finger and flexion of the phalanx nearest the hand.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165997>	C13056	Abductor Pollicis Brevis Muscle|ABDUCTOR POLLICIS BREVIS MUSCLE	A muscle of the hand, in general extending from the flexor retinaculum and the tubercles of the scaphoid and trapezium bones to the outer side of the base of the proximal phalanx of the thumb. Primary function is abduction of the thumb away from the palm.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165998>	C13056	Flexor Hallucis Brevis Muscle|FLEXOR HALLUCIS BREVIS MUSCLE	A muscle in the foot that is involved in the flexion of the first toe and the support of the medial longitudinal arch. It originates on the plantar surface of the cuboid bone and inserts into the medial and lateral sesamoid bones at the base of the proximal phalanx of the first toe. It is innervated by the medial plantar nerve and supplied by the medial plantar artery.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C165999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C165999>	C13039	Hymenal Ring|HYMENAL RING	The outer edge of the hymen or hymenal remnants.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16599>	C21173	Gametogenesis	Gametogenesis is the phase of sexual reproduction in which certain cells of a female or male individual (parent) are transformed into specialized reproductive cells (gametes) that will initiate development of a progeny individual (offspring) upon fertilization.			Cell Function	
C1659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1659>	C776	Melengestrol|17-hydroxy-6-methyl-16-methylenepregna-4,6-diene-3,20-dione|MELENGESTROL|MGA|Melengesterol|Melengestrel	A progestogen-like compound used as a cattle feed additive for its growth promoting effects and suppression of estrus (heat) in heifers. Critics have claimed that hormones used as growth promotants in cattle may cause breast cancer. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166000>	C12680	Paraspinal Region|PARASPINAL REGION	The area of the body near the spinal column.			Body Location or Region	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166001>	C13073	Procerus Muscle|PROCERUS MUSCLE	A pyramid-shaped muscle in the face that allows movement of the skin between the eyebrows. It originates on the lower part of the nasal bone and inserts into the frontalis muscle in the forehead. It is innervated by branches of the facial nerve and supplied by the facial artery.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166003>	C13056	Wrist Joint Extensor Muscles|WRIST JOINT EXTENSOR MUSCLES	A group of muscles located in the posterior compartment of the forearm that allow dorsiflexion of the wrist, as well as other movements of the wrist and fingers. The wrist extensors, including the extensor carpi radialis longus, extensor carpi radialis brevis, extensor digitorum, extensor digiti minimi, extensor carpi ulnaris, extensor indicis, extensor pollicis longus, extensor pollicis brevis, and abductor pollicis longus muscles, originate on the posterior ulna and radius, and the distal humerus, and insert into the backs of the carpals, metacarpals and phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166004>	C13056	Wrist Joint Flexor Muscles|WRIST JOINT FLEXOR MUSCLES	A group of muscles located in the anterior compartment of the forearm that allow plantar flexion of the wrist, as well as other movements of the wrist and fingers. The wrist flexors, including the flexor carpi radialis, palmaris longus, flexor carpi ulnaris, flexor digitorum superficialis, flexor digitorum profundus, and flexor pollicis longus muscles, originate on the medial distal humerus or anterior ulna and radius, and insert into the anterior surfaces of the carpals, metacarpals and phalanges.			Body Part, Organ, or Organ Component	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166005>	C81971	Norovirus Genogroup II.4 IgG Antibody Measurement	A measurement of Norovirus genogroup II.4 IgG antibody present in a sample.			Laboratory Procedure	
C166006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166006>	C81969	Norovirus Genogroup II.4 IgA Antibody Measurement	A measurement of Norovirus genogroup II.4 IgA antibody present in a sample.			Laboratory Procedure	
C166007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166007>	C81972	Norovirus Genogroup II.4 IgM Antibody Measurement	A measurement of Norovirus genogroup II.4 IgM antibody present in a sample.			Laboratory Procedure	
C166008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166008>	C49188|C135409	Vibrio cholerae, Vibrio parahaemolyticus, and/or Vibrio vulnificus DNA Measurement|C166008|V. chol/parahaemolyticus/vulnificus DNA|V. chol/parahaemolyticus/vulnificus DNA|Vibrio cholerae/parahaemolyticus/vulnificus DNA	The determination of the amount of Vibrio cholerae, Vibrio parahaemolyticus, and/or Vibrio vulnificus DNA present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166009>	C186186	Shigella and/or Enteroinvasive Escherichia coli ipaH DNA Measurement|C166009|Invasion Plasmid Antigen H Gene|Shigella species and/or Enteroinvasive Escherichia coli Invasion Plasmid Antigen H DNA|Shigella/EIEC ipaH DNA|Shigella/EIEC ipaH DNA|ipaH gene	The determination of the amount of invasion plasmid antigen H DNA from any members of the genus Shigella and/or enteroinvasive Escherichia coli present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16600>	C19747	Gamma Camera	An instrument used in medicine to produce images of internal organs after the injection of a radioactive drug into the body, where the drug releases gamma rays. It is used especially in medical diagnostic scanning. (Encarta Dictionary and Merriam-Webster Online Dictionary)			Medical Device	
C166010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166010>	C49188|C132301	Sapovirus Genogroups I, II, IV, and/or V RNA Measurement|C166010|Sapovirus Genogroups I/II/IV/V RNA|Sapovirus Genogroups I/II/IV/V RNA	The determination of the amount of Sapovirus genogroups I, II, IV and/or V RNA present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166011>	C184668	Norovirus Genogroup I and/or II RNA Measurement|C166011|Norovirus GI/GII RNA|Norovirus Genogroup I/II RNA|Norovirus genogroup I and/or genogroup II RNA	A measurement of Norovirus genogroup I and/or II RNA present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166012>	C191314	Enterotoxigenic Escherichia coli LtA, ST1a, and/or ST1b DNA Measurement|C166012|ETEC LtA/ST1a/ST1b DNA|ETEC LtA/ST1a/ST1b DNA|ETEC LtA/ST1a/ST1b DNA Measurement|Enterotoxigenic Escherichia coli LtA/ST1a/ST1b DNA	The determination of the amount of enterotoxigenic Escherichia coli LtA, ST1a and/or ST1b DNA present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166013>	C191314	Enteropathogenic Escherichia coli eae DNA Measurement|C166013|EPEC eae DNA|EPEC eae DNA|EPEC eae DNA Measurement|Enteropathogenic Escherichia coli eae DNA	The determination of the amount of enteropathogenic Escherichia coli eae DNA present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166014>	C191314	Enteroaggregative Escherichia coli pAA Plasmid aggR and/or aatA DNA Measurement|C166014|EAEC pAA Plasmid aggR/aatA DNA|EAEC pAA Plasmid aggR/aatA DNA|EAEC pAA Plasmid aggR/aatA DNA Measurement|Enteroaggregative Escherichia coli pAA Plasmid aggR/aatA DNA	The determination of the amount of enteroaggregative Escherichia coli pAA plasmid aggR and/or aatA DNA present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166015>	C189578|C135409	Campylobacter coli, Campylobacter jejuni and/or Campylobacter upsaliensis DNA Measurement|C. coli/jejuni/upsaliensis DNA|C. coli/jejuni/upsaliensis DNA|C166015|Campylobacter coli/jejuni/upsaliensis DNA	The determination of the amount of Campylobacter coli, Campylobacter jejuni and/or Campylobacter upsaliensis DNA present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166016>	C49188|C132301	Human astrovirus 1, 2, 3, 4, 5, 6, 7, and/or 8 RNA Measurement|C166016|Human astrovirus 1/2/3/4/5/6/7/8 RNA|Human astrovirus 1/2/3/4/5/6/7/8 RNA	The determination of the amount of Human astrovirus 1, 2, 3, 4, 5, 6, 7 and/or 8 RNA present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166017>	C191310	Human adenovirus 40 and/or Human adenovirus 41 DNA Measurement|C166017|Human adenovirus 40/41 DNA|Human adenovirus 40/41 DNA|Human adenovirus F40/F41 DNA|Mastadenovirus 40/41 DNA	The determination of the amount of Human adenovirus type 40 and/or Human adenovirus type 41 DNA present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166018>	C81971|C78179|C182150	Mucor racemosus IgG Antibody RAST Score Measurement	A classification of the amount of Mucor racemosus IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C166019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166019>	C81971|C78179|C182150	Aspergillus fumigatus IgG Antibody RAST Score Measurement	A classification of the amount of Aspergillus fumigatus antigen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C16601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16601>	C17125	Gamma Globulin	A type of globulin in plasma that in electrically charged solutions exhibits slowest colloidal mobility after that of the alpha and beta globulins. All immunoglobulins belong to this group of serum protein.			Amino Acid, Peptide, or Protein|Immunologic Factor	
C166020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166020>	C81971|C78179|C182150	Penicillium notatum IgG Antibody RAST Score Measurement	A classification of the amount of Penicillium notatum antigen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C166021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166021>	C81971|C78179|C182150	Alternaria alternata IgG Antibody RAST Score Measurement	A classification of the amount of Alternaria alternata antigen IgG antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C166022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166022>	C78179|C181398	Mucor racemosus IgE Antibody RAST Score Measurement	A classification of the amount of Mucor racemosus antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C166023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166023>	C78179|C181398	Aspergillus fumigatus IgE Antibody RAST Score Measurement	A classification of the amount of Aspergillus fumigatus antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C166024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166024>	C78179|C181398	Penicillium notatum IgE Antibody RAST Score Measurement	A classification of the amount of Penicillium notatum antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C166025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166025>	C78179|C181398	Alternaria alternata IgE Antibody RAST Score Measurement	A classification of the amount of Alternaria alternata antigen IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C166026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166026>	C78179|C181398	Cladosporium herbarum IgE Antibody RAST Score Measurement	A classification of the amount of Cladosporium herbarum IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C166027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166027>	C78179|C181398	Penicillium chrysogenum IgE Antibody RAST Score Measurement	A classification of the amount of Penicillium chrysogenum IgE antibody present in a sample using the radioallergosorbent test (RAST) scoring system.			Laboratory Procedure	
C166028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166028>	C210010	Aspergillus Antibody Measurement	The determination of the amount of antibody to any member of the genus Aspergillus present in a sample.			Laboratory Procedure	
C166029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166029>	C49188|C135409	Cyclospora cayetanensis DNA Measurement|CCADNA|Cyclospora cayetanensis DNA|Cyclospora cayetanensis DNA	The determination of the amount of Cyclospora cayetanensis DNA present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16602>	C21176	Gamma-Glutamylcysteine Synthetase|EC 6.3.2.2|Gamma-Glutamylcysteinyl Synthetase|Glutamate-Cysteine Ligase	Glutamate-cysteine ligase, also known as gamma-glutamylcysteine synthetase is the first rate limiting enzyme of glutathione synthesis. The enzyme consists of two subunits, a heavy catalytic subunit and a light regulatory subunit. The gene encoding the catalytic subunit encodes a protein of 367 amino acids with a calculated molecular weight of 72.773 kDa and maps to chromosome 6. The regulatory subunit is derived from a different gene located on chromosome 1p22-p21. Deficiency of gamma-glutamylcysteine synthetase in human is associated with enzymopathic hemolytic anemia. (LocusLink)			Amino Acid, Peptide, or Protein|Enzyme	
C166030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166030>	C111160	Coccidioides immitis Antibody Measurement	The determination of the amount of Coccidioides immitis antibody present in a sample.			Laboratory Procedure	
C166031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166031>	C81971	Coccidioides IgG Antibody Measurement	The determination of the amount of IgG antibody from any member of the genus Coccidioides present in a sample.			Laboratory Procedure	
C166032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166032>	C81972	Coccidioides IgM Antibody Measurement	The determination of the amount of IgM antibody from any member of the genus Coccidioides present in a sample.			Laboratory Procedure	
C166033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166033>	C49188|C135409	Cryptosporidium DNA Measurement|CRYPTDNA|Cryptosporidium DNA|Cryptosporidium DNA	The determination of the amount of DNA from any member of the genus Cryptosporidium present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166034>	C210011	Cryptosporidium Antigen Measurement|CSPORAG|Cryptosporidium Antigen|Cryptosporidium Antigen	The determination of the amount of antigen from any member of the genus Cryptosporidium present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166035>	C171143|C135409	Epstein-Barr DNA Measurement|EBDNA|EBV DNA|Epstein-Barr DNA|Epstein-Barr DNA|Human Herpesvirus 4 DNA	The determination of the amount of Epstein-Barr virus DNA present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|HL Authorized Value Terminology|HL Lab Table
C166036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166036>	C49188|C135409	Entamoeba histolytica DNA Measurement|EHIDNA|Entamoeba histolytica DNA|Entamoeba histolytica DNA	The determination of the amount of Entamoeba histolytica DNA present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166037>	C191314	Escherichia coli O157 DNA Measurement|EO157DNA|Escherichia coli O157 DNA|Escherichia coli O157 DNA	The determination of the amount of Escherichia coli O157 DNA present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166038>	C186155	Giardia lamblia DNA Measurement|GLADNA|Giardia duodenalis DNA|Giardia intestinalis DNA|Giardia lamblia DNA|Giardia lamblia DNA	The determination of the amount of Giardia lamblia DNA present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166039>	C210012	Hepatitis B Virus Core Antigen Measurement|HBCAG|Hepatitis B Virus Core Antigen|Hepatitis B Virus Core Antigen	The determination of the amount of Hepatitis B virus core antigen present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16603>	C16749	Gastroenterology	The branch of medicine that focuses on diagnosis and treatment of conditions affecting the gastrointestinal tract.			Biomedical Occupation or Discipline	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C166040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166040>	C189553	Hepatitis B Virus Nucleic Acid Measurement|HBNUAC|HBV Nucleic Acid Measurement|Hepatitis B Virus Nucleic Acid|Hepatitis B Virus Nucleic Acid	The determination of the amount of hepatitis B virus nucleic acid present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166041>	C189554	Hepatitis C Virus Nucleic Acid Measurement|HCNUAC|HCV Nucleic Acid Measurement|Hepatitis C Virus Nucleic Acid|Hepatitis C Virus Nucleic Acid	The determination of the amount of hepatitis C virus nucleic acid present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166042>	C210012	Hepatitis E Virus Antigen Measurement|HEAG|Hepatitis E Virus Antigen|Hepatitis E Virus Antigen	The determination of the amount of Hepatitis E virus antigen present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166043>	C163539	HIV-1 Antibody and HIV-1 p24 Antigen Measurement|HIV-1 Antibody + HIV-1 p24 Antigen|HIV-1 Antibody + HIV-1 p24 Antigen|HIV1AB24	The determination of the amount of antibody reaction to the HIV-1 virus and the measurement of HIV-1 p24 antigen present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166044>	C163539	HIV-2 Antibody And HIV-1 p24 Antigen Measurement|HIV-2 Antibody + HIV-1 p24 Antigen|HIV-2 Antibody + HIV-1 p24 Antigen|HIV2AB24	The determination of the amount of antibody reaction to the HIV-2 virus and the measurement of HIV-1 p24 antigen present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166045>	C92266|C132301	HIV-2 RNA Measurement|HIV-2 RNA|HIV-2 RNA|HIV2RNA	The determination of the amount of HIV-2 RNA present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166046>	C221613|C135409	Lactobacillus crispatus DNA Measurement|LCRDNA|Lactobacillus crispatus DNA|Lactobacillus crispatus DNA	The determination of the amount of Lactobacillus crispatus DNA present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166047>	C187863	Mycoplasma genitalium Measurement|MGE|Mycoplasma genitalium|Mycoplasma genitalium	The determination of the amount of Mycoplasma genitalium present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166048>	C81971	Mycoplasma pneumophila IgG Antibody Measurement	The determination of the amount of Mycoplasma pneumophila IgG antibody present in a sample.			Laboratory Procedure	
C166049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166049>	C81972	Mycoplasma pneumophila IgM Antibody Measurement	The determination of the amount of Mycoplasma pneumophila IgM antibody present in a sample.			Laboratory Procedure	
C16604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16604>	C78162	Gastroscopy|gastroscopy|upper endoscopy	Endoscopic examination of the stomach.	Gastroscopy		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C166050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166050>	C49188|C132301	Norwalk virus RNA Measurement|NOVRNA|Norwalk calicivirus RNA|Norwalk virus RNA|Norwalk virus RNA	The determination of the amount of Norwalk virus RNA present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166051>	C184668	Norovirus Genogroup II RNA Measurement|Human Calicivirus Genogroup 2 RNA|NVGIIRNA|Norovirus GII RNA|Norovirus Genogroup II RNA|Norovirus Genogroup II RNA	A measurement of Norovirus genogroup II RNA present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166052>	C184668	Norovirus Genogroup I RNA Measurement|Human Calicivirus Genogroup 1 RNA|NVGIRNA|Norovirus GI RNA|Norovirus Genogroup 1 RNA|Norovirus Genogroup I RNA	A measurement of Norovirus genogroup I RNA present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166053>	C49188|C135409	Plesiomonas shigelloides DNA Measurement|PSHDNA|Plesiomonas shigelloides DNA|Plesiomonas shigelloides DNA	The determination of the amount of Plesiomonas shigelloides DNA present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166054>	C186180	Rotavirus A RNA Measurement|RROARNA|Rotavirus A RNA|Rotavirus A RNA|Rotavirus Group A RNA	The determination of the amount of Rotavirus A RNA present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166055>	C186183	Salmonella enterica and/or Salmonella bongori DNA Measurement|SENBODNA|Salmonella enterica/bongori DNA|Salmonella enterica/bongori DNA	The determination of the amount of Salmonella enterica and/or Salmonella bongori DNA present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166056>	C210010	Schistosoma mansoni Antibody Measurement	The determination of the amount of Schistosoma mansoni antibody present in a sample.			Laboratory Procedure	
C166057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166057>	C178941	Toxoplasma gondii IgG and/or IgM Antibody Measurement	The determination of the amount of Toxoplasma gondii IgG and/or IgM antibody present in a sample.			Laboratory Procedure	
C166058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166058>	C49188|C135409	Vibrio cholerae DNA Measurement|VCHDNA|Vibrio cholerae DNA|Vibrio cholerae DNA	The determination of the amount of Vibrio cholerae DNA present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166059>	C49188|C135409	Yersinia enterocolitica DNA Measurement|YENDNA|Yersinia enterocolitica DNA|Yersinia enterocolitica DNA	The determination of the amount of Yersinia enterocolitica DNA present in a sample.			Laboratory Procedure	CDISC SDTM Microbiology Test Code Terminology|CDISC SDTM Microbiology Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16605>	C16607	Gene Amplification|Amplification|Transcript Amplification|gene amplification	Any DNA sequence rearrangement that results in the gain of one or more copies of a DNA segment that contains at least one gene.			Genetic Function	
C166060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166060>	C16357	Automated Capillary Electrophoresis Western Blot|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|Simple Western Assay|Simple Western Size-based Assay	An automated Western Blot system that uses capillary electrophoresis to characterize and separate proteins of interest by size or charge.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166061>	C60819	Chromogenic Assay|CHROMOGENIC ASSAY	An assay in which the reaction product produces a visible color change.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166062>	C198401	Cystometry|CYSTOMETRY	A method of bladder function testing in which pressure and volume measurements are taken during the filling and voiding phases of micturition.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166063>	C17003	Digital Polymerase Chain Reaction|DIGITAL PCR|dPCR|dPCR	A type of polymerase chain reaction technique in which the sample is fractionated, within which individual PCR reactions occur in each fraction.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166064>	C116158	Droplet Digital PCR|DROPLET DIGITAL PCR|ddPCR|ddPCR|ddPCR	A type of digital polymerase chain reaction technique in which the sample is fractionated into thousands of tiny droplets using a water-oil emulsion droplet technology, within which individual PCR reactions occur in each droplet.			Molecular Biology Research Technique	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GCT Authorized Value Terminology|GCT Lab Table
C166065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166065>	C38056	Electrical Impedance Myography|EIM|EIM|ELECTRICAL IMPEDANCE MYOGRAPHY	A method of applying and measuring high-frequency, low-intensity electrical currents at the surface of localized areas of muscle to assess neuromuscular disorders.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166066>	C18641	Mouse Protection Assay|MOUSE PROTECTION ASSAY|MPA|MPA	An assay method that is used for the detection of neutralizing antibodies in serum by determining the ability of the serum to prevent the death of mice that are exposed to a lethal dose of toxin.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166067>	C19771|C179019	Multiplexed Digital Gene Expression Analysis|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS	A type of digital gene expression analysis to detect or quantify targeted RNA transcripts using bar code indexing.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166068>	C116550	Non-Invasive Dielectric Sensing|NON-INVASIVE DIELECTRIC SENSING|Noninvasive Remote Dielectric Sensing|ReDS (BR)|Remote Dielectric Sensing	A method in which the dielectric tissue properties are measured based on the emission and reflection of low-power electromagnetic signals in between two sensors attached to the body.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166069>	C38056	Polygraphy|POLYGRAPHY	A method of simultaneously recording variations in multiple physiological pulsations.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16606>	C19296|C133155	Gene Deletion|Gene Deletion Mutation|Transcript Ablation|Transcript Ablation|Whole Gene Deletion|gene deletion	A deletion that results in the loss of a DNA segment encompassing an entire gene sequence.			Cell or Molecular Dysfunction	GDC Terminology|GDC Value Terminology
C166070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166070>	C49286	Sickle Cell Solubility Test|SICKLE CELL SOLUBILITY TEST	A method of screening for sickle cell disease or trait in which sodium dithionite or a similar chemical is used to lyse red blood cells in a blood sample. This allows any hemoglobin S, which does not dissolve easily in plasma, to form crystals that visibly cloud the plasma.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166071>	C112362	Norovirus Genogroup II.4|NOROVIRUS GENOGROUP II.4|Norovirus GII.4|Norovirus Genogroup GII.4	A viral organism belonging to the Norovirus genogroup II.4.			Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166072>	C64430	Forkhead Box Protein P3 Measurement|AIID|DIETER|FOXP3|FOXP3 Measurement|Forkhead Box P3|Forkhead Box Protein 3|Forkhead Box Protein 3|IPEX|JM2|PIDX|SCURFIN|XPID	The determination of the amount of forkhead box protein 3 present in a sample.			Laboratory Procedure	CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166073>	C64430	Granzyme B Measurement|C11|CCPI|CGL1|CSPB|CTLA1|CTSGL1|GZMB|GZMB|GZMB Measurement|Granzyme B|Granzyme B|Granzyme B|HLP|SECT	The determination of the amount of granzyme B present in a sample.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Microscopic Findings Test Code Terminology|CDISC SDTM Microscopic Findings Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166074>	C70732|C41202	Screening Not Completed|SCREENING NOT COMPLETED	An indication that recruitment was closed before the subject could be randomized.			Qualitative Concept	CDISC SDTM Arm Null Reason Response Terminology|CDISC SDTM Reason for Non-Completion Terminology|CDISC SDTM Terminology|CDISC SDTM Tobacco Study Completion/Reason for Non-Completion Terminology|Clinical Data Interchange Standards Consortium Terminology|SDTM Implementation Guide Medical Device Version
C166075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166075>	C85777	Percent Recovered To Last Nonzero Concentration|Pct Rec to Last Nonzero Conc|Pct Rec to Last Nonzero Conc|RCPCLST	The percentage of the administered dose that is recovered from the specimen type, from the time of dosing to the last non-zero concentration.			Quantitative Concept	CDISC SDTM Pharmacokinetic Parameter Long Name Terminology|CDISC SDTM Pharmacokinetic Parameter Short Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166076>	C92571	Hour Times Nanogram Equivalents Per Milliliter|h*ngEq/mL|h*ngEq/mL|h.ng.eq/mL|h.ng.eq/mL|h.ng.eq/ml|h.ng.eq/ml	A unit of measure defined as hours times nanogram equivalents per milliliter.			Intellectual Product	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166077>	C92571	Hour Times Nanogram Equivalents Per Milliliter Per Milligram Equivalents|h*ngEq/mL/mgEq|h*ngEq/mL/mgEq|h.ng.eq/mL/mg.eq|h.ng.eq/mL/mg.eq|h.ng.eq/ml/mg.eq|h.ng.eq/ml/mg.eq	A unit of measure defined as hours times nanogram equivalents per milliliter per milligram equivalents.			Intellectual Product	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166078>	C92571	Hour Times Picogram Equivalents Per Milliliter|h*ngEq/L|h*pgEq/mL|h*pgEq/mL|h.pg.eq/mL|h.pg.eq/mL|h.pg.eq/ml|h.pg.eq/ml	A unit of measure defined as hours times picogram equivalents per milliliter.			Intellectual Product	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166079>	C92571	Hour Times Picogram Equivalents Per Milliliter Per Milligram Equivalents|h*pgEq/mL/mgEq|h*pgEq/mL/mgEq|h.pg.eq/mL/mg.eq|h.pg.eq/mL/mg.eq|h.pg.eq/ml/mg.eq|h.pg.eq/ml/mg.eq	A unit of measure defined as hours times picogram equivalents per milliliter per milligram equivalents.			Intellectual Product	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16607>	C21069	Genetic Duplication Process|Gene Duplication	Any DNA sequence rearrangement that results in the gain of copies of a genomic region, typically in the form of long interspersed sequences, short interspersed sequences, satellite sequences and retrotransposons. The appearance of duplications of DNA within the genome plays an important role in the diversification of genomes.			Genetic Function	
C166080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166080>	C92571	Hour Times Microgram Equivalents Per Milliliter|h*ugEq/mL|h*ugEq/mL|h.ug.eq/mL|h.ug.eq/mL|h.ug.eq/ml|h.ug.eq/ml	A unit of measure defined as hours times microgram equivalents per milliliter.			Intellectual Product	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166081>	C92571	Hour Times Microgram Equivalents Per Milliliter Per Milligram Equivalents|h*ugEq/mL/mgEq|h*ugEq/mL/mgEq|h.ug.eq/mL/mg.eq|h.ug.eq/mL/mg.eq|h.ug.eq/ml/mg.eq|h.ug.eq/ml/mg.eq	A unit of measure defined as hours times microgram equivalents per milliliter per milligram equivalents.			Intellectual Product	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166082>	C92571	Nanogram Equivalents Per Gram|ng.Eq/g|ng.Eq/g|ng.eq/g|ng.eq/g|ngEq/g|ngEq/g|pgEq/mg	A concentration unit measured as a number of nanogram equivalents per gram of substance.			Intellectual Product	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166083>	C92571	Nanogram Equivalents Per Milliliter Per Milligram Equivalents|ng.eq/mL/mg.eq|ng.eq/mL/mg.eq|ng.eq/ml/mg.eq|ng.eq/ml/mg.eq|ngEq/mL/mgEq|ngEq/mL/mgEq	A concentration unit measured as a number of nanogram equivalents of solute per milliliter of solution per milligram equivalents.			Intellectual Product	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166084>	C92571	Picogram Equivalents Per Gram|pg.eq/g|pg.eq/g|pgEq/g|pgEq/g	A concentration unit measured as a number of picogram equivalents per gram of substance.			Intellectual Product	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166085>	C92571	Picogram Equivalents Per Milliliter|ngEq/L|ngEq/L|pg.eq/mL|pg.eq/mL|pg.eq/ml|pg.eq/ml|pgEq/mL|pgEq/mL	A concentration unit measured as a number of picogram equivalents of solute per milliliter of solution.			Intellectual Product	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166086>	C92571	Picogram Equivalents Per Milliliter Per Milligram Equivalents|pg.eq/mL/mg.eq|pg.eq/mL/mg.eq|pg.eq/ml/mg.eq|pg.eq/ml/mg.eq|pgEq/mL/mgEq|pgEq/mL/mgEq	A concentration unit measured as a number of picogram equivalents of solute per milliliter of solution per milligram equivalents.			Intellectual Product	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166087>	C92571	Microgram Equivalents Per Gram|Milligram Equivalents/Kilogram|mgEq/kg|ngEq/mg|ngEq/mg|pgEq/ug|ug.eq/g|ug.eq/g|ugEq/g|ugEq/g|ugEq/g	A concentration unit measured as a number of microgram equivalents per gram of substance.			Intellectual Product	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166088>	C92571	Microgram Equivalents Per Milliliter Per Milligram Equivalents|ug.eq/mL/mg.eq|ug.eq/mL/mg.eq|ug.eq/ml/mg.eq|ug.eq/ml/mg.eq|ugEq/mL/mgEq|ugEq/mL/mgEq	A concentration unit measured as a number of microgram equivalents of solute per milliliter of solution per milligram equivalents.			Intellectual Product	CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166089>	C19342|C147467	Digital Wide Field Fundus Photography|DIGITAL WIDE FIELD FUNDUS PHOTOGRAPHY	A type of digital fundus photography that makes use of a significantly wider viewing angle than traditional fundus photography.			Occupational Activity	CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16608>	C21049	Gene Expression|Expressed|Expression|gene expression	Typically involves transcription of genetically encoded information into an intermediary message (messenger RNA) and subsequent translation into a functional protein.	Gene Expression		Genetic Function	CTRP Biomarker Terminology|CTRP Terminology
C166090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166090>	C85429	Likert Scale 7-Point|LIKERT SCALE 7-POINT	A type of Likert rating scale composed of 7 points.			Intellectual Product	CDISC SDTM QRS Method Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166091>	C121548	Numerical Rating Scale 6-Point|NRS 6-Point|NUMERICAL RATING SCALE 6-POINT|Numeric Rating Scale 6-Point	A type of numerical rating scale composed of 7 points, ranging from 0-6.			Intellectual Product	CDISC SDTM QRS Method Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166092>	C96572	Biological Father of Subject's Child|FATHER, BIOLOGICAL OF SUBJECT'S CHILD	The biological father of the offspring of the female subject.			Human	CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166093>	C96580	Biological Mother of Subject's Child|MOTHER, BIOLOGICAL OF SUBJECT'S CHILD	The biological mother of the offspring of the male subject.			Human	CDISC SDTM Relationship to Subject Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166094>	C19157	Agglutinated Specimen|AGGLUTINATED	A specimen that has undergone agglutination, a process by which particles collect to form a cohesive mass or cluster.			Physical Object	CDISC SDTM Specimen Condition Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166095>	C67375	Ten Thousand Colony Forming Units Per Liter|10*4.[CFU]/mL|10*4.[CFU]/mL|10*4.[CFU]/ml|10*4.[CFU]/ml|10^4 CFU/mL|10^4 CFU/mL|10^4.[CFU]/mL|10^4.[CFU]/mL|10^4.[CFU]/ml|10^4.[CFU]/ml|Ten Thousand CFU/mL|Ten Thousand Colony Forming Units per Milliliter	A unit of measurement of viable bacterial organisms in a unit volume of substance of interest defined as the number of 10 to the fourth power colony forming units in one liter of substance.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166096>	C68902	Ten Million Colony Forming Units Per Liter|10*7.[CFU]/mL|10*7.[CFU]/mL|10*7.[CFU]/ml|10*7.[CFU]/ml|10^7 CFU/mL|10^7 CFU/mL|10^7.[CFU]/mL|10^7.[CFU]/mL|10^7.[CFU]/ml|10^7.[CFU]/ml|Ten Million CFU/mL|Ten Million Colony Forming Units per Milliliter	A unit of measurement of viable bacterial organisms in a unit volume of substance of interest defined as the number of 10 to the seventh power colony forming units in one liter of substance.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166097>	C48565	Degrees Per Second|deg/s|deg/s|deg/s|deg/s|deg/s|degree per second	A unit of angular velocity defined as the number of degrees per unit of time equal to one second.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|HL7 FHIR v5.0.0 R5 Unit of Measure Terminology|HL7 Unit of Measure Terminology
C166098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166098>	C48459	Degrees Squared|deg2|deg2|deg2|sq. deg.	A non-SI unit of solid angle equal to approximately 3.0462x10^-4 steradians.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166099>	C42575	Gram Per Unit|g/U|g/U|g/{U}|g/{U}	A unit of concentration or mass density equal to one gram of substance per unit(s) of substance.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C1660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1660>	C281	Anti-HIV Agent|Anti-Human Immunodeficiency Virus Agents	Any agent that prevents the human immunodeficiency virus (HIV) from reproducing.			Chemical Viewed Functionally	
C166100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166100>	C48568	Milliliter Per Second Per Square Meter|Milliliter Per Second Per Meter Squared|mL/s/m2|mL/s/m2|mL/s/m2|mL/sec/m2|ml/s/m2|ml/s/m2	A metric unit of volumetric flow rate defined as the rate at which one milliliter of matter travels during the period of time equal to one second per meter squared.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166101>	C67313	Steps Per Minute|steps/min|steps/min|{steps}/min|{steps}/min	The number of steps occurring within a minute unit of time.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166102>	C69180	Microvolts Squared|uV2|uV2|uV2	A unit of electromotive force equal to a microvolt squared.			Quantitative Concept	CDISC SDTM Terminology|CDISC SDTM Unit of Measure Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166103>	C25598	Cage Observation|CAGE OBSERVATION	An observation made on the contents of the animal's housing environment (e.g., presence of blood, vomit).			Activity	CDISC SEND Category for Clinical Observation Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166104>	C110937	Increased Bone Remodeling|BONE REMODELING, INCREASED	Increase in the removal of mineralized bone matrix and/or mature bone and the formation of new bone.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166105>	C117719	Hypospermatogenesis|HYPOSPERMATOGENESIS	A decrease in the number of germ cells but all stages of sperm cell development are present.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166106>	C35867	Lymph Node Intrasinusoidal Erythrocytes|Erythrocytes, Intrasinusoidal|INTRASINUSOIDAL ERYTHROCYTES	The presence of red blood cells within lymph node sinuses.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166107>	C41548	Decreased Secretion|SECRETION, DECREASED	Decrease in the amount of a secretory content present in the glandular lumen.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166108>	C41548	Increased Secretion|SECRETION, INCREASED	Increased amount of a secretory content present in the glandular lumen.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166109>	C35867	Increased Tingible Body Macrophages|TINGIBLE BODY MACROPHAGES, INCREASED	Increase in the amount of tingible body macrophages.			Finding	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16610>	C17254	ENV Protein|Envelope Protein	Proteins that comprise the membrane or envelope that encapsulates a virus. These proteins often require proteolytic cleavage for functional activity.			Amino Acid, Peptide, or Protein|Biologically Active Substance	
C166110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166110>	C25613	Test Article Percent Purity|TAPCTPUR	A relative measurement (percentage) of the fractional composition of the test article with respect to the active substance.			Conceptual Entity	CDISC SEND Terminology|CDISC SEND Trial Summary Parameter Long Name Terminology|CDISC SEND Trial Summary Parameter Short Name Terminology|Clinical Data Interchange Standards Consortium Terminology
C166111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166111>	C12877	Sinus Sigmoideus|Pars Sigmoid|Pars Signmoid|SIGMOID SINUS|Sigmoid Sinus	Either of the two dural venous sinuses that receive blood from the transverse sinus and empty into the internal jugular vein.			Body Space or Junction	CDISC SDTM Anatomical Location Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C166112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166112>	C71391|C71383	Maternal Half Sibling|Maternal Half-Sibling|Maternal Half-Sibling	A relative with whom you share a biological mother but you have different fathers.			Human	GDC Terminology|GDC Value Terminology
C166113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166113>	C71391|C132451	Paternal Half Sibling|Paternal Half-Sibling|Paternal Half-Sibling	A relative with whom you share a biological father but you have different mothers.			Human	GDC Terminology|GDC Value Terminology
C166114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166114>	C42709|C161420	Biological Parent|Natural Parent	The male who supplied the sperm or the female who supplied the egg which resulted in one's conception.			Human	ALL Authorized Value Terminology|ALL Stem Cell Transplant Table|AML Authorized Value Terminology|AML Stem Cell Transplant Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Stem Cell Transplant Table
C166115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166115>	C71408|C161421	Biological Niece|Niece Second Degree Relative	A daughter of one's biological sibling.			Human	GDC Terminology|GDC Value Terminology
C166116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166116>	C71395|C42709	Step Parent	A non-biological parent through current or prior marriage to the subject's biological or legal parent.			Human	
C166117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166117>	C71395|C150886	Step Child|Stepchild	A child of one's spouse, acquired through marriage.			Human	GDC Terminology|GDC Value Terminology
C166118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166118>	C71395|C25204	Step Sibling	A child of one's step parent.			Human	GDC Terminology|GDC Value Terminology
C166119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166119>	C25289|C166118	Stepbrother|Step Brother	A male child of one's step parent.			Human	GDC Terminology|GDC Value Terminology
C16611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16611>	C21069	Gene Rearrangement Process	Any DNA sequence rearrangement that results in the creation of a novel protein-coding capacity. Within certain genes, gene rearrangement is a normal part of development, facilitating the affinity maturation of B and T lymphocytes as well as class switching of immunoglobulins.			Genetic Function	
C166120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166120>	C223844|C156074	Oligometastatic Esophageal Adenocarcinoma	An esophageal adenocarcinoma that has metastasized to a limited number of sites.	Oligometastatic Esophageal Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C166121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166121>	C223844|C153319	Oligometastatic Gastric Adenocarcinoma	A gastric adenocarcinoma that has metastasized to a limited number of sites.	Oligometastatic Gastric Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C166122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166122>	C199169	Ifebemtinib|BI 853520|BI-853520|BI853520|FAK1 Inhibitor IN10018|IFEBEMTINIB|IN 10018|IN-10018|IN10018|PTK2 Inhibitor IN10018|Protein Tyrosine Kinase 2 Inhibitor BI 853520|Protein Tyrosine Kinase 2 Inhibitor IN10018	An orally bioavailable inhibitor of the non-receptor, cytoplasmic tyrosine kinase protein tyrosine kinase 2 (focal adhesion kinase 1; FAK1; FAK: PTK2) with potential antineoplastic activity. Upon oral administration, ifebemtinib targets and inhibits, in an adenosine triphosphate (ATP)-competitive manner, PTK2. This prevents PTK2-mediated downstream signaling and inhibits migration, proliferation, invasion, and survival in PTK2-overexpressing tumor cells. The cytoplasmic tyrosine kinase PTK2, a signal transducer for integrins overexpressed in various tumor cell types, is involved in tumor cell invasion, migration and proliferation.	Ifebemtinib		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C166123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166123>	C25165|C166117	Stepdaughter|Step Daughter	A female child of one's spouse, acquired through marriage.			Human	GDC Terminology|GDC Value Terminology
C166124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166124>	C25680|C166118	Stepsister|Step Sister	A female child of one's step parent.			Human	GDC Terminology|GDC Value Terminology
C166125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166125>	C25205|C166117	Stepson|Step Son	A male child of one's spouse, acquired through marriage.			Human	GDC Terminology|GDC Value Terminology
C166126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166126>	C71389	Great Grandparent|Great-Grandparent	A parent of one's grandparent.			Human	
C166127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166127>	C71383|C166126	Maternal Great Grandparent|Maternal Great-Grandparent	A parent of one's maternal grandparent.			Human	GDC Terminology|GDC Value Terminology
C166128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166128>	C71382|C166126	Paternal Great Grandparent|Paternal Great-Grandparent	A parent of one's paternal grandparent.			Human	GDC Terminology|GDC Value Terminology
C166129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166129>	C71394|C42709	Adoptive Parent	A parent in the parent-child relationship established by a legal adoption proceeding.			Human	
C16612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16612>		Gene|Genes|gene	A functional unit of heredity which occupies a specific position on a particular chromosome and serves as the template for a product that contributes to a phenotype or a biological function.			Gene or Genome	BRIDG Class Terminology|BRIDG Terminology
C166130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166130>	C71392|C150886	Adopted Child	A child in the parent-child relationship established by a legal adoption proceeding.			Human	
C166131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166131>	C25165|C166130	Adopted Daughter	A female child in the parent-child relationship established by a legal adoption proceeding.			Human	GDC Terminology|GDC Value Terminology
C166132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166132>	C25205|C166130	Adopted Son	A male child in the parent-child relationship established by a legal adoption proceeding.			Human	GDC Terminology|GDC Value Terminology
C166133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166133>	C25174|C166129	Adoptive Father	A male parent in the parent-child relationship established by a legal adoption proceeding.			Human	GDC Terminology|GDC Value Terminology
C166134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166134>	C25189|C166129	Adoptive Mother	A female parent in the parent-child relationship established by a legal adoption proceeding.			Human	GDC Terminology|GDC Value Terminology
C166135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166135>	C61074|C129825	RSK1-4 Inhibitor PMD-026|PMD 026|PMD-026|PMD026|RSK Inhibitor PMD-026	An orally bioavailable inhibitor of the serine/threonine kinase p90 ribosomal S6 kinase (p90RSK; RSK) subtypes 1-4, with high selectivity for RSK subtype 2 (RSK2), with potential antineoplastic activity. Upon administration of the RSK1-4 inhibitor PMD-026, this agent targets and inhibits the RSK subtypes, thereby inhibiting RSK-mediated signaling. This prevents the phosphorylation and activation of the transcription factor Y-box binding protein-1 (YB-1) and leads to cell cycle arrest, an induction of apoptosis, and an inhibition of tumor cell proliferation in RSK-expressing tumor cells. RSK is overexpressed in a variety of cancers, especially in triple negative breast cancer (TNBC). It plays a key role in tumor cell proliferation, differentiation, survival, and metastasis.	RSK1-4 Inhibitor PMD-026		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C166136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166136>	C201557	Engineered Mobilized Peripheral Blood-derived Donor Graft OGFT-001|OGFT 001|OGFT-001|OGFT001|OrcaGraft	An engineered donor graft derived from mobilized peripheral blood stem cells (PBSCs) that can potentially be used for immune reconstitution purposes. Upon administration of the engineered mobilized peripheral blood-derived donor graft OGFT-001 after an allogeneic hematopoietic cell transplantation, these cells provide hematopoietic cell recovery.	Engineered Mobilized Peripheral Blood-derived Donor Graft OGFT-001		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C166137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166137>	C28227|C159583|C112889	Zeripatamig|Anti-CD47/CD19 Bispecific Monoclonal Antibody TG-1801|Bispecific Monoclonal Antibody TG-1801|TG 1801|TG-1801|TG1801|ZERIPATAMIG	A bispecific monoclonal antibody composed of two single-chain variable fragments (scFv), one directed against the B-cell-specific membrane protein CD19, and another that is directed against the human cell surface antigen CD47, with potential immunostimulating, phagocytosis-inducing and antineoplastic activities. Upon administration of zeripatamig, the anti-CD19 moiety selectively targets and binds to CD19 on CD19-positive B-cells, thereby improving binding of the anti-CD47 moiety to the CD19+ malignant B-cells. The CD47 binding by TG-1801 blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of the CD19/CD47-expressing tumor cells. Additionally, blocking CD47 signaling activates an anti-tumor T-lymphocyte immune response and T-cell-mediated killing of CD19/CD47-expressing tumor cells. In addition, zeripatamig induces an anti-tumor activity through the induction of antibody dependent cellular cytotoxicity (ADCC). CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA), widely expressed on normal, healthy cells, such as red blood cells and platelets, and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate. CD19 is a membrane antigen that is widely expressed during B-cell development and in B-cell malignancies. By co-targeting CD47 and CD19, zeripatamig has the potential to overcome the limitations of existing CD47-targeted therapies by possibly avoiding the side effects caused by binding to CD47 on healthy hematopoietic stem cells (HSCs) which causes unwanted macrophage-mediated phagocytosis.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C166138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166138>	C217488	Pan-KRAS Inhibitor BI 1701963|BI 1701963|BI-1701963|BI1701963|PPI Inhibitor BI 1701963|Protein-protein Interaction Inhibitor BI 1701963|SOS1:KRAS Interaction Inhibitor BI 1701963	An orally available protein-protein interaction (PPI) inhibitor that targets the guanine nucleotide exchange factor Son of sevenless homolog 1 (SOS1), with potential antineoplastic activity. Upon oral administration, pan-KRAS inhibitor BI 1701963 selectively targets and binds to SOS1, thereby preventing the interaction of SOS1 with Kirsten rat sarcoma viral oncogene homolog (KRAS) in the guanosine diphosphate (GDP)-bound 'off' state, which is the inactivated state of KRAS. This abrogates the exchange of RAS-bound GDP for guanosine triphosphate (GTP) and prevents the formation of GTP-loaded KRAS, which is the activated 'on' state of KRAS. This prevents activation of downstream RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway by GTP-loaded KRAS. This inhibits mutant KRAS-dependent signaling and may inhibit growth and survival of KRAS-expressing tumor cells. KRAS is a member of the RAS family of oncogenes that is mutated in many cancer cell types. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell proliferation, survival, invasion, and metastasis. SOS1 regulates the KRAS GDP-GTP cycle and promotes nucleotide exchange and formation of 'active' KRAS-GTP.	Pan-KRAS Inhibitor BI 1701963		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C166139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166139>	C129822|C128036	Firastotug|ADG 116|ADG-116|ADG116|Anti-CTLA-4 Monoclonal Antibody ADG116|FIRASTOTUG	A human monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon intravenous administration, firastotug targets and binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.	Firastotug		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C16613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16613>	C19108	ENV|ENV Gene|Envelope Gene|Retroviral Envelope Gene	This retroviral gene, which encodes envelope glycoprotein, plays a role in viral coat structure, host cell recognition, and viral entry.			Gene or Genome	
C166140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166140>	C141215|C129822	Anti-CD20 Monoclonal Antibody MIL62|MIL 62|MIL-62|MIL62	A glyco-engineered recombinant humanized monoclonal antibody directed against the human B-cell-specific cell surface antigen CD20, with potential antineoplastic and immunomodulating activities. Upon administration of anti-CD20 monoclonal antibody MIL62, the antibody specifically targets and binds to CD20. This induces antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B-cells, which leads to B-cell apoptosis and the inhibition of tumor cell proliferation. In addition, MIL62 inhibits CD20-mediated signaling which further induces apoptosis in and inhibits proliferation of CD20-expressing tumor cells. CD20, a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B-cells during most stages of B-cell development, is often overexpressed in B-cell malignancies.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C166141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166141>	C129820	Macrocycle-bridged STING Agonist E7766|E 7766|E-7766|E-7766|E7766|MBSA E7766|Stimulator of Interferon Genes Agonist E7766|Sting Agonist E7766	An agonist of macrocycle-bridged stimulator of interferon genes (STING) protein, with potential immunoactivating and antineoplastic activities. Upon intravenous administration, macrocycle-bridged STING agonist (MBSA) E7766 targets and binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor microenvironment (TME). This leads to the production of pro-inflammatory cytokines, including interferons (IFNs). Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens (TAAs) by CD8alpha-positive and CD103-positive dendritic cells (DCs) to cytotoxic T-lymphocytes (CTLs). This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis. Compared to conventional STING agonists, MBSA E7766 allows for conformational rigidity of the unique macrocycle bridge which enhances its stability and STING affinity, thereby increasing its efficacy.	Macrocycle-bridged STING Agonist E7766		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C166142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166142>	C4345|C172132	Recurrent Myeloproliferative Neoplasm	The reemergence of a myeloproliferative neoplasm after a period of remission.	Recurrent Myeloproliferative Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C166143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166143>	C27262|C172132	Recurrent Myelodysplastic/Myeloproliferative Neoplasm	The reemergence of a myelodysplastic/myeloproliferative neoplasm after a period of remission.	Recurrent Myelodysplastic/Myeloproliferative Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C166144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166144>	C20993	Acute Oxaliplatin-Induced Peripheral Neuropathy Measure|Acute OIPN Measure|OIPN|OIPN Measure	A questionnaire for measuring the severity of neuropathy symptoms that a patient is experiencing following chemotherapy with oxaliplatin.			Intellectual Product	
C166145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166145>	C175990	Sensitivity to Touching Cold Items Question|Did you experience sensitivity to touching cold items within the last 24 hours|Experience Sensitivity to Touching Cold Items|Sensitivity to Touching Cold Items	A question about whether an individual experienced sensitivity to touching cold items.			Intellectual Product	Acute Oxaliplatin-Induced Peripheral Neuropathy Measure
C166146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166146>	C173518|C173454	Discomfort Swallowing Cold Liquids Question|Did you experience discomfort swallowing cold liquids within the last 24 hours|Discomfort Swallowing Cold Liquids|Experience Discomfort Swallowing Cold Liquids	A question about whether an individual experienced discomfort swallowing cold liquids.			Intellectual Product	Acute Oxaliplatin-Induced Peripheral Neuropathy Measure
C166147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166147>	C173518	Have Throat Discomfort Question|Did you notice any throat discomfort within the last 24 hours|Have Throat Discomfort|Notice Throat Discomfort;Throat Discomfort	A question about whether an individual noticed any throat discomfort.			Intellectual Product	Acute Oxaliplatin-Induced Peripheral Neuropathy Measure
C166148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166148>	C173981	Have Muscle Cramps Question|Did you suffer from muscle cramps within the last 24 hours|Have Muscle Cramps|Suffer Muscle Cramps	A question about whether an individual suffered from muscle cramps.			Intellectual Product	Acute Oxaliplatin-Induced Peripheral Neuropathy Measure
C166149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166149>	C173398	Difficulty Buttoning Shirt or Tying Shoelaces Question|Did you have any difficulties buttoning your shirt or tying shoelaces within the last 24 hours|Difficulty Buttoning Shirt or Tying Shoelaces	A question about whether an individual had difficulties buttoning their shirt or tying their shoelaces.			Intellectual Product	Acute Oxaliplatin-Induced Peripheral Neuropathy Measure
C16614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16614>	C16620	GAG Gene|GAG|Group-Specific Antigen Gene	This gene is involved in retroviral core structure.			Gene or Genome	
C166150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166150>	C173933|C173812	Experience Other Side Effects From Chemotherapy Treatment Question|Did you experience any other side effects from the chemotherapy treatment that we did not mention|Experience Other Side Effects From Chemotherapy Treatment|Experience Other Side Effects From Chemotherapy Treatment Not Mentioned	A question about whether an individual experienced other side effects from chemotherapy treatment that was not mentioned.			Intellectual Product	Acute Oxaliplatin-Induced Peripheral Neuropathy Measure
C166151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166151>	C3207	Head and Neck Lymphedema|Lymphedema of the Head and Neck|Lymphedema of the Head and Neck	Lymphedema that manifests in the head and neck.	Lymphedema of the Head and Neck		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C166152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166152>	C61242	Severe Congenital Neutropenia|SCN	A congenital disorder characterized by chronic neutropenia with absolute neutrophil count less than 500/uL and arrest of neutrophil maturation at the promyelocyte/myelocyte level. It is inherited in autosomal recessive or autosomal dominant patterns. Sporadic cases have also been reported. It is usually diagnosed in the first year of life. Patients present with frequent and life-threatening infections.	Severe Congenital Neutropenia		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C166153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166153>	C176624	Severe Congenital Neutropenia Type 3, Autosomal Recessive|Autosomal Recessive SCN, Type 3|Kostmann Syndrome|Kostmann disease|Kostmann neutropenia|Kostmann syndrome|Neutropenia, Severe Congenital, 3, Autosomal Recessive	Severe congenital neutropenia inherited in an autosomal recessive pattern and caused by HCLS1-associated protein X-1 (HAX1) mutations.			Disease or Syndrome	Cellosaurus Disease Terminology
C166154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166154>	C20993	Trier Social Stress Test|TSST	A protocol for induction of moderate psychological stress in a laboratory setting and for evaluating its effects on physiological responses. It mainly consists of a 10 minute anticipation period, followed by a 10 minute test period during which the subject has to deliver a free speech and perform mental arithmetic in front of an audience. This protocol has been found to induce changes in the concentration of adrenocorticotropic hormone, cortisol (serum and saliva), somatotropin, and prolactin, as well as significant increases in heart rate.	Trier Social Stress Test		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C166155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166155>	C166152	Autosomal Dominant Severe Congenital Neutropenia|Autosomal Dominant SCN	Severe congenital neutropenia inherited in an autosomal dominant pattern. Mutations in the ELANE gene have been reported in approximately half of the cases.			Disease or Syndrome	
C166156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166156>	C3058|C206428	Resectable Glioblastoma	A glioblastoma that is amenable to surgical resection.	Resectable Glioblastoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C166157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166157>	C226653	Complete Disagreement|Completely Disagree|Disagree Completely|Full Disagreement|Fully Disagree	A subjective answer of complete disagreement.			Intellectual Product	
C166158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166158>	C105906	JAK2 NP_004963.1:p.G996R|JAK2 G996R|JAK2 Gly996Arg|JAK2 NP_004963.1:p.Gly996Arg|JAK2 p.G996R|JAK2 p.Gly996Arg|Janus Kinase 2 G996R|Janus Kinase 2 Gly996Arg|NP_004963.1:p.G996R|NP_004963.1:p.Gly996Arg|Tyrosine-Protein Kinase JAK2 G996R|Tyrosine-Protein Kinase JAK2 Gly996Arg	A change in the amino acid residue at position 996 in the tyrosine-protein kinase JAK2 protein where glycine has been replaced by arginine.			Cell or Molecular Dysfunction	
C166159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166159>	C174179|C136641	JAK2 NM_004972.3:c.2047A>G|JAK-2 c.2047A>G|JAK2 c.2047A>G|JTK10 c.2047A>G|Janus Kinase 2 c.2047A>G|NM_004972.3:c.2047A>G	A nucleotide substitution at position 2047 of the coding sequence of the JAK2 gene where adenine has been mutated to guanine.			Cell or Molecular Dysfunction	
C16615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16615>	C20420	Homeobox Gene|Homeobox Family Gene|Homeodomain Gene|Hox Gene	A family of genes that contain a highly conserved sequence of approximately 180 nucleotides, which encode an approximately 60 amino acid helix-turn-helix DNA binding domain made up of 2 antiparallel alpha helices and one nearly perpendicular alpha helix connected by short chains of unstructured amino acid sequences. This gene family is involved in transcriptional regulation during embryonic development.			Gene or Genome	
C166160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166160>	C105906	JAK2 NP_004963.1:p.R683G|JAK2 Arg683Gly|JAK2 NP_004963.1:p.Arg683Gly|JAK2 R683G|JAK2 p.Arg683Gly|JAK2 p.R683G|Janus Kinase 2 Arg683Gly|Janus Kinase 2 R683G|NP_004963.1:p.Arg683Gly|NP_004963.1:p.R683G|Tyrosine-Protein Kinase JAK2 Arg683Gly|Tyrosine-Protein Kinase JAK2 R683G	A change in the amino acid residue at position 683 in the tyrosine-protein kinase JAK2 protein where arginine has been replaced by glycine.			Cell or Molecular Dysfunction	
C166161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166161>	C97928	JAK3 Protein Variant|JAK-3 Protein Variant|Janus Kinase 3 Protein Variant|L-JAK Protein Variant|Leukocyte Janus Kinase Protein Variant|Tyrosine-Protein Kinase JAK3 Protein Variant	A variation in the amino acid sequence for the tyrosine-protein kinase JAK3 protein.			Cell or Molecular Dysfunction	Pediatric Oncology Target Molecular Abnormalities Terminology
C166162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166162>	C166161	JAK3 NP_000206.2:p.L857P|JAK-3 L857P|JAK-3 Leu857Pro|JAK3 L857P|JAK3 Leu857Pro|JAK3 NP_000206.2:p.Leu857Pro|JAK3 p.L857P|JAK3 p.Leu857Pro|Janus Kinase 3 L857P|Janus Kinase 3 Leu857Pro|L-JAK L857P|L-JAK Leu857Pro|Leukocyte Janus Kinase L857P|Leukocyte Janus Kinase Leu857Pro|NP_000206.2:p.L857P|NP_000206.2:p.Leu857Pro|Tyrosine-Protein Kinase JAK3 L857P|Tyrosine-Protein Kinase JAK3 Leu857Pro	A change in the amino acid residue at position 857 in the tyrosine-protein kinase JAK3 protein where leucine has been replaced by proline.			Cell or Molecular Dysfunction	
C166163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166163>	C51896	Bilateral Pelvic Lymph Node Dissection	Removal of one or more pelvic lymph nodes from both sides of the body.			Therapeutic or Preventive Procedure	
C166164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166164>	C126819	KIT NP_000213.1:p.S590I|CD117 Antigen S590I|CD117 Antigen Ser590Ile|KIT NP_000213.1:p.Ser590Ile|KIT S590I|KIT Ser590Ile|KIT p.S590I|KIT p.Ser590Ile|Mast/Stem Cell Growth Factor Receptor Kit S590I|Mast/Stem Cell Growth Factor Receptor Kit Ser590Ile|NP_000213.1:p.S590I|NP_000213.1:p.Ser590Ile|Proto-Oncogene Tyrosine-Protein Kinase Kit S590I|Proto-Oncogene Tyrosine-Protein Kinase Kit Ser590Ile|Proto-Oncogene c-Kit S590I|Proto-Oncogene c-Kit Ser590Ile|Stem Cell Factor Receptor S590I|Stem Cell Factor Receptor Ser590Ile|Tyrosine-Protein Kinase Kit S590I|Tyrosine-Protein Kinase Kit Ser590Ile|c-KIT S590I|c-KIT Ser590Ile|c-KIT p.S590I|c-KIT p.Ser590Ile	A change in the amino acid residue at position 590 in the mast/stem cell growth factor receptor Kit protein where serine has been replaced by isoleucine.			Cell or Molecular Dysfunction	
C166165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166165>	C28554	Treatment-Related Mortality|TRM	A death that is considered to be causally linked to a treatment.			Quantitative Concept	ALL Authorized Value Terminology|ALL Survival Characteristics Table|AML Authorized Value Terminology|AML Survival Characteristics Table|EWS Authorized Value Terminology|EWS Survival Characteristics Table|GCT Authorized Value Terminology|GCT Survival Characteristics Table|HL Authorized Value Terminology|HL Survival Characteristics Table|OS Authorized Value Terminology|OS Survival Characteristics Table
C166166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166166>	C97928	MAP2K2 Protein Variant|Dual Specificity Mitogen-Activated Protein Kinase Kinase 2 Protein Variant|ERK Activator Kinase 2 Protein Variant|MAP Kinase Kinase 2 Protein Variant|MAPK/ERK Kinase 2 Protein Variant|MAPKK 2 Protein Variant|MEK 2 Protein Variant|Mitogen-Activated Protein Kinase Kinase 2 Protein Variant	A variation in the amino acid sequence for the dual specificity mitogen-activated protein kinase kinase 2 protein.			Cell or Molecular Dysfunction	Pediatric Oncology Target Molecular Abnormalities Terminology
C166167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166167>	C153256|C136639	MAP2K2 NM_030662.3:c.383C>T|MAP2K2 c.383C>T|MAPKK2 c.383C>T|MEK2 c.383C>T|MKK2 c.383C>T|Mitogen-Activated Protein Kinase Kinase 2 c.383C>T|NM_030662.3:c.383C>T|PRKMK2 c.383C>T	A nucleotide substitution at position 383 of the coding sequence of the MAP2K2 gene where cytosine has been mutated to thymine.			Cell or Molecular Dysfunction	
C166168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166168>	C166166	MAP2K2 NP_109587.1:p.P128L|Dual Specificity Mitogen-Activated Protein Kinase Kinase 2 P128L|Dual Specificity Mitogen-Activated Protein Kinase Kinase 2 Pro128Leu|ERK Activator Kinase 2 P128L|ERK Activator Kinase 2 Pro128Leu|MAP Kinase Kinase 2 P128L|MAP Kinase Kinase 2 Pro128Leu|MAP2K2 NP_109587.1:p.Pro128Leu|MAP2K2 P128L|MAP2K2 Pro128Leu|MAP2K2 p.P128L|MAP2K2 p.Pro128Leu|MAPK/ERK Kinase 2 P128L|MAPK/ERK Kinase 2 Pro128Leu|MAPKK 2 P128L|MAPKK 2 Pro128Leu|MEK 2 P128L|MEK 2 Pro128Leu|Mitogen-Activated Protein Kinase Kinase 2 P128L|Mitogen-Activated Protein Kinase Kinase 2 Pro128Leu|NP_109587.1:p.P128L|NP_109587.1:p.Pro128Leu	A change in the amino acid residue at position 128 in the dual specificity mitogen-activated protein kinase kinase 2 protein where proline has been replaced by leucine.			Cell or Molecular Dysfunction	
C166169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166169>	C2124	Copper Cu 64 NOTA-PSMAi-PEG-Cy5.5-C' Dots|(64Cu)-labeled PSMA-targeting -PEG Cy5.5-C' Dots|64Cu-NOTA-PSMA-PEG-Cy5.5-C' Dot Tracer|64Cu-NOTA-PSMA-PEG-Cy5.5-C' Dots|64Cu-NOTA-PSMAi-PEG-Cy5.5-C' Dots	An imaging agent composed of silica-based nanoparticles labeled with a near-infrared (NIR) fluorophore, cyanine 5.5 (Cy5.5), and surrounded by polyethylene glycol (PEG) chains attached to a human prostate-specific membrane antigen (PSMA) inhibitor (PSMAi) and labeled with, via the macrocyclic chelating agent 1,4,7-triazacyclononane-N,N',N''-triacetic acid (NOTA), the radioisotope copper Cu 64, with potential tumor-selective diagnostic properties upon positron emission tomography (PET) imaging. Upon administration of the copper Cu 64 NOTA-PSMAi-PEG-Cy5.5-C' dots, the PSMAi moiety selectively targets and binds to PSMA expressed on tumor cells. Upon PET imaging, PSMA-expressing tumor cells can be visualized and assessed. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells. The nanoparticle formulation may allow for enhanced uptake in PSMA-positive tumors.	Copper Cu 64 NOTA-PSMAi-PEG-Cy5.5-C' Dots		Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C16616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16616>	C16812	MHC Class II Gene|Class II MHC|MHC Class II	A family of genes expressed mainly by antigen presenting cells that encode major histocompatibility complex proteins and are involved in the presentation of fragments from phagocytized extracellular proteins to cytotoxic lymphocytes.	MHC Class II Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C166171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166171>	C3513|C216181	Localized Esophageal Carcinoma|Non-Metastatic Esophageal Carcinoma|Non-Metastatic Esophageal Carcinoma	An esophageal carcinoma that is confined to the site in which it initially manifested without evidence of spread to other anatomic sites.	Non-Metastatic Esophageal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C166172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166172>	C36279	Non-Recurrent Esophageal Carcinoma	A finding indicating that a patient with a history of esophageal carcinoma does not have evidence of recurrent disease.	Non-Recurrent Esophageal Carcinoma		Finding	CTRP Disease Terminology|CTRP Terminology
C166173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166173>	C45233	Non-Recurrent Lung Carcinoma	A finding indicating that a patient with a history of lung carcinoma does not have evidence of recurrent disease.	Non-Recurrent Lung Carcinoma		Finding	CTRP Disease Terminology|CTRP Terminology
C166174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166174>	C93221	Fermented Soybean Extract|Fermented Soy|Fermented Soy Extract|Q-Can Plus	A nutritional supplement composed of an organic fermented soybean extract, with potential antioxidant, chemoprotective, anti-inflammatory, and immunostimulatory activities. During the microbial fermentation process, the nutrients in the soybean are broken down in many different substances, such as fatty acids, various amino acids and isoflavones, such as genistein and daidzein. The extract also contains other beneficial dietary nutrients, including certain trace elements and vitamins. Upon oral administration of the fermented soybean extract, the active ingredients in the extract provide essential nutrients to the body and may have immunostimulatory, pro-apoptotic, anti-proliferative, and anti-inflammatory activities and may scavenge free radicals. In addition, many ingredients in the soy extract may modulate key estrogen and androgen signaling pathways, which may further induce apoptosis and reduce proliferation in tumor cells in which these hormones are overactivated. The fermentation process allows for enhanced bioavailability of the soy nutrients.	Fermented Soybean Extract		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C166175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166175>	C3331	Large Pleural Effusion	A pleural effusion that is typically characterized as more than one liter.			Finding	
C166176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166176>	C166175	Recurrent Large Pleural Effusion	The reemergence of a large pleural effusion after a period of remission.	Recurrent Large Pleural Effusion		Finding	CTRP Disease Terminology|CTRP Terminology
C166177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166177>	C217652	Baloxavir Marboxil|(((12aR)-12-((11S)-7,8-Difluoro-6,11-dihydrodibenzo(b,E)thiepin-11-yl)-6,8-dioxo-3,4,6,8,12,12ahexahydro-1H-(1,4)oxazino(3,4-C)pyrido(2,1-F)(1,2,4)triazin-7-yl)oxy)methyl Methyl Carbonate|BALOXAVIR MARBOXIL|BXM|Carbonic Acid, (((12aR)-12-((11S)-7,8-Difluoro-6,11-dihydrodibenzo(b,E)thiepin-11-yl)-3,4,6,8,12,12a-hexahydro-6,8-dioxo-1H-(1,4)oxazino(3,4-C)pyrido(2,1-F)(1,2,4)triazin-7-yl)oxy)methyl Methyl Ester|Xofluza	An orally bioavailable prodrug and influenza cap-dependent endonuclease (CEN) inhibitor, with antiviral activity. Upon administration of baloxavir marboxil, the agent is converted by hydrolysis to its active metabolite baloxavir. Baloxavir targets, binds to and inhibits the CEN activity of the influenza polymerase acidic (PA) protein, an influenza virus-specific enzyme in the viral RNA polymerase complex required for the initiation of influenza gene transcription. By inhibiting PA endonuclease, influenza virus mRNA replication is halted. This reduces viral load and prevents further influenza infection.	Baloxavir Marboxil		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C166178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166178>	C15632	Neurotoxic Chemotherapy	Chemotherapy that causes damage to the nervous system.			Therapeutic or Preventive Procedure	
C166179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166179>	C4938|C3720	Localized Anaplastic Large Cell Lymphoma	Anaplastic large cell lymphoma that is confined to a specific site without evidence of spread to other anatomic sites.	Localized Anaplastic Large Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16617>	C16812	MHC Class I Gene|Class I MHC|MHC Class I	A family of genes that encode major histocompatibility complex proteins and are involved in the presentation of cytoplasmic protein fragments to cytotoxic lymphocytes.			Gene or Genome	
C166180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166180>	C3720|C217102	Advanced Anaplastic Large Cell Lymphoma	An anaplastic large cell lymphoma that has spread extensively to distant anatomic sites.	Advanced Anaplastic Large Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C166181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166181>	C36263|C102871	Metastatic Primary Malignant Central Nervous System Neoplasm	A malignant neoplasm that arises from the central nervous system and has spread from its original site of growth to other sites.	Metastatic Primary Malignant Central Nervous System Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C166182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166182>	C8524|C166181	Locally Advanced Primary Malignant Central Nervous System Neoplasm	A malignant neoplasm that arises from the central nervous system and has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Primary Malignant Central Nervous System Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C166183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166183>	C100110	CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|FAC075TN|Functional Assessment of Cancer Therapy-Cognitive Function Version 3 Questionnaire Test Name|QS-FACT-COG Version 3 TEST	Test names of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166184>	C100110	CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|FAC075TC|Functional Assessment of Cancer Therapy-Cognitive Function Version 3 Questionnaire Test Code|QS-FACT-COG Version 3 TESTCD	Test codes of questionnaire questions associated with the Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166185>	C100110	CDISC Questionnaire WPAI-GH Version 2 Test Name Terminology|QS-WPAI-GH Version 2 TEST|The Work Productivity and Activity Impairment - General Health Version 2.0 Questionnaire Test Name|WPAI02TN	Test names of questionnaire questions associated with the Work Productivity and Activity Impairment - General Health Version 2.0 (WPAI-GH Version 2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166186>	C100110	CDISC Questionnaire WPAI-GH Version 2 Test Code Terminology|QS-WPAI-GH Version 2 TESTCD|The Work Productivity and Activity Impairment - General Health Version 2.0 Questionnaire Test Code|WPAI02TC	Test codes of questionnaire questions associated with the Work Productivity and Activity Impairment - General Health Version 2.0 (WPAI-GH Version 2) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166187>	C115302	CDISC Functional Test HD-CAB Test Name Terminology|FT-HD-CAB TEST|HDCAB1TN|Huntington's Disease Cognitive Assessment Battery Functional Test Test Name	Test names of functional test questions associated with the Huntington's Disease Cognitive Assessment Battery (HD-CAB) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166188>	C115302	CDISC Functional Test HD-CAB Test Code Terminology|FT-HD-CAB TESTCD|HDCAB1TC|Huntington's Disease Cognitive Assessment Battery Functional Test Test Code	Test codes of functional test questions associated with the Huntington's Disease Cognitive Assessment Battery (HD-CAB) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166189>	C115302	CDISC Functional Test RFWT Version 1 Test Name Terminology|FT-RFWT Version 1 TEST|ROCK01TN|Rockport One Mile Walk Test Version 1.0 Functional Test Test Name	Test names of functional test questions associated with the Rockport One Mile Walk Test Version 1.0 (RFWT Version 1) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16618>	C16620	POL Gene|POL	This gene is involved in the replication of the retroviral genome.			Gene or Genome	
C166190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166190>	C115302	CDISC Functional Test RFWT Version 1 Test Code Terminology|FT-RFWT Version 1 TESTCD|ROCK01TC|Rockport One Mile Walk Test Version 1.0 Functional Test Test Code	Test codes of functional test questions associated with the Rockport One Mile Walk Test Version 1.0 (RFWT Version 1) for the Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM).			Intellectual Product	CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166191>	C211913	FACT-COG Version 3 Questionnaire Question	A question associated with the FACT-COG Version 3 questionnaire.			Intellectual Product	
C166192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166192>	C211913	WPAI-GH Version 2 Questionnaire Question	A question associated with the WPAI-GH Version 2 questionnaire.			Intellectual Product	
C166193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166193>	C211913	HD-CAB Functional Test Question	A question associated with the HD-CAB functional test.			Intellectual Product	
C166194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166194>	C211913	RFWT Version 1 Functional Test Question	A question associated with the RFWT Version 1 functional test.			Intellectual Product	
C166195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166195>	C25289	Adopted Brother	A male sibling who is legally adopted by one's biological parent or legal guardian.			Human	GDC Terminology|GDC Value Terminology
C166196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166196>	C25680	Adopted Sister	A female sibling who is legally adopted by one's biological parent or legal guardian.			Human	GDC Terminology|GDC Value Terminology
C166197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166197>	C71394|C25289	Male Sibling of Adopted Child	A male sibling of an adopted child. The said male is a biological or legal child of the parents who facilitated the adoption.			Human	GDC Terminology|GDC Value Terminology
C166198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166198>	C71394|C25680	Female Sibling of Adopted Child	A female sibling of an adopted child. The said female is a biological or legal child of the parents who facilitated the adoption.			Human	GDC Terminology|GDC Value Terminology
C166199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166199>	C48572	Agent Unit of Measure|agent units of measure|agent_units_of_measure|treatment dose units|treatment_dose_units	The unit of measure that is associated with an agent for administration.			Quantitative Concept	GDC Property Terminology|GDC Terminology|ICDC Property Terminology|ICDC Terminology
C16619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16619>	C16620	HIV TAT Gene|HIV tat|Human Immunodeficiency Virus Transactivating Regulatory Protein Gene|TAT|Trans-Activator of Transcription Gene|tat	This HIV gene, which encodes protein tat, is involved in the positive regulation of viral gene transcription.			Gene or Genome	
C1661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1661>	C1909	Nucleic Acid Synthesis Inhibitor|Inhibitors, Nucleic Acid Synthesis	A pharmacological agent that inhibits DNA replication or RNA synthesis.			Chemical Viewed Functionally	
C166200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166200>	C52680	Adverse Event Severity Grade|AE_GRADE|AE_GRADE|AE_GRADE|AE_GRADE|AE_GRADE|AE_GRADE|adverse event grade|adverse_event_grade	A numeric value corresponding to the degree of severity of an adverse event.			Finding	ALL Adverse Events Table|ALL Variable Terminology|AML Adverse Events Table|AML Variable Terminology|EWS Adverse Events Table|EWS Variable Terminology|GCT Adverse Events Table|GCT Variable Terminology|HL Adverse Events Table|HL Variable Terminology|ICDC Property Terminology|ICDC Terminology|OS Adverse Event Table|OS Variable Terminology
C166201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166201>	C48570	Percent of Glass in Analysis Area|Analysis Area Percentage Glass|analysis area percentage glass|analysis_area_percentage_glass	The area of a sample on a slide that is represented by glass; the area of the sample that represents gaps in the sample.			Quantitative Concept	ICDC Property Terminology|ICDC Terminology
C166202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166202>	C166204	Percent Pigmented Tumor in Analysis Area|Analysis Area Percentage Pigmented Tumor|analysis area percentage pigmented tumor|analysis_area_percentage_pigmented_tumor	The area of a sample on a slide that is represented by pigmented tumor tissue, which will be analyzed.			Quantitative Concept	ICDC Property Terminology|ICDC Terminology
C166203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166203>	C166245	Percent Stroma in Analysis Area|Analysis Area Percentage Stroma|analysis area percentage stroma|analysis_area_percentage_stroma	The percentage of the analysis area that is represented by stromal tissue.			Quantitative Concept	ICDC Property Terminology|ICDC Terminology
C166204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166204>	C166246	Percent Tumor in Analysis Area|Analysis Area Percentage Tumor|analysis area percentage tumor|analysis_area_percentage_tumor	The percentage of the analysis area that is represented by tumor tissue.			Quantitative Concept	ICDC Property Terminology|ICDC Terminology
C166205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166205>	C25244	Area of Analysis|analysis area|analysis_area	The total area of a sample that is used for analysis.			Spatial Concept	ICDC Property Terminology|ICDC Terminology
C166206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166206>	C68617	Chemotherapeutic Cycle End Date|date of cycle end|date_of_cycle_end	The date on which a chemotherapeutic cycle is ended.			Temporal Concept	ICDC Property Terminology|ICDC Terminology
C166207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166207>	C68616	Chemotherapeutic Cycle Start Date|date of cycle start|date_of_cycle_start	The date on which a chemotherapeutic cycle is started.			Temporal Concept	ICDC Property Terminology|ICDC Terminology
C166208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166208>	C25337	Chemotherapeutic Cycle Number|CYCLE_NUMBER|Cycle Number|Therapeutic Cycle Number|cycle number|cycle_number|number of cycles|number_of_cycles	The number of the individual chemotherapeutic cycle.			Quantitative Concept	GDC Property Terminology|GDC Terminology|HL Course Timing Table|HL Total Dose Table|HL Variable Terminology|ICDC Property Terminology|ICDC Terminology
C166209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166209>	C25365	Cohort Description|cohort description|cohort_description	The description of the characteristics that define a cohort.			Intellectual Product	ICDC Property Terminology|ICDC Terminology
C16620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16620>	C20157	Viral Gene	Genes of viral origin.			Gene or Genome	
C166210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166210>	C25488	Cohort Dose|cohort dose|cohort_dose	The dose of medication administered to a particular cohort.			Conceptual Entity	ICDC Property Terminology|ICDC Terminology
C166211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166211>	C226739	Do Not Own Smartphone or Tablet|I do not own a smartphone/tablet	A response indicating that an individual does not own a smartphone or tablet.			Intellectual Product	
C166212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166212>	C226739	Have Concerns About Data Privacy or Security with the App|I have concerns about data privacy/security with the app	A response indicating that an individual has concerns about data privacy or security with the app.			Intellectual Product	
C166213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166213>	C226739	Do Not Want to Download Apps to Personal Smartphone or Tablet for the Trial|I do not want to download apps to my personal smartphone/tablet for the trial	A response indicating that an individual does not want to download apps to their personal smartphone or tablet for the trial.			Intellectual Product	
C166214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166214>	C226688	Do Not Have Wi-Fi and/or Have Concerns with Having Reliable Internet Connection|I do not have a Wi-Fi connection and/or have concerns with using reliable internet connection	A response indicating that an individual does not have a Wi-Fi connection and/or has concerns with using a reliable internet connection.			Intellectual Product	
C166215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166215>	C226688	Have Concerns About Data Usage and/or no Data Plan|I have concerns about data usage and/or no data plan	A response indicating that an individual has concerns about data usage and/or no data plan.			Intellectual Product	
C166216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166216>	C226739	Uncomfortable and/or Unfamiliar with Technology|I am uncomfortable and/or unfamiliar with technology	A response indicating that an individual is uncomfortable and/or unfamiliar with technology.			Intellectual Product	
C166217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166217>	C226739|C176243	Have Difficulties Using Smartphones or Tablets|I have difficulties using smartphones/tablets (seeing information on the screen, using a touch screen, etc.)	A response indicating that an individual has difficulties using smartphones or tablets.			Intellectual Product	
C166218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166218>	C25164	Date of Best Response|date of best response|date_of_best_response	The date on which the best response to therapy was observed and recorded.			Temporal Concept	ICDC Property Terminology|ICDC Terminology
C166219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166219>	C25164	Date of Disease Progression|date of disease progression|date_of_disease_progression	The date on which disease progression was observed and recorded.			Temporal Concept	ICDC Property Terminology|ICDC Terminology
C16621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16621>	C16351	Genetic Engineering|Biotechnology, Genetic Engineering|Gene Splicing|Genetically Engineered|Molecular Biology, Genetic Engineering|Recombinant DNA Technology	The application of genetic-based biotechnology to modify the characteristics of an organism by cutting, splicing, and transferring genetic materials, especially DNA, from one or more species of organism.			Molecular Biology Research Technique	
C166220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166220>	C25164	Date Off Treatment|Off Treatment Date|date off treatment|date_off_treatment	The date on which a subject is no longer receiving therapy.			Temporal Concept	ICDC Property Terminology|ICDC Terminology
C166221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166221>	C25337	Treatment Cycle Day Number|Cycle Day Number|Day in Cycle|day in cycle|day_in_cycle	A number that indicates the position of a day within a treatment cycle.			Temporal Concept	ICDC Property Terminology|ICDC Terminology
C166222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166222>	C2124	Fluorine F 18-BMS-986229|18F-BMS-986229|Fluorine F 18 BMS-986229|Fluorine F 18-labeled BMS-986229	A radiotracer composed of BMS-986229, a tracer targeting programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), labeled with the radioisotope fluorine F 18, with potential use for assessing PD-L1 tumor antigen expression using positron emission tomography (PET). Upon administration of fluorine F 18-BMS-986229, the BMS-986229 moiety targets and binds to PD-L1 expressed on certain tumor cells. Upon PET imaging, the radiotracer can be visualized and the extent of PD-L1 expression can be assessed.	Fluorine F 18-BMS-986229		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C166224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166224>	C93399	Enrollment Document Number|enrollment document number|enrollment_document_number	The identifier assigned to an enrollment document.			Intellectual Product	ICDC Property Terminology|ICDC Terminology
C166225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166225>	C15275	Complete Lymph Node Dissection|CLND|Complete Lymphadenectomy|Completion Lymph Node Dissection|Completion Lymphadenectomy	Surgical removal of all lymphatic tissue in a nodal basin.			Health Care Activity	
C166226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166226>	C25162	Evaluation Code|evaluation code|evaluation_code	The code assigned to an evaluation.			Intellectual Product	ICDC Property Terminology|ICDC Terminology
C166227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166227>	C70710	Evaluation Sequence Number|Evaluation Number|evaluation number|evaluation_number	The number assigned to an evaluation, indicating where a particular evaluation falls within a sequence of multiple evaluations.			Quantitative Concept	ICDC Property Terminology|ICDC Terminology
C166228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166228>	C156846	Follow-Up Type of Contact|Follow Up Type of Contact|contact type|contact_type	A description of the type of interaction that occurs between provider and subject during the follow-up period.			Conceptual Entity	ICDC Property Terminology|ICDC Terminology
C166229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166229>	C25180	Normal or Tumor Sample Pathology Indicator|General Sample Pathology Indicator|general sample pathology|general_sample_pathology|specimen type|specimen_type|tumor descriptor|tumor_descriptor	Specifies whether a sample is derived from normal or tumor-bearing tissue.			Conceptual Entity	CTDC Property Terminology|GDC Property Terminology|GDC Terminology|ICDC Property Terminology|ICDC Terminology
C16622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16622>	C68753	Genetic Marker|genetic marker	A segment of DNA with an identifiable physical location on a chromosome and whose inheritance can be followed.			Nucleotide Sequence	
C166230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166230>	C25180	Histopathology-Cytopathology Indicator|histology cytopathology|histology_cytopathology	An indicator denoting whether a diagnosis was assigned based on histopathology or cytopathology.			Conceptual Entity	ICDC Property Terminology|ICDC Terminology
C166231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166231>	C25365	Lesion Description|lesion description|lesion_description	Specifies the description of a localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.			Intellectual Product	ICDC Property Terminology|ICDC Terminology
C166232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166232>	C13717	Lesion Site|LESION_SITE|Location|lesion site|lesion_site	Specifies the anatomic site of a localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.			Body Location or Region	CRF6 DIPG Imaging Assessment Morphology Table|CRF6 DMG Imaging Assessment Table|HL Lesion Characteristics Table|HL Variable Terminology|ICDC Property Terminology|ICDC Terminology
C166233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166233>	C192240	Medication Acutal Unit of Measure|medication actual units of measure|medication_actual_units_of_measure	The actual unit of measure used to quantify an administered dose of a therapeutic agent to a subject.			Quantitative Concept	ICDC Property Terminology|ICDC Terminology
C166234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166234>	C166259	Missed Dose Unit of Measure|missed dose units of measure|missed_dose_units_of_measure	The unit of measure used to quantify a missed dose of a therapeutic agent to a subject.			Quantitative Concept	ICDC Property Terminology|ICDC Terminology
C166235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166235>	C25337	Medication Course Number|COURSE_NUMBER|COURSE_NUMBER|COURSE_NUMBER|COURSE_NUMBER|COURSE_NUMBER|Course Number|course number|course_number|medication course number|medication_course_number	The number assigned to a course of therapeutic agent administration, indicating where a particular course of treatment falls within a sequence of treatments.			Quantitative Concept	ALL Course Timing Table|ALL Histology Table|ALL Off Protocol Therapy/Study Table|ALL Variable Terminology|ALL Vitals Table|AML Adverse Events Table|AML Cellular Immunotherapy Table|AML Concomitant Medication Table|AML Course Timing Table|AML Function Test Table|AML Lab Table|AML Minimal Residual Disease Table|AML Molecular Analysis Table|AML Myeloid Sarcoma Involvement Table|AML Off Protocol Therapy/Study Table|AML Radiation Therapy Table|AML Secondary Malignant Neoplasm Table|AML Stem Cell Transplant Table|AML Subject Response Table|AML Survival Characteristics Table|AML Total Dose Table|AML Transfusion Medicine Procedures Table|AML Variable Terminology|AML Vitals Table|EWS Adverse Events Table|EWS Biopsy/Surgical Procedures Table|EWS Course Timing Table|EWS Histology Table|EWS Immunohistochemistry Table|EWS Lab Table|EWS Molecular Analysis Table|EWS Non-Protocol Therapy Table|EWS Off Protocol Therapy/Study Table|EWS Radiation Therapy Table|EWS Secondary Malignant Neoplasm Table|EWS Stem Cell Transplant Table|EWS Subject Response Table|EWS Survival Characteristics Table|EWS Tumor Assessment Table|EWS Variable Terminology|EWS Vitals Table|GDC Property Terminology|GDC Terminology|HL Adverse Events Table|HL Biopsy/Surgical Procedures Table|HL Concomitant Medication Table|HL Course Timing Table|HL Function Test Table|HL Histology Table|HL Imaging Table|HL Immunohistochemistry Table|HL Lab Table|HL Lesion Characteristics Table|HL Off Protocol Therapy/Study Table|HL Protocol Treatment Modifications Table|HL Radiation Therapy Table|HL Secondary Malignant Neoplasm Table|HL Staging Table|HL Stem Cell Transplant Table|HL Subject Response Table|HL Survival Characteristics Table|HL Total Dose Table|HL Transfusion Medicine Procedures Table|HL Variable Terminology|HL Vitals Table|ICDC Property Terminology|ICDC Terminology|OS Adverse Event Table|OS Biopsy/Surgical Procedures Table|OS Course Timing Table|OS Function Test Table|OS Histology Table|OS Lab Table|OS Molecular Analysis Table|OS Off Protocol Therapy/Study Table|OS Radiation Therapy Table|OS Secondary Malignant Neoplasm Table|OS Subject Response Table|OS Survival Characteristics Table|OS Total Dose Table|OS Tumor Assessment Table|OS Variable Terminology|OS Vitals Table
C166236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166236>	C25364	Medication Vial Identifier|medication vial id|medication_vial_id	An identifier associated with a particular vial of medication.			Intellectual Product	ICDC Property Terminology|ICDC Terminology
C166237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166237>	C25536	Middle Initial|pi middle initial|pi_middle_initial	The first letter of a person's middle name.			Conceptual Entity	ICDC Property Terminology|ICDC Terminology
C166238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166238>	C25244	Non-Tumor Tissue Area|non tumor tissue area|non_tumor_tissue_area	The area within a sample that is represented by non-tumor tissue.			Spatial Concept	GDC Terminology|GDC Value Terminology|ICDC Property Terminology|ICDC Terminology
C166239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166239>	C25244	Total Sample Tissue Area|total tissue area|total_tissue_area	The total area of a tissue sample.			Spatial Concept	ICDC Property Terminology|ICDC Terminology
C16623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16623>	C20368	Genetic Technique	Chromosomal, biochemical, intracellular, and other methods used in the study of genetics, including RNA and DNA chemistry.			Molecular Biology Research Technique	
C166240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166240>	C25244	Tumor Tissue Area|tumor tissue area|tumor_tissue_area	The area within a sample that is comprised of tumor tissue.			Spatial Concept	ICDC Property Terminology|ICDC Terminology
C166241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166241>	C25337	Number of Prior Regimens|number of prior regimens any therapy|number_of_prior_regimens_any_therapy	A number that identifies the number of prior cycles of any therapy a subject has received.			Quantitative Concept	ICDC Property Terminology|ICDC Terminology
C166242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166242>	C166241	Number of Prior Regimens of NSAID|number of prior regimens nsaid|number_of_prior_regimens_nsaid	A number that identifies the number of prior cycles of NSAID therapy a subject has received.			Quantitative Concept	ICDC Property Terminology|ICDC Terminology
C166243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166243>	C166241	Number of Prior Regimens of Steroids|Number of Prior Steroid Regimens|number of prior regimens steroid|number_of_prior_regimens_steroid	A number that identifies the number of prior cycles of steroid therapy a subject has received.			Quantitative Concept	ICDC Property Terminology|ICDC Terminology
C166244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166244>	C16669	Patient Status|Patient Health Status|patient status|patient status|patient_status|patient_status	An indicator that provides information on the current health status of a patient.			Organism Attribute	CTDC Property Terminology|ICDC Property Terminology|ICDC Terminology
C166245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166245>	C48570	Percent Stromal Tissue|Percentage Stromal Tissue|percentage stroma|percentage_stroma	The percentage of stromal tissue in a sample.			Quantitative Concept	ICDC Property Terminology|ICDC Terminology
C166246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166246>	C48570	Percent Tumor Tissue|HISTOLOGY_RESULT|Percentage Tumor Tissue|percentage tumor|percentage_tumor	The percentage of tumor tissue in a sample.			Quantitative Concept	GCT Histology Table|GCT Variable Terminology|ICDC Property Terminology|ICDC Terminology
C166247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166247>	C25393	Physical Examination Comment|pe comment|pe_comment	A field for use to add comments regarding a physical examination.			Intellectual Product	ICDC Property Terminology|ICDC Terminology
C166248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166248>	C88080	Prior NSAID Exposure Indicator|prior nsaid exposure|prior_nsaid_exposure	Specifies wheter a subject has had prior exposure to NSAID.			Intellectual Product	ICDC Property Terminology|ICDC Terminology
C166249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166249>	C88080	Prior Steroid Exposure Indicator|prior steroid exposure|prior_steroid_exposure	Specifies wheter a subject has had prior exposure to steroids.			Intellectual Product	ICDC Property Terminology|ICDC Terminology
C16624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16624>	C16345	Genetics|genetics	The branch of biology that deals with heredity, especially the mechanisms of hereditary transmission and the variation of inherited characteristics among similar or related organisms			Biomedical Occupation or Discipline	
C166250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166250>	C25284	Prior Therapy Type|prior therapy type|prior_therapy_type	Specifies the type of prior therapy.			Functional Concept	ICDC Property Terminology|ICDC Terminology
C166251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166251>	C93545	Study Conduct Date Range|dates of conduct|dates_of_conduct	The date range that encompasses the dates that a study was performed.			Temporal Concept	ICDC Property Terminology|ICDC Terminology
C166253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166253>	C25164	Date of Missed Dose|Missed Dose Date|date of missed dose|date_of_missed_dose	Specifies the date of a missed dose of a therapeutic agent.			Temporal Concept	ICDC Property Terminology|ICDC Terminology
C166254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166254>	C25446	Change Since Last Physical Exam|Change Since Last Physical Examination|Physical Exam Changes|Physical Examination Changes|physical exam changes|physical_exam_changes	Changes from the previous physical examination that are noted during the current physical examination.			Qualitative Concept	ICDC Property Terminology|ICDC Terminology
C166255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166255>	C165299|C159556|C153319	Advanced Gastric Adenocarcinoma|Advanced Unresectable Gastric Adenocarcinoma|Unresectable Advanced Gastric (Stomach) Adenocarcinoma	A gastric adenocarcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Gastric Adenocarcinoma|Advanced Unresectable Gastric Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C166256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166256>	C160599|C159556|C156074	Advanced Esophageal Adenocarcinoma	An esophageal adenocarcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Esophageal Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C166257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166257>	C162475|C161048|C159556	Advanced Colorectal Adenocarcinoma	Colorectal adenocarcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Colorectal Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C166258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166258>	C201282|C129822	Anti-CD3/Anti-GUCY2C Bispecific Antibody PF-07062119|Anti-CD3 x Anti-GUCY2C Bispecific Antibody PF-07062119|Anti-GUCY2C/Anti-CD3 Bispecific Antibody PF-07062119|PF 07062119|PF-07062119|PF07062119|T-cell Bispecific Antibody PF-07062119	A bispecific antibody against human CD3, a T-cell surface antigen, and human guanylate cyclase 2C (GUCY2C; GCC; guanylyl cyclase C; heat-stable enterotoxin receptor; hSTAR), with potential antineoplastic activity. Upon administration, anti-CD3/anti-GUCY2C bispecific antibody PF-07062119 targets and binds to both CD3 on T-cells and GUCY2C expressed on certain tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a cytotoxic T-lymphocyte (CTL) response against GUCY2C-expressing tumor cells. GUCY2C, a transmembrane receptor expressed on intestinal epithelial cells, is overexpressed on certain tumors of the gastrointestinal (GI) tract.	Anti-CD3/Anti-GUCY2C Bispecific Antibody PF-07062119		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C166259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166259>	C48572	Dose Unit of Measure|dose units of measure|dose_units_of_measure	The unit of measure that is associated with the dose of a substance administered to the subject.			Quantitative Concept	ICDC Property Terminology|ICDC Terminology
C16625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16625>	C16624	Behavioral Genetics|Genetic Determinants of Behavior	The study of the genetic factors of behavioral phenotypes such as eating or mating activity, substance abuse, social attitudes, violence, and mental abilities. (from online American Heritage Dictionary of the English Language)			Biomedical Occupation or Discipline	
C166260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166260>	C52681	Adverse Event Attributed to Commercial Product|attribution to commercial|attribution_to_commercial	An indication that an adverse event is causally related to the use of a commercially available product.			Finding	ICDC Property Terminology|ICDC Terminology
C166261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166261>	C52681	Adverse Event Attributed to Disease|attribution to disease|attribution_to_disease	An indication that an adverse event is causally related to the natural history of disease.			Finding	ICDC Property Terminology|ICDC Terminology
C166262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166262>	C52681	Adverse Event Attributed to Investigational New Drug|attribution to ind|attribution_to_ind	An indication that an adverse event is causally related to the use of an investigational new drug (IND).			Finding	ICDC Property Terminology|ICDC Terminology
C166263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166263>	C52681	Adverse Event Attributed to Other Cause|attribution to other|attribution_to_other	An indication that an adverse event is causally related to an entity that is a not a disease- or research-related process nor a commercial product or investigational new drug (IND).			Finding	ICDC Property Terminology|ICDC Terminology
C166264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166264>	C52681	Adverse Event Attributed to Research|attribution to research|attribution_to_research	An indication that an adverse event is causally related to processes a subject was exposed to during a research study.			Finding	ICDC Property Terminology|ICDC Terminology
C166265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166265>	C25164	Histologic Confirmation Date|Date of Histology Confirmation|date of histology confirmation|date_of_histology_confirmation	The date that a histological diagnosis was confirmed.			Temporal Concept	ICDC Property Terminology|ICDC Terminology
C166266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166266>	C71476	Institutional Animal Care and Use Committee Approval Date|Date of IACUC Approval|IACUC Approval Date|date of iacuc approval|date_of_iacuc_approval	The date that the Institutional Animal Care and Use Committee (IACUC) approved an animal study protocol. This date cannot be released to funding agencies until congruency between the animal use in the funding proposal and the IACUC approved protocol has been verified.			Temporal Concept	ICDC Property Terminology|ICDC Terminology
C166267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166267>	C25638	Unknown Status Reason|Explain Unknown Status|Unknown Status Explanation|explain unknown status|explain_unknown_status	An explanation of why the status of a subject is unknown.			Idea or Concept	ICDC Property Terminology|ICDC Terminology
C166268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166268>	C91102	How was the Extent of Disease Measured Question|Disease Extent Assessment Method|Disease Extent Measured How|How was the Extent of Disease Measured|Measured How|measured how|measured_how	A question pertaining to how the extent of a disease or lesion was measured.			Intellectual Product	ICDC Property Terminology|ICDC Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C166269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166269>	C164322	Missed Medication Dose Name|medication missed dose|medication_missed_dose	The name of the medication that was not taken when a dose was missed.			Intellectual Product	ICDC Property Terminology|ICDC Terminology
C16626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16626>	C16624	Biochemical Genetics	The science concerned with the chemical and physical nature of genes and the genome.			Biomedical Occupation or Discipline	
C166270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166270>	C70699	Necropsy Sample|necropsy sample|necropsy_sample	A biospecimen collected during the surgical examination of a dead body.			Body Substance	ICDC Property Terminology|ICDC Terminology
C166271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166271>	C15645	Non-responsive Therapy Type|Non-Responsive Therapy Type|Non-Responsive Treatment Type|Nonresponsive Treatment Type|nonresponse therapy type|nonresponse_therapy_type	The categorization of the treatment that was administered to a subject that did not produce the intended (therapeutic) effect.			Therapeutic or Preventive Procedure	ICDC Property Terminology|ICDC Terminology
C166272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166272>	C42743	Program External URL|Research Program External URL|program external url|program_external_url	A URL address for a research program or study that is accessible by those outside the host institution.			Intellectual Product	ICDC Property Terminology|ICDC Terminology
C166273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166273>	C25365	Program Full Description|program full description|program_full_description	An unabridged description of a research program or study.			Intellectual Product	ICDC Property Terminology|ICDC Terminology
C166274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166274>	C42614	Program Name|program name|program_name	The name applied to a research program.			Conceptual Entity	ICDC Property Terminology|ICDC Terminology
C166275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166275>	C25365	Program Short Description|program short description|program_short_description	An abbreviated description of a research program or study.			Intellectual Product	ICDC Property Terminology|ICDC Terminology
C166276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166276>	C25638	Reason Off Treatment|reason off treatment|reason treatment ended|reason_off_treatment|reason_treatment_ended	The reason the administration of a drug or therapeutic procedure was interrupted or stopped.			Idea or Concept	GDC Property Terminology|GDC Terminology|ICDC Property Terminology|ICDC Terminology
C166277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166277>	C42614	Short Site Name|short name|short_name|site short name|site_short_name	The abbreviation or abridged identifier representing the place hosting a research program or study.			Conceptual Entity	GDC Property Terminology|GDC Terminology|ICDC Property Terminology|ICDC Terminology
C166278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166278>	C222259	Huntington's Disease Cognitive Assessment Battery Functional Test|HD-CAB|HD-CAB|HDCAB1	A set of six tests that were combined by Stout et al. in 2014 as an assessment tool for the effects of Huntington's disease treatment on cognition. The battery of tests, which include the Symbol Digit Modalities Test (SDMT), Emotion Recognition, Trail Making Test, Hopkins Verbal Learning Test (HVLT), Paced Tapping, and One Touch Stockings of Cambridge (OTS), cover a range of cognitive abilities known to decline in Huntington's disease, including attention, processing speed, visuospatial processing, timing, emotion processing, memory, and executive function.			Intellectual Product	CDISC Functional Test Category Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166279>	C222260	Rockport One Mile Walk Test Version 1.0 Functional Test|RFWT Version 1|ROCK01|ROCKPORT ONE MILE WALK TEST V1.0	A submaximal fitness test, developed by Kline et al. in 1987, that utilizes the fastest time taken to walk one mile (T1), heart rate measured at the fourth quarter of the mile (HR1-4), sex (SEX; male = 1, female = 0), age in years (AGE), and body weight in pounds (WT) to estimate maximal oxygen consumption (VO2max) using the equation: VO2max = 6.9652 + (0.0091*WT) - (0.0257*AGE) + (0.5955*SEX) - (0.2240*T1) - (0.0115*HR1-4). IMPORTANT NOTICE: The NCI Thesaurus contains biomedical terminologies that NCI does not own or control. This concept contains gender-related content that does not comply with Executive Order 14168.			Intellectual Product	CDISC Functional Test Category Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16627>	C17153	Medical Genetics|Genetics, Medical	A medical specialty concerned with the diagnosis and management of hereditary disorders.			Biomedical Occupation or Discipline	
C166280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166280>	C166191	FACT-COG Version 3 - I Have Trouble Forming Thoughts|FAC075-I Have Trouble Forming Thoughts|FAC075-I Have Trouble Forming Thoughts|FAC07501	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Impairments: I have had trouble forming thoughts.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166281>	C166191	FACT-COG Version 3 - My Thinking Has Been Slow|FAC075-My Thinking Has Been Slow|FAC075-My Thinking Has Been Slow|FAC07502	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Impairments: My thinking has been slow.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166282>	C166191	FACT-COG Version 3 - I Have Had Trouble Concentrating|FAC075-I Have Had Trouble Concentrating|FAC075-I Have Had Trouble Concentrating|FAC07503	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Impairments: I have had trouble concentrating.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166283>	C166191	FACT-COG Version 3 - Trouble Finding Familiar Place|FAC075-Trouble Finding Familiar Place|FAC075-Trouble Finding Familiar Place|FAC07504	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Impairments: I have had trouble finding my way to a familiar place.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166284>	C166191	FACT-COG Version 3 - Trouble Remember Where Put Things|FAC075-Trouble Remember Where Put Things|FAC075-Trouble Remember Where Put Things|FAC07505	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Impairments: I have had trouble remembering where I put things, like my keys or my wallet.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166285>	C166191	FACT-COG Version 3 - Trouble Remembering New Info|FAC075-Trouble Remembering New Info|FAC075-Trouble Remembering New Info|FAC07506	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Impairments: I have had trouble remembering new information, like phone numbers or simple instructions.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166286>	C166191	FACT-COG Version 3 - Trouble Recalling Name of Object|FAC075-Trouble Recalling Name of Object|FAC075-Trouble Recalling Name of Object|FAC07507	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Impairments: I have had trouble recalling the name of an object while talking to someone.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166287>	C166191	FACT-COG Version 3 - Trouble Finding Right Words|FAC075-Trouble Finding Right Words|FAC075-Trouble Finding Right Words|FAC07508	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Impairments: I have had trouble finding the right word(s) to express myself.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166288>	C166191	FACT-COG Version 3 - Used Wrong Word When Refer Object|FAC075-Used Wrong Word When Refer Object|FAC075-Used Wrong Word When Refer Object|FAC07509	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Impairments: I have used the wrong word when I referred to an object.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166289>	C166191	FACT-COG Version 3 - Trouble Saying What I Mean|FAC075-Trouble Saying What I Mean|FAC075-Trouble Saying What I Mean|FAC07510	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Impairments: I have had trouble saying what I mean in conversations with others.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16628>	C16624	Population Genetics|Genetics, Population	The branch of genetics that focuses on gene distribution and transmission through populations.			Biomedical Occupation or Discipline	
C166290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166290>	C166191	FACT-COG Version 3 - Walked Into a Room and Forgotten|FAC075-Walked Into a Room and Forgotten|FAC075-Walked Into a Room and Forgotten|FAC07511	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Impairments: I have walked into a room and forgotten what I meant to get or do there.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166291>	C166191	FACT-COG Version 3 - Work Hard to Pay Attention|FAC075-Work Hard to Pay Attention|FAC075-Work Hard to Pay Attention|FAC07512	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Impairments: I have had to work really hard to pay attention or I would make a mistake.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166292>	C166191	FACT-COG Version 3 - Forgotten Names After Introduced|FAC075-Forgotten Names After Introduced|FAC075-Forgotten Names After Introduced|FAC07513	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Impairments: I have forgotten names of people soon after being introduced.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166293>	C166191	FACT-COG Version 3 - Reaction Everyday Situations Slow|FAC075-Reaction Everyday Situations Slow|FAC075-Reaction Everyday Situations Slow|FAC07514	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Impairments: My reactions in everyday situations have been slow.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166294>	C166191	FACT-COG Version 3 - Work Harder Than Usual to Track|FAC075-Work Harder Than Usual to Track|FAC075-Work Harder Than Usual to Track|FAC07515	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Impairments: I have had to work harder than usual to keep track of what I was doing.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166295>	C166191	FACT-COG Version 3 - My Thinking Slower Than Usual|FAC075-My Thinking Slower Than Usual|FAC075-My Thinking Slower Than Usual|FAC07516	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Impairments: My thinking has been slower than usual.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166296>	C166191	FACT-COG Version 3 - Work Harder Than Usual to Express|FAC075-Work Harder Than Usual to Express|FAC075-Work Harder Than Usual to Express|FAC07517	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Impairments: I have had to work harder than usual to express myself clearly.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166297>	C166191	FACT-COG Version 3 - Use Written Lists More Often|FAC075-Use Written Lists More Often|FAC075-Use Written Lists More Often|FAC07518	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Impairments: I have had to use written lists more often than usual so I would not forget things.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166298>	C166191	FACT-COG Version 3 - Trouble Keeping Track Interrupted|FAC075-Trouble Keeping Track Interrupted|FAC075-Trouble Keeping Track Interrupted|FAC07519	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Impairments: I have trouble keeping track of what I am doing if I am interrupted.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166299>	C166191	FACT-COG Version 3 - Trouble Shifting Back and Forth|FAC075-Trouble Shifting Back and Forth|FAC075-Trouble Shifting Back and Forth|FAC07520	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Impairments: I have trouble shifting back and forth between different activities that require thinking.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16629>	C19896	Genome|Genomic|Genomic|genome	The complete genomic content of an organism, and possibly the full DNA sequence of that organism. It is contained in a set of chromosomes in eukaryotes, a single chromosome in bacteria, or a DNA or RNA molecule in viruses.			Gene or Genome	BRIDG Class Terminology|BRIDG Terminology
C1662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1662>	C97366	Indinavir Sulfate|Crixivan|D-erythro-Pentonamide, 2,3,5-trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-, monohydrate, (1(1S,2R),5(S))-, sulfate (1:1) (salt)|DRG-0233|INDINAVIR SULFATE|L-735,524|MK-639	A synthetic antiviral agent. Indinavir selectively binds to the active site of human immunodeficiency virus (HIV) protease and inhibits its activity, preventing the protease-mediated cleavage of gag-pol viral polyproteins; as a result immature, noninfectious virions are produced.	Indinavir Sulfate		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C166300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166300>	C166191	FACT-COG Version 3 - Told Me Trouble Remembering Info|FAC075-Told Me Trouble Remembering Info|FAC075-Told Me Trouble Remembering Info|FAC07521	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Comments From Others: Other people have told me I seemed to have trouble remembering information.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166301>	C166191	FACT-COG Version 3 - Told Me Trouble Speaking Clearly|FAC075-Told Me Trouble Speaking Clearly|FAC075-Told Me Trouble Speaking Clearly|FAC07522	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Comments From Others: Other people have told me I seemed to have trouble speaking clearly.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166302>	C166191	FACT-COG Version 3 - Told Me Trouble Thinking Clearly|FAC075-Told Me Trouble Thinking Clearly|FAC075-Told Me Trouble Thinking Clearly|FAC07523	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Comments From Others: Other people have told me I seemed to have trouble thinking clearly.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166303>	C166191	FACT-COG Version 3 - People Told Me I Seemed Confused|FAC075-People Told Me I Seemed Confused|FAC075-People Told Me I Seemed Confused|FAC07524	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Comments From Others: Other people have told me I seemed confused.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166304>	C166191	FACT-COG Version 3 - I Have Been Able to Concentrate|FAC075-I Have Been Able to Concentrate|FAC075-I Have Been Able to Concentrate|FAC07525	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Abilities: I have been able to concentrate.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166305>	C166191	FACT-COG Version 3 - Able to Bring to Mind Words|FAC075-Able to Bring to Mind Words|FAC075-Able to Bring to Mind Words|FAC07526	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Abilities: I have been able to bring to mind words that I wanted to use while talking to someone.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166306>	C166191	FACT-COG Version 3 - Able Remember Things Where Left|FAC075-Able Remember Things Where Left|FAC075-Able Remember Things Where Left|FAC07527	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Abilities: I have been able to remember things, like where I left my keys or wallet.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166307>	C166191	FACT-COG Version 3 - Able Remember to Do Things|FAC075-Able Remember to Do Things|FAC075-Able Remember to Do Things|FAC07528	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Abilities: I have been able to remember to do things, like take medicine or buy something I needed.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166308>	C166191	FACT-COG Version 3 - Able to Pay Attention Without Effort|FAC075-Able to Pay Attention w/o Effort|FAC075-Able to Pay Attention w/o Effort|FAC07529	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Abilities: I am able to pay attention and keep track of what I am doing without extra effort.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166309>	C166191	FACT-COG Version 3 - Mind Is as Sharp as Always Been|FAC075-Mind Is as Sharp as Always Been|FAC075-Mind Is as Sharp as Always Been|FAC07530	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Abilities: My mind is as sharp as it has always been.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16630>	C16629	Human Genome	The total gene complement, about 3 billion base pairs of DNA, contained in the human chromosomes.			Gene or Genome	
C166310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166310>	C166191	FACT-COG Version 3 - Memory Is as Good as Always Been|FAC075-Memory Is as Good as Always Been|FAC075-Memory Is as Good as Always Been|FAC07531	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Abilities: My memory is as good as it has always been.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166311>	C166191	FACT-COG Version 3 - Able to Shift Between Activities|FAC075-Able to Shift Between Activities|FAC075-Able to Shift Between Activities|FAC07532	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Abilities: I am able to shift back and forth between two activities that require thinking.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166312>	C166191	FACT-COG Version 3 - Able to Track What I Am Doing|FAC075-Able to Track What I Am Doing|FAC075-Able to Track What I Am Doing|FAC07533	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Abilities: I am able to keep track of what I am doing, even if I am interrupted.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166313>	C166191	FACT-COG Version 3 - Been Upset about These Problems|FAC075-Been Upset about These Problems|FAC075-Been Upset about These Problems|FAC07534	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Impact on Quality of Life: I have been upset about these problems.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166314>	C166191	FACT-COG Version 3 - Problems Interfered Ability Work|FAC075-Problems Interfered Ability Work|FAC075-Problems Interfered Ability Work|FAC07535	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Impact on Quality of Life: These problems have interfered with my ability to work.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166315>	C166191	FACT-COG Version 3 - Problems Interfered Ability Enjoy|FAC075-Problems Interfered Ability Enjoy|FAC075-Problems Interfered Ability Enjoy|FAC07536	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Impact on Quality of Life: These problems have interfered with my ability to do things I enjoy.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166316>	C166191	FACT-COG Version 3 - Problems Interfered Quality Life|FAC075-Problems Interfered Quality Life|FAC075-Problems Interfered Quality Life|FAC07537	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Impact on Quality of Life: These problems have interfered with the quality of my life.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166317>	C166191	FACT-COG Version 3 - Cognitive Impairments Score|FAC075-Cognitive Impairments Score|FAC075-Cognitive Impairments Score|FAC07538	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Impairments: Subscale score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166318>	C166191	FACT-COG Version 3 - Comments From Others Score|FAC075-Comments From Others Score|FAC075-Comments From Others Score|FAC07539	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Comments From Others: Subscale score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166319>	C166191	FACT-COG Version 3 - Cognitive Abilities Score|FAC075-Cognitive Abilities Score|FAC075-Cognitive Abilities Score|FAC07540	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Perceived Cognitive Abilities: Subscale score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16631>	C19896	Genotype|Genotypic|genotype	The genetic constitution of an organism or cell, as distinct from its expressed features or phenotype.			Organism Attribute	
C166320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166320>	C166191	FACT-COG Version 3 - Impact on Quality of Life Score|FAC075-Impact on Quality of Life Score|FAC075-Impact on Quality of Life Score|FAC07541	Functional Assessment of Cancer Therapy-Cognitive Function Version 3 (FACT-COG Version 3) Impact on Quality of Life: Subscale score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-COG Version 3 Test Code Terminology|CDISC Questionnaire FACT-COG Version 3 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166321>	C166192	WPAI-GH Version 2 - Currently Employed|WPAI02-Currently Employed|WPAI02-Currently Employed|WPAI0201	Work Productivity and Activity Impairment Questionnaire - General Health Version 2.0 (WPAI-GH Version 2) Are you currently employed (working for pay)?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WPAI-GH Version 2 Test Code Terminology|CDISC Questionnaire WPAI-GH Version 2 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166322>	C166192	WPAI-GH Version 2 - Hours Miss Work Health Problems|WPAI02-Hours Miss Work Health Problems|WPAI02-Hours Miss Work Health Problems|WPAI0202	Work Productivity and Activity Impairment Questionnaire - General Health Version 2.0 (WPAI-GH Version 2) During the past seven days, how many hours did you miss from work because of your health problems?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WPAI-GH Version 2 Test Code Terminology|CDISC Questionnaire WPAI-GH Version 2 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166323>	C166192	WPAI-GH Version 2 - Hours Miss Work Other Reason|WPAI02-Hours Miss Work Other Reason|WPAI02-Hours Miss Work Other Reason|WPAI0203	Work Productivity and Activity Impairment Questionnaire - General Health Version 2.0 (WPAI-GH Version 2) During the past seven days, how many hours did you miss from work because of any other reason, such as vacation, holidays, time off to participate in this study?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WPAI-GH Version 2 Test Code Terminology|CDISC Questionnaire WPAI-GH Version 2 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166324>	C166192	WPAI-GH Version 2 - Hours Actually Work|WPAI02-Hours Actually Work|WPAI02-Hours Actually Work|WPAI0204	Work Productivity and Activity Impairment Questionnaire - General Health Version 2.0 (WPAI-GH Version 2) During the past seven days, how many hours did you actually work?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WPAI-GH Version 2 Test Code Terminology|CDISC Questionnaire WPAI-GH Version 2 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166325>	C166192	WPAI-GH Version 2 - Problems Affect Productivity|WPAI02-Problems Affect Productivity|WPAI02-Problems Affect Productivity|WPAI0205	Work Productivity and Activity Impairment Questionnaire - General Health Version 2.0 (WPAI-GH Version 2) During the past seven days, how much did your health problems affect your productivity while you were working?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WPAI-GH Version 2 Test Code Terminology|CDISC Questionnaire WPAI-GH Version 2 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166326>	C166192	WPAI-GH Version 2 - Problems Affect Daily Activities|WPAI02-Problems Affect Daily Activities|WPAI02-Problems Affect Daily Activities|WPAI0206	Work Productivity and Activity Impairment Questionnaire - General Health Version 2.0 (WPAI-GH Version 2) During the past seven days, how much did your health problems affect your ability to do your regular daily activities, other than work at a job?			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WPAI-GH Version 2 Test Code Terminology|CDISC Questionnaire WPAI-GH Version 2 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166327>	C166192	WPAI-GH Version 2 - Absenteeism Score|WPAI02-Absenteeism Score|WPAI02-Absenteeism Score|WPAI0207	Work Productivity and Activity Impairment Questionnaire - General Health Version 2.0 (WPAI-GH Version 2) Absenteeism score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WPAI-GH Version 2 Test Code Terminology|CDISC Questionnaire WPAI-GH Version 2 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166328>	C166192	WPAI-GH Version 2 - Presenteeism Score|WPAI02-Presenteeism Score|WPAI02-Presenteeism Score|WPAI0208	Work Productivity and Activity Impairment Questionnaire - General Health Version 2.0 (WPAI-GH Version 2) Presenteeism score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WPAI-GH Version 2 Test Code Terminology|CDISC Questionnaire WPAI-GH Version 2 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166329>	C166192	WPAI-GH Version 2 - Work Productivity Loss Score|WPAI02-Work Productivity Loss Score|WPAI02-Work Productivity Loss Score|WPAI0209	Work Productivity and Activity Impairment Questionnaire - General Health Version 2.0 (WPAI-GH Version 2) Work productivity loss score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WPAI-GH Version 2 Test Code Terminology|CDISC Questionnaire WPAI-GH Version 2 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16632>	C20181	Geographic Area|Area|Geographic Location|Geographic Region|Region	Any demarcated area of the Earth; may be determined by both natural and human boundaries.			Geographic Area	
C166330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166330>	C166192	WPAI-GH Version 2 - Activity Impairment Score|WPAI02-Activity Impairment Score|WPAI02-Activity Impairment Score|WPAI0210	Work Productivity and Activity Impairment Questionnaire - General Health Version 2.0 (WPAI-GH Version 2) Activity impairment score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WPAI-GH Version 2 Test Code Terminology|CDISC Questionnaire WPAI-GH Version 2 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166331>	C166193	HD-CAB - Paced Tapping|HDCAB1-Paced Tapping|HDCAB1-Paced Tapping|HDCAB101	Huntington's Disease Cognitive Assessment Battery (HD-CAB) Paced Tapping key variable for composite score: 1/SD of the inter-tap interval for the self-paced taps.			Intellectual Product	CDISC Functional Test HD-CAB Test Code Terminology|CDISC Functional Test HD-CAB Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166332>	C166193	HD-CAB - Emotion Recognition|HDCAB1-Emotion Recognition|HDCAB1-Emotion Recognition|HDCAB102	Huntington's Disease Cognitive Assessment Battery (HD-CAB) Emotion Recognition key variable for composite score: Number of correct responses to the negative expressions (anger, fear, sadness, disgust) out of 24 possible.			Intellectual Product	CDISC Functional Test HD-CAB Test Code Terminology|CDISC Functional Test HD-CAB Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166333>	C166193	HD-CAB - One Touch Stockings of Cambridge|HDCAB1-One Touch Stockings of Cambridge|HDCAB1-One Touch Stockings of Cambridge|HDCAB103	Huntington's Disease Cognitive Assessment Battery (HD-CAB) One Touch Stockings of Cambridge key variable for composite score: Mean time to correct response (sec) averaged across all 10 trials (reverse scored).			Intellectual Product	CDISC Functional Test HD-CAB Test Code Terminology|CDISC Functional Test HD-CAB Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166334>	C166193	HD-CAB - Symbol Digit Modalities Test|HDCAB1-Symbol Digit Modalities Test|HDCAB1-Symbol Digit Modalities Test|HDCAB104	Huntington's Disease Cognitive Assessment Battery (HD-CAB) Symbol Digit Modalities Test key variable for composite score: Number of correct responses in 90 seconds out of 110 possible responses.			Intellectual Product	CDISC Functional Test HD-CAB Test Code Terminology|CDISC Functional Test HD-CAB Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166335>	C166193	HD-CAB - Hopkins Verbal Learning Test Revised|HDCAB1-Hopkins Verbal Learning Test Rev|HDCAB1-Hopkins Verbal Learning Test Rev|HDCAB105	Huntington's Disease Cognitive Assessment Battery (HD-CAB) Hopkins Verbal Learning Test - Revised key variable for composite score: Total number of words correctly recalled over Trials 1-4 out of 48 possible.			Intellectual Product	CDISC Functional Test HD-CAB Test Code Terminology|CDISC Functional Test HD-CAB Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166336>	C166193	HD-CAB - Trail Making Test-B|HDCAB1-Trail Making Test-B|HDCAB1-Trail Making Test-B|HDCAB106	Huntington's Disease Cognitive Assessment Battery (HD-CAB) Trail Making Test-B key variable for composite score: Time to completion (sec) of TMT Part B with upper time limit of 240 seconds (reverse scored).			Intellectual Product	CDISC Functional Test HD-CAB Test Code Terminology|CDISC Functional Test HD-CAB Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166337>	C166193	HD-CAB - HD-CAB Total Score|HDCAB1-HD-CAB Total Score|HDCAB1-HD-CAB Total Score|HDCAB107	Huntington's Disease Cognitive Assessment Battery (HD-CAB) HD-CAB total score.			Intellectual Product	CDISC Functional Test HD-CAB Test Code Terminology|CDISC Functional Test HD-CAB Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166338>	C166194	RFWT Version 1 - Time To Complete One Mile Walk|ROCK01-Time To Complete One Mile Walk|ROCK01-Time To Complete One Mile Walk|ROCK0101	Rockport One Mile Walk Test Version 1.0 (RFWT Version 1) Time to complete one-mile walk.			Intellectual Product	CDISC Functional Test RFWT Version 1 Test Code Terminology|CDISC Functional Test RFWT Version 1 Test Name Terminology|CDISC Functional Test Terminology|CDISC QRS Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166339>	C150797	FACT-C Version 4 - Trial Outcome Index Score|FAC008-Trial Outcome Index Score|FAC008-Trial Outcome Index Score|FAC00843	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) Trial outcome index score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16633>	C16987	Geography	The science that deals with the world and its inhabitants; a description of the earth, or a portion of the earth, including its structure, features, products, political divisions, and the people by whom it is inhabited.			Occupation or Discipline	
C166340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166340>	C150797	FACT-C Version 4 - FACT-G Total Score|FAC008-FACT-G Total Score|FAC008-FACT-G Total Score|FAC00844	Functional Assessment of Cancer Therapy-Colorectal Version 4 (FACT-C Version 4) FACT-G total score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACT-C Version 4 Test Code Terminology|CDISC Questionnaire FACT-C Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166341>	C129099	FACIT-F Version 4 - Physical Subscale Score|FAC071-Physical Subscale Score|FAC071-Physical Subscale Score|FAC07141	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Physical Well-Being: Subscale score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166342>	C129099	FACIT-F Version 4 - Social/Family Subscale Score|FAC071-Social/Family Subscale Score|FAC071-Social/Family Subscale Score|FAC07142	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Socia/Family Well-Being: Subscale score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166343>	C129099	FACIT-F Version 4 - Emotional Subscale Score|FAC071-Emotional Subscale Score|FAC071-Emotional Subscale Score|FAC07143	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Emotional Well-Being: Subscale score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166344>	C129099	FACIT-F Version 4 - Functional Subscale Score|FAC071-Functional Subscale Score|FAC071-Functional Subscale Score|FAC07144	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Functional Well-Being: Subscale score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166345>	C129099	FACIT-F Version 4 - Additional Concern Subscale Score|FAC071-Additional Concern Subscale Score|FAC071-Additional Concern Subscale Score|FAC07145	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Additional Concerns: Subscale score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166346>	C129099	FACIT-F Version 4 - Trial Outcome Index Score|FAC071-Trial Outcome Index Score|FAC071-Trial Outcome Index Score|FAC07146	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Trial outcome index score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166347>	C129099	FACIT-F Version 4 - FACT-G Total Score|FAC071-FACT-G Total Score|FAC071-FACT-G Total Score|FAC07147	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) FACT-G total score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166348>	C129099	FACIT-F Version 4 - Total Score|FAC071-Total Score|FAC071-Total Score|FAC07148	Functional Assessment of Chronic Illness Therapy-Fatigue Version 4 (FACIT-F Version 4) Total score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire FACIT-F Version 4 Test Code Terminology|CDISC Questionnaire FACIT-F Version 4 Test Name Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166349>	C100172	WPAI:SHP v2.0 - Absenteeism Score|WPAI01-Absenteeism Score|WPAI01-Absenteeism Score|WPAI0107	Work Productivity and Activity Impairment Questionnaire-Specific Health Problem v2.0 (WPAI:SHP) Absenteeism score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WPAI:SHP v2.0 Test Code Terminology|CDISC Questionnaire WPAI:SHP v2.0 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16634>	C25464	Georgia (Republic)|268|GE|GEO|GEO|GEORGIA|GEORGIA|Georgia|Georgia	A country in southwestern Asia, bordering the Black Sea, between Turkey and Russia.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C166350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166350>	C100172	WPAI:SHP v2.0 - Presenteeism Score|WPAI01-Presenteeism Score|WPAI01-Presenteeism Score|WPAI0108	Work Productivity and Activity Impairment Questionnaire-Specific Health Problem v2.0 (WPAI:SHP) Presenteeism score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WPAI:SHP v2.0 Test Code Terminology|CDISC Questionnaire WPAI:SHP v2.0 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166351>	C100172	WPAI:SHP v2.0 - Work Productivity Loss Score|WPAI01-Work Productivity Loss Score|WPAI01-Work Productivity Loss Score|WPAI0109	Work Productivity and Activity Impairment Questionnaire-Specific Health Problem v2.0 (WPAI:SHP) Work productivity loss score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WPAI:SHP v2.0 Test Code Terminology|CDISC Questionnaire WPAI:SHP v2.0 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166352>	C100172	WPAI:SHP v2.0 - Activity Impairment Score|WPAI01-Activity Impairment Score|WPAI01-Activity Impairment Score|WPAI0110	Work Productivity and Activity Impairment Questionnaire-Specific Health Problem v2.0 (WPAI:SHP) Activity impairment score.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Terminology|CDISC Questionnaire WPAI:SHP v2.0 Test Code Terminology|CDISC Questionnaire WPAI:SHP v2.0 Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C166353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166353>	C18772	Procedure History	A descriptive account of an individual's past medical procedures.			Clinical Attribute	
C166354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166354>	C3810|C107377	Musculoskeletal Neoplasm|Musculoskeletal System Neoplasm	A benign, intermediate, or malignant neoplasm that affects muscles and bones.	Musculoskeletal Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C166355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166355>	C26326|C107377	Non-Neoplastic Musculoskeletal Disorder|Non-Neoplastic Musculoskeletal System Disorder	A non-neoplastic disorder that affects muscles and bones.			Disease or Syndrome	
C166356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166356>	C53684|C166354	Benign Musculoskeletal Neoplasm	A mesenchymal neoplasm that arises from muscle or bone and is characterized by the absence of atypical or malignant cytological and architectural features, and absence of invasive features or metastatic potential.			Neoplastic Process	
C166357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166357>	C9305|C166354	Malignant Musculoskeletal Neoplasm	A primary or metastatic malignant neoplasm that affects muscles and bones.	Malignant Musculoskeletal Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C166358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166358>	C25404	Offer|Offered|Offering	To provide or supply something, such as a product or service.			Activity	
C166359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166359>	C140180	Lapatinib/Temozolomide Regimen|Lapatinib-Temozolomide|Lapatinib-Temozolomide Regimen|Lapatinib/Temozolomide|Temozolomide-Lapatinib|Temozolomide/Lapatinib|Temozolomide/Lapatinib Regimen	A regimen consisting of lapatinib and temozolomide that can be used for the treatment of recurrent ependymoma.			Therapeutic or Preventive Procedure	Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C16635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16635>	C17153	Geriatrics|Geriatric Health|Gerontological|Gerontology|Gerontology|Gerontology / Geriatrics	The branch of medical science that deals with diseases and problems specific to elderly people.			Biomedical Occupation or Discipline	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C166360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166360>	C172299	Crosslinking Process|Crosslinking	The process of forming one or more covalent links between two polymers or two different regions within the same polymer.			Phenomenon or Process	CBDD Process Terminology|CBDD Terminology
C166361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166361>	C63358	Cisplatin/Epirubicin/Paclitaxel Regimen|Cisplatin-Epirubicin-Paclitaxel|Cisplatin-Epirubicin-Paclitaxel Regimen|Cisplatin/Epirubicin/Paclitaxel|PET|PET Regimen|Platinol/Epirubicin/Taxol	A regimen consisting of cisplatin, epirubicin and paclitaxel that may be used in the treatment of breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C166362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166362>	C177176	TLR7 Agonist LHC165|LHC 165|LHC-165|LHC-165|LHC165	A benzonapthyridine Toll-like receptor (TLR) 7 agonist that is adsorbed to aluminum hydroxide with immunostimulating and potential antitumor activities. Upon intratumoral administration of TLR7 agonist LHC165, the agent is slowly released and targets, binds to and activates TLR7.  This may trigger, in addition to other possible responses, the activation of cluster of differentiation (CD) 8+ T cells and natural killer (NK) cells, the blockage of the suppressive function of regulatory T cells (Tregs), and the production of interferon alpha (IFNa).  TLR7 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.	TLR7 Agonist LHC165		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C166363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166363>	C19044	Creatinine Clearance Formula	Any formula to estimate creatinine clearance.			Quantitative Concept	
C166364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166364>	C166363	Jelliffe Equation for Creatinine Clearance|Jelliffe	A formula for evaluating renal function for adults with normal muscle mass and Scr less than 5 mg/dL. For males: 98 - 0.8 (A - 20) / Scr; for females: 88 - 0.7 (A - 20) / Scr; where A = age in yrs; CLcr = creatinine clearance in mL/min/1.73 m^2			Quantitative Concept	
C166367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166367>	C166363	Sanaka Equation for Creatinine Clearance|Sanaka	A formula to predict creatinine clearance (CCr, ml/min) in the elderly with chronic muscle atrophy using serum albumin (Alb, g/dl). For males: ABW (19 Alb +32) / 100 Scr; for females: ABW (13 Alb +29) / 100 Scr; where: Alb = plasma albumin level (g/dL); Scr = serum creatinine (mg/dL); ABW = actual body weight in Kg			Quantitative Concept	
C166368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166368>	C161342	Cockcroft-Gault Formula Utilizing Adjusted Body Weight	A variation of the Cockcroft-Gault formula to predict creatinine clearance that uses an adjusted body weight.			Quantitative Concept	
C166369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166369>	C161342	Cockcroft-Gault Formula Utilizing Ideal Body Weight	A variation of the Cockcroft-Gault formula to predict creatinine clearance that uses an idealized body weight. For males, ideal body weight=50 kg + 2.3 kg for each inch over 5 feet; for females, 45.5 kg + 2.3 kg for each inch over 5 feet.			Quantitative Concept	
C16636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16636>	C25464	Germany|276|DE|DEU|DEU|GERMANY|GERMANY	A country in central Europe, bordering the Baltic Sea and the North Sea, between the Netherlands and Poland, south of Denmark.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C166370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166370>	C161342	Cockcroft-Gault Formula Utilizing Total Body Weight	A variation of the Cockcroft-Gault formula to predict creatinine clearance that uses total body weight.			Quantitative Concept	
C166371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166371>	C165451	ICDC Data Model Terminology	Terminology representing the data categories and values collected by the Integrated Canine Data Commons (ICDC).			Intellectual Product	
C166372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166372>	C165451	Canine Glioma Project Property Terminology	Terminology representing the data categories for which values are collected by the Canine Glioma Project.			Intellectual Product	
C166373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166373>	C166371	ICDC Property Terminology|property	Terminology representing the data properties collected by the Integrated Canine Data Commons (ICDC).			Intellectual Product	ICDC Data Model Terminology
C166374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166374>	C165451	PRECINCT Property Terminology|PRE-medical Cancer Immunotherapy Network Canine Trials Consortium Property Terminology|PRECINCT Variable / Field Name|PRECINCT Variable/Field Name Terminology	Terminology representing the data categories for which values are collected by the PRE-medical Cancer Immunotherapy Network Canine Trials (PRECINCT) consortium.			Intellectual Product	
C166375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166375>	C222322|C213431|C1962|C129820	IL-12sc, IL-15sushi, IFNa and GM-CSF mRNA-based Immunotherapeutic Agent SAR441000|BNT 131|BNT-131|BNT131|SAR 441000|SAR-441000|SAR441000	An immunotherapeutic agent utilizing mRNA to encode the cytokines interleukin-12sc (IL-12sc), interleukin-15sushi (IL-15sushi), interferon alpha (IFNa) and granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating and antineoplastic activities. Upon intratumoral administration of IL-12sc, IL-15sushi, IFNa and GM-CSF mRNA-based immunotherapeutic agent SAR441000, mRNA is picked up by nearby cells, translated and released into the local tumor microenvironment (TME). Secretion of these cytokines activate the immune system by promoting the activation of natural killer cells (NKs) and inducing cytotoxic T-lymphocyte (CTL) responses, which may result in an immune-mediated destruction of tumor cells.	IL-12sc, IL-15sushi, IFNa and GM-CSF mRNA-based Immunotherapeutic Agent SAR441000		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C166376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166376>	C155321|C129822	Anti-CD38 Monoclonal Antibody SAR442085|SAR 442085|SAR-442085|SAR442085	A preparation of Fc-engineered monoclonal antibody that targets the cell surface glycoprotein CD-38 with potential antineoplastic activity. Although the exact mechanisms(s) through which this agent exerts its effects have yet to be fully elucidated, upon administration, anti-CD38 monoclonal antibody SAR442085 targets and binds to CD38 on CD38-positive tumor cells. This may trigger, in addition to other possible responses, antitumoral antibody-dependent cellular cytotoxicity (ADCC) and may eventually lead to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies.	Anti-CD38 Monoclonal Antibody SAR442085		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C166377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166377>	C2189	Plumbagin|PCUR 101|PCUR-101|PCUR101|PLUMBAGIN|Synthetic Plumbagin PCUR-101|Synthetic Plumbagin PCUR-101	A synthetic form of the plant-derived medicinal agent, plumbagin, with potential antineoplastic activity.  Plumbagin may act by inhibiting the expression of protein kinase C epsilon (PKCe), signal transducers and activators of transcription 3 phosphorylation (Stat3), protein kinase B (AKT), and certain epithelial-to-mesenchymal transition (EMT) markers, including vimentin and slug. This results in possible inhibition of proliferation in susceptible tumor cells.  PKCe, Stat3, AKT, and the EMT markers vimentin and slug have been linked to the induction and progression of prostate cancer.	Plumbagin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C166378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166378>	C136286	MET NP_000236.2:p.Q1276L|C-MET Gln1276Leu|C-MET Q1276L|HGF Receptor Gln1276Leu|HGF Receptor Q1276L|HGFR Gln1276Leu|HGFR Q1276L|Hepatocyte Growth Factor Receptor Gln1276Leu|Hepatocyte Growth Factor Receptor Q1276L|MET Gln1276Leu|MET NP_000236.2:p.Gln1276Leu|MET Q1276L|MET p.Gln1276Leu|MET p.Q1276L|NP_000236.2:p.Gln1276Leu|NP_000236.2:p.Q1276L|Proto-Oncogene c-Met Gln1276Leu|Proto-Oncogene c-Met Q1276L|Scatter Factor Receptor Gln1276Leu|Scatter Factor Receptor Q1276L|Tyrosine-Protein Kinase Met Gln1276Leu|Tyrosine-Protein Kinase Met Q1276L	A change in the amino acid residue at position 1276 in the hepatocyte growth factor receptor protein where glutamine has been replaced by leucine.			Cell or Molecular Dysfunction	
C166379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166379>	C39788	MET NM_000245.3:c.3708T>A|HGFR c.3708T>A|MET Proto-Oncogene, Receptor Tyrosine Kinase c.3708T>A|Met Proto-Oncogene (Hepatocyte Growth Factor Receptor) c.3708T>A|NM_000245.3:c.3708T>A|c-Met c.3708T>A	A nucleotide substitution at position 3708 of the coding sequence of the MET gene where thymine has been mutated to adenine.			Cell or Molecular Dysfunction	
C166380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166380>	C136286	MET NP_000236.2:p.K324M|C-MET K324M|C-MET Lys324Met|HGF Receptor K324M|HGF Receptor Lys324Met|HGFR K324M|HGFR Lys324Met|Hepatocyte Growth Factor Receptor K324M|Hepatocyte Growth Factor Receptor Lys324Met|MET K324M|MET Lys324Met|MET NP_000236.2:p.Lys324Met|MET p.K324M|MET p.Lys324Met|NP_000236.2:p.K324M|NP_000236.2:p.Lys324Met|Proto-Oncogene c-Met K324M|Proto-Oncogene c-Met Lys324Met|Scatter Factor Receptor K324M|Scatter Factor Receptor Lys324Met|Tyrosine-Protein Kinase Met K324M|Tyrosine-Protein Kinase Met Lys324Met	A change in the amino acid residue at position 324 in the hepatocyte growth factor receptor protein where lysine has been replaced by methionine.			Cell or Molecular Dysfunction	
C166381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166381>	C133686	MTOR NM_004958.4:c.5664C>G|FK506 Binding Protein 12-Rapamycin Associated Protein 1 c.5664C>G|FRAP c.5664C>G|FRAP1 c.5664C>G|MTOR c.5664C>G|Mammalian Target of Rapamycin c.5664C>G|Mechanistic Target of Rapamycin c.5664C>G|NM_004958.4:c.5664C>G|Rapamycin and FKBP12 Target 1 c.5664C>G	A nucleotide substitution at position 5664 of the coding sequence of the MAP2K2 gene where cytosine has been mutated to guanine.			Cell or Molecular Dysfunction	
C166382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166382>	C133686	MTOR NM_004958.4:c.5664C>A|FK506 Binding Protein 12-Rapamycin Associated Protein 1 c.5664C>A|FRAP c.5664C>A|FRAP1 c.5664C>A|MTOR c.5664C>A|Mammalian Target of Rapamycin c.5664C>A|Mechanistic Target of Rapamycin c.5664C>A|NM_004958.4:c.5664C>A|Rapamycin and FKBP12 Target 1 c.5664C>A	A nucleotide substitution at position 5664 of the coding sequence of the MAP2K2 gene where cytosine has been mutated to adenine.			Cell or Molecular Dysfunction	
C166383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166383>	C133686	MTOR NM_004958.4:c.5662T>C|FK506 Binding Protein 12-Rapamycin Associated Protein 1 c.5662T>C|FRAP c.5662T>C|FRAP1 c.5662T>C|MTOR c.5662T>C|Mammalian Target of Rapamycin c.5662T>C|Mechanistic Target of Rapamycin c.5662T>C|NM_004958.4:c.5662T>C|Rapamycin and FKBP12 Target 1 c.5662T>C	A nucleotide substitution at position 5662 of the coding sequence of the MAP2K2 gene where thymine has been mutated to cytosine.			Cell or Molecular Dysfunction	
C166384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166384>	C97928	MTOR Protein Variant|FK506-Binding Protein 12-Rapamycin Complex-Associated Protein 1 Protein Variant|FKBP12-Rapamycin Complex-Associated Protein Variant|Mammalian Target of Rapamycin Protein Variant|Mechanistic Target of Rapamycin Protein Variant|Rapamycin Target Protein 1 Protein Variant|Serine/Threonine-Protein Kinase mTOR Protein Variant|mTOR Protein Variant	A variation in the amino acid sequence for the serine/threonine-protein kinase mTOR protein.			Cell or Molecular Dysfunction	Pediatric Oncology Target Molecular Abnormalities Terminology
C166385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166385>	C166384	MTOR NP_004949.1:p.G1954R|FK506-Binding Protein 12-Rapamycin Complex-Associated Protein 1 G1954R|FK506-Binding Protein 12-Rapamycin Complex-Associated Protein 1 Gly1954Arg|FKBP12-Rapamycin Complex-Associated G1954R|FKBP12-Rapamycin Complex-Associated Gly1954Arg|MTOR G1954R|MTOR Gly1954Arg|MTOR p.G1954R|MTOR p.Gly1954Arg|Mammalian Target of Rapamycin G1954R|Mammalian Target of Rapamycin Gly1954Arg|Mechanistic Target of Rapamycin G1954R|Mechanistic Target of Rapamycin Gly1954Arg|NP_004949.1:p.G1954R|NP_004949.1:p.Gly1954Arg|Rapamycin Target Protein 1 G1954R|Rapamycin Target Protein 1 Gly1954Arg|Serine/Threonine-Protein Kinase mTOR G1954R|Serine/Threonine-Protein Kinase mTOR Gly1954Arg|mTOR G1954R|mTOR Gly1954Arg	A change in the amino acid residue at position 1954 in the serine/threonine-protein kinase mTOR2 protein where glycine has been replaced by arginine.			Cell or Molecular Dysfunction	
C166386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166386>	C166384	MTOR NP_004949.1:p.F1888L|FK506-Binding Protein 12-Rapamycin Complex-Associated Protein 1 F1888L|FK506-Binding Protein 12-Rapamycin Complex-Associated Protein 1 Phe1888Leu|FKBP12-Rapamycin Complex-Associated F1888L|FKBP12-Rapamycin Complex-Associated Phe1888Leu|MTOR F1888L|MTOR Phe1888Leu|MTOR p.F1888L|MTOR p.Phe1888Leu|Mammalian Target of Rapamycin F1888L|Mammalian Target of Rapamycin Phe1888Leu|Mechanistic Target of Rapamycin F1888L|Mechanistic Target of Rapamycin Phe1888Leu|NP_004949.1:p.F1888L|NP_004949.1:p.Phe1888Leu|Rapamycin Target Protein 1 F1888L|Rapamycin Target Protein 1 Phe1888Leu|Serine/Threonine-Protein Kinase mTOR F1888L|Serine/Threonine-Protein Kinase mTOR Phe1888Leu|mTOR F1888L|mTOR Phe1888Leu	A change in the amino acid residue at position 1888 in the serine/threonine-protein kinase mTOR2 protein where phenylalanine has been replaced by leucine.			Cell or Molecular Dysfunction	
C166387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166387>	C2152|C129825	Parsaclisib Hydrochloride|(4R)-4-(3-((1S)-1-(4-amino-3-methyl-1h-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-onehydrochloric Acid (1:1)|2-Pyrrolidinone, 4-(3-((1S)-1-(4-amino-3-methyl-1h-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)-, Hydrochloride (1:1), (4R)-|INCB 50465 Hydrochloride|INCB050465 Hydrochloride|PARSACLISIB HYDROCHLORIDE	The hydrochloride salt form of parsaclisib, an inhibitor of the delta isoform of phosphoinositide-3 kinase (PI3K) with potential antineoplastic activity. Parsaclisib inhibits the delta isoform of PI3K and prevents the activation of the PI3K/AKT signaling pathway. This both decreases proliferation and induces cell death in PI3K-delta-overexpressing tumor cells. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic disease and cell lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C166388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166388>	C62634	Regimen Used to Treat Malignant Skin Neoplasm	Any regimen that can be used for the treatment of malignant skin neoplasms.			Therapeutic or Preventive Procedure	
C166389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166389>	C63360	Atezolizumab/Carboplatin/Nab-paclitaxel Regimen|Atezolizumab/Carboplatin/Albumin-bound Paclitaxel|Atezolizumab/Carboplatin/Nab-paclitaxel|Atezolizumab/Carboplatin/Nanoparticle Albumin-bound Paclitaxel|Atezolizumab/Carboplatin/Paclitaxel Protein-bound|Carboplatin, nab-Paclitaxel, Atezolizumab|Tecentriq/Carboplatin/Abraxane	A regimen consisting of atezolizumab, carboplatin and nab-paclitaxel that may be used in the treatment of metastatic non-squamous non-small cell lung cancer (NSCLC).			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C16638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16638>	C25464	Gibraltar|292|GI|GIB|GIB|GIBRALTAR|GIBRALTAR	A dependency in southwestern Europe, on the southern coast of Spain, bordering the Strait of Gibraltar.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C166391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166391>	C19967	Cxbladder	A proprietary, non-invasive, urine-based laboratory test for bladder cancer. Cxbladder works by measuring the gene expression of five specific messenger RNA biomarkers (IGF, HOXA, MDK, CDC and IL8R) that represent a bladder cancer signature.	Cxbladder		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C166393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166393>	C25364	Specimen Identifier|Sample ID|Sample Identifier|Sample_ID|sample id|sample_id|specimen id|specimen_id	A unique string of characters used to identify a specimen.			Intellectual Product	Canine Glioma Project Property Terminology|CTDC Property Terminology|ICDC Property Terminology|ICDC Terminology
C166394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166394>	C166393	Sub-Specimen Identifier	A unique alphanumeric identifier assigned to a discrete part of a specimen, such as an individual tube from a multi-tube blood draw.			Intellectual Product	
C166395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166395>	C219691|C186720|C186719	Fedratinib Regimen|Fedratinib monotherapy|Inrebic Regimen	A regimen consisting of fedratinib that may be used in the treatment of myeloproliferative neoplasms and myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C166396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166396>	C166388|C140180	Vismodegib Regimen|Erivedge Regimen|Vismodegib monotherapy	A regimen consisting of vismodegib that may be used in the treatment of basal cell skin cancer and medulloblastoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C166398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166398>	C2124	Uniformly-labeled [13C]glutamine|U-13C-Gln|U-13C-Glutamine|[U-13C]glutamine	A uniformly-labeled radioconjugate composed of glutamine, a naturally occurring non-essential amino acid, in which all five carbons are labeled with the isotope 13C, with potential imaging application. Upon administration of uniformly-labeled [13C]glutamine, the glutamine is taken up and metabolized by tumors and the 13C-containing metabolites can be imaged by 13C nuclear magnetic resonance (NMR) spectroscopy. Since tumor cells take up and metabolize glutamine in higher amounts and through different pathways than normal cells, this agent may help assess the metabolic phenotype of the tumor.	Uniformly-labeled [13C]glutamine		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C166399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166399>	C173097|C133187	Sinonasal Mucosal Melanoma|Nasal Cavity and Paranasal Sinus Melanoma|Sinonasal Melanoma	Melanoma that arises from the mucosal surface of the nasal cavity and paranasal sinus.			Neoplastic Process	
C16639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16639>	C25464	Kiribati|296|KI|KIR|KIR|KIRIBATI|KIRIBATI|Republic of Kiribati	A group of 33 coral atolls in the Pacific Ocean, south of Hawaii and northeast of Jarvis Island.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C1663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1663>	C923|C129820	Antineoplastic Vaccine|Cancer Vaccine|Neoplasm Vaccine|Tumor Vaccine|cancer treatment vaccine|cancer vaccine	A type of vaccine that prevents or treats cancer.	Antineoplastic Vaccine		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology
C166400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166400>	C27993	Inclusive|Including	Including the stated limits.			Qualitative Concept	
C166401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166401>	C2124	Uniformly-labeled [13C]lactate|U-13C-Lactate|[U-13C]lactate	A uniformly-labeled radioconjugate composed of lactate in which all three carbons are labeled with the isotope carbon C 13 (13C), with potential imaging application. Upon administration of uniformly-labeled [13C]lactate, lactate is taken up and metabolized by tumors, via the tricarboxylic acid (TCA) cycle, and the 13C-containing metabolites can be imaged by 13C nuclear magnetic resonance (NMR) spectroscopy. As certain tumor cells preferentially take up and metabolize lactate for fuel, this agent may help assess the extent of lactate metabolism in tumor cells.	Uniformly-labeled [13C]lactate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C166402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166402>	C2124	Uniformly-labeled [13C]fructose|U-13C-Fructose|[U-13C]fructose	A uniformly-labeled radioconjugate composed of the monosaccharide fructose in which all six carbons are labeled with the isotope carbon C 13 (13C), with potential imaging application. Upon administration of uniformly-labeled [13C]fructose, fructose is taken up and metabolized by tumors and the 13C-containing metabolites can be imaged by 13C nuclear magnetic resonance (NMR) spectroscopy. As certain tumor cells preferentially take up and metabolize fructose for fuel, this agent may help assess the extent of fructose metabolism in tumor cells.	Uniformly-labeled [13C]fructose		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C166403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166403>	C65070|C63586|C63360|C210232|C191676|C166388|C159893|C159457|C159439	Cemiplimab Regimen|Cemiplimab monotherapy|Cemiplimab-rwlc Regimen|Libtayo Regimen	A regimen consisting of cemiplimab that may be used in the treatment of basal and squamous cell skin cancer, anal, colorectal, vaginal, vulvar, cervical and non-small cell lung cancer (NSCLC), appendiceal and small bowel adenocarcinoma.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Pharmacotherapy Regimens|Single-agent Therapeutic Regimens
C166405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166405>	C205125|C114828	Mucosal Nodular Melanoma	Nodular melanoma that arises from a mucosal site.			Neoplastic Process	
C166407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166407>	C36327	Cyclin Gene Mutation|CCNx Gene Mutation|Cyclin Gene Family Mutation|Cyclin Mutation	A change in the nucleotide sequence in a cyclin family gene.			Cell or Molecular Dysfunction	
C166408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166408>	C18016	Chromosome Arm 19q Loss of Heterozygosity|19q LOH|19q Loss of Heterozygosity|Chromosome 19q Loss of Heterozygosity	A molecular abnormality that results in monoallelic loss of function mutations located within the long arm of chromosome 19 (19q).			Cell or Molecular Dysfunction	
C166409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166409>	C204999|C200106	Sacituzumab Tirumotecan|ADC MK-2870|ADC SKB264|Anti-TROP2 Antibody-drug Conjugate MK-2870|Anti-TROP2 Antibody-drug Conjugate SKB264|MK 2870|MK-2870|MK2870|SACITUZUMAB TIRUMOTECAN|SKB 264|SKB-264|SKB264	An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) conjugated, via a methyl sulfonyl pyrimidine linker, to the belotecan derivative and topoisomerase I inhibitor tirumotecan, with potential antineoplastic activity. Upon administration of sacituzumab tirumotecan, sacituzumab targets and binds to TROP2 expressed on tumor cells. Upon both extracellular pH-sensitive cleavage and intracellular enzymatic cleavage of the linker, tirumotecan is released and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and apoptosis in tumor cells expressing TROP2. In addition, the bystander effect induced by sacituzumab tirumotecan further inhibits tumor cell proliferation. TROP2 is a transmembrane protein overexpressed in various tumors while its expression is low and/or restricted in normal, healthy tissues; its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival.	Sacituzumab Tirumotecan		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C16640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16640>	C16946	Glucose-6-Phosphate 1-Dehydrogenase|EC 1.1.1.49|G6PD|Glucose-6-Phosphate Dehydrogenase	Glucose-6-phosphate 1-dehydrogenase (515 aa, ~59 kDa) is encoded by the human G6PD gene. This protein plays a role in pentose metabolism to produce NADPH.	Glucose-6-Phosphate 1-Dehydrogenase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C166410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166410>	C201853	KRAS G12C Inhibitor LY3499446|LY 3499446|LY-3499446|LY-3499446|LY3499446	An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration, LY3499446 targets and covalently binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C, thereby inhibiting mutant KRAS-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.	KRAS G12C Inhibitor LY3499446		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C166411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166411>	C97927	NCSTN Gene Mutation|APH2 Gene Mutation|ATAG1874 Gene Mutation|Anterior Pharynx-Defective 2 Gene Mutation|Nicastrin Gene Mutation	A change in the nucleotide sequence of the NCSTN gene.			Cell or Molecular Dysfunction	
C166412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166412>	C97928	NCSTN Protein Variant	A variation in the amino acid sequence for the nicastrin protein.			Cell or Molecular Dysfunction	
C166413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166413>	C166412	NCSTN NP_056146.1:p.A572G|NCSTN A572G|NCSTN Ala572Gly|NCSTN NP_056146.1:p.Ala572Gly|NCSTN p.A572G|NCSTN p.Ala572Gly|NP_056146.1:p.A572G|NP_056146.1:p.Ala572Gly|Nicastrin A572G|Nicastrin Ala572Gly	A change in the amino acid residue at position 572 in the nicastrin protein where alanine has been replaced by glycine.			Cell or Molecular Dysfunction	
C166414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166414>	C3359|C152076	Metastatic Rhabdomyosarcoma	Rhabdomyosarcoma that has spread from its original site of growth to another anatomic site.	Metastatic Rhabdomyosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C166415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166415>	C166414|C153071	Locally Advanced Rhabdomyosarcoma	A rhabdomyosarcoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Rhabdomyosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C166416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166416>	C25763	Pancreatobiliary System|Pancreaticobiliary System	A system that includes the liver, pancreas, bile ducts, and gallbladder.			Body Part, Organ, or Organ Component	
C166417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166417>	C308	Zegocractin|CM 4620|CM-4620|CM4620|CRAC Inhibitor CM4620|Calcium Release-activated Channel Inhibitor CM4620|Orai Ca2+ Channel Inhibitor CM4620|Orai1 Inhibitor CM4620|ZEGOCRACTIN	A calcium (Ca2+) release-activated channel (CRAC) inhibitor, with potential anti-inflammatory and protective activities. Upon administration, zegocractin targets, binds to and inhibits the calcium release-activated calcium channel protein 1 (Orai1), which forms the pore of CRAC, and is expressed on both parenchymal cells and immune cells. This prevents the transport of extracellular Ca2+ into the cell and inhibits the subsequent activation of Ca2+-mediated signaling and transcription of target genes. This may prevent Ca2+ entry-mediated cell death. It may also inhibit the proliferation of immune cells and prevents the release of various inflammatory cytokines in immune cells, such as interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-a). This may lead to a reduction of inflammatory responses in inflammatory-mediated diseases. CRACs, specialized plasma membrane Ca2+ ion channels composed of the plasma membrane based Orai channels and the endoplasmic reticulum (ER) stromal interaction molecules (STIMs), mediate store operated Ca2+ entry (SOCE) and play a key role in calcium homeostasis. CRACs are overactivated in a variety of cell types, especially certain immune cells during inflammation, including T-lymphocytes, neutrophils and macrophages.	Zegocractin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C166418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166418>	C223357|C214986	Pancreatobiliary Carcinoma|Pancreaticobiliary Cancer|Pancreaticobiliary Carcinoma|Pancreatobiliary Cancer	A carcinoma that arises from the pancreas, bile ducts, or gallbladder.	Pancreatobiliary Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C166419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166419>	C47795	Difluanazine|DIFLUANINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16641>	C20130	Glutathione S-Transferase|EC 2.5.1.18|GST|Glutathione S-Alkyltransferase|Glutathione S-Aralkyltransferase|Glutathione S-Aryltransferase|S-(Hydroxyalkyl)Glutathione Lyase|glutathione S-transferase	A class of enzymes that catalyze the reaction of glutathione with an acceptor molecule (an arene oxide) to form an S-substituted glutathione; a key step in detoxification of many substances; start of the mercapturic acid pathway.	Glutathione S-Transferase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C166420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166420>	C47795	Serdexmethylphenidate|SERDEXMETHYLPHENIDATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166421>	C20401	Lodelcizumab|LODELCIZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166422>	C29750	Monteplase|MONTEPLASE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166423>	C201818	Pozelimab|POZELIMAB|REGN 3918|REGN-3918|REGN3918|WHO 10945	A human immunoglobulin G4 (IgG4) monoclonal antibody directed against terminal complement protein C5, with potential anti-inflammatory activity. Upon administration, pozelimab targets and binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and preventing the complement-mediated destruction of red blood cells (RBCs) as seen in paroxysmal nocturnal hemoglobinuria (PNH). C5, a complement pathway protein, is expressed at high levels by the liver.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C166424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166424>	C142786	Lemborexant|LEMBOREXANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166425>	C112889	Denintuzumab|DENINTUZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166426>	C78276	Idremcinal|IDREMCINAL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166427>	C265	Modaline|MODALINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166428>	C29576	Butaxamine|BUTOXAMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166429>	C66884	Ordopidine|ORDOPIDINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16642>	C20028	Glycoprotein|glycoprotein	A conjugated protein having a carbohydrate component.			Amino Acid, Peptide, or Protein	
C166430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166430>	C333	Levamlodipine|LEVAMLODIPINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166431>	C78322|C48149	Levdobutamine|LEVDOBUTAMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166432>	C264	Padsevonil|PADSEVONIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166433>	C2083	Guadecitabine Sodium|GUADECITABINE SODIUM	The sodium salt form of guadecitabine, a dinucleotide antimetabolite composed of a decitabine linked via phosphodiester bond to a deoxyguanosine, with potential antineoplastic activity. Following metabolic activation via cleavage of the phosphodiester bond and incorporation of the decitabine moiety into DNA, guadecitabine inhibits DNA methyltransferase, thereby causing non-specific, genome-wide hypomethylation, and induction of cell cycle arrest at S-phase. This agent is resistant to cytidine deaminase, which may result in gradual release of decitabine both extra- and intra-cellularly, leading to prolonged exposure to decitabine.	Guadecitabine Sodium		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166434>	C243	Methenolone Enanthate|METHENOLONE ENANTHATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166435>	C584	Peginterferon Lambda-1A|PEGINTERFERON LAMBDA-1A|Peginterferon Lambda|Pegylated IFN Lambda-1a|Pegylated Interferon Lambda-1a	A covalent conjugate of human recombinant interferon (IFN) lambda-1 (IFN-L1; IL-29), a type III IFN, and a linear polyethylene glycol (PEG) chain, with antiviral and immunomodulating activities. Upon administration, peginterferon lambda-1A targets and binds to type III IFN receptors, which activates the JAK-STAT signaling cascade and upregulates IFN-stimulated genes (ISGs), leading to cell-mediated immune responses. The PEG chain of peginterferon lambda-1A lowers the clearance of interferon lambda-1A, thereby extending the duration of its therapeutic effects. Endogenous IFN-L1 is produced following viral infection and it plays a key role in innate immune response against the viral pathogens.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C166436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166436>	C20401	Marstacimab|MARSTACIMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166437>	C217517	Furaprevir|FURAPREVIR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166438>	C280	Pentizidone|PENTIZIDONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166439>	C29707	Bupicomide|BUPICOMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16643>	C21034|C17019	Protein Glycosylation|Glycosylation|Glycosylation	The covalent chemical or post-translational biochemical addition of carbohydrate or glycosyl groups to peptides or proteins by glycosyl transferases.			Molecular Function	PQ/CMC Test Subcategory Terminology
C166440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166440>	C1937	Fluorfenidine (18F)|FLUORFENIDINE F-18|FLUORFENIDINE F-18				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166441>	C921	Epaminurad|EPAMINURAD				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166442>	C308	Abecomotide|ABECOMOTIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166443>	C471	Mercuderamide|MERCUDERAMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166444>	C20401	Aducanumab|ADUCANUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166445>	C574	Blisibimod|BLISIBIMOD				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166446>	C20401	Fasinumab|FASINUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166447>	C29710	Cinperene|CINPERENE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166448>	C471	Crisdesalazine|CRISDESALAZINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166449>	C2144	Risuteganib|RISUTEGANIB				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16644>	C20020	Grant|Grants	A financial assistance mechanism through which money and/or direct assistance is provided to carry out approved activities.			Governmental or Regulatory Activity	
C166450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166450>	C20401	Ozanezumab|OZANEZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166451>	C1505	Levocarnitine Propionate Hydrochloride|PROPIONYL-L-CARNITINE CHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166452>	C257	Metiazinic Acid|METIAZINIC ACID				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166453>	C471	Lanopepden|LANOPEPDEN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166454>	C2167|C129825	Naquotinib Mesylate|NAQUOTINIB MESYLATE	The mesylate salt form of naquotinib, an orally available, irreversible, third-generation, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, naquotinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. Naquotinib preferentially inhibits mutated forms of EGFR including T790M, a secondarily acquired resistance mutation, and may have therapeutic benefits in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166455>	C63817	Elubrixin Tosylate|ELUBRIXIN TOSYLATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166456>	C83486	Glycol Distearate|GLYCOL DISTEARATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166457>	C257	Diftalone|DIFTALONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166458>	C521	Mapracorat|MAPRACORAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166459>	C276	Melarsonyl Potassium|MELARSONYL POTASSIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16645>	C25464	Greece|300|GR|GRC|GRC|GREECE|GREECE	A country in southern Europe, bordering the Aegean, Ionian, and Mediterranean Seas, between Albania and Turkey.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C166460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166460>	C217517	Faldaprevir Sodium|FALDAPREVIR SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166461>	C81924	Polysorbate 65|POLYSORBATE 65				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166462>	C82130	Policapram|POLICAPRAM				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166463>	C66886	Dimethyltubocurarinium Chloride|METOCURINE CHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166464>	C226773|C226765	Cenicriviroc|CENICRIVIROC|CVC	An orally bioavailable, dual inhibitor of human C-C chemokine receptor types 2 (CCR2; CD192) and 5 (CCR5; CD195), with potential immunomodulating, anti-inflammatory and antiviral activities. Upon oral administration, cenicriviroc specifically binds to and prevents the activation of both CCR2 and CCR5. This inhibits the activation of CCR2/CCR5-mediated signal transduction pathways and may inhibit inflammatory processes. The G-protein coupled chemokine receptors CCR2 and CCR5 are expressed on the surface of monocytes and macrophages and stimulate their migration and infiltration; they play key roles in inflammation and autoimmune diseases. In addition, cenicriviroc inhibits human immunodeficiency virus (HIV)-1 entry via CCR5 coreceptor interaction.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C166465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166465>	C20401	Lutikizumab|ABT 981|ABT-981|ABT981|LUTIKIZUMAB	A dual-variable domain (DVD) immunoglobulin G1 kappa (IgG1k) against the inflammatory cytokine human interleukin-1 alpha (IL-1a) and beta (IL-1b), with potential anti-inflammatory activity. Upon administration, lutikizumab targets, binds to, and neutralizes IL-1a/b thereby preventing the activity of IL-1a and IL-1b. This may inhibit IL1a/b-mediated inflammatory responses. This may reduce pain and slows tissue destruction and structural progression in diseases in which IL-1a/b are upregulated. IL1a/b, inflammatory mediators, play key roles in immune regulation and inflammatory processes.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C166466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166466>	C20401	Eldelumab|ELDELUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166467>	C78322	Pengitoxin|PENGITOXIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166468>	C82130	Ompinamer|OMPINAMER				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166469>	C29701	Hydrotalcite|HYDROTALCITE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16646>	C25464	Greenland|304|GL|GREENLAND|GREENLAND|GRL|GRL	An island between the Arctic Ocean and the North Atlantic Ocean, northeast of Canada.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C166470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166470>	C471	Soticlestat|SOTICLESTAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166471>	C28500	Iomeprol|IOMEPROL				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166472>	C264	Citenamide|CITENAMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166473>	C81123	Beroctocog Alfa|BEROCTOCOG ALFA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166474>	C154291	Pemafibrate|PEMAFIBRATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166475>	C20401	Larcaviximab|LARCAVIXIMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166476>	C98148	Polidexide Sulfate|POLIDEXIDE SULFATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166477>	C82130	Tolevamer Sodium|TOLEVAMER SODIUM				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166478>	C1291	Mipomersen Sodium|MIPOMERSEN SODIUM				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166479>	C250	Alazanine Triclofenate|ALAZANINE TRICLOFENATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16647>	C25464	Grenada|308|GD|GRD|GRD|GRENADA|GRENADA	An island between the Caribbean Sea and Atlantic Ocean, south of Saint Vincent and the Grenadines and north of Trinidad and Tobago.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C166480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166480>	C20401	Nerelimomab|NERELIMOMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166481>	C52588	Exeporfinium Chloride|EXEPORFINIUM CHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166482>	C78275	Glaspimod|GLASPIMOD				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166483>	C185721	Ampreloxetine|AMPRELOXETINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166484>	C20401	Donanemab|DONANEMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166485>	C20401	Bedinvetmab|BEDINVETMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166486>	C1288	Ecogramostim|ECOGRAMOSTIM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166487>	C243	Bolenol|BOLENOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166488>	C38149	Pareptide Sulfate|PAREPTIDE SULFATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166489>	C164163	Eftansomatropin Alfa|EFTANSOMATROPIN ALFA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16648>	C21147	Tissue Growth|Growth	An increase is the size or mass of a tissue due to an increase in cell number.			Organ or Tissue Function	
C166490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166490>	C147908	Dersimelagon|1-[2-[(3R,4S)-1-[(3S,4S)-1-Cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidine-3-carbonyl]-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl]piperidine-4-carboxylic Acid|DERSIMELAGON|MC1R Agonist MT-7117|MT 7117|MT-7117|MT7117	An orally bioavailable selective, non-peptide melanocortin-1 receptor (MC1R; melanocyte-stimulating hormone receptor; MSHR; melanin-activating peptide receptor; melanotropin receptor) agonist, that can potentially be used to prevent phototoxicity. Upon administration, dersimelagon targets, binds to and activates MC1R. This may prevent phototoxicity and related pain in erythropoietic protoporphyria (EPP) or X-Linked Protoporphyria (XLP) patients. MC1R, a G protein-coupled receptor that binds to melanocortins and are located on melanocytes, is involved in regulating mammalian skin and hair color.	Dersimelagon		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C166491	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166491>	C129823	Clivatuzumab Tetraxetan|CLIVATUZUMAB TETRAXETAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166492>	C461	Chlorophyllin Copper Complex|SODIUM COPPER CHLOROPHYLLIN				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166493	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166493>	C29712	Oxalinast|OXALINAST				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166494	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166494>	C80482	Bempedoic Acid|BEMPEDOIC ACID|Bempedoic acid|Nexletol	An orally bioavailable prodrug and inhibitor of adenosine triphosphate-citrate lyase (ACL), with anti-hyperlipidemic activity. Upon oral administration, bempedoic acid becomes activated to its thioester form with coenzyme A (CoA) by the enzyme very long-chain acyl-CoA synthetase 1 (ACSVL1; SLC27A2) in the liver. The activated form inhibits ACL, thereby preventing the liver's biosynthesis of cholesterol. This lowers low-density lipoprotein cholesterol (LDL-C) levels. ACL is an enzyme upstream of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase in the cholesterol biosynthesis pathway.			Pharmacologic Substance	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|Appendix 8: Pharmacological Therapy Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|Therapies for Preexisting Cardiovascular Disease (Patient Taking Prior to Admission) Terminology
C166495	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166495>	C681	Diprenorphine|DIPRENORPHINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166496	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166496>	C78322|C270	Colforsin|COLFORSIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166497>	C129824	Mitogillin|MITOGILLIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166498>	C574|C208255	Telitacicept|RC 18|RC-18|RC18|TELITACICEPT	A fusion protein composed of the extracellular domain of human tumor necrosis factor receptor superfamily member 13B (TNFRSF13B; transmembrane activator and calcium modulator and cyclophilin ligand interactor; TACI) fused to a human immunoglobulin (Ig) fragment crystallizable (Fc) domain, with potential immunomodulating activity. Upon administration, telitacicept targets both tumor necrosis factor ligand superfamily member 13B (TNFSF13B; BAFF; B lymphocyte stimulator; BLyS) and tumor necrosis factor ligand superfamily member 13 (TNFSF13; a proliferation-inducing ligand; APRIL) and inhibits their interaction with their cell membrane receptors, including TACI, tumor necrosis factor receptor superfamily member 17 (TNFRSF17; B-cell maturation antigen; BCMA) and tumor necrosis factor receptor superfamily member 13C (TNFRSF13C; BAFF receptor; BAFF-R). This inhibits B-cell proliferation and maturation, thereby inhibiting B-cell mediated autoimmune responses. APRIL and BAFF, and their interactions with their receptors TACI, BCMA and BAFF-R, play important roles in in B-cell proliferation and survival.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C166499	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166499>	C1946|C129825	Alteminostat|ALTEMINOSTAT|CKD 581|CKD-581|CKD581|HDAC Inhibitor CKD-581	A highly water-soluble, pan histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon administration, alteminostat targets and inhibits HDAC, resulting in an accumulation of highly acetylated histones, the induction of chromatin remodeling, and an altered pattern of gene expression. This leads to the inhibition of tumor oncogene transcription, and the selective transcription of tumor suppressor genes, which results in the inhibition of tumor cell division and the induction of tumor cell apoptosis. HDACs, upregulated in many tumor cell types, are a family of metalloenzymes responsible for the deacetylation of chromatin histone proteins.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C16649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16649>	C19988	Embryogenesis|Embryonal Development|Embryonic Development	Embryogenesis is the developmental process by which an embryo is formed and developed.  The process begins following fertilization and involves cellular differentiation, leading to the completion of the embryonic stage.			Organism Function	
C1664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1664>	C1592	Recombinant Interferon-alpha Inducible Protein 10|CXCL10|IP 10|Interferon-gamma Inducible Protein 10	A recombinant agent, chemically identical or similar to the endogenous small inducible cytokine B10 (IP-10). Interferon-alpha inducible protein 10 is secreted from macrophages, endothelial cells, and keratinocytes in response to stimulation of IFN-gamma. This agent is a potent inhibitor of angiogenesis, bone marrow colony formation, and is a chemoattractant for monocytes and T-cells, promotes T-cell adhesion to endothelial cells, and probably participates in chronic cell-mediated inflammatory reactions.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C166500	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166500>	C82130	Patiromer|PATIROMER				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166501>	C314	Hydroxyethyl Starch 130/0.4|HYDROXYETHYL STARCH 130/0.4				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166502	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166502>	C78276	Ibodutant|IBODUTANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166503	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166503>	C48149	Batefenterol|BATEFENTEROL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166504	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166504>	C82130	Polyoxypropylene 15 Stearyl Ether|POLYPROPYLENE GLYCOL 15 STEARYL ETHER|Polypropylene Glycol 15 Stearyl Ether|Ppg-15 Stearyl Ether				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166505	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166505>	C308	Forigerimod|FORIGERIMOD				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166506>	C78568	Esuberaprost|ESUBERAPROST				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166507	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166507>	C319	Piquizil|PIQUIZIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166508	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166508>	C1291	Bazlitoran Sodium|BAZLITORAN SODIUM				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166509	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166509>	C496	Ersofermin|ERSOFERMIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16650>	C16701	GTPase|Guanosinetriphosphatase	Proteins that hydrolyze guanine triphosphate to yield guanine diphosphate. This is a class of proteins that belongs to a family of high energy phosphate hydrolases. Members of this family play major roles in biological signal transduction pathways.			Amino Acid, Peptide, or Protein|Enzyme	
C166510	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166510>	C47795	Dasolampanel|DASOLAMPANEL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166511	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166511>	C29704	Glycopyrronium Tosylate|GLYCOPYRRONIUM TOSYLATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166512	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166512>	C129822	Tamrintamab|TAMRINTAMAB				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166513	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166513>	C29576	Pamatolol Sulfate|PAMATOLOL SULFATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166514	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166514>	C62358	Gadocoletic Acid|GADOCOLETIC ACID				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166515	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166515>	C1012	Oxazolam|OXAZOLAM				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166516	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166516>	C221361	Coumermycin Sodium|COUMERMYCIN SODIUM				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166517>	C78272	Dasotraline Hydrochloride|DASOTRALINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166518	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166518>	C471	Giripladib|GIRIPLADIB				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166519>	C78272	Elpetrigine|ELPETRIGINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16651>	C25464	Guadeloupe|312|GLP|GLP|GP|GUADELOUPE|GUADELOUPE	A group of islands in the Caribbean Seas, southeast of Montserrat.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C166520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166520>	C78276	Mizagliflozin|MIZAGLIFLOZIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166521>	C548	Afamelanotide Acetate|AFAMELANOTIDE ACETATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166522>	C314	Hemoglobin Glutamer-250 (Bovine)|HEMOGLOBIN GLUTAMER-250 (BOVINE)				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166523>	C87006	Ivacaftor|IVACAFTOR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166524>	C66880	Pentapiperide|PENTAPIPERIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166525>	C29709	Lerimazoline|LERIMAZOLINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166526>	C2021	Metesind|METESIND				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166527>	C29576	Pamatolol|PAMATOLOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166528>	C213309	Alipogene Tiparvovec|ALIPOGENE TIPARVOVEC				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166529>	C1323	Naproxen Etemesil|NAPROXEN ETEMESIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16652>	C25464	Guam|316|GU|GUAM|GUAM|GUM|GUM	An island in the North Pacific Ocean, about three-quarters of the way from Hawaii to the Philippines, south of the Northern Mariana Islands.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology|SeroNet Authorized Values|SeroNet Study Descriptors
C166530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166530>	C217517	Danoprevir Sodium|DANOPREVIR SODIUM	The sodium salt form of danoprevir, an orally bioavailable, peptidomimetic inhibitor of hepatitis C virus (HCV) NS3/4A protease, with antiviral activity against HCV and potential antiviral activity against SARS-CoV-2. Upon oral administration, danoprevir binds to and blocks the activity of HCV NS3/4A protease. This prevents the cleavage and processing of HCV viral proteins leading to the inhibition of HCV replication. Danoprevir may also bind to and block of the activity of SARS-CoV-2 protease. This prevents the cleavage and processing of SARS-CoV-2 viral proteins leading to the inhibition of SARS-CoV-2 replication. NS3/4A, a chymotrypsin-like serine protease, is responsible for cleavage at four sites of the HCV polyprotein to form the viral proteins required for HCV replication. It plays a key role in the HCV viral replication process. HCV infection is associated with the development of hepatocellular carcinoma (HCC). A chymotrypsin-like protease is responsible for cleavage of the SARS-CoV-2 viral polyprotein to form the RNA replicase-transcriptase complex, which plays a key role in the SARS-CoV-2 viral transcription and replication process.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C166531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166531>	C52588	Lefamulin|LEFAMULIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166532>	C281	Eprociclovir|EPROCICLOVIR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166533>	C66884	Naxagolide|NAXAGOLIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166534>	C93038	Dexsotalol Hydrochloride|DEXSOTALOL HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166535>	C20401	Lanadelumab|DX-2930|LANADELUMAB|Lanadelumab-flyo|SHP643|TAK-743|Takhzyro	A fully human immunoglobulin G1 (IgG1) monoclonal antibody against plasma kallikrein that can be used for the treatment of hereditary angioedema (HAE). Upon administration, lanadelumab targets and binds to plasma kallikrein, thereby inhibiting its proteolytic activity. This inhibits the cleavage of high-molecular-weight-kininogen (HMWK) into cleaved HMWK (cHMWK) and bradykinin. This in turn may prevent bradykinin-driven vasodilation, the resulting increase in vascular permeability, and the swelling and pain associated with HAE. This may also prevent or improve pulmonary edema not associated with HAE and improve the associated decrease in blood oxygen levels.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C166536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166536>	C245	Chloralose|CHLORALOSE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166537>	C521	Halopredone Acetate|HALOPREDONE ACETATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166538>	C29578	Isamoxole|ISAMOXOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166539>	C52588	Cetrimide|CETRIMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16653>	C20130	Guanylate Cyclase|EC 4.6.1.2	Guanylate cyclase (GC) is an enzyme that converts GTP to the second messenger cyclic GMP (cGMP). There are two forms: plasma membrane GCs that are receptors for hormones, and intracellular soluble GCs that are activated by the gaseous second messenger nitric oxide (NO). EC 4.6.1.2			Amino Acid, Peptide, or Protein|Enzyme	
C166540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166540>	C28500	Iosulamide Meglumine|IOSULAMIDE MEGLUMINE				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166541>	C921	Lesinurad Sodium|LESINURAD SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166542>	C308	Dirucotide|DIRUCOTIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166543>	C265	Centanafadine Hydrochloride|CENTANAFADINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166544>	C1506	Methyldihydromorphine|METHYLDIHYDROMORPHINE				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166545>	C29696	Nafomine|NAFOMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166546>	C67413	Noracymethadol Hydrochloride|NORACYMETHADOL HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166547>	C67413	Phenomorphan|PHENOMORPHAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166548	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166548>	C1291	Cobomarsen Sodium|COBOMARSEN SODIUM				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166549>	C265	Nemifitide Ditriflutate|NEMIFITIDE DITRIFLUTATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16654>	C25464	Guatemala|320|GT|GTM|GTM|GUATEMALA|GUATEMALA	A country in Central America, bordering the Caribbean Sea and the North Pacific Ocean, east of Mexico and west of Belize and Honduras.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C166550	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166550>	C241	Doxpicomine Hydrochloride|DOXPICOMINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166551	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166551>	C314	Hemoglobin Crosfumaril (Bovine)|HEMOGLOBIN CROSFUMARIL (BOVINE)				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166552	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166552>	C78311	Nonacog Beta Pegol|NONACOG BETA PEGOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166553	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166553>	C210975	Atabecestat|ATABECESTAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166554>	C217517	Narlaprevir|NARLAPREVIR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166555>	C129825	Pevonedistat Hydrochloride|PEVONEDISTAT HYDROCHLORIDE	The hydrochloride salt form of pevonedistat, a small molecule inhibitor of Nedd8 activating enzyme (NAE) with potential antineoplastic activity. Pevonedistat binds to and inhibits NAE, which may result in the inhibition of tumor cell proliferation and survival. NAE activates Nedd8 (Neural precursor cell expressed, developmentally down-regulated 8), an ubiquitin-like (UBL) protein that modifies cellular targets in a pathway that is parallel to but distinct from the ubiquitin-proteasome pathway (UPP). Functioning in diverse regulatory activities, proteins conjugated to UBLs like Nedd8 typically are not targeted for proteasomal degradation.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166556>	C154291	Lanifibranor|LANIFIBRANOR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166557>	C133878	Losatuxizumab|LOSATUXIZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166558>	C47795	Difluanine Hydrochloride|DIFLUANINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166559>	C2127	Lodenafil Carbonate|LODENAFIL CARBONATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16655>	C25464	Guinea|324|GIN|GIN|GN|GUINEA|GUINEA	A country in western Africa, bordering the North Atlantic Ocean, between Guinea-Bissau and Sierra Leone.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C166560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166560>	C263	Antithrombin Gamma|ANTITHROMBIN GAMMA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166561>	C20401	Obiltoxaximab|OBILTOXAXIMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166562	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166562>	C574	Aurothioglycanide|AUROTHIOGLYCANIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166563>	C776	Methynodiol Diacetate|METHYNODIOL DIACETATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166564>	C243	Metribolone|METRIBOLONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166565	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166565>	C129650	Filgotinib Hydrochloride|FILGOTINIB HYDROCHLORIDE	The hydrochloride salt form of filgotinib, an orally bioavailable inhibitor of the tyrosine kinase Janus kinase 1 (JAK1), with potential anti-inflammatory and immunomodulating activities. Upon oral administration, filgotinib specifically targets, binds to, and inhibits the phosphorylation of JAK1, which interferes with JAK/STAT (signal transducer and activator of transcription)-dependent signaling. As JAK1 mediates signaling of many pro-inflammatory cytokines, JAK1 inhibition prevents cytokine signaling and activity in many inflammatory and immune-mediated processes and leads to a decrease in inflammation and activation of certain immune cells. JAK1 plays a key role in the signaling and activity of many cytokines and growth factors and is often dysregulated in a variety of autoimmune and inflammatory diseases, as well as some malignancies.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166566>	C883	Timbetasin|TIMBETASIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166567>	C2149	Acumapimod|ACUMAPIMOD				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166568	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166568>	C448	Mercumatilin Sodium|MERCUMATILIN SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166569	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166569>	C241	Nabitan Hydrochloride|NABITAN HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16656>	C25464	Guinea-Bissau|624|GNB|GNB|GUINEA-BISSAU|GUINEA-BISSAU|GW	A country in western Africa, bordering the North Atlantic Ocean, between Guinea and Senegal.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C166570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166570>	C308	Moxilubant|MOXILUBANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166571>	C29701	Meciadanol|MECIADANOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166572>	C66885	Intepirdine|INTEPIRDINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166573>	C277	Acoziborole|ACOZIBOROLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166574>	C154291	Elafibranor|ELAFIBRANOR|GFT 505|GFT-505|GFT505|IQIRVO	An orally bioavailable agonist of peroxisome proliferator-activated receptor (PPAR)-alpha (PPARa) and -delta (PPARd), with bile acids reducing activity. Upon oral administration, elafibranor, and its main active metabolite GFT1007, target, bind to and activate PPARa and PPARd in the liver. This induces the expression of fibroblast growth factor 21 (FGF21) and downregulates CYP7A1, the key enzyme responsible for the synthesis of bile acids from cholesterol. By reducing CYP7A1 expression, bile acid synthesis is reduced. This leads to reduced bile toxicity, and reduced inflammation and scarring associated with primary biliary cholangitis (PBC).	Elafibranor		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C166575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166575>	C29710	Brexpiprazole|BREXPIPRAZOLE|Rexulti				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166576>	C2149	Brimapitide|BRIMAPITIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166577>	C129820	Bifikafusp Alfa|BIFIKAFUSP ALFA		Bifikafusp Alfa		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C166578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166578>	C257	Isoxepac|ISOXEPAC				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166579>	C78322	Omecamtiv Mecarbil|OMECAMTIV MECARBIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16657>	C25464	Guyana|328|GUY|GUY|GUYANA|GUYANA|GY	A country in northern South America, bordering the North Atlantic Ocean, between Suriname and Venezuela.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C166580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166580>	C29697	Cofisatin|COFISATIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166581>	C802	Choline Gluconate|CHOLINE GLUCONATE				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166582>	C319	Hoquizil|HOQUIZIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166583>	C257	Diflumidone Sodium|DIFLUMIDONE SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166584	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166584>	C1291	Tofersen|TOFERSEN				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166585>	C20401	Orticumab|ORTICUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166586>	C2198	Leconotide|LECONOTIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166587>	C1505	Triheptanoin|TRIHEPTANOIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166588>	C29712|C177182	Fevipiprant|FEVIPIPRANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166589>	C270	Guanacline|GUANACLINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16658>	C16749	Gynecology|GYN	The branch of medicine that deals with the diseases and hygiene of women.			Biomedical Occupation or Discipline	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C166590	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166590>	C1937	Iodopyracet I 125|IODOPYRACET I-125				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166591>	C1287	Eflenograstim Alfa|EFLENOGRASTIM ALFA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166592>	C29703	Pradigastat|PRADIGASTAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166593>	C47794	Flurdihydroergotamine|FLURDIHYDROERGOTAMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166594>	C78322	Cimlanod|CIMLANOD				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166595>	C667	Carbenzide|CARBENZIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166596>	C66885	Cerlapirdine Hydrochloride|CERLAPIRDINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166597>	C1446	Calcium Chloride Ca 47|CALCIUM CHLORIDE CA-47				Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166598>	C177170	Odevixibat|ODEVIXIBAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166599>	C241	Desmetramadol|DESMETRAMADOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16659>	C17061	Oncogene H-Ras|HRAS|HRAS1|Harvey Rat Sarcoma Viral Oncogene Homolog|v-Ha-RAS Harvey Rat Sarcoma Viral Oncogene Homolog	The oncogene (v-ras-Ha or v-Ha-ras) of Harvey murine sarcoma virus (Ha-MuSV) encodes a transforming protein.	Oncogene H-Ras		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C1665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1665>	C1946	Trapoxin|Cyclo((S)-gamma-oxo-L-alpha-aminooxiraneoctanoyl-L-phenylalanyl-L-phenylalanyl-D-2-piperidinecarbonyl)|Cyclo((S)-phenylalanyl-(S)-phenylalanyl-(R)-pipecolinyl-(2S,9S)-2-amino-8-oxo-9,10-epoxydecanoyl)|Cyclo(L-phenylalanyl-L-phenylalanyl-D-pipecolinyl-L-2-amino-8-oxo -9,10-epoxy - decanoyl)|TRAPOXIN A|Trapoxin A|Trapoxin A	An epoxide-containing cyclotetrapeptide with antitumor activity.  It is an irreversible inhibitor of histone deacetylase.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C166600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166600>	C39713	Elocalcitol|ELOCALCITOL				Vitamin	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166601>	C217549	Pibrentasvir|PIBRENTASVIR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166602>	C47793	Bidisomide|BIDISOMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166603>	C159200	Rosomidnar|ROSOMIDNAR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166604>	C157400	Fostemsavir Tromethamine|FOSTEMSAVIR TROMETHAMINE|Rukobia|Rukobia	The tromethamine salt form of fostemsavir, an orally bioavailable phosphonooxymethyl prodrug of the human immunodeficiency virus type 1 (HIV-1) attachment inhibitor temsavir, with activity against HIV. Upon oral administration, fostemsavir is hydrolyzed to the active moiety temsavir. Temsavir targets and binds to the gp120 subunit within the HIV-1 envelope glycoprotein gp160. This selectively inhibits the interaction between HIV-1 virus and host cellular CD4 receptors, thereby preventing HIV-1 virus attachment. This also inhibits gp120-dependent post-attachment steps that are needed for HIV-1 viral entry into host cells.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166605>	C45678	Betasizofiran|BETASIZOFIRAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166606>	C280	Pretomanid|PRETOMANID				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166607>	C1941	Tengonermin|TENGONERMIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166608>	C223122	Dapansutrile|DAPANSUTRILE|OLT 1177|OLT-1177|OLT1177	An orally bioavailable inhibitor of the innate immune signaling sensor nucleotide-binding domain and leucine-rich repeat (NLR) family pyrin domain containing 3 (NLRP3; NACHT, LRR and PYD containing protein 3; NALP3), with potential immunomodulatory and anti-inflammatory activities. Upon oral administration, dapansutrile specifically binds to and inhibits NLRP3, the sensor component of the NLRP3 inflammasome, and prevents the formation of the NLRP3 inflammasome. This inhibits the production of the pro-inflammatory cytokines interleukin-1-beta (IL-1beta) and interleukin-18 (IL-18), which may prevent or reduce inflammation. NLRP3 plays an important role in immunity and inflammation.	Dapansutrile		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C166609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166609>	C20401	Pritoxaximab|PRITOXAXIMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16660>	C25464	Haiti|332|HAITI|HAITI|HT|HTI|HTI|Haïti	A country comprising the western one-third of the island of Hispaniola, between the Caribbean Sea and the North Atlantic Ocean, west of the Dominican Republic.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C166610	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166610>	C129818	Erteberel|ERTEBEREL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166611>	C94727	Fluotracen|FLUOTRACEN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166612	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166612>	C129820	Litenimod|LITENIMOD				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166613	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166613>	C29713	Pentamoxane|PENTAMOXANE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166614>	C921	Dotinurad|DOTINURAD				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166615>	C29709	Piclidenoson|1-Deoxy-1-(6-(((3-iodophenyl)methyl)amino)-9H-purin-9-yl)-N-methyl-beta-D-ribofuranuronamide|3-IB-Meca|CF-101|CF101|IB-MECA|Methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-b-D-ribofuronamide|N(6)-(3-Iodobenzyl)-5'-N-methylcarboxamidoadenosine|N(6)-Ibamu|PICLIDENOSON|SI-615|beta-D-Ribofuranuronamide, 1-Deoxy-1-(6-(((3-iodophenyl)methyl)amo)-9H-purin-9-yl)-N-methyl-	An orally bioavailable, adenosine A3 receptor (A3AR) agonist with potential anti-inflammatory activity. Upon administration, piclidenoson selectively targets, binds to and activates the cell surface-expressed A3AR, thereby activating transduction pathways in which A3AR plays a key role. This inhibits nuclear factor-kappa B (NF-kB) signaling and inhibits inflammatory cytokine production, such as tumor necrosis factor (TNF) and several interleukins. A3AR, a G protein-coupled receptor, plays a key role in many inflammatory diseases, and in certain types of cancer.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C166616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166616>	C82130	Dextranomer|DEXTRANOMER				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166617>	C1663	Asudemotide|ASUDEMOTIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166618>	C448	Carzenide|CARZENIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166619>	C265	Basimglurant|BASIMGLURANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16661>	C199141	Disabled Population|Disabled	Groups with similar restrictions or lack or ability to perform physical or mental activities in a manner or within the range considered normal for a human being.			Patient or Disabled Group	
C166620	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166620>	C183052	Miricorilant|CORT 118335|CORT-118335|CORT118335|MIRICORILANT	An orally bioavailable, selective glucocorticoid receptor (GR) mixed agonist/antagonist and mineralocorticoid receptor (MR) antagonist, with potential metabolic regulating and hepatoprotective activities. Upon oral administration, miricorilant selectively targets and binds to GRs, thereby modulating the effects of cortisol-mediated GR pathways, and binds to and inhibits the activity of MR. This improves lipid efflux from the liver, reduces liver fat content (LFC) and lipid levels, reduces liver inflammation, reduces liver injury and fibrosis, improves insulin sensitivity and resistance, and prevents weight gain.	Miricorilant		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C166621	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166621>	C258	Linopristin|LINOPRISTIN				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166622>	C78275	Bixalomer|BIXALOMER				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166623>	C1752	Amilomotide|AMILOMOTIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166624>	C744	Lavamilast|LAVAMILAST				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166625>	C20401	Tuvirumab|TUVIRUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166626>	C28394	Oxychlorosene|OXYCHLOROSENE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166627>	C265	Cyprolidol|CYPROLIDOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166628>	C254	Polihexanide|POLIHEXANIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166629>	C78272	Hydromethylthionine Mesylate|HYDROMETHYLTHIONINE MESYLATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16662>	C16835	Harding-Passey Malignant Melanoma|Harding-Passey Melanoma	A melanin-forming tumor that arose spontaneously in a non-inbred mouse, and that is transplantable to mice of many strains but does not ordinarily metastasize. (dictionarybarn.com)	Harding-Passey Melanoma		Experimental Model of Disease|Neoplastic Process	
C166630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166630>	C257	Cicloprofen|CICLOPROFEN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166631>	C47795	Dimoxamine Hydrochloride|DIMOXAMINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166632>	C308	Cobitolimod|COBITOLIMOD				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166633>	C20401	Garadacimab|CSL 312|CSL-312|CSL312|GARADACIMAB	A humanized monoclonal antibody against the activated coagulation factor XIIa (FXIIa), with potential anti-inflammatory and anticoagulant activities. Upon administration, garadacimab targets and binds to FXIIa, blocking the activation of both the kallikrein-kinin system and the intrinsic pathway of coagulation. Blocking the activation of the kallikrein-kinin system may reduce inflammation as well as the production of bradykinin (BK). This may prevent BK-driven edema in hereditary angioedema (HAE). Blocking the activation of the intrinsic pathway of coagulation may lead to anti-coagulation. This may also prevent or improve pulmonary edema not associated with HAE and improve the associated decrease in blood oxygen levels.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C166634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166634>	C1657	Norcodeine|NORCODEINE				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166635>	C47795	Clortermine Hydrochloride|CLORTERMINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166636>	C78275	Delparantag Pentahydrochloride|DELPARANTAG PENTAHYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166637	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166637>	C29698	Camylofin|CAMYLOFIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166638>	C314	Hemoglobin Glutamer-256 (Human)|HEMOGLOBIN GLUTAMER-256 (HUMAN)				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166639	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166639>	C29747	Lubabegron Fumarate|LUBABEGRON FUMARATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16663>	C19683	Health Behavior|Health and Behavior	The actions taken by an individual to maintain, attain, and protect their good health. Health behavior reflects a person's health beliefs.	Health Behavior		Individual Behavior	CTRP Intervention Terminology|CTRP Terminology|National Health Interview Survey
C166640	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166640>	C66917	Ethyl Dibunate|ETHYL DIBUNATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166641>	C574	Amiselimod|AMISELIMOD				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166642>	C281	Inarigivir Soproxil|INARIGIVIR SOPROXIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166643>	C29712	Epafipase|EPAFIPASE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166644>	C2319	Bexlosteride|BEXLOSTERIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166645>	C2152	Leniolisib Phosphate|LENIOLISIB PHOSPHATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166646>	C265	Levomilnacipran Hydrochloride|LEVOMILNACIPRAN HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166647	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166647>	C98292	Nolasiban|NOLASIBAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166648	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166648>	C1291	Afovirsen|AFOVIRSEN				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166649	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166649>	C29709	Berefrine|BEREFRINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16664>	C19141	Health Education	Health information provided to individuals or communities designed to reduce ill health and enhance good health by influencing beliefs, attitudes and behavior.	Health Education		Educational Activity	CTRP Intervention Terminology|CTRP Terminology
C166650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166650>	C217652	Lomibuvir|LOMIBUVIR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166651>	C66884	Foslevodopa|FOSLEVODOPA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166652>	C177170	Linerixibat|LINERIXIBAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166653>	C78322	Gitalin Amorphous|GITALIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166654>	C264	Progabide|PROGABIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166655>	C47793	Cifenline Succinate|CIFENLINE SUCCINATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166656>	C98085	Beinaglutide|BEINAGLUTIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166657>	C29704	Decitropine|DECITROPINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166658>	C20401	Anifrolumab|ANIFROLUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166659>	C261	Carbomycin|CARBOMYCIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16665>	C157356	Medicare|Medicare Program|Public Health Insurance Medicare	The US federal health insurance program run by the Health Care Financing Administration for people 65 years of age or older, certain people with disabilities who have not reached this age, and individuals with permanent kidney failure with dialysis or a transplant.  People over 65 years old, younger disabled people, and dialysis patients are eligible for the program regardless of their income. Participating beneficiaries pay part of healthcare costs through deductible amounts. Limited monthly premiums are required from beneficiaries for non-hospital coverage.			Intellectual Product	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C166660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166660>	C62799	Ilatreotide|ILATREOTIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166661>	C29704	Esoxybutynin|ESOXYBUTYNIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166662>	C574|C208255	Lenercept|LENERCEPT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166663>	C797	Batilol|BATILOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166664>	C78568	Nobiprostolan|NOBIPROSTOLAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166665>	C266	Lagatide|LAGATIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166666>	C275	Pegorgotein|PEGORGOTEIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166667>	C29726	Bucelipase Alfa|BUCELIPASE ALFA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166668>	C78276	Camicinal|CAMICINAL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166669>	C29730	Calcium Glubionate|CALCIUM GLUBIONATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16666>	C53287	Health Care Provider|Healthcare Provider|HealthcareProvider|HealthcareProvider|healthcare provider|healthcare provider	Persons who provides health care as part of their job responsibilities: or a person or organization who is licensed to supply health care.	Health Care Provider		Professional or Occupational Group	BRIDG Class Terminology|BRIDG Terminology|CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C166670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166670>	C20401	Lokivetmab|LOKIVETMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166671>	C254	Miripirium Chloride|MIRIPIRIUM CHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166672>	C52588	Pleuromulin|PLEUROMULIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166673>	C78322	Heptaminol|HEPTAMINOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166674>	C744	Ensifentrine|ENSIFENTRINE|RPL 554|RPL-554|RPL554	An inhaled inhibitor of the phosphodiesterase (PDE) types 3 (PDE3) and 4 (PDE4), with potential anti-inflammatory and bronchodilator activities. Upon administration, ensifentrine targets, binds to and inhibits PDE3 and PDE4, which leads to an increase of both intracellular levels of cyclic-3',5'-adenosine monophosphate (cAMP) and cAMP-mediated signaling. This may lead to bronchial smooth muscle relaxation and modulate inflammatory responses. PDE3 and PDE4, members of the PDE superfamily, hydrolyze cAMP and 3',5'-cyclic guanosine monophosphate (cGMP) to their inactive 5' monophosphates. PDE3 is the most expressed PDE isoenzyme in bronchial smooth muscle. PDE4 is expressed in immune cells including T-cells, monocytes, macrophages, neutrophils, dendritic cells and eosinophils. It plays an important role in inflammation, especially in inflammatory airway diseases.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C166675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166675>	C28500	Iosimide|IOSIMIDE				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166676>	C82130	Pegoxol 7 Stearate|PEGOXOL 7 STEARATE				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166677>	C2363	Neomycin Palmitate|NEOMYCIN PALMITATE				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166678>	C776	Algestone|ALGESTONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166679>	C261	Lucimycin|LUCIMYCIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16667>	C18766	Health Physics	The scientific discipline that evaluates the effects of ionizing radiation and the conditions for its safe use.			Biomedical Occupation or Discipline	
C166680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166680>	C129823	Tabituximab Barzuxetan|OTSA-101-DTPA|TABITUXIMAB BARZUXETAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166681>	C157401	Cabotegravir Sodium|CABOTEGRAVIR SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166682>	C98085	Efpeglenatide|EFPEGLENATIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166683>	C154290	Satoreotide Trizoxetan|JR-11-NODAGA|NODAGA-JR11|OPS-202|OPS202|SATOREOTIDE TRIZOXETAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166684>	C271	Arterolane|ARTEROLANE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166685>	C98083	Ipragliflozin|IPRAGLIFLOZIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166686>	C211609	Cevidoplenib|CEVIDOPLENIB|SKI O 592|SKI-O-592|SKIO592	An orally available inhibitor of spleen tyrosine kinase (SYK), with potential anti-inflammatory and immunomodulating activities. Upon oral administration, cevidoplenib binds to and inhibits the activity of SYK, blocking Fc receptor and B-cell receptor (BCR)-mediated signaling in inflammatory cells, including macrophages, neutrophils, mast cells, natural killer (NK) cells and B-cells. This leads to the inhibition of the activation of these inflammatory cells, and the related inflammatory responses and tissue damage. SYK, a non-receptor cytoplasmic protein tyrosine kinase widely expressed in hematopoietic cells, plays a key role in Fc receptor and B-cell receptor signaling in inflammatory cells. It is involved in coupling activated immunoreceptors, such as Fc receptors and B-cell receptors, to signal downstream events that mediate diverse cellular responses, including proliferation, differentiation, and phagocytosis, which are important for allergic and antibody-mediated immune diseases such as immune thrombocytopenia (ITP).			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166687>	C308	Disitertide|DISITERTIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166688>	C448	Meralluride|MERALLURIDE SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166689>	C78311	Eptacog Alfa Pegol (Activated)|EPTACOG ALFA PEGOL (ACTIVATED)				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16668>	C17735	Health Policy	A set of decisions and courses of action undertaken to achieve specific health care goals within a community or society.			Regulation or Law	
C166690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166690>	C20401	Gremubamab|GREMUBAMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166691>	C1595	Penimepicycline|PENIMEPICYCLINE				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166692>	C97453	Loviride|LOVIRIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166693>	C2491	Mipeginterferon Alfa-2B|MIPEGINTERFERON ALFA-2B				Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166694>	C314	Perfluamine|PERFLUAMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166695>	C1500	Penicillin V Benzathine|PENICILLIN V BENZATHINE				Antibiotic|Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166696>	C29698	Hymecromone|HYMECROMONE				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166697>	C47795	Gamfexine|GAMFEXINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166698>	C142789	Pavinetant|PAVINETANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166699>	C1512	Imciromab Pentetate|IMCIROMAB PENTETATE				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16669>	C171086|C171082	Health Status	The state of a subject's mental or physical condition.			Organism Attribute	
C1666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1666>	C1757	Tyrphostin A30|AG 30	A potent protein tyrosine kinase inhibitor that exhibits greater specificity for c-ErbB oncoprotein. (NCI)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C166700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166700>	C208296	Ozanimod Hydrochloride|OZANIMOD HYDROCHLORIDE|Zeposia	The hydrochloride salt form of ozanimod, an orally bioavailable sphingosine-1-phosphate (S1P) receptors 1 (S1PR1, S1P1) and 5 (S1PR5, S1P5) modulator, with potential anti-inflammatory and immunomodulating activities. Upon oral administration, ozanimod selectively targets and binds to S1PR1 on lymphocytes and induces S1PR1 internalization and degradation. This results in the sequestration of lymphocytes in lymph nodes. By preventing egress of lymphocytes, ozanimod reduces both the amount of circulating peripheral lymphocytes and the infiltration of lymphocytes into target tissues. This prevents a lymphocyte-mediated immune response and may reduce inflammation. S1PR1, a G-protein coupled receptor, plays a key role in lymphocyte migration from lymphoid tissues. Modulation of S1PR5 by ozanimod may be neuroprotective.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C166701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166701>	C581	Insulin Tregopil|INSULIN TREGOPIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166702>	C94727	Oxaprotiline|OXAPROTILINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166703>	C29710	Pomaglumetad Methionil Anhydrous|2-Thiabicyclo(3.1.0)hexane-4,6-dicarboxylic Acid, 4-(((2S)-2-Amino-4-(methylthio)-1- oxobutyl)amino)-, 2,2-Dioxide, (1R,4S,5S,6S)-|POMAGLUMETAD METHIONIL ANHYDROUS				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166704>	C226473	Asivatrep|ASIVATREP				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166705>	C471	Managlinat Dialanetil|MANAGLINAT DIALANETIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166706>	C265|C185721	Edivoxetine|EDIVOXETINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166707>	C29704	Atropine Oxide|ATROPINE OXIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166708>	C390	Perflisopent|PERFLISOPENT				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166709>	C1506	Myrophine|MYROPHINE				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16670>	C19989	Hearing	The auditory faculty, the perception of sound by the ear.			Organism Function	
C166710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166710>	C1506	Profadol|PROFADOL				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166711>	C78272	Deudextromethorphan|DEUDEXTROMETHORPHAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166712>	C173066	Inogatran|INOGATRAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166713>	C222317	Lorecivivint|LORECIVIVINT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166714>	C29712	Gemilukast|GEMILUKAST				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166715>	C1937	Desglugastrin|DESGLUGASTRIN				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166716>	C581	Dalanated Insulin|DALANATED INSULIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166717>	C258	Delpazolid|DELPAZOLID				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166718>	C2180	Pecavaptan|PECAVAPTAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166719>	C477	Peginesatide Acetate|PEGINESATIDE ACETATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16671>	C17764	Heat Shock Protein Beta-1|28 kDa Heat Shock Protein|Estrogen-regulated 24 kDa Protein|HSP 27|HSPB1|Heat Shock 27 kDa Protein|Heat Shock Protein 27|Hsp27|HspB1|SRP27|Stress-responsive Protein 27	Heat shock protein beta-1 (205 aa, ~23 kDa) is encoded by the human HSPB1 gene. This protein is involved in protein denaturation and the cellular response to oxidative stress.	Heat Shock Protein Beta-1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C166720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166720>	C2491	Peginterferon Alfacon-2|PEGINTERFERON ALFACON-2				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166721>	C471	Setanaxib|GKT 137831|GKT 831|GKT-137831|GKT-831|GKT137831|GKT831|SETANAXIB	An orally bioavailable inhibitor of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidases (NOX) 1 and 4, with potential anti-inflammatory, anti-fibrotic and antineoplastic activities. Upon oral administration, setanaxib targets, binds to and inhibits the activity of NOX1 and NOX4. This inhibits NOX1- and NOX4- mediated signal transduction pathways, thereby reducing inflammation and fibrosis. By targeting NOX4-overexpressing cancer-associated fibroblasts (CAFs) in the tumor microenvironment (TME), setanaxib may also inhibit myofibroblastic activation and enhance both the penetration of tumor-infiltrating lymphocytes (TILs) and antitumor T-cell immune responses. The NOX enzymes NOX1 and NOX4 primarily produce reactive oxygen species (ROS), which plays important roles in cellular signaling processes that regulate cell proliferation, differentiation and migration, and inflammation and fibrosis.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C166722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166722>	C1509	Monomethyl Fumarate|MONOMETHYL FUMARATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166723>	C20401|C190797	Bococizumab|BOCOCIZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166724>	C45678	Calteridol|CALTERIDOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166725>	C67413	Eluxadoline|ELUXADOLINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166726>	C210975	Umibecestat|UMIBECESTAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166727>	C2080	Fosfructose Trisodium|FOSFRUCTOSE TRISODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166728>	C1506	Dinalbuphine Sebacate|DINALBUPHINE SEBACATE				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166729>	C737	Esafoxolaner|ESAFOXOLANER				Hazardous or Poisonous Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16672>	C20130	Heat Shock Protein|HSP|HSP|Heat Shock Proteins|heat-shock protein|stress protein	A family of highly-conserved proteins that are synthesized in response to hyperthermia (heat shock), hypoxia, or other stresses that appear to increase cellular thermal tolerance and enable cells to recover from stress. Some heat shock proteins may protect other proteins from denaturation, degradation or perform functions essential to cell survival under these conditions.			Amino Acid, Peptide, or Protein	
C166730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166730>	C29703	Detrothyronine|DETROTHYRONINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166731>	C477	Epoetin Delta|EPOETIN DELTA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166732>	C155711	Disitamab|DISITAMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166733>	C308	Bifarcept|BIFARCEPT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166734>	C1404	Golvatinib Tartrate|GOLVATINIB TARTRATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166735>	C29726	Eufauserase|EUFAUSERASE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166736>	C1967	Gusacitinib|ASN002|EN3351|GUSACITINIB				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166737>	C29709	Etiguanfacine|ETIGUANFACINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166738>	C308	Dirucotide Acetate|DIRUCOTIDE ACETATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166739>	C29698	Pipoxolan|PIPOXOLAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16673>	C16749	Hematology|Hematologic	The branch of medicine that deals with the blood and blood-forming organs and the diseases thereof.			Biomedical Occupation or Discipline	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C166740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166740>	C180619|C173066	Atecegatran|ATECEGATRAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166741>	C62358	Gadoxanum|GADOXANUM				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166742>	C129822	Blontuvetmab|BLONTUVETMAB				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166743>	C243	Bolandiol|BOLANDIOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166744>	C261	Diproleandomycin|DIPROLEANDOMYCIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166745>	C20401	Metelimumab|METELIMUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166746>	C78322	Azelaprag|AZELAPRAG				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166747>	C78272	Pitolisant|PITOLISANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166748>	C802	Hexadimethrine Bromide|HEXADIMETHRINE BROMIDE				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166749>	C133878	Laprituximab|LAPRITUXIMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16674>	C21128	Hematopoietic Process|Hematopoiesis|Hemopoiesis|hematopoiesis	A process of blood formation and more specifically formation of blood cells that are all derived from hematopoietic stem cells.			Cell Function	
C166750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166750>	C78272	Dasotraline|DASOTRALINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166751>	C78276	Lesogaberan|LESOGABERAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166752>	C241	Dioxadrol|DIOXADROL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166753>	C360	Deferitazole|DEFERITAZOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166754>	C29576	Diacetolol|DIACETOLOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166755>	C52588	Cethexonium Chloride|CETHEXONIUM CHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166756>	C217652	Baloxavir|BALOXAVIR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166757>	C258	Enramycin|ENRAMYCIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166758>	C180619|C173066	Atecegatran Metoxil|ATECEGATRAN METOXIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166759>	C78281	Diacerein|DIACEREIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16675>	C16844	Heme Protein|Hemeprotein|Hemoprotein	Proteins that contain a metal-containing cofactor that consists of an iron atom contained in the center of a large heterocyclic organic ring called a porphyrin. One of the main functions of heme proteins is the retention of molecular oxygen to deliver it for enzymatic reactions. As a result, many heme-containing enzymes are located in the mitochondrion.			Amino Acid, Peptide, or Protein|Biologically Active Substance	
C166760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166760>	C29710	Piquindone Hydrochloride|PIQUINDONE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166761>	C47795	Azabon|AZABON				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166762>	C20401	Crotedumab|CROTEDUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166763>	C28676	Adimlecleucel|ADIMLECLEUCEL				Cell|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166764>	C52588	Furazolium Chloride|FURAZOLIUM CHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166765>	C227058	Glepaglutide|GLEPAGLUTIDE				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166766>	C129822	Mirvetuximab|MIRVETUXIMAB				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166767>	C2079	Bimakalim|BIMAKALIM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166768>	C217517	Grazoprevir|GRAZOPREVIR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166769>	C258	Pristinamycin|PRISTINAMYCIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16676>	C21176|C16675	Hemoglobin|Hb|Hgb|hemoglobin	The red respiratory protein of erythrocytes, consisting of approximately 3.8% heme and 96.2% globin (64.5 KD), which as oxyhemoglobin (HbO2) transports oxygen from the lungs to the tissues where the oxygen is readily released and HbO2 becomes Hb.	Hemoglobin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C166770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166770>	C308	Oxamisole Hydrochloride|OXAMISOLE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166771>	C94431	Anivamersen|ANIVAMERSEN				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166772>	C29710	Roluperidone|ROLUPERIDONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166773>	C28500	Iopronic Acid|IOPRONIC ACID				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166774>	C2198	Olvanil|OLVANIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166775>	C281	Besifovir|BESIFOVIR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166776>	C514	Partricin|PARTRICIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166777>	C1505	Omberacetam|OMBERACETAM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166778>	C67413	Dextrorphan Hydrochloride|DEXTRORPHAN HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166779>	C80212	Argipressin Tannate|VASOPRESSIN TANNATE				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16677>	C20130	Canonical HMG Protein|Archetypal HMG Protein|HMG Motif Protein|HMG Nuclear Protein|HMG Protein|High Mobility Group Protein	The High Mobility Group (HMG) proteins were originally isolated from mammalian cells, named according to their electrophoretic mobility in polyacrylamide gels, and were arbitrarily classed as a specific type of non-histone proteins based on the observation that they are ubiquitous to mammalian cells, that they share certain physical properties, and that they are associated with isolated chromatin. Those mammalian proteins considered to be Canonical HMG proteins are now subdivided into 3 superfamilies: the HMGB (formerly HMG-1/-2) family, the HMGN (formerly HMG-14/-17) family, and the HMGA (formerly HMG-I/Y/C) family.  Each HMG family has a characteristic functional sequence motif. (www.informatics.jax.org/mgihome/nomen/genefamilies/hmgfamily.shtml)			Amino Acid, Peptide, or Protein	
C166780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166780>	C1971	Muparfostat Sodium|MUPARFOSTAT SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166781>	C78281	Reldesemtiv|RELDESEMTIV				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166782>	C29704	Eucatropine|EUCATROPINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166783>	C257	Bufexamac|BUFEXAMAC				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166784>	C257	Flufenisal|FLUFENISAL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166785>	C360	Emeramide|EMERAMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166786>	C1291	Edifoligide|EDIFOLIGIDE				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166787>	C2578	Adomiparin Sodium|ADOMIPARIN SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166788>	C52588	Nifuratrone|NIFURATRONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166789>	C48149	Procaterol Hydrochloride|PROCATEROL HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166790>	C681	Ondelopran|ONDELOPRAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166791>	C471|C226473	Olumacostat Glasaretil|OLUMACOSTAT GLASARETIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166792>	C45678	Methylbenzethonium Chloride|METHYLBENZETHONIUM CHLORIDE ANHYDROUS				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166793>	C1512	Vipivotide Tetraxetan|VIPIVOTIDE TETRAXETAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166795>	C20401	Brazikumab|BRAZIKUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166796>	C744	Lixazinone Sulfate|LIXAZINONE SULFATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166797>	C921	Pegadricase|PEGADRICASE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166798>	C217549	Daclatasvir Dihydrochloride|DACLATASVIR HYDROCHLORIDE|Daclatasvir Hydrochloride	The dihydrochloride salt form of daclatasvir, an orally available inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex, with potential activity against HCV. Although the exact mechanism of action of daclatasvir has yet to be fully determined, this agent, upon oral administration and after intracellular uptake, appears to bind to domain I of the NS5A protein. This inhibits the activity of the NS5A protein and results in the disruption of the viral RNA replication complex, blockage of viral HCV RNA production, and inhibition of viral replication. NS5A, a zinc-binding and proline-rich hydrophilic phosphoprotein, plays a crucial role in HCV RNA replication. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family.			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C166799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166799>	C94727	Dibenzepin|DIBENZEPIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C1667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1667>	C1757	RG 14620|RG-14620|Tyrphostin RG-14620	A non-phenolic tyrphostin-class tyrosine kinase inhibitor that inhibits epidermal growth factor receptor, affecting cell proliferation and tumor growth in vivo. (NCI)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166800>	C20401	Domagrozumab|DOMAGROZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166801>	C2124	Ferric (59Fe) Citrate Injection|FERRIC CITRATE FE-59				Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166802>	C94431	Dematirsen|DEMATIRSEN				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166803>	C82130	Polyglactin 910|POLYGLACTIN 910				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166804>	C29703	Evacetrapib|EVACETRAPIB				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166805>	C257	Dexpemedolac|DEXPEMEDOLAC				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166806>	C20401	Zampilimab|ZAMPILIMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166807>	C29707	Chromonar Hydrochloride|CHROMONAR HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166808>	C1752	Latromotide|LATROMOTIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166809>	C20401	Besilesomab|BESILESOMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16680>	C74942	Histological Procedure|Histologic Procedure|Histological Technique|Histological Techniques|histologic examination	Technique or procedure used for the study of the microanatomy of tissues and their cellular structure; usually involves microscopic examination of tissue slices.	Histological Procedure		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C166810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166810>	C73579	Cytisinicline|CYTISINICLINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166811>	C270	Guanacline Sulfate|GUANACLINE SULFATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166812>	C47795	Cathinone|CATHINONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166813>	C1937	Bibapcitide|BIBAPCITIDE				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166814>	C226473	Picotrin Diolamine|PICOTRIN DIOLAMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166815>	C66885	Metitepine|METITEPINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166816>	C20401	Galcanezumab|Emgality|Emgality|GALCANEZUMAB|Galcanezumab-gnlm	A humanized immunoglobulin G4 (IgG4) monoclonal antibody targeting calcitonin-gene related peptide (CGRP) ligand, that can be used in the preventive treatment of migraine. Upon subcutaneous administration, galcanezumab specifically targets and binds to CGRP ligand, and blocks the binding of the CGRP ligand to its receptor. This blocks the CGRP pathway and prevents migraine.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166817>	C126712	Lascufloxacin|LASCUFLOXACIN				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166818>	C29728	Oxifentorex|OXIFENTOREX				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166819>	C97936	Butadiazamide|BUTADIAZAMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16681>	C16344	Histology|HISTOLOGY|HISTOLOGY|HISTOLOGY|HISTOLOGY|Microanatomy|histology	The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.			Biomedical Occupation or Discipline	CRF7 Pathology Review Table|EWS Histology Table|EWS Variable Terminology|GCT Histology Table|GCT Variable Terminology|GDC Terminology|GDC Value Terminology|HL Histology Table|HL Variable Terminology|OS Histology Table|OS Variable Terminology
C166820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166820>	C29703	Icosabutate|ICOSABUTATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166821>	C78281	Efmitermant Alfa|EFMITERMANT ALFA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166822>	C29633	Almagate|ALMAGATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166823>	C126712	Alalevonadifloxacin|ALALEVONADIFLOXACIN				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166824>	C2843	Delimotecan|DELIMOTECAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166825>	C2198	Olorinab|OLORINAB				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166826>	C217652	Deleobuvir|DELEOBUVIR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166827>	C20401	Glenzocimab|GLENZOCIMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166828>	C448	Mercaptomerin|MERCAPTOMERIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166829>	C78274	Calcium Dobesilate|CALCIUM DOBESILATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16682>	C26503	Histone Deacetylase|HDAC|HDAC|histone deacetylase	Histone acetylation and deacetylation alternately exposes and occludes DNA to transcription factors. Histone deacetylation is catalyzed by the histone deacetylases.  There are at least 2 classes of HDACs, class I consisting of proteins homologous to yeast Rpd3 (e.g., HDAC1, HDAC2, and HDAC3) and class II consisting of proteins homologous to yeast Hda1 (e.g., HDAC4 and HDAC6). (from OMIM)	Histone Deacetylase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Biomarkers/Targets Associated with Other Relevant Evidence
C166830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166830>	C1323	Pifoxime|PIFOXIME				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166831>	C2092	Elagolix Sodium|ELAGOLIX SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166832>	C280	Calcium Benzamidosalicylate|BENZOYLPAS CALCIUM ANHYDROUS				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166833>	C29723	Leminoprazole|LEMINOPRAZOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166834>	C308	Nangibotide|LR 12|LR-12|LR12|NANGIBOTIDE	A synthetic and inhibitory triggering receptor expressed on myeloid cells-1 (TREM-1) peptide, with potential anti-inflammatory and immunomodulatory activities. Upon administration, nangibotide binds to TREM-1 ligand and inhibits the binding of the TREM-1 ligand to TREM-1. This blocks the TREM-1-mediated amplification of innate immunity signaling, and prevents the production of pro-inflammatory mediators and inflammation. TREM-1, an immune-receptor expressed in neutrophils, mature monocytes, macrophages, natural killer (NK) cells and endothelial cells, is up-regulated following Toll-Like Receptors (TLR) or NOD-like receptors (NLR) signaling. It plays a key role in the amplification of inflammatory and innate immune responses.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C166835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166835>	C66885	Idalopirdine|IDALOPIRDINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166836>	C707	Inosine|INOSINE				Nucleic Acid, Nucleoside, or Nucleotide	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166837>	C2136	Upacicalcet|PLS 240 Free Base|PLS-240 Free Base|PLS240 Free Base|UPACICALCET	An agonist of calcium-sensing receptors (CaSR), with potential use in the treatment of secondary hyperparathyroidism (SHPT). Upon administration, upacicalcet targets and binds to CaSRs expressed on the membranes of cells in the parathyroid glands, which suppresses osteoclast activity and reduces the excessive secretion of parathyroid hormone (PTH). This prevents the excessive PTH-mediated efflux of phosphorus and calcium from bone into the blood and normalizes serum calcium and phosphorus levels. Upacicalcet may decrease the risk of bone fracture, may lower depositions of phosphorus and calcium salts in non-bone tissues, may reduce bone and joint pain and may slow the progression of other diseases related to increased levels of PTH. CaSR controls calcium homeostasis and regulates the release of PTH.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166838>	C1976	Plauracin|PLAURACIN				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166839>	C257	Intrazole|INTRAZOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16683>	C16687	Histone H1|H1|HISTONE H1	Linker Histone H1 interacts with DNA between nucleosome units in mediating chromatin compaction into higher order structures. Histones are basic nuclear proteins responsible for the nucleosome structure of eukaryotic chromatin. Repeating nucleosome units contain two molecules each of core Histones H2A, H2B, H3, and H4 that form an octamer complex around which approximately 146 base pairs of DNA is wrapped. (NCI)	Histone H1		Amino Acid, Peptide, or Protein	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C166840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166840>	C1937	Benpenolisin|BENPENOLISIN				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166841>	C823	Polisaponin|POLISAPONIN				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166842>	C210759	Runcaciguat|RUNCACIGUAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166843>	C78274	Ethomoxane|ETHOMOXANE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166844>	C73579	Encenicline|ENCENICLINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166845>	C28500	Iotasul|IOTASUL				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166846>	C29726	Idursulfase Beta|IDURSULFASE BETA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166847>	C1966	Omocianine|OMOCIANINE				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166848>	C47793	Moxaprindine|MOXAPRINDINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166849>	C20401	Spesolimab|SPESOLIMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16684>	C114866	Histone H2A|H2A|H2A|HIST1H2A|HISTONE H2A|Histone 2A	Slightly lysine rich histone.  One of four histones assembled into a nucleosomal core octamer.  Various posttranslationally modified forms and variants exist.  Combines with histone H2B in a heterodimer; two H2A/H2B dimers are incorporated in the nucleosomal octamer.	Histone H2A		Amino Acid, Peptide, or Protein	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C166850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166850>	C61101	Orientiparcin|ORIENTIPARCIN				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166851>	C47793	Detajmium Bitartrate Anhydrous|DETAJMIUM BITARTRATE ANHYDROUS				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166852>	C49185	Methalthiazide|METHALTHIAZIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166853>	C66884	Foscarbidopa|FOSCARBIDOPA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166854>	C29750	Anistreplase|ANISTREPLASE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166855>	C78275	Ciraparantag Acetate|CIRAPARANTAG ACETATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166856>	C243	Hydroxystenozole|HYDROXYSTENOZOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166857>	C52588	Gepotidacin Mesylate|GEPOTIDACIN MESYLATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166858>	C281	Exbivirumab|EXBIVIRUMAB				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166859>	C2486	Isunakinra|ISUNAKINRA	A recombinant protein resembling interleukin-1 (IL-1) receptor antagonist (IL-1Ra), with potential anti-inflammatory, immunomodulatory and antineoplastic activities. Upon administration, isunakinra targets and binds to the IL-1 receptor type 1 (IL-1-R1; IL-1R1; IL1R1), thereby blocking the binding of IL-1 alpha and beta to and activation of its receptor. Blockade of IL-1 activity and IL-1R1-mediated signaling inhibits the release of other pro-inflammatory mediators and may suppress inflammation and immunological responses. This may also abrogate the inflammatory and the immunosuppressive nature of the tumor microenvironment (TME), and may inhibit tumor growth, invasion, metastasis, and angiogenesis. IL-1/IL-1R1 signaling plays a key role in inflammation, which is present in various disease states including certain types of cancer.	Isunakinra		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C16685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16685>	C16687	Histone H3|H3|HISTONE H3	Histone H3 is a core subunit of the eukaryotic nucleosome complex. Histones are basic nuclear proteins responsible for the nucleosome structure of chromatin. Repeating nucleosome units contain two molecules each of Histones H2A, H2B, H3, and H4 that form an octamer complex around which approximately 146 base pairs of DNA is wrapped. Linker Histone H1 interacts with DNA between nucleosome units in mediating chromatin compaction into higher order structures. (NCI)	Histone H3		Amino Acid, Peptide, or Protein	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|Pediatric Oncology Target Genes/Proteins Terminology
C166860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166860>	C66894	Lanatoside C|LANATOSIDE C				Biologically Active Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166861>	C277	Maduramicin|MADURAMICIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166862>	C2139	Agatolimod|AGATOLIMOD	A synthetic 24-mer oligonucleotide containing 3 CpG motifs, with potential antineoplastic and immunostimulatory activities. Upon administration, agatolimod selectively targets Toll-like receptor 9 (TLR9), thereby activating dendritic and B cells and stimulating cytotoxic T cell and antibody responses against tumor cells bearing tumor antigens.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology
C166863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166863>	C82130	Nonoxynol 15|NONOXYNOL-15				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166864>	C1742	Necuparanib Sodium|NECUPARANIB SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166865>	C265	Decoglurant|DECOGLURANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166866>	C82130	Poliglecaprone 25|POLIGLECAPRONE 25				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166867>	C45678	Fosveset|FOSVESET				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166868>	C213366	Donaperminogene Seltoplasmid|DONAPERMINOGENE SELTOPLASMID				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166869>	C52588	Evernimicin|EVERNIMICIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16686>	C16687	Histone H4|H4|HIST1H4|HISTONE H4|Histone 1, H4	Histone H4 (103 aa, ~11 kDa) is encoded by the human H4C1, H4C2, H4C3, H4C4, H4C5, H4C6, H4C6, H4C8, H4C9, H4C11, H4C12, H4C13, H4C14, H4C15, H4-16 genes. This protein plays a role in nucleating the formation of high order chromatin structures as a part of nucleosomes.	Histone H4		Amino Acid, Peptide, or Protein	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C166870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166870>	C212	Codactide|CODACTIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166871>	C66886	Dexmecamylamine|DEXMECAMYLAMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166872>	C98085	Albenatide|ALBENATIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166873>	C1291	Tofersen Sodium|TOFERSEN SODIUM				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166874>	C1446	Ferrous Sulfate Fe 59|FERROUS SULFATE FE-59				Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166875>	C1291	Nusinersen|NUSINERSEN				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166876>	C217517	Deldeprevir|DELDEPREVIR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166877>	C2089	Ilmofosine|ILMOFOSINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166878>	C29696	Flumetramide|FLUMETRAMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166879>	C20401	Bertilimumab|BERTILIMUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16687>	C18073	Histone|HISTONE|histone|histone family|histone_family	Major protein component of chromatin.  Highly conserved basic proteins, originally classified into classes based on the relative amounts of arginine and lysine in each protein.  The various classes are now termed H1, H2A, H2B, H3, and H4.  In chromatin, they are found in an octamer, containing two each of H2A, H2B, H3, and H4, complexed with DNA in nucleosomes.  The histones in the octamer complex are also known as the core histones.  The H1 class of histones, termed the linker histones, is loosely associated with the nucleosome.	Histone		Amino Acid, Peptide, or Protein	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Property Terminology|GDC Terminology
C166880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166880>	C521	Methylprednisolone Sodium Phosphate|METHYLPREDNISOLONE SODIUM PHOSPHATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166881>	C360	Pendetide|PENDETIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166882>	C1323	Flufenamic Acid|FLUFENAMIC ACID				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166883>	C47796	Choline Alfoscerate|CHOLINE ALFOSCERATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166884>	C1967	Epertinib|EPERTINIB				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166885>	C190412	Deltibant|DELTIBANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166886>	C258	Omiganan|OMIGANAN				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166887>	C29726	Lesinidase Alfa|LESINIDASE ALFA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166888>	C94726	Arazasetron|ARAZASETRON				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166889>	C28394	Phenylmercuric Borate|PHENYLMERCURIC BORATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16688>	C16295	HIV Antibody|Anti-HIV Antibody|Anti-Human Immunodeficiency Virus Antibody|HIV antibody|Human Immunodeficiency Virus Antibody	Produced by B-cells, human immunodeficiency virus (HIV) antibodies reacts with HIV antigens. HIV is a virus which affects white blood cells and eventually destroys the body's natural ability to fight infections.			Amino Acid, Peptide, or Protein|Immunologic Factor	
C166890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166890>	C212892	Drinabant|DRINABANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166891>	C258	Ornidazole|ORNIDAZOLE				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166892>	C217549	Elbasvir|ELBASVIR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166893>	C261	Erythromycin Acistrate|ERYTHROMYCIN ACISTRATE				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166894>	C783	Firibastat|FIRIBASTAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166895>	C52588	Lysostaphin|LYSOSTAPHIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166896>	C52588	Pexiganan Acetate|PEXIGANAN ACETATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166897>	C78281	Ezutromid|EZUTROMID				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166898>	C2124	Merisoprol Acetate Hg 203|MERISOPROL ACETATE HG-203				Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166899>	C1657	Morphine Glucuronide|MORPHINE-6-GLUCURONIDE				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16689>	C16610	HIV Envelope Protein gp120|gp120 ENV Glycoprotein	A protein produced by the human immunodeficiency virus that functions as a viral anti-receptor attachment protein. The protein is localized to the viral envelope and mediates fusion between viral and cellular membranes.			Amino Acid, Peptide, or Protein	
C1668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1668>	C755	Becaplermin|BECAPLERMIN|PDGF Beta Chain|Platelet-Derived Growth Factor Beta Chain|Platlet-Derived Growth Factor Beta Chain|Recombinant Platelet Derived Growth Factor Beta Chain|Regranex|rhPDGF-BB	The recombinant analog of endogenous beta (B) chain of the cytokine platelet-derived growth factor (PDGF).  Synthesized primarily by megakaryocytes, endogenous PDGF consists of two related peptide chains, PDGF-A and PDGF-B.  PDGF functions as a local autocrine and paracrine growth factor in many cellular processes.  Recombinant PDGF, alone and in combination with other agents, may be useful in promoting bone formation and soft tissue repair. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166900>	C78311	Oreptacog Alfa (Activated)|OREPTACOG ALFA (ACTIVATED)				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166901>	C29756	Etoxybamide|ETOXYBAMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166902>	C210688	Ferrotrenine|FERROTRENINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166903>	C258	Fusafungine|FUSAFUNGINE				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166904>	C48149	Olodaterol Hydrochloride|OLODATEROL HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166905>	C224655	Balipodect|BALIPODECT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166906>	C52588	Polidronium Chloride|POLIDRONIUM CHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166907>	C257	Dexibuprofen|DEXIBUPROFEN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166908>	C52588	Exebacase|CF 301|CF-301|CF301|EXEBACASE	A recombinant peptidoglycan hydrolase, with potential bacteriolytic activity against Staphylococcus aureus. Upon administration, exebacase targets a highly conserved and vital region of the bacterial cell wall of S. aureus and acts as a direct lytic agent. This results in bacteriolysis and biofilm eradication.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C166909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166909>	C390	Phenobutiodil|PHENOBUTIODIL				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16690>	C16610	HIV Envelope Protein gp41	A protein produced by the human immunodeficiency virus that functions as a viral attachment protein on the viral envelope. This transmembrane protein is a glycoprotein that non-covalently anchors gp120 to the virus particle.			Amino Acid, Peptide, or Protein|Biologically Active Substance	
C166910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166910>	C20401	Oxelumab|OXELUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166911>	C1505	Cetotiamine|CETOTIAMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166912>	C217549	Coblopasvir|COBLOPASVIR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166913>	C29702	Oxmetidine Mesylate|OXMETIDINE MESYLATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166914>	C20401	Concizumab|Alhemo|CONCIZUMAB	A humanized monoclonal antibody targeting the tissue factor pathway inhibitor (TFPI) binding site for factor Xa (FXa), the Kunitz-2 domain, with potential coagulant activity. Upon subcutaneous or intravenous administration, concizumab specifically targets and binds to the Kunitz-2 domain of TFPI, thereby preventing the activity of TFPI. This prevents TFPI from binding to and blocking the active site of FXa. As TFPI reversibly inhibits FXa, concizumab prevents FXa inhibition. This allows for the activation and continuation of the coagulation cascade, which may prevent bleeding in hemophilia and may rebalance hemostasis.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology
C166915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166915>	C78275	Ferric Carboxymaltose|FCM|FERRIC CARBOXYMALTOSE|Ferinject|Ferric Carboxymaltose Injection|Ferric Carboxymaltose Solution|Ferric carboxymaltose|Injectafer	A parenteral iron solution containing ferric iron complexed with carboxymaltose polymers, used in parenteral iron-replacement therapy. Upon administration, ferric carboxymaltose is removed from plasma by the reticuloendothelial system. Subsequently, ferric iron binds to transferrin or is stored as ferritin. Transferrin-bound iron is transported in the plasma to the liver, spleen and bone marrow, where it is incorporated into hemoglobin, and to muscle, where it is incorporated into myoglobin.	Ferric Carboxymaltose		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C166916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166916>	C47793	Pranolium Chloride|PRANOLIUM CHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166917>	C258	Fungimycin|FUNGIMYCIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166918>	C314	Hemoglobin Raffimer|HEMOGLOBIN RAFFIMER				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166919>	C29707	Pirsidomine|PIRSIDOMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16691>	C113513	HLA Class I Histocompatibility Antigen, A-2 Alpha Chain|HLA Class I Histocompatibility Antigen, A*02 Alpha Chain|HLA-A|HLA-A Class I Antigen 2|HLA-A Histocompatibility Type Antigen 2|HLA-A Histocompatibility Type Antigen*02|HLA-A*02|HLA-A2|HLA-A2|HLA-A2 ANTIGEN|HLA-A2 Antigen|MHC Class I Antigen A*02|MHC Class I Antigen A*2|Major Histocompatibility Complex, Class I, A2 Antigen	HLA class I histocompatibility antigen, A-2 alpha chain (365 aa, ~41 kDa) is encoded by the human HLA-A gene. This protein is involved in antigen presentation.	HLA Class I Histocompatibility Antigen, A-2 Alpha Chain		Amino Acid, Peptide, or Protein|Immunologic Factor	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C166920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166920>	C258	Efepristin|EFEPRISTIN				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166921>	C94727	Iprindole|IPRINDOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166922>	C277	Arprinocid|ARPRINOCID				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166923>	C73579	Facinicline|FACINICLINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166924>	C78272	Alirinetide|ALIRINETIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166925>	C98083	Ertugliflozin|ERTUGLIFLOZIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166926>	C78568	Esuberaprost Sodium|Beraprost-314d|CTO 1681|CTO-1681|CTO1681|ESUBERAPROST SODIUM|GP 1681|GP-1681|GP1681	The sodium salt form of esuberaprost, the 314-d isomer of beraprost, with potential anti-inflammatory activity. Upon administration, esuberaprost activates the prostaglandin E2 receptor EP4 subtype (PTGER4; EP4), and inhibits the nuclear factor-kappa B (NF-kB) pro-inflammatory pathway. This may attenuate cytokine production and decrease inflammation.	Esuberaprost Sodium		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C166927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166927>	C126712	Nadifloxacin|NADIFLOXACIN				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166928>	C129820	Lapretolimod|LAPRETOLIMOD				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166929>	C29726	Olipudase Alfa|OLIPUDASE ALFA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16692>	C20705	HLA-DR Antigen|HLA-DR|HLA-DR|HLA-DR|Human Leukocyte Antigen - DR Isotype|Human Leukocyte Antigen-DR Isotype	Encoded by multiple HLA-DRA and HLA-DRB genes in a complex variable 5 cM region of MHC between HLA-B and -D, HLA-DR Antigens are Class II histocompatibility transmembrane glycoprotein heterodimers of alpha (heavy, 35-kD) and beta (light, 27-kD) chains. Located predominantly on B cells and macrophages, HLA-DR antigens function in antigen presentation to regulatory T cells in the immune response and in self/nonself discrimination. Invariant alpha and polymorphic beta chains have glycosylated N-termini, hydrophobic membrane regions, and hydrophilic C-termini. The heterodimer consists of 4 extracellular domains; invariant alpha-1, polymorphic N-terminal beta-1, and conserved Ig-like alpha-2 and beta-2. Alpha-1 and alpha-2 contain disulfide loops. Beta-1 contains 2 small variable regions. Alpha sequences have relatively simple structure; beta chains carry the major polymorphic determinants.	HLA-DR Antigen		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C166930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166930>	C190801	Selatogrel|SELATOGREL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166931>	C254	Iodine Povacrylex|IODINE POVACRYLEX				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166932>	C69145|C129825	Cobimetinib Fumarate|COBIMETINIB FUMARATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166933>	C521	Halopredone|HALOPREDONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166934>	C210975	Lanabecestat Camsylate|LANABECESTAT CAMSYLATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166935>	C69145|C129825	Pimasertib Hydrochloride|PIMASERTIB HYDROCHLORIDE	The hydrochloride salt form of pimasertib, an orally bioavailable small-molecule inhibitor of mitogen activated protein kinase kinases 1 (MEK1) and 2 (MEK2), with potential antineoplastic activity. Upon oral administration, pimasertib selectively binds to and inhibits the activity of MEK1 and 2, thereby preventing the activation of MEK1/2-dependent effector proteins and transcription factors. This results in the inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK1/2 (MAP2K1/K2) are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.	Pimasertib Hydrochloride		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C166936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166936>	C1320	Ilodecakin|ILODECAKIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166937>	C29696	Nafomine Malate|NAFOMINE MALATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166938>	C390	Ferumoxsil|FERUMOXSIL				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166939>	C1512|C129820	Onfekafusp Alfa|Fibromun|L19-TNF-alpha|ONFEKAFUSP ALFA|Recombinant Human Fusion Protein L19TNFalpha	An immunocytokine consisting of human pro-inflammatory cytokine tumor necrosis factor alpha (TNFalpha) fused to a human single-chain variable fragment (scFv) directed against the extra-domain B (ED-B) of fibronectin (L19), with potential immunopotentiating and antineoplastic activities. Upon adinistration, the L19 moiety of onfekafusp alfa binds to the ED-B domain of fibronectin on tumor cells in the tumor neovasculature. In turn, the TNFalpha moiety may locally induce an immune response against ED-B fibronectin-expressing tumor cells and may specifically decrease the proliferation of ED-B-expressing tumor cells. ED-B is predominantly expressed during angiogenesis and tumor growth.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C16693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16693>	C26199	Non-Histone Chromosomal Protein HMG-17|Chromosomal Protein, Nonhistone, HMG17|HMG-17|HMG17|HMGN2|High Mobility Group Nucleosomal Binding Protein 2|High Mobility Group Nucleosome-Binding Domain-Containing Protein 2|High Mobility Group Protein 17|High Mobility Group Protein N2|High-Mobility Group (Nonhistone Chromosomal) Protein 17|High-Mobility Group Nucleosomal Binding Domain|High-Mobility Group Nucleosomal Binding Domain 2|High-Mobility Group Nucleosome Binding Domain 2|MGC5629|Nonhistone Chromosomal Protein HMG-17|Nonhistone Chromosomal Protein HMG1|Nonhistone Chromosomal Protein HMG17	Non-histone chromosomal protein HMG-17 (90 aa, ~9 kDa) is encoded by the human HMGN2 gene. This protein is involved in the reorganization of chromatin.			Amino Acid, Peptide, or Protein	
C166940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166940>	C28394	Policresulen|POLICRESULEN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166941>	C78272	Naboctate Hydrochloride|NABOCTATE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166942>	C97452	Censavudine|CENSAVUDINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166943>	C20401	Gedivumab|GEDIVUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166944>	C2491	Cepeginterferon Alfa-2B|CEPEGINTERFERON ALFA-2B				Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166945>	C177180	Gefapixant|GEFAPIXANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166946>	C1821	Droloxifene Citrate|DROLOXIFENE CITRATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166947>	C20401	Ontamalimab|ONTAMALIMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166948>	C210737	Lusutrombopag|LUSUTROMBOPAG|Mulpleo|Mulpleta	An orally available thrombopoietin (TPO) receptor (TPOR; MPL) agonist, with potential megakaryopoiesis stimulating activity. Upon administration, lusutrombopag binds to and interacts with the transmembrane domain of human TPO receptor expressed on megakaryocytes, which leads to the proliferation and differentiation of megakaryocytic progenitor cells from hematopoietic stem cells. This increases the production of platelets and may prevent or treat thrombocytopenia in patients with chronic liver disease. TPOR is a cytokine receptor and member of the hematopoietic receptor superfamily.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology
C166949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166949>	C264	Dizocilpine Maleate|DIZOCILPINE MALEATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16694>	C25464	Honduras|340|HN|HND|HND|HONDURAS|HONDURAS	A country in Central America, bordering the Caribbean Sea, between Guatemala and Nicaragua.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C166950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166950>	C52588	Epetraborole|EPETRABOROLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166951>	C241	Isalmadol|ISALMADOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166952>	C521	Fluocortin Butyl|FLUOCORTIN BUTYL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166953>	C28197	Brofoxine|BROFOXINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166954>	C156804	Tazemetostat Hydrobromide|(1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-, hydrobromide (1:1)|EPZ-6438 Monohydrobromide|TAZEMETOSTAT HYDROBROMIDE|TAZVERIK|Tazemetostat Monohydrobromide	The hydrobromide salt form of tazemetostat, an orally available, small molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone methyl transferase EZH2, with potential antineoplastic activity. Upon oral administration, tazemetostat selectively inhibits the activity of both wild-type and mutated forms of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased tumor cell proliferation in EZH2 mutated cancer cells. EZH2, which belongs to the class of histone methyltransferases (HMTs), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation.	Tazemetostat Hydrobromide		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C166955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166955>	C67477	Soravtansine|SORAVTANSINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166956>	C2089	Delcasertib Acetate|DELCASERTIB ACETATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166957>	C45496	Eprodisate|EPRODISATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166958>	C257	Aloxiprin|ALOXIPRIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166959>	C1331	Mitopodozide|MITOPODOZIDE				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16695>	C25464	Hong Kong|344|HK|HKG|HKG|HONG KONG|HONG KONG	A special administrative region of China, bordering the South China Sea, east of Macao.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C166960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166960>	C20401	Afelimomab|AFELIMOMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166961>	C29701	Potassium Glucaldrate|POTASSIUM GLUCALDRATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166962>	C308	Dalazatide|DALAZATIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166963>	C521	Drocinonide|DROCINONIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166964>	C29727	Abametapir|ABAMETAPIR				Hazardous or Poisonous Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166965>	C208296	Etrasimod|ETRASIMOD				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166966>	C217652	Deleobuvir Sodium|DELEOBUVIR SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166967>	C78276	Mitemcinal|MITEMCINAL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166968>	C1663	Biropepimut-S|BIROPEPIMUT-S|GL-0817|GL-0817 Vaccine|GL0817|MAGE-A3 Multipeptide Vaccine GL-0817|MAGE-A3 Peptide Vaccine GL-0817	A proprietary, peptide cancer vaccine comprised of multiple peptides derived from human melanoma antigen A3 (MAGE-A3; MAGEA3), with potential immunostimulating and antineoplastic activities. Upon administration, biropepimut-S may stimulate the immune system to mount specific responses from B-cells, and CD4-positive and CD8-positive cells against tumor cells expressing MAGE-A3, resulting in tumor cell lysis. MAGE-A3, a tumor-associated antigen (TAA), is overexpressed by a variety of cancer cell types.	Biropepimut-S		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C166969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166969>	C67413	Levomethadone|LEVOMETHADONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16696>	C19326	Hospital|HOSPITAL|HOSPITAL	An institution that provides medical, surgical, or psychiatric care and treatment for the sick or the injured.			Health Care Related Organization	CDISC SDTM Environmental Setting Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Individual Case Safety Report Terminology|Location of Event Occurrence ICSR Terminology
C166970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166970>	C581	Insulin Peglispro|INSULIN PEGLISPRO				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166971>	C20401	Brodalumab|BRODALUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166972>	C258	Iprocinodine Hydrochloride|IPROCINODINE HYDROCHLORIDE				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166973>	C1663	Ovemotide|OVEMOTIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166974>	C737	Phenothrin|PHENOTHRIN				Hazardous or Poisonous Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166975>	C29710	Lumateperone|LUMATEPERONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166976>	C443	Oxidronic Acid|OXIDRONIC ACID				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166977>	C29576	Bunolol|BUNOLOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166978>	C258	Avilamycin|AVILAMYCIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166979>	C29578	Bisfentidine|BISFENTIDINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16697>	C16956	Host-Parasite Relationship	The interactions between two organisms, one of which lives at the expense of the other. (NCI)			Pathologic Function	
C166980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166980>	C98151	Nicodicosapent|NICODICOSAPENT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166981>	C78275	Etelcalcetide Hydrochloride|ETELCALCETIDE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166982>	C265	Dazepinil|DAZEPINIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166983>	C129822	Indusatumab|INDUSATUMAB				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166984>	C1291	Drisapersen|DRISAPERSEN				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166985>	C129650	Abrocitinib|ABROCITINIB				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166986>	C201688	Asvasiran|ASVASIRAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166987>	C29701	Lactalfate|LACTALFATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166988>	C98085	Lixisenatide|LIXISENATIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166989>	C29711	Adomeglivant|ADOMEGLIVANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16698>	C19613	Human Genetics	The branch of genetics focusing on human heredity.			Biomedical Occupation or Discipline	
C166990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166990>	C78272	Naranol|NARANOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166991>	C261	Nafithromycin|NAFITHROMYCIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166992>	C67413	Benzhydrocodone|BENZHYDROCODONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166993>	C764	Motexafin|MOTEXAFIN				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166994>	C67413	Metkephamid Acetate|METKEPHAMID ACETATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166995>	C29712	Fiboflapon Sodium|FIBOFLAPON SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166996>	C47794	Lasmiditan|LASMIDITAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166997>	C20401	Dectrekumab|DECTREKUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166998>	C78281|C208255	Talditercept Alfa|TALDEFGROBEP ALFA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C166999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C166999>	C52588	Nifurthiazole|NIFURTHIAZOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16699>	C25464	Hungary|348|HU|HUN|HUN|HUNGARY|HUNGARY	A country in central Europe, northwest of Romania and south of Slovakia.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C1669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1669>	C1420	Temoporfin|5,10,15,20-Tetra-(m-hydroxyphenyl)chlorin|Foscan|TEMOPORFIN|m-Tetrahydroxyphenyl-chlorin|mTHPC|meta-Tetrahydroxyphenyl Chlorin|meta-Tetrahydroxyphenylchlorin|temoporfin	A synthetic light-activated chlorin with photodynamic activity. Upon systemic administration, temoporfin distributes throughout the body and is taken up by tumor cells. Upon stimulation of temoporfin by non-thermal laser light (at 652 nm), and in the presence of oxygen, this agent produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to tumor cells. This may kill tumor cells and may reduce the tumor size.	Temoporfin		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C167000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167000>	C242	Nordinone|NORDINONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167001>	C78272	Risdiplam|RISDIPLAM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167002>	C1012	Midazolam Maleate|MIDAZOLAM MALEATE				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167003>	C514	Flutrimazole|FLUTRIMAZOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167004>	C66913	Piprozolin|PIPROZOLIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167005>	C20401	Volagidemab|AMG-477|REMD 477|REMD-477|REMD477|VOLAGIDEMAB	A fully human immunoglobulin G2 (IgG2) monoclonal antibody targeting the human glucagon receptor (GCGR), that may be used for the treatment of hyperglycemia. Upon administration, volagidemab specifically targets and binds to GCGR, thereby blocking GCGR signaling. This may inhibit glucagon activity, thereby decreasing hepatic glycogenolysis and gluconeogenesis and ultimately lowering blood glucose levels. Glucagon, a hormone that increases blood sugar, plays an important role in the regulation of blood glucose levels.	Volagidemab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C167006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167006>	C20401	Frunevetmab|FRUNEVETMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167007>	C1450	Miriplatin|MIRIPLATIN|Miripla|SM-11355	A lipophilic platinum complex and oxaliplatin analog that contains two myristate chains, with potential antineoplastic activity. Upon administration of miraplatin, the platinum moiety forms complexes with nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links, resulting in apoptosis and cell growth inhibition. Compared to platinum alone, the lipophilic formulation allows increased delivery of platinum to the tumor site, thereby increasing efficacy while reducing systemic toxicity.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology
C167008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167008>	C581	Insulin Argine|INSULIN ARGINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167009>	C78272	Basmisanil|BASMISANIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16700>	C70699	Hybridoma	A tumor of hybrid cells used in the in vitro production of specific monoclonal antibodies; produced by fusion of an established tissue culture line of lymphocyte tumor cells (e.g., mouse plasmacytoma cells) and specific antibody-producing cells (e.g., splenocytes from specifically immunized mice); fusions are accomplished by use of polyethylene glycol or other methods.			Cell	
C167010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167010>	C66884	Dexpramipexole Dihydrochloride|DEXPRAMIPEXOLE DIHYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167011>	C547	Avexitide Acetate|AVEXITIDE ACETATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167012>	C574|C254|C2080	Nomacopan|Complement C5-inhibitor rEV576|Coversin|NOMACOPAN|Recombinant EV576|Recombinant OmCI|Recombinant Ornithodoros moubata Complement Inhibitor|Recombinant Ornithodoros moubata Saliva-derived Small Protein Complement C5 Inhibitor|rEV576	A recombinant small peptide inhibitor of the terminal complement pathway protein C5 originally derived from a protein in the saliva of the Ornithodoros moubata tick, with potential anti-inflammatory and cytoprotective activities. Upon administration, nomacopan targets and binds to a unique site on the terminal complement protein C5, which blocks C5 cleavage into the pro-inflammatory components C5a and C5b, and prevents the C5b-dependent assembly of the membrane-attack complex (MAC; C5b-9). This prevents MAC-mediated lysis and destruction of red blood cells (RBCs) in paroxysmal nocturnal hemoglobinuria (PNH) and prevents tissue destruction in various other complement-mediated inflammatory and autoimmune diseases. In addition, this C5 inhibitor targets, binds to and inhibits the activity of leukotriene B4 (LTB4), thereby further preventing inflammatory-mediated cell destruction.	Nomacopan		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C167013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167013>	C78322	Danicamtiv|DANICAMTIV				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167014>	C1504	Murodermin|MURODERMIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167015>	C154291	Seladelpar|SELADELPAR	An orally bioavailable agonist of peroxisome proliferator-activated receptor (PPAR)-delta (PPARd), with bile acids reducing activity. Upon oral administration, seladelpar targets, binds to and activates PPARd in the liver. This induces the expression of fibroblast growth factor 21 (FGF21), which downregulates CYP7A1, the key enzyme for the synthesis of bile acids from cholesterol. By reducing CYP7A1 expression, bile acid synthesis is reduced. This leads to reduced inflammation and scarring associated with primary biliary cholangitis (PBC).	Seladelpar		Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C167016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167016>	C29697	Bisoxatin|BISOXATIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167017>	C78281	Encaleret Sulfate|ENCALERET SULFATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167018>	C212891	Atogepant|ATOGEPANT|Qulipta|Qulipta	An orally bioavailable calcitonin gene-related peptide (CGRP) receptor antagonist that can be used in the preventive treatment of migraines. Upon oral administration, atogepant targets, binds to and blocks the activity of CGRP receptor, thereby preventing CGRP-mediated signaling. By blocking the CGRP-mediated pathways, atogepant is able to relieve or prevent migraine. CGRP-mediated signaling plays a key role in migraine pathogenesis.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167019>	C47795	Phenpromethamine|PHENPROMETHAMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16701>	C16554	Hydrolase|EC 3|Hydrolases	Enzymes (EC class 3) cleaving substrates with addition of H2O at the point of cleavage; e.g., esterases, phosphatases, nucleases, peptidases. SYN hydrolyzing enzymes.			Amino Acid, Peptide, or Protein|Enzyme	
C167020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167020>	C28500	Iopentol|IOPENTOL				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167021>	C737	Fospirate|FOSPIRATE				Hazardous or Poisonous Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167022>	C29756	Dexclamol Hydrochloride|DEXCLAMOL HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167023>	C574	Frentizole|FRENTIZOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167024>	C29707	Ciclonicate|CICLONICATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167025>	C258	Kalafungin|KALAFUNGIN				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167026>	C776	Oxogestone Phenpropionate|OXOGESTONE PHENPROPIONATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167027>	C78276	Plecanatide|PLECANATIDE|Trulance	An agonist of intestinal guanylate cyclase type C (GC-C) which is almost structurally identical to human uroguanylin, with laxative and anti-nociceptive activities.  Upon oral administration, plecanatide binds to and activates GC-C receptors located on endothelial cells on the luminal surface of the intestinal epithelium. This increases the concentration of intracellular cyclic guanosine monophosphate (cGMP). cGMP activates the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel and stimulates the secretion of chloride and bicarbonate into the intestinal lumen. This also promotes sodium excretion into the lumen and osmosis. The increased intestinal fluid secretion accelerates gastrointestinal transit of intestinal contents, improves bowel movement, softens stool, and relieves constipation. In addition, plecanatide exerts its anti-nociceptive effects by increasing the concentration of extracellular cGMP which inhibits the activity of pain-sensitive nerves, decreases muscle contractions and may relieve intestinal pain.	Plecanatide		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C167028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167028>	C243	Bolmantalate|BOLMANTALATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167029>	C2139	Idramantone|IDRAMANTONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16702>	C19899	Hydrolysis|Hydrolytic Process|hydrolysis	A chemical reaction in which a water molecule is added to a compound. This addition often involves the splitting or cleavage of the molecule. The hydroxyl group is incorporated into one fragment of the compound and the hydrogen atom in the other.			Physiologic Function	CBDD Process Terminology|CBDD Terminology
C167030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167030>	C190412	Fasitibant Chloride|FASITIBANT CHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167031>	C1891	Asoprisnil Ecamate|ASOPRISNIL ECAMATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167032>	C277	Diaveridine|DIAVERIDINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167033>	C213665	Branebrutinib|BRANEBRUTINIB				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167034>	C245	Midafotel|MIDAFOTEL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167035>	C243	Nisterime Acetate|NISTERIME ACETATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167036>	C78311	Oxamarin|OXAMARIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167037>	C29703	Gemcadiol|GEMCADIOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167038>	C29750	Ocrase|OCRASE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167039>	C81123	Efmoroctocog Alfa|EFMOROCTOCOG ALFA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167040>	C78568	Nocloprost|NOCLOPROST				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167041>	C72900	Medroxalol|MEDROXALOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167042>	C154292	Tavilermide Hydrochloride|TAVILERMIDE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167043>	C29710	Naranol Hydrochloride|NARANOL HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167044>	C357	Ceftolozane Sulfate|CEFTOLOZANE SULFATE				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167045>	C29710	Gevotroline|GEVOTROLINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167046>	C82130	Patiromer Calcium|PATIROMER CALCIUM				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167047>	C52588	Iclaprim Mesylate|ICLAPRIM MESYLATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167048>	C265	Cyprolidol Hydrochloride|CYPROLIDOL HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167049>	C20401	Etokimab|ETOKIMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16704>	C25464	Iceland|352|ICELAND|ICELAND|IS|ISL|ISL	A country in northern Europe, island between the Greenland Sea and the North Atlantic Ocean, northwest of the UK.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C167050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167050>	C20401	Abrezekimab|ABREZEKIMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167051>	C217122	Disease Risk Index for Allogeneic Stem Cell Transplantation|DRI|Disease Risk Index|Disease Risk Index (DRI)	A tool designed to assign allogeneic hematopoietic cell transplantation patients into one of four overall survival (OS) risk groups based on disease type and disease status at the time of transplantation. This index applies regardless of age, conditioning regimen, donor type, and graft source.			Intellectual Product	
C167052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167052>	C167051	Disease Risk Index Low Risk|DRI Low Risk|Low Risk	A Disease Risk Index category corresponding to low disease risk and low stage risk.			Intellectual Product	
C167053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167053>	C167051	Disease Risk Index Intermediate Risk|DRI Intermediate Risk|Intermediate Risk|Intermediate Risk	A Disease Risk Index category corresponding to low disease risk and high stage risk.			Intellectual Product	
C167054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167054>	C167051	Disease Risk Index High Risk|DRI High Risk|High Risk|High Risk	A Disease Risk Index category corresponding to intermediate disease risk and high stage risk.			Intellectual Product	
C167055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167055>	C167051	Disease Risk Index Very High Risk|DRI Very High Risk|Very High Risk	A Disease Risk Index category corresponding to high disease risk and high stage risk.			Intellectual Product	
C167056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167056>	C137999|C129826	Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes|Chlorotoxin-CD28-CD3z-CD19t-expressing CAR T-cells	A preparation of genetically modified T-lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) comprised of a CD28 co-stimulatory signaling domain fused to the zeta chain of the TCR/CD3 complex (CD3zeta), a truncated form of CD19 (CD19t), an immunoglobulin (Ig) G4-Fc (EQ) spacer, and a peptide derived from chlorotoxin (CLTX), with potential imaging and antineoplastic activities. Upon administration, chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes are re-directed to specific tumor cells in the brain inducing selective toxicity in these tumor cells. CLTX, a 36-amino acid peptide found in the venom of the deathstalker scorpion (Leiurus quinquestriatus) and a chloride channel blocker, preferentially binds to glioma (and other neuroectodermal origin) cells via membrane bound forms of the endopeptidase matrix metalloproteinase-2 (MMP-2). This may direct the T-lymphocytes to and induce selective toxicity in MMP-2-expressing tumor cells. Additionally, binding to MMP-2 on glioma cells may both interfere with transmembrane chloride exchange and inhibit proteolytic extracellular matrix remodeling by MMP-2, which may further limit the spread of these tumor cells. MMP-2 is specifically upregulated in gliomas and related cancers, but is not normally expressed in brain. The CD28 co-stimulatory molecule signaling domain enhances activation and signaling; its inclusion may increase proliferation of T-cells and antitumor activity compared to the inclusion of the CD3 zeta chain alone. IgG4-Fc (EQ) contains two point mutations in its spacer region which prevents recognition of the CAR by Fc receptors (FcRs) without altering the ability of the CAR to mediate antigen-specific lysis. CD19t, which lacks the cytoplasmic signaling tail, provides a non-immunogenic surface marker that allows for accurate measurement, efficient cell tracking and/or imaging of the therapeutic T-cells in vivo following adoptive transfer. Additionally, co-expression of CD19t functions as a "suicide" switch via clinically available antibodies or immunotoxins which can be used to selectively eliminate the genetically modified cells.	Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C167057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167057>	C62103	Pressure Stimulation Device|Pressure Pain Stimulation|Pressure Pain Stimulation Device	A device designed to deliver pressure to a thumbnail and stimulate pain.	Pressure Stimulation Device		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C167058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167058>	C97928	NF1 Protein Variant|Neurofibromatosis-Related Protein NF-1 Protein Variant|Neurofibromin Protein Variant	A variation in the amino acid sequence for the neurofibromin protein.			Cell or Molecular Dysfunction	Pediatric Oncology Target Molecular Abnormalities Terminology
C167059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167059>	C118388	NF1 NM_001042492.2:c.4394A>G|NF1 c.4394A>G|NFNS c.4394A>G|NM_001042492.2:c.4394A>G|Neurofibromin 1 c.4394A>G	A nucleotide substitution at position 4394 of the coding sequence of the NF1 gene where adenine has been mutated to guanine.			Cell or Molecular Dysfunction	
C167060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167060>	C167058	NF1 NP_001035957.1:p.N1465S|NF1 Asn1465Ser|NF1 N1465S|NF1 NP_001035957.1:p.Asn1465Ser|NF1 p.Asn1465Ser|NF1 p.N1465S|NP_001035957.1:p.Asn1465Ser|NP_001035957.1:p.N1465S|Neurofibromatosis-Related Protein NF-1 Asn1465Ser|Neurofibromatosis-Related Protein NF-1 N1465S|Neurofibromin Asn1465Ser|Neurofibromin N1465S	A change in the amino acid residue at position 1465 in the neurofibromin protein where asparagine has been replaced by serine.			Cell or Molecular Dysfunction	
C167061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167061>	C189780	NF1 NM_001042492.2:c.6926del|NF1 c.6926del|NFNS c.6926del|NM_001042492.2:c.6926del|Neurofibromin 1 c.6926del	A nucleotide deletion of position 6926 of the coding sequence of the NF1 gene.			Cell or Molecular Dysfunction	
C167062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167062>	C167058	NF1 NP_001035957.1:p.S2309Cfs*10|NF1 NP_001035957.1:p.Ser2309CysfsTer10|NF1 S2309Cfs*10|NF1 Ser2309CysfsTer10|NF1 p.S2309Cfs*10|NF1 p.Ser2309CysfsTer10|NP_001035957.1:p.S2309Cfs*10|NP_001035957.1:p.Ser2309CysfsTer10|Neurofibromatosis-Related Protein NF-1 Ser2309CysfsTer10|Neurofibromatosis-Related Protein NF-1 p.S2309Cfs*10|Neurofibromin S2309Cfs*10|Neurofibromin Ser2309CysfsTer10	A change in the amino acid composition of the neurofibromin protein where a frameshift mutation results in the substitution of the serine at postion 2093 with a cysteine and 9 non-canonic amino acids followed by a stop codon.			Cell or Molecular Dysfunction	
C167063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167063>	C97928	NOTCH1 Protein Variant|Neurogenic Locus Notch Homolog Protein 1 Protein Variant|TAN-1 Protein Variant|TAN1 Protein Variant|Translocation-Associated Notch Protein TAN-1 Protein Variant	A variation in the amino acid sequence for the neurogenic locus notch homolog protein 1 protein.			Cell or Molecular Dysfunction	Pediatric Oncology Target Molecular Abnormalities Terminology
C167064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167064>	C199630	Azenosertib|AZENOSERTIB|Wee1 Inhibitor ZN-c3|ZN c3|ZN-c3|ZNc3	An inhibitor of the tyrosine kinase Wee1 (Wee1-like protein kinase; Wee1A kinase; WEE1hu) with potential antineoplastic sensitizing activity. Although the exact mechanism of action by which this agent inhibits Wee1 has yet to be disclosed, upon administration of ZN-c3, this agent targets and inhibits Wee1. Inhibition of Wee1 promotes both premature mitosis and a prolonged mitotic arrest leading to cell death in susceptible tumor cells, such as p53-deficient or mutated human cancers that lack the G1 checkpoint, upon treatment with DNA-damaging chemotherapeutic agents. Unlike normal cells, most p53-deficient or mutated human cancers lack the G1 checkpoint as p53 is the key regulator of the G1 checkpoint and these cells rely on the G2 checkpoint for DNA repair to damaged cells. Annulment of the G2 checkpoint may therefore make p53-deficient tumor cells more vulnerable to antineoplastic agents and enhance their cytotoxic effect. Overexpression of Wee1 occurs in several cancer types and high expression of Wee1 is associated with poor outcomes. Wee1 phosphorylates Cdc2 in the Cdc2/cyclin B (CDK1/cyclin B) complex which blocks progression from G2 into mitosis; it negatively regulates the G2 checkpoint by disallowing entry into mitosis in response to DNA damage.	Azenosertib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C167065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167065>	C142112	Blasts 6-24 Percent of Bone Marrow Nucleated Cells|Blasts 6-24% of Bone Marrow Nucleated Cells|Blasts Between 6 and 24 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that between 6 and 24 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts 6-24 Percent of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Disease Terminology|CTRP Terminology
C167066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167066>	C45403	NOTCH1 NM_017617.4:c.3587G>A|NM_017617.4:c.3587G>A|NOTCH1 c.3587G>A|Notch 1 c.3587G>A|Notch Homolog 1 c.3587G>A|Notch, Drosophila, Homolog of, 1 c.3587G>A|TAN1 c.3587G>A|hN1 c.3587G>A	A nucleotide substitution at position 3587 of the coding sequence of the NOTCH1 gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C167067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167067>	C167063	NOTCH1 NP_060087.3:p.G1196D|NOTCH1 G1196D|NOTCH1 Gly1196Asp|NOTCH1 NP_060087.3:p.Gly1196Asp|NOTCH1 p.G1196D|NOTCH1 p.Gly1196Asp|NP_060087.3:p.G1196D|NP_060087.3:p.Gly1196Asp|Neurogenic Locus Notch Homolog Protein 1 G1196D|Neurogenic Locus Notch Homolog Protein 1 Gly1196Asp|TAN-1 G1196D|TAN-1 Gly1196Asp|TAN1 G1196D|TAN1 Gly1196Asp|Translocation-Associated Notch Protein TAN-1 G1196D|Translocation-Associated Notch Protein TAN-1 Gly1196Asp	A change in the amino acid residue at position 1196 in the neurogenic locus notch homolog protein 1 where glycine has been replaced by aspartic acid.			Cell or Molecular Dysfunction	
C167068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167068>	C3015	Eosinophilia Greater than 1500 cells per Microliter|Eosinophilia Greater than 1500 cells/ul|Eosinophilia More than 1500 cells per microliter|Eosinophilia More than 1500 cells/ul|Eosinophilia Over 1500 cells per microliter|Eosinophilia Over 1500 cells/ul	A semi-quantitative microscopic finding indicating that more than 1500 eosinophils are present per microliter of sample.	Eosinophilia Greater than 1500 cells per Microliter		Laboratory or Test Result	CTRP Disease Terminology|CTRP Terminology
C167069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167069>	C213717|C148130|C146893	Locally Advanced Genitourinary System Carcinoma	A genitourinary system carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.			Neoplastic Process	
C167071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167071>	C213707|C156062	Locally Advanced Bladder Carcinoma	A bladder carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Bladder Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C167072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167072>	C213703|C156064	Locally Advanced Ovarian Carcinoma	An ovarian carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Ovarian Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C167073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167073>	C4908|C213701	Unresectable Ovarian Carcinoma	An ovarian carcinoma that is not amenable to surgical resection.	Unresectable Ovarian Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C167074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167074>	C4004|C159563|C147996	Refractory Gastric Adenocarcinoma	A gastric adenocarcinoma that is resistant to treatment.	Refractory Gastric Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C167075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167075>	C4912|C224632	Unresectable Bladder Carcinoma	Bladder carcinoma that is not amenable to surgical resection.	Unresectable Bladder Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C167076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167076>	C71732|C165703	Refractory Triple-Negative Breast Carcinoma|Refractory Triple Negative Breast Carcinoma	Triple-negative breast carcinoma that is resistant to treatment.	Refractory Triple-Negative Breast Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C167077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167077>	C54443	SEER Terminology	The terminology that includes terms from the surveillance, epidemiology, and end results (SEER) program.			Intellectual Product	
C167078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167078>	C167077	SEER Rx Interactive Antineoplastic Drugs Database	The terminology that includes terms from the surveillance, epidemiology, and end results (SEER) Rx interactive antineoplastic drugs database.			Intellectual Product	SEER Terminology
C167079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167079>	C167078	SEER Rx Interactive Antineoplastic Drugs Database-Drugs	The terminology that includes drug terms from the surveillance, epidemiology, and end results (SEER) Rx interactive antineoplastic drugs database.			Intellectual Product	SEER Rx Interactive Antineoplastic Drugs Database
C167080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167080>	C167078	SEER Rx Interactive Antineoplastic Drugs Database-Regimen	The terminology that includes regimens from the surveillance, epidemiology, and end results (SEER) Rx interactive antineoplastic drugs database.			Intellectual Product	SEER Rx Interactive Antineoplastic Drugs Database
C167081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167081>	C7173|C203285|C176464|C148037	Recurrent Diffuse Astrocytoma	The reemergence of diffuse astrocytoma after a period of remission.	Recurrent Diffuse Astrocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C167082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167082>	C4050|C203285|C148037	Recurrent Oligoastrocytoma	The reemergence of oligoastrocytoma after a period of remission.			Neoplastic Process	
C167083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167083>	C345	Homovanillic Acid|(4-Hydroxy-3-methoxyphenyl)acetic Acid|3-Methoxy-4-hydroxyphenylacetic Acid|4-Hydroxy-3-methoxybenzeneacetic Acid|4-Hydroxy-3-methoxyphenylacetic Acid|Acetic Acid, (4-Hydroxy-3-methoxyphenyl)- (8CI)|Benzeneacetic Acid, 4-Hydroxy-3-methoxy-|HMPA|HVA|Vanillacetic Acid	A monocarboxylic acid that is a catecholamine metabolite.  Homovanillic acid may be used a marker for metabolic stress, tobacco usage or the presence of a catecholamine secreting tumor, such as neuroblastoma or pheochromocytoma.	Homovanillic Acid		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C167084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167084>	C345	Vanillylmandelic Acid|2-Hydroxy-2-(4-hydroxy-3-methoxyphenyl)acetic Acid|3-Methoxy-4-hydroxymandelic Acid|4-Hydroxy-3-methoxymandelic Acid|Benzeneacetic Acid, 4-Hydroxy-3-methoxy-|VMA|Vanillyl Mandelic Acid|Vanilmandelic Acid	An aromatic ether that is a product of catecholamine metabolism. Vanillylmandelic acid may be a used as marker for tumors that secrete catecholamines, such as neuroblastoma or pheochromocytoma.	Vanillylmandelic Acid		Organic Chemical	CTRP Biomarker Terminology|CTRP Terminology
C167085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167085>	C45296	Neoplastic Cells with Bright CD56 Expression Present	An immunophenotypic finding indicating the presence of neoplastic cells with bright CD56 expression.			Finding	
C167086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167086>	C40998|C177694	Neoplastic Cells with CD45 Dim-to-Negative Expression Present	An immunophenotypic finding indicating the presence of neoplastic cells with dim-to-negative CD45 expression.			Finding	
C167087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167087>	C40998|C177694	Neoplastic Cells with CD38 Dim-to-Negative Expression Present	An immunophenotypic finding indicating the presence of neoplastic cells with dim-to-negative CD38 expression.			Finding	
C167088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167088>	C40998|C162075	HLA-DR-Negative Neoplastic Cells Present	An immunophenotypic finding indicating the presence of neoplastic cells negative for HLA-DR expression.			Finding	
C167089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167089>	C9160	Acute Myeloid Leukemia with RAM Immunophenotype|AML with RAM Immunophenotype	A high risk pediatric acute myeloid leukemia with an extremely poor prognosis. The blasts show bright CD56 expression, dim-to-negative expression of CD45 and CD38, and lack of HLA-DR expression. This immunophenotype was named after one of the pediatric patient's initials (RAM), from Children's Oncology Group (COG) clinical trial AAML0531.			Neoplastic Process	
C167090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167090>	C178119|C131783	Inactivating BRCA Gene Mutation|BRCA Family Gene Inactivation|BRCA Gene Inactivation|BRCA Loss of Function Gene Mutation|BRCA Loss of Function Mutation|Inactivating BRCA Family Mutation|Inactivating BRCA Gene Family Mutation|Inactivating BRCA Mutation|Non-Functional BRCA Mutation	A change in the nucleotide sequence of a gene in the BRCA family that either inhibits expression or results in the translation of an inactive BRCA family protein.	Inactivating BRCA Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167091>	C179406	BRCA Variant of Unknown Significance|BRCA Family Gene VUS|BRCA Family VUS|BRCA Gene Family VUS|BRCA Gene VUS|BRCA Gene Variant of Unknown Significance|BRCA VUS|VUS BRCA	A change in the nucleotide sequence of a gene in the BRCA family whose association with disease risk is unknown or uncertain.	BRCA Variant of Unknown Significance		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167092>	C97927	DAXX Gene Mutation|BING2 Gene Mutation|DAP6 Gene Mutation|DAXX mutation|Death-Associated Protein 6 Gene Mutation|Death-Domain Associated Protein Gene Mutation|EAP1 Gene Mutation	A change in the nucleotide sequence of the DAXX gene.	DAXX Gene Mutation		Cell or Molecular Dysfunction	CRF8 Pathology Review Targeted Genomics Table|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167093>	C178119|C167092	Inactivating DAXX Gene Mutation|DAXX Gene Inactivation|DAXX Loss of Function Gene Mutation|DAXX Loss of Function Mutation|Inactivating BING2 Gene Mutation|Inactivating DAP6 Gene Mutation|Inactivating DAXX Mutation|Inactivating Death-Associated Protein 6 Gene Mutation|Inactivating Death-Domain Associated Protein Gene Mutation|Inactivating EAP1 Gene Mutation|Loss of Function DAXX Gene Mutation|Loss of Function DAXX Mutation	A change in the nucleotide sequence of the DAXX gene that either inhibits expression or results in the translation of an inactive death domain-associated protein 6 protein.	Inactivating DAXX Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167094>	C178119|C148041	Inactivating ATRX Gene Mutation|ATRX Gene Inactivation|ATRX Loss of Function Gene Mutation|ATRX Loss of Function Mutation|Inactivating ATRX Mutation|Inactivating ATRX, Chromatin Remodeler Gene Mutation|Inactivating Alpha Thalassemia/Mental Retardation Syndrome X-Linked Gene Mutation|Inactivating RAD54 Gene Mutation|Inactivating RAD54 Homolog Gene Mutation|Inactivating RAD54L Gene Mutation|Inactivating XH2 Gene Mutation|Inactivating XNP Gene Mutation|Inactivating ZNF-HX Gene Mutation|Loss of Function ATRX Gene Mutation|Loss of Function ATRX Mutation	A change in the nucleotide sequence of the ATRX gene that either inhibits expression or results in the translation of an inactive transcriptional regulator ATRX protein.	Inactivating ATRX Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167095>	C178119|C157462	Inactivating ARID1A Gene Mutation|ARID1A Gene Inactivation|ARID1A Loss of Function Gene Mutation|ARID1A Loss of Function Mutation|Inactivating ARID1A Mutation|Inactivating AT Rich Interactive Domain 1A Gene Mutation|Inactivating B120 Gene Mutation|Inactivating BAF250 Gene Mutation|Inactivating BAF250a Gene Mutation|Inactivating BRG1-Associated Factor 250a Gene Mutation|Inactivating ZNF-HX Gene Mutation|Loss of Function ARID1A Gene Mutation|Loss of Function ARID1A Mutation	A change in the nucleotide sequence of the ARID1A gene that either inhibits expression or results in the translation of an inactive AT-rich interactive domain-containing protein 1A protein.	Inactivating ARID1A Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167096>	C97927	SMC3 Gene Mutation|BAM Gene Mutation|BMH Gene Mutation|Bamacan Gene Mutation|CSPG6 Gene Mutation|Chondroitin Sulfate Proteoglycan 6 Gene Mutation|HCAP Gene Mutation|SMC3L1 Gene Mutation|Structural Maintenance of Chromosomes 3 Gene Mutation	A change in the nucleotide sequence of the SMC3 gene.	SMC3 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167097>	C97927	PDS5B Gene Mutation|APRIN Gene Mutation|AS3 Gene Mutation|Androgen-Induced Proliferation Inhibitor Gene Mutation|PDS5 Cohesin Associated Factor B Gene Mutation	A change in the nucleotide sequence of the PDS5B gene.	PDS5B Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167098>	C97927	RAD21 Gene Mutation|HR21 Gene Mutation|HRAD21 Gene Mutation|MCD1 Gene Mutation|NXP1 Gene Mutation|RAD21 Cohesin Complex Component Gene Mutation|RAD21 Homolog Gene Mutation|SCC1 Gene Mutation|hHR21 Gene Mutation	A change in the nucleotide sequence of the RAD21 gene.	RAD21 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167099>	C35508|C159854	Clonal Plasma Cells in Bone Marrow|Clonal Plasma Cells Detected in Bone Marrow|Clonal Plasma Cells Present in Bone Marrow|Detectable Clonal Bone Marrow Plasma Cells	A finding indicating that clonal plasma cells have been detected in a bone marrow sample.	Clonal Plasma Cells in Bone Marrow		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C1670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1670>	C67439|C443	Ibandronate Sodium|Bondronate|Boniva|IBANDRONATE SODIUM|ibandronate	The sodium salt form of ibandronic acid, a synthetic nitrogen-containing bisphosphonate. Ibandronic acid inhibits farnesyl pyrophosphate synthase, resulting in a reduction in geranylgeranyl GTPase signaling proteins and apoptosis of osteoclasts. This agent increases bone mineral density, decreases bone remodeling, inhibits osteoclast-mediated bone resorption, and reduces metastases-related and corticosteroid-related bone pain.	Ibandronate Sodium		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C167100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167100>	C190667|C177687	MET Exon 14 Skipping Mutation Negative|Deletion of MET Exon 14 Negative|Deletion of c-MET Exon 14 Negative|HGFR Exon 14 Skipping Alteration Negative|HGFR Exon 14 Skipping Mutation Negative|HGFR Exon 14 Splice Mutation Negative|Loss of MET Exon 14 Negative|Loss of c-MET Exon 14 Negative|MET Exon 14 Deletion Mutation Negative|MET Exon 14 Skipping Alteration Negative|MET Exon 14 Splice Mutation Negative|c-MET Exon 14 Deletion Mutation Negative|c-MET Exon 14 Splice Mutation Negative|c-Met Exon 14 Skipping Alteration Negative|c-Met Exon 14 Skipping Mutation Negative	A genetic finding indicating that activating MET exon 14 skipping mutations have not been detected in a sample.	MET Exon 14 Skipping Mutation Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167101>	C177687	Activating KRAS Gene Mutation Negative|Activating KRAS Mutation Negative|KRAS Activating Mutation Negative|KRAS Proto-Oncogene, GTPase Activating Mutation Negative|KRAS-2 Activating Mutation Negative|KRAS2 Activating Mutation Negative|c-K-ras Activating Mutation Negative|v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Activating Mutation Negative	A genetic finding indicating that mutations in the KRAS gene which encode constitutively active forms of the GTPase KRas protein are not present in a sample.	Activating KRAS Gene Mutation Negative		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167102>	C177684|C147054|C142839	ROS1 Gene Fusion Negative|MCF3 Gene Fusion Negative|ROS Fusion Negative|ROS Gene Fusion Negative|ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene Fusion Negative|ROS1 Fusion Gene Negative|Receptor Tyrosine Kinase c-Ros Oncogene 1 Gene Fusion Negative|c-ros-1 Gene Fusion Negative	An indication that a ROS1 fusion gene has not been detected in a sample.	ROS1 Gene Fusion Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167103>	C165233|C158949	ALK Fusion Negative|ALK Receptor Tyrosine Kinase Fusion Negative|ALK Tyrosine Kinase Receptor Fusion Negative|Anaplastic Lymphoma Kinase Fusion Negative|Anaplastic Lymphoma Kinase Receptor Fusion Negative|Anaplastic Lymphoma Receptor Tyrosine Kinase Fusion Negative|CD246 Antigen Fusion Negative|CD246 Fusion Negative	An indication that the expression of a fusion involving ALK has not been detected in a sample.	ALK Fusion Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167104>	C177684|C167103|C134487	ALK Gene Fusion Negative|ALK Fusion Gene Negative|ALK Fusion Oncogene Negative|Anaplastic Lymphoma Kinase Fusion Gene Negative|Anaplastic Lymphoma Kinase Fusion Oncogene Negative|Anaplastic Lymphoma Receptor Tyrosine Kinase Fusion Gene Negative|CD246 Fusion Gene Negative	An indication that an ALK fusion gene has not been detected in a sample.	ALK Gene Fusion Negative		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167105>	C183567	NTRK3 Gene Amplification|NTRK3 Amplification|Neurotrophic Receptor Tyrosine Kinase 3 Gene Amplification|Neurotrophic Tyrosine Kinase Receptor 3 Gene Amplification|Neurotrophic Tyrosine Kinase Receptor Type 3 Gene Amplification|Neurotrophic Tyrosine Kinase, Receptor, Type 3 Gene Amplification|TRKC Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the NTRK3 gene.	NTRK3 Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167106>	C183567	NTRK2 Gene Amplification|NTRK2 Amplification|Neurotrophic Receptor Tyrosine Kinase 2 Gene Amplification|Neurotrophic Tyrosine Kinase Receptor 2 Gene Amplification|Neurotrophic Tyrosine Kinase Receptor Type 2 Gene Amplification|TRKB Tyrosine Kinase Gene Amplification|Tropomyosin-Related Kinase B Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the NTRK2 gene.	NTRK2 Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167107>	C41613|C178119	Inactivating CDKN2C Gene Mutation|CDKN2C Gene Inactivation|CDKN2C Loss of Function Gene Mutation|CDKN2C Loss of Function Mutation|Inactivating CDKN2C Mutation|Inactivating CDKN6 Gene Mutation|Inactivating Cyclin Dependent Kinase Inhibitor 2C Gene Mutation|Inactivating Cyclin-Dependent Kinase Inhibitor 2C Gene Mutation|Inactivating INK4C Gene Mutation|Inactivating p18 Gene Mutation|Inactivating p18(INK4C) Gene Mutation|Inactivating p18-INK4C Gene Mutation|Inactivating p18-INK6 Gene Mutation|Loss of Function CDKN2C Gene Mutation|Loss of Function CDKN2C Mutation	A change in the nucleotide sequence of the CDKN2C gene that either inhibits expression or results in the translation of an inactive cyclin-dependent kinase 4 inhibitor C protein.	Inactivating CDKN2C Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167108>	C97927	CDKN2B Gene Mutation|CDK4I Gene Mutation|Cyclin Dependent Kinase Inhibitor 2B Gene Mutation|Cyclin-Dependent Kinase Inhibitor 2B Gene Mutation|INK4B Gene Mutation|MTS2 Gene Mutation|P15 Gene Mutation|TP15 Gene Mutation|p15INK4b Gene Mutation	A change in the nucleotide sequence of the CDKN2B gene.	CDKN2B Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167109>	C178119|C167108	Inactivating CDKN2B Gene Mutation|CDKN2B Gene Inactivation|CDKN2B Loss of Function Gene Mutation|CDKN2B Loss of Function Mutation|Inactivating CDK4I Gene Mutation|Inactivating CDKN2B Mutation|Inactivating Cyclin Dependent Kinase Inhibitor 2B Gene Mutation|Inactivating Cyclin-Dependent Kinase Inhibitor 2B Gene Mutation|Inactivating INK4B Gene Mutation|Inactivating MTS2 Gene Mutation|Inactivating P15 Gene Mutation|Inactivating TP15 Gene Mutation|Inactivating p15INK4b Gene Mutation|Loss of Function CDKN2B Gene Mutation|Loss of Function CDKN2B Mutation	A change in the nucleotide sequence of the CDKN2B gene that either inhibits expression or results in the translation of an inactive cyclin-dependent kinase 4 inhibitor B protein.	Inactivating CDKN2B Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C16710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16710>	C17937	Immunity|immunity	The protection against infectious disease conferred by the immune response. It encompasses the capacity to distinguish foreign material from self, and to neutralize, eliminate, or metabolize that which is foreign.			Organ or Tissue Function	
C167110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167110>	C19618	STAT5 Protein Family|STAT5|STAT5 Protein|Signal Transducer and Activator of Transcription 5|Signal Transducer and Activator of Transcription 5 Protein	Two highly conserved members of the signal transducer and activator of transcription (STAT) protein family, STAT5A and STAT5B. Constitutive phosphorylation of STAT5 proteins, which leads to constitutive activation and aberrant expression of STAT5-dependent genes, has been observed in various neoplastic diseases.	STAT5 Protein Family		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167111>	C97927	AXIN2 Gene Mutation|AXIL Gene Mutation|AXIS Inhibitor 2 Gene Mutation|Axin 2 Gene Mutation|Conductin, Mouse, Homolog of Gene Mutation|ODCRCS Gene Mutation	A change in the nucleotide sequence of the AXIN2 gene.	AXIN2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167112>	C97927	AXIN1 Gene Mutation|AXIN Gene Mutation|AXIS Inhibitor 1 Gene Mutation|Axin 1 Gene Mutation|Fused, Mouse, Homolog of Gene Mutation|PPP1R49 Gene Mutation	A change in the nucleotide sequence of the AXIN1 gene.	AXIN1 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167113>	C97927	RSPO3 Gene Mutation|CRISTIN1 Gene Mutation|PWTSR Gene Mutation|R-Spondin 3 Gene Mutation|THSD2 Gene Mutation|Thrombospondin, Type I, Domain Containing 2 Gene Mutation	A change in the nucleotide sequence of the RSPO3 gene.	RSPO3 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167114>	C97927	RSPO2 Gene Mutation|CRISTIN2 Gene Mutation|HHRRD Gene Mutation|R-Spondin 2 Gene Mutation|TETAMS2 Gene Mutation	A change in the nucleotide sequence of the RSPO2 gene.	RSPO2 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167115>	C97927	ZNRF3 Gene Mutation|RNF203 Gene Mutation|Zinc and Ring Finger 3 Gene Mutation	A change in the nucleotide sequence of the ZNRF3 gene.	ZNRF3 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167116>	C15425	Creatine Supplementation	The addition of creatine to an individual's daily diet. It is most commonly used for improving exercise performance and increasing muscle mass in athletes and older adults.	Creatine Supplementation		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C167117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167117>	C35682	Influenza B Virus Positive|Influenza Type B Virus Positive	An indication that influenza B virus has been detected in a sample.	Influenza B Virus Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C167118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167118>	C35682	Influenza A Virus Positive|Influenza Type A Virus Positive	An indication that influenza A virus has been detected in a sample.	Influenza A Virus Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C167119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167119>	C97927	SBDS Gene Mutation|CGI-97 Gene Mutation|SBDS Ribosome Maturation Factor Gene Mutation|SDS Gene Mutation|SWDS Gene Mutation|Shwachman-Bodian-Diamond Syndrome Gene Mutation	A change in the nucleotide sequence of the SBDS gene.	SBDS Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C16711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16711>	C16710	Cell-Mediated Immunity|Cell Mediated Immunity|Cell Mediated Immunology|Cellular Immunity	Those manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role.			Cell Function	
C167121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167121>	C97928	SRSF2 Protein Variant|Protein PR264 Protein Variant|SC-35 Protein Variant|SR Splicing Factor 2 Protein Variant|Serine/Arginine-Rich Splicing Factor 2 Protein Variant|Splicing Component, 35 kDa Protein Variant|Splicing Factor SC35 Protein Variant|Splicing Factor, Arginine/Serine-Rich 2 Protein Variant	A variation in the amino acid sequence for the serine/arginine-rich splicing factor 2 protein.	SRSF2 Protein Variant		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167122>	C167121	SRSF2 NP_003007.2:p.P95 Deletion|NP_003007.2:p.P95 Deletion|NP_003007.2:p.Pro95 Deletion|Protein PR264 P95 Deletion|Protein PR264 Pro95 Deletion|SC-35 P95 Deletion|SC-35 Pro95 Deletion|SR Splicing Factor 2 P95 Deletion|SR Splicing Factor 2 Pro95 Deletion|SRSF2 NP_003007.2:p.Pro95 Deletion|SRSF2 P95 Deletion|SRSF2 Pro95 Deletion|SRSF2 p.P95 Deletion|SRSF2 p.Pro95 Deletion|Serine/Arginine-Rich Splicing Factor 2 P95 Deletion|Serine/Arginine-Rich Splicing Factor 2 Pro95 Deletion|Splicing Component, 35 kDa P95 Deletion|Splicing Component, 35 kDa Pro95 Deletion|Splicing Factor SC35 P95 Deletion|Splicing Factor SC35 Pro95 Deletion|Splicing Factor, Arginine/Serine-Rich 2 P95 Deletion|Splicing Factor, Arginine/Serine-Rich 2 Pro95 Deletion	Any deletion in the amino acid sequence for the serine/arginine-rich splicing factor 2 protein that includes the proline at position 95.	SRSF2 NP_003007.2:p.P95 Deletion		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167123>	C97928	U2AF1 Protein Variant|Splicing Factor U2AF 35 kDa Subunit Protein Variant|U2 Auxiliary Factor 35 kDa Subunit Protein Variant|U2 snRNP Auxiliary Factor Small Subunit Protein Variant|U2(RNU2) Small Nuclear RNA Auxiliary Factor Binding Protein Protein Variant	A variation in the amino acid sequence for the splicing factor U2AF 35 kDa subunit protein.	U2AF1 Protein Variant		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167124>	C390|C2124	Gallium Ga-labeled PSMA-11-Gadoxetate|68Ga-PSMA-11-Gadoxetate	A radioconjugate composed of a human prostate specific membrane antigen (PSMA)-targeting ligand, Glu-urea-Lys(Ahx) (Glu-NH-CO-NH-Lys(Ahx)) conjugated to both the paramagnetic contrast enhancer gadoxetate and the radioisotope gallium Ga 68, the latter is conjugated via an acyclic radiometal chelator N,N'-bis [2-hydroxy-5-(carboxyethyl)benzyl] ethylenediamine-N,N'-diacetic acid (HBED-CC), with potential use as a tracer for PSMA-expressing tumors during magnetic resonance imaging (MRI) and positron emission tomography (PET). Upon intravenous administration of the gallium Ga 68-labeled PSMA-11-gadoxetate, the Glu-urea-Lys(Ahx) moiety targets and binds to PSMA-expressing tumor cells. PSMA-expressing tumor cells can be detected during PET imaging and MRI. The dual imaging capabilities of this agent may improve both visualization of PSMA-expressing tumor cells and tumor assessment. PSMA, a tumor-associated antigen and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells as well as on some other tumor cell types.	Gallium Ga-labeled PSMA-11-Gadoxetate		Amino Acid, Peptide, or Protein|Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C167125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167125>	C167123	U2AF1 NP_006749.1:p.Q157X|NP_006749.1:p.Gln157Xxx|NP_006749.1:p.Q157X|Splicing Factor U2AF 35 kDa Subunit Gln157Xxx|Splicing Factor U2AF 35 kDa Subunit Q157X|U2 Auxiliary Factor 35 kDa Subunit Gln157Xxx|U2 Auxiliary Factor 35 kDa Subunit Q157X|U2 snRNP Auxiliary Factor Small Subunit Gln157Xxx|U2 snRNP Auxiliary Factor Small Subunit Q157X|U2(RNU2) Small Nuclear RNA Auxiliary Factor Binding Protein Gln157Xxx|U2(RNU2) Small Nuclear RNA Auxiliary Factor Binding Protein Q157X|U2AF1 Gln157Xxx|U2AF1 NP_006749.1:p.Gln157Xxx|U2AF1 Q157 Mutation|U2AF1 Q157X|U2AF1 p.Gln157Xxx|U2AF1 p.Q157X	A change in the amino acid residue at position 157 in the splicing factor U2AF 35 kDa subunit protein where glutamine has been replaced by another amino acid.	U2AF1 NP_006749.1:p.Q157X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167126>	C167123	U2AF1 NP_006749.1:p.R156X|NP_006749.1:p.Arg156Xxx|NP_006749.1:p.R156X|Splicing Factor U2AF 35 kDa Subunit Arg156Xxx|Splicing Factor U2AF 35 kDa Subunit R156X|U2 Auxiliary Factor 35 kDa Subunit Arg156Xxx|U2 Auxiliary Factor 35 kDa Subunit R156X|U2 snRNP Auxiliary Factor Small Subunit Arg156Xxx|U2 snRNP Auxiliary Factor Small Subunit R156X|U2(RNU2) Small Nuclear RNA Auxiliary Factor Binding Protein Arg156Xxx|U2(RNU2) Small Nuclear RNA Auxiliary Factor Binding Protein R156X|U2AF1 Arg156Xxx|U2AF1 NP_006749.1:p.Arg156Xxx|U2AF1 R156 Mutation|U2AF1 R156X|U2AF1 p.Arg156Xxx|U2AF1 p.R156X	A change in the amino acid residue at position 156 in the splicing factor U2AF 35 kDa subunit protein where arginine has been replaced by another amino acid.	U2AF1 NP_006749.1:p.R156X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167127>	C167123	U2AF1 NP_006749.1:p.S34X|NP_006749.1:p.S34X|NP_006749.1:p.Ser34Xxx|Splicing Factor U2AF 35 kDa Subunit S34X|Splicing Factor U2AF 35 kDa Subunit Ser34Xxx|U2 Auxiliary Factor 35 kDa Subunit S34X|U2 Auxiliary Factor 35 kDa Subunit Ser34Xxx|U2 snRNP Auxiliary Factor Small Subunit S34X|U2 snRNP Auxiliary Factor Small Subunit Ser34Xxx|U2(RNU2) Small Nuclear RNA Auxiliary Factor Binding Protein Protein Variant Ser34Xxx|U2(RNU2) Small Nuclear RNA Auxiliary Factor Binding Protein S34X|U2AF1 NP_006749.1:p.Ser34Xxx|U2AF1 S34 Mutation|U2AF1 S34X|U2AF1 Ser34Xxx|U2AF1 p.S34X|U2AF1 p.Ser34Xxx	A change in the amino acid residue at position 34 in the splicing factor U2AF 35 kDa subunit protein where serine has been replaced by another amino acid.	U2AF1 NP_006749.1:p.S34X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167128>	C97928	SF3B1 Protein Variant|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Protein Variant|SAP 155 Protein Variant|SF3b155 Protein Variant|Spliceosome-Associated Protein 155 Protein Variant|Splicing Factor 3B Subunit 1 Protein Variant	A variation in the amino acid sequence for the splicing factor 3B subunit 1 protein.	SF3B1 Protein Variant		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167129>	C167128	SF3B1 NP_036565.2:p.D781X|NP_036565.2:p.Asp781Xxx|NP_036565.2:p.D781X|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Asp781Xxx|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit D781X|SAP 155 Asp781Xxx|SAP 155 D781X|SF3B1 Asp781Xxx|SF3B1 D781 Mutation|SF3B1 D781X|SF3B1 NP_036565.2:p.Asp781Xxx|SF3B1 p.Asp781Xxx|SF3B1 p.D781X|SF3b155 Asp781Xxx|SF3b155 D781X|Spliceosome-Associated Protein 155 Asp781Xxx|Spliceosome-Associated Protein 155 D781X|Splicing Factor 3B Subunit 1 Asp781Xxx|Splicing Factor 3B Subunit 1 D781X	A change in the amino acid residue at position 781 in the splicing factor 3B subunit 1 protein where aspartic acid has been replaced by another amino acid.	SF3B1 NP_036565.2:p.D781X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C16712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16712>	C16710	Humoral Immunity|Humoral Immune Response	Immune processes mediated by antibodies			Cell Function	
C167130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167130>	C167128	SF3B1 NP_036565.2:p.A774X|NP_036565.2:p.A774X|NP_036565.2:p.Ala774Xxx|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit A774X|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Ala774Xxx|SAP 155 A774X|SAP 155 Ala774Xxx|SF3B1 A774 Mutation|SF3B1 A774X|SF3B1 Ala774Xxx|SF3B1 NP_036565.2:p.Ala774Xxx|SF3B1 p.A774X|SF3B1 p.Ala774Xxx|SF3b155 A774X|SF3b155 Ala774Xxx|Spliceosome-Associated Protein 155 A774X|Spliceosome-Associated Protein 155 Ala774Xxx|Splicing Factor 3B Subunit 1 A774X|Splicing Factor 3B Subunit 1 Ala774Xxx	A change in the amino acid residue at position 774 in the splicing factor 3B subunit 1 protein where alanine has been replaced by another amino acid.	SF3B1 NP_036565.2:p.A774X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167131>	C167128	SF3B1 NP_036565.2:p.G742X|NP_036565.2:p.G742X|NP_036565.2:p.Gly742Xxx|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit G742X|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Gly742Xxx|SAP 155 G742X|SAP 155 Gly742Xxx|SF3B1 G742 Mutation|SF3B1 G742X|SF3B1 Gly742Xxx|SF3B1 NP_036565.2:p.Gly742Xxx|SF3B1 p.G742X|SF3B1 p.Gly742Xxx|SF3b155 G742X|SF3b155 Gly742Xxx|Spliceosome-Associated Protein 155 G742X|Spliceosome-Associated Protein 155 Gly742Xxx|Splicing Factor 3B Subunit 1 G742X|Splicing Factor 3B Subunit 1 Gly742Xxx	A change in the amino acid residue at position 742 in the splicing factor 3B subunit 1 protein where glycine has been replaced by another amino acid.	SF3B1 NP_036565.2:p.G742X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167132>	C167128	SF3B1 NP_036565.2:p.K741X|NP_036565.2:p.K741X|NP_036565.2:p.Lys741Xxx|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit K741X|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Lys741Xxx|SAP 155 K741X|SAP 155 Lys741Xxx|SF3B1 K741 Mutation|SF3B1 K741X|SF3B1 Lys741Xxx|SF3B1 NP_036565.2:p.Lys741Xxx|SF3B1 p.K741X|SF3B1 p.Lys741Xxx|SF3b155 K741X|SF3b155 Lys741Xxx|Spliceosome-Associated Protein 155 K741X|Spliceosome-Associated Protein 155 Lys741Xxx|Splicing Factor 3B Subunit 1 K741X|Splicing Factor 3B Subunit 1 Lys741Xxx	A change in the amino acid residue at position 741 in the splicing factor 3B subunit 1 protein where lysine has been replaced by another amino acid.	SF3B1 NP_036565.2:p.K741X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167133>	C167128	SF3B1 NP_036565.2:p.G740X|NP_036565.2:p.G740X|NP_036565.2:p.Gly740Xxx|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit G740X|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Gly740Xxx|SAP 155 G740X|SAP 155 Gly740Xxx|SF3B1 G740 Mutation|SF3B1 G740X|SF3B1 Gly740Xxx|SF3B1 NP_036565.2:p.Gly740Xxx|SF3B1 p.G740X|SF3B1 p.Gly740Xxx|SF3b155 G740X|SF3b155 Gly740Xxx|Spliceosome-Associated Protein 155 G740X|Spliceosome-Associated Protein 155 Gly740Xxx|Splicing Factor 3B Subunit 1 G740X|Splicing Factor 3B Subunit 1 Gly740Xxx	A change in the amino acid residue at position 740 in the splicing factor 3B subunit 1 protein where glycine has been replaced by another amino acid.	SF3B1 NP_036565.2:p.G740X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167134>	C167128	SF3B1 NP_036565.2:p.I704X|NP_036565.2:p.I704X|NP_036565.2:p.Ile704Xxx|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit I704X|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Ile704Xxx|SAP 155 I704X|SAP 155 Ile704Xxx|SF3B1 I704 Mutation|SF3B1 I704X|SF3B1 Ile704Xxx|SF3B1 NP_036565.2:p.Ile704Xxx|SF3B1 p.I704X|SF3B1 p.Ile704Xxx|SF3b155 I704X|SF3b155 Ile704Xxx|Spliceosome-Associated Protein 155 I704X|Spliceosome-Associated Protein 155 Ile704Xxx|Splicing Factor 3B Subunit 1 I704X|Splicing Factor 3B Subunit 1 Ile704Xxx	A change in the amino acid residue at position 704 in the splicing factor 3B subunit 1 protein where isoleucine has been replaced by another amino acid.	SF3B1 NP_036565.2:p.I704X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167135>	C167128	SF3B1 NP_036565.2:p.V701X|NP_036565.2:p.V701X|NP_036565.2:p.Val701Xxx|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit V701X|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Val701Xxx|SAP 155 V701X|SAP 155 Val701Xxx|SF3B1 NP_036565.2:p.Val701Xxx|SF3B1 V701 Mutation|SF3B1 V701X|SF3B1 Val701Xxx|SF3B1 p.V701X|SF3B1 p.Val701Xxx|SF3b155 V701X|SF3b155 Val701Xxx|Spliceosome-Associated Protein 155 V701X|Spliceosome-Associated Protein 155 Val701Xxx|Splicing Factor 3B Subunit 1 V701X|Splicing Factor 3B Subunit 1 Val701Xxx	A change in the amino acid residue at position 701 in the splicing factor 3B subunit 1 protein where valine has been replaced by another amino acid.	SF3B1 NP_036565.2:p.V701X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167136>	C167128	SF3B1 NP_036565.2:p.K700X|NP_036565.2:p.K700X|NP_036565.2:p.Lys700Xxx|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit K700X|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Lys700Xxx|SAP 155 K700X|SAP 155 Lys700Xxx|SF3B1 K700 Mutation|SF3B1 K700X|SF3B1 Lys700Xxx|SF3B1 NP_036565.2:p.Lys700Xxx|SF3B1 p.K700X|SF3B1 p.Lys700Xxx|SF3b155 K700X|SF3b155 Lys700Xxx|Spliceosome-Associated Protein 155 K700X|Spliceosome-Associated Protein 155 Lys700Xxx|Splicing Factor 3B Subunit 1 K700X|Splicing Factor 3B Subunit 1 Lys700Xxx	A change in the amino acid residue at position 700 in the splicing factor 3B subunit 1 protein where lysine has been replaced by another amino acid.	SF3B1 NP_036565.2:p.K700X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167137>	C167128	SF3B1 NP_036565.2:p.K666X|NP_036565.2:p.K666X|NP_036565.2:p.Lys666Xxx|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit K666X|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Lys666Xxx|SAP 155 K666X|SAP 155 Lys666Xxx|SF3B1 K666 Mutation|SF3B1 K666X|SF3B1 Lys666Xxx|SF3B1 NP_036565.2:p.Lys666Xxx|SF3B1 p.K666X|SF3B1 p.Lys666Xxx|SF3b155 K666X|SF3b155 Lys666Xxx|Spliceosome-Associated Protein 155 K666X|Spliceosome-Associated Protein 155 Lys666Xxx|Splicing Factor 3B Subunit 1 K666X|Splicing Factor 3B Subunit 1 Lys666Xxx	A change in the amino acid residue at position 666 in the splicing factor 3B subunit 1 protein where lysine has been replaced by another amino acid.	SF3B1 NP_036565.2:p.K666X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167138>	C167128	SF3B1 NP_036565.2:p.T663X|NP_036565.2:p.T663X|NP_036565.2:p.Thr663Xxx|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit T663X|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Thr663Xxx|SAP 155 T663X|SAP 155 Thr663Xxx|SF3B1 NP_036565.2:p.Thr663Xxx|SF3B1 T663 Mutation|SF3B1 T663X|SF3B1 Thr663Xxx|SF3B1 p.T663X|SF3B1 p.Thr663Xxx|SF3b155 T663X|SF3b155 Thr663Xxx|Spliceosome-Associated Protein 155 T663X|Spliceosome-Associated Protein 155 Thr663Xxx|Splicing Factor 3B Subunit 1 T663X|Splicing Factor 3B Subunit 1 Thr663Xxx	A change in the amino acid residue at position 663 in the splicing factor 3B subunit 1 protein where threonine has been replaced by another amino acid.	SF3B1 NP_036565.2:p.T663X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167139>	C167128	SF3B1 NP_036565.2:p.H662X|NP_036565.2:p.H662X|NP_036565.2:p.His662Xxx|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit H662X|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit His662Xxx|SAP 155 H662X|SAP 155 His662Xxx|SF3B1 H662 Mutation|SF3B1 H662X|SF3B1 His662Xxx|SF3B1 NP_036565.2:p.His662Xxx|SF3B1 p.H662X|SF3B1 p.His662Xxx|SF3b155 H662X|SF3b155 His662Xxx|Spliceosome-Associated Protein 155 H662X|Spliceosome-Associated Protein 155 His662Xxx|Splicing Factor 3B Subunit 1 H662X|Splicing Factor 3B Subunit 1 His662Xxx	A change in the amino acid residue at position 662 in the splicing factor 3B subunit 1 protein where histidine has been replaced by another amino acid.	SF3B1 NP_036565.2:p.H662X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C16713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16713>	C16414	Immunochemistry	The field of chemistry concerned with chemical processes in immunology (such as chemical studies of antigens and antibodies).			Biomedical Occupation or Discipline	
C167140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167140>	C167128	SF3B1 NP_036565.2:p.N626X|NP_036565.2:p.Asn626Xxx|NP_036565.2:p.N626X|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Asn626Xxx|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit N626X|SAP 155 Asn626Xxx|SAP 155 N626X|SF3B1 Asn626Xxx|SF3B1 N626 Mutation|SF3B1 N626X|SF3B1 NP_036565.2:p.Asn626Xxx|SF3B1 p.Asn626Xxx|SF3B1 p.N626X|SF3b155 Asn626Xxx|SF3b155 N626X|Spliceosome-Associated Protein 155 Asn626Xxx|Spliceosome-Associated Protein 155 N626X|Splicing Factor 3B Subunit 1 Asn626Xxx|Splicing Factor 3B Subunit 1 N626X	A change in the amino acid residue at position 626 in the splicing factor 3B subunit 1 protein where asparagine has been replaced by another amino acid.	SF3B1 NP_036565.2:p.N626X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167141>	C167128	SF3B1 NP_036565.2:p.R625X|NP_036565.2:p.Arg625Xxx|NP_036565.2:p.R625X|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Arg625Xxx|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit R625X|SAP 155 Arg625Xxx|SAP 155 R625X|SF3B1 Arg625Xxx|SF3B1 NP_036565.2:p.Arg625Xxx|SF3B1 R625 Mutation|SF3B1 R625X|SF3B1 p.Arg625Xxx|SF3B1 p.R625X|SF3b155 Arg625Xxx|SF3b155 R625X|Spliceosome-Associated Protein 155 Arg625Xxx|Spliceosome-Associated Protein 155 R625X|Splicing Factor 3B Subunit 1 Arg625Xxx|Splicing Factor 3B Subunit 1 R625X	A change in the amino acid residue at position 625 in the splicing factor 3B subunit 1 protein where arginine has been replaced by another amino acid.	SF3B1 NP_036565.2:p.R625X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167142>	C167128	SF3B1 NP_036565.2:p.Y623X|NP_036565.2:p.Tyr623Xxx|NP_036565.2:p.Y623X|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Tyr623Xxx|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Y623X|SAP 155 Tyr623Xxx|SAP 155 Y623X|SF3B1 NP_036565.2:p.Tyr623Xxx|SF3B1 Tyr623Xxx|SF3B1 Y623 Mutation|SF3B1 Y623X|SF3B1 p.Tyr623Xxx|SF3B1 p.Y623X|SF3b155 Tyr623Xxx|SF3b155 Y623X|Spliceosome-Associated Protein 155 Tyr623Xxx|Spliceosome-Associated Protein 155 Y623X|Splicing Factor 3B Subunit 1 Tyr623Xxx|Splicing Factor 3B Subunit 1 Y623X	A change in the amino acid residue at position 623 in the splicing factor 3B subunit 1 protein where tyrosine has been replaced by another amino acid.	SF3B1 NP_036565.2:p.Y623X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167143>	C167128	SF3B1 NP_036565.2:p.E622X|NP_036565.2:p.E622X|NP_036565.2:p.Glu622Xxx|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit E622X|Pre-mRNA-Splicing Factor SF3b 155 kDa Subunit Glu622Xxx|SAP 155 E622X|SAP 155 Glu622Xxx|SF3B1 E622 Mutation|SF3B1 E622X|SF3B1 Glu622Xxx|SF3B1 NP_036565.2:p.Glu622Xxx|SF3B1 p.E622X|SF3B1 p.Glu622Xxx|SF3b155 E622X|SF3b155 Glu622Xxx|Spliceosome-Associated Protein 155 E622X|Spliceosome-Associated Protein 155 Glu622Xxx|Splicing Factor 3B Subunit 1 E622X|Splicing Factor 3B Subunit 1 Glu622Xxx	A change in the amino acid residue at position 622 in the splicing factor 3B subunit 1 protein where glutamic acid has been replaced by another amino acid.	SF3B1 NP_036565.2:p.E622X		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167144>	C133693|C122623	KMT2A Gene Translocation|KMT2A (MLL) Translocation|KMT2A Translocation|Lysine (K)-Specific Methyltransferase 2A Gene Translocation|Lysine Methyltransferase 2A Gene Translocation|MLL (KMT2A) Translocation|MLL Rearrangement (Translocation)|MLL Translocation|MLL Translocation|Mixed Lineage Leukemia Gene Translocation|Myeloid/Lymphoid Leukemia Gene Translocation|Myeloid/Lymphoid or Mixed Lineage Leukemia Gene Translocation|Myeloid/Lymphoid or Mixed-Lineage Leukemia (Trithorax Homolog, Drosophila) Gene Translocation	A cytogenetic abnormality that refers to any translocation involving the MLL (KMT2A) gene.	KMT2A Gene Translocation		Cell or Molecular Dysfunction	ALL Authorized Value Terminology|ALL Molecular Analysis Table|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C167145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167145>	C158948	ERBB2 Fusion Positive|Erb-B2 Receptor Tyrosine Kinase 2 Fusion Positive|HER-2 Fusion Positive|HER2 Fusion Positive|HER2/neu Fusion Positive|NEU Fusion Positive|Proto-Oncogene Neu Fusion Positive|Receptor Tyrosine-Protein Kinase erbB-2 Protein Variant Fusion Positive|Tyrosine Kinase-Type Cell Surface Receptor HER2 Fusion Positive|v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 Fusion Positive	An indication that the expression of a fusion involving ERBB2 has been detected in a sample.	ERBB2 Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167146>	C180783|C168524|C167145	ERBB2 Gene Fusion Positive|ERBB2 Fusion Gene Positive|Erb-B2 Receptor Tyrosine Kinase 2 Gene Fusion Positive|HER-2 Fusion Gene Positive|HER-2 Gene Fusion Positive|HER2 Fusion Gene Positive|HER2 Gene Fusion Positive|HER2/neu Gene Fusion Positive|NEU Gene Fusion Positive|v-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 Gene Fusion Positive	An indication that an ERBB2 fusion gene has been detected in a sample.	ERBB2 Fusion Gene Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167147>	C156029	ERBB3 Gene Amplification|ERBB3 Amplification|Erb-B2 Receptor Tyrosine Kinase 3 Gene Amplification|ErbB-3 Gene Amplification|HER-3 Gene Amplification|HER3 Gene Amplification|V-Erb-A Erythroblastic Leukemia Viral Oncogene Homolog 3 Gene Amplification|c-erbB-3 Gene Amplification|c-erbB3 Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the ERBB3 gene.	ERBB3 Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167148>	C158948	ERBB3 Fusion Positive|ERBB3 Receptor Protein-Tyrosine Kinase Fusion Positive|ErbB-3 Fusion Positive|HER-3 Fusion Positive|HER3 Fusion Positive|Receptor Tyrosine-Protein Kinase erbB-3 Fusion Positive|Tyrosine Kinase-Type Cell Surface Receptor HER3 Fusion Positive|c-erbB-3 Fusion Positive|c-erbB3 Fusion Positive	An indication that the expression of a fusion involving ERBB3 has been detected in a sample.	ERBB3 Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167149>	C168524|C167148	ERBB3 Gene Fusion Positive|ERBB3 Fusion Gene Positive|Erb-B2 Receptor Tyrosine Kinase 3 Gene Fusion Positive|ErbB-3 Gene Fusion Positive|HER-3 Fusion Gene Positive|HER-3 Gene Fusion Positive|HER3 Fusion Gene Positive|HER3 Gene Fusion Positive|V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 3 Gene Fusion Positive|c-erbB-3 Gene Fusion Positive|c-erbB3 Gene Fusion Positive|v-Erb-A Avian Erythroblastic Leukemia Viral Oncogene Homolog 3 Gene Fusion Positive	An indication that an ERBB3 fusion gene has been detected in a sample.	ERBB3 Fusion Gene Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C16714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16714>	C116640	Immunoenzyme Procedure|IMMUNOASSAY	An immunological procedure used for the microscopic examination of tissues.  It involves the usage of enzyme-antibody or enzyme-antigen conjugates, antienzyme antibodies, or enzyme-antienzyme complexes.	Immunoenzyme Procedure		Occupational Activity	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C167150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167150>	C118378	FGFR4 Gene Amplification|CD334 Gene Amplification|FGFR-4 Gene Amplification|FGFR4 Amplification|Fibroblast Growth Factor Receptor 4 Gene Amplification|JTK2 Gene Amplification|TKF Gene Amplification	A molecular genetic abnormality indicating the presence of multiple copies of the FGFR4 gene.	FGFR4 Gene Amplification		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167151>	C189905|C129700	Activating ERBB2 Point Mutation|Activating ERBB2 Gene Point Mutation|Activating HER2 Point Mutation|CD340 Activating Point Mutation|ERBB2 Activating Point Mutation|HER-2 Activating Point Mutation|HER2 Activating Point Mutation|HER2/Neu Activating Point Mutation|c-erbB2 Activating Point Mutation	A point mutation in the nucleotide sequence of the ERBB2 gene that that results in constitutive receptor tyrosine-protein kinase erbB-2-dependent signal transduction and activation of downstream signaling pathways.	Activating ERBB2 Point Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167152>	C21295	PA2G4 Gene|PA2G4|PA2G4|Proliferation-Associated 2G4 Gene	This gene is involved in RNA processing, cell survival and cellular differentiation.	PA2G4 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C167153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167153>	C167152	PA2G4 wt Allele|EBP1|HG4-1|Proliferation-Associated 2G4 wt Allele|Proliferation-Associated 2G4, 38-kD Gene|Proliferation-Associated 2G4, 38kD Gene|Proliferation-Associated 2G4, 38kDa Gene|p38-2G4	Human PA2G4 wild-type allele is located in the vicinity of 12q13.2 and is approximately 10 kb in length. This allele, which encodes proliferation-associated protein 2G4, plays a role in ribosomal RNA binding, the negative regulation of apoptosis and the promotion of cell differentiation.	PA2G4 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167154>	C21298	Proliferation-Associated Protein 2G4|Cell Cycle Protein p38-2G4 Homolog|EBP1|ErbB-3 Binding Protein 1|ErbB3-Binding Protein 1|ErbB3-Binding Protein Ebp1|PA2G4|hG4-1	Proliferation-associated protein 2G4 (394 aa, ~44 kDa) is encoded by the human PA2G4 gene. This protein is involved in the regulation of RNA processing and apoptosis.	Proliferation-Associated Protein 2G4		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167155>	C162512	Blasts 2 Percent or More of Bone Marrow Nucleated Cells|Blasts Greater than or Equal to 2 Percent of Bone Marrow Nucleated Cells	A semi-quantitative microscopic finding indicating that at least 2 percent of the nucleated cells in a bone marrow sample are immature mononuclear cells.	Blasts 2 Percent or More of Bone Marrow Nucleated Cells		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Terminology
C167156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167156>	C203020|C129820	Quemliclustat|AB 680|AB-680|AB680|CD73 Inhibitor AB680|QUEMLICLUSTAT	A small molecule, competitive inhibitor of the ectoenzyme CD73 (cluster of differentiation 73; 5'-ecto-nucleotidase; 5'-NT; ecto-5'-nucleotidase), with potential immunomodulating and antineoplastic activities. Upon administration, quemliclustat targets and binds to CD73, leading to clustering of and internalization of CD73. This prevents CD73-mediated conversion of adenosine monophosphate (AMP) to adenosine and decreases the amount of free adenosine in the tumor microenvironment (TME). This prevents adenosine-mediated lymphocyte suppression and increases the activity of CD8-positive effector cells and natural killer (NK) cells. This also activates macrophages and reduces the activity of myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes (Tregs). By abrogating the inhibitory effect on the immune system and enhancing the cytotoxic T-cell-mediated immune response against cancer cells, tumor cell growth decreases. In addition, clustering and internalization of CD73 decreases the migration of cancer cells and prevents metastasis. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, upregulated on a number of cancer cell types, catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the TME.	Quemliclustat		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C167157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167157>	C201853	KRAS G12C Inhibitor JNJ-74699157|ARS 3248|ARS-3248|ARS3248|G12C Mutant KRAS Protein Inhibitor JNJ-74699157|JNJ 74699157|JNJ-74699157|JNJ74699157|KRASG12C Inhibitor JNJ-74699157	An orally available, small molecule inhibitor of the oncogenic Kirsten rat sarcoma virus homolog KRAS glycine-to-cysteine substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration JNJ-74699157 targets and binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C, thereby inhibiting mutant KRAS-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.	KRASG12C Inhibitor JNJ-74699157		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C167158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167158>	C136634	FLT3 NM_004119.2:c.2039C>T|CD135 c.2039C>T|FLK2 c.2039C>T|FLT3 c.2039C>T|FMS-Related Tyrosine Kinase 3 c.2039C>T|NM_004119.2:c.2039C>T	A nucleotide substitution at position 2039 of the coding sequence of the FLT3 gene where cytosine has been mutated to thymine.			Cell or Molecular Dysfunction	
C167159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167159>	C128920	FLT3 NP_004110.2:p.A690V|A690V|CD135 Antigen A690V|CD135 Antigen Ala690Val|FLT3 A690V|FLT3 Ala690Val|FLT3 NP_004110.2:p.Ala690Val|FLT3 p.A690V|FLT3 p.Ala690Val|Fetal Liver Kinase-2 A690V|Fetal Liver Kinase-2 Ala690Val|Flt-3 Receptor A690V|Flt-3 Receptor Ala690Val|Fms-Related Tyrosine Kinase 3 A690V|Fms-Related Tyrosine Kinase 3 Ala690Val|NP_004110.2:p.A690V|NP_004110.2:p.Ala690Val|Receptor-Type Tyrosine-Protein Kinase FLT3 A690V|Receptor-Type Tyrosine-Protein Kinase FLT3 Ala690Val|Stem Cell Tyrosine Kinase 1 A690V|Stem Cell Tyrosine Kinase 1 Ala690Val	A change in the amino acid residue at position 680 in the receptor-type tyrosine-protein kinase FLT3 protein where alanine has been replaced by valine.			Cell or Molecular Dysfunction	
C16715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16715>	C16624	Immunogenetics	A sub-field of genetics that uses both genetic and immunological analyses to study the genetics behind antibody formation and the immune response. (Biotech Life Science Dictionary)			Biomedical Occupation or Discipline	
C167160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167160>	C67495|C136634	FLT3 NM_004119.2:c.2517T>A|CD135 c.2517T>A|FLK2 c.2517T>A|FLT3 c.2517T>A|FMS-Related Tyrosine Kinase 3 c.2517T>A|NM_004119.2:c.2517T>A	A nucleotide substitution at position 2517 of the coding sequence of the FLT3 gene where thymine has been mutated to adenine.			Cell or Molecular Dysfunction	
C167161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167161>	C128920	FLT3 NP_004110.2:p.D839E|CD135 Antigen Asp839Glu|CD135 Antigen D839E|D839E|FLT3 Asp839Glu|FLT3 D839E|FLT3 NP_004110.2:p.Asp839Glu|FLT3 p.Asp839Glu|FLT3 p.D839E|Fetal Liver Kinase-2 Asp839Glu|Fetal Liver Kinase-2 D839E|Flt-3 Receptor Asp839Glu|Flt-3 Receptor D839E|Fms-Related Tyrosine Kinase 3 Asp839Glu|Fms-Related Tyrosine Kinase 3 D839E|NP_004110.2:p.Asp839Glu|NP_004110.2:p.D839E|Receptor-Type Tyrosine-Protein Kinase FLT3 Asp839Glu|Receptor-Type Tyrosine-Protein Kinase FLT3 D839E|Stem Cell Tyrosine Kinase 1 Asp839Glu|Stem Cell Tyrosine Kinase 1 D839E	A change in the amino acid residue at position 839 in the receptor-type tyrosine-protein kinase FLT3 protein where aspartic acid has been replaced by glutamic acid.			Cell or Molecular Dysfunction	
C167162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167162>	C67495|C136634	FLT3 NM_004119.2:c.2516A>G|CD135 c.2516A>G|FLK2 c.2516A>G|FLT3 c.2516A>G|FMS-Related Tyrosine Kinase 3 c.2516A>G|NM_004119.2:c.2516A>G	A nucleotide substitution at position 2516 of the coding sequence of the FLT3 gene where adenine has been mutated to guanine.			Cell or Molecular Dysfunction	
C167163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167163>	C128920	FLT3 NP_004110.2:p.D839G|CD135 Antigen Asp839Gly|CD135 Antigen D839G|D839G|FLT3 Asp839Gly|FLT3 D839G|FLT3 NP_004110.2:p.Asp839Gly|FLT3 p.Asp839Gly|FLT3 p.D839G|Fetal Liver Kinase-2 Asp839Gly|Fetal Liver Kinase-2 D839G|Flt-3 Receptor Asp839Gly|Flt-3 Receptor D839G|Fms-Related Tyrosine Kinase 3 Asp839Gly|Fms-Related Tyrosine Kinase 3 D839G|NP_004110.2:p.Asp839Gly|NP_004110.2:p.D839G|Receptor-Type Tyrosine-Protein Kinase FLT3 Asp839Gly|Receptor-Type Tyrosine-Protein Kinase FLT3 D839G|Stem Cell Tyrosine Kinase 1 Asp839Gly|Stem Cell Tyrosine Kinase 1 D839G	A change in the amino acid residue at position 839 in the receptor-type tyrosine-protein kinase FLT3 protein where aspartic acid has been replaced by glycine.			Cell or Molecular Dysfunction	
C167164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167164>	C128920	FLT3 NP_004110.2:p.F594Y|CD135 Antigen F594Y|CD135 Antigen Phe594Tyr|F594Y|FLT3 F594Y|FLT3 NP_004110.2:p.Phe594Tyr|FLT3 Phe594Tyr|FLT3 p.F594Y|FLT3 p.Phe594Tyr|Fetal Liver Kinase-2 F594Y|Fetal Liver Kinase-2 Phe594Tyr|Flt-3 Receptor F594Y|Flt-3 Receptor Phe594Tyr|Fms-Related Tyrosine Kinase 3 F594Y|Fms-Related Tyrosine Kinase 3 Phe594Tyr|NP_004110.2:p.F594Y|NP_004110.2:p.Phe594Tyr|Receptor-Type Tyrosine-Protein Kinase FLT3 F594Y|Receptor-Type Tyrosine-Protein Kinase FLT3 Phe594Tyr|Stem Cell Tyrosine Kinase 1 F594Y|Stem Cell Tyrosine Kinase 1 Phe594Tyr	A change in the amino acid residue at position 594 in the receptor-type tyrosine-protein kinase FLT3 protein where phenylalanine has been replaced by tyrosine.			Cell or Molecular Dysfunction	
C167165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167165>	C128920	FLT3 NP_004110.2:p.F594C|CD135 Antigen F594C|CD135 Antigen Phe594Cys|F594C|FLT3 F594C|FLT3 NP_004110.2:p.Phe594Cys|FLT3 Phe594Cys|FLT3 p.F594C|FLT3 p.Phe594Cys|Fetal Liver Kinase-2 F594C|Fetal Liver Kinase-2 Phe594Cys|Flt-3 Receptor F594C|Flt-3 Receptor Phe594Cys|Fms-Related Tyrosine Kinase 3 F594C|Fms-Related Tyrosine Kinase 3 Phe594Cys|NP_004110.2:p.F594C|NP_004110.2:p.Phe594Cys|Receptor-Type Tyrosine-Protein Kinase FLT3 F594C|Receptor-Type Tyrosine-Protein Kinase FLT3 Phe594Cys|Stem Cell Tyrosine Kinase 1 F594C|Stem Cell Tyrosine Kinase 1 Phe594Cys	A change in the amino acid residue at position 594 in the receptor-type tyrosine-protein kinase FLT3 protein where phenylalanine has been replaced by cysteine.			Cell or Molecular Dysfunction	
C167166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167166>	C67496|C136634	FLT3 NM_004119.2:c.1727T>G|CD135 c.1727T>G|FLK2 c.1727T>G|FLT3 c.1727T>G|FMS-Related Tyrosine Kinase 3 c.1727T>G|NM_004119.2:c.1727T>G	A nucleotide substitution at position 1727 of the coding sequence of the FLT3 gene where thymine has been mutated to guanine.			Cell or Molecular Dysfunction	
C167167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167167>	C128920	FLT3 NP_004110.2:p.L576R|CD135 Antigen L576R|CD135 Antigen Leu576Arg|FLT3 L576R|FLT3 Leu576Arg|FLT3 NP_004110.2:p.Leu576Arg|FLT3 p.L576R|FLT3 p.Leu576Arg|Fetal Liver Kinase-2 L576R|Fetal Liver Kinase-2 Leu576Arg|Flt-3 Receptor L576R|Flt-3 Receptor Leu576Arg|Fms-Related Tyrosine Kinase 3 L576R|Fms-Related Tyrosine Kinase 3 Leu576Arg|L576R|NP_004110.2:p.L576R|NP_004110.2:p.Leu576Arg|Receptor-Type Tyrosine-Protein Kinase FLT3 L576R|Receptor-Type Tyrosine-Protein Kinase FLT3 Leu576Arg|Stem Cell Tyrosine Kinase 1 L576R|Stem Cell Tyrosine Kinase 1 Leu576Arg	A change in the amino acid residue at position 576 in the receptor-type tyrosine-protein kinase FLT3 protein where leucine has been replaced by arginine.			Cell or Molecular Dysfunction	
C167168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167168>	C9305	Obesity-Related Malignant Neoplasm	A malignant neoplasm that occurs in the context of obesity.	Obesity-Related Malignant Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C167169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167169>	C136634	FLT3 NM_004119.2:c.1992G>A|CD135 c.1992G>A|FLK2 c.1992G>A|FLT3 c.1992G>A|FMS-Related Tyrosine Kinase 3 c.1992G>A|NM_004119.2:c.1992G>A	A nucleotide substitution at position 1992 of the coding sequence of the FLT3 gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C16716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16716>	C19896	Idiotype	The antigenic specificity of an antibody as determined by the unique sequence of its antigen combining site.			Functional Concept	
C167170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167170>	C136634	FLT3 NM_004119.2:c.1992G>C|CD135 c.1992G>C|FLK2 c.1992G>C|FLT3 c.1992G>C|FMS-Related Tyrosine Kinase 3 c.1992G>C|NM_004119.2:c.1992G>C	A nucleotide substitution at position 1992 of the coding sequence of the FLT3 gene where guanine has been mutated to cytosine.			Cell or Molecular Dysfunction	
C167171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167171>	C136634	FLT3 NM_004119.2:c.1992G>T|CD135 c.1992G>T|FLK2 c.1992G>T|FLT3 c.1992G>T|FMS-Related Tyrosine Kinase 3 c.1992G>T|NM_004119.2:c.1992G>T	A nucleotide substitution at position 1992 of the coding sequence of the FLT3 gene where guanine has been mutated to thymine.			Cell or Molecular Dysfunction	
C167172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167172>	C63362	Vacutainer with K2EDTA|Blood Collection Tube with K2EDTA|K2-EDTA Tube	An evacuated blood collection tube containing K2-EDTA, designed to work as an anti-coagulant.			Medical Device	
C167173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167173>	C128920	FLT3 NP_004110.2:p.M664I|CD135 Antigen M664I|CD135 Antigen Met664Ile|FLT3 M664I|FLT3 Met664Ile|FLT3 NP_004110.2:p.Met664Ile|FLT3 p.M664I|FLT3 p.Met664Ile|Fetal Liver Kinase-2 M664I|Fetal Liver Kinase-2 Met664Ile|Flt-3 Receptor M664I|Flt-3 Receptor Met664Ile|Fms-Related Tyrosine Kinase 3 M664I|Fms-Related Tyrosine Kinase 3 Met664Ile|M664I|NP_004110.2:p.M664I|NP_004110.2:p.Met664Ile|Receptor-Type Tyrosine-Protein Kinase FLT3 M664I|Receptor-Type Tyrosine-Protein Kinase FLT3 Met664Ile|Stem Cell Tyrosine Kinase 1 M664I|Stem Cell Tyrosine Kinase 1 Met664Ile	A change in the amino acid residue at position 664 in the receptor-type tyrosine-protein kinase FLT3 protein where methionine has been replaced by isoleucine.			Cell or Molecular Dysfunction	
C167174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167174>	C136634	FLT3 NM_004119.2:c.2028C>A|CD135 c.2028C>A|FLK2 c.2028C>A|FLT3 c.2028C>A|FMS-Related Tyrosine Kinase 3 c.2028C>A|NM_004119.2:c.2028C>A	A nucleotide substitution at position 2028 of the coding sequence of the FLT3 gene where cytosine has been mutated to adenine.			Cell or Molecular Dysfunction	
C167175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167175>	C136634	FLT3 NM_004119.2:c.2028C>G|CD135 c.2028C>G|FLK2 c.2028C>G|FLT3 c.2028C>G|FMS-Related Tyrosine Kinase 3 c.2028C>G|NM_004119.2:c.2028C>G	A nucleotide substitution at position 2028 of the coding sequence of the FLT3 gene where cytosine has been mutated to guanine.			Cell or Molecular Dysfunction	
C167176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167176>	C128920	FLT3 NP_004110.2:p.N676K|CD135 Antigen Asn676Lys|CD135 Antigen N676K|FLT3 Asn676Lys|FLT3 N676K|FLT3 NP_004110.2:p.Asn676Lys|FLT3 p.Asn676Lys|FLT3 p.N676K|Fetal Liver Kinase-2 Asn676Lys|Fetal Liver Kinase-2 N676K|Flt-3 Receptor Asn676Lys|Flt-3 Receptor N676K|Fms-Related Tyrosine Kinase 3 Asn676Lys|Fms-Related Tyrosine Kinase 3 N676K|N676K|NP_004110.2:p.Asn676Lys|NP_004110.2:p.N676K|Receptor-Type Tyrosine-Protein Kinase FLT3 Asn676Lys|Receptor-Type Tyrosine-Protein Kinase FLT3 N676K|Stem Cell Tyrosine Kinase 1 Asn676Lys|Stem Cell Tyrosine Kinase 1 N676K	A change in the amino acid residue at position 676 in the receptor-type tyrosine-protein kinase FLT3 protein where asparagine has been replaced by lysine.			Cell or Molecular Dysfunction	
C167177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167177>	C136634	FLT3 NM_004119.2:c.2027A>G|CD135 c.2027A>G|FLK2 c.2027A>G|FLT3 c.2027A>G|FMS-Related Tyrosine Kinase 3 c.2027A>G|NM_004119.2:c.2027A>G	A nucleotide substitution at position 2027 of the coding sequence of the FLT3 gene where adenine has been mutated to guanine.			Cell or Molecular Dysfunction	
C167178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167178>	C128920	FLT3 NP_004110.2:p.N676S|CD135 Antigen Asn676Ser|CD135 Antigen N676S|FLT3 Asn676Ser|FLT3 N676S|FLT3 NP_004110.2:p.Asn676Ser|FLT3 p.Asn676Ser|FLT3 p.N676S|Fetal Liver Kinase-2 Asn676Ser|Fetal Liver Kinase-2 N676S|Flt-3 Receptor Asn676Ser|Flt-3 Receptor N676S|Fms-Related Tyrosine Kinase 3 Asn676Ser|Fms-Related Tyrosine Kinase 3 N676S|N676S|NP_004110.2:p.Asn676Ser|NP_004110.2:p.N676S|Receptor-Type Tyrosine-Protein Kinase FLT3 Asn676Ser|Receptor-Type Tyrosine-Protein Kinase FLT3 N676S|Stem Cell Tyrosine Kinase 1 Asn676Ser|Stem Cell Tyrosine Kinase 1 N676S	A change in the amino acid residue at position 676 in the receptor-type tyrosine-protein kinase FLT3 protein where asparagine has been replaced by serine.			Cell or Molecular Dysfunction	
C16717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16717>	C20184|C16725	Immunoglobulin Heavy Chain|IGH	A protein complex that consists of two heavy chains (gamma, alpha, delta, epsilon or mu). The larger of the two immunoglobulin chain types determines the immunoglobulin class (G, A, D, E or M, respectively). The heavy chain molecules exhibit the same structure and composition, which consists of constant, variable, and hypervariable regions.	Immunoglobulin Heavy Chain		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167180>	C128920	FLT3 NP_004110.2:p.N841X|CD135 Antigen Asn841Xxx|CD135 Antigen N841X|FLT3 Asn841Xxx|FLT3 N841 Mutation|FLT3 N841X|FLT3 NP_004110.2:p.Asn841Xxx|FLT3 p.Asn841Xxx|FLT3 p.N841X|Fetal Liver Kinase-2 Asn841Xxx|Fetal Liver Kinase-2 N841X|Flt-3 Receptor Asn841Xxx|Flt-3 Receptor N841X|Fms-Related Tyrosine Kinase 3 Asn841Xxx|Fms-Related Tyrosine Kinase 3 N841X|N841|N841X|NP_004110.2:p.Asn841Xxx|NP_004110.2:p.N841X|Receptor-Type Tyrosine-Protein Kinase FLT3 Asn841Xxx|Receptor-Type Tyrosine-Protein Kinase FLT3 N841X|Stem Cell Tyrosine Kinase 1 Asn841Xxx|Stem Cell Tyrosine Kinase 1 N841X	A change in the amino acid residue at position 841 in the receptor-type tyrosine-protein kinase FLT3 protein where asparagine has been replaced by another amino acid.			Cell or Molecular Dysfunction	
C167181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167181>	C67496|C136634	FLT3 NM_004119.2:c.1775T>C|CD135 c.1775T>C|FLK2 c.1775T>C|FLT3 c.1775T>C|FMS-Related Tyrosine Kinase 3 c.1775T>C|NM_004119.2:c.1775T>C	A nucleotide substitution at position 1775 of the coding sequence of the FLT3 gene where thymine has been mutated to cytosine.			Cell or Molecular Dysfunction	
C167182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167182>	C128920	FLT3 NP_004110.2:p.V592A|CD135 Antigen V592A|CD135 Antigen Val592Ala|FLT3 NP_004110.2:p.Val592Ala|FLT3 V592A|FLT3 Val592Ala|FLT3 p.V592A|FLT3 p.Val592Ala|Fetal Liver Kinase-2 V592A|Fetal Liver Kinase-2 Val592Ala|Flt-3 Receptor V592A|Flt-3 Receptor Val592Ala|Fms-Related Tyrosine Kinase 3 V592A|Fms-Related Tyrosine Kinase 3 Val592Ala|NP_004110.2:p.V592A|NP_004110.2:p.Val592Ala|Receptor-Type Tyrosine-Protein Kinase FLT3 V592A|Receptor-Type Tyrosine-Protein Kinase FLT3 Val592Ala|Stem Cell Tyrosine Kinase 1 V592A|Stem Cell Tyrosine Kinase 1 Val592Ala|V592A	A change in the amino acid residue at position 592 in the receptor-type tyrosine-protein kinase FLT3 protein where valine has been replaced by alanine.			Cell or Molecular Dysfunction	
C167183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167183>	C67496|C136634	FLT3 NM_004119.2:c.1775T>G|CD135 c.1775T>G|FLK2 c.1775T>G|FLT3 c.1775T>G|FMS-Related Tyrosine Kinase 3 c.1775T>G|NM_004119.2:c.1775T>G	A nucleotide substitution at position 1775 of the coding sequence of the FLT3 gene where thymine has been mutated to guanine.			Cell or Molecular Dysfunction	
C167184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167184>	C128920	FLT3 NP_004110.2:p.V592G|CD135 Antigen V592G|CD135 Antigen Val592Gly|FLT3 NP_004110.2:p.Val592Gly|FLT3 V592G|FLT3 Val592Gly|FLT3 p.V592G|FLT3 p.Val592Gly|Fetal Liver Kinase-2 V592G|Fetal Liver Kinase-2 Val592Gly|Flt-3 Receptor V592G|Flt-3 Receptor Val592Gly|Fms-Related Tyrosine Kinase 3 V592G|Fms-Related Tyrosine Kinase 3 Val592Gly|NP_004110.2:p.V592G|NP_004110.2:p.Val592Gly|Receptor-Type Tyrosine-Protein Kinase FLT3 V592G|Receptor-Type Tyrosine-Protein Kinase FLT3 Val592Gly|Stem Cell Tyrosine Kinase 1 V592G|Stem Cell Tyrosine Kinase 1 Val592Gly|V592A	A change in the amino acid residue at position 592 in the receptor-type tyrosine-protein kinase FLT3 protein where valine has been replaced by glycine.			Cell or Molecular Dysfunction	
C167185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167185>	C67496|C136634	FLT3 NM_004119.2:c.1796A>G|CD135 c.1796A>G|FLK2 c.1796A>G|FLT3 c.1796A>G|FMS-Related Tyrosine Kinase 3 c.1796A>G|NM_004119.2:c.1796A>G	A nucleotide substitution at position 1796 of the coding sequence of the FLT3 gene where adenine has been mutated to guanine.			Cell or Molecular Dysfunction	
C167186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167186>	C128920	FLT3 NP_004110.2:p.Y599C|CD135 Antigen Tyr599Cys|CD135 Antigen Y599C|FLT3 NP_004110.2:p.Tyr599Cys|FLT3 Tyr599Cys|FLT3 Y599C|FLT3 p.Tyr599Cys|FLT3 p.Y599C|Fetal Liver Kinase-2 Tyr599Cys|Fetal Liver Kinase-2 Y599C|Flt-3 Receptor Tyr599Cys|Flt-3 Receptor Y599C|Fms-Related Tyrosine Kinase 3 Tyr599Cys|Fms-Related Tyrosine Kinase 3 Y599C|NP_004110.2:p.Tyr599Cys|NP_004110.2:p.Y599C|Receptor-Type Tyrosine-Protein Kinase FLT3 Tyr599Cys|Receptor-Type Tyrosine-Protein Kinase FLT3 Y599C|Stem Cell Tyrosine Kinase 1 Tyr599Cys|Stem Cell Tyrosine Kinase 1 Y599C	A change in the amino acid residue at position 599 in the receptor-type tyrosine-protein kinase FLT3 protein where tyrosine has been replaced by cysteine.			Cell or Molecular Dysfunction	
C167187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167187>	C128920	FLT3 NP_004110.2:p.Y842X|CD135 Antigen Tyr842Xxx|CD135 Antigen Y842X|FLT3 NP_004110.2:p.Tyr842Xxx|FLT3 Tyr842Xxx|FLT3 Y842 Mutation|FLT3 Y842X|FLT3 p.Tyr842Xxx|FLT3 p.Y842X|Fetal Liver Kinase-2 Tyr842Xxx|Fetal Liver Kinase-2 Y842X|Flt-3 Receptor Tyr842Xxx|Flt-3 Receptor Y842X|Fms-Related Tyrosine Kinase 3 Tyr842Xxx|Fms-Related Tyrosine Kinase 3 Y842X|NP_004110.2:p.Tyr842Xxx|NP_004110.2:p.Y842X|Receptor-Type Tyrosine-Protein Kinase FLT3 Tyr842Xxx|Receptor-Type Tyrosine-Protein Kinase FLT3 Y842X|Stem Cell Tyrosine Kinase 1 Tyr842Xxx|Stem Cell Tyrosine Kinase 1 Y842X|Y842|Y842X	A change in the amino acid residue at position 842 in the receptor-type tyrosine-protein kinase FLT3 protein where tyrosine has been replaced by another amino acid.			Cell or Molecular Dysfunction	
C167188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167188>	C28227|C164001|C129822	Davutamig|Anti-c-Met Bispecific Antibody REGN5093|DAVUTAMIG|MET x MET Bispecific Antibody REGN5093|METxMET Antibody REGN5093|METxMET Bispecific Antibody REGN5093|REGN 5093|REGN-5093|REGN5093	A bispecific monoclonal antibody that targets two different epitopes of the human tumor-associated antigen (TAA) MET (c-MET; hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon administration, davutamig targets and binds to two different, non-overlapping epitopes on MET expressed on thd tumor cell surface, thereby forming unique davutamig-MET complexes. The binding of davutamig to the MET epitopes and the unique complex formation causes MET internalization and degradation. This prevents MET-mediated signaling and inhibits growth of MET-driven tumor cells. MET, a receptor tyrosine kinase, is overexpressed on the cell surfaces of various solid tumor cell types where it is involved in epithelial-mesenchymal transition; it plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.	Davutamig		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C167189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167189>	C4503	BRCA Hereditary Breast Carcinoma|BRCA Familial Breast Cancer|BRCA Familial Breast Carcinoma|BRCA Hereditary Breast Cancer|BRCA-Associated Breast Carcinoma|BRCA-Mutated Breast Carcinoma	Hereditary breast carcinoma caused by deleterious germline mutation in a gene of the BRCA family.			Neoplastic Process	
C16718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16718>	C16720	Immunoglobulin Light Chain, Kappa|IGK|Ig Kappa Chain|Ig Light Chain Kappa|Immunoglobulin Kappa|Immunoglobulin Kappa Chain|Immunoglobulin Kappa Light Chain|Immunoglobulin Kappa Light-Chain|Kappa Light Chain	Immunoglobulin Light Chain Kappa is one of two Ig light chain types. Each Ig molecule is typically composed of two heavy chains and two light chains. Ig kappa light chains contain a variable and a constant region. Kappa light chains are encoded by multiple V, J, and C gene segments, which are separated in the genomes of cells undifferentiated with regard to antibody gene expression. Diversity in the kappa light chain V region arises during differentiation of an activated (kappa-type) antibody-producing B-cell from variable recombination of kappa V genes with kappa J genes and somatic point mutation, which plays a major role in antibody diversity. (from OMIM and NCI)	Immunoglobulin Light Chain, Kappa		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167190>	C25488	Dose Administered|Administration Dose|Dosage|Dose Delivered|Medication Dosage|medication actual dose|medication_actual_dose	A quantity of an agent given to an individual at one time.			Conceptual Entity	CDISC DDF Agent Administration Attribute Terminology|CDISC DDF Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF4 Treatment Chemotherapy Table|CRF4 Treatment Complementary Table|ICDC Property Terminology|ICDC Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C167191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167191>	C28133	Absolute Phagocyte Count|APC|Absolute phagocyte count (APC)	The number of phagocytes (neutrophils and monocytes-macrophages) in a cubic millimeter of blood. The APC is the sum of the neutrophils (segs and bands), monocytes, and macrophages times one hundredth (1/100) of the white blood cell count.			Laboratory Procedure	
C167192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167192>	C36286	Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma (NMIBC) with a Prior History of Low or Intermediate Risk NMIBC|Recurrent NMIBC with a Prior History of Low or Intermediate Risk NMIBC|Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma with a Prior History of Low or Intermediate Risk Non-Muscle Invasive Bladder Urothelial Carcinoma	A finding indicating the reemergence of non-muscle invasive bladder urothelial carcinoma after a period of remission, in patients with a prior history of low or intermediate risk non-muscle invasive bladder urothelial carcinoma.	Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma (NMIBC) with a Prior History of Low or Intermediate Risk NMIBC		Finding	CTRP Disease Terminology|CTRP Terminology
C167193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167193>	C206118	PALB2 Hereditary Breast Carcinoma|PALB2 Familial Breast Cancer|PALB2 Familial Breast Carcinoma|PALB2 Hereditary Breast Cancer|PALB2-Associated Breast Carcinoma|PALB2-Mutated Breast Carcinoma	Hereditary breast carcinoma caused by deleterious germline mutation in the PALB2 gene.			Neoplastic Process	
C167194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167194>	C186894|C186837|C175583	t(8;16)(p11.2;p13.3)|t(8;16)(p11;p13)	A cytogenetic abnormality that refers to the translocation of the short arm (p11.2) of chromosome 8 and the short arm (p13.3) of chromosome 16. It is associated with KAT6A/CREBBP fusions and acute myeloid leukemia.	t(8;16)(p11.2;p13.3)		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167195>	C28446|C186818|C119609	inv(16)(p13.3;q24.3)|inv(16)(p13.3q24.3)|inv(16)(p13.3q24.3)|inv(16)(p13;q24)|inv(16)(p13q24)	A pericentric chromosomal inversion that involves chromosome 16. It is associated with CBFA2T3/GLIS2 fusions and pediatric acute megakaryoblastic leukemia.	inv(16)(p13.3;q24.3)		Cell or Molecular Dysfunction	AML Authorized Value Terminology|AML Minimal Residual Disease Table|AML Molecular Analysis Table|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167196>	C167198|C167144	t(10;11)(p12.3;q23.3)	A cytogenetic abnormality that refers to the translocation of the short arm (p12.3) of chromosome 10 and the long arm (q23.3) of chromosome 11. It is associated with KMT2A (MLL) fusions and acute myeloid leukemia.	t(10;11)(p12.3;q23.3)		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167197>	C219858|C167144	t(10;11)(p12.1;q23.3)	A cytogenetic abnormality that refers to the translocation of the short arm (p12.1) of chromosome 10 and the long arm (q23.3) of chromosome 11. It is associated with KMT2A (MLL) fusions.	t(10;11)(p12.1;q23.3)		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167198>	C36541|C219858	Rearrangement of 10p12.3|10p12.3 Rearrangement	A cytogenetic abnormality indicating the presence of rearrangement involving the short arm segment p12.3 of chromosome 10.	Rearrangement of 10p12.3		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167199>	C38372	CEBPA bZIP Domain Mutation|C/EBP-Alpha bZIP Domain Mutation|C/EBPalpha bZIP Domain Mutation|CCAAT Enhancer Binding Protein Alpha bZIP Domain Mutation|CCAAT/Enhancer Binding Protein, Alpha bZIP Domain Mutation|CEBP bZIP Domain Mutation|CEBPA bZIP Domain Gene Mutation|CEBPA bZIP Mutation|CEBPalpha bZIP Domain Mutation|CEBPalpha bZIP Mutation	A change in the nucleotide sequence of the CEBPA gene that alters the amino acid sequence of the DNA-binding basic leucine zipper domain of CCAAT/enhancer binding protein alpha.	CEBPA bZIP Domain Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C16719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16719>	C16720	Immunoglobulin Light Chain, Lambda|IGL|Ig Lambda Chain|Ig Light Chain Lambda|Immunoglobulin Lambda|Immunoglobulin Lambda Chain|Immunoglobulin Lambda Light Chain|Immunoglobulin Lambda Light-Chain|Lambda Light Chain	Immunoglobulin Light Chain Lambda is one of two Ig light chain types. Each Ig molecule is typically composed of two heavy chains and two light chains but Ig lambda light chains contain a variable and a constant region. Lambda light chains are encoded by multiple V, J, and C gene segments, which are separated in the genomes of cells undifferentiated with regard to antibody gene expression. During differentiation of an activated (lambda-type) antibody-producing B-cell, diversity in the lambda light chain V region arises from variable recombination of lambda V genes with lambda J genes and somatic point mutation, which plays a major role in antibody diversity. (from OMIM 147220 and NCI)	Immunoglobulin Light Chain, Lambda		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C1671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1671>	C1591	Recombinant Human Monocyte Chemoattractant Protein-2|CCL8|Human Monocyte Chemoattractant Protein-2|MCP-2	A recombinant agent, chemically identical or similar to the endogenous small inducible cytokine A8 (MCP-2). This agent is a member of the Cys-Cys chemokine family, with potent chemoattractant effect for monocytes, basophils and T lymphocytes and antiviral activity. MCP-2 is a ligand for CC chemokine receptor 5 (CCR5) on CD4+ lymphocytes, and competitively block R5 HIV-1 cellular entry via interaction with CCR5, through direct interference with HIV-1 gp120 binding. This agent induces a robust, pertussis toxin-sensitive calcium flux in primary lymphocytes.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C167200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167200>	C173160	Felt I Had Nothing to Look Forward To Question|Felt I Had Nothing to Look Forward To|I felt that I had nothing to look forward to	A question about whether an individual feels or felt they had nothing to look forward to.			Intellectual Product	
C167201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167201>	C173160	Felt That Nothing Could Cheer Me Up Question|Felt That Nothing Could Cheer Me Up|I felt that nothing could cheer me up	A question about whether an individual feels or felt that nothing could cheer them up.			Intellectual Product	
C167202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167202>	C213703|C156063	Locally Advanced Fallopian Tube Carcinoma	A fallopian tube carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Fallopian Tube Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C167203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167203>	C40022|C3482	Metastatic Primary Peritoneal Carcinoma	A carcinoma that arises from the peritoneum and has metastasized to another anatomic site.	Metastatic Primary Peritoneal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C167204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167204>	C167203|C148130	Locally Advanced Primary Peritoneal Carcinoma	Primary peritoneal carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Primary Peritoneal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C167205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167205>	C213472|C199379|C159156	Sunvozertinib|DZD 9008|DZD-9008|DZD9008|EGFR/HER2 Inhibitor DZD9008|SUNVOZERTINIB|Zegfrovy	An orally available, irreversible, dual kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) that shows similar activity against certain activating mutations, including exon 20 insertions (exon20ins), with potential antineoplastic activity. Upon oral administration,sunvozertinib binds to and inhibits EGFR and HER2, which may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumors. EGFR and HER2 are receptor tyrosine kinases that play major roles in tumor cell proliferation and tumor vascularization. In contrast to other agents active against exon20ins mutations, sunvozertinib appears to be more selective against mutated EGFR than wild-type (wt) EGFR. This may lessen wtEGFR-related dose-limiting toxicity and may allow for the administration of the desired therapeutic dose of sunvozertinib.	Sunvozertinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C167206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167206>	C207756|C129820	Dalutrafusp Alfa|AGEN 1423|AGEN-1423|AGEN1423|Bispecific Antibody GS-1423|DALUTRAFUSP ALFA|GS 1423|GS-1423|GS1423	A bifunctional fusion protein composed of a humanized aglycosylated immunoglobulin G1 kappa (IgG1k) antibody directed against the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), fused to the extracellular domain of human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), with potential immunomodulating and antineoplastic activities. Upon administration, dalutrafusp alfa targets and binds to both CD73 expressed on tumor cells and TGFbeta in the tumor microenvironment (TME). The binding of dalutrafusp alfa to CD73 prevents CD73-mediated conversion of extracellular adenosine monophosphate (AMP) to adenosine and the adenosine-mediated suppression of lymphocyte activity and trafficking. This increases the activity of cytotoxic T-lymphocytes (CTLs), activates macrophages and reduces the activity of both myeloid-derived suppressor cells (MDSCs) and regulatory T-lymphocytes (Tregs). By abrogating the inhibitory effect on the immune system and enhancing the CTL-mediated immune response against cancer cells, tumor cell growth is decreased. The binding of dalutrafusp alfa to TGFbeta neutralizes TGFbeta and prevents TGFbeta-mediated signaling. This abrogates TGFbeta-mediated immunosuppression in the TME, enhances immune cell infiltration and anti-tumor immunity in the TME, and promotes the CTL-mediated immune response against tumor cells leading to tumor cell death. CD73, a plasma membrane protein belonging to the 5'-nucleotidase (NTase) family, is upregulated on a number of cancer cell types and catalyzes the conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides, such as adenosine; it plays a key role in adenosine-mediated immunosuppression within the TME. TGFbeta, overproduced in many types of cancer, plays a key role in immunosuppression in the TME, enhances tumor cell proliferation, and promotes cancer progression.	Dalutrafusp Alfa		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C167207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167207>	C28676	Partially Engineered T-regulatory Cell Donor Graft TRGFT-201|Orca-T|Partially Engineered and Enriched Treg Donor Graft TRGFT-201|T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells|TRGFT 201|TRGFT-201|TRGFT201|TregGraft	A T-regulatory (Treg) cell donor graft that has been partially engineered by depleting all the T-cells and then enriching the graft with infusions of conventional T-cells, Tregs and CD34+ stem cells derived from peripheral blood from either related or unrelated matched donors, with potential immunomodulating activity. Upon administration of the partially engineered T-regulatory cell donor graft TRGFT-201 following myeloablation, the allograft may induce tolerance in patients undergoing allogeneic hematopoietic stem cell transplantation (AHSCT) as treatment for hematologic malignancies.	Partially Engineered T-regulatory Cell Donor Graft TRGFT-201		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology
C167208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167208>	C28681	Autologous Peripheral Blood Lymphocytes from Ibrutinib-treated Chronic Lymphocytic Leukemia Patients IOV-2001|Autologous PBLs IOV-2001|Autologous PBLs from Ibrutinib-treated CLL Patients|IOV 2001|IOV-2001|IOV-2001|IOV2001	A preparation of autologous peripheral blood lymphocytes (PBLs) harvested from chronic lymphocytic leukemia (CLL) patients previously treated with the Brutons' tyrosine kinase (BTK) inhibitor ibrutinib with potential immunostimulating and antineoplastic activities. Upon intravenous administration, IOV-2001 generates an enhanced cytotoxic T-cell response against autologous leukemic B-cells in patients who have relapsed during treatment with ibrutinib. IOV-2001 is mostly comprised of T-cells of which the majority are of the effector memory phenotype which augments the specificity of the immune response.	Autologous Peripheral Blood Lymphocytes from Ibrutinib-treated Chronic Lymphocytic Leukemia Patients IOV-2001		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C167209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167209>	C3824	Measurable Lesion|measurable lesion|measurable_lesion	A finding indicating that a localized pathological lesion can be measured in at least one dimension.			Finding	ICDC Property Terminology|ICDC Terminology
C16720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16720>	C20184|C16725	Immunoglobulin Light Chain|Ig Light Chain	A protein complex that consists of two light chains (kappa and lambda). The light chain molecules are of the same structure and composition, consisting of constant, variable, and hypervariable regions.	Immunoglobulin Light Chain		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C167210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167210>	C159438	Enbezotinib|(3aR,11S,20aS)-7-Fluoro-2,3,3a,12,13,20a-hexahydro-11-methyl-17,19-metheno-1H,5H-cyclopent[5,6][1,4]oxazino[3,4-i]pyrazolo[4,3-f]pyrido[3,2-l][1,4,8,10]oxatriazacyclotridecin-14(11H)-one|17,19-Metheno-1H,5H-cyclopent[5,6][1,4]oxazino[3,4-i]pyrazolo[4,3-f]pyrido[3,2-l][1,4,8,10]oxatriazacyclotridecin-14(11H)-one, 7-fluoro-2,3,3a,12,13,20a-hexahydro-11-methyl-, (3aR,11S,20aS)-|ENBEZOTINIB|RET/SRC Inhibitor TPX-0046|RET/SRC Tyrosine Kinase Inhibitor TPX-0046|TPX 0046|TPX-0046|TPX0046	An orally bioavailable selective dual inhibitor of fusions and mutations involving the proto-oncogene receptor tyrosine kinase rearranged during transfection (ret) and the src family tyrosine kinases, with potential antineoplastic activity. Upon oral administration, enbezotinib specifically targets and binds to ret mutants and ret-containing fusion products. This results in an inhibition of cell growth of tumor cells that exhibit increased ret activity. By inhibiting src kinase-mediated signaling and reducing the src-initiated recruitment of multiple receptor tyrosine kinases involved in bypass resistance, enbezotinib may be able to overcome tumor resistance which may increase its therapeutic effect. Ret overexpression, activating mutations, and fusions result in the upregulation and/or overactivation of ret tyrosine kinase activity in various cancer cell types; dysregulation of ret activity plays a key role in the development and progression of these cancers. Src tyrosine kinases are upregulated in many tumor cells and play important roles in tumor cell proliferation, survival, migration, invasion and angiogenesis. Src upregulation is seen in tumors with acquired resistance to RET inhibitors.	Enbezotinib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C167211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167211>	C162534	Gastrectomy Patient	A person who is undergoing a gastrectomy.	Gastrectomy Patient		Patient or Disabled Group	CTRP Intervention Terminology|CTRP Terminology
C167212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167212>	C360	Phytate Persodium|Myo-Inositol, Hexakis(dihydrogen Phosphate), Dodecasodium Salt|PHYTATE PERSODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C167213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167213>	C15236|C116509	Robotic Bariatric Sleeve Gastrectomy|Robotic Gastric Sleeve Surgery|Robotic Lap Sleeve Gastrectomy|Robotic Sleeve Gastrectomy|Robotic Vertical Sleeve Gastrectomy	A robotic bariatric procedure that removes most of the stomach, with the remaining stomach reformed into a tube.	Robotic Bariatric Sleeve Gastrectomy		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C167214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167214>	C15256|C116509	Robotic Hysterectomy	Hysterectomy done with the assistance of robotic techniques.	Robotic Hysterectomy		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C167215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167215>	C129733	Autosomal Recessive Osteopetrosis 1|ARO1|Autosomal Recessive Albers-Schonberg Disease|Autosomal Recessive Marble Bones|Autosomal Recessive Osteopetrosis Type 1|Infantile Malignant Osteopetrosis 1|OPTB1	A sub-type of autosomal recessive osteopetrosis caused by mutation(s) in the TCIRG1 gene on chromosome 11q13, encoding the osteoclast-specific (alpha 3) subunit of the vacuolar proton pump. It is characterized by macrocephaly, frontal bossing, nystagmus, optic atrophy, blindness, deafness, and facial palsy.			Congenital Abnormality	Cellosaurus Disease Terminology
C167216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167216>	C85865|C84392|C53543	Intellectual Developmental Disorder, X-Linked, Syndromic, Cabezas Type|Cabezas Syndrome|MRSS|MRXS15|MRXSC|Mental Retardation, X-Linked, Syndromic 15|Mental Retardation, X-Linked, Syndromic, Cabezas Type|Mental Retardation, X-Linked, with Short Stature|Mental Retardation, X-Linked, with Short Stature, Hypogonadism, and Abnormal Gait	An X-linked recessive condition caused by mutations(s) in the CUL4B gene on chromosome Xq23, encoding a core component of the E3 ubiquitin ligase complex. It is characterized by short stature, hypogonadism, and abnormal gait.			Disease or Syndrome	Cellosaurus Disease Terminology
C167217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167217>	C158375	Radical Prostatectomy Patient	A patient who is undergoing surgical removal of the prostate as well as some surrounding tissues, including seminal vesicles and lymph nodes.	Radical Prostatectomy Patient		Patient or Disabled Group	CTRP Intervention Terminology|CTRP Terminology
C167218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167218>	C158375	Pelvic Lymphadenectomy Patient	A patient who is undergoing surgical removal of pelvic lymph nodes.	Pelvic Lymphadenectomy Patient		Patient or Disabled Group	CTRP Intervention Terminology|CTRP Terminology
C167219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167219>	C2124	Fluorine F 18 NOS|(18)F-NOS|18F NOS|18F-NOS|FNOS|NOS F-18|[18F]NOS	A radiotracer composed of an analog of the reversible nitric oxide synthase (NOS) inhibitor, 2-amino 4-methylpyridine, radiolabeled with fluorine F 18, with potential imaging activity upon positron emission tomography/computed tomography (PET/CT). Upon administration of fluorine F 18 NOS, the NOS moiety targets and binds to inducible NOS (iNOS). Upon PET/CT imaging, iNOS expression and thus the extent of inflammation can be assessed. iNOS expression is upregulated in a variety of inflammatory diseases and certain cancers and may invoke a chronic inflammatory state in tumor cells.	Fluorine F 18 NOS		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C167220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167220>	C200765	Allogeneic NKG2DL-targeting CAR-grafted Gamma Delta T Cells|Allogeneic NKG2DL-targeting CAR-gd T-cells|CTM-N2D	A preparation of a subset of allogeneic T-lymphocytes that express only gamma chain and delta chain T-cell receptors (TCRs) and that are engineered to express a chimeric antigen receptor (CAR) encoding for human natural-killer group 2, member D receptor protein (NKG2D or KLRK1; natural killer cell activating receptor group 2D), with potential immunomodulating and antineoplastic activities. Upon administration of the NKG2DL-targeting CAR-grafted gamma delta T cells, these cells specifically target and bind to tumor cells expressing NKG2D ligands (NKG2DL). This induces secretion of pro-inflammatory cytokines and results in the lysis of NKG2DL-expressing tumor cells. In addition, these cells target, bind to and kill NKG2DL-expressing tumor-associated endothelial cells in the neovasculature and immunosuppressive cells, such as regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (TME) that express NKG2D ligands. Gamma/delta T-lymphocytes play a key role in the activation of the immune system and do not require major histocompatibility complex (MHC)-mediated antigen presentation to exert their cytotoxic effect. Ligands for NKG2D, such as MHC class I chain-related protein A (MICA), MICB, and members of the UL16-binding proteins (ULBP)/retinoic acid early transcript 1 (RAET1) family, are overexpressed on infected cells and most cancer cell types, but are not expressed on most normal, healthy cells.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C167221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167221>	C67502	Doxorubicin Prodrug/Prodrug-activating Biomaterial SQ3370|Doxorubicin Prodrug SQP33/Prodrug-activating Biomaterial SQL7|SQ 3370|SQ-3370|SQ3370|SQL70-SQP33|SQL70/SQP33	A formulation consisting of SQL70, a prodrug-activating biomaterial, and SQP33, a prodrug of the anthracycline antineoplastic antibiotic doxorubicin, with potential antineoplastic activity. Upon administration of SQ3370, which consists of the injection of SQL70 at the tumor site followed by the intravenous administration of SQ3370, the prodrug SQP33 binds to, through an as of yet not identifiable mechanism, to SQL70 at the tumor site. After binding, doxorubicin is released over a period of days, intercalates into DNA and interacts with topoisomerase II. This leads to an inhibition of DNA replication and repair, and prevents RNA and protein synthesis. Compared to the systemic administration of doxorubicin alone, SQ3370 may allow for higher and sustained delivery of active doxorubicin directly to the tumor, which may increase its efficacy and limit its off-site, systemic toxicity.	Doxorubicin Prodrug/Prodrug-activating Biomaterial SQ3370		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C167222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167222>	C45403	NOTCH1 NM_017617.4:c.5153T>C|NM_017617.4:c.5153T>C|NOTCH1 c.5153T>C|Notch 1 c.5153T>C|Notch Homolog 1 c.5153T>C|Notch, Drosophila, Homolog of, 1 c.5153T>C|TAN1 c.5153T>C|hN1 c.5153T>C	A nucleotide substitution at position 5153 of the coding sequence of the NOTCH1 gene where thymine has been mutated to cytosine.			Cell or Molecular Dysfunction	
C167223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167223>	C167063	NOTCH1 NP_060087.3:p.I1718T|NOTCH1 I1718T|NOTCH1 Ile1718Thr|NOTCH1 NP_060087.3:p.Ile1718Thr|NOTCH1 p.I1718T|NOTCH1 p.Ile1718Thr|NP_060087.3:p.I1718T|NP_060087.3:p.Ile1718Thr|Neurogenic Locus Notch Homolog Protein 1 I1718T|Neurogenic Locus Notch Homolog Protein 1 Ile1718Thr|TAN-1 I1718T|TAN-1 Ile1718Thr|TAN1 I1718T|TAN1 Ile1718Thr|Translocation-Associated Notch Protein TAN-1 I1718T|Translocation-Associated Notch Protein TAN-1 Ile1718Thr	A change in the amino acid residue at position 1718 in the neurogenic locus notch homolog protein 1 where isoleucine has been replaced by threonine.			Cell or Molecular Dysfunction	
C167224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167224>	C1420	Hemoporfin|HEMATOPORPHYRIN	A light-activated compound, with potential photosensitizing activity upon photodynamic therapy (PDT). Upon administration of hemoporfin and following photoactivation with an appropriate wavelength, hemoporfin generates highly reactive oxygen species (ROS), such as cytotoxic singlet oxygen species, and induces oxidative stress that results in the damage and death of cells.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C167225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167225>	C62198|C45403	NOTCH1 NM_017617.4:c.7507C>T|NM_017617.4:c.7507C>T|NOTCH1 c.7507C>T|Notch 1 c.7507C>T|Notch Homolog 1 c.7507C>T|Notch, Drosophila, Homolog of, 1 c.7507C>T|TAN1 c.7507C>T|hN1 c.7507C>T	A nucleotide substitution at position 7507 of the coding sequence of the NOTCH1 gene where cytosine has been mutated to thymine.			Cell or Molecular Dysfunction	
C167226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167226>	C167063	NOTCH1 NP_060087.3:p.Q2503*|NOTCH1 Gln2503Ter|NOTCH1 NP_060087.3:p.Gln2503Ter|NOTCH1 Q2503*|NOTCH1 p.Gln2503Ter|NOTCH1 p.Q2503*|NP_060087.3:p.Gln2503Ter|NP_060087.3:p.Q2503*|Neurogenic Locus Notch Homolog Protein 1 Gln2503Ter|Neurogenic Locus Notch Homolog Protein 1 Q2503*|TAN-1 Gln2503Ter|TAN-1 Q2503*|TAN1 Gln2503Ter|TAN1 Q2503*|Translocation-Associated Notch Protein TAN-1 Gln2503Ter|Translocation-Associated Notch Protein TAN-1 Q2503*	A change in the amino acid composition of the neurogenic locus notch homolog protein 1 where a nonsense mutation results in the substitution of the glutamine at position 2503 with a stop codon.			Cell or Molecular Dysfunction	
C167227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167227>	C167063	NOTCH1 NP_060087.3:p.S1674F|NOTCH1 NP_060087.3:p.Ser1674Phe|NOTCH1 S1674F|NOTCH1 Ser1674Phe|NOTCH1 p.S1674F|NOTCH1 p.Ser1674Phe|NP_060087.3:p.S1674F|NP_060087.3:p.Ser1674Phe|Neurogenic Locus Notch Homolog Protein 1 S1674F|Neurogenic Locus Notch Homolog Protein 1 Ser1674Phe|TAN-1 S1674F|TAN-1 Ser1674Phe|TAN1 S1674F|TAN1 Ser1674Phe|Translocation-Associated Notch Protein TAN-1 S1674F|Translocation-Associated Notch Protein TAN-1 Ser1674Phe	A change in the amino acid residue at position 1674 in the neurogenic locus notch homolog protein 1 where serine has been replaced by phenylalanine.			Cell or Molecular Dysfunction	
C167228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167228>	C167063	NOTCH1 NP_060087.3:p.S1674P|NOTCH1 NP_060087.3:p.Ser1674Pro|NOTCH1 S1674P|NOTCH1 Ser1674Pro|NOTCH1 p.S1674P|NOTCH1 p.Ser1674Pro|NP_060087.3:p.S1674P|NP_060087.3:p.Ser1674Pro|Neurogenic Locus Notch Homolog Protein 1 S1674P|Neurogenic Locus Notch Homolog Protein 1 Ser1674Pro|TAN-1 S1674P|TAN-1 Ser1674Pro|TAN1 S1674P|TAN1 Ser1674Pro|Translocation-Associated Notch Protein TAN-1 S1674P|Translocation-Associated Notch Protein TAN-1 Ser1674Pro	A change in the amino acid residue at position 1674 in the neurogenic locus notch homolog protein 1 where serine has been replaced by proline.			Cell or Molecular Dysfunction	
C167229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167229>	C62198|C45403	NOTCH1 NM_017617.4:c.7396_7397ins8|NM_017617.4:c.7396_7397ins8|NOTCH1 c.7396_7397ins8|Notch 1 c.7396_7397ins8|Notch Homolog 1 c.7396_7397ins8|Notch, Drosophila, Homolog of, 1 c.7396_7397ins8|TAN1 c.7396_7397ins8|hN1 c.7396_7397ins8	An insertion of eight nucleotides between position 7396 and 7397 of the coding sequence of the NOTCH1 gene.			Cell or Molecular Dysfunction	
C167230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167230>	C167063	NOTCH1 NP_060087.3:p.S2467*|NOTCH1 NP_060087.3:p.Ser2467Ter|NOTCH1 S2467*|NOTCH1 Ser2467Ter|NOTCH1 p.S2467*|NOTCH1 p.Ser2467Ter|NP_060087.3:p.S2467*|NP_060087.3:p.Ser2467Ter|Neurogenic Locus Notch Homolog Protein 1 S2467*|Neurogenic Locus Notch Homolog Protein 1 Ser2467Ter|TAN-1 S2467*|TAN-1 Ser2467Ter|TAN1 S2467*|TAN1 Ser2467Ter|Translocation-Associated Notch Protein TAN-1 S2467*|Translocation-Associated Notch Protein TAN-1 Ser2467Ter	A change in the amino acid composition at position 2467 of the neurogenic locus notch homolog protein 1 where a nonsense mutation results in the substitution of the serine with a stop codon.			Cell or Molecular Dysfunction	
C167231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167231>	C1511	Zirconium Zr 89-DFO-SC16.56|89Zr-DFO-SC16.56	A radioimmunoconjugate composed of SC16.56, a monoclonal antibody directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3; delta like canonical notch ligand 3; drosophila delta homolog 3; delta3; delta-like 3; SCDO1), and linked, via the chelator desferrioxamine (DFO), to the radioisotope zirconium Zr 89 (Zr89), with potential diagnostic properties upon positron emission tomography (PET) imaging. Upon administration of zirconium Zr 89-DFO-SC16.56, the monoclonal antibody moiety specifically targets and binds to DLL3. Upon binding, the radioisotope moiety is detected using PET, thereby allowing the imaging and quantification of DLL3-expressing tumor cells. DLL3, a Notch pathway protein, is overexpressed on a variety of cancer cell types. It plays a key role in embryonic development and in tumor initiation and proliferation.	Zirconium Zr 89-DFO-SC16.56		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C167232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167232>	C62198|C45403	NOTCH1 NM_017617.4:c.7396_7397ins5|NM_017617.4:c.7396_7397ins5|NOTCH1 c.7396_7397ins5|Notch 1 c.7396_7397ins5|Notch Homolog 1 c.7396_7397ins5|Notch, Drosophila, Homolog of, 1 c.7396_7397ins5|TAN1 c.7396_7397ins5|hN1 c.7396_7397ins5	An insertion of five nucleotides between position 7396 and 7397 of the coding sequence of the NOTCH1 gene.			Cell or Molecular Dysfunction	
C167233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167233>	C124351	Blood Pressure Measurement	The act of determining an individual's diastolic and systolic blood pressures.	Blood Pressure Measurement		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C167234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167234>	C62198|C45403	NOTCH1 NM_017617.4:c.7399_7400insAGGTTACCC|NM_017617.4:c.7396_7397ins9|NM_017617.4:c.7399_7400insAGGTTACCC|NOTCH1 NM_017617.4:c.7396_7397ins9|NOTCH1 c.7396_7397ins9|NOTCH1 c.7399_7400insAGGTTACCC|Notch 1 c.7399_7400insAGGTTACCC|Notch Homolog 1 c.7399_7400insAGGTTACCC|Notch, Drosophila, Homolog of, 1 c.7399_7400insAGGTTACCC|TAN1 c.7399_7400insAGGTTACCC|hN1 c.7399_7400insAGGTTACCC	An insertion of nine nucleotides, AGGTTACCC, between position 7399 and 7400 of the coding sequence of the NOTCH1 gene.			Cell or Molecular Dysfunction	
C167235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167235>	C167063	NOTCH1 NP_060087.3:p.S2467 Frameshift|NOTCH1 NP_060087.3:p.S2467fs|NOTCH1 NP_060087.3:p.Ser2467fs|NOTCH1 S2467fs|NOTCH1 Ser2467fs|NOTCH1 p.S2467fs|NOTCH1 p.Ser2467fs|NP_060087.3:p.S2467fs|NP_060087.3:p.Ser2467fs|Neurogenic Locus Notch Homolog Protein 1 S2467fs|Neurogenic Locus Notch Homolog Protein 1 Ser2467fs|TAN-1 S2467fs|TAN-1 Ser2467fs|TAN1 S2467fs|TAN1 Ser2467fs|Translocation-Associated Notch Protein TAN-1 S2467fs|Translocation-Associated Notch Protein TAN-1 Ser2467fs	A change in the amino acid composition at position 2467 of the neurogenic locus notch homolog protein 1 where a frameshift mutation results in the substitution of the serine with several non-canonical amino acids followed by a stop codon.			Cell or Molecular Dysfunction	
C167236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167236>	C8192|C162882	Metastatic Nasal Cavity Squamous Cell Carcinoma	A nasal cavity squamous cell carcinoma that has spread from its original site of growth to another anatomic site.	Metastatic Nasal Cavity Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C167237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167237>	C4910|C162257	Resectable Colon Carcinoma	Colon carcinoma that is amenable to surgical resection.	Resectable Colon Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C167238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167238>	C162475|C156097	Advanced Colon Carcinoma	Colon carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Colon Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C167239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167239>	C390	Cathepsin-cleavable NIR Substrate Probe 6QC-ICG|6QC ICG|6QC-ICG|6QCICG|Fluorescently Quenched Protease Substrate Probe 6QC-ICG	A fluorescently quenched, cysteine cathepsin-cleavable near infrared (NIR) substrate probe containing the dye indocyanine green (ICG), that may be used for cancer imaging purposes using an NIR imaging system. In 6QC-NIR, the cathepsin-activatable fluorescent probe contains the fluorophore, ICG, linked, via a cathepsin protease cleavable peptide, with a core Cbz-Phe-Lys peptide sequence, to a fluorescent quencher, QC-1. Upon administration of 6QC-NIR, the amide bond of the peptide can be cleaved by cathepsin proteases overexpressed by tumor cells and highly abundant in the tumor microenvironment (TME). Upon proteolysis, the quencher is released, the fluorophore becomes activated and accumulates in the lysosome. Upon clinical NIR imaging, using the da Vinci Si surgical system, tumor cells expressing cathepsin family proteases can be detected which allows for visualization of the tumor.	Cathepsin-cleavable NIR Substrate Probe 6QC-ICG		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C16723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16723>	C74944	Immunology Test|Immunoassay|Immunological Laboratory Method|immunoassay	Laboratory test involving interaction of antigens with specific antibodies.			Laboratory Procedure	
C167240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167240>	C390	Cathepsin-cleavable NIR Substrate Probe 6QC-NIR|6QC NIR|6QC-NIR|6QCNIR|Fluorescently Quenched Protease Substrate Probe 6QC-NIR	A cysteine cathepsin-cleavable near infrared (NIR) substrate probe, that may be used for cancer imaging purposes using an NIR imaging system. In 6QC-NIR, the cathepsin-activatable fluorescent probe contains the NIR fluorophore, Dylight 780-B1, linked, via a cathepsin protease cleavable peptide, with a core Cbz-Phe-Lys peptide sequence, to a fluorescent quencher, QC-1. Upon administration of 6QC-NIR, the amide bond of the peptide can be cleaved by cathepsins overexpressed by tumor cells and highly abundant in the tumor microenvironment (TME). Upon cleavage, the quencher is released, the fluorophore becomes activated and accumulates in the lysosome. Upon fluorescence imaging, using the da Vinci Si surgical system, tumor cells expressing cathepsin family proteases can be detected which allows for visualization of the tumor.	Cathepsin-cleavable NIR Substrate Probe 6QC-NIR		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C167241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167241>	C45403|C17354	NOTCH1 NM_017617.4:c.7398_7399insAGGGACCG|NM_017617.4:c.7398_7399ins8|NM_017617.4:c.7398_7399insAGGGACCG|NOTCH1 NM_017617.4:c.7398_7399ins8|NOTCH1 c.7398_7399ins8|NOTCH1 c.7398_7399insAGGGACCG|Notch 1 c.7398_7399insAGGGACCG|Notch Homolog 1 c.7398_7399insAGGGACCG|Notch, Drosophila, Homolog of, 1 c.7398_7399insAGGGACCG|TAN1 c.7398_7399insAGGGACCG|hN1 c.7398_7399insAGGGACCG	An insertion of eight nucleotides, AGGGACCG, between position 7398 and 7399 of the coding sequence of the NOTCH1 gene.			Cell or Molecular Dysfunction	
C167242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167242>	C167235	NOTCH1 NP_060087.3:p.S2467Rfs*13|NOTCH1 NP_060087.3:p.Ser2467ArgfsTer13|NOTCH1 S2467Rfs*13|NOTCH1 Ser2467ArgfsTer13|NOTCH1 p.S2467Rfs*13|NOTCH1 p.Ser2467ArgfsTer13|NP_060087.3:p.S2467Rfs*13|NP_060087.3:p.Ser2467ArgfsTer13|Neurogenic Locus Notch Homolog Protein 1 S2467Rfs*13|Neurogenic Locus Notch Homolog Protein 1 Ser2467ArgfsTer13|TAN-1 S2467Rfs*13|TAN-1 Ser2467ArgfsTer13|TAN1 S2467Rfs*13|TAN1 Ser2467ArgfsTer13|Translocation-Associated Notch Protein TAN-1 S2467Rfs*13|Translocation-Associated Notch Protein TAN-1 Ser2467ArgfsTer13	A change in the amino acid composition at position 2467 of the neurogenic locus notch homolog protein 1 where a frameshift mutation results in the substitution of the serine with an arginine followed by 12 non-canonical amino acids and stop codon.			Cell or Molecular Dysfunction	
C167243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167243>	C45403|C17354	NOTCH1 NM_017617.4:c.7398_7399insGCCTTGGGAACCCG|NM_017617.4:c.7398_7399ins14|NM_017617.4:c.7398_7399insGCCTTGGGAACCCG|NOTCH1 NM_017617.4:c.7398_7399ins14|NOTCH1 c.7398_7399ins14|NOTCH1 c.7398_7399insGCCTTGGGAACCCG|Notch 1 c.7398_7399insGCCTTGGGAACCCG|Notch Homolog 1 c.7398_7399insGCCTTGGGAACCCG|Notch, Drosophila, Homolog of, 1 c.7398_7399insGCCTTGGGAACCCG|TAN1 c.7398_7399insGCCTTGGGAACCCG|hN1 c.7398_7399insGCCTTGGGAACCCG	An insertion of 14 nucleotides, GCCTTGGGAACCCG, between position 7398 and 7399 of the coding sequence of the NOTCH1 gene.			Cell or Molecular Dysfunction	
C167244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167244>	C167235	NOTCH1 NP_060087.3:p.S2467Afs*15|NOTCH1 NP_060087.3:p.Ser2467AlafsTer15|NOTCH1 S2467Afs*15|NOTCH1 Ser2467AlafsTer15|NOTCH1 p.S2467Afs*15|NOTCH1 p.Ser2467AlafsTer15|NP_060087.3:p.S2467Afs*15|NP_060087.3:p.Ser2467AlafsTer15|Neurogenic Locus Notch Homolog Protein 1 S2467Afs*15|Neurogenic Locus Notch Homolog Protein 1 Ser2467AlafsTer15|TAN-1 S2467Afs*15|TAN-1 Ser2467AlafsTer15|TAN1 S2467Afs*15|TAN1 Ser2467AlafsTer15|Translocation-Associated Notch Protein TAN-1 S2467Afs*15|Translocation-Associated Notch Protein TAN-1 Ser2467AlafsTer15	A change in the amino acid composition at position 2467 of the neurogenic locus notch homolog protein 1 where a frameshift mutation results in the substitution of the serine with an alanine followed by 14 non-canonical amino acids and stop codon.			Cell or Molecular Dysfunction	
C167246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167246>	C45403|C17354	NOTCH1 NM_017617.4:c.7398_7399insGG|NM_017617.4:c.7398_7399insGG|NOTCH1 c.7398_7399insGG|Notch 1 c.7398_7399insGG|Notch Homolog 1 c.7398_7399insGG|Notch, Drosophila, Homolog of, 1 c.7398_7399insGG|TAN1 c.7398_7399insGG|hN1 c.7398_7399insGG	An insertion of two nucleotides, guanine-guanine, between position 7398 and 7399 of the coding sequence of the NOTCH1 gene.			Cell or Molecular Dysfunction	
C167247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167247>	C167235	NOTCH1 NP_060087.3:p.S2467Gfs*11|NOTCH1 NP_060087.3:p.Ser2467GlyfsTer11|NOTCH1 S2467Gfs*11|NOTCH1 Ser2467GlyfsTer11|NOTCH1 p.S2467Gfs*11|NOTCH1 p.Ser2467GlyfsTer11|NP_060087.3:p.S2467Gfs*11|NP_060087.3:p.Ser2467GlyfsTer11|Neurogenic Locus Notch Homolog Protein 1 S2467Gfs*11|Neurogenic Locus Notch Homolog Protein 1 Ser2467GlyfsTer11|TAN-1 S2467Gfs*11|TAN-1 Ser2467GlyfsTer11|TAN1 S2467Gfs*11|TAN1 Ser2467GlyfsTer11|Translocation-Associated Notch Protein TAN-1 S2467Gfs*11|Translocation-Associated Notch Protein TAN-1 Ser2467GlyfsTer15	A change in the amino acid composition at position 2467 of the neurogenic locus notch homolog protein 1 where a frameshift mutation results in the substitution of the serine with a glycine followed by 10 non-canonical amino acids and stop codon.			Cell or Molecular Dysfunction	
C167248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167248>	C45403|C17354	NOTCH1 NM_017617.4:c.7398_7407del|NM_017617.4:c.7398_7407del|NOTCH1 c.7398_7407del|Notch 1 c.7398_7407del|Notch Homolog 1 c.7398_7407del|Notch, Drosophila, Homolog of, 1 c.7398_7407del|TAN1 c.7398_7407del|hN1 c.7398_7407del	A deletion of ten nucleotides starting at position 7398 and ending with position 7407 of the coding sequence of the NOTCH1 gene.			Cell or Molecular Dysfunction	
C167249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167249>	C167235	NOTCH1 NP_060087.3:p.S2467Pfs*7|NOTCH1 NP_060087.3:p.Ser2467ProfsTer7|NOTCH1 S2467Pfs*7|NOTCH1 Ser2467ProfsTer7|NOTCH1 p.S2467Pfs*7|NOTCH1 p.Ser2467ProfsTer7|NP_060087.3:p.S2467Pfs*7|NP_060087.3:p.Ser2467ProfsTer7|Neurogenic Locus Notch Homolog Protein 1 S2467Pfs*7|Neurogenic Locus Notch Homolog Protein 1 Ser2467ProfsTer7|TAN-1 S2467Pfs*7|TAN-1 Ser2467ProfsTer7|TAN1 S2467Pfs*7|TAN1 Ser2467ProfsTer7|Translocation-Associated Notch Protein TAN-1 S2467Pfs*7|Translocation-Associated Notch Protein TAN-1 Ser2467ProfsTer7	A change in the amino acid composition at position 2467 of the neurogenic locus notch homolog protein 1 where a frameshift mutation results in the substitution of the serine with a proline followed by 6 non-canonical amino acids and stop codon.			Cell or Molecular Dysfunction	
C16724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16724>	C116640	Immunoprecipitation|IMMUNOPRECIPITATION|IP	Antigen aggregation with antibody, in the right ratios, to cause precipitation.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C167250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167250>	C45403|C17354	NOTCH1 NM_017617.4:c.7398del|NM_017617.4:c.7398del|NOTCH1 c.7398del|Notch 1 c.7398del|Notch Homolog 1 c.7398del|Notch, Drosophila, Homolog of, 1 c.7398del|TAN1 c.7398del|hN1 c.7398del	A deletion of the nucleotide at position 7398 of the coding sequence of the NOTCH1 gene.			Cell or Molecular Dysfunction	
C167251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167251>	C167235	NOTCH1 NP_060087.3:p.S2467Rfs*10|NOTCH1 NP_060087.3:p.Ser2467ArgfsTer10|NOTCH1 S2467Rfs*10|NOTCH1 Ser2467ArgfsTer10|NOTCH1 p.S2467Rfs*10|NOTCH1 p.Ser2467ArgfsTer10|NP_060087.3:p.S2467Rfs*10|NP_060087.3:p.Ser2467ArgfsTer10|Neurogenic Locus Notch Homolog Protein 1 S2467Rfs*10|Neurogenic Locus Notch Homolog Protein 1 Ser2467ArgfsTer10|TAN-1 S2467Rfs*10|TAN-1 Ser2467ArgfsTer10|TAN1 S2467Rfs*10|TAN1 Ser2467ArgfsTer10|Translocation-Associated Notch Protein TAN-1 S2467Rfs*10|Translocation-Associated Notch Protein TAN-1 Ser2467ArgfsTer10	A change in the amino acid composition at position 2467 of the neurogenic locus notch homolog protein 1 where a frameshift mutation results in the substitution of the serine with an arginine followed by 9 non-canonical amino acids and stop codon.			Cell or Molecular Dysfunction	
C167252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167252>	C45403|C17354	NOTCH1 NM_017617.4:c.7399del|NM_017617.4:c.7399del|NOTCH1 c.7399del|Notch 1 c.7399del|Notch Homolog 1 c.7399del|Notch, Drosophila, Homolog of, 1 c.7399del|TAN1 c.7399del|hN1 c.7399del	A deletion of the nucleotide at position 7399 of the coding sequence of the NOTCH1 gene.			Cell or Molecular Dysfunction	
C167253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167253>	C45403|C17354	NOTCH1 NM_017617.4:c.7399_7400insGG|NM_017617.4:c.7399_7400insGG|NOTCH1 c.7399_7400insGG|Notch 1 c.7399_7400insGG|Notch Homolog 1 c.7399_7400insGG|Notch, Drosophila, Homolog of, 1 c.7399_7400insGG|TAN1 c.7399_7400insGG|hN1 c.7399_7400insGG	An insertion of two nucleotides, guanine-guanine, between position 7399 and 7400 of the coding sequence of the NOTCH1 gene.			Cell or Molecular Dysfunction	
C167254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167254>	C167235	NOTCH1 NP_060087.3:p.S2467Wfs*11|NOTCH1 NP_060087.3:p.Ser2467TrpfsTer11|NOTCH1 S2467Wfs*11|NOTCH1 Ser2467TrpfsTer11|NOTCH1 p.S2467Wfs*11|NOTCH1 p.Ser2467TrpfsTer11|NP_060087.3:p.S2467Wfs*11|NP_060087.3:p.Ser2467TrpfsTer11|Neurogenic Locus Notch Homolog Protein 1 S2467Wfs*11|Neurogenic Locus Notch Homolog Protein 1 Ser2467TrpfsTer11|TAN-1 S2467Wfs*11|TAN-1 Ser2467TrpfsTer11|TAN1 S2467Wfs*11|TAN1 Ser2467TrpfsTer11|Translocation-Associated Notch Protein TAN-1 S2467Wfs*11|Translocation-Associated Notch Protein TAN-1 Ser2467TrpfsTer11	A change in the amino acid composition at position 2467 of the neurogenic locus notch homolog protein 1 where a frameshift mutation results in the substitution of the serine with a tryptophan followed by 10 non-canonical amino acids and stop codon.			Cell or Molecular Dysfunction	
C167255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167255>	C4863|C177149	Refractory Prostate Carcinoma	A prostate carcinoma that is resistant to treatment.	Refractory Prostate Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C167256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167256>	C2919|C167255|C159563	Refractory Prostate Adenocarcinoma	A prostate adenocarcinoma that is resistant to treatment.	Refractory Prostate Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C167257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167257>	C471	p97 Inhibitor CB-5339|CB 5339|CB-5339|CB5339	An orally bioavailable, selective, second-generation inhibitor of valosin-containing protein (VCP)/p97, with potential antineoplastic activity.  Upon oral administration, p97 inhibitor CB-5339 binds to and inhibits the activity of p97.  This prevents ubiquitin-dependent protein degradation and causes cellular accumulation of poly-ubiquitinated proteins.  The inhibition of endoplasmic reticulum (ER)-associated protein degradation activates the ER-dependent stress response pathway, and leads to both an induction of apoptosis and the inhibition of cell proliferation in susceptible tumor cells.  VCP/p97, a type II AAA+ ATPase, plays a key role in cellular protein homeostasis processes including ER-associated degradation (ERAD), chromatin associated degradation (CAD) and the DNA damage response (DDR).  Its overexpression in many tumor cell types is associated with increased tumor cell proliferation and survival.	p97 Inhibitor CB-5339		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C167258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167258>	C117281	IDH2 NP_002159.2:p.R140G|IDH2 Arg140Gly|IDH2 NP_002159.2:p.Arg140Gly|IDH2 R140G|IDH2 R140G Mutation|IDH2 p.Arg140Gly|IDH2 p.R140G|Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial Arg140Gly|Isocitrate Dehydrogenase 2 (NADP+) Mitochondrial R140G|Isocitrate Dehydrogenase [NADP], Mitochondrial Arg140Gly|Isocitrate Dehydrogenase [NADP], Mitochondrial R140G|NP_002159.2:p.Arg140Gly|NP_002159.2:p.R140G	A change in the amino acid residue at position 140 in the isocitrate dehydrogenase [NADP], mitochondrial protein where arginine has been replaced by glycine.			Cell or Molecular Dysfunction	
C167259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167259>	C219645|C172344	IDH2 NM_002168.3:c.418C>G|IDH c.418C>G|IDH2 c.418C>G|Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial c.418C>G|Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial c.418C>G|NM_002168.3:c.418C>G	A nucleotide substitution at position 418 of the coding sequence of the IDH2 gene where cytosine has been mutated to guanine.			Cell or Molecular Dysfunction	
C16725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16725>	C20027	Immunoprotein|Immune Regulatory Proteins	A protein whose activities affect or play a role in immune system functions.			Amino Acid, Peptide, or Protein|Immunologic Factor	
C167260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167260>	C176859|C162254	Advanced Malignant Female Reproductive System Neoplasm	A malignant female reproductive system neoplasm that has spread extensively from its original site of growth to other anatomic sites or is no longer responding to treatment.	Advanced Malignant Female Reproductive System Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C167262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167262>	C471	p97 Inhibitor CB-5339 Tosylate|CB 5339 Tosylate|CB-5339 Tosylate|CB5339 Tosylate	The tosylate salt of  CB-5339, an orally bioavailable, selective, second-generation inhibitor of valosin-containing protein (VCP)/p97, with potential antineoplastic activity.  Upon oral administration, p97 inhibitor CB-5339 binds to and inhibits the activity of p97.  This prevents ubiquitin-dependent protein degradation and causes cellular accumulation of poly-ubiquitinated proteins.  The inhibition of endoplasmic reticulum (ER)-associated protein degradation activates the ER-dependent stress response pathway, and leads to both an induction of apoptosis and the inhibition of cell proliferation in susceptible tumor cells.  VCP/p97, a type II AAA+ ATPase, plays a key role in cellular protein homeostasis processes including endoplasmic reticulum associated degradation (ERAD), chromatin associated degradation (CAD) and the DNA damage response (DDR).  Its overexpression in many tumor cell types is associated with increased tumor cell proliferation and survival.	p97 Inhibitor CB-5339 Tosylate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C167263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167263>	C17204	Multi-Energy Computed Tomography|MECT|Multi Energy Computed Tomography	An application of computed tomography that uses energy-sensitive photon-counting detectors to more accurately distinguish tissue in images acquired using multiple x-ray spectra.	Multi-Energy Computed Tomography		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C167264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167264>	C124598	Musculoskeletal Examination|MKEXAM|Musculoskeletal Exam|Musculoskeletal Exam|Musculoskeletal System Examination|Musculoskeletal System Examination	Physical examination pertaining to the musculoskeletal system.	Musculoskeletal Examination		Diagnostic Procedure	CDISC SDTM Musculoskeletal System Finding Test Code Terminology|CDISC SDTM Musculoskeletal System Finding Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C167265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167265>	C3871|C102872	Nasopharyngeal Squamous Cell Carcinoma	A squamous cell carcinoma that arises from the nasopharynx.	Nasopharyngeal Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C167266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167266>	C9240|C173689|C167265	Recurrent Nasopharyngeal Squamous Cell Carcinoma	The reemergence of squamous cell carcinoma of the nasopharynx after a period of remission.			Neoplastic Process	
C167267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167267>	C2116	SERD ZN-c5|Selective Estrogen Receptor Degrader ZN-c5|Selective Estrogen Receptor Downregulator ZN-c5|ZN c5|ZN-c5|ZNc5	An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, SERD ZN-c5 specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that results in ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.	SERD ZN-c5		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C167268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167268>	C45678	Liposomal-based Cream Base|Lipoderm	A smooth, thick cream that is used as a base for topical and transdermal delivery of pharmaceuticals. The proprietary formula utilizes a multi-emulsion liposomic system that is insoluble in water and alcohol.	Liposomal-based Cream Base		Biomedical or Dental Material|Organic Chemical	CTRP Agent Terminology|CTRP Terminology|NCIt Antineoplastic Agent Terminology
C167269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167269>	C71460	Photovoice	A qualitative method in which participants use photographic techniques to facilitate the documentation and communication of issues.	Photovoice		Conceptual Entity	CTRP Intervention Terminology|CTRP Terminology
C16726	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16726>	C17258	Incidence|incidence|incidence|incidence	The relative frequency of occurrence of something.			Quantitative Concept	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C167270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167270>	C176586	STING-expressing E. coli SYNB1891|STING-expressing Escherichia coli strain SYNB1891|SYNB 1891|SYNB-1891|SYNB1891	A non-pathogenic strain of Escherichia coli (E. coli) bacteria that has been engineered to express stimulator of interferon genes (STING; transmembrane protein 173; TMEM173) protein, with potential immunoactivating and antineoplastic activities. Upon intratumoral administration, STING-expressing E. coli SYNB1891 are engulfed by antigen presenting cells (APCs) within the tumor. STING-mediated pathways within the APCs are then activated resulting in a type I interferon (IFN) response which promotes initiation and propagation of tumor-specific T-cell responses. In addition, the bacterial component of SYNB1891 may further stimulate the innate immune system via Toll-like receptors (TLRs) which may enhance the magnitude of the overall immune response. STING, a transmembrane protein that activates immune cells in the tumor microenvironment (TME), plays a key role in the activation of the innate immune system.	STING-expressing E. coli SYNB1891		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C167271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167271>	C129824|C107589	CXCR4/E-selectin Antagonist GMI-1359|GMI 1359|GMI-1359|GMI1359	An antagonist of both the C-X-C chemokine receptor type 4 (CXCR4) and E-selectin (CD62E), with potential antineoplastic activity. Upon administration, CXCR4/E-selectin antagonist GMI-1359 binds to both CXCR4 and E-selectin expressed on endothelial cells. The binding to CXCR4 prevents the binding of stromal-cell derived factor-1 (SDF-1; CXCL12) to CXCR4 and inhibits CXCR4 activation, which may result in decreased proliferation and migration of CXCR4-expressing tumor cells. The binding to E-selectin expressed on endothelial cells prevents their interaction with E-selectin ligand-expressing cancer cells. This may prevent tumor cell activation, migration and metastasis. CXCR4, a chemokine receptor belonging to the G protein-coupled receptor (GPCR) family, plays an important role in chemotaxis and angiogenesis, and is upregulated in several tumor cell types. E-selectin is a cell adhesion molecule involved in cell rolling, signaling and chemotaxis. Its overexpression has been associated with tumor angiogenesis and metastasis in several cancers. 	CXCR4/E-selectin Antagonist GMI-1359		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C167272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167272>	C54362	ZNF532 Gene|ZNF532|ZNF532|Zinc Finger Protein 532 Gene	This gene may be involved in DNA binding and transcriptional regulation.	ZNF532 Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C167273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167273>	C167272	ZNF532 wt Allele|FLJ10697|KIAA1629|Zinc Finger Protein 532 wt Allele	Human ZNF532 wild-type allele is located in the vicinity of 18q21.32 and is approximately 124 kb in length. This allele, which encodes zinc finger protein 532, plays a role in transcriptional regulation. Rare fusions involving this gene and the NUTM1 gene are involved in NUT carcinoma.	ZNF532 wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167274>	C26199	Zinc Finger Protein 532|ZNF532	Zinc finger protein 532 (1301 aa, ~142 kDa) is encoded by the human ZNF532 gene. This protein is involved in transcriptional regulation and DNA binding.	Zinc Finger Protein 532		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167275>	C212857	ZNF532/NUTM1 Fusion Gene|ZNF532-NUT Fusion Gene|ZNF532-NUT Translocation|ZNF532-NUTM1 Fusion Gene|ZNF532/NUT Fusion Gene|ZNF532/NUT Translocation|ZNF532::NUTM1 Fusion Gene	A fusion gene that results from a chromosomal translocation t(15;18)(q14;q21.32) which fuses either the first 4 exons or the first 10 exons of the ZNF532 gene with either intron 1 or exon 2 of the NUTM1 gene, respectively. This rare rearrangement is associated with NUT carcinoma.	ZNF532/NUTM1 Fusion Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C167276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167276>	C213259	ZNF532/NUTM1 Fusion Protein|ZNF532-NUT Fusion Protein|ZNF532-NUTM1 Fusion Protein|ZNF532/NUT Fusion Protein|ZNF532::NUTM1 Fusion Protein|Zinc Finger Protein 532-NUT Family Member 1 Fusion Protein|Zinc Finger Protein 532/NUT Family Member 1 Fusion Protein	A fusion protein encoded by the ZNF532/NUTM1 fusion gene. This protein is comprised of either 778 or 1091 N-terminal amino acids of zinc finger protein 532, including 2 or 11 of the DNA-binding C2H2 zinc fingers, respectively, which is fused to all but the first 3 amino acids of NUT family member 1 protein.	ZNF532/NUTM1 Fusion Protein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Target Molecular Abnormalities Terminology
C167278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167278>	C62554	PARP Inhibitor NMS-03305293|NMS 03305293|NMS-03305293|NMS03305293	An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. Upon administration, PARP inhibitor NMS-03305293 selectively binds to PARP and prevents PARP-mediated DNA repair of single-strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks and promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.	PARP Inhibitor NMS-03305293		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C167279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167279>	C142623	Original Dog Breed Data|Dog Breed Orig|Dog Breed Original|Dog_Breed_Orig	The original text for the dog breed name in the initial documentation.			Idea or Concept	Canine Glioma Project Property Terminology|ICDC Terminology
C16727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16727>	C25464	India|356|IN|IND|IND|INDIA|INDIA	A country in southern Asia, bordering the Arabian Sea and the Bay of Bengal, between Pakistan and China.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF1 Registration Table|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C167280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167280>	C171435	Anatomic Site of Origin for Matched Normal Tissue|Matched Normal Tissue Origin|Source Matched Normal Tissue|Source_Matched_Normal_Tissue	The anatomic site from which a matched normal tissue sample was procured.			Body Location or Region	Canine Glioma Project Property Terminology|ICDC Terminology
C167281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167281>	C37908	Dog Age in Years|Dog Age years|Dog_Age_years	The length of a dog's life, stated in years since birth.			Organism Attribute	Canine Glioma Project Property Terminology|ICDC Terminology
C167282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167282>	C103223	Mutation Rate	The frequency of mutations in a sample.			Laboratory or Test Result	
C167283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167283>	C167282	Adjusted Coding Mutation Rate Per Megabase|Adjusted coding mutation rate per megabase|Adjusted_coding_mutation_rate_per_megabase	The frequency that coding region mutations occur in a sample per megabase of DNA sequence adjusted for the baseline mutation rate.			Laboratory or Test Result	Canine Glioma Project Property Terminology|ICDC Terminology
C167284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167284>	C106054	Reduced-Representation Bisulfite Sequencing|RRBS|RRBS|RRBS-Seq	A bisulfite-based sequencing techinque where genomic DNA is exposed to one or more restriction enzymes prior to sequencing to produce sequence-specific fragmentation.			Molecular Biology Research Technique	Canine Glioma Project Property Terminology|ICDC Terminology
C167285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167285>	C155320	Mean Exome Read Depth|Mean Exome Coverage|mean exome coverage|mean_exome_coverage	The mean number of times each gene encoding an RNA transcript was fully sequenced.			Conceptual Entity	Canine Glioma Project Property Terminology|ICDC Terminology
C167286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167286>	C181844	Percent Exome Covered at Read Depth of 30X|percent exome covered at 30X|percent_exome_covered_at_30X	A measurement of the percent of the exome sequenced at a read depth of 30X.			Conceptual Entity	Canine Glioma Project Property Terminology|ICDC Terminology
C167287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167287>	C103223	DNA Methylation-Dependent Predicted Disease Class|DNA Methylation-Dependent Predicted Disease Type|Methylation Predicted Class|Methylation-Based Disease Classification|Methylation-Based Disease Type|Methylation_Predicted_Class	A genetic finding that predicts the disease type based on the DNA methylation profile of the sample.			Laboratory or Test Result	Canine Glioma Project Property Terminology|ICDC Terminology
C167288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167288>	C54154	DNA Methylation-Dependent Predicted Disease Class Probability|DNA Methylation-Dependent Predicted Disease Type Probability|Methylation Prediction Probability|Methylation-Based Disease Classification Probability|Methylation-Based Disease Type Probability|Methylation_Prediction_Probability	An estimate of the likelihood that the DNA methylation-based disease class prediction is accurate.			Quantitative Concept	Canine Glioma Project Property Terminology|ICDC Terminology
C167289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167289>	C91102	Comparative Brain Tumor Consortium Annotation Present Question|CBTC Annotation Present|Comparative Brain Tumor Consortium Annotation Present|cbtc annot present|cbtc_annot_present	A question regarding whether any annotations were made by a member of the NCI Comparative Brain Tumor Consortium (CBTC).			Intellectual Product	Canine Glioma Project Property Terminology|ICDC Terminology
C16728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16728>	C25464	Indonesia|360|ID|IDN|IDN|INDONESIA|INDONESIA	A country in southeastern Asia, comprising the archipelago and islands between the Indian Ocean and the Pacific Ocean, north of Australia.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C167290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167290>	C25393	Comments from CBTC Review|comments cbtc review|comments_cbtc_review	A textual explanation, observation, suggestion or question added by the NCI Comparative Brain Tumor Consortium (CBTC) reviewer.			Intellectual Product	Canine Glioma Project Property Terminology|ICDC Terminology
C167291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167291>	C20171	Comparative Brain Tumor Consortium|CBTC	A project within the Comparative Oncology Program (COP), which is a core resource program launched by National Cancer Institute's (NCI) Center for Cancer Research (CCR). The goal of the Comparative Brain Tumor Consortium (CBTC) is to evaluate the features of canine brain tumors and establish their relevance as models for human brain tumors.			Organization	
C167292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167292>	C176586	STING Agonist BMS-986301|BMS 986301|BMS-986301|BMS986301|STING Agonist IBMS-986301	An agonist of stimulator of interferon genes (STING) protein, with potential immunoactivating and antineoplastic activities. Upon administration, STING agonist BMS-986301 targets and binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor microenvironment (TME). This leads to the production of pro-inflammatory cytokines, including interferons (IFNs). Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens (TAAs) by dendritic cells (DCs) to cytotoxic T-lymphocytes (CTLs). This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis. STING, a transmembrane protein that activates immune cells in the TME, plays a key role in the activation of the innate immune system.	STING Agonist BMS-986301		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C167293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167293>	C20993	QuickDASH Outcome Measure|Q-DASH|QuickDASH	An 11-item questionnaire designed to measure physical function and symptoms in people with any or multiple musculoskeletal disorders of the upper limb.			Intellectual Product	
C167294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167294>	C173045	Ability to Open Tight or New Jar Question|Ability to Open Tight or New Jar|Open a tight or new jar	A question about an individual's ability to open a tight or new jar.			Intellectual Product	QuickDASH Outcome Measure
C167297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167297>	C173045	Ability to Wash Your Back Question|Ability to Wash Your Back|Wash your back	A question about an individual's ability to wash their back.			Intellectual Product	QuickDASH Outcome Measure
C167298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167298>	C173045	Ability to Use Knife to Cut Food Question|Ability to Use Knife to Cut Food|Use a knife to cut food	A question about an individual's ability to use a knife to cut food.			Intellectual Product	QuickDASH Outcome Measure
C167299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167299>	C173466|C173045	Ability to do Recreational Activities which Require Force or Impact Through Arm, Shoulder, or Hand Question|Ability to do Recreational Activities Which Takes Some Force or Impact Through Arm, Shoulder or Hand|Ability to do Recreational Activities which Require Force or Impact Through Arm, Shoulder, or Hand|Recreational activities in which you take some force or impact through your arm, shoulder or hand (e.g., golf, hammering, tennis, etc.)	A question about an individual's ability to do recreational activities which require force or impact through their arm, shoulder, or hand.			Intellectual Product	QuickDASH Outcome Measure
C16729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16729>	C60811	Infant Mortality|Infant Death|Infant Mortality Total	Any disease or condition resulting in postnatal death before age 1 yr. (NCI)			Qualitative Concept	
C1672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1672>	C2124	Indium In-111 Pentetreotide|INDIUM IN-111 PENTETREOTIDE|Indium In 111 Pentetreotide|Indium In 111-Pentetreotide|Indium-111-DTPA-D-Phe-1-octreotide|Indium-In 111 Pentetreotide|Indium-In-111-Pentetreotide|OctreoScan|indium In 111 pentetreotide	An indium 111 radioconjugate of pentetreotide, the diethylenetriaminopentaacetic (DTPA) conjugate of the human hormone somatostatin peptide analogue (octreotide), used for radioimaging neuroendocrine tumor cells. The pentetreotide moiety of indium In 111 pentetreotide binds to somatostatin receptors (SSTRs), especially type 2 receptors, present on the cell membranes of many types of neuroendocrine tumor cells. Upon binding and internalization, this radioconjugate allows for specific imaging of neuroendocrine tumors that overexpress somatostatin using scintigraphic imaging techniques. In addition, high dose indium In 111 pentetreotide may specifically deliver a cytotoxic dose of gamma radiation to SSTR-positive cells thereby killing SSTR-expressing tumor cells.	Indium In-111 Pentetreotide		Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C167300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167300>	C173584|C173466|C173150	Extent that Arm, Shoulder, or Hand Problem Interfered with Normal Social Activities Question|Extent that Arm, Shoulder, or Hand Problem Interfered with Normal Social Activities|To what extent has your arm, shoulder or hand problem interfered with your normal social activities with family, friends, neighbors or groups	A question about the extent that an individual's arm, shoulder, or hand problems interfered with their normal social activities.			Intellectual Product	QuickDASH Outcome Measure
C167301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167301>	C173924|C173787|C173695|C173466|C173150	Extent that Arm, Shoulder, or Hand Problem Limited Work or Other Regular Activities Question|Extent that Arm, Shoulder, or Hand Problem Limited Work or Other Regular Activities|Limited in Work or Other Regular Daily Activities as Result of Arm, Shoulder or Hand Problem	A question about the extent that an individual's arm, shoulder, or hand problems limited their work or other regular, daily activities.			Intellectual Product	QuickDASH Outcome Measure
C167302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167302>	C210431|C173466	Severity of Arm, Shoulder, or Hand Pain Question|Arm, Shoulder or Hand Pain|Severity of Arm, Shoulder, or Hand Pain	A question about the severity of pain in an individual's arm, shoulder, or hand.			Intellectual Product	QuickDASH Outcome Measure
C167303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167303>	C173734|C173466	Severity of Tingling in Arm, Shoulder, or Hand Question|Severity of Tingling in Arm, Shoulder, or Hand|Tingling (pins and needles) in your arm, shoulder or hand	A question about the severity of tingling in an individual's arm, shoulder, or hand.			Intellectual Product	QuickDASH Outcome Measure
C167304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167304>	C173925|C173466|C173398|C173346	Severity of Sleep Difficulty Because of Pain in Arm, Shoulder, or Hand Question|How much difficulty have you had sleeping because of the pain in your arm, shoulder or hand|Severity of Sleep Difficulty Because of Pain in Arm, Shoulder, or Hand	A question about the difficulty an individual had in sleeping because of the pain in their arm, shoulder, or hand.			Intellectual Product	QuickDASH Outcome Measure
C167305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167305>	C173924|C173466	Impact of Arm, Shoulder, or Hand Problem on Ability to Use Usual Technique for Work Question|Impact of Arm, Shoulder, or Hand Problem on Ability to Use Usual Technique for Work|Using your usual technique for your work	A question about the impact of an individual's arm, shoulder, or hand problem in using their usual technique for their work.			Intellectual Product	QuickDASH Outcome Measure
C167306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167306>	C173924|C173466|C173346	Impact of Arm, Shoulder, or Hand Problem on Ability to Do Usual Work Question|Doing your usual work because of arm, shoulder or hand pain|Impact of Arm, Shoulder, or Hand Problem on Ability to Do Usual Work	A question about the impact of an individual's arm, shoulder, or hand problem in doing their usual work.			Intellectual Product	QuickDASH Outcome Measure
C167307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167307>	C173924|C173466	Impact of Arm, Shoulder, or Hand Problem on Ability to Do Work as Well as Would Like Question|Doing your work as well as you would like|Impact of Arm, Shoulder, or Hand Problem on Ability to Do Work as Well as Would Like	A question about the impact of an individual's arm, shoulder, or hand problem in working as well as they would like.			Intellectual Product	QuickDASH Outcome Measure
C167308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167308>	C173924|C173466	Impact of Arm, Shoulder, or Hand Problem on Ability to Spend Usual Amount of Time Doing Work Question|Impact of Arm, Shoulder, or Hand Problem on Ability to Spend Usual Amount of Time Doing Work|Spending your usual amount of time doing your work	A question about the impact of an individual's arm, shoulder, or hand problem in spending the usual amount of time doing their work.			Intellectual Product	QuickDASH Outcome Measure
C167309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167309>	C173466|C173458	Impact of Arm, Shoulder, or Hand Problem on Ability to Use Usual Technique for Playing Instrument or Sport Question|Impact of Arm, Shoulder, or Hand Problem on Ability to Use Usual Technique for Playing Instrument or Sport|Using your usual technique for playing your instrument or sport	A question about the impact of an individual's arm, shoulder, or hand problem in using their usual technique for playing their instrument or sport.			Intellectual Product	QuickDASH Outcome Measure
C16730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16730>	C18740	Developmental Psychology, Infant	Developmental psychology research focusing on the infant period.			Biomedical Occupation or Discipline	
C167310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167310>	C173466|C173458|C173346	Impact of Arm, Shoulder, or Hand Problem on Ability to Play Instrument or Sport Question|Impact of Arm, Shoulder, or Hand Problem on Ability to Play Instrument or Sport|Playing your musical instrument or sport because of arm, shoulder or hand pain	A question about the impact of an individual's arm, shoulder, or hand problem for playing their instrument or sport.			Intellectual Product	QuickDASH Outcome Measure
C167311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167311>	C173466|C173458	Impact of Arm, Shoulder, or Hand Problem on Ability to Play Instrument or Sport as Well as Would Like Question|Impact of Arm, Shoulder, or Hand Problem on Ability to Play Instrument or Sport as Well as Would Like|Playing your musical instrument or sport as well as you would like	A question about the impact of an individual's arm, shoulder, or hand problem for playing their instrument or sport as well as they would like.			Intellectual Product	QuickDASH Outcome Measure
C167312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167312>	C173466|C173458	Impact of Arm, Shoulder, or Hand Problem on Ability to Spend Usual Amount of Time Playing Instrument or Sport Question|Impact of Arm, Shoulder, or Hand Problem on Ability to Spend Usual Amount of Time Playing Instrument or Sport|Spending your usual amount of time practising or playing your instrument or sport	A question about the impact of an individual's arm, shoulder, or hand problem in spending the usual amount of time playing their instrument or sport.			Intellectual Product	QuickDASH Outcome Measure
C167313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167313>	C176243	No Difficulty	A response indicating that an individual has or had no difficulty doing something.			Intellectual Product	QuickDASH Outcome Measure
C167314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167314>	C176243	Mild Difficulty	A response indicating that an individual has or had mild difficulty doing something.			Intellectual Product	QuickDASH Outcome Measure
C167315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167315>	C176243	Moderate Difficulty	A response indicating that an individual has or had moderate difficulty doing something.			Intellectual Product	QuickDASH Outcome Measure
C167316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167316>	C176243	Severe Difficulty	A response indicating that an individual has or had sevete difficulty doing something.			Intellectual Product	QuickDASH Outcome Measure
C167317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167317>	C177167	Does Not Interfere|Does Not Interfere at All|Interferes Not at All|Not at All	A response indicating that something does not interfere at all.			Intellectual Product	QuickDASH Outcome Measure
C167318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167318>	C177167	Interferes Slightly|Slightly|Slightly Interfering|Some	A response indicating that something interferes slightly.			Intellectual Product	QuickDASH Outcome Measure
C167319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167319>	C177167	Interferes Moderately|Moderately|Moderately Interfering	A response indicating that something interferes moderately.			Intellectual Product	QuickDASH Outcome Measure
C16731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16731>	C27956	Newborn|NEONATE|Neonatal|Neonate	An age group comprised of infants during the first month after birth.			Age Group	Newborn Screening Terminology|NICHD Terminology
C167320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167320>	C177167	Interferes Quite a Bit|A lot|Quite a Bit|Quite a Bit Interfering	A response indicating that something interferes quite a bit.			Intellectual Product	QuickDASH Outcome Measure
C167321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167321>	C177167	Extremely Interfering|A whole lot|Extremely	A response indicating that something is extremely interfering.			Intellectual Product	QuickDASH Outcome Measure
C167322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167322>	C177163	Moderately Limited|Moderately limited	A response indicating that an individual is or feels moderately limited.			Intellectual Product	Food Allergy Quality of Life - Parental Burden|QuickDASH Outcome Measure
C167323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167323>	C176243|C172932	So Much Difficulty Can't Sleep|So much difficulty that I can't sleep	A response indicating that an individual had so much pain in their arm, shoulder, or hand that they could not sleep.			Intellectual Product	QuickDASH Outcome Measure
C167324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167324>	C204038|C156488	Locally Advanced Pancreatic Neuroendocrine Tumor	A pancreatic neuroendocrine tumor that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Pancreatic Neuroendocrine Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C167326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167326>	C201557	Fas Ligand-treated Allogeneic Mobilized Peripheral Blood Cells|Allogeneic Apograft Stem Cells|Apograft-incubated Mobilized Peripheral Blood Stem Cells|Apograft-treated Allogeneic MPBCs|Apograft-treated MPBCs|Fas Ligand-treated Allogeneic Mobilized Peripheral Blood Cell Product|FasL-treated Mobilized Peripheral Blood Cells	A donor graft derived from allogeneic filgrastim (granulocyte-colony stimulating factor; G-CSF)-mobilized peripheral blood cells (MPBC) that have been incubated with the recombinant human Fas ligand (FasL) APO010 ex vivo, and that can potentially be used for immune reconstitution purposes. The incubation of the hematopoietic stem cell graft with the apoptotic mediator Fas ligand (FasL) selectively induces apoptosis of mature T-cells which express high levels of Fas receptor, such as T stem cell memory (TSCM), T central memory (TCM), and T effector memory (TEM) cells and the pro-inflammatory T-helper cells (Th) Th1 and Th17 subsets while sparing CD34-positive stem and progenitor cells. Upon washing and further ex vivo preparations, and upon allogeneic hematopoietic stem cell transplantation (HSCT) with the FasL-treated allogeneic MPBCs, these cells provide hematopoietic cell recovery, preserve the graft-versus-leukemia (GvL) effects, and may prevent graft-versus-host disease (GvHD).	Fas Ligand-treated Allogeneic Mobilized Peripheral Blood Cells		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology
C167327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167327>	C95404	Midgut Neuroendocrine Tumor	A neuroendocrine tumor that arises from the jejunum, ileum, proximal colon, or appendix.	Midgut Neuroendocrine Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C167328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167328>	C96166|C167327	Midgut Neuroendocrine Tumor G2|Malignant carcinoid tumor of the midgut, unspecified	A well-differentiated, intermediate-grade neuroendocrine neoplasm that arises from the jejunum, ileum, proximal colon, or appendix. The mitotic count is 2-20 per 2 mm2 and/or the Ki-67 index is 3 to 20%.	Midgut Neuroendocrine Tumor G2		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology|mCode Cancer Disorder Value Set|mCode Elixhauser Malignant Solid Tumors without Metastases Value Set|mCode Primary Cancer Disorder Value Set|mCode Primary Malignant Neoplasm Disorder Value Set|mCode Terminology
C167329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167329>	C204037|C167327	Metastatic Midgut Neuroendocrine Tumor	A midgut neuroendocrine tumor that has spread from its original site of growth to another anatomic site.	Metastatic Midgut Neuroendocrine Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16732>	C17827	Information Dissemination	For information to be useful, not only does it need to be made available at the right time to those who need it such as policy makers, program planners, and health professionals, and patients but it has to be in the right form.  Information Dissemination includes both research into means of information distribution and the actual distribution of information.			Occupational Activity	
C167330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167330>	C204038|C167329	Locally Advanced Midgut Neuroendocrine Tumor	A midgut neuroendocrine tumor that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Midgut Neuroendocrine Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C167331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167331>	C226909|C167327	Unresectable Midgut Neuroendocrine Tumor	A midgut neuroendocrine tumor that is not amenable to surgical resection.	Unresectable Midgut Neuroendocrine Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C167332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167332>	C8524|C156485	Locally Advanced Neuroendocrine Neoplasm	A neuroendocrine neoplasm that has spread from its original site of growth to nearby tissues or lymph nodes.			Neoplastic Process	
C167333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167333>	C167332|C147065	Locally Advanced Neuroendocrine Tumor|Locally Advanced Carcinoid Tumor|Locally Advanced Well Differentiated Neuroendocrine Neoplasm	A neuroendocrine tumor that has spread from its original site of growth to nearby tissues or lymph nodes.			Neoplastic Process	
C167334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167334>	C203332|C1904	Pegylated SN-38 Conjugate PLX038|PLX 038|PLX-038|PLX038|Pegylated SN-38 PLX038	A pegylated conjugate of SN-38 (7-ethyl-10-hydroxy-camptothecin), a biologically active metabolite of the prodrug irinotecan, with potential antineoplastic activity. Upon administration, the proprietary linker slowly releases SN-38 from the pegylated SN-38 conjugate PLX038. SN-38 binds to and inhibits topoisomerase I by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks, inhibition of DNA replication, and apoptosis. Compared with irinotecan, this formulation allows higher accumulation in solid tumors due to its nanoparticle size and long half-life.	Pegylated SN-38 Conjugate PLX038		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C167335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167335>	C36025|C200758|C185167|C129325|C102897	Astrocytoma, IDH-Mutant, Grade 4|Astrocytoma, IDH-Mutant, Grade IV|Glioblastoma, IDH-Mutant|Glioblastoma, IDH-mutant	IDH-mutant astrocytoma characterized by the presence of necrosis and/or microvascular proliferation or homozygous deletion of CDKN2A and/or CDKN2B genes. The term glioblastoma no longer applies to central nervous system WHO grade 4 IDH-mutant astrocytomas. (WHO 2021)			Neoplastic Process	Cellosaurus Disease Terminology|GDC Terminology|GDC Value Terminology|Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C167336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167336>	C211962|C159556|C154091	Advanced Hepatocellular Carcinoma	A hepatocellular carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Hepatocellular Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C167337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167337>	C176023	Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA|ARC-T Plus Anti-BCMA SparX|Anti-TAG ARC-T Cells Directed by BCMA Bi-valent/TAG SparX Protein|Immunotherapeutic Combination Agent SparX Protein Plus CART-ddBCMA|TAG-containing SparX /Bivalent BCMA-targeted ARC-T Cells	An immunotherapeutic combination agent composed of antigen receptor complex T cells (ARC-T cells) which contain a proprietary binding domain specific for a universal TAG instead of a single chain variable fragment (scFv) binding domain, and a tumor-targeting antigen protein, soluble protein antigen-receptor X-linker (sparX) protein, containing a TAG moiety fused to two B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) binding domains, with potential antineoplastic activities. Upon administration of the anti-BCMA sparX protein plus BCMA-directed ARC T-cells CART-ddBCMA, the sparX protein, with its two BCMA binding domains, specifically targets and binds to two BCMA expressed on tumor cells. In turn, the ARC-T cells, with their anti-TAG domain, target and bind to the TAG domain on the sparX protein. This directly links the ARC-T cells to the BCMA-expressing tumor cells, through the ARC-T cell- sparX -tumor cell complex formation, thereby causing direct tumor cell killing. BCMA, a tumor-associated antigen (TAA), is found on the surfaces of plasma cells and is overexpressed on a variety of tumor cell types. Compared to anti-BCMA CAR-T cells, CART-ddBCMA, containing ARC-T cells that are re-programmed in vivo by the TAG sparX protein, shows enhanced efficiency and an improved safety profile. As ARC-T activity is dependent on the sparX dose administered, the rate of tumor cell killing, and related toxicities are also dependent on the sparX dose administered.	Anti-BCMA SparX Protein Plus BCMA-directed Anti-TAAG ARC T-cells CART-ddBCMA		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C167338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167338>	C213708|C156062	Advanced Bladder Carcinoma	A bladder carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Bladder Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C167339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167339>	C116518	Text Message-Based Navigation Intervention|Automated Text Message-Based Navigation|Text Message-Based Navigation	A text message-based system designed to guide a patient through a procedure and improve patient engagement and compliance.	Text Message-based Navigation Intervention		Health Care Activity	CTRP Intervention Terminology|CTRP Terminology
C16733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16733>	C17187	Information Sciences|Information Technology	The sciences concerned with gathering and manipulating and storing and retrieving and classifying recorded information.			Occupation or Discipline	
C167341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167341>	C6938	Adnexal Adenocarcinoma, Not Otherwise Specified|Adnexal Adenocarcinoma, NOS|Sweat Gland Adenocarcinoma, NOS|Sweat Gland Adenocarcinoma, Not Otherwise Specified	An adenocarcinoma that arises from the sweat glands and is characterized by the absence of specific morphological features to allow further classification.			Neoplastic Process	Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C167342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167342>	C4879	Spiradenocylindroma	A benign adnexal neoplasm with histological features of both spiradenoma and cylindroma in a single nodular lesion.			Neoplastic Process	
C167344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167344>	C6938|C36310	Carcinoma Arising from Spiradenocylindroma|Carcinoma ex Spiradenocylindroma|Malignant Neoplasm Arising from Spiradenocylindroma|Malignant Spiradenocylindroma|Spiradenocylindrocarcinoma	A carcinoma that arises from a spiradenocylindroma.			Neoplastic Process	
C167346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167346>	C4810|C3729	Malignant Mixed Tumor of the Skin|Cutaneous Malignant Mixed Tumor|Malignant Chondroid Syringoma	A rare malignant skin neoplasm that arises from a benign mixed tumor of the skin.			Neoplastic Process	
C167347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167347>	C156804	Tulmimetostat|1,3-Benzodioxole-5-carboxamide, 7-chloro-N-((1,2-dihydro-6-methyl-4-(methylthio)-2-oxo-3-pyridinyl)methyl)-2-(trans-4-(3-methoxy-1-azetidinyl)cyclohexyl)-2,4-dimethyl-, (2R)-|CPI 0209|CPI-0209|CPI0209|EZH2 Inhibitor CPI-0209|TULMIMETOSTAT	An orally available selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2), with potential antineoplastic activity. Upon oral administration, tulmimetostat selectively targets, binds to and inhibits the activity of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 on lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased proliferation of EZH2-expressing cancer cells. EZH2, an HMT class enzyme and the catalytic subunit of the polycomb repressive complex 2 (PRC2), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation; its expression is correlated with tumor initiation, progression, stem cell self-renewal, migration and angiogenesis.	Tulmimetostat		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C167348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167348>	C2124	Fluorine F 18 PSMA-1007|18F-PSMA-1007|18FPSMA-1007|F-18-PSMA-1007|Fluorine-18 PSMA-1007|PSMA-1007 F-18|PSMA-1007 F-18|[18F]-PSMA-1007	A radioconjugate containing the human prostate-specific membrane antigen (PSMA)-targeting ligand, PSMA-1007, labeled with the radioisotope fluorine F 18, with potential imaging activity using positron emission tomography/computed tomography (PET/CT). Upon administration of fluorine F 18 PSMA-1007, the PSMA-1007 moiety targets and binds to PSMA-expressing tumor cells. This allows for visualization of PSMA-expressing cells upon imaging. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and strongly overexpressed in prostate cancer (PCa) cells, with its level rising with increasing tumor differentiation and in hormone-refractory cancers.	Fluorine F 18 PSMA-1007		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C167349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167349>	C1951|C1663|C1572	HPV E6/E7-encoding Arenavirus Vaccine HB-201|Arenavirus Vector-based Vaccine HB-201|Arenavirus Vector-based Vaccine-expressing HPV 16 E7E6 HB-201|HB 201|HB-201|HB-201|HB-201 Cancer Vaccine|HB201|TT1-E7E6	A cancer vaccine consisting of a replication-attenuated arenavirus lymphocytic choriomeningitis virus (LCMV) encoding the inactivated fusion protein of the viral oncoproteins E6 and E7 derived from the human papillomavirus (HPV) serotype 16, with potential immunomodulating and antineoplastic activities. Upon administration, HPV E6/E7-encoding arenavirus vaccine HB-201 induces expression of the E6/E7 proteins and stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 E6 and E7, resulting in tumor cell lysis. Oncoproteins E6 and E7 play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.	HPV E6/E7-encoding Arenavirus Vaccine HB-201		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C16734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16734>	C17827	Information Storage and Retrieval|Information Processing/Storage/Retrieval	Research regarding the systematic process of collecting and cataloging data so that they can be located and displayed on request.			Occupational Activity	
C167350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167350>	C177176	TLR7 agonist BNT411|BNT 411|BNT-411|BNT411	A Toll-like receptor (TLR) 7 agonist with potential immunostimulating and antitumor activities. Upon administration, TLR7 agonist BNT411 binds to and activates TLR7. This may trigger, in addition to other possible responses, the activation of cluster of differentiation (CD) 8+ T cells, B cells, and innate immune cells including natural killer (NK) cells and macrophages. TLR7 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.	TLR7 agonist BNT411		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C167351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167351>	C171256	Musical Instrument	A device used to make musical tones or sounds.			Manufactured Object	
C167352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167352>	C165561|C162758|C150209	Locally Advanced Nasopharyngeal Squamous Cell Carcinoma	Nasopharyngeal squamous cell carcinoma that has spread to nearby tissues or lymph nodes.	Locally Advanced Nasopharyngeal Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C167353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167353>	C49236	Whole Body Vibration|WBV|Whole Body Vibration Therapy	Therapy where an individual stands, sits, or lies on a machine with a vibrating platform, forcing muscles to contract and relax.	Whole Body Vibration		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C167354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167354>	C9480|C9291|C36028	Microinvasive Anal Carcinoma	Anal carcinoma with minimal stromal invasion.	Microinvasive Anal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16735>	C19683	Informed Consent|Formal Consent|INFORMED CONSENT OBTAINED|informed consent|informed consent|informed consent	Consent by a patient to a surgical or medical procedure or participation in a clinical study after achieving an understanding of the relevant medical facts and the risks involved.	Informed Consent		Health Care Activity	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|CDISC SDTM Protocol Milestone Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C167360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167360>	C49146|C1663	Adenovirus Serotype 26-expressing HPV16 Vaccine JNJ-63682918|Ad26-expressing HPV16 Vaccine JNJ-63682918|Ad26.HPV16 JNJ-63682918|Adenovirus Serotype 26-Human Papillomavirus 16 JNJ-63682918|JNJ 63682918|JNJ-63682918|JNJ63682918|Monovalent HPV16 Ad26-vectored Vaccine JNJ-63682918	A prime cancer vaccine comprised of a genetically engineered, replication-deficient adenovirus serotype 26 (Ad26) encoding the oncogenic human papillomavirus 16 (HPV16), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration of Ad26-expressing HPV16 vaccine JNJ-63682918, the adenovirus infects and expresses HPV16. The expressed proteins stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 antigens, thereby inducing tumor cell lysis. HPV16 infection plays a key role in the development of a variety of cancers.	Adenovirus Serotype 26-expressing HPV16 Vaccine JNJ-63682918		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C167361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167361>	C49146|C1663	Adenovirus Serotype 26-expressing HPV18 Vaccine JNJ-63682931|Ad26-expressing HPV18 Vaccine JNJ-63682931|Ad26.HPV18 JNJ-63682931|Adenovirus Serotype 26-Human Papillomavirus 18 JNJ-63682931|JNJ 63682931|JNJ-63682931|JNJ63682931|Monovalent HPV18 Ad26-vectored Vaccine JNJ-63682931	A prime cancer vaccine comprised of a genetically engineered, replication-deficient adenovirus serotype 26 (Ad26) encoding the oncogenic human papillomavirus 18 (HPV18), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration of Ad26-expressing HPV18 vaccine JNJ-63682931, the adenovirus infects and expresses HPV18. The expressed proteins stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV18 antigens, thereby inducing tumor cell lysis. HPV18 infection plays a key role in the development of a variety of cancers.	Adenovirus Serotype 26-expressing HPV18 Vaccine JNJ-63682931		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C167362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167362>	C2313|C1663	Modified Vaccinia Ankara-vectored HPV16/18 Vaccine JNJ-65195208|JNJ 65195208|JNJ-65195208|JNJ65195208|MVA BN HPV16/18 JNJ-65195208|MVA-HPV16/18 Vaccine JNJ-65195208|MVA-vectored HPV16/18 Vaccine JNJ-65195208|MVA-vectored Vaccine JNJ-65195208|MVA.HPV16/18 JNJ-65195208|Modified Vaccinia Ankara-HPV16/18 JNJ-65195208	A booster cancer vaccine comprised of a modified, replication-defective, vaccinia virus Ankara (MVA) Bavarian Nordic (MVA-BN) strain encoding the oncogenic human papillomavirus types 16 (HPV16) and 18 (HPV18), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration of MVA-vectored HPV16/18 vaccine JNJ-65195208, and after the administration of the prime vaccine(s) adenovirus serotype 26 (Ad26)-expressing HPV16 vaccine JNJ-63682918 and/or Ad26-expressing HPV18 vaccine JNJ-63682931, this vaccine further stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16/18 proteins, resulting in tumor cell lysis. HPV16/18 infection plays a key role in the development of a variety of cancers.	Modified Vaccinia Ankara-vectored HPV16/18 Vaccine JNJ-65195208		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C167363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167363>	C215112	Gait Assessment Test	Any method or test designed to identify structural, biomechanical, and functional limitations in walking, and to develop treatment plans and assess the effect of treatment.	Gait Assessment Test		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C167364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167364>	C6938|C66745|C27379	Endocrine Mucin-Producing Sweat Gland Carcinoma|Cutaneous Analogue of Papillary Solid Carcinoma of the Breast|EMPSGC	A rare, low-grade sweat gland carcinoma with neuroendocrine differentiation. It usually arises on the eyelids and periorbital skin. It affects mostly older individuals. Women are affected more frequently than men. Morphologically, it is characterized by well-demarcated nodules with cystic, papillary, or cribriform architectural patterns. The neoplastic cells are small to intermediate polygonal to round cells. Small amounts of intracellular or extracellular mucin are present. In some cases, this carcinoma is a precursor of mucinous carcinoma.			Neoplastic Process	
C167365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167365>	C6938	Syringocystadenocarcinoma Papilliferum	A sweat gland carcinoma usually arising from a pre-existing syringocystadenoma papilliferum.			Neoplastic Process	Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C167366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167366>	C3646|C3398	Adnexal Cribriform Tumor|Adnexal Cribriform Carcinoma|Adnexal Solid-Cribriform Carcinoma|Primary Cutaneous Cribriform Carcinoma|Sweat Gland Cribriform Tumor	An indolent epithelial neoplasm that arises from the sweat glands. It is composed of neoplastic cells with eosinophilic cytoplasm that form cribriform and solid patterns. It was originally called a carcinoma, but it has an uncertain malignant potential.			Neoplastic Process	
C167368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167368>	C6938	Adnexal Secretory Carcinoma|Mammary-Type Secretory Carcinoma of the Skin|Primary Cutaneous Mammary Analogue Secretory Carcinoma	A rare adnexal carcinoma characterized by the presence of morphological features identical to those seen in salivary gland and breast secretory carcinomas.			Neoplastic Process	
C167369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167369>	C6938	Signet Ring Cell/Histiocytoid Carcinoma|SRCHC|Signet-Ring Cell/Histiocytoid Carcinoma	A rare aggressive adnexal carcinoma that affects the eyelid and rarely the axilla. Morphologically, it is characterized by the presence of signet ring cells or histiocytoid epithelial cells with eosinophilic cytoplasm infiltrating the dermis and subcutis, often in a single file pattern.			Neoplastic Process	
C16736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16736>	C17053	Infrared Radiation|Radiation, Infrared	Electromagnetic radiation with wavelengths between 750 nanometers and 1 millimeter, between those of visible light and microwaves. This portion of the electromagnetic spectrum can usually be sensed as heat.			Natural Phenomenon or Process	
C167370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167370>	C7442|C4615	Skin Myoepithelioma|Cutaneous Myoepithelioma	A benign skin neoplasm composed exclusively of myoepithelial cells.			Neoplastic Process	
C167375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167375>	C47925	Data Refresh	A process where all the data in a database environment is updated.			Machine Activity	
C167378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167378>	C8799|C153066	Locally Advanced Epithelioid Sarcoma	Epithelioid sarcoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Epithelioid Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C167379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167379>	C3714|C153068	Unresectable Epithelioid Sarcoma	An epithelioid sarcoma that is not amenable to surgical resection.	Unresectable Epithelioid Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16737>	C50128|C17423	Implantable Pump|implantable pump	A small device installed under the skin to provide long-term controlled-rate delivery of drugs such as chemotherapeutic agents or analgesics. Delivery rate may be externally controlled or osmotically or peristaltically controlled with the aid of transcutaneous monitoring.	Implantable Pump		Medical Device	CTRP Intervention Terminology|CTRP Terminology
C167380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167380>	C8799|C162194	Advanced Epithelioid Sarcoma	Epithelioid sarcoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Epithelioid Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C167381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167381>	C43310|C3775	Trichoblastic Carcinoma	A rare hair follicle carcinoma characterized by the presence of two components: a malignant epithelial component that resembles follicular germinative cells and a non-malignant stromal component identical to that of trichoblastoma.			Neoplastic Process	Mapped ICDO3.2 Morphology PT Terminology|Mapped ICDO3.2 Morphology Terminology|Mapped ICDO3.2 Terminology
C167382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167382>	C43310|C34448	Trichoblastic Carcinosarcoma	A rare hair follicle malignant neoplasm characterized by the presence of two components: a malignant epithelial component that resembles follicular germinative cells and a malignant stromal component that resembles follicular mesenchyme.			Neoplastic Process	
C167384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167384>	C51944	PD-L1 IHC 22C3 PharmDx|22C3 PharmDx|Dako 22C3|PD-L1 by clone 22C3 [Presence] in Tissue by Immune stain	A proprietary assay for PD-L1 (Programmed Cell Death 1 Ligand 1). It uses antibody 22C3 to specifically bind PD-L1 on the cell membrane of immune cells and normal and tumor cells of epithelial origin in formalin-fixed, paraffin-embedded (FFPE) specimens.			Laboratory Procedure	mCode Terminology|mCode Tumor Marker Test Value Set
C167385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167385>	C51944	PD-L1 IHC 28-8 PharmDx|28-8 PharmDx|Dako 28-8|PD-L1 by clone 28-8 [Presence] in Tissue by Immune stain	A proprietary assay for PD-L1 (Programmed Cell Death 1 Ligand 1). It uses antibody 28-8 to specifically bind PD-L1 on the cell membrane of immune cells and normal and tumor cells of epithelial origin in formalin-fixed, paraffin-embedded (FFPE) specimens.			Laboratory Procedure	mCode Terminology|mCode Tumor Marker Test Value Set
C167386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167386>	C15372	QuitBot Smoking Cessation Program|QuitBot	A smoking cessation program. One arm gives participants immediate access to the QuitBot tool, while the second arm delays this access for 3 months. Participants in either arm will get guidance on quitting, tools to help deal with urges to smoke, and help on staying motivated to quit. They will also receive scientifically-based recommendations for how to select medications to help in quitting smoking.	QuitBot Smoking Cessation Program		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C167387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167387>	C15372	SmokefreeTXT Smoking Cessation Program|SmokefreeTXT	A smoking cessation program that utilizes automated text messaging to provide 24/7 support to help adults quit tobacco smoking.	SmokefreeTXT Smoking Cessation Program		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C167388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167388>	C20993	Canine Quality of Life Survey|Canine-QOL|PRECINCT Canine Quality of Life Survey|quality_of_life_survey	A questionnaire from the PRE-medical Cancer Immunotherapy Network Canine Trials (PRECINCT) consortium designed to collect data about the health status of an individual's dog.			Intellectual Product	ICDC Terminology|PRECINCT Property Terminology
C167389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167389>	C25164	Survey Date|qol_date	The date on which a survey or questionnaire was done.			Temporal Concept	Canine Quality of Life Survey|ICDC Terminology|PRECINCT Property Terminology
C16738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16738>	C43164	Inhaler|INHALER|INHALER|INHALER|inhaler	A device by means of which a medicinal product can be administered by inspiration through the nose or the mouth.			Medical Device	EDQM Health Care Terminology|EDQM-HC Administration Device Terminology|FDA Structured Product Labeling Terminology|PQ/CMC Container Type Terminology|SPL Package Type Terminology
C167390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167390>	C173482	Pet Wants to Play Question|My pet wants to play|Pet Wants to Play|qol_play	A question about whether an individual's pet wants to play.			Intellectual Product	Canine Quality of Life Survey|ICDC Terminology|PRECINCT Property Terminology
C167391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167391>	C173482	Pet Responds to Presence Question|My pet responds to my presence|Pet Responds to Presence|responds	A question about whether an individual's pet responds to their presence.			Intellectual Product	Canine Quality of Life Survey|ICDC Terminology|PRECINCT Property Terminology
C167392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167392>	C173482	Pet Enjoys Life Question|My pet enjoys life|Pet Enjoys Life|enjoys_life	A question about whether an individual's pet enjoys life.			Intellectual Product	Canine Quality of Life Survey|ICDC Terminology|PRECINCT Property Terminology
C167393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167393>	C200760	Commensal Bacterial Strain Formulation VE800|Bacterial Consortium-based Formulation VE800|LBP VE800|Live Biotherapeutic Product VE800|VE 800|VE-800|VE800	An orally bioavailable formulation composed of eleven alive, distinct nonpathogenic, nontoxigenic, human commensal bacterial strains, isolated from healthy human donor feces, with potential immunostimulating and antineoplastic activities. Upon administration of the commensal bacterial strain formulation VE800, the bacterial strains induce an interferon-gamma (IFN-g)-producing CD8-positive T-cell-mediated immune response in the intestines. This may activate an IFN-g-expressing CD8+ T-cell -mediated anti-cancer immune response and may eradicate tumor cells.	Commensal Bacterial Strain Formulation VE800		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C167394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167394>	C173482	Pet Has More Good Days Than Bad Question|My pet has more good days than bad days|Pet Has More Good Days Than Bad|good_bad_days	A question about whether an individual's pet has more good days than bad days.			Intellectual Product	Canine Quality of Life Survey|ICDC Terminology|PRECINCT Property Terminology
C167395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167395>	C213709|C156063	Advanced Fallopian Tube Carcinoma	A fallopian tube carcinoma that has spread extensively from its original site of growth to other anatomic sites or is no longer responding to treatment.	Advanced Fallopian Tube Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C167396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167396>	C167203|C153171	Advanced Primary Peritoneal Carcinoma	A primary peritoneal carcinoma that has spread extensively from its original site of growth to other anatomic sites or is no longer responding to treatment.	Advanced Primary Peritoneal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C167397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167397>	C173482	Pet Sleeps More, Is Awake Less Question|My pet sleeps more, is awake less|Pet Sleeps More, Is Awake Less|sleep_awake	A question about whether an individual's pet sleeps more and/or is awake less.			Intellectual Product	Canine Quality of Life Survey|ICDC Terminology|PRECINCT Property Terminology
C167398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167398>	C51944	Ventana PD-L1 SP263|SP263|Ventana PD-L1 (SP263) Assay|Ventana SP263	A proprietary assay for PD-L1 (Programmed Cell Death 1 Ligand 1). It uses antibody SP263 to specifically bind PD-L1 on the cell membrane of immune cells and normal and tumor cells of epithelial origin in formalin-fixed, paraffin-embedded (FFPE) specimens.			Laboratory Procedure	
C167399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167399>	C173482	Pet Seems Dull or Depressed, Not Alert Question|My pet seems dull or depressed, not alert|Pet Seems Dull or Depressed, Not Alert|not_alert	A question about whether an individual's pet seems dull, depressed, or not alert.			Intellectual Product	Canine Quality of Life Survey|ICDC Terminology|PRECINCT Property Terminology
C16739	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16739>	C19166	Artificial Insemination	Introduction of sperm into the female reproductive tract by artificial means in order to achieve fertilization.			Therapeutic or Preventive Procedure	
C1673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1673>	C2090|C2076	Sardomozide|2-[4-(Aminoiminomethyl)-2,3-dihydro-1H-inden-1-ylidene]hydrazinecarboximidamide|2-[4-(Aminoiminomethyl)-2,3-dihydro-1H-inden-1-ylidene]hydrazinecarboximidamide|Amidinoindan-1-one.2'-amidinohydrazone|CGP 48664|CGP-48664|SAM 486A|SARDOMOZIDE	A methylglyoxal-bis(guanylhydrazone) (MGBG) derivative with potential antineoplastic and antiviral properties. Sardomozide selectively binds to and inhibits S-adenosylmethionine decarboxylase (SAMDC), an enzyme essential for the biosynthesis of polyamines, such as spermine and spermidine that bind to DNA and play critical roles in cell division, cell differentiation and membrane function. By inhibiting SAMDC, sardomozide reduces the intracellular polyamine concentration, thereby interfering with cell growth and differentiation. In addition, this agent also exhibits anti-HIV effect via suppressing expression of eukaryotic translation initiation factor 5A (eIF-5A), which is essential for retroviral replication.			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C167400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167400>	C173482	Pet is in Pain Question|My pet is in pain|Pet is in Pain|pain_34a22c	A question about whether an individual's pet is in pain.			Intellectual Product	Canine Quality of Life Survey|ICDC Terminology|PRECINCT Property Terminology
C167401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167401>	C173482	Pet Pants Frequently, Even at Rest Question|My pet pants frequently, even at rest|Pet Pants Frequently, Even at Rest|pants	A question about whether an individual's pet pants frequentky, even at rest.			Intellectual Product	Canine Quality of Life Survey|ICDC Terminology|PRECINCT Property Terminology
C167402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167402>	C173482	Pet Shakes or Trembles Occasionally Question|My pet shakes or trembles occasionally|Pet Shakes or Trembles Occasionally|trembles	A question about whether an individual's pet shakes or trembles occasionally.			Intellectual Product	Canine Quality of Life Survey|ICDC Terminology|PRECINCT Property Terminology
C167403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167403>	C173482	Pet Eats Usual Amount of Food Question|My pet eats the usual amount of food|Pet Eats Usual Amount of Food|eats	A question about whether an individual's pet eats their usual amount of food.			Intellectual Product	Canine Quality of Life Survey|ICDC Terminology|PRECINCT Property Terminology
C167404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167404>	C173482	Pet Acts Nauseous or Vomits Question|My pet acts nauseous or vomits|Pet Acts Nauseous or Vomits|vomits	A question about whether an individual's pet acts nauseous or vomits.			Intellectual Product	Canine Quality of Life Survey|ICDC Terminology|PRECINCT Property Terminology
C167405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167405>	C54443	ACC/AHA EHR Terminology|American College of Cardiology/American Heart Association EHR Terminology|American College of Cardiology/American Heart Association Electronic Health Records Terminology	Terminology used in support of the American College of Cardiology (ACC)/American Heart Association's (AHA) efforts to collect key elements pertaining to clinical data obtained from electronic health records.			Intellectual Product	
C167406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167406>	C173482	Pet Keeps Itself Clean Question|My pet keeps him/herself clean|Pet Keeps Itself Clean|keep_clean	A question about whether an individual's pet keeps itself clean.			Intellectual Product	Canine Quality of Life Survey|ICDC Terminology|PRECINCT Property Terminology
C167407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167407>	C173482	Pet Eats Treats or Snacks Question|My pet eats treats/snacks|Pet Eats Treats or Snacks|eats_treats	A question about whether an individual's pet eats treats or snacks.			Intellectual Product	Canine Quality of Life Survey|ICDC Terminology|PRECINCT Property Terminology
C167409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167409>	C167405	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|ACC/AHA PCC EHR Terminology|American College of Cardiology/American Heart Association Pediatric and Congenital Cardiology Electronic Health Records Terminology|American College of Cardiology/American Heart Association Pediatric and Congenital Cardiology Terminology|PCC	Terminology used in support of the American College of Cardiology (ACC)/American Heart Association's (AHA) efforts to collect key elements pertaining to clinical data obtained from electronic health records with a focus on pediatric and congenital cardiology.			Intellectual Product	ACC/AHA EHR Terminology
C16740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16740>	C199143	Institute of Medicine|NAS/IOM	As part of the National Academy of Science, identifies, for study and analysis, important issues and problems that relate to health and medicine. The Institute initiates and conducts studies of national policy and planning for health care and health-related education and research; it also responds to requests from the federal government and other agencies for studies and advice.			Health Care Related Organization	
C167412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167412>	C173482	Pet Smells Like Urine or Has Skin Irritation Question|My pet smells like urine or has skin irritation|Pet Smells Like Urine or Has Skin Irritation|smells_irritation	A question about whether an individual's pet smells like urine or has skin irritation.			Intellectual Product	Canine Quality of Life Survey|ICDC Terminology|PRECINCT Property Terminology
C167413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167413>	C173482	Pet's Hair is Greasy, Matted, Rough Looking Question|My pet's hair is greasy, matted, rough looking|Pet's Hair is Greasy, Matted, Rough Looking|hair	A question about whether an individual's pet has greasy, matted, or rough looking  hair.			Intellectual Product	Canine Quality of Life Survey|ICDC Terminology|PRECINCT Property Terminology
C167414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167414>	C173482	Pet Drinks Adequately Question|My pet drinks adequately|Pet Drinks Adequately|drinks	A question about whether an individual's pet drinks adequately.			Intellectual Product	Canine Quality of Life Survey|ICDC Terminology|PRECINCT Property Terminology
C167415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167415>	C124351	Abdominal Examination|Examination of the Abdomen	An assessment of the abdomen including the organs within the abdominal cavity.			Diagnostic Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C167416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167416>	C82547	Abnormal Cardiac Study	A history of having had an abnormal cardiac study.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C167417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167417>	C226696	No Known Allergy	A response indicating that an individual has no known allergies.			Intellectual Product	
C167418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167418>	C156293	Recurrent High Risk Chronic Myelomonocytic Leukemia	The reemergence of high risk chronic myelomonocytic leukemia after a period of remission.	Recurrent High Risk Chronic Myelomonocytic Leukemia		Finding	CTRP Disease Terminology|CTRP Terminology
C167419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167419>	C156293	Refractory High Risk Chronic Myelomonocytic Leukemia	High risk chronic myelomonocytic leukemia that does not respond to treatment.	Refractory High Risk Chronic Myelomonocytic Leukemia		Finding	CTRP Disease Terminology|CTRP Terminology
C16741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16741>	C199143	Institutional Review Board|Human Subjects Protection Review Board|Human Subjects Protection and Institutional Review Board|IRB|IRB|IRB|Institutional Review Board (IRB)|committee for the protection of human subjects|independent ethics committee|independent review board|institutional review board (IRB)	A specially constituted independent review body comprised of medical, scientific and non-scientific members established and designated by an entity to ensure the protection of the rights, safety and well-being of human subjects recruited to participate in biomedical or behavioral research according to the requirements outlined in Title 38, part 16 (same as Title 45, part 46 and Title 21, part 56) of the U.S. Code of Federal Regulations. IRB responsibilities include reviewing, approving, and providing continuing review of trial protocol and amendments and of the methods and material(s) to be used in obtaining and documenting informed consent of the trial. Other equivalent committees with the same or similar functions are also considered to be IRBs.			Health Care Related Organization	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C167420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167420>	C173482	Pet Has Diarrhea Question|My pet has diarrhea|Pet Has Diarrhea|diarrhea_8303fd	A question about whether an individual's pet has diarrhea.			Intellectual Product	Canine Quality of Life Survey|ICDC Terminology|PRECINCT Property Terminology
C167421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167421>	C173482	Pet is Urinating a Normal Amount Question|My pet is urinating a normal amount|Pet is Urinating a Normal Amount|urinating	A question about whether an individual's pet is urinating a normal amount.			Intellectual Product	Canine Quality of Life Survey|ICDC Terminology|PRECINCT Property Terminology
C167422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167422>	C173482	Pet Moves Normally Question|My pet moves normally|Pet Moves Normally|moves	A question about whether an individual's pet moves normally.			Intellectual Product	Canine Quality of Life Survey|ICDC Terminology|PRECINCT Property Terminology
C167423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167423>	C38665	Chest Pain Along Anterior Axillary Line|Anterior axillary line	The location of the chest pain is along an imaginary vertical line that descends along the lateral aspect of the chest wall originating from the armpit.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C167424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167424>	C38665	Chest Pain Along Sternal Border|Sternal Border	The location of the chest pain is along the lateral edge of the sternum.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C167425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167425>	C38665	Chest Pain Along Midclavicular Line|Midclavicular line	The location of the chest pain is along an imaginary vertical line on the chest originating from the midpoint of a clavicle.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C167426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167426>	C38665	Chest Pain in Intercostal Space|Intercostal space	The location of the chest pain is in the area defined by a superior rib margin and an inferior rib margin.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C167427	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167427>	C38665	Chest Pain in Sternum|Sternum	The location of the chest pain is in the middle of the anterior wall of the thorax, bounded by the clavicles, above, and with the cartilages of the first seven ribs, along the sides.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C167428	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167428>	C173482	Pet Lays in One Place All Day Question|My pet lays in one place all day long|Pet Lays in One Place All Day|lays	A question about whether an individual's pet lays in one place all day.			Intellectual Product	Canine Quality of Life Survey|ICDC Terminology|PRECINCT Property Terminology
C167429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167429>	C173482	Pet is as Active as it Has Been Question|My pet is as active a he/she has been|Pet is as Active as it Has Been|active	A question about whether an individual's pet is as active as it has been.			Intellectual Product	Canine Quality of Life Survey|ICDC Terminology|PRECINCT Property Terminology
C16742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16742>	C19238	Instrumentation|Instrument	Any object, or item of electrical or electronic equipment, which is designed to carry out a specific function or set of functions.			Manufactured Object	
C167430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167430>	C173482	Pet's General Health Compared to Last Evaluation Question|General health compared to last evaluation|Pet's General Health Compared to Last Evaluation|last_evaluation	A question about a pet's current general health as compared to its last evaluation.			Intellectual Product	Canine Quality of Life Survey|ICDC Terminology|PRECINCT Property Terminology
C167431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167431>	C173482	Pet's General Health Compared to Initial Diagnosis of Cancer Question|General health compared to initial diagnosis of cancer|Pet's General Health Compared to Initial Diagnosis of Cancer|initial_dianosis	A question about a pet's current general health as compared to its health at initial diagnosis of cancer.			Intellectual Product	Canine Quality of Life Survey|ICDC Terminology|PRECINCT Property Terminology
C167432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167432>	C173482	Pet's Current Quality of Life Question|Current Quality of Life|Pet's Current Quality of Life|current_qol	A question about a pet's quality of life.			Intellectual Product	Canine Quality of Life Survey|ICDC Terminology|PRECINCT Property Terminology
C167433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167433>	C36289	Plasma Cell Neoplasm Finding	A term that refers to clinicopathologic findings related to plasma cell neoplasms.			Finding	
C167434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167434>	C36289|C173902	Myeloid Neoplasm Finding	A term that refers to clinicopathologic findings related to myeloid neoplasms.			Finding	
C167435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167435>	C36289|C173902	Leukemia Finding	A term that refers to clinicopathologic findings related to leukemias.	Leukemia Finding		Finding	CTRP Disease Terminology|CTRP Terminology
C167436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167436>	C35552	Heart Murmur Categorized by Duration|Cardiac Examination – Heart Sounds, Systolic Murmur Types	The classification of a heart murmur based on its duration.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C167437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167437>	C167438	Systolic Heart Murmur|Systolic|Systolic|Systolic Murmur	A heart murmur that occurs during ventricular ejection, while the semilunar valves are open.			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|Appendix 6: Symptoms and Signs Terminology|Physical Examination Terminology
C167438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167438>	C35552	Heart Murmur Categorized by Phase or Timing|Cardiac Examination – Heart Sounds, Phase of Murmur|Heart murmur timing	The classification of a heart murmur based on the phase of the cardiac cycle or timing of its occurrence.			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|Appendix 6: Symptoms and Signs Terminology|Physical Examination Terminology
C167439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167439>	C35552	Heart Murmur Categorized by Quality|Cardiac Examination – Heart Sounds, Murmurs, Characteristic	The classification of a heart murmur based on its characteristic quality.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16743>	C20442	Insulin-Like Growth Factor I|IGF I|IGF-1|IGF-I|IGF1|Insulin-Like Growth Factor 1|Insulin-Like Growth Factor-I|MGF|Mechano Growth Factor|Somatomedin C|Somatomedin-C	Insulin-like growth factor I (195 aa, ~22 kDa) is encoded by the human IGF1 gene. This protein may be involved in the regulation of glucose metabolism.	Insulin-Like Growth Factor I		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167440>	C167437	Early Systolic Heart Murmur|Early Systolic Murmur|Early systolic	A heart murmur that occurs during the early portion of the ventricular ejection phase.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C167441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167441>	C167437	Ejection Systolic Heart Murmur|Ejection Systolic Murmur|Ejection systolic murmur	A heart murmur that occurs predominantly in midsystole, when ejection volume and velocity of blood flow are at their maximum; it is produced by ejection of blood into the pulmonary artery and aorta. It is typically crescendo-decrescendo.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C167442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167442>	C167437	Late Systolic Heart Murmur|Late Systolic Murmur|Late systolic	A heart murmur that occurs during the last half of the ventricular ejection phase. This may or may not extend to the second heart sound.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C167443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167443>	C167437	Midsystolic Heart Murmur|Mid-systolic Murmur|Midsystolic|Midsystolic Murmur	A heart murmur that occurs during the middle portion of the ventricular ejection phase.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C167444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167444>	C167437	Pansystolic Heart Murmur|Holosystolic Heart Murmur|Holosystolic Murmur|Pansystolic Murmur|Pansystolic/holosystolic	A heart murmur that occurs during the entire systolic interval, from the first to second heart sounds.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C167445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167445>	C167438	Diastolic Heart Murmur|Diastolic|Diastolic|Diastolic Murmur	A heart murmur that occurs between ventricular ejection, while the semilunar valves are closed.			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|Appendix 6: Symptoms and Signs Terminology|Physical Examination Terminology
C167446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167446>	C167438	Continuous Heart Murmur|Continuous|Continuous Murmur	A heart murmur that occurs throughout both systole and diastole.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C167447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167447>	C36289	Lymphoma Finding	A term that refers to clinicopathologic findings related to lymphomas.			Finding	
C167448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167448>	C17726	Family Surgical History				Clinical Attribute	
C167449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167449>	C17726	Family History of Heart Disease	A history of a first-degree relative with heart disease.			Group Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16744>	C20442	Insulin-Like Growth Factor II|IGF-2|IGF-II|IGF2|Insulin-Like Growth Factor 2|Somatomedin A|Somatomedin-A	Insulin-like growth factor II (180 aa, ~20 kDa) is encoded by the human IGF2 gene. This protein plays a role in cellular growth, development, and mitogenesis.	Insulin-Like Growth Factor II		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167450>	C35552	Heart Sound|Cardiac Examination – Heart Sounds	Auditory vibrations of varying intensity (loudness), frequency (pitch), quality, and duration noted during auscultation of the thorax as part of the examination of the cardiovascular system. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C167451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167451>	C198359	Genitalia Examination|Examination of the Genitalia	An assessment of the genitalia.			Diagnostic Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C167452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167452>	C167450	Heart Sound Categorized by Grade|Cardiac Examination – Heart Sounds, Grade	The classification of a heart sound based on its intensity.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C167453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167453>	C167450	Heart Sound Categorized by Pitch|Cardiac Examination – Heart Sounds, Pitch	The classification of a heart sound based on its frequency.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C167454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167454>	C84480	Innocent Murmur|Innocent murmur	A clinical finding in which turbulent flow is noted by auscultation that is not associated with any structural cardiac defects. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C167455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167455>	C225397|C173902	High Risk Multiple Myeloma|High Risk Plasma Cell Myeloma|High Risk Plasma Cell Myeloma	A term that refers to clinicopathologic, cytogenetic, and molecular findings that define a myeloma as high risk. They include: ISS (International Staging System) stage III, elevated LDH, t(4;14), del(17/17p), t(14;16), t(14;20), hypodiploidy, gain(1q), and gene expression profile with high risk signature in which several genes are mapped to chromosome 1(q) and (1p).	High Risk Plasma Cell Myeloma		Finding	CTRP Disease Terminology|CTRP Terminology
C167456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167456>	C78238	Musculoskeletal Chest Pain due to Myositis|Musculoskeletal chest pain due to myositis	A condition in which there is musculoskeletal chest pain secondary to inflammation of the muscle tissue. (ACC/AHA)			Sign or Symptom	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C167457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167457>	C78238	Psychogenic Musculoskeletal Chest Pain|Musculoskeletal chest pain: psychogenic	A condition in which there is the sensation of musculoskeletal chest pain due to a conversion disorder. (ACC/AHA)			Sign or Symptom	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16745	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16745>	C115464	Insurance	A mechanism for guarding against financial aspects of risk by making payments in the form of premiums to an insurance company, which pays an agreed-upon sum to the insured in the event of loss.			Intellectual Product	
C16746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16746>	C70680	Health Insurance Reimbursement|Insurance, Health, Reimbursement|Third Party Payment	Money paid out by an insurance company to an individual, or their designated recipient, for covered medical expenses.			Health Care Activity	
C167478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167478>	C38665	No Radiating Chest Pain|None	An indication that the chest pain dose not radiate.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C167479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167479>	C38665	Radiating Chest Pain Along Anterior Axillary Line|Anterior axillary line	The location of the radiating chest pain is along an imaginary vertical line that descends along the lateral aspect of the chest wall originating from the armpit.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16747>	C16837	Transmembrane Protein|Integral Membrane Protein|Intrinsic Membrane Protein	A protein that is an integral membrane protein with a transmembrane region.			Amino Acid, Peptide, or Protein|Receptor	
C167480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167480>	C38665	Radiating Chest Pain Along Midclavicular Line|Midclavicular line	The location of the radiating chest pain is along an imaginary vertical line on the chest originating from the midpoint of a clavicle.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C167481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167481>	C38665	Radiating Chest Pain Along Sternal Border|Sternal Border	The location of the radiating chest pain is along the lateral edge of the sternum.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C167482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167482>	C38665	Radiating Chest Pain in Abdomen|Abdomen	The location of the radiating chest pain is in the abdomen.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C167483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167483>	C38665	Radiating Chest Pain in Back|Back	The location of the radiating chest pain is in the back.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C167484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167484>	C38665	Radiating Chest Pain in Left Arm|Left arm	The location of the radiating chest pain is in the left arm.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C167485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167485>	C38665	Radiating Chest Pain in Neck|Neck	The location of the radiating chest pain is in the neck.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C167486	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167486>	C38665	Radiating Chest Pain in Sternum|Sternum	The location of the radiating chest pain is in the middle of the anterior wall of the thorax, bounded by the clavicles, above, and with the cartilages of the first seven ribs, along the sides.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C167487	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167487>	C38665	Radiating Chest Pain to Other Location|Other	An indication that the chest pain radiates to a location other than those listed.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C167488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167488>	C168319	Location of Radiating Chest Pain|Radiation of Chest Pain	The anatomic location of where one's chest pain radiates.			Diagnostic Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C167489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167489>	C167450	S1 Heart Sound|S1	An auscultated finding describing the heart sound that occurs with ventricular systole and is produced mainly by closure of the atrioventricular valves, signifying the first heart sound. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16748>	C21176	Integrin|Extracellular Matrix, Integrins|Integrin Receptor|RGD Receptor	Integrins are transmembrane glycoprotein receptors that mediate cell-matrix or cell-cell adhesion, and transduce signals that regulate gene expression and cell growth.  They are heterodimeric molecules consisting of noncovalently linked alpha and beta subunits. Different combinations of alpha and beta polypeptides form complexes that vary in their ligand-binding specificities. Both alpha and beta subunits display a cytoplasmic domain that interacts with the cytoskeleton (and possibly signaling molecules), a transmembrane region, and a large extracellular domain that interacts with the extracellular matrix. (from OMIM 147557)	Integrin		Amino Acid, Peptide, or Protein|Receptor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C167490	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C167490>	C167450	S2 Heart Sound|S2	An auscultated finding describing the heart sound that signifies the beginning of diastole and is caused by closure of the semilunar valves, signifying the second heart sound. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16749>	C17153	Internal Medicine|General Medicine|Medicine, Internal	A medical specialty concerned with the diagnosis of diseases of the internal organs and non-surgical treatments.			Biomedical Occupation or Discipline	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C1674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1674>	C496	Recombinant Fibroblast Growth Factor 2|Basic Fibroblast Growth Factor|FGF2|Fibroblast Growth Factor 2|HBGF-2|Prostatropin|bFGF	A recombinant therapeutic agent which is chemically identical to or similar to endogenous fibroblast growth factor 2 (FGF-2).  Reflecting its endogenous role, therapeutic FGF-2 exhibits a wide spectrum of biological activities, including the promotion of growth and differentiation in target cells, the regulation of hormone secretion, and the promotion of angiogenesis.  This agent's mitogenic effects on fibroblasts and endothelial cells indicates a potential role in therapeutic angiogenesis and wound healing.  In addition, therapeutic FGF-2 may stimulate neurogenesis and protect neurons against degeneration; FGF-2 supplementation via gene transfer may reduce neuronal degeneration in experimental animal models. (NCI04)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C16750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16750>	C16397	Interphase Process|Interphase	The interval between two successive cell divisions during which the chromosomes are not individually distinguishable. Interphase is considered the resting stage of the cell.			Cell Function	
C16751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16751>	C64255	Interview	A conversation with an individual regarding his or her background and other personal and professional details, opinions on specific subjects posed by the interviewer, etc.	Interview		Activity	CTRP Intervention Terminology|CTRP Terminology
C16752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16752>	C16946	Thyroid Peroxidase|EC 1.11.1.8|Iodide Peroxidase|Iodinase|Iodoperoxidase (Heme Type)|Iodotyrosine Deiodase|Iodotyrosine Deiodinase|Monoiodotyrosine Deiodinase|THYROID PEROXIDASE|TPO|TPO|Thyroperoxidase|Thyroperoxidase|Tyrosine Iodinase	Thyroid peroxidase (933 aa, ~103 kDa) is encoded by the human TPO gene. This protein plays a role in thyroid hormone synthesis.	Thyroid Peroxidase		Amino Acid, Peptide, or Protein|Enzyme	CDISC SDTM Binding Agent for Immunogenicity Tests Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C16753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16753>	C16754	Gated Ion Channel	An ion channel in which the ion transport is regulated by a specific stimulus of either a change in membrane potential or binding of a ligand. Once the stimulus occurs the channel may undergo conformational changes that allow selective permeability.			Cell Component	
C16754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16754>	C33904	Ion Channel	A transmembrane pore that presents a hydrophilic channel for ions to cross a lipid bilayer down their electrochemical gradients.  Some degree of ion specificity is usually observed and typically a million ions per second may flow. Channels may be permanently open, like the potassium leak channel or they may be voltage gated, like the sodium channel or ligand gated like the acetylcholine receptor.			Cell Component	
C16755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16755>	C25464	Iran, Islamic Republic of|364|IR|IRAN|IRAN|IRN|IRN|Iran|Iran	A country in the Middle East, bordering the Gulf of Oman, the Persian Gulf, and the Caspian Sea, between Iraq and Pakistan.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16756>	C25464	Iraq|368|IQ|IRAQ|IRAQ|IRQ|IRQ	A country in the Middle East, bordering the Persian Gulf, between Iran and Syria.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16757>	C25464	Ireland|372|IE|IRELAND|IRELAND|IRL|IRL	A country in western Europe, occupying five-sixths of the island of Ireland in the North Atlantic Ocean, west of Great Britain.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16758>	C18091	Isoelectric Focusing|Fractionation, Isoelectric Focusing	A type of gel electrophoresis in which charged molecules travel through a pH gradient.  The molecules will come to stop at the point where the net charge on the molecule is equal to that of the surrounding gel.			Occupational Activity	
C16759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16759>	C16554	Isomerase|EC 5	An enzyme that transfers functional groups to catalyze the geometric or structural rearrangement of atoms within a given molecule to form an isomer of the original molecule.			Amino Acid, Peptide, or Protein|Enzyme	
C1675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1675>	C1757	Tyrphostin B46|AG 555	A potent inhibitor of epidermal growth factor receptor kinase autophosphorylation. (NCI)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C16760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16760>	C25464	Israel|376|IL|ISR|ISR|ISRAEL|ISRAEL	A country in the Middle East, bordering the Mediterranean Sea, between Egypt and Lebanon.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF1 Registration Table|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16761>	C25464	Italy|380|IT|ITA|ITA|ITALY|ITALY	A country in southern Europe, occupying a peninsula extending into the central Mediterranean Sea, northeast of Tunisia.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16762>	C25464	Cote d'Ivoire|384|CI|CIV|CIV|COTE D'IVOIRE|CÔTE D'IVOIRE|Côte d'Ivoire|Ivory Coast	A country in western Africa, bordering the North Atlantic Ocean, between Ghana and Liberia.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16763>	C25464	Jamaica|388|JAM|JAM|JAMAICA|JAMAICA|JM	An island in the Caribbean Sea, south of Cuba, between the Cayman Islands and Haiti.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16764>	C25464	Japan|392|JAPAN|JAPAN|JP|JPN|JPN	A country in eastern Asia, occupying an island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF1 Registration Table|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16765>	C25464	Jordan|400|JO|JOR|JOR|JORDAN|JORDAN	A country in the Middle East, northwest of Saudi Arabia.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16766>	C17061	Oncogene K-Ras|KRAS|KRAS2|Ki-RAS|Oncogene, K-Ras|Oncogene, K-Ras-2|RASK2|v-Ki-RAS2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog	Human Oncogene K-Ras is a mutated variant of KRAS2 Gene, which encodes two alternative isoforms of monomeric p21 K-RAS protein, a monomeric GTPase involved in transmembrane signal transduction that alternates between inactive GDP-bound and active GTP-bound forms. K-Ras is activated by a guanine nucleotide-exchange factor and inactivated by a GTPase-activating protein. Mitogen-stimulated RAS stabilizes MYC protein and enhances MYC accumulation by the RAS/RAF/MAPK pathway, which appears to inhibit the proteasome-dependent degradation of MYC. Implicated in a variety of human tumors, mutations of specific amino acids activate RAS to transform cells. KRAS is involved in malignancy much more often than is HRAS. Oncogene K-Ras disrupts normal cell function.	Oncogene K-Ras		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C16767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16767>	C20130	Kallikrein|Human Glandular Kallikrein|KLK|Kallikrein Enzyme Family|Kallikrein-Related Peptidase	Serine proteases that are found in many different tissues and fluids in the body. The kallikrein protease family is comprised of potent vasodilators and hypotensives agents, thus they play important roles in inflammation and blood pressure. These enzymes normally reside in the body as inactive prekallikreins, which are activated by Hageman factor.			Amino Acid, Peptide, or Protein|Enzyme	
C16768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16768>	C18280	Karyotyping|Genetics, Karyotyping|KARYOTYPING|Karotype Analysis|Karyotype	The preparation, analysis, and interpretation of a karyotype, the representation of the chromosome set of a cell.			Laboratory Procedure	AML Authorized Value Terminology|AML Molecular Analysis Table|CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GCT Authorized Value Terminology|GCT Molecular Analysis Table|GDC Terminology|GDC Value Terminology
C16769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16769>	C25464	Kenya|404|KE|KEN|KEN|KENYA|KENYA	A country in eastern Africa, bordering the Indian Ocean, between Somalia and Tanzania.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C1676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1676>	C67421	Curacin B	The B isomer of Curacin compound.  Cruacin B inhibits tubulin polymerization, thereby inhibiting mitosis and cell proliferation. (NCI)			Organic Chemical|Pharmacologic Substance	
C16770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16770>	C16989	Kinetics	Kinetics is the branch of mechanics concerned with the forces that cause motions of bodies and govern the rates at which molecules and compounds react.			Occupation or Discipline	
C16771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16771>	C25464	Kyrgyzstan|417|KG|KGZ|KGZ|KYRGYZSTAN|KYRGYZSTAN	A country in central Asia, between southern Kazakhstan and western China.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16772>	C19291	Knowledge, Attitudes, Behaviors	The consideration of knowledge, attitude, or behavior as variables in disease processes such as incident, transmission, and control.			Functional Concept	
C16773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16773>	C25464	Korea, Democratic People's Republic of|408|KOREA, DEMOCRATIC PEOPLE'S REPUBLIC OF|KOREA, NORTH|KP|NORTH KOREA|North Korea|North Korea|PRK|PRK	A country in eastern Asia, occupying the northern half of the Korean Peninsula, bordering the Korea Bay and the Sea of Japan, between China and South Korea.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16774>	C25464	Korea, Republic of|410|KOR|KOR|KOREA, REPUBLIC OF|KOREA, SOUTH|KR|Republic of Korea|SOUTH KOREA|South Korea|South Korea	A country in eastern Asia, occupying the southern half of the Korean Peninsula, bordering the Sea of Japan and the Yellow Sea.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16775>	C25464	Kuwait|414|KUWAIT|KUWAIT|KW|KWT|KWT	A country in the Middle East, bordering the Persian Gulf, between Iraq and Saudi Arabia.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16776>	C17187	Laboratory Animal Science	The science and technology concerned with the procurement, selection, health and welfare of animals used in research and testing.			Biomedical Occupation or Discipline	
C16777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16777>	C17661	LacZ Gene|LacZ	The lacZ gene is a popular reporter gene in transfection experiments because its product, b-galactosidase, is very stable, resistant to proteolytic degradation, and easily assayed.			Gene or Genome	
C16778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16778>	C20130	Laminin	A family of basement membrane extracellular basement proteins. Each molecule is composed of 3 nonidentical chains which are arranged in a cross-shaped structure. There are at least 5 alpha, 4 beta, and 3 gamma laminin genes.	Laminin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C16779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16779>	C20181	Language|Language Name	A systematic means of communicating by the use of sounds, symbols, or gestures.			Language	
C1677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1677>	C67421	Curacin C	The C isomer of Curacin compound.  Cruacin C inhibits tubulin polymerization, thereby inhibiting mitosis and cell proliferation. (NCI)			Organic Chemical|Pharmacologic Substance	
C16780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16780>	C25464	Lao People's Democratic Republic|418|LA|LAO|LAO|LAO PEOPLE'S DEMOCRATIC REPUBLIC|LAOS|Laos|Laos	A country in southeastern Asia, north and east of Thailand, west of Vietnam.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16781>	C16546	Laryngoscopy|laryngoscopy	Endoscopic examination of the larynx.			Diagnostic Procedure	
C16782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16782>	C50026|C16830	Laser|Electromagnetic, Laser|Radiation, Laser|laser	An acronym for light amplification by stimulated emission of radiation; an optical device that produces an intense monochromatic beam of coherent light.			Manufactured Object	
C16783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16783>	C25464	Latvia|428|LATVIA|LATVIA|LV|LVA|LVA	A country in eastern Europe, bordering the Baltic Sea, between Estonia and Lithuania.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16784>	C25464	Lebanon|422|LB|LBN|LBN|LEBANON|LEBANON	A country in the Middle East, bordering the Mediterranean Sea, between Israel and Syria.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF1 Registration Table|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16785>	C20130	Lectin|lectin	Proteins that specifically bind to the branching sugar molecules of glycoproteins and glycolipids on cell surfaces to cause biochemical changes. They are often classified according to either the saccharide or sugar specificity.			Amino Acid, Peptide, or Protein|Immunologic Factor	
C16786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16786>	C17143	Law|Law Profession	The learned profession that is mastered by graduate study in a law school and that is responsible for the judicial system.			Occupation or Discipline	
C16787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16787>	C25464	Lesotho|426|LESOTHO|LESOTHO|LS|LSO|LSO	A country in southern Africa, an enclave of South Africa.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16788>	C19996	LD-50|LC-50|LC50|LD50|Lethal Dose - 50%|Median Lethal Dose	The dose of a chemical or biologic preparation (e.g., a bacterial exotoxin or a suspension of bacteria) that is likely to cause death in 50% of the animals being tested; it varies in relation to the type of animal and the route of administration; (the absolute lethal dose is LD100, and minimal lethal dose is LD05).			Quantitative Concept	
C16789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16789>	C16393	Integrin Alpha-X|Alphax Integrin Chain|Antigen Cd11c (P150), Alpha Polypeptide|Axb2|CD11 Antigen-Like Family Member C|CD11c|Cr4|ITGAX|Integrin Alpha X|Leu M5|Leukocyte Adhesion Glycoprotein P150,95, Alpha Chain|Leukocyte Adhesion Receptor P150,95|Leukocyte Surface Antigen P150, 95|Myeloid Membrane Antigen, Alpha Subunit|p150 95 Integrin Alpha Chain	Integrin alpha-X (1163 aa, ~128 kDa) is encoded by the human ITGAX gene. This protein is involved in cell-matrix interactions and integrin signaling.	Integrin Alpha-X		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C1678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1678>	C67421	Curacin A	The A isomer of Curacin compound.  Cruacin A inhibits tubulin polymerization, thereby inhibiting mitosis and cell proliferation. (NCI)			Organic Chemical|Pharmacologic Substance	
C16790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16790>	C210735	Mixed Lymphocyte Reaction Test|MLR|Mixed Leukocyte Reaction|Mixed Lymphocyte Culture|Mixed Lymphocyte Reaction|Mixed Lymphocyte Reaction|Mixed T Cells, B Cells	An assay that measures the proliferative response of lymphocytes from one individual when they are exposed to inactivated lymphocytes from another individual. The reaction can be performed on lymphocytes from the same individual (auto-MLR), from different individuals of the same species (allo-MLR), or individuals from different species (xeno-MLR). It is used to evaluate the potential for graft-versus-host or host-versus-graft reactions during transplantation procedures involving mismatched tissue types or individuals.			Laboratory Procedure	CDISC SDTM Laboratory Test Code Terminology|CDISC SDTM Laboratory Test Name Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16791>	C25464	Liberia|430|LBR|LBR|LIBERIA|LIBERIA|LR	A country in western Africa, bordering the North Atlantic Ocean, between Cote d'Ivoire and Sierra Leone.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16792>	C16733	Library Science	The principles, practice, or study of library administration.			Occupation or Discipline	
C16793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16793>	C25464	Libya|434|LBY|LBY|LIBYA|LIBYA|LY|Libyan Arab Jamahiriya	A country in northern Africa, bordering the Mediterranean Sea, between Egypt and Algeria.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16794>	C25464	Liechtenstein|438|LI|LIE|LIE|LIECHTENSTEIN|LIECHTENSTEIN	A country in central Europe, between Austria and Switzerland.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16795>	C16326	Lifestyle	A manner of living that reflects the person's values and attitudes.			Social Behavior	
C16796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16796>	C16554	Ligase|EC 6	Major class of enzymes that catalyze the linking together of two molecules (EC class 6) for example DNA ligases that link two fragments of DNA by forming a phosphodiester bond.			Amino Acid, Peptide, or Protein|Enzyme	
C16797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16797>	C19770	Genetic Linkage Analysis|Linkage Analysis|linkage analysis	The process of measuring the extent of crossovers between chromosomes as a gauge of the distance between genes.	Genetic Linkage Analysis		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C16798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16798>	C19896	Linkage Disequilibrium|LD|linkage disequilibrium	Nonrandom association of linked genes; the occurrence of some genes together, more often than would be expected based upon their physical separation, presumably because the combination confers some selective advantage.			Quantitative Concept	
C16799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16799>	C25464	Lithuania|440|LITHUANIA|LITHUANIA|LT|LTU|LTU	A country in eastern Europe, bordering the Baltic Sea, between Latvia and Russia.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C1679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1679>	C2843	Exatecan Mesylate|10H,13H-Benzo(de)pyrano(3'm4':6,7)indolizino(1,2-b)quinoline-10,13-dione, 1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-, (1S-trans)-, Methanesulfonate (1:1) (Salt), Dihydrate|DX-8951f|DX-8951f|EXATECAN MESYLATE|Exatecan Mesylate Dihydrate|Exatecan Mesylate Hydrate|exatecan mesylate	A semisynthetic, water-soluble derivative of camptothecin with antineoplastic activity. Exatecan mesylate inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA and inhibiting religation of DNA breaks, thereby inhibiting DNA replication and triggering apoptotic cell death. This agent does not require enzymatic activation and exhibits greater potency than camptothecin and other camptothecin analogues. (NCI04)			Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C16800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16800>	C54154	LOD Score|LOD score|logarithm of the odd score	The statistical probability that two genetic loci are likely to be inherited together.			Quantitative Concept	
C168016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168016>	C167449	Family History of Cardiomyopathy|Cardiomyopathy	A history of a first-degree relative that was diagnosed with cardiomyopathy.			Group Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168017>	C167449	Family History of Congenital Heart Disease|Family History of CHD|Family history of CHD	A history of a first-degree relative with congenital heart disease.			Group Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168018>	C167449	Family History of Long QTc|Long QTc	A history of a first-degree relative that was diagnosed with prolongation of the heart rate corrected QT interval as calculated by the Bazett formula.			Group Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168019>	C167449	Family History of Sudden Arrythmia Death Syndrome|Family History of SADS|Family History of Sudden Arrhythmic Death Syndrome|SADS	A history of a first-degree relative whose death was attributed to sudden arrythmia death syndrome (SADS).			Group Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16801>	C19155	Long-Term Care for Elderly	Long-term care encompasses a broad range of help with daily activities that chronically disabled individuals need for a prolonged period of time.			Health Care Activity	
C168020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168020>	C167448	Family History of Coronary Artery Bypass Graft Surgery|CABG|Family History of CABG	A history of a first-degree relative that has had coronary artery bypass graft surgery.			Clinical Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168021>	C167448	Family History of Percutaneous Coronary Intervention|Family History of PCI|PCI	A history of a first-degree relative that has had a percutaneous coronary intervention.			Clinical Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168022>	C167451|C124596	External Genitalia Examination|Genital Examination – External Genitalia	An assessment of the external genitalia.			Diagnostic Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168023>	C167450	Opening Snap|Opening snap	An auscultated finding describing a crisp, sharp sound that can be heard in the midprecordial location, caused by thickening and deformity of the atrioventricular valve. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168024>	C167450	Pericardial Knock|Knock	An auscultated finding describing an early diastolic banging sound associated with pericardial constriction. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168025>	C167450	Pericardial Rub|Rub|Rub	An auscultated finding describing high or medium pitched and scratchy sound, generated by inflammation of the pericardial sac. (ACC/AHA)			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|Appendix 6: Symptoms and Signs Terminology|Physical Examination Terminology
C168026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168026>	C167450	S4 Heart Sound|Fourth heart sound (S4)|S4	An auscultated finding that describes a low-frequency sound, heard late in diastole just before S1, caused by forceful atrial contractions, signifying the fourth heart sound. It is typically abnormal, except in highly trained athletes and the elderly. (ACC/AHA)			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|Appendix 6: Symptoms and Signs Terminology|Physical Examination Terminology
C168027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168027>	C167450	Summation Gallop|Gallop rhythm|Summation gallop	An auscultated finding in which S3 and S4 fuse, during tachycardia or a prolonged PR interval or both. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168028>	C167450	Systolic Click|Systolic click	An auscultated finding describing a sharp, high-frequency sound heard during auscultation of the thorax caused by valvular prolapse or stenosis. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168029>	C167450	Systolic Whoop|Whoop	An auscultated finding describing a loud musical or sonorous vibratory systolic murmur that may be heard in patients with atrioventricular valve prolapse. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16802>	C20158	Luciferase|Immunologic, Luciferase	An enzyme first isolated from firefly tails that catalyzes the production of light in the reaction between luciferin and ATP.			Amino Acid, Peptide, or Protein|Enzyme	
C168030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168030>	C167452	Grade I Heart Sound|Grade I	A heart sound that is very soft or intermittently heard.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168031>	C167452	Grade II Heart Sound|Grade II	A heart sound that is as loud as the breath sounds.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168032>	C167452	Grade III Heart Sound|Grade III	A heart sound that is louder than breath sounds.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168033>	C167452	Grade IV Heart Sound|Grade IV	A heart sound that is louder than breath sounds in the presence of a palpated thrill.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168034>	C167452	Grade V Heart Sound|Grade V	A heart sound that can be auscultated with the stethoscope on a 45-degree angle or on its side in the presence of a palpated thrill.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168035>	C167452	Grade VI Heart Sound|Grade VI	A heart sound that can be auscultated with the stethoscope off of the chest wall or with the naked ear.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168036>	C167453	High Frequency Heart Sound|High frequency	A heart sound that can be auscultated only with the diaphragm of the stethoscope.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168037>	C167453	Low Frequency Heart Sound|Low frequency	A heart sound that can only be auscultated with the bell of the stethoscope.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168038>	C167453	Medium Frequency Heart Sound|Medium frequency	A heart sound that can be auscultated with both the diaphragm and the bell of the stethoscope.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168039>	C167454	Carotid Bruit|Carotid bruit	An innocent murmur with a medium pitched, harsh character heard at the right or left upper sternal border, supraclavicular region, or anterior portion of the lower neck that disappears with bilateral shoulder hyperextension. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16803>	C25464	Luxembourg|442|LU|LUX|LUX|LUXEMBOURG|LUXEMBOURG	A country in western Europe, between France, Belgium, and Germany.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C168040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168040>	C167454	Innocent Pulmonary Systolic Murmur|Innocent pulmonary systolic murmur	An innocent murmur with a medium pitched, harsh character heard at the left middle and left upper sternal border that disappears with upright position. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168041>	C167454	Mammary Souffle|Mammary souffle	An innocent murmur with a medium or high pitched, blowing character with continuous flow with systolic accentuation heard over or above the breasts that disappears with compression of the breast tissue. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168042>	C167454	Physiologic Pulmonary Artery Stenosis Murmur|Physiologic pulmonary artery stenosis	An innocent murmur with a medium or high pitched, blowing character heard at the left middle sternal border that can also be heard at the same volume across the precordium and back that does not disappear with maneuvers but is only heard in infants less than six months of age. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168043>	C167454	Still's Murmur|Still's murmur	An innocent murmur with a medium pitched, vibratory character heard at the apex, left lower sternal border, left middle sternal border, and right upper sternal border that disappears or becomes quieter and localizes to the left lower sternal border on upright position. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168044>	C167454	Venous Hum|Venous hum	An innocent murmur with a medium pitched, blowing character with diastolic accentuation heard at the right or left upper sternal border that disappears with jugular venous compression or supine position. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168045>	C167456	Musculoskeletal Chest Pain due to Epidemic Myalgia|Musculoskeletal Chest Pain due to Bornholm Disease|Musculoskeletal Chest Pain due to Epidemic Pleurodynia|Musculoskeletal chest pain due to Bornholm Disease|Musculoskeletal chest pain due to Enterovirus|Musculoskeletal chest pain due to epidemic myalgia|Musculoskeletal chest pain due to epidemic pleurodynia	A condition in which there is myositis secondary to an infectious etiology. (ACC/AHA)			Sign or Symptom	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168046>	C167457	Psychogenic Musculoskeletal Chest Pain with Dysfunctional Breathing|Musculoskeletal chest pain: psychogenic with dysfunctional breathing|Musculoskeletal chest pain: psychogenic with hyperventilation|Psychogenic Musculoskeletal Chest Pain with Hyperventilation	A condition in which there is musculoskeletal chest pain associated with inappropriate hyperpnea or tachypnea. (ACC/AHA)			Sign or Symptom	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168047>	C167479	Radiating Chest Pain Along Left Anterior Axillary Line	The location of the radiating chest pain is along the left anterior axillary line.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168048>	C167479	Radiating Chest Pain Along Right Anterior Axillary Line	The location of the radiating chest pain is along the right anterior axillary line.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168049>	C167480	Radiating Chest Pain Along Left Midclavicular Line	The location of the radiating chest pain is along the left midclavicular line.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16804>	C16554	Lyase|EC 4	Trivial name applied, together with dehydratase, to certain hydro-lyases (EC class 4.2.1) catalyzing hydration-dehydration.			Amino Acid, Peptide, or Protein|Enzyme	
C168050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168050>	C167480	Radiating Chest Pain Along Right Midclavicular Line	The location of the radiating chest pain is along the right midclavicular line.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168051>	C167481	Radiating Chest Pain Along Left Lower Sternal Border	The location of the radiating chest pain is along the left lower sternal border.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168052>	C167481	Radiating Chest Pain Along Left Middle Sternal Border	The location of the radiating chest pain is along the left middle sternal border.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168053>	C167481	Radiating Chest Pain Along Left Upper Sternal Border	The location of the radiating chest pain is along the left upper sternal border.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168054>	C167481	Radiating Chest Pain Along Right Lower Sternal Border	The location of the radiating chest pain is along the right lower sternal border.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168055>	C167481	Radiating Chest Pain Along Right Middle Sternal Border	The location of the radiating chest pain is along the right middle sternal border.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168056>	C167481	Radiating Chest Pain Along Right Upper Sternal Border	The location of the radiating chest pain is along the right upper sternal border.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168057>	C167486	Radiating Chest Pain in Lower Sternum	The location of the radiating chest pain is in the lower portion of the sternum.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168058>	C167486	Radiating Chest Pain in Mid Sternum	The location of the radiating chest pain is in the middle portion of the sternum.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168059>	C167486	Radiating Chest Pain in Upper Sternum	The location of the radiating chest pain is in the upper portion of the sternum.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16805>	C60727	Lymphangiogram|lymphangiogram	An x-ray image of the lymphatic system using a radiopaque imaging agent.			Laboratory or Test Result	HL Authorized Value Terminology|HL Lesion Characteristics Table
C168060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168060>	C167489	Abnormal S1 Heart Sound|Abnormal S1	An auscultated finding in which the components of the first heart sound are not normal. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168061>	C167489	Loud S1 Heart Sound|Loud S1	An auscultated finding in which the sounds comprising the first heart sound are louder than normal. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168062>	C167489	Normal Split S1 Heart Sound|Normally split S1	An auscultated finding in which there is appropriate splitting between the closure sounds of the atrioventricular valve.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168063>	C167489	Reverse Split S1 Heart Sound|Reverse split S1	An auscultated finding in which the tricuspid valve closure sound occurs before the mitral closure sound. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168064>	C167489	Single S1 Heart Sound|Single S1	An auscultated finding in which the atrioventricular valve closure sounds occur so close together as to sound single. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168065>	C167489	Soft S1 Heart Sound|Soft S1	An auscultated finding in which the sounds comprising the first heart sound are quieter than normal. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168066>	C167489	Widened S1 Heart Sound|Widened S1	An auscultated finding in which the mitral and tricuspid closure sounds are wider apart in time than normal. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168067>	C167490	Abnormal S2 Heart Sound|Abnormal S2	An auscultated finding in which the semilunar valve closure sounds are not normal. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168068>	C167490	Fixed Split S2 Heart Sound|Fixed split S2	An auscultated finding in which the semilunar valve closure sounds do not vary with respiration. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168069>	C167490	Loud P2 Heart Sound|Loud P2 (pulmonary component) of S2	An auscultated finding in which the pulmonary valve closure sound is louder than normal. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168070>	C167490	Normal Split S2 Heart Sound|Normally split S2	An auscultated finding in which the semilunar valve closure sounds occur close together without occurring simultaneously and vary with respiration. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168071>	C167490	Reverse Split S2 Heart Sound|Reverse split S2	An auscultated finding in which the pulmonic valve closure sound occurs prior to the aortic valve closure sound. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168072>	C167490	Single S2 Heart Sound|Single S2	An auscultated finding in which the semilunar valve closure sounds occur simultaneously. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168073>	C167490	Widely Split S2 Heart Sound|Widely split S2	An auscultated finding in which the semilunar valve closure sounds occur further apart in time than normal. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168074>	C83119	Abdominal Auscultation Finding|Abdominal Examination – Auscultation	A finding noted on auscultation of the abdomen.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168075>	C137852	Abdominal Palpation Finding|Abdominal Examination – Palpation	A finding noted on palpation of the abdomen.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168076>	C168189	Appearance of Extremities Assessment|Appearance of Extremities|Appearance of the Extremities|Examination of Extremities – Appearance	An assessment of the appearance of the upper and lower extremities.			Diagnostic Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168079>	C117719	Edematous Scrotum|Edematous scrotum	An indication that on visual inspection the scrotal skin is found to have become taut due to excessive fluid.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16807>	C25464	Macau|446|MAC|MAC|MACAO|MACAU|MO|Macao|Macao	A special administrative region of China, bordering the South China Sea, west of Hong Kong.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C168080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168080>	C20989	Extracardiac Examination	A physical examination focusing on areas of interest other than the heart.			Diagnostic Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168082>	C116518	Intervention for Rheumatic Fever	The type of treatment the patient received for rheumatic fever. (ACC/AHA)			Health Care Activity	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168083>	C36292	Kawasaki Disease Laboratory Finding|Laboratory Findings for Kawasaki Disease	The laboratory findings indicating diagnosis of Kawasaki disease. The criteria for incomplete Kawasaki disease are: 1) Elevated ESR or CRP 2) Sterile pyuria 3) Anemia 4) Decreased albumin 5) Elevated alanine aminotransferase 6) Leukocytosis 7) Thrombocytosis. (ACC/AHA)			Laboratory or Test Result	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168084>	C68741	Kawasaki Disease-Associated Coronary Artery Aneurysm Z-Score|Kawasaki Z-Score Classification	A classification used to quantify the risk for a coronary artery aneurysm in Kawasaki disease patients. Baseline dimensions of coronary arteries are adjusted for body surface area.			Quantitative Concept	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168085>	C20047	Minor Criteria for Rheumatic Heart Disease|Minor Criteria for Rheumatic Fever	The minor symptom criteria for rheumatic heart disease which include fever, arthralgia, elevated erythrocyte sedimentation rate (ESR), elevated C-reactive protein (CRP), elevated white blood cells (WBCs), and prolonged P-R interval.			Clinical Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168088>	C117719	Normal Male External Genitalia|Normal	An indication that on visual inspection the male external genitalia demonstrate no anomalies or abnormal findings.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168089>	C35552	Point of Maximum Impulse|PMI|PMI|Point of Maximal Impulse	A clinical finding demonstrating the pulsation associated with the contraction of the systemic ventricle. Typically associated with the apex of the heart. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16808>	C25464	Madagascar|450|MADAGASCAR|MADAGASCAR|MDG|MDG|MG	A country in southern Africa, occupying an island in the Indian Ocean, east of Mozambique.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C168093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168093>	C157742	Valve Replacement|Valve replacement	Surgery performed with the purpose of replacing a degenerated, calcified, malformed, dysfunctional, etc. cardiac valve with a bioprosthetic, homograft, or autograft valve.			Therapeutic or Preventive Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168094>	C159511	504 Plan|504 plan	Indicates that a person has been educated through a plan created under section 504 of the Rehabilitation Act which prohibits discrimination against individuals with disabilities and allows for accommodations for the child to be able to achieve academic success in primary or secondary school.			Organism Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168095>	C168074	Abdominal Bruit Present|Abdominal bruits	An indication that auscultation of the major arteries of the abdomen demonstrates the presence of turbulent vascular sounds.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168096>	C167415	Abdominal Visual Inspection|Abdominal Inspection|Visual Inspection of the Abdomen	A visual assessment of the abdomen.			Diagnostic Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168097>	C167416	Abnormal Cardiac Event Monitoring Finding|Abnormal Event Monitoring Finding|Event monitor	A history of having had an abnormal finding during cardiac event monitoring.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168098>	C174187	Abnormal Chest Radiograph|Abnormal Chest X-Ray|Chest x-ray|Patient_had_abnormal_chest_X-ray	A history of having had an abnormal chest radiograph.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|SeroNet Research Participant Metadata|SeroNet Variables
C168099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168099>	C174187|C167416	Abnormal Echocardiogram|Echocardiogram	A history of having had an abnormal echocardiogram.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16809>	C16502	Magnetic Resonance Imaging|MR|MR|MR Imaging|MRI|MRI|MRI|MRI|MRI|MRI|MRI Scan|MRI Scan|MRI Scan|MRI Scan|MRIs|Magnetic Resonance|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging Scan|Magnetic resonance imaging (procedure)|Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance|NMR Imaging|NMRI|NMRI|Nuclear Magnetic Resonance Imaging|Structural MRI|magnetic resonance imaging|nuclear magnetic resonance imaging|sMRI	Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders.	Magnetic Resonance Imaging		Diagnostic Procedure	ALL Adverse Events Table|ALL Authorized Value Terminology|CDISC MRCT Center Clinical Research Glossary|CDISC SDTM Method Terminology|CDISC SDTM Procedure Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF5 Response Evaluation Image Evaluation Table|CRF6 DIPG Imaging Assessment Table|CRF6 DMG Imaging Assessment Table|CTRP Intervention Terminology|CTRP Terminology|EWS Authorized Value Terminology|EWS Tumor Assessment Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Imaging Table|HL Lesion Characteristics Table|HL Subject Response Table|mCode Terminology|mCode Tumor Size Method Value Set|Operational Ontology for Radiation Oncology Prostate Cancer Terminology|OS Authorized Value Terminology|OS Tumor Assessment Table
C1680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1680>	C593	Iboctadekin|Human Interleukin-18 (Recombinant, Expressed in Escherichia coli)|Human Recombinant Interleukin-18|IBOCTADEKIN|IFN-Gamma-Inducing Factor|IL-18|Interferon-Gamma-Inducing Factor|Interleukin-18|Recombinant Interleukin-18|SB 485232|SB-485232	A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin-18 (IL-18). Produced primarily by macrophages, IL-18 induces the production of interferon-gamma (IFN-gamma), and enhances the activity of natural killer (NK) and cytotoxic T lymphocytes (CTL).  As a potential immunotherapeutic agent, iboctadekin displays antitumor effects in vitro and in animal models. (NCI04)	Iboctadekin		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C168100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168100>	C174187|C167416	Abnormal Electrocardiogram|Abnormal ECG|Abnormal EKG|ECG|Patient_had_abnormal_EKG	A history of having had an abnormal electrocardiogram (ECG).			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|SeroNet Research Participant Metadata|SeroNet Variables
C168101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168101>	C167416	Abnormal Holter Monitoring Finding|Holter monitor	A history of having had an abnormal finding during Holter monitoring.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168102>	C167446	Continuous with Diastolic Spillover Heart Murmur|Continuous with Diastolic Spillover Murmur|Continuous with diastolic spillover	A heart murmur that occurs throughout systole and the early part of diastole.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168103>	C167445	Late Diastolic Heart Murmur|Late Diastolic Murmur|Late diastolic	A heart murmur that occurs during the last half of the ventricular filling phase. This may or may not extend to the first heart sound.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168104>	C35552	Abnormally Displaced Point of Maximum Impulse|Abnormally displaced	A clinical finding in which the point of maximum impulse is located lateral to the anticipated position in the left midclavicular clavicular line, fifth intercostal space.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168105>	C35552	Abnormally Located Point of Maximum Impulse|Abnormally located	A clinical finding in which the point of maximum impulse is located in a place other than the left anterior chest.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168106>	C17708	Activity Associated with Chief Complaint|Activity Associated With Chief Complaint	Any associated activity noted when chief complaint occurs or that induces onset of the chief complaint.			Activity	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168107>	C169077	Adequacy of Daily Caloric Intake|Dietary: Caloric Intake	The appropriateness of daily caloric intake for a given patent based primarily on age and energy requirements.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168108>	C169077	Adequacy of Daily Fluid Intake|Dietary: Fluid Intake	The appropriateness of daily fluid intake for a given patent.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168109>	C169077	Adequacy of Salt Intake|Dietary: Salt Intake	The appropriateness of daily salt intake for a given patent.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16810>	C17155	Nuclear Magnetic Resonance Spectroscopy|MS|Magnetic Resonance Spectroscopy|Magnetic Resonance Spectroscopy|NMR Spectroscopy|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY|Spectroscopy, MR|Spectroscopy, NMR|Spectroscopy, Nuclear Magnetic Resonance	Detection and measurement of the resonant spectra of molecular species in a tissue or sample.			Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C168110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168110>	C169077	Adequate Daily Caloric Intake|Adequate caloric intake	The daily caloric intake is sufficient.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168111>	C169077	Adequate Daily Fluid Intake|Adequate	The daily fluid intake is sufficient.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168112>	C169077	Adequate Daily Salt Intake|Adequate	The daily salt intake is sufficient.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168113>	C156420	Age at Diagnosis of Congenital Heart Disease|Age Diagnosed	The age of the patient when congenital heart disease was diagnosed.			Organism Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168114>	C25506	Alleviating Factor to Chief Complaint|Alleviating Factors	Any factor that lessens or improves the chief complaint.			Functional Concept	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168115>	C124596	Anterior Chest Examination|Anterior Chest Inspection|Cardiac Examination – Anterior Chest Inspection	Inspection of the region encompassing the anterior surface of the chest and epigastrium.			Diagnostic Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168116>	C168327	Anticongestive Medications Given for Rheumatic Fever|Anticongestive medications	An indication that anticongestive medications were given as treatment for rheumatic fever.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168117>	C35053	Arrhythmogenic Syncope|Arrhythmogenic syncope	A condition in which syncope occurs due to an arrhythmia. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168118>	C168327	Aspirin Given for Kawasaki Disease|Aspirin	An indication that aspirin was given as treatment for Kawasaki disease.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168119>	C168327	Aspirin Given for Rheumatic Fever|Aspirin	An indication that aspirin was given as treatment for rheumatic fever.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16811>	C17369	Magnetoencephalography|MAGNETOENCEPHALOGRAPHY|MEG|MEG|MEG Scan	The measurement of the magnetic fields produced by electrical activity in the brain, usually conducted externally, using extremely sensitive devices. The measurement of electric fields in the brain provides information about the localization of brain activity which is complementary to that provided by electroencephalography.	Magnetoencephalography		Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C168120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168120>	C83023	Asymmetric Chest Appearance|Asymmetric Thoracic Appearance|Asymmetry	Inspection of the region of the anterior surface of the chest and epigastrium reveals disparate configuration on opposite sides of a vertical central dividing line.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168121>	C83119	Asymptomatic Presentation|Asymptomatic	A clinical description in which a patient does not demonstrate evidence of clinical findings to suggest underlying pathology. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168122>	C167445	Middiastolic Heart Murmur|Mid-diastolic Murmur|Middiastolic	A heart murmur that occurs during the middle portion of the ventricular filling phase.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168123>	C201990	Caffeine Not Routinely Consumed|No	An indication that the patient does not consume caffeine on a regular basis.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168124>	C201990	Caffeine Routinely Consumed|Caffeine intake	An indication that the patient consumes caffeine on a regular basis.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168125>	C122008	Capillary Refill Test|CPLRFLT|CPLRFLT|Capillary Refill Time|Capillary Refill Time|Capillary Refill Time|Examination of the Extremities – Capillary Refill Time	An assessment performed to estimate peripheral perfusion and hydration status. The test is most often conducted by applying constant manual pressure for a set time on a patient's nail bed and then releasing while observing the length of time it takes for color to return to the tissue. A prolonged return to baseline coloring may indicate compromise of peripheral blood flow.			Diagnostic Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|CDISC SDTM Terminology|CDISC SDTM Vital Sign Test Code Terminology|CDISC SDTM Vital Sign Test Name Terminology|CDISC SEND Cardiovascular Test Code Terminology|CDISC SEND Cardiovascular Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C168126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168126>	C15419	Cardiac Disease Screening|Screening for cardiac condition	An evaluation to determine whether an individual has any current condition that affects the heart.			Diagnostic Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168127>	C35120	Cardioinhibitory Syncope|Cardioinhibitory syncope	A condition in which neurally-mediated syncope occurs in which the blood pressure falls and heart rate falls. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168128>	C35741	Carditis	Inflammation of the heart or its surroundings. (ACC/AHA)			Disease or Syndrome	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168129>	C35120	Carotid Sinus Syncope|Carotid sinus syncope	A condition in which neurally mediated syncope occurs due to massage of the carotid body. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16812>	C25790	Major Histocompatibility Complex Gene|HLA Complex Gene	A group of linked loci, collectively termed H-2 complex in the mouse and HLA complex in humans, that codes for cell-surface histocompatibility antigens and is the principal determinant of tissue type and transplant compatibility.			Gene or Genome	
C168130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168130>	C50656	Carpal Spasm|Carpal spasm	A spasmodic contraction of the muscles of the hands, especially the wrists, such as during alkalosis or tetany. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168131>	C62164	Change to Upright Position|Change to upright position	The state of going from a supine or seated position to a standing position. (ACC/AHA)			Spatial Concept	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168132>	C167423	Chest Pain Along Left Anterior Axillary Line	The location of the chest pain is along the anterior axillary line on the left side.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168133>	C167424	Chest Pain Along Left Lower Sternal Border	The location of the chest pain is along the left lower border of the sternum.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168134>	C167425	Chest Pain Along Left Midclavicular Line	The location of the chest pain is along the left midclavicular line.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168135>	C167424	Chest Pain Along Left Middle Sternal Border	The location of the chest pain is along the left middle border of the sternum.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168136>	C167424	Chest Pain Along Left Upper Sternal Border	The location of the chest pain is along the left upper border of the sternum.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168137>	C167423	Chest Pain Along Right Anterior Axillary Line	The location of the chest pain is along the anterior axillary line on the right side.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168138>	C167424	Chest Pain Along Right Lower Sternal Border	The location of the chest pain is along the right lower border of the sternum.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168139	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168139>	C167425	Chest Pain Along Right Midclavicular Line	The location of the chest pain is along the right midclavicular line.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16813>	C25464	Malawi|454|MALAWI|MALAWI|MW|MWI|MWI	A country in southern Africa, east of Zambia and west of Mozambique and Tanzania.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C168140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168140>	C167424	Chest Pain Along Right Middle Sternal Border	The location of the chest pain is along the right middle border of the sternum.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168141>	C167424	Chest Pain Along Right Upper Sternal Border	The location of the chest pain is along the right upper border of the sternum.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168142>	C167426	Chest Pain in Left Fifth Intercostal Space	The location of the chest pain is within the fifth intercostal space on the left side.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168143>	C167426	Chest Pain in Left Fourth Intercostal Space	The location of the chest pain is within the fourth intercostal space on the left side.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168144>	C167426	Chest Pain in Left Second Intercostal Space	The location of the chest pain is within the second intercostal space on the left side.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168145>	C167426	Chest Pain in Left Third Intercostal Space	The location of the chest pain is within the third intercostal space on the left side.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168146>	C167427	Chest Pain in Lower Sternum	The location of the chest pain is in the lower portion of the sternum.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168147>	C167427	Chest Pain in Mid Sternum	The location of the chest pain is in the middle of the sternum.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168148>	C167426	Chest Pain in Right Fifth Intercostal Space	The location of the chest pain is within the fifth intercostal space on the right side.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168149>	C167426	Chest Pain in Right Fourth Intercostal Space	The location of the chest pain is within the fourth intercostal space on the right side.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16814>	C25464	Malaysia|458|MALAYSIA|MALAYSIA|MY|MYS|MYS	A country in southeastern Asia bordering Indonesia and the South China Sea, occupying a peninsula south of Thailand and the northern one-third of the island of Borneo.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C168150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168150>	C167426	Chest Pain in Right Second Intercostal Space	The location of the chest pain is within the second intercostal space on the right side.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168151>	C167426	Chest Pain in Right Third Intercostal Space	The location of the chest pain is within the third intercostal space on the right side.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168152>	C167427	Chest Pain in Upper Sternum	The location of the chest pain is in the upper portion of the sternum.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168153>	C85497	Chief Complaint Caused by Trauma|Yes	An indication that the chief complaint was caused by a traumatic event.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168154>	C85497	Chief Complaint Continuously Present|Continuous	The chief complaint continues without interruption.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168155>	C85497	Chief Complaint Intermittently Present|Intermittent	The chief complaint intermittently stops then starts again.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168156>	C85497	Chief Complaint is Present Daily|Daily	The chief complaint is noted to occur at least once per day.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168157>	C85497	Chief Complaint is Present Monthly|Monthly	The chief complaint is noted to occur at least once per month.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168158>	C85497	Chief Complaint is Present Multiple Times per Day|Multiple times/day	The chief complaint is noted to occur more than once per day.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168159>	C85497	Chief Complaint is Present Weekly|Weekly	The chief complaint is noted to occur at least once per week.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16815>	C25464	Maldives|462|MALDIVES|MALDIVES|MDV|MDV|MV	A country in southern Asia, occupying a group of atolls in the Indian Ocean, south-southwest of India and north of the British Indian Ocean Territory.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C168160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168160>	C85497	Chief Complaint Not Caused by Trauma|No	An indication that the chief complaint was not caused by a traumatic event.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168161>	C85497	Chief Complaint Occurs After Exercise|After Exercise	The chief complaint typically occurs after exercise.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168162>	C85497	Chief Complaint Occurs at Rest|At rest	The chief complaint typically occurs at rest.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168163>	C85497	Chief Complaint Occurs During Exercise|During exercise	The chief complaint typically occurs during exercise.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168164>	C85497	Chief Complaint Occurs Without Pattern|No pattern	The chief complaint occurs both at rest or with exercise.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168165>	C85497	Chief Complaint Present at Midday|Midday	The chief complaint is noted to primarily occur in the period on or around noon.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168166>	C85497	Chief Complaint Present at Night|Night	The chief complaint is noted to primarily occur between sunset and sunrise.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168167>	C85497	Chief Complaint Present in the Afternoon|Afternoon	The chief complaint is noted to primarily occur after noon but before sunset.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168168>	C85497	Chief Complaint Present in the Evening|Evening	The chief complaint is noted to primarily occur after sunset but before bedtime.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168169>	C85497	Chief Complaint Present in the Morning|Morning	The chief complaint is noted to primarily occur in the period after sunrise and before noon.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16816>	C25464	Mali|466|MALI|MALI|ML|MLI|MLI	A country in western Africa, southwest of Algeria and east of Mauritania.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C168170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168170>	C85497	Chief Complaint was Not Witnessed|No	An indication that the chief complaint was not witnessed.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168171>	C85497	Chief Complaint was Witnessed|Yes	An indication that the chief complaint was witnessed.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168172>	C84973	Chronic Orthostatic Intolerance|Chronic orthostatic intolerance	A condition in which there is orthostatic intolerance lasting for at least three months with associated functional impairment. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168173>	C5040	Cold Sensation|Sensation of Cold|Sensation of cold	An internal feeling of being cooler without a concomitant change in the ambient environment. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168174>	C121558	Complex Breath Holding|Complex Breath Holding Spell|Complex Breath-holding Spell|Complex breath-holding spell	A clinical condition in which there is a breath-holding spell associated with syncope. (ACC/AHA)			Sign or Symptom	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168175>	C17204	Computed Tomography of the Heart|Cardiac CT|Cardiac CT|Heart CT	Non-invasive imaging of the heart utilizing computed tomography (CT).			Diagnostic Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168176	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168176>	C26693	Coronary Artery Aneurysm|Coronary artery aneurysm|Coronary artery aneurysm	Focal dilation of a coronary artery secondary to arterial wall weakening. (ACC/AHA)			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|Appendix 7: Diagnostic Procedures Terminology
C168177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168177>	C45481	Coronary Artery Ectasia|Coronary artery ectasia	Diffuse dilation of a coronary artery segment.			Disease or Syndrome	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168178>	C168327	Coumadin Given for Kawasaki Disease|Coumadin	An indication that coumadin was given as treatment for Kawasaki disease.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168179>	C121558	Cyanotic Breath Holding|Cyanotic Breath Holding Spell|Cyanotic Breath-holding Spell|Cyanotic breath-holding spell	A clinical condition in which there is a breath-holding spell associated with cyanotic appearance. (ACC/AHA)			Sign or Symptom	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16817>	C25464	Malta|470|MALTA|MALTA|MLT|MLT|MT	A country in southern Europe, occupying islands in the Mediterranean Sea, south of Sicily (Italy).			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C168180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168180>	C164340	Date of Patient Evaluation Prior to Current Chief Complaint|Prior Evaluation: Date	The date of the prior clinical assessment of the patient for the current chief complaint.			Temporal Concept	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168181>	C83119	Delayed Capillary Refill Time|Delayed|Delayed Capillary Refill	A clinical finding in which a capillary nail refill test returns to pink color in greater than two seconds after pressure is removed. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168182>	C36280	Developmental Finding|Developmental	Symptoms, physical examination results, and/or laboratory test results related to physical, emotional, behavioral, or social development.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168183>	C15220	Diagnosis at Patient Evaluation Prior to Current Chief Complaint|Prior Evaluation: Diagnosis	The diagnosis given at the prior clinical assessment of the patient for the current chief complaint.			Diagnostic Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168184>	C35053	Drug-induced Syncope|Drug-induced syncope	A condition in which syncope occurs due to the ingestion or administration of a chemical substance. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168185>	C25330	Duration of Chief Complaint|Chief Complaint – Duration	The length of time that the chief complaint persists.			Temporal Concept	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168186>	C19477	Electrocardiogram|ECG|ECG|ECG|EKG|EKG|EKG|Electrocardiograms|electrocardiogram	A record of the electrical activity of the heart.	Electrocardiogram		Laboratory or Test Result	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|CTRP Intervention Terminology|CTRP Terminology|HL Authorized Value Terminology|HL Function Test Table|ICH M11 Protocol Section 8 Data Element Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C168187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168187>	C165196	Evidence of Previous Streptococcal Infection|Evidence of previous streptococcus infection	The presence of a positive anti-Streptolysin-O or anti-DNase B, demonstrating that the patient was previously infected with Streptococcus. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168188>	C25506	Exacerbating Factor to Chief Complaint|Aggravating Factor to Chief Complaint|Exacerbating Factors	Any factor that worsens the chief complaint.			Functional Concept	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168189>	C124596|C124351	Examination of Extremities|Examination of the Extremities|Examination of the Extremities	An assessment of the upper and lower extremities.			Diagnostic Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16818>	C16502	Mammography|MAMMOGRAPHY|MG|mammography	A type of radiography used specifically to examine breast tissue. The procedure utilizes a low-dose of x-rays or radiation to generate an image. A mammography exam or mammogram, is used as a screening tool to detect early breast cancer in women experiencing no symptoms and to detect and diagnose breast disease.	Mammography		Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C168190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168190>	C169077	Excessive Daily Caloric Intake|Excessive caloric intake	The daily caloric intake is excessive.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168191>	C169077	Excessive Daily Salt Intake|Excessive	The daily salt intake is excessive.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168192>	C100075	Exercise Cardiac Stress Test|ECST|Exercise Stress Test|Exercise Stress Test	A graded test to measure an individual's heart rate and oxygen intake while undergoing strenuous physical exercise; most often assessed on a treadmill.			Diagnostic Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168193>	C35053	Faceplant	A syncopal event in which there is no attempt to protect oneself from the effects of the fall.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168194>	C17726	Family History of Arrhythmia|Arrhythmia	A history of a first-degree relative that has had an arrhythmia.			Group Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168195>	C17726	Family History of Chronic Disease|Other chronic diseases	A history of a first-degree relative that has had a chronic disease.			Group Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168196>	C167436	Long Heart Murmur|Long|Long Murmur	A heart murmur that occurs for an extended length of time after a valve closure sound.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168198>	C167436	Medium Heart Murmur|Medium|Medium Murmur	A heart murmur that occurs for a medium length of time after a valve closure sound.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168199	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168199>	C167436	Short Heart Murmur|Short|Short Murmur	A heart murmur that occurs for a brief length of time after a valve closure sound.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16819>	C17172	Superoxide Dismutase [Mn], Mitochondrial|EC 1.15.1.1|IPO-B|MNSOD|Manangese Superoxide Dismutase|Manganese Superoxide Dismutase|Mitochondrial Superoxide Dismutase|Mitochondrial Superoxide Dismutase 2|Mn Superoxide Dismutase|SOD2|Superoxide Dismutase 2	Superoxide dismutase [Mn], mitochondrial (222 aa, ~25 kDa) is encoded by the human SOD2 gene. This protein plays a role in superoxide reduction.	Superoxide Dismutase [Mn], Mitochondrial		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C1681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1681>	C72960|C129822	Alemtuzumab|ALEMTUZUMAB|Campath|Campath-1H|Campath-1H|LDP 03|LDP-03|LDP03|Lemtrada|MabCampath|alemtuzumab	A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)	Alemtuzumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C168200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168200>	C17726	Family History of Ehlers-Danlos Syndrome|Ehlers-Danlos syndrome	A history of a first-degree relative with Ehlers-Danlos syndrome.			Group Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168202>	C17726	Family History of Hyperlipidemia|Hyperlipidemia	A history of a first-degree relative that has hyperlipidemia.			Group Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168203>	C17726	Family History of Hypertension|Hypertension	A history of a first-degree relative that has hypertension.			Group Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168205>	C17726	Family History of Marfan Syndrome|Marfan syndrome	A history of a first-degree relative with Marfan syndrome.			Group Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168206>	C17726	Family History of Myocardial Infarction|Family History of MI|MI	A history of a first-degree relative that has had a myocardial infarction.			Group Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168208>	C17726	Family History of Stroke|Stroke	A history of a first-degree relative that has had a stroke.			Group Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168209>	C17726	Family History of Sudden Infant Death Syndrome|Family History of SIDS|Sudden death/SIDS	A history of a first-degree relative whose death was attributed to sudden infant death syndrome (SIDS).			Group Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16820>	C19236	Manometry|Biochemistry, Manometry	The measurement of pressure using a manometer.	Manometry		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C168210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168210>	C17726	Family History of Syncope|Syncope	A history of a first-degree relative that has had syncope.			Group Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168211>	C50560	Feeding Fatigue|Fatigue with Feeding|Fatigue with feeding	A state of increased discomfort and decreased efficiency due to prolonged or excessive exertion during the taking of food. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168212>	C167438	Systolic-Diastolic Heart Murmur|Systolic-Diastolic Murmur|To and Fro Murmur|To and fro or systolic-diastolic murmur	An accentuated heart murmur that occurs during both ventricular ejection and ventricular filling phases.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168213>	C35552	Forceful Heartbeats|Forceful heartbeats	The sensation of an isolated cardiac contraction occurring with greater strength than that of a typical or normal contraction. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168214>	C21514	Frequency of Chief Complaint|Chief Complaint – Frequency	The number of occurrences of the chief complaint over a given period of time.			Qualitative Concept	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168215>	C169077	Frequency of Routine Caffeine Intake|Dietary: Routine Caffeine Intake	The frequency of caffeine consumed on a regular basis.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168216>	C96717	Gallbladder Mucocele|Gallbladder Hydrops|Gallbladder hydrops	The enlargement of the gallbladder secondary to prolonged obstruction of the cystic duct.			Disease or Syndrome	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168217>	C3101	Genetic Syndrome Associated with Congenital Heart Defect|Syndrome	Genetic anomalies and collections of malformations that are known to cluster together that can be associated with congenital heart defects. (ACC/AHA)			Congenital Abnormality	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168218>	C34941	Gestational Complication|Gestational Complications	A difficulty or problem that occurs during intrauterine development that can jeopardize the health of the fetus. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168219>	C167439	Blowing Heart Murmur|Blowing|Blowing Murmur	A heart murmur that has an auditory quality similar to the sound of a person blowing air.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16821>	C16345	Marine Biology|Marine/Aquatic Biology	The study of organisms that live in the sea or in other bodies of water.			Occupation or Discipline	
C168220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168220>	C167439	Harsh Heart Murmur|Harsh|Harsh Murmur	A heart murmur that has an auditory quality in which the flow sounds highly turbulent.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168221>	C167439	Machinery Heart Murmur|Gibson's Murmur|Machine-like Murmur|Machinery	A heart murmur that has an auditory quality in which turbulence sounds similar to the workings of an industrial machine.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168222>	C167439	Multifrequency Heart Murmur|Multifrequency|Multifrequency Murmur	A heart murmur that has an auditory quality in which multiple frequencies are heard either simultaneously or in rapid succession.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168223>	C17953	Grade School Completion|Elementary School|Elementary School Completion|Grade school completion	Indicates that a person has attended grade school to completion. Depending on school system, this may indicate completion of sixth, seventh or eight grade.			Organism Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C168224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168224>	C167439	Nonspecific Heart Murmur|Nonspecific|Nonspecific Murmur	A heart murmur that has an auditory quality in which there are no recognizable characteristics to describe the turbulent sound.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168225>	C167439	Squeaky Heart Murmur|Squeaky|Squeaky Murmur	A heart murmur that has an auditory quality in which the turbulence is brief and noted with the diaphragm of the stethoscope only.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168226>	C17953	Graduate Studies Completion|Graduate studies	Indicates that a person has completed a graduate studies program beyond a bachelor's degree.			Organism Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|GDC Terminology|GDC Value Terminology
C168227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168227>	C19683	Hair Brushing|Hair brushing	The use of an implement with bristles to groom one's hair.			Individual Behavior	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168228>	C167439	Vibratory Heart Murmur|Vibratory|Vibratory Murmur	A heart murmur that has an auditory quality with a distinct groaning, croaking, buzzing or twanging.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168229>	C19332	Has No Sibling|No	An indication that an individual does not have a sibling.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16822>	C25464	Marshall Islands|584|MARSHALL ISLANDS|MARSHALL ISLANDS|MH|MHL|MHL	A group of atolls and reefs in the North Pacific Ocean, about one-half of the way from Hawaii to Australia, south of Wake Island and north of Nauru.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C168230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168230>	C50995	Has Response to Intervention for Kawasaki Disease|Yes	An indication that a patient responded to a treatment for Kawasaki disease.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168231>	C19332	Has Sibling|Yes	An indication that an individual has a sibling.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168232>	C168320	Hear Sound Auscultation at Left Infraclavicular Region|Heart Sound Auscultation under Left Clavicle|Infraclavicular, left	Heart sounds are auscultated on the precordial location corresponding to the anterior portion of the thorax directly below the left clavicle.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168233>	C168320	Heart Sound Auscultation at Right Infraclavicular Region|Heart Sound Auscultation under Right Clavicle|Infraclavicular, right	Heart sounds are auscultated on the precordial location corresponding to the anterior portion of the thorax directly below the right clavicle.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168234>	C168320	Heart Sound Auscultation at Apex|Apex|Apex	Heart sounds are auscultated on the precordial location corresponding to the blunt extremity of the heart formed by the left ventricle.			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|Appendix 6: Symptoms and Signs Terminology|Physical Examination Terminology
C168235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168235>	C168320	Heart Sound Auscultation at Back|Back	Heart sounds are auscultated on the posterior portion of the trunk of the human body between the neck and the pelvis; the dorsum.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168236>	C168320	Heart Sound Auscultation at Left Anterior Axillary Line|Left anterior axillary line	Heart sounds are auscultated on the precordial location delineated by a coronal line on the anterior torso marked by the anterior axillary fold on the left side.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168237>	C168320	Heart Sound Auscultation at Left Axilla|Left axilla	Heart sounds are auscultated on the precordial location delineated by a pyramid-shaped space forming the underside of the shoulder between the upper arm and the side of the chest on the left side.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168238>	C168320	Heart Sound Auscultation at Left Lower Sternal Border|Left lower sternal border|Left lower sternal border	Heart sounds are auscultated on the precordial location corresponding to the tricuspid region, between the fifth, and sixth intercostal spaces at the left sternal border.			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|Appendix 6: Symptoms and Signs Terminology|Physical Examination Terminology
C168239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168239>	C168320	Heart Sound Auscultation at Left Lung Field|Heart Sound Auscultation at Left Chest|Left lung field/left chest	Heart sounds are auscultated on the precordial location corresponding to the pleural apices, middle and lower or base, posteriorly, laterally and anteriorly of the left lung.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16823>	C25464	Martinique|474|MARTINIQUE|MARTINIQUE|MQ|MTQ|MTQ	An island between the Caribbean Sea and the North Atlantic Ocean, south of Dominica and north of Saint Lucia.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C168240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168240>	C168320	Heart Sound Auscultation at Left Middle Sternal Border|Left middle sternal border|Left middle sternal border	Heart sounds are auscultated on the precordial location corresponding to the region between the third and fifth intercostal spaces at the left sternal border.			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|Appendix 6: Symptoms and Signs Terminology|Physical Examination Terminology
C168241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168241>	C168320	Heart Sound Auscultation at Left Upper Sternal Border|Left upper sternal border|Left upper sternal border	Heart sounds are auscultated on the precordial location corresponding to the pulmonic region, between the second and third intercostal spaces at the left sternal border.			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|Appendix 6: Symptoms and Signs Terminology|Physical Examination Terminology
C168242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168242>	C168320	Heart Sound Auscultation at Right Anterior Axillary Line|Right anterior axillary line	Heart sounds are auscultated on the precordial location delineated by a coronal line on the anterior torso marked by the anterior axillary fold on the right side.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168243>	C168320	Heart Sound Auscultation at Right Axilla|Right axilla	Heart sounds are auscultated on the precordial location delineated by a pyramid-shaped space forming the underside of the shoulder between the upper arm and the side of the chest on the right side.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168244>	C168320	Heart Sound Auscultation at Right Lower Sternal Border|Right lower sternal border	Heart sounds are auscultated on the precordial location corresponding to the region between the fifth, and sixth intercostal spaces at the right sternal border.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168245>	C168320	Heart Sound Auscultation at Right Lung Field|Heart Sound Auscultation at Right Chest|Right lung field/right chest	Heart sounds are auscultated on the precordial location corresponding the pleural apices, middle and lower or base, posteriorly, laterally and anteriorly of the right lung.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168246>	C168320	Heart Sound Auscultation at Right Middle Sternal Border|Right middle sternal border	Heart sounds are auscultated on the precordial location corresponding to the region between the third and fifth intercostal spaces at the right sternal border.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168247	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168247>	C168320	Heart Sound Auscultation at Right Upper Sternal Border|Right upper sternal border|Right upper sternal border	Heart sounds are auscultated on the precordial location corresponding to the aortic region, between the second and third intercostal spaces at the right sternal border.			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Authorized Values|ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|Appendix 6: Symptoms and Signs Terminology|Physical Examination Terminology
C168248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168248>	C5040	Heat Sensation|Sensation of Heat|Sensation of heat	An internal feeling of being warmer without a concomitant change in the ambient environment. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168249>	C64982	Herniorrhaphy|Hernia Repair	The surgical repair of a hernia by approximation of the intact tissues surrounding the defect.			Therapeutic or Preventive Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16824>	C16990	Maternal Physiology	Study of the physiologic, biochemical, and anatomic changes that occur during pregnancy.			Biomedical Occupation or Discipline	
C168250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168250>	C53263	History of Allergic Reaction|Allergic reaction	A history of any allergic reaction that the patient has had.			Clinical Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168251>	C66921	History of Congenital Heart Disease|History of CHD	An abnormality of cardiac structure or function was present at birth.			Clinical Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168252>	C153307	History of Failure to Gain Weight|Failure to Gain Weight/Thrive	A history of less than normal weight gain.			Clinical Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168253>	C53263	History of Medication|Medications	A history of the medication that the patient has taken.			Clinical Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168254>	C166353	History of Non-Cardiac Surgery|Noncardiac Surgical History	A history of a surgery not involving the heart.			Clinical Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168255>	C166353	History of Other Non-Cardiac Surgery|Other	An indication that the patient has a history of a non-cardiac surgery other than those listed.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168256>	C18772	History of Trauma in Chief Complaint|History of trauma	A traumatic event preceded the chief complaint.			Diagnostic Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168257>	C86050	Hot Bath or Shower|Hot bath/shower	Bathing or showering with water that has an extremely elevated temperature.			Activity	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168258>	C90380	Hot Weather|Hot weather	Increased ambient temperature. (ACC/AHA)			Quantitative Concept	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168259>	C38665	Hyperactive Chest Appearance|Hyperactive|Hyperactive Thoracic Appearance	Inspection of the region of the anterior surface of the chest and epigastrium reveals a highly or excessively active or hyperkinetic apical impulse.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16825>	C16987	Mathematics|Math|Mathematical	The study of numbers, shapes, patterns, and logical reasoning.			Occupation or Discipline	
C168260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168260>	C53458	Hypercyanotic Spell|Hypercyanotic spell	A clinical finding in which a patient has profound cyanosis associated with hyperpnea; classically associated with tetralogy of Fallot. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168261>	C35552	Hyperdynamic Precordial Palpation Finding|Hyperdynamic|Precordial Palpation Finding of Hyperkinetic Cardiac Impulse	A clinical finding in which palpation of the precordium reveals a hyperkinetic cardiac impulse with increased amplitude and forcefulness. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168262>	C3676	Hyperpnea	A clinical finding in which there is deeper breathing than normal. (ACC/AHA)			Sign or Symptom	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168263>	C3128	Hypotension due to Cardiac Dysfunction|Hypotension due to cardiac dysfunction	A condition in which there is hypotension because of inadequate pumping function of the heart. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168264>	C3128	Hypotension due to Drug|Hypotension due to drug	A condition in which there is hypotension because of the effects of a medication or other substance. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168265>	C81246	Illicit Drug Use History|Illicit Drug Use	A description of an individual's current and past use of illicit drugs.			Clinical Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168266>	C17994	Inadequate Daily Caloric Intake|Inadequate caloric intake	The daily caloric intake is deficient.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168267>	C17994	Inadequate Daily Fluid Intake|Inadequate	The daily fluid intake is deficient.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168268>	C17994	Inadequate Daily Salt Intake|Inadequate	The daily salt intake is deficient.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168269>	C3858	Increased Emotional State|Increased Emotions|Increased emotional state	A state of mental excitement, characterized by physiological and behavioral changes.			Sign or Symptom	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16826>	C25464	Mauritania|478|MAURITANIA|MAURITANIA|MR|MRT|MRT	A country in northern Africa, bordering the North Atlantic Ocean, between Senegal, Western Sahara, and Mali.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C168270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168270>	C17953	Individualized Education Plan|IEP|IEP	Indicates that a person has been educated through a Individualized education plan in primary and secondary school.			Organism Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168271>	C51993	Infective Endocarditis Prophylaxis	The use of antibiotics for the prevention of endocarditis.			Therapeutic or Preventive Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168272>	C168327	Infliximab Given for Kawasaki Disease|Infliximab	An indication that infliximab was given as treatment for Kawasaki disease.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168273>	C156809	Intercurrent Illness at Onset of Chief Complaint|Intercurrent Illness Present	The presence of any other illnesses at the time the chief complaint was first noted.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168274>	C16669	Intercurrent Illness is Absent at Onset of Chief Complaint|No	An indication that the patient was in their usual state of health when the chief complaint was manifested.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168275>	C16669	Intercurrent Illness is Present at Onset of Chief Complaint|Yes	An indication that the patient was unwell at the time the chief complaint was manifested.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168276>	C16669	Intercurrent Illness is Unknown at Onset of Chief Complaint|Unknown	An indication that it is not known whether the patient was in their usual state of health when the chief complaint was manifested.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168277>	C116518	Intervention for Congenital Heart Disease|Intervention(s)	The treatment the patient had for congenital heart disease.			Diagnostic Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168278>	C116518	Intervention for Kawasaki Disease	The treatment the patient had for Kawasaki disease.			Diagnostic Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168279>	C168456	Intervention for Kawasaki Disease Given Beyond Ten Days of Onset of Initial Symptoms|Greater than 10 days within the onset of initial symptoms	An indication that the patient was given treatment for Kawasaki disease beyond 10 days of the onset of initial symptoms.			Temporal Concept	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16827>	C25464	Mauritius|480|MAURITIUS|MAURITIUS|MU|MUS|MUS	A country in southern Africa, occupying an island in the Indian Ocean, off the coast of Madagascar, east of Reunion.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C168280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168280>	C168456	Intervention for Kawasaki Disease Given Within Ten Days of Onset of Initial Symptoms|Less than 10 days within the onset of initial symptoms	An indication that the patient was given treatment for Kawasaki disease within 10 days of the onset of initial symptoms.			Temporal Concept	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168281>	C45501	Intervention Given for Kawasaki Disease|Yes	An indication that the patient was given treatment for Kawasaki disease.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168282>	C45501	Intervention Not Given for Kawasaki Disease|No	An indication that the patient was not given treatment for Kawasaki disease.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168283>	C38044	Interventional Cardiac Catheterization|Interventional catheterization	The performance of cardiac catheterization with the intent of making a modification to the structures of the heart or surrounding vessels.			Health Care Activity	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168284>	C35552	Irregular Heart Beat|Dysrhythmia|Irregular heart beat	A clinical finding in which the rhythm of the heart is noted to be abnormal. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168285	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168285>	C168281	IVIG Given for Kawasaki Disease|IVIG	An indication that intravenously administered pooled immunoglobulins were given as treatment for Kawasaki disease.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168286>	C4876	Kawasaki Disease Symptom|Symptoms	The symptoms of Kawasaki disease that the patient had. (ACC/AHA)			Sign or Symptom	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168287>	C124438	Kawasaki Disease Symptom Onset Age|Age When First Noted	The age of the patient when the symptoms of Kawasaki disease were first noted. (ACC/AHA)			Organism Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168288>	C119242	Kawasaki Disease Symptom Onset Date|Symptom Onset	The date of the first onset of the symptoms of Kawasaki disease.			Temporal Concept	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168289>	C170802	Kawasaki Disease-Associated Coronary Artery Aneurysm Z-Score Suggests Dilatation Only|Dilatation only	The Kawasaki disease-associated coronary artery aneurysm Z-score is between 2 and 2.5 mm, or if less than 2 mm on first assessment, then a decrease during follow-up of greater than 1 mm, suggesting dilatation only of the coronary arteries.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16828>	C25464	Mayotte|175|MAYOTTE|MAYOTTE|MYT|MYT|YT	A country in southern Africa, occupying an island in the Mozambique Channel, about one-half of the way from northern Madagascar to northern Mozambique, southeast of Comoros.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C168290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168290>	C170802	Kawasaki Disease-Associated Coronary Artery Aneurysm Z-Score Suggests Large or Giant Aneurysm|Large or giant aneurysm	The Kawasaki disease-associated coronary artery aneurysm Z-score is greater than or equal to 10 mm, or is greater than 8 mm in absolute dimension, suggesting a large or giant aneurysm of the coronary arteries.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168291>	C170802	Kawasaki Disease-Associated Coronary Artery Aneurysm Z-Score Suggests Medium Aneurysm|Medium aneurysm	The Kawasaki disease-associated coronary artery aneurysm Z-score is greater than or equal to 5 mm but less than 10 mm, and has absolute dimension less than 8 mm, suggesting a medium aneurysm of the coronary arteries.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168292>	C170802	Kawasaki Disease-Associated Coronary Artery Aneurysm Z-Score Suggests No Involvement|No involvement	The Kawasaki disease-associated coronary artery aneurysm Z-score is always less than 2 mm, suggesting no involvement of the coronary arteries.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168293>	C170802	Kawasaki Disease-Associated Coronary Artery Aneurysm Z-Score Suggests Small Aneurysm|Small aneurysm	The Kawasaki disease-associated coronary artery aneurysm Z-score is greater than or equal to 2.5 mm but less than 5 mm, suggesting a small aneurysm of the coronary arteries.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168294>	C17726	Known Family History of Rheumatic Fever or Rheumatic Heart Disease|Family history of rheumatic fever/ rheumatic heart disease	An indication that the patient has a family history of rheumatic fever or rheumatic heart disease.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168295>	C18772	Known History of Acute Rheumatic Fever or Rheumatic Heart Disease|Previous acute rheumatic fever or rheumatic heart disease	An indication that the patient has a history of acute rheumatic fever or rheumatic heart disease.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168296	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168296>	C81229	Known History of Alcohol Use|Yes	An indication that the patient has a history of alcohol use.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168297>	C168250	Known History of Allergy to Fish|Fish [allergy]	An indication that the patient has a history of an allergic reaction to fish.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168298>	C168250	Known History of Allergy to Medication|Medication [allergy]	An indication that the patient has a history of an allergic reaction to medication.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168299>	C66921	Known History of Congenital Heart Disease|Yes	An indication that the patient has a history of congenital heart disease.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16829>	C17196	Mediastinoscopy|Diagnostic Mediastinoscopy|Endoscopic Exploration of Mediastinum|MEDIASTINOSCOPY|mediastinoscopy	A surgical procedure during which a mediastinoscope is inserted into the thorax to view the its contents for diagnostic and/or therapeutic purposes.	Mediastinoscopy		Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C1682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1682>	C2020	L-744,832|L-744832	A farnesyl transferase inhibitors.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C168300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168300>	C18772	Known History of Gestational Complication|Yes	An indication that the patient's mother had a gestational complication while pregnant with the patient.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168301>	C81246	Known History of Illicit Drug Use|Yes	An indication that the patient has a history of illicit drug use.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168302>	C18772	Known History of Kawasaki Disease|Yes	An indication that the patient has a history of Kawasaki disease.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168303>	C18772	Known History of Neonatal Complication|Yes	An indication that the patient had a neonatal complication during the period around their birth.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168304>	C168250	Known History of Other Allergy|Others [allergy]	An indication that the patient has a history of an allergic reaction to an allergen other than those listed.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168305>	C18772	Known History of Rheumatic Fever|Yes	An indication that the patient has a history of rheumatic fever.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168306>	C3858	Labile Affect|Labile affect	Emotional instability characterized by rapid and dramatic mood swings. (ACC/AHA)			Sign or Symptom	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168307>	C15330	Ladd Procedure|Correction of Intestinal Malrotation|Ladd's Procedure|Ladd's or other malrotation procedures	A surgical procedure performed to correct intestinal malrotation via division of the mesenteric (Ladd's) bands and detorsion of the affected segment(s) of the bowel. This procedure often includes appendectomy as the dissection of the bands often causes damage to the appendiceal vessels.			Therapeutic or Preventive Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168308>	C94852	Lives Alone|Living Alone|Living alone	An indication that an individual lives alone.			Conceptual Entity	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168309>	C94852	Lives with Aunt|Lives with aunt|Living with Aunt	An indication that an individual lives with their aunt.			Conceptual Entity	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16830>	C62103	Medical Device|DEVICE|Device|Device|Device|Device|Medical Devices|medical device|medical device|medical device	Any physical object that is useful for prevention, diagnosis, monitoring, or treatment of disease or other conditions.	Medical Device		Medical Device	BRIDG Class Terminology|BRIDG Terminology|CDISC DDF Entities Terminology|CDISC DDF Terminology|CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|CDISC SDTM Intervention Type Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|ICH M11 Intervention Type Value Set Terminology|ICH M11 Terminology|International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Terminology
C168310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168310>	C94852	Lives with Father|Lives with father|Living with Father	An indication that an individual lives with their father.			Conceptual Entity	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168311>	C94852	Lives with Foster Parent|Lives with foster parent|Living with Foster Parent	An indication that an individual lives with their foster parent.			Conceptual Entity	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168312>	C94852	Lives with Legal Guardian|Living with Legal Guardian|Living with legal guardian other than above	An indication that an individual lives with a legal guardian other than those listed elsewhere.			Conceptual Entity	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168313>	C94852	Lives with Mother|Lives with mother|Living with Mother	An indication that an individual lives with their mother.			Conceptual Entity	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168314>	C94852	Lives with Partner or Spouse|Lives with partner/spouse|Living with Partner or Spouse	An indication that an individual lives with their partner or spouse.			Conceptual Entity	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168315>	C94852	Lives with Sibling|Lives with sibling|Living with Sibling	An indication that an individual lives with their sibling.			Conceptual Entity	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168316>	C94852	Lives with Stepfather|Lives with Step-Father|Lives with step-father|Living with Stepfather	An indication that an individual lives with their stepfather.			Conceptual Entity	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168317>	C94852	Lives with Stepmother|Lives with Step-Mother|Lives with step-mother|Living with Stepmother	An indication that an individual lives with their stepmother.			Conceptual Entity	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168318>	C94852	Lives with Uncle|Lives with uncle|Living with Uncle	An indication that an individual lives with their uncle.			Conceptual Entity	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168319>	C35552	Location of Chest Pain	The anatomic location of one's chest pain.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168320	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168320>	C35552	Location of Heart Sound Auscultation|Cardiac Examination – Heart Sounds, Location (Including Murmurs)|Heart sounds – location (including murmurs)	The location on the anterior chest wall where auscultation is undertaken.			Finding	ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology|ACC/AHA COVID-19 Appendix Variables|ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|Appendix 6: Symptoms and Signs Terminology|Physical Examination Terminology
C168321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168321>	C25341	Location of Patient Evaluation Prior to Current Chief Complaint|Prior Evaluation: Location	The location of the prior clinical assessment of the patient for the current chief complaint.			Spatial Concept	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168322>	C35552	Location of Point of Maximum Impulse|Cardiac Examination – PMI Type|Location of PMI|Location of Point of Maximal Impulse	The location on the anterior chest wall where the point of maximum impulse is noted.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168323>	C35552	Location of Pulse Measurement|Examination of the Extremities – Pulses, Location	The arterial location where palpation of a pulse is performed.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168324>	C168278	Medication for Kawasaki Disease|Intervention for Kawasaki Disease, Medications	The medication(s) given to the patient for treatment of Kawasaki disease.			Diagnostic Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168325>	C168082	Medication for Rheumatic Fever	The medication(s) given to the patient for treatment of rheumatic fever.			Diagnostic Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168326>	C176720	Medication Not Taken|No	An indication that the patient has not taken medication.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168327>	C176720	Medication Taken|Yes	An indication that the patient has taken medication.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168328>	C176721	Minor Criteria for Rheumatic Heart Disease Not Present|No	An indication that the minor criteria for rheumatic heart disease are not present.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168329>	C176722	Minor Criteria for Rheumatic Heart Disease Present|Yes	An indication that the minor criteria for rheumatic heart disease are present.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16832>	C17837	Medical Oncology|Oncology, Medical	The study and treatment of cancers with chemicals, biological products or immunotherapy.			Biomedical Occupation or Discipline	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C168330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168330>	C110937	Muscular Dystrophies and Storage Diseases Leading to Cardiomyopathy|Other Muscular Dystrophies and Storage Diseases That Lead to Cardiomyopathies	A finding indicating that muscular dystrophies and storage diseases have affected the heart, resulting in cardiomyopathy.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168331>	C84910	Muscular Dystrophy Secondary to Mitochondrial Disorder|Mitochondrial	A muscular dystrophy that was caused by a primary mitochondrial disorder.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168332	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168332>	C84910	Muscular Dystrophy Secondary to Oxidative Phosphorylation Disorder|Ox/Phos	A muscular dystrophy that was caused by a primary disorder of oxidative phosphorylation.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168333	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168333>	C78238	Musculoskeletal Chest Pain due to Costochondral Junction Syndrome|Musculoskeletal chest pain due to costochondral junction syndrome|Tietze|Tietze Syndrome	A condition in which there is musculoskeletal chest pain associated with localized inflammation of one or more joints between the rib and the costal cartilage. (ACC/AHA)			Sign or Symptom	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168334	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168334>	C78238	Musculoskeletal Chest Pain due to Costochondritis|Musculoskeletal chest pain due to costochondritis	A condition in which there is musculoskeletal chest pain associated with inflammation of one or more ribs and/or cartilages. (ACC/AHA)			Sign or Symptom	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168335	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168335>	C78238	Musculoskeletal Chest Pain due to Intercostal Myofascial Injury|Musculoskeletal chest pain due to intercostal myofascial injury	A condition in which there is musculoskeletal chest pain secondary to trauma to the connective tissues between the ribs. (ACC/AHA)			Sign or Symptom	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168336	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168336>	C78238	Musculoskeletal Chest Pain due to Rib Injury|Musculoskeletal chest pain due to rib injury	A condition in which there is musculoskeletal chest pain secondary to trauma to one or more ribs. (ACC/AHA)			Sign or Symptom	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168337	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168337>	C78238	Musculoskeletal Chest Pain due to Slipping Rib Syndrome|Musculoskeletal chest pain due to slipping rib syndrome	A condition in which there is musculoskeletal chest pain associated with one or more ribs subluxing from the joint. (ACC/AHA)			Sign or Symptom	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168338	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168338>	C78238	Musculoskeletal Chest Pain due to Sternal Injury|Musculoskeletal chest pain due to sternal injury	A condition in which there is musculoskeletal chest pain secondary to trauma to the sternum. (ACC/AHA)			Sign or Symptom	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168339	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168339>	C98985	Myopathy Secondary to Fatty Acid Oxidation Disorder|Fatty acid oxidation disorder	A myopathy that was caused by a primary disorder of fatty acid oxidation.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16833>	C45427	Medicine|medicine	The branches of medical science that deal with nonsurgical techniques.			Biomedical Occupation or Discipline	
C168340	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168340>	C98985	Myopathy Secondary to Glycogen Storage Disorder|Glycogen storage disorder	A myopathy that was caused by a primary disorder of glycogen storage.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168341	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168341>	C168074	No Abdominal Bruit|No abdominal bruits	An indication that auscultation of the major arteries of the abdomen demonstrates an absence of vascular sounds.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168342	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168342>	C176723	No Alleviating Factor to Chief Complaint|None	An indication that the chief complaint was not lessened or improved by another factor.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168343	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168343>	C77140	No Exacerbating Factor to Chief Complaint|None	An indication that the chief complaint was not worsened by another factor.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168344	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168344>	C66921	No History of Congenital Heart Disease|No	An indication that the patient does not have a history of congenital heart disease.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168345	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168345>	C18772	No History of Gestational Complication|No	An indication that the patient's mother did not have a gestational complication while pregnant with the patient.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168346	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168346>	C18772	No History of Kawasaki Disease|No	An indication that the patient does not have a history of a Kawasaki disease.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168347	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168347>	C18772	No History of Myopathy|No	An indication that the patient does not have a history of myopathy.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168348	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168348>	C18772	No History of Neonatal Complication|No	An indication that the patient did not have a neonatal complication during the period around their birth.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168349	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168349>	C166353	No History of Non-Cardiac Surgery|No	An indication that the patient does not have a history of a surgery not involving the heart.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16834>	C20349	Meiosis|meiosis	A special form of cell division in which each daughter cell receives half the amount of DNA as the parent cell. Meiosis occurs during formation of egg and sperm cells in mammals.			Phenomenon or Process	
C168350	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168350>	C18772	No History of Other Muscular Dystrophy or Glycogen Storage Disorder|No	An indication that the patient does not have a history of a muscular dystrophy or storage disorder other than those listed.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168351	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168351>	C18772	No History of Rheumatic Fever|No	An indication that the patient does not have a history of rheumatic fever.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168352	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168352>	C81229	No Known History of Alcohol Use|No	An indication that the patient does not have a history of alcohol use.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168353	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168353>	C168250	No Known History of Allergy|None [allergy]	An indication that the patient does not have a history of an allergic reaction.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168354	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168354>	C81246	No Known History of Illicit Drug Use|No	An indication that the patient does not have a history of illicit drug use.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168355	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168355>	C168420|C123600	No Response to Intervention for Kawasaki Disease|No	An indication that a patient did not respond to a treatment for Kawasaki disease.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168356	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168356>	C176724	No Sequelae of Intervention for Kawasaki Disease|None	An indication that no sequelae were noted following treatment for Kawasaki disease.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168357	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168357>	C106101	No Signs and Symptoms Associated with Chief Complaint|None	An indication that no signs or symptoms associated with the chief complaint are present.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168358	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168358>	C137852	Normal Abdomen on Palpation|Normal	An indication that palpation of the abdomen demonstrates no organomegaly or masses found.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168359	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168359>	C83119	Normal Abdomen on Visual Inspection|Normal	An indication that there are no abnormal findings on visual inspection of the abdomen.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16835>	C23988	Experimental Malignant Melanoma|Experimental Melanoma		Malignant Melanoma		Neoplastic Process	
C168360	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168360>	C83119	Normal Appearance of Extremities|Normal|Normal Appearance of the Extremities	An indication that the extremities demonstrate no anomalies on visual inspection.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168361	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168361>	C35655	Normal Blood Oxygen Saturation|Normal saturation	A measure of level of the degree to which oxygen is bound to hemoglobin is in the normal range.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168362	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168362>	C83119	Normal Capillary Refill Time|Normal|Normal Capillary Refill	A clinical finding in which a capillary nail refill test returns to pink color in less than 2 seconds after pressure is removed.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168363	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168363>	C83119	Normal Chest Appearance|Normal|Normal Thoracic Appearance	Inspection of the region of the anterior surface of the chest and epigastrium reveals a normally shaped thorax, free from any infection, other form of disease or malformation or asymmetry; and a point of maximal impulse (apical impulse) that is a single outward impulse, usually located inside the mid clavicular point at the fifth intercostal space.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168364	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168364>	C83119	Normal Point of Maximum Impulse|Normal	A clinical finding in which the point of maximum impulse is located in the midclavicular line, fifth intercostal space.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168365	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168365>	C137852	Normal Precordial Palpation Finding|Normal	A clinical finding in which palpation of the chest wall anterior to the heart reveals normal location and characteristic of the right ventricular and apical impulses without other palpable impulses. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168366	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168366>	C41210	Noxious Stimulus|Noxious stimulus	Hurtful, injurious, or pernicious action that produces a reaction in a receptor or tissue.			Functional Concept	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168367	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168367>	C25279	Onset of Chief Complaint|Chief Complaint – Onset	The time period when the chief complaint first occurred.			Temporal Concept	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168368	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168368>	C167416	Other Abnormal Cardiac Study|Other	A history of having had an abnormal finding during a cardiac study other than those listed.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168369	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168369>	C85497	Other Chief Complaint|Others	An indication that the primary reason for a patient visit to a healthcare provider is other than those listed.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16836>	C16843	Neprilysin|Antigen CD10|Atriopeptidase|CALLA|CD10|CD10|CD10 Antigen|Common ALL Antigen|Common Acute Lymphoblastic Leukemia Antigen|EC 3.4.24.11|Enkephalinase|MME|Membrane Metalloendopeptidase|NEP|Neutral Endopeptidase|SFE|Skin Fibroblast Elastase|cALLa	Neprilysin (750 aa, ~86 kDa) is encoded by the human MME gene. This protein is involved in the metabolism of biologically active peptides.	Neprilysin		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C168370	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168370>	C181043	Other Common Clinical Findings Noted During the Evaluation for Cardiac Disease	Other clinical findings noted during the patient's evaluation for cardiac disease.			Conceptual Entity	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168371	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168371>	C77140	Other Exacerbating Factor to Chief Complaint|Other	An indication that the chief complaint was worsened by another factor other than those listed.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168372	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168372>	C167233	Other Extremity Blood Pressure Measurement|Vital Signs – Other Extremity Blood Pressure	The arterial blood pressure as measured from any extremity other than the right arm.			Diagnostic Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168373	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168373>	C167449	Other Family History of Heart Disease|Others	A history of a first-degree relative with diagnosed with a heart disease other than those listed.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168374	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168374>	C168214	Other Frequency of Chief Complaint|Other	The chief complaint is noted to occur at a frequency other than those listed.			Qualitative Concept	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168375	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168375>	C168217	Other Genetic Syndrome Associated with Congenital Heart Defect|Other	An indication that the patient has a history of a genetic syndrome associated with a congenital heart defect other than those listed.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168376	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168376>	C168327	Other Medication Given for Kawasaki Disease|Other	An indication that other non-listed medications were given as treatment for Kawasaki disease.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168377	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168377>	C168327	Other Medication Given for Rheumatic Fever|Other	An indication that other non-listed medications were given as treatment for rheumatic fever.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168378	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168378>	C35552	Other Presenting Finding of Congenital Heart Disease|Other	An indication that the patient had a presenting finding of congenital heart disease other than those listed.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168379	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168379>	C83119	Pain in Epigastrium|Epigastric Pain|Epigastrium	The location of the pain is in the upper and middle region of the abdomen, located within the sternal angle.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16837>	C20030	Membrane Protein	Proteins that are physically associated with the membrane. This class of proteins resides in cellular or intracellular membranes. The physical association of each protein is divided into two classes: integral and peripheral.			Amino Acid, Peptide, or Protein	
C168380	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168380>	C15454	Palatorrhaphy|Cleft Palate Repair|Cleft palate repair	The surgical repair of a cleft palate by approximation of the intact tissues surrounding the defect.			Therapeutic or Preventive Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168381	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168381>	C121558	Pallid Breath Holding|Pallid Breath Holding Spell|Pallid Breath-holding Spell|Pallid breath-holding spell	A clinical condition in which there is a breath-holding spell associated with pale appearance. (ACC/AHA)			Sign or Symptom	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168382	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168382>	C84480	Pathologic Murmur|Pathologic murmur	A clinical finding in which turbulent flow is noted by auscultation that is associated with a structural cardiac defect. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168383	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168383>	C18772	Patient was Not Previously Evaluated for Current Chief Complaint|No	An indication that the patient was not previously clinically assessed for the same chief complaint.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168384	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168384>	C18772	Patient was Previously Evaluated for Current Chief Complaint|Yes	An indication that the patient was previously clinically assessed for the same chief complaint.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168385	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168385>	C110937	Pectus Carinatum|Pectus carinatum	A clinical finding in which there is protuberance of the sternum visible on examination of the chest. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168386	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168386>	C110937	Pectus Excavatum|Pectus excavatum	A clinical finding in which there is depression of the sternum visible on examination of the chest. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168387	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168387>	C50656	Pedal Spasm|Pedal spasm	A spasmodic contraction of the muscles of the feet, especially the ankles, such as during alkalosis or tetany. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168388	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168388>	C168327	Penicillin Given for Rheumatic Fever|Penicillin	An indication that penicillin was given as treatment for rheumatic fever.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168389	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168389>	C21514	Periodicity of Chief Complaint|Chief Complaint – Periodicity	The regular interval of time when the chief complaint recurs.			Temporal Concept	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16838>	C21173	Menstrual Cycle|menstrual cycle	The Menstrual Cycle involves regularly recurring hormonal changes and physiologic endometrial changes during the reproductive period in human females, and some primates, and culminates in partial sloughing of the endometrium (menstruation) in the absence of fertilization. For most women, one cycle takes 28 days. (NCI)			Physiologic Function	
C168390	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168390>	C35552	Poorly Perfused|Poorly perfused	A clinical condition in which there is insufficient blood flow to the core or to the extremities. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168391	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168391>	C37928	Postictal Confusion|Postictal confusion	A period of confusion following a seizure in which the patient does not respond appropriately despite appearing awake.			Sign or Symptom	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168392	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168392>	C78238	Precordial Catch Syndrome|Musculoskeletal chest pain: idiopathic/precordial catch syndrome|Texidor's Twinge|Texidor's twinge	A condition in which there is musculoskeletal chest pain characterized by brief, sharp discomfort associated with inspiration. (ACC/AHA)			Sign or Symptom	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168393	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168393>	C122008	Precordial Palpation|Cardiac Examination – Precordium, Palpation|Palpation of Precordium	Palpation of the part of the chest wall that is located anterior to the heart. (ACC/AHA)			Diagnostic Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168394	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168394>	C35552	Precordial Palpation Finding of Lift or Heave|Lift or heave	A clinical finding in which there is an abnormally increased and sustained systolic pulsation found on palpation of the chest wall over the heart, including over a ventricle or the pulmonary artery area. This is typically associated with increased blood volume or pressure in the associated chamber. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168395	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168395>	C35552	Precordial Palpation Finding of Palpable Heart Sound|Palpable heart sound	A clinical finding in which a heart sound is felt during palpation of the chest wall. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168396	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168396>	C35552	Precordial Palpation Finding of Tap|Tap	A clinical finding in which there is an abnormally increased and localized brief pulsation found on palpation of the chest wall over the heart, typically associated with ventricular hypertrophy or increased intraventricular pressure. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168397	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168397>	C35552	Precordial Palpation Finding of Thrill|Thrill	A clinical finding in which humming vibration; accompanying a loud, harsh or rumbling murmur felt during palpation of the precordium or over the blood vessels. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168398	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168398>	C35552	Presenting Finding of Congenital Heart Disease|Presenting Finding	The presenting findings of congenital heart disease in the patient.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168399	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168399>	C16124	Previous Therapies at Patient Evaluation Prior to Current Chief Complaint|Prior Evaluation: Previous Therapies	The previous therapies given at the prior clinical assessment of the patient for the current chief complaint.			Diagnostic Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16839>	C16669	Psychological Health	mental health status.			Conceptual Entity	
C1683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1683>	C1757	Tyrphostin A47|AG 213|RG 50864	A member of the tyrphostin family of tyrosine kinase inhibitors that inhibits epidermal growth factor receptor, capacitative calcium ion entry into cells, blocks HT-29 colon cancer cell proliferation and induces non-apoptotic cell death. (NCI)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C168400	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168400>	C3120	Primary Pulmonary Hypertension|Primary pulmonary hypertension|Primary pulmonary hypertension	Pulmonary hypertension that is not caused by any other disease or condition.			Disease or Syndrome	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|mCode Elixhauser Pulmonary Circulation Disorder Value Set|mCode Terminology
C168401	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168401>	C18772	Prior Patient Evaluation for Current Chief Complaint|Prior Evaluation	A prior clinical assessment of the patient for the current chief complaint.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168402	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168402>	C62166	Prolonged Standing|Prolonged standing	The state of being in an upright position continuing for a time greater than what would be considered normal. (ACC/AHA)			Spatial Concept	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168403	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168403>	C83119	Protuberant Abdomen|Protuberant	An indication that there is unusual or prominent convexity of the abdomen on visual inspection.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168404	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168404>	C36280	Psychiatric Finding|Psychiatric	Symptoms, physical examination results, and/or laboratory test results related to mental health.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168405	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168405>	C35053	Psychogenic Syncope|Psychogenic syncope	A condition in which syncope occurs due to a conversion disorder. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168406	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168406>	C35552	Pulse Wave Absent|0 (absent)|0 Pulse|Pulse 0	A clinical finding in which palpation of a pulse demonstrates no upstroke or amplitude. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168407	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168407>	C122008	Pulse Wave Amplitude Measurement|Examination of the Extremities – Pulses, Amplitude	The measurement a pulse wave's amplitude by palpation.			Diagnostic Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168408	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168408>	C35552	Pulse Wave Decreased|1+ (decreased)|1+ Pulse|Pulse 1+	A clinical finding in which palpation of a pulse demonstrates a diminished upstroke and/or amplitude. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168409	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168409>	C35552	Pulse Wave Increased|3+ (increased)|3+ Pulse|Pulse 3+	A clinical finding in which palpation of the pulse demonstrates a significantly increased upstroke and/or amplitude. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16840>	C21074	Mental Process	Any cognitive activity.			Mental Process	
C168410	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168410>	C35552	Pulse Wave Markedly Increased|4+ (water hammer or markedly increased)|4+ Pulse|Water Hammer Pulse	A clinical finding in which palpation of the pulse demonstrates a significantly increased upstroke, amplitude, and rapid decay. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168411	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168411>	C35552	Pulse Wave Normal|2+ (normal)|2+ Pulse|Pulse 2+	A clinical finding in which palpation of the pulse demonstrates appropriate upstroke, amplitude, and decay. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168412	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168412>	C38665|C35552	Quality of Chest Pain	The characteristics of chest pain as described by the patient. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168413	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168413>	C35552	Quality of Palpitations	The characteristics of the palpitations as described by the patient. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168414	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168414>	C35552	Racing Heartbeats|Racing heartbeats	The sensation of an abnormally rapid heart rate. (AHA/CC)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168415	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168415>	C35552	Radial-Femoral Lag|Examination of Extremities – Radial-Femoral Lag|Radiofemoral Delay	A delay between the upstroke of the right radial pulse and a femoral pulse who presence indicates coarctation of the aorta.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168416	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168416>	C35552	Radial-Femoral Lag Absent|Absent|Radiofemoral Delay Absent	An indication that a radial-femoral lag is not present.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168417	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168417>	C35552	Radial-Femoral Lag Present|Present|Radiofemoral Delay Present	An indication that a radial-femoral lag is present.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168418	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168418>	C38155	Relapse Following Intervention for Kawasaki Disease|Relapse	An indication that there was a relapse following treatment for Kawasaki disease.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168419	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168419>	C50995	Resolution of Findings Following Intervention for Kawasaki Disease|Resolution of findings	An indication that findings were resolved following treatment for Kawasaki disease.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16841>	C19536	Detoxification|Detoxification Process|Metabolism of Toxic Agents|detoxify	A process to transform a substance with pharmacologic or toxic activities into an alternative form with reduced activity or which can be cleared from the organism more quickly.			Organism Function	
C168420	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168420>	C50995	Response to Intervention for Kawasaki Disease|Intervention for Kawasaki Disease, Response	The patient’s response to treatment of Kawasaki disease. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168421	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168421>	C54055	Retreatment Following Intervention for Kawasaki Disease|Retreatment	An indication that retreatment was required following initial treatment for Kawasaki disease.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168422	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168422>	C4876	Rheumatic Fever Symptom|Symptoms	The symptoms of rheumatic fever that the patient had. (ACC/AHA)			Sign or Symptom	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168423	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168423>	C124438	Rheumatic Fever Symptom Onset Age|Age When First Symptoms Occurred	The age of the patient when the symptoms of rheumatic fever were first noted.			Organism Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168424	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168424>	C119242	Rheumatic Fever Symptom Onset Date|Onset	The date of the first onset of the symptoms of rheumatic fever.			Temporal Concept	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168425	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168425>	C36288	Rheumatological Finding|Rheumatological	Symptoms, physical examination results, and/or laboratory test results related to diseases and disorders of the connective tissues.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168426	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168426>	C167233	Right Arm Blood Pressure Measurement|Vital Signs – RABP	The arterial blood pressure as measured from the right arm.			Diagnostic Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168429	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168429>	C83119	Scaphoid Abdomen|Scaphoid	An indication that the anterior abdominal wall is sunken or has a concave appearance on visual inspection.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168430	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168430>	C3120	Secondary Pulmonary Hypertension|Secondary pulmonary hypertension	Pulmonary hypertension that is caused by an underlying condition.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168431	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168431>	C126361	Sequelae of Intervention for Kawasaki Disease|Intervention for Kawasaki Disease, Sequelae	The sequelae of treatment given for Kawasaki disease.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168432	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168432>	C25676	Severity of Chief Complaint|Chief Complaint – Severity	The intensity of the chief complaint perceived by the patient.			Qualitative Concept	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168433	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168433>	C100104	Signs and Symptoms Associated with Chief Complaint|Associated Symptoms	The signs and symptoms present with the chief complaint.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168434	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168434>	C121558	Simple Breath Holding|Simple Breath Holding Spell|Simple Breath-holding Spell|Simple breath-holding spell	A clinical condition in which there is a breath-holding spell without syncope. (ACC/AHA)			Sign or Symptom	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168435	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168435>	C35120	Situational Syncope|Situational syncope	A condition in which neurally-mediated syncope occurs due to a specific circumstance, such as micturition, defecation, coughing, or traction of the hair. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168436	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168436>	C198262	Skin Examination|Dermal Examination|SKEXAM	An assessment of the skin via physical examination.	Skin Examination		Diagnostic Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|CDISC SEND Skin Test Code Terminology|CDISC SEND Skin Test Name Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology
C168437	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168437>	C35552	Skipped Heartbeats|Early Heartbeats|Skipped/early heartbeats	The sensation of an isolated cardiac contraction occurring prior to the normal or regular rhythm. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168438	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168438>	C3858	Startle	A quick involuntary movement in response to an alarm, surprise, or fright.			Sign or Symptom	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168439	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168439>	C119028	Sterile Pyuria|Sterile pyuria	The presence of leukocytes in the urine without evidence of an infection. (ACC/AHA)			Sign or Symptom	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16843>	C16965	Metallopeptidase|METALLOPROTEASE|Metalloproteinase	A proteolytic enzyme that uses a metal ion, usually zinc, to catalyze the hydrolysis of peptide bonds. This protease is inhibited by metal chelating agents.			Amino Acid, Peptide, or Protein|Enzyme	
C168440	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168440>	C50737	Sternotomy Scar|Sternotomy scar	Replacement of destroyed tissue by fibrous tissue due to a surgical procedure where a vertical inline incision is made along the sternum, after which the sternum itself is divided. (ACC/AHA)			Disease or Syndrome	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168441	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168441>	C168327	Steroids Given for Kawasaki Disease|Steroids	An indication that steroids were given as treatment for Kawasaki disease.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168442	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168442>	C168327	Steroids Given for Rheumatic Fever|Steroids	An indication that steroids were given as treatment for rheumatic fever.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168443	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168443>	C53458	Strawberry Tongue|Strawberry tongue	A pathological finding in which inflammation, hyperemia and enlarged papillae of the dorsum of the tongue resemble a strawberry. It may be seen in variety of bacterial and viral disorders, and in non-infectious disorders such as Kawasaki disease.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168444	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168444>	C168082	Surgery for Rheumatic Fever	A surgical procedure performed as part of the treatment for the sequelae of rheumatic fever.			Diagnostic Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168445	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168445>	C84633	Sydenham Chorea|Chorea Minor|St. Vitus' Dance|Sydenham's chorea	A neurologic disorder characterized by smooth involuntary, uncoordinated movements affecting especially the hands, feet, and face. (ACC/AHA)			Disease or Syndrome	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168446	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168446>	C38665	Symmetric Chest Appearance|Symmetric|Symmetric Thoracic Appearance	Inspection of the region of the anterior surface of the chest and epigastrium reveals an approximate correspondence of form and constituent configuration on opposite sides of a vertical central dividing line.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168447	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168447>	C83119	Symptomatic Presentation|Currently has symptoms|Symptomatic|Symptomatic	A clinical description in which a patient demonstrates evidence of more than one clinical finding suggestive of underlying pathology. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|GDC Terminology|GDC Value Terminology
C168448	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168448>	C35053	Syncope due to Acquired Heart Lesion|Syncope due to acquired heart lesion	A condition in which syncope occurs due to a disease process of the heart with which the patient was not born. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168449	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168449>	C35053	Syncope due to Congenital Heart Lesion|Syncope due to congenital heart lesion	A condition in which syncope occurs due to a disease process of the heart with which the patient was born. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16844>	C20028	Metalloprotein	Proteins that include a metal ion as part of their structure or they contain a metal cofactor. The metal ion can be an isolated ion or coordinated with a nonprotein organic compound, such as the porphyrin moiety found in hemoproteins. Additionally, the metal can be co-coordinated with both a side chain of the protein and an inorganic nonmetallic ion.			Amino Acid, Peptide, or Protein	
C168450	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168450>	C35053	Syncope due to Migraine|Syncope due to migraine	A condition in which syncope occurs associated with the occurrence of cerebral vasospasm. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168451	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168451>	C35053	Syncope due to Pulmonary Hypertension|Syncope due to pulmonary hypertension	A condition in which syncope occurs associated with a sudden and severe increase in pulmonary vascular resistance. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168452	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168452>	C35053	Syncope with Exertion|Syncope with exertion	A condition in which syncope occurs either during or after physical activity. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168453	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168453>	C124351	Tests Performed at Patient Evaluation Prior to Current Chief Complaint|Prior Evaluation: Tests Performed	The studies performed during the prior clinical assessment of the patient for the current chief complaint.			Diagnostic Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168454	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168454>	C50737	Thoracotomy Scar|Thoracotomy scar	Replacement of destroyed tissue by fibrous tissue due to a surgical procedure where an incision was made into the chest wall to the left or to the right of the midline.			Disease or Syndrome	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168455	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168455>	C25207	Time of Day of Chief Complaint|Chief Complaint – Time of Day	The time of day when the chief complaint occurs.			Temporal Concept	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168456	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168456>	C80484	Timing of Intervention for Kawasaki Disease|Intervention for Kawasaki Disease, Timing	The timing of the treatment given to the patient from the onset of the initial symptoms of Kawasaki disease.			Temporal Concept	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168457	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168457>	C3837	Tongue Biting|Biting of Tongue|Tongue-biting	Clamping of the teeth on the tongue, as can accompany a seizure. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168458	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168458>	C50995	Type of Response to Intervention for Kawasaki Disease|Intervention for Kawasaki Disease, Type of Response	The type of response noted after treatment was given for Kawasaki disease.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168459	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168459>	C45501	Unknown if Medication Taken|Unknown	An indication that it is unknown whether the patient has taken medication.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16845>	C20315	Metallothionein	A family of cysteine-rich proteins that bind to and transport heavy metal ions.			Amino Acid, Peptide, or Protein	
C168460	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168460>	C169077	Unknown Daily Caloric Intake|Unknown	The daily caloric intake is unknown.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168461	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168461>	C169077	Unknown Daily Fluid Intake|Unknown	The daily fluid intake is unknown.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168462	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168462>	C169077	Unknown Daily Salt Intake|Unknown	The daily salt intake is unknown.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168463	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168463>	C17726	Unknown Family History Cardiovascular Disease or Cardiovascular Disease Risk Factors|Unknown	An indication that the patient has a unknown family history of cardiovascular disease or cardiovascular disease risk factors.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168464	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168464>	C81229	Unknown History of Alcohol Use|Unknown	An indication that it is unknown whether the patient has a history of alcohol use.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168465	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168465>	C168250	Unknown History of Allergy|Unknown [allergy]	An indication that it is unknown whether the patient has a history of an allergic reaction.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168466	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168466>	C66921	Unknown History of Congenital Heart Disease|Unknown	An indication that it is unknown whether the patient has a history of congenital heart disease.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168467	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168467>	C18772	Unknown History of Gestational Complication|Unknown	An indication that it is unknown whether the patient's mother had a gestational complication while pregnant with the patient.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168468	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168468>	C81246	Unknown History of Illicit Drug Use|Unknown	An indication that it is unknown whether the patient has a history of illicit drug use.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168469	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168469>	C18772	Unknown History of Kawasaki Disease|Unknown	An indication that it is unknown whether the patient has a history of Kawasaki disease.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16846>	C20349	Metaphase Process|Metaphase|Mitotic Metaphase	The second phase of mitosis, in which the chromosomes line up across the equatorial plane of the spindle prior to separation.			Phenomenon or Process	
C168470	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168470>	C18772	Unknown History of Myopathy|Unknown	An indication that it is unknown whether the patient has a history of myopathy.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168471	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168471>	C18772	Unknown History of Neonatal Complication|Unknown	An indication that it is unknown whether the patient had a neonatal complication during the period around their birth.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168472	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168472>	C166353	Unknown History of Non-Cardiac Surgery|Unknown	An indication that it is unknown whether the patient has a history of a surgery not involving the heart.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168473	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168473>	C18772	Unknown History of Other Muscular Dystrophy or Glycogen Storage Disorder|Unknown	An indication that it is unknown whether the patient has a history of a muscular dystrophy or storage disorder other than those listed.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168474	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168474>	C18772	Unknown History of Rheumatic Fever|Unknown	An indication that it is unknown whether the patient has a history of rheumatic fever.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168475	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168475>	C18772	Unknown if Caffeine Consumption is Routine|Unknown	An indication that it is unknown whether the patient consumes caffeine on a regular basis.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168476	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168476>	C18772	Unknown if Chief Complaint Caused by Trauma|Unknown	An indication that it is unknown whether the chief complaint was caused by a traumatic event.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168477	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168477>	C18772	Unknown if Chief Complaint was Witnessed|Unknown	An indication that it is unknown whether the chief complaint was witnessed.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168478	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168478>	C18772	Unknown if Has Sibling|Other	An indication that it is unknown whether an individual has a sibling.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168479	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168479>	C18772	Unknown if Patient Has Genetic Syndrome Associated with Congenital Heart Defect|Unknown	An indication that it is unknown whether the patient has a history of a genetic syndrome associated with a congenital heart defect.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16847>	C43431	Technique|Method|Methods|Methods and Techniques|Methods, Other|Technical|Techniques	A practiced and regimented skill or series of actions.			Activity	
C168480	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168480>	C18772	Unknown if Patient was Previously Evaluated for Current Chief Complaint|Unknown	An indication that it is not known whether the patient was previously clinically assessed for the same chief complaint.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168481	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168481>	C18772	Unknown when Chief Complaint Present|Unknown	The time of day that the chief complaint occurs is not known.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168482	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168482>	C35120	Vasodepressor Syncope|Vasodepressor syncope	A condition in which neurally-mediated syncope occurs in which the blood pressure falls and the heart rate increases. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168483	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168483>	C93208	Ventriculoperitoneal Shunt Placement|Ventriculo-peritoneal shunt|Ventriculoperitoneal shunt	A therapeutic procedure that involves the placement of a tube in one of the ventricles of the brain to allow for drainage of cerebrospinal fluid (CSF) into the peritoneal cavity. It is used to relieve hydrocephalus.	Ventriculoperitoneal Shunt Placement		Therapeutic or Preventive Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|CRF4 Treatment Table|CTRP Intervention Terminology|CTRP Terminology
C168484	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168484>	C83119	Well Perfused|Well perfused	A clinical finding in which there is sufficient blood flow to the core and extremities. (ACC/AHA)			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168485	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168485>	C82438	Witnessing of Chief Complaint|Witnessed	An indication that a witness was present when chief complaint was noted by patient.			Diagnostic Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168488	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168488>	C101172	Burning Chest Pain|Burning Pain	The sensation of chest pain described as an intense discomfort, similar to that experience as a result of a thermal burn, distinct from sharp, stabbing or aching, often related to nerves; sometimes used to describe gastric or esophageal pain.			Sign or Symptom	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168489	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168489>	C101175	Dull Chest Pain|Dull Pain	The sensation of chest pain described as a mild or blunted discomfort.			Sign or Symptom	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16848>	C40468	Methylation|methylation	The covalent chemical or biochemical addition of a methyl group(s) to a compound. (NCI)			Phenomenon or Process	GDC Terminology|GDC Value Terminology
C168492	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168492>	C66921|C17726	Family History of Cardiovascular Disease or Cardiovascular Disease Risk Factors	A history of a first-degree relative with cardiovascular disease or cardiovascular disease risk factors.			Clinical Attribute	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168497	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168497>	C2849	Multiple Congenital Anomalies|Multiple anomalies	The presence of multiple congenital malformations in a patient.			Disease or Syndrome	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168498	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168498>	C2959	Neonatal Complication|Neonatal Complications	A difficulty or problem that occurs at or just after delivery of an infant that can jeopardize the health of the infant.			Finding	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16849>	C17210	Methyltransferase|EC 2.1.1	A class of enzymes that transfers a functional methyl group from one chemical compound to another.			Amino Acid, Peptide, or Protein|Enzyme	
C1684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1684>	C593	Recombinant Interleukin-17|CTLA-8 (Therapeutic)|IL-17|Interleukin-17	A recombinant agent, which is chemically identical or similar to the endogenous cytokine interleukin-17 (IL-17). IL-17 is produced by cytotoxic T cells and stimulates stromal cells to produce pro-inflammatory and hematopoietic cytokines. This cytokine enhances expression of IL-6, IL-8, and ICAM-1 in fibroblasts and appears to induce osteoclastogenesis.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C168501	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168501>	C101177	Pressure Chest Pain|Pressure Pain	The sensation of chest pain described as an object creating physical force.			Sign or Symptom	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168506	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168506>	C101179	Sharp Chest Pain|Sharp Pain	The sensation of chest pain described as a stabbing feeling.			Sign or Symptom	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C16850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16850>	C25464	Mexico|484|MEX|MEX|MEXICO|MEXICO|MX	A country in southern North America, bordering the North Pacific Ocean and the Gulf of Mexico, south of the US.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C168517	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168517>	C101183	Tearing Chest Pain|Tearing Pain	The sensation of chest pain described as a sharp, lacerating, intense, discomfort; sometimes used to describe the pain felt during an aortic dissection.			Sign or Symptom	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology
C168519	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168519>	C5214	HER2-Negative Breast Carcinoma|HER2 Negative Breast Adenocarcinoma|HER2 Negative Breast Carcinoma|HER2 Negative Breast Carcinoma	A breast adenocarcinoma that is negative for the expression of the HER2 receptor.	HER2 Negative Breast Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16851>	C16345	Microbiology	The science that deals with the study of microorganisms, including algae, archaea, bacteria, fungi, protozoa, and viruses.			Biomedical Occupation or Discipline	
C168520	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168520>	C208186	Fecal Microbiota Transplantation Capsule|FMPCapDE|FMT Capsule DE|FMT Capsule Delivery|FMT DE Capsule|Fecal Microbiota Preparation Delivery Capsule	An oral capsule formulation composed of frozen ready-to-use human fecal microbiota from screened, healthy donors with healthy gut microbiota, for the potential treatment of recurrent Clostridium difficile (C. difficile) infections. Upon oral administration of the fecal microbiota transplantation (FMT) capsule, the microbiota in the capsule populate the gastrointestinal (GI) tract. The transplanted microbiota allows re-population of the patient's microbiome with diverse protective microorganisms that competitively exclude C. difficile. This prevents recurrent C. difficile infections.	Fecal Microbiota Transplantation Capsule		Bacterium|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology
C168521	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168521>	C15277	Bilateral Mastectomy	Surgical removal of both breasts.	Bilateral Mastectomy		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C168522	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168522>	C155745	Anti-CD137 Agonistic Monoclonal Antibody AGEN2373|AGEN 2373|AGEN-2373|AGEN2373|Anti-4-1BB Agonistic Monoclonal Antibody AGEN2373|Anti-CD137 Agonist Monoclonal Antibody AGEN2373|Anti-CD137 Monoclonal Antibody AGEN2373	A conditionally-active, fully human immunoglobulin G1 (IgG1) agonistic monoclonal antibody targeting the costimulatory receptor CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD137 agonistic monoclonal antibody AGEN2373 targets and binds to a non-ligand blocking epitope on CD137, thereby activating CD137 expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes a CTL-mediated anti-tumor immune response as well as induces NK-mediated tumor cell killing and suppresses the immunosuppressive activity of T-regulatory cells (Tregs). CD137, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. In addition, as AGEN2373 engages with CD137 only in the presence of CD137 ligand and/or Fc gamma receptor-expressing antigen-presenting cells (APCs), this agent may have a decreased toxicity profile and improved tolerability compared to other agents that activate CD137 signaling beyond the tumor site in humans.	Anti-CD137 Agonistic Monoclonal Antibody AGEN2373		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C168523	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168523>	C171054|C133155	KRAS Gene Rearrangement|KRAS Rearrangement|KRAS-2 Gene Rearrangement|KRAS2 Gene Rearrangement|c-K-ras Gene Rearrangement|v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Gene Rearrangement	A molecular abnormality indicating rearrangement of the KRAS gene.	KRAS Gene Rearrangement		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C168524	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168524>	C177683	ERBB Family Gene Fusion Positive|EGF Receptor Family Gene Fusion Positive|ERBB Family Gene Fusion|ERBB Receptor-Tyrosine Kinase Family Gene Fusion Positive|Epidermal Growth Factor Receptor Family Gene Fusion Positive|ErbB Receptor Family Gene Fusion Positive|ErbB Receptor Tyrosine Kinase Family Gene Fusion Positive|HER Family Gene Fusion Positive|HER Family Receptor Gene Fusion Positive|Human Epidermal Growth Factor Receptor Family Gene Fusion Positive	An indication that a fusion containing ERBB family gene sequences have been detected in a sample.	ERBB Family Gene Fusion Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C168525	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168525>	C35682	FH Alteration Positive|FH Alteration|FMRD Alteration Positive|Fumarase Alteration Positive|Fumarate Hydratase Alteration Positive|HsFH Alteration Positive|MCL Alteration Positive|MCUL1 Alteration Positive	An indication that mislocalization, loss or gain of activity, underexpression, overexpression, mutation, fusion or rearrangement involving FH has been detected in a sample.	FH Alteration Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C168526	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168526>	C35682	SDH Complex Alteration Positive|Mitochondrial Complex II Alteration Positive|Mitochondrial Respiratory Chain Complex II Alteration Positive|SDH Alteration|SDH Alteration Positive|SDH Family Alteration Positive|Succinate Dehydrogenase Alteration Positive|Succinate-CoQ Reductase Alteration Positive|Succinate-Coenzyme Q Reductase Alteration Positive	An indication that mislocalization, loss or gain of activity, underexpression, overexpression, mutation, fusion or rearrangement involving a either a member of or the entire SDH complex has been detected in a sample.	SDH Complex Alteration Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C168527	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168527>	C390	Manganese/L-alanine/Vitamin D3-containing Contrast Agent Formulation|CMC 001|CMC-001|CMC001|Manganese-based Contrast Agent CMC 001|Mangoral	An orally bioavailable contrast agent formulation composed of the contrast agent manganese chloride tetrahydrate (MnCl2 4H2O), and the absorption promoters L-alanine and vitamin D3, that can potentially be used as a contrast enhancer during hepatobiliary magnetic resonance imaging (MRI). Upon oral administration of the manganese/L-alanine/vitamin D3-containing contrast agent formulation, L-alanine and vitamin D3 enhance the absorption of the poorly absorbable contrast agent manganese, mainly from the small intestines. Upon absorption, the trace element manganese is taken up by normal, healthy hepatocytes. Due to the retention of manganese in the hepatocytes and its paramagnetic properties, this contrast agent enhances the visualization of normal liver tissue during an MRI. As tumor cells do not accumulate manganese, abnormal hepatic cells, such as hepatic tumor cells, will become clearly detectable against the enhanced normal liver tissue on the MR image. This enhances the visualization and detection of liver lesions, including liver metastases.	Manganese/L-alanine/Vitamin D3-containing Contrast Agent Formulation		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C168528	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168528>	C35682	VHL Alteration Positive|VHL Alteration|VHL1 Alteration Positive|Von Hippel-Lindau Disease Tumor Suppressor Alteration Positive|von Hippel Lindau Tumor Suppressor Alteration Positive	An indication that mislocalization, loss or gain of activity, underexpression, overexpression, mutation, fusion or rearrangement involving VHL has been detected in a sample.	VHL Alteration Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C168529	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168529>	C148403	Elevated MET Protein Expression|Elevated HGF Receptor Protein Expression|Elevated HGFR Protein Expression|Elevated Hepatocyte Growth Factor Receptor Protein Expression|Elevated Proto-Oncogene c-Met Protein Expression|Elevated Scatter Factor Receptor Protein Expression|Elevated Tyrosine-Protein Kinase Met Protein Expression|Elevated c-Met Protein Expression	An indication that elevated concentrations of MET protein were found in a sample.	Elevated MET Protein Expression		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C16852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16852>	C16492	Microfilament Protein	Structurally complex proteins that are comprised of microfilaments, which are necessary components of the cellular cytoskeleton for motility and shape. Microfilaments physically associate with microtubules to play a structural role in cytoskeleton integrity.			Amino Acid, Peptide, or Protein	
C168530	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168530>	C179848|C174462	FUS Gene Translocation|FUS RNA Binding Protein Gene Translocation|FUS Translocation|FUS Translocation Present|FUS1 Gene Translocation|Fused In Sarcoma Gene Translocation|Fusion Gene In Myxoid Liposarcoma Gene Translocation|TLS Gene Translocation|Translocated In Liposarcoma Gene Translocation	A cytogenetic abnormality that refers to any translocation involving the FUS gene.	FUS Gene Translocation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|EWS Authorized Value Terminology|EWS Molecular Analysis Table
C168531	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168531>	C163968	PRMT5 Inhibitor PRT811|PRT 811|PRT-811|PRT811|Protein Arginine Methyltransferase 5 Inhibitor PRT811	An orally available small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), with potential antiproliferative and antineoplastic activities. Upon oral administration, PRMT5 inhibitor PRT811 selectively binds to PRMT5 and inhibits its function. By inhibiting its methyltransferase activity, levels of both monomethylated and dimethylated arginine residues in histones H2A, H3 and H4 are decreased. This modulates the expression of genes involved in several cellular processes, including cellular proliferation. This may increase the expression of antiproliferative genes and/or decrease the expression of genes that promote cell proliferation, which may lead to decreased growth of rapidly proliferating cells, including cancer cells. PRMT5, a type II methyltransferase that catalyzes the formation of both omega-N monomethylarginine (MMA) and symmetric dimethylarginine (sDMA) on histones and a variety of other protein substrates involved in signal transduction and cellular transcription, is overexpressed in several neoplasms. Elevated levels are associated with decreased patient survival.	PRMT5 Inhibitor PRT811		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C168532	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168532>	C16295	EGF Antibody|Anti-EGF|Anti-EGF Antibody|Anti-Epidermal Growth Factor|Anti-Epidermal Growth Factor Antibody|Anti-Urogastrone Antibody|Epidermal Growth Factor Antibody|Urogastrone Antibody	Any immunoglobulin that recognizes epidermal growth factor protein.	EGF Antibody		Amino Acid, Peptide, or Protein|Immunologic Factor	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C168533	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168533>	C82009	Circulating EGF Measurement|Circulating Epidermal Growth Factor Measurement|Free EGF Measurement|Free Epidermal Growth Factor Measurement	A measurement of the unbound epidermal growth factor in a peripheral blood-derived specimen.	Circulating EGF Measurement		Laboratory Procedure	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C168534	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168534>	C36843	Cancer-Associated Fibroblast|CAF|CAFs|Cancer Associated Fibroblast|TAF|Tumor Associated Fibroblast|Tumor-Associated Fibroblast	A fibroblast found proximal to or within cancerous tissue.	Cancer-Associated Fibroblast		Cell	CTRP Biomarker Terminology|CTRP Terminology
C168535	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168535>	C168534	Circulating Cancer-Associated Fibroblast|Circulating Cancer Associated Fibroblast|cCAF|cCAFs	A fibroblast found in the peripheral blood that is associated with a neoplastic disease and may colocalize with circulating tumor cells.	Circulating Cancer-Associated Fibroblast		Cell	CTRP Biomarker Terminology|CTRP Terminology
C168536	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168536>	C26683	Kappa Light Chain-Restriction|IGK Restriction|Kappa Light Chain Restriction|Kappa Restriction	An increase in the ratio of cells expressing the immunoglobulin light chain (Ig LC) kappa versus those expressing Ig LC lambda in a sample.	Kappa Light Chain-Restriction		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C168537	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168537>	C35682	KEAP1 Alteration Positive|KLHL19 Alteration Positive|Kelch-Like ECH-Associated Protein 1 Alteration Positive|Kelch-Like Family Member 19 Alteration Positive	An indication that mislocalization, loss or gain of activity, underexpression, overexpression, mutation, fusion or rearrangement involving KEAP1 has been detected in a sample.	KEAP1 Alteration Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C168538	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168538>	C168537|C103223	KEAP1 Gene Alteration Positive|INRF2 Gene Alteration Positive|KLHL19 Gene Alteration Positive|Kelch-Like ECH-Associated Protein 1 Gene Alteration Positive	An indication that underexpression, overexpression, mutation, amplification, fusion or rearrangement involving the KEAP1 gene has been detected in a sample.	KEAP1 Gene Alteration Positive		Laboratory or Test Result	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C168539	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168539>	C4980	Gastrointestinal Tract Acute Graft Versus Host Disease	Acute graft versus host disease occurring in the gastrointestinal tract.	Gastrointestinal Tract Acute Graft Versus Host Disease		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C16853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16853>	C74957|C17369	Microscopy|GM|MICROSCOPY	The use of various technologies to resolve the structure or features of objects too small or fine to naturally be seen by eye.	Microscopy		Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Genetic Toxicology In vivo Method Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|SeroNet Authorized Values|SeroNet Study Descriptors
C168540	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168540>	C168582|C168539	Steroid Resistant Gastrointestinal Tract Acute Graft Versus Host Disease|Steroid Refractory Gastrointestinal Tract Acute Graft Versus Host Disease	Acute graft versus host disease occurring in the gastrointestinal tract that is resistant to treatment with steroids.	Steroid Resistant Gastrointestinal Tract Acute Graft Versus Host Disease		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C168541	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168541>	C168539	Severe Gastrointestinal Tract Acute Graft Versus Host Disease	Graft versus host disease occurring in the gastrointestinal tract and is characterized by complications that may be life-threatening.	Severe Gastrointestinal Tract Acute Graft Versus Host Disease		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C168542	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168542>	C170812|C162653|C143013	Advanced Skin Squamous Cell Carcinoma	A skin squamous cell carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Skin Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168543	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168543>	C191983|C170965|C162706	Locally Advanced Thyroid Gland Medullary Carcinoma	A thyroid gland medullary carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Thyroid Gland Medullary Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168544	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168544>	C25995|C2196	Metarrestin|ML 246|ML-246|ML-246|ML246|Trans-4-(7-benzyl-4-imino-5,6-diphenylpyrrolo[2,3-d]pyrimidin-3-yl)cyclohexan-1-ol	An orally available small molecule inhibitor of perinucleolar compartment (PNC), with potential antineoplastic activities. Although the exact mechanisms(s) through which this agent exerts its effects have yet to be fully elucidated, upon oral administration, metarrestin disrupts the structure of PNC and inhibits RNA polymerase (Pol) I transcription. This leads to the reduction in the prevalence of PNC in cancer cells and decrease in tumor growth and spread. PNC is a subnuclear structure and a phenotypic marker of metastatic cancer cells. A high PNC prevalence has been associated with disease progression and poor patient outcomes.	Metarrestin		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C168545	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168545>	C7376|C165252	Metastatic Pleural Malignant Mesothelioma	Pleural malignant mesothelioma that has spread from its original site of growth to another anatomic site.	Metastatic Pleural Malignant Mesothelioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168546	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168546>	C16742	ExAblate 4000 Type 2.0|ExAblate 4000 - Type 2|Exablate|Exablate Neuro	A proprietary device that uses focused ultrasound to induce disruption of the blood-brain barrier.	ExAblate 4000 Type 2.0		Manufactured Object	CTRP Intervention Terminology|CTRP Terminology
C168547	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168547>	C54443	PCDC Terminology|Pediatric Cancer Data Commons	Terminology developed with the University of Chicago to support the Pediatric Cancer Data Commons.			Intellectual Product	
C168549	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168549>	C174234	AML Table Terminology|Acute Myeloid Leukemia Table Terminology	Tables of data developed by PCDC to group the data in the AML project.			Intellectual Product	AML Project Terminology|PCDC Terminology
C16854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16854>	C16853	Electron Microscopy	Any form of microscopy in which the interactions of electrons with the specimens are used to provide information about the final structure of that specimen.	Electron Microscopy		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C168554	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168554>	C21609	Squamous Cell Carcinoma of the Mouse Tongue	Squamous cell carcinoma arising from the tongue in a mouse.			Neoplastic Process	Cellosaurus Disease Terminology
C168555	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168555>	C91105	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 Items|EOR18|EORTC QLQ Lung Cancer Module|EORTC QLQ-LC13|EORTC QLQ-LC13|EORTC Study Group on Quality of Life 13-item Lung Cancer-Specific Questionnaire|European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer Module	A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials.			Intellectual Product	CDISC QRS Terminology|CDISC Questionnaire Category Terminology|CDISC Questionnaire Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30
C168556	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168556>	C173134	How Much Did You Cough Question|How Much Did You Cough|How much did you cough	A question about how much an individual coughed.			Intellectual Product	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 Items
C168557	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168557>	C173134	Did You Cough Up Blood Question|Coughed Up Blood|Did You Cough Up Blood|Did you cough up blood	A question about whether an individual coughed up blood.			Intellectual Product	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 Items
C168558	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168558>	C175903	Short of Breath When You Rested Question|Short of Breath When You Rested|Were you short of breath when you rested	A question about whether an individual is or was short of breath when they rested.			Intellectual Product	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 Items
C168559	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168559>	C175903|C173135	Short of Breath When You Walked Question|Short of Breath When You Walked|Were you short of breath when you walked	A question about whether an individual is or was short of breath when they walked.			Intellectual Product	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 Items
C16855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16855>	C16854	Scanning Electron Microscopy|Microscopy, Electron, Scanning|SCANNING ELECTRON MICROSCOPY	Technique of electron microscopy in which the specimen is coated with heavy metal and then scanned by an electron beam. The resolution is not as great as with transmission electron microscopy, but preparation is easier (often by fixation followed by critical point drying), the depth of focus is relatively enormous, the surface of a specimen can be seen (though not the interior unless the specimen is cracked open) and the image is aesthetically pleasing.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Microscopic Findings Method Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C168560	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168560>	C175903	Short of Breath When You Climbed Stairs Question|Short of Breath When You Climbed Stairs|Were you short of breath when you climbed stairs	A question about whether an individual is or was short of breath when they climbed stairs.			Intellectual Product	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 Items
C168561	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168561>	C173981	Had Sore Mouth or Tongue Question|Had Sore Mouth or Tongue|Have you had a sore mouth or tongue	A question about whether an individual has or had a sore mouth or tongue.			Intellectual Product	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 Items
C168563	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168563>	C173734	Tingling Hands or Feet Question|Had Tingling Hands or Feet|Have you had tingling hands or feet|Tingling Hands or Feet	A question about whether an individual has or had tingling in hands or feet.			Intellectual Product	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 Items
C168564	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168564>	C206077	Aicardi-Goutieres Syndrome 5|AGS5	A genetic condition usually inherited in an autosomal recessive pattern. It is cause by mutation(s) in the SAMHD1 gene, encoding deoxynucleoside triphosphate triphosphohydrolase SAMHD1. Clinical features and onset may vary significantly, but is characterized in its most severe form by cerebral atrophy, leukodystrophy, intracranial calcifications, chronic cerebrospinal fluid (CSF) lymphocytosis, and increased concentrations of CSF alpha-interferon.			Disease or Syndrome	Cellosaurus Disease Terminology
C168566	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168566>	C91126	Had Pain in Other Parts of Body Question|Had Pain in Other Parts of Body|Have you had pain in other parts of your body	A question about whether an individual has or had pain in other parts of their body.			Intellectual Product	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 Items
C168567	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168567>	C173346	Take Medicine for Pain Question|Did you take any medicine for pain|Take Medicine for Pain	A question about whether an individual took or is taking any medicine for their pain.			Intellectual Product	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 Items
C16856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16856>	C17995	Fluorescence Microscopy|FLUORESCENT MICROSCOPY|Fluorescence Light Microscopy|Microscopy, Light, Fluorescence|fluorescence microscopy	A technique in which samples that either contain fluorescent compounds or are stained with fluorescent dyes are exposed to a wavelength of light that excites the fluorophore, allowing for an image to be captured by a microscope.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Genetic Toxicology In vivo Method Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C168570	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168570>	C201174|C200765	Allogeneic Anti-CD20-CAR T-cells PBCAR20A|Allogeneic Anti-CD20 CAR T-lymphocytes PBCAR20A|PBCAR 20A|PBCAR-20A|PBCAR20A	A preparation of allogeneic, off-the-shelf (OTS), T-lymphocytes, derived from healthy donors, that have been genetically modified using a proprietary synthetic endonuclease-based system to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD20 (cluster of differentiation 20), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-CD20-CAR T-cells PBCAR20A specifically recognize and kill CD20-expressing tumor cells. The CD20 antigen, a non-glycosylated cell surface phosphoprotein, is a B-cell specific cell surface antigen expressed in B-cell lineage malignancies.	Allogeneic Anti-CD20-CAR T-cells PBCAR20A		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C168571	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168571>	C28193	IDH Inhibitor Associated Differentiation Syndrome|IDH-DS	A constellation of signs and symptoms occurring in the context of administration of isocitrate dehydrogenase (IDH) inhibitors in hematologic malignancies. It is characterized by dyspnea, unexplained fever, pulmonary infiltrates, hypoxia, pleural effusion, acute kidney injury, pericardial effusion, arthralgia, lymphadenopathy, edema and weight gain.			Disease or Syndrome	
C168572	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168572>	C7153|C224636	Unresectable Differentiated Thyroid Gland Carcinoma	Differentiated thyroid gland carcinoma that is not amenable to surgical resection.	Unresectable Differentiated Thyroid Gland Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168573	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168573>	C3059	Resectable Glioma	A glioma that is amenable to surgical resection.	Resectable Glioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168574	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168574>	C159511	Multimodal Education|MME|Multi-modal Education|Multi-modal Education Intervention	Teaching concepts using multiple learning styles and various types of media.	Multimodal Education		Educational Activity	CTRP Intervention Terminology|CTRP Terminology
C168575	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168575>	C28076	European Consensus on Grading of Bone Marrow Fibrosis|Grading for Marrow Fibrosis|Marrow Fibrosis Grading System|Updated WHO Fibrosis Classification	A grading scheme that includes both a qualitative (reticulin or collagen) and quantitative evaluation of bone marrow fibrosis comprising four increasing categories.			Classification	
C168576	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168576>	C168575	Marrow Fibrosis Grade 0|MF-0	Scattered linear reticulin with no intersections (crossovers) corresponding to normal bone marrow.			Classification	
C168577	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168577>	C168575	Marrow Fibrosis Grade 1|MF-1	Loose network of reticulin with many intersections, especially in perivascular areas.			Classification	
C168578	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168578>	C168575	Marrow Fibrosis Grade 2|MF-2	Diffuse and dense increase in reticulin with extensive intersections, occasionally with focal bundles of thick fibers mostly consistent with collagen and/or focal osteosclerosis.			Classification	
C168579	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168579>	C168575	Marrow Fibrosis Grade 3|MF-3	Diffuse and dense increase in reticulin with extensive intersections and coarse bundles of thick fibers mostly consistent with collagen, usually associated with osteosclerosis.			Classification	
C16857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16857>	C17995	Phase-Contrast Microscopy|Microscopy, Phase-Contrast|PHASE CONTRAST MICROSCOPY	A simple non-quantitative form of interference microscopy of great utility in visualising live cells. Small differences in optical path length due to differences in refractive index and thickness of structures are visualised as differences in light intensity.			Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C168580	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168580>	C212043|C201282	Xaluritamig|AMG 509|AMG-509|AMG509|Bispecific Antibody AMG 509|XALURITAMIG	A humanized immunoglobulin G1 (IgG1) bispecific antibody directed against both the tumor-associated antigen (TAA) six transmembrane epithelial antigen of the prostate 1 (STEAP1) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, xaluritamig targets and binds to both STEAP1 expressed on the surface of tumor cells and CD3 expressed on T-cells. This results in the cross-linking of tumor cells and T-cells, and induces a cytotoxic T-lymphocyte (CTL) response against STEAP1-expressing tumor cells. STEAP1 is overexpressed in a variety of cancers including prostate cancer.	Xaluritamig		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C168581	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168581>	C3044	Liver Fibrosis|Hepatic fibrosis|Hepatic fibrosis, unspecified	A condition in which the liver parenchyma is replaced by fibrous tissue. It may progress to cirrhosis of the liver.	Liver Fibrosis		Finding	CTRP Disease Terminology|CTRP Terminology|mCode Elixhauser Mild Liver Disease Value Set|mCode Terminology|SeroNet Authorized Values|SeroNet Study Descriptors
C168582	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168582>	C4980|C147114	Steroid Resistant Acute Graft Versus Host Disease|Steroid Refractory Acute GVHD|Steroid Refractory Acute Graft Versus Host Disease|Steroid Resistant Acute GVHD	Acute graft versus host disease that is resistant to treatment with steroids.	Steroid Resistant Acute Graft Versus Host Disease		Disease or Syndrome	CTRP Disease Terminology|CTRP Terminology
C168583	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168583>	C8933|C162015|C151904	Refractory Metastatic Pancreatic Adenocarcinoma	A metastatic pancreatic adenocarcinoma that is resistant to treatment.	Refractory Metastatic Pancreatic Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168585	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168585>	C206077	Aicardi-Goutieres Syndrome 7|AGS7	A genetic condition usually inherited in an autosomal dominant pattern. It is cause by mutation(s) in the IFIH1 gene, encoding interferon-induced helicase C domain-containing protein 1. Clinical features and onset may vary significantly, but is characterized in its most severe form by cerebral atrophy, leukodystrophy, intracranial calcifications, chronic cerebrospinal fluid (CSF) lymphocytosis, and increased concentrations of CSF alpha-interferon.			Disease or Syndrome	Cellosaurus Disease Terminology
C168586	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168586>	C53543	Asparagine Synthetase Deficiency|ASNSD	An autosomal recessive condition caused by mutation(s) in the ASNS gene, encoding asparagine synthetase. It is characterized by microcephaly, severely delayed psychomotor development, progressive encephalopathy, seizures, and cortical atrophy.			Disease or Syndrome	Cellosaurus Disease Terminology
C168587	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168587>	C35194	Retinal Dystrophy with Inner Retinal Dysfunction and Ganglion Cell Abnormalities|RDGCA	An autosomal dominant condition caused by mutation(s) in the ITM2B gene, encoding integral membrane protein 2B. It is characterized by progressive loss of central vision, and inner retinal dystrophy with ganglion cell abnormalities.			Disease or Syndrome	Cellosaurus Disease Terminology
C168588	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168588>	C28193	Senior-Loken Syndrome|SLSN	A genetically heterogenous condition usually inherited in an autosomal recessive pattern. It is characterized by nephronophthisis and retinitis pigmentosa.			Disease or Syndrome	Cellosaurus Disease Terminology
C168589	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168589>	C156804	Valemetostat Tosylate|1,3-Benzodioxole-5-carboxamide, 7-Chloro-N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-2-(trans-4-(dimethylamino)cyclohexyl)-2,4-dimethyl-, (2R)-, Compd. with 4-Methylbenzenesulfonate (1:1)|DS 3201b|DS-3201 Tosylate|DS-3201b|Ezharmia|VALEMETOSTAT TOSYLATE	The tosylate form of valemetostat, an orally available selective inhibitor of the histone lysine methyltransferases enhancer of zeste homolog 1 (EZH1) and 2 (EZH2), with potential antineoplastic activity. Upon oral administration, valemetostat selectively inhibits the activity of both wild-type and mutated forms of EZH1 and EZH2. Inhibition of EZH1/2 specifically prevents the methylation of lysine 27 on histone H3 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways, enhances transcription of certain target genes, and results in decreased proliferation of EZH1/2-expressing cancer cells. EZH1/2, histone lysine methyltransferase (HMT) class enzymes and catalytic subunits of the polycomb repressive complex 2 (PRC2), are overexpressed or mutated in a variety of cancer cells and play key roles in tumor cell proliferation, progression, stem cell self-renewal and migration.	Valemetostat Tosylate		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C16858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16858>	C17995	Polarization Microscopy|Microscopy, Polarized Light	Any form of microscopy capable of detecting birefringent objects. Usually performed with a polarizing element below the stage to produce plane polarized light and an analyzer that is set to give total extinction of the background and thus to detect any birefringence.			Laboratory Procedure	
C168591	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168591>	C3131	CD70 Deficiency	A rare primary immunodeficiency caused by homozygous CD70 mutation. It is characterized by susceptibility to Epstein-Barr virus infection, hypogammaglobulinemia, and development of B-cell non-Hodgkin lymphomas and Hodgkin lymphomas.			Disease or Syndrome	Cellosaurus Disease Terminology
C168592	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168592>	C27520	Melanocytic Matricoma	A rare benign pilar tumor with numerous intratumoral pigmented dendritic melanocytes. It typically affects elderly men. The most common location is the head and neck, followed by the trunk and the limbs. It manifests as a small, pigmented, purple or brownish-black papule or nodule. (WHO 2018)			Neoplastic Process	
C168593	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168593>	C42076	Pigmented Dendritic Melanocytes Present	A morphologic finding indicating the presence of pigmented dendritic melanocytes in a tissue sample.			Finding	
C168594	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168594>	C45501	Low Transfusion Burden|LTB	Generally defined as 3-7 RBC units in 16 weeks in at least 2 transfusion episodes, maximum 3 in 8 weeks.			Finding	
C168595	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168595>	C45501	High Transfusion Burden|HTB	Generally defined as greater than or equal to 8 RBC units in 16 weeks, greater than or equal to 4 transfusion episodes in 8 weeks.			Finding	
C168596	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168596>	C18194	Elective Plasma-based CancerSEEK Testing|CancerSEEK|CancerSEEK Assay|CancerSEEK Screening Test	A blood-base screening assay for early cancer detection. It uses a liquid biopsy test to detect genomic mutations in circulating tumor DNA, and cancer-associated protein markers in plasma, to identify abnormalities that are common across multiple cancers.	Elective Plasma-based CancerSEEK Testing		Laboratory Procedure	CTRP Intervention Terminology|CTRP Terminology
C168597	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168597>	C122814	Developmental and Epileptic Encephalopathy 25|EIEE25|Early Infantile Epileptic Encephalopathy 25|SLC13A5 Deficiency	An autosomal recessive form of early infantile epileptic encephalopathy, caused by mutation(s) in the SLC13A5 gene, encoding solute carrier family 13 member 5.			Disease or Syndrome	Cellosaurus Disease Terminology
C168598	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168598>	C53543	Epilepsy, Focal, with Speech Disorder and with or without Intellectual Developmental Disorder|Aphasia, Acquired, with Epilepsy|Epilepsy, Focal, with Speech Disorder and with or without Mental Retardation|FESD with or without Mental Retardation	An autosomal dominant condition caused by mutation(s) in the GRIN2A gene, encoding glutamate receptor ionotropic NMDA 2A. It is characterized by childhood-onset seizures affecting the temporal lobe or rolandic area of the brain, with a variable phenotype. It often affects speech and language.			Disease or Syndrome	Cellosaurus Disease Terminology
C168599	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168599>	C28193	GLUT1 Deficiency Syndrome 1|GLUT1DS1	A genetic condition usually inherited in an autosomal dominant pattern. It is caused by mutation(s) in the SCL2A1 gene, encoding solute carrier family 2, facilitated glucose transporter member 1. It is characterized by wide phenotypic variability, but may include infantile onset epileptic encephalopathy with delayed development, acquired microcephaly, motor dysfunction, and spasticity.			Disease or Syndrome	Cellosaurus Disease Terminology
C16859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16859>	C17995	Ultraviolet Microscopy|Microscopy, Ultraviolet	The study and photographing of microscope specimens in ultraviolet light. It is particularly useful when all parts of the specimen viewed are equally transparent in the visible region. (The Photonics Dictionary)			Laboratory Procedure	
C1685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1685>	C1941	Dulanermin|114-281-protein TRAIL|AMG 951|APO2L/TRAIL|DULANERMIN|RG3639|rTRAIL	A recombinant human soluble protein corresponding to amino acids 114-281 of the Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand (RhApo2L/TRAIL) with potential antineoplastic activity. Dulanermin binds to and activates TRAIL receptors 1 and 2 (TRAIL-R1/R2), which may activate caspases and induce p53-independent apoptosis in TRAIL-R1/R2-expressing tumor cells. The pro-apoptotic cell surface receptors TRAIL-R1 and -R2, also known as DR4 (death receptor 4) and DR5 (death receptor 5), are members of the TNF receptor family and are overexpressed by a variety of cancer cell types.	Dulanermin		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C168600	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168600>	C192655|C129820|C124946	Anti-PD-1/CD47 Fusion Protein HX009|Anti-PD1/CD47 Bi-specific Antibody Fusion Protein HX009|HX 009|HX-009|HX009	A bispecific antibody fusion protein directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human cell surface antigen CD47, with potential immunostimulating, phagocytosis-inducing and antineoplastic activities. Upon administration of anti-PD-1/CD47 fusion protein HX009, the agent simultaneously and selectively targets and binds to PD-1 expressed on T-lymphocytes and CD47 on tumor cells. The CD47 binding by HX009 blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of the CD47-expressing tumor cells. The binding of HX009 to PD-1 blocks the interaction between PD-1 and its ligands, PD-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore effector T-cell functions and may further activate cytotoxic T-lymphocyte (CTL)-mediated tumor cell killing. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA), widely expressed on normal, healthy cells, such as red blood cells and platelets, and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate. By co-targeting CD47 and PD-1, HX009 has the potential to overcome the limitations of existing CD47-targeted therapies by possibly avoiding the side effects caused by binding to CD47 on healthy hematopoietic stem cells (HSCs), which causes unwanted macrophage-mediated phagocytosis. PD-1, an inhibitory receptor belonging to the immunoglobulin superfamily (IgSF), is expressed on activated T-lymphocytes; it functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, and plays an important role in tumor evasion from host immunity.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C168601	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168601>	C62554	Senaparib|IMP 4297|IMP-4297|IMP4297|PARP 1/2 Inhibitor IMP4297|SENAPARIB	An orally bioavailable inhibitor of the nuclear enzymes poly (ADP-ribose) polymerase (PARP) 1 and 2, with potential antineoplastic activity. Upon administration, senaparib selectively binds to PARP 1 and 2 and prevents PARP-mediated DNA repair of single-strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks and promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C168602	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168602>	C2977	Phyllodes Tumor of Anogenital Mammary-Type Glands|Phyllodes Tumor of Anogenital Mammary-Like Glands	A rare phyllodes tumor that arises from mammary-like glands in the anogenital region.			Neoplastic Process	
C168603	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168603>	C134305	Negalstobart|Anti-LAG-3 Monoclonal Antibody IBI-110|Anti-LAG-3 Monoclonal Antibody IBI110|IBI 110|IBI-110|IBI110|NEGALSTOBART	A monoclonal antibody targeting the co-inhibitory receptor lymphocyte-activation gene 3 protein (LAG-3; LAG3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, negalstobart targets and binds to LAG-3 expressed by tumor infiltrating lymphocytes (TILs) and blocks the interaction between LAG-3 and major histocompatibility complex class II (MHC II) molecules on the surface of antigen-presenting cells (APCs) and tumor cells. This prevents the negative regulation of T-cell activity that occurs via LAG-3-MHC II binding and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells, leading to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF), negatively regulates both the proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C168604	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168604>	C155745|C133877	Tecaginlimab|Anti-CD40/Anti-4-1BB Bispecific Agonist Monoclonal Antibody GEN1042|Anti-CD40/Anti-CD137 Bispecific Agonist Monoclonal Antibody GEN1042|BNT 312|BNT-312|BNT312|DuoBody-CD40x4-1BB GEN1042|GEN 1042|GEN-1042|GEN1042|TECAGINLIMAB	A humanized immunoglobulin (Ig) G1, Fc-silenced, bispecific, agonistic monoclonal antibody targeting both CD40 and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulatory and antineoplastic activity. Upon administration,  tecaginlimab simultaneously binds to CD40 and 4-1BB, crosslinks CD40 and 4-1BB positive cells, induces conditional stimulation, and activates both CD40- and 4-1BB-medicated signaling. The activation of CD40-mediated signaling triggers the proliferation and activation of antigen-presenting cells (APCs) and activates T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. The activation of 4-1BB-mediated signaling induces cytokine production and promotes T-cell mediated anti-tumor immune responses. CD40, a cell surface receptor and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on various immune cells, such as dendritic cells (DCs), macrophages and B-cells, and plays a key role in the activation of the immune system. 4-1BB, a surface glycoprotein of the TNFRSF, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.	Tecaginlimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C168605	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168605>	C1572	Recombinant Human Papillomavirus 11-valent Vaccine|11-valent Recombinant HPV Vaccine|11-valent Recombinant Human Papillomavirus Vaccine|11-valent Recombinant Human Papillomavirus Vaccine (Hansenula polymorpha)	A recombinant, 11-valent, human papillomavirus (HPV) vaccine, produced in Hansenula polymorpha, with potential immunoprotective and antineoplastic properties. Upon administration, recombinant HPV 11-valent vaccine may generate humoral and cellular immunity against the 11 undisclosed types of HPV antigens, thereby preventing cervical infection upon exposure to these 11 types of HPV. In addition, this agent may stimulate an antitumoral cellular immune response against cervical cancer associated with HPV infection.			Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C168606	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168606>	C2116	Selective Estrogen Receptor Degrader LX-039|LX 039|LX-039|LX039|SERD LX-039	An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, SERD LX-039 specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that results in ER degradation. This prevents ER-mediated signaling and inhibits both the growth and survival of ER-expressing cancer cells.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C168607	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168607>	C717|C204256	Oncolytic Adenovirus ORCA-010|Modified Ad5 ORCA-010|ORCA 010|ORCA-010|ORCA010	A replication competent, oncolytic adenovirus serotype 5 (Ad5) that has been modified with a delta24 (d24) deletion, an incorporation of an RGD-4C motif in the Ad fiber protein, and an insertion of the T1 mutation in E3/19K gene, with potential oncolytic activity. Upon administration, oncolytic adenovirus ORCA-010 binds to specific Ad3 receptors that are highly expressed on certain tumor cells. This results in the replication of oncolytic adenovirus Ad5/3-delta24 in tumor cells and induces tumor cell lysis which may potentially result in the activation of a systemic immune response against tumor-associated antigens (TAAs). The Ad5/3-delta24 has a 24 base pair deletion in constant region 2 of the E1A gene which allows for selective replication in cells that are defective in the retinoblastoma gene (Rb) or cyclin-dependent kinase inhibitor-2A (CDKN2A or p16INK4a). As most tumor cells are defective in the Rb/p16 pathway, this virus selectively replicates in these cells. The RGD-4C motif is a 9-amino acid peptide that binds to various and enhances viral-cell receptor binding by allowing for a Coxsackie-adenovirus receptor (CAR)-independent infection of tumor cells, which is the natural route of viral binding, as CAR expression is often deficient on cancer cells. As integrins are often overexpressed on tumor cell surfaces, integrin receptor binding enhances tumor cells binding and infection by the Ad. The T1 mutation enhances the Ad5 release from tumor cells and promotes spreading throughout the tumor, thereby enhancing anti-tumor activity. The T1 mutation, a single Adenine insertion at position 445 of the nucleotide sequence of the E3/19K gene of Adenovirus, creates a truncated E3/19K protein that is relocated to the plasma membrane due to the disruption of its ER retention signal. This increases plasma membrane permeability and enhances the release of Ad5.			Pharmacologic Substance|Virus	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C168608	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168608>	C93259|C213472|C129825	Kanitinib|CX 1003|CX-1003|CX1003	A tyrosine kinase inhibitor targeting the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR; MET) and vascular endothelial growth factor receptor 2 (VEGFR2), with potential anti-angiogenic and antineoplastic activities. Upon oral administration, kanitinib targets and binds to c-Met and VEGFR2, thereby disrupting c-Met- and VEGFR2-dependent signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met and/or VEGFR2 protein. c-Met and VEGFR2 are both overexpressed in many tumor cell types and play key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C168609	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168609>	C2021	Thymidylate Synthase Inhibitor CX1106|CX 1106|CX-1106|CX1106|TS Inhibitor CX1106|TSI CX1106	A thymidylate synthase (TS) inhibitor with potential antineoplastic activity. Upon administration, TS inhibitor CX1106 binds to and inhibits TS. This reduces thymine nucleotide synthesis, inhibits DNA synthesis and cell division, causes DNA damage and leads to tumor cell apoptosis. TS catalyzes the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), an essential precursor for DNA synthesis, and plays a key role in cell growth and division.			Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C16860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16860>	C16701	Epoxide Hydrolase 1|EC 3.3.2.9|EPHX1|Epoxide Hydratase|Epoxide Hydroxylase 1, Microsomal|Epoxide Hydroxylase 1, Microsomal (Xenobiotic)|Microsomal Epoxide Hydrolase|mEH	Epoxide hydrolase 1 (455 aa, ~53 kDa) is encoded by the human EPHX1 gene. This protein is involved in the hydrolysis of cyclic organic compounds.			Amino Acid, Peptide, or Protein|Enzyme	
C168611	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168611>	C17146	Kinect-Enhanced Training for The-Optimal-Lymph-Flow|Kinect-Enhanced The-Optimal-Lymph-Flow Training System|Kinect-Enhanced Training System for Lymphatic Exercises|Kinect-TOLF	A computer program and mobile app that uses a motion sensor to help patients perform The-Optimal-Lymph-Flow lymphatic exercises correctly. The Kinect system can automatically detect whether a user is performing the set of lymphatic exercises correctly in real time and provide instantaneous feedback, thus enhancing patients' self-efficacy to perform the lymphatic exercises correctly.	Kinect-Enhanced Training for The-Optimal-Lymph-Flow		Intellectual Product	CTRP Intervention Terminology|CTRP Terminology
C168614	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168614>	C1505	N-oleyl-phosphatidylethanolamine/Epigallocatechin Gallate Supplement|N-oleoyl-PE/EGCG|N-oleyl-phosphatidylethanolamine/Epigallocatechin Gallate|NOPE Plus EGCG|NOPE-EGCG|NOPE/EGCG|OEA-PE/EGCG|Oleoyl Ethanolamine-Phosphatidylethanolamine Plus EGCG|PhosphoLean	A dietary supplement composed of a phosphobioflavonic complex containing two naturally occurring dietary ingredients: the phospholipid N-oleyl-phosphatidylethanolamine (NOPE), which consists of the fatty acid amide oleoyl ethanolamine (OEA) bound to phosphatidylethanolamine (PE),  and the flavonol epigallocatechin gallate (EGCG), which is derived from standardized green tea extract, with potential anorexic activity. Upon oral administration of the NOPE/EGCG supplement, NOPE is hydrolyzed into the N-acylethanolamine N-oleyl-ethanolamide (NOE) and phosphatidic acid. NOE inhibits anandamide, thereby preventing the increase in appetite and promotes the activation of several intestinal receptors, which signal the brain center to reduce food intake. EGCG inhibits enzymes that contribute to the degradation of catecholamines, stimulates lipolysis, and promotes weight loss. NOPE and EGCG  may work together to provide satiety, improve adherence to a diet, improve performance on impulsivity, and shift fat and sweet preference. This may reduce weight gain and may increase weight loss.	N-oleyl-phosphatidylethanolamine/Epigallocatechin Gallate Supplement		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C168615	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168615>	C15436	Mindset Intervention	Intervention designed to help instill more useful mindsets in order to improve physical and psychological health.	Mindset Intervention		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C168616	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168616>	C15436	Reflection Activities	Activities and exercises designed to internalize a helpful message.	Reflection Activities		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C168617	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168617>	C20401|C143250|C129822	Tifcemalimab|Anti-B- and T-lymphocyte Attenuator Monoclonal Antibody TAB004|Anti-BTLA Monoclonal Antibody TAB004|Icatolimab|JS 004|JS-004|JS004|TAB 004|TAB-004|TAB004|TIFCEMALIMAB	A recombinant humanized immunoglobulin G4 kappa (IgG4k) monoclonal antibody directed against B- and T-lymphocyte attenuator (BTLA), with potential immunomodulating and antineoplastic activities. Upon intravenous infusion administration, tifcemalimab targets and binds to BTLA. This prevents BTLA-mediated inhibition of T-cell activation leading to antigen specific T-cell proliferation and activation of a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. BTLA, an immunoglobulin (Ig) receptor family member expressed on activated T- and B- lymphocytes, subsets of dendritic cells (DCs), macrophages, and nature killer (NK) cells, is an immune checkpoint involved in suppressing immune responses. It mediates inhibition of human tumor-specific CTLs upon engagement by tumor expressed herpesvirus-entry mediator (HVEM).	Tifcemalimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C168618	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168618>	C137826|C129825	IDH1 Inhibitor|Cytosolic Isocitrate Dehydrogenase (NADP(+)) 1 Inhibitor|IDH1 inhibitor|Isocitrate Dehydrogenase Type 1 Inhibitor	Any agent that inhibits isocitrate dehydrogenase (IDH) type 1 (IDH1, IDH1 [NADP+] soluble) found in the cytoplasm.	IDH1 Inhibitor		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C168619	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168619>	C137826|C129825	IDH2 Inhibitor|IDH2 inhibitor|Isocitrate Dehydrogenase Type 2 Inhibitor|Mitochondrial Isocitrate Dehydrogenase (NADP (+)) 2 Inhibitor	Any agent that inhibits isocitrate dehydrogenase (IDH) type 2 (IDH2, isocitrate dehydrogenase [NADP+], mitochondrial) found in the mitochondria.			Chemical Viewed Functionally	
C16861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16861>	C16492	Microtubule Associated Protein|MAP|MAPs|Microtubule-Associated Protein|Microtubule-Associated Proteins	Proteins associated with the microtubule assembly infrastructure.  These proteins include specialized motor proteins (dynein and kinesin) and smaller tubulin-crosslinking proteins (tau proteins). The proteins are required for both microtubule assembly and stabilization.			Amino Acid, Peptide, or Protein	
C168622	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168622>	C133805	PQ/CMC Strength Operator Terminology|Pharmaceutical Quality/CMC Strength Operator Terminology|Pharmaceutical Quality/Chemistry Manufacturing and Controls Strength Operator Terminology	A category of terminology used to qualify the information pertaining to strength operators in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls.			Intellectual Product	FDA Pharmaceutical Quality/CMC Terminology
C168623	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168623>	C157106	Specify Other Adverse Event|ae other|ae_other	A directive to identify the cause of an adverse event when the listed responses are not applicable.			Activity	ICDC Property Terminology|ICDC Terminology
C168624	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168624>	C133805	PQ/CMC Organization-Site Identifier Type Terminology|Pharmaceutical Quality/CMC Organization-Site Identifier Type Terminology|Pharmaceutical Quality/Chemistry, Manuracturing and Controls Organization-Site Identifier Type Terminology	A category of terminology used to qualify the information pertaining to organization site identifier types in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.			Intellectual Product	FDA Pharmaceutical Quality/CMC Terminology
C168625	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168625>	C94536	Best Overall Response Registered from Start of Therapy to a Time Point of Interest|best resp vet tx tp best response|best_resp_vet_tx_tp_best_response	The most clinically favorable response recorded from the start of the treatment until a specified time point in a study.			Finding	ICDC Property Terminology|ICDC Terminology
C168626	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168626>	C50995	Best Secondary Endpoint Response Registered from Start of Therapy to a Time Point of Interest|best resp vet tx tp secondary response|best_resp_vet_tx_tp_secondary_response	The most favorable response measured for a secondary endpoint recorded from the start of the treatment until a specified time point in a study.			Finding	ICDC Property Terminology|ICDC Terminology
C168627	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168627>	C133805	PQ/CMC Strength Type Terminology|Pharmaceutical Quality/CMC Strength Type Terminology|Pharmaceutical Quality/Chemistry, Manufacturing and Controls Strength Operator Terminology	A category of terminology used to qualify the information pertaining to strength types in the framework of the Pharmaceutical Quality/Chemistry, Manufacturing and Controls documents.			Intellectual Product	FDA Pharmaceutical Quality/CMC Terminology
C168628	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168628>	C43246	Drug Component Mass|Mass	The mass of the active and inactive substances in a drug component.			Quantitative Concept	PQ/CMC Strength Type Terminology
C168629	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168629>	C25364	ICDC Program Sort Order|program sort order|program_sort_order	A value assigned by the Integrated Canine Data Commons (ICDC) that indicates where a particular project is located in the list of all of the projects included in ICDC.			Intellectual Product	ICDC Property Terminology|ICDC Terminology
C16862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16862>	C17053	Microwave Radiation|Electromagnetic, Microwave|Radiation, Microwave	Electromagnetic radiation between the ultrahigh frequency radio and infrared (in the 10e-3 (micro) to about 0.5 X 10e-1 meter) region of the spectrum.			Natural Phenomenon or Process	
C168630	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168630>	C169028	ICDC Study Identifier|clinical study designation|clinical_study_designation	A unique alphanumeric code assigned to a project by the Integrated Canine Data Commons (ICDC) that includes an abbreviation representing the project's sponsor organization.			Intellectual Product	ICDC Property Terminology|ICDC Terminology
C168631	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168631>	C25180	Therapeutic Indicator|Therapy Indicator|Treatment Indicator|therapeutic indicator|therapeutic_indicator	An indication as to whether a specified treatment has been administered to a subject.			Conceptual Entity	ICDC Property Terminology|ICDC Terminology
C168632	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168632>	C54452	SPL UCUM Terminology	A list of units of measure adopted by SPL from the Unified Code for Units of Measure (UCUM) list.			Intellectual Product	FDA Structured Product Labeling Terminology
C168633	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168633>	C170518	IWG-MRT Criteria for Treatment Response in Myelofibrosis	Criteria in inducing remission or improvement in myelofibrosis according to the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT).			Finding	
C168634	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168634>	C4870|C168633	IWG-MRT Myelofibrosis Complete Remission	Bone marrow: Age-adjusted normocellularity; less than 5 percent blasts; less than or equal to grade 1 myelofibrosis and Peripheral blood: Hemoglobin greater than or equal to 100 g/L and less than upper normal limit; neutrophil count greater than or equal 1x10^9/L and less than upper normal limit; Platelet count greater or equal to 100x10^9/L and less than upper normal limit; less than 2 percent immature myeloid cells and Clinical: Resolution of disease symptoms; spleen and liver not palpable; no evidence of extramedullary hematopoiesis (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)			Finding	
C168635	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168635>	C18058|C168633	IWG-MRT Myelofibrosis Partial Remission	Peripheral blood: Hemoglobin greater than or equal to 100 g/L and less than upper normal limit; neutrophil count greater than or equal to 1x10^9/L and less than upper normal limit; platelet count greater than or equal to 100x10^9/L and less than upper normal limit; less than 2 percent immature myeloid cells and Clinical: Resolution of disease symptoms; spleen and liver not palpable; no evidence of extramedullary hematopoiesis or Bone marrow: Age-adjusted normocellularity; less than 5 percent blasts; less than grade 1 myelofibrosis and peripheral blood: Hemoglobin greater than or equal to 85 but less than 100 g/L and less than upper normal limit; neutrophil count greater than 1x10^9/L and less than upper normal limit; platelet count greater than or equal to 50 but less than 100x10^9/L and less than upper normal limit; less than 2 percent immature myeloid cells and Clinical: Resolution of disease symptoms; spleen and liver not palpable; no evidence of extramedullary hematopoiesis(adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)			Finding	
C168636	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168636>	C35571|C168633	IWG-MRT Myelofibrosis Cytogenetic/Molecular Relapse	Re-emergence of a pre-existing cytogenetic or molecular abnormality that is confirmed by repeat testing (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)			Finding	
C168638	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168638>	C34076	Epiphyseal Plate|Growth Plate|Growth Plate|Physis|Structure of epiphyseal plate (body structure)	A layer of cartilage located in the metaphysis of long bones in children and adolescents that is the site of longitudinal bone growth until skeletal maturity.			Body Part, Organ, or Organ Component	mCode Radiotherapy Treatment Location Value Set|mCode Terminology
C16863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16863>	C161324	Minority Group|Ethnic and Racial Minorities|Minorities|Minority	A minority is a group that is outnumbered by persons who do not belong to it, often people with different nationality, religion, culture or lifestyle from that of the mainstream in the society; racial or ethnic groups officially recognized by the U.S. government as minority populations.			Population Group	
C168641	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168641>	C168633	IWG-MRT Myelofibrosis Clinical Improvement	The achievement of anemia spleen or symptoms response without progressive disease or increase in severity of anemia thrombocytopenia or neutropenia (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)			Finding	
C168642	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168642>	C168633	IWG-MRT Myelofibrosis Relapse	No longer meeting criteria for at least clinical improvement after achieving complete response partial response or clinical improvement or loss of anemia response persisting for at least 1 month or loss of spleen response persisting for at least 1 month (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)			Finding	
C168643	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168643>	C168633	IWG-MRT Myelofibrosis Symptom Response	A greater than or equal to 50 percent reduction in the myeloproliferative neoplasm symptom assessment form total symptom score (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)			Finding	
C168644	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168644>	C168633	IWG-MRT Myelofibrosis Stable Disease	Belonging to none of the above listed response categories (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)			Finding	
C168645	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168645>	C168633	IWG-MRT Myelofibrosis Progressive Disease	Appearance of a new splenomegaly that is palpable at least 5 cm below the left costal margin or A greater than or equal to 100 percent increase in palpable distance, below left costal margin, for baseline splenomegaly of 5 to 10 cm or A 50 percent increase in palpable distance, below left costal margin, for baseline splenomegaly of greater than 10 cm or Leukemic transformation confirmed by a bone marrow blast count of greater than or equal to 20 percent or A peripheral blood blast content of greater than or equal to 20 percent associated with an absolute blast count of greater than or equal to 1x10^9/L that lasts for at least 2 weeks (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD, 22 AUGUST 2013 x VOLUME 122, NUMBER 8)			Finding	
C168646	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168646>	C168633	IWG-MRT Myelofibrosis Anemia Response	Transfusion-independent patients: a greater than or equal to 20 g/L increase in hemoglobin level or for transfusion-dependent patients: becoming transfusion-independent (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)			Finding	
C16864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16864>	C20349	Mitosis|Mitotic Process|mitosis|mitotic cycle	The usual process of somatic reproduction of cells consisting of a sequence of modifications of the nucleus that result in the formation of two daughter cells with exactly the same chromosome and DNA content as that of the original cell. It is the process by which the body grows and replaces cells and is divided into four phases. In Prophase, paired chromosomes form, nuclear membrane disappears, the achromatic spindle appears, and polar bodies form. In Metaphase, chromosomes are arranged in the equatorial plane of the central spindle to form the monaster and chromosomes separate into exactly similar halves. In Anaphase, the two groups of daughter chromosomes separate and move along the fibers of the central spindle, each toward one of the asters, forming the diaster. In Telophase, the daughter chromosomes resolve themselves into a reticulum, the daughter nuclei are formed, and the cytoplasm divides forming two complete daughter cells.			Phenomenon or Process	
C168650	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168650>	C168633	IWG-MRT Myelofibrosis Cytogenetic Remission	At least 10 metaphases must be analyzed for cytogenetic response evaluation and requires confirmation by repeat testing within 6 months window. Complete response: eradication of a preexisting abnormality. Partial response: greater than or equal to 50 percent reduction in abnormal metaphases. (partial response applies only to patients with at least ten abnormal metaphases at baseline) (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)			Finding	
C168651	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168651>	C45249|C2912|C171101	Cutaneous Burkitt Lymphoma	Burkitt lymphoma that affects the skin.			Neoplastic Process	
C168652	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168652>	C168633	IWG-MRT Myelofibrosis Spleen Response	A baseline splenomegaly that is palpable at 5-10 cm below the left costal margin becomes not palpable or A baseline splenomegaly that is palpable at greater than 10 cm below the left costal margin decreases by greater than or equal to 50 percent. A baseline splenomegaly that is palpable at less than 5 cm below the left costal margin is not eligible for spleen response. A spleen response requires confirmation by MRI or computed tomography showing greater than or equal to 35 percent spleen volume reduction. (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)			Finding	
C168653	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168653>	C168633	IWG-MRT Myelofibrosis Molecular Remission	Molecular response evaluation must be analyzed in peripheral blood granulocytes and requires confirmation by repeat testing within 6 months window. Complete response: Eradication of a pre-existing abnormality. Partial response: greater than or equal to 50 percent decrease in allele burden (partial response applies only to patients with at least 20 percent mutant allele burden at baseline.) (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)			Finding	
C168654	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168654>	C54443	Mapped ICDO Terminology|Mapped ICD-O Terminology	The set of terms that have been mapped to terms with equivalent meaning in the International Classification of Disease for Oncology (ICD-O).			Intellectual Product	
C168655	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168655>	C168654	Mapped ICDO3.1 Terminology|Mapped ICD-O-3.1 Terminology	The set of terms that have been mapped to terms with equivalent meaning in the International Classification of Disease for Oncology third edition first revision (ICD-O-3.1).			Intellectual Product	Mapped ICDO Terminology
C168656	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168656>	C168654	Mapped ICDO3.2 Terminology|Mapped ICD-O-3.2 Terminology	The set of terms that have been mapped to terms with equivalent meaning in the International Classification of Disease for Oncology third edition second revision (ICD-O-3.2).			Intellectual Product	Mapped ICDO Terminology
C168657	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168657>	C168655	Mapped ICDO3.1 Morphology Terminology|Mapped ICD-O-3.1 Morphology Terminology	The set of terms that have been mapped to the Morphology terms with equivalent meaning in ICD-O-3.1.			Intellectual Product	
C168658	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168658>	C168657	Mapped ICDO3.1 Morphology PT Terminology|Mapped ICD-O-3.1 Morphology PT Terminology	The set of terms that have been mapped to the Morphology preferred terms (PTs) with equivalent meaning in ICD-O-3.1.			Intellectual Product	
C168659	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168659>	C168655	Mapped ICDO3.1 Topography Terminology|Mapped ICD-O-3.1 Topography Terminology	The set of terms that have been mapped to the Topography terms with equivalent meaning in ICD-O-3.1.			Intellectual Product	
C16865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16865>	C28459	Mixed Function Oxidase|Mixed Function Oxygenase|Monooxygenase	These enzymes use molecular oxygen catalyze the donation of one oxygen atom to a substrate specific site, while the other atom is donated to the generation of water. The enzyme uses molecular oxygen as the oxygen source instead of water, and is critical for several endocrine function operations.			Amino Acid, Peptide, or Protein|Enzyme	
C168660	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168660>	C168659	Mapped ICDO3.1 Topography PT Terminology|Mapped ICD-O-3.1 Topography PT Terminology	The set of terms that have been mapped to the Topography preferred terms (PTs) with equivalent meaning in ICD-O-3.1.			Intellectual Product	
C168661	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168661>	C168656	Mapped ICDO3.2 Morphology Terminology|Mapped ICD-O-3.2 Morphology Terminology	The set of terms that have been mapped to the Morphology terms with equivalent meaning in ICD-O-3.2.			Intellectual Product	
C168662	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168662>	C168661	Mapped ICDO3.2 Morphology PT Terminology|Mapped ICD-O-3.2 Morphology PT Terminology	The set of terms that have been mapped to the Morphology preferred terms (PTs) with equivalent meaning in ICD-O-3.2.			Intellectual Product	
C168663	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168663>	C168656	Mapped ICDO3.2 Topography Terminology|Mapped ICD-O-3.2 Topography Terminology	The set of terms that have been mapped to the Topography terms with equivalent meaning in ICD-O-3.2.			Intellectual Product	
C168664	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168664>	C168663	Mapped ICDO3.2 Topography PT Terminology|Mapped ICD-O-3.2 Topography PT Terminology	The set of terms that have been mapped to the Topography preferred terms (PTs) with equivalent meaning in ICD-O-3.2.			Intellectual Product	
C168665	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168665>	C39766|C202126	Aesthetic Primary Post-Nonreconstructive Mastectomy Flat Closure|Post-Mastectomy Aesthetic Flat Closure	Closure of a nonreconstructive mastectomy using surgical techniques to achieve a flat, natural appearing chest wall contour.			Therapeutic or Preventive Procedure	
C168666	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168666>	C3693|C168669	Gastrointestinal Carcinomatosis	Carcinoma that has spread diffusely to the gastrointestinal system.	Gastrointestinal Carcinomatosis		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168667	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168667>	C9418|C152076	Metastatic High Grade Sarcoma|Metastatic High-Grade Sarcoma	A high-grade sarcoma that has spread from its original site of growth to another anatomic site.	Metastatic High Grade Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168668	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168668>	C168667|C153071	Locally Advanced High Grade Sarcoma|Locally Advanced High-Grade Sarcoma	A high-grade sarcoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced High Grade Sarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168669	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168669>	C4890|C36263	Metastatic Malignant Neoplasm in the Digestive System|Secondary malignant neoplasm of unspecified digestive organ	A malignant neoplasm that has spread to the digestive system from another anatomic site.			Neoplastic Process	mCode Cancer Disorder Value Set|mCode Elixhauser Metastatic Cancer Value Set|mCode Secondary Cancer Disorder Value Set|mCode Terminology
C16866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16866>	C20181	Model|Model System|Modeling System|Models|model	A representation of something, often idealized or modified to make it conceptually easier to understand.			Intellectual Product	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C168670	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168670>	C8812|C6496|C153069	Metastatic Myxofibrosarcoma	Myxofibrosarcoma that has spread from its original site of growth to another anatomic site.	Metastatic Myxofibrosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168671	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168671>	C171317|C168670|C153066	Locally Advanced Myxofibrosarcoma	Myxofibrosarcoma that has spread from its original site of growth to nearby tissues or lymph nodes.	Locally Advanced Myxofibrosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168672	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168672>	C168693	Thoracic Spine Neoplasm	A benign or malignant neoplasm that affects the thoracic region of the spine.	Thoracic Spine Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168673	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168673>	C168693	Lumbar Spine Neoplasm	A benign or malignant neoplasm that affects the lumbar region of the spine.	Lumbar Spine Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168674	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168674>	C168693	Sacral Spine Neoplasm	A benign or malignant neoplasm that affects the sacral region of the spine.	Sacral Spine Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168675	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168675>	C147055	Blasts 1 Percent of Peripheral Blood White Cells	A semi-quantitative microscopic finding indicating that 1 percent of the nucleated cells in a peripheral leukocyte sample are immature mononuclear cells.			Laboratory or Test Result	
C168676	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168676>	C168680	Myeloblasts 1 Percent of Peripheral Blood White Cells	A microscopic finding indicating that 1 percent of the white cells in a peripheral blood sample are myeloblasts.			Laboratory or Test Result	
C168677	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168677>	C8648	Myelodysplastic Syndrome, Unclassifiable, with 1 Percent Blasts	Myelodysplastic syndrome, unclassifiable characterized by refractory cytopenia with unilineage dysplasia or refractory cytopenia with multilineage dysplasia but with 1 percent blasts in the peripheral blood.			Neoplastic Process	
C168678	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168678>	C8648	Myelodysplastic Syndrome, Unclassifiable, with Defining Cytogenetic Abnormality|Myelodysplastic Syndrome, Unclassifiable, Based on Defining Cytogenetic Abnormality|Myelodysplastic Syndrome, Unclassifiable, Based on Defining Cytogenetic Abnormality	Myelodysplastic syndrome, unclassifiable characterized by persistent cytopenia (s) with 1 percent or fewer blasts in the blood and fewer than 5% in the bone marrow, unequivocal dysplasia in less than 10 percent of the cells in one or more myeloid lineages, and cytogenetic abnormalities considered as presumptive evidence of myelodysplastic syndrome.			Neoplastic Process	
C168679	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168679>	C36235	Bone Marrow Dysplasia Present in Less than 10 Percent of Myeloid Cells	A morphologic finding indicating the presence of dysplasia in less than 10 percent of the myeloid cells in a bone marrow sample.			Laboratory or Test Result	
C16867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16867>	C80519|C17456	Molecular Model	A model that represents molecules, their components, and their properties. It can be physical or electronic.			Intellectual Product	SeroNet Authorized Values|SeroNet Study Descriptors
C168680	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168680>	C36208	Myeloblasts 1 Percent or Less of Peripheral Blood White Cells	A microscopic finding indicating that 1 percent or less of the white cells in a peripheral blood sample are myeloblasts.			Laboratory or Test Result	
C168681	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168681>	C8648	Myelodysplastic Syndrome, Unclassifiable, with Single Lineage Dysplasia	Myelodysplastic syndrome, unclassifiable characterized by unilineage dysplasia and associated pancytopenia.			Neoplastic Process	
C168682	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168682>	C226330	High Risk Chronic Myeloid Leukemia, BCR-ABL1 Positive|High Risk Chronic Myeloid Leukemia, BCR::ABL1 Positive|High-Risk Chronic Myeloid Leukemia, BCR-ABL1 Positive|High-Risk Chronic Myeloid Leukemia, BCR::ABL1 Positive	A chronic myeloid leukemia, BCR-ABL1 positive with clinicopathologic, cytogenetic, and molecular findings that define it as high risk.	High Risk Chronic Myeloid Leukemia, BCR-ABL1 Positive		Finding	CTRP Disease Terminology|CTRP Terminology
C168683	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168683>	C226330	Very High Risk Chronic Myelogenous Leukemia, BCR-ABL1 Positive	A BCR-ABL1 positive chronic myelogenous leukemia with clinicopathologic, cytogenetic, and molecular findings that define a chronic myelogenous leukemia as very high risk.	Very High Risk Chronic Myelogenous Leukemia, BCR-ABL1 Positive		Finding	CTRP Disease Terminology|CTRP Terminology
C168684	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168684>	C117719	High Risk Prostate Carcinoma	Prostate carcinoma with clinicopathologic, cytogenetic, and molecular findings that define a prostate carcinoma as high risk.	High Risk Prostate Carcinoma		Finding	CTRP Disease Terminology|CTRP Terminology
C168685	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168685>	C117719	Very High Risk Prostate Carcinoma	Prostate carcinoma with clinicopathologic, cytogenetic, and molecular findings that define a prostate carcinoma as very high risk.	Very High Risk Prostate Carcinoma		Finding	CTRP Disease Terminology|CTRP Terminology
C168686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168686>	C122458	High Risk Acute Lymphoblastic Leukemia	Acute lymphoblastic leukemia with clinicopathologic, cytogenetic, and molecular findings that define an acute lymphoblastic leukemia as high risk.	High Risk Acute Lymphoblastic Leukemia		Finding	CTRP Disease Terminology|CTRP Terminology
C168687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168687>	C177430|C1509	Anhydrous Enol-oxaloacetate|AEO|OXALOACETIC ACID	The anhydrous form of enol-oxaloacetate, a small molecule blood glutamate scavenger, that can be used to lower glutamate plasma levels, and has potential neuroprotective activity. Upon administration, enol-oxaloacetate targets and binds to glutamate in the bloodstream. This lowers glutamate plasma levels and lowers the free glutamate available to be picked up by cells, such as tumor brain cells, thereby preventing glutamate metabolism and glutamate-mediated signaling. This prevents the proliferation of rapidly growing cells, such as brain tumor cells. And by lowering glutamate plasma levels, a molecular imbalance is formed and glutamate is excreted across the blood-brain barrier, resulting in lower free brain glutamate.  This may help protect the brain from excitotoxicity in conditions where there is a surge of glutamate production, such as traumatic brain injury, thereby protecting neuronal cells. Glutamate, a non-essential amino acid and the major excitatory neurotransmitter in the central nervous system (CNS), provides energy and generates building blocks for the production of macromolecules, which are needed for cellular growth and survival.	Anhydrous Enol-oxaloacetate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C168688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168688>	C42568	Unit of Height	An indication of the type of unit of measure being used to express a height.			Classification	
C168689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168689>	C25351	Lymphatic Reconstruction|Lymphatic Reconstructive Surgery	Microsurgical techniques, including lymphovenous bypass and vascularized lymph node transplant, to reconstruct critical lymphatic pathways that have been disrupted by surgery.	Lymphatic Reconstruction		Therapeutic or Preventive Procedure	CTRP Intervention Terminology|CTRP Terminology
C16868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16868>	C80519	Neurological Model	A model that simulates behavior or neurological activity using computers and/or mathematical representation.			Intellectual Product	
C168690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168690>	C12680	Spinal Region	The body region that includes the vertebrae, vertebral canal, and spinal cord.			Body Location or Region	
C168691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168691>	C168690	Thoracic Region	The part of the body located between the cervical and lumbar spinal regions.			Body Location or Region	
C168692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168692>	C192218	DNA-PK inhibitor AZD7648|7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one|AZD 7648|AZD-7648|AZD-7648|AZD7648|DNA-dependent Protein Kinase Inhibitor AZD7648	An orally bioavailable ATP-competitive inhibitor of DNA-dependent protein kinase (DNA-PK), with potential chemo/radiosensitizing and antineoplastic activites. Upon oral administration, DNA-PK inhibitor AZD7648 selectively targets, binds to and inhibits the activity of DNA-PK, thereby interfering with the non-homologous end joining (NHEJ) process and preventing repair of DNA double strand breaks (DSBs) caused by ionizing radiation or chemotherapeutic treatment. This increases chemo- and radiotherapy cytotoxicity leading to enhanced tumor cell death. AZD7648 may also increase the effect of poly(ADP-ribose) polymerase (PARP) inhibitors and may work as a monotherapy in tumors with high endogenous levels of DNA damage resulting from defects in other DNA repair pathways. The enhanced ability of tumor cells to repair DSBs plays a major role in the resistance of tumor cells to chemo- and radiotherapy. DNA-PK plays a key role in the NHEJ pathway and DSB repair.	DNA-PK inhibitor AZD7648		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C168693	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168693>	C9343|C215182	Spinal Neoplasm|Neoplasm of the Spine|Spinal Column Neoplasm|Spine Neoplasm|Vertebral Column Neoplasm	A benign or malignant neoplasm that affects the vertebrae and/or vertebral canal.			Neoplastic Process	
C168694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168694>	C168693	Lumbosacral Spine Neoplasm	A benign or malignant neoplasm that affects the lumbosacral region of the spine.			Neoplastic Process	
C168695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168695>	C97927	NT5C2 Gene Mutation|5'-Nucleotidase, Cytosolic II Gene Mutation|NT5B Gene Mutation|NT5CP Gene Mutation|PNT5 Gene Mutation|cN-II Gene Mutation	A change in the nucleotide sequence of the NT5C2 gene.			Cell or Molecular Dysfunction	Pediatric Oncology Target Molecular Abnormalities Terminology
C168696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168696>	C157225	CBDD Process Terminology|Chemical Biology and Drug Development Process Terminology	A set of terms used  to support the chemoinformatics community's effort to design, develop, and describe drug substances, mainly but not exclusively pertaining to the processes (including chemical and biochemical reactions) that either represent the activity or are involved in the construction of small molecules and polymers.			Intellectual Product	
C168697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168697>	C157225	CBDD Structure Terminology|Chemical Biology and Drug Development Structure Terminology	A set of terms used  to support the chemoinformatics community's effort to design, develop, and describe drug substances, mainly but not exclusively pertaining to the chemical structures found in small molecules and polymers.			Intellectual Product	
C168698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168698>	C168693	Cervical Spine Neoplasm	A benign or malignant neoplasm that affects the neck region of the spine.			Neoplastic Process	
C168699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168699>	C73579	Nicotine Replacement Agent|NRT Agent|Nicotine Replacement|Nicotine Replacement Therapy Agent	Any agent that systemically delivers nicotine with the intent to reduce the urge to smoke or to chew tobacco.	Nicotine Replacement Agent		Chemical Viewed Functionally	CTRP Agent Terminology|CTRP Terminology
C16869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16869>	C16461	Statistical Modeling	The statistical characterization of a system to estimate its future behavior based on past behavior and extrapolation.			Activity	
C1686	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1686>	C2129|C1512	ZD2767|N-[[4-[Bis(2-iodoethyl)amino]phenoxy]carbonyl]-L-glutamic Acid|N-[[4-[Bis(2-iodoethyl)amino]phenoxy]carbonyl]-L-glutamic Acid	A phenol mustard glutamate prodrug which induces apoptosis by cross-linking DNA and with potential use in Antibody Directed Enzyme Prodrug Therapy (ADEPT). (NCI)			Organic Chemical|Pharmacologic Substance	
C168700	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168700>	C173150|C172982|C172828	Bothered by Genital Itching and/or Irritation Question|Bothered by Genital Itching and/or Irritation|Extent Bothered by Genital Itching and/or Irritation|Genital itching/irritation	A question about the extent to which an individual is bothered by genital itching and/or irritation.			Intellectual Product	
C168701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168701>	C8816|C153185	Advanced Liposarcoma	A liposarcoma that has spread extensively to other anatomic sites or is no longer responding to treatment.			Neoplastic Process	
C168702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168702>	C173150|C172982	Bothered by Decreased Appetite Question|Bothered by Decreased Appetite|Decreased appetite	A question about the extent to which an individual is bothered by decreased appetite			Intellectual Product	
C168703	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168703>	C173150|C172982	Bothered by Upset Stomach and/or Indigestion Question|Bothered by Stomach Upset and/or Indigestion|Bothered by Upset Stomach and/or Indigestion|Extent Bothered by Upset Stomach and/or Indigestion|Upset stomach, indigestion	A question about the extent to which an individual is bothered by upset stomach and/or indigestion.			Intellectual Product	
C168704	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168704>	C173150|C172982	Bothered by Sinus Problems Question|Bothered by Sinus Problems|Extent Bothered by Sinus Problems|Sinus problems	A question about the extent to which an individual is bothered by sinus problems.			Intellectual Product	
C168705	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168705>	C173150|C173134|C172982	Bothered by Coughing Question|Bothered by Coughing|Coughing|Extent Bothered by Coughing	A question about the extent to which an individual is bothered by coughing.			Intellectual Product	
C168706	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168706>	C173593|C173150|C172982	Bothered by Swelling of Hands or Feet Question|Bothered by Swelling of Hands or Feet|Extent Bothered by Swelling of Hands or Feet|Swelling of hands or feet	A question about the extent to which an individual is bothered by swelling of hands or feet.			Intellectual Product	
C168707	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168707>	C173150|C172982	Bothered by Early Awakening Question|Bothered by Early Awakening|Early awakening|Extent Bothered by Early Awakening	A question about the extent to which an individual is bothered by early awakening.			Intellectual Product	
C168708	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168708>	C85429	Extent of Symptoms Likert Scale|Extent of Symptoms|Extent of Symptoms Scale	A scale for the subject scoring of symptoms extent that ranges from 0: Not at All to 4: Very Bothered.			Intellectual Product	
C168709	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168709>	C221038	Symptoms Extent Score 0|0|Not at All Bothered	A subject score of 0 on a symptoms extent scale that ranges from 0: Not at All to 4: Very Bothered.			Intellectual Product	
C16870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16870>	C16866	Mathematical Model|Math Models	Theoretical representations that simulate the behavior or activity of systems, processes, or phenomena.			Intellectual Product	SeroNet Authorized Values|SeroNet Study Descriptors
C168710	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168710>	C221038	Symptoms Extent Score 1|1	A subject score of 1 on a symptoms extent scale that ranges from 0: Not at All to 4: Very Bothered.			Intellectual Product	
C168711	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168711>	C221038	Symptoms Extent Score 2|2|Somewhat Bothered	A subject score of 2 on a symptoms extent scale that ranges from 0: Not at All to 4: Very Bothered.			Intellectual Product	
C168712	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168712>	C221038	Symptoms Extent Score 3|3	A subject score of 3 on a symptoms extent scale that ranges from 0: Not at All to 4: Very Bothered.			Intellectual Product	
C168713	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168713>	C221038	Symptoms Extent Score 4|4|Very Bothered	A subject score of 4 on a symptoms extent scale that ranges from 0: Not at All to 4: Very Bothered.			Intellectual Product	
C168714	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168714>	C8822|C153185	Advanced Malignant Peripheral Nerve Sheath Tumor	A malignant peripheral nerve sheath tumor that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Malignant Peripheral Nerve Sheath Tumor		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168715	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168715>	C168701|C164070	Advanced Dedifferentiated Liposarcoma	A dedifferentiated liposarcoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Dedifferentiated Liposarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168716	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168716>	C8812|C153185	Advanced Fibrosarcoma	Fibrosarcoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Fibrosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168717	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168717>	C3043|C148331	Unresectable Fibrosarcoma	A fibrosarcoma that is not amenable to surgical resection.	Unresectable Fibrosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168718	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168718>	C3088|C148331	Unresectable Angiosarcoma	An angiosarcoma that is not amenable to surgical resection.	Unresectable Angiosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168719	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168719>	C27781|C132148	Unresectable Myxoid Liposarcoma	A myxoid liposarcoma that is not amenable to surgical resection.	Unresectable Myxoid Liposarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16871>	C25464	Moldova, Republic of|498|MD|MDA|MDA|MOLDOVA|MOLDOVA, REPUBLIC OF|Moldova|Moldova|Republic of Moldova	A country in eastern Europe, northeast of Romania.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C168720	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168720>	C8708|C153185	Advanced Angiosarcoma	An angiosarcoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Angiosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168721	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168721>	C9270|C146858	Advanced Epithelioid Hemangioendothelioma	An epithelioid hemangioendothelioma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Epithelioid Hemangioendothelioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168722	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168722>	C148300	Advanced Round Cell Liposarcoma	A round cell liposarcoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Round Cell Liposarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168723	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168723>	C3800|C27359	Unresectable Epithelioid Hemangioendothelioma	An epithelioid hemangioendothelioma that is not amenable to surgical resection.	Unresectable Epithelioid Hemangioendothelioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168724	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168724>	C4252	Unresectable Round Cell Liposarcoma	A round cell liposarcoma that is not amenable to surgical resection.	Unresectable Round Cell Liposarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168725	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168725>	C8813|C153069	Metastatic Soft Tissue Leiomyosarcoma	A soft tissue leiomyosarcoma that has spread from the original site of growth to another anatomic site.	Metastatic Soft Tissue Leiomyosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168727	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168727>	C168725|C165780|C162194	Advanced Soft Tissue Leiomyosarcoma	A soft tissue leiomyosarcoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced Soft Tissue Leiomyosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168728	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168728>	C153068|C132147	Unresectable Soft Tissue Leiomyosarcoma	A soft tissue leiomyosarcoma that is not amenable to surgical resection.	Unresectable Soft Tissue Leiomyosarcoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168729	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168729>	C34563	Dystonia 16|DYT16	An extremely rare autosomal recessive dystonia-parkinsonism condition caused by mutation(s) in the PRKRA gene encoding interferon-inducible double-stranded RNA-dependent protein kinase activator A.			Disease or Syndrome	Cellosaurus Disease Terminology
C16872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16872>	C16345	Molecular Biology|DNA Molecular Biology	The study of biology at a molecular level. It chiefly concerns itself with understanding the interactions between the various systems of a cell, including the interrelationship of DNA, RNA and protein synthesis and learning how these interactions are regulated. The field overlaps with other areas of biology, particularly genetics and biochemistry.			Biomedical Occupation or Discipline	
C168730	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168730>	C85865|C84685	Emery-Dreifuss Muscular Dystrophy 1, X-Linked|EDMD1	Emery-Dreifuss muscular dystrophy inherited in an X-linked recessive pattern and caused by mutations in the EMD gene, encoding emerin.			Disease or Syndrome	Cellosaurus Disease Terminology
C168731	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168731>	C84941	Oculocutaneous Albinism Type 1A|OCA1A	Oculocutaneous albinism inherited in an autosomal recessive pattern, and caused by mutation(s) in the TYR gene, encoding tyrosinase.			Disease or Syndrome	Cellosaurus Disease Terminology
C168732	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168732>	C137858	Eligibility for Surgery Question|Eligibility for Surgery|Patient Eligibility for Surgery	A question pertaining to a patient's eligibility to undergo a surgical procedure.			Intellectual Product	
C168733	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168733>	C74984	Stickler Syndrome Type 1|STL1	Stickler syndrome inherited in an autosomal dominant pattern, caused by mutation(s) in the COL2A1 gene, encoding collagen alpha-1(II) chain.			Disease or Syndrome	Cellosaurus Disease Terminology
C168734	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168734>	C20194	SAMD9L Gene|SAMD9L|SAMD9L|SAMD9L|Sterile Alpha Motif Domain Containing 9 Like Gene	This gene may be involved in endocytosis and the attenuation of receptor signaling.	SAMD9L Gene		Gene or Genome	CCPS Genetics Terminology|Childhood Cancer Predisposition Study Terminology|CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C168735	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168735>	C168734	SAMD9L wt Allele|ATXPC|C7orf6|Chromosome 7 Open Reading Frame 6 Gene|DRIF2|FLJ39885|KIAA2005|M7MLS1|MLSM7|SCA49|Sterile Alpha Motif Domain Containing 9 Like wt Allele|Sterile Alpha Motif Domain Containing 9-Like Gene|UEF|UEF1	Human SAMD9L wild-type allele is located in the vicinity of 7q21.2 and is approximately 18 kb in length. This allele, which encodes sterile alpha motif domain-containing protein 9-like protein, plays a role in signaling regulation, tumor suppression and endocytosis. Mutations in the gene are associated with myeloid disorders, hepatitis-B related hepatocellular carcinoma, normophosphatemic familial tumoral calcinosis, and ataxia-pancytopenia syndrome.	SAMD9L wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C168736	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168736>	C18466	Sterile Alpha Motif Domain-Containing Protein 9-Like|SAM Domain-Containing Protein 9-Like|SAMD9L|Sterile Alpha Motif Domain Containing 9-Like	Sterile alpha motif domain-containing protein 9-like (1584 aa, ~185 kDa) is encoded by the human SAMD9L gene. This protein is involved in tumor suppression, endocytosis and the regulation of receptor mediated signaling.	Sterile Alpha Motif Domain-Containing Protein 9-Like		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C168737	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168737>	C25681	Lymph Node Size|Size of Lymph Node	The physical dimensions of a lymph node.			Quantitative Concept	
C168738	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168738>	C2124	Fluorine F 18 Flotufolastat Gallium|(18F)-rhPSMA-7.3|18F-rhPSMA-7.3|18FrhPSMA-7.3|F-18-rhPSMA-7.3|FLOTUFOLASTAT F-18 GALLIUM|Fluorine F 18 Radiohybrid PSMA-7.3|Fluorine F 18 rhPSMA-7.3|Fluorine-18 rhPSMA-7.3|Posluma|Posluma|rhPSMA-7.3 (18F)	A radiohybrid prostate specific membrane antigen (rhPSMA) ligand, rhPSMA-7.3, labeled, via the bifunctional, macrocyclic chelating agent 1,4,7,10-tetraazacyclododecane-1-(glutamic acid)-4,7,10-triacetic acid (DOTAGA; DOTA-GA) in complex with nonradioactive gallium, with the radioisotope fluorine F 18, which is covalently bound to silicon, with potential imaging activity using positron emission tomography/computed tomography (PET/CT) or positron emission tomography/magnetic resonance imaging (PET/MRI). Upon administration of fluorine F 18 flotufolastat gallium, the rhPSMA-7.3 moiety targets and binds to PSMA-expressing tumor cells. This allows for visualization of PSMA-expressing cells upon imaging. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and strongly overexpressed in prostate cancer (PCa) cells, with its level rising with increasing tumor differentiation and in hormone-refractory cancers.	Fluorine F 18 Flotufolastat Gallium		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt Antineoplastic Agent Terminology
C16873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16873>	C16912	Molecular Neurobiology	The branch of neurobiology that tries to understand the anatomy, physiology, and pathology of the nervous system by understanding the way that genes, proteins, and molecules interact.			Biomedical Occupation or Discipline	
C168740	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168740>	C28394	Chlorhexidine Gluconate Skin Cleanser|Skin Cleanser with Chlorhexidine Gluconate	A skin cleanser containing chlorhexidine gluconate. Chlorhexidine gluconate is a biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine gluconate is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine gluconate penetrates the cell and causes leakage of intracellular components leading to cell death.	Chlorhexidine Gluconate Skin Cleanser		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C168741	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168741>	C29639	Mild Soap Skin Cleanser|Skin Cleanser with Mild Soap	A skin cleanser containing mild soap.  Soap is an anionic surfactant used for cleansing.	Mild Soap Skin Cleanser		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology
C168742	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168742>	C9479|C3266|C3247	Hereditary Myelodysplastic Syndrome|Familial MDS|Familial Myelodysplastic Syndrome|Hereditary MDS|Myelodysplastic Syndrome with Genetic Predisposition	Myelodysplastic syndrome caused by inherited damaging mutations in cancer susceptibility genes.			Neoplastic Process	
C168743	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168743>	C97927	SAMD9 Gene Mutation|C7orf5 Gene Mutation|Expressed in Aggressive Fibromatosis Gene Mutation|MIRAGE Gene Mutation|NFTC Gene Mutation|OEF1 Gene Mutation|OEF2 Gene Mutation|Sterile Alpha Motif Domain Containing 9 Gene Mutation	A change in the nucleotide sequence of the SAMD9 gene.	SAMD9 Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C168744	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168744>	C97927	SAMD9L Gene Mutation|ATXPC Gene Mutation|C7orf6 Gene Mutation|DRIF2 Gene Mutation|Sterile Alpha Motif Domain Containing 9 Like Gene Mutation|UEF Gene Mutation|UEF1 Gene Mutation	A change in the nucleotide sequence of the SAMD9L gene.	SAMD9L Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C168746	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168746>	C185293|C168742	SAMD9-Associated Hereditary Myelodysplastic Syndrome|SAMD9- Associated Familial MDS|SAMD9-Associated Familial Myelodysplastic Syndrome|SAMD9-Associated Familial Myelodysplastic Syndrome	A familial myelodysplastic syndrome caused by inherited mutations in the SAMD9 gene.			Neoplastic Process	
C168747	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168747>	C185294|C168742	SAMD9L-Associated Hereditary Myelodysplastic Syndrome|SAMD9L-Associated Familial MDS|SAMD9L-Associated Familial Myelodysplastic Syndrome|SAMD9L-Associated Familial Myelodysplastic Syndrome	A familial myelodysplastic syndrome caused by inherited mutations in the SAMD9L gene.			Neoplastic Process	
C168748	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168748>	C168732	Eligibility for Lymph Node Dissection Question|Eligibility for Lymph Node Dissection|Patient Eligibility for Lymph Node Dissection	A question pertaining to a patient's eligibility to undergo a lymph node dissection.			Intellectual Product	
C168749	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168749>	C34373	Amyotrophic Lateral Sclerosis 1|ALS1	An inherited form of amyotrophic lateral sclerosis, usually inherited in an autosomal dominant pattern, caused by mutation(s) in the SOD1 gene, encoding superoxide dismutase.			Disease or Syndrome	Cellosaurus Disease Terminology
C16874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16874>	C25464	Monaco|492|MC|MCO|MCO|MONACO|MONACO	A country in western Europe, bordering the Mediterranean Sea on the southern coast of France, near the border with Italy.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C168750	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168750>	C34373	Amyotrophic Lateral Sclerosis 6, with or without Frontotemporal Dementia|ALS6	A form of amyotrophic lateral sclerosis caused by heterozygous mutation(s) in the FUS gene, encoding RNA-binding protein FUS.			Disease or Syndrome	Cellosaurus Disease Terminology
C168751	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168751>	C34373	Amyotrophic Lateral Sclerosis 8|ALS8	An autosomal dominant form of amyotrophic lateral sclerosis caused by mutation(s) in the VAPB gene, encoding vesicle-associated membrane protein-associated protein B/C.			Disease or Syndrome	Cellosaurus Disease Terminology
C168752	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168752>	C34373	Amyotrophic Lateral Sclerosis 10, with or without Frontotemporal Dementia|ALS10	An autosomal dominant form of amyotrophic lateral sclerosis caused by mutation(s) in the TARDBP gene, encoding TAR DNA-binding protein 43.			Disease or Syndrome	Cellosaurus Disease Terminology
C168753	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168753>	C34373	Amyotrophic Lateral Sclerosis 11|ALS11	An autosomal dominant form of amyotrophic lateral sclerosis caused by mutation(s) in the FIG4 gene, encoding polyphosphoinositide phosphatase.			Disease or Syndrome	Cellosaurus Disease Terminology
C168754	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168754>	C34373	Amyotrophic Lateral Sclerosis 14, with or without Frontotemporal Dementia|ALS14	A form of amyotrophic lateral sclerosis caused by heterozygous mutation(s) in the VCP gene, encoding transitional endoplasmic reticulum ATPase.			Disease or Syndrome	Cellosaurus Disease Terminology
C168755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168755>	C34373	Amyotrophic Lateral Sclerosis 21|ALS21	An autosomal dominant form of amyotrophic lateral sclerosis caused by mutation(s) in the MATR3 gene, encoding matrin-3.			Disease or Syndrome	Cellosaurus Disease Terminology
C168756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168756>	C4802|C176696	Frontotemporal Dementia and/or Amyotrophic Lateral Sclerosis 1|FTDALS1	An autosomal dominant condition caused by heterozygous hexanucleotide repeat expansion in a noncoding region of the C9ORF72 gene , encoding guanine nucleotide exchange C9orf72. It is characterized by amyotrophic lateral sclerosis with frontotemporal dementia.			Disease or Syndrome	Cellosaurus Disease Terminology
C168757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168757>	C84528	Achromatopsia 2|ACHM2	An autosomal recessive condition caused by mutation(s) in the CNGA3 gene, encoding cyclic nucleotide-gated cation channel subunit alpha-3. It is characterized by achromatopsia.			Disease or Syndrome	Cellosaurus Disease Terminology
C168758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168758>	C186791|C167144	t(10;11)(p11.2;q23)	A cytogenetic abnormality that refers to the translocation of the short arm (p11.2) of chromosome 10 and the long arm (q23) of chromosome 11. It is associated with KMT2A (MLL)/ABI1 fusions and acute myeloid leukemia.			Cell or Molecular Dysfunction	AML Authorized Value Terminology|AML Minimal Residual Disease Table|AML Molecular Analysis Table|GDC Terminology|GDC Value Terminology
C168759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168759>	C36386|C167144	t(1;11)(q21;q23)	A cytogenetic abnormality that refers to the translocation of the long arm (q21) of chromosome 1 and the long arm (q23) of chromosome 11. It is associated with KMT2A (MLL)/MLLT11 (AF1Q) fusions, acute myeloid leukemia and some cases of acute lymphoblastic leukemia.			Cell or Molecular Dysfunction	AML Authorized Value Terminology|AML Minimal Residual Disease Table|AML Molecular Analysis Table
C16875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16875>	C25464	Mongolia|496|MN|MNG|MNG|MONGOLIA|MONGOLIA	A country in northern Asia, between China and Russia.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C168760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168760>	C186913|C175582|C167144	t(11;17)(q23;q12-21)	A cytogenetic abnormality that refers to the translocation of the long arm (q23) of chromosome 11 and the long arm (q12-21) of chromosome 19. It is associated with KMT2A (MLL) fusions, including those with MLLT6 (AF17), and acute myeloid leukemia.			Cell or Molecular Dysfunction	
C168761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168761>	C212853	KMT2A/MLLT6 Fusion Gene|KMT2A-MLLT6 Fusion Gene|KMT2A::MLLT6 Fusion Gene|MLL-AF17 Fusion Gene|MLL-MLLT6 Fusion Gene|MLL/AF17 Fusion Gene|MLL/MLLT6 Fusion Gene	A fusion gene that results from a chromosomal translocation t(11;17)(q23;q12) which fuses the 5' half of the KMT2A (MLL) gene to the 3' half of the coding region of the MLLT6 (AF17) gene. This rearrangement is associated with acute myeloid leukemia.	MLL/MLLT11 Fusion Gene		Gene or Genome	
C168763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168763>	C213256	KMT2A/MLLT6 Fusion Protein|Histone-Lysine N-Methyltransferase MLL-Protein AF-17 Fusion Protein|Histone-Lysine N-Methyltransferase MLL/Protein AF-17 Fusion Protein|KMT2A-MLLT6 FusionProtein|KMT2A::MLLT6 Fusion Protein|MLL-AF17 Fusion Protein|MLL-MLLT6 FusionProtein|MLL/AF17 FusionProtein|MLL/MLLT6 FusionProtein	A fusion protein encoded by the KMT2A/MLLT6 fusion gene. This protein is comprised of the N-terminal half of the histone-lysine N-methyltransferase MLL protein, including the AT hook DNA binding domain and the DNA methyltransferase domain, fused to the C-terminal half, including the octapeptide (OM) and the leucine-zipper (LZ) dimerization motif, of protein AF-17.			Amino Acid, Peptide, or Protein	
C168764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168764>	C167144	t(11;19)(q23;p13)	A cytogenetic abnormality that refers to the translocation of the long arm (q23) of chromosome 11 and the short arm (p13) of chromosome 19. It is associated with KMT2A (MLL) fusions, including those with MLLT1 (ENL) and ELL, and acute myeloid leukemia.			Cell or Molecular Dysfunction	AML Authorized Value Terminology|AML Minimal Residual Disease Table|AML Molecular Analysis Table
C168765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168765>	C28510	GATA2/MECOM Fusion Gene|GATA2-MECOM Fusion Gene|GATA2::MECOM Fusion Gene|RPN1/MECOM Fusion Gene|RPN1/MECOM Fusion Gene	A fusion gene that results from a chromosomal rearrangement either t(3;3)(q21;q26) or inv(3)(q21q26) which fuses the promoter sequences from the GATA2 gene on either the 5' or 3' side of the coding sequence of the MECOM gene. This rearrangement is associated with overexpression of the histone-lysine N-methyltransferase MECOM protein and 3q21q26 syndrome-related leukemias.	GATA2/MECOM Fusion Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C168766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168766>	C226401|C186908|C155992	t(3;12)(q23;p12.3)	A cytogenetic abnormality that refers to the translocation of the long arm (q23) of chromosome 3 and the short arm (p12.3) of chromosome 12. It is associated with ETV6/MECOM (EVI1) fusions, myeloproliferative disorders, myelodysplastic syndromes and acute myelogenous leukemia.			Cell or Molecular Dysfunction	AML Authorized Value Terminology|AML Minimal Residual Disease Table|AML Molecular Analysis Table
C168767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168767>	C212851	ETV6/MECOM Fusion Gene|ETV6-EVI1 Fusion Gene|ETV6-MECOM Fusion Gene|ETV6/EVI1 Fusion Gene|ETV6::MECOM Fusion Gene	A fusion gene that results from a chromosomal translocation t(3;12)(q26;p13) which exon 2 of the ETV6 gene with exon 2 of the MECOM gene. This rearrangement is associated with myeloproliferative disorders, myelodysplastic syndromes and acute myelogenous leukemia.			Gene or Genome	
C168768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168768>	C213236	ETV6/MECOM Fusion Protein|ETV6-EVI1 Fusion Protein|ETV6-MECOM FusionProtein|ETV6/EVI1 FusionProtein|ETV6::MECOM Fusion Protein|Transcription Factor ETV6/Histone-Lysine N-Methyltransferase MECOM Fusion Protein	A fusion protein encoded by the ETV6/MECOM fusion gene. This protein is comprised of a few N-terminal amino acids containing no functional domains of the transcription factor ETV6 protein fused to the entire the histone-lysine N-methyltransferase MECOM protein.			Amino Acid, Peptide, or Protein	
C168769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168769>	C9484|C150478	del(5q31-q32)|5q31-32 Deletion|del(5)(q31-q32)|del(5)(q31q32)|del(5q)(5q31-q32)|del(5q31q32)	A cytogenetic abnormality that refers to deletion of chromosome bands 31-32 on the long arm of chromosome 5.			Cell or Molecular Dysfunction	AML Authorized Value Terminology|AML Minimal Residual Disease Table|AML Molecular Analysis Table
C16876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16876>	C25464	Montserrat|500|MONTSERRAT|MONTSERRAT|MS|MSR|MSR	An island in the Caribbean Seas, southeast of Saint Kitts and Nevis.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C168770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168770>	C9484|C171055	del(13q14-q21)|13q14-q21 Deletion|del(13)(q14-q21)|del(13)(q14q21)|del(13q)(13q14-21)|del(13q14q21)	A cytogenetic abnormality that refers to deletion of chromosome bands 14-21 on the long arm of chromosome 13.			Cell or Molecular Dysfunction	AML Authorized Value Terminology|AML Minimal Residual Disease Table|AML Molecular Analysis Table
C168771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168771>	C158948	Non-KMT2A MLLT10 Rearrangement Positive|Non-KMT2A MLLT10|Non-KMT2A MLLT10 Rearrangement|Non-MLL MLLT10 Rearrangement|Non-MLL MLLT10 Rearrangement Positive	An indication that a cytogenetic rearrangement involving MLLT10 but not involving KMT2A was detected in a sample.			Laboratory or Test Result	AML Authorized Value Terminology|AML Minimal Residual Disease Table|AML Molecular Analysis Table
C168772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168772>	C211912|C208190	Anti-CD228/MMAE Antibody-drug Conjugate SGN-CD228A|Anti-CD228 Antibody-drug Conjugate SGN-CD228A|Anti-CD228-MMAE ADC SGN-CD228A|Anti-CD228/MMAE ADC SGN-CD228A|Anti-melanotransferrin ADC SGN-CD228A|SGN CD228A|SGN-CD228A|SGNCD228A	An antibody-drug conjugate (ADC) composed of a humanized antibody targeting the cell surface antigen cluster of differentiation 228 (CD228; melanotransferrin; MFI2; MELTF) that is conjugated, via a beta-glucuronidase-cleavable linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Following administration, the antibody moiety of anti-CD228/MMAE ADC SGN-CD228A targets and binds to CD228 on the surface of tumor cells. Following internalization of SGN-CD228A and release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in CD228-expressing tumor cells. CD228, a cell-surfaced, glycosylphosphatidylinoitol (GPI)-anchored glycoprotein, belongs to the transferrin family of iron-binding proteins.	Anti-CD228/MMAE Antibody-drug Conjugate SGN-CD228A		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C168773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168773>	C3420|C186972|C186818	t(16;21)(q24;q22)	A cytogenetic abnormality that refers to the translocation of the long arm (q24) of chromosome 16 and the long arm (q22) of chromosome 22. It is associated with RUNX1/CBFA2T3 fusions, myelodysplastic syndromes and acute myeloid leukemia.			Cell or Molecular Dysfunction	AML Authorized Value Terminology|AML Minimal Residual Disease Table|AML Molecular Analysis Table
C168774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168774>	C38372|C129830	Monoallelic CEBPA Gene Mutation|C/EBP-Alpha Monoallelic Gene Mutation|C/EBPalpha Monoallelic Gene Mutation|CCAAT Enhancer Binding Protein Alpha Monoallelic Gene Mutation|CCAAT/Enhancer Binding Protein Alpha Monoallelic Gene Mutation|CCAAT/Enhancer Binding Protein, Alpha Monoallelic Gene Mutation|CEBP Monoallelic Gene Mutation|CEBPA Monoallelic Gene Mutation|CEBPA Monoallelic Mutation|moCEBPA	The presence of mutations in only one allele of the CEBPA gene.			Cell or Molecular Dysfunction	AML Authorized Value Terminology|AML Minimal Residual Disease Table|AML Molecular Analysis Table
C168775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168775>	C28310	Autologous Tetravalent Dendritic Cell Vaccine MIDRIX4-LUNG|Autologous DC Vaccine MIDRIX4-LUNG|Autologous Tetravalent DC Vaccine MIDRIX4-LUNG|MIDRIX4-LUNG|Tetravalent Autologous Dendritic Cell Vaccine MIDRIX4-LUNG	A therapeutic cancer vaccine composed of autologous, dendritic cells (DCs) that have been loaded with a proprietary selection of four antigens that covers more than ninety percent of all non-small cell lung cancer (NSCLC) patients, with potential immunostimulatory and antineoplastic activities. Upon administration, autologous tetravalent dendritic cell vaccine MIDRIX4-LUNG may induce and stimulate both T-helper and antigen-specific cytotoxic T-lymphocyte (CTL) responses, leading to tumor cell lysis in patients with NSCLC.			Cell|Immunologic Factor|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C168776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168776>	C275|C226473	Caffeine-based Cream|Caffeine Based Cream|Caffeine-Lipoderm Cream|Caffeine-containing Lipoderm Cream	A topical cream containing the alkaloid caffeine in a lipoderm base, with potential anti-inflammatory, anti-fibrotic, protective and antioxidant activities. Upon topical application of the caffeine-based cream to the affected area(s), the caffeine inhibits phosphodiesterase (PDE) activity, thereby stimulating the degradation of fats during lipolysis. Caffeine also reduces the levels of certain pro-inflammatory cytokines, such as the profibrotic cytokine transforming growth factor beta (TGFb,) and matrix metalloproteinases (MMPs), thereby preventing inflammation and protecting against collagen degradation. In addition, caffeine protects cells from oxidative stress. This may help protect skin, reduce skin-related complications and improve skin appearance.	Caffeine-based Cream		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C168777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168777>	C168519|C165698	Metastatic HER2-Negative Breast Carcinoma|Metastatic HER2 Negative Breast Adenocarcinoma|Metastatic HER2 Negative Breast Carcinoma	A HER2-negative breast adenocarcinoma that has spread to another anatomic site.			Neoplastic Process	
C168778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168778>	C8688|C139005	Recurrent Follicular Helper T-Cell Lymphoma|Recurrent Nodal Peripheral T-Cell Lymphoma with TFH Phenotype	The reemergence of follicular helper T-cell lymphoma after a period of remission.	Recurrent Nodal Peripheral T-Cell Lymphoma with TFH Phenotype		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168779>	C8689|C139005	Refractory Follicular Helper T-Cell Lymphoma|Refractory Nodal Peripheral T-Cell Lymphoma with TFH Phenotype	A follicular helper T-cell lymphoma that is resistant to treatment.	Refractory Nodal Peripheral T-Cell Lymphoma with TFH Phenotype		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16877>	C16495	Morbidity|morbidity|morbidity	Morbidity; the relative incidence of a particular disease in a population.			Quantitative Concept	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C168780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168780>	C80375|C168778	Recurrent Follicular Helper T-Cell Lymphoma, Follicular-Type|Recurrent Follicular T-Cell Lymphoma|Recurrent Follicular T-Cell Lymphoma	The reemergence of follicular helper T-cell lymphoma, follicular-type after a period of remission.	Recurrent Follicular T-Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168781>	C80375|C168779	Refractory Follicular Helper T-Cell Lymphoma, Follicular-Type|Refractory Follicular T-Cell Lymphoma|Refractory Follicular T-Cell Lymphoma	A follicular helper T-cell lymphoma, follicular-type that is resistant to treatment.	Refractory Follicular T-Cell Lymphoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168782>	C168777|C165700	Advanced HER2-Negative Breast Carcinoma|Advanced HER2 Negative Breast Adenocarcinoma|Advanced HER2 Negative Breast Carcinoma|Advanced HER2 Negative Breast Carcinoma	A HER2-negative breast adenocarcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.	Advanced HER2 Negative Breast Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168783>	C175588|C168519	Recurrent HER2-Negative Breast Carcinoma|Recurrent HER2 Negative Breast Adenocarcinoma|Recurrent HER2 Negative Breast Carcinoma|Recurrent HER2 Negative Breast Carcinoma|Relapsed HER2 Negative Breast Carcinoma	The reemergence of HER2-negative breast adenocarcinoma after a period of remission.	Recurrent HER2 Negative Breast Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168784>	C168519|C165703	Refractory HER2-Negative Breast Carcinoma|Refractory HER2 Negative Breast Adenocarcinoma|Refractory HER2 Negative Breast Carcinoma|Refractory HER2 Negative Breast Carcinoma	A HER2-negative breast adenocarcinoma that is resistant to treatment.	Refractory HER2 Negative Breast Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168785>	C18466	MECOM Gene Product	A protein encoded by the MECOM gene.	MECOM Gene Product		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C168786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168786>	C168785|C16849	Histone-Lysine N-Methyltransferase MECOM|EC 2.1.1.367|EVI-1|Ecotropic Virus Integration 1 Site Protein|Ecotropic Virus Integration Site 1 Protein Homolog|MDS1 and EVI1 Complex Locus Protein|MECOM|Myelodysplasia Syndrome 1 Protein|Myelodysplasia Syndrome-Associated Protein 1	Histone-lysine N-methyltransferase MECOM (1230 aa, ~138 kDa) is encoded by the human MECOM gene. This protein plays a role in monomethylation of lysine-9 in histone H3 (H3K9me1).	Histone-Lysine N-Methyltransferase MECOM		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C168787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168787>	C168785	MECOM Protein Isoform MDS1|MDS1|MDS1 and EVI1 Complex Locus Protein MDS1	MECOM protein isoform MDS1 (19 aa, ~169 kDa) is encoded by the human MECOM gene. This protein may be involved in leukemogenesis.	MECOM Protein Isoform MDS1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C168788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168788>	C168785	MECOM Protein Isoform Mds1/Evi1|Evi-1c|Evi1c|MDS1 and EVI1 Complex Locus Protein MDS1-EVI1|MDS1-EVI1|MECOM Protein Isoform Evi-1c|Mds1/Evi1	MECOM protein isoform Mds1/Evi1 (1239 aa, ~139 kDa) is encoded by the human MECOM gene. This protein may play a role in transcriptional regulation.	MECOM Protein Isoform Mds1/Evi1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C16878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16878>	C25464	Morocco|504|MA|MAR|MAR|MOROCCO|MOROCCO	A country in northern Africa, bordering the North Atlantic Ocean and the Mediterranean Sea, south of Spain and between Algeria and Western Sahara.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C168790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168790>	C717|C308|C222795	Enadenotucirev-expressing FAP/CD3 Bispecific FAP-TAc NG-641|NG 641|NG-641|NG-641|NG641|Oncolytic Adenoviral Vector Expressing FAP/CD3 Bispecific Molecule NG-641|Oncolytic Adenoviral Vector-expressing FAP/CD3 Bispecific FAP-TAc NG-641	An oncolytic adenoviral vector, a transgene-modified variant of enadenotucirev (EnAd), that expresses a bi-specific T-cell activator molecule FAP-TAc together with immune enhancer molecules C-X-C motif chemokine 9 (CXCL9), C-X-C motif chemokine 10 (CXCL10) and interferon alpha (IFNalpha), with potential immunomodulating and antineoplastic activities. Upon administration of NG-641, EnAd specifically infects and replicates in tumor cells and not in normal, noncancerous tissue, and selectively expresses FAP-TAc. The locally expressed FAP-TAc targets and binds to both fibroblast activating protein (FAP) on cancer associated fibroblasts (CAFs) and CD3 on T-cells. This leads to T-cell activation and T-cell mediated killing of CAFs in tumor stroma. NG-641 also encodes the transgenes CXCL9, CXCL10 and IFNalpha. The production of CXCL9, CXCL10 and IFNalpha leads to the recruitment and further activation of T-cells, enhancing the overall immune response and cancer cell killing. FAP, a cell surface glycoprotein, is overexpressed on tumor-associated fibroblasts but minimally expressed on normal, healthy cells.	Enadenotucirev-expressing FAP/CD3 Bispecific FAP-TAc NG-641		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C168791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168791>	C28533	MELTF Gene|MELTF|MELTF|Melanotransferrin Gene	This gene is involved in cellular iron uptake.	MELTF Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology
C168792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168792>	C168791	MELTF wt Allele|Antigen p97 (Melanoma Associated) Identified by Monoclonal Antibodies 133.2 And 96.5 Gene|CD228|FLJ38863|MAP97|MFI2|MGC4856|MTF1|MTf|Melanotransferrin wt Allele	Human MELTF wild-type allele is located in the vicinity of 3q29 and is approximately 42 kb in length. This allele, which encodes melanotransferrin protein, plays a role in iron ion transport. Aberrant expression of this gene is associated with melanoma.	MELTF wt Allele		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C168793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168793>	C16386	Melanotransferrin|CD228 Antigen|MELTF|MTf|Melanoma-Associated Antigen p97|Membrane-Bound Transferrin-Like Protein|p97 Melanoma Antigen	Melanotransferrin (738 aa, ~80 kDa) is encoded by the human MELTF gene. This protein is involved in cellular iron homeostasis.	Melanotransferrin		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C168794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168794>	C62634	Hematopoietic Cell Transplantation Conditioning Regimen|HCT Conditioning Regimen|HSCT Conditioning Regimen|Stem Cell Transplant Conditioning|Stem Cell Transplant Conditioning	A regimen that can be used as a conditioning regimen for hematopoietic stem cell transplantation (HSCT).			Therapeutic or Preventive Procedure	ALL Authorized Value Terminology|ALL Course Timing Table|ALL Histology Table|ALL Off Protocol Therapy/Study Table|ALL Vitals Table|AML Adverse Events Table|AML Authorized Value Terminology|AML Cellular Immunotherapy Table|AML Concomitant Medication Table|AML Course Timing Table|AML Function Test Table|AML Lab Table|AML Minimal Residual Disease Table|AML Molecular Analysis Table|AML Myeloid Sarcoma Involvement Table|AML Off Protocol Therapy/Study Table|AML Radiation Therapy Table|AML Secondary Malignant Neoplasm Table|AML Stem Cell Transplant Table|AML Subject Response Table|AML Survival Characteristics Table|AML Total Dose Table|AML Transfusion Medicine Procedures Table|AML Vitals Table
C168795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168795>	C17708	Operation of Heavy Machinery|Operate Heavy Machinery	The use of heavy-duty vehicles or equipment for personal or professional work.			Daily or Recreational Activity	
C168796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168796>	C20189	Pathogenicity|pathogenicity	The likelihood of an entity to produce pathologic changes or disease.			Conceptual Entity	GDC Property Terminology|GDC Terminology
C168797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168797>	C168796	Germline Pathogenicity	The likelihood that germline variant is causally related to a heritable disease.			Conceptual Entity	
C168798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168798>	C118969	ACMG Classification of Genomic Variant Pathogenicity|American College of Medical Genetics Classification of Genomic Variant Pathogenicity	A five-tiered classification from the American College of Medical Genetics designed to describe the likelihood that a genomic sequence variant is causative of an inherited disease.			Intellectual Product	
C168799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168799>	C17248	Pathogenic Variant|Pathogenic	A genetic variant that is known to directly contribute to the development of disease.			Nucleotide Sequence	GDC Terminology|GDC Value Terminology
C16879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16879>	C21147	Morphogenesis	The process of shape formation: the processes that are responsible for producing the complex shapes of adults from the simple ball of cells that derives from division of the fertilized egg.			Organ or Tissue Function	
C1687	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1687>	C213472|C159199|C159198|C155700	Imatinib Mesylate|4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate|CGP 57148|CGP 57148B|CGP-57148|CGP-57148B|CGP57148|CGP57148B|Gleevec|Gleevec|Gleevec|Glivec|IMATINIB MESYLATE|Imarech|Imat|Imkeldi|STI 571|STI-571|STI571|STI571|imatinib mesylate	The mesylate salt of imatinib, a tyrosine kinase inhibitor with antineoplastic activity. Imatinib binds to an intracellular pocket located within tyrosine kinases (TK), thereby inhibiting ATP binding and preventing phosphorylation and the subsequent activation of growth receptors and their downstream signal transduction pathways. This agent inhibits TK encoded by the bcr-abl oncogene as well as receptor TKs encoded by the c-kit and platelet-derived growth factor receptor (PDGFR) oncogenes. Inhibition of the bcr-abl TK results in decreased proliferation and enhanced apoptosis in malignant cells of Philadelphia-positive (Ph+) hematological malignancies such as CML and ALL; effects on c-kit TK activity inhibit mast-cell and cellular proliferation in those diseases overexpressing c-kit, such as mastocytosis and gastrointestinal stromal tumor (GIST).	Imatinib Mesylate		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C168800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168800>	C17248	Likely Pathogenic Variant|Likely Pathogenic	A genetic variant that is known to have a high likelihood (greater than 90% certainty) to contribute to the development of a disease.			Nucleotide Sequence	GDC Terminology|GDC Value Terminology
C168801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168801>	C17248	Variant Likely Benign|Likely Benign|Likely Benign Variant	A genetic variant that is not expected to contribute to the development of a disease, but the scientific evidence may be insufficient to prove this conclusively.			Nucleotide Sequence	GDC Terminology|GDC Value Terminology
C168802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168802>	C17248	Variant Benign|Benign|Benign Variant	A genetic variant that is known to not contribute to the development of a disease.			Nucleotide Sequence	GDC Terminology|GDC Value Terminology
C168803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168803>	C17248	Variant Pathogenic/Likely Pathogenic|Pathogenic/Likely Pathogenic|Pathogenic/Likely Pathogenic Variant	An ad hoc category that describes genetic variants with 90% or greater certainty of contributing to the development of a disease.	Variant Pathogenic/Likely Pathogenic		Nucleotide Sequence	CTRP Biomarker Terminology|CTRP Terminology
C168804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168804>	C9350|C45655	Peritoneal Sarcomatoid Mesothelioma	Malignant mesothelioma that arises from the peritoneum. It is characterized by the presence of spindle cells. Anaplastic morphologic features and multinucleated malignant cells may also be seen.	Peritoneal Sarcomatoid Mesothelioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168805>	C9350|C4282	Peritoneal Biphasic Mesothelioma	Malignant mesothelioma that arises from the peritoneum. It is characterized by the presence of epithelioid and sarcomatoid components, with each component representing at least 10% of the tumor.	Peritoneal Biphasic Mesothelioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168806>	C177683	NUTM1 Gene Fusion Positive|C15orf55 Fusion Gene Positive|FAM22H Fusion Gene Positive|NUT Fusion Gene Positive|NUT Gene Fusion Positive|NUT Midline Carcinoma, Family Member 1 Fusion Gene Positive|NUTM1 Fusion Gene Positive|Nuclear Protein in Testis Fusion Gene Positive	An indication that a NUTM1 fusion gene has been detected in a sample.			Laboratory or Test Result	
C168807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168807>	C25379	Protocol Treatment Course|COURSE|COURSE|COURSE|COURSE|COURSE|Treatment Course	The type of protocol treatment course administered.			Clinical Attribute	ALL Course Timing Table|ALL Histology Table|ALL Off Protocol Therapy/Study Table|ALL Variable Terminology|ALL Vitals Table|AML Adverse Events Table|AML Cellular Immunotherapy Table|AML Concomitant Medication Table|AML Course Timing Table|AML Function Test Table|AML Lab Table|AML Minimal Residual Disease Table|AML Molecular Analysis Table|AML Myeloid Sarcoma Involvement Table|AML Off Protocol Therapy/Study Table|AML Radiation Therapy Table|AML Secondary Malignant Neoplasm Table|AML Stem Cell Transplant Table|AML Subject Response Table|AML Survival Characteristics Table|AML Total Dose Table|AML Transfusion Medicine Procedures Table|AML Variable Terminology|AML Vitals Table|EWS Adverse Events Table|EWS Biopsy/Surgical Procedures Table|EWS Course Timing Table|EWS Histology Table|EWS Immunohistochemistry Table|EWS Lab Table|EWS Molecular Analysis Table|EWS Non-Protocol Therapy Table|EWS Off Protocol Therapy/Study Table|EWS Radiation Therapy Table|EWS Secondary Malignant Neoplasm Table|EWS Stem Cell Transplant Table|EWS Subject Response Table|EWS Survival Characteristics Table|EWS Tumor Assessment Table|EWS Variable Terminology|EWS Vitals Table|HL Adverse Events Table|HL Biopsy/Surgical Procedures Table|HL Concomitant Medication Table|HL Course Timing Table|HL Function Test Table|HL Histology Table|HL Imaging Table|HL Immunohistochemistry Table|HL Lab Table|HL Lesion Characteristics Table|HL Off Protocol Therapy/Study Table|HL Protocol Treatment Modifications Table|HL Radiation Therapy Table|HL Secondary Malignant Neoplasm Table|HL Staging Table|HL Stem Cell Transplant Table|HL Subject Response Table|HL Survival Characteristics Table|HL Total Dose Table|HL Transfusion Medicine Procedures Table|HL Variable Terminology|HL Vitals Table|OS Adverse Event Table|OS Biopsy/Surgical Procedures Table|OS Function Test Table|OS Histology Table|OS Lab Table|OS Molecular Analysis Table|OS Off Protocol Therapy/Study Table|OS Radiation Therapy Table|OS Secondary Malignant Neoplasm Table|OS Subject Response Table|OS Survival Characteristics Table|OS Total Dose Table|OS Tumor Assessment Table|OS Variable Terminology|OS Vitals Table
C168808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168808>	C141137|C129820	IDO1/TDO2 Inhibitor M4112|Indoleamine 2,3-Dioxygenase-1/Tryptophan 2,3-Dioxygenase 2 Inhibitor M4112|M 4112|M-4112|M4112|MS201408-0005	An inhibitor of both the enzymes indoleamine 2,3-dioxygenase 1 (IDO1; IDO-1) and tryptophan 2,3-dioxygenase 2 (TDO2; TDO-2), with potential immunomodulating and antineoplastic activities. Upon administration, IDO1/TDO2 inhibitor M4112 targets, binds to and inhibits both IDO1 and TDO2, which catalyze the first and rate-limiting step in the production of the immunosuppressive transcription factor aryl hydrocarbon receptor (AhR) ligand kynurenine (Kyn). This inhibits the IDO1/TDO2-Kyn-AhR pathway and abrogates AhR activation. This prevents the activation of immune-tolerant dendritic cells (DCs) and regulatory T-cells (Tregs) in the tumor microenvironment (TME), and may restore the immune response by stimulating a cytotoxic T-lymphocyte (CTL) immune response against tumor cells in which IDO1 and/or TDO2 are overexpressed. The IDO1/TDO2-KYN-AhR pathway is overexpressed in a variety of tumor cell types and plays a key role in immunosuppression. Its expression is correlated with poor prognosis.	IDO1/TDO2 Inhibitor M4112		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C168809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168809>	C36285	Malglycemia	A finding indicative of dysregulated glucose metabolism. The glycemic abnormalities may include hyperglycemia, hypoglycemia or glycemic variability.	Malglycemia		Finding	CTRP Disease Terminology|CTRP Terminology
C16880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16880>	C17258	Mortality Rate|Death Rate|Mortality|mortality|mortality (rate)|mortality rate	The proportion of deaths occurring in a population over a specified time.			Quantitative Concept	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C168811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168811>	C173545	FLT3-Internal Tandem Duplication Allelic Ratio|FLT3-ITD AR|ITD-AR	A laboratory procedure used to determine the ratio of FLT3 alleles possessing an internal tandem duplication mutation (FLT3-ITD) compared to the number of wild-type FLT3 alleles in a bone marrow- or peripheral blood-derived sample.			Laboratory Procedure	
C168812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168812>	C113003	Flow Cytometry for Leukemia-Associated Immunophenotypes|Leukemia-Associated Immunophenotypes|Leukemia-Associated Immunophenotypes	A technique with leukemia-associated immunophenotypes for counting, examining or sorting microscopic particles suspended in a stream of fluid based on tagging the population of interest with antibody-based reagents.			Laboratory Procedure	ALL Authorized Value Terminology|ALL Minimal Residual Disease Table|AML Authorized Value Terminology|AML Minimal Residual Disease Table
C168813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168813>	C123400	Second Relapse	The reemergence of a disorder as diagnosed by clinical and/or laboratory evidence following two documented periods of remission.			Finding	
C168814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168814>	C123400	Third Relapse	The reemergence of a disorder as diagnosed by clinical and/or laboratory evidence following three documented periods of remission.			Finding	
C168815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168815>	C123400	Fourth Relapse	The reemergence of a disorder as diagnosed by clinical and/or laboratory evidence following four documented periods of remission.			Finding	
C168816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168816>	C123400	Fifth Relapse	The reemergence of a disorder as diagnosed by clinical and/or laboratory evidence following five documented periods of remission.			Finding	
C168817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168817>	C123400	Sixth Relapse	The reemergence of a disorder as diagnosed by clinical and/or laboratory evidence following six documented periods of remission.			Finding	
C168819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168819>	C126298	Mismatch at One HLA Allele|One Allele Mismatched	One allele matches for one HLA locus.			Classification	AML Authorized Value Terminology|AML Stem Cell Transplant Table
C16881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16881>	C25873	MOS Gene|MOS|MOS|v-MOS Moloney Murine Sarcoma Viral Oncogene Homolog Gene	This gene is involved in signal transduction and the control of meioses.			Gene or Genome	
C168820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168820>	C126298	Mismatch at Both HLA Alleles|Two Alleles Mismatched	A mismatch exists at both alleles.			Classification	AML Authorized Value Terminology|AML Stem Cell Transplant Table
C168821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168821>	C129972	Match at Both HLA Alleles|Both Alleles Matched	Both alleles match for one HLA locus			Classification	AML Authorized Value Terminology|AML Stem Cell Transplant Table
C168822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168822>	C173263	Extramedullary Myeloid Sarcoma Site|MYELOID_SARCOMA_SITE	The site of the extramedullary myeloid sarcoma.			Body Location or Region	AML Myeloid Sarcoma Involvement Table|AML Variable Terminology
C168823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168823>	C159612	Year at Disease Phase|YEAR_AT_DISEASE_PHASE|YEAR_AT_DISEASE_PHASE|YEAR_AT_DISEASE_PHASE|YEAR_AT_DISEASE_PHASE|YEAR_AT_DISEASE_PHASE|YEAR_AT_DISEASE_PHASE	The year when a disease phase was assigned to an individual's condition.			Temporal Concept	ALL Disease Phase Timing Table|ALL Variable Terminology|AML Disease Phase Timing Table|AML Variable Terminology|EWS Disease Phase Timing Table|EWS Variable Terminology|GCT Disease Phase Timing Table|GCT Variable Terminology|HL Disease Phase Timing Table|HL Variable Terminology|OS Disease Phase Timing Table|OS Variable Terminology
C168824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168824>	C150836	CSF PCT Blasts	The percentage of blasts in the cerebrospinal fluid sample.			Laboratory Procedure	
C168826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168826>	C15632	Prephase Chemotherapy Treatment|Prephase|Prephase	A chemotherapy treatment administered prior to the definitive chemotherapy treatment.			Therapeutic or Preventive Procedure	ALL Authorized Value Terminology|ALL Course Timing Table|ALL Histology Table|ALL Off Protocol Therapy/Study Table|ALL Vitals Table|AML Adverse Events Table|AML Authorized Value Terminology|AML Cellular Immunotherapy Table|AML Concomitant Medication Table|AML Course Timing Table|AML Function Test Table|AML Lab Table|AML Minimal Residual Disease Table|AML Molecular Analysis Table|AML Myeloid Sarcoma Involvement Table|AML Off Protocol Therapy/Study Table|AML Radiation Therapy Table|AML Secondary Malignant Neoplasm Table|AML Stem Cell Transplant Table|AML Subject Response Table|AML Survival Characteristics Table|AML Total Dose Table|AML Transfusion Medicine Procedures Table|AML Vitals Table
C168828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168828>	C16358	Reported BMI	Subject's body mass index (in kg/m2), as reported.			Clinical Attribute	
C168829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168829>	C16490	Bone Marrow Blast Analysis Modality	The modality used to determine the bone marrow percent blasts.			Laboratory Procedure	
C16882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16882>	C25464	Mozambique|508|MOZ|MOZ|MOZAMBIQUE|MOZAMBIQUE|MZ	A country in southeastern Africa, bordering the Mozambique Channel, between South Africa and Tanzania.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C168830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168830>	C166165	Mortality related to Stem Cell Treatment	An indication that the mortality of the individual was related to the stem cell treatment.			Quantitative Concept	
C168831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168831>	C190594|C167190	Cranial Radiation Dose Administered	The actual dose of the cranial radiation administered.			Conceptual Entity	
C168832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168832>	C15750	Single Intrathecal Chemotherapy|Single IT Therapy	Any therapy that consists of the administration of a single chemotherapeutic agent intrathecally.			Therapeutic or Preventive Procedure	
C168833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168833>	C15750	Double Intrathecal Chemotherapy|Double Combination IT Chemotherapy|Double IT Chemotherapy	Any therapy that consists of the administration of two chemotherapeutic agents intrathecally.			Therapeutic or Preventive Procedure	
C168834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168834>	C15750	Triple Intrathecal Chemotherapy|Triple Combination IT Chemotherapy|Triple IT Chemotherapy	Any therapy that consists of the administration of three chemotherapeutic agents intrathecally.			Therapeutic or Preventive Procedure	
C168835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168835>	C15750	Variable Intrathecal Chemotherapy|Variable Combination IT Therapy|Variable IT Chemotherapy	Any therapy that consists of the administration of a variable number of chemotherapeutic agents intrathecally.			Therapeutic or Preventive Procedure	
C168836	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168836>	C168807	Chemotherapy Course 1	The first chemotherapy course planned.			Clinical Attribute	
C168837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168837>	C168807	Chemotherapy Course 2	The second chemotherapy course planned.			Clinical Attribute	
C168838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168838>	C168807	Chemotherapy Course 3	The third chemotherapy course planned.			Clinical Attribute	
C168839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168839>	C168807	Chemotherapy Course 4	The fourth chemotherapy course planned.			Clinical Attribute	
C16883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16883>	C16642	Mucin|Mucus Glycoprotein	An albuminoid substance containing mucopolysaccharides and protein which is contained in mucus, and gives to the latter secretion its peculiar ropy character. It is found in all the secretions from mucous glands, and also between the fibres of connective tissue, as in tendons.			Amino Acid, Peptide, or Protein	
C168840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168840>	C168807	Chemotherapy Course 5	The fifth chemotherapy course planned.			Clinical Attribute	
C168841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168841>	C168807	Chemotherapy Course 6	The sixth chemotherapy course planned.			Clinical Attribute	
C168842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168842>	C199143	European Society for Blood and Marrow Transplantation|European Society for Blood and Marrow Transplantation (EBMT)	A non-profit organization established in 1974 to allow scientists and physicians involved in clinical bone marrow transplantations to share experiences and develop co-operative studies.			Professional or Occupational Group	AML Adverse Events Table|AML Authorized Value Terminology
C168843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168843>	C172676|C164338	Age in Days at Enrollment|AGE_AT_ENROLLMENT|AGE_AT_ENROLLMENT|AGE_AT_ENROLLMENT|AGE_AT_ENROLLMENT|AGE_AT_ENROLLMENT|AGE_AT_ENROLLMENT|Age at Enrollment	Age of subject (in days) when the subject enrolled in the study.			Organism Attribute	ALL Subject Characteristics Table|ALL Variable Terminology|AML Subject Characteristics Table|AML Variable Terminology|EWS Subject Characteristics Table|EWS Variable Terminology|GCT Subject Characteristics Table|GCT Variable Terminology|HL Subject Characteristics Table|HL Variable Terminology|OS Subject Characteristics Table|OS Variable Terminology
C168844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168844>	C201612	Age in Days at Last Known Survival Status|AGE_AT_LKSS|AGE_AT_LKSS|AGE_AT_LKSS|AGE_AT_LKSS|AGE_AT_LKSS|AGE_AT_LKSS|Age at Last Known Survival Status	Age of subject (in days) at the last known survival status.			Organism Attribute	ALL Survival Characteristics Table|ALL Variable Terminology|AML Survival Characteristics Table|AML Variable Terminology|EWS Survival Characteristics Table|EWS Variable Terminology|GCT Survival Characteristics Table|GCT Variable Terminology|HL Survival Characteristics Table|HL Variable Terminology|OS Survival Characteristics Table|OS Variable Terminology
C168845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168845>	C201633	Age in Days at Vitals|AGE_AT_VITALS|AGE_AT_VITALS|AGE_AT_VITALS|AGE_AT_VITALS|AGE_AT_VITALS|Age at Vitals	Age of subject (in days) when vital signs were recorded.			Organism Attribute	ALL Variable Terminology|ALL Vitals Table|AML Variable Terminology|AML Vitals Table|EWS Variable Terminology|EWS Vitals Table|GCT Variable Terminology|GCT Vitals Table|HL Variable Terminology|HL Vitals Table
C168846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168846>	C213227|C172676	Age in Days at Blood Analysis	Age of subject (in days) at the time of blood analysis.			Organism Attribute	
C168847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168847>	C201615|C172676	Age in Days at Lumbar Puncture	Age of subject (in days) at the time of lumbar puncture.			Organism Attribute	
C168848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168848>	C201921	Age in Days at Molecular Analysis|AGE_AT_MOLECULAR_ANALYSIS|AGE_AT_MOLECULAR_ANALYSIS|AGE_AT_MOLECULAR_ANALYSIS|AGE_AT_MOLECULAR_ANALYSIS|AGE_AT_MOLECULAR_ANALYSIS|Age at Molecular Analysis|Age in Days at Molecular Test|Age in Days at Molecular Test	Age of subject (in days) when molecular analysis was performed.			Organism Attribute	ALL Molecular Analysis Table|ALL Variable Terminology|AML Molecular Analysis Table|AML Variable Terminology|EWS Molecular Analysis Table|EWS Variable Terminology|GCT Molecular Analysis Table|GCT Variable Terminology|OS Molecular Analysis Table|OS Variable Terminology
C168849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168849>	C168850	Age in Days at Adjuvant Therapy Start	Age of subject (in days) at the start of the adjuvant therapy.			Organism Attribute	
C16884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16884>	C20030	Muscle Protein	A special subset of proteins whose roles are directly related to the function of muscle cells. This group is comprised of both short and long filament polypeptides that are primarily involved in movement and muscle contraction and extension. Muscle proteins are also responsible for the conversion of chemical energy into mechanical energy.			Amino Acid, Peptide, or Protein	
C168850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168850>	C201628|C175008	Age in Days at Start of Treatment Course|AGE_AT_COURSE_START|AGE_AT_COURSE_START|AGE_AT_COURSE_START|AGE_AT_COURSE_START|AGE_AT_COURSE_START|Age at Start of Treatment Course|Age in Days at Treatment Start	Age of subject (in days) at the start of the course of treatment.			Organism Attribute	ALL Course Timing Table|ALL Variable Terminology|AML Course Timing Table|AML Variable Terminology|EWS Course Timing Table|EWS Variable Terminology|HL Course Timing Table|HL Variable Terminology|OS Course Timing Table|OS Variable Terminology
C168851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168851>	C201607	Age in Days at End of Treatment Course|AGE_AT_COURSE_END|AGE_AT_COURSE_END|AGE_AT_COURSE_END|AGE_AT_COURSE_END|AGE_AT_COURSE_END|Age at End of Treatment Course|Age in Days at Treatment End	Age of subject (in days) at the end of the treatment course.			Organism Attribute	ALL Course Timing Table|ALL Variable Terminology|AML Course Timing Table|AML Variable Terminology|EWS Course Timing Table|EWS Variable Terminology|HL Course Timing Table|HL Variable Terminology|OS Course Timing Table|OS Variable Terminology
C168852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168852>	C172676	Age in Days at Course ANC 500|AGE_AT_COURSE_ANC_500|Age at Course ANC 500	Age of subject (in days) when their neutrophil count exceeded a threshold of 500 (ANC/mm3) during the course.			Organism Attribute	AML Course Timing Table|AML Variable Terminology
C168853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168853>	C201629	Age in Days at Stem Cell Transplant|AGE_AT_SCT|AGE_AT_SCT|AGE_AT_SCT|AGE_AT_SCT|AGE_AT_SCT|Age at Stem Cell Transplant	Age of subject (in days) at the time of stem cell transplantation.			Organism Attribute	ALL Stem Cell Transplant Table|ALL Variable Terminology|AML Stem Cell Transplant Table|AML Variable Terminology|EWS Stem Cell Transplant Table|EWS Variable Terminology|GCT Stem Cell Transplant Table|GCT Variable Terminology|HL Stem Cell Transplant Table|HL Variable Terminology
C168854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168854>	C213227|C172676	Age in Days at Bone Marrow Analysis	Age of subject (in days) at the time of bone marrow analysis.			Organism Attribute	
C168855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168855>	C201613	Age in Days at Measurable Residual Disease Assessment|AGE_AT_MRD_ASSESSMENT|AGE_AT_MRD_ASSESSMENT|Age at Measurable Residual Disease Assessment|Age in Days at Minimal Residual Disease Assessment	Age of subject (in days) at assessment of minimal residual disease.			Organism Attribute	ALL Minimal Residual Disease Table|ALL Variable Terminology|AML Minimal Residual Disease Table|AML Variable Terminology
C168856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168856>	C201618	Age in Days at Response Assessment|AGE_AT_RESPONSE|AGE_AT_RESPONSE|AGE_AT_RESPONSE|AGE_AT_RESPONSE|AGE_AT_RESPONSE|Age at Response Assessment	Age of subject (in days) when the response assessment was made.			Organism Attribute	AML Subject Response Table|AML Variable Terminology|EWS Subject Response Table|EWS Variable Terminology|GCT Subject Response Table|GCT Variable Terminology|HL Subject Response Table|HL Variable Terminology|OS Subject Response Table|OS Variable Terminology
C168857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168857>	C168856	Age in Days at Central Nervous System Response Assessment	Age of subject (in days) at the time of the Central Nervous System response assessment.			Organism Attribute	
C168858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168858>	C172676	Age in Days at Myeloid Sarcoma Response	Age of subject (in days) at the time of the myeloid sarcoma response assessment (excluding CNS involvement).			Organism Attribute	
C168859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168859>	C201615|C172676	Age in Days at Echocardiogram	Age of subject (in days) at the time of echocardiogram.			Organism Attribute	
C168860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168860>	C201619	Age in Days at Secondary Malignancy Neoplasm|AGE_AT_SMN|AGE_AT_SMN|AGE_AT_SMN|AGE_AT_SMN|AGE_AT_SMN|AGE_AT_SMN|Age at Secondary Malignancy Neoplasm|Age in Days at Secondary Malignant Neoplasm	Age of subject (in days) at the diagnosis of the secondary malignant neoplasm.			Organism Attribute	ALL Secondary Malignant Neoplasm Table|ALL Variable Terminology|AML Secondary Malignant Neoplasm Table|AML Variable Terminology|EWS Secondary Malignant Neoplasm Table|EWS Variable Terminology|GCT Secondary Malignant Neoplasm Table|GCT Variable Terminology|HL Secondary Malignant Neoplasm Table|HL Variable Terminology|OS Secondary Malignant Neoplasm Table|OS Variable Terminology
C168861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168861>	C25676	GVHD Acuity|Assessed GVHD Severity|GVHD Severity|GVHD Severity|GVHD_ACUITY	The assessed level of seriousness assigned to the graft versus host disease.			Qualitative Concept	AML Adverse Events Table|AML Variable Terminology
C168862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168862>	C25162	SMN ICD-O Morphology Code|SMN_ICD_O_MORPH|SMN_ICD_O_MORPH|SMN_ICD_O_MORPH|SMN_ICD_O_MORPH|SMN_ICD_O_MORPH|SMN_ICD_O_MORPH	ICD-O morphology code of the secondary malignant neoplasm.			Intellectual Product	ALL Secondary Malignant Neoplasm Table|ALL Variable Terminology|AML Secondary Malignant Neoplasm Table|AML Variable Terminology|EWS Secondary Malignant Neoplasm Table|EWS Variable Terminology|GCT Secondary Malignant Neoplasm Table|GCT Variable Terminology|HL Secondary Malignant Neoplasm Table|HL Variable Terminology|OS Secondary Malignant Neoplasm Table|OS Variable Terminology
C168863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168863>	C25162	SMN ICD-O Topography Code|SMN_ICD_O_TOP|SMN_ICD_O_TOP|SMN_ICD_O_TOP|SMN_ICD_O_TOP|SMN_ICD_O_TOP|SMN_ICD_O_TOP	ICD-O topography code of the secondary malignant neoplasm.			Intellectual Product	ALL Secondary Malignant Neoplasm Table|ALL Variable Terminology|AML Secondary Malignant Neoplasm Table|AML Variable Terminology|EWS Secondary Malignant Neoplasm Table|EWS Variable Terminology|GCT Secondary Malignant Neoplasm Table|GCT Variable Terminology|HL Secondary Malignant Neoplasm Table|HL Variable Terminology|OS Secondary Malignant Neoplasm Table|OS Variable Terminology
C168864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168864>	C98747	Type of Stem Cell Transplant|SCT_TYPE|SCT_TYPE|SCT_TYPE|SCT_TYPE	Type of stem-cell transplantation the subject received.			Functional Concept	ALL Stem Cell Transplant Table|ALL Variable Terminology|AML Stem Cell Transplant Table|AML Variable Terminology|EWS Stem Cell Transplant Table|EWS Variable Terminology|HL Stem Cell Transplant Table|HL Variable Terminology
C168865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168865>	C173293	Number of Intended Intrathecal Chemotherapy Doses	Number of doses of intrathecal chemotherapy the subject was designated to receive in that round, based on intention-to-treat.			Quantitative Concept	
C168867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168867>	C25466	CNS Involvement Criteria	The criteria that were used to determine that the subject had central nervous system involvement.			Idea or Concept	
C168868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168868>	C25480	Cause of Death Detail|CAUSE_OF_DEATH_DETAIL|CAUSE_OF_DEATH_DETAIL|CAUSE_OF_DEATH_DETAIL	Specific details of the cause of death.			Idea or Concept	ALL Survival Characteristics Table|ALL Variable Terminology|AML Survival Characteristics Table|AML Variable Terminology|HL Survival Characteristics Table|HL Variable Terminology
C168869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168869>	C198679	Stem Cell Transplant Donor Relationship|SCT_DONOR_RELATIONSHIP|SCT_DONOR_RELATIONSHIP|SCT_DONOR_RELATIONSHIP	The biological relationship between the stem cell donor and the recipients.			Conceptual Entity	ALL Stem Cell Transplant Table|ALL Variable Terminology|AML Stem Cell Transplant Table|AML Variable Terminology|HL Stem Cell Transplant Table|HL Variable Terminology
C16886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16886>	C18431	Oncogene MYB|Avian Myeloblastosis Viral (v-MYB) Oncogene Homolog|MYB|Oncogene AMV|v-MYB Avian Myeloblastosis Viral Oncogene Homolog	Human Oncogene MYB is a mutated variant of MYB Gene, which encodes 6 alternative isoforms of 640 aa 72-kDa nuclear c-MYB protein, a DNA-binding transcriptional activator critical for hematopoietic progenitor cell proliferation and differentiation. MYB contains 3 N-terminal MYB-like DNA-binding domains that specifically recognize YAAC[GT]G, a central transcriptional activation domain and a C-terminal transcriptional repression domain. MYB may interact with HIPK2 and NLK; phosphorylation by NLK on multiple sites may induce proteasomal degradation. Ubiquitination may be mediated by SIAH1. Oncogene MYB disrupts normal cell function.			Gene or Genome	
C168870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168870>	C25683	Stem Cell Transplant Source|SCT_SOURCE|SCT_SOURCE|SCT_SOURCE|SCT_SOURCE	The source of the stem cells for the stem cell transplant.			Qualitative Concept	ALL Stem Cell Transplant Table|ALL Variable Terminology|AML Stem Cell Transplant Table|AML Variable Terminology|EWS Stem Cell Transplant Table|EWS Variable Terminology|HL Stem Cell Transplant Table|HL Variable Terminology
C168871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168871>	C103223	Karyotype Status|KARYOTYPE_STATUS|KARYOTYPE_STATUS|Karyotype Finding	The status of the subject's karyotype.			Laboratory or Test Result	ALL Molecular Analysis Table|ALL Variable Terminology|GCT Molecular Analysis Table|GCT Variable Terminology
C168872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168872>	C20993	Adverse Event Grading System|AE_SYSTEM|AE_SYSTEM|AE_SYSTEM|AE_SYSTEM|AE_SYSTEM	The name of the system used to grade the adverse events.			Classification	ALL Adverse Events Table|ALL Variable Terminology|AML Adverse Events Table|AML Variable Terminology|EWS Adverse Events Table|EWS Variable Terminology|HL Adverse Events Table|HL Variable Terminology|OS Adverse Event Table|OS Variable Terminology
C168874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168874>	C2861	Immunotherapy-Related	An observation that a situation is related to immunotherapy received.			Finding	ALL Authorized Value Terminology|ALL Survival Characteristics Table
C168875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168875>	C2950	Abnormal Karyotype	Any abnormality in the number, length, centromere position, banding pattern or differences between the chromosomes that is not representative of a normal set of chromosomes.			Cell or Molecular Dysfunction	ALL Authorized Value Terminology|ALL Molecular Analysis Table|GCT Authorized Value Terminology|GCT Molecular Analysis Table
C168876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168876>	C2959	Pre-treatment Disease Complication|Pre-Treatment Disease Complications|Pre-Treatment Disease Complications	A complication of the disease that existed prior to treatment.			Finding	AML Authorized Value Terminology|AML Survival Characteristics Table|HL Authorized Value Terminology|HL Survival Characteristics Table
C168877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168877>	C2959	Post-treatment Disease Complication|Post-treatment disease complications	A complication of the disease that occurred after treatment.			Finding	AML Authorized Value Terminology|AML Survival Characteristics Table
C168878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168878>	C35461	Disease Phase|DISEASE_PHASE|DISEASE_PHASE|DISEASE_PHASE|DISEASE_PHASE|DISEASE_PHASE|DISEASE_PHASE	The stage or period of an individual's disease.			Finding	ALL Disease Characteristics Table|ALL Disease Phase Timing Table|ALL Histology Table|ALL Off Protocol Therapy/Study Table|ALL Variable Terminology|ALL Vitals Table|AML Adverse Events Table|AML Cellular Immunotherapy Table|AML Concomitant Medication Table|AML Disease Characteristics Table|AML Disease Phase Timing Table|AML Function Test Table|AML Lab Table|AML Minimal Residual Disease Table|AML Molecular Analysis Table|AML Myeloid Sarcoma Involvement Table|AML Off Protocol Therapy/Study Table|AML Radiation Therapy Table|AML Secondary Malignant Neoplasm Table|AML Stem Cell Transplant Table|AML Subject Response Table|AML Survival Characteristics Table|AML Total Dose Table|AML Transfusion Medicine Procedures Table|AML Variable Terminology|AML Vitals Table|EWS Adverse Events Table|EWS Biopsy/Surgical Procedures Table|EWS Disease Characteristics Table|EWS Disease Phase Timing Table|EWS Histology Table|EWS Immunohistochemistry Table|EWS Lab Table|EWS Molecular Analysis Table|EWS Non-Protocol Therapy Table|EWS Off Protocol Therapy/Study Table|EWS Radiation Therapy Table|EWS Secondary Malignant Neoplasm Table|EWS Stem Cell Transplant Table|EWS Subject Response Table|EWS Survival Characteristics Table|EWS Tumor Assessment Table|EWS Variable Terminology|EWS Vitals Table|GCT Adverse Events Table|GCT Biopsy/Surgical Procedures Table|GCT Concomitant Medication Table|GCT Cytology Table|GCT Disease Characteristics Table|GCT Disease Phase Timing Table|GCT Growing Teratoma Syndrome Table|GCT Histology Table|GCT Immunohistochemistry Table|GCT Lab Table|GCT Molecular Analysis Table|GCT Radiation Therapy Table|GCT Secondary Malignant Neoplasm Table|GCT Staging Table|GCT Stem Cell Transplant Table|GCT Subject Response Table|GCT Survival Characteristics Table|GCT Total Dose Table|GCT Tumor Assessment Table|GCT Variable Terminology|GCT Vitals Table|HL Adverse Events Table|HL Biopsy/Surgical Procedures Table|HL Concomitant Medication Table|HL Disease Characteristics Table|HL Disease Phase Timing Table|HL Function Test Table|HL Histology Table|HL Imaging Table|HL Immunohistochemistry Table|HL Lab Table|HL Lesion Characteristics Table|HL Off Protocol Therapy/Study Table|HL Protocol Treatment Modifications Table|HL Radiation Therapy Table|HL Secondary Malignant Neoplasm Table|HL Staging Table|HL Stem Cell Transplant Table|HL Subject Response Table|HL Survival Characteristics Table|HL Total Dose Table|HL Transfusion Medicine Procedures Table|HL Variable Terminology|HL Vitals Table|OS Adverse Event Table|OS Biopsy/Surgical Procedures Table|OS Disease Phase Timing Table|OS Function Test Table|OS Histology Table|OS Lab Table|OS Molecular Analysis Table|OS Off Protocol Therapy/Study Table|OS Radiation Therapy Table|OS Secondary Malignant Neoplasm Table|OS Subject Response Table|OS Survival Characteristics Table|OS Total Dose Table|OS Tumor Assessment Table|OS Variable Terminology|OS Vitals Table
C168879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168879>	C35682	Traumatic Tap|TRAUMATIC_TAP|TRAUMATIC_TAP	Contamination of a cerebrospinal fluid sample by red blood cells greater than 10/mm3.			Laboratory or Test Result	ALL Lab Table|ALL Variable Terminology|AML Lab Table|AML Variable Terminology
C16887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16887>	C18537	MYC Gene|MYC|MYC|MYC|v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog Gene	This gene plays a role in cell cycle progression and apoptosis. Cytogenetic aberrations in the gene are involved in cellular transformation and are associated with a variety of hematopoietic tumors, leukemias and lymphomas.	MYC Gene		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Reference Gene Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology|Pediatric Oncology Target Genes/Proteins Terminology
C168880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168880>	C42076	CSF Leukocytes Present	An indication that leukocytes were found in a cerebrospinal fluid sample.			Finding	
C168881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168881>	C42076	CSF Blasts Present	An indication that blasts were found in the cerebrospinal fluid sample.			Finding	
C168882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168882>	C42076	CSF RBCs Present	An indication that erythrocytes were found in the cerebrospinal fluid sample.			Finding	
C168883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168883>	C36291	GVHD Organ|GVHD_ORGAN	The organs involved in the graft vs host disease.			Finding	AML Adverse Events Table|AML Variable Terminology
C168884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168884>	C36292	CSF Results	The results of cerebrospinal fluid laboratory tests.			Laboratory or Test Result	AML Authorized Value Terminology|AML Disease Characteristics Table
C168885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168885>	C173263	Site of Relapse	The physical site of the relapse of a disease.			Body Location or Region	
C168886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168886>	C45305	Stem Cell Mixture	A mixture of different sources of stem cells.			Substance	AML Authorized Value Terminology|AML Stem Cell Transplant Table|HL Authorized Value Terminology|HL Stem Cell Transplant Table
C168887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168887>	C48168	Italian Association of Pediatric Hematology and Oncology|AIEOP|AIEOP|AIEOP|Associazione Italiana Ematologia Oncologia Pediatrica	A group from Bologna, Italy, comprised mainly of pediatricians, hematologists, oncologists, surgeons, biologists, nurses and psychologists who are devoted to addressing the problems of hematology, oncology and immunology in the child and adolescent.			Health Care Related Organization	AML Authorized Value Terminology|AML Subject Characteristics Table|GCT Authorized Value Terminology|GCT Subject Characteristics Table
C168888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168888>	C48168	Berlin-Frankfurt-Munster Study Group|BFM-SG|BFM-SG|Berlin-Frankfurt-Münster Study Group	A study group formed in 1975 by three individuals, Hansjorg Riehm in Berlin (B), Bernhard Kornhuber in Frankfurt (F) and Gunther Schellong in Munster (M), who initiated the first multicenter BFM trial. The BFM treatment concept was based on an intensive chemotherapeutic approach employing eight different drugs which led to a revolutionary increase in the survival of children and adolescents with acute lymphoblastic leukemia.			Health Care Related Organization	AML Authorized Value Terminology|AML Subject Characteristics Table
C168889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168889>	C48168	Dutch Childhood Oncology Group|DCOG|DCOG	A collaborating partner in Innovative Therapies for Children with Cancer Consortium (ITCC), a European based consortium to promote the clinical evaluation of new anti-cancer compounds in children with cancer.			Health Care Related Organization	AML Authorized Value Terminology|AML Subject Characteristics Table
C16888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16888>	C60727	Myelogram|myelogram		Myelogram		Laboratory or Test Result	CTRP Intervention Terminology|CTRP Terminology
C168890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168890>	C48168	Japan Association of Childhood Leukemia Study|JACLS|JACLS	A study group in Japan investigating childhood leukemia.			Health Care Related Organization	AML Authorized Value Terminology|AML Subject Characteristics Table
C168891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168891>	C48168	Japanese Pediatric Leukemia/Lymphoma Study Group|JPLSG|JPLSG	A study group in Japan investigating pediatric leukemia and lymphoma.			Health Care Related Organization	AML Authorized Value Terminology|AML Subject Characteristics Table
C168892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168892>	C48168	Medical Research Council|MRC|MRC|MRC|MRC	A publicly funded organization that is part of United Kingdom Research and Innovation, and is dedicated to improving human health through world-class medical research.			Health Care Related Organization	AML Authorized Value Terminology|AML Subject Characteristics Table|GCT Authorized Value Terminology|GCT Subject Characteristics Table|OS Authorized Value Terminology|OS Subject Characteristics Table
C168893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168893>	C48168	Nordic Society of Pediatric Haematology and Oncology|NOPHO|NOPHO	A collaborative group formed in 1984 with members from Denmark, Finland, Iceland, Lithuania, Norway and Sweden and whose goal was to secure that all Nordic children suffering from leukemia would receive optimal therapy wherever they lived.			Health Care Related Organization	AML Authorized Value Terminology|AML Subject Characteristics Table
C168894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168894>	C48168	Polish Pediatric Leukemia/Lymphoma Study Group|PPLLSG|PPLLSG	A collaborative group established in 1974 that had the original goal of implementing unified protocols with standardized diagnostic criteria and therapy regimens for Hodgkin's disease and acute lymphoblastic leukemia. The prospects were widened to include non-Hodgkin's lymphomas and acute myelogenous leukemia in 1983.			Health Care Related Organization	AML Authorized Value Terminology|AML Subject Characteristics Table
C168895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168895>	C48181	Measurable Residual Disease Molecular Marker|MRD Marker|MRD Molecular Marker|MRD Signature|MRD_MOLECULAR_MARKERS|Minimal Residual Disease Molecular Marker|Minimal Residual Disease Signature	A one or more molecular characteristics that are used as a biomarker for minimal residual disease.			Functional Concept	AML Minimal Residual Disease Table|AML Variable Terminology
C168896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168896>	C48693	Study Characteristics Table	A table of data specifically regarding study characteristics.			Intellectual Product	
C168897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168897>	C48693	Demographics Table	A table of data specifically regarding demographics.			Intellectual Product	
C168898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168898>	C48693	Survival Characteristics Table	A table of data specifically regarding survival characteristics.			Intellectual Product	
C168899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168899>	C48693	Disease Characteristics Table	A table of data specifically regarding disease characteristics.			Intellectual Product	
C16889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16889>	C17061	Oncogene N-RAS|NRAS|NRAS1|Neuroblastoma RAS Viral Oncogene Homolog	Human Oncogene N-RAS is a mutated variant of NRAS Gene (RAS Family), which encodes p21 N-Ras Protein, a monomeric GTPase involved in transmembrane signal transduction that alternates between inactive GDP-bound and active GTP-bound forms. RAS is activated by a guanine nucleotide-exchange factor and inactivated by a GTPase-activating protein. Mitogen-stimulated RAS stabilizes MYC protein and enhances MYC accumulation by the RAS/RAF/MAPK pathway, which appears to inhibit the proteasome-dependent degradation of MYC. Implicated in a variety of human tumors, specific amino acid mutations activate c-RAS and transform cells. Oncogene NRAS disrupts normal cell function.	Oncogene N-RAS		Gene or Genome	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C1688	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1688>	C1757	Tyrphostin AG 825|AG 825	A member of the tyrphostin family of tyrosine kinase inhibitors, which selectively inhibits HER2. (NCI)			Amino Acid, Peptide, or Protein|Pharmacologic Substance	
C168900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168900>	C48693	Extramedullary Myeloid Sarcoma Involvement Table	A table of data specifically regarding extramedullary myeloid sarcoma involvement.			Intellectual Product	
C168901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168901>	C48693	CNS Involvement Table	A table of data specifically regarding central nervous system involvement.			Intellectual Product	
C168902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168902>	C48693	Vitals Table	A table of data specifically regarding vitals.			Intellectual Product	
C168903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168903>	C48693	Blood Analysis Table	A table of data specifically regarding blood analysis.			Intellectual Product	
C168904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168904>	C48693	CSF Analysis Table	A table of data specifically regarding cerebrospinal fluid analysis.			Intellectual Product	
C168905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168905>	C48693	Molecular Analysis Table	A table of data specifically regarding molecular analysis.			Intellectual Product	
C168906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168906>	C48693	Adjuvant Therapy Table	A table of data specifically regarding adjuvant therapy.			Intellectual Product	
C168907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168907>	C48693	Systemic Chemotherapy Table	A table of data specifically regarding systemic chemotherapy.			Intellectual Product	
C168908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168908>	C48693	Total Dose Table	A table of data specifically regarding total dose.			Intellectual Product	
C168909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168909>	C48693	Stem-cell Transplant Table	A table of data specifically regarding stem-cell transplant.			Intellectual Product	
C16890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16890>	C16946	NADPH-Cytochrome P450 Reductase|CPR|Cytochrome P450 Reductase|EC 1.6.2.4|NADPH--Cytochrome P450 Reductase|NADPH-Specific Cytochrome C Reductase|P450R|POR	NADPH-cytochrome P450 reductase (677 aa, ~77 kDa) is encoded by the human POR gene. This protein plays a role in electron transfer.			Amino Acid, Peptide, or Protein|Enzyme	
C168910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168910>	C48693	Bone Marrow Analysis Table	A table of data specifically regarding bone marrow analysis.			Intellectual Product	
C168911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168911>	C48693	Measurable Residual Disease Table|Minimal Residual Disease Table	A table of data specifically regarding minimal residual disease.			Intellectual Product	
C168912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168912>	C48693	Response Table	A table of data specifically regarding response.			Intellectual Product	
C168913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168913>	C48693	CNS Response Table	A table of data specifically regarding central nervous system response.			Intellectual Product	
C168914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168914>	C48693	Extramedullary Response Table	A table of data specifically regarding extramedullary response.			Intellectual Product	
C168915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168915>	C48693	Echocardiogram Table	A table of data specifically regarding echocardiogram.			Intellectual Product	
C168916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168916>	C48693	Adverse Events Table	A table of data specifically regarding adverse events.			Intellectual Product	
C168917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168917>	C48693	Secondary Malignancy Table	A table of data specifically regarding secondary malignancy.			Intellectual Product	
C168918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168918>	C25337	Number of Cells in Metaphase during Karyotyping|NUM_METAPHASES	The number of cells in metaphase during karyotype analysis.			Quantitative Concept	AML Molecular Analysis Table|AML Variable Terminology|GDC Terminology|GDC Value Terminology
C168919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168919>	C49236	Sinusoidal Obstruction Syndrome Treatment	Treatment for sinusoidal obstruction syndrome.			Therapeutic or Preventive Procedure	
C16891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16891>	C25464	Namibia|516|NA|NAM|NAM|NAMIBIA|NAMIBIA	A country in southwestern Africa, bordering the South Atlantic Ocean, between Angola and South Africa.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C168920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168920>	C51946	CSF RBC Count	The number of erythrocytes in the cerebrospinal fluid sample.			Laboratory Procedure	
C168921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168921>	C51948	CSF Leukocyte Count	The number of leukocytes in the cerebrospinal fluid sample.			Laboratory Procedure	
C168922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168922>	C49286	CSF Leukocytes Technique	The technique used to examine leukocytes in the cerebrospinal fluid sample.			Diagnostic Procedure	
C168923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168923>	C169009	HLA-A Match Finding|HLA-A Match Status|HLA_A_RESULT	The extent of HLA-A matching between the donor and the recipient.			Laboratory or Test Result	AML Stem Cell Transplant Table|AML Variable Terminology
C168924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168924>	C169009	HLA-B Match Finding|HLA-B Match Status|HLA_B_RESULT	The extent of HLA-B matching between the donor and the recipient.			Laboratory or Test Result	AML Stem Cell Transplant Table|AML Variable Terminology
C168925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168925>	C169009	HLA-C Match Finding|HLA-C Match Status|HLA_C_RESULT	The extent of HLA-C matching between the donor and the recipient.			Laboratory or Test Result	AML Stem Cell Transplant Table|AML Variable Terminology
C168926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168926>	C169009	HLA-DRB1 Match Finding|HLA-DRB1 Match Status|HLA_DRB1_RESULT	The extent of HLA-DRB1 matching between the donor and the recipient.			Laboratory or Test Result	AML Stem Cell Transplant Table|AML Variable Terminology
C168927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168927>	C169009	HLA-DQ Match Finding|HLA-DQ Match Status|HLA_DQ_RESULT	The extent of HLA-DQ matching between the donor and the recipient.			Laboratory or Test Result	AML Stem Cell Transplant Table|AML Variable Terminology
C168928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168928>	C70732	Subject Enrollment Status|ENROLLED_STATUS|ENROLLED_STATUS|Enrollment Status|Subject Registration Status	The current status of the subject's enrollment.			Functional Concept	ALL Subject Characteristics Table|ALL Variable Terminology|AML Subject Characteristics Table|AML Variable Terminology
C168929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168929>	C168928	Study Subject Not Enrolled|Not Enrolled|Not Enrolled|Subject Not Registered	The study subject is/was not enrolled.			Functional Concept	ALL Authorized Value Terminology|ALL Subject Characteristics Table|AML Authorized Value Terminology|AML Subject Characteristics Table
C16892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16892>	C199144	National Academy of Science|NAS	A private, non-profit society of distinguished scholars established by an Act of Congress in 1863 and charged with providing independent, objective advice to the nation on matters related to science and technology.			Organization	
C168930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168930>	C19743|C171082	Trisomy 21 Status	The trisomy 21 status of the individual.			Functional Concept	
C168931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168931>	C70703	Last Known Survival Status|LKSS|LKSS|LKSS|LKSS|LKSS|LKSS	The individual's last known survival status.			Functional Concept	ALL Survival Characteristics Table|ALL Variable Terminology|AML Survival Characteristics Table|AML Variable Terminology|EWS Survival Characteristics Table|EWS Variable Terminology|GCT Survival Characteristics Table|GCT Variable Terminology|HL Survival Characteristics Table|HL Variable Terminology|OS Survival Characteristics Table|OS Variable Terminology
C168932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168932>	C48904	Cause of Death Ranking|CAUSE_OF_DEATH_RANKING|CAUSE_OF_DEATH_RANKING|CAUSE_OF_DEATH_RANKING|CAUSE_OF_DEATH_RANKING|CAUSE_OF_DEATH_RANKING	Assigning a weighted relevance to the cause of death.			Quantitative Concept	ALL Survival Characteristics Table|ALL Variable Terminology|AML Survival Characteristics Table|AML Variable Terminology|EWS Survival Characteristics Table|EWS Variable Terminology|HL Survival Characteristics Table|HL Variable Terminology|OS Survival Characteristics Table|OS Variable Terminology
C168933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168933>	C71460	Measurable Residual Disease Method|MRD_METHOD|MRD_METHOD|Minimal Residual Disease Method	Modality used to determine minimal residual disease.			Conceptual Entity	ALL Minimal Residual Disease Table|ALL Variable Terminology|AML Minimal Residual Disease Table|AML Variable Terminology
C168934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168934>	C82556	Subject/Guardian Refused Further Treatment	The subject or their guardian has refused further treatment.			Idea or Concept	ALL Authorized Value Terminology|ALL Off Protocol Therapy/Study Table|AML Authorized Value Terminology|AML Off Protocol Therapy/Study Table|EWS Authorized Value Terminology|EWS Off Protocol Therapy/Study Table|HL Authorized Value Terminology|HL Off Protocol Therapy/Study Table|OS Authorized Value Terminology|OS Off Protocol Therapy/Study Table
C168935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168935>	C82556	End of Planned Treatment|Completion of Planned Therapy|Completion of Planned Therapy|Completion of Planned Therapy|Completion of Planned Therapy|Completion of Planned Therapy	The end of the planned treatment.			Idea or Concept	ALL Authorized Value Terminology|ALL Off Protocol Therapy/Study Table|AML Authorized Value Terminology|AML Off Protocol Therapy/Study Table|EWS Authorized Value Terminology|EWS Off Protocol Therapy/Study Table|HL Authorized Value Terminology|HL Off Protocol Therapy/Study Table|HL Patient Reported Outcomes Metadata Table|OS Authorized Value Terminology|OS Off Protocol Therapy/Study Table
C168936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168936>	C173192	AAML03P1 AML Study Identifier|AAML03P1|AAML03P1 Acute Myeloid Leukemia Study Identifier	The identifier AAML03P1, assigned to a study in an AML clinical trial.			Intellectual Product	AML Authorized Value Terminology|AML Subject Characteristics Table
C168937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168937>	C173192	AAML0531 AML Study Identifier|AAML0531|AAML0531 Acute Myeloid Leukemia Study Identifier	The identifier AAML0531, assigned to an AML study in a clinical trial.			Intellectual Product	AML Authorized Value Terminology|AML Subject Characteristics Table
C168938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168938>	C173192	AAML1031 AML Study Identifier|AAML1031|AAML1031 Acute Myeloid Leukemia Study Identifier	The identifier AAML1031, assigned to a study in an AML clinical trial.			Intellectual Product	AML Authorized Value Terminology|AML Subject Characteristics Table
C168939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168939>	C173192	AMLBFM2004 AML Study Identifier|AMLBFM2004|AMLBFM2004 Acute Myeloid Leukemia Study Identifier	The identifier AMLBFM2004, assigned to a study in an AML clinical trial.			Intellectual Product	AML Authorized Value Terminology|AML Subject Characteristics Table
C16893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16893>	C199143	National Center for Health Statistics|NCHS	A part of the Centers for Disease Control and Prevention, the NCHS is the primary Federal organization responsible for the collection, analyses, and dissemination of health statistics.			Health Care Related Organization	
C168940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168940>	C173192	SJCRHAML02 AML Study Identifier|SJCRHAML02|SJCRHAML02 Acute Myeloid Leukemia Study Identifier	The identifier SJCRHAML02, assigned to a study in an AML clinical trial.			Intellectual Product	AML Authorized Value Terminology|AML Subject Characteristics Table
C168941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168941>	C173192	JPLSGAML05 AML Study Identifier|JPLSGAML05|JPLSGAML05 Acute Myeloid Leukemia Study Identifier	The identifier JPLSGAML05, assigned to a study in an AML clinical trial.			Intellectual Product	AML Authorized Value Terminology|AML Subject Characteristics Table
C168942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168942>	C173192	AEIOPLAM2002 AML Study Identifier|AEIOPLAM2002|AEIOPLAM2002 Acute Myeloid Leukemia Study Identifier	The identifier AEIOPLAM2002, assigned to a study in an AML clinical trial.			Intellectual Product	AML Authorized Value Terminology|AML Subject Characteristics Table
C168943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168943>	C173192	JACLSAML99 AML Study Identifier|JACLSAML99|JACLSAML99 Acute Myeloid Leukemia Study Identifier	The identifier JACLSAML99, assigned to a study in an AML clinical trial.			Intellectual Product	AML Authorized Value Terminology|AML Subject Characteristics Table
C168944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168944>	C173192	DBAML01 AML Study Identifier|DBAML01|DBAML01 Acute Myeloid Leukemia Study Identifier	The identifier DBAML01, assigned to a study in an AML clinical trial.			Intellectual Product	AML Authorized Value Terminology|AML Subject Characteristics Table
C168945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168945>	C173192	MRCAML12 AML Study Identifier|MRCAML12|MRCAML12Acute Myeloid Leukemia Study Identifier	The identifier MRCAML12, assigned to a study in an AML clinical trial.			Intellectual Product	AML Authorized Value Terminology|AML Subject Characteristics Table
C168946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168946>	C173192	NOPHOAML2004 AML Study Identifier|NOPHOAML2004|NOPHOAML2004 Acute Myeloid Leukemia Study Identifier	The identifier NOPHOAML2004, assigned to a study in an AML clinical trial.			Intellectual Product	AML Authorized Value Terminology|AML Subject Characteristics Table
C168947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168947>	C173192	PPLLSGAML98 AML Study Identifier|PPLLSGAML98|PPLLSGAML98 Acute Myeloid Leukemia Study Identifier	The identifier PPLLSGAML98, assigned to a study in an AML clinical trial.			Intellectual Product	AML Authorized Value Terminology|AML Subject Characteristics Table
C168948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168948>	C53255	Adverse Event Contributory to Cause of Death|Contributory Cause of Death|Death, Contributory|Death, Contributory|Death, Contributory|Death, Contributory|Death, Contributory|Death, contributory	Any adverse event contributing to the cause of death.			Intellectual Product	ALL Authorized Value Terminology|ALL Survival Characteristics Table|AML Adverse Events Table|AML Authorized Value Terminology|AML Survival Characteristics Table|EWS Authorized Value Terminology|EWS Survival Characteristics Table|GCT Adverse Events Table|GCT Authorized Value Terminology|HL Adverse Events Table|HL Authorized Value Terminology|HL Survival Characteristics Table|OS Authorized Value Terminology|OS Survival Characteristics Table
C168949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168949>	C83083	Honest Broker Subject ID|HONEST_BROKER_SUBJECT_ID|HONEST_BROKER_SUBJECT_ID|HONEST_BROKER_SUBJECT_ID|HONEST_BROKER_SUBJECT_ID|HONEST_BROKER_SUBJECT_ID|HONEST_BROKER_SUBJECT_ID	Subject identifier assigned by the honest broker.			Intellectual Product	ALL Subject Characteristics Table|ALL Variable Terminology|AML Subject Characteristics Table|AML Variable Terminology|EWS Subject Characteristics Table|EWS Variable Terminology|GCT Subject Characteristics Table|GCT Variable Terminology|HL Subject Characteristics Table|HL Variable Terminology|OS Subject Characteristics Table|OS Variable Terminology
C16894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16894>	C20172	National Institute of Mental Health|NIMH	An institute within the National Institutes of Health with the mission to transform the understanding and treatment of mental illnesses through basic and clinical research, paving the way for prevention, recovery and cure.			Health Care Related Organization	
C168950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168950>	C25364	Data Contributor ID|DATA_CONTRIBUTOR_ID|DATA_CONTRIBUTOR_ID|DATA_CONTRIBUTOR_ID|DATA_CONTRIBUTOR_ID|DATA_CONTRIBUTOR_ID|DATA_CONTRIBUTOR_ID|Data Contributor Identifier	An identifier assigned to a data contributor.			Intellectual Product	ALL Subject Characteristics Table|ALL Variable Terminology|AML Subject Characteristics Table|AML Variable Terminology|EWS Subject Characteristics Table|EWS Variable Terminology|GCT Subject Characteristics Table|GCT Variable Terminology|HL Subject Characteristics Table|HL Variable Terminology|OS Subject Characteristics Table|OS Variable Terminology
C168951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168951>	C91102	Measurable Residual Disease Value Question|MRD_RESULT_NUMERIC|MRD_RESULT_NUMERIC|Measurable Residual Disease Value|Minimal Residual Disease Value	Minimal residual disease value expressed as a percent, fraction or ratio.			Intellectual Product	ALL Minimal Residual Disease Table|ALL Variable Terminology|AML Minimal Residual Disease Table|AML Variable Terminology
C168952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168952>	C50995	CNS Response	The response of the central nervous system to treatment.			Finding	AML Authorized Value Terminology|AML Subject Response Table
C168953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168953>	C173812	Dexrazoxane Administered Question|Dexrazoxane Administered	Dexrazoxane was administered.			Intellectual Product	
C168954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168954>	C173812	Cardiac Interventions Administered Question|Cardiac Interventions Administered	Cardiac interventions administered.			Intellectual Product	
C168955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168955>	C25180	Pathogen Confirmation Indicator|AE_PATHOGEN_CONFIRMATION|AE_PATHOGEN_CONFIRMATION	An indication that the reported pathogen was confirmed or suspected as the cause of an infection.			Intellectual Product	AML Adverse Events Table|AML Variable Terminology|HL Adverse Events Table|HL Variable Terminology
C168956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168956>	C16585	Flow Cytometry Different from Normal|Different-from-Normal	The use of flow cytometry to detect whether material or cells in a sample or specimen is sorted differently than a normal control analyte.			Laboratory Procedure	AML Authorized Value Terminology|AML Minimal Residual Disease Table
C168957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168957>	C16081	Measurable Residual Disease Sensitivity|MRD_SENSITIVITY|MRD_SENSITIVITY|Minimal Residual Disease Sensitivity	Sensitivity of modality used to determine minimal residual disease.			Intellectual Product	ALL Minimal Residual Disease Table|ALL Variable Terminology|AML Minimal Residual Disease Table|AML Variable Terminology
C168958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168958>	C25683	Measurable Residual Disease Sample Source|MRD_SAMPLE_SOURCE|MRD_SAMPLE_SOURCE|Minimal Residual Disease Sample Source	Source of sample used for minimal residual disease assessment.			Intellectual Product	ALL Minimal Residual Disease Table|ALL Variable Terminology|AML Minimal Residual Disease Table|AML Variable Terminology
C168959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168959>	C173307	BM PCT Blasts At Response|BM_PCT_BLASTS_AT_RESPONSE	The percent of cells that were blasts in the subject's bone marrow used to make the response assessment.			Finding	AML Subject Response Table|AML Variable Terminology
C16895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16895>	C20168	National Institutes of Health|NIH|NIH				Health Care Related Organization	
C168960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168960>	C117039	BM Analysis Modality at Response|BM_ANALYSIS_METHOD_AT_RESPONSE	The modality used to determine the bone marrow percent blasts.			Conceptual Entity	AML Subject Response Table|AML Variable Terminology
C168961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168961>	C63321	ANC at Response|ANC_AT_RESPONSE	The absolute neutrophil count used to make the response assessment.			Quantitative Concept	AML Subject Response Table|AML Variable Terminology
C168962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168962>	C63321	ANC Threshold at Response|ANC_THRESHOLD_AT_RESPONSE	Subject exceeded an absolute neutrophil count threshold of >= 500 (ANC/mm3) at the time of the response assessment.			Quantitative Concept	AML Subject Response Table|AML Variable Terminology
C168963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168963>	C91102	Platelet Count At Response Question|PLATELET_COUNT_AT_RESPONSE|Platelet Count At Response	The platelet count used to make the response assessment.			Intellectual Product	AML Subject Response Table|AML Variable Terminology
C168964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168964>	C202442	Platelet Threshold At Response|PLATELET_THRESHOLD_AT_RESPONSE|Platelet Threshold Exceeded At Response	Subject exceeded a platelet count threshold of >=50,000 (platelets/mm3) at the time of the response assessment.			Finding	AML Subject Response Table|AML Variable Terminology
C168965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168965>	C50995	Myeloid Sarcoma Response	The response of the myeloid sarcoma to the treatment.			Finding	AML Authorized Value Terminology|AML Subject Response Table
C168966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168966>	C1708	Inotropic Support|Inotrope|Inotropic Agent	An agent used to modify the strength of the contraction of the heart muscle.			Chemical Viewed Functionally	AML Adverse Events Table|AML Authorized Value Terminology
C168967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168967>	C97567	Bone Marrow Blast to Total Cell Ratio Measurement|Bone Marrow Blasts to Total Cells Ratio Measurement	Percent of cells that were blasts in subject's bone marrow.			Classification	
C168968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168968>	C116094	FDG-Avid Tumor|FDG Avid|FDG-AVID|FDG-PET Avid|Fluorine 18 Fluorodeoxyglucose-Avid Tumor	A radiologic finding indicating high uptake of FDG by a solid tumor during positron emission tomography (PET).			Finding	
C16896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16896>	C25464	Nauru|520|NAURU|NAURU|NR|NRU|NRU	A country in Oceania, occupying an island in the South Pacific Ocean, south of the Marshall Islands.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C168970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168970>	C28554	Death due to Disease Progression|Disease Progression|Disease Progression|Disease Progression|Disease Progression|Disease Progression|Terminal Disease Progression	An indication that the subject has died due to the progression of their disease.			Finding	ALL Authorized Value Terminology|ALL Survival Characteristics Table|AML Authorized Value Terminology|AML Survival Characteristics Table|GCT Authorized Value Terminology|GCT Survival Characteristics Table|HL Authorized Value Terminology|HL Survival Characteristics Table|OS Authorized Value Terminology|OS Survival Characteristics Table
C168971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168971>	C35867|C35681	Necrosis Negative|Negative for Necrosis|No Necrosis	An indication that signs of necrosis were not found in a sample.			Finding	GDC Terminology|GDC Value Terminology
C168972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168972>	C198003|C172676	Age in Days at Disease Phase|AGE_AT_DISEASE_PHASE|AGE_AT_DISEASE_PHASE|AGE_AT_DISEASE_PHASE|AGE_AT_DISEASE_PHASE|AGE_AT_DISEASE_PHASE|AGE_AT_DISEASE_PHASE|Age at Disease Phase	Age of subject (in days) at the disease phase.			Organism Attribute	ALL Disease Phase Timing Table|ALL Variable Terminology|AML Disease Phase Timing Table|AML Myeloid Sarcoma Involvement Table|AML Variable Terminology|EWS Disease Phase Timing Table|EWS Variable Terminology|GCT Disease Phase Timing Table|GCT Variable Terminology|HL Disease Phase Timing Table|HL Variable Terminology|OS Disease Phase Timing Table|OS Variable Terminology
C168973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168973>	C3809|C3575|C27359	Unresectable Neuroendocrine Neoplasm	A neuroendocrine neoplasm that is not amenable to surgical resection.	Unresectable Neuroendocrine Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168974>	C75467	Charcot-Marie-Tooth Disease Type 2Y|CMT2Y	An autosomal dominant form of Charcot-Marie-Tooth disease caused by mutations in the VCP gene, encoding transitional endoplasmic reticulum ATPase.			Disease or Syndrome	Cellosaurus Disease Terminology
C168975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168975>	C34568	Ehlers-Danlos Syndrome, Musculocontractural Type 1|EDSMC1	An autosomal recessive form of Ehlers-Danlos syndrome caused by mutation(s) in the CHST14 gene, encoding carbohydrate sulfotransferase 14.			Disease or Syndrome	Cellosaurus Disease Terminology
C168976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168976>	C156073|C153358	Locally Advanced Esophageal Carcinoma	An esophageal carcinoma that has spread to nearby tissues or lymph nodes.	Locally Advanced Esophageal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168977>	C170514|C153358	Locally Advanced Anal Carcinoma	An anal carcinoma that has spread to nearby tissues or lymph nodes.	Locally Advanced Anal Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168978>	C4124|C148130	Locally Advanced Adenocarcinoma	Adenocarcinoma that has spread to nearby tissues or lymph nodes.			Neoplastic Process	
C168979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168979>	C171298|C168978|C154091	Locally Advanced Hepatocellular Carcinoma	Hepatocellular carcinoma that has spread to nearby tissues or lymph nodes.	Locally Advanced Hepatocellular Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16897>	C16956	Necrotic Process|NECROSIS|Necrosis|Necrosis|Necrosis|necrosis	A cell death process that is morphologically characterized by a gain in cell volume (oncosis), swelling of organelles, plasma membrane rupture and subsequent loss of intracellular contents.	Necrotic Process		Pathologic Function	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF6 DMG Imaging Assessment Signal Characteristics Table|CTRP Biomarker Terminology|CTRP Terminology
C168980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168980>	C9294|C45240	Cutaneous Histiocytic and Dendritic Cell Neoplasm	A histiocytic and dendritic cell neoplasm that affects the skin.			Neoplastic Process	
C168981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168981>	C170459|C162751	Locally Advanced Biliary Tract Carcinoma	Carcinoma that arises from the intrahepatic, hilar, extrahepatic bile ducts, cystic duct, or gallbladder and has spread to nearby tissues or lymph nodes.	Locally Advanced Biliary Tract Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168983>	C3107|C168980	Cutaneous Langerhans Cell Histiocytosis	Langerhans cell histiocytosis that affects the skin. It manifests with skin papules and plaques.			Neoplastic Process	
C168984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168984>	C81767|C168980	Cutaneous Indeterminate Dendritic Cell Tumor|Cutaneous Indeterminate Cell Histiocytosis|Cutaneous Indeterminate Dendritic Cell Histiocytosis	A very rare dendritic cell tumor affecting the skin. It is composed of spindle to ovoid cells with a phenotype that is similar to the Langerhans cells. It manifests with cutaneous papules, nodules, and plaques.  The clinical course is variable.			Neoplastic Process	
C168985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168985>	C170459|C156069	Locally Advanced Pancreatic Carcinoma	A pancreatic carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.			Neoplastic Process	
C168986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168986>	C36075|C168980	Cutaneous Rosai-Dorfman-Destombes Disease|Cutaneous Rosai-Dorfman Disease|Cutaneous Sinus Histiocytosis With Massive Lymphadenopathy	Rosai-Dorfman-Destombes disease affecting the skin. It manifests with multiple papules, nodules, or plaques.			Neoplastic Process	
C168987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168987>	C3235	High Density Lipoprotein Cholesterol Level Quantitative Trait Locus 6|HDLCQ6|High Density Lipoprotein Cholesterol Level QTL6	A lipid transport disorder characterized by extremely elevated levels of high density lipoprotein cholesterol (HDL C; HDLC). It is caused by heterozygous mutations in the SCARB1 gene that result in decreased transport of HCL C into the liver by scavenger receptor class B member 1.			Disease or Syndrome	Cellosaurus Disease Terminology
C168988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168988>	C28193	Sertoli Cell-Only Syndrome|Del Castillo Syndrome|SCOS	A condition in which the seminiferous tubules are lined only by Sertoli cells.			Disease or Syndrome	Cellosaurus Disease Terminology
C168989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168989>	C222065	Mosaic Variegated Aneuploidy Syndrome 2|MVA2	An extremely rare mosaic variegated aneuploidy syndrome caused by mutations in the CEP57 gene. It manifests with growth retardation. Unlike the other mosaic variegated aneuploidy syndrome subtypes, there are no reports of development of malignant neoplasms.			Disease or Syndrome	Cellosaurus Disease Terminology
C16898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16898>	C17254	NEF Protein	An integral component of HIV-1 particles. Nef facilitates a step in the viral life cycle occurring between penetration and reverse transcription (Aiken. Virology 1998; 248:139-147)			Amino Acid, Peptide, or Protein	
C168990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168990>	C28193	Bartsocas-Papas Syndrome|Autosomal Recessive Popliteal Pterygium Syndrome|BPS	An autosomal recessive condition caused by mutation(s) in the RIPK4 gene, encoding receptor-interacting serine/threonine-protein kinase 4. It is characterized by popliteal pterygia, ankyloblepharon, cleft lip/palate, and syndactyly. Early lethality is common.			Disease or Syndrome	Cellosaurus Disease Terminology
C168991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168991>	C53972|C168980	Cutaneous Erdheim-Chester Disease	Erdheim-Chester disease that affects the skin.			Neoplastic Process	
C168992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168992>	C27555	Solitary Cutaneous Reticulohistiocytosis|SCR	A reactive cutaneous proliferation of macrophages associated with local trauma. It is characterized by the presence of giant cells with ground-glass cytoplasm. It presents as a single, asymptomatic, cutaneous or mucosal, firm xanthomatous to dark-red papule or nodule. (WHO 2018)			Disease or Syndrome	
C168993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168993>	C27555	Generalized Cutaneous Reticulohistiocytosis|GCR	A reactive cutaneous proliferation of macrophages. It is characterized by the presence of giant cells with ground-glass cytoplasm. It presents with multiple cutaneous or mucosal papules or nodules.			Disease or Syndrome	
C168994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168994>	C222832|C157623|C151971	Locally Advanced Cholangiocarcinoma	A cholangiocarcinoma that has spread to nearby tissues or lymph nodes.	Locally Advanced Cholangiocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168995>	C172618|C168978|C150595	Locally Advanced Renal Cell Carcinoma	A renal cell carcinoma that has spread to nearby tissues or lymph nodes.	Locally Advanced Renal Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C168996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168996>	C200225|C1511	Thorium Th 227 Trastuzumab Corixetan|227Th Anti-HER2 Monoclonal Antibody BAY2701439|227Th Trastuzumab Corixetan|BAY 2701439|BAY-2701439|BAY2701439|HER2-TTC|TRASTUZUMAB CORIXETAN THORIUM TH-227|Th 227 Anti-HER2 Monoclonal Antibody BAY2701439|Th-227-Anti-HER2 Monoclonal Antibody BAY2701439|Thorium Th 227 Anti-HER2 Monoclonal Antibody BAY2701439|Thorium Th 227 MOAB BAY2701439|Thorium Th 227 Monoclonal Antibody BAY2701439|Thorium-227 Anti-HER2 Monoclonal Antibody BAY2701439|Trastuzumab Corixetan Thorium Th-227	A radioimmunoconjugate consisting of trastuzumab, a monoclonal antibody targeting the tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2), conjugated to the chelating agent corixetan, and labeled with the alpha-emitting radioisotope thorium Th 227, with potential antineoplastic activity. Upon administration of thorium Th 227 trastuzumab corixetan, the trastuzumab moiety targets and specifically binds to HER2 on tumor cells, thereby delivering a cytotoxic dose of alpha radiation to cells expressing HER2. HER2 is overexpressed in a variety of cancer cell types and is associated with increased tumor cell proliferation.	Thorium Th 227 Trastuzumab Corixetan		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C168997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168997>	C84647	Congenital Myasthenic Syndrome 12|CMS12	An autosomal recessive form of congenital myasthenic syndrome caused by mutation(s) in the GFPT1 gene, encoding glutamine--fructose-6-phosphate aminotransferase 1.			Disease or Syndrome	Cellosaurus Disease Terminology
C168998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168998>	C61272	Glycogen Storage Disease Type XI|Fanconi-Bickel Syndrome|Glycogen Storage Disease Due to GLUT2 Deficiency	Glycogen storage disease caused by mutation(s) in the SLC2A2 gene, encoding solute carrier family 2, facilitated glucose transporter member 2. It is characterized by marked proximal renal tubular dysfunction and hepatorenal glycogen accumulation.			Disease or Syndrome	Cellosaurus Disease Terminology
C168999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C168999>	C140264	Macular Dystrophy, Retinal, 1|MCDR1|NCMD|North Carolina Macular Dystrophy|Retinal Macular Dystrophy-1	An autosomal dominant form of macular dystrophy associated with mutation(s) in the DNase1 hypersensitivity site DHS6S1.			Disease or Syndrome	Cellosaurus Disease Terminology
C16899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16899>	C27992	Neoplasm Stage|STAGE|STAGE|Stage|Stage|Stage|Tumor Stage|stage	The extent of a cancer in the body.	Stage		Qualitative Concept	CTRP Disease Terminology|CTRP Terminology|GCT Staging Table|GCT Variable Terminology|HL Staging Table|HL Variable Terminology
C1689	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1689>	C784|C1976	Plitidepsin|APLD|Aplidin|Aplidine|Aplidine|DDB|Dehydrodemnin B|Dehydrodidemnin B|N-[1-(1,2-Dioxopropyl)-L-prolyl]didemnin A|PLITIDEPSIN|aplidine	A cyclic depsipeptide isolated from the marine tunicate Aplidium albicans. Plitidepsin displays a broad spectrum of antitumor activities, inducing apoptosis by triggering mitochondrial cytochrome c release, initiating the Fas/DC95, JNK pathway and activating caspase 3 activation. This agent also inhibits elongation factor 1-a, thereby interfering with protein synthesis, and induces G1 arrest and G2 blockade, thereby inhibiting tumor cell growth.	Plitidepsin		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C169000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169000>	C84577	Optic Atrophy 1|Kjer-type Optic Atrophy|OPA1	An autosomal dominant form of hereditary optic atrophy caused by mutation(s) in the OPA1 gene, encoding dynamin-like 120 kDa protein, mitochondrial.			Disease or Syndrome	Cellosaurus Disease Terminology
C169001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169001>	C28193	Ring Chromosome 20 Syndrome	A rare condition in which the two arms of chromosome 20 are fused resulting in a ring chromosome. It is characterized by recurrent seizures with an onset in childhood. Additional features my include microcephaly and short stature.			Disease or Syndrome	Cellosaurus Disease Terminology
C169002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169002>	C168695	NT5C2 NM_001134373.2:c.1100G>A|5'-Nucleotidase, Cytosolic II c.1100G>A|NM_001134373.2:c.1100G>A|NT5B c.1100G>A|NT5C2 c.1100G>A|NT5CP c.1100G>A|PNT5 c.1100G>A|cN-II c.1100G>A	A nucleotide substitution at position 1100 of the coding sequence of the NT5C2 gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C169003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169003>	C97928	NT5C2 Protein Variant|Cytosolic 5'-Nucleotidase II Protein Variant|Cytosolic Purine 5'-Nucleotidase Protein Variant|Purine 5'-Nucleotidase Protein Variant	A variation in the amino acid sequence for the cytosolic purine 5'-nucleotidase protein.			Cell or Molecular Dysfunction	Pediatric Oncology Target Molecular Abnormalities Terminology
C169004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169004>	C169003	NT5C2 NP_001127845.1:p.R367Q|Cytosolic 5'-Nucleotidase II Arg367Gln|Cytosolic 5'-Nucleotidase II R367Q|Cytosolic Purine 5'-Nucleotidase Arg367Gln|Cytosolic Purine 5'-Nucleotidase R367Q|NP_001127845.1:p.Arg367Gln|NP_001127845.1:p.R367Q|NT5C2 Arg367Gln|NT5C2 NP_001127845.1:p.Arg367Gln|NT5C2 R367Q|NT5C2 p.Arg367Gln|NT5C2 p.R367Q|Purine 5'-Nucleotidase Arg367Gln|Purine 5'-Nucleotidase R367Q	A change in the amino acid residue at position 367 in the cytosolic purine 5'-nucleotidase protein where arginine has been replaced by glutamine.			Cell or Molecular Dysfunction	
C169005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169005>	C25638	Reason Off Protocol|REASON_OFF	The reason the protocol-specified drug or therapeutic procedure was interrupted or stopped.			Idea or Concept	HL Off Protocol Therapy/Study Table|HL Variable Terminology
C169006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169006>	C153059	NTRK1 NM_001012331.1:c.1820G>T|MTC c.1820G>T|NM_001012331.1:c.1820G>T|NTRK1 c.1820G>T|Neurotrophic Receptor Tyrosine Kinase 1 c.1820G>T|TRK c.1820G>T|TRK1 c.1820G>T|Trk-A c.1820G>T|TrkA c.1820G>T|p140-TrkA c.1820G>T	A nucleotide substitution at position 1820 of the coding sequence of the NTRK1 gene where guanine has been mutated to thymine.			Cell or Molecular Dysfunction	
C169007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169007>	C97928	NTRK1 Protein Variant|High Affinity Nerve Growth Factor Receptor Protein Variant|Nerve Growth Factor Receptor Type 1 Protein Variant|Neurotrophic Tyrosine Kinase Receptor Type 1 Protein Variant|Trk-A Protein Variant|TrkA Protein Variant|Tropomyosin-Related Kinase A Protein Variant|Tyrosine Kinase Receptor A Protein Variant	A variation in the amino acid sequence for the high affinity nerve growth factor receptor protein.			Cell or Molecular Dysfunction	
C169008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169008>	C169007	NTRK1 NP_001012331.1:p.G607V|High Affinity Nerve Growth Factor Receptor G607V|High Affinity Nerve Growth Factor Receptor Gly607Val|NP_001012331.1:p.G607V|NP_001012331.1:p.Gly607Val|NTRK1 G607V|NTRK1 Gly607Val|NTRK1 NP_001012331.1:p.Gly607Val|NTRK1 p.G607V|Nerve Growth Factor Receptor Type 1 G607V|Nerve Growth Factor Receptor Type 1 Gly607Val|Neurotrophic Tyrosine Kinase Receptor Type 1 G607V|Neurotrophic Tyrosine Kinase Receptor Type 1 Gly607Val|Trk-A G607V|Trk-A Gly607Val|TrkA G607V|TrkA Gly607Val|Tropomyosin-Related Kinase A G607V|Tropomyosin-Related Kinase A Gly607Val|Tyrosine Kinase Receptor A G607V|Tyrosine Kinase Receptor A Gly607Val	A change in the amino acid residue at position 607 in the high affinity nerve growth factor receptor protein where glycine has been replaced by valine.			Cell or Molecular Dysfunction	
C169009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169009>	C36292	HLA Match Finding|HLA Match|HLA Match Status|HLA_MATCH|HLA_MATCH	A process in which blood or tissue samples are analyzed to determine their human leukocyte antigen (HLA) profiles so that transplant materials can be transferred into a patient with the same or similar profile.			Laboratory or Test Result	ALL Stem Cell Transplant Table|ALL Variable Terminology|AML Stem Cell Transplant Table|AML Variable Terminology
C16900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16900>	C16956	Neovascularization|NEOVASCULARIZATION|Neoangiogenesis|Neovascularization, Pathologic|Vascularization	The formation of new or recent blood vessels. The vasculature network is critical to the development of neoplasms. As the tumor burden grows, vascular endothelial cells are recruited to form new blood vessels as an increased demand for blood and nourishment is required.	Neovascularization		Pathologic Function	CDISC SEND Non-Neoplastic Finding Type Terminology|CDISC SEND Terminology|CDRH Health Effects - Clinical Signs and Symptoms or Conditions Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology
C169010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169010>	C153059	NTRK1 NM_001012331.1:c.1792C>T|MTC c.1792C>T|NM_001012331.1:c.1792C>T|NTRK1 c.1792C>T|Neurotrophic Receptor Tyrosine Kinase 1 c.1792C>T|TRK c.1792C>T|TRK1 c.1792C>T|Trk-A c.1792C>T|TrkA c.1792C>T|p140-TrkA c.1792C>T	A nucleotide substitution at position 1792 of the coding sequence of the NTRK1 gene where cytosine has been mutated to thymine.			Cell or Molecular Dysfunction	
C169011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169011>	C169007	NTRK1 NP_001012331.1:p.H598T|High Affinity Nerve Growth Factor Receptor H598Y|High Affinity Nerve Growth Factor Receptor His598Tyr|NP_001012331.1:p.H598Y|NP_001012331.1:p.His598Tyr|NTRK1 H598Y|NTRK1 His598Tyr|NTRK1 NP_001012331.1:p.His598Tyr|NTRK1 p.H598Y|NTRK1 p.His598Tyr|Nerve Growth Factor Receptor Type 1 H598Y|Nerve Growth Factor Receptor Type 1 His598Tyr|Neurotrophic Tyrosine Kinase Receptor Type 1 H598Y|Neurotrophic Tyrosine Kinase Receptor Type 1 His598Tyr|Trk-A H598Y|Trk-A His598Tyr|TrkA H598Y|TrkA His598Tyr|Tropomyosin-Related Kinase A H598Y|Tropomyosin-Related Kinase A His598Tyr|Tyrosine Kinase Receptor A H598Y|Tyrosine Kinase Receptor A His598Tyr	A change in the amino acid residue at position 598 in the high affinity nerve growth factor receptor protein where histidine has been replaced by tyrosine.			Cell or Molecular Dysfunction	
C169012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169012>	C158139	PAX5 NM_016734.3:c.964G>A|ALL3 c.964G>A|BSAP c.964G>A|NM_016734.2:c.964G>A|PAX5 c.964G>A|Paired Box 5 c.964G>A|Paired Box Gene 5 c.964G>A	A nucleotide substitution at position 964 of the coding sequence of the PAX5 gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C169013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169013>	C158140	PAX5 NP_057953.1:p.A322T|B-Cell Lineage Specific Activator Protein A322T|B-Cell Lineage Specific Activator Protein Ala322Thr|B-Cell-Specific Transcription Factor A322T|B-Cell-Specific Transcription Factor Ala322Thr|BSAP A322T|BSAP Ala322Thr|NP_057953.1:p.A322T|NP_057953.1:p.Ala322Thr|PAX5 A322T|PAX5 Ala322Thr|PAX5 NP_057953.1:p.Ala322Thr|PAX5 p.A322T|PAX5 p.Ala322Thr|Paired Box Protein Pax-5 A322T|Paired Box Protein Pax-5 Ala322Thr	A change in the amino acid residue at position 322 in paired box protein Pax-5 where alanine has been replaced by threonine.			Cell or Molecular Dysfunction	
C169014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169014>	C173812	Type of Stem Cell Transplant Conditioning Prior to Transplant Question|SCT_CONDITIONING_TYPE|SCT_CONDITIONING_TYPE|SCT_CONDITIONING_TYPE|Type of Stem Cell Transplant Conditioning Prior to Transplant	Type of conditioning the subject received prior to stem-cell transplantation.			Intellectual Product	ALL Stem Cell Transplant Table|ALL Variable Terminology|AML Stem Cell Transplant Table|AML Variable Terminology|HL Stem Cell Transplant Table|HL Variable Terminology
C169015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169015>	C97928	PHF6 Protein Variant|Centromere Protein 31 Protein Variant|PHD Finger Protein 6 Protein Variant|PHD-Like Zinc Finger Protein Variant	A variation in the amino acid sequence for PHD finger protein 6.			Cell or Molecular Dysfunction	
C169016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169016>	C169015	PHF6 NP_115834.1:p.R225X|Centromere Protein 31 Arg225Xxx|Centromere Protein 31 R225X|NP_115834.1:p.Arg225Xxx|NP_115834.1:p.R225X|PHD Finger Protein 6 Arg225Xxx|PHD Finger Protein 6 R225X|PHD-Like Zinc Finger Protein Arg225Xxx|PHD-Like Zinc Finger Protein R225X|PHF6 Arg225Xxx|PHF6 NP_115834.1:p.Arg225Xxx|PHF6 R225 Mutation|PHF6 R225X|PHF6 p.Arg225Xxx|PHF6 p.R225X	A change in the amino acid residue at position 225 in PHD finger protein 6 where arginine has been replaced by another amino acid.			Cell or Molecular Dysfunction	
C169018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169018>	C133669	PTCH1 NM_000264.4:c.3583A>T|NM_000264.4:c.3583A>T|PTC c.3583A>T|PTC1 c.3583A>T|PTCH c.3583A>T|PTCH1 c.3583A>T|Patched 1 c.3583A>T|Patched Homolog 1 c.3583A>T	A nucleotide substitution at position 3583 of the coding sequence of the PTCH1 gene where adenine has been mutated to thymine.			Cell or Molecular Dysfunction	
C169019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169019>	C97928	PTCH1 Protein Variant|PTC Protein Variant|PTC1 Protein Variant|PTCH Protein Variant|Protein Patched Homolog 1 Protein Variant	A variation in the amino acid sequence for the protein patched homolog 1 protein.			Cell or Molecular Dysfunction	Pediatric Oncology Target Molecular Abnormalities Terminology
C16901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16901>	C25464	Nepal|524|NEPAL|NEPAL|NP|NPL|NPL	A country in southern Asia, between China and India, west of Bhutan.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C169020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169020>	C169019	PTCH1 NP_000255.2:p.T1195S|NP_000255.2:p.T1195S|NP_000255.2:p.Thr1195Ser|PTC T1195S|PTC Thr1195Ser|PTC1 T1195S|PTC1 Thr1195Ser|PTCH T1195S|PTCH Thr1195Ser|PTCH1 NP_000255.2:p.Thr1195Ser|PTCH1 T1195S|PTCH1 Thr1195Ser|PTCH1 p.T1195S|PTCH1 p.Thr1195Ser|Protein Patched Homolog 1 T1195S|Protein Patched Homolog 1 Thr1195Ser	A change in the amino acid residue at position 1195 in the protein patched homolog 1 protein where threonine has been replaced by serine.			Cell or Molecular Dysfunction	
C169021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169021>	C4913	Platinum-Resistant Malignant Female Reproductive System Neoplasm	A malignant female reproductive system neoplasm that progresses between one and six months of completing platinum therapy.	Platinum-Resistant Malignant Female Reproductive System Neoplasm		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C169022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169022>	C97928	PTPN11 Protein Variant|PTP-1D Protein Variant|PTP-2C Protein Variant|Protein Tyrosine Phosphatase 2C Protein Variant|Protein-Tyrosine Phosphatase 1D Protein Variant|SH-PTP2 Protein Variant|SH-PTP3 Protein Variant|SHP-2 Protein Variant|Tyrosine Phosphatase SHP2 Protein Variant|Tyrosine-Protein Phosphatase Non-Receptor Type 11 Protein Variant	A variation in the amino acid sequence for the tyrosine-protein phosphatase non-receptor type 11 protein.			Cell or Molecular Dysfunction	Pediatric Oncology Target Molecular Abnormalities Terminology
C169023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169023>	C165569	PTEN NP_000305.3:p.L182 Frameshift|Mutated in Multiple Advanced Cancers 1 L182fs|Mutated in Multiple Advanced Cancers 1 Leu182fs|NP_000305.3:p.L182fs|NP_000305.3:p.Leu182fs|PTEN L182fs|PTEN Leu182fs|PTEN NP_000305.3:p.L182fs|PTEN NP_000305.3:p.Leu182fs|PTEN Tyrosine Phosphatase L182fs|PTEN Tyrosine Phosphatase Leu182fs|PTEN p.L182fs|PTEN p.Leu182fs|Phosphatase and Tensin Homolog L182fs|Phosphatase and Tensin Homolog Leu182fs|Phosphatase and Tensin-Like Protein L182fs|Phosphatase and Tensin-Like Protein Leu182fs|Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN L182fs|Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN Leu182fs	A change in the amino acid residue at position 182 in the phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN protein where leucine has been replaced one or more non-canonical amino acids followed by a stop codon.			Cell or Molecular Dysfunction	
C169024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169024>	C175696	PTEN NM_000314.7:c.545T>G|MMAC1 c.545T>G|Mutated in Multiple Advanced Cancers 1 c.545T>G|NM_000314.7:c.545T>G|PTEN c.545T>G|PTEN1 c.545T>G|Phosphatase and Tensin Homolog c.545T>G|TEP1 c.545T>G	A nucleotide substitution at position 545 of the coding sequence of the PTEN gene where thymine has been mutated to guanine.			Cell or Molecular Dysfunction	
C169025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169025>	C175696	PTEN NM_000314.7:c.545T>A|MMAC1 c.545T>A|Mutated in Multiple Advanced Cancers 1 c.545T>A|NM_000314.7:c.545T>A|PTEN c.545T>A|PTEN1 c.545T>A|Phosphatase and Tensin Homolog c.545T>A|TEP1 c.545T>A	A nucleotide substitution at position 545 of the coding sequence of the PTEN gene where thymine has been mutated to adenine.			Cell or Molecular Dysfunction	
C169026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169026>	C165569	PTEN NP_000305.3:p.L182*|Mutated in Multiple Advanced Cancers 1 L182*|Mutated in Multiple Advanced Cancers 1 Leu182Ter|NP_000305.3:p.L182*|NP_000305.3:p.Leu182Ter|PTEN L182*|PTEN Leu182Ter|PTEN NP_000305.3:p.Leu182Ter|PTEN Tyrosine Phosphatase L182*|PTEN Tyrosine Phosphatase Leu182Ter|PTEN p.L182*|PTEN p.Leu182Ter|Phosphatase and Tensin Homolog L182*|Phosphatase and Tensin Homolog Leu182Ter|Phosphatase and Tensin-Like Protein L182*|Phosphatase and Tensin-Like Protein Leu182Ter|Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN L182*|Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase and Dual-Specificity Protein Phosphatase PTEN Leu182Ter	A change in the amino acid residue at position 182 in the phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN protein where leucine has been replaced by a stop codon.			Cell or Molecular Dysfunction	
C169027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169027>	C213863|C200258	CK1alpha/CDK7/CDK9 Inhibitor BTX-A51|BTX A51|BTX-A51|BTX-A51|BTXA51	The ditosylated salt of A51, an orally bioavailable inhibitor of casein kinase 1alpha (CK1alpha) and cyclin-dependent kinases 7 and 9 (CDK7 and CDK9), with potential antineoplastic activity. Upon administration, BTX-A51 binds to and inhibits the activity of CK1alpha, CDK7, and CDK9. Blocking the phosphorylation and kinase activity of CK1alpha prevents the enhanced binding of murine double minute X (MDMX) to p53, the formation of CK1alpha and MDM2 complex, and the resulting inhibition of p53. This induces p53-mediated cell cycle arrest, slowing tumor cell proliferation. Blocking the phosphorylation and kinase activity of CDK7 and CDK9 prevents the positive transcription elongation factor b (PTEFb)-mediated activation of RNA polymerase II (RNA Pol II) and leads to the inhibition of gene transcription of various anti-apoptotic proteins. This also induces cell cycle arrest and apoptosis, slowing tumor cell proliferation. CK1alpha, a serine/threonine kinase and a leukemic stem cell target, acts as a tumor suppressor in several cancers through the negative regulation of Wnt/beta-catenin signaling and p53. It negatively regulates p53 by phosphorylating MDMX, thus enhancing binding of MDMX to p53, as well as by forming a complex with MDM2. CDK7, a serine/threonine kinase, plays a role in controlling cell cycle progression, transcriptional regulation, and promotes the expression of key oncogenes such as c-Myc through the phosphorylation of RNA Pol II. CDK9, also a serine/threonine kinase, regulates elongation of transcription through phosphorylation of RNA Pol II at serine 2 (p-Ser2-RNAPII). It is upregulated in various tumor cell types and plays a key role in the regulation of RNA Pol II-mediated transcription of anti-apoptotic proteins. Tumor cells are dependent on anti-apoptotic proteins for their survival.	CK1alpha/CDK7/CDK9 Inhibitor BTX-A51		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C169028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169028>	C83082|C70663	Study Unique Identifier	A unique identifier assigned to a study.			Intellectual Product	
C169029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169029>	C139794	PTPN11 NM_002834.4:c.1508G>C|BPTP3 c.1508G>C|NM_002834.4:c.1508G>C|PTP-1D c.1508G>C|PTP2C c.1508G>C|PTPN11 c.1508G>C|Protein Tyrosine Phosphatase Non-Receptor Type 11 c.1508G>C|SH-PTP2 c.1508G>C|SHP-2 c.1508G>C|SHP2 c.1508G>C	A nucleotide substitution at position 1508 of the coding sequence of the PTPN11 gene where guanine has been mutated to cytosine.			Cell or Molecular Dysfunction	
C16902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16902>	C16749	Nephrology	A branch of medicine concerned with the development, anatomy, function, and dysfunction of the kidney.			Biomedical Occupation or Discipline	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C169030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169030>	C169022	PTPN11 NP_002825.3:p.G503A|NP_002825.3:p.G503A|NP_002825.3:p.Gly503Ala|PTP-1D G503A|PTP-1D Gly503Ala|PTP-2C G503A|PTP-2C Gly503Ala|PTPN11 G503A|PTPN11 Gly503Ala|PTPN11 NP_002825.3:p.Gly503Ala|PTPN11 p.G503A|PTPN11 p.Gly503Ala|Protein Tyrosine Phosphatase 2C G503A|Protein Tyrosine Phosphatase 2C Gly503Ala|Protein-Tyrosine Phosphatase 1D G503A|Protein-Tyrosine Phosphatase 1D Gly503Ala|SH-PTP2 G503A|SH-PTP2 Gly503Ala|SH-PTP3 G503A|SH-PTP3 Gly503Ala|SHP-2 G503A|SHP-2 Gly503Ala|Tyrosine Phosphatase SHP2 G503A|Tyrosine Phosphatase SHP2 Gly503Ala|Tyrosine-Protein Phosphatase Non-Receptor Type 11 G503A|Tyrosine-Protein Phosphatase Non-Receptor Type 11 Gly503Ala	A change in the amino acid residue at position 503 in the  tyrosine-protein phosphatase non-receptor type 11 protein where glycine has been replaced by alanine.			Cell or Molecular Dysfunction	
C169031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169031>	C97928	RB1 Protein Variant|Rb Protein Variant|Retinoblastoma Protein Variant|Retinoblastoma-Associated Protein Variant|p105-Rb Protein Variant|p110-RB1 Protein Variant|pRb Protein Variant	A variation in the amino acid sequence for the retinoblastoma-associated protein.			Cell or Molecular Dysfunction	
C169032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169032>	C169031	RB1 NP_000312.2:p.F650S|NP_000312.2:p.F650S|NP_000312.2:p.Phe650Ser|RB1 F650S|RB1 NP_000312.2:p.Phe650Ser|RB1 Phe650Ser|RB1 p.F650S|RB1 p.Phe650Ser|Rb F650S|Rb Phe650Ser|Retinoblastoma Protein F650S|Retinoblastoma Protein Phe650Ser|Retinoblastoma-Associated Protein F650S|Retinoblastoma-Associated Protein Phe650Ser|p105-Rb F650S|p105-Rb Phe650Ser|p110-RB1 F650S|p110-RB1 Phe650Ser|pRb F650S|pRb Phe650Ser	A change in the amino acid residue at position 650 in the retinoblastoma-associated protein where phenylalanine has been replaced by serine.			Cell or Molecular Dysfunction	
C169033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169033>	C97928	SDHB Protein Variant|Ip Protein Variant|Iron-Sulfur Subunit of Complex II Protein Variant|Succinate Dehydrogenase [Ubiquinone] Iron-Sulfur Subunit, Mitochondrial Protein Variant	A variation in the amino acid sequence for the succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial protein.			Cell or Molecular Dysfunction	
C169034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169034>	C48302	SDHB NM_003000.2:c.487T>C|IP c.487T>C|NM_003000.2:c.487T>C|SDH1 c.487T>C|SDH2 c.487T>C|SDHB c.487T>C|SDHIP c.487T>C|Succinate Dehydrogenase Complex Iron Sulfur Subunit B c.487T>C	A nucleotide substitution at position 487 of the coding sequence of the SDHB gene where thymine has been mutated to cytosine.			Cell or Molecular Dysfunction	
C169035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169035>	C169033	SDHB NP_002991.2:p.S163P|Ip S163P|Ip Ser163Pro|Iron-Sulfur Subunit of Complex II S163P|Iron-Sulfur Subunit of Complex II Ser163Pro|NP_002991.2:p.S163P|NP_002991.2:p.Ser163Pro|SDHB NP_002991.2:p.Ser163Pro|SDHB S163P|SDHB Ser163Pro|SDHB p.S163P|SDHB p.Ser163Pro|Succinate Dehydrogenase [Ubiquinone] Iron-Sulfur Subunit, Mitochondrial S163P|Succinate Dehydrogenase [Ubiquinone] Iron-Sulfur Subunit, Mitochondrial Ser163Pro	A change in the amino acid residue at position 163 in the succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial protein where serine has been replaced by proline.			Cell or Molecular Dysfunction	
C169036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169036>	C97928	SDHD Protein Variant|CII-4 Protein Variant|CybS Protein Variant|QPs3 Protein Variant|Succinate Dehydrogenase Complex Subunit D Protein Variant|Succinate Dehydrogenase [Ubiquinone] Cytochrome B Small Subunit, Mitochondrial Protein Variant|Succinate-Ubiquinone Oxidoreductase Cytochrome B Small Subunit Protein Variant|Succinate-Ubiquinone Reductase Membrane Anchor Subunit Protein Variant	A variation in the amino acid sequence for the succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial protein.			Cell or Molecular Dysfunction	
C169037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169037>	C48304	SDHD NM_003002.4:c.34G>A|CII-4 c.34G>A|NM_003002.4:c.34G>A|SDH4 c.34G>A|SDHD c.34G>A|Succinate Dehydrogenase Complex Subunit D c.34G>A|cybS c.34G>A	A nucleotide substitution at position 34 of the coding sequence of the SDHD gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C169038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169038>	C169036	SDHD NP_002993.1:p.G12S|CII-4 G12S|CII-4 Gly12Ser|CybS G12S|CybS Gly12Ser|NP_002993.1:p.G12S|NP_002993.1:p.Gly12Ser|QPs3 G12S|QPs3 Gly12Ser|SDHD G12S|SDHD Gly12Ser|SDHD NP_002993.1:p.Gly12Ser|SDHD p.G12S|SDHD p.Gly12Ser|Succinate Dehydrogenase Complex Subunit D G12S|Succinate Dehydrogenase Complex Subunit D Gly12Ser|Succinate Dehydrogenase [Ubiquinone] Cytochrome B Small Subunit, Mitochondrial G12S|Succinate Dehydrogenase [Ubiquinone] Cytochrome B Small Subunit, Mitochondrial Gly12Ser|Succinate-Ubiquinone Oxidoreductase Cytochrome B Small Subunit G12S|Succinate-Ubiquinone Oxidoreductase Cytochrome B Small Subunit Gly12Ser|Succinate-Ubiquinone Reductase Membrane Anchor Subunit G12S|Succinate-Ubiquinone Reductase Membrane Anchor Subunit Gly12Ser	A change in the amino acid residue at position 12 in the succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial protein where glycine has been replaced by serine.			Cell or Molecular Dysfunction	
C169039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169039>	C97928	SETD2 Protein Variant|HIF-1 Protein Variant|HIP-1 Protein Variant|Histone-Lysine N-Methyltransferase SETD2 Protein Variant|Huntingtin Yeast Partner B Protein Variant|Huntingtin-Interacting Protein 1 Protein Variant|Huntingtin-Interacting Protein B Protein Variant|Lysine N-Methyltransferase 3A Protein Variant|SET Domain-Containing Protein 2 Protein Variant|p231HBP Protein Variant	A variation in the amino acid sequence for the histone-lysine methyltransferase SETD2 protein.			Cell or Molecular Dysfunction	
C16903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16903>	C25464	Netherlands|528|Kingdom of the Netherlands|NETHERLANDS|NETHERLANDS|NL|NLD|NLD	A country in western Europe, bordering the North Sea, between Belgium and Germany.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C169040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169040>	C169039	SETD2 NP_054878.5:p.E1265 Frameshift|HIF-1 E1265fs|HIF-1 Glu1265fs|HIP-1 E1265fs|HIP-1 Glu1265fs|Histone-Lysine N-Methyltransferase SETD2 E1265fs|Histone-Lysine N-Methyltransferase SETD2 Glu1265fs|Huntingtin Yeast Partner B E1265fs|Huntingtin Yeast Partner B Glu1265fs|Huntingtin-Interacting Protein 1 E1265fs|Huntingtin-Interacting Protein 1 Glu1265fs|Huntingtin-Interacting Protein B E1265fs|Huntingtin-Interacting Protein B Glu1265fs|Lysine N-Methyltransferase 3A E1265fs|Lysine N-Methyltransferase 3A Glu1265fs|NP_054878.5:p.E1265fs|NP_054878.5:p.Glu1265fs|SET Domain-Containing Protein 2 E1265fs|SET Domain-Containing Protein 2 Glu1265fs|SETD2 E1265fs|SETD2 Glu1265fs|SETD2 NP_054878.5:p.E1265fs|SETD2 NP_054878.5:p.Glu1265fs|SETD2 p.E1265fs|SETD2 p.Glu1265fs|p231HBP E1265fs|p231HBP Glu1265fs	A change in the amino acid residue at position 1265 in the histone-lysine methyltransferase SETD2 protein where  glutamic acid has been replaced one or more non-canonical amino acids followed by a stop codon.			Cell or Molecular Dysfunction	
C169041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169041>	C8294|C216181|C165631	Localized Pancreatic Adenocarcinoma	An adenocarcinoma that arises from the pancreas and has not spread to other anatomic sites.	Localized Pancreatic Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C169042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169042>	C203001|C119988	Exagamglogene Autotemcel|Autologous CD34+ HSPCs Modified with CRISPR-Cas9 at the Erythroid Lineage-specific Enhancer of the BCL11A Gene|Autologous CD34-positive BCL11A Enhancer-disrupted HSPCs CTX001|Autologous CRISPR-Cas9 Engineered CD34+ hHSPCs CTX001|Autologous CRISPR-Cas9 Genetically-modified CD34+ HSPCs CTX001|Autologous CRISPR-Cas9 Modified/ BCL11A Enhancer-disrupted CD34-positive HSPCs CTX001|Autologous CRISPR-Cas9 Modified/BCL11A Enhancer-disrupted CD34-positive Human Hematopoietic Stem and Progenitor Cells CTX001|CTX 001|CTX-001|CTX001|Casgevy|EXAGAMGLOGENE AUTOTEMCEL|Exa-cel|Exagamglogene autotemcel	A population of autologous cluster of differentiation 34 (CD34)-positive human hematopoietic stem and progenitor cells (hHSPCs) that are ex-vivo gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex at the erythroid lineage-specific enhancer of the B-cell lymphoma/leukemia 11A (BCL11A) gene, with potential usage for transplantation in patients with sickle cell disease (SCD) and beta-thalassemia. CD34-positive HSPCs are isolated from human blood upon apheresis and are genetically modified in vitro using CRISPR/Cas9 technology to specifically disrupt the erythroid enhancer of the BCL11A gene. As BCL11A is a suppressor of fetal hemoglobin (HbF; hemoglobin F) expression, disruption of the BCL11A enhancer decreases the expression of BCL11A and stimulates the expression of HbF in erythrocytes that differentiate from CTX001. Upon infusion back into the patient following myeloablative, conditioning chemotherapy, exagamglogene autotemcel can populate the bone marrow and differentiate into a variety of blood cell types including lymphoid cells, myeloid cells and erythroblasts. The increased production of high levels of HbF in red blood cells (RBCs) compensates for the defective or reduced adult hemoglobin (Hb) in patients with SCD and beta-thalassemia. HbF is a form of the oxygen carrying Hb that is naturally present at birth and is then replaced by the adult form of hemoglobin.	Exagamglogene Autotemcel		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C169043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169043>	C39844|C150513	Metastatic Urachal Urothelial Carcinoma|Metastatic Bladder Urachal Urothelial Carcinoma|Metastatic Bladder Urachal Urothelial Carcinoma	A bladder urachal urothelial carcinoma that has spread to another anatomic site.	Metastatic Bladder Urachal Urothelial Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C169044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169044>	C97928	SMO Protein Variant|Protein Gx Protein Variant|SMOH Protein Variant|Smoothened Homolog Protein Variant|Smoothened Protein Variant	A variation in the amino acid sequence for the smoothened homolog protein.			Cell or Molecular Dysfunction	Pediatric Oncology Target Molecular Abnormalities Terminology
C169045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169045>	C169044	SMO NP_005622.1:p.A374E|NP_005622.1:p.A374E|NP_005622.1:p.Ala374Glu|Protein Gx A374E|Protein Gx Ala374Glu|SMO A374E|SMO Ala374Glu|SMO NP_005622.1:p.Ala374Glu|SMO p.A374E|SMO p.Ala374Glu|SMOH A374E|SMOH Ala374Glu|Smoothened A374E|Smoothened Ala374Glu|Smoothened Homolog A374E|Smoothened Homolog Ala374Glu	A change in the amino acid residue at position 374 in the smoothened homolog protein where alanine has been replaced by glutamic acid.			Cell or Molecular Dysfunction	
C169046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169046>	C20993	AUA Risk Stratification for Non-Muscle Invasive Bladder Cancer|American Urological Association Risk Stratification for Non-Muscle Invasive Bladder Cancer	A guideline from the American Urological Association that provides a risk-stratified clinical framework for the management of non-muscle invasive bladder cancer.			Intellectual Product	
C169047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169047>	C226473	Ointment OQL011|OQL 011|OQL-011|OQL011	An ointment that can potentially be used to treat vascular endothelial growth factor receptor (VEGFR) inhibitor (VEGFRi)-associated hand-foot skin reaction (HFSR).	Ointment OQL011		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology
C169048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169048>	C390	Nanoparticle-based Manganese-containing Contrast Agent SN132D|MRI Contrast Agent SN132D|Manganese-based Macromolecular Contrast Agent SN132D|Manganese-containing Nanoparticle Contrast Agent SN132D|Nanoparticle-based Contrast Agent with Manganese SN132D|SN132D|SpagoPix	A contrast agent formulation composed of a polymeric core containing the paramagnetic contrast agent manganese chloride tetrahydrate (MnCl2 4H2O), in which the Mn2+ ions are chelated to phosphonate groups, and covered with a coating layer of covalently attached polyetyleneglycol (PEG)-polymers, that can potentially be used as a contrast enhancer during magnetic resonance imaging (MRI). Upon intravenous administration of the nanoparticle-based manganese-containing contrast agent SN132D, the nanoparticles enhance absorption of the poorly absorbable contrast agent manganese, and selectively accumulates in the tumor microenvironment (TME). Due to the retention of manganese in the TME and its paramagnetic properties, this contrast agent enhances the visualization and detection of tumor cells during MRI.			Indicator, Reagent, or Diagnostic Aid	NCI Drug Dictionary Terminology
C169049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169049>	C129826	WT1-loaded Artificial Adjuvant Vector Cell Immunotherapeutic ASP7517|ASP 7517|ASP-7517|ASP7517|WT1-loaded Artificial Adjuvant Vector Cells ASP7517|WT1-loaded aAVC Immunotherapeutic ASP7517|WT1-loaded aAVCs ASP7517	A preparation of artificial adjuvant vector cells (aAVCs) composed of cells from the cell line HEK293, which is derived from human embryonic kidney cells, that are transfected with the natural killer T (NKT) immune cell receptor cluster of differentiation 1d (CD1d) and loaded with the glycolipid and CD1d ligand alpha-galactosylceramide (alpha-GalCer) on the cell surface, and loaded with the full-length tumor-associated antigen (TAA) Wilms' tumor 1 (WT1), with potential immunomodulating and antineoplastic activities. Upon administration of the WT1-loaded aAVC immunotherapeutic ASP7517, the alphaGalCer on the cell surface activates invariant NKT (iNKT) cells, thereby eliciting WT1-specific NKT cell responses against ASP7517. This in turn activates a natural killer (NK) cell response against WT1-expressing tumor cells. Also, the WT1 released from destroyed ASP7517 is taken up by antigen-presenting cells (APCs), mainly by dendritic cells (DCs), which in turn activates cytotoxic T-lymphocytes (CTL) and results in a CTL-mediated immune response against WT1-expressing tumor cells, thereby further destroying WT1-expressing tumor cells. In addition, the activation of antigen-specific memory T cells provides long-lasting anti-tumor effects against the WT1-expressing tumor cells.	WT1-loaded Artificial Adjuvant Vector Cell Immunotherapeutic ASP7517		Cell|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C16904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16904>	C25464	Netherlands Antilles|NN	A group of islands in the Caribbean, formerly an autonomous Caribbean country within the Kingdom of the Netherlands and now a constituent of the Kingdom.			Geographic Area	
C169050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169050>	C165190|C139002	Recurrent Soft Tissue Sarcoma of the Trunk and Extremities	The reemergence of a soft tissue sarcoma of the trunk and extremities after a period of remission.	Recurrent Soft Tissue Sarcoma of the Trunk and Extremities		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C169051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169051>	C201492|C200766	Autologous Anti-B7-H3 CAR Retroviral Vector-transduced T Cells|Autologous B7-H3 CAR-retroviral Vector-transduced T Cells|Autologous B7-H3-targeting CAR T Cells	A preparation of autologous T-lymphocytes that have been transduced with a retroviral vector expressing a chimeric antigen receptor (CAR) targeting the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) and containing, as of yet undisclosed co-stimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon infusion back into the patient, autologous anti-B7-H3 CAR retroviral vector-transduced T cells target and bind to B7-H3-expressing tumor cells, thereby inducing selective toxicity in B7-H3-expressing tumor cells. B7-H3, a type I transmembrane protein and a member of the B7 co-stimulatory protein superfamily, is overexpressed on certain tumor cell types and on various immune cells. It is a negative regulator of the T-cell activation and its overexpression plays a key role in tumor cell invasion and metastasis.			Cell|Pharmacologic Substance	NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C169052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169052>	C198634|C192997	Ensomafusp Alfa|CD19-4-1BBL RO7227166|CD19-targeted 4-1BB Ligand RO7227166|ENGLUMAFUSP ALFA|RG 6076|RG-6076|RG6076|RO 7227166|RO-7227166|RO7227166	An immunotherapeutic agent that targets both CD19 and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential immunostimulatory and antineoplastic activity. Upon administration, ensomafusp alfa simultaneously binds to CD19 and 4-1BB, thereby crosslinking CD19 and 4-1BB positive cells. This triggers, through the 4-1BB ligand, the proliferation and activation of natural killer cells (NKs) and T-cells. This results in an enhanced cytotoxic T-lymphocyte (CTL)-mediated immune response against CD19-expressing tumor cells. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily (TNFRSF), is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.	Ensomafusp Alfa		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C169053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169053>	C226341|C201282|C129822	Anti-PSMA/CD3 Bispecific Antibody CCW702|CCW 702|CCW-702|CCW702	A bispecific antibody that targets both the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA) and the CD3 antigen found on T-lymphocytes, with potential immunostimulatory and antineoplastic activities. Upon administration of anti-PSMA/CD3 bispecific antibody CCW702, this bispecific antibody binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and PSMA found on PSMA-expressing tumor cells. This activates and redirects CTLs to PSMA-expressing tumor cells, which results in the CTL-mediated cell death of PSMA-expressing tumor cells. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.	Anti-PSMA/CD3 Bispecific Antibody CCW702		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C169054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169054>	C97928	STAG2 Protein Variant|Cohesin Subunit SA-2 Protein Variant|SCC3 Homolog 2 Protein Variant|Stromal Antigen 2 Protein Variant	A variation in the amino acid sequence for the cohesin subunit SA-2 protein.			Cell or Molecular Dysfunction	
C169055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169055>	C169054	STAG2 NP_006594.3:p.R1012X|Cohesin Subunit SA-2 Arg1012Xxx|Cohesin Subunit SA-2 R1012X|NP_006594.3:p.Arg1012Xxx|NP_006594.3:p.R1012X|SCC3 Homolog 2 Arg1012Xxx|SCC3 Homolog 2 R1012X|STAG2 Arg1012Xxx|STAG2 NP_006594.3:p.Arg1012Xxx|STAG2 R1012X|STAG2 p.Arg1012Xxx|STAG2 p.R1012X|Stromal Antigen 2 Arg1012Xxx|Stromal Antigen 2 R1012X	A change in the amino acid residue at position 1012 in the cohesin subunit SA-2 protein where arginine has been replaced by another amino acid.			Cell or Molecular Dysfunction	
C169056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169056>	C97927|C136421	STAT5B Gene Mutation|Signal Transducer and Activator of Transcription 5 Gene Mutation	A change in the nucleotide sequence of the STAT5B gene.			Cell or Molecular Dysfunction	
C169057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169057>	C169056	STAT5B NM_012448.3:c.1924A>C|NM_012448.3:c.1924A>C|STAT5B c.1924A>C|Signal Transducer and Activator of Transcription 5B c.1924A>C	A nucleotide substitution at position 1924 of the coding sequence of the STAT5B gene where adenine has been mutated to cytosine.			Cell or Molecular Dysfunction	
C169058	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169058>	C97928	STAT5B Protein Variant|Signal Transducer and Activator of Transcription 5B Protein Variant	A variation in the amino acid sequence for the signal transducer and activator of transcription 5B protein.			Cell or Molecular Dysfunction	
C169059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169059>	C169058	STAT5B NP_036580.2:p.N642H|NP_036580.2:p.Asn642His|NP_036580.2:p.N642H|STAT5B Asn642His|STAT5B N642H|STAT5B NP_036580.2:p.Asn642His|STAT5B p.Asn642His|STAT5B p.N642H|Signal Transducer and Activator of Transcription 5B Asn642His|Signal Transducer and Activator of Transcription 5B N642H	A change in the amino acid residue at position 642 in the signal transducer and activator of transcription 5B protein where asparagine has been replaced by histidine.			Cell or Molecular Dysfunction	
C16905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16905>	C16912|C16287	Neuroanatomy	A branch of medicine concerned with the anatomy of the nervous system.			Biomedical Occupation or Discipline	
C169060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169060>	C2160	LMP7 Inhibitor M3258|Immunoproteasome Inhibitor M3258|M 3258|M-3258|M-3258|M3258	An orally bioavailable, potent, selective, reversible inhibitor of the large multifunctional peptidase 7 (LMP7, Beta5i, PSMB8), a chymotrypsin-like, proteolytic subunit of the immunoproteasome, with potential antineoplastic activity. Upon oral administration, LMP7 inhibitor M3258 targets and inhibits the proteolytic activity of the LMP7 subunit of immunoproteasome, thereby blocking its deubiquitylating activity. This blocks the ubiquitin proteasome degradation pathway, prevents the degradation of defective proteins, and leads to an accumulation of poly-ubiquitylated proteins. This induces the unfolded protein response (UPR) and results in both the induction of tumor cell apoptosis and the inhibition of tumor cell growth. Proteasomes are large multi-subunit protease complexes that degrade unneeded or damaged proteins that have been ubiquitinated, thereby restoring protein homeostasis. Unlike the constitutive proteasome, which is expressed in most tissues, immunoproteasome is specifically present in normal and malignant hematopoietic cells, including multiple myeloma. Immunoproteasome degrades ubiquitinated proteins, generates peptides for presentation on MHC class I, and plays a key role in the adaptive immune response and inflammatory diseases.	LMP7 Inhibitor M3258		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C169061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169061>	C169058	STAT5B NP_036580.2:p.N713_A714insKGKGGG|NP_036580.2:p.Asn713_Ala714insLysGlyLysGlyGlyGly|NP_036580.2:p.N713_A714insKGKGGG|STAT5B Asn713_Ala714insLysGlyLysGlyGlyGly|STAT5B N713_A714insKGKGGG|STAT5B NP_036580.2:p.Asn713_Ala714insLysGlyLysGlyGlyGly|STAT5B p.Asn713_Ala714insLysGlyLysGlyGlyGly|STAT5B p.N713_A714insKGKGGG|Signal Transducer and Activator of Transcription 5B Asn713_Ala714insLysGlyLysGlyGlyGly|Signal Transducer and Activator of Transcription 5B N713_A714insKGKGGG	An insertion of the amino acid sequence lysine-glycine-lysine-glycine-glycine-glycine between the asparagine at position 713 and the alanine at position 714 of the signal transducer and activator of transcription 5B protein..			Cell or Molecular Dysfunction	
C169062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169062>	C133463	ALK NP_004295.2:p.G159 Frameshift|ALK G159fs|ALK Gly159fs|ALK NP_004295.2:p.G159fs|ALK NP_004295.2:p.Gly159fs|ALK Tyrosine Kinase Receptor G159fs|ALK Tyrosine Kinase Receptor Gly159fs|ALK p.G159fs|ALK p.Gly159fs|Anaplastic Lymphoma Kinase G159fs|Anaplastic Lymphoma Kinase Gly159fs|CD246 Antigen G159fs|CD246 Antigen Gly159fs|NP_004295.2:p.G159fs|NP_004295.2:p.Gly159fs	A change in the amino acid composition at position 159 in the ALK tyrosine kinase receptor protein where a frameshift mutation results in the substitution of the glycine with one or more non-canonical amino acids followed by a stop codon.			Cell or Molecular Dysfunction	
C169063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169063>	C308|C208255	CD80-Fc Fusion Protein FPT155|FPT 155|FPT-155|FPT-155|FPT155	A recombinant fusion protein composed of the extracellular domain (ECD) of human CD80 (B7.1) fused to a human immunoglobulin G1 (IgG1) Fc fragment, with potential immunostimulatory, immune checkpoint inhibitory and antineoplastic activities. Upon administration of CD80-Fc fusion protein FPT155, the CD80 moiety targets and binds to CD28, which in the presence of antigenic T-cell receptor (TCR) signaling, leads to the co-stimulation of T-cell responses including the activation of naïve and memory T-cells. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells, thereby killing cancer cells. FPT155 also targets and binds to CTL-associated antigen 4 (CTLA4; CTLA-4), preventing the binding of CTLA-4 to endogenous CD80, thereby enabling CD80-CD28 engagement, CD28 signaling, and T-cell activation in the tumor microenvironment. CD80 is a co-stimulatory molecule expressed on activated antigen presenting cells that plays a key role in T-cell activation upon binding to CD28 on T-cells. On the other hand, binding of CD80 to CTLA-4 prevents CD80-CD28 engagement, thereby inhibiting T-cell activity and immune activation. CTLA-4 is a member of the immunoglobulin superfamily (IgSF) and an inhibitory molecule upregulated by T-cells following T-cell activation. It plays a key role in the downregulation of the immune system.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C169064	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169064>	C97927|C141240	TEK Gene Mutation|CD202b Gene Mutation|TEK Receptor Tyrosine Kinase Gene Mutation|TIE-2 Gene Mutation|TIE2 Gene Mutation	A change in the nucleotide sequence of the TEK gene.	TEK Gene Mutation		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C169065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169065>	C97928	TEK Protein Variant|Angiopoietin-1 Receptor Protein Variant|CD202b Protein Variant|Endothelial Tyrosine Kinase Protein Variant|Tunica Interna Endothelial Cell Kinase Protein Variant|Tyrosine Kinase with Ig and EGF Homology Domains-2 Protein Variant|Tyrosine-Protein Kinase Receptor TEK Protein Variant|Tyrosine-Protein Kinase Receptor TIE-2 Protein Variant	A variation in the amino acid sequence for the angiopoietin-1 receptor protein.			Cell or Molecular Dysfunction	
C169066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169066>	C169065	TEK NP_000450.2:p.N452D|Angiopoietin-1 Receptor Asn452Asp|Angiopoietin-1 Receptor N452D|CD202b Asn452Asp|CD202b N452D|Endothelial Tyrosine Kinase Asn452Asp|Endothelial Tyrosine Kinase N452D|NP_000450.2:p.Asn452Asp|NP_000450.2:p.N452D|TEK Asn452Asp|TEK N452D|TEK NP_000450.2:p.Asn452Asp|TEK p.Asn452Asp|TEK p.N452D|Tunica Interna Endothelial Cell Kinase Asn452Asp|Tunica Interna Endothelial Cell Kinase N452D|Tyrosine Kinase with Ig and EGF Homology Domains-2 Asn452Asp|Tyrosine Kinase with Ig and EGF Homology Domains-2 N452D|Tyrosine-Protein Kinase Receptor TEK Asn452Asp|Tyrosine-Protein Kinase Receptor TEK N452D|Tyrosine-Protein Kinase Receptor TIE-2 Asn452Asp|Tyrosine-Protein Kinase Receptor TIE-2 N452D	A change in the amino acid residue at position 452 in the angiopoietin-1 receptor protein where asparagine has been replaced by aspartic acid.			Cell or Molecular Dysfunction	
C169067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169067>	C97927	TLR8 Gene Mutation|CD288 Gene Mutation|Toll Like Receptor 8 Gene Mutation	A change in the nucleotide sequence of the TLR8 gene.			Cell or Molecular Dysfunction	
C169068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169068>	C97928	TLR8 Protein Variant|CD288 Protein Variant|Toll-Like Receptor 8 Protein Variant	A variation in the amino acid sequence for the toll-like receptor 8 protein.			Cell or Molecular Dysfunction	
C169069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169069>	C169068	TLR8 NP_619542.1:p.N515H|CD288 Asn515His|CD288 N515H|NP_619542.1:p.Asn515His|NP_619542.1:p.N515H|TLR8 Asn515His|TLR8 N515H|TLR8 NP_619542.1:p.Asn515His|TLR8 p.Asn515His|TLR8 p.N515H|Toll-Like Receptor 8 Asn515His|Toll-Like Receptor 8 N515H	A change in the amino acid residue at position 515 in the toll-like receptor 8 protein where asparagine has been replaced by histidine.			Cell or Molecular Dysfunction	
C16906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16906>	C16912	Neurochemistry	A branch of neurology concerned with the chemistry of the nervous system.			Biomedical Occupation or Discipline	
C169070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169070>	C97927	TOP2A Gene Mutation|DNA Topoisomerase II Alpha Gene Mutation|TOP2 Gene Mutation|TP2A Gene Mutation	A change in the nucleotide sequence of the TOP2A gene.			Cell or Molecular Dysfunction	
C169071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169071>	C97928	TOP2A Protein Variant|DNA Topoisomerase 2-Alpha Protein Variant|DNA Topoisomerase II, Alpha Isozyme Protein Variant	A variation in the amino acid sequence for the DNA topoisomerase 2-alpha protein.			Cell or Molecular Dysfunction	
C169072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169072>	C169071	TOP2A NP_001058.2:p.A1515S|DNA Topoisomerase 2-Alpha A1515S|DNA Topoisomerase 2-Alpha Ala1515Ser|DNA Topoisomerase II, Alpha Isozyme A1515S|DNA Topoisomerase II, Alpha Isozyme Ala1515Ser|NP_001058.2:p.A1515S|NP_001058.2:p.Ala1515Ser|TOP2A A1515S|TOP2A Ala1515Ser|TOP2A NP_001058.2:p.Ala1515Ser|TOP2A p.A1515S|TOP2A p.Ala1515Ser	A change in the amino acid residue at position 1515 in the  DNA topoisomerase 2-alpha protein where alanine has been replaced by serine.			Cell or Molecular Dysfunction	
C169073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169073>	C169071	TOP2A NP_001058.2:p.G1386D|DNA Topoisomerase 2-Alpha G1386D|DNA Topoisomerase 2-Alpha Gly1386Asp|DNA Topoisomerase II, Alpha Isozyme G1386D|DNA Topoisomerase II, Alpha Isozyme Gly1386Asp|NP_001058.2:p.G1386D|NP_001058.2:p.Gly1386Asp|TOP2A G1386D|TOP2A Gly1386Asp|TOP2A NP_001058.2:p.Gly1386Asp|TOP2A p.G1386D|TOP2A p.Gly1386Asp	A change in the amino acid residue at position 1386 in the DNA topoisomerase 2-alpha protein where glycine has been replaced by aspartic acid.			Cell or Molecular Dysfunction	
C169074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169074>	C4326|C153865	Refractory Anaplastic Oligodendroglioma	An anaplastic oligodendroglioma that is resistant to treatment.	Refractory Anaplastic Oligodendroglioma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C169075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169075>	C9477|C216102|C153865	Refractory Anaplastic Astrocytoma	An anaplastic astrocytoma that is resistant to treatment.	Refractory Anaplastic Astrocytoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C169076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169076>	C113207	SARS Coronavirus 2|2019 Novel Coronavirus|2019-nCoV|2019-nCoV|COVID-19 Virus|COVID-19 Virus|HCoV-19|Human Coronavirus 2019|Novel Coronavirus|SARS-2|SARS-CoV-2|SARS-CoV-2|SARS2|SARS2|SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2|Severe Acute Respiratory Syndrome Coronavirus 2|nCoV	A positive-sense single-stranded RNA virus in the genus Betacoronavirus. It is the causative agent of the 2019-2020 severe acute respiratory syndrome outbreak.	SARS Coronavirus 2		Virus	CDISC SDTM Microorganism Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Biomarker Terminology|CTRP Terminology|NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology
C169077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169077>	C36291	Dietary Intake Finding	A finding related to the food and liquid consumed by an individual.			Finding	
C169078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169078>	C175689	TP53 NM_000546.5:c.396G>C|LFS1 c.396G>C|Li-Fraumeni Syndrome c.396G>C|NM_000546.5:c.396G>C|P53 c.396G>C|TP53 c.396G>C|Tumor Protein p53 c.396G>C	A nucleotide substitution at position 396 of the coding sequence of the TP53 gene where guanine has been mutated to cytosine.	TP53 NM_000546.5:c.396G>C		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C169079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169079>	C146884	TP53 NP_000537.3:p.K132N|Antigen NY-CO-13 K132N|Antigen NY-CO-13 Lys132Asn|Cellular Tumor Antigen p53 K132N|Cellular Tumor Antigen p53 Lys132Asn|NP_000537.3:p.K132N|NP_000537.3:p.Lys132Asn|TP53 K132N|TP53 K132N Mutation|TP53 Lys132Asn|TP53 NP_000537.3:p.Lys132Asn|TP53 p.K132N|TP53 p.Lys132Asn|Transformation-Related Protein 53 K132N|Transformation-Related Protein 53 Lys132Asn|Tumor Protein p53 K132N|Tumor Protein p53 Lys132Asn|Tumor Suppressor p53 K132N|Tumor Suppressor p53 Lys132Asn	A change in the amino acid residue at position 132 in the cellular tumor antigen p53 protein where lysine has been replaced by asparagine.	TP53 NP_000537.3:p.K132N		Cell or Molecular Dysfunction	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C16907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16907>	C16912|C16543	Neuroendocrinology	The study of how the nervous and endocrine systems act together to regulate each other and physiological processes throughout the body.			Biomedical Occupation or Discipline	
C169080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169080>	C146884	TP53 NP_000537.3:p.G302 Frameshift|Antigen NY-CO-13 G302fs|Antigen NY-CO-13 Gly302fs|Cellular Tumor Antigen p53 G302fs|Cellular Tumor Antigen p53 Gly302fs|NP_000537.3:p.G302fs|NP_000537.3:p.Gly302fs|TP53 G302fs|TP53 Gly302fs|TP53 NP_000537.3:p.G302fs|TP53 NP_000537.3:p.Gly302fs|TP53 p.G302fs|TP53 p.Gly302fs|Transformation-Related Protein 53 G302fs|Transformation-Related Protein 53 Gly302fs|Tumor Protein p53 G302fs|Tumor Protein p53 Gly302fs|Tumor Suppressor p53 G302fs|Tumor Suppressor p53 Gly302fs	A change in the amino acid composition at position 302 of the cellular tumor antigen p53 protein where a frameshift mutation results in the substitution of the glycine with one or more non-canonical amino acids followed by a stop codon.			Cell or Molecular Dysfunction	
C169081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169081>	C175689	TP53 NM_000546.5:c.1010G>A|LFS1 c.1010G>A|Li-Fraumeni Syndrome c.1010G>A|NM_000546.5:c.1010G>A|P53 c.1010G>A|TP53 c.1010G>A|Tumor Protein p53 c.1010G>A	A nucleotide substitution at position 1010 of the coding sequence of the TP53 gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C169082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169082>	C146884	TP53 NP_000537.3:p.R337H|Antigen NY-CO-13 Arg337His|Antigen NY-CO-13 R337H|Cellular Tumor Antigen p53 Arg337His|Cellular Tumor Antigen p53 R337H|NP_000537.3:p.Arg337His|NP_000537.3:p.R337H|TP53 Arg337His|TP53 NP_000537.3:p.Arg337His|TP53 R337H|TP53 p.Arg337His|TP53 p.R337H|Transformation-Related Protein 53 Arg337His|Transformation-Related Protein 53 R337H|Tumor Protein p53 Arg337His|Tumor Protein p53 R337H|Tumor Suppressor p53 Arg337His|Tumor Suppressor p53 R337H	A change in the amino acid residue at position 337 in the cellular tumor antigen p53 protein where arginine has been replaced by histidine.			Cell or Molecular Dysfunction	
C169083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169083>	C175689	TP53 NM_000546.5:c.638G>A|LFS1 c.638G>A|Li-Fraumeni Syndrome c.638G>A|NM_000546.5:c.638G>A|P53 c.638G>A|TP53 c.638G>A|Tumor Protein p53 c.638G>A	A nucleotide substitution at position 638 of the coding sequence of the TP53 gene where guanine has been mutated to adenine.			Cell or Molecular Dysfunction	
C169084	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169084>	C146884	TP53 NP_000537.3:p.R213Q|Antigen NY-CO-13 Arg213Gln|Antigen NY-CO-13 R213Q|Cellular Tumor Antigen p53 Arg213Gln|Cellular Tumor Antigen p53 R213Q|NP_000537.3:p.Arg213Gln|NP_000537.3:p.R213Q|TP53 Arg213Gln|TP53 NP_000537.3:p.Arg213Gln|TP53 R213Q|TP53 p.Arg213Gln|TP53 p.R213Q|Transformation-Related Protein 53 Arg213Gln|Transformation-Related Protein 53 R213Q|Tumor Protein p53 Arg213Gln|Tumor Protein p53 R213Q|Tumor Suppressor p53 Arg213Gln|Tumor Suppressor p53 R213Q	A change in the amino acid residue at position 213 in the cellular tumor antigen p53 protein where arginine has been replaced by glutamine.			Cell or Molecular Dysfunction	
C169085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169085>	C4561|C148514	Metastatic Choroid Melanoma	A choroid melanoma that has spread from its original site of growth to another anatomic site.	Metastatic Choroid Melanoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C169086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169086>	C7092|C114828	Metastatic Mucosal Melanoma	Mucosal melanoma that has spread from its primary site to another anatomic site.	Metastatic Mucosal Melanoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C169087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169087>	C175689	TP53 NM_000546.5:c.815T>C|LFS1 c.815T>C|Li-Fraumeni Syndrome c.815T>C|NM_000546.5:c.815T>C|P53 c.815T>C|TP53 c.815T>C|Tumor Protein p53 c.815T>C	A nucleotide substitution at position 815 of the coding sequence of the TP53 gene where thymine has been mutated to cytosine.			Cell or Molecular Dysfunction	
C169088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169088>	C146884	TP53 NP_000537.3:p.V272A|Antigen NY-CO-13 V272A|Antigen NY-CO-13 Val272Ala|Cellular Tumor Antigen p53 V272A|Cellular Tumor Antigen p53 Val272Ala|NP_000537.3:p.V272A|NP_000537.3:p.Val272Ala|TP53 NP_000537.3:p.Val272Ala|TP53 V272A|TP53 Val272Ala|TP53 p.V272A|TP53 p.Val272Ala|Transformation-Related Protein 53 V272A|Transformation-Related Protein 53 Val272Ala|Tumor Protein p53 V272A|Tumor Protein p53 Val272Ala|Tumor Suppressor p53 V272A|Tumor Suppressor p53 Val272Ala	A change in the amino acid residue at position 272 in the cellular tumor antigen p53 protein where valine has been replaced by alanine.			Cell or Molecular Dysfunction	
C169089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169089>	C97927|C131783	XPC Gene Mutation|RAD4 Gene Mutation|XP3 Gene Mutation|XPC Complex Subunit, DNA Damage Recognition and Repair Factor Gene Mutation|XPCC Gene Mutation|Xeroderma Pigmentosum, Complementation Group C Gene Mutation	A change in the nucleotide sequence of the XPC gene.			Cell or Molecular Dysfunction	
C16908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16908>	C17153	Neurology	A branch of medicine concerned with the development, anatomy, function, and dysfunction of the nervous system.			Biomedical Occupation or Discipline	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C169090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169090>	C97928	XPC Protein Variant|DNA Repair Protein Complementing XP-C Cells Protein Variant|Xeroderma Pigmentosum Group C Protein Variant	A variation in the amino acid sequence for the DNA repair protein complementing XP-C cells.			Cell or Molecular Dysfunction	
C169091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169091>	C169090	XPC NP_004619.3:p.S346P|DNA Repair Protein Complementing XP-C Cells S346P|DNA Repair Protein Complementing XP-C Cells Ser346Pro|NP_004619.3:p.S346P|NP_004619.3:p.Ser346Pro|XPC NP_004619.3:p.Ser346Pro|XPC S346P|XPC Ser346Pro|XPC p.S346P|XPC p.Ser346Pro|Xeroderma Pigmentosum Group C Protein S346P|Xeroderma Pigmentosum Group C Protein Ser346Pro	A change in the amino acid residue at position 346 in the DNA repair protein complementing XP-C cells where serine has been replaced by proline.			Cell or Molecular Dysfunction	
C169092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169092>	C97928	FLT4 Protein Variant|FMS-Like Tyrosine Kinase 4 Protein Variant|FMS-Related Tyrosine Kinase 4 Protein Variant|Tyrosine-Protein Kinase Receptor FLT4 Protein Variant|VEGFR-3 Protein Variant|VEGFR3 Protein Variant|Vascular Endothelial Growth Factor Receptor 3 Protein Variant	A variation in the amino acid sequence for the vascular endothelial growth factor receptor 3 protein.			Cell or Molecular Dysfunction	
C169093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169093>	C169092	FLT4 NP_891555.2:p.A992 Frameshift|FLT4 A992fs|FLT4 Ala992fs|FLT4 NP_891555.2:p.A992fs|FLT4 NP_891555.2:p.Ala992fs|FLT4 p.A992fs|FLT4 p.Ala992fs|FMS-Like Tyrosine Kinase 4 A992fs|FMS-Like Tyrosine Kinase 4 Ala992fs|FMS-Related Tyrosine Kinase 4 A992fs|FMS-Related Tyrosine Kinase 4 Ala992fs|NP_891555.2:p.A992fs|NP_891555.2:p.Ala992fs|Tyrosine-Protein Kinase Receptor FLT4 A992fs|Tyrosine-Protein Kinase Receptor FLT4 Ala992fs|VEGFR-3 A992fs|VEGFR-3 Ala992fs|VEGFR3 A992fs|VEGFR3 Ala992fs|Vascular Endothelial Growth Factor Receptor 3 A992fs|Vascular Endothelial Growth Factor Receptor 3 Ala992fs	A change in the amino acid composition at position 992 in the vascular endothelial growth factor receptor 3 protein where a frameshift mutation results in the substitution of the alanine with one or more non-canonical amino acids followed by a stop codon.			Cell or Molecular Dysfunction	
C169094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169094>	C97928	MED12 Protein Variant|ARC240 Protein Variant|Activator-Recruited Cofactor 240 kDa Component Protein Variant|CAG Repeat Protein 45 Protein Variant|Mediator Complex Subunit 12 Protein Variant|Mediator of RNA Polymerase II Transcription Subunit 12 Protein Variant|OPA-Containing Protein Variant|Thyroid Hormone Receptor-Associated Protein Complex 230 kDa Component Protein Variant|Trap230 Protein Variant|Trinucleotide Repeat-Containing Gene 11 Protein Variant	A variation in the amino acid sequence for the mediator of RNA polymerase II transcription subunit 12 protein.			Cell or Molecular Dysfunction	
C169095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169095>	C169094	MED12 NP_891555.2:p.S672 Frameshift|ARC240 S672fs|ARC240 Ser672fs|Activator-Recruited Cofactor 240 kDa Component S672fs|Activator-Recruited Cofactor 240 kDa Component Ser672fs|CAG Repeat Protein 45 S672fs|CAG Repeat Protein 45 Ser672fs|MED12 NP_891555.2:p.S672fs|MED12 NP_891555.2:p.Ser672fs|MED12 S672fs|MED12 Ser672fs|MED12 p.S672fs|MED12 p.Ser672fs|Mediator Complex Subunit 12 S672fs|Mediator Complex Subunit 12 Ser672fs|Mediator of RNA Polymerase II Transcription Subunit 12 S672fs|Mediator of RNA Polymerase II Transcription Subunit 12 Ser672fs|NP_891555.2:p.S672fs|NP_891555.2:p.Ser672fs|OPA-Containing Protein S672fs|OPA-Containing Protein Ser672fs|Thyroid Hormone Receptor-Associated Protein Complex 230 kDa Component S672fs|Thyroid Hormone Receptor-Associated Protein Complex 230 kDa Component Ser672fs|Trap230 S672fs|Trap230 Ser672fs|Trinucleotide Repeat-Containing Gene 11 Protein S672fs|Trinucleotide Repeat-Containing Gene 11 Protein Ser672fs	A change in the amino acid composition at position 672 in the mediator of RNA polymerase II transcription subunit 12 protein where a frameshift mutation results in the substitution of the serine with one or more non-canonical amino acids followed by a stop codon.			Cell or Molecular Dysfunction	
C169096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169096>	C97928	MUTYH Protein Variant|A/G-Specific Adenine DNA Glycosylase Protein Variant|Adenine DNA Glycosylase Protein Variant|MutY Homolog Protein Variant|MutY-Like Protein Variant	A variation in the amino acid sequence for the adenine DNA glycosylase protein.			Cell or Molecular Dysfunction	
C169097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169097>	C169096	MUTYH NP_001280119.1:p.Q338H|A/G-Specific Adenine DNA Glycosylase Gln338His|A/G-Specific Adenine DNA Glycosylase Q338H|Adenine DNA Glycosylase Gln338His|Adenine DNA Glycosylase Q338H|MUTYH Gln338His|MUTYH NP_001280119.1:p.Gln338His|MUTYH Q338H|MUTYH p.Gln338His|MUTYH p.Q338H|MutY Homolog Gln338His|MutY Homolog Q338H|MutY-Like Protein Gln338His|MutY-Like Protein Q338H|NP_001041639.1:p.Gln323His|NP_001041639.1:p.Q323H|NP_001280119.1:p.Gln338His|NP_001280119.1:p.Q338H	A change in the amino acid residue at position 338 in the adenine DNA glycosylase protein where glutamine has been replaced by histidine.			Cell or Molecular Dysfunction	
C169099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169099>	C168995|C162768	Locally Advanced Clear Cell Renal Cell Carcinoma	A clear cell renal cell carcinoma that has spread to nearby tissues or lymph nodes.	Locally Advanced Clear Cell Renal Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C16909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16909>	C16974	Neuropharmacology	A branch of pharmacology concerned with the effects of drugs on the nervous system.			Biomedical Occupation or Discipline	
C1690	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1690>	C1663	Sialyl Tn-KLH Vaccine|STn-KLH Vaccine|Sialyl Tn-KLH|Theratope|Theratope STn-KLH Vaccine|Theratope Vaccine|Theratope siayl-Tn-KLH vaccine|sialyl Tn-KLH	A vaccine containing a pancarcinoma carbohydrate antigen conjugated with keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Sialylated Tn antigen (sTn) is a monosaccharide glycan usually O-linked to serine or threonine residues of mucins found on most epithelial cancers. Conjugation with KLH, a hapten carrier and an immunostimulant, improves host immune responses. Vaccination with sTn-KLH vaccine may produce antibodies and elicit a cytotoxic T lymphocyte (CTL) response against those tumor cells expressing sTn, resulting in decreased tumor growth.	Sialyl Tn-KLH Vaccine		Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C169100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169100>	C3377|C3372	Skin Soft Tissue Neoplasm	A mesenchymal neoplasm that arises from the skin.			Neoplastic Process	
C169101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169101>	C20644|C161405	High Resolution Peripheral Quantitative Computed Tomography|HR-pQCT|High-Resolution Peripheral Quantitative Computed Tomography	A non-invasive, low-radiation method for assessing bone microarchitecture and volumetric bone mineral density.	High Resolution Peripheral Quantitative Computed Tomography		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C169102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169102>	C9161|C208295|C162652	Recurrent Anal Squamous Cell Carcinoma	The reemergence of anal squamous cell carcinoma after a period of remission.	Recurrent Anal Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C169103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169103>	C9161|C4104|C170514	Metastatic Anal Squamous Cell Carcinoma	Anal squamous cell carcinoma that has spread from its primary site to another anatomic site.	Metastatic Anal Squamous Cell Carcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C169104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169104>	C2866	Alzheimer's Disease 17|AD17|Alzheimer Disease 17	A form of Alzheimer's disease associated with mutation(s) in the TREM2 gene, encoding triggering receptor expressed on myeloid cells 2.			Mental or Behavioral Dysfunction	Cellosaurus Disease Terminology
C169105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169105>	C129820	Amezalpat|AMEZALPAT|PPAR Alpha Antagonist TPST-1120|PPARA Antagonist TPST-1120|PPARalpha Antagonist TPST-1120|Peroxisome Proliferator Activated Receptor Alpha Antagonist TPST-1120|TPST 1120|TPST-1120|TPST1120	An orally bioavailable, small molecule, selective and competitive antagonist of peroxisome proliferator activated receptor alpha (PPARa), with potential immunomodulating and antineoplastic activities. Upon oral administration, amezalpat targets, binds to and blocks the activity of PPARa, thereby blocking transcription of PPARa target genes leading to an intracellular metabolism shift from fatty acid oxidation (FAO) to glycolysis in FAO-dependent tumors and reducing the production of fatty acids in the tumor microenvironment (TME). As fatty acids are essential for tumor cell growth in FAO-dependent tumor cells and are needed for the metabolism of suppressive immune cells in the TME, including regulatory T-cells (Tregs), reducing the amount of fatty acids leads to a direct killing of FAO-dependent tumor cells. It also skews macrophages from the immune suppressive M2 phenotype to an effector M1 phenotype and facilitates the cytotoxicity of immune effector cells, thereby stimulating an anti-tumor immune response and further killing tumor cells. Amezalpat also restores the natural inhibitor of angiogenesis thrombospondin-1 (TSP-1) and stimulator of interferon genes (STING) in the TME. PPARa, a ligand-activated nuclear transcription factor and metabolic checkpoint, regulates the expression of FAO genes and lipid metabolism. It plays a key role in immunosuppression in the TME. FAO is a metabolic pathway essential to tumor growth, survival and immunosuppression.	Amezalpat		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C169106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169106>	C198567	Environmental DNA|eDNA	DNA obtained directly from environmental samples (soil, sediment, water, etc.) without any obvious signs of biological source material. It originates from cellular material shed by organisms (via skin, excrement, etc.) into aquatic or terrestrial environments.			Body Substance	
C169107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169107>	C3182|C208355	Recurrent Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA|Recurrent Acute Promyelocytic Leukemia with PML-RARA|Recurrent Acute Promyelocytic Leukemia with PML-RARA Fusion|Recurrent Acute Promyelocytic Leukemia with PML::RARA|Recurrent Acute Promyelocytic Leukemia with PML::RARA Fusion|Recurrent Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA Fusion|Recurrent Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML::RARA|Recurrent Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML::RARA Fusion	The reemergence of acute promyelocytic leukemia with t(15;17)(q24.1;q21.2); PML-RARA after a period of remission.			Neoplastic Process	
C169108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169108>	C27323|C27322|C210620	Resectable Periampullary Adenocarcinoma	A periampullary adenocarcinoma that is amenable to surgical removal.	Resectable Periampullary Adenocarcinoma		Neoplastic Process	CTRP Disease Terminology|CTRP Terminology
C169109	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169109>	C134971	AIDS-Related Kaposi Sarcoma T0 (Good Risk): Skin and/or Lymph Nodes|AIDS-Related Kaposi Sarcoma T0: Skin and/or Lymph Nodes|Stage 0 - Skin and/or Lymph Nodes	AIDS-related Kaposi sarcoma localized in the skin and/or the lymph nodes. This stage is associated with good risk of recovery.			Classification	
C16910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16910>	C16990|C16912	Neurophysiology	A branch of neuroscience concerned with the physiology of the nervous system.			Biomedical Occupation or Discipline	
C169110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169110>	C134971	AIDS-Related Kaposi Sarcoma T0 (Good Risk): Minimal Oral Disease|AIDS-Related Kaposi Sarcoma T0: Minimal Oral Disease|Stage 0 - Minimal Oral Disease	AIDS-related Kaposi sarcoma localized on the palate. The lesions are small and flat rather than raised. This stage is associated with good risk of recovery.			Classification	
C169111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169111>	C36284	Left-Sided Breast Carcinoma	A finding of carcinoma arising from the left breast.	Left-Sided Breast Carcinoma		Finding	CTRP Disease Terminology|CTRP Terminology
C169112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169112>	C63358	Capecitabine/Neratinib Regimen|Capecitabine and Neratinib|Capecitabine-Neratinib|Capecitabine/Neratinib|Capecitabine/Nerlynx|Neratinib-Capecitabine|Neratinib/Capecitabine|Neratinib/Capecitabine Regimen|Nerlynx-Capecitabine	A regimen consisting of capecitabine and neratinib that may be used in the treatment of advanced or metastatic HER2-positive breast cancer.			Therapeutic or Preventive Procedure	HemOnc Regimen Terminology|Multi-agent Therapeutic Regimens|Pharmacotherapy Regimens
C16911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16911>	C16912	Neuropsychology|neuropsychology	The study of how the physiology of the brain and central nervous system are related to behavior.			Biomedical Occupation or Discipline	
C16912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16912>	C16344	Neurosciences	The disciplines concerned with the study of the nervous system.			Biomedical Occupation or Discipline	
C16913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16913>	C25464	New Caledonia|540|NC|NCL|NCL|NEW CALEDONIA|NEW CALEDONIA	A country in the Pacific, comprised of islands in the South Pacific Ocean, east of Australia.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16914>	C25464	New Zealand|554|NEW ZEALAND|NEW ZEALAND|NZ|NZL|NZL	A country in the Pacific, comprised of islands in the South Pacific Ocean, southeast of Australia.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CRF1 Registration Table|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16915>	C25464	Nicaragua|558|NI|NIC|NIC|NICARAGUA|NICARAGUA	A country in Central America, bordering both the Caribbean Sea and the North Pacific Ocean, between Costa Rica and Honduras.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16916>	C25464	Niger|562|NE|NER|NER|NIGER|NIGER	A country in western Africa, southeast of Algeria and north of Nigeria.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16917>	C25464	Nigeria|566|NG|NGA|NGA|NIGERIA|NIGERIA	A country in western Africa, bordering the Gulf of Guinea, between Benin and Cameroon.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16918>	C25464	Niue|570|NIU|NIU|NIUE|NIUE|NU	A country in the Pacific, occupying an island in the South Pacific Ocean, east of Tonga and south of American Samoa.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16919>	C25464	Norfolk Island|574|NF|NFK|NFK|NORFOLK ISLAND|NORFOLK ISLAND	A country in the Pacific, occupying an island in the South Pacific Ocean, east of Australia and between New Caledonia and New Zealand.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Geopolitical Entities, Names, and Codes Terminology
C1691	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1691>	C2115	Trabectedin|ET 743|ET-743|ET-743|ET743|Ecteinascidin|Ecteinascidin 743|Ecteinascidin 743|Spiro(6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo(7,8)isoquino(3,2,-b)(3)benzazocine-20,1'(2'H)-isoquinolin)-19-one, 3',4',6,6a,7,13,14,16-Octahydro-5-(acetyloxy)-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-, (6R-(6-alpha,6a-beta,7-beta,13-beta,14-beta,16-alpha,20R*))-|TRABECTEDIN|Yondelis|Yondelis|ecteinascidin 743|trabectedin	A tetrahydroisoquinoline alkaloid isolated from the marine tunicate Ecteinascidia turbinata with potential antineoplastic activity. Binding to the minor groove of DNA, trabectedin interferes with the transcription-coupled nucleotide excision repair machinery to induce lethal DNA strand breaks and blocks the cell cycle in the G2 phase.	Trabectedin		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C16920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16920>	C25464	Norway|578|NO|NOR|NOR|NORWAY|NORWAY	A country in northern Europe, bordering the North Sea and the North Atlantic Ocean, west of Sweden.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16921>	C158424	Nuclear Magnetic Resonance|Magnetic Resonance|NMR	A physical phenomenon involving the interaction of atomic nuclei placed in an external magnetic field with an applied electromagnetic field oscillating at a particular frequency. Magnetic conditions within the material are measured by monitoring the radiation absorbed and emitted by the atomic nuclei. It is the underlying principle of Magnetic Resonance Imaging (MRI).			Natural Phenomenon or Process	
C16922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16922>	C17059	Nuclear Medicine|Radiology / Radiation Biology / Nuclear Medicine|Radiology-Nuclear Medicine	Nuclear Medicine is the branch of medicine that uses radioactive materials either to image a patient's body or to destroy diseased cells.			Biomedical Occupation or Discipline	
C16923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16923>	C20030	Nuclear Protein	Proteins that are localized to the nucleus of the cell. These proteins are involved in a variety of cellular regulation functions including transport, gene expression, and cell signaling.			Amino Acid, Peptide, or Protein	
C16924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16924>	C19770	Nucleic Acid Hybridization|Hybridization|Molecular Biology, Molecular Hybridization|NUCLEIC ACID HYBRIDIZATION	Laboratory procedure in which single stranded nucleic acids are allowed to interact so that complexes, or hybrids, are formed by molecules with sufficiently similar, complementary sequences. By this means the degree of sequence identity can be assessed and specific sequences detected. (From Biology-online)			Molecular Biology Research Technique	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16925>	C16984	Nucleotidyltransferase|EC 2.7.7	nucleotidyltransferases. Enzymes (EC class 2.7.7) transferring nucleotide residues (nucleotidyls) from nucleoside di- or triphosphates into dimer or polymer forms. Some nucleotidyltransferases bear specific names (e.g., adenylyltransferases), or trivial names indicating the linkage hydrolyzed in the synthesis (pyrophosphorylases, phosphorylases), or names of the material synthesized (RNA or DNA polymerase).			Amino Acid, Peptide, or Protein|Enzyme	
C16926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16926>	C19199	Nursing|Discipline of Nursing|Nursing Field|Nursing Profession	Nursing encompasses autonomous and collaborative care of individuals of all ages, families, groups and communities, sick or well and in all settings. Nursing includes the promotion of health, prevention of illness, and the care of ill, disabled and dying people. Advocacy, promotion of a safe environment, research, participation in shaping health policy and in patient and health systems management, and education are also key nursing roles. (ICN 2002)			Biomedical Occupation or Discipline	
C16927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16927>	C19199	Nutritional Science|Nutrition	The science of food, the nutrients and other substances contained therein, their action, interaction, and balance in relation to health and disease.			Biomedical Occupation or Discipline	
C16928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16928>	C17153	Obstetrics|Obstetrical	A medical-surgical specialty dealing with the care of a woman and her offspring during pregnancy, childbirth and the puerperium (the period shortly after birth).			Biomedical Occupation or Discipline	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C16929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16929>	C19447	Occupational Exposure|OCCUPATIONAL EXPOSURE|Occupational|Work-related Exposure	The exposure to potentially harmful agents that occurs as a result of one's occupation.			Human-caused Phenomenon or Process	CDISC SDTM Mode of Disease Transmission Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology
C1692	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1692>	C1663	Gastrin Immunotoxin|Anti-Gastrin Therapeutic Vaccine|Anti-gastrin 17|G17DT|G17DT IMMUNOGEN|G17DT Immunogen|Gastrimmune|Neutralize Hormone G17|Neutralizing G17 Hormone	An immunotoxin containing an epitope of human gastrin conjugated to diphtheria toxin, with antineoplastic activity. The gastrin epitope in this vaccine is chemically identical or similar to the endogenous gastrin-17 (G-17), a 17-amino acid peptide hormone that stimulates secretion of gastric acid by the stomach. Diphtheria toxin inhibits protein synthesis via modifying translation elongation factor 2 (EF-2). Vaccination with this immunotoxin may elicit production of antibodies against gastrinoma cells overexpressing gastrin, in addition to the toxic effects on protein synthesis exerted by the diphtheria toxin moiety.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C16930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16930>	C16926	Occupational Health Nursing	Nursing that focuses on observation and assessment of worker's health status with respect to job tasks and hazards, with a goal to recognize and prevent health effects from hazardous exposures and treat workers' injuries or illnesses.			Biomedical Occupation or Discipline	
C16931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16931>	C17153	Occupational Medicine|Occupational or Industrial Medicine	This branch of medicine is concerned with the prevention, diagnosis, and treatment of injuries and illnesses that occur at the workplace or as a result of toxic exposures, stress, or accidents at the workplace. Occupational medicine encompasses issues such as industrial hygiene, safety, pollution control, ergonomics, industrial and agricultural toxicology, disability evaluation, physical rehabilitation, industrial psychology and emergency medicine. (BioTech Life Science Dictionary)			Biomedical Occupation or Discipline	
C16932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16932>	C19015	Odds Ratio|ODDS RATIO|OR|odds ratio|odds ratio|relative odds	The ratio of the odds of an event occurring in one group to the odds of it occurring in another group, or to a sample-based estimate of that ratio.			Quantitative Concept	CDISC MRCT Center Clinical Research Glossary|CDISC SDTM Result Type Response Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology
C16933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16933>	C25464	Oman|512|OM|OMAN|OMAN|OMN|OMN	A country in the Middle East, bordering the Arabian Sea, southeast of Saudi Arabia.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16934>	C20027	Oncoprotein	A general term referring to the gene product of an oncogene.			Amino Acid, Peptide, or Protein	
C16935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16935>	C17254|C16934	Viral Oncogene Protein	Viral proteins that have the potential to cause transformation of the infected cell and may result in carcinogenesis.			Amino Acid, Peptide, or Protein	
C16936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16936>	C19540	Oncogene|Cancer-Promoting Gene|oncogene	A gene that normally directs cell growth. If mutated or overexpressed in a dominant fashion, it can release the cell from normal restraints on growth. It alone or in concert with other changes, converts the cell into a tumor cell. Alterations can be inherited or caused by an environmental exposure to carcinogens.			Gene or Genome	
C16937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16937>	C16926	Oncology Nursing|Oncologic Nursing|Oncological Nursing	Nursing that focuses on treating and caring for people who have cancer.			Biomedical Occupation or Discipline	
C16938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16938>	C16599	Oogenesis	The development of ovum, which are the female germ cells. Oogenesis occurs by meiosis and is essential for the production of mature eggs.			Cell Function	
C16939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16939>	C17153	Ophthalmology|OPHTHALMOLOGY|Ophthalmologic	A medical specialty concerned with the structure and function of the eye and the medical and surgical treatment of its defects and diseases.			Biomedical Occupation or Discipline	CDISC SEND Category for Clinical Observation Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C16940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16940>	C16989	Optics|Optical	The branch of physics that describes the behavior and properties of light and the interaction of light with matter.			Occupation or Discipline	
C16941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16941>	C17201	Organ Culture|Culturing, in vitro Organ|Culturing, in vitro Vertebrate, Organ	The maintenance or growth of tissues, organ primordia, or the parts or whole of an organ in vitro in such a way as to allow differentiation or preservation of the architecture or function.			Laboratory Procedure	
C16942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16942>	C17173	Orthopedics|Orthopedic|Orthopedic Surgery|Orthopedic Surgical Profession	The branch of surgery broadly concerned with the skeletal system (bones and joints).			Biomedical Occupation or Discipline	
C16943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16943>	C17153	Otolaryngology|ENT|Ear, Nose, and Throat|Oto/Rhino/Laryngology|Otorhinolaryngology	A medical specialty concerned with the study and treatment of disorders of the ear, nose, and throat.			Biomedical Occupation or Discipline	
C16944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16944>	C19899	Oxidation|oxidation|oxidize	The process of oxidizing; the addition of oxygen to a compound accompanied by a loss of electrons.			Molecular Function	CBDD Process Terminology|CBDD Terminology
C16945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16945>	C19899	Oxidation/Reduction|Oxidoreduction|Redox	All electron-transfer reactions are considered oxidation/reduction reactions. The substance gaining electrons ("oxidizing agent" or "oxidant") is oxidizing the substance that is losing electrons ("reducing agent" or "reductant"). In the process, the "oxidizing agent" is itself reduced by the "reducing agent."			Molecular Function	
C16946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16946>	C16554	Oxidoreductase|EC 1	The class of all enzymes catalyzing oxidoreduction reactions (EC class 1). The substrate that is oxidized is regarded as a hydrogen donor. The systematic name is based on donor: acceptor oxidoreductase. The recommended name will be dehydrogenase, wherever this is possible; as an alternative, reductase can be used. Oxidase is only used in cases where O2 is the acceptor. (Enzyme Nomenclature, 1992, p9)			Amino Acid, Peptide, or Protein|Enzyme	
C16947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16947>	C16997	Plasminogen Activator Inhibitor 1|Endothelial Plasminogen Activator Inhibitor|Nexin|PAI|PAI-1|PAI1|PLANH1|Plasminogen Activator Inhibitor Type 1|Plasminogen Activator Inhibitor-1|SERPINE1|Serine or Cysteine Proteinase Inhibitor Clade E Member 1|Serpin E1	Plasminogen activator inhibitor 1 (402 aa, ~45 kDa) is encoded by the human SERPINE1 gene. This protein plays a role in both cell adhesion and the modulation of plasmin activity.	Plasminogen Activator Inhibitor 1		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C16948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16948>	C16997	Plasminogen Activator Inhibitor 2|Arginine-Serpin|Monocyte Arg-Serpin|PAI-2|PAI2|PLANH2|Placental Plasminogen Activator Inhibitor|Plasminogen Activator Inhibitor Type II|Plasminogen Activator Inhibitor-2|SERPINB2|Serine or Cysteine Proteinase Inhibitor Clade B Member 2|Serpin B2|Urokinase Inhibitor	Plasminogen activator inhibitor 2 (415 aa, ~47 kDa) is encoded by the human SERPINB2 gene. This protein plays a role in the modulation of both plasmin activation and apoptosis.			Amino Acid, Peptide, or Protein	
C16949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16949>	C25464	Pakistan|586|PAK|PAK|PAKISTAN|PAKISTAN|PK	A country in southern Asia, bordering the Arabian Sea, between India on the east and Iran and Afghanistan on the west and China in the north.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C1694	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1694>	C1975	Bruceanol G	A natural quassinoid agent extracted from Brucea antidysenterica with potential antineoplastic activity that is cytotoxic to certain cancer cell lines. (NCI04)			Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C16950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16950>	C124351	Palpation|PALPATION|palpation	A method of feeling with the hands during a physical examination. The health care provider touches and feels the patient's body to examine the size, consistency, texture, location and tenderness of an organ or body part.			Diagnostic Procedure	ACC/AHA Pediatric and Congenital Cardiology EHR Terminology|CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C16951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16951>	C25464	Panama|591|PA|PAN|PAN|PANAMA|PANAMA	A country in Central America, bordering both the Caribbean Sea and the North Pacific Ocean, between Colombia and Costa Rica.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16952>	C25464	Papua New Guinea|598|PAPUA NEW GUINEA|PAPUA NEW GUINEA|PG|PNG|PNG	A country in southeastern Asia, comprising a group of islands and including the eastern half of the island of New Guinea, between the Coral Sea and the South Pacific Ocean, east of Indonesia.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16953>	C25464	Paraguay|600|PARAGUAY|PARAGUAY|PRY|PRY|PY	A country in central South America, northeast of Argentina.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16954>	C201957	Parasitology|Microbiology, Virology, Parasitology	A branch of biology which deals with parasitic organisms with a strong emphasis on their role in disease.			Biomedical Occupation or Discipline	
C16955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16955>	C19332	Parity|Maternal Parity|PARITY|Para	The number of pregnancies reaching 20 weeks and 0 days of gestation or beyond, regardless of the number of fetuses or outcomes.			Organism Attribute	CDISC SDTM Reproductive System Findings Test Code Terminology|CDISC SDTM Reproductive System Findings Test Name Terminology|CDISC SDTM Terminology|Clinical Data Interchange Standards Consortium Terminology|INC Demographic and Maternal Terminology|INC Terminology|NICHD Terminology|Perinatal Terminology
C16956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16956>	C17828	Pathologic Process|Pathological Process	A biologic function or a process having an abnormal or deleterious effect at the subcellular, cellular, multicellular, or organismal level.			Phenomenon or Process	
C16957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16957>	C52653|C18189	Oral Pathology	The branch of pathology focusing on diseases and disorders of the oral cavity.			Biomedical Occupation or Discipline	
C16958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16958>	C18189	Surgical Pathology	A field of anatomical pathology in which tissue or cells removed from a living organism are macroscopically and microscopically reviewed for the purpose of disease diagnosis.			Biomedical Occupation or Discipline	
C16959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16959>	C16664	Patient Education	The process of imparting information to a patient that will help them to maintain or improve their health.	Patient Education		Educational Activity	CTRP Intervention Terminology|CTRP Terminology
C1695	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1695>	C1975	Bruceanol H	A quassinoid phytochemical isolated from the plant Brucea antidysenterica with potential antineoplastic activity. (NCI04)			Organic Chemical|Pharmacologic Substance	GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCIt Antineoplastic Agent Terminology
C16960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16960>	C199001	Patient|LAY USER/PATIENT|PATIENT|PT|Patients|patient	A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.			Patient or Disabled Group	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Individual Case Safety Report Terminology|Operator of Medical Device ICSR Terminology|Type of Reporter ICSR Terminology
C16961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16961>	C19233	Pattern Recognition|Pattern Recognition/Display/Analysis	A branch of artificial intelligence concerned with the identification of visual or audio patterns by computers.For the computer to recognize the patterns, the patterns must be converted into digital signals and compared with patterns already stored in memory.Some uses of this technology are in character recognition, voice recognition, handwriting recognition, and robotics. (High-Tech Dictionary)			Mental Process	
C16962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16962>	C17153	Pediatrics|Pediatric Medicine	The branch of medicine concerned with the treatment of infants and children.			Biomedical Occupation or Discipline	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C16963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16963>	C19475	Peer Review|peer review|peer review|peer review process	A scholarly process that subjects an author's work or ideas to the scrutiny of one or more others who are experts in the field. These referees each return an evaluation of the work, including suggestions for improvement. Evaluations usually include an explicit recommendation of what to do with the manuscript or proposal. A chief rationale for peer review is that rarely is just one person, or one closely working group, able to spot every mistake or weakness in a complicated piece of work. This is not necessarily because these deficiencies represent needles in a haystack, but because in a new and creative and perhaps eclectic intellectual product, any one of these opportunities for improvement may stand out only to someone with a particular expertise and/or history of experience. Therefore showing a work to various others increases the probability that the weakness will be identified and fixed.			Occupational Activity	CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C16964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16964>	C16319	Beta-Lactamase|Cephalosporinase|Penicillinase	An enzyme that brings about the hydrolysis of a beta-lactam (as penicillin to penicilloic acid); found in most staphylococcus strains that are naturally resistant to penicillin.	Beta-Lactamase		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Terminology
C16965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16965>	C16701	Peptidase|Peptide Hydrolase|Protease|Proteases|Proteinase|Proteolytic Enzyme	Enzymes acting on peptide bonds. EC 3.4.-			Amino Acid, Peptide, or Protein|Enzyme	
C16966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16966>	C61408	Peptide Synthesis	The sequential formation of peptide bonds between amino acids			Laboratory Procedure	
C16967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16967>	C16840	Perception|Perceived	The process of producing an internal, conscious image through stimulating a sensory system; it involves the recognition that stimulation has occurred, and the ability to discriminate various aspects of the stimulus.			Mental Process	
C16968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16968>	C41481	Peristalsis|peristalsis	A series of coordinated, rhythmic muscle contractions that occur throughout the length of the gastrointestinal tract and in the ureters. The body utilizes alternating muscles that contract and relax to move fluids and solids from one cavity to another.			Organ or Tissue Function	
C16969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16969>	C16546	Laparoscopy|LAPAROSCOPY|LP|Laparoscopic|laparoscopy	A surgical procedure during which a laparoscope is inserted into the abdomen to view the abdominopelvic contents for diagnostic and/or therapeutic purposes.	Laparoscopy		Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Codelists Terminology|CPTAC Terminology|CPTAC Treatments Codelist|CTRP Intervention Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C1696	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1696>	C1946	Oxamflatin|(2E)-5-[3-[(phenylsufonyl)amino]phenyl]-pent-2-en-4-ynohydroxamic Acid|(2E)-N-Hydroxy-5-[3-[(phenylsulfonyl)amino]phenyl]-2-penten-4-ynamide|(2E)-N-Hydroxy-5-[3-[(phenylsulfonyl)amino]phenyl]-2-penten-4-ynamide|N-hydroxy-5-[3-[(phenylsulfonyl)amino]phenyl]-2E-penten-4-ynamide	An inhibitor of histone deacetylase.  It is an aromatic sulfonamide hydroxamate initially found in a screen for inhibitors of the tumorigenic phenotype of K-ras-transformed NIH3T3 cells.			Organic Chemical|Pharmacologic Substance	
C16970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16970>	C16386	Permease	An extensive group of membrane proteins that function as channels to transport specific molecules in or out of the cell. The enzymatic activity results in the increased permeability of cellular membranes.			Amino Acid, Peptide, or Protein|Enzyme	
C16971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16971>	C19683	Permissiveness|Permissive Behavior|Permissiveness, Behavior	An attitude that is accepting or tolerant of behaviors that may disregard traditional social mores.			Individual Behavior	
C16972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16972>	C25464	Peru|604|PE|PER|PER|PERU|PERU	A country in western South America, bordering the South Pacific Ocean, between Chile and Ecuador.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C16973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16973>	C16974|C16624	Pharmacogenetics|PGt|pharmacogenetics|pharmacogenetics	The investigation of the impact of individual gene variations on drug responses.			Biomedical Occupation or Discipline	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology
C16974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16974>	C16344	Pharmacology|P|Pharmacologic|Pharmacological|pharmacology|pharmacology	The study of pharmacologic agents. This includes the preparation, compounding, and dispensing of drugs, as well as the characteristics and properties of drugs, their effects on the body, and how they are metabolized and eliminated from the body.			Biomedical Occupation or Discipline	CDISC Glossary Terminology|CDISC SEND Study Category Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology
C169755	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169755>	C20401	Abelacimab|ABELACIMAB|MAA 868|MAA-868|MAA868	A human anti-factor XI (FXI) monoclonal antibody, with potential anti-thrombotic activity. Upon administration, abelacimab targets and binds to the catalytic domain of FXI, thereby inactivating FXI, and also inhibits the activated form of FXI factor XIa. This prevents the activation of factor XIIa (FXIIa). The abrogation of FXI activation prolongs the activated partial thromboplastin time (aPTT) and reduces platelet and fibrin accumulation. This results in the inhibition of contact activation-initiated blood coagulation and prevents thrombus formation. FXI contributes to thrombotic disease while playing a limited role in normal hemostasis. Activation of FXI is essential for thrombus growth and stabilization.	Abelacimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C169756	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169756>	C2167|C129825	Abivertinib Maleate|ABIVERTINIB MALEATE	The maleate salt form of abivertinib, an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. Upon oral administration, abivertinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the drug-resistant T790M EGFR mutant, which prevents signaling mediated by mutant forms of EGFR. This may both induce cell death and inhibit tumor growth in EGFR-mutated tumor cells. EGFR, a receptor tyrosine kinase that is mutated in a variety of cancers, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors, which also inhibit wild-type EGFR.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C169757	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169757>	C574	Acebilustat|ACEBILUSTAT|CTX-4430|EP-501	An orally bioavailable, small molecule inhibitor of the enzyme leukotriene A4 hydrolase (LTA4H), with potential anti-inflammatory activity. Upon oral administration, acebilustat targets and inhibits the activity of LTA4H, thereby inhibiting the synthesis of the pro-inflammatory mediator leukotriene B4 (LTB4). This may reduce inflammation in various inflammatory disorders including cystic fibrosis and serious pulmonary inflammatory diseases. LTA4H catalyzes a major and rate-limiting step in LTB4 production, and LTB4 plays an important role in pulmonary and systemic inflammation.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C169758	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169758>	C1907	Acemannan|ACEMANNAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169759	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169759>	C226473	Aclerastide|ACLERASTIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16975>	C16974	Clinical Pharmacology|clinical pharmacology	The branch of pharmacology that studies the effectiveness and safety of drug treatment in humans.			Biomedical Occupation or Discipline	CDISC Glossary Terminology
C169760	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169760>	C29711|C217486	Aclimostat|ACLIMOSTAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169761	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169761>	C93259|C78283	Acrizanib|ACRIZANIB				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169762	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169762>	C20401	Actoxumab|ACTOXUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169763	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169763>	C217652	Adafosbuvir|ADAFOSBUVIR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169764	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169764>	C667	Adarigiline|ADARIGILINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169765	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169765>	C29708	Adriforant|ADRIFORANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169766	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169766>	C258	Afabicin|AFABICIN				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169767	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169767>	C20401	Afasevikumab|AFASEVIKUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169768	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169768>	C78272	Afizagabar|AFIZAGABAR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169769	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169769>	C548	Aldafermin|ALDAFERMIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16976>	C16974	Pharmaceutics|Pharmaceutical|Pharmacy	The science of preparing and dispensing drugs.			Biomedical Occupation or Discipline	
C169770	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169770>	C78276	Alexitol Sodium|ALEXITOL SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169771	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169771>	C1291	Alicaforsen|ALICAFORSEN				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169772	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169772>	C308	Alicdamotide|ALICDAMOTIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169773	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169773>	C29726	Alidornase Alfa|ALIDORNASE ALFA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169774	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169774>	C281	Alisporivir|ALISPORIVIR|Debio 025	A non-immunosuppressive analogue of cyclosporine A and an inhibitor of cyclophilins, with potential antiviral activity. Upon oral administration, alisporivir targets and inhibits human host cyclophilins, thereby inhibiting hepatitis C virus (HCV) replication in hepatocytes. Alisporivir may also inhibit the replication of various coronaviruses. In addition, it may inhibit mitochondrial cyclophilin-D, which regulates mitochondrial permeability transition pore (mPTP) opening. This may prevent cell death and tissue damage.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C169775	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169775>	C2364	Alsactide|ALSACTIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169776	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169776>	C45678	Alusulf|ALUSULF				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169777	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169777>	C1509	Amediplase|AMEDIPLASE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169778	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169778>	C62554	Amelparib|AMELPARIB				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169779	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169779>	C265	Amesergide|AMESERGIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16977>	C19896	Phenotype|phenotype	The assemblage of traits or outward appearance of an individual. It is the product of interactions between genes and between genes and the environment.			Organism Attribute	
C169780	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169780>	C265	Amitifadine|AMITIFADINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169781	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169781>	C224690	Amlintide|AMLINTIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169782	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169782>	C281	Amlivirsen|AMLIVIRSEN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169783	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169783>	C250	Amoscanate|AMOSCANATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169784	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169784>	C29726	Apadamtase Alfa|ADAMTS13 recombinant|APADAMTASE ALFA|Adzynma|BAX 930|BAX-930|BAX930|Recombinant ADAMTS13|Recombinant Human ADAMTS-13|Recombinant Human ADAMTS13|Recombinant a Disintegrin and Metalloproteinase with Thrombospondin Motifs 13|Recombinant a Disintegrin and Metalloproteinase with a Thrombospondin Type 1 Motif Member 13|SHP 655|SHP-655|SHP655|TAK 755|TAK-755|TAK755|rADAMTS13	A recombinant human form of a disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13) that may be used as a replacement therapy for ADAMTS13 with indirect anti-thrombotic and anti-thrombocytopenic activities. Upon administration, apadamtase alfa acts similarly as endogenous ADAMTS13 and mediates the cleavage of von Willebrand factor (VWF) at the Tyr1605-Met1606 bond in the A2 domain. The cleavage of ultralarge (UL) VWF multimers into smaller forms helps regulate the size of VWF multimers, preventing the binding of platelets to UL VWF and the resulting thrombotic thrombocytopenic purpura (TTP). ADAMTS13 plays a key role in the proteolysis of VWF multimers. VWF is involved in platelet adhesion and blood coagulation.	Apadamtase Alfa		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology
C169785	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169785>	C265	Apimostinel|APIMOSTINEL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169786	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169786>	C258	Ardacin|ARDACIN				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169787	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169787>	C271	Artefenomel|ARTEFENOMEL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169788	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169788>	C29726	Asfotase Alfa|ASFOTASE ALFA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169789	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169789>	C94242	Astodrimer|ASTODRIMER				Hazardous or Poisonous Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16978>	C25464	Philippines|608|PH|PHILIPPINES|PHILIPPINES|PHL|PHL	A country in southeastern Asia, comprised of an archipelago between the Philippine Sea and the South China Sea, east of Vietnam.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C169790	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169790>	C29756	Atagabalin|ATAGABALIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169791	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169791>	C78281	Ataluren|ATALUREN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169792	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169792>	C20401	Atidortoxumab|ATIDORTOXUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169793	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169793>	C20401	Atoltivimab|ATOLTIVIMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169794	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169794>	C210771	Atopaxar|ATOPAXAR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169795	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169795>	C29726	Avalglucosidase Alfa|AVALGLUCOSIDASE ALFA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169796	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169796>	C25974	Avanbulin|AVANBULIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169797	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169797>	C275	Avasopasem Manganese|AVASOPASEM MANGANESE|GC 4419|GC-4419|GC4419	A mimetic of the enzyme superoxide dismutase (SOD) that may potentially be used to reduce oral mucositis and esophagitis associated with radiation therapy and chemoradiotherapy. Upon administration, avasopasem manganese may mimic native SODs and catalyze the formation of molecular oxygen and hydrogen peroxide from the burst of superoxide anion present in the irradiated tissues upon radiation and/or induced by chemotherapy. This may decrease the damage of radiation and/or chemotherapy to normal tissues.	Avasopasem Manganese		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C169798	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169798>	C61101	Avoparcin|AVOPARCIN				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169799	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169799>	C471	Avoralstat|AVORALSTAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16979>	C20130	Phospholipase A2 Enzyme Family|EC 3.1.1.4|PLA2|Phospholipase A2	Various types of calcium-dependent or -independent Phospholipases A2 hydrolyze phospholipids. Group I, II, and III phospholipases are secreted, while group IV phospholipases are cytosolic. The best characterized phospholipases are group II. (NCI)			Amino Acid, Peptide, or Protein|Enzyme	
C1697	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1697>	C737	Fungicide|fungicide	Any substance or physical agent that inhibits development and kills fungus spores and mycelium. In the United States, fungicides are governed by the 1972 federal Environmental Protection and Control Act. They must be registered with the Environmental Protection Agency and must conform to specifications. They must control the disease without injuring the plant and must leave no poisonous residue on edible crops. Antifungal drugs are approved by the FDA. (NCI)			Hazardous or Poisonous Substance	
C169800	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169800>	C261	Azalomycin|AZALOMYCIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169801	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169801>	C1291	Baliforsen|BALIFORSEN				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169802	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169802>	C2180	Balovaptan|BALOVAPTAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169803	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169803>	C177170	Barixibat|BARIXIBAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169804	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169804>	C213472|C155765|C141136	Belizatinib|ALK/TRK Inhibitor TSR-011|BELIZATINIB|TSR 011|TSR-011|TSR011	An orally available inhibitor of both the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the tropomyosin-related kinases (TRK) TRKA, TRKB, and TRKC, with potential antineoplastic activity. Upon oral administration, belizatinib binds to and inhibits both ALK and TRK kinases. The inhibition leads to disruption of ALK- and TRK-mediated signaling and impedes tumor cell growth in ALK/TRK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. TRK, a family of receptor tyrosine kinases activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C169805	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169805>	C1505	Benfotiamine|BENFOTIAMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169806	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169806>	C1500	Penicillin G Benzathine Anhydrous|Benzathine Benzylpenicillin|Benzathine Benzylpenicillin Anhydrous|PENICILLIN G BENZATHINE ANHYDROUS				Antibiotic|Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169807	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169807>	C52588|C20401	Berlimatoxumab|BERLIMATOXUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169808	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169808>	C783	Berotralstat|BEROTRALSTAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169809	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169809>	C94431|C78283	Bevasiranib|BEVASIRANIB				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16980>	C16561	Phospholipase|Lecithinase	Enzymes that catalyze the cleavage of a phospholipid molecule by the addition of water, thereby causing hydrolysis. The classification is based on the specificity of the bond cleaved. Hydrolytic activity initiates signaling cascades in the cell.			Amino Acid, Peptide, or Protein|Enzyme	
C169810	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169810>	C681	Bevenopran|BEVENOPRAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169811	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169811>	C98083	Bexagliflozin|BEXAGLIFLOZIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169812	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169812>	C78272	Bifemelane|BIFEMELANE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169813	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169813>	C29576	Bopindolol|BOPINDOLOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169814	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169814>	C78272	Bradanicline|BRADANICLINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169815	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169815>	C265	Brexanolone|BREXANOLONE|Zulresso				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169816	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169816>	C258	Brilacidin|BRILACIDIN|PMX 30063|PMX-30063|PMX30063	A synthetic, nonpeptidic, small molecule mimetic of defensin, a type of host defense proteins/peptides (HDPs) or antimicrobial peptides (AMPs), with potential antibacterial and antiviral activities. Upon administration, brilacidin selectively destabilizes bacterial and viral membrane integrity, which leads to their proteolysis and degradation. HDPs are part of the innate immune response and act as the first line of defense against foreign pathogens. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has been shown to suppress defensins.			Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C169817	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169817>	C29710	Brilaroxazine|BRILAROXAZINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169818	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169818>	C20401	Brolucizumab|BROLUCIZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169819	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169819>	C281	Bulevirtide|BULEVIRTIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16981>	C16561	Phosphatase|EC 3.1.3.-	A class of enzymes that catalyze the removal of phosphate groups from their substrates.			Amino Acid, Peptide, or Protein|Enzyme	
C169820	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169820>	C157401	Cabotegravir|Apretude|CABOTEGRAVIR	A human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI), that is used for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. Upon gluteal intramuscular administration, cabotegravir binds to the active site of HIV integrase and inhibits the activity of HIV integrase, an HIV-1 coded enzyme that is necessary for viral replication. Inhibition of integrase prevents the integration of HIV-1 DNA into host genomic DNA.	Cabotegravir		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C169821	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169821>	C75525	Camidanlumab|CAMIDANLUMAB	A human immunoglobulin (Ig) G1 monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha or CD25). Upon administration, camidanlumab specifically targets and binds to the cell surface antigen CD25. CD25, a transmembrane receptor and tumor-associated antigen (TAA), is expressed on certain cancer cells.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169822	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169822>	C82130	Carbomer 934|CARBOMER HOMOPOLYMER TYPE B (ALLYL SUCROSE CROSSLINKED)|Carbomer Homopolymer Type B (Allyl Sucrose Crosslinked)				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169823	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169823>	C82130	Carbomer Homopolymer Type A (Allyl Pentaerythritol Crosslinked)|CARBOMER HOMOPOLYMER TYPE A (ALLYL PENTAERYTHRITOL CROSSLINKED)				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169824	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169824>	C82130	Carbomer Homopolymer Type B (Allyl Pentaerythritol or Allyl Sucrose Crosslinked)|CARBOMER HOMOPOLYMER TYPE B (ALLYL PENTAERYTHRITOL OR ALLYL SUCROSE CROSSLINKED)				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169825	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169825>	C78568	Carboprost Methyl|CARBOPROST METHYL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169826	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169826>	C29710	Cariprazine|CARIPRAZINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169827	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169827>	C29710	Cariprazine Hydrochloride|CARIPRAZINE HYDROCHLORIDE|RGH-188 Hydrochloride|Vraylar|Vraylar	The hydrochloride salt form of cariprazine, an orally bioavailable partial agonist of the dopamine D2 and D3 receptors, a partial agonist of the serotonin 1A (5-HT1A) receptor, and an antagonist of the serotonin 2A (5-HT2A) and 2B (5-HT2B) receptors, with antipsychotic activity. Although its exact mechanism of action in schizophrenia is unknown, it has been proposed that cariprazine's antipsychotic activity is mediated through a combination of agonist and antagonist activities at various dopamine and serotonin receptors, particularly through its partial agonist activity at central dopamine D2 and 5-HT1A receptors, and its antagonist activity at 5-HT2A receptor.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169828	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169828>	C574	Carotegrast|CAROTEGRAST				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169829	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169829>	C548	Carperitide|CARPERITIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16982>	C20028	Phosphoprotein	Proteins that contain phosphate groups esterified to serine, threonine or tyrosine. The phosphate group usually regulates protein function.	Phosphoprotein		Amino Acid, Peptide, or Protein	CTRP Biomarker Terminology|CTRP Terminology
C169830	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169830>	C1291	Casimersen|CASIMERSEN				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169831	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169831>	C357	Cefiderocol|CEFIDEROCOL				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169832	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169832>	C357	Cefiderocol Sulfate Tosylate|CEFIDEROCOL SULFATE TOSYLATE				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169833	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169833>	C61101|C357	Cefilavancin|CEFILAVANCIN				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169834	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169834>	C45678	Cellacefate|CELLACEFATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169835	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169835>	C2099	Cellulose Sodium Phosphate|CELLULOSE SODIUM PHOSPHATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169837	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169837>	C574	Cenerimod|CENERIMOD				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169838	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169838>	C226773|C226765	Cenicriviroc Mesylate|CENICRIVIROC MESYLATE|TAK 652|TAK-652|TAK652|TBR 652|TBR-652|TBR652	The mesylate salt form of cenicriviroc, an orally bioavailable, dual inhibitor of human C-C chemokine receptor types 2 (CCR2; CD192) and 5 (CCR5; CD195), with potential immunomodulating, anti-inflammatory and antiviral activities. Upon oral administration, cenicriviroc specifically binds to and prevents the activation of both CCR2 and CCR5. This inhibits the activation of CCR2/CCR5-mediated signal transduction pathways and may inhibit inflammatory processes. The G-protein coupled chemokine receptors CCR2 and CCR5 are expressed on the surface of monocytes and macrophages and stimulate their migration and infiltration; they play key roles in inflammation and autoimmune diseases. In addition, cenicriviroc inhibits human immunodeficiency virus (HIV)-1 entry via CCR5 coreceptor interaction.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C169839	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169839>	C66885	Cerlapirdine|CERLAPIRDINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16983>	C19899	Phosphorylation Process|Phosphorylation|phosphorylation	The creation of a phosphate derivative of an organic molecule. This is usually achieved by transferring a phosphate group from ATP via the action of a kinase.			Molecular Function	
C169840	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169840>	C29726	Cerliponase Alfa|CERLIPONASE ALFA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169841	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169841>	C247	Ceronapril|CERONAPRIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169842	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169842>	C45564	Cetoxime|CETOXIME				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169843	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169843>	C29756	Chloralodol|CHLORALODOL|Chlorhexadol				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169844	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169844>	C28394	Chlorhexidine Phosphanilate|CHLORHEXIDINE PHOSPHANILATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169845	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169845>	C1937	Chlormerodrin Hg-203|CHLORMERODRIN HG-203				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169846	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169846>	C1505	Cideferron|CIDEFERRON				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169847	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169847>	C1288	Cilmostim|CILMOSTIM				Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169848	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169848>	C212879	Cilofexor|CILOFEXOR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169849	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169849>	C471	Cindunistat|CINDUNISTAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16984>	C17210	Phosphotransferase|EC 2.7|Phosphotransferases	A class of enzymes that transfer phosphate or phosphate-containing molecules to organic substrates. These proteins play a role in the regulation of many cellular processes.			Amino Acid, Peptide, or Protein|Enzyme	
C169850	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169850>	C471	Cindunistat Hydrochloride Maleate|CINDUNISTAT HYDROCHLORIDE MALEATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169851	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169851>	C29707	Cinepazet Maleate|CINEPAZET MALEATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169852	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169852>	C38149|C20401	Cinpanemab|CINPANEMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169853	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169853>	C271	Cipargamin|CIPARGAMIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169854	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169854>	C78275	Ciraparantag|CIRAPARANTAG				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169855	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169855>	C146993	Clascoterone|CLASCOTERONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169856	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169856>	C1012	Clazolam|CLAZOLAM				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169857	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169857>	C333	Clentiazem Maleate|CLENTIAZEM MALEATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169858	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169858>	C20401	Clervonafusp Alfa|CLERVONAFUSP ALFA				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169859	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169859>	C45812	Cobamamide|COBAMAMIDE				Vitamin	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16985>	C16421	Photochemistry	The branch of chemistry that focuses on the changes that chemicals undergo when exposed to light.			Occupation or Discipline	
C169860	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169860>	C1506	Codoxime|CODOXIME				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169861	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169861>	C1509	Coleneuramide|COLENEURAMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169862	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169862>	C1595	Colimecycline|COLIMECYCLINE				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169863	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169863>	C213472|C141136|C129825	Conteltinib|ALK/FAK/Pyk2 Inhibitor CT-707|CONTELTINIB|CT 707|CT-707	An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2), with potential antineoplastic activity. Upon administration, conteltinib selectively binds to and inhibits ALK , FAK and Pyk2. The inhibition leads to disruption of ALK- , FAK- and Pyk2-mediated signal transduction pathways and eventually inhibits tumor cell growth in ALK-, FAK- and Pyk2-overexpressing tumor cells. Expression of these tyrosine kinases is dysregulated in various tumor types; they play a key role in tumor cell migration, proliferation, survival, and tumor angiogenesis.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C169864	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169864>	C258	Contezolid Acefosamil|CONTEZOLID ACEFOSAMIL				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169865	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169865>	C1822	Corifollitropin Alfa|CORIFOLLITROPIN ALFA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169866	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169866>	C2348	Corticotropin-Zinc Hydroxide|CORTICOTROPIN ZINC HYDROXIDE				Hormone|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169867	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169867>	C201818	Crovalimab|CROVALIMAB|RO7112689|SKY59	A humanized recycling monoclonal antibody directed against the complement pathway protein C5, with potential complement pathway inhibitory and immunomodulating activities. Upon administration, crovalimab targets and binds to a specific C5 epitope, thereby preventing C5 convertase-mediated cleavage of C5, inhibiting the formation of C5a and C5b, and the C5b6 deposition on membranes. This inhibits C5-mediated signal transduction, the formation of the membrane attack complex (MAC) and the activation of the terminal complement pathway. This results in the prevention and/or inhibition of both complement-mediated inflammation and cell destruction of red blood cells (RBCs) as seen in paroxysmal nocturnal hemoglobinuria (PNH). C5 plays a key role in the activation of the complement cascade. Crovalimab is engineered with sequential monoclonal antibody recycling technology (SMART).	Crovalimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C169868	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169868>	C308	Cupabimod|CUPABIMOD				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169869	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169869>	C1291	Custirsen|CUSTIRSEN	A mixed-backbone antisense oligodeoxynucleotide, with potential chemosensitizing activity. Upon administration, custirsen prevents the translation of testosterone-repressed prostate message-2 (TRPM-2). This abrogates the anti-apoptotic effect of TRPM-2, thereby sensitizing cells to chemotherapy and resulting in tumor cell death. TRPM-2 is an anti-apoptotic clusterin that is overexpressed by prostate cancer cells and is associated with chemoresistance.			Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology
C16986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16986>	C17702	Photosynthesis	The process through which light energy, water, and carbon dioxide are converted to carbohydrate and oxygen in the presence of chlorophyll. Occurs in plants, algae, cyanobacteria and lichens. (BioTech Life Science Dictionary)			Molecular Function	
C169870	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169870>	C47795	Cypenamine|CYPENAMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169871	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169871>	C29701	Cysteamine Hydrochloride|CYSTEAMINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169872	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169872>	C265|C185721	Daledalin|DALEDALIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169873	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169873>	C2079	Daltroban|DALTROBAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169874	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169874>	C63817	Danirixin|DANIRIXIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169875	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169875>	C1291	Danvatirsen Sodium|DANVATIRSEN SODIUM				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169876	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169876>	C514	Dapaconazole|DAPACONAZOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169877	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169877>	C210736	Daprodustat|DAPRODUSTAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169878	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169878>	C78272	Davunetide|DAVUNETIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169879	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169879>	C29750|C210971	Dazoxiben Hydrochloride|DAZOXIBEN HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16987>	C19160	Physical Sciences	The sciences that focus on the properties and behavior of nonliving matter.			Occupation or Discipline	
C169880	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169880>	C2139	Defoslimod|DEFOSLIMOD				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169881	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169881>	C29713	Delequamine|DELEQUAMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169882	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169882>	C29713	Delequamine Hydrochloride|DELEQUAMINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169883	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169883>	C2578	Deligoparin Sodium|DELIGOPARIN SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169884	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169884>	C242	Delmadinone|DELMADINONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169885	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169885>	C257	Delparantag|DELPARANTAG				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169886	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169886>	C29704	Desfesoterodine|DESFESOTERODINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169887	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169887>	C210736	Desidustat|DESIDUSTAT|Glycine, N-((1-(cyclopropylmethoxy)-1,2-dihydro-4-hydroxy-2-oxo-3-quinolinyl)carbonyl)-|N-(1-(Cyclopropylmethoxy)-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbonyl)glycine	An orally bioavailable, hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor (HIF-PHI), with potential anti-anemic and anti-inflammatory activities. Upon administration, desidustat binds to and inhibits HIF-PH, an enzyme responsible for the degradation of transcription factors in the HIF family under normal oxygen conditions. This prevents HIF breakdown and promotes HIF activity. Increased HIF activity leads to an increase in endogenous erythropoietin production, thereby enhancing erythropoiesis. It also reduces the expression of the peptide hormone hepcidin, improves iron availability, and boosts hemoglobin (Hb) levels. HIF regulates the expression of genes in response to reduced oxygen levels, including genes required for erythropoiesis and iron metabolism. In addition, HIF 1-alpha (HIF1A) may play a role in reducing inflammation during acute lung injury (ALI) through HIF-dependent control of glucose metabolism in the alveolar epithelium.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C169888	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169888>	C48149	Deterenol Hydrochloride|DETERENOL HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169889	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169889>	C2092	Detirelix Acetate|DETIRELIX ACETATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16988>	C211578	Physician Office|Doctor Office|Doctor's Office|Physician Offices|Physician's Office|Physician's Office	A medical facility where a doctor sees and treats patients.			Health Care Related Organization	
C169890	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169890>	C29701	Detralfate|DETRALFATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169891	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169891>	C78272	Deudextromethorphan Hydrobromide|DEUDEXTROMETHORPHAN HYDROBROMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169892	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169892>	C87006	Deutivacaftor|DEUTIVACAFTOR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169893	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169893>	C29710	Dexclamol|DEXCLAMOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169894	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169894>	C1505	Dexfosfoserine|DEXFOSFOSERINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169895	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169895>	C257	Dexibuprofen Lysine|DEXIBUPROFEN LYSINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169896	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169896>	C29747	Dexisometheptene|DEXISOMETHEPTENE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169897	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169897>	C29709	Dexisometheptene Mucate|DEXISOMETHEPTENE MUCATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169898	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169898>	C66886	Dexmecamylamine Hydrochloride|DEXMECAMYLAMINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169899	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169899>	C66884	Dexpramipexole|DEXPRAMIPEXOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16989>	C16987	Physics	The study of those aspects of nature which can be understood in a fundamental way in terms of elementary principles and laws; the laws and properties of matter, and the forces acting upon it.			Occupation or Discipline	
C1698	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1698>	C799	Phosphorus P-32|P-32|P32|PHOSPHORUS P-32|Phosphorus P 32|phosphorus-32	A radioactive isotope of phosphorus with beta particle-emitting radiocytotoxic activity. Emitted by phosphorus P32, beta particles directly damage cellular DNA and, by ionizing intracellular water to produce several types of cytotoxic free radicals and superoxides, indirectly damage intracellular biological macromolecules, resulting in tumor cell death.			Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C169900	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169900>	C93038	Dexsotalol|DEXSOTALOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169901	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169901>	C314	Dextran 40|DEXTRAN 40				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169902	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169902>	C314	Dextran 75|DEXTRAN 75				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169903	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169903>	C1553	Dextrothyroxine Sodium Anhydrous|DEXTROTHYROXINE SODIUM ANHYDROUS				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169904	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169904>	C29576	Diacetolol Hydrochloride|DIACETOLOL HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169905	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169905>	C78275	Dianexin|DIANEXIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169906	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169906>	C94727	Dibenzepin Hydrochloride|DIBENZEPIN HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169907	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169907>	C78275	Diciferron|DICIFERRON				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169908	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169908>	C737	Dieldrin|DIELDRIN				Hazardous or Poisonous Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169909	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169909>	C744	Difamilast|DIFAMILAST				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16990>	C16344	Physiology	The study of the mechanical, physical, and biochemical functions of living organisms.			Biomedical Occupation or Discipline	
C169910	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169910>	C78272	Dimecamine|DIMECAMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169911	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169911>	C265	Dimethazan|DIMETHAZAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169912	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169912>	C737	Dimpylate|DIAZINON|DIMPYLATE|Diazinon	A synthetic organophosphate acetylcholinesterase inhibitor and neurotoxicant that is used as a pesticide. It is characterized as a colorless to dark brown odorless liquid, and exposure occurs by inhalation, ingestion, or contact.			Hazardous or Poisonous Substance|Pharmacologic Substance	CDISC SEND Chemical Challenge Agent Name Response Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169913	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169913>	C2124	Diotyrosine I-125|DIOTYROSINE I-125				Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169914	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169914>	C737	Dioxation|DIOXATION				Hazardous or Poisonous Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169915	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169915>	C20401	Diridavumab|DIRIDAVUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169916	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169916>	C574	Diroximel Fumarate|DIROXIMEL FUMARATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169917	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169917>	C25974	Disermolide|DISERMOLIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169918	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169918>	C211912|C155712	Disitamab Vedotin|ADC RC48|Anti-HER2 ADC RC48|Anti-HER2 Antibody-drug Conjugate RC48|DISITAMAB VEDOTIN|RC48	An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of trastuzumab vedotin, the trastuzumab moiety targets and binds to HER2 on the surface of tumor cells. Following internalization, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.	Disitamab Vedotin		Amino Acid, Peptide, or Protein|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C169919	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169919>	C29703	Dorzagliatin|DORZAGLIATIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16991>	C19301	Comparative Physiology	The study of similarities and differences of the vital processes of different organisms.			Biomedical Occupation or Discipline	
C169920	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169920>	C66884	Dosergoside|DOSERGOSIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169921	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169921>	C1291	Drisapersen Sodium|DRISAPERSEN SODIUM				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169922	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169922>	C259	Duazomycin|DUAZOMYCIN				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169923	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169923>	C98085	Dulaglutide|DULAGLUTIDE|LY2189265|Trulicity	A glucagon-like peptide-1 (GLP-1) receptor agonist that is 90% homologous to native human GLP-1 (7-37) and is composed of a dipeptidyl peptidase-IV-protected GLP-1 analog covalently linked to a human immunoglobulin G4 (IgG4)-Fc heavy chain, with antihyperglycemic activity. Upon administration, dulaglutide binds to and activates GLP-1 receptors, thereby increasing intracellular cyclic AMP (cAMP) in pancreatic beta cells. This increases glucose-dependent insulin release. Dulaglutide also reduces the elevated glucagon secretion by inhibiting alpha cells of the pancreas and slows gastric emptying. Altogether this lowers the postprandial glucose level. GLP-1 is normally secreted by L cells of the gastrointestinal (GI) mucosa in response to a meal to normalize blood glucose levels.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169924	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169924>	C76358	Dumorelin|DUMORELIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169925	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169925>	C1590	Duocarmazine|DUOCARMAZINE|VC-SECO-DUBA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169926	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169926>	C29750	Duteplase|DUTEPLASE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169927	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169927>	C198646	Edicotinib Hydrochloride|EDICOTINIB HYDROCHLORIDE	The hydrochloride salt form of edicotinib, a small molecule and orally available inhibitor of colony-stimulating factor-1 receptor (CSF1R; FMS) with potential antineoplastic activity. Edicotinib blocks the receptor-ligand interaction between FMS and its ligand CSF1, thereby preventing autophosphorylation of FMS. As a result, unphosphorylated FMS can not activate FMS-mediated signaling pathways, thus potentially inhibiting cell proliferation in FMS-overexpressed tumor cells. FMS, a tyrosine kinase receptor, is overexpressed in certain tumor cell types and plays an essential role in macrophage differentiation, recruitment, and activation as well as the regulation of cell proliferation.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169928	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169928>	C208255|C201119	Efaprinermin Alfa|EFAPRINERMIN ALFA|GITRL-Fc|GITRL-Fc Trimer|OMP 336B11|OMP-336B11|Trimeric GITRL-Fc OMP-336B11	A Fc-engineered human fusion protein composed of two trimers of tumor necrosis factor (ligand) superfamily, member 18 (TNFSF18; GlTRL) linked to an immunoglobulin Fc domain (GITRL-Fc), with potential immunostimulatory and antineoplastic activities. Upon administration, efaprinermin alfa targets, binds to and activates its co-stimulatory surface receptor (glucocorticoid-induced tumor necrosis factor receptor (GITR; TNFRSF18) expressed on T-lymphocytes and certain tumor cell types. This activates T-lymphocytes, causes T-lymphocyte proliferation and suppresses the activity of regulatory T-cells (Treg). This promotes cytotoxic T-lymphocyte (CTL)-mediated killing of tumor cells. GITRL, a member of the tumor necrosis factor (TNF) family of ligands, functions to activate the co-stimulatory receptor GITR to enhance T-cell modulated immune responses.	Efaprinermin Alfa		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C169929	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169929>	C222318|C208255|C1512	Efavaleukin Alfa|AMG 592|AMG-592|AMG592|EFAVALEUKIN ALFA|IL-2 Mutein Fc-fusion Molecule AMG 592|IL-2 Mutein/Fc Fusion Protein AMG 592|IL-2 Mutein/Fc Fusion Protein AMG 592|Interleukin-2-Fc Fusion Protein AMG 592	A recombinant fusion protein consisting of a variant form of the human cytokine interleukin 2 (IL-2; IL2), IL-2 mutein, fused to a human Fc molecule, with potential cell-protective and anti-inflammatory activities. Upon intravenous administration of recombinant human IL-2 mutein/Fc fusion protein AMG 592, the IL-2 mutein moiety binds to its receptors, and activates IL-2-mediated signaling pathways. IL-2 mutein preferentially expands and activates regulatory T-cells (Tregs), thereby preventing inadequate immune responses and restoring immune homeostasis. This may help control or prevent inflammatory reactions as seen in inflammatory-based diseases, such as autoimmune diseases and graft-versus-host disease (GvHD). IL-2 mutein is less able to stimulate natural killer (NK) cells and conventional T-cells, which may lead to reduced toxicity compared to treatment with recombinant IL-2. Fusion to the Fc increases the stability and half-life of AMG 592. Tregs play a key role in the prevention of inflammatory diseases and immune homeostasis.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169930	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169930>	C477	Efepoetin Alfa|EFEPOETIN ALFA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169931	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169931>	C208255|C201119|C1512|C141144	Efgivanermin Alfa|EFGIVANERMIN ALFA|GITR Agonist MEDI1873|GITR Stimulant MEDI1873|MEDI 1873|MEDI1873|TNFRSF18 Agonist MEDI1873|TNFRSF18 Protein Stimulant MEDI1873	A homogenous hexameric agonist fusion protein composed of the extracellular domain (ECD) of the T-cell costimulatory receptor human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor superfamily, member 18; TNFRSF18; GITR) ligand (GITRL) and an immunoglobulin (Ig) G1 Fc domain, with potential immunomodulating and antineoplastic activities. Upon administration, efgivanermin alfa binds to and activates GITR found on multiple types of T-cells, thereby inducing both the activation and proliferation of tumor antigen-specific T effector cells. This abrogates the suppression of T effector cells which is induced by inappropriately activated T regulatory cells (Tregs), suppresses Tregs and decreases Treg tumor infiltration, and activates the immune system to help eradicate tumor cells. GITR, a member of the TNF receptor superfamily, is expressed on the surface of multiple types of immune cells, including Tregs, effector T-cells, B-cells, dendritic cells (DCs) and natural killer (NK) cells.	Efgivanermin Alfa		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C169932	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169932>	C224819	Efinopegdutide|EFINOPEGDUTIDE|HM 12525A|HM-12525A|HM12525A|JN J64565111|JNJ-64565111|JNJ64565111|MK 6024|MK-6024|MK6024	A synthetic peptide of oxyntomodulin conjugated to the constant region of human immunoglobulin G4 (IgG4) and dual glucagon-like peptide-1 (GLP-1)/glucagon receptor co-agonist, with potential weight reducing and anti-diabetic activities and that may potentially be used for the treatment of non-alcoholic steatohepatitis (NASH). Upon subcutaneous administration, efinopegdutide targets, binds to, and activates GLP-1 and glucagon receptors. GLP-1 receptor activation increases glucose-dependent insulin release and reduces the elevated glucagon secretion by inhibiting alpha cells of the pancreas and slows gastric emptying. This lowers the postprandial glucose level. In the brain, the binding to and activation of GLP-1 receptor suppresses appetite, which decreases caloric intake and lowers body weight. Glucagon receptor agonism further stimulates insulin secretion, decreases glucagon production, and increases satiety. This leads to a reduction in food intake, and improves blood sugar control and weight loss. Reduction in weight by efinopegdutide also indirectly reduces liver fat content (LFC), reduces NASH-induced hepatic inflammation and may prevent liver damage. In addition, glucagon receptor activation directly stimulates fatty acid oxidation and reduces lipogenesis, which further reduces LFC and hepatic inflammation.	Efinopegdutide		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C169933	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169933>	C164163	Efpegsomatropin|EFPEGSOMATROPIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169934	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169934>	C210975	Elenbecestat|ELENBECESTAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169935	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169935>	C87006	Elexacaftor|ELEXACAFTOR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169936	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169936>	C20401	Elezanumab|ELEZANUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169937	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169937>	C78272	Elismetrep|ELISMETREP				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169938	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169938>	C213309	Elivaldogene Tavalentivec|ELIVALDOGENE TAVALENTIVEC				Cell|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169939	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169939>	C97453	Elsulfavirine|ELSULFAVIRINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16993>	C25464	Pitcairn|612|PCN|PCN|PITCAIRN|PITCAIRN ISLANDS|PN|Pitcairn Island	A country in the Pacific, comprised of islands in the South Pacific Ocean, about midway between Peru and New Zealand, southeast of French Polynesia.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|Geopolitical Entities, Names, and Codes Terminology
C169940	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169940>	C94431	Eluforsen|ELUFORSEN				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169941	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169941>	C66880|C29698	Emepronium Bromide|EMEPRONIUM BROMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169942	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169942>	C208118	Emiplacel|EMIPLACEL				Cell|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169943	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169943>	C20401	Enapotamab|ENAPOTAMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169944	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169944>	C210736	Enarodustat|ENARODUSTAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169945	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169945>	C16338	Enbucrilate|ENBUCRILATE				Biomedical or Dental Material	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169946	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169946>	C78281	Encaleret|ENCALERET				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169947	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169947>	C73579	Encenicline Hydrochloride|ENCENICLINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169948	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169948>	C1509	Enerisant|ENERISANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169949	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169949>	C1512	Enfortumab|ENFORTUMAB				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16994>	C17123	Plasminogen|EC 3.4.21.7|Fibrinase Precursor|Fibrinolysin Precursor|PLG|PLMN|Plasmin Precursor|Thrombolysin Precursor	Plasminogen (810 aa, ~91 kDa) is encoded by the human PLG gene. This protein is involved in fibrinolysis, platelet activation and tissue remodeling.	Plasminogen		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C169950	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169950>	C78568	Enisoprost|ENISOPROST				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169951	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169951>	C29701	Enprostil|ENPROSTIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169952	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169952>	C308	Ensereptide|ENSEREPTIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169953	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169953>	C1968	Entasobulin|ENTASOBULIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169954	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169954>	C280|C258	Enviomycin|ENVIOMYCIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169955	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169955>	C29703	Epeleuton|EPELEUTON				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169956	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169956>	C45564	Epolamine|EPOLAMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169957	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169957>	C1595	Eravacycline Dihydrochloride|ERAVACYCLINE DIHYDROCHLORIDE				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169958	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169958>	C20401	Erenumab|AMG 334|AMG-334|AMG334|Aimovig|ERENUMAB	A human immunoglobulin G2 (IgG2) monoclonal antibody targeting calcitonin gene-related peptide receptor (CGRPR), that can be used in the preventive treatment of migraine. Upon subcutaneous administration, erenumab specifically targets, binds to and blocks the activity of CGRPR. This may relief CGRPR-triggered migraine.	Erenumab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C169959	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169959>	C574	Erlizumab|ERLIZUMAB				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16995>	C16996	Tissue-Type Plasminogen Activator|EC 3.4.21.68|PLAT|T-Plasminogen Activator|TPA|Tissue Plasminogen Activator|t-PA|tPA|tissue plasminogen activator	Tissue-type plasminogen activator (562 aa, ~63 kDa) is encoded by the human PLAT gene. This protein plays a role in the cleavage of plasminogen between Arg-580 and Val-581 to form the fibrinolytic enzyme plasmin.	Tissue-Type Plasminogen Activator		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology
C169960	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169960>	C261	Erythromycin Propionate|ERYTHROMYCIN PROPIONATE				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169961	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169961>	C261	Erythromycin Salnacedin|ERYTHROMYCIN SALNACEDIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169962	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169962>	C29723	Esomeprazole Potassium|ESOMEPRAZOLE POTASSIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169963	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169963>	C68928	Estetrol Monohydrate|ESTETROL MONOHYDRATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169964	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169964>	C2293	Estradiol Undecylate|ESTRADIOL UNDECYLATE				Hormone	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169965	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169965>	C697|C25974	Estramustine Phosphate Sodium Anhydrous|ESTRAMUSTINE PHOSPHATE SODIUM ANHYDROUS				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169966	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169966>	C78568	Esuberaprost Potassium|ESUBERAPROST POTASSIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169967	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169967>	C254	Ethacridine|ETHACRIDINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169968	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169968>	C29711	Ethoxazorutoside|ETHOXAZORUTOSIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169969	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169969>	C61199|C129821	Etidaligide|AsiDNA|DNA Repair Inhibiting Oligonucleotide|DNA Repair Inhibiting Oligonucleotide AsiDNA|DSBs Mimic|ETIDALIGIDE|Oligonucleotide-mimicking Double-stranded DNA Breaks	A preparation of cell-permeant, short double-stranded DNA fragment that mimics double-strand breaks (DSBs) and linked to a cholesterol molecule, with potential antineoplastic activity. Upon administration of etidaligide, the cholesterol moiety enables tumoral and nuclear uptake of the DNA fragment, which mimics DNA DSBs. Inside the tumor cells, the DNA fragment triggers false DNA break signals, and binds to and activates DNA repair proteins including both poly (ADP-ribose) polymerase (PARP) and DNA-dependent protein kinase (DNA-PK). This prevents the recruitment of these repair proteins at the actual damage site and inhibits various DNA DSB repair pathways including homologous recombination (HR) and non-homologous end joining (NHEJ). This promotes genetic instability and enhances the accumulation of single and double strand DNA breaks, ultimately leading to apoptosis.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C16996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16996>	C17123	Plasminogen Activator	A family of serine proteases that catalyze the proteolytic conversion of plasminogen to plasmin.			Amino Acid, Peptide, or Protein|Enzyme	
C169970	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169970>	C1904	Etirinotecan Pegol Tetrahydrochloride|ETIRINOTECAN PEGOL TETRAHYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169971	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169971>	C1904	Etirinotecan Pegol Tetratriflutate|ETIRINOTECAN PEGOL TETRATRIFLUTATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169972	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169972>	C333	Etripamil|ETRIPAMIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169973	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169973>	C20401	Evinacumab|EVINACUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169974	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169974>	C29705	Evodenoson|EVODENOSON				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169975	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169975>	C2180	Fedovapagon|FEDOVAPAGON				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169976	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169976>	C210688	Ferric Pyrophosphate Citrate|FERRIC PYROPHOSPHATE CITRATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169977	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169977>	C210688	Ferropolimaler|FERROPOLIMALER				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169978	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169978>	C29712	Fiboflapon|FIBOFLAPON				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169979	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169979>	C281	Filociclovir|FILOCICLOVIR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16997>	C17122	Plasminogen Activator Inhibitor	A member of the serpin family of serine protease inhibitor proteins that inhibits plasminogen activator type proteases.			Amino Acid, Peptide, or Protein	
C169980	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169980>	C265	Filorexant|FILOREXANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169981	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169981>	C78274	Finerenone|BAY 94-8862|BAY94-8862|FINERENONE|Kerendia				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169982	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169982>	C20401	Firivumab|FIRIVUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169983	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169983>	C471	Firsocostat|FIRSOCOSTAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169984	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169984>	C201688	Fitusiran|ALN 57213|ALN AT3SC|ALN-57213|ALN-AT3SC|ALN57213|ALNAT3SC|FITUSIRAN	A small-interfering RNA (siRNA) directed against the human glycoprotein antithrombin (AT), with potential coagulant activity. Upon subcutaneous administration of fitusiran, the siRNAs bind to AT mRNAs, which may result in the inhibition of translation of the AT protein. By preventing AT expression, the coagulation factor thrombin is increased and activated, which leads to the conversion of fibrinogen to fibrin, and thus clot formation. This reduces bleeding in hemophilia and rebalances hemostasis.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology
C169985	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169985>	C270	Flavodilol Maleate|FLAVODILOL MALEATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169986	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169986>	C2124|C1937	Flortanidazole (18F)|FLORTANIDAZOLE F-18|Flortanidazole F-18				Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169987	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169987>	C2081	Flumecinol|FLUMECINOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169988	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169988>	C257	Flumizole|FLUMIZOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169989	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169989>	C211	Flumoxonide|FLUMOXONIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16998>	C616	Platelet Activating Factor|1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine|PAF	A phosphatidylcholine derivative that modulates inflammation, vascular permeability, allergic responses and the functions of leukocytes and platelets.			Biologically Active Substance|Organic Chemical	
C169990	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169990>	C277	Flunidazole|FLUNIDAZOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169991	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169991>	C61766	Fluorescein Lisicol|FLUORESCEIN LISICOL				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169992	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169992>	C94727	Fluotracen Hydrochloride|FLUOTRACEN HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169993	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169993>	C265	Fluparoxan|FLUPAROXAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169994	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169994>	C1636	Fluperolone|FLUPEROLONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169995	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169995>	C521	Fluperolone Acetate|FLUPEROLONE ACETATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169996	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169996>	C2152	Fluproquazone|FLUPROQUAZONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169997	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169997>	C737	Fluralaner|FLURALANER				Hazardous or Poisonous Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169998	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169998>	C29710	Flutroline|FLUTROLINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C169999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169999>	C264	Fluzinamide|FLUZINAMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C16999	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C16999>	C41514	Platelet Aggregation Process|Platelet Aggregation	Any cell adhesion process that involves the association of platelets via adhesion molecules.	Platelet Aggregation Process		Phenomenon or Process	CTRP Biomarker Terminology|CTRP Terminology
C1699	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1699>	C67439|C443|C2136	Zoledronic Acid|Aclasta|CGP 42446|CGP42446A|NDC-Zoledronate|Reclast|ZOL 446|ZOLEDRONIC ACID|Zoledronate|Zoledronic acid|Zometa|Zometa|[1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic Acid|[1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic Acid|zoledronic acid	A synthetic imidazole bisphosphonate analog of pyrophosphate with anti-bone-resorption activity. A third-generation bisphosphonate, zoledronic acid binds to hydroxyapatite crystals in the bone matrix, slowing their dissolution and inhibiting the formation and aggregation of these crystals. This agent also inhibits farnesyl pyrophosphate synthase, an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids, donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which are important in the process of osteoclast turnover. Decreased bone turnover and stabilization of the bone matrix contribute to the analgesic effect of zoledronic acid with respect to painful osteoblastic lesions. The agent also reduces serum calcium concentrations associated with hypercalcemia.	Zoledronic Acid		Organic Chemical|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology|OS Authorized Value Terminology|OS Total Dose Table
C170000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170000>	C38149	Foliglurax|FOLIGLURAX				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170001>	C2078	Folitixorin Calcium|FOLITIXORIN CALCIUM				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170002>	C66917	Fominoben|FOMINOBEN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170003>	C78283	Fonadelpar|FONADELPAR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170004>	C574	Forigerimod Acetate|FORIGERIMOD ACETATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170005>	C97452	Fosalvudine Tidoxil|FOSALVUDINE TIDOXIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170006>	C1932	Foscolic Acid|FOSCOLIC ACID				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170007>	C521	Fosdagrocorat|FOSDAGROCORAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170008>	C97453|C1660	Fosdevirine|FOSDEVIRINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170009>	C2021	Fosfluridine Tidoxil|FOSFLURIDINE TIDOXIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C17000	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17000>	C19896	Pleomorphism	Having different forms at different stages of the life cycle.			Functional Concept	
C170010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170010>	C29726	Fosmetpantotenate|FOSMETPANTOTENATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170011>	C267|C211679	Fosnetupitant|FOSNETUPITANT	A prodrug of netupitant, a selective neurokinin 1 receptor (NK1R; TACR1) antagonist, with potential antiemetic activity. Upon intravenous administration, fosnetupitant is converted by phosphatases to its active form netupitant. Netupitant competitively binds to and blocks the activity of NK1Rs in the central nervous system (CNS), by inhibiting binding of the endogenous tachykinin-derived neuropeptide substance P (SP) to NK1R. This prevents delayed emesis, which is associated with SP secretion. This may prevent chemotherapy-induced nausea and vomiting (CINV).			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology
C170012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170012>	C78274|C471	Fulacimstat|FULACIMSTAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170013>	C254	Fuladectin|FULADECTIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170014>	C448	Furacrinic Acid|FURACRINIC ACID				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170015>	C52588	Furazolium Tartrate|FURAZOLIUM TARTRATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170016>	C254	Fursalan|FURSALAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170018>	C87006	Galicaftor|GALICAFTOR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170019>	C261	Gamithromycin|GAMITHROMYCIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C17001	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17001>	C70766	Ploidy|DNA Content|DNA Ploidy|ploidy|ploidy	The number of chromosome sets per cell.			Quantitative Concept	GDC Property Terminology|GDC Terminology
C170020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170020>	C20401	Gancotamab|GANCOTAMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170021>	C261	Ganefromycin|GANEFROMYCIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170022>	C20401	Garetosmab|GARETOSMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170023>	C98086	Garvagliptin|GARVAGLIPTIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170024>	C146638	Geclosporin|GECLOSPORIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170025>	C258	Gepotidacin|GEPOTIDACIN				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170026>	C29710	Gevotroline Hydrochloride|GEVOTROLINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170027>	C212	Giractide|GIRACTIDE				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170028>	C45653	Gitaloxin|GITALOXIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170029>	C217517	Glecaprevir|GLECAPREVIR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C17002	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17002>	C25464	Poland|616|PL|POL|POL|POLAND|POLAND	A country in central Europe, east of Germany.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C170030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170030>	C78275	Glusoferron|GLUSOFERRON				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170031>	C78275	Glycerol Phenylbutyrate|GLYCEROL PHENYLBUTYRATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170032>	C97936	Glyhexamide|GLYHEXAMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170033	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170033>	C2459	Goralatide|GORALATIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170034	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170034>	C28394	Gramicidin S|GRAMICIDIN S				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170035	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170035>	C308	Graunimotide|GRAUNIMOTIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170036	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170036>	C270	Guanoctine Hydrochloride|GUANOCTINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170037	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170037>	C270	Guanoctine|GUANOCTINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170038	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170038>	C29505	Halometasone|HALOMETASONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170039	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170039>	C28394	Halquinols|HALQUINOLS				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C17003	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17003>	C20589|C19770	Polymerase Chain Reaction|PCR|PCR|PCR|PCR|PCR|PCR|POLYMERASE CHAIN REACTION|polymerase chain reaction	A method for amplifying a DNA base sequence using multiple rounds of heat denaturation of the DNA and annealing of oligonucleotide primers complementary to flanking regions in the presence of a heat-stable polymerase.  This results in duplication of the targeted DNA region. Newly synthesized DNA strands can subsequently serve as additional templates for the same primer sequences, so that successive rounds of primer annealing, strand elongation, and dissociation produce rapid and highly specific amplification of the desired sequence. PCR also can be used to detect the existence of the defined sequence in a DNA sample.	Polymerase Chain Reaction		Laboratory Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CPTAC Baseline Medical Forms Terminology|CPTAC Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma Baseline Form|CPTAC Terminology|CTRP Intervention Terminology|CTRP Terminology|EWS Authorized Value Terminology|EWS Molecular Analysis Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Lab Table|NCIt COVID-19 Clinical Terminology|NCIt COVID-19 Terminology|OS Authorized Value Terminology|OS Molecular Analysis Table|SeroNet Authorized Values|SeroNet Study Descriptors
C170040	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170040>	C254	Hedaquinium Chloride|HEDAQUINIUM CHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170041	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170041>	C78275	Hemoglobin Betafumaril (Bovine)|HEMOGLOBIN BETAFUMARIL (BOVINE)				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170042	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170042>	C314	Hemoglobin Crosfumaril|HEMOGLOBIN CROSFUMARIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170043	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170043>	C314	Hemoglobin Glutamer-200 (Bovine)|HEMOGLOBIN GLUTAMER-200 (BOVINE)				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170044	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170044>	C48149	Hexoprenaline|HEXOPRENALINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170045	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170045>	C514	Hydrargaphen|HYDRARGAPHEN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170046	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170046>	C1509	Hydromethylthionine|HYDROMETHYLTHIONINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170047	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170047>	C45678	Hydroxypyridine Tartrate|HYDROXYPYRIDINE TARTRATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170048	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170048>	C1323	Ibuprofen Sodium|IBUPROFEN SODIUM	The sodium salt form of ibuprofen, a propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic activities. Upon administration, ibuprofen inhibits the activity of cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. This leads to decreased prostaglandin synthesis, by prostaglandin synthase, the main physiologic effect of ibuprofen. Ibuprofen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C170049	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170049>	C29713	Idazoxan|IDAZOXAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C17004	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17004>	C17248	Genetic Polymorphism|Polymorphism|polymorphism	The regular and simultaneous occurrence of alternative nucleotide sequences at equivalent locations of the genetic material among individuals of a single interbreeding population that are not maintained by recurrent mutation. Polymorphisms may range in size from single nucleotide to large nucleotide sequence variation visible at the chromosomal level.	Genetic Polymorphism		Nucleotide Sequence	CTRP Biomarker Terminology|CTRP Terminology|GDC Terminology|GDC Value Terminology
C170050	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170050>	C263	Idrabiotaparinux Sodium|IDRABIOTAPARINUX SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170051	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170051>	C263	Idraparinux Sodium|IDRAPARINUX SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170052	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170052>	C78272	Igmesine|IGMESINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170053	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170053>	C265	Igmesine Hydrochloride|IGMESINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170054	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170054>	C20401	Iladatuzumab|ILADATUZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170055	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170055>	C29704	Ilmetropium Iodide|ILMETROPIUM IODIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170056	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170056>	C20401	Imaprelimab|IMAPRELIMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170057	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170057>	C20401	Imciromab|IMCIROMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170059	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170059>	C66883	Imidoline|IMIDOLINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C17005	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17005>	C43359	Population Group|Group|Population|Subpopulation|population|population group|population_group	A group of individuals united by a common factor (e.g., geographic location, ethnicity, disease, age, sex).			Population Group	CDISC Glossary Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Property Terminology
C170060	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170060>	C66883	Imidoline Hydrochloride|IMIDOLINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170061	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170061>	C307	Imlifidase|IMLIFIDASE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170062	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170062>	C190797	Inclisiran|INCLISIRAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170063	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170063>	C94725	Indalpine|INDALPINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170065	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170065>	C744	Indimilast|INDIMILAST				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170066	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170066>	C29713	Indoramin hydrochloride|INDORAMIN HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170067	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170067>	C47795	Indriline Hydrochloride|INDRILINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170068	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170068>	C265	Indriline|INDRILINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170069	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170069>	C20401	Inolimomab|INOLIMOMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C17006	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17006>	C25464	Portugal|620|PORTUGAL|PORTUGAL|PRT|PRT|PT	A country in southwestern Europe, bordering the North Atlantic Ocean, west of Spain.			Geographic Area	CDISC SEND Country Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|GDC Terminology|GDC Value Terminology|Geopolitical Entities, Names, and Codes Terminology
C170070	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170070>	C581	Insulin Defalan (Bovine)|INSULIN DEFALAN (BOVINE)				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170071	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170071>	C581	Insulin Defalan (Porcine)|INSULIN DEFALAN (PORCINE)				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170072	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170072>	C390	Iobenzamic Acid|IOBENZAMIC ACID				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170073	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170073>	C1937	Iodopyracet I 131|IODOPYRACET I-131				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170074	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170074>	C1446	Iofetamine Hydrochloride I 123|IOFETAMINE HYDROCHLORIDE I-123				Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170075	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170075>	C1937	Iosefamic Acid|IOSEFAMIC ACID				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170076	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170076>	C28500	Iosulamide|IOSULAMIDE				Indicator, Reagent, or Diagnostic Aid	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170077	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170077>	C29698	Ipragratine|IPRAGRATINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170078	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170078>	C47795	Irdabisant|IRDABISANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170079	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170079>	C514	Isavuconazonium|ISAVUCONAZONIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C17007	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17007>	C38093	Positron Emission Tomography|Medical Imaging, Positron Emission Tomography|PET|PET|PET SCAN|PET Scan|PET Scan|PET Scan|PET scan|PT|Pet Scan|Positron Emission Tomography Scan|Positron emission tomography (procedure)|Positron-Emission Tomography|positron emission tomography scan	A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.	Positron Emission Tomography		Diagnostic Procedure	CDISC SDTM Method Terminology|CDISC SDTM Terminology|CDISC SEND Terminology|Clinical Data Interchange Standards Consortium Terminology|CTRP Intervention Terminology|CTRP Terminology|GCT Authorized Value Terminology|GCT Tumor Assessment Table|GDC Terminology|GDC Value Terminology|HL Authorized Value Terminology|HL Imaging Table|HL Lesion Characteristics Table|HL Subject Response Table|mCode Terminology|mCode Tumor Size Method Value Set|Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C170080	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170080>	C514	Isavuconazonium Chloride|ISAVUCONAZONIUM CHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170081	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170081>	C66884	Isomolpan Hydrochloride|ISOMOLPAN HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170082	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170082>	C66884	Isomolpan|ISOMOLPAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170083	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170083>	C29578	Isothipendyl|ISOTHIPENDYL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170085	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170085>	C1930	Kasal|KASAL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170086	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170086>	C258	Kitasamycin|KITASAMYCIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170087	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170087>	C63817	Ladarixin|LADARIXIN	An orally bioavailable, small molecule, dual inhibitor of C-X-C motif chemokine receptors 1 (CXCR1) and 2 (CXCR2), with potential anti-inflammatory and antineoplastic activities. Upon oral administration, ladarixin selectively targets and allosterically binds to CXCR 1 and 2, thereby preventing CXCR1 and CXCR2 activation by their ligand and pro-inflammatory chemokine interleukin 8 (IL-8 or CXCL8). This inhibits CXCR1/2-mediated signaling, which inhibits inflammatory processes, reduces both the recruitment and migration of immunosuppressive myeloid-derived suppressor cells (MDSCs) and neutrophils in the tumor microenvironment (TME), and abrogates the immunosuppressive-induced nature of the TME. This allows effector cells, such as natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs), to kill and eliminate cancer cells, and inhibits tumor cell migration, metastasis, angiogenesis and tumor cell proliferation. CXCR1 and 2, G protein-coupled receptor proteins located on myeloid cells and certain tumor cells, play key roles in the immunosuppressive nature of the TME, tumor metastasis, resistance to chemotherapeutic agents and myeloid cell suppression. They also play a key role in inflammation and their expression is elevated in several inflammatory-driven diseases.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|NCIt Antineoplastic Agent Terminology
C170088	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170088>	C1291	Lademirsen Sodium|LADEMIRSEN SODIUM				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170089	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170089>	C1962	Lademirsen|LADEMIRSEN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C17008	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17008>	C16754	Potassium Channel	Ion channel selective for potassium ions. There are several types, each with different functions.			Cell Component	
C170090	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170090>	C20401	Ladiratuzumab|LADIRATUZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170091	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170091>	C210975	Lanabecestat|LANABECESTAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170092	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170092>	C66885	Landipirdine|LANDIPIRDINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170093	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170093>	C52588	Lanopepden Mesylate|LANOPEPDEN MESYLATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170094	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170094>	C47794	Lasmiditan Succinate|LASMIDITAN SUCCINATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170095	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170095>	C29705	Latanoprostene Bunod|LATANOPROSTENE BUNOD				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170096	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170096>	C250	Latidectin|LATIDECTIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170097	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170097>	C45678	Laureth-10S|LAURETH-10S				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170098	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170098>	C29702	Lavoltidine|LAVOLTIDINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170099	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170099>	C29702	Lavoltidine Succinate|LAVOLTIDINE SUCCINATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C17009	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17009>	C17468	Poverty|Low Income|Poor	A subjective and comparative term describing a lack of sufficient wealth (usually understood as capital, money, material goods, or resources especially natural resources) to live what is understood in a society as a "normal" life: for instance, to be capable of raising a healthy family, and especially educating children and participating in society. A person living in this condition of poverty is said to be poor. The meaning of "sufficient" varies widely across the different political and economic areas of the world.			Group Attribute	National Health Interview Survey
C170100	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170100>	C52588	Lefamulin Acetate|LEFAMULIN ACETATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170101	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170101>	C1740	Leflutrozole|LEFLUTROZOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170102	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170102>	C333	Lemildipine|LEMILDIPINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170103	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170103>	C2152	Leniolisib|LENIOLISIB				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170104	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170104>	C29713|C270	Leniquinsin|LENIQUINSIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170105	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170105>	C84868	Lenomorelin|LENOMORELIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170106	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170106>	C20401	Lenvervimab|LENVERVIMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170107	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170107>	C20401	Lerdelimumab|LERDELIMUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170108	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170108>	C78272	Leriglitazone|2,4-Thiazolidinedione, 5-((4-(2-(5-(1-Hydroxyethyl)-2-pyridinyl)ethoxy)phenyl)methyl)-|LERIGLITAZONE|MIN 102|MIN-102|MIN102	An orally bioavailable, blood-brain-barrier (BBB) penetrable, selective peroxisome proliferator-activated receptor (PPAR) subtype gamma agonist, with potential neuroprotective activity that could be used for certain central nervous system (CNS) diseases, such as adrenomyeloneuropathy, cerebral adrenoleukodystrophy (cALD), Friedreich's ataxia, and certain other CNS diseases. Upon oral administration, leriglitazone selectively targets, binds to and activates PPARgamma, thereby regulating the expression of genes involved in mitochondrial biogenesis. This modulates pathways leading to the restoration of mitochondrial function in which dysfunction is caused by the accumulation of very long-chain fatty acids (VLCFAs), and increases energy production, decreases oxidative stress, decreases nuclear factor kappa B (NF-kB) levels, inhibits neuroinflammation, protects the BBB integrity, prevents demyelination and axonal degeneration, increases neuronal survival, increases myelination and oligodendrocyte survival and improves motor function. Mutations in the ABCD1 gene, which encodes the peroxisomal membrane adrenoleukodystrophy protein, cause a defective function of the ABCD1 transporter leading to an accumulation of VLCFA. VLCFA accumulation contributes to membrane destabilization of the myelin sheath, mitochondrial dysfunction, oxidative stress, neuroinflammation and compromised BBB integrity.	Leriglitazone		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C17010	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17010>	C17258	Prevalence|PREVALENCE|prevalence|prevalence	The ratio (for a given time period) of the number of occurrences of a disease or event to the number of units at risk in the population.			Quantitative Concept	CDISC ADaM Input Parameter Terminology|CDISC ADaM Terminology|CDISC Glossary Terminology|CDISC MRCT Center Clinical Research Glossary|Clinical Data Interchange Standards Consortium Terminology
C170110	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170110>	C20401	Lesofavumab|LESOFAVUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170111	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170111>	C82623	Letibotulinumtoxina|LETIBOTULINUMTOXINA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170112	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170112>	C241	Letimide Hydrochloride|LETIMIDE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170113	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170113>	C254	Letrazuril|LETRAZURIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170114	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170114>	C47795	Levamfetamine|LEVAMFETAMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170115	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170115>	C47795	Levamfetamine Succinate|LEVAMFETAMINE SUCCINATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170116	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170116>	C29723	Levolansoprazole|LEVOLANSOPRAZOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170117	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170117>	C265	Levomilnacipran|LEVOMILNACIPRAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170118	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170118>	C66917	Levopropoxyphene|LEVOPROPOXYPHENE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170119	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170119>	C241	Lexanopadol|LEXANOPADOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C17011	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17011>	C17153	Preventive Medicine|Community Medicine	A branch of medicine that focuses on disease prevention.			Biomedical Occupation or Discipline	
C170120	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170120>	C210960	Lexipafant|LEXIPAFANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170121	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170121>	C94725	Liafensine|LIAFENSINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170122	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170122>	C20401	Libivirumab|LIBIVIRUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170123	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170123>	C29711|C1327	Limiglidole|LIMIGLIDOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170124	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170124>	C29714	Lodoxamide Ethyl|LODOXAMIDE ETHYL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170125	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170125>	C52588|C514	Lomofungin|LOMOFUNGIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170126	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170126>	C29708	Lonapalene|LONAPALENE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170127	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170127>	C81123	Lonoctocog Alfa|LONOCTOCOG ALFA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170128	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170128>	C47793	Lorajmine|LORAJMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170129	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170129>	C29756	Lorediplon|LOREDIPLON				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C17012	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17012>	C78162	Proctoscopy|proctoscopy	Endoscopic examination of the rectum.	Proctoscopy		Diagnostic Procedure	CTRP Intervention Terminology|CTRP Terminology
C170130	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170130>	C29756	Lorzafone|LORZAFONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170131	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170131>	C744	Lotamilast|LOTAMILAST				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170132	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170132>	C276	Lotilaner|LOTILANER				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170133	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170133>	C258	Lotilibcin|LOTILIBCIN				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170134	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170134>	C1509	Lubeluzole|LUBELUZOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170135	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170135>	C471	Lucerastat|LUCERASTAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170136	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170136>	C87006	Lumacaftor|LUMACAFTOR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170137	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170137>	C201688	Lumasiran|LUMASIRAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170138	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170138>	C29710	Lumateperone Tosylate|LUMATEPERONE TOSYLATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C17013	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17013>	C54156	Prognosis|Prediction of Outcome|prognosis	Prediction of the probable course and outcome of a disease.			Idea or Concept	
C170140	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170140>	C39713	Lunacalcipol|LUNACALCIPOL				Vitamin	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170141	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170141>	C20401	Lupartumab|LUPARTUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170142	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170142>	C29702	Lupitidine|LUPITIDINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170143	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170143>	C29702	Lupitidine Hydrochloride|LUPITIDINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170144	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170144>	C681	Aticaprant|ATICAPRANT|LY-2456302				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170145	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170145>	C737	Lycetamine|LYCETAMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170146	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170146>	C20401	Maftivimab|MAFTIVIMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170147	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170147>	C2081	Malotilate|MALOTILATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170148	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170148>	C177170	Maralixibat|MARALIXIBAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170149	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170149>	C177170	Maralixibat Chloride|MARALIXIBAT CHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C17014	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17014>	C20349	Prophase Process|Mitotic Prophase|Prophase	The first phase of mitosis, in which the chromosomes become visible, the nucleus starts to lose its identity, the spindle appears, and the centrioles migrate toward opposite poles.			Phenomenon or Process	
C170150	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170150>	C224655	Mardepodect|MARDEPODECT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170151	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170151>	C261	Maridomycin|MARIDOMYCIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170152	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170152>	C78311	Marzeptacog Alfa (Activated)|MARZEPTACOG ALFA (ACTIVATED)				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170153	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170153>	C2198	Mavatrep|MAVATREP				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170154	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170154>	C78272	Mavoglurant|MAVOGLURANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170155	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170155>	C1287	Mecapegfilgrastim|MECAPEGFILGRASTIM	A long-acting, pegylated, recombinant analog of the endogenous human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Upon administration, mecapegfilgrastim binds to and activates specific cell surface receptors and stimulates neutrophil progenitor proliferation and differentiation, as well as selected neutrophil functions. This may decrease the duration and incidence of chemotherapy-induced neutropenia (CIN). Pegylation significantly increases the therapeutic half-life.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C170156	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170156>	C29576	Medroxalol Hydrochloride|MEDROXALOL HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170157	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170157>	C49185	Mefruside|MEFRUSIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170158	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170158>	C276	Megalomicin|MEGALOMICIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170159	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170159>	C277	Melarsoprol|MELARSOPROL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C17015	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17015>	C28459	Cyclooxygenase|COX|Prostaglandin Synthase|Prostaglandin Synthetase	An enzyme that converts arachidonic acid into biologically active prostanoids, such as prostaglandins, prostacyclins, and thromboxanes.			Amino Acid, Peptide, or Protein|Enzyme	
C170160	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170160>	C1932	Menfegol|MENFEGOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170161	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170161>	C47793	Meobentine|MEOBENTINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170162	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170162>	C29578	Mequitazine|MEQUITAZINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170163	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170163>	C66884	Mergocriptine|MERGOCRIPTINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170164	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170164>	C548	Merotocin|MEROTOCIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170165	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170165>	C48149|C29696	Mesuprine Hydrochloride|MESUPRINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170166	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170166>	C2356	Metamizole Sodium|Dipyrone Anhydrous|METAMIZOLE SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170167	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170167>	C47794	Metergotamine|METERGOTAMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170168	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170168>	C98234	Metformin Glycinate|METFORMIN GLYCINATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170169	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170169>	C2360	Methenolone Acetate|METHENOLONE ACETATE				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C17016	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17016>	C52653	Prosthodontics	The branch of dentistry dealing with the replacement of teeth and related mouth or jaw structures by artificial devices.			Biomedical Occupation or Discipline	
C170170	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170170>	C823|C78322	Metildigoxin|METILDIGOXIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170171	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170171>	C29703	Metreleptin|METRELEPTIN|Myalept|N-Methionylleptin	A recombinant human leptin analog composed of human leptin with the addition of a methionine residue at its amino terminus, that may be used for the treatment of leptin deficiency. Upon administration, metreleptin binds to and activates the human leptin receptor (ObR). This activates leptin/ObR-mediated signaling pathways. Leptin, a hormone predominantly secreted by adipose tissue, plays an important role in maintaining energy homeostasis.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C170172	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170172>	C776	Metynodiol|METYNODIOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170173	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170173>	C270	Mexrenoate Potassium|MEXRENOATE POTASSIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170174	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170174>	C2139	Mifamurtide Acid|MIFAMURTIDE ACID				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170175	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170175>	C154291	Mifobate|MIFOBATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170177	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170177>	C47794	Minesapride|MINESAPRIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170178	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170178>	C210960	Minopafant|MINOPAFANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170179	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170179>	C333	Mioflazine Hydrochloride|MIOFLAZINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C17017	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17017>	C21176	Protein Kinase C|EC 2.7.11.13|PKC|PKC|protein kinase C	A family of serine/threonine protein kinases that have a structurally conserved catalytic subunit and a regulatory subunit that are connected by a hinge domain.	Protein Kinase C		Amino Acid, Peptide, or Protein|Enzyme	CTRP Biomarker Terminology|CTRP Molecular Genetic Biomarker Terminology|CTRP Terminology|Pediatric Oncology Biomarkers/Targets Associated with Other Relevant Evidence
C170180	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170180>	C78283	Mipragoside|MIPRAGOSIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170181	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170181>	C155764	Miransertib Mesylate|MIRANSERTIB MESYLATE	The mesylate salt form of miransertib, an orally bioavailable inhibitor of the serine/threonine protein kinase AKT (protein kinase B), with potential antineoplastic activity. Miransertib binds to and inhibits the activity of AKT in a non-ATP competitive manner, which may result in the inhibition of the PI3K/AKT signaling pathway. This may lead to the reduction in tumor cell proliferation and the induction of tumor cell apoptosis. The AKT signaling pathway is often deregulated in cancer and is associated with tumor cell proliferation, survival and migration.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170182	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170182>	C29708|C20401	Mirikizumab|MIRIKIZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170183	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170183>	C1290	Mirimostim|MIRIMOSTIM				Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170184	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170184>	C82922	Mirincamycin|MIRINCAMYCIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170185	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170185>	C308	Mirococept|MIROCOCEPT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170186	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170186>	C2198	Mirogabalin|MIROGABALIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170187	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170187>	C78276	Mitemcinal Fumarate|MITEMCINAL FUMARATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170188	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170188>	C1931	Mitosper|MITOSPER				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170189	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170189>	C208296	Mocravimod|1,3-Propanediol, 2-amino-2-(2-(2-chloro-4-((3-(phenylmethoxy)phenyl)thio)phenyl)ethyl)-|2-Amino-2-(2-(2-chloro-4-(3-benzyloxyphenylthio)phenyl)ethyl)-1,3-propanediol|KRP-203 Free Base|MOCRAVIMOD	A sphingosine 1-phosphate (S1P) receptor agonist, with potential immunosuppressive activity. Upon administration of mocravimod, this agent binds to S1P receptors on lymphocytes, which prevents binding of serum S1P to S1P receptors and leads to S1P receptor internalization. This reduces the number of circulating blood leukocytes and accelerates lymphocyte homing into peripheral lymph nodes, thereby preventing their infiltration into peripheral inflammatory sites. This agent also decreases the production of inflammatory cytokines by lymphocytes, such as interferon gamma (IFN-g), interleukin-12 (IL-12), and tumor necrosis factor (TNF).			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C17018	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17018>	C16984	Protein Kinase	A class of phosphotransferase proteins that posttranslationally modify protein substrates through the addition of phosphate groups.			Amino Acid, Peptide, or Protein|Enzyme	
C170190	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170190>	C29707	Molsidomine|MOLSIDOMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170191	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170191>	C129825|C129650|C125450	Momelotinib Dihydrochloride|MOMELOTINIB DIHYDROCHLORIDE	The dihydrochloride salt form of momelotinib, an orally bioavailable small molecule inhibitor of wild-type (WT) Janus kinases 1 and 2 (JAK1/2), the JAK2 mutant form JAK2V617F, and activin A receptor type 1 (ACVR1; activin receptor like kinase 2; ALK2), with antineoplastic activity. Upon oral administration, momelotinib competes with JAK1/2 for ATP binding, which results in inhibition of JAK1/2 activation, inhibition of the JAK-STAT signaling pathway, and leads to the induction of apoptosis and a reduction of tumor cell proliferation in JAK1/2-expressing tumor cells. In addition, the inhibition of ALK2 prevents liver hepcidin formation, increases iron availability and increases red blood cell (RBC) production. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders; the JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617. The JAK-STAT signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170192	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170192>	C308|C1291	Mongersen Sodium|MONGERSEN SODIUM				Nucleic Acid, Nucleoside, or Nucleotide|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170193	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170193>	C241	Nabitan|NABITAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170194	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170194>	C448	Nacartocin|NACARTOCIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170195	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170195>	C172787	Nadorameran|NADORAMERAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170196	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170196>	C264	Nafimidone|NAFIMIDONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170197	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170197>	C681	Naldemedine Tosylate|NALDEMEDINE TOSYLATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170198	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170198>	C67413	Nalorphine|NALORPHINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C17019	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17019>	C19903	Post-Translational Modification|Post Translational Modification|Post-Translational Modification Alteration|Posttranslational Modification|Protein Modification|Protein/Amino Acid Biochemistry, Post-Translational Modification	The enzymatic processing of a polypeptide chain after translation from messenger RNA and after peptide bond formation has occurred. Examples include glycosylation, acylation, limited proteolysis, phosphorylation, isoprenylation.	Post-Translational Modification		Molecular Function	CTRP Biomarker Terminology|CTRP Terminology
C1701	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1701>	C2313|C1663	Vaccinia CEA Vaccine|Vaccinia Carcinoembryonic Antigen Vaccine|Vaccinia-CEA Vaccine|Vaccinia-CEA Vaccine (180KD)|Vaccinia-Carcinoembryonic Antigen Vaccine|rV-CEA (Vaccinia-CEA, TBC-CEA)|vaccinia CEA vaccine				Chemical Viewed Functionally	NCI Drug Dictionary Terminology
C170200	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170200>	C206201|C20401	Naratuximab|Immunoglobulin G1-kappa, Anti-(Homo sapiens CD37(Tetraspanin-26, tspan26)), Chimeric Monoclonal Antibody|NARATUXIMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170201	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170201>	C1287	Nartograstim|NARTOGRASTIM				Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170202	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170202>	C204154|C159200	Navitoclax Dihydrochloride|NAVITOCLAX DIHYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170203	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170203>	C281|C20401	Navivumab|NAVIVUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170204	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170204>	C38149	Naxagolide Hydrochloride|NAXAGOLIDE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170205	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170205>	C2167|C129825	Nazartinib Mesylate|NAZARTINIB MESYLATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170206	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170206>	C1742	Necuparanib|HSGAG Mimetic M402|Heparan Sulfate Glycosaminoglycan Mimetic M402|M402|NECUPARANIB	A low molecular weight heparin derivative and heparan sulfate proteoglycan (HSPG) mimetic with no or minimal anticoagulant activity and potential antineoplastic activities. Upon administration, necuparanib mimics HSPGs by binding to and inhibiting various heparin-binding growth factors, chemokines, and cytokines such as VEGF, HGF, FGF2, SDF-1a, heparanase and P-selectin all of which are essential for tumor angiogenesis and metastasis to occur. This inhibits heparin binding growth factor-mediated signaling and disrupts tumor-stromal interactions eventually leading to an inhibition of angiogenesis and tumor cell progression. In addition, M402 may enhance the cytotoxic effect of other chemotherapeutic agents.	Necuparanib		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C170207	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170207>	C61074	Neflamapimod|NEFLAMAPIMOD				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170208	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170208>	C78274	Neladenoson Bialanate|NELADENOSON BIALANATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170209	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170209>	C47796	Nelonicline|NELONICLINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C17020	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17020>	C17018	Protein Tyrosine Kinase|EC 2.7.10|PTK|Protein-Tyrosine Kinase|Tyrosine Kinase|Tyrosine Protein Kinase|Tyrosine-Protein Kinase|Tyrosine-Specific Protein Kinase	Kinases that phosphorylate protein tyrosine residues. These kinases play major roles in mitogenic signalling, and can be divided into two subfamilies: receptor tyrosine kinases, that have an extracellular ligand-binding domain, a single transmembrane domain, and an intracellular tyrosine kinase domain; and nonreceptor tyrosine kinases, which are soluble, cytoplasmic kinases. (Dictionary of Cell and Molecular Biology Online)			Amino Acid, Peptide, or Protein|Enzyme	
C170210	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170210>	C78273|C2152	Nemiralisib Succinate|NEMIRALISIB SUCCINATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170211	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170211>	C20401	Nemolizumab|NEMOLIZUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170212	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170212>	C78272|C1509	Nerinetide|NERINETIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170213	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170213>	C29705	Netarsudil|NETARSUDIL	An amino-isoquinoline amide and inhibitor of Rho kinase (ROCK) and norepinephrine transporter (NET), with potential intraocular pressure (IOP)-lowering activity. Upon ocular administration, netarsudil inhibits ROCK and the Rho pathway, increases aqueous humor (AH) outflow via the trabecular pathway, and lowers IOP. In addition, netarsudil may lower IOP by decreasing episcleral venous pressure and decreasing the production of aqueous humor through inhibition of NET. 			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170214	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170214>	C29705	Netarsudil Mesylate|NETARSUDIL MESYLATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170215	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170215>	C261	Neutramycin|NEUTRAMYCIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170216	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170216>	C471	Nevanimibe|NEVANIMIBE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170217	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170217>	C471	Nevanimibe Hydrochloride|NEVANIMIBE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170218	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170218>	C67413	Nicomorphine|NICOMORPHINE				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170219	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170219>	C73579	Nicotine Bitartrate|NICOTINE BITARTRATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C17021	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17021>	C26548	Protein|Protein (NOS)|Proteins|protein	A group of complex organic macromolecules composed of one or more chains (linear polymers) of alpha-L-amino acids linked by peptide bonds and ranging in size from a few thousand to over 1 million Daltons. Proteins are fundamental genetically encoded components of living cells with specific structures and functions dictated by amino acid sequence.			Amino Acid, Peptide, or Protein	BRIDG Class Terminology|BRIDG Terminology|GDC Terminology|GDC Value Terminology|OS Authorized Value Terminology|OS Lab Table|PQ/CMC Substance Classification Terminology
C170220	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170220>	C514|C277	Nifuratel|NIFURATEL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170221	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170221>	C52588	Nifurdazil|NIFURDAZIL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170222	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170222>	C255	Nifurpipone|NIFURPIPONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170223	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170223>	C258	Nifursol|NIFURSOL				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170224	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170224>	C281|C20401	Nirsevimab|Beyfortus|MEDI8897|NIRSEVIMAB|Nirsevimab-alip	A Fc-engineered recombinant human immunoglobulin (Ig) G1 kappa monoclonal antibody against the fusion protein (F protein) of human respiratory syncytial virus (RSV), that can be used for prophylactic and protective purposes in RSV infections. Upon administration, nirsevimab targets and binds to the F1 and F2 subunits of the RSV fusion (F) protein, thereby locking the RSV F protein in the prefusion conformation and blocking viral entry into the host cell. This neutralizes the virus and prevents syncytia formation. This may prevent RSV and RSV-associated lower respiratory tract infection (LRTI) among infants and young children. RSV F protein, a small envelop glycoprotein, is required for cytopathic syncytia formation resulting from cell-to-cell fusion. It is necessary for viral infection and spreading. Nirsevimab has an extended half-life and one administration may therefore provide seasonal protection against RSV.	Nirsevimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C170225	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170225>	C29739	Nitrosulfathiazole|NITROSULFATHIAZOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170226	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170226>	C163032	Nivobotulinumtoxin A|NIVOBOTULINUMTOXINA				Hazardous or Poisonous Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170227	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170227>	C54060	Nonivamide|NONIVAMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170228	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170228>	C82130	Nonoxynol 10|NONOXYNOL-10				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170229	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170229>	C82130	Nonoxynol 4|NONOXYNOL-4				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C17022	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17022>	C16642	Proteoglycan|proteoglycan	A protein that has one or more glycosaminoglycans covalently attached.			Amino Acid, Peptide, or Protein|Biologically Active Substance	
C170230	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170230>	C82130	Nonoxynol 30|NONOXYNOL-30				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170231	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170231>	C67413	Noracymethadol|NORACYMETHADOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170232	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170232>	C212	Norleusactide|NORLEUSACTIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170233	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170233>	C1657	Norlevorphanol|NORLEVORPHANOL				Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170234	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170234>	C67413	Normorphine|NORMORPHINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170235	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170235>	C258	Nosiheptide|NOSIHEPTIDE				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170236	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170236>	C112889	Obexelimab|OBEXELIMAB|XMAB 5871|XMAB-5871|XMAB5871|ZB 012|ZB-012|ZB012	A humanized immunoglobulin G1 (IgG1) noncytolytic monoclonal antibody directed against the B-cell-specific cell surface antigen CD-19, Fc-engineered for increased affinity to Fc gamma receptor IIB (FcgRIIB; CD32B), with potential immunomodulatory activity. Upon administration, obexelimab simultaneously targets and binds to both CD19 and FcgRIIB expressed on the surface of B-cells, and inhibits B-cell receptor (BCR) signaling and the activity of B-cells without depleting the B-cells. This may alleviate manifestations of autoimmune diseases including systemic lupus erythematosus (SLE). CD19 and FcgRIIB, both expressed on the surface of B-cells, play important roles in BCR signaling, and B-cell activity and survival.	Obexelimab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C170237	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170237>	C129650	Oclacitinib Maleate|OCLACITINIB MALEATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170238	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170238>	C28394	Octenidine Hydrochloride|OCTENIDINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170239	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170239>	C45812	Octotiamine|OCTOTIAMINE				Vitamin	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C17023	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17023>	C19896	Proto-Oncogene|Cellular Oncogene|Cellular Oncogenes|c-ONC|proto-oncogene	Oncogenes are altered forms of normal cellular genes called proto-oncogene. Many proto-oncogenes are homologous to viral oncogenes and involved in the control of cell proliferation or differentiation. Mutations, amplifications or rearrangements of proto-oncogenes lead to upregulated or deregulated cell growth and allow them to function as oncogenes.			Classification	
C170240	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170240>	C62799	Octreotide Hydrochloride|OCTREOTIDE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170241	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170241>	C94727	Octriptyline Phosphate|OCTRIPTYLINE PHOSPHATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170242	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170242>	C281|C20401	Odesivimab|ODESIVIMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170243	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170243>	C87006	Olacaftor|OLACAFTOR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170244	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170244>	C254	Olanexidine Hydrochloride|OLANEXIDINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170245	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170245>	C212891	Olcegepant|OLCEGEPANT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170246	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170246>	C574	Olcorolimus|OLCOROLIMUS				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170248	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170248>	C2167|C129825	Olmutinib Hydrochloride|OLMUTINIB HYDROCHLORIDE	The hydrochloride salt form of olmutinib, an orally available small molecule, mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Olmutinib binds to and inhibits mutant forms of EGFR, thereby leading to cell death of EGFR-expressing tumor cells. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors which also inhibit the EGFR wild type form.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170249	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170249>	C48149|C319	Olodaterol|OLODATEROL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C17024	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17024>	C40429	Proton|proton	A fundamental particle with a positive charge.			Physical Object	
C170250	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170250>	C514	Olorofim|Antifungal Agent F901318|F901318|OLOROFIM	A systemic antifungal agent that can potentially be used in the treatment of systemic fungal infections.	Olorofim		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C170251	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170251>	C20401	Omburtamab|8H9|OMBURTAMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170252	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170252>	C29703	Omega-3-carboxylic Acids|OMEGA-3-CARBOXYLIC ACIDS				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170253	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170253>	C29705	Omidenepag|OMIDENEPAG				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170254	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170254>	C29705	Omidenepag Isopropyl|OMIDENEPAG ISOPROPYL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170255	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170255>	C1891	Onapristone|ONAPRISTONE	An orally bioavailable progesterone receptor (PR) antagonist, with potential antineoplastic activity. Upon oral administration, onapristone binds to the PR and inhibits both PR activation and the associated expression of PR-responsive genes. This may inhibit PR-mediated proliferative effects in cancer cells overexpressing PR. In addition, onapristone may downregulate cancer stem cell mobilization and block immune evasion. PR is expressed on certain cancer cell types and plays a key role in tumor cell proliferation and survival.	Onapristone		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C170256	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170256>	C681	Ondelopran Hydrochloride|ONDELOPRAN HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170257	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170257>	C177899	Onvansertib Fumarate|ONVANSERTIB FUMARATE	The fumarate form of onvansertib, an orally bioavailable, adenosine triphosphate (ATP) competitive inhibitor of polo-like kinase 1 (PLK1; PLK-1; STPK13), with potential antineoplastic activity. Upon administration, onvansertib selectively binds to and inhibits PLK1, which disrupts mitosis and induces selective G2/M cell-cycle arrest followed by apoptosis in PLK1-overexpressing tumor cells. PLK1, named after the polo gene of Drosophila melanogaster, is a serine/threonine kinase that is crucial for the regulation of mitosis, and plays a key role in tumor cell proliferation. PLK1 expression is upregulated in a variety of tumor cell types and high expression is associated with increased aggressiveness and poor prognosis.	Onvansertib Fumarate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C170258	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170258>	C38149	Opicapone|OPICAPONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170259	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170259>	C20401	Opicinumab|OPICINUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C17025	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17025>	C16926	Psychiatric Nursing|Psychiatric/Mental Health Nursing	Nursing that focuses on care for the mentally ill patient.			Biomedical Occupation or Discipline	
C170260	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170260>	C101256	Orbofiban Acetate|ORBOFIBAN ACETATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170261	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170261>	C101256	Orbofiban|ORBOFIBAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170262	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170262>	C61101	Oritavancin Diphosphate|ORITAVANCIN DIPHOSPHATE				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170263	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170263>	C257	Orpanoxin|ORPANOXIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170264	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170264>	C29710|C142789	Osanetant|ACER 801|ACER-801|ACER801|OSANETANT|SR 14280|SR-142,801|SR-14280|SR14280	An orally bioavailable, brain penetrating, non-peptide neurokinin/tachykinin 3 receptor (NK1-receptor; NK3R; NK-3R) antagonist, that may potentially be used to treat vasomotor symptoms (VMS) in menopausal woman and in men on androgen deprivation therapy (ADT) and to suppress the production of certain hormones. Upon oral administration, osanetant targets, competitively binds to and blocks the activity of NK3R in the central nervous system (CNS), thereby inhibiting NK3R-mediated signal transduction and may prevent certain menopausal symptoms such as hot flashes and VMS in men deprived of androgen. Neurokinin-mediated signaling may increase during hormone deficiency and may cause hot flashes. In addition, osanetant may, by inhibiting NK3R, suppress secretion of various hormones, such as testosterone, luteinizing hormone (LH) and follicle-stimulating hormone (FSH). By suppressing testosterone production, osanetant may inhibit the proliferation of hormone-sensitive prostate cancer.	Osanetant		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C170265	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170265>	C210973	Osilodrostat Phosphate|OSILODROSTAT PHOSPHATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170266	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170266>	C2167|C129825	Osimertinib Mesylate|2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-, Methanesulfonate (1:1)|AZD9291 Mesylate|OSIMERTINIB MESYLATE|Tagrisso|Tagrix	The mesylate salt form of osimertinib, a third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, osimertinib covalently binds to and inhibits the activity of numerous mutant forms of EGFR, including the secondarily-acquired resistance mutation T790M, L858R, and exon 19 deletions, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.	Osimertinib Mesylate		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170267	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170267>	C241	Osmadizone|OSMADIZONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170268	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170268>	C263	Osocimab|BAY 1213790|BAY-1213790|BAY1213790|OSOCIMAB	A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against activated coagulation factor XI (FXIa), with potential anticoagulant and anti-thrombotic activities. Upon administration, osocimab targets, binds to, and allosterically inhibits FXIa. This prevents the activation of coagulation factor IX (FIX) by FXIa and the formation of thrombin. FXI plays an important role in thrombosis.			Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|HemOnc Agent Terminology
C170269	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170269>	C1509	Otaplimastat|OTAPLIMASTAT				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C17026	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17026>	C201958|C17153	Psychiatry|Psychiatric	The medical specialty that deals with the medical management of mental disorders.			Biomedical Occupation or Discipline	Operational Ontology for Radiation Oncology Prostate Cancer Terminology
C170270	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170270>	C514	Oteseconazole|OTESECONAZOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170271	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170271>	C574|C20401	Otilimab|GSK3196165|Immunoglobulin G1, Anti-(Human Granulocyte-Macrophage Colony-stimulating Factor) (Human Monoclonal GSK3196165 Heavy Chain), Disulfide with Human Monoclonal GSK3196165 Lambda-chain, Dimer|MOR103|OTILIMAB	A fully human monoclonal antibody directed against the inflammatory mediator granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunomodulating activity. Upon administration, otilimab targets, binds to and neutralizes GM-CSF. This prevents the binding of GM-CSF to its targeted inflammatory cells, and prevents proliferation and activation of various immune cells, and subsequent release of cytokines and B- and T-cell responses. GM-CSF, a monomeric glycoprotein functioning as a cytokine promoting both proliferation and activation of macrophages and neutrophils. GM-CSF levels are elevated in certain immune-mediated diseases. It increases the production of pro-inflammatory mediators, such as cytokines, chemokines and proteases.			Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C170272	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170272>	C66917	Oxeladin|OXELADIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170273	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170273>	C29702	Oxmetidine|OXMETIDINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170274	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170274>	C29702	Oxmetidine Hydrochloride|OXMETIDINE HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170275	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170275>	C333	Oxodipine|OXODIPINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170276	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170276>	C241	Oxycodegol Phosphate|OXYCODEGOL PHOSPHATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170277	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170277>	C241	Oxycodegol|OXYCODEGOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170278	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170278>	C29697	Oxyphenisatin Acetate|OXYPHENISATIN ACETATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170279	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170279>	C208296	Ozanimod|OZANIMOD|RPC 1063|RPC-1063|RPC1063	An orally bioavailable sphingosine-1-phosphate (S1P) receptors 1 (S1PR1, S1P1) and 5 (S1PR5, S1P5) modulator, with potential anti-inflammatory and immunomodulating activities. Upon oral administration, ozanimod selectively targets and binds to S1PR1 on lymphocytes and induces S1PR1 internalization and degradation. This results in the sequestration of lymphocytes in lymph nodes. By preventing egress of lymphocytes, ozanimod reduces both the amount of circulating peripheral lymphocytes and the infiltration of lymphocytes into target tissues. This prevents a lymphocyte-mediated immune response and may reduce inflammation. S1PR1, a G-protein coupled receptor, plays a key role in lymphocyte migration from lymphoid tissues. Modulation of S1PR5 by ozanimod may be neuroprotective.			Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCIt COVID-19 Agent Terminology|NCIt COVID-19 Terminology
C17027	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17027>	C201958|C16328	Psychology	The study of behavior and cognition.			Biomedical Occupation or Discipline	
C170280	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170280>	C1927	Ozogamicin|OZOGAMICIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170281	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170281>	C1512	Pabinafusp Alfa|PABINAFUSP ALFA				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170282	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170282>	C47793	Palatrigine|PALATRIGINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170283	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170283>	C258	Paldimycin|PALDIMYCIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170284	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170284>	C823|C29703	Pamaqueside|PAMAQUESIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170286	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170286>	C308	Parimifasor|PARIMIFASOR				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170287	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170287>	C155725	Patidegib Hydrochloride|PATIDEGIB HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170288	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170288>	C258	Paulomycin|PAULOMYCIN				Amino Acid, Peptide, or Protein|Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170289	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170289>	C29708	Pefcalcitol|PEFCALCITOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C17028	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17028>	C17027	Clinical Psychology	The branch of psychology that deals with the diagnosis and treatment of psychological and behavioral problems.			Biomedical Occupation or Discipline	
C170290	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170290>	C172200	Peficitinib Hydrobromide|PEFICITINIB HYDROBROMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170291	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170291>	C172200	Peficitinib|PEFICITINIB				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170292	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170292>	C1910	Peforelin|PEFORELIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170293	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170293>	C387	Pegacaristim|PEGACARISTIM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170294	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170294>	C224819	Pegapamodutide|PEGAPAMODUTIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170295	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170295>	C29708	Pegcantratinib|PEGCANTRATINIB				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170297	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170297>	C177280	Pegcrisantaspase|Asparec|JZP 416|JZP-416|JZP416|PEGCRISANTASPASE|Pegylated Erwinia asparaginase|Pegylated Recombinant L-asparaginase Erwinia chrysanthemi|mPEG-R-crisantaspase	A recombinant, pegylated form of Erwinia asparaginase (crisantaspase), derived from the bacterium Erwinia chrysanthemi and genetically engineered to be produced in Pseudomonas fluorescens, with potential antineoplastic activity. Recombinant Erwinia asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia. This depletes cancer cells of asparagine, which blocks protein synthesis and tumor cell proliferation. Asparagine is critical to protein synthesis in cancer cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Recombinant Erwinia asparaginase can be used as an alternative in patients who are hypersensitive to Escherichia (E.) coli-derived asparaginase products.			Amino Acid, Peptide, or Protein|Enzyme|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C170298	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170298>	C1823	Peginterferon Beta-1A|PEGINTERFERON BETA-1A				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170299	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170299>	C1966	Pegloprastide|AVB-620|Fluorescent Protease-activated Peptide AVB-620|PEGLOPRASTIDE	A protease-cleavable peptide linked to a fluorescent probe, with potential imaging activity. Upon intravenous infusion of pegloprastidebefore surgery, the peptide moiety of AVB-620 can be cleaved by proteases overexpressed by tumor cells. This activates the fluorescent probe and the tumor cells expressing the prote ases can be detected using a fluorescence imaging system. This allows for the visualization and removal of the tumor during surgery.	Pegloprastide		Indicator, Reagent, or Diagnostic Aid|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C17029	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17029>	C17027	Comparative Psychology	The study of animal behavior, with an emphasis on the similarities and differences that relate to evolutionary and developmental processes.			Biomedical Occupation or Discipline	
C1702	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1702>	C141215|C129822	Rituximab|ABP 798|ABP-798|ABP798|BI 695500|BI-695500|BI695500|Blitzima|C2B8 Monoclonal Antibody|CT P10|CT-P10|CTP10|Chimeric Anti-CD20 Antibody|GP 2013|GP-2013|GP2013|IDEC 102|IDEC-102|IDEC-C2B8|IDEC-C2B8 Monoclonal Antibody|IDEC102|Ikgdar|MabThera|Mabtas|Monoclonal Antibody IDEC-C2B8|PF 05280586|PF-05280586|PF05280586|RITUXIMAB|RTXM 83|RTXM-83|RTXM83|Riabni|Ritemvia|Rituxan|Rituxan|Rituximab ABBS|Rituximab ARRX|Rituximab Biosimilar ABP 798|Rituximab Biosimilar BI 695500|Rituximab Biosimilar CT-P10|Rituximab Biosimilar GB241|Rituximab Biosimilar GP2013|Rituximab Biosimilar IBI301|Rituximab Biosimilar JHL1101|Rituximab Biosimilar PF-05280586|Rituximab Biosimilar RTXM83|Rituximab Biosimilar SAIT101|Rituximab Biosimilar SIBP-02|Rituximab PVVR|Rituximab-abbs|Rituximab-arrx|Rituximab-arrx|Rituximab-blit|Rituximab-pvvr|Rituximab-pvvr|Rituximab-rite|Rituximab-rixa|Rituximab-rixi|Rixathon|Riximyo|Ruxience|Truxima|rituximab|rituximab biosimilar TQB2303|rituximab-abbs	A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)	Rituximab		Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|GDC Terminology|GDC Therapeutic Agent Terminology|GDC Value Terminology|HemOnc Agent Terminology|NCI Drug Dictionary Terminology|NCIt Antineoplastic Agent Terminology
C170300	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170300>	C1287	Pegnartograstim|PEGNARTOGRASTIM				Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170301	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170301>	C263	Pegnivacogin Sodium|PEGNIVACOGIN SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170302	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170302>	C82130	Pegoterate|PEGOTERATE				Organic Chemical	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170303	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170303>	C129821	Pegpleranib|PEGPLERANIB				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170304	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170304>	C78283	Pegpleranib Sodium|PEGPLERANIB SODIUM				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170305	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170305>	C804	Pelretin|PELRETIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170306	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170306>	C2021	Pemetrexed Tromethamine|PEMETREXED TROMETHAMINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170307	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170307>	C1500	Penamecillin|PENAMECILLIN				Antibiotic|Organic Chemical|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170308	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170308>	C243	Penmesterol|PENMESTEROL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170309	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170309>	C776	Pentagestrone|PENTAGESTRONE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C17030	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17030>	C17027	Educational Psychology|Psychology of Teaching	A branch of psychology concerned with educational techniques and assessment of academic aptitude.			Biomedical Occupation or Discipline	
C170310	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170310>	C574	Pentigetide|PENTIGETIDE				Amino Acid, Peptide, or Protein|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170311	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170311>	C333	Perhexiline|PERHEXILINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170312	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170312>	C257	Perisoxal|PERISOXAL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170313	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170313>	C29756	Petrichloral|PETRICHLORAL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170314	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170314>	C213472|C198646|C159198|C124800	Pexidartinib Hydrochloride|(5-(5-Chloro-1H-pyrrolo(2,3-b)pyridin-3-ylmethyl)-pyridin-2-yl)-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine Hydrochloride Salt|5[(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-{[6-(trifluoromethyl)pyridin-3yl]methyl}pyridin-2-amine Monohydrochloride|FP-113|PEXIDARTINIB HYDROCHLORIDE|PLX3397 Hydrochloride|Pexidartinib Monohydrochloride|Turalio	The hydrochloride salt form of pexidartinib, a small-molecule receptor tyrosine kinase (RTK) inhibitor of proto-oncogene receptor tyrosine kinase (KIT), colony-stimulating factor-1 receptor (CSF1R) and FMS-like tyrosine kinase 3 (FLT3), with antineoplastic activity. Upon oral administration, pexidartinib targets, binds to and inhibits phosphorylation of KIT, CSF1R and FLT3 harboring an internal tandem duplication (ITD) mutation. This results in the inhibition of tumor cell proliferation. FLT3, CSF1R and FLT3 are overexpressed or mutated in many cancer cell types and play major roles in tumor cell proliferation and metastasis.	Pexidartinib Hydrochloride		Pharmacologic Substance	CTRP Agent Terminology|CTRP Terminology|FDA Established Names and Unique Ingredient Identifier Codes Terminology|NCI Drug Dictionary Terminology
C170315	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170315>	C52588	Pexiganan|PEXIGANAN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170316	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170316>	C260	Pheneticillin|PHENETICILLIN				Antibiotic|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170317	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170317>	C29723	Picoprazole|PICOPRAZOLE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170318	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170318>	C29710	Piflutixol|PIFLUTIXOL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170319	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170319>	C29703	Pimetine|PIMETINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C17031	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17031>	C17026	Experimental Psychiatry	A subdiscipline of psychiatry that is concerned with the study of conditioning, learning, perception, motivation, emotion, language, and thinking; also used in relation to subject-matter areas in which experimental methods are emphasized.			Biomedical Occupation or Discipline	
C170321	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170321>	C29704	Pipenzolate Bromide|PIPENZOLATE BROMIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170322	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170322>	C29704	Piperidolate|PIPERIDOLATE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170323	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170323>	C29698	Pipoxolan Hydrochloride|PIPOXOLAN HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170324	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170324>	C47795	Pipradrol|PIPRADROL				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170325	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170325>	C29696	Piprocurarium Iodide|PIPROCURARIUM IODIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170326	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170326>	C78272	Piromelatine|PIROMELATINE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170327	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170327>	C29703	Pirprofen|PIRPROFEN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170328	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170328>	C78272	Pitolisant Hydrochloride|PITOLISANT HYDROCHLORIDE				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170329	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170329>	C20401	Placulumab|PLACULUMAB				Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C17032	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17032>	C17027	Industrial Psychology|Industrial/Organizational Psychology|Psychology, Industrial	The branch of applied psychology that is concerned with efficient management of an industrial labor force and especially with problems encountered by workers in a mechanized environment. (Bartleby.com)			Biomedical Occupation or Discipline	
C170330	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170330>	C1941	Plusonermin|PLUSONERMIN				Pharmacologic Substance	FDA Established Names and Unique Ingredient Identifier Codes Terminology
C170331	<http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C170331>	C45678	